Cancer_type	QTL_type	tag_SNP	LD	SNP	SNP_position	Alleles	Methylation_probe	Methylation_position	Probe_related_gene	Beta	t-stat	Correlation_coefficient (r)	p-value	Traits
TGCT	cis	rs11578119	0.933	rs12128140	chr1:170406363	C/T	cg09767346	chr1:170501363	GORAB	0.71	5.65	0.45	1.04e-7	Male-pattern baldness;
TGCT	cis	rs12711979	0.765	rs881852	chr2:3821508	A/G	cg17052675	chr2:3827356	NA	-0.4	-7.74	-0.57	2.93e-12	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs9381040	0.537	rs9462669	chr6:41013659	C/A	cg03526776	chr6:41159608	TREML2	0.26	5.01	0.41	1.86e-6	Alzheimer's disease (late onset);
TGCT	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg17971929	chr21:40555470	PSMG1	-0.51	-4.6	-0.38	1.02e-5	Menarche (age at onset);
TGCT	cis	rs6089584	0.927	rs3787427	chr20:60579789	T/C	cg06108461	chr20:60628389	TAF4	-0.58	-8.35	-0.6	1.12e-13	Body mass index;
TGCT	cis	rs2230307	0.572	rs17122001	chr1:100628311	A/T	cg24955406	chr1:100503596	HIAT1	0.73	4.96	0.41	2.25e-6	Carotid intima media thickness;
TGCT	cis	rs3540	0.574	rs2657947	chr15:90968977	C/T	cg22089800	chr15:90895588	ZNF774	-0.72	-7.7	-0.57	3.66e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg20637647	chr7:64974828	NA	1.0	5.59	0.45	1.4e-7	Diabetic kidney disease;
TGCT	cis	rs7635838	0.892	rs66974661	chr3:11482729	A/G	cg00170343	chr3:11313890	ATG7	0.64	6.05	0.48	1.57e-8	HDL cholesterol;
TGCT	cis	rs35146811	0.735	rs1636975	chr7:99812089	A/G	cg22906224	chr7:99728672	NA	-0.49	-4.45	-0.37	1.88e-5	Coronary artery disease;
TGCT	cis	rs929354	0.772	rs6459738	chr7:156998532	T/G	cg05182265	chr7:156933206	UBE3C	-0.39	-8.79	-0.62	1.03e-14	Body mass index;
TGCT	cis	rs35934224	0.783	rs34593728	chr22:19857489	T/C	cg11182965	chr22:19864308	TXNRD2	-0.36	-4.95	-0.41	2.33e-6	Glaucoma (primary open-angle);
TGCT	trans	rs208520	0.690	rs12198745	chr6:66722598	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	11.06	0.7	3.28e-20	Exhaled nitric oxide output;
TGCT	cis	rs35306767	0.669	rs2101051	chr10:1158791	G/T	cg26597838	chr10:835615	NA	0.52	5.59	0.45	1.4e-7	Eosinophil percentage of granulocytes;
TGCT	cis	rs7524258	0.903	rs4908608	chr1:7292772	T/C	cg07173049	chr1:7289937	CAMTA1	0.32	5.37	0.43	3.78e-7	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.48	-0.37	1.66e-5	Bipolar disorder;
TGCT	trans	rs1974653	0.672	rs9606254	chr22:20100409	C/T	cg08822737	chr17:71088851	SLC39A11	-0.93	-7.65	-0.57	4.76e-12	Schizophrenia;
TGCT	cis	rs2629540	0.793	rs10794180	chr10:126449306	T/A	cg08799069	chr10:126477246	METTL10	-0.3	-4.49	-0.37	1.6e-5	Cocaine dependence;
TGCT	cis	rs9303401	0.614	rs35308719	chr17:57163501	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.64	5.87	0.47	3.79e-8	Cognitive test performance;
TGCT	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg12311346	chr5:56204834	C5orf35	-0.67	-6.82	-0.52	3.63e-10	Initial pursuit acceleration;
TGCT	cis	rs854765	0.547	rs4459604	chr17:17888549	A/G	cg04398451	chr17:18023971	MYO15A	-0.32	-5.07	-0.41	1.44e-6	Total body bone mineral density;
TGCT	cis	rs7937682	0.921	rs4616071	chr11:111440865	C/G	cg09085632	chr11:111637200	PPP2R1B	0.85	7.07	0.54	9.77e-11	Primary sclerosing cholangitis;
TGCT	trans	rs459571	0.792	rs55923934	chr9:136888233	C/G	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.72	-7.8	-0.57	2.18e-12	Platelet distribution width;
TGCT	cis	rs67073037	0.955	rs1131880	chr2:29170676	G/C	cg09522027	chr2:28974177	PPP1CB	0.57	4.49	0.37	1.59e-5	Breast cancer;Breast cancer (estrogen-receptor negative);
TGCT	cis	rs7772486	0.654	rs9376958	chr6:146023040	C/T	cg23711669	chr6:146136114	FBXO30	-0.88	-9.69	-0.66	7.23e-17	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs62103177	0.714	rs28691615	chr18:77612254	C/T	cg05926928	chr17:57297772	GDPD1	1.06	10.16	0.67	5.19e-18	Opioid sensitivity;
TGCT	cis	rs372883	0.564	rs13051579	chr21:30589840	C/T	cg24692254	chr21:30365293	RNF160	0.52	4.92	0.4	2.66e-6	Pancreatic cancer;
TGCT	cis	rs1805008	0.568	rs76888998	chr16:89884310	G/T	cg02628002	chr16:89649608	CPNE7	0.48	5.26	0.43	6.06e-7	Skin colour saturation;
TGCT	cis	rs868036	0.681	rs1026737	chr15:68107072	A/C	cg05925327	chr15:68127851	NA	-0.5	-4.85	-0.4	3.57e-6	Restless legs syndrome;
TGCT	cis	rs6540559	0.673	rs41305104	chr1:209950848	G/A	cg21951975	chr1:209979733	IRF6	0.64	4.81	0.4	4.38e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs7776786	0.934	rs17349342	chr7:18815473	A/C	cg13420273	chr7:18810212	HDAC9	0.25	4.58	0.38	1.1e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.97	-8.51	-0.61	4.86e-14	Platelet count;
TGCT	cis	rs1153858	1.000	rs1613559	chr15:45622116	A/G	cg26924012	chr15:45694286	SPATA5L1	0.96	11.77	0.73	6.36e-22	Homoarginine levels;
TGCT	cis	rs2760061	0.598	rs2796056	chr1:228122901	G/A	cg18477163	chr1:228402036	OBSCN	-0.32	-6.37	-0.5	3.31e-9	Diastolic blood pressure;
TGCT	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg22920501	chr2:26401640	FAM59B	-0.72	-6.22	-0.49	7.14e-9	Gut microbiome composition (summer);
TGCT	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg16325326	chr1:53192061	ZYG11B	-0.7	-8.51	-0.61	4.8e-14	Monocyte count;
TGCT	cis	rs6426558	0.537	rs12139758	chr1:227260519	A/G	cg10327440	chr1:227177885	CDC42BPA	0.6	7.14	0.54	6.84e-11	Neutrophil percentage of white cells;
TGCT	cis	rs3008870	0.585	rs2815382	chr1:67515228	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.73	7.05	0.53	1.1e-10	Lymphocyte percentage of white cells;
TGCT	cis	rs4494114	1.000	rs7547273	chr1:39372590	G/A	cg25970120	chr1:39325951	RRAGC	-0.6	-6.19	-0.49	8.18e-9	Blood protein levels;
TGCT	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg26338869	chr17:61819248	STRADA	-0.55	-5.08	-0.42	1.34e-6	Prudent dietary pattern;
TGCT	cis	rs4843747	0.671	rs28451517	chr16:88109127	A/C	cg06915872	chr16:87998081	BANP	-0.3	-4.54	-0.38	1.33e-5	Menopause (age at onset);
TGCT	cis	rs10782582	0.569	rs2131557	chr1:76388589	A/C	cg10523679	chr1:76189770	ACADM	0.5	4.47	0.37	1.72e-5	Daytime sleep phenotypes;
TGCT	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	6.05	0.48	1.59e-8	Alzheimer's disease;
TGCT	cis	rs10751667	0.577	rs7946461	chr11:974035	A/G	cg06064525	chr11:970664	AP2A2	-0.34	-7.97	-0.58	9.04e-13	Alzheimer's disease (late onset);
TGCT	cis	rs6545883	0.965	rs6718887	chr2:61727215	G/A	cg15711740	chr2:61764176	XPO1	-0.5	-4.51	-0.38	1.46e-5	Tuberculosis;
TGCT	cis	rs727563	0.608	rs2076200	chr22:41985956	G/T	cg06634786	chr22:41940651	POLR3H	-0.89	-8.16	-0.59	3.16e-13	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs6500602	0.673	rs4786513	chr16:4576423	T/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.41	6.01	0.48	1.88e-8	Schizophrenia;
TGCT	cis	rs593531	0.571	rs10898983	chr11:74093992	C/T	cg25592907	chr11:73676012	DNAJB13	0.31	4.52	0.38	1.45e-5	Neuroticism;
TGCT	cis	rs9611565	0.729	rs203320	chr22:41913477	T/C	cg13695892	chr22:41940480	POLR3H	-0.83	-8.58	-0.61	3.21e-14	Vitiligo;
TGCT	cis	rs796364	1.000	rs11895190	chr2:200838613	A/G	cg17644776	chr2:200775616	C2orf69	-0.3	-4.49	-0.37	1.59e-5	Schizophrenia;
TGCT	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg04944784	chr2:26401820	FAM59B	-0.78	-6.56	-0.51	1.34e-9	Gut microbiome composition (summer);
TGCT	cis	rs1008375	0.646	rs4235387	chr4:17569327	T/G	cg16339924	chr4:17578868	LAP3	0.78	6.45	0.5	2.27e-9	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg11494091	chr17:61959527	GH2	0.61	14.34	0.79	4.3e-28	Prudent dietary pattern;
TGCT	cis	rs62244186	0.520	rs9311361	chr3:44796132	T/G	cg11003573	chr3:44754125	ZNF502	-0.46	-5.34	-0.43	4.35e-7	Depressive symptoms;
TGCT	cis	rs9302065	0.595	rs1547746	chr13:95964267	G/A	cg26751094	chr13:95954534	ABCC4	-0.35	-5.66	-0.45	1.02e-7	Blood metabolite levels;
TGCT	cis	rs2455799	0.517	rs2345742	chr3:15939832	C/T	cg12172478	chr3:16357591	RFTN1	-0.33	-4.81	-0.4	4.31e-6	Mean platelet volume;
TGCT	cis	rs9916302	0.800	rs8081220	chr17:37473157	A/C	cg07936489	chr17:37558343	FBXL20	0.63	4.91	0.4	2.83e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7826238	0.524	rs2921055	chr8:8319342	C/A	cg06636001	chr8:8085503	FLJ10661	0.79	7.34	0.55	2.4e-11	Systolic blood pressure;
TGCT	cis	rs3806843	0.838	rs2337514	chr5:140132732	T/C	cg19875535	chr5:140030758	IK	-0.35	-5.97	-0.47	2.27e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2147959	0.766	rs35598069	chr1:228782548	C/G	cg22700015	chr1:228743131	NA	0.58	5.02	0.41	1.71e-6	Adult asthma;
TGCT	cis	rs17345786	0.954	rs17508319	chr3:101318903	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.88	9.32	0.64	5.46e-16	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7666738	0.830	rs7672127	chr4:98938477	A/G	cg18180107	chr4:99064573	C4orf37	0.56	5.06	0.41	1.49e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9393777	0.844	rs35909544	chr6:27163456	G/A	cg10876282	chr6:28092338	ZSCAN16	0.73	4.55	0.38	1.26e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2404602	0.647	rs3812909	chr15:77176200	A/T	cg23625390	chr15:77176239	SCAPER	-0.39	-5.04	-0.41	1.6e-6	Blood metabolite levels;
TGCT	cis	rs6840360	0.935	rs3919716	chr4:152456387	A/G	cg17479576	chr4:152424074	FAM160A1	-0.47	-4.98	-0.41	2.06e-6	Intelligence (multi-trait analysis);
TGCT	trans	rs1973993	0.903	rs2038646	chr1:96940371	C/G	cg10631902	chr5:14652156	NA	0.31	6.82	0.52	3.6e-10	Weight;
TGCT	cis	rs6840360	1.000	rs6823002	chr4:152604467	T/G	cg17479576	chr4:152424074	FAM160A1	-0.49	-5.1	-0.42	1.25e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.84	7.5	0.56	1.08e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9911578	1.000	rs2531734	chr17:56550804	T/C	cg12560992	chr17:57184187	TRIM37	-0.76	-9.28	-0.64	7.12e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs9399135	0.935	rs11754504	chr6:135321509	C/T	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.36e-6	Red blood cell count;
TGCT	cis	rs344364	0.511	rs337286	chr16:1965719	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.46	-4.71	-0.39	6.58e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs9296092	0.538	rs9461882	chr6:33520221	A/C	cg13560919	chr6:33536144	NA	-0.2	-4.64	-0.38	8.68e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs12950390	0.853	rs56137679	chr17:45862112	C/G	cg06532163	chr17:45867833	NA	0.37	5.96	0.47	2.45e-8	IgG glycosylation;
TGCT	cis	rs1552244	0.554	rs6768339	chr3:10006079	G/T	cg00149659	chr3:10157352	C3orf10	-0.63	-4.81	-0.4	4.27e-6	Alzheimer's disease;
TGCT	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg11494091	chr17:61959527	GH2	0.44	7.34	0.55	2.52e-11	Height;
TGCT	cis	rs185694	0.947	rs202079	chr13:30879154	C/T	cg07600127	chr13:30881527	KATNAL1	-0.87	-6.77	-0.52	4.55e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
TGCT	cis	rs12142240	0.698	rs17357621	chr1:46807697	C/T	cg00530320	chr1:46809349	NSUN4	0.29	5.88	0.47	3.63e-8	Menopause (age at onset);
TGCT	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.64	0.51	8.85e-10	Electroencephalogram traits;
TGCT	cis	rs2594989	0.831	rs7651790	chr3:11572610	C/T	cg00170343	chr3:11313890	ATG7	-0.64	-4.77	-0.39	5.18e-6	Circulating chemerin levels;
TGCT	cis	rs11874712	0.965	rs28694780	chr18:43665338	C/T	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	5.23	0.42	7.11e-7	Migraine - clinic-based;
TGCT	cis	rs6688613	0.729	rs7545806	chr1:166938555	T/C	cg07049167	chr1:166818506	POGK	0.27	5.16	0.42	9.39e-7	Refractive astigmatism;
TGCT	cis	rs1801251	1.000	rs1947105	chr2:233721455	A/G	cg08000102	chr2:233561755	GIGYF2	0.63	6.35	0.5	3.77e-9	Coronary artery disease;
TGCT	cis	rs10883723	0.810	rs2296582	chr10:104244139	G/T	cg05855489	chr10:104503620	C10orf26	-0.57	-5.09	-0.42	1.29e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg03709012	chr19:19516395	GATAD2A	0.67	5.74	0.46	6.83e-8	Tonsillectomy;
TGCT	cis	rs2288278	0.601	rs11651168	chr17:46597193	A/G	cg25032089	chr17:46643351	HOXB3	-0.42	-5.01	-0.41	1.86e-6	Hand grip strength;
TGCT	cis	rs2760061	0.626	rs672977	chr1:228120288	A/C	cg18477163	chr1:228402036	OBSCN	-0.32	-6.37	-0.5	3.31e-9	Diastolic blood pressure;
TGCT	cis	rs7267979	0.932	rs446649	chr20:25467359	A/G	cg16686733	chr20:25566563	NINL	0.56	5.81	0.46	4.96e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6700896	0.522	rs11208720	chr1:66159055	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.54	4.44	0.37	1.98e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs9611565	0.512	rs5758465	chr22:42175314	T/C	cg13695892	chr22:41940480	POLR3H	0.85	8.06	0.59	5.4e-13	Vitiligo;
TGCT	cis	rs73198271	0.737	rs535094	chr8:8633928	A/G	cg06671706	chr8:8559999	CLDN23	-0.36	-4.68	-0.39	7.27e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg24531977	chr5:56204891	C5orf35	-0.78	-7.74	-0.57	2.95e-12	Type 2 diabetes;
TGCT	cis	rs6831352	0.918	rs29001201	chr4:100053861	T/C	cg12011299	chr4:100065546	ADH4	-0.4	-4.88	-0.4	3.26e-6	Alcohol dependence;
TGCT	cis	rs12042938	0.600	rs1094656	chr1:231773675	T/C	cg04892437	chr1:231737901	TSNAX-DISC1	0.46	4.81	0.4	4.33e-6	Neuranatomic and neurocognitive phenotypes;
TGCT	cis	rs8141529	0.748	rs132529	chr22:29296652	A/G	cg02153584	chr22:29168773	CCDC117	-0.62	-4.93	-0.4	2.58e-6	Lymphocyte counts;
TGCT	cis	rs7772486	0.875	rs7766595	chr6:146364507	A/T	cg05347473	chr6:146136440	FBXO30	0.56	5.42	0.44	2.96e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4460629	0.742	rs7365544	chr1:155068748	C/A	cg23973274	chr1:155060172	NA	-0.25	-4.64	-0.38	8.88e-6	Serum magnesium levels;
TGCT	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg22166914	chr1:53195759	ZYG11B	-0.39	-6.57	-0.51	1.25e-9	Monocyte count;
TGCT	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg12419862	chr22:24373484	LOC391322	-0.81	-8.51	-0.61	4.7e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs35146811	0.961	rs11771139	chr7:99736059	C/T	cg00553149	chr7:99775558	STAG3;GPC2	0.3	4.62	0.38	9.28e-6	Coronary artery disease;
TGCT	cis	rs28595532	0.920	rs17324968	chr4:119772316	A/G	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs733175	0.951	rs7669090	chr4:10028131	C/T	cg11266682	chr4:10021025	SLC2A9	0.48	4.48	0.37	1.7e-5	Psychosis and Alzheimer's disease;
TGCT	cis	rs2760061	0.583	rs708124	chr1:228220771	A/T	cg18477163	chr1:228402036	OBSCN	0.34	6.95	0.53	1.87e-10	Diastolic blood pressure;
TGCT	cis	rs8017423	0.605	rs3742673	chr14:90735707	C/T	cg04374321	chr14:90722782	PSMC1	0.6	5.53	0.44	1.79e-7	Mortality in heart failure;
TGCT	cis	rs782590	0.869	rs782599	chr2:55847423	C/T	cg18811423	chr2:55921094	PNPT1	0.65	6.91	0.53	2.23e-10	Metabolic syndrome;
TGCT	cis	rs7474896	0.515	rs688608	chr10:38331624	G/A	cg13720705	chr10:37990370	NA	-0.43	-5.47	-0.44	2.43e-7	Obesity (extreme);
TGCT	trans	rs28735056	0.904	rs11665111	chr18:77622996	T/C	cg05926928	chr17:57297772	GDPD1	0.64	6.76	0.52	4.85e-10	Schizophrenia;
TGCT	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	6.14	0.48	1.03e-8	Bipolar disorder;
TGCT	cis	rs5833486	1	rs5833486	chr2:113957180	T/TA	cg27425262	chr2:113953981	PSD4;LOC440839	0.4	4.63	0.38	9.02e-6	Red blood cell count;
TGCT	cis	rs12497850	0.805	rs6446198	chr3:49007638	T/A	cg07636037	chr3:49044803	WDR6	0.96	10.52	0.69	6.9e-19	Parkinson's disease;
TGCT	cis	rs6671200	0.915	rs34266846	chr1:95739748	G/A	cg26537280	chr1:95699037	RWDD3	0.72	5.18	0.42	8.67e-7	Stearic acid (18:0) levels;
TGCT	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg13393036	chr8:95962371	TP53INP1	-0.63	-8.52	-0.61	4.43e-14	Type 2 diabetes;
TGCT	cis	rs3764400	0.567	rs1452662	chr17:46293310	C/T	cg02340556	chr17:46797764	NA	0.42	4.51	0.38	1.46e-5	Body mass index;
TGCT	cis	rs67072384	0.818	rs7926287	chr11:72464525	A/G	cg03713592	chr11:72463424	ARAP1	-0.82	-4.47	-0.37	1.71e-5	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg04772025	chr11:68637568	NA	0.61	6.93	0.53	2.02e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7647973	0.588	rs62262675	chr3:49673662	A/G	cg03060546	chr3:49711283	APEH	-0.59	-4.93	-0.41	2.54e-6	Menarche (age at onset);
TGCT	cis	rs10779751	0.708	rs2746640	chr1:11292952	T/A	cg08854313	chr1:11322531	MTOR	0.97	8.9	0.62	5.52e-15	Body mass index;
TGCT	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs6912958	0.781	rs7761814	chr6:88188309	G/A	cg06598631	chr6:88300029	RARS2;ORC3L	-0.53	-4.85	-0.4	3.69e-6	Monocyte percentage of white cells;
TGCT	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg06634786	chr22:41940651	POLR3H	-0.9	-8.93	-0.63	4.7e-15	Vitiligo;
TGCT	cis	rs28785552	0.800	rs10853855	chr19:53232293	A/G	cg22067481	chr19:53234126	ZNF611	-0.5	-7.34	-0.55	2.42e-11	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs611744	0.967	rs655722	chr8:109197541	A/T	cg21045802	chr8:109455806	TTC35	0.5	4.63	0.38	9.18e-6	Dupuytren's disease;
TGCT	cis	rs12210905	0.841	rs72839470	chr6:27309304	T/A	cg08851530	chr6:28072375	NA	1.32	5.79	0.46	5.48e-8	Hip circumference adjusted for BMI;
TGCT	cis	rs6840360	0.615	rs9996320	chr4:152610587	T/G	cg17479576	chr4:152424074	FAM160A1	-0.54	-5.28	-0.43	5.69e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs753778	0.629	rs2278447	chr8:142206905	G/C	cg18755752	chr8:142205143	DENND3	-0.29	-5.18	-0.42	8.69e-7	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs12497850	0.931	rs11705888	chr3:48817289	T/C	cg18654377	chr3:49208889	KLHDC8B	-0.41	-5.49	-0.44	2.15e-7	Parkinson's disease;
TGCT	trans	rs57221529	0.766	rs12521988	chr5:556421	C/T	cg25482853	chr8:67687455	SGK3	1.2	10.16	0.67	5.25e-18	Lung disease severity in cystic fibrosis;
TGCT	cis	rs916888	0.610	rs199529	chr17:44837217	A/C	cg01570182	chr17:44337453	NA	0.98	8.73	0.62	1.41e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.52	-5.99	-0.47	2.08e-8	Longevity;Endometriosis;
TGCT	cis	rs7511006	0.858	rs2294402	chr22:50654428	T/G	cg16473166	chr22:50639996	SELO	0.63	6.42	0.5	2.56e-9	Obesity-related traits;
TGCT	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg05573699	chr3:52720067	GNL3;PBRM1	0.49	4.5	0.37	1.56e-5	Bipolar disorder;
TGCT	cis	rs9303542	0.625	rs9905940	chr17:46614102	A/C	cg25032089	chr17:46643351	HOXB3	-0.53	-5.49	-0.44	2.16e-7	Ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs4788570	0.547	rs7202479	chr16:71759679	A/C	cg06353428	chr16:71660113	MARVELD3	1.49	12.95	0.76	8.56e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg06634786	chr22:41940651	POLR3H	-0.88	-8.54	-0.61	3.98e-14	Vitiligo;
TGCT	cis	rs11096990	0.593	rs35937374	chr4:39186355	C/T	cg20847110	chr4:39482781	LOC401127	0.16	4.52	0.38	1.42e-5	Cognitive function;
TGCT	cis	rs617219	0.671	rs1062326	chr5:78617534	A/C	cg23514016	chr5:78407564	BHMT	-0.32	-4.78	-0.39	4.85e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.64	-6.17	-0.48	8.7e-9	Bipolar disorder;
TGCT	cis	rs1891275	0.515	rs7092745	chr10:93483820	C/T	cg07889827	chr10:93443413	NA	-0.32	-6.74	-0.52	5.19e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg08736216	chr1:53307985	ZYG11A	0.27	5.5	0.44	2.11e-7	Monocyte count;
TGCT	cis	rs1729951	0.546	rs835632	chr3:136676525	A/T	cg12473912	chr3:136751656	NA	0.39	6.18	0.49	8.36e-9	Neuroticism;
TGCT	cis	rs8050907	0.744	rs13330134	chr16:4526923	T/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.53	4.57	0.38	1.15e-5	Obesity-related traits;
TGCT	cis	rs7523050	0.730	rs34254854	chr1:109419875	C/T	cg08274380	chr1:109419600	GPSM2	1.35	6.86	0.52	2.89e-10	Fat distribution (HIV);
TGCT	cis	rs909002	1.000	rs909002	chr1:32139635	C/T	cg11573219	chr1:32083031	HCRTR1	-0.38	-4.72	-0.39	6.34e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs62244186	0.659	rs62251383	chr3:44552421	A/G	cg21672276	chr3:44754072	ZNF502	-0.43	-4.78	-0.39	4.89e-6	Depressive symptoms;
TGCT	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg26338869	chr17:61819248	STRADA	-0.56	-5.11	-0.42	1.17e-6	Prudent dietary pattern;
TGCT	cis	rs9419702	0.538	rs9322837	chr10:133539229	G/A	cg20568497	chr10:133558893	NA	0.43	4.65	0.39	8.41e-6	Survival in rectal cancer;
TGCT	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.49	-6.64	-0.51	8.8e-10	Alzheimer's disease;
TGCT	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg04772025	chr11:68637568	NA	0.6	6.68	0.51	7.03e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs6088580	0.561	rs3761147	chr20:32996689	G/T	cg24642439	chr20:33292090	TP53INP2	-0.49	-4.49	-0.37	1.59e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs2562456	0.917	rs6511253	chr19:21678798	A/G	cg01304269	chr19:21688519	ZNF429	-0.55	-4.66	-0.39	8.05e-6	Pain;
TGCT	cis	rs17376456	0.877	rs10066791	chr5:93350255	G/T	cg25358565	chr5:93447407	FAM172A	0.93	8.63	0.61	2.46e-14	Diabetic retinopathy;
TGCT	cis	rs910316	0.935	rs3742771	chr14:75599647	A/G	cg23033748	chr14:75592666	NEK9	0.28	4.81	0.4	4.24e-6	Height;
TGCT	cis	rs1982963	1.000	rs1982963	chr14:52509101	C/T	cg10843707	chr14:52510701	NID2	-0.41	-6.53	-0.51	1.54e-9	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9394438	0.628	rs4714080	chr6:37544618	A/G	cg00985040	chr6:37553208	NA	0.25	4.98	0.41	2.1e-6	IgG glycosylation;
TGCT	cis	rs13217239	0.646	rs9379956	chr6:27033735	T/C	cg06035815	chr6:26189597	HIST1H4D	0.44	4.53	0.38	1.39e-5	Schizophrenia;
TGCT	cis	rs9457247	1.000	rs4710147	chr6:167374239	G/A	cg23791538	chr6:167370224	RNASET2	0.5	4.98	0.41	2.05e-6	Crohn's disease;
TGCT	cis	rs7225537	0.559	rs3744138	chr17:17045861	C/T	cg26176665	chr17:16994978	MPRIP	0.25	5.87	0.47	3.65e-8	Mean platelet volume;
TGCT	cis	rs2354432	0.607	rs72692962	chr1:146802674	C/A	cg25205988	chr1:146714368	CHD1L	-1.41	-5.83	-0.46	4.57e-8	Mitochondrial DNA levels;
TGCT	cis	rs13064447	0.789	rs55976129	chr3:12762067	T/C	cg20675869	chr3:12750130	NA	-0.2	-4.99	-0.41	2.03e-6	Major depression and alcohol dependence;
TGCT	cis	rs2688608	0.618	rs28553894	chr10:75489843	C/A	cg19442545	chr10:75533431	FUT11	-0.37	-5.87	-0.47	3.81e-8	Inflammatory bowel disease;
TGCT	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg10047753	chr17:41438598	NA	0.84	7.61	0.56	5.9e-12	Menopause (age at onset);
TGCT	cis	rs78487399	0.808	rs17030835	chr2:43686245	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-5.19	-0.42	8.37e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs35883536	0.647	rs12046413	chr1:101047430	T/C	cg06223162	chr1:101003688	GPR88	-0.41	-7.64	-0.57	5.04e-12	Monocyte count;
TGCT	cis	rs525592	1	rs525592	chr11:68195104	C/T	cg16797656	chr11:68205561	LRP5	0.29	5.19	0.42	8.33e-7	Bone mineral density;
TGCT	cis	rs9814567	1.000	rs1814337	chr3:134200682	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.95	-9.64	-0.65	9.67e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs6722750	0.818	rs12104940	chr2:64385774	A/G	cg22352474	chr2:64371530	PELI1	0.68	6.45	0.5	2.27e-9	Neuroticism;
TGCT	cis	rs1215050	0.791	rs165242	chr4:98686482	A/C	cg17366294	chr4:99064904	C4orf37	-0.47	-4.68	-0.39	7.54e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs11754661	1.000	rs73011397	chr6:151205678	A/G	cg01354656	chr6:151411710	MTHFD1L	0.48	4.49	0.37	1.61e-5	Alzheimer's disease (late onset);
TGCT	cis	rs896854	0.714	rs572547	chr8:95966286	A/G	cg13393036	chr8:95962371	TP53INP1	0.56	6.85	0.52	3.02e-10	Type 2 diabetes;
TGCT	trans	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.86	9.4	0.65	3.49e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs1215050	0.791	rs6813619	chr4:98830768	C/T	cg05340658	chr4:99064831	C4orf37	-0.47	-5.89	-0.47	3.41e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs4689592	0.503	rs4689064	chr4:7055603	A/G	cg26116260	chr4:7069785	GRPEL1	-0.87	-6.75	-0.52	4.98e-10	Monocyte percentage of white cells;
TGCT	cis	rs250677	0.958	rs36067	chr5:148417553	T/G	cg23229984	chr5:148520753	ABLIM3	0.21	4.81	0.4	4.35e-6	Breast cancer;
TGCT	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg22968622	chr17:43663579	NA	1.23	10.98	0.7	5.31e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs904251	0.523	rs2776871	chr6:37481759	A/G	cg08126542	chr6:37504118	NA	-0.44	-6.51	-0.5	1.71e-9	Cognitive performance;
TGCT	cis	rs6912958	0.535	rs448580	chr6:88040399	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.67	6.87	0.52	2.81e-10	Monocyte percentage of white cells;
TGCT	cis	rs9787249	0.957	rs12074147	chr1:40203722	T/C	cg24920358	chr1:40204285	PPIE	0.56	10.07	0.67	8.56e-18	Blood protein levels;
TGCT	cis	rs453301	0.624	rs2288671	chr8:8860894	T/C	cg15556689	chr8:8085844	FLJ10661	0.74	6.44	0.5	2.37e-9	Joint mobility (Beighton score);
TGCT	cis	rs9906944	0.657	rs4643373	chr17:47123423	T/C	cg20966754	chr17:47091339	IGF2BP1	-0.49	-5.4	-0.44	3.3e-7	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs453301	0.624	rs7014430	chr8:8827737	T/G	cg15556689	chr8:8085844	FLJ10661	0.69	5.82	0.46	4.65e-8	Joint mobility (Beighton score);
TGCT	trans	rs208520	0.754	rs7753158	chr6:66875633	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-9.61	-0.65	1.11e-16	Exhaled nitric oxide output;
TGCT	cis	rs28595532	0.920	rs17258830	chr4:119725543	A/T	cg21605333	chr4:119757512	SEC24D	-1.72	-8.96	-0.63	3.99e-15	Cannabis dependence symptom count;
TGCT	cis	rs2235642	0.893	rs2143285	chr16:1593171	A/G	cg07341220	chr16:1583899	IFT140;TMEM204	-0.29	-4.51	-0.38	1.45e-5	Coronary artery disease;
TGCT	cis	rs4332037	0.539	rs56305291	chr7:2048706	A/G	cg25834613	chr7:1915315	MAD1L1	-0.49	-4.79	-0.39	4.71e-6	Bipolar disorder;
TGCT	cis	rs9425326	0.508	rs2500105	chr1:183809103	G/C	cg15569801	chr1:184197096	NA	-0.14	-5.03	-0.41	1.7e-6	Antipsychotic drug-induced QTc interval change in schizophrenia;
TGCT	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg02353165	chr6:42928485	GNMT	0.95	9.59	0.65	1.25e-16	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs9393692	0.645	rs6939048	chr6:26327953	G/A	cg00631329	chr6:26305371	NA	-0.46	-6.9	-0.53	2.32e-10	Educational attainment;
TGCT	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg24060327	chr5:131705240	SLC22A5	0.64	6.82	0.52	3.52e-10	Acylcarnitine levels;
TGCT	cis	rs9393777	0.920	rs35869525	chr6:26946687	C/T	cg16898833	chr6:26189333	HIST1H4D	1.28	6.15	0.48	9.89e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs736408	0.562	rs1014969	chr3:52808341	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.72	6.65	0.51	8.38e-10	Bipolar disorder;
TGCT	cis	rs11252926	0.537	rs4554800	chr10:458477	G/T	cg18196295	chr10:418757	DIP2C	-0.28	-4.76	-0.39	5.28e-6	Psychosis in Alzheimer's disease;
TGCT	cis	rs1577917	0.771	rs3812133	chr6:86354411	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.78	-0.46	5.58e-8	Response to antipsychotic treatment;
TGCT	cis	rs9911578	0.967	rs1267542	chr17:56654690	T/C	cg12560992	chr17:57184187	TRIM37	-0.76	-9.32	-0.64	5.54e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs6582630	0.519	rs8189561	chr12:38296178	G/A	cg26384229	chr12:38710491	ALG10B	0.8	7.04	0.53	1.17e-10	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs17473412	1.000	rs17473944	chr5:122716797	T/C	cg15125798	chr5:122621645	NA	-0.57	-5.13	-0.42	1.08e-6	Total body bone mineral density;
TGCT	cis	rs7582180	0.629	rs11678148	chr2:100966950	A/T	cg08017756	chr2:100939284	LONRF2	-0.3	-4.87	-0.4	3.27e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7264396	0.561	rs6060741	chr20:34571484	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.28	4.75	0.39	5.52e-6	Total cholesterol levels;
TGCT	cis	rs7020830	0.898	rs495863	chr9:37346955	T/C	cg14294708	chr9:37120828	ZCCHC7	1.06	13.82	0.78	7.29e-27	Schizophrenia;
TGCT	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg04944784	chr2:26401820	FAM59B	-0.68	-6.13	-0.48	1.1e-8	Gut microbiome composition (summer);
TGCT	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg21724239	chr8:58056113	NA	0.38	5.12	0.42	1.11e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg18876405	chr7:65276391	NA	0.31	4.79	0.4	4.58e-6	Aortic root size;
TGCT	cis	rs3091242	0.933	rs909833	chr1:25754140	C/G	cg00786635	chr1:25594202	NA	0.57	5.96	0.47	2.4e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs17376456	0.569	rs7735009	chr5:93260865	T/C	cg25358565	chr5:93447407	FAM172A	-0.62	-5.97	-0.47	2.33e-8	Diabetic retinopathy;
TGCT	cis	rs7666738	0.830	rs10028505	chr4:98962310	C/A	cg05340658	chr4:99064831	C4orf37	0.53	5.93	0.47	2.85e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3087591	0.960	rs2952979	chr17:29474298	T/A	cg24425628	chr17:29625626	OMG;NF1	0.47	7.52	0.56	9.75e-12	Hip circumference;
TGCT	cis	rs11031096	0.782	rs7130580	chr11:4169301	G/A	cg18678763	chr11:4115507	RRM1	-0.47	-5.95	-0.47	2.51e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs11249608	0.548	rs7709054	chr5:178462757	C/T	cg21905437	chr5:178450457	ZNF879	0.44	4.55	0.38	1.25e-5	Pubertal anthropometrics;
TGCT	cis	rs10504229	1.000	rs59275611	chr8:58195191	G/A	cg08280861	chr8:58055591	NA	0.37	4.69	0.39	7.18e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg22535103	chr8:58192502	C8orf71	-0.4	-5.0	-0.41	1.94e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1005277	0.505	rs200937	chr10:38135772	T/C	cg25427524	chr10:38739819	LOC399744	-0.37	-7.41	-0.55	1.75e-11	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7044106	0.762	rs7849566	chr9:123460769	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	6.73	0.52	5.66e-10	Hip circumference adjusted for BMI;
TGCT	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg10802521	chr3:52805072	NEK4	-0.71	-8.64	-0.61	2.36e-14	Electroencephalogram traits;
TGCT	cis	rs9326248	1.000	rs7107152	chr11:117056080	C/T	cg26566898	chr11:117069891	TAGLN	-0.34	-5.21	-0.42	7.59e-7	Blood protein levels;
TGCT	cis	rs7714584	1.000	rs10065172	chr5:150227998	C/T	cg22134413	chr5:150180641	NA	0.83	6.53	0.51	1.54e-9	Crohn's disease;
TGCT	cis	rs7524258	0.835	rs7543228	chr1:7306538	G/C	cg07173049	chr1:7289937	CAMTA1	0.29	4.66	0.39	8e-6	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg03806693	chr22:41940476	POLR3H	-1.13	-13.26	-0.77	1.59e-25	Vitiligo;
TGCT	cis	rs644799	0.965	rs499076	chr11:95546341	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	8.74	0.62	1.39e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9894429	0.683	rs112612275	chr17:79552604	C/A	cg21028142	chr17:79581711	NPLOC4	-0.3	-6.96	-0.53	1.79e-10	Eye color traits;
TGCT	trans	rs3780486	0.505	rs10217267	chr9:33146528	T/C	cg04842962	chr6:43655489	MRPS18A	0.8	8.57	0.61	3.51e-14	IgG glycosylation;
TGCT	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg19748678	chr4:122722346	EXOSC9	0.89	8.79	0.62	1.02e-14	Type 2 diabetes;
TGCT	cis	rs28595532	0.920	rs115046587	chr4:119779604	T/C	cg11846333	chr4:119757529	SEC24D	0.92	4.64	0.38	8.74e-6	Cannabis dependence symptom count;
TGCT	cis	rs11677416	1.000	rs17561	chr2:113537223	C/A	cg27083787	chr2:113543245	IL1A	0.17	4.46	0.37	1.85e-5	Response to antipsychotic treatment in schizophrenia (working memory);
TGCT	cis	rs7917772	0.536	rs12357172	chr10:104388549	C/T	cg05855489	chr10:104503620	C10orf26	-0.58	-4.76	-0.39	5.28e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs548181	0.736	rs543389	chr11:125464841	A/G	cg03464685	chr11:125439445	EI24	1.18	8.27	0.6	1.78e-13	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg03264133	chr6:25882463	NA	-0.61	-5.53	-0.44	1.79e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs76878669	0.561	rs7117630	chr11:66154777	C/T	cg18002602	chr11:66138449	SLC29A2	-0.53	-6.54	-0.51	1.43e-9	Educational attainment (years of education);
TGCT	cis	rs7364180	0.515	rs6002503	chr22:42208672	A/G	cg06634786	chr22:41940651	POLR3H	-0.51	-4.85	-0.4	3.57e-6	Alzheimer's disease biomarkers;
TGCT	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg08219700	chr8:58056026	NA	0.3	4.64	0.38	8.7e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4953076	0.573	rs7593987	chr2:44393532	C/T	cg04920474	chr2:44395004	PPM1B	-0.6	-6.01	-0.47	1.93e-8	Height;
TGCT	cis	rs317865	0.748	rs73234656	chr4:16212702	G/A	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.79	5.25	0.43	6.38e-7	Kidney disease (early stage) in type 1 diabetes;
TGCT	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.49	-6.74	-0.52	5.34e-10	Alzheimer's disease;
TGCT	cis	rs12541335	0.639	rs3923433	chr8:22169798	A/T	cg02788857	chr8:22132959	PIWIL2	0.27	5.06	0.41	1.45e-6	Hypertriglyceridemia;
TGCT	cis	rs2050392	0.630	rs303426	chr10:30740379	A/G	cg18806716	chr10:30721971	MAP3K8	0.44	4.69	0.39	6.96e-6	Inflammatory bowel disease;
TGCT	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg11905131	chr22:24372483	LOC391322	0.89	10.29	0.68	2.56e-18	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs62103177	0.608	rs4442895	chr18:77826399	C/G	cg07235805	chr18:78004237	PARD6G	-0.47	-4.58	-0.38	1.1e-5	Opioid sensitivity;
TGCT	cis	rs7647973	1.000	rs6785045	chr3:49435243	G/C	cg06212747	chr3:49208901	KLHDC8B	-0.59	-4.72	-0.39	6.19e-6	Menarche (age at onset);
TGCT	cis	rs17376456	0.877	rs2085960	chr5:93399934	A/G	cg21475434	chr5:93447410	FAM172A	0.59	4.66	0.39	8.09e-6	Diabetic retinopathy;
TGCT	cis	rs10883723	0.775	rs7917158	chr10:104246471	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs344364	0.511	rs2982452	chr16:1949511	G/A	cg26617929	chr16:1858877	NA	-0.27	-4.9	-0.4	2.99e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs1008375	0.933	rs6449324	chr4:17694880	G/C	cg18681998	chr4:17616180	MED28	0.76	7.18	0.54	5.69e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg00814883	chr7:100076585	TSC22D4	-0.83	-8.34	-0.6	1.18e-13	Platelet count;
TGCT	cis	rs6893300	0.506	rs35320050	chr5:179131013	C/T	cg14593053	chr5:179126677	CANX	0.47	5.27	0.43	5.73e-7	Resting heart rate;
TGCT	cis	rs12765878	0.580	rs2295786	chr10:105616482	A/T	cg11005552	chr10:105648138	OBFC1	-0.39	-6.07	-0.48	1.43e-8	Coronary artery disease;
TGCT	cis	rs931608	0.640	rs4932758	chr19:22540094	G/A	cg15554505	chr19:22123728	NA	-0.63	-4.57	-0.38	1.18e-5	Dental caries;Response to statins (LDL cholesterol change);
TGCT	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg16680214	chr1:154839983	KCNN3	-0.36	-7.12	-0.54	7.57e-11	Prostate cancer;
TGCT	cis	rs2439831	0.867	rs496584	chr15:43831923	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	6.02	0.48	1.84e-8	Lung cancer in ever smokers;
TGCT	cis	rs9914544	0.545	rs8073436	chr17:18801841	A/G	cg26378065	chr17:18585709	ZNF286B	0.51	4.59	0.38	1.09e-5	Educational attainment (years of education);
TGCT	cis	rs8017423	0.647	rs11626821	chr14:90824945	A/G	cg04374321	chr14:90722782	PSMC1	-0.55	-5.49	-0.44	2.18e-7	Mortality in heart failure;
TGCT	cis	rs2290402	0.536	rs4690203	chr4:881228	C/T	cg11315544	chr4:1222440	CTBP1	0.26	4.46	0.37	1.84e-5	Type 2 diabetes;
TGCT	cis	rs713587	0.713	rs1982200	chr2:25205427	C/T	cg01884057	chr2:25150051	NA	-0.38	-7.81	-0.57	2.04e-12	Body mass index in non-asthmatics;
TGCT	cis	rs7714584	1.000	rs11951694	chr5:150254338	G/A	cg22134413	chr5:150180641	NA	0.83	6.53	0.51	1.54e-9	Crohn's disease;
TGCT	cis	rs3027009	0.881	rs12045546	chr1:159132532	A/G	cg24432768	chr1:158149974	CD1D	0.53	5.01	0.41	1.85e-6	Lean body mass and age at menarche (combined);
TGCT	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	8.99	0.63	3.48e-15	Platelet count;
TGCT	cis	rs13191362	0.938	rs13192618	chr6:163132822	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.88	6.98	0.53	1.57e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs911555	0.662	rs4906322	chr14:103879032	A/G	cg23461800	chr14:103021989	NA	-0.33	-4.46	-0.37	1.8e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs67311347	1.000	rs1004655	chr3:40490009	G/A	cg17264618	chr3:40429014	ENTPD3	0.32	4.61	0.38	9.76e-6	Renal cell carcinoma;
TGCT	cis	rs7085104	0.632	rs7096475	chr10:104609676	A/G	cg15744005	chr10:104629667	AS3MT	-0.46	-5.8	-0.46	5.17e-8	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs11688816	0.569	rs7591708	chr2:63022050	T/C	cg17519650	chr2:63277830	OTX1	-0.52	-4.49	-0.37	1.63e-5	Body mass index;
TGCT	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg00484396	chr16:3507460	NAT15	0.43	6.5	0.5	1.74e-9	Tuberculosis;
TGCT	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	9.52	0.65	1.86e-16	Platelet count;
TGCT	cis	rs2204008	0.754	rs11514074	chr12:38401128	C/T	cg13010199	chr12:38710504	ALG10B	0.61	4.82	0.4	4.12e-6	Bladder cancer;
TGCT	cis	rs66561647	0.520	rs13260853	chr8:128911213	C/T	cg11792826	chr8:129160931	MIR1208	0.23	5.15	0.42	1e-6	Hemoglobin concentration;
TGCT	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs17331151	0.573	rs3755801	chr3:52865798	G/A	cg12962167	chr3:53033115	SFMBT1	0.43	4.89	0.4	3.1e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs77861329	1.000	rs352149	chr3:52209530	C/A	cg08692210	chr3:52188851	WDR51A	0.94	4.83	0.4	3.91e-6	Macrophage inflammatory protein 1b levels;
TGCT	cis	rs2228479	0.717	rs1800358	chr16:89809319	T/C	cg26513180	chr16:89883248	FANCA	0.78	4.54	0.38	1.32e-5	Skin colour saturation;
TGCT	cis	rs77106637	0.932	rs17244499	chr11:72629946	C/T	cg03713592	chr11:72463424	ARAP1	-0.82	-5.51	-0.44	1.96e-7	Type 2 diabetes;
TGCT	cis	rs892961	0.932	rs66886702	chr17:75412714	G/A	cg05865280	chr17:75406074	SEPT9	0.28	6.86	0.52	2.9e-10	Airflow obstruction;
TGCT	cis	rs11190604	1.000	rs9419897	chr10:102246125	T/C	cg16342193	chr10:102329863	NA	-0.39	-5.17	-0.42	9.29e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2239547	0.603	rs9870898	chr3:53092375	A/G	cg11645453	chr3:52864694	ITIH4	0.31	4.95	0.41	2.33e-6	Schizophrenia;
TGCT	cis	rs7772486	0.875	rs10457795	chr6:146415665	A/G	cg23711669	chr6:146136114	FBXO30	0.91	9.95	0.67	1.67e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2806561	0.765	rs4333826	chr1:23517514	C/T	cg12483005	chr1:23474871	LUZP1	0.38	4.73	0.39	5.93e-6	Height;
TGCT	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg24060327	chr5:131705240	SLC22A5	-0.56	-5.61	-0.45	1.26e-7	Breast cancer;
TGCT	cis	rs7216064	0.636	rs62084696	chr17:66038181	C/G	cg12091567	chr17:66097778	LOC651250	1.08	8.86	0.62	7.21e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs6733011	0.628	rs1983352	chr2:99454227	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-4.61	-0.38	9.76e-6	Bipolar disorder;
TGCT	cis	rs57920188	0.535	rs10915659	chr1:4092949	G/A	cg20703997	chr1:4087676	NA	0.48	5.7	0.46	8.27e-8	Interleukin-17 levels;
TGCT	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg21951975	chr1:209979733	IRF6	0.66	5.69	0.45	8.77e-8	Cleft lip with or without cleft palate;
TGCT	cis	rs35264875	0.808	rs921675	chr11:68869034	A/G	cg02660097	chr11:68866761	NA	-0.31	-4.96	-0.41	2.3e-6	Blond vs. brown hair color;
TGCT	cis	rs9549367	0.789	rs9549708	chr13:113891887	A/G	cg18105134	chr13:113819100	PROZ	-0.34	-5.52	-0.44	1.9e-7	Platelet distribution width;
TGCT	cis	rs9302001	0.920	rs1359409	chr13:95457725	C/T	cg07483244	chr13:95358924	NA	0.37	4.8	0.4	4.42e-6	Panic disorder;
TGCT	cis	rs6565180	0.926	rs8046445	chr16:30386262	A/G	cg17640201	chr16:30407289	ZNF48	-0.98	-9.41	-0.65	3.46e-16	Tonsillectomy;
TGCT	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.0	7.42	0.55	1.64e-11	Gut microbiome composition (summer);
TGCT	cis	rs4689388	0.853	rs4293850	chr4:6292020	A/C	cg25554036	chr4:6271136	WFS1	0.54	7.5	0.56	1.05e-11	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs929354	0.713	rs6459733	chr7:156930550	G/C	cg05182265	chr7:156933206	UBE3C	-0.39	-8.69	-0.62	1.76e-14	Body mass index;
TGCT	cis	rs1005224	0.853	rs6574251	chr14:76136883	C/T	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.56	-4.89	-0.4	3.08e-6	Large artery stroke;
TGCT	cis	rs17384381	0.700	rs11161617	chr1:85913538	A/G	cg16011679	chr1:85725395	C1orf52	0.84	7.03	0.53	1.21e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7666738	0.830	rs35491210	chr4:99003364	T/C	cg18180107	chr4:99064573	C4orf37	0.51	4.68	0.39	7.37e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg24675658	chr1:53192096	ZYG11B	-0.69	-7.9	-0.58	1.31e-12	Monocyte count;
TGCT	cis	rs7666738	0.830	rs10017201	chr4:98983561	G/A	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs17601876	0.814	rs8038715	chr15:51561120	T/A	cg19946085	chr15:51559439	CYP19A1	-0.33	-5.06	-0.41	1.45e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs9611519	1.000	rs2273085	chr22:41615376	C/T	cg13695892	chr22:41940480	POLR3H	-0.51	-4.71	-0.39	6.49e-6	Neuroticism;
TGCT	cis	rs2657888	0.931	rs7301093	chr12:56933244	G/T	cg23932658	chr12:57637574	STAC3	0.48	4.56	0.38	1.19e-5	Adiponectin levels;
TGCT	cis	rs11741688	0.631	rs4444956	chr5:178325515	A/G	cg08270223	chr5:178322770	ZFP2	-0.4	-5.51	-0.44	2e-7	Sleep duration;
TGCT	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg21724239	chr8:58056113	NA	0.34	4.64	0.38	8.88e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs12477438	0.520	rs1044575	chr2:99812070	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	8.52	0.61	4.42e-14	Chronic sinus infection;
TGCT	cis	rs7772486	0.817	rs2748491	chr6:146327759	T/C	cg23711669	chr6:146136114	FBXO30	0.86	9.55	0.65	1.57e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg11845111	chr2:191398756	TMEM194B	0.41	6.02	0.48	1.85e-8	Pulse pressure;
TGCT	cis	rs9611565	0.879	rs2235845	chr22:41729294	T/G	cg06634786	chr22:41940651	POLR3H	-0.62	-5.93	-0.47	2.82e-8	Vitiligo;
TGCT	trans	rs3780486	1.000	rs10813951	chr9:33128021	C/T	cg04842962	chr6:43655489	MRPS18A	-1.15	-11.47	-0.72	3.37e-21	IgG glycosylation;
TGCT	cis	rs8036030	0.604	rs11852686	chr15:74715205	A/G	cg10253484	chr15:75165896	SCAMP2	-0.6	-5.58	-0.45	1.45e-7	Airflow obstruction;
TGCT	cis	rs79349575	0.783	rs59270107	chr17:47026185	A/T	cg07967210	chr17:47022446	SNF8	0.44	6.13	0.48	1.1e-8	Type 2 diabetes;
TGCT	cis	rs2736345	0.672	rs2618473	chr8:11344127	C/T	cg24861686	chr8:11418058	BLK	-0.22	-4.53	-0.38	1.35e-5	Sjögren's syndrome;Systemic lupus erythematosus;
TGCT	cis	rs6912958	0.515	rs381782	chr6:88040649	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.39	4.48	0.37	1.7e-5	Monocyte percentage of white cells;
TGCT	cis	rs8179	0.620	rs73232029	chr7:92287283	G/C	cg15732164	chr7:92237376	CDK6	-0.29	-5.1	-0.42	1.24e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
TGCT	cis	rs637571	0.510	rs10896052	chr11:65579600	C/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.67	-6.01	-0.48	1.9e-8	Eosinophil percentage of white cells;
TGCT	cis	rs2013441	1.000	rs11870147	chr17:20216095	A/G	cg18979559	chr17:20280153	CCDC144C	-0.46	-4.82	-0.4	4.19e-6	Obesity-related traits;
TGCT	cis	rs739496	0.579	rs73422318	chr12:112275973	C/T	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs17473412	1.000	rs114337292	chr5:122738201	A/C	cg15125798	chr5:122621645	NA	-0.6	-5.38	-0.43	3.61e-7	Total body bone mineral density;
TGCT	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg04287289	chr16:89883240	FANCA	0.93	12.17	0.74	6.69e-23	Vitiligo;
TGCT	cis	rs28595532	0.920	rs56302493	chr4:119772382	A/T	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs9534288	1.000	rs9534288	chr13:46605441	T/C	cg15192986	chr13:46630673	CPB2	-0.51	-6.62	-0.51	9.95e-10	Blood protein levels;
TGCT	cis	rs2404602	0.716	rs12592171	chr15:76755133	G/C	cg26408565	chr15:76604113	ETFA	-0.4	-5.26	-0.43	6.23e-7	Blood metabolite levels;
TGCT	cis	rs861020	0.630	rs655713	chr1:210006438	C/T	cg05527609	chr1:210001259	C1orf107	0.86	7.54	0.56	8.69e-12	Orofacial clefts;
TGCT	cis	rs6138458	1.000	rs1977540	chr20:24900290	G/T	cg26195577	chr20:24973756	C20orf3	-1.2	-12.04	-0.73	1.35e-22	Blood protein levels;
TGCT	cis	rs61332075	0.531	rs11885695	chr2:239338632	G/A	cg08773314	chr2:239334832	ASB1	-0.47	-4.99	-0.41	2.02e-6	Lung function (FEV1/FVC);
TGCT	cis	rs7666738	0.830	rs72882693	chr4:98960804	T/A	cg18180107	chr4:99064573	C4orf37	0.57	5.18	0.42	8.63e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9486719	0.948	rs12203657	chr6:96883285	G/A	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.21	-0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs9883204	0.817	rs11715633	chr3:123129946	G/A	cg04890266	chr3:123102914	ADCY5	0.36	5.08	0.42	1.34e-6	Birth weight;
TGCT	cis	rs4409675	0.576	rs10751725	chr1:28216191	A/C	cg23691781	chr1:28212827	C1orf38	-0.26	-5.32	-0.43	4.68e-7	Corneal astigmatism;
TGCT	cis	rs4499344	0.730	rs434020	chr19:33104070	C/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	8.81	0.62	9.52e-15	Mean platelet volume;
TGCT	cis	rs6545883	0.894	rs12620105	chr2:61512321	A/T	cg15711740	chr2:61764176	XPO1	0.56	4.78	0.39	4.81e-6	Tuberculosis;
TGCT	cis	rs7647973	0.516	rs12490393	chr3:49196132	C/T	cg03060546	chr3:49711283	APEH	0.51	4.82	0.4	4.2e-6	Menarche (age at onset);
TGCT	cis	rs4803468	1.000	rs9304593	chr19:41942875	A/C	cg09537434	chr19:41945824	ATP5SL	0.91	10.21	0.68	3.82e-18	Height;
TGCT	cis	rs7246657	0.722	rs1564206	chr19:38040076	C/T	cg18154014	chr19:37997991	ZNF793	0.69	4.63	0.38	9.25e-6	Coronary artery calcification;
TGCT	cis	rs10927875	0.541	rs1763596	chr1:16343835	C/T	cg22431228	chr1:16359049	CLCNKA	-0.29	-6.01	-0.47	1.92e-8	Dilated cardiomyopathy;
TGCT	cis	rs7086627	0.515	rs10887894	chr10:82209952	A/G	cg00277334	chr10:82204260	NA	-0.54	-8.46	-0.61	6.23e-14	Post bronchodilator FEV1;
TGCT	cis	rs10751667	0.643	rs7396407	chr11:929374	A/T	cg06064525	chr11:970664	AP2A2	-0.35	-8.09	-0.59	4.54e-13	Alzheimer's disease (late onset);
TGCT	cis	rs3772130	0.962	rs17742508	chr3:121559895	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.65	0.39	8.49e-6	Cognitive performance;
TGCT	cis	rs6570726	0.791	rs12208812	chr6:145900924	T/G	cg05347473	chr6:146136440	FBXO30	0.54	5.12	0.42	1.14e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs116095464	0.558	rs56081398	chr5:247318	C/T	cg22857025	chr5:266934	NA	-0.35	-6.87	-0.53	2.7e-10	Breast cancer;
TGCT	cis	rs2562456	0.876	rs11085467	chr19:21751843	A/G	cg25650185	chr19:21324782	ZNF431	-0.66	-5.85	-0.46	4.18e-8	Pain;
TGCT	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg21285383	chr16:89894308	SPIRE2	0.47	7.48	0.56	1.18e-11	Vitiligo;
TGCT	cis	rs9556958	0.635	rs4529985	chr13:99167120	G/C	cg15168958	chr13:99100528	FARP1	0.22	4.94	0.41	2.48e-6	Educational attainment (years of education);
TGCT	cis	rs2070488	0.804	rs1817364	chr3:38474513	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.78	7.96	0.58	9.56e-13	Electrocardiographic conduction measures;
TGCT	cis	rs79387448	0.745	rs59126438	chr2:103165142	T/G	cg09003973	chr2:102972529	NA	0.95	6.15	0.48	9.95e-9	Gut microbiota (bacterial taxa);
TGCT	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg03709012	chr19:19516395	GATAD2A	0.76	6.42	0.5	2.64e-9	Tonsillectomy;
TGCT	cis	rs9902453	0.765	rs2729447	chr17:28099002	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.84	-8.19	-0.59	2.73e-13	Coffee consumption (cups per day);
TGCT	cis	rs904251	0.523	rs2776872	chr6:37482787	C/G	cg25019722	chr6:37503610	NA	-0.52	-7.9	-0.58	1.28e-12	Cognitive performance;
TGCT	cis	rs7119	0.717	rs12904348	chr15:77815738	G/C	cg27398640	chr15:77910606	LINGO1	-0.25	-4.55	-0.38	1.26e-5	Type 2 diabetes;
TGCT	cis	rs921968	0.613	rs1344642	chr2:219555262	G/A	cg02176678	chr2:219576539	TTLL4	-0.35	-4.77	-0.39	5.04e-6	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs225245	0.755	rs6505493	chr17:34028901	A/G	cg05299278	chr17:33885742	SLFN14	0.21	4.5	0.37	1.54e-5	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs589249	0.963	rs682330	chr1:37154795	T/G	cg04012535	chr1:37176647	NA	-0.32	-5.23	-0.43	6.89e-7	Neuroticism (multi-trait analysis);Schizophrenia;
TGCT	cis	rs12579753	0.917	rs11610365	chr12:82218108	C/T	cg07988820	chr12:82153109	PPFIA2	-0.59	-6.21	-0.49	7.45e-9	Resting heart rate;
TGCT	cis	rs7677751	1.000	rs73252946	chr4:55125992	G/A	cg17187183	chr4:55093834	PDGFRA	0.52	5.24	0.43	6.61e-7	Corneal astigmatism;
TGCT	cis	rs826838	0.616	rs7966266	chr12:38626138	G/A	cg26384229	chr12:38710491	ALG10B	-0.54	-4.74	-0.39	5.87e-6	Heart rate;
TGCT	cis	rs8032315	1.000	rs8032315	chr15:91418297	A/T	cg03209642	chr15:91427605	FES	0.45	4.58	0.38	1.11e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg19318889	chr4:1322082	MAEA	0.2	4.74	0.39	5.72e-6	Longevity;
TGCT	cis	rs7829975	0.560	rs56094035	chr8:8551622	G/A	cg15556689	chr8:8085844	FLJ10661	-0.54	-4.61	-0.38	1e-5	Mood instability;
TGCT	cis	rs3820928	0.934	rs60141402	chr2:227761445	A/C	cg11843606	chr2:227700838	RHBDD1	-0.53	-4.68	-0.39	7.31e-6	Pulmonary function;
TGCT	cis	rs9653442	0.675	rs7605430	chr2:100647552	C/G	cg22139774	chr2:100720529	AFF3	0.4	7.17	0.54	6.04e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs10986311	0.775	rs7864941	chr9:127162888	G/A	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.21	-4.91	-0.4	2.83e-6	Vitiligo;
TGCT	cis	rs6089584	1.000	rs6089581	chr20:60562394	G/A	cg13770153	chr20:60521292	NA	-0.44	-5.62	-0.45	1.21e-7	Body mass index;
TGCT	cis	rs2739330	1.000	rs2739330	chr22:24295286	T/C	cg25703541	chr22:24373054	LOC391322	-0.81	-8.68	-0.61	1.84e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs921968	0.643	rs524902	chr2:219433357	A/C	cg02176678	chr2:219576539	TTLL4	0.38	5.48	0.44	2.31e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs9527	0.590	rs10883843	chr10:104947493	C/G	cg04362960	chr10:104952993	NT5C2	0.65	5.59	0.45	1.36e-7	Arsenic metabolism;
TGCT	cis	rs67478160	0.608	rs4906368	chr14:104242397	A/C	cg26031613	chr14:104095156	KLC1	-0.63	-6.38	-0.5	3.18e-9	Schizophrenia;
TGCT	cis	rs4742903	0.935	rs726203	chr9:106906437	A/G	cg21169611	chr9:106856078	SMC2	0.5	4.66	0.39	8.07e-6	High-grade serous ovarian cancer;Breast cancer;
TGCT	cis	rs7172809	0.573	rs17470952	chr15:77700916	G/T	cg22256960	chr15:77711686	NA	-0.5	-4.75	-0.39	5.55e-6	Glucose homeostasis traits;
TGCT	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg03806693	chr22:41940476	POLR3H	1.01	11.44	0.72	3.94e-21	Vitiligo;
TGCT	cis	rs6964587	1.000	rs28735847	chr7:91592755	T/C	cg22709100	chr7:91322751	NA	0.27	4.48	0.37	1.68e-5	Breast cancer;
TGCT	cis	rs2404602	0.647	rs11072626	chr15:77090826	A/G	cg23625390	chr15:77176239	SCAPER	-0.41	-5.12	-0.42	1.14e-6	Blood metabolite levels;
TGCT	trans	rs208520	0.526	rs2881644	chr6:66803535	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.08	16.96	0.84	4.18e-34	Exhaled nitric oxide output;
TGCT	cis	rs919433	0.679	rs6719832	chr2:198533369	C/T	cg00792783	chr2:198669748	PLCL1	-0.53	-4.78	-0.39	4.81e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs9549367	0.789	rs7999579	chr13:113879357	T/C	cg00898013	chr13:113819073	PROZ	-0.39	-4.78	-0.39	4.78e-6	Platelet distribution width;
TGCT	trans	rs1864729	0.818	rs2583510	chr8:98294452	A/G	cg08679828	chr8:102218111	ZNF706	-1.05	-6.92	-0.53	2.16e-10	Estradiol plasma levels (breast cancer);
TGCT	cis	rs10986311	0.609	rs10118498	chr9:127060124	A/G	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.19	4.59	0.38	1.07e-5	Vitiligo;
TGCT	cis	rs514406	0.505	rs6703127	chr1:53180565	C/T	cg01802117	chr1:53393560	SCP2	-0.42	-4.95	-0.41	2.32e-6	Monocyte count;
TGCT	cis	rs858239	0.539	rs2178139	chr7:23191636	A/G	cg05602783	chr7:23145260	KLHL7	-0.63	-4.98	-0.41	2.09e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs11718455	0.767	rs6785433	chr3:43964265	A/G	cg08738300	chr3:44038990	NA	0.75	5.45	0.44	2.55e-7	Coronary artery disease;
TGCT	cis	rs36051895	0.603	rs1590804	chr9:5177573	T/C	cg02405213	chr9:5042618	JAK2	-0.77	-10.92	-0.7	7.2e-20	Pediatric autoimmune diseases;
TGCT	cis	rs3820068	0.581	rs3940061	chr1:15941276	C/T	cg05660106	chr1:15850417	CASP9	0.83	8.16	0.59	3.26e-13	Systolic blood pressure;
TGCT	cis	rs9640161	0.673	rs11773351	chr7:150030963	T/C	cg10018233	chr7:150070692	REPIN1	0.32	4.59	0.38	1.09e-5	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs4879913	0.768	rs2297877	chr9:35604128	C/G	cg18130437	chr9:35658183	CCDC107;RMRP	-0.47	-4.62	-0.38	9.48e-6	Electroencephalogram traits;
TGCT	cis	rs9911578	0.967	rs12944948	chr17:56951474	A/G	cg12560992	chr17:57184187	TRIM37	0.76	9.21	0.64	1.03e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs12701220	0.817	rs59471534	chr7:1085224	G/A	cg07217954	chr7:1067459	C7orf50	-0.47	-4.6	-0.38	1.03e-5	Bronchopulmonary dysplasia;
TGCT	cis	rs5760092	0.755	rs5760096	chr22:24247310	A/G	cg02953382	chr22:24373134	LOC391322	-0.73	-6.75	-0.52	4.94e-10	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs12477438	0.520	rs720229	chr2:99704273	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	10.06	0.67	8.99e-18	Chronic sinus infection;
TGCT	cis	rs10501293	0.703	rs7937137	chr11:43031342	C/T	cg03447554	chr11:43094025	NA	0.44	6.29	0.49	5.05e-9	Cognitive performance;
TGCT	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg12311346	chr5:56204834	C5orf35	-0.65	-6.48	-0.5	1.99e-9	Initial pursuit acceleration;
TGCT	cis	rs9486715	1.000	rs11153085	chr6:97066355	A/T	cg06623918	chr6:96969491	KIAA0776	-1.08	-13.52	-0.77	3.67e-26	Headache;
TGCT	cis	rs6964587	1.000	rs9969198	chr7:91567492	G/T	cg17063962	chr7:91808500	NA	-0.9	-9.67	-0.66	7.91e-17	Breast cancer;
TGCT	cis	rs478304	0.651	rs10896037	chr11:65503424	A/G	cg10518572	chr11:65560635	OVOL1	-0.24	-4.68	-0.39	7.53e-6	Acne (severe);
TGCT	cis	rs3096299	0.967	rs16965692	chr16:89471482	C/T	cg06640241	chr16:89574553	SPG7	0.65	6.21	0.49	7.49e-9	Multiple myeloma (IgH translocation);
TGCT	cis	rs7647973	1.000	rs11710434	chr3:49346130	T/C	cg06212747	chr3:49208901	KLHDC8B	0.59	4.72	0.39	6.22e-6	Menarche (age at onset);
TGCT	cis	rs7552404	1.000	rs4949674	chr1:76213715	C/A	cg10523679	chr1:76189770	ACADM	0.89	9.53	0.65	1.72e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs4689388	0.890	rs4342257	chr4:6290037	G/C	cg00701064	chr4:6280414	WFS1	0.4	5.11	0.42	1.2e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs2404602	0.583	rs3759853	chr15:76587777	C/T	cg26408565	chr15:76604113	ETFA	-0.45	-6.35	-0.5	3.66e-9	Blood metabolite levels;
TGCT	cis	rs644799	0.540	rs10831419	chr11:95478037	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.65	6.26	0.49	5.81e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs2439831	0.867	rs16957627	chr15:43642657	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	6.61	0.51	1e-9	Lung cancer in ever smokers;
TGCT	cis	rs208520	0.690	rs12202401	chr6:66760544	A/G	cg07460842	chr6:66804631	NA	0.96	10.26	0.68	2.92e-18	Exhaled nitric oxide output;
TGCT	cis	rs4253772	0.591	rs6008361	chr22:46652372	A/G	cg09491104	chr22:46646882	C22orf40	0.62	6.49	0.5	1.87e-9	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs2797160	0.547	rs9401836	chr6:125956736	T/C	cg05901451	chr6:126070800	HEY2	-0.62	-5.17	-0.42	9.25e-7	Endometrial cancer;
TGCT	cis	rs12615966	0.872	rs55688943	chr2:105374842	T/A	cg16465502	chr2:105461796	NA	0.81	4.47	0.37	1.76e-5	Pancreatic cancer;
TGCT	cis	rs1949733	0.523	rs4619877	chr4:8543235	G/A	cg13073564	chr4:8508604	NA	0.5	4.94	0.41	2.46e-6	Response to antineoplastic agents;
TGCT	cis	rs6500602	0.893	rs6500598	chr16:4470964	G/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.43	5.29	0.43	5.42e-7	Schizophrenia;
TGCT	cis	rs2172802	1.000	rs11131333	chr4:62456231	T/C	cg04118610	chr4:62707027	LPHN3	-0.41	-4.83	-0.4	3.92e-6	Partial epilepsies;
TGCT	cis	rs4319547	0.585	rs7952868	chr12:122846949	A/G	cg08088222	chr12:122070432	ORAI1	0.26	4.62	0.38	9.37e-6	Body mass index;
TGCT	cis	rs2617583	0.530	rs12652860	chr5:1453772	G/T	cg13982541	chr5:1466431	LPCAT1	-0.2	-4.6	-0.38	1.02e-5	Breast cancer;
TGCT	cis	rs13064411	0.696	rs9836396	chr3:113184282	T/C	cg18753928	chr3:113234510	CCDC52	-0.67	-5.46	-0.44	2.45e-7	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs9894429	0.966	rs6565601	chr17:79580173	C/T	cg21028142	chr17:79581711	NPLOC4	0.29	6.81	0.52	3.83e-10	Eye color traits;
TGCT	cis	rs17152411	0.843	rs7895425	chr10:126582653	T/C	cg07906193	chr10:126599966	NA	0.42	5.13	0.42	1.08e-6	Height;
TGCT	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg05785598	chr3:49045655	WDR6	0.36	4.85	0.4	3.7e-6	Menarche (age at onset);
TGCT	cis	rs7193541	0.550	rs28607667	chr16:74476015	C/T	cg01733217	chr16:74700730	RFWD3	-0.64	-6.1	-0.48	1.24e-8	Multiple myeloma;
TGCT	cis	rs11167764	1.000	rs7730511	chr5:141480418	T/C	cg08523384	chr5:141488047	NDFIP1	-0.25	-5.03	-0.41	1.71e-6	Crohn's disease;
TGCT	cis	rs10782582	0.609	rs1159215	chr1:76317869	A/T	cg03433033	chr1:76189801	ACADM	-0.45	-4.57	-0.38	1.16e-5	Daytime sleep phenotypes;
TGCT	cis	rs3793917	0.894	rs36212731	chr10:124214976	G/T	cg09507567	chr10:124027408	NA	0.4	4.92	0.4	2.66e-6	Age-related macular degeneration;
TGCT	cis	rs308403	0.568	rs13101575	chr4:123617561	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.59	5.75	0.46	6.43e-8	Blood protein levels;
TGCT	cis	rs9902453	0.967	rs4356528	chr17:28489670	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	6.56	0.51	1.32e-9	Coffee consumption (cups per day);
TGCT	cis	rs11098499	0.629	rs28369518	chr4:120271630	T/C	cg09307838	chr4:120376055	NA	0.56	5.5	0.44	2.05e-7	Corneal astigmatism;
TGCT	cis	rs1580019	0.844	rs1376290	chr7:32486922	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.9	8.65	0.61	2.27e-14	Cognitive ability;
TGCT	cis	rs11031096	0.617	rs12288918	chr11:4191466	G/T	cg18678763	chr11:4115507	RRM1	-0.46	-6.03	-0.48	1.78e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs7647973	0.925	rs4955421	chr3:49218888	G/A	cg05785598	chr3:49045655	WDR6	0.38	4.68	0.39	7.48e-6	Menarche (age at onset);
TGCT	cis	rs9308731	0.644	rs10189015	chr2:111918472	G/A	cg04202892	chr2:111875749	ACOXL	0.55	6.46	0.5	2.1e-9	Chronic lymphocytic leukemia;
TGCT	trans	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg17470723	chr8:74884337	TCEB1	0.71	6.77	0.52	4.48e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg12756686	chr19:29218302	NA	0.66	5.13	0.42	1.09e-6	Methadone dose in opioid dependence;
TGCT	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg00343986	chr7:65444356	GUSB	0.23	5.16	0.42	9.66e-7	Aortic root size;
TGCT	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg12564285	chr5:131593104	PDLIM4	-0.39	-4.77	-0.39	5.03e-6	Acylcarnitine levels;
TGCT	cis	rs9811920	0.603	rs2638948	chr3:99501539	G/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.42	4.66	0.39	7.99e-6	Axial length;
TGCT	cis	rs7666738	0.830	rs28802909	chr4:99039410	G/A	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1372520	0.684	rs2619356	chr4:90750844	C/T	cg20003494	chr4:90757398	SNCA	-0.63	-5.09	-0.42	1.3e-6	Neuroticism;
TGCT	cis	rs35306767	0.761	rs11253537	chr10:1010735	G/A	cg20503657	chr10:835505	NA	0.57	6.33	0.49	4.06e-9	Eosinophil percentage of granulocytes;
TGCT	cis	rs9814567	1.000	rs10804632	chr3:134294501	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.91	-8.83	-0.62	8.17e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs3935685	0.874	rs11072662	chr15:77999436	A/G	cg25212270	chr15:78015279	NA	0.26	5.63	0.45	1.16e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg21775007	chr8:11205619	TDH	0.5	4.61	0.38	9.83e-6	Triglycerides;
TGCT	cis	rs6450176	1.000	rs3776706	chr5:53304933	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.49	-4.6	-0.38	1.03e-5	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs12693043	0.967	rs2358639	chr2:175372957	A/G	cg11778734	chr2:175439522	WIPF1	-0.39	-4.83	-0.4	3.96e-6	Urate levels (BMI interaction);
TGCT	cis	rs9611519	0.828	rs9611460	chr22:41418297	T/C	cg03806693	chr22:41940476	POLR3H	-0.7	-6.07	-0.48	1.41e-8	Neuroticism;
TGCT	cis	rs60154123	0.764	rs1418257	chr1:210452846	G/A	cg22029157	chr1:209979665	IRF6	0.68	4.7	0.39	6.88e-6	Coronary artery disease;
TGCT	cis	rs1801251	0.778	rs2592116	chr2:233735709	G/A	cg25237894	chr2:233734115	C2orf82	-0.29	-5.63	-0.45	1.14e-7	Coronary artery disease;
TGCT	cis	rs7772486	0.790	rs6570724	chr6:146151283	T/C	cg05347473	chr6:146136440	FBXO30	0.5	4.72	0.39	6.31e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7267979	1.000	rs2500424	chr20:25391969	C/T	cg16686733	chr20:25566563	NINL	-0.59	-6.0	-0.47	2.04e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9393777	0.513	rs11967852	chr6:26612870	G/T	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.49	-4.45	-0.37	1.9e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs425277	0.958	rs262688	chr1:2113565	T/G	cg24578937	chr1:2090814	PRKCZ	0.31	7.78	0.57	2.37e-12	Height;
TGCT	cis	rs1867631	1.000	rs1867631	chr1:67046126	C/A	cg13052034	chr1:66999238	SGIP1	0.56	4.79	0.39	4.75e-6	Menopause (age at onset);
TGCT	cis	rs4700695	0.668	rs36837	chr5:65480007	C/A	cg21114390	chr5:65439923	SFRS12	-0.79	-7.23	-0.54	4.31e-11	Facial morphology (factor 19);
TGCT	cis	rs8070740	0.898	rs4605225	chr17:5324136	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.47	4.61	0.38	9.92e-6	Menopause (age at onset);
TGCT	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg04267008	chr7:1944627	MAD1L1	0.38	5.04	0.41	1.62e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs4888262	0.526	rs4887776	chr16:74635632	A/G	cg01733217	chr16:74700730	RFWD3	0.74	7.42	0.55	1.6e-11	Testicular germ cell tumor;
TGCT	cis	rs826838	1.000	rs10506122	chr12:38699232	A/G	cg13010199	chr12:38710504	ALG10B	0.67	5.42	0.44	2.94e-7	Heart rate;
TGCT	cis	rs7216064	1.000	rs2046323	chr17:65849927	T/G	cg12091567	chr17:66097778	LOC651250	-0.83	-6.49	-0.5	1.9e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs6490294	0.904	rs12423061	chr12:112404895	C/T	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Mean platelet volume;
TGCT	cis	rs3796352	1.000	rs71301814	chr3:53117663	G/A	cg15956490	chr3:53032818	SFMBT1	0.56	6.25	0.49	6.01e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs7959452	0.535	rs11177577	chr12:69671791	C/T	cg14784868	chr12:69753453	YEATS4	0.69	7.03	0.53	1.23e-10	Blood protein levels;
TGCT	cis	rs7923452	0.507	rs612802	chr10:30756441	G/A	cg18806716	chr10:30721971	MAP3K8	-0.55	-6.7	-0.52	6.64e-10	Itch intensity from mosquito bite;
TGCT	cis	rs2153535	0.541	rs6923558	chr6:8461467	T/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs2677744	0.597	rs16945091	chr15:91499081	A/T	cg22570213	chr15:91497863	RCCD1	0.4	4.93	0.4	2.6e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs986417	0.818	rs4901993	chr14:61081453	G/A	cg27398547	chr14:60952738	C14orf39	1.33	9.79	0.66	4e-17	Gut microbiota (bacterial taxa);
TGCT	cis	rs4273100	0.834	rs59415593	chr17:19223224	T/G	cg01534423	chr17:18965556	NA	0.92	5.96	0.47	2.42e-8	Schizophrenia;
TGCT	cis	rs9581857	0.579	rs3759433	chr13:27997999	C/T	cg22138327	chr13:27999177	GTF3A	0.84	7.14	0.54	7.01e-11	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs587847	0.737	rs4924153	chr15:37666010	A/T	cg12309653	chr15:37170454	LOC145845	-0.3	-4.44	-0.37	1.95e-5	Intraocular pressure;
TGCT	cis	rs8014204	1.000	rs10483863	chr14:75322327	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.63	-5.97	-0.47	2.35e-8	Caffeine consumption;
TGCT	cis	rs7249142	0.562	rs10854009	chr19:19284705	A/C	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.45	-4.5	-0.37	1.56e-5	IgG glycosylation;
TGCT	cis	rs709400	0.663	rs11628969	chr14:103940911	G/A	cg26031613	chr14:104095156	KLC1	0.85	9.72	0.66	5.87e-17	Body mass index;
TGCT	cis	rs9858542	0.953	rs9859556	chr3:49455986	G/T	cg03060546	chr3:49711283	APEH	-0.62	-5.47	-0.44	2.4e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg11494091	chr17:61959527	GH2	0.61	14.07	0.78	1.86e-27	Prudent dietary pattern;
TGCT	cis	rs9911578	0.842	rs12450766	chr17:56832965	G/C	cg12560992	chr17:57184187	TRIM37	-0.72	-7.51	-0.56	1.01e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs10791097	0.967	rs10894268	chr11:130717153	C/T	cg05962950	chr11:130786565	SNX19	0.73	7.82	0.57	1.97e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs7727544	0.606	rs10058074	chr5:131686146	G/A	cg24060327	chr5:131705240	SLC22A5	-0.5	-5.39	-0.44	3.44e-7	Blood metabolite levels;
TGCT	cis	rs6840360	0.593	rs4696107	chr4:152606823	G/A	cg22705602	chr4:152727874	NA	-0.32	-5.27	-0.43	5.96e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs34467563	1.000	rs12541366	chr8:97398842	A/T	cg15747595	chr8:98289880	TSPYL5	0.41	4.44	0.37	1.99e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3749237	0.595	rs1464568	chr3:49458266	G/A	cg03060546	chr3:49711283	APEH	0.75	8.62	0.61	2.66e-14	Resting heart rate;
TGCT	cis	rs12134245	0.747	rs35654098	chr1:92001452	T/A	cg25838465	chr1:92012736	NA	-0.41	-6.57	-0.51	1.23e-9	Breast cancer;
TGCT	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg07507251	chr3:52567010	NT5DC2	0.48	6.76	0.52	4.9e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs6074578	0.679	rs4142303	chr20:139841	A/T	cg16931068	chr20:139680	DEFB127	-0.26	-4.7	-0.39	6.68e-6	Hirschsprung disease;
TGCT	cis	rs11122272	0.766	rs2486732	chr1:231531476	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.19	-0.54	5.3e-11	Hemoglobin concentration;
TGCT	cis	rs1953600	0.540	rs2784773	chr10:81919800	A/G	cg01528321	chr10:82214614	TSPAN14	0.57	5.51	0.44	2.01e-7	Sarcoidosis;
TGCT	cis	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg07424592	chr7:64974309	NA	1.34	8.08	0.59	4.95e-13	Diabetic kidney disease;
TGCT	cis	rs208520	1.000	rs12216109	chr6:66987488	C/G	cg07460842	chr6:66804631	NA	0.78	6.82	0.52	3.61e-10	Exhaled nitric oxide output;
TGCT	cis	rs1577917	0.771	rs2842607	chr6:86345039	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.58	-0.45	1.43e-7	Response to antipsychotic treatment;
TGCT	cis	rs1008375	1.000	rs4698641	chr4:17642630	C/T	cg16339924	chr4:17578868	LAP3	0.63	5.26	0.43	6.22e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7829975	0.517	rs12542733	chr8:8824858	G/T	cg08975724	chr8:8085496	FLJ10661	-0.57	-4.98	-0.41	2.06e-6	Mood instability;
TGCT	cis	rs4805272	0.962	rs8110833	chr19:29322794	A/G	cg15000279	chr19:29285009	NA	-0.52	-5.61	-0.45	1.28e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
TGCT	cis	rs4478858	0.735	rs11576621	chr1:31795460	A/G	cg00250761	chr1:31883323	NA	-0.27	-4.84	-0.4	3.76e-6	Alcohol dependence;
TGCT	cis	rs9948	0.786	rs6756482	chr2:97458561	A/G	cg01990225	chr2:97406019	LMAN2L	-0.76	-4.76	-0.39	5.32e-6	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs1577917	0.958	rs11755048	chr6:86514334	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.22	-0.42	7.15e-7	Response to antipsychotic treatment;
TGCT	cis	rs13022357	1.000	rs2042497	chr2:160085788	T/C	cg00168785	chr2:160142643	WDSUB1	0.46	4.6	0.38	1.04e-5	Sudden cardiac arrest;
TGCT	cis	rs7666738	0.830	rs11097609	chr4:99011707	C/T	cg17366294	chr4:99064904	C4orf37	0.68	7.04	0.53	1.17e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs988913	1.000	rs6902422	chr6:54811210	C/T	cg04690482	chr6:54711388	FAM83B	-0.29	-4.44	-0.37	1.97e-5	Menarche (age at onset);
TGCT	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg06481639	chr22:41940642	POLR3H	-0.72	-6.52	-0.51	1.61e-9	Vitiligo;
TGCT	cis	rs2354432	0.505	rs3737845	chr1:146724408	A/G	cg25205988	chr1:146714368	CHD1L	1.35	5.95	0.47	2.5e-8	Mitochondrial DNA levels;
TGCT	trans	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg21659725	chr3:3221576	CRBN	-0.75	-9.19	-0.64	1.13e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs7586879	0.521	rs1865689	chr2:25108197	C/T	cg01884057	chr2:25150051	NA	-0.29	-5.57	-0.45	1.51e-7	Body mass index;
TGCT	cis	rs3751972	0.911	rs2191058	chr17:26232917	T/C	cg02948944	chr17:26242737	NA	0.51	7.12	0.54	7.68e-11	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs9611519	0.894	rs9611486	chr22:41458784	C/G	cg13695892	chr22:41940480	POLR3H	-0.54	-4.75	-0.39	5.56e-6	Neuroticism;
TGCT	cis	rs10779751	1.000	rs4845986	chr1:11288633	G/C	cg08854313	chr1:11322531	MTOR	0.96	10.11	0.67	6.65e-18	Body mass index;
TGCT	cis	rs7267979	0.844	rs2424703	chr20:25270124	G/A	cg14121845	chr20:25566513	NINL	0.45	4.6	0.38	1.02e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11679640	0.543	rs10208080	chr2:43106956	A/G	cg00484711	chr2:42331922	NA	0.2	4.48	0.37	1.65e-5	White matter hyperintensity burden;
TGCT	cis	rs12477438	0.520	rs11695379	chr2:99742161	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.01	12.33	0.74	2.69e-23	Chronic sinus infection;
TGCT	cis	rs999943	0.810	rs62407648	chr6:33622436	C/G	cg14003231	chr6:33640908	ITPR3	0.4	4.92	0.4	2.69e-6	Obesity (extreme);
TGCT	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg04267008	chr7:1944627	MAD1L1	-0.37	-4.98	-0.41	2.08e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs36405	1.000	rs36404	chr14:72358082	C/A	cg10066683	chr14:71515513	PCNX	0.24	4.7	0.39	6.69e-6	Yang-deficiency constitution;
TGCT	cis	rs4372836	0.828	rs6728459	chr2:28999336	A/G	cg09522027	chr2:28974177	PPP1CB	-0.72	-6.02	-0.48	1.86e-8	Body mass index;
TGCT	cis	rs1395	0.744	rs57881048	chr2:27474165	T/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.62	7.72	0.57	3.38e-12	Blood metabolite levels;
TGCT	cis	rs36051895	0.522	rs12341844	chr9:5177872	C/T	cg02405213	chr9:5042618	JAK2	-0.74	-10.38	-0.68	1.47e-18	Pediatric autoimmune diseases;
TGCT	cis	rs67311347	0.955	rs6764102	chr3:40378153	C/G	cg17264618	chr3:40429014	ENTPD3	0.31	4.46	0.37	1.81e-5	Renal cell carcinoma;
TGCT	cis	rs7611238	0.560	rs12054406	chr3:195038772	G/A	cg27323046	chr3:195102265	ACAP2	0.36	4.9	0.4	2.94e-6	Body mass index;
TGCT	cis	rs9486719	1.000	rs11152959	chr6:96900272	C/T	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.86	-0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs9583531	0.891	rs9515270	chr13:111352073	C/T	cg24331049	chr13:111365604	ING1	-0.71	-4.65	-0.38	8.54e-6	Coronary artery disease;
TGCT	cis	rs3796352	1.000	rs113995589	chr3:53132372	A/T	cg15956490	chr3:53032818	SFMBT1	0.54	6.37	0.5	3.42e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs9611565	1.000	rs5751086	chr22:41768862	C/T	cg06481639	chr22:41940642	POLR3H	-0.51	-4.64	-0.38	8.64e-6	Vitiligo;
TGCT	cis	rs1532993	0.518	rs6812613	chr4:98630198	G/A	cg05340658	chr4:99064831	C4orf37	-0.4	-4.91	-0.4	2.77e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs7953249	0.656	rs2243616	chr12:121406370	G/T	cg02403541	chr12:121454288	C12orf43	-0.63	-5.44	-0.44	2.7e-7	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs1670533	1.000	rs13134921	chr4:1054177	A/G	cg27284194	chr4:1044797	NA	0.67	5.79	0.46	5.37e-8	Recombination rate (females);
TGCT	cis	rs9486715	0.758	rs9386528	chr6:96928514	G/A	cg06623918	chr6:96969491	KIAA0776	-1.04	-11.84	-0.73	4.12e-22	Headache;
TGCT	cis	rs8013055	0.846	rs10136015	chr14:105973469	A/C	cg23356831	chr14:105996513	TMEM121	0.41	6.33	0.49	4.01e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs477895	0.878	rs7478730	chr11:64018827	C/T	cg23719950	chr11:63933701	MACROD1	-0.69	-5.74	-0.46	6.94e-8	Mean platelet volume;
TGCT	cis	rs9814567	1.000	rs11706117	chr3:134212526	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.96	-9.06	-0.63	2.4e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs72720396	0.789	rs12048450	chr1:91199660	G/A	cg13456504	chr1:91191583	NA	0.64	5.34	0.43	4.22e-7	Morning vs. evening chronotype;Chronotype;
TGCT	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg00814883	chr7:100076585	TSC22D4	-0.92	-9.69	-0.66	7.12e-17	Platelet count;
TGCT	cis	rs732765	0.734	rs4899530	chr14:75165825	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.57	-5.0	-0.41	1.93e-6	Non-small cell lung cancer;
TGCT	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg18305652	chr10:134549665	INPP5A	0.34	5.79	0.46	5.31e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs7937612	1.000	rs7478880	chr11:120261791	C/T	cg24566217	chr11:120254723	ARHGEF12	-0.28	-4.5	-0.37	1.53e-5	Intraocular pressure;
TGCT	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg24060327	chr5:131705240	SLC22A5	-0.58	-5.92	-0.47	2.93e-8	Breast cancer;
TGCT	cis	rs3540	0.960	rs2238327	chr15:91012949	G/A	cg22089800	chr15:90895588	ZNF774	0.74	6.91	0.53	2.27e-10	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg26516362	chr5:178986906	RUFY1	0.44	4.91	0.4	2.84e-6	Lung cancer;
TGCT	cis	rs9581857	0.547	rs75783371	chr13:28109961	T/C	cg22138327	chr13:27999177	GTF3A	0.7	4.53	0.38	1.36e-5	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs6684514	1.000	rs12041164	chr1:156279811	G/A	cg20302342	chr1:156215951	PAQR6	0.36	4.77	0.39	5.1e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs35306767	0.903	rs34270014	chr10:904666	T/C	cg20503657	chr10:835505	NA	0.75	10.41	0.68	1.3e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs9399401	0.667	rs34018047	chr6:142790873	G/C	cg03128060	chr6:142623767	GPR126	0.37	4.54	0.38	1.33e-5	Chronic obstructive pulmonary disease;
TGCT	cis	rs6545977	0.527	rs2710647	chr2:63213970	T/C	cg17519650	chr2:63277830	OTX1	0.71	7.11	0.54	8.2e-11	Prostate cancer;
TGCT	cis	rs8002180	0.959	rs9590229	chr13:95923399	C/T	cg24476569	chr13:95954382	ABCC4	0.41	5.07	0.41	1.42e-6	Blood metabolite levels;
TGCT	cis	rs4273100	0.512	rs1355128	chr17:19299144	G/A	cg03910582	chr17:19030146	GRAPL	-0.43	-5.78	-0.46	5.6e-8	Schizophrenia;
TGCT	cis	rs10782582	0.593	rs6675076	chr1:76118503	A/C	cg10523679	chr1:76189770	ACADM	-0.68	-7.22	-0.54	4.52e-11	Daytime sleep phenotypes;
TGCT	cis	rs523522	0.923	rs10774553	chr12:120954984	T/C	cg27279351	chr12:120934652	DYNLL1	0.76	6.59	0.51	1.15e-9	High light scatter reticulocyte count;
TGCT	cis	rs7666738	0.830	rs4334758	chr4:98971875	A/G	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7666738	0.830	rs28465658	chr4:99035866	T/C	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2153535	0.580	rs9393033	chr6:8521446	G/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.01	0.41	1.86e-6	Motion sickness;
TGCT	cis	rs17293817	0.650	rs12778422	chr10:1413776	A/G	cg19299265	chr10:1975631	NA	0.27	4.6	0.38	1.04e-5	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg22920501	chr2:26401640	FAM59B	0.77	5.98	0.47	2.26e-8	Gut microbiome composition (summer);
TGCT	cis	rs910187	0.605	rs6122559	chr20:45810617	T/G	cg27589058	chr20:45804311	EYA2	-0.37	-7.96	-0.58	9.41e-13	Migraine;
TGCT	cis	rs12497850	0.931	rs6791542	chr3:48787219	A/G	cg06212747	chr3:49208901	KLHDC8B	0.62	5.75	0.46	6.47e-8	Parkinson's disease;
TGCT	trans	rs877282	0.853	rs12763400	chr10:763617	C/T	cg22713356	chr15:30763199	NA	1.2	9.39	0.64	3.76e-16	Uric acid levels;
TGCT	cis	rs8042680	0.554	rs6496746	chr15:91532869	C/A	cg22570213	chr15:91497863	RCCD1	0.42	4.51	0.38	1.51e-5	Type 2 diabetes;
TGCT	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg06108461	chr20:60628389	TAF4	-0.69	-10.77	-0.7	1.71e-19	Body mass index;
TGCT	cis	rs12479064	0.724	rs3792143	chr2:100057020	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.71	-6.02	-0.48	1.85e-8	Chronic sinus infection;
TGCT	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg03709012	chr19:19516395	GATAD2A	0.75	6.2	0.49	7.59e-9	Tonsillectomy;
TGCT	cis	rs7552404	0.924	rs1146581	chr1:76213024	T/G	cg10523679	chr1:76189770	ACADM	0.84	9.32	0.64	5.67e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs910316	0.646	rs11546525	chr14:75537381	C/T	cg08847533	chr14:75593920	NEK9	0.7	6.59	0.51	1.14e-9	Height;
TGCT	cis	rs1218582	0.510	rs2878411	chr1:154823545	C/T	cg06221963	chr1:154839813	KCNN3	-0.55	-7.64	-0.57	5.13e-12	Prostate cancer;
TGCT	cis	rs7666738	0.830	rs35752787	chr4:98935202	G/A	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3026101	0.671	rs748486	chr17:5290824	C/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	4.57	0.38	1.16e-5	Body mass index;
TGCT	cis	rs916888	0.697	rs199516	chr17:44856485	C/T	cg15921436	chr17:44337874	NA	-0.51	-7.04	-0.53	1.17e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg10876282	chr6:28092338	ZSCAN16	0.51	4.79	0.39	4.75e-6	Cardiac Troponin-T levels;
TGCT	cis	rs3749237	0.595	rs11130196	chr3:49490149	A/C	cg02487422	chr3:49467188	NICN1	0.58	5.92	0.47	3e-8	Resting heart rate;
TGCT	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg27211696	chr2:191398769	TMEM194B	-0.27	-5.03	-0.41	1.71e-6	Pulse pressure;
TGCT	cis	rs28595532	0.920	rs17258050	chr4:119672019	G/A	cg21605333	chr4:119757512	SEC24D	1.33	7.24	0.55	4.06e-11	Cannabis dependence symptom count;
TGCT	cis	rs8014204	0.566	rs12587457	chr14:75164141	C/T	cg06637938	chr14:75390232	RPS6KL1	0.62	5.6	0.45	1.33e-7	Caffeine consumption;
TGCT	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg20607798	chr8:58055168	NA	0.45	4.68	0.39	7.47e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs3733585	0.638	rs17185835	chr4:9958180	T/G	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.68	-0.51	7.16e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs877282	0.898	rs2004478	chr10:770709	C/A	cg17470449	chr10:769945	NA	0.32	4.93	0.4	2.56e-6	Uric acid levels;
TGCT	cis	rs9911578	1.000	rs9911578	chr17:56953147	C/T	cg12560992	chr17:57184187	TRIM37	0.76	9.21	0.64	1.03e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg10150615	chr22:24372951	LOC391322	-0.76	-8.15	-0.59	3.33e-13	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs13191362	0.935	rs34141091	chr6:162953893	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.67	5.16	0.42	9.64e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs3096299	0.503	rs9940093	chr16:89558705	G/A	cg08392591	chr16:89556376	ANKRD11	0.55	5.27	0.43	5.97e-7	Multiple myeloma (IgH translocation);
TGCT	cis	rs10214930	0.553	rs6943712	chr7:27917884	T/C	cg05786569	chr7:27702416	HIBADH	0.75	5.17	0.42	9.13e-7	Hypospadias;
TGCT	cis	rs2204008	0.837	rs12370891	chr12:37984531	A/G	cg13010199	chr12:38710504	ALG10B	0.65	5.29	0.43	5.47e-7	Bladder cancer;
TGCT	cis	rs6964587	1.000	rs2188154	chr7:91595138	T/A	cg22709100	chr7:91322751	NA	0.27	4.48	0.37	1.68e-5	Breast cancer;
TGCT	cis	rs42648	0.806	rs6951894	chr7:89893945	A/G	cg25739043	chr7:89950458	NA	-0.53	-4.71	-0.39	6.61e-6	Homocysteine levels;
TGCT	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg00149659	chr3:10157352	C3orf10	0.73	4.72	0.39	6.17e-6	Alzheimer's disease;
TGCT	cis	rs6582630	0.555	rs10785454	chr12:38476260	C/T	cg26384229	chr12:38710491	ALG10B	0.83	7.6	0.56	6.18e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs308403	0.509	rs1849430	chr4:123674701	C/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.82	11.78	0.73	5.72e-22	Blood protein levels;
TGCT	cis	rs6911131	0.730	rs12206238	chr6:143867406	C/T	cg26846959	chr6:143998958	PHACTR2	0.84	4.52	0.38	1.44e-5	Response to paliperidone in schizophrenia (positive Marder score);
TGCT	cis	rs9435341	0.896	rs1730851	chr1:107596443	A/G	cg09367891	chr1:107599246	PRMT6	-0.61	-5.35	-0.43	4.09e-7	Facial morphology (factor 21, depth of nasal alae);
TGCT	cis	rs950027	0.549	rs11070452	chr15:45594836	C/A	cg14582100	chr15:45693742	SPATA5L1	-0.47	-5.85	-0.46	4.14e-8	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs7647973	0.592	rs6774202	chr3:49687779	T/G	cg05785598	chr3:49045655	WDR6	0.42	5.24	0.43	6.67e-7	Menarche (age at onset);
TGCT	cis	rs35306767	0.953	rs11253517	chr10:970524	A/G	cg20503657	chr10:835505	NA	-0.65	-9.23	-0.64	9.26e-16	Eosinophil percentage of granulocytes;
TGCT	cis	rs9560113	0.550	rs1163633	chr13:112231561	G/T	cg10483660	chr13:112241077	NA	-0.31	-4.94	-0.41	2.47e-6	Menarche (age at onset);
TGCT	cis	rs79839061	0.732	rs35177456	chr4:828994	C/T	cg07828340	chr4:882639	GAK	0.4	5.03	0.41	1.71e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs11642862	1.000	rs112691371	chr16:30868216	C/T	cg02466173	chr16:30829666	NA	-0.41	-4.85	-0.4	3.69e-6	Tonsillectomy;
TGCT	cis	rs2153535	0.580	rs6597332	chr6:8504748	C/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg17554472	chr22:41940697	POLR3H	0.49	5.16	0.42	9.72e-7	Vitiligo;
TGCT	cis	rs9611565	0.512	rs5758450	chr22:42141640	G/A	cg13695892	chr22:41940480	POLR3H	0.85	8.06	0.59	5.44e-13	Vitiligo;
TGCT	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg12310025	chr6:25882481	NA	-0.54	-4.78	-0.39	4.83e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7552404	0.731	rs5745445	chr1:76344332	G/A	cg10523679	chr1:76189770	ACADM	0.85	7.88	0.58	1.45e-12	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9560113	0.573	rs9560132	chr13:112237456	C/T	cg10483660	chr13:112241077	NA	0.31	4.92	0.4	2.67e-6	Menarche (age at onset);
TGCT	cis	rs758129	1.000	rs758129	chr15:89900887	A/G	cg24365117	chr15:89879190	POLG	-0.31	-4.54	-0.38	1.3e-5	Schizophrenia;
TGCT	cis	rs9325144	0.647	rs11168741	chr12:38989120	C/T	cg26384229	chr12:38710491	ALG10B	-0.58	-5.55	-0.45	1.67e-7	Morning vs. evening chronotype;
TGCT	cis	rs9814567	1.000	rs2887797	chr3:134202506	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.99	-10.02	-0.67	1.12e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs6912958	0.559	rs2985039	chr6:88041757	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.45	5.88	0.47	3.49e-8	Monocyte percentage of white cells;
TGCT	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.51	-4.82	-0.4	4.16e-6	Bipolar disorder;
TGCT	cis	rs2880765	0.835	rs6497206	chr15:86029225	A/G	cg13263323	chr15:86062960	AKAP13	-0.22	-4.7	-0.39	6.86e-6	Coronary artery disease;
TGCT	cis	rs826838	0.935	rs10875816	chr12:38955014	C/A	cg26384229	chr12:38710491	ALG10B	1.03	10.33	0.68	1.97e-18	Heart rate;
TGCT	cis	rs8031584	0.678	rs798125	chr15:31116800	C/T	cg08109568	chr15:31115862	NA	0.4	5.22	0.42	7.31e-7	Huntington's disease progression;
TGCT	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg17971929	chr21:40555470	PSMG1	0.68	6.1	0.48	1.28e-8	Cognitive function;
TGCT	cis	rs12579753	0.879	rs1987116	chr12:82156478	G/A	cg21231944	chr12:82153410	PPFIA2	-0.34	-4.52	-0.38	1.4e-5	Resting heart rate;
TGCT	cis	rs7103648	0.695	rs10838726	chr11:47568344	C/G	cg20307385	chr11:47447363	PSMC3	0.88	8.62	0.61	2.57e-14	Diastolic blood pressure;Systolic blood pressure;
TGCT	cis	rs2692947	0.537	rs72821435	chr2:96187935	C/T	cg23100626	chr2:96804247	ASTL	0.45	5.33	0.43	4.5e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs644799	0.622	rs1255167	chr11:95500213	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.6	6.5	0.5	1.78e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg25703541	chr22:24373054	LOC391322	-0.59	-4.73	-0.39	5.92e-6	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs9527	0.615	rs11191401	chr10:104573403	A/G	cg15744005	chr10:104629667	AS3MT	-0.49	-5.76	-0.46	6.12e-8	Arsenic metabolism;
TGCT	cis	rs76419734	0.558	rs2305212	chr4:106534691	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.78	4.45	0.37	1.87e-5	Post bronchodilator FEV1;
TGCT	cis	rs7954584	0.531	rs6486781	chr12:122318985	A/C	cg21016266	chr12:122356598	WDR66	0.43	5.65	0.45	1.04e-7	Mean corpuscular volume;
TGCT	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg06634786	chr22:41940651	POLR3H	-0.86	-8.34	-0.6	1.18e-13	Vitiligo;
TGCT	cis	rs6088580	0.619	rs1205335	chr20:32927507	C/T	cg06115741	chr20:33292138	TP53INP2	-0.55	-4.84	-0.4	3.85e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg03517284	chr6:25882590	NA	-0.63	-6.57	-0.51	1.26e-9	Blood metabolite levels;
TGCT	cis	rs4849845	0.653	rs3925970	chr2:121018153	C/A	cg24070213	chr2:121070622	NA	0.35	4.64	0.38	8.58e-6	Mean platelet volume;
TGCT	cis	rs4654899	1.000	rs7543126	chr1:21406088	T/G	cg01072550	chr1:21505969	NA	-0.51	-8.1	-0.59	4.46e-13	Superior frontal gyrus grey matter volume;
TGCT	cis	rs28595532	0.920	rs116246794	chr4:119732491	C/T	cg14228332	chr4:119757509	SEC24D	1.32	6.38	0.5	3.2e-9	Cannabis dependence symptom count;
TGCT	cis	rs7267979	0.586	rs1007707	chr20:25190598	A/G	cg14121845	chr20:25566513	NINL	0.45	4.86	0.4	3.51e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs12497850	0.897	rs9850134	chr3:48957147	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.42	-5.52	-0.44	1.93e-7	Parkinson's disease;
TGCT	cis	rs7666738	0.962	rs2865991	chr4:99067369	C/A	cg17366294	chr4:99064904	C4orf37	0.73	6.51	0.5	1.72e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg03264133	chr6:25882463	NA	-0.66	-6.01	-0.47	1.94e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs12052801	0.648	rs7599687	chr2:68348011	C/T	cg00095431	chr2:67775781	NA	-0.32	-4.63	-0.38	9.18e-6	Schizophrenia;
TGCT	cis	rs12541335	0.639	rs4872468	chr8:22179844	G/C	cg07298985	chr8:22133076	PIWIL2	0.33	5.29	0.43	5.4e-7	Hypertriglyceridemia;
TGCT	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg07332563	chr6:291687	DUSP22	-0.75	-7.74	-0.57	3.04e-12	Menopause (age at onset);
TGCT	cis	rs4072705	0.646	rs915034	chr9:127244955	G/A	cg13476313	chr9:127244764	NR5A1	0.31	5.09	0.42	1.29e-6	Menarche (age at onset);
TGCT	trans	rs210152	0.588	rs1755040	chr6:33495175	A/C	cg08795360	chr21:41033440	B3GALT5	-0.44	-6.68	-0.51	7.12e-10	Schizophrenia;
TGCT	cis	rs11190604	0.767	rs10883489	chr10:102194532	T/C	cg16342193	chr10:102329863	NA	-0.41	-5.22	-0.42	7.22e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9916302	0.706	rs12950186	chr17:37393395	A/C	cg07936489	chr17:37558343	FBXL20	-0.83	-6.26	-0.49	5.7e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg23758822	chr17:41437982	NA	0.71	6.75	0.52	5.16e-10	Menopause (age at onset);
TGCT	cis	rs7635838	0.855	rs9816564	chr3:11475297	T/C	cg00170343	chr3:11313890	ATG7	0.66	6.3	0.49	4.75e-9	HDL cholesterol;
TGCT	cis	rs2070488	0.775	rs4679066	chr3:38568527	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.71	-6.89	-0.53	2.46e-10	Electrocardiographic conduction measures;
TGCT	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg11494091	chr17:61959527	GH2	0.6	14.54	0.79	1.46e-28	Prudent dietary pattern;
TGCT	cis	rs7811142	1.000	rs6972167	chr7:100080013	G/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.07	-9.54	-0.65	1.69e-16	Platelet count;
TGCT	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg08736216	chr1:53307985	ZYG11A	-0.23	-4.7	-0.39	6.81e-6	Monocyte count;
TGCT	cis	rs986417	0.748	rs4381505	chr14:61035968	C/T	cg27398547	chr14:60952738	C14orf39	1.33	10.37	0.68	1.56e-18	Gut microbiota (bacterial taxa);
TGCT	cis	rs9894429	0.546	rs9906979	chr17:79608765	A/G	cg21028142	chr17:79581711	NPLOC4	0.29	6.01	0.48	1.9e-8	Eye color traits;
TGCT	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg09436375	chr6:42928200	GNMT	-0.39	-5.03	-0.41	1.67e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs2067615	0.524	rs10778500	chr12:107074410	T/A	cg15890332	chr12:107067104	RFX4	0.29	5.77	0.46	5.9e-8	Heart rate;
TGCT	cis	rs4654899	1.000	rs7550267	chr1:21448792	T/C	cg01072550	chr1:21505969	NA	-0.49	-7.88	-0.58	1.41e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs11096990	0.892	rs6531696	chr4:39191754	A/G	ch.4.37949012R	chr4:38272617	NA	-0.38	-4.62	-0.38	9.31e-6	Cognitive function;
TGCT	cis	rs739496	0.947	rs3742003	chr12:111844218	G/A	cg10833066	chr12:111807467	FAM109A	0.37	5.54	0.45	1.76e-7	Platelet count;
TGCT	cis	rs868036	0.672	rs7175517	chr15:68077630	A/G	cg05925327	chr15:68127851	NA	-0.5	-4.85	-0.4	3.57e-6	Restless legs syndrome;
TGCT	cis	rs13064411	0.696	rs6438156	chr3:113206929	C/A	cg18753928	chr3:113234510	CCDC52	-0.7	-5.64	-0.45	1.08e-7	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs11190604	1.000	rs4919464	chr10:102221195	A/G	cg16342193	chr10:102329863	NA	-0.4	-5.31	-0.43	4.85e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs1008375	0.606	rs6828925	chr4:17561139	C/T	cg16339924	chr4:17578868	LAP3	0.59	5.03	0.41	1.66e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs5760092	0.755	rs11090298	chr22:24262061	G/A	cg25703541	chr22:24373054	LOC391322	0.84	7.2	0.54	5.15e-11	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs2760061	0.583	rs697763	chr1:228192622	G/C	cg02753203	chr1:228287806	NA	0.38	7.5	0.56	1.04e-11	Diastolic blood pressure;
TGCT	cis	rs1552244	0.515	rs6768768	chr3:10177653	C/T	cg00149659	chr3:10157352	C3orf10	0.95	7.06	0.54	1.07e-10	Alzheimer's disease;
TGCT	trans	rs525455	1.000	rs1659839	chr10:13103022	G/T	cg21721093	chr17:8906386	NA	0.64	6.7	0.52	6.38e-10	Platelet aggregation;
TGCT	cis	rs9611565	0.879	rs5758311	chr22:41759375	G/T	cg06634786	chr22:41940651	POLR3H	-0.8	-7.65	-0.57	4.81e-12	Vitiligo;
TGCT	cis	rs6840360	0.550	rs4696289	chr4:152621237	C/T	cg17479576	chr4:152424074	FAM160A1	-0.67	-6.69	-0.52	6.7e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg18230493	chr5:56204884	C5orf35	-0.68	-5.85	-0.46	4.13e-8	Initial pursuit acceleration;
TGCT	cis	rs72945132	0.882	rs2276001	chr11:70181560	T/C	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs9359856	0.510	rs6454775	chr6:90465000	A/T	cg13799429	chr6:90582589	CASP8AP2	0.45	4.66	0.39	7.9e-6	Bipolar disorder;
TGCT	cis	rs6840360	0.642	rs2724578	chr4:152367304	A/G	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.83e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs6933660	0.800	rs9383900	chr6:151782816	A/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.95	-10.84	-0.7	1.14e-19	Menarche (age at onset);
TGCT	cis	rs763014	0.931	rs7192508	chr16:630367	C/T	cg27436995	chr16:743998	FBXL16	-0.45	-4.82	-0.4	4.17e-6	Height;
TGCT	cis	rs7428	0.527	rs7608892	chr2:85542718	G/A	cg03728395	chr2:85555865	TGOLN2	-0.32	-5.51	-0.44	2.02e-7	Ear protrusion;
TGCT	cis	rs17376456	0.542	rs35672980	chr5:93284877	A/T	cg25358565	chr5:93447407	FAM172A	-0.62	-5.97	-0.47	2.33e-8	Diabetic retinopathy;
TGCT	cis	rs8177253	0.507	rs4241357	chr3:133475563	A/C	cg08048268	chr3:133502702	NA	0.38	4.84	0.4	3.76e-6	Iron status biomarkers;
TGCT	cis	rs6088580	0.713	rs1884669	chr20:33171287	G/A	cg08999081	chr20:33150536	PIGU	0.25	4.99	0.41	1.97e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs3820928	0.874	rs56324594	chr2:227868854	C/T	cg11843606	chr2:227700838	RHBDD1	-0.52	-4.63	-0.38	9.03e-6	Pulmonary function;
TGCT	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg24829409	chr8:58192753	C8orf71	-0.57	-4.73	-0.39	6.09e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg19626725	chr5:178986131	RUFY1	0.45	5.7	0.46	8.26e-8	Lung cancer;
TGCT	cis	rs7914558	1.000	rs7077097	chr10:104945463	G/A	cg04362960	chr10:104952993	NT5C2	0.61	5.47	0.44	2.42e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs832540	0.593	rs96844	chr5:56196604	G/A	cg24531977	chr5:56204891	C5orf35	-0.56	-5.05	-0.41	1.57e-6	Coronary artery disease;
TGCT	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg13695892	chr22:41940480	POLR3H	-0.77	-7.47	-0.56	1.24e-11	Vitiligo;
TGCT	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg02487422	chr3:49467188	NICN1	0.53	5.12	0.42	1.13e-6	Menarche (age at onset);
TGCT	cis	rs35306767	0.807	rs72778228	chr10:938435	A/G	cg26597838	chr10:835615	NA	0.81	12.42	0.74	1.61e-23	Eosinophil percentage of granulocytes;
TGCT	cis	rs559928	0.606	rs55942618	chr11:63936005	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	4.56	0.38	1.22e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
TGCT	cis	rs62244186	0.659	rs56234157	chr3:44516221	G/A	cg02073558	chr3:44770973	ZNF501	0.57	5.5	0.44	2.07e-7	Depressive symptoms;
TGCT	cis	rs4711350	0.734	rs7739273	chr6:33758065	G/A	cg13859433	chr6:33739653	LEMD2	-0.33	-4.93	-0.4	2.6e-6	Schizophrenia;
TGCT	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.45	4.84	0.4	3.81e-6	Menopause (age at onset);
TGCT	cis	rs2688608	0.592	rs7909544	chr10:75484004	G/C	cg19442545	chr10:75533431	FUT11	-0.37	-5.77	-0.46	5.89e-8	Inflammatory bowel disease;
TGCT	cis	rs950776	0.518	rs3813572	chr15:78832588	T/C	cg06917634	chr15:78832804	PSMA4	0.95	9.52	0.65	1.81e-16	Sudden cardiac arrest;
TGCT	cis	rs7647973	0.560	rs7638154	chr3:49299375	C/A	cg07636037	chr3:49044803	WDR6	0.88	9.28	0.64	6.89e-16	Menarche (age at onset);
TGCT	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg24675658	chr1:53192096	ZYG11B	-0.75	-9.16	-0.64	1.38e-15	Monocyte count;
TGCT	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg27454412	chr7:1067447	C7orf50	0.6	4.73	0.39	5.89e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9929218	0.559	rs12923775	chr16:68756450	C/T	cg01251360	chr16:68772225	CDH1	-0.26	-4.77	-0.39	5.14e-6	Colorectal cancer;
TGCT	cis	rs9894429	0.646	rs7405870	chr17:79617284	G/A	cg21028142	chr17:79581711	NPLOC4	0.28	5.87	0.47	3.73e-8	Eye color traits;
TGCT	cis	rs950776	0.531	rs12915652	chr15:78831928	G/A	cg06917634	chr15:78832804	PSMA4	0.95	9.33	0.64	5.42e-16	Sudden cardiac arrest;
TGCT	cis	rs6988636	1.000	rs13261066	chr8:124190276	G/A	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg24250549	chr1:154909240	PMVK	0.62	6.28	0.49	5.29e-9	Prostate cancer;
TGCT	cis	rs12220238	1.000	rs12359456	chr10:75937994	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.28	0.55	3.4e-11	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs7552404	0.731	rs12078299	chr1:76365764	T/A	cg10523679	chr1:76189770	ACADM	0.82	7.17	0.54	5.99e-11	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs10089	1.000	rs4836370	chr5:127499224	A/G	cg19767477	chr5:127420684	SLC12A2	-0.44	-4.63	-0.38	9.27e-6	Ileal carcinoids;
TGCT	cis	rs2486012	1.000	rs3011231	chr1:44342235	A/G	cg12908607	chr1:44402522	ARTN	-0.73	-5.67	-0.45	9.51e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs763121	0.785	rs6001203	chr22:39099602	T/C	cg06022373	chr22:39101656	GTPBP1	0.78	8.1	0.59	4.34e-13	Menopause (age at onset);
TGCT	cis	rs1997103	1.000	rs10228182	chr7:55406695	A/T	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs3749237	0.555	rs7637665	chr3:49552295	T/C	cg03060546	chr3:49711283	APEH	0.75	8.62	0.61	2.66e-14	Resting heart rate;
TGCT	cis	rs56309584	0.715	rs78286057	chr17:8152039	C/A	cg08322244	chr17:8066669	VAMP2	-0.58	-5.43	-0.44	2.79e-7	Initial pursuit acceleration;
TGCT	cis	rs6690583	0.562	rs76839162	chr1:85530021	A/G	cg20280350	chr1:85513789	MCOLN3	-0.72	-4.59	-0.38	1.08e-5	Serum sulfate level;
TGCT	cis	rs11122272	0.735	rs2790892	chr1:231512771	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.14	-0.54	6.86e-11	Hemoglobin concentration;
TGCT	cis	rs3796352	0.571	rs71301816	chr3:53142071	G/A	cg15956490	chr3:53032818	SFMBT1	0.52	6.07	0.48	1.43e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs11785400	0.701	rs9721143	chr8:143727511	A/T	cg24634471	chr8:143751801	JRK	0.53	5.33	0.43	4.41e-7	Schizophrenia;
TGCT	cis	rs9486715	0.929	rs7775721	chr6:97056979	C/T	cg06623918	chr6:96969491	KIAA0776	-1.13	-15.01	-0.8	1.13e-29	Headache;
TGCT	cis	rs9653442	0.593	rs6737502	chr2:100862903	C/T	cg22139774	chr2:100720529	AFF3	-0.39	-6.4	-0.5	2.93e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs1525293	0.659	rs12698983	chr7:70509647	G/A	cg21135135	chr7:70597687	WBSCR17	0.48	4.59	0.38	1.05e-5	Colonoscopy-negative controls vs population controls;Major depressive disorder;
TGCT	cis	rs394563	0.726	rs6942381	chr6:149662991	G/C	cg11245181	chr6:149772854	ZC3H12D	0.29	4.7	0.39	6.79e-6	Dupuytren's disease;
TGCT	cis	rs1692580	0.807	rs4648628	chr1:2203490	C/T	cg21194808	chr1:2205498	SKI	0.29	5.54	0.45	1.72e-7	Coronary artery disease;
TGCT	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg18135555	chr8:22132992	PIWIL2	0.3	6.2	0.49	7.71e-9	Hypertriglyceridemia;
TGCT	cis	rs763121	0.819	rs5757126	chr22:38923675	T/C	cg06022373	chr22:39101656	GTPBP1	0.76	7.29	0.55	3.15e-11	Menopause (age at onset);
TGCT	cis	rs4727443	0.966	rs66748925	chr7:99589843	A/G	cg13334819	chr7:99746414	C7orf59	0.54	4.5	0.37	1.55e-5	Interstitial lung disease;
TGCT	cis	rs5167	0.504	rs8100120	chr19:45466058	T/C	cg13119609	chr19:45449297	APOC2	0.23	4.44	0.37	1.94e-5	Blood protein levels;
TGCT	cis	rs11077998	0.869	rs6502123	chr17:80532170	T/C	cg10255544	chr17:80519551	FOXK2	0.24	4.51	0.38	1.5e-5	Reticulocyte fraction of red cells;
TGCT	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg10802521	chr3:52805072	NEK4	-0.66	-7.8	-0.57	2.22e-12	Bipolar disorder;
TGCT	cis	rs308403	0.509	rs6811183	chr4:123671551	T/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.82	11.84	0.73	4.22e-22	Blood protein levels;
TGCT	cis	rs9467603	0.800	rs4236040	chr6:25761209	T/C	cg16898833	chr6:26189333	HIST1H4D	-0.99	-4.75	-0.39	5.62e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg22963979	chr7:1858916	MAD1L1	-0.38	-5.96	-0.47	2.46e-8	Schizophrenia, schizoaffective disorder or bipolar disorder;
TGCT	cis	rs250677	0.652	rs250680	chr5:148436024	T/C	cg18129178	chr5:148520854	ABLIM3	-0.43	-6.29	-0.49	5.05e-9	Breast cancer;
TGCT	cis	rs11030122	0.687	rs10835521	chr11:4056004	A/T	cg18678763	chr11:4115507	RRM1	-0.45	-5.6	-0.45	1.3e-7	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs240764	0.658	rs9485410	chr6:101261007	A/G	cg21058520	chr6:100914733	NA	-0.34	-4.47	-0.37	1.72e-5	Neuroticism;
TGCT	cis	rs2075165	0.836	rs7512751	chr1:156234439	T/G	cg20302342	chr1:156215951	PAQR6	0.38	5.44	0.44	2.72e-7	Tonsillectomy;
TGCT	cis	rs12681287	0.888	rs13042	chr8:87484913	G/A	cg27223183	chr8:87520930	FAM82B	-0.8	-5.99	-0.47	2.13e-8	Caudate activity during reward;
TGCT	cis	rs675209	0.635	rs1334577	chr6:7211751	G/A	cg27097018	chr6:6320614	F13A1	0.37	5.24	0.43	6.62e-7	Urate levels;
TGCT	cis	rs1691799	0.899	rs1168322	chr12:66743769	C/T	cg16791601	chr12:66731901	HELB	-0.28	-6.18	-0.49	8.52e-9	White blood cell count (basophil);
TGCT	cis	rs6087990	0.899	rs4911262	chr20:31393352	G/A	cg13636640	chr20:31349939	DNMT3B	1.09	15.71	0.82	2.82e-31	Ulcerative colitis;
TGCT	cis	rs9308731	0.931	rs616130	chr2:111912681	C/A	cg04202892	chr2:111875749	ACOXL	0.43	4.58	0.38	1.13e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg06634786	chr22:41940651	POLR3H	-0.86	-8.32	-0.6	1.34e-13	Vitiligo;
TGCT	trans	rs1974653	0.672	rs9605063	chr22:20090038	A/C	cg08822737	chr17:71088851	SLC39A11	0.82	7.04	0.53	1.17e-10	Schizophrenia;
TGCT	cis	rs2795502	0.766	rs947549	chr10:43265880	G/C	cg20628663	chr10:43360327	NA	-0.41	-4.81	-0.4	4.3e-6	Blood protein levels;
TGCT	cis	rs10782582	0.609	rs1628063	chr1:76391646	A/G	cg03433033	chr1:76189801	ACADM	-0.47	-4.65	-0.39	8.23e-6	Daytime sleep phenotypes;
TGCT	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.01	8.32	0.6	1.34e-13	Platelet count;
TGCT	cis	rs57221529	0.709	rs4957056	chr5:570105	T/C	cg09021430	chr5:549028	NA	-0.41	-5.69	-0.46	8.58e-8	Lung disease severity in cystic fibrosis;
TGCT	cis	rs9733	0.596	rs72702573	chr1:150689050	C/T	cg04414720	chr1:150670196	GOLPH3L	0.37	4.91	0.4	2.76e-6	Tonsillectomy;
TGCT	cis	rs11627546	0.528	rs59997769	chr14:70362154	T/C	cg10496350	chr14:71275911	MAP3K9	-1.01	-4.93	-0.41	2.54e-6	Red blood cell traits;
TGCT	cis	rs208520	0.874	rs208481	chr6:66922636	A/G	cg07460842	chr6:66804631	NA	-0.9	-9.16	-0.64	1.34e-15	Exhaled nitric oxide output;
TGCT	cis	rs250677	0.687	rs384979	chr5:148459267	C/T	cg18129178	chr5:148520854	ABLIM3	0.42	5.87	0.47	3.8e-8	Breast cancer;
TGCT	cis	rs4478858	0.595	rs4949387	chr1:31803440	T/A	cg00250761	chr1:31883323	NA	-0.28	-4.96	-0.41	2.32e-6	Alcohol dependence;
TGCT	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg15691649	chr6:25882328	NA	-0.42	-5.35	-0.43	4.11e-7	Blood metabolite levels;
TGCT	cis	rs7666738	0.830	rs880472	chr4:98922595	C/A	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7267979	1.000	rs2482927	chr20:25327151	T/C	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs916888	0.821	rs70602	chr17:44859715	T/C	cg17911788	chr17:44343683	NA	0.59	6.13	0.48	1.09e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	trans	rs4919669	0.668	rs10883757	chr10:104400133	C/T	cg24066601	chr6:26271455	HIST1H3G	0.7	6.69	0.51	6.98e-10	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs6920965	0.602	rs10872302	chr6:126180631	G/T	cg05901451	chr6:126070800	HEY2	-0.6	-6.29	-0.49	4.97e-9	High light scatter reticulocyte count;
TGCT	cis	rs7635838	0.785	rs2594972	chr3:11397417	A/G	cg00170343	chr3:11313890	ATG7	0.64	6.15	0.48	9.73e-9	HDL cholesterol;
TGCT	cis	rs11249608	0.548	rs17078988	chr5:178459283	A/G	cg21905437	chr5:178450457	ZNF879	0.44	4.72	0.39	6.21e-6	Pubertal anthropometrics;
TGCT	cis	rs12579753	0.912	rs4417392	chr12:82158722	C/A	cg07988820	chr12:82153109	PPFIA2	-0.68	-7.51	-0.56	1.01e-11	Resting heart rate;
TGCT	cis	rs6540559	0.605	rs3753518	chr1:209977964	G/C	cg22029157	chr1:209979665	IRF6	0.74	5.53	0.44	1.84e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs9611565	0.921	rs6002333	chr22:41719469	C/T	cg03806693	chr22:41940476	POLR3H	-1.0	-11.1	-0.71	2.65e-20	Vitiligo;
TGCT	cis	rs4478858	0.735	rs4949389	chr1:31824023	A/G	cg00250761	chr1:31883323	NA	0.25	4.45	0.37	1.87e-5	Alcohol dependence;
TGCT	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg23708337	chr7:1209742	NA	0.64	5.94	0.47	2.63e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs17376456	0.877	rs13170509	chr5:93378564	T/C	cg25358565	chr5:93447407	FAM172A	0.93	8.37	0.6	1.04e-13	Diabetic retinopathy;
TGCT	cis	rs317689	0.918	rs610192	chr12:69739941	T/C	cg19645103	chr12:69753606	YEATS4	-0.58	-4.66	-0.39	7.99e-6	Response to diuretic therapy;
TGCT	cis	rs4689388	0.926	rs9998519	chr4:6292909	C/T	cg00701064	chr4:6280414	WFS1	0.37	4.72	0.39	6.3e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs9660992	0.710	rs1768587	chr1:205236432	C/T	cg00857998	chr1:205179979	DSTYK	0.52	4.56	0.38	1.19e-5	Mean corpuscular volume;Mean platelet volume;
TGCT	cis	rs56104184	0.775	rs117016425	chr19:49400216	C/T	cg17863274	chr19:49399704	TULP2	-0.54	-7.43	-0.55	1.58e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs992157	0.965	rs13419763	chr2:219134950	C/T	cg00012203	chr2:219082015	ARPC2	0.78	8.24	0.6	2.02e-13	Colorectal cancer;
TGCT	cis	rs11118844	0.793	rs4433402	chr1:221946172	A/G	cg04222084	chr1:221915650	DUSP10	-0.7	-4.96	-0.41	2.25e-6	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
TGCT	cis	rs9858542	1.000	rs9812791	chr3:49682311	G/A	cg03060546	chr3:49711283	APEH	-0.67	-6.09	-0.48	1.28e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs6570726	0.791	rs387376	chr6:145822565	T/C	cg05347473	chr6:146136440	FBXO30	0.53	4.95	0.41	2.4e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1483890	0.632	rs111868405	chr3:69412154	A/T	cg22125112	chr3:69402811	FRMD4B	0.29	4.74	0.39	5.85e-6	Resting heart rate;
TGCT	cis	rs2721195	0.743	rs2306386	chr8:145742879	T/C	cg17328964	chr8:145687451	CYHR1	-0.39	-5.4	-0.44	3.32e-7	Age at first birth;
TGCT	cis	rs6831352	0.918	rs29001211	chr4:100051941	C/T	cg12011299	chr4:100065546	ADH4	-0.41	-4.92	-0.4	2.72e-6	Alcohol dependence;
TGCT	cis	rs2072499	0.750	rs57056972	chr1:156159064	C/A	cg25208724	chr1:156163844	SLC25A44	1.01	9.25	0.64	8.38e-16	Testicular germ cell tumor;
TGCT	cis	rs1008375	1.000	rs114490726	chr4:17680898	T/C	cg18681998	chr4:17616180	MED28	0.91	10.53	0.69	6.55e-19	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7586879	0.687	rs11892869	chr2:25096692	A/T	cg01884057	chr2:25150051	NA	0.31	5.94	0.47	2.72e-8	Body mass index;
TGCT	cis	rs1008375	0.898	rs4698620	chr4:17587361	C/T	cg18681998	chr4:17616180	MED28	0.94	9.56	0.65	1.44e-16	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	trans	rs7824557	0.527	rs2736298	chr8:11235136	C/G	cg15556689	chr8:8085844	FLJ10661	-0.74	-6.7	-0.52	6.42e-10	Retinal vascular caliber;
TGCT	cis	rs4563143	0.675	rs17498203	chr19:29279734	G/T	cg12756686	chr19:29218302	NA	0.78	6.69	0.51	6.93e-10	Methadone dose in opioid dependence;
TGCT	cis	rs7100689	0.725	rs10749574	chr10:82136856	T/C	cg01528321	chr10:82214614	TSPAN14	0.87	8.35	0.6	1.14e-13	Post bronchodilator FEV1;
TGCT	cis	rs1008375	0.966	rs10939735	chr4:17578891	A/G	cg16339924	chr4:17578868	LAP3	0.83	7.21	0.54	4.92e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7412746	0.658	rs72704652	chr1:150819470	A/G	cg04414720	chr1:150670196	GOLPH3L	0.39	4.75	0.39	5.55e-6	Melanoma;
TGCT	cis	rs6964587	1.000	rs4644173	chr7:91759597	A/G	cg17063962	chr7:91808500	NA	0.89	9.48	0.65	2.27e-16	Breast cancer;
TGCT	cis	rs2898290	0.506	rs2736311	chr8:11252170	C/T	cg21775007	chr8:11205619	TDH	-0.62	-6.23	-0.49	6.5e-9	Systolic blood pressure;
TGCT	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg06753367	chr22:24256600	NA	0.24	4.51	0.38	1.5e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2440129	0.611	rs10852889	chr17:6900845	C/T	cg19536664	chr17:6899085	ALOX12	0.39	6.35	0.5	3.67e-9	Tonsillectomy;
TGCT	cis	rs6050267	0.556	rs62217177	chr20:25012178	A/G	cg26195577	chr20:24973756	C20orf3	0.9	6.16	0.48	9.54e-9	Cognitive performance;
TGCT	cis	rs6714710	0.603	rs11684749	chr2:98420142	G/C	cg26665480	chr2:98280029	ACTR1B	0.66	6.24	0.49	6.33e-9	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs7917772	0.503	rs7904955	chr10:104367092	C/T	cg05855489	chr10:104503620	C10orf26	-0.6	-5.28	-0.43	5.49e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg04772025	chr11:68637568	NA	0.59	6.69	0.52	6.73e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs35306767	0.761	rs1871621	chr10:1049596	C/T	cg18964960	chr10:1102726	WDR37	0.78	5.46	0.44	2.45e-7	Eosinophil percentage of granulocytes;
TGCT	trans	rs10506458	0.915	rs1009540	chr12:63414872	C/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.47	-7.59	-0.56	6.63e-12	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs763121	0.889	rs9607557	chr22:39040279	G/A	cg06022373	chr22:39101656	GTPBP1	0.8	8.17	0.59	2.97e-13	Menopause (age at onset);
TGCT	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg06221963	chr1:154839813	KCNN3	-0.76	-13.06	-0.76	4.81e-25	Prostate cancer;
TGCT	cis	rs75686122	0.892	rs75784460	chr8:104710728	T/G	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs10876993	0.890	rs774891	chr12:58068571	G/A	cg15848620	chr12:58087721	OS9	-0.72	-5.91	-0.47	3.12e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs7727544	0.606	rs2631360	chr5:131707429	A/G	cg24060327	chr5:131705240	SLC22A5	-0.51	-5.41	-0.44	3.16e-7	Blood metabolite levels;
TGCT	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg21963583	chr11:68658836	MRPL21	0.36	5.97	0.47	2.28e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.54	-5.1	-0.42	1.22e-6	Electroencephalogram traits;
TGCT	cis	rs9929218	0.906	rs9933844	chr16:68747001	G/A	cg01251360	chr16:68772225	CDH1	0.29	4.71	0.39	6.63e-6	Colorectal cancer;
TGCT	cis	rs4851254	0.961	rs11680586	chr2:100746207	G/T	cg04109781	chr2:100722022	AFF3	0.42	4.56	0.38	1.2e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs11098499	0.570	rs6832740	chr4:120546136	T/C	cg09307838	chr4:120376055	NA	0.62	5.86	0.47	3.86e-8	Corneal astigmatism;
TGCT	cis	rs2721195	0.816	rs4251689	chr8:145741130	C/T	cg17328964	chr8:145687451	CYHR1	-0.44	-6.23	-0.49	6.72e-9	Age at first birth;
TGCT	cis	rs11030122	0.673	rs11030660	chr11:4043268	T/C	cg18678763	chr11:4115507	RRM1	-0.49	-6.11	-0.48	1.19e-8	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs2688608	0.592	rs2306328	chr10:75579510	C/T	cg15838173	chr10:75533400	FUT11	-0.3	-4.83	-0.4	3.97e-6	Inflammatory bowel disease;
TGCT	cis	rs7647973	0.710	rs12637313	chr3:49645458	A/G	cg05785598	chr3:49045655	WDR6	0.41	4.66	0.39	8.03e-6	Menarche (age at onset);
TGCT	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg17178900	chr1:205818956	PM20D1	0.67	9.22	0.64	9.59e-16	Menarche (age at onset);
TGCT	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.54	-0.38	1.33e-5	Bipolar disorder;
TGCT	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.09	13.7	0.78	1.38e-26	Height;
TGCT	cis	rs6598955	0.670	rs3795685	chr1:26601385	A/G	cg04990556	chr1:26633338	UBXN11	0.92	11.91	0.73	2.89e-22	Obesity-related traits;
TGCT	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg18876405	chr7:65276391	NA	0.31	4.79	0.4	4.58e-6	Aortic root size;
TGCT	cis	rs7226408	0.857	rs11660125	chr18:34476622	A/G	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs6121246	0.559	rs6058352	chr20:30269179	T/C	cg13852791	chr20:30311386	BCL2L1	0.82	8.0	0.58	7.65e-13	Mean corpuscular hemoglobin;
TGCT	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg26354017	chr1:205819088	PM20D1	0.53	6.31	0.49	4.43e-9	Menarche (age at onset);
TGCT	cis	rs11122272	0.701	rs2883799	chr1:231531166	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-6.34	-0.49	3.83e-9	Hemoglobin concentration;
TGCT	cis	rs13223928	0.538	rs10951042	chr7:3139417	T/C	cg19214707	chr7:3157722	NA	-0.47	-6.77	-0.52	4.53e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
TGCT	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg05665937	chr4:1216051	CTBP1	0.25	4.96	0.41	2.28e-6	Obesity-related traits;
TGCT	cis	rs7647973	1.000	rs6805609	chr3:49471522	C/G	cg07636037	chr3:49044803	WDR6	-0.76	-5.69	-0.45	8.74e-8	Menarche (age at onset);
TGCT	trans	rs73720034	1.000	rs78520622	chr7:125566859	G/A	cg18231848	chr1:26499103	NA	0.51	6.66	0.51	8.09e-10	Response to selective serotonin reuptake inhibitors and depression;
TGCT	cis	rs7412746	0.658	rs10888397	chr1:150886752	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.36	-4.48	-0.37	1.66e-5	Melanoma;
TGCT	cis	rs7179456	0.513	rs640704	chr15:59049021	A/G	cg05156742	chr15:59063176	FAM63B	0.51	4.84	0.4	3.8e-6	Asperger disorder;
TGCT	cis	rs9357506	1.000	rs716493	chr6:46307942	C/T	cg21115430	chr6:46460003	NA	-0.26	-5.17	-0.42	9.2e-7	Body mass index;
TGCT	cis	rs4499344	0.730	rs453804	chr19:33105612	T/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.86	9.0	0.63	3.29e-15	Mean platelet volume;
TGCT	cis	rs4478858	0.684	rs11578407	chr1:31728543	A/G	cg07478791	chr1:31886160	SERINC2	-0.48	-4.61	-0.38	9.77e-6	Alcohol dependence;
TGCT	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg23131131	chr22:24373011	LOC391322	-0.6	-5.97	-0.47	2.29e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9868809	0.542	rs9873726	chr3:48712367	C/T	cg00383909	chr3:49044727	WDR6	0.88	5.3	0.43	5.17e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs7208859	0.623	rs216446	chr17:28933718	T/G	cg13385521	chr17:29058706	SUZ12P	0.81	4.87	0.4	3.39e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs66573146	1.000	rs6812391	chr4:6963893	G/A	cg00086871	chr4:6988644	TBC1D14	0.98	4.57	0.38	1.16e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs8100891	0.614	rs6510243	chr19:32833671	A/G	cg16662424	chr19:32837316	ZNF507	-0.41	-5.0	-0.41	1.93e-6	Neuroticism;
TGCT	cis	rs9527	0.590	rs11191578	chr10:104902337	A/T	cg15744005	chr10:104629667	AS3MT	-0.42	-4.86	-0.4	3.41e-6	Arsenic metabolism;
TGCT	cis	rs911263	0.887	rs8015139	chr14:68739301	G/T	cg18825221	chr14:68749962	RAD51L1	-0.28	-5.53	-0.44	1.85e-7	Primary biliary cholangitis;
TGCT	cis	rs6088580	0.634	rs6141471	chr20:33006730	A/G	cg24642439	chr20:33292090	TP53INP2	-0.49	-4.49	-0.37	1.59e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs6121246	0.529	rs6060171	chr20:30183269	C/T	cg21427119	chr20:30132790	HM13	-0.43	-6.28	-0.49	5.3e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg11890956	chr21:40555474	PSMG1	1.12	12.26	0.74	4.02e-23	Cognitive function;
TGCT	cis	rs4499344	0.604	rs259287	chr19:33164859	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.87	9.38	0.64	3.95e-16	Mean platelet volume;
TGCT	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	6.74	0.52	5.34e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7586879	0.616	rs13410999	chr2:25097939	T/C	cg01884057	chr2:25150051	NA	0.31	5.94	0.47	2.72e-8	Body mass index;
TGCT	cis	rs614226	0.872	rs12307148	chr12:120903179	T/C	cg10072921	chr12:121022843	NA	0.45	4.69	0.39	7.09e-6	Type 1 diabetes nephropathy;
TGCT	cis	rs3806843	0.706	rs1089305	chr5:140066306	T/C	cg19875535	chr5:140030758	IK	-0.36	-6.15	-0.48	9.57e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2370759	1.000	rs79578760	chr10:32611264	C/A	cg01819863	chr10:32635814	EPC1	1.03	10.07	0.67	8.33e-18	Sexual dysfunction (female);
TGCT	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg12311346	chr5:56204834	C5orf35	-0.67	-6.82	-0.52	3.63e-10	Initial pursuit acceleration;
TGCT	cis	rs478304	0.934	rs603645	chr11:65533000	A/C	cg27068330	chr11:65405492	SIPA1	0.74	7.41	0.55	1.67e-11	Acne (severe);
TGCT	cis	rs8013055	0.846	rs35590487	chr14:105989599	C/T	cg23356831	chr14:105996513	TMEM121	0.34	4.98	0.41	2.05e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs7267979	0.966	rs6050611	chr20:25414419	A/G	cg16686733	chr20:25566563	NINL	0.56	5.57	0.45	1.48e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7845219	0.555	rs1129152	chr8:95888307	C/T	cg23172400	chr8:95962367	TP53INP1	-0.34	-5.02	-0.41	1.72e-6	Type 2 diabetes;
TGCT	cis	rs3008870	1.000	rs2182143	chr1:67378936	T/C	cg03991309	chr1:68237761	GNG12	0.27	4.68	0.39	7.28e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs17122693	0.551	rs3015456	chr14:51059923	T/C	cg04730355	chr14:51134070	SAV1	1.19	12.02	0.73	1.56e-22	Cognitive performance;
TGCT	cis	rs7119038	0.818	rs77209083	chr11:118607569	A/G	cg19308663	chr11:118741387	NA	0.26	4.86	0.4	3.52e-6	Sjögren's syndrome;
TGCT	cis	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg20637647	chr7:64974828	NA	1.0	5.57	0.45	1.53e-7	Diabetic kidney disease;
TGCT	cis	rs7714584	1.000	rs11950957	chr5:150253914	G/A	cg22134413	chr5:150180641	NA	0.83	6.53	0.51	1.54e-9	Crohn's disease;
TGCT	cis	rs9303401	0.659	rs714959	chr17:56628601	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs6564219	1	rs6564219	chr16:75222006	G/C	cg09066997	chr16:75300724	BCAR1	0.27	4.79	0.39	4.75e-6	Alcoholic chronic pancreatitis;
TGCT	cis	rs2692947	0.508	rs2216793	chr2:96196322	A/G	cg23100626	chr2:96804247	ASTL	0.45	5.34	0.43	4.21e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs6088580	0.668	rs1205337	chr20:32926041	T/A	cg06115741	chr20:33292138	TP53INP2	-0.55	-4.84	-0.4	3.85e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs9467773	1.000	rs9393729	chr6:26514166	C/T	cg26531700	chr6:26746687	NA	0.47	4.57	0.38	1.14e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	6.14	0.48	1.03e-8	Bipolar disorder;
TGCT	cis	rs6977660	0.607	rs12113916	chr7:19781424	G/T	cg07541023	chr7:19748670	TWISTNB	0.83	4.69	0.39	7.01e-6	Thyroid stimulating hormone;
TGCT	cis	rs931127	0.747	rs11820062	chr11:65429936	T/C	cg17480646	chr11:65405466	SIPA1	-0.42	-5.47	-0.44	2.34e-7	Systemic lupus erythematosus;
TGCT	cis	rs394563	0.591	rs805026	chr6:149728254	G/C	cg16235748	chr6:149772707	ZC3H12D	-0.45	-5.01	-0.41	1.8e-6	Dupuytren's disease;
TGCT	cis	rs7020830	0.861	rs13295981	chr9:37330067	C/T	cg14235030	chr9:37121269	ZCCHC7	0.41	4.51	0.38	1.49e-5	Schizophrenia;
TGCT	cis	rs4319547	0.695	rs11836188	chr12:122865507	T/C	cg05707623	chr12:122985044	ZCCHC8	0.62	4.83	0.4	3.91e-6	Body mass index;
TGCT	cis	rs9300255	0.602	rs1727296	chr12:123647725	G/C	cg00376283	chr12:123451042	ABCB9	0.73	5.64	0.45	1.09e-7	Neutrophil percentage of white cells;
TGCT	cis	rs7147624	1.000	rs2898816	chr14:66008160	T/C	cg03016385	chr14:66212404	NA	-0.49	-7.08	-0.54	9.33e-11	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs74233809	1.000	rs11191505	chr10:104766891	C/T	cg05855489	chr10:104503620	C10orf26	0.75	4.47	0.37	1.72e-5	Birth weight;
TGCT	cis	rs9527	0.662	rs743575	chr10:104594906	T/G	cg15744005	chr10:104629667	AS3MT	-0.46	-5.74	-0.46	7e-8	Arsenic metabolism;
TGCT	cis	rs1950500	0.617	rs10362	chr14:24846961	G/T	cg07162820	chr14:24837146	NFATC4	0.42	4.47	0.37	1.77e-5	Height;
TGCT	cis	rs642803	0.551	rs1308020	chr11:65497558	G/A	cg27068330	chr11:65405492	SIPA1	0.65	5.71	0.46	7.78e-8	Urate levels;
TGCT	cis	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg07424592	chr7:64974309	NA	1.34	8.08	0.59	4.95e-13	Diabetic kidney disease;
TGCT	cis	rs6988636	1.000	rs11993411	chr8:124180537	T/C	cg22384356	chr8:124195192	FAM83A	-0.42	-5.46	-0.44	2.5e-7	Urinary uromodulin levels;
TGCT	cis	rs478304	0.651	rs11604451	chr11:65551710	C/T	cg17480646	chr11:65405466	SIPA1	-0.55	-6.45	-0.5	2.28e-9	Acne (severe);
TGCT	cis	rs7542091	0.637	rs9429826	chr1:210052146	G/A	cg22029157	chr1:209979665	IRF6	0.62	5.96	0.47	2.44e-8	Monobrow;
TGCT	cis	rs10984561	0.881	rs58379881	chr9:122243802	C/T	cg14242995	chr9:122249943	NA	0.75	6.45	0.5	2.25e-9	Pulmonary function decline;
TGCT	cis	rs9929218	0.508	rs6499194	chr16:68744100	T/C	cg01251360	chr16:68772225	CDH1	-0.25	-4.57	-0.38	1.18e-5	Colorectal cancer;
TGCT	cis	rs6964587	0.934	rs35968894	chr7:91762145	A/G	cg17063962	chr7:91808500	NA	0.84	8.15	0.59	3.39e-13	Breast cancer;
TGCT	cis	rs3796352	1.000	rs13078971	chr3:53103645	G/C	cg07884673	chr3:53033167	SFMBT1	0.59	6.04	0.48	1.63e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs9427116	0.502	rs3766922	chr1:154577055	A/C	cg17218026	chr1:154582156	ADAR	0.29	6.99	0.53	1.47e-10	Blood protein levels;
TGCT	cis	rs10949834	1.000	rs10949835	chr7:73488922	A/G	cg07137043	chr7:73588983	EIF4H	-0.74	-4.6	-0.38	1.03e-5	Verbal memory performance (residualized delayed recall change);
TGCT	cis	rs7674212	0.541	rs2623070	chr4:104037388	A/G	cg16532752	chr4:104119610	CENPE	0.6	5.31	0.43	4.97e-7	Type 2 diabetes;
TGCT	cis	rs1580019	0.563	rs13244332	chr7:32537679	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.14	14.18	0.79	1.03e-27	Cognitive ability;
TGCT	cis	rs6785206	0.527	rs36110719	chr3:128657106	C/A	cg25356066	chr3:128598488	ACAD9	-0.74	-4.65	-0.39	8.51e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg05552183	chr6:42928497	GNMT	0.52	4.57	0.38	1.17e-5	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs4727027	0.933	rs12154382	chr7:148862284	C/T	cg23583168	chr7:148888333	NA	-0.76	-10.09	-0.67	7.46e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs7666738	0.800	rs7684523	chr4:98983175	G/T	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7582180	0.652	rs11687865	chr2:100947000	T/A	cg08017756	chr2:100939284	LONRF2	-0.3	-4.87	-0.4	3.27e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1056053	0.514	rs3099268	chr6:166572826	T/C	cg17219086	chr6:166541254	NA	-0.19	-4.47	-0.37	1.77e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs7542091	1.000	rs7542091	chr1:210031948	G/C	cg00989853	chr1:209979345	IRF6	0.4	4.46	0.37	1.81e-5	Monobrow;
TGCT	cis	rs36051895	0.659	rs7025540	chr9:5043152	T/C	cg02405213	chr9:5042618	JAK2	-0.78	-10.85	-0.7	1.1e-19	Pediatric autoimmune diseases;
TGCT	cis	rs6500602	0.739	rs4786502	chr16:4537104	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.31	5.64	0.45	1.09e-7	Schizophrenia;
TGCT	cis	rs12142240	0.698	rs72677589	chr1:46817770	T/C	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs7909167	0.661	rs7067627	chr10:25912666	G/T	cg00154333	chr10:25012173	ARHGAP21	0.75	5.01	0.41	1.82e-6	Carboplatin disposition in epthelial ovarian cancer;
TGCT	cis	rs1577917	1.000	rs12201571	chr6:86609750	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.54	-0.45	1.73e-7	Response to antipsychotic treatment;
TGCT	cis	rs11931598	0.509	rs13140943	chr4:6977109	A/G	cg26116260	chr4:7069785	GRPEL1	0.59	5.38	0.43	3.59e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs6831352	0.918	rs2851251	chr4:100044111	A/G	cg12011299	chr4:100065546	ADH4	0.43	5.02	0.41	1.71e-6	Alcohol dependence;
TGCT	cis	rs6490294	0.583	rs2339973	chr12:112520883	C/T	cg10833066	chr12:111807467	FAM109A	0.34	5.22	0.42	7.39e-7	Mean platelet volume;
TGCT	cis	rs981844	0.740	rs7653960	chr4:154697430	T/G	cg14289246	chr4:154710475	SFRP2	-0.91	-8.31	-0.6	1.38e-13	Response to statins (LDL cholesterol change);
TGCT	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg10047753	chr17:41438598	NA	0.97	9.89	0.66	2.27e-17	Menopause (age at onset);
TGCT	cis	rs4713118	0.866	rs9468217	chr6:27726467	G/A	cg20933634	chr6:27740509	NA	0.34	4.75	0.39	5.58e-6	Parkinson's disease;
TGCT	cis	rs7412746	0.658	rs72704652	chr1:150819470	A/G	cg09365446	chr1:150670422	GOLPH3L	0.35	4.98	0.41	2.11e-6	Melanoma;
TGCT	cis	rs1691799	0.867	rs1168342	chr12:66758734	A/T	cg16791601	chr12:66731901	HELB	-0.29	-6.18	-0.49	8.39e-9	White blood cell count (basophil);
TGCT	cis	rs4372836	0.741	rs4563180	chr2:29093695	C/G	cg09522027	chr2:28974177	PPP1CB	0.67	6.91	0.53	2.24e-10	Body mass index;
TGCT	cis	rs4986172	0.700	rs71373536	chr17:43221808	G/A	cg10701640	chr17:43249399	NA	0.55	6.58	0.51	1.18e-9	Height;
TGCT	cis	rs7617480	0.648	rs14018	chr3:48784270	G/A	cg07636037	chr3:49044803	WDR6	0.76	5.93	0.47	2.8e-8	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs66731853	0.769	rs476582	chr1:20894450	A/G	cg04087271	chr1:20915334	CDA	-0.51	-6.45	-0.5	2.22e-9	Mean corpuscular volume;
TGCT	cis	rs3617	0.573	rs9810807	chr3:52924227	C/T	cg11645453	chr3:52864694	ITIH4	-0.28	-5.41	-0.44	3.16e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1629083	0.935	rs1793149	chr11:118127347	A/G	cg16594165	chr11:118135105	MPZL2	-0.33	-4.62	-0.38	9.51e-6	Lung cancer;
TGCT	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg24531977	chr5:56204891	C5orf35	-0.76	-7.34	-0.55	2.45e-11	Initial pursuit acceleration;
TGCT	cis	rs3008870	0.959	rs2985826	chr1:67412918	G/C	cg11518657	chr1:67396239	MIER1	0.54	4.65	0.39	8.44e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs4499344	0.730	rs10413061	chr19:33103278	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.83	8.63	0.61	2.53e-14	Mean platelet volume;
TGCT	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg24675658	chr1:53192096	ZYG11B	0.64	7.31	0.55	2.82e-11	Monocyte count;
TGCT	cis	rs10206020	0.797	rs72778008	chr2:1573182	T/G	cg12573674	chr2:1569213	NA	-0.49	-5.3	-0.43	5.1e-7	IgG glycosylation;
TGCT	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg18402987	chr7:1209562	NA	0.89	7.56	0.56	7.92e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs11662586	0.517	rs7228070	chr18:77698967	C/T	cg20368463	chr18:77673604	PQLC1	0.57	6.78	0.52	4.33e-10	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
TGCT	cis	rs36051895	0.664	rs3780377	chr9:5110899	T/C	cg02405213	chr9:5042618	JAK2	-0.74	-9.68	-0.66	7.72e-17	Pediatric autoimmune diseases;
TGCT	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.29	-4.49	-0.37	1.64e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	trans	rs3780486	0.846	rs10116966	chr9:33122370	T/A	cg04842962	chr6:43655489	MRPS18A	1.23	15.36	0.81	1.81e-30	IgG glycosylation;
TGCT	cis	rs62380364	0.507	rs34321	chr5:88020319	C/G	cg22951263	chr5:87985283	NA	-0.57	-6.18	-0.49	8.28e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs4700695	0.719	rs36923	chr5:65464783	G/C	cg21114390	chr5:65439923	SFRS12	-0.82	-6.8	-0.52	4.03e-10	Facial morphology (factor 19);
TGCT	cis	rs778371	0.723	rs2592104	chr2:233645970	G/A	cg08000102	chr2:233561755	GIGYF2	0.68	7.84	0.58	1.75e-12	Schizophrenia;
TGCT	cis	rs6121246	0.567	rs6058197	chr20:30194899	A/G	cg13852791	chr20:30311386	BCL2L1	0.69	4.54	0.38	1.33e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs12142240	0.659	rs67547686	chr1:46832229	G/C	cg14993813	chr1:46806288	NSUN4	-0.58	-4.8	-0.4	4.46e-6	Menopause (age at onset);
TGCT	cis	rs17030434	0.906	rs4696491	chr4:154679865	T/C	cg14289246	chr4:154710475	SFRP2	0.95	7.5	0.56	1.06e-11	Electrocardiographic conduction measures;
TGCT	cis	rs6912958	0.678	rs9450744	chr6:88280529	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-5.06	-0.41	1.45e-6	Monocyte percentage of white cells;
TGCT	cis	rs9467773	0.869	rs9295689	chr6:26455811	T/C	cg05738196	chr6:26577821	NA	0.68	7.81	0.57	2.02e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs4072705	0.615	rs7851737	chr9:127247931	G/A	cg13476313	chr9:127244764	NR5A1	-0.3	-5.17	-0.42	8.97e-7	Menarche (age at onset);
TGCT	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg05368731	chr17:41323189	NBR1	1.21	14.63	0.8	8.89e-29	Menopause (age at onset);
TGCT	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg08392591	chr16:89556376	ANKRD11	0.6	5.71	0.46	8.03e-8	Multiple myeloma (IgH translocation);
TGCT	cis	rs11690935	0.959	rs7604918	chr2:172588094	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.18	-12.58	-0.75	6.59e-24	Schizophrenia;
TGCT	cis	rs11190604	1.000	rs2495759	chr10:102320363	C/T	cg23241863	chr10:102295624	HIF1AN	0.62	4.76	0.39	5.38e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2456568	0.867	rs2456569	chr11:93691393	C/A	cg14065697	chr11:93583672	C11orf90	-0.38	-4.68	-0.39	7.41e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg11890956	chr21:40555474	PSMG1	1.14	12.22	0.74	4.93e-23	Cognitive function;
TGCT	cis	rs815815	0.583	rs878665	chr2:47403129	G/T	cg27223769	chr2:47403360	CALM2	-0.53	-4.6	-0.38	1.01e-5	Dialysis-related mortality;
TGCT	cis	rs17253792	0.822	rs10137364	chr14:56059987	G/A	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	trans	rs10203711	1.000	rs6731675	chr2:239566943	T/C	cg16021909	chr1:248021091	TRIM58	-0.66	-6.66	-0.51	7.94e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6427499	0.563	rs11265297	chr1:159890459	A/G	cg15641364	chr1:159892206	TAGLN2	-0.28	-4.85	-0.4	3.6e-6	Platelet distribution width;
TGCT	cis	rs6684514	1.000	rs12027741	chr1:156248148	T/G	cg16558208	chr1:156270281	VHLL	0.46	9.38	0.64	3.92e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg07424592	chr7:64974309	NA	-1.33	-7.99	-0.58	7.81e-13	Diabetic kidney disease;
TGCT	cis	rs9486719	1.000	rs2472897	chr6:96870569	G/T	cg06623918	chr6:96969491	KIAA0776	1.01	8.86	0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs1801251	0.727	rs283482	chr2:233646920	A/T	cg08000102	chr2:233561755	GIGYF2	0.66	7.42	0.55	1.6e-11	Coronary artery disease;
TGCT	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg12311346	chr5:56204834	C5orf35	-0.67	-6.77	-0.52	4.59e-10	Initial pursuit acceleration;
TGCT	cis	rs6087990	0.806	rs2424918	chr20:31382770	C/T	cg13636640	chr20:31349939	DNMT3B	1.08	15.49	0.81	8.74e-31	Ulcerative colitis;
TGCT	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.71	-0.39	6.54e-6	Prudent dietary pattern;
TGCT	cis	rs8180040	1.000	rs4858888	chr3:47405305	C/T	cg27129171	chr3:47204927	SETD2	-0.7	-8.46	-0.6	6.33e-14	Colorectal cancer;
TGCT	cis	rs13191362	1.000	rs71567659	chr6:163001736	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs2439831	0.867	rs2278860	chr15:43659046	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.86	-6.45	-0.5	2.3e-9	Lung cancer in ever smokers;
TGCT	cis	rs2404602	0.647	rs12898416	chr15:77042292	C/G	cg22467129	chr15:76604101	ETFA	0.47	4.58	0.38	1.13e-5	Blood metabolite levels;
TGCT	cis	rs986417	0.901	rs1950316	chr14:61018305	T/C	cg27398547	chr14:60952738	C14orf39	1.49	10.43	0.68	1.12e-18	Gut microbiota (bacterial taxa);
TGCT	cis	rs7772486	0.597	rs6912351	chr6:146264071	T/C	cg13319975	chr6:146136371	FBXO30	0.63	5.67	0.45	9.51e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7582180	0.585	rs6736311	chr2:100950599	C/G	cg14675211	chr2:100938903	LONRF2	0.53	5.16	0.42	9.36e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1843834	0.755	rs10192196	chr2:225577135	C/T	cg22455342	chr2:225449267	CUL3	0.63	6.12	0.48	1.16e-8	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg09021430	chr5:549028	NA	-0.37	-4.98	-0.41	2.07e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs7119	0.651	rs12902898	chr15:77849191	A/G	cg27398640	chr15:77910606	LINGO1	-0.26	-5.08	-0.41	1.36e-6	Type 2 diabetes;
TGCT	cis	rs9296092	0.517	rs76361685	chr6:33536458	G/C	cg13560919	chr6:33536144	NA	-0.23	-4.95	-0.41	2.4e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs6499255	0.638	rs57824734	chr16:69811995	C/T	cg15192750	chr16:69999425	NA	0.48	5.01	0.41	1.85e-6	IgE levels;
TGCT	cis	rs6570726	0.902	rs9390326	chr6:145791222	A/G	cg23711669	chr6:146136114	FBXO30	-0.68	-6.24	-0.49	6.2e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.56	4.97	0.41	2.19e-6	Height;
TGCT	cis	rs1113500	0.509	rs1619485	chr1:108608347	T/C	cg22161131	chr1:109420278	GPSM2	-0.5	-4.49	-0.37	1.61e-5	Growth-regulated protein alpha levels;
TGCT	cis	rs881375	0.900	rs2241003	chr9:123666777	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	5.76	0.46	6.25e-8	Rheumatoid arthritis;
TGCT	cis	rs6504340	0.793	rs12946855	chr17:46608030	G/A	cg25032089	chr17:46643351	HOXB3	0.57	5.84	0.46	4.27e-8	Primary tooth development (number of teeth);
TGCT	cis	rs7833790	0.654	rs7835342	chr8:82698092	A/G	cg17211192	chr8:82754475	SNX16	-0.84	-7.67	-0.57	4.24e-12	Diastolic blood pressure;
TGCT	cis	rs2153535	0.580	rs1932276	chr6:8442593	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.58	0.45	1.42e-7	Motion sickness;
TGCT	cis	rs892961	0.932	rs7208671	chr17:75413129	T/C	cg05865280	chr17:75406074	SEPT9	0.28	6.86	0.52	2.9e-10	Airflow obstruction;
TGCT	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg11764359	chr7:65958608	NA	0.61	5.53	0.44	1.84e-7	Aortic root size;
TGCT	cis	rs7714584	1.000	rs12652003	chr5:150231945	T/C	cg22134413	chr5:150180641	NA	1.1	7.95	0.58	1e-12	Crohn's disease;
TGCT	cis	rs1538970	0.962	rs2153607	chr1:45813820	G/A	cg05343316	chr1:45956843	TESK2	0.64	5.06	0.41	1.46e-6	Platelet count;
TGCT	cis	rs739496	0.615	rs7977828	chr12:112094766	A/G	cg10833066	chr12:111807467	FAM109A	0.36	5.06	0.41	1.46e-6	Platelet count;
TGCT	cis	rs7607369	0.596	rs56304256	chr2:219276138	T/C	cg02176678	chr2:219576539	TTLL4	-0.49	-6.24	-0.49	6.26e-9	Red blood cell count;Amyotrophic lateral sclerosis;
TGCT	cis	rs3749237	0.964	rs13084243	chr3:49821878	G/C	cg07636037	chr3:49044803	WDR6	0.61	5.32	0.43	4.68e-7	Resting heart rate;
TGCT	cis	rs9611565	0.559	rs12483860	chr22:41961916	C/T	cg06634786	chr22:41940651	POLR3H	-0.88	-8.25	-0.6	1.98e-13	Vitiligo;
TGCT	cis	rs4319547	1.000	rs7309390	chr12:123110422	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.68	-5.35	-0.43	4.1e-7	Body mass index;
TGCT	cis	rs826838	0.900	rs1403523	chr12:39130570	T/A	cg13010199	chr12:38710504	ALG10B	-0.63	-5.06	-0.41	1.46e-6	Heart rate;
TGCT	cis	rs8032315	0.965	rs4932373	chr15:91429287	A/C	cg05211768	chr15:91427848	FES	0.49	4.89	0.4	3.02e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs11677416	0.885	rs4849119	chr2:113523463	G/C	cg27083787	chr2:113543245	IL1A	0.17	4.46	0.37	1.83e-5	Response to antipsychotic treatment in schizophrenia (working memory);
TGCT	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-5.29	-0.43	5.34e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs3733585	0.660	rs13122290	chr4:9933832	A/G	cg11266682	chr4:10021025	SLC2A9	-0.57	-7.3	-0.55	3.08e-11	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-6.74	-0.52	5.26e-10	Alzheimer's disease;
TGCT	cis	rs5769765	0.704	rs138837	chr22:50180714	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.32	4.59	0.38	1.09e-5	Schizophrenia;
TGCT	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg18876405	chr7:65276391	NA	-0.35	-5.2	-0.42	7.81e-7	Aortic root size;
TGCT	cis	rs6460942	0.908	rs73677570	chr7:12280329	T/C	cg06484146	chr7:12443880	VWDE	-0.53	-4.65	-0.39	8.3e-6	Coronary artery disease;
TGCT	cis	rs533581	0.866	rs502258	chr16:88968547	G/A	cg16701003	chr16:89028210	CBFA2T3	0.39	5.15	0.42	9.84e-7	Social autistic-like traits;
TGCT	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg04944784	chr2:26401820	FAM59B	0.69	6.18	0.49	8.53e-9	Gut microbiome composition (summer);
TGCT	cis	rs4727027	0.899	rs6464942	chr7:148826368	T/C	cg23583168	chr7:148888333	NA	-0.72	-9.18	-0.64	1.18e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg02782426	chr3:40428986	ENTPD3	0.39	4.47	0.37	1.77e-5	Renal cell carcinoma;
TGCT	cis	rs4972806	0.849	rs2071581	chr2:177026148	G/T	cg03152288	chr2:177042942	NA	0.61	5.16	0.42	9.51e-7	IgG glycosylation;
TGCT	cis	rs7914558	1.000	rs11191541	chr10:104824199	A/G	cg04362960	chr10:104952993	NT5C2	0.59	5.28	0.43	5.56e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs9787249	1.000	rs9787249	chr1:40212878	G/A	cg24920358	chr1:40204285	PPIE	0.57	10.56	0.69	5.57e-19	Blood protein levels;
TGCT	cis	rs478304	0.651	rs11227279	chr11:65495211	G/A	cg10518572	chr11:65560635	OVOL1	-0.23	-4.45	-0.37	1.91e-5	Acne (severe);
TGCT	cis	rs10791097	0.694	rs4937581	chr11:130740335	T/C	cg05962950	chr11:130786565	SNX19	0.92	11.55	0.72	2.13e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs3862260	0.509	rs12076924	chr1:120165826	C/T	cg11530693	chr1:120165357	ZNF697	0.21	4.63	0.38	9.07e-6	Systemic lupus erythematosus;
TGCT	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg06618935	chr21:46677482	NA	-0.36	-4.82	-0.4	4.18e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs10089	1.000	rs72794392	chr5:127490061	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.85	8.09	0.59	4.71e-13	Ileal carcinoids;
TGCT	cis	rs7552404	1.000	rs12091720	chr1:76186949	G/A	cg10523679	chr1:76189770	ACADM	0.9	9.73	0.66	5.57e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs1371867	0.846	rs2047249	chr8:101234126	A/G	cg06002616	chr8:101225028	SPAG1	0.48	5.2	0.42	8.15e-7	Atrioventricular conduction;
TGCT	cis	rs704	0.726	rs2073867	chr17:26678960	G/C	cg10342447	chr17:26645325	TMEM97	-0.55	-5.2	-0.42	7.94e-7	Osteoprotegerin levels;
TGCT	cis	rs11105298	0.891	rs10777185	chr12:89921275	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.67	-4.91	-0.4	2.78e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs12765878	0.967	rs34887477	chr10:105643436	C/T	cg11005552	chr10:105648138	OBFC1	0.44	7.6	0.56	6.24e-12	Coronary artery disease;
TGCT	cis	rs12458462	0.892	rs3786228	chr18:77464170	C/T	cg11879182	chr18:77439856	CTDP1	-0.71	-8.43	-0.6	7.53e-14	Monocyte count;
TGCT	cis	rs10464366	0.746	rs6945547	chr7:39145389	C/G	cg15212455	chr7:39170539	POU6F2	0.26	5.63	0.45	1.15e-7	IgG glycosylation;
TGCT	cis	rs17253792	0.822	rs76164147	chr14:56140369	T/C	cg01858014	chr14:56050164	KTN1	-0.35	-4.62	-0.38	9.37e-6	Putamen volume;
TGCT	cis	rs9388451	0.839	rs3799709	chr6:126078361	A/G	cg05901451	chr6:126070800	HEY2	-1.02	-15.34	-0.81	2e-30	Brugada syndrome;
TGCT	cis	rs6977660	0.714	rs2390156	chr7:19786138	A/T	cg07541023	chr7:19748670	TWISTNB	0.81	4.46	0.37	1.81e-5	Thyroid stimulating hormone;
TGCT	cis	rs35306767	0.903	rs11253493	chr10:936931	T/C	cg20503657	chr10:835505	NA	0.74	10.3	0.68	2.41e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs9902453	0.967	rs55744550	chr17:28475729	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	6.39	0.5	3.03e-9	Coffee consumption (cups per day);
TGCT	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg03396347	chr1:1875803	NA	0.34	5.72	0.46	7.58e-8	Body mass index;
TGCT	cis	rs751728	0.664	rs12196293	chr6:33749151	A/G	cg13859433	chr6:33739653	LEMD2	-0.32	-5.64	-0.45	1.1e-7	Crohn's disease;
TGCT	cis	rs9556958	0.527	rs9517313	chr13:99105892	C/G	cg07423050	chr13:99094983	FARP1	0.33	7.07	0.54	9.78e-11	Educational attainment (years of education);
TGCT	cis	rs35306767	0.903	rs12254002	chr10:929133	A/G	cg26597838	chr10:835615	NA	-0.7	-9.58	-0.65	1.3e-16	Eosinophil percentage of granulocytes;
TGCT	trans	rs3808502	0.647	rs7821302	chr8:11236572	T/A	cg15556689	chr8:8085844	FLJ10661	-0.74	-6.68	-0.51	7.12e-10	Neuroticism;
TGCT	trans	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg21659725	chr3:3221576	CRBN	0.76	9.35	0.64	4.6e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs55823223	0.564	rs9894009	chr17:73850414	C/T	cg10935138	chr17:73851978	WBP2	0.82	7.59	0.56	6.81e-12	Psoriasis;
TGCT	cis	rs9858542	1.000	rs3197999	chr3:49721532	G/A	cg03060546	chr3:49711283	APEH	-0.69	-5.87	-0.47	3.67e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs1153858	1.000	rs4775906	chr15:45638294	C/T	cg14582100	chr15:45693742	SPATA5L1	0.48	5.7	0.46	8.17e-8	Homoarginine levels;
TGCT	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2180341	1.000	rs7776136	chr6:127638348	A/T	cg24812749	chr6:127587940	RNF146	0.94	7.43	0.55	1.56e-11	Breast cancer;
TGCT	cis	rs651907	0.557	rs3806654	chr3:101396529	G/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.24	0.43	6.66e-7	Colorectal cancer;
TGCT	cis	rs319204	0.877	rs319172	chr5:146288339	G/T	cg25021259	chr5:146258546	PPP2R2B	0.35	4.53	0.38	1.39e-5	Schizophrenia;
TGCT	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.55	4.92	0.4	2.74e-6	Prudent dietary pattern;
TGCT	cis	rs6674176	0.542	rs2906468	chr1:44319007	A/G	cg12908607	chr1:44402522	ARTN	-0.63	-7.18	-0.54	5.58e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg22920501	chr2:26401640	FAM59B	-0.81	-6.36	-0.5	3.52e-9	Gut microbiome composition (summer);
TGCT	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg13877915	chr19:58951672	ZNF132	0.89	11.13	0.71	2.22e-20	Uric acid clearance;
TGCT	cis	rs35771425	0.619	rs7538812	chr1:211442186	A/G	cg25617285	chr1:211431773	RCOR3	-0.5	-5.88	-0.47	3.63e-8	Educational attainment (years of education);
TGCT	cis	rs2115630	0.967	rs10438428	chr15:85330745	C/T	cg17173187	chr15:85201210	NMB	-0.38	-4.75	-0.39	5.52e-6	P wave terminal force;
TGCT	cis	rs17741873	0.779	rs2242255	chr10:75597289	T/A	cg07699608	chr10:75541558	CHCHD1	0.72	5.15	0.42	1.02e-6	Paclitaxel disposition in epithelial ovarian cancer;
TGCT	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg10047753	chr17:41438598	NA	0.88	7.8	0.57	2.22e-12	Menopause (age at onset);
TGCT	cis	rs12935418	0.616	rs11863536	chr16:80969674	C/T	cg07676361	chr16:80966860	NA	-0.35	-4.69	-0.39	6.99e-6	Mean corpuscular volume;
TGCT	cis	rs4930561	0.690	rs6591334	chr11:67924559	A/G	cg04465784	chr11:67976953	SUV420H1	-0.4	-5.37	-0.43	3.72e-7	Breast cancer in childhood cancer survivors;IgG glycosylation;
TGCT	cis	rs2354432	1.000	rs11239944	chr1:146691015	C/T	cg25205988	chr1:146714368	CHD1L	0.94	7.15	0.54	6.76e-11	Mitochondrial DNA levels;
TGCT	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1385374	0.858	rs10773578	chr12:129290026	G/C	cg09035930	chr12:129282057	SLC15A4	-0.55	-4.76	-0.39	5.27e-6	Systemic lupus erythematosus;
TGCT	cis	rs11105298	0.891	rs10858898	chr12:89922111	A/G	cg00757033	chr12:89920650	WDR51B	0.32	5.13	0.42	1.11e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs447921	0.861	rs66686654	chr17:74430310	A/T	cg09812376	chr17:74270190	QRICH2	-0.48	-4.71	-0.39	6.4e-6	Mitochondrial DNA levels;
TGCT	cis	rs7681440	0.904	rs10004413	chr4:90769479	T/C	cg20003494	chr4:90757398	SNCA	-0.6	-5.76	-0.46	6.3e-8	Dementia with Lewy bodies;
TGCT	cis	rs739496	0.843	rs616668	chr12:111974280	T/G	cg10833066	chr12:111807467	FAM109A	0.37	4.93	0.4	2.61e-6	Platelet count;
TGCT	trans	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg21659725	chr3:3221576	CRBN	0.69	7.57	0.56	7.35e-12	Body mass index;
TGCT	cis	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg07424592	chr7:64974309	NA	1.31	8.14	0.59	3.55e-13	Diabetic kidney disease;
TGCT	cis	rs4689388	0.926	rs10937720	chr4:6295451	A/G	cg14416269	chr4:6271139	WFS1	0.37	4.85	0.4	3.58e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs7582180	0.676	rs4264577	chr2:100930662	T/C	cg14675211	chr2:100938903	LONRF2	0.53	5.24	0.43	6.82e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs737008	0.922	rs1559394	chr16:11369205	A/G	cg00044050	chr16:11439710	C16orf75	-0.71	-7.21	-0.54	4.91e-11	Obesity-related traits;
TGCT	cis	rs1729951	0.575	rs16844325	chr3:136678161	C/G	cg12473912	chr3:136751656	NA	0.39	6.18	0.49	8.36e-9	Neuroticism;
TGCT	cis	rs926938	0.967	rs11587596	chr1:115241857	A/G	cg12756093	chr1:115239321	AMPD1	-0.48	-6.99	-0.53	1.51e-10	Autism;
TGCT	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg13665807	chr20:60559372	TAF4	-0.46	-4.9	-0.4	2.87e-6	Body mass index;
TGCT	cis	rs12701220	0.948	rs12690826	chr7:1081618	A/G	cg07217954	chr7:1067459	C7orf50	-0.48	-4.7	-0.39	6.77e-6	Bronchopulmonary dysplasia;
TGCT	cis	rs11122272	0.735	rs2250734	chr1:231485958	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.13	-0.54	7.37e-11	Hemoglobin concentration;
TGCT	cis	rs3806843	0.741	rs2563293	chr5:140110536	T/C	cg19875535	chr5:140030758	IK	-0.37	-6.19	-0.49	7.89e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs6912958	1.000	rs9294379	chr6:88152535	C/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.37	-4.74	-0.39	5.79e-6	Monocyte percentage of white cells;
TGCT	cis	rs2404602	1.000	rs2404602	chr15:77030792	A/G	cg26408565	chr15:76604113	ETFA	-0.42	-5.48	-0.44	2.31e-7	Blood metabolite levels;
TGCT	cis	rs7781977	0.575	rs7782210	chr7:50348745	A/G	cg01139861	chr7:50343298	IKZF1	0.5	5.9	0.47	3.17e-8	IgG glycosylation;
TGCT	cis	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg20362242	chr5:692897	TPPP	0.5	4.57	0.38	1.17e-5	Obesity-related traits;
TGCT	cis	rs748404	0.660	rs690472	chr15:43764368	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	4.77	0.39	5.05e-6	Lung cancer;
TGCT	trans	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.86	-9.4	-0.65	3.49e-16	Intelligence (multi-trait analysis);
TGCT	trans	rs1864729	0.901	rs2451114	chr8:98273762	G/A	cg08679828	chr8:102218111	ZNF706	-1.01	-7.04	-0.53	1.17e-10	Estradiol plasma levels (breast cancer);
TGCT	cis	rs1348850	0.914	rs2060929	chr2:178280031	T/C	cg22681709	chr2:178499509	PDE11A	-0.34	-4.47	-0.37	1.74e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs10791323	0.569	rs329664	chr11:133754975	G/T	cg03690763	chr11:133734501	NA	-0.31	-5.33	-0.43	4.52e-7	Childhood ear infection;
TGCT	cis	rs7611238	0.560	rs7652612	chr3:195025186	A/T	cg27323046	chr3:195102265	ACAP2	0.36	4.8	0.4	4.41e-6	Body mass index;
TGCT	cis	rs2299587	0.527	rs7843715	chr8:17733526	C/A	cg01800426	chr8:17659068	MTUS1	-0.54	-4.85	-0.4	3.69e-6	Economic and political preferences;
TGCT	cis	rs3749237	0.576	rs62259939	chr3:49386047	G/A	cg03060546	chr3:49711283	APEH	0.76	8.63	0.61	2.46e-14	Resting heart rate;
TGCT	cis	rs1045529	0.524	rs34251783	chr8:8891376	T/C	cg06636001	chr8:8085503	FLJ10661	-0.66	-5.58	-0.45	1.42e-7	Myopia;Myopia (pathological);
TGCT	cis	rs317865	0.737	rs73234651	chr4:16196651	G/A	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.78	5.11	0.42	1.18e-6	Kidney disease (early stage) in type 1 diabetes;
TGCT	cis	rs2836950	0.805	rs2836961	chr21:40627020	A/C	cg11890956	chr21:40555474	PSMG1	-0.63	-5.98	-0.47	2.26e-8	Menarche (age at onset);
TGCT	trans	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg17830980	chr10:43048298	ZNF37B	-0.87	-11.3	-0.71	8.5e-21	Extrinsic epigenetic age acceleration;
TGCT	cis	rs8103278	0.507	rs10422883	chr19:46247641	A/G	cg14061069	chr19:46274453	DMPK	0.62	10.19	0.68	4.35e-18	Coronary artery disease;
TGCT	cis	rs2762353	0.935	rs11754288	chr6:25776949	G/A	cg12310025	chr6:25882481	NA	0.51	5.26	0.43	6.01e-7	Blood metabolite levels;
TGCT	cis	rs2677744	0.534	rs6496739	chr15:91494430	C/T	cg01710897	chr15:91497902	RCCD1	0.36	5.08	0.42	1.33e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg22920501	chr2:26401640	FAM59B	-0.79	-6.31	-0.49	4.58e-9	Gut microbiome composition (summer);
TGCT	cis	rs669446	0.561	rs664336	chr1:44101800	A/G	cg12908607	chr1:44402522	ARTN	-0.55	-5.9	-0.47	3.25e-8	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs3741404	1.000	rs3741404	chr11:63999240	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.88	9.42	0.65	3.23e-16	Platelet count;
TGCT	trans	rs561341	1.000	rs8077092	chr17:30281992	T/C	cg20587970	chr11:113659929	NA	-1.03	-10.98	-0.7	5.21e-20	Hip circumference adjusted for BMI;
TGCT	cis	rs459571	0.920	rs417142	chr9:136891370	G/T	cg13789015	chr9:136890014	NCRNA00094	0.4	7.27	0.55	3.55e-11	Platelet distribution width;
TGCT	cis	rs6840360	0.642	rs6855845	chr4:152417380	A/G	cg17479576	chr4:152424074	FAM160A1	-0.57	-6.02	-0.48	1.85e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2688608	0.620	rs7076525	chr10:75512797	C/T	cg15838173	chr10:75533400	FUT11	-0.3	-5.02	-0.41	1.76e-6	Inflammatory bowel disease;
TGCT	cis	rs826838	1.000	rs10880826	chr12:38672787	G/C	cg13010199	chr12:38710504	ALG10B	0.77	6.31	0.49	4.59e-9	Heart rate;
TGCT	cis	rs9911578	1.000	rs4398153	chr17:56968181	T/C	cg05425664	chr17:57184151	TRIM37	0.62	6.18	0.49	8.33e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs3087591	0.960	rs2905803	chr17:29520056	T/C	cg24425628	chr17:29625626	OMG;NF1	0.46	7.39	0.55	1.91e-11	Hip circumference;
TGCT	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.96	7.8	0.57	2.16e-12	Platelet count;
TGCT	cis	rs11677370	0.561	rs11687254	chr2:3830906	C/T	cg17052675	chr2:3827356	NA	-0.44	-7.23	-0.54	4.4e-11	Type 2 diabetes;
TGCT	cis	rs7542091	0.704	rs1108628	chr1:210041150	A/G	cg00989853	chr1:209979345	IRF6	0.42	4.44	0.37	1.97e-5	Monobrow;
TGCT	cis	rs651907	0.557	rs13077925	chr3:101488181	T/A	cg11279151	chr3:101281821	RG9MTD1	-0.32	-6.74	-0.52	5.44e-10	Colorectal cancer;
TGCT	cis	rs4700695	0.841	rs706680	chr5:65317338	T/C	cg21114390	chr5:65439923	SFRS12	0.6	4.47	0.37	1.74e-5	Facial morphology (factor 19);
TGCT	trans	rs10802346	0.545	rs1361408	chr1:246410054	T/G	cg13514129	chr1:39547527	MACF1	1.03	9.45	0.65	2.71e-16	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs10504229	1.000	rs68114352	chr8:58196081	C/T	cg24829409	chr8:58192753	C8orf71	-0.55	-4.77	-0.39	5.18e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9517320	0.534	rs61971163	chr13:99188883	G/A	cg07423050	chr13:99094983	FARP1	-0.28	-5.53	-0.44	1.83e-7	Longevity;
TGCT	cis	rs7772486	0.686	rs702305	chr6:145973840	A/G	cg05347473	chr6:146136440	FBXO30	-0.47	-4.45	-0.37	1.9e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs910316	1.000	rs910316	chr14:75626042	A/C	cg11812906	chr14:75593930	NEK9	0.75	7.44	0.56	1.43e-11	Height;
TGCT	cis	rs12188164	0.930	rs11743825	chr5:475463	C/T	cg21144161	chr5:423903	AHRR	0.25	4.65	0.39	8.21e-6	Cystic fibrosis severity;
TGCT	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg11905131	chr22:24372483	LOC391322	-0.85	-9.56	-0.65	1.49e-16	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs77741769	0.529	rs10849791	chr12:121235280	T/C	cg02419362	chr12:121203948	SPPL3	0.19	4.46	0.37	1.83e-5	Mean corpuscular volume;
TGCT	cis	rs7208859	0.623	rs11656844	chr17:29060597	G/T	cg14008862	chr17:28927542	LRRC37B2	0.77	4.59	0.38	1.08e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs4304924	0.500	rs9601109	chr13:79220114	A/G	cg01819759	chr13:79234251	RNF219	0.86	7.64	0.57	5.22e-12	Large artery stroke;
TGCT	cis	rs12136530	0.554	rs4912093	chr1:19762321	T/C	cg18923740	chr1:19971790	NBL1	0.35	4.57	0.38	1.16e-5	Lead levels in blood;
TGCT	cis	rs992157	0.835	rs10932768	chr2:219146199	T/A	cg00012203	chr2:219082015	ARPC2	-0.8	-7.9	-0.58	1.31e-12	Colorectal cancer;
TGCT	cis	rs911263	0.961	rs2104047	chr14:68754417	T/C	cg18825221	chr14:68749962	RAD51L1	0.28	5.57	0.45	1.52e-7	Primary biliary cholangitis;
TGCT	cis	rs1943345	0.686	rs10898088	chr11:82874970	G/A	cg07047830	chr11:82868014	PCF11	0.53	5.42	0.44	3e-7	Obesity-related traits;
TGCT	cis	rs9611519	0.732	rs1883826	chr22:41703428	G/A	cg06634786	chr22:41940651	POLR3H	-0.61	-5.53	-0.44	1.8e-7	Neuroticism;
TGCT	cis	rs2663905	0.706	rs7162859	chr15:81360038	C/T	cg05624577	chr15:81411055	NA	0.55	4.67	0.39	7.64e-6	QT interval (drug interaction);
TGCT	cis	rs9916302	0.904	rs9894500	chr17:37515735	G/C	cg15445000	chr17:37608096	MED1	-0.35	-5.08	-0.42	1.33e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs10883723	0.962	rs1056740	chr10:104236552	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	7.52	0.56	9.74e-12	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs112591243	0.570	rs2839340	chr21:47989804	C/T	cg10657630	chr21:48055338	PRMT2	1.0	5.07	0.41	1.43e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs933688	0.941	rs2887007	chr5:90740531	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.11	10.58	0.69	4.97e-19	Smoking behavior;
TGCT	cis	rs6570726	0.846	rs409553	chr6:145886963	C/T	cg23711669	chr6:146136114	FBXO30	0.84	8.89	0.62	6.14e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3806843	0.735	rs813897	chr5:140070029	T/C	cg19875535	chr5:140030758	IK	-0.37	-6.23	-0.49	6.51e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs748404	0.676	rs4401024	chr15:43650335	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	4.72	0.39	6.3e-6	Lung cancer;
TGCT	cis	rs6141769	0.542	rs6058840	chr20:31319116	A/T	cg13636640	chr20:31349939	DNMT3B	0.52	4.55	0.38	1.26e-5	Subjective well-being;
TGCT	cis	rs916888	0.610	rs199446	chr17:44813169	G/A	cg17911788	chr17:44343683	NA	0.48	5.67	0.45	9.45e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2342371	0.816	rs11707744	chr3:196213855	C/G	cg15048948	chr3:196158458	UBXN7	-0.53	-4.57	-0.38	1.18e-5	Fat distribution (HIV);
TGCT	trans	rs10203711	1.000	rs907103	chr2:239564541	A/G	cg16021909	chr1:248021091	TRIM58	-0.66	-6.64	-0.51	8.68e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs26868	0.816	rs26873	chr16:2247362	C/T	cg25665528	chr16:2260870	C16orf79	-0.3	-4.67	-0.39	7.73e-6	Height;
TGCT	cis	rs3008870	0.959	rs2985826	chr1:67412918	G/C	cg03991309	chr1:68237761	GNG12	0.27	4.57	0.38	1.18e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs1042058	0.565	rs650110	chr10:30753132	A/G	cg13289132	chr10:30722225	MAP3K8	-0.4	-4.75	-0.39	5.6e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
TGCT	cis	rs6598955	0.671	rs59143843	chr1:26641595	G/T	cg04990556	chr1:26633338	UBXN11	0.64	4.91	0.4	2.78e-6	Obesity-related traits;
TGCT	cis	rs3617	0.539	rs9825369	chr3:52953311	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	0.46	4.6	0.38	1.03e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4851266	1.000	rs4583487	chr2:100837126	G/T	cg07810366	chr2:100720526	AFF3	-0.37	-5.33	-0.43	4.53e-7	Educational attainment;
TGCT	trans	rs208520	0.690	rs866452	chr6:66849936	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.95	-10.32	-0.68	2.16e-18	Exhaled nitric oxide output;
TGCT	cis	rs9364220	1.000	rs9364220	chr6:168490568	G/A	cg02770688	chr6:168491649	NA	-0.29	-4.86	-0.4	3.52e-6	Attention deficit hyperactivity disorder (inattention symptoms);Attention deficit hyperactivity disorder (combined symptoms);
TGCT	cis	rs2688608	0.592	rs3933085	chr10:75483331	C/T	cg23231163	chr10:75533350	FUT11	-0.28	-4.68	-0.39	7.4e-6	Inflammatory bowel disease;
TGCT	cis	rs66561647	0.634	rs7821856	chr8:128939499	A/G	cg05480350	chr8:128972681	MIR1205;PVT1	0.22	4.52	0.38	1.43e-5	Hemoglobin concentration;
TGCT	cis	rs12935418	0.583	rs7186230	chr16:80964620	A/G	cg07676361	chr16:80966860	NA	-0.36	-4.73	-0.39	6.04e-6	Mean corpuscular volume;
TGCT	cis	rs11031096	0.782	rs11031110	chr11:4162652	G/C	cg18678763	chr11:4115507	RRM1	-0.52	-6.66	-0.51	7.83e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs4803468	0.967	rs67047091	chr19:41938684	C/T	cg09537434	chr19:41945824	ATP5SL	0.91	10.05	0.67	9.48e-18	Height;
TGCT	cis	rs7772486	0.790	rs1133832	chr6:146205604	C/T	cg05347473	chr6:146136440	FBXO30	-0.5	-4.74	-0.39	5.79e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9303401	0.659	rs34382037	chr17:56643550	G/T	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg18230493	chr5:56204884	C5orf35	-0.68	-5.92	-0.47	2.92e-8	Initial pursuit acceleration;
TGCT	cis	rs7666738	0.830	rs3852122	chr4:98697400	T/C	cg05340658	chr4:99064831	C4orf37	0.49	5.77	0.46	6.02e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2594989	0.831	rs9840982	chr3:11564940	C/A	cg00170343	chr3:11313890	ATG7	-0.66	-4.9	-0.4	2.95e-6	Circulating chemerin levels;
TGCT	cis	rs6845621	0.700	rs10008431	chr4:18934125	T/C	cg12196642	chr4:18937545	NA	-0.25	-4.47	-0.37	1.78e-5	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
TGCT	cis	rs9914544	0.762	rs4322727	chr17:18798573	A/T	cg26306683	chr17:18585705	ZNF286B	-0.55	-5.02	-0.41	1.78e-6	Educational attainment (years of education);
TGCT	cis	rs2153535	0.580	rs4960413	chr6:8438466	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.58	0.45	1.42e-7	Motion sickness;
TGCT	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg02953382	chr22:24373134	LOC391322	-0.78	-8.12	-0.59	4.06e-13	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	15.94	0.82	8.5e-32	Prudent dietary pattern;
TGCT	cis	rs112591243	0.570	rs77436553	chr21:47759343	G/A	cg10657630	chr21:48055338	PRMT2	1.11	5.44	0.44	2.75e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg21237687	chr17:6899380	ALOX12	-0.53	-5.69	-0.46	8.5e-8	Tonsillectomy;
TGCT	cis	rs7937612	1.000	rs7951250	chr11:120309036	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.31	-5.19	-0.42	8.16e-7	Intraocular pressure;
TGCT	cis	rs9467711	0.606	rs9393712	chr6:26371000	G/C	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2439831	1.000	rs2245054	chr15:43751909	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.01	8.18	0.59	2.83e-13	Lung cancer in ever smokers;
TGCT	cis	rs3772130	0.583	rs4296627	chr3:121567684	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.59	5.43	0.44	2.8e-7	Cognitive performance;
TGCT	cis	rs35146811	0.586	rs34213597	chr7:99591021	C/T	cg13334819	chr7:99746414	C7orf59	-0.61	-5.29	-0.43	5.32e-7	Coronary artery disease;
TGCT	cis	rs4886920	0.573	rs34709918	chr15:78104683	A/G	cg25212270	chr15:78015279	NA	-0.24	-4.54	-0.38	1.34e-5	Neuroticism;
TGCT	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg02487422	chr3:49467188	NICN1	-0.54	-5.05	-0.41	1.51e-6	Menarche (age at onset);
TGCT	cis	rs736408	0.812	rs2071506	chr3:52826276	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	4.92	0.4	2.72e-6	Bipolar disorder;
TGCT	cis	rs11190604	0.790	rs11190535	chr10:102197441	A/T	cg23241863	chr10:102295624	HIF1AN	0.64	4.8	0.4	4.42e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2439831	0.867	rs2255051	chr15:43846161	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.97	7.38	0.55	2.03e-11	Lung cancer in ever smokers;
TGCT	cis	rs7412746	0.563	rs3768013	chr1:150815411	G/A	cg09365446	chr1:150670422	GOLPH3L	0.34	4.71	0.39	6.61e-6	Melanoma;
TGCT	cis	rs9796	0.870	rs4923890	chr15:41258990	T/C	cg18705301	chr15:41695430	NDUFAF1	0.43	5.63	0.45	1.13e-7	Menopause (age at onset);
TGCT	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg21724239	chr8:58056113	NA	0.39	5.08	0.41	1.37e-6	Developmental language disorder (linguistic errors);
TGCT	trans	rs1814175	0.519	rs3913237	chr11:49551828	G/A	cg11707556	chr5:10655725	ANKRD33B	0.42	8.63	0.61	2.5e-14	Height;
TGCT	cis	rs7568458	0.783	rs2166529	chr2:85742175	A/C	cg17127132	chr2:85788382	GGCX	-0.63	-5.51	-0.44	1.99e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs3862435	0.518	rs2601189	chr15:90929874	G/A	cg14166756	chr15:90894880	ZNF774	-0.33	-5.32	-0.43	4.59e-7	Response to exercise (triglyceride level interaction);
TGCT	cis	rs4808199	1.000	rs60003758	chr19:19557353	A/G	cg03709012	chr19:19516395	GATAD2A	0.97	7.52	0.56	9.52e-12	Nonalcoholic fatty liver disease;
TGCT	cis	rs7617773	0.780	rs34589064	chr3:48339549	G/A	cg11946769	chr3:48343235	NME6	0.82	7.06	0.54	1.03e-10	Coronary artery disease;
TGCT	cis	rs1395	0.744	rs4665962	chr2:27515105	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.62	8.02	0.58	6.76e-13	Blood metabolite levels;
TGCT	cis	rs7818688	0.697	rs76631135	chr8:95980988	G/T	cg16049864	chr8:95962084	TP53INP1	0.54	4.64	0.38	8.87e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg07507251	chr3:52567010	NT5DC2	0.42	5.92	0.47	2.94e-8	Bipolar disorder;
TGCT	cis	rs10197940	0.662	rs10175134	chr2:152299355	G/A	cg19508488	chr2:152266495	RIF1	0.72	6.56	0.51	1.31e-9	Lung cancer;
TGCT	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg08736216	chr1:53307985	ZYG11A	0.25	4.93	0.41	2.55e-6	Monocyte count;
TGCT	cis	rs67311347	1.000	rs4974017	chr3:40473519	C/T	cg17264618	chr3:40429014	ENTPD3	0.32	4.76	0.39	5.36e-6	Renal cell carcinoma;
TGCT	cis	rs7582180	0.627	rs2241811	chr2:101011724	C/T	cg14675211	chr2:100938903	LONRF2	0.47	4.56	0.38	1.19e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs4499344	0.633	rs166310	chr19:33155187	G/A	cg26639809	chr19:33781782	NA	0.22	4.47	0.37	1.75e-5	Mean platelet volume;
TGCT	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg19318889	chr4:1322082	MAEA	0.28	6.78	0.52	4.46e-10	Longevity;
TGCT	cis	rs4746818	1.000	rs10823301	chr10:70885875	G/A	cg04149295	chr10:70884716	VPS26A	0.73	5.25	0.43	6.31e-7	Left atrial antero-posterior diameter;
TGCT	cis	rs3806843	0.549	rs246012	chr5:140336277	C/T	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	trans	rs931812	0.895	rs4734493	chr8:101902169	C/T	cg20993868	chr7:22813445	NA	-0.38	-8.58	-0.61	3.32e-14	Attention deficit hyperactivity disorder and conduct disorder;
TGCT	cis	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg15556689	chr8:8085844	FLJ10661	0.68	6.37	0.5	3.33e-9	Mood instability;
TGCT	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg24250549	chr1:154909240	PMVK	0.62	6.28	0.49	5.29e-9	Prostate cancer;
TGCT	cis	rs3806843	0.521	rs246061	chr5:140324656	C/A	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg22857025	chr5:266934	NA	-0.34	-6.7	-0.52	6.65e-10	Breast cancer;
TGCT	cis	rs12477438	0.520	rs4588238	chr2:99749350	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	17.43	0.84	3.73e-35	Chronic sinus infection;
TGCT	cis	rs9807989	1.000	rs9807989	chr2:102971200	T/C	cg09003973	chr2:102972529	NA	0.64	5.7	0.46	8.28e-8	Asthma;
TGCT	cis	rs12220898	0.679	rs12254955	chr10:50480763	T/G	cg06072769	chr10:50146962	WDFY4	0.38	4.98	0.41	2.07e-6	Inflammatory biomarkers;
TGCT	trans	rs877282	0.853	rs11596346	chr10:756673	A/T	cg22713356	chr15:30763199	NA	1.07	8.27	0.6	1.75e-13	Uric acid levels;
TGCT	cis	rs10193935	0.901	rs9309082	chr2:42581412	A/G	cg27598129	chr2:42591480	NA	-0.42	-5.69	-0.46	8.5e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg07507251	chr3:52567010	NT5DC2	0.48	6.91	0.53	2.24e-10	Bipolar disorder;
TGCT	cis	rs1008375	1.000	rs28497813	chr4:17685503	A/G	cg10189774	chr4:17578691	LAP3	0.52	4.74	0.39	5.82e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs208520	0.661	rs207111	chr6:66792513	C/T	cg07460842	chr6:66804631	NA	-0.94	-9.86	-0.66	2.74e-17	Exhaled nitric oxide output;
TGCT	cis	rs67311347	0.955	rs12487955	chr3:40412853	T/C	cg17264618	chr3:40429014	ENTPD3	0.33	4.71	0.39	6.52e-6	Renal cell carcinoma;
TGCT	cis	rs3008870	1.000	rs2755244	chr1:67484470	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.07	-10.97	-0.7	5.49e-20	Lymphocyte percentage of white cells;
TGCT	cis	rs10751667	0.714	rs7933889	chr11:972270	C/T	cg06064525	chr11:970664	AP2A2	-0.36	-8.28	-0.6	1.67e-13	Alzheimer's disease (late onset);
TGCT	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.46	-6.43	-0.5	2.53e-9	Alzheimer's disease;
TGCT	cis	rs7666738	0.962	rs2865991	chr4:99067369	C/A	cg18180107	chr4:99064573	C4orf37	0.56	4.54	0.38	1.33e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2072499	1.000	rs2540173	chr1:156188214	A/G	cg25208724	chr1:156163844	SLC25A44	1.08	15.41	0.81	1.37e-30	Testicular germ cell tumor;
TGCT	cis	rs1729951	0.575	rs361244	chr3:136697506	C/T	cg12473912	chr3:136751656	NA	0.39	6.18	0.49	8.62e-9	Neuroticism;
TGCT	cis	rs7659604	0.540	rs11098643	chr4:122701507	C/A	cg06713675	chr4:122721982	EXOSC9	0.36	4.52	0.38	1.45e-5	Type 2 diabetes;
TGCT	cis	rs4924935	1.000	rs9905565	chr17:18758641	C/T	cg26378065	chr17:18585709	ZNF286B	0.57	4.8	0.4	4.45e-6	Pancreatic cancer;
TGCT	cis	rs9807989	0.839	rs4988957	chr2:102968075	C/T	cg09003973	chr2:102972529	NA	-0.64	-5.7	-0.46	8.28e-8	Asthma;
TGCT	cis	rs7216064	1.000	rs62084246	chr17:65867911	G/C	cg12091567	chr17:66097778	LOC651250	-0.83	-6.49	-0.5	1.9e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg03213289	chr20:61660250	NA	0.68	9.9	0.66	2.25e-17	Prostate cancer (SNP x SNP interaction);
TGCT	trans	rs8073060	0.586	rs2626625	chr17:34027607	C/G	cg19694781	chr19:47549865	TMEM160	-0.6	-13.37	-0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs35306767	0.668	rs12356612	chr10:1055055	C/T	cg26597838	chr10:835615	NA	0.57	6.58	0.51	1.21e-9	Eosinophil percentage of granulocytes;
TGCT	cis	rs1997103	0.911	rs6945663	chr7:55407011	C/G	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg04944784	chr2:26401820	FAM59B	0.76	6.24	0.49	6.46e-9	Gut microbiome composition (summer);
TGCT	cis	rs4906332	1.000	rs17617307	chr14:103904965	C/G	cg26031613	chr14:104095156	KLC1	-0.53	-4.72	-0.39	6.2e-6	Coronary artery disease;
TGCT	cis	rs42648	0.693	rs194533	chr7:89870777	A/G	cg25739043	chr7:89950458	NA	-0.54	-5.04	-0.41	1.64e-6	Homocysteine levels;
TGCT	cis	rs2404602	0.647	rs11632765	chr15:76974261	A/T	cg23625390	chr15:77176239	SCAPER	0.39	5.03	0.41	1.65e-6	Blood metabolite levels;
TGCT	cis	rs9926296	0.609	rs4785709	chr16:89796665	G/A	cg08627397	chr16:89984028	MC1R	0.31	4.98	0.41	2.05e-6	Vitiligo;
TGCT	cis	rs981844	0.775	rs56101345	chr4:154764261	C/T	cg14289246	chr4:154710475	SFRP2	1.01	8.89	0.62	5.85e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs7119038	0.818	rs57494551	chr11:118661398	C/T	cg19308663	chr11:118741387	NA	0.32	6.21	0.49	7.32e-9	Sjögren's syndrome;
TGCT	cis	rs7208859	0.623	rs55638872	chr17:29149552	G/C	cg13385521	chr17:29058706	SUZ12P	0.81	4.85	0.4	3.68e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs3849570	0.643	rs6548779	chr3:81968512	A/G	cg07356753	chr3:81810745	GBE1	-0.67	-5.97	-0.47	2.3e-8	Waist circumference;Body mass index;
TGCT	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg16325326	chr1:53192061	ZYG11B	-0.71	-8.81	-0.62	9.22e-15	Monocyte count;
TGCT	cis	rs62244186	0.593	rs9814298	chr3:44871899	T/A	cg04389838	chr3:44770851	ZNF501	-0.35	-4.5	-0.37	1.57e-5	Depressive symptoms;
TGCT	cis	rs12579753	1.000	rs11519754	chr12:82209181	A/T	cg07988820	chr12:82153109	PPFIA2	-0.65	-6.79	-0.52	4.09e-10	Resting heart rate;
TGCT	cis	rs992157	0.835	rs7585702	chr2:219146607	T/C	cg00012203	chr2:219082015	ARPC2	-0.79	-7.87	-0.58	1.48e-12	Colorectal cancer;
TGCT	trans	rs10504390	0.656	rs77264178	chr8:66515086	G/A	cg18118147	chr19:51128640	SYT3	-0.77	-6.85	-0.52	2.99e-10	IgG glycosylation;
TGCT	cis	rs78487399	0.808	rs7591387	chr2:43756032	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.02	-0.41	1.75e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs666930	1.000	rs666930	chr1:120258970	A/G	cg19096424	chr1:120255104	PHGDH	0.54	5.06	0.41	1.46e-6	Breast cancer;
TGCT	cis	rs4252435	0.614	rs8176036	chr7:142640596	T/G	cg21621906	chr7:142494914	NA	-1.08	-4.53	-0.38	1.36e-5	Cancer;
TGCT	cis	rs7044106	0.791	rs747819	chr9:123488441	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	7.88	0.58	1.46e-12	Hip circumference adjusted for BMI;
TGCT	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg05985448	chr10:134359359	INPP5A	0.21	4.63	0.38	9.16e-6	Migraine;
TGCT	cis	rs637571	0.522	rs528736	chr11:65705108	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.62	6.32	0.49	4.22e-9	Eosinophil percentage of white cells;
TGCT	cis	rs2738048	0.545	rs2738045	chr8:6823568	T/C	cg24860332	chr8:6827800	DEFA10P	-0.42	-6.08	-0.48	1.36e-8	IgA nephropathy;
TGCT	cis	rs6831352	0.918	rs2602894	chr4:100045647	A/G	cg12011299	chr4:100065546	ADH4	0.41	4.92	0.4	2.72e-6	Alcohol dependence;
TGCT	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg11644478	chr21:40555479	PSMG1	0.97	9.14	0.63	1.54e-15	Cognitive function;
TGCT	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	8.99	0.63	3.48e-15	Platelet count;
TGCT	cis	rs7926906	0.713	rs10741373	chr11:90520993	G/A	cg26138821	chr11:89956704	CHORDC1	-0.44	-4.7	-0.39	6.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9916302	0.706	rs1874226	chr17:37729031	C/T	cg03321784	chr17:37729644	NA	-0.44	-4.58	-0.38	1.1e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs2456568	0.548	rs4402256	chr11:93660803	T/C	cg16099599	chr11:93583650	C11orf90	-0.38	-4.62	-0.38	9.53e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs2228479	0.867	rs75110337	chr16:89962635	C/A	cg04013166	chr16:89971882	TCF25	0.33	4.47	0.37	1.75e-5	Skin colour saturation;
TGCT	cis	rs9914988	0.725	rs9905510	chr17:27092325	G/A	cg20469991	chr17:27169893	C17orf63	-0.72	-5.04	-0.41	1.58e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs7769051	0.614	rs6912936	chr6:133102664	A/G	cg07930552	chr6:133119739	C6orf192	0.93	5.0	0.41	1.87e-6	Type 2 diabetes nephropathy;
TGCT	cis	rs12477438	1.000	rs12477438	chr2:99841085	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.81	-6.36	-0.5	3.59e-9	Chronic sinus infection;
TGCT	cis	rs2243480	1.000	rs1796228	chr7:66033084	G/A	cg18252515	chr7:66147081	NA	-1.22	-8.04	-0.59	6.02e-13	Diabetic kidney disease;
TGCT	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.08	0.48	1.37e-8	Bipolar disorder;
TGCT	cis	rs910316	1.000	rs1043674	chr14:75549370	T/C	cg23033748	chr14:75592666	NEK9	0.27	4.57	0.38	1.16e-5	Height;
TGCT	cis	rs892961	1.000	rs2164449	chr17:75401190	G/A	cg05865280	chr17:75406074	SEPT9	0.28	6.57	0.51	1.22e-9	Airflow obstruction;
TGCT	cis	rs921968	0.613	rs2303565	chr2:219545309	T/C	cg02176678	chr2:219576539	TTLL4	-0.33	-4.45	-0.37	1.91e-5	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs9814567	1.000	rs13090969	chr3:134307257	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.95	8.76	0.62	1.21e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs9556958	0.527	rs9517313	chr13:99105892	C/G	cg20487152	chr13:99095054	FARP1	0.26	5.07	0.41	1.41e-6	Educational attainment (years of education);
TGCT	cis	rs11190604	1.000	rs2489048	chr10:102348497	G/T	cg23241863	chr10:102295624	HIF1AN	0.67	4.87	0.4	3.36e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9911578	0.967	rs3826353	chr17:57075299	C/T	cg05425664	chr17:57184151	TRIM37	-0.65	-6.66	-0.51	7.92e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	5.65	0.45	1.06e-7	Height;
TGCT	cis	rs4253772	0.591	rs73886791	chr22:46687212	A/G	cg24881330	chr22:46731750	TRMU	0.96	6.38	0.5	3.18e-9	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg11871910	chr12:69753446	YEATS4	0.87	10.07	0.67	8.72e-18	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs10479542	0.806	rs4700835	chr5:178976313	A/G	cg21226059	chr5:178986404	RUFY1	0.44	4.74	0.39	5.79e-6	Lung cancer;
TGCT	cis	rs35306767	0.903	rs10508208	chr10:910983	C/T	cg26597838	chr10:835615	NA	0.75	10.54	0.69	6.3e-19	Eosinophil percentage of granulocytes;
TGCT	cis	rs2014572	0.967	rs4801452	chr19:57768066	A/G	cg24459738	chr19:57751996	ZNF805	-0.58	-5.71	-0.46	7.75e-8	Hyperactive-impulsive symptoms;
TGCT	cis	rs3749237	0.964	rs7431078	chr3:49808190	G/A	cg03060546	chr3:49711283	APEH	0.72	7.38	0.55	2.02e-11	Resting heart rate;
TGCT	cis	rs4700695	0.764	rs36299	chr5:65348120	G/T	cg21114390	chr5:65439923	SFRS12	0.61	4.51	0.38	1.46e-5	Facial morphology (factor 19);
TGCT	cis	rs10875746	0.903	rs11168420	chr12:48515896	C/T	cg20731937	chr12:48336164	NA	0.61	5.01	0.41	1.81e-6	Longevity (90 years and older);
TGCT	cis	rs9611565	0.568	rs5758441	chr22:42132888	C/A	cg13695892	chr22:41940480	POLR3H	0.84	7.96	0.58	9.2e-13	Vitiligo;
TGCT	cis	rs1538970	0.884	rs781232	chr1:45890399	C/T	cg05343316	chr1:45956843	TESK2	-0.75	-6.08	-0.48	1.39e-8	Platelet count;
TGCT	cis	rs13217239	0.646	rs7768407	chr6:27016795	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.44	4.95	0.41	2.39e-6	Schizophrenia;
TGCT	trans	rs916888	0.647	rs199523	chr17:44848517	C/A	cg22433210	chr17:43662623	NA	-0.92	-7.55	-0.56	8e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs72945132	0.882	rs67283107	chr11:70221204	C/T	cg00319359	chr11:70116639	PPFIA1	0.99	7.39	0.55	1.94e-11	Coronary artery disease;
TGCT	cis	rs3741404	0.825	rs2515241	chr11:63975331	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.9	10.32	0.68	2.07e-18	Platelet count;
TGCT	cis	rs10507380	0.824	rs117253068	chr13:27925061	C/T	cg25543773	chr13:27185723	WASF3	0.32	4.52	0.38	1.45e-5	Electrocardiographic traits;
TGCT	cis	rs459571	0.959	rs460888	chr9:136913123	C/G	cg13789015	chr9:136890014	NCRNA00094	0.4	7.15	0.54	6.64e-11	Platelet distribution width;
TGCT	cis	rs67133203	0.632	rs706802	chr12:51373742	C/T	cg01517968	chr12:52348879	ACVR1B	-0.38	-4.91	-0.4	2.81e-6	Urinary tract infection frequency;
TGCT	cis	rs12765878	0.934	rs58543155	chr10:105643244	G/A	cg11005552	chr10:105648138	OBFC1	0.44	7.6	0.56	6.24e-12	Coronary artery disease;
TGCT	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.49	-5.62	-0.45	1.2e-7	Longevity;Endometriosis;
TGCT	cis	rs7666738	0.830	rs1426663	chr4:98990092	T/G	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1629083	0.935	rs2051480	chr11:118094513	A/G	cg16594165	chr11:118135105	MPZL2	-0.33	-4.7	-0.39	6.73e-6	Lung cancer;
TGCT	cis	rs3733585	0.605	rs4235355	chr4:10123078	C/A	cg11266682	chr4:10021025	SLC2A9	-0.55	-6.43	-0.5	2.44e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg07507251	chr3:52567010	NT5DC2	0.48	6.95	0.53	1.82e-10	Bipolar disorder;
TGCT	cis	rs13191362	1.000	rs13220181	chr6:163004401	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.57	4.94	0.41	2.45e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs28595532	0.920	rs6818519	chr4:119787820	G/T	cg00700008	chr4:120138107	USP53	0.49	4.48	0.37	1.71e-5	Cannabis dependence symptom count;
TGCT	cis	rs3806843	0.546	rs246023	chr5:140333990	G/T	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9300255	0.602	rs2851435	chr12:123712416	G/A	cg00376283	chr12:123451042	ABCB9	0.73	5.07	0.41	1.42e-6	Neutrophil percentage of white cells;
TGCT	cis	rs6088580	0.634	rs3746455	chr20:32957216	G/A	cg06115741	chr20:33292138	TP53INP2	-0.55	-4.8	-0.4	4.5e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7524258	0.868	rs2412152	chr1:7303213	C/T	cg07173049	chr1:7289937	CAMTA1	0.29	4.82	0.4	4.2e-6	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs2235642	1.000	rs2235642	chr16:1584866	T/C	cg00463982	chr16:1583984	IFT140;TMEM204	-0.28	-4.82	-0.4	4.09e-6	Coronary artery disease;
TGCT	cis	rs854765	0.547	rs2955370	chr17:17966945	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.79	-8.28	-0.6	1.68e-13	Total body bone mineral density;
TGCT	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg23708337	chr7:1209742	NA	0.51	4.46	0.37	1.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs17376456	1.000	rs34068652	chr5:93563319	G/A	cg25358565	chr5:93447407	FAM172A	0.95	7.18	0.54	5.63e-11	Diabetic retinopathy;
TGCT	cis	rs9309473	0.607	rs7574291	chr2:73594941	A/G	cg20560298	chr2:73613845	ALMS1	-0.41	-4.56	-0.38	1.23e-5	Metabolite levels;
TGCT	cis	rs5750830	0.594	rs5757647	chr22:39775047	C/A	cg01416388	chr22:39784598	NA	-0.59	-5.8	-0.46	5.09e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg20887711	chr4:1340912	KIAA1530	0.91	8.34	0.6	1.22e-13	Longevity;
TGCT	cis	rs2115630	0.645	rs1107179	chr15:85198362	A/C	cg12863693	chr15:85201151	NMB	0.4	5.31	0.43	4.85e-7	P wave terminal force;
TGCT	cis	rs453301	0.653	rs7005133	chr8:8901222	T/G	cg08975724	chr8:8085496	FLJ10661	0.58	4.95	0.41	2.33e-6	Joint mobility (Beighton score);
TGCT	cis	rs11190604	1.000	rs11190607	chr10:102303614	C/T	cg16342193	chr10:102329863	NA	-0.4	-4.89	-0.4	3.08e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg04546413	chr19:29218101	NA	0.83	6.68	0.51	7.35e-10	Methadone dose in opioid dependence;
TGCT	cis	rs950169	0.922	rs62028133	chr15:84919375	A/C	cg17173187	chr15:85201210	NMB	0.54	5.55	0.45	1.67e-7	Schizophrenia;
TGCT	cis	rs10901296	0.588	rs12003046	chr9:133741626	T/C	cg03924115	chr9:133768966	QRFP	0.27	4.57	0.38	1.14e-5	Bilirubin levels;
TGCT	cis	rs2228479	0.850	rs12599473	chr16:89827435	A/C	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs7809950	0.817	rs2222845	chr7:107281829	C/T	cg23024343	chr7:107201750	COG5	0.48	6.85	0.52	3.11e-10	Coronary artery disease;
TGCT	cis	rs4808199	0.901	rs12973258	chr19:19488718	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.69	4.99	0.41	2.02e-6	Nonalcoholic fatty liver disease;
TGCT	cis	rs6500602	1.000	rs12447826	chr16:4464617	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.3	5.1	0.42	1.24e-6	Schizophrenia;
TGCT	cis	rs3780378	0.935	rs7875908	chr9:5081334	C/T	cg03508284	chr9:4985524	JAK2	-0.47	-4.44	-0.37	1.97e-5	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg10047753	chr17:41438598	NA	0.97	10.04	0.67	1.04e-17	Menopause (age at onset);
TGCT	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg11890956	chr21:40555474	PSMG1	1.12	12.59	0.75	6.25e-24	Cognitive function;
TGCT	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg23758822	chr17:41437982	NA	0.72	6.81	0.52	3.77e-10	Menopause (age at onset);
TGCT	cis	rs9393777	0.513	rs6936555	chr6:26640886	C/T	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.51	-4.68	-0.39	7.36e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.34	0.43	4.23e-7	Prudent dietary pattern;
TGCT	cis	rs17162190	0.590	rs3127010	chr1:26782700	A/G	cg02450742	chr1:26856648	RPS6KA1	-0.55	-4.61	-0.38	9.69e-6	Mean corpuscular volume;
TGCT	cis	rs55794721	0.509	rs12027135	chr1:25775733	A/T	cg23205692	chr1:25664452	TMEM50A	0.47	4.95	0.41	2.32e-6	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs7027203	0.964	rs7853688	chr9:96523254	C/A	cg14396892	chr9:96623032	NA	0.23	4.6	0.38	1.03e-5	DNA methylation (variation);
TGCT	cis	rs2013441	1.000	rs9897328	chr17:20174852	G/A	cg18979559	chr17:20280153	CCDC144C	-0.45	-4.67	-0.39	7.61e-6	Obesity-related traits;
TGCT	cis	rs921968	0.541	rs7603816	chr2:219396255	C/T	cg02176678	chr2:219576539	TTLL4	-0.49	-6.94	-0.53	1.95e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs2013441	1.000	rs9896709	chr17:20180550	G/A	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.63	-0.38	9.19e-6	Obesity-related traits;
TGCT	cis	rs6840360	0.573	rs11099806	chr4:152269116	G/T	cg17479576	chr4:152424074	FAM160A1	-0.45	-4.77	-0.39	5.1e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs3008870	1.000	rs3008870	chr1:67418027	C/T	cg03991309	chr1:68237761	GNG12	0.27	4.57	0.38	1.18e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs2370759	1.000	rs79806114	chr10:32618022	T/C	cg01819863	chr10:32635814	EPC1	1.03	10.0	0.67	1.27e-17	Sexual dysfunction (female);
TGCT	cis	rs7267979	1.000	rs11087520	chr20:25436827	C/T	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11190604	0.767	rs7085426	chr10:102163640	T/C	cg23241863	chr10:102295624	HIF1AN	0.6	4.57	0.38	1.17e-5	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs12142240	0.698	rs6695043	chr1:46844530	A/G	cg00530320	chr1:46809349	NSUN4	-0.29	-5.73	-0.46	7.12e-8	Menopause (age at onset);
TGCT	cis	rs11190604	1.000	rs11190601	chr10:102296730	A/G	cg16342193	chr10:102329863	NA	-0.41	-5.37	-0.43	3.78e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7937682	1.000	rs9734135	chr11:111536190	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.05	-10.05	-0.67	9.54e-18	Primary sclerosing cholangitis;
TGCT	cis	rs4332037	0.539	rs4719416	chr7:2106608	G/A	cg24505167	chr7:1915268	MAD1L1	-0.28	-4.69	-0.39	7.11e-6	Bipolar disorder;
TGCT	cis	rs734999	0.545	rs4474198	chr1:2553758	C/T	cg18854424	chr1:2615690	NA	0.5	5.95	0.47	2.54e-8	Ulcerative colitis;
TGCT	cis	rs9303542	0.625	rs9904760	chr17:46575031	C/T	cg25032089	chr17:46643351	HOXB3	0.49	5.36	0.43	3.93e-7	Ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg09021430	chr5:549028	NA	-0.38	-5.06	-0.41	1.45e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs7267979	0.706	rs6037069	chr20:25234166	C/T	cg14121845	chr20:25566513	NINL	0.48	5.22	0.42	7.27e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg17554472	chr22:41940697	POLR3H	-0.5	-5.2	-0.42	8.14e-7	Vitiligo;
TGCT	cis	rs67311347	1.000	rs9875245	chr3:40442280	G/T	cg13683864	chr3:40499215	RPL14	-1.19	-13.2	-0.76	2.17e-25	Renal cell carcinoma;
TGCT	cis	rs6121246	0.529	rs6060118	chr20:30171209	T/C	cg18721089	chr20:30220636	NA	-0.58	-6.34	-0.5	3.81e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs1215050	0.791	rs1648546	chr4:98899294	T/C	cg17366294	chr4:99064904	C4orf37	-0.53	-5.69	-0.45	8.67e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg16414030	chr3:133502952	NA	-0.67	-11.16	-0.71	1.94e-20	Iron status biomarkers;
TGCT	cis	rs6835174	0.730	rs74217404	chr4:5987735	C/T	cg13644262	chr4:6449564	PPP2R2C	-0.34	-4.74	-0.39	5.88e-6	Cannabis use (initiation);
TGCT	cis	rs12682352	0.602	rs4841044	chr8:8664940	A/G	cg15556689	chr8:8085844	FLJ10661	-0.62	-5.5	-0.44	2.1e-7	Neuroticism;
TGCT	cis	rs3739821	0.793	rs7023663	chr9:130714930	T/C	cg17308606	chr9:130706144	FAM102A	0.28	4.59	0.38	1.08e-5	Glaucoma (primary angle closure);
TGCT	cis	rs6684514	1.000	rs12045339	chr1:156294211	C/T	cg20302342	chr1:156215951	PAQR6	0.35	4.74	0.39	5.77e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs78461346	0.610	rs117607873	chr17:80476066	G/A	cg15014069	chr17:80540666	FOXK2	0.4	5.27	0.43	5.9e-7	3-hydroxypropylmercapturic acid levels in smokers;
TGCT	cis	rs10791097	0.667	rs4937584	chr11:130741761	A/G	cg05962950	chr11:130786565	SNX19	0.92	11.55	0.72	2.13e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs1865760	0.593	rs9393676	chr6:25936944	G/A	cg12310025	chr6:25882481	NA	-0.52	-5.28	-0.43	5.47e-7	Height;
TGCT	cis	rs28785552	0.769	rs7253672	chr19:53243212	G/C	cg22067481	chr19:53234126	ZNF611	-0.47	-6.81	-0.52	3.68e-10	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs10927875	0.615	rs10927886	chr1:16339313	C/G	cg21385522	chr1:16154831	NA	-0.46	-4.86	-0.4	3.42e-6	Dilated cardiomyopathy;
TGCT	cis	rs5769765	1.000	rs910800	chr22:50278642	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	-0.4	-6.07	-0.48	1.46e-8	Schizophrenia;
TGCT	cis	rs698833	0.506	rs713448	chr2:44504877	T/C	cg00619915	chr2:44497795	NA	-0.22	-4.95	-0.41	2.38e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
TGCT	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs7044106	0.791	rs4617229	chr9:123480696	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	4.78	0.39	4.8e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs10088262	0.629	rs1367829	chr8:124797135	A/G	cg20713898	chr8:124780851	FAM91A1	-0.84	-7.19	-0.54	5.3e-11	Pancreatic cancer;
TGCT	cis	rs59698941	0.527	rs1557852	chr5:132181800	G/A	cg21474247	chr5:131268130	NA	0.31	4.97	0.41	2.16e-6	Apolipoprotein A-IV levels;
TGCT	cis	rs1691799	0.899	rs1168329	chr12:66731864	C/A	cg16791601	chr12:66731901	HELB	-0.29	-6.38	-0.5	3.25e-9	White blood cell count (basophil);
TGCT	cis	rs524281	0.814	rs10896098	chr11:65968416	G/A	cg00563793	chr11:65837595	PACS1	0.53	4.67	0.39	7.6e-6	Electroencephalogram traits;
TGCT	cis	rs4663866	0.901	rs35713061	chr2:239183774	C/T	cg17283117	chr2:239148619	HES6	0.99	4.58	0.38	1.12e-5	Irritable bowel syndrome;
TGCT	cis	rs7524258	0.903	rs763197	chr1:7289959	A/G	cg04342483	chr1:7259290	CAMTA1	-0.31	-4.49	-0.37	1.6e-5	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg02503808	chr4:7069936	GRPEL1	0.98	9.27	0.64	7.53e-16	Monocyte percentage of white cells;
TGCT	cis	rs2242116	0.932	rs4683301	chr3:46931478	A/T	cg16339096	chr3:46934204	PTH1R	-0.41	-4.61	-0.38	9.67e-6	Birth weight;
TGCT	cis	rs459571	0.959	rs2520100	chr9:136918137	A/T	cg14405625	chr9:136855902	VAV2	-0.32	-4.72	-0.39	6.15e-6	Platelet distribution width;
TGCT	cis	rs200810	0.664	rs35600586	chr6:98008034	G/A	cg16511841	chr6:97730490	C6orf167;MIR548H3	-0.64	-4.45	-0.37	1.91e-5	Body mass index;
TGCT	cis	rs3008870	0.792	rs72673729	chr1:67441673	T/TG	cg08660285	chr1:67390436	MIER1;WDR78	-1.1	-11.89	-0.73	3.12e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs858239	0.539	rs10279194	chr7:23191083	T/C	cg05602783	chr7:23145260	KLHL7	-0.63	-4.98	-0.41	2.09e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs9383153	1.000	rs9370887	chr6:16329258	G/C	cg14009473	chr6:15502099	JARID2	0.61	4.85	0.4	3.62e-6	Gambling;
TGCT	cis	rs1475911	1.000	rs55645900	chr21:43515728	G/T	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.26	-5.07	-0.41	1.4e-6	IgG glycosylation;
TGCT	cis	rs8072100	0.713	rs8074451	chr17:45477573	C/T	cg08085267	chr17:45401833	C17orf57	-0.51	-5.57	-0.45	1.51e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs28595532	1.000	rs114778020	chr4:119662584	C/A	cg21605333	chr4:119757512	SEC24D	1.4	7.94	0.58	1.04e-12	Cannabis dependence symptom count;
TGCT	cis	rs1215050	0.567	rs1567288	chr4:98582985	A/G	cg05340658	chr4:99064831	C4orf37	-0.41	-4.8	-0.4	4.45e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg03517284	chr6:25882590	NA	-0.52	-4.66	-0.39	7.92e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2795502	0.873	rs3121282	chr10:43423626	T/A	cg20628663	chr10:43360327	NA	0.35	5.21	0.42	7.79e-7	Blood protein levels;
TGCT	cis	rs12142240	0.698	rs10158572	chr1:46822440	G/T	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs11992186	0.505	rs7845203	chr8:8145440	A/G	cg06636001	chr8:8085503	FLJ10661	0.58	4.89	0.4	3.05e-6	Neuroticism;
TGCT	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	5.11	0.42	1.18e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs12210905	1.000	rs72843619	chr6:27154830	A/G	cg08851530	chr6:28072375	NA	1.12	5.43	0.44	2.82e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg20573242	chr4:122745356	CCNA2	0.63	5.54	0.45	1.72e-7	Type 2 diabetes;
TGCT	cis	rs319204	1.000	rs319233	chr5:146241258	C/T	cg25021259	chr5:146258546	PPP2R2B	0.36	4.53	0.38	1.37e-5	Schizophrenia;
TGCT	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	5.05	0.41	1.51e-6	Menopause (age at onset);
TGCT	cis	rs6500602	0.727	rs12443748	chr16:4541831	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.3	5.52	0.44	1.86e-7	Schizophrenia;
TGCT	cis	rs295140	0.743	rs952530	chr2:201081745	A/G	cg04283868	chr2:201171347	SPATS2L	0.53	5.25	0.43	6.53e-7	QT interval;
TGCT	cis	rs55962025	0.883	rs3121419	chr4:3232257	C/T	cg06533319	chr4:3265114	C4orf44	0.24	4.72	0.39	6.35e-6	Parental longevity (mother's age at death);
TGCT	cis	rs6490294	0.904	rs2339908	chr12:112418496	G/A	cg10833066	chr12:111807467	FAM109A	0.35	5.13	0.42	1.09e-6	Mean platelet volume;
TGCT	cis	rs1568889	0.730	rs6484350	chr11:28113658	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.92	-11.35	-0.71	6.62e-21	Bipolar disorder;
TGCT	cis	rs807669	0.903	rs1018764	chr22:19172006	T/C	cg02655711	chr22:19163373	SLC25A1	0.42	10.01	0.67	1.23e-17	Metabolite levels;
TGCT	cis	rs1215050	0.765	rs181521	chr4:98745728	A/C	cg17366294	chr4:99064904	C4orf37	0.52	5.61	0.45	1.27e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1552244	0.882	rs13100734	chr3:10022878	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.63	-0.51	9.16e-10	Alzheimer's disease;
TGCT	cis	rs12541335	0.639	rs3923439	chr8:22170079	G/A	cg18135555	chr8:22132992	PIWIL2	0.29	5.98	0.47	2.23e-8	Hypertriglyceridemia;
TGCT	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.7	-0.39	6.79e-6	Prudent dietary pattern;
TGCT	cis	rs12142240	0.698	rs67941619	chr1:46838219	A/G	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs9467773	1.000	rs1321480	chr6:26532742	A/G	cg05738196	chr6:26577821	NA	0.88	12.46	0.75	1.33e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9549367	0.789	rs2316442	chr13:113877487	C/T	cg00898013	chr13:113819073	PROZ	-0.39	-4.76	-0.39	5.36e-6	Platelet distribution width;
TGCT	cis	rs9430161	0.579	rs9659356	chr1:11034817	A/G	cg02454025	chr1:11042201	C1orf127	0.95	12.18	0.74	6.17e-23	Ewing sarcoma;
TGCT	cis	rs7246657	0.678	rs2927740	chr19:38140966	A/G	cg18154014	chr19:37997991	ZNF793	-0.67	-4.69	-0.39	6.96e-6	Coronary artery calcification;
TGCT	cis	rs6582630	0.555	rs10880613	chr12:38509553	C/T	cg26384229	chr12:38710491	ALG10B	0.89	8.14	0.59	3.55e-13	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs71636778	0.509	rs6656815	chr1:27292462	G/A	cg23921621	chr1:27994728	IFI6	-0.43	-4.61	-0.38	9.92e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
TGCT	cis	rs7267979	0.586	rs6050439	chr20:25192331	T/C	cg03522245	chr20:25566470	NINL	0.5	5.24	0.43	6.66e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11874712	1.000	rs9945606	chr18:43673325	A/G	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	5.23	0.42	7.11e-7	Migraine - clinic-based;
TGCT	cis	rs4478858	0.735	rs6685728	chr1:31802550	T/C	cg00250761	chr1:31883323	NA	-0.28	-4.96	-0.41	2.32e-6	Alcohol dependence;
TGCT	cis	rs3806843	0.676	rs2569159	chr5:140030710	C/T	cg19875535	chr5:140030758	IK	-0.36	-6.26	-0.49	5.68e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs17433780	0.928	rs12127787	chr1:89458761	T/C	cg09516651	chr1:89888402	LOC400759	0.32	5.89	0.47	3.35e-8	Carotid intima media thickness;
TGCT	cis	rs2197308	0.740	rs11182967	chr12:37935140	A/C	cg26384229	chr12:38710491	ALG10B	0.87	7.83	0.58	1.85e-12	Morning vs. evening chronotype;
TGCT	cis	rs2880765	0.835	rs4843063	chr15:86048748	G/T	cg13263323	chr15:86062960	AKAP13	-0.23	-4.82	-0.4	4.1e-6	Coronary artery disease;
TGCT	cis	rs8051431	0.504	rs2335711	chr16:71907559	T/A	cg06353428	chr16:71660113	MARVELD3	0.83	6.97	0.53	1.65e-10	LDL cholesterol levels;
TGCT	cis	rs17826219	0.706	rs55764512	chr17:29085758	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Body mass index;
TGCT	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg03188948	chr7:1209495	NA	0.59	4.82	0.4	4.06e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg10819733	chr22:24237672	NA	0.28	4.59	0.38	1.09e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	trans	rs783396	0.818	rs2353043	chr6:107000383	C/T	cg27564810	chr2:201635376	AOX2P	-0.43	-6.75	-0.52	5.02e-10	Stroke;
TGCT	cis	rs916888	0.821	rs415430	chr17:44859144	C/T	cg01570182	chr17:44337453	NA	-1.01	-9.1	-0.63	1.83e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs644799	0.710	rs1852535	chr11:95501241	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.8	8.99	0.63	3.39e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs610932	0.517	rs1530915	chr11:60028917	A/G	cg18570331	chr11:60101691	MS4A6E	0.5	4.44	0.37	1.93e-5	Alzheimer's disease;
TGCT	cis	rs797680	0.856	rs6688230	chr1:93641124	C/T	cg17826107	chr1:92977322	EVI5	-0.24	-5.27	-0.43	5.93e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs8177253	0.696	rs4459901	chr3:133465699	T/C	cg01448562	chr3:133502909	NA	-0.26	-4.94	-0.41	2.46e-6	Iron status biomarkers;
TGCT	cis	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg11764359	chr7:65958608	NA	0.54	4.85	0.4	3.67e-6	Aortic root size;
TGCT	cis	rs12142240	0.698	rs66911505	chr1:46823298	A/G	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs62283056	0.512	rs4568307	chr4:6284965	A/G	cg25554036	chr4:6271136	WFS1	0.56	7.26	0.55	3.68e-11	Cisplatin-induced ototoxicity;
TGCT	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg13395646	chr4:1353034	KIAA1530	-0.36	-4.47	-0.37	1.72e-5	Obesity-related traits;
TGCT	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg10047753	chr17:41438598	NA	0.96	9.6	0.65	1.16e-16	Menopause (age at onset);
TGCT	cis	rs7777754	0.512	rs3757472	chr7:50537983	A/C	cg18232548	chr7:50535776	DDC	-0.39	-6.03	-0.48	1.72e-8	Response to zileuton treatment in asthma (FEV1 change interaction);
TGCT	cis	rs28595532	1.000	rs28595532	chr4:119716950	A/C	cg21605333	chr4:119757512	SEC24D	1.22	7.4	0.55	1.83e-11	Cannabis dependence symptom count;
TGCT	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg22920501	chr2:26401640	FAM59B	-0.73	-6.44	-0.5	2.35e-9	Gut microbiome composition (summer);
TGCT	cis	rs428668	0.523	rs6898671	chr5:150677643	A/T	cg11125805	chr5:150678162	SLC36A3	0.32	8.06	0.59	5.36e-13	Skin aging (microtopography measurement);
TGCT	cis	rs4919044	0.641	rs11187231	chr10:94736462	T/A	cg05127821	chr10:94822908	CYP26C1	-0.73	-4.47	-0.37	1.74e-5	Coronary artery disease;
TGCT	cis	rs4812048	1.000	rs6070692	chr20:57586374	A/G	cg24457521	chr20:57607420	ATP5E	-0.7	-4.58	-0.38	1.13e-5	Mean platelet volume;
TGCT	cis	rs1008375	1.000	rs2315556	chr4:17670861	T/C	cg16339924	chr4:17578868	LAP3	0.55	4.76	0.39	5.3e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs17826219	0.500	rs57005940	chr17:29066329	C/G	cg13385521	chr17:29058706	SUZ12P	0.8	4.87	0.4	3.36e-6	Body mass index;
TGCT	cis	rs7513165	0.932	rs12040580	chr1:204148168	T/C	cg04791601	chr1:204159016	NA	0.25	5.09	0.42	1.32e-6	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
TGCT	cis	rs877282	0.898	rs36064821	chr10:760952	C/T	cg17470449	chr10:769945	NA	0.36	5.35	0.43	4.04e-7	Uric acid levels;
TGCT	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg20891283	chr12:69753455	YEATS4	0.91	10.33	0.68	1.96e-18	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6988636	1.000	rs61422480	chr8:124188940	C/A	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg17747265	chr1:1875780	NA	-0.42	-8.11	-0.59	4.23e-13	Body mass index;
TGCT	cis	rs7917772	0.503	rs56397707	chr10:104302693	T/C	cg05855489	chr10:104503620	C10orf26	-0.58	-5.06	-0.41	1.47e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs17401966	0.838	rs12125535	chr1:10350849	T/A	cg19773385	chr1:10388646	KIF1B	-0.21	-4.57	-0.38	1.17e-5	Hepatocellular carcinoma;
TGCT	cis	rs7412746	0.611	rs10888395	chr1:150762171	C/T	cg09365446	chr1:150670422	GOLPH3L	0.36	5.19	0.42	8.25e-7	Melanoma;
TGCT	cis	rs4325129	0.954	rs12118188	chr1:159492663	T/A	cg07417683	chr1:159440267	NA	-0.45	-4.59	-0.38	1.07e-5	Obesity-related traits;
TGCT	cis	rs4788570	0.578	rs8062188	chr16:71729825	T/C	cg06353428	chr16:71660113	MARVELD3	1.57	13.04	0.76	5.38e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs7439150	1.000	rs4333166	chr4:155481511	A/G	cg22130008	chr4:155548532	NA	0.4	4.86	0.4	3.46e-6	Fibrinogen levels;
TGCT	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg03303774	chr4:1407052	NA	0.27	4.48	0.37	1.7e-5	Obesity-related traits;
TGCT	cis	rs7258465	0.931	rs875396	chr19:18611147	A/G	cg06462663	chr19:18546047	ISYNA1	0.2	4.67	0.39	7.74e-6	Breast cancer;
TGCT	cis	rs556990	0.574	rs473598	chr13:113801189	C/T	cg18105134	chr13:113819100	PROZ	-0.44	-7.46	-0.56	1.34e-11	Blood protein levels;
TGCT	cis	rs4595586	0.545	rs4768505	chr12:39380338	C/A	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs7216064	1.000	rs58122682	chr17:65876915	T/C	cg12091567	chr17:66097778	LOC651250	-0.82	-6.37	-0.5	3.32e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs12477438	0.798	rs13409996	chr2:99575497	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-6.25	-0.49	5.98e-9	Chronic sinus infection;
TGCT	cis	rs35306767	0.715	rs17221456	chr10:1037234	T/C	cg20503657	chr10:835505	NA	0.63	6.97	0.53	1.64e-10	Eosinophil percentage of granulocytes;
TGCT	cis	rs12908161	1.000	rs12908161	chr15:85207825	A/G	cg12863693	chr15:85201151	NMB	0.46	5.53	0.44	1.79e-7	Schizophrenia;
TGCT	cis	rs7258465	0.965	rs7253990	chr19:18604085	C/G	cg06462663	chr19:18546047	ISYNA1	0.2	4.67	0.39	7.74e-6	Breast cancer;
TGCT	cis	rs10493773	0.609	rs3753789	chr1:86174814	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.52	-8.15	-0.59	3.45e-13	Urate levels in overweight individuals;
TGCT	cis	rs832540	0.552	rs702681	chr5:56218029	C/T	cg12311346	chr5:56204834	C5orf35	-0.55	-5.48	-0.44	2.23e-7	Coronary artery disease;
TGCT	cis	rs9914988	0.943	rs67327562	chr17:27108828	G/A	cg20469991	chr17:27169893	C17orf63	-0.72	-5.04	-0.41	1.58e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs6570726	0.791	rs418701	chr6:145889992	C/T	cg05347473	chr6:146136440	FBXO30	0.52	4.95	0.41	2.33e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2334880	0.678	rs6499520	chr16:71458100	C/T	cg06353428	chr16:71660113	MARVELD3	-1.26	-8.32	-0.6	1.34e-13	Malaria;
TGCT	cis	rs9303401	0.659	rs66514313	chr17:56714057	C/T	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.05	-0.48	1.57e-8	Gut microbiome composition (summer);
TGCT	cis	rs7582180	0.629	rs13004216	chr2:100945402	G/A	cg08017756	chr2:100939284	LONRF2	-0.3	-4.87	-0.4	3.27e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7192750	0.586	rs6499552	chr16:71943169	G/C	cg06353428	chr16:71660113	MARVELD3	0.83	7.32	0.55	2.74e-11	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs9814567	0.858	rs4955548	chr3:134341060	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.93	-8.62	-0.61	2.62e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs9611565	0.649	rs139553	chr22:42187199	A/G	cg03806693	chr22:41940476	POLR3H	0.95	9.29	0.64	6.6e-16	Vitiligo;
TGCT	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg03188948	chr7:1209495	NA	0.64	5.77	0.46	6.01e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7666738	0.962	rs11932892	chr4:99072967	C/T	cg18180107	chr4:99064573	C4orf37	0.61	4.63	0.38	8.94e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg00149659	chr3:10157352	C3orf10	0.73	4.72	0.39	6.17e-6	Alzheimer's disease;
TGCT	cis	rs8141529	0.764	rs5752812	chr22:29225603	T/A	cg02153584	chr22:29168773	CCDC117	0.67	5.69	0.45	8.82e-8	Lymphocyte counts;
TGCT	cis	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg07424592	chr7:64974309	NA	-1.31	-7.72	-0.57	3.33e-12	Diabetic kidney disease;
TGCT	cis	rs9911578	1.000	rs2567911	chr17:56734977	A/G	cg12560992	chr17:57184187	TRIM37	0.75	9.21	0.64	1.04e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs12762955	0.561	rs6560863	chr10:1013535	C/A	cg18964960	chr10:1102726	WDR37	-0.65	-5.81	-0.46	4.9e-8	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs8031584	0.652	rs2691683	chr15:31135060	A/G	cg14829155	chr15:31115871	NA	0.36	4.72	0.39	6.14e-6	Huntington's disease progression;
TGCT	cis	rs10744422	0.748	rs2292138	chr12:123339712	A/G	cg25930673	chr12:123319894	HIP1R	-0.86	-5.02	-0.41	1.72e-6	Schizophrenia;
TGCT	cis	rs7582180	0.764	rs10180423	chr2:100919012	C/G	cg14675211	chr2:100938903	LONRF2	0.49	4.8	0.4	4.45e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg09517075	chr8:22133004	PIWIL2	0.25	4.97	0.41	2.21e-6	Hypertriglyceridemia;
TGCT	cis	rs4460629	0.742	rs4625273	chr1:155076043	C/T	cg23973274	chr1:155060172	NA	-0.26	-4.66	-0.39	8.1e-6	Serum magnesium levels;
TGCT	cis	rs7772486	0.875	rs7766595	chr6:146364507	A/T	cg23711669	chr6:146136114	FBXO30	0.87	9.53	0.65	1.75e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9611565	0.545	rs5758432	chr22:42111693	T/C	cg13695892	chr22:41940480	POLR3H	0.88	8.64	0.61	2.39e-14	Vitiligo;
TGCT	cis	rs7666738	0.753	rs2865957	chr4:99040725	G/A	cg18180107	chr4:99064573	C4orf37	0.56	5.08	0.41	1.37e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs453301	0.719	rs34004903	chr8:8892604	C/T	cg00184457	chr8:8946301	NA	-0.26	-4.94	-0.41	2.45e-6	Joint mobility (Beighton score);
TGCT	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg11062466	chr8:58055876	NA	0.37	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2721195	0.816	rs4925826	chr8:145706276	G/A	cg17328964	chr8:145687451	CYHR1	-0.45	-6.35	-0.5	3.64e-9	Age at first birth;
TGCT	cis	rs66573146	1.000	rs6812771	chr4:6964048	G/A	cg05069807	chr4:6945702	TBC1D14	0.31	4.6	0.38	1.03e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs13256369	1.000	rs10095733	chr8:8574646	A/G	cg06671706	chr8:8559999	CLDN23	0.35	4.62	0.38	9.35e-6	Obesity-related traits;
TGCT	cis	rs36051895	0.664	rs10815157	chr9:5108771	C/G	cg02405213	chr9:5042618	JAK2	-0.74	-9.85	-0.66	2.99e-17	Pediatric autoimmune diseases;
TGCT	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg04944784	chr2:26401820	FAM59B	-0.76	-6.24	-0.49	6.46e-9	Gut microbiome composition (summer);
TGCT	cis	rs10949834	0.618	rs810551	chr7:73492093	C/G	cg07137043	chr7:73588983	EIF4H	-0.59	-4.73	-0.39	5.96e-6	Verbal memory performance (residualized delayed recall change);
TGCT	cis	rs11644362	0.932	rs3848239	chr16:12996642	A/G	cg06890432	chr16:12997467	SHISA9	-0.6	-6.59	-0.51	1.11e-9	Positive affect;Subjective well-being;
TGCT	cis	rs6429082	0.715	rs2172718	chr1:235580727	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.57	-5.03	-0.41	1.7e-6	Adiposity;
TGCT	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg13206674	chr6:150067644	NUP43	0.52	4.46	0.37	1.78e-5	Lung cancer;
TGCT	cis	rs67311347	1.000	rs1466237	chr3:40462026	C/G	cg17264618	chr3:40429014	ENTPD3	0.32	4.69	0.39	7e-6	Renal cell carcinoma;
TGCT	cis	rs9611565	0.879	rs5758307	chr22:41750219	A/G	cg17554472	chr22:41940697	POLR3H	-0.45	-4.77	-0.39	5.1e-6	Vitiligo;
TGCT	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7226408	0.749	rs17567737	chr18:34499369	A/T	cg06757138	chr18:34340585	FHOD3	0.24	4.59	0.38	1.06e-5	Obesity-related traits;
TGCT	cis	rs9911578	1.000	rs304292	chr17:56824123	G/A	cg12560992	chr17:57184187	TRIM37	0.76	9.34	0.64	4.88e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg11764359	chr7:65958608	NA	0.52	4.6	0.38	1.04e-5	Aortic root size;
TGCT	cis	rs11030122	0.673	rs10835596	chr11:4099666	C/T	cg18678763	chr11:4115507	RRM1	-0.46	-5.59	-0.45	1.38e-7	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs4499344	0.556	rs259227	chr19:33134791	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.82	8.26	0.6	1.84e-13	Mean platelet volume;
TGCT	cis	rs1401999	1.000	rs6805913	chr3:183662924	T/G	cg01324343	chr3:183735012	ABCC5	0.82	10.93	0.7	6.83e-20	Anterior chamber depth;
TGCT	cis	rs6490294	0.649	rs7306804	chr12:112441089	A/G	cg10833066	chr12:111807467	FAM109A	0.37	5.78	0.46	5.71e-8	Mean platelet volume;
TGCT	cis	rs950169	0.580	rs11634322	chr15:85172209	C/T	cg17173187	chr15:85201210	NMB	0.62	7.09	0.54	8.99e-11	Schizophrenia;
TGCT	cis	rs7772486	0.521	rs9485017	chr6:146023326	C/T	cg13319975	chr6:146136371	FBXO30	-0.63	-5.77	-0.46	6.08e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs727563	0.635	rs5751141	chr22:42107745	A/G	cg06481639	chr22:41940642	POLR3H	0.74	6.64	0.51	8.66e-10	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs4595586	0.525	rs7968458	chr12:39377139	C/A	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs12935418	0.583	rs12446698	chr16:80964421	G/A	cg07676361	chr16:80966860	NA	-0.35	-4.66	-0.39	8.02e-6	Mean corpuscular volume;
TGCT	cis	rs896854	0.654	rs10104909	chr8:95977973	C/T	cg13393036	chr8:95962371	TP53INP1	-0.59	-8.08	-0.59	4.92e-13	Type 2 diabetes;
TGCT	cis	rs6088580	0.608	rs2105109	chr20:32971932	A/G	cg08999081	chr20:33150536	PIGU	-0.29	-5.65	-0.45	1.02e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs7666738	0.830	rs62318470	chr4:98925846	A/C	cg17366294	chr4:99064904	C4orf37	0.72	7.19	0.54	5.3e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2243480	0.614	rs34032527	chr7:65565141	C/G	cg20637647	chr7:64974828	NA	0.88	5.34	0.43	4.19e-7	Diabetic kidney disease;
TGCT	cis	rs3091242	0.933	rs11249250	chr1:25767609	G/A	cg10117171	chr1:25599238	RHD	-0.32	-5.31	-0.43	4.85e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs1577917	0.771	rs2842608	chr6:86295858	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.57	-0.45	1.5e-7	Response to antipsychotic treatment;
TGCT	cis	rs10992471	0.603	rs10114932	chr9:95307901	C/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.6	-5.68	-0.45	9.01e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs9682041	0.696	rs11927807	chr3:170096623	A/G	cg11886554	chr3:170076028	SKIL	0.61	4.78	0.39	4.77e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs7611238	0.560	rs12054139	chr3:195098427	T/C	cg27323046	chr3:195102265	ACAP2	0.37	4.93	0.4	2.56e-6	Body mass index;
TGCT	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg22535103	chr8:58192502	C8orf71	-0.41	-4.81	-0.4	4.27e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs854765	0.587	rs4077828	chr17:17833644	A/T	cg09796270	chr17:17721594	SREBF1	0.24	4.77	0.39	5.16e-6	Total body bone mineral density;
TGCT	cis	rs7582180	0.764	rs10460478	chr2:100919735	G/A	cg08017756	chr2:100939284	LONRF2	-0.32	-5.31	-0.43	4.89e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1348850	0.602	rs1453373	chr2:178221668	G/A	cg22681709	chr2:178499509	PDE11A	-0.34	-4.48	-0.37	1.65e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs35374984	1.000	rs35374984	chr10:30234190	C/A	cg22629853	chr10:30638455	MTPAP	-0.57	-5.51	-0.44	1.94e-7	Emphysema distribution in smoking;
TGCT	cis	rs7017914	0.934	rs62508771	chr8:71692688	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.53	-4.98	-0.41	2.09e-6	Bone mineral density;
TGCT	cis	rs34783982	0.529	rs8039998	chr15:89474659	C/T	cg26213453	chr15:89455860	MFGE8	0.33	4.86	0.4	3.5e-6	Squamous cell lung carcinoma;
TGCT	cis	rs7267979	1.000	rs4815421	chr20:25386509	G/A	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs877282	0.898	rs11253352	chr10:766598	C/A	cg22713356	chr15:30763199	NA	1.15	9.41	0.65	3.45e-16	Uric acid levels;
TGCT	cis	rs7474896	0.507	rs2474555	chr10:38465220	G/C	cg25427524	chr10:38739819	LOC399744	-0.35	-4.55	-0.38	1.24e-5	Obesity (extreme);
TGCT	cis	rs5771225	0.563	rs6010220	chr22:50693554	A/G	cg16473166	chr22:50639996	SELO	0.69	5.69	0.45	8.74e-8	Late-onset Alzheimer's disease;
TGCT	cis	rs6964587	0.843	rs56075286	chr7:91731518	G/A	cg22709100	chr7:91322751	NA	0.28	4.58	0.38	1.12e-5	Breast cancer;
TGCT	cis	rs12579753	0.879	rs7958566	chr12:82131478	A/T	cg07988820	chr12:82153109	PPFIA2	-0.68	-7.32	-0.55	2.7e-11	Resting heart rate;
TGCT	cis	rs41271473	0.500	rs4606285	chr1:228887544	G/T	cg10167378	chr1:228756711	NA	0.5	4.56	0.38	1.19e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs10771431	0.967	rs7137443	chr12:9372029	C/T	cg13987825	chr12:9392948	NA	-0.27	-4.49	-0.37	1.63e-5	Breast size;
TGCT	cis	rs7635838	0.892	rs9310384	chr3:11491980	A/G	cg00170343	chr3:11313890	ATG7	0.64	5.94	0.47	2.69e-8	HDL cholesterol;
TGCT	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg13395646	chr4:1353034	KIAA1530	-0.36	-4.62	-0.38	9.52e-6	Obesity-related traits;
TGCT	cis	rs11098499	0.863	rs9884402	chr4:120489982	A/G	cg09307838	chr4:120376055	NA	0.69	6.53	0.51	1.49e-9	Corneal astigmatism;
TGCT	cis	rs7017914	0.934	rs2732092	chr8:71918599	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.57	-5.31	-0.43	4.8e-7	Bone mineral density;
TGCT	cis	rs6964587	1.000	rs55745934	chr7:91670998	T/C	cg17063962	chr7:91808500	NA	0.88	9.54	0.65	1.69e-16	Breast cancer;
TGCT	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs950776	0.612	rs8038920	chr15:78974545	A/G	cg03762349	chr15:79060523	ADAMTS7	-0.25	-5.33	-0.43	4.45e-7	Sudden cardiac arrest;
TGCT	cis	rs2456568	0.805	rs55784864	chr11:93682887	G/A	cg14065697	chr11:93583672	C11orf90	-0.38	-4.58	-0.38	1.13e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7267979	0.966	rs2151144	chr20:25414924	G/C	cg14121845	chr20:25566513	NINL	-0.5	-5.32	-0.43	4.73e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg03303774	chr4:1407052	NA	0.3	4.78	0.39	4.8e-6	Obesity-related traits;
TGCT	cis	rs9611565	0.625	rs12483991	chr22:41935285	A/G	cg13695892	chr22:41940480	POLR3H	-0.86	-8.85	-0.62	7.6e-15	Vitiligo;
TGCT	cis	rs9611565	0.503	rs5751156	chr22:42170025	A/G	cg13695892	chr22:41940480	POLR3H	0.84	7.89	0.58	1.34e-12	Vitiligo;
TGCT	cis	rs17152411	0.895	rs61872118	chr10:126583450	C/T	cg07906193	chr10:126599966	NA	0.43	5.25	0.43	6.46e-7	Height;
TGCT	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg11764359	chr7:65958608	NA	-0.54	-4.9	-0.4	2.94e-6	Aortic root size;
TGCT	cis	rs7552404	1.000	rs4646961	chr1:76217169	G/A	cg10523679	chr1:76189770	ACADM	0.89	9.53	0.65	1.72e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs6582630	0.555	rs34884627	chr12:38443831	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-4.81	-0.4	4.32e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg21951975	chr1:209979733	IRF6	-0.66	-5.75	-0.46	6.51e-8	Cleft lip with or without cleft palate;
TGCT	cis	rs2439831	0.681	rs7175434	chr15:43628542	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.04	8.86	0.62	7.03e-15	Lung cancer in ever smokers;
TGCT	cis	rs713587	0.935	rs4430895	chr2:25161386	C/T	cg15423357	chr2:25149977	NA	0.58	5.85	0.47	4.03e-8	Body mass index in non-asthmatics;
TGCT	cis	rs9906944	0.545	rs11079850	chr17:47092252	G/T	cg20966754	chr17:47091339	IGF2BP1	-0.41	-4.48	-0.37	1.65e-5	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs10782582	0.593	rs11578480	chr1:76208989	T/G	cg10523679	chr1:76189770	ACADM	-0.67	-6.71	-0.52	6.18e-10	Daytime sleep phenotypes;
TGCT	cis	rs9467773	0.595	rs2172007	chr6:26639777	A/C	cg26531700	chr6:26746687	NA	0.61	5.84	0.46	4.23e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs11935103	0.569	rs7656944	chr4:187294897	C/G	cg16785698	chr4:186456103	PDLIM3	0.45	4.57	0.38	1.18e-5	Response to citalopram treatment;
TGCT	cis	rs2932538	0.961	rs3013441	chr1:113192605	C/T	cg22162597	chr1:113214053	CAPZA1	-0.31	-6.31	-0.49	4.42e-9	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs1371867	0.846	rs1788203	chr8:101303721	T/C	cg06002616	chr8:101225028	SPAG1	-0.56	-6.58	-0.51	1.2e-9	Atrioventricular conduction;
TGCT	cis	rs1372520	0.873	rs2736989	chr4:90776257	T/C	cg01966878	chr4:90757139	SNCA	-0.3	-4.71	-0.39	6.55e-6	Neuroticism;
TGCT	cis	rs12477438	0.765	rs2309521	chr2:99592069	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-4.62	-0.38	9.47e-6	Chronic sinus infection;
TGCT	cis	rs11098499	0.644	rs28787668	chr4:120554687	G/A	cg09307838	chr4:120376055	NA	0.62	5.87	0.47	3.71e-8	Corneal astigmatism;
TGCT	cis	rs4906332	1.000	rs7155822	chr14:103922390	A/G	cg26031613	chr14:104095156	KLC1	-0.52	-4.65	-0.39	8.5e-6	Coronary artery disease;
TGCT	cis	rs1401999	1.000	rs6802849	chr3:183698943	A/C	cg01324343	chr3:183735012	ABCC5	0.82	10.97	0.7	5.41e-20	Anterior chamber depth;
TGCT	cis	rs5769707	0.967	rs8141807	chr22:50043738	C/G	cg10356904	chr22:49881777	NA	-0.22	-4.52	-0.38	1.4e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs6831352	0.918	rs13140423	chr4:100050400	T/C	cg12011299	chr4:100065546	ADH4	-0.41	-4.92	-0.4	2.72e-6	Alcohol dependence;
TGCT	cis	rs9611565	0.580	rs5758449	chr22:42140160	C/T	cg17554472	chr22:41940697	POLR3H	0.43	4.54	0.38	1.31e-5	Vitiligo;
TGCT	cis	rs6754311	0.593	rs1446584	chr2:136419961	C/T	cg07169764	chr2:136633963	MCM6	-0.68	-6.14	-0.48	1.03e-8	Mosquito bite size;
TGCT	cis	rs17826219	0.500	rs2874724	chr17:29072433	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Body mass index;
TGCT	cis	rs7666738	0.830	rs10470951	chr4:99037051	G/A	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs17376456	0.877	rs28575883	chr5:93346035	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.62	4.44	0.37	1.98e-5	Diabetic retinopathy;
TGCT	cis	rs9467773	0.620	rs2494692	chr6:26615223	G/A	cg11502198	chr6:26597334	ABT1	0.53	4.93	0.41	2.53e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10791097	0.720	rs6590516	chr11:130733393	G/T	cg12179176	chr11:130786555	SNX19	0.83	10.09	0.67	7.59e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9443645	0.901	rs55755815	chr6:79607121	G/T	cg09184832	chr6:79620586	NA	-0.49	-5.29	-0.43	5.29e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs12682352	0.602	rs11783966	chr8:8665147	A/G	cg08975724	chr8:8085496	FLJ10661	-0.53	-4.66	-0.39	8.09e-6	Neuroticism;
TGCT	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg11890956	chr21:40555474	PSMG1	1.12	12.59	0.75	6.25e-24	Cognitive function;
TGCT	cis	rs6545883	0.929	rs1186700	chr2:61663372	A/C	cg15711740	chr2:61764176	XPO1	-0.52	-4.67	-0.39	7.58e-6	Tuberculosis;
TGCT	cis	rs7666738	0.830	rs36028444	chr4:98968635	G/T	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6671200	1.000	rs12749053	chr1:95660556	A/G	cg03123541	chr1:95699097	RWDD3	0.87	6.17	0.48	8.81e-9	Stearic acid (18:0) levels;
TGCT	cis	rs854765	0.547	rs4925135	chr17:17952868	T/C	cg04398451	chr17:18023971	MYO15A	0.34	5.49	0.44	2.21e-7	Total body bone mineral density;
TGCT	cis	rs4891159	0.527	rs690593	chr18:74160408	C/G	cg24786174	chr18:74118243	ZNF516	0.63	10.66	0.69	3.07e-19	Longevity;
TGCT	cis	rs9914544	1.000	rs28436199	chr17:18751730	C/T	cg26306683	chr17:18585705	ZNF286B	0.57	5.08	0.42	1.33e-6	Educational attainment (years of education);
TGCT	cis	rs6540559	0.673	rs17015218	chr1:209967915	A/G	cg04352962	chr1:209979756	IRF6	0.65	4.6	0.38	1.05e-5	Cleft lip with or without cleft palate;
TGCT	cis	rs10946940	0.965	rs6921256	chr6:27587518	C/T	cg10876282	chr6:28092338	ZSCAN16	0.48	4.83	0.4	4e-6	Systemic lupus erythematosus;
TGCT	cis	rs72781680	1.000	rs7581107	chr2:24173565	C/T	cg08917208	chr2:24149416	ATAD2B	0.73	4.51	0.38	1.48e-5	Lymphocyte counts;
TGCT	cis	rs10114408	0.959	rs10739964	chr9:96651432	T/A	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs651907	0.514	rs55654108	chr3:101425703	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.34	-7.13	-0.54	7.37e-11	Colorectal cancer;
TGCT	cis	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg22121687	chr7:65037720	NA	-0.78	-4.7	-0.39	6.74e-6	Diabetic kidney disease;
TGCT	cis	rs6500602	0.673	rs4786512	chr16:4573040	A/G	cg08645402	chr16:4508243	NA	0.21	5.09	0.42	1.27e-6	Schizophrenia;
TGCT	cis	rs950776	0.642	rs58946838	chr15:78961449	A/C	cg21242079	chr15:79101063	ADAMTS7	-0.3	-4.58	-0.38	1.13e-5	Sudden cardiac arrest;
TGCT	cis	rs826838	0.935	rs10875816	chr12:38955014	C/A	cg13010199	chr12:38710504	ALG10B	0.8	6.77	0.52	4.58e-10	Heart rate;
TGCT	cis	rs709400	0.628	rs1989565	chr14:103862193	G/A	cg26031613	chr14:104095156	KLC1	-0.83	-9.22	-0.64	9.94e-16	Body mass index;
TGCT	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.06	-9.57	-0.65	1.41e-16	Platelet count;
TGCT	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg05896524	chr21:47604654	C21orf56	0.44	4.55	0.38	1.24e-5	Testicular germ cell tumor;
TGCT	cis	rs7020830	0.931	rs6476613	chr9:37084340	A/G	cg14294708	chr9:37120828	ZCCHC7	1.2	18.29	0.85	5.19e-37	Schizophrenia;
TGCT	cis	rs7044106	0.791	rs10985008	chr9:123492960	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	7.83	0.58	1.82e-12	Hip circumference adjusted for BMI;
TGCT	cis	rs10080237	0.564	rs2490230	chr6:80812464	G/A	cg08355045	chr6:80787529	NA	0.33	5.69	0.45	8.76e-8	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
TGCT	cis	rs644799	0.965	rs11021317	chr11:95517576	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	8.53	0.61	4.41e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9309473	0.632	rs7599076	chr2:73585519	G/T	cg20560298	chr2:73613845	ALMS1	-0.41	-4.54	-0.38	1.31e-5	Metabolite levels;
TGCT	cis	rs3845702	0.736	rs6433816	chr2:180809317	G/C	cg01881094	chr2:180872142	CWC22	-1.03	-6.51	-0.5	1.72e-9	Schizophrenia;
TGCT	cis	rs910316	1.000	rs10142865	chr14:75555624	G/A	cg23033748	chr14:75592666	NEK9	0.27	4.57	0.38	1.16e-5	Height;
TGCT	cis	rs986417	0.818	rs2882601	chr14:61096879	A/T	cg27398547	chr14:60952738	C14orf39	1.44	10.1	0.67	7.17e-18	Gut microbiota (bacterial taxa);
TGCT	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg13695892	chr22:41940480	POLR3H	0.9	9.06	0.63	2.38e-15	Vitiligo;
TGCT	cis	rs2692947	0.673	rs584811	chr2:97069879	A/G	cg22654517	chr2:96458247	NA	-0.2	-4.6	-0.38	1.05e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs4555082	0.834	rs2735822	chr14:105712734	C/T	cg01266790	chr14:105781312	PACS2	0.55	4.49	0.37	1.58e-5	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs7660520	0.524	rs4862101	chr4:183733177	T/C	cg04181038	chr4:183730758	NA	0.65	6.11	0.48	1.2e-8	Pediatric autoimmune diseases;
TGCT	cis	rs7614311	0.681	rs57766205	chr3:63895303	G/C	cg22134162	chr3:63841271	THOC7	-0.35	-4.72	-0.39	6.29e-6	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs459571	0.959	rs408307	chr9:136892523	A/G	cg13789015	chr9:136890014	NCRNA00094	-0.42	-7.87	-0.58	1.51e-12	Platelet distribution width;
TGCT	cis	rs4808199	0.894	rs9304960	chr19:19465529	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.69	5.33	0.43	4.49e-7	Nonalcoholic fatty liver disease;
TGCT	cis	rs4727027	0.754	rs917124	chr7:148851213	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.57	5.0	0.41	1.91e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg24250549	chr1:154909240	PMVK	0.63	6.25	0.49	6.03e-9	Prostate cancer;
TGCT	trans	rs4332037	0.624	rs11764124	chr7:1891723	C/G	cg25206134	chr2:45395956	NA	0.95	7.99	0.58	8.14e-13	Bipolar disorder;
TGCT	cis	rs4808199	0.895	rs2163805	chr19:19575945	G/A	cg03709012	chr19:19516395	GATAD2A	1.02	7.83	0.58	1.82e-12	Nonalcoholic fatty liver disease;
TGCT	cis	rs2229238	0.911	rs7556449	chr1:154505886	C/T	cg13067139	chr1:155221277	FAM189B	-0.2	-4.51	-0.38	1.47e-5	Coronary heart disease;
TGCT	cis	rs1541995	1.000	rs1541995	chr15:96316457	C/A	cg00882281	chr15:96346592	NA	0.29	4.68	0.39	7.26e-6	Photic sneeze reflex;
TGCT	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg04546413	chr19:29218101	NA	0.84	6.76	0.52	4.71e-10	Methadone dose in opioid dependence;
TGCT	cis	rs9796	0.558	rs7166905	chr15:41514876	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.52	-7.18	-0.54	5.56e-11	Menopause (age at onset);
TGCT	cis	rs4924935	0.770	rs4924946	chr17:18846525	A/T	cg26306683	chr17:18585705	ZNF286B	-0.48	-4.46	-0.37	1.81e-5	Pancreatic cancer;
TGCT	cis	rs1215050	0.791	rs165247	chr4:98692399	A/G	cg05340658	chr4:99064831	C4orf37	0.44	5.52	0.44	1.85e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9926296	0.744	rs154656	chr16:89708003	T/A	cg04287289	chr16:89883240	FANCA	-0.5	-4.76	-0.39	5.35e-6	Vitiligo;
TGCT	cis	rs17122693	0.818	rs113230118	chr14:51160977	G/A	cg04730355	chr14:51134070	SAV1	1.17	9.45	0.65	2.78e-16	Cognitive performance;
TGCT	cis	rs9329289	0.632	rs2452187	chr10:2551147	C/G	cg15501526	chr10:2543763	NA	0.43	4.73	0.39	6.13e-6	Age-related hearing impairment;
TGCT	cis	rs9467711	0.606	rs9379897	chr6:26601526	T/C	cg16898833	chr6:26189333	HIST1H4D	1.02	5.25	0.43	6.32e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4664308	0.935	rs4637057	chr2:160950161	G/T	cg03641300	chr2:160917029	PLA2R1	-0.28	-6.83	-0.52	3.44e-10	Idiopathic membranous nephropathy;
TGCT	cis	rs7772486	0.654	rs6906402	chr6:146089307	C/G	cg05347473	chr6:146136440	FBXO30	-0.53	-5.01	-0.41	1.84e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs13008689	0.875	rs12616139	chr2:8522651	C/T	cg21129864	chr2:9369739	ASAP2	0.18	4.47	0.37	1.73e-5	Longevity;
TGCT	cis	rs1171582	0.584	rs10128501	chr10:61508784	A/G	cg23572703	chr10:62241191	NA	-0.27	-4.54	-0.38	1.31e-5	Alopecia areata;
TGCT	cis	rs7659604	0.592	rs56077950	chr4:122721412	C/T	cg06713675	chr4:122721982	EXOSC9	-0.69	-9.57	-0.65	1.4e-16	Type 2 diabetes;
TGCT	cis	rs1865760	1.000	rs9393675	chr6:25930116	G/A	cg16482183	chr6:26056742	HIST1H1C	0.51	4.57	0.38	1.17e-5	Height;
TGCT	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2295359	0.892	rs56920441	chr1:67652012	A/G	cg12940439	chr1:67600707	NA	0.59	6.16	0.48	9.32e-9	Psoriasis;
TGCT	cis	rs1008375	0.966	rs12503517	chr4:17698725	G/A	cg18681998	chr4:17616180	MED28	0.78	7.49	0.56	1.11e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2233152	0.611	rs28660501	chr19:41300277	G/T	cg23743927	chr19:41304969	EGLN2	-0.69	-4.76	-0.39	5.4e-6	Kawasaki disease;
TGCT	cis	rs8141529	0.748	rs5997412	chr22:29276747	G/A	cg02153584	chr22:29168773	CCDC117	0.66	5.19	0.42	8.5e-7	Lymphocyte counts;
TGCT	cis	rs9457247	0.935	rs2757046	chr6:167374353	C/T	cg25258033	chr6:167368657	RNASET2	-0.18	-4.48	-0.37	1.65e-5	Crohn's disease;
TGCT	cis	rs4595586	0.525	rs11613788	chr12:39390710	T/C	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs624899	1.000	rs624899	chr19:11612498	C/T	cg14128973	chr19:11649462	CNN1	0.42	4.95	0.41	2.36e-6	Presence of antiphospholipid antibodies;
TGCT	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg26338869	chr17:61819248	STRADA	-0.55	-5.08	-0.41	1.37e-6	Prudent dietary pattern;
TGCT	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg27454412	chr7:1067447	C7orf50	0.6	4.7	0.39	6.76e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2777491	0.957	rs8026197	chr15:41711447	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.75	-11.01	-0.7	4.47e-20	Ulcerative colitis;
TGCT	cis	rs2580764	0.566	rs2968795	chr2:55287989	G/A	cg09592903	chr2:55203963	RTN4	0.25	5.79	0.46	5.55e-8	Mean platelet volume;
TGCT	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg22433210	chr17:43662623	NA	1.04	7.37	0.55	2.07e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg03517284	chr6:25882590	NA	0.89	9.16	0.64	1.32e-15	Blood metabolite levels;
TGCT	cis	rs308403	0.509	rs309382	chr4:123669772	T/C	cg10495464	chr4:123653540	BBS12;LOC729338	0.83	12.16	0.74	6.83e-23	Blood protein levels;
TGCT	cis	rs1570884	0.556	rs2146146	chr13:50170368	C/T	cg08779649	chr13:50194554	NA	0.37	5.82	0.46	4.74e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
TGCT	cis	rs4824093	0.541	rs8142132	chr22:50211294	C/T	cg14114931	chr22:50943910	LMF2	0.45	5.29	0.43	5.39e-7	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs9303401	0.659	rs17822908	chr17:56801778	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.59	5.99	0.47	2.08e-8	Cognitive test performance;
TGCT	cis	rs67311347	0.544	rs13097602	chr3:40339247	T/C	cg13683864	chr3:40499215	RPL14	0.77	7.13	0.54	7.26e-11	Renal cell carcinoma;
TGCT	cis	rs210152	0.541	rs35432298	chr6:33457013	T/A	cg16739976	chr6:34101401	GRM4	0.57	4.72	0.39	6.15e-6	Schizophrenia;
TGCT	cis	rs62103177	0.568	rs2365388	chr18:77973702	G/T	cg07235805	chr18:78004237	PARD6G	0.52	4.97	0.41	2.18e-6	Opioid sensitivity;
TGCT	cis	rs9807989	0.507	rs1420096	chr2:103010912	C/T	cg03938978	chr2:103052716	IL18RAP	0.27	5.41	0.44	3.17e-7	Asthma;
TGCT	cis	rs877282	1.000	rs11253367	chr10:773389	G/A	cg17470449	chr10:769945	NA	0.31	4.88	0.4	3.2e-6	Uric acid levels;
TGCT	cis	rs1008375	1.000	rs4698199	chr4:17656738	G/C	cg18681998	chr4:17616180	MED28	1.01	11.89	0.73	3.17e-22	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg08280861	chr8:58055591	NA	0.52	5.78	0.46	5.78e-8	Developmental language disorder (linguistic errors);
TGCT	cis	rs9733	0.526	rs11204696	chr1:150658721	T/C	cg09365446	chr1:150670422	GOLPH3L	0.31	4.64	0.38	8.7e-6	Tonsillectomy;
TGCT	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg08219700	chr8:58056026	NA	0.38	4.69	0.39	6.95e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs28595532	0.920	rs55869953	chr4:119751893	T/C	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs7829975	0.606	rs6422352	chr8:8794193	A/G	cg15556689	chr8:8085844	FLJ10661	-0.7	-6.26	-0.49	5.66e-9	Mood instability;
TGCT	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg03303774	chr4:1407052	NA	0.38	5.82	0.46	4.78e-8	Obesity-related traits;
TGCT	cis	rs1865760	0.713	rs9461229	chr6:25992279	G/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.72	6.94	0.53	1.97e-10	Height;
TGCT	cis	rs933688	1.000	rs6452953	chr5:90723034	T/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.06	10.49	0.69	8.29e-19	Smoking behavior;
TGCT	cis	rs711830	1.000	rs711830	chr2:177037311	C/T	cg13092806	chr2:177043255	NA	-0.68	-5.65	-0.45	1.02e-7	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
TGCT	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg00149659	chr3:10157352	C3orf10	0.91	5.89	0.47	3.32e-8	Alzheimer's disease;
TGCT	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg17554472	chr22:41940697	POLR3H	0.5	5.16	0.42	9.35e-7	Vitiligo;
TGCT	trans	rs7618501	0.699	rs2681781	chr3:49898273	A/G	cg21659725	chr3:3221576	CRBN	0.77	8.99	0.63	3.47e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg06028808	chr11:68637592	NA	0.53	6.86	0.52	2.89e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7552404	0.727	rs7547508	chr1:76327958	A/G	cg10523679	chr1:76189770	ACADM	-0.67	-6.27	-0.49	5.47e-9	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs12477438	0.520	rs11890338	chr2:99767868	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	13.05	0.76	4.93e-25	Chronic sinus infection;
TGCT	trans	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg25482853	chr8:67687455	SGK3	1.32	11.02	0.7	4.19e-20	Lung disease severity in cystic fibrosis;
TGCT	cis	rs28595532	0.920	rs56117870	chr4:119766583	T/C	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs7044106	0.791	rs4617229	chr9:123480696	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	6.98	0.53	1.61e-10	Hip circumference adjusted for BMI;
TGCT	cis	rs6671200	1.000	rs71654419	chr1:95664497	C/G	cg03123541	chr1:95699097	RWDD3	0.87	6.17	0.48	8.81e-9	Stearic acid (18:0) levels;
TGCT	trans	rs10435719	0.902	rs4840599	chr8:11805380	C/T	cg15556689	chr8:8085844	FLJ10661	-0.75	-7.0	-0.53	1.39e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs11031096	0.738	rs2923950	chr11:4042069	G/C	cg18678763	chr11:4115507	RRM1	0.36	4.7	0.39	6.93e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs2589561	0.830	rs1612986	chr10:9064716	T/C	cg08738443	chr10:8487762	NA	0.36	4.74	0.39	5.7e-6	Asthma;
TGCT	cis	rs10779751	0.649	rs1318348	chr1:11130418	A/G	cg08854313	chr1:11322531	MTOR	0.82	7.04	0.53	1.19e-10	Body mass index;
TGCT	cis	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg22857025	chr5:266934	NA	-0.31	-6.32	-0.49	4.33e-9	Breast cancer;
TGCT	cis	rs319204	0.761	rs319142	chr5:146305665	T/C	cg25021259	chr5:146258546	PPP2R2B	0.37	4.54	0.38	1.31e-5	Schizophrenia;
TGCT	cis	rs9611519	0.929	rs13055800	chr22:41440424	G/A	cg13695892	chr22:41940480	POLR3H	-0.55	-4.9	-0.4	2.99e-6	Neuroticism;
TGCT	cis	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg18252515	chr7:66147081	NA	-1.31	-8.18	-0.59	2.87e-13	Diabetic kidney disease;
TGCT	cis	rs727505	1.000	rs7777947	chr7:124436063	T/G	cg23710748	chr7:124431027	NA	-0.25	-4.59	-0.38	1.06e-5	Lewy body disease;
TGCT	cis	rs4803468	0.934	rs8103531	chr19:41891974	C/T	cg09537434	chr19:41945824	ATP5SL	-0.9	-10.08	-0.67	8.25e-18	Height;
TGCT	cis	rs9467711	0.606	rs67509210	chr6:26354100	G/T	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6500602	0.727	rs1477123	chr16:4560627	T/A	cg08645402	chr16:4508243	NA	0.19	4.83	0.4	4e-6	Schizophrenia;
TGCT	cis	rs7927771	0.864	rs4752999	chr11:47428565	C/T	cg10139015	chr11:47448256	PSMC3	0.54	4.58	0.38	1.13e-5	Subjective well-being;
TGCT	cis	rs4383453	0.539	rs11923120	chr3:123101592	A/G	cg04890266	chr3:123102914	ADCY5	-0.49	-7.91	-0.58	1.23e-12	Gestational age at birth (maternal effect);
TGCT	cis	rs3806843	1.000	rs3822346	chr5:140187322	C/T	cg19875535	chr5:140030758	IK	0.35	5.85	0.47	4.01e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs3796352	1.000	rs7625448	chr3:53120766	C/A	cg07884673	chr3:53033167	SFMBT1	0.53	5.68	0.45	9.21e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg09359103	chr1:154839909	KCNN3	-0.64	-11.6	-0.72	1.58e-21	Prostate cancer;
TGCT	cis	rs4711350	0.765	rs756139	chr6:33755541	G/A	cg13859433	chr6:33739653	LEMD2	-0.33	-4.93	-0.4	2.6e-6	Schizophrenia;
TGCT	cis	rs68170813	0.559	rs77605964	chr7:106962948	G/A	cg02696742	chr7:106810147	HBP1	-0.69	-5.61	-0.45	1.27e-7	Coronary artery disease;
TGCT	cis	rs137699	0.687	rs4821887	chr22:39756985	C/T	cg01416388	chr22:39784598	NA	-0.53	-4.59	-0.38	1.06e-5	IgG glycosylation;
TGCT	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	6.13	0.48	1.06e-8	Bipolar disorder;
TGCT	cis	rs3806843	0.576	rs246041	chr5:140331128	C/G	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7772486	0.790	rs2253654	chr6:146199445	T/C	cg23711669	chr6:146136114	FBXO30	0.97	11.36	0.71	6.35e-21	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9534288	0.912	rs3736944	chr13:46619316	T/C	cg15192986	chr13:46630673	CPB2	-0.49	-6.18	-0.49	8.64e-9	Blood protein levels;
TGCT	cis	rs2204008	0.627	rs10878486	chr12:38148601	T/G	cg13010199	chr12:38710504	ALG10B	0.65	5.15	0.42	1.01e-6	Bladder cancer;
TGCT	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg12963246	chr6:28129442	ZNF389	0.52	5.01	0.41	1.85e-6	Depression;
TGCT	cis	rs9325144	0.647	rs11169222	chr12:39105210	C/T	cg26384229	chr12:38710491	ALG10B	-0.57	-5.29	-0.43	5.23e-7	Morning vs. evening chronotype;
TGCT	cis	rs523522	0.962	rs4767905	chr12:120930835	C/T	cg12219531	chr12:120966889	COQ5	0.83	7.27	0.55	3.46e-11	High light scatter reticulocyte count;
TGCT	cis	rs7914558	0.966	rs11191438	chr10:104637864	C/G	cg15744005	chr10:104629667	AS3MT	-0.4	-5.04	-0.41	1.59e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs912057	0.695	rs1294419	chr6:6742549	C/G	cg06612196	chr6:6737390	NA	0.36	4.79	0.4	4.59e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg08564027	chr20:61660810	NA	0.38	7.08	0.54	9.36e-11	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg08280861	chr8:58055591	NA	0.52	5.82	0.46	4.78e-8	Developmental language disorder (linguistic errors);
TGCT	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg24549020	chr5:56110836	MAP3K1	0.67	5.78	0.46	5.74e-8	Initial pursuit acceleration;
TGCT	trans	rs7726839	0.540	rs7558	chr5:660491	C/T	cg11887960	chr12:57824829	NA	1.14	9.02	0.63	2.9e-15	Obesity-related traits;
TGCT	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg06028605	chr16:24865363	SLC5A11	0.42	4.63	0.38	9.1e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4372836	0.729	rs55785599	chr2:29087814	C/A	cg09522027	chr2:28974177	PPP1CB	0.67	6.91	0.53	2.25e-10	Body mass index;
TGCT	cis	rs586688	1.000	rs635979	chr1:201637811	C/T	cg22851694	chr1:202075546	NA	-0.37	-4.47	-0.37	1.76e-5	Obesity-related traits;
TGCT	cis	rs295140	1.000	rs4516413	chr2:201163920	T/C	cg04283868	chr2:201171347	SPATS2L	0.63	6.39	0.5	3.03e-9	QT interval;
TGCT	cis	rs9443645	0.901	rs2174742	chr6:79610101	G/T	cg05283184	chr6:79620031	NA	-0.22	-4.98	-0.41	2.11e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs33794	0.901	rs28288	chr3:45290007	C/T	cg18645101	chr3:44551900	NA	0.56	4.93	0.4	2.55e-6	Lung function (forced expiratory volume in 1 second);
TGCT	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg20607798	chr8:58055168	NA	0.49	4.67	0.39	7.56e-6	Developmental language disorder (linguistic errors);
TGCT	trans	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg23505145	chr19:12996616	KLF1	0.78	8.12	0.59	4.03e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg10802521	chr3:52805072	NEK4	0.73	9.39	0.64	3.73e-16	Bipolar disorder;
TGCT	cis	rs9325144	0.560	rs10506127	chr12:39126686	C/G	cg13010199	chr12:38710504	ALG10B	-0.55	-5.02	-0.41	1.73e-6	Morning vs. evening chronotype;
TGCT	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg07507251	chr3:52567010	NT5DC2	0.47	6.64	0.51	8.85e-10	Electroencephalogram traits;
TGCT	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg00343986	chr7:65444356	GUSB	-0.24	-5.29	-0.43	5.43e-7	Aortic root size;
TGCT	cis	rs2338224	1.000	rs6859727	chr5:71742622	T/C	cg01187920	chr5:71015162	CARTPT	-0.53	-4.57	-0.38	1.15e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Granulocyte count;Myeloid white cell count;
TGCT	cis	rs2832191	0.692	rs2776240	chr21:30310639	C/T	cg08807101	chr21:30365312	RNF160	0.62	5.89	0.47	3.33e-8	Dental caries;
TGCT	cis	rs72634258	0.503	rs72632055	chr1:7835774	T/G	cg26816564	chr1:7831052	VAMP3	0.98	7.19	0.54	5.47e-11	Inflammatory bowel disease;
TGCT	cis	rs922182	0.557	rs4776662	chr15:64203562	G/A	cg02919090	chr15:64263738	DAPK2	-0.38	-6.93	-0.53	2.07e-10	Blood protein levels;
TGCT	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg25703541	chr22:24373054	LOC391322	-0.89	-10.45	-0.68	1.02e-18	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs4689592	0.554	rs66925245	chr4:7071999	C/T	cg25660036	chr4:7070649	GRPEL1	0.6	4.78	0.39	4.9100000000000004e-06	Monocyte percentage of white cells;
TGCT	cis	rs7666738	0.830	rs36028444	chr4:98968635	G/T	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4566357	0.615	rs12618793	chr2:227909552	T/C	cg11843606	chr2:227700838	RHBDD1	-0.55	-5.17	-0.42	8.92e-7	Coronary artery disease;
TGCT	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg16325326	chr1:53192061	ZYG11B	-0.7	-8.53	-0.61	4.4e-14	Monocyte count;
TGCT	cis	rs8103278	1.000	rs7256192	chr19:46338492	G/A	cg11657440	chr19:46296263	DMWD	-0.6	-5.75	-0.46	6.51e-8	Coronary artery disease;
TGCT	cis	rs317689	0.513	rs529268	chr12:69687051	G/A	cg20891283	chr12:69753455	YEATS4	0.56	5.13	0.42	1.1e-6	Response to diuretic therapy;
TGCT	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.54	-0.38	1.33e-5	Bipolar disorder;
TGCT	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg03264133	chr6:25882463	NA	0.79	8.04	0.59	6e-13	Blood metabolite levels;
TGCT	cis	rs36051895	0.659	rs2149555	chr9:5053743	C/T	cg02405213	chr9:5042618	JAK2	-0.72	-9.64	-0.65	9.46e-17	Pediatric autoimmune diseases;
TGCT	cis	rs1008375	0.932	rs9884565	chr4:17655096	A/G	cg18681998	chr4:17616180	MED28	1.05	12.0	0.73	1.69e-22	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4072980	0.545	rs12120737	chr1:38422544	C/T	cg17077180	chr1:38461687	NA	0.49	4.78	0.39	4.89e-6	Coronary artery disease;
TGCT	cis	rs2549003	1.000	rs2549002	chr5:131829578	C/A	cg21138405	chr5:131827807	IRF1	-0.19	-4.85	-0.4	3.6e-6	Asthma (sex interaction);
TGCT	cis	rs7208859	0.623	rs1061346	chr17:29114229	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs548987	0.529	rs1165165	chr6:25862466	C/T	cg12310025	chr6:25882481	NA	-0.62	-5.1	-0.42	1.24e-6	Homocysteine levels;
TGCT	cis	rs10875746	0.855	rs10875728	chr12:48426392	T/G	cg20731937	chr12:48336164	NA	0.67	5.15	0.42	9.92e-7	Longevity (90 years and older);
TGCT	cis	rs1903068	0.886	rs1551644	chr4:55994266	A/T	cg09978860	chr4:56023921	NA	0.58	6.38	0.5	3.16e-9	Endometriosis;
TGCT	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg13409248	chr3:40428643	ENTPD3	0.57	4.53	0.38	1.37e-5	Renal cell carcinoma;
TGCT	cis	rs75686122	0.772	rs1079944	chr8:104555187	A/G	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs17376456	0.569	rs896729	chr5:93222178	A/G	cg25358565	chr5:93447407	FAM172A	-0.76	-6.04	-0.48	1.62e-8	Diabetic retinopathy;
TGCT	cis	rs7829975	0.782	rs6990746	chr8:8547811	A/G	cg15556689	chr8:8085844	FLJ10661	-0.71	-6.29	-0.49	4.97e-9	Mood instability;
TGCT	cis	rs150268548	1	rs150268548	chr19:19494483	G/A	cg03709012	chr19:19516395	GATAD2A	1.13	5.25	0.43	6.41e-7	LDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;Response to fenofibrate (LDL cholesterol levels);
TGCT	cis	rs4654899	1.000	rs10916921	chr1:21334542	C/T	cg01072550	chr1:21505969	NA	-0.5	-7.94	-0.58	1.04e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs7027203	0.828	rs3996239	chr9:96611290	T/A	cg14396892	chr9:96623032	NA	-0.26	-5.47	-0.44	2.35e-7	DNA methylation (variation);
TGCT	cis	rs2836974	0.545	rs2776311	chr21:40716885	A/G	cg17971929	chr21:40555470	PSMG1	0.62	5.52	0.44	1.92e-7	Cognitive function;
TGCT	trans	rs4650994	0.525	rs4076563	chr1:178516901	C/T	cg05059571	chr16:84539110	KIAA1609	-0.54	-11.05	-0.7	3.43e-20	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg11890956	chr21:40555474	PSMG1	-0.8	-7.75	-0.57	2.91e-12	Cognitive function;
TGCT	cis	rs7043114	0.525	rs10820969	chr9:95106678	G/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-5.54	-0.45	1.72e-7	Height;
TGCT	cis	rs7617773	0.779	rs11718329	chr3:48309828	C/G	cg11946769	chr3:48343235	NME6	0.71	6.14	0.48	1.01e-8	Coronary artery disease;
TGCT	cis	rs909674	0.818	rs8137426	chr22:39844350	T/G	cg05872129	chr22:39784769	NA	-0.99	-9.82	-0.66	3.44e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs62244186	0.748	rs6441861	chr3:44652287	A/G	cg21672276	chr3:44754072	ZNF502	-0.46	-5.12	-0.42	1.13e-6	Depressive symptoms;
TGCT	cis	rs5769765	0.862	rs138870	chr22:50209737	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.04	-11.13	-0.71	2.21e-20	Schizophrenia;
TGCT	cis	rs2439831	0.850	rs61390361	chr15:44159842	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	6.2	0.49	7.73e-9	Lung cancer in ever smokers;
TGCT	cis	rs7666738	0.830	rs11944035	chr4:98931618	C/T	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs61990749	0.597	rs1006039	chr14:78263196	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.6	-4.44	-0.37	1.93e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs35306767	0.951	rs55742421	chr10:961037	A/C	cg26597838	chr10:835615	NA	0.75	10.39	0.68	1.43e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs10488031	0.557	rs13231302	chr7:37104329	G/A	cg06458904	chr7:36312573	EEPD1	0.58	4.79	0.39	4.72e-6	QT interval;
TGCT	cis	rs651907	0.535	rs58658478	chr3:101511667	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.31	-6.31	-0.49	4.5e-9	Colorectal cancer;
TGCT	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg01341218	chr17:43662625	NA	1.04	7.82	0.57	1.97e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs12477438	0.539	rs12999417	chr2:99865548	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.09	-16.29	-0.83	1.32e-32	Chronic sinus infection;
TGCT	cis	rs6671200	0.831	rs79662819	chr1:95619804	C/T	cg03123541	chr1:95699097	RWDD3	0.76	4.92	0.4	2.65e-6	Stearic acid (18:0) levels;
TGCT	cis	rs9362426	1.000	rs1203156	chr6:88079694	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.4	4.49	0.37	1.6e-5	Depressive episodes in bipolar disorder;
TGCT	cis	rs2832191	0.791	rs8134407	chr21:30476586	G/A	cg24692254	chr21:30365293	RNF160	0.94	10.38	0.68	1.49e-18	Dental caries;
TGCT	cis	rs826838	0.678	rs11182781	chr12:38610178	C/T	cg26384229	chr12:38710491	ALG10B	0.9	8.06	0.59	5.32e-13	Heart rate;
TGCT	cis	rs12765878	1.000	rs11191843	chr10:105648651	G/C	cg11005552	chr10:105648138	OBFC1	0.44	7.69	0.57	4.01e-12	Coronary artery disease;
TGCT	cis	rs6663390	0.510	rs61601393	chr1:208088684	C/G	cg03990033	chr1:208084030	CD34	0.57	4.94	0.41	2.45e-6	Facial morphology (factor 18);
TGCT	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg08280861	chr8:58055591	NA	0.32	4.49	0.37	1.63e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs11792861	0.926	rs72607172	chr9:111876523	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.49	4.6	0.38	1.02e-5	Menarche (age at onset);
TGCT	cis	rs2594989	1.000	rs388407	chr3:11320709	C/T	cg00170343	chr3:11313890	ATG7	0.66	4.99	0.41	2.02e-6	Circulating chemerin levels;
TGCT	cis	rs7666738	0.830	rs6532701	chr4:98745134	C/T	cg05340658	chr4:99064831	C4orf37	0.49	5.75	0.46	6.58e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8072100	0.651	rs1912484	chr17:45443664	C/G	cg08085267	chr17:45401833	C17orf57	-0.5	-5.63	-0.45	1.14e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs7843479	0.582	rs7009693	chr8:21775314	C/T	cg17168535	chr8:21777572	XPO7	0.72	7.06	0.54	1.02e-10	Mean corpuscular volume;
TGCT	cis	rs9372253	1.000	rs7740028	chr6:110719180	A/G	cg13266496	chr6:110720918	DDO	-0.48	-5.81	-0.46	4.92e-8	Platelet distribution width;
TGCT	cis	rs62392365	0.686	rs79070667	chr6:25194649	T/C	cg16898833	chr6:26189333	HIST1H4D	0.95	4.57	0.38	1.17e-5	Schizophrenia;Intelligence (multi-trait analysis);
TGCT	cis	rs4972806	0.849	rs2113561	chr2:177030925	G/A	cg13092806	chr2:177043255	NA	0.55	4.72	0.39	6.25e-6	IgG glycosylation;
TGCT	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7216064	0.953	rs8073510	chr17:65839210	A/G	cg12091567	chr17:66097778	LOC651250	-0.83	-6.49	-0.5	1.9e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs11648796	0.680	rs11248946	chr16:768597	A/G	cg07343612	chr16:622815	PIGQ	-0.38	-5.37	-0.43	3.71e-7	Height;
TGCT	cis	rs2172802	0.629	rs62304005	chr4:62494219	C/T	cg04118610	chr4:62707027	LPHN3	0.43	4.65	0.39	8.53e-6	Partial epilepsies;
TGCT	cis	rs1857353	1.000	rs1936359	chr1:75891016	T/C	cg11838876	chr1:75668600	SLC44A5	-0.47	-4.56	-0.38	1.2e-5	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg10802521	chr3:52805072	NEK4	-0.72	-9.11	-0.63	1.82e-15	Bipolar disorder;
TGCT	cis	rs17712049	0.908	rs62447154	chr7:48200369	C/A	cg16849860	chr7:48352531	ABCA13	0.32	5.26	0.43	6.19e-7	Refractive astigmatism;
TGCT	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg12379764	chr21:47803548	PCNT	-0.49	-5.03	-0.41	1.71e-6	Testicular germ cell tumor;
TGCT	cis	rs2836633	0.894	rs55955614	chr21:40037330	T/G	cg05519781	chr21:40033154	ERG	0.69	6.81	0.52	3.81e-10	Coronary artery disease;
TGCT	cis	rs7191439	0.858	rs8050715	chr16:88780923	C/G	cg27087555	chr16:88793112	FAM38A	-0.48	-5.53	-0.44	1.84e-7	Plateletcrit;
TGCT	cis	rs2243480	0.803	rs13224048	chr7:65993766	G/A	cg18252515	chr7:66147081	NA	-1.21	-7.96	-0.58	9.08e-13	Diabetic kidney disease;
TGCT	cis	rs2066819	1.000	rs744051	chr12:56667298	C/T	cg26714650	chr12:56694279	CS	1.36	6.06	0.48	1.54e-8	Psoriasis vulgaris;
TGCT	cis	rs3820068	0.705	rs11589076	chr1:15827027	C/T	cg05660106	chr1:15850417	CASP9	1.18	13.63	0.77	2.04e-26	Systolic blood pressure;
TGCT	cis	rs1670533	1.000	rs10084888	chr4:1053814	G/T	cg20887711	chr4:1340912	KIAA1530	0.7	5.65	0.45	1.03e-7	Recombination rate (females);
TGCT	cis	rs514406	0.505	rs269287	chr1:53168842	T/C	cg22166914	chr1:53195759	ZYG11B	0.44	7.67	0.57	4.47e-12	Monocyte count;
TGCT	cis	rs669446	0.533	rs7543520	chr1:44243866	T/C	cg12908607	chr1:44402522	ARTN	-0.61	-6.89	-0.53	2.55e-10	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs7647973	0.626	rs4855845	chr3:49687043	T/C	cg05785598	chr3:49045655	WDR6	0.41	4.88	0.4	3.22e-6	Menarche (age at onset);
TGCT	cis	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg06636001	chr8:8085503	FLJ10661	0.69	6.25	0.49	6.14e-9	Mood instability;
TGCT	trans	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg21659725	chr3:3221576	CRBN	0.76	9.02	0.63	2.92e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs2739330	0.615	rs2858911	chr22:24297195	G/T	cg10819733	chr22:24237672	NA	-0.3	-5.01	-0.41	1.87e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9457247	0.967	rs377753	chr6:167389496	A/T	cg25258033	chr6:167368657	RNASET2	0.18	4.49	0.37	1.63e-5	Crohn's disease;
TGCT	cis	rs11249608	0.636	rs6888567	chr5:178449074	C/T	cg01312482	chr5:178451176	ZNF879	0.56	5.45	0.44	2.62e-7	Pubertal anthropometrics;
TGCT	cis	rs3803170	0.513	rs10774622	chr12:111833348	C/T	cg10833066	chr12:111807467	FAM109A	0.36	5.3	0.43	5.16e-7	Mean corpuscular hemoglobin;
TGCT	cis	rs9611565	0.592	rs5751129	chr22:42015765	C/T	cg17554472	chr22:41940697	POLR3H	0.47	5.08	0.41	1.38e-6	Vitiligo;
TGCT	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.55	-7.04	-0.53	1.17e-10	Longevity;Endometriosis;
TGCT	cis	rs12908161	1.000	rs62019464	chr15:85294469	T/A	cg12863693	chr15:85201151	NMB	0.41	4.89	0.4	3.05e-6	Schizophrenia;
TGCT	cis	rs6815814	0.768	rs6851685	chr4:38893843	G/T	cg02016764	chr4:38805732	TLR1	-0.28	-4.45	-0.37	1.92e-5	Breast cancer;
TGCT	cis	rs1008375	0.931	rs2109519	chr4:17695453	A/G	cg18681998	chr4:17616180	MED28	0.76	7.09	0.54	8.93e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs250677	0.687	rs2963484	chr5:148451127	A/T	cg18129178	chr5:148520854	ABLIM3	-0.43	-6.29	-0.49	5.05e-9	Breast cancer;
TGCT	cis	rs1536827	0.541	rs11592587	chr10:135363653	G/A	cg14503168	chr10:134895446	NA	-0.55	-4.53	-0.38	1.36e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs5022636	0.525	rs7539584	chr1:151182953	C/T	cg12798035	chr1:150981329	FAM63A;PRUNE	-0.41	-4.55	-0.38	1.25e-5	Gut microbiota (functional units);
TGCT	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.31	-4.82	-0.4	4.12e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs6570726	0.620	rs367693	chr6:145815949	G/A	cg13319975	chr6:146136371	FBXO30	-0.65	-5.77	-0.46	5.93e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7208487	0.684	rs12449852	chr17:37632088	A/G	cg07936489	chr17:37558343	FBXL20	-0.85	-6.04	-0.48	1.7e-8	Primary biliary cholangitis;Glomerular filtration rate in non diabetics (creatinine);
TGCT	cis	rs4237845	0.715	rs4760340	chr12:58275176	A/T	cg12615879	chr12:58013172	SLC26A10	-0.42	-4.91	-0.4	2.78e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg23758822	chr17:41437982	NA	0.71	6.77	0.52	4.56e-10	Menopause (age at onset);
TGCT	cis	rs9419702	0.538	rs4074772	chr10:133540006	A/T	cg04492858	chr10:133558786	NA	0.58	6.24	0.49	6.34e-9	Survival in rectal cancer;
TGCT	cis	rs13064411	0.735	rs9875025	chr3:113147552	T/C	cg18753928	chr3:113234510	CCDC52	-0.69	-5.23	-0.43	6.83e-7	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs2836974	0.565	rs34304022	chr21:40579619	G/A	cg11644478	chr21:40555479	PSMG1	0.8	5.92	0.47	2.9e-8	Cognitive function;
TGCT	cis	rs11711311	1.000	rs3806641	chr3:113465761	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.79	-7.32	-0.55	2.75e-11	IgG glycosylation;
TGCT	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg15691649	chr6:25882328	NA	-0.35	-4.55	-0.38	1.25e-5	Blood metabolite levels;
TGCT	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	16.07	0.82	4.16e-32	Prudent dietary pattern;
TGCT	cis	rs4689592	0.583	rs6823154	chr4:7078145	C/T	cg26116260	chr4:7069785	GRPEL1	0.98	9.1	0.63	1.91e-15	Monocyte percentage of white cells;
TGCT	cis	rs4664308	1.000	rs16844715	chr2:160915106	A/G	cg03641300	chr2:160917029	PLA2R1	0.25	6.42	0.5	2.63e-9	Idiopathic membranous nephropathy;
TGCT	cis	rs2010099	0.583	rs112519474	chr3:124315623	G/A	cg04915618	chr3:124304960	KALRN	0.51	4.62	0.38	9.44e-6	Thyroid peroxidase antibody levels;
TGCT	cis	rs9916302	0.706	rs649180	chr17:37464959	A/C	cg07936489	chr17:37558343	FBXL20	0.84	6.16	0.48	9.3e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs1775715	0.707	rs2808088	chr10:32146150	A/G	cg14930904	chr10:32216787	ARHGAP12	0.53	5.1	0.42	1.22e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs9443645	0.835	rs1044309	chr6:79646575	A/G	cg09184832	chr6:79620586	NA	-0.49	-5.29	-0.43	5.29e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7044106	0.762	rs13291660	chr9:123392748	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	4.57	0.38	1.14e-5	Hip circumference adjusted for BMI;
TGCT	cis	rs4595586	0.546	rs11609849	chr12:39258090	C/G	cg26384229	chr12:38710491	ALG10B	0.66	5.41	0.44	3.13e-7	Morning vs. evening chronotype;
TGCT	cis	rs6964587	1.000	rs2888851	chr7:91648341	G/A	cg22709100	chr7:91322751	NA	0.27	4.48	0.37	1.68e-5	Breast cancer;
TGCT	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.07	-9.63	-0.65	1.01e-16	Platelet count;
TGCT	cis	rs763014	0.931	rs2071981	chr16:630025	C/G	cg27436995	chr16:743998	FBXL16	-0.45	-4.82	-0.4	4.17e-6	Height;
TGCT	cis	rs7267979	0.702	rs449801	chr20:25491847	C/T	cg21995068	chr20:25989032	LOC100134868	-0.43	-5.33	-0.43	4.55e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs427394	0.659	rs419128	chr5:6739791	G/A	cg10857441	chr5:6722123	POLS	-0.28	-6.08	-0.48	1.38e-8	Menopause (age at onset);
TGCT	cis	rs155076	1.000	rs261406	chr13:21855854	G/A	cg11317459	chr13:21872234	NA	-1.33	-11.41	-0.72	4.71e-21	White matter hyperintensity burden;
TGCT	cis	rs7589728	0.514	rs12465706	chr2:88467459	C/A	cg04511125	chr2:88470314	THNSL2	0.83	6.93	0.53	2e-10	Plasma clusterin levels;
TGCT	cis	rs734999	0.545	rs6666788	chr1:2567500	A/G	cg18854424	chr1:2615690	NA	-0.47	-5.38	-0.44	3.57e-7	Ulcerative colitis;
TGCT	cis	rs6490294	0.796	rs7972112	chr12:112505182	T/A	cg10833066	chr12:111807467	FAM109A	0.37	5.44	0.44	2.68e-7	Mean platelet volume;
TGCT	cis	rs11098499	0.820	rs13122709	chr4:120555356	T/A	cg09307838	chr4:120376055	NA	0.67	6.29	0.49	5.06e-9	Corneal astigmatism;
TGCT	cis	rs10509586	0.522	rs17411458	chr10:91683749	G/A	cg25278353	chr10:91717815	NA	0.43	5.05	0.41	1.55e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
TGCT	cis	rs4253772	0.550	rs9615951	chr22:46728056	C/A	cg24881330	chr22:46731750	TRMU	1.0	4.89	0.4	3.03e-6	LDL cholesterol;Cholesterol, total;
TGCT	trans	rs6089829	0.962	rs6089826	chr20:61668595	G/A	cg17470723	chr8:74884337	TCEB1	0.77	7.4	0.55	1.82e-11	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs4820539	0.966	rs2301554	chr22:23484254	A/C	cg21100191	chr22:23484243	RTDR1	0.92	11.33	0.71	7.15e-21	Bone mineral density;
TGCT	cis	rs6543140	0.964	rs6748390	chr2:103062175	A/G	cg09003973	chr2:102972529	NA	0.57	4.8	0.4	4.41e-6	Blood protein levels;
TGCT	cis	rs7914558	1.000	rs943036	chr10:104836047	T/C	cg15744005	chr10:104629667	AS3MT	-0.39	-4.69	-0.39	7.05e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs10883723	1.000	rs10883723	chr10:104225832	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	7.48	0.56	1.19e-11	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs11190604	0.767	rs4919459	chr10:102200371	C/T	cg16342193	chr10:102329863	NA	-0.41	-5.22	-0.42	7.22e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2933343	0.729	rs6790091	chr3:128608751	G/C	cg11901034	chr3:128598214	ACAD9	-0.68	-6.63	-0.51	9.16e-10	IgG glycosylation;
TGCT	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg25036284	chr2:26402008	FAM59B	-0.55	-4.76	-0.39	5.33e-6	Gut microbiome composition (summer);
TGCT	cis	rs523522	1.000	rs523522	chr12:121020250	A/T	cg12219531	chr12:120966889	COQ5	0.8	7.08	0.54	9.41e-11	High light scatter reticulocyte count;
TGCT	cis	rs78487399	0.908	rs12467420	chr2:43831150	G/A	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.66	4.67	0.39	7.66e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs1775715	0.870	rs11008696	chr10:32218614	G/A	cg14930904	chr10:32216787	ARHGAP12	0.48	4.53	0.38	1.39e-5	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs1865760	1.000	rs9348698	chr6:25929689	T/A	cg17042849	chr6:26104293	HIST1H4C	-0.5	-4.44	-0.37	2e-5	Height;
TGCT	cis	rs12682352	0.602	rs6988939	chr8:8666916	C/T	cg08975724	chr8:8085496	FLJ10661	0.52	4.46	0.37	1.84e-5	Neuroticism;
TGCT	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg17178900	chr1:205818956	PM20D1	0.59	7.5	0.56	1.05e-11	Menarche (age at onset);
TGCT	cis	rs9486719	1.000	rs2263192	chr6:96873037	C/G	cg06623918	chr6:96969491	KIAA0776	1.01	8.86	0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs9790314	0.586	rs16832279	chr3:161120483	C/T	cg03342759	chr3:160939853	NMD3	-0.55	-5.7	-0.46	8.15e-8	Morning vs. evening chronotype;
TGCT	cis	rs8180040	0.620	rs9845728	chr3:47103376	C/T	cg27129171	chr3:47204927	SETD2	0.71	8.55	0.61	3.9e-14	Colorectal cancer;
TGCT	cis	rs7772486	0.875	rs9390372	chr6:146363638	G/C	cg05347473	chr6:146136440	FBXO30	0.56	5.42	0.44	2.96e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg26338869	chr17:61819248	STRADA	-0.53	-4.9	-0.4	2.95e-6	Prudent dietary pattern;
TGCT	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg20607798	chr8:58055168	NA	0.49	4.52	0.38	1.43e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs10779751	1.000	rs4845982	chr1:11271576	T/C	cg08854313	chr1:11322531	MTOR	0.94	8.51	0.61	4.75e-14	Body mass index;
TGCT	cis	rs11785400	0.928	rs10100287	chr8:143734836	C/T	cg10596483	chr8:143751796	JRK	0.56	6.02	0.48	1.87e-8	Schizophrenia;
TGCT	cis	rs35146811	0.660	rs3779046	chr7:99779243	A/G	cg04778012	chr7:99775508	STAG3;GPC2	0.35	4.93	0.41	2.55e-6	Coronary artery disease;
TGCT	cis	rs9357506	1.000	rs11962674	chr6:46320349	G/A	cg21115430	chr6:46460003	NA	-0.23	-4.53	-0.38	1.35e-5	Body mass index;
TGCT	cis	rs2549003	1.000	rs10214312	chr5:131821866	T/G	cg21138405	chr5:131827807	IRF1	0.19	4.79	0.39	4.76e-6	Asthma (sex interaction);
TGCT	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg16414030	chr3:133502952	NA	-0.52	-7.29	-0.55	3.17e-11	Iron status biomarkers;
TGCT	cis	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg08045932	chr20:61659980	NA	0.49	9.56	0.65	1.5e-16	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs56804039	0.524	rs73190526	chr8:8423249	C/T	cg14215082	chr8:9055850	NA	0.5	4.9	0.4	2.91e-6	Cervical cancer;
TGCT	cis	rs9814567	0.752	rs13064209	chr3:134335993	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.75	6.75	0.52	4.98e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs62064224	0.554	rs9889352	chr17:30775761	T/C	cg18200150	chr17:30822561	MYO1D	0.44	5.47	0.44	2.35e-7	Schizophrenia;
TGCT	cis	rs9858542	0.953	rs34363169	chr3:49537712	G/A	cg03060546	chr3:49711283	APEH	-0.61	-5.37	-0.43	3.78e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs4372836	0.580	rs6718662	chr2:29048758	G/C	cg09522027	chr2:28974177	PPP1CB	-0.67	-6.94	-0.53	1.97e-10	Body mass index;
TGCT	cis	rs709400	0.633	rs1136165	chr14:103988180	G/T	cg26031613	chr14:104095156	KLC1	-0.82	-8.3	-0.6	1.46e-13	Body mass index;
TGCT	cis	rs9467711	0.516	rs1324088	chr6:25841122	C/T	cg12310025	chr6:25882481	NA	-0.68	-4.44	-0.37	2e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6598955	0.671	rs41285347	chr1:26644399	C/T	cg04990556	chr1:26633338	UBXN11	0.62	4.6	0.38	1.04e-5	Obesity-related traits;
TGCT	cis	rs612683	0.690	rs11166440	chr1:100808363	C/T	cg06223162	chr1:101003688	GPR88	-0.32	-5.19	-0.42	8.46e-7	Breast cancer;
TGCT	cis	rs10489202	1.000	rs66950781	chr1:168018779	C/A	cg24449463	chr1:168025552	DCAF6	-0.42	-4.46	-0.37	1.85e-5	Schizophrenia;
TGCT	cis	rs7221595	0.825	rs71366590	chr17:4006685	T/A	cg09580393	chr17:4869866	SPAG7	-0.38	-4.46	-0.37	1.83e-5	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
TGCT	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.29	-4.49	-0.37	1.64e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs11077998	0.933	rs7215465	chr17:80532532	C/T	cg10255544	chr17:80519551	FOXK2	0.23	4.44	0.37	1.96e-5	Reticulocyte fraction of red cells;
TGCT	cis	rs793571	0.502	rs395601	chr15:59063196	G/C	cg05156742	chr15:59063176	FAM63B	0.55	5.18	0.42	8.61e-7	Schizophrenia;
TGCT	cis	rs10927875	0.541	rs1048245	chr1:16341354	T/G	cg22431228	chr1:16359049	CLCNKA	-0.29	-6.07	-0.48	1.42e-8	Dilated cardiomyopathy;
TGCT	cis	rs6735179	0.916	rs4143566	chr2:1771399	G/C	cg08534653	chr2:1747700	PXDN	0.55	4.49	0.37	1.62e-5	Response to antipsychotic treatment;
TGCT	cis	rs7809950	1.000	rs10243340	chr7:107090955	A/G	cg23024343	chr7:107201750	COG5	-0.36	-5.63	-0.45	1.12e-7	Coronary artery disease;
TGCT	cis	rs829880	0.789	rs1096146	chr12:98850966	A/G	cg25150519	chr12:98850993	NA	0.62	6.22	0.49	7e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12579753	0.917	rs10862361	chr12:82197946	T/C	cg07988820	chr12:82153109	PPFIA2	-0.59	-6.19	-0.49	7.93e-9	Resting heart rate;
TGCT	cis	rs10779751	0.690	rs910661	chr1:11130116	C/A	cg08854313	chr1:11322531	MTOR	0.82	7.04	0.53	1.19e-10	Body mass index;
TGCT	cis	rs2016266	0.964	rs1609474	chr12:53676814	C/T	cg16917193	chr12:54089295	NA	-0.59	-4.76	-0.39	5.29e-6	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs7647973	0.593	rs62262730	chr3:49808274	T/G	cg05785598	chr3:49045655	WDR6	-0.42	-4.98	-0.41	2.06e-6	Menarche (age at onset);
TGCT	cis	rs9910055	0.636	rs7089	chr17:42269017	T/C	cg19774624	chr17:42201019	HDAC5	-0.87	-10.63	-0.69	3.81e-19	Total body bone mineral density;
TGCT	cis	rs6940638	0.956	rs12203454	chr6:27031100	C/T	cg16898833	chr6:26189333	HIST1H4D	0.71	5.34	0.43	4.2e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs6854594	chr4:99065312	A/T	cg17366294	chr4:99064904	C4orf37	0.73	7.45	0.56	1.4e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs317689	0.918	rs689415	chr12:69738139	A/G	cg20891283	chr12:69753455	YEATS4	-0.56	-4.6	-0.38	1.03e-5	Response to diuretic therapy;
TGCT	cis	rs11718455	0.960	rs11929518	chr3:44016874	A/G	cg08738300	chr3:44038990	NA	0.87	6.63	0.51	9.07e-10	Coronary artery disease;
TGCT	cis	rs858239	1.000	rs156425	chr7:23309119	C/T	cg05602783	chr7:23145260	KLHL7	0.57	4.81	0.4	4.26e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg06481639	chr22:41940642	POLR3H	-0.72	-6.29	-0.49	4.98e-9	Vitiligo;
TGCT	cis	rs5769707	0.616	rs135869	chr22:50008366	T/C	cg05373962	chr22:49881684	NA	-0.3	-5.03	-0.41	1.64e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs55794721	0.509	rs12027110	chr1:25775682	A/T	cg00786635	chr1:25594202	NA	0.53	5.64	0.45	1.11e-7	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs77861329	1.000	rs13319566	chr3:52095555	C/G	cg08692210	chr3:52188851	WDR51A	0.96	4.5	0.37	1.54e-5	Macrophage inflammatory protein 1b levels;
TGCT	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg23719950	chr11:63933701	MACROD1	-0.7	-5.87	-0.47	3.66e-8	Mean platelet volume;
TGCT	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg20276088	chr3:133502917	NA	-0.27	-5.79	-0.46	5.51e-8	Iron status biomarkers;
TGCT	cis	rs80282103	0.867	rs12241632	chr10:1069070	A/T	cg08668510	chr10:1095578	IDI1	1.07	5.19	0.42	8.23e-7	Glomerular filtration rate (creatinine);
TGCT	trans	rs3780486	0.846	rs4584234	chr9:33147479	G/A	cg04842962	chr6:43655489	MRPS18A	1.17	14.6	0.8	1.07e-28	IgG glycosylation;
TGCT	cis	rs950169	1.000	rs11638297	chr15:84782417	A/C	cg17173187	chr15:85201210	NMB	0.44	4.71	0.39	6.46e-6	Schizophrenia;
TGCT	cis	rs651907	0.535	rs12633089	chr3:101528763	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	4.86	0.4	3.51e-6	Colorectal cancer;
TGCT	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg09436375	chr6:42928200	GNMT	-0.4	-5.21	-0.42	7.49e-7	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs1609391	0.543	rs9881139	chr3:136634040	A/G	cg15507776	chr3:136538369	TMEM22	0.66	6.84	0.52	3.27e-10	Neuroticism;
TGCT	cis	rs1865760	0.566	rs9366634	chr6:26072396	C/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.78	7.45	0.56	1.39e-11	Height;
TGCT	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg10560079	chr2:191398806	TMEM194B	0.37	5.19	0.42	8.16e-7	Pulse pressure;
TGCT	cis	rs4642101	0.793	rs13320486	chr3:12822069	C/A	cg05775895	chr3:12838266	CAND2	0.79	8.91	0.62	5.38e-15	QRS complex (12-leadsum);
TGCT	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg21548813	chr6:291882	DUSP22	-0.71	-7.45	-0.56	1.36e-11	Menopause (age at onset);
TGCT	cis	rs6938	0.534	rs12904897	chr15:75217686	A/G	cg09165964	chr15:75287851	SCAMP5	0.55	5.23	0.42	7.05e-7	Breast cancer;
TGCT	cis	rs3734905	1.000	rs4716364	chr6:169949322	A/G	cg05229362	chr6:169789120	NA	0.47	4.63	0.38	9.18e-6	HIV-1 control;
TGCT	cis	rs7772486	0.558	rs9497403	chr6:146054695	T/G	cg23711669	chr6:146136114	FBXO30	-0.73	-6.61	-0.51	1.04e-9	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg22968622	chr17:43663579	NA	-1.23	-10.98	-0.7	5.31e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs3820928	0.874	rs12467261	chr2:227888838	T/C	cg11843606	chr2:227700838	RHBDD1	-0.57	-5.23	-0.42	7.12e-7	Pulmonary function;
TGCT	cis	rs12142240	0.698	rs58162700	chr1:46816659	T/A	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs9486715	0.867	rs2499774	chr6:97006581	C/G	cg06623918	chr6:96969491	KIAA0776	-1.1	-14.65	-0.8	7.83e-29	Headache;
TGCT	cis	rs7666738	0.830	rs6834014	chr4:98951431	G/A	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs751728	0.687	rs9357164	chr6:33761021	T/C	cg13859433	chr6:33739653	LEMD2	-0.33	-5.78	-0.46	5.71e-8	Crohn's disease;
TGCT	cis	rs319204	0.885	rs488072	chr5:146280390	A/G	cg25021259	chr5:146258546	PPP2R2B	0.36	4.6	0.38	1.01e-5	Schizophrenia;
TGCT	cis	rs9682041	0.808	rs9875109	chr3:170064776	A/G	cg07589077	chr3:170072950	NA	-0.31	-5.48	-0.44	2.3e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs6912958	0.781	rs2268993	chr6:88184111	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.54	-5.23	-0.43	7.03e-7	Monocyte percentage of white cells;
TGCT	cis	rs1865760	0.593	rs9295678	chr6:25937033	G/A	cg03517284	chr6:25882590	NA	-0.47	-4.73	-0.39	5.95e-6	Height;
TGCT	cis	rs67072384	0.818	rs2291293	chr11:72470653	C/T	cg03713592	chr11:72463424	ARAP1	-1.01	-5.04	-0.41	1.59e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs9993613	0.808	rs1518489	chr4:73429638	C/T	cg15102770	chr4:73434591	ADAMTS3	0.5	4.68	0.39	7.41e-6	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs12220898	0.749	rs4838482	chr10:50477414	G/A	cg06072769	chr10:50146962	WDFY4	0.35	4.5	0.37	1.56e-5	Inflammatory biomarkers;
TGCT	cis	rs3617	0.625	rs2071042	chr3:52864584	A/G	cg11645453	chr3:52864694	ITIH4	0.29	5.71	0.46	7.84e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9487051	0.872	rs1111863	chr6:109611206	C/T	cg01475377	chr6:109611718	NA	0.3	4.62	0.38	9.65e-6	Reticulocyte fraction of red cells;
TGCT	cis	rs3733585	0.673	rs6840802	chr4:9965633	C/G	cg11266682	chr4:10021025	SLC2A9	0.57	7.6	0.56	6.26e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs478304	0.934	rs574483	chr11:65515277	A/G	cg27068330	chr11:65405492	SIPA1	0.75	7.57	0.56	7.2e-12	Acne (severe);
TGCT	cis	rs644799	1.000	rs474442	chr11:95583995	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	11.54	0.72	2.27e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9972944	0.756	rs6504344	chr17:63756668	C/T	cg07283582	chr17:63770753	CCDC46	-0.26	-5.11	-0.42	1.18e-6	Total body bone mineral density;
TGCT	cis	rs12620999	0.938	rs4575672	chr2:238070572	T/C	cg23555395	chr2:238036564	NA	-0.28	-4.8	-0.4	4.49e-6	Systemic lupus erythematosus;
TGCT	cis	rs7267979	1.000	rs2258769	chr20:25276680	G/C	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10464366	0.544	rs4723824	chr7:39153698	T/C	cg15212455	chr7:39170539	POU6F2	0.3	6.7	0.52	6.63e-10	IgG glycosylation;
TGCT	cis	rs250677	0.687	rs250663	chr5:148453117	T/C	cg23229984	chr5:148520753	ABLIM3	0.21	4.89	0.4	3.11e-6	Breast cancer;
TGCT	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg18876405	chr7:65276391	NA	-0.36	-5.41	-0.44	3.12e-7	Aortic root size;
TGCT	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs56104184	0.830	rs73061617	chr19:49350984	G/A	cg17863274	chr19:49399704	TULP2	-0.51	-6.28	-0.49	5.21e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs4699052	0.662	rs6533082	chr4:104241205	G/A	cg16532752	chr4:104119610	CENPE	-0.57	-5.72	-0.46	7.37e-8	Testicular germ cell tumor;
TGCT	cis	rs9467773	1.000	rs6903973	chr6:26499942	C/A	cg09904177	chr6:26538194	HMGN4	0.64	6.49	0.5	1.89e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs10927875	1.000	rs4307563	chr1:16313788	C/T	cg21385522	chr1:16154831	NA	-0.77	-8.44	-0.6	7.05e-14	Dilated cardiomyopathy;
TGCT	cis	rs9300255	0.543	rs520088	chr12:123522150	C/G	cg00376283	chr12:123451042	ABCB9	0.7	5.17	0.42	9.08e-7	Neutrophil percentage of white cells;
TGCT	cis	rs2242116	0.833	rs6442038	chr3:46960742	A/G	cg27129171	chr3:47204927	SETD2	0.65	6.2	0.49	7.6e-9	Birth weight;
TGCT	cis	rs7607369	0.791	rs12468043	chr2:219354197	C/A	cg02176678	chr2:219576539	TTLL4	0.48	6.78	0.52	4.32e-10	Red blood cell count;Amyotrophic lateral sclerosis;
TGCT	cis	rs79349575	0.756	rs62078385	chr17:47045009	C/T	cg26022315	chr17:47021804	SNF8	0.47	4.56	0.38	1.2e-5	Type 2 diabetes;
TGCT	cis	rs7666738	0.830	rs9998582	chr4:98938949	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10782582	0.609	rs5745547	chr1:76378275	G/C	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.54	4.64	0.38	8.88e-6	Daytime sleep phenotypes;
TGCT	cis	rs12367572	0.796	rs7979141	chr12:45282630	A/T	cg04608330	chr12:45269318	NELL2	-0.64	-6.7	-0.52	6.46e-10	Gut microbiome composition (summer);
TGCT	cis	rs11203032	0.831	rs10887921	chr10:90925667	T/G	cg16672925	chr10:90967113	CH25H	0.73	4.5	0.37	1.55e-5	Heart failure;
TGCT	cis	rs9309473	0.687	rs7576824	chr2:73611281	C/T	cg20560298	chr2:73613845	ALMS1	0.48	5.39	0.44	3.36e-7	Metabolite levels;
TGCT	cis	rs6582630	0.519	rs4405392	chr12:38293661	A/C	cg13010199	chr12:38710504	ALG10B	0.57	4.49	0.37	1.62e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs2692947	0.655	rs4605406	chr2:96583735	A/C	cg23100626	chr2:96804247	ASTL	0.38	4.58	0.38	1.09e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.51	-4.89	-0.4	3.03e-6	Longevity;Endometriosis;
TGCT	cis	rs950169	1.000	rs1848093	chr15:84755527	G/C	cg17173187	chr15:85201210	NMB	0.47	5.23	0.42	7.11e-7	Schizophrenia;
TGCT	cis	rs9303542	0.559	rs12946931	chr17:46614080	T/C	cg25032089	chr17:46643351	HOXB3	0.58	5.48	0.44	2.23e-7	Ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg01448562	chr3:133502909	NA	-0.33	-6.58	-0.51	1.16e-9	Iron status biomarkers;
TGCT	cis	rs524023	0.958	rs2021860	chr11:64361384	G/T	cg07733098	chr11:64478343	NRXN2	0.32	4.97	0.41	2.17e-6	Urate levels in obese individuals;
TGCT	cis	rs68170813	0.641	rs12539895	chr7:107091849	C/A	cg02696742	chr7:106810147	HBP1	-0.65	-5.15	-0.42	1.01e-6	Coronary artery disease;
TGCT	cis	rs735396	0.770	rs2464196	chr12:121435427	G/A	cg15155738	chr12:121454335	C12orf43	0.52	4.56	0.38	1.19e-5	N-glycan levels;
TGCT	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg23302884	chr18:44338147	ST8SIA5	-0.4	-4.58	-0.38	1.11e-5	Personality dimensions;
TGCT	cis	rs6840360	0.533	rs4696297	chr4:152725838	T/G	cg17479576	chr4:152424074	FAM160A1	0.46	4.83	0.4	3.88e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4843185	0.637	rs4143866	chr16:85716366	A/G	cg02644593	chr16:85391138	NA	0.22	4.94	0.41	2.43e-6	Platelet distribution width;
TGCT	cis	rs42648	0.935	rs42660	chr7:89982522	C/T	cg25739043	chr7:89950458	NA	-0.65	-6.22	-0.49	6.96e-9	Homocysteine levels;
TGCT	trans	rs66573146	1.000	rs9942188	chr4:6984181	C/T	cg07817883	chr1:32538562	TMEM39B	1.66	8.29	0.6	1.56e-13	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs514406	0.505	rs395169	chr1:53174071	G/A	cg25767906	chr1:53392781	SCP2	-0.46	-5.12	-0.42	1.14e-6	Monocyte count;
TGCT	cis	rs7824557	0.689	rs10481454	chr8:11109303	C/G	cg21775007	chr8:11205619	TDH	-0.62	-5.42	-0.44	3.03e-7	Retinal vascular caliber;
TGCT	cis	rs8180040	0.764	rs13084117	chr3:47183239	C/A	cg27129171	chr3:47204927	SETD2	0.75	9.86	0.66	2.82e-17	Colorectal cancer;
TGCT	cis	rs8177253	0.696	rs4459901	chr3:133465699	T/C	cg16414030	chr3:133502952	NA	-0.51	-7.01	-0.53	1.32e-10	Iron status biomarkers;
TGCT	cis	rs1008375	0.932	rs6841784	chr4:17626418	G/A	cg10189774	chr4:17578691	LAP3	0.64	5.47	0.44	2.42e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg18252515	chr7:66147081	NA	1.2	7.83	0.58	1.89e-12	Diabetic kidney disease;
TGCT	cis	rs12472274	0.941	rs6748440	chr2:239100375	C/T	cg17459225	chr2:239074497	NA	0.33	4.84	0.4	3.79e-6	Phospholipid levels (plasma);
TGCT	cis	rs13217239	0.646	rs2142685	chr6:27054497	C/T	cg05738196	chr6:26577821	NA	-0.51	-4.92	-0.4	2.71e-6	Schizophrenia;
TGCT	cis	rs7394190	0.688	rs76033784	chr10:75535970	A/G	cg07699608	chr10:75541558	CHCHD1	0.79	5.44	0.44	2.72e-7	Incident atrial fibrillation;
TGCT	trans	rs1864982	1.000	rs560157	chr5:146314099	C/A	cg14363954	chr9:139437479	NOTCH1	0.41	6.65	0.51	8.27e-10	Alcohol dependence;
TGCT	cis	rs796364	0.906	rs1658810	chr2:200816382	C/T	cg17644776	chr2:200775616	C2orf69	0.3	4.65	0.39	8.22e-6	Schizophrenia;
TGCT	cis	rs6582630	0.554	rs8189625	chr12:38401177	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-4.52	-0.38	1.43e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg05368731	chr17:41323189	NBR1	1.17	13.8	0.78	7.84e-27	Menopause (age at onset);
TGCT	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg20607798	chr8:58055168	NA	0.65	5.46	0.44	2.47e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs10791097	0.547	rs10791101	chr11:130739133	C/T	cg14779329	chr11:130786720	SNX19	0.29	4.79	0.4	4.58e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs13424612	1.000	rs10206993	chr2:240900919	C/A	cg26363272	chr2:240904871	NDUFA10	0.31	5.13	0.42	1.08e-6	Odorant perception (isobutyraldehyde);
TGCT	cis	rs7666738	0.830	rs4699601	chr4:99034429	G/A	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4273100	0.688	rs12939947	chr17:19204531	A/T	cg01534423	chr17:18965556	NA	0.8	7.29	0.55	3.17e-11	Schizophrenia;
TGCT	cis	rs7655841	0.704	rs6824219	chr4:129876836	C/T	cg26347359	chr4:129759716	PHF17	0.49	5.04	0.41	1.6e-6	Chronic obstructive pulmonary disease (moderate to severe);
TGCT	cis	rs35484700	1	rs35484700	chr4:55498781	CG/C	cg02821500	chr4:54931072	CHIC2	0.48	4.71	0.39	6.54e-6	White blood cell count;
TGCT	cis	rs12477438	0.834	rs6757019	chr2:99676936	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-6.1	-0.48	1.22e-8	Chronic sinus infection;
TGCT	cis	rs2288884	1.000	rs72483951	chr19:52573682	G/C	cg15405931	chr19:52693188	PPP2R1A	-0.69	-4.5	-0.37	1.56e-5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs9902453	0.967	rs55748380	chr17:28469782	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	6.51	0.5	1.66e-9	Coffee consumption (cups per day);
TGCT	cis	rs8141529	0.748	rs7287918	chr22:29281710	G/A	cg02153584	chr22:29168773	CCDC117	0.63	4.87	0.4	3.3e-6	Lymphocyte counts;
TGCT	cis	rs2658782	0.654	rs2248524	chr11:93255715	G/A	cg15737290	chr11:93063684	CCDC67	0.63	4.85	0.4	3.66e-6	Pulmonary function decline;
TGCT	cis	rs9972944	0.691	rs7225471	chr17:63777913	T/C	cg07283582	chr17:63770753	CCDC46	0.26	5.05	0.41	1.53e-6	Total body bone mineral density;
TGCT	cis	rs367615	0.918	rs72797472	chr5:108881343	C/T	cg17395555	chr5:108820864	NA	0.31	5.01	0.41	1.85e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs288326	0.561	rs76829215	chr2:183894452	A/G	cg09997497	chr2:183902928	NCKAP1	1.11	4.95	0.41	2.38e-6	Blood protein levels;
TGCT	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg27170947	chr2:26402098	FAM59B	-0.4	-4.58	-0.38	1.1e-5	Gut microbiome composition (summer);
TGCT	cis	rs7726839	0.540	rs11738281	chr5:662547	T/C	cg09021430	chr5:549028	NA	-0.39	-5.35	-0.43	4.11e-7	Obesity-related traits;
TGCT	cis	rs28595532	0.920	rs116205107	chr4:119730910	G/A	cg21605333	chr4:119757512	SEC24D	1.66	8.33	0.6	1.28e-13	Cannabis dependence symptom count;
TGCT	cis	rs7178572	0.568	rs11854193	chr15:77458136	C/A	cg22256960	chr15:77711686	NA	-0.89	-8.95	-0.63	4.29e-15	Type 2 diabetes;
TGCT	cis	rs6450176	0.625	rs56193151	chr5:53287790	C/T	ch.5.1024479R	chr5:53302184	ARL15	-0.69	-5.65	-0.45	1.05e-7	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs7208859	0.623	rs9893422	chr17:29111715	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs921968	0.643	rs832802	chr2:219386899	C/T	cg02176678	chr2:219576539	TTLL4	0.44	6.33	0.49	4.17e-9	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs11175492	0.528	rs10506537	chr12:65030890	G/A	cg18624581	chr12:65153313	GNS	-0.87	-4.86	-0.4	3.47e-6	Platelet count;
TGCT	cis	rs9818758	0.607	rs34784192	chr3:49274823	G/T	cg07636037	chr3:49044803	WDR6	-1.04	-5.13	-0.42	1.09e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs13082711	0.522	rs6790344	chr3:27336531	G/C	cg02860705	chr3:27208620	NA	0.33	5.45	0.44	2.62e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs2455799	0.517	rs3846131	chr3:15932357	C/T	cg12172478	chr3:16357591	RFTN1	-0.32	-4.66	-0.39	8.01e-6	Mean platelet volume;
TGCT	cis	rs7772486	0.641	rs2777485	chr6:146334377	G/A	cg23711669	chr6:146136114	FBXO30	0.68	6.39	0.5	3e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9486719	0.895	rs11152960	chr6:96900398	A/G	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.21	-0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs7246657	0.943	rs9676967	chr19:37928089	G/C	cg18154014	chr19:37997991	ZNF793	0.73	5.4	0.44	3.23e-7	Coronary artery calcification;
TGCT	cis	rs2239547	0.618	rs2071041	chr3:52864693	T/G	cg10802521	chr3:52805072	NEK4	-0.64	-6.2	-0.49	7.68e-9	Schizophrenia;
TGCT	cis	rs1371867	0.513	rs1542812	chr8:101207064	G/A	cg06002616	chr8:101225028	SPAG1	0.63	8.12	0.59	4.02e-13	Atrioventricular conduction;
TGCT	cis	rs6594499	0.542	rs7722241	chr5:110460747	T/A	cg04022379	chr5:110408740	TSLP	0.57	5.72	0.46	7.71e-8	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs425277	1.000	rs12401379	chr1:2058580	G/C	cg03732007	chr1:2071316	PRKCZ	0.25	5.0	0.41	1.92e-6	Height;
TGCT	cis	rs13315871	1.000	rs9864824	chr3:58394835	A/G	cg12435725	chr3:58293450	RPP14	0.43	4.47	0.37	1.71e-5	Cholesterol, total;
TGCT	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg16414030	chr3:133502952	NA	-0.61	-9.47	-0.65	2.44e-16	Iron status biomarkers;
TGCT	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg10295955	chr4:187884368	NA	-0.95	-14.83	-0.8	2.95e-29	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9915657	0.660	rs982534	chr17:70081366	T/G	cg06234051	chr17:70120541	SOX9	-0.24	-4.89	-0.4	3.05e-6	Thyroid hormone levels;
TGCT	cis	rs7119038	0.774	rs2004781	chr11:118619253	C/T	cg19308663	chr11:118741387	NA	0.29	5.39	0.44	3.41e-7	Sjögren's syndrome;
TGCT	cis	rs7772486	0.686	rs1569540	chr6:146069112	A/G	cg23711669	chr6:146136114	FBXO30	-0.88	-9.63	-0.65	1.01e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg25427524	chr10:38739819	LOC399744	-0.41	-8.54	-0.61	4.04e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2594989	0.733	rs6777022	chr3:11577636	G/A	cg00170343	chr3:11313890	ATG7	-0.65	-4.91	-0.4	2.8e-6	Circulating chemerin levels;
TGCT	cis	rs7172971	0.655	rs72727731	chr15:42342164	T/C	cg05886115	chr15:42349113	NA	0.32	5.1	0.42	1.25e-6	3-hydroxypropylmercapturic acid levels in smokers;
TGCT	cis	rs6940638	0.513	rs4424065	chr6:27036456	C/T	cg06035815	chr6:26189597	HIST1H4D	0.46	4.71	0.39	6.42e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1018836	0.892	rs7819519	chr8:91565504	C/T	cg16814680	chr8:91681699	NA	-0.8	-8.57	-0.61	3.46e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7937682	1.000	rs4936661	chr11:111587495	G/A	cg09085632	chr11:111637200	PPP2R1B	1.12	11.52	0.72	2.58e-21	Primary sclerosing cholangitis;
TGCT	cis	rs9467773	0.626	rs6936006	chr6:26350565	A/G	cg15659132	chr6:26577336	NA	-0.55	-5.68	-0.45	9.13e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs6542838	0.704	rs12474283	chr2:99527310	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.56	-5.41	-0.44	3.05e-7	Fear of minor pain;
TGCT	cis	rs524281	1.000	rs489337	chr11:65854561	A/G	cg00563793	chr11:65837595	PACS1	-0.53	-4.47	-0.37	1.71e-5	Electroencephalogram traits;
TGCT	cis	rs11249608	0.548	rs17078991	chr5:178459426	A/C	cg21905437	chr5:178450457	ZNF879	0.45	4.65	0.39	8.3e-6	Pubertal anthropometrics;
TGCT	cis	rs2730245	1.000	rs2527199	chr7:158737113	G/A	cg11984989	chr7:158649758	WDR60	-0.95	-8.47	-0.61	5.89e-14	Height;
TGCT	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg14159672	chr1:205819179	PM20D1	0.63	7.94	0.58	1.04e-12	Menarche (age at onset);
TGCT	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg03806693	chr22:41940476	POLR3H	-1.14	-13.51	-0.77	4e-26	Vitiligo;
TGCT	trans	rs17685	0.753	rs7804598	chr7:75702578	C/T	cg19862616	chr7:65841803	NCRNA00174	0.52	9.01	0.63	3.02e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	trans	rs3780486	0.846	rs2209948	chr9:33138247	G/A	cg20290983	chr6:43655470	MRPS18A	1.2	14.83	0.8	3.07e-29	IgG glycosylation;
TGCT	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg25036284	chr2:26402008	FAM59B	-0.58	-5.0	-0.41	1.92e-6	Gut microbiome composition (summer);
TGCT	cis	rs7208859	0.673	rs12949860	chr17:29223032	A/G	cg18442181	chr17:29233375	C17orf42	-0.76	-4.55	-0.38	1.27e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs6876348	0.564	rs2577427	chr5:128311818	C/T	cg25555059	chr5:128301488	SLC27A6	-0.29	-4.79	-0.4	4.64e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg07507251	chr3:52567010	NT5DC2	0.46	6.68	0.51	7.37e-10	Bipolar disorder;
TGCT	cis	rs17221829	0.965	rs10830363	chr11:89458468	A/G	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.68	-0.39	7.38e-6	Anxiety in major depressive disorder;
TGCT	cis	rs2299587	0.554	rs9325823	chr8:17735871	A/G	cg01800426	chr8:17659068	MTUS1	0.54	4.84	0.4	3.83e-6	Economic and political preferences;
TGCT	cis	rs7429990	0.896	rs34448818	chr3:47841312	G/A	cg11946769	chr3:48343235	NME6	0.59	4.45	0.37	1.87e-5	Educational attainment (years of education);
TGCT	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg00814883	chr7:100076585	TSC22D4	-0.85	-8.49	-0.61	5.27e-14	Platelet count;
TGCT	cis	rs7246657	1.000	rs7246657	chr19:37747108	C/T	cg18154014	chr19:37997991	ZNF793	-0.68	-4.69	-0.39	6.97e-6	Coronary artery calcification;
TGCT	cis	rs473651	0.837	rs563458	chr2:239345613	T/A	cg18131467	chr2:239335373	ASB1	1.02	15.1	0.8	7.25e-30	Multiple system atrophy;
TGCT	cis	rs3096299	0.748	rs3102339	chr16:89442711	C/T	cg02187348	chr16:89574699	SPG7	0.52	4.83	0.4	3.86e-6	Multiple myeloma (IgH translocation);
TGCT	cis	rs9858542	0.953	rs9821311	chr3:49543656	C/T	cg03060546	chr3:49711283	APEH	-0.61	-5.37	-0.43	3.78e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs9914544	1.000	rs1737944	chr17:18840433	G/A	cg26306683	chr17:18585705	ZNF286B	0.58	5.24	0.43	6.55e-7	Educational attainment (years of education);
TGCT	cis	rs981844	0.712	rs921882	chr4:154752878	A/C	cg14289246	chr4:154710475	SFRP2	-0.99	-9.12	-0.63	1.65e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs250677	0.917	rs36066	chr5:148419771	A/G	cg23229984	chr5:148520753	ABLIM3	0.21	4.93	0.41	2.54e-6	Breast cancer;
TGCT	cis	rs35306767	0.953	rs12354639	chr10:963681	G/A	cg20503657	chr10:835505	NA	0.65	9.54	0.65	1.66e-16	Eosinophil percentage of granulocytes;
TGCT	cis	rs4372836	0.964	rs4408686	chr2:28940526	T/C	cg09522027	chr2:28974177	PPP1CB	0.59	5.01	0.41	1.86e-6	Body mass index;
TGCT	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg25767906	chr1:53392781	SCP2	0.44	4.79	0.4	4.68e-6	Monocyte count;
TGCT	cis	rs9926296	0.632	rs2011925	chr16:89814064	T/G	cg03388025	chr16:89894329	SPIRE2	0.33	4.79	0.4	4.66e-6	Vitiligo;
TGCT	cis	rs17001654	0.588	rs72655511	chr4:77021915	G/A	cg22606062	chr4:77996244	CCNI	-0.91	-4.56	-0.38	1.2e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7666738	0.830	rs13124689	chr4:98961182	A/T	cg05340658	chr4:99064831	C4orf37	0.53	5.93	0.47	2.85e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11671005	0.735	rs12981875	chr19:58935130	A/C	cg13877915	chr19:58951672	ZNF132	0.65	5.14	0.42	1.04e-6	Mean platelet volume;
TGCT	cis	rs12477438	0.798	rs13412764	chr2:99583733	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-6.25	-0.49	5.98e-9	Chronic sinus infection;
TGCT	cis	rs9425766	0.678	rs1951625	chr1:173836602	G/A	cg07177756	chr1:173836307	SNORD75;SNORD78;ZBTB37;SNORD76;GAS5;SNORD77;SNORD44	0.53	4.67	0.39	7.65e-6	Life satisfaction;
TGCT	cis	rs12497850	0.805	rs6446198	chr3:49007638	T/A	cg06212747	chr3:49208901	KLHDC8B	0.61	5.5	0.44	2.06e-7	Parkinson's disease;
TGCT	cis	rs2404602	0.622	rs11632670	chr15:76974055	A/G	cg23625390	chr15:77176239	SCAPER	-0.39	-4.93	-0.41	2.53e-6	Blood metabolite levels;
TGCT	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg25767906	chr1:53392781	SCP2	0.5	5.85	0.46	4.15e-8	Monocyte count;
TGCT	cis	rs6840360	0.615	rs12641441	chr4:152607623	A/G	cg22705602	chr4:152727874	NA	-0.32	-5.41	-0.44	3.12e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs28595532	0.920	rs116834347	chr4:119774155	C/A	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg06634786	chr22:41940651	POLR3H	0.89	8.4	0.6	8.56e-14	Vitiligo;
TGCT	trans	rs1974653	0.672	rs9606258	chr22:20119712	A/G	cg08822737	chr17:71088851	SLC39A11	-0.95	-7.53	-0.56	8.93e-12	Schizophrenia;
TGCT	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg18735214	chr6:43276756	CRIP3	-0.56	-4.88	-0.4	3.24e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs9436747	0.770	rs6697315	chr1:65993556	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.53	5.21	0.42	7.71e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs17376456	0.877	rs10052428	chr5:93476530	T/C	cg21475434	chr5:93447410	FAM172A	0.61	4.73	0.39	5.98e-6	Diabetic retinopathy;
TGCT	cis	rs6693567	0.565	rs2264417	chr1:150368501	C/T	cg09579323	chr1:150459698	TARS2	0.52	4.64	0.38	8.63e-6	Migraine;
TGCT	cis	rs4372836	0.729	rs10174533	chr2:28968928	G/A	cg09522027	chr2:28974177	PPP1CB	-0.63	-6.25	-0.49	6.12e-9	Body mass index;
TGCT	cis	rs9900497	0.569	rs2072327	chr17:19651482	G/T	cg22552966	chr17:19620595	SLC47A2	-0.23	-5.65	-0.45	1.02e-7	Response to paliperidone in schizophrenia (CGI-S score);
TGCT	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg13607699	chr17:42295918	UBTF	0.84	7.76	0.57	2.72e-12	Total body bone mineral density;
TGCT	cis	rs3096299	0.802	rs3102336	chr16:89442006	C/T	cg06640241	chr16:89574553	SPG7	0.63	5.72	0.46	7.38e-8	Multiple myeloma (IgH translocation);
TGCT	cis	rs7618915	1.000	rs59565798	chr3:52307169	G/A	cg10802521	chr3:52805072	NEK4	-0.56	-5.89	-0.47	3.42e-8	Bipolar disorder;
TGCT	cis	rs7954584	0.583	rs6486782	chr12:122359172	T/C	cg21016266	chr12:122356598	WDR66	0.43	5.65	0.45	1.03e-7	Mean corpuscular volume;
TGCT	trans	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg17830980	chr10:43048298	ZNF37B	-0.81	-10.13	-0.67	6.19e-18	Extrinsic epigenetic age acceleration;
TGCT	cis	rs4563143	0.514	rs55727361	chr19:29300415	A/T	cg04546413	chr19:29218101	NA	0.73	5.38	0.43	3.65e-7	Methadone dose in opioid dependence;
TGCT	cis	rs7666738	0.800	rs2865987	chr4:99067852	A/C	cg05340658	chr4:99064831	C4orf37	0.54	6.02	0.48	1.85e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.73	-0.39	5.93e-6	Prudent dietary pattern;
TGCT	cis	rs6988636	0.792	rs62521803	chr8:124152970	A/C	cg23067535	chr8:124195133	FAM83A	-0.38	-4.64	-0.38	8.89e-6	Urinary uromodulin levels;
TGCT	cis	rs7772486	0.875	rs2748501	chr6:146312258	G/A	cg13319975	chr6:146136371	FBXO30	-0.55	-4.82	-0.4	4.08e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7208859	0.673	rs11656845	chr17:29206164	G/T	cg14008862	chr17:28927542	LRRC37B2	0.72	4.66	0.39	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs11585357	0.947	rs6684387	chr1:17611519	T/C	cg08277548	chr1:17600880	PADI3	0.97	9.95	0.67	1.7e-17	Hair shape;
TGCT	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg10802521	chr3:52805072	NEK4	-0.71	-8.79	-0.62	1.04e-14	Bipolar disorder;
TGCT	cis	rs10490913	0.806	rs1857269	chr10:120172638	G/T	cg23160142	chr10:120154512	NA	0.29	4.46	0.37	1.78e-5	Cancer;
TGCT	cis	rs929354	0.742	rs62491945	chr7:156955580	G/A	cg05182265	chr7:156933206	UBE3C	-0.39	-8.79	-0.62	1.03e-14	Body mass index;
TGCT	trans	rs2801405	0.584	rs1596653	chr10:100644548	G/A	cg04906546	chr1:208317836	PLXNA2	-0.29	-6.86	-0.52	2.94e-10	Obesity-related traits;
TGCT	cis	rs6977660	0.714	rs10252597	chr7:19791171	G/T	cg05791153	chr7:19748676	TWISTNB	-0.88	-5.05	-0.41	1.52e-6	Thyroid stimulating hormone;
TGCT	cis	rs10037670	0.557	rs2351481	chr5:153823460	G/A	cg21964928	chr5:153872958	NA	0.26	4.69	0.39	6.96e-6	Behavioural disinhibition (generation interaction);
TGCT	cis	rs72843506	0.591	rs74319100	chr17:20221392	A/G	cg18979559	chr17:20280153	CCDC144C	-0.62	-4.69	-0.39	7.2e-6	Schizophrenia;
TGCT	cis	rs2637266	1.000	rs1907319	chr10:78337049	A/G	cg18941641	chr10:78392320	NA	-0.41	-5.11	-0.42	1.19e-6	Pulmonary function;
TGCT	cis	rs9303401	0.659	rs62083368	chr17:56878062	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs7412746	0.658	rs12097963	chr1:150870450	T/C	cg04414720	chr1:150670196	GOLPH3L	0.37	4.46	0.37	1.81e-5	Melanoma;
TGCT	cis	rs986417	1.000	rs958504	chr14:60949740	G/A	cg27398547	chr14:60952738	C14orf39	1.39	10.61	0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs6088580	0.634	rs1890002	chr20:32919219	A/G	cg08999081	chr20:33150536	PIGU	-0.27	-5.19	-0.42	8.22e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs7666738	0.830	rs6532719	chr4:99043691	A/G	cg05340658	chr4:99064831	C4orf37	0.52	5.94	0.47	2.68e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg11861562	chr11:117069780	TAGLN	0.27	4.48	0.37	1.69e-5	Blood protein levels;
TGCT	trans	rs2229238	0.911	rs59239860	chr1:154492107	G/T	cg22838003	chr14:96730482	BDKRB1	0.4	6.66	0.51	8.03e-10	Coronary heart disease;
TGCT	cis	rs9916302	0.904	rs11655531	chr17:37697959	T/C	cg15445000	chr17:37608096	MED1	0.31	4.5	0.37	1.53e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs10823500	0.640	rs7077538	chr10:71993094	T/G	cg04118878	chr10:71993077	PPA1	0.61	5.61	0.45	1.23e-7	Blood protein levels;
TGCT	cis	rs56104184	1.000	rs56104184	chr19:49370310	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.64	-8.96	-0.63	4.09e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	trans	rs561341	0.505	rs28708703	chr17:30386845	C/G	cg20587970	chr11:113659929	NA	-0.98	-12.58	-0.75	6.87e-24	Hip circumference adjusted for BMI;
TGCT	cis	rs6495367	1.000	rs1961579	chr15:79380516	G/A	cg17916960	chr15:79447300	NA	0.37	5.24	0.43	6.57e-7	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg27286337	chr10:134555280	INPP5A	0.39	4.73	0.39	6.02e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs7582180	0.764	rs13001423	chr2:100925340	A/G	cg14675211	chr2:100938903	LONRF2	0.49	4.8	0.4	4.49e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg08564027	chr20:61660810	NA	0.38	7.08	0.54	9.36e-11	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs3820928	0.874	rs13423046	chr2:227901805	G/T	cg11843606	chr2:227700838	RHBDD1	-0.54	-4.96	-0.41	2.29e-6	Pulmonary function;
TGCT	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg23758822	chr17:41437982	NA	-0.69	-6.78	-0.52	4.42e-10	Menopause (age at onset);
TGCT	cis	rs7208859	0.623	rs9915546	chr17:29132144	G/T	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg15782153	chr7:917662	C7orf20	0.53	6.89	0.53	2.52e-10	Perceived unattractiveness to mosquitoes;
TGCT	cis	rs6076065	0.748	rs2236023	chr20:23373043	A/C	cg11657817	chr20:23433608	CST11	0.31	5.42	0.44	3.02e-7	Facial morphology (factor 15, philtrum width);
TGCT	cis	rs2153535	0.580	rs4140586	chr6:8503192	A/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs1867631	0.959	rs11208914	chr1:67049728	C/T	cg13052034	chr1:66999238	SGIP1	0.59	5.02	0.41	1.75e-6	Menopause (age at onset);
TGCT	cis	rs6426558	0.515	rs7521110	chr1:227384459	T/A	cg10327440	chr1:227177885	CDC42BPA	-0.61	-7.04	-0.53	1.14e-10	Neutrophil percentage of white cells;
TGCT	cis	rs3091242	0.933	rs4649084	chr1:25752617	A/G	cg00786635	chr1:25594202	NA	0.56	5.94	0.47	2.64e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg11890956	chr21:40555474	PSMG1	-0.75	-7.38	-0.55	1.98e-11	Cognitive function;
TGCT	cis	rs593982	0.920	rs72939198	chr11:65438079	G/A	cg08755490	chr11:65554678	OVOL1	-1.26	-7.15	-0.54	6.6e-11	Atopic dermatitis;
TGCT	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg06618935	chr21:46677482	NA	-0.37	-5.58	-0.45	1.41e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6121246	0.697	rs6060446	chr20:30231637	T/C	cg13852791	chr20:30311386	BCL2L1	0.74	4.84	0.4	3.77e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs62244186	0.659	rs9311358	chr3:44538748	C/G	cg15687855	chr3:44754131	ZNF502	-0.44	-5.15	-0.42	1e-6	Depressive symptoms;
TGCT	cis	rs2806561	0.765	rs2806565	chr1:23507068	A/G	cg12483005	chr1:23474871	LUZP1	0.37	4.76	0.39	5.23e-6	Height;
TGCT	cis	rs587847	0.737	rs28848193	chr15:37604276	C/G	cg00216138	chr15:37171175	LOC145845	0.3	4.52	0.38	1.43e-5	Intraocular pressure;
TGCT	cis	rs904251	0.523	rs2797796	chr6:37480886	T/C	cg01843034	chr6:37503916	NA	-0.56	-7.56	-0.56	7.84e-12	Cognitive performance;
TGCT	cis	rs17376456	0.877	rs12109629	chr5:93359702	A/G	cg21475434	chr5:93447410	FAM172A	0.6	4.73	0.39	6.08e-6	Diabetic retinopathy;
TGCT	cis	rs11030122	0.702	rs10835340	chr11:3960420	A/G	cg18678763	chr11:4115507	RRM1	0.46	5.77	0.46	5.94e-8	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg18252515	chr7:66147081	NA	-1.31	-8.18	-0.59	2.87e-13	Diabetic kidney disease;
TGCT	cis	rs10173297	0.686	rs6738533	chr2:3711919	G/T	cg21484315	chr2:2712669	NA	-0.38	-4.67	-0.39	7.61e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
TGCT	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg10295955	chr4:187884368	NA	-0.97	-15.16	-0.81	5.09e-30	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9303401	0.659	rs12150264	chr17:56939927	G/A	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg05721485	chr17:44071124	MAPT	0.24	4.44	0.37	1.99e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs877282	0.853	rs12763400	chr10:763617	C/T	cg17470449	chr10:769945	NA	0.37	5.59	0.45	1.37e-7	Uric acid levels;
TGCT	cis	rs7666738	0.830	rs3907020	chr4:99038583	T/C	cg18180107	chr4:99064573	C4orf37	0.56	5.08	0.41	1.37e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12682352	0.602	rs11783966	chr8:8665147	A/G	cg15556689	chr8:8085844	FLJ10661	-0.61	-5.28	-0.43	5.63e-7	Neuroticism;
TGCT	cis	rs651907	0.557	rs3094295	chr3:101401995	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.35	-7.28	-0.55	3.4e-11	Colorectal cancer;
TGCT	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	5.07	0.41	1.42e-6	Electroencephalogram traits;
TGCT	cis	rs397020	0.904	rs203547	chr20:1195245	T/A	cg23117778	chr20:1206693	RAD21L1	0.84	10.65	0.69	3.32e-19	Multiple sclerosis;
TGCT	cis	rs10788264	0.538	rs1998344	chr10:124030137	A/G	cg09507567	chr10:124027408	NA	0.34	4.89	0.4	3.05e-6	Total body bone mineral density;
TGCT	cis	rs36051895	0.594	rs7029244	chr9:5180961	A/C	cg02405213	chr9:5042618	JAK2	-0.76	-10.76	-0.69	1.8e-19	Pediatric autoimmune diseases;
TGCT	cis	rs6095298	0.595	rs752420	chr20:47435056	C/T	cg12307787	chr20:48099359	KCNB1	0.43	4.53	0.38	1.37e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs10501293	0.746	rs4611191	chr11:43015676	C/G	cg03447554	chr11:43094025	NA	0.44	6.29	0.49	4.98e-9	Cognitive performance;
TGCT	cis	rs13326165	0.715	rs7643570	chr3:52373792	G/T	cg07884673	chr3:53033167	SFMBT1	0.39	4.8	0.4	4.54e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs9910055	0.530	rs2269905	chr17:42294462	A/G	cg19774624	chr17:42201019	HDAC5	-0.7	-7.47	-0.56	1.24e-11	Total body bone mineral density;
TGCT	cis	rs8056742	0.642	rs11645050	chr16:85042212	A/C	cg00229868	chr16:85520891	NA	0.41	4.89	0.4	3.09e-6	Amyotrophic lateral sclerosis;
TGCT	cis	rs12220238	1.000	rs10824110	chr10:75968098	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.91	7.77	0.57	2.63e-12	Soluble interleukin-2 receptor subunit alpha;
TGCT	trans	rs3780486	0.801	rs3780495	chr9:33125942	A/C	cg04842962	chr6:43655489	MRPS18A	1.23	15.58	0.81	5.51e-31	IgG glycosylation;
TGCT	cis	rs3820068	0.581	rs12385690	chr1:15932932	A/T	cg05660106	chr1:15850417	CASP9	0.76	7.47	0.56	1.28e-11	Systolic blood pressure;
TGCT	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg20887711	chr4:1340912	KIAA1530	0.91	8.31	0.6	1.41e-13	Longevity;
TGCT	cis	rs250677	0.522	rs10050928	chr5:148353463	C/A	cg18129178	chr5:148520854	ABLIM3	0.37	4.83	0.4	4.02e-6	Breast cancer;
TGCT	cis	rs9581857	0.579	rs79904593	chr13:27996893	G/A	cg22138327	chr13:27999177	GTF3A	0.85	5.88	0.47	3.55e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs6570726	0.791	rs11759979	chr6:145918881	C/T	cg13319975	chr6:146136371	FBXO30	-0.54	-4.77	-0.39	5.1e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg06238570	chr21:40685208	BRWD1	-0.8	-9.1	-0.63	1.9e-15	Cognitive function;
TGCT	cis	rs6430585	0.527	rs1438303	chr2:136429857	C/T	cg07169764	chr2:136633963	MCM6	0.97	8.68	0.61	1.89e-14	Corneal structure;
TGCT	cis	rs7513165	0.935	rs4951316	chr1:204161490	C/T	cg04791601	chr1:204159016	NA	-0.26	-5.21	-0.42	7.68e-7	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
TGCT	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg11235426	chr6:292522	DUSP22	-0.65	-6.78	-0.52	4.4e-10	Menopause (age at onset);
TGCT	cis	rs902774	0.530	rs11834907	chr12:53350985	C/T	cg16329197	chr12:53359506	NA	-0.55	-4.62	-0.38	9.52e-6	Prostate cancer;
TGCT	cis	rs6912958	0.781	rs7742965	chr6:88278196	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-5.06	-0.41	1.45e-6	Monocyte percentage of white cells;
TGCT	cis	rs6051080	1	rs6051080	chr20:25975674	A/G	cg14121845	chr20:25566513	NINL	0.5	5.78	0.46	5.81e-8	Colorectal or endometrial cancer;
TGCT	cis	rs7614311	0.681	rs10510903	chr3:63970192	C/G	cg22134162	chr3:63841271	THOC7	-0.42	-5.73	-0.46	7.35e-8	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg09263875	chr16:632152	PIGQ	0.31	6.89	0.53	2.52e-10	Height;
TGCT	trans	rs1496653	0.602	rs13091625	chr3:23606191	G/C	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs2721195	1.000	rs1871541	chr8:145681713	G/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.8	-8.29	-0.6	1.61e-13	Age at first birth;
TGCT	cis	rs7666738	0.830	rs28729647	chr4:99059552	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.79	0.46	5.32e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4689592	0.523	rs4256224	chr4:7074583	T/C	cg06697600	chr4:7070879	GRPEL1	-0.43	-4.46	-0.37	1.83e-5	Monocyte percentage of white cells;
TGCT	cis	rs72901758	0.768	rs11650317	chr17:76251306	A/T	cg25512537	chr17:76250053	NA	0.25	4.51	0.38	1.49e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs1008375	0.932	rs2302389	chr4:17661889	T/C	cg18681998	chr4:17616180	MED28	0.92	10.26	0.68	2.88e-18	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs617219	0.726	rs7717669	chr5:78452983	A/C	cg23514016	chr5:78407564	BHMT	0.34	5.26	0.43	6.16e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs7809950	1.000	rs2237677	chr7:107202502	A/C	cg23024343	chr7:107201750	COG5	-0.3	-4.72	-0.39	6.34e-6	Coronary artery disease;
TGCT	trans	rs3780486	0.846	rs10738905	chr9:33123627	A/G	cg04842962	chr6:43655489	MRPS18A	1.23	15.36	0.81	1.81e-30	IgG glycosylation;
TGCT	trans	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg27523141	chr10:43048294	ZNF37B	0.71	8.32	0.6	1.35e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2688608	0.587	rs2894040	chr10:75478159	A/C	cg04320760	chr10:75533139	FUT11	-0.4	-6.25	-0.49	6.11e-9	Inflammatory bowel disease;
TGCT	cis	rs7224685	0.569	rs8082227	chr17:3991563	C/T	cg09580393	chr17:4869866	SPAG7	-0.39	-4.49	-0.37	1.62e-5	Type 2 diabetes;
TGCT	cis	rs9330316	0.654	rs9330320	chr2:110289984	C/G	cg25199208	chr2:109402912	CCDC138	0.42	4.63	0.38	9.26e-6	Schizophrenia;
TGCT	cis	rs4654899	0.931	rs58762579	chr1:21257831	G/A	cg01072550	chr1:21505969	NA	-0.49	-7.99	-0.58	7.94e-13	Superior frontal gyrus grey matter volume;
TGCT	trans	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg21659725	chr3:3221576	CRBN	0.75	9.11	0.63	1.79e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs13141752	chr4:98893128	G/A	cg18180107	chr4:99064573	C4orf37	0.53	4.84	0.4	3.83e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg12756686	chr19:29218302	NA	0.65	6.06	0.48	1.52e-8	Methadone dose in opioid dependence;
TGCT	cis	rs9467773	0.967	rs9461267	chr6:26525455	T/G	cg15659132	chr6:26577336	NA	0.86	12.21	0.74	5.3e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.822	rs28512427	chr4:98919029	G/A	cg05340658	chr4:99064831	C4orf37	0.53	6.12	0.48	1.13e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs60154123	0.505	rs77990373	chr1:210041111	T/C	cg23283495	chr1:209979779	IRF6	0.67	4.99	0.41	1.96e-6	Coronary artery disease;
TGCT	cis	rs2072499	0.932	rs2736613	chr1:156196016	T/C	cg24450063	chr1:156163899	SLC25A44	1.2	14.13	0.79	1.31e-27	Testicular germ cell tumor;
TGCT	cis	rs208520	0.690	rs851467	chr6:66802721	A/G	cg07460842	chr6:66804631	NA	-0.94	-9.91	-0.66	2.15e-17	Exhaled nitric oxide output;
TGCT	cis	rs78545713	1.000	rs11753610	chr6:26251601	C/T	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	0.66	4.48	0.37	1.64e-5	Iron status biomarkers (total iron binding capacity);
TGCT	cis	rs6912958	0.935	rs6454629	chr6:88165515	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.63	-6.22	-0.49	7.06e-9	Monocyte percentage of white cells;
TGCT	cis	rs6426558	0.537	rs6685823	chr1:227270835	A/G	cg10327440	chr1:227177885	CDC42BPA	0.59	7.16	0.54	6.34e-11	Neutrophil percentage of white cells;
TGCT	cis	rs9549367	0.789	rs9604040	chr13:113910611	A/G	cg18105134	chr13:113819100	PROZ	0.32	5.3	0.43	5.06e-7	Platelet distribution width;
TGCT	trans	rs62103177	0.561	rs891488	chr18:77637424	T/C	cg05926928	chr17:57297772	GDPD1	-0.98	-9.6	-0.65	1.19e-16	Opioid sensitivity;
TGCT	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg22105103	chr4:187893119	NA	0.34	4.86	0.4	3.41e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg13395646	chr4:1353034	KIAA1530	-0.38	-4.72	-0.39	6.28e-6	Obesity-related traits;
TGCT	cis	rs950169	1.000	rs12915234	chr15:84758301	G/A	cg12863693	chr15:85201151	NMB	0.38	4.66	0.39	8.17e-6	Schizophrenia;
TGCT	cis	rs7666738	0.761	rs28758886	chr4:99059704	C/T	cg17366294	chr4:99064904	C4orf37	0.73	7.45	0.56	1.4e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10946940	0.965	rs10946935	chr6:27501345	T/C	cg10876282	chr6:28092338	ZSCAN16	-0.46	-4.6	-0.38	1.04e-5	Systemic lupus erythematosus;
TGCT	cis	rs9297145	0.724	rs6958790	chr7:98774738	C/T	cg05967295	chr7:98741636	SMURF1	-0.96	-12.36	-0.74	2.3e-23	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs79387448	0.745	rs7593444	chr2:103158561	G/A	cg09003973	chr2:102972529	NA	0.92	5.89	0.47	3.39e-8	Gut microbiota (bacterial taxa);
TGCT	cis	rs62064224	0.614	rs9900089	chr17:30772577	C/T	cg18200150	chr17:30822561	MYO1D	0.44	5.28	0.43	5.61e-7	Schizophrenia;
TGCT	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg13393036	chr8:95962371	TP53INP1	-0.63	-8.52	-0.61	4.43e-14	Type 2 diabetes;
TGCT	cis	rs6088580	0.609	rs945674	chr20:32964247	G/C	cg24642439	chr20:33292090	TP53INP2	-0.49	-4.49	-0.37	1.59e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg23758822	chr17:41437982	NA	0.69	6.45	0.5	2.26e-9	Menopause (age at onset);
TGCT	cis	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg20637647	chr7:64974828	NA	-0.9	-5.06	-0.41	1.45e-6	Diabetic kidney disease;
TGCT	cis	rs2115536	1.000	rs2903105	chr15:80189523	C/G	cg00225070	chr15:80189496	MTHFS	0.61	5.53	0.44	1.82e-7	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs10465746	0.935	rs2389647	chr1:84403041	C/T	cg10977910	chr1:84465055	TTLL7	0.63	6.25	0.49	5.95e-9	Obesity-related traits;
TGCT	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg26338869	chr17:61819248	STRADA	-0.53	-4.87	-0.4	3.29e-6	Prudent dietary pattern;
TGCT	cis	rs12510870	0.535	rs9997572	chr4:74438988	T/C	cg05868023	chr4:75230803	EREG	0.55	4.97	0.41	2.18e-6	Iris color (b* coordinate);
TGCT	cis	rs1401999	1.000	rs939337	chr3:183701147	G/C	cg01324343	chr3:183735012	ABCC5	0.82	10.97	0.7	5.41e-20	Anterior chamber depth;
TGCT	cis	rs4252435	0.614	rs6968468	chr7:142599997	T/C	cg09833174	chr7:143059591	FAM131B	-0.96	-4.52	-0.38	1.41e-5	Cancer;
TGCT	cis	rs7943191	0.805	rs12226821	chr11:62369018	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.6	7.18	0.54	5.56e-11	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg13342137	chr4:2252803	MXD4	0.17	4.44	0.37	1.94e-5	Obesity-related traits;
TGCT	cis	rs1801251	1.000	rs991873	chr2:233711046	A/G	cg25237894	chr2:233734115	C2orf82	-0.33	-5.94	-0.47	2.71e-8	Coronary artery disease;
TGCT	cis	rs8111998	0.826	rs59427371	chr19:22766462	C/T	cg19914732	chr19:22715077	NA	-0.56	-4.51	-0.38	1.46e-5	Corneal structure;
TGCT	cis	rs1857353	1.000	rs3899859	chr1:75884904	T/A	cg11838876	chr1:75668600	SLC44A5	-0.51	-4.81	-0.4	4.23e-6	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs7666738	0.716	rs28792413	chr4:99083707	G/A	cg18180107	chr4:99064573	C4orf37	0.55	4.91	0.4	2.8e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12497850	0.897	rs6446252	chr3:48911125	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.42	-5.52	-0.44	1.93e-7	Parkinson's disease;
TGCT	cis	rs709400	0.663	rs9671911	chr14:103967343	T/C	cg12935359	chr14:103987150	CKB	-0.36	-5.64	-0.45	1.11e-7	Body mass index;
TGCT	cis	rs2795502	1.000	rs2795502	chr10:43340662	G/A	cg20628663	chr10:43360327	NA	-0.44	-6.23	-0.49	6.74e-9	Blood protein levels;
TGCT	cis	rs617219	0.671	rs1062326	chr5:78617534	A/C	cg09550809	chr5:78407562	BHMT	-0.39	-5.29	-0.43	5.32e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs1008375	1.000	rs10019856	chr4:17615742	T/A	cg18681998	chr4:17616180	MED28	1.08	12.03	0.73	1.45e-22	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs12136530	0.774	rs4912094	chr1:19762466	A/G	cg18923740	chr1:19971790	NBL1	-0.35	-4.57	-0.38	1.16e-5	Lead levels in blood;
TGCT	cis	rs7267979	1.000	rs2500404	chr20:25359758	A/C	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6582630	0.502	rs10880092	chr12:38262965	A/T	cg13010199	chr12:38710504	ALG10B	0.64	4.97	0.41	2.15e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs60871478	0.636	rs6976929	chr7:901382	C/T	cg15782153	chr7:917662	C7orf20	0.54	4.91	0.4	2.8e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs3806843	0.966	rs3756341	chr5:140171194	C/T	cg19875535	chr5:140030758	IK	0.37	6.34	0.49	3.89e-9	Depressive symptoms (multi-trait analysis);
TGCT	trans	rs531864	0.690	rs558922	chr2:169681749	C/T	cg16341836	chr10:90641389	STAMBPL1	0.27	6.62	0.51	9.59e-10	Mitochondrial DNA levels;
TGCT	cis	rs62244186	0.606	rs6798590	chr3:44556861	T/A	cg10263370	chr3:44754102	ZNF502	-0.42	-4.81	-0.4	4.3e-6	Depressive symptoms;
TGCT	cis	rs9914988	0.537	rs28448745	chr17:27188296	A/C	cg20469991	chr17:27169893	C17orf63	0.67	4.48	0.37	1.69e-5	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs72717009	0.825	rs11810143	chr1:161480649	A/G	cg23840854	chr1:161414152	NA	-1.02	-6.12	-0.48	1.12e-8	Rheumatoid arthritis;
TGCT	cis	rs11096990	0.634	rs6815855	chr4:39296546	C/A	cg20847110	chr4:39482781	LOC401127	-0.16	-4.51	-0.38	1.48e-5	Cognitive function;
TGCT	cis	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg02380750	chr20:61661411	NA	0.33	5.96	0.47	2.4e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7255045	0.788	rs8111370	chr19:12948864	G/T	cg23899408	chr19:12877188	HOOK2	-0.58	-4.66	-0.39	7.88e-6	Mean corpuscular volume;
TGCT	trans	rs77457752	0.690	rs10123356	chr9:13912564	T/C	cg23609682	chr1:3070786	PRDM16	0.48	6.96	0.53	1.78e-10	Breast cancer;
TGCT	cis	rs617219	0.596	rs2131977	chr5:78613916	G/C	cg09550809	chr5:78407562	BHMT	-0.39	-5.43	-0.44	2.81e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	trans	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg17830980	chr10:43048298	ZNF37B	-0.81	-10.13	-0.67	6.19e-18	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2439831	0.850	rs10438303	chr15:44016417	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	5.91	0.47	3.05e-8	Lung cancer in ever smokers;
TGCT	cis	rs7666738	0.830	rs7657179	chr4:98948569	G/A	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2456568	0.709	rs1354765	chr11:93637776	G/T	cg26875233	chr11:93583750	C11orf90	0.47	6.01	0.47	1.95e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs1971762	0.712	rs7302232	chr12:53965423	A/T	cg16917193	chr12:54089295	NA	0.91	9.39	0.64	3.77e-16	Height;
TGCT	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	6.87	0.52	2.82e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg02038168	chr22:39784481	NA	-0.74	-6.02	-0.48	1.8e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs1784581	0.802	rs9365359	chr6:162423945	C/A	cg17173639	chr6:162384350	PARK2	0.42	7.31	0.55	2.86e-11	Itch intensity from mosquito bite;
TGCT	cis	rs12142240	0.738	rs41293277	chr1:46806550	C/T	cg00530320	chr1:46809349	NSUN4	0.29	5.95	0.47	2.58e-8	Menopause (age at onset);
TGCT	cis	rs7659604	1.000	rs6816071	chr4:122665185	G/A	cg19748678	chr4:122722346	EXOSC9	0.55	5.32	0.43	4.61e-7	Type 2 diabetes;
TGCT	cis	rs295140	0.535	rs1975583	chr2:201225902	A/C	cg04283868	chr2:201171347	SPATS2L	0.56	5.4	0.44	3.24e-7	QT interval;
TGCT	cis	rs7698623	0.850	rs4693192	chr4:88797913	T/C	cg27387453	chr4:88533842	DSPP	-0.61	-4.6	-0.38	1.03e-5	Cardiovascular disease risk factors;
TGCT	cis	rs394563	0.591	rs6570963	chr6:149691355	T/G	cg16235748	chr6:149772707	ZC3H12D	0.44	5.03	0.41	1.66e-6	Dupuytren's disease;
TGCT	cis	rs7264396	0.528	rs6058370	chr20:34518592	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.28	-4.69	-0.39	6.98e-6	Total cholesterol levels;
TGCT	cis	rs4319547	0.774	rs7307233	chr12:123124301	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.65	-5.52	-0.44	1.89e-7	Body mass index;
TGCT	cis	rs896854	0.517	rs10112447	chr8:95955701	C/T	cg16049864	chr8:95962084	TP53INP1	-0.55	-6.07	-0.48	1.47e-8	Type 2 diabetes;
TGCT	cis	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg18252515	chr7:66147081	NA	-1.22	-7.98	-0.58	8.46e-13	Diabetic kidney disease;
TGCT	cis	rs3125734	0.633	rs4979782	chr10:63998527	C/T	cg05499367	chr10:63213510	TMEM26	-0.33	-4.45	-0.37	1.91e-5	Rheumatoid arthritis;
TGCT	cis	rs62012628	0.527	rs12437868	chr15:79088460	T/C	cg00639195	chr15:79103007	ADAMTS7	0.56	5.48	0.44	2.32e-7	Diastolic blood pressure;
TGCT	cis	rs2235642	0.826	rs8053605	chr16:1594158	G/A	cg07341220	chr16:1583899	IFT140;TMEM204	-0.3	-4.67	-0.39	7.76e-6	Coronary artery disease;
TGCT	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	6.8	0.52	4e-10	Mean platelet volume;
TGCT	cis	rs11098499	0.866	rs12499602	chr4:120284387	T/A	cg09307838	chr4:120376055	NA	0.58	5.76	0.46	6.16e-8	Corneal astigmatism;
TGCT	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg13683864	chr3:40499215	RPL14	-1.18	-13.68	-0.78	1.54e-26	Renal cell carcinoma;
TGCT	cis	rs9788682	1.000	rs12441354	chr15:78821016	G/A	cg06917634	chr15:78832804	PSMA4	-0.7	-5.01	-0.41	1.83e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs9858542	1.000	rs13085791	chr3:49721798	C/A	cg03060546	chr3:49711283	APEH	-0.67	-6.09	-0.48	1.28e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs7829975	0.623	rs10087493	chr8:8373557	A/G	cg06636001	chr8:8085503	FLJ10661	-0.8	-8.09	-0.59	4.68e-13	Mood instability;
TGCT	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg13699009	chr12:122356056	WDR66	0.29	5.7	0.46	8.39e-8	Mean corpuscular volume;
TGCT	cis	rs9677476	0.516	rs765458	chr2:231990667	G/A	cg27665808	chr2:232055229	NA	0.36	4.52	0.38	1.44e-5	Food antigen IgG levels;
TGCT	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg24531977	chr5:56204891	C5orf35	-0.77	-7.61	-0.56	5.83e-12	Initial pursuit acceleration;
TGCT	cis	rs12615966	0.872	rs11898434	chr2:105376704	G/A	cg16465502	chr2:105461796	NA	0.78	5.01	0.41	1.83e-6	Pancreatic cancer;
TGCT	cis	rs2307449	0.894	rs62020316	chr15:89787908	G/T	cg24365117	chr15:89879190	POLG	0.33	4.51	0.38	1.49e-5	Menopause (age at onset);
TGCT	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg13206674	chr6:150067644	NUP43	0.51	4.45	0.37	1.86e-5	Lung cancer;
TGCT	cis	rs3741151	0.892	rs77127734	chr11:73018413	T/A	cg17517138	chr11:73019481	ARHGEF17	0.94	4.48	0.37	1.66e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
TGCT	cis	rs7843479	0.965	rs733543	chr8:21835465	A/G	cg17168535	chr8:21777572	XPO7	0.63	5.8	0.46	5.08e-8	Mean corpuscular volume;
TGCT	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg27286337	chr10:134555280	INPP5A	0.41	4.98	0.41	2.05e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs11785693	0.862	rs11786186	chr8:4999059	G/C	cg26367366	chr8:4980734	NA	0.54	4.44	0.37	1.97e-5	Neuroticism (multi-trait analysis);Neuroticism;
TGCT	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg05985448	chr10:134359359	INPP5A	0.23	4.96	0.41	2.24e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg26338869	chr17:61819248	STRADA	-0.52	-4.8	-0.4	4.53e-6	Prudent dietary pattern;
TGCT	cis	rs832540	0.966	rs33321	chr5:56206073	G/T	cg24531977	chr5:56204891	C5orf35	-0.55	-5.68	-0.45	9.28e-8	Coronary artery disease;
TGCT	cis	rs651907	0.514	rs11706494	chr3:101509475	A/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.86	10.4	0.68	1.35e-18	Colorectal cancer;
TGCT	cis	rs72843506	0.586	rs113833946	chr17:19858906	T/C	cg18979559	chr17:20280153	CCDC144C	-0.59	-4.44	-0.37	1.99e-5	Schizophrenia;
TGCT	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg11764359	chr7:65958608	NA	-0.55	-5.08	-0.42	1.34e-6	Aortic root size;
TGCT	cis	rs1403694	0.695	rs3821815	chr3:186434262	A/G	cg12454167	chr3:186435060	KNG1	0.51	8.68	0.61	1.93e-14	Blood protein levels;
TGCT	cis	rs2228479	0.867	rs34604714	chr16:89948985	A/G	cg04013166	chr16:89971882	TCF25	0.32	4.46	0.37	1.84e-5	Skin colour saturation;
TGCT	cis	rs9788682	0.948	rs34664138	chr15:78831624	T/G	cg06917634	chr15:78832804	PSMA4	-0.7	-4.86	-0.4	3.47e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs903263	0.901	rs6576961	chr1:84604712	T/C	cg09664975	chr1:84543551	PRKACB	0.5	4.68	0.39	7.47e-6	Breast cancer (male);
TGCT	cis	rs2016266	0.787	rs4520636	chr12:53752133	G/T	cg16917193	chr12:54089295	NA	0.67	4.46	0.37	1.78e-5	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs909002	0.772	rs7525618	chr1:32073766	C/T	cg11573219	chr1:32083031	HCRTR1	-0.45	-5.87	-0.47	3.67e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7772486	0.686	rs702305	chr6:145973840	A/G	cg13319975	chr6:146136371	FBXO30	0.53	4.9	0.4	2.91e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11098499	0.874	rs6851169	chr4:120117510	T/C	cg09307838	chr4:120376055	NA	0.5	4.64	0.38	8.86e-6	Corneal astigmatism;
TGCT	cis	rs9816784	0.596	rs11185511	chr3:195835259	A/G	cg14488913	chr3:195402182	SDHAP2	-0.34	-4.44	-0.37	1.96e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs950776	0.518	rs12915428	chr15:78823368	G/A	cg06917634	chr15:78832804	PSMA4	0.95	9.52	0.65	1.81e-16	Sudden cardiac arrest;
TGCT	cis	rs6088580	0.609	rs6058029	chr20:32969643	T/C	cg06115741	chr20:33292138	TP53INP2	-0.55	-4.81	-0.4	4.28e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg00149659	chr3:10157352	C3orf10	0.94	6.0	0.47	2e-8	Alzheimer's disease;
TGCT	cis	rs595982	0.510	rs3826817	chr19:49401444	C/T	cg11637076	chr19:49575188	KCNA7	-0.43	-5.31	-0.43	4.85e-7	Red cell distribution width;
TGCT	cis	rs1865760	0.865	rs1436306	chr6:25948421	A/G	cg16482183	chr6:26056742	HIST1H1C	0.53	4.88	0.4	3.14e-6	Height;
TGCT	cis	rs2404602	0.583	rs2139190	chr15:76555539	G/C	cg22467129	chr15:76604101	ETFA	-0.62	-8.06	-0.59	5.34e-13	Blood metabolite levels;
TGCT	cis	rs6540559	0.673	rs7525951	chr1:210018306	C/T	cg22029157	chr1:209979665	IRF6	-0.68	-4.88	-0.4	3.22e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs7552404	0.924	rs1146579	chr1:76209792	C/T	cg10523679	chr1:76189770	ACADM	-0.84	-9.27	-0.64	7.19e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7769051	0.803	rs12193474	chr6:133186168	T/C	cg22852734	chr6:133119734	C6orf192	1.24	6.95	0.53	1.85e-10	Type 2 diabetes nephropathy;
TGCT	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.97	-6.06	-0.48	1.48e-8	Gut microbiome composition (summer);
TGCT	cis	rs796364	1.000	rs4410273	chr2:200818258	T/C	cg17644776	chr2:200775616	C2orf69	0.31	4.85	0.4	3.58e-6	Schizophrenia;
TGCT	cis	rs10883723	0.810	rs7092622	chr10:104249919	T/G	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg12311346	chr5:56204834	C5orf35	-0.67	-6.77	-0.52	4.59e-10	Initial pursuit acceleration;
TGCT	cis	rs9911578	0.935	rs9893351	chr17:57023326	G/A	cg12560992	chr17:57184187	TRIM37	0.73	8.7	0.62	1.69e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg06618935	chr21:46677482	NA	-0.37	-5.51	-0.44	1.98e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg12419862	chr22:24373484	LOC391322	-0.79	-8.17	-0.59	3e-13	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg00814883	chr7:100076585	TSC22D4	-0.92	-9.76	-0.66	4.73e-17	Platelet count;
TGCT	cis	rs204693	1.000	rs204693	chr20:543638	C/T	cg15180867	chr20:591076	TCF15	0.78	4.58	0.38	1.12e-5	Pursuit maintenance gain;
TGCT	cis	rs3916	0.911	rs2239758	chr12:121162637	A/G	cg21892295	chr12:121157589	UNC119B	-0.23	-4.48	-0.37	1.69e-5	Urinary metabolites (H-NMR features);
TGCT	cis	rs377070	0.934	rs309396	chr4:123614282	C/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.46	5.16	0.42	9.5e-7	Mosquito bite size;
TGCT	cis	rs950169	0.840	rs72748702	chr15:84915246	A/G	cg12863693	chr15:85201151	NMB	0.41	4.5	0.38	1.51e-5	Schizophrenia;
TGCT	cis	rs12477438	0.765	rs1054042	chr2:99614396	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.56	-4.86	-0.4	3.51e-6	Chronic sinus infection;
TGCT	cis	rs4499344	0.730	rs12460624	chr19:33098042	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	8.81	0.62	9.52e-15	Mean platelet volume;
TGCT	cis	rs10875746	0.903	rs11168427	chr12:48538979	A/G	cg20731937	chr12:48336164	NA	0.62	4.94	0.41	2.46e-6	Longevity (90 years and older);
TGCT	cis	rs6835098	0.924	rs1991727	chr4:174163169	A/G	cg08422745	chr4:174089978	GALNT7	-0.83	-8.82	-0.62	9.04e-15	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg18876405	chr7:65276391	NA	-0.33	-4.99	-0.41	1.97e-6	Aortic root size;
TGCT	cis	rs4711350	0.765	rs943476	chr6:33750086	A/G	cg13859433	chr6:33739653	LEMD2	-0.31	-4.49	-0.37	1.59e-5	Schizophrenia;
TGCT	trans	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg25482853	chr8:67687455	SGK3	1.19	10.77	0.7	1.71e-19	Obesity-related traits;
TGCT	cis	rs6484504	0.576	rs441975	chr11:31233351	C/T	cg26647111	chr11:31128758	NA	-0.34	-4.73	-0.39	5.88e-6	Red blood cell count;
TGCT	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg02725872	chr8:58115012	NA	-0.38	-5.16	-0.42	9.32e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs11190604	1.000	rs2495753	chr10:102325640	C/T	cg16342193	chr10:102329863	NA	-0.43	-5.39	-0.44	3.43e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7833790	0.963	rs72686466	chr8:82758928	G/T	cg27398817	chr8:82754497	SNX16	0.84	5.98	0.47	2.18e-8	Diastolic blood pressure;
TGCT	cis	rs28595532	0.688	rs116580819	chr4:119767362	T/A	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs7572733	0.534	rs700662	chr2:198668751	T/C	cg00792783	chr2:198669748	PLCL1	0.56	5.08	0.42	1.35e-6	Dermatomyositis;
TGCT	cis	rs2229238	0.911	rs4633282	chr1:154507899	T/C	cg13067139	chr1:155221277	FAM189B	0.2	4.51	0.38	1.47e-5	Coronary heart disease;
TGCT	cis	rs7178572	0.568	rs11853460	chr15:77515319	C/T	cg22256960	chr15:77711686	NA	-0.87	-8.8	-0.62	9.73e-15	Type 2 diabetes;
TGCT	cis	rs6977660	0.714	rs10228783	chr7:19789290	C/T	cg05791153	chr7:19748676	TWISTNB	0.84	4.86	0.4	3.49e-6	Thyroid stimulating hormone;
TGCT	cis	rs9549367	0.713	rs9549681	chr13:113829873	T/C	cg18105134	chr13:113819100	PROZ	-0.47	-8.24	-0.59	2.05e-13	Platelet distribution width;
TGCT	cis	rs9644630	0.897	rs6984644	chr8:19363425	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.26	4.65	0.39	8.48e-6	Oropharynx cancer;
TGCT	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg06481639	chr22:41940642	POLR3H	0.72	6.3	0.49	4.73e-9	Vitiligo;
TGCT	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.01	0.41	1.86e-6	Prudent dietary pattern;
TGCT	cis	rs11105298	0.891	rs1008764	chr12:89887649	T/C	cg00757033	chr12:89920650	WDR51B	0.34	5.37	0.43	3.75e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs3087591	1.000	rs12600974	chr17:29589360	A/G	cg24425628	chr17:29625626	OMG;NF1	0.46	7.32	0.55	2.68e-11	Hip circumference;
TGCT	trans	rs7726839	0.561	rs3915384	chr5:573395	G/T	cg11887960	chr12:57824829	NA	0.95	7.66	0.57	4.58e-12	Obesity-related traits;
TGCT	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg12310025	chr6:25882481	NA	-0.53	-5.45	-0.44	2.63e-7	Blood metabolite levels;
TGCT	cis	rs13191362	0.507	rs2023037	chr6:163120385	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.6	5.58	0.45	1.42e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs6460942	0.643	rs80264734	chr7:12233800	T/A	cg06484146	chr7:12443880	VWDE	-0.54	-4.76	-0.39	5.21e-6	Coronary artery disease;
TGCT	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg03188948	chr7:1209495	NA	0.68	5.8	0.46	5.09e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs79839061	0.610	rs11726280	chr4:864077	C/T	cg15843217	chr4:699224	PCGF3	-0.63	-4.68	-0.39	7.3e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg17775962	chr7:1200435	ZFAND2A	0.28	4.88	0.4	3.22e-6	Longevity;Endometriosis;
TGCT	cis	rs8031584	0.958	rs8034856	chr15:31240957	T/C	cg08704250	chr15:31115839	NA	-0.36	-4.96	-0.41	2.29e-6	Huntington's disease progression;
TGCT	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.29	-4.56	-0.38	1.19e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg12419862	chr22:24373484	LOC391322	0.81	8.51	0.61	4.7e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs12188164	0.965	rs72717430	chr5:444502	T/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.4	-4.71	-0.39	6.42e-6	Cystic fibrosis severity;
TGCT	trans	rs2688608	0.592	rs10824031	chr10:75509273	C/T	cg13918328	chr10:52500089	ASAH2B	0.67	6.83	0.52	3.39e-10	Inflammatory bowel disease;
TGCT	cis	rs9443645	0.901	rs1354832	chr6:79613763	A/G	cg05283184	chr6:79620031	NA	0.21	4.83	0.4	3.96e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10744422	1.000	rs3852537	chr12:123361501	T/C	cg25930673	chr12:123319894	HIP1R	-0.85	-5.03	-0.41	1.69e-6	Schizophrenia;
TGCT	cis	rs1362404	0.592	rs10163230	chr16:52000507	C/T	cg03955530	chr16:52681474	NA	0.29	4.47	0.37	1.75e-5	Gut microbiota (bacterial taxa);
TGCT	cis	rs2933343	0.729	rs789228	chr3:128601050	A/G	cg11901034	chr3:128598214	ACAD9	-0.69	-6.55	-0.51	1.39e-9	IgG glycosylation;
TGCT	cis	rs4911259	0.552	rs13037833	chr20:31459562	C/T	cg13636640	chr20:31349939	DNMT3B	-0.89	-9.82	-0.66	3.4e-17	Inflammatory bowel disease;
TGCT	cis	rs3749237	0.595	rs3924462	chr3:49524236	T/G	cg07636037	chr3:49044803	WDR6	0.63	6.07	0.48	1.47e-8	Resting heart rate;
TGCT	cis	rs892961	0.932	rs9916143	chr17:75409282	C/G	cg05865280	chr17:75406074	SEPT9	-0.29	-6.99	-0.53	1.49e-10	Airflow obstruction;
TGCT	cis	rs1371867	0.846	rs1788203	chr8:101303721	T/C	cg00191853	chr8:101177733	SPAG1	-0.22	-4.47	-0.37	1.75e-5	Atrioventricular conduction;
TGCT	cis	rs4820539	0.966	rs2301554	chr22:23484254	A/C	cg14186256	chr22:23484241	RTDR1	1.02	13.65	0.77	1.86e-26	Bone mineral density;
TGCT	cis	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg02380750	chr20:61661411	NA	0.34	6.02	0.48	1.86e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7772486	0.875	rs9399572	chr6:146362945	T/G	cg05347473	chr6:146136440	FBXO30	0.56	5.42	0.44	2.96e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6665290	0.835	rs7549465	chr1:227214399	A/C	cg11404489	chr1:228071452	NA	-0.19	-4.45	-0.37	1.87e-5	Myeloid white cell count;
TGCT	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg03452623	chr4:187889614	NA	-0.34	-5.17	-0.42	8.97e-7	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs7726839	0.574	rs12517345	chr5:628294	G/A	cg11887960	chr12:57824829	NA	1.14	9.28	0.64	6.87e-16	Obesity-related traits;
TGCT	cis	rs4555082	0.834	rs2816653	chr14:105713973	A/G	cg01266790	chr14:105781312	PACS2	0.53	4.47	0.37	1.76e-5	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs9467711	0.606	rs28362606	chr6:26365586	T/C	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4478037	0.558	rs72854777	chr3:33069965	C/T	cg19404215	chr3:33155277	CRTAP	1.04	4.98	0.41	2.12e-6	Major depressive disorder;
TGCT	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg05457628	chr5:178986728	RUFY1	0.44	4.65	0.39	8.28e-6	Lung cancer;
TGCT	cis	rs9467773	0.526	rs3734536	chr6:26365346	C/G	cg15659132	chr6:26577336	NA	-0.48	-4.81	-0.4	4.25e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6543140	0.964	rs6736135	chr2:103064924	A/G	cg09003973	chr2:102972529	NA	0.56	4.67	0.39	7.86e-6	Blood protein levels;
TGCT	cis	rs7647973	0.710	rs11130208	chr3:49615624	G/T	cg05785598	chr3:49045655	WDR6	0.41	4.66	0.39	8.03e-6	Menarche (age at onset);
TGCT	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg06634786	chr22:41940651	POLR3H	-0.87	-8.08	-0.59	4.79e-13	Vitiligo;
TGCT	cis	rs919433	0.679	rs10203581	chr2:198515900	G/A	cg00792783	chr2:198669748	PLCL1	0.54	4.8	0.4	4.55e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs3806843	0.576	rs405192	chr5:140324710	T/G	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.42	-5.37	-0.43	3.69e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs73198271	0.710	rs11779561	chr8:8679988	G/C	cg06671706	chr8:8559999	CLDN23	-0.35	-4.46	-0.37	1.84e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs62283056	0.512	rs1079215	chr4:6282393	A/G	cg14416269	chr4:6271139	WFS1	0.39	4.97	0.41	2.18e-6	Cisplatin-induced ototoxicity;
TGCT	cis	rs10089	0.909	rs7732599	chr5:127370421	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	6.93	0.53	2e-10	Ileal carcinoids;
TGCT	trans	rs3790455	0.610	rs746527	chr1:156460511	C/T	cg16443977	chr5:115884994	SEMA6A	0.41	7.14	0.54	6.85e-11	Migraine;
TGCT	cis	rs1843834	0.898	rs12623277	chr2:225548072	T/G	cg22455342	chr2:225449267	CUL3	0.74	7.25	0.55	3.94e-11	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs77372450	0.551	rs11739081	chr5:157087119	C/G	cg19063654	chr5:156516798	HAVCR2	-0.37	-4.52	-0.38	1.44e-5	Bipolar disorder (body mass index interaction);
TGCT	cis	rs3820068	0.581	rs6692489	chr1:15928517	A/G	cg05660106	chr1:15850417	CASP9	0.74	7.27	0.55	3.53e-11	Systolic blood pressure;
TGCT	cis	rs1670533	1.000	rs28562028	chr4:1055115	G/A	cg27284194	chr4:1044797	NA	0.67	5.79	0.46	5.37e-8	Recombination rate (females);
TGCT	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg07298985	chr8:22133076	PIWIL2	0.34	5.09	0.42	1.28e-6	Hypertriglyceridemia;
TGCT	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg13206674	chr6:150067644	NUP43	0.52	4.51	0.38	1.5e-5	Lung cancer;
TGCT	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg10150615	chr22:24372951	LOC391322	-0.8	-8.88	-0.62	6.18e-15	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9993613	1.000	rs9993613	chr4:73476014	T/G	cg15102770	chr4:73434591	ADAMTS3	-0.53	-4.95	-0.41	2.4e-6	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs1865760	0.625	rs9393681	chr6:26008260	A/G	cg17042849	chr6:26104293	HIST1H4C	-0.65	-5.72	-0.46	7.7e-8	Height;
TGCT	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg13342137	chr4:2252803	MXD4	0.16	4.46	0.37	1.83e-5	Obesity-related traits;
TGCT	cis	rs17445774	1.000	rs17445774	chr2:200859249	A/G	cg17644776	chr2:200775616	C2orf69	-0.31	-4.96	-0.41	2.26e-6	LDL cholesterol to HDL cholesterol ratio;
TGCT	cis	rs1799949	1.000	rs4793236	chr17:41436440	T/C	cg10047753	chr17:41438598	NA	0.94	9.17	0.64	1.28e-15	Menopause (age at onset);
TGCT	cis	rs1008375	0.898	rs7678654	chr4:17575376	T/G	cg16339924	chr4:17578868	LAP3	0.83	7.37	0.55	2.06e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs5769707	0.967	rs2071904	chr22:50034477	C/T	cg20744362	chr22:50050164	C22orf34	0.27	4.57	0.38	1.18e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs10791323	0.581	rs2723608	chr11:133710149	A/G	cg03690763	chr11:133734501	NA	-0.31	-4.88	-0.4	3.13e-6	Childhood ear infection;
TGCT	cis	rs76473307	1.000	rs1800902	chr20:57415455	C/T	cg06163629	chr20:57414884	GNASAS;GNAS	-0.64	-4.5	-0.37	1.54e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg23708337	chr7:1209742	NA	0.74	6.83	0.52	3.36e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs6840360	0.934	rs6817058	chr4:152603865	T/C	cg17479576	chr4:152424074	FAM160A1	-0.5	-5.3	-0.43	5.1e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs3125734	0.633	rs3852412	chr10:64050288	C/T	cg09941381	chr10:64027924	RTKN2	-0.33	-4.9	-0.4	2.94e-6	Rheumatoid arthritis;
TGCT	trans	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg21659725	chr3:3221576	CRBN	0.7	7.95	0.58	9.9e-13	Body mass index;
TGCT	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg06896619	chr17:61851486	DDX42;CCDC47	-0.5	-4.78	-0.39	4.78e-6	Prudent dietary pattern;
TGCT	cis	rs4499344	0.921	rs12982788	chr19:33085501	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.7	-6.29	-0.49	5.01e-9	Mean platelet volume;
TGCT	cis	rs10992471	0.528	rs7037194	chr9:95216745	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.52	-4.91	-0.4	2.8e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs11030122	0.702	rs4910866	chr11:3950554	A/T	cg18678763	chr11:4115507	RRM1	-0.49	-6.14	-0.48	1.01e-8	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs2242194	0.816	rs11264296	chr1:154994750	T/C	cg09359103	chr1:154839909	KCNN3	-0.45	-6.24	-0.49	6.41e-9	Schizophrenia;
TGCT	cis	rs1577917	0.545	rs9294338	chr6:86474368	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.57	4.87	0.4	3.37e-6	Response to antipsychotic treatment;
TGCT	cis	rs3806843	0.548	rs246052	chr5:140326413	G/A	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9517320	0.534	rs3858778	chr13:99172249	A/C	cg20487152	chr13:99095054	FARP1	0.26	4.66	0.39	8.16e-6	Longevity;
TGCT	cis	rs1053338	0.529	rs34003604	chr3:63747528	A/G	cg22134162	chr3:63841271	THOC7	-0.3	-4.58	-0.38	1.12e-5	Breast cancer;
TGCT	cis	rs1843834	0.539	rs2047135	chr2:225427302	G/C	cg22455342	chr2:225449267	CUL3	1.04	10.75	0.69	1.87e-19	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs11105298	0.891	rs4842653	chr12:89834113	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.67	-4.74	-0.39	5.67e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs1538970	0.816	rs9727262	chr1:45998579	T/G	cg05343316	chr1:45956843	TESK2	0.75	5.9	0.47	3.16e-8	Platelet count;
TGCT	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.0	7.42	0.55	1.64e-11	Gut microbiome composition (summer);
TGCT	cis	rs9549367	0.664	rs9549689	chr13:113848387	G/A	cg00898013	chr13:113819073	PROZ	-0.53	-6.94	-0.53	1.89e-10	Platelet distribution width;
TGCT	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	5.25	0.43	6.47e-7	Height;
TGCT	cis	rs9894429	0.646	rs6565609	chr17:79592267	G/A	cg18240062	chr17:79603768	NPLOC4	0.56	4.92	0.4	2.67e-6	Eye color traits;
TGCT	cis	rs11123694	1.000	rs11123694	chr2:109064563	C/T	cg01745370	chr2:109065127	GCC2	0.43	4.93	0.4	2.55e-6	Mean platelet volume;
TGCT	cis	rs1153858	1.000	rs1049508	chr15:45653592	A/G	cg14582100	chr15:45693742	SPATA5L1	0.48	5.69	0.46	8.56e-8	Homoarginine levels;
TGCT	cis	rs9303401	0.659	rs62081314	chr17:56778328	A/G	cg25039879	chr17:56429692	SUPT4H1	0.52	4.62	0.38	9.48e-6	Cognitive test performance;
TGCT	trans	rs877282	1.000	rs2004479	chr10:770854	G/A	cg22713356	chr15:30763199	NA	1.21	10.47	0.69	8.99e-19	Uric acid levels;
TGCT	cis	rs826838	0.904	rs11612004	chr12:39204282	G/A	cg26384229	chr12:38710491	ALG10B	0.98	8.78	0.62	1.07e-14	Heart rate;
TGCT	cis	rs2309752	1	rs2309752	chr2:100762169	T/A	cg07810366	chr2:100720526	AFF3	-0.47	-8.0	-0.58	7.55e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs73198271	1.000	rs11775821	chr8:8609153	A/G	ch.8.214553F	chr8:8189620	PRAGMIN	-0.27	-4.62	-0.38	9.34e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg25767906	chr1:53392781	SCP2	-0.61	-7.81	-0.57	2.07e-12	Monocyte count;
TGCT	cis	rs941408	0.964	rs1736195	chr19:2786557	C/T	cg06609049	chr19:2785107	THOP1	0.84	7.88	0.58	1.43e-12	Total cholesterol levels;
TGCT	cis	rs8031584	0.752	rs2001686	chr15:31185772	G/A	cg08109568	chr15:31115862	NA	-0.35	-4.79	-0.4	4.66e-6	Huntington's disease progression;
TGCT	cis	rs137603	0.644	rs137635	chr22:39720656	G/C	cg01093212	chr22:39715156	SNORD43;RPL3	-0.5	-4.7	-0.39	6.73e-6	Primary biliary cholangitis;
TGCT	cis	rs12682352	0.602	rs1473029	chr8:8668917	A/C	cg15556689	chr8:8085844	FLJ10661	0.59	5.1	0.42	1.26e-6	Neuroticism;
TGCT	cis	rs7582180	0.591	rs12991577	chr2:101010867	C/A	cg14675211	chr2:100938903	LONRF2	0.5	4.69	0.39	6.95e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg23982607	chr1:1823379	GNB1	-0.5	-7.65	-0.57	4.8e-12	Body mass index;
TGCT	cis	rs7666738	0.800	rs10008654	chr4:98820498	C/A	cg05340658	chr4:99064831	C4orf37	0.51	6.03	0.48	1.76e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1801251	1.000	rs2592113	chr2:233669553	C/T	cg08000102	chr2:233561755	GIGYF2	0.64	6.51	0.5	1.71e-9	Coronary artery disease;
TGCT	cis	rs8062405	1.000	rs28403629	chr16:28854769	A/G	cg09754948	chr16:28834200	ATXN2L	0.59	4.45	0.37	1.91e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs17122693	1.000	rs72679584	chr14:51092320	T/C	cg04730355	chr14:51134070	SAV1	1.24	8.74	0.62	1.38e-14	Cognitive performance;
TGCT	cis	rs7432375	0.966	rs6808312	chr3:136371504	C/T	cg12473912	chr3:136751656	NA	-0.34	-4.93	-0.41	2.55e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg00149659	chr3:10157352	C3orf10	0.94	5.98	0.47	2.23e-8	Alzheimer's disease;
TGCT	cis	rs4319547	1.000	rs10998	chr12:122989412	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.71	-5.67	-0.45	9.65e-8	Body mass index;
TGCT	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg20607798	chr8:58055168	NA	0.61	5.16	0.42	9.38e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9916302	0.752	rs6503513	chr17:37561613	A/G	cg15445000	chr17:37608096	MED1	-0.33	-4.64	-0.38	8.86e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs11098499	0.754	rs12711071	chr4:120240934	A/G	cg09307838	chr4:120376055	NA	0.6	5.74	0.46	6.79e-8	Corneal astigmatism;
TGCT	trans	rs1814175	0.817	rs4881645	chr11:49791168	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.46	-0.56	1.33e-11	Height;
TGCT	cis	rs28785552	0.800	rs1971063	chr19:53232854	G/C	cg10871876	chr19:53194124	ZNF83	0.55	7.66	0.57	4.65e-12	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs62244186	1.000	rs62244186	chr3:44739783	G/A	cg04389838	chr3:44770851	ZNF501	-0.37	-4.89	-0.4	3.12e-6	Depressive symptoms;
TGCT	cis	rs12134133	1.000	rs7535532	chr1:207438336	C/T	cg02152968	chr1:207494213	CD55	0.61	4.66	0.39	7.94e-6	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs6933660	0.646	rs6911456	chr6:151778934	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.73	7.65	0.57	4.75e-12	Menarche (age at onset);
TGCT	cis	rs7589728	0.563	rs2292868	chr2:88475047	A/G	cg04511125	chr2:88470314	THNSL2	-0.63	-4.98	-0.41	2.04e-6	Plasma clusterin levels;
TGCT	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg18876405	chr7:65276391	NA	0.35	5.2	0.42	8.09e-7	Aortic root size;
TGCT	trans	rs7819412	0.715	rs35223712	chr8:11043926	C/T	cg15556689	chr8:8085844	FLJ10661	-0.74	-6.64	-0.51	8.75e-10	Triglycerides;
TGCT	cis	rs7666738	0.830	rs2865981	chr4:99031493	G/A	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.54	4.47	0.37	1.77e-5	Tonsillectomy;
TGCT	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg12140144	chr1:2984275	FLJ42875;PRDM16	-0.32	-4.46	-0.37	1.81e-5	Height;
TGCT	cis	rs1205863	1.000	rs209813	chr6:11953633	A/G	cg07106625	chr6:11870215	NA	0.48	4.72	0.39	6.15e-6	Disc degeneration (lumbar);
TGCT	cis	rs977747	0.872	rs4926726	chr1:47679486	G/A	cg03885399	chr1:47691550	TAL1	-0.4	-5.15	-0.42	1e-6	Body mass index;
TGCT	cis	rs208520	1.000	rs72880045	chr6:66965232	A/C	cg07460842	chr6:66804631	NA	0.83	7.52	0.56	9.8e-12	Exhaled nitric oxide output;
TGCT	cis	rs9467773	0.869	rs9295689	chr6:26455811	T/C	cg02458000	chr6:26745757	NA	0.47	4.59	0.38	1.09e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg07061783	chr6:25882402	NA	-0.42	-4.51	-0.38	1.51e-5	Blood metabolite levels;
TGCT	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg00149659	chr3:10157352	C3orf10	0.95	5.83	0.46	4.51e-8	Alzheimer's disease;
TGCT	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg11764359	chr7:65958608	NA	0.55	5.08	0.42	1.34e-6	Aortic root size;
TGCT	trans	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	1.03	13.16	0.76	2.65e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs9790314	0.846	rs7636941	chr3:160993928	A/G	cg03342759	chr3:160939853	NMD3	-0.51	-5.66	-0.45	9.96e-8	Morning vs. evening chronotype;
TGCT	cis	rs13040088	1.000	rs6090155	chr20:61527378	G/A	cg12680822	chr20:61666554	NCRNA00029	0.28	4.45	0.37	1.87e-5	Menopause (age at onset);
TGCT	cis	rs3617	0.625	rs7617468	chr3:52849549	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.5	-0.38	1.51e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6708331	0.517	rs12614547	chr2:70283971	T/A	cg16435808	chr2:70475954	TIA1	0.57	4.54	0.38	1.31e-5	Obesity-related traits;
TGCT	cis	rs5769765	0.908	rs9616376	chr22:50310829	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.24	-12.97	-0.76	7.81e-25	Schizophrenia;
TGCT	cis	rs10788264	0.652	rs9633732	chr10:124056473	G/T	cg09507567	chr10:124027408	NA	0.37	5.32	0.43	4.71e-7	Total body bone mineral density;
TGCT	cis	rs11614913	0.551	rs1867297	chr12:54396971	A/G	cg16264616	chr12:54390824	NA	0.35	4.8	0.4	4.41e-6	Waist circumference adjusted for body mass index;
TGCT	cis	rs9948	0.655	rs7568206	chr2:97393108	A/C	cg01990225	chr2:97406019	LMAN2L	-0.94	-5.33	-0.43	4.44e-7	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg00684032	chr4:1343700	KIAA1530	0.22	4.82	0.4	4.11e-6	Obesity-related traits;
TGCT	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.45	-5.37	-0.43	3.72e-7	Alzheimer's disease;
TGCT	cis	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg18252515	chr7:66147081	NA	-1.27	-7.73	-0.57	3.17e-12	Diabetic kidney disease;
TGCT	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg19761014	chr17:28927070	LRRC37B2	0.55	4.77	0.39	5.12e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs240764	0.621	rs6570930	chr6:101181258	C/A	cg09795085	chr6:101329169	ASCC3	-0.51	-4.51	-0.38	1.48e-5	Neuroticism;
TGCT	cis	rs4780401	0.609	rs7205994	chr16:11815964	C/T	cg01061890	chr16:11836724	TXNDC11	-0.6	-5.82	-0.46	4.74e-8	Rheumatoid arthritis;
TGCT	trans	rs1814175	0.692	rs1851873	chr11:49937767	A/G	cg03929089	chr4:120376271	NA	-0.59	-6.77	-0.52	4.5e-10	Height;
TGCT	cis	rs13191362	1.000	rs13220048	chr6:163004325	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs9549260	0.753	rs2297628	chr13:41233905	T/C	cg21288729	chr13:41239152	FOXO1	0.69	4.87	0.4	3.31e-6	Red blood cell count;
TGCT	trans	rs77457752	0.523	rs9696661	chr9:13901539	T/C	cg23609682	chr1:3070786	PRDM16	0.51	6.81	0.52	3.8e-10	Breast cancer;
TGCT	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg14624950	chr17:62577106	SMURF2	-0.21	-4.73	-0.39	5.88e-6	Prudent dietary pattern;
TGCT	cis	rs17331151	0.573	rs4687556	chr3:52890475	T/C	cg27565382	chr3:53032988	SFMBT1	-0.45	-5.76	-0.46	6.25e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs151997	1.000	rs373030	chr5:50215836	G/A	cg06027927	chr5:50259733	NA	0.47	4.83	0.4	3.9e-6	Callous-unemotional behaviour;
TGCT	cis	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg12570787	chr5:219185	SDHA;CCDC127	0.65	4.46	0.37	1.83e-5	Breast cancer;
TGCT	cis	rs6752107	1.000	rs2241879	chr2:234183468	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.2	4.81	0.4	4.36e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs514406	0.536	rs878957	chr1:53197559	C/T	cg16325326	chr1:53192061	ZYG11B	-0.85	-11.44	-0.72	4.04e-21	Monocyte count;
TGCT	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg10802521	chr3:52805072	NEK4	-0.71	-8.79	-0.62	1.04e-14	Bipolar disorder;
TGCT	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg00684032	chr4:1343700	KIAA1530	0.22	4.83	0.4	3.99e-6	Obesity-related traits;
TGCT	cis	rs9902453	0.817	rs2617881	chr17:28063275	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-6.89	-0.53	2.55e-10	Coffee consumption (cups per day);
TGCT	cis	rs2230307	0.572	rs514090	chr1:100563186	C/G	cg24955406	chr1:100503596	HIAT1	0.75	5.13	0.42	1.1e-6	Carotid intima media thickness;
TGCT	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.74	-7.02	-0.53	1.26e-10	Prudent dietary pattern;
TGCT	cis	rs9486719	1.000	rs11757063	chr6:96884886	C/T	cg18709589	chr6:96969512	KIAA0776	-0.72	-5.27	-0.43	5.96e-7	Migraine;Coronary artery disease;
TGCT	cis	rs8033133	0.678	rs7496110	chr15:25347013	A/G	cg14481604	chr15:25334117	SNORD116-22	-0.27	-5.36	-0.43	3.96e-7	Blood osmolality (transformed sodium);
TGCT	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg19635926	chr16:89946313	TCF25	0.25	4.53	0.38	1.39e-5	Skin colour saturation;
TGCT	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg23758822	chr17:41437982	NA	0.69	6.37	0.5	3.34e-9	Menopause (age at onset);
TGCT	cis	rs12549902	0.966	rs4317621	chr8:41516581	A/G	cg21772509	chr8:41503840	NKX6-3	0.85	9.35	0.64	4.7e-16	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
TGCT	cis	rs7191700	0.673	rs12325495	chr16:11418328	C/T	cg00044050	chr16:11439710	C16orf75	0.95	12.37	0.74	2.23e-23	Multiple sclerosis;
TGCT	cis	rs9911578	1.000	rs6503870	chr17:56659018	C/T	cg12560992	chr17:57184187	TRIM37	0.76	9.34	0.64	4.88e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs7582180	0.629	rs11685406	chr2:100946638	A/G	cg14675211	chr2:100938903	LONRF2	0.5	4.78	0.39	4.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs453301	0.686	rs6601281	chr8:8911004	A/G	cg15556689	chr8:8085844	FLJ10661	-0.64	-5.26	-0.43	6.09e-7	Joint mobility (Beighton score);
TGCT	cis	rs600231	0.665	rs1784858	chr11:65222952	T/C	cg11802864	chr11:65308245	LTBP3	0.45	4.64	0.38	8.62e-6	Bone mineral density;
TGCT	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg08859206	chr1:53392774	SCP2	-0.49	-8.02	-0.58	6.87e-13	Monocyte count;
TGCT	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg18230493	chr5:56204884	C5orf35	-0.66	-5.74	-0.46	6.99e-8	Initial pursuit acceleration;
TGCT	cis	rs12908161	0.959	rs34342559	chr15:85331271	A/G	cg12863693	chr15:85201151	NMB	0.42	4.95	0.41	2.38e-6	Schizophrenia;
TGCT	cis	rs10782582	0.593	rs6675212	chr1:76230829	C/A	cg03433033	chr1:76189801	ACADM	-0.55	-6.04	-0.48	1.66e-8	Daytime sleep phenotypes;
TGCT	cis	rs28595532	0.841	rs56046449	chr4:119769302	T/C	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs1171582	0.545	rs4948360	chr10:61521501	T/C	cg23572703	chr10:62241191	NA	-0.27	-4.64	-0.38	8.55e-6	Alopecia areata;
TGCT	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg14851468	chr5:179071604	C5orf60	-0.22	-4.49	-0.37	1.64e-5	Lung cancer;
TGCT	cis	rs2204008	0.837	rs11519926	chr12:38348992	G/A	cg26384229	chr12:38710491	ALG10B	0.83	7.25	0.55	4e-11	Bladder cancer;
TGCT	cis	rs7172809	0.573	rs74027549	chr15:77524761	A/G	cg22256960	chr15:77711686	NA	-0.49	-4.62	-0.38	9.51e-6	Glucose homeostasis traits;
TGCT	cis	rs17601876	0.843	rs17523541	chr15:51554844	G/A	cg19946085	chr15:51559439	CYP19A1	-0.32	-4.84	-0.4	3.84e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg06112835	chr11:68658793	MRPL21	0.45	7.45	0.56	1.39e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	trans	rs1864729	1.000	rs2053480	chr8:98278951	A/T	cg08679828	chr8:102218111	ZNF706	1.1	7.71	0.57	3.56e-12	Estradiol plasma levels (breast cancer);
TGCT	cis	rs1878931	0.582	rs27227	chr16:3429778	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.76	-6.41	-0.5	2.7e-9	Body mass index (adult);
TGCT	cis	rs4654899	0.931	rs10799671	chr1:21196764	C/T	cg01072550	chr1:21505969	NA	0.5	7.93	0.58	1.08e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs4824093	0.535	rs73441802	chr22:50273916	G/A	cg20569369	chr22:51173646	NA	0.29	4.84	0.4	3.86e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs13256369	0.760	rs7816171	chr8:8575835	T/C	cg17143192	chr8:8559678	CLDN23	0.63	5.93	0.47	2.8e-8	Obesity-related traits;
TGCT	trans	rs2749592	0.550	rs7081464	chr10:37883937	C/T	cg17830980	chr10:43048298	ZNF37B	0.64	6.76	0.52	4.71e-10	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs642803	1.000	rs557675	chr11:65566719	G/T	cg27068330	chr11:65405492	SIPA1	-0.56	-5.03	-0.41	1.67e-6	Urate levels;
TGCT	cis	rs13256369	1.000	rs885000	chr8:8568875	G/T	cg06671706	chr8:8559999	CLDN23	0.34	4.57	0.38	1.18e-5	Obesity-related traits;
TGCT	cis	rs4654899	1.000	rs4654899	chr1:21410231	G/T	cg01072550	chr1:21505969	NA	-0.5	-8.04	-0.59	6.23e-13	Superior frontal gyrus grey matter volume;
TGCT	cis	rs36051895	0.659	rs10974935	chr9:5050307	C/T	cg02405213	chr9:5042618	JAK2	-0.78	-10.85	-0.7	1.1e-19	Pediatric autoimmune diseases;
TGCT	cis	rs6988636	1.000	rs60362869	chr8:124189971	A/G	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs1371867	0.875	rs1125706	chr8:101326739	T/A	cg06636551	chr8:101224915	SPAG1	-0.48	-6.52	-0.51	1.62e-9	Atrioventricular conduction;
TGCT	cis	rs7267979	1.000	rs2500418	chr20:25382268	C/T	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.73e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs9329221	0.905	rs6601451	chr8:10243681	C/G	cg15556689	chr8:8085844	FLJ10661	-0.79	-7.35	-0.55	2.39e-11	Neuroticism;
TGCT	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.51	5.4	0.44	3.28e-7	Lymphocyte counts;
TGCT	cis	rs7772486	0.875	rs2748501	chr6:146312258	G/A	cg05347473	chr6:146136440	FBXO30	0.57	5.26	0.43	6.18e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs854765	0.575	rs2955357	chr17:17946401	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.79	-8.32	-0.6	1.37e-13	Total body bone mineral density;
TGCT	cis	rs9796	0.835	rs2927062	chr15:41302687	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.45	-5.83	-0.46	4.59e-8	Menopause (age at onset);
TGCT	cis	rs12042938	0.507	rs1765778	chr1:231732356	G/A	cg04892437	chr1:231737901	TSNAX-DISC1	-0.42	-4.83	-0.4	3.98e-6	Neuranatomic and neurocognitive phenotypes;
TGCT	cis	rs11122272	0.735	rs2790882	chr1:231532783	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.64	5.95	0.47	2.5e-8	Hemoglobin concentration;
TGCT	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	8.39	0.6	9.03e-14	Platelet count;
TGCT	cis	rs6815814	0.851	rs4274855	chr4:38777471	C/T	cg02016764	chr4:38805732	TLR1	-0.35	-5.51	-0.44	1.96e-7	Breast cancer;
TGCT	cis	rs459571	0.629	rs441233	chr9:136876021	A/G	cg13789015	chr9:136890014	NCRNA00094	-0.32	-5.27	-0.43	5.74e-7	Platelet distribution width;
TGCT	cis	rs727505	0.954	rs67146030	chr7:124561790	T/G	cg23710748	chr7:124431027	NA	-0.26	-4.49	-0.37	1.6e-5	Lewy body disease;
TGCT	cis	rs7666738	0.830	rs13108422	chr4:99059267	G/A	cg17366294	chr4:99064904	C4orf37	0.72	7.39	0.55	1.9e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs17376456	0.877	rs10060160	chr5:93387879	G/A	cg25358565	chr5:93447407	FAM172A	0.93	8.37	0.6	1.04e-13	Diabetic retinopathy;
TGCT	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	15.97	0.82	6.97e-32	Prudent dietary pattern;
TGCT	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg08280861	chr8:58055591	NA	0.4	6.18	0.49	8.45e-9	Developmental language disorder (linguistic errors);
TGCT	cis	rs13242816	1.000	rs12672717	chr7:116128270	G/A	cg02799643	chr7:116139180	CAV2	-0.46	-5.53	-0.44	1.78e-7	P wave duration;
TGCT	cis	rs9393692	0.905	rs1124999	chr6:26287043	G/T	cg00631329	chr6:26305371	NA	-0.44	-6.59	-0.51	1.15e-9	Educational attainment;
TGCT	cis	rs8031584	0.651	rs28664821	chr15:31172323	G/A	cg08704250	chr15:31115839	NA	0.43	6.21	0.49	7.43e-9	Huntington's disease progression;
TGCT	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg23131131	chr22:24373011	LOC391322	-0.81	-8.78	-0.62	1.11e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9303401	0.659	rs714959	chr17:56628601	A/G	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs9457247	0.534	rs1130033	chr6:167385623	C/T	cg23791538	chr6:167370224	RNASET2	-0.61	-6.03	-0.48	1.78e-8	Crohn's disease;
TGCT	cis	rs1887596	0.624	rs9319305	chr13:27151048	T/A	cg01312412	chr13:27282625	NA	0.27	4.86	0.4	3.51e-6	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs79387448	0.745	rs78136548	chr2:103103740	T/G	cg09003973	chr2:102972529	NA	1.13	6.68	0.51	7.38e-10	Gut microbiota (bacterial taxa);
TGCT	cis	rs7172809	0.615	rs907371	chr15:77844375	C/T	cg22256960	chr15:77711686	NA	0.48	4.77	0.39	5.1e-6	Glucose homeostasis traits;
TGCT	cis	rs1534166	0.647	rs1464937	chr3:133536655	C/G	cg16414030	chr3:133502952	NA	0.42	5.4	0.44	3.27e-7	Alcohol consumption (transferrin glycosylation);
TGCT	cis	rs5769765	0.542	rs761878	chr22:50249677	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.97	6.35	0.5	3.69e-9	Schizophrenia;
TGCT	cis	rs709400	0.567	rs28496120	chr14:103897899	C/T	cg26031613	chr14:104095156	KLC1	0.84	9.26	0.64	7.9e-16	Body mass index;
TGCT	cis	rs6840360	0.642	rs11099819	chr4:152430178	T/C	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.82e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg17264618	chr3:40429014	ENTPD3	0.33	4.76	0.39	5.38e-6	Renal cell carcinoma;
TGCT	cis	rs3749237	0.555	rs2117939	chr3:49415179	C/A	cg07636037	chr3:49044803	WDR6	0.64	6.04	0.48	1.63e-8	Resting heart rate;
TGCT	cis	rs9372498	0.536	rs9489436	chr6:118873817	A/C	cg07617317	chr6:118971624	C6orf204	0.52	5.54	0.45	1.71e-7	Diastolic blood pressure;
TGCT	cis	rs12477438	0.784	rs13407840	chr2:99569928	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-4.88	-0.4	3.17e-6	Chronic sinus infection;
TGCT	cis	rs13191362	1.000	rs34637087	chr6:163004064	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs3087591	1.000	rs4239229	chr17:29425170	T/G	cg24425628	chr17:29625626	OMG;NF1	0.49	7.41	0.55	1.74e-11	Hip circumference;
TGCT	cis	rs2120019	0.935	rs34913788	chr15:75372617	A/C	cg17294928	chr15:75287854	SCAMP5	-0.86	-6.62	-0.51	9.55e-10	Blood trace element (Zn levels);
TGCT	cis	rs7639513	0.545	rs13061104	chr3:12717321	G/T	cg23032965	chr3:12705835	RAF1	0.75	6.87	0.53	2.7e-10	Itch intensity from mosquito bite;
TGCT	cis	rs7914558	0.966	rs943035	chr10:104839152	T/C	cg15744005	chr10:104629667	AS3MT	-0.39	-4.69	-0.39	7.05e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs9611519	0.929	rs926914	chr22:41418154	C/T	cg03806693	chr22:41940476	POLR3H	-0.69	-6.22	-0.49	6.89e-9	Neuroticism;
TGCT	cis	rs1865760	0.964	rs1324084	chr6:25915134	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.65	6.18	0.49	8.59e-9	Height;
TGCT	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg09365446	chr1:150670422	GOLPH3L	0.3	4.49	0.37	1.63e-5	Tonsillectomy;
TGCT	cis	rs35146811	0.735	rs858505	chr7:99819577	G/A	cg22906224	chr7:99728672	NA	-0.5	-4.51	-0.38	1.48e-5	Coronary artery disease;
TGCT	cis	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg18252515	chr7:66147081	NA	1.2	7.83	0.58	1.89e-12	Diabetic kidney disease;
TGCT	cis	rs10791323	0.569	rs10736608	chr11:133740048	C/T	cg15485101	chr11:133734466	NA	0.38	5.56	0.45	1.6e-7	Childhood ear infection;
TGCT	cis	rs7267979	0.844	rs35735333	chr20:25337205	T/G	cg16686733	chr20:25566563	NINL	-0.52	-4.93	-0.4	2.61e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3806843	0.676	rs778593	chr5:140027216	T/C	cg19875535	chr5:140030758	IK	-0.36	-6.34	-0.49	3.84e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs6570726	0.738	rs4495284	chr6:145916617	T/A	cg13319975	chr6:146136371	FBXO30	-0.51	-4.48	-0.37	1.71e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1348850	0.632	rs11678875	chr2:178509068	A/G	cg22681709	chr2:178499509	PDE11A	-0.51	-6.34	-0.49	3.93e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs7666738	0.830	rs2903154	chr4:99048151	A/G	cg17366294	chr4:99064904	C4orf37	0.73	7.49	0.56	1.11e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7584330	0.657	rs10202292	chr2:238352185	A/T	cg14458575	chr2:238380390	NA	0.51	7.51	0.56	1e-11	Prostate cancer;
TGCT	cis	rs921968	0.643	rs497983	chr2:219415189	A/G	cg02176678	chr2:219576539	TTLL4	0.38	5.56	0.45	1.58e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.57	0.38	1.15e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs992157	0.764	rs2891077	chr2:219184430	A/C	cg00012203	chr2:219082015	ARPC2	0.7	6.59	0.51	1.11e-9	Colorectal cancer;
TGCT	cis	rs453301	0.682	rs2929308	chr8:9084121	T/A	cg15556689	chr8:8085844	FLJ10661	-0.7	-6.54	-0.51	1.47e-9	Joint mobility (Beighton score);
TGCT	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.75	5.41	0.44	3.09e-7	Platelet count;
TGCT	cis	rs9443645	0.869	rs9443626	chr6:79629564	G/C	cg09184832	chr6:79620586	NA	-0.49	-5.29	-0.43	5.29e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7772486	0.875	rs9376975	chr6:146355581	T/G	cg05347473	chr6:146136440	FBXO30	0.57	5.51	0.44	2.02e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9303401	0.659	rs12944971	chr17:56988801	A/T	cg25039879	chr17:56429692	SUPT4H1	0.52	4.57	0.38	1.15e-5	Cognitive test performance;
TGCT	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.51	5.38	0.44	3.51e-7	Menopause (age at onset);
TGCT	cis	rs704	0.790	rs4795433	chr17:26716821	C/T	cg10342447	chr17:26645325	TMEM97	-0.51	-4.91	-0.4	2.84e-6	Osteoprotegerin levels;
TGCT	cis	rs1153858	1.000	rs3759899	chr15:45655903	T/C	cg26924012	chr15:45694286	SPATA5L1	1.09	15.16	0.81	5.15e-30	Homoarginine levels;
TGCT	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg24531977	chr5:56204891	C5orf35	-0.77	-7.61	-0.56	5.83e-12	Initial pursuit acceleration;
TGCT	cis	rs1801251	0.896	rs7573208	chr2:233696701	C/A	cg25237894	chr2:233734115	C2orf82	-0.27	-4.99	-0.41	2.02e-6	Coronary artery disease;
TGCT	cis	rs71636778	0.509	rs78581866	chr1:27247566	T/C	cg23921621	chr1:27994728	IFI6	-0.43	-4.61	-0.38	9.95e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
TGCT	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg07507251	chr3:52567010	NT5DC2	-0.48	-6.87	-0.53	2.77e-10	Bipolar disorder;
TGCT	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg14784868	chr12:69753453	YEATS4	-0.87	-10.24	-0.68	3.35e-18	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs72945132	0.882	rs17160039	chr11:70145489	A/G	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs6952808	0.792	rs34269264	chr7:1948712	C/T	cg04267008	chr7:1944627	MAD1L1	-0.4	-5.44	-0.44	2.71e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs3749237	1.000	rs11710675	chr3:49751900	C/A	cg03060546	chr3:49711283	APEH	0.74	7.53	0.56	9.17e-12	Resting heart rate;
TGCT	cis	rs2066819	1.000	rs117779516	chr12:56750872	G/C	cg26714650	chr12:56694279	CS	-1.36	-5.89	-0.47	3.4e-8	Psoriasis vulgaris;
TGCT	cis	rs7726839	0.578	rs10080150	chr5:593160	C/T	cg18765565	chr5:669397	TPPP	-0.53	-4.82	-0.4	4.05e-6	Obesity-related traits;
TGCT	cis	rs10751667	0.714	rs7396700	chr11:963863	A/C	cg06064525	chr11:970664	AP2A2	-0.35	-8.23	-0.59	2.17e-13	Alzheimer's disease (late onset);
TGCT	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg20607798	chr8:58055168	NA	0.61	5.16	0.42	9.38e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6671200	0.915	rs259334	chr1:95739701	C/T	cg26537280	chr1:95699037	RWDD3	-0.72	-5.18	-0.42	8.67e-7	Stearic acid (18:0) levels;
TGCT	cis	rs8017423	0.967	rs7151776	chr14:90724803	A/G	cg04374321	chr14:90722782	PSMC1	0.74	7.45	0.56	1.39e-11	Mortality in heart failure;
TGCT	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg04267008	chr7:1944627	MAD1L1	-0.39	-5.22	-0.42	7.29e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs7249142	0.562	rs12980955	chr19:19283646	T/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.34	-4.62	-0.38	9.65e-6	IgG glycosylation;
TGCT	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg00149659	chr3:10157352	C3orf10	1.15	7.49	0.56	1.12e-11	Alzheimer's disease;
TGCT	cis	rs6840360	0.593	rs4696106	chr4:152606818	A/G	cg17479576	chr4:152424074	FAM160A1	-0.62	-6.23	-0.49	6.69e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs2594989	0.831	rs7642605	chr3:11469503	T/C	cg00170343	chr3:11313890	ATG7	0.79	5.8	0.46	5.18e-8	Circulating chemerin levels;
TGCT	cis	rs4595586	0.545	rs61939641	chr12:39378001	T/C	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs2153535	0.580	rs7766852	chr6:8472417	C/T	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.29e-6	Motion sickness;
TGCT	cis	rs7020830	0.858	rs67036212	chr9:37133538	A/G	cg14294708	chr9:37120828	ZCCHC7	1.29	19.04	0.86	1.29e-38	Schizophrenia;
TGCT	cis	rs1532993	0.518	rs11097570	chr4:98623645	C/T	cg05340658	chr4:99064831	C4orf37	-0.38	-4.54	-0.38	1.32e-5	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs9616064	0.744	rs9616058	chr22:46974203	G/A	cg04500879	chr22:46327243	WNT7B	0.3	4.79	0.4	4.68e-6	Urate levels in obese individuals;
TGCT	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg11247378	chr22:39784982	NA	-0.73	-9.43	-0.65	3.04e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs7772486	0.846	rs9376976	chr6:146355605	T/C	cg23711669	chr6:146136114	FBXO30	0.89	10.0	0.67	1.25e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1153858	1.000	rs12591058	chr15:45640172	T/C	cg26924012	chr15:45694286	SPATA5L1	1.07	14.56	0.79	1.32e-28	Homoarginine levels;
TGCT	cis	rs3092073	0.617	rs8123864	chr20:44598670	T/C	cg23252815	chr20:44420276	WFDC3;DNTTIP1	-0.27	-4.44	-0.37	1.93e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs9787249	0.957	rs1046988	chr1:40219065	A/G	cg20968010	chr1:40505947	CAP1	0.48	4.63	0.38	9.18e-6	Blood protein levels;
TGCT	cis	rs6671200	1.000	rs34396223	chr1:95697828	C/T	cg20701556	chr1:95698924	RWDD3	0.67	5.63	0.45	1.13e-7	Stearic acid (18:0) levels;
TGCT	cis	rs7568458	0.870	rs1058588	chr2:85808871	A/G	cg17127132	chr2:85788382	GGCX	-0.68	-6.2	-0.49	7.7e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs9916302	0.904	rs7210488	chr17:37539819	T/G	cg07936489	chr17:37558343	FBXL20	0.65	5.08	0.41	1.36e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs12497850	0.931	rs7627404	chr3:48819668	A/C	cg06212747	chr3:49208901	KLHDC8B	0.61	5.62	0.45	1.2e-7	Parkinson's disease;
TGCT	cis	rs6714710	0.535	rs13033383	chr2:98339513	C/T	cg26665480	chr2:98280029	ACTR1B	0.63	5.82	0.46	4.65e-8	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs9527	1.000	rs9527	chr10:104623578	C/T	cg15744005	chr10:104629667	AS3MT	-0.52	-6.08	-0.48	1.39e-8	Arsenic metabolism;
TGCT	cis	rs9733	0.526	rs11204698	chr1:150659545	G/A	cg04414720	chr1:150670196	GOLPH3L	0.39	5.04	0.41	1.58e-6	Tonsillectomy;
TGCT	cis	rs7772486	0.754	rs10872580	chr6:146140281	C/T	cg23711669	chr6:146136114	FBXO30	-0.9	-10.27	-0.68	2.76e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg21724239	chr8:58056113	NA	0.38	5.15	0.42	1e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg21724239	chr8:58056113	NA	0.39	5.24	0.43	6.73e-7	Developmental language disorder (linguistic errors);
TGCT	trans	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg17470723	chr8:74884337	TCEB1	0.74	6.99	0.53	1.46e-10	Prostate cancer (SNP x SNP interaction);
TGCT	trans	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg20587970	chr11:113659929	NA	-0.97	-12.13	-0.74	8.27e-23	Hip circumference adjusted for BMI;
TGCT	cis	rs2033711	0.870	rs1465789	chr19:58946056	C/T	cg04608855	chr19:58913158	NA	0.56	5.37	0.43	3.69e-7	Uric acid clearance;
TGCT	cis	rs5769765	0.818	rs138850	chr22:50193337	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	-0.29	-4.47	-0.37	1.75e-5	Schizophrenia;
TGCT	cis	rs7829975	0.577	rs17684466	chr8:8545233	G/A	cg17143192	chr8:8559678	CLDN23	-0.52	-5.21	-0.42	7.57e-7	Mood instability;
TGCT	cis	rs7131987	0.565	rs7968883	chr12:29394191	T/C	cg09582351	chr12:29534625	ERGIC2	-0.22	-4.49	-0.37	1.6e-5	QT interval;
TGCT	trans	rs8004664	0.513	rs17126053	chr14:90033633	C/T	cg22481606	chr17:56429567	SUPT4H1	-0.66	-6.83	-0.52	3.32e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
TGCT	cis	rs114540395	0.858	rs78810836	chr10:103178514	G/A	cg18276125	chr10:102749041	C10orf2	0.38	4.6	0.38	1.05e-5	Schizophrenia;
TGCT	cis	rs6547741	1.000	rs4666009	chr2:27857992	T/A	cg27432699	chr2:27873401	GPN1	0.19	4.71	0.39	6.65e-6	Oral cavity cancer;
TGCT	cis	rs4689388	0.926	rs11732178	chr4:6292643	G/C	cg14416269	chr4:6271139	WFS1	0.4	5.29	0.43	5.44e-7	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs11822910	0.815	rs12422015	chr11:57193653	A/G	cg00522883	chr11:57194120	SLC43A3	0.35	5.07	0.41	1.43e-6	Platelet distribution width;
TGCT	cis	rs6543140	0.964	rs6543142	chr2:103082006	T/C	cg09003973	chr2:102972529	NA	0.55	4.56	0.38	1.2e-5	Blood protein levels;
TGCT	cis	rs931608	0.640	rs2082478	chr19:22539848	G/A	cg23859931	chr19:22123797	NA	-0.64	-4.8	-0.4	4.43e-6	Dental caries;Response to statins (LDL cholesterol change);
TGCT	cis	rs60733400	0.500	rs72644697	chr1:2533605	G/A	cg18854424	chr1:2615690	NA	0.44	5.1	0.42	1.22e-6	Multiple sclerosis;
TGCT	trans	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg21659725	chr3:3221576	CRBN	-0.98	-15.33	-0.81	2.1000000000000002e-30	Intelligence (multi-trait analysis);
TGCT	cis	rs6987853	0.931	rs2923431	chr8:42394425	G/C	cg20539142	chr8:42623718	CHRNA6	-0.19	-4.55	-0.38	1.26e-5	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs2235642	0.928	rs56289115	chr16:1608934	A/G	cg07639376	chr16:1584516	IFT140;TMEM204	-0.32	-5.69	-0.46	8.63e-8	Coronary artery disease;
TGCT	cis	rs9911578	0.967	rs1588322	chr17:56990099	T/C	cg12560992	chr17:57184187	TRIM37	0.76	9.21	0.64	1.03e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg03609598	chr5:56110824	MAP3K1	-0.59	-4.78	-0.39	4.81e-6	Initial pursuit acceleration;
TGCT	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg09060608	chr5:178986726	RUFY1	0.49	5.59	0.45	1.35e-7	Lung cancer;
TGCT	cis	rs9677476	0.515	rs13430145	chr2:231931133	T/C	cg27665808	chr2:232055229	NA	0.36	4.6	0.38	1.01e-5	Food antigen IgG levels;
TGCT	cis	rs425277	0.606	rs2460001	chr1:2111030	T/C	cg03732007	chr1:2071316	PRKCZ	0.28	6.64	0.51	8.63e-10	Height;
TGCT	cis	rs208520	0.909	rs55813840	chr6:67012508	A/C	cg07460842	chr6:66804631	NA	0.69	5.72	0.46	7.53e-8	Exhaled nitric oxide output;
TGCT	cis	rs7829975	0.617	rs4841072	chr8:8791253	C/A	cg06636001	chr8:8085503	FLJ10661	-0.72	-6.68	-0.51	7.28e-10	Mood instability;
TGCT	cis	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg05590025	chr7:65112418	INTS4L2	-0.77	-4.5	-0.37	1.52e-5	Diabetic kidney disease;
TGCT	cis	rs6430585	0.591	rs12476135	chr2:136486340	T/C	cg07169764	chr2:136633963	MCM6	1.12	10.49	0.69	8.04e-19	Corneal structure;
TGCT	cis	rs10927875	0.691	rs2017583	chr1:16350028	A/G	cg22431228	chr1:16359049	CLCNKA	-0.25	-4.68	-0.39	7.47e-6	Dilated cardiomyopathy;
TGCT	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg03188948	chr7:1209495	NA	0.71	6.04	0.48	1.68e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2204008	0.774	rs9669565	chr12:38294428	C/A	cg13010199	chr12:38710504	ALG10B	0.57	4.45	0.37	1.89e-5	Bladder cancer;
TGCT	cis	rs986417	1.000	rs1254318	chr14:60902549	T/C	cg27398547	chr14:60952738	C14orf39	-1.41	-9.11	-0.63	1.75e-15	Gut microbiota (bacterial taxa);
TGCT	cis	rs546131	0.642	rs512013	chr11:34842225	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.54	4.67	0.39	7.64e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs9733	0.628	rs11807409	chr1:150683423	C/T	cg09365446	chr1:150670422	GOLPH3L	0.3	4.52	0.38	1.4e-5	Tonsillectomy;
TGCT	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg13342137	chr4:2252803	MXD4	0.17	4.44	0.37	1.94e-5	Obesity-related traits;
TGCT	cis	rs1982963	1.000	rs3742536	chr14:52507429	C/T	cg10843707	chr14:52510701	NID2	0.43	6.63	0.51	9.33e-10	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs933360	0.895	rs4521715	chr7:50769251	G/A	cg18232548	chr7:50535776	DDC	-0.33	-4.81	-0.4	4.3e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
TGCT	cis	rs853679	0.657	rs1778482	chr6:28240992	G/C	cg18815343	chr6:28367644	ZSCAN12	-0.51	-5.14	-0.42	1.02e-6	Depression;
TGCT	cis	rs208520	0.633	rs79679034	chr6:66701724	A/C	cg07460842	chr6:66804631	NA	0.9	9.57	0.65	1.41e-16	Exhaled nitric oxide output;
TGCT	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg03188948	chr7:1209495	NA	0.41	5.37	0.43	3.66e-7	Longevity;Endometriosis;
TGCT	cis	rs459571	1.000	rs459571	chr9:136912626	C/T	cg13789015	chr9:136890014	NCRNA00094	0.4	7.18	0.54	5.63e-11	Platelet distribution width;
TGCT	cis	rs7772486	0.686	rs857877	chr6:145976230	A/C	cg13319975	chr6:146136371	FBXO30	0.54	4.98	0.41	2.09e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7909074	1.000	rs10900128	chr10:45393201	G/T	cg05187965	chr10:45406764	TMEM72	-0.25	-5.34	-0.43	4.2e-7	Mean corpuscular volume;
TGCT	cis	rs1200821	0.535	rs1208784	chr10:37768433	A/G	cg25427524	chr10:38739819	LOC399744	-0.3	-5.39	-0.44	3.43e-7	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg26338869	chr17:61819248	STRADA	-0.53	-4.85	-0.4	3.68e-6	Prudent dietary pattern;
TGCT	cis	rs1014246	0.541	rs887195	chr10:118507976	G/A	cg14919929	chr10:118506882	NA	-0.37	-5.82	-0.46	4.69e-8	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs9486719	0.741	rs2049927	chr6:96848958	C/G	cg06623918	chr6:96969491	KIAA0776	-0.84	-6.27	-0.49	5.56e-9	Migraine;Coronary artery disease;
TGCT	cis	rs763121	0.853	rs5750633	chr22:38993467	A/G	cg06022373	chr22:39101656	GTPBP1	0.81	8.26	0.6	1.84e-13	Menopause (age at onset);
TGCT	cis	rs6988636	1.000	rs28694222	chr8:124195017	C/T	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg17554472	chr22:41940697	POLR3H	-0.49	-5.27	-0.43	5.9e-7	Vitiligo;
TGCT	cis	rs7586879	0.558	rs6718510	chr2:25122323	A/C	cg01884057	chr2:25150051	NA	0.35	6.9	0.53	2.39e-10	Body mass index;
TGCT	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg18876405	chr7:65276391	NA	0.35	5.46	0.44	2.48e-7	Aortic root size;
TGCT	cis	rs938554	0.826	rs7376960	chr4:9970570	A/G	cg11197905	chr4:10459435	ZNF518B	-0.32	-4.44	-0.37	1.97e-5	Blood metabolite levels;
TGCT	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg17971929	chr21:40555470	PSMG1	-0.7	-6.62	-0.51	9.53e-10	Cognitive function;
TGCT	trans	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.89	-10.03	-0.67	1.1e-17	Intelligence (multi-trait analysis);
TGCT	trans	rs2915864	0.800	rs78403069	chr5:141514866	T/C	cg00220413	chr17:7319074	NLGN2	0.47	6.69	0.51	6.88e-10	Facial morphology (factor 20);
TGCT	cis	rs12135062	0.901	rs2651928	chr1:3101722	C/T	cg25382214	chr1:3105252	PRDM16	-0.28	-5.01	-0.41	1.81e-6	Migraine;
TGCT	cis	rs6840360	1.000	rs2007445	chr4:152600370	C/T	cg17479576	chr4:152424074	FAM160A1	-0.52	-5.66	-0.45	9.86e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg13206674	chr6:150067644	NUP43	0.52	4.51	0.38	1.5e-5	Lung cancer;
TGCT	cis	rs1371867	0.839	rs1788186	chr8:101335686	T/C	cg06002616	chr8:101225028	SPAG1	-0.53	-6.21	-0.49	7.16e-9	Atrioventricular conduction;
TGCT	trans	rs9388451	0.537	rs1739383	chr6:126098915	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.79	-9.13	-0.63	1.57e-15	Brugada syndrome;
TGCT	cis	rs1843834	0.838	rs6436506	chr2:225558242	T/C	cg22455342	chr2:225449267	CUL3	0.74	7.25	0.55	3.94e-11	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs17376456	0.569	rs7713956	chr5:93133185	T/C	cg21475434	chr5:93447410	FAM172A	-0.62	-5.06	-0.41	1.45e-6	Diabetic retinopathy;
TGCT	cis	rs7949030	0.620	rs2428551	chr11:62329758	T/A	cg11742103	chr11:62369870	EML3;MTA2	0.6	8.94	0.63	4.65e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs8017423	0.935	rs12880102	chr14:90793526	G/T	cg04374321	chr14:90722782	PSMC1	-0.74	-7.09	-0.54	8.75e-11	Mortality in heart failure;
TGCT	cis	rs13064411	0.696	rs9860549	chr3:113148368	G/A	cg10517650	chr3:113235015	CCDC52	-0.35	-4.69	-0.39	7.18e-6	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs10984561	0.881	rs7032151	chr9:122254047	A/G	cg14242995	chr9:122249943	NA	0.72	5.82	0.46	4.75e-8	Pulmonary function decline;
TGCT	cis	rs1008375	0.932	rs964012	chr4:17619184	A/G	cg18681998	chr4:17616180	MED28	1.0	10.26	0.68	2.93e-18	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	trans	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg17470723	chr8:74884337	TCEB1	0.71	6.77	0.52	4.48e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2836950	0.501	rs4818018	chr21:40694072	C/T	cg17971929	chr21:40555470	PSMG1	-0.52	-4.55	-0.38	1.26e-5	Menarche (age at onset);
TGCT	cis	rs10876993	0.893	rs4760168	chr12:58087737	T/G	cg15848620	chr12:58087721	OS9	-0.72	-5.86	-0.47	3.82e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs7666738	0.830	rs2865981	chr4:99031493	G/A	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs17401966	0.931	rs11121545	chr1:10411211	A/G	cg19773385	chr1:10388646	KIF1B	-0.24	-5.5	-0.44	2.03e-7	Hepatocellular carcinoma;
TGCT	cis	rs7926906	1.000	rs1540170	chr11:90529456	A/G	cg26138821	chr11:89956704	CHORDC1	-0.52	-5.62	-0.45	1.17e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs858239	0.738	rs7807879	chr7:23260588	G/T	cg05602783	chr7:23145260	KLHL7	-0.66	-5.18	-0.42	8.78e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs5750830	0.594	rs9611165	chr22:39775250	A/G	cg02038168	chr22:39784481	NA	-0.64	-5.48	-0.44	2.32e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs10940138	0.830	rs16897180	chr5:67220196	A/C	ch.5.1281357F	chr5:67228439	NA	-0.46	-5.23	-0.42	7.11e-7	Menarche (age at onset);
TGCT	trans	rs3780486	0.846	rs2209948	chr9:33138247	G/A	cg04842962	chr6:43655489	MRPS18A	1.24	15.76	0.82	2.18e-31	IgG glycosylation;
TGCT	cis	rs6840360	0.593	rs7654294	chr4:152690975	T/C	cg22705602	chr4:152727874	NA	-0.34	-5.91	-0.47	3.06e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs6693567	0.507	rs863862	chr1:150352361	T/A	cg09579323	chr1:150459698	TARS2	0.54	4.79	0.4	4.59e-6	Migraine;
TGCT	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7542091	0.704	rs4133950	chr1:210044393	C/G	cg23283495	chr1:209979779	IRF6	0.55	5.47	0.44	2.34e-7	Monobrow;
TGCT	cis	rs637571	0.522	rs606978	chr11:65711517	A/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.61	6.22	0.49	7.07e-9	Eosinophil percentage of white cells;
TGCT	cis	rs12950390	0.893	rs4239165	chr17:45847272	A/T	cg24803719	chr17:45855879	NA	-0.47	-4.75	-0.39	5.6e-6	IgG glycosylation;
TGCT	cis	rs854765	0.663	rs12941550	chr17:17753828	C/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.72	-6.9	-0.53	2.36e-10	Total body bone mineral density;
TGCT	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg02187348	chr16:89574699	SPG7	0.59	6.15	0.48	9.78e-9	Multiple myeloma (IgH translocation);
TGCT	cis	rs79387448	0.701	rs11465584	chr2:102982629	G/A	cg09003973	chr2:102972529	NA	1.47	10.36	0.68	1.69e-18	Gut microbiota (bacterial taxa);
TGCT	cis	rs10114408	0.959	rs7846905	chr9:96642298	T/C	cg13679303	chr9:96623674	NA	-0.35	-4.45	-0.37	1.85e-5	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs896854	0.714	rs6471503	chr8:95990283	G/A	cg13393036	chr8:95962371	TP53INP1	-0.58	-7.97	-0.58	8.83e-13	Type 2 diabetes;
TGCT	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.5	-6.72	-0.52	5.9e-10	Alzheimer's disease;
TGCT	cis	rs6061231	1.000	rs11696991	chr20:60959694	G/T	cg24112000	chr20:60950667	NA	-0.38	-5.49	-0.44	2.22e-7	Colorectal cancer;
TGCT	cis	rs9457247	1.000	rs444988	chr6:167389674	A/T	cg25258033	chr6:167368657	RNASET2	0.2	4.82	0.4	4.03e-6	Crohn's disease;
TGCT	cis	rs7845219	0.525	rs6471501	chr8:95922491	A/G	cg13393036	chr8:95962371	TP53INP1	-0.49	-5.49	-0.44	2.2e-7	Type 2 diabetes;
TGCT	cis	rs1008375	0.966	rs6825133	chr4:17577776	C/T	cg16339924	chr4:17578868	LAP3	0.8	6.96	0.53	1.73e-10	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6700896	0.522	rs6699885	chr1:66159788	C/A	cg14976592	chr1:65886160	LEPROT;LEPR	-0.54	-4.44	-0.37	1.98e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.98	-7.22	-0.54	4.68e-11	Gut microbiome composition (summer);
TGCT	cis	rs9611519	0.590	rs4821980	chr22:41415479	C/G	cg03806693	chr22:41940476	POLR3H	-0.64	-6.09	-0.48	1.29e-8	Neuroticism;
TGCT	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.07	0.82	4.17e-32	Prudent dietary pattern;
TGCT	cis	rs17761864	0.762	rs11658881	chr17:2072949	A/G	cg02171503	chr17:1588363	PRPF8	-0.49	-4.74	-0.39	5.67e-6	Esophageal cancer (squamous cell);
TGCT	cis	rs7917772	0.536	rs17783771	chr10:104410736	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	7.97	0.58	8.86e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs4366490	0.687	rs1939750	chr11:62910271	G/T	cg21002970	chr11:62369079	MTA2	0.71	5.03	0.41	1.66e-6	Conotruncal heart defects;
TGCT	cis	rs10782582	0.609	rs1159215	chr1:76317869	A/T	cg10523679	chr1:76189770	ACADM	-0.5	-4.66	-0.39	7.87e-6	Daytime sleep phenotypes;
TGCT	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg17554472	chr22:41940697	POLR3H	0.49	5.07	0.41	1.38e-6	Vitiligo;
TGCT	cis	rs7937682	0.632	rs14133	chr11:111782697	C/G	cg09085632	chr11:111637200	PPP2R1B	0.8	7.18	0.54	5.74e-11	Primary sclerosing cholangitis;
TGCT	cis	rs62244186	0.541	rs9859879	chr3:44840166	G/A	cg10263370	chr3:44754102	ZNF502	-0.44	-5.39	-0.44	3.36e-7	Depressive symptoms;
TGCT	cis	rs2354432	0.607	rs7523812	chr1:146673489	A/G	cg25205988	chr1:146714368	CHD1L	-1.33	-6.35	-0.5	3.68e-9	Mitochondrial DNA levels;
TGCT	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg18876405	chr7:65276391	NA	0.37	5.89	0.47	3.33e-8	Aortic root size;
TGCT	trans	rs10506458	0.915	rs79133015	chr12:63396838	G/A	cg22491629	chr6:157744540	C6orf35	-0.99	-8.55	-0.61	3.94e-14	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs7666738	0.830	rs7667796	chr4:99071415	G/T	cg18180107	chr4:99064573	C4orf37	-0.57	-5.14	-0.42	1.05e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9372498	0.536	rs17080302	chr6:118854037	A/G	cg07617317	chr6:118971624	C6orf204	0.52	5.55	0.45	1.69e-7	Diastolic blood pressure;
TGCT	cis	rs734999	0.588	rs2843402	chr1:2528682	T/C	cg18854424	chr1:2615690	NA	-0.46	-5.23	-0.43	6.92e-7	Ulcerative colitis;
TGCT	cis	rs11676348	0.846	rs4674257	chr2:218988774	A/G	cg00012203	chr2:219082015	ARPC2	-0.52	-4.98	-0.41	2.08e-6	Ulcerative colitis;
TGCT	cis	rs79057730	0.527	rs35316052	chr7:802954	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.66	6.27	0.49	5.39e-9	Initial pursuit acceleration;
TGCT	cis	rs700590	0.692	rs700589	chr5:88108453	T/A	cg22951263	chr5:87985283	NA	0.56	5.4	0.44	3.24e-7	Educational attainment (years of education);
TGCT	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg04944784	chr2:26401820	FAM59B	0.76	6.24	0.49	6.46e-9	Gut microbiome composition (summer);
TGCT	cis	rs7772486	0.686	rs4895684	chr6:146114023	A/C	cg23711669	chr6:146136114	FBXO30	-0.84	-9.35	-0.64	4.84e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs78487399	0.808	rs6751161	chr2:43752548	G/A	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.78	4.84	0.4	3.8e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs6671200	0.607	rs7528790	chr1:95709074	A/G	cg20701556	chr1:95698924	RWDD3	-0.52	-5.34	-0.43	4.26e-7	Stearic acid (18:0) levels;
TGCT	cis	rs7980687	0.596	rs1727319	chr12:123701353	T/C	cg00376283	chr12:123451042	ABCB9	0.79	6.8	0.52	3.88e-10	Height;Educational attainment;Head circumference (infant);
TGCT	cis	rs6598955	0.671	rs75517917	chr1:26612926	G/T	cg04990556	chr1:26633338	UBXN11	0.64	4.91	0.4	2.78e-6	Obesity-related traits;
TGCT	cis	rs1580019	0.587	rs7806941	chr7:32553319	G/T	cg06627557	chr7:32535165	LSM5;AVL9	1.11	14.04	0.78	2.14e-27	Cognitive ability;
TGCT	cis	rs76455782	1.000	rs58194956	chr4:110131158	A/T	cg23196549	chr4:110480700	CCDC109B	-0.43	-4.83	-0.4	3.93e-6	Common carotid intima-media thickness in HIV negative individuals;
TGCT	cis	rs7909074	0.798	rs10900126	chr10:45386322	G/T	cg05187965	chr10:45406764	TMEM72	-0.25	-5.33	-0.43	4.47e-7	Mean corpuscular volume;
TGCT	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg07507251	chr3:52567010	NT5DC2	0.46	6.68	0.51	7.37e-10	Bipolar disorder;
TGCT	cis	rs9549367	0.789	rs2287251	chr13:113889499	A/G	cg18105134	chr13:113819100	PROZ	-0.34	-5.49	-0.44	2.18e-7	Platelet distribution width;
TGCT	cis	rs7772486	0.875	rs2207785	chr6:146332784	T/G	cg13319975	chr6:146136371	FBXO30	-0.5	-4.48	-0.37	1.67e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1577917	1.000	rs12207610	chr6:86688016	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.22	-0.42	7.27e-7	Response to antipsychotic treatment;
TGCT	cis	rs1023500	0.573	rs2269524	chr22:42475703	T/G	cg05082376	chr22:42548792	NA	0.23	5.43	0.44	2.83e-7	Schizophrenia;
TGCT	cis	rs7184046	0.797	rs13737	chr15:75932129	G/T	cg20655648	chr15:75932815	IMP3	0.61	4.95	0.41	2.33e-6	Height;
TGCT	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg13395646	chr4:1353034	KIAA1530	-0.41	-5.03	-0.41	1.7e-6	Longevity;
TGCT	cis	rs651907	0.535	rs35810977	chr3:101531380	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.31	-6.58	-0.51	1.19e-9	Colorectal cancer;
TGCT	cis	rs854765	0.583	rs7207395	chr17:17819335	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	7.91	0.58	1.2e-12	Total body bone mineral density;
TGCT	cis	rs7772486	0.875	rs2814871	chr6:146312274	G/T	cg05347473	chr6:146136440	FBXO30	0.52	4.92	0.4	2.7e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg06618935	chr21:46677482	NA	-0.37	-5.81	-0.46	5.06e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2120019	0.567	rs72625793	chr15:75207083	A/G	cg09165964	chr15:75287851	SCAMP5	-0.89	-6.78	-0.52	4.42e-10	Blood trace element (Zn levels);
TGCT	cis	rs2361718	0.603	rs12951255	chr17:78085597	A/G	cg09238746	chr17:78121135	EIF4A3	-0.63	-5.71	-0.46	8.05e-8	Yeast infection;
TGCT	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg24675658	chr1:53192096	ZYG11B	0.7	8.11	0.59	4.16e-13	Monocyte count;
TGCT	cis	rs8056742	0.643	rs34168095	chr16:85046750	C/G	cg00229868	chr16:85520891	NA	0.4	5.09	0.42	1.3e-6	Amyotrophic lateral sclerosis;
TGCT	cis	rs7120118	0.517	rs78310113	chr11:47293553	T/G	cg13308137	chr11:47528955	CUGBP1	0.33	5.19	0.42	8.16e-7	HDL cholesterol;
TGCT	cis	rs6570726	0.935	rs413916	chr6:145831400	T/C	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg24829409	chr8:58192753	C8orf71	-0.56	-5.29	-0.43	5.34e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2464469	0.631	rs2704218	chr15:58345001	A/T	cg12031962	chr15:58353849	ALDH1A2	-0.34	-4.89	-0.4	3.1e-6	Barrett's esophagus  or Esophageal adenocarcinoma;
TGCT	cis	rs10501293	0.703	rs4755684	chr11:42988175	C/T	cg03447554	chr11:43094025	NA	0.46	6.58	0.51	1.2e-9	Cognitive performance;
TGCT	cis	rs10949834	0.504	rs13238778	chr7:73567709	G/A	cg07137043	chr7:73588983	EIF4H	-0.74	-5.38	-0.43	3.65e-7	Verbal memory performance (residualized delayed recall change);
TGCT	cis	rs7822232	0.908	rs4977164	chr8:145144912	T/G	cg06495924	chr8:145149574	CYC1	-1.04	-4.49	-0.37	1.6e-5	Blood metabolite levels;
TGCT	cis	rs904251	0.861	rs2776877	chr6:37487135	G/A	cg08126542	chr6:37504118	NA	-0.44	-5.94	-0.47	2.73e-8	Cognitive performance;
TGCT	cis	rs79057730	0.599	rs4720893	chr7:804434	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.76	5.84	0.46	4.31e-8	Initial pursuit acceleration;
TGCT	cis	rs10883723	0.810	rs6584508	chr10:104258567	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.0	7.42	0.55	1.64e-11	Gut microbiome composition (summer);
TGCT	cis	rs11077998	0.901	rs4789798	chr17:80531643	C/G	cg10255544	chr17:80519551	FOXK2	0.23	4.44	0.37	1.96e-5	Reticulocyte fraction of red cells;
TGCT	cis	rs7592578	0.766	rs62181052	chr2:191387858	A/G	cg11845111	chr2:191398756	TMEM194B	-0.43	-4.63	-0.38	9.26e-6	Diastolic blood pressure;
TGCT	cis	rs7647973	1.000	rs74471041	chr3:49542543	T/G	cg06212747	chr3:49208901	KLHDC8B	-0.57	-4.56	-0.38	1.21e-5	Menarche (age at onset);
TGCT	cis	rs12477438	0.765	rs56167745	chr2:99600478	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-5.43	-0.44	2.89e-7	Chronic sinus infection;
TGCT	cis	rs826838	1.000	rs12366971	chr12:38737687	T/G	cg13010199	chr12:38710504	ALG10B	0.83	6.88	0.53	2.58e-10	Heart rate;
TGCT	cis	rs6684514	1.000	rs12141236	chr1:156302575	A/C	cg20302342	chr1:156215951	PAQR6	0.35	4.74	0.39	5.77e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs10256972	0.626	rs62433138	chr7:1050877	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.47	-5.54	-0.45	1.7e-7	Longevity;Endometriosis;
TGCT	cis	rs1008375	1.000	rs1860596	chr4:17660082	C/T	cg16339924	chr4:17578868	LAP3	0.61	5.11	0.42	1.16e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6429082	0.783	rs291364	chr1:235687179	A/G	cg26050004	chr1:235667680	B3GALNT2	0.64	5.99	0.47	2.13e-8	Adiposity;
TGCT	cis	rs6754311	0.731	rs309168	chr2:136670298	C/T	cg07169764	chr2:136633963	MCM6	0.62	5.75	0.46	6.66e-8	Mosquito bite size;
TGCT	cis	rs8056446	1.000	rs12716853	chr16:78188800	A/G	cg00663719	chr16:78231199	WWOX	0.24	4.44	0.37	1.93e-5	Pulmonary function (smoking interaction);
TGCT	cis	rs7681440	0.715	rs17016305	chr4:90791381	A/G	cg10208370	chr4:90758469	SNCA	-0.54	-5.1	-0.42	1.25e-6	Dementia with Lewy bodies;
TGCT	cis	rs2153535	0.580	rs9406162	chr6:8466196	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs4689388	0.926	rs11725500	chr4:6293919	C/G	cg14416269	chr4:6271139	WFS1	0.37	4.9	0.4	2.95e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs10504229	0.906	rs2270608	chr8:58194688	T/C	cg08280861	chr8:58055591	NA	0.35	4.47	0.37	1.72e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs1153858	1.000	rs12437887	chr15:45669094	G/A	cg14582100	chr15:45693742	SPATA5L1	0.49	5.73	0.46	7.14e-8	Homoarginine levels;
TGCT	cis	rs11931598	0.783	rs28385900	chr4:7050836	C/T	cg26116260	chr4:7069785	GRPEL1	0.54	4.8	0.4	4.54e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs66887589	0.616	rs11098498	chr4:120187119	T/C	cg24670566	chr4:120433619	PDE5A	0.21	4.57	0.38	1.14e-5	Diastolic blood pressure;
TGCT	cis	rs6867032	0.874	rs4975786	chr5:2004724	T/C	cg26168224	chr5:2018326	NA	-0.38	-6.03	-0.48	1.72e-8	Gut microbiome composition (winter);
TGCT	cis	rs7772486	0.754	rs4895682	chr6:146062861	G/A	cg23711669	chr6:146136114	FBXO30	-0.97	-11.02	-0.7	4.06e-20	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7646881	0.504	rs7617304	chr3:158463101	C/T	cg18349298	chr3:158450550	RARRES1	0.41	4.49	0.37	1.64e-5	Tetralogy of Fallot;
TGCT	cis	rs8062405	1.000	rs62037365	chr16:28868962	C/G	cg09754948	chr16:28834200	ATXN2L	0.59	4.45	0.37	1.91e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs524023	1.000	rs537246	chr11:64360630	G/A	cg07733098	chr11:64478343	NRXN2	-0.31	-4.67	-0.39	7.7e-6	Urate levels in obese individuals;
TGCT	cis	rs9457247	0.935	rs1794697	chr6:167395410	C/T	cg25258033	chr6:167368657	RNASET2	0.18	4.49	0.37	1.63e-5	Crohn's disease;
TGCT	cis	rs10186029	0.680	rs13007271	chr2:213937767	G/C	cg08319019	chr2:214017104	IKZF2	0.63	5.81	0.46	5.05e-8	Systemic sclerosis;
TGCT	cis	rs2836974	0.897	rs2776308	chr21:40715175	A/G	cg11644478	chr21:40555479	PSMG1	0.87	7.77	0.57	2.59e-12	Cognitive function;
TGCT	cis	rs3733585	0.673	rs10000983	chr4:9951606	T/C	cg00071950	chr4:10020882	SLC2A9	-0.55	-6.46	-0.5	2.14e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7192750	0.563	rs12921084	chr16:71880965	T/C	cg06353428	chr16:71660113	MARVELD3	0.83	7.37	0.55	2.07e-11	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs6582630	0.502	rs3902522	chr12:38271203	T/C	cg26384229	chr12:38710491	ALG10B	0.84	7.33	0.55	2.58e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs9522267	0.535	rs9522304	chr13:112237316	C/T	cg10483660	chr13:112241077	NA	-0.27	-4.61	-0.38	9.78e-6	Hepatitis;
TGCT	cis	rs595982	0.546	rs9941490	chr19:49396737	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.41	-5.3	-0.43	5.08e-7	Red cell distribution width;
TGCT	cis	rs9372498	0.908	rs72967573	chr6:118696532	C/T	cg18833306	chr6:118973337	C6orf204	-0.61	-4.81	-0.4	4.28e-6	Diastolic blood pressure;
TGCT	cis	rs7819412	0.511	rs10108511	chr8:11435516	T/C	cg21775007	chr8:11205619	TDH	-0.53	-4.97	-0.41	2.16e-6	Triglycerides;
TGCT	cis	rs2153535	0.580	rs2225766	chr6:8481833	G/A	cg07606381	chr6:8435919	SLC35B3	0.55	5.17	0.42	9.11e-7	Motion sickness;
TGCT	cis	rs8013055	0.796	rs11628497	chr14:105970789	C/T	cg25008857	chr14:105974488	NA	0.27	4.63	0.38	8.92e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg07167872	chr1:205819463	PM20D1	0.57	7.37	0.55	2.12e-11	Menarche (age at onset);
TGCT	cis	rs7552404	0.696	rs12140121	chr1:76455001	A/G	cg03433033	chr1:76189801	ACADM	0.73	6.52	0.51	1.61e-9	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs12367572	0.965	rs10880696	chr12:45234989	A/G	cg04608330	chr12:45269318	NELL2	0.55	5.52	0.44	1.88e-7	Gut microbiome composition (summer);
TGCT	cis	rs6733011	0.578	rs12712038	chr2:99497710	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-4.68	-0.39	7.53e-6	Bipolar disorder;
TGCT	trans	rs1814175	0.647	rs1404157	chr11:49917301	G/C	cg03929089	chr4:120376271	NA	-0.59	-6.76	-0.52	4.86e-10	Height;
TGCT	cis	rs1552244	0.554	rs7349576	chr3:10050893	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.33	-4.95	-0.41	2.39e-6	Alzheimer's disease;
TGCT	cis	rs9393692	0.620	rs6908402	chr6:26293014	A/T	cg05868516	chr6:26286170	HIST1H4H	0.5	4.55	0.38	1.29e-5	Educational attainment;
TGCT	cis	rs7655441	0.964	rs6534702	chr4:80930417	G/T	cg02241357	chr4:80885279	ANTXR2	-0.23	-4.45	-0.37	1.92e-5	Neutrophil percentage of white cells;
TGCT	cis	rs7731657	0.537	rs4705907	chr5:130191437	T/A	cg08523029	chr5:130500466	HINT1	-0.55	-4.57	-0.38	1.15e-5	Fasting plasma glucose;
TGCT	cis	rs7582180	0.629	rs11693471	chr2:100948062	G/A	cg14675211	chr2:100938903	LONRF2	0.5	4.73	0.39	5.96e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs910316	1.000	rs2268617	chr14:75608728	G/A	cg11812906	chr14:75593930	NEK9	0.73	7.23	0.54	4.34e-11	Height;
TGCT	cis	rs1538970	0.962	rs2153609	chr1:45814058	A/G	cg05343316	chr1:45956843	TESK2	0.66	5.54	0.45	1.74e-7	Platelet count;
TGCT	cis	rs9611565	0.592	rs5758405	chr22:42076381	C/A	cg03806693	chr22:41940476	POLR3H	1.06	11.74	0.73	7.15e-22	Vitiligo;
TGCT	cis	rs3008870	0.920	rs3008860	chr1:67391003	G/C	cg03991309	chr1:68237761	GNG12	0.27	4.56	0.38	1.23e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs2455799	0.613	rs4685258	chr3:15792315	G/A	cg16303742	chr3:15540471	COLQ	-0.25	-4.88	-0.4	3.18e-6	Mean platelet volume;
TGCT	cis	rs11252926	0.598	rs4881256	chr10:453831	T/A	cg13477178	chr10:375248	DIP2C	-0.25	-4.63	-0.38	9.23e-6	Psychosis in Alzheimer's disease;
TGCT	trans	rs1496653	0.602	rs71322190	chr3:23482493	G/A	cg02770683	chr12:57597238	LRP1	0.38	6.89	0.53	2.53e-10	Type 2 diabetes;
TGCT	cis	rs2235642	0.893	rs2076442	chr16:1591112	G/T	cg07341220	chr16:1583899	IFT140;TMEM204	-0.3	-4.7	-0.39	6.89e-6	Coronary artery disease;
TGCT	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg02891314	chr5:179741120	GFPT2	-0.41	-7.16	-0.54	6.21e-11	Height;
TGCT	cis	rs9534288	0.843	rs2094245	chr13:46602207	T/C	cg15192986	chr13:46630673	CPB2	-0.52	-7.53	-0.56	9.22e-12	Blood protein levels;
TGCT	cis	rs590121	0.876	rs649257	chr11:75279846	C/T	cg26104986	chr11:75275303	SERPINH1	-0.24	-4.55	-0.38	1.25e-5	Coronary artery disease;
TGCT	cis	rs6582630	0.519	rs10880629	chr12:38533611	T/G	cg13010199	chr12:38710504	ALG10B	0.62	4.98	0.41	2.12e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs986417	1.000	rs986417	chr14:60858761	C/T	cg27398547	chr14:60952738	C14orf39	-1.25	-8.18	-0.59	2.78e-13	Gut microbiota (bacterial taxa);
TGCT	cis	rs7226408	0.948	rs72883576	chr18:34383714	C/T	cg06757138	chr18:34340585	FHOD3	0.26	4.79	0.4	4.62e-6	Obesity-related traits;
TGCT	cis	rs6570726	0.791	rs383841	chr6:145888329	G/T	cg05347473	chr6:146136440	FBXO30	-0.54	-5.15	-0.42	1.01e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2303745	0.589	rs1864116	chr19:17393015	C/T	cg04248312	chr19:17393744	ANKLE1	-0.33	-5.55	-0.45	1.62e-7	Systemic lupus erythematosus;
TGCT	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg03264133	chr6:25882463	NA	-0.61	-6.51	-0.5	1.69e-9	Blood metabolite levels;
TGCT	cis	rs11858159	0.525	rs7497832	chr15:24829541	C/G	cg08449389	chr15:24672285	NA	-0.41	-4.79	-0.4	4.61e-6	Platelet thrombus formation;
TGCT	cis	rs7621025	0.500	rs71630059	chr3:136581611	G/A	cg15507776	chr3:136538369	TMEM22	-0.66	-5.68	-0.45	9e-8	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
TGCT	cis	rs1497406	0.744	rs12057222	chr1:16508534	A/G	cg20430773	chr1:16534157	ARHGEF19	0.54	6.27	0.49	5.36e-9	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs8177179	0.666	rs4075352	chr3:133468012	A/G	cg08048268	chr3:133502702	NA	-0.41	-5.32	-0.43	4.68e-7	Iron status biomarkers (transferrin levels);
TGCT	cis	rs6840360	1.000	rs2278304	chr4:152593409	C/T	cg17479576	chr4:152424074	FAM160A1	0.47	4.92	0.4	2.64e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-6.98	-0.53	1.57e-10	Gut microbiome composition (summer);
TGCT	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg06238570	chr21:40685208	BRWD1	-0.82	-8.76	-0.62	1.19e-14	Cognitive function;
TGCT	cis	rs7582180	0.629	rs13010911	chr2:100953390	G/C	cg08017756	chr2:100939284	LONRF2	-0.3	-4.87	-0.4	3.27e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg27535305	chr1:53392650	SCP2	-0.28	-5.42	-0.44	2.98e-7	Monocyte count;
TGCT	trans	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg23505145	chr19:12996616	KLF1	0.79	8.3	0.6	1.47e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg18402987	chr7:1209562	NA	0.37	4.52	0.38	1.42e-5	Longevity;Endometriosis;
TGCT	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg22963979	chr7:1858916	MAD1L1	-0.44	-7.12	-0.54	7.59e-11	Bipolar disorder and schizophrenia;
TGCT	cis	rs13188771	0.690	rs12521514	chr5:100898219	G/A	cg10455971	chr5:101119566	NA	0.44	4.45	0.37	1.87e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs4478858	0.684	rs2271074	chr1:31734841	C/T	cg07478791	chr1:31886160	SERINC2	-0.52	-5.02	-0.41	1.73e-6	Alcohol dependence;
TGCT	cis	rs7267979	0.718	rs2983489	chr20:25244120	C/A	cg16686733	chr20:25566563	NINL	0.51	5.1	0.42	1.22e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs67311347	1.000	rs13095055	chr3:40505666	G/T	cg13683864	chr3:40499215	RPL14	1.14	12.22	0.74	4.89e-23	Renal cell carcinoma;
TGCT	cis	rs7666738	0.791	rs4699324	chr4:98967496	G/A	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9473924	0.542	rs2857514	chr6:50811283	C/T	cg14470998	chr6:50812995	TFAP2B	1.34	6.82	0.52	3.52e-10	Body mass index;
TGCT	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg00343986	chr7:65444356	GUSB	0.23	5.14	0.42	1.06e-6	Aortic root size;
TGCT	cis	rs1577917	0.874	rs11756621	chr6:86740063	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.43	-0.44	2.86e-7	Response to antipsychotic treatment;
TGCT	cis	rs1018836	0.637	rs6471113	chr8:91519735	A/G	cg16814680	chr8:91681699	NA	-0.65	-6.42	-0.5	2.58e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs62244186	0.715	rs10212378	chr3:44667286	C/G	cg15687855	chr3:44754131	ZNF502	-0.4	-4.77	-0.39	5.01e-6	Depressive symptoms;
TGCT	cis	rs2172802	0.961	rs7690595	chr4:62464414	A/G	cg04118610	chr4:62707027	LPHN3	-0.43	-5.1	-0.42	1.21e-6	Partial epilepsies;
TGCT	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg22535103	chr8:58192502	C8orf71	-0.43	-5.5	-0.44	2.09e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.69	4.91	0.4	2.75e-6	Platelet count;
TGCT	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg06112835	chr11:68658793	MRPL21	0.41	6.7	0.52	6.45e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9311474	0.652	rs352158	chr3:52217704	C/T	cg07507251	chr3:52567010	NT5DC2	0.36	4.6	0.38	1.03e-5	Electroencephalogram traits;
TGCT	cis	rs933688	1.000	rs6862125	chr5:90724598	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.01	8.65	0.61	2.18e-14	Smoking behavior;
TGCT	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg13395646	chr4:1353034	KIAA1530	-0.36	-4.78	-0.39	4.85e-6	Obesity-related traits;
TGCT	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg02187348	chr16:89574699	SPG7	0.64	7.09	0.54	9.2e-11	Multiple myeloma (IgH translocation);
TGCT	cis	rs7582180	0.663	rs2309794	chr2:100954270	G/A	cg14675211	chr2:100938903	LONRF2	0.49	4.89	0.4	3.02e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg02038168	chr22:39784481	NA	-0.76	-6.36	-0.5	3.47e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs561341	0.700	rs886223	chr17:30229877	G/T	cg13647721	chr17:30228624	UTP6	0.6	5.33	0.43	4.5e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs2637266	0.967	rs12254242	chr10:78352934	T/C	cg18941641	chr10:78392320	NA	0.42	5.2	0.42	8.09e-7	Pulmonary function;
TGCT	cis	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg20637647	chr7:64974828	NA	1.0	5.59	0.45	1.4e-7	Diabetic kidney disease;
TGCT	cis	rs902774	0.554	rs4503623	chr12:53353759	T/C	cg05393297	chr12:53359155	NA	-0.74	-8.0	-0.58	7.43e-13	Prostate cancer;
TGCT	cis	rs1552244	0.554	rs34391585	chr3:9999208	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.31	-4.82	-0.4	4.12e-6	Alzheimer's disease;
TGCT	cis	rs637571	0.544	rs12361552	chr11:65701204	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.5	-4.82	-0.4	4.04e-6	Eosinophil percentage of white cells;
TGCT	cis	rs56399783	0.901	rs6967664	chr7:2816384	A/G	cg19731401	chr7:2775893	GNA12	0.35	4.91	0.4	2.76e-6	Childhood ear infection;
TGCT	cis	rs11809207	0.810	rs17356937	chr1:26504036	G/A	cg03844060	chr1:26490628	NA	0.28	5.07	0.41	1.43e-6	Height;
TGCT	cis	rs9467711	0.606	rs9358939	chr6:26416787	C/G	cg16898833	chr6:26189333	HIST1H4D	1.12	5.36	0.43	3.91e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg18876405	chr7:65276391	NA	-0.36	-5.41	-0.44	3.12e-7	Aortic root size;
TGCT	cis	rs9611565	0.649	rs2064189	chr22:42127999	A/G	cg06634786	chr22:41940651	POLR3H	0.81	7.59	0.56	6.75e-12	Vitiligo;
TGCT	cis	rs10504229	1.000	rs73591706	chr8:58195633	C/T	cg21724239	chr8:58056113	NA	0.38	4.76	0.39	5.41e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg16325326	chr1:53192061	ZYG11B	-0.71	-8.81	-0.62	9.22e-15	Monocyte count;
TGCT	cis	rs10484885	0.878	rs17763820	chr6:90569634	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.47	-4.58	-0.38	1.11e-5	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs11822910	0.871	rs2581928	chr11:57202790	A/G	cg00522883	chr11:57194120	SLC43A3	-0.33	-4.66	-0.39	7.97e-6	Platelet distribution width;
TGCT	cis	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg02503808	chr4:7069936	GRPEL1	-0.9	-7.39	-0.55	1.93e-11	Monocyte percentage of white cells;
TGCT	cis	rs9443645	0.838	rs9350800	chr6:79729489	A/C	cg09184832	chr6:79620586	NA	-0.48	-5.34	-0.43	4.21e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7258465	0.931	rs11673604	chr19:18540988	T/C	cg06462663	chr19:18546047	ISYNA1	0.2	4.7	0.39	6.89e-6	Breast cancer;
TGCT	cis	rs2153535	0.580	rs1115078	chr6:8449638	G/A	cg07606381	chr6:8435919	SLC35B3	0.53	5.02	0.41	1.79e-6	Motion sickness;
TGCT	cis	rs4663866	0.908	rs2304670	chr2:239165636	C/T	cg17283117	chr2:239148619	HES6	1.0	4.58	0.38	1.1e-5	Irritable bowel syndrome;
TGCT	cis	rs9905704	0.647	rs2108435	chr17:57102133	T/C	cg12560992	chr17:57184187	TRIM37	-0.58	-5.33	-0.43	4.39e-7	Testicular germ cell tumor;
TGCT	cis	rs59721556	0.655	rs2364581	chr14:78120752	A/G	cg04906283	chr14:77965859	ISM2	0.4	4.5	0.37	1.53e-5	Response to paliperidone in schizophrenia (positive Marder score);Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (CGI-S score);Red cell distribution width;Response to paliperidone in schizophrenia (Multivariate);
TGCT	cis	rs7267979	1.000	rs4815405	chr20:25317492	T/C	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7714584	1.000	rs2344181	chr5:150262574	T/G	cg22134413	chr5:150180641	NA	0.78	6.12	0.48	1.16e-8	Crohn's disease;
TGCT	cis	rs10875595	0.836	rs1363450	chr5:140658363	A/T	cg24830062	chr5:140700576	TAF7	0.61	5.2	0.42	8.12e-7	Pulmonary function decline;
TGCT	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg10047753	chr17:41438598	NA	0.96	9.6	0.65	1.16e-16	Menopause (age at onset);
TGCT	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg00814883	chr7:100076585	TSC22D4	-0.85	-8.62	-0.61	2.62e-14	Platelet count;
TGCT	cis	rs5760092	0.842	rs5751763	chr22:24247793	T/C	cg07154950	chr22:24370586	NA	-0.21	-4.53	-0.38	1.39e-5	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs7223966	1.000	rs11079509	chr17:61762148	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	4.83	0.4	3.93e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs4820539	0.502	rs4820543	chr22:23542535	A/G	cg21100191	chr22:23484243	RTDR1	0.74	7.63	0.57	5.45e-12	Bone mineral density;
TGCT	cis	rs7308116	0.935	rs7136201	chr12:108191069	A/G	cg19508191	chr12:109124361	CORO1C	-0.46	-4.59	-0.38	1.05e-5	Pelvic organ prolapse (moderate/severe);
TGCT	cis	rs2288073	0.965	rs13387930	chr2:24414400	A/G	cg02683114	chr2:24398427	C2orf84	-0.25	-5.67	-0.45	9.72e-8	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs6969780	0.630	rs10238095	chr7:27196643	A/G	cg04317399	chr7:27170313	HOXA4	-0.45	-4.85	-0.4	3.61e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs1568889	1.000	rs12797155	chr11:28290866	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.81	7.87	0.58	1.54e-12	Bipolar disorder;
TGCT	cis	rs2997447	0.761	rs17257113	chr1:26449595	G/A	cg03844060	chr1:26490628	NA	0.28	4.57	0.38	1.17e-5	QRS complex (12-leadsum);
TGCT	cis	rs2639990	1.000	rs1702831	chr18:72897368	C/A	cg03972071	chr18:72917163	ZADH2	0.79	5.47	0.44	2.42e-7	Vascular endothelial growth factor levels;
TGCT	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg11301795	chr4:187892539	NA	-0.32	-4.81	-0.4	4.32e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9357506	0.967	rs1891036	chr6:46323630	T/A	cg21115430	chr6:46460003	NA	-0.24	-4.77	-0.39	5.02e-6	Body mass index;
TGCT	cis	rs3008870	1.000	rs12137403	chr1:67437043	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.05	-11.32	-0.71	7.78e-21	Lymphocyte percentage of white cells;
TGCT	cis	rs2235642	0.928	rs9932984	chr16:1605051	A/G	cg08296037	chr16:1584118	IFT140;TMEM204	-0.31	-5.47	-0.44	2.39e-7	Coronary artery disease;
TGCT	cis	rs36051895	0.664	rs884132	chr9:5114522	G/A	cg02405213	chr9:5042618	JAK2	-0.69	-9.14	-0.63	1.54e-15	Pediatric autoimmune diseases;
TGCT	cis	rs9291683	0.588	rs12506364	chr4:10023448	C/T	cg00071950	chr4:10020882	SLC2A9	0.7	9.52	0.65	1.86e-16	Bone mineral density;
TGCT	cis	rs2956278	0.717	rs2947125	chr12:84687344	G/A	cg25678815	chr12:85673915	ALX1	-0.53	-4.76	-0.39	5.4e-6	Depressive symptoms;Depressive symptoms (multi-trait analysis);
TGCT	cis	rs4499344	0.556	rs865659	chr19:33139967	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.82	8.26	0.6	1.84e-13	Mean platelet volume;
TGCT	cis	rs7666738	0.830	rs3846444	chr4:99032888	T/C	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12188164	0.965	rs72717415	chr5:430059	G/A	cg21144161	chr5:423903	AHRR	0.26	4.93	0.4	2.59e-6	Cystic fibrosis severity;
TGCT	cis	rs6076065	0.513	rs13037663	chr20:23425812	A/T	cg11657817	chr20:23433608	CST11	0.29	4.75	0.39	5.44e-6	Facial morphology (factor 15, philtrum width);
TGCT	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg00343986	chr7:65444356	GUSB	0.23	5.13	0.42	1.1e-6	Aortic root size;
TGCT	cis	rs2933343	0.601	rs1680758	chr3:128594897	T/C	cg11901034	chr3:128598214	ACAD9	-0.66	-6.11	-0.48	1.2e-8	IgG glycosylation;
TGCT	cis	rs7582180	0.544	rs13026570	chr2:100939498	A/C	cg08017756	chr2:100939284	LONRF2	-0.3	-4.94	-0.41	2.43e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7635838	0.684	rs2606762	chr3:11343889	G/C	cg00170343	chr3:11313890	ATG7	0.62	6.09	0.48	1.28e-8	HDL cholesterol;
TGCT	cis	rs4950928	0.712	rs7518666	chr1:203163590	C/T	cg17014757	chr1:203156097	CHI3L1	-0.38	-4.75	-0.39	5.55e-6	YKL-40 levels;
TGCT	cis	rs9527	0.590	rs11191513	chr10:104772984	T/G	cg04362960	chr10:104952993	NT5C2	0.65	5.54	0.45	1.73e-7	Arsenic metabolism;
TGCT	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg16325326	chr1:53192061	ZYG11B	0.59	6.41	0.5	2.81e-9	Monocyte count;
TGCT	cis	rs11577318	0.853	rs12728971	chr1:26626612	C/T	cg12733254	chr1:26682999	NA	-0.2	-4.45	-0.37	1.89e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg12311346	chr5:56204834	C5orf35	-0.59	-6.14	-0.48	1.02e-8	Coronary artery disease;
TGCT	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg10802521	chr3:52805072	NEK4	-0.78	-10.0	-0.67	1.26e-17	Electroencephalogram traits;
TGCT	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-6.74	-0.52	5.26e-10	Alzheimer's disease;
TGCT	cis	rs3806843	0.576	rs246028	chr5:140333513	C/T	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg03609598	chr5:56110824	MAP3K1	0.58	4.75	0.39	5.54e-6	Initial pursuit acceleration;
TGCT	cis	rs9788682	1.000	rs7181245	chr15:78814389	C/T	cg06917634	chr15:78832804	PSMA4	-0.71	-5.22	-0.42	7.38e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs9790314	0.586	rs1839491	chr3:161126429	C/A	cg03342759	chr3:160939853	NMD3	-0.57	-5.94	-0.47	2.64e-8	Morning vs. evening chronotype;
TGCT	cis	rs317689	0.718	rs315122	chr12:69771073	G/T	cg20891283	chr12:69753455	YEATS4	0.55	4.62	0.38	9.53e-6	Response to diuretic therapy;
TGCT	cis	rs72615157	0.645	rs76281814	chr7:99846414	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.69	5.32	0.43	4.67e-7	Lung function (FEV1/FVC);
TGCT	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	7.4	0.55	1.78e-11	Schizophrenia;
TGCT	cis	rs12510870	0.599	rs7665972	chr4:74453210	G/A	cg05868023	chr4:75230803	EREG	-0.55	-4.7	-0.39	6.93e-6	Iris color (b* coordinate);
TGCT	cis	rs7424096	0.719	rs3770772	chr2:37192607	T/C	cg14987922	chr2:37194071	STRN	0.59	5.15	0.42	9.86e-7	High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs4253772	0.550	rs9615953	chr22:46731024	C/G	cg24881330	chr22:46731750	TRMU	0.96	4.79	0.4	4.65e-6	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs36051895	0.664	rs10974960	chr9:5095842	G/A	cg02405213	chr9:5042618	JAK2	-0.77	-10.84	-0.7	1.15e-19	Pediatric autoimmune diseases;
TGCT	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.71	0.39	6.53e-6	Prudent dietary pattern;
TGCT	cis	rs12780845	0.540	rs3780962	chr10:17193346	A/G	cg01003015	chr10:17271136	VIM	-0.62	-5.77	-0.46	5.84e-8	Homocysteine levels;
TGCT	cis	rs886126	0.650	rs2339718	chr12:111702646	A/G	cg10833066	chr12:111807467	FAM109A	0.36	5.74	0.46	6.99e-8	Coronary heart disease;
TGCT	cis	rs7216064	0.953	rs1599859	chr17:65837193	C/G	cg12091567	chr17:66097778	LOC651250	-0.87	-6.85	-0.52	3.1e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs78487399	0.710	rs72879290	chr2:43633268	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-4.87	-0.4	3.39e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs2456568	0.548	rs7113080	chr11:93657520	G/A	cg26875233	chr11:93583750	C11orf90	-0.43	-5.36	-0.43	3.96e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	trans	rs17685	0.712	rs6953342	chr7:75776753	T/C	cg19862616	chr7:65841803	NCRNA00174	0.53	9.19	0.64	1.13e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs478304	0.934	rs474483	chr11:65520060	T/G	cg27068330	chr11:65405492	SIPA1	0.75	7.57	0.56	7.2e-12	Acne (severe);
TGCT	cis	rs10894604	0.600	rs4486641	chr11:132705848	G/A	cg16919708	chr11:133023150	OPCML	-0.5	-4.55	-0.38	1.25e-5	Waist-hip ratio;
TGCT	cis	rs908922	0.542	rs4845785	chr1:152510143	C/T	cg20991723	chr1:152506922	NA	0.45	6.16	0.48	9.53e-9	Hair morphology;
TGCT	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.43	4.64	0.38	8.73e-6	Menopause (age at onset);
TGCT	cis	rs9682041	1.000	rs6773095	chr3:170082181	A/G	cg11886554	chr3:170076028	SKIL	0.83	6.42	0.5	2.66e-9	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs877282	0.891	rs12767043	chr10:797943	C/T	cg17470449	chr10:769945	NA	0.3	4.72	0.39	6.34e-6	Uric acid levels;
TGCT	cis	rs9486715	1.000	rs9486725	chr6:97061159	C/T	cg06623918	chr6:96969491	KIAA0776	-1.12	-15.49	-0.81	8.72e-31	Headache;
TGCT	cis	rs6964587	1.000	rs12536529	chr7:91684086	C/T	cg22709100	chr7:91322751	NA	-0.28	-4.6	-0.38	1.01e-5	Breast cancer;
TGCT	cis	rs6450176	0.909	rs67199213	chr5:53290648	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.49	-4.59	-0.38	1.09e-5	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs909674	0.909	rs1557541	chr22:39851970	C/A	cg11247378	chr22:39784982	NA	-0.71	-8.43	-0.6	7.29e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs9436747	0.615	rs3828038	chr1:66053620	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.53	4.7	0.39	6.85e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs7267979	0.844	rs6083824	chr20:25363057	G/A	cg03522245	chr20:25566470	NINL	-0.55	-5.55	-0.45	1.68e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7044106	0.762	rs1547268	chr9:123408688	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.62	6.6	0.51	1.08e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs35160687	0.901	rs11127026	chr2:86531748	C/T	cg12542933	chr2:85804724	VAMP8	0.41	4.9	0.4	2.97e-6	Night sleep phenotypes;
TGCT	cis	rs7666738	0.791	rs11730069	chr4:98945772	A/G	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs968451	0.789	rs1003644	chr22:39676744	G/A	cg17798944	chr22:39715225	SNORD43;RPL3	0.74	7.37	0.55	2.13e-11	Primary biliary cholangitis;
TGCT	cis	rs9435341	0.929	rs1730865	chr1:107605611	A/C	cg09367891	chr1:107599246	PRMT6	0.59	4.91	0.4	2.85e-6	Facial morphology (factor 21, depth of nasal alae);
TGCT	cis	rs9388451	0.626	rs3734637	chr6:126081319	G/T	cg05901451	chr6:126070800	HEY2	-0.99	-12.54	-0.75	8.6e-24	Brugada syndrome;
TGCT	cis	rs2268241	0.877	rs9975473	chr21:34776441	T/G	cg14850771	chr21:34775459	IFNGR2	0.59	4.58	0.38	1.09e-5	Obesity-related traits;
TGCT	cis	rs921968	0.643	rs1850169	chr2:219487299	A/T	cg02176678	chr2:219576539	TTLL4	0.37	5.31	0.43	5e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs9457247	0.967	rs2769355	chr6:167380493	G/A	cg23791538	chr6:167370224	RNASET2	0.5	4.98	0.41	2.08e-6	Crohn's disease;
TGCT	cis	rs9611565	0.525	rs9611548	chr22:41704143	G/T	cg13695892	chr22:41940480	POLR3H	-0.67	-6.5	-0.5	1.74e-9	Vitiligo;
TGCT	cis	rs4478858	0.684	rs12135540	chr1:31764693	G/A	cg07478791	chr1:31886160	SERINC2	-0.48	-4.6	-0.38	1.05e-5	Alcohol dependence;
TGCT	cis	rs9291683	0.609	rs36084205	chr4:10028678	A/C	cg11266682	chr4:10021025	SLC2A9	0.66	9.54	0.65	1.61e-16	Bone mineral density;
TGCT	cis	rs8062405	0.964	rs7193733	chr16:28875482	A/G	cg09754948	chr16:28834200	ATXN2L	0.59	4.45	0.37	1.91e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs8103278	0.507	rs4802276	chr19:46260748	T/C	cg14061069	chr19:46274453	DMPK	0.6	10.08	0.67	8.3e-18	Coronary artery disease;
TGCT	cis	rs6540559	0.673	rs6540564	chr1:210019910	T/C	cg21951975	chr1:209979733	IRF6	0.64	4.82	0.4	4.12e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs8013055	0.796	rs8005568	chr14:105971794	A/G	cg25008857	chr14:105974488	NA	0.27	4.52	0.38	1.43e-5	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg03351412	chr1:154909251	PMVK	0.53	4.93	0.4	2.6e-6	Prostate cancer;
TGCT	cis	rs6500602	0.826	rs9932461	chr16:4454170	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.44	5.61	0.45	1.27e-7	Schizophrenia;
TGCT	cis	rs929354	0.553	rs34498858	chr7:156931337	T/C	cg05182265	chr7:156933206	UBE3C	-0.39	-8.98	-0.63	3.72e-15	Body mass index;
TGCT	cis	rs34130287	0.904	rs11775115	chr8:1213744	T/G	cg03028061	chr8:218468	NA	0.26	4.45	0.37	1.91e-5	Residual cognition;
TGCT	cis	rs35306767	0.715	rs11253539	chr10:1011347	G/A	cg18964960	chr10:1102726	WDR37	0.69	4.82	0.4	4.12e-6	Eosinophil percentage of granulocytes;
TGCT	cis	rs10851411	0.789	rs12913324	chr15:42768379	A/G	cg12711755	chr15:41779622	NA	-0.18	-4.55	-0.38	1.26e-5	Glucose homeostasis traits;
TGCT	cis	rs7666738	0.830	rs35491210	chr4:99003364	T/C	cg17366294	chr4:99064904	C4orf37	0.68	6.96	0.53	1.75e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9616064	0.744	rs9616058	chr22:46974203	G/A	cg12346269	chr22:46322472	WNT7B	0.22	4.49	0.37	1.62e-5	Urate levels in obese individuals;
TGCT	cis	rs2067615	0.579	rs11113119	chr12:107200056	C/A	cg15890332	chr12:107067104	RFX4	0.28	5.61	0.45	1.27e-7	Heart rate;
TGCT	cis	rs10744422	0.800	rs2343110	chr12:123343571	T/G	cg25930673	chr12:123319894	HIP1R	-0.88	-5.22	-0.42	7.41e-7	Schizophrenia;
TGCT	cis	rs11785400	1.000	rs6988393	chr8:143740596	A/G	cg10596483	chr8:143751796	JRK	0.56	6.05	0.48	1.61e-8	Schizophrenia;
TGCT	cis	rs6545883	0.868	rs2518932	chr2:61801277	T/A	cg15711740	chr2:61764176	XPO1	-0.6	-5.66	-0.45	1e-7	Tuberculosis;
TGCT	cis	rs1801251	0.964	rs13007783	chr2:233566679	G/A	cg25237894	chr2:233734115	C2orf82	0.32	5.58	0.45	1.45e-7	Coronary artery disease;
TGCT	cis	rs1552244	0.543	rs28719585	chr3:10050813	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.33	-4.95	-0.41	2.39e-6	Alzheimer's disease;
TGCT	cis	rs611744	0.647	rs589347	chr8:109253929	T/A	cg21045802	chr8:109455806	TTC35	0.72	7.28	0.55	3.32e-11	Dupuytren's disease;
TGCT	cis	rs17270561	0.525	rs12201678	chr6:25978993	C/T	cg16482183	chr6:26056742	HIST1H1C	1.02	7.76	0.57	2.74e-12	Iron status biomarkers;
TGCT	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg10047753	chr17:41438598	NA	0.96	9.49	0.65	2.15e-16	Menopause (age at onset);
TGCT	cis	rs10858047	0.943	rs12034144	chr1:115078549	G/A	cg12756093	chr1:115239321	AMPD1	0.46	4.75	0.39	5.61e-6	Autism;
TGCT	cis	rs1215050	0.740	rs783938	chr4:99010336	A/T	cg05340658	chr4:99064831	C4orf37	-0.4	-4.77	-0.39	5.09e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7666738	0.830	rs13138438	chr4:99050545	C/A	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6558174	0.630	rs6558176	chr8:22522502	C/T	cg03733263	chr8:22462867	KIAA1967	-0.52	-4.47	-0.37	1.77e-5	Breast cancer;
TGCT	cis	rs9303401	0.659	rs62081314	chr17:56778328	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.67	6.3	0.49	4.7e-9	Cognitive test performance;
TGCT	cis	rs55794721	0.509	rs7554255	chr1:25778106	C/T	cg10117171	chr1:25599238	RHD	-0.32	-5.22	-0.42	7.32e-7	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs11098499	0.863	rs11098532	chr4:120490726	C/A	cg09307838	chr4:120376055	NA	0.69	6.53	0.51	1.49e-9	Corneal astigmatism;
TGCT	cis	rs3617	0.625	rs2535633	chr3:52859630	C/G	cg11645453	chr3:52864694	ITIH4	-0.28	-5.45	-0.44	2.63e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs3818285	0.655	rs588160	chr10:111641538	C/T	cg00817464	chr10:111662876	XPNPEP1	0.32	5.56	0.45	1.55e-7	Superior crus of antihelix expression;
TGCT	cis	rs7666738	0.716	rs6827474	chr4:99089683	T/G	cg17366294	chr4:99064904	C4orf37	0.69	6.76	0.52	4.88e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg18538332	chr22:24372958	LOC391322	-0.84	-9.45	-0.65	2.7e-16	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7020830	0.931	rs13288178	chr9:37107799	A/G	cg14294708	chr9:37120828	ZCCHC7	1.29	19.04	0.86	1.29e-38	Schizophrenia;
TGCT	cis	rs17331151	0.573	rs76029595	chr3:52868523	C/T	cg07884673	chr3:53033167	SFMBT1	0.49	5.66	0.45	1.01e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs2439831	0.867	rs76542740	chr15:43891512	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.93	6.59	0.51	1.14e-9	Lung cancer in ever smokers;
TGCT	cis	rs1046896	0.503	rs2459703	chr17:80690632	C/T	cg00960700	chr17:80709150	TBCD	-0.5	-5.07	-0.41	1.42e-6	Glycated hemoglobin levels;
TGCT	cis	rs7296418	0.961	rs4275659	chr12:123447928	C/T	cg00376283	chr12:123451042	ABCB9	-0.86	-7.9	-0.58	1.27e-12	Platelet count;
TGCT	cis	rs8017423	0.967	rs8022531	chr14:90729931	T/C	cg04374321	chr14:90722782	PSMC1	0.78	7.86	0.58	1.59e-12	Mortality in heart failure;
TGCT	cis	rs262150	0.592	rs56062559	chr7:158769109	T/C	cg01219135	chr7:158766336	NA	-0.51	-5.34	-0.43	4.25e-7	Facial morphology (factor 20);
TGCT	cis	rs4237845	0.537	rs10747787	chr12:58260657	A/G	cg23860436	chr12:58378763	NA	0.35	4.77	0.39	5.18e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs12477438	0.765	rs6750876	chr2:99679673	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-7.6	-0.56	6.47e-12	Chronic sinus infection;
TGCT	cis	rs526231	0.578	rs6876278	chr5:102249546	A/G	cg23492399	chr5:102201601	PAM	-0.51	-4.49	-0.37	1.62e-5	Primary biliary cholangitis;
TGCT	cis	rs10875595	0.732	rs62378370	chr5:140679460	T/C	cg20560182	chr5:140700478	TAF7	-0.64	-4.78	-0.39	4.77e-6	Pulmonary function decline;
TGCT	cis	rs11992186	0.597	rs11781841	chr8:8595263	T/A	cg06636001	chr8:8085503	FLJ10661	-0.61	-5.05	-0.41	1.56e-6	Neuroticism;
TGCT	cis	rs3772130	0.923	rs28674947	chr3:121529421	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.72	0.39	6.25e-6	Cognitive performance;
TGCT	cis	rs1692580	0.807	rs4648627	chr1:2200404	C/T	cg21194808	chr1:2205498	SKI	0.29	5.64	0.45	1.08e-7	Coronary artery disease;
TGCT	trans	rs1814175	0.616	rs1794139	chr11:49910855	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.51	-0.69	7.2e-19	Height;
TGCT	cis	rs4689388	0.926	rs9998835	chr4:6293237	C/G	cg25554036	chr4:6271136	WFS1	0.54	7.37	0.55	2.11e-11	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs797680	0.856	rs7526112	chr1:93747683	T/G	cg17826107	chr1:92977322	EVI5	0.23	5.17	0.42	8.96e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs67311347	1.000	rs9827461	chr3:40489351	T/A	cg02782426	chr3:40428986	ENTPD3	0.39	4.51	0.38	1.51e-5	Renal cell carcinoma;
TGCT	cis	rs9583531	0.660	rs61971610	chr13:111330476	T/C	cg15747390	chr13:111297551	CARS2	0.89	6.16	0.48	9.18e-9	Coronary artery disease;
TGCT	cis	rs5769765	0.773	rs138861	chr22:50202276	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.06	-11.14	-0.71	2.11e-20	Schizophrenia;
TGCT	cis	rs11785400	1.000	rs3735994	chr8:143742683	C/T	cg24634471	chr8:143751801	JRK	0.57	6.12	0.48	1.11e-8	Schizophrenia;
TGCT	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg23758822	chr17:41437982	NA	0.71	6.75	0.52	5.16e-10	Menopause (age at onset);
TGCT	cis	rs2847297	1.000	rs6505765	chr18:12782849	C/G	cg23544223	chr18:12777786	NA	-0.39	-4.55	-0.38	1.26e-5	Rheumatoid arthritis;
TGCT	cis	rs7017914	0.902	rs11991273	chr8:71645860	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.03	-0.41	1.69e-6	Bone mineral density;
TGCT	cis	rs1538970	0.962	rs9429076	chr1:45819489	A/G	cg05343316	chr1:45956843	TESK2	0.7	5.63	0.45	1.13e-7	Platelet count;
TGCT	cis	rs1843834	0.755	rs11898692	chr2:225575173	T/C	cg22455342	chr2:225449267	CUL3	0.64	6.04	0.48	1.65e-8	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg08045932	chr20:61659980	NA	0.48	9.28	0.64	7.07e-16	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1635	0.655	rs16893929	chr6:28270817	C/T	cg15743358	chr6:28303923	ZNF323	-1.34	-5.96	-0.47	2.44e-8	Schizophrenia;
TGCT	cis	rs13191362	1.000	rs71567659	chr6:163001736	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs6500602	0.702	rs2270366	chr16:4558615	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.31	-5.67	-0.45	9.57e-8	Schizophrenia;
TGCT	cis	rs2721195	1.000	rs1871541	chr8:145681713	G/T	cg17328964	chr8:145687451	CYHR1	0.48	6.95	0.53	1.84e-10	Age at first birth;
TGCT	cis	rs950169	0.881	rs62029599	chr15:84956565	A/C	cg12863693	chr15:85201151	NMB	0.45	4.96	0.41	2.28e-6	Schizophrenia;
TGCT	cis	rs6909279	0.678	rs9479056	chr6:151848899	C/A	cg14416726	chr6:151773293	C6orf211;RMND1	0.64	5.79	0.46	5.32e-8	Bone mineral density;
TGCT	cis	rs28595532	0.920	rs115838006	chr4:119754356	T/C	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs7216064	1.000	rs8071463	chr17:65938655	C/T	cg12091567	chr17:66097778	LOC651250	0.86	6.36	0.5	3.47e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs2201728	0.967	rs13117371	chr4:100222067	C/T	cg07219303	chr4:100140905	ADH6	-0.35	-5.14	-0.42	1.04e-6	Cardiac Troponin-T levels;
TGCT	cis	rs743757	1.000	rs734767	chr3:50431410	C/G	cg27186011	chr3:49840712	C3orf54	0.73	4.73	0.39	5.97e-6	Diastolic blood pressure;
TGCT	cis	rs7044106	0.791	rs3904196	chr9:123480369	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	4.85	0.4	3.57e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs9534288	0.797	rs718530	chr13:46563653	T/C	cg15192986	chr13:46630673	CPB2	-0.53	-7.62	-0.56	5.82e-12	Blood protein levels;
TGCT	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg03188948	chr7:1209495	NA	0.58	5.61	0.45	1.27e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs739496	0.843	rs650887	chr12:112008242	C/T	cg10833066	chr12:111807467	FAM109A	0.37	5.59	0.45	1.4e-7	Platelet count;
TGCT	cis	rs10782582	0.609	rs5745430	chr1:76332994	C/T	cg03433033	chr1:76189801	ACADM	-0.5	-4.98	-0.41	2.11e-6	Daytime sleep phenotypes;
TGCT	cis	rs7949030	0.626	rs11231144	chr11:62328038	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.73	9.21	0.64	9.99e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9372498	0.536	rs28605789	chr6:118889952	G/A	cg07617317	chr6:118971624	C6orf204	0.5	5.32	0.43	4.71e-7	Diastolic blood pressure;
TGCT	cis	rs9790314	0.902	rs9863590	chr3:161116445	T/C	cg03342759	chr3:160939853	NMD3	-0.44	-4.53	-0.38	1.34e-5	Morning vs. evening chronotype;
TGCT	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg04944784	chr2:26401820	FAM59B	0.76	6.24	0.49	6.46e-9	Gut microbiome composition (summer);
TGCT	cis	rs75686122	0.892	rs17807832	chr8:104633966	G/T	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs7940866	0.874	rs7111478	chr11:130819628	A/G	cg12179176	chr11:130786555	SNX19	0.55	5.42	0.44	3.03e-7	Schizophrenia;
TGCT	cis	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg07424592	chr7:64974309	NA	-1.27	-7.28	-0.55	3.29e-11	Diabetic kidney disease;
TGCT	cis	rs1475911	0.671	rs12483409	chr21:43521902	G/A	cg19766460	chr21:43528205	UMODL1;C21orf128	0.64	9.26	0.64	7.72e-16	IgG glycosylation;
TGCT	cis	rs9910055	0.529	rs228749	chr17:42174570	A/G	cg13607699	chr17:42295918	UBTF	-0.63	-5.13	-0.42	1.11e-6	Total body bone mineral density;
TGCT	cis	rs9486719	1.000	rs12529248	chr6:96895377	T/G	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.86	-0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs9486715	0.867	rs3849199	chr6:97049191	T/C	cg06623918	chr6:96969491	KIAA0776	-1.11	-15.34	-0.81	1.96e-30	Headache;
TGCT	cis	rs8077889	0.619	rs1230399	chr17:41845403	C/T	cg26893861	chr17:41843967	DUSP3	-1.16	-21.87	-0.89	2.22e-44	Triglycerides;
TGCT	cis	rs7959452	0.640	rs12370042	chr12:69692420	C/G	cg11871910	chr12:69753446	YEATS4	0.63	6.37	0.5	3.34e-9	Blood protein levels;
TGCT	cis	rs11679640	0.543	rs4487134	chr2:43107129	G/T	cg00484711	chr2:42331922	NA	-0.2	-4.59	-0.38	1.06e-5	White matter hyperintensity burden;
TGCT	cis	rs736408	1.000	rs2710331	chr3:52837855	T/C	cg07507251	chr3:52567010	NT5DC2	0.49	6.55	0.51	1.41e-9	Bipolar disorder;
TGCT	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg08736216	chr1:53307985	ZYG11A	0.25	4.93	0.4	2.59e-6	Monocyte count;
TGCT	cis	rs587847	0.558	rs624991	chr15:37658208	T/G	cg16890051	chr15:37175029	LOC145845	-0.37	-4.44	-0.37	1.95e-5	Intraocular pressure;
TGCT	cis	rs7208859	0.673	rs9889968	chr17:29220128	C/A	cg14008862	chr17:28927542	LRRC37B2	0.72	4.66	0.39	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs2580764	0.566	rs2968794	chr2:55290651	C/G	cg09592903	chr2:55203963	RTN4	-0.25	-5.65	-0.45	1.04e-7	Mean platelet volume;
TGCT	cis	rs858239	0.669	rs6461687	chr7:23116580	A/G	cg05407003	chr7:23246146	NA	-0.31	-5.05	-0.41	1.54e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg22920501	chr2:26401640	FAM59B	0.83	5.42	0.44	3.04e-7	Gut microbiome composition (summer);
TGCT	cis	rs4654899	0.758	rs6658679	chr1:21376451	T/C	cg01072550	chr1:21505969	NA	-0.57	-9.39	-0.64	3.77e-16	Superior frontal gyrus grey matter volume;
TGCT	cis	rs2180341	0.960	rs7756884	chr6:127684018	A/G	cg24812749	chr6:127587940	RNF146	1.01	7.62	0.56	5.59e-12	Breast cancer;
TGCT	cis	rs644799	1.000	rs563653	chr11:95561488	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	10.52	0.69	6.94e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7523050	0.643	rs35860016	chr1:109404639	C/T	cg08274380	chr1:109419600	GPSM2	1.3	6.39	0.5	2.99e-9	Fat distribution (HIV);
TGCT	cis	rs6845621	0.754	rs9992560	chr4:18881056	G/A	cg12196642	chr4:18937545	NA	-0.24	-4.49	-0.37	1.62e-5	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
TGCT	cis	rs2797160	1.000	rs1630556	chr6:126013155	A/G	cg05901451	chr6:126070800	HEY2	0.74	6.12	0.48	1.15e-8	Endometrial cancer;
TGCT	cis	rs2281845	0.965	rs7516023	chr1:201085521	C/T	cg22815214	chr1:201083145	CACNA1S	0.26	4.67	0.39	7.77e-6	Permanent tooth development;
TGCT	cis	rs921968	0.541	rs3770216	chr2:219443717	A/G	cg02176678	chr2:219576539	TTLL4	-0.49	-6.93	-0.53	1.99e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs12681288	0.862	rs2600487	chr8:1016903	C/T	cg08872321	chr8:1308229	NA	-0.26	-4.68	-0.39	7.47e-6	Schizophrenia;
TGCT	cis	rs2677744	0.626	rs11207	chr15:91497239	C/T	cg01710897	chr15:91497902	RCCD1	0.33	4.52	0.38	1.41e-5	Attention deficit hyperactivity disorder;
TGCT	cis	rs9926296	0.581	rs1108064	chr16:89894150	G/C	cg05177932	chr16:89631655	NA	0.29	4.89	0.4	3.12e-6	Vitiligo;
TGCT	cis	rs13223928	0.592	rs4722439	chr7:3155858	C/T	cg19214707	chr7:3157722	NA	0.46	6.97	0.53	1.7e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
TGCT	cis	rs9534288	0.797	rs7995256	chr13:46579414	A/T	cg15192986	chr13:46630673	CPB2	-0.53	-7.62	-0.56	5.82e-12	Blood protein levels;
TGCT	cis	rs79149102	0.579	rs8039433	chr15:75367367	T/C	cg09165964	chr15:75287851	SCAMP5	-1.03	-5.67	-0.45	9.4e-8	Lung cancer;
TGCT	cis	rs798766	1.000	rs3099555	chr4:1725651	T/C	cg05874882	chr4:1763078	NA	-0.34	-4.49	-0.37	1.62e-5	Bladder cancer;Urinary bladder cancer;
TGCT	cis	rs2239547	0.603	rs4687698	chr3:53097108	C/T	cg11645453	chr3:52864694	ITIH4	0.31	4.99	0.41	1.98e-6	Schizophrenia;
TGCT	cis	rs6570726	0.791	rs1280275	chr6:145892402	C/T	cg23711669	chr6:146136114	FBXO30	0.86	9.54	0.65	1.64e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg03351412	chr1:154909251	PMVK	-0.46	-4.46	-0.37	1.82e-5	Prostate cancer;
TGCT	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg06481639	chr22:41940642	POLR3H	-0.74	-6.74	-0.52	5.38e-10	Vitiligo;
TGCT	cis	rs6964587	0.967	rs28615927	chr7:91600648	C/A	cg22709100	chr7:91322751	NA	0.27	4.48	0.37	1.68e-5	Breast cancer;
TGCT	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs155076	1.000	rs261427	chr13:21860998	G/A	cg14456004	chr13:21872349	NA	-1.23	-9.97	-0.67	1.49e-17	White matter hyperintensity burden;
TGCT	cis	rs174601	0.861	rs174547	chr11:61570783	C/T	cg01500311	chr11:61656094	FADS3	0.3	5.09	0.42	1.31e-6	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
TGCT	cis	rs174479	0.677	rs1000778	chr11:61655305	A/G	cg01500311	chr11:61656094	FADS3	0.29	5.16	0.42	9.71e-7	Sphingolipid levels;
TGCT	cis	rs7255045	0.752	rs2242512	chr19:12975599	G/A	cg23899408	chr19:12877188	HOOK2	-0.61	-4.99	-0.41	1.97e-6	Mean corpuscular volume;
TGCT	cis	rs59197085	0.636	rs62479609	chr7:128443492	C/G	cg00260937	chr7:128520193	KCP	0.47	4.86	0.4	3.49e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
TGCT	cis	rs2692947	0.673	rs2917662	chr2:96794957	G/A	cg22654517	chr2:96458247	NA	0.22	4.58	0.38	1.11e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs6921919	0.583	rs6907950	chr6:28370246	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.56	-5.27	-0.43	5.78e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.63	-5.4	-0.44	3.3e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs644799	0.965	rs2508713	chr11:95547927	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	10.57	0.69	5.17e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs11096990	0.634	rs2381371	chr4:39273034	A/G	cg20847110	chr4:39482781	LOC401127	0.16	4.55	0.38	1.26e-5	Cognitive function;
TGCT	cis	rs826838	0.616	rs2200605	chr12:38624088	G/A	cg26384229	chr12:38710491	ALG10B	0.55	5.0	0.41	1.93e-6	Heart rate;
TGCT	trans	rs10435719	0.744	rs11250175	chr8:11792758	G/T	cg15556689	chr8:8085844	FLJ10661	0.77	7.37	0.55	2.13e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs10927875	1.000	rs3979179	chr1:16306846	A/G	cg21385522	chr1:16154831	NA	0.76	8.44	0.6	7.12e-14	Dilated cardiomyopathy;
TGCT	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg08048268	chr3:133502702	NA	-0.65	-9.71	-0.66	6.45e-17	Iron status biomarkers;
TGCT	cis	rs2204008	0.811	rs8189445	chr12:38276295	T/C	cg13010199	chr12:38710504	ALG10B	0.61	4.67	0.39	7.69e-6	Bladder cancer;
TGCT	cis	rs9972944	0.756	rs9899781	chr17:63769384	C/T	cg07283582	chr17:63770753	CCDC46	-0.26	-5.27	-0.43	5.91e-7	Total body bone mineral density;
TGCT	cis	rs17376456	0.542	rs17083380	chr5:93170476	C/G	cg25358565	chr5:93447407	FAM172A	-0.6	-5.69	-0.45	8.75e-8	Diabetic retinopathy;
TGCT	cis	rs7937682	0.883	rs1789351	chr11:111456436	T/A	cg09085632	chr11:111637200	PPP2R1B	-0.97	-9.75	-0.66	5.24e-17	Primary sclerosing cholangitis;
TGCT	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg06896619	chr17:61851486	DDX42;CCDC47	-0.48	-4.48	-0.37	1.69e-5	Prudent dietary pattern;
TGCT	cis	rs11696501	0.688	rs1013562	chr20:44310744	A/G	cg11783356	chr20:44313418	WFDC10B	-0.33	-4.57	-0.38	1.18e-5	Brain structure;
TGCT	cis	rs4820539	0.902	rs9612237	chr22:23472954	T/C	cg21100191	chr22:23484243	RTDR1	0.89	10.51	0.69	7.38e-19	Bone mineral density;
TGCT	cis	rs9814567	0.762	rs13067564	chr3:134209956	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.83	6.53	0.51	1.51e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs2742417	0.967	rs9311378	chr3:45763135	C/T	cg04837898	chr3:45731254	SACM1L	-0.51	-5.27	-0.43	5.85e-7	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs6912958	0.781	rs9444522	chr6:88309705	G/A	cg06598631	chr6:88300029	RARS2;ORC3L	-0.57	-5.2	-0.42	7.9e-7	Monocyte percentage of white cells;
TGCT	cis	rs11249608	0.548	rs6860309	chr5:178451428	T/C	cg01312482	chr5:178451176	ZNF879	-0.56	-5.5	-0.44	2.09e-7	Pubertal anthropometrics;
TGCT	cis	rs7635838	0.785	rs7427412	chr3:11535020	G/A	cg00170343	chr3:11313890	ATG7	0.68	6.36	0.5	3.46e-9	HDL cholesterol;
TGCT	cis	rs7666738	0.830	rs13102369	chr4:99045912	A/G	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7264396	0.673	rs2425163	chr20:34432670	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.28	-4.83	-0.4	3.89e-6	Total cholesterol levels;
TGCT	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg17747265	chr1:1875780	NA	-0.38	-7.18	-0.54	5.67e-11	Body mass index;
TGCT	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg12963246	chr6:28129442	ZNF389	0.51	5.02	0.41	1.73e-6	Depression;
TGCT	cis	rs36051895	0.659	rs16922576	chr9:5064193	T/C	cg02405213	chr9:5042618	JAK2	-0.69	-8.63	-0.61	2.43e-14	Pediatric autoimmune diseases;
TGCT	trans	rs12339966	0.653	rs1489174	chr9:11284628	T/G	cg07173112	chr1:1114698	TTLL10	-0.34	-6.84	-0.52	3.15e-10	Systolic blood pressure;
TGCT	cis	rs2708240	0.666	rs2710121	chr7:147608448	C/T	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.17	-4.45	-0.37	1.9e-5	QT interval (drug interaction);
TGCT	cis	rs6815814	0.904	rs73236628	chr4:38825443	C/T	cg02016764	chr4:38805732	TLR1	-0.3	-4.62	-0.38	9.47e-6	Breast cancer;
TGCT	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg02725872	chr8:58115012	NA	-0.38	-5.16	-0.42	9.32e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs11627546	0.615	rs75507160	chr14:70366060	A/T	cg10496350	chr14:71275911	MAP3K9	-0.94	-4.44	-0.37	1.96e-5	Red blood cell traits;
TGCT	cis	rs28374715	0.532	rs28463309	chr15:41666716	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.89	-14.75	-0.8	4.62e-29	Ulcerative colitis;
TGCT	cis	rs933688	1.000	rs11950530	chr5:90688740	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.02	8.42	0.6	7.91e-14	Smoking behavior;
TGCT	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg17971929	chr21:40555470	PSMG1	0.98	9.13	0.63	1.6e-15	Cognitive function;
TGCT	cis	rs10186029	0.680	rs11689451	chr2:213937840	C/T	cg08319019	chr2:214017104	IKZF2	0.63	5.81	0.46	5.05e-8	Systemic sclerosis;
TGCT	cis	rs986417	1.000	rs8004736	chr14:61053061	T/C	cg27398547	chr14:60952738	C14orf39	1.57	8.46	0.6	6.32e-14	Gut microbiota (bacterial taxa);
TGCT	cis	rs732765	0.734	rs7152804	chr14:75164008	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.58	-5.03	-0.41	1.67e-6	Non-small cell lung cancer;
TGCT	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg04944784	chr2:26401820	FAM59B	-0.68	-6.13	-0.48	1.1e-8	Gut microbiome composition (summer);
TGCT	cis	rs7973719	1.000	rs1839622	chr12:7334534	G/C	cg07052231	chr12:7363540	PEX5	0.35	5.17	0.42	9.04e-7	IgG glycosylation;
TGCT	cis	rs28595532	0.920	rs116514715	chr4:119756280	G/T	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs6582630	0.537	rs7299661	chr12:38527713	C/T	cg13010199	chr12:38710504	ALG10B	0.58	4.72	0.39	6.37e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs9311474	1.000	rs6445358	chr3:52308845	C/G	cg07507251	chr3:52567010	NT5DC2	0.43	6.02	0.48	1.81e-8	Electroencephalogram traits;
TGCT	cis	rs6831352	0.918	rs34936974	chr4:100052384	A/G	cg12011299	chr4:100065546	ADH4	0.42	4.98	0.41	2.06e-6	Alcohol dependence;
TGCT	cis	rs2455799	0.613	rs3856830	chr3:15806520	A/C	cg16303742	chr3:15540471	COLQ	-0.25	-4.8	-0.4	4.53e-6	Mean platelet volume;
TGCT	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg10802521	chr3:52805072	NEK4	-0.73	-8.77	-0.62	1.13e-14	Bipolar disorder;
TGCT	cis	rs9911578	0.835	rs9904993	chr17:56468569	G/T	cg12560992	chr17:57184187	TRIM37	-0.72	-7.97	-0.58	8.62e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs9400467	0.537	rs12210707	chr6:111538387	C/T	cg15721981	chr6:111408429	SLC16A10	0.73	4.79	0.4	4.71e-6	Blood metabolite levels;Amino acid levels;
TGCT	cis	rs28595532	0.920	rs56342843	chr4:119765070	G/A	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs2932538	0.961	rs1238	chr1:113214097	G/A	cg22162597	chr1:113214053	CAPZA1	-0.28	-6.31	-0.49	4.46e-9	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg00343986	chr7:65444356	GUSB	0.2	4.51	0.38	1.51e-5	Aortic root size;
TGCT	trans	rs1814175	0.616	rs847641	chr11:49919261	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.51	-0.69	7.2e-19	Height;
TGCT	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg07507251	chr3:52567010	NT5DC2	0.48	6.95	0.53	1.82e-10	Bipolar disorder;
TGCT	cis	rs35883536	0.565	rs2647322	chr1:101031962	G/T	cg10298815	chr1:101004474	GPR88	0.25	4.69	0.39	7.06e-6	Monocyte count;
TGCT	cis	rs7772486	0.658	rs6570706	chr6:145962922	T/C	cg23711669	chr6:146136114	FBXO30	0.84	9.16	0.64	1.36e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg12311346	chr5:56204834	C5orf35	-0.63	-6.36	-0.5	3.5e-9	Initial pursuit acceleration;
TGCT	cis	rs2204008	0.777	rs2049130	chr12:38444837	G/A	cg26384229	chr12:38710491	ALG10B	0.83	7.46	0.56	1.32e-11	Bladder cancer;
TGCT	cis	rs2458413	0.933	rs2669450	chr8:105371752	C/T	cg13045555	chr8:105342365	NA	0.42	6.92	0.53	2.11e-10	Paget's disease;
TGCT	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg05754148	chr16:3507555	NAT15	-0.44	-5.35	-0.43	4.09e-7	Tuberculosis;
TGCT	cis	rs595982	0.702	rs626974	chr19:49375900	T/C	cg21252483	chr19:49399788	TULP2	-0.27	-4.81	-0.4	4.37e-6	Red cell distribution width;
TGCT	cis	rs8063160	0.778	rs11076649	chr16:90059336	C/G	cg12064134	chr16:90016061	DEF8	-0.52	-4.44	-0.37	2e-5	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
TGCT	cis	rs10992471	0.756	rs2761681	chr9:95186937	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.61	-6.31	-0.49	4.46e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs7267979	0.933	rs2387887	chr20:25427081	G/T	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs908922	0.702	rs569232	chr1:152526643	A/G	cg20991723	chr1:152506922	NA	0.41	5.47	0.44	2.43e-7	Hair morphology;
TGCT	cis	rs763121	0.853	rs10135	chr22:39082174	C/T	cg06022373	chr22:39101656	GTPBP1	-0.74	-7.88	-0.58	1.43e-12	Menopause (age at onset);
TGCT	cis	rs7833790	0.963	rs2400473	chr8:82703403	C/T	cg06027949	chr8:82754900	SNX16	-0.73	-4.66	-0.39	8.1e-6	Diastolic blood pressure;
TGCT	cis	rs6882076	1.000	rs9715911	chr5:156394441	G/A	cg12943317	chr5:156479607	HAVCR1	-0.31	-6.09	-0.48	1.31e-8	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
TGCT	cis	rs9435341	0.826	rs1730858	chr1:107619244	T/C	cg09367891	chr1:107599246	PRMT6	-0.62	-5.29	-0.43	5.29e-7	Facial morphology (factor 21, depth of nasal alae);
TGCT	cis	rs7220711	1.000	rs8072333	chr17:41793893	C/T	cg26893861	chr17:41843967	DUSP3	0.5	4.49	0.37	1.61e-5	Bone mineral density (spine);Bone mineral density (hip);
TGCT	cis	rs12497850	1.000	rs4858831	chr3:48735558	C/T	cg07636037	chr3:49044803	WDR6	0.91	10.29	0.68	2.43e-18	Parkinson's disease;
TGCT	cis	rs826838	0.804	rs6580755	chr12:39159190	C/T	cg26384229	chr12:38710491	ALG10B	1.06	10.03	0.67	1.05e-17	Heart rate;
TGCT	cis	rs7586879	0.789	rs13428763	chr2:25132855	T/G	cg01884057	chr2:25150051	NA	0.27	4.82	0.4	4.16e-6	Body mass index;
TGCT	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.55	-4.92	-0.4	2.74e-6	Prudent dietary pattern;
TGCT	cis	rs3733631	1.000	rs28688000	chr4:104620713	A/G	cg24090629	chr4:104641072	TACR3	-0.73	-5.72	-0.46	7.65e-8	Menarche (age at onset);
TGCT	cis	rs9527	0.590	rs10883836	chr10:104891198	T/C	cg15744005	chr10:104629667	AS3MT	-0.43	-4.94	-0.41	2.45e-6	Arsenic metabolism;
TGCT	cis	rs4144743	1.000	rs7223003	chr17:45324293	G/A	cg18085866	chr17:45331354	ITGB3	-0.72	-4.8	-0.4	4.39e-6	Body mass index;
TGCT	cis	rs868036	0.681	rs4548812	chr15:68060552	G/A	cg05925327	chr15:68127851	NA	-0.51	-4.97	-0.41	2.21e-6	Restless legs syndrome;
TGCT	cis	rs13217239	0.621	rs12527231	chr6:27001288	G/A	cg26531700	chr6:26746687	NA	0.68	6.86	0.52	2.83e-10	Schizophrenia;
TGCT	cis	rs13191362	1.000	rs13206253	chr6:163166902	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.68	5.79	0.46	5.5e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg21951975	chr1:209979733	IRF6	0.7	6.01	0.47	1.92e-8	Cleft lip with or without cleft palate;
TGCT	cis	rs899997	1.000	rs11072794	chr15:79006582	A/G	cg04896959	chr15:78267971	NA	0.36	5.53	0.44	1.81e-7	Coronary artery disease or large artery stroke;
TGCT	cis	rs4713118	0.628	rs12179134	chr6:27675469	A/G	cg27179866	chr6:27740120	NA	0.41	4.5	0.37	1.53e-5	Parkinson's disease;
TGCT	cis	rs6978712	1.000	rs80308641	chr7:127147638	C/A	cg01017541	chr7:127776461	NA	0.76	4.6	0.38	1.01e-5	Medication adherence in chronic diseases;
TGCT	cis	rs13242816	1.000	rs3801994	chr7:116190469	G/A	cg02799643	chr7:116139180	CAV2	-0.45	-5.55	-0.45	1.66e-7	P wave duration;
TGCT	trans	rs114540395	0.858	rs17767748	chr10:103285900	A/G	cg25791773	chr11:129910324	NA	-0.76	-6.72	-0.52	5.95e-10	Schizophrenia;
TGCT	cis	rs58688157	0.960	rs11246213	chr11:612967	A/G	cg16486109	chr11:613632	IRF7	0.36	5.26	0.43	6.02e-7	Systemic lupus erythematosus;
TGCT	cis	rs2070433	0.539	rs1008549	chr21:47959698	C/T	cg12379764	chr21:47803548	PCNT	0.53	5.46	0.44	2.51e-7	Lymphocyte counts;
TGCT	cis	rs35306767	0.761	rs12773961	chr10:1013215	C/G	cg20503657	chr10:835505	NA	0.57	6.34	0.49	3.86e-9	Eosinophil percentage of granulocytes;
TGCT	cis	rs853679	0.546	rs200996	chr6:27811828	G/A	cg10876282	chr6:28092338	ZSCAN16	0.74	4.44	0.37	1.98e-5	Depression;
TGCT	cis	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg22857025	chr5:266934	NA	-0.34	-6.59	-0.51	1.1e-9	Breast cancer;
TGCT	cis	rs7312933	0.558	rs3747560	chr12:42719890	A/G	cg19980929	chr12:42632907	YAF2	-0.41	-5.76	-0.46	6.3e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs10782582	0.569	rs2131557	chr1:76388589	A/C	cg03433033	chr1:76189801	ACADM	0.46	4.54	0.38	1.32e-5	Daytime sleep phenotypes;
TGCT	cis	rs6570726	0.755	rs2092297	chr6:145893765	A/G	cg23711669	chr6:146136114	FBXO30	0.86	9.54	0.65	1.64e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg01802117	chr1:53393560	SCP2	0.43	5.12	0.42	1.14e-6	Monocyte count;
TGCT	cis	rs892961	0.899	rs747482	chr17:75412109	T/C	cg05865280	chr17:75406074	SEPT9	0.28	6.82	0.52	3.51e-10	Airflow obstruction;
TGCT	cis	rs4727027	0.635	rs12111923	chr7:148885877	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.05	0.41	1.53e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs9911578	0.785	rs10853008	chr17:56993407	T/C	cg05425664	chr17:57184151	TRIM37	0.6	4.97	0.41	2.18e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg08509172	chr19:19383838	TM6SF2	-0.34	-4.48	-0.37	1.71e-5	Tonsillectomy;
TGCT	trans	rs561341	0.609	rs9906443	chr17:30185565	C/T	cg20587970	chr11:113659929	NA	0.66	7.7	0.57	3.76e-12	Hip circumference adjusted for BMI;
TGCT	cis	rs7072216	0.763	rs7910014	chr10:100172110	C/T	cg26618903	chr10:100175079	PYROXD2	-0.4	-4.49	-0.37	1.64e-5	Metabolite levels;
TGCT	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg22535103	chr8:58192502	C8orf71	-0.42	-4.79	-0.4	4.7e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs3774830	0.685	rs73212741	chr4:5464450	G/C	cg26943120	chr4:5472116	STK32B	0.21	4.71	0.39	6.48e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs3096299	0.967	rs2911255	chr16:89487137	C/T	cg06640241	chr16:89574553	SPG7	0.64	6.33	0.49	4.18e-9	Multiple myeloma (IgH translocation);
TGCT	cis	rs6570726	0.935	rs408723	chr6:145838535	A/G	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7178572	1.000	rs6495240	chr15:77766556	T/C	cg15453836	chr15:77711506	NA	-0.4	-4.59	-0.38	1.07e-5	Type 2 diabetes;
TGCT	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg03351412	chr1:154909251	PMVK	0.54	5.02	0.41	1.72e-6	Prostate cancer;
TGCT	cis	rs7666738	0.830	rs6840766	chr4:99016260	C/G	cg17366294	chr4:99064904	C4orf37	0.68	7.04	0.53	1.17e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1018836	0.923	rs13277387	chr8:91633713	C/G	cg16814680	chr8:91681699	NA	-0.84	-8.98	-0.63	3.58e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs16957091	0.607	rs28633493	chr15:43263307	T/C	cg17935677	chr15:44119062	WDR76	0.53	4.72	0.39	6.35e-6	MGMT methylation in smokers;
TGCT	cis	rs7312933	0.670	rs10880258	chr12:42547531	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	5.06	0.41	1.45e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs10484885	0.680	rs72921943	chr6:90581542	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.55	-6.49	-0.5	1.87e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg26338869	chr17:61819248	STRADA	-0.55	-5.08	-0.41	1.37e-6	Prudent dietary pattern;
TGCT	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg13866156	chr1:1669148	SLC35E2	0.2	4.45	0.37	1.89e-5	Body mass index;
TGCT	cis	rs6693567	0.565	rs1694379	chr1:150292417	C/A	cg09579323	chr1:150459698	TARS2	0.54	4.84	0.4	3.86e-6	Migraine;
TGCT	cis	rs892961	0.965	rs2411111	chr17:75402540	A/T	cg05865280	chr17:75406074	SEPT9	0.3	7.18	0.54	5.59e-11	Airflow obstruction;
TGCT	cis	rs7267979	0.706	rs6037069	chr20:25234166	C/T	cg03522245	chr20:25566470	NINL	0.58	6.22	0.49	6.92e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs346785	0.692	rs6501883	chr17:74289908	A/G	cg09812376	chr17:74270190	QRICH2	-0.36	-5.33	-0.43	4.43e-7	White matter hyperintensities in ischemic stroke;
TGCT	cis	rs1045714	0.887	rs73033694	chr7:2637139	G/A	cg17215154	chr7:2644645	IQCE	0.29	5.12	0.42	1.12e-6	Urate levels in lean individuals;
TGCT	cis	rs6586111	1.000	rs7071690	chr10:82376017	C/T	cg03086067	chr10:82368399	SH2D4B	-0.23	-4.54	-0.38	1.33e-5	Capecitabine sensitivity;
TGCT	cis	rs9611519	0.828	rs4822008	chr22:41539206	C/G	cg13695892	chr22:41940480	POLR3H	-0.51	-4.58	-0.38	1.1e-5	Neuroticism;
TGCT	cis	rs12971120	0.891	rs3764510	chr18:72166846	A/G	cg26446133	chr18:72167187	CNDP2	-0.36	-6.11	-0.48	1.2e-8	Refractive error;
TGCT	cis	rs600231	0.577	rs35826299	chr11:65240964	T/C	cg17120908	chr11:65337727	SSSCA1	-0.57	-4.45	-0.37	1.9e-5	Bone mineral density;
TGCT	cis	rs1775715	0.707	rs2799019	chr10:32142850	C/T	cg14930904	chr10:32216787	ARHGAP12	0.55	5.41	0.44	3.12e-7	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs11690935	0.921	rs6710698	chr2:172596078	G/C	cg13550731	chr2:172543902	DYNC1I2	-1.17	-12.34	-0.74	2.55e-23	Schizophrenia;
TGCT	cis	rs7666738	0.830	rs17483521	chr4:98974058	A/T	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7914558	1.000	rs7077291	chr10:104945751	C/T	cg05855489	chr10:104503620	C10orf26	0.51	4.48	0.37	1.65e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg20203395	chr5:56204925	C5orf35	-0.59	-5.09	-0.42	1.32e-6	Initial pursuit acceleration;
TGCT	cis	rs6840360	0.615	rs12647586	chr4:152607568	G/C	cg22705602	chr4:152727874	NA	-0.32	-5.43	-0.44	2.85e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs10465746	0.967	rs12732697	chr1:84349283	A/G	cg10977910	chr1:84465055	TTLL7	0.64	6.27	0.49	5.53e-9	Obesity-related traits;
TGCT	cis	rs514406	0.893	rs6588445	chr1:53424928	T/C	cg08859206	chr1:53392774	SCP2	0.41	6.31	0.49	4.48e-9	Monocyte count;
TGCT	cis	rs7666738	0.830	rs62321587	chr4:98997958	T/C	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs1178127	0.694	rs1178136	chr7:18772264	A/G	cg04900931	chr7:6644352	C7orf26	0.21	6.73	0.52	5.66e-10	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
TGCT	cis	rs9611565	0.729	rs169362	chr22:41827589	G/C	cg03806693	chr22:41940476	POLR3H	1.03	11.32	0.71	7.58e-21	Vitiligo;
TGCT	cis	rs61990749	0.597	rs72685264	chr14:78152998	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	-0.66	-4.69	-0.39	7.04e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs2562456	0.917	rs2681389	chr19:21692575	G/A	cg25650185	chr19:21324782	ZNF431	0.61	5.38	0.43	3.6e-7	Pain;
TGCT	cis	rs2688608	0.592	rs3849967	chr10:75483366	C/T	cg19442545	chr10:75533431	FUT11	-0.37	-5.77	-0.46	5.89e-8	Inflammatory bowel disease;
TGCT	cis	rs10927875	0.541	rs1763601	chr1:16340460	G/T	cg22431228	chr1:16359049	CLCNKA	-0.29	-6.07	-0.48	1.42e-8	Dilated cardiomyopathy;
TGCT	cis	rs6912958	0.559	rs395358	chr6:88057924	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.44	5.71	0.46	7.78e-8	Monocyte percentage of white cells;
TGCT	cis	rs7666738	0.830	rs10034330	chr4:99064849	G/A	cg05340658	chr4:99064831	C4orf37	0.52	5.86	0.47	3.86e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10791097	0.694	rs11222369	chr11:130744670	A/G	cg14779329	chr11:130786720	SNX19	0.28	4.82	0.4	4.09e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs12477438	0.765	rs62154861	chr2:99590235	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-6.33	-0.49	4.13e-9	Chronic sinus infection;
TGCT	cis	rs473651	0.935	rs578510	chr2:239343140	C/T	cg21699342	chr2:239360505	ASB1	0.17	4.78	0.39	4.78e-6	Multiple system atrophy;
TGCT	cis	rs9810089	0.934	rs66691851	chr3:136154828	C/T	cg12473912	chr3:136751656	NA	0.34	4.96	0.41	2.3e-6	Gestational age at birth (child effect);
TGCT	cis	rs10984561	0.881	rs7023869	chr9:122252359	C/A	cg14242995	chr9:122249943	NA	0.73	5.96	0.47	2.46e-8	Pulmonary function decline;
TGCT	cis	rs9796	0.505	rs28665387	chr15:41532869	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.54	-6.9	-0.53	2.43e-10	Menopause (age at onset);
TGCT	trans	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg20587970	chr11:113659929	NA	-0.97	-11.47	-0.72	3.31e-21	Hip circumference adjusted for BMI;
TGCT	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	16.1	0.82	3.69e-32	Prudent dietary pattern;
TGCT	cis	rs904251	0.523	rs2797798	chr6:37481437	C/T	cg25019722	chr6:37503610	NA	-0.53	-8.19	-0.59	2.75e-13	Cognitive performance;
TGCT	cis	rs2153535	0.601	rs7741024	chr6:8530313	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.55e-8	Motion sickness;
TGCT	cis	rs2832191	0.633	rs2832166	chr21:30462395	G/C	cg08807101	chr21:30365312	RNF160	0.65	6.02	0.48	1.82e-8	Dental caries;
TGCT	cis	rs7000551	0.751	rs2469755	chr8:22360212	G/A	cg12081754	chr8:22256438	SLC39A14	0.29	4.6	0.38	1.03e-5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs10489202	0.913	rs380753	chr1:168035273	G/T	cg24449463	chr1:168025552	DCAF6	-0.47	-5.26	-0.43	6.01e-7	Schizophrenia;
TGCT	cis	rs7647973	0.961	rs7619016	chr3:49272589	C/T	cg07636037	chr3:49044803	WDR6	0.7	5.69	0.45	8.73e-8	Menarche (age at onset);
TGCT	trans	rs1814175	0.817	rs2866545	chr11:49630824	A/C	cg15704280	chr7:45808275	SEPT13	-0.73	-8.4	-0.6	8.93e-14	Height;
TGCT	cis	rs28595532	0.920	rs114093638	chr4:119729819	T/C	cg14228332	chr4:119757509	SEC24D	1.32	6.38	0.5	3.2e-9	Cannabis dependence symptom count;
TGCT	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	5.53	0.44	1.8e-7	Alzheimer's disease;
TGCT	cis	rs9467773	1.000	rs767471	chr6:26557854	C/T	cg09904177	chr6:26538194	HMGN4	0.66	6.6	0.51	1.05e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs1023500	0.505	rs134878	chr22:42663874	A/G	cg05082376	chr22:42548792	NA	-0.21	-4.61	-0.38	9.93e-6	Schizophrenia;
TGCT	cis	rs2361718	0.500	rs4889970	chr17:78096086	C/T	cg21238619	chr17:78079768	GAA	0.38	4.71	0.39	6.59e-6	Yeast infection;
TGCT	trans	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg27523141	chr10:43048294	ZNF37B	0.71	8.31	0.6	1.4e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs8177179	0.904	rs1130459	chr3:133465283	A/G	cg16262614	chr3:133464971	TF	0.34	4.57	0.38	1.15e-5	Iron status biomarkers (transferrin levels);
TGCT	cis	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg05590025	chr7:65112418	INTS4L2	-0.77	-4.5	-0.37	1.52e-5	Diabetic kidney disease;
TGCT	cis	rs7611238	0.583	rs62288441	chr3:195151602	C/G	cg27323046	chr3:195102265	ACAP2	0.39	5.14	0.42	1.05e-6	Body mass index;
TGCT	cis	rs56235845	0.964	rs11741640	chr5:176792743	G/A	cg06060754	chr5:176797920	RGS14	0.61	10.77	0.7	1.71e-19	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs7000551	0.751	rs2469770	chr8:22379856	G/A	cg12081754	chr8:22256438	SLC39A14	0.28	4.53	0.38	1.36e-5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs3849570	0.565	rs1851926	chr3:81977231	A/C	cg07356753	chr3:81810745	GBE1	-0.64	-5.61	-0.45	1.28e-7	Waist circumference;Body mass index;
TGCT	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg12756686	chr19:29218302	NA	0.76	6.49	0.5	1.85e-9	Methadone dose in opioid dependence;
TGCT	cis	rs7914558	0.966	rs7085598	chr10:104650128	T/C	cg15744005	chr10:104629667	AS3MT	-0.41	-5.09	-0.42	1.29e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg08048268	chr3:133502702	NA	-0.53	-7.17	-0.54	5.89e-11	Iron status biomarkers;
TGCT	cis	rs1062177	1.000	rs2915882	chr5:151145436	T/C	cg00977110	chr5:151150581	G3BP1	0.4	4.62	0.38	9.43e-6	Preschool internalizing problems;
TGCT	cis	rs9902453	0.967	rs34323226	chr17:28517454	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	6.39	0.5	3.03e-9	Coffee consumption (cups per day);
TGCT	cis	rs2299587	0.554	rs7815429	chr8:17737357	T/C	cg01800426	chr8:17659068	MTUS1	-0.57	-5.05	-0.41	1.57e-6	Economic and political preferences;
TGCT	cis	rs73110464	0.562	rs2363634	chr12:53354683	A/G	cg14581129	chr12:53358946	NA	-0.63	-6.77	-0.52	4.65e-10	Cancer (pleiotropy);
TGCT	cis	rs617219	0.671	rs6414979	chr5:78548010	T/G	cg23514016	chr5:78407564	BHMT	0.34	5.09	0.42	1.29e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs7107174	0.901	rs4945275	chr11:78119822	G/A	cg12700464	chr11:78128424	GAB2	-0.61	-4.46	-0.37	1.85e-5	Testicular germ cell tumor;
TGCT	cis	rs933688	1.000	rs2059208	chr5:90732065	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.88	8.25	0.6	1.91e-13	Smoking behavior;
TGCT	cis	rs7208859	0.673	rs61223749	chr17:29163747	G/A	cg18442181	chr17:29233375	C17orf42	-0.78	-4.61	-0.38	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs6051080	1	rs6051080	chr20:25975674	A/G	cg16686733	chr20:25566563	NINL	0.56	5.96	0.47	2.4e-8	Colorectal or endometrial cancer;
TGCT	cis	rs9653442	0.527	rs11123812	chr2:100761548	T/C	cg22139774	chr2:100720529	AFF3	-0.36	-5.72	-0.46	7.68e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs7647973	0.626	rs4855882	chr3:49715354	G/T	cg05785598	chr3:49045655	WDR6	0.42	4.98	0.41	2.06e-6	Menarche (age at onset);
TGCT	cis	rs7428	0.962	rs3637	chr2:85549874	A/G	cg24342717	chr2:85555507	TGOLN2	-0.4	-6.41	-0.5	2.8e-9	Ear protrusion;
TGCT	cis	rs7666738	0.830	rs7678911	chr4:99057430	C/T	cg05340658	chr4:99064831	C4orf37	0.52	5.79	0.46	5.32e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7811142	1.000	rs6953107	chr7:100095664	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.71	5.07	0.41	1.4e-6	Platelet count;
TGCT	cis	rs16854884	0.837	rs4362712	chr3:143801076	G/A	cg06585982	chr3:143692056	C3orf58	0.62	4.82	0.4	4.11e-6	Economic and political preferences (feminism/equality);
TGCT	cis	rs6684514	1.000	rs12139321	chr1:156230429	A/G	cg16558208	chr1:156270281	VHLL	0.46	8.56	0.61	3.68e-14	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs9300255	0.602	rs1616131	chr12:123619838	G/A	cg00376283	chr12:123451042	ABCB9	0.71	5.54	0.45	1.7e-7	Neutrophil percentage of white cells;
TGCT	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg08859206	chr1:53392774	SCP2	-0.42	-6.4	-0.5	2.95e-9	Monocyte count;
TGCT	cis	rs10197940	0.624	rs13393122	chr2:152413315	A/G	cg19508488	chr2:152266495	RIF1	0.7	6.44	0.5	2.36e-9	Lung cancer;
TGCT	cis	rs2692947	0.537	rs11688045	chr2:96243805	A/T	cg14612417	chr2:95688557	NA	0.37	4.68	0.39	7.34e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs902774	0.597	rs7299694	chr12:53352572	A/C	cg05393297	chr12:53359155	NA	-0.74	-8.08	-0.59	4.77e-13	Prostate cancer;
TGCT	cis	rs981844	1.000	rs2251900	chr4:154654145	C/T	cg14289246	chr4:154710475	SFRP2	1.01	7.95	0.58	9.84e-13	Response to statins (LDL cholesterol change);
TGCT	cis	rs9291683	0.588	rs12647117	chr4:10022059	T/C	cg11266682	chr4:10021025	SLC2A9	0.68	9.96	0.67	1.58e-17	Bone mineral density;
TGCT	cis	rs12497850	0.644	rs11928552	chr3:48739883	T/C	cg18654377	chr3:49208889	KLHDC8B	-0.43	-5.76	-0.46	6.24e-8	Parkinson's disease;
TGCT	cis	rs7586879	0.681	rs6545800	chr2:25118885	A/G	cg01884057	chr2:25150051	NA	-0.35	-6.9	-0.53	2.39e-10	Body mass index;
TGCT	cis	rs5760092	0.755	rs11090298	chr22:24262061	G/A	cg12419862	chr22:24373484	LOC391322	0.91	8.2	0.59	2.51e-13	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs6121246	0.567	rs6058189	chr20:30192389	A/G	cg10886678	chr20:30946050	ASXL1	-0.71	-4.8	-0.4	4.42e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs2562456	0.917	rs9304987	chr19:21682274	A/T	cg01304269	chr19:21688519	ZNF429	-0.58	-4.89	-0.4	3.06e-6	Pain;
TGCT	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg20887711	chr4:1340912	KIAA1530	0.77	6.49	0.5	1.82e-9	Longevity;
TGCT	cis	rs1055129	0.681	rs7221792	chr17:73834690	T/G	cg10935138	chr17:73851978	WBP2	0.53	4.56	0.38	1.22e-5	White matter hyperintensity burden;
TGCT	cis	rs138249	0.898	rs84504	chr22:50559247	G/A	cg24864161	chr22:50528282	MOV10L1	0.47	5.02	0.41	1.77e-6	Gestational age at birth in labor-initiated deliveries (child effect);
TGCT	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	8.0	0.58	7.67e-13	Platelet count;
TGCT	cis	rs617219	0.671	rs2607144	chr5:78556798	G/T	cg23514016	chr5:78407564	BHMT	0.36	5.24	0.43	6.81e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs1903068	0.853	rs12498317	chr4:56007093	G/A	cg01777861	chr4:56023843	NA	0.55	6.18	0.49	8.58e-9	Endometriosis;
TGCT	cis	rs10883723	0.962	rs1056740	chr10:104236552	C/T	cg05855489	chr10:104503620	C10orf26	-0.55	-4.68	-0.39	7.42e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs9733	0.680	rs3738484	chr1:150552330	G/T	cg13175981	chr1:150552382	MCL1	0.52	5.75	0.46	6.55e-8	Tonsillectomy;
TGCT	cis	rs9517320	0.515	rs4772099	chr13:99196121	A/C	cg07423050	chr13:99094983	FARP1	-0.27	-5.46	-0.44	2.52e-7	Longevity;
TGCT	cis	rs2404602	0.655	rs3829489	chr15:77223256	A/C	cg22467129	chr15:76604101	ETFA	-0.5	-5.65	-0.45	1.06e-7	Blood metabolite levels;
TGCT	cis	rs7729723	0.522	rs6596434	chr5:137815044	T/A	cg19169342	chr5:137827400	NA	0.33	4.68	0.39	7.46e-6	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);
TGCT	cis	rs116095464	0.558	rs13356367	chr5:242395	C/T	cg22857025	chr5:266934	NA	-0.34	-6.72	-0.52	5.96e-10	Breast cancer;
TGCT	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg22963979	chr7:1858916	MAD1L1	-0.36	-5.63	-0.45	1.13e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs3806843	0.576	rs246029	chr5:140333226	G/A	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7819412	0.511	rs2409798	chr8:11435564	C/T	cg21775007	chr8:11205619	TDH	-0.53	-5.01	-0.41	1.8e-6	Triglycerides;
TGCT	cis	rs9676308	0.677	rs74893436	chr19:57634972	G/A	cg25972591	chr19:58627987	ZSCAN18	-0.5	-4.47	-0.37	1.73e-5	Colorectal cancer;
TGCT	cis	rs992157	0.764	rs1870124	chr2:219187740	C/T	cg00012203	chr2:219082015	ARPC2	0.71	6.65	0.51	8.23e-10	Colorectal cancer;
TGCT	cis	rs2276314	0.857	rs62101394	chr18:33592299	C/T	cg19628046	chr18:33552617	C18orf21	0.51	4.46	0.37	1.79e-5	Endometriosis;Drug-induced torsades de pointes;
TGCT	cis	rs9913156	0.793	rs9436	chr17:4574751	T/A	cg23387401	chr17:4582204	PELP1	0.31	4.59	0.38	1.09e-5	Lymphocyte counts;
TGCT	trans	rs7819412	0.660	rs7462931	chr8:10910343	G/C	cg06636001	chr8:8085503	FLJ10661	-0.74	-7.11	-0.54	8.3e-11	Triglycerides;
TGCT	cis	rs1971762	0.762	rs7312853	chr12:54073597	C/G	cg22546318	chr12:54070378	ATP5G2	0.31	4.46	0.37	1.79e-5	Height;
TGCT	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg20607798	chr8:58055168	NA	0.45	4.59	0.38	1.06e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs4944092	0.855	rs596339	chr11:75916507	T/C	cg04588336	chr11:75916460	WNT11	-0.43	-5.89	-0.47	3.41e-8	PR interval;
TGCT	cis	rs7714584	1.000	rs17800987	chr5:150323428	A/G	cg22134413	chr5:150180641	NA	0.82	4.99	0.41	2.03e-6	Crohn's disease;
TGCT	cis	rs826838	1.000	rs826891	chr12:39100824	A/G	cg13010199	chr12:38710504	ALG10B	-0.59	-4.88	-0.4	3.25e-6	Heart rate;
TGCT	cis	rs62244186	0.566	rs55901755	chr3:44834707	C/T	cg02073558	chr3:44770973	ZNF501	0.69	6.85	0.52	3.06e-10	Depressive symptoms;
TGCT	cis	rs3733585	0.654	rs4447863	chr4:9938969	T/C	cg11266682	chr4:10021025	SLC2A9	-0.59	-7.6	-0.56	6.41e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs9814567	0.727	rs9809344	chr3:134342758	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-6.09	-0.48	1.3e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs3796352	1.000	rs3806692	chr3:53080987	C/G	cg07884673	chr3:53033167	SFMBT1	0.55	6.0	0.47	2.04e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg18876405	chr7:65276391	NA	0.35	5.1	0.42	1.24e-6	Aortic root size;
TGCT	cis	rs4689388	0.926	rs10937718	chr4:6295217	T/C	cg00701064	chr4:6280414	WFS1	0.37	4.72	0.39	6.3e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg25427524	chr10:38739819	LOC399744	-0.38	-7.92	-0.58	1.13e-12	Extrinsic epigenetic age acceleration;
TGCT	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg21724239	chr8:58056113	NA	0.4	5.01	0.41	1.8e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg07138768	chr7:917805	C7orf20	0.42	5.16	0.42	9.68e-7	Perceived unattractiveness to mosquitoes;
TGCT	trans	rs1908814	0.503	rs34657250	chr8:11795373	A/G	cg15556689	chr8:8085844	FLJ10661	-0.72	-6.65	-0.51	8.2e-10	Neuroticism;
TGCT	cis	rs13188771	0.651	rs114484620	chr5:100889920	T/C	cg18665594	chr5:101119420	NA	0.44	4.47	0.37	1.74e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs4780401	0.567	rs12920377	chr16:11781582	A/C	cg01061890	chr16:11836724	TXNDC11	-0.44	-4.46	-0.37	1.82e-5	Rheumatoid arthritis;
TGCT	cis	rs734999	0.869	rs1555791	chr1:2498862	G/C	cg18854424	chr1:2615690	NA	0.46	5.62	0.45	1.18e-7	Ulcerative colitis;
TGCT	cis	rs854765	0.547	rs4925135	chr17:17952868	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.79	-8.27	-0.6	1.76e-13	Total body bone mineral density;
TGCT	cis	rs6546537	1.000	rs12478540	chr2:69844524	C/T	cg10773587	chr2:69614142	GFPT1	-0.77	-6.45	-0.5	2.31e-9	Serum thyroid-stimulating hormone levels;
TGCT	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg13342137	chr4:2252803	MXD4	0.17	4.44	0.37	1.94e-5	Obesity-related traits;
TGCT	cis	rs7178572	0.524	rs2175941	chr15:77584498	T/C	cg22256960	chr15:77711686	NA	-0.85	-8.73	-0.62	1.4e-14	Type 2 diabetes;
TGCT	cis	rs727563	0.594	rs132807	chr22:42071584	T/C	cg13695892	chr22:41940480	POLR3H	0.89	8.6	0.61	2.92e-14	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs11626933	1.000	rs11621007	chr14:90743967	G/A	cg14092571	chr14:90743983	NA	-0.3	-6.18	-0.48	8.66e-9	Gut microbiota (bacterial taxa);
TGCT	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg23758822	chr17:41437982	NA	-0.71	-6.99	-0.53	1.49e-10	Menopause (age at onset);
TGCT	cis	rs17221829	0.673	rs10830335	chr11:89403934	T/C	cg02982614	chr11:89391479	FOLH1B	-0.28	-4.67	-0.39	7.81e-6	Anxiety in major depressive disorder;
TGCT	cis	rs644799	0.625	rs1255175	chr11:95471186	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.5	4.8	0.4	4.53e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7760949	0.889	rs9396272	chr6:13938080	C/T	cg27413430	chr6:13925136	RNF182	-0.75	-6.91	-0.53	2.26e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg18252515	chr7:66147081	NA	-1.17	-7.49	-0.56	1.13e-11	Diabetic kidney disease;
TGCT	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-5.1	-0.42	1.23e-6	Bipolar disorder;
TGCT	cis	rs28595532	0.688	rs116566508	chr4:119619195	G/A	cg11846333	chr4:119757529	SEC24D	0.92	5.01	0.41	1.85e-6	Cannabis dependence symptom count;
TGCT	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.57	-5.38	-0.44	3.56e-7	Menarche (age at onset);
TGCT	cis	rs1008375	1.000	rs1121090	chr4:17676437	C/G	cg10189774	chr4:17578691	LAP3	0.53	5.0	0.41	1.91e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs56104184	0.578	rs7254608	chr19:49395774	G/T	cg21252483	chr19:49399788	TULP2	-0.3	-5.05	-0.41	1.54e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs2180341	0.694	rs2875972	chr6:127585522	T/C	cg27446573	chr6:127587934	RNF146	0.98	8.94	0.63	4.63e-15	Breast cancer;
TGCT	cis	rs2153535	0.601	rs1855765	chr6:8444325	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.58	0.45	1.42e-7	Motion sickness;
TGCT	cis	rs9611565	0.559	rs9611619	chr22:41986714	C/T	cg13695892	chr22:41940480	POLR3H	-0.87	-8.01	-0.58	6.94e-13	Vitiligo;
TGCT	cis	rs7208859	0.673	rs11651802	chr17:29159660	T/C	cg18442181	chr17:29233375	C17orf42	-0.78	-4.61	-0.38	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7666738	0.830	rs4392515	chr4:98957431	A/G	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7584330	0.554	rs74001399	chr2:238445440	G/A	cg08992911	chr2:238395768	MLPH	0.64	4.49	0.37	1.63e-5	Prostate cancer;
TGCT	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg13395646	chr4:1353034	KIAA1530	-0.41	-4.46	-0.37	1.78e-5	Longevity;
TGCT	cis	rs7726839	0.540	rs7558	chr5:660491	C/T	cg09021430	chr5:549028	NA	-0.45	-6.19	-0.49	7.91e-9	Obesity-related traits;
TGCT	cis	rs1008375	0.966	rs6839660	chr4:17667987	C/T	cg18681998	chr4:17616180	MED28	0.9	10.37	0.68	1.6e-18	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2486288	0.656	rs8039138	chr15:45551592	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.72	-7.46	-0.56	1.34e-11	Glomerular filtration rate;
TGCT	cis	rs13326165	0.760	rs61150019	chr3:52354376	G/A	cg07884673	chr3:53033167	SFMBT1	0.41	4.98	0.41	2.07e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs6545883	0.826	rs1186697	chr2:61661417	G/A	cg15711740	chr2:61764176	XPO1	-0.56	-4.99	-0.41	1.98e-6	Tuberculosis;
TGCT	cis	rs12477438	0.765	rs62154861	chr2:99590235	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-5.99	-0.47	2.09e-8	Chronic sinus infection;
TGCT	cis	rs1865760	0.892	rs6456705	chr6:25936056	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.64	6.15	0.48	9.9e-9	Height;
TGCT	cis	rs858239	0.669	rs12539467	chr7:23115859	A/G	cg05602783	chr7:23145260	KLHL7	-0.7	-5.94	-0.47	2.72e-8	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs1008375	0.932	rs2302394	chr4:17641188	A/G	cg18681998	chr4:17616180	MED28	0.96	10.38	0.68	1.51e-18	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2204008	0.527	rs9804958	chr12:38192810	G/T	cg26384229	chr12:38710491	ALG10B	-0.54	-4.58	-0.38	1.12e-5	Bladder cancer;
TGCT	cis	rs6967414	0.786	rs7782227	chr7:6748594	T/C	cg00387323	chr7:6746715	ZNF12	0.79	4.92	0.4	2.67e-6	Hematocrit;Hemoglobin concentration;
TGCT	cis	rs11864453	0.713	rs2241412	chr16:72144284	A/G	cg14768367	chr16:72042858	DHODH	0.51	4.95	0.41	2.32e-6	Fibrinogen levels;
TGCT	cis	rs4680	0.737	rs4646312	chr22:19948337	C/T	cg22546130	chr22:19950026	COMT	0.34	5.23	0.43	6.86e-7	Blood metabolite levels;
TGCT	cis	rs950169	1.000	rs35297609	chr15:84772896	A/G	cg11189052	chr15:85197271	WDR73	0.69	5.91	0.47	3.07e-8	Schizophrenia;
TGCT	cis	rs617219	0.710	rs2166344	chr5:78534134	T/G	cg05890484	chr5:78407552	BHMT	0.34	4.63	0.38	9.24e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs806215	0.526	rs16871926	chr7:127517785	C/T	cg11539674	chr7:127291444	SND1	-0.36	-4.65	-0.39	8.46e-6	Type 2 diabetes;
TGCT	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg24399712	chr22:39784796	NA	-1.06	-12.58	-0.75	6.72e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs9443189	0.526	rs10943255	chr6:76225928	T/A	cg01950844	chr6:76311363	SENP6	0.94	5.69	0.46	8.52e-8	Prostate cancer;
TGCT	cis	rs782590	0.837	rs2627769	chr2:55927288	G/C	cg18811423	chr2:55921094	PNPT1	0.71	7.86	0.58	1.59e-12	Metabolic syndrome;
TGCT	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg06221963	chr1:154839813	KCNN3	-0.74	-13.19	-0.76	2.3e-25	Prostate cancer;
TGCT	cis	rs35306767	0.855	rs11253459	chr10:886402	C/T	cg26597838	chr10:835615	NA	0.71	10.12	0.67	6.47e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs72627509	0.638	rs78933653	chr4:57854840	A/G	cg26694713	chr4:57773883	REST	0.62	4.59	0.38	1.06e-5	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs7917772	0.582	rs6584512	chr10:104329685	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	5.36	0.43	3.84e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg22029157	chr1:209979665	IRF6	0.78	6.42	0.5	2.58e-9	Cleft lip with or without cleft palate;
TGCT	cis	rs7833790	0.676	rs7834555	chr8:82697625	A/G	cg06027949	chr8:82754900	SNX16	-0.6	-4.69	-0.39	7.14e-6	Diastolic blood pressure;
TGCT	cis	rs7267979	0.932	rs431579	chr20:25470056	T/C	cg14121845	chr20:25566513	NINL	0.49	5.36	0.43	3.83e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs514406	0.505	rs835609	chr1:53170494	T/C	cg22166914	chr1:53195759	ZYG11B	0.45	7.68	0.57	4.04e-12	Monocyte count;
TGCT	cis	rs514406	0.505	rs405208	chr1:53176674	C/T	cg16325326	chr1:53192061	ZYG11B	0.86	12.25	0.74	4.3e-23	Monocyte count;
TGCT	trans	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg11887960	chr12:57824829	NA	1.2	9.56	0.65	1.47e-16	Obesity-related traits;
TGCT	cis	rs523395	0.630	rs616111	chr1:120269991	C/G	cg19096424	chr1:120255104	PHGDH	-0.48	-4.45	-0.37	1.9e-5	Red blood cell count;
TGCT	cis	rs9457247	0.935	rs9348211	chr6:167375173	G/C	cg23791538	chr6:167370224	RNASET2	0.53	5.19	0.42	8.41e-7	Crohn's disease;
TGCT	cis	rs1008375	1.000	rs10009541	chr4:17682218	C/T	cg18681998	chr4:17616180	MED28	-0.83	-8.43	-0.6	7.25e-14	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	-0.62	-5.23	-0.43	6.93e-7	Tonsillectomy;
TGCT	cis	rs9522267	0.535	rs914031	chr13:112240176	C/A	cg10483660	chr13:112241077	NA	-0.3	-5.02	-0.41	1.78e-6	Hepatitis;
TGCT	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg08280861	chr8:58055591	NA	0.36	4.6	0.38	1.04e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg06618935	chr21:46677482	NA	-0.37	-5.56	-0.45	1.58e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs950169	0.887	rs62029593	chr15:84955180	A/G	cg17173187	chr15:85201210	NMB	0.58	5.93	0.47	2.77e-8	Schizophrenia;
TGCT	cis	rs7474896	0.616	rs2474561	chr10:38373544	C/T	cg25427524	chr10:38739819	LOC399744	-0.37	-5.16	-0.42	9.57e-7	Obesity (extreme);
TGCT	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg26338869	chr17:61819248	STRADA	-0.55	-5.08	-0.41	1.37e-6	Prudent dietary pattern;
TGCT	cis	rs727563	0.562	rs5758458	chr22:42154132	G/A	cg13695892	chr22:41940480	POLR3H	0.87	8.24	0.59	2.06e-13	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs3796352	0.881	rs13100714	chr3:53074824	T/G	cg07884673	chr3:53033167	SFMBT1	0.6	6.24	0.49	6.25e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs9814567	1.000	rs6765505	chr3:134208132	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.95	-9.62	-0.65	1.04e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs950169	1.000	rs35648189	chr15:84740748	T/C	cg11189052	chr15:85197271	WDR73	0.69	5.91	0.47	3.14e-8	Schizophrenia;
TGCT	cis	rs10754283	0.967	rs1320563	chr1:90121032	G/A	cg03145924	chr1:90228473	NA	-0.4	-4.52	-0.38	1.4e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs7772486	0.790	rs9497425	chr6:146234197	G/A	cg23711669	chr6:146136114	FBXO30	-0.85	-9.7	-0.66	6.73e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs986417	0.901	rs1955690	chr14:61000492	A/G	cg27398547	chr14:60952738	C14orf39	-1.22	-9.97	-0.67	1.52e-17	Gut microbiota (bacterial taxa);
TGCT	cis	rs6912958	0.512	rs910563	chr6:88058885	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.68	6.88	0.53	2.68e-10	Monocyte percentage of white cells;
TGCT	cis	rs4727443	0.691	rs6975827	chr7:99585798	C/G	cg13334819	chr7:99746414	C7orf59	-0.57	-4.92	-0.4	2.71e-6	Interstitial lung disease;
TGCT	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg21016266	chr12:122356598	WDR66	-0.49	-6.44	-0.5	2.35e-9	Mean corpuscular volume;
TGCT	cis	rs7772486	0.738	rs9485039	chr6:146319387	C/T	cg23711669	chr6:146136114	FBXO30	0.85	8.53	0.61	4.22e-14	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9393692	0.967	rs6456712	chr6:26302573	A/C	cg00631329	chr6:26305371	NA	-0.46	-6.92	-0.53	2.19e-10	Educational attainment;
TGCT	trans	rs61931739	0.500	rs11053201	chr12:34453903	T/A	cg26384229	chr12:38710491	ALG10B	0.73	6.92	0.53	2.09e-10	Morning vs. evening chronotype;
TGCT	cis	rs7267979	0.903	rs6107015	chr20:25216764	G/A	cg03522245	chr20:25566470	NINL	0.6	6.57	0.51	1.22e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs62244186	0.566	rs6766221	chr3:44882784	C/T	cg02073558	chr3:44770973	ZNF501	0.69	6.85	0.52	3.1e-10	Depressive symptoms;
TGCT	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg02038168	chr22:39784481	NA	-0.76	-6.36	-0.5	3.47e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs72781680	0.898	rs72786270	chr2:24059049	G/A	cg08917208	chr2:24149416	ATAD2B	0.78	4.79	0.4	4.69e-6	Lymphocyte counts;
TGCT	cis	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg18188782	chr20:61659543	NA	0.44	5.37	0.43	3.73e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.92	7.33	0.55	2.53e-11	Platelet count;
TGCT	cis	rs6684514	1.000	rs6679145	chr1:156256000	T/C	cg16558208	chr1:156270281	VHLL	0.46	9.38	0.64	3.92e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs9527	0.614	rs2153774	chr10:104881035	T/C	cg15744005	chr10:104629667	AS3MT	-0.43	-4.9	-0.4	2.89e-6	Arsenic metabolism;
TGCT	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg17971929	chr21:40555470	PSMG1	-0.73	-6.87	-0.52	2.82e-10	Cognitive function;
TGCT	cis	rs3733606	0.775	rs66514314	chr4:6827238	C/T	cg18365211	chr4:7770554	AFAP1;LOC84740	0.32	4.5	0.37	1.56e-5	Platelet count;
TGCT	cis	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg18252515	chr7:66147081	NA	-1.27	-7.54	-0.56	8.64e-12	Diabetic kidney disease;
TGCT	cis	rs2469997	1.000	rs2470017	chr8:120361534	G/A	cg00681363	chr8:120844660	TAF2	0.69	4.48	0.37	1.64e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs7937682	0.883	rs542831	chr11:111471392	T/A	cg09085632	chr11:111637200	PPP2R1B	-1.07	-11.36	-0.71	6.19e-21	Primary sclerosing cholangitis;
TGCT	cis	rs2932538	0.922	rs9429694	chr1:113158289	G/A	cg22162597	chr1:113214053	CAPZA1	0.27	5.98	0.47	2.24e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs11190604	1.000	rs3750627	chr10:102275642	G/T	cg23241863	chr10:102295624	HIF1AN	0.66	5.01	0.41	1.82e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs3806843	1.000	rs2098058	chr5:140157427	A/C	cg19875535	chr5:140030758	IK	-0.36	-6.01	-0.47	1.96e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs4642101	0.590	rs6799544	chr3:12812979	T/C	cg05775895	chr3:12838266	CAND2	0.52	5.06	0.41	1.45e-6	QRS complex (12-leadsum);
TGCT	cis	rs9858542	0.537	rs56038006	chr3:49362369	C/T	cg00383909	chr3:49044727	WDR6	0.67	4.56	0.38	1.19e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs1056107	0.931	rs2027384	chr9:115000234	G/A	cg02332936	chr9:115140584	NA	-0.25	-4.44	-0.37	1.96e-5	Colorectal cancer;
TGCT	cis	rs2204008	0.654	rs1290325	chr12:38152910	C/T	cg26384229	chr12:38710491	ALG10B	-0.63	-5.69	-0.46	8.47e-8	Bladder cancer;
TGCT	cis	rs3008870	1.000	rs3008854	chr1:67385951	T/C	cg11518657	chr1:67396239	MIER1	0.52	4.53	0.38	1.39e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg11644478	chr21:40555479	PSMG1	0.64	6.35	0.5	3.61e-9	Cognitive function;
TGCT	cis	rs28493229	0.708	rs10408310	chr19:41161190	T/C	cg11601297	chr19:41224147	ITPKC;ADCK4	0.57	5.15	0.42	9.78e-7	Kawasaki disease;
TGCT	cis	rs72945132	0.882	rs72949081	chr11:70219070	A/G	cg00319359	chr11:70116639	PPFIA1	0.97	7.07	0.54	1.01e-10	Coronary artery disease;
TGCT	cis	rs903263	0.601	rs11163900	chr1:84557569	G/A	cg09664975	chr1:84543551	PRKACB	0.5	4.86	0.4	3.47e-6	Breast cancer (male);
TGCT	cis	rs6088590	0.710	rs6059992	chr20:33282275	T/C	cg08999081	chr20:33150536	PIGU	0.26	4.88	0.4	3.17e-6	Coronary artery disease;
TGCT	cis	rs1008375	0.900	rs10019460	chr4:17686337	T/C	cg10189774	chr4:17578691	LAP3	-0.56	-4.89	-0.4	3.01e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9303401	0.527	rs2116450	chr17:56745561	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.61	5.41	0.44	3.12e-7	Cognitive test performance;
TGCT	cis	rs12893668	0.703	rs7140568	chr14:104041374	C/T	cg26031613	chr14:104095156	KLC1	-0.54	-4.44	-0.37	1.97e-5	Reticulocyte count;
TGCT	cis	rs9682041	0.627	rs3772172	chr3:170077713	C/T	cg07589077	chr3:170072950	NA	-0.27	-4.66	-0.39	8.08e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs80282103	0.867	rs80254477	chr10:1077387	T/G	cg15531433	chr10:1639090	ADARB2	0.41	4.5	0.37	1.52e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg05025164	chr4:1340916	KIAA1530	0.74	6.14	0.48	1.02e-8	Longevity;
TGCT	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg08219700	chr8:58056026	NA	0.3	4.53	0.38	1.35e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs6978712	1.000	rs7789577	chr7:127150498	C/T	cg01017541	chr7:127776461	NA	0.76	4.6	0.38	1.01e-5	Medication adherence in chronic diseases;
TGCT	cis	rs7829975	0.653	rs13259070	chr8:8690787	C/T	cg06636001	chr8:8085503	FLJ10661	0.74	6.57	0.51	1.25e-9	Mood instability;
TGCT	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.31	-4.82	-0.4	4.12e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs79149102	0.579	rs58294763	chr15:75299768	G/A	cg09165964	chr15:75287851	SCAMP5	-1.06	-5.71	-0.46	7.92e-8	Lung cancer;
TGCT	cis	rs9894429	0.646	rs8080391	chr17:79566319	A/T	cg18240062	chr17:79603768	NPLOC4	-0.84	-9.67	-0.66	8.03e-17	Eye color traits;
TGCT	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg18110333	chr6:292329	DUSP22	-0.71	-7.67	-0.57	4.25e-12	Menopause (age at onset);
TGCT	cis	rs7833790	0.963	rs2400473	chr8:82703403	C/T	cg17211192	chr8:82754475	SNX16	-1.14	-8.89	-0.62	5.9e-15	Diastolic blood pressure;
TGCT	cis	rs3782455	1.000	rs16943545	chr12:114406337	T/C	cg10631684	chr12:113795897	PLBD2	-0.78	-5.28	-0.43	5.52e-7	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs981844	0.857	rs62325140	chr4:154714161	C/A	cg14289246	chr4:154710475	SFRP2	1.04	8.85	0.62	7.29e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs71435601	0.600	rs312982	chr2:21378226	G/C	cg25035485	chr2:21266500	APOB	0.51	4.48	0.37	1.66e-5	Cholesterol, total;
TGCT	cis	rs10883723	0.810	rs2296590	chr10:104262628	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs1153858	1.000	rs2066090	chr15:45650018	T/C	cg26924012	chr15:45694286	SPATA5L1	1.09	15.16	0.81	5.15e-30	Homoarginine levels;
TGCT	cis	rs5769765	0.955	rs5769761	chr22:50263641	G/T	cg15316289	chr22:50310904	ALG12;CRELD2	-0.41	-6.13	-0.48	1.08e-8	Schizophrenia;
TGCT	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg02891314	chr5:179741120	GFPT2	-0.41	-7.09	-0.54	8.78e-11	Height;
TGCT	cis	rs2180341	0.960	rs7766942	chr6:127691323	G/T	cg27446573	chr6:127587934	RNF146	1.1	10.61	0.69	4.22e-19	Breast cancer;
TGCT	cis	rs611744	0.967	rs569701	chr8:109239207	G/A	cg21045802	chr8:109455806	TTC35	0.52	4.72	0.39	6.21e-6	Dupuytren's disease;
TGCT	cis	rs9814567	0.752	rs9836401	chr3:134336897	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-6.5	-0.5	1.78e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs6565180	1.000	rs8049108	chr16:30376486	A/G	cg17640201	chr16:30407289	ZNF48	-0.87	-8.85	-0.62	7.53e-15	Tonsillectomy;
TGCT	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg24531977	chr5:56204891	C5orf35	-0.76	-7.66	-0.57	4.53e-12	Initial pursuit acceleration;
TGCT	cis	rs4820539	1.000	rs756631	chr22:23463183	A/G	cg21100191	chr22:23484243	RTDR1	0.92	10.84	0.7	1.13e-19	Bone mineral density;
TGCT	cis	rs10744422	0.764	rs4038080	chr12:123292915	T/C	cg18912006	chr12:123335444	HIP1R	0.56	4.78	0.39	4.84e-6	Schizophrenia;
TGCT	cis	rs7713065	0.531	rs2522051	chr5:131797578	C/T	cg24060327	chr5:131705240	SLC22A5	-0.51	-5.01	-0.41	1.8e-6	Lung function (FEV1/FVC);
TGCT	cis	rs6993813	0.620	rs6469802	chr8:120029323	C/T	cg17171407	chr8:119960777	TNFRSF11B	0.26	4.66	0.39	8.02e-6	Bone mineral density (hip);
TGCT	cis	rs7169223	0.653	rs1994017	chr15:79080306	T/C	cg21242079	chr15:79101063	ADAMTS7	0.32	5.31	0.43	4.92e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
TGCT	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg12310025	chr6:25882481	NA	-0.67	-5.89	-0.47	3.36e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg02725872	chr8:58115012	NA	-0.41	-5.42	-0.44	3.01e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs858239	0.669	rs6461687	chr7:23116580	A/G	cg05602783	chr7:23145260	KLHL7	-0.63	-5.39	-0.44	3.47e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs6582630	0.519	rs11514056	chr12:38284001	G/T	cg13010199	chr12:38710504	ALG10B	0.59	4.61	0.38	9.88e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs9584850	0.834	rs3783005	chr13:99111337	A/T	cg15168958	chr13:99100528	FARP1	0.23	4.58	0.38	1.12e-5	Neuroticism;
TGCT	cis	rs853679	0.506	rs1150711	chr6:28208535	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.45	-4.43	-0.37	2.01e-5	Depression;
TGCT	cis	rs6121246	0.522	rs6088736	chr20:30195166	C/G	cg21427119	chr20:30132790	HM13	-0.42	-6.17	-0.48	8.75e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs62244186	0.566	rs3762636	chr3:44854563	A/G	cg11003573	chr3:44754125	ZNF502	-0.48	-5.75	-0.46	6.47e-8	Depressive symptoms;
TGCT	cis	rs9894429	0.934	rs35868252	chr17:79575472	C/G	cg21028142	chr17:79581711	NPLOC4	-0.29	-6.81	-0.52	3.83e-10	Eye color traits;
TGCT	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg00080972	chr5:178986291	RUFY1	-0.45	-5.24	-0.43	6.73e-7	Lung cancer;
TGCT	cis	rs7727544	0.836	rs10463892	chr5:131598705	T/C	cg24060327	chr5:131705240	SLC22A5	-0.6	-6.4	-0.5	2.92e-9	Blood metabolite levels;
TGCT	cis	rs7552404	0.924	rs1858536	chr1:76161595	G/T	cg10523679	chr1:76189770	ACADM	0.9	9.92	0.67	2e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs12484776	0.729	rs8140112	chr22:40533130	A/G	cg07138101	chr22:40742427	ADSL	0.61	4.6	0.38	1.01e-5	Uterine fibroids;
TGCT	cis	rs7772486	0.754	rs13214277	chr6:146136125	G/T	cg13319975	chr6:146136371	FBXO30	-0.57	-5.1	-0.42	1.22e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9308731	0.966	rs4848393	chr2:111877297	T/C	cg04202892	chr2:111875749	ACOXL	0.43	4.58	0.38	1.1e-5	Chronic lymphocytic leukemia;
TGCT	trans	rs1974653	0.672	rs9606239	chr22:20070285	G/A	cg08822737	chr17:71088851	SLC39A11	-0.93	-7.61	-0.56	5.97e-12	Schizophrenia;
TGCT	cis	rs13188771	0.690	rs12519215	chr5:100898218	A/G	cg18665594	chr5:101119420	NA	0.44	4.47	0.37	1.74e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs7226408	0.857	rs72885260	chr18:34431004	A/G	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg11764359	chr7:65958608	NA	-0.59	-5.28	-0.43	5.5e-7	Aortic root size;
TGCT	cis	rs2153535	0.580	rs4639392	chr6:8446547	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.76	0.46	6.39e-8	Motion sickness;
TGCT	cis	rs9818758	0.505	rs11716159	chr3:49631585	G/A	cg08550065	chr3:50336684	HYAL3;NAT6	1.04	5.13	0.42	1.08e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs7666738	0.830	rs10005173	chr4:98816062	T/C	cg18180107	chr4:99064573	C4orf37	0.55	5.25	0.43	6.31e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs826838	0.967	rs2892410	chr12:38990282	A/G	cg13010199	chr12:38710504	ALG10B	-0.74	-6.17	-0.48	8.84e-9	Heart rate;
TGCT	cis	rs9818758	0.607	rs71324929	chr3:49044713	C/T	cg07636037	chr3:49044803	WDR6	-1.04	-4.98	-0.41	2.07e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs868036	0.718	rs922494	chr15:68120644	T/C	cg05925327	chr15:68127851	NA	-0.51	-5.04	-0.41	1.63e-6	Restless legs syndrome;
TGCT	cis	rs929354	0.772	rs10229630	chr7:157004790	C/T	cg05182265	chr7:156933206	UBE3C	-0.37	-8.4	-0.6	8.86e-14	Body mass index;
TGCT	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	4.71	0.39	6.6e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7582180	0.629	rs4851296	chr2:100949570	T/C	cg08017756	chr2:100939284	LONRF2	-0.3	-4.95	-0.41	2.34e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1800469	1.000	rs1800469	chr19:41860296	A/G	cg09537434	chr19:41945824	ATP5SL	-0.5	-4.58	-0.38	1.09e-5	Colorectal cancer;
TGCT	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg17971929	chr21:40555470	PSMG1	-0.67	-6.29	-0.49	5.06e-9	Cognitive function;
TGCT	cis	rs4654899	1.000	rs4654902	chr1:21435056	T/G	cg01072550	chr1:21505969	NA	-0.49	-7.88	-0.58	1.41e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs9393777	0.720	rs36022097	chr6:26995168	G/A	cg16898833	chr6:26189333	HIST1H4D	0.97	5.95	0.47	2.6e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs59104589	0.959	rs3771555	chr2:242322680	C/T	cg21155796	chr2:242212141	HDLBP	-0.55	-4.75	-0.39	5.56e-6	Fibrinogen levels;
TGCT	cis	rs651907	0.535	rs13059470	chr3:101424800	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.89	-10.59	-0.69	4.52e-19	Colorectal cancer;
TGCT	cis	rs6088580	0.609	rs6059844	chr20:33036482	A/G	cg24642439	chr20:33292090	TP53INP2	0.47	4.47	0.37	1.75e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs9611565	0.918	rs9611562	chr22:41760172	T/G	cg06481639	chr22:41940642	POLR3H	-0.74	-6.51	-0.5	1.71e-9	Vitiligo;
TGCT	cis	rs4900538	0.855	rs60215817	chr14:102873886	A/G	cg18135206	chr14:102964638	TECPR2	-0.2	-4.55	-0.38	1.24e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs2439831	1.000	rs689781	chr15:43792097	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.01	8.19	0.59	2.67e-13	Lung cancer in ever smokers;
TGCT	cis	rs6138458	0.626	rs6050261	chr20:25014206	C/T	cg26195577	chr20:24973756	C20orf3	0.99	9.24	0.64	8.46e-16	Blood protein levels;
TGCT	cis	rs7662987	0.517	rs2602858	chr4:100030461	T/C	cg12011299	chr4:100065546	ADH4	0.39	4.81	0.4	4.36e-6	Smoking initiation;
TGCT	cis	rs4699052	0.963	rs7672802	chr4:104212233	A/T	cg16532752	chr4:104119610	CENPE	-0.56	-5.1	-0.42	1.26e-6	Testicular germ cell tumor;
TGCT	cis	rs3008870	0.959	rs4655658	chr1:67389608	C/T	cg03991309	chr1:68237761	GNG12	0.27	4.56	0.38	1.23e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs4901869	0.966	rs12893803	chr14:59329655	T/C	cg02291164	chr14:59296302	NA	0.26	4.97	0.41	2.21e-6	Panic disorder;
TGCT	cis	rs10927875	0.832	rs4661342	chr1:16160773	C/G	cg21385522	chr1:16154831	NA	-0.89	-11.06	-0.7	3.27e-20	Dilated cardiomyopathy;
TGCT	cis	rs7586879	0.575	rs6744205	chr2:25133148	T/C	cg15423357	chr2:25149977	NA	0.52	5.04	0.41	1.63e-6	Body mass index;
TGCT	cis	rs11696501	0.694	rs6073823	chr20:44256910	G/C	cg11783356	chr20:44313418	WFDC10B	-0.32	-4.63	-0.38	9.25e-6	Brain structure;
TGCT	cis	rs4819052	0.590	rs414743	chr21:46512075	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.61	4.69	0.39	7.09e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs344364	0.602	rs2983907	chr16:1913336	C/T	cg01422476	chr16:1922425	C16orf73	-0.47	-4.52	-0.38	1.43e-5	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs3820068	0.705	rs2042369	chr1:15843244	A/G	cg05660106	chr1:15850417	CASP9	-1.17	-13.71	-0.78	1.29e-26	Systolic blood pressure;
TGCT	cis	rs9818758	0.607	rs56306491	chr3:49314960	G/A	cg07636037	chr3:49044803	WDR6	-1.01	-4.93	-0.4	2.63e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs6967414	0.786	rs7804259	chr7:6755448	C/G	cg09896999	chr7:6746977	ZNF12	-0.59	-6.54	-0.51	1.45e-9	Hematocrit;Hemoglobin concentration;
TGCT	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs36051895	0.587	rs7019418	chr9:5259847	G/C	cg02405213	chr9:5042618	JAK2	-0.71	-9.72	-0.66	6.17e-17	Pediatric autoimmune diseases;
TGCT	cis	rs1483890	0.723	rs13077078	chr3:69411402	C/A	cg22125112	chr3:69402811	FRMD4B	0.29	4.74	0.39	5.85e-6	Resting heart rate;
TGCT	cis	rs372883	0.638	rs371432	chr21:30710876	G/A	cg24692254	chr21:30365293	RNF160	-0.54	-4.85	-0.4	3.62e-6	Pancreatic cancer;
TGCT	cis	rs3733585	0.699	rs17245723	chr4:9962218	A/T	cg00071950	chr4:10020882	SLC2A9	-0.55	-6.38	-0.5	3.14e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg06873352	chr17:61820015	STRADA	0.55	6.03	0.48	1.71e-8	Prudent dietary pattern;
TGCT	cis	rs1552244	0.832	rs73024591	chr3:10203194	A/T	cg00149659	chr3:10157352	C3orf10	1.04	5.76	0.46	6.32e-8	Alzheimer's disease;
TGCT	cis	rs8177253	0.509	rs6762415	chr3:133478557	T/G	cg01448562	chr3:133502909	NA	-0.32	-5.57	-0.45	1.51e-7	Iron status biomarkers;
TGCT	cis	rs1008375	0.966	rs6832414	chr4:17696866	C/G	cg18681998	chr4:17616180	MED28	0.78	7.35	0.55	2.35e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs8014204	0.762	rs10138360	chr14:75293386	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.54	-4.9	-0.4	2.95e-6	Caffeine consumption;
TGCT	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg09704166	chr2:114031854	PAX8;LOC440839	-0.32	-4.82	-0.4	4.04e-6	Lymphocyte counts;
TGCT	cis	rs12477438	0.834	rs1563108	chr2:99701153	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.92	-9.58	-0.65	1.29e-16	Chronic sinus infection;
TGCT	cis	rs9303401	0.659	rs62083525	chr17:56658088	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs10751667	0.961	rs6597951	chr11:991530	C/T	cg06064525	chr11:970664	AP2A2	-0.3	-6.04	-0.48	1.64e-8	Alzheimer's disease (late onset);
TGCT	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg04772025	chr11:68637568	NA	0.59	6.61	0.51	1.04e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs17376456	0.877	rs12374470	chr5:93481046	A/G	cg25358565	chr5:93447407	FAM172A	0.97	8.35	0.6	1.16e-13	Diabetic retinopathy;
TGCT	cis	rs1949733	0.656	rs2631762	chr4:8423122	A/T	cg13073564	chr4:8508604	NA	-0.41	-4.49	-0.37	1.63e-5	Response to antineoplastic agents;
TGCT	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg10047753	chr17:41438598	NA	-0.78	-7.41	-0.55	1.68e-11	Menopause (age at onset);
TGCT	cis	rs2153535	0.562	rs9379211	chr6:8463927	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs559928	0.606	rs57021319	chr11:63956102	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	4.57	0.38	1.18e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
TGCT	cis	rs10089	1.000	rs3816006	chr5:127450581	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	7.41	0.55	1.72e-11	Ileal carcinoids;
TGCT	cis	rs4919669	0.668	rs17114810	chr10:104391545	C/T	cg05855489	chr10:104503620	C10orf26	0.74	4.73	0.39	5.9e-6	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs9916302	0.904	rs9898773	chr17:37532507	C/G	cg07936489	chr17:37558343	FBXL20	0.65	5.08	0.41	1.36e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs2439831	0.867	rs2470134	chr15:43849886	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.85	-5.33	-0.43	4.52e-7	Lung cancer in ever smokers;
TGCT	cis	rs12048904	0.964	rs12027668	chr1:101330984	G/A	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.5	4.54	0.38	1.31e-5	Multiple sclerosis;
TGCT	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg23248424	chr5:179741104	GFPT2	-0.38	-7.0	-0.53	1.41e-10	Height;
TGCT	cis	rs56104184	0.775	rs73061692	chr19:49399676	T/C	cg21252483	chr19:49399788	TULP2	-0.42	-5.89	-0.47	3.47e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs10114408	0.959	rs1890379	chr9:96665767	A/G	cg13679303	chr9:96623674	NA	-0.36	-4.63	-0.38	9.04e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs67311347	1.000	rs9841335	chr3:40475858	G/A	cg17264618	chr3:40429014	ENTPD3	0.32	4.76	0.39	5.36e-6	Renal cell carcinoma;
TGCT	cis	rs7809950	0.954	rs2520241	chr7:107135443	A/G	cg23024343	chr7:107201750	COG5	-0.33	-5.16	-0.42	9.43e-7	Coronary artery disease;
TGCT	trans	rs4919669	0.582	rs4919649	chr10:104272336	T/C	cg19053889	chr7:1098703	C7orf50;GPR146	0.51	6.78	0.52	4.25e-10	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs2758596	1.000	rs2842866	chr1:156159721	G/A	cg24450063	chr1:156163899	SLC25A44	0.8	4.65	0.39	8.25e-6	Paclitaxel disposition in epithelial ovarian cancer;
TGCT	cis	rs7666738	0.830	rs13108871	chr4:98803872	T/C	cg05340658	chr4:99064831	C4orf37	0.48	5.64	0.45	1.11e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11098499	0.731	rs6846966	chr4:120293208	A/G	cg09307838	chr4:120376055	NA	0.57	5.56	0.45	1.6e-7	Corneal astigmatism;
TGCT	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg17747265	chr1:1875780	NA	-0.3	-5.07	-0.41	1.42e-6	Body mass index;
TGCT	cis	rs9291683	0.588	rs11732054	chr4:9999877	C/T	cg00071950	chr4:10020882	SLC2A9	0.7	9.28	0.64	6.94e-16	Bone mineral density;
TGCT	cis	rs1555895	0.599	rs12243303	chr10:861390	C/T	cg02193355	chr10:851439	NA	0.25	5.62	0.45	1.22e-7	Survival in rectal cancer;
TGCT	cis	rs12620999	1.000	rs12620999	chr2:238036367	C/T	cg23555395	chr2:238036564	NA	-0.31	-5.51	-0.44	2.02e-7	Systemic lupus erythematosus;
TGCT	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg18230493	chr5:56204884	C5orf35	0.68	5.92	0.47	2.92e-8	Initial pursuit acceleration;
TGCT	cis	rs854624	0.792	rs2687497	chr17:34335167	T/C	cg02022384	chr17:34097390	MMP28	0.49	4.55	0.38	1.28e-5	Blood protein levels;
TGCT	cis	rs2857078	0.654	rs4793083	chr17:42312973	C/T	cg13607699	chr17:42295918	UBTF	-0.96	-9.88	-0.66	2.46e-17	Red cell distribution width;Reticulocyte count;
TGCT	cis	rs11641365	0.678	rs877579	chr16:88770621	A/G	cg09735908	chr16:88770558	RNF166	-0.27	-4.49	-0.37	1.61e-5	Autism spectrum disorder-related traits;
TGCT	cis	rs9291683	0.588	rs35438220	chr4:9999398	C/T	cg00071950	chr4:10020882	SLC2A9	0.7	9.28	0.64	6.94e-16	Bone mineral density;
TGCT	trans	rs561341	0.623	rs4795665	chr17:30233657	C/T	cg20587970	chr11:113659929	NA	-0.68	-9.46	-0.65	2.55e-16	Hip circumference adjusted for BMI;
TGCT	trans	rs797680	0.856	rs2031226	chr1:93786764	G/T	cg27528825	chr2:159282178	CCDC148	-0.33	-6.67	-0.51	7.68e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs9911578	1.000	rs2531732	chr17:56548420	T/A	cg05425664	chr17:57184151	TRIM37	0.63	6.21	0.49	7.48e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs4700695	0.614	rs251285	chr5:65211137	A/T	cg21114390	chr5:65439923	SFRS12	0.62	4.44	0.37	1.99e-5	Facial morphology (factor 19);
TGCT	cis	rs7246657	0.943	rs10417844	chr19:37837587	C/T	cg03233940	chr19:37894644	NA	-0.34	-4.49	-0.37	1.59e-5	Coronary artery calcification;
TGCT	cis	rs4851266	1.000	rs1160543	chr2:100832182	C/T	cg07810366	chr2:100720526	AFF3	-0.38	-5.44	-0.44	2.7e-7	Educational attainment;
TGCT	cis	rs17401966	0.931	rs1002076	chr1:10438892	G/A	cg19773385	chr1:10388646	KIF1B	-0.24	-5.5	-0.44	2.03e-7	Hepatocellular carcinoma;
TGCT	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg09517075	chr8:22133004	PIWIL2	0.25	4.99	0.41	1.95e-6	Hypertriglyceridemia;
TGCT	cis	rs9457247	1.000	rs400176	chr6:167406238	T/C	cg23791538	chr6:167370224	RNASET2	-0.49	-4.96	-0.41	2.26e-6	Crohn's disease;
TGCT	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.14	0.42	1.06e-6	Prudent dietary pattern;
TGCT	cis	rs11105298	0.891	rs10858899	chr12:89923811	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.67	-4.91	-0.4	2.78e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs2535633	0.631	rs6799185	chr3:53101580	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.52	-4.84	-0.4	3.73e-6	Body mass index;
TGCT	cis	rs2013441	0.932	rs2526488	chr17:20098617	T/A	cg23224458	chr17:20280056	CCDC144C	-0.37	-4.46	-0.37	1.83e-5	Obesity-related traits;
TGCT	cis	rs881375	0.967	rs2109896	chr9:123683106	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	5.24	0.43	6.64e-7	Rheumatoid arthritis;
TGCT	cis	rs9467711	0.790	rs13220495	chr6:26441640	C/T	cg12315302	chr6:26189340	HIST1H4D	0.99	4.44	0.37	1.93e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7605378	1.000	rs7605378	chr2:200676926	A/C	cg23649088	chr2:200775458	C2orf69	0.33	5.61	0.45	1.25e-7	Osteoporosis;
TGCT	cis	rs12477438	0.559	rs6733285	chr2:99725575	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	14.89	0.8	2.21e-29	Chronic sinus infection;
TGCT	cis	rs2180341	0.521	rs12189967	chr6:127718058	G/A	cg24812749	chr6:127587940	RNF146	0.61	5.25	0.43	6.27e-7	Breast cancer;
TGCT	cis	rs137603	0.644	rs137620	chr22:39709776	T/C	cg17798944	chr22:39715225	SNORD43;RPL3	-0.68	-7.19	-0.54	5.24e-11	Primary biliary cholangitis;
TGCT	cis	rs9549260	0.755	rs2701869	chr13:41157372	G/A	cg21288729	chr13:41239152	FOXO1	1.0	10.06	0.67	9.29e-18	Red blood cell count;
TGCT	cis	rs765787	0.530	rs12915804	chr15:45512562	T/C	cg24006582	chr15:45444508	DUOX1	0.25	5.35	0.43	4.11e-7	Uric acid levels;
TGCT	cis	rs4663866	0.901	rs76312449	chr2:239190906	A/G	cg17283117	chr2:239148619	HES6	1.01	4.66	0.39	8.09e-6	Irritable bowel syndrome;
TGCT	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg03452623	chr4:187889614	NA	-0.36	-5.24	-0.43	6.6e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg10819733	chr22:24237672	NA	-0.28	-4.51	-0.38	1.49e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs524281	0.861	rs9645684	chr11:65907964	G/A	cg00563793	chr11:65837595	PACS1	0.57	4.79	0.39	4.77e-6	Electroencephalogram traits;
TGCT	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	8.99	0.63	3.48e-15	Platelet count;
TGCT	cis	rs9303401	0.625	rs34963822	chr17:56988424	C/A	cg25039879	chr17:56429692	SUPT4H1	0.52	4.57	0.38	1.15e-5	Cognitive test performance;
TGCT	trans	rs629535	0.773	rs72654090	chr8:70118666	G/A	cg21567404	chr3:27674614	NA	-0.56	-9.04	-0.63	2.69e-15	Dupuytren's disease;
TGCT	cis	rs4722585	0.533	rs12334205	chr7:26202490	G/A	cg03781084	chr7:26191726	NFE2L3	-0.45	-4.53	-0.38	1.39e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
TGCT	cis	rs7312933	0.558	rs61926593	chr12:42818912	C/T	cg19980929	chr12:42632907	YAF2	0.42	5.91	0.47	3.05e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs7611238	0.560	rs9846555	chr3:195114549	G/T	cg27323046	chr3:195102265	ACAP2	0.39	5.13	0.42	1.08e-6	Body mass index;
TGCT	cis	rs1371867	0.846	rs1616833	chr8:101271821	C/T	cg06636551	chr8:101224915	SPAG1	0.43	5.95	0.47	2.58e-8	Atrioventricular conduction;
TGCT	cis	rs651907	0.557	rs1056579	chr3:101397877	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.03	0.41	1.65e-6	Colorectal cancer;
TGCT	cis	rs7312933	0.703	rs10880264	chr12:42586535	A/G	cg19980929	chr12:42632907	YAF2	0.45	6.29	0.49	4.84e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs6671200	1.000	rs259359	chr1:95709039	A/G	cg26537280	chr1:95699037	RWDD3	-0.69	-5.49	-0.44	2.19e-7	Stearic acid (18:0) levels;
TGCT	cis	rs4455778	0.561	rs13243449	chr7:49129765	T/C	cg26309511	chr7:48887640	NA	0.5	6.51	0.5	1.66e-9	Lung cancer in never smokers;
TGCT	cis	rs4851266	0.898	rs12053126	chr2:100864646	A/T	cg07810366	chr2:100720526	AFF3	-0.39	-5.89	-0.47	3.35e-8	Educational attainment;
TGCT	cis	rs12510870	0.599	rs10011419	chr4:74453691	T/C	cg05868023	chr4:75230803	EREG	-0.55	-4.74	-0.39	5.71e-6	Iris color (b* coordinate);
TGCT	cis	rs12477438	0.798	rs12468419	chr2:99579680	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.79	-7.94	-0.58	1.06e-12	Chronic sinus infection;
TGCT	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg02953382	chr22:24373134	LOC391322	-0.81	-9.11	-0.63	1.79e-15	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7412746	0.611	rs2271076	chr1:150916657	C/T	cg09365446	chr1:150670422	GOLPH3L	0.34	4.71	0.39	6.58e-6	Melanoma;
TGCT	cis	rs2549003	0.966	rs10072571	chr5:131816711	A/C	cg00255919	chr5:131827918	IRF1	0.22	5.15	0.42	1.01e-6	Asthma (sex interaction);
TGCT	cis	rs2153535	0.541	rs9405386	chr6:8458067	C/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.7	0.46	8.33e-8	Motion sickness;
TGCT	cis	rs7666738	0.830	rs4492007	chr4:98959848	A/T	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg23982607	chr1:1823379	GNB1	-0.55	-8.34	-0.6	1.23e-13	Body mass index;
TGCT	cis	rs10782582	0.593	rs79552201	chr1:76215497	A/T	cg10523679	chr1:76189770	ACADM	-0.67	-6.71	-0.52	6.18e-10	Daytime sleep phenotypes;
TGCT	cis	rs1475911	0.708	rs11701371	chr21:43523972	C/G	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.31	-5.91	-0.47	3.08e-8	IgG glycosylation;
TGCT	cis	rs2153535	0.580	rs9328484	chr6:8524843	A/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.55e-8	Motion sickness;
TGCT	cis	rs7412746	0.586	rs2864882	chr1:150883037	C/T	cg09365446	chr1:150670422	GOLPH3L	0.34	4.71	0.39	6.58e-6	Melanoma;
TGCT	cis	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg03213289	chr20:61660250	NA	-0.64	-8.48	-0.61	5.78e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs12548939	0.560	rs4733803	chr8:128907875	G/A	cg11792826	chr8:129160931	MIR1208	0.2	4.54	0.38	1.32e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs2956278	0.717	rs2947126	chr12:84687359	T/C	cg25678815	chr12:85673915	ALX1	-0.53	-4.76	-0.39	5.4e-6	Depressive symptoms;Depressive symptoms (multi-trait analysis);
TGCT	cis	rs6089829	0.926	rs6011552	chr20:61667894	T/C	cg02380750	chr20:61661411	NA	0.34	5.96	0.47	2.47e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs634534	0.622	rs531612	chr11:65705432	C/T	cg04055107	chr11:65626734	MUS81;CFL1	-0.5	-5.11	-0.42	1.19e-6	Sum eosinophil basophil counts;Eosinophil counts;
TGCT	cis	rs7027203	1.000	rs34624092	chr9:96523092	G/A	cg13679303	chr9:96623674	NA	0.64	9.79	0.66	4.09e-17	DNA methylation (variation);
TGCT	cis	rs600231	0.651	rs2846862	chr11:65219790	A/G	cg11802864	chr11:65308245	LTBP3	0.46	4.59	0.38	1.07e-5	Bone mineral density;
TGCT	cis	rs858239	1.000	rs199348	chr7:23293098	C/A	cg05602783	chr7:23145260	KLHL7	-0.6	-4.83	-0.4	3.97e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs9894429	0.752	rs6565610	chr17:79592652	A/G	cg21984481	chr17:79567631	NPLOC4	-0.26	-4.9	-0.4	2.91e-6	Eye color traits;
TGCT	cis	rs11585357	1.000	rs72646785	chr1:17603472	G/T	cg08277548	chr1:17600880	PADI3	-0.97	-9.95	-0.67	1.7e-17	Hair shape;
TGCT	cis	rs11190604	0.767	rs11190531	chr10:102187310	T/A	cg16005271	chr10:102321736	NA	0.46	4.67	0.39	7.62e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg12963246	chr6:28129442	ZNF389	0.48	4.79	0.4	4.58e-6	Parkinson's disease;
TGCT	cis	rs4595586	0.545	rs2197941	chr12:39402223	G/A	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg20362242	chr5:692897	TPPP	0.5	4.71	0.39	6.66e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg25036284	chr2:26402008	FAM59B	-0.67	-5.32	-0.43	4.71e-7	Gut microbiome composition (summer);
TGCT	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg18876405	chr7:65276391	NA	0.37	5.85	0.47	4.02e-8	Calcium levels;
TGCT	cis	rs3806843	0.766	rs702397	chr5:140050265	A/G	cg19875535	chr5:140030758	IK	-0.35	-5.95	-0.47	2.61e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2153535	0.580	rs6597337	chr6:8531652	C/T	cg07606381	chr6:8435919	SLC35B3	0.54	5.01	0.41	1.86e-6	Motion sickness;
TGCT	cis	rs6121246	0.908	rs17093657	chr20:30428894	G/A	cg13852791	chr20:30311386	BCL2L1	0.76	5.67	0.45	9.7e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs9372253	1.000	rs9386894	chr6:110718853	A/G	cg13266496	chr6:110720918	DDO	-0.48	-5.82	-0.46	4.76e-8	Platelet distribution width;
TGCT	cis	rs6912958	0.712	rs2307379	chr6:88366771	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-4.6	-0.38	1.04e-5	Monocyte percentage of white cells;
TGCT	cis	rs896854	0.540	rs2011567	chr8:95971920	G/A	cg16049864	chr8:95962084	TP53INP1	-0.75	-10.47	-0.69	8.97e-19	Type 2 diabetes;
TGCT	cis	rs10892173	0.566	rs2298649	chr11:117672225	A/G	cg21640587	chr11:117668038	DSCAML1	0.71	8.27	0.6	1.73e-13	Myopia;
TGCT	cis	rs4727027	0.800	rs10952796	chr7:148813138	G/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	4.6	0.38	1.04e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.4	5.83	0.46	4.52e-8	Schizophrenia;
TGCT	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.12	0.42	1.15e-6	Prudent dietary pattern;
TGCT	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg06112835	chr11:68658793	MRPL21	0.46	7.64	0.57	5.15e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs753778	0.570	rs6985866	chr8:142210336	C/T	cg18755752	chr8:142205143	DENND3	0.26	5.05	0.41	1.54e-6	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs4499344	0.604	rs259275	chr19:33159693	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.85	9.09	0.63	2.01e-15	Mean platelet volume;
TGCT	cis	rs7909074	0.898	rs10793565	chr10:45388231	G/C	cg04218760	chr10:45406644	TMEM72	-0.28	-5.66	-0.45	1.01e-7	Mean corpuscular volume;
TGCT	cis	rs6500602	0.647	rs1684600	chr16:4594671	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.31	-5.88	-0.47	3.62e-8	Schizophrenia;
TGCT	cis	rs2243480	1.000	rs160646	chr7:65556280	C/T	cg20637647	chr7:64974828	NA	0.89	5.39	0.44	3.46e-7	Diabetic kidney disease;
TGCT	cis	rs17102423	0.660	rs7152277	chr14:65535391	G/C	cg11161011	chr14:65562177	MAX	-0.46	-6.12	-0.48	1.11e-8	Obesity-related traits;
TGCT	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg04352962	chr1:209979756	IRF6	0.69	5.07	0.41	1.39e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs9913156	0.894	rs28365158	chr17:4620928	T/C	cg19197139	chr17:4613644	ARRB2	0.86	7.84	0.58	1.73e-12	Lymphocyte counts;
TGCT	cis	rs1371867	0.846	rs1788194	chr8:101277916	T/C	cg06002616	chr8:101225028	SPAG1	-0.57	-6.77	-0.52	4.48e-10	Atrioventricular conduction;
TGCT	cis	rs796364	1.000	rs35594306	chr2:200775125	T/C	cg17644776	chr2:200775616	C2orf69	-0.31	-4.83	-0.4	3.99e-6	Schizophrenia;
TGCT	cis	rs3008870	0.755	rs2208577	chr1:67513574	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.8	7.47	0.56	1.28e-11	Lymphocyte percentage of white cells;
TGCT	cis	rs6598955	0.724	rs12132137	chr1:26631243	C/T	cg04990556	chr1:26633338	UBXN11	-0.92	-12.21	-0.74	5.2e-23	Obesity-related traits;
TGCT	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg17554472	chr22:41940697	POLR3H	-0.49	-5.29	-0.43	5.45e-7	Vitiligo;
TGCT	cis	rs7914558	1.000	rs10883824	chr10:104812897	A/G	cg04362960	chr10:104952993	NT5C2	0.62	5.51	0.44	1.97e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	trans	rs365060	0.749	rs260687	chr2:109578855	C/T	cg13735819	chr19:2253850	JSRP1	-0.7	-6.65	-0.51	8.52e-10	Beard thickness;
TGCT	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg13695892	chr22:41940480	POLR3H	0.92	9.06	0.63	2.36e-15	Vitiligo;
TGCT	cis	rs12477438	0.520	rs1133978	chr2:99741964	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	14.89	0.8	2.21e-29	Chronic sinus infection;
TGCT	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg13257436	chr8:145726034	PPP1R16A	-0.31	-4.82	-0.4	4.04e-6	Age at first birth;
TGCT	cis	rs651907	0.535	rs35799195	chr3:101521927	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.31	-6.4	-0.5	2.91e-9	Colorectal cancer;
TGCT	cis	rs3733585	0.673	rs6836706	chr4:9964251	T/A	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.67	-0.51	7.44e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs10876993	0.622	rs7978394	chr12:58091695	C/A	cg15848620	chr12:58087721	OS9	-0.76	-6.37	-0.5	3.3e-9	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs861020	0.630	rs655712	chr1:210006437	G/A	cg05527609	chr1:210001259	C1orf107	0.86	7.54	0.56	8.69e-12	Orofacial clefts;
TGCT	cis	rs7312933	0.533	rs11181499	chr12:42818761	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.54	5.14	0.42	1.06e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs7364180	0.515	rs6002503	chr22:42208672	A/G	cg03806693	chr22:41940476	POLR3H	-0.63	-6.26	-0.49	5.79e-9	Alzheimer's disease biomarkers;
TGCT	cis	rs2862064	0.872	rs1393209	chr5:156477540	G/A	cg12943317	chr5:156479607	HAVCR1	-0.46	-5.59	-0.45	1.35e-7	Platelet count;
TGCT	cis	rs2439831	0.850	rs8042868	chr15:43939642	C/T	cg19166733	chr15:44192098	FRMD5	-0.25	-4.62	-0.38	9.4e-6	Lung cancer in ever smokers;
TGCT	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg20203395	chr5:56204925	C5orf35	-0.56	-4.8	-0.4	4.39e-6	Initial pursuit acceleration;
TGCT	cis	rs8064299	0.655	rs2305214	chr17:72768970	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.62	5.76	0.46	6.21e-8	Monocyte count;
TGCT	cis	rs7027203	0.576	rs4509402	chr9:96543377	C/T	cg14598338	chr9:96623480	NA	0.49	7.16	0.54	6.37e-11	DNA methylation (variation);
TGCT	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg06481639	chr22:41940642	POLR3H	-0.73	-6.64	-0.51	8.91e-10	Vitiligo;
TGCT	cis	rs2120019	1.000	rs7168680	chr15:75369212	G/A	cg11632617	chr15:75315747	PPCDC	-0.33	-4.78	-0.39	4.82e-6	Blood trace element (Zn levels);
TGCT	cis	rs9326248	0.906	rs171052	chr11:117081763	C/G	cg16524733	chr11:117070046	TAGLN	-0.35	-4.87	-0.4	3.27e-6	Blood protein levels;
TGCT	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg11494091	chr17:61959527	GH2	0.52	11.94	0.73	2.4e-22	Prudent dietary pattern;
TGCT	cis	rs2594989	0.691	rs2596816	chr3:11581200	A/C	cg00170343	chr3:11313890	ATG7	0.67	5.18	0.42	8.69e-7	Circulating chemerin levels;
TGCT	cis	rs11190604	0.806	rs11190510	chr10:102157175	G/A	cg16342193	chr10:102329863	NA	-0.39	-5.06	-0.41	1.49e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg00343986	chr7:65444356	GUSB	-0.2	-4.54	-0.38	1.3e-5	Aortic root size;
TGCT	cis	rs589249	0.963	rs4147222	chr1:37176422	G/A	cg04012535	chr1:37176647	NA	0.33	5.39	0.44	3.46e-7	Neuroticism (multi-trait analysis);Schizophrenia;
TGCT	cis	rs9296092	0.560	rs9469505	chr6:33527348	A/G	cg13560919	chr6:33536144	NA	-0.23	-5.06	-0.41	1.49e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs3741151	1.000	rs76570090	chr11:73066321	A/T	cg17517138	chr11:73019481	ARHGEF17	0.91	4.63	0.38	9e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
TGCT	cis	rs7020830	0.931	rs13295115	chr9:37157964	T/G	cg14294708	chr9:37120828	ZCCHC7	1.3	18.09	0.85	1.38e-36	Schizophrenia;
TGCT	cis	rs4776059	1.000	rs10851521	chr15:52942111	G/A	cg25063058	chr15:52860530	ARPP19	0.51	4.57	0.38	1.18e-5	Schizophrenia;
TGCT	cis	rs806215	0.547	rs3757778	chr7:127456607	C/T	cg11539674	chr7:127291444	SND1	-0.36	-4.67	-0.39	7.77e-6	Type 2 diabetes;
TGCT	cis	rs9291683	0.566	rs13122689	chr4:10044648	A/G	cg00071950	chr4:10020882	SLC2A9	0.57	6.47	0.5	2.01e-9	Bone mineral density;
TGCT	cis	rs2836950	0.501	rs4818018	chr21:40694072	C/T	cg11890956	chr21:40555474	PSMG1	-0.66	-6.23	-0.49	6.75e-9	Menarche (age at onset);
TGCT	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg22920501	chr2:26401640	FAM59B	-0.74	-6.4	-0.5	2.86e-9	Gut microbiome composition (summer);
TGCT	cis	rs6671200	0.573	rs3738171	chr1:95699594	A/G	cg20701556	chr1:95698924	RWDD3	-0.54	-5.31	-0.43	4.83e-7	Stearic acid (18:0) levels;
TGCT	trans	rs564343	0.563	rs570760	chr11:65833631	C/T	cg26701943	chr11:108369231	KDELC2	-0.73	-6.91	-0.53	2.21e-10	Obesity (early onset extreme);
TGCT	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg18876405	chr7:65276391	NA	-0.32	-4.92	-0.4	2.69e-6	Aortic root size;
TGCT	cis	rs6969780	0.722	rs3823764	chr7:27187753	C/T	cg03724423	chr7:27170755	HOXA4	-0.43	-4.59	-0.38	1.05e-5	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs425277	1.000	rs421992	chr1:2077260	C/T	cg03732007	chr1:2071316	PRKCZ	0.26	5.44	0.44	2.77e-7	Height;
TGCT	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg17971929	chr21:40555470	PSMG1	0.98	9.13	0.63	1.6e-15	Cognitive function;
TGCT	cis	rs10207060	0.500	rs6731870	chr2:240708096	C/A	cg15726768	chr2:241314588	NA	-0.32	-4.49	-0.37	1.63e-5	Obesity-related traits;
TGCT	cis	rs9302001	1.000	rs9302001	chr13:95463392	A/G	cg07483244	chr13:95358924	NA	-0.38	-4.9	-0.4	2.97e-6	Panic disorder;
TGCT	cis	rs9467711	0.606	rs16891725	chr6:26479150	C/T	cg10795676	chr6:26370623	BTN3A2	-0.44	-4.72	-0.39	6.29e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs910187	0.678	rs6066231	chr20:45818895	C/T	cg27589058	chr20:45804311	EYA2	-0.35	-7.32	-0.55	2.76e-11	Migraine;
TGCT	cis	rs9926296	0.643	rs12596429	chr16:89841374	T/C	cg04287289	chr16:89883240	FANCA	0.66	6.55	0.51	1.36e-9	Vitiligo;
TGCT	cis	rs7394190	0.748	rs4746147	chr10:75527708	A/G	cg07699608	chr10:75541558	CHCHD1	0.8	5.21	0.42	7.72e-7	Incident atrial fibrillation;
TGCT	cis	rs763014	0.898	rs1981484	chr16:630710	A/G	cg27436995	chr16:743998	FBXL16	-0.45	-4.82	-0.4	4.17e-6	Height;
TGCT	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg04944784	chr2:26401820	FAM59B	0.72	5.92	0.47	2.93e-8	Gut microbiome composition (summer);
TGCT	cis	rs3803170	0.513	rs10849943	chr12:111819589	A/G	cg10833066	chr12:111807467	FAM109A	-0.36	-5.66	-0.45	9.9e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs5769707	0.967	rs2187891	chr22:49994094	C/T	cg05373962	chr22:49881684	NA	-0.29	-6.04	-0.48	1.63e-8	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs7829975	0.545	rs13261926	chr8:8551610	T/C	cg17143192	chr8:8559678	CLDN23	-0.46	-4.46	-0.37	1.79e-5	Mood instability;
TGCT	cis	rs6121246	0.609	rs6060652	chr20:30266845	A/G	cg10886678	chr20:30946050	ASXL1	-0.52	-4.44	-0.37	1.97e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs2963155	0.518	rs6196	chr5:142661490	A/G	cg17617527	chr5:142782415	NR3C1	0.86	6.46	0.5	2.2e-9	Breast cancer;
TGCT	cis	rs7666738	0.830	rs62321564	chr4:98976496	C/G	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg11494091	chr17:61959527	GH2	0.6	14.54	0.79	1.46e-28	Prudent dietary pattern;
TGCT	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg11494091	chr17:61959527	GH2	0.61	14.49	0.79	1.92e-28	Prudent dietary pattern;
TGCT	cis	rs2739330	1.000	rs2739330	chr22:24295286	T/C	cg10819733	chr22:24237672	NA	-0.3	-5.02	-0.41	1.77e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7394190	0.748	rs12572278	chr10:75504513	C/A	cg07699608	chr10:75541558	CHCHD1	0.77	4.86	0.4	3.44e-6	Incident atrial fibrillation;
TGCT	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg03806693	chr22:41940476	POLR3H	-1.13	-13.26	-0.77	1.59e-25	Vitiligo;
TGCT	cis	rs568617	1.000	rs693824	chr11:65654783	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.57	5.22	0.42	7.39e-7	Crohn's disease;
TGCT	cis	rs12681287	0.547	rs13249177	chr8:87513034	A/G	cg27223183	chr8:87520930	FAM82B	-0.95	-6.95	-0.53	1.81e-10	Caudate activity during reward;
TGCT	cis	rs3540	0.553	rs8042861	chr15:90977333	G/T	cg22089800	chr15:90895588	ZNF774	0.74	7.82	0.57	2.01e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg01577475	chr2:114033581	PAX8;LOC440839	-0.44	-4.75	-0.39	5.42e-6	Lymphocyte counts;
TGCT	cis	rs763121	0.853	rs5750622	chr22:38956464	C/G	cg06022373	chr22:39101656	GTPBP1	0.8	7.79	0.57	2.29e-12	Menopause (age at onset);
TGCT	cis	rs909002	0.849	rs10914453	chr1:32075036	A/G	cg11573219	chr1:32083031	HCRTR1	-0.49	-6.41	-0.5	2.73e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs13326165	0.715	rs11709658	chr3:52399627	G/A	cg27565382	chr3:53032988	SFMBT1	0.36	4.8	0.4	4.54e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	5.06	0.41	1.46e-6	Menopause (age at onset);
TGCT	cis	rs17001868	0.568	rs9611328	chr22:40791972	C/T	cg07138101	chr22:40742427	ADSL	0.73	5.47	0.44	2.38e-7	Mammographic density (dense area);
TGCT	cis	rs72949976	0.934	rs1922794	chr2:214026181	G/A	cg08319019	chr2:214017104	IKZF2	-0.81	-7.57	-0.56	7.36e-12	Lung cancer;Squamous cell lung carcinoma;
TGCT	cis	rs68170813	0.652	rs12533694	chr7:107102817	C/T	cg02696742	chr7:106810147	HBP1	-0.62	-4.63	-0.38	9.11e-6	Coronary artery disease;
TGCT	cis	rs919433	0.679	rs6708239	chr2:198525084	A/G	cg00792783	chr2:198669748	PLCL1	0.55	4.88	0.4	3.24e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs240764	0.658	rs11155618	chr6:101181811	C/T	cg09795085	chr6:101329169	ASCC3	-0.51	-4.51	-0.38	1.48e-5	Neuroticism;
TGCT	cis	rs7264396	0.790	rs6121020	chr20:34252006	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.25	-0.43	6.33e-7	Total cholesterol levels;
TGCT	cis	rs804280	0.662	rs810738	chr8:11611206	A/G	cg26752888	chr8:11627280	NEIL2	-0.68	-5.34	-0.43	4.21e-7	Myopia (pathological);
TGCT	cis	rs459571	0.959	rs410876	chr9:136893867	C/A	cg13789015	chr9:136890014	NCRNA00094	0.41	7.73	0.57	3.24e-12	Platelet distribution width;
TGCT	cis	rs73198271	0.740	rs10112989	chr8:8647334	A/C	cg15556689	chr8:8085844	FLJ10661	-0.6	-4.46	-0.37	1.8e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs1670533	1.000	rs2045066	chr4:1052401	C/T	cg27284194	chr4:1044797	NA	0.7	6.1	0.48	1.25e-8	Recombination rate (females);
TGCT	cis	rs350251	0.837	rs1641850	chr16:12188433	C/G	cg02910054	chr16:12241554	SNX29	0.33	4.46	0.37	1.85e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs2933343	0.679	rs789254	chr3:128574593	A/G	cg11901034	chr3:128598214	ACAD9	-0.6	-5.58	-0.45	1.45e-7	IgG glycosylation;
TGCT	cis	rs933688	1.000	rs186717	chr5:90780467	T/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.95	8.92	0.63	5.13e-15	Smoking behavior;
TGCT	cis	rs929354	0.566	rs6979947	chr7:157005863	C/T	cg05182265	chr7:156933206	UBE3C	0.35	7.05	0.54	1.08e-10	Body mass index;
TGCT	cis	rs3764628	1.000	rs3752218	chr19:18761213	C/T	cg20098710	chr19:19640075	YJEFN3	-0.44	-4.64	-0.38	8.89e-6	Orofacial clefts;
TGCT	cis	rs4689592	0.583	rs6823154	chr4:7078145	C/T	cg02503808	chr4:7069936	GRPEL1	0.9	8.26	0.6	1.86e-13	Monocyte percentage of white cells;
TGCT	cis	rs7975161	0.882	rs4964270	chr12:104652398	A/G	cg25273343	chr12:104657179	TXNRD1	-0.36	-5.28	-0.43	5.53e-7	Toenail selenium levels;
TGCT	cis	rs12908161	1.000	rs12905057	chr15:85210765	A/G	cg11189052	chr15:85197271	WDR73	0.77	6.28	0.49	5.27e-9	Schizophrenia;
TGCT	cis	rs11030122	0.702	rs4910868	chr11:3980224	A/C	cg18678763	chr11:4115507	RRM1	-0.49	-6.13	-0.48	1.08e-8	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs8064299	0.655	rs12797	chr17:72766993	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.61	5.59	0.45	1.35e-7	Monocyte count;
TGCT	cis	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg03213289	chr20:61660250	NA	0.68	9.9	0.66	2.25e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs6504663	0.596	rs7208018	chr17:48557863	C/T	cg03168497	chr17:48586147	MYCBPAP	-0.45	-5.18	-0.42	8.67e-7	Visceral fat;
TGCT	cis	rs13256369	0.756	rs13282580	chr8:8562903	C/T	cg17143192	chr8:8559678	CLDN23	0.56	5.31	0.43	4.9e-7	Obesity-related traits;
TGCT	cis	rs921968	0.643	rs2556385	chr2:219532905	G/A	cg02176678	chr2:219576539	TTLL4	-0.38	-5.47	-0.44	2.34e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs72901758	0.662	rs56326958	chr17:76250439	C/G	cg25512537	chr17:76250053	NA	0.25	4.51	0.38	1.49e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
TGCT	trans	rs4824093	0.610	rs13340054	chr22:50311726	G/A	cg09872104	chr7:134855509	C7orf49	-0.93	-6.91	-0.53	2.29e-10	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs9916302	0.904	rs11078915	chr17:37715426	T/C	cg15445000	chr17:37608096	MED1	0.31	4.5	0.37	1.53e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg06028808	chr11:68637592	NA	0.51	6.66	0.51	7.87e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs2486288	0.656	rs10519018	chr15:45549265	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.72	-7.33	-0.55	2.57e-11	Glomerular filtration rate;
TGCT	cis	rs2153535	0.580	rs9505454	chr6:8478532	T/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg07424592	chr7:64974309	NA	1.34	8.08	0.59	4.95e-13	Diabetic kidney disease;
TGCT	cis	rs904251	0.523	rs9349039	chr6:37480392	A/G	cg01843034	chr6:37503916	NA	-0.55	-7.01	-0.53	1.36e-10	Cognitive performance;
TGCT	cis	rs2440129	0.611	rs10852889	chr17:6900845	C/T	cg09737314	chr17:6899359	ALOX12	0.48	5.27	0.43	5.84e-7	Tonsillectomy;
TGCT	cis	rs28735056	0.935	rs537962	chr18:77592660	C/G	cg20368463	chr18:77673604	PQLC1	0.46	5.67	0.45	9.72e-8	Schizophrenia;
TGCT	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg24829409	chr8:58192753	C8orf71	-0.59	-4.97	-0.41	2.17e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs727479	0.502	rs12591172	chr15:51503727	G/A	cg19946085	chr15:51559439	CYP19A1	-0.31	-4.53	-0.38	1.39e-5	Estradiol levels;
TGCT	cis	rs7666738	0.830	rs7687958	chr4:99014495	T/C	cg05340658	chr4:99064831	C4orf37	0.48	5.43	0.44	2.92e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11105298	0.891	rs10858896	chr12:89920184	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.67	-4.91	-0.4	2.78e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs9467773	1.000	rs6933176	chr6:26540178	G/A	cg09904177	chr6:26538194	HMGN4	0.65	6.53	0.51	1.53e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg06481639	chr22:41940642	POLR3H	-0.73	-6.49	-0.5	1.83e-9	Vitiligo;
TGCT	cis	rs35306767	0.807	rs34527494	chr10:935192	T/C	cg20503657	chr10:835505	NA	0.8	11.88	0.73	3.41e-22	Eosinophil percentage of granulocytes;
TGCT	trans	rs6040399	1.000	rs6040399	chr20:11157011	A/T	cg11320084	chr1:185014181	RNF2	-0.35	-6.81	-0.52	3.83e-10	Response to citalopram treatment;
TGCT	cis	rs1461503	0.900	rs3751047	chr11:122828439	G/A	cg27398637	chr11:122830231	C11orf63	-0.41	-4.77	-0.39	5.14e-6	Menarche (age at onset);
TGCT	cis	rs2404602	0.709	rs11072597	chr15:76763514	C/A	cg22467129	chr15:76604101	ETFA	0.48	5.11	0.42	1.16e-6	Blood metabolite levels;
TGCT	cis	rs4689388	0.926	rs4458523	chr4:6289986	G/T	cg25554036	chr4:6271136	WFS1	-0.54	-7.54	-0.56	8.85e-12	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs7829975	0.902	rs777707	chr8:8584344	A/G	cg06636001	chr8:8085503	FLJ10661	0.59	5.12	0.42	1.14e-6	Mood instability;
TGCT	cis	rs7647973	1.000	rs9871024	chr3:49554241	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.54	-4.45	-0.37	1.87e-5	Menarche (age at onset);
TGCT	cis	rs11105298	0.891	rs12228177	chr12:89862030	G/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.7	-5.02	-0.41	1.79e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.96	10.35	0.68	1.75e-18	Intelligence (multi-trait analysis);
TGCT	cis	rs1541995	1.000	rs35336871	chr15:96357133	C/T	cg00882281	chr15:96346592	NA	0.29	4.76	0.39	5.31e-6	Photic sneeze reflex;
TGCT	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg22920501	chr2:26401640	FAM59B	0.8	6.34	0.49	3.84e-9	Gut microbiome composition (summer);
TGCT	cis	rs8077577	0.895	rs62073607	chr17:18071338	A/G	cg09161412	chr17:18057145	MYO15A	-0.63	-5.21	-0.42	7.62e-7	Obesity-related traits;
TGCT	cis	rs950027	0.620	rs1145077	chr15:45683795	A/C	cg26924012	chr15:45694286	SPATA5L1	-0.8	-8.55	-0.61	3.95e-14	Response to fenofibrate (adiponectin levels);
TGCT	trans	rs8073060	0.963	rs11080353	chr17:33871281	C/T	cg19694781	chr19:47549865	TMEM160	0.42	7.69	0.57	3.98e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs2820315	1.000	rs2459761	chr1:201808469	C/G	cg12730843	chr1:201915899	LMOD1	-0.26	-4.73	-0.39	6.01e-6	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
TGCT	cis	rs644799	0.509	rs580181	chr11:95643040	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.48	5.0	0.41	1.87e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs873917	0.577	rs784612	chr1:40122939	T/C	cg06209491	chr1:40138402	NT5C1A	-0.35	-5.84	-0.46	4.21e-8	Amyotrophic lateral sclerosis;
TGCT	cis	rs981844	0.885	rs72731673	chr4:154667446	A/G	cg14289246	chr4:154710475	SFRP2	1.01	8.67	0.61	2.02e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs57590327	0.503	rs11706976	chr3:81899653	C/T	cg07356753	chr3:81810745	GBE1	-0.7	-6.42	-0.5	2.68e-9	Extraversion;
TGCT	cis	rs2521263	1.000	rs2074018	chr11:2309634	A/T	cg10151367	chr11:2847642	KCNQ1	0.48	4.61	0.38	9.75e-6	Obesity-related traits;
TGCT	cis	rs9674544	0.740	rs11870560	chr17:47114033	T/C	cg10950924	chr17:47092072	IGF2BP1	-0.35	-4.51	-0.38	1.51e-5	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
TGCT	cis	rs6940638	0.688	rs1028308	chr6:27129757	G/A	cg26531700	chr6:26746687	NA	-0.53	-4.57	-0.38	1.15e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7647973	0.560	rs7638154	chr3:49299375	C/A	cg02487422	chr3:49467188	NICN1	0.55	5.32	0.43	4.77e-7	Menarche (age at onset);
TGCT	cis	rs7909074	0.832	rs10793564	chr10:45386352	C/A	cg05187965	chr10:45406764	TMEM72	-0.26	-5.42	-0.44	2.96e-7	Mean corpuscular volume;
TGCT	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg18402987	chr7:1209562	NA	0.78	6.64	0.51	8.96e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg12311346	chr5:56204834	C5orf35	0.57	6.09	0.48	1.28e-8	Initial pursuit acceleration;
TGCT	cis	rs2688608	0.905	rs2633300	chr10:75656647	A/C	cg23231163	chr10:75533350	FUT11	-0.25	-4.45	-0.37	1.89e-5	Inflammatory bowel disease;
TGCT	cis	rs611744	0.523	rs13253581	chr8:109343105	A/G	cg21045802	chr8:109455806	TTC35	0.83	9.03	0.63	2.75e-15	Dupuytren's disease;
TGCT	cis	rs7916697	0.891	rs7897809	chr10:70000293	A/G	cg18338521	chr10:69995036	NA	-0.28	-4.47	-0.37	1.75e-5	Optic disc area;
TGCT	cis	rs4460629	0.742	rs6427158	chr1:155074903	G/T	cg23973274	chr1:155060172	NA	-0.26	-4.66	-0.39	8.1e-6	Serum magnesium levels;
TGCT	cis	rs9583531	0.600	rs7986286	chr13:111357207	A/G	cg24331049	chr13:111365604	ING1	0.77	7.44	0.56	1.45e-11	Coronary artery disease;
TGCT	cis	rs6582630	0.502	rs11181230	chr12:38300085	A/G	cg26384229	chr12:38710491	ALG10B	0.8	7.04	0.53	1.17e-10	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs617219	0.659	rs13182512	chr5:78573790	A/T	cg23514016	chr5:78407564	BHMT	-0.32	-4.87	-0.4	3.38e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs28493229	0.708	rs10408065	chr19:41161096	T/C	cg11601297	chr19:41224147	ITPKC;ADCK4	0.57	5.15	0.42	9.78e-7	Kawasaki disease;
TGCT	cis	rs2692947	0.644	rs772175	chr2:96944553	G/A	cg23100626	chr2:96804247	ASTL	0.45	5.73	0.46	7.26e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs2180341	0.538	rs3756993	chr6:127651551	A/C	cg27446573	chr6:127587934	RNF146	0.66	5.86	0.47	3.96e-8	Breast cancer;
TGCT	cis	rs3741151	1.000	rs1892855	chr11:73017972	G/T	cg17517138	chr11:73019481	ARHGEF17	1.16	5.5	0.44	2.11e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
TGCT	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs10927875	0.800	rs1627145	chr1:16328116	C/T	cg21385522	chr1:16154831	NA	0.64	6.9	0.53	2.33e-10	Dilated cardiomyopathy;
TGCT	cis	rs3820068	0.603	rs6695903	chr1:15985940	C/T	cg05660106	chr1:15850417	CASP9	0.84	8.69	0.62	1.82e-14	Systolic blood pressure;
TGCT	cis	rs9611519	0.780	rs2284079	chr22:41658632	C/T	cg13695892	chr22:41940480	POLR3H	-0.64	-6.04	-0.48	1.62e-8	Neuroticism;
TGCT	cis	rs1008375	0.966	rs3796813	chr4:17591648	A/G	cg18681998	chr4:17616180	MED28	0.96	9.84	0.66	3.1e-17	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9393692	0.875	rs9393690	chr6:26271713	A/T	cg00631329	chr6:26305371	NA	-0.43	-6.41	-0.5	2.72e-9	Educational attainment;
TGCT	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg00343986	chr7:65444356	GUSB	-0.23	-5.13	-0.42	1.07e-6	Aortic root size;
TGCT	cis	rs1577917	0.917	rs12665464	chr6:86574133	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.47	-0.44	2.33e-7	Response to antipsychotic treatment;
TGCT	cis	rs2836633	0.929	rs62217519	chr21:40034390	G/A	cg12884169	chr21:40033163	ERG	0.43	4.57	0.38	1.16e-5	Coronary artery disease;
TGCT	cis	rs11648796	0.759	rs12597195	chr16:769026	G/C	cg07343612	chr16:622815	PIGQ	-0.38	-5.28	-0.43	5.53e-7	Height;
TGCT	cis	rs1691799	0.899	rs1168321	chr12:66744517	C/G	cg16791601	chr12:66731901	HELB	0.28	6.17	0.48	8.87e-9	White blood cell count (basophil);
TGCT	cis	rs8010715	1.000	rs3742500	chr14:24611978	G/T	cg23112188	chr14:24563095	PCK2	-0.41	-4.94	-0.41	2.49e-6	IgG glycosylation;
TGCT	cis	rs707040	0.921	rs2348925	chr2:155229374	T/C	cg18104148	chr2:154337490	NA	0.19	4.63	0.38	9.05e-6	Sudden cardiac arrest;
TGCT	cis	rs12971120	0.891	rs12968731	chr18:72169708	G/T	cg25817165	chr18:72167213	CNDP2	-0.29	-5.11	-0.42	1.16e-6	Refractive error;
TGCT	cis	rs9911578	0.900	rs7214335	chr17:57158840	G/A	cg12560992	chr17:57184187	TRIM37	0.8	9.86	0.66	2.69e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs60871478	0.947	rs4074610	chr7:791755	G/A	cg05535760	chr7:792225	HEATR2	0.33	4.57	0.38	1.15e-5	Cerebrospinal P-tau181p levels;
TGCT	cis	rs11112613	0.775	rs12305225	chr12:105963266	G/C	cg03607813	chr12:105948248	NA	0.44	5.31	0.43	4.89e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	cis	rs12497850	0.864	rs4521268	chr3:49137904	G/T	cg07636037	chr3:49044803	WDR6	0.95	10.21	0.68	3.98e-18	Parkinson's disease;
TGCT	cis	rs2354432	0.607	rs59689207	chr1:146722484	G/A	cg25205988	chr1:146714368	CHD1L	-1.34	-6.07	-0.48	1.44e-8	Mitochondrial DNA levels;
TGCT	cis	rs2204008	0.543	rs2387018	chr12:38065638	C/T	cg26384229	chr12:38710491	ALG10B	0.87	7.79	0.57	2.32e-12	Bladder cancer;
TGCT	cis	rs921968	0.643	rs579610	chr2:219327582	C/A	cg02176678	chr2:219576539	TTLL4	0.43	6.29	0.49	5.03e-9	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs9952991	0.941	rs9952749	chr18:12780456	A/G	cg23544223	chr18:12777786	NA	0.63	6.02	0.48	1.85e-8	Inflammatory skin disease;
TGCT	cis	rs59197085	0.551	rs60384027	chr7:128437514	G/A	cg00260937	chr7:128520193	KCP	0.45	4.66	0.39	7.95e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
TGCT	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg08859206	chr1:53392774	SCP2	-0.42	-6.23	-0.49	6.54e-9	Monocyte count;
TGCT	cis	rs6500602	0.561	rs62039231	chr16:4519548	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.31	5.69	0.45	8.69e-8	Schizophrenia;
TGCT	cis	rs6547741	0.743	rs7564625	chr2:27862397	C/T	cg27432699	chr2:27873401	GPN1	-0.24	-6.05	-0.48	1.57e-8	Oral cavity cancer;
TGCT	cis	rs11096990	0.634	rs12651217	chr4:39273584	C/T	cg20847110	chr4:39482781	LOC401127	0.16	4.53	0.38	1.38e-5	Cognitive function;
TGCT	cis	rs2806561	0.704	rs856510	chr1:23524407	A/C	cg12483005	chr1:23474871	LUZP1	0.42	5.41	0.44	3.15e-7	Height;
TGCT	cis	rs11167764	0.945	rs891991	chr5:141484977	A/T	cg08523384	chr5:141488047	NDFIP1	-0.26	-5.41	-0.44	3.08e-7	Crohn's disease;
TGCT	cis	rs72781680	0.898	rs12619592	chr2:23971415	C/A	cg08917208	chr2:24149416	ATAD2B	0.83	5.24	0.43	6.62e-7	Lymphocyte counts;
TGCT	cis	rs4689388	0.824	rs114669221	chr4:6301459	G/A	cg14416269	chr4:6271139	WFS1	0.37	4.8	0.4	4.4e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs910316	0.763	rs175057	chr14:75489632	C/T	cg11812906	chr14:75593930	NEK9	-0.56	-5.3	-0.43	5.11e-7	Height;
TGCT	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg08280861	chr8:58055591	NA	0.51	5.73	0.46	7.17e-8	Developmental language disorder (linguistic errors);
TGCT	cis	rs7216064	1.000	rs12451707	chr17:65871598	G/A	cg12091567	chr17:66097778	LOC651250	-0.83	-6.49	-0.5	1.9e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs4699052	0.787	rs2169508	chr4:104066890	T/A	cg16532752	chr4:104119610	CENPE	-0.6	-5.47	-0.44	2.34e-7	Testicular germ cell tumor;
TGCT	cis	rs67478160	0.619	rs1187416	chr14:104311465	A/G	cg26031613	chr14:104095156	KLC1	-0.63	-6.53	-0.51	1.56e-9	Schizophrenia;
TGCT	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg23131131	chr22:24373011	LOC391322	-0.81	-8.79	-0.62	1.03e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9921192	0.967	rs251735	chr16:4320672	G/C	cg00021532	chr16:4324280	TFAP4	0.83	9.42	0.65	3.22e-16	Prostate-specific antigen levels;
TGCT	cis	rs909002	0.772	rs10914452	chr1:32074575	G/A	cg11573219	chr1:32083031	HCRTR1	-0.45	-5.87	-0.47	3.67e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7769051	1.000	rs73554431	chr6:133129922	T/G	cg07930552	chr6:133119739	C6orf192	0.94	5.09	0.42	1.28e-6	Type 2 diabetes nephropathy;
TGCT	cis	rs4851266	1.000	rs1465801	chr2:100836060	C/T	cg07810366	chr2:100720526	AFF3	-0.38	-5.48	-0.44	2.24e-7	Educational attainment;
TGCT	cis	rs7726839	0.561	rs4957049	chr5:579080	C/A	cg09021430	chr5:549028	NA	-0.37	-5.39	-0.44	3.37e-7	Obesity-related traits;
TGCT	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg00149659	chr3:10157352	C3orf10	0.96	6.13	0.48	1.1e-8	Alzheimer's disease;
TGCT	cis	rs59698941	0.550	rs60042615	chr5:132193220	A/G	cg27099455	chr5:132201840	GDF9;UQCRQ	0.3	4.94	0.41	2.44e-6	Apolipoprotein A-IV levels;
TGCT	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg25767906	chr1:53392781	SCP2	0.47	5.26	0.43	6.03e-7	Monocyte count;
TGCT	cis	rs2243480	1.000	rs410128	chr7:65603173	C/T	cg07424592	chr7:64974309	NA	1.26	7.55	0.56	7.99e-12	Diabetic kidney disease;
TGCT	cis	rs56399783	0.901	rs56356906	chr7:2774383	G/A	cg19731401	chr7:2775893	GNA12	0.36	5.07	0.41	1.4e-6	Childhood ear infection;
TGCT	cis	rs172166	0.561	rs149971	chr6:27982152	G/A	cg11262757	chr6:27280423	POM121L2	0.5	4.81	0.4	4.25e-6	Cardiac Troponin-T levels;
TGCT	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg00343986	chr7:65444356	GUSB	0.23	5.13	0.42	1.08e-6	Aortic root size;
TGCT	cis	rs1008375	0.931	rs6449310	chr4:17575530	T/C	cg18681998	chr4:17616180	MED28	0.93	9.3	0.64	6.29e-16	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs72781680	1.000	rs72796389	chr2:24171761	A/G	cg08917208	chr2:24149416	ATAD2B	0.73	4.51	0.38	1.48e-5	Lymphocyte counts;
TGCT	cis	rs56235845	0.694	rs11949401	chr5:176765989	A/G	cg16006841	chr5:176797999	RGS14	0.5	7.45	0.56	1.38e-11	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg06753367	chr22:24256600	NA	-0.24	-4.59	-0.38	1.05e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7824557	0.505	rs2572440	chr8:11249010	G/T	cg21775007	chr8:11205619	TDH	0.66	6.92	0.53	2.1e-10	Retinal vascular caliber;
TGCT	cis	rs2153535	0.580	rs9393019	chr6:8462091	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs7267979	1.000	rs2500436	chr20:25406366	G/C	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg11644478	chr21:40555479	PSMG1	0.64	5.74	0.46	6.99e-8	Cognitive function;
TGCT	cis	rs3784262	0.669	rs12594082	chr15:58267779	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.42	-5.94	-0.47	2.7e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs950169	1.000	rs12915234	chr15:84758301	G/A	cg17173187	chr15:85201210	NMB	0.48	5.39	0.44	3.36e-7	Schizophrenia;
TGCT	cis	rs11030122	0.660	rs10160753	chr11:3894712	T/G	cg18678763	chr11:4115507	RRM1	-0.35	-4.47	-0.37	1.71e-5	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs6882046	0.513	rs601942	chr5:88031820	T/C	cg22951263	chr5:87985283	NA	-0.55	-5.94	-0.47	2.74e-8	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs7772486	0.558	rs9497403	chr6:146054695	T/G	cg13319975	chr6:146136371	FBXO30	0.74	6.68	0.51	7.36e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4727027	0.704	rs13229244	chr7:148898219	A/C	cg23583168	chr7:148888333	NA	0.78	10.81	0.7	1.32e-19	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs7659604	0.540	rs28394772	chr4:122678543	C/T	cg19748678	chr4:122722346	EXOSC9	-0.51	-5.0	-0.41	1.92e-6	Type 2 diabetes;
TGCT	cis	rs112591243	0.570	rs17302700	chr21:47969793	C/T	cg10657630	chr21:48055338	PRMT2	1.03	4.63	0.38	9.08e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs1801251	1.000	rs2592105	chr2:233645968	C/G	cg25237894	chr2:233734115	C2orf82	0.33	5.95	0.47	2.53e-8	Coronary artery disease;
TGCT	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg25036284	chr2:26402008	FAM59B	-0.57	-4.97	-0.41	2.15e-6	Gut microbiome composition (summer);
TGCT	cis	rs909002	0.925	rs4949455	chr1:32114793	C/T	cg11573219	chr1:32083031	HCRTR1	-0.45	-5.79	-0.46	5.44e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7119038	0.509	rs10790261	chr11:118579747	C/T	cg19308663	chr11:118741387	NA	-0.26	-4.58	-0.38	1.14e-5	Sjögren's syndrome;
TGCT	cis	rs35160687	0.901	rs12714179	chr2:86514958	T/C	cg03171300	chr2:86307199	POLR1A	0.32	5.54	0.45	1.73e-7	Night sleep phenotypes;
TGCT	cis	rs3806843	0.676	rs778591	chr5:140025484	G/A	cg19875535	chr5:140030758	IK	-0.35	-6.07	-0.48	1.46e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs1878931	0.543	rs17612463	chr16:3420479	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.76	6.35	0.5	3.66e-9	Body mass index (adult);
TGCT	cis	rs9549367	0.673	rs575453	chr13:113837871	C/A	cg00898013	chr13:113819073	PROZ	0.53	7.2	0.54	5.17e-11	Platelet distribution width;
TGCT	cis	rs1372520	0.684	rs2197120	chr4:90729602	A/G	cg20003494	chr4:90757398	SNCA	-0.66	-5.21	-0.42	7.59e-7	Neuroticism;
TGCT	cis	rs4788570	0.578	rs9934789	chr16:71662467	A/G	cg06353428	chr16:71660113	MARVELD3	1.56	12.61	0.75	5.63e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs797680	0.856	rs10874762	chr1:93639101	T/G	cg17826107	chr1:92977322	EVI5	-0.24	-5.23	-0.43	6.93e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs9611519	0.929	rs9611509	chr22:41565827	A/G	cg03806693	chr22:41940476	POLR3H	-0.67	-6.19	-0.49	7.94e-9	Neuroticism;
TGCT	cis	rs1843834	1.000	rs4624372	chr2:225553128	A/G	cg22455342	chr2:225449267	CUL3	0.75	7.37	0.55	2.15e-11	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs7666738	0.606	rs28625338	chr4:99076996	A/G	cg17366294	chr4:99064904	C4orf37	0.58	5.46	0.44	2.55e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg06028605	chr16:24865363	SLC5A11	-0.42	-4.69	-0.39	7.14e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg23283495	chr1:209979779	IRF6	0.65	5.53	0.44	1.81e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs8084125	0.832	rs62105179	chr18:74950858	A/G	cg15443732	chr18:74961078	GALR1	0.48	4.7	0.39	6.76e-6	Obesity-related traits;
TGCT	cis	rs185538822	1	rs185538822	chr4:106803682	A/C	cg24545054	chr4:106630052	GSTCD;INTS12	1.01	4.61	0.38	9.71e-6	Post bronchodilator FEV1;
TGCT	cis	rs11098499	0.754	rs28643450	chr4:120245242	G/A	cg09307838	chr4:120376055	NA	0.6	5.65	0.45	1.02e-7	Corneal astigmatism;
TGCT	cis	rs7666738	0.830	rs10022331	chr4:98960392	C/A	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9372253	0.678	rs9487392	chr6:110708626	C/T	cg13266496	chr6:110720918	DDO	0.39	4.52	0.38	1.41e-5	Platelet distribution width;
TGCT	cis	rs11031096	0.542	rs6578424	chr11:3973140	G/A	cg18678763	chr11:4115507	RRM1	-0.42	-5.14	-0.42	1.05e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs1994135	0.692	rs1816958	chr12:33695066	A/T	cg06521331	chr12:34319734	NA	-0.3	-4.69	-0.39	6.97e-6	Resting heart rate;
TGCT	cis	rs3820928	0.874	rs6718057	chr2:227834349	T/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-4.58	-0.38	1.1e-5	Pulmonary function;
TGCT	cis	rs6540559	0.546	rs75308488	chr1:210030639	T/C	cg23283495	chr1:209979779	IRF6	0.66	4.95	0.41	2.37e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs1949733	0.848	rs2255501	chr4:8475014	G/A	cg13073564	chr4:8508604	NA	0.44	4.65	0.39	8.24e-6	Response to antineoplastic agents;
TGCT	cis	rs6831352	0.589	rs2924584	chr4:99988208	A/G	cg12011299	chr4:100065546	ADH4	0.38	5.47	0.44	2.4e-7	Alcohol dependence;
TGCT	cis	rs10875595	0.836	rs59933130	chr5:140667303	G/A	cg24830062	chr5:140700576	TAF7	-0.6	-5.13	-0.42	1.09e-6	Pulmonary function decline;
TGCT	cis	rs61774743	0.636	rs1892423	chr1:41849340	A/C	cg01193554	chr1:41846683	NA	-0.44	-5.49	-0.44	2.13e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg05368731	chr17:41323189	NBR1	1.16	13.76	0.78	1.03e-26	Menopause (age at onset);
TGCT	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg03161606	chr19:29218774	NA	0.6	5.84	0.46	4.28e-8	Methadone dose in opioid dependence;
TGCT	cis	rs12681287	0.640	rs12678720	chr8:87457929	T/G	cg27223183	chr8:87520930	FAM82B	-0.89	-6.43	-0.5	2.54e-9	Caudate activity during reward;
TGCT	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg23758822	chr17:41437982	NA	0.69	6.56	0.51	1.33e-9	Menopause (age at onset);
TGCT	cis	rs8013055	0.796	rs8005568	chr14:105971794	A/G	cg23356831	chr14:105996513	TMEM121	0.38	5.91	0.47	3.1e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs33794	0.901	rs33776	chr3:45286898	C/T	cg18645101	chr3:44551900	NA	0.55	4.82	0.4	4.08e-6	Lung function (forced expiratory volume in 1 second);
TGCT	cis	rs244731	0.959	rs6556307	chr5:176641434	C/T	cg17509989	chr5:176798049	RGS14	0.61	7.3	0.55	2.98e-11	Urate levels in lean individuals;
TGCT	cis	rs9549367	0.673	rs575453	chr13:113837871	C/A	cg09473364	chr13:112927190	NA	0.29	4.64	0.38	8.73e-6	Platelet distribution width;
TGCT	cis	rs7914558	0.966	rs10748839	chr10:104953547	A/G	cg05855489	chr10:104503620	C10orf26	0.52	4.58	0.38	1.1e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs3772130	0.962	rs6776670	chr3:121543120	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.5	4.49	0.37	1.63e-5	Cognitive performance;
TGCT	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg00684032	chr4:1343700	KIAA1530	0.23	4.95	0.41	2.36e-6	Obesity-related traits;
TGCT	cis	rs57920188	0.584	rs57277002	chr1:4092054	T/G	cg20703997	chr1:4087676	NA	0.49	5.79	0.46	5.39e-8	Interleukin-17 levels;
TGCT	cis	rs7666738	0.830	rs9992639	chr4:98940400	G/T	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs9650657	0.515	rs6601560	chr8:10950866	T/C	cg15556689	chr8:8085844	FLJ10661	-0.85	-8.3	-0.6	1.46e-13	Neuroticism;
TGCT	cis	rs8014252	0.803	rs7157618	chr14:71010166	C/T	cg11204974	chr14:71022665	NA	-0.53	-4.46	-0.37	1.79e-5	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
TGCT	cis	rs992157	0.775	rs7559428	chr2:219150238	A/G	cg00012203	chr2:219082015	ARPC2	-0.8	-7.98	-0.58	8.26e-13	Colorectal cancer;
TGCT	cis	rs11264213	0.901	rs649152	chr1:36438649	T/G	cg07093915	chr1:36184400	C1orf216	0.65	4.47	0.37	1.77e-5	Schizophrenia;
TGCT	cis	rs9467773	0.967	rs1056347	chr6:26527524	G/C	cg15659132	chr6:26577336	NA	0.86	12.21	0.74	5.3e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg02725872	chr8:58115012	NA	-0.38	-5.05	-0.41	1.55e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2594989	0.943	rs2454493	chr3:11506458	A/G	cg26283222	chr3:11613257	VGLL4	-0.22	-4.65	-0.39	8.53e-6	Circulating chemerin levels;
TGCT	cis	rs6424115	0.867	rs2501432	chr1:24201920	T/C	cg15997130	chr1:24165203	NA	0.85	9.25	0.64	8.02e-16	Immature fraction of reticulocytes;
TGCT	cis	rs9972944	0.756	rs6504357	chr17:63770621	C/T	cg07283582	chr17:63770753	CCDC46	-0.26	-5.27	-0.43	5.91e-7	Total body bone mineral density;
TGCT	cis	rs2288884	0.943	rs11084131	chr19:52514446	G/A	cg15405931	chr19:52693188	PPP2R1A	-0.69	-4.47	-0.37	1.77e-5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg03188948	chr7:1209495	NA	0.68	5.8	0.46	5.09e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg24060327	chr5:131705240	SLC22A5	-0.76	-8.4	-0.6	8.54e-14	Blood metabolite levels;
TGCT	cis	rs17102423	0.594	rs4902360	chr14:65546722	A/C	cg11161011	chr14:65562177	MAX	-0.46	-6.47	-0.5	2.04e-9	Obesity-related traits;
TGCT	cis	rs9393692	0.875	rs2142703	chr6:26289605	A/G	cg00631329	chr6:26305371	NA	-0.44	-6.59	-0.51	1.14e-9	Educational attainment;
TGCT	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.89	6.51	0.5	1.66e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7582180	0.629	rs13031508	chr2:100952757	A/G	cg14675211	chr2:100938903	LONRF2	0.5	4.76	0.39	5.35e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1971762	0.762	rs4759282	chr12:54072435	C/A	cg16917193	chr12:54089295	NA	0.6	4.79	0.4	4.69e-6	Height;
TGCT	cis	rs137603	0.502	rs137627	chr22:39716341	G/A	cg01093212	chr22:39715156	SNORD43;RPL3	-0.5	-4.8	-0.4	4.49e-6	Primary biliary cholangitis;
TGCT	cis	rs62244186	0.520	rs9311361	chr3:44796132	T/G	cg10263370	chr3:44754102	ZNF502	-0.46	-5.56	-0.45	1.61e-7	Depressive symptoms;
TGCT	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg13695892	chr22:41940480	POLR3H	0.8	8.01	0.58	7.2e-13	Vitiligo;
TGCT	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.08	0.48	1.37e-8	Bipolar disorder;
TGCT	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg27535305	chr1:53392650	SCP2	-0.24	-4.69	-0.39	6.96e-6	Monocyte count;
TGCT	cis	rs41271951	0.512	rs12090246	chr1:151107496	G/A	cg00666978	chr1:150947442	LASS2	0.89	4.64	0.38	8.54e-6	Blood protein levels;
TGCT	cis	rs78456975	0.506	rs10206900	chr2:1552841	T/C	cg01028140	chr2:1542097	TPO	-0.34	-4.86	-0.4	3.54e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs7666738	0.830	rs1426666	chr4:99030887	A/G	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg20818283	chr2:191399100	TMEM194B	0.48	4.52	0.38	1.44e-5	Pulse pressure;
TGCT	cis	rs2180341	0.596	rs12215298	chr6:127676833	C/T	cg27446573	chr6:127587934	RNF146	0.76	6.71	0.52	6.24e-10	Breast cancer;
TGCT	cis	rs9549367	0.789	rs9549699	chr13:113878263	T/A	cg18105134	chr13:113819100	PROZ	-0.33	-5.38	-0.43	3.61e-7	Platelet distribution width;
TGCT	cis	rs13191362	0.938	rs13208970	chr6:163006368	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.57	4.94	0.41	2.45e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs2404602	0.692	rs55729975	chr15:76803226	G/A	cg22467129	chr15:76604101	ETFA	-0.48	-5.56	-0.45	1.58e-7	Blood metabolite levels;
TGCT	trans	rs10022799	0.725	rs10002479	chr4:168136279	A/G	cg08507725	chr4:8239220	SH3TC1	-0.4	-7.28	-0.55	3.31e-11	Cognitive function;
TGCT	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg10802521	chr3:52805072	NEK4	-0.73	-9.41	-0.65	3.43e-16	Bipolar disorder;
TGCT	cis	rs10193935	0.901	rs6544533	chr2:42516372	G/C	cg27598129	chr2:42591480	NA	-0.33	-4.7	-0.39	6.93e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg13342137	chr4:2252803	MXD4	0.17	4.56	0.38	1.23e-5	Obesity-related traits;
TGCT	cis	rs1062177	1.000	rs973529	chr5:151188158	T/C	cg12924095	chr5:151150029	G3BP1	0.35	4.94	0.41	2.52e-6	Preschool internalizing problems;
TGCT	cis	rs7617773	0.780	rs11130164	chr3:48369034	G/A	cg11946769	chr3:48343235	NME6	0.8	6.91	0.53	2.26e-10	Coronary artery disease;
TGCT	cis	rs2456568	0.802	rs8181578	chr11:93637442	G/A	cg17595323	chr11:93583763	C11orf90	-0.47	-6.52	-0.51	1.58e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs10875595	0.836	rs3749780	chr5:140682757	C/T	cg24830062	chr5:140700576	TAF7	-0.64	-5.37	-0.43	3.7e-7	Pulmonary function decline;
TGCT	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg01585852	chr22:24235823	MIF	-0.21	-4.56	-0.38	1.23e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6964587	0.933	rs13230837	chr7:91779017	A/G	cg17063962	chr7:91808500	NA	0.92	9.89	0.66	2.4e-17	Breast cancer;
TGCT	cis	rs6840360	0.571	rs1822347	chr4:152525319	A/G	cg17479576	chr4:152424074	FAM160A1	-0.73	-7.94	-0.58	1.03e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs4689388	0.890	rs3821941	chr4:6286954	A/G	cg25554036	chr4:6271136	WFS1	0.57	8.16	0.59	3.18e-13	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs603424	0.597	rs574122	chr10:102089174	C/A	cg00409684	chr10:102984527	NA	0.61	4.69	0.39	7.04e-6	Phospholipid levels (plasma);Palmitic acid (16:0) levels;Palmitoleic acid (16:1n-7) levels;Mean platelet volume;Serum metabolite levels;Blood metabolite levels;Vaccenic acid (18:1n-7) levels;Metabolic traits;Coronary artery disease;Blood metabolite ratios;Glycerophospholipid levels;
TGCT	cis	rs11578119	1.000	rs12138428	chr1:170505188	T/G	cg09767346	chr1:170501363	GORAB	0.65	5.17	0.42	9.21e-7	Male-pattern baldness;
TGCT	cis	rs4776059	1.000	rs4776059	chr15:52886962	C/T	cg25063058	chr15:52860530	ARPP19	0.53	4.79	0.4	4.59e-6	Schizophrenia;
TGCT	cis	rs4517514	0.509	rs11018869	chr11:89865168	A/G	cg05041596	chr11:89867385	NAALAD2	0.52	4.56	0.38	1.22e-5	Trans fatty acid levels;
TGCT	cis	rs892961	0.931	rs2411110	chr17:75400143	A/C	cg05865280	chr17:75406074	SEPT9	0.28	5.81	0.46	4.95e-8	Airflow obstruction;
TGCT	cis	rs910316	0.870	rs7147712	chr14:75670707	C/G	cg11812906	chr14:75593930	NEK9	-0.68	-6.9	-0.53	2.39e-10	Height;
TGCT	cis	rs7089973	0.604	rs1359079	chr10:116582502	A/G	cg03647239	chr10:116582469	FAM160B1	0.58	5.63	0.45	1.16e-7	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs11148252	0.904	rs9536079	chr13:53030565	G/A	cg00495681	chr13:53174319	NA	0.6	6.32	0.49	4.23e-9	Lewy body disease;
TGCT	cis	rs796364	0.789	rs176008	chr2:200814720	A/T	cg17644776	chr2:200775616	C2orf69	0.31	4.85	0.4	3.58e-6	Schizophrenia;
TGCT	cis	rs6484504	0.576	rs169623	chr11:31184157	T/C	cg26647111	chr11:31128758	NA	-0.34	-4.63	-0.38	9.09e-6	Red blood cell count;
TGCT	cis	rs8177253	0.665	rs6774822	chr3:133442012	G/T	cg16414030	chr3:133502952	NA	-0.52	-7.29	-0.55	3.17e-11	Iron status biomarkers;
TGCT	cis	rs3617	0.573	rs4687680	chr3:52907372	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.5	-4.84	-0.4	3.85e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs17221829	0.673	rs56004718	chr11:89413190	A/G	cg02982614	chr11:89391479	FOLH1B	-0.28	-4.66	-0.39	7.94e-6	Anxiety in major depressive disorder;
TGCT	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg17971929	chr21:40555470	PSMG1	-0.9	-8.51	-0.61	4.66e-14	Cognitive function;
TGCT	cis	rs2404602	0.583	rs12913096	chr15:76551852	C/T	cg22467129	chr15:76604101	ETFA	-0.61	-7.83	-0.58	1.89e-12	Blood metabolite levels;
TGCT	cis	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg25660036	chr4:7070649	GRPEL1	0.62	5.52	0.44	1.91e-7	Monocyte percentage of white cells;
TGCT	cis	rs6684514	1.000	rs10908498	chr1:156278175	T/C	cg16558208	chr1:156270281	VHLL	0.48	9.61	0.65	1.13e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs28595532	0.920	rs17325129	chr4:119778284	T/C	cg21605333	chr4:119757512	SEC24D	1.53	8.87	0.62	6.71e-15	Cannabis dependence symptom count;
TGCT	cis	rs9443645	0.810	rs9443637	chr6:79714708	C/T	cg09184832	chr6:79620586	NA	-0.43	-4.83	-0.4	3.93e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs35883536	0.647	rs10493929	chr1:101043928	A/C	cg10298815	chr1:101004474	GPR88	-0.26	-4.8	-0.4	4.47e-6	Monocyte count;
TGCT	cis	rs12220898	0.749	rs7098191	chr10:50481213	A/G	cg06072769	chr10:50146962	WDFY4	0.38	4.98	0.41	2.07e-6	Inflammatory biomarkers;
TGCT	cis	rs12579753	0.917	rs10862375	chr12:82254809	C/G	cg07988820	chr12:82153109	PPFIA2	0.5	5.29	0.43	5.43e-7	Resting heart rate;
TGCT	cis	rs2456568	0.803	rs10765641	chr11:93640312	T/C	cg14065697	chr11:93583672	C11orf90	-0.36	-4.45	-0.37	1.85e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs6088580	0.634	rs2184836	chr20:32963369	A/G	cg24642439	chr20:33292090	TP53INP2	-0.49	-4.49	-0.37	1.59e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs919433	0.713	rs55642934	chr2:198491110	C/T	cg00792783	chr2:198669748	PLCL1	0.49	4.51	0.38	1.46e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs4713118	0.824	rs9366702	chr6:27734470	T/C	cg02458000	chr6:26745757	NA	-0.52	-4.49	-0.37	1.64e-5	Parkinson's disease;
TGCT	cis	rs4713118	0.955	rs9380012	chr6:27684654	A/G	cg10876282	chr6:28092338	ZSCAN16	0.5	4.62	0.38	9.35e-6	Parkinson's disease;
TGCT	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg25036284	chr2:26402008	FAM59B	0.65	5.19	0.42	8.36e-7	Gut microbiome composition (summer);
TGCT	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg07061783	chr6:25882402	NA	-0.58	-5.58	-0.45	1.46e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg01765077	chr12:122356316	WDR66	0.32	4.64	0.38	8.82e-6	Mean corpuscular volume;
TGCT	cis	rs7826238	0.535	rs2979179	chr8:8320029	C/T	cg08975724	chr8:8085496	FLJ10661	0.59	5.42	0.44	2.96e-7	Systolic blood pressure;
TGCT	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg25767906	chr1:53392781	SCP2	-0.57	-6.63	-0.51	9.03e-10	Monocyte count;
TGCT	cis	rs7100689	0.577	rs9421464	chr10:82043426	C/T	cg01528321	chr10:82214614	TSPAN14	0.67	6.45	0.5	2.31e-9	Post bronchodilator FEV1;
TGCT	cis	rs3125734	0.653	rs1007976	chr10:63970144	C/T	cg19640130	chr10:64028056	RTKN2	0.41	5.24	0.43	6.58e-7	Rheumatoid arthritis;
TGCT	cis	rs7940866	0.903	rs1433980	chr11:130870956	A/G	cg05962950	chr11:130786565	SNX19	0.59	5.34	0.43	4.3e-7	Schizophrenia;
TGCT	cis	rs1362404	0.653	rs1118081	chr16:51964912	C/T	cg03955530	chr16:52681474	NA	0.3	4.62	0.38	9.63e-6	Gut microbiota (bacterial taxa);
TGCT	cis	rs17718580	0.536	rs56285552	chr14:51044852	G/C	cg04730355	chr14:51134070	SAV1	1.25	8.77	0.62	1.16e-14	Cognitive performance;
TGCT	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg03351412	chr1:154909251	PMVK	0.52	4.8	0.4	4.51e-6	Prostate cancer;
TGCT	cis	rs13064447	0.817	rs3732687	chr3:12776428	A/C	cg20675869	chr3:12750130	NA	-0.2	-5.01	-0.41	1.79e-6	Major depression and alcohol dependence;
TGCT	cis	rs4372836	1.000	rs4666118	chr2:28951698	C/T	cg09522027	chr2:28974177	PPP1CB	-0.59	-5.11	-0.42	1.19e-6	Body mass index;
TGCT	cis	rs709400	1.000	rs7150141	chr14:104129352	G/A	cg26031613	chr14:104095156	KLC1	1.14	17.16	0.84	1.53e-34	Body mass index;
TGCT	cis	rs7937682	0.855	rs10891285	chr11:111527775	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.1	-11.66	-0.72	1.13e-21	Primary sclerosing cholangitis;
TGCT	cis	rs4478858	0.698	rs4949204	chr1:31800415	A/G	cg07478791	chr1:31886160	SERINC2	-0.51	-4.95	-0.41	2.33e-6	Alcohol dependence;
TGCT	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg23758822	chr17:41437982	NA	0.72	6.91	0.53	2.23e-10	Menopause (age at onset);
TGCT	cis	rs13242816	1.000	rs12668226	chr7:116187690	A/C	cg16553024	chr7:116138462	CAV2	-0.45	-5.3	-0.43	5.1e-7	P wave duration;
TGCT	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg10295955	chr4:187884368	NA	-0.97	-14.67	-0.8	7e-29	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg16414030	chr3:133502952	NA	-0.68	-11.13	-0.71	2.23e-20	Iron status biomarkers;
TGCT	cis	rs7429990	0.870	rs13089844	chr3:48140231	G/A	cg11946769	chr3:48343235	NME6	-0.57	-4.77	-0.39	5.14e-6	Educational attainment (years of education);
TGCT	cis	rs7772486	0.727	rs11155442	chr6:146140725	T/C	cg05347473	chr6:146136440	FBXO30	0.55	5.16	0.42	9.53e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs35306767	0.953	rs35693858	chr10:979813	C/T	cg20503657	chr10:835505	NA	0.6	8.41	0.6	8.02e-14	Eosinophil percentage of granulocytes;
TGCT	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg17747265	chr1:1875780	NA	0.36	6.02	0.48	1.86e-8	Body mass index;
TGCT	cis	rs6840360	0.642	rs4235219	chr4:152346103	T/G	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.41	-0.5	2.81e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs9611565	0.649	rs2064189	chr22:42127999	A/G	cg13695892	chr22:41940480	POLR3H	0.83	7.93	0.58	1.09e-12	Vitiligo;
TGCT	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg22535103	chr8:58192502	C8orf71	-0.41	-5.24	-0.43	6.57e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg26338869	chr17:61819248	STRADA	-0.55	-5.08	-0.41	1.37e-6	Prudent dietary pattern;
TGCT	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg20528787	chr7:158032352	PTPRN2	0.32	4.51	0.38	1.48e-5	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg16423285	chr20:60520624	NA	-0.69	-7.45	-0.56	1.39e-11	Body mass index;
TGCT	cis	rs9296661	0.680	rs12197299	chr6:51685513	C/T	cg00593404	chr6:52377740	TRAM2	-0.26	-4.46	-0.37	1.81e-5	Weight loss (gastric bypass surgery);
TGCT	cis	rs55883249	0.958	rs17362734	chr2:9730208	A/G	cg23886495	chr2:9695866	ADAM17	0.77	4.69	0.39	7.19e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs425277	0.583	rs12059660	chr1:2041461	C/T	cg03732007	chr1:2071316	PRKCZ	-0.26	-5.88	-0.47	3.59e-8	Height;
TGCT	cis	rs826838	1.000	rs1963562	chr12:38662896	C/T	cg26384229	chr12:38710491	ALG10B	1.05	10.25	0.68	3.18e-18	Heart rate;
TGCT	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.6	0.51	1.05e-9	Bipolar disorder;
TGCT	cis	rs1057239	0.510	rs3766694	chr1:175143207	T/C	cg08873628	chr1:175162347	KIAA0040	-0.66	-7.02	-0.53	1.27e-10	Diastolic blood pressure;
TGCT	cis	rs3733585	0.682	rs13124563	chr4:9927553	A/G	cg11266682	chr4:10021025	SLC2A9	0.58	7.38	0.55	2.04e-11	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs2147959	0.824	rs4653970	chr1:228690292	T/C	cg22700015	chr1:228743131	NA	-0.61	-4.61	-0.38	9.95e-6	Adult asthma;
TGCT	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg23758822	chr17:41437982	NA	0.71	6.75	0.52	5.16e-10	Menopause (age at onset);
TGCT	cis	rs769267	1.000	rs2285627	chr19:19467937	T/C	cg03709012	chr19:19516395	GATAD2A	-0.68	-5.78	-0.46	5.56e-8	Tonsillectomy;
TGCT	cis	rs138249	0.505	rs138219	chr22:50548985	T/C	cg24864161	chr22:50528282	MOV10L1	0.5	4.45	0.37	1.91e-5	Gestational age at birth in labor-initiated deliveries (child effect);
TGCT	cis	rs11731606	0.508	rs9307140	chr4:95288670	G/C	cg00507259	chr4:95128692	SMARCAD1	0.65	4.89	0.4	3.02e-6	Mean platelet volume;
TGCT	cis	rs10206020	0.885	rs11885392	chr2:1578182	C/A	cg01028140	chr2:1542097	TPO	-0.28	-4.51	-0.38	1.47e-5	IgG glycosylation;
TGCT	cis	rs7213347	0.610	rs8077194	chr17:2119475	A/G	cg20777128	chr17:1945076	DPH1;OVCA2	-0.59	-5.41	-0.44	3.14e-7	Total body bone mineral density;
TGCT	trans	rs797680	0.754	rs12118230	chr1:93651461	T/G	cg27528825	chr2:159282178	CCDC148	-0.35	-6.82	-0.52	3.53e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs6121246	0.567	rs6060261	chr20:30192948	C/G	cg13852791	chr20:30311386	BCL2L1	0.69	4.54	0.38	1.33e-5	Mean corpuscular hemoglobin;
TGCT	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg10053473	chr17:62856997	LRRC37A3	0.4	7.11	0.54	8.09e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs12142240	0.698	rs72886907	chr1:46814265	C/T	cg00530320	chr1:46809349	NSUN4	0.28	5.75	0.46	6.47e-8	Menopause (age at onset);
TGCT	cis	rs12220238	1.000	rs7909664	chr10:75869754	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.91	7.94	0.58	1.02e-12	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs61935443	1.000	rs4761691	chr12:95248171	C/G	cg21533806	chr12:95267307	NA	0.52	4.55	0.38	1.26e-5	Schizophrenia;
TGCT	cis	rs6906287	0.537	rs13192336	chr6:118875162	A/T	cg21191810	chr6:118973309	C6orf204	0.26	4.5	0.38	1.51e-5	Electrocardiographic conduction measures;
TGCT	cis	rs1577917	0.771	rs2758847	chr6:86349103	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.58	-0.45	1.43e-7	Response to antipsychotic treatment;
TGCT	cis	rs4713118	0.826	rs2893929	chr6:27738732	A/T	cg20933634	chr6:27740509	NA	0.35	4.83	0.4	3.92e-6	Parkinson's disease;
TGCT	cis	rs6901250	0.744	rs636872	chr6:117087944	C/T	cg12892004	chr6:117198278	RFX6	0.51	6.25	0.49	6.07e-9	C-reactive protein levels;
TGCT	cis	rs9787249	0.957	rs41267029	chr1:40214367	A/G	cg20968010	chr1:40505947	CAP1	-0.53	-5.0	-0.41	1.91e-6	Blood protein levels;
TGCT	cis	rs12615966	0.651	rs60920571	chr2:105408284	C/G	cg16465502	chr2:105461796	NA	0.85	5.6	0.45	1.34e-7	Pancreatic cancer;
TGCT	cis	rs2456568	0.548	rs7117597	chr11:93655091	A/G	cg26875233	chr11:93583750	C11orf90	-0.43	-5.36	-0.43	3.96e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg22920501	chr2:26401640	FAM59B	0.81	6.36	0.5	3.52e-9	Gut microbiome composition (summer);
TGCT	cis	rs4733781	0.527	rs11774659	chr8:131190336	C/T	cg16277922	chr8:131349729	ASAP1	0.35	4.87	0.4	3.33e-6	Tuberculosis;
TGCT	cis	rs2639990	1.000	rs655156	chr18:72898181	T/C	cg03972071	chr18:72917163	ZADH2	0.8	5.54	0.45	1.75e-7	Vascular endothelial growth factor levels;
TGCT	cis	rs7714584	1.000	rs6875011	chr5:150182710	G/A	cg22134413	chr5:150180641	NA	1.17	8.69	0.62	1.76e-14	Crohn's disease;
TGCT	cis	rs35306767	0.761	rs12770910	chr10:1050318	A/G	cg18964960	chr10:1102726	WDR37	0.78	5.46	0.44	2.45e-7	Eosinophil percentage of granulocytes;
TGCT	cis	rs139371	0.575	rs139347	chr22:39507887	A/G	cg18708252	chr22:39545030	CBX7	-0.31	-4.65	-0.39	8.52e-6	Multiple myeloma (IgH translocation);Multiple myeloma (hyperdiploidy);
TGCT	cis	rs2730260	0.537	rs73169234	chr7:158882366	C/T	cg27122614	chr7:157913741	PTPRN2	0.42	4.47	0.37	1.74e-5	Myopia (pathological);
TGCT	cis	rs9549367	0.713	rs3024746	chr13:113821777	G/A	cg18105134	chr13:113819100	PROZ	-0.47	-8.21	-0.59	2.49e-13	Platelet distribution width;
TGCT	cis	rs2721195	0.845	rs2721150	chr8:145724973	C/G	cg15857475	chr8:145742913	RECQL4;LRRC14	0.89	9.55	0.65	1.57e-16	Age at first birth;
TGCT	cis	rs6484504	0.576	rs11031324	chr11:31250299	T/C	cg26647111	chr11:31128758	NA	-0.35	-4.86	-0.4	3.52e-6	Red blood cell count;
TGCT	cis	rs1801251	1.000	rs2592113	chr2:233669553	C/T	cg25237894	chr2:233734115	C2orf82	0.3	5.44	0.44	2.74e-7	Coronary artery disease;
TGCT	cis	rs2224391	0.590	rs17140068	chr6:5282227	T/G	cg09085698	chr6:5261316	LYRM4;FARS2	-1.04	-5.28	-0.43	5.56e-7	Height;
TGCT	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg13395646	chr4:1353034	KIAA1530	0.39	4.84	0.4	3.81e-6	Obesity-related traits;
TGCT	cis	rs8180040	0.676	rs11130114	chr3:47154651	T/G	cg27129171	chr3:47204927	SETD2	0.76	9.9	0.66	2.25e-17	Colorectal cancer;
TGCT	cis	rs593982	1.000	rs650619	chr11:65506483	G/A	cg08755490	chr11:65554678	OVOL1	1.42	12.09	0.74	1.03e-22	Atopic dermatitis;
TGCT	cis	rs2933343	0.700	rs1680788	chr3:128625318	C/T	cg11901034	chr3:128598214	ACAD9	-0.63	-6.06	-0.48	1.54e-8	IgG glycosylation;
TGCT	cis	rs17125944	0.505	rs10483617	chr14:53202605	A/G	cg00686598	chr14:53173677	PSMC6	-1.07	-5.67	-0.45	9.62e-8	Alzheimer's disease (late onset);
TGCT	cis	rs3791556	0.842	rs55840142	chr2:240106884	G/A	cg03281426	chr2:240109471	HDAC4	0.29	4.9	0.4	2.98e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs1933488	0.931	rs3870365	chr6:153426932	C/G	cg24028809	chr6:153414101	RGS17	0.21	4.67	0.39	7.69e-6	Prostate cancer;
TGCT	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg06481639	chr22:41940642	POLR3H	0.75	6.66	0.51	8.03e-10	Vitiligo;
TGCT	cis	rs12477438	0.765	rs2278895	chr2:99613484	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-4.62	-0.38	9.47e-6	Chronic sinus infection;
TGCT	cis	rs2075671	0.855	rs11974395	chr7:100282538	G/A	cg20848291	chr7:100343083	ZAN	-0.52	-4.56	-0.38	1.21e-5	Other erythrocyte phenotypes;
TGCT	cis	rs11122272	0.677	rs2808615	chr1:231550171	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.71	6.89	0.53	2.5e-10	Hemoglobin concentration;
TGCT	cis	rs7659604	1.000	rs7659604	chr4:122665514	A/G	cg19748678	chr4:122722346	EXOSC9	-0.5	-4.46	-0.37	1.78e-5	Type 2 diabetes;
TGCT	cis	rs7178572	1.000	rs2055901	chr15:77759295	G/A	cg22256960	chr15:77711686	NA	-0.95	-10.89	-0.7	8.57e-20	Type 2 diabetes;
TGCT	cis	rs6988636	0.792	rs62521807	chr8:124163621	T/C	cg27053337	chr8:124217698	FAM83A	0.71	5.42	0.44	3e-7	Urinary uromodulin levels;
TGCT	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg25703541	chr22:24373054	LOC391322	-0.81	-8.41	-0.6	8.37e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2204008	0.543	rs2387018	chr12:38065638	C/T	cg13010199	chr12:38710504	ALG10B	0.63	5.0	0.41	1.93e-6	Bladder cancer;
TGCT	cis	rs669446	0.561	rs643445	chr1:44089632	C/T	cg12908607	chr1:44402522	ARTN	0.54	5.77	0.46	5.93e-8	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs17401966	0.838	rs11121551	chr1:10435170	T/C	cg19773385	chr1:10388646	KIF1B	-0.23	-5.38	-0.44	3.57e-7	Hepatocellular carcinoma;
TGCT	cis	rs11112613	0.775	rs12371537	chr12:105971425	T/C	cg03607813	chr12:105948248	NA	0.47	5.74	0.46	6.71e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	cis	rs6089584	0.566	rs2181589	chr20:60622817	C/T	cg13770153	chr20:60521292	NA	0.39	4.72	0.39	6.35e-6	Body mass index;
TGCT	cis	rs2273156	0.929	rs8017225	chr14:35470049	G/A	cg15394648	chr14:35761551	PSMA6	-0.58	-4.63	-0.38	9.15e-6	Immunoglobulin light chain (AL) amyloidosis;
TGCT	cis	rs6964587	1.000	rs28410528	chr7:91647390	A/G	cg22709100	chr7:91322751	NA	0.27	4.48	0.37	1.68e-5	Breast cancer;
TGCT	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.53	-5.13	-0.42	1.09e-6	Menarche (age at onset);
TGCT	cis	rs9653442	0.545	rs11681227	chr2:100754997	A/G	cg22139774	chr2:100720529	AFF3	-0.37	-5.68	-0.45	8.91e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs11719291	0.915	rs9834996	chr3:48754877	G/T	cg00383909	chr3:49044727	WDR6	1.02	5.61	0.45	1.24e-7	Cognitive function;
TGCT	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg22968622	chr17:43663579	NA	1.22	10.97	0.7	5.53e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs922182	0.579	rs4620909	chr15:64192739	C/T	cg02919090	chr15:64263738	DAPK2	-0.32	-5.7	-0.46	8.35e-8	Blood protein levels;
TGCT	cis	rs17345786	0.798	rs9817043	chr3:101281852	A/G	cg12386194	chr3:101231763	SENP7	0.56	5.39	0.44	3.41e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7264396	0.635	rs6058355	chr20:34491343	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.06	-0.41	1.47e-6	Total cholesterol levels;
TGCT	trans	rs10802346	0.545	rs4478780	chr1:246372241	T/C	cg13514129	chr1:39547527	MACF1	0.83	7.33	0.55	2.59e-11	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs9611565	0.649	rs5758466	chr22:42176059	G/A	cg06634786	chr22:41940651	POLR3H	0.78	7.31	0.55	2.85e-11	Vitiligo;
TGCT	cis	rs7949030	0.596	rs11231137	chr11:62315699	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.55	6.31	0.49	4.46e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1018836	0.786	rs10086401	chr8:91572818	C/T	cg16814680	chr8:91681699	NA	-0.75	-7.85	-0.58	1.71e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9549367	0.662	rs3818334	chr13:113825174	C/G	cg00898013	chr13:113819073	PROZ	-0.54	-6.83	-0.52	3.32e-10	Platelet distribution width;
TGCT	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg01448562	chr3:133502909	NA	-0.33	-6.71	-0.52	6.07e-10	Iron status biomarkers;
TGCT	cis	rs7726839	0.540	rs3749618	chr5:602650	A/G	cg16624210	chr5:671434	TPPP	0.41	4.68	0.39	7.53e-6	Obesity-related traits;
TGCT	trans	rs1974653	0.672	rs74576059	chr22:20079973	G/A	cg08822737	chr17:71088851	SLC39A11	-0.93	-7.61	-0.56	5.97e-12	Schizophrenia;
TGCT	cis	rs28595532	0.920	rs114940990	chr4:119758568	A/G	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs72949976	0.606	rs2178756	chr2:214031423	A/G	cg08319019	chr2:214017104	IKZF2	0.87	8.64	0.61	2.34e-14	Lung cancer;Squamous cell lung carcinoma;
TGCT	cis	rs28595532	0.920	rs114938162	chr4:119756407	T/G	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs4919694	1.000	rs77505796	chr10:104647774	A/T	cg04362960	chr10:104952993	NT5C2	1.05	6.9	0.53	2.39e-10	Arsenic metabolism;
TGCT	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg11644478	chr21:40555479	PSMG1	-0.6	-5.69	-0.46	8.53e-8	Cognitive function;
TGCT	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg11890956	chr21:40555474	PSMG1	1.11	12.32	0.74	2.91e-23	Cognitive function;
TGCT	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg24675658	chr1:53192096	ZYG11B	0.7	7.98	0.58	8.42e-13	Monocyte count;
TGCT	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg20891558	chr2:74357851	NA	0.59	7.36	0.55	2.2e-11	Gestational age at birth (maternal effect);
TGCT	cis	rs7191700	0.578	rs243327	chr16:11353304	C/T	cg00044050	chr16:11439710	C16orf75	-0.84	-8.78	-0.62	1.11e-14	Multiple sclerosis;
TGCT	cis	rs295140	1.000	rs55677233	chr2:201168695	T/C	cg04283868	chr2:201171347	SPATS2L	0.63	6.43	0.5	2.46e-9	QT interval;
TGCT	cis	rs60154123	0.730	rs10489391	chr1:210458861	C/T	cg22029157	chr1:209979665	IRF6	-0.62	-4.61	-0.38	9.94e-6	Coronary artery disease;
TGCT	cis	rs6088580	0.634	rs6142153	chr20:32968747	C/G	cg08999081	chr20:33150536	PIGU	-0.28	-5.51	-0.44	1.96e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs6684514	1.000	rs10908494	chr1:156263097	A/G	cg20302342	chr1:156215951	PAQR6	0.34	4.6	0.38	1.01e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs4713118	0.527	rs36042294	chr6:27720712	C/G	cg10876282	chr6:28092338	ZSCAN16	0.5	5.09	0.42	1.29e-6	Parkinson's disease;
TGCT	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg10411590	chr13:21900810	NA	0.34	4.56	0.38	1.19e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	cis	rs4631830	0.720	rs2611475	chr10:51503178	G/A	cg10326726	chr10:51549505	MSMB	-0.23	-4.64	-0.38	8.74e-6	Prostate-specific antigen levels;
TGCT	cis	rs4700695	0.614	rs153388	chr5:65422308	G/T	cg21114390	chr5:65439923	SFRS12	-0.71	-4.81	-0.4	4.37e-6	Facial morphology (factor 19);
TGCT	cis	rs4654899	0.606	rs13376428	chr1:21120027	T/C	cg01072550	chr1:21505969	NA	-0.53	-8.58	-0.61	3.23e-14	Superior frontal gyrus grey matter volume;
TGCT	cis	rs9467773	0.967	rs9295694	chr6:26512994	A/T	cg05738196	chr6:26577821	NA	0.88	12.5	0.75	1.03e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs614226	0.938	rs12857	chr12:120933946	T/G	cg10072921	chr12:121022843	NA	-0.42	-4.52	-0.38	1.42e-5	Type 1 diabetes nephropathy;
TGCT	cis	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg08564027	chr20:61660810	NA	0.38	7.08	0.54	9.36e-11	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs3729931	0.507	rs79945102	chr3:12711975	A/C	cg23032965	chr3:12705835	RAF1	0.75	8.05	0.59	5.87e-13	Cardiac hypertrophy;
TGCT	cis	rs2290402	0.536	rs3775127	chr4:886061	G/A	cg11315544	chr4:1222440	CTBP1	0.26	4.46	0.37	1.84e-5	Type 2 diabetes;
TGCT	cis	rs12579753	1.000	rs7975863	chr12:82227288	C/T	cg07988820	chr12:82153109	PPFIA2	-0.6	-6.48	-0.5	1.91e-9	Resting heart rate;
TGCT	cis	rs11105298	0.891	rs10858894	chr12:89914261	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.7	-5.02	-0.41	1.75e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs6728642	0.908	rs17842456	chr2:98014319	C/T	cg26665480	chr2:98280029	ACTR1B	0.99	5.33	0.43	4.39e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	cis	rs9765602	1	rs9765602	chr5:35426631	A/G	cg21115018	chr5:34597807	NA	0.64	4.84	0.4	3.75e-6	Post bronchodilator FEV1 in COPD;
TGCT	cis	rs3806843	0.966	rs3756338	chr5:140180561	A/G	cg19875535	chr5:140030758	IK	0.36	6.11	0.48	1.21e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs6088590	1.000	rs6120705	chr20:33313740	T/C	cg06115741	chr20:33292138	TP53INP2	0.67	5.61	0.45	1.24e-7	Coronary artery disease;
TGCT	cis	rs7246657	0.653	rs10414983	chr19:37665732	T/C	cg24025825	chr19:37761650	NA	-0.33	-5.06	-0.41	1.49e-6	Coronary artery calcification;
TGCT	cis	rs514406	0.505	rs146750	chr1:53183447	C/G	cg24675658	chr1:53192096	ZYG11B	-0.79	-9.7	-0.66	6.86e-17	Monocyte count;
TGCT	cis	rs2153535	0.580	rs9505457	chr6:8479142	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs899997	1.000	rs7182694	chr15:79045030	C/T	cg04896959	chr15:78267971	NA	0.35	5.07	0.41	1.4e-6	Coronary artery disease or large artery stroke;
TGCT	cis	rs12891047	0.966	rs181572	chr14:68274020	C/G	cg26938013	chr14:69015199	RAD51L1	0.44	4.43	0.37	2.02e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs9326248	0.954	rs10790177	chr11:117048417	A/G	cg26566898	chr11:117069891	TAGLN	0.32	4.54	0.38	1.3e-5	Blood protein levels;
TGCT	cis	rs3784262	0.740	rs12898976	chr15:58276358	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.41	-5.93	-0.47	2.74e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs6088590	1.000	rs2295354	chr20:33356541	T/C	cg06115741	chr20:33292138	TP53INP2	0.67	5.6	0.45	1.34e-7	Coronary artery disease;
TGCT	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg18230493	chr5:56204884	C5orf35	-0.67	-5.88	-0.47	3.5e-8	Initial pursuit acceleration;
TGCT	cis	rs2014572	1.000	rs2014572	chr19:57760018	G/A	cg24459738	chr19:57751996	ZNF805	-0.56	-5.6	-0.45	1.29e-7	Hyperactive-impulsive symptoms;
TGCT	cis	rs317689	0.600	rs478863	chr12:69639207	G/A	cg14784868	chr12:69753453	YEATS4	0.55	4.56	0.38	1.21e-5	Response to diuretic therapy;
TGCT	cis	rs1475911	0.708	rs8129075	chr21:43523430	G/T	cg19766460	chr21:43528205	UMODL1;C21orf128	0.61	8.78	0.62	1.07e-14	IgG glycosylation;
TGCT	cis	rs838147	0.508	rs507766	chr19:49208543	T/C	cg10667338	chr19:49617042	LIN7B	-0.34	-4.57	-0.38	1.18e-5	Dietary macronutrient intake;
TGCT	cis	rs9467773	1.000	rs1884948	chr6:26567988	G/A	cg09904177	chr6:26538194	HMGN4	0.69	6.84	0.52	3.23e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs9326248	0.906	rs171052	chr11:117081763	C/G	cg11861562	chr11:117069780	TAGLN	-0.3	-4.72	-0.39	6.39e-6	Blood protein levels;
TGCT	cis	rs896854	0.738	rs527234	chr8:95963798	C/G	cg23172400	chr8:95962367	TP53INP1	0.37	5.83	0.46	4.44e-8	Type 2 diabetes;
TGCT	cis	rs10746514	1.000	rs61835640	chr1:232245014	G/A	cg09506761	chr1:232265262	NA	0.49	4.98	0.41	2.12e-6	Response to statin therapy;
TGCT	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg18404041	chr3:52824283	ITIH1	-0.21	-4.58	-0.38	1.12e-5	Bipolar disorder;
TGCT	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg03709012	chr19:19516395	GATAD2A	-0.74	-6.22	-0.49	7.04e-9	Tonsillectomy;
TGCT	cis	rs1971762	0.762	rs7976793	chr12:54073069	G/T	cg22546318	chr12:54070378	ATP5G2	-0.31	-4.48	-0.37	1.68e-5	Height;
TGCT	cis	rs7552404	0.727	rs6678348	chr1:76332463	C/T	cg22875332	chr1:76189707	ACADM	0.58	6.08	0.48	1.36e-8	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs6882046	0.513	rs187270	chr5:88026870	C/T	cg22951263	chr5:87985283	NA	-0.54	-5.8	-0.46	5.2100000000000003e-08	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs10089	0.953	rs7713860	chr5:127428789	G/T	cg19767477	chr5:127420684	SLC12A2	-0.42	-4.47	-0.37	1.74e-5	Ileal carcinoids;
TGCT	cis	rs5769765	0.954	rs5770709	chr22:50245196	G/T	cg15316289	chr22:50310904	ALG12;CRELD2	-0.37	-5.7	-0.46	8.42e-8	Schizophrenia;
TGCT	cis	rs7552404	0.731	rs6699682	chr1:76340123	A/G	cg10523679	chr1:76189770	ACADM	-0.85	-8.03	-0.58	6.57e-13	Blood metabolite levels;Acylcarnitine levels;
TGCT	trans	rs10953454	1.000	rs10953455	chr7:104503978	T/C	cg04208666	chr6:19734707	NA	-0.57	-6.89	-0.53	2.52e-10	Obesity;
TGCT	cis	rs2404602	0.716	rs1946650	chr15:76848463	T/C	cg22467129	chr15:76604101	ETFA	-0.55	-6.51	-0.5	1.65e-9	Blood metabolite levels;
TGCT	trans	rs877282	0.755	rs2486579	chr10:785647	G/A	cg22713356	chr15:30763199	NA	0.94	8.1	0.59	4.33e-13	Uric acid levels;
TGCT	cis	rs9611565	0.694	rs79008	chr22:41850500	C/T	cg06634786	chr22:41940651	POLR3H	-0.86	-7.93	-0.58	1.09e-12	Vitiligo;
TGCT	cis	rs992157	0.835	rs2292551	chr2:219143229	G/A	cg00012203	chr2:219082015	ARPC2	-0.79	-7.87	-0.58	1.48e-12	Colorectal cancer;
TGCT	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6714710	0.603	rs6738389	chr2:98386731	A/G	cg26665480	chr2:98280029	ACTR1B	0.66	6.27	0.49	5.45e-9	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs1420338	0.967	rs10271544	chr7:34147159	C/T	cg01275685	chr7:34179230	BMPER	-0.26	-4.76	-0.39	5.23e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs9325144	0.625	rs11534879	chr12:38968165	A/G	cg10518543	chr12:38710700	ALG10B	-0.49	-4.68	-0.39	7.26e-6	Morning vs. evening chronotype;
TGCT	cis	rs9372498	0.536	rs72954806	chr6:118899965	C/G	cg21191810	chr6:118973309	C6orf204	-0.39	-5.06	-0.41	1.5e-6	Diastolic blood pressure;
TGCT	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg11764359	chr7:65958608	NA	0.58	5.31	0.43	4.91e-7	Aortic root size;
TGCT	cis	rs9357506	1.000	rs6458500	chr6:46305204	A/G	cg21115430	chr6:46460003	NA	-0.26	-5.16	-0.42	9.37e-7	Body mass index;
TGCT	cis	rs7772486	0.754	rs702306	chr6:145991029	T/C	cg05347473	chr6:146136440	FBXO30	-0.53	-4.95	-0.41	2.4e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6570726	0.791	rs440477	chr6:145854188	C/T	cg05347473	chr6:146136440	FBXO30	0.54	5.15	0.42	1.01e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2295359	0.892	rs12401432	chr1:67656931	C/G	cg12940439	chr1:67600707	NA	0.61	6.35	0.5	3.77e-9	Psoriasis;
TGCT	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg06028808	chr11:68637592	NA	0.56	7.0	0.53	1.43e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9326248	1.000	rs3736120	chr11:117032125	G/T	cg26566898	chr11:117069891	TAGLN	0.33	4.55	0.38	1.27e-5	Blood protein levels;
TGCT	cis	rs12477438	0.520	rs6542864	chr2:99725223	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	17.43	0.84	3.73e-35	Chronic sinus infection;
TGCT	cis	rs7659604	1.000	rs7660078	chr4:122665577	G/T	cg19748678	chr4:122722346	EXOSC9	0.55	5.31	0.43	4.92e-7	Type 2 diabetes;
TGCT	cis	rs4851266	1.000	rs12991254	chr2:100817933	T/C	cg07810366	chr2:100720526	AFF3	-0.41	-5.76	-0.46	6.26e-8	Educational attainment;
TGCT	cis	rs4319547	0.695	rs55834409	chr12:122862560	C/G	cg08088222	chr12:122070432	ORAI1	-0.25	-4.49	-0.37	1.58e-5	Body mass index;
TGCT	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg23262073	chr20:60523788	NA	-0.32	-5.27	-0.43	5.92e-7	Obesity-related traits;
TGCT	cis	rs858239	0.568	rs6970694	chr7:23250828	T/C	cg05602783	chr7:23145260	KLHL7	-0.71	-5.45	-0.44	2.55e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg11890956	chr21:40555474	PSMG1	1.13	12.1	0.74	1e-22	Cognitive function;
TGCT	cis	rs13064411	0.696	rs6438161	chr3:113227637	G/A	cg18753928	chr3:113234510	CCDC52	-0.71	-5.78	-0.46	5.63e-8	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg05368731	chr17:41323189	NBR1	0.94	9.21	0.64	1.05e-15	Menopause (age at onset);
TGCT	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.71	5.14	0.42	1.02e-6	Platelet count;
TGCT	cis	rs72781680	0.716	rs17045975	chr2:24099611	A/T	cg08917208	chr2:24149416	ATAD2B	-0.79	-4.94	-0.41	2.51e-6	Lymphocyte counts;
TGCT	cis	rs1532993	0.518	rs3913986	chr4:98606407	C/T	cg05340658	chr4:99064831	C4orf37	-0.37	-4.44	-0.37	1.98e-5	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs1865760	0.568	rs2032450	chr6:25993114	C/G	cg17042849	chr6:26104293	HIST1H4C	-0.55	-4.8	-0.4	4.4e-6	Height;
TGCT	cis	rs10193935	0.792	rs6735571	chr2:42491951	C/T	cg27598129	chr2:42591480	NA	-0.32	-4.52	-0.38	1.4e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3820928	1.000	rs10210763	chr2:227776029	G/T	cg11843606	chr2:227700838	RHBDD1	-0.54	-4.82	-0.4	4.12e-6	Pulmonary function;
TGCT	cis	rs425277	1.000	rs385039	chr1:2077409	C/T	cg24578937	chr1:2090814	PRKCZ	-0.32	-8.09	-0.59	4.65e-13	Height;
TGCT	cis	rs116095464	0.558	rs6866632	chr5:264429	C/G	cg22857025	chr5:266934	NA	-0.35	-6.93	-0.53	2.06e-10	Breast cancer;
TGCT	cis	rs6746896	1.000	rs67570263	chr2:97383007	T/C	cg26085987	chr2:97230376	NA	0.19	4.66	0.39	8.15e-6	Bipolar disorder;
TGCT	cis	rs2832191	0.716	rs1888439	chr21:30454457	A/G	cg08807101	chr21:30365312	RNF160	0.59	5.86	0.47	3.88e-8	Dental caries;
TGCT	cis	rs2180341	0.889	rs9321074	chr6:127618019	G/A	cg24812749	chr6:127587940	RNF146	0.99	7.72	0.57	3.33e-12	Breast cancer;
TGCT	cis	rs1865760	1.000	rs2071299	chr6:25914801	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.65	6.18	0.49	8.59e-9	Height;
TGCT	cis	rs1865760	0.625	rs9393681	chr6:26008260	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.75	7.13	0.54	7.46e-11	Height;
TGCT	cis	rs5769707	0.656	rs135878	chr22:50014369	T/A	cg05373962	chr22:49881684	NA	-0.3	-4.96	-0.41	2.26e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9443189	0.737	rs2842553	chr6:76456632	A/T	cg01950844	chr6:76311363	SENP6	-0.6	-4.48	-0.37	1.69e-5	Prostate cancer;
TGCT	cis	rs3935685	0.967	rs62009151	chr15:77999264	C/A	cg03457338	chr15:78040120	NA	-0.22	-5.12	-0.42	1.13e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg09021430	chr5:549028	NA	-0.4	-5.48	-0.44	2.24e-7	Lung disease severity in cystic fibrosis;
TGCT	cis	rs72634258	0.503	rs697675	chr1:7838113	A/C	cg26816564	chr1:7831052	VAMP3	0.98	7.19	0.54	5.47e-11	Inflammatory bowel disease;
TGCT	cis	rs3733585	0.673	rs9993410	chr4:9951264	C/T	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.5	-0.56	1.04e-11	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs910316	1.000	rs7156328	chr14:75532941	T/C	cg08847533	chr14:75593920	NEK9	0.96	10.6	0.69	4.3e-19	Height;
TGCT	trans	rs629535	0.814	rs488231	chr8:70064993	T/C	cg21567404	chr3:27674614	NA	0.57	8.99	0.63	3.38e-15	Dupuytren's disease;
TGCT	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg21171335	chr12:122356390	WDR66	0.7	7.03	0.53	1.24e-10	Mean corpuscular volume;
TGCT	cis	rs372883	0.600	rs1312254	chr21:30695401	A/G	cg24692254	chr21:30365293	RNF160	-0.53	-4.76	-0.39	5.24e-6	Pancreatic cancer;
TGCT	cis	rs6076065	0.802	rs2424527	chr20:23357329	A/C	cg11657817	chr20:23433608	CST11	0.31	5.41	0.44	3.07e-7	Facial morphology (factor 15, philtrum width);
TGCT	cis	rs3960554	0.529	rs6465049	chr7:75874489	A/G	cg19105122	chr7:75896889	SRRM3	0.55	4.59	0.38	1.08e-5	Eotaxin levels;
TGCT	cis	rs500492	0.618	rs2473158	chr16:1075241	G/A	cg02729011	chr16:699500	WDR90	-0.47	-4.43	-0.37	2.01e-5	Polycystic ovary syndrome;
TGCT	cis	rs12477438	0.559	rs6733285	chr2:99725575	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	10.3	0.68	2.42e-18	Chronic sinus infection;
TGCT	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg11764359	chr7:65958608	NA	-0.61	-5.39	-0.44	3.45e-7	Aortic root size;
TGCT	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9611565	0.546	rs2092274	chr22:42123737	A/G	cg13695892	chr22:41940480	POLR3H	0.89	9.04	0.63	2.55e-15	Vitiligo;
TGCT	cis	rs7647973	0.710	rs34890793	chr3:49619493	C/T	cg03060546	chr3:49711283	APEH	0.62	5.21	0.42	7.77e-7	Menarche (age at onset);
TGCT	cis	rs10488031	0.557	rs34286271	chr7:37106007	G/T	cg06458904	chr7:36312573	EEPD1	0.58	4.79	0.39	4.72e-6	QT interval;
TGCT	trans	rs629535	0.862	rs638412	chr8:70047690	C/T	cg21567404	chr3:27674614	NA	0.58	9.18	0.64	1.22e-15	Dupuytren's disease;
TGCT	cis	rs2243480	1.000	rs67536397	chr7:65947917	G/A	cg20637647	chr7:64974828	NA	0.91	5.33	0.43	4.55e-7	Diabetic kidney disease;
TGCT	cis	rs3099143	1.000	rs4541044	chr15:77173193	C/T	cg21673338	chr15:77095150	SCAPER	0.52	5.05	0.41	1.54e-6	Recalcitrant atopic dermatitis;
TGCT	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg18402987	chr7:1209562	NA	0.72	6.28	0.49	5.25e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs6977660	0.507	rs72591449	chr7:19775443	T/C	cg05791153	chr7:19748676	TWISTNB	1.01	6.63	0.51	9.26e-10	Thyroid stimulating hormone;
TGCT	cis	rs11122272	0.766	rs2790871	chr1:231543555	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-6.71	-0.52	6.09e-10	Hemoglobin concentration;
TGCT	cis	rs12367572	0.965	rs10748405	chr12:45321341	C/G	cg04608330	chr12:45269318	NELL2	-0.66	-6.75	-0.52	5.11e-10	Gut microbiome composition (summer);
TGCT	trans	rs77457752	0.525	rs10961293	chr9:13894250	A/G	cg25510823	chr7:47085976	NA	0.44	6.89	0.53	2.5e-10	Breast cancer;
TGCT	cis	rs6912958	0.514	rs7767449	chr6:87887985	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.44	-0.44	2.74e-7	Monocyte percentage of white cells;
TGCT	cis	rs1982963	0.901	rs2516589	chr14:52512610	A/G	cg10843707	chr14:52510701	NID2	-0.43	-6.63	-0.51	9.33e-10	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg03609598	chr5:56110824	MAP3K1	-0.56	-4.57	-0.38	1.14e-5	Initial pursuit acceleration;
TGCT	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg18305652	chr10:134549665	INPP5A	0.35	5.94	0.47	2.73e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg04267008	chr7:1944627	MAD1L1	-0.35	-4.44	-0.37	1.95e-5	Bipolar disorder and schizophrenia;
TGCT	cis	rs7178572	0.568	rs28524916	chr15:77599002	T/A	cg22256960	chr15:77711686	NA	0.85	8.73	0.62	1.4e-14	Type 2 diabetes;
TGCT	trans	rs2970818	0.831	rs2970810	chr12:4608103	A/G	cg06357314	chr7:73275436	WBSCR28	0.29	6.78	0.52	4.39e-10	Phosphorus levels;
TGCT	cis	rs7044106	0.708	rs959558	chr9:123368911	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.58	6.26	0.49	5.67e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs5769707	0.967	rs763127	chr22:50006078	C/T	cg10356904	chr22:49881777	NA	-0.25	-4.96	-0.41	2.25e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs4851254	0.660	rs74340261	chr2:100696827	C/T	cg07810366	chr2:100720526	AFF3	-0.47	-4.92	-0.4	2.66e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs17490626	0.568	rs2033371	chr10:71212310	G/A	cg12610070	chr10:71211762	TSPAN15	-0.6	-6.99	-0.53	1.47e-10	Thrombosis;
TGCT	cis	rs4654899	0.897	rs12121807	chr1:21069129	A/C	cg01072550	chr1:21505969	NA	-0.49	-7.89	-0.58	1.37e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs7267979	1.000	rs2259873	chr20:25280781	A/G	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7772486	0.654	rs4896829	chr6:145953675	T/A	cg23711669	chr6:146136114	FBXO30	0.75	7.84	0.58	1.75e-12	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10193935	0.901	rs9808509	chr2:42479644	T/C	cg27598129	chr2:42591480	NA	-0.39	-5.41	-0.44	3.06e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12681288	0.748	rs2701932	chr8:1026946	C/G	cg04851639	chr8:1020857	NA	-0.34	-6.07	-0.48	1.44e-8	Schizophrenia;
TGCT	cis	rs644799	1.000	rs525404	chr11:95566520	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.88	9.75	0.66	5.14e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs28785552	0.931	rs8113078	chr19:53239084	T/G	cg22067481	chr19:53234126	ZNF611	-0.5	-7.33	-0.55	2.6e-11	Response to paliperidone in schizophrenia (PANSS score);
TGCT	trans	rs7618501	0.815	rs3819325	chr3:49843723	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	1.02	12.56	0.75	7.47e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs769267	0.929	rs2905424	chr19:19473445	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.68	-5.63	-0.45	1.14e-7	Tonsillectomy;
TGCT	cis	rs3796352	1.000	rs7622420	chr3:53111069	A/G	cg15956490	chr3:53032818	SFMBT1	0.56	7.22	0.54	4.56e-11	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs1949733	1.000	rs6447875	chr4:8503206	T/C	cg11789530	chr4:8429930	ACOX3	0.64	5.95	0.47	2.52e-8	Response to antineoplastic agents;
TGCT	cis	rs36051895	0.632	rs11791281	chr9:5172540	G/A	cg02405213	chr9:5042618	JAK2	-0.75	-10.25	-0.68	3.13e-18	Pediatric autoimmune diseases;
TGCT	cis	rs10088262	0.629	rs7015861	chr8:124795613	C/T	cg02993010	chr8:124780839	FAM91A1	-0.63	-5.14	-0.42	1.05e-6	Pancreatic cancer;
TGCT	cis	rs12579753	0.917	rs10862360	chr12:82187411	A/G	cg07988820	chr12:82153109	PPFIA2	-0.59	-6.19	-0.49	7.93e-9	Resting heart rate;
TGCT	cis	rs7772486	0.686	rs857883	chr6:145969214	G/T	cg05347473	chr6:146136440	FBXO30	-0.49	-4.59	-0.38	1.06e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg13395646	chr4:1353034	KIAA1530	0.38	4.64	0.38	8.74e-6	Obesity-related traits;
TGCT	cis	rs6906287	0.647	rs12192682	chr6:118863594	A/G	cg21191810	chr6:118973309	C6orf204	0.27	4.53	0.38	1.36e-5	Electrocardiographic conduction measures;
TGCT	cis	rs17376456	0.877	rs17315943	chr5:93442830	T/C	cg21475434	chr5:93447410	FAM172A	0.59	4.66	0.39	8.09e-6	Diabetic retinopathy;
TGCT	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg09323728	chr8:95962352	TP53INP1	-0.52	-6.6	-0.51	1.05e-9	Type 2 diabetes;
TGCT	cis	rs12950390	0.853	rs11658511	chr17:45856918	T/C	cg03474202	chr17:45855739	NA	-0.44	-4.51	-0.38	1.5e-5	IgG glycosylation;
TGCT	cis	rs9911578	1.000	rs11870671	chr17:56605360	A/G	cg05425664	chr17:57184151	TRIM37	0.63	6.26	0.49	5.86e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs6542838	0.702	rs6419564	chr2:99534113	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.57	-5.44	-0.44	2.74e-7	Fear of minor pain;
TGCT	cis	rs7568458	0.783	rs1561198	chr2:85809989	C/T	cg17127132	chr2:85788382	GGCX	0.68	6.16	0.48	9.47e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs154659	1.000	rs154659	chr16:89667337	C/T	cg01710450	chr16:89662404	CPNE7	0.37	6.3	0.49	4.76e-9	Tanning;
TGCT	trans	rs986417	0.818	rs761557	chr14:61077484	C/T	cg08930843	chr10:31182298	ZNF438	-0.74	-6.73	-0.52	5.48e-10	Gut microbiota (bacterial taxa);
TGCT	cis	rs6840360	0.607	rs2724547	chr4:152365576	G/A	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.83e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg03188948	chr7:1209495	NA	-0.4	-5.2	-0.42	7.93e-7	Longevity;Endometriosis;
TGCT	cis	rs4595586	0.545	rs2218761	chr12:39393593	A/G	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg03264133	chr6:25882463	NA	-0.5	-4.65	-0.39	8.31e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs854765	0.547	rs9912096	chr17:17896673	A/C	cg04398451	chr17:18023971	MYO15A	-0.32	-5.12	-0.42	1.15e-6	Total body bone mineral density;
TGCT	cis	rs2836633	1.000	rs2836633	chr21:40067445	C/T	cg05519781	chr21:40033154	ERG	-0.58	-5.74	-0.46	7e-8	Coronary artery disease;
TGCT	cis	rs4845570	1.000	rs7416415	chr1:151757798	C/T	cg07092448	chr1:151763213	TDRKH	1.17	9.47	0.65	2.44e-16	Coronary artery disease;
TGCT	cis	rs13082711	0.554	rs35840701	chr3:27334231	A/C	cg02860705	chr3:27208620	NA	0.48	7.57	0.56	7.46e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs317689	0.513	rs317678	chr12:69692166	C/G	cg14784868	chr12:69753453	YEATS4	0.66	6.45	0.5	2.31e-9	Response to diuretic therapy;
TGCT	cis	rs10823500	0.777	rs10509321	chr10:71985733	A/G	cg04118878	chr10:71993077	PPA1	-0.56	-5.26	-0.43	6.16e-7	Blood protein levels;
TGCT	cis	rs3749237	0.595	rs4855859	chr3:49526300	C/T	cg03060546	chr3:49711283	APEH	0.76	8.69	0.62	1.77e-14	Resting heart rate;
TGCT	cis	rs7772486	0.727	rs2235481	chr6:146056848	T/C	cg05347473	chr6:146136440	FBXO30	-0.65	-5.89	-0.47	3.34e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3809566	1.000	rs4775612	chr15:63332157	T/C	cg08198488	chr15:63333792	TPM1	-0.35	-5.23	-0.43	7e-7	Platelet count;
TGCT	cis	rs7772486	0.790	rs7753833	chr6:146161432	C/A	cg13319975	chr6:146136371	FBXO30	-0.5	-4.48	-0.37	1.66e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs593982	0.920	rs10896044	chr11:65554680	C/G	cg08755490	chr11:65554678	OVOL1	1.41	11.59	0.72	1.74e-21	Atopic dermatitis;
TGCT	cis	rs7432375	0.901	rs900818	chr3:136471815	C/T	cg12473912	chr3:136751656	NA	-0.36	-5.03	-0.41	1.68e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2242194	0.816	rs11264296	chr1:154994750	T/C	cg06418219	chr1:154948305	SHC1;CKS1B	-0.57	-5.25	-0.43	6.38e-7	Schizophrenia;
TGCT	cis	rs2204008	0.837	rs11495722	chr12:38337245	G/A	cg26384229	chr12:38710491	ALG10B	0.83	7.29	0.55	3.15e-11	Bladder cancer;
TGCT	cis	rs4888262	0.564	rs8050850	chr16:74582597	C/A	cg01733217	chr16:74700730	RFWD3	0.71	7.11	0.54	7.94e-11	Testicular germ cell tumor;
TGCT	cis	rs6688613	0.685	rs742048	chr1:166910145	A/C	cg07049167	chr1:166818506	POGK	-0.24	-5.17	-0.42	8.99e-7	Refractive astigmatism;
TGCT	trans	rs877282	0.945	rs71491303	chr10:772884	G/T	cg22713356	chr15:30763199	NA	1.16	10.02	0.67	1.16e-17	Uric acid levels;
TGCT	cis	rs832540	0.656	rs6893754	chr5:56100006	G/A	cg24531977	chr5:56204891	C5orf35	-0.51	-5.13	-0.42	1.08e-6	Coronary artery disease;
TGCT	cis	rs9926296	0.656	rs2376883	chr16:89826926	A/G	cg04287289	chr16:89883240	FANCA	0.66	6.63	0.51	9.24e-10	Vitiligo;
TGCT	cis	rs9303401	0.659	rs56162835	chr17:56687315	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs17384381	0.953	rs1498374	chr1:85787334	C/T	cg16011679	chr1:85725395	C1orf52	0.84	6.46	0.5	2.2e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1891275	0.515	rs1361552	chr10:93534624	T/C	cg07889827	chr10:93443413	NA	-0.32	-6.85	-0.52	3.11e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs7223966	1.000	rs8067064	chr17:61825984	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	4.68	0.39	7.5e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg03352830	chr11:487213	PTDSS2	0.26	4.58	0.38	1.12e-5	Body mass index;
TGCT	trans	rs2727020	0.595	rs10769583	chr11:49483193	G/A	cg03929089	chr4:120376271	NA	-0.76	-9.09	-0.63	2.01e-15	Coronary artery disease;
TGCT	cis	rs9902453	0.765	rs2729436	chr17:28120670	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.84	-8.19	-0.59	2.73e-13	Coffee consumption (cups per day);
TGCT	cis	rs9796	0.689	rs9888718	chr15:41446254	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.53	-6.88	-0.53	2.57e-10	Menopause (age at onset);
TGCT	cis	rs72781680	1.000	rs11553491	chr2:24225901	G/C	cg08917208	chr2:24149416	ATAD2B	0.76	4.67	0.39	7.83e-6	Lymphocyte counts;
TGCT	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg04944784	chr2:26401820	FAM59B	-0.67	-6.0	-0.47	2.03e-8	Gut microbiome composition (summer);
TGCT	cis	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg07424592	chr7:64974309	NA	-1.4	-8.42	-0.6	7.87e-14	Diabetic kidney disease;
TGCT	cis	rs7666738	0.830	rs2015828	chr4:98984594	A/G	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1801251	0.963	rs13011298	chr2:233612996	A/G	cg25237894	chr2:233734115	C2orf82	0.32	5.68	0.45	8.93e-8	Coronary artery disease;
TGCT	cis	rs4555082	0.874	rs11625098	chr14:105756891	A/G	cg01266790	chr14:105781312	PACS2	0.59	4.86	0.4	3.45e-6	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs6882046	0.513	rs187270	chr5:88026870	C/T	cg24804195	chr5:87968844	LOC645323	-0.61	-6.24	-0.49	6.2e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs1008375	0.966	rs758483	chr4:17703614	G/T	cg18681998	chr4:17616180	MED28	-0.81	-7.53	-0.56	9.25e-12	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs11785400	0.793	rs4371985	chr8:143737279	C/T	cg10596483	chr8:143751796	JRK	0.53	5.07	0.41	1.44e-6	Schizophrenia;
TGCT	cis	rs7666738	0.830	rs3857217	chr4:99034347	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9913156	0.793	rs55682338	chr17:4582183	G/A	cg23387401	chr17:4582204	PELP1	0.3	4.5	0.37	1.57e-5	Lymphocyte counts;
TGCT	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg04267008	chr7:1944627	MAD1L1	-0.41	-5.45	-0.44	2.65e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs939574	1.000	rs56927225	chr2:220100922	A/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.05	6.38	0.5	3.13e-9	Platelet distribution width;
TGCT	cis	rs67311347	0.911	rs58282210	chr3:40417943	C/T	cg17264618	chr3:40429014	ENTPD3	0.33	4.71	0.39	6.52e-6	Renal cell carcinoma;
TGCT	cis	rs854765	0.663	rs3744113	chr17:17748645	T/C	cg04398451	chr17:18023971	MYO15A	0.3	4.6	0.38	1.04e-5	Total body bone mineral density;
TGCT	cis	rs832540	1.000	rs192249	chr5:56197514	C/G	cg24531977	chr5:56204891	C5orf35	-0.51	-5.12	-0.42	1.14e-6	Coronary artery disease;
TGCT	trans	rs9393777	0.920	rs35869525	chr6:26946687	C/T	cg20516262	chr7:155325649	CNPY1	0.63	7.11	0.54	7.99e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs941408	0.515	rs1640262	chr19:2779134	C/T	cg26465405	chr19:3039745	TLE2	0.23	4.9	0.4	2.93e-6	Total cholesterol levels;
TGCT	cis	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg20362242	chr5:692897	TPPP	0.52	4.59	0.38	1.07e-5	Obesity-related traits;
TGCT	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg05754148	chr16:3507555	NAT15	0.43	5.12	0.42	1.14e-6	Tuberculosis;
TGCT	cis	rs11809207	1.000	rs41284333	chr1:26517267	A/G	cg03844060	chr1:26490628	NA	0.25	4.62	0.38	9.44e-6	Height;
TGCT	cis	rs7666738	0.830	rs28687737	chr4:99009226	G/A	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2243480	0.522	rs73150635	chr7:65972490	C/T	cg20637647	chr7:64974828	NA	0.92	5.1	0.42	1.23e-6	Diabetic kidney disease;
TGCT	cis	rs13188771	0.634	rs10043001	chr5:100894557	T/G	cg18665594	chr5:101119420	NA	0.44	4.47	0.37	1.74e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs78245978	0.744	rs2388293	chr10:2632999	A/G	cg17670436	chr10:3374199	NA	0.54	4.93	0.41	2.54e-6	Major depressive disorder;
TGCT	cis	rs2153535	0.541	rs9505456	chr6:8479001	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs2797780	1.000	rs7774013	chr6:37513945	A/G	cg00985040	chr6:37553208	NA	0.25	4.54	0.38	1.34e-5	Systemic lupus erythematosus;
TGCT	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg20276088	chr3:133502917	NA	0.27	5.84	0.46	4.32e-8	Iron status biomarkers;
TGCT	cis	rs2067615	0.524	rs7309351	chr12:107077432	C/T	cg15890332	chr12:107067104	RFX4	-0.29	-5.77	-0.46	5.9e-8	Heart rate;
TGCT	cis	rs7223966	1.000	rs55674647	chr17:61794195	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	4.87	0.4	3.27e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	trans	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg17830980	chr10:43048298	ZNF37B	-0.81	-10.13	-0.67	6.19e-18	Extrinsic epigenetic age acceleration;
TGCT	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg18230493	chr5:56204884	C5orf35	0.68	6.02	0.48	1.84e-8	Initial pursuit acceleration;
TGCT	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg04772025	chr11:68637568	NA	0.62	6.77	0.52	4.49e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs17030434	1.000	rs79094565	chr4:154718997	T/C	cg14289246	chr4:154710475	SFRP2	-0.91	-7.2	-0.54	5.18e-11	Electrocardiographic conduction measures;
TGCT	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg22764044	chr5:178986830	RUFY1	0.43	4.71	0.39	6.55e-6	Lung cancer;
TGCT	cis	rs11172134	0.508	rs1800187	chr12:57587839	C/T	cg19258868	chr12:57585184	LRP1	0.34	6.5	0.5	1.81e-9	Urate levels in overweight individuals;
TGCT	cis	rs854765	0.693	rs12941039	chr17:17765655	C/T	cg09796270	chr17:17721594	SREBF1	-0.27	-5.52	-0.44	1.94e-7	Total body bone mineral density;
TGCT	cis	rs6546537	0.915	rs4852866	chr2:69829916	T/C	cg10773587	chr2:69614142	GFPT1	-0.66	-5.91	-0.47	3.14e-8	Serum thyroid-stimulating hormone levels;
TGCT	cis	rs447921	0.861	rs4789301	chr17:74454212	A/C	cg09812376	chr17:74270190	QRICH2	0.45	4.65	0.39	8.4e-6	Mitochondrial DNA levels;
TGCT	trans	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg23505145	chr19:12996616	KLF1	0.79	8.07	0.59	5.16e-13	Prostate cancer (SNP x SNP interaction);
TGCT	trans	rs9383153	0.590	rs2072736	chr6:16328068	T/C	cg22767166	chr8:49833685	SNAI2	0.92	6.66	0.51	7.98e-10	Gambling;
TGCT	cis	rs7666738	0.753	rs11097607	chr4:99011640	C/T	cg18180107	chr4:99064573	C4orf37	0.54	5.03	0.41	1.7e-6	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs17685	0.753	rs13240404	chr7:75675719	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.52	-8.84	-0.62	7.72e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs2486012	0.737	rs246778	chr1:44272761	T/C	cg12908607	chr1:44402522	ARTN	-0.66	-5.18	-0.42	8.53e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7959452	0.590	rs28778648	chr12:69771911	C/A	cg14784868	chr12:69753453	YEATS4	0.83	8.96	0.63	4.14e-15	Blood protein levels;
TGCT	cis	rs7044106	0.762	rs10984972	chr9:123409864	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.59	6.2	0.49	7.76e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs1215050	0.765	rs588851	chr4:98678247	C/T	cg05340658	chr4:99064831	C4orf37	0.43	5.4	0.44	3.2e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7267979	0.966	rs2500433	chr20:25296335	A/G	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6906287	0.647	rs6938226	chr6:118852561	C/A	cg21191810	chr6:118973309	C6orf204	0.26	4.49	0.37	1.58e-5	Electrocardiographic conduction measures;
TGCT	cis	rs9916302	0.847	rs7218670	chr17:37500424	G/A	cg15445000	chr17:37608096	MED1	-0.33	-4.71	-0.39	6.46e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs6088580	0.634	rs6059875	chr20:33086090	T/G	cg06115741	chr20:33292138	TP53INP2	0.53	4.65	0.39	8.41e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7927771	0.864	rs7107726	chr11:47429245	T/A	cg10139015	chr11:47448256	PSMC3	0.52	4.44	0.37	1.97e-5	Subjective well-being;
TGCT	cis	rs11648796	0.757	rs3809666	chr16:764753	C/G	cg27144592	chr16:783916	NARFL	0.39	5.46	0.44	2.54e-7	Height;
TGCT	cis	rs12477438	0.520	rs11123762	chr2:99727789	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.82	0.62	8.67e-15	Chronic sinus infection;
TGCT	cis	rs2760061	0.598	rs849904	chr1:228137145	G/C	cg02753203	chr1:228287806	NA	-0.34	-6.56	-0.51	1.33e-9	Diastolic blood pressure;
TGCT	cis	rs367943	1.000	rs348941	chr5:112824166	G/C	cg12552261	chr5:112820674	MCC	-0.23	-4.57	-0.38	1.17e-5	Type 2 diabetes;
TGCT	cis	rs7937682	0.855	rs521947	chr11:111492616	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.05	-11.36	-0.71	6.21e-21	Primary sclerosing cholangitis;
TGCT	cis	rs12049351	0.774	rs6701186	chr1:229626486	C/G	cg12130225	chr1:229698885	NA	0.39	4.59	0.38	1.06e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs231513	0.954	rs231494	chr17:41976928	G/C	cg26893861	chr17:41843967	DUSP3	-0.71	-5.33	-0.43	4.45e-7	Cognitive function;
TGCT	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg00814883	chr7:100076585	TSC22D4	-0.55	-5.42	-0.44	3.01e-7	Lung function (FEV1/FVC);
TGCT	cis	rs2637266	0.667	rs2395405	chr10:78380518	C/T	cg18941641	chr10:78392320	NA	0.43	5.53	0.44	1.81e-7	Pulmonary function;
TGCT	cis	rs7666738	0.830	rs6848397	chr4:98946738	A/G	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4253772	0.550	rs6007819	chr22:46704916	C/G	cg24881330	chr22:46731750	TRMU	1.04	5.41	0.44	3.12e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs10883723	0.962	rs11191294	chr10:104225837	T/G	cg05855489	chr10:104503620	C10orf26	-0.54	-4.55	-0.38	1.25e-5	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg20007245	chr22:24372913	LOC391322	0.77	6.38	0.5	3.25e-9	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs6121246	0.529	rs6060134	chr20:30176794	A/G	cg21427119	chr20:30132790	HM13	-0.43	-6.28	-0.49	5.3e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7208859	0.623	rs9900144	chr17:29208389	T/C	cg18442181	chr17:29233375	C17orf42	-0.79	-4.78	-0.39	4.95e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs2836974	0.544	rs8128919	chr21:40711862	C/T	cg11644478	chr21:40555479	PSMG1	0.65	6.25	0.49	5.89e-9	Cognitive function;
TGCT	cis	rs3741404	0.574	rs638227	chr11:63871549	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.72	7.35	0.55	2.29e-11	Platelet count;
TGCT	cis	rs13256369	1.000	rs7004438	chr8:8574379	C/T	cg06671706	chr8:8559999	CLDN23	0.35	4.62	0.38	9.35e-6	Obesity-related traits;
TGCT	cis	rs6121246	0.697	rs6088864	chr20:30228157	G/A	cg13852791	chr20:30311386	BCL2L1	0.74	4.84	0.4	3.77e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs425277	0.561	rs11584491	chr1:2042543	A/G	cg03732007	chr1:2071316	PRKCZ	-0.28	-6.27	-0.49	5.51e-9	Height;
TGCT	cis	rs1406084	0.526	rs13001515	chr2:154720147	A/G	cg25703346	chr2:154729189	GALNT13	0.77	4.6	0.38	1.03e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs79349575	0.783	rs56046215	chr17:47008757	A/T	cg26022315	chr17:47021804	SNF8	0.49	4.9	0.4	2.94e-6	Type 2 diabetes;
TGCT	cis	rs7582180	0.817	rs1437967	chr2:100929072	C/G	cg08017756	chr2:100939284	LONRF2	-0.33	-5.58	-0.45	1.45e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs10875746	0.669	rs11168508	chr12:48683511	G/C	cg20731937	chr12:48336164	NA	0.59	4.52	0.38	1.45e-5	Longevity (90 years and older);
TGCT	trans	rs28735056	0.933	rs72980085	chr18:77631679	A/C	cg05926928	chr17:57297772	GDPD1	-0.71	-7.6	-0.56	6.2e-12	Schizophrenia;
TGCT	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6460942	0.908	rs73677573	chr7:12283598	G/A	cg06484146	chr7:12443880	VWDE	-0.55	-4.78	-0.39	4.97e-6	Coronary artery disease;
TGCT	cis	rs2204008	0.618	rs8186932	chr12:38338386	G/A	cg26384229	chr12:38710491	ALG10B	-0.53	-4.66	-0.39	8.04e-6	Bladder cancer;
TGCT	cis	rs3772130	1.000	rs13087578	chr3:121369207	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.54	4.89	0.4	3.12e-6	Cognitive performance;
TGCT	cis	rs2721195	1.000	rs11542372	chr8:145677089	G/A	cg11211951	chr8:145729740	GPT	-0.22	-4.99	-0.41	1.95e-6	Age at first birth;
TGCT	cis	rs9303401	0.659	rs36109237	chr17:56653834	A/G	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs6500602	0.767	rs8060219	chr16:4480158	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.3	5.16	0.42	9.6e-7	Schizophrenia;
TGCT	cis	rs727479	0.543	rs8023263	chr15:51517597	G/T	cg19946085	chr15:51559439	CYP19A1	-0.32	-4.71	-0.39	6.49e-6	Estradiol levels;
TGCT	cis	rs11997175	0.574	rs4389890	chr8:33658018	C/T	ch.8.33884649F	chr8:33765107	NA	0.28	4.54	0.38	1.33e-5	Body mass index;
TGCT	cis	rs3844412	0.593	rs34409669	chr16:82651234	G/A	cg09415485	chr16:82663111	CDH13	0.28	5.11	0.42	1.16e-6	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
TGCT	cis	rs7714584	1.000	rs17111376	chr5:150226899	T/C	cg22134413	chr5:150180641	NA	0.83	6.53	0.51	1.54e-9	Crohn's disease;
TGCT	cis	rs9325144	0.555	rs7977200	chr12:38713745	C/T	cg26384229	chr12:38710491	ALG10B	0.68	6.32	0.49	4.19e-9	Morning vs. evening chronotype;
TGCT	cis	rs4786125	0.636	rs11644404	chr16:6904030	C/A	cg03623568	chr16:6915990	A2BP1	-0.42	-6.03	-0.48	1.72e-8	Heart rate variability traits (SDNN);
TGCT	cis	rs28595532	0.920	rs116145969	chr4:119770908	T/C	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs3096299	0.754	rs2965942	chr16:89510327	G/A	cg02187348	chr16:89574699	SPG7	0.62	6.54	0.51	1.42e-9	Multiple myeloma (IgH translocation);
TGCT	cis	rs929354	0.713	rs10085650	chr7:156993413	T/C	cg05182265	chr7:156933206	UBE3C	-0.39	-8.79	-0.62	1.03e-14	Body mass index;
TGCT	cis	rs12776158	0.901	rs61848389	chr10:71216569	G/A	cg12610070	chr10:71211762	TSPAN15	-0.59	-4.99	-0.41	1.99e-6	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs2463822	0.748	rs2513053	chr11:62109473	T/A	cg23876832	chr11:62092739	NA	0.66	4.78	0.39	4.95e-6	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.41	-4.45	-0.37	1.92e-5	Longevity;Endometriosis;
TGCT	cis	rs10782582	0.593	rs17647178	chr1:76210524	A/G	cg10523679	chr1:76189770	ACADM	-0.67	-6.71	-0.52	6.18e-10	Daytime sleep phenotypes;
TGCT	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg05064044	chr6:292385	DUSP22	-0.7	-7.14	-0.54	6.88e-11	Menopause (age at onset);
TGCT	cis	rs2637266	1.000	rs10219107	chr10:78364369	T/C	cg18941641	chr10:78392320	NA	0.39	4.88	0.4	3.24e-6	Pulmonary function;
TGCT	cis	rs7572733	0.536	rs6732517	chr2:198912902	G/C	cg00792783	chr2:198669748	PLCL1	0.57	5.03	0.41	1.66e-6	Dermatomyositis;
TGCT	cis	rs9790314	0.730	rs4856705	chr3:161100219	T/G	cg03342759	chr3:160939853	NMD3	-0.48	-4.8	-0.4	4.52e-6	Morning vs. evening chronotype;
TGCT	cis	rs6992820	0.967	rs13254746	chr8:56719430	C/G	cg06880721	chr8:56792545	LYN	-0.53	-4.44	-0.37	1.97e-5	Mean platelet volume;
TGCT	cis	rs6939532	0.522	rs6933583	chr6:26355283	A/C	cg05738196	chr6:26577821	NA	-0.51	-4.98	-0.41	2.11e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg12667521	chr19:29218732	NA	0.51	6.12	0.48	1.15e-8	Methadone dose in opioid dependence;
TGCT	cis	rs7666738	0.830	rs28417716	chr4:98864859	C/T	cg05340658	chr4:99064831	C4orf37	0.52	6.0	0.47	1.98e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6964587	1.000	rs12666179	chr7:91574110	T/C	cg17063962	chr7:91808500	NA	-0.91	-10.02	-0.67	1.13e-17	Breast cancer;
TGCT	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	5.06	0.41	1.46e-6	Menopause (age at onset);
TGCT	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg20203395	chr5:56204925	C5orf35	-0.56	-4.8	-0.4	4.39e-6	Initial pursuit acceleration;
TGCT	cis	rs3125734	0.633	rs6479791	chr10:63980341	T/C	cg19640130	chr10:64028056	RTKN2	-0.39	-5.11	-0.42	1.19e-6	Rheumatoid arthritis;
TGCT	cis	rs854765	0.619	rs4561528	chr17:17979099	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	7.52	0.56	9.79e-12	Total body bone mineral density;
TGCT	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.18	0.49	8.32e-9	Bipolar disorder;
TGCT	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	16.07	0.82	4.16e-32	Prudent dietary pattern;
TGCT	cis	rs8020441	1.000	rs8018822	chr14:51170609	C/T	cg04730355	chr14:51134070	SAV1	0.7	5.74	0.46	6.85e-8	Cognitive performance;
TGCT	cis	rs6688613	0.579	rs4657609	chr1:166839174	G/A	cg07049167	chr1:166818506	POGK	0.25	5.23	0.43	6.88e-7	Refractive astigmatism;
TGCT	cis	rs9910055	0.529	rs400460	chr17:42182770	A/G	cg19774624	chr17:42201019	HDAC5	0.66	6.38	0.5	3.18e-9	Total body bone mineral density;
TGCT	cis	rs7599312	0.534	rs6435711	chr2:213410065	G/A	cg16329650	chr2:213403929	ERBB4	1.05	15.34	0.81	1.97e-30	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg04234412	chr22:24373322	LOC391322	-0.92	-10.83	-0.7	1.2e-19	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2013441	1.000	rs11654025	chr17:20198160	A/T	cg18979559	chr17:20280153	CCDC144C	-0.48	-5.18	-0.42	8.54e-7	Obesity-related traits;
TGCT	cis	rs8177253	0.633	rs10935073	chr3:133439184	T/C	cg08439880	chr3:133502540	NA	-0.28	-5.01	-0.41	1.84e-6	Iron status biomarkers;
TGCT	cis	rs1941184	0.500	rs11873153	chr18:29011968	C/T	cg14871544	chr18:29027885	DSG3	0.43	4.57	0.38	1.17e-5	Parkinson's disease (age of onset);
TGCT	cis	rs6121246	0.529	rs7261354	chr20:30202414	T/C	cg10886678	chr20:30946050	ASXL1	-0.71	-4.8	-0.4	4.39e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs9921338	0.886	rs4780363	chr16:11415891	C/T	cg00044050	chr16:11439710	C16orf75	0.97	7.47	0.56	1.25e-11	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg27535305	chr1:53392650	SCP2	0.23	4.52	0.38	1.44e-5	Monocyte count;
TGCT	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs284491	0.511	rs35701310	chr8:105961456	T/C	cg10331154	chr8:105600724	LRP12	-0.71	-4.5	-0.37	1.52e-5	Glaucoma (low intraocular pressure);
TGCT	cis	rs6988636	0.818	rs62521808	chr8:124169568	C/T	cg27053337	chr8:124217698	FAM83A	0.67	4.77	0.39	5.15e-6	Urinary uromodulin levels;
TGCT	cis	rs1865760	1.000	rs6910138	chr6:25904352	C/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.65	6.24	0.49	6.27e-9	Height;
TGCT	cis	rs8180040	0.627	rs9821119	chr3:47198437	C/G	cg27129171	chr3:47204927	SETD2	0.7	8.33	0.6	1.26e-13	Colorectal cancer;
TGCT	cis	rs9467773	0.620	rs1027204	chr6:26639613	T/C	cg11502198	chr6:26597334	ABT1	0.54	4.97	0.41	2.14e-6	Intelligence (multi-trait analysis);
TGCT	trans	rs1974653	0.672	rs9606234	chr22:20067517	T/G	cg08822737	chr17:71088851	SLC39A11	-0.92	-7.35	-0.55	2.29e-11	Schizophrenia;
TGCT	cis	rs763121	0.853	rs5750662	chr22:39072472	G/A	cg06022373	chr22:39101656	GTPBP1	0.77	7.46	0.56	1.35e-11	Menopause (age at onset);
TGCT	trans	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg20587970	chr11:113659929	NA	-1.03	-10.98	-0.7	5.21e-20	Hip circumference adjusted for BMI;
TGCT	cis	rs11690935	0.877	rs72890834	chr2:172835802	G/T	cg13550731	chr2:172543902	DYNC1I2	-1.18	-11.86	-0.73	3.8e-22	Schizophrenia;
TGCT	cis	rs8020441	0.945	rs61238948	chr14:51167617	A/G	cg04730355	chr14:51134070	SAV1	0.71	5.77	0.46	5.92e-8	Cognitive performance;
TGCT	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs17767294	0.614	rs72854521	chr6:28284798	T/A	cg08851530	chr6:28072375	NA	1.54	6.89	0.53	2.51e-10	Parkinson's disease;
TGCT	cis	rs12765878	0.756	rs6584579	chr10:105645725	A/G	cg04788957	chr10:105438008	SH3PXD2A	0.28	4.52	0.38	1.44e-5	Coronary artery disease;
TGCT	cis	rs7666738	0.791	rs7658177	chr4:99035192	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs975752	0.867	rs61166818	chr10:102032865	G/A	cg04750910	chr10:102416409	NA	0.73	4.48	0.37	1.69e-5	Schizophrenia;
TGCT	cis	rs4699052	0.507	rs6533085	chr4:104281586	A/T	cg16532752	chr4:104119610	CENPE	-0.75	-6.26	-0.49	5.8e-9	Testicular germ cell tumor;
TGCT	cis	rs3821902	0.501	rs6799578	chr3:63745668	C/A	cg22134162	chr3:63841271	THOC7	-0.3	-4.58	-0.38	1.12e-5	Breast cancer;
TGCT	cis	rs523522	0.962	rs655530	chr12:121022275	T/C	cg27279351	chr12:120934652	DYNLL1	0.74	6.46	0.5	2.19e-9	High light scatter reticulocyte count;
TGCT	trans	rs7824557	0.547	rs4512344	chr8:11078781	A/C	cg15556689	chr8:8085844	FLJ10661	-0.86	-8.37	-0.6	1.01e-13	Retinal vascular caliber;
TGCT	cis	rs7914558	1.000	rs6584540	chr10:104927634	A/G	cg04362960	chr10:104952993	NT5C2	0.61	5.45	0.44	2.6e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs12681287	0.547	rs6998303	chr8:87510185	T/C	cg19078186	chr8:87526527	CPNE3	-0.37	-4.57	-0.38	1.15e-5	Caudate activity during reward;
TGCT	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg08439880	chr3:133502540	NA	0.33	6.17	0.48	9.01e-9	Iron status biomarkers;
TGCT	cis	rs854765	0.547	rs6502632	chr17:17913057	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.78	8.27	0.6	1.72e-13	Total body bone mineral density;
TGCT	cis	rs2095921	1	rs2095921	chr1:11033322	C/G	cg27631724	chr1:11040367	C1orf127	0.53	6.05	0.48	1.58e-8	Male-pattern baldness;
TGCT	cis	rs10276381	0.579	rs73072543	chr7:28146850	A/G	cg23620719	chr7:28220237	JAZF1	0.74	4.5	0.37	1.56e-5	Crohn's disease;
TGCT	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg08439880	chr3:133502540	NA	0.27	4.97	0.41	2.17e-6	Iron status biomarkers;
TGCT	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg17971929	chr21:40555470	PSMG1	0.96	9.01	0.63	3.05e-15	Cognitive function;
TGCT	cis	rs10193935	0.901	rs10202848	chr2:42515661	A/G	cg27598129	chr2:42591480	NA	-0.42	-5.72	-0.46	7.48e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7927771	0.864	rs4752999	chr11:47428565	C/T	cg21462715	chr11:47870315	NUP160	0.58	4.5	0.37	1.52e-5	Subjective well-being;
TGCT	cis	rs7208859	0.623	rs7503542	chr17:29073830	A/C	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs34734847	0.842	rs556001	chr12:121152967	A/G	cg21892295	chr12:121157589	UNC119B	-0.21	-4.94	-0.41	2.47e-6	Mean corpuscular volume;
TGCT	cis	rs7949030	0.626	rs71490390	chr11:62329185	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.61	8.71	0.62	1.65e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9388451	0.839	rs1811852	chr6:126071575	G/C	cg10911889	chr6:126070802	HEY2	0.57	6.06	0.48	1.51e-8	Brugada syndrome;
TGCT	cis	rs9467711	1.000	rs34569761	chr6:26334306	A/G	cg26531700	chr6:26746687	NA	-1.04	-5.71	-0.46	7.81e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4849845	0.598	rs4848586	chr2:121061291	C/T	cg24070213	chr2:121070622	NA	0.35	4.72	0.39	6.29e-6	Mean platelet volume;
TGCT	trans	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg13615516	chr5:77269221	NA	0.67	8.36	0.6	1.09e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs372883	0.519	rs2832274	chr21:30600189	A/T	cg24692254	chr21:30365293	RNF160	0.6	5.61	0.45	1.23e-7	Pancreatic cancer;
TGCT	cis	rs28595532	1.000	rs75497896	chr4:119636703	T/C	cg11846333	chr4:119757529	SEC24D	0.95	4.68	0.39	7.54e-6	Cannabis dependence symptom count;
TGCT	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg12311346	chr5:56204834	C5orf35	0.57	6.13	0.48	1.07e-8	Initial pursuit acceleration;
TGCT	cis	rs6733011	0.628	rs4263159	chr2:99456151	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-4.64	-0.38	8.7e-6	Bipolar disorder;
TGCT	cis	rs11122272	0.735	rs2739516	chr1:231505527	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.14	-0.54	6.86e-11	Hemoglobin concentration;
TGCT	cis	rs9913156	0.639	rs72824971	chr17:4604270	A/G	cg19197139	chr17:4613644	ARRB2	0.86	7.87	0.58	1.5e-12	Lymphocyte counts;
TGCT	cis	rs2594989	0.943	rs2454493	chr3:11506458	A/G	cg00170343	chr3:11313890	ATG7	0.74	5.47	0.44	2.4e-7	Circulating chemerin levels;
TGCT	cis	rs7655841	0.704	rs28711799	chr4:129874496	T/A	cg26347359	chr4:129759716	PHF17	0.43	4.81	0.4	4.37e-6	Chronic obstructive pulmonary disease (moderate to severe);
TGCT	cis	rs10751667	0.714	rs7395879	chr11:963855	G/C	cg06064525	chr11:970664	AP2A2	-0.35	-8.23	-0.59	2.17e-13	Alzheimer's disease (late onset);
TGCT	trans	rs853356	0.947	rs853384	chr6:14182305	T/G	cg14262035	chr17:42019790	PPY	0.5	6.73	0.52	5.54e-10	Height;
TGCT	cis	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg20637647	chr7:64974828	NA	0.89	4.99	0.41	2.01e-6	Diabetic kidney disease;
TGCT	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	5.46	0.44	2.53e-7	Height;
TGCT	cis	rs9894429	0.966	rs7405901	chr17:79587813	T/C	cg18240062	chr17:79603768	NPLOC4	0.67	6.85	0.52	3.11e-10	Eye color traits;
TGCT	cis	rs539096	0.706	rs618369	chr1:44071796	G/T	cg12908607	chr1:44402522	ARTN	-0.49	-4.94	-0.41	2.49e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10832169	0.967	rs1528640	chr11:14070828	A/G	cg04547675	chr11:13986162	SPON1	0.54	4.78	0.39	4.9100000000000004e-06	Blood protein levels;
TGCT	trans	rs1814175	0.529	rs1988417	chr11:49932430	A/G	cg18944383	chr4:111397179	ENPEP	0.45	6.9	0.53	2.36e-10	Height;
TGCT	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	6.78	0.52	4.27e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs12497850	1.000	rs4858828	chr3:48724811	C/T	cg06212747	chr3:49208901	KLHDC8B	0.62	5.94	0.47	2.65e-8	Parkinson's disease;
TGCT	cis	rs7927592	0.763	rs10896327	chr11:68235275	G/C	cg16797656	chr11:68205561	LRP5	0.26	4.54	0.38	1.29e-5	Total body bone mineral density;
TGCT	cis	rs9818758	0.607	rs35283189	chr3:49113668	T/C	cg07636037	chr3:49044803	WDR6	-1.04	-5.16	-0.42	9.65e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg11301795	chr4:187892539	NA	-0.33	-4.88	-0.4	3.19e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9807841	0.670	rs10948	chr19:10754905	G/T	cg17848348	chr19:10766748	ILF3	-0.4	-4.5	-0.37	1.55e-5	Inflammatory skin disease;
TGCT	cis	rs17608059	0.710	rs8080167	chr17:13949828	G/A	cg11395062	chr17:14139857	CDRT15	0.39	5.08	0.41	1.36e-6	Temperament;
TGCT	cis	rs1475911	1.000	rs1475911	chr21:43513480	A/C	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.26	-5.21	-0.42	7.57e-7	IgG glycosylation;
TGCT	cis	rs74233809	1.000	rs11191515	chr10:104776527	G/A	cg05855489	chr10:104503620	C10orf26	0.77	4.55	0.38	1.27e-5	Birth weight;
TGCT	cis	rs2760061	0.624	rs10442629	chr1:228191070	T/A	cg18477163	chr1:228402036	OBSCN	0.36	7.06	0.54	1.04e-10	Diastolic blood pressure;
TGCT	cis	rs10791097	0.547	rs1050078	chr11:130746146	T/C	cg05962950	chr11:130786565	SNX19	0.93	11.63	0.72	1.37e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs12478296	0.786	rs13409307	chr2:242995499	G/C	cg06360820	chr2:242988706	NA	-0.63	-5.43	-0.44	2.86e-7	Obesity-related traits;
TGCT	cis	rs28595532	0.920	rs116046128	chr4:119741990	C/T	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs4689388	0.853	rs6817447	chr4:6286847	G/T	cg25554036	chr4:6271136	WFS1	0.56	7.96	0.58	9.45e-13	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs10791323	0.592	rs2851115	chr11:133705381	C/A	cg15485101	chr11:133734466	NA	0.41	5.18	0.42	8.59e-7	Childhood ear infection;
TGCT	cis	rs12989701	0.825	rs4663096	chr2:127861766	T/A	cg08168897	chr2:127865431	BIN1	0.55	6.59	0.51	1.13e-9	Alzheimer's disease (late onset);
TGCT	cis	rs911555	0.755	rs7148567	chr14:103882234	C/T	cg23461800	chr14:103021989	NA	0.33	4.46	0.37	1.83e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	6.13	0.48	1.06e-8	Bipolar disorder;
TGCT	cis	rs6740322	0.948	rs6722694	chr2:43569798	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.38	-6.17	-0.48	8.72e-9	Coronary artery disease;
TGCT	cis	rs79387448	0.745	rs1989399	chr2:103166742	G/A	cg09003973	chr2:102972529	NA	0.95	6.15	0.48	9.95e-9	Gut microbiota (bacterial taxa);
TGCT	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg03452623	chr4:187889614	NA	-0.36	-5.3	-0.43	5.01e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10254284	0.959	rs881850	chr7:28152675	C/T	cg23620719	chr7:28220237	JAZF1	-0.54	-4.79	-0.4	4.7e-6	Lymphocyte percentage of white cells;Systemic lupus erythematosus;
TGCT	cis	rs6570726	0.935	rs429306	chr6:145827016	T/C	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6582630	0.519	rs8189599	chr12:38280748	A/G	cg13010199	chr12:38710504	ALG10B	0.6	4.62	0.38	9.49e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs10057188	0.868	rs35252676	chr5:77916444	C/T	cg24853438	chr5:77139492	NA	-0.22	-4.47	-0.37	1.74e-5	Pulse pressure;
TGCT	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.63	-0.51	9.04e-10	Alzheimer's disease;
TGCT	cis	rs7829975	0.511	rs2976906	chr8:8342415	A/T	cg08975724	chr8:8085496	FLJ10661	0.55	5.37	0.43	3.82e-7	Mood instability;
TGCT	cis	rs7666738	0.830	rs6854994	chr4:98977624	C/G	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12142240	0.698	rs72677589	chr1:46817770	T/C	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs2404602	0.679	rs12899871	chr15:76757347	T/C	cg22467129	chr15:76604101	ETFA	-0.57	-6.83	-0.52	3.31e-10	Blood metabolite levels;
TGCT	cis	rs617219	0.726	rs955897	chr5:78431486	A/C	cg09550809	chr5:78407562	BHMT	0.4	5.43	0.44	2.88e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs7524258	0.867	rs35399313	chr1:7277293	T/C	cg07173049	chr1:7289937	CAMTA1	0.28	4.55	0.38	1.27e-5	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs1577917	0.917	rs4098044	chr6:86462066	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.27	-0.43	5.96e-7	Response to antipsychotic treatment;
TGCT	cis	rs9611565	0.765	rs132909	chr22:41802031	G/A	cg06634786	chr22:41940651	POLR3H	0.7	6.65	0.51	8.51e-10	Vitiligo;
TGCT	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg12000995	chr2:27665139	KRTCAP3	-0.37	-4.74	-0.39	5.83e-6	Menopause (age at onset);
TGCT	cis	rs1552244	0.608	rs2075310	chr3:10067651	C/T	cg00149659	chr3:10157352	C3orf10	0.82	5.99	0.47	2.09e-8	Alzheimer's disease;
TGCT	cis	rs3806843	0.900	rs2563287	chr5:140124786	C/T	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.3	-4.61	-0.38	1e-5	Depressive symptoms (multi-trait analysis);
TGCT	trans	rs1814175	0.645	rs28634872	chr11:50042175	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.84	-0.7	1.13e-19	Height;
TGCT	cis	rs11785400	0.793	rs4371985	chr8:143737279	C/T	cg24634471	chr8:143751801	JRK	0.54	5.11	0.42	1.19e-6	Schizophrenia;
TGCT	cis	rs9311474	0.596	rs524986	chr3:52228496	T/C	cg07507251	chr3:52567010	NT5DC2	0.35	4.56	0.38	1.19e-5	Electroencephalogram traits;
TGCT	cis	rs2458413	0.542	rs2514670	chr8:105363452	C/G	cg04554929	chr8:105342491	NA	-0.49	-5.88	-0.47	3.59e-8	Paget's disease;
TGCT	cis	rs208520	0.526	rs7771233	chr6:66819784	A/G	cg07460842	chr6:66804631	NA	-0.97	-11.82	-0.73	4.61e-22	Exhaled nitric oxide output;
TGCT	trans	rs2243480	1.000	rs1638734	chr7:66097539	A/C	cg07424592	chr7:64974309	NA	1.31	7.65	0.57	4.73e-12	Diabetic kidney disease;
TGCT	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg23758822	chr17:41437982	NA	0.72	6.96	0.53	1.76e-10	Menopause (age at onset);
TGCT	cis	rs3820068	0.608	rs10927836	chr1:16034368	G/C	cg05660106	chr1:15850417	CASP9	0.69	6.45	0.5	2.28e-9	Systolic blood pressure;
TGCT	cis	rs6088590	0.710	rs6059992	chr20:33282275	T/C	cg06115741	chr20:33292138	TP53INP2	0.56	4.7	0.39	6.83e-6	Coronary artery disease;
TGCT	cis	rs4699052	0.739	rs6836157	chr4:104242990	A/G	cg16532752	chr4:104119610	CENPE	-0.54	-5.43	-0.44	2.87e-7	Testicular germ cell tumor;
TGCT	cis	rs7226408	0.857	rs56391099	chr18:34478627	G/T	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs9534288	0.830	rs7987953	chr13:46634395	C/T	cg15192986	chr13:46630673	CPB2	-0.5	-6.23	-0.49	6.66e-9	Blood protein levels;
TGCT	cis	rs3011225	0.710	rs3011224	chr1:44318483	C/T	cg12908607	chr1:44402522	ARTN	-0.64	-7.74	-0.57	3e-12	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs67340775	0.541	rs200974	chr6:27855845	A/G	cg26587870	chr6:27730563	NA	-0.34	-4.62	-0.38	9.28e-6	Lung cancer in ever smokers;
TGCT	cis	rs644799	0.672	rs61902245	chr11:95517737	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.28	0.6	1.63e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg20203395	chr5:56204925	C5orf35	0.79	6.24	0.49	6.41e-9	Initial pursuit acceleration;
TGCT	trans	rs1814175	0.669	rs12416837	chr11:49669761	G/T	cg15704280	chr7:45808275	SEPT13	-0.61	-7.11	-0.54	8.12e-11	Height;
TGCT	cis	rs73198271	1.000	rs55971558	chr8:8614403	G/T	ch.8.214553F	chr8:8189620	PRAGMIN	-0.27	-4.79	-0.39	4.72e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs10193935	0.818	rs2374428	chr2:42667961	T/C	cg27598129	chr2:42591480	NA	0.38	5.41	0.44	3.09e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1334894	0.892	rs11545925	chr6:35542526	T/A	cg24281267	chr6:35479648	TULP1	-0.44	-4.49	-0.37	1.59e-5	Coronary artery disease;
TGCT	trans	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg21659725	chr3:3221576	CRBN	-0.74	-8.78	-0.62	1.08e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs514406	0.505	rs269289	chr1:53167151	A/C	cg22166914	chr1:53195759	ZYG11B	0.44	7.58	0.56	6.98e-12	Monocyte count;
TGCT	cis	rs26868	0.816	rs26871	chr16:2248133	G/A	cg25665528	chr16:2260870	C16orf79	-0.31	-4.79	-0.4	4.62e-6	Height;
TGCT	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg27436995	chr16:743998	FBXL16	-0.47	-5.11	-0.42	1.17e-6	Height;
TGCT	cis	rs492146	0.765	rs673197	chr6:52844257	A/G	cg06706454	chr6:52930286	FBXO9	-0.51	-4.66	-0.39	8.12e-6	Epilepsy (remission after treatment);
TGCT	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg10150615	chr22:24372951	LOC391322	-1.0	-12.85	-0.76	1.47e-24	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2439831	0.850	rs2277531	chr15:44069069	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	5.7	0.46	8.13e-8	Lung cancer in ever smokers;
TGCT	cis	rs1670533	1.000	rs629260	chr4:1086764	A/G	cg20887711	chr4:1340912	KIAA1530	0.66	5.33	0.43	4.49e-7	Recombination rate (females);
TGCT	cis	rs60843830	1.000	rs10193373	chr2:281886	T/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.73	7.33	0.55	2.65e-11	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs62380364	0.542	rs2247885	chr5:88047999	T/C	cg24804195	chr5:87968844	LOC645323	-0.58	-5.68	-0.45	9.18e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs4727027	0.866	rs3735311	chr7:148877737	T/C	cg23583168	chr7:148888333	NA	-0.74	-9.81	-0.66	3.64e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs6725041	0.819	rs939224	chr2:213089095	T/C	cg20637307	chr2:213403960	ERBB4	-0.52	-4.47	-0.37	1.72e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs4689388	0.853	rs1079216	chr4:6282473	T/C	cg14416269	chr4:6271139	WFS1	0.4	5.13	0.42	1.07e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg07332563	chr6:291687	DUSP22	-0.76	-7.73	-0.57	3.11e-12	Menopause (age at onset);
TGCT	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.58	-5.67	-0.45	9.32e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7089973	0.628	rs11196953	chr10:116607707	A/G	cg03647239	chr10:116582469	FAM160B1	0.59	5.74	0.46	6.72e-8	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg19318889	chr4:1322082	MAEA	-0.2	-4.91	-0.4	2.8e-6	Obesity-related traits;
TGCT	cis	rs617219	0.671	rs2607144	chr5:78556798	G/T	cg23987322	chr5:78407566	BHMT	0.39	4.98	0.41	2.1e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs12681287	0.547	rs7461366	chr8:87511685	C/T	cg27223183	chr8:87520930	FAM82B	-0.95	-6.95	-0.53	1.81e-10	Caudate activity during reward;
TGCT	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg18876405	chr7:65276391	NA	-0.34	-5.08	-0.41	1.38e-6	Aortic root size;
TGCT	cis	rs10089	0.951	rs1864923	chr5:127420843	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.8	7.64	0.57	5.24e-12	Ileal carcinoids;
TGCT	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg10349874	chr16:420996	TMEM8A;MRPL28	-0.25	-4.48	-0.37	1.7e-5	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs1670533	1.000	rs6852850	chr4:1052857	C/G	cg20887711	chr4:1340912	KIAA1530	0.7	5.65	0.45	1.03e-7	Recombination rate (females);
TGCT	trans	rs4332037	0.950	rs56403963	chr7:1946130	C/G	cg25206134	chr2:45395956	NA	1.1	9.34	0.64	5.11e-16	Bipolar disorder;
TGCT	trans	rs1973993	0.967	rs2181375	chr1:96940119	A/G	cg10631902	chr5:14652156	NA	0.31	6.82	0.52	3.6e-10	Weight;
TGCT	cis	rs7772486	0.817	rs2144477	chr6:146406248	C/T	cg23711669	chr6:146136114	FBXO30	0.91	9.95	0.67	1.67e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs34779708	0.931	rs4934524	chr10:35270921	G/C	cg04310649	chr10:35416472	CREM	-0.51	-4.54	-0.38	1.31e-5	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg23156509	chr2:114033830	PAX8;LOC440839	-0.31	-4.83	-0.4	3.92e-6	Lymphocyte counts;
TGCT	cis	rs8013055	0.846	rs11624007	chr14:105992183	A/C	cg23356831	chr14:105996513	TMEM121	0.36	5.43	0.44	2.85e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs765787	0.530	rs11636440	chr15:45535982	C/T	cg24006582	chr15:45444508	DUOX1	-0.25	-5.54	-0.45	1.76e-7	Uric acid levels;
TGCT	cis	rs28374715	0.681	rs7165396	chr15:41586947	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.89	-13.11	-0.76	3.54e-25	Ulcerative colitis;
TGCT	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs478304	0.651	rs4014192	chr11:65498915	C/T	cg17480646	chr11:65405466	SIPA1	-0.57	-6.93	-0.53	2.05e-10	Acne (severe);
TGCT	cis	rs1903068	0.853	rs9997685	chr4:56022903	A/T	cg16572876	chr4:56024045	NA	0.44	4.76	0.39	5.27e-6	Endometriosis;
TGCT	cis	rs9911578	0.835	rs723991	chr17:56482039	G/A	cg05425664	chr17:57184151	TRIM37	0.61	5.73	0.46	7.03e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs77972916	0.536	rs59362315	chr2:43594931	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.39	-6.06	-0.48	1.52e-8	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs17490626	0.512	rs12241097	chr10:71216678	T/G	cg12610070	chr10:71211762	TSPAN15	-0.62	-7.12	-0.54	7.54e-11	Thrombosis;
TGCT	cis	rs2204008	0.837	rs2892296	chr12:37969785	C/T	cg26384229	chr12:38710491	ALG10B	-0.7	-6.12	-0.48	1.11e-8	Bladder cancer;
TGCT	cis	rs7666738	0.830	rs921522	chr4:98841608	C/T	cg18180107	chr4:99064573	C4orf37	0.6	5.25	0.43	6.5e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1341267	0.529	rs6492721	chr13:95258944	A/G	cg18412871	chr13:95254051	GPR180	-0.6	-5.45	-0.44	2.66e-7	Triglyceride levels;
TGCT	cis	rs7246657	0.943	rs10405064	chr19:37861861	C/T	cg18154014	chr19:37997991	ZNF793	0.97	6.49	0.5	1.82e-9	Coronary artery calcification;
TGCT	cis	rs453301	0.686	rs2409120	chr8:8882571	G/C	cg06636001	chr8:8085503	FLJ10661	-0.68	-5.66	-0.45	9.87e-8	Joint mobility (Beighton score);
TGCT	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg23719950	chr11:63933701	MACROD1	-0.72	-6.01	-0.47	1.92e-8	Mean platelet volume;
TGCT	cis	rs12474538	0.704	rs10209687	chr2:69508284	C/T	cg24886176	chr2:70142158	MXD1	0.71	4.52	0.38	1.43e-5	Breast cancer;
TGCT	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg11301795	chr4:187892539	NA	-0.3	-4.49	-0.37	1.62e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9796	0.689	rs561301	chr15:41444723	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.53	-6.84	-0.52	3.16e-10	Menopause (age at onset);
TGCT	cis	rs4944092	1.000	rs7125695	chr11:75908131	A/G	cg04588336	chr11:75916460	WNT11	0.44	6.09	0.48	1.29e-8	PR interval;
TGCT	cis	rs9436747	0.740	rs1171265	chr1:66003252	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	-0.5	-4.85	-0.4	3.57e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs8038465	0.592	rs1542579	chr15:73935897	A/G	cg15420318	chr15:73925796	NPTN	0.64	6.67	0.51	7.56e-10	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs11651000	0.625	rs4794067	chr17:45808828	T/C	cg06532163	chr17:45867833	NA	0.33	5.21	0.42	7.7300000000000005e-07	IgG glycosylation;
TGCT	cis	rs8072100	1.000	rs8065437	chr17:45721653	C/T	cg08085267	chr17:45401833	C17orf57	-0.47	-5.13	-0.42	1.07e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs9916302	0.904	rs35335692	chr17:37710006	A/G	cg07936489	chr17:37558343	FBXL20	-0.61	-4.87	-0.4	3.29e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs3734905	0.831	rs12529773	chr6:169926440	G/C	cg20469989	chr6:170102314	C6orf120;WDR27	-0.97	-5.18	-0.42	8.62e-7	HIV-1 control;
TGCT	cis	rs7666738	0.830	rs7672901	chr4:98938781	C/T	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12579753	0.917	rs10778833	chr12:82197983	G/T	cg07988820	chr12:82153109	PPFIA2	-0.59	-6.19	-0.49	7.93e-9	Resting heart rate;
TGCT	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.62	5.04	0.41	1.63e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg18876405	chr7:65276391	NA	0.31	4.79	0.4	4.58e-6	Aortic root size;
TGCT	cis	rs9581857	0.547	rs9319374	chr13:28047587	A/C	cg22138327	chr13:27999177	GTF3A	0.74	4.82	0.4	4.15e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.45	4.65	0.39	8.33e-6	Lymphocyte counts;
TGCT	cis	rs7119038	0.818	rs10892288	chr11:118644694	A/G	cg19308663	chr11:118741387	NA	0.31	6.12	0.48	1.14e-8	Sjögren's syndrome;
TGCT	cis	rs4478858	0.735	rs6681286	chr1:31799384	G/C	cg07478791	chr1:31886160	SERINC2	-0.51	-4.95	-0.41	2.33e-6	Alcohol dependence;
TGCT	cis	rs17221829	0.965	rs10830364	chr11:89458632	T/G	cg02982614	chr11:89391479	FOLH1B	-0.27	-4.66	-0.39	8.19e-6	Anxiety in major depressive disorder;
TGCT	cis	rs380904	0.963	rs410822	chr8:144574611	A/C	cg22012530	chr8:144635309	GSDMD	0.47	4.9	0.4	2.99e-6	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs3796352	1.000	rs2336540	chr3:52974589	G/A	cg15956490	chr3:53032818	SFMBT1	0.59	6.04	0.48	1.65e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs8084125	0.832	rs62105180	chr18:74951197	C/G	cg05528293	chr18:74961138	GALR1	0.52	5.18	0.42	8.65e-7	Obesity-related traits;
TGCT	cis	rs9915657	0.870	rs1042678	chr17:70122108	G/A	cg06234051	chr17:70120541	SOX9	-0.26	-5.34	-0.43	4.36e-7	Thyroid hormone levels;
TGCT	cis	rs4919044	0.808	rs835256	chr10:94779550	C/T	cg05127821	chr10:94822908	CYP26C1	-0.77	-5.03	-0.41	1.71e-6	Coronary artery disease;
TGCT	cis	rs9972944	0.729	rs7222147	chr17:63774100	C/T	cg07283582	chr17:63770753	CCDC46	0.26	5.05	0.41	1.53e-6	Total body bone mineral density;
TGCT	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg22920501	chr2:26401640	FAM59B	0.7	6.28	0.49	5.13e-9	Gut microbiome composition (summer);
TGCT	cis	rs992157	0.767	rs2014615	chr2:219171191	A/G	cg00012203	chr2:219082015	ARPC2	0.81	7.91	0.58	1.2e-12	Colorectal cancer;
TGCT	cis	rs1670533	1.000	rs935972	chr4:1045171	A/G	cg18657303	chr4:1051139	NA	0.3	4.46	0.37	1.79e-5	Recombination rate (females);
TGCT	cis	rs3858526	0.883	rs4758183	chr11:5925178	C/G	cg13902645	chr11:5959945	NA	-0.43	-4.62	-0.38	9.28e-6	DNA methylation (variation);
TGCT	cis	rs13191362	1.000	rs13206253	chr6:163166902	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.88	7.89	0.58	1.34e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7726839	0.540	rs72703087	chr5:598029	C/T	cg16624210	chr5:671434	TPPP	0.44	4.85	0.4	3.68e-6	Obesity-related traits;
TGCT	cis	rs7959452	0.640	rs1598543	chr12:69688757	G/T	cg20891283	chr12:69753455	YEATS4	0.66	6.57	0.51	1.26e-9	Blood protein levels;
TGCT	cis	rs7760949	1.000	rs7760949	chr6:13920538	A/C	cg27413430	chr6:13925136	RNF182	0.64	5.97	0.47	2.32e-8	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs6426558	0.515	rs7412928	chr1:227332148	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.57	-6.65	-0.51	8.31e-10	Neutrophil percentage of white cells;
TGCT	cis	rs1577917	0.958	rs884842	chr6:86680397	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.16	-0.42	9.39e-7	Response to antipsychotic treatment;
TGCT	cis	rs137603	0.966	rs126228	chr22:39681436	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.57	5.3	0.43	5.05e-7	Primary biliary cholangitis;
TGCT	cis	rs3087591	1.000	rs2905884	chr17:29512476	A/G	cg24425628	chr17:29625626	OMG;NF1	0.46	7.04	0.53	1.17e-10	Hip circumference;
TGCT	cis	rs1062177	1.000	rs2915880	chr5:151147334	G/A	cg12924095	chr5:151150029	G3BP1	0.35	5.07	0.41	1.41e-6	Preschool internalizing problems;
TGCT	cis	rs2797160	0.904	rs1739370	chr6:126011231	C/T	cg05901451	chr6:126070800	HEY2	0.76	6.58	0.51	1.19e-9	Endometrial cancer;
TGCT	cis	rs2456568	0.900	rs2511373	chr11:93671414	T/C	cg17595323	chr11:93583763	C11orf90	-0.46	-5.86	-0.47	3.88e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs2836950	0.565	rs2836945	chr21:40596757	C/T	cg11644478	chr21:40555479	PSMG1	-0.54	-5.1	-0.42	1.25e-6	Menarche (age at onset);
TGCT	cis	rs910316	1.000	rs7147118	chr14:75610170	G/C	cg11812906	chr14:75593930	NEK9	0.74	7.37	0.55	2.12e-11	Height;
TGCT	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg06618935	chr21:46677482	NA	-0.37	-5.81	-0.46	5.06e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg08048268	chr3:133502702	NA	0.7	11.4	0.72	4.94e-21	Iron status biomarkers;
TGCT	cis	rs909674	0.818	rs8136980	chr22:39844574	G/A	cg02038168	chr22:39784481	NA	-0.7	-5.63	-0.45	1.16e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs4499344	0.921	rs2277927	chr19:33088366	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.73	6.69	0.51	6.9e-10	Mean platelet volume;
TGCT	cis	rs8072100	0.875	rs9635762	chr17:45648446	A/C	cg08085267	chr17:45401833	C17orf57	0.43	4.63	0.38	9.02e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs8037137	0.915	rs77554484	chr15:91509215	C/A	cg22570213	chr15:91497863	RCCD1	0.54	5.04	0.41	1.6e-6	Platelet count;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
TGCT	cis	rs2075165	0.901	rs7522860	chr1:156275281	C/T	cg20302342	chr1:156215951	PAQR6	0.34	5.24	0.43	6.83e-7	Tonsillectomy;
TGCT	cis	rs1129187	0.935	rs9462859	chr6:42946943	G/A	cg18735214	chr6:43276756	CRIP3	-0.56	-4.84	-0.4	3.78e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg01802117	chr1:53393560	SCP2	0.5	6.08	0.48	1.36e-8	Monocyte count;
TGCT	cis	rs11621121	0.637	rs4902387	chr14:65792839	C/T	cg04536575	chr14:65016802	C14orf50	-0.64	-4.53	-0.38	1.36e-5	N-glycan levels;
TGCT	cis	rs2580764	0.517	rs2972070	chr2:55301691	G/A	cg09592903	chr2:55203963	RTN4	0.25	5.64	0.45	1.09e-7	Mean platelet volume;
TGCT	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9467711	0.606	rs9393713	chr6:26373678	C/T	cg16898833	chr6:26189333	HIST1H4D	1.07	5.08	0.41	1.36e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg27286337	chr10:134555280	INPP5A	0.38	4.57	0.38	1.17e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs4478858	0.709	rs7514640	chr1:31752316	G/A	cg07478791	chr1:31886160	SERINC2	-0.52	-5.02	-0.41	1.73e-6	Alcohol dependence;
TGCT	cis	rs2120019	0.938	rs2289582	chr15:75310394	T/C	cg09165964	chr15:75287851	SCAMP5	-1.18	-10.31	-0.68	2.22e-18	Blood trace element (Zn levels);
TGCT	cis	rs2242116	0.727	rs6442040	chr3:46963035	C/A	cg27129171	chr3:47204927	SETD2	0.62	6.08	0.48	1.36e-8	Birth weight;
TGCT	cis	rs12142240	0.698	rs56284503	chr1:46847127	C/G	cg00530320	chr1:46809349	NSUN4	0.29	5.79	0.46	5.34e-8	Menopause (age at onset);
TGCT	cis	rs899997	1.000	rs11634628	chr15:79005579	G/A	cg04896959	chr15:78267971	NA	0.36	5.57	0.45	1.52e-7	Coronary artery disease or large artery stroke;
TGCT	cis	rs8013055	0.699	rs66798104	chr14:105987782	C/G	cg23356831	chr14:105996513	TMEM121	0.36	5.5	0.44	2.12e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs3784262	0.669	rs4646623	chr15:58257123	T/G	cg12031962	chr15:58353849	ALDH1A2	-0.42	-6.11	-0.48	1.19e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg22968622	chr17:43663579	NA	-1.23	-10.98	-0.7	5.31e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs6500602	0.727	rs1477123	chr16:4560627	T/A	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.26	4.81	0.4	4.35e-6	Schizophrenia;
TGCT	trans	rs561341	0.660	rs7406043	chr17:30220152	C/G	cg20587970	chr11:113659929	NA	-0.8	-9.56	-0.65	1.44e-16	Hip circumference adjusted for BMI;
TGCT	cis	rs3796352	1.000	rs71617204	chr3:53042951	G/A	cg27565382	chr3:53032988	SFMBT1	0.45	4.58	0.38	1.14e-5	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs2153535	0.541	rs945304	chr6:8442892	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.58	0.45	1.42e-7	Motion sickness;
TGCT	cis	rs7267979	1.000	rs7018	chr20:25278261	A/G	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg03517284	chr6:25882590	NA	-0.92	-8.89	-0.62	6.09e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs1555895	0.576	rs4362075	chr10:865476	A/G	cg02193355	chr10:851439	NA	0.2	4.55	0.38	1.28e-5	Survival in rectal cancer;
TGCT	cis	rs4851266	0.898	rs12615145	chr2:100853116	C/T	cg22139774	chr2:100720529	AFF3	-0.32	-4.66	-0.39	7.89e-6	Educational attainment;
TGCT	cis	rs2228479	0.867	rs12930606	chr16:89946682	A/G	cg19635926	chr16:89946313	TCF25	0.28	4.8	0.4	4.47e-6	Skin colour saturation;
TGCT	cis	rs7666738	0.546	rs11727151	chr4:98837353	A/C	cg18180107	chr4:99064573	C4orf37	0.58	5.02	0.41	1.75e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1577917	1.000	rs34281561	chr6:86701872	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.54	-0.45	1.73e-7	Response to antipsychotic treatment;
TGCT	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg08859206	chr1:53392774	SCP2	-0.46	-7.42	-0.55	1.64e-11	Monocyte count;
TGCT	cis	rs5760092	0.755	rs11090298	chr22:24262061	G/A	cg04234412	chr22:24373322	LOC391322	0.95	8.89	0.62	5.96e-15	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs7831492	0.564	rs11787479	chr8:41613496	A/G	cg17182837	chr8:41585554	ANK1	-0.18	-4.62	-0.38	9.31e-6	Colorectal cancer;
TGCT	cis	rs3820068	0.608	rs12740492	chr1:16048951	A/T	cg05660106	chr1:15850417	CASP9	0.73	6.71	0.52	6.18e-10	Systolic blood pressure;
TGCT	cis	rs12200560	0.505	rs211165	chr6:97068520	A/T	cg06623918	chr6:96969491	KIAA0776	0.57	4.83	0.4	3.93e-6	Coronary heart disease;
TGCT	cis	rs9916302	0.904	rs2061338	chr17:37421767	T/C	cg07936489	chr17:37558343	FBXL20	-0.62	-4.91	-0.4	2.77e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs17331151	0.573	rs4687556	chr3:52890475	T/C	cg12962167	chr3:53033115	SFMBT1	-0.42	-4.83	-0.4	3.88e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs6582630	0.615	rs10880642	chr12:38554152	A/G	cg26384229	chr12:38710491	ALG10B	-0.51	-4.73	-0.39	5.94e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs3749237	0.964	rs34522271	chr3:49808517	A/G	cg07636037	chr3:49044803	WDR6	0.62	5.48	0.44	2.23e-7	Resting heart rate;
TGCT	cis	rs11574514	1.000	rs79437914	chr16:67578143	C/A	cg00545966	chr16:67701244	C16orf86;C16orf48	0.72	4.45	0.37	1.87e-5	Crohn's disease;
TGCT	trans	rs2727020	0.521	rs10839296	chr11:49537617	T/C	cg11707556	chr5:10655725	ANKRD33B	0.42	8.63	0.61	2.5e-14	Coronary artery disease;
TGCT	cis	rs7104764	0.957	rs1128321	chr11:244171	T/C	cg18336825	chr11:236787	PSMD13;SIRT3	1.07	11.19	0.71	1.61e-20	Menarche (age at onset);
TGCT	cis	rs992157	0.687	rs35271699	chr2:219117482	G/A	cg00012203	chr2:219082015	ARPC2	0.8	9.77	0.66	4.54e-17	Colorectal cancer;
TGCT	cis	rs7914558	1.000	rs10883824	chr10:104812897	A/G	cg15744005	chr10:104629667	AS3MT	-0.37	-4.48	-0.37	1.64e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg18876405	chr7:65276391	NA	0.32	4.89	0.4	3.11e-6	Aortic root size;
TGCT	cis	rs9300255	0.537	rs2682429	chr12:123642955	C/G	cg00376283	chr12:123451042	ABCB9	0.73	5.64	0.45	1.09e-7	Neutrophil percentage of white cells;
TGCT	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg13695892	chr22:41940480	POLR3H	-0.91	-9.11	-0.63	1.82e-15	Vitiligo;
TGCT	cis	rs3027234	0.723	rs11653623	chr17:8202620	G/C	cg08322244	chr17:8066669	VAMP2	-0.56	-5.23	-0.43	6.87e-7	Telomere length;
TGCT	cis	rs4654899	1.000	rs7525438	chr1:21458217	G/A	cg01072550	chr1:21505969	NA	-0.5	-8.07	-0.59	5.13e-13	Superior frontal gyrus grey matter volume;
TGCT	cis	rs5769765	0.646	rs9616205	chr22:50309915	A/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.46	6.09	0.48	1.29e-8	Schizophrenia;
TGCT	cis	rs782590	0.729	rs706548	chr2:55850106	C/G	cg03859395	chr2:55845619	SMEK2	0.77	8.95	0.63	4.29e-15	Metabolic syndrome;
TGCT	trans	rs11088226	0.681	rs8131384	chr21:33944127	C/T	cg09050820	chr6:167586206	TCP10L2	0.82	7.4	0.55	1.8e-11	Gastritis;
TGCT	cis	rs67073037	0.955	rs67873458	chr2:29119773	T/C	cg09522027	chr2:28974177	PPP1CB	0.57	4.49	0.37	1.59e-5	Breast cancer;Breast cancer (estrogen-receptor negative);
TGCT	cis	rs9902453	0.765	rs62068653	chr17:28212663	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.9	8.65	0.61	2.29e-14	Coffee consumption (cups per day);
TGCT	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.73	-0.39	5.93e-6	Prudent dietary pattern;
TGCT	cis	rs35306767	0.903	rs7077278	chr10:911291	A/G	cg26597838	chr10:835615	NA	-0.74	-10.34	-0.68	1.86e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs265548	0.608	rs265544	chr19:17903479	G/C	cg21960279	chr19:17905606	B3GNT3	0.48	5.3	0.43	5.08e-7	Tumor biomarkers;
TGCT	cis	rs9527	0.545	rs12247514	chr10:104958066	C/A	cg04362960	chr10:104952993	NT5C2	0.68	5.73	0.46	7.14e-8	Arsenic metabolism;
TGCT	cis	rs12142240	0.698	rs7548675	chr1:46809321	C/G	cg14993813	chr1:46806288	NSUN4	-0.58	-4.81	-0.4	4.34e-6	Menopause (age at onset);
TGCT	cis	rs7772486	0.720	rs4896837	chr6:146014168	C/T	cg13319975	chr6:146136371	FBXO30	0.52	4.68	0.39	7.31e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2227564	0.620	rs3911887	chr10:75548026	A/G	cg19442545	chr10:75533431	FUT11	-0.3	-4.48	-0.37	1.7e-5	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs11112613	0.713	rs2374502	chr12:105938939	T/C	cg03607813	chr12:105948248	NA	0.44	5.36	0.43	3.85e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	cis	rs6582630	0.555	rs2387598	chr12:38510472	G/A	cg26384229	chr12:38710491	ALG10B	-0.8	-7.43	-0.56	1.51e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs4700695	0.719	rs153390	chr5:65431087	G/C	cg21114390	chr5:65439923	SFRS12	-0.88	-8.02	-0.58	6.82e-13	Facial morphology (factor 19);
TGCT	cis	rs10782582	0.609	rs1689270	chr1:76390937	A/G	cg03433033	chr1:76189801	ACADM	-0.49	-4.81	-0.4	4.29e-6	Daytime sleep phenotypes;
TGCT	cis	rs7312933	0.670	rs10880258	chr12:42547531	C/T	cg19980929	chr12:42632907	YAF2	0.47	6.46	0.5	2.13e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs7772486	0.790	rs9497435	chr6:146265340	C/A	cg05347473	chr6:146136440	FBXO30	-0.5	-4.85	-0.4	3.68e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.21	0.82	2.06e-32	Prudent dietary pattern;
TGCT	cis	rs12681287	0.752	rs12675974	chr8:87247845	T/C	cg27223183	chr8:87520930	FAM82B	-0.83	-5.76	-0.46	6.33e-8	Caudate activity during reward;
TGCT	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.53	-4.96	-0.41	2.3e-6	Electroencephalogram traits;
TGCT	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg00343986	chr7:65444356	GUSB	-0.23	-5.13	-0.42	1.07e-6	Aortic root size;
TGCT	cis	rs8050907	0.744	rs7194436	chr16:4539832	G/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.58	4.65	0.39	8.46e-6	Obesity-related traits;
TGCT	cis	rs4788570	0.609	rs72795869	chr16:71485515	C/T	cg06353428	chr16:71660113	MARVELD3	-1.33	-7.91	-0.58	1.24e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs854765	0.583	rs62064158	chr17:17826935	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.74	7.73	0.57	3.18e-12	Total body bone mineral density;
TGCT	cis	rs9976767	0.637	rs2156309	chr21:43824529	G/A	cg23042151	chr21:43824109	UBASH3A	-0.23	-5.14	-0.42	1.02e-6	Type 1 diabetes;
TGCT	cis	rs11105298	0.891	rs10777185	chr12:89921275	C/T	cg00757033	chr12:89920650	WDR51B	0.32	5.13	0.42	1.11e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg04546413	chr19:29218101	NA	0.84	6.76	0.52	4.71e-10	Methadone dose in opioid dependence;
TGCT	cis	rs9911578	1.000	rs9901181	chr17:56964271	C/T	cg12560992	chr17:57184187	TRIM37	0.76	9.21	0.64	1.03e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs9916302	0.861	rs33933929	chr17:37426441	A/C	cg07936489	chr17:37558343	FBXL20	-0.62	-4.91	-0.4	2.77e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs13082711	0.522	rs640065	chr3:27363937	A/T	cg02860705	chr3:27208620	NA	0.29	4.63	0.38	9.02e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs8180040	0.726	rs7628747	chr3:47001990	A/T	cg27129171	chr3:47204927	SETD2	0.73	9.51	0.65	1.94e-16	Colorectal cancer;
TGCT	cis	rs7647973	1.000	rs11720542	chr3:49357427	A/G	cg05785598	chr3:49045655	WDR6	0.39	4.62	0.38	9.58e-6	Menarche (age at onset);
TGCT	cis	rs7552404	0.924	rs7535991	chr1:76162624	C/T	cg10523679	chr1:76189770	ACADM	0.9	9.92	0.67	2e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs6998277	1.000	rs6998277	chr8:103639941	T/C	cg10187029	chr8:103597600	NA	0.45	5.6	0.45	1.32e-7	Migraine;
TGCT	cis	rs10501293	0.703	rs7937503	chr11:43008602	G/C	cg03447554	chr11:43094025	NA	0.44	6.28	0.49	5.2e-9	Cognitive performance;
TGCT	cis	rs2832077	0.527	rs9980449	chr21:30224889	G/C	cg24692254	chr21:30365293	RNF160	-0.59	-5.05	-0.41	1.53e-6	Cognitive test performance;
TGCT	cis	rs72901758	0.768	rs55782477	chr17:76250703	G/C	cg25512537	chr17:76250053	NA	0.25	4.51	0.38	1.49e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs6546537	0.911	rs13027712	chr2:69891367	C/T	cg10773587	chr2:69614142	GFPT1	-0.82	-7.07	-0.54	1.01e-10	Serum thyroid-stimulating hormone levels;
TGCT	cis	rs7043114	0.525	rs7023004	chr9:95098712	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-5.56	-0.45	1.55e-7	Height;
TGCT	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg26513180	chr16:89883248	FANCA	1.07	14.91	0.8	1.99e-29	Vitiligo;
TGCT	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg02353165	chr6:42928485	GNMT	1.05	11.69	0.72	9.89e-22	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs763014	0.931	rs7191939	chr16:630089	C/T	cg09263875	chr16:632152	PIGQ	0.3	6.4	0.5	2.88e-9	Height;
TGCT	trans	rs877282	0.947	rs7904978	chr10:768078	C/T	cg22713356	chr15:30763199	NA	1.19	9.85	0.66	2.99e-17	Uric acid levels;
TGCT	cis	rs4285028	0.948	rs79103597	chr3:121667629	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.77	-6.55	-0.51	1.35e-9	Multiple sclerosis;
TGCT	cis	rs9303401	0.659	rs11079357	chr17:56902778	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs5769707	0.967	rs8141807	chr22:50043738	C/G	cg05373962	chr22:49881684	NA	-0.31	-6.42	-0.5	2.6e-9	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs826838	1.000	rs11183747	chr12:38822595	A/G	cg13010199	chr12:38710504	ALG10B	-0.77	-6.42	-0.5	2.63e-9	Heart rate;
TGCT	cis	rs7552404	0.727	rs1146653	chr1:76280438	A/G	cg03433033	chr1:76189801	ACADM	0.66	6.9	0.53	2.36e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs644799	1.000	rs560854	chr11:95584905	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	10.67	0.69	2.95e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs11030122	0.702	rs10835399	chr11:3989182	G/A	cg18678763	chr11:4115507	RRM1	-0.49	-6.13	-0.48	1.08e-8	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs939574	0.790	rs72955439	chr2:220090804	T/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.11	5.34	0.43	4.31e-7	Platelet distribution width;
TGCT	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg02975922	chr3:195473998	MUC4	-0.24	-5.47	-0.44	2.4e-7	Pancreatic cancer;
TGCT	cis	rs796364	0.715	rs78988795	chr2:201095739	G/A	cg17644776	chr2:200775616	C2orf69	-0.39	-5.16	-0.42	9.43e-7	Schizophrenia;
TGCT	cis	rs6500602	0.701	rs8053770	chr16:4539030	T/A	cg08645402	chr16:4508243	NA	0.2	5.02	0.41	1.73e-6	Schizophrenia;
TGCT	cis	rs7914558	1.000	rs7077291	chr10:104945751	C/T	cg15744005	chr10:104629667	AS3MT	-0.39	-4.73	-0.39	5.91e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs2797160	1.000	rs4895798	chr6:126000162	A/G	cg05901451	chr6:126070800	HEY2	-0.74	-6.48	-0.5	1.96e-9	Endometrial cancer;
TGCT	cis	rs7572733	0.534	rs4850815	chr2:198786167	G/T	cg00792783	chr2:198669748	PLCL1	-0.57	-5.14	-0.42	1.03e-6	Dermatomyositis;
TGCT	cis	rs36051895	0.622	rs12686652	chr9:5071942	C/G	cg02405213	chr9:5042618	JAK2	-0.76	-9.95	-0.67	1.69e-17	Pediatric autoimmune diseases;
TGCT	cis	rs9807841	0.670	rs1982075	chr19:10787744	C/G	cg17848348	chr19:10766748	ILF3	-0.4	-4.58	-0.38	1.12e-5	Inflammatory skin disease;
TGCT	cis	rs12908161	1.000	rs58416181	chr15:85264461	G/A	cg17173187	chr15:85201210	NMB	0.59	6.77	0.52	4.55e-10	Schizophrenia;
TGCT	cis	rs8078723	1.000	rs3826331	chr17:38150492	T/C	cg17467752	chr17:38218738	THRA	-0.57	-5.5	-0.44	2.04e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs2997447	0.761	rs61776576	chr1:26429898	G/A	cg03844060	chr1:26490628	NA	0.27	4.47	0.37	1.76e-5	QRS complex (12-leadsum);
TGCT	cis	rs6681544	0.544	rs1492258	chr1:82395964	A/G	cg04226724	chr1:82268649	LPHN2	0.47	4.99	0.41	2.02e-6	Metabolite levels  (X-11787);
TGCT	cis	rs1801251	0.896	rs79793315	chr2:233690864	C/T	cg25237894	chr2:233734115	C2orf82	-0.29	-5.41	-0.44	3.14e-7	Coronary artery disease;
TGCT	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.64	-6.18	-0.49	8.32e-9	Electroencephalogram traits;
TGCT	cis	rs2708977	0.637	rs679414	chr2:97087788	A/C	cg01950434	chr2:97203154	ARID5A	-0.61	-5.19	-0.42	8.42e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg23758822	chr17:41437982	NA	0.72	6.91	0.53	2.23e-10	Menopause (age at onset);
TGCT	cis	rs17152411	1.000	rs11245451	chr10:126661428	C/T	cg07906193	chr10:126599966	NA	0.39	4.53	0.38	1.35e-5	Height;
TGCT	cis	rs6570726	0.818	rs399516	chr6:145810849	C/A	cg23711669	chr6:146136114	FBXO30	0.76	7.62	0.56	5.74e-12	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs13088645	0.532	rs9851770	chr3:134160593	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.68	6.22	0.49	6.96e-9	Coronary artery disease;
TGCT	cis	rs1348850	0.608	rs2364845	chr2:178226240	T/C	cg22681709	chr2:178499509	PDE11A	-0.35	-4.54	-0.38	1.3e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg18876405	chr7:65276391	NA	-0.36	-5.41	-0.44	3.08e-7	Aortic root size;
TGCT	trans	rs4332037	0.539	rs56305291	chr7:2048706	A/G	cg10840412	chr1:235813424	GNG4	0.92	6.66	0.51	8e-10	Bipolar disorder;
TGCT	cis	rs727563	0.608	rs2076200	chr22:41985956	G/T	cg17554472	chr22:41940697	POLR3H	-0.52	-5.37	-0.43	3.79e-7	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg10150615	chr22:24372951	LOC391322	-0.78	-8.72	-0.62	1.56e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs174601	0.861	rs174584	chr11:61610750	G/A	cg19610905	chr11:61596333	FADS2	-0.88	-8.16	-0.59	3.2e-13	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
TGCT	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.62	-5.11	-0.42	1.17e-6	Tonsillectomy;
TGCT	cis	rs1670533	0.932	rs13140341	chr4:1054235	T/C	cg20887711	chr4:1340912	KIAA1530	0.71	5.7	0.46	8.33e-8	Recombination rate (females);
TGCT	cis	rs3859192	0.561	rs12453343	chr17:38181176	C/A	cg17467752	chr17:38218738	THRA	-0.52	-4.59	-0.38	1.09e-5	White blood cell count;
TGCT	cis	rs9372498	0.908	rs17080082	chr6:118700137	C/T	cg18833306	chr6:118973337	C6orf204	-0.61	-4.81	-0.4	4.28e-6	Diastolic blood pressure;
TGCT	cis	rs7772486	0.686	rs9399565	chr6:146081906	G/T	cg23711669	chr6:146136114	FBXO30	-0.89	-9.88	-0.66	2.48e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11864453	0.614	rs12445586	chr16:72126276	C/T	cg14768367	chr16:72042858	DHODH	0.51	4.82	0.4	4.06e-6	Fibrinogen levels;
TGCT	cis	rs7089973	0.604	rs10885620	chr10:116630048	A/T	cg03647239	chr10:116582469	FAM160B1	0.58	5.48	0.44	2.29e-7	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs950027	0.620	rs1145084	chr15:45675440	G/A	cg14582100	chr15:45693742	SPATA5L1	0.48	6.04	0.48	1.7e-8	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs17331151	0.505	rs13066389	chr3:52565317	C/T	cg07884673	chr3:53033167	SFMBT1	0.74	4.99	0.41	1.98e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs3784262	0.565	rs3784264	chr15:58250246	T/G	cg12031962	chr15:58353849	ALDH1A2	0.37	5.17	0.42	8.99e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs10782582	0.593	rs6664254	chr1:76235084	G/T	cg03433033	chr1:76189801	ACADM	-0.55	-6.05	-0.48	1.61e-8	Daytime sleep phenotypes;
TGCT	cis	rs77972916	0.609	rs13414381	chr2:43567218	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.38	-4.83	-0.4	4e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs986417	0.901	rs1955687	chr14:60988606	A/G	cg27398547	chr14:60952738	C14orf39	1.38	10.8	0.7	1.4e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs7020830	0.571	rs3780335	chr9:37376587	A/G	cg14294708	chr9:37120828	ZCCHC7	-0.94	-8.94	-0.63	4.48e-15	Schizophrenia;
TGCT	cis	rs62064224	0.614	rs6505294	chr17:30687415	C/T	cg18200150	chr17:30822561	MYO1D	0.4	4.73	0.39	6.05e-6	Schizophrenia;
TGCT	cis	rs7552404	1.000	rs12123977	chr1:76209754	A/G	cg22875332	chr1:76189707	ACADM	-0.88	-7.44	-0.56	1.48e-11	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2404602	0.967	rs7174096	chr15:77072400	A/G	cg22467129	chr15:76604101	ETFA	-0.46	-5.04	-0.41	1.58e-6	Blood metabolite levels;
TGCT	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg21226059	chr5:178986404	RUFY1	0.63	7.74	0.57	2.98e-12	Lung cancer;
TGCT	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg03188948	chr7:1209495	NA	0.5	5.23	0.43	6.99e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2153535	0.580	rs1414344	chr6:8471365	C/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	trans	rs561341	1.000	rs555629	chr17:30294136	T/C	cg20587970	chr11:113659929	NA	-1.03	-10.98	-0.7	5.21e-20	Hip circumference adjusted for BMI;
TGCT	trans	rs208520	0.955	rs208538	chr6:66964492	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.87	-8.1	-0.59	4.41e-13	Exhaled nitric oxide output;
TGCT	cis	rs425277	0.958	rs7546523	chr1:2043792	G/A	cg24578937	chr1:2090814	PRKCZ	0.3	6.88	0.53	2.61e-10	Height;
TGCT	cis	rs7119	0.651	rs12917044	chr15:77850146	A/G	cg27398640	chr15:77910606	LINGO1	0.27	5.09	0.42	1.32e-6	Type 2 diabetes;
TGCT	cis	rs6671200	0.607	rs3767313	chr1:95712797	G/A	cg03123541	chr1:95699097	RWDD3	-0.81	-7.26	-0.55	3.81e-11	Stearic acid (18:0) levels;
TGCT	cis	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg04267008	chr7:1944627	MAD1L1	-0.35	-4.44	-0.37	1.95e-5	Bipolar disorder and schizophrenia;
TGCT	cis	rs7223966	0.961	rs17631394	chr17:61646000	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.57	-4.64	-0.38	8.68e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs7567389	0.564	rs10209483	chr2:128158637	C/T	cg09760422	chr2:128146352	NA	-0.38	-4.93	-0.41	2.54e-6	Self-rated health;
TGCT	cis	rs2180341	0.961	rs3798857	chr6:127659473	A/T	cg27446573	chr6:127587934	RNF146	1.12	10.11	0.67	6.87e-18	Breast cancer;
TGCT	cis	rs57221529	0.766	rs28563961	chr5:554498	C/G	cg09021430	chr5:549028	NA	-0.41	-5.48	-0.44	2.23e-7	Lung disease severity in cystic fibrosis;
TGCT	cis	rs3617	0.625	rs56019197	chr3:52874753	T/C	cg10802521	chr3:52805072	NEK4	0.62	7.18	0.54	5.66e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs554111	0.571	rs4537519	chr1:21461370	T/C	cg01072550	chr1:21505969	NA	0.37	5.56	0.45	1.56e-7	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs9393692	0.905	rs7746807	chr6:26293338	C/A	cg13736514	chr6:26305472	NA	-0.39	-5.65	-0.45	1.04e-7	Educational attainment;
TGCT	cis	rs7017914	0.905	rs4504667	chr8:71956792	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	0.55	5.11	0.42	1.17e-6	Bone mineral density;
TGCT	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	5.05	0.41	1.51e-6	Menopause (age at onset);
TGCT	cis	rs5760092	0.755	rs6003959	chr22:24264395	C/T	cg02953382	chr22:24373134	LOC391322	0.8	6.87	0.53	2.77e-10	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs9611565	0.512	rs1983576	chr22:42166486	G/A	cg03806693	chr22:41940476	POLR3H	1.02	10.49	0.69	7.92e-19	Vitiligo;
TGCT	cis	rs42648	0.935	rs42664	chr7:89984409	A/G	cg25739043	chr7:89950458	NA	-0.65	-6.22	-0.49	6.96e-9	Homocysteine levels;
TGCT	cis	rs6815814	0.699	rs11730390	chr4:38881414	T/C	cg02016764	chr4:38805732	TLR1	-0.34	-5.08	-0.41	1.37e-6	Breast cancer;
TGCT	cis	rs1153858	1.000	rs7164602	chr15:45671325	A/G	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.62e-8	Homoarginine levels;
TGCT	cis	rs2439831	0.867	rs2243434	chr15:43689867	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	8.14	0.59	3.58e-13	Lung cancer in ever smokers;
TGCT	cis	rs7666738	0.791	rs1967978	chr4:98966152	T/C	cg05340658	chr4:99064831	C4orf37	0.53	5.93	0.47	2.84e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1008375	0.900	rs10019460	chr4:17686337	T/C	cg16339924	chr4:17578868	LAP3	-0.6	-4.87	-0.4	3.34e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs11209002	0.614	rs7544189	chr1:67568351	C/T	cg02640540	chr1:67518911	SLC35D1	0.59	4.97	0.41	2.18e-6	Crohn's disease;
TGCT	cis	rs35883536	0.587	rs2809812	chr1:101032087	G/T	cg06223162	chr1:101003688	GPR88	0.42	8.32	0.6	1.36e-13	Monocyte count;
TGCT	cis	rs1372520	0.577	rs748849	chr4:90734961	G/A	cg01966878	chr4:90757139	SNCA	-0.31	-4.91	-0.4	2.85e-6	Neuroticism;
TGCT	cis	rs782590	0.582	rs2627767	chr2:55926815	A/T	cg18811423	chr2:55921094	PNPT1	0.56	5.56	0.45	1.54e-7	Metabolic syndrome;
TGCT	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs62103177	0.608	rs59300126	chr18:77694439	C/A	cg12964065	chr18:77638022	KCNG2	0.34	4.83	0.4	3.91e-6	Opioid sensitivity;
TGCT	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg06618935	chr21:46677482	NA	-0.36	-5.61	-0.45	1.25e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs72627509	1.000	rs57265257	chr4:57839280	A/T	cg26694713	chr4:57773883	REST	0.74	6.45	0.5	2.3e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs1055129	0.537	rs2467100	chr17:73949038	C/G	cg10935138	chr17:73851978	WBP2	0.51	4.6	0.38	1.01e-5	White matter hyperintensity burden;
TGCT	cis	rs9894429	0.789	rs6565611	chr17:79598319	T/C	cg21028142	chr17:79581711	NPLOC4	0.3	7.03	0.53	1.2e-10	Eye color traits;
TGCT	cis	rs8180040	0.903	rs11130124	chr3:47292183	T/C	cg27129171	chr3:47204927	SETD2	0.71	8.58	0.61	3.22e-14	Colorectal cancer;
TGCT	cis	rs4595586	0.545	rs7136002	chr12:39369168	G/A	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs28489187	0.617	rs7547571	chr1:85884091	G/T	cg16011679	chr1:85725395	C1orf52	-0.48	-4.45	-0.37	1.91e-5	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
TGCT	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg16145915	chr7:1198662	ZFAND2A	-0.54	-7.02	-0.53	1.27e-10	Longevity;Endometriosis;
TGCT	cis	rs12134133	1.000	rs7526831	chr1:207438606	G/C	cg02152968	chr1:207494213	CD55	0.64	4.78	0.39	4.94e-6	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs3015497	0.526	rs10136630	chr14:51046474	G/A	cg04730355	chr14:51134070	SAV1	-0.64	-6.18	-0.49	8.59e-9	Mean platelet volume;
TGCT	cis	rs6831352	0.840	rs29001223	chr4:100047433	C/T	cg12011299	chr4:100065546	ADH4	-0.44	-5.06	-0.41	1.45e-6	Alcohol dependence;
TGCT	cis	rs2228479	0.867	rs34272502	chr16:89949000	G/C	cg06558623	chr16:89946397	TCF25	0.56	6.83	0.52	3.38e-10	Skin colour saturation;
TGCT	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.91	0.4	2.75e-6	Electroencephalogram traits;
TGCT	cis	rs2730245	1.000	rs6965685	chr7:158726462	C/T	cg24397884	chr7:158709396	WDR60	0.39	5.13	0.42	1.07e-6	Height;
TGCT	cis	rs12497850	0.897	rs6795025	chr3:49081247	T/C	cg18654377	chr3:49208889	KLHDC8B	-0.42	-5.42	-0.44	3e-7	Parkinson's disease;
TGCT	cis	rs7833790	0.929	rs10958048	chr8:82792914	C/T	cg17211192	chr8:82754475	SNX16	0.95	7.32	0.55	2.79e-11	Diastolic blood pressure;
TGCT	cis	rs72627509	0.629	rs1718824	chr4:57903747	A/C	cg26694713	chr4:57773883	REST	-0.59	-4.85	-0.4	3.57e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs911263	0.603	rs12881502	chr14:68783791	A/C	cg18825221	chr14:68749962	RAD51L1	0.22	4.46	0.37	1.82e-5	Primary biliary cholangitis;
TGCT	cis	rs7246657	0.722	rs10410588	chr19:38042410	C/G	cg18154014	chr19:37997991	ZNF793	0.69	4.63	0.38	9.25e-6	Coronary artery calcification;
TGCT	cis	rs9549367	0.577	rs513479	chr13:113815200	C/T	cg18105134	chr13:113819100	PROZ	-0.46	-7.48	-0.56	1.18e-11	Platelet distribution width;
TGCT	cis	rs7666738	0.830	rs1426664	chr4:98988264	A/C	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4409675	0.576	rs6703851	chr1:28237556	G/A	cg23691781	chr1:28212827	C1orf38	0.27	5.61	0.45	1.24e-7	Corneal astigmatism;
TGCT	cis	rs7264396	0.635	rs6121102	chr20:34544274	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.04	-0.41	1.58e-6	Total cholesterol levels;
TGCT	cis	rs9787249	0.874	rs12094291	chr1:40226046	G/A	cg24920358	chr1:40204285	PPIE	0.58	10.69	0.69	2.69e-19	Blood protein levels;
TGCT	cis	rs4713118	0.662	rs149961	chr6:28015569	A/C	cg12963246	chr6:28129442	ZNF389	0.45	4.55	0.38	1.27e-5	Parkinson's disease;
TGCT	cis	rs986417	0.792	rs4901990	chr14:61015474	C/T	cg27398547	chr14:60952738	C14orf39	-1.37	-8.5	-0.61	5.08e-14	Gut microbiota (bacterial taxa);
TGCT	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg03452623	chr4:187889614	NA	-0.36	-5.46	-0.44	2.45e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg21963583	chr11:68658836	MRPL21	0.36	6.08	0.48	1.35e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs10782582	0.609	rs5745543	chr1:76365111	A/T	cg03433033	chr1:76189801	ACADM	-0.5	-4.92	-0.4	2.7e-6	Daytime sleep phenotypes;
TGCT	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.12	0.42	1.15e-6	Prudent dietary pattern;
TGCT	cis	rs1008375	1.000	rs4698648	chr4:17692715	C/G	cg18681998	chr4:17616180	MED28	0.76	7.28	0.55	3.42e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6690583	0.573	rs61768854	chr1:85460021	T/C	cg20280350	chr1:85513789	MCOLN3	-0.78	-5.19	-0.42	8.21e-7	Serum sulfate level;
TGCT	cis	rs6840360	0.904	rs6825241	chr4:152543783	C/A	cg17479576	chr4:152424074	FAM160A1	-0.53	-5.85	-0.46	4.14e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs6061231	0.740	rs11698650	chr20:60958374	A/T	cg15674680	chr20:60982522	CABLES2	0.5	4.47	0.37	1.74e-5	Colorectal cancer;
TGCT	cis	rs7014346	0.767	rs7013328	chr8:128423911	G/A	cg04263511	chr8:128962092	PVT1	-0.31	-4.5	-0.37	1.54e-5	Colorectal cancer;
TGCT	cis	rs2458413	0.542	rs1810113	chr8:105364594	C/T	cg04554929	chr8:105342491	NA	-0.47	-5.7	-0.46	8.11e-8	Paget's disease;
TGCT	cis	rs2204008	0.837	rs1589395	chr12:38420405	C/T	cg13010199	chr12:38710504	ALG10B	0.59	4.79	0.4	4.67e-6	Bladder cancer;
TGCT	cis	rs6121246	0.559	rs6058468	chr20:30406448	C/A	cg18721089	chr20:30220636	NA	-0.35	-4.5	-0.37	1.58e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs2073300	1.000	rs12625804	chr20:23441981	G/A	cg09953122	chr20:23471693	CST8	-0.64	-4.56	-0.38	1.19e-5	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs7666738	0.830	rs10007261	chr4:98926155	C/T	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7809950	0.635	rs62483629	chr7:106866178	T/C	cg23024343	chr7:107201750	COG5	-0.43	-5.91	-0.47	3.13e-8	Coronary artery disease;
TGCT	cis	rs7805747	0.961	rs10224002	chr7:151415041	C/T	cg17611936	chr7:151411526	PRKAG2	-0.54	-7.09	-0.54	8.88e-11	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
TGCT	cis	rs17376456	0.825	rs13164315	chr5:93147421	A/G	cg21475434	chr5:93447410	FAM172A	0.62	4.67	0.39	7.58e-6	Diabetic retinopathy;
TGCT	cis	rs61472021	1	rs61472021	chr6:26090025	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.52	-0.38	1.43e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7666738	0.800	rs13107586	chr4:99028788	G/C	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7666738	0.830	rs3852123	chr4:98697586	A/G	cg18180107	chr4:99064573	C4orf37	0.56	5.32	0.43	4.72e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2982552	0.873	rs1415194	chr6:152063998	A/G	cg22157087	chr6:152012887	ESR1	0.21	4.92	0.4	2.65e-6	Bone properties (heel);
TGCT	cis	rs76878669	0.561	rs6591215	chr11:66170611	A/C	cg18002602	chr11:66138449	SLC29A2	-0.52	-6.38	-0.5	3.21e-9	Educational attainment (years of education);
TGCT	cis	rs2832191	0.679	rs2705659	chr21:30363908	G/C	cg08807101	chr21:30365312	RNF160	0.64	6.05	0.48	1.57e-8	Dental caries;
TGCT	cis	rs2235642	0.893	rs2076439	chr16:1587277	C/T	cg10465839	chr16:1584050	IFT140;TMEM204	-0.32	-5.23	-0.43	6.98e-7	Coronary artery disease;
TGCT	cis	rs2862064	0.745	rs2902133	chr5:156445687	G/A	cg12943317	chr5:156479607	HAVCR1	-0.38	-5.2	-0.42	8.06e-7	Platelet count;
TGCT	cis	rs308403	0.568	rs13146929	chr4:123671151	C/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.7	6.51	0.5	1.66e-9	Blood protein levels;
TGCT	cis	rs4242434	0.597	rs876714	chr8:22482799	A/G	cg03733263	chr8:22462867	KIAA1967	0.98	13.34	0.77	1.01e-25	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs6840360	0.571	rs10007653	chr4:152524055	A/G	cg17479576	chr4:152424074	FAM160A1	-0.68	-7.2	-0.54	5.05e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs7017914	0.967	rs56112621	chr8:71588394	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.03	-0.41	1.69e-6	Bone mineral density;
TGCT	cis	rs319204	0.918	rs547882	chr5:146288069	A/C	cg25021259	chr5:146258546	PPP2R2B	-0.36	-4.56	-0.38	1.19e-5	Schizophrenia;
TGCT	cis	rs350251	0.868	rs350231	chr16:12186376	T/G	cg02910054	chr16:12241554	SNX29	0.35	4.54	0.38	1.29e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7586879	0.681	rs6705446	chr2:25118608	T/C	cg01884057	chr2:25150051	NA	0.35	6.9	0.53	2.39e-10	Body mass index;
TGCT	cis	rs7617773	0.817	rs13068265	chr3:48301614	A/C	cg11946769	chr3:48343235	NME6	0.76	6.63	0.51	9.31e-10	Coronary artery disease;
TGCT	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg03806693	chr22:41940476	POLR3H	1.11	12.05	0.73	1.3e-22	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs922182	0.633	rs12904468	chr15:64268890	A/T	cg02919090	chr15:64263738	DAPK2	-0.29	-5.08	-0.42	1.33e-6	Blood protein levels;
TGCT	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg17554472	chr22:41940697	POLR3H	-0.49	-5.26	-0.43	6.14e-7	Vitiligo;
TGCT	cis	rs10514758	0.744	rs72947749	chr3:114927068	C/A	cg05943254	chr3:114009756	NA	-0.76	-4.53	-0.38	1.39e-5	Urate levels in obese individuals;
TGCT	cis	rs57994353	0.568	rs10870166	chr9:139316916	C/G	cg13741927	chr9:139327495	INPP5E	-0.24	-5.35	-0.43	4.07e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	trans	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg13615516	chr5:77269221	NA	0.65	8.04	0.59	6.2e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1847202	0.859	rs13096870	chr3:72948172	G/A	cg25664220	chr3:72788482	NA	-0.36	-4.48	-0.37	1.69e-5	Motion sickness;
TGCT	cis	rs9486715	0.838	rs4839840	chr6:96941149	T/C	cg06623918	chr6:96969491	KIAA0776	1.1	15.44	0.81	1.17e-30	Headache;
TGCT	cis	rs9549367	0.789	rs3764124	chr13:113897320	C/T	cg18105134	chr13:113819100	PROZ	-0.35	-5.96	-0.47	2.43e-8	Platelet distribution width;
TGCT	cis	rs6121246	0.559	rs1484994	chr20:30305975	A/G	cg13852791	chr20:30311386	BCL2L1	0.8	7.42	0.55	1.61e-11	Mean corpuscular hemoglobin;
TGCT	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg04944784	chr2:26401820	FAM59B	-0.77	-6.37	-0.5	3.27e-9	Gut microbiome composition (summer);
TGCT	cis	rs6684514	0.961	rs10908503	chr1:156300683	C/T	cg20302342	chr1:156215951	PAQR6	0.35	4.74	0.39	5.77e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.61	4.99	0.41	1.98e-6	Lung function (FEV1/FVC);
TGCT	cis	rs6912958	0.703	rs9362427	chr6:88097634	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.62	6.09	0.48	1.29e-8	Monocyte percentage of white cells;
TGCT	cis	rs12765878	1.000	rs1980653	chr10:105654164	A/G	cg11005552	chr10:105648138	OBFC1	0.44	7.7	0.57	3.69e-12	Coronary artery disease;
TGCT	cis	rs13256369	1.000	rs10110591	chr8:8576608	G/T	cg18904891	chr8:8559673	CLDN23	-0.62	-5.68	-0.45	9.21e-8	Obesity-related traits;
TGCT	cis	rs7267979	0.966	rs2261698	chr20:25259910	A/G	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9527	0.614	rs11191589	chr10:104930382	T/C	cg04362960	chr10:104952993	NT5C2	0.67	5.64	0.45	1.07e-7	Arsenic metabolism;
TGCT	cis	rs2762353	0.935	rs11754288	chr6:25776949	G/A	cg03264133	chr6:25882463	NA	0.49	5.23	0.42	7.04e-7	Blood metabolite levels;
TGCT	cis	rs7666738	0.830	rs10012003	chr4:99064881	A/G	cg18180107	chr4:99064573	C4orf37	0.58	5.31	0.43	4.87e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3806843	0.966	rs2240693	chr5:140183325	G/C	cg19875535	chr5:140030758	IK	0.35	5.85	0.47	4.01e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs12681288	0.782	rs2600499	chr8:1026619	C/T	cg04851639	chr8:1020857	NA	-0.34	-6.07	-0.48	1.44e-8	Schizophrenia;
TGCT	cis	rs7584330	0.554	rs7573177	chr2:238444467	C/T	cg08992911	chr2:238395768	MLPH	-0.66	-4.62	-0.38	9.28e-6	Prostate cancer;
TGCT	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg07636037	chr3:49044803	WDR6	0.88	9.28	0.64	6.89e-16	Menarche (age at onset);
TGCT	cis	rs6088580	0.634	rs62212172	chr20:32987705	G/A	cg06115741	chr20:33292138	TP53INP2	-0.53	-4.67	-0.39	7.83e-6	Glomerular filtration rate (creatinine);
TGCT	trans	rs17780086	0.527	rs72827711	chr17:30537920	T/A	cg20587970	chr11:113659929	NA	-0.89	-7.15	-0.54	6.46e-11	Height;
TGCT	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg24675658	chr1:53192096	ZYG11B	0.7	7.98	0.58	8.59e-13	Monocyte count;
TGCT	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg21016266	chr12:122356598	WDR66	0.54	7.02	0.53	1.26e-10	Mean corpuscular volume;
TGCT	cis	rs7147624	0.882	rs1956008	chr14:66085429	G/T	cg03016385	chr14:66212404	NA	-0.49	-7.08	-0.54	9.33e-11	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs9894429	0.690	rs12949956	chr17:79542813	C/T	cg18240062	chr17:79603768	NPLOC4	-0.85	-10.0	-0.67	1.28e-17	Eye color traits;
TGCT	cis	rs17253792	0.822	rs78143160	chr14:56150097	A/G	cg01858014	chr14:56050164	KTN1	-0.35	-4.62	-0.38	9.37e-6	Putamen volume;
TGCT	cis	rs11030122	0.702	rs66503725	chr11:3980998	G/A	cg18678763	chr11:4115507	RRM1	-0.49	-6.13	-0.48	1.08e-8	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs9325144	0.647	rs12831609	chr12:39051576	C/A	cg26384229	chr12:38710491	ALG10B	-0.56	-5.1	-0.42	1.25e-6	Morning vs. evening chronotype;
TGCT	cis	rs7226408	0.857	rs55917307	chr18:34503664	G/A	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs6740731	0.518	rs34586719	chr2:145295647	C/T	cg07679370	chr2:145795797	NA	0.29	5.63	0.45	1.14e-7	Coronary artery disease;
TGCT	cis	rs11249608	0.548	rs7707587	chr5:178462590	G/C	cg01312482	chr5:178451176	ZNF879	-0.49	-4.83	-0.4	3.96e-6	Pubertal anthropometrics;
TGCT	trans	rs9951602	0.512	rs8097996	chr18:76648035	A/G	cg02800362	chr5:177631904	HNRNPAB	1.15	12.91	0.76	1.08e-24	Obesity-related traits;
TGCT	trans	rs17685	0.702	rs6960598	chr7:75772991	T/C	cg19862616	chr7:65841803	NCRNA00174	0.53	9.19	0.64	1.13e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs981844	0.775	rs17371468	chr4:154759826	G/C	cg14289246	chr4:154710475	SFRP2	1.01	8.89	0.62	5.85e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg24399712	chr22:39784796	NA	-1.06	-12.58	-0.75	6.72e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs28595532	0.541	rs56055826	chr4:119789424	T/A	cg21605333	chr4:119757512	SEC24D	1.55	8.04	0.59	6.15e-13	Cannabis dependence symptom count;
TGCT	trans	rs561341	0.714	rs474455	chr17:30312465	A/T	cg20587970	chr11:113659929	NA	-1.05	-12.74	-0.75	2.84e-24	Hip circumference adjusted for BMI;
TGCT	cis	rs11031096	0.754	rs10742242	chr11:4156851	T/C	cg18678763	chr11:4115507	RRM1	-0.46	-5.87	-0.47	3.74e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs644799	0.544	rs499637	chr11:95569183	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.57	5.84	0.46	4.36e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg22963979	chr7:1858916	MAD1L1	-0.34	-5.13	-0.42	1.08e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs7524258	0.900	rs6689574	chr1:7288534	C/G	cg07173049	chr1:7289937	CAMTA1	0.28	4.68	0.39	7.24e-6	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg13409248	chr3:40428643	ENTPD3	0.57	4.53	0.38	1.37e-5	Renal cell carcinoma;
TGCT	cis	rs7582180	0.614	rs1530030	chr2:101009600	G/A	cg14675211	chr2:100938903	LONRF2	0.5	4.77	0.39	5.18e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs12908161	0.960	rs62019463	chr15:85288087	G/A	cg11189052	chr15:85197271	WDR73	0.7	5.76	0.46	6.18e-8	Schizophrenia;
TGCT	cis	rs7104764	0.917	rs7107362	chr11:244108	A/G	cg18336825	chr11:236787	PSMD13;SIRT3	1.07	11.19	0.71	1.61e-20	Menarche (age at onset);
TGCT	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg24531977	chr5:56204891	C5orf35	0.68	7.22	0.54	4.69e-11	Initial pursuit acceleration;
TGCT	cis	rs6952808	0.575	rs10280993	chr7:1948096	T/C	cg04267008	chr7:1944627	MAD1L1	-0.37	-4.83	-0.4	3.94e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg25427524	chr10:38739819	LOC399744	-0.4	-8.32	-0.6	1.33e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs11148252	0.774	rs7334583	chr13:52930352	G/T	cg02158880	chr13:53174818	NA	-0.38	-4.51	-0.38	1.5e-5	Lewy body disease;
TGCT	cis	rs9916302	0.784	rs4795382	chr17:37700860	A/G	cg15445000	chr17:37608096	MED1	0.31	4.5	0.37	1.53e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs3125734	0.633	rs4979774	chr10:63967795	A/T	cg19640130	chr10:64028056	RTKN2	-0.4	-5.2	-0.42	8e-7	Rheumatoid arthritis;
TGCT	cis	rs1670533	1.000	rs4690213	chr4:1054868	C/T	cg20887711	chr4:1340912	KIAA1530	0.69	5.48	0.44	2.32e-7	Recombination rate (females);
TGCT	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg11764359	chr7:65958608	NA	-0.55	-4.99	-0.41	1.98e-6	Aortic root size;
TGCT	cis	rs4808199	0.895	rs10403731	chr19:19469296	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.65	4.79	0.39	4.73e-6	Nonalcoholic fatty liver disease;
TGCT	cis	rs7772486	0.840	rs854144	chr6:146360880	G/T	cg05347473	chr6:146136440	FBXO30	-0.54	-5.1	-0.42	1.26e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.04	11.52	0.72	2.57e-21	Height;
TGCT	cis	rs4900538	0.819	rs72698595	chr14:102863099	G/A	cg18135206	chr14:102964638	TECPR2	-0.2	-4.49	-0.37	1.6e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.31	0.55	2.94e-11	Prudent dietary pattern;
TGCT	cis	rs12701220	0.894	rs13224488	chr7:1052353	C/A	cg07217954	chr7:1067459	C7orf50	-0.49	-4.76	-0.39	5.27e-6	Bronchopulmonary dysplasia;
TGCT	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg10802521	chr3:52805072	NEK4	-0.7	-8.75	-0.62	1.28e-14	Bipolar disorder;
TGCT	cis	rs7698623	0.850	rs4693194	chr4:88798005	T/C	cg02735620	chr4:88950514	PKD2	-0.44	-4.81	-0.4	4.22e-6	Cardiovascular disease risk factors;
TGCT	cis	rs1008375	1.000	rs6818639	chr4:17633049	A/G	cg10189774	chr4:17578691	LAP3	0.62	5.5	0.44	2.08e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs3820068	0.581	rs16851819	chr1:15918739	C/T	cg05660106	chr1:15850417	CASP9	-0.76	-7.46	-0.56	1.35e-11	Systolic blood pressure;
TGCT	cis	rs7568458	0.905	rs6714709	chr2:85756375	C/G	cg17127132	chr2:85788382	GGCX	0.73	6.98	0.53	1.59e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs8013055	0.846	rs10136015	chr14:105973469	A/C	cg25008857	chr14:105974488	NA	0.27	4.65	0.39	8.35e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs950880	0.560	rs10189711	chr2:102930881	A/G	cg09003973	chr2:102972529	NA	-0.53	-4.71	-0.39	6.47e-6	Serum protein levels (sST2);
TGCT	cis	rs7224685	0.569	rs8082425	chr17:3991706	C/G	cg09580393	chr17:4869866	SPAG7	-0.38	-4.48	-0.37	1.64e-5	Type 2 diabetes;
TGCT	cis	rs3008870	0.583	rs11208978	chr1:67442210	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.97	-8.16	-0.59	3.17e-13	Lymphocyte percentage of white cells;
TGCT	cis	rs3087591	0.708	rs2525574	chr17:29705947	T/C	cg24425628	chr17:29625626	OMG;NF1	0.41	5.93	0.47	2.87e-8	Hip circumference;
TGCT	cis	rs6809651	0.524	rs56940353	chr3:185798296	T/C	cg00760338	chr3:185826511	ETV5	-0.68	-5.05	-0.41	1.51e-6	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
TGCT	cis	rs7614311	0.555	rs3774715	chr3:63919876	T/C	cg22134162	chr3:63841271	THOC7	-0.49	-6.29	-0.49	4.93e-9	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs12643440	0.538	rs56235875	chr4:17138883	T/C	cg22650099	chr4:17144496	NA	-0.46	-4.7	-0.39	6.79e-6	Metabolite levels (Pyroglutamine);
TGCT	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6089829	0.962	rs1116450	chr20:61658210	T/C	cg18188782	chr20:61659543	NA	0.44	5.37	0.43	3.73e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs11578119	0.933	rs12135132	chr1:170493630	A/T	cg09767346	chr1:170501363	GORAB	0.65	5.26	0.43	6.06e-7	Male-pattern baldness;
TGCT	cis	rs295140	0.535	rs2033804	chr2:201222403	A/T	cg04283868	chr2:201171347	SPATS2L	0.58	5.8	0.46	5.13e-8	QT interval;
TGCT	cis	rs78456975	0.506	rs13402886	chr2:1575348	G/A	cg01028140	chr2:1542097	TPO	-0.28	-4.51	-0.38	1.47e-5	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs57994353	0.897	rs12551527	chr9:139358425	C/G	cg13741927	chr9:139327495	INPP5E	-0.26	-5.95	-0.47	2.51e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs56104184	0.779	rs17272666	chr19:49356294	T/C	cg21252483	chr19:49399788	TULP2	-0.36	-4.65	-0.39	8.27e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs6546537	1.000	rs3899666	chr2:69867871	A/G	cg10773587	chr2:69614142	GFPT1	0.6	4.96	0.41	2.24e-6	Serum thyroid-stimulating hormone levels;
TGCT	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg22166914	chr1:53195759	ZYG11B	-0.39	-6.57	-0.51	1.25e-9	Monocyte count;
TGCT	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg22920501	chr2:26401640	FAM59B	0.81	5.39	0.44	3.37e-7	Gut microbiome composition (summer);
TGCT	cis	rs13064411	0.696	rs6768648	chr3:113234141	C/G	cg18753928	chr3:113234510	CCDC52	-0.7	-5.64	-0.45	1.07e-7	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs7179456	0.557	rs446126	chr15:59113102	A/G	cg05156742	chr15:59063176	FAM63B	0.56	5.25	0.43	6.3e-7	Asperger disorder;
TGCT	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9916302	0.653	rs11657058	chr17:37699378	T/G	cg03321784	chr17:37729644	NA	0.44	4.58	0.38	1.1e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs9911578	1.000	rs2079703	chr17:56603978	G/A	cg05425664	chr17:57184151	TRIM37	0.63	6.26	0.49	5.86e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs36051895	0.658	rs10974910	chr9:5010091	G/A	cg02405213	chr9:5042618	JAK2	-0.75	-10.06	-0.67	8.84e-18	Pediatric autoimmune diseases;
TGCT	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg11941060	chr3:133502564	NA	-0.3	-6.3	-0.49	4.78e-9	Iron status biomarkers;
TGCT	cis	rs2762353	0.574	rs9467570	chr6:25699283	C/A	cg03264133	chr6:25882463	NA	0.89	8.91	0.62	5.33e-15	Blood metabolite levels;
TGCT	cis	rs709400	0.663	rs11626787	chr14:103991749	A/G	cg26031613	chr14:104095156	KLC1	0.88	9.39	0.64	3.88e-16	Body mass index;
TGCT	cis	rs9467773	1.000	rs1884949	chr6:26568067	G/A	cg15659132	chr6:26577336	NA	0.88	12.27	0.74	3.83e-23	Intelligence (multi-trait analysis);
TGCT	trans	rs551517	0.541	rs491855	chr9:113638739	T/C	cg18410444	chr5:89825535	LYSMD3	0.69	6.98	0.53	1.55e-10	Post bronchodilator FEV1 in COPD;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
TGCT	cis	rs11785400	0.793	rs7459963	chr8:143737129	C/T	cg10596483	chr8:143751796	JRK	0.57	5.64	0.45	1.11e-7	Schizophrenia;
TGCT	cis	rs8033133	0.957	rs3742952	chr15:25351026	A/G	cg14481604	chr15:25334117	SNORD116-22	-0.3	-6.15	-0.48	9.95e-9	Blood osmolality (transformed sodium);
TGCT	cis	rs3820928	0.874	rs6717168	chr2:227901342	C/T	cg11843606	chr2:227700838	RHBDD1	-0.53	-4.78	-0.39	4.8e-6	Pulmonary function;
TGCT	cis	rs10465746	0.967	rs942849	chr1:84427499	G/A	cg10977910	chr1:84465055	TTLL7	0.63	6.25	0.49	5.95e-9	Obesity-related traits;
TGCT	cis	rs6693567	0.545	rs4970922	chr1:150458094	C/A	cg09579323	chr1:150459698	TARS2	0.52	4.58	0.38	1.12e-5	Migraine;
TGCT	cis	rs10883723	0.775	rs7917158	chr10:104246471	C/A	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs7829975	0.748	rs693109	chr8:8640172	C/A	cg06636001	chr8:8085503	FLJ10661	-0.65	-5.5	-0.44	2.07e-7	Mood instability;
TGCT	cis	rs13191362	1.000	rs35820211	chr6:163046252	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.92	7.24	0.55	4.11e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs79349575	0.749	rs2546491	chr17:46977916	A/G	cg07967210	chr17:47022446	SNF8	0.43	6.08	0.48	1.4e-8	Type 2 diabetes;
TGCT	cis	rs7647973	0.516	rs4499638	chr3:49202782	C/G	cg16497277	chr3:49208875	KLHDC8B	-0.55	-5.26	-0.43	6.09e-7	Menarche (age at onset);
TGCT	cis	rs5769707	0.967	rs12485195	chr22:50053871	G/A	cg10356904	chr22:49881777	NA	-0.23	-4.6	-0.38	1.02e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg27170947	chr2:26402098	FAM59B	-0.4	-4.58	-0.38	1.1e-5	Gut microbiome composition (summer);
TGCT	cis	rs7666738	0.791	rs2865958	chr4:99040732	G/T	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12908161	1.000	rs17600551	chr15:85319258	A/G	cg12863693	chr15:85201151	NMB	0.43	5.12	0.42	1.15e-6	Schizophrenia;
TGCT	cis	rs12908161	1.000	rs12908549	chr15:85322351	C/G	cg11189052	chr15:85197271	WDR73	0.71	5.85	0.47	4.04e-8	Schizophrenia;
TGCT	cis	rs877282	1.000	rs12219807	chr10:772870	A/C	cg17470449	chr10:769945	NA	0.31	4.8	0.4	4.44e-6	Uric acid levels;
TGCT	cis	rs910316	0.687	rs11627442	chr14:75669649	A/G	cg08847533	chr14:75593920	NEK9	-0.81	-7.71	-0.57	3.55e-12	Height;
TGCT	cis	rs877282	0.797	rs7079164	chr10:756363	A/G	cg17470449	chr10:769945	NA	0.32	4.91	0.4	2.76e-6	Uric acid levels;
TGCT	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg21171335	chr12:122356390	WDR66	0.64	6.54	0.51	1.41e-9	Mean platelet volume;
TGCT	cis	rs950169	0.922	rs67804993	chr15:85104030	T/G	cg12863693	chr15:85201151	NMB	0.41	4.63	0.38	9.27e-6	Schizophrenia;
TGCT	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg25767906	chr1:53392781	SCP2	0.45	5.08	0.42	1.35e-6	Monocyte count;
TGCT	cis	rs7666738	0.791	rs13127542	chr4:98949159	C/T	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6921919	0.583	rs28360638	chr6:28362329	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.56	-5.27	-0.43	5.78e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4563143	0.675	rs56407818	chr19:29279379	G/A	cg12667521	chr19:29218732	NA	0.55	5.9	0.47	3.29e-8	Methadone dose in opioid dependence;
TGCT	cis	rs3806843	0.576	rs246003	chr5:140340865	C/G	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs546131	0.928	rs535719	chr11:34853382	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.62	5.64	0.45	1.1e-7	Lung disease severity in cystic fibrosis;
TGCT	cis	rs6964587	0.839	rs6949881	chr7:91433827	C/T	cg17063962	chr7:91808500	NA	0.82	8.45	0.6	6.54e-14	Breast cancer;
TGCT	cis	rs806215	0.547	rs12540484	chr7:127370040	G/A	cg11539674	chr7:127291444	SND1	-0.37	-4.66	-0.39	8.12e-6	Type 2 diabetes;
TGCT	cis	rs7617480	0.585	rs7373072	chr3:48960017	T/A	cg07636037	chr3:49044803	WDR6	0.78	6.55	0.51	1.38e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs28595532	0.920	rs17325192	chr4:119780345	A/G	cg21605333	chr4:119757512	SEC24D	-0.81	-5.35	-0.43	4.05e-7	Cannabis dependence symptom count;
TGCT	trans	rs2727020	0.894	rs3862342	chr11:49357043	C/T	cg03929089	chr4:120376271	NA	-0.65	-6.9	-0.53	2.32e-10	Coronary artery disease;
TGCT	cis	rs7705042	0.865	rs2043280	chr5:141513691	C/G	cg07392085	chr5:141489673	NDFIP1	-0.3	-4.54	-0.38	1.3e-5	Asthma;
TGCT	cis	rs2645424	0.635	rs6980952	chr8:11716473	C/G	cg18999641	chr8:11876646	NA	-0.23	-4.95	-0.41	2.32e-6	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
TGCT	cis	rs7017914	0.905	rs3098876	chr8:71936244	T/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-4.97	-0.41	2.16e-6	Bone mineral density;
TGCT	cis	rs11098499	0.863	rs3775843	chr4:120427844	T/C	cg09307838	chr4:120376055	NA	0.68	6.45	0.5	2.28e-9	Corneal astigmatism;
TGCT	cis	rs710216	0.957	rs859511	chr1:43430260	C/T	cg03128534	chr1:43423976	SLC2A1	0.6	4.59	0.38	1.07e-5	Red cell distribution width;
TGCT	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg02725872	chr8:58115012	NA	-0.38	-5.16	-0.42	9.32e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7647973	0.961	rs7619016	chr3:49272589	C/T	cg05785598	chr3:49045655	WDR6	0.38	4.53	0.38	1.37e-5	Menarche (age at onset);
TGCT	cis	rs554111	0.963	rs666371	chr1:21041555	A/G	cg08890418	chr1:21044141	KIF17	0.57	5.95	0.47	2.59e-8	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs7100689	0.784	rs4934083	chr10:82116501	G/C	cg01528321	chr10:82214614	TSPAN14	0.88	8.48	0.61	5.61e-14	Post bronchodilator FEV1;
TGCT	cis	rs7666738	0.791	rs1593571	chr4:98963763	T/C	cg05340658	chr4:99064831	C4orf37	0.53	5.93	0.47	2.85e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6782228	1.000	rs11718130	chr3:128330027	G/C	cg15113803	chr3:129247119	RHO	0.2	5.28	0.43	5.7e-7	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
TGCT	cis	rs9611565	0.512	rs715498	chr22:42148467	G/A	cg17554472	chr22:41940697	POLR3H	0.46	4.8	0.4	4.46e-6	Vitiligo;
TGCT	cis	rs8017423	1.000	rs59052550	chr14:90665098	C/T	cg04374321	chr14:90722782	PSMC1	0.78	8.11	0.59	4.18e-13	Mortality in heart failure;
TGCT	cis	rs9527	0.545	rs7894588	chr10:104756030	A/T	cg04362960	chr10:104952993	NT5C2	0.72	5.59	0.45	1.37e-7	Arsenic metabolism;
TGCT	cis	rs7772486	0.790	rs2247429	chr6:146217769	T/C	cg23711669	chr6:146136114	FBXO30	0.91	10.65	0.69	3.26e-19	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg21644426	chr2:191273491	MFSD6	0.62	6.11	0.48	1.21e-8	Pulse pressure;
TGCT	cis	rs113084984	0.684	rs4669745	chr2:11681572	A/G	cg25804072	chr2:10829725	NOL10	0.56	4.69	0.39	7.01e-6	Breast cancer;
TGCT	cis	rs7246657	1.000	rs8110011	chr19:37745813	G/T	cg18154014	chr19:37997991	ZNF793	0.84	5.58	0.45	1.46e-7	Coronary artery calcification;
TGCT	cis	rs7833790	0.777	rs10958042	chr8:82678393	G/T	cg17211192	chr8:82754475	SNX16	-1.03	-8.39	-0.6	9.37e-14	Diastolic blood pressure;
TGCT	cis	rs10484885	0.793	rs1465954	chr6:90475013	G/A	cg13799429	chr6:90582589	CASP8AP2	0.45	4.66	0.39	7.9e-6	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs2730245	1.000	rs2252502	chr7:158738634	G/C	cg24397884	chr7:158709396	WDR60	-0.38	-5.08	-0.42	1.33e-6	Height;
TGCT	cis	rs4517514	0.509	rs10830434	chr11:89912652	T/C	cg05041596	chr11:89867385	NAALAD2	0.55	5.14	0.42	1.05e-6	Trans fatty acid levels;
TGCT	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg24060327	chr5:131705240	SLC22A5	-0.66	-6.85	-0.52	3.07e-10	Acylcarnitine levels;
TGCT	cis	rs7727544	0.547	rs56083751	chr5:131664638	T/A	cg24060327	chr5:131705240	SLC22A5	-0.53	-5.73	-0.46	7.13e-8	Blood metabolite levels;
TGCT	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg03609598	chr5:56110824	MAP3K1	-0.59	-4.78	-0.39	4.81e-6	Initial pursuit acceleration;
TGCT	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg27286337	chr10:134555280	INPP5A	-0.41	-5.06	-0.41	1.45e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs12188164	1.000	rs72717414	chr5:429818	C/G	cg17553881	chr5:443987	EXOC3;C5orf55	-0.4	-4.76	-0.39	5.27e-6	Cystic fibrosis severity;
TGCT	cis	rs12548874	0.618	rs10100651	chr8:95887225	G/C	cg16049864	chr8:95962084	TP53INP1	-0.59	-6.7	-0.52	6.51e-10	Hemoglobin concentration;
TGCT	cis	rs1113500	0.636	rs3853493	chr1:108637193	G/A	cg22161131	chr1:109420278	GPSM2	0.49	4.54	0.38	1.34e-5	Growth-regulated protein alpha levels;
TGCT	trans	rs10962181	0.590	rs74308120	chr9:1547609	G/A	cg26433494	chr7:132068972	PLXNA4	0.48	6.82	0.52	3.48e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg04317338	chr11:64019027	PLCB3	0.77	6.33	0.49	4e-9	Mean platelet volume;
TGCT	cis	rs11190604	1.000	rs11190572	chr10:102232879	A/G	cg16342193	chr10:102329863	NA	-0.4	-5.31	-0.43	4.85e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg10819733	chr22:24237672	NA	0.29	4.98	0.41	2.13e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	trans	rs459571	0.959	rs467379	chr9:136905474	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.69	-7.44	-0.56	1.49e-11	Platelet distribution width;
TGCT	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg26338869	chr17:61819248	STRADA	-0.53	-4.94	-0.41	2.48e-6	Prudent dietary pattern;
TGCT	cis	rs3091242	0.933	rs35403885	chr1:25784551	G/A	cg00786635	chr1:25594202	NA	-0.52	-5.56	-0.45	1.59e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs10131894	0.611	rs174994	chr14:75434102	A/G	cg08847533	chr14:75593920	NEK9	-0.64	-6.16	-0.48	9.38e-9	Coronary artery disease;
TGCT	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg11494091	chr17:61959527	GH2	0.6	14.54	0.79	1.46e-28	Prudent dietary pattern;
TGCT	cis	rs7752195	0.643	rs76798435	chr6:25231495	A/C	cg16898833	chr6:26189333	HIST1H4D	1.27	5.88	0.47	3.55e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7172971	0.752	rs17690068	chr15:42342929	G/A	cg05886115	chr15:42349113	NA	0.31	4.88	0.4	3.21e-6	3-hydroxypropylmercapturic acid levels in smokers;
TGCT	cis	rs6426558	0.537	rs694740	chr1:227293451	A/G	cg10327440	chr1:227177885	CDC42BPA	0.57	6.57	0.51	1.26e-9	Neutrophil percentage of white cells;
TGCT	cis	rs137603	0.502	rs137627	chr22:39716341	G/A	cg17798944	chr22:39715225	SNORD43;RPL3	-0.67	-7.15	-0.54	6.74e-11	Primary biliary cholangitis;
TGCT	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg18538332	chr22:24372958	LOC391322	-0.87	-10.13	-0.67	6.14e-18	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs3749237	0.964	rs1799845	chr3:49847623	A/G	cg07636037	chr3:49044803	WDR6	0.58	5.12	0.42	1.15e-6	Resting heart rate;
TGCT	cis	rs651907	0.535	rs34263427	chr3:101507805	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.86	10.4	0.68	1.35e-18	Colorectal cancer;
TGCT	cis	rs114540395	0.858	rs7900797	chr10:103192220	A/G	cg18276125	chr10:102749041	C10orf2	0.39	4.74	0.39	5.85e-6	Schizophrenia;
TGCT	cis	rs6500602	0.647	rs4786519	chr16:4584406	C/T	cg08645402	chr16:4508243	NA	0.19	5.23	0.43	6.94e-7	Schizophrenia;
TGCT	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg24531977	chr5:56204891	C5orf35	0.69	7.29	0.55	3.25e-11	Initial pursuit acceleration;
TGCT	cis	rs4689388	0.926	rs11725494	chr4:6293855	C/T	cg14416269	chr4:6271139	WFS1	0.4	5.29	0.43	5.44e-7	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg15242686	chr22:24348715	GSTTP1	0.48	6.98	0.53	1.54e-10	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs911555	0.617	rs7156036	chr14:103908142	A/G	cg23461800	chr14:103021989	NA	-0.34	-4.5	-0.37	1.57e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg01448562	chr3:133502909	NA	-0.33	-6.67	-0.51	7.64e-10	Iron status biomarkers;
TGCT	cis	rs79057730	0.528	rs4719313	chr7:822501	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.76	5.69	0.46	8.5e-8	Initial pursuit acceleration;
TGCT	cis	rs9811920	0.809	rs7649349	chr3:99725629	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.46	5.18	0.42	8.58e-7	Axial length;
TGCT	cis	rs9653442	0.576	rs6542921	chr2:100864498	C/A	cg07810366	chr2:100720526	AFF3	-0.41	-6.26	-0.49	5.76e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs7523050	0.643	rs12725689	chr1:109405151	T/C	cg08274380	chr1:109419600	GPSM2	1.3	6.39	0.5	2.99e-9	Fat distribution (HIV);
TGCT	cis	rs57994353	0.861	rs13301660	chr9:139340802	C/T	cg13741927	chr9:139327495	INPP5E	-0.27	-6.15	-0.48	9.78e-9	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg11890956	chr21:40555474	PSMG1	-0.68	-6.6	-0.51	1.09e-9	Menarche (age at onset);
TGCT	cis	rs77861329	1.000	rs352151	chr3:52210272	C/G	cg08692210	chr3:52188851	WDR51A	0.94	4.83	0.4	3.91e-6	Macrophage inflammatory protein 1b levels;
TGCT	cis	rs7937682	0.814	rs1784788	chr11:111486136	T/G	cg09085632	chr11:111637200	PPP2R1B	-1.03	-10.8	-0.7	1.39e-19	Primary sclerosing cholangitis;
TGCT	cis	rs875971	1.000	rs697970	chr7:65560052	G/C	cg11764359	chr7:65958608	NA	-0.58	-4.99	-0.41	2.01e-6	Aortic root size;
TGCT	cis	rs287982	0.611	rs115657324	chr2:9983856	A/G	cg10881225	chr2:9984929	TAF1B	0.49	4.49	0.37	1.6e-5	Nonsyndromic cleft lip with cleft palate;
TGCT	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg13012494	chr21:47604986	C21orf56	-0.39	-4.66	-0.39	7.88e-6	Testicular germ cell tumor;
TGCT	cis	rs17253792	0.822	rs75560658	chr14:56079896	C/T	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs7666738	0.830	rs6854703	chr4:98977586	A/T	cg18180107	chr4:99064573	C4orf37	0.53	4.89	0.4	3.01e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs453301	0.571	rs2929305	chr8:9085217	G/A	cg06636001	chr8:8085503	FLJ10661	-0.56	-4.97	-0.41	2.14e-6	Joint mobility (Beighton score);
TGCT	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.85	-7.2	-0.54	5.14e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6964587	1.000	rs7781066	chr7:91691946	G/T	cg17063962	chr7:91808500	NA	0.88	9.65	0.66	8.73e-17	Breast cancer;
TGCT	cis	rs10779751	0.770	rs4845853	chr1:11243470	A/G	cg08854313	chr1:11322531	MTOR	0.83	8.03	0.58	6.53e-13	Body mass index;
TGCT	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg18402987	chr7:1209562	NA	0.7	5.67	0.45	9.66e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs28595532	1.000	rs11931194	chr4:119631160	C/T	cg14228332	chr4:119757509	SEC24D	1.02	5.39	0.44	3.44e-7	Cannabis dependence symptom count;
TGCT	cis	rs6500602	0.727	rs12443748	chr16:4541831	C/T	cg08645402	chr16:4508243	NA	0.18	5.06	0.41	1.44e-6	Schizophrenia;
TGCT	cis	rs7598759	0.548	rs11686485	chr2:232360697	C/T	cg19187155	chr2:232395269	NMUR1	0.48	5.62	0.45	1.2e-7	Noise-induced hearing loss;
TGCT	cis	rs1075232	1.000	rs12437749	chr15:31649888	C/T	cg01030201	chr15:31746330	NA	-1.01	-5.25	-0.43	6.38e-7	Survival in colorectal cancer (non-distant metastatic);
TGCT	cis	rs600231	0.706	rs4244811	chr11:65320780	G/A	cg17120908	chr11:65337727	SSSCA1	0.54	5.12	0.42	1.11e-6	Bone mineral density;
TGCT	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg10802521	chr3:52805072	NEK4	-0.78	-10.0	-0.67	1.26e-17	Bipolar disorder;
TGCT	trans	rs10506458	0.834	rs12426893	chr12:63388120	G/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.47	-7.54	-0.56	8.62e-12	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg25036284	chr2:26402008	FAM59B	-0.54	-4.7	-0.39	6.93e-6	Gut microbiome composition (summer);
TGCT	cis	rs7027203	1.000	rs13288708	chr9:96509653	T/C	cg13679303	chr9:96623674	NA	0.62	8.74	0.62	1.34e-14	DNA methylation (variation);
TGCT	cis	rs10986311	0.733	rs10760356	chr9:127156083	T/A	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.21	-4.94	-0.41	2.48e-6	Vitiligo;
TGCT	cis	rs826838	0.874	rs10880943	chr12:38734317	C/T	cg13010199	chr12:38710504	ALG10B	0.83	6.88	0.53	2.58e-10	Heart rate;
TGCT	cis	rs10510102	0.872	rs12255832	chr10:123718277	A/G	cg23691251	chr10:123688108	ATE1	-0.59	-4.7	-0.39	6.75e-6	Breast cancer;
TGCT	cis	rs9372498	0.536	rs55697388	chr6:118891544	C/T	cg07617317	chr6:118971624	C6orf204	0.5	5.32	0.43	4.71e-7	Diastolic blood pressure;
TGCT	cis	rs10876993	0.784	rs7314152	chr12:58017701	T/G	cg15848620	chr12:58087721	OS9	0.71	5.2	0.42	7.98e-7	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg26338869	chr17:61819248	STRADA	0.52	4.83	0.4	3.94e-6	Prudent dietary pattern;
TGCT	cis	rs2239547	0.618	rs1573815	chr3:52870132	A/G	cg11645453	chr3:52864694	ITIH4	-0.31	-5.42	-0.44	3.05e-7	Schizophrenia;
TGCT	cis	rs2455799	0.533	rs2470550	chr3:15743721	C/T	cg16303742	chr3:15540471	COLQ	-0.26	-4.77	-0.39	5.11e-6	Mean platelet volume;
TGCT	cis	rs9549367	0.737	rs9549712	chr13:113902355	G/A	cg18105134	chr13:113819100	PROZ	-0.34	-5.58	-0.45	1.41e-7	Platelet distribution width;
TGCT	cis	rs6545883	0.931	rs11125885	chr2:61755728	G/C	cg15711740	chr2:61764176	XPO1	-0.57	-5.23	-0.43	6.89e-7	Tuberculosis;
TGCT	cis	rs11997175	0.574	rs7001404	chr8:33645219	G/A	ch.8.33884649F	chr8:33765107	NA	0.28	4.53	0.38	1.35e-5	Body mass index;
TGCT	cis	rs10744422	1.000	rs3817094	chr12:123332032	T/C	cg25930673	chr12:123319894	HIP1R	-0.86	-5.02	-0.41	1.72e-6	Schizophrenia;
TGCT	cis	rs854765	0.547	rs2955353	chr17:17948979	T/C	cg04398451	chr17:18023971	MYO15A	0.34	5.49	0.44	2.21e-7	Total body bone mineral density;
TGCT	cis	rs6815814	0.768	rs2013740	chr4:38891737	A/G	cg02016764	chr4:38805732	TLR1	-0.28	-4.46	-0.37	1.82e-5	Breast cancer;
TGCT	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg13877915	chr19:58951672	ZNF132	0.88	11.12	0.71	2.43e-20	Uric acid clearance;
TGCT	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg24675658	chr1:53192096	ZYG11B	-0.75	-9.11	-0.63	1.78e-15	Monocyte count;
TGCT	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg11764359	chr7:65958608	NA	-0.55	-4.99	-0.41	1.98e-6	Aortic root size;
TGCT	cis	rs60871478	0.636	rs4276575	chr7:900035	C/T	cg15782153	chr7:917662	C7orf20	0.54	4.95	0.41	2.37e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs6424115	0.830	rs1130320	chr1:24200606	A/G	cg15997130	chr1:24165203	NA	0.85	9.25	0.64	8.02e-16	Immature fraction of reticulocytes;
TGCT	cis	rs13256369	0.802	rs2280560	chr8:8560602	C/T	cg17143192	chr8:8559678	CLDN23	0.54	4.86	0.4	3.53e-6	Obesity-related traits;
TGCT	cis	rs7666738	0.830	rs7662218	chr4:98983126	T/G	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs68170813	0.652	rs77056542	chr7:107089751	G/C	cg02696742	chr7:106810147	HBP1	-0.62	-4.63	-0.38	9.11e-6	Coronary artery disease;
TGCT	cis	rs7178572	1.000	rs12904938	chr15:77721225	A/G	cg22256960	chr15:77711686	NA	-0.95	-10.73	-0.69	2.17e-19	Type 2 diabetes;
TGCT	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	-0.5	-6.65	-0.51	8.34e-10	Lymphocyte counts;
TGCT	cis	rs6854137	0.553	rs924511	chr4:169702964	A/G	cg20607169	chr4:169750834	PALLD	0.2	4.52	0.38	1.43e-5	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs9467711	0.651	rs13212534	chr6:25983010	G/A	cg16898833	chr6:26189333	HIST1H4D	1.36	6.0	0.47	2.05e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12620999	0.838	rs13007071	chr2:238038755	A/G	cg23555395	chr2:238036564	NA	-0.31	-5.51	-0.44	2.02e-7	Systemic lupus erythematosus;
TGCT	cis	rs9902453	0.904	rs7225686	chr17:28356744	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.81	-7.67	-0.57	4.37e-12	Coffee consumption (cups per day);
TGCT	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg04944784	chr2:26401820	FAM59B	-0.76	-6.45	-0.5	2.29e-9	Gut microbiome composition (summer);
TGCT	cis	rs7843479	0.965	rs11135741	chr8:21801091	C/T	cg17168535	chr8:21777572	XPO7	0.65	5.99	0.47	2.14e-8	Mean corpuscular volume;
TGCT	cis	rs651907	0.535	rs34063583	chr3:101509948	C/T	cg12386194	chr3:101231763	SENP7	0.48	4.81	0.4	4.36e-6	Colorectal cancer;
TGCT	cis	rs9990220	0.643	rs4682103	chr3:112055793	A/G	cg03525433	chr3:111259817	CD96	0.24	4.5	0.37	1.53e-5	Eosinophil percentage of white cells;
TGCT	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg06112835	chr11:68658793	MRPL21	0.47	8.09	0.59	4.66e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7568458	0.777	rs12473819	chr2:85773061	A/G	cg02493740	chr2:85810744	VAMP5	-0.31	-5.87	-0.47	3.74e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs4478858	0.684	rs7528066	chr1:31749092	C/G	cg07478791	chr1:31886160	SERINC2	-0.52	-5.02	-0.41	1.73e-6	Alcohol dependence;
TGCT	cis	rs7044106	0.791	rs4836830	chr9:123483668	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	5.05	0.41	1.56e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs854765	0.649	rs4924821	chr17:17735952	T/C	cg09796270	chr17:17721594	SREBF1	-0.25	-4.93	-0.4	2.63e-6	Total body bone mineral density;
TGCT	cis	rs11679640	0.610	rs4350801	chr2:43113357	C/T	cg00484711	chr2:42331922	NA	-0.2	-4.63	-0.38	9.27e-6	White matter hyperintensity burden;
TGCT	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg00343986	chr7:65444356	GUSB	-0.24	-5.3	-0.43	5.2e-7	Aortic root size;
TGCT	cis	rs17253792	0.822	rs10150498	chr14:56064124	G/T	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs7714584	1.000	rs17727568	chr5:150244688	A/G	cg22134413	chr5:150180641	NA	1.13	8.18	0.59	2.91e-13	Crohn's disease;
TGCT	cis	rs9674544	0.646	rs6504594	chr17:47142697	C/A	cg10950924	chr17:47092072	IGF2BP1	-0.33	-4.54	-0.38	1.29e-5	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
TGCT	cis	rs601339	1.000	rs7969523	chr12:123168636	T/G	cg11919336	chr12:123188078	GPR109A	0.64	7.49	0.56	1.1e-11	Adiponectin levels;
TGCT	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg18876405	chr7:65276391	NA	0.37	5.58	0.45	1.47e-7	Aortic root size;
TGCT	cis	rs62244186	0.593	rs9814298	chr3:44871899	T/A	cg15687855	chr3:44754131	ZNF502	-0.55	-6.84	-0.52	3.2e-10	Depressive symptoms;
TGCT	cis	rs7394190	0.630	rs113799665	chr10:75575138	C/T	cg07699608	chr10:75541558	CHCHD1	0.81	5.6	0.45	1.33e-7	Incident atrial fibrillation;
TGCT	cis	rs6598955	0.724	rs12732295	chr1:26602251	C/T	cg04990556	chr1:26633338	UBXN11	-0.9	-11.22	-0.71	1.34e-20	Obesity-related traits;
TGCT	cis	rs6831352	0.918	rs6813415	chr4:100048509	T/C	cg12011299	chr4:100065546	ADH4	-0.41	-4.92	-0.4	2.72e-6	Alcohol dependence;
TGCT	cis	rs78456975	0.689	rs13391992	chr2:1542153	G/A	cg12573674	chr2:1569213	NA	-0.49	-4.8	-0.4	4.43e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs9611519	0.780	rs2235849	chr22:41653540	T/G	cg06634786	chr22:41940651	POLR3H	-0.52	-4.66	-0.39	7.89e-6	Neuroticism;
TGCT	cis	rs9467773	0.620	rs2498351	chr6:26659642	C/T	cg11502198	chr6:26597334	ABT1	0.55	4.89	0.4	3.05e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2839186	0.504	rs11702278	chr21:47936295	T/G	cg12379764	chr21:47803548	PCNT	0.5	5.96	0.47	2.39e-8	Testicular germ cell tumor;
TGCT	cis	rs7267979	0.899	rs6115213	chr20:25550372	G/A	cg16686733	chr20:25566563	NINL	0.56	5.69	0.46	8.49e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs17221829	0.699	rs7118152	chr11:89383654	T/C	cg02982614	chr11:89391479	FOLH1B	-0.27	-4.64	-0.38	8.55e-6	Anxiety in major depressive disorder;
TGCT	cis	rs3809566	1.000	rs3809566	chr15:63333724	A/G	cg00520135	chr15:63333846	TPM1	-0.45	-5.56	-0.45	1.55e-7	Platelet count;
TGCT	cis	rs453301	0.658	rs6983877	chr8:8904639	T/C	cg15556689	chr8:8085844	FLJ10661	-0.67	-5.46	-0.44	2.51e-7	Joint mobility (Beighton score);
TGCT	trans	rs17685	0.753	rs6951808	chr7:75772413	A/G	cg19862616	chr7:65841803	NCRNA00174	0.52	9.01	0.63	3.02e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs12220238	0.908	rs10824133	chr10:76020585	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.91	7.62	0.56	5.55e-12	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs1355223	0.583	rs2941058	chr11:34880245	C/G	cg11058730	chr11:34937778	PDHX;APIP	0.79	8.32	0.6	1.36e-13	Systemic lupus erythematosus and Systemic sclerosis;
TGCT	cis	rs67311347	0.544	rs35112505	chr3:40337075	A/G	cg13683864	chr3:40499215	RPL14	-0.78	-7.5	-0.56	1.06e-11	Renal cell carcinoma;
TGCT	trans	rs7726839	0.574	rs11739866	chr5:636299	C/T	cg25482853	chr8:67687455	SGK3	1.22	10.53	0.69	6.33e-19	Obesity-related traits;
TGCT	cis	rs3008870	1.000	rs3008859	chr1:67390999	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.1	12.09	0.74	1.01e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs11650494	0.831	rs8065389	chr17:47456064	G/T	cg08112188	chr17:47440006	ZNF652	-0.88	-4.83	-0.4	3.91e-6	Prostate cancer;
TGCT	cis	rs9341808	0.718	rs12203867	chr6:80820833	G/T	cg08355045	chr6:80787529	NA	0.32	5.83	0.46	4.48e-8	Sitting height ratio;
TGCT	cis	rs72634258	0.519	rs4908487	chr1:7937437	C/T	cg26816564	chr1:7831052	VAMP3	0.65	4.98	0.41	2.11e-6	Inflammatory bowel disease;
TGCT	cis	rs950169	0.544	rs2036949	chr15:85163605	T/C	cg12863693	chr15:85201151	NMB	0.44	5.25	0.43	6.32e-7	Schizophrenia;
TGCT	cis	rs7772486	0.754	rs702318	chr6:146005873	G/T	cg05347473	chr6:146136440	FBXO30	-0.51	-4.8	-0.4	4.44e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10193935	0.901	rs7605782	chr2:42502332	C/T	cg27598129	chr2:42591480	NA	-0.38	-5.43	-0.44	2.86e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2073300	1.000	rs12625999	chr20:23442085	A/G	cg09953122	chr20:23471693	CST8	0.65	4.62	0.38	9.56e-6	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	trans	rs2688608	0.620	rs7076525	chr10:75512797	C/T	cg13918328	chr10:52500089	ASAH2B	0.67	6.83	0.52	3.39e-10	Inflammatory bowel disease;
TGCT	cis	rs514406	0.505	rs387436	chr1:53179376	C/T	cg01802117	chr1:53393560	SCP2	0.4	4.75	0.39	5.55e-6	Monocyte count;
TGCT	cis	rs9611565	0.592	rs28750375	chr22:41990644	A/C	cg06634786	chr22:41940651	POLR3H	-0.83	-7.66	-0.57	4.6e-12	Vitiligo;
TGCT	cis	rs2204008	0.744	rs11495519	chr12:38060546	C/A	cg13010199	chr12:38710504	ALG10B	0.65	5.29	0.43	5.47e-7	Bladder cancer;
TGCT	cis	rs9325144	0.723	rs11169535	chr12:39183494	C/T	cg26384229	chr12:38710491	ALG10B	-0.61	-5.67	-0.45	9.5e-8	Morning vs. evening chronotype;
TGCT	cis	rs7666738	0.830	rs13124689	chr4:98961182	A/T	cg18180107	chr4:99064573	C4orf37	0.57	5.18	0.42	8.63e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg06108461	chr20:60628389	TAF4	-0.4	-4.87	-0.4	3.35e-6	Obesity-related traits;
TGCT	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.46	-6.43	-0.5	2.53e-9	Alzheimer's disease;
TGCT	trans	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg13615516	chr5:77269221	NA	0.68	8.54	0.61	3.97e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs4713118	0.955	rs9468203	chr6:27688667	A/G	cg10876282	chr6:28092338	ZSCAN16	0.51	4.85	0.4	3.63e-6	Parkinson's disease;
TGCT	cis	rs6089829	0.962	rs1116450	chr20:61658210	T/C	cg08564027	chr20:61660810	NA	0.37	6.85	0.52	3.1e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7914558	1.000	rs7920251	chr10:104950197	C/T	cg04362960	chr10:104952993	NT5C2	0.62	5.55	0.45	1.67e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs9379850	0.527	rs9393704	chr6:26358775	T/C	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2677744	0.626	rs3743452	chr15:91497515	C/T	cg23684204	chr15:91497937	RCCD1	-0.41	-6.29	-0.49	4.99e-9	Attention deficit hyperactivity disorder;
TGCT	cis	rs7635838	0.892	rs12163566	chr3:11483096	T/A	cg00170343	chr3:11313890	ATG7	0.64	6.04	0.48	1.69e-8	HDL cholesterol;
TGCT	cis	rs7772486	0.720	rs4896844	chr6:146075224	T/C	cg05347473	chr6:146136440	FBXO30	-0.54	-4.95	-0.41	2.33e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1577917	0.958	rs11756510	chr6:86699794	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.13	-0.42	1.07e-6	Response to antipsychotic treatment;
TGCT	cis	rs6762	0.748	rs7929032	chr11:839078	G/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.47	-4.65	-0.39	8.32e-6	Mean platelet volume;
TGCT	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg05665937	chr4:1216051	CTBP1	0.24	4.47	0.37	1.72e-5	Obesity-related traits;
TGCT	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg24549020	chr5:56110836	MAP3K1	0.7	6.0	0.47	2.02e-8	Initial pursuit acceleration;
TGCT	cis	rs514406	0.505	rs835609	chr1:53170494	T/C	cg24675658	chr1:53192096	ZYG11B	-0.75	-8.49	-0.61	5.43e-14	Monocyte count;
TGCT	cis	rs765787	0.530	rs2433229	chr15:45515235	C/A	cg24006582	chr15:45444508	DUOX1	-0.26	-5.59	-0.45	1.35e-7	Uric acid levels;
TGCT	cis	rs1150668	0.830	rs2859365	chr6:28391465	C/T	cg13525197	chr6:28411240	ZSCAN23	0.52	5.12	0.42	1.13e-6	Pubertal anthropometrics;
TGCT	cis	rs2688608	0.592	rs7909802	chr10:75484186	G/C	cg15838173	chr10:75533400	FUT11	-0.31	-5.02	-0.41	1.73e-6	Inflammatory bowel disease;
TGCT	cis	rs6811802	1	rs6811802	chr4:78932838	G/C	cg07207937	chr4:78783799	MRPL1	-1.17	-6.45	-0.5	2.21e-9	Left ventricular obstructive tract defect (inherited effect);
TGCT	cis	rs3806843	0.657	rs2563283	chr5:140105978	C/A	cg19875535	chr5:140030758	IK	-0.36	-6.1	-0.48	1.23e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs62244186	0.627	rs3935212	chr3:44460954	G/A	cg04389838	chr3:44770851	ZNF501	-0.41	-5.64	-0.45	1.12e-7	Depressive symptoms;
TGCT	cis	rs2235642	0.750	rs763152	chr16:1658056	T/C	cg10465839	chr16:1584050	IFT140;TMEM204	-0.28	-4.65	-0.39	8.32e-6	Coronary artery disease;
TGCT	cis	rs1348850	0.793	rs13020788	chr2:178480714	C/A	cg22681709	chr2:178499509	PDE11A	-0.47	-5.66	-0.45	9.97e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs4638749	0.773	rs4676190	chr2:108858619	A/G	cg06795125	chr2:108905320	SULT1C2	-0.43	-5.09	-0.42	1.3e-6	Blood pressure;
TGCT	cis	rs1008375	0.872	rs6831115	chr4:17640463	A/G	cg10189774	chr4:17578691	LAP3	0.56	5.04	0.41	1.57e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs704	0.628	rs4795435	chr17:26720564	G/A	cg10342447	chr17:26645325	TMEM97	-0.48	-4.87	-0.4	3.36e-6	Osteoprotegerin levels;
TGCT	cis	rs2463822	0.925	rs1881535	chr11:62121623	C/T	cg23876832	chr11:62092739	NA	0.64	4.72	0.39	6.28e-6	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs2204008	0.837	rs34381557	chr12:38181983	T/C	cg13010199	chr12:38710504	ALG10B	0.64	5.16	0.42	9.41e-7	Bladder cancer;
TGCT	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg18538332	chr22:24372958	LOC391322	-1.01	-12.94	-0.76	9.13e-25	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7584330	0.704	rs72620820	chr2:238358844	G/A	cg14458575	chr2:238380390	NA	0.61	8.95	0.63	4.33e-15	Prostate cancer;
TGCT	cis	rs1008375	1.000	rs7673500	chr4:17621383	C/T	cg10189774	chr4:17578691	LAP3	0.59	5.09	0.42	1.32e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	7.39	0.55	1.93e-11	Schizophrenia;
TGCT	cis	rs6426558	0.537	rs2718193	chr1:227404672	C/G	cg10327440	chr1:227177885	CDC42BPA	0.53	6.19	0.49	8.13e-9	Neutrophil percentage of white cells;
TGCT	cis	rs7178572	0.889	rs7170877	chr15:77832019	C/G	cg22256960	chr15:77711686	NA	-0.95	-10.78	-0.7	1.59e-19	Type 2 diabetes;
TGCT	cis	rs7027203	0.797	rs7870672	chr9:96606693	A/C	cg14598338	chr9:96623480	NA	-0.61	-9.54	-0.65	1.68e-16	DNA methylation (variation);
TGCT	cis	rs3820068	0.603	rs932602	chr1:15986087	A/G	cg05660106	chr1:15850417	CASP9	0.81	7.67	0.57	4.28e-12	Systolic blood pressure;
TGCT	cis	rs79349575	0.756	rs4793605	chr17:47035869	T/C	cg26022315	chr17:47021804	SNF8	0.47	4.61	0.38	9.94e-6	Type 2 diabetes;
TGCT	cis	rs4076764	0.846	rs4255362	chr1:163424630	G/A	cg24596788	chr1:163392923	NA	-0.17	-4.89	-0.4	3e-6	Motion sickness;
TGCT	cis	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg20637647	chr7:64974828	NA	0.92	5.36	0.43	3.87e-7	Diabetic kidney disease;
TGCT	cis	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg18252515	chr7:66147081	NA	-1.17	-7.49	-0.56	1.13e-11	Diabetic kidney disease;
TGCT	cis	rs9513593	1.000	rs12875982	chr13:99850615	C/T	cg21788972	chr13:99853209	UBAC2	0.62	4.98	0.41	2.05e-6	Psoriasis;
TGCT	cis	rs9372498	0.536	rs55697388	chr6:118891544	C/T	cg21191810	chr6:118973309	C6orf204	-0.39	-5.04	-0.41	1.59e-6	Diastolic blood pressure;
TGCT	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg23982607	chr1:1823379	GNB1	-0.56	-8.44	-0.6	6.83e-14	Body mass index;
TGCT	cis	rs7267979	0.966	rs6107031	chr20:25350677	C/T	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg03188948	chr7:1209495	NA	0.59	4.82	0.4	4.06e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg08859206	chr1:53392774	SCP2	0.34	4.9	0.4	2.93e-6	Monocyte count;
TGCT	cis	rs2073300	1.000	rs6036411	chr20:23441706	A/C	cg09953122	chr20:23471693	CST8	-0.61	-4.5	-0.37	1.52e-5	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs8177253	0.665	rs8177178	chr3:133463272	G/A	cg11941060	chr3:133502564	NA	-0.26	-5.25	-0.43	6.38e-7	Iron status biomarkers;
TGCT	cis	rs7000551	0.642	rs2449328	chr8:22375043	A/G	cg12081754	chr8:22256438	SLC39A14	0.31	4.97	0.41	2.17e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.95	-11.06	-0.7	3.42e-20	Menarche (age at onset);
TGCT	cis	rs6988636	1.000	rs60362869	chr8:124189971	A/G	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs9921338	0.961	rs7200667	chr16:11440404	C/A	cg00044050	chr16:11439710	C16orf75	-0.87	-6.68	-0.51	7.37e-10	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs2120019	0.508	rs8030528	chr15:75171825	C/T	cg09165964	chr15:75287851	SCAMP5	-0.84	-6.58	-0.51	1.19e-9	Blood trace element (Zn levels);
TGCT	cis	rs6430585	0.528	rs6743537	chr2:136702601	C/T	cg07169764	chr2:136633963	MCM6	1.24	12.33	0.74	2.7e-23	Corneal structure;
TGCT	cis	rs9372498	0.536	rs7356947	chr6:118767920	A/G	cg21191810	chr6:118973309	C6orf204	-0.37	-4.77	-0.39	5.03e-6	Diastolic blood pressure;
TGCT	cis	rs6087990	0.806	rs6141814	chr20:31368960	C/A	cg13636640	chr20:31349939	DNMT3B	1.06	12.99	0.76	6.85e-25	Ulcerative colitis;
TGCT	cis	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg18876405	chr7:65276391	NA	-0.4	-6.08	-0.48	1.38e-8	Aortic root size;
TGCT	cis	rs12753569	0.934	rs6593523	chr1:76486908	C/T	cg00791851	chr1:76518896	NA	-0.33	-4.44	-0.37	1.94e-5	Personality dimensions;
TGCT	cis	rs854765	0.624	rs11657130	chr17:17733826	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.69	-6.67	-0.51	7.5e-10	Total body bone mineral density;
TGCT	cis	rs9549260	0.755	rs9549244	chr13:41218685	C/T	cg21288729	chr13:41239152	FOXO1	0.98	10.15	0.67	5.43e-18	Red blood cell count;
TGCT	cis	rs9527	0.571	rs7904113	chr10:104633114	G/T	cg04362960	chr10:104952993	NT5C2	0.55	4.74	0.39	5.71e-6	Arsenic metabolism;
TGCT	cis	rs11577318	0.853	rs12743998	chr1:26629882	G/A	cg12733254	chr1:26682999	NA	-0.2	-4.45	-0.37	1.89e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs3015497	0.586	rs7144714	chr14:51078585	G/A	cg04730355	chr14:51134070	SAV1	-0.64	-6.14	-0.48	1.01e-8	Mean platelet volume;
TGCT	cis	rs8032315	0.965	rs7497304	chr15:91429176	G/T	cg06330618	chr15:91428456	FES	0.18	4.45	0.37	1.89e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6570726	0.577	rs9497315	chr6:145791967	C/T	cg23711669	chr6:146136114	FBXO30	-0.71	-6.52	-0.51	1.62e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs939574	0.790	rs2276635	chr2:220087441	T/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.0	4.56	0.38	1.2e-5	Platelet distribution width;
TGCT	cis	rs61990749	0.544	rs11628888	chr14:78161506	T/C	cg23188588	chr14:78226832	SNW1;C14orf178	-0.65	-4.59	-0.38	1.08e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs28735056	1.000	rs56376220	chr18:77609462	C/T	cg20368463	chr18:77673604	PQLC1	-0.44	-5.5	-0.44	2.07e-7	Schizophrenia;
TGCT	cis	rs17473412	0.677	rs17475188	chr5:122882751	A/G	cg15125798	chr5:122621645	NA	-0.53	-4.9	-0.4	2.93e-6	Total body bone mineral density;
TGCT	cis	rs10992471	0.702	rs10120915	chr9:95547725	A/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.58	-5.27	-0.43	5.82e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs3015497	0.752	rs6572682	chr14:51144800	A/T	cg04730355	chr14:51134070	SAV1	-0.63	-6.03	-0.48	1.77e-8	Mean platelet volume;
TGCT	cis	rs9467711	0.656	rs34961555	chr6:26199903	C/T	cg16898833	chr6:26189333	HIST1H4D	1.44	6.24	0.49	6.22e-9	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg13695892	chr22:41940480	POLR3H	-0.85	-7.86	-0.58	1.6e-12	Vitiligo;
TGCT	trans	rs797680	0.856	rs12124011	chr1:93652544	C/A	cg27528825	chr2:159282178	CCDC148	-0.35	-6.82	-0.52	3.53e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs2032447	0.641	rs442601	chr6:25934524	G/A	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.61	-6.27	-0.49	5.54e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs9505270	0.729	rs35884426	chr6:7745935	G/A	cg16988958	chr6:7987739	MGC26597	0.21	4.47	0.37	1.71e-5	Myopia (pathological);
TGCT	cis	rs9914988	0.887	rs34644886	chr17:27168327	T/C	cg20469991	chr17:27169893	C17orf63	-0.72	-5.09	-0.42	1.28e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs8180040	0.726	rs1463393	chr3:46994987	G/A	cg27129171	chr3:47204927	SETD2	-0.71	-8.9	-0.62	5.58e-15	Colorectal cancer;
TGCT	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg02038168	chr22:39784481	NA	-0.79	-6.79	-0.52	4.07e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs1055129	0.560	rs3682	chr17:73942150	A/G	cg10935138	chr17:73851978	WBP2	0.55	4.95	0.41	2.38e-6	White matter hyperintensity burden;
TGCT	cis	rs9611565	0.918	rs6002351	chr22:41757223	C/T	cg02107564	chr22:41488750	EP300	-0.54	-4.44	-0.37	1.95e-5	Vitiligo;
TGCT	cis	rs10489202	0.657	rs3767479	chr1:168069840	C/A	cg24449463	chr1:168025552	DCAF6	-0.52	-5.45	-0.44	2.58e-7	Schizophrenia;
TGCT	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg08048268	chr3:133502702	NA	-0.73	-11.39	-0.71	5.35e-21	Iron status biomarkers;
TGCT	cis	rs12762955	0.561	rs2620942	chr10:1048398	C/T	cg20503657	chr10:835505	NA	0.41	5.31	0.43	4.97e-7	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs6500602	0.702	rs17761816	chr16:4548832	C/G	cg08645402	chr16:4508243	NA	0.18	5.19	0.42	8.41e-7	Schizophrenia;
TGCT	cis	rs79911532	0.515	rs8509	chr7:75616577	G/A	cg24069840	chr7:75623858	TMEM120A	0.78	4.45	0.37	1.86e-5	Mononucleosis;
TGCT	cis	rs4794202	0.629	rs7212099	chr17:45925890	A/G	cg02219949	chr17:45927392	SP6	0.42	4.57	0.38	1.16e-5	Alzheimer's disease (cognitive decline);
TGCT	cis	rs317689	0.690	rs7969559	chr12:69655167	A/G	cg11871910	chr12:69753446	YEATS4	0.52	4.58	0.38	1.1e-5	Response to diuretic therapy;
TGCT	cis	rs2836974	0.583	rs2735307	chr21:40713358	C/T	cg17971929	chr21:40555470	PSMG1	0.61	5.52	0.44	1.87e-7	Cognitive function;
TGCT	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg06618935	chr21:46677482	NA	-0.34	-5.34	-0.43	4.32e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs921968	0.509	rs10932782	chr2:219353195	C/T	cg02176678	chr2:219576539	TTLL4	0.48	6.78	0.52	4.32e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs6121246	0.529	rs6060142	chr20:30178028	A/G	cg10886678	chr20:30946050	ASXL1	-0.71	-4.82	-0.4	4.04e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg09165964	chr15:75287851	SCAMP5	0.55	5.14	0.42	1.06e-6	Breast cancer;
TGCT	cis	rs453301	0.686	rs11785819	chr8:8870378	T/G	cg00184457	chr8:8946301	NA	-0.27	-4.92	-0.4	2.72e-6	Joint mobility (Beighton score);
TGCT	trans	rs2290610	1.000	rs2290610	chr3:3139957	C/T	cg14557510	chr2:122042345	TFCP2L1	-0.69	-6.99	-0.53	1.48e-10	Blood protein levels;
TGCT	cis	rs4975616	0.804	rs462608	chr5:1336626	T/A	cg07493874	chr5:1342172	CLPTM1L	-0.27	-6.55	-0.51	1.39e-9	Lung cancer;
TGCT	cis	rs36051895	0.589	rs1322222	chr9:5190444	A/G	cg02405213	chr9:5042618	JAK2	-0.72	-9.77	-0.66	4.46e-17	Pediatric autoimmune diseases;
TGCT	cis	rs6725517	0.737	rs7576788	chr2:25083310	A/G	cg01884057	chr2:25150051	NA	0.27	5.2	0.42	8.04e-7	Breast cancer;
TGCT	cis	rs13082711	0.522	rs480238	chr3:27347577	A/T	cg02860705	chr3:27208620	NA	0.34	5.58	0.45	1.43e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs10769945	0.679	rs7102920	chr11:1917872	C/T	cg06503573	chr11:1949039	TNNT3	0.26	4.96	0.41	2.25e-6	DNA methylation (variation);
TGCT	cis	rs10504229	0.906	rs2270608	chr8:58194688	T/C	cg24829409	chr8:58192753	C8orf71	-0.55	-4.83	-0.4	3.91e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs523522	0.962	rs670568	chr12:121021206	C/T	cg27279351	chr12:120934652	DYNLL1	0.74	6.46	0.5	2.19e-9	High light scatter reticulocyte count;
TGCT	cis	rs4727027	0.901	rs34201592	chr7:148842403	C/G	cg23583168	chr7:148888333	NA	-0.72	-9.17	-0.64	1.31e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs7226408	0.948	rs11660669	chr18:34394481	A/G	cg06757138	chr18:34340585	FHOD3	0.26	4.79	0.4	4.62e-6	Obesity-related traits;
TGCT	cis	rs12765878	1.000	rs9325507	chr10:105645622	C/T	cg11005552	chr10:105648138	OBFC1	0.44	7.69	0.57	4.01e-12	Coronary artery disease;
TGCT	cis	rs33794	0.901	rs28213	chr3:45290708	A/G	cg18645101	chr3:44551900	NA	0.54	4.74	0.39	5.75e-6	Lung function (forced expiratory volume in 1 second);
TGCT	cis	rs6121246	0.909	rs6060870	chr20:30303299	C/T	cg13852791	chr20:30311386	BCL2L1	0.78	5.8	0.46	5.15e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs10032931	0.926	rs17024152	chr4:96456402	T/A	cg03008707	chr4:96468962	UNC5C	-0.34	-4.7	-0.39	6.78e-6	Optic nerve measurement (cup-to-disc ratio);
TGCT	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.42	6.05	0.48	1.57e-8	Lymphocyte counts;
TGCT	cis	rs858239	0.665	rs858305	chr7:23242830	C/G	cg05602783	chr7:23145260	KLHL7	0.63	5.23	0.43	6.93e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs2549003	1.000	rs2070723	chr5:131823187	A/G	cg02551604	chr5:131831745	NA	-0.92	-12.33	-0.74	2.72e-23	Asthma (sex interaction);
TGCT	cis	rs9357506	1.000	rs1345058	chr6:46306927	C/T	cg21115430	chr6:46460003	NA	-0.26	-5.17	-0.42	9.2e-7	Body mass index;
TGCT	cis	rs4819052	1.000	rs2297284	chr21:46705345	G/A	cg06618935	chr21:46677482	NA	-0.42	-5.37	-0.43	3.76e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs13064411	0.542	rs7631335	chr3:113209166	C/T	cg18753928	chr3:113234510	CCDC52	-0.54	-4.58	-0.38	1.12e-5	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	trans	rs7342694	0.965	rs9924101	chr16:81907362	T/C	cg04928372	chr6:27720905	NA	0.69	6.72	0.52	5.86e-10	Coronary artery disease;
TGCT	cis	rs35883536	0.647	rs12026951	chr1:101046273	C/T	cg06223162	chr1:101003688	GPR88	-0.41	-7.64	-0.57	5.04e-12	Monocyte count;
TGCT	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg22920501	chr2:26401640	FAM59B	-0.73	-6.28	-0.49	5.18e-9	Gut microbiome composition (summer);
TGCT	cis	rs7010267	0.570	rs1485295	chr8:120039462	A/G	cg17171407	chr8:119960777	TNFRSF11B	0.26	4.59	0.38	1.06e-5	Total body bone mineral density (age 45-60);
TGCT	cis	rs9985766	0.958	rs10011368	chr4:150988934	G/A	cg05926478	chr4:151174724	DCLK2	-0.24	-4.64	-0.38	8.63e-6	Coronary artery disease;Myocardial infarction;
TGCT	cis	rs10465746	0.935	rs12758441	chr1:84352034	A/G	cg10977910	chr1:84465055	TTLL7	0.63	6.19	0.49	8.08e-9	Obesity-related traits;
TGCT	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg21724239	chr8:58056113	NA	0.51	5.46	0.44	2.51e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.0	-7.42	-0.55	1.64e-11	Gut microbiome composition (summer);
TGCT	cis	rs10170846	0.789	rs972650	chr2:223520287	C/T	cg25565276	chr2:223520875	FARSB	0.55	4.58	0.38	1.11e-5	Schizophrenia (inflammation and infection response interaction);
TGCT	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg18876405	chr7:65276391	NA	0.37	5.85	0.46	4.19e-8	Calcium levels;
TGCT	cis	rs4919694	0.572	rs12240508	chr10:104939232	G/A	cg04362960	chr10:104952993	NT5C2	0.97	6.81	0.52	3.82e-10	Arsenic metabolism;
TGCT	cis	rs2692947	0.526	rs4907225	chr2:96576670	C/T	cg23100626	chr2:96804247	ASTL	0.38	4.61	0.38	9.79e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs4886920	0.563	rs4420498	chr15:78079425	T/C	cg03457338	chr15:78040120	NA	0.18	4.51	0.38	1.48e-5	Neuroticism;
TGCT	cis	rs289997	1.000	rs289997	chr7:25569548	C/T	cg14064488	chr7:26331273	SNX10	-0.34	-4.66	-0.39	8.01e-6	Breast cancer;
TGCT	cis	rs7833790	1.000	rs7833384	chr8:82730915	T/C	cg06027949	chr8:82754900	SNX16	-0.67	-4.61	-0.38	9.99e-6	Diastolic blood pressure;
TGCT	cis	rs73001065	0.901	rs73004951	chr19:19695228	C/T	cg03709012	chr19:19516395	GATAD2A	0.97	4.82	0.4	4.07e-6	LDL cholesterol;
TGCT	cis	rs611744	0.967	rs635624	chr8:109197799	G/C	cg21045802	chr8:109455806	TTC35	0.5	4.5	0.37	1.53e-5	Dupuytren's disease;
TGCT	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	5.45	0.44	2.63e-7	Menopause (age at onset);
TGCT	cis	rs7223966	1.000	rs8081541	chr17:61812483	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	4.68	0.39	7.5e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs7914558	1.000	rs7081075	chr10:104929191	C/T	cg04362960	chr10:104952993	NT5C2	0.61	5.45	0.44	2.6e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs3099143	1.000	rs3102710	chr15:77061148	T/C	cg21673338	chr15:77095150	SCAPER	-0.51	-5.12	-0.42	1.11e-6	Recalcitrant atopic dermatitis;
TGCT	cis	rs6840360	0.868	rs6823462	chr4:152708740	G/A	cg22705602	chr4:152727874	NA	-0.24	-4.47	-0.37	1.75e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs854765	0.547	rs7224047	chr17:17932931	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.78	8.1	0.59	4.3e-13	Total body bone mineral density;
TGCT	cis	rs1670533	0.769	rs6814833	chr4:1057679	A/C	cg27284194	chr4:1044797	NA	0.66	5.51	0.44	1.99e-7	Recombination rate (females);
TGCT	trans	rs17685	0.753	rs4728586	chr7:75802869	T/C	cg19862616	chr7:65841803	NCRNA00174	0.53	9.03	0.63	2.83e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg24675658	chr1:53192096	ZYG11B	0.7	7.98	0.58	8.59e-13	Monocyte count;
TGCT	cis	rs62244186	0.545	rs725866	chr3:44765533	A/G	cg04389838	chr3:44770851	ZNF501	-0.37	-4.83	-0.4	4.02e-6	Depressive symptoms;
TGCT	cis	rs2816062	0.760	rs2244192	chr1:18890939	A/T	cg18795169	chr1:18902165	NA	-0.6	-14.18	-0.79	1.04e-27	Urate levels in lean individuals;
TGCT	cis	rs986417	0.818	rs10873125	chr14:61035024	G/A	cg27398547	chr14:60952738	C14orf39	1.38	10.8	0.7	1.4e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs7412746	0.658	rs3768016	chr1:150809919	T/C	cg09365446	chr1:150670422	GOLPH3L	0.35	5.13	0.42	1.1e-6	Melanoma;
TGCT	cis	rs3733585	0.673	rs6814664	chr4:9956228	C/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.7	-0.52	6.62e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs4689388	0.926	rs10012946	chr4:6293350	C/T	cg00701064	chr4:6280414	WFS1	-0.41	-4.85	-0.4	3.61e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs933688	0.532	rs2367292	chr5:90556785	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.55	-4.67	-0.39	7.83e-6	Smoking behavior;
TGCT	cis	rs317689	0.684	rs315125	chr12:69758884	C/T	cg20891283	chr12:69753455	YEATS4	0.56	4.71	0.39	6.52e-6	Response to diuretic therapy;
TGCT	cis	rs8017423	0.935	rs7154695	chr14:90795705	C/G	cg04374321	chr14:90722782	PSMC1	0.71	6.51	0.5	1.71e-9	Mortality in heart failure;
TGCT	cis	rs17030434	0.906	rs57446135	chr4:154679331	A/G	cg14289246	chr4:154710475	SFRP2	-0.97	-7.69	-0.57	4e-12	Electrocardiographic conduction measures;
TGCT	cis	rs5850	0.557	rs10270788	chr7:23189000	T/C	cg05602783	chr7:23145260	KLHL7	-0.62	-5.03	-0.41	1.67e-6	Blood protein levels;
TGCT	cis	rs362272	0.524	rs7435601	chr4:3369645	A/G	cg06533319	chr4:3265114	C4orf44	-0.27	-5.53	-0.44	1.8e-7	Serum sulfate level;
TGCT	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg10047753	chr17:41438598	NA	0.94	9.23	0.64	9.06e-16	Menopause (age at onset);
TGCT	cis	rs10746514	0.768	rs11122427	chr1:232261085	C/T	cg09506761	chr1:232265262	NA	-0.49	-4.99	-0.41	2.01e-6	Response to statin therapy;
TGCT	cis	rs2204008	0.806	rs7305409	chr12:38349133	G/A	cg13010199	chr12:38710504	ALG10B	0.6	4.74	0.39	5.87e-6	Bladder cancer;
TGCT	cis	rs11874712	1.000	rs9945751	chr18:43673265	G/A	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	5.23	0.42	7.11e-7	Migraine - clinic-based;
TGCT	cis	rs11252926	0.528	rs11252090	chr10:436547	C/T	cg13477178	chr10:375248	DIP2C	0.24	4.71	0.39	6.57e-6	Psychosis in Alzheimer's disease;
TGCT	cis	rs4711350	0.765	rs6921772	chr6:33749686	A/G	cg13859433	chr6:33739653	LEMD2	-0.32	-4.79	-0.39	4.75e-6	Schizophrenia;
TGCT	cis	rs6504950	0.720	rs12602751	chr17:52994174	C/A	cg07707039	chr17:53042137	COX11	0.27	4.66	0.39	8.15e-6	Breast cancer;
TGCT	cis	rs17345786	0.953	rs78645744	chr3:101327789	T/A	cg11279151	chr3:101281821	RG9MTD1	-0.44	-9.51	-0.65	1.94e-16	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1568889	0.838	rs10835304	chr11:28296529	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.93	10.99	0.7	4.8e-20	Bipolar disorder;
TGCT	cis	rs6087990	0.584	rs6058897	chr20:31398105	G/T	cg13636640	chr20:31349939	DNMT3B	-0.85	-10.07	-0.67	8.59e-18	Ulcerative colitis;
TGCT	cis	rs858239	0.539	rs6971673	chr7:23159523	C/G	cg05602783	chr7:23145260	KLHL7	-0.65	-5.52	-0.44	1.93e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs11122272	0.735	rs2749716	chr1:231486908	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-6.61	-0.51	1.01e-9	Hemoglobin concentration;
TGCT	cis	rs7208859	0.673	rs12103759	chr17:29235687	G/A	cg14008862	chr17:28927542	LRRC37B2	0.72	4.66	0.39	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	trans	rs1814175	0.717	rs11040450	chr11:49650638	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.34	-6.67	-0.51	7.47e-10	Height;
TGCT	cis	rs7659604	0.702	rs6826506	chr4:122710865	T/G	cg06713675	chr4:122721982	EXOSC9	-0.65	-8.68	-0.61	1.88e-14	Type 2 diabetes;
TGCT	cis	rs4906332	1.000	rs12885234	chr14:103889181	A/G	cg26031613	chr14:104095156	KLC1	-0.54	-4.82	-0.4	4.04e-6	Coronary artery disease;
TGCT	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg11764359	chr7:65958608	NA	-0.61	-5.39	-0.44	3.45e-7	Aortic root size;
TGCT	cis	rs7246657	0.943	rs4803229	chr19:37864682	T/G	cg03233940	chr19:37894644	NA	-0.35	-4.54	-0.38	1.3e-5	Coronary artery calcification;
TGCT	cis	rs67311347	0.955	rs9821036	chr3:40379007	A/G	cg13683864	chr3:40499215	RPL14	-1.11	-11.84	-0.73	4.15e-22	Renal cell carcinoma;
TGCT	cis	rs40363	0.523	rs757270	chr16:3534451	C/T	cg00484396	chr16:3507460	NAT15	-0.32	-4.58	-0.38	1.11e-5	Tuberculosis;
TGCT	cis	rs7000551	0.508	rs11780977	chr8:22245028	G/A	cg12081754	chr8:22256438	SLC39A14	0.34	4.95	0.41	2.39e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs9905704	0.647	rs8077332	chr17:57105223	A/G	cg12560992	chr17:57184187	TRIM37	0.61	5.43	0.44	2.83e-7	Testicular germ cell tumor;
TGCT	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg17054783	chr10:134559939	INPP5A	0.26	5.0	0.41	1.94e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg27541892	chr1:1571801	CDK11B	-0.41	-5.33	-0.43	4.51e-7	Body mass index;
TGCT	cis	rs7726839	0.561	rs4957050	chr5:579066	A/C	cg09021430	chr5:549028	NA	-0.37	-5.39	-0.44	3.37e-7	Obesity-related traits;
TGCT	cis	rs896854	0.517	rs2013597	chr8:95951807	G/A	cg09323728	chr8:95962352	TP53INP1	-0.43	-4.85	-0.4	3.68e-6	Type 2 diabetes;
TGCT	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg24531977	chr5:56204891	C5orf35	-0.73	-7.73	-0.57	3.11e-12	Initial pursuit acceleration;
TGCT	cis	rs2486012	1.000	rs2906463	chr1:44330048	A/G	cg12908607	chr1:44402522	ARTN	-0.69	-5.57	-0.45	1.49e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs13064411	0.696	rs9808893	chr3:113228444	G/A	cg10517650	chr3:113235015	CCDC52	-0.32	-4.45	-0.37	1.85e-5	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs6430585	0.527	rs1446586	chr2:136407445	C/T	cg07169764	chr2:136633963	MCM6	-0.94	-7.14	-0.54	7.04e-11	Corneal structure;
TGCT	cis	rs9383153	0.793	rs2016498	chr6:16344914	C/T	cg03173502	chr6:15505345	JARID2	0.77	4.8	0.4	4.54e-6	Gambling;
TGCT	cis	rs11098499	0.954	rs1480931	chr4:120395809	G/T	cg09307838	chr4:120376055	NA	0.7	6.66	0.51	8.02e-10	Corneal astigmatism;
TGCT	trans	rs1908814	0.516	rs10113042	chr8:11793178	A/G	cg15556689	chr8:8085844	FLJ10661	0.77	7.37	0.55	2.13e-11	Neuroticism;
TGCT	cis	rs12497850	0.966	rs6792510	chr3:48723302	G/C	cg06212747	chr3:49208901	KLHDC8B	0.59	5.38	0.43	3.61e-7	Parkinson's disease;
TGCT	cis	rs3015497	0.753	rs4643225	chr14:51122205	G/C	cg04730355	chr14:51134070	SAV1	-0.63	-6.19	-0.49	8.18e-9	Mean platelet volume;
TGCT	cis	rs9308731	0.666	rs4849402	chr2:111873932	G/A	cg04202892	chr2:111875749	ACOXL	0.54	6.22	0.49	7.04e-9	Chronic lymphocytic leukemia;
TGCT	cis	rs7267979	1.000	rs2027004	chr20:25350618	C/T	cg14121845	chr20:25566513	NINL	-0.49	-5.38	-0.43	3.61e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6088580	0.634	rs6059887	chr20:33101102	C/G	cg06115741	chr20:33292138	TP53INP2	0.54	4.63	0.38	9.06e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs6964587	1.000	rs415	chr7:91580490	A/G	cg17063962	chr7:91808500	NA	-0.91	-9.99	-0.67	1.32e-17	Breast cancer;
TGCT	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg06634786	chr22:41940651	POLR3H	-0.86	-8.34	-0.6	1.18e-13	Vitiligo;
TGCT	cis	rs116095464	0.558	rs1968374	chr5:249025	A/C	cg22857025	chr5:266934	NA	-0.34	-6.23	-0.49	6.59e-9	Breast cancer;
TGCT	cis	rs7089973	0.604	rs11196936	chr10:116588630	C/T	cg03647239	chr10:116582469	FAM160B1	0.59	5.75	0.46	6.46e-8	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg18876405	chr7:65276391	NA	0.31	4.79	0.4	4.58e-6	Aortic root size;
TGCT	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg24531977	chr5:56204891	C5orf35	-0.76	-7.57	-0.56	7.52e-12	Initial pursuit acceleration;
TGCT	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg19318889	chr4:1322082	MAEA	0.27	6.52	0.51	1.57e-9	Longevity;
TGCT	cis	rs7772486	0.902	rs2144476	chr6:146322484	G/A	cg05347473	chr6:146136440	FBXO30	0.51	4.92	0.4	2.7e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs782590	0.683	rs782633	chr2:55898203	A/G	cg03859395	chr2:55845619	SMEK2	0.85	9.64	0.65	9.63e-17	Metabolic syndrome;
TGCT	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg13342137	chr4:2252803	MXD4	0.17	4.44	0.37	1.94e-5	Obesity-related traits;
TGCT	cis	rs1775715	0.678	rs2778649	chr10:32146803	C/G	cg14930904	chr10:32216787	ARHGAP12	0.53	5.1	0.42	1.22e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs68170813	0.559	rs2107319	chr7:106863744	T/C	cg02696742	chr7:106810147	HBP1	-0.68	-5.74	-0.46	7e-8	Coronary artery disease;
TGCT	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.33	-5.17	-0.42	9.08e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs17345786	0.906	rs11708616	chr3:101231731	C/T	cg12386194	chr3:101231763	SENP7	0.63	5.94	0.47	2.63e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs17539620	0.534	rs6557363	chr6:154827813	A/G	cg20019720	chr6:154832845	CNKSR3	0.47	4.59	0.38	1.07e-5	Lipoprotein (a) levels;
TGCT	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg12756686	chr19:29218302	NA	0.77	6.61	0.51	1.01e-9	Methadone dose in opioid dependence;
TGCT	cis	rs7394190	0.748	rs11541237	chr10:75530962	C/T	cg07699608	chr10:75541558	CHCHD1	0.8	5.21	0.42	7.72e-7	Incident atrial fibrillation;
TGCT	cis	rs17152411	1.000	rs7089014	chr10:126590342	G/A	cg07906193	chr10:126599966	NA	0.42	5.16	0.42	9.55e-7	Height;
TGCT	cis	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg06636001	chr8:8085503	FLJ10661	0.71	6.29	0.49	4.94e-9	Mood instability;
TGCT	cis	rs7822232	0.908	rs56138570	chr8:145142206	G/A	cg06495924	chr8:145149574	CYC1	-1.04	-4.49	-0.37	1.6e-5	Blood metabolite levels;
TGCT	cis	rs617219	0.726	rs955897	chr5:78431486	A/C	cg05890484	chr5:78407552	BHMT	0.38	5.13	0.42	1.1e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs7208859	0.623	rs75136574	chr17:28934549	C/A	cg13385521	chr17:29058706	SUZ12P	0.81	4.87	0.4	3.39e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs6582630	0.576	rs3900594	chr12:38272429	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-4.7	-0.39	6.68e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs7681440	0.874	rs1372524	chr4:90776045	A/G	cg26578617	chr4:90757533	SNCA	-0.44	-4.54	-0.38	1.31e-5	Dementia with Lewy bodies;
TGCT	cis	rs6060960	0.537	rs6089103	chr20:30464919	G/T	cg06102403	chr20:30458708	TTLL9;DUSP15	0.41	5.11	0.42	1.19e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
TGCT	cis	rs12510870	0.599	rs12505842	chr4:74449889	A/G	cg05868023	chr4:75230803	EREG	-0.54	-4.76	-0.39	5.33e-6	Iris color (b* coordinate);
TGCT	cis	rs9611565	0.649	rs126092	chr22:42178441	A/G	cg13695892	chr22:41940480	POLR3H	0.82	7.47	0.56	1.27e-11	Vitiligo;
TGCT	cis	rs2012796	1.000	rs12436146	chr14:81821282	A/G	cg02996355	chr14:81879375	NA	0.47	4.61	0.38	9.68e-6	Night sleep phenotypes;
TGCT	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg23758822	chr17:41437982	NA	0.71	6.75	0.52	5.16e-10	Menopause (age at onset);
TGCT	cis	rs881375	0.702	rs3761847	chr9:123690239	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	4.88	0.4	3.16e-6	Rheumatoid arthritis;
TGCT	cis	rs79349575	0.783	rs962272	chr17:46978283	A/G	cg07967210	chr17:47022446	SNF8	0.43	6.06	0.48	1.54e-8	Type 2 diabetes;
TGCT	trans	rs7819412	0.745	rs6601569	chr8:11073578	C/T	cg06636001	chr8:8085503	FLJ10661	-0.75	-7.02	-0.53	1.27e-10	Triglycerides;
TGCT	cis	rs9916302	0.851	rs4794810	chr17:37603774	T/C	cg07936489	chr17:37558343	FBXL20	-0.62	-4.91	-0.4	2.77e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs2562456	0.793	rs2562428	chr19:21625454	G/C	cg25650185	chr19:21324782	ZNF431	0.55	4.58	0.38	1.14e-5	Pain;
TGCT	cis	rs67311347	1.000	rs28707772	chr3:40504666	G/A	cg13683864	chr3:40499215	RPL14	-1.2	-13.3	-0.77	1.27e-25	Renal cell carcinoma;
TGCT	cis	rs6582630	0.519	rs12819814	chr12:38332568	G/C	cg26384229	chr12:38710491	ALG10B	0.79	6.98	0.53	1.61e-10	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs7223966	0.921	rs6504186	chr17:61863932	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	4.68	0.39	7.5e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs9926296	0.632	rs4785716	chr16:89801127	T/C	cg03388025	chr16:89894329	SPIRE2	0.32	4.69	0.39	7.03e-6	Vitiligo;
TGCT	cis	rs6076065	0.963	rs999072	chr20:23347553	C/T	cg11657817	chr20:23433608	CST11	0.28	4.55	0.38	1.25e-5	Facial morphology (factor 15, philtrum width);
TGCT	cis	rs3096299	0.719	rs2911265	chr16:89511328	G/A	cg08392591	chr16:89556376	ANKRD11	0.63	6.06	0.48	1.5e-8	Multiple myeloma (IgH translocation);
TGCT	cis	rs67072384	1.000	rs12289259	chr11:72446731	A/C	cg03713592	chr11:72463424	ARAP1	-0.94	-4.8	-0.4	4.41e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg22535103	chr8:58192502	C8orf71	-0.41	-5.23	-0.42	7.07e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs4803468	0.967	rs11670583	chr19:41920440	A/T	cg09537434	chr19:41945824	ATP5SL	-0.9	-10.59	-0.69	4.65e-19	Height;
TGCT	cis	rs28595532	0.702	rs72670256	chr4:119391043	G/A	cg21605333	chr4:119757512	SEC24D	0.82	5.41	0.44	3.15e-7	Cannabis dependence symptom count;
TGCT	cis	rs7824557	0.603	rs7016671	chr8:11182455	A/G	cg21775007	chr8:11205619	TDH	0.66	6.45	0.5	2.27e-9	Retinal vascular caliber;
TGCT	cis	rs36051895	0.664	rs10116560	chr9:5096433	A/G	cg02405213	chr9:5042618	JAK2	-0.71	-9.43	-0.65	3.07e-16	Pediatric autoimmune diseases;
TGCT	cis	rs11105298	0.891	rs10858890	chr12:89907166	A/G	cg00757033	chr12:89920650	WDR51B	0.31	5.09	0.42	1.28e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs6430585	0.528	rs309154	chr2:136726567	C/T	cg07169764	chr2:136633963	MCM6	1.25	12.67	0.75	4.02e-24	Corneal structure;
TGCT	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.03	0.41	1.68e-6	Prudent dietary pattern;
TGCT	cis	rs72949976	0.606	rs11898263	chr2:214030649	A/G	cg08319019	chr2:214017104	IKZF2	0.84	8.21	0.59	2.46e-13	Lung cancer;Squamous cell lung carcinoma;
TGCT	cis	rs10484885	0.793	rs9359862	chr6:90474508	A/G	cg13799429	chr6:90582589	CASP8AP2	0.45	4.66	0.39	7.9e-6	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs8180040	0.900	rs4858894	chr3:47484953	C/G	cg27129171	chr3:47204927	SETD2	0.66	8.01	0.58	7.07e-13	Colorectal cancer;
TGCT	cis	rs7666738	0.791	rs28579101	chr4:98843203	T/C	cg18180107	chr4:99064573	C4orf37	0.56	5.17	0.42	9.04e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs62244186	0.632	rs1402751	chr3:44594030	C/A	cg11003573	chr3:44754125	ZNF502	-0.41	-4.61	-0.38	9.8200000000000008e-06	Depressive symptoms;
TGCT	cis	rs9611519	0.603	rs8142276	chr22:41471447	T/C	cg03806693	chr22:41940476	POLR3H	-0.51	-4.57	-0.38	1.14e-5	Neuroticism;
TGCT	cis	rs950169	0.544	rs12913702	chr15:85153184	G/A	cg11189052	chr15:85197271	WDR73	0.78	6.71	0.52	6.11e-10	Schizophrenia;
TGCT	cis	rs1538970	0.924	rs10890327	chr1:45891458	C/T	cg05343316	chr1:45956843	TESK2	0.76	6.19	0.49	7.93e-9	Platelet count;
TGCT	cis	rs1205863	1.000	rs1205852	chr6:11942371	A/G	cg07106625	chr6:11870215	NA	0.51	5.05	0.41	1.51e-6	Disc degeneration (lumbar);
TGCT	cis	rs8014252	0.803	rs2877672	chr14:71036259	T/C	cg11204974	chr14:71022665	NA	-0.55	-4.66	-0.39	7.98e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
TGCT	cis	rs10465746	0.967	rs12140068	chr1:84394286	A/C	cg10977910	chr1:84465055	TTLL7	0.65	6.29	0.49	5.05e-9	Obesity-related traits;
TGCT	cis	rs1538970	0.962	rs9429072	chr1:45810091	C/T	cg05343316	chr1:45956843	TESK2	-0.64	-5.12	-0.42	1.12e-6	Platelet count;
TGCT	trans	rs877282	0.945	rs11253391	chr10:788752	G/A	cg22713356	chr15:30763199	NA	1.16	10.26	0.68	3.01e-18	Uric acid levels;
TGCT	trans	rs1864982	0.685	rs12519616	chr5:146210844	A/G	cg07017998	chr4:733617	PCGF3	0.28	7.12	0.54	7.8e-11	Alcohol dependence;
TGCT	cis	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg20637647	chr7:64974828	NA	-0.9	-5.31	-0.43	4.87e-7	Diabetic kidney disease;
TGCT	cis	rs4843747	0.636	rs11117358	chr16:88105053	T/A	cg06915872	chr16:87998081	BANP	-0.3	-4.55	-0.38	1.25e-5	Menopause (age at onset);
TGCT	cis	rs11716531	0.574	rs7624067	chr3:27267853	G/A	cg02860705	chr3:27208620	NA	0.39	5.89	0.47	3.39e-8	Diastolic blood pressure;
TGCT	cis	rs13188771	0.690	rs12521514	chr5:100898219	G/A	cg18665594	chr5:101119420	NA	0.44	4.47	0.37	1.74e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs950169	0.580	rs11635597	chr15:85165699	C/T	cg11189052	chr15:85197271	WDR73	0.75	6.38	0.5	3.2e-9	Schizophrenia;
TGCT	cis	rs9399135	0.967	rs45544135	chr6:135324051	T/C	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.36e-6	Red blood cell count;
TGCT	cis	rs4654899	0.796	rs77366434	chr1:21520069	C/T	cg01072550	chr1:21505969	NA	-0.48	-7.14	-0.54	7.03e-11	Superior frontal gyrus grey matter volume;
TGCT	cis	rs35883536	0.605	rs2133118	chr1:101034337	C/T	cg06223162	chr1:101003688	GPR88	-0.42	-7.96	-0.58	9.26e-13	Monocyte count;
TGCT	cis	rs6693567	0.507	rs828784	chr1:150335240	T/A	cg09579323	chr1:150459698	TARS2	0.54	4.79	0.4	4.59e-6	Migraine;
TGCT	trans	rs2727020	0.658	rs4980440	chr11:49386017	C/T	cg03929089	chr4:120376271	NA	-0.75	-8.58	-0.61	3.35e-14	Coronary artery disease;
TGCT	cis	rs3784262	0.631	rs3742961	chr15:58247977	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.44	-6.32	-0.49	4.39e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs2718812	0.766	rs10935071	chr3:133394159	T/C	cg16414030	chr3:133502952	NA	-0.4	-5.2	-0.42	8.03e-7	Iron status biomarkers;
TGCT	trans	rs2727020	0.688	rs11040338	chr11:49360601	A/G	cg03929089	chr4:120376271	NA	0.73	8.73	0.62	1.45e-14	Coronary artery disease;
TGCT	cis	rs3820928	0.934	rs1366756	chr2:227772038	G/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-4.82	-0.4	4.12e-6	Pulmonary function;
TGCT	cis	rs2458413	0.903	rs2669448	chr8:105372324	T/G	cg23108931	chr8:105342351	NA	0.32	5.13	0.42	1.07e-6	Paget's disease;
TGCT	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	5.98	0.47	2.23e-8	Alzheimer's disease;
TGCT	cis	rs1894292	0.527	rs2141465	chr4:74376680	G/T	cg05868023	chr4:75230803	EREG	0.56	5.05	0.41	1.56e-6	Prostate cancer;
TGCT	cis	rs7914558	0.966	rs10786724	chr10:104668942	A/G	cg15744005	chr10:104629667	AS3MT	-0.41	-5.11	-0.42	1.16e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs3813567	0.759	rs7163204	chr15:78953740	G/A	cg24631222	chr15:78858424	CHRNA5	0.68	4.72	0.39	6.35e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
TGCT	cis	rs13242816	1.000	rs36004201	chr7:116126310	C/A	cg16553024	chr7:116138462	CAV2	-0.43	-4.88	-0.4	3.26e-6	P wave duration;
TGCT	cis	rs1797081	0.840	rs10904820	chr10:16848473	A/G	cg14835575	chr10:16859367	RSU1	0.4	4.94	0.41	2.44e-6	Platelet distribution width;
TGCT	cis	rs7614311	0.636	rs73117047	chr3:63910779	G/A	cg22134162	chr3:63841271	THOC7	-0.49	-6.17	-0.48	8.78e-9	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs425277	0.761	rs6603813	chr1:2043080	T/G	cg24578937	chr1:2090814	PRKCZ	0.28	6.14	0.48	1.02e-8	Height;
TGCT	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	5.03	0.41	1.69e-6	Prudent dietary pattern;
TGCT	cis	rs9814567	0.964	rs6776203	chr3:134234345	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.95	-9.55	-0.65	1.56e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs314370	0.951	rs6706	chr7:100471044	C/T	cg10426581	chr7:100472382	SRRT	1.0	10.93	0.7	6.98e-20	Resting heart rate;
TGCT	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg27535305	chr1:53392650	SCP2	-0.29	-6.13	-0.48	1.08e-8	Monocyte count;
TGCT	cis	rs4988958	0.565	rs6760621	chr2:102999952	T/C	cg03938978	chr2:103052716	IL18RAP	0.26	5.22	0.42	7.15e-7	Asthma (childhood onset);
TGCT	cis	rs6545883	0.868	rs6752938	chr2:61841588	C/T	cg15711740	chr2:61764176	XPO1	-0.55	-5.19	-0.42	8.37e-7	Tuberculosis;
TGCT	cis	rs7666738	0.830	rs35915560	chr4:98978649	C/T	cg05340658	chr4:99064831	C4orf37	0.51	5.93	0.47	2.87e-8	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs8073060	0.963	rs11080354	chr17:33872407	A/G	cg19694781	chr19:47549865	TMEM160	-0.4	-7.1	-0.54	8.33e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs877282	0.945	rs71491311	chr10:791747	G/A	cg17470449	chr10:769945	NA	0.3	4.82	0.4	4.14e-6	Uric acid levels;
TGCT	cis	rs3902035	0.964	rs10485390	chr6:119013074	C/G	cg07617317	chr6:118971624	C6orf204	0.43	5.01	0.41	1.79e-6	QT interval;
TGCT	cis	rs9303401	0.538	rs35454383	chr17:56475599	C/T	cg25039879	chr17:56429692	SUPT4H1	0.58	4.98	0.41	2.12e-6	Cognitive test performance;
TGCT	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.28	-0.43	5.51e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs10791323	0.720	rs2851117	chr11:133705905	A/G	cg03690763	chr11:133734501	NA	0.31	4.78	0.39	4.96e-6	Childhood ear infection;
TGCT	cis	rs4786125	0.665	rs1873704	chr16:6907021	C/G	cg03623568	chr16:6915990	A2BP1	-0.41	-6.11	-0.48	1.21e-8	Heart rate variability traits (SDNN);
TGCT	cis	rs10782582	0.609	rs5745485	chr1:76349534	C/G	cg10523679	chr1:76189770	ACADM	-0.59	-5.42	-0.44	2.94e-7	Daytime sleep phenotypes;
TGCT	cis	rs13064411	0.735	rs10511326	chr3:113216325	T/C	cg18753928	chr3:113234510	CCDC52	-0.7	-5.75	-0.46	6.6e-8	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs6882046	0.533	rs599402	chr5:88043656	G/C	cg22951263	chr5:87985283	NA	-0.55	-5.88	-0.47	3.54e-8	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs3741489	1.000	rs11147098	chr12:133406374	G/A	cg08320014	chr12:133707169	ZNF10	-1.24	-4.54	-0.38	1.31e-5	Cognitive function;
TGCT	cis	rs4389656	0.857	rs453536	chr5:6736458	T/G	cg10857441	chr5:6722123	POLS	-0.22	-4.74	-0.39	5.75e-6	Coronary artery disease;
TGCT	cis	rs7336332	0.598	rs45622135	chr13:28011594	T/C	cg22138327	chr13:27999177	GTF3A	0.81	6.35	0.5	3.66e-9	Weight;
TGCT	cis	rs28595532	0.920	rs116550416	chr4:119753467	A/C	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs317689	0.819	rs317683	chr12:69713630	T/G	cg20891283	chr12:69753455	YEATS4	0.54	4.49	0.37	1.61e-5	Response to diuretic therapy;
TGCT	cis	rs7584330	0.910	rs880930	chr2:238396872	G/C	cg14458575	chr2:238380390	NA	0.5	7.15	0.54	6.63e-11	Prostate cancer;
TGCT	cis	rs9436747	0.667	rs11208674	chr1:66039317	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	-0.52	-4.83	-0.4	3.88e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs4455778	0.580	rs3924857	chr7:49121682	C/G	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs4642101	0.618	rs9877079	chr3:12821287	A/G	cg05775895	chr3:12838266	CAND2	0.92	11.11	0.71	2.53e-20	QRS complex (12-leadsum);
TGCT	cis	rs17376456	0.877	rs12153506	chr5:93360953	T/G	cg25358565	chr5:93447407	FAM172A	0.92	8.4	0.6	8.88e-14	Diabetic retinopathy;
TGCT	cis	rs7666738	0.724	rs28451676	chr4:98966990	C/T	cg05340658	chr4:99064831	C4orf37	0.53	5.92	0.47	2.92e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2455799	0.559	rs2345741	chr3:15919575	A/G	cg12172478	chr3:16357591	RFTN1	-0.36	-5.3	-0.43	5.07e-7	Mean platelet volume;
TGCT	cis	rs1538970	0.924	rs7528573	chr1:45913860	T/C	cg05343316	chr1:45956843	TESK2	0.76	6.19	0.49	7.93e-9	Platelet count;
TGCT	cis	rs1865760	0.713	rs1130000	chr6:25985396	A/G	cg16482183	chr6:26056742	HIST1H1C	0.54	4.77	0.39	5.15e-6	Height;
TGCT	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg04944784	chr2:26401820	FAM59B	-0.76	-6.24	-0.49	6.46e-9	Gut microbiome composition (summer);
TGCT	trans	rs1814175	0.754	rs28663627	chr11:50048829	C/T	cg15704280	chr7:45808275	SEPT13	-0.72	-8.47	-0.61	6.02e-14	Height;
TGCT	cis	rs1008375	0.933	rs7689101	chr4:17694034	G/A	cg18681998	chr4:17616180	MED28	0.78	7.27	0.55	3.58e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9640161	0.789	rs3735172	chr7:150028958	C/T	cg17279839	chr7:150038598	RARRES2	-0.43	-4.65	-0.39	8.28e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs910316	1.000	rs7145159	chr14:75583268	A/G	cg08847533	chr14:75593920	NEK9	0.97	10.85	0.7	1.1e-19	Height;
TGCT	cis	rs6500602	0.727	rs11644481	chr16:4581002	T/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.32	6.01	0.48	1.9e-8	Schizophrenia;
TGCT	cis	rs7666738	0.830	rs13110498	chr4:98959150	G/A	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28595532	0.920	rs115430947	chr4:119737149	C/A	cg21605333	chr4:119757512	SEC24D	1.61	8.95	0.63	4.36e-15	Cannabis dependence symptom count;
TGCT	cis	rs8031584	0.918	rs34693097	chr15:31253984	A/G	cg08704250	chr15:31115839	NA	-0.35	-4.94	-0.41	2.47e-6	Huntington's disease progression;
TGCT	cis	rs12497850	0.864	rs12493001	chr3:49181885	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.5	-4.55	-0.38	1.25e-5	Parkinson's disease;
TGCT	cis	rs1552244	0.766	rs34232505	chr3:10186216	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.53	-6.55	-0.51	1.37e-9	Alzheimer's disease;
TGCT	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7081476	0.579	rs11015436	chr10:27259820	G/A	cg15286905	chr10:27530250	ACBD5	-0.62	-4.62	-0.38	9.52e-6	Age-related diseases and mortality;Age-related diseases, mortality and associated endophenotypes;
TGCT	cis	rs3806843	0.966	rs3806844	chr5:140206263	A/T	cg19875535	chr5:140030758	IK	0.37	6.16	0.48	9.4e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2463822	0.925	rs72923272	chr11:62166832	G/A	cg06239285	chr11:62104954	ASRGL1	-0.89	-5.9	-0.47	3.19e-8	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs651907	0.514	rs11706494	chr3:101509475	A/T	cg11279151	chr3:101281821	RG9MTD1	-0.31	-6.4	-0.5	2.91e-9	Colorectal cancer;
TGCT	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg17554472	chr22:41940697	POLR3H	-0.43	-4.74	-0.39	5.78e-6	Vitiligo;
TGCT	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg06850241	chr22:41845214	NA	0.28	4.45	0.37	1.92e-5	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs10465746	0.846	rs9700285	chr1:84336685	G/A	cg10977910	chr1:84465055	TTLL7	0.63	6.19	0.49	8.08e-9	Obesity-related traits;
TGCT	cis	rs6740322	0.841	rs10210507	chr2:43556636	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.39	-6.58	-0.51	1.17e-9	Coronary artery disease;
TGCT	cis	rs2862064	0.685	rs2862066	chr5:156447395	T/G	cg12943317	chr5:156479607	HAVCR1	-0.39	-5.26	-0.43	6.24e-7	Platelet count;
TGCT	cis	rs4601821	0.823	rs17115439	chr11:113264272	T/C	cg14159747	chr11:113255604	NA	0.39	4.9	0.4	2.99e-6	Alcoholic chronic pancreatitis;
TGCT	cis	rs881375	0.902	rs7021880	chr9:123673890	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.44	-4.77	-0.39	4.98e-6	Rheumatoid arthritis;
TGCT	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	trans	rs208520	0.690	rs1100981	chr6:66852052	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-10.43	-0.68	1.13e-18	Exhaled nitric oxide output;
TGCT	cis	rs6087990	0.871	rs4911252	chr20:31330115	A/G	cg13636640	chr20:31349939	DNMT3B	-1.02	-14.79	-0.8	3.8e-29	Ulcerative colitis;
TGCT	cis	rs317865	0.737	rs73234642	chr4:16186730	G/C	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.8	5.2	0.42	8.01e-7	Kidney disease (early stage) in type 1 diabetes;
TGCT	cis	rs9291683	0.588	rs2240721	chr4:10020564	G/A	cg11266682	chr4:10021025	SLC2A9	0.69	10.28	0.68	2.66e-18	Bone mineral density;
TGCT	cis	rs9584850	0.874	rs3742136	chr13:99102607	C/T	cg15168958	chr13:99100528	FARP1	-0.24	-4.52	-0.38	1.4e-5	Neuroticism;
TGCT	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg22963979	chr7:1858916	MAD1L1	-0.34	-5.25	-0.43	6.44e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs9611565	0.729	rs137831	chr22:41903813	A/C	cg06481639	chr22:41940642	POLR3H	-0.61	-5.33	-0.43	4.41e-7	Vitiligo;
TGCT	cis	rs9549260	0.816	rs7324090	chr13:41253958	A/T	cg21288729	chr13:41239152	FOXO1	1.0	10.16	0.67	5.24e-18	Red blood cell count;
TGCT	cis	rs10782582	0.609	rs5745553	chr1:76379135	A/T	cg22875332	chr1:76189707	ACADM	-0.44	-4.45	-0.37	1.89e-5	Daytime sleep phenotypes;
TGCT	cis	rs7412746	0.611	rs9661876	chr1:150910911	C/T	cg09365446	chr1:150670422	GOLPH3L	0.34	4.71	0.39	6.58e-6	Melanoma;
TGCT	cis	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.68	6.71	0.52	6.09e-10	Eosinophil percentage of white cells;
TGCT	cis	rs7208859	0.623	rs216439	chr17:28927884	T/C	cg13385521	chr17:29058706	SUZ12P	0.81	4.87	0.4	3.39e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs12681287	0.752	rs9297861	chr8:87254730	G/C	cg27223183	chr8:87520930	FAM82B	-0.81	-5.66	-0.45	9.9e-8	Caudate activity during reward;
TGCT	cis	rs2013441	1.000	rs12451216	chr17:20025840	C/A	cg23224458	chr17:20280056	CCDC144C	0.39	4.7	0.39	6.83e-6	Obesity-related traits;
TGCT	cis	rs7617773	0.780	rs13081169	chr3:48356797	G/A	cg11946769	chr3:48343235	NME6	0.82	7.09	0.54	9.1e-11	Coronary artery disease;
TGCT	cis	rs986417	1.000	rs1254270	chr14:60843134	G/T	cg27398547	chr14:60952738	C14orf39	-1.37	-8.31	-0.6	1.44e-13	Gut microbiota (bacterial taxa);
TGCT	cis	rs79349575	0.783	rs12602933	chr17:47029280	G/C	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.52	-0.38	1.44e-5	Type 2 diabetes;
TGCT	cis	rs9436747	0.615	rs2105462	chr1:66047880	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.56	5.03	0.41	1.69e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs6988636	1.000	rs10505430	chr8:124191933	A/G	cg27053337	chr8:124217698	FAM83A	-0.58	-4.81	-0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs7917772	0.503	rs11191321	chr10:104293412	C/T	cg05855489	chr10:104503620	C10orf26	-0.58	-5.06	-0.41	1.47e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs8028182	0.636	rs28610581	chr15:75812474	A/G	cg20655648	chr15:75932815	IMP3	0.6	4.65	0.38	8.54e-6	Sudden cardiac arrest;
TGCT	cis	rs6922617	0.685	rs6908026	chr6:41345896	G/A	cg07798131	chr6:41471673	NA	0.97	4.79	0.4	4.65e-6	Alzheimer's disease biomarkers;
TGCT	cis	rs17221829	0.965	rs10830362	chr11:89457908	T/C	cg02982614	chr11:89391479	FOLH1B	-0.27	-4.88	-0.4	3.23e-6	Anxiety in major depressive disorder;
TGCT	cis	rs7173743	0.525	rs7175271	chr15:79144509	A/G	cg00540400	chr15:79124168	NA	-0.18	-4.52	-0.38	1.4e-5	Coronary artery disease;
TGCT	cis	rs6882076	1.000	rs6874202	chr5:156391628	T/C	cg12943317	chr5:156479607	HAVCR1	-0.29	-5.6	-0.45	1.3e-7	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
TGCT	cis	rs7072216	0.727	rs10748728	chr10:100171198	C/T	cg26618903	chr10:100175079	PYROXD2	-0.4	-4.49	-0.37	1.64e-5	Metabolite levels;
TGCT	cis	rs2469997	0.925	rs2447180	chr8:120355728	T/G	cg00681363	chr8:120844660	TAF2	0.65	4.52	0.38	1.45e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs4851254	0.961	rs11680485	chr2:100749744	A/G	cg23118464	chr2:100721844	AFF3	0.71	5.28	0.43	5.6e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs262150	1.000	rs262154	chr7:158773936	G/A	cg19418458	chr7:158789849	NA	-0.46	-4.66	-0.39	7.89e-6	Facial morphology (factor 20);
TGCT	cis	rs12048904	0.512	rs932798	chr1:101249355	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.83	-7.11	-0.54	7.95e-11	Multiple sclerosis;
TGCT	cis	rs3935685	0.874	rs4578613	chr15:78002360	A/T	cg03457338	chr15:78040120	NA	-0.23	-5.79	-0.46	5.55e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs13004237	1	rs13004237	chr2:172833139	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.81	-7.08	-0.54	9.26e-11	Schizophrenia;
TGCT	cis	rs2688608	0.618	rs28553894	chr10:75489843	C/A	cg23231163	chr10:75533350	FUT11	-0.29	-4.87	-0.4	3.37e-6	Inflammatory bowel disease;
TGCT	cis	rs10465746	0.935	rs12133778	chr1:84367626	A/G	cg10977910	chr1:84465055	TTLL7	0.63	6.19	0.49	8.08e-9	Obesity-related traits;
TGCT	cis	rs3740393	0.562	rs2297450	chr10:104503174	T/C	cg05855489	chr10:104503620	C10orf26	0.74	6.05	0.48	1.57e-8	Microalbuminuria;
TGCT	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg03452623	chr4:187889614	NA	0.37	5.71	0.46	7.99e-8	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg17830980	chr10:43048298	ZNF37B	-0.86	-11.18	-0.71	1.68e-20	Extrinsic epigenetic age acceleration;
TGCT	trans	rs9650657	0.572	rs4841465	chr8:10819854	C/T	cg06636001	chr8:8085503	FLJ10661	-0.86	-8.42	-0.6	7.64e-14	Neuroticism;
TGCT	cis	rs6988636	1.000	rs28624331	chr8:124190768	G/A	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs7208859	0.673	rs2433	chr17:29226228	T/C	cg14008862	chr17:28927542	LRRC37B2	0.72	4.66	0.39	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs62103177	0.810	rs62103187	chr18:77627633	G/C	cg12964065	chr18:77638022	KCNG2	0.37	4.76	0.39	5.4e-6	Opioid sensitivity;
TGCT	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg03188948	chr7:1209495	NA	0.59	4.82	0.4	4.06e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs6500602	0.727	rs7193136	chr16:4580034	C/T	cg09549813	chr16:4587862	C16orf5	-0.28	-4.51	-0.38	1.5e-5	Schizophrenia;
TGCT	cis	rs67340775	0.541	rs200968	chr6:27859568	T/C	cg26587870	chr6:27730563	NA	-0.31	-4.48	-0.37	1.67e-5	Lung cancer in ever smokers;
TGCT	cis	rs3902035	0.964	rs1891714	chr6:119009444	A/G	cg07617317	chr6:118971624	C6orf204	0.43	5.01	0.41	1.79e-6	QT interval;
TGCT	cis	rs7584330	0.910	rs7606177	chr2:238394913	G/C	cg08992911	chr2:238395768	MLPH	0.63	5.21	0.42	7.75e-7	Prostate cancer;
TGCT	cis	rs2439831	0.850	rs8042868	chr15:43939642	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.48	0.37	1.69e-5	Lung cancer in ever smokers;
TGCT	cis	rs2932538	0.922	rs6658555	chr1:113098534	C/T	cg10983938	chr1:113465962	AFARP1;SLC16A1	0.22	4.64	0.38	8.78e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs35146811	0.695	rs858509	chr7:99821470	A/G	cg22906224	chr7:99728672	NA	-0.5	-4.51	-0.38	1.48e-5	Coronary artery disease;
TGCT	cis	rs10838634	1.000	rs7938960	chr11:46877082	T/C	cg18332754	chr11:46939436	LRP4	0.89	4.77	0.39	5.13e-6	Schizophrenia;
TGCT	cis	rs3091242	0.900	rs1883427	chr1:25744468	C/T	cg09222892	chr1:25734099	RHCE	-0.43	-6.92	-0.53	2.1e-10	Erythrocyte sedimentation rate;
TGCT	cis	rs7703051	0.513	rs59014134	chr5:74589385	C/T	cg19683494	chr5:74908142	NA	0.75	7.29	0.55	3.18e-11	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
TGCT	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg06028808	chr11:68637592	NA	0.52	6.73	0.52	5.54e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg04944784	chr2:26401820	FAM59B	-0.68	-6.07	-0.48	1.45e-8	Gut microbiome composition (summer);
TGCT	cis	rs1985732	1	rs1985732	chr6:26376161	A/G	cg05738196	chr6:26577821	NA	-0.57	-5.55	-0.45	1.66e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs10782582	0.593	rs2147039	chr1:76143166	C/T	cg10523679	chr1:76189770	ACADM	-0.71	-7.4	-0.55	1.81e-11	Daytime sleep phenotypes;
TGCT	cis	rs17001868	1.000	rs17001868	chr22:40778231	A/C	cg07138101	chr22:40742427	ADSL	0.69	4.65	0.39	8.38e-6	Mammographic density (dense area);
TGCT	cis	rs4499344	0.730	rs2545357	chr19:33104610	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	8.81	0.62	9.52e-15	Mean platelet volume;
TGCT	cis	rs453301	0.686	rs13252797	chr8:8861430	A/G	cg06636001	chr8:8085503	FLJ10661	0.66	5.23	0.43	6.87e-7	Joint mobility (Beighton score);
TGCT	cis	rs2204008	0.806	rs3922574	chr12:38329069	C/T	cg13010199	chr12:38710504	ALG10B	0.58	4.55	0.38	1.26e-5	Bladder cancer;
TGCT	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.47	0.56	1.28e-11	Prudent dietary pattern;
TGCT	cis	rs56176327	0.600	rs7628207	chr3:49754970	T/C	cg05785598	chr3:49045655	WDR6	0.42	5.24	0.43	6.67e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2832191	0.791	rs2832198	chr21:30498240	C/T	cg08807101	chr21:30365312	RNF160	0.63	5.87	0.47	3.66e-8	Dental caries;
TGCT	cis	rs11190604	1.000	rs2495739	chr10:102335507	C/T	cg23241863	chr10:102295624	HIF1AN	0.67	4.9	0.4	2.99e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs644799	0.965	rs2950522	chr11:95524719	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	10.57	0.69	5.17e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9611565	0.546	rs34077262	chr22:42061639	A/G	cg06481639	chr22:41940642	POLR3H	0.61	5.3	0.43	5.06e-7	Vitiligo;
TGCT	cis	rs1903068	0.853	rs12331471	chr4:56001509	T/C	cg09978860	chr4:56023921	NA	0.57	6.47	0.5	2.1e-9	Endometriosis;
TGCT	cis	rs4478858	0.684	rs7544946	chr1:31749736	T/C	cg07478791	chr1:31886160	SERINC2	-0.49	-4.91	-0.4	2.82e-6	Alcohol dependence;
TGCT	cis	rs5760092	0.755	rs5760096	chr22:24247310	A/G	cg15242686	chr22:24348715	GSTTP1	0.44	5.5	0.44	2.06e-7	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	trans	rs2243480	0.803	rs13224048	chr7:65993766	G/A	cg07424592	chr7:64974309	NA	1.31	8.32	0.6	1.36e-13	Diabetic kidney disease;
TGCT	cis	rs12497850	0.931	rs7616815	chr3:48779715	C/T	cg05785598	chr3:49045655	WDR6	0.34	4.61	0.38	9.92e-6	Parkinson's disease;
TGCT	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg03934478	chr11:495069	RNH1	0.35	5.89	0.47	3.34e-8	Body mass index;
TGCT	cis	rs981844	0.683	rs1105495	chr4:154756867	T/C	cg14289246	chr4:154710475	SFRP2	-0.96	-8.97	-0.63	3.91e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.61	-5.07	-0.41	1.42e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs1857353	1.000	rs74089232	chr1:75884420	T/C	cg11838876	chr1:75668600	SLC44A5	-0.51	-4.81	-0.4	4.23e-6	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs7826238	0.623	rs2976893	chr8:8338219	G/T	cg15556689	chr8:8085844	FLJ10661	-0.56	-5.12	-0.42	1.11e-6	Systolic blood pressure;
TGCT	cis	rs6430585	0.591	rs12475553	chr2:136483355	G/T	cg07169764	chr2:136633963	MCM6	1.12	10.49	0.69	8.04e-19	Corneal structure;
TGCT	cis	rs600550	0.857	rs12221613	chr11:60002262	A/C	cg18570331	chr11:60101691	MS4A6E	0.5	4.45	0.37	1.89e-5	Lipoprotein-associated phospholipase A2 activity and mass;
TGCT	cis	rs36051895	0.632	rs12337480	chr9:5134567	T/A	cg02405213	chr9:5042618	JAK2	-0.75	-10.52	-0.69	6.97e-19	Pediatric autoimmune diseases;
TGCT	cis	rs8103278	1.000	rs17571725	chr19:46290822	C/T	cg11657440	chr19:46296263	DMWD	-0.58	-5.71	-0.46	7.73e-8	Coronary artery disease;
TGCT	cis	rs7089973	0.604	rs61596353	chr10:116597763	T/C	cg03647239	chr10:116582469	FAM160B1	0.59	5.74	0.46	6.72e-8	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs4906332	0.933	rs4906330	chr14:103971202	T/G	cg26031613	chr14:104095156	KLC1	-0.54	-4.66	-0.39	8.15e-6	Coronary artery disease;
TGCT	cis	rs2120019	0.935	rs12591119	chr15:75355944	A/G	cg17294928	chr15:75287854	SCAMP5	-0.84	-6.3	-0.49	4.75e-9	Blood trace element (Zn levels);
TGCT	cis	rs78487399	0.665	rs17031016	chr2:43764442	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.41	-5.35	-0.43	4.09e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg09737314	chr17:6899359	ALOX12	0.49	5.22	0.42	7.18e-7	Tonsillectomy;
TGCT	cis	rs868036	0.681	rs28688285	chr15:68110297	T/C	cg05925327	chr15:68127851	NA	-0.48	-4.46	-0.37	1.83e-5	Restless legs syndrome;
TGCT	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg25811766	chr13:21894605	NA	0.26	5.27	0.43	5.79e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	cis	rs9733	0.596	rs12086472	chr1:150697710	G/A	cg04414720	chr1:150670196	GOLPH3L	0.37	4.91	0.4	2.76e-6	Tonsillectomy;
TGCT	cis	rs751728	0.664	rs12190029	chr6:33749152	T/A	cg13859433	chr6:33739653	LEMD2	-0.32	-5.64	-0.45	1.1e-7	Crohn's disease;
TGCT	cis	rs2836950	0.501	rs35994303	chr21:40686020	C/T	cg22974920	chr21:40686053	BRWD1	-0.51	-4.53	-0.38	1.35e-5	Menarche (age at onset);
TGCT	cis	rs7666738	0.830	rs921521	chr4:98838339	A/G	cg17366294	chr4:99064904	C4orf37	0.72	7.56	0.56	7.78e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg22920501	chr2:26401640	FAM59B	0.81	6.36	0.5	3.52e-9	Gut microbiome composition (summer);
TGCT	cis	rs4891159	0.790	rs7234653	chr18:74111988	C/T	cg24786174	chr18:74118243	ZNF516	-0.62	-9.75	-0.66	5.12e-17	Longevity;
TGCT	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.14	0.42	1.06e-6	Prudent dietary pattern;
TGCT	cis	rs936229	0.768	rs11072509	chr15:75114374	C/G	cg10253484	chr15:75165896	SCAMP2	-0.66	-5.34	-0.43	4.28e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
TGCT	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2439831	1.000	rs2254321	chr15:43707542	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	6.22	0.49	6.97e-9	Lung cancer in ever smokers;
TGCT	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.05	-0.48	1.57e-8	Gut microbiome composition (summer);
TGCT	cis	rs6570726	0.791	rs446362	chr6:145878716	G/T	cg23711669	chr6:146136114	FBXO30	0.89	9.93	0.67	1.82e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1348850	0.793	rs12990917	chr2:178487259	T/G	cg22681709	chr2:178499509	PDE11A	-0.47	-5.66	-0.45	9.97e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs2072499	0.966	rs2842882	chr1:156165342	T/G	cg06970220	chr1:156163860	SLC25A44	0.73	6.46	0.5	2.13e-9	Testicular germ cell tumor;
TGCT	cis	rs7412746	0.658	rs4970988	chr1:150950062	A/G	cg09365446	chr1:150670422	GOLPH3L	-0.35	-4.93	-0.41	2.54e-6	Melanoma;
TGCT	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg19774624	chr17:42201019	HDAC5	-0.84	-10.18	-0.67	4.67e-18	Total body bone mineral density;
TGCT	cis	rs72781680	0.898	rs12623333	chr2:24111823	T/G	cg08917208	chr2:24149416	ATAD2B	0.78	4.79	0.4	4.69e-6	Lymphocyte counts;
TGCT	cis	rs1153858	1.000	rs7163720	chr15:45639374	G/A	cg26924012	chr15:45694286	SPATA5L1	1.07	14.56	0.79	1.32e-28	Homoarginine levels;
TGCT	cis	rs7178572	0.568	rs11853460	chr15:77515319	C/T	cg15453836	chr15:77711506	NA	-0.44	-4.92	-0.4	2.67e-6	Type 2 diabetes;
TGCT	cis	rs12579753	0.879	rs12829053	chr12:82161926	T/A	cg07988820	chr12:82153109	PPFIA2	-0.68	-7.51	-0.56	1.01e-11	Resting heart rate;
TGCT	cis	rs7584330	0.780	rs9973650	chr2:238380266	G/A	cg14458575	chr2:238380390	NA	0.46	7.57	0.56	7.49e-12	Prostate cancer;
TGCT	cis	rs2730245	0.583	rs2788473	chr7:158649280	T/C	cg24397884	chr7:158709396	WDR60	0.37	4.73	0.39	6.11e-6	Height;
TGCT	cis	rs2235642	0.928	rs2076435	chr16:1607574	C/T	cg10465839	chr16:1584050	IFT140;TMEM204	-0.29	-4.83	-0.4	3.88e-6	Coronary artery disease;
TGCT	cis	rs7818688	0.697	rs11782590	chr8:95970158	G/C	cg16049864	chr8:95962084	TP53INP1	0.54	4.64	0.38	8.87e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs28785552	0.897	rs7259466	chr19:53239369	G/A	cg04754360	chr19:53238445	ZNF611	-0.67	-5.42	-0.44	2.95e-7	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs11098499	0.754	rs11732087	chr4:120239831	A/G	cg09307838	chr4:120376055	NA	0.6	5.78	0.46	5.75e-8	Corneal astigmatism;
TGCT	cis	rs9611565	0.879	rs4820437	chr22:41761290	T/C	cg13695892	chr22:41940480	POLR3H	-0.85	-8.45	-0.6	6.59e-14	Vitiligo;
TGCT	cis	rs586688	0.625	rs481966	chr1:201655746	A/G	cg07139329	chr1:201708558	NAV1	-0.52	-5.32	-0.43	4.74e-7	Obesity-related traits;
TGCT	cis	rs2639990	1.000	rs609303	chr18:72895242	C/T	cg03972071	chr18:72917163	ZADH2	0.79	5.47	0.44	2.42e-7	Vascular endothelial growth factor levels;
TGCT	cis	rs9811920	0.598	rs793470	chr3:99548274	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.54	-6.49	-0.5	1.87e-9	Axial length;
TGCT	trans	rs2727020	0.595	rs10466496	chr11:49501514	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.36	-7.03	-0.53	1.25e-10	Coronary artery disease;
TGCT	cis	rs2115630	0.967	rs11073731	chr15:85355113	C/A	cg12501888	chr15:85177176	SCAND2	-0.51	-4.82	-0.4	4.19e-6	P wave terminal force;
TGCT	cis	rs523522	0.962	rs2233676	chr12:120933607	G/A	cg12219531	chr12:120966889	COQ5	0.83	7.27	0.55	3.46e-11	High light scatter reticulocyte count;
TGCT	cis	rs7959452	0.590	rs11177619	chr12:69758871	G/A	cg20891283	chr12:69753455	YEATS4	0.83	8.61	0.61	2.8e-14	Blood protein levels;
TGCT	cis	rs9811920	0.838	rs12488245	chr3:99835254	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.41	-4.47	-0.37	1.73e-5	Axial length;
TGCT	cis	rs2594989	0.733	rs9882513	chr3:11558377	T/C	cg00170343	chr3:11313890	ATG7	-0.68	-5.36	-0.43	3.97e-7	Circulating chemerin levels;
TGCT	trans	rs9992966	0.510	rs10017486	chr4:188634426	G/C	cg21037265	chr19:6481819	DENND1C	-0.48	-6.65	-0.51	8.5e-10	Trans fatty acid levels;
TGCT	cis	rs9894429	1.000	rs7406003	chr17:79597597	C/T	cg21028142	chr17:79581711	NPLOC4	0.29	6.86	0.52	2.94e-10	Eye color traits;
TGCT	cis	rs6049375	1.000	rs6049370	chr20:24046836	C/T	cg14741141	chr20:24973699	C20orf3	-0.76	-4.87	-0.4	3.33e-6	Erectile dysfunction and prostate cancer treatment;
TGCT	trans	rs1814175	0.615	rs4545557	chr11:50027329	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.84	-0.7	1.13e-19	Height;
TGCT	cis	rs13256369	0.851	rs13266562	chr8:8564065	T/C	cg17143192	chr8:8559678	CLDN23	0.57	5.35	0.43	4.09e-7	Obesity-related traits;
TGCT	cis	rs9948	0.655	rs17119562	chr2:97381844	G/C	cg01990225	chr2:97406019	LMAN2L	-1.01	-5.13	-0.42	1.08e-6	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs2996428	0.667	rs111640545	chr1:3752792	G/A	cg13057898	chr1:3703894	LRRC47	0.21	4.62	0.38	9.46e-6	Red cell distribution width;
TGCT	cis	rs7959452	0.640	rs12370042	chr12:69692420	C/G	cg14784868	chr12:69753453	YEATS4	0.68	6.95	0.53	1.81e-10	Blood protein levels;
TGCT	cis	rs7843479	0.965	rs13278159	chr8:21799737	C/A	cg17168535	chr8:21777572	XPO7	0.65	5.99	0.47	2.14e-8	Mean corpuscular volume;
TGCT	cis	rs3780378	0.935	rs7875908	chr9:5081334	C/T	cg02405213	chr9:5042618	JAK2	-0.62	-8.3	-0.6	1.48e-13	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs12477438	0.520	rs2171359	chr2:99795360	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.82	0.62	8.67e-15	Chronic sinus infection;
TGCT	cis	rs7572733	0.534	rs1518365	chr2:198809410	T/C	cg00792783	chr2:198669748	PLCL1	0.57	5.23	0.43	6.99e-7	Dermatomyositis;
TGCT	cis	rs7481584	0.624	rs1077335	chr11:3030524	A/G	cg26513837	chr11:3014269	NAP1L4	-0.44	-4.51	-0.38	1.51e-5	Calcium levels;
TGCT	cis	rs13418410	0.539	rs35866672	chr2:33842174	G/A	cg04131969	chr2:33951647	MYADML	-0.78	-7.55	-0.56	8.23e-12	Non-response to antidepressants and depression;
TGCT	cis	rs1828853	1.000	rs1403275	chr11:82111758	A/C	cg08066407	chr11:81789082	NA	0.67	4.8	0.4	4.55e-6	Curve progression in adolescent idiopathic scoliosis;
TGCT	cis	rs2153535	0.580	rs9505467	chr6:8520219	G/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.01	0.41	1.86e-6	Motion sickness;
TGCT	cis	rs8013055	0.898	rs8004007	chr14:105971435	G/C	cg23356831	chr14:105996513	TMEM121	0.41	6.39	0.5	3.04e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs7582180	0.764	rs7425449	chr2:100928393	A/G	cg14675211	chr2:100938903	LONRF2	0.52	4.98	0.41	2.1e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6582630	0.555	rs10880520	chr12:38464111	C/T	cg26384229	chr12:38710491	ALG10B	0.83	7.6	0.56	6.18e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs12541335	0.692	rs2290274	chr8:22214374	C/T	cg26039829	chr8:22132926	PIWIL2	0.28	5.2	0.42	8.03e-7	Hypertriglyceridemia;
TGCT	cis	rs2299587	0.554	rs2073566	chr8:17743655	G/A	cg04898035	chr8:17640624	MTUS1	-0.2	-4.67	-0.39	7.77e-6	Economic and political preferences;
TGCT	cis	rs2180341	1.000	rs9401950	chr6:127655485	C/T	cg27446573	chr6:127587934	RNF146	1.12	10.11	0.67	6.87e-18	Breast cancer;
TGCT	cis	rs11031096	0.711	rs11031156	chr11:4179021	C/T	cg18678763	chr11:4115507	RRM1	-0.44	-5.75	-0.46	6.43e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs1401999	0.966	rs1533682	chr3:183634879	A/G	cg01324343	chr3:183735012	ABCC5	0.84	11.21	0.71	1.41e-20	Anterior chamber depth;
TGCT	cis	rs2115630	1.000	rs11073730	chr15:85354596	C/T	cg17173187	chr15:85201210	NMB	-0.39	-4.76	-0.39	5.4e-6	P wave terminal force;
TGCT	cis	rs16966142	1.000	rs3890534	chr16:89835289	A/G	cg26513180	chr16:89883248	FANCA	-0.88	-5.33	-0.43	4.57e-7	Caffeine consumption;
TGCT	cis	rs12048904	0.930	rs11166529	chr1:101333733	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.48	4.56	0.38	1.21e-5	Multiple sclerosis;
TGCT	cis	rs10510102	0.872	rs12258234	chr10:123712343	G/C	cg23691251	chr10:123688108	ATE1	-0.59	-4.7	-0.39	6.75e-6	Breast cancer;
TGCT	trans	rs7248779	0.512	rs12610522	chr19:2413228	C/T	cg25835954	chr13:50160062	RCBTB1	0.79	7.51	0.56	9.92e-12	Cortisol levels (saliva);
TGCT	trans	rs797680	0.856	rs1335679	chr1:93645182	C/T	cg27528825	chr2:159282178	CCDC148	-0.35	-6.85	-0.52	3.08e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs7267979	0.903	rs6050482	chr20:25226327	C/T	cg16686733	chr20:25566563	NINL	0.55	5.58	0.45	1.47e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs17376456	0.757	rs10066431	chr5:93198204	A/G	cg25358565	chr5:93447407	FAM172A	0.98	7.67	0.57	4.38e-12	Diabetic retinopathy;
TGCT	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg21724239	chr8:58056113	NA	0.5	5.31	0.43	4.87e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6992820	0.900	rs34751862	chr8:56703319	C/G	cg06880721	chr8:56792545	LYN	-0.55	-4.68	-0.39	7.33e-6	Mean platelet volume;
TGCT	cis	rs7267979	0.816	rs374701	chr20:25483616	A/G	cg14121845	chr20:25566513	NINL	0.46	4.76	0.39	5.36e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs5762813	0.524	rs5762835	chr22:29230754	A/G	cg02153584	chr22:29168773	CCDC117	0.78	5.31	0.43	4.91e-7	Hematocrit;Hemoglobin concentration;
TGCT	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg20203395	chr5:56204925	C5orf35	-0.65	-4.56	-0.38	1.2e-5	Initial pursuit acceleration;
TGCT	cis	rs11764590	0.950	rs11514731	chr7:2051503	C/G	cg25834613	chr7:1915315	MAD1L1	-0.52	-5.06	-0.41	1.45e-6	Neuroticism;
TGCT	cis	rs11920090	0.932	rs56819515	chr3:170712913	T/A	cg07434518	chr3:170136327	CLDN11	-0.59	-4.45	-0.37	1.88e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
TGCT	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg24829409	chr8:58192753	C8orf71	-0.59	-4.97	-0.41	2.17e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs992157	0.764	rs3731861	chr2:219191256	T/C	cg00012203	chr2:219082015	ARPC2	-0.73	-6.61	-0.51	1.04e-9	Colorectal cancer;
TGCT	cis	rs616402	0.564	rs602601	chr1:10567058	C/T	cg17425144	chr1:10567563	PEX14	0.56	8.14	0.59	3.58e-13	Breast size;
TGCT	cis	rs9910055	0.920	rs2855818	chr17:42290015	G/A	cg19774624	chr17:42201019	HDAC5	-0.82	-7.94	-0.58	1.04e-12	Total body bone mineral density;
TGCT	cis	rs9611519	0.894	rs13053242	chr22:41459486	G/A	cg13695892	chr22:41940480	POLR3H	-0.54	-4.75	-0.39	5.56e-6	Neuroticism;
TGCT	cis	rs174601	0.861	rs174581	chr11:61606683	G/A	cg20584555	chr11:61717780	BEST1	-0.23	-4.45	-0.37	1.88e-5	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
TGCT	cis	rs910316	0.763	rs175042	chr14:75470833	A/T	cg08847533	chr14:75593920	NEK9	-0.84	-8.92	-0.63	5.19e-15	Height;
TGCT	cis	rs17221829	0.733	rs112601489	chr11:89365849	A/C	cg02982614	chr11:89391479	FOLH1B	-0.28	-4.88	-0.4	3.25e-6	Anxiety in major depressive disorder;
TGCT	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg13628971	chr7:2884303	GNA12	0.54	4.56	0.38	1.19e-5	Height;
TGCT	cis	rs2447097	0.935	rs2447094	chr17:2294048	A/C	cg27406664	chr17:2294951	MNT	0.3	6.7	0.52	6.41e-10	Autism spectrum disorder;
TGCT	cis	rs7246657	0.678	rs2972446	chr19:38129893	G/A	cg18154014	chr19:37997991	ZNF793	-0.69	-4.67	-0.39	7.7e-6	Coronary artery calcification;
TGCT	cis	rs10186029	0.623	rs10497996	chr2:213997865	T/C	cg08319019	chr2:214017104	IKZF2	0.53	4.48	0.37	1.64e-5	Systemic sclerosis;
TGCT	cis	rs7027203	0.964	rs7853688	chr9:96523254	C/A	cg14598338	chr9:96623480	NA	0.58	8.57	0.61	3.49e-14	DNA methylation (variation);
TGCT	cis	rs73110464	0.609	rs6580923	chr12:53358352	A/G	cg14581129	chr12:53358946	NA	-0.63	-6.78	-0.52	4.39e-10	Cancer (pleiotropy);
TGCT	cis	rs4660261	0.562	rs3011223	chr1:44318286	T/C	cg12908607	chr1:44402522	ARTN	-0.64	-7.66	-0.57	4.69e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs670523	0.804	rs12128541	chr1:156003992	A/G	cg05700447	chr1:155978627	NA	-0.18	-4.49	-0.37	1.62e-5	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs3772130	0.924	rs55643643	chr3:121440197	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.54	4.85	0.4	3.66e-6	Cognitive performance;
TGCT	cis	rs1865760	0.622	rs9295685	chr6:26071725	G/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.79	7.44	0.56	1.47e-11	Height;
TGCT	cis	rs36051895	0.664	rs10117501	chr9:5094246	G/A	cg02405213	chr9:5042618	JAK2	-0.78	-10.82	-0.7	1.31e-19	Pediatric autoimmune diseases;
TGCT	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg13257436	chr8:145726034	PPP1R16A	-0.32	-4.96	-0.41	2.27e-6	Age at first birth;
TGCT	cis	rs1887596	0.624	rs9579026	chr13:27123830	C/T	cg01312412	chr13:27282625	NA	0.26	4.59	0.38	1.09e-5	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs10507380	0.824	rs77168898	chr13:27921242	G/A	cg25543773	chr13:27185723	WASF3	0.34	4.83	0.4	3.97e-6	Electrocardiographic traits;
TGCT	cis	rs7772486	0.790	rs9399571	chr6:146282061	A/G	cg23711669	chr6:146136114	FBXO30	-0.87	-9.69	-0.66	6.98e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg25660036	chr4:7070649	GRPEL1	-0.68	-5.95	-0.47	2.6e-8	Monocyte percentage of white cells;
TGCT	cis	rs13217239	0.646	rs10946891	chr6:26973215	T/C	cg02458000	chr6:26745757	NA	0.5	4.61	0.38	9.84e-6	Schizophrenia;
TGCT	cis	rs727479	0.502	rs3825800	chr15:51506663	A/C	cg19946085	chr15:51559439	CYP19A1	-0.31	-4.52	-0.38	1.42e-5	Estradiol levels;
TGCT	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg11764359	chr7:65958608	NA	-0.54	-4.69	-0.39	7.03e-6	Aortic root size;
TGCT	cis	rs2153535	0.580	rs1932284	chr6:8477694	A/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs1401999	0.714	rs1533683	chr3:183635488	C/T	cg01324343	chr3:183735012	ABCC5	0.74	8.86	0.62	7.21e-15	Anterior chamber depth;
TGCT	cis	rs9381040	1.000	rs9381040	chr6:41154650	C/T	cg03526776	chr6:41159608	TREML2	0.34	6.97	0.53	1.62e-10	Alzheimer's disease (late onset);
TGCT	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg00684032	chr4:1343700	KIAA1530	0.23	4.95	0.41	2.36e-6	Obesity-related traits;
TGCT	cis	rs6977660	0.660	rs61670426	chr7:19790460	A/G	cg07541023	chr7:19748670	TWISTNB	0.85	4.84	0.4	3.74e-6	Thyroid stimulating hormone;
TGCT	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg01570182	chr17:44337453	NA	1.08	9.71	0.66	6.43e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs6831352	0.918	rs2602893	chr4:100044095	G/T	cg12011299	chr4:100065546	ADH4	0.43	5.02	0.41	1.71e-6	Alcohol dependence;
TGCT	trans	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg27523141	chr10:43048294	ZNF37B	0.73	8.58	0.61	3.32e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs992157	1.000	rs3731859	chr2:219124222	G/A	cg00012203	chr2:219082015	ARPC2	0.77	8.2	0.59	2.56e-13	Colorectal cancer;
TGCT	cis	rs7666738	0.830	rs1967980	chr4:98966426	C/G	cg05340658	chr4:99064831	C4orf37	0.53	5.93	0.47	2.84e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12142240	0.698	rs4372193	chr1:46853233	G/T	cg14993813	chr1:46806288	NSUN4	-0.59	-4.86	-0.4	3.45e-6	Menopause (age at onset);
TGCT	cis	rs9388451	0.626	rs3799712	chr6:126075103	A/G	cg05901451	chr6:126070800	HEY2	-1.04	-12.94	-0.76	8.99e-25	Brugada syndrome;
TGCT	cis	rs3806843	0.547	rs246033	chr5:140332115	A/C	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs1008375	0.932	rs9291660	chr4:17663414	A/G	cg18681998	chr4:17616180	MED28	0.95	10.23	0.68	3.5e-18	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	4.67	0.39	7.7e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6545883	0.868	rs2518933	chr2:61797030	C/A	cg15711740	chr2:61764176	XPO1	-0.59	-5.71	-0.46	7.8e-8	Tuberculosis;
TGCT	cis	rs28595532	0.841	rs115907265	chr4:119730593	G/A	cg21605333	chr4:119757512	SEC24D	1.66	8.33	0.6	1.28e-13	Cannabis dependence symptom count;
TGCT	cis	rs231513	0.954	rs231498	chr17:41975251	C/G	cg26893861	chr17:41843967	DUSP3	-0.69	-5.16	-0.42	9.31e-7	Cognitive function;
TGCT	cis	rs3796352	1.000	rs58660500	chr3:53086573	C/T	cg27565382	chr3:53032988	SFMBT1	0.43	4.6	0.38	1.01e-5	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs2243480	0.666	rs1880311	chr7:65276752	G/C	cg07424592	chr7:64974309	NA	-1.4	-7.6	-0.56	6.46e-12	Diabetic kidney disease;
TGCT	cis	rs10992471	0.598	rs10761156	chr9:95171852	C/T	cg13798575	chr9:95087839	CENPP;NOL8	0.63	6.12	0.48	1.13e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs2688608	0.592	rs10762559	chr10:75486453	G/C	cg15838173	chr10:75533400	FUT11	-0.31	-5.02	-0.41	1.78e-6	Inflammatory bowel disease;
TGCT	cis	rs11249608	0.548	rs13156530	chr5:178475017	C/T	cg01312482	chr5:178451176	ZNF879	-0.5	-4.93	-0.41	2.55e-6	Pubertal anthropometrics;
TGCT	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.54	4.88	0.4	3.18e-6	Prudent dietary pattern;
TGCT	cis	rs7027203	0.717	rs7869328	chr9:96588782	A/G	cg13679303	chr9:96623674	NA	-0.67	-10.55	-0.69	5.94e-19	DNA methylation (variation);
TGCT	cis	rs4845570	0.749	rs11586446	chr1:151712488	A/G	cg07092448	chr1:151763213	TDRKH	-1.02	-7.36	-0.55	2.17e-11	Coronary artery disease;
TGCT	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg07507251	chr3:52567010	NT5DC2	0.48	6.91	0.53	2.24e-10	Bipolar disorder;
TGCT	cis	rs7119	0.700	rs2867311	chr15:77902191	A/C	cg27398640	chr15:77910606	LINGO1	0.32	6.7	0.52	6.54e-10	Type 2 diabetes;
TGCT	cis	rs7568458	0.709	rs11895399	chr2:85753806	C/A	cg17127132	chr2:85788382	GGCX	0.51	4.73	0.39	5.89e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs10746514	0.786	rs9308486	chr1:232246418	A/G	cg09506761	chr1:232265262	NA	0.44	4.54	0.38	1.32e-5	Response to statin therapy;
TGCT	cis	rs61935443	0.720	rs10859780	chr12:95282601	T/C	cg21533806	chr12:95267307	NA	0.52	4.49	0.37	1.61e-5	Schizophrenia;
TGCT	cis	rs7267979	1.000	rs448396	chr20:25440269	G/A	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg00149659	chr3:10157352	C3orf10	1.17	7.24	0.55	4.13e-11	Alzheimer's disease;
TGCT	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg27454412	chr7:1067447	C7orf50	0.57	4.46	0.37	1.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	trans	rs11722228	0.549	rs73212830	chr4:10078759	A/T	cg26043149	chr18:55253948	FECH	1.15	11.28	0.71	9.49e-21	Gout;Urate levels;Serum uric acid levels;
TGCT	trans	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-1.03	-13.16	-0.76	2.65e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs3796352	1.000	rs11710292	chr3:53117798	T/C	cg15956490	chr3:53032818	SFMBT1	0.5	5.38	0.43	3.65e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs950027	0.620	rs1719246	chr15:45625479	T/A	cg14582100	chr15:45693742	SPATA5L1	0.48	6.07	0.48	1.44e-8	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs4788439	0.901	rs8045116	chr16:24994761	G/A	cg07626409	chr16:25250191	ZKSCAN2	0.32	4.45	0.37	1.87e-5	Blood metabolite levels;
TGCT	cis	rs12643440	0.538	rs60281935	chr4:17143251	G/A	cg22650099	chr4:17144496	NA	-0.46	-4.7	-0.39	6.79e-6	Metabolite levels (Pyroglutamine);
TGCT	cis	rs6076065	0.707	rs2424555	chr20:23417705	A/G	cg11657817	chr20:23433608	CST11	0.3	5.14	0.42	1.04e-6	Facial morphology (factor 15, philtrum width);
TGCT	cis	rs7715806	0.500	rs17649362	chr5:75008958	C/T	cg19683494	chr5:74908142	NA	0.56	4.85	0.4	3.63e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs11627546	0.615	rs61980615	chr14:70366377	T/C	cg10496350	chr14:71275911	MAP3K9	-0.94	-4.44	-0.37	1.96e-5	Red blood cell traits;
TGCT	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg04546413	chr19:29218101	NA	0.76	6.73	0.52	5.48e-10	Methadone dose in opioid dependence;
TGCT	cis	rs7267979	1.000	rs2258617	chr20:25274318	C/T	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2445762	0.642	rs8041933	chr15:51617746	G/A	cg00184732	chr15:51633821	GLDN	0.52	5.35	0.43	4.11e-7	Hormone measurements;
TGCT	cis	rs28595532	0.920	rs114724233	chr4:119754918	T/A	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs151997	0.962	rs27271	chr5:50183369	A/G	cg06027927	chr5:50259733	NA	0.47	4.83	0.4	4e-6	Callous-unemotional behaviour;
TGCT	cis	rs7044106	0.718	rs1960421	chr9:123394894	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	6.78	0.52	4.27e-10	Hip circumference adjusted for BMI;
TGCT	cis	rs11105298	0.891	rs6538189	chr12:89885923	C/A	cg00757033	chr12:89920650	WDR51B	0.34	5.37	0.43	3.75e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs72945132	0.678	rs7113595	chr11:70236819	T/C	cg00319359	chr11:70116639	PPFIA1	1.0	7.12	0.54	7.76e-11	Coronary artery disease;
TGCT	cis	rs6430585	0.697	rs6724569	chr2:136516970	G/A	cg07169764	chr2:136633963	MCM6	1.21	11.47	0.72	3.36e-21	Corneal structure;
TGCT	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.29	-4.49	-0.37	1.64e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2404602	0.647	rs1443115	chr15:77041829	T/C	cg22467129	chr15:76604101	ETFA	0.47	4.58	0.38	1.13e-5	Blood metabolite levels;
TGCT	cis	rs644799	0.710	rs11021311	chr11:95505227	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.29	0.6	1.54e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs6740322	0.895	rs9309097	chr2:43554397	T/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.39	-6.58	-0.51	1.17e-9	Coronary artery disease;
TGCT	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.82	8.75	0.62	1.29e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs6121246	0.529	rs6060195	chr20:30185638	C/T	cg13852791	chr20:30311386	BCL2L1	0.69	4.54	0.38	1.33e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs7635838	0.718	rs2249051	chr3:11403234	G/A	cg00170343	chr3:11313890	ATG7	0.66	6.47	0.5	2.01e-9	HDL cholesterol;
TGCT	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	6.14	0.48	1.03e-8	Bipolar disorder;
TGCT	cis	rs7572733	0.555	rs7590828	chr2:198940251	A/G	cg00792783	chr2:198669748	PLCL1	-0.53	-4.82	-0.4	4.19e-6	Dermatomyositis;
TGCT	cis	rs6912958	0.967	rs6905947	chr6:88161949	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.64	-6.31	-0.49	4.58e-9	Monocyte percentage of white cells;
TGCT	cis	rs12971120	0.685	rs34780792	chr18:72173278	G/A	cg26446133	chr18:72167187	CNDP2	-0.36	-5.96	-0.47	2.48e-8	Refractive error;
TGCT	cis	rs1691799	0.867	rs1168341	chr12:66759080	G/C	cg16791601	chr12:66731901	HELB	-0.29	-6.18	-0.49	8.39e-9	White blood cell count (basophil);
TGCT	cis	rs3849570	0.500	rs9868037	chr3:81517244	A/T	cg07356753	chr3:81810745	GBE1	0.59	4.88	0.4	3.26e-6	Waist circumference;Body mass index;
TGCT	cis	rs60154123	0.505	rs115881613	chr1:210040369	C/T	cg12034118	chr1:209979487	IRF6	0.65	4.56	0.38	1.2e-5	Coronary artery disease;
TGCT	cis	rs4499344	0.526	rs10412141	chr19:33034189	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.68	-5.73	-0.46	7.27e-8	Mean platelet volume;
TGCT	cis	rs2806561	0.664	rs4620508	chr1:23307438	C/T	cg12483005	chr1:23474871	LUZP1	0.39	4.99	0.41	2.03e-6	Height;
TGCT	cis	rs7264396	0.561	rs6142470	chr20:34570579	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.28	-4.83	-0.4	4.01e-6	Total cholesterol levels;
TGCT	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	trans	rs62103177	0.810	rs62103191	chr18:77628769	C/G	cg05926928	chr17:57297772	GDPD1	1.22	11.16	0.71	1.85e-20	Opioid sensitivity;
TGCT	cis	rs7552404	1.000	rs4949876	chr1:76173377	C/T	cg10523679	chr1:76189770	ACADM	0.91	9.92	0.67	2.01e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.72	5.19	0.42	8.33e-7	Platelet count;
TGCT	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg03303774	chr4:1407052	NA	0.38	5.9	0.47	3.24e-8	Obesity-related traits;
TGCT	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2440129	0.632	rs13396	chr17:6905624	T/C	cg03407747	chr17:6899364	ALOX12	0.54	5.85	0.47	4.06e-8	Tonsillectomy;
TGCT	cis	rs910187	0.678	rs6018328	chr20:45813180	T/C	cg27589058	chr20:45804311	EYA2	-0.36	-7.88	-0.58	1.44e-12	Migraine;
TGCT	cis	rs7412746	0.634	rs12096831	chr1:150864113	T/G	cg04414720	chr1:150670196	GOLPH3L	0.39	4.64	0.38	8.63e-6	Melanoma;
TGCT	cis	rs2046867	0.908	rs9841994	chr3:72820503	A/C	cg25664220	chr3:72788482	NA	-0.53	-6.67	-0.51	7.68e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg06753367	chr22:24256600	NA	0.23	4.47	0.37	1.73e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs10791323	0.559	rs10750549	chr11:133730820	A/G	cg15485101	chr11:133734466	NA	0.42	5.26	0.43	6.25e-7	Childhood ear infection;
TGCT	cis	rs8084125	0.832	rs62105175	chr18:74948498	T/C	cg15443732	chr18:74961078	GALR1	0.48	4.7	0.39	6.75e-6	Obesity-related traits;
TGCT	cis	rs9457247	0.967	rs1794696	chr6:167396174	T/C	cg23791538	chr6:167370224	RNASET2	-0.53	-5.19	-0.42	8.38e-7	Crohn's disease;
TGCT	cis	rs2214681	0.521	rs2527049	chr7:147742084	A/G	cg23013736	chr7:148584684	NA	-0.23	-4.59	-0.38	1.08e-5	Bone mineral density;
TGCT	cis	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg13531842	chr10:38383804	ZNF37A	-0.39	-4.64	-0.38	8.78e-6	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7927592	0.513	rs556442	chr11:68192690	G/A	cg16797656	chr11:68205561	LRP5	-0.29	-5.11	-0.42	1.17e-6	Total body bone mineral density;
TGCT	trans	rs1005277	0.505	rs10827835	chr10:38150709	G/A	cg17830980	chr10:43048298	ZNF37B	0.73	8.42	0.6	7.98e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2798269	0.604	rs2185883	chr13:22157265	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.5	-4.45	-0.37	1.88e-5	PR segment;
TGCT	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg13695892	chr22:41940480	POLR3H	-0.91	-9.07	-0.63	2.18e-15	Vitiligo;
TGCT	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg20891558	chr2:74357851	NA	0.65	9.59	0.65	1.25e-16	Gestational age at birth (maternal effect);
TGCT	cis	rs910316	1.000	rs11623413	chr14:75588824	C/T	cg11812906	chr14:75593930	NEK9	-0.72	-7.17	-0.54	5.83e-11	Height;
TGCT	cis	rs929354	1.000	rs1182385	chr7:157040583	C/T	cg05182265	chr7:156933206	UBE3C	0.27	5.91	0.47	3.02e-8	Body mass index;
TGCT	cis	rs208515	0.525	rs10944870	chr6:66687757	G/C	cg07460842	chr6:66804631	NA	0.88	9.35	0.64	4.63e-16	Exhaled nitric oxide levels;
TGCT	cis	rs1215050	0.547	rs11097572	chr4:98627088	A/G	cg05340658	chr4:99064831	C4orf37	-0.41	-4.96	-0.41	2.3e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9859260	0.744	rs492288	chr3:195784210	C/T	cg22891161	chr3:195456627	MUC20	0.23	4.6	0.38	1.04e-5	Mean corpuscular volume;
TGCT	trans	rs11671005	0.504	rs3794964	chr19:59070916	T/C	cg22037779	chr5:139682734	PFDN1	-0.85	-6.91	-0.53	2.25e-10	Mean platelet volume;
TGCT	cis	rs6121246	0.529	rs6060142	chr20:30178028	A/G	cg18721089	chr20:30220636	NA	-0.57	-6.21	-0.49	7.33e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg11890956	chr21:40555474	PSMG1	1.13	12.1	0.74	1e-22	Cognitive function;
TGCT	cis	rs6570726	0.905	rs421032	chr6:145827771	A/G	cg23711669	chr6:146136114	FBXO30	0.7	6.46	0.5	2.12e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs17712049	1.000	rs62447153	chr7:48200023	G/A	cg16849860	chr7:48352531	ABCA13	0.32	5.26	0.43	6.19e-7	Refractive astigmatism;
TGCT	cis	rs7542091	0.635	rs985431	chr1:210043948	A/T	cg22029157	chr1:209979665	IRF6	0.64	6.1	0.48	1.23e-8	Monobrow;
TGCT	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg16423285	chr20:60520624	NA	-0.61	-6.46	-0.5	2.12e-9	Body mass index;
TGCT	cis	rs2440129	0.632	rs15966	chr17:6905643	T/C	cg19536664	chr17:6899085	ALOX12	0.39	6.1	0.48	1.23e-8	Tonsillectomy;
TGCT	trans	rs1814175	0.935	rs11040462	chr11:49683158	G/A	cg03929089	chr4:120376271	NA	-0.63	-7.14	-0.54	6.84e-11	Height;
TGCT	trans	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg17830980	chr10:43048298	ZNF37B	-0.85	-10.98	-0.7	5.08e-20	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg00814883	chr7:100076585	TSC22D4	-0.85	-8.62	-0.61	2.62e-14	Platelet count;
TGCT	cis	rs909674	0.865	rs5757683	chr22:39850174	G/A	cg11247378	chr22:39784982	NA	-0.72	-8.68	-0.61	1.9e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs7647973	0.626	rs62260723	chr3:49872124	T/C	cg05785598	chr3:49045655	WDR6	-0.42	-5.23	-0.42	7.1e-7	Menarche (age at onset);
TGCT	cis	rs9911578	0.935	rs7216698	chr17:57007495	G/A	cg05425664	chr17:57184151	TRIM37	-0.56	-5.42	-0.44	2.99e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1865760	1.000	rs9358893	chr6:25921761	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.65	6.21	0.49	7.42e-9	Height;
TGCT	cis	rs2013441	1.000	rs17686798	chr17:20029170	A/C	cg23224458	chr17:20280056	CCDC144C	-0.36	-4.47	-0.37	1.72e-5	Obesity-related traits;
TGCT	cis	rs1023500	0.505	rs134901	chr22:42683520	C/T	cg15557168	chr22:42548783	NA	-0.2	-4.68	-0.39	7.46e-6	Schizophrenia;
TGCT	cis	rs10851411	0.862	rs1060291	chr15:42820589	G/A	cg23803468	chr15:43513504	EPB42	0.29	5.33	0.43	4.57e-7	Glucose homeostasis traits;
TGCT	cis	rs6598955	1.000	rs6598955	chr1:26619649	C/T	cg04990556	chr1:26633338	UBXN11	0.86	10.39	0.68	1.4e-18	Obesity-related traits;
TGCT	cis	rs6570726	0.935	rs421268	chr6:145845558	A/T	cg23711669	chr6:146136114	FBXO30	0.68	6.67	0.51	7.58e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs77861329	1.000	rs28452586	chr3:52176007	A/G	cg08692210	chr3:52188851	WDR51A	0.81	4.57	0.38	1.17e-5	Macrophage inflammatory protein 1b levels;
TGCT	cis	rs2243480	1.000	rs958550	chr7:65635679	C/T	cg18252515	chr7:66147081	NA	1.13	7.12	0.54	7.8e-11	Diabetic kidney disease;
TGCT	cis	rs17401966	0.838	rs34636442	chr1:10427459	T/G	cg19773385	chr1:10388646	KIF1B	-0.23	-5.38	-0.44	3.57e-7	Hepatocellular carcinoma;
TGCT	cis	rs2795502	0.873	rs3123753	chr10:43404899	C/T	cg20628663	chr10:43360327	NA	0.36	5.45	0.44	2.66e-7	Blood protein levels;
TGCT	cis	rs2228479	0.618	rs72477006	chr16:89950299	G/C	cg06558623	chr16:89946397	TCF25	0.56	6.8	0.52	3.92e-10	Skin colour saturation;
TGCT	cis	rs6490294	0.904	rs4767264	chr12:112425746	C/T	cg10833066	chr12:111807467	FAM109A	-0.36	-5.9	-0.47	3.25e-8	Mean platelet volume;
TGCT	cis	rs76419734	0.850	rs17036341	chr4:106796829	C/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.95	4.74	0.39	5.71e-6	Post bronchodilator FEV1;
TGCT	cis	rs3087591	0.887	rs2905796	chr17:29537586	G/A	cg24425628	chr17:29625626	OMG;NF1	0.48	6.99	0.53	1.52e-10	Hip circumference;
TGCT	trans	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg21659725	chr3:3221576	CRBN	-0.73	-8.46	-0.6	6.37e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs9814567	0.964	rs9820150	chr3:134223011	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.96	-9.19	-0.64	1.16e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs6095298	0.595	rs1078624	chr20:47434385	A/G	cg12307787	chr20:48099359	KCNB1	0.41	4.44	0.37	1.95e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs1997103	0.954	rs1917769	chr7:55392325	T/A	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs1865760	0.566	rs4529296	chr6:26083135	C/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.78	7.49	0.56	1.15e-11	Height;
TGCT	cis	rs554111	0.656	rs3121071	chr1:21128420	C/T	cg01072550	chr1:21505969	NA	0.34	5.12	0.42	1.15e-6	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs523522	0.962	rs687873	chr12:121019634	G/A	cg12219531	chr12:120966889	COQ5	0.82	7.38	0.55	2.05e-11	High light scatter reticulocyte count;
TGCT	cis	rs10875746	0.904	rs11168422	chr12:48519505	T/G	cg20731937	chr12:48336164	NA	0.61	4.82	0.4	4.14e-6	Longevity (90 years and older);
TGCT	cis	rs67311347	1.000	rs7636719	chr3:40432084	C/T	cg17264618	chr3:40429014	ENTPD3	0.32	4.76	0.39	5.29e-6	Renal cell carcinoma;
TGCT	cis	rs7208859	0.623	rs11658022	chr17:29085359	A/T	cg14008862	chr17:28927542	LRRC37B2	0.77	4.61	0.38	9.76e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7267979	1.000	rs8125868	chr20:25324410	A/G	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9902453	1.000	rs4533340	chr17:28277951	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	7.0	0.53	1.44e-10	Coffee consumption (cups per day);
TGCT	cis	rs10986311	0.862	rs10818950	chr9:127130137	A/G	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.2	-4.95	-0.41	2.33e-6	Vitiligo;
TGCT	cis	rs6424115	0.800	rs6665733	chr1:24200158	T/C	cg15997130	chr1:24165203	NA	0.85	9.25	0.64	8.02e-16	Immature fraction of reticulocytes;
TGCT	cis	rs1532993	0.518	rs34218077	chr4:98602104	C/G	cg05340658	chr4:99064831	C4orf37	-0.42	-5.02	-0.41	1.72e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs8078723	0.714	rs3785550	chr17:38149727	C/T	cg17467752	chr17:38218738	THRA	-0.53	-5.37	-0.43	3.8e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs17253792	0.822	rs78395034	chr14:56069783	G/A	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs3087591	1.000	rs9904169	chr17:29572518	C/T	cg24425628	chr17:29625626	OMG;NF1	-0.47	-7.51	-0.56	1.01e-11	Hip circumference;
TGCT	cis	rs11627546	0.615	rs6573916	chr14:70366603	C/G	cg10496350	chr14:71275911	MAP3K9	-0.89	-4.5	-0.37	1.52e-5	Red blood cell traits;
TGCT	cis	rs17331151	0.573	rs28552648	chr3:52865593	G/A	cg27565382	chr3:53032988	SFMBT1	0.47	5.96	0.47	2.42e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg22963979	chr7:1858916	MAD1L1	0.38	6.01	0.48	1.91e-8	Bipolar disorder and schizophrenia;
TGCT	cis	rs28595532	0.920	rs10018977	chr4:119785229	C/T	cg21605333	chr4:119757512	SEC24D	1.44	8.24	0.6	2.03e-13	Cannabis dependence symptom count;
TGCT	cis	rs6840360	0.642	rs7657747	chr4:152394254	A/G	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.82e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7954584	0.813	rs1523261	chr12:122462877	C/A	cg21016266	chr12:122356598	WDR66	0.4	5.05	0.41	1.54e-6	Mean corpuscular volume;
TGCT	cis	rs4711350	0.765	rs756139	chr6:33755541	G/A	cg18005901	chr6:33739558	LEMD2	-0.59	-6.61	-0.51	1.01e-9	Schizophrenia;
TGCT	cis	rs9868809	0.772	rs2286651	chr3:48694147	G/A	cg00383909	chr3:49044727	WDR6	1.13	6.17	0.48	8.69e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs4824093	0.610	rs60036544	chr22:50264019	C/T	cg20569369	chr22:51173646	NA	0.28	4.69	0.39	7.23e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs8062405	1.000	rs4788095	chr16:28831359	T/C	cg09754948	chr16:28834200	ATXN2L	0.61	4.54	0.38	1.34e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs587847	0.558	rs638182	chr15:37658915	C/T	cg16890051	chr15:37175029	LOC145845	-0.39	-4.6	-0.38	1.03e-5	Intraocular pressure;
TGCT	cis	rs12142240	0.659	rs72677591	chr1:46818219	T/G	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs8016982	0.634	rs1035948	chr14:81682392	C/T	cg01989461	chr14:81687754	GTF2A1	0.81	8.55	0.61	3.82e-14	Schizophrenia;
TGCT	cis	rs17253792	0.571	rs112129578	chr14:56028415	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.69	4.46	0.37	1.81e-5	Putamen volume;
TGCT	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg17554472	chr22:41940697	POLR3H	-0.49	-5.24	-0.43	6.58e-7	Vitiligo;
TGCT	cis	rs7246657	0.722	rs6508736	chr19:38061757	A/G	cg03611452	chr19:38183253	ZNF781	0.58	4.64	0.38	8.62e-6	Coronary artery calcification;
TGCT	cis	rs56399783	0.803	rs7811164	chr7:2822416	G/A	cg19731401	chr7:2775893	GNA12	0.34	4.8	0.4	4.43e-6	Childhood ear infection;
TGCT	cis	rs3911569	0.511	rs530356	chr11:95069694	A/G	cg00455452	chr11:94474125	NA	-0.67	-4.47	-0.37	1.72e-5	Alzheimer disease and age of onset;
TGCT	cis	rs7698623	0.850	rs1381958	chr4:88796785	T/C	cg02735620	chr4:88950514	PKD2	-0.44	-4.81	-0.4	4.22e-6	Cardiovascular disease risk factors;
TGCT	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg24531977	chr5:56204891	C5orf35	0.97	8.9	0.62	5.58e-15	Initial pursuit acceleration;
TGCT	cis	rs6693567	0.565	rs12093148	chr1:150265173	G/A	cg09579323	chr1:150459698	TARS2	-0.52	-4.76	-0.39	5.38e-6	Migraine;
TGCT	cis	rs6750795	0.746	rs1667301	chr2:232423717	C/T	cg19187155	chr2:232395269	NMUR1	0.52	5.96	0.47	2.46e-8	Height;
TGCT	cis	rs2832191	0.740	rs2832168	chr21:30463695	G/A	cg24692254	chr21:30365293	RNF160	1.0	11.65	0.72	1.19e-21	Dental caries;
TGCT	cis	rs9467711	1.000	rs6939978	chr6:26328462	G/C	cg16898833	chr6:26189333	HIST1H4D	1.04	5.51	0.44	1.97e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1008375	0.646	rs13145480	chr4:17565143	T/C	cg16339924	chr4:17578868	LAP3	-0.75	-6.29	-0.49	5.06e-9	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2239547	0.563	rs2581820	chr3:53020544	A/G	cg10802521	chr3:52805072	NEK4	0.59	5.53	0.44	1.85e-7	Schizophrenia;
TGCT	cis	rs903263	0.901	rs4907194	chr1:84665968	G/C	cg09664975	chr1:84543551	PRKACB	0.49	4.65	0.39	8.48e-6	Breast cancer (male);
TGCT	cis	rs6893300	0.524	rs10516146	chr5:179166974	A/G	cg14593053	chr5:179126677	CANX	0.5	5.75	0.46	6.63e-8	Resting heart rate;
TGCT	cis	rs3772130	0.540	rs7627354	chr3:121562434	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.59	5.43	0.44	2.8e-7	Cognitive performance;
TGCT	cis	rs708547	0.836	rs1625691	chr4:57845740	T/C	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.54	-5.15	-0.42	9.88e-7	Response to bleomycin (chromatid breaks);
TGCT	cis	rs4786125	0.587	rs1473515	chr16:6923092	T/G	cg03623568	chr16:6915990	A2BP1	-0.44	-6.44	-0.5	2.39e-9	Heart rate variability traits (SDNN);
TGCT	cis	rs12188164	1.000	rs34847072	chr5:437862	G/C	cg21144161	chr5:423903	AHRR	0.26	5.04	0.41	1.59e-6	Cystic fibrosis severity;
TGCT	cis	rs8010715	1.000	rs8010715	chr14:24609147	T/C	cg23112188	chr14:24563095	PCK2	-0.41	-4.92	-0.4	2.69e-6	IgG glycosylation;
TGCT	cis	rs10197940	0.662	rs4335940	chr2:152275304	A/G	cg19508488	chr2:152266495	RIF1	-0.74	-6.66	-0.51	7.77e-10	Lung cancer;
TGCT	cis	rs7824557	0.564	rs7828263	chr8:11231886	A/G	cg21775007	chr8:11205619	TDH	-0.59	-5.47	-0.44	2.35e-7	Retinal vascular caliber;
TGCT	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg13665807	chr20:60559372	TAF4	-0.46	-4.9	-0.4	2.87e-6	Body mass index;
TGCT	cis	rs3796352	1.000	rs11706035	chr3:53011868	A/T	cg15956490	chr3:53032818	SFMBT1	0.61	6.76	0.52	4.92e-10	Immune reponse to smallpox (secreted IL-2);
TGCT	trans	rs7819412	0.659	rs4073948	chr8:10772644	A/T	cg15556689	chr8:8085844	FLJ10661	-0.75	-7.0	-0.53	1.4e-10	Triglycerides;
TGCT	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg11644478	chr21:40555479	PSMG1	-0.54	-4.69	-0.39	7.19e-6	Cognitive function;
TGCT	cis	rs35883536	0.566	rs10783141	chr1:101043897	G/A	cg14855972	chr1:101004472	GPR88	-0.23	-4.44	-0.37	1.97e-5	Monocyte count;
TGCT	cis	rs11148252	0.553	rs7999849	chr13:53249414	A/G	cg00495681	chr13:53174319	NA	0.64	6.46	0.5	2.14e-9	Lewy body disease;
TGCT	cis	rs66573146	0.656	rs66517061	chr4:6935163	C/G	cg05069807	chr4:6945702	TBC1D14	0.35	4.92	0.4	2.74e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs72945132	0.882	rs7928686	chr11:70134528	T/C	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs854765	0.618	rs9908017	chr17:17774422	C/T	cg04398451	chr17:18023971	MYO15A	0.28	4.51	0.38	1.49e-5	Total body bone mineral density;
TGCT	cis	rs763121	0.853	rs5757187	chr22:39021522	A/G	cg06022373	chr22:39101656	GTPBP1	-0.78	-7.44	-0.56	1.48e-11	Menopause (age at onset);
TGCT	cis	rs2688608	0.618	rs28718766	chr10:75489844	C/A	cg15838173	chr10:75533400	FUT11	-0.31	-5.16	-0.42	9.66e-7	Inflammatory bowel disease;
TGCT	cis	rs7772486	0.875	rs2777476	chr6:146345024	A/G	cg13319975	chr6:146136371	FBXO30	-0.52	-4.65	-0.39	8.22e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3749237	0.595	rs1464568	chr3:49458266	G/A	cg07636037	chr3:49044803	WDR6	0.62	5.83	0.46	4.59e-8	Resting heart rate;
TGCT	cis	rs9611565	0.694	rs4822032	chr22:41925535	T/C	cg13695892	chr22:41940480	POLR3H	-0.83	-8.63	-0.61	2.52e-14	Vitiligo;
TGCT	cis	rs7923609	0.935	rs10995477	chr10:65010672	T/C	cg08743896	chr10:65200160	JMJD1C	-0.34	-4.55	-0.38	1.25e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs16866061	1.000	rs72974222	chr2:225424143	C/T	cg12698349	chr2:225449008	CUL3	1.0	9.83	0.66	3.23e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	cis	rs708547	0.836	rs781554	chr4:57717537	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	0.53	4.45	0.37	1.89e-5	Response to bleomycin (chromatid breaks);
TGCT	cis	rs7000551	0.779	rs2443507	chr8:22373231	G/A	cg12081754	chr8:22256438	SLC39A14	0.3	4.87	0.4	3.26e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs28595532	0.920	rs116145969	chr4:119770908	T/C	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs6121246	0.567	rs6120937	chr20:30219721	C/T	cg13852791	chr20:30311386	BCL2L1	0.7	4.58	0.38	1.1e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs6840360	0.571	rs17275577	chr4:152519899	G/A	cg17479576	chr4:152424074	FAM160A1	-0.71	-7.72	-0.57	3.41e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg10295955	chr4:187884368	NA	-1.02	-15.84	-0.82	1.42e-31	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6545883	0.525	rs1729662	chr2:61391305	G/A	cg15711740	chr2:61764176	XPO1	-0.51	-4.54	-0.38	1.29e-5	Tuberculosis;
TGCT	cis	rs1018836	0.608	rs10094978	chr8:91509054	C/T	cg16814680	chr8:91681699	NA	-0.67	-6.8	-0.52	3.85e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6570726	0.516	rs9376932	chr6:145729490	T/C	cg23711669	chr6:146136114	FBXO30	0.61	5.53	0.44	1.82e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2241685	0.764	rs12471967	chr2:1941173	G/A	cg21862353	chr2:1801628	MYT1L	-0.54	-5.11	-0.42	1.2e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs265548	0.608	rs265544	chr19:17903479	G/C	cg04517722	chr19:17905589	B3GNT3	0.46	5.88	0.47	3.63e-8	Tumor biomarkers;
TGCT	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg03188948	chr7:1209495	NA	0.47	6.42	0.5	2.6e-9	Longevity;Endometriosis;
TGCT	cis	rs739496	0.843	rs598711	chr12:111973140	A/G	cg10833066	chr12:111807467	FAM109A	0.35	4.58	0.38	1.13e-5	Platelet count;
TGCT	cis	rs4953076	0.613	rs11124981	chr2:44462133	A/T	cg04920474	chr2:44395004	PPM1B	0.59	5.87	0.47	3.66e-8	Height;
TGCT	cis	rs6582630	0.502	rs1915395	chr12:38420726	A/G	cg13010199	chr12:38710504	ALG10B	0.61	4.94	0.41	2.52e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs41271951	0.512	rs16832976	chr1:151038135	T/C	cg00666978	chr1:150947442	LASS2	0.89	4.64	0.38	8.54e-6	Blood protein levels;
TGCT	cis	rs568617	1.000	rs694994	chr11:65653309	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.57	5.17	0.42	9.24e-7	Crohn's disease;
TGCT	cis	rs8177179	0.967	rs4994581	chr3:133437563	T/C	cg16262614	chr3:133464971	TF	0.34	4.52	0.38	1.44e-5	Iron status biomarkers (transferrin levels);
TGCT	cis	rs2932538	0.922	rs999923	chr1:113110548	T/C	cg22162597	chr1:113214053	CAPZA1	0.27	5.98	0.47	2.24e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs861020	0.630	rs628445	chr1:210004953	C/T	cg05527609	chr1:210001259	C1orf107	0.86	7.54	0.56	8.69e-12	Orofacial clefts;
TGCT	cis	rs7772486	0.594	rs6901864	chr6:146023050	C/A	cg13319975	chr6:146136371	FBXO30	0.53	4.7	0.39	6.72e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9473924	0.618	rs61236902	chr6:50813055	C/G	cg14470998	chr6:50812995	TFAP2B	1.36	8.61	0.61	2.74e-14	Body mass index;
TGCT	cis	rs9549367	0.789	rs3794422	chr13:113893729	G/A	cg00898013	chr13:113819073	PROZ	-0.4	-4.94	-0.41	2.52e-6	Platelet distribution width;
TGCT	cis	rs78487399	0.808	rs13396401	chr2:43701213	G/A	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.69	4.55	0.38	1.27e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs9640161	0.663	rs1916932	chr7:150021644	T/C	cg10018233	chr7:150070692	REPIN1	0.32	4.63	0.38	9.08e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs9467773	0.869	rs742090	chr6:26415637	A/C	cg09904177	chr6:26538194	HMGN4	-0.53	-4.9	-0.4	2.91e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs11077998	0.840	rs9910991	chr17:80481193	G/A	cg10255544	chr17:80519551	FOXK2	0.23	4.45	0.37	1.92e-5	Reticulocyte fraction of red cells;
TGCT	cis	rs9399135	0.967	rs4896122	chr6:135295081	T/C	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.36e-6	Red blood cell count;
TGCT	cis	rs896854	0.684	rs10099059	chr8:95986972	G/C	cg23172400	chr8:95962367	TP53INP1	-0.36	-6.07	-0.48	1.44e-8	Type 2 diabetes;
TGCT	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg24829409	chr8:58192753	C8orf71	-0.64	-5.27	-0.43	5.83e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs10276381	1.000	rs10276381	chr7:28190121	A/G	cg23620719	chr7:28220237	JAZF1	-0.85	-5.46	-0.44	2.54e-7	Crohn's disease;
TGCT	cis	rs7582180	0.663	rs2053263	chr2:100971407	A/G	cg08017756	chr2:100939284	LONRF2	-0.31	-5.01	-0.41	1.85e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs3125734	0.633	rs1864836	chr10:64028538	C/G	cg19640130	chr10:64028056	RTKN2	-0.4	-5.17	-0.42	9.02e-7	Rheumatoid arthritis;
TGCT	cis	rs10804591	1.000	rs2811434	chr3:129339615	G/T	cg07730360	chr3:128845626	NA	-0.2	-4.66	-0.39	7.91e-6	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Hip circumference adjusted for BMI;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2072499	0.750	rs2241109	chr1:156173082	C/T	cg24450063	chr1:156163899	SLC25A44	1.13	10.64	0.69	3.48e-19	Testicular germ cell tumor;
TGCT	cis	rs7726839	0.540	rs72703095	chr5:601789	T/C	cg16624210	chr5:671434	TPPP	0.44	4.85	0.4	3.68e-6	Obesity-related traits;
TGCT	cis	rs2677744	1.000	rs1550636	chr15:91477461	A/G	cg22288577	chr15:91498497	RCCD1	0.49	5.01	0.41	1.82e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg04944784	chr2:26401820	FAM59B	0.72	5.92	0.47	2.93e-8	Gut microbiome composition (summer);
TGCT	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg05985448	chr10:134359359	INPP5A	0.23	4.99	0.41	2.01e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs7267979	0.866	rs437635	chr20:25456888	A/G	cg03522245	chr20:25566470	NINL	0.6	6.46	0.5	2.14e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs514406	0.644	rs4926928	chr1:53210163	G/T	cg22166914	chr1:53195759	ZYG11B	0.5	9.65	0.65	8.98e-17	Monocyte count;
TGCT	cis	rs10883723	0.847	rs3808934	chr10:104264280	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs7666738	0.830	rs11932942	chr4:98998939	T/C	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg06238570	chr21:40685208	BRWD1	-0.8	-8.77	-0.62	1.14e-14	Cognitive function;
TGCT	cis	rs35883536	0.647	rs10493929	chr1:101043928	A/C	cg06223162	chr1:101003688	GPR88	-0.43	-8.11	-0.59	4.18e-13	Monocyte count;
TGCT	cis	rs4805272	0.512	rs11879141	chr19:29320335	G/A	cg04546413	chr19:29218101	NA	0.72	4.97	0.41	2.16e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
TGCT	cis	rs826838	1.000	rs7315028	chr12:38710523	G/A	cg26384229	chr12:38710491	ALG10B	1.11	11.22	0.71	1.39e-20	Heart rate;
TGCT	cis	rs4478858	0.611	rs7527645	chr1:31763787	T/C	cg00250761	chr1:31883323	NA	-0.25	-4.52	-0.38	1.45e-5	Alcohol dependence;
TGCT	cis	rs921968	0.643	rs2556384	chr2:219532903	C/T	cg02176678	chr2:219576539	TTLL4	-0.38	-5.47	-0.44	2.34e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs854765	0.693	rs9907287	chr17:17774118	C/T	cg04398451	chr17:18023971	MYO15A	0.29	4.57	0.38	1.15e-5	Total body bone mineral density;
TGCT	cis	rs6121246	0.609	rs6089054	chr20:30323141	A/G	cg10886678	chr20:30946050	ASXL1	-0.52	-4.44	-0.37	1.97e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs2073300	1.000	rs6132622	chr20:23442240	A/T	cg09953122	chr20:23471693	CST8	-0.64	-4.56	-0.38	1.19e-5	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs769267	0.929	rs2905424	chr19:19473445	T/C	cg08509172	chr19:19383838	TM6SF2	0.34	4.46	0.37	1.78e-5	Tonsillectomy;
TGCT	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg03188948	chr7:1209495	NA	0.43	5.17	0.42	9.26e-7	Longevity;Endometriosis;
TGCT	cis	rs941408	1.000	rs1640273	chr19:2803227	C/T	cg06609049	chr19:2785107	THOP1	0.83	8.2	0.59	2.61e-13	Total cholesterol levels;
TGCT	cis	rs921968	0.541	rs496674	chr2:219432569	G/A	cg02176678	chr2:219576539	TTLL4	0.48	6.78	0.52	4.32e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs3020736	0.500	rs8138678	chr22:42516229	A/G	cg05082376	chr22:42548792	NA	0.23	5.43	0.44	2.83e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs651907	0.535	rs13094753	chr3:101525082	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	4.86	0.4	3.51e-6	Colorectal cancer;
TGCT	cis	rs2730260	0.537	rs55864635	chr7:158859744	C/T	cg09066883	chr7:157932951	PTPRN2	0.44	4.83	0.4	3.96e-6	Myopia (pathological);
TGCT	cis	rs3820068	0.705	rs72645803	chr1:15868232	G/A	cg05660106	chr1:15850417	CASP9	1.15	13.74	0.78	1.14e-26	Systolic blood pressure;
TGCT	cis	rs7923609	1.000	rs7923609	chr10:65133822	A/G	cg08743896	chr10:65200160	JMJD1C	-0.34	-4.58	-0.38	1.13e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs13223928	0.666	rs9986825	chr7:3151177	C/T	cg19214707	chr7:3157722	NA	0.44	5.9	0.47	3.28e-8	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
TGCT	cis	rs7524258	0.867	rs35399313	chr1:7277293	T/C	cg04342483	chr1:7259290	CAMTA1	-0.31	-4.52	-0.38	1.45e-5	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs7937612	0.965	rs7131046	chr11:120238534	G/A	cg24566217	chr11:120254723	ARHGEF12	-0.29	-4.62	-0.38	9.51e-6	Intraocular pressure;
TGCT	cis	rs9902453	0.817	rs62068625	chr17:28176581	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	7.17	0.54	5.79e-11	Coffee consumption (cups per day);
TGCT	trans	rs1814175	0.765	rs1721990	chr11:49912154	G/C	cg03929089	chr4:120376271	NA	-0.71	-8.09	-0.59	4.66e-13	Height;
TGCT	cis	rs288326	0.561	rs80099669	chr2:183776981	G/T	cg09997497	chr2:183902928	NCKAP1	1.11	4.95	0.41	2.38e-6	Blood protein levels;
TGCT	cis	rs11190604	1.000	rs7905961	chr10:102297391	G/C	cg16342193	chr10:102329863	NA	-0.41	-5.12	-0.42	1.15e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs5769765	0.773	rs9616382	chr22:50312979	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.24	-12.97	-0.76	7.81e-25	Schizophrenia;
TGCT	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg08280861	chr8:58055591	NA	0.39	4.76	0.39	5.35e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10992471	0.603	rs10116813	chr9:95090360	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.6	-5.48	-0.44	2.23e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs763014	1.000	rs8054842	chr16:672799	T/C	cg07343612	chr16:622815	PIGQ	-0.42	-8.21	-0.59	2.44e-13	Height;
TGCT	cis	rs10791097	0.667	rs4937585	chr11:130741940	A/G	cg14779329	chr11:130786720	SNX19	0.28	4.82	0.4	4.09e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg08859206	chr1:53392774	SCP2	0.45	6.89	0.53	2.54e-10	Monocyte count;
TGCT	cis	rs5769707	0.904	rs7288869	chr22:50015327	C/T	cg05373962	chr22:49881684	NA	-0.31	-6.29	-0.49	4.89e-9	Monocyte count;Monocyte percentage of white cells;
TGCT	trans	rs7618501	1.000	rs4855862	chr3:49748833	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-1.04	-13.29	-0.77	1.33e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs2204008	0.665	rs11495668	chr12:38221018	C/T	cg13010199	chr12:38710504	ALG10B	0.62	4.96	0.41	2.32e-6	Bladder cancer;
TGCT	cis	rs11676348	0.791	rs4133195	chr2:218951245	A/G	cg00012203	chr2:219082015	ARPC2	0.51	4.7	0.39	6.78e-6	Ulcerative colitis;
TGCT	cis	rs933688	1.000	rs6867219	chr5:90718008	T/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.99	8.17	0.59	3.05e-13	Smoking behavior;
TGCT	cis	rs2153535	0.546	rs9378559	chr6:8539058	A/T	cg07606381	chr6:8435919	SLC35B3	0.54	4.99	0.41	2.02e-6	Motion sickness;
TGCT	cis	rs9393692	0.905	rs2393592	chr6:26285560	A/G	cg05868516	chr6:26286170	HIST1H4H	0.63	5.91	0.47	3.02e-8	Educational attainment;
TGCT	cis	rs3820928	0.692	rs17416354	chr2:227770844	A/G	cg11843606	chr2:227700838	RHBDD1	-0.53	-5.15	-0.42	9.84e-7	Pulmonary function;
TGCT	cis	rs259282	0.605	rs8101920	chr19:33109270	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.52	4.79	0.4	4.59e-6	Schizophrenia;
TGCT	cis	rs6964587	1.000	rs56072181	chr7:91690457	A/G	cg17063962	chr7:91808500	NA	0.88	9.65	0.66	8.73e-17	Breast cancer;
TGCT	cis	rs514406	0.505	rs431427	chr1:53179094	C/A	cg01802117	chr1:53393560	SCP2	-0.4	-4.75	-0.39	5.55e-6	Monocyte count;
TGCT	cis	rs12497850	0.797	rs61583136	chr3:49189195	C/T	cg06212747	chr3:49208901	KLHDC8B	0.61	5.55	0.45	1.66e-7	Parkinson's disease;
TGCT	cis	rs317689	0.613	rs315112	chr12:69785926	T/A	cg20891283	chr12:69753455	YEATS4	0.64	5.66	0.45	9.8e-8	Response to diuretic therapy;
TGCT	cis	rs6121246	0.909	rs1994251	chr20:30287328	T/G	cg13852791	chr20:30311386	BCL2L1	0.78	5.8	0.46	5.15e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs2346177	0.580	rs7565770	chr2:46683683	A/C	cg26688816	chr2:46740690	ATP6V1E2	-0.42	-4.74	-0.39	5.8e-6	HDL cholesterol;
TGCT	cis	rs6088590	0.523	rs6059913	chr20:33143288	G/A	cg06115741	chr20:33292138	TP53INP2	0.54	4.72	0.39	6.29e-6	Coronary artery disease;
TGCT	cis	rs11190604	1.000	rs11190595	chr10:102291761	T/C	cg16342193	chr10:102329863	NA	-0.42	-5.37	-0.43	3.74e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	trans	rs6762477	0.748	rs11714799	chr3:50217899	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.78	-8.07	-0.59	5.08e-13	Menarche (age at onset);
TGCT	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.73	-0.39	6.05e-6	Prudent dietary pattern;
TGCT	cis	rs6450176	1.000	rs67430852	chr5:53290586	T/A	ch.5.1024479R	chr5:53302184	ARL15	-0.5	-4.66	-0.39	7.96e-6	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs6598955	0.671	rs12141563	chr1:26589636	A/G	cg04990556	chr1:26633338	UBXN11	0.64	4.91	0.4	2.78e-6	Obesity-related traits;
TGCT	cis	rs7940866	0.801	rs10894288	chr11:130808679	T/C	cg05962950	chr11:130786565	SNX19	0.67	6.75	0.52	5.05e-10	Schizophrenia;
TGCT	cis	rs36051895	0.626	rs7870694	chr9:5100628	T/C	cg02405213	chr9:5042618	JAK2	-0.78	-11.04	-0.7	3.71e-20	Pediatric autoimmune diseases;
TGCT	cis	rs1943345	0.519	rs11233504	chr11:82886525	A/G	cg07047830	chr11:82868014	PCF11	0.54	5.42	0.44	2.95e-7	Obesity-related traits;
TGCT	cis	rs6570726	0.934	rs9484995	chr6:145781114	T/A	cg23711669	chr6:146136114	FBXO30	-0.7	-6.53	-0.51	1.54e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs34779708	0.897	rs4934527	chr10:35281118	T/A	cg04310649	chr10:35416472	CREM	-0.5	-4.45	-0.37	1.91e-5	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs1483890	0.642	rs9825845	chr3:69404572	C/A	cg22125112	chr3:69402811	FRMD4B	0.28	4.57	0.38	1.18e-5	Resting heart rate;
TGCT	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg20276088	chr3:133502917	NA	-0.24	-4.96	-0.41	2.28e-6	Iron status biomarkers;
TGCT	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg21724239	chr8:58056113	NA	0.4	5.01	0.41	1.8e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2180341	1.000	rs3798852	chr6:127636733	A/G	cg27446573	chr6:127587934	RNF146	1.12	10.11	0.67	6.87e-18	Breast cancer;
TGCT	cis	rs9467711	1.000	rs9467707	chr6:26327905	G/C	cg03264133	chr6:25882463	NA	-0.82	-4.48	-0.37	1.65e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6754311	0.544	rs11678022	chr2:136809033	A/T	cg07169764	chr2:136633963	MCM6	-0.57	-5.6	-0.45	1.33e-7	Mosquito bite size;
TGCT	cis	rs6582630	0.502	rs4385963	chr12:38295264	G/A	cg13010199	chr12:38710504	ALG10B	0.57	4.45	0.37	1.89e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs62244186	0.606	rs6798590	chr3:44556861	T/A	cg15687855	chr3:44754131	ZNF502	-0.46	-5.29	-0.43	5.45e-7	Depressive symptoms;
TGCT	cis	rs561655	0.663	rs7938634	chr11:85845473	A/G	cg07180834	chr11:85838833	NA	-0.32	-4.6	-0.38	1.01e-5	Alzheimer's disease (late onset);
TGCT	cis	rs9910055	0.530	rs11656758	chr17:42301541	A/G	cg13607699	chr17:42295918	UBTF	0.96	11.05	0.7	3.49e-20	Total body bone mineral density;
TGCT	cis	rs10851411	0.789	rs11638208	chr15:42777190	C/G	cg23803468	chr15:43513504	EPB42	-0.24	-4.77	-0.39	4.98e-6	Glucose homeostasis traits;
TGCT	cis	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg07424592	chr7:64974309	NA	-1.27	-7.28	-0.55	3.29e-11	Diabetic kidney disease;
TGCT	cis	rs6591182	0.503	rs11227241	chr11:65389890	G/C	cg17480646	chr11:65405466	SIPA1	-0.55	-7.09	-0.54	9.03e-11	Non-alcoholic fatty liver disease histology (lobular);
TGCT	cis	rs992157	0.560	rs1514132	chr2:219084082	C/T	cg00012203	chr2:219082015	ARPC2	-0.81	-9.29	-0.64	6.53e-16	Colorectal cancer;
TGCT	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.88	7.55	0.56	8.16e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs3784262	0.904	rs3784263	chr15:58253062	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.49	-7.59	-0.56	6.66e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs901683	0.702	rs74940001	chr10:46144294	G/A	cg09623279	chr10:45395734	NA	-0.49	-5.33	-0.43	4.55e-7	Red blood cell traits;Mean corpuscular volume;
TGCT	cis	rs67072384	1.000	rs2365442	chr11:72450218	G/A	cg03713592	chr11:72463424	ARAP1	-0.93	-4.66	-0.39	7.89e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs9640161	0.830	rs35840727	chr7:150063204	A/G	cg10018233	chr7:150070692	REPIN1	0.31	4.63	0.38	9.16e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs1519814	0.654	rs6469882	chr8:121010471	A/G	cg22335954	chr8:121166405	COL14A1	-0.36	-4.52	-0.38	1.44e-5	Breast cancer;
TGCT	cis	rs7246657	0.943	rs8109038	chr19:38015709	A/G	cg18154014	chr19:37997991	ZNF793	-0.93	-6.54	-0.51	1.48e-9	Coronary artery calcification;
TGCT	cis	rs3008870	1.000	rs3008848	chr1:67379284	C/T	cg03991309	chr1:68237761	GNG12	0.27	4.68	0.39	7.28e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg07298985	chr8:22133076	PIWIL2	0.33	5.28	0.43	5.7e-7	Hypertriglyceridemia;
TGCT	cis	rs6088580	0.634	rs4911152	chr20:32955024	T/C	cg08999081	chr20:33150536	PIGU	-0.27	-5.33	-0.43	4.46e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs1887596	0.554	rs565885	chr13:27115431	C/G	cg01312412	chr13:27282625	NA	-0.28	-4.94	-0.41	2.46e-6	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs7666738	0.830	rs28618180	chr4:98912184	A/C	cg17366294	chr4:99064904	C4orf37	0.69	7.2	0.54	5.03e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10751667	0.643	rs10902257	chr11:973577	T/C	cg06064525	chr11:970664	AP2A2	-0.34	-7.97	-0.58	9.04e-13	Alzheimer's disease (late onset);
TGCT	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg08280861	chr8:58055591	NA	0.51	5.73	0.46	7.17e-8	Developmental language disorder (linguistic errors);
TGCT	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg27454412	chr7:1067447	C7orf50	0.6	4.7	0.39	6.76e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs80282103	0.618	rs11250264	chr10:1151723	A/C	cg08668510	chr10:1095578	IDI1	1.05	5.31	0.43	4.8e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs2204008	0.640	rs11520199	chr12:38211026	T/C	cg26384229	chr12:38710491	ALG10B	0.84	7.43	0.56	1.51e-11	Bladder cancer;
TGCT	trans	rs1814175	0.869	rs10769600	chr11:49681832	C/T	cg03929089	chr4:120376271	NA	-0.63	-7.04	-0.53	1.14e-10	Height;
TGCT	cis	rs7729723	0.591	rs11750582	chr5:137816983	T/C	cg19169342	chr5:137827400	NA	0.35	4.99	0.41	1.97e-6	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);
TGCT	cis	rs4841097	0.806	rs6992247	chr8:8948469	G/T	cg06636001	chr8:8085503	FLJ10661	0.66	4.82	0.4	4.05e-6	Platelet distribution width;
TGCT	cis	rs8180040	0.726	rs34344887	chr3:47042161	A/G	cg27129171	chr3:47204927	SETD2	0.76	9.79	0.66	4.14e-17	Colorectal cancer;
TGCT	cis	rs2274273	0.712	rs9806049	chr14:55525589	C/A	cg01923255	chr14:55878535	KIAA0831	0.58	4.85	0.4	3.6e-6	Protein biomarker;
TGCT	cis	rs514406	0.505	rs374662	chr1:53164549	C/A	cg08859206	chr1:53392774	SCP2	-0.34	-4.74	-0.39	5.65e-6	Monocyte count;
TGCT	trans	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg21659725	chr3:3221576	CRBN	0.77	9.39	0.64	3.86e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs10037670	0.530	rs58067943	chr5:153819496	T/C	cg21964928	chr5:153872958	NA	0.25	4.49	0.37	1.63e-5	Behavioural disinhibition (generation interaction);
TGCT	cis	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg06558623	chr16:89946397	TCF25	0.45	4.52	0.38	1.42e-5	Skin colour saturation;
TGCT	cis	rs1577917	0.958	rs12203457	chr6:86689277	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.22	-0.42	7.27e-7	Response to antipsychotic treatment;
TGCT	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg17971929	chr21:40555470	PSMG1	-0.54	-4.92	-0.4	2.71e-6	Menarche (age at onset);
TGCT	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg18876405	chr7:65276391	NA	-0.33	-5.05	-0.41	1.55e-6	Aortic root size;
TGCT	cis	rs6589563	0.609	rs12292921	chr11:116621963	T/G	cg20660624	chr11:117307972	DSCAML1	-0.36	-4.63	-0.38	9.26e-6	Eosinophil counts;
TGCT	cis	rs7809950	0.862	rs12112877	chr7:106941324	T/C	cg23024343	chr7:107201750	COG5	-0.3	-4.52	-0.38	1.42e-5	Coronary artery disease;
TGCT	cis	rs9467711	1.000	rs9467704	chr6:26319486	A/G	cg16898833	chr6:26189333	HIST1H4D	-1.04	-5.41	-0.44	3.12e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.51	-4.81	-0.4	4.29e-6	Bipolar disorder;
TGCT	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg24399712	chr22:39784796	NA	-1.05	-12.52	-0.75	9.61e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs9394841	0.667	rs3747749	chr6:41770604	G/A	cg08135965	chr6:41755394	TOMM6	0.55	5.15	0.42	9.77e-7	Mean corpuscular hemoglobin;Red cell distribution width;
TGCT	cis	rs9300255	0.550	rs10772997	chr12:123719880	C/A	cg00376283	chr12:123451042	ABCB9	0.79	6.75	0.52	5.15e-10	Neutrophil percentage of white cells;
TGCT	cis	rs727505	1.000	rs720613	chr7:124452670	C/T	cg23710748	chr7:124431027	NA	-0.27	-4.54	-0.38	1.33e-5	Lewy body disease;
TGCT	cis	rs950776	0.678	rs12910237	chr15:78956338	C/T	cg21242079	chr15:79101063	ADAMTS7	-0.31	-4.81	-0.4	4.29e-6	Sudden cardiac arrest;
TGCT	cis	rs10493773	0.502	rs12066742	chr1:86081149	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.4	-4.92	-0.4	2.7e-6	Urate levels in overweight individuals;
TGCT	cis	rs10193935	0.901	rs55978605	chr2:42573402	C/A	cg27598129	chr2:42591480	NA	-0.4	-5.57	-0.45	1.51e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11098499	0.820	rs12503082	chr4:120284317	A/G	cg09307838	chr4:120376055	NA	0.58	5.76	0.46	6.16e-8	Corneal astigmatism;
TGCT	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg18867708	chr6:26865862	GUSBL1	-0.38	-5.03	-0.41	1.65e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg19318889	chr4:1322082	MAEA	-0.24	-5.93	-0.47	2.77e-8	Longevity;
TGCT	cis	rs2842992	0.709	rs1853257	chr6:160212710	C/G	cg11366901	chr6:160182831	ACAT2	1.07	7.2	0.54	5.07e-11	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs12142240	0.659	rs17361873	chr1:46832686	A/G	cg00530320	chr1:46809349	NSUN4	0.29	6.03	0.48	1.71e-8	Menopause (age at onset);
TGCT	cis	rs1451375	0.698	rs56233242	chr7:50634053	C/A	cg18232548	chr7:50535776	DDC	0.44	6.72	0.52	5.81e-10	Malaria;
TGCT	cis	rs72615157	0.645	rs11771660	chr7:99851269	T/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.63	-5.16	-0.42	9.65e-7	Lung function (FEV1/FVC);
TGCT	cis	rs7267979	0.966	rs2482948	chr20:25296499	T/C	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs713587	0.624	rs1550110	chr2:25124563	T/C	cg15423357	chr2:25149977	NA	0.5	4.89	0.4	3.06e-6	Body mass index in non-asthmatics;
TGCT	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg08439880	chr3:133502540	NA	-0.31	-5.87	-0.47	3.69e-8	Iron status biomarkers;
TGCT	cis	rs1005224	0.819	rs10147492	chr14:76155309	T/G	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.54	-4.72	-0.39	6.23e-6	Large artery stroke;
TGCT	cis	rs896854	0.530	rs10956934	chr8:95992473	C/A	cg16049864	chr8:95962084	TP53INP1	-0.67	-8.1	-0.59	4.32e-13	Type 2 diabetes;
TGCT	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.9	7.25	0.55	3.93e-11	Platelet count;
TGCT	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg02018176	chr4:1364513	KIAA1530	0.27	4.52	0.38	1.41e-5	Longevity;
TGCT	cis	rs651907	0.535	rs13059470	chr3:101424800	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.54	-5.0	-0.41	1.91e-6	Colorectal cancer;
TGCT	cis	rs4654899	0.802	rs17449966	chr1:21203996	A/G	cg01072550	chr1:21505969	NA	-0.46	-6.94	-0.53	1.96e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg18402987	chr7:1209562	NA	0.7	5.67	0.45	9.66e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg23758822	chr17:41437982	NA	0.72	6.96	0.53	1.76e-10	Menopause (age at onset);
TGCT	cis	rs3806843	0.608	rs246042	chr5:140330967	G/A	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs514406	0.584	rs7548832	chr1:53193576	A/T	cg25767906	chr1:53392781	SCP2	-0.47	-5.2	-0.42	8.1e-7	Monocyte count;
TGCT	cis	rs6714710	0.603	rs13034929	chr2:98402772	G/C	cg26665480	chr2:98280029	ACTR1B	0.7	6.54	0.51	1.43e-9	Posterior cortical atrophy and Alzheimer's disease;
TGCT	trans	rs28735056	0.967	rs623546	chr18:77595228	C/T	cg05926928	chr17:57297772	GDPD1	-0.71	-7.64	-0.57	5.03e-12	Schizophrenia;
TGCT	cis	rs7617773	0.780	rs11714176	chr3:48360862	C/T	cg11946769	chr3:48343235	NME6	0.82	7.08	0.54	9.69e-11	Coronary artery disease;
TGCT	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg10047753	chr17:41438598	NA	0.95	9.5	0.65	2.09e-16	Menopause (age at onset);
TGCT	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg02187348	chr16:89574699	SPG7	-0.62	-6.79	-0.52	4.17e-10	Multiple myeloma (IgH translocation);
TGCT	cis	rs10744422	0.686	rs4038070	chr12:123299525	C/T	cg18912006	chr12:123335444	HIP1R	0.56	4.78	0.39	4.84e-6	Schizophrenia;
TGCT	trans	rs7819412	0.805	rs4333549	chr8:10979561	C/G	cg06636001	chr8:8085503	FLJ10661	-0.75	-7.1	-0.54	8.52e-11	Triglycerides;
TGCT	cis	rs7647973	0.922	rs7620024	chr3:49451691	G/A	cg05785598	chr3:49045655	WDR6	-0.38	-4.52	-0.38	1.4e-5	Menarche (age at onset);
TGCT	cis	rs1933488	0.931	rs7740777	chr6:153413309	G/T	cg24028809	chr6:153414101	RGS17	-0.2	-4.49	-0.37	1.63e-5	Prostate cancer;
TGCT	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg11301795	chr4:187892539	NA	-0.33	-4.88	-0.4	3.19e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7843479	1.000	rs1032094	chr8:21820479	A/T	cg17168535	chr8:21777572	XPO7	0.65	5.99	0.47	2.14e-8	Mean corpuscular volume;
TGCT	cis	rs3858526	0.883	rs7481882	chr11:5944221	A/G	cg13902645	chr11:5959945	NA	-0.45	-4.65	-0.39	8.37e-6	DNA methylation (variation);
TGCT	trans	rs28595532	0.557	rs12498329	chr4:119311524	C/T	cg26518628	chr1:97050305	NA	-0.52	-7.12	-0.54	7.52e-11	Cannabis dependence symptom count;
TGCT	cis	rs778371	0.676	rs17164	chr2:233593499	C/T	cg08000102	chr2:233561755	GIGYF2	0.69	7.65	0.57	4.94e-12	Schizophrenia;
TGCT	cis	rs3820928	0.874	rs7576081	chr2:227843634	C/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-4.59	-0.38	1.05e-5	Pulmonary function;
TGCT	cis	rs7845219	0.544	rs7017487	chr8:95922752	A/G	cg13393036	chr8:95962371	TP53INP1	0.44	5.14	0.42	1.05e-6	Type 2 diabetes;
TGCT	cis	rs2295359	0.824	rs11209003	chr1:67601132	G/T	cg12940439	chr1:67600707	NA	0.64	6.74	0.52	5.26e-10	Psoriasis;
TGCT	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg18876405	chr7:65276391	NA	0.4	6.37	0.5	3.34e-9	Aortic root size;
TGCT	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg05368731	chr17:41323189	NBR1	1.21	14.63	0.8	8.89e-29	Menopause (age at onset);
TGCT	cis	rs2404602	0.647	rs7181506	chr15:76935677	G/T	cg22467129	chr15:76604101	ETFA	-0.45	-4.49	-0.37	1.62e-5	Blood metabolite levels;
TGCT	cis	rs9300255	0.739	rs1879380	chr12:123739111	G/A	cg00376283	chr12:123451042	ABCB9	-0.73	-5.03	-0.41	1.69e-6	Neutrophil percentage of white cells;
TGCT	cis	rs6840360	1.000	rs6535813	chr4:152599652	A/T	cg17479576	chr4:152424074	FAM160A1	-0.5	-5.4	-0.44	3.26e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9914544	0.545	rs12452289	chr17:18781809	T/G	cg26378065	chr17:18585709	ZNF286B	0.53	4.63	0.38	9.06e-6	Educational attainment (years of education);
TGCT	cis	rs7909074	1.000	rs4948927	chr10:45397071	G/A	cg05187965	chr10:45406764	TMEM72	-0.24	-5.23	-0.42	7.12e-7	Mean corpuscular volume;
TGCT	cis	rs17376456	0.877	rs10065056	chr5:93380123	G/T	cg21475434	chr5:93447410	FAM172A	0.59	4.66	0.39	8.09e-6	Diabetic retinopathy;
TGCT	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg22029157	chr1:209979665	IRF6	0.76	6.32	0.49	4.37e-9	Cleft lip with or without cleft palate;
TGCT	cis	rs12210905	0.925	rs858985	chr6:27178028	T/C	cg08851530	chr6:28072375	NA	-0.99	-4.79	-0.4	4.65e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs28595532	0.920	rs114653217	chr4:119769216	G/A	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs1505368	0.817	rs6435701	chr2:213283512	A/G	cg20637307	chr2:213403960	ERBB4	0.51	4.84	0.4	3.75e-6	Symmetrical dimethylarginine levels;
TGCT	cis	rs7818688	0.697	rs74633235	chr8:95981476	A/G	cg16049864	chr8:95962084	TP53INP1	0.54	4.64	0.38	8.87e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs739496	0.615	rs57303367	chr12:112265083	C/T	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs2439831	0.867	rs2255440	chr15:43830467	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.98	7.56	0.56	7.97e-12	Lung cancer in ever smokers;
TGCT	cis	rs425277	0.583	rs12059660	chr1:2041461	C/T	cg24578937	chr1:2090814	PRKCZ	-0.22	-5.19	-0.42	8.29e-7	Height;
TGCT	cis	rs36093844	0.747	rs11234420	chr11:85528580	G/A	cg25872744	chr11:85566296	CCDC83	-0.59	-5.04	-0.41	1.62e-6	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
TGCT	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	6.78	0.52	4.27e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs586688	0.625	rs609396	chr1:201655233	C/T	cg14168733	chr1:201708718	NAV1	-0.55	-4.44	-0.37	1.93e-5	Obesity-related traits;
TGCT	cis	rs3733585	0.673	rs6843873	chr4:9958788	A/C	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.7	-0.57	3.69e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg21862992	chr11:68658383	NA	0.47	6.61	0.51	1.03e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs1008375	0.835	rs9760627	chr4:17651508	C/T	cg18681998	chr4:17616180	MED28	1.06	12.08	0.74	1.11e-22	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg26338869	chr17:61819248	STRADA	-0.52	-4.79	-0.4	4.69e-6	Prudent dietary pattern;
TGCT	cis	rs9549260	0.755	rs9549252	chr13:41230141	A/G	cg21288729	chr13:41239152	FOXO1	0.98	10.47	0.69	9.04e-19	Red blood cell count;
TGCT	cis	rs1577917	1.000	rs13199006	chr6:86608708	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.05	-0.41	1.57e-6	Response to antipsychotic treatment;
TGCT	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg17971929	chr21:40555470	PSMG1	-0.53	-4.74	-0.39	5.69e-6	Menarche (age at onset);
TGCT	cis	rs3092073	0.617	rs3746513	chr20:44594228	G/A	cg23252815	chr20:44420276	WFDC3;DNTTIP1	-0.27	-4.44	-0.37	1.93e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.593	rs16921589	chr8:58024387	C/A	cg08280861	chr8:58055591	NA	0.36	5.16	0.42	9.31e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs904251	0.861	rs2776877	chr6:37487135	G/A	cg01843034	chr6:37503916	NA	-0.52	-6.28	-0.49	5.17e-9	Cognitive performance;
TGCT	cis	rs7772486	0.720	rs991507	chr6:146023609	G/A	cg23711669	chr6:146136114	FBXO30	-0.95	-11.14	-0.71	2.17e-20	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs751728	1.000	rs11752297	chr6:33735154	G/C	cg13859433	chr6:33739653	LEMD2	-0.4	-7.63	-0.57	5.49e-12	Crohn's disease;
TGCT	cis	rs2070488	0.775	rs2051214	chr3:38560303	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.64	-5.68	-0.45	9.01e-8	Electrocardiographic conduction measures;
TGCT	cis	rs4803468	1.000	rs8105833	chr19:41896145	G/A	cg09537434	chr19:41945824	ATP5SL	-0.9	-10.06	-0.67	9.09e-18	Height;
TGCT	cis	rs2729354	0.953	rs2848625	chr11:57330650	G/C	cg24343310	chr11:57249947	NA	0.28	4.82	0.4	4.14e-6	Blood protein levels;
TGCT	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.7	0.52	6.47e-10	Bipolar disorder;
TGCT	cis	rs2070488	0.804	rs2268755	chr3:38501916	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.78	-7.9	-0.58	1.26e-12	Electrocardiographic conduction measures;
TGCT	cis	rs1568889	1.000	rs12797689	chr11:28076042	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.85	9.04	0.63	2.64e-15	Bipolar disorder;
TGCT	cis	rs9486719	1.000	rs2971603	chr6:97035418	C/T	cg18709589	chr6:96969512	KIAA0776	-0.78	-6.38	-0.5	3.24e-9	Migraine;Coronary artery disease;
TGCT	cis	rs7412746	0.634	rs4451553	chr1:150937329	C/T	cg09365446	chr1:150670422	GOLPH3L	0.34	4.55	0.38	1.26e-5	Melanoma;
TGCT	cis	rs12142240	0.698	rs72890727	chr1:46860237	G/A	cg00530320	chr1:46809349	NSUN4	0.29	5.79	0.46	5.34e-8	Menopause (age at onset);
TGCT	cis	rs13256369	0.851	rs11786125	chr8:8564570	T/G	cg18904891	chr8:8559673	CLDN23	0.59	5.46	0.44	2.54e-7	Obesity-related traits;
TGCT	cis	rs1577917	0.771	rs2475791	chr6:86368164	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.58	-0.45	1.43e-7	Response to antipsychotic treatment;
TGCT	cis	rs9291683	0.510	rs4318649	chr4:10016815	T/C	cg11266682	chr4:10021025	SLC2A9	0.69	9.1	0.63	1.93e-15	Bone mineral density;
TGCT	cis	rs2637266	0.678	rs2894345	chr10:78454561	A/C	cg18941641	chr10:78392320	NA	0.4	4.88	0.4	3.24e-6	Pulmonary function;
TGCT	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg23982607	chr1:1823379	GNB1	-0.55	-8.5	-0.61	5.16e-14	Body mass index;
TGCT	cis	rs3849570	0.961	rs13340130	chr3:81790970	A/T	cg07356753	chr3:81810745	GBE1	-0.85	-8.17	-0.59	3.06e-13	Waist circumference;Body mass index;
TGCT	cis	rs1971762	0.527	rs4019971	chr12:53978715	A/G	cg16917193	chr12:54089295	NA	0.89	9.11	0.63	1.74e-15	Height;
TGCT	cis	rs7937682	1.000	rs11213973	chr11:111538903	A/T	cg09085632	chr11:111637200	PPP2R1B	-1.02	-9.74	-0.66	5.34e-17	Primary sclerosing cholangitis;
TGCT	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg06634786	chr22:41940651	POLR3H	0.87	8.08	0.59	4.79e-13	Vitiligo;
TGCT	cis	rs7829975	0.711	rs1039916	chr8:8685854	A/G	cg06636001	chr8:8085503	FLJ10661	0.74	6.63	0.51	9.09e-10	Mood instability;
TGCT	cis	rs9393777	0.513	rs7740197	chr6:26663478	C/T	cg15659132	chr6:26577336	NA	0.74	5.21	0.42	7.65e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs6933660	0.720	rs6914656	chr6:151753421	C/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.5	4.76	0.39	5.36e-6	Menarche (age at onset);
TGCT	cis	rs4478037	1.000	rs57477065	chr3:33162532	A/C	cg19404215	chr3:33155277	CRTAP	1.33	8.79	0.62	1.04e-14	Major depressive disorder;
TGCT	cis	rs9611565	0.649	rs5758434	chr22:42116163	G/A	cg03806693	chr22:41940476	POLR3H	0.96	9.91	0.66	2.06e-17	Vitiligo;
TGCT	cis	rs2046867	0.908	rs62251634	chr3:72788705	A/C	cg25664220	chr3:72788482	NA	-0.56	-7.15	-0.54	6.59e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs12893668	0.572	rs2273175	chr14:104160141	T/C	cg26031613	chr14:104095156	KLC1	-0.59	-5.05	-0.41	1.53e-6	Reticulocyte count;
TGCT	cis	rs4918072	0.606	rs78381949	chr10:105612418	G/A	cg11005552	chr10:105648138	OBFC1	0.39	4.73	0.39	6.1e-6	Coronary artery disease;
TGCT	cis	rs4689388	0.889	rs4629534	chr4:6294124	G/T	cg00701064	chr4:6280414	WFS1	0.37	4.72	0.39	6.3e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs28785552	0.769	rs28796114	chr19:53234319	T/C	cg22067481	chr19:53234126	ZNF611	-0.51	-7.5	-0.56	1.09e-11	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs7523273	0.565	rs11118451	chr1:207887493	A/G	cg22525895	chr1:207977042	MIR29B2	0.35	5.75	0.46	6.66e-8	Schizophrenia;
TGCT	cis	rs7647973	0.593	rs58339610	chr3:49845006	T/A	cg05785598	chr3:49045655	WDR6	-0.42	-5.32	-0.43	4.71e-7	Menarche (age at onset);
TGCT	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg13607699	chr17:42295918	UBTF	0.84	7.5	0.56	1.05e-11	Total body bone mineral density;
TGCT	cis	rs916888	0.697	rs199516	chr17:44856485	C/T	cg05721485	chr17:44071124	MAPT	-0.25	-4.58	-0.38	1.1e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs4644046	0.545	rs10948626	chr6:51429680	A/G	cg14391730	chr6:52021665	NA	0.31	4.46	0.37	1.8e-5	Coronary artery disease;
TGCT	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs617219	0.765	rs10053349	chr5:78475423	T/C	cg09550809	chr5:78407562	BHMT	0.4	5.75	0.46	6.44e-8	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs6570726	0.791	rs621382	chr6:145799144	T/C	cg05347473	chr6:146136440	FBXO30	0.51	4.74	0.39	5.78e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg20887711	chr4:1340912	KIAA1530	0.77	6.45	0.5	2.3e-9	Longevity;
TGCT	cis	rs13082711	0.554	rs4973729	chr3:27390637	G/A	cg02860705	chr3:27208620	NA	0.43	6.0	0.47	2.03e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs3087591	0.919	rs2952983	chr17:29470288	G/C	cg24425628	chr17:29625626	OMG;NF1	0.44	6.44	0.5	2.39e-9	Hip circumference;
TGCT	cis	rs654950	0.934	rs654220	chr1:42002556	A/T	cg06885757	chr1:42089581	HIVEP3	-0.26	-4.6	-0.38	1.01e-5	Airway imaging phenotypes;
TGCT	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg06873352	chr17:61820015	STRADA	0.54	5.91	0.47	3.07e-8	Prudent dietary pattern;
TGCT	cis	rs7223966	1.000	rs6504182	chr17:61823672	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	5.08	0.42	1.34e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs858239	0.699	rs1881201	chr7:23194013	C/T	cg05602783	chr7:23145260	KLHL7	0.65	5.75	0.46	6.52e-8	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg03388025	chr16:89894329	SPIRE2	0.53	9.44	0.65	2.83e-16	Vitiligo;
TGCT	cis	rs7666738	0.800	rs13106995	chr4:99028790	A/T	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9532580	0.778	rs61963319	chr13:41244220	A/T	cg21288729	chr13:41239152	FOXO1	1.01	10.56	0.69	5.52e-19	Mean corpuscular hemoglobin;
TGCT	cis	rs9913156	0.589	rs7213481	chr17:4547906	C/T	cg00122941	chr17:4613640	ARRB2	0.87	7.39	0.55	1.89e-11	Lymphocyte counts;
TGCT	cis	rs896854	0.846	rs2340584	chr8:95916811	A/G	cg13393036	chr8:95962371	TP53INP1	-0.59	-8.02	-0.58	6.81e-13	Type 2 diabetes;
TGCT	cis	rs36051895	0.632	rs2381213	chr9:5168871	A/G	cg02405213	chr9:5042618	JAK2	0.67	8.11	0.59	4.24e-13	Pediatric autoimmune diseases;
TGCT	cis	rs910316	0.763	rs6574205	chr14:75453039	G/C	cg11812906	chr14:75593930	NEK9	0.58	5.61	0.45	1.23e-7	Height;
TGCT	cis	rs873946	0.564	rs2803991	chr10:134557068	A/G	cg26818010	chr10:134567672	INPP5A	-0.36	-4.99	-0.41	2e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs2464469	0.526	rs11071363	chr15:58333961	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.43	-6.39	-0.5	3.11e-9	Barrett's esophagus  or Esophageal adenocarcinoma;
TGCT	cis	rs6121246	0.559	rs6121038	chr20:30254773	T/G	cg13852791	chr20:30311386	BCL2L1	0.78	7.1	0.54	8.37e-11	Mean corpuscular hemoglobin;
TGCT	cis	rs6088580	0.601	rs6120668	chr20:33099793	A/G	cg06115741	chr20:33292138	TP53INP2	0.54	4.63	0.38	9.06e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs1371867	0.846	rs1660317	chr8:101333252	G/T	cg00191853	chr8:101177733	SPAG1	-0.22	-4.47	-0.37	1.75e-5	Atrioventricular conduction;
TGCT	cis	rs896854	0.738	rs509594	chr8:95967156	C/G	cg09323728	chr8:95962352	TP53INP1	0.45	5.26	0.43	6.17e-7	Type 2 diabetes;
TGCT	cis	rs12765878	0.580	rs11191829	chr10:105614452	G/T	cg11005552	chr10:105648138	OBFC1	-0.37	-5.91	-0.47	3.14e-8	Coronary artery disease;
TGCT	cis	rs2013441	1.000	rs4924808	chr17:20026548	C/T	cg13482628	chr17:19912719	NA	-0.52	-4.48	-0.37	1.68e-5	Obesity-related traits;
TGCT	cis	rs3008870	1.000	rs3008874	chr1:67431365	A/T	cg03991309	chr1:68237761	GNG12	0.27	4.53	0.38	1.36e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg05890377	chr2:74357713	NA	0.44	5.15	0.42	9.84e-7	Gestational age at birth (maternal effect);
TGCT	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg04287289	chr16:89883240	FANCA	0.92	11.5	0.72	2.84e-21	Vitiligo;
TGCT	cis	rs7193541	0.965	rs4402594	chr16:74701360	C/T	cg01733217	chr16:74700730	RFWD3	0.84	8.52	0.61	4.64e-14	Multiple myeloma;
TGCT	cis	rs8032315	0.965	rs12906125	chr15:91427612	G/A	cg06330618	chr15:91428456	FES	0.19	4.64	0.38	8.6e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7647973	0.925	rs4955423	chr3:49220448	G/A	cg07636037	chr3:49044803	WDR6	0.63	5.09	0.42	1.27e-6	Menarche (age at onset);
TGCT	cis	rs12477438	0.798	rs1349778	chr2:99645011	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-5.75	-0.46	6.58e-8	Chronic sinus infection;
TGCT	cis	rs9910055	0.960	rs9911991	chr17:42278916	G/C	cg19774624	chr17:42201019	HDAC5	-0.86	-8.52	-0.61	4.46e-14	Total body bone mineral density;
TGCT	cis	rs55883249	1.000	rs10495571	chr2:9736066	A/G	cg23886495	chr2:9695866	ADAM17	0.81	5.0	0.41	1.93e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg13531842	chr10:38383804	ZNF37A	-0.38	-4.51	-0.38	1.49e-5	Extrinsic epigenetic age acceleration;
TGCT	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.48	-5.53	-0.44	1.83e-7	Longevity;Endometriosis;
TGCT	cis	rs10504229	0.679	rs2218271	chr8:58052446	T/A	cg08280861	chr8:58055591	NA	0.36	5.14	0.42	1.03e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9393692	0.905	rs6940237	chr6:26282322	T/C	cg00631329	chr6:26305371	NA	-0.44	-6.59	-0.51	1.14e-9	Educational attainment;
TGCT	cis	rs877282	1.000	rs11253361	chr10:770387	T/C	cg17470449	chr10:769945	NA	0.35	5.19	0.42	8.21e-7	Uric acid levels;
TGCT	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg03264133	chr6:25882463	NA	0.74	7.71	0.57	3.43e-12	Blood metabolite levels;
TGCT	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg08280861	chr8:58055591	NA	0.4	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs4919044	0.641	rs7914449	chr10:94723370	G/T	cg05127821	chr10:94822908	CYP26C1	-0.73	-4.47	-0.37	1.74e-5	Coronary artery disease;
TGCT	cis	rs2980439	0.517	rs17594093	chr8:8106406	G/T	cg06636001	chr8:8085503	FLJ10661	-0.6	-4.98	-0.41	2.12e-6	Neuroticism;
TGCT	cis	rs3008870	0.583	rs17497947	chr1:67457199	G/T	cg11518657	chr1:67396239	MIER1	-0.6	-4.76	-0.39	5.32e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs910316	0.673	rs2012627	chr14:75443103	C/T	cg11812906	chr14:75593930	NEK9	0.54	5.01	0.41	1.81e-6	Height;
TGCT	cis	rs17253792	0.822	rs17746033	chr14:56061837	G/A	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs9309473	0.660	rs11686541	chr2:73704475	C/G	cg07208825	chr2:73871855	ALMS1P	0.24	4.6	0.38	1.03e-5	Metabolite levels;
TGCT	cis	rs9788682	0.694	rs3825845	chr15:78910258	C/T	cg24631222	chr15:78858424	CHRNA5	0.92	6.59	0.51	1.11e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs2797160	0.651	rs6939969	chr6:126034563	C/T	cg05901451	chr6:126070800	HEY2	0.74	6.65	0.51	8.31e-10	Endometrial cancer;
TGCT	cis	rs74181299	0.964	rs2540951	chr2:65276736	A/G	cg05010058	chr2:65284262	CEP68	0.42	4.77	0.39	5.16e-6	Pulse pressure;
TGCT	cis	rs7267979	1.000	rs4815424	chr20:25390284	T/C	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10489202	0.657	rs201540	chr1:167992883	G/A	cg24449463	chr1:168025552	DCAF6	-0.6	-7.13	-0.54	7.21e-11	Schizophrenia;
TGCT	cis	rs10509586	0.826	rs76962974	chr10:91898542	C/G	cg25278353	chr10:91717815	NA	0.49	4.67	0.39	7.77e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
TGCT	cis	rs4722585	0.764	rs4259314	chr7:26182214	A/G	cg03781084	chr7:26191726	NFE2L3	0.5	5.37	0.43	3.81e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
TGCT	cis	rs5757676	0.858	rs6001585	chr22:39812986	G/T	cg01416388	chr22:39784598	NA	-0.78	-6.72	-0.52	5.79e-10	IgG glycosylation;
TGCT	cis	rs9527	0.590	rs10786741	chr10:104939182	G/A	cg15744005	chr10:104629667	AS3MT	-0.4	-4.59	-0.38	1.08e-5	Arsenic metabolism;
TGCT	cis	rs798554	0.679	rs798499	chr7:2792013	G/A	cg25467336	chr7:2757616	NA	-0.24	-4.71	-0.39	6.54e-6	Height;
TGCT	cis	rs903263	0.965	rs7515976	chr1:84627743	T/G	cg09664975	chr1:84543551	PRKACB	0.48	4.54	0.38	1.31e-5	Breast cancer (male);
TGCT	cis	rs2153535	0.580	rs2184582	chr6:8447793	G/A	cg07606381	chr6:8435919	SLC35B3	0.53	5.02	0.41	1.79e-6	Motion sickness;
TGCT	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg22920501	chr2:26401640	FAM59B	-0.72	-6.2	-0.49	7.73e-9	Gut microbiome composition (summer);
TGCT	trans	rs7819412	0.775	rs11773990	chr8:10935082	T/C	cg06636001	chr8:8085503	FLJ10661	-0.77	-7.07	-0.54	1.01e-10	Triglycerides;
TGCT	cis	rs1997103	1.000	rs6593238	chr7:55411048	A/G	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs921968	0.541	rs3821031	chr2:219295249	C/T	cg02176678	chr2:219576539	TTLL4	-0.46	-6.55	-0.51	1.36e-9	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs7822232	0.908	rs6558295	chr8:145139522	C/G	cg26272248	chr8:145163034	KIAA1875	-0.49	-4.81	-0.4	4.24e-6	Blood metabolite levels;
TGCT	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/C	cg06212747	chr3:49208901	KLHDC8B	0.62	5.94	0.47	2.65e-8	Parkinson's disease;
TGCT	cis	rs2120019	0.938	rs8033925	chr15:75311959	A/G	cg09165964	chr15:75287851	SCAMP5	-1.14	-10.33	-0.68	2.05e-18	Blood trace element (Zn levels);
TGCT	cis	rs7226408	0.857	rs72887044	chr18:34481573	A/G	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs637571	0.565	rs633800	chr11:65638719	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.61	-6.31	-0.49	4.43e-9	Eosinophil percentage of white cells;
TGCT	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg06634786	chr22:41940651	POLR3H	-0.88	-8.54	-0.61	3.98e-14	Vitiligo;
TGCT	cis	rs4455778	0.580	rs6944916	chr7:49113732	T/A	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs6582630	0.537	rs11520294	chr12:38402705	C/A	cg13010199	chr12:38710504	ALG10B	0.61	4.82	0.4	4.12e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs2115630	1.000	rs11854291	chr15:85363708	T/C	cg12501888	chr15:85177176	SCAND2	-0.47	-4.45	-0.37	1.91e-5	P wave terminal force;
TGCT	cis	rs17102423	0.755	rs8009396	chr14:65573438	C/G	cg11161011	chr14:65562177	MAX	-0.54	-7.49	-0.56	1.15e-11	Obesity-related traits;
TGCT	cis	rs7267979	1.000	rs6050547	chr20:25326012	C/T	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3015497	0.789	rs7147956	chr14:51142605	G/A	cg04730355	chr14:51134070	SAV1	-0.67	-6.4	-0.5	2.96e-9	Mean platelet volume;
TGCT	cis	rs858239	0.601	rs15775	chr7:23164701	C/T	cg05602783	chr7:23145260	KLHL7	-0.65	-5.52	-0.44	1.93e-7	Cerebrospinal fluid biomarker levels;
TGCT	trans	rs3780486	0.505	rs7868663	chr9:33141229	A/G	cg20290983	chr6:43655470	MRPS18A	0.78	8.34	0.6	1.23e-13	IgG glycosylation;
TGCT	cis	rs7949030	0.620	rs2428551	chr11:62329758	T/A	cg13298116	chr11:62369859	EML3;MTA2	0.63	9.54	0.65	1.64e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs425277	1.000	rs262654	chr1:2089526	G/A	cg24578937	chr1:2090814	PRKCZ	0.32	8.03	0.58	6.41e-13	Height;
TGCT	cis	rs7104764	0.701	rs3782115	chr11:223272	A/G	cg18336825	chr11:236787	PSMD13;SIRT3	1.0	9.93	0.67	1.92e-17	Menarche (age at onset);
TGCT	cis	rs6582630	0.502	rs11520234	chr12:38255005	G/A	cg13010199	chr12:38710504	ALG10B	0.64	4.97	0.41	2.15e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9902453	0.902	rs4075014	chr17:28305674	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.76	6.61	0.51	1.02e-9	Coffee consumption (cups per day);
TGCT	cis	rs56091001	0.528	rs9616387	chr22:50313219	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.11	-5.95	-0.47	2.57e-8	Acne (severe);
TGCT	cis	rs634534	0.562	rs1151505	chr11:65734539	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.56	5.43	0.44	2.87e-7	Sum eosinophil basophil counts;Eosinophil counts;
TGCT	cis	rs4523957	0.651	rs898748	chr17:2085475	G/T	cg16513277	chr17:2031491	SMG6	-0.2	-4.64	-0.38	8.83e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs12477438	0.765	rs10181344	chr2:99692829	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-7.6	-0.56	6.47e-12	Chronic sinus infection;
TGCT	cis	rs3770081	1.000	rs2164879	chr2:86261579	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.18	-4.81	-0.4	4.33e-6	Facial emotion recognition (sad faces);
TGCT	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg03388025	chr16:89894329	SPIRE2	0.5	8.7	0.62	1.73e-14	Vitiligo;
TGCT	trans	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg13615516	chr5:77269221	NA	0.68	8.54	0.61	3.97e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs601339	1.000	rs630408	chr12:123172822	C/T	cg11919336	chr12:123188078	GPR109A	0.64	7.49	0.56	1.1e-11	Adiponectin levels;
TGCT	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg27535305	chr1:53392650	SCP2	-0.24	-4.69	-0.39	6.96e-6	Monocyte count;
TGCT	cis	rs111544199	1	rs111544199	chr19:50091221	GT/G	cg09250473	chr19:50168907	IRF3;BCL2L12	0.68	5.65	0.45	1.02e-7	Red blood cell count;
TGCT	trans	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg21659725	chr3:3221576	CRBN	0.76	9.03	0.63	2.74e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs651907	0.557	rs2303474	chr3:101371899	G/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	4.78	0.39	4.77e-6	Colorectal cancer;
TGCT	cis	rs727563	0.593	rs132770	chr22:42017264	A/G	cg17554472	chr22:41940697	POLR3H	0.49	5.12	0.42	1.13e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs739496	0.615	rs886205	chr12:112204427	A/G	cg10833066	chr12:111807467	FAM109A	0.35	5.18	0.42	8.83e-7	Platelet count;
TGCT	cis	rs6088590	1.000	rs6120748	chr20:33458284	T/G	cg06115741	chr20:33292138	TP53INP2	0.64	5.1	0.42	1.25e-6	Coronary artery disease;
TGCT	cis	rs651907	0.535	rs34263427	chr3:101507805	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.31	-6.4	-0.5	2.91e-9	Colorectal cancer;
TGCT	cis	rs7267979	1.000	rs2424713	chr20:25418482	C/T	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2180341	1.000	rs6910763	chr6:127630925	T/C	cg27446573	chr6:127587934	RNF146	1.12	10.11	0.67	6.87e-18	Breast cancer;
TGCT	cis	rs7586879	0.520	rs6718511	chr2:25122324	A/G	cg15423357	chr2:25149977	NA	0.5	4.89	0.4	3.06e-6	Body mass index;
TGCT	cis	rs9467773	1.000	rs3736782	chr6:26505403	C/A	cg15659132	chr6:26577336	NA	0.86	12.18	0.74	6.14e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs68170813	0.523	rs11762152	chr7:106811374	G/A	cg02696742	chr7:106810147	HBP1	-0.71	-6.08	-0.48	1.38e-8	Coronary artery disease;
TGCT	cis	rs4076764	0.846	rs12036398	chr1:163422204	C/T	cg24596788	chr1:163392923	NA	0.17	4.87	0.4	3.33e-6	Motion sickness;
TGCT	cis	rs6089584	0.927	rs1886007	chr20:60581049	G/A	cg13770153	chr20:60521292	NA	-0.53	-7.22	-0.54	4.51e-11	Body mass index;
TGCT	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg05368731	chr17:41323189	NBR1	1.1	11.08	0.71	2.94e-20	Menopause (age at onset);
TGCT	cis	rs3764400	0.564	rs1452663	chr17:46293386	C/G	cg02340556	chr17:46797764	NA	0.42	4.51	0.38	1.46e-5	Body mass index;
TGCT	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg25036284	chr2:26402008	FAM59B	-0.57	-4.97	-0.41	2.15e-6	Gut microbiome composition (summer);
TGCT	cis	rs910316	0.967	rs1071989	chr14:75564659	G/T	cg23033748	chr14:75592666	NEK9	0.28	4.68	0.39	7.29e-6	Height;
TGCT	cis	rs74233809	1.000	rs12220375	chr10:104901491	T/C	cg05855489	chr10:104503620	C10orf26	0.85	4.45	0.37	1.88e-5	Birth weight;
TGCT	cis	rs849898	1	rs849898	chr1:228153917	A/G	cg18477163	chr1:228402036	OBSCN	-0.3	-5.68	-0.45	9.15e-8	Parkinson's disease;
TGCT	cis	rs17102423	0.661	rs45604339	chr14:65543102	C/T	cg11161011	chr14:65562177	MAX	-0.55	-7.71	-0.57	3.47e-12	Obesity-related traits;
TGCT	cis	rs858239	1.000	rs156421	chr7:23312487	A/G	cg05602783	chr7:23145260	KLHL7	-0.58	-4.81	-0.4	4.35e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs4654899	0.758	rs2874367	chr1:21324491	A/C	cg01072550	chr1:21505969	NA	0.57	9.37	0.64	4.22e-16	Superior frontal gyrus grey matter volume;
TGCT	cis	rs7178572	0.568	rs4243045	chr15:77455914	A/C	cg22256960	chr15:77711686	NA	-0.89	-8.95	-0.63	4.29e-15	Type 2 diabetes;
TGCT	cis	rs910316	1.000	rs1047418	chr14:75605792	A/G	cg08847533	chr14:75593920	NEK9	0.95	10.55	0.69	5.78e-19	Height;
TGCT	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg18876405	chr7:65276391	NA	0.35	5.2	0.42	8.09e-7	Aortic root size;
TGCT	trans	rs35851103	0.506	rs4841659	chr8:11828200	C/T	cg15556689	chr8:8085844	FLJ10661	0.87	7.83	0.58	1.91e-12	Neuroticism;
TGCT	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg08859206	chr1:53392774	SCP2	-0.45	-7.07	-0.54	1.01e-10	Monocyte count;
TGCT	cis	rs11024102	0.830	rs11024110	chr11:17028390	T/A	cg15378786	chr11:17036137	PLEKHA7	0.49	4.72	0.39	6.17e-6	Glaucoma (primary angle closure);
TGCT	cis	rs10875746	0.903	rs10875740	chr12:48489117	C/T	cg20731937	chr12:48336164	NA	0.62	4.95	0.41	2.36e-6	Longevity (90 years and older);
TGCT	cis	rs3734905	1.000	rs16888119	chr6:169937237	C/T	cg20469989	chr6:170102314	C6orf120;WDR27	-0.88	-4.67	-0.39	7.59e-6	HIV-1 control;
TGCT	cis	rs7017914	0.902	rs35580034	chr8:71572073	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.53	-4.9	-0.4	2.87e-6	Bone mineral density;
TGCT	cis	rs17376456	0.569	rs6881815	chr5:93105666	A/G	cg25358565	chr5:93447407	FAM172A	0.76	6.68	0.51	7.23e-10	Diabetic retinopathy;
TGCT	cis	rs13191362	1.000	rs35818596	chr6:163001874	C/G	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs921968	0.544	rs58827325	chr2:219415166	A/T	cg02176678	chr2:219576539	TTLL4	0.48	6.86	0.52	2.94e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs10992471	0.756	rs7027595	chr9:95131553	C/T	cg14631576	chr9:95140430	CENPP	-0.3	-4.88	-0.4	3.25e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs185694	0.857	rs200511	chr13:30904316	G/A	cg07600127	chr13:30881527	KATNAL1	-0.54	-4.7	-0.39	6.94e-6	Antineutrophil cytoplasmic antibody-associated vasculitis;
TGCT	cis	rs6901250	0.788	rs571296	chr6:117092558	A/G	cg12892004	chr6:117198278	RFX6	-0.51	-6.28	-0.49	5.29e-9	C-reactive protein levels;
TGCT	cis	rs7772486	0.840	rs854144	chr6:146360880	G/T	cg23711669	chr6:146136114	FBXO30	-0.68	-6.49	-0.5	1.9e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2204008	0.744	rs8186814	chr12:38335169	C/T	cg13010199	chr12:38710504	ALG10B	0.58	4.55	0.38	1.26e-5	Bladder cancer;
TGCT	cis	rs7681440	0.804	rs763443	chr4:90819961	T/C	cg14346243	chr4:90757452	SNCA	-0.47	-4.54	-0.38	1.3e-5	Dementia with Lewy bodies;
TGCT	cis	rs2898681	0.519	rs6848200	chr4:53730181	A/G	cg00791764	chr4:53727839	RASL11B	0.54	4.58	0.38	1.1e-5	Optic nerve measurement (cup area);
TGCT	trans	rs561341	0.883	rs886224	chr17:30229902	T/C	cg20587970	chr11:113659929	NA	-0.82	-9.73	-0.66	5.87e-17	Hip circumference adjusted for BMI;
TGCT	cis	rs12220238	0.818	rs115350439	chr10:75899365	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.28	0.55	3.4e-11	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg06873352	chr17:61820015	STRADA	0.55	6.13	0.48	1.09e-8	Prudent dietary pattern;
TGCT	cis	rs7267979	0.966	rs6083818	chr20:25346082	G/A	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg01570182	chr17:44337453	NA	1.07	10.3	0.68	2.41e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs909674	0.515	rs9611170	chr22:39784845	G/C	cg11247378	chr22:39784982	NA	-0.76	-10.63	-0.69	3.71e-19	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs7666738	0.606	rs13108868	chr4:99083753	C/T	cg18180107	chr4:99064573	C4orf37	0.53	4.67	0.39	7.61e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs881375	0.935	rs7034390	chr9:123646488	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.39	4.55	0.38	1.25e-5	Rheumatoid arthritis;
TGCT	cis	rs2346177	0.519	rs1597040	chr2:46673903	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.44	-4.77	-0.39	5.08e-6	HDL cholesterol;
TGCT	cis	rs11190604	1.000	rs7477246	chr10:102261538	C/T	cg16342193	chr10:102329863	NA	-0.38	-4.89	-0.4	3.06e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs6088580	0.601	rs6059827	chr20:33016358	C/T	cg24642439	chr20:33292090	TP53INP2	0.49	4.57	0.38	1.16e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs10789285	0.681	rs2248775	chr1:69697308	G/T	ch.1.69469992R	chr1:69697404	NA	0.31	4.52	0.38	1.4e-5	Psoriasis;
TGCT	cis	rs9303401	0.659	rs17222523	chr17:56620501	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs6121246	0.738	rs2376996	chr20:30316667	T/A	cg13852791	chr20:30311386	BCL2L1	0.78	5.8	0.46	5.15e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs2404602	0.647	rs7178250	chr15:77099107	T/C	cg23625390	chr15:77176239	SCAPER	-0.38	-4.83	-0.4	4.01e-6	Blood metabolite levels;
TGCT	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	5.8	0.46	5.19e-8	Alzheimer's disease;
TGCT	cis	rs2404602	0.692	rs12437733	chr15:77155562	A/G	cg22467129	chr15:76604101	ETFA	-0.47	-5.3	-0.43	5.08e-7	Blood metabolite levels;
TGCT	cis	rs7666738	0.830	rs13149346	chr4:99009933	C/T	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs61931739	0.500	rs11053217	chr12:34470036	A/C	cg06521331	chr12:34319734	NA	-0.26	-4.45	-0.37	1.87e-5	Morning vs. evening chronotype;
TGCT	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg11644478	chr21:40555479	PSMG1	1.0	10.51	0.69	7.16e-19	Cognitive function;
TGCT	cis	rs4888262	0.507	rs9888976	chr16:74580924	C/T	cg01733217	chr16:74700730	RFWD3	0.71	7.11	0.54	7.94e-11	Testicular germ cell tumor;
TGCT	cis	rs477895	0.713	rs1059440	chr11:63991801	C/T	cg04317338	chr11:64019027	PLCB3	-0.82	-6.85	-0.52	3.06e-10	Mean platelet volume;
TGCT	cis	rs1775715	0.737	rs55859032	chr10:32213239	C/T	cg14930904	chr10:32216787	ARHGAP12	0.54	5.3	0.43	5.12e-7	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.07	0.82	4.17e-32	Prudent dietary pattern;
TGCT	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg04267008	chr7:1944627	MAD1L1	-0.36	-4.82	-0.4	4.05e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs3617	0.625	rs2240915	chr3:52859526	T/A	cg11645453	chr3:52864694	ITIH4	0.28	5.45	0.44	2.63e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.76	6.02	0.48	1.8e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9926296	0.744	rs154656	chr16:89708003	T/A	cg03388025	chr16:89894329	SPIRE2	-0.34	-5.15	-0.42	9.94e-7	Vitiligo;
TGCT	cis	rs12510870	0.599	rs1528916	chr4:74452469	C/A	cg05868023	chr4:75230803	EREG	-0.55	-4.74	-0.39	5.71e-6	Iris color (b* coordinate);
TGCT	cis	rs594074	0.951	rs581403	chr6:6556120	C/T	cg03251356	chr6:7151709	RREB1	-0.3	-4.82	-0.4	4.09e-6	Diabetic kidney disease;
TGCT	cis	rs5009270	0.524	rs11763427	chr7:112162843	C/T	cg06717068	chr7:111370856	DOCK4	-0.25	-4.49	-0.37	1.61e-5	Osteoarthritis (hip);
TGCT	cis	rs6088580	0.634	rs4258875	chr20:32924895	C/A	cg08999081	chr20:33150536	PIGU	-0.25	-4.85	-0.4	3.66e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs10501293	0.746	rs10742662	chr11:43005385	A/G	cg03447554	chr11:43094025	NA	0.45	6.36	0.5	3.57e-9	Cognitive performance;
TGCT	cis	rs6424115	0.867	rs11588187	chr1:24145047	T/A	cg15997130	chr1:24165203	NA	0.89	9.81	0.66	3.7e-17	Immature fraction of reticulocytes;
TGCT	cis	rs1385374	0.858	rs10847697	chr12:129299385	C/T	cg09035930	chr12:129282057	SLC15A4	-0.55	-4.76	-0.39	5.27e-6	Systemic lupus erythematosus;
TGCT	cis	rs7772486	0.837	rs2474354	chr6:146323795	T/A	cg23711669	chr6:146136114	FBXO30	0.77	8.1	0.59	4.35e-13	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7937682	0.855	rs539553	chr11:111477333	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.06	-11.27	-0.71	1.04e-20	Primary sclerosing cholangitis;
TGCT	cis	rs6671200	0.790	rs640527	chr1:95705615	G/A	cg20701556	chr1:95698924	RWDD3	-0.67	-5.63	-0.45	1.13e-7	Stearic acid (18:0) levels;
TGCT	trans	rs1496653	0.602	rs13065375	chr3:23526686	A/G	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs7659604	0.502	rs13106764	chr4:122699630	C/G	cg06713675	chr4:122721982	EXOSC9	0.37	4.61	0.38	9.99e-6	Type 2 diabetes;
TGCT	trans	rs3780486	0.718	rs7859454	chr9:33119583	T/A	cg20290983	chr6:43655470	MRPS18A	1.01	7.36	0.55	2.25e-11	IgG glycosylation;
TGCT	cis	rs3820068	0.608	rs12760450	chr1:16037282	G/A	cg17385448	chr1:15911702	AGMAT	0.37	4.98	0.41	2.06e-6	Systolic blood pressure;
TGCT	cis	rs36051895	0.695	rs7851556	chr9:5022807	C/T	cg02405213	chr9:5042618	JAK2	-0.8	-11.04	-0.7	3.76e-20	Pediatric autoimmune diseases;
TGCT	trans	rs2727020	0.619	rs1164665	chr11:49295630	T/C	cg15704280	chr7:45808275	SEPT13	0.67	6.8	0.52	4.02e-10	Coronary artery disease;
TGCT	cis	rs6815814	0.950	rs5743556	chr4:38806851	A/G	cg02016764	chr4:38805732	TLR1	-0.35	-5.58	-0.45	1.44e-7	Breast cancer;
TGCT	cis	rs933688	1.000	rs933688	chr5:90762748	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.88	8.16	0.59	3.2e-13	Smoking behavior;
TGCT	cis	rs929354	0.772	rs10228145	chr7:157007337	A/G	cg05182265	chr7:156933206	UBE3C	-0.37	-8.69	-0.62	1.8e-14	Body mass index;
TGCT	cis	rs11031096	0.678	rs17284356	chr11:4189232	G/C	cg18678763	chr11:4115507	RRM1	-0.46	-6.03	-0.48	1.78e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs9467711	0.606	rs4634439	chr6:26598004	C/T	cg16898833	chr6:26189333	HIST1H4D	-1.02	-5.25	-0.43	6.32e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg18188782	chr20:61659543	NA	0.44	5.37	0.43	3.73e-7	Prostate cancer (SNP x SNP interaction);
TGCT	trans	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg11887960	chr12:57824829	NA	1.2	9.65	0.65	8.99e-17	Obesity-related traits;
TGCT	cis	rs9633740	1.000	rs10749609	chr10:82249752	G/A	cg01528321	chr10:82214614	TSPAN14	0.96	8.21	0.59	2.39e-13	Post bronchodilator FEV1;
TGCT	cis	rs2456568	0.802	rs7101791	chr11:93638998	A/G	cg17595323	chr11:93583763	C11orf90	-0.47	-6.52	-0.51	1.58e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs1670533	1.000	rs10084889	chr4:1053815	G/A	cg20887711	chr4:1340912	KIAA1530	0.7	5.65	0.45	1.03e-7	Recombination rate (females);
TGCT	cis	rs1008375	1.000	rs10939749	chr4:17692319	A/C	cg18681998	chr4:17616180	MED28	0.76	7.28	0.55	3.42e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs910316	0.967	rs175498	chr14:75536369	G/A	cg11812906	chr14:75593930	NEK9	-0.73	-7.08	-0.54	9.58e-11	Height;
TGCT	cis	rs62244186	0.748	rs13319803	chr3:44635461	G/A	cg21672276	chr3:44754072	ZNF502	-0.45	-5.06	-0.41	1.47e-6	Depressive symptoms;
TGCT	cis	rs6988636	1.000	rs4377946	chr8:124185887	T/C	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg25767906	chr1:53392781	SCP2	-0.57	-6.53	-0.51	1.55e-9	Monocyte count;
TGCT	cis	rs11190604	1.000	rs10883497	chr10:102228519	A/G	cg07570687	chr10:102243282	WNT8B	0.31	4.61	0.38	9.72e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs877282	0.838	rs11253374	chr10:774961	C/T	cg17470449	chr10:769945	NA	0.31	5.08	0.42	1.34e-6	Uric acid levels;
TGCT	cis	rs651907	0.535	rs13085776	chr3:101505507	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.76	9.11	0.63	1.77e-15	Colorectal cancer;
TGCT	cis	rs28595532	0.920	rs115430947	chr4:119737149	C/A	cg14228332	chr4:119757509	SEC24D	1.31	7.06	0.54	1.06e-10	Cannabis dependence symptom count;
TGCT	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs72781680	0.699	rs72794291	chr2:23897935	C/T	cg08917208	chr2:24149416	ATAD2B	1.0	5.56	0.45	1.59e-7	Lymphocyte counts;
TGCT	trans	rs11662586	0.517	rs7230837	chr18:77695384	A/T	cg05926928	chr17:57297772	GDPD1	0.77	7.85	0.58	1.71e-12	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
TGCT	cis	rs10751667	1.000	rs11246359	chr11:967943	T/C	cg06064525	chr11:970664	AP2A2	-0.33	-6.52	-0.51	1.62e-9	Alzheimer's disease (late onset);
TGCT	cis	rs1691799	0.867	rs1168297	chr12:66735644	T/C	cg16791601	chr12:66731901	HELB	-0.28	-6.11	-0.48	1.19e-8	White blood cell count (basophil);
TGCT	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg07061783	chr6:25882402	NA	-0.57	-5.44	-0.44	2.74e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs3749237	0.595	rs11130196	chr3:49490149	A/C	cg07636037	chr3:49044803	WDR6	0.63	5.98	0.47	2.26e-8	Resting heart rate;
TGCT	cis	rs9457247	0.646	rs4710160	chr6:167409241	T/A	cg23791538	chr6:167370224	RNASET2	-0.49	-4.96	-0.41	2.31e-6	Crohn's disease;
TGCT	cis	rs11711311	0.824	rs9833810	chr3:113363762	C/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.69	-5.83	-0.46	4.49e-8	IgG glycosylation;
TGCT	cis	rs6684514	1.000	rs11264467	chr1:156273061	A/G	cg16558208	chr1:156270281	VHLL	-0.47	-8.77	-0.62	1.16e-14	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs6835098	0.692	rs1316411	chr4:174075143	A/G	cg08422745	chr4:174089978	GALNT7	-0.77	-8.6	-0.61	2.87e-14	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	trans	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg21659725	chr3:3221576	CRBN	-0.98	-15.33	-0.81	2.1000000000000002e-30	Intelligence (multi-trait analysis);
TGCT	cis	rs73001065	0.636	rs28720066	chr19:19572220	G/T	cg03709012	chr19:19516395	GATAD2A	0.9	4.77	0.39	5.17e-6	LDL cholesterol;
TGCT	cis	rs7552404	0.731	rs10873808	chr1:76406767	T/C	cg10523679	chr1:76189770	ACADM	0.85	7.56	0.56	7.7e-12	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs67311347	0.910	rs13089215	chr3:40495894	T/C	cg13683864	chr3:40499215	RPL14	1.12	10.58	0.69	4.95e-19	Renal cell carcinoma;
TGCT	cis	rs1843834	0.505	rs940317	chr2:225358118	C/T	cg22455342	chr2:225449267	CUL3	1.04	10.75	0.69	1.87e-19	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs244731	0.919	rs12652509	chr5:176626441	A/G	cg06060754	chr5:176797920	RGS14	-0.44	-6.2	-0.49	7.79e-9	Urate levels in lean individuals;
TGCT	cis	rs7909074	0.933	rs879073	chr10:45399882	C/G	cg05187965	chr10:45406764	TMEM72	-0.23	-4.88	-0.4	3.25e-6	Mean corpuscular volume;
TGCT	cis	rs9611565	0.559	rs739136	chr22:42100275	C/T	cg17554472	chr22:41940697	POLR3H	-0.47	-5.04	-0.41	1.63e-6	Vitiligo;
TGCT	cis	rs7216064	1.000	rs62084248	chr17:65874541	C/T	cg12091567	chr17:66097778	LOC651250	-0.83	-6.49	-0.5	1.9e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs2760061	0.583	rs708124	chr1:228220771	A/T	cg02753203	chr1:228287806	NA	0.4	8.32	0.6	1.31e-13	Diastolic blood pressure;
TGCT	cis	rs11105298	0.838	rs4842488	chr12:89881564	C/G	cg00757033	chr12:89920650	WDR51B	0.34	5.37	0.43	3.75e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs739496	0.615	rs12582964	chr12:112090779	C/T	cg10833066	chr12:111807467	FAM109A	0.37	5.1	0.42	1.23e-6	Platelet count;
TGCT	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg02725872	chr8:58115012	NA	-0.39	-5.15	-0.42	1.01e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs3026101	0.671	rs3026115	chr17:5285222	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	4.52	0.38	1.45e-5	Body mass index;
TGCT	cis	rs1514658	0.868	rs13145902	chr4:119282478	C/A	cg21605333	chr4:119757512	SEC24D	-0.5	-4.53	-0.38	1.35e-5	Congenital heart disease (maternal effect);
TGCT	cis	rs477895	0.838	rs2001003	chr11:64018687	C/A	cg04317338	chr11:64019027	PLCB3	0.81	6.9	0.53	2.35e-10	Mean platelet volume;
TGCT	cis	rs3820928	1.000	rs61067328	chr2:227761256	G/A	cg11843606	chr2:227700838	RHBDD1	-0.51	-4.51	-0.38	1.47e-5	Pulmonary function;
TGCT	cis	rs933688	1.000	rs10045280	chr5:90717675	T/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.88	8.18	0.59	2.89e-13	Smoking behavior;
TGCT	cis	rs9921338	0.961	rs72773833	chr16:11413274	G/A	cg00044050	chr16:11439710	C16orf75	-0.93	-6.96	-0.53	1.7e-10	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs12579753	0.872	rs7956132	chr12:82178709	A/G	cg07988820	chr12:82153109	PPFIA2	-0.55	-5.63	-0.45	1.14e-7	Resting heart rate;
TGCT	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg11890956	chr21:40555474	PSMG1	-0.76	-7.45	-0.56	1.39e-11	Cognitive function;
TGCT	cis	rs13191362	1.000	rs68144677	chr6:163149024	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.0	7.73	0.57	3.24e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs11030122	0.604	rs10835557	chr11:4083121	A/G	cg18678763	chr11:4115507	RRM1	-0.48	-5.88	-0.47	3.49e-8	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs4727027	0.901	rs6944781	chr7:148829566	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	4.58	0.38	1.13e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs11167764	0.945	rs891991	chr5:141484977	A/T	cg23435118	chr5:141488016	NDFIP1	-0.3	-5.11	-0.42	1.18e-6	Crohn's disease;
TGCT	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg11644478	chr21:40555479	PSMG1	0.96	9.75	0.66	5.14e-17	Cognitive function;
TGCT	cis	rs62064224	0.902	rs35830939	chr17:30627564	A/C	cg18200150	chr17:30822561	MYO1D	0.45	5.93	0.47	2.82e-8	Schizophrenia;
TGCT	cis	rs9372253	0.967	rs9400379	chr6:110713783	A/G	cg19196401	chr6:110721138	DDO	-0.47	-6.8	-0.52	4e-10	Platelet distribution width;
TGCT	cis	rs9677476	0.632	rs6437008	chr2:232091948	C/G	cg07929768	chr2:232055508	NA	0.35	5.57	0.45	1.49e-7	Food antigen IgG levels;
TGCT	trans	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg27523141	chr10:43048294	ZNF37B	0.73	8.58	0.61	3.32e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs17376456	0.877	rs10035340	chr5:93490465	C/T	cg21475434	chr5:93447410	FAM172A	0.63	4.63	0.38	8.98e-6	Diabetic retinopathy;
TGCT	cis	rs9486719	0.790	rs2499790	chr6:96845078	G/A	cg06623918	chr6:96969491	KIAA0776	0.93	7.08	0.54	9.59e-11	Migraine;Coronary artery disease;
TGCT	cis	rs4478037	1.000	rs4074415	chr3:33161745	A/G	cg19404215	chr3:33155277	CRTAP	1.33	8.79	0.62	1.04e-14	Major depressive disorder;
TGCT	cis	rs10514758	0.590	rs16823509	chr3:114836254	T/C	cg05943254	chr3:114009756	NA	-0.85	-5.06	-0.41	1.48e-6	Urate levels in obese individuals;
TGCT	cis	rs72945132	0.598	rs61887433	chr11:70240997	A/G	cg00319359	chr11:70116639	PPFIA1	1.0	7.01	0.53	1.35e-10	Coronary artery disease;
TGCT	cis	rs9467773	0.609	rs12663780	chr6:26397573	T/C	cg05738196	chr6:26577821	NA	-0.48	-4.94	-0.41	2.51e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6671200	0.607	rs2147587	chr1:95714884	G/A	cg06440946	chr1:95699313	RWDD3	-0.62	-5.3	-0.43	5.09e-7	Stearic acid (18:0) levels;
TGCT	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.71	5.14	0.42	1.02e-6	Platelet count;
TGCT	trans	rs208515	0.525	rs12215007	chr6:66671008	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.9	-9.83	-0.66	3.19e-17	Exhaled nitric oxide levels;
TGCT	cis	rs6854137	0.553	rs17614715	chr4:169701578	A/T	cg20607169	chr4:169750834	PALLD	-0.2	-4.48	-0.37	1.66e-5	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs6671200	0.790	rs640527	chr1:95705615	G/A	cg26537280	chr1:95699037	RWDD3	-0.7	-5.55	-0.45	1.62e-7	Stearic acid (18:0) levels;
TGCT	cis	rs17155006	0.651	rs416811	chr7:107724047	G/C	cg05962710	chr7:107745446	LAMB4	-0.19	-4.75	-0.39	5.44e-6	Pneumococcal bacteremia;
TGCT	cis	rs7095607	0.606	rs4746739	chr10:69960091	C/T	cg18986048	chr10:69913749	MYPN	-0.56	-5.87	-0.47	3.81e-8	Lung function (FVC);
TGCT	cis	rs7428	0.924	rs908304	chr2:85573049	G/A	cg24342717	chr2:85555507	TGOLN2	-0.4	-6.41	-0.5	2.78e-9	Ear protrusion;
TGCT	cis	rs6430585	0.528	rs309162	chr2:136690783	T/A	cg07169764	chr2:136633963	MCM6	1.26	12.74	0.75	2.79e-24	Corneal structure;
TGCT	cis	rs9611519	0.894	rs9611488	chr22:41462592	G/T	cg13695892	chr22:41940480	POLR3H	-0.54	-4.79	-0.39	4.76e-6	Neuroticism;
TGCT	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.31	-4.76	-0.39	5.36e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2688608	0.592	rs7923045	chr10:75487498	A/T	cg17411546	chr10:75410026	SYNPO2L	-0.46	-4.51	-0.38	1.51e-5	Inflammatory bowel disease;
TGCT	cis	rs4443100	0.670	rs9608071	chr22:23408118	G/T	cg14186256	chr22:23484241	RTDR1	0.61	4.89	0.4	3.03e-6	Serum parathyroid hormone levels;
TGCT	cis	rs7666738	0.830	rs10007261	chr4:98926155	C/T	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11098499	0.954	rs9685777	chr4:120365965	C/A	cg09307838	chr4:120376055	NA	0.68	6.53	0.51	1.54e-9	Corneal astigmatism;
TGCT	cis	rs1023500	0.596	rs5751209	chr22:42451603	A/G	cg05082376	chr22:42548792	NA	-0.22	-5.29	-0.43	5.32e-7	Schizophrenia;
TGCT	cis	rs12118280	0.612	rs591141	chr1:108694894	A/G	cg11967332	chr1:108735228	SLC25A24	0.35	5.17	0.42	9.01e-7	Myeloid white cell count;
TGCT	cis	rs11030122	0.673	rs66596383	chr11:3979745	C/T	cg18678763	chr11:4115507	RRM1	-0.47	-5.82	-0.46	4.73e-8	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs17767294	0.708	rs72848792	chr6:27997656	A/G	cg08851530	chr6:28072375	NA	1.56	7.22	0.54	4.47e-11	Parkinson's disease;
TGCT	cis	rs6840360	0.582	rs59714108	chr4:152325939	G/A	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.35	-0.5	3.68e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7811142	1.000	rs6953107	chr7:100095664	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.05	-9.36	-0.64	4.35e-16	Platelet count;
TGCT	cis	rs7225537	0.532	rs11551189	chr17:17062241	C/G	cg26176665	chr17:16994978	MPRIP	0.23	5.3	0.43	5.11e-7	Mean platelet volume;
TGCT	cis	rs2795502	0.873	rs2795527	chr10:43270240	T/C	cg20628663	chr10:43360327	NA	-0.41	-4.81	-0.4	4.3e-6	Blood protein levels;
TGCT	cis	rs367943	1.000	rs191553	chr5:112823659	A/G	cg12552261	chr5:112820674	MCC	-0.24	-4.91	-0.4	2.81e-6	Type 2 diabetes;
TGCT	cis	rs7772486	0.754	rs6906258	chr6:146089356	A/G	cg13319975	chr6:146136371	FBXO30	0.58	5.29	0.43	5.27e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2708977	0.842	rs10209780	chr2:97140142	T/G	cg01950434	chr2:97203154	ARID5A	-0.68	-6.22	-0.49	7.09e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs2458413	0.564	rs2669452	chr8:105370385	C/A	cg04554929	chr8:105342491	NA	0.48	5.77	0.46	5.95e-8	Paget's disease;
TGCT	cis	rs7523273	0.853	rs7537216	chr1:208006429	A/T	cg22525895	chr1:207977042	MIR29B2	-0.48	-8.33	-0.6	1.26e-13	Schizophrenia;
TGCT	cis	rs9640161	0.750	rs11764936	chr7:150025915	G/T	cg10018233	chr7:150070692	REPIN1	0.33	4.81	0.4	4.35e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs992157	0.560	rs7605980	chr2:219100869	C/G	cg00012203	chr2:219082015	ARPC2	0.81	9.56	0.65	1.49e-16	Colorectal cancer;
TGCT	cis	rs709400	0.628	rs2010281	chr14:103862322	G/A	cg26031613	chr14:104095156	KLC1	0.85	9.32	0.64	5.53e-16	Body mass index;
TGCT	cis	rs950169	0.580	rs11634322	chr15:85172209	C/T	cg11189052	chr15:85197271	WDR73	0.73	6.01	0.47	1.96e-8	Schizophrenia;
TGCT	cis	rs3749237	0.595	rs6784820	chr3:49450864	C/T	cg07636037	chr3:49044803	WDR6	-0.63	-6.05	-0.48	1.56e-8	Resting heart rate;
TGCT	cis	rs4499344	0.633	rs411328	chr19:33140178	T/G	cg26639809	chr19:33781782	NA	0.22	4.64	0.38	8.84e-6	Mean platelet volume;
TGCT	cis	rs11214589	0.651	rs17600713	chr11:113259947	C/T	cg14159747	chr11:113255604	NA	0.36	4.67	0.39	7.63e-6	Neuroticism;
TGCT	cis	rs9300255	0.602	rs11057192	chr12:123693420	T/C	cg00376283	chr12:123451042	ABCB9	0.72	5.66	0.45	1.01e-7	Neutrophil percentage of white cells;
TGCT	cis	rs4975709	0.798	rs4975757	chr5:1882579	G/A	cg14773178	chr5:1868261	NA	0.35	4.7	0.39	6.74e-6	Cardiovascular disease risk factors;
TGCT	cis	rs1580019	0.563	rs13244332	chr7:32537679	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.58	5.0	0.41	1.94e-6	Cognitive ability;
TGCT	cis	rs8103278	0.507	rs10401971	chr19:46261982	C/T	cg11657440	chr19:46296263	DMWD	0.74	7.77	0.57	2.62e-12	Coronary artery disease;
TGCT	cis	rs889312	0.500	rs702691	chr5:56114526	T/G	cg12311346	chr5:56204834	C5orf35	-0.47	-5.03	-0.41	1.7e-6	Breast cancer;Breast cancer (early onset);
TGCT	cis	rs2204008	0.606	rs6582502	chr12:38543352	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-4.75	-0.39	5.51e-6	Bladder cancer;
TGCT	cis	rs295140	0.605	rs159321	chr2:201184713	C/T	cg04283868	chr2:201171347	SPATS2L	0.47	4.57	0.38	1.14e-5	QT interval;
TGCT	cis	rs72781680	1.000	rs72796339	chr2:24143063	T/C	cg08917208	chr2:24149416	ATAD2B	0.73	4.51	0.38	1.48e-5	Lymphocyte counts;
TGCT	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg20607798	chr8:58055168	NA	0.49	4.67	0.39	7.56e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg16624210	chr5:671434	TPPP	0.4	4.66	0.39	8.03e-6	Obesity-related traits;
TGCT	cis	rs9467773	0.935	rs9461270	chr6:26544110	A/G	cg09904177	chr6:26538194	HMGN4	0.65	6.48	0.5	1.95e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs3846443	chr4:99032666	G/A	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	7.42	0.55	1.62e-11	Schizophrenia;
TGCT	cis	rs9853921	0.674	rs9843822	chr3:117966792	G/A	cg15509235	chr3:117715573	NA	-0.53	-4.51	-0.38	1.46e-5	JT interval (sulfonylurea treatment interaction);
TGCT	trans	rs2727020	0.635	rs7124266	chr11:49280857	T/G	cg03929089	chr4:120376271	NA	0.72	8.01	0.58	7.19e-13	Coronary artery disease;
TGCT	cis	rs751728	0.588	rs7774620	chr6:33736285	T/A	cg13859433	chr6:33739653	LEMD2	-0.32	-5.93	-0.47	2.78e-8	Crohn's disease;
TGCT	cis	rs4953076	0.573	rs7595470	chr2:44402467	A/G	cg04920474	chr2:44395004	PPM1B	0.57	5.6	0.45	1.29e-7	Height;
TGCT	cis	rs11122272	0.735	rs2572251	chr1:231514243	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.14	-0.54	6.86e-11	Hemoglobin concentration;
TGCT	cis	rs9549260	0.755	rs17061491	chr13:41228210	T/A	cg21288729	chr13:41239152	FOXO1	0.99	10.42	0.68	1.22e-18	Red blood cell count;
TGCT	cis	rs3617	0.573	rs9825230	chr3:52901974	G/A	cg11645453	chr3:52864694	ITIH4	0.26	4.95	0.41	2.34e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs3772130	0.926	rs13072767	chr3:121504098	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.72	0.39	6.25e-6	Cognitive performance;
TGCT	cis	rs7666738	0.800	rs1559858	chr4:99024075	A/G	cg05340658	chr4:99064831	C4orf37	0.51	5.75	0.46	6.42e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs13424612	0.930	rs4149545	chr2:240942818	G/T	cg26363272	chr2:240904871	NDUFA10	0.28	4.79	0.4	4.65e-6	Odorant perception (isobutyraldehyde);
TGCT	cis	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg07424592	chr7:64974309	NA	1.4	8.42	0.6	7.87e-14	Diabetic kidney disease;
TGCT	cis	rs57994353	0.897	rs66477686	chr9:139372224	T/C	cg13741927	chr9:139327495	INPP5E	-0.24	-5.42	-0.44	2.93e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs2204008	0.689	rs1581357	chr12:38391479	C/G	cg26384229	chr12:38710491	ALG10B	0.83	7.26	0.55	3.72e-11	Bladder cancer;
TGCT	cis	rs12477438	0.765	rs4851183	chr2:99629149	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-7.6	-0.56	6.47e-12	Chronic sinus infection;
TGCT	cis	rs7098414	0.511	rs7071752	chr10:82159539	C/A	cg01528321	chr10:82214614	TSPAN14	0.56	4.98	0.41	2.09e-6	Post bronchodilator FEV1;
TGCT	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg23283495	chr1:209979779	IRF6	0.65	5.53	0.44	1.81e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs72945132	0.556	rs57172967	chr11:70160060	G/A	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs3091242	0.933	rs11249251	chr1:25770188	C/G	cg10117171	chr1:25599238	RHD	-0.3	-4.92	-0.4	2.69e-6	Erythrocyte sedimentation rate;
TGCT	cis	rs12142240	0.698	rs57267378	chr1:46816644	A/G	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs12049351	0.774	rs754025	chr1:229637297	C/T	cg12130225	chr1:229698885	NA	0.39	4.59	0.38	1.06e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs12497850	0.931	rs7643368	chr3:48992855	T/G	cg18654377	chr3:49208889	KLHDC8B	-0.42	-5.41	-0.44	3.09e-7	Parkinson's disease;
TGCT	cis	rs13191362	0.935	rs35537826	chr6:163145867	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.93	7.06	0.54	1.05e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs6912958	0.781	rs2300906	chr6:88207155	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-5.06	-0.41	1.45e-6	Monocyte percentage of white cells;
TGCT	cis	rs4654899	0.865	rs6700459	chr1:21279396	T/C	cg01072550	chr1:21505969	NA	-0.47	-7.06	-0.54	1.03e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs6545883	0.931	rs7557230	chr2:61736652	A/T	cg15711740	chr2:61764176	XPO1	-0.56	-5.11	-0.42	1.17e-6	Tuberculosis;
TGCT	cis	rs514406	0.644	rs4926928	chr1:53210163	G/T	cg01802117	chr1:53393560	SCP2	-0.41	-4.86	-0.4	3.48e-6	Monocyte count;
TGCT	cis	rs7647973	0.922	rs57273516	chr3:49483074	A/G	cg05785598	chr3:49045655	WDR6	0.37	4.52	0.38	1.42e-5	Menarche (age at onset);
TGCT	cis	rs6460942	0.841	rs62448597	chr7:12449110	G/C	cg06484146	chr7:12443880	VWDE	-0.57	-5.52	-0.44	1.92e-7	Coronary artery disease;
TGCT	cis	rs4460629	0.742	rs7548955	chr1:155082298	T/C	cg23973274	chr1:155060172	NA	-0.26	-4.72	-0.39	6.25e-6	Serum magnesium levels;
TGCT	cis	rs12200560	0.505	rs1988040	chr6:97076271	G/A	cg06623918	chr6:96969491	KIAA0776	0.59	5.03	0.41	1.71e-6	Coronary heart disease;
TGCT	cis	rs17253792	0.822	rs79921041	chr14:56090779	T/C	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs3791556	0.741	rs3791542	chr2:240103955	A/G	cg03281426	chr2:240109471	HDAC4	-0.27	-4.65	-0.39	8.44e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs669446	0.533	rs4660261	chr1:44229597	G/A	cg12908607	chr1:44402522	ARTN	-0.63	-7.47	-0.56	1.25e-11	Amyotrophic lateral sclerosis (age of onset);
TGCT	trans	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg17830980	chr10:43048298	ZNF37B	0.86	9.99	0.67	1.31e-17	Extrinsic epigenetic age acceleration;
TGCT	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg11965913	chr1:205819406	PM20D1	0.54	7.73	0.57	3.21e-12	Menarche (age at onset);
TGCT	cis	rs524281	0.692	rs10791845	chr11:65834340	C/G	cg00563793	chr11:65837595	PACS1	-0.51	-4.52	-0.38	1.44e-5	Electroencephalogram traits;
TGCT	cis	rs57920188	0.535	rs10915664	chr1:4093700	G/A	cg20703997	chr1:4087676	NA	0.49	5.75	0.46	6.69e-8	Interleukin-17 levels;
TGCT	cis	rs7412746	0.587	rs3849279	chr1:150944707	T/C	cg04414720	chr1:150670196	GOLPH3L	0.38	4.5	0.37	1.52e-5	Melanoma;
TGCT	cis	rs34734847	1.000	rs2948149	chr12:121162854	T/G	cg21892295	chr12:121157589	UNC119B	-0.22	-5.39	-0.44	3.48e-7	Mean corpuscular volume;
TGCT	cis	rs7255045	0.789	rs1078264	chr19:12963143	T/C	cg06537894	chr19:12978706	MAST1	-0.49	-4.48	-0.37	1.69e-5	Mean corpuscular volume;
TGCT	cis	rs1799949	0.965	rs4793237	chr17:41436595	A/T	cg05368731	chr17:41323189	NBR1	1.07	12.31	0.74	3.02e-23	Menopause (age at onset);
TGCT	cis	rs6674176	0.696	rs4448553	chr1:44411589	A/G	cg12908607	chr1:44402522	ARTN	-0.73	-9.26	-0.64	7.67e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs12478296	0.681	rs55802421	chr2:243033962	C/T	cg06360820	chr2:242988706	NA	-0.61	-4.75	-0.39	5.52e-6	Obesity-related traits;
TGCT	cis	rs3020736	0.500	rs2413672	chr22:42513261	C/T	cg05082376	chr22:42548792	NA	0.23	5.43	0.44	2.83e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12049351	0.774	rs2145395	chr1:229670981	T/C	cg12130225	chr1:229698885	NA	0.38	4.63	0.38	8.95e-6	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs13242816	1.000	rs1018859	chr7:116067347	C/T	cg02799643	chr7:116139180	CAV2	-0.44	-5.08	-0.42	1.33e-6	P wave duration;
TGCT	trans	rs10504390	0.656	rs78310018	chr8:66486522	T/C	cg26037026	chr7:1641922	NA	-0.64	-6.84	-0.52	3.26e-10	IgG glycosylation;
TGCT	cis	rs12579753	0.879	rs11115007	chr12:82164673	A/T	cg07988820	chr12:82153109	PPFIA2	-0.7	-7.9	-0.58	1.31e-12	Resting heart rate;
TGCT	cis	rs7666738	0.710	rs7674407	chr4:98838522	A/G	cg18180107	chr4:99064573	C4orf37	0.56	5.17	0.42	9.04e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs804292	0.763	rs8191514	chr8:11627113	C/G	cg26752888	chr8:11627280	NEIL2	1.1	11.91	0.73	2.89e-22	Alcohol dependence;Nicotine use;
TGCT	cis	rs7044106	0.762	rs1886337	chr9:123443776	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.61	6.47	0.5	2.01e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs9296092	0.521	rs9461886	chr6:33526770	T/C	cg13560919	chr6:33536144	NA	-0.23	-5.06	-0.41	1.49e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg06558623	chr16:89946397	TCF25	0.53	6.48	0.5	1.99e-9	Skin colour saturation;
TGCT	cis	rs10501293	0.956	rs10837999	chr11:43068860	T/G	cg03447554	chr11:43094025	NA	0.46	6.64	0.51	8.94e-10	Cognitive performance;
TGCT	trans	rs9951602	0.512	rs12455566	chr18:76655926	A/G	cg02800362	chr5:177631904	HNRNPAB	1.13	12.71	0.75	3.32e-24	Obesity-related traits;
TGCT	cis	rs6714710	0.627	rs6748124	chr2:98519014	T/C	cg26665480	chr2:98280029	ACTR1B	0.64	6.03	0.48	1.71e-8	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg25767906	chr1:53392781	SCP2	0.48	5.55	0.45	1.62e-7	Monocyte count;
TGCT	cis	rs910316	0.789	rs12894419	chr14:75471802	C/T	cg11812906	chr14:75593930	NEK9	0.58	5.56	0.45	1.6e-7	Height;
TGCT	cis	rs4149423	1.000	rs4149423	chr2:108916044	A/G	cg06795125	chr2:108905320	SULT1C2	-0.45	-6.85	-0.52	3.06e-10	Lobe size;
TGCT	trans	rs10501293	0.746	rs1565252	chr11:43009119	A/C	cg23728189	chr2:10470961	HPCAL1	-0.27	-6.67	-0.51	7.41e-10	Cognitive performance;
TGCT	cis	rs7681440	0.904	rs6532192	chr4:90764131	G/A	cg20003494	chr4:90757398	SNCA	-0.63	-6.09	-0.48	1.3e-8	Dementia with Lewy bodies;
TGCT	cis	rs6598955	0.543	rs3795687	chr1:26560745	G/A	cg24519413	chr1:26490540	NA	-0.26	-4.73	-0.39	6.1e-6	Obesity-related traits;
TGCT	cis	rs155076	1.000	rs658244	chr13:21850976	T/C	cg11317459	chr13:21872234	NA	-1.42	-12.26	-0.74	4.07e-23	White matter hyperintensity burden;
TGCT	cis	rs71435601	0.600	rs312984	chr2:21378778	C/T	cg25035485	chr2:21266500	APOB	0.51	4.48	0.37	1.66e-5	Cholesterol, total;
TGCT	cis	rs950027	0.620	rs1049518	chr15:45653367	G/A	cg26924012	chr15:45694286	SPATA5L1	0.79	8.86	0.62	6.92e-15	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs7659604	0.676	rs6534323	chr4:122695888	G/A	cg20573242	chr4:122745356	CCNA2	0.52	4.61	0.38	9.67e-6	Type 2 diabetes;
TGCT	cis	rs9611565	0.592	rs5751139	chr22:42099981	G/C	cg03806693	chr22:41940476	POLR3H	1.08	11.99	0.73	1.84e-22	Vitiligo;
TGCT	cis	rs3806843	0.517	rs246031	chr5:140333107	G/A	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg01238044	chr22:24384105	GSTT1	-0.5	-4.61	-0.38	9.97e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6964587	0.626	rs10280301	chr7:91524258	A/T	cg17063962	chr7:91808500	NA	-0.76	-7.15	-0.54	6.42e-11	Breast cancer;
TGCT	cis	rs5167	0.536	rs1882752	chr19:45461342	G/C	cg09555818	chr19:45449301	APOC2	0.23	4.66	0.39	7.96e-6	Blood protein levels;
TGCT	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg21724239	chr8:58056113	NA	0.45	4.94	0.41	2.44e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9549367	0.712	rs2316443	chr13:113864837	G/A	cg18105134	chr13:113819100	PROZ	-0.38	-6.47	-0.5	2.08e-9	Platelet distribution width;
TGCT	cis	rs3849570	0.555	rs6548783	chr3:81993621	G/A	cg07356753	chr3:81810745	GBE1	-0.61	-5.39	-0.44	3.47e-7	Waist circumference;Body mass index;
TGCT	cis	rs6495367	1.000	rs13380109	chr15:79378775	G/A	cg17916960	chr15:79447300	NA	0.35	4.94	0.41	2.48e-6	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	trans	rs2469997	0.925	rs2470004	chr8:120358445	C/T	cg01792902	chr3:178864926	PIK3CA	0.83	6.77	0.52	4.49e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs12477438	0.520	rs11123761	chr2:99705903	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	16.87	0.83	6.81e-34	Chronic sinus infection;
TGCT	cis	rs9296092	0.538	rs62405941	chr6:33517297	G/A	cg13560919	chr6:33536144	NA	-0.2	-4.63	-0.38	9.25e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs3008870	1.000	rs2755248	chr1:67492624	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.07	11.4	0.72	5.07e-21	Lymphocyte percentage of white cells;
TGCT	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.54	5.28	0.43	5.5e-7	Menarche (age at onset);
TGCT	cis	rs3784262	0.565	rs3809535	chr15:58359787	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.36	-5.13	-0.42	1.08e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs1215050	0.791	rs1025201	chr4:98902938	A/G	cg05340658	chr4:99064831	C4orf37	-0.46	-5.82	-0.46	4.74e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7539409	0.915	rs6576945	chr1:84252882	A/G	cg10977910	chr1:84465055	TTLL7	0.83	4.5	0.37	1.58e-5	Alzheimer's disease;
TGCT	cis	rs2932538	0.922	rs6659677	chr1:113087076	G/C	cg22162597	chr1:113214053	CAPZA1	0.27	5.89	0.47	3.46e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs10489202	0.608	rs7533646	chr1:168077593	A/C	cg24449463	chr1:168025552	DCAF6	-0.49	-5.06	-0.41	1.49e-6	Schizophrenia;
TGCT	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	5.03	0.41	1.69e-6	Prudent dietary pattern;
TGCT	cis	rs7027203	1.000	rs7854820	chr9:96526027	A/G	cg14396892	chr9:96623032	NA	0.24	4.66	0.39	8.02e-6	DNA methylation (variation);
TGCT	cis	rs11785400	0.793	rs7017851	chr8:143722038	G/T	cg24634471	chr8:143751801	JRK	0.53	5.11	0.42	1.17e-6	Schizophrenia;
TGCT	cis	rs12549902	0.966	rs10504042	chr8:41515993	G/A	cg00088007	chr8:41504566	NKX6-3	0.34	5.31	0.43	4.93e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
TGCT	cis	rs9611519	1.000	rs9611520	chr22:41613303	C/T	cg13695892	chr22:41940480	POLR3H	-0.5	-4.5	-0.37	1.56e-5	Neuroticism;
TGCT	cis	rs11098499	0.754	rs2036856	chr4:120249288	G/A	cg09307838	chr4:120376055	NA	0.61	5.91	0.47	3.14e-8	Corneal astigmatism;
TGCT	cis	rs8067545	0.750	rs9897246	chr17:19965702	T/G	cg13482628	chr17:19912719	NA	0.54	4.64	0.38	8.78e-6	Schizophrenia;
TGCT	cis	rs514406	0.683	rs6588440	chr1:53209587	C/T	cg24675658	chr1:53192096	ZYG11B	0.83	10.09	0.67	7.59e-18	Monocyte count;
TGCT	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg08219700	chr8:58056026	NA	0.31	4.53	0.38	1.36e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs112217694	1.000	rs77015219	chr4:104655062	A/T	cg24090629	chr4:104641072	TACR3	-0.97	-4.81	-0.4	4.25e-6	Menarche (age at onset);
TGCT	cis	rs1215050	0.669	rs783962	chr4:98884473	G/A	cg17366294	chr4:99064904	C4orf37	-0.58	-6.12	-0.48	1.13e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg20276088	chr3:133502917	NA	-0.24	-5.02	-0.41	1.77e-6	Iron status biomarkers;
TGCT	cis	rs6545883	0.894	rs6709441	chr2:61436930	A/T	cg15711740	chr2:61764176	XPO1	0.54	4.47	0.37	1.73e-5	Tuberculosis;
TGCT	cis	rs12477438	0.501	rs6708878	chr2:99801564	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.75	7.25	0.55	3.92e-11	Chronic sinus infection;
TGCT	cis	rs6840360	0.571	rs11940881	chr4:152501050	C/G	cg17479576	chr4:152424074	FAM160A1	-0.71	-7.72	-0.57	3.41e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg04944784	chr2:26401820	FAM59B	-0.73	-6.04	-0.48	1.65e-8	Gut microbiome composition (summer);
TGCT	cis	rs6582630	0.502	rs11504451	chr12:38425294	G/A	cg13010199	chr12:38710504	ALG10B	0.56	4.44	0.37	2e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs4654899	0.802	rs3767247	chr1:21227338	T/C	cg01072550	chr1:21505969	NA	-0.47	-7.06	-0.54	1.03e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs6424115	0.867	rs34902309	chr1:24192200	A/G	cg15997130	chr1:24165203	NA	-0.89	-10.26	-0.68	2.96e-18	Immature fraction of reticulocytes;
TGCT	cis	rs2617583	0.509	rs62331137	chr5:1459573	A/G	cg13982541	chr5:1466431	LPCAT1	0.19	4.51	0.38	1.48e-5	Breast cancer;
TGCT	cis	rs7249142	0.512	rs12981160	chr19:19298099	T/A	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.57	5.62	0.45	1.21e-7	IgG glycosylation;
TGCT	cis	rs9682041	1.000	rs9682041	chr3:170091902	C/T	cg11886554	chr3:170076028	SKIL	0.83	6.37	0.5	3.41e-9	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs7523273	0.606	rs2724387	chr1:207932617	T/G	cg22525895	chr1:207977042	MIR29B2	0.52	8.49	0.61	5.2e-14	Schizophrenia;
TGCT	cis	rs2243480	1.000	rs160633	chr7:65528228	T/C	cg07424592	chr7:64974309	NA	1.33	8.82	0.62	8.94e-15	Diabetic kidney disease;
TGCT	cis	rs11190604	1.000	rs2495745	chr10:102329075	A/G	cg16342193	chr10:102329863	NA	-0.42	-5.39	-0.44	3.47e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.49	-4.58	-0.38	1.09e-5	Prudent dietary pattern;
TGCT	cis	rs7772486	0.790	rs4280983	chr6:146280790	G/C	cg05347473	chr6:146136440	FBXO30	-0.54	-5.22	-0.42	7.44e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs8180040	0.966	rs13072802	chr3:47346415	G/C	cg27129171	chr3:47204927	SETD2	0.7	8.88	0.62	6.43e-15	Colorectal cancer;
TGCT	cis	rs9512730	0.553	rs6491212	chr13:28049631	T/C	cg04070771	chr13:27998621	GTF3A	0.52	4.7	0.39	6.83e-6	Schizophrenia;
TGCT	cis	rs10242455	0.702	rs116671616	chr7:98954558	C/T	cg13560068	chr7:99070416	ZNF789	1.1	4.68	0.39	7.38e-6	Blood metabolite levels;
TGCT	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2153535	0.541	rs5026687	chr6:8473957	A/T	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.3e-6	Motion sickness;
TGCT	cis	rs9928842	0.882	rs9927264	chr16:75260241	T/C	cg09066997	chr16:75300724	BCAR1	0.28	5.04	0.41	1.63e-6	Alcoholic chronic pancreatitis;
TGCT	cis	rs7666738	0.830	rs10470893	chr4:99038756	C/T	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7614311	0.636	rs73117045	chr3:63910613	A/G	cg22134162	chr3:63841271	THOC7	-0.49	-6.17	-0.48	8.78e-9	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs9517320	0.534	rs9556963	chr13:99157026	G/A	cg07423050	chr13:99094983	FARP1	-0.29	-5.81	-0.46	5.02e-8	Longevity;
TGCT	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg19635926	chr16:89946313	TCF25	0.29	4.84	0.4	3.84e-6	Skin colour saturation;
TGCT	cis	rs8026198	0.929	rs1659212	chr15:42625952	C/T	cg02624051	chr15:42371635	PLA2G4D	-0.34	-4.46	-0.37	1.82e-5	Fibrinogen levels;
TGCT	cis	rs2361718	0.933	rs8066452	chr17:78104080	A/G	cg09238746	chr17:78121135	EIF4A3	-0.56	-4.84	-0.4	3.83e-6	Yeast infection;
TGCT	cis	rs3796352	1.000	rs34943350	chr3:53012888	C/T	cg07884673	chr3:53033167	SFMBT1	0.64	6.39	0.5	3.03e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs4824093	0.610	rs4824113	chr22:50284974	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.5	5.14	0.42	1.05e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs28595532	0.920	rs114684527	chr4:119749252	G/T	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs4072705	0.935	rs2184219	chr9:127532904	A/G	cg13476313	chr9:127244764	NR5A1	0.3	4.67	0.39	7.59e-6	Menarche (age at onset);
TGCT	cis	rs2458413	0.522	rs2514657	chr8:105331215	T/C	cg04554929	chr8:105342491	NA	-0.62	-9.39	-0.64	3.73e-16	Paget's disease;
TGCT	cis	rs909674	0.818	rs5757680	chr22:39844793	C/T	cg11247378	chr22:39784982	NA	0.69	8.25	0.6	1.96e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs75059851	0.756	rs73036086	chr11:133841782	C/T	cg14047540	chr11:133829660	NA	-0.57	-5.69	-0.45	8.72e-8	Schizophrenia;
TGCT	cis	rs593982	1.000	rs56257941	chr11:65505641	C/T	cg08755490	chr11:65554678	OVOL1	-1.48	-10.77	-0.7	1.68e-19	Atopic dermatitis;
TGCT	cis	rs1023500	0.505	rs134887	chr22:42674239	A/G	cg05082376	chr22:42548792	NA	-0.21	-4.47	-0.37	1.76e-5	Schizophrenia;
TGCT	cis	rs2439831	0.681	rs7175434	chr15:43628542	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	6.73	0.52	5.55e-10	Lung cancer in ever smokers;
TGCT	cis	rs931608	0.640	rs2957824	chr19:22579316	T/C	cg23859931	chr19:22123797	NA	0.61	4.91	0.4	2.77e-6	Dental caries;Response to statins (LDL cholesterol change);
TGCT	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg02353165	chr6:42928485	GNMT	0.94	10.95	0.7	6.33e-20	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs10858047	0.883	rs41312702	chr1:115118622	A/G	cg12756093	chr1:115239321	AMPD1	0.47	4.96	0.41	2.27e-6	Autism;
TGCT	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg18876405	chr7:65276391	NA	0.31	4.78	0.39	4.81e-6	Aortic root size;
TGCT	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg11764359	chr7:65958608	NA	0.61	5.53	0.44	1.84e-7	Aortic root size;
TGCT	cis	rs3806843	0.576	rs246009	chr5:140338069	A/G	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	0.41	5.24	0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9399135	0.935	rs6908681	chr6:135337733	A/G	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.36e-6	Red blood cell count;
TGCT	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.65	-5.2	-0.42	8.01e-7	Lung function (FEV1/FVC);
TGCT	cis	rs2204008	0.774	rs7305085	chr12:38263511	C/T	cg26384229	chr12:38710491	ALG10B	0.86	7.48	0.56	1.17e-11	Bladder cancer;
TGCT	cis	rs5167	0.533	rs55778858	chr19:45485465	G/A	cg09555818	chr19:45449301	APOC2	0.23	4.62	0.38	9.53e-6	Blood protein levels;
TGCT	cis	rs9486719	1.000	rs11152951	chr6:96894135	C/G	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.86	-0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.65	-5.2	-0.42	8.01e-7	Lung function (FEV1/FVC);
TGCT	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg06221963	chr1:154839813	KCNN3	-0.78	-13.2	-0.76	2.22e-25	Prostate cancer;
TGCT	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs7647973	1.000	rs3905330	chr3:49550774	A/G	cg05785598	chr3:49045655	WDR6	0.37	4.59	0.38	1.05e-5	Menarche (age at onset);
TGCT	cis	rs2334880	0.680	rs1364210	chr16:71603487	G/A	cg06353428	chr16:71660113	MARVELD3	-1.3	-10.66	-0.69	3.08e-19	Malaria;
TGCT	cis	rs2932538	0.922	rs34531155	chr1:113141550	C/T	cg10983938	chr1:113465962	AFARP1;SLC16A1	0.21	4.44	0.37	1.99e-5	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg17971929	chr21:40555470	PSMG1	0.98	9.57	0.65	1.43e-16	Cognitive function;
TGCT	cis	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg12570787	chr5:219185	SDHA;CCDC127	0.66	4.49	0.37	1.62e-5	Breast cancer;
TGCT	cis	rs1865760	0.534	rs72834629	chr6:26023032	C/T	cg16482183	chr6:26056742	HIST1H1C	0.67	5.44	0.44	2.72e-7	Height;
TGCT	cis	rs797680	0.897	rs12133907	chr1:93850283	C/A	cg17826107	chr1:92977322	EVI5	-0.24	-5.6	-0.45	1.29e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs7666738	0.606	rs4637413	chr4:99088151	A/G	cg18180107	chr4:99064573	C4orf37	0.53	4.67	0.39	7.61e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg03806693	chr22:41940476	POLR3H	1.11	12.05	0.73	1.3e-22	Vitiligo;
TGCT	cis	rs17764205	0.777	rs10424519	chr19:3253532	C/G	cg20583073	chr19:3178759	S1PR4	-0.32	-4.63	-0.38	9.24e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs9325144	0.647	rs11168819	chr12:39011082	C/A	cg10518543	chr12:38710700	ALG10B	-0.51	-4.94	-0.41	2.49e-6	Morning vs. evening chronotype;
TGCT	cis	rs1153858	0.668	rs63603561	chr15:45593323	T/A	cg26924012	chr15:45694286	SPATA5L1	-1.0	-10.83	-0.7	1.22e-19	Homoarginine levels;
TGCT	cis	rs12142240	0.660	rs72890715	chr1:46852077	A/G	cg14993813	chr1:46806288	NSUN4	-0.59	-4.86	-0.4	3.45e-6	Menopause (age at onset);
TGCT	cis	rs28595532	0.920	rs10025640	chr4:119787451	G/A	cg21605333	chr4:119757512	SEC24D	1.44	8.24	0.6	2.03e-13	Cannabis dependence symptom count;
TGCT	cis	rs2046867	0.862	rs6549483	chr3:72805316	T/G	cg25664220	chr3:72788482	NA	-0.55	-6.96	-0.53	1.79e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs1865760	0.566	rs2051544	chr6:26071093	C/T	cg17042849	chr6:26104293	HIST1H4C	-0.63	-5.5	-0.44	2.1e-7	Height;
TGCT	cis	rs8180040	0.966	rs9683177	chr3:47490493	G/A	cg27129171	chr3:47204927	SETD2	0.66	8.01	0.58	7.07e-13	Colorectal cancer;
TGCT	cis	rs1903068	0.853	rs10012589	chr4:56002689	A/T	cg01777861	chr4:56023843	NA	0.53	6.21	0.49	7.2e-9	Endometriosis;
TGCT	cis	rs9926296	0.557	rs11076618	chr16:89807705	T/C	cg04287289	chr16:89883240	FANCA	0.67	6.7	0.52	6.53e-10	Vitiligo;
TGCT	cis	rs6089584	0.566	rs6061972	chr20:60610245	C/T	cg06108461	chr20:60628389	TAF4	-0.44	-5.58	-0.45	1.44e-7	Body mass index;
TGCT	cis	rs617219	0.698	rs13177470	chr5:78495899	T/C	cg09550809	chr5:78407562	BHMT	0.4	5.71	0.46	7.79e-8	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs1008375	0.900	rs12650220	chr4:17595365	A/T	cg16339924	chr4:17578868	LAP3	0.8	6.56	0.51	1.34e-9	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs826838	1.000	rs10875717	chr12:38911174	T/C	cg13010199	chr12:38710504	ALG10B	0.78	6.42	0.5	2.61e-9	Heart rate;
TGCT	cis	rs7666738	0.830	rs13133619	chr4:99067312	C/G	cg18180107	chr4:99064573	C4orf37	-0.58	-5.32	-0.43	4.68e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.44	6.28	0.49	5.28e-9	Lymphocyte counts;
TGCT	cis	rs7714584	1.000	rs59980321	chr5:150241813	A/T	cg22134413	chr5:150180641	NA	0.93	6.99	0.53	1.52e-10	Crohn's disease;
TGCT	cis	rs6840360	0.571	rs4696278	chr4:152558978	A/G	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.0	-0.58	7.69e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs28451001	chr4:98924544	T/A	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs35146811	0.735	rs1636978	chr7:99813912	G/A	cg00553149	chr7:99775558	STAG3;GPC2	-0.32	-4.81	-0.4	4.28e-6	Coronary artery disease;
TGCT	cis	rs4727027	0.865	rs12154368	chr7:148862041	C/T	cg23583168	chr7:148888333	NA	-0.76	-10.09	-0.67	7.46e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs1348850	0.651	rs1901824	chr2:178225466	T/C	cg22681709	chr2:178499509	PDE11A	-0.35	-4.54	-0.38	1.3e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs11098499	0.779	rs72918579	chr4:120333222	G/C	cg09307838	chr4:120376055	NA	0.7	6.72	0.52	5.94e-10	Corneal astigmatism;
TGCT	cis	rs17443541	0.507	rs2346107	chr2:200447353	G/A	cg00055341	chr2:200446845	NA	-0.38	-4.6	-0.38	1.02e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs9549367	0.673	rs3024735	chr13:113819513	G/A	cg00898013	chr13:113819073	PROZ	-0.52	-6.43	-0.5	2.52e-9	Platelet distribution width;
TGCT	cis	rs4478858	0.735	rs7547897	chr1:31797593	G/A	cg07478791	chr1:31886160	SERINC2	-0.51	-4.95	-0.41	2.33e-6	Alcohol dependence;
TGCT	cis	rs858239	0.600	rs1115941	chr7:23137188	C/T	cg05602783	chr7:23145260	KLHL7	-0.66	-5.55	-0.45	1.65e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs6831352	0.918	rs34805407	chr4:100050786	C/A	cg12011299	chr4:100065546	ADH4	-0.41	-4.92	-0.4	2.72e-6	Alcohol dependence;
TGCT	cis	rs2033711	0.837	rs3764535	chr19:58929052	G/A	cg13877915	chr19:58951672	ZNF132	0.88	10.81	0.7	1.36e-19	Uric acid clearance;
TGCT	cis	rs13256369	0.802	rs11781257	chr8:8559663	A/T	cg18904891	chr8:8559673	CLDN23	0.56	5.0	0.41	1.94e-6	Obesity-related traits;
TGCT	cis	rs2688608	0.934	rs2675679	chr10:75658581	C/T	cg19442545	chr10:75533431	FUT11	-0.3	-4.76	-0.39	5.23e-6	Inflammatory bowel disease;
TGCT	cis	rs1215050	0.791	rs165247	chr4:98692399	A/G	cg17366294	chr4:99064904	C4orf37	0.52	5.61	0.45	1.27e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs10883723	0.810	rs2296582	chr10:104244139	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.8	8.53	0.61	4.33e-14	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs2760061	0.659	rs708107	chr1:228189495	C/T	cg18477163	chr1:228402036	OBSCN	0.34	6.92	0.53	2.17e-10	Diastolic blood pressure;
TGCT	cis	rs1538970	0.884	rs1771551	chr1:45883643	C/G	cg05343316	chr1:45956843	TESK2	0.74	5.81	0.46	4.85e-8	Platelet count;
TGCT	cis	rs6089829	0.962	rs1116450	chr20:61658210	T/C	cg02380750	chr20:61661411	NA	0.33	5.96	0.47	2.4e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg00080972	chr5:178986291	RUFY1	0.54	6.6	0.51	1.07e-9	Lung cancer;
TGCT	cis	rs6121246	0.567	rs6060247	chr20:30190720	C/G	cg18721089	chr20:30220636	NA	-0.63	-6.86	-0.52	2.95e-10	Mean corpuscular hemoglobin;
TGCT	cis	rs8017423	0.522	rs12887028	chr14:90819605	A/G	cg04374321	chr14:90722782	PSMC1	-0.56	-5.62	-0.45	1.19e-7	Mortality in heart failure;
TGCT	trans	rs2970818	0.831	rs2909381	chr12:4606527	T/C	cg22985033	chr20:36975012	LBP	0.27	6.71	0.52	6.11e-10	Phosphorus levels;
TGCT	trans	rs1005277	0.577	rs4934906	chr10:38015028	C/T	cg17830980	chr10:43048298	ZNF37B	-0.63	-6.84	-0.52	3.16e-10	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7267979	1.000	rs2482930	chr20:25334115	G/C	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10507380	0.824	rs79079188	chr13:27926284	A/G	cg25543773	chr13:27185723	WASF3	0.32	4.52	0.38	1.45e-5	Electrocardiographic traits;
TGCT	cis	rs17764205	0.568	rs72987040	chr19:3251116	C/A	cg18738857	chr19:3606974	TBXA2R	-0.73	-4.53	-0.38	1.35e-5	Bipolar disorder and schizophrenia;
TGCT	cis	rs7769051	0.808	rs1467403	chr6:133089952	T/A	cg07930552	chr6:133119739	C6orf192	0.93	5.0	0.41	1.87e-6	Type 2 diabetes nephropathy;
TGCT	cis	rs11696845	0.666	rs13042905	chr20:43379454	T/C	cg25301532	chr20:43378953	KCNK15	0.45	5.03	0.41	1.69e-6	Obesity-related traits;
TGCT	cis	rs2233152	0.519	rs11083567	chr19:41318306	C/T	cg23743927	chr19:41304969	EGLN2	-0.57	-4.45	-0.37	1.89e-5	Kawasaki disease;
TGCT	cis	rs7246657	0.722	rs2927747	chr19:38159530	C/T	cg03611452	chr19:38183253	ZNF781	-0.57	-4.79	-0.39	4.72e-6	Coronary artery calcification;
TGCT	cis	rs7681440	0.845	rs6843084	chr4:90766230	T/C	cg14346243	chr4:90757452	SNCA	-0.57	-5.6	-0.45	1.31e-7	Dementia with Lewy bodies;
TGCT	cis	rs2840044	0.517	rs2124247	chr17:33885468	G/A	cg05299278	chr17:33885742	SLFN14	0.22	4.92	0.4	2.7e-6	Response to radiotherapy in cancer (late toxicity);
TGCT	cis	rs6815814	0.851	rs5743551	chr4:38807654	T/C	cg02016764	chr4:38805732	TLR1	-0.3	-5.24	-0.43	6.74e-7	Breast cancer;
TGCT	cis	rs1729951	0.546	rs12054408	chr3:136677645	T/C	cg21827317	chr3:136751795	NA	0.4	5.61	0.45	1.28e-7	Neuroticism;
TGCT	cis	rs2439831	0.850	rs28509275	chr15:44098105	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.96	6.13	0.48	1.1e-8	Lung cancer in ever smokers;
TGCT	cis	rs6570726	0.935	rs382910	chr6:145865941	G/A	cg05347473	chr6:146136440	FBXO30	0.49	4.51	0.38	1.46e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs17102423	0.826	rs17825846	chr14:65598752	C/G	cg11161011	chr14:65562177	MAX	-0.57	-7.95	-0.58	1.01e-12	Obesity-related traits;
TGCT	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg04546413	chr19:29218101	NA	0.84	6.76	0.52	4.71e-10	Methadone dose in opioid dependence;
TGCT	cis	rs78487399	0.808	rs13414140	chr2:43671176	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.66	-0.45	9.88e-8	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs7822232	0.908	rs1127096	chr8:145140472	A/G	cg06239191	chr8:145163136	KIAA1875	-0.88	-6.45	-0.5	2.26e-9	Blood metabolite levels;
TGCT	cis	rs709400	0.659	rs3825566	chr14:103852725	C/T	cg12935359	chr14:103987150	CKB	0.35	5.28	0.43	5.62e-7	Body mass index;
TGCT	cis	rs2455799	0.573	rs2255248	chr3:15754849	A/G	cg16303742	chr3:15540471	COLQ	0.24	4.71	0.39	6.64e-6	Mean platelet volume;
TGCT	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg01171360	chr6:293285	DUSP22	-0.78	-7.87	-0.58	1.47e-12	Menopause (age at onset);
TGCT	trans	rs7824557	0.569	rs10106207	chr8:11015338	C/T	cg15556689	chr8:8085844	FLJ10661	-0.86	-8.59	-0.61	3.03e-14	Retinal vascular caliber;
TGCT	cis	rs7258465	1.000	rs7251653	chr19:18608283	C/T	cg06462663	chr19:18546047	ISYNA1	0.2	4.67	0.39	7.74e-6	Breast cancer;
TGCT	cis	rs7017914	0.811	rs1389204	chr8:71928298	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.56	-5.11	-0.42	1.21e-6	Bone mineral density;
TGCT	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/A	cg00383909	chr3:49044727	WDR6	1.06	6.28	0.49	5.26e-9	Parkinson's disease;
TGCT	cis	rs734999	0.505	rs4278312	chr1:2539555	A/G	cg18854424	chr1:2615690	NA	0.46	5.36	0.43	4e-7	Ulcerative colitis;
TGCT	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg02725872	chr8:58115012	NA	-0.42	-5.11	-0.42	1.2e-6	Developmental language disorder (linguistic errors);
TGCT	trans	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg11887960	chr12:57824829	NA	1.12	9.19	0.64	1.16e-15	Obesity-related traits;
TGCT	cis	rs9549367	0.713	rs56002882	chr13:113830694	T/C	cg18105134	chr13:113819100	PROZ	-0.47	-8.24	-0.59	2.05e-13	Platelet distribution width;
TGCT	cis	rs7659604	0.540	rs4240264	chr4:122683818	A/G	cg19748678	chr4:122722346	EXOSC9	-0.51	-5.06	-0.41	1.46e-6	Type 2 diabetes;
TGCT	cis	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg08564027	chr20:61660810	NA	0.37	6.85	0.52	3.1e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7178572	1.000	rs34591043	chr15:77713586	A/G	cg22256960	chr15:77711686	NA	-0.95	-10.93	-0.7	6.95e-20	Type 2 diabetes;
TGCT	cis	rs9393692	0.905	rs7450556	chr6:26299900	C/T	cg13736514	chr6:26305472	NA	-0.41	-5.77	-0.46	6.03e-8	Educational attainment;
TGCT	cis	rs7267979	0.714	rs6132825	chr20:25238309	A/T	cg16686733	chr20:25566563	NINL	0.49	4.46	0.37	1.8e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7772486	0.534	rs34541797	chr6:146205304	A/G	cg23711669	chr6:146136114	FBXO30	0.74	6.96	0.53	1.75e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3888647	0.561	rs4758617	chr11:2995185	T/A	cg05729581	chr11:3078854	CARS	-0.54	-4.82	-0.4	4.19e-6	Type 2 diabetes;
TGCT	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg15595755	chr5:1867978	NA	0.46	5.31	0.43	4.79e-7	Cardiovascular disease risk factors;
TGCT	cis	rs1371867	0.846	rs1660347	chr8:101314980	G/A	cg06636551	chr8:101224915	SPAG1	-0.48	-6.52	-0.51	1.62e-9	Atrioventricular conduction;
TGCT	cis	rs7726839	0.561	rs72703046	chr5:580129	T/C	cg09021430	chr5:549028	NA	-0.37	-5.39	-0.44	3.37e-7	Obesity-related traits;
TGCT	cis	rs8180040	0.587	rs1466741	chr3:47247214	C/T	cg27129171	chr3:47204927	SETD2	-0.7	-8.35	-0.6	1.13e-13	Colorectal cancer;
TGCT	cis	rs546131	0.614	rs473885	chr11:34851961	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.52	4.55	0.38	1.28e-5	Lung disease severity in cystic fibrosis;
TGCT	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg03452623	chr4:187889614	NA	-0.36	-5.3	-0.43	5.01e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3820068	0.603	rs35509554	chr1:15993514	C/T	cg05660106	chr1:15850417	CASP9	0.7	6.58	0.51	1.21e-9	Systolic blood pressure;
TGCT	cis	rs10465746	0.905	rs12127266	chr1:84360767	T/G	cg10977910	chr1:84465055	TTLL7	0.63	6.19	0.49	8.08e-9	Obesity-related traits;
TGCT	cis	rs35160687	0.871	rs11127028	chr2:86537509	A/T	cg12542933	chr2:85804724	VAMP8	0.41	4.9	0.4	2.97e-6	Night sleep phenotypes;
TGCT	cis	rs7829975	0.871	rs7829826	chr8:8578120	T/A	cg15556689	chr8:8085844	FLJ10661	-0.7	-6.06	-0.48	1.53e-8	Mood instability;
TGCT	trans	rs1814175	0.817	rs1615305	chr11:49895222	T/A	cg03929089	chr4:120376271	NA	-0.72	-8.26	-0.6	1.86e-13	Height;
TGCT	cis	rs17001868	0.892	rs73167027	chr22:40808676	A/T	cg07138101	chr22:40742427	ADSL	0.78	5.29	0.43	5.4e-7	Mammographic density (dense area);
TGCT	cis	rs6430585	0.640	rs3816155	chr2:136552526	A/C	cg07169764	chr2:136633963	MCM6	-1.19	-11.11	-0.71	2.49e-20	Corneal structure;
TGCT	cis	rs7914558	1.000	rs7914558	chr10:104775908	G/A	cg04362960	chr10:104952993	NT5C2	0.6	5.34	0.43	4.34e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs599083	0.744	rs603129	chr11:68186669	A/T	cg16797656	chr11:68205561	LRP5	-0.26	-4.44	-0.37	2.01e-5	Bone mineral density (spine);
TGCT	cis	rs2580764	0.515	rs7570629	chr2:55255935	A/T	cg09592903	chr2:55203963	RTN4	-0.27	-6.07	-0.48	1.46e-8	Mean platelet volume;
TGCT	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg06634786	chr22:41940651	POLR3H	-0.9	-8.58	-0.61	3.3e-14	Vitiligo;
TGCT	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg12419862	chr22:24373484	LOC391322	-0.79	-8.23	-0.59	2.19e-13	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2032447	0.677	rs199737	chr6:25933538	A/T	cg15691649	chr6:25882328	NA	-0.41	-4.73	-0.39	5.91e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7615952	0.673	rs3811677	chr3:125648080	G/A	cg05084668	chr3:125655381	ALG1L	-0.76	-6.08	-0.48	1.39e-8	Blood pressure (smoking interaction);
TGCT	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg22168489	chr12:122356033	WDR66	0.22	4.68	0.39	7.36e-6	Mean corpuscular volume;
TGCT	cis	rs7811142	0.945	rs6978739	chr7:100098680	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.1	9.08	0.63	2.06e-15	Platelet count;
TGCT	cis	rs7818688	0.697	rs35032356	chr8:95977484	G/T	cg16049864	chr8:95962084	TP53INP1	0.54	4.64	0.38	8.87e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs7210837	0.527	rs35638255	chr17:16784344	G/C	cg00849854	chr17:17780937	TOM1L2	0.35	4.45	0.37	1.85e-5	Response to platinum-based chemotherapy (cisplatin);
TGCT	cis	rs11785400	1.000	rs754957	chr8:143746416	A/G	cg24634471	chr8:143751801	JRK	0.55	5.92	0.47	2.93e-8	Schizophrenia;
TGCT	cis	rs12682352	0.650	rs13265731	chr8:8673320	T/C	cg06636001	chr8:8085503	FLJ10661	0.6	5.07	0.41	1.41e-6	Neuroticism;
TGCT	cis	rs9830388	1.000	rs60430884	chr3:23559661	G/T	cg26146027	chr3:24536889	THRB	0.5	4.44	0.37	1.96e-5	RR interval (tricyclic/tetracyclic antidepressant use interaction);
TGCT	cis	rs4455778	0.561	rs56235551	chr7:49128132	C/T	cg26309511	chr7:48887640	NA	0.5	6.51	0.5	1.66e-9	Lung cancer in never smokers;
TGCT	cis	rs6121246	0.567	rs6060249	chr20:30190944	G/A	cg13852791	chr20:30311386	BCL2L1	0.69	4.54	0.38	1.33e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs61931739	0.500	rs6488215	chr12:34434803	A/T	cg06521331	chr12:34319734	NA	-0.28	-4.51	-0.38	1.47e-5	Morning vs. evening chronotype;
TGCT	cis	rs910316	0.737	rs175065	chr14:75494983	T/C	cg08847533	chr14:75593920	NEK9	-0.83	-8.74	-0.62	1.4e-14	Height;
TGCT	cis	rs10751667	0.666	rs11246357	chr11:963980	A/C	cg06064525	chr11:970664	AP2A2	-0.35	-8.23	-0.59	2.17e-13	Alzheimer's disease (late onset);
TGCT	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg13866156	chr1:1669148	SLC35E2	-0.22	-5.21	-0.42	7.51e-7	Body mass index;
TGCT	cis	rs9796	0.689	rs11855797	chr15:41434679	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.53	-6.84	-0.52	3.24e-10	Menopause (age at onset);
TGCT	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg06112835	chr11:68658793	MRPL21	0.48	8.13	0.59	3.78e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg06618935	chr21:46677482	NA	-0.37	-5.64	-0.45	1.1e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs344364	0.511	rs1742472	chr16:1953040	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.46	-5.31	-0.43	4.97e-7	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs9611565	0.559	rs4822048	chr22:41988225	C/T	cg06634786	chr22:41940651	POLR3H	-0.89	-8.16	-0.59	3.16e-13	Vitiligo;
TGCT	cis	rs7044106	0.791	rs2416797	chr9:123480600	C/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	7.1	0.54	8.41e-11	Hip circumference adjusted for BMI;
TGCT	cis	rs7208859	0.524	rs11653605	chr17:29088385	T/G	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs2295359	1.000	rs9729046	chr1:67607082	C/G	cg12940439	chr1:67600707	NA	0.59	6.16	0.48	9.5e-9	Psoriasis;
TGCT	cis	rs9581857	0.547	rs7989917	chr13:28071271	G/A	cg22138327	chr13:27999177	GTF3A	0.77	5.02	0.41	1.78e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs3617	0.539	rs4687687	chr3:52948332	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	0.49	4.85	0.4	3.57e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg00024416	chr22:24240387	NA	0.33	5.56	0.45	1.55e-7	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg24829409	chr8:58192753	C8orf71	-0.59	-4.97	-0.41	2.17e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.61	-8.66	-0.61	2.16e-14	Longevity;Endometriosis;
TGCT	cis	rs4409675	0.576	rs6662916	chr1:28219873	G/T	cg23691781	chr1:28212827	C1orf38	0.26	5.32	0.43	4.68e-7	Corneal astigmatism;
TGCT	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg08048268	chr3:133502702	NA	0.6	8.64	0.61	2.33e-14	Iron status biomarkers;
TGCT	cis	rs4383453	0.539	rs4678021	chr3:123102376	A/G	cg04890266	chr3:123102914	ADCY5	-0.49	-7.91	-0.58	1.23e-12	Gestational age at birth (maternal effect);
TGCT	cis	rs637571	0.780	rs677029	chr11:65683531	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.58	5.66	0.45	1.01e-7	Eosinophil percentage of white cells;
TGCT	cis	rs2710642	0.888	rs13418889	chr2:63079775	T/C	cg17519650	chr2:63277830	OTX1	0.66	6.14	0.48	1.02e-8	LDL cholesterol levels;LDL cholesterol;
TGCT	cis	rs7666738	0.830	rs11097600	chr4:98959564	T/G	cg05340658	chr4:99064831	C4orf37	0.53	6.02	0.48	1.8e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1355223	0.583	rs1396881	chr11:34870506	G/T	cg24088639	chr11:34937564	PDHX;APIP	-0.51	-4.54	-0.38	1.31e-5	Systemic lupus erythematosus and Systemic sclerosis;
TGCT	cis	rs1878931	0.582	rs40633	chr16:3425325	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.76	-6.41	-0.5	2.7e-9	Body mass index (adult);
TGCT	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg11644478	chr21:40555479	PSMG1	0.97	10.04	0.67	9.92e-18	Cognitive function;
TGCT	cis	rs853679	0.567	rs3799499	chr6:28354250	G/T	cg18815343	chr6:28367644	ZSCAN12	-0.52	-4.74	-0.39	5.68e-6	Depression;
TGCT	cis	rs1577917	0.538	rs6454483	chr6:86418283	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.55	5.0	0.41	1.88e-6	Response to antipsychotic treatment;
TGCT	cis	rs12887734	0.546	rs12886637	chr14:104222892	A/G	cg26031613	chr14:104095156	KLC1	0.72	6.2	0.49	7.61e-9	Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7760949	0.888	rs9296853	chr6:13893945	T/A	cg27413430	chr6:13925136	RNF182	0.52	4.74	0.39	5.64e-6	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs7909074	1.000	rs10736831	chr10:45402311	G/A	cg04218760	chr10:45406644	TMEM72	-0.27	-5.33	-0.43	4.54e-7	Mean corpuscular volume;
TGCT	cis	rs7647973	0.580	rs12637576	chr3:49237334	C/T	cg06212747	chr3:49208901	KLHDC8B	0.62	5.74	0.46	6.79e-8	Menarche (age at onset);
TGCT	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg18876405	chr7:65276391	NA	0.36	5.36	0.43	3.84e-7	Aortic root size;
TGCT	cis	rs6693567	0.516	rs3850844	chr1:150413940	G/T	cg09579323	chr1:150459698	TARS2	0.52	4.62	0.38	9.56e-6	Migraine;
TGCT	cis	rs7824557	0.614	rs2293860	chr8:11219386	G/T	cg21775007	chr8:11205619	TDH	0.67	6.47	0.5	2.03e-9	Retinal vascular caliber;
TGCT	cis	rs9467773	0.620	rs2504567	chr6:26662920	C/G	cg09904177	chr6:26538194	HMGN4	0.68	6.31	0.49	4.52e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs2050392	0.517	rs160017	chr10:30772894	A/G	cg18806716	chr10:30721971	MAP3K8	-0.5	-5.74	-0.46	6.88e-8	Inflammatory bowel disease;
TGCT	cis	rs4699052	0.625	rs11734836	chr4:104253203	G/A	cg16532752	chr4:104119610	CENPE	-0.5	-4.92	-0.4	2.71e-6	Testicular germ cell tumor;
TGCT	cis	rs9807989	0.507	rs10200952	chr2:103027651	A/C	cg03938978	chr2:103052716	IL18RAP	0.27	5.41	0.44	3.17e-7	Asthma;
TGCT	cis	rs17376456	0.877	rs34595581	chr5:93369422	G/A	cg25358565	chr5:93447407	FAM172A	0.92	8.38	0.6	9.58e-14	Diabetic retinopathy;
TGCT	cis	rs3091242	0.904	rs6661533	chr1:25771715	A/G	cg00786635	chr1:25594202	NA	0.54	5.78	0.46	5.67e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs5769707	0.935	rs739239	chr22:50050468	G/A	cg20744362	chr22:50050164	C22orf34	0.28	4.62	0.38	9.53e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs5760092	0.755	rs6003959	chr22:24264395	C/T	cg04234412	chr22:24373322	LOC391322	0.92	8.61	0.61	2.85e-14	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs453301	0.686	rs7814328	chr8:8876229	T/C	cg00184457	chr8:8946301	NA	-0.27	-4.93	-0.4	2.62e-6	Joint mobility (Beighton score);
TGCT	cis	rs6993813	0.653	rs4355805	chr8:120016374	A/G	cg17171407	chr8:119960777	TNFRSF11B	0.26	4.66	0.39	8.02e-6	Bone mineral density (hip);
TGCT	cis	rs12142240	0.698	rs41293273	chr1:46806393	T/C	cg00530320	chr1:46809349	NSUN4	0.29	5.95	0.47	2.58e-8	Menopause (age at onset);
TGCT	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg06634786	chr22:41940651	POLR3H	0.89	8.31	0.6	1.44e-13	Vitiligo;
TGCT	cis	rs7192750	0.535	rs152826	chr16:72126180	A/G	cg06353428	chr16:71660113	MARVELD3	1.12	5.56	0.45	1.59e-7	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs6840360	0.967	rs10028410	chr4:152606573	T/C	cg17479576	chr4:152424074	FAM160A1	-0.48	-5.17	-0.42	9.02e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs67460515	0.563	rs6441362	chr3:160877613	G/A	cg03342759	chr3:160939853	NMD3	-0.45	-4.53	-0.38	1.38e-5	Parkinson's disease;
TGCT	cis	rs13188771	0.651	rs68082730	chr5:100903250	C/T	cg18665594	chr5:101119420	NA	0.44	4.47	0.37	1.74e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs2241685	0.850	rs3748989	chr2:1946968	C/T	cg21862353	chr2:1801628	MYT1L	-0.52	-4.77	-0.39	5.05e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs3125734	0.633	rs1368157	chr10:64001114	T/C	cg05499367	chr10:63213510	TMEM26	-0.33	-4.44	-0.37	1.96e-5	Rheumatoid arthritis;
TGCT	cis	rs2204008	0.744	rs11514071	chr12:38392076	C/T	cg26384229	chr12:38710491	ALG10B	0.83	7.26	0.55	3.72e-11	Bladder cancer;
TGCT	cis	rs6912958	0.525	rs59322	chr6:88020521	C/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.4	4.6	0.38	1.04e-5	Monocyte percentage of white cells;
TGCT	cis	rs9341808	0.754	rs3805907	chr6:80973665	A/G	cg08355045	chr6:80787529	NA	-0.29	-5.0	-0.41	1.94e-6	Sitting height ratio;
TGCT	cis	rs9309473	0.607	rs7586361	chr2:73601606	G/A	cg20560298	chr2:73613845	ALMS1	-0.41	-4.54	-0.38	1.31e-5	Metabolite levels;
TGCT	trans	rs208520	1.000	rs72882079	chr6:66973878	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.86	7.83	0.58	1.85e-12	Exhaled nitric oxide output;
TGCT	cis	rs1865760	0.532	rs2794719	chr6:26088890	T/G	cg16482183	chr6:26056742	HIST1H1C	0.57	4.82	0.4	4.06e-6	Height;
TGCT	cis	rs9527	0.615	rs7917295	chr10:104701187	A/G	cg15744005	chr10:104629667	AS3MT	-0.45	-5.31	-0.43	4.9e-7	Arsenic metabolism;
TGCT	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.08	0.48	1.37e-8	Bipolar disorder;
TGCT	cis	rs17152411	0.895	rs7094116	chr10:126587644	T/G	cg07906193	chr10:126599966	NA	0.41	5.05	0.41	1.52e-6	Height;
TGCT	cis	rs11874712	1.000	rs11082510	chr18:43656620	T/A	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	5.23	0.42	7.11e-7	Migraine - clinic-based;
TGCT	cis	rs2637266	1.000	rs1077916	chr10:78381951	G/A	cg18941641	chr10:78392320	NA	0.39	4.88	0.4	3.24e-6	Pulmonary function;
TGCT	cis	rs6598955	0.671	rs17163749	chr1:26568165	A/G	cg04990556	chr1:26633338	UBXN11	0.62	4.82	0.4	4.06e-6	Obesity-related traits;
TGCT	cis	rs651907	0.557	rs1056579	chr3:101397877	T/G	cg12386194	chr3:101231763	SENP7	0.53	5.13	0.42	1.08e-6	Colorectal cancer;
TGCT	cis	rs931608	0.585	rs55851405	chr19:22541686	T/C	cg15554505	chr19:22123728	NA	-0.65	-4.68	-0.39	7.41e-6	Dental caries;Response to statins (LDL cholesterol change);
TGCT	cis	rs10464366	0.746	rs4723821	chr7:39141532	A/G	cg18850127	chr7:39170497	POU6F2	0.27	5.7	0.46	8.11e-8	IgG glycosylation;
TGCT	trans	rs877282	0.898	rs11253356	chr10:768604	G/A	cg22713356	chr15:30763199	NA	1.04	8.6	0.61	2.95e-14	Uric acid levels;
TGCT	cis	rs12549902	0.897	rs12549294	chr8:41506380	A/G	cg00088007	chr8:41504566	NKX6-3	0.34	5.47	0.44	2.33e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
TGCT	cis	rs60733400	0.782	rs4648564	chr1:2562169	C/T	cg18854424	chr1:2615690	NA	-0.47	-5.38	-0.44	3.57e-7	Multiple sclerosis;
TGCT	cis	rs7772486	0.790	rs2249386	chr6:146186611	G/A	cg23711669	chr6:146136114	FBXO30	0.97	11.36	0.71	6.35e-21	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7760949	0.889	rs9475795	chr6:13931270	A/C	cg27413430	chr6:13925136	RNF182	0.73	6.76	0.52	4.76e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs7666738	0.830	rs4492007	chr4:98959848	A/T	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2070488	0.804	rs4678605	chr3:38444489	T/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	7.75	0.57	2.92e-12	Electrocardiographic conduction measures;
TGCT	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg06112835	chr11:68658793	MRPL21	0.47	8.28	0.6	1.65e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg02953382	chr22:24373134	LOC391322	-0.83	-9.54	-0.65	1.69e-16	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7043114	0.525	rs8067	chr9:95218829	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-5.37	-0.43	3.72e-7	Height;
TGCT	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg18876405	chr7:65276391	NA	0.33	5.05	0.41	1.55e-6	Aortic root size;
TGCT	cis	rs61680841	0.627	rs16945457	chr15:91795758	A/C	cg13615036	chr15:91475826	UNC45A;HDDC3	-0.71	-4.82	-0.4	4.1e-6	Age-related hearing impairment;
TGCT	cis	rs9581857	0.547	rs9581878	chr13:28104552	T/A	cg22138327	chr13:27999177	GTF3A	0.72	4.75	0.39	5.45e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs881375	0.967	rs2270231	chr9:123650982	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.39	4.53	0.38	1.35e-5	Rheumatoid arthritis;
TGCT	cis	rs2242116	0.793	rs9855938	chr3:46957298	G/A	cg23352942	chr3:46931381	PTH1R	-0.33	-4.92	-0.4	2.67e-6	Birth weight;
TGCT	cis	rs826838	0.684	rs12367400	chr12:38618673	G/T	cg13010199	chr12:38710504	ALG10B	0.65	5.15	0.42	9.92e-7	Heart rate;
TGCT	cis	rs6754311	0.773	rs2322818	chr2:136775898	T/C	cg07169764	chr2:136633963	MCM6	0.64	5.97	0.47	2.28e-8	Mosquito bite size;
TGCT	cis	rs9443189	0.530	rs614065	chr6:76315633	G/A	cg01950844	chr6:76311363	SENP6	0.99	6.27	0.49	5.49e-9	Prostate cancer;
TGCT	cis	rs6089584	0.527	rs927589	chr20:60606363	A/G	cg13770153	chr20:60521292	NA	-0.39	-4.77	-0.39	5.17e-6	Body mass index;
TGCT	cis	rs6665290	0.901	rs68087483	chr1:227202668	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.98	-20.12	-0.87	7.08e-41	Myeloid white cell count;
TGCT	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg11890956	chr21:40555474	PSMG1	1.03	10.49	0.69	7.98e-19	Cognitive function;
TGCT	cis	rs9926296	0.656	rs2376884	chr16:89826922	C/T	cg26513180	chr16:89883248	FANCA	0.7	6.76	0.52	4.76e-10	Vitiligo;
TGCT	trans	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg27523141	chr10:43048294	ZNF37B	0.68	7.92	0.58	1.12e-12	Extrinsic epigenetic age acceleration;
TGCT	cis	rs42648	0.564	rs10224488	chr7:89810261	A/G	cg25739043	chr7:89950458	NA	-0.49	-4.51	-0.38	1.48e-5	Homocysteine levels;
TGCT	cis	rs3784262	0.669	rs3742960	chr15:58248088	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.43	-6.23	-0.49	6.77e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs4285028	0.898	rs4305455	chr3:121619774	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.73	-6.28	-0.49	5.25e-9	Multiple sclerosis;
TGCT	cis	rs9443645	0.869	rs9448591	chr6:79606490	C/T	cg09184832	chr6:79620586	NA	-0.49	-5.29	-0.43	5.29e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs57994353	0.828	rs11146021	chr9:139327858	A/G	cg13741927	chr9:139327495	INPP5E	0.26	6.27	0.49	5.41e-9	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs35306767	0.714	rs10508206	chr10:1075777	A/C	cg26597838	chr10:835615	NA	0.53	6.08	0.48	1.35e-8	Eosinophil percentage of granulocytes;
TGCT	cis	rs7208859	0.623	rs56378576	chr17:29010120	C/T	cg14008862	chr17:28927542	LRRC37B2	0.84	5.1	0.42	1.22e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs9457247	1.000	rs2769352	chr6:167378619	A/G	cg23791538	chr6:167370224	RNASET2	0.53	5.19	0.42	8.41e-7	Crohn's disease;
TGCT	cis	rs2228479	0.850	rs117285117	chr16:89910250	T/G	cg06558623	chr16:89946397	TCF25	0.55	4.86	0.4	3.55e-6	Skin colour saturation;
TGCT	cis	rs9993613	0.935	rs10019152	chr4:73518770	A/C	cg15102770	chr4:73434591	ADAMTS3	-0.49	-4.52	-0.38	1.41e-5	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg02353165	chr6:42928485	GNMT	0.97	9.68	0.66	7.73e-17	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg11764359	chr7:65958608	NA	0.55	5.07	0.41	1.42e-6	Aortic root size;
TGCT	cis	rs317689	0.613	rs315112	chr12:69785926	T/A	cg19645103	chr12:69753606	YEATS4	-0.57	-4.8	-0.4	4.51e-6	Response to diuretic therapy;
TGCT	cis	rs2657888	0.598	rs2657909	chr12:56895503	T/C	cg23002907	chr12:56915593	RBMS2	0.41	5.35	0.43	4.14e-7	Adiponectin levels;
TGCT	cis	rs1629083	1.000	rs1629083	chr11:118126576	C/T	cg16594165	chr11:118135105	MPZL2	-0.34	-4.67	-0.39	7.79e-6	Lung cancer;
TGCT	cis	rs67311347	1.000	rs7642552	chr3:40424816	T/C	cg13683864	chr3:40499215	RPL14	-1.12	-11.97	-0.73	2.07e-22	Renal cell carcinoma;
TGCT	cis	rs2303745	0.589	rs6512179	chr19:17399105	T/C	cg04248312	chr19:17393744	ANKLE1	-0.34	-5.57	-0.45	1.54e-7	Systemic lupus erythematosus;
TGCT	cis	rs10782582	0.609	rs112205173	chr1:76310100	C/T	cg10523679	chr1:76189770	ACADM	-0.59	-5.42	-0.44	2.94e-7	Daytime sleep phenotypes;
TGCT	trans	rs561341	1.000	rs497479	chr17:30328605	C/T	cg20587970	chr11:113659929	NA	-1.03	-12.59	-0.75	6.52e-24	Hip circumference adjusted for BMI;
TGCT	cis	rs9653442	1.000	rs11676922	chr2:100806940	T/A	cg22139774	chr2:100720529	AFF3	-0.43	-7.69	-0.57	3.95e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs10883723	0.847	rs3808934	chr10:104264280	C/T	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs11118844	0.793	rs17010720	chr1:221946403	A/G	cg04222084	chr1:221915650	DUSP10	-0.7	-4.96	-0.41	2.25e-6	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
TGCT	cis	rs4906332	1.000	rs3783398	chr14:103949378	C/T	cg26031613	chr14:104095156	KLC1	0.56	4.56	0.38	1.21e-5	Coronary artery disease;
TGCT	cis	rs765787	0.530	rs2668751	chr15:45517293	T/C	cg24006582	chr15:45444508	DUOX1	-0.26	-5.62	-0.45	1.19e-7	Uric acid levels;
TGCT	cis	rs3617	0.599	rs12487379	chr3:52895785	G/A	cg10802521	chr3:52805072	NEK4	-0.56	-6.46	-0.5	2.14e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9952991	0.941	rs8096138	chr18:12808140	C/G	cg23544223	chr18:12777786	NA	-0.6	-5.33	-0.43	4.56e-7	Inflammatory skin disease;
TGCT	cis	rs2067615	0.524	rs9971765	chr12:107092299	G/A	cg15890332	chr12:107067104	RFX4	0.29	5.75	0.46	6.61e-8	Heart rate;
TGCT	cis	rs6750047	0.585	rs4670808	chr2:38267794	A/G	cg07380506	chr2:38303506	CYP1B1	0.56	5.25	0.43	6.42e-7	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs9534288	0.797	rs9534279	chr13:46584999	T/C	cg15192986	chr13:46630673	CPB2	-0.53	-7.62	-0.56	5.82e-12	Blood protein levels;
TGCT	cis	rs7095607	0.813	rs4745947	chr10:69931840	A/C	cg18986048	chr10:69913749	MYPN	0.44	5.02	0.41	1.72e-6	Lung function (FVC);
TGCT	trans	rs629535	0.814	rs62513378	chr8:70095788	G/C	cg21567404	chr3:27674614	NA	-0.57	-9.03	-0.63	2.83e-15	Dupuytren's disease;
TGCT	cis	rs28595532	0.688	rs116053430	chr4:119731375	G/A	cg14228332	chr4:119757509	SEC24D	1.32	6.38	0.5	3.2e-9	Cannabis dependence symptom count;
TGCT	cis	rs9513593	1.000	rs1964898	chr13:99997181	A/G	cg21788972	chr13:99853209	UBAC2	0.56	4.47	0.37	1.76e-5	Psoriasis;
TGCT	cis	rs992157	0.798	rs4674284	chr2:219161241	C/T	cg00012203	chr2:219082015	ARPC2	-0.82	-8.11	-0.59	4.07e-13	Colorectal cancer;
TGCT	cis	rs514406	0.584	rs12095247	chr1:53193796	A/C	cg22166914	chr1:53195759	ZYG11B	-0.5	-9.39	-0.64	3.79e-16	Monocyte count;
TGCT	cis	rs7267979	0.966	rs2261794	chr20:25263062	T/G	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10744422	0.764	rs3844369	chr12:123293559	T/C	cg18912006	chr12:123335444	HIP1R	0.56	4.78	0.39	4.84e-6	Schizophrenia;
TGCT	cis	rs9527	0.590	rs10509766	chr10:104926334	T/C	cg15744005	chr10:104629667	AS3MT	-0.4	-4.59	-0.38	1.08e-5	Arsenic metabolism;
TGCT	cis	rs7017914	0.905	rs2732115	chr8:71928854	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.56	-5.11	-0.42	1.21e-6	Bone mineral density;
TGCT	cis	rs9640161	0.711	rs60268791	chr7:150023800	G/T	cg10018233	chr7:150070692	REPIN1	0.32	4.63	0.38	9.08e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg06634786	chr22:41940651	POLR3H	-0.88	-8.54	-0.61	3.98e-14	Vitiligo;
TGCT	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg07424592	chr7:64974309	NA	1.27	7.84	0.58	1.8e-12	Diabetic kidney disease;
TGCT	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg11905131	chr22:24372483	LOC391322	-0.88	-10.14	-0.67	5.74e-18	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs208520	0.507	rs9453585	chr6:66796668	C/T	cg07460842	chr6:66804631	NA	-1.08	-15.99	-0.82	6.47e-32	Exhaled nitric oxide output;
TGCT	cis	rs79349575	0.783	rs28409394	chr17:46998118	T/C	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.51	-0.38	1.48e-5	Type 2 diabetes;
TGCT	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.46	-5.65	-0.45	1.03e-7	Longevity;Endometriosis;
TGCT	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg22963979	chr7:1858916	MAD1L1	-0.38	-5.8	-0.46	5.26e-8	Bipolar disorder and schizophrenia;
TGCT	cis	rs7584330	0.868	rs6760842	chr2:238398165	C/T	cg16989719	chr2:238392110	NA	0.26	4.55	0.38	1.24e-5	Prostate cancer;
TGCT	cis	rs7542091	0.748	rs2357231	chr1:210028454	A/C	cg05527609	chr1:210001259	C1orf107	0.53	4.97	0.41	2.13e-6	Monobrow;
TGCT	cis	rs6725041	0.547	rs1505353	chr2:213203057	C/A	cg16329650	chr2:213403929	ERBB4	-0.67	-5.72	-0.46	7.68e-8	QT interval (ambient particulate matter interaction);
TGCT	cis	rs1371867	0.846	rs1788182	chr8:101334620	C/T	cg00191853	chr8:101177733	SPAG1	-0.23	-4.76	-0.39	5.2e-6	Atrioventricular conduction;
TGCT	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	5.08	0.42	1.35e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2013441	0.965	rs8068720	chr17:20214171	G/T	cg23224458	chr17:20280056	CCDC144C	-0.4	-4.75	-0.39	5.53e-6	Obesity-related traits;
TGCT	cis	rs7666738	0.716	rs13136721	chr4:99085602	G/A	cg18180107	chr4:99064573	C4orf37	0.55	4.91	0.4	2.8e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10465746	0.746	rs6699501	chr1:84389993	A/G	cg10977910	chr1:84465055	TTLL7	0.71	7.15	0.54	6.64e-11	Obesity-related traits;
TGCT	cis	rs7666738	0.830	rs1025204	chr4:99023441	G/A	cg18180107	chr4:99064573	C4orf37	0.55	5.01	0.41	1.82e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg21724239	chr8:58056113	NA	0.42	5.04	0.41	1.59e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.25	4.47	0.37	1.75e-5	Total body bone mineral density;
TGCT	cis	rs514406	0.560	rs1889033	chr1:53211887	A/G	cg22166914	chr1:53195759	ZYG11B	-0.5	-9.19	-0.64	1.16e-15	Monocyte count;
TGCT	cis	rs858239	0.539	rs4559148	chr7:23185967	G/A	cg05602783	chr7:23145260	KLHL7	-0.68	-5.62	-0.45	1.2e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg12570787	chr5:219185	SDHA;CCDC127	0.65	4.46	0.37	1.83e-5	Breast cancer;
TGCT	cis	rs9640161	0.742	rs11767726	chr7:150018096	A/C	cg10018233	chr7:150070692	REPIN1	-0.32	-4.7	-0.39	6.93e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs711245	0.637	rs6729495	chr2:36834192	T/A	cg01206211	chr2:36825736	FEZ2	0.33	5.47	0.44	2.37e-7	Height;
TGCT	cis	rs589249	0.889	rs4653212	chr1:37175329	G/C	cg04012535	chr1:37176647	NA	0.33	5.39	0.44	3.46e-7	Neuroticism (multi-trait analysis);Schizophrenia;
TGCT	cis	rs12477438	0.520	rs10865029	chr2:99718298	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.82	0.62	8.67e-15	Chronic sinus infection;
TGCT	cis	rs6840360	0.582	rs2709826	chr4:152332120	G/T	cg17479576	chr4:152424074	FAM160A1	-0.57	-5.98	-0.47	2.18e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs17433780	1.000	rs17433780	chr1:89474818	C/T	cg09516651	chr1:89888402	LOC400759	-0.28	-5.04	-0.41	1.62e-6	Carotid intima media thickness;
TGCT	cis	rs727505	1.000	rs10230610	chr7:124425398	A/C	cg23710748	chr7:124431027	NA	-0.27	-4.78	-0.39	4.82e-6	Lewy body disease;
TGCT	cis	rs6570726	0.764	rs376257	chr6:145862949	G/A	cg05347473	chr6:146136440	FBXO30	0.54	5.15	0.42	1.01e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7586879	0.593	rs10198356	chr2:25130592	A/G	cg01884057	chr2:25150051	NA	0.36	7.1	0.54	8.43e-11	Body mass index;
TGCT	cis	rs7017914	0.905	rs3098873	chr8:71932586	G/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-4.97	-0.41	2.16e-6	Bone mineral density;
TGCT	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs185694	0.779	rs639234	chr13:30893984	G/A	cg07600127	chr13:30881527	KATNAL1	-0.76	-6.17	-0.48	8.73e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
TGCT	cis	rs1971762	0.762	rs4759282	chr12:54072435	C/A	cg09709951	chr12:54017699	ATF7	0.33	5.06	0.41	1.48e-6	Height;
TGCT	cis	rs9303401	0.659	rs3809724	chr17:57061238	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.69	6.41	0.5	2.7e-9	Cognitive test performance;
TGCT	cis	rs6542838	0.641	rs13005124	chr2:99527680	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.56	-5.26	-0.43	6.04e-7	Fear of minor pain;
TGCT	cis	rs2224391	0.534	rs2753228	chr6:5246623	G/T	cg09085698	chr6:5261316	LYRM4;FARS2	-1.04	-6.69	-0.51	6.87e-10	Height;
TGCT	cis	rs7668190	0.924	rs2114039	chr4:55092626	T/C	cg17187183	chr4:55093834	PDGFRA	0.43	5.99	0.47	2.1e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg11494091	chr17:61959527	GH2	0.61	14.34	0.79	4.3e-28	Prudent dietary pattern;
TGCT	cis	rs2153535	0.580	rs9393016	chr6:8458573	T/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg17554472	chr22:41940697	POLR3H	-0.49	-5.05	-0.41	1.55e-6	Vitiligo;
TGCT	cis	rs4654899	0.931	rs3767241	chr1:21166144	C/T	cg01072550	chr1:21505969	NA	0.5	7.75	0.57	2.84e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs9318086	0.648	rs9510927	chr13:24467641	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.83	9.04	0.63	2.62e-15	Myopia (pathological);
TGCT	cis	rs910316	1.000	rs175449	chr14:75590846	A/T	cg23033748	chr14:75592666	NEK9	-0.28	-4.84	-0.4	3.71e-6	Height;
TGCT	cis	rs55794721	0.509	rs6699113	chr1:25777743	C/T	cg00786635	chr1:25594202	NA	0.54	5.78	0.46	5.67e-8	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs651907	0.514	rs55654108	chr3:101425703	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.89	10.59	0.69	4.52e-19	Colorectal cancer;
TGCT	cis	rs6988636	0.710	rs73339626	chr8:124142757	A/G	cg22384356	chr8:124195192	FAM83A	-0.42	-4.59	-0.38	1.06e-5	Urinary uromodulin levels;
TGCT	cis	rs6061231	0.761	rs2427312	chr20:60970591	C/T	cg24112000	chr20:60950667	NA	-0.41	-4.51	-0.38	1.5e-5	Colorectal cancer;
TGCT	cis	rs9399135	0.967	rs6929661	chr6:135328792	G/A	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.36e-6	Red blood cell count;
TGCT	cis	rs12681287	0.571	rs13254675	chr8:87353594	C/T	cg27223183	chr8:87520930	FAM82B	-0.9	-6.71	-0.52	6.12e-10	Caudate activity during reward;
TGCT	cis	rs921968	0.541	rs832798	chr2:219464810	G/A	cg02176678	chr2:219576539	TTLL4	0.48	6.78	0.52	4.32e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs1129187	0.805	rs1053539	chr6:42903766	T/G	cg02353165	chr6:42928485	GNMT	0.66	5.84	0.46	4.31e-8	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs7582180	0.739	rs11687352	chr2:100919888	A/C	cg08017756	chr2:100939284	LONRF2	-0.32	-5.31	-0.43	4.89e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs6669919	0.647	rs4951753	chr1:211671794	C/T	cg26515805	chr1:211431828	RCOR3	-0.45	-4.56	-0.38	1.2e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs6671200	0.510	rs35556400	chr1:95916885	G/A	cg03123541	chr1:95699097	RWDD3	0.92	5.6	0.45	1.34e-7	Stearic acid (18:0) levels;
TGCT	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg12516959	chr21:47718080	NA	-0.33	-4.75	-0.39	5.53e-6	Testicular germ cell tumor;
TGCT	cis	rs7681440	0.801	rs1372513	chr4:90790237	G/A	cg20003494	chr4:90757398	SNCA	-0.6	-5.54	-0.45	1.73e-7	Dementia with Lewy bodies;
TGCT	cis	rs8050907	0.744	rs28680621	chr16:4518994	G/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.53	4.56	0.38	1.23e-5	Obesity-related traits;
TGCT	cis	rs7917772	0.565	rs61869210	chr10:104437175	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	5.8	0.46	5.3e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs514475	0.526	rs12201389	chr6:137955452	G/A	cg02673417	chr6:137105249	MAP3K5	0.29	4.45	0.37	1.88e-5	Inflammatory skin disease;
TGCT	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg11494091	chr17:61959527	GH2	0.61	14.81	0.8	3.37e-29	Prudent dietary pattern;
TGCT	cis	rs12497850	0.865	rs7649458	chr3:48920127	C/T	cg07636037	chr3:49044803	WDR6	0.95	10.74	0.69	2e-19	Parkinson's disease;
TGCT	cis	rs2440129	0.591	rs312466	chr17:6899221	G/A	cg03404566	chr17:6899310	ALOX12	-0.42	-4.9	-0.4	2.95e-6	Tonsillectomy;
TGCT	cis	rs7647973	0.961	rs10154992	chr3:49276077	C/T	cg07636037	chr3:49044803	WDR6	0.67	5.41	0.44	3.15e-7	Menarche (age at onset);
TGCT	cis	rs909002	0.800	rs968335	chr1:32085776	G/A	cg11573219	chr1:32083031	HCRTR1	-0.45	-5.86	-0.47	3.83e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs6674176	0.660	rs12726706	chr1:44399942	G/A	cg12908607	chr1:44402522	ARTN	-0.73	-9.11	-0.63	1.78e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs9611519	1.000	rs2273085	chr22:41615376	C/T	cg03806693	chr22:41940476	POLR3H	-0.66	-6.3	-0.49	4.65e-9	Neuroticism;
TGCT	cis	rs9399135	0.967	rs59329760	chr6:135342437	G/A	cg24558204	chr6:135376177	HBS1L	0.5	5.0	0.41	1.89e-6	Red blood cell count;
TGCT	cis	rs7845219	0.544	rs2945554	chr8:95939594	C/A	cg09323728	chr8:95962352	TP53INP1	-0.4	-4.6	-0.38	1.04e-5	Type 2 diabetes;
TGCT	cis	rs4888262	0.564	rs8062404	chr16:74611675	T/C	cg01733217	chr16:74700730	RFWD3	0.75	7.54	0.56	8.8e-12	Testicular germ cell tumor;
TGCT	cis	rs791357	0.840	rs791361	chr5:173208633	A/C	cg04561637	chr5:172480106	NA	-0.26	-4.6	-0.38	1.04e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Granulocyte count;Myeloid white cell count;
TGCT	cis	rs7726839	0.540	rs72703087	chr5:598029	C/T	cg20362242	chr5:692897	TPPP	0.53	4.56	0.38	1.22e-5	Obesity-related traits;
TGCT	cis	rs17376456	0.825	rs10036024	chr5:93074804	C/A	cg25358565	chr5:93447407	FAM172A	0.89	5.88	0.47	3.58e-8	Diabetic retinopathy;
TGCT	cis	rs7647973	1.000	rs3448	chr3:49396751	T/C	cg07636037	chr3:49044803	WDR6	0.71	5.76	0.46	6.26e-8	Menarche (age at onset);
TGCT	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg17554472	chr22:41940697	POLR3H	-0.47	-4.91	-0.4	2.87e-6	Vitiligo;
TGCT	cis	rs1059312	0.808	rs4482069	chr12:129294252	G/C	cg09035930	chr12:129282057	SLC15A4	0.55	10.73	0.69	2.06e-19	Systemic lupus erythematosus;
TGCT	cis	rs185694	0.857	rs200510	chr13:30904134	A/G	cg07600127	chr13:30881527	KATNAL1	-0.54	-4.7	-0.39	6.94e-6	Antineutrophil cytoplasmic antibody-associated vasculitis;
TGCT	cis	rs10883723	0.773	rs11191303	chr10:104255158	T/C	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	5.92	0.47	2.92e-8	Alzheimer's disease;
TGCT	trans	rs941408	0.963	rs1640267	chr19:2789337	T/C	cg22153745	chr1:153894579	GATAD2B	-0.68	-6.78	-0.52	4.46e-10	Total cholesterol levels;
TGCT	cis	rs8038465	0.967	rs61012032	chr15:73973978	C/T	cg15420318	chr15:73925796	NPTN	0.7	6.53	0.51	1.56e-9	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs8077889	0.869	rs11713	chr17:41845824	A/G	cg26893861	chr17:41843967	DUSP3	-1.06	-12.71	-0.75	3.21e-24	Triglycerides;
TGCT	cis	rs12142240	0.698	rs1135460	chr1:46815970	T/C	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs4788570	0.584	rs6499534	chr16:71755278	C/G	cg06353428	chr16:71660113	MARVELD3	1.56	12.67	0.75	4.05e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs2153535	0.580	rs1577470	chr6:8462426	G/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs8070624	0.502	rs12951376	chr17:17752809	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.7	6.36	0.5	3.52e-9	Total body bone mineral density;
TGCT	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg06618935	chr21:46677482	NA	-0.37	-5.83	-0.46	4.48e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2663905	0.611	rs1509559	chr15:81391411	G/A	cg18837035	chr15:81426597	C15orf26	-0.6	-5.42	-0.44	2.98e-7	QT interval (drug interaction);
TGCT	cis	rs7178424	0.846	rs13379492	chr15:62184636	T/A	cg00456672	chr15:62358751	C2CD4A	-0.31	-4.6	-0.38	1.02e-5	Height;
TGCT	cis	rs7772486	0.846	rs2748499	chr6:146315002	T/C	cg05347473	chr6:146136440	FBXO30	0.54	5.13	0.42	1.1e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2204008	0.591	rs11495396	chr12:38380182	C/T	cg13010199	chr12:38710504	ALG10B	0.59	4.64	0.38	8.86e-6	Bladder cancer;
TGCT	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg06238570	chr21:40685208	BRWD1	-0.82	-9.26	-0.64	7.63e-16	Cognitive function;
TGCT	cis	rs13191362	0.872	rs13194619	chr6:163203657	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.94	6.77	0.52	4.6e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs11792861	0.781	rs72607158	chr9:111763010	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.51	4.73	0.39	5.99e-6	Menarche (age at onset);
TGCT	cis	rs6089584	0.821	rs4925332	chr20:60604639	C/T	cg16423285	chr20:60520624	NA	-0.62	-6.91	-0.53	2.25e-10	Body mass index;
TGCT	cis	rs10875746	0.951	rs11168433	chr12:48558064	C/G	cg20731937	chr12:48336164	NA	0.64	5.13	0.42	1.07e-6	Longevity (90 years and older);
TGCT	cis	rs9788682	1.000	rs9788682	chr15:78802586	A/G	cg24631222	chr15:78858424	CHRNA5	-0.87	-7.92	-0.58	1.15e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs79057730	0.599	rs35928068	chr7:805363	G/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.66	6.27	0.49	5.39e-9	Initial pursuit acceleration;
TGCT	cis	rs9291683	0.588	rs17246745	chr4:9994583	T/C	cg11266682	chr4:10021025	SLC2A9	0.68	9.45	0.65	2.67e-16	Bone mineral density;
TGCT	cis	rs554111	0.656	rs6695218	chr1:21190512	A/C	cg01072550	chr1:21505969	NA	0.34	5.11	0.42	1.19e-6	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg20637647	chr7:64974828	NA	0.89	4.99	0.41	2.01e-6	Diabetic kidney disease;
TGCT	cis	rs2688608	0.587	rs2894040	chr10:75478159	A/C	cg19442545	chr10:75533431	FUT11	-0.37	-5.77	-0.46	5.89e-8	Inflammatory bowel disease;
TGCT	cis	rs595982	0.527	rs35087747	chr19:49377918	G/T	cg17863274	chr19:49399704	TULP2	-0.55	-7.9	-0.58	1.31e-12	Red cell distribution width;
TGCT	cis	rs9522267	0.535	rs9515454	chr13:112236885	A/G	cg10483660	chr13:112241077	NA	-0.27	-4.61	-0.38	9.78e-6	Hepatitis;
TGCT	cis	rs6952809	0.532	rs6461361	chr7:2432167	A/G	cg23289794	chr7:2394357	EIF3B	-0.82	-7.14	-0.54	7.04e-11	Multiple sclerosis;
TGCT	cis	rs9393692	0.846	rs7771202	chr6:26279907	A/G	cg05868516	chr6:26286170	HIST1H4H	0.63	5.91	0.47	3.02e-8	Educational attainment;
TGCT	cis	rs7159131	0.502	rs17765618	chr14:36969462	G/T	cg07345734	chr14:36986363	NKX2-1	-0.55	-4.68	-0.39	7.39e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs12291225	0.753	rs1431374	chr11:14303975	T/C	cg19336497	chr11:14380999	RRAS2	-0.38	-5.9	-0.47	3.23e-8	Sense of smell;
TGCT	cis	rs9291683	0.588	rs6857693	chr4:10018435	G/A	cg11266682	chr4:10021025	SLC2A9	0.73	10.98	0.7	5.33e-20	Bone mineral density;
TGCT	cis	rs2120019	1.000	rs12901243	chr15:75374233	C/T	cg11632617	chr15:75315747	PPCDC	-0.33	-4.78	-0.39	4.82e-6	Blood trace element (Zn levels);
TGCT	cis	rs7584330	0.518	rs74003105	chr2:238446851	T/C	cg14458575	chr2:238380390	NA	0.43	4.51	0.38	1.48e-5	Prostate cancer;
TGCT	cis	rs1670533	0.932	rs6599276	chr4:1056827	T/C	cg27284194	chr4:1044797	NA	0.67	5.79	0.46	5.37e-8	Recombination rate (females);
TGCT	cis	rs2456568	0.802	rs11020585	chr11:93638493	A/C	cg16099599	chr11:93583650	C11orf90	0.39	4.91	0.4	2.76e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs62244186	0.714	rs2293600	chr3:44599103	G/T	cg10108389	chr3:44770937	ZNF501	0.46	4.63	0.38	9.02e-6	Depressive symptoms;
TGCT	trans	rs11088226	0.681	rs2833912	chr21:33949822	G/A	cg09050820	chr6:167586206	TCP10L2	0.76	7.31	0.55	2.88e-11	Gastritis;
TGCT	cis	rs2439831	0.867	rs16957630	chr15:43642780	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	6.61	0.51	1e-9	Lung cancer in ever smokers;
TGCT	cis	rs7940866	0.845	rs1433976	chr11:130875123	C/T	cg05962950	chr11:130786565	SNX19	-0.62	-6.42	-0.5	2.64e-9	Schizophrenia;
TGCT	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg07870213	chr5:140052090	DND1	-0.62	-7.46	-0.56	1.33e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs3617	0.598	rs56214994	chr3:52878600	G/C	cg10802521	chr3:52805072	NEK4	0.62	7.17	0.54	6e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7909074	0.933	rs879073	chr10:45399882	C/G	cg04218760	chr10:45406644	TMEM72	-0.27	-5.35	-0.43	4.05e-7	Mean corpuscular volume;
TGCT	cis	rs6684514	1.000	rs2273832	chr1:156233143	A/G	cg20302342	chr1:156215951	PAQR6	0.35	4.57	0.38	1.17e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg08280861	chr8:58055591	NA	0.36	4.8	0.4	4.43e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg13732083	chr21:47605072	C21orf56	0.34	4.48	0.37	1.68e-5	Testicular germ cell tumor;
TGCT	cis	rs2657888	0.965	rs2657905	chr12:56935402	T/A	cg23932658	chr12:57637574	STAC3	0.48	4.57	0.38	1.18e-5	Adiponectin levels;
TGCT	cis	rs35000415	0.938	rs34381587	chr7:128666825	A/G	cg06242719	chr7:129414860	MIR183;MIR96	-0.31	-4.52	-0.38	1.4e-5	Systemic lupus erythematosus;
TGCT	cis	rs938554	0.513	rs3775946	chr4:9995256	A/G	cg11266682	chr4:10021025	SLC2A9	0.53	4.7	0.39	6.68e-6	Blood metabolite levels;
TGCT	trans	rs116975820	0.698	rs11181497	chr12:42814962	A/G	cg26084949	chr14:75039090	LTBP2	-0.76	-6.73	-0.52	5.51e-10	PR interval in Tripanosoma cruzi seropositivity;
TGCT	cis	rs12541335	0.579	rs59283125	chr8:22212311	G/A	cg18135555	chr8:22132992	PIWIL2	0.31	6.17	0.48	9.09e-9	Hypertriglyceridemia;
TGCT	cis	rs526631	0.564	rs10896051	chr11:65578759	C/T	cg04055107	chr11:65626734	MUS81;CFL1	-0.67	-6.01	-0.48	1.9e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs910316	0.712	rs175015	chr14:75457075	A/C	cg08847533	chr14:75593920	NEK9	-0.84	-8.91	-0.62	5.45e-15	Height;
TGCT	cis	rs2299587	0.554	rs3853531	chr8:17748920	C/T	cg04898035	chr8:17640624	MTUS1	0.2	4.63	0.38	9.19e-6	Economic and political preferences;
TGCT	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg05025164	chr4:1340916	KIAA1530	-0.56	-4.81	-0.4	4.29e-6	Obesity-related traits;
TGCT	cis	rs992157	0.735	rs13430006	chr2:219113089	A/C	cg00012203	chr2:219082015	ARPC2	-0.81	-10.19	-0.68	4.34e-18	Colorectal cancer;
TGCT	cis	rs6700896	0.522	rs11208719	chr1:66159001	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.54	4.44	0.37	1.98e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg08736216	chr1:53307985	ZYG11A	0.25	4.93	0.4	2.59e-6	Monocyte count;
TGCT	cis	rs7312933	0.584	rs6582395	chr12:42700141	T/C	cg19980929	chr12:42632907	YAF2	0.43	5.78	0.46	5.7e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs9677476	0.657	rs9679430	chr2:232122482	C/T	cg07929768	chr2:232055508	NA	-0.32	-5.29	-0.43	5.45e-7	Food antigen IgG levels;
TGCT	cis	rs4663866	0.901	rs2304672	chr2:239186589	C/G	cg17283117	chr2:239148619	HES6	-0.99	-4.88	-0.4	3.13e-6	Irritable bowel syndrome;
TGCT	cis	rs4242434	0.927	rs57594397	chr8:22475657	T/C	cg03733263	chr8:22462867	KIAA1967	1.15	18.91	0.86	2.43e-38	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs77861329	1.000	rs352148	chr3:52208898	A/G	cg08692210	chr3:52188851	WDR51A	0.93	4.91	0.4	2.84e-6	Macrophage inflammatory protein 1b levels;
TGCT	cis	rs11235843	0.602	rs1830069	chr11:73433229	C/G	cg18195628	chr11:73498948	MRPL48	-0.64	-4.52	-0.38	1.42e-5	Hand grip strength;
TGCT	cis	rs5769707	0.967	rs4524218	chr22:50018639	G/A	cg10356904	chr22:49881777	NA	-0.22	-4.52	-0.38	1.4e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs7246657	0.722	rs10404031	chr19:38035954	A/G	cg18154014	chr19:37997991	ZNF793	0.69	4.63	0.38	9.25e-6	Coronary artery calcification;
TGCT	cis	rs367615	0.704	rs72804385	chr5:108848143	T/C	cg17395555	chr5:108820864	NA	0.31	5.72	0.46	7.47e-8	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs11696501	0.688	rs6073833	chr20:44279894	T/G	cg11783356	chr20:44313418	WFDC10B	-0.32	-4.63	-0.38	9.25e-6	Brain structure;
TGCT	cis	rs8013055	1.000	rs8013055	chr14:105990620	T/A	cg23356831	chr14:105996513	TMEM121	0.35	5.1	0.42	1.22e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs7772486	0.727	rs6941429	chr6:145952283	G/A	cg05347473	chr6:146136440	FBXO30	0.53	4.97	0.41	2.2e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4851266	0.898	rs2309812	chr2:100869702	C/T	cg07810366	chr2:100720526	AFF3	-0.36	-5.21	-0.42	7.59e-7	Educational attainment;
TGCT	cis	rs9868809	0.649	rs3733086	chr3:48699519	C/T	cg00383909	chr3:49044727	WDR6	1.13	6.17	0.48	8.69e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs611744	0.967	rs2212704	chr8:109198415	C/T	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs478304	0.718	rs1151490	chr11:65390485	A/C	cg27068330	chr11:65405492	SIPA1	0.83	8.42	0.6	7.95e-14	Acne (severe);
TGCT	cis	rs73198271	0.751	rs55816468	chr8:8605876	C/A	cg06671706	chr8:8559999	CLDN23	-0.36	-4.56	-0.38	1.21e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs9393692	0.875	rs2142703	chr6:26289605	A/G	cg13736514	chr6:26305472	NA	-0.41	-5.77	-0.46	6.09e-8	Educational attainment;
TGCT	cis	rs793571	0.543	rs4775087	chr15:58974904	T/C	cg05156742	chr15:59063176	FAM63B	0.49	4.66	0.39	8.19e-6	Schizophrenia;
TGCT	cis	rs6558530	0.932	rs4370560	chr8:1708194	G/A	cg09410841	chr8:1729607	CLN8	0.91	10.31	0.68	2.23e-18	Systolic blood pressure;
TGCT	cis	rs2412208	0.545	rs7414485	chr1:7121397	G/A	cg20434152	chr1:7120926	CAMTA1	-0.3	-4.93	-0.4	2.56e-6	Survival in sporadic amyotrophic lateral sclerosis;
TGCT	cis	rs433598	0.828	rs163270	chr16:20675829	G/A	cg16616769	chr16:19727142	IQCK;C16orf88	-0.2	-4.47	-0.37	1.71e-5	Schizophrenia;
TGCT	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg23758822	chr17:41437982	NA	0.75	7.03	0.53	1.22e-10	Menopause (age at onset);
TGCT	cis	rs7659604	0.521	rs13114801	chr4:122670855	C/A	cg19748678	chr4:122722346	EXOSC9	-0.51	-4.93	-0.4	2.58e-6	Type 2 diabetes;
TGCT	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg22963979	chr7:1858916	MAD1L1	-0.39	-6.41	-0.5	2.79e-9	Schizophrenia;
TGCT	cis	rs4803468	1.000	rs284654	chr19:41928724	G/A	cg09537434	chr19:41945824	ATP5SL	-0.93	-10.91	-0.7	7.92e-20	Height;
TGCT	cis	rs2180341	0.960	rs6900074	chr6:127685893	A/G	cg27446573	chr6:127587934	RNF146	1.15	10.91	0.7	7.65e-20	Breast cancer;
TGCT	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg10819733	chr22:24237672	NA	-0.29	-4.83	-0.4	3.97e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs12135062	1.000	rs12135062	chr1:3103312	A/C	cg25382214	chr1:3105252	PRDM16	0.27	4.76	0.39	5.37e-6	Migraine;
TGCT	cis	rs2299587	0.554	rs17634704	chr8:17753306	A/G	cg04898035	chr8:17640624	MTUS1	-0.21	-4.72	-0.39	6.17e-6	Economic and political preferences;
TGCT	cis	rs68170813	0.559	rs12536603	chr7:107002573	T/C	cg02696742	chr7:106810147	HBP1	-0.7	-5.7	-0.46	8.16e-8	Coronary artery disease;
TGCT	cis	rs12908161	1.000	rs12910012	chr15:85298662	T/C	cg12863693	chr15:85201151	NMB	0.43	5.06	0.41	1.46e-6	Schizophrenia;
TGCT	cis	rs9993613	0.875	rs1481831	chr4:73480019	T/C	cg15102770	chr4:73434591	ADAMTS3	0.52	4.89	0.4	3.07e-6	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs7917772	0.582	rs4919663	chr10:104363293	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	5.36	0.43	3.84e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1801251	0.778	rs709933	chr2:233733144	G/A	cg25237894	chr2:233734115	C2orf82	-0.32	-6.23	-0.49	6.73e-9	Coronary artery disease;
TGCT	cis	rs7940866	0.903	rs1820353	chr11:130870765	A/G	cg12179176	chr11:130786555	SNX19	0.48	4.61	0.38	9.97e-6	Schizophrenia;
TGCT	cis	rs7923452	0.688	rs117895480	chr10:30788921	A/G	cg18806716	chr10:30721971	MAP3K8	0.73	6.26	0.49	5.84e-9	Itch intensity from mosquito bite;
TGCT	cis	rs3820068	0.705	rs11583306	chr1:15860803	A/G	cg05660106	chr1:15850417	CASP9	-1.14	-13.98	-0.78	2.98e-27	Systolic blood pressure;
TGCT	cis	rs7617773	0.817	rs11130162	chr3:48297611	A/G	cg11946769	chr3:48343235	NME6	0.74	7.03	0.53	1.21e-10	Coronary artery disease;
TGCT	trans	rs17685	0.753	rs8200	chr7:75696606	C/G	cg19862616	chr7:65841803	NCRNA00174	-0.52	-9.14	-0.63	1.49e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs10489202	0.634	rs6427119	chr1:168074145	A/G	cg24449463	chr1:168025552	DCAF6	0.52	5.49	0.44	2.12e-7	Schizophrenia;
TGCT	cis	rs7027203	1.000	rs34624092	chr9:96523092	G/A	cg14598338	chr9:96623480	NA	0.58	8.57	0.61	3.49e-14	DNA methylation (variation);
TGCT	cis	rs6831352	0.918	rs2602896	chr4:100046207	C/T	cg12011299	chr4:100065546	ADH4	-0.44	-4.98	-0.41	2.12e-6	Alcohol dependence;
TGCT	cis	rs9790314	1.000	rs9790314	chr3:161019558	T/C	cg03342759	chr3:160939853	NMD3	-0.43	-4.55	-0.38	1.25e-5	Morning vs. evening chronotype;
TGCT	cis	rs9467711	0.651	rs13210041	chr6:26037601	G/A	cg16898833	chr6:26189333	HIST1H4D	1.34	6.07	0.48	1.47e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs975752	0.867	rs66728174	chr10:102020626	C/T	cg04750910	chr10:102416409	NA	0.73	4.48	0.37	1.69e-5	Schizophrenia;
TGCT	cis	rs79387448	0.745	rs1880000	chr2:103099953	T/C	cg09003973	chr2:102972529	NA	0.89	5.92	0.47	2.95e-8	Gut microbiota (bacterial taxa);
TGCT	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	5.03	0.41	1.69e-6	Prudent dietary pattern;
TGCT	cis	rs7226408	0.857	rs55809464	chr18:34608316	A/G	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs2637266	0.739	rs2579736	chr10:78427688	G/A	cg18941641	chr10:78392320	NA	0.4	4.91	0.4	2.79e-6	Pulmonary function;
TGCT	trans	rs629535	0.748	rs58675625	chr8:70034924	T/C	cg21567404	chr3:27674614	NA	0.58	9.18	0.64	1.22e-15	Dupuytren's disease;
TGCT	trans	rs1496653	0.602	rs35408638	chr3:23454175	C/T	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg27454412	chr7:1067447	C7orf50	0.6	4.7	0.39	6.76e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.0	7.42	0.55	1.64e-11	Gut microbiome composition (summer);
TGCT	cis	rs1232027	0.700	rs1650694	chr5:79952426	G/A	cg07324116	chr5:80060102	MSH3	-0.25	-4.61	-0.38	9.94e-6	Huntington's disease progression;
TGCT	cis	rs9914544	1.000	rs7223231	chr17:18811846	C/T	cg26306683	chr17:18585705	ZNF286B	0.58	5.18	0.42	8.8e-7	Educational attainment (years of education);
TGCT	cis	rs8031584	0.918	rs61997138	chr15:31270776	C/T	cg08704250	chr15:31115839	NA	-0.35	-4.93	-0.4	2.6e-6	Huntington's disease progression;
TGCT	cis	rs3733585	0.699	rs7658170	chr4:9966593	C/T	cg11266682	chr4:10021025	SLC2A9	0.57	7.65	0.57	4.88e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs9902453	0.716	rs3098949	chr17:27978694	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.83	8.2	0.59	2.54e-13	Coffee consumption (cups per day);
TGCT	cis	rs4319547	0.956	rs7316149	chr12:123063912	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.69	-5.43	-0.44	2.83e-7	Body mass index;
TGCT	cis	rs11031096	0.505	rs10835743	chr11:4226692	C/T	cg18678763	chr11:4115507	RRM1	-0.42	-5.37	-0.43	3.81e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs9372498	0.572	rs10484289	chr6:118827836	T/C	cg07617317	chr6:118971624	C6orf204	0.51	5.42	0.44	3.01e-7	Diastolic blood pressure;
TGCT	cis	rs2338224	1.000	rs4703888	chr5:71746042	A/T	cg01187920	chr5:71015162	CARTPT	-0.53	-4.57	-0.38	1.15e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Granulocyte count;Myeloid white cell count;
TGCT	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs4240897	0.935	rs4846082	chr1:12042443	C/T	cg13216073	chr1:12042593	MFN2	0.19	5.73	0.46	7.18e-8	Tuberculosis;
TGCT	cis	rs7226408	0.857	rs72885296	chr18:34451891	C/G	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs9467773	0.620	rs2504567	chr6:26662920	C/G	cg05738196	chr6:26577821	NA	0.88	10.71	0.69	2.37e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs78487399	0.908	rs55855805	chr2:43808490	A/G	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.66	4.67	0.39	7.66e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs7523273	0.597	rs2724384	chr1:207930203	G/A	cg22525895	chr1:207977042	MIR29B2	0.45	6.59	0.51	1.14e-9	Schizophrenia;
TGCT	cis	rs4727027	0.870	rs13237714	chr7:148884083	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	4.77	0.39	5.16e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs80282103	0.618	rs1079389	chr10:1161980	A/G	cg08668510	chr10:1095578	IDI1	1.06	5.03	0.41	1.7e-6	Glomerular filtration rate (creatinine);
TGCT	trans	rs3774749	0.565	rs2518795	chr3:50208819	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.79	7.68	0.57	4.11e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs11585357	0.947	rs72646789	chr1:17610030	C/T	cg08277548	chr1:17600880	PADI3	-0.97	-9.95	-0.67	1.7e-17	Hair shape;
TGCT	cis	rs208520	0.690	rs1738970	chr6:66809491	T/G	cg07460842	chr6:66804631	NA	-0.93	-9.66	-0.66	8.29e-17	Exhaled nitric oxide output;
TGCT	cis	rs295140	0.585	rs4233996	chr2:201131228	A/T	cg23649088	chr2:200775458	C2orf69	-0.29	-5.02	-0.41	1.77e-6	QT interval;
TGCT	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.05	8.68	0.61	1.9e-14	Platelet count;
TGCT	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	5.23	0.43	6.92e-7	Menopause (age at onset);
TGCT	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg18404041	chr3:52824283	ITIH1	0.21	4.63	0.38	9.15e-6	Bipolar disorder;
TGCT	cis	rs7216064	1.000	rs7224923	chr17:65842265	T/G	cg12091567	chr17:66097778	LOC651250	-0.83	-6.49	-0.5	1.9e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs4973397	0.810	rs12999051	chr2:232276992	T/A	cg09339159	chr2:232260559	B3GNT7	0.54	4.68	0.39	7.25e-6	Anti-saccade response;
TGCT	cis	rs16921914	0.559	rs2985140	chr11:31315886	C/T	cg26647111	chr11:31128758	NA	0.33	4.74	0.39	5.71e-6	Bone mineral density (spine);
TGCT	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg27425262	chr2:113953981	PSD4;LOC440839	-0.52	-8.2	-0.59	2.52e-13	Lymphocyte counts;
TGCT	cis	rs66561647	0.719	rs7812386	chr8:128937609	C/A	cg05480350	chr8:128972681	MIR1205;PVT1	0.22	4.73	0.39	5.97e-6	Hemoglobin concentration;
TGCT	cis	rs7940866	0.740	rs2162060	chr11:130830763	A/G	cg12179176	chr11:130786555	SNX19	0.57	5.4	0.44	3.23e-7	Schizophrenia;
TGCT	cis	rs9611565	0.512	rs139572	chr22:42214532	C/T	cg17554472	chr22:41940697	POLR3H	-0.46	-4.69	-0.39	7.09e-6	Vitiligo;
TGCT	cis	rs72781680	1.000	rs72788278	chr2:24095285	A/C	cg08917208	chr2:24149416	ATAD2B	0.73	4.51	0.38	1.48e-5	Lymphocyte counts;
TGCT	cis	rs7772486	0.686	rs1292334	chr6:145968288	A/G	cg05347473	chr6:146136440	FBXO30	0.5	4.65	0.39	8.34e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1580019	0.587	rs34488151	chr7:32548146	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.58	4.96	0.41	2.25e-6	Cognitive ability;
TGCT	cis	rs7666738	0.830	rs59751489	chr4:98933802	A/G	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9467773	0.620	rs2451711	chr6:26663110	A/G	cg11502198	chr6:26597334	ABT1	0.55	4.9	0.4	2.92e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs644799	1.000	rs693597	chr11:95589629	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	8.63	0.61	2.51e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs12210905	0.688	rs12374607	chr6:27343620	A/G	cg08851530	chr6:28072375	NA	1.25	5.39	0.44	3.38e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs1062177	1.000	rs72802204	chr5:151183183	T/C	cg12924095	chr5:151150029	G3BP1	0.35	5.02	0.41	1.77e-6	Preschool internalizing problems;
TGCT	cis	rs67460515	0.892	rs11711695	chr3:161057593	A/G	cg03342759	chr3:160939853	NMD3	-0.47	-5.12	-0.42	1.12e-6	Parkinson's disease;
TGCT	cis	rs6684514	1.000	rs10494304	chr1:156285764	C/G	cg16558208	chr1:156270281	VHLL	-0.48	-9.6	-0.65	1.19e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs7726839	0.540	rs7434	chr5:660804	A/G	cg16624210	chr5:671434	TPPP	-0.41	-4.84	-0.4	3.74e-6	Obesity-related traits;
TGCT	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg22968622	chr17:43663579	NA	1.3	11.87	0.73	3.46e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs10904887	1.000	rs7900163	chr10:17188637	C/T	cg01003015	chr10:17271136	VIM	-0.65	-6.01	-0.47	1.93e-8	Telomere length;
TGCT	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg08219700	chr8:58056026	NA	0.39	4.73	0.39	5.99e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4285028	0.747	rs77570895	chr3:121384565	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.94	-7.35	-0.55	2.36e-11	Multiple sclerosis;
TGCT	cis	rs56176327	0.532	rs9849038	chr3:49771990	A/G	cg03034192	chr3:50606346	HEMK1;C3orf18	0.36	4.75	0.39	5.61e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs34014631	1.000	rs114132090	chr10:103590342	C/A	cg22630918	chr10:102748988	C10orf2	0.44	4.85	0.4	3.57e-6	Coronary artery calcification;
TGCT	cis	rs9486719	1.000	rs3798289	chr6:97023632	T/C	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.0	-0.41	1.9e-6	Migraine;Coronary artery disease;
TGCT	cis	rs66561647	0.857	rs12548939	chr8:128958771	C/T	cg11792826	chr8:129160931	MIR1208	0.22	4.7	0.39	6.94e-6	Hemoglobin concentration;
TGCT	cis	rs67311347	1.000	rs9835219	chr3:40424093	C/T	cg17264618	chr3:40429014	ENTPD3	0.33	4.82	0.4	4.12e-6	Renal cell carcinoma;
TGCT	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.48	-0.37	1.66e-5	Bipolar disorder;
TGCT	cis	rs12142240	0.667	rs45524035	chr1:46862780	C/T	cg14993813	chr1:46806288	NSUN4	-0.59	-4.86	-0.4	3.45e-6	Menopause (age at onset);
TGCT	cis	rs9916302	0.904	rs7501488	chr17:37576417	T/G	cg15445000	chr17:37608096	MED1	0.34	4.8	0.4	4.43e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs765787	0.530	rs3759892	chr15:45542709	A/G	cg24006582	chr15:45444508	DUOX1	0.24	5.3	0.43	5.13e-7	Uric acid levels;
TGCT	cis	rs10791097	0.720	rs6590515	chr11:130733365	A/G	cg05962950	chr11:130786565	SNX19	-0.9	-11.61	-0.72	1.52e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs2235642	0.821	rs2281236	chr16:1603576	G/A	cg10465839	chr16:1584050	IFT140;TMEM204	-0.31	-5.23	-0.43	7.02e-7	Coronary artery disease;
TGCT	cis	rs9372498	0.536	rs9481821	chr6:118846022	A/C	cg21191810	chr6:118973309	C6orf204	-0.37	-4.75	-0.39	5.61e-6	Diastolic blood pressure;
TGCT	cis	rs1023500	0.596	rs133352	chr22:42434022	C/A	cg05082376	chr22:42548792	NA	-0.23	-5.43	-0.44	2.81e-7	Schizophrenia;
TGCT	cis	rs938554	0.744	rs13129697	chr4:9926967	T/G	cg11266682	chr4:10021025	SLC2A9	-0.47	-4.83	-0.4	3.9e-6	Blood metabolite levels;
TGCT	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg12419862	chr22:24373484	LOC391322	-0.78	-8.1	-0.59	4.41e-13	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2832191	0.967	rs2898160	chr21:30487496	A/G	cg24692254	chr21:30365293	RNF160	-0.83	-8.71	-0.62	1.58e-14	Dental caries;
TGCT	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg03806693	chr22:41940476	POLR3H	-1.13	-13.26	-0.77	1.59e-25	Vitiligo;
TGCT	cis	rs13102973	0.682	rs6535054	chr4:135886055	A/C	cg14419869	chr4:135874104	NA	0.26	4.6	0.38	1.03e-5	Subjective well-being;
TGCT	cis	rs2439831	1.000	rs28666488	chr15:43741090	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.01	8.37	0.6	1.02e-13	Lung cancer in ever smokers;
TGCT	cis	rs11172134	0.532	rs1800168	chr12:57592557	A/G	cg19258868	chr12:57585184	LRP1	-0.3	-6.08	-0.48	1.39e-8	Urate levels in overweight individuals;
TGCT	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs11711311	1.000	rs28394480	chr3:113485143	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.79	-7.32	-0.55	2.75e-11	IgG glycosylation;
TGCT	cis	rs2692947	0.673	rs3111873	chr2:96781986	G/C	cg22654517	chr2:96458247	NA	-0.22	-4.76	-0.39	5.19e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs8020441	0.541	rs72681665	chr14:51167012	C/A	cg04730355	chr14:51134070	SAV1	1.11	7.23	0.54	4.26e-11	Cognitive performance;
TGCT	cis	rs10883723	0.737	rs7074444	chr10:104249922	A/G	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs704	0.726	rs11080055	chr17:26649724	A/C	cg10342447	chr17:26645325	TMEM97	-0.56	-5.5	-0.44	2.03e-7	Osteoprotegerin levels;
TGCT	cis	rs72781680	0.528	rs56258075	chr2:24104256	C/G	cg08917208	chr2:24149416	ATAD2B	0.78	4.79	0.4	4.69e-6	Lymphocyte counts;
TGCT	cis	rs1420338	1.000	rs4723351	chr7:34155813	T/G	cg01275685	chr7:34179230	BMPER	-0.26	-4.83	-0.4	3.89e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs2832191	0.633	rs2832166	chr21:30462395	G/C	cg24692254	chr21:30365293	RNF160	0.94	10.29	0.68	2.51e-18	Dental caries;
TGCT	cis	rs7772486	0.686	rs857883	chr6:145969214	G/T	cg23711669	chr6:146136114	FBXO30	-0.86	-9.6	-0.65	1.2e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9902453	1.000	rs4465650	chr17:28396721	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.74	6.54	0.51	1.44e-9	Coffee consumption (cups per day);
TGCT	cis	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg08564027	chr20:61660810	NA	0.37	6.85	0.52	3.1e-10	Prostate cancer (SNP x SNP interaction);
TGCT	trans	rs9388451	0.807	rs1268065	chr6:126042783	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.7	7.4	0.55	1.84e-11	Brugada syndrome;
TGCT	cis	rs1023500	0.596	rs133369	chr22:42463814	C/T	cg15557168	chr22:42548783	NA	-0.22	-5.6	-0.45	1.33e-7	Schizophrenia;
TGCT	cis	rs601339	1.000	rs11059384	chr12:123170301	C/A	cg11919336	chr12:123188078	GPR109A	0.64	7.49	0.56	1.1e-11	Adiponectin levels;
TGCT	cis	rs1982963	0.587	rs2516593	chr14:52503369	T/C	cg10843707	chr14:52510701	NID2	-0.36	-7.22	-0.54	4.54e-11	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs6570726	0.791	rs427128	chr6:145865917	T/C	cg13319975	chr6:146136371	FBXO30	-0.51	-4.6	-0.38	1.01e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7267979	1.000	rs6050632	chr20:25432601	A/G	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11098499	0.754	rs4443261	chr4:120249301	T/C	cg09307838	chr4:120376055	NA	0.61	5.91	0.47	3.14e-8	Corneal astigmatism;
TGCT	cis	rs4148883	0.689	rs1800760	chr4:100065626	A/T	cg12011299	chr4:100065546	ADH4	0.39	5.89	0.47	3.35e-8	Alcohol dependence;
TGCT	cis	rs807669	0.903	rs2854643	chr22:19189706	T/C	cg02655711	chr22:19163373	SLC25A1	0.4	9.32	0.64	5.62e-16	Metabolite levels;
TGCT	cis	rs1372520	0.684	rs1442144	chr4:90736113	T/C	cg01966878	chr4:90757139	SNCA	-0.31	-4.91	-0.4	2.85e-6	Neuroticism;
TGCT	cis	rs7216064	0.655	rs8078543	chr17:66037251	G/T	cg12091567	chr17:66097778	LOC651250	1.08	8.86	0.62	7.21e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs9952991	0.883	rs2542148	chr18:12777573	C/G	cg24737193	chr18:12778029	NA	0.53	5.93	0.47	2.8e-8	Inflammatory skin disease;
TGCT	cis	rs78487399	0.808	rs6752964	chr2:43754655	T/C	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.76	4.68	0.39	7.27e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs7582180	0.764	rs12999779	chr2:100924321	T/G	cg08017756	chr2:100939284	LONRF2	-0.32	-5.26	-0.43	6.1e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs870825	0.616	rs10428373	chr4:185639002	A/G	cg21366198	chr4:185655624	MLF1IP	-0.67	-4.95	-0.41	2.37e-6	Blood protein levels;
TGCT	cis	rs10193935	0.901	rs10200353	chr2:42509554	A/G	cg27598129	chr2:42591480	NA	-0.41	-5.57	-0.45	1.53e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9325144	0.555	rs2387847	chr12:38687434	C/T	cg26384229	chr12:38710491	ALG10B	0.66	6.12	0.48	1.11e-8	Morning vs. evening chronotype;
TGCT	cis	rs55883249	1.000	rs11676903	chr2:9763201	G/C	cg23886495	chr2:9695866	ADAM17	0.78	4.66	0.39	8.08e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg18876405	chr7:65276391	NA	-0.36	-5.41	-0.44	3.12e-7	Aortic root size;
TGCT	cis	rs2228479	0.867	rs12930056	chr16:89946649	C/A	cg19635926	chr16:89946313	TCF25	0.28	4.8	0.4	4.47e-6	Skin colour saturation;
TGCT	cis	rs12142240	0.660	rs7520497	chr1:46824919	C/A	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg06873352	chr17:61820015	STRADA	-0.55	-6.13	-0.48	1.09e-8	Prudent dietary pattern;
TGCT	cis	rs10484885	0.887	rs114928443	chr6:90602455	A/T	cg13799429	chr6:90582589	CASP8AP2	-0.43	-4.46	-0.37	1.8e-5	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs1784581	0.588	rs7758559	chr6:162438635	G/T	cg17173639	chr6:162384350	PARK2	0.42	6.95	0.53	1.8e-10	Itch intensity from mosquito bite;
TGCT	cis	rs12497850	0.931	rs13316620	chr3:49045355	T/C	cg18654377	chr3:49208889	KLHDC8B	-0.42	-5.42	-0.44	3e-7	Parkinson's disease;
TGCT	cis	rs1670533	1.000	rs6839931	chr4:1053172	A/G	cg20887711	chr4:1340912	KIAA1530	0.7	5.65	0.45	1.03e-7	Recombination rate (females);
TGCT	cis	rs854765	0.647	rs854808	chr17:18006634	C/T	cg04398451	chr17:18023971	MYO15A	-0.38	-6.48	-0.5	1.91e-9	Total body bone mineral density;
TGCT	cis	rs3892630	0.824	rs2287882	chr19:33332952	C/T	cg22980127	chr19:33182716	NUDT19	0.67	4.91	0.4	2.85e-6	Red blood cell traits;
TGCT	cis	rs6754311	0.517	rs1865452	chr2:136539330	C/T	cg07169764	chr2:136633963	MCM6	0.89	7.96	0.58	9.17e-13	Mosquito bite size;
TGCT	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg21171335	chr12:122356390	WDR66	0.7	7.03	0.53	1.24e-10	Mean corpuscular volume;
TGCT	cis	rs11190604	1.000	rs2295779	chr10:102296061	A/G	cg16342193	chr10:102329863	NA	-0.4	-5.46	-0.44	2.53e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9393777	0.513	rs13195210	chr6:26646521	C/T	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.53	-4.88	-0.4	3.19e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs28374715	0.528	rs7178360	chr15:41631175	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.9	-14.93	-0.8	1.76e-29	Ulcerative colitis;
TGCT	cis	rs17221829	0.617	rs1844194	chr11:89389367	C/T	cg02982614	chr11:89391479	FOLH1B	-0.25	-4.46	-0.37	1.8e-5	Anxiety in major depressive disorder;
TGCT	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg17178900	chr1:205818956	PM20D1	0.59	7.37	0.55	2.06e-11	Menarche (age at onset);
TGCT	cis	rs11190604	1.000	rs2003284	chr10:102202338	A/G	cg23241863	chr10:102295624	HIF1AN	0.62	4.87	0.4	3.27e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg22963979	chr7:1858916	MAD1L1	-0.37	-5.77	-0.46	5.99e-8	Bipolar disorder and schizophrenia;
TGCT	cis	rs1903068	1.000	rs9312658	chr4:56005526	C/A	cg01777861	chr4:56023843	NA	0.56	6.54	0.51	1.45e-9	Endometriosis;
TGCT	cis	rs7959452	0.535	rs7133487	chr12:69774377	G/A	cg11871910	chr12:69753446	YEATS4	0.82	8.95	0.63	4.38e-15	Blood protein levels;
TGCT	cis	rs6484504	0.532	rs2774403	chr11:31320530	A/T	cg26647111	chr11:31128758	NA	0.31	4.48	0.37	1.66e-5	Red blood cell count;
TGCT	cis	rs9902453	1.000	rs7207021	chr17:28400516	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.76	-6.77	-0.52	4.47e-10	Coffee consumption (cups per day);
TGCT	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg00908189	chr16:619842	PIGQ	0.87	10.61	0.69	4.21e-19	Height;
TGCT	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg07507251	chr3:52567010	NT5DC2	0.46	6.55	0.51	1.41e-9	Bipolar disorder;
TGCT	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg26338869	chr17:61819248	STRADA	-0.53	-4.94	-0.41	2.48e-6	Prudent dietary pattern;
TGCT	cis	rs7582180	0.764	rs11686293	chr2:100922830	C/T	cg08017756	chr2:100939284	LONRF2	-0.32	-5.31	-0.43	4.86e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg03517284	chr6:25882590	NA	-0.9	-8.6	-0.61	2.87e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs617219	0.710	rs16876598	chr5:78573970	T/C	cg05890484	chr5:78407552	BHMT	-0.34	-4.63	-0.38	9.24e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg00814883	chr7:100076585	TSC22D4	-0.92	-9.76	-0.66	4.73e-17	Platelet count;
TGCT	cis	rs526231	0.819	rs35803	chr5:102606942	A/G	cg05225461	chr5:102596755	C5orf30	0.23	4.62	0.38	9.51e-6	Primary biliary cholangitis;
TGCT	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg21285383	chr16:89894308	SPIRE2	0.44	7.03	0.53	1.23e-10	Vitiligo;
TGCT	cis	rs4919044	0.688	rs59539045	chr10:94776594	C/A	cg05127821	chr10:94822908	CYP26C1	-0.77	-5.03	-0.41	1.71e-6	Coronary artery disease;
TGCT	cis	rs2387326	1.000	rs34558168	chr10:129932106	T/C	cg03458096	chr10:129105057	DOCK1	-0.3	-4.67	-0.39	7.78e-6	Select biomarker traits;
TGCT	cis	rs921968	0.584	rs2305833	chr2:219305404	G/C	cg02176678	chr2:219576539	TTLL4	0.37	5.34	0.43	4.32e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg12419862	chr22:24373484	LOC391322	-0.8	-8.43	-0.6	7.54e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs909674	0.909	rs1557541	chr22:39851970	C/A	cg24399712	chr22:39784796	NA	-1.05	-11.09	-0.71	2.82e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.87	0.47	3.73e-8	Alzheimer's disease;
TGCT	cis	rs9653442	0.593	rs4851273	chr2:100848321	A/G	cg22139774	chr2:100720529	AFF3	-0.38	-5.88	-0.47	3.5e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs10540	1.000	rs61742833	chr11:490035	C/T	cg03352830	chr11:487213	PTDSS2	0.32	5.46	0.44	2.44e-7	Body mass index;
TGCT	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg03517284	chr6:25882590	NA	0.52	4.67	0.39	7.55e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg03264133	chr6:25882463	NA	-0.6	-5.49	-0.44	2.18e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs12220898	0.749	rs10776553	chr10:50482929	C/T	cg12697796	chr10:49954016	WDFY4	0.49	4.44	0.37	2e-5	Inflammatory biomarkers;
TGCT	cis	rs950776	0.518	rs11630349	chr15:78824608	C/T	cg06917634	chr15:78832804	PSMA4	0.95	9.52	0.65	1.81e-16	Sudden cardiac arrest;
TGCT	cis	rs11112613	0.713	rs58066965	chr12:105952505	C/G	cg03607813	chr12:105948248	NA	0.47	5.72	0.46	7.49e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	cis	rs1372520	0.684	rs2619355	chr4:90748374	A/C	cg15133208	chr4:90757351	SNCA	-0.5	-5.86	-0.47	4e-8	Neuroticism;
TGCT	cis	rs9300255	0.544	rs1790100	chr12:123656725	G/T	cg00376283	chr12:123451042	ABCB9	0.72	5.55	0.45	1.65e-7	Neutrophil percentage of white cells;
TGCT	cis	rs7267979	0.966	rs910996	chr20:25264196	A/G	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg22166914	chr1:53195759	ZYG11B	0.37	5.95	0.47	2.57e-8	Monocyte count;
TGCT	cis	rs4253772	0.550	rs739164	chr22:46684558	C/T	cg24881330	chr22:46731750	TRMU	-0.96	-6.38	-0.5	3.18e-9	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-5.79	-0.46	5.39e-8	Alzheimer's disease;
TGCT	trans	rs1814175	0.646	rs61904497	chr11:49883449	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.45	-11.09	-0.71	2.8e-20	Height;
TGCT	cis	rs6866344	0.570	rs56236920	chr5:178144617	C/T	cg03877680	chr5:178157825	ZNF354A	0.78	6.69	0.51	6.86e-10	Neutrophil percentage of white cells;
TGCT	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	6.13	0.48	1.06e-8	Bipolar disorder;
TGCT	cis	rs826838	1.000	rs1684395	chr12:39083161	T/G	cg13010199	chr12:38710504	ALG10B	-0.59	-4.89	-0.4	3e-6	Heart rate;
TGCT	cis	rs36051895	0.623	rs6476956	chr9:5261238	A/G	cg02405213	chr9:5042618	JAK2	-0.68	-9.0	-0.63	3.29e-15	Pediatric autoimmune diseases;
TGCT	cis	rs6121246	0.567	rs6058189	chr20:30192389	A/G	cg13852791	chr20:30311386	BCL2L1	0.69	4.65	0.39	8.44e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs57590327	0.503	rs4856350	chr3:81503374	G/A	cg07356753	chr3:81810745	GBE1	0.58	4.89	0.4	3.06e-6	Extraversion;
TGCT	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg06238570	chr21:40685208	BRWD1	-0.82	-8.85	-0.62	7.34e-15	Cognitive function;
TGCT	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg10047753	chr17:41438598	NA	0.95	9.61	0.65	1.12e-16	Menopause (age at onset);
TGCT	cis	rs9486719	0.947	rs12208556	chr6:96903486	C/T	cg18709589	chr6:96969512	KIAA0776	-0.67	-5.23	-0.43	7e-7	Migraine;Coronary artery disease;
TGCT	cis	rs11690935	0.959	rs7562356	chr2:172626611	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.19	-12.78	-0.75	2.24e-24	Schizophrenia;
TGCT	trans	rs2688608	0.901	rs2633312	chr10:75631755	T/A	cg13918328	chr10:52500089	ASAH2B	0.66	6.85	0.52	3.11e-10	Inflammatory bowel disease;
TGCT	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg00343986	chr7:65444356	GUSB	-0.23	-5.16	-0.42	9.66e-7	Aortic root size;
TGCT	cis	rs7246657	0.943	rs10422074	chr19:37894236	T/C	cg18154014	chr19:37997991	ZNF793	0.95	6.61	0.51	1.04e-9	Coronary artery calcification;
TGCT	cis	rs7666738	0.716	rs2865982	chr4:99031661	T/G	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6815814	0.950	rs45588337	chr4:38807328	A/G	cg02016764	chr4:38805732	TLR1	-0.35	-5.65	-0.45	1.04e-7	Breast cancer;
TGCT	cis	rs11969893	0.850	rs9498418	chr6:101331838	A/T	cg12253828	chr6:101329408	ASCC3	1.07	5.1	0.42	1.25e-6	Economic and political preferences (immigration/crime);
TGCT	cis	rs2439831	0.850	rs16963953	chr15:44081719	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	6.01	0.47	1.91e-8	Lung cancer in ever smokers;
TGCT	cis	rs854765	0.619	rs6502636	chr17:17983817	A/T	cg04398451	chr17:18023971	MYO15A	-0.37	-6.51	-0.5	1.71e-9	Total body bone mineral density;
TGCT	cis	rs9308731	0.583	rs7596789	chr2:111932616	G/A	cg04202892	chr2:111875749	ACOXL	0.46	5.14	0.42	1.02e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs910187	0.564	rs6124949	chr20:45764370	C/T	cg27589058	chr20:45804311	EYA2	-0.33	-6.01	-0.47	1.93e-8	Migraine;
TGCT	cis	rs10782582	0.592	rs7513194	chr1:76382664	A/C	cg03433033	chr1:76189801	ACADM	0.46	4.59	0.38	1.08e-5	Daytime sleep phenotypes;
TGCT	cis	rs2658782	0.951	rs72972364	chr11:93122128	C/T	cg26827247	chr11:93063208	CCDC67	0.61	4.67	0.39	7.86e-6	Pulmonary function decline;
TGCT	cis	rs7086627	0.515	rs7088877	chr10:82208860	C/G	cg00277334	chr10:82204260	NA	-0.54	-8.46	-0.61	6.23e-14	Post bronchodilator FEV1;
TGCT	cis	rs3849570	0.555	rs6790351	chr3:82008988	C/T	cg07356753	chr3:81810745	GBE1	-0.62	-5.38	-0.44	3.5e-7	Waist circumference;Body mass index;
TGCT	cis	rs4727027	0.901	rs1534198	chr7:148772323	T/C	cg23583168	chr7:148888333	NA	-0.69	-8.67	-0.61	2.04e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs2243480	1.000	rs462853	chr7:65558167	G/C	cg20637647	chr7:64974828	NA	0.88	5.34	0.43	4.19e-7	Diabetic kidney disease;
TGCT	cis	rs7772486	0.754	rs864148	chr6:145976675	T/C	cg23711669	chr6:146136114	FBXO30	-0.91	-10.25	-0.68	3.12e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs8072100	0.713	rs3871595	chr17:45511388	C/T	cg08085267	chr17:45401833	C17orf57	-0.53	-5.93	-0.47	2.77e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs8103278	1.000	rs8108864	chr19:46301671	G/A	cg14061069	chr19:46274453	DMPK	-0.41	-5.78	-0.46	5.56e-8	Coronary artery disease;
TGCT	cis	rs9611519	1.000	rs5751069	chr22:41627775	C/G	cg13695892	chr22:41940480	POLR3H	-0.52	-4.78	-0.39	4.81e-6	Neuroticism;
TGCT	cis	rs6582630	0.519	rs8189609	chr12:38281408	A/G	cg26384229	chr12:38710491	ALG10B	0.86	7.48	0.56	1.17e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs73198271	1.000	rs4841030	chr8:8607011	C/T	ch.8.214553F	chr8:8189620	PRAGMIN	-0.27	-4.57	-0.38	1.17e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs9467773	0.620	rs1490488	chr6:26614808	T/C	cg26531700	chr6:26746687	NA	0.53	5.04	0.41	1.58e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg21226059	chr5:178986404	RUFY1	-0.62	-7.52	-0.56	9.7e-12	Lung cancer;
TGCT	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg03352830	chr11:487213	PTDSS2	0.26	4.46	0.37	1.8e-5	Body mass index;
TGCT	cis	rs739496	0.579	rs2106697	chr12:112260065	T/C	cg10833066	chr12:111807467	FAM109A	0.38	5.67	0.45	9.69e-8	Platelet count;
TGCT	cis	rs2153535	0.601	rs7775274	chr6:8530303	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.55e-8	Motion sickness;
TGCT	cis	rs35883536	0.611	rs72977390	chr1:101107147	C/T	cg06223162	chr1:101003688	GPR88	0.34	5.67	0.45	9.44e-8	Monocyte count;
TGCT	cis	rs2072499	0.966	rs6427307	chr1:156190083	A/G	cg06970220	chr1:156163860	SLC25A44	0.67	5.98	0.47	2.22e-8	Testicular germ cell tumor;
TGCT	cis	rs2303745	0.841	rs10409801	chr19:17407415	A/G	cg10664184	chr19:17420304	DDA1	0.62	4.75	0.39	5.64e-6	Systemic lupus erythematosus;
TGCT	cis	rs1577917	0.917	rs13213603	chr6:86534758	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-5.53	-0.44	1.82e-7	Response to antipsychotic treatment;
TGCT	cis	rs1008375	0.933	rs6847966	chr4:17634255	G/A	cg18681998	chr4:17616180	MED28	1.07	11.98	0.73	1.97e-22	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs3770081	0.826	rs1019591	chr2:86298599	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.17	-4.56	-0.38	1.21e-5	Facial emotion recognition (sad faces);
TGCT	cis	rs6840360	0.638	rs2406974	chr4:152601841	G/A	cg17479576	chr4:152424074	FAM160A1	-0.64	-6.59	-0.51	1.16e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs6701037	0.681	rs1057246	chr1:175127534	C/G	cg00321850	chr1:175162397	KIAA0040	0.45	5.53	0.44	1.82e-7	Alcohol dependence;
TGCT	cis	rs6831352	0.918	rs13143133	chr4:100054970	A/G	cg12011299	chr4:100065546	ADH4	-0.4	-4.88	-0.4	3.26e-6	Alcohol dependence;
TGCT	cis	rs2456568	0.548	rs4753113	chr11:93660974	G/A	cg26875233	chr11:93583750	C11orf90	-0.41	-4.97	-0.41	2.14e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs11626933	0.959	rs17799226	chr14:90754538	C/T	cg14092571	chr14:90743983	NA	-0.29	-6.02	-0.48	1.86e-8	Gut microbiota (bacterial taxa);
TGCT	cis	rs7819412	0.811	rs2409691	chr8:10943276	C/T	cg27411982	chr8:10470053	RP1L1	-0.21	-4.6	-0.38	1.02e-5	Triglycerides;
TGCT	cis	rs9300255	0.544	rs1727310	chr12:123660510	A/G	cg00376283	chr12:123451042	ABCB9	0.74	5.09	0.42	1.27e-6	Neutrophil percentage of white cells;
TGCT	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg11494091	chr17:61959527	GH2	0.61	14.68	0.8	6.78e-29	Prudent dietary pattern;
TGCT	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs17767294	0.614	rs75043119	chr6:28187424	A/C	cg08851530	chr6:28072375	NA	1.46	6.76	0.52	4.79e-10	Parkinson's disease;
TGCT	cis	rs4072705	0.967	rs4240486	chr9:127341110	C/T	cg13476313	chr9:127244764	NR5A1	0.28	4.5	0.37	1.52e-5	Menarche (age at onset);
TGCT	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg04772025	chr11:68637568	NA	0.6	6.67	0.51	7.4e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	trans	rs4942242	1.000	rs9533572	chr13:44234265	A/C	cg19169023	chr15:41853346	TYRO3	-0.33	-6.64	-0.51	9.02e-10	Response to tocilizumab in rheumatoid arthritis;
TGCT	cis	rs765787	0.530	rs1706835	chr15:45517884	G/A	cg24006582	chr15:45444508	DUOX1	-0.26	-5.62	-0.45	1.19e-7	Uric acid levels;
TGCT	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg06675538	chr2:114033490	PAX8;LOC440839	-0.42	-4.65	-0.39	8.23e-6	Lymphocyte counts;
TGCT	cis	rs7918232	0.662	rs10764662	chr10:27300643	T/A	cg14442939	chr10:27389572	ANKRD26	0.58	4.63	0.38	9.13e-6	Breast cancer;
TGCT	cis	rs67072384	1.000	rs12294368	chr11:72451239	G/A	cg03713592	chr11:72463424	ARAP1	-0.93	-4.66	-0.39	7.89e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg18402987	chr7:1209562	NA	0.76	6.47	0.5	2.05e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9611565	0.572	rs139569	chr22:42211141	A/G	cg06481639	chr22:41940642	POLR3H	-0.53	-4.51	-0.38	1.51e-5	Vitiligo;
TGCT	cis	rs933688	1.000	rs6866191	chr5:90746852	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.96	8.25	0.6	1.91e-13	Smoking behavior;
TGCT	cis	rs10089	1.000	rs4836367	chr5:127482592	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	8.19	0.59	2.64e-13	Ileal carcinoids;
TGCT	cis	rs72945132	0.825	rs2277273	chr11:70223992	T/C	cg00319359	chr11:70116639	PPFIA1	0.99	7.39	0.55	1.94e-11	Coronary artery disease;
TGCT	cis	rs3820068	0.577	rs9728986	chr1:16040603	G/A	cg05660106	chr1:15850417	CASP9	0.67	6.48	0.5	1.96e-9	Systolic blood pressure;
TGCT	cis	rs7528684	0.816	rs2873405	chr1:157692044	T/G	cg17134153	chr1:157670328	FCRL3	-0.26	-4.69	-0.39	7e-6	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;
TGCT	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg15556689	chr8:8085844	FLJ10661	-0.85	-9.08	-0.63	2.14e-15	Schizophrenia;
TGCT	cis	rs3771570	1.000	rs62186422	chr2:242249499	A/G	cg21155796	chr2:242212141	HDLBP	0.98	6.68	0.51	7.29e-10	Prostate cancer;
TGCT	cis	rs9894429	0.604	rs9912071	chr17:79609654	G/A	cg18240062	chr17:79603768	NPLOC4	0.84	9.37	0.64	4.28e-16	Eye color traits;
TGCT	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.68	5.6	0.45	1.31e-7	Tonsillectomy;
TGCT	cis	rs4727027	0.716	rs4727020	chr7:148837317	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.17	0.42	9.03e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs826838	0.967	rs1684414	chr12:39129553	A/G	cg26384229	chr12:38710491	ALG10B	-0.86	-7.7	-0.57	3.65e-12	Heart rate;
TGCT	cis	rs916888	0.610	rs199454	chr17:44800110	G/A	cg17911788	chr17:44343683	NA	0.48	5.71	0.46	7.77e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg12963246	chr6:28129442	ZNF389	-0.51	-5.14	-0.42	1.04e-6	Depression;
TGCT	cis	rs6582630	0.576	rs11504369	chr12:38274566	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-4.59	-0.38	1.08e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs9291683	0.507	rs6849273	chr4:10021595	C/T	cg00071950	chr4:10020882	SLC2A9	0.62	7.35	0.55	2.37e-11	Bone mineral density;
TGCT	cis	rs2456568	0.548	rs10501809	chr11:93666263	C/G	cg17595323	chr11:93583763	C11orf90	-0.43	-5.46	-0.44	2.53e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs854765	0.964	rs854762	chr17:18009102	G/A	cg09796270	chr17:17721594	SREBF1	-0.26	-5.22	-0.42	7.3e-7	Total body bone mineral density;
TGCT	cis	rs9291683	0.655	rs55941493	chr4:10100341	G/A	cg11266682	chr4:10021025	SLC2A9	-0.49	-5.6	-0.45	1.29e-7	Bone mineral density;
TGCT	cis	rs6430585	0.591	rs72970243	chr2:136484232	G/A	cg07169764	chr2:136633963	MCM6	0.91	8.33	0.6	1.28e-13	Corneal structure;
TGCT	cis	rs6840360	0.530	rs62327350	chr4:152641202	G/A	cg17479576	chr4:152424074	FAM160A1	-0.63	-6.36	-0.5	3.58e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs9916302	0.851	rs12936996	chr17:37665554	A/G	cg15445000	chr17:37608096	MED1	-0.31	-4.59	-0.38	1.06e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs6940638	0.688	rs9295730	chr6:27128806	T/C	cg26531700	chr6:26746687	NA	-0.53	-4.57	-0.38	1.15e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs4478858	0.684	rs7528066	chr1:31749092	C/G	cg00250761	chr1:31883323	NA	-0.26	-4.55	-0.38	1.28e-5	Alcohol dependence;
TGCT	cis	rs10791323	0.559	rs10750549	chr11:133730820	A/G	cg03690763	chr11:133734501	NA	-0.3	-4.53	-0.38	1.38e-5	Childhood ear infection;
TGCT	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg07061783	chr6:25882402	NA	-0.45	-4.82	-0.4	4.14e-6	Blood metabolite levels;
TGCT	cis	rs45509595	0.749	rs401763	chr6:27782528	T/C	cg08798685	chr6:27730294	NA	-0.35	-4.76	-0.39	5.24e-6	Breast cancer;
TGCT	cis	rs1401999	0.714	rs1000002	chr3:183635768	A/G	cg01324343	chr3:183735012	ABCC5	-0.67	-8.25	-0.6	1.93e-13	Anterior chamber depth;
TGCT	cis	rs56176327	0.600	rs7628207	chr3:49754970	T/C	cg03060546	chr3:49711283	APEH	0.63	5.63	0.45	1.12e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs61776719	0.875	rs4072980	chr1:38456106	G/A	cg26398791	chr1:38455867	SF3A3	0.6	5.77	0.46	5.94e-8	Coronary artery disease;
TGCT	cis	rs1552244	0.554	rs2272119	chr3:10049352	A/G	cg00149659	chr3:10157352	C3orf10	0.69	4.99	0.41	2.03e-6	Alzheimer's disease;
TGCT	cis	rs11690935	0.959	rs77280952	chr2:172620151	G/C	cg13550731	chr2:172543902	DYNC1I2	-1.2	-12.28	-0.74	3.49e-23	Schizophrenia;
TGCT	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.52	5.83	0.46	4.51e-8	Autism spectrum disorder or schizophrenia;
TGCT	trans	rs208520	0.690	rs851459	chr6:66813989	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.97	-10.61	-0.69	4.11e-19	Exhaled nitric oxide output;
TGCT	cis	rs10193935	0.901	rs6544536	chr2:42522042	G/A	cg27598129	chr2:42591480	NA	-0.35	-4.89	-0.4	3.09e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg05985448	chr10:134359359	INPP5A	0.24	5.13	0.42	1.1e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg16325326	chr1:53192061	ZYG11B	-0.71	-8.98	-0.63	3.64e-15	Monocyte count;
TGCT	cis	rs7617480	0.648	rs9864243	chr3:48982732	G/A	cg05785598	chr3:49045655	WDR6	0.39	4.52	0.38	1.42e-5	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs7586879	0.964	rs6545795	chr2:25116783	C/T	cg01884057	chr2:25150051	NA	0.28	5.03	0.41	1.69e-6	Body mass index;
TGCT	cis	rs6088580	0.634	rs6142157	chr20:32984172	C/G	cg06115741	chr20:33292138	TP53INP2	-0.53	-4.67	-0.39	7.83e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs11786130	0.544	rs4733823	chr8:129014697	C/T	cg00780520	chr8:128808554	PVT1	0.2	4.53	0.38	1.37e-5	Eosinophil counts;Sum eosinophil basophil counts;
TGCT	cis	rs9329221	0.592	rs7832708	chr8:10190040	C/T	cg27411982	chr8:10470053	RP1L1	0.21	4.7	0.39	6.72e-6	Neuroticism;
TGCT	cis	rs7312933	0.533	rs11181499	chr12:42818761	A/G	cg19980929	chr12:42632907	YAF2	0.42	5.91	0.47	3.05e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs6964587	0.967	rs6973896	chr7:91778465	A/G	cg22709100	chr7:91322751	NA	0.29	4.62	0.38	9.33e-6	Breast cancer;
TGCT	cis	rs7666738	0.791	rs6828752	chr4:99063382	C/T	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.44e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10461617	0.535	rs7709874	chr5:56047451	C/T	cg24531977	chr5:56204891	C5orf35	-0.46	-4.52	-0.38	1.45e-5	Type 2 diabetes;
TGCT	cis	rs4700695	0.543	rs37233	chr5:65222207	C/G	cg21114390	chr5:65439923	SFRS12	0.7	4.89	0.4	3.03e-6	Facial morphology (factor 19);
TGCT	cis	rs2464469	0.618	rs8024164	chr15:58205900	A/G	cg12031962	chr15:58353849	ALDH1A2	0.34	4.67	0.39	7.86e-6	Barrett's esophagus  or Esophageal adenocarcinoma;
TGCT	cis	rs62244186	0.748	rs6441861	chr3:44652287	A/G	cg10263370	chr3:44754102	ZNF502	-0.44	-5.23	-0.43	7.03e-7	Depressive symptoms;
TGCT	cis	rs28595532	1.000	rs11098451	chr4:119717673	C/T	cg11846333	chr4:119757529	SEC24D	0.81	4.75	0.39	5.62e-6	Cannabis dependence symptom count;
TGCT	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg21963583	chr11:68658836	MRPL21	0.36	6.04	0.48	1.7e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs12681287	0.640	rs7830480	chr8:87403137	T/C	cg27223183	chr8:87520930	FAM82B	0.87	6.39	0.5	3e-9	Caudate activity during reward;
TGCT	cis	rs4268898	0.735	rs12469585	chr2:24489054	A/T	cg02683114	chr2:24398427	C2orf84	0.2	4.95	0.41	2.39e-6	Asthma;
TGCT	cis	rs6460942	0.915	rs2192842	chr7:12315752	C/G	cg06484146	chr7:12443880	VWDE	-0.48	-4.82	-0.4	4.08e-6	Coronary artery disease;
TGCT	cis	rs6558530	0.692	rs6558521	chr8:1700818	C/T	cg09410841	chr8:1729607	CLN8	-0.68	-6.27	-0.49	5.45e-9	Systolic blood pressure;
TGCT	cis	rs634534	0.562	rs642293	chr11:65730217	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.6	6.03	0.48	1.75e-8	Sum eosinophil basophil counts;Eosinophil counts;
TGCT	cis	rs78487399	0.808	rs6752448	chr2:43682596	G/C	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.72	4.62	0.38	9.53e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs3806843	0.576	rs155363	chr5:140301543	A/G	cg09824255	chr5:140014002	CD14	0.25	4.49	0.37	1.63e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2739330	0.576	rs2858912	chr22:24297197	A/G	cg18538332	chr22:24372958	LOC391322	-0.99	-12.8	-0.75	2e-24	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs739496	0.527	rs61440627	chr12:112318997	T/C	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs79149102	0.579	rs7342591	chr15:75306863	C/T	cg09165964	chr15:75287851	SCAMP5	1.04	5.73	0.46	7.2e-8	Lung cancer;
TGCT	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg19748678	chr4:122722346	EXOSC9	0.9	9.34	0.64	4.9e-16	Type 2 diabetes;
TGCT	cis	rs7809950	0.817	rs2253833	chr7:107205669	A/G	cg23024343	chr7:107201750	COG5	0.42	5.95	0.47	2.56e-8	Coronary artery disease;
TGCT	cis	rs2795502	1.000	rs2142991	chr10:43341105	C/T	cg20628663	chr10:43360327	NA	-0.44	-6.23	-0.49	6.74e-9	Blood protein levels;
TGCT	cis	rs9929218	0.954	rs72785165	chr16:68755635	T/A	cg01251360	chr16:68772225	CDH1	0.29	4.8	0.4	4.46e-6	Colorectal cancer;
TGCT	cis	rs3772130	0.540	rs11717089	chr3:121563271	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.59	5.43	0.44	2.8e-7	Cognitive performance;
TGCT	cis	rs3749237	0.615	rs11130202	chr3:49566715	C/T	cg03060546	chr3:49711283	APEH	0.75	8.65	0.61	2.25e-14	Resting heart rate;
TGCT	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg05896524	chr21:47604654	C21orf56	0.43	4.62	0.38	9.37e-6	Testicular germ cell tumor;
TGCT	cis	rs74233809	0.515	rs72841270	chr10:104642237	T/G	cg05855489	chr10:104503620	C10orf26	0.72	5.42	0.44	2.99e-7	Birth weight;
TGCT	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg25036284	chr2:26402008	FAM59B	-0.54	-4.7	-0.39	6.93e-6	Gut microbiome composition (summer);
TGCT	cis	rs1005277	0.522	rs9417256	chr10:37976990	A/G	cg25427524	chr10:38739819	LOC399744	-0.33	-6.48	-0.5	1.99e-9	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7953508	0.506	rs2053196	chr12:93962959	T/C	cg18151635	chr12:93972918	NA	-0.19	-4.53	-0.38	1.35e-5	Pubertal anthropometrics;
TGCT	cis	rs2072499	0.966	rs2842857	chr1:156168736	T/C	cg06970220	chr1:156163860	SLC25A44	0.73	6.46	0.5	2.13e-9	Testicular germ cell tumor;
TGCT	cis	rs79349575	0.783	rs56046215	chr17:47008757	A/T	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.52	-0.38	1.44e-5	Type 2 diabetes;
TGCT	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg01448562	chr3:133502909	NA	-0.33	-6.8	-0.52	3.92e-10	Iron status biomarkers;
TGCT	cis	rs12477438	0.520	rs12467504	chr2:99543208	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.57	-4.83	-0.4	4e-6	Chronic sinus infection;
TGCT	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg17054783	chr10:134559939	INPP5A	0.28	5.64	0.45	1.07e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs28595532	0.920	rs116098781	chr4:119771613	G/A	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs6459788	0.693	rs11981578	chr7:157250133	C/T	cg03453431	chr7:157225567	NA	-0.4	-6.01	-0.47	1.93e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs1372520	0.627	rs2737025	chr4:90719192	A/G	cg01966878	chr4:90757139	SNCA	-0.31	-4.84	-0.4	3.8e-6	Neuroticism;
TGCT	cis	rs4642101	0.597	rs12638595	chr3:12819281	T/C	cg05775895	chr3:12838266	CAND2	0.89	9.52	0.65	1.87e-16	QRS complex (12-leadsum);
TGCT	cis	rs7666738	0.830	rs10031292	chr4:99056877	A/G	cg05340658	chr4:99064831	C4orf37	0.51	5.69	0.45	8.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7085104	0.660	rs3781286	chr10:104595719	C/T	cg05855489	chr10:104503620	C10orf26	0.54	4.94	0.41	2.47e-6	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs9297145	0.715	rs62473008	chr7:98751541	A/G	cg05967295	chr7:98741636	SMURF1	1.0	12.82	0.75	1.81e-24	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs12762955	0.507	rs7095853	chr10:1040798	T/C	cg18964960	chr10:1102726	WDR37	-0.68	-5.86	-0.47	3.86e-8	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs7829975	0.501	rs74345345	chr8:8578435	C/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-4.44	-0.37	1.96e-5	Mood instability;
TGCT	cis	rs6671200	1.000	rs259354	chr1:95718205	T/C	cg03123541	chr1:95699097	RWDD3	-0.91	-6.4	-0.5	2.93e-9	Stearic acid (18:0) levels;
TGCT	cis	rs10875746	0.669	rs10875770	chr12:48600520	A/G	cg20731937	chr12:48336164	NA	0.58	4.52	0.38	1.44e-5	Longevity (90 years and older);
TGCT	cis	rs4771122	0.697	rs1475220	chr13:28037448	G/C	cg22138327	chr13:27999177	GTF3A	-0.68	-5.35	-0.43	4.15e-7	Body mass index;
TGCT	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.7	6.33	0.49	4.02e-9	Tonsillectomy;
TGCT	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg18876405	chr7:65276391	NA	-0.34	-5.19	-0.42	8.37e-7	Aortic root size;
TGCT	cis	rs6500602	0.727	rs4786510	chr16:4571247	A/G	cg09549813	chr16:4587862	C16orf5	-0.28	-4.51	-0.38	1.5e-5	Schizophrenia;
TGCT	cis	rs60154123	0.505	rs115881613	chr1:210040369	C/T	cg23283495	chr1:209979779	IRF6	0.67	4.99	0.41	1.96e-6	Coronary artery disease;
TGCT	cis	rs7819412	0.668	rs2409715	chr8:11010136	A/T	cg21775007	chr8:11205619	TDH	-0.62	-5.74	-0.46	6.75e-8	Triglycerides;
TGCT	cis	rs6831352	0.879	rs67311928	chr4:100048999	A/G	cg12011299	chr4:100065546	ADH4	-0.41	-4.92	-0.4	2.72e-6	Alcohol dependence;
TGCT	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg03188948	chr7:1209495	NA	0.41	5.42	0.44	2.98e-7	Longevity;Endometriosis;
TGCT	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg00149659	chr3:10157352	C3orf10	0.97	5.98	0.47	2.19e-8	Alzheimer's disease;
TGCT	cis	rs854765	0.663	rs16960744	chr17:17755259	A/G	cg04398451	chr17:18023971	MYO15A	0.29	4.52	0.38	1.44e-5	Total body bone mineral density;
TGCT	cis	rs2282802	0.685	rs2436391	chr5:139557385	C/T	cg01081189	chr5:139537190	NA	-0.3	-5.37	-0.43	3.82e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs11864453	0.713	rs3764312	chr16:72125733	A/C	cg14768367	chr16:72042858	DHODH	0.5	4.8	0.4	4.5e-6	Fibrinogen levels;
TGCT	cis	rs3020736	0.500	rs764481	chr22:42518426	G/A	cg15557168	chr22:42548783	NA	0.22	5.58	0.45	1.47e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.72	5.19	0.42	8.33e-7	Platelet count;
TGCT	cis	rs1372520	1.000	rs1372520	chr4:90757505	T/C	cg26578617	chr4:90757533	SNCA	-0.55	-4.71	-0.39	6.51e-6	Neuroticism;
TGCT	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg26513180	chr16:89883248	FANCA	1.07	14.67	0.8	7.16e-29	Vitiligo;
TGCT	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg05025164	chr4:1340916	KIAA1530	-0.55	-4.75	-0.39	5.41e-6	Obesity-related traits;
TGCT	cis	rs61867294	0.501	rs7076627	chr10:106714848	A/G	cg08000847	chr10:105880925	C10orf78	0.47	4.45	0.37	1.91e-5	Schizophrenia;
TGCT	cis	rs12693043	0.790	rs17257938	chr2:175407780	C/T	cg11778734	chr2:175439522	WIPF1	-0.37	-4.9	-0.4	2.94e-6	Urate levels (BMI interaction);
TGCT	cis	rs9560113	0.597	rs947170	chr13:112241062	G/A	cg10483660	chr13:112241077	NA	-0.34	-5.34	-0.43	4.18e-7	Menarche (age at onset);
TGCT	cis	rs6681544	0.760	rs11163394	chr1:82398752	G/A	cg04226724	chr1:82268649	LPHN2	0.48	4.97	0.41	2.19e-6	Metabolite levels  (X-11787);
TGCT	cis	rs7192750	0.517	rs152827	chr16:72126753	C/G	cg06353428	chr16:71660113	MARVELD3	1.12	5.56	0.45	1.59e-7	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs9291683	0.610	rs993173	chr4:10323935	T/C	cg11266682	chr4:10021025	SLC2A9	-0.51	-6.04	-0.48	1.64e-8	Bone mineral density;
TGCT	cis	rs9677476	0.542	rs10179264	chr2:232050603	G/C	cg07929768	chr2:232055508	NA	0.32	5.05	0.41	1.53e-6	Food antigen IgG levels;
TGCT	cis	rs67478160	0.679	rs8011109	chr14:104279974	G/A	cg26031613	chr14:104095156	KLC1	-0.63	-6.53	-0.51	1.56e-9	Schizophrenia;
TGCT	cis	rs9640161	0.789	rs28439010	chr7:150046276	C/T	cg10018233	chr7:150070692	REPIN1	0.31	4.55	0.38	1.25e-5	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg11644478	chr21:40555479	PSMG1	-0.54	-4.89	-0.4	3.02e-6	Menarche (age at onset);
TGCT	cis	rs11644362	0.966	rs976011	chr16:12992910	C/T	cg06890432	chr16:12997467	SHISA9	-0.61	-6.77	-0.52	4.49e-10	Positive affect;Subjective well-being;
TGCT	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg13695892	chr22:41940480	POLR3H	1.0	7.98	0.58	8.2e-13	Vitiligo;
TGCT	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg17054783	chr10:134559939	INPP5A	0.25	4.89	0.4	3e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs6074578	0.679	rs6055460	chr20:139362	G/A	cg16931068	chr20:139680	DEFB127	-0.28	-4.83	-0.4	3.89e-6	Hirschsprung disease;
TGCT	cis	rs3540	0.960	rs12440447	chr15:91022694	C/G	cg22089800	chr15:90895588	ZNF774	0.74	6.91	0.53	2.27e-10	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs4555082	0.750	rs2816650	chr14:105708343	C/T	cg01266790	chr14:105781312	PACS2	0.55	4.49	0.37	1.58e-5	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs11190604	1.000	rs2495734	chr10:102338686	G/A	cg23241863	chr10:102295624	HIF1AN	0.67	4.9	0.4	2.99e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs8111998	0.625	rs7255845	chr19:22766051	C/T	cg19914732	chr19:22715077	NA	-0.56	-4.51	-0.38	1.46e-5	Corneal structure;
TGCT	cis	rs2075371	0.501	rs1421469	chr7:134028260	C/G	cg11752832	chr7:134001865	SLC35B4	0.59	5.08	0.42	1.35e-6	Mean platelet volume;
TGCT	cis	rs3820068	0.705	rs4646022	chr1:15839112	G/A	cg05660106	chr1:15850417	CASP9	1.16	14.82	0.8	3.11e-29	Systolic blood pressure;
TGCT	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg18876405	chr7:65276391	NA	0.31	4.79	0.4	4.58e-6	Aortic root size;
TGCT	cis	rs6582630	0.519	rs4002440	chr12:38485012	A/G	cg26384229	chr12:38710491	ALG10B	0.83	7.6	0.56	6.18e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs9733	0.519	rs7529194	chr1:150622620	A/T	cg04414720	chr1:150670196	GOLPH3L	0.38	4.91	0.4	2.82e-6	Tonsillectomy;
TGCT	cis	rs79349575	0.691	rs11079847	chr17:47037024	A/T	cg26022315	chr17:47021804	SNF8	-0.49	-4.5	-0.38	1.51e-5	Type 2 diabetes;
TGCT	cis	rs11864453	0.713	rs8051882	chr16:72142072	A/G	cg14768367	chr16:72042858	DHODH	-0.5	-4.92	-0.4	2.64e-6	Fibrinogen levels;
TGCT	trans	rs877282	1.000	rs11253362	chr10:770979	G/T	cg22713356	chr15:30763199	NA	1.2	10.69	0.69	2.63e-19	Uric acid levels;
TGCT	cis	rs2456568	0.867	rs1827931	chr11:93663170	T/C	cg16099599	chr11:93583650	C11orf90	-0.4	-4.72	-0.39	6.23e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs1008375	1.000	rs6449319	chr4:17640283	T/A	cg10189774	chr4:17578691	LAP3	0.65	5.7	0.46	8.42e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs11148252	0.574	rs73186430	chr13:53232891	T/C	cg02158880	chr13:53174818	NA	0.41	4.9	0.4	2.96e-6	Lewy body disease;
TGCT	cis	rs4319547	0.661	rs7398014	chr12:122943980	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.7	-5.65	-0.45	1.05e-7	Body mass index;
TGCT	cis	rs644799	0.932	rs10831447	chr11:95663017	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.83	-5.83	-0.46	4.46e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs10504229	1.000	rs10504229	chr8:58196495	A/G	cg08280861	chr8:58055591	NA	0.36	4.6	0.38	1.05e-5	Developmental language disorder (linguistic errors);
TGCT	trans	rs8073060	0.572	rs1634683	chr17:33941560	G/C	cg19694781	chr19:47549865	TMEM160	-0.59	-12.7	-0.75	3.37e-24	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs1055129	0.560	rs56248937	chr17:73915153	T/A	cg08125733	chr17:73851984	WBP2	0.57	5.25	0.43	6.4e-7	White matter hyperintensity burden;
TGCT	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg07870213	chr5:140052090	DND1	-0.62	-7.4	-0.55	1.84e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs8067545	1.000	rs4925067	chr17:19921222	C/G	cg13482628	chr17:19912719	NA	0.54	4.74	0.39	5.86e-6	Schizophrenia;
TGCT	cis	rs1371867	0.875	rs1788174	chr8:101330957	C/G	cg00191853	chr8:101177733	SPAG1	0.23	4.57	0.38	1.18e-5	Atrioventricular conduction;
TGCT	cis	rs7201929	1.000	rs7499878	chr16:28868464	C/T	cg09754948	chr16:28834200	ATXN2L	-0.63	-4.94	-0.41	2.42e-6	QT interval;
TGCT	cis	rs7772486	0.754	rs9497419	chr6:146142609	T/C	cg05347473	chr6:146136440	FBXO30	0.5	4.72	0.39	6.35e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11651000	0.625	rs4794063	chr17:45804494	C/T	cg06532163	chr17:45867833	NA	0.32	5.14	0.42	1.04e-6	IgG glycosylation;
TGCT	cis	rs2456568	0.867	rs4753111	chr11:93658410	A/G	cg16099599	chr11:93583650	C11orf90	-0.41	-4.78	-0.39	4.87e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs34014631	1.000	rs41291490	chr10:103590737	T/A	cg22630918	chr10:102748988	C10orf2	0.43	4.83	0.4	3.98e-6	Coronary artery calcification;
TGCT	cis	rs1878931	0.567	rs7196196	chr16:3411855	C/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.97	11.5	0.72	2.84e-21	Body mass index (adult);
TGCT	cis	rs9532580	0.620	rs2701859	chr13:41141232	T/C	cg21288729	chr13:41239152	FOXO1	0.89	7.47	0.56	1.24e-11	Mean corpuscular hemoglobin;
TGCT	trans	rs7698623	0.717	rs4693193	chr4:88797992	T/C	cg01186725	chr1:53905612	FLJ40434	-0.48	-6.63	-0.51	9.21e-10	Cardiovascular disease risk factors;
TGCT	cis	rs7824557	0.585	rs2572385	chr8:11208903	G/A	cg21775007	chr8:11205619	TDH	0.75	7.15	0.54	6.5e-11	Retinal vascular caliber;
TGCT	cis	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg18252515	chr7:66147081	NA	-1.21	-7.89	-0.58	1.36e-12	Diabetic kidney disease;
TGCT	cis	rs2073300	1.000	rs6132621	chr20:23442180	C/T	cg09953122	chr20:23471693	CST8	-0.64	-4.56	-0.38	1.19e-5	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs2422052	0.519	rs11123458	chr2:118633602	A/G	cg05295388	chr2:118594304	NA	-0.28	-4.88	-0.4	3.22e-6	Mosquito bite size;
TGCT	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg25703541	chr22:24373054	LOC391322	-0.81	-8.47	-0.61	5.88e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs10206020	0.921	rs2280127	chr2:1546531	C/T	cg12573674	chr2:1569213	NA	-0.49	-4.93	-0.41	2.54e-6	IgG glycosylation;
TGCT	cis	rs6427419	1.000	rs6427419	chr1:158058109	C/A	cg07184316	chr1:157669111	FCRL3	0.25	4.62	0.38	9.6e-6	Obesity-related traits;
TGCT	cis	rs4919694	1.000	rs4917988	chr10:104752830	T/G	cg04362960	chr10:104952993	NT5C2	1.07	7.07	0.54	9.73e-11	Arsenic metabolism;
TGCT	cis	rs3091242	0.933	rs9438904	chr1:25756860	T/C	cg10117171	chr1:25599238	RHD	-0.33	-5.46	-0.44	2.44e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg18735214	chr6:43276756	CRIP3	-0.56	-4.88	-0.4	3.24e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs4237845	0.761	rs11172378	chr12:58298161	C/T	cg23860436	chr12:58378763	NA	0.34	4.97	0.41	2.18e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9325144	0.723	rs10161183	chr12:39182087	T/C	cg10518543	chr12:38710700	ALG10B	-0.5	-4.65	-0.39	8.28e-6	Morning vs. evening chronotype;
TGCT	cis	rs4891159	0.790	rs35516239	chr18:74129942	C/T	cg24786174	chr18:74118243	ZNF516	-0.59	-8.98	-0.63	3.73e-15	Longevity;
TGCT	cis	rs16867321	0.950	rs2887180	chr2:181449305	C/A	cg23363182	chr2:181467187	NA	-0.39	-5.47	-0.44	2.38e-7	Obesity;
TGCT	cis	rs524281	0.861	rs471484	chr11:65955144	A/G	cg00563793	chr11:65837595	PACS1	0.55	5.01	0.41	1.84e-6	Electroencephalogram traits;
TGCT	cis	rs11190604	1.000	rs1054399	chr10:102312565	C/T	cg16342193	chr10:102329863	NA	-0.39	-4.95	-0.41	2.36e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7639513	0.767	rs7648488	chr3:12708946	T/C	cg23032965	chr3:12705835	RAF1	0.77	8.55	0.61	3.81e-14	Itch intensity from mosquito bite;
TGCT	cis	rs5769707	0.967	rs4524218	chr22:50018639	G/A	cg20744362	chr22:50050164	C22orf34	0.27	4.47	0.37	1.77e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs10769025	0.511	rs7930973	chr11:44181028	A/G	cg17479956	chr11:44115929	EXT2	0.19	4.47	0.37	1.73e-5	Gout;
TGCT	cis	rs56104184	0.668	rs73063523	chr19:49408943	T/C	cg21252483	chr19:49399788	TULP2	-0.42	-5.89	-0.47	3.47e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs4566357	0.615	rs3769643	chr2:227917270	T/C	cg11843606	chr2:227700838	RHBDD1	-0.54	-5.24	-0.43	6.55e-7	Coronary artery disease;
TGCT	cis	rs7394190	0.748	rs3088070	chr10:75530013	C/T	cg07699608	chr10:75541558	CHCHD1	0.8	5.21	0.42	7.72e-7	Incident atrial fibrillation;
TGCT	cis	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg22121687	chr7:65037720	NA	-0.78	-4.7	-0.39	6.74e-6	Diabetic kidney disease;
TGCT	cis	rs9916302	0.851	rs12936646	chr17:37647450	A/T	cg15445000	chr17:37608096	MED1	0.31	4.59	0.38	1.06e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs12497850	0.931	rs13315711	chr3:48986399	A/T	cg06212747	chr3:49208901	KLHDC8B	0.6	5.43	0.44	2.82e-7	Parkinson's disease;
TGCT	cis	rs34526934	0.566	rs62624470	chr2:177040907	C/T	cg26754761	chr2:177040938	NA	-0.3	-5.6	-0.45	1.33e-7	Obstructive sleep apnea trait (apnea hypopnea index);
TGCT	cis	rs11792861	0.926	rs59904140	chr9:111910051	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.51	4.75	0.39	5.61e-6	Menarche (age at onset);
TGCT	cis	rs13217239	0.646	rs12201393	chr6:26975690	C/A	cg02458000	chr6:26745757	NA	0.5	4.61	0.38	9.84e-6	Schizophrenia;
TGCT	cis	rs6570726	0.791	rs9322029	chr6:145906683	A/G	cg23711669	chr6:146136114	FBXO30	0.86	9.54	0.65	1.64e-16	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs10506458	0.915	rs12424908	chr12:63402364	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.47	-7.58	-0.56	6.97e-12	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs7552404	0.960	rs4949877	chr1:76201668	C/G	cg10523679	chr1:76189770	ACADM	0.9	9.71	0.66	6.5e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs548987	0.507	rs35875210	chr6:25827484	A/G	cg03517284	chr6:25882590	NA	-0.55	-4.44	-0.37	1.93e-5	Homocysteine levels;
TGCT	cis	rs9914544	0.545	rs4290526	chr17:18772967	T/C	cg26378065	chr17:18585709	ZNF286B	0.51	4.45	0.37	1.88e-5	Educational attainment (years of education);
TGCT	cis	rs7539409	0.604	rs910183	chr1:84297285	A/G	cg10977910	chr1:84465055	TTLL7	0.96	5.87	0.47	3.76e-8	Alzheimer's disease;
TGCT	cis	rs7605378	1.000	rs796363	chr2:200693668	T/C	cg23649088	chr2:200775458	C2orf69	0.35	5.83	0.46	4.53e-8	Osteoporosis;
TGCT	cis	rs617219	0.737	rs13158309	chr5:78463395	C/T	cg05890484	chr5:78407552	BHMT	-0.36	-4.96	-0.41	2.32e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs12368653	0.544	rs11172304	chr12:58097862	T/C	cg12615879	chr12:58013172	SLC26A10	0.45	5.28	0.43	5.47e-7	Multiple sclerosis;
TGCT	cis	rs7302981	0.967	rs12815871	chr12:50550948	G/A	cg23855989	chr12:50355821	AQP5	0.3	4.5	0.38	1.52e-5	Systolic blood pressure;
TGCT	cis	rs1801251	1.000	rs7578299	chr2:233573469	G/T	cg25237894	chr2:233734115	C2orf82	0.31	5.52	0.44	1.92e-7	Coronary artery disease;
TGCT	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	8.3	0.6	1.49e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7666738	0.830	rs35865860	chr4:98968822	C/T	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	5.11	0.42	1.18e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs3820068	0.603	rs927207	chr1:15990552	A/G	cg05660106	chr1:15850417	CASP9	0.79	7.22	0.54	4.55e-11	Systolic blood pressure;
TGCT	cis	rs617219	0.710	rs2255913	chr5:78562399	G/C	cg05890484	chr5:78407552	BHMT	0.34	4.63	0.38	9.24e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs6582630	0.502	rs1607867	chr12:38385463	C/T	cg26384229	chr12:38710491	ALG10B	0.83	7.26	0.55	3.72e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg10862848	chr6:42927986	GNMT	-0.39	-4.7	-0.39	6.86e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs6988636	1.000	rs16898095	chr8:124193523	T/C	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs6940638	1.000	rs12204280	chr6:27033104	T/C	cg16898833	chr6:26189333	HIST1H4D	0.71	5.34	0.43	4.2e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs4589502	0.502	rs2169460	chr15:67197240	A/G	cg12317470	chr15:67143691	NA	-0.52	-5.12	-0.42	1.12e-6	Lung cancer (smoking interaction);
TGCT	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg07061783	chr6:25882402	NA	0.72	7.17	0.54	5.98e-11	Blood metabolite levels;
TGCT	cis	rs7088591	1.000	rs80032439	chr10:59730438	A/T	cg07264682	chr10:60082823	NA	0.39	4.65	0.39	8.44e-6	Blood pressure;
TGCT	cis	rs2153535	0.541	rs6905934	chr6:8440043	C/A	cg07606381	chr6:8435919	SLC35B3	0.57	5.25	0.43	6.46e-7	Motion sickness;
TGCT	cis	rs7617773	0.780	rs35297486	chr3:48378147	T/A	cg11946769	chr3:48343235	NME6	0.82	6.99	0.53	1.49e-10	Coronary artery disease;
TGCT	cis	rs7552167	1.000	rs59960858	chr1:24519437	C/A	cg01960748	chr1:24522592	NA	0.6	6.44	0.5	2.42e-9	Psoriasis vulgaris;
TGCT	cis	rs7914558	1.000	rs11191542	chr10:104824324	T/A	cg04362960	chr10:104952993	NT5C2	0.6	5.34	0.43	4.37e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs3733585	0.631	rs7699671	chr4:10125874	C/T	cg00071950	chr4:10020882	SLC2A9	-0.49	-5.1	-0.42	1.26e-6	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs8102137	0.665	rs3218069	chr19:30313576	C/T	cg09247459	chr19:30364939	NA	0.31	4.7	0.39	6.85e-6	Bladder cancer;
TGCT	cis	rs3733585	0.673	rs6836706	chr4:9964251	T/A	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.7	-0.57	3.69e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7267979	1.000	rs2258617	chr20:25274318	C/T	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg11941060	chr3:133502564	NA	-0.29	-6.12	-0.48	1.12e-8	Iron status biomarkers;
TGCT	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg16049864	chr8:95962084	TP53INP1	-0.75	-10.48	-0.69	8.55e-19	Type 2 diabetes;
TGCT	cis	rs10832963	1.000	rs4757676	chr11:18640477	C/T	cg20219074	chr11:18656078	SPTY2D1	1.0	9.93	0.67	1.85e-17	Breast cancer;
TGCT	cis	rs12477438	0.765	rs7591992	chr2:99668954	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-4.88	-0.4	3.17e-6	Chronic sinus infection;
TGCT	cis	rs9308731	1.000	rs2241845	chr2:111879100	A/G	cg04202892	chr2:111875749	ACOXL	0.43	4.68	0.39	7.48e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs7714584	1.000	rs73284141	chr5:150266086	A/G	cg22134413	chr5:150180641	NA	0.78	6.12	0.48	1.16e-8	Crohn's disease;
TGCT	cis	rs6725041	0.819	rs939226	chr2:213088846	A/G	cg16329650	chr2:213403929	ERBB4	-0.53	-4.52	-0.38	1.44e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs981844	0.778	rs55895613	chr4:154638121	G/T	cg14289246	chr4:154710475	SFRP2	0.98	7.59	0.56	6.55e-12	Response to statins (LDL cholesterol change);
TGCT	cis	rs1372520	0.808	rs1372518	chr4:90757294	A/C	cg01966878	chr4:90757139	SNCA	-0.3	-4.59	-0.38	1.09e-5	Neuroticism;
TGCT	trans	rs877282	0.898	rs11253347	chr10:765769	A/G	cg22713356	chr15:30763199	NA	1.2	9.39	0.64	3.76e-16	Uric acid levels;
TGCT	cis	rs4727027	0.933	rs10238826	chr7:148830888	A/G	cg23583168	chr7:148888333	NA	-0.72	-9.18	-0.64	1.18e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs8014204	1.000	rs8014374	chr14:75322914	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.74	-7.11	-0.54	8e-11	Caffeine consumption;
TGCT	cis	rs2197308	0.765	rs11182992	chr12:37935572	G/C	cg13010199	chr12:38710504	ALG10B	0.66	5.33	0.43	4.41e-7	Morning vs. evening chronotype;
TGCT	cis	rs651907	0.557	rs13077925	chr3:101488181	T/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	4.61	0.38	9.98e-6	Colorectal cancer;
TGCT	cis	rs9902453	1.000	rs9890886	chr17:28391076	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-6.56	-0.51	1.3e-9	Coffee consumption (cups per day);
TGCT	cis	rs2282802	0.685	rs2337138	chr5:139691664	A/C	cg01081189	chr5:139537190	NA	0.27	5.01	0.41	1.87e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	8.55	0.61	3.84e-14	Platelet count;
TGCT	cis	rs62380364	0.602	rs610217	chr5:88065263	G/A	cg24804195	chr5:87968844	LOC645323	-0.57	-5.46	-0.44	2.54e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs10510102	0.872	rs11200277	chr10:123703810	A/G	cg23691251	chr10:123688108	ATE1	-0.62	-4.66	-0.39	8.16e-6	Breast cancer;
TGCT	cis	rs981844	0.583	rs2289318	chr4:154633734	G/C	cg14289246	chr4:154710475	SFRP2	0.97	7.51	0.56	1.03e-11	Response to statins (LDL cholesterol change);
TGCT	cis	rs2153535	0.580	rs6920779	chr6:8437624	C/T	cg07606381	chr6:8435919	SLC35B3	0.57	5.25	0.43	6.46e-7	Motion sickness;
TGCT	cis	rs546131	0.928	rs516228	chr11:34838823	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.57	5.11	0.42	1.2e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs35883536	0.647	rs7524322	chr1:101047730	C/G	cg10298815	chr1:101004474	GPR88	0.24	4.47	0.37	1.73e-5	Monocyte count;
TGCT	cis	rs17826219	0.500	rs9891256	chr17:29072692	C/T	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Body mass index;
TGCT	cis	rs1691799	0.899	rs1168325	chr12:66728234	C/G	cg16791601	chr12:66731901	HELB	-0.28	-6.17	-0.48	8.77e-9	White blood cell count (basophil);
TGCT	cis	rs4886920	0.563	rs8040813	chr15:78073289	A/G	cg03457338	chr15:78040120	NA	-0.18	-4.57	-0.38	1.16e-5	Neuroticism;
TGCT	cis	rs9486719	0.741	rs976356	chr6:96849437	T/A	cg06623918	chr6:96969491	KIAA0776	0.93	7.08	0.54	9.59e-11	Migraine;Coronary artery disease;
TGCT	cis	rs9467711	0.516	rs1165163	chr6:25863487	G/C	cg03264133	chr6:25882463	NA	-0.67	-4.47	-0.37	1.76e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs34517613	0.589	rs12937920	chr17:26590657	C/T	cg08652245	chr17:26833078	NA	0.33	4.44	0.37	1.98e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg04287289	chr16:89883240	FANCA	0.92	11.34	0.71	6.88e-21	Vitiligo;
TGCT	cis	rs3125734	0.633	rs10740068	chr10:63982254	A/C	cg05499367	chr10:63213510	TMEM26	-0.33	-4.52	-0.38	1.4e-5	Rheumatoid arthritis;
TGCT	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg22166914	chr1:53195759	ZYG11B	-0.46	-8.45	-0.6	6.74e-14	Monocyte count;
TGCT	cis	rs603424	0.593	rs3853519	chr10:102085327	C/T	cg22671421	chr10:102507979	PAX2	-0.54	-4.61	-0.38	9.72e-6	Phospholipid levels (plasma);Palmitic acid (16:0) levels;Palmitoleic acid (16:1n-7) levels;Mean platelet volume;Serum metabolite levels;Blood metabolite levels;Vaccenic acid (18:1n-7) levels;Metabolic traits;Coronary artery disease;Blood metabolite ratios;Glycerophospholipid levels;
TGCT	cis	rs1801251	1.000	rs283471	chr2:233656627	G/A	cg08000102	chr2:233561755	GIGYF2	0.62	6.15	0.48	9.79e-9	Coronary artery disease;
TGCT	cis	rs6542838	0.583	rs7565819	chr2:99519265	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.51	-4.64	-0.38	8.77e-6	Fear of minor pain;
TGCT	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg21862992	chr11:68658383	NA	0.47	6.58	0.51	1.19e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs13191362	0.935	rs67889271	chr6:163045753	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.92	7.24	0.55	4.11e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs1801251	1.000	rs12478564	chr2:233598340	C/T	cg08000102	chr2:233561755	GIGYF2	0.64	6.53	0.51	1.53e-9	Coronary artery disease;
TGCT	cis	rs3935685	0.934	rs11072664	chr15:77999859	C/G	cg03457338	chr15:78040120	NA	-0.22	-5.17	-0.42	9.25e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs3096299	0.719	rs12934708	chr16:89523790	C/T	cg06640241	chr16:89574553	SPG7	0.76	8.5	0.61	5.12e-14	Multiple myeloma (IgH translocation);
TGCT	cis	rs4664308	0.870	rs2198918	chr2:161015052	C/T	cg03641300	chr2:160917029	PLA2R1	-0.27	-6.89	-0.53	2.48e-10	Idiopathic membranous nephropathy;
TGCT	trans	rs9951602	0.512	rs6506868	chr18:76642559	C/G	cg02800362	chr5:177631904	HNRNPAB	1.12	12.7	0.75	3.48e-24	Obesity-related traits;
TGCT	cis	rs6430585	0.528	rs7606267	chr2:136668123	T/C	cg07169764	chr2:136633963	MCM6	1.25	12.45	0.75	1.36e-23	Corneal structure;
TGCT	cis	rs11874712	0.545	rs9955008	chr18:43658888	A/G	cg20479805	chr18:43684716	ATP5A1;HAUS1	-0.48	-4.68	-0.39	7.25e-6	Migraine - clinic-based;
TGCT	cis	rs2882877	0.648	rs66883355	chr2:190397021	G/A	cg10752008	chr2:190445175	SLC40A1	0.62	4.53	0.38	1.39e-5	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs12950390	0.853	rs67441169	chr17:45854462	T/G	cg24803719	chr17:45855879	NA	-0.5	-5.05	-0.41	1.51e-6	IgG glycosylation;
TGCT	cis	rs4141404	0.748	rs2232170	chr22:31537122	A/G	cg01546248	chr22:31477006	SMTN	-0.63	-4.74	-0.39	5.71e-6	Paclitaxel-induced neuropathy;
TGCT	cis	rs9611519	0.589	rs8138917	chr22:41412425	T/C	cg03806693	chr22:41940476	POLR3H	-0.65	-6.15	-0.48	9.75e-9	Neuroticism;
TGCT	cis	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg18252515	chr7:66147081	NA	-1.21	-7.69	-0.57	3.87e-12	Diabetic kidney disease;
TGCT	cis	rs10751667	0.580	rs10751664	chr11:927077	T/G	cg06064525	chr11:970664	AP2A2	-0.35	-8.09	-0.59	4.54e-13	Alzheimer's disease (late onset);
TGCT	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg06108461	chr20:60628389	TAF4	-0.69	-10.56	-0.69	5.46e-19	Body mass index;
TGCT	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg10802521	chr3:52805072	NEK4	0.72	9.11	0.63	1.82e-15	Bipolar disorder;
TGCT	cis	rs651907	0.557	rs34947019	chr3:101532235	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	4.87	0.4	3.32e-6	Colorectal cancer;
TGCT	cis	rs7666738	0.830	rs28818180	chr4:98953625	A/G	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg25811766	chr13:21894605	NA	0.26	5.19	0.42	8.46e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	cis	rs921968	0.643	rs6708683	chr2:219504503	G/A	cg02176678	chr2:219576539	TTLL4	0.38	5.47	0.44	2.34e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs2742417	1.000	rs1609554	chr3:45735192	A/G	cg04837898	chr3:45731254	SACM1L	-0.55	-5.68	-0.45	9.14e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs7666738	0.830	rs13148363	chr4:98847498	T/C	cg17366294	chr4:99064904	C4orf37	0.7	7.23	0.54	4.35e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs56235845	0.694	rs6860069	chr5:176755841	C/T	cg17509989	chr5:176798049	RGS14	0.56	7.47	0.56	1.23e-11	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs80282103	0.618	rs11819230	chr10:1128812	A/G	cg08668510	chr10:1095578	IDI1	1.07	5.31	0.43	5e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs36051895	0.664	rs10115172	chr9:5098549	C/T	cg02405213	chr9:5042618	JAK2	-0.71	-9.43	-0.65	3.07e-16	Pediatric autoimmune diseases;
TGCT	cis	rs2404602	0.684	rs965818	chr15:76866785	T/C	cg23625390	chr15:77176239	SCAPER	-0.37	-4.67	-0.39	7.71e-6	Blood metabolite levels;
TGCT	cis	rs644799	0.544	rs1254935	chr11:95631470	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.53	5.32	0.43	4.67e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7917772	0.503	rs6584510	chr10:104299868	T/G	cg05855489	chr10:104503620	C10orf26	-0.58	-5.06	-0.41	1.47e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7572733	0.576	rs1368989	chr2:198937082	T/C	cg00792783	chr2:198669748	PLCL1	0.59	5.19	0.42	8.41e-7	Dermatomyositis;
TGCT	cis	rs61990749	0.544	rs2544566	chr14:78181738	C/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.66	4.65	0.39	8.45e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs11231629	1	rs11231629	chr11:63648573	C/T	cg04850017	chr11:63683019	RCOR2	0.35	5.63	0.45	1.17e-7	Schizophrenia;
TGCT	cis	rs4851254	0.660	rs77023845	chr2:100712346	G/A	cg04109781	chr2:100722022	AFF3	0.47	4.63	0.38	8.9e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1801251	1.000	rs36007169	chr2:233621834	A/G	cg25237894	chr2:233734115	C2orf82	0.33	5.95	0.47	2.53e-8	Coronary artery disease;
TGCT	cis	rs11605924	0.901	rs11038672	chr11:45846498	C/G	ch.11.939596F	chr11:45881766	CRY2	-0.36	-4.47	-0.37	1.73e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);
TGCT	cis	rs7582180	0.630	rs13021801	chr2:100935129	C/A	cg08017756	chr2:100939284	LONRF2	-0.3	-4.78	-0.39	4.95e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs796364	0.616	rs2030653	chr2:200677625	C/T	cg17644776	chr2:200775616	C2orf69	0.34	4.84	0.4	3.76e-6	Schizophrenia;
TGCT	cis	rs7226408	0.857	rs56217642	chr18:34687844	G/C	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6671200	0.607	rs3753872	chr1:95699184	T/G	cg20701556	chr1:95698924	RWDD3	-0.52	-5.34	-0.43	4.26e-7	Stearic acid (18:0) levels;
TGCT	cis	rs7772486	0.686	rs1292337	chr6:145967807	A/G	cg23711669	chr6:146136114	FBXO30	-0.83	-8.98	-0.63	3.75e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7635838	0.596	rs13353463	chr3:11260221	T/C	cg00170343	chr3:11313890	ATG7	0.59	5.61	0.45	1.26e-7	HDL cholesterol;
TGCT	cis	rs9303401	0.614	rs34550282	chr17:57092788	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.58	5.82	0.46	4.69e-8	Cognitive test performance;
TGCT	cis	rs3617	0.625	rs2336558	chr3:52886240	C/T	cg11645453	chr3:52864694	ITIH4	-0.3	-5.91	-0.47	3.03e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg22891161	chr3:195456627	MUC20	-0.23	-5.38	-0.44	3.53e-7	Pancreatic cancer;
TGCT	cis	rs739496	0.615	rs634389	chr12:112164715	C/G	cg10833066	chr12:111807467	FAM109A	0.34	4.81	0.4	4.27e-6	Platelet count;
TGCT	cis	rs4722166	0.630	rs6461667	chr7:22796743	A/G	cg26061582	chr7:22766209	IL6	0.53	6.9	0.53	2.31e-10	Lung cancer;
TGCT	cis	rs2197308	0.667	rs61920838	chr12:37856814	T/C	cg26384229	chr12:38710491	ALG10B	-0.67	-6.04	-0.48	1.63e-8	Morning vs. evening chronotype;
TGCT	cis	rs1799949	0.965	rs8071278	chr17:41193910	A/T	cg05368731	chr17:41323189	NBR1	0.9	8.79	0.62	1.03e-14	Menopause (age at onset);
TGCT	trans	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg27523141	chr10:43048294	ZNF37B	0.73	8.58	0.61	3.32e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7172809	0.897	rs16968893	chr15:77825082	A/G	cg22256960	chr15:77711686	NA	-0.44	-4.48	-0.37	1.67e-5	Glucose homeostasis traits;
TGCT	cis	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg20637647	chr7:64974828	NA	0.92	5.36	0.43	3.87e-7	Diabetic kidney disease;
TGCT	cis	rs9914544	0.505	rs59633160	chr17:18761396	C/T	cg26378065	chr17:18585709	ZNF286B	0.52	4.5	0.37	1.56e-5	Educational attainment (years of education);
TGCT	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg25767906	chr1:53392781	SCP2	0.48	5.56	0.45	1.57e-7	Monocyte count;
TGCT	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg16325326	chr1:53192061	ZYG11B	0.71	8.94	0.63	4.44e-15	Monocyte count;
TGCT	cis	rs12135062	0.851	rs2651925	chr1:3101863	C/G	cg00254258	chr1:3105189	PRDM16	0.35	5.85	0.47	4.02e-8	Migraine;
TGCT	cis	rs6912958	0.712	rs2787927	chr6:88412786	A/G	cg06598631	chr6:88300029	RARS2;ORC3L	-0.51	-4.88	-0.4	3.2e-6	Monocyte percentage of white cells;
TGCT	cis	rs2204008	0.546	rs11519978	chr12:37998170	C/T	cg26384229	chr12:38710491	ALG10B	0.87	7.79	0.57	2.32e-12	Bladder cancer;
TGCT	cis	rs782590	0.967	rs4672054	chr2:55773093	C/A	cg03859395	chr2:55845619	SMEK2	0.91	11.32	0.71	7.6e-21	Metabolic syndrome;
TGCT	cis	rs1050631	1.000	rs1789550	chr18:33699553	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	-0.56	-4.68	-0.39	7.3e-6	Esophageal squamous cell cancer (length of survival);
TGCT	cis	rs208520	0.754	rs851592	chr6:66875175	G/T	cg07460842	chr6:66804631	NA	-0.91	-9.43	-0.65	2.99e-16	Exhaled nitric oxide output;
TGCT	cis	rs2282802	0.651	rs13353827	chr5:139654537	T/C	cg01081189	chr5:139537190	NA	0.28	5.15	0.42	9.75e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs28595532	0.920	rs56331118	chr4:119767054	G/T	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs1801251	0.963	rs283481	chr2:233648091	A/G	cg25237894	chr2:233734115	C2orf82	0.28	4.82	0.4	4.05e-6	Coronary artery disease;
TGCT	cis	rs950169	0.922	rs11633075	chr15:85113972	C/A	cg17173187	chr15:85201210	NMB	0.47	4.93	0.4	2.62e-6	Schizophrenia;
TGCT	cis	rs2070488	0.965	rs13079145	chr3:38517992	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.88	9.05	0.63	2.52e-15	Electrocardiographic conduction measures;
TGCT	cis	rs9329289	0.926	rs9329290	chr10:2542751	G/T	cg15501526	chr10:2543763	NA	0.41	5.15	0.42	9.91e-7	Age-related hearing impairment;
TGCT	cis	rs1729951	0.575	rs35289288	chr3:136680568	C/T	cg12473912	chr3:136751656	NA	0.39	6.18	0.49	8.36e-9	Neuroticism;
TGCT	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.72	7.39	0.55	1.87e-11	Menarche (age at onset);
TGCT	cis	rs7772486	0.558	rs62435775	chr6:146136415	G/C	cg23711669	chr6:146136114	FBXO30	0.73	6.75	0.52	5.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3741404	0.895	rs2429455	chr11:63995302	C/G	cg01727686	chr11:63997306	NUDT22;DNAJC4	0.22	4.71	0.39	6.44e-6	Platelet count;
TGCT	cis	rs8072100	0.840	rs9895746	chr17:45479099	C/A	cg08085267	chr17:45401833	C17orf57	-0.45	-5.08	-0.42	1.33e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs11249608	0.548	rs2132671	chr5:178457434	A/G	cg23951258	chr5:178450506	ZNF879	-0.46	-4.66	-0.39	7.95e-6	Pubertal anthropometrics;
TGCT	cis	rs7772486	0.875	rs2814869	chr6:146315509	G/A	cg23711669	chr6:146136114	FBXO30	0.87	9.39	0.64	3.74e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3947	1.000	rs4839	chr8:11701933	A/G	cg02840367	chr8:11660030	FDFT1	0.86	5.99	0.47	2.07e-8	Blood protein levels;
TGCT	cis	rs3806843	1.000	rs6898906	chr5:140169299	C/G	cg19875535	chr5:140030758	IK	0.37	6.34	0.49	3.89e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs12210905	0.688	rs72843191	chr6:27383301	G/C	cg08851530	chr6:28072375	NA	1.34	6.07	0.48	1.44e-8	Hip circumference adjusted for BMI;
TGCT	cis	rs778371	0.723	rs1078323	chr2:233681512	T/G	cg08000102	chr2:233561755	GIGYF2	-0.64	-7.23	-0.54	4.36e-11	Schizophrenia;
TGCT	cis	rs782590	0.774	rs782629	chr2:55900283	C/T	cg18811423	chr2:55921094	PNPT1	-0.62	-6.51	-0.5	1.67e-9	Metabolic syndrome;
TGCT	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg03709012	chr19:19516395	GATAD2A	0.67	5.75	0.46	6.45e-8	Tonsillectomy;
TGCT	cis	rs6430585	0.528	rs309122	chr2:136761853	A/G	cg07169764	chr2:136633963	MCM6	1.19	11.39	0.72	5.11e-21	Corneal structure;
TGCT	cis	rs1568079	0.516	rs2361382	chr10:125220299	C/G	cg14250450	chr10:124578544	NA	-0.34	-4.71	-0.39	6.57e-6	Body mass index;
TGCT	cis	rs17011478	0.744	rs17011523	chr2:75830612	T/C	cg04669895	chr2:74941807	NA	-0.54	-4.9	-0.4	2.88e-6	Obesity-related traits;
TGCT	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg21644426	chr2:191273491	MFSD6	0.62	6.15	0.48	9.57e-9	Pulse pressure;
TGCT	cis	rs4372836	0.964	rs17007191	chr2:28932502	C/T	cg09522027	chr2:28974177	PPP1CB	0.58	4.92	0.4	2.67e-6	Body mass index;
TGCT	trans	rs877282	0.853	rs11595507	chr10:756703	C/T	cg22713356	chr15:30763199	NA	1.07	8.27	0.6	1.75e-13	Uric acid levels;
TGCT	cis	rs9393777	0.557	rs6933999	chr6:27074929	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.58	-5.73	-0.46	7.03e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9914988	0.943	rs12951232	chr17:27132638	G/C	cg20469991	chr17:27169893	C17orf63	-0.72	-5.09	-0.42	1.28e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs57506017	0.585	rs5011438	chr7:12268798	C/T	cg07541786	chr7:12610355	SCIN	0.45	4.58	0.38	1.12e-5	Neuroticism;
TGCT	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg22535103	chr8:58192502	C8orf71	-0.42	-4.79	-0.4	4.7e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg17971929	chr21:40555470	PSMG1	-0.71	-6.5	-0.5	1.79e-9	Cognitive function;
TGCT	cis	rs6725041	0.792	rs1521643	chr2:213091417	A/G	cg16329650	chr2:213403929	ERBB4	-0.53	-4.58	-0.38	1.12e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs55794721	0.509	rs7554255	chr1:25778106	C/T	cg00786635	chr1:25594202	NA	0.54	5.78	0.46	5.67e-8	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs4727027	0.870	rs1534196	chr7:148790591	G/A	cg23583168	chr7:148888333	NA	-0.7	-8.85	-0.62	7.39e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs67311347	1.000	rs12638199	chr3:40475285	A/G	cg13683864	chr3:40499215	RPL14	-1.04	-10.79	-0.7	1.54e-19	Renal cell carcinoma;
TGCT	cis	rs5771225	0.563	rs738334	chr22:50688235	T/C	cg16473166	chr22:50639996	SELO	0.72	5.92	0.47	2.92e-8	Late-onset Alzheimer's disease;
TGCT	cis	rs9902453	0.765	rs9890747	chr17:28007442	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.84	8.27	0.6	1.73e-13	Coffee consumption (cups per day);
TGCT	cis	rs9942416	0.517	rs116509898	chr5:74994361	C/T	cg19683494	chr5:74908142	NA	0.59	6.26	0.49	5.62e-9	Age-related disease endophenotypes;
TGCT	cis	rs6840360	0.593	rs1366907	chr4:152682749	T/C	cg17479576	chr4:152424074	FAM160A1	-0.52	-5.16	-0.42	9.49e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1997103	0.954	rs2177807	chr7:55391002	G/T	cg17469321	chr7:55412551	NA	-0.54	-6.45	-0.5	2.26e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs6088580	0.634	rs6088471	chr20:32932643	C/A	cg06115741	chr20:33292138	TP53INP2	-0.55	-4.9	-0.4	2.97e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs2832191	0.791	rs2832179	chr21:30480366	C/T	cg08807101	chr21:30365312	RNF160	-0.66	-6.19	-0.49	8.16e-9	Dental caries;
TGCT	cis	rs992157	0.798	rs7587220	chr2:219160864	C/A	cg00012203	chr2:219082015	ARPC2	-0.82	-8.11	-0.59	4.07e-13	Colorectal cancer;
TGCT	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9894429	1.000	rs4074915	chr17:79579230	G/A	cg18240062	chr17:79603768	NPLOC4	-0.67	-6.84	-0.52	3.23e-10	Eye color traits;
TGCT	cis	rs2153535	0.580	rs9406159	chr6:8464859	C/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.67	0.45	9.42e-8	Motion sickness;
TGCT	cis	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg18252515	chr7:66147081	NA	-1.31	-8.18	-0.59	2.87e-13	Diabetic kidney disease;
TGCT	cis	rs295140	0.967	rs4673906	chr2:201163812	G/T	cg04283868	chr2:201171347	SPATS2L	0.63	6.39	0.5	3.03e-9	QT interval;
TGCT	cis	rs9393692	0.627	rs2179517	chr6:26198845	G/C	cg05868516	chr6:26286170	HIST1H4H	0.52	5.18	0.42	8.72e-7	Educational attainment;
TGCT	cis	rs7824557	0.628	rs11782706	chr8:11186215	A/C	cg21775007	chr8:11205619	TDH	0.66	6.47	0.5	2.08e-9	Retinal vascular caliber;
TGCT	cis	rs854765	0.647	rs7211714	chr17:17986955	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.69	7.2	0.54	5.04e-11	Total body bone mineral density;
TGCT	cis	rs11864453	0.612	rs12924413	chr16:72129745	T/C	cg14768367	chr16:72042858	DHODH	0.52	5.27	0.43	5.78e-7	Fibrinogen levels;
TGCT	cis	rs1692580	0.774	rs10797416	chr1:2182342	T/C	cg24578937	chr1:2090814	PRKCZ	0.24	5.25	0.43	6.42e-7	Coronary artery disease;
TGCT	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.8	6.47	0.5	2.06e-9	Mean platelet volume;
TGCT	cis	rs9611565	0.512	rs5751147	chr22:42139054	G/A	cg13695892	chr22:41940480	POLR3H	0.89	8.43	0.6	7.37e-14	Vitiligo;
TGCT	cis	rs6088590	0.561	rs6088527	chr20:33155841	C/T	cg06115741	chr20:33292138	TP53INP2	0.51	4.47	0.37	1.76e-5	Coronary artery disease;
TGCT	trans	rs783396	0.792	rs783418	chr6:106962679	G/C	cg09013229	chr1:225332226	DNAH14	-0.53	-6.66	-0.51	8.13e-10	Stroke;
TGCT	cis	rs4076764	0.958	rs11580702	chr1:163385523	C/G	cg24596788	chr1:163392923	NA	-0.18	-5.11	-0.42	1.19e-6	Motion sickness;
TGCT	cis	rs6901250	0.569	rs594940	chr6:117090358	C/T	cg12892004	chr6:117198278	RFX6	0.38	4.79	0.4	4.68e-6	C-reactive protein levels;
TGCT	cis	rs854765	0.718	rs7224815	chr17:17845800	A/T	cg09796270	chr17:17721594	SREBF1	0.27	5.49	0.44	2.21e-7	Total body bone mineral density;
TGCT	cis	rs1355223	0.583	rs1549789	chr11:34867947	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.75	8.13	0.59	3.8e-13	Systemic lupus erythematosus and Systemic sclerosis;
TGCT	cis	rs75686122	0.892	rs2028083	chr8:104515794	T/C	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs9894429	0.809	rs9889642	chr17:79591762	T/C	cg18240062	chr17:79603768	NPLOC4	0.67	6.84	0.52	3.23e-10	Eye color traits;
TGCT	cis	rs6545883	0.929	rs2593635	chr2:61634706	A/C	cg15711740	chr2:61764176	XPO1	0.59	5.4	0.44	3.28e-7	Tuberculosis;
TGCT	cis	rs2204008	0.658	rs11181310	chr12:38315963	C/A	cg26384229	chr12:38710491	ALG10B	0.83	7.26	0.55	3.76e-11	Bladder cancer;
TGCT	cis	rs9653442	0.835	rs11885529	chr2:100746935	A/G	cg07810366	chr2:100720526	AFF3	-0.47	-7.79	-0.57	2.36e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs9467711	0.606	rs12174631	chr6:26373150	C/T	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs739496	0.579	rs7488629	chr12:112273500	G/A	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs28595532	0.841	rs112953035	chr4:119752450	T/C	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs4654899	0.680	rs4654874	chr1:21156667	C/T	cg01072550	chr1:21505969	NA	-0.55	-8.7	-0.62	1.66e-14	Superior frontal gyrus grey matter volume;
TGCT	cis	rs9388451	0.531	rs9401850	chr6:126151000	T/G	cg05901451	chr6:126070800	HEY2	-0.74	-7.68	-0.57	4.2e-12	Brugada syndrome;
TGCT	cis	rs56104184	0.775	rs3760785	chr19:49403178	G/T	cg17863274	chr19:49399704	TULP2	-0.53	-7.38	-0.55	1.97e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs1055129	0.560	rs2666003	chr17:73942976	G/A	cg08125733	chr17:73851984	WBP2	0.57	5.29	0.43	5.29e-7	White matter hyperintensity burden;
TGCT	cis	rs7552404	1.000	rs4949872	chr1:76131392	C/G	cg10523679	chr1:76189770	ACADM	0.93	10.24	0.68	3.34e-18	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7524258	0.868	rs7544314	chr1:7266744	G/C	cg07173049	chr1:7289937	CAMTA1	0.31	5.29	0.43	5.39e-7	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs7565124	0.909	rs6747473	chr2:20252008	C/G	cg00462460	chr2:20212509	MATN3	-0.44	-4.66	-0.39	8.07e-6	Major depressive disorder;
TGCT	cis	rs28595532	0.920	rs114924396	chr4:119755621	A/G	cg21605333	chr4:119757512	SEC24D	1.62	7.49	0.56	1.1e-11	Cannabis dependence symptom count;
TGCT	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg21724239	chr8:58056113	NA	0.42	5.04	0.41	1.59e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs896854	0.548	rs574183	chr8:95973816	A/G	cg13393036	chr8:95962371	TP53INP1	0.54	6.59	0.51	1.11e-9	Type 2 diabetes;
TGCT	cis	rs9894429	1.000	rs7406003	chr17:79597597	C/T	cg18240062	chr17:79603768	NPLOC4	0.69	7.22	0.54	4.67e-11	Eye color traits;
TGCT	cis	rs7809950	0.678	rs62482507	chr7:107024488	T/G	cg23024343	chr7:107201750	COG5	-0.45	-6.07	-0.48	1.42e-8	Coronary artery disease;
TGCT	cis	rs2201728	0.967	rs12512084	chr4:100173159	A/G	cg07219303	chr4:100140905	ADH6	-0.35	-5.21	-0.42	7.63e-7	Cardiac Troponin-T levels;
TGCT	cis	rs7191700	0.511	rs8058983	chr16:11360849	A/G	cg00044050	chr16:11439710	C16orf75	-0.81	-8.38	-0.6	9.95e-14	Multiple sclerosis;
TGCT	cis	rs2439831	1.000	rs7173487	chr15:43750239	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.75	4.8	0.4	4.55e-6	Lung cancer in ever smokers;
TGCT	cis	rs6728642	0.572	rs13387563	chr2:97600916	C/A	cg26665480	chr2:98280029	ACTR1B	-0.91	-6.94	-0.53	1.9e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	cis	rs6540559	0.546	rs735693	chr1:210033988	A/C	cg23283495	chr1:209979779	IRF6	0.73	5.67	0.45	9.34e-8	Cleft lip with or without cleft palate;
TGCT	cis	rs1865760	0.566	rs3752420	chr6:26027135	G/A	cg17042849	chr6:26104293	HIST1H4C	-0.61	-5.3	-0.43	5.08e-7	Height;
TGCT	cis	rs8028182	0.537	rs4371118	chr15:75898890	C/G	cg20655648	chr15:75932815	IMP3	0.65	4.93	0.4	2.61e-6	Sudden cardiac arrest;
TGCT	trans	rs2727020	0.615	rs35423199	chr11:49514914	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.36	-7.1	-0.54	8.32e-11	Coronary artery disease;
TGCT	cis	rs9467603	0.566	rs13212936	chr6:25588815	C/T	cg16898833	chr6:26189333	HIST1H4D	1.0	4.51	0.38	1.49e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs4494114	1.000	rs9438973	chr1:39344879	G/A	cg25970120	chr1:39325951	RRAGC	-0.57	-5.57	-0.45	1.48e-7	Blood protein levels;
TGCT	cis	rs11190604	1.000	rs4919466	chr10:102241213	T/C	cg16342193	chr10:102329863	NA	-0.39	-5.17	-0.42	9.29e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs17376456	0.877	rs10213956	chr5:93460839	C/T	cg25358565	chr5:93447407	FAM172A	0.92	8.38	0.6	9.58e-14	Diabetic retinopathy;
TGCT	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg20573242	chr4:122745356	CCNA2	0.63	5.59	0.45	1.37e-7	Type 2 diabetes;
TGCT	cis	rs7568458	0.709	rs56819945	chr2:85755139	C/T	cg17127132	chr2:85788382	GGCX	0.51	4.58	0.38	1.12e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs9393777	0.513	rs9295702	chr6:26634040	T/C	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.51	-4.68	-0.39	7.36e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs13326165	0.715	rs11709658	chr3:52399627	G/A	cg07884673	chr3:53033167	SFMBT1	0.38	4.65	0.39	8.36e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs3858526	0.508	rs10838734	chr11:5876325	T/G	cg13902645	chr11:5959945	NA	-0.49	-5.11	-0.42	1.2e-6	DNA methylation (variation);
TGCT	cis	rs13191362	0.935	rs67368176	chr6:162968436	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.64	4.8	0.4	4.48e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.35	-4.46	-0.37	1.84e-5	Total body bone mineral density;
TGCT	cis	rs13191362	1.000	rs34655790	chr6:163202739	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.19	0.59	2.72e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7666738	0.830	rs28867388	chr4:98962794	A/T	cg18180107	chr4:99064573	C4orf37	0.57	5.18	0.42	8.63e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12451471	0.500	rs8077056	chr17:78076006	C/T	cg06718696	chr17:78121285	EIF4A3	0.69	5.48	0.44	2.25e-7	Plateletcrit;Mean corpuscular hemoglobin concentration;
TGCT	cis	rs6831352	0.734	rs2602857	chr4:100030318	G/A	cg12011299	chr4:100065546	ADH4	0.39	5.2	0.42	8.04e-7	Alcohol dependence;
TGCT	cis	rs2066819	1.000	rs2306693	chr12:56680531	T/C	cg26714650	chr12:56694279	CS	-1.36	-6.06	-0.48	1.54e-8	Psoriasis vulgaris;
TGCT	cis	rs7267979	1.000	rs4815412	chr20:25350325	A/G	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs981844	0.775	rs62323975	chr4:154737617	A/G	cg14289246	chr4:154710475	SFRP2	1.01	8.88	0.62	6.23e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs1372520	0.567	rs2619349	chr4:90746646	G/T	cg14346243	chr4:90757452	SNCA	-0.67	-5.64	-0.45	1.09e-7	Neuroticism;
TGCT	cis	rs11098499	0.863	rs12508173	chr4:120318526	T/C	cg09307838	chr4:120376055	NA	0.65	6.17	0.48	8.93e-9	Corneal astigmatism;
TGCT	cis	rs60843830	1.000	rs55946380	chr2:268293	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.71	6.79	0.52	4.24e-10	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs4252435	0.614	rs4252526	chr7:142603041	T/C	cg09833174	chr7:143059591	FAM131B	-0.96	-4.52	-0.38	1.41e-5	Cancer;
TGCT	cis	rs12477438	0.822	rs6727170	chr2:99588042	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-4.89	-0.4	3.1e-6	Chronic sinus infection;
TGCT	cis	rs2887571	0.580	rs2887570	chr12:1637787	A/G	cg01940102	chr12:1095972	NA	0.25	4.66	0.39	8.17e-6	Bone mineral density;
TGCT	cis	rs3099143	1.000	rs3099137	chr15:77123626	G/A	cg21673338	chr15:77095150	SCAPER	-0.51	-4.88	-0.4	3.17e-6	Recalcitrant atopic dermatitis;
TGCT	cis	rs17197710	0.621	rs12576935	chr11:47246542	G/A	cg13308137	chr11:47528955	CUGBP1	0.42	5.99	0.47	2.11e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs6933660	0.800	rs9383900	chr6:151782816	A/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.53	5.03	0.41	1.67e-6	Menarche (age at onset);
TGCT	cis	rs13191362	0.810	rs35509380	chr6:163053028	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.03	7.35	0.55	2.37e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs2180341	0.920	rs4472373	chr6:127705983	G/A	cg27446573	chr6:127587934	RNF146	1.16	10.52	0.69	6.95e-19	Breast cancer;
TGCT	cis	rs9527	0.590	rs7092029	chr10:104823909	A/T	cg15744005	chr10:104629667	AS3MT	-0.42	-4.87	-0.4	3.29e-6	Arsenic metabolism;
TGCT	cis	rs12188164	0.714	rs11741954	chr5:421455	G/T	cg26850624	chr5:429559	AHRR	-0.21	-4.99	-0.41	1.98e-6	Cystic fibrosis severity;
TGCT	cis	rs492146	0.765	rs597348	chr6:52845397	C/G	cg06706454	chr6:52930286	FBXO9	-0.5	-4.44	-0.37	1.99e-5	Epilepsy (remission after treatment);
TGCT	cis	rs797680	0.964	rs547866	chr1:93725053	C/T	cg17826107	chr1:92977322	EVI5	0.24	5.33	0.43	4.45e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs67311347	1.000	rs2305522	chr3:40429358	A/G	cg17264618	chr3:40429014	ENTPD3	0.32	4.76	0.39	5.29e-6	Renal cell carcinoma;
TGCT	cis	rs7646507	1.000	rs7644191	chr3:172520818	G/C	cg10532262	chr3:172428426	NCEH1	0.97	4.9	0.4	2.89e-6	Obesity-related traits;
TGCT	cis	rs9467711	1.000	rs1883215	chr6:26314233	G/C	cg02458000	chr6:26745757	NA	-1.05	-5.54	-0.45	1.75e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2070488	0.775	rs2070489	chr3:38519424	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.78	7.53	0.56	9.15e-12	Electrocardiographic conduction measures;
TGCT	cis	rs9527	0.615	rs4919685	chr10:104587362	G/T	cg04362960	chr10:104952993	NT5C2	0.64	5.42	0.44	3.02e-7	Arsenic metabolism;
TGCT	cis	rs7666738	0.519	rs11732209	chr4:98801643	A/G	cg18180107	chr4:99064573	C4orf37	0.52	4.57	0.38	1.16e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3617	0.625	rs2336558	chr3:52886240	C/T	cg10802521	chr3:52805072	NEK4	0.6	6.93	0.53	2.07e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6598955	0.671	rs11247904	chr1:26621804	G/A	cg04990556	chr1:26633338	UBXN11	0.66	5.0	0.41	1.88e-6	Obesity-related traits;
TGCT	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	14.88	0.8	2.36e-29	Height;
TGCT	cis	rs7605378	0.528	rs7592587	chr2:200786516	C/G	cg19045956	chr2:200819837	C2orf60;C2orf47	0.54	5.74	0.46	6.88e-8	Osteoporosis;
TGCT	trans	rs9951602	0.512	rs9946120	chr18:76654548	A/T	cg02800362	chr5:177631904	HNRNPAB	1.14	12.55	0.75	7.84e-24	Obesity-related traits;
TGCT	cis	rs4319547	0.915	rs10734924	chr12:123018894	T/G	cg23029597	chr12:123009494	RSRC2	-0.32	-5.22	-0.42	7.44e-7	Body mass index;
TGCT	cis	rs7104764	1.000	rs10902113	chr11:245523	C/T	cg18336825	chr11:236787	PSMD13;SIRT3	1.07	11.19	0.71	1.61e-20	Menarche (age at onset);
TGCT	cis	rs7178572	0.568	rs11857294	chr15:77596725	C/T	cg22256960	chr15:77711686	NA	-0.85	-8.73	-0.62	1.4e-14	Type 2 diabetes;
TGCT	cis	rs7226408	0.749	rs11664744	chr18:34435111	T/G	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg22535103	chr8:58192502	C8orf71	-0.41	-4.81	-0.4	4.27e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9894429	0.789	rs9747336	chr17:79584189	C/T	cg21028142	chr17:79581711	NPLOC4	0.3	7.03	0.53	1.2e-10	Eye color traits;
TGCT	cis	rs739496	0.947	rs12580300	chr12:111849271	G/A	cg10833066	chr12:111807467	FAM109A	0.37	4.95	0.41	2.32e-6	Platelet count;
TGCT	cis	rs3812831	0.629	rs7318527	chr13:114946956	C/T	cg06611532	chr13:114900021	NA	0.35	6.42	0.5	2.62e-9	Schizophrenia;
TGCT	cis	rs5769707	0.642	rs135880	chr22:50018654	T/A	cg05373962	chr22:49881684	NA	-0.3	-5.25	-0.43	6.29e-7	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg11941060	chr3:133502564	NA	0.29	6.13	0.48	1.09e-8	Iron status biomarkers;
TGCT	cis	rs904251	0.737	rs914347	chr6:37484970	A/C	cg01843034	chr6:37503916	NA	-0.5	-6.05	-0.48	1.6e-8	Cognitive performance;
TGCT	cis	rs2295359	0.892	rs72676067	chr1:67658803	G/A	cg12940439	chr1:67600707	NA	0.6	6.2	0.49	7.79e-9	Psoriasis;
TGCT	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg06634786	chr22:41940651	POLR3H	0.89	8.55	0.61	3.83e-14	Vitiligo;
TGCT	cis	rs3820068	0.581	rs72645877	chr1:15928106	G/T	cg05660106	chr1:15850417	CASP9	0.82	8.02	0.58	6.63e-13	Systolic blood pressure;
TGCT	cis	rs6121246	0.954	rs6060992	chr20:30431255	G/T	cg18721089	chr20:30220636	NA	-0.45	-4.98	-0.41	2.12e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs611744	0.967	rs631031	chr8:109190032	G/A	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs7523050	0.643	rs7551142	chr1:109399710	G/T	cg08274380	chr1:109419600	GPSM2	1.3	6.39	0.5	2.99e-9	Fat distribution (HIV);
TGCT	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg03806693	chr22:41940476	POLR3H	-1.12	-12.98	-0.76	7.45e-25	Vitiligo;
TGCT	cis	rs73001065	0.551	rs10424702	chr19:19508013	A/G	cg03709012	chr19:19516395	GATAD2A	0.96	5.31	0.43	4.93e-7	LDL cholesterol;
TGCT	cis	rs9926296	0.656	rs2376883	chr16:89826926	A/G	cg27121462	chr16:89883253	FANCA	0.54	4.97	0.41	2.14e-6	Vitiligo;
TGCT	cis	rs4478858	0.647	rs10798835	chr1:31709055	T/C	cg00250761	chr1:31883323	NA	-0.26	-4.71	-0.39	6.49e-6	Alcohol dependence;
TGCT	cis	rs7666738	0.830	rs7662596	chr4:99019962	G/T	cg17366294	chr4:99064904	C4orf37	0.68	7.04	0.53	1.17e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs651907	0.557	rs34624546	chr3:101374226	T/G	cg11279151	chr3:101281821	RG9MTD1	-0.35	-7.28	-0.55	3.4e-11	Colorectal cancer;
TGCT	cis	rs17539620	0.624	rs12665520	chr6:154835273	C/T	cg20019720	chr6:154832845	CNKSR3	0.57	5.02	0.41	1.72e-6	Lipoprotein (a) levels;
TGCT	cis	rs12220898	0.749	rs4838481	chr10:50477364	T/C	cg06072769	chr10:50146962	WDFY4	0.35	4.5	0.37	1.56e-5	Inflammatory biomarkers;
TGCT	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.31	0.43	4.9e-7	Prudent dietary pattern;
TGCT	cis	rs67072384	1.000	rs11235577	chr11:72451380	C/T	cg03713592	chr11:72463424	ARAP1	-0.93	-4.66	-0.39	7.89e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs7945705	0.840	rs10840136	chr11:8885024	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.41	-4.5	-0.37	1.56e-5	Hemoglobin concentration;
TGCT	cis	rs17331151	0.505	rs79993196	chr3:52697566	T/C	cg24616795	chr3:53032891	SFMBT1	0.58	4.85	0.4	3.59e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs67072384	0.818	rs12287481	chr11:72472336	A/C	cg03713592	chr11:72463424	ARAP1	1.02	5.24	0.43	6.8e-7	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs155076	1.000	rs2478824	chr13:21844144	G/C	cg11317459	chr13:21872234	NA	-1.42	-12.02	-0.73	1.53e-22	White matter hyperintensity burden;
TGCT	cis	rs9443189	0.570	rs9343316	chr6:76411800	G/A	cg01950844	chr6:76311363	SENP6	1.0	6.24	0.49	6.35e-9	Prostate cancer;
TGCT	cis	rs151997	0.925	rs26089	chr5:50172251	A/G	cg06027927	chr5:50259733	NA	-0.45	-4.58	-0.38	1.11e-5	Callous-unemotional behaviour;
TGCT	cis	rs7666738	0.830	rs6852015	chr4:99054373	C/A	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28595532	0.920	rs17324807	chr4:119770638	G/A	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.62	-5.11	-0.42	1.17e-6	Tonsillectomy;
TGCT	cis	rs28374715	0.532	rs316607	chr15:41772693	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.93	-17.19	-0.84	1.29e-34	Ulcerative colitis;
TGCT	cis	rs2562456	0.833	rs2562507	chr19:21726337	C/T	cg01304269	chr19:21688519	ZNF429	-0.54	-4.56	-0.38	1.22e-5	Pain;
TGCT	cis	rs7809950	1.000	rs2520277	chr7:107130234	C/T	cg23024343	chr7:107201750	COG5	-0.34	-5.45	-0.44	2.58e-7	Coronary artery disease;
TGCT	cis	rs9948	0.655	rs6576981	chr2:97394406	G/C	cg01990225	chr2:97406019	LMAN2L	-0.94	-5.33	-0.43	4.44e-7	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg05665937	chr4:1216051	CTBP1	0.24	4.52	0.38	1.4e-5	Obesity-related traits;
TGCT	cis	rs10193935	0.901	rs12620021	chr2:42477034	T/C	cg27598129	chr2:42591480	NA	-0.38	-5.29	-0.43	5.36e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs727563	0.636	rs2187795	chr22:42092225	C/A	cg06634786	chr22:41940651	POLR3H	0.9	8.74	0.62	1.34e-14	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs7226408	0.857	rs17652769	chr18:34731828	G/A	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs4601821	0.858	rs4938012	chr11:113259654	A/G	cg14159747	chr11:113255604	NA	0.38	4.51	0.38	1.5e-5	Alcoholic chronic pancreatitis;
TGCT	cis	rs1865760	0.566	rs1800702	chr6:26086463	C/G	cg17042849	chr6:26104293	HIST1H4C	-0.63	-5.47	-0.44	2.43e-7	Height;
TGCT	cis	rs7647973	0.696	rs7100	chr3:49053219	A/G	cg05785598	chr3:49045655	WDR6	0.39	4.52	0.38	1.42e-5	Menarche (age at onset);
TGCT	cis	rs3749237	0.537	rs4459909	chr3:49469217	T/C	cg02487422	chr3:49467188	NICN1	0.58	5.92	0.47	3e-8	Resting heart rate;
TGCT	cis	rs7072216	0.806	rs9804285	chr10:100169472	C/T	cg26618903	chr10:100175079	PYROXD2	-0.4	-4.49	-0.37	1.64e-5	Metabolite levels;
TGCT	trans	rs208520	0.954	rs12190073	chr6:66983740	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.83	7.46	0.56	1.31e-11	Exhaled nitric oxide output;
TGCT	cis	rs478304	0.651	rs11227281	chr11:65496558	T/C	cg10518572	chr11:65560635	OVOL1	-0.24	-4.68	-0.39	7.53e-6	Acne (severe);
TGCT	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg06618935	chr21:46677482	NA	-0.37	-5.81	-0.46	5.06e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg02380750	chr20:61661411	NA	0.34	6.02	0.48	1.86e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7772486	0.623	rs735535	chr6:146036829	C/T	cg05347473	chr6:146136440	FBXO30	-0.49	-4.62	-0.38	9.3e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2760061	0.598	rs605410	chr1:228116281	A/G	cg02753203	chr1:228287806	NA	-0.34	-6.57	-0.51	1.23e-9	Diastolic blood pressure;
TGCT	cis	rs35306767	0.714	rs12777800	chr10:1070361	G/A	cg20503657	chr10:835505	NA	0.6	6.95	0.53	1.88e-10	Eosinophil percentage of granulocytes;
TGCT	cis	rs2153535	0.601	rs2143352	chr6:8530248	G/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.55e-8	Motion sickness;
TGCT	cis	rs8016982	0.674	rs759939	chr14:81663453	G/C	cg01989461	chr14:81687754	GTF2A1	0.78	7.94	0.58	1.06e-12	Schizophrenia;
TGCT	cis	rs4372836	0.729	rs10865508	chr2:29053704	G/C	cg09522027	chr2:28974177	PPP1CB	0.67	6.89	0.53	2.45e-10	Body mass index;
TGCT	cis	rs921968	0.643	rs833083	chr2:219336959	A/T	cg02176678	chr2:219576539	TTLL4	-0.38	-5.48	-0.44	2.31e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs4499344	0.696	rs2868153	chr19:33099277	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	8.79	0.62	1.01e-14	Mean platelet volume;
TGCT	cis	rs1367858	0.654	rs994280	chr2:201240086	A/G	cg04283868	chr2:201171347	SPATS2L	0.51	4.55	0.38	1.28e-5	Schizophrenia;
TGCT	cis	rs7809950	0.798	rs10281535	chr7:107229618	T/G	cg23024343	chr7:107201750	COG5	0.35	5.41	0.44	3.18e-7	Coronary artery disease;
TGCT	cis	rs763014	0.898	rs916414	chr16:632073	C/T	cg00908189	chr16:619842	PIGQ	0.87	10.5	0.69	7.53e-19	Height;
TGCT	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg11247378	chr22:39784982	NA	-0.73	-9.59	-0.65	1.22e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs8135665	0.600	rs3026682	chr22:38452482	G/A	cg13116946	chr22:38479732	SLC16A8	0.31	5.88	0.47	3.52e-8	Advanced age-related macular degeneration;Age-related macular degeneration;
TGCT	cis	rs908922	0.651	rs548252	chr1:152489742	A/G	cg20991723	chr1:152506922	NA	-0.46	-6.37	-0.5	3.39e-9	Hair morphology;
TGCT	cis	rs4389656	1.000	rs4389656	chr5:6753728	A/G	cg10857441	chr5:6722123	POLS	-0.22	-4.45	-0.37	1.87e-5	Coronary artery disease;
TGCT	cis	rs9650657	0.537	rs7016385	chr8:10779472	A/G	cg27411982	chr8:10470053	RP1L1	0.22	4.87	0.4	3.32e-6	Neuroticism;
TGCT	cis	rs909002	0.830	rs10914461	chr1:32113217	G/A	cg11573219	chr1:32083031	HCRTR1	-0.41	-5.26	-0.43	6.14e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs6570726	0.791	rs1280276	chr6:145892350	A/C	cg13319975	chr6:146136371	FBXO30	-0.51	-4.58	-0.38	1.11e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg04772025	chr11:68637568	NA	0.59	6.69	0.52	6.73e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7180079	0.502	rs8033972	chr15:64524980	G/A	cg02848875	chr15:64387786	SNX1	-0.35	-5.37	-0.43	3.7e-7	Monocyte count;
TGCT	trans	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg21659725	chr3:3221576	CRBN	-0.98	-15.33	-0.81	2.1000000000000002e-30	Intelligence (multi-trait analysis);
TGCT	cis	rs79349575	0.715	rs55724082	chr17:47017879	G/A	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.5	-0.37	1.53e-5	Type 2 diabetes;
TGCT	cis	rs6141769	0.542	rs6057627	chr20:31306728	C/G	cg13636640	chr20:31349939	DNMT3B	-0.51	-4.48	-0.37	1.68e-5	Subjective well-being;
TGCT	cis	rs12477438	0.798	rs10167015	chr2:99570707	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-6.33	-0.49	4.07e-9	Chronic sinus infection;
TGCT	cis	rs9916302	0.718	rs7219909	chr17:37706243	C/T	cg15445000	chr17:37608096	MED1	0.31	4.5	0.37	1.53e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs41308713	0.681	rs8116426	chr20:37034643	A/C	cg09132763	chr20:37064059	LOC388796;SNORA71D	1.26	5.95	0.47	2.53e-8	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
TGCT	cis	rs295140	0.647	rs295129	chr2:201229473	G/A	cg04283868	chr2:201171347	SPATS2L	-0.54	-5.22	-0.42	7.46e-7	QT interval;
TGCT	cis	rs986417	0.606	rs4899014	chr14:61118783	C/T	cg27398547	chr14:60952738	C14orf39	1.69	9.43	0.65	3.06e-16	Gut microbiota (bacterial taxa);
TGCT	cis	rs6866344	0.570	rs59259518	chr5:178142628	C/T	cg03877680	chr5:178157825	ZNF354A	0.75	6.39	0.5	3.03e-9	Neutrophil percentage of white cells;
TGCT	cis	rs2594989	0.779	rs62245949	chr3:11575969	C/G	cg00170343	chr3:11313890	ATG7	-0.67	-5.24	-0.43	6.68e-7	Circulating chemerin levels;
TGCT	cis	rs12220238	1.000	rs11000897	chr10:75911276	C/A	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.28	0.55	3.4e-11	Soluble interleukin-2 receptor subunit alpha;
TGCT	trans	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg17830980	chr10:43048298	ZNF37B	0.73	8.35	0.6	1.13e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7666738	0.830	rs4502686	chr4:98765117	T/C	cg18180107	chr4:99064573	C4orf37	0.53	5.07	0.41	1.38e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs25422	0.938	rs9489443	chr6:118886163	T/A	cg21191810	chr6:118973309	C6orf204	-0.38	-4.86	-0.4	3.47e-6	Renal cell carcinoma;
TGCT	cis	rs72781680	0.948	rs72790326	chr2:24126153	C/T	cg08917208	chr2:24149416	ATAD2B	0.73	4.51	0.38	1.48e-5	Lymphocyte counts;
TGCT	cis	rs9611565	0.694	rs5758389	chr22:41941749	T/C	cg03806693	chr22:41940476	POLR3H	-1.01	-11.48	-0.72	3.1e-21	Vitiligo;
TGCT	cis	rs1008375	0.966	rs3775924	chr4:17585984	T/C	cg10189774	chr4:17578691	LAP3	0.64	5.61	0.45	1.28e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6693567	0.545	rs4451552	chr1:150455854	C/G	cg09579323	chr1:150459698	TARS2	0.49	4.44	0.37	1.96e-5	Migraine;
TGCT	cis	rs3751972	0.681	rs2108952	chr17:26181865	C/T	cg02948944	chr17:26242737	NA	0.4	5.62	0.45	1.18e-7	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg02725872	chr8:58115012	NA	-0.38	-4.76	-0.39	5.39e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1008375	0.966	rs1860591	chr4:17577329	A/G	cg10189774	chr4:17578691	LAP3	0.57	5.13	0.42	1.08e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2730260	0.537	rs73169239	chr7:158884305	C/A	cg02078164	chr7:157982224	PTPRN2	0.41	4.58	0.38	1.11e-5	Myopia (pathological);
TGCT	cis	rs950169	0.922	rs12910334	chr15:84958318	G/A	cg17173187	chr15:85201210	NMB	0.58	5.93	0.47	2.77e-8	Schizophrenia;
TGCT	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	4.67	0.39	7.7e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg13866156	chr1:1669148	SLC35E2	-0.24	-5.87	-0.47	3.74e-8	Body mass index;
TGCT	cis	rs986417	1.000	rs1254323	chr14:60908378	G/A	cg27398547	chr14:60952738	C14orf39	-1.39	-10.61	-0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs3784262	0.528	rs11071364	chr15:58334113	C/G	cg12031962	chr15:58353849	ALDH1A2	-0.43	-6.39	-0.5	3.11e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs709400	0.663	rs62007684	chr14:103894223	T/C	cg12935359	chr14:103987150	CKB	-0.34	-4.87	-0.4	3.35e-6	Body mass index;
TGCT	cis	rs909002	0.887	rs10914463	chr1:32132063	C/T	cg11573219	chr1:32083031	HCRTR1	-0.43	-5.41	-0.44	3.14e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9318086	0.578	rs75752641	chr13:24473240	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.82	8.98	0.63	3.58e-15	Myopia (pathological);
TGCT	cis	rs694419	0.602	rs7227643	chr18:60193628	T/C	cg13506219	chr18:60193840	ZCCHC2	-0.54	-4.93	-0.4	2.57e-6	Serum albumin level;
TGCT	trans	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg17470723	chr8:74884337	TCEB1	0.72	6.94	0.53	1.91e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9611565	0.592	rs9611613	chr22:41961831	T/C	cg17554472	chr22:41940697	POLR3H	-0.48	-4.94	-0.41	2.47e-6	Vitiligo;
TGCT	cis	rs67478160	0.643	rs7156697	chr14:104211136	G/A	cg26031613	chr14:104095156	KLC1	-0.63	-6.37	-0.5	3.33e-9	Schizophrenia;
TGCT	cis	rs7772486	0.720	rs6901888	chr6:146023144	A/G	cg05347473	chr6:146136440	FBXO30	-0.52	-4.85	-0.4	3.61e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9532580	0.656	rs2721068	chr13:41139712	T/C	cg21288729	chr13:41239152	FOXO1	0.89	7.41	0.55	1.7e-11	Mean corpuscular hemoglobin;
TGCT	cis	rs79349575	0.783	rs4794000	chr17:47022755	C/G	cg07967210	chr17:47022446	SNF8	0.44	6.13	0.48	1.1e-8	Type 2 diabetes;
TGCT	cis	rs9611519	0.894	rs9611488	chr22:41462592	G/T	cg03806693	chr22:41940476	POLR3H	-0.67	-6.07	-0.48	1.45e-8	Neuroticism;
TGCT	cis	rs3015497	0.575	rs8023035	chr14:51162419	A/G	cg04730355	chr14:51134070	SAV1	-0.59	-5.68	-0.45	9.22e-8	Mean platelet volume;
TGCT	cis	rs9611565	0.694	rs4822032	chr22:41925535	T/C	cg06634786	chr22:41940651	POLR3H	-0.77	-7.72	-0.57	3.42e-12	Vitiligo;
TGCT	cis	rs259282	0.669	rs731673	chr19:33132295	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.64	5.99	0.47	2.08e-8	Schizophrenia;
TGCT	cis	rs7824557	0.564	rs6601584	chr8:11232343	C/G	cg21775007	chr8:11205619	TDH	-0.62	-5.96	-0.47	2.44e-8	Retinal vascular caliber;
TGCT	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	-0.52	-5.48	-0.44	2.3e-7	Menopause (age at onset);
TGCT	cis	rs1878931	0.697	rs10048148	chr16:3417450	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.98	11.98	0.73	1.97e-22	Body mass index (adult);
TGCT	cis	rs9467773	0.844	rs2393669	chr6:26503873	C/T	cg15659132	chr6:26577336	NA	0.86	12.18	0.74	6.14e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.518	rs13133925	chr4:98706398	G/T	cg17366294	chr4:99064904	C4orf37	0.62	5.77	0.46	6.03e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7552404	0.690	rs12723575	chr1:76335203	T/C	cg22875332	chr1:76189707	ACADM	-0.57	-6.14	-0.48	1.05e-8	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg18402987	chr7:1209562	NA	0.7	5.74	0.46	6.77e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs11785400	0.793	rs13255558	chr8:143748080	C/T	cg24634471	chr8:143751801	JRK	0.55	5.38	0.44	3.52e-7	Schizophrenia;
TGCT	cis	rs7267979	0.586	rs6050432	chr20:25184028	T/C	cg03522245	chr20:25566470	NINL	0.5	5.27	0.43	5.88e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6669384	0.774	rs4844624	chr1:208035446	A/G	cg22525895	chr1:207977042	MIR29B2	-0.39	-5.53	-0.44	1.82e-7	Immune response to measles vaccine (measles-specific neutralising antibody titre);
TGCT	cis	rs35934224	0.843	rs34175429	chr22:19867276	T/C	cg11182965	chr22:19864308	TXNRD2	-0.38	-5.37	-0.43	3.79e-7	Glaucoma (primary open-angle);
TGCT	cis	rs12142240	0.698	rs17361763	chr1:46810670	T/C	cg00530320	chr1:46809349	NSUN4	0.29	5.88	0.47	3.63e-8	Menopause (age at onset);
TGCT	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg17971929	chr21:40555470	PSMG1	-0.52	-4.59	-0.38	1.05e-5	Menarche (age at onset);
TGCT	cis	rs7809950	0.954	rs11977187	chr7:107210383	C/T	cg23024343	chr7:107201750	COG5	0.35	5.35	0.43	4.13e-7	Coronary artery disease;
TGCT	cis	rs3820068	0.608	rs10927836	chr1:16034368	G/C	cg17385448	chr1:15911702	AGMAT	0.36	4.92	0.4	2.67e-6	Systolic blood pressure;
TGCT	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg26338869	chr17:61819248	STRADA	-0.53	-4.87	-0.4	3.29e-6	Prudent dietary pattern;
TGCT	trans	rs9329221	0.741	rs13264066	chr8:9804075	C/G	cg15556689	chr8:8085844	FLJ10661	-0.82	-7.75	-0.57	2.92e-12	Neuroticism;
TGCT	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg03709012	chr19:19516395	GATAD2A	-0.66	-5.7	-0.46	8.46e-8	Tonsillectomy;
TGCT	cis	rs12142240	0.698	rs72677585	chr1:46812374	T/C	cg00530320	chr1:46809349	NSUN4	0.29	5.84	0.46	4.33e-8	Menopause (age at onset);
TGCT	cis	rs826838	0.967	rs11183022	chr12:38652519	G/A	cg13010199	chr12:38710504	ALG10B	0.77	6.31	0.49	4.59e-9	Heart rate;
TGCT	cis	rs4788570	0.615	rs7188675	chr16:71680002	C/T	cg06353428	chr16:71660113	MARVELD3	1.55	12.51	0.75	9.87e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs55962025	0.824	rs61348208	chr4:3089564	C/T	cg06533319	chr4:3265114	C4orf44	0.22	4.7	0.39	6.91e-6	Parental longevity (mother's age at death);
TGCT	cis	rs2739330	0.964	rs2739338	chr22:24297130	T/C	cg00024416	chr22:24240387	NA	-0.25	-4.91	-0.4	2.86e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9527	0.615	rs4919682	chr10:104584330	C/T	cg15744005	chr10:104629667	AS3MT	-0.49	-5.77	-0.46	5.9e-8	Arsenic metabolism;
TGCT	cis	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg18188782	chr20:61659543	NA	0.44	5.37	0.43	3.73e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs899997	0.773	rs11072784	chr15:78966058	T/C	cg00061860	chr15:78953028	NA	-0.33	-5.21	-0.42	7.75e-7	Coronary artery disease or large artery stroke;
TGCT	cis	rs1532993	0.518	rs10005829	chr4:98606970	A/T	cg05340658	chr4:99064831	C4orf37	-0.41	-4.96	-0.41	2.3e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs8072100	0.817	rs7213086	chr17:45752310	C/G	cg08085267	chr17:45401833	C17orf57	-0.47	-4.99	-0.41	2.02e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg03388025	chr16:89894329	SPIRE2	0.48	8.33	0.6	1.26e-13	Vitiligo;
TGCT	cis	rs28595532	0.920	rs114649974	chr4:119735341	T/C	cg21605333	chr4:119757512	SEC24D	1.66	8.33	0.6	1.28e-13	Cannabis dependence symptom count;
TGCT	cis	rs2120019	1.000	rs12324912	chr15:75361006	G/A	cg09165964	chr15:75287851	SCAMP5	-1.16	-9.78	-0.66	4.33e-17	Blood trace element (Zn levels);
TGCT	cis	rs992157	1.000	rs736730	chr2:219120255	C/T	cg00012203	chr2:219082015	ARPC2	0.77	8.2	0.59	2.56e-13	Colorectal cancer;
TGCT	cis	rs25645	0.823	rs12453334	chr17:38153473	C/T	cg17467752	chr17:38218738	THRA	-0.54	-4.68	-0.39	7.4e-6	Myeloid white cell count;
TGCT	cis	rs12510870	0.634	rs10805065	chr4:74379938	C/T	cg05868023	chr4:75230803	EREG	0.55	4.7	0.39	6.84e-6	Iris color (b* coordinate);
TGCT	cis	rs9916302	0.706	rs4332770	chr17:37704712	T/C	cg07936489	chr17:37558343	FBXL20	-0.84	-6.16	-0.48	9.13e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs2637266	0.967	rs12246430	chr10:78352879	C/T	cg18941641	chr10:78392320	NA	0.43	5.07	0.41	1.42e-6	Pulmonary function;
TGCT	cis	rs11080466	1.000	rs8095990	chr18:10896602	A/G	cg02393756	chr18:9912783	VAPA	-0.26	-4.71	-0.39	6.56e-6	Non-small cell lung cancer;
TGCT	cis	rs6725041	0.819	rs2049180	chr2:213081740	G/A	cg16329650	chr2:213403929	ERBB4	-0.54	-4.61	-0.38	9.88e-6	QT interval (ambient particulate matter interaction);
TGCT	cis	rs6840360	0.533	rs13121178	chr4:152729047	T/C	cg22705602	chr4:152727874	NA	0.34	6.14	0.48	1.02e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.54	-5.24	-0.43	6.69e-7	Bipolar disorder;
TGCT	cis	rs9467773	1.000	rs10214634	chr6:26564582	T/A	cg09904177	chr6:26538194	HMGN4	0.66	6.6	0.51	1.05e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs3935685	0.874	rs11072665	chr15:78006256	T/C	cg25212270	chr15:78015279	NA	0.26	5.59	0.45	1.38e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1018836	0.923	rs12545279	chr8:91636373	C/G	cg16814680	chr8:91681699	NA	-0.85	-9.0	-0.63	3.35e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs651907	0.514	rs55654108	chr3:101425703	A/G	cg12386194	chr3:101231763	SENP7	0.51	5.0	0.41	1.9e-6	Colorectal cancer;
TGCT	cis	rs6582630	0.519	rs8189609	chr12:38281408	A/G	cg13010199	chr12:38710504	ALG10B	0.64	4.97	0.41	2.15e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs7428	0.545	rs4832163	chr2:85541083	T/C	cg03728395	chr2:85555865	TGOLN2	-0.29	-5.29	-0.43	5.28e-7	Ear protrusion;
TGCT	cis	rs1962636	1	rs1962636	chr16:22064395	A/C	cg09370801	chr16:22207107	NA	0.58	5.28	0.43	5.57e-7	Schizophrenia;
TGCT	cis	rs9929218	1.000	rs11865026	chr16:68774283	A/G	cg01251360	chr16:68772225	CDH1	0.28	4.74	0.39	5.65e-6	Colorectal cancer;
TGCT	cis	rs2486012	1.000	rs3791097	chr1:44349381	G/C	cg12908607	chr1:44402522	ARTN	0.71	5.86	0.47	3.87e-8	Intelligence (multi-trait analysis);
TGCT	trans	rs561341	0.769	rs8074383	chr17:30178793	C/T	cg20587970	chr11:113659929	NA	0.89	9.02	0.63	2.99e-15	Hip circumference adjusted for BMI;
TGCT	cis	rs4332037	0.575	rs55952733	chr7:2070680	G/A	cg25834613	chr7:1915315	MAD1L1	-0.52	-5.11	-0.42	1.2e-6	Bipolar disorder;
TGCT	cis	rs35160687	0.901	rs17738096	chr2:86513893	C/G	cg12542933	chr2:85804724	VAMP8	0.4	4.79	0.39	4.75e-6	Night sleep phenotypes;
TGCT	cis	rs2404602	0.692	rs12594556	chr15:77165363	G/A	cg22467129	chr15:76604101	ETFA	-0.47	-5.39	-0.44	3.44e-7	Blood metabolite levels;
TGCT	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.57	-5.69	-0.45	8.8e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs8067545	0.640	rs10083840	chr17:19965972	A/G	cg18979559	chr17:20280153	CCDC144C	0.47	4.91	0.4	2.8e-6	Schizophrenia;
TGCT	cis	rs9910055	0.762	rs2526020	chr17:42216588	G/T	cg19774624	chr17:42201019	HDAC5	-0.85	-8.95	-0.63	4.27e-15	Total body bone mineral density;
TGCT	cis	rs2718812	0.792	rs1867503	chr3:133410648	G/A	cg08048268	chr3:133502702	NA	0.38	4.66	0.39	8.01e-6	Iron status biomarkers;
TGCT	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg25036284	chr2:26402008	FAM59B	-0.57	-5.0	-0.41	1.94e-6	Gut microbiome composition (summer);
TGCT	cis	rs8014204	0.816	rs11159107	chr14:75341266	C/A	cg06637938	chr14:75390232	RPS6KL1	-0.53	-4.6	-0.38	1.04e-5	Caffeine consumption;
TGCT	cis	rs7267979	0.844	rs1555330	chr20:25232097	A/C	cg14121845	chr20:25566513	NINL	0.49	4.96	0.41	2.24e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs13191362	1.000	rs35017019	chr6:162982581	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.57	4.94	0.41	2.45e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs6901250	0.851	rs168128	chr6:117166865	A/G	cg12892004	chr6:117198278	RFX6	-0.54	-6.66	-0.51	7.82e-10	C-reactive protein levels;
TGCT	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg07507251	chr3:52567010	NT5DC2	0.47	6.64	0.51	8.85e-10	Electroencephalogram traits;
TGCT	cis	rs7302981	0.934	rs7532	chr12:50523964	T/C	cg23855989	chr12:50355821	AQP5	-0.3	-4.44	-0.37	2e-5	Systolic blood pressure;
TGCT	cis	rs11605924	0.901	rs7112505	chr11:45840939	A/T	ch.11.939596F	chr11:45881766	CRY2	-0.35	-4.47	-0.37	1.76e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);
TGCT	cis	rs13256369	0.802	rs4840350	chr8:8561442	A/G	cg18904891	chr8:8559673	CLDN23	0.57	5.27	0.43	5.87e-7	Obesity-related traits;
TGCT	cis	rs1901167	0.908	rs1996343	chr5:40978926	C/T	cg02441090	chr5:41871058	OXCT1	-0.31	-4.61	-0.38	9.86e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs13191362	0.935	rs34035978	chr6:163165336	G/C	cg06582575	chr6:163149167	PACRG;PARK2	0.66	5.66	0.45	1.01e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs2562456	0.917	rs2681392	chr19:21695987	T/G	cg25650185	chr19:21324782	ZNF431	0.61	5.38	0.43	3.6e-7	Pain;
TGCT	cis	rs6570726	0.599	rs9376951	chr6:145898911	C/T	cg23711669	chr6:146136114	FBXO30	0.7	6.45	0.5	2.23e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2153535	0.601	rs9505474	chr6:8539794	C/G	cg07606381	chr6:8435919	SLC35B3	0.55	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg04944784	chr2:26401820	FAM59B	-0.78	-6.56	-0.51	1.34e-9	Gut microbiome composition (summer);
TGCT	cis	rs2299587	0.610	rs6987474	chr8:17773298	T/C	cg01800426	chr8:17659068	MTUS1	-0.7	-6.03	-0.48	1.72e-8	Economic and political preferences;
TGCT	cis	rs727563	0.593	rs132770	chr22:42017264	A/G	cg06634786	chr22:41940651	POLR3H	0.88	8.33	0.6	1.28e-13	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs367615	0.879	rs2201015	chr5:108947450	C/T	cg17395555	chr5:108820864	NA	0.29	4.84	0.4	3.84e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs950776	0.714	rs660652	chr15:78887832	A/G	cg06917634	chr15:78832804	PSMA4	-0.65	-5.33	-0.43	4.48e-7	Sudden cardiac arrest;
TGCT	cis	rs2797160	0.967	rs2797159	chr6:126009557	G/A	cg05901451	chr6:126070800	HEY2	0.72	6.11	0.48	1.18e-8	Endometrial cancer;
TGCT	cis	rs13217239	0.646	rs10946898	chr6:27003884	T/C	cg26531700	chr6:26746687	NA	0.68	6.86	0.52	2.83e-10	Schizophrenia;
TGCT	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg17971929	chr21:40555470	PSMG1	-0.64	-5.55	-0.45	1.68e-7	Cognitive function;
TGCT	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg06221963	chr1:154839813	KCNN3	-0.7	-11.65	-0.72	1.22e-21	Prostate cancer;
TGCT	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg07507251	chr3:52567010	NT5DC2	-0.49	-6.75	-0.52	4.96e-10	Bipolar disorder;
TGCT	cis	rs514406	0.698	rs11206043	chr1:53402552	C/T	cg22166914	chr1:53195759	ZYG11B	0.3	4.8	0.4	4.46e-6	Monocyte count;
TGCT	cis	rs17221829	0.703	rs11018680	chr11:89364011	G/A	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.65	-0.39	8.43e-6	Anxiety in major depressive disorder;
TGCT	cis	rs11648796	0.717	rs10682	chr16:767430	C/G	cg07343612	chr16:622815	PIGQ	-0.35	-5.07	-0.41	1.43e-6	Height;
TGCT	cis	rs12762955	0.677	rs11250267	chr10:1156487	A/G	cg26597838	chr10:835615	NA	0.5	5.56	0.45	1.55e-7	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs6754311	0.731	rs892715	chr2:136576577	T/C	cg07169764	chr2:136633963	MCM6	-0.61	-5.61	-0.45	1.25e-7	Mosquito bite size;
TGCT	cis	rs2019216	0.500	rs12450390	chr17:21910636	G/T	cg22648282	chr17:21454238	C17orf51	-0.6	-5.54	-0.45	1.75e-7	Pelvic organ prolapse;
TGCT	cis	rs2549003	1.000	rs6873426	chr5:131818631	G/T	cg02551604	chr5:131831745	NA	-0.89	-11.77	-0.73	6.36e-22	Asthma (sex interaction);
TGCT	cis	rs2301573	1.000	rs61319406	chr3:129307957	T/G	cg07730360	chr3:128845626	NA	0.33	4.61	0.38	9.84e-6	Hip circumference;
TGCT	cis	rs9788721	0.836	rs55983731	chr15:78735269	C/T	cg18825076	chr15:78729989	IREB2	-0.33	-5.22	-0.42	7.38e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
TGCT	cis	rs1403694	0.695	rs5029969	chr3:186434405	G/T	cg12454167	chr3:186435060	KNG1	0.51	8.67	0.61	1.95e-14	Blood protein levels;
TGCT	cis	rs7666738	0.830	rs4443293	chr4:99063120	G/A	cg05340658	chr4:99064831	C4orf37	0.52	5.79	0.46	5.32e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs539096	0.830	rs3000761	chr1:44026089	C/T	cg12908607	chr1:44402522	ARTN	0.5	5.25	0.43	6.3e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg22963979	chr7:1858916	MAD1L1	-0.36	-5.62	-0.45	1.21e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs2997447	0.761	rs56078964	chr1:26442600	C/A	cg03844060	chr1:26490628	NA	0.28	4.55	0.38	1.27e-5	QRS complex (12-leadsum);
TGCT	cis	rs860554	0.705	rs700469	chr1:201259981	C/T	cg01022117	chr1:201258280	PKP1	0.32	4.88	0.4	3.15e-6	Panic disorder;
TGCT	cis	rs12497850	0.931	rs9840684	chr3:48893780	T/C	cg18654377	chr3:49208889	KLHDC8B	-0.42	-5.52	-0.44	1.93e-7	Parkinson's disease;
TGCT	cis	rs7772486	0.686	rs857877	chr6:145976230	A/C	cg23711669	chr6:146136114	FBXO30	-0.86	-9.6	-0.65	1.2e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs17102423	0.602	rs1270073	chr14:65566257	C/A	cg11161011	chr14:65562177	MAX	-0.47	-6.42	-0.5	2.57e-9	Obesity-related traits;
TGCT	cis	rs11096990	0.892	rs1473364	chr4:39212879	A/G	ch.4.37949012R	chr4:38272617	NA	0.38	4.67	0.39	7.82e-6	Cognitive function;
TGCT	cis	rs9467773	0.620	rs9461275	chr6:26590801	C/T	cg15659132	chr6:26577336	NA	0.87	11.0	0.7	4.77e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs9611565	0.649	rs139559	chr22:42191636	A/G	cg06481639	chr22:41940642	POLR3H	-0.55	-4.75	-0.39	5.55e-6	Vitiligo;
TGCT	cis	rs3008870	0.583	rs3008892	chr1:67373558	A/T	cg11518657	chr1:67396239	MIER1	0.56	4.54	0.38	1.29e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs6725041	0.819	rs10196229	chr2:213081987	C/T	cg20637307	chr2:213403960	ERBB4	-0.51	-4.48	-0.37	1.68e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs4713118	0.513	rs156738	chr6:28014025	G/C	cg10876282	chr6:28092338	ZSCAN16	0.51	4.75	0.39	5.48e-6	Parkinson's disease;
TGCT	cis	rs4242434	0.927	rs2291231	chr8:22463912	C/T	cg21658235	chr8:22456391	C8orf58	0.43	4.47	0.37	1.72e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs7223966	1.000	rs7216798	chr17:61740963	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	5.05	0.41	1.51e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs2074038	1.000	rs2074038	chr11:44087989	G/T	cg15894661	chr11:44088124	ACCS	-0.6	-4.44	-0.37	2e-5	IgA nephropathy;
TGCT	cis	rs12753569	0.967	rs6696116	chr1:76483732	C/T	cg00791851	chr1:76518896	NA	-0.36	-4.58	-0.38	1.14e-5	Personality dimensions;
TGCT	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg24531977	chr5:56204891	C5orf35	-0.77	-7.61	-0.56	5.83e-12	Initial pursuit acceleration;
TGCT	cis	rs9788721	0.836	rs17483929	chr15:78742376	C/T	cg18825076	chr15:78729989	IREB2	-0.33	-5.1	-0.42	1.25e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
TGCT	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg20818283	chr2:191399100	TMEM194B	0.47	4.55	0.38	1.25e-5	Pulse pressure;
TGCT	cis	rs17401966	1.000	rs12118323	chr1:10469641	A/G	cg19773385	chr1:10388646	KIF1B	-0.23	-5.42	-0.44	2.97e-7	Hepatocellular carcinoma;
TGCT	cis	rs4889855	0.530	rs4889865	chr17:78568447	A/T	cg16591659	chr17:78472290	NA	0.28	4.46	0.37	1.84e-5	Fractional excretion of uric acid;
TGCT	trans	rs2832077	0.527	rs2250141	chr21:30241984	A/T	cg14791747	chr16:20752902	THUMPD1	-1.0	-10.45	-0.68	1e-18	Cognitive test performance;
TGCT	cis	rs7010267	0.570	rs28893333	chr8:120046473	A/G	cg17171407	chr8:119960777	TNFRSF11B	0.26	4.59	0.38	1.06e-5	Total body bone mineral density (age 45-60);
TGCT	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg03396347	chr1:1875803	NA	-0.38	-6.9	-0.53	2.33e-10	Body mass index;
TGCT	cis	rs11658309	1	rs11658309	chr17:17762247	T/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.75	-7.78	-0.57	2.42e-12	Strep throat;
TGCT	cis	rs7249142	0.549	rs741706	chr19:19281672	C/T	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.56	5.55	0.45	1.67e-7	IgG glycosylation;
TGCT	cis	rs6500602	0.701	rs4786500	chr16:4525265	A/G	cg08645402	chr16:4508243	NA	-0.19	-4.61	-0.38	9.67e-6	Schizophrenia;
TGCT	cis	rs2070488	0.662	rs7373930	chr3:38454931	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.65	4.96	0.41	2.28e-6	Electrocardiographic conduction measures;
TGCT	cis	rs4727027	0.901	rs6943937	chr7:148869915	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	4.65	0.39	8.3e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs17345786	1.000	rs11715368	chr3:101336380	G/A	cg12386194	chr3:101231763	SENP7	0.6	5.61	0.45	1.27e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs28374715	0.662	rs11852419	chr15:41456374	A/T	cg18705301	chr15:41695430	NDUFAF1	0.74	10.35	0.68	1.75e-18	Ulcerative colitis;
TGCT	cis	rs10838634	1.000	rs11038987	chr11:46792695	A/T	cg18332754	chr11:46939436	LRP4	0.84	4.54	0.38	1.29e-5	Schizophrenia;
TGCT	cis	rs4689388	0.853	rs1079214	chr4:6282157	T/C	cg25554036	chr4:6271136	WFS1	0.57	7.77	0.57	2.63e-12	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg18135555	chr8:22132992	PIWIL2	0.3	6.12	0.48	1.13e-8	Hypertriglyceridemia;
TGCT	cis	rs9457247	1.000	rs2769352	chr6:167378619	A/G	cg25258033	chr6:167368657	RNASET2	-0.2	-4.82	-0.4	4.19e-6	Crohn's disease;
TGCT	cis	rs2463822	0.844	rs1919359	chr11:62055703	A/G	cg06239285	chr11:62104954	ASRGL1	0.81	5.15	0.42	1.01e-6	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs7264396	0.623	rs2590984	chr20:34597031	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.28	-4.96	-0.41	2.29e-6	Total cholesterol levels;
TGCT	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg00343986	chr7:65444356	GUSB	-0.25	-5.51	-0.44	1.95e-7	Aortic root size;
TGCT	cis	rs4654899	0.865	rs12410467	chr1:21356055	G/A	cg01072550	chr1:21505969	NA	-0.46	-6.95	-0.53	1.88e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs2832077	0.506	rs2832081	chr21:30152992	A/C	cg24692254	chr21:30365293	RNF160	0.53	5.05	0.41	1.52e-6	Cognitive test performance;
TGCT	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg07061783	chr6:25882402	NA	-0.81	-8.85	-0.62	7.54e-15	Uric acid levels;
TGCT	cis	rs2370759	0.945	rs10508773	chr10:32575444	C/T	cg01819863	chr10:32635814	EPC1	1.03	10.03	0.67	1.05e-17	Sexual dysfunction (female);
TGCT	cis	rs9291683	0.526	rs6827785	chr4:10018205	C/T	cg00071950	chr4:10020882	SLC2A9	0.66	7.74	0.57	3.07e-12	Bone mineral density;
TGCT	cis	rs4654899	1.000	rs6697555	chr1:21287938	C/T	cg01072550	chr1:21505969	NA	-0.5	-8.13	-0.59	3.72e-13	Superior frontal gyrus grey matter volume;
TGCT	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg23758822	chr17:41437982	NA	0.72	6.81	0.52	3.83e-10	Menopause (age at onset);
TGCT	cis	rs7904368	0.568	rs7075036	chr10:16864810	C/T	cg23933602	chr10:16859644	RSU1	0.7	6.5	0.5	1.81e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
TGCT	cis	rs7091068	0.706	rs4919398	chr10:95429162	C/T	cg20715218	chr10:95462985	C10orf4	0.5	4.59	0.38	1.09e-5	Urinary tract infection frequency;
TGCT	trans	rs2229238	0.911	rs58348886	chr1:154446198	T/C	cg22838003	chr14:96730482	BDKRB1	0.41	6.87	0.53	2.78e-10	Coronary heart disease;
TGCT	cis	rs17767294	0.614	rs72845068	chr6:27668147	A/C	cg08851530	chr6:28072375	NA	1.56	7.38	0.55	1.95e-11	Parkinson's disease;
TGCT	cis	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg07424592	chr7:64974309	NA	1.31	8.14	0.59	3.55e-13	Diabetic kidney disease;
TGCT	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg11062466	chr8:58055876	NA	0.38	4.62	0.38	9.5e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	0.5	4.7	0.39	6.7e-6	Electroencephalogram traits;
TGCT	cis	rs12286929	0.651	rs12274772	chr11:115098768	C/T	cg04580443	chr11:115547056	NA	-0.25	-4.67	-0.39	7.72e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs12497850	0.931	rs4974087	chr3:48919232	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.42	-5.52	-0.44	1.93e-7	Parkinson's disease;
TGCT	cis	rs111326718	1	rs111326718	chr10:104771211	A/AAAAAT	cg04362960	chr10:104952993	NT5C2	0.6	5.34	0.43	4.34e-7	Reticulocyte count;
TGCT	cis	rs1887596	0.624	rs1546258	chr13:27134551	A/G	cg01312412	chr13:27282625	NA	0.27	4.74	0.39	5.68e-6	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs17253792	0.822	rs113649689	chr14:56088065	G/A	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs6495367	1.000	rs13380104	chr15:79378821	C/T	cg17916960	chr15:79447300	NA	0.36	5.13	0.42	1.06e-6	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	trans	rs7618501	0.519	rs3774750	chr3:50208406	C/G	cg21659725	chr3:3221576	CRBN	-0.7	-7.99	-0.58	8.03e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg09704166	chr2:114031854	PAX8;LOC440839	0.33	4.89	0.4	3.1e-6	Lymphocyte counts;
TGCT	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs9527	0.590	rs7894959	chr10:104756182	C/T	cg04362960	chr10:104952993	NT5C2	0.65	5.64	0.45	1.08e-7	Arsenic metabolism;
TGCT	trans	rs17685	0.753	rs10085567	chr7:75734206	A/C	cg19862616	chr7:65841803	NCRNA00174	0.51	8.38	0.6	9.94e-14	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs7824557	0.583	rs2736306	chr8:11239762	A/T	cg21775007	chr8:11205619	TDH	0.68	7.3	0.55	3e-11	Retinal vascular caliber;
TGCT	cis	rs2013441	1.000	rs9900166	chr17:20192969	G/A	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.63	-0.38	9.19e-6	Obesity-related traits;
TGCT	cis	rs28595532	0.920	rs115090549	chr4:119753554	T/C	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs7267979	1.000	rs1888998	chr20:25291826	A/G	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs797680	0.856	rs7513705	chr1:93666349	T/C	cg27528825	chr2:159282178	CCDC148	-0.35	-6.81	-0.52	3.79e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg22166914	chr1:53195759	ZYG11B	0.36	5.96	0.47	2.45e-8	Monocyte count;
TGCT	cis	rs7647973	0.626	rs11709734	chr3:49745235	G/A	cg03060546	chr3:49711283	APEH	0.63	5.63	0.45	1.12e-7	Menarche (age at onset);
TGCT	cis	rs12893668	0.572	rs4906356	chr14:104138701	C/T	cg26031613	chr14:104095156	KLC1	-0.59	-5.02	-0.41	1.75e-6	Reticulocyte count;
TGCT	cis	rs7677751	0.806	rs60806423	chr4:55086816	C/T	cg17187183	chr4:55093834	PDGFRA	0.55	7.16	0.54	6.22e-11	Corneal astigmatism;
TGCT	cis	rs6840360	0.593	rs59350867	chr4:152695935	G/A	cg22705602	chr4:152727874	NA	-0.34	-5.9	-0.47	3.24e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs4076764	0.830	rs10917770	chr1:163442214	G/C	cg24596788	chr1:163392923	NA	-0.17	-4.99	-0.41	2.01e-6	Motion sickness;
TGCT	cis	rs2637266	0.967	rs4581393	chr10:78376123	A/C	cg18941641	chr10:78392320	NA	0.4	4.73	0.39	6.03e-6	Pulmonary function;
TGCT	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg04234412	chr22:24373322	LOC391322	0.92	8.38	0.6	9.67e-14	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs796364	0.507	rs13035874	chr2:201109553	G/A	cg04283868	chr2:201171347	SPATS2L	0.53	5.06	0.41	1.47e-6	Schizophrenia;
TGCT	cis	rs75229567	0.541	rs775443	chr12:70122623	C/T	cg10114359	chr12:70132523	RAB3IP	-1.06	-5.99	-0.47	2.14e-8	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
TGCT	trans	rs17471911	0.708	rs11189928	chr10:100755581	T/C	cg03484267	chr2:207988651	KLF7	-0.52	-6.7	-0.52	6.49e-10	Neuroticism;
TGCT	cis	rs651907	0.557	rs11711079	chr3:101386918	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.35	-7.28	-0.55	3.4e-11	Colorectal cancer;
TGCT	cis	rs12681288	0.644	rs2600494	chr8:1025517	C/T	cg08872321	chr8:1308229	NA	-0.24	-4.45	-0.37	1.86e-5	Schizophrenia;
TGCT	cis	rs4803468	1.000	rs284652	chr19:41928652	C/T	cg09537434	chr19:41945824	ATP5SL	-0.92	-10.57	-0.69	5.19e-19	Height;
TGCT	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg05552183	chr6:42928497	GNMT	0.58	5.05	0.41	1.51e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs8014252	0.803	rs57339942	chr14:71083307	T/A	cg11204974	chr14:71022665	NA	-0.56	-4.55	-0.38	1.25e-5	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
TGCT	cis	rs910316	0.763	rs735452	chr14:75497984	A/G	cg11812906	chr14:75593930	NEK9	-0.58	-5.61	-0.45	1.25e-7	Height;
TGCT	cis	rs35146811	0.700	rs7788301	chr7:99782753	C/G	cg04778012	chr7:99775508	STAG3;GPC2	0.35	4.93	0.41	2.55e-6	Coronary artery disease;
TGCT	cis	rs986417	1.000	rs8015462	chr14:61046687	G/A	cg27398547	chr14:60952738	C14orf39	1.48	11.08	0.71	2.96e-20	Gut microbiota (bacterial taxa);
TGCT	cis	rs6840360	0.615	rs4696096	chr4:152475387	A/G	cg17479576	chr4:152424074	FAM160A1	-0.72	-7.98	-0.58	8.25e-13	Intelligence (multi-trait analysis);
TGCT	trans	rs9951602	0.512	rs6506874	chr18:76653467	G/T	cg02800362	chr5:177631904	HNRNPAB	1.13	12.84	0.76	1.57e-24	Obesity-related traits;
TGCT	cis	rs174601	0.861	rs174547	chr11:61570783	C/T	cg19610905	chr11:61596333	FADS2	1.01	10.23	0.68	3.53e-18	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
TGCT	cis	rs6831352	0.918	rs1126672	chr4:100047812	G/A	cg12011299	chr4:100065546	ADH4	-0.41	-4.92	-0.4	2.72e-6	Alcohol dependence;
TGCT	cis	rs7666738	0.830	rs7687315	chr4:98900613	A/G	cg05340658	chr4:99064831	C4orf37	0.51	5.93	0.47	2.84e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg06238570	chr21:40685208	BRWD1	0.68	6.32	0.49	4.29e-9	Cognitive function;
TGCT	cis	rs72945132	0.882	rs61260732	chr11:70162145	G/A	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs2742417	1.000	rs2673056	chr3:45737802	C/T	cg04837898	chr3:45731254	SACM1L	-0.55	-5.68	-0.45	9.14e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs921968	0.643	rs1055816	chr2:219501328	G/A	cg02176678	chr2:219576539	TTLL4	0.38	5.47	0.44	2.34e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs11671005	0.735	rs3764532	chr19:58929222	G/A	cg13877915	chr19:58951672	ZNF132	0.63	4.99	0.41	1.95e-6	Mean platelet volume;
TGCT	trans	rs524675	0.581	rs515965	chr4:13959797	G/A	cg02315626	chr17:27188560	MIR451;MIR144	0.4	6.75	0.52	5.03e-10	Amyotrophic lateral sclerosis in C9orf72 mutation negative individuals;
TGCT	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg05368731	chr17:41323189	NBR1	1.16	13.76	0.78	1.03e-26	Menopause (age at onset);
TGCT	cis	rs57590327	0.555	rs13099615	chr3:81729101	T/A	cg07356753	chr3:81810745	GBE1	-0.77	-7.15	-0.54	6.69e-11	Extraversion;
TGCT	cis	rs9467773	1.000	rs9467779	chr6:26536687	A/T	cg09904177	chr6:26538194	HMGN4	-0.62	-6.3	-0.49	4.83e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs6460942	0.908	rs73301032	chr7:12256799	C/G	cg06484146	chr7:12443880	VWDE	-0.55	-4.68	-0.39	7.25e-6	Coronary artery disease;
TGCT	cis	rs10875595	0.836	rs6889723	chr5:140676524	C/T	cg20560182	chr5:140700478	TAF7	-0.64	-4.6	-0.38	1.01e-5	Pulmonary function decline;
TGCT	cis	rs1050631	1.000	rs1107840	chr18:33707164	A/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.49	4.83	0.4	3.95e-6	Esophageal squamous cell cancer (length of survival);
TGCT	cis	rs6450176	1.000	rs3776718	chr5:53298714	G/C	ch.5.1024479R	chr5:53302184	ARL15	-0.53	-5.1	-0.42	1.23e-6	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs9443189	0.570	rs775075	chr6:76380035	A/C	cg01950844	chr6:76311363	SENP6	-1.0	-6.24	-0.49	6.35e-9	Prostate cancer;
TGCT	cis	rs2404602	0.622	rs1567671	chr15:77209200	C/G	cg22467129	chr15:76604101	ETFA	0.54	5.4	0.44	3.25e-7	Blood metabolite levels;
TGCT	cis	rs3096299	0.967	rs2911256	chr16:89485096	G/C	cg06640241	chr16:89574553	SPG7	0.65	6.44	0.5	2.34e-9	Multiple myeloma (IgH translocation);
TGCT	cis	rs9868809	0.505	rs11708786	chr3:48752654	C/T	cg00383909	chr3:49044727	WDR6	0.95	5.79	0.46	5.34e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.63	-6.3	-0.49	4.82e-9	Prostate cancer;
TGCT	cis	rs8070740	0.592	rs2189338	chr17:5326341	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.59	5.92	0.47	2.94e-8	Menopause (age at onset);
TGCT	cis	rs826838	0.967	rs7965656	chr12:38807244	G/A	cg13010199	chr12:38710504	ALG10B	0.82	6.86	0.52	2.89e-10	Heart rate;
TGCT	cis	rs4851254	0.961	rs13000759	chr2:100753903	A/T	cg23118464	chr2:100721844	AFF3	-0.73	-5.44	-0.44	2.78e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs763121	0.626	rs5750643	chr22:39009017	A/G	cg06022373	chr22:39101656	GTPBP1	0.81	8.26	0.6	1.84e-13	Menopause (age at onset);
TGCT	cis	rs6977955	1.000	rs11495981	chr7:28177301	A/G	cg23620719	chr7:28220237	JAZF1	-0.64	-4.86	-0.4	3.48e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs67478160	0.643	rs2223937	chr14:104286380	A/G	cg26031613	chr14:104095156	KLC1	-0.63	-6.53	-0.51	1.56e-9	Schizophrenia;
TGCT	cis	rs4711350	0.765	rs1318691	chr6:33761884	G/A	cg13859433	chr6:33739653	LEMD2	-0.33	-4.97	-0.41	2.18e-6	Schizophrenia;
TGCT	cis	rs35306767	0.855	rs35666723	chr10:867346	A/G	cg20503657	chr10:835505	NA	0.77	11.28	0.71	9.73e-21	Eosinophil percentage of granulocytes;
TGCT	cis	rs6424115	0.830	rs2501423	chr1:24199026	A/C	cg15997130	chr1:24165203	NA	0.85	9.26	0.64	7.92e-16	Immature fraction of reticulocytes;
TGCT	cis	rs79349575	0.783	rs4294857	chr17:46983391	G/A	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.44	-0.37	1.95e-5	Type 2 diabetes;
TGCT	cis	rs6598955	0.616	rs11247890	chr1:26590182	G/A	cg04990556	chr1:26633338	UBXN11	0.64	4.91	0.4	2.78e-6	Obesity-related traits;
TGCT	cis	rs11085466	1.000	rs73552479	chr19:21778816	G/T	cg23026602	chr19:21646605	NA	-0.53	-4.55	-0.38	1.28e-5	Colorectal or endometrial cancer;
TGCT	cis	rs2688608	0.592	rs10824032	chr10:75528130	G/A	cg23231163	chr10:75533350	FUT11	-0.27	-4.68	-0.39	7.45e-6	Inflammatory bowel disease;
TGCT	cis	rs7216064	1.000	rs4790908	chr17:65852907	T/G	cg12091567	chr17:66097778	LOC651250	-0.87	-6.75	-0.52	5.12e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs1609391	0.543	rs9859810	chr3:136629986	A/G	cg15507776	chr3:136538369	TMEM22	0.66	6.84	0.52	3.27e-10	Neuroticism;
TGCT	cis	rs7772486	0.719	rs7753770	chr6:146066161	G/A	cg05347473	chr6:146136440	FBXO30	-0.54	-4.95	-0.41	2.33e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7119	0.717	rs12911854	chr15:77817288	T/C	cg27398640	chr15:77910606	LINGO1	-0.25	-4.6	-0.38	1.05e-5	Type 2 diabetes;
TGCT	cis	rs6684514	1.000	rs6800	chr1:156262653	A/C	cg20302342	chr1:156215951	PAQR6	0.34	4.6	0.38	1.01e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs3092073	0.617	rs3893276	chr20:44591089	G/C	cg23252815	chr20:44420276	WFDC3;DNTTIP1	-0.27	-4.48	-0.37	1.68e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs2033711	0.905	rs893186	chr19:58969179	C/A	cg04608855	chr19:58913158	NA	0.58	5.48	0.44	2.29e-7	Uric acid clearance;
TGCT	cis	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg21775007	chr8:11205619	TDH	0.51	4.68	0.39	7.4e-6	Retinal vascular caliber;
TGCT	cis	rs910316	1.000	rs2300601	chr14:75639571	A/G	cg11812906	chr14:75593930	NEK9	0.71	7.11	0.54	8.26e-11	Height;
TGCT	cis	rs7666738	0.830	rs10000573	chr4:99048785	G/C	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6733011	0.500	rs7560696	chr2:99405800	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-4.65	-0.39	8.2e-6	Bipolar disorder;
TGCT	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg26513180	chr16:89883248	FANCA	1.03	13.79	0.78	8.46e-27	Vitiligo;
TGCT	cis	rs7043114	0.525	rs10761153	chr9:95130769	A/G	cg14311495	chr9:95764742	FGD3	-0.22	-4.47	-0.37	1.75e-5	Height;
TGCT	cis	rs4727027	0.933	rs917122	chr7:148848257	T/C	cg23583168	chr7:148888333	NA	-0.77	-10.06	-0.67	9.29e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs28595532	0.920	rs17323034	chr4:119606518	G/A	cg21605333	chr4:119757512	SEC24D	1.33	8.02	0.58	6.93e-13	Cannabis dependence symptom count;
TGCT	cis	rs9914544	1.000	rs6502677	chr17:18803658	A/G	cg26378065	chr17:18585709	ZNF286B	0.5	4.45	0.37	1.9e-5	Educational attainment (years of education);
TGCT	trans	rs210152	0.541	rs36003672	chr6:33457816	T/A	cg08795360	chr21:41033440	B3GALT5	0.45	7.17	0.54	5.98e-11	Schizophrenia;
TGCT	cis	rs12477438	0.798	rs2123686	chr2:99690135	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-7.6	-0.56	6.47e-12	Chronic sinus infection;
TGCT	trans	rs1814175	0.817	rs4881645	chr11:49791168	G/A	cg15704280	chr7:45808275	SEPT13	-0.7	-8.08	-0.59	4.89e-13	Height;
TGCT	cis	rs9486715	0.867	rs11152924	chr6:96877383	A/G	cg18709589	chr6:96969512	KIAA0776	0.79	7.77	0.57	2.5e-12	Headache;
TGCT	cis	rs9486719	0.843	rs2472875	chr6:96844691	G/A	cg18709589	chr6:96969512	KIAA0776	0.75	5.13	0.42	1.1e-6	Migraine;Coronary artery disease;
TGCT	cis	rs9916302	0.904	rs4795356	chr17:37535631	C/T	cg07936489	chr17:37558343	FBXL20	0.65	5.08	0.41	1.36e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs12422267	0.536	rs12303540	chr12:132609679	A/G	cg09764611	chr12:132620959	NA	0.37	5.68	0.45	9e-8	Plasma amyloid beta peptide concentrations (ABx-40);
TGCT	cis	rs3749237	0.595	rs4855864	chr3:49521974	C/T	cg07636037	chr3:49044803	WDR6	0.63	5.98	0.47	2.26e-8	Resting heart rate;
TGCT	cis	rs9457247	1.000	rs400837	chr6:167411008	T/C	cg23791538	chr6:167370224	RNASET2	-0.49	-4.96	-0.41	2.31e-6	Crohn's disease;
TGCT	cis	rs7100689	0.753	rs1856773	chr10:82060484	T/A	cg01528321	chr10:82214614	TSPAN14	0.8	7.9	0.58	1.29e-12	Post bronchodilator FEV1;
TGCT	cis	rs6988636	1.000	rs28600861	chr8:124189063	C/T	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs9911578	1.000	rs8067571	chr17:56868856	C/T	cg12560992	chr17:57184187	TRIM37	0.76	9.34	0.64	4.88e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs28687737	chr4:99009226	G/A	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4478037	0.822	rs3924696	chr3:33122013	T/C	cg19404215	chr3:33155277	CRTAP	0.98	5.13	0.42	1.1e-6	Major depressive disorder;
TGCT	cis	rs2075371	0.932	rs11766132	chr7:133993062	T/C	cg11752832	chr7:134001865	SLC35B4	0.67	5.9	0.47	3.17e-8	Mean platelet volume;
TGCT	cis	rs7662987	0.517	rs2851260	chr4:100033574	C/T	cg12011299	chr4:100065546	ADH4	0.39	4.81	0.4	4.36e-6	Smoking initiation;
TGCT	cis	rs7666738	0.830	rs114722517	chr4:99042061	G/A	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10206020	0.921	rs4072986	chr2:1547734	C/G	cg12573674	chr2:1569213	NA	-0.49	-4.95	-0.41	2.41e-6	IgG glycosylation;
TGCT	cis	rs7267979	0.866	rs2424698	chr20:25256106	C/T	cg03522245	chr20:25566470	NINL	0.62	6.79	0.52	4.07e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11018874	0.532	rs11018867	chr11:89862345	C/T	cg14505434	chr11:89522851	NA	0.42	4.68	0.39	7.34e-6	White blood cell types;
TGCT	cis	rs453301	0.571	rs2929454	chr8:9083854	A/C	cg15556689	chr8:8085844	FLJ10661	-0.64	-6.05	-0.48	1.6e-8	Joint mobility (Beighton score);
TGCT	cis	rs7513165	1.000	rs11240695	chr1:204158132	C/A	cg12731349	chr1:204159619	KISS1	0.52	5.73	0.46	7.09e-8	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
TGCT	cis	rs6678914	0.966	rs4950836	chr1:202192624	A/G	cg08883485	chr1:201619787	NAV1	-0.39	-4.48	-0.37	1.68e-5	Breast cancer (estrogen-receptor negative);Breast cancer;
TGCT	cis	rs2404602	1.000	rs4886818	chr15:76880939	G/A	cg22467129	chr15:76604101	ETFA	-0.44	-4.86	-0.4	3.41e-6	Blood metabolite levels;
TGCT	cis	rs17221829	0.562	rs10830306	chr11:89366979	G/A	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.65	-0.39	8.43e-6	Anxiety in major depressive disorder;
TGCT	cis	rs6867032	0.834	rs10043083	chr5:1995687	C/G	cg26168224	chr5:2018326	NA	-0.36	-5.54	-0.45	1.69e-7	Gut microbiome composition (winter);
TGCT	cis	rs6433857	0.505	rs16867320	chr2:181362312	A/G	cg23363182	chr2:181467187	NA	0.3	4.5	0.37	1.52e-5	Body mass index;
TGCT	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.46	4.86	0.4	3.51e-6	Lymphocyte counts;
TGCT	cis	rs9467711	0.606	rs2073529	chr6:26375159	C/T	cg10795676	chr6:26370623	BTN3A2	0.46	4.75	0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6089584	0.627	rs35560719	chr20:60561917	A/C	cg06108461	chr20:60628389	TAF4	-0.4	-4.8	-0.4	4.4e-6	Body mass index;
TGCT	cis	rs12643440	0.511	rs10489115	chr4:17127327	C/G	cg22650099	chr4:17144496	NA	0.53	5.0	0.41	1.87e-6	Metabolite levels (Pyroglutamine);
TGCT	cis	rs13217239	0.646	rs4403259	chr6:26997617	C/T	cg05738196	chr6:26577821	NA	0.49	4.75	0.39	5.45e-6	Schizophrenia;
TGCT	cis	rs1691799	0.899	rs1168292	chr12:66732660	C/T	cg16791601	chr12:66731901	HELB	-0.28	-6.11	-0.48	1.19e-8	White blood cell count (basophil);
TGCT	cis	rs9883204	1.000	rs6798189	chr3:123095312	G/A	cg04890266	chr3:123102914	ADCY5	0.36	5.11	0.42	1.17e-6	Birth weight;
TGCT	cis	rs17001868	0.568	rs73167007	chr22:40734241	G/C	cg07138101	chr22:40742427	ADSL	0.73	5.38	0.44	3.57e-7	Mammographic density (dense area);
TGCT	cis	rs7666738	0.830	rs62318471	chr4:98925848	G/A	cg18180107	chr4:99064573	C4orf37	0.54	4.85	0.4	3.59e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6952808	0.626	rs57633152	chr7:2042547	C/G	cg14004847	chr7:1930337	MAD1L1	-0.28	-4.46	-0.37	1.79e-5	Bipolar disorder and schizophrenia;
TGCT	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.12	0.54	7.78e-11	Prudent dietary pattern;
TGCT	cis	rs7772486	0.641	rs9390374	chr6:146368175	A/T	cg13319975	chr6:146136371	FBXO30	-0.67	-6.34	-0.49	3.98e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7208859	0.623	rs8082537	chr17:29015932	T/C	cg04154034	chr17:28927549	LRRC37B2	0.8	4.73	0.39	5.94e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs73058052	1.000	rs73058052	chr19:50099422	C/T	cg09250473	chr19:50168907	IRF3;BCL2L12	0.81	5.63	0.45	1.15e-7	Fibrinogen levels;
TGCT	cis	rs6430585	0.583	rs730005	chr2:136582694	T/C	cg07169764	chr2:136633963	MCM6	1.22	11.84	0.73	4.08e-22	Corneal structure;
TGCT	cis	rs9291683	0.655	rs35750364	chr4:10049049	T/C	cg11266682	chr4:10021025	SLC2A9	0.65	9.01	0.63	3.01e-15	Bone mineral density;
TGCT	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs35146811	0.657	rs36019559	chr7:99814586	A/G	cg22906224	chr7:99728672	NA	-0.49	-4.45	-0.37	1.88e-5	Coronary artery disease;
TGCT	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg08859206	chr1:53392774	SCP2	-0.47	-7.78	-0.57	2.39e-12	Monocyte count;
TGCT	cis	rs523522	0.926	rs10774555	chr12:120971978	G/A	cg27279351	chr12:120934652	DYNLL1	0.76	6.59	0.51	1.15e-9	High light scatter reticulocyte count;
TGCT	cis	rs28595532	0.920	rs56104443	chr4:119752052	G/A	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs2289583	0.544	rs12050759	chr15:75265191	G/A	cg10253484	chr15:75165896	SCAMP2	0.56	4.99	0.41	2e-6	Systemic lupus erythematosus;
TGCT	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg13607699	chr17:42295918	UBTF	0.59	5.38	0.43	3.65e-7	Total body bone mineral density;
TGCT	cis	rs612683	0.658	rs12407689	chr1:100999585	C/G	cg06223162	chr1:101003688	GPR88	0.34	5.72	0.46	7.52e-8	Breast cancer;
TGCT	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.15	0.82	2.71e-32	Prudent dietary pattern;
TGCT	cis	rs698813	0.604	rs7565928	chr2:44489956	T/C	cg00619915	chr2:44497795	NA	-0.24	-5.5	-0.44	2.05e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
TGCT	cis	rs137699	0.568	rs137682	chr22:39738425	A/C	cg11247378	chr22:39784982	NA	-0.48	-4.46	-0.37	1.8e-5	IgG glycosylation;
TGCT	cis	rs950169	0.723	rs17589320	chr15:84919996	C/A	cg12863693	chr15:85201151	NMB	0.41	4.5	0.38	1.51e-5	Schizophrenia;
TGCT	cis	rs9467773	1.000	rs9467774	chr6:26505036	C/A	cg26531700	chr6:26746687	NA	0.47	4.56	0.38	1.19e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs17376456	1.000	rs34854140	chr5:93538169	G/A	cg21475434	chr5:93447410	FAM172A	0.61	4.51	0.38	1.47e-5	Diabetic retinopathy;
TGCT	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.55	-5.64	-0.45	1.08e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs12134133	0.888	rs11580394	chr1:207411912	T/C	cg02152968	chr1:207494213	CD55	0.6	4.65	0.39	8.43e-6	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs911263	0.603	rs1956529	chr14:68788924	A/G	cg18825221	chr14:68749962	RAD51L1	-0.22	-4.46	-0.37	1.82e-5	Primary biliary cholangitis;
TGCT	cis	rs2072499	0.966	rs887953	chr1:156191149	T/C	cg25208724	chr1:156163844	SLC25A44	1.11	12.8	0.75	1.94e-24	Testicular germ cell tumor;
TGCT	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg18402987	chr7:1209562	NA	0.4	5.17	0.42	9.17e-7	Longevity;Endometriosis;
TGCT	cis	rs79976124	0.837	rs12201218	chr6:66653619	C/T	cg07460842	chr6:66804631	NA	-0.57	-5.22	-0.42	7.44e-7	Type 2 diabetes;
TGCT	cis	rs3784262	0.740	rs12910267	chr15:58374603	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.48	-6.94	-0.53	1.93e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs67311347	0.955	rs11711994	chr3:40391086	T/C	cg13409248	chr3:40428643	ENTPD3	0.56	4.64	0.38	8.57e-6	Renal cell carcinoma;
TGCT	cis	rs7777754	0.512	rs4470989	chr7:50562698	T/A	cg18232548	chr7:50535776	DDC	-0.38	-5.84	-0.46	4.38e-8	Response to zileuton treatment in asthma (FEV1 change interaction);
TGCT	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg17554472	chr22:41940697	POLR3H	-0.42	-4.56	-0.38	1.19e-5	Vitiligo;
TGCT	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg22166914	chr1:53195759	ZYG11B	0.33	5.32	0.43	4.6e-7	Monocyte count;
TGCT	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg00080972	chr5:178986291	RUFY1	0.56	6.86	0.52	2.95e-10	Lung cancer;
TGCT	cis	rs7674212	0.507	rs223317	chr4:103802824	T/C	cg16532752	chr4:104119610	CENPE	-0.62	-5.59	-0.45	1.41e-7	Type 2 diabetes;
TGCT	cis	rs2455799	0.586	rs1345161	chr3:15863426	C/T	cg12172478	chr3:16357591	RFTN1	0.31	4.74	0.39	5.64e-6	Mean platelet volume;
TGCT	cis	rs11190604	1.000	rs11190578	chr10:102238953	C/T	cg23241863	chr10:102295624	HIF1AN	0.63	4.95	0.41	2.41e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9388451	0.874	rs13209968	chr6:126089285	G/C	cg10911889	chr6:126070802	HEY2	0.54	5.64	0.45	1.08e-7	Brugada syndrome;
TGCT	cis	rs899997	0.731	rs58717592	chr15:79030417	T/C	cg04896959	chr15:78267971	NA	-0.37	-5.02	-0.41	1.79e-6	Coronary artery disease or large artery stroke;
TGCT	cis	rs11785400	0.793	rs4736362	chr8:143741381	G/A	cg10596483	chr8:143751796	JRK	0.56	5.5	0.44	2.05e-7	Schizophrenia;
TGCT	trans	rs28595532	0.623	rs10016452	chr4:119277490	A/G	cg26518628	chr1:97050305	NA	-0.6	-7.07	-0.54	1.01e-10	Cannabis dependence symptom count;
TGCT	cis	rs12477438	0.501	rs11683188	chr2:99724512	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	10.3	0.68	2.42e-18	Chronic sinus infection;
TGCT	cis	rs514406	0.505	rs269286	chr1:53169018	C/T	cg01802117	chr1:53393560	SCP2	0.45	5.27	0.43	5.74e-7	Monocyte count;
TGCT	cis	rs4268898	0.697	rs6714652	chr2:24383059	C/T	cg02683114	chr2:24398427	C2orf84	0.2	4.79	0.4	4.63e-6	Asthma;
TGCT	cis	rs6598955	0.671	rs7417505	chr1:26575523	A/G	cg04990556	chr1:26633338	UBXN11	0.62	4.73	0.39	6.12e-6	Obesity-related traits;
TGCT	cis	rs2980439	0.807	rs2980438	chr8:8094825	T/C	cg08975724	chr8:8085496	FLJ10661	0.63	5.94	0.47	2.72e-8	Neuroticism;
TGCT	cis	rs9397585	0.667	rs9479509	chr6:153427265	G/A	cg24028809	chr6:153414101	RGS17	0.23	4.92	0.4	2.69e-6	Body mass index;
TGCT	cis	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg18252515	chr7:66147081	NA	-1.31	-8.18	-0.59	2.87e-13	Diabetic kidney disease;
TGCT	cis	rs9611519	0.566	rs4821981	chr22:41415644	A/C	cg03806693	chr22:41940476	POLR3H	0.64	6.09	0.48	1.29e-8	Neuroticism;
TGCT	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg03517284	chr6:25882590	NA	-0.65	-6.72	-0.52	5.87e-10	Blood metabolite levels;
TGCT	cis	rs12497850	0.931	rs9311434	chr3:48884147	T/C	cg07636037	chr3:49044803	WDR6	0.95	10.74	0.69	2e-19	Parkinson's disease;
TGCT	cis	rs11671005	0.735	rs12981649	chr19:58930043	G/C	cg13877915	chr19:58951672	ZNF132	0.63	4.99	0.41	1.95e-6	Mean platelet volume;
TGCT	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg07061783	chr6:25882402	NA	-0.6	-5.59	-0.45	1.35e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2486012	0.737	rs2906465	chr1:44323736	T/C	cg12908607	chr1:44402522	ARTN	-0.72	-5.68	-0.45	8.89e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs4253772	0.550	rs6008615	chr22:46707928	G/A	cg24881330	chr22:46731750	TRMU	1.04	5.41	0.44	3.12e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs6424115	0.830	rs2502993	chr1:24201262	A/G	cg15997130	chr1:24165203	NA	0.85	9.25	0.64	8.02e-16	Immature fraction of reticulocytes;
TGCT	cis	rs6785206	0.614	rs73198879	chr3:128542368	T/G	cg25356066	chr3:128598488	ACAD9	-0.91	-4.79	-0.4	4.69e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs4285028	0.747	rs1128163	chr3:121350573	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.93	-7.34	-0.55	2.49e-11	Multiple sclerosis;
TGCT	cis	rs2050392	0.929	rs10826798	chr10:30700904	G/A	cg13289132	chr10:30722225	MAP3K8	0.36	4.47	0.37	1.72e-5	Inflammatory bowel disease;
TGCT	cis	rs9916302	0.904	rs13341996	chr17:37536862	C/T	cg07936489	chr17:37558343	FBXL20	0.65	5.08	0.41	1.36e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg25737836	chr21:47705150	C21orf57;MCM3AP	0.2	4.55	0.38	1.28e-5	Testicular germ cell tumor;
TGCT	cis	rs13396424	0.639	rs2711302	chr2:46220888	A/G	cg04380228	chr2:47142555	MCFD2	0.7	4.76	0.39	5.38e-6	Metabolite levels  (X-11787);
TGCT	cis	rs11190604	1.000	rs10786596	chr10:102282126	C/A	cg16342193	chr10:102329863	NA	-0.42	-5.37	-0.43	3.72e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7617773	0.563	rs13082269	chr3:48392274	G/A	cg11946769	chr3:48343235	NME6	0.59	4.91	0.4	2.83e-6	Coronary artery disease;
TGCT	cis	rs7586879	0.616	rs10206196	chr2:25137323	T/C	cg01884057	chr2:25150051	NA	0.35	6.84	0.52	3.21e-10	Body mass index;
TGCT	cis	rs28595532	0.748	rs55949457	chr4:119336174	A/G	cg21605333	chr4:119757512	SEC24D	0.85	5.43	0.44	2.84e-7	Cannabis dependence symptom count;
TGCT	cis	rs28595532	0.920	rs116401323	chr4:119721727	C/T	cg14228332	chr4:119757509	SEC24D	1.38	6.91	0.53	2.21e-10	Cannabis dependence symptom count;
TGCT	cis	rs3733585	0.699	rs4588456	chr4:9963895	A/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.67	-0.51	7.44e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs908922	0.887	rs7535188	chr1:152475899	G/A	cg20991723	chr1:152506922	NA	0.47	6.38	0.5	3.23e-9	Hair morphology;
TGCT	cis	rs28785552	0.536	rs7246050	chr19:53248632	T/C	cg10871876	chr19:53194124	ZNF83	0.47	5.9	0.47	3.24e-8	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs3733585	0.577	rs5014939	chr4:9953253	T/A	cg00071950	chr4:10020882	SLC2A9	-0.55	-6.46	-0.5	2.12e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg08859206	chr1:53392774	SCP2	-0.41	-6.12	-0.48	1.12e-8	Monocyte count;
TGCT	cis	rs4319547	0.741	rs4758663	chr12:122939483	A/G	cg23029597	chr12:123009494	RSRC2	-0.27	-4.44	-0.37	1.99e-5	Body mass index;
TGCT	cis	rs3849570	0.695	rs9830445	chr3:81508063	T/G	cg07356753	chr3:81810745	GBE1	0.57	4.72	0.39	6.25e-6	Waist circumference;Body mass index;
TGCT	cis	rs3772130	1.000	rs3772128	chr3:121345094	G/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.55	4.95	0.41	2.32e-6	Cognitive performance;
TGCT	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg21016266	chr12:122356598	WDR66	0.53	6.61	0.51	1.04e-9	Mean corpuscular volume;
TGCT	cis	rs11105298	0.891	rs6538189	chr12:89885923	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.7	-5.02	-0.41	1.79e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs67460515	0.892	rs13059340	chr3:161062631	T/C	cg03342759	chr3:160939853	NMD3	-0.51	-5.49	-0.44	2.14e-7	Parkinson's disease;
TGCT	cis	rs7666738	0.791	rs1830231	chr4:99026185	A/C	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7586879	0.521	rs7597332	chr2:25075675	A/G	cg01884057	chr2:25150051	NA	0.3	5.61	0.45	1.26e-7	Body mass index;
TGCT	cis	rs1878931	0.507	rs67218524	chr16:3403057	G/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.66	-5.22	-0.42	7.21e-7	Body mass index (adult);
TGCT	cis	rs3020736	0.500	rs1801311	chr22:42486723	G/A	cg15557168	chr22:42548783	NA	0.22	5.58	0.45	1.47e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs3091242	0.900	rs1883427	chr1:25744468	C/T	cg23205692	chr1:25664452	TMEM50A	0.52	5.34	0.43	4.2e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg22105103	chr4:187893119	NA	0.35	5.08	0.41	1.38e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9393777	0.513	rs3999471	chr6:26650306	T/C	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.53	-4.88	-0.4	3.19e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9308731	0.842	rs56173510	chr2:111928436	G/T	cg04202892	chr2:111875749	ACOXL	0.45	4.94	0.41	2.44e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs1997103	1.000	rs2331067	chr7:55408232	A/T	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs7829975	0.509	rs7838674	chr8:8797073	A/T	cg15556689	chr8:8085844	FLJ10661	-0.69	-6.14	-0.48	1.01e-8	Mood instability;
TGCT	cis	rs6688613	0.759	rs61815132	chr1:166920911	A/G	cg07049167	chr1:166818506	POGK	0.25	5.23	0.42	7.11e-7	Refractive astigmatism;
TGCT	cis	rs986417	0.818	rs8014133	chr14:61104738	A/G	cg27398547	chr14:60952738	C14orf39	1.45	9.82	0.66	3.5e-17	Gut microbiota (bacterial taxa);
TGCT	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg11890956	chr21:40555474	PSMG1	-0.73	-6.98	-0.53	1.59e-10	Menarche (age at onset);
TGCT	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg15921436	chr17:44337874	NA	0.53	7.54	0.56	8.43e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	trans	rs1814175	0.791	rs11040472	chr11:49703116	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.38	-7.6	-0.56	6.14e-12	Height;
TGCT	cis	rs9611565	0.918	rs9538	chr22:41755857	G/T	cg06481639	chr22:41940642	POLR3H	-0.74	-6.51	-0.5	1.71e-9	Vitiligo;
TGCT	cis	rs9913156	0.517	rs11868227	chr17:4614539	G/A	cg19197139	chr17:4613644	ARRB2	0.63	5.81	0.46	4.96e-8	Lymphocyte counts;
TGCT	cis	rs6988636	1.000	rs10096350	chr8:124184470	T/C	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs9303401	0.659	rs11079358	chr17:56920949	G/T	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs1729951	0.575	rs747842	chr3:136703121	A/C	cg12473912	chr3:136751656	NA	0.39	6.18	0.49	8.36e-9	Neuroticism;
TGCT	cis	rs6542838	0.611	rs6742047	chr2:99531460	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.56	-5.27	-0.43	5.77e-7	Fear of minor pain;
TGCT	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg08280861	chr8:58055591	NA	0.42	4.82	0.4	4.15e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs654950	0.934	rs662999	chr1:42001160	A/C	cg06885757	chr1:42089581	HIVEP3	0.28	4.53	0.38	1.35e-5	Airway imaging phenotypes;
TGCT	cis	rs9811920	0.609	rs793501	chr3:99591638	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.58	-6.55	-0.51	1.35e-9	Axial length;
TGCT	cis	rs7666738	0.830	rs10021044	chr4:99002488	A/T	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs56235845	0.694	rs11748912	chr5:176765395	G/A	cg17509989	chr5:176798049	RGS14	0.55	7.58	0.56	6.89e-12	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs4851254	0.961	rs6713524	chr2:100747357	A/G	cg04109781	chr2:100722022	AFF3	0.42	4.5	0.37	1.53e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs2688608	0.592	rs12253482	chr10:75496130	G/A	cg19442545	chr10:75533431	FUT11	-0.37	-5.82	-0.46	4.69e-8	Inflammatory bowel disease;
TGCT	trans	rs17684571	0.938	rs35619924	chr6:56560666	T/C	cg14229071	chr15:89282588	NA	0.51	6.79	0.52	4.04e-10	Schizophrenia;
TGCT	cis	rs9399135	0.967	rs4896123	chr6:135295410	T/G	cg24558204	chr6:135376177	HBS1L	0.48	4.79	0.39	4.76e-6	Red blood cell count;
TGCT	trans	rs57221529	0.766	rs72703075	chr5:592819	C/T	cg11887960	chr12:57824829	NA	1.2	9.53	0.65	1.75e-16	Lung disease severity in cystic fibrosis;
TGCT	cis	rs7100689	0.646	rs10788562	chr10:82072310	C/T	cg01528321	chr10:82214614	TSPAN14	-0.75	-7.56	-0.56	7.74e-12	Post bronchodilator FEV1;
TGCT	cis	rs765787	0.530	rs11636367	chr15:45535862	A/G	cg24006582	chr15:45444508	DUOX1	-0.25	-5.54	-0.45	1.76e-7	Uric acid levels;
TGCT	cis	rs2153535	0.580	rs1932276	chr6:8442593	G/A	cg07606381	chr6:8435919	SLC35B3	0.57	5.25	0.43	6.46e-7	Motion sickness;
TGCT	cis	rs11644362	1.000	rs976243	chr16:12991679	A/T	cg06890432	chr16:12997467	SHISA9	-0.6	-6.73	-0.52	5.59e-10	Positive affect;Subjective well-being;
TGCT	cis	rs1008375	0.544	rs56227066	chr4:17565713	G/A	cg16339924	chr4:17578868	LAP3	0.57	4.84	0.4	3.71e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg10819733	chr22:24237672	NA	-0.28	-4.59	-0.38	1.09e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9296092	0.560	rs9469502	chr6:33526648	G/A	cg13560919	chr6:33536144	NA	-0.23	-5.06	-0.41	1.49e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg20203395	chr5:56204925	C5orf35	0.55	5.18	0.42	8.85e-7	Initial pursuit acceleration;
TGCT	cis	rs9467773	0.620	rs2494716	chr6:26662736	T/C	cg09904177	chr6:26538194	HMGN4	0.68	6.27	0.49	5.41e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs6032067	0.673	rs13039345	chr20:43895932	G/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.45	-6.75	-0.52	4.97e-10	Blood protein levels;
TGCT	cis	rs12477438	0.765	rs9710648	chr2:99673129	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-4.62	-0.38	9.47e-6	Chronic sinus infection;
TGCT	cis	rs950776	0.752	rs62010327	chr15:78892784	G/A	cg06917634	chr15:78832804	PSMA4	0.65	5.07	0.41	1.41e-6	Sudden cardiac arrest;
TGCT	cis	rs9296092	0.517	rs62405949	chr6:33522800	G/A	cg13560919	chr6:33536144	NA	-0.2	-4.64	-0.38	8.68e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs9467773	0.620	rs9295701	chr6:26627508	T/C	cg26531700	chr6:26746687	NA	0.5	4.68	0.39	7.52e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs350251	0.868	rs350232	chr16:12190947	G/C	cg01574788	chr16:12184133	SNX29	0.41	5.24	0.43	6.57e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7267979	1.000	rs4815426	chr20:25405186	A/C	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs8073060	0.785	rs11659054	chr17:33867678	C/T	cg19694781	chr19:47549865	TMEM160	0.45	8.13	0.59	3.84e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs8077577	0.848	rs12600694	chr17:18091019	C/T	cg09161412	chr17:18057145	MYO15A	-0.6	-4.99	-0.41	2.02e-6	Obesity-related traits;
TGCT	cis	rs9807989	0.801	rs6734742	chr2:102967857	C/T	cg09003973	chr2:102972529	NA	0.69	6.22	0.49	6.84e-9	Asthma;
TGCT	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg03264133	chr6:25882463	NA	0.67	6.3	0.49	4.73e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg26531700	chr6:26746687	NA	-0.57	-5.21	-0.42	7.62e-7	Autism spectrum disorder or schizophrenia;
TGCT	trans	rs208515	0.525	rs10944868	chr6:66687508	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.92	10.09	0.67	7.45e-18	Exhaled nitric oxide levels;
TGCT	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg03806693	chr22:41940476	POLR3H	1.15	13.16	0.76	2.69e-25	Vitiligo;
TGCT	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg05368731	chr17:41323189	NBR1	1.2	14.48	0.79	1.98e-28	Menopause (age at onset);
TGCT	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg06896619	chr17:61851486	DDX42;CCDC47	-0.47	-4.54	-0.38	1.32e-5	Prudent dietary pattern;
TGCT	cis	rs6460942	1.000	rs117657017	chr7:12318891	T/C	cg06484146	chr7:12443880	VWDE	-0.55	-4.56	-0.38	1.22e-5	Coronary artery disease;
TGCT	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg25767906	chr1:53392781	SCP2	-0.61	-7.41	-0.55	1.74e-11	Monocyte count;
TGCT	cis	rs4919669	0.668	rs10883740	chr10:104334822	A/C	cg05855489	chr10:104503620	C10orf26	0.7	4.44	0.37	1.94e-5	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg11644478	chr21:40555479	PSMG1	1.03	11.02	0.7	4.14e-20	Cognitive function;
TGCT	cis	rs11190604	0.767	rs35508946	chr10:102191156	A/G	cg23241863	chr10:102295624	HIF1AN	0.62	4.79	0.4	4.69e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs11098499	0.874	rs6822498	chr4:120120183	T/C	cg09307838	chr4:120376055	NA	0.5	4.64	0.38	8.86e-6	Corneal astigmatism;
TGCT	cis	rs6912958	0.535	rs242283	chr6:88030931	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.44	5.76	0.46	6.31e-8	Monocyte percentage of white cells;
TGCT	cis	rs4689388	0.926	rs10937717	chr4:6295087	T/A	cg00701064	chr4:6280414	WFS1	0.39	4.92	0.4	2.72e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs1008375	1.000	rs2159584	chr4:17620568	G/A	cg18681998	chr4:17616180	MED28	1.01	11.3	0.71	8.54e-21	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs651907	0.557	rs36002990	chr3:101437862	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.87	10.21	0.68	3.89e-18	Colorectal cancer;
TGCT	cis	rs7917772	0.582	rs7899004	chr10:104341435	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.56	-5.47	-0.44	2.4e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2729354	0.953	rs2649663	chr11:57357305	C/T	cg24343310	chr11:57249947	NA	0.28	4.89	0.4	3.04e-6	Blood protein levels;
TGCT	cis	rs7582180	0.614	rs1030901	chr2:101007314	G/A	cg14675211	chr2:100938903	LONRF2	0.5	4.81	0.4	4.21e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1008375	1.000	rs10019856	chr4:17615742	T/A	cg16339924	chr4:17578868	LAP3	0.74	6.0	0.47	2.02e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg06481639	chr22:41940642	POLR3H	0.6	5.48	0.44	2.23e-7	Vitiligo;
TGCT	cis	rs13217239	0.646	rs12209886	chr6:26984757	G/A	cg26531700	chr6:26746687	NA	0.68	6.79	0.52	4.1e-10	Schizophrenia;
TGCT	cis	rs858239	0.669	rs6461688	chr7:23116615	G/A	cg05602783	chr7:23145260	KLHL7	-0.63	-5.39	-0.44	3.47e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs7552404	1.000	rs1498312	chr1:76177849	C/T	cg22875332	chr1:76189707	ACADM	0.79	9.77	0.66	4.68e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9468186	1	rs9468186	chr6:27626631	A/G	cg26587870	chr6:27730563	NA	-0.26	-4.48	-0.37	1.69e-5	Neuroticism;
TGCT	cis	rs6450176	0.904	rs4351101	chr5:53300591	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.53	-5.1	-0.42	1.23e-6	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs6671200	1.000	rs259354	chr1:95718205	T/C	cg26537280	chr1:95699037	RWDD3	-0.7	-5.55	-0.45	1.62e-7	Stearic acid (18:0) levels;
TGCT	cis	rs7428	0.527	rs7607284	chr2:85547376	C/G	cg03728395	chr2:85555865	TGOLN2	-0.31	-5.17	-0.42	9.27e-7	Ear protrusion;
TGCT	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	6.03	0.48	1.72e-8	Bipolar disorder;
TGCT	cis	rs7085104	0.700	rs6163	chr10:104596924	C/A	cg04362960	chr10:104952993	NT5C2	0.57	5.05	0.41	1.54e-6	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg14827481	chr10:134361889	INPP5A	-0.29	-4.69	-0.39	7.09e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs950027	1.000	rs950027	chr15:45801035	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.47	-5.04	-0.41	1.6e-6	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg03452623	chr4:187889614	NA	-0.34	-4.94	-0.41	2.46e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9443645	0.901	rs9448588	chr6:79590061	T/G	cg05283184	chr6:79620031	NA	-0.22	-4.98	-0.41	2.11e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7474896	0.537	rs1022449	chr10:38279467	T/A	cg13720705	chr10:37990370	NA	-0.35	-4.73	-0.39	5.99e-6	Obesity (extreme);
TGCT	cis	rs9948	0.786	rs62152765	chr2:97440420	G/A	cg01990225	chr2:97406019	LMAN2L	-0.88	-4.81	-0.4	4.37e-6	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs6728642	1.000	rs113934577	chr2:97888047	G/A	cg26665480	chr2:98280029	ACTR1B	-0.97	-4.85	-0.4	3.69e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	cis	rs17152411	1.000	rs7077936	chr10:126650065	C/T	cg07906193	chr10:126599966	NA	0.37	4.64	0.38	8.78e-6	Height;
TGCT	cis	rs11650494	0.710	rs11654557	chr17:47390136	A/G	cg08112188	chr17:47440006	ZNF652	1.04	5.35	0.43	4.09e-7	Prostate cancer;
TGCT	cis	rs57590327	0.504	rs13065281	chr3:81693550	G/A	cg07356753	chr3:81810745	GBE1	-0.76	-6.9	-0.53	2.43e-10	Extraversion;
TGCT	cis	rs6977660	0.714	rs1468287	chr7:19784210	T/A	cg07541023	chr7:19748670	TWISTNB	0.83	4.69	0.39	7.01e-6	Thyroid stimulating hormone;
TGCT	cis	rs9914544	0.545	rs8069826	chr17:18765490	G/T	cg26378065	chr17:18585709	ZNF286B	0.52	4.5	0.37	1.56e-5	Educational attainment (years of education);
TGCT	cis	rs1371867	0.846	rs1788197	chr8:101290928	T/C	cg00191853	chr8:101177733	SPAG1	-0.23	-4.8	-0.4	4.44e-6	Atrioventricular conduction;
TGCT	cis	rs11578119	0.866	rs12132288	chr1:170366441	A/G	cg09767346	chr1:170501363	GORAB	0.63	4.82	0.4	4.09e-6	Male-pattern baldness;
TGCT	cis	rs42648	0.869	rs12374728	chr7:89941884	T/C	cg25739043	chr7:89950458	NA	-0.73	-7.31	-0.55	2.83e-11	Homocysteine levels;
TGCT	cis	rs6582630	0.555	rs2090785	chr12:38424342	G/A	cg26384229	chr12:38710491	ALG10B	0.84	7.7	0.57	3.77e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs727505	0.954	rs59379598	chr7:124596903	C/G	cg23710748	chr7:124431027	NA	-0.26	-4.55	-0.38	1.27e-5	Lewy body disease;
TGCT	cis	rs6570726	0.577	rs399502	chr6:145805874	A/G	cg23711669	chr6:146136114	FBXO30	0.71	6.52	0.51	1.62e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3766606	0.505	rs60057745	chr1:7946819	G/A	cg26816564	chr1:7831052	VAMP3	0.64	4.98	0.41	2.05e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg03609598	chr5:56110824	MAP3K1	-0.58	-4.66	-0.39	8.17e-6	Initial pursuit acceleration;
TGCT	cis	rs736408	0.812	rs746694	chr3:52826620	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	4.92	0.4	2.72e-6	Bipolar disorder;
TGCT	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.93	7.44	0.56	1.44e-11	Platelet count;
TGCT	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg05872129	chr22:39784769	NA	-0.86	-9.51	-0.65	1.92e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs12497850	0.829	rs12636030	chr3:49182237	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.38	-4.81	-0.4	4.25e-6	Parkinson's disease;
TGCT	cis	rs3749237	0.595	rs7621003	chr3:49411404	T/C	cg02487422	chr3:49467188	NICN1	0.59	6.01	0.47	1.92e-8	Resting heart rate;
TGCT	cis	rs881375	1.000	rs10760121	chr9:123647915	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.38	4.45	0.37	1.92e-5	Rheumatoid arthritis;
TGCT	trans	rs28595532	0.748	rs113336496	chr4:119336957	C/T	cg26518628	chr1:97050305	NA	-0.56	-6.79	-0.52	4.19e-10	Cannabis dependence symptom count;
TGCT	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg06238570	chr21:40685208	BRWD1	0.59	5.1	0.42	1.23e-6	Cognitive function;
TGCT	cis	rs3749237	0.964	rs35210174	chr3:49812606	C/T	cg07636037	chr3:49044803	WDR6	0.64	5.63	0.45	1.13e-7	Resting heart rate;
TGCT	trans	rs9951602	0.512	rs8089247	chr18:76651467	C/A	cg02800362	chr5:177631904	HNRNPAB	1.15	13.03	0.76	5.64e-25	Obesity-related traits;
TGCT	cis	rs453301	0.686	rs7017868	chr8:8873293	G/A	cg11995313	chr8:8860691	ERI1	0.51	4.46	0.37	1.84e-5	Joint mobility (Beighton score);
TGCT	cis	rs9467711	0.516	rs1165163	chr6:25863487	G/C	cg03517284	chr6:25882590	NA	-0.73	-4.85	-0.4	3.62e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7258465	0.931	rs271629	chr19:18623198	G/A	cg06462663	chr19:18546047	ISYNA1	0.2	4.67	0.39	7.74e-6	Breast cancer;
TGCT	cis	rs3806843	0.576	rs246063	chr5:140324492	T/A	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7937682	0.602	rs503905	chr11:111390762	G/C	cg09085632	chr11:111637200	PPP2R1B	-0.67	-6.3	-0.49	4.63e-9	Primary sclerosing cholangitis;
TGCT	cis	rs2115630	0.653	rs61394864	chr15:85170174	T/C	cg12863693	chr15:85201151	NMB	-0.4	-5.46	-0.44	2.47e-7	P wave terminal force;
TGCT	cis	rs11190604	1.000	rs35106985	chr10:102307542	T/C	cg16342193	chr10:102329863	NA	-0.4	-5.06	-0.41	1.48e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9303401	0.659	rs34556735	chr17:56694447	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs4711350	0.911	rs9461907	chr6:33726990	A/C	cg18005901	chr6:33739558	LEMD2	-0.46	-4.96	-0.41	2.27e-6	Schizophrenia;
TGCT	cis	rs10493773	0.894	rs12067749	chr1:86197922	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.42	-5.58	-0.45	1.46e-7	Urate levels in overweight individuals;
TGCT	cis	rs587847	0.737	rs1520950	chr15:37667807	C/T	cg00216138	chr15:37171175	LOC145845	0.31	4.45	0.37	1.91e-5	Intraocular pressure;
TGCT	cis	rs2251381	0.722	rs2251278	chr21:30529234	A/G	cg24692254	chr21:30365293	RNF160	0.76	7.08	0.54	9.5e-11	Selective IgA deficiency;
TGCT	cis	rs7666738	0.830	rs13133619	chr4:99067312	C/G	cg17366294	chr4:99064904	C4orf37	-0.7	-7.08	-0.54	9.29e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg07424592	chr7:64974309	NA	-1.31	-7.72	-0.57	3.33e-12	Diabetic kidney disease;
TGCT	cis	rs651907	0.535	rs35810977	chr3:101531380	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	4.82	0.4	4.05e-6	Colorectal cancer;
TGCT	cis	rs28595532	0.920	rs114683212	chr4:119760209	A/G	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs4733781	0.509	rs1158569	chr8:131331012	A/C	cg16277922	chr8:131349729	ASAP1	0.53	8.77	0.62	1.15e-14	Tuberculosis;
TGCT	cis	rs2692947	0.655	rs60090597	chr2:96406266	G/A	cg23100626	chr2:96804247	ASTL	0.37	4.49	0.37	1.62e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs10782582	0.609	rs78556436	chr1:76352875	G/A	cg03433033	chr1:76189801	ACADM	-0.5	-4.95	-0.41	2.39e-6	Daytime sleep phenotypes;
TGCT	cis	rs1008375	0.966	rs2872957	chr4:17651757	C/A	cg16339924	chr4:17578868	LAP3	0.67	5.55	0.45	1.68e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs651907	0.557	rs34947019	chr3:101532235	C/T	cg12386194	chr3:101231763	SENP7	0.45	4.45	0.37	1.87e-5	Colorectal cancer;
TGCT	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg08280861	chr8:58055591	NA	0.49	5.26	0.43	6.19e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs11098499	0.863	rs59732491	chr4:120489588	G/C	cg09307838	chr4:120376055	NA	0.68	6.47	0.5	2.02e-9	Corneal astigmatism;
TGCT	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg26338869	chr17:61819248	STRADA	-0.53	-4.87	-0.4	3.29e-6	Prudent dietary pattern;
TGCT	cis	rs7178572	0.568	rs62008452	chr15:77591007	A/G	cg15453836	chr15:77711506	NA	-0.42	-4.79	-0.4	4.68e-6	Type 2 diabetes;
TGCT	trans	rs214785	0.790	rs6075877	chr20:2261782	A/G	cg24980040	chr10:1714535	ADARB2	0.45	6.75	0.52	4.95e-10	Basal cell carcinoma;
TGCT	cis	rs2404602	0.716	rs12440815	chr15:76627328	C/A	cg22467129	chr15:76604101	ETFA	-0.6	-7.44	-0.56	1.45e-11	Blood metabolite levels;
TGCT	cis	rs739496	0.615	rs640783	chr12:112168050	A/G	cg10833066	chr12:111807467	FAM109A	0.36	5.06	0.41	1.46e-6	Platelet count;
TGCT	cis	rs9527	0.640	rs6584541	chr10:104929124	A/G	cg04362960	chr10:104952993	NT5C2	0.65	5.59	0.45	1.36e-7	Arsenic metabolism;
TGCT	cis	rs7662987	0.517	rs2602877	chr4:100039847	T/A	cg12011299	chr4:100065546	ADH4	0.42	4.94	0.41	2.44e-6	Smoking initiation;
TGCT	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg22963979	chr7:1858916	MAD1L1	-0.36	-5.64	-0.45	1.1e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs12477438	0.508	rs2516832	chr2:99771268	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	13.05	0.76	4.93e-25	Chronic sinus infection;
TGCT	cis	rs4906332	1.000	rs12892062	chr14:103883512	A/G	cg26031613	chr14:104095156	KLC1	-0.51	-4.63	-0.38	9.17e-6	Coronary artery disease;
TGCT	cis	rs11252926	0.574	rs7068976	chr10:453112	A/G	cg18196295	chr10:418757	DIP2C	0.29	4.73	0.39	5.91e-6	Psychosis in Alzheimer's disease;
TGCT	cis	rs10504229	0.861	rs60346509	chr8:58196050	G/T	cg22535103	chr8:58192502	C8orf71	-0.39	-4.62	-0.38	9.61e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs12711979	0.509	rs13005405	chr2:3826324	C/T	cg17052675	chr2:3827356	NA	-0.55	-12.72	-0.75	3.04e-24	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	6.23	0.49	6.56e-9	Bipolar disorder;
TGCT	cis	rs3733585	0.624	rs7376154	chr4:9952587	C/A	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.65	-0.57	4.78e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs10791097	0.720	rs6590516	chr11:130733393	G/T	cg05962950	chr11:130786565	SNX19	0.89	11.06	0.7	3.3e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs3796352	0.892	rs35076015	chr3:53026366	C/T	cg15956490	chr3:53032818	SFMBT1	0.62	6.82	0.52	3.6e-10	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs4730250	0.554	rs17428504	chr7:106914944	T/C	cg02696742	chr7:106810147	HBP1	-0.72	-5.29	-0.43	5.34e-7	Osteoarthritis;
TGCT	cis	rs10779751	0.881	rs2744815	chr1:11360957	C/T	cg08854313	chr1:11322531	MTOR	0.77	8.73	0.62	1.45e-14	Body mass index;
TGCT	cis	rs6087990	0.735	rs6058892	chr20:31388461	C/T	cg13636640	chr20:31349939	DNMT3B	0.97	12.84	0.76	1.63e-24	Ulcerative colitis;
TGCT	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg03264133	chr6:25882463	NA	-0.52	-5.38	-0.44	3.53e-7	Blood metabolite levels;
TGCT	cis	rs7607369	0.637	rs17462630	chr2:219286541	C/G	cg02176678	chr2:219576539	TTLL4	-0.5	-6.57	-0.51	1.27e-9	Red blood cell count;Amyotrophic lateral sclerosis;
TGCT	cis	rs9372253	0.678	rs6568644	chr6:110707820	C/T	cg00083206	chr6:110721305	DDO	-0.36	-5.22	-0.42	7.2e-7	Platelet distribution width;
TGCT	cis	rs2180341	0.960	rs7753913	chr6:127671296	A/G	cg24812749	chr6:127587940	RNF146	1.01	7.62	0.56	5.59e-12	Breast cancer;
TGCT	cis	rs11626933	1.000	rs3742669	chr14:90767746	C/A	cg14092571	chr14:90743983	NA	0.31	6.54	0.51	1.42e-9	Gut microbiota (bacterial taxa);
TGCT	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg22963979	chr7:1858916	MAD1L1	-0.42	-6.64	-0.51	9.01e-10	Schizophrenia;
TGCT	cis	rs12950390	0.893	rs11079789	chr17:45849715	A/G	cg24803719	chr17:45855879	NA	-0.47	-4.75	-0.39	5.6e-6	IgG glycosylation;
TGCT	cis	rs877529	0.625	rs713841	chr22:39529029	A/G	cg18708252	chr22:39545030	CBX7	-0.36	-5.18	-0.42	8.55e-7	Multiple myeloma;
TGCT	cis	rs9985766	0.958	rs7659009	chr4:150992596	T/C	cg05926478	chr4:151174724	DCLK2	-0.24	-4.64	-0.38	8.63e-6	Coronary artery disease;Myocardial infarction;
TGCT	cis	rs61931739	0.517	rs12815556	chr12:34319670	G/A	cg06521331	chr12:34319734	NA	-0.3	-4.45	-0.37	1.87e-5	Morning vs. evening chronotype;
TGCT	cis	rs8180040	1.000	rs807810	chr3:47403892	G/A	cg27129171	chr3:47204927	SETD2	-0.7	-8.88	-0.62	6.43e-15	Colorectal cancer;
TGCT	cis	rs7267979	0.780	rs6050679	chr20:25537827	A/T	cg16686733	chr20:25566563	NINL	0.53	5.17	0.42	9.02e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1348850	0.793	rs6734528	chr2:178493731	G/A	cg22681709	chr2:178499509	PDE11A	-0.47	-5.67	-0.45	9.41e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg10047753	chr17:41438598	NA	0.84	7.61	0.56	5.9e-12	Menopause (age at onset);
TGCT	cis	rs6901250	0.851	rs9374624	chr6:117145837	A/C	cg12892004	chr6:117198278	RFX6	0.55	6.79	0.52	4.21e-10	C-reactive protein levels;
TGCT	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg03188948	chr7:1209495	NA	0.5	5.32	0.43	4.65e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg22433210	chr17:43662623	NA	1.06	7.46	0.56	1.32e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs79149102	0.579	rs73438569	chr15:75354486	T/A	cg09165964	chr15:75287851	SCAMP5	-1.15	-6.31	-0.49	4.4e-9	Lung cancer;
TGCT	cis	rs1865760	0.593	rs2097273	chr6:25941310	A/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.63	6.66	0.51	8.14e-10	Height;
TGCT	cis	rs7552404	1.000	rs942270	chr1:76177332	G/A	cg03433033	chr1:76189801	ACADM	0.82	9.72	0.66	6.06e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs62244186	0.566	rs55852922	chr3:44826188	A/G	cg04389838	chr3:44770851	ZNF501	-0.37	-4.76	-0.39	5.25e-6	Depressive symptoms;
TGCT	cis	rs9436747	0.667	rs12033452	chr1:66038435	C/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.55	5.18	0.42	8.81e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	trans	rs4332037	0.539	rs62444881	chr7:2052318	C/T	cg10840412	chr1:235813424	GNG4	0.97	6.99	0.53	1.47e-10	Bipolar disorder;
TGCT	cis	rs77741769	0.571	rs12831094	chr12:121292704	T/C	cg02419362	chr12:121203948	SPPL3	0.19	4.5	0.37	1.58e-5	Mean corpuscular volume;
TGCT	trans	rs2624839	0.704	rs2624833	chr3:50212512	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.81	7.08	0.54	9.41e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs12477438	0.561	rs2084988	chr2:99655755	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-4.62	-0.38	9.47e-6	Chronic sinus infection;
TGCT	cis	rs11085466	1.000	rs2292986	chr19:21776332	A/C	cg02997983	chr19:21646781	NA	0.6	4.74	0.39	5.72e-6	Colorectal or endometrial cancer;
TGCT	cis	rs7666738	0.830	rs17550735	chr4:99014076	T/G	cg18180107	chr4:99064573	C4orf37	0.54	5.03	0.41	1.7e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9549260	0.564	rs4943804	chr13:41269994	A/G	cg21288729	chr13:41239152	FOXO1	0.94	9.15	0.63	1.47e-15	Red blood cell count;
TGCT	cis	rs910316	1.000	rs876403	chr14:75602834	A/T	cg23033748	chr14:75592666	NEK9	0.29	4.93	0.4	2.61e-6	Height;
TGCT	cis	rs651907	0.557	rs3806654	chr3:101396529	G/C	cg11279151	chr3:101281821	RG9MTD1	-0.34	-7.08	-0.54	9.37e-11	Colorectal cancer;
TGCT	cis	rs2948294	0.566	rs13274039	chr8:8111659	A/G	cg15556689	chr8:8085844	FLJ10661	0.76	6.22	0.49	6.92e-9	Red cell distribution width;
TGCT	cis	rs617219	0.710	rs2607142	chr5:78557948	T/C	cg23514016	chr5:78407564	BHMT	0.32	4.87	0.4	3.38e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs7937682	1.000	rs505372	chr11:111507189	A/C	cg09085632	chr11:111637200	PPP2R1B	-1.02	-9.92	-0.67	1.98e-17	Primary sclerosing cholangitis;
TGCT	cis	rs1997103	0.863	rs2140916	chr7:55403154	A/C	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs35146811	0.586	rs12666107	chr7:99778019	G/C	cg22906224	chr7:99728672	NA	0.52	4.55	0.38	1.24e-5	Coronary artery disease;
TGCT	cis	rs377070	0.816	rs309416	chr4:123621916	T/C	cg10495464	chr4:123653540	BBS12;LOC729338	0.44	4.85	0.4	3.6e-6	Mosquito bite size;
TGCT	cis	rs933688	1.000	rs2059207	chr5:90731931	C/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.01	9.89	0.66	2.31e-17	Smoking behavior;
TGCT	cis	rs17750015	0.733	rs7506986	chr18:54404558	C/T	cg18434998	chr18:54306185	TXNL1	-0.53	-5.18	-0.42	8.85e-7	Depression and alcohol dependence;
TGCT	cis	rs9527	0.668	rs7092815	chr10:104736345	G/T	cg04362960	chr10:104952993	NT5C2	0.66	5.45	0.44	2.58e-7	Arsenic metabolism;
TGCT	cis	rs7666738	0.830	rs11941844	chr4:99042722	A/T	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6840360	0.571	rs4696276	chr4:152532682	G/A	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.0	-0.58	7.69e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs9381040	0.610	rs6940462	chr6:41020223	G/A	cg03526776	chr6:41159608	TREML2	0.27	5.27	0.43	5.78e-7	Alzheimer's disease (late onset);
TGCT	trans	rs1005277	0.505	rs200936	chr10:38134935	T/C	cg17830980	chr10:43048298	ZNF37B	-0.72	-8.22	-0.59	2.27e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs4776059	0.916	rs2414161	chr15:52883285	T/C	cg25063058	chr15:52860530	ARPP19	0.53	4.78	0.39	4.84e-6	Schizophrenia;
TGCT	cis	rs617219	0.671	rs12189188	chr5:78552312	C/T	cg09550809	chr5:78407562	BHMT	0.4	5.49	0.44	2.19e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs9467711	1.000	rs6939978	chr6:26328462	G/C	cg03264133	chr6:25882463	NA	-0.82	-4.48	-0.37	1.65e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7914558	0.966	rs11191518	chr10:104782853	C/G	cg15744005	chr10:104629667	AS3MT	-0.38	-4.69	-0.39	7.04e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs7568458	0.709	rs11895399	chr2:85753806	C/A	cg02493740	chr2:85810744	VAMP5	-0.29	-5.7	-0.46	8.09e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs9322193	0.884	rs10872647	chr6:150079823	T/C	cg13206674	chr6:150067644	NUP43	0.52	4.51	0.38	1.46e-5	Lung cancer;
TGCT	cis	rs7614311	0.681	rs6809100	chr3:63901180	A/G	cg22134162	chr3:63841271	THOC7	-0.4	-5.19	-0.42	8.38e-7	Lung function (FVC);Lung function (FEV1);
TGCT	trans	rs3780486	0.846	rs6476402	chr9:33148552	G/A	cg20290983	chr6:43655470	MRPS18A	1.14	14.03	0.78	2.25e-27	IgG glycosylation;
TGCT	cis	rs10832963	1.000	rs4757676	chr11:18640477	C/T	cg09201001	chr11:18656081	SPTY2D1	1.05	11.63	0.72	1.34e-21	Breast cancer;
TGCT	cis	rs4664308	0.875	rs2124969	chr2:160989486	T/C	cg03641300	chr2:160917029	PLA2R1	-0.27	-6.79	-0.52	4.08e-10	Idiopathic membranous nephropathy;
TGCT	cis	rs6840360	0.642	rs11726254	chr4:152438850	G/C	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.82e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs9650657	0.615	rs11986845	chr8:10691318	T/C	cg16664915	chr8:10907788	XKR6	-0.29	-4.51	-0.38	1.5e-5	Neuroticism;
TGCT	cis	rs11098499	0.863	rs7695620	chr4:120452776	G/A	cg09307838	chr4:120376055	NA	0.69	6.53	0.51	1.49e-9	Corneal astigmatism;
TGCT	cis	rs9985766	0.958	rs76947074	chr4:150996295	G/A	cg05926478	chr4:151174724	DCLK2	-0.24	-4.64	-0.38	8.63e-6	Coronary artery disease;Myocardial infarction;
TGCT	cis	rs12681287	0.752	rs13255058	chr8:87287445	G/A	cg27223183	chr8:87520930	FAM82B	-0.82	-5.86	-0.47	3.98e-8	Caudate activity during reward;
TGCT	trans	rs2469997	1.000	rs2470003	chr8:120357482	C/T	cg01792902	chr3:178864926	PIK3CA	0.83	6.77	0.52	4.49e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs6558530	0.666	rs11136422	chr8:1695909	T/C	cg09410841	chr8:1729607	CLN8	0.67	6.0	0.47	2.05e-8	Systolic blood pressure;
TGCT	cis	rs2197308	0.634	rs11173475	chr12:38086665	G/C	cg26384229	chr12:38710491	ALG10B	0.63	5.62	0.45	1.2e-7	Morning vs. evening chronotype;
TGCT	cis	rs4851266	1.000	rs4851268	chr2:100825864	C/T	cg07810366	chr2:100720526	AFF3	-0.38	-5.44	-0.44	2.7e-7	Educational attainment;
TGCT	cis	rs2463822	0.844	rs7104149	chr11:62171627	A/G	cg06239285	chr11:62104954	ASRGL1	-0.79	-5.22	-0.42	7.43e-7	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs9325144	0.555	rs4882279	chr12:38688918	C/A	cg26384229	chr12:38710491	ALG10B	0.66	6.12	0.48	1.11e-8	Morning vs. evening chronotype;
TGCT	cis	rs3820068	0.580	rs61169376	chr1:16003832	A/G	cg05660106	chr1:15850417	CASP9	0.66	5.93	0.47	2.8e-8	Systolic blood pressure;
TGCT	cis	rs700651	0.821	rs700690	chr2:198727626	A/G	cg00792783	chr2:198669748	PLCL1	0.56	5.08	0.42	1.35e-6	Intracranial aneurysm;
TGCT	cis	rs9388451	0.839	rs3799709	chr6:126078361	A/G	cg10911889	chr6:126070802	HEY2	0.53	5.52	0.44	1.88e-7	Brugada syndrome;
TGCT	cis	rs2486288	0.656	rs12915314	chr15:45551491	C/G	cg26924012	chr15:45694286	SPATA5L1	-0.72	-7.46	-0.56	1.34e-11	Glomerular filtration rate;
TGCT	cis	rs74233809	0.786	rs11191564	chr10:104878543	C/T	cg05855489	chr10:104503620	C10orf26	0.82	4.44	0.37	1.97e-5	Birth weight;
TGCT	cis	rs9611565	0.559	rs132765	chr22:42008068	A/G	cg17554472	chr22:41940697	POLR3H	0.5	5.35	0.43	4.07e-7	Vitiligo;
TGCT	cis	rs2982552	0.873	rs1999805	chr6:152068364	G/A	cg22157087	chr6:152012887	ESR1	0.2	4.77	0.39	5e-6	Bone properties (heel);
TGCT	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg00343986	chr7:65444356	GUSB	-0.23	-5.16	-0.42	9.66e-7	Aortic root size;
TGCT	cis	rs9362426	0.608	rs6940716	chr6:88142979	A/G	cg10919329	chr6:88182879	SLC35A1	-0.6	-4.52	-0.38	1.4e-5	Depressive episodes in bipolar disorder;
TGCT	cis	rs7666738	0.830	rs7673385	chr4:99024922	T/G	cg17366294	chr4:99064904	C4orf37	0.72	7.54	0.56	8.52e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7772486	0.875	rs1929523	chr6:146339989	T/A	cg05347473	chr6:146136440	FBXO30	0.56	5.29	0.43	5.34e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs909002	0.772	rs12740754	chr1:32083273	G/C	cg11573219	chr1:32083031	HCRTR1	-0.45	-5.86	-0.47	3.83e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs394563	0.559	rs13219868	chr6:149686518	T/G	cg11245181	chr6:149772854	ZC3H12D	0.28	4.48	0.37	1.7e-5	Dupuytren's disease;
TGCT	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg11644478	chr21:40555479	PSMG1	-0.64	-5.91	-0.47	3.02e-8	Cognitive function;
TGCT	cis	rs2455799	0.613	rs11128762	chr3:15883439	C/T	cg16303742	chr3:15540471	COLQ	-0.25	-4.73	-0.39	6.09e-6	Mean platelet volume;
TGCT	trans	rs1973993	0.691	rs2985636	chr1:96889884	T/A	cg10631902	chr5:14652156	NA	0.4	10.91	0.7	7.68e-20	Weight;
TGCT	cis	rs28595532	0.920	rs114611353	chr4:119736607	C/T	cg14228332	chr4:119757509	SEC24D	1.31	7.06	0.54	1.06e-10	Cannabis dependence symptom count;
TGCT	cis	rs1322512	1.000	rs1744369	chr6:152946531	T/A	cg03415253	chr6:152958462	SYNE1	-0.57	-4.99	-0.41	2e-6	Tonometry;
TGCT	cis	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg25427524	chr10:38739819	LOC399744	0.4	7.63	0.57	5.31e-12	Extrinsic epigenetic age acceleration;
TGCT	cis	rs17401966	1.000	rs2229687	chr1:10473196	C/T	cg19773385	chr1:10388646	KIF1B	-0.23	-5.42	-0.44	2.97e-7	Hepatocellular carcinoma;
TGCT	cis	rs7731657	0.537	rs112876284	chr5:130293884	G/C	cg08523029	chr5:130500466	HINT1	-0.58	-4.84	-0.4	3.8e-6	Fasting plasma glucose;
TGCT	cis	rs9297145	0.678	rs62473007	chr7:98749598	G/C	cg05967295	chr7:98741636	SMURF1	1.01	12.87	0.76	1.33e-24	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs8111998	0.826	rs10421310	chr19:22768069	G/A	cg19914732	chr19:22715077	NA	-0.56	-4.51	-0.38	1.46e-5	Corneal structure;
TGCT	cis	rs6840360	0.593	rs2089811	chr4:152685171	C/T	cg22705602	chr4:152727874	NA	0.34	5.94	0.47	2.71e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg00343986	chr7:65444356	GUSB	-0.26	-6.12	-0.48	1.15e-8	Aortic root size;
TGCT	cis	rs4242434	0.757	rs2280104	chr8:22525980	C/T	cg03733263	chr8:22462867	KIAA1967	1.03	15.98	0.82	6.64e-32	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs8077889	0.672	rs1234612	chr17:41840802	A/G	cg26893861	chr17:41843967	DUSP3	1.12	19.55	0.87	1.08e-39	Triglycerides;
TGCT	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs3806843	1.000	rs7710794	chr5:140209467	T/G	cg19875535	chr5:140030758	IK	0.35	5.86	0.47	3.93e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9303401	0.659	rs62083525	chr17:56658088	A/G	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs9788721	0.806	rs72738704	chr15:78719832	G/C	cg18825076	chr15:78729989	IREB2	-0.34	-5.25	-0.43	6.28e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
TGCT	cis	rs67478160	0.619	rs11623546	chr14:104269098	A/G	cg26031613	chr14:104095156	KLC1	-0.64	-6.58	-0.51	1.2e-9	Schizophrenia;
TGCT	cis	rs11190604	1.000	rs2489053	chr10:102353341	A/G	cg16342193	chr10:102329863	NA	-0.41	-4.82	-0.4	4.1e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs3820928	0.874	rs2177593	chr2:227833869	G/A	cg11843606	chr2:227700838	RHBDD1	-0.52	-4.58	-0.38	1.1e-5	Pulmonary function;
TGCT	cis	rs858239	0.704	rs466240	chr7:23338774	C/T	cg05602783	chr7:23145260	KLHL7	0.57	4.66	0.39	8.07e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs6504950	0.720	rs2877634	chr17:52987545	A/G	cg07707039	chr17:53042137	COX11	0.26	4.47	0.37	1.71e-5	Breast cancer;
TGCT	cis	rs2120019	1.000	rs2415253	chr15:75375699	A/G	cg11632617	chr15:75315747	PPCDC	-0.33	-4.78	-0.39	4.82e-6	Blood trace element (Zn levels);
TGCT	cis	rs9611519	0.780	rs1535048	chr22:41684093	C/T	cg06634786	chr22:41940651	POLR3H	-0.64	-5.76	-0.46	6.22e-8	Neuroticism;
TGCT	cis	rs7727544	0.684	rs274546	chr5:131699867	A/G	cg24060327	chr5:131705240	SLC22A5	-0.61	-6.61	-0.51	1.04e-9	Blood metabolite levels;
TGCT	cis	rs734999	0.588	rs10910098	chr1:2533250	C/A	cg18854424	chr1:2615690	NA	0.44	5.1	0.42	1.22e-6	Ulcerative colitis;
TGCT	cis	rs12950390	0.853	rs4793647	chr17:45854090	G/C	cg24803719	chr17:45855879	NA	-0.5	-5.05	-0.41	1.51e-6	IgG glycosylation;
TGCT	cis	rs9910055	0.530	rs2269905	chr17:42294462	A/G	cg13607699	chr17:42295918	UBTF	0.97	11.16	0.71	1.87e-20	Total body bone mineral density;
TGCT	cis	rs10782582	0.593	rs11802717	chr1:76124648	C/T	cg03433033	chr1:76189801	ACADM	-0.63	-7.27	-0.55	3.6e-11	Daytime sleep phenotypes;
TGCT	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg06896619	chr17:61851486	DDX42;CCDC47	0.51	5.0	0.41	1.9e-6	Prudent dietary pattern;
TGCT	cis	rs806215	1.000	rs712704	chr7:127258208	A/G	cg25922125	chr7:127225783	GCC1	-0.62	-6.46	-0.5	2.14e-9	Type 2 diabetes;
TGCT	cis	rs4555082	0.834	rs2735826	chr14:105710866	G/A	cg01266790	chr14:105781312	PACS2	0.55	4.49	0.37	1.58e-5	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs2721195	0.719	rs4925812	chr8:145808035	C/T	cg17328964	chr8:145687451	CYHR1	-0.42	-5.51	-0.44	1.99e-7	Age at first birth;
TGCT	cis	rs12220238	0.554	rs11001029	chr10:76154777	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.9	6.17	0.48	9.08e-9	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs6582630	0.502	rs1115515	chr12:38279830	C/T	cg26384229	chr12:38710491	ALG10B	0.86	7.48	0.56	1.19e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs2224391	1.000	rs9784870	chr6:5261359	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.79	-6.05	-0.48	1.61e-8	Height;
TGCT	cis	rs7917772	0.582	rs10883744	chr10:104347247	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	5.36	0.43	3.84e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9894429	1.000	rs4074915	chr17:79579230	G/A	cg21028142	chr17:79581711	NPLOC4	-0.29	-6.81	-0.52	3.83e-10	Eye color traits;
TGCT	cis	rs4820792	0.725	rs7289973	chr22:29121760	G/C	cg03733026	chr22:29445468	ZNRF3	0.25	4.89	0.4	3.01e-6	Breast size;
TGCT	cis	rs1949733	0.656	rs2688243	chr4:8436286	A/G	cg11789530	chr4:8429930	ACOX3	0.58	5.2	0.42	8.11e-7	Response to antineoplastic agents;
TGCT	cis	rs514406	0.825	rs12089511	chr1:53436427	A/T	cg08736216	chr1:53307985	ZYG11A	0.29	5.93	0.47	2.8e-8	Monocyte count;
TGCT	cis	rs288326	0.561	rs17265894	chr2:183858168	A/G	cg09997497	chr2:183902928	NCKAP1	1.11	4.95	0.41	2.38e-6	Blood protein levels;
TGCT	cis	rs6138458	0.626	rs6138473	chr20:25012155	A/G	cg26195577	chr20:24973756	C20orf3	-0.89	-6.8	-0.52	3.86e-10	Blood protein levels;
TGCT	cis	rs778371	0.748	rs2675953	chr2:233749565	G/C	cg08000102	chr2:233561755	GIGYF2	-0.6	-6.42	-0.5	2.62e-9	Schizophrenia;
TGCT	cis	rs7267979	1.000	rs2500405	chr20:25360826	A/G	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3796352	1.000	rs7622420	chr3:53111069	A/G	cg07884673	chr3:53033167	SFMBT1	0.54	6.2	0.49	7.73e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs62380364	0.774	rs55740951	chr5:88153874	C/T	cg22951263	chr5:87985283	NA	-0.47	-4.49	-0.37	1.58e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs78707713	0.560	rs61848398	chr10:71226103	G/A	cg14388049	chr10:71211838	TSPAN15	-0.39	-4.68	-0.39	7.52e-6	Venous thromboembolism;
TGCT	cis	rs669446	0.828	rs656131	chr1:44129099	C/T	cg12908607	chr1:44402522	ARTN	0.46	4.96	0.41	2.25e-6	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs886126	0.950	rs2078851	chr12:111690579	C/T	cg10833066	chr12:111807467	FAM109A	-0.33	-5.67	-0.45	9.38e-8	Coronary heart disease;
TGCT	cis	rs9486719	1.000	rs2472897	chr6:96870569	G/T	cg18709589	chr6:96969512	KIAA0776	0.71	5.21	0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs2840044	1.000	rs9891800	chr17:33895015	G/C	cg05299278	chr17:33885742	SLFN14	-0.23	-5.32	-0.43	4.65e-7	Response to radiotherapy in cancer (late toxicity);
TGCT	cis	rs7647973	0.667	rs4241405	chr3:49642027	C/T	cg03060546	chr3:49711283	APEH	0.63	5.14	0.42	1.03e-6	Menarche (age at onset);
TGCT	cis	rs6964587	1.000	rs35653487	chr7:91745441	C/G	cg17063962	chr7:91808500	NA	0.88	9.42	0.65	3.2e-16	Breast cancer;
TGCT	trans	rs57221529	0.766	rs72704799	chr5:551457	C/G	cg25482853	chr8:67687455	SGK3	1.2	9.5	0.65	2.01e-16	Lung disease severity in cystic fibrosis;
TGCT	cis	rs2862064	1.000	rs6555787	chr5:156433699	T/C	cg12943317	chr5:156479607	HAVCR1	-0.45	-5.77	-0.46	5.83e-8	Platelet count;
TGCT	cis	rs79349575	0.783	rs4793991	chr17:47001801	A/G	cg26022315	chr17:47021804	SNF8	0.49	4.89	0.4	3.03e-6	Type 2 diabetes;
TGCT	cis	rs12477438	0.520	rs13004491	chr2:99738008	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	17.43	0.84	3.73e-35	Chronic sinus infection;
TGCT	cis	rs62244186	0.715	rs11130032	chr3:44704083	G/A	cg04389838	chr3:44770851	ZNF501	-0.39	-5.11	-0.42	1.18e-6	Depressive symptoms;
TGCT	cis	rs290268	0.874	rs290988	chr9:93562955	C/G	cg02608019	chr9:93564028	SYK	0.44	4.44	0.37	1.94e-5	Platelet count;
TGCT	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg23758822	chr17:41437982	NA	0.69	6.37	0.5	3.34e-9	Menopause (age at onset);
TGCT	cis	rs7172809	0.599	rs74026910	chr15:77728444	G/C	cg22256960	chr15:77711686	NA	-0.51	-4.87	-0.4	3.32e-6	Glucose homeostasis traits;
TGCT	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg00814883	chr7:100076585	TSC22D4	-0.82	-8.37	-0.6	1.03e-13	Platelet count;
TGCT	cis	rs3935685	0.874	rs11072663	chr15:77999542	A/G	cg25212270	chr15:78015279	NA	0.26	5.55	0.45	1.66e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg13206674	chr6:150067644	NUP43	0.52	4.46	0.37	1.78e-5	Lung cancer;
TGCT	cis	rs709400	0.628	rs7154246	chr14:103876794	G/A	cg26031613	chr14:104095156	KLC1	-0.83	-9.19	-0.64	1.17e-15	Body mass index;
TGCT	cis	rs28595532	0.920	rs116612909	chr4:119749823	C/T	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs10875746	0.903	rs4760681	chr12:48505230	C/T	cg20731937	chr12:48336164	NA	0.62	4.94	0.41	2.46e-6	Longevity (90 years and older);
TGCT	cis	rs7224685	0.515	rs7207986	chr17:3979949	G/A	cg09580393	chr17:4869866	SPAG7	-0.39	-4.5	-0.37	1.56e-5	Type 2 diabetes;
TGCT	trans	rs2624839	0.704	rs1046956	chr3:50222926	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.78	-7.03	-0.53	1.24e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg24531977	chr5:56204891	C5orf35	-0.87	-7.03	-0.53	1.22e-10	Initial pursuit acceleration;
TGCT	cis	rs9400467	0.537	rs12215291	chr6:111463520	A/G	cg15721981	chr6:111408429	SLC16A10	0.68	4.48	0.37	1.69e-5	Blood metabolite levels;Amino acid levels;
TGCT	cis	rs1218582	0.651	rs4845396	chr1:154828409	A/G	cg09359103	chr1:154839909	KCNN3	0.5	7.51	0.56	1.01e-11	Prostate cancer;
TGCT	cis	rs79976124	0.837	rs11751994	chr6:66644028	A/C	cg07460842	chr6:66804631	NA	0.57	5.22	0.42	7.44e-7	Type 2 diabetes;
TGCT	cis	rs7833790	0.654	rs6415652	chr8:82702257	G/A	cg27398817	chr8:82754497	SNX16	-0.62	-4.76	-0.39	5.33e-6	Diastolic blood pressure;
TGCT	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg05025164	chr4:1340916	KIAA1530	-0.83	-7.15	-0.54	6.74e-11	Longevity;
TGCT	cis	rs57590327	0.503	rs6764261	chr3:81620370	T/G	cg07356753	chr3:81810745	GBE1	-0.62	-5.24	-0.43	6.69e-7	Extraversion;
TGCT	cis	rs6490294	0.748	rs73422316	chr12:112273674	G/A	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Mean platelet volume;
TGCT	cis	rs447921	0.861	rs117544870	chr17:74415206	T/G	cg09812376	chr17:74270190	QRICH2	-0.46	-4.6	-0.38	1.01e-5	Mitochondrial DNA levels;
TGCT	cis	rs2594989	0.895	rs2606739	chr3:11394611	C/A	cg00170343	chr3:11313890	ATG7	0.68	5.13	0.42	1.1e-6	Circulating chemerin levels;
TGCT	cis	rs854765	0.551	rs6502626	chr17:17849450	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	7.71	0.57	3.44e-12	Total body bone mineral density;
TGCT	trans	rs797680	0.856	rs682514	chr1:93719430	A/C	cg27528825	chr2:159282178	CCDC148	0.35	6.88	0.53	2.65e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.08	0.48	1.37e-8	Bipolar disorder;
TGCT	cis	rs2721195	0.845	rs4244611	chr8:145739924	G/A	cg15320075	chr8:145703422	NA	0.7	7.04	0.53	1.17e-10	Age at first birth;
TGCT	cis	rs1534166	0.601	rs13324779	chr3:133510413	G/A	cg08048268	chr3:133502702	NA	0.45	5.58	0.45	1.44e-7	Alcohol consumption (transferrin glycosylation);
TGCT	cis	rs9916302	0.706	rs6503504	chr17:37514412	A/G	cg07936489	chr17:37558343	FBXL20	0.87	6.27	0.49	5.47e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs2760061	0.655	rs686533	chr1:228119604	A/G	cg02753203	chr1:228287806	NA	-0.35	-6.84	-0.52	3.29e-10	Diastolic blood pressure;
TGCT	cis	rs57994353	0.897	rs36101132	chr9:139367566	G/A	cg13741927	chr9:139327495	INPP5E	-0.25	-5.59	-0.45	1.38e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg19678392	chr7:94953810	PON1	-0.59	-6.69	-0.52	6.79e-10	Paraoxonase activity;
TGCT	cis	rs838147	0.537	rs485186	chr19:49207206	A/G	cg13540341	chr19:49222985	MAMSTR	-0.37	-4.91	-0.4	2.84e-6	Dietary macronutrient intake;
TGCT	cis	rs3806843	0.576	rs246041	chr5:140331128	C/G	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs17767294	0.541	rs72845051	chr6:27610545	G/A	cg08851530	chr6:28072375	NA	1.34	6.29	0.49	5.02e-9	Parkinson's disease;
TGCT	cis	rs1476679	0.962	rs34995835	chr7:99990364	T/G	cg13334819	chr7:99746414	C7orf59	0.63	5.31	0.43	4.86e-7	Alzheimer's disease (late onset);
TGCT	cis	rs7666738	0.830	rs11726604	chr4:99000969	T/C	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7586879	1.000	rs1865687	chr2:25112885	G/A	cg01884057	chr2:25150051	NA	0.28	5.03	0.41	1.69e-6	Body mass index;
TGCT	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg27286337	chr10:134555280	INPP5A	0.41	4.89	0.4	3.1e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg09359103	chr1:154839909	KCNN3	0.63	12.67	0.75	4.02e-24	Prostate cancer;
TGCT	cis	rs8180040	0.903	rs11710013	chr3:47296921	T/C	cg27129171	chr3:47204927	SETD2	0.69	8.59	0.61	3.04e-14	Colorectal cancer;
TGCT	cis	rs514406	0.893	rs6588446	chr1:53425260	G/A	cg01802117	chr1:53393560	SCP2	0.39	4.6	0.38	1.05e-5	Monocyte count;
TGCT	cis	rs10883723	0.810	rs1056857	chr10:104240003	C/T	cg05855489	chr10:104503620	C10orf26	-0.58	-5.06	-0.41	1.47e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs904251	0.861	rs1776456	chr6:37484698	C/G	cg08126542	chr6:37504118	NA	-0.43	-5.92	-0.47	2.99e-8	Cognitive performance;
TGCT	cis	rs35306767	0.903	rs11253460	chr10:887382	C/G	cg20503657	chr10:835505	NA	0.7	9.83	0.66	3.22e-17	Eosinophil percentage of granulocytes;
TGCT	cis	rs6815814	0.950	rs5743557	chr4:38806827	G/A	cg02016764	chr4:38805732	TLR1	-0.35	-5.58	-0.45	1.44e-7	Breast cancer;
TGCT	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg19536664	chr17:6899085	ALOX12	0.38	6.28	0.49	5.32e-9	Tonsillectomy;
TGCT	cis	rs7772486	0.875	rs2474356	chr6:146296798	G/A	cg05347473	chr6:146136440	FBXO30	0.56	5.33	0.43	4.4e-7	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs2727020	0.566	rs10839234	chr11:49185524	C/T	cg03929089	chr4:120376271	NA	-0.69	-7.92	-0.58	1.17e-12	Coronary artery disease;
TGCT	trans	rs9383153	1.000	rs9370888	chr6:16335544	A/G	cg26757820	chr10:76349278	ADK	0.95	7.01	0.53	1.39e-10	Gambling;
TGCT	cis	rs6071524	0.508	rs2425367	chr20:37385240	C/T	cg09937324	chr20:37376998	ACTR5	0.54	4.45	0.37	1.91e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs737008	0.960	rs949429	chr16:11376029	C/T	cg00044050	chr16:11439710	C16orf75	-0.71	-7.23	-0.54	4.44e-11	Obesity-related traits;
TGCT	cis	rs7178572	0.568	rs1602925	chr15:77685857	T/C	cg15453836	chr15:77711506	NA	-0.42	-4.78	-0.39	4.92e-6	Type 2 diabetes;
TGCT	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	8.39	0.6	9.03e-14	Platelet count;
TGCT	cis	rs4891159	0.824	rs17059362	chr18:74144307	G/A	cg24786174	chr18:74118243	ZNF516	-0.53	-6.98	-0.53	1.6e-10	Longevity;
TGCT	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg08509172	chr19:19383838	TM6SF2	-0.34	-4.48	-0.37	1.71e-5	Tonsillectomy;
TGCT	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg18876405	chr7:65276391	NA	0.35	5.2	0.42	7.81e-7	Aortic root size;
TGCT	cis	rs4455778	0.600	rs34886560	chr7:49120470	G/T	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs2191566	0.747	rs4803667	chr19:44533604	T/C	cg03039196	chr19:44506973	ZNF230	0.56	4.76	0.39	5.38e-6	Acute lymphoblastic leukemia (childhood);
TGCT	cis	rs10751667	0.666	rs6597967	chr11:950583	G/T	cg06064525	chr11:970664	AP2A2	-0.35	-8.06	-0.59	5.6e-13	Alzheimer's disease (late onset);
TGCT	cis	rs7647973	0.516	rs4955419	chr3:49200692	T/A	cg16497277	chr3:49208875	KLHDC8B	-0.54	-5.18	-0.42	8.8e-7	Menarche (age at onset);
TGCT	cis	rs3099143	1.000	rs3106375	chr15:77142243	T/C	cg21673338	chr15:77095150	SCAPER	-0.51	-4.88	-0.4	3.17e-6	Recalcitrant atopic dermatitis;
TGCT	cis	rs6969780	0.915	rs4722657	chr7:27157756	G/A	cg04317399	chr7:27170313	HOXA4	-0.44	-4.87	-0.4	3.3e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs12762955	0.561	rs6560863	chr10:1013535	C/A	cg20503657	chr10:835505	NA	-0.39	-5.04	-0.41	1.58e-6	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs2070729	0.523	rs743562	chr5:131872383	C/T	cg02551604	chr5:131831745	NA	0.47	4.53	0.38	1.39e-5	Platelet count;
TGCT	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg03517284	chr6:25882590	NA	-0.69	-7.5	-0.56	1.07e-11	Blood metabolite levels;
TGCT	cis	rs13256369	0.901	rs12679831	chr8:8566411	T/G	cg06671706	chr8:8559999	CLDN23	0.34	4.59	0.38	1.09e-5	Obesity-related traits;
TGCT	cis	rs13064411	0.696	rs2399479	chr3:113227050	G/A	cg18753928	chr3:113234510	CCDC52	-0.7	-5.61	-0.45	1.23e-7	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg04772025	chr11:68637568	NA	0.6	6.75	0.52	5.08e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7010267	0.716	rs3134065	chr8:119959921	T/C	cg17171407	chr8:119960777	TNFRSF11B	0.28	5.1	0.42	1.25e-6	Total body bone mineral density (age 45-60);
TGCT	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg07167872	chr1:205819463	PM20D1	0.55	6.99	0.53	1.47e-10	Menarche (age at onset);
TGCT	cis	rs6141769	0.542	rs6058845	chr20:31323919	G/T	cg13636640	chr20:31349939	DNMT3B	0.52	4.55	0.38	1.26e-5	Subjective well-being;
TGCT	cis	rs10484885	0.824	rs112817281	chr6:90555658	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.47	-4.58	-0.38	1.11e-5	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs477895	0.878	rs7478730	chr11:64018827	C/T	cg04317338	chr11:64019027	PLCB3	0.81	6.9	0.53	2.35e-10	Mean platelet volume;
TGCT	cis	rs3096299	0.967	rs2965827	chr16:89457350	A/C	cg06640241	chr16:89574553	SPG7	-0.69	-6.62	-0.51	9.72e-10	Multiple myeloma (IgH translocation);
TGCT	cis	rs9457247	1.000	rs422694	chr6:167406074	G/T	cg23791538	chr6:167370224	RNASET2	-0.49	-4.96	-0.41	2.26e-6	Crohn's disease;
TGCT	trans	rs9859260	0.710	rs34906439	chr3:195779706	A/G	cg17074656	chr11:63784126	MACROD1	0.52	6.67	0.51	7.49e-10	Mean corpuscular volume;
TGCT	cis	rs9486719	1.000	rs9400016	chr6:96940883	G/T	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.21	-0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs1997103	0.954	rs2030807	chr7:55378485	A/G	cg17469321	chr7:55412551	NA	0.66	6.94	0.53	1.92e-10	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs7267979	0.932	rs424487	chr20:25468131	C/G	cg14121845	chr20:25566513	NINL	0.49	5.36	0.43	3.83e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs13191362	1.000	rs66534429	chr6:163003322	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.57	4.94	0.41	2.45e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg20607798	chr8:58055168	NA	0.62	5.17	0.42	9.2e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs68170813	0.559	rs80153759	chr7:106944145	C/A	cg02696742	chr7:106810147	HBP1	-0.69	-5.81	-0.46	4.85e-8	Coronary artery disease;
TGCT	cis	rs9814567	1.000	rs4974483	chr3:134219001	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.93	-9.27	-0.64	7.51e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs529866	0.519	rs4451969	chr16:11383519	A/G	cg00044050	chr16:11439710	C16orf75	-0.65	-6.77	-0.52	4.53e-10	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg26513180	chr16:89883248	FANCA	1.04	14.77	0.8	4.11e-29	Vitiligo;
TGCT	trans	rs1814175	0.817	rs6486046	chr11:49997017	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.36	-7.14	-0.54	6.88e-11	Height;
TGCT	cis	rs7666738	1.000	rs13144055	chr4:99026849	A/G	cg17366294	chr4:99064904	C4orf37	0.76	7.12	0.54	7.6e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs17001868	0.527	rs9611324	chr22:40781162	T/C	cg07138101	chr22:40742427	ADSL	0.71	5.38	0.44	3.55e-7	Mammographic density (dense area);
TGCT	cis	rs2762353	0.845	rs35720558	chr6:25784800	A/C	cg03264133	chr6:25882463	NA	0.49	5.23	0.43	7e-7	Blood metabolite levels;
TGCT	cis	rs7172809	0.548	rs79036117	chr15:77474832	G/A	cg22256960	chr15:77711686	NA	-0.49	-4.63	-0.38	9.01e-6	Glucose homeostasis traits;
TGCT	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.76	-7.09	-0.54	8.94e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs2832191	0.716	rs8132085	chr21:30501389	G/T	cg08807101	chr21:30365312	RNF160	-0.61	-5.79	-0.46	5.31e-8	Dental caries;
TGCT	cis	rs9814567	1.000	rs7374158	chr3:134270156	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.95	-9.55	-0.65	1.56e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs1348850	0.793	rs13027299	chr2:178455501	T/G	cg22681709	chr2:178499509	PDE11A	-0.45	-5.28	-0.43	5.7e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs6969780	0.841	rs2301720	chr7:27196069	A/C	cg04321618	chr7:27170880	HOXA4	-0.51	-4.46	-0.37	1.83e-5	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs6912958	0.559	rs2985039	chr6:88041757	A/G	cg10393598	chr6:87862264	NA	-0.31	-4.51	-0.38	1.5e-5	Monocyte percentage of white cells;
TGCT	cis	rs889312	0.500	rs3099460	chr5:56133748	G/C	cg24531977	chr5:56204891	C5orf35	-0.52	-5.39	-0.44	3.44e-7	Breast cancer;Breast cancer (early onset);
TGCT	cis	rs2204008	0.774	rs4534658	chr12:38246783	G/A	cg13010199	chr12:38710504	ALG10B	0.61	4.7	0.39	6.69e-6	Bladder cancer;
TGCT	cis	rs79387448	0.808	rs77518775	chr2:103237642	T/C	cg09003973	chr2:102972529	NA	0.87	5.24	0.43	6.8e-7	Gut microbiota (bacterial taxa);
TGCT	cis	rs1205863	0.915	rs1205880	chr6:11947263	T/C	cg07106625	chr6:11870215	NA	0.51	5.05	0.41	1.51e-6	Disc degeneration (lumbar);
TGCT	cis	rs62229266	0.740	rs2835233	chr21:37393582	A/G	cg08632701	chr21:37451849	NA	-0.14	-4.44	-0.37	1.99e-5	Mitral valve prolapse;
TGCT	cis	rs9303401	0.573	rs35104446	chr17:57180234	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.58	5.74	0.46	6.76e-8	Cognitive test performance;
TGCT	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg06108461	chr20:60628389	TAF4	-0.75	-11.02	-0.7	4.27e-20	Body mass index;
TGCT	cis	rs115056730	0.520	rs114113305	chr2:98189209	A/T	cg26665480	chr2:98280029	ACTR1B	-0.96	-4.48	-0.37	1.67e-5	Monocyte chemoattractant protein-3 levels;
TGCT	cis	rs2458413	0.543	rs2514658	chr8:105337871	G/A	cg13045555	chr8:105342365	NA	-0.39	-6.6	-0.51	1.05e-9	Paget's disease;
TGCT	cis	rs4906332	1.000	rs17617094	chr14:103893428	T/C	cg26031613	chr14:104095156	KLC1	-0.54	-4.82	-0.4	4.04e-6	Coronary artery disease;
TGCT	cis	rs34172651	0.517	rs11642954	chr16:24824248	G/A	cg06028605	chr16:24865363	SLC5A11	0.41	4.6	0.38	1.01e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs57244997	0.929	rs9346891	chr6:162369311	G/A	cg17173639	chr6:162384350	PARK2	-0.41	-4.53	-0.38	1.38e-5	Mosquito bite size;
TGCT	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg21862992	chr11:68658383	NA	0.46	6.4	0.5	2.89e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs6938	0.534	rs11854704	chr15:75221015	C/T	cg10253484	chr15:75165896	SCAMP2	-0.54	-4.83	-0.4	3.99e-6	Breast cancer;
TGCT	cis	rs60432013	0.584	rs3764167	chr14:23519975	A/G	cg15959986	chr14:23564790	ACIN1;C14orf119	-0.88	-4.47	-0.37	1.75e-5	Red cell distribution width;
TGCT	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg20607798	chr8:58055168	NA	0.49	4.67	0.39	7.56e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs3008870	0.958	rs34367328	chr1:67445321	T/C	cg03991309	chr1:68237761	GNG12	-0.27	-4.53	-0.38	1.36e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs41271951	0.512	rs76649628	chr1:151041851	A/G	cg00666978	chr1:150947442	LASS2	0.89	4.64	0.38	8.54e-6	Blood protein levels;
TGCT	cis	rs79349575	0.783	rs12603969	chr17:47034419	A/G	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.48	-0.37	1.67e-5	Type 2 diabetes;
TGCT	cis	rs1857353	1.000	rs4949855	chr1:75917162	G/T	cg11838876	chr1:75668600	SLC44A5	-0.51	-4.81	-0.4	4.23e-6	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs7662987	0.517	rs1453873	chr4:100022571	T/C	cg12011299	chr4:100065546	ADH4	0.4	4.82	0.4	4.07e-6	Smoking initiation;
TGCT	cis	rs10927875	1.000	rs10927875	chr1:16299312	A/G	cg21385522	chr1:16154831	NA	0.77	8.62	0.61	2.67e-14	Dilated cardiomyopathy;
TGCT	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg08859206	chr1:53392774	SCP2	0.35	4.9	0.4	2.98e-6	Monocyte count;
TGCT	cis	rs62244186	0.748	rs12635624	chr3:44678498	G/A	cg10263370	chr3:44754102	ZNF502	-0.42	-5.02	-0.41	1.78e-6	Depressive symptoms;
TGCT	cis	rs7617773	0.817	rs13059037	chr3:48287879	A/G	cg11946769	chr3:48343235	NME6	0.76	6.67	0.51	7.64e-10	Coronary artery disease;
TGCT	cis	rs80282103	0.618	rs57514701	chr10:1146169	G/A	cg08668510	chr10:1095578	IDI1	1.05	5.31	0.43	4.8e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg08280861	chr8:58055591	NA	0.36	4.91	0.4	2.77e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2153535	0.542	rs6912740	chr6:8439959	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.58	0.45	1.42e-7	Motion sickness;
TGCT	cis	rs1008375	0.864	rs4698196	chr4:17574735	T/C	cg10189774	chr4:17578691	LAP3	0.6	4.97	0.41	2.17e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9640161	0.659	rs17837498	chr7:150009679	A/G	cg17279839	chr7:150038598	RARRES2	0.42	4.45	0.37	1.88e-5	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs2762353	0.574	rs4409177	chr6:25694491	T/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.75	7.75	0.57	2.9e-12	Blood metabolite levels;
TGCT	cis	rs1008375	1.000	rs2215450	chr4:17675394	T/G	cg18681998	chr4:17616180	MED28	0.93	10.58	0.69	4.83e-19	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg24503407	chr1:205819492	PM20D1	0.42	5.16	0.42	9.41e-7	Menarche (age at onset);
TGCT	cis	rs6089584	0.566	rs6061401	chr20:60607482	G/A	cg06108461	chr20:60628389	TAF4	-0.45	-5.65	-0.45	1.04e-7	Body mass index;
TGCT	cis	rs7804356	0.651	rs56374720	chr7:26815776	G/A	cg03456212	chr7:26904342	SKAP2	-0.54	-4.6	-0.38	1.04e-5	Type 1 diabetes;
TGCT	cis	rs909674	0.731	rs6001594	chr22:39837472	C/T	cg02038168	chr22:39784481	NA	-0.72	-5.42	-0.44	3.03e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs1008375	0.932	rs11934968	chr4:17667766	A/G	cg10189774	chr4:17578691	LAP3	0.52	4.44	0.37	1.96e-5	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg06873352	chr17:61820015	STRADA	-0.48	-5.56	-0.45	1.59e-7	Prudent dietary pattern;
TGCT	cis	rs13188771	0.525	rs10477735	chr5:100918100	T/C	cg17598923	chr5:101119084	NA	0.48	4.48	0.37	1.67e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs11971779	0.838	rs11764161	chr7:139115198	T/C	cg07862535	chr7:139043722	LUC7L2	0.75	5.43	0.44	2.86e-7	Diisocyanate-induced asthma;
TGCT	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg20007245	chr22:24372913	LOC391322	-0.7	-6.93	-0.53	2.09e-10	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1580019	0.713	rs2122632	chr7:32524686	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-1.0	-10.41	-0.68	1.27e-18	Cognitive ability;
TGCT	cis	rs1008375	1.000	rs10440301	chr4:17663199	G/A	cg18681998	chr4:17616180	MED28	0.95	10.44	0.68	1.1e-18	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4478037	0.822	rs9825335	chr3:33123292	A/C	cg19404215	chr3:33155277	CRTAP	0.98	5.13	0.42	1.1e-6	Major depressive disorder;
TGCT	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg27211696	chr2:191398769	TMEM194B	0.29	5.3	0.43	5.19e-7	Pulse pressure;
TGCT	cis	rs6831352	0.879	rs2851255	chr4:100042103	C/G	cg12011299	chr4:100065546	ADH4	0.42	4.92	0.4	2.74e-6	Alcohol dependence;
TGCT	cis	rs35146811	0.735	rs1727130	chr7:99811464	C/G	cg04778012	chr7:99775508	STAG3;GPC2	-0.35	-4.93	-0.41	2.55e-6	Coronary artery disease;
TGCT	cis	rs644799	0.544	rs555556	chr11:95618425	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.57	5.85	0.47	4.03e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7772486	0.754	rs4895682	chr6:146062861	G/A	cg13319975	chr6:146136371	FBXO30	0.56	4.95	0.41	2.37e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg04267008	chr7:1944627	MAD1L1	0.38	5.15	0.42	1e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs752092	1.000	rs11247277	chr15:101784664	A/G	cg19997662	chr15:101784653	CHSY1	-0.31	-5.89	-0.47	3.44e-8	Corneal structure;
TGCT	cis	rs931127	0.547	rs3886859	chr11:65458310	C/T	cg17480646	chr11:65405466	SIPA1	-0.43	-5.74	-0.46	6.76e-8	Systemic lupus erythematosus;
TGCT	cis	rs9311474	0.967	rs610060	chr3:52273421	G/A	cg07507251	chr3:52567010	NT5DC2	-0.42	-5.81	-0.46	4.94e-8	Electroencephalogram traits;
TGCT	cis	rs9660992	0.573	rs1318187	chr1:205206172	T/A	cg00857998	chr1:205179979	DSTYK	0.51	4.67	0.39	7.77e-6	Mean corpuscular volume;Mean platelet volume;
TGCT	cis	rs9926296	0.687	rs258317	chr16:89732238	C/T	cg04287289	chr16:89883240	FANCA	-0.54	-4.99	-0.41	2.01e-6	Vitiligo;
TGCT	cis	rs8020441	1.000	rs67186984	chr14:51169287	C/T	cg04730355	chr14:51134070	SAV1	0.73	6.02	0.48	1.84e-8	Cognitive performance;
TGCT	cis	rs1372520	0.684	rs1837891	chr4:90736131	C/G	cg14346243	chr4:90757452	SNCA	0.65	5.52	0.44	1.88e-7	Neuroticism;
TGCT	cis	rs9325144	0.505	rs826893	chr12:39100536	A/G	cg13010199	chr12:38710504	ALG10B	-0.56	-4.6	-0.38	1.04e-5	Morning vs. evening chronotype;
TGCT	cis	rs28595532	0.920	rs55806110	chr4:119742583	A/G	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs1577917	0.771	rs9353318	chr6:86231721	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.6	5.27	0.43	5.84e-7	Response to antipsychotic treatment;
TGCT	cis	rs10751667	0.666	rs7936830	chr11:959686	A/G	cg06064525	chr11:970664	AP2A2	-0.35	-8.23	-0.59	2.17e-13	Alzheimer's disease (late onset);
TGCT	cis	rs7715806	0.500	rs17563995	chr5:75007556	A/G	cg19683494	chr5:74908142	NA	0.57	5.02	0.41	1.76e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs13202913	0.581	rs12662412	chr6:151824309	T/A	cg03627880	chr6:151815985	C6orf97	-0.62	-5.56	-0.45	1.6e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs910316	0.737	rs424120	chr14:75482828	G/T	cg11812906	chr14:75593930	NEK9	-0.59	-5.59	-0.45	1.38e-7	Height;
TGCT	cis	rs11971779	0.680	rs6947215	chr7:139026638	A/G	cg07862535	chr7:139043722	LUC7L2	0.58	4.69	0.39	6.97e-6	Diisocyanate-induced asthma;
TGCT	cis	rs732765	0.734	rs10438025	chr14:75183239	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.55	-4.48	-0.37	1.71e-5	Non-small cell lung cancer;
TGCT	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg18876405	chr7:65276391	NA	0.36	5.7	0.46	8.31e-8	Aortic root size;
TGCT	cis	rs4660261	0.526	rs810680	chr1:44347856	C/T	cg12908607	chr1:44402522	ARTN	-0.66	-8.26	-0.6	1.85e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs67072384	0.901	rs11235580	chr11:72455645	G/A	cg03713592	chr11:72463424	ARAP1	-0.93	-4.66	-0.39	7.89e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs6684514	0.961	rs12029695	chr1:156299847	C/T	cg20302342	chr1:156215951	PAQR6	0.35	4.74	0.39	5.77e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs2236918	0.710	rs3094880	chr1:242020391	T/A	cg04158730	chr1:242011433	EXO1	0.56	5.14	0.42	1.05e-6	Menopause (age at onset);
TGCT	cis	rs8072100	0.967	rs4239162	chr17:45755810	G/A	cg08085267	chr17:45401833	C17orf57	-0.42	-4.6	-0.38	1.04e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg22168489	chr12:122356033	WDR66	0.2	4.73	0.39	6.08e-6	Mean corpuscular volume;
TGCT	cis	rs1205863	1.000	rs1205882	chr6:11947708	C/T	cg07106625	chr6:11870215	NA	-0.55	-5.77	-0.46	5.95e-8	Disc degeneration (lumbar);
TGCT	cis	rs587847	0.540	rs62637	chr15:37681202	C/T	cg16890051	chr15:37175029	LOC145845	-0.37	-4.44	-0.37	1.95e-5	Intraocular pressure;
TGCT	cis	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg18188782	chr20:61659543	NA	0.44	5.38	0.43	3.6e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg15691649	chr6:25882328	NA	-0.36	-4.71	-0.39	6.5e-6	Blood metabolite levels;
TGCT	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg24829409	chr8:58192753	C8orf71	-0.57	-4.72	-0.39	6.14e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2153535	0.542	rs915353	chr6:8440370	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.56	0.45	1.55e-7	Motion sickness;
TGCT	trans	rs11088226	0.681	rs9622	chr21:33951068	T/C	cg09050820	chr6:167586206	TCP10L2	0.76	7.31	0.55	2.88e-11	Gastritis;
TGCT	cis	rs28595532	0.920	rs115076001	chr4:119764346	T/G	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs911555	0.755	rs7147664	chr14:103963420	G/A	cg12935359	chr14:103987150	CKB	-0.33	-4.59	-0.38	1.07e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs77741769	0.571	rs3861797	chr12:121255334	T/C	cg02419362	chr12:121203948	SPPL3	0.19	4.49	0.37	1.63e-5	Mean corpuscular volume;
TGCT	cis	rs11577318	0.685	rs4262530	chr1:26682034	G/A	cg14210634	chr1:25870291	LDLRAP1	0.49	4.46	0.37	1.84e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs17473412	0.963	rs56006955	chr5:122718341	C/T	cg15125798	chr5:122621645	NA	-0.57	-5.13	-0.42	1.08e-6	Total body bone mineral density;
TGCT	cis	rs7100689	0.622	rs7090351	chr10:82142047	T/G	cg01528321	chr10:82214614	TSPAN14	0.79	8.14	0.59	3.57e-13	Post bronchodilator FEV1;
TGCT	cis	rs11098499	0.722	rs28713555	chr4:120251995	C/T	cg09307838	chr4:120376055	NA	0.61	5.91	0.47	3.14e-8	Corneal astigmatism;
TGCT	cis	rs6088580	0.660	rs6059893	chr20:33105897	T/G	cg08999081	chr20:33150536	PIGU	0.29	5.57	0.45	1.54e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs6545883	0.929	rs778154	chr2:61646631	T/C	cg15711740	chr2:61764176	XPO1	0.59	5.4	0.44	3.28e-7	Tuberculosis;
TGCT	cis	rs7043114	0.525	rs1053446	chr9:95146761	T/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-5.59	-0.45	1.36e-7	Height;
TGCT	cis	rs4851266	1.000	rs4851266	chr2:100818479	C/T	cg22139774	chr2:100720529	AFF3	-0.35	-5.25	-0.43	6.39e-7	Educational attainment;
TGCT	cis	rs2469997	1.000	rs2470009	chr8:120359377	T/C	cg00681363	chr8:120844660	TAF2	0.69	4.48	0.37	1.64e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs10851411	0.862	rs4923948	chr15:42826823	C/A	cg23803468	chr15:43513504	EPB42	0.29	5.38	0.43	3.6e-7	Glucose homeostasis traits;
TGCT	trans	rs12339966	0.615	rs62529425	chr9:11358789	A/G	cg03488587	chr11:64876988	C11orf2	0.3	6.92	0.53	2.12e-10	Systolic blood pressure;
TGCT	cis	rs10276381	0.901	rs73300638	chr7:28187344	A/C	cg23620719	chr7:28220237	JAZF1	0.99	5.13	0.42	1.08e-6	Crohn's disease;
TGCT	cis	rs4409675	0.576	rs7533918	chr1:28230667	G/A	cg23691781	chr1:28212827	C1orf38	0.26	5.44	0.44	2.76e-7	Corneal astigmatism;
TGCT	cis	rs7267979	1.000	rs2482928	chr20:25331530	A/G	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9914988	0.619	rs34580233	chr17:27317935	A/T	cg17523868	chr17:27313033	SEZ6	-0.58	-4.9	-0.4	2.99e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs950169	0.881	rs34117475	chr15:85108443	T/C	cg11189052	chr15:85197271	WDR73	0.77	6.42	0.5	2.68e-9	Schizophrenia;
TGCT	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg18402987	chr7:1209562	NA	0.75	6.35	0.5	3.67e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs909002	0.849	rs10798881	chr1:32101775	G/C	cg11573219	chr1:32083031	HCRTR1	-0.46	-6.05	-0.48	1.58e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7937682	0.961	rs11828343	chr11:111491322	A/G	cg09085632	chr11:111637200	PPP2R1B	0.96	9.07	0.63	2.23e-15	Primary sclerosing cholangitis;
TGCT	cis	rs7208859	0.623	rs9911490	chr17:29073013	C/T	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7769051	1.000	rs58832890	chr6:133127139	C/T	cg07930552	chr6:133119739	C6orf192	0.95	5.13	0.42	1.1e-6	Type 2 diabetes nephropathy;
TGCT	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg07507251	chr3:52567010	NT5DC2	0.51	7.63	0.57	5.48e-12	Hemoglobin concentration;
TGCT	cis	rs933688	0.938	rs10063683	chr5:90714595	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.96	8.06	0.59	5.53e-13	Smoking behavior;
TGCT	cis	rs3617	0.625	rs6769789	chr3:52874446	C/T	cg10802521	chr3:52805072	NEK4	0.62	7.17	0.54	6e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9303401	0.659	rs35564417	chr17:56718286	G/T	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs9611565	0.512	rs715498	chr22:42148467	G/A	cg03806693	chr22:41940476	POLR3H	1.02	10.49	0.69	7.92e-19	Vitiligo;
TGCT	cis	rs7119	0.679	rs12902698	chr15:77809010	A/C	cg27398640	chr15:77910606	LINGO1	-0.25	-4.52	-0.38	1.45e-5	Type 2 diabetes;
TGCT	cis	rs9300255	0.602	rs1716160	chr12:123700225	C/T	cg00376283	chr12:123451042	ABCB9	0.73	5.67	0.45	9.46e-8	Neutrophil percentage of white cells;
TGCT	cis	rs17712049	0.908	rs9639997	chr7:48201016	G/A	cg16849860	chr7:48352531	ABCA13	0.32	5.26	0.43	6.19e-7	Refractive astigmatism;
TGCT	cis	rs709400	0.894	rs10143293	chr14:104063014	G/A	cg26031613	chr14:104095156	KLC1	1.14	15.24	0.81	3.31e-30	Body mass index;
TGCT	cis	rs4730250	0.707	rs257375	chr7:106799043	A/G	cg02696742	chr7:106810147	HBP1	-0.65	-5.3	-0.43	5.23e-7	Osteoarthritis;
TGCT	cis	rs2762353	0.639	rs566530	chr6:25878361	T/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.43	-4.85	-0.4	3.65e-6	Blood metabolite levels;
TGCT	cis	rs910316	0.737	rs175424	chr14:75626257	T/C	cg11812906	chr14:75593930	NEK9	-0.64	-5.91	-0.47	3.14e-8	Height;
TGCT	cis	rs4888262	0.526	rs7205992	chr16:74590578	T/A	cg01733217	chr16:74700730	RFWD3	0.71	7.11	0.54	7.94e-11	Testicular germ cell tumor;
TGCT	cis	rs2549003	1.000	rs10214312	chr5:131821866	T/G	cg00255919	chr5:131827918	IRF1	0.2	4.65	0.39	8.22e-6	Asthma (sex interaction);
TGCT	cis	rs5769765	0.865	rs4824108	chr22:50271428	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.41	-6.13	-0.48	1.08e-8	Schizophrenia;
TGCT	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg21724239	chr8:58056113	NA	0.41	4.87	0.4	3.33e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs17433780	0.808	rs7541867	chr1:89513537	G/A	cg09516651	chr1:89888402	LOC400759	0.26	4.94	0.41	2.48e-6	Carotid intima media thickness;
TGCT	cis	rs909674	0.514	rs7423	chr22:39781429	C/T	cg24399712	chr22:39784796	NA	-1.04	-13.31	-0.77	1.21e-25	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs7246657	0.943	rs13343471	chr19:37932130	A/G	cg18154014	chr19:37997991	ZNF793	0.94	6.29	0.49	4.95e-9	Coronary artery calcification;
TGCT	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg04772025	chr11:68637568	NA	0.61	6.7	0.52	6.38e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs3784262	0.631	rs4646584	chr15:58305402	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.42	-6.17	-0.48	8.83e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	trans	rs9951602	0.512	rs7234283	chr18:76640552	T/G	cg02800362	chr5:177631904	HNRNPAB	1.13	12.94	0.76	9.39e-25	Obesity-related traits;
TGCT	cis	rs7917772	0.503	rs56219824	chr10:104302337	C/T	cg05855489	chr10:104503620	C10orf26	-0.58	-5.06	-0.41	1.47e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9581857	0.547	rs7336332	chr13:28058404	A/G	cg22138327	chr13:27999177	GTF3A	0.75	4.96	0.41	2.24e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs7809950	1.000	rs7778270	chr7:107224667	A/G	cg23024343	chr7:107201750	COG5	0.33	5.23	0.42	7.11e-7	Coronary artery disease;
TGCT	cis	rs1420338	0.837	rs17753041	chr7:34176925	G/A	cg01275685	chr7:34179230	BMPER	-0.28	-5.0	-0.41	1.88e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs4925386	0.840	rs6143035	chr20:60920700	C/T	cg24112000	chr20:60950667	NA	0.37	4.44	0.37	1.97e-5	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs60154123	0.505	rs76101197	chr1:210044089	T/C	cg04352962	chr1:209979756	IRF6	0.69	4.73	0.39	6.04e-6	Coronary artery disease;
TGCT	cis	rs7412746	0.658	rs4970987	chr1:150949682	T/C	cg04414720	chr1:150670196	GOLPH3L	0.38	4.55	0.38	1.25e-5	Melanoma;
TGCT	cis	rs17221829	0.703	rs10765229	chr11:89392575	T/G	cg02982614	chr11:89391479	FOLH1B	-0.25	-4.46	-0.37	1.8e-5	Anxiety in major depressive disorder;
TGCT	cis	rs11190604	1.000	rs11190541	chr10:102203071	A/G	cg16342193	chr10:102329863	NA	-0.4	-5.31	-0.43	4.85e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs6426558	0.537	rs648877	chr1:227283614	A/G	cg10327440	chr1:227177885	CDC42BPA	0.61	7.42	0.55	1.59e-11	Neutrophil percentage of white cells;
TGCT	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg05872129	chr22:39784769	NA	-0.97	-8.79	-0.62	1.03e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs17345786	0.817	rs11720560	chr3:101328484	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.44	-9.51	-0.65	1.94e-16	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs4650994	0.816	rs2811301	chr1:178594196	T/C	cg05059571	chr16:84539110	KIAA1609	0.41	7.51	0.56	1e-11	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs751728	1.000	rs4711351	chr6:33754592	G/A	cg13859433	chr6:33739653	LEMD2	-0.39	-7.23	-0.54	4.25e-11	Crohn's disease;
TGCT	cis	rs2067615	0.579	rs4385986	chr12:107133775	C/T	cg15890332	chr12:107067104	RFX4	0.3	5.93	0.47	2.85e-8	Heart rate;
TGCT	cis	rs611744	0.967	rs859788	chr8:109227570	A/G	cg21045802	chr8:109455806	TTC35	0.52	4.72	0.39	6.21e-6	Dupuytren's disease;
TGCT	cis	rs10782582	0.609	rs112205173	chr1:76310100	C/T	cg03433033	chr1:76189801	ACADM	-0.5	-4.98	-0.41	2.11e-6	Daytime sleep phenotypes;
TGCT	cis	rs9611565	0.570	rs12159188	chr22:42121125	A/T	cg13695892	chr22:41940480	POLR3H	0.87	8.74	0.62	1.33e-14	Vitiligo;
TGCT	cis	rs6076065	0.748	rs2424542	chr20:23386800	C/T	cg11657817	chr20:23433608	CST11	0.31	5.42	0.44	3.02e-7	Facial morphology (factor 15, philtrum width);
TGCT	cis	rs9916302	0.904	rs4795355	chr17:37427382	C/T	cg15445000	chr17:37608096	MED1	0.32	4.69	0.39	7.11e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7826238	0.601	rs2979206	chr8:8345581	G/C	cg15556689	chr8:8085844	FLJ10661	0.6	5.55	0.45	1.62e-7	Systolic blood pressure;
TGCT	cis	rs7267979	1.000	rs6037099	chr20:25356876	T/G	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs651907	0.535	rs9830943	chr3:101428899	T/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.87	9.88	0.66	2.44e-17	Colorectal cancer;
TGCT	cis	rs6725041	0.766	rs13415721	chr2:213092242	C/T	cg16329650	chr2:213403929	ERBB4	-0.53	-4.52	-0.38	1.44e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs10883723	0.810	rs10883728	chr10:104269301	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.83	-9.13	-0.63	1.62e-15	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs7312933	0.702	rs10785333	chr12:42586470	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.55	-5.06	-0.41	1.45e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs1023500	0.573	rs8135801	chr22:42475568	A/G	cg15557168	chr22:42548783	NA	0.22	5.58	0.45	1.47e-7	Schizophrenia;
TGCT	cis	rs9640161	0.789	rs6964110	chr7:150041836	A/C	cg17279839	chr7:150038598	RARRES2	0.42	4.53	0.38	1.38e-5	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs9926296	0.744	rs6860	chr16:89711120	C/T	cg03388025	chr16:89894329	SPIRE2	-0.35	-5.05	-0.41	1.54e-6	Vitiligo;
TGCT	cis	rs7267979	1.000	rs6050566	chr20:25351071	G/A	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7582180	0.700	rs4851303	chr2:100962064	T/C	cg14675211	chr2:100938903	LONRF2	0.47	4.57	0.38	1.16e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg17554472	chr22:41940697	POLR3H	0.48	4.92	0.4	2.64e-6	Vitiligo;
TGCT	cis	rs9611565	0.512	rs4820444	chr22:42202606	A/G	cg06634786	chr22:41940651	POLR3H	0.86	8.01	0.58	7.16e-13	Vitiligo;
TGCT	cis	rs4478858	0.684	rs12121165	chr1:31725542	G/A	cg07478791	chr1:31886160	SERINC2	-0.52	-5.03	-0.41	1.67e-6	Alcohol dependence;
TGCT	cis	rs933688	1.000	rs889213	chr5:90682151	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.96	8.05	0.59	5.84e-13	Smoking behavior;
TGCT	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg12667521	chr19:29218732	NA	0.54	5.72	0.46	7.65e-8	Methadone dose in opioid dependence;
TGCT	cis	rs2354432	0.607	rs11239980	chr1:146782698	G/A	cg25205988	chr1:146714368	CHD1L	-1.34	-6.07	-0.48	1.44e-8	Mitochondrial DNA levels;
TGCT	cis	rs6665290	0.669	rs7552783	chr1:227174145	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.85	-13.09	-0.76	4.03e-25	Myeloid white cell count;
TGCT	cis	rs2832191	1.000	rs2832189	chr21:30487414	C/T	cg24692254	chr21:30365293	RNF160	-0.83	-8.71	-0.62	1.58e-14	Dental caries;
TGCT	cis	rs3806843	0.547	rs246010	chr5:140336635	A/T	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs4285028	0.948	rs76593525	chr3:121690477	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.77	-6.5	-0.5	1.78e-9	Multiple sclerosis;
TGCT	cis	rs3020736	0.519	rs5996116	chr22:42517492	G/A	cg15557168	chr22:42548783	NA	0.22	5.58	0.45	1.47e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg07747251	chr5:1868357	NA	0.39	5.58	0.45	1.47e-7	Cardiovascular disease risk factors;
TGCT	cis	rs10791323	0.519	rs329663	chr11:133754543	A/G	cg15485101	chr11:133734466	NA	0.38	5.49	0.44	2.13e-7	Childhood ear infection;
TGCT	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg26516362	chr5:178986906	RUFY1	-0.42	-4.6	-0.38	1.01e-5	Lung cancer;
TGCT	cis	rs4711350	0.954	rs1536501	chr6:33727885	C/T	cg18005901	chr6:33739558	LEMD2	0.57	5.92	0.47	2.9e-8	Schizophrenia;
TGCT	cis	rs854765	0.547	rs9896837	chr17:17924868	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.78	8.01	0.58	7.06e-13	Total body bone mineral density;
TGCT	cis	rs7666738	0.830	rs13134819	chr4:98919885	G/C	cg05340658	chr4:99064831	C4orf37	0.53	6.11	0.48	1.21e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg22920501	chr2:26401640	FAM59B	-0.82	-6.45	-0.5	2.27e-9	Gut microbiome composition (summer);
TGCT	cis	rs2820315	0.964	rs2644109	chr1:201797535	C/T	cg12730843	chr1:201915899	LMOD1	-0.27	-4.77	-0.39	5.13e-6	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
TGCT	cis	rs9859260	0.744	rs557527	chr3:195780709	G/A	cg22891161	chr3:195456627	MUC20	0.23	4.65	0.39	8.28e-6	Mean corpuscular volume;
TGCT	cis	rs2153535	0.580	rs2327061	chr6:8447231	G/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.76	0.46	6.39e-8	Motion sickness;
TGCT	cis	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg05590025	chr7:65112418	INTS4L2	-0.77	-4.5	-0.37	1.52e-5	Diabetic kidney disease;
TGCT	cis	rs13064447	0.817	rs11128611	chr3:12772365	C/G	cg20675869	chr3:12750130	NA	-0.2	-5.01	-0.41	1.79e-6	Major depression and alcohol dependence;
TGCT	cis	rs7267979	1.000	rs4813563	chr20:25365340	T/C	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs8067545	0.750	rs4005937	chr17:19959828	A/C	cg13482628	chr17:19912719	NA	0.54	4.62	0.38	9.49e-6	Schizophrenia;
TGCT	cis	rs2204008	0.522	rs117743143	chr12:38030824	C/T	cg26384229	chr12:38710491	ALG10B	0.7	6.14	0.48	1.01e-8	Bladder cancer;
TGCT	cis	rs911555	0.713	rs1107070	chr14:103970508	G/T	cg23461800	chr14:103021989	NA	-0.35	-4.55	-0.38	1.28e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs6851253	chr4:99029980	A/G	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs72781680	0.898	rs10490751	chr2:24001356	A/G	cg08917208	chr2:24149416	ATAD2B	0.81	5.01	0.41	1.8e-6	Lymphocyte counts;
TGCT	cis	rs9926296	0.681	rs12923946	chr16:89821080	C/T	cg26513180	chr16:89883248	FANCA	0.74	7.25	0.55	3.86e-11	Vitiligo;
TGCT	cis	rs67311347	1.000	rs34762643	chr3:40475433	C/T	cg13683864	chr3:40499215	RPL14	-1.04	-10.79	-0.7	1.54e-19	Renal cell carcinoma;
TGCT	cis	rs7772486	0.686	rs1292334	chr6:145968288	A/G	cg23711669	chr6:146136114	FBXO30	0.89	9.91	0.66	2.12e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg05368731	chr17:41323189	NBR1	-1.16	-14.14	-0.79	1.28e-27	Menopause (age at onset);
TGCT	cis	rs644799	1.000	rs10831431	chr11:95510089	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	11.08	0.71	2.9e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs1997103	0.954	rs940880	chr7:55392619	C/G	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.54	-5.22	-0.42	7.39e-7	Bipolar disorder;
TGCT	cis	rs7226408	0.948	rs72885219	chr18:34400995	A/T	cg06757138	chr18:34340585	FHOD3	0.26	4.79	0.4	4.62e-6	Obesity-related traits;
TGCT	cis	rs7552404	0.731	rs10732723	chr1:76392437	C/T	cg03433033	chr1:76189801	ACADM	-0.75	-7.61	-0.56	5.97e-12	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs10876993	0.890	rs1678516	chr12:58047458	G/A	cg15848620	chr12:58087721	OS9	-0.72	-5.82	-0.46	4.71e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs6964587	1.000	rs2299232	chr7:91626699	A/C	cg22709100	chr7:91322751	NA	0.27	4.46	0.37	1.84e-5	Breast cancer;
TGCT	cis	rs11785400	0.701	rs9297968	chr8:143723009	A/G	cg10596483	chr8:143751796	JRK	0.53	5.23	0.43	7.02e-7	Schizophrenia;
TGCT	cis	rs1215050	0.740	rs783949	chr4:99001933	A/G	cg17366294	chr4:99064904	C4orf37	-0.54	-5.81	-0.46	4.85e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2956278	0.678	rs10161501	chr12:84685594	A/G	cg25678815	chr12:85673915	ALX1	-0.53	-4.76	-0.39	5.4e-6	Depressive symptoms;Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2688608	1.000	rs2675680	chr10:75658864	T/C	cg02947784	chr10:75434997	AGAP5	0.16	4.52	0.38	1.4e-5	Inflammatory bowel disease;
TGCT	cis	rs11252926	0.599	rs11252213	chr10:454694	C/T	cg13477178	chr10:375248	DIP2C	-0.24	-4.46	-0.37	1.82e-5	Psychosis in Alzheimer's disease;
TGCT	cis	rs17345786	1.000	rs17345786	chr3:101318318	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.53	-4.6	-0.38	1.02e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs67311347	0.910	rs7617361	chr3:40373259	G/T	cg17264618	chr3:40429014	ENTPD3	0.3	4.47	0.37	1.72e-5	Renal cell carcinoma;
TGCT	cis	rs2197308	0.740	rs1842595	chr12:37906223	G/A	cg26384229	chr12:38710491	ALG10B	-0.7	-6.15	-0.48	9.71e-9	Morning vs. evening chronotype;
TGCT	cis	rs2201728	0.935	rs1497378	chr4:100158023	T/G	cg07219303	chr4:100140905	ADH6	-0.35	-5.22	-0.42	7.29e-7	Cardiac Troponin-T levels;
TGCT	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg00864171	chr11:67383662	NA	-0.33	-5.08	-0.41	1.35e-6	Mean corpuscular volume;
TGCT	cis	rs5769707	0.935	rs739239	chr22:50050468	G/A	cg05373962	chr22:49881684	NA	-0.32	-6.56	-0.51	1.34e-9	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs922182	0.547	rs12594348	chr15:64269127	C/T	cg02919090	chr15:64263738	DAPK2	-0.27	-4.77	-0.39	5.12e-6	Blood protein levels;
TGCT	trans	rs7618501	1.000	rs9872864	chr3:49792023	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-1.03	-13.16	-0.76	2.65e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs7657179	chr4:98948569	G/A	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs807669	0.903	rs1780640	chr22:19174597	C/T	cg02655711	chr22:19163373	SLC25A1	0.42	10.11	0.67	6.78e-18	Metabolite levels;
TGCT	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg18876405	chr7:65276391	NA	0.35	5.2	0.42	7.81e-7	Aortic root size;
TGCT	cis	rs13392177	0.660	rs62185964	chr2:219073745	A/G	cg00012203	chr2:219082015	ARPC2	-0.79	-8.02	-0.58	6.73e-13	Pyoderma gangrenosum in inflammatory bowel disease;
TGCT	cis	rs926938	0.527	rs360678	chr1:115493902	T/A	cg12756093	chr1:115239321	AMPD1	0.34	4.96	0.41	2.28e-6	Autism;
TGCT	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	5.82	0.46	4.65e-8	Bipolar disorder;
TGCT	cis	rs765787	0.530	rs4331289	chr15:45515338	C/T	cg24006582	chr15:45444508	DUOX1	-0.26	-5.59	-0.45	1.35e-7	Uric acid levels;
TGCT	cis	rs7617773	0.539	rs12486944	chr3:48390016	G/A	cg11946769	chr3:48343235	NME6	0.57	4.89	0.4	3.05e-6	Coronary artery disease;
TGCT	cis	rs7829975	0.846	rs1879957	chr8:8544808	T/C	cg15556689	chr8:8085844	FLJ10661	-0.69	-6.12	-0.48	1.11e-8	Mood instability;
TGCT	cis	rs2013441	1.000	rs2703774	chr17:20133538	C/T	cg18979559	chr17:20280153	CCDC144C	-0.45	-4.59	-0.38	1.08e-5	Obesity-related traits;
TGCT	cis	rs13217239	0.646	rs7451149	chr6:27057518	A/G	cg05738196	chr6:26577821	NA	-0.48	-4.62	-0.38	9.5e-6	Schizophrenia;
TGCT	cis	rs4332037	0.539	rs56016347	chr7:2060126	C/T	cg25834613	chr7:1915315	MAD1L1	-0.51	-4.99	-0.41	1.95e-6	Bipolar disorder;
TGCT	cis	rs289997	1.000	rs2938108	chr7:25584697	C/T	cg14064488	chr7:26331273	SNX10	-0.34	-4.74	-0.39	5.83e-6	Breast cancer;
TGCT	cis	rs10484885	0.775	rs72919985	chr6:90534641	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.47	-4.58	-0.38	1.11e-5	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs319204	0.885	rs319184	chr5:146272865	T/G	cg25021259	chr5:146258546	PPP2R2B	0.34	4.47	0.37	1.75e-5	Schizophrenia;
TGCT	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg24503407	chr1:205819492	PM20D1	0.59	8.15	0.59	3.41e-13	Menarche (age at onset);
TGCT	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg11890956	chr21:40555474	PSMG1	-0.75	-6.78	-0.52	4.36e-10	Cognitive function;
TGCT	trans	rs4710191	0.510	rs2180713	chr6:167615010	G/A	cg04222842	chr1:225965391	SRP9	0.61	6.66	0.51	8.01e-10	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs262150	0.625	rs55882200	chr7:158769280	G/C	cg01219135	chr7:158766336	NA	-0.51	-5.34	-0.43	4.25e-7	Facial morphology (factor 20);
TGCT	cis	rs644799	1.000	rs617999	chr11:95589935	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.88	10.59	0.69	4.58e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	trans	rs4650994	0.816	rs2093770	chr1:178604633	C/A	cg05059571	chr16:84539110	KIAA1609	0.41	7.63	0.57	5.38e-12	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg20637647	chr7:64974828	NA	0.89	4.95	0.41	2.37e-6	Diabetic kidney disease;
TGCT	cis	rs11209002	0.614	rs7519768	chr1:67555522	C/T	cg02640540	chr1:67518911	SLC35D1	0.56	4.66	0.39	8.05e-6	Crohn's disease;
TGCT	cis	rs2013441	1.000	rs2703774	chr17:20133538	C/T	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.44	-0.37	1.99e-5	Obesity-related traits;
TGCT	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg13732083	chr21:47605072	C21orf56	0.33	4.48	0.37	1.7e-5	Testicular germ cell tumor;
TGCT	cis	rs28595532	0.920	rs116231457	chr4:119762396	A/C	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs4555082	0.718	rs2816619	chr14:105732551	G/C	cg01266790	chr14:105781312	PACS2	0.56	4.6	0.38	1.04e-5	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs6665290	0.904	rs6426559	chr1:227195876	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.99	-20.13	-0.88	6.85e-41	Myeloid white cell count;
TGCT	cis	rs2224391	0.590	rs9405813	chr6:5251850	G/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.96	-5.44	-0.44	2.67e-7	Height;
TGCT	cis	rs12477438	0.520	rs2969379	chr2:99776686	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.05	13.31	0.77	1.16e-25	Chronic sinus infection;
TGCT	cis	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg20637647	chr7:64974828	NA	0.88	5.12	0.42	1.13e-6	Diabetic kidney disease;
TGCT	cis	rs56309584	0.673	rs11658322	chr17:8171329	T/C	cg08322244	chr17:8066669	VAMP2	-0.57	-5.31	-0.43	4.89e-7	Initial pursuit acceleration;
TGCT	cis	rs2562456	0.837	rs11085462	chr19:21750251	C/G	cg01304269	chr19:21688519	ZNF429	0.58	4.73	0.39	5.93e-6	Pain;
TGCT	cis	rs3820068	0.580	rs7556473	chr1:15996858	C/T	cg05660106	chr1:15850417	CASP9	-0.67	-6.02	-0.48	1.86e-8	Systolic blood pressure;
TGCT	cis	rs9467773	0.526	rs10946817	chr6:26364056	C/T	cg15659132	chr6:26577336	NA	-0.5	-5.05	-0.41	1.53e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7731657	0.537	rs17621442	chr5:130205555	T/C	cg08523029	chr5:130500466	HINT1	-0.59	-4.9	-0.4	2.87e-6	Fasting plasma glucose;
TGCT	cis	rs950880	0.560	rs11685424	chr2:102926981	G/A	cg09003973	chr2:102972529	NA	-0.54	-4.72	-0.39	6.3e-6	Serum protein levels (sST2);
TGCT	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	5.24	0.43	6.73e-7	Menopause (age at onset);
TGCT	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg23302884	chr18:44338147	ST8SIA5	-0.4	-4.61	-0.38	9.88e-6	Personality dimensions;
TGCT	cis	rs114540395	0.858	rs77691531	chr10:103123526	G/A	cg18276125	chr10:102749041	C10orf2	0.36	4.44	0.37	1.98e-5	Schizophrenia;
TGCT	cis	rs6121246	0.512	rs45443696	chr20:30311396	A/C	cg10886678	chr20:30946050	ASXL1	-0.57	-4.83	-0.4	3.98e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs78487399	0.808	rs7599799	chr2:43685493	A/G	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.74	4.77	0.39	5.16e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs7601155	1.000	rs7601155	chr2:28347682	C/T	cg09958967	chr2:27485780	SLC30A3	0.9	4.76	0.39	5.35e-6	Waist circumference;
TGCT	cis	rs36051895	0.589	rs16922772	chr9:5194521	C/A	cg02405213	chr9:5042618	JAK2	-0.73	-9.46	-0.65	2.62e-16	Pediatric autoimmune diseases;
TGCT	cis	rs6089584	0.888	rs6061405	chr20:60617033	A/G	cg13665807	chr20:60559372	TAF4	-0.46	-5.0	-0.41	1.92e-6	Body mass index;
TGCT	cis	rs2251381	0.565	rs2832279	chr21:30613466	G/T	cg24692254	chr21:30365293	RNF160	0.58	5.37	0.43	3.66e-7	Selective IgA deficiency;
TGCT	cis	rs10883723	0.810	rs3740406	chr10:104272789	C/T	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs11648796	0.879	rs12448432	chr16:778820	G/A	cg27436995	chr16:743998	FBXL16	-0.51	-4.44	-0.37	1.96e-5	Height;
TGCT	cis	rs4824093	0.610	rs4824113	chr22:50284974	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.13	-6.81	-0.52	3.83e-10	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs5744897	0.708	rs5744769	chr12:133250734	C/G	cg17341477	chr12:133246679	POLE	0.39	4.98	0.41	2.05e-6	Urate levels in overweight individuals;
TGCT	cis	rs1865760	0.929	rs9358896	chr6:25943197	C/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.65	6.15	0.48	9.65e-9	Height;
TGCT	trans	rs11088226	0.681	rs2833902	chr21:33940458	A/G	cg09050820	chr6:167586206	TCP10L2	0.8	7.19	0.54	5.26e-11	Gastritis;
TGCT	trans	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg20587970	chr11:113659929	NA	-1.04	-12.57	-0.75	6.97e-24	Hip circumference adjusted for BMI;
TGCT	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg14784868	chr12:69753453	YEATS4	0.89	10.43	0.68	1.11e-18	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs10751667	1.000	rs4074232	chr11:977682	C/G	cg06064525	chr11:970664	AP2A2	-0.33	-6.51	-0.5	1.71e-9	Alzheimer's disease (late onset);
TGCT	cis	rs2013441	1.000	rs2386429	chr17:20210809	G/A	cg18979559	chr17:20280153	CCDC144C	-0.49	-5.0	-0.41	1.88e-6	Obesity-related traits;
TGCT	cis	rs7552404	1.000	rs12127402	chr1:76205643	C/A	cg03433033	chr1:76189801	ACADM	0.82	9.74	0.66	5.46e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs3091242	0.967	rs1053438	chr1:25687901	T/C	cg23205692	chr1:25664452	TMEM50A	-0.51	-5.22	-0.42	7.4e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs8103278	0.507	rs16939	chr19:46276056	C/A	cg11657440	chr19:46296263	DMWD	0.75	8.06	0.59	5.37e-13	Coronary artery disease;
TGCT	cis	rs858239	0.730	rs858289	chr7:23248158	C/T	cg05602783	chr7:23145260	KLHL7	-0.64	-5.39	-0.44	3.41e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs2153535	0.580	rs7341206	chr6:8470489	T/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs7655841	0.704	rs789982	chr4:129999071	T/C	cg26347359	chr4:129759716	PHF17	-0.44	-4.97	-0.41	2.16e-6	Chronic obstructive pulmonary disease (moderate to severe);
TGCT	cis	rs11685299	1	rs11685299	chr2:225391296	C/A	cg12698349	chr2:225449008	CUL3	0.98	9.44	0.65	2.87e-16	Schizophrenia;
TGCT	cis	rs3126085	0.935	rs11204981	chr1:152298212	C/T	cg03465714	chr1:152285911	FLG	0.41	4.67	0.39	7.63e-6	Atopic dermatitis;
TGCT	cis	rs3087591	0.639	rs1048317	chr17:29704002	T/C	cg24425628	chr17:29625626	OMG;NF1	0.36	5.06	0.41	1.47e-6	Hip circumference;
TGCT	cis	rs2130392	0.962	rs13132498	chr4:185611454	T/C	cg14471096	chr4:185570637	CCDC111;CASP3	-0.55	-4.99	-0.41	1.97e-6	Kawasaki disease;
TGCT	cis	rs6089584	0.586	rs4925216	chr20:60599923	G/A	cg13770153	chr20:60521292	NA	-0.41	-5.0	-0.41	1.88e-6	Body mass index;
TGCT	trans	rs3102947	0.539	rs1473233	chr2:8499766	C/T	cg01718733	chr15:29409410	APBA2	0.31	6.79	0.52	4.09e-10	IgE levels;
TGCT	cis	rs2404602	0.735	rs12906143	chr15:76709523	T/A	cg26408565	chr15:76604113	ETFA	0.38	4.49	0.37	1.58e-5	Blood metabolite levels;
TGCT	cis	rs4843185	0.669	rs889502	chr16:85716832	A/G	cg06784122	chr16:85688175	KIAA0182	0.27	4.47	0.37	1.72e-5	Platelet distribution width;
TGCT	cis	rs986417	1.000	rs2351175	chr14:61066730	C/T	cg27398547	chr14:60952738	C14orf39	1.49	9.97	0.67	1.46e-17	Gut microbiota (bacterial taxa);
TGCT	cis	rs2933343	0.729	rs6767104	chr3:128648117	G/T	cg11901034	chr3:128598214	ACAD9	0.66	6.45	0.5	2.3e-9	IgG glycosylation;
TGCT	cis	rs4148883	0.713	rs3828541	chr4:100042262	A/G	cg12011299	chr4:100065546	ADH4	0.36	5.36	0.43	3.85e-7	Alcohol dependence;
TGCT	cis	rs425277	0.958	rs7546523	chr1:2043792	G/A	cg03732007	chr1:2071316	PRKCZ	0.24	4.65	0.39	8.46e-6	Height;
TGCT	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg04546413	chr19:29218101	NA	0.84	6.82	0.52	3.52e-10	Methadone dose in opioid dependence;
TGCT	cis	rs13256369	1.000	rs9329165	chr8:8576642	C/T	cg06671706	chr8:8559999	CLDN23	-0.36	-4.88	-0.4	3.15e-6	Obesity-related traits;
TGCT	cis	rs61990749	0.597	rs1978416	chr14:78227901	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	0.65	4.59	0.38	1.06e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs2204008	0.628	rs10876106	chr12:37990767	A/G	cg13010199	chr12:38710504	ALG10B	0.61	4.89	0.4	3.05e-6	Bladder cancer;
TGCT	cis	rs137603	1.000	rs137604	chr22:39694594	C/G	cg17798944	chr22:39715225	SNORD43;RPL3	-0.54	-5.12	-0.42	1.13e-6	Primary biliary cholangitis;
TGCT	cis	rs1215050	0.755	rs9991112	chr4:98651479	A/C	cg17366294	chr4:99064904	C4orf37	-0.52	-5.51	-0.44	1.97e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7940866	0.801	rs10894300	chr11:130845943	A/G	cg05962950	chr11:130786565	SNX19	0.73	7.14	0.54	6.99e-11	Schizophrenia;
TGCT	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg03264133	chr6:25882463	NA	-0.53	-5.53	-0.44	1.81e-7	Blood metabolite levels;
TGCT	cis	rs28595532	0.920	rs116799007	chr4:119763562	A/G	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg03303774	chr4:1407052	NA	0.32	4.73	0.39	6.03e-6	Obesity-related traits;
TGCT	cis	rs6499129	0.558	rs7203742	chr16:67605794	A/G	cg03412735	chr16:68482518	SMPD3	0.64	4.44	0.37	1.93e-5	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7582180	0.629	rs4851294	chr2:100941109	C/T	cg08017756	chr2:100939284	LONRF2	-0.3	-4.86	-0.4	3.49e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg04944784	chr2:26401820	FAM59B	-0.67	-6.16	-0.48	9.54e-9	Gut microbiome composition (summer);
TGCT	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg03806693	chr22:41940476	POLR3H	-1.14	-13.38	-0.77	8.05e-26	Vitiligo;
TGCT	cis	rs9300255	0.602	rs2682434	chr12:123694724	C/T	cg00376283	chr12:123451042	ABCB9	0.73	5.67	0.45	9.46e-8	Neutrophil percentage of white cells;
TGCT	trans	rs17685	0.671	rs10274404	chr7:75706634	G/A	cg19862616	chr7:65841803	NCRNA00174	0.52	8.99	0.63	3.49e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs2404602	0.647	rs8025991	chr15:77155268	C/T	cg23625390	chr15:77176239	SCAPER	-0.39	-5.15	-0.42	9.85e-7	Blood metabolite levels;
TGCT	cis	rs9916302	0.706	rs4332770	chr17:37704712	T/C	cg03321784	chr17:37729644	NA	0.44	4.58	0.38	1.1e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs259282	0.707	rs1103851	chr19:33146414	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.79	7.63	0.57	5.27e-12	Schizophrenia;
TGCT	cis	rs2688608	0.869	rs2250140	chr10:75612881	T/C	cg04320760	chr10:75533139	FUT11	-0.31	-4.65	-0.39	8.27e-6	Inflammatory bowel disease;
TGCT	trans	rs28735056	0.587	rs8093548	chr18:77636451	G/A	cg05926928	chr17:57297772	GDPD1	-0.83	-9.64	-0.65	9.38e-17	Schizophrenia;
TGCT	cis	rs514406	0.893	rs6588446	chr1:53425260	G/A	cg08736216	chr1:53307985	ZYG11A	0.28	5.65	0.45	1.03e-7	Monocyte count;
TGCT	cis	rs2663905	0.664	rs2460855	chr15:81361729	G/T	cg09236163	chr15:81426669	C15orf26	-0.46	-4.55	-0.38	1.27e-5	QT interval (drug interaction);
TGCT	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg11644478	chr21:40555479	PSMG1	1.03	11.02	0.7	4.14e-20	Cognitive function;
TGCT	cis	rs7582180	0.629	rs11684516	chr2:100949883	C/A	cg14675211	chr2:100938903	LONRF2	0.5	4.78	0.39	4.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1843834	0.858	rs12105685	chr2:225513164	A/G	cg22455342	chr2:225449267	CUL3	0.73	7.31	0.55	2.88e-11	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg11764359	chr7:65958608	NA	0.62	5.53	0.44	1.82e-7	Aortic root size;
TGCT	cis	rs7917772	0.582	rs3977756	chr10:104398582	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-5.28	-0.43	5.48e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs12497850	0.931	rs9311432	chr3:48850443	T/A	cg06212747	chr3:49208901	KLHDC8B	0.62	5.83	0.46	4.42e-8	Parkinson's disease;
TGCT	cis	rs3125734	0.633	rs10821968	chr10:63993905	C/T	cg19640130	chr10:64028056	RTKN2	0.39	5.11	0.42	1.21e-6	Rheumatoid arthritis;
TGCT	cis	rs12541335	0.639	rs3923439	chr8:22170079	G/A	cg02463440	chr8:22132932	PIWIL2	0.26	5.09	0.42	1.29e-6	Hypertriglyceridemia;
TGCT	cis	rs3812831	0.635	rs6560937	chr13:114945991	C/G	cg08824895	chr13:115047677	UPF3A	0.49	4.76	0.39	5.26e-6	Schizophrenia;
TGCT	cis	rs9381040	0.655	rs879491	chr6:41026953	A/G	cg03526776	chr6:41159608	TREML2	0.27	5.27	0.43	5.78e-7	Alzheimer's disease (late onset);
TGCT	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg03806693	chr22:41940476	POLR3H	-1.01	-11.18	-0.71	1.71e-20	Vitiligo;
TGCT	cis	rs612683	0.759	rs12722868	chr1:100956478	A/G	cg06223162	chr1:101003688	GPR88	0.32	4.98	0.41	2.1e-6	Breast cancer;
TGCT	cis	rs1942	0.742	rs1655558	chr15:41787585	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.45	-5.9	-0.47	3.28e-8	Eosinophil percentage of granulocytes;
TGCT	trans	rs208520	0.874	rs208514	chr6:66945520	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-9.93	-0.67	1.84e-17	Exhaled nitric oxide output;
TGCT	cis	rs3540	0.533	rs2352601	chr15:91053125	G/A	cg22089800	chr15:90895588	ZNF774	-0.76	-7.96	-0.58	9.24e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs459571	1.000	rs456207	chr9:136911140	G/A	cg13789015	chr9:136890014	NCRNA00094	0.39	6.81	0.52	3.72e-10	Platelet distribution width;
TGCT	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.59	-5.43	-0.44	2.87e-7	Height;
TGCT	cis	rs7829975	0.511	rs2976906	chr8:8342415	A/T	cg06636001	chr8:8085503	FLJ10661	0.61	5.69	0.46	8.54e-8	Mood instability;
TGCT	cis	rs57920188	0.585	rs12117500	chr1:4072315	G/A	cg20703997	chr1:4087676	NA	0.47	5.8	0.46	5.14e-8	Interleukin-17 levels;
TGCT	cis	rs7572733	0.534	rs700692	chr2:198728500	T/C	cg00792783	chr2:198669748	PLCL1	0.56	5.08	0.42	1.35e-6	Dermatomyositis;
TGCT	cis	rs17826219	0.706	rs8075357	chr17:29057197	A/C	cg13385521	chr17:29058706	SUZ12P	0.79	4.77	0.39	5.16e-6	Body mass index;
TGCT	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg26338869	chr17:61819248	STRADA	-0.53	-4.9	-0.4	2.95e-6	Prudent dietary pattern;
TGCT	cis	rs7258465	0.965	rs748609	chr19:18560282	T/C	cg06462663	chr19:18546047	ISYNA1	0.2	4.5	0.37	1.56e-5	Breast cancer;
TGCT	cis	rs7432375	0.580	rs4678441	chr3:136532828	T/C	cg15507776	chr3:136538369	TMEM22	0.55	5.63	0.45	1.15e-7	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2227564	0.620	rs4746148	chr10:75534488	C/T	cg04320760	chr10:75533139	FUT11	-0.31	-4.49	-0.37	1.64e-5	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs6671200	1.000	rs12755552	chr1:95685026	A/G	cg26537280	chr1:95699037	RWDD3	0.68	5.49	0.44	2.15e-7	Stearic acid (18:0) levels;
TGCT	cis	rs2562456	0.755	rs2650773	chr19:21644088	A/G	cg01304269	chr19:21688519	ZNF429	-0.6	-4.89	-0.4	3.07e-6	Pain;
TGCT	cis	rs3782455	1.000	rs117470230	chr12:114403053	G/C	cg10631684	chr12:113795897	PLBD2	-0.7	-4.61	-0.38	1e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg11494091	chr17:61959527	GH2	0.43	7.3	0.55	3.05e-11	Height;
TGCT	cis	rs77861329	1.000	rs352153	chr3:52211184	A/T	cg08692210	chr3:52188851	WDR51A	0.9	4.85	0.4	3.66e-6	Macrophage inflammatory protein 1b levels;
TGCT	cis	rs9341808	0.935	rs9448894	chr6:80837253	G/T	cg08355045	chr6:80787529	NA	0.28	4.98	0.41	2.11e-6	Sitting height ratio;
TGCT	cis	rs10992471	0.528	rs6479423	chr9:95265580	A/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.51	-4.81	-0.4	4.31e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs17376456	0.877	rs12374488	chr5:93481407	A/G	cg21475434	chr5:93447410	FAM172A	0.63	4.63	0.38	8.98e-6	Diabetic retinopathy;
TGCT	cis	rs2072499	1.000	rs2253809	chr1:156172125	T/C	cg24450063	chr1:156163899	SLC25A44	1.17	17.33	0.84	6.21e-35	Testicular germ cell tumor;
TGCT	cis	rs7324557	0.717	rs9507164	chr13:24380539	A/G	cg16602799	chr13:25254742	ATP12A	0.57	4.45	0.37	1.93e-5	Visceral adipose tissue adjusted for BMI;
TGCT	cis	rs4886920	0.563	rs4511491	chr15:78079304	A/G	cg25212270	chr15:78015279	NA	-0.23	-4.87	-0.4	3.36e-6	Neuroticism;
TGCT	cis	rs727505	0.721	rs67607629	chr7:124765867	C/T	cg23710748	chr7:124431027	NA	-0.25	-4.63	-0.38	9.13e-6	Lewy body disease;
TGCT	cis	rs9611565	0.571	rs7364123	chr22:42216326	A/G	cg06481639	chr22:41940642	POLR3H	-0.53	-4.46	-0.37	1.81e-5	Vitiligo;
TGCT	cis	rs6671200	0.607	rs2147587	chr1:95714884	G/A	cg03123541	chr1:95699097	RWDD3	-0.81	-7.26	-0.55	3.81e-11	Stearic acid (18:0) levels;
TGCT	cis	rs7659604	0.628	rs3828485	chr4:122722368	G/A	cg19748678	chr4:122722346	EXOSC9	0.94	9.97	0.67	1.5e-17	Type 2 diabetes;
TGCT	cis	rs61990749	0.597	rs12887606	chr14:78200620	G/A	cg23188588	chr14:78226832	SNW1;C14orf178	0.65	4.59	0.38	1.06e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs2075165	0.838	rs12072638	chr1:156267480	T/G	cg20302342	chr1:156215951	PAQR6	0.36	5.38	0.44	3.56e-7	Tonsillectomy;
TGCT	cis	rs7647973	0.626	rs9870858	chr3:49769071	C/T	cg05785598	chr3:49045655	WDR6	0.42	5.24	0.43	6.67e-7	Menarche (age at onset);
TGCT	cis	rs10782582	0.609	rs11584577	chr1:76242378	A/G	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.51	4.59	0.38	1.06e-5	Daytime sleep phenotypes;
TGCT	cis	rs1333657	0.782	rs13217528	chr6:10295896	A/C	cg24286789	chr6:10417726	TFAP2A	-0.27	-4.52	-0.38	1.43e-5	Orofacial clefts;
TGCT	cis	rs9902453	0.967	rs9904336	chr17:28357080	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-6.56	-0.51	1.3e-9	Coffee consumption (cups per day);
TGCT	cis	rs644799	0.965	rs502521	chr11:95533557	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	10.57	0.69	5.17e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs6969780	0.915	rs12666919	chr7:27189498	A/T	cg04321618	chr7:27170880	HOXA4	-0.51	-4.45	-0.37	1.86e-5	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs56104184	0.775	rs73061697	chr19:49400000	C/T	cg21252483	chr19:49399788	TULP2	-0.42	-5.89	-0.47	3.47e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg21280719	chr6:42927975	GNMT	-0.37	-4.56	-0.38	1.22e-5	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg14983838	chr19:29218262	NA	0.76	6.92	0.53	2.11e-10	Methadone dose in opioid dependence;
TGCT	cis	rs7267979	1.000	rs7267979	chr20:25298087	C/T	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2777491	0.915	rs28578057	chr15:41621921	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.75	-10.44	-0.68	1.07e-18	Ulcerative colitis;
TGCT	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg12042659	chr19:58951599	ZNF132	0.51	4.66	0.39	7.97e-6	Uric acid clearance;
TGCT	trans	rs12339966	0.653	rs10733233	chr9:11298203	T/A	cg07173112	chr1:1114698	TTLL10	-0.34	-6.86	-0.52	2.97e-10	Systolic blood pressure;
TGCT	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	16.1	0.82	3.69e-32	Prudent dietary pattern;
TGCT	cis	rs6500602	0.893	rs8061742	chr16:4489436	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.3	5.19	0.42	8.41e-7	Schizophrenia;
TGCT	cis	rs9303401	0.659	rs34468504	chr17:56648277	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs4563143	0.675	rs55849754	chr19:29279665	G/A	cg03161606	chr19:29218774	NA	0.62	6.0	0.47	2e-8	Methadone dose in opioid dependence;
TGCT	cis	rs6490294	0.687	rs648300	chr12:112175819	C/G	cg10833066	chr12:111807467	FAM109A	0.32	4.96	0.41	2.25e-6	Mean platelet volume;
TGCT	cis	rs6754311	0.589	rs749873	chr2:136817088	C/T	cg07169764	chr2:136633963	MCM6	-0.56	-5.48	-0.44	2.29e-7	Mosquito bite size;
TGCT	cis	rs670523	0.722	rs4661079	chr1:155983298	A/G	cg05700447	chr1:155978627	NA	-0.19	-4.79	-0.39	4.75e-6	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs704	0.739	rs733914	chr17:26671196	C/G	cg10342447	chr17:26645325	TMEM97	-0.55	-5.2	-0.42	7.94e-7	Osteoprotegerin levels;
TGCT	cis	rs68170813	0.559	rs12537785	chr7:107050221	T/C	cg02696742	chr7:106810147	HBP1	-0.71	-5.9	-0.47	3.17e-8	Coronary artery disease;
TGCT	cis	rs17376456	0.877	rs13185660	chr5:93336500	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.62	4.44	0.37	1.98e-5	Diabetic retinopathy;
TGCT	cis	rs1153858	1.000	rs2467864	chr15:45641098	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.97	-11.62	-0.72	1.44e-21	Homoarginine levels;
TGCT	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg18230493	chr5:56204884	C5orf35	-0.68	-5.92	-0.47	2.92e-8	Initial pursuit acceleration;
TGCT	cis	rs10883723	0.810	rs12265877	chr10:104247247	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs240110	0.515	rs12530388	chr6:101329173	A/C	cg09795085	chr6:101329169	ASCC3	0.6	4.89	0.4	3.01e-6	Neuroticism;
TGCT	cis	rs35883536	0.647	rs17402630	chr1:101046587	C/T	cg06223162	chr1:101003688	GPR88	-0.41	-7.64	-0.57	5.04e-12	Monocyte count;
TGCT	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.74	-0.39	5.77e-6	Prudent dietary pattern;
TGCT	cis	rs910316	0.967	rs2024653	chr14:75595154	G/A	cg23033748	chr14:75592666	NEK9	0.29	4.9	0.4	2.95e-6	Height;
TGCT	cis	rs1552244	0.515	rs7613004	chr3:9999913	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.31	-4.82	-0.4	4.12e-6	Alzheimer's disease;
TGCT	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg21724239	chr8:58056113	NA	0.44	4.57	0.38	1.18e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs709400	0.567	rs11624343	chr14:103859156	T/A	cg12935359	chr14:103987150	CKB	-0.36	-5.38	-0.43	3.63e-7	Body mass index;
TGCT	cis	rs7439150	1.000	rs2227401	chr4:155486381	C/T	cg22130008	chr4:155548532	NA	-0.47	-5.8	-0.46	5.25e-8	Fibrinogen levels;
TGCT	cis	rs7264396	0.677	rs6060553	chr20:34267386	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.3	-5.31	-0.43	4.87e-7	Total cholesterol levels;
TGCT	cis	rs4455778	0.580	rs6970665	chr7:49124091	T/A	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs2180341	0.960	rs7745944	chr6:127709574	A/G	cg24812749	chr6:127587940	RNF146	0.98	7.53	0.56	9.29e-12	Breast cancer;
TGCT	cis	rs6088590	1.000	rs6087632	chr20:33407704	A/C	cg24642439	chr20:33292090	TP53INP2	0.68	6.09	0.48	1.32e-8	Coronary artery disease;
TGCT	cis	rs9467773	0.620	rs2504571	chr6:26643435	C/T	cg05738196	chr6:26577821	NA	0.87	10.82	0.7	1.29e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs2180341	1.000	rs2180341	chr6:127600630	C/T	cg27446573	chr6:127587934	RNF146	1.12	10.04	0.67	1.02e-17	Breast cancer;
TGCT	cis	rs28595532	0.920	rs115744897	chr4:119749064	A/G	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs210152	0.588	rs449978	chr6:33496060	G/A	cg07735790	chr6:34101545	GRM4	-0.52	-4.79	-0.4	4.68e-6	Schizophrenia;
TGCT	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.0	0.41	1.89e-6	Menopause (age at onset);
TGCT	cis	rs7772486	0.686	rs857875	chr6:145980033	T/G	cg05347473	chr6:146136440	FBXO30	-0.47	-4.45	-0.37	1.9e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7552404	0.628	rs4949686	chr1:76473299	G/C	cg03433033	chr1:76189801	ACADM	0.77	6.8	0.52	3.85e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs6519955	0.765	rs7292527	chr22:46423125	G/T	cg05468064	chr22:46423449	NA	-0.57	-5.92	-0.47	2.88e-8	Dupuytren's disease;
TGCT	cis	rs3806843	0.607	rs246060	chr5:140324749	T/C	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7191700	0.509	rs416603	chr16:11364079	A/T	cg00044050	chr16:11439710	C16orf75	-0.65	-6.15	-0.48	9.84e-9	Multiple sclerosis;
TGCT	cis	rs7552404	0.883	rs11161493	chr1:76206254	T/A	cg10523679	chr1:76189770	ACADM	0.89	9.88	0.66	2.42e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7249142	0.597	rs759999	chr19:19281207	A/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.33	-4.52	-0.38	1.42e-5	IgG glycosylation;
TGCT	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg11764359	chr7:65958608	NA	0.61	5.54	0.45	1.76e-7	Aortic root size;
TGCT	cis	rs1018836	0.608	rs7821069	chr8:91465548	C/G	cg16814680	chr8:91681699	NA	-0.71	-7.16	-0.54	6.36e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs11098499	0.909	rs79026312	chr4:120440677	C/A	cg09307838	chr4:120376055	NA	0.69	6.53	0.51	1.49e-9	Corneal astigmatism;
TGCT	cis	rs8014204	0.935	rs1799900	chr14:75367740	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.73	-6.94	-0.53	1.96e-10	Caffeine consumption;
TGCT	cis	rs7324557	0.717	rs9510869	chr13:24384129	C/T	cg16602799	chr13:25254742	ATP12A	0.57	4.45	0.37	1.93e-5	Visceral adipose tissue adjusted for BMI;
TGCT	cis	rs9318086	0.648	rs7331047	chr13:24467342	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.83	9.04	0.63	2.62e-15	Myopia (pathological);
TGCT	cis	rs244731	0.959	rs7721671	chr5:176630984	A/G	cg17509989	chr5:176798049	RGS14	-0.6	-7.32	-0.55	2.69e-11	Urate levels in lean individuals;
TGCT	cis	rs76473307	1.000	rs6026540	chr20:57391435	A/G	cg06163629	chr20:57414884	GNASAS;GNAS	-0.66	-4.53	-0.38	1.39e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs208520	0.754	rs12204635	chr6:66740779	C/A	cg07460842	chr6:66804631	NA	0.94	9.91	0.66	2.15e-17	Exhaled nitric oxide output;
TGCT	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg03303774	chr4:1407052	NA	0.32	4.73	0.39	6.03e-6	Obesity-related traits;
TGCT	cis	rs1577917	0.958	rs67024565	chr6:86553997	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.42	-0.44	3.02e-7	Response to antipsychotic treatment;
TGCT	cis	rs11943027	0.840	rs10034699	chr4:38835868	A/T	cg02016764	chr4:38805732	TLR1	-0.26	-4.46	-0.37	1.85e-5	Alcohol dependence;
TGCT	cis	rs12477438	0.765	rs9710648	chr2:99673129	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-4.88	-0.4	3.17e-6	Chronic sinus infection;
TGCT	cis	rs35306767	0.903	rs12244355	chr10:944465	T/C	cg20503657	chr10:835505	NA	0.75	10.55	0.69	5.67e-19	Eosinophil percentage of granulocytes;
TGCT	trans	rs17685	0.712	rs28506984	chr7:75763484	A/G	cg19862616	chr7:65841803	NCRNA00174	0.51	8.59	0.61	3.07e-14	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs208520	0.661	rs1100950	chr6:66827285	A/C	cg07460842	chr6:66804631	NA	-0.95	-9.74	-0.66	5.26e-17	Exhaled nitric oxide output;
TGCT	cis	rs2506155	0.838	rs2474713	chr10:33497150	A/C	cg25928881	chr10:32632685	EPC1	0.28	4.47	0.37	1.77e-5	Migraine;
TGCT	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg06221963	chr1:154839813	KCNN3	-0.75	-13.71	-0.78	1.3e-26	Prostate cancer;
TGCT	cis	rs2236918	0.710	rs2526702	chr1:242017983	G/A	cg04158730	chr1:242011433	EXO1	0.58	5.47	0.44	2.42e-7	Menopause (age at onset);
TGCT	cis	rs68170813	0.559	rs4730229	chr7:106925353	A/G	cg02696742	chr7:106810147	HBP1	-0.69	-5.81	-0.46	4.85e-8	Coronary artery disease;
TGCT	cis	rs9467773	0.534	rs34453863	chr6:26628005	T/C	cg15659132	chr6:26577336	NA	0.83	10.06	0.67	9.18e-18	Intelligence (multi-trait analysis);
TGCT	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	5.07	0.41	1.4e-6	Height;
TGCT	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	4.99	0.41	1.98e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9894429	0.752	rs7502883	chr17:79588557	T/C	cg21028142	chr17:79581711	NPLOC4	0.3	7.03	0.53	1.22e-10	Eye color traits;
TGCT	cis	rs3008870	1.000	rs11208979	chr1:67442275	C/T	cg03991309	chr1:68237761	GNG12	-0.27	-4.53	-0.38	1.36e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs916888	0.610	rs199530	chr17:44836653	C/T	cg15921436	chr17:44337874	NA	-0.39	-6.06	-0.48	1.51e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.15	10.22	0.68	3.75e-18	Platelet count;
TGCT	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg21782813	chr7:2030301	MAD1L1	0.32	4.58	0.38	1.12e-5	Bipolar disorder and schizophrenia;
TGCT	cis	rs8180040	0.966	rs12486969	chr3:47429003	G/C	cg27129171	chr3:47204927	SETD2	-0.64	-7.39	-0.55	1.89e-11	Colorectal cancer;
TGCT	cis	rs3125734	0.660	rs10733769	chr10:63974255	G/T	cg09941381	chr10:64027924	RTKN2	-0.36	-5.38	-0.44	3.55e-7	Rheumatoid arthritis;
TGCT	cis	rs636291	0.517	rs12565133	chr1:10544988	A/C	cg17425144	chr1:10567563	PEX14	-0.51	-7.42	-0.55	1.66e-11	Prostate cancer;
TGCT	trans	rs7726839	0.561	rs72703044	chr5:579737	G/A	cg11887960	chr12:57824829	NA	0.96	8.01	0.58	7.22e-13	Obesity-related traits;
TGCT	cis	rs308403	0.568	rs309344	chr4:123644812	G/A	cg10495464	chr4:123653540	BBS12;LOC729338	0.72	6.64	0.51	8.74e-10	Blood protein levels;
TGCT	cis	rs7226408	0.857	rs11081989	chr18:34713367	A/T	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs929596	0.785	rs6714634	chr2:234664765	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.31	4.86	0.4	3.45e-6	Total bilirubin levels in HIV-1 infection;
TGCT	cis	rs10832963	1.000	rs10832956	chr11:18645668	A/G	cg20219074	chr11:18656078	SPTY2D1	0.98	10.07	0.67	8.69e-18	Breast cancer;
TGCT	cis	rs832540	0.931	rs33318	chr5:56208414	G/T	cg12311346	chr5:56204834	C5orf35	-0.48	-5.14	-0.42	1.06e-6	Coronary artery disease;
TGCT	cis	rs12776158	0.901	rs57805780	chr10:71216455	A/C	cg12610070	chr10:71211762	TSPAN15	-0.55	-4.83	-0.4	3.87e-6	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs12048904	0.541	rs6699536	chr1:101276544	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.82	7.43	0.56	1.5e-11	Multiple sclerosis;
TGCT	cis	rs1348850	0.914	rs1348849	chr2:178358072	C/T	cg22681709	chr2:178499509	PDE11A	-0.35	-4.53	-0.38	1.39e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs9790314	0.502	rs7647118	chr3:161016165	T/C	cg03342759	chr3:160939853	NMD3	-0.49	-5.3	-0.43	5.16e-7	Morning vs. evening chronotype;
TGCT	cis	rs4319547	0.695	rs4758662	chr12:122924778	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.69	-5.38	-0.44	3.58e-7	Body mass index;
TGCT	cis	rs3947	0.855	rs1293327	chr8:11694986	G/A	cg02840367	chr8:11660030	FDFT1	0.89	6.56	0.51	1.3e-9	Blood protein levels;
TGCT	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg19318889	chr4:1322082	MAEA	-0.27	-6.51	-0.5	1.69e-9	Longevity;
TGCT	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg22920501	chr2:26401640	FAM59B	-0.71	-6.11	-0.48	1.21e-8	Gut microbiome composition (summer);
TGCT	cis	rs3087591	0.960	rs2905790	chr17:29476110	A/G	cg24425628	chr17:29625626	OMG;NF1	0.46	7.23	0.54	4.3e-11	Hip circumference;
TGCT	cis	rs11690935	0.959	rs7572215	chr2:172634228	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.19	-12.78	-0.75	2.24e-24	Schizophrenia;
TGCT	cis	rs9325144	0.532	rs1352121	chr12:39130696	A/G	cg26384229	chr12:38710491	ALG10B	-0.62	-5.85	-0.47	4.06e-8	Morning vs. evening chronotype;
TGCT	cis	rs174449	0.603	rs174460	chr11:61657110	C/T	cg01500311	chr11:61656094	FADS3	0.35	6.7	0.52	6.49e-10	Trans fatty acid levels;
TGCT	cis	rs739496	0.527	rs10774639	chr12:112258445	G/A	cg10833066	chr12:111807467	FAM109A	0.38	5.61	0.45	1.24e-7	Platelet count;
TGCT	cis	rs4727027	0.933	rs12704063	chr7:148827909	T/C	cg23583168	chr7:148888333	NA	-0.72	-9.18	-0.64	1.18e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg22618164	chr12:122356400	WDR66	0.64	6.46	0.5	2.15e-9	Mean corpuscular volume;
TGCT	cis	rs2404602	0.647	rs11637096	chr15:76931102	T/C	cg22467129	chr15:76604101	ETFA	0.47	4.61	0.38	9.77e-6	Blood metabolite levels;
TGCT	cis	rs10949834	0.793	rs810532	chr7:73505188	A/G	cg07137043	chr7:73588983	EIF4H	-0.61	-4.61	-0.38	9.71e-6	Verbal memory performance (residualized delayed recall change);
TGCT	cis	rs12477438	0.798	rs9808541	chr2:99642179	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-6.1	-0.48	1.22e-8	Chronic sinus infection;
TGCT	cis	rs1371867	0.846	rs1788181	chr8:101334068	C/T	cg06636551	chr8:101224915	SPAG1	-0.42	-5.65	-0.45	1.06e-7	Atrioventricular conduction;
TGCT	cis	rs2120019	1.000	rs34237279	chr15:75361121	A/G	cg17294928	chr15:75287854	SCAMP5	-0.84	-6.34	-0.5	3.8e-9	Blood trace element (Zn levels);
TGCT	cis	rs9611565	0.614	rs4822053	chr22:42212936	C/A	cg03806693	chr22:41940476	POLR3H	-0.85	-8.06	-0.59	5.38e-13	Vitiligo;
TGCT	cis	rs797680	0.856	rs2031226	chr1:93786764	G/T	cg17826107	chr1:92977322	EVI5	-0.22	-5.05	-0.41	1.53e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs60843830	1.000	rs7566279	chr2:281178	C/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.72	7.12	0.54	7.7e-11	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs1018836	0.851	rs6986359	chr8:91643162	A/G	cg16814680	chr8:91681699	NA	-0.8	-8.6	-0.61	2.89e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs17345786	0.906	rs59359251	chr3:101146362	A/C	cg11279151	chr3:101281821	RG9MTD1	-0.4	-8.36	-0.6	1.09e-13	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7020830	0.861	rs2291589	chr9:37079661	T/G	cg14294708	chr9:37120828	ZCCHC7	1.29	20.57	0.88	8.64e-42	Schizophrenia;
TGCT	cis	rs854765	0.547	rs7212167	chr17:17913504	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.78	8.27	0.6	1.72e-13	Total body bone mineral density;
TGCT	trans	rs1814175	0.817	rs10769648	chr11:50013992	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.26	-0.55	3.77e-11	Height;
TGCT	cis	rs2204008	0.560	rs1315354	chr12:38165716	A/G	cg26384229	chr12:38710491	ALG10B	-0.58	-5.09	-0.42	1.32e-6	Bladder cancer;
TGCT	cis	rs9644630	0.965	rs10105097	chr8:19364883	A/C	cg01280390	chr8:19363452	CSGALNACT1	-0.27	-4.68	-0.39	7.47e-6	Oropharynx cancer;
TGCT	trans	rs10504390	0.656	rs77264178	chr8:66515086	G/A	cg26037026	chr7:1641922	NA	-0.64	-6.84	-0.52	3.29e-10	IgG glycosylation;
TGCT	cis	rs7769051	1.000	rs5006218	chr6:133126220	T/G	cg22852734	chr6:133119734	C6orf192	1.23	7.09	0.54	9.13e-11	Type 2 diabetes nephropathy;
TGCT	cis	rs12479064	0.505	rs62153764	chr2:99818612	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.95	-8.52	-0.61	4.42e-14	Chronic sinus infection;
TGCT	cis	rs75686122	0.892	rs80327507	chr8:104533054	A/G	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs9993613	1.000	rs7697556	chr4:73515313	C/T	cg15102770	chr4:73434591	ADAMTS3	0.51	4.83	0.4	3.96e-6	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg08280861	chr8:58055591	NA	0.4	4.73	0.39	5.97e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs11891	0.881	rs8079368	chr17:76989062	C/T	cg25730791	chr17:76457213	DNAH17	0.4	4.61	0.38	9.67e-6	Magnesium levels;
TGCT	cis	rs644799	1.000	rs474252	chr11:95619292	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.74	7.63	0.57	5.29e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7567389	0.599	rs6430938	chr2:128162623	A/G	cg09760422	chr2:128146352	NA	-0.35	-4.52	-0.38	1.4e-5	Self-rated health;
TGCT	cis	rs2777491	0.874	rs13379756	chr15:41663896	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.75	-10.1	-0.67	7.43e-18	Ulcerative colitis;
TGCT	cis	rs9611565	0.614	rs4822053	chr22:42212936	C/A	cg06634786	chr22:41940651	POLR3H	-0.78	-7.33	-0.55	2.57e-11	Vitiligo;
TGCT	cis	rs7772486	0.754	rs6570718	chr6:146088443	T/G	cg23711669	chr6:146136114	FBXO30	-0.92	-10.41	-0.68	1.3e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs72781680	0.898	rs72780123	chr2:23996009	G/A	cg08917208	chr2:24149416	ATAD2B	0.81	5.01	0.41	1.8e-6	Lymphocyte counts;
TGCT	cis	rs13217239	0.646	rs35691005	chr6:26972070	A/G	cg15659132	chr6:26577336	NA	0.55	5.55	0.45	1.62e-7	Schizophrenia;
TGCT	cis	rs6598955	0.671	rs12129482	chr1:26623641	C/T	cg04990556	chr1:26633338	UBXN11	0.67	5.44	0.44	2.77e-7	Obesity-related traits;
TGCT	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.51	-5.93	-0.47	2.76e-8	Longevity;Endometriosis;
TGCT	cis	rs3820068	0.608	rs58140482	chr1:16043979	A/G	cg05660106	chr1:15850417	CASP9	0.69	6.45	0.5	2.28e-9	Systolic blood pressure;
TGCT	cis	rs16867321	0.951	rs9989767	chr2:181429886	C/T	cg23363182	chr2:181467187	NA	-0.39	-5.37	-0.43	3.75e-7	Obesity;
TGCT	cis	rs4972806	0.814	rs2113560	chr2:177030986	T/C	cg03152288	chr2:177042942	NA	0.61	5.21	0.42	7.53e-7	IgG glycosylation;
TGCT	cis	rs79349575	0.749	rs58838744	chr17:46998902	A/G	cg26022315	chr17:47021804	SNF8	0.49	4.89	0.4	3.03e-6	Type 2 diabetes;
TGCT	cis	rs2288073	0.930	rs7604097	chr2:24401805	G/C	cg05570707	chr2:24270316	C2orf44	-0.5	-4.49	-0.37	1.58e-5	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs6500550	0.530	rs6501178	chr16:3566362	G/A	cg07396092	chr16:3662230	BTBD12	0.55	4.71	0.39	6.42e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;White blood cell count;Neutrophil count;
TGCT	cis	rs13631	0.894	rs7856589	chr9:140003921	A/G	cg14289826	chr9:140003911	NA	-0.27	-6.42	-0.5	2.69e-9	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs7017914	0.905	rs2732109	chr8:71926223	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.56	-5.11	-0.42	1.21e-6	Bone mineral density;
TGCT	cis	rs611744	0.934	rs682954	chr8:109210559	C/T	cg21045802	chr8:109455806	TTC35	0.52	4.72	0.39	6.21e-6	Dupuytren's disease;
TGCT	cis	rs2486288	0.656	rs12908818	chr15:45571668	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.47	-5.32	-0.43	4.64e-7	Glomerular filtration rate;
TGCT	cis	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg07424592	chr7:64974309	NA	1.33	7.99	0.58	7.81e-13	Diabetic kidney disease;
TGCT	cis	rs9976767	0.608	rs9784208	chr21:43824986	A/G	cg23042151	chr21:43824109	UBASH3A	-0.23	-5.14	-0.42	1.02e-6	Type 1 diabetes;
TGCT	cis	rs2072499	0.750	rs10159384	chr1:156160822	C/T	cg24450063	chr1:156163899	SLC25A44	1.11	10.16	0.67	5.03e-18	Testicular germ cell tumor;
TGCT	cis	rs68170813	0.559	rs2299422	chr7:106959832	A/T	cg02696742	chr7:106810147	HBP1	-0.69	-5.81	-0.46	4.85e-8	Coronary artery disease;
TGCT	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg16680214	chr1:154839983	KCNN3	-0.38	-8.27	-0.6	1.72e-13	Prostate cancer;
TGCT	cis	rs9467773	0.967	rs9467775	chr6:26513435	G/A	cg09904177	chr6:26538194	HMGN4	0.65	6.53	0.51	1.53e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs6540559	0.673	rs6540560	chr1:209982073	A/G	cg21951975	chr1:209979733	IRF6	-0.6	-5.28	-0.43	5.53e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg16405210	chr4:1374714	KIAA1530	-0.21	-4.62	-0.38	9.6e-6	Obesity-related traits;
TGCT	cis	rs6866344	0.697	rs11749438	chr5:178131245	C/T	cg10224037	chr5:178157518	ZNF354A	0.93	8.17	0.59	3.01e-13	Neutrophil percentage of white cells;
TGCT	cis	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg25427524	chr10:38739819	LOC399744	-0.4	-8.23	-0.59	2.17e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs116095464	0.558	rs62347677	chr5:227453	A/G	cg22857025	chr5:266934	NA	-0.32	-6.53	-0.51	1.5e-9	Breast cancer;
TGCT	cis	rs4805272	0.626	rs12608533	chr19:29331405	C/G	cg04546413	chr19:29218101	NA	0.55	4.44	0.37	2e-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
TGCT	cis	rs2439831	0.867	rs2899082	chr15:43656043	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	8.65	0.61	2.26e-14	Lung cancer in ever smokers;
TGCT	cis	rs16854884	0.770	rs920158	chr3:143799289	A/T	cg06585982	chr3:143692056	C3orf58	0.55	4.47	0.37	1.76e-5	Economic and political preferences (feminism/equality);
TGCT	cis	rs2191566	0.960	rs11083732	chr19:44520743	T/C	cg03039196	chr19:44506973	ZNF230	0.52	4.45	0.37	1.87e-5	Acute lymphoblastic leukemia (childhood);
TGCT	cis	rs2544527	0.586	rs2544532	chr2:15904993	C/T	cg26669897	chr2:15909070	NA	-0.41	-5.06	-0.41	1.5e-6	Pulmonary function (smoking interaction);Pulmonary function;
TGCT	cis	rs9462846	0.691	rs9462853	chr6:42910666	T/C	cg02353165	chr6:42928485	GNMT	0.71	5.54	0.45	1.74e-7	Blood protein levels;
TGCT	cis	rs9467773	1.000	rs9467783	chr6:26542894	C/T	cg05738196	chr6:26577821	NA	0.88	12.59	0.75	6.52e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs1008375	0.931	rs2315558	chr4:17674558	C/A	cg16339924	chr4:17578868	LAP3	0.6	5.14	0.42	1.05e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10056811	0.538	rs56174528	chr5:74400516	G/C	cg19683494	chr5:74908142	NA	0.63	5.06	0.41	1.49e-6	Coronary artery disease;
TGCT	cis	rs35146811	0.735	rs1727138	chr7:99815247	A/G	cg04778012	chr7:99775508	STAG3;GPC2	-0.35	-4.93	-0.41	2.55e-6	Coronary artery disease;
TGCT	cis	rs288326	0.561	rs74564500	chr2:183786420	C/A	cg09997497	chr2:183902928	NCKAP1	1.11	4.95	0.41	2.38e-6	Blood protein levels;
TGCT	cis	rs7267979	1.000	rs6515651	chr20:25414539	T/G	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3749237	1.000	rs11717256	chr3:49868520	C/T	cg07636037	chr3:49044803	WDR6	0.61	5.41	0.44	3.08e-7	Resting heart rate;
TGCT	cis	rs7312933	0.703	rs12371615	chr12:42563989	C/G	cg19980929	chr12:42632907	YAF2	0.47	6.47	0.5	2.03e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs12142240	0.698	rs6679898	chr1:46820589	A/C	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg06713675	chr4:122721982	EXOSC9	-0.66	-8.76	-0.62	1.24e-14	Type 2 diabetes;
TGCT	cis	rs314370	1.000	rs10278546	chr7:100516003	G/T	cg10426581	chr7:100472382	SRRT	-0.9	-9.19	-0.64	1.14e-15	Resting heart rate;
TGCT	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	9.52	0.65	1.86e-16	Platelet count;
TGCT	cis	rs4901869	0.966	rs425764	chr14:59334997	A/G	cg02291164	chr14:59296302	NA	0.24	4.6	0.38	1.04e-5	Panic disorder;
TGCT	cis	rs921968	0.643	rs832806	chr2:219473914	A/T	cg02176678	chr2:219576539	TTLL4	0.36	5.11	0.42	1.2e-6	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg08045932	chr20:61659980	NA	0.48	9.28	0.64	7.07e-16	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs6570726	0.791	rs407887	chr6:145843759	C/T	cg05347473	chr6:146136440	FBXO30	0.52	4.84	0.4	3.75e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg08280861	chr8:58055591	NA	0.4	4.73	0.39	5.97e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg02493798	chr17:6899577	ALOX12	-0.39	-4.55	-0.38	1.24e-5	Tonsillectomy;
TGCT	cis	rs896854	0.654	rs13274945	chr8:95986626	C/T	cg13393036	chr8:95962371	TP53INP1	-0.59	-8.08	-0.59	4.84e-13	Type 2 diabetes;
TGCT	cis	rs3096299	0.503	rs9940093	chr16:89558705	G/A	cg02187348	chr16:89574699	SPG7	0.56	5.98	0.47	2.21e-8	Multiple myeloma (IgH translocation);
TGCT	cis	rs7216064	1.000	rs34872586	chr17:65863466	T/C	cg12091567	chr17:66097778	LOC651250	-0.83	-6.49	-0.5	1.9e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs6964587	1.000	rs12530646	chr7:91588036	A/G	cg17063962	chr7:91808500	NA	-0.89	-9.8	-0.66	3.93e-17	Breast cancer;
TGCT	cis	rs28595532	0.920	rs114162429	chr4:119741078	T/C	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs2180341	0.920	rs6916990	chr6:127698759	G/A	cg27446573	chr6:127587934	RNF146	1.16	10.52	0.69	6.95e-19	Breast cancer;
TGCT	cis	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg20637647	chr7:64974828	NA	0.9	5.31	0.43	4.87e-7	Diabetic kidney disease;
TGCT	cis	rs6490294	0.799	rs7315642	chr12:112286796	G/C	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Mean platelet volume;
TGCT	cis	rs35160687	0.901	rs12999029	chr2:86502913	G/A	cg12542933	chr2:85804724	VAMP8	0.39	4.7	0.39	6.7e-6	Night sleep phenotypes;
TGCT	cis	rs2688608	0.901	rs2664282	chr10:75620757	T/C	cg19442545	chr10:75533431	FUT11	-0.32	-5.08	-0.41	1.36e-6	Inflammatory bowel disease;
TGCT	cis	rs13242816	0.892	rs34205980	chr7:116078406	T/A	cg16553024	chr7:116138462	CAV2	-0.47	-5.25	-0.43	6.52e-7	P wave duration;
TGCT	cis	rs7937682	0.883	rs1784775	chr11:111472460	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.07	-11.27	-0.71	1.04e-20	Primary sclerosing cholangitis;
TGCT	cis	rs7394190	0.748	rs16930909	chr10:75561582	T/C	cg07699608	chr10:75541558	CHCHD1	0.79	5.44	0.44	2.72e-7	Incident atrial fibrillation;
TGCT	cis	rs11190604	1.000	rs3750629	chr10:102275727	A/G	cg23241863	chr10:102295624	HIF1AN	0.71	5.43	0.44	2.9e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg03806693	chr22:41940476	POLR3H	-1.03	-11.51	-0.72	2.62e-21	Vitiligo;
TGCT	cis	rs12497850	0.543	rs6446218	chr3:49075513	A/T	cg05785598	chr3:49045655	WDR6	0.36	4.77	0.39	5e-6	Parkinson's disease;
TGCT	cis	rs5769707	0.935	rs5770594	chr22:50018497	G/A	cg05373962	chr22:49881684	NA	-0.3	-6.29	-0.49	5.08e-9	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs17401966	0.931	rs4846205	chr1:10310214	A/T	cg19773385	chr1:10388646	KIF1B	-0.21	-4.6	-0.38	1.02e-5	Hepatocellular carcinoma;
TGCT	cis	rs4727027	0.704	rs12704070	chr7:148902789	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	4.51	0.38	1.49e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs12497850	1.000	rs4858831	chr3:48735558	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.5	-4.82	-0.4	4.06e-6	Parkinson's disease;
TGCT	cis	rs6912958	0.559	rs451829	chr6:88041919	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.41	4.81	0.4	4.22e-6	Monocyte percentage of white cells;
TGCT	cis	rs7267979	1.000	rs2482940	chr20:25349830	C/T	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10089	0.953	rs1985268	chr5:127375931	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	6.93	0.53	2e-10	Ileal carcinoids;
TGCT	cis	rs6570726	0.846	rs6570698	chr6:145918635	C/G	cg13319975	chr6:146136371	FBXO30	-0.51	-4.5	-0.37	1.53e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9297145	0.565	rs4729516	chr7:98745679	G/A	cg05967295	chr7:98741636	SMURF1	-0.68	-8.66	-0.61	2.13e-14	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg17178900	chr1:205818956	PM20D1	0.55	6.81	0.52	3.67e-10	Menarche (age at onset);
TGCT	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg08859206	chr1:53392774	SCP2	-0.39	-5.76	-0.46	6.38e-8	Monocyte count;
TGCT	cis	rs2153535	0.504	rs4493781	chr6:8473941	G/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.7	0.46	8.28e-8	Motion sickness;
TGCT	cis	rs6733011	0.508	rs925887	chr2:99514671	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.56	5.55	0.45	1.64e-7	Bipolar disorder;
TGCT	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg07217954	chr7:1067459	C7orf50	-0.48	-4.69	-0.39	7.22e-6	Bronchopulmonary dysplasia;
TGCT	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.62	6.62	0.51	9.68e-10	Height;
TGCT	cis	rs28362721	0.585	rs17159702	chr7:30959002	A/G	cg04863452	chr7:30722163	CRHR2	0.5	4.52	0.38	1.41e-5	Total body bone mineral density;
TGCT	cis	rs295140	0.903	rs10931898	chr2:201171191	C/G	cg04283868	chr2:201171347	SPATS2L	0.6	5.95	0.47	2.55e-8	QT interval;
TGCT	cis	rs6121246	0.542	rs6059761	chr20:30110522	G/C	cg21427119	chr20:30132790	HM13	-0.39	-5.6	-0.45	1.32e-7	Mean corpuscular hemoglobin;
TGCT	cis	rs7681440	0.904	rs10004413	chr4:90769479	T/C	cg01966878	chr4:90757139	SNCA	-0.25	-4.53	-0.38	1.39e-5	Dementia with Lewy bodies;
TGCT	cis	rs7845219	0.544	rs6987400	chr8:95921295	T/C	cg16049864	chr8:95962084	TP53INP1	-0.48	-5.3	-0.43	5.23e-7	Type 2 diabetes;
TGCT	cis	rs4383453	0.539	rs4677888	chr3:123101253	G/T	cg04890266	chr3:123102914	ADCY5	-0.49	-8.13	-0.59	3.67e-13	Gestational age at birth (maternal effect);
TGCT	cis	rs7666738	0.830	rs7696715	chr4:98938486	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg06618935	chr21:46677482	NA	-0.34	-5.25	-0.43	6.33e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs447921	0.861	rs452868	chr17:74421483	C/A	cg09812376	chr17:74270190	QRICH2	0.46	4.6	0.38	1.01e-5	Mitochondrial DNA levels;
TGCT	cis	rs5167	0.534	rs56803710	chr19:45481884	C/T	cg13119609	chr19:45449297	APOC2	0.23	4.65	0.39	8.26e-6	Blood protein levels;
TGCT	cis	rs17030434	0.834	rs6535958	chr4:154760834	C/G	cg14289246	chr4:154710475	SFRP2	0.88	7.58	0.56	6.86e-12	Electrocardiographic conduction measures;
TGCT	cis	rs3020333	0.653	rs851985	chr6:152020390	G/T	cg22157087	chr6:152012887	ESR1	-0.23	-5.52	-0.44	1.93e-7	Total body bone mineral density;
TGCT	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg25703541	chr22:24373054	LOC391322	-0.82	-8.61	-0.61	2.77e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg17054783	chr10:134559939	INPP5A	0.23	4.67	0.39	7.74e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs3764563	0.660	rs8107923	chr19:15737899	A/T	cg20725493	chr19:15740067	CYP4F8	-0.43	-4.67	-0.39	7.75e-6	Inflammatory biomarkers;
TGCT	cis	rs2439831	0.681	rs1549523	chr15:43624189	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	6.73	0.52	5.55e-10	Lung cancer in ever smokers;
TGCT	cis	rs7769051	1.000	rs7765224	chr6:133101624	T/C	cg22852734	chr6:133119734	C6orf192	1.22	7.01	0.53	1.38e-10	Type 2 diabetes nephropathy;
TGCT	cis	rs7698623	0.850	rs1477604	chr4:88771060	C/T	cg02735620	chr4:88950514	PKD2	-0.43	-4.66	-0.39	8.05e-6	Cardiovascular disease risk factors;
TGCT	cis	rs2346177	0.844	rs12991646	chr2:46643831	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.42	-4.48	-0.37	1.66e-5	HDL cholesterol;
TGCT	cis	rs854765	0.583	rs9908832	chr17:17871068	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.74	7.55	0.56	8.23e-12	Total body bone mineral density;
TGCT	cis	rs736408	1.000	rs4687552	chr3:52838402	T/C	cg10802521	chr3:52805072	NEK4	-0.67	-7.27	-0.55	3.55e-11	Bipolar disorder;
TGCT	cis	rs7617773	0.851	rs13068288	chr3:48331751	A/T	cg11946769	chr3:48343235	NME6	0.74	6.16	0.48	9.49e-9	Coronary artery disease;
TGCT	cis	rs11722228	0.964	rs10939614	chr4:9926613	T/C	cg00071950	chr4:10020882	SLC2A9	-0.47	-4.81	-0.4	4.22e-6	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg22920501	chr2:26401640	FAM59B	0.81	6.36	0.5	3.52e-9	Gut microbiome composition (summer);
TGCT	cis	rs7677751	0.806	rs4864859	chr4:55090015	A/G	cg17187183	chr4:55093834	PDGFRA	0.53	6.87	0.52	2.83e-10	Corneal astigmatism;
TGCT	cis	rs7647973	0.925	rs4384984	chr3:49289878	T/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.55	-4.48	-0.37	1.68e-5	Menarche (age at onset);
TGCT	trans	rs2727020	0.894	rs10839265	chr11:49369733	C/T	cg03929089	chr4:120376271	NA	-0.67	-6.99	-0.53	1.52e-10	Coronary artery disease;
TGCT	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.66	0.39	8.18e-6	Prudent dietary pattern;
TGCT	cis	rs896854	0.625	rs4735336	chr8:95973410	A/C	cg16049864	chr8:95962084	TP53INP1	0.7	9.92	0.67	1.94e-17	Type 2 diabetes;
TGCT	cis	rs12477438	0.798	rs1993230	chr2:99686079	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-5.87	-0.47	3.74e-8	Chronic sinus infection;
TGCT	trans	rs7615952	0.673	rs3811677	chr3:125648080	G/A	cg07211511	chr3:129823064	LOC729375	-0.47	-7.55	-0.56	8.34e-12	Blood pressure (smoking interaction);
TGCT	cis	rs12368653	0.591	rs1038914	chr12:58011066	G/A	cg00700412	chr12:58011837	NA	-0.23	-4.62	-0.38	9.42e-6	Multiple sclerosis;
TGCT	cis	rs6484504	0.576	rs158146	chr11:31210433	G/A	cg26647111	chr11:31128758	NA	-0.34	-4.62	-0.38	9.36e-6	Red blood cell count;
TGCT	cis	rs2067615	0.579	rs4964492	chr12:107222774	C/T	cg15890332	chr12:107067104	RFX4	0.28	5.64	0.45	1.1e-7	Heart rate;
TGCT	cis	rs7216064	0.953	rs2086744	chr17:65849275	C/G	cg12091567	chr17:66097778	LOC651250	-0.83	-6.49	-0.5	1.9e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs7666738	0.830	rs60994860	chr4:99046753	G/A	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6988636	0.901	rs62521825	chr8:124185786	C/A	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs1372520	0.564	rs356186	chr4:90705364	A/G	cg14346243	chr4:90757452	SNCA	-0.59	-4.84	-0.4	3.76e-6	Neuroticism;
TGCT	trans	rs751984	0.706	rs7947046	chr11:61259751	C/T	cg03305746	chr2:106927199	NA	0.54	6.62	0.51	9.83e-10	Diastolic blood pressure;Systolic blood pressure;Mean arterial pressure;
TGCT	trans	rs561341	1.000	rs8070262	chr17:30262467	A/G	cg20587970	chr11:113659929	NA	-0.83	-7.97	-0.58	8.86e-13	Hip circumference adjusted for BMI;
TGCT	cis	rs11190604	1.000	rs2298074	chr10:102247526	G/C	cg23241863	chr10:102295624	HIF1AN	0.6	4.54	0.38	1.3e-5	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2708977	0.637	rs654224	chr2:97080123	A/C	cg01950434	chr2:97203154	ARID5A	-0.55	-4.72	-0.39	6.22e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs7727544	0.606	rs2631360	chr5:131707429	A/G	cg14196790	chr5:131705035	SLC22A5	0.38	5.37	0.43	3.8e-7	Blood metabolite levels;
TGCT	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg14159672	chr1:205819179	PM20D1	-0.57	-7.15	-0.54	6.7e-11	Monocyte percentage of white cells;
TGCT	cis	rs2115630	1.000	rs58581703	chr15:85276935	C/T	cg17173187	chr15:85201210	NMB	-0.39	-4.85	-0.4	3.67e-6	P wave terminal force;
TGCT	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	4.44	0.37	1.93e-5	Menopause (age at onset);
TGCT	cis	rs28735056	1.000	rs28735056	chr18:77622879	A/G	cg20368463	chr18:77673604	PQLC1	-0.45	-5.66	-0.45	9.83e-8	Schizophrenia;
TGCT	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	9.52	0.65	1.86e-16	Platelet count;
TGCT	cis	rs11785400	0.753	rs9694286	chr8:143737157	G/T	cg10596483	chr8:143751796	JRK	0.57	5.64	0.45	1.11e-7	Schizophrenia;
TGCT	cis	rs9811920	0.514	rs1287283	chr3:99515750	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.59	6.81	0.52	3.75e-10	Axial length;
TGCT	cis	rs9611565	0.649	rs2413659	chr22:42164862	A/G	cg03806693	chr22:41940476	POLR3H	0.9	8.7	0.62	1.7e-14	Vitiligo;
TGCT	cis	rs4805272	0.626	rs12610050	chr19:29331324	A/T	cg04546413	chr19:29218101	NA	0.55	4.44	0.37	2e-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
TGCT	cis	rs1205863	1.000	rs864245	chr6:11943505	A/G	cg07106625	chr6:11870215	NA	0.49	4.94	0.41	2.46e-6	Disc degeneration (lumbar);
TGCT	cis	rs7394190	0.630	rs78845904	chr10:75517249	C/A	cg07699608	chr10:75541558	CHCHD1	0.77	4.86	0.4	3.48e-6	Incident atrial fibrillation;
TGCT	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg06481639	chr22:41940642	POLR3H	0.75	6.66	0.51	8.03e-10	Vitiligo;
TGCT	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg13206674	chr6:150067644	NUP43	0.52	4.51	0.38	1.5e-5	Lung cancer;
TGCT	cis	rs7909074	0.766	rs5000415	chr10:45383674	C/T	cg05187965	chr10:45406764	TMEM72	-0.27	-5.76	-0.46	6.14e-8	Mean corpuscular volume;
TGCT	cis	rs763121	0.853	rs6519119	chr22:38989007	C/G	cg06022373	chr22:39101656	GTPBP1	0.78	7.44	0.56	1.48e-11	Menopause (age at onset);
TGCT	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7772486	0.875	rs2777483	chr6:146329235	A/G	cg23711669	chr6:146136114	FBXO30	0.86	9.55	0.65	1.57e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6426558	0.537	rs2813950	chr1:227426072	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.56	-6.82	-0.52	3.54e-10	Neutrophil percentage of white cells;
TGCT	cis	rs2637266	0.935	rs2579751	chr10:78339890	G/A	cg18941641	chr10:78392320	NA	0.4	5.02	0.41	1.77e-6	Pulmonary function;
TGCT	cis	rs79349575	0.756	rs4793605	chr17:47035869	T/C	cg07967210	chr17:47022446	SNF8	0.44	6.15	0.48	9.98e-9	Type 2 diabetes;
TGCT	cis	rs288326	0.561	rs74942055	chr2:183793653	A/G	cg09997497	chr2:183902928	NCKAP1	1.11	4.95	0.41	2.38e-6	Blood protein levels;
TGCT	cis	rs2066819	0.786	rs116934693	chr12:56696545	T/G	cg26714650	chr12:56694279	CS	-1.36	-6.06	-0.48	1.54e-8	Psoriasis vulgaris;
TGCT	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.74	-7.68	-0.57	4.18e-12	Prudent dietary pattern;
TGCT	cis	rs1153858	1.000	rs2668747	chr15:45617216	T/C	cg26924012	chr15:45694286	SPATA5L1	0.95	11.32	0.71	7.65e-21	Homoarginine levels;
TGCT	trans	rs2832077	0.689	rs2832052	chr21:30130073	G/C	cg14791747	chr16:20752902	THUMPD1	0.78	6.62	0.51	9.6e-10	Cognitive test performance;
TGCT	cis	rs9929218	0.954	rs12599393	chr16:68829021	C/T	cg03880890	chr16:69439245	NA	-0.23	-4.66	-0.39	7.95e-6	Colorectal cancer;
TGCT	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg06238570	chr21:40685208	BRWD1	-0.61	-6.29	-0.49	5.04e-9	Menarche (age at onset);
TGCT	cis	rs916888	0.821	rs199507	chr17:44858855	A/G	cg15921436	chr17:44337874	NA	-0.51	-6.96	-0.53	1.77e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	trans	rs12655019	0.920	rs3756586	chr5:56217196	A/G	cg25190722	chr1:3801660	DFFB	0.62	7.17	0.54	5.87e-11	Breast cancer (early onset);
TGCT	cis	rs6988636	1.000	rs16898086	chr8:124190445	A/G	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs17125944	0.572	rs79312783	chr14:53250296	A/T	cg00686598	chr14:53173677	PSMC6	1.08	6.32	0.49	4.37e-9	Alzheimer's disease (late onset);
TGCT	trans	rs11690035	1.000	rs11682833	chr2:145623920	A/G	cg23726408	chr3:123498880	MYLK	-0.59	-6.74	-0.52	5.29e-10	Breast cancer;
TGCT	cis	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg25427524	chr10:38739819	LOC399744	-0.39	-7.88	-0.58	1.44e-12	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7646507	1.000	rs7646507	chr3:172476419	G/A	cg10532262	chr3:172428426	NCEH1	0.97	4.9	0.4	2.89e-6	Obesity-related traits;
TGCT	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg22920501	chr2:26401640	FAM59B	-0.78	-6.16	-0.48	9.43e-9	Gut microbiome composition (summer);
TGCT	cis	rs6088580	0.634	rs2225837	chr20:33005634	C/T	cg08999081	chr20:33150536	PIGU	-0.29	-5.65	-0.45	1.02e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs11249608	0.548	rs2132671	chr5:178457434	A/G	cg01312482	chr5:178451176	ZNF879	0.49	4.79	0.39	4.73e-6	Pubertal anthropometrics;
TGCT	cis	rs2997447	0.668	rs59978831	chr1:26446351	T/A	cg03844060	chr1:26490628	NA	0.28	4.55	0.38	1.27e-5	QRS complex (12-leadsum);
TGCT	cis	rs2066819	0.892	rs17118431	chr12:56667100	A/G	cg26714650	chr12:56694279	CS	-1.36	-6.06	-0.48	1.54e-8	Psoriasis vulgaris;
TGCT	cis	rs7617480	0.648	rs9882443	chr3:48749064	G/A	cg06212747	chr3:49208901	KLHDC8B	0.57	4.48	0.37	1.66e-5	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs17221829	0.965	rs12278734	chr11:89461172	G/A	cg02982614	chr11:89391479	FOLH1B	-0.31	-5.44	-0.44	2.67e-7	Anxiety in major depressive disorder;
TGCT	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg12042659	chr19:58951599	ZNF132	0.51	4.66	0.39	7.97e-6	Uric acid clearance;
TGCT	cis	rs13168506	0.552	rs889010	chr5:135572910	C/A	cg00308130	chr5:135415190	NA	0.3	4.46	0.37	1.84e-5	Stroke;
TGCT	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg06896619	chr17:61851486	DDX42;CCDC47	0.52	5.28	0.43	5.68e-7	Prudent dietary pattern;
TGCT	cis	rs2115536	1.000	rs7163338	chr15:80198408	C/G	cg00225070	chr15:80189496	MTHFS	0.59	5.26	0.43	6.05e-7	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs6061231	0.834	rs2427307	chr20:60966686	G/A	cg24112000	chr20:60950667	NA	-0.35	-4.86	-0.4	3.49e-6	Colorectal cancer;
TGCT	cis	rs9653442	0.510	rs13415583	chr2:100764087	T/G	cg22139774	chr2:100720529	AFF3	-0.36	-5.72	-0.46	7.68e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs950027	0.549	rs9920634	chr15:45596546	G/T	cg14582100	chr15:45693742	SPATA5L1	-0.47	-5.86	-0.47	3.9e-8	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs250677	0.522	rs1432798	chr5:148383345	C/G	cg18129178	chr5:148520854	ABLIM3	-0.39	-5.47	-0.44	2.39e-7	Breast cancer;
TGCT	trans	rs208520	0.874	rs208517	chr6:66947040	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-9.93	-0.67	1.84e-17	Exhaled nitric oxide output;
TGCT	cis	rs7613051	0.891	rs4343578	chr3:33052750	T/C	cg19000631	chr3:33138515	GLB1;TMPPE	0.66	4.77	0.39	5.1e-6	Atopic dermatitis;
TGCT	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg22920501	chr2:26401640	FAM59B	0.71	6.41	0.5	2.74e-9	Gut microbiome composition (summer);
TGCT	cis	rs208520	0.526	rs9354370	chr6:66808209	C/T	cg07460842	chr6:66804631	NA	1.06	15.79	0.82	1.8e-31	Exhaled nitric oxide output;
TGCT	cis	rs36051895	0.632	rs10974979	chr9:5131731	C/A	cg02405213	chr9:5042618	JAK2	-0.71	-9.55	-0.65	1.57e-16	Pediatric autoimmune diseases;
TGCT	cis	rs17681684	0.565	rs12150182	chr17:9764757	C/T	cg15743799	chr17:9805578	RCVRN	-0.27	-5.89	-0.47	3.45e-8	GIP levels in response to oral glucose tolerance test (fasting);
TGCT	cis	rs17401966	0.800	rs12122029	chr1:10339822	G/A	cg19773385	chr1:10388646	KIF1B	-0.2	-4.5	-0.37	1.54e-5	Hepatocellular carcinoma;
TGCT	cis	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg18252515	chr7:66147081	NA	-1.09	-6.4	-0.5	2.88e-9	Diabetic kidney disease;
TGCT	cis	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg20637647	chr7:64974828	NA	-0.92	-5.09	-0.42	1.26e-6	Diabetic kidney disease;
TGCT	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg22920501	chr2:26401640	FAM59B	-0.79	-5.42	-0.44	2.94e-7	Gut microbiome composition (summer);
TGCT	cis	rs7547997	0.685	rs11264965	chr1:158352400	T/G	cg07950803	chr1:158223934	CD1A	0.32	4.78	0.39	4.95e-6	QRS duration;
TGCT	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg17554472	chr22:41940697	POLR3H	-0.46	-4.71	-0.39	6.63e-6	Vitiligo;
TGCT	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	4.86	0.4	3.5e-6	Bipolar disorder;
TGCT	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg04025307	chr7:1156635	C7orf50	0.22	5.3	0.43	5.19e-7	Longevity;Endometriosis;
TGCT	cis	rs910187	0.571	rs6512428	chr20:45807822	T/C	cg27589058	chr20:45804311	EYA2	-0.4	-9.0	-0.63	3.33e-15	Migraine;
TGCT	cis	rs9814567	0.964	rs9815983	chr3:134222507	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.95	-9.62	-0.65	1.04e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	trans	rs208520	0.874	rs208491	chr6:66928459	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.97	-10.05	-0.67	9.41e-18	Exhaled nitric oxide output;
TGCT	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg24531977	chr5:56204891	C5orf35	0.97	9.1	0.63	1.86e-15	Initial pursuit acceleration;
TGCT	cis	rs3733585	0.638	rs6414766	chr4:9956474	G/A	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.73	-0.57	3.25e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs8067545	1.000	rs7211535	chr17:19922364	A/G	cg13482628	chr17:19912719	NA	0.56	4.82	0.4	4.18e-6	Schizophrenia;
TGCT	cis	rs4321325	0.733	rs4510165	chr2:127936284	C/T	cg09760422	chr2:128146352	NA	0.41	4.5	0.37	1.56e-5	Protein C levels;
TGCT	cis	rs58688157	0.960	rs12422022	chr11:613192	A/G	cg16486109	chr11:613632	IRF7	0.36	5.26	0.43	6.02e-7	Systemic lupus erythematosus;
TGCT	cis	rs10510102	0.872	rs11200267	chr10:123689366	A/T	cg23691251	chr10:123688108	ATE1	-0.56	-4.51	-0.38	1.46e-5	Breast cancer;
TGCT	cis	rs4889855	0.614	rs7208670	chr17:78494220	T/G	cg16591659	chr17:78472290	NA	-0.35	-5.56	-0.45	1.58e-7	Fractional excretion of uric acid;
TGCT	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.71	6.36	0.5	3.53e-9	Tonsillectomy;
TGCT	cis	rs9291683	0.561	rs3733584	chr4:10036506	T/C	cg00071950	chr4:10020882	SLC2A9	0.68	8.84	0.62	7.71e-15	Bone mineral density;
TGCT	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.46	-6.76	-0.52	4.77e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg13206674	chr6:150067644	NUP43	0.52	4.51	0.38	1.5e-5	Lung cancer;
TGCT	cis	rs2535633	0.631	rs2710346	chr3:52974152	C/T	cg10802521	chr3:52805072	NEK4	0.54	5.71	0.46	7.74e-8	Body mass index;
TGCT	cis	rs7744392	0.557	rs9658083	chr6:35337291	G/C	cg06087101	chr6:35551932	FKBP5	0.61	4.56	0.38	1.21e-5	Cataracts in type 2 diabetes;
TGCT	cis	rs9914988	0.943	rs4795467	chr17:27180784	C/T	cg20469991	chr17:27169893	C17orf63	-0.72	-4.72	-0.39	6.29e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs3093024	0.839	rs968334	chr6:167526096	T/C	cg07741184	chr6:167504864	NA	-0.24	-4.69	-0.39	7.01e-6	Rheumatoid arthritis;
TGCT	cis	rs8016982	0.674	rs1957549	chr14:81706179	G/A	cg01989461	chr14:81687754	GTF2A1	0.84	8.66	0.61	2.12e-14	Schizophrenia;
TGCT	cis	rs1055129	0.655	rs7223416	chr17:73836162	C/G	cg10935138	chr17:73851978	WBP2	0.53	4.58	0.38	1.13e-5	White matter hyperintensity burden;
TGCT	cis	rs7246657	0.765	rs4803262	chr19:38066760	G/A	cg03611452	chr19:38183253	ZNF781	0.58	4.64	0.38	8.62e-6	Coronary artery calcification;
TGCT	cis	rs765787	0.530	rs1706834	chr15:45517854	G/A	cg24006582	chr15:45444508	DUOX1	-0.25	-5.37	-0.43	3.78e-7	Uric acid levels;
TGCT	cis	rs1200821	0.529	rs4934856	chr10:37807847	T/C	cg25427524	chr10:38739819	LOC399744	0.3	5.29	0.43	5.23e-7	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs9611565	0.921	rs2235846	chr22:41741042	G/C	cg13695892	chr22:41940480	POLR3H	-0.72	-7.37	-0.55	2.15e-11	Vitiligo;
TGCT	cis	rs12451471	0.620	rs11150846	chr17:78098520	C/T	cg06718696	chr17:78121285	EIF4A3	0.74	6.04	0.48	1.69e-8	Plateletcrit;Mean corpuscular hemoglobin concentration;
TGCT	cis	rs3087591	0.639	rs734403	chr17:29723346	T/C	cg24425628	chr17:29625626	OMG;NF1	0.4	5.85	0.47	4.05e-8	Hip circumference;
TGCT	trans	rs11082438	1.000	rs11082438	chr18:42865210	G/T	cg03885119	chr10:117885028	GFRA1	-0.86	-6.85	-0.52	3.06e-10	Follicular lymphoma;
TGCT	cis	rs7267979	0.844	rs6132824	chr20:25238173	T/C	cg03522245	chr20:25566470	NINL	0.57	5.67	0.45	9.54e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2806561	0.704	rs674386	chr1:23521835	G/A	cg12483005	chr1:23474871	LUZP1	0.42	5.41	0.44	3.15e-7	Height;
TGCT	cis	rs739496	0.947	rs7973120	chr12:111856738	T/A	cg10833066	chr12:111807467	FAM109A	0.37	5.2	0.42	8.01e-7	Platelet count;
TGCT	cis	rs35146811	0.586	rs12666107	chr7:99778019	G/C	cg04778012	chr7:99775508	STAG3;GPC2	0.34	4.66	0.39	8.03e-6	Coronary artery disease;
TGCT	cis	rs6815814	0.898	rs5743592	chr4:38803063	A/G	cg02016764	chr4:38805732	TLR1	-0.37	-6.35	-0.5	3.67e-9	Breast cancer;
TGCT	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg20607798	chr8:58055168	NA	0.59	4.94	0.41	2.46e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.6	0.51	1.05e-9	Bipolar disorder;
TGCT	cis	rs921968	0.643	rs537520	chr2:219381852	A/G	cg02176678	chr2:219576539	TTLL4	0.43	6.35	0.5	3.63e-9	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs80282103	0.618	rs2387299	chr10:1163427	A/G	cg08668510	chr10:1095578	IDI1	1.06	5.02	0.41	1.79e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs11190604	1.000	rs3793706	chr10:102269085	A/C	cg16342193	chr10:102329863	NA	0.39	5.01	0.41	1.83e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs667920	0.573	rs9682783	chr3:136539689	T/C	cg15507776	chr3:136538369	TMEM22	0.67	6.5	0.5	1.81e-9	Coronary artery disease;
TGCT	cis	rs5769765	0.624	rs138843	chr22:50183162	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.94	-8.34	-0.6	1.21e-13	Schizophrenia;
TGCT	cis	rs11190604	0.767	rs7090150	chr10:102173446	G/T	cg23241863	chr10:102295624	HIF1AN	0.6	4.57	0.38	1.17e-5	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg22168489	chr12:122356033	WDR66	0.23	5.55	0.45	1.63e-7	Mean corpuscular volume;
TGCT	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg03264133	chr6:25882463	NA	-0.61	-5.68	-0.45	8.98e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9910055	0.529	rs228764	chr17:42185469	A/G	cg13607699	chr17:42295918	UBTF	-0.62	-4.97	-0.41	2.18e-6	Total body bone mineral density;
TGCT	cis	rs9921338	0.961	rs72773829	chr16:11412623	G/A	cg00044050	chr16:11439710	C16orf75	-0.93	-6.96	-0.53	1.7e-10	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs4629710	0.592	rs9492865	chr6:131534403	T/A	cg12606694	chr6:131520996	AKAP7	0.39	4.62	0.38	9.58e-6	Multiple myeloma (IgH translocation);
TGCT	cis	rs6430585	0.702	rs2304601	chr2:136528034	C/A	cg07169764	chr2:136633963	MCM6	1.2	11.43	0.72	4.14e-21	Corneal structure;
TGCT	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg07061783	chr6:25882402	NA	-0.58	-5.6	-0.45	1.34e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9383153	1.000	rs2237223	chr6:16329741	G/A	cg23850913	chr6:15505452	JARID2	0.92	4.86	0.4	3.42e-6	Gambling;
TGCT	cis	rs6750047	0.719	rs4670232	chr2:38272033	C/G	cg07380506	chr2:38303506	CYP1B1	0.56	5.05	0.41	1.51e-6	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.47	0.56	1.28e-11	Prudent dietary pattern;
TGCT	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg24250549	chr1:154909240	PMVK	0.63	6.25	0.49	6.03e-9	Prostate cancer;
TGCT	cis	rs3020736	0.500	rs2839708	chr22:42500745	A/G	cg15557168	chr22:42548783	NA	0.22	5.58	0.45	1.47e-7	Autism spectrum disorder or schizophrenia;
TGCT	trans	rs7615952	0.932	rs9841157	chr3:125635655	C/A	cg07211511	chr3:129823064	LOC729375	-0.45	-6.72	-0.52	5.83e-10	Blood pressure (smoking interaction);
TGCT	cis	rs4851254	0.920	rs13011874	chr2:100752497	C/T	cg23118464	chr2:100721844	AFF3	0.71	5.28	0.43	5.6e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg11644478	chr21:40555479	PSMG1	-0.53	-4.86	-0.4	3.53e-6	Menarche (age at onset);
TGCT	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.43	6.12	0.48	1.13e-8	Alzheimer's disease;
TGCT	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg25703541	chr22:24373054	LOC391322	-0.82	-8.62	-0.61	2.61e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg04772025	chr11:68637568	NA	0.62	6.89	0.53	2.52e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7226408	0.857	rs72885275	chr18:34439624	G/A	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg18252515	chr7:66147081	NA	1.25	7.75	0.57	2.92e-12	Diabetic kidney disease;
TGCT	cis	rs8072100	0.905	rs8078686	chr17:45735706	T/C	cg08085267	chr17:45401833	C17orf57	0.43	4.74	0.39	5.86e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg20607798	chr8:58055168	NA	0.45	4.68	0.39	7.52e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs3741404	0.931	rs594942	chr11:64006292	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.87	-9.49	-0.65	2.14e-16	Platelet count;
TGCT	cis	rs7681440	0.728	rs974711	chr4:90737327	G/A	cg26578617	chr4:90757533	SNCA	-0.45	-4.58	-0.38	1.1e-5	Dementia with Lewy bodies;
TGCT	cis	rs514406	0.621	rs928452	chr1:53195926	G/C	cg24675658	chr1:53192096	ZYG11B	0.84	10.45	0.68	1.03e-18	Monocyte count;
TGCT	cis	rs7255045	0.742	rs10420014	chr19:12960947	G/T	cg23899408	chr19:12877188	HOOK2	-0.56	-4.44	-0.37	1.96e-5	Mean corpuscular volume;
TGCT	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg08280861	chr8:58055591	NA	0.39	4.86	0.4	3.45e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2346177	0.875	rs2166745	chr2:46646879	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.43	-4.75	-0.39	5.45e-6	HDL cholesterol;
TGCT	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg27541892	chr1:1571801	CDK11B	-0.4	-5.34	-0.43	4.24e-7	Body mass index;
TGCT	cis	rs35146811	0.735	rs6948729	chr7:99787372	A/G	cg00553149	chr7:99775558	STAG3;GPC2	0.31	4.61	0.38	9.75e-6	Coronary artery disease;
TGCT	cis	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg25427524	chr10:38739819	LOC399744	-0.39	-8.03	-0.58	6.56e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs9560113	1.000	rs60374273	chr13:112179206	A/T	cg14154082	chr13:112174009	NA	0.37	5.07	0.41	1.42e-6	Menarche (age at onset);
TGCT	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg05872129	chr22:39784769	NA	-1.01	-11.09	-0.71	2.82e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs10927875	0.632	rs6699394	chr1:16145143	C/A	cg21385522	chr1:16154831	NA	-1.0	-17.85	-0.85	4.62e-36	Dilated cardiomyopathy;
TGCT	cis	rs885389	1.000	rs885389	chr12:131621762	C/T	cg07124762	chr12:131619285	GPR133	0.3	5.94	0.47	2.74e-8	RR interval (heart rate);
TGCT	cis	rs11122272	0.705	rs2572260	chr1:231486189	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-6.88	-0.53	2.66e-10	Hemoglobin concentration;
TGCT	cis	rs3733585	0.683	rs13112015	chr4:9933796	C/T	cg00071950	chr4:10020882	SLC2A9	-0.61	-7.25	-0.55	3.96e-11	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs2455799	0.613	rs4685269	chr3:15942354	A/G	cg16303742	chr3:15540471	COLQ	-0.24	-4.53	-0.38	1.36e-5	Mean platelet volume;
TGCT	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg26338869	chr17:61819248	STRADA	-0.53	-4.94	-0.41	2.48e-6	Prudent dietary pattern;
TGCT	cis	rs35306767	0.714	rs7075188	chr10:1088746	G/T	cg26597838	chr10:835615	NA	-0.46	-5.12	-0.42	1.16e-6	Eosinophil percentage of granulocytes;
TGCT	cis	rs7215564	0.818	rs4889776	chr17:78592385	C/T	cg23263226	chr17:78226839	SLC26A11	0.45	4.56	0.38	1.23e-5	Myopia (pathological);
TGCT	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.94	7.92	0.58	1.17e-12	Platelet count;
TGCT	cis	rs9611565	0.504	rs5758452	chr22:42144927	G/A	cg03806693	chr22:41940476	POLR3H	0.9	8.76	0.62	1.2e-14	Vitiligo;
TGCT	cis	rs17443541	0.507	rs1450568	chr2:200446732	A/T	cg00055341	chr2:200446845	NA	-0.38	-4.6	-0.38	1.02e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs66561647	0.661	rs7387614	chr8:128929353	C/T	cg05480350	chr8:128972681	MIR1205;PVT1	0.22	4.55	0.38	1.24e-5	Hemoglobin concentration;
TGCT	cis	rs12220238	0.722	rs11001087	chr10:76384602	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.63	4.89	0.4	3.02e-6	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs9534288	0.797	rs1134071	chr13:46562935	A/G	cg15192986	chr13:46630673	CPB2	-0.53	-7.62	-0.56	5.82e-12	Blood protein levels;
TGCT	cis	rs35883536	1.000	rs964906	chr1:101087479	G/A	cg06223162	chr1:101003688	GPR88	0.31	4.89	0.4	3.07e-6	Monocyte count;
TGCT	cis	rs11578119	0.933	rs12130086	chr1:170483041	T/A	cg09767346	chr1:170501363	GORAB	0.66	5.29	0.43	5.27e-7	Male-pattern baldness;
TGCT	cis	rs2551802	0.615	rs17395735	chr2:177067780	C/T	cg13092806	chr2:177043255	NA	0.55	4.45	0.37	1.92e-5	Motion sickness;
TGCT	cis	rs9467773	1.000	rs9467782	chr6:26542773	G/A	cg09904177	chr6:26538194	HMGN4	0.65	6.53	0.51	1.53e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs8031584	0.723	rs711224	chr15:31127921	G/C	cg08109568	chr15:31115862	NA	0.39	5.19	0.42	8.33e-7	Huntington's disease progression;
TGCT	cis	rs9560113	0.960	rs950891	chr13:112173992	G/A	cg14154082	chr13:112174009	NA	-0.36	-5.06	-0.41	1.46e-6	Menarche (age at onset);
TGCT	cis	rs9435341	0.965	rs56111229	chr1:107566689	T/A	cg09367891	chr1:107599246	PRMT6	0.62	5.4	0.44	3.22e-7	Facial morphology (factor 21, depth of nasal alae);
TGCT	cis	rs1023500	0.596	rs5758562	chr22:42448238	C/G	cg05082376	chr22:42548792	NA	-0.22	-5.29	-0.43	5.32e-7	Schizophrenia;
TGCT	cis	rs7605378	1.000	rs2577852	chr2:200687248	C/T	cg17644776	chr2:200775616	C2orf69	0.29	5.51	0.44	1.94e-7	Osteoporosis;
TGCT	cis	rs8102137	0.588	rs7257694	chr19:30314666	C/T	cg09247459	chr19:30364939	NA	0.3	4.61	0.38	9.9e-6	Bladder cancer;
TGCT	cis	rs2120019	1.000	rs67544533	chr15:75361539	A/G	cg17294928	chr15:75287854	SCAMP5	-0.83	-6.32	-0.49	4.37e-9	Blood trace element (Zn levels);
TGCT	cis	rs7178572	0.539	rs16968809	chr15:77672118	C/T	cg22256960	chr15:77711686	NA	0.84	8.15	0.59	3.39e-13	Type 2 diabetes;
TGCT	cis	rs7781977	0.735	rs716719	chr7:50325717	A/C	cg01139861	chr7:50343298	IKZF1	-0.44	-4.64	-0.38	8.75e-6	IgG glycosylation;
TGCT	cis	rs826838	0.510	rs10876149	chr12:39228083	C/G	cg26384229	chr12:38710491	ALG10B	-0.59	-4.8	-0.4	4.41e-6	Heart rate;
TGCT	cis	rs13064411	0.660	rs11916690	chr3:113012343	A/C	cg18753928	chr3:113234510	CCDC52	-0.69	-4.93	-0.4	2.58e-6	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs71636778	0.509	rs12739698	chr1:27230033	G/A	cg23921621	chr1:27994728	IFI6	-0.43	-4.61	-0.38	9.95e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
TGCT	cis	rs73001065	0.901	rs73004959	chr19:19711139	C/T	cg03709012	chr19:19516395	GATAD2A	1.03	5.08	0.41	1.36e-6	LDL cholesterol;
TGCT	cis	rs514406	0.505	rs374662	chr1:53164549	C/A	cg01802117	chr1:53393560	SCP2	-0.42	-4.84	-0.4	3.86e-6	Monocyte count;
TGCT	trans	rs7726839	0.794	rs6883536	chr5:599274	G/A	cg11887960	chr12:57824829	NA	0.97	7.56	0.56	7.58e-12	Obesity-related traits;
TGCT	cis	rs59197085	0.534	rs2307038	chr7:128449356	A/C	cg00260937	chr7:128520193	KCP	0.47	4.9	0.4	2.92e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
TGCT	cis	rs2180341	0.889	rs2000909	chr6:127711173	G/A	cg24812749	chr6:127587940	RNF146	0.79	6.58	0.51	1.21e-9	Breast cancer;
TGCT	cis	rs875971	0.830	rs427973	chr7:65526648	C/A	cg18876405	chr7:65276391	NA	0.33	4.95	0.41	2.39e-6	Aortic root size;
TGCT	cis	rs3849570	0.533	rs4440144	chr3:81988359	A/G	cg07356753	chr3:81810745	GBE1	-0.54	-4.5	-0.37	1.52e-5	Waist circumference;Body mass index;
TGCT	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg13665807	chr20:60559372	TAF4	-0.46	-4.9	-0.4	2.87e-6	Body mass index;
TGCT	cis	rs7542091	0.506	rs992976	chr1:210066658	A/T	cg22029157	chr1:209979665	IRF6	-0.52	-4.89	-0.4	3.03e-6	Monobrow;
TGCT	cis	rs61990749	0.544	rs8003979	chr14:78211290	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	0.67	4.73	0.39	6.09e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs28735056	0.933	rs499260	chr18:77589689	G/A	cg20368463	chr18:77673604	PQLC1	-0.45	-5.53	-0.44	1.84e-7	Schizophrenia;
TGCT	cis	rs1712517	0.525	rs2271751	chr10:105175131	A/G	cg04362960	chr10:104952993	NT5C2	-0.56	-4.67	-0.39	7.69e-6	Migraine;
TGCT	cis	rs921968	0.541	rs2241527	chr2:219537224	A/G	cg02176678	chr2:219576539	TTLL4	0.51	7.55	0.56	8.06e-12	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs1801251	1.000	rs4517962	chr2:233578337	T/C	cg08000102	chr2:233561755	GIGYF2	0.64	6.56	0.51	1.3e-9	Coronary artery disease;
TGCT	cis	rs950169	0.580	rs11633762	chr15:85187152	T/C	cg17173187	chr15:85201210	NMB	0.61	6.94	0.53	1.92e-10	Schizophrenia;
TGCT	cis	rs10206020	0.921	rs6605278	chr2:1547230	C/T	cg01028140	chr2:1542097	TPO	-0.32	-4.65	-0.39	8.2e-6	IgG glycosylation;
TGCT	cis	rs651907	0.557	rs11914318	chr3:101453858	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.33	-6.78	-0.52	4.35e-10	Colorectal cancer;
TGCT	cis	rs13256369	0.951	rs10503394	chr8:8565775	A/G	cg06671706	chr8:8559999	CLDN23	0.34	4.52	0.38	1.45e-5	Obesity-related traits;
TGCT	cis	rs734999	0.869	rs61054170	chr1:2498052	C/T	cg17806162	chr1:2472133	NA	-0.26	-4.46	-0.37	1.78e-5	Ulcerative colitis;
TGCT	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg15242686	chr22:24348715	GSTTP1	0.45	6.4	0.5	2.86e-9	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs17345786	0.817	rs11720560	chr3:101328484	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.57	4.85	0.4	3.59e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2439831	0.850	rs694985	chr15:43813387	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.94	7.52	0.56	9.73e-12	Lung cancer in ever smokers;
TGCT	cis	rs4455778	0.580	rs4607559	chr7:49121902	G/A	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs28785552	0.931	rs10424385	chr19:53239133	C/G	cg10871876	chr19:53194124	ZNF83	0.62	8.85	0.62	7.42e-15	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs11148252	0.557	rs9536223	chr13:53233194	A/T	cg00495681	chr13:53174319	NA	0.65	6.56	0.51	1.32e-9	Lewy body disease;
TGCT	cis	rs8016982	0.617	rs2241621	chr14:81737076	G/T	cg01989461	chr14:81687754	GTF2A1	-0.65	-6.49	-0.5	1.85e-9	Schizophrenia;
TGCT	cis	rs7255045	0.742	rs6511840	chr19:12954720	C/T	cg23899408	chr19:12877188	HOOK2	-0.59	-4.86	-0.4	3.44e-6	Mean corpuscular volume;
TGCT	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs950169	0.922	rs12915832	chr15:85111457	C/T	cg17173187	chr15:85201210	NMB	0.48	5.02	0.41	1.75e-6	Schizophrenia;
TGCT	cis	rs2439831	0.681	rs1549525	chr15:43627855	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	6.73	0.52	5.55e-10	Lung cancer in ever smokers;
TGCT	cis	rs3820068	0.705	rs4646072	chr1:15827711	G/A	cg05660106	chr1:15850417	CASP9	1.18	13.63	0.77	2.04e-26	Systolic blood pressure;
TGCT	cis	rs7552404	0.731	rs12090849	chr1:76400261	A/G	cg10523679	chr1:76189770	ACADM	0.8	6.99	0.53	1.52e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2361710	1.000	rs2361710	chr17:78111877	C/T	cg09238746	chr17:78121135	EIF4A3	0.69	6.43	0.5	2.51e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
TGCT	cis	rs7666738	1.000	rs880471	chr4:98922541	C/T	cg17366294	chr4:99064904	C4orf37	0.72	6.58	0.51	1.17e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7772486	0.743	rs9403742	chr6:146060193	A/C	cg05347473	chr6:146136440	FBXO30	0.48	4.51	0.38	1.48e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1670533	1.000	rs62294756	chr4:1097676	G/A	cg20518497	chr4:1046821	NA	0.27	4.46	0.37	1.84e-5	Recombination rate (females);
TGCT	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg11644478	chr21:40555479	PSMG1	1.03	11.02	0.7	4.14e-20	Cognitive function;
TGCT	cis	rs7017914	0.967	rs12675271	chr8:71602009	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.51	-4.68	-0.39	7.43e-6	Bone mineral density;
TGCT	cis	rs7267979	1.000	rs6115153	chr20:25325567	T/C	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2657888	0.899	rs7300877	chr12:56933233	C/A	cg23932658	chr12:57637574	STAC3	0.48	4.56	0.38	1.19e-5	Adiponectin levels;
TGCT	cis	rs7258465	1.000	rs10427083	chr19:18550276	C/A	cg06462663	chr19:18546047	ISYNA1	0.2	4.54	0.38	1.33e-5	Breast cancer;
TGCT	cis	rs17376456	0.597	rs7733142	chr5:93322795	C/A	cg25358565	chr5:93447407	FAM172A	-0.64	-6.0	-0.47	2e-8	Diabetic retinopathy;
TGCT	cis	rs7917772	0.539	rs12572775	chr10:104285594	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.56	-5.31	-0.43	4.92e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2153535	0.580	rs7341201	chr6:8470270	T/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs9381040	0.655	rs6903444	chr6:41014220	C/T	cg03526776	chr6:41159608	TREML2	-0.27	-5.34	-0.43	4.33e-7	Alzheimer's disease (late onset);
TGCT	cis	rs2760061	0.819	rs708111	chr1:228191365	G/A	cg18477163	chr1:228402036	OBSCN	0.34	7.16	0.54	6.26e-11	Diastolic blood pressure;
TGCT	cis	rs9467711	0.606	rs2235251	chr6:26431982	C/T	cg10795676	chr6:26370623	BTN3A2	-0.45	-4.56	-0.38	1.23e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7208859	0.623	rs9914242	chr17:29216245	G/T	cg14008862	chr17:28927542	LRRC37B2	0.69	4.46	0.37	1.83e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs2159324	1.000	rs2109065	chr19:45695610	T/A	cg24080119	chr19:45644694	NA	0.3	4.78	0.39	4.78e-6	Quantitative traits;
TGCT	cis	rs2777491	0.574	rs28700583	chr15:41714072	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.94	-17.34	-0.84	6.15e-35	Ulcerative colitis;
TGCT	cis	rs7614311	0.636	rs73130576	chr3:63890875	T/C	cg22134162	chr3:63841271	THOC7	-0.4	-5.16	-0.42	9.41e-7	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs11122272	0.735	rs2739506	chr1:231529183	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-6.34	-0.49	3.83e-9	Hemoglobin concentration;
TGCT	cis	rs3820068	0.705	rs951225	chr1:15826292	G/A	cg05660106	chr1:15850417	CASP9	1.16	14.82	0.8	3.11e-29	Systolic blood pressure;
TGCT	cis	rs6964587	1.000	rs7797834	chr7:91743150	C/T	cg22709100	chr7:91322751	NA	-0.3	-4.83	-0.4	4.02e-6	Breast cancer;
TGCT	cis	rs13191362	1.000	rs35583420	chr6:163214327	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.94	5.88	0.47	3.54e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs11676348	0.846	rs4674260	chr2:219002376	T/C	cg00012203	chr2:219082015	ARPC2	-0.51	-4.86	-0.4	3.53e-6	Ulcerative colitis;
TGCT	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg14159672	chr1:205819179	PM20D1	0.72	10.29	0.68	2.45e-18	Menarche (age at onset);
TGCT	cis	rs651907	0.557	rs17411983	chr3:101399126	A/G	cg11279151	chr3:101281821	RG9MTD1	0.35	7.28	0.55	3.4e-11	Colorectal cancer;
TGCT	cis	rs4642101	0.561	rs9831765	chr3:12805934	A/T	cg05775895	chr3:12838266	CAND2	0.53	5.22	0.42	7.19e-7	QRS complex (12-leadsum);
TGCT	cis	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg20637647	chr7:64974828	NA	1.0	5.59	0.45	1.4e-7	Diabetic kidney disease;
TGCT	trans	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.86	9.38	0.64	3.95e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs694419	0.602	rs4941141	chr18:60194470	C/G	cg13506219	chr18:60193840	ZCCHC2	-0.54	-4.93	-0.4	2.57e-6	Serum albumin level;
TGCT	cis	rs9388451	0.868	rs1268083	chr6:126049040	T/C	cg10911889	chr6:126070802	HEY2	-0.5	-4.84	-0.4	3.72e-6	Brugada syndrome;
TGCT	cis	rs10089	1.000	rs4836363	chr5:127462737	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	7.41	0.55	1.72e-11	Ileal carcinoids;
TGCT	cis	rs4523957	0.583	rs2760745	chr17:2035591	T/C	cg16513277	chr17:2031491	SMG6	-0.2	-4.58	-0.38	1.13e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs2282802	0.685	rs7717576	chr5:139623591	G/A	cg01081189	chr5:139537190	NA	0.28	5.08	0.41	1.36e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs319204	0.959	rs599812	chr5:146280414	C/A	cg25021259	chr5:146258546	PPP2R2B	0.36	4.6	0.38	1.02e-5	Schizophrenia;
TGCT	cis	rs12643440	0.538	rs10939707	chr4:17146776	G/T	cg22650099	chr4:17144496	NA	-0.49	-5.03	-0.41	1.66e-6	Metabolite levels (Pyroglutamine);
TGCT	cis	rs3806843	0.676	rs2245640	chr5:140029958	A/G	cg19875535	chr5:140030758	IK	-0.37	-6.36	-0.5	3.6e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs17601876	0.814	rs35939475	chr15:51554710	C/A	cg19946085	chr15:51559439	CYP19A1	-0.32	-4.84	-0.4	3.84e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg06713675	chr4:122721982	EXOSC9	-0.69	-9.69	-0.66	7.11e-17	Type 2 diabetes;
TGCT	cis	rs1577917	0.958	rs10806337	chr6:86474249	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.48	-0.44	2.28e-7	Response to antipsychotic treatment;
TGCT	cis	rs9898058	0.556	rs1135034	chr17:47783663	C/T	cg10517230	chr17:48661425	CACNA1G	0.47	4.51	0.38	1.48e-5	Milk allergy;
TGCT	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg06112835	chr11:68658793	MRPL21	0.45	7.64	0.57	5.19e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs79149102	0.579	rs3910748	chr15:75318652	A/G	cg09165964	chr15:75287851	SCAMP5	-1.05	-5.73	-0.46	7.26e-8	Lung cancer;
TGCT	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg00814883	chr7:100076585	TSC22D4	-0.9	-9.56	-0.65	1.5e-16	Platelet count;
TGCT	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs11122272	0.735	rs2474633	chr1:231486989	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-6.61	-0.51	1.01e-9	Hemoglobin concentration;
TGCT	cis	rs9467773	0.869	rs1796521	chr6:26421392	T/C	cg15659132	chr6:26577336	NA	-0.54	-5.67	-0.45	9.4e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs514406	0.763	rs6685599	chr1:53213172	G/A	cg24675658	chr1:53192096	ZYG11B	0.71	7.96	0.58	9.48e-13	Monocyte count;
TGCT	cis	rs9318086	0.935	rs9652080	chr13:24435426	A/C	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.68	-6.87	-0.52	2.82e-10	Myopia (pathological);
TGCT	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg08280861	chr8:58055591	NA	0.39	4.86	0.4	3.45e-6	Developmental language disorder (linguistic errors);
TGCT	trans	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg27523141	chr10:43048294	ZNF37B	0.71	8.17	0.59	3.03e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs1697139	0.583	rs13186050	chr5:66528139	C/T	cg11553311	chr5:66541588	NA	0.3	6.37	0.5	3.36e-9	Breast cancer;
TGCT	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg17971929	chr21:40555470	PSMG1	-0.52	-4.64	-0.38	8.72e-6	Menarche (age at onset);
TGCT	cis	rs72781680	0.898	rs7563564	chr2:23993404	T/C	cg08917208	chr2:24149416	ATAD2B	0.81	5.01	0.41	1.8e-6	Lymphocyte counts;
TGCT	cis	rs6490294	0.748	rs2269802	chr12:112326138	A/G	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Mean platelet volume;
TGCT	cis	rs2639990	1.000	rs1702831	chr18:72897368	C/A	cg02750262	chr18:72916776	ZADH2	0.87	6.6	0.51	1.08e-9	Vascular endothelial growth factor levels;
TGCT	cis	rs4478037	0.643	rs9875798	chr3:33120448	G/C	cg19404215	chr3:33155277	CRTAP	1.28	6.37	0.5	3.33e-9	Major depressive disorder;
TGCT	cis	rs6570726	0.791	rs9390336	chr6:145896823	A/T	cg13319975	chr6:146136371	FBXO30	-0.5	-4.51	-0.38	1.48e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs763121	0.853	rs5750652	chr22:39048316	A/G	cg06022373	chr22:39101656	GTPBP1	0.8	8.25	0.6	1.95e-13	Menopause (age at onset);
TGCT	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	5.84	0.46	4.3e-8	Bipolar disorder;
TGCT	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg17971929	chr21:40555470	PSMG1	-0.7	-6.7	-0.52	6.41e-10	Cognitive function;
TGCT	cis	rs3859192	0.539	rs2302774	chr17:38183090	G/T	cg17467752	chr17:38218738	THRA	-0.57	-5.13	-0.42	1.08e-6	White blood cell count;
TGCT	cis	rs2235642	0.821	rs8051895	chr16:1602811	A/G	cg07341220	chr16:1583899	IFT140;TMEM204	-0.29	-4.56	-0.38	1.23e-5	Coronary artery disease;
TGCT	cis	rs13394619	0.875	rs7576826	chr2:11723021	C/T	cg07314298	chr2:11723111	GREB1	-0.28	-4.85	-0.4	3.7e-6	Endometriosis;
TGCT	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg07061783	chr6:25882402	NA	-0.64	-6.43	-0.5	2.55e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7726839	0.540	rs72703083	chr5:595365	C/T	cg09021430	chr5:549028	NA	-0.43	-5.77	-0.46	5.99e-8	Obesity-related traits;
TGCT	cis	rs651907	0.535	rs13065944	chr3:101473088	G/A	cg12386194	chr3:101231763	SENP7	0.48	4.63	0.38	9.23e-6	Colorectal cancer;
TGCT	cis	rs7208859	0.673	rs1347360	chr17:28914532	T/C	cg14008862	chr17:28927542	LRRC37B2	0.76	4.62	0.38	9.48e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg27535305	chr1:53392650	SCP2	-0.23	-4.63	-0.38	9.11e-6	Monocyte count;
TGCT	cis	rs11864453	0.713	rs12708926	chr16:72126063	T/C	cg14768367	chr16:72042858	DHODH	0.5	4.8	0.4	4.5e-6	Fibrinogen levels;
TGCT	cis	rs1949733	1.000	rs1357481	chr4:8496221	A/T	cg13073564	chr4:8508604	NA	-0.51	-5.79	-0.46	5.44e-8	Response to antineoplastic agents;
TGCT	cis	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg09021430	chr5:549028	NA	-0.38	-5.23	-0.42	7.13e-7	Obesity-related traits;
TGCT	cis	rs2276314	0.947	rs4799831	chr18:33554775	A/G	cg19628046	chr18:33552617	C18orf21	0.52	4.46	0.37	1.8e-5	Endometriosis;Drug-induced torsades de pointes;
TGCT	cis	rs711245	0.573	rs3770796	chr2:36799515	T/C	cg01206211	chr2:36825736	FEZ2	0.31	4.8	0.4	4.51e-6	Height;
TGCT	cis	rs6665290	0.935	rs6659424	chr1:227197875	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.99	-20.11	-0.87	7.47e-41	Myeloid white cell count;
TGCT	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg05665937	chr4:1216051	CTBP1	0.24	4.61	0.38	1e-5	Obesity-related traits;
TGCT	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	5.02	0.41	1.78e-6	Prudent dietary pattern;
TGCT	cis	rs6754311	0.551	rs6739713	chr2:136488978	A/G	cg07169764	chr2:136633963	MCM6	0.76	6.25	0.49	6.14e-9	Mosquito bite size;
TGCT	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg01341218	chr17:43662625	NA	1.04	7.8	0.57	2.14e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7552404	0.731	rs17650138	chr1:76398887	C/T	cg10523679	chr1:76189770	ACADM	-0.93	-7.9	-0.58	1.28e-12	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs10431058	0.644	rs614759	chr11:107464386	G/T	cg18204760	chr11:107461044	ELMOD1;LOC643923	0.59	5.09	0.42	1.31e-6	Common traits (Other);
TGCT	cis	rs921968	0.612	rs496908	chr2:219357742	A/T	cg02176678	chr2:219576539	TTLL4	0.45	6.57	0.51	1.23e-9	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs2797160	0.967	rs984041	chr6:126021328	A/T	cg05901451	chr6:126070800	HEY2	0.75	6.66	0.51	8e-10	Endometrial cancer;
TGCT	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg26338869	chr17:61819248	STRADA	-0.53	-4.9	-0.4	2.95e-6	Prudent dietary pattern;
TGCT	cis	rs1395	0.778	rs4665960	chr2:27467598	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.7	9.35	0.64	4.81e-16	Blood metabolite levels;
TGCT	cis	rs3845702	1.000	rs262279	chr2:180869145	G/A	cg01881094	chr2:180872142	CWC22	0.68	6.11	0.48	1.16e-8	Schizophrenia;
TGCT	cis	rs8017423	0.874	rs2149656	chr14:90707508	A/C	cg04374321	chr14:90722782	PSMC1	0.78	7.88	0.58	1.45e-12	Mortality in heart failure;
TGCT	cis	rs4654899	0.714	rs12401630	chr1:21495049	G/A	cg01072550	chr1:21505969	NA	-0.47	-6.96	-0.53	1.72e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs12908161	1.000	rs62021219	chr15:85256159	C/T	cg17173187	chr15:85201210	NMB	0.59	6.77	0.52	4.55e-10	Schizophrenia;
TGCT	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg19723775	chr5:179050963	HNRNPH1	0.53	5.32	0.43	4.71e-7	Lung cancer;
TGCT	cis	rs4499344	0.960	rs17833075	chr19:33075134	G/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.69	-6.26	-0.49	5.75e-9	Mean platelet volume;
TGCT	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg03517284	chr6:25882590	NA	-0.68	-6.01	-0.47	1.94e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs4700695	0.640	rs27083	chr5:65435865	C/T	cg21114390	chr5:65439923	SFRS12	-0.85	-7.61	-0.56	5.94e-12	Facial morphology (factor 19);
TGCT	cis	rs9818758	0.607	rs67060340	chr3:48915321	C/T	cg07636037	chr3:49044803	WDR6	-1.0	-4.98	-0.41	2.11e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs7020830	0.898	rs506981	chr9:37351348	A/T	cg14294708	chr9:37120828	ZCCHC7	-1.06	-14.42	-0.79	2.83e-28	Schizophrenia;
TGCT	cis	rs736801	0.504	rs2070721	chr5:131825842	T/G	cg02551604	chr5:131831745	NA	-0.76	-8.6	-0.61	2.97e-14	Breast cancer;Mosquito bite size;
TGCT	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg26338869	chr17:61819248	STRADA	-0.53	-4.87	-0.4	3.38e-6	Prudent dietary pattern;
TGCT	cis	rs35883536	0.609	rs12747197	chr1:101036831	A/C	cg10298815	chr1:101004474	GPR88	-0.24	-4.5	-0.37	1.57e-5	Monocyte count;
TGCT	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg11644478	chr21:40555479	PSMG1	0.97	9.14	0.63	1.52e-15	Cognitive function;
TGCT	cis	rs10493773	1.000	rs10493773	chr1:86125753	C/T	cg17807903	chr1:86174739	ZNHIT6	0.39	4.94	0.41	2.5e-6	Urate levels in overweight individuals;
TGCT	trans	rs1814175	0.791	rs10839395	chr11:49846274	G/T	cg03929089	chr4:120376271	NA	-0.72	-8.26	-0.6	1.85e-13	Height;
TGCT	cis	rs67385638	1.000	rs2855036	chr11:5272682	C/T	cg12559170	chr11:5275217	HBG2	0.48	8.68	0.61	1.93e-14	Hemoglobin levels;
TGCT	cis	rs2456568	0.571	rs1105113	chr11:93693323	G/A	cg26875233	chr11:93583750	C11orf90	0.43	5.16	0.42	9.71e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs1580019	0.961	rs4320456	chr7:32496003	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.79	7.42	0.55	1.63e-11	Cognitive ability;
TGCT	cis	rs17001868	0.892	rs117667045	chr22:40736961	C/T	cg07138101	chr22:40742427	ADSL	0.72	4.64	0.38	8.84e-6	Mammographic density (dense area);
TGCT	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg00343986	chr7:65444356	GUSB	-0.22	-5.47	-0.44	2.4e-7	Calcium levels;
TGCT	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.46	0.56	1.3e-11	Prudent dietary pattern;
TGCT	cis	rs6545883	0.929	rs778140	chr2:61682976	C/T	cg15711740	chr2:61764176	XPO1	-0.53	-4.79	-0.4	4.59e-6	Tuberculosis;
TGCT	cis	rs929354	0.772	rs3802118	chr7:156986814	T/C	cg05182265	chr7:156933206	UBE3C	-0.39	-8.79	-0.62	1.03e-14	Body mass index;
TGCT	cis	rs2688608	0.967	rs9971038	chr10:75661149	C/T	cg04320760	chr10:75533139	FUT11	-0.31	-4.84	-0.4	3.72e-6	Inflammatory bowel disease;
TGCT	cis	rs9467773	0.620	rs2504571	chr6:26643435	C/T	cg11502198	chr6:26597334	ABT1	0.54	4.93	0.4	2.62e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs17331151	0.541	rs1139106	chr3:52871101	G/A	cg15956490	chr3:53032818	SFMBT1	0.46	5.7	0.46	8.34e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs7677751	0.806	rs61320297	chr4:55088175	G/A	cg17187183	chr4:55093834	PDGFRA	0.54	7.13	0.54	7.45e-11	Corneal astigmatism;
TGCT	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg19774624	chr17:42201019	HDAC5	-0.87	-10.63	-0.69	3.81e-19	Total body bone mineral density;
TGCT	cis	rs17826219	0.706	rs8075357	chr17:29057197	A/C	cg14008862	chr17:28927542	LRRC37B2	0.77	4.59	0.38	1.08e-5	Body mass index;
TGCT	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.18	0.49	8.46e-9	Electroencephalogram traits;
TGCT	cis	rs7439150	0.954	rs28365897	chr4:155471982	A/C	cg22130008	chr4:155548532	NA	-0.45	-5.55	-0.45	1.64e-7	Fibrinogen levels;
TGCT	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7172809	0.573	rs17384809	chr15:77622006	A/G	cg22256960	chr15:77711686	NA	0.51	5.04	0.41	1.58e-6	Glucose homeostasis traits;
TGCT	cis	rs7772486	0.875	rs10457793	chr6:146415403	A/G	cg13319975	chr6:146136371	FBXO30	-0.51	-4.48	-0.37	1.69e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7666738	0.830	rs6832568	chr4:98994061	G/A	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10992471	0.630	rs10992322	chr9:95159196	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-5.59	-0.45	1.36e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	trans	rs8073060	0.586	rs225292	chr17:33926383	G/A	cg19694781	chr19:47549865	TMEM160	-0.5	-10.74	-0.69	1.96e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs2243480	1.000	rs1796220	chr7:66062100	C/T	cg18252515	chr7:66147081	NA	-1.22	-8.04	-0.59	6.02e-13	Diabetic kidney disease;
TGCT	cis	rs7267979	0.933	rs2387887	chr20:25427081	G/T	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2439831	0.681	rs11858152	chr15:43634196	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.05	9.14	0.63	1.54e-15	Lung cancer in ever smokers;
TGCT	cis	rs10782582	0.609	rs2881785	chr1:76318096	T/C	cg22875332	chr1:76189707	ACADM	-0.44	-4.48	-0.37	1.7e-5	Daytime sleep phenotypes;
TGCT	cis	rs8177179	0.967	rs4287912	chr3:133437778	A/G	cg16262614	chr3:133464971	TF	0.34	4.55	0.38	1.24e-5	Iron status biomarkers (transferrin levels);
TGCT	cis	rs4252435	0.614	rs4252417	chr7:142625258	G/A	cg21621906	chr7:142494914	NA	-1.06	-4.6	-0.38	1.04e-5	Cancer;
TGCT	cis	rs295140	0.706	rs3769484	chr2:201172999	C/T	cg04283868	chr2:201171347	SPATS2L	0.6	5.68	0.45	9.27e-8	QT interval;
TGCT	cis	rs9929218	1.000	rs9937664	chr16:68784603	T/C	cg01251360	chr16:68772225	CDH1	0.29	4.89	0.4	3.01e-6	Colorectal cancer;
TGCT	cis	rs713587	0.719	rs58048722	chr2:25187825	C/T	cg01884057	chr2:25150051	NA	-0.38	-7.8	-0.57	2.16e-12	Body mass index in non-asthmatics;
TGCT	cis	rs12765878	0.603	rs2475216	chr10:105660651	G/A	cg11005552	chr10:105648138	OBFC1	-0.4	-6.21	-0.49	7.49e-9	Coronary artery disease;
TGCT	cis	rs595982	0.559	rs17206714	chr19:49362001	T/A	cg15549821	chr19:49342101	PLEKHA4	-0.7	-9.6	-0.65	1.17e-16	Red cell distribution width;
TGCT	cis	rs13191362	1.000	rs13200329	chr6:163004418	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.68	5.79	0.46	5.33e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg07298985	chr8:22133076	PIWIL2	0.34	5.41	0.44	3.07e-7	Hypertriglyceridemia;
TGCT	cis	rs7267979	0.586	rs6050432	chr20:25184028	T/C	cg14121845	chr20:25566513	NINL	0.45	4.88	0.4	3.23e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg02725872	chr8:58115012	NA	-0.41	-5.42	-0.44	3.01e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs12510870	0.600	rs11733767	chr4:74427805	T/C	cg05868023	chr4:75230803	EREG	0.54	4.89	0.4	3.07e-6	Iris color (b* coordinate);
TGCT	cis	rs9611519	0.761	rs35445172	chr22:41660301	G/A	cg03806693	chr22:41940476	POLR3H	-0.74	-7.23	-0.54	4.46e-11	Neuroticism;
TGCT	cis	rs7267979	0.816	rs376742	chr20:25487417	A/C	cg16686733	chr20:25566563	NINL	0.51	4.91	0.4	2.82e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7681440	0.804	rs763443	chr4:90819961	T/C	cg26578617	chr4:90757533	SNCA	-0.43	-4.48	-0.37	1.71e-5	Dementia with Lewy bodies;
TGCT	cis	rs826838	0.967	rs12823908	chr12:38845686	T/C	cg26384229	chr12:38710491	ALG10B	1.06	10.68	0.69	2.84e-19	Heart rate;
TGCT	cis	rs28595532	0.764	rs56359736	chr4:119769689	G/A	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs2797160	0.935	rs60515555	chr6:126000638	T/G	cg05901451	chr6:126070800	HEY2	-0.74	-6.48	-0.5	1.96e-9	Endometrial cancer;
TGCT	cis	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg18876405	chr7:65276391	NA	0.33	4.97	0.41	2.19e-6	Aortic root size;
TGCT	cis	rs4788570	0.584	rs979790	chr16:71665985	A/T	cg06353428	chr16:71660113	MARVELD3	-1.35	-9.32	-0.64	5.62e-16	Intelligence (multi-trait analysis);
TGCT	trans	rs1005277	0.540	rs11011351	chr10:38030525	A/G	cg17830980	chr10:43048298	ZNF37B	-0.65	-7.34	-0.55	2.4e-11	Extrinsic epigenetic age acceleration;
TGCT	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg21963583	chr11:68658836	MRPL21	0.37	6.08	0.48	1.39e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs11080466	1.000	rs11080466	chr18:10899028	C/T	cg02393756	chr18:9912783	VAPA	0.27	4.76	0.39	5.35e-6	Non-small cell lung cancer;
TGCT	cis	rs9814567	1.000	rs1534026	chr3:134284767	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.94	-9.18	-0.64	1.2e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs62380364	0.870	rs17559709	chr5:88149326	G/A	cg22951263	chr5:87985283	NA	-0.48	-4.62	-0.38	9.39e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs12643440	0.538	rs2041443	chr4:17137996	G/A	cg22650099	chr4:17144496	NA	-0.46	-4.66	-0.39	8.14e-6	Metabolite levels (Pyroglutamine);
TGCT	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg00343986	chr7:65444356	GUSB	-0.23	-5.14	-0.42	1.06e-6	Aortic root size;
TGCT	cis	rs7786808	0.707	rs10247026	chr7:158230595	C/T	cg01191920	chr7:158217561	PTPRN2	-0.44	-6.69	-0.51	7.02e-10	Obesity-related traits;
TGCT	cis	rs67478160	0.619	rs55824307	chr14:104271207	C/T	cg26031613	chr14:104095156	KLC1	-0.64	-6.58	-0.51	1.2e-9	Schizophrenia;
TGCT	cis	rs17376456	0.935	rs13156002	chr5:93508931	G/A	cg21475434	chr5:93447410	FAM172A	0.62	4.5	0.37	1.54e-5	Diabetic retinopathy;
TGCT	cis	rs3806843	1.000	rs10053586	chr5:140210760	T/C	cg19875535	chr5:140030758	IK	0.37	6.04	0.48	1.69e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2239547	0.563	rs6797399	chr3:52905917	G/A	cg10802521	chr3:52805072	NEK4	-0.58	-5.46	-0.44	2.53e-7	Schizophrenia;
TGCT	cis	rs796364	0.806	rs6743396	chr2:200860138	T/C	cg17644776	chr2:200775616	C2orf69	0.33	5.0	0.41	1.91e-6	Schizophrenia;
TGCT	cis	rs2050392	0.965	rs1543725	chr10:30698873	A/G	cg18806716	chr10:30721971	MAP3K8	-0.53	-6.6	-0.51	1.07e-9	Inflammatory bowel disease;
TGCT	cis	rs7614311	0.636	rs3846221	chr3:64008510	T/C	cg22134162	chr3:63841271	THOC7	-0.5	-6.31	-0.49	4.61e-9	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs3858526	0.883	rs11039686	chr11:5948725	T/C	cg13902645	chr11:5959945	NA	-0.46	-4.8	-0.4	4.54e-6	DNA methylation (variation);
TGCT	cis	rs2012796	0.704	rs57670850	chr14:81841577	C/T	cg02996355	chr14:81879375	NA	0.54	5.35	0.43	4.05e-7	Night sleep phenotypes;
TGCT	cis	rs344364	0.511	rs1742472	chr16:1953040	A/G	cg26617929	chr16:1858877	NA	-0.26	-4.66	-0.39	8.04e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs75059851	0.756	rs55747998	chr11:133840793	C/T	cg14047540	chr11:133829660	NA	-0.57	-5.69	-0.45	8.72e-8	Schizophrenia;
TGCT	cis	rs9393692	0.967	rs6456712	chr6:26302573	A/C	cg13736514	chr6:26305472	NA	-0.43	-6.34	-0.49	3.98e-9	Educational attainment;
TGCT	cis	rs9926296	0.744	rs6860	chr16:89711120	C/T	cg01097406	chr16:89675127	NA	0.36	6.22	0.49	7.03e-9	Vitiligo;
TGCT	cis	rs72781680	0.559	rs72796103	chr2:23900382	G/A	cg08917208	chr2:24149416	ATAD2B	1.0	5.56	0.45	1.59e-7	Lymphocyte counts;
TGCT	cis	rs11122272	0.735	rs2790881	chr1:231534181	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-6.64	-0.51	8.59e-10	Hemoglobin concentration;
TGCT	cis	rs9902453	0.845	rs7209622	chr17:28256807	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.92	9.01	0.63	3.1e-15	Coffee consumption (cups per day);
TGCT	cis	rs2857078	0.720	rs9906669	chr17:42305706	A/G	cg19774624	chr17:42201019	HDAC5	-0.69	-7.14	-0.54	6.91e-11	Red cell distribution width;Reticulocyte count;
TGCT	cis	rs17718580	0.793	rs113053719	chr14:50958256	C/A	cg04730355	chr14:51134070	SAV1	0.99	5.36	0.43	3.97e-7	Cognitive performance;
TGCT	cis	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg13531842	chr10:38383804	ZNF37A	-0.37	-4.46	-0.37	1.78e-5	Extrinsic epigenetic age acceleration;
TGCT	cis	rs5769765	0.908	rs9616388	chr22:50313438	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.42	5.93	0.47	2.77e-8	Schizophrenia;
TGCT	cis	rs922182	0.569	rs72752984	chr15:64264082	G/T	cg02919090	chr15:64263738	DAPK2	0.36	6.87	0.53	2.76e-10	Blood protein levels;
TGCT	cis	rs62283056	0.636	rs17718958	chr4:6275735	G/A	cg25554036	chr4:6271136	WFS1	-0.51	-4.71	-0.39	6.51e-6	Cisplatin-induced ototoxicity;
TGCT	cis	rs57590327	0.508	rs9820349	chr3:81958587	A/G	cg07356753	chr3:81810745	GBE1	-0.73	-6.76	-0.52	4.88e-10	Extraversion;
TGCT	cis	rs2404602	0.692	rs55676827	chr15:76961716	C/T	cg22467129	chr15:76604101	ETFA	-0.45	-5.11	-0.42	1.2e-6	Blood metabolite levels;
TGCT	cis	rs910316	1.000	rs7142235	chr14:75559963	T/C	cg23033748	chr14:75592666	NEK9	0.27	4.57	0.38	1.16e-5	Height;
TGCT	cis	rs3784262	0.679	rs4238326	chr15:58336000	C/T	cg12031962	chr15:58353849	ALDH1A2	0.55	8.56	0.61	3.56e-14	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs2718812	0.766	rs12497513	chr3:133388670	C/G	cg08048268	chr3:133502702	NA	0.38	4.76	0.39	5.38e-6	Iron status biomarkers;
TGCT	cis	rs9649213	0.614	rs62479858	chr7:97924226	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.96	-8.87	-0.62	6.66e-15	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs17761864	0.791	rs4362428	chr17:2090341	C/A	cg02171503	chr17:1588363	PRPF8	-0.51	-5.04	-0.41	1.62e-6	Esophageal cancer (squamous cell);
TGCT	cis	rs13217239	0.646	rs2142685	chr6:27054497	C/T	cg02458000	chr6:26745757	NA	-0.5	-4.55	-0.38	1.25e-5	Schizophrenia;
TGCT	cis	rs6988636	1.000	rs16898086	chr8:124190445	A/G	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs9467773	0.596	rs2451750	chr6:26646579	A/T	cg09904177	chr6:26538194	HMGN4	0.68	6.27	0.49	5.41e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs9911578	1.000	rs2567911	chr17:56734977	A/G	cg05425664	chr17:57184151	TRIM37	-0.64	-6.48	-0.5	1.99e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs3796352	1.000	rs33999310	chr3:52883332	G/A	cg27565382	chr3:53032988	SFMBT1	0.49	4.47	0.37	1.75e-5	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg17971929	chr21:40555470	PSMG1	0.98	9.51	0.65	1.95e-16	Cognitive function;
TGCT	cis	rs7666738	0.546	rs28590002	chr4:98722642	C/T	cg18180107	chr4:99064573	C4orf37	0.52	4.61	0.38	9.77e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6882046	0.513	rs447801	chr5:88002653	T/C	cg24804195	chr5:87968844	LOC645323	-0.59	-5.71	-0.46	7.96e-8	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs7208859	0.623	rs609063	chr17:28951513	A/G	cg13385521	chr17:29058706	SUZ12P	0.81	4.87	0.4	3.39e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg05590025	chr7:65112418	INTS4L2	-0.77	-4.5	-0.37	1.52e-5	Diabetic kidney disease;
TGCT	cis	rs7923452	0.507	rs103441	chr10:30778184	C/T	cg13289132	chr10:30722225	MAP3K8	-0.42	-4.65	-0.39	8.47e-6	Itch intensity from mosquito bite;
TGCT	cis	rs9399135	1.000	rs35123050	chr6:135302740	G/A	cg24558204	chr6:135376177	HBS1L	0.48	4.79	0.39	4.76e-6	Red blood cell count;
TGCT	cis	rs854765	0.583	rs9904163	chr17:17830553	C/T	cg09796270	chr17:17721594	SREBF1	0.24	4.77	0.39	5.16e-6	Total body bone mineral density;
TGCT	cis	rs798766	1.000	rs798755	chr4:1720824	A/G	cg05874882	chr4:1763078	NA	-0.36	-4.87	-0.4	3.27e-6	Bladder cancer;Urinary bladder cancer;
TGCT	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.5	-4.78	-0.39	4.81e-6	Prudent dietary pattern;
TGCT	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.02	0.53	1.3e-10	Prudent dietary pattern;
TGCT	cis	rs6598955	0.543	rs12122527	chr1:26549748	C/T	cg04990556	chr1:26633338	UBXN11	0.8	7.3	0.55	3.01e-11	Obesity-related traits;
TGCT	cis	rs61931739	0.500	rs10844829	chr12:34304916	G/T	cg06521331	chr12:34319734	NA	-0.3	-4.46	-0.37	1.83e-5	Morning vs. evening chronotype;
TGCT	cis	rs2354432	0.607	rs7537483	chr1:146709877	C/G	cg25205988	chr1:146714368	CHD1L	1.18	4.82	0.4	4.2e-6	Mitochondrial DNA levels;
TGCT	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg13395646	chr4:1353034	KIAA1530	-0.36	-4.75	-0.39	5.64e-6	Obesity-related traits;
TGCT	trans	rs877282	1.000	rs12775643	chr10:773242	G/A	cg22713356	chr15:30763199	NA	1.16	10.02	0.67	1.16e-17	Uric acid levels;
TGCT	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg01238044	chr22:24384105	GSTT1	-0.54	-5.21	-0.42	7.52e-7	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1577917	1.000	rs12664335	chr6:86597774	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.58	4.85	0.4	3.65e-6	Response to antipsychotic treatment;
TGCT	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.68	4.89	0.4	3e-6	Platelet count;
TGCT	cis	rs7937682	1.000	rs10789843	chr11:111576158	C/T	cg09085632	chr11:111637200	PPP2R1B	1.07	9.76	0.66	4.89e-17	Primary sclerosing cholangitis;
TGCT	cis	rs9638182	1.000	rs9638182	chr7:72999105	T/G	cg14087351	chr7:73037990	MLXIPL	-0.54	-4.53	-0.38	1.35e-5	Triglycerides;
TGCT	cis	rs6831352	0.879	rs35146617	chr4:100066686	C/T	cg12011299	chr4:100065546	ADH4	-0.46	-5.22	-0.42	7.38e-7	Alcohol dependence;
TGCT	cis	rs8068544	0.818	rs79892925	chr17:40171819	A/G	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.08	-5.02	-0.41	1.75e-6	Reticulocyte fraction of red cells;Reticulocyte count;
TGCT	cis	rs13256369	1.000	rs1109619	chr8:8571616	G/T	cg18904891	chr8:8559673	CLDN23	0.59	5.52	0.44	1.93e-7	Obesity-related traits;
TGCT	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg12923728	chr3:195709715	SDHAP1	-0.36	-7.57	-0.56	7.39e-12	Pancreatic cancer;
TGCT	cis	rs11785400	0.731	rs4294163	chr8:143730830	G/T	cg24634471	chr8:143751801	JRK	0.53	5.24	0.43	6.79e-7	Schizophrenia;
TGCT	cis	rs3784262	0.669	rs4646579	chr15:58329528	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.43	-6.19	-0.49	7.94e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs4253772	0.530	rs9615933	chr22:46677298	G/A	cg24881330	chr22:46731750	TRMU	0.96	4.74	0.39	5.77e-6	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs2235642	0.893	rs2143285	chr16:1593171	A/G	cg07639376	chr16:1584516	IFT140;TMEM204	-0.32	-5.7	-0.46	8.36e-8	Coronary artery disease;
TGCT	cis	rs7582180	0.663	rs930374	chr2:100962700	A/G	cg08017756	chr2:100939284	LONRF2	-0.3	-4.86	-0.4	3.52e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg07061783	chr6:25882402	NA	-0.41	-4.45	-0.37	1.89e-5	Height;
TGCT	cis	rs11249608	0.636	rs62393070	chr5:178447943	A/G	cg01312482	chr5:178451176	ZNF879	-0.58	-5.68	-0.45	8.97e-8	Pubertal anthropometrics;
TGCT	cis	rs10464366	0.544	rs2280667	chr7:39172228	A/C	cg15212455	chr7:39170539	POU6F2	0.34	7.63	0.57	5.29e-12	IgG glycosylation;
TGCT	cis	rs611744	0.608	rs1448152	chr8:109278249	C/T	cg21045802	chr8:109455806	TTC35	0.72	7.44	0.56	1.46e-11	Dupuytren's disease;
TGCT	cis	rs6987853	0.933	rs2974355	chr8:42414117	C/T	cg20539142	chr8:42623718	CHRNA6	-0.21	-5.1	-0.42	1.21e-6	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs9894429	0.966	rs7405901	chr17:79587813	T/C	cg21028142	chr17:79581711	NPLOC4	0.29	6.83	0.52	3.44e-10	Eye color traits;
TGCT	cis	rs1005277	0.522	rs200943	chr10:38148730	A/G	cg25427524	chr10:38739819	LOC399744	-0.37	-7.61	-0.56	5.93e-12	Extrinsic epigenetic age acceleration;
TGCT	cis	rs826838	1.000	rs851934	chr12:39104453	G/T	cg13010199	chr12:38710504	ALG10B	-0.59	-4.91	-0.4	2.83e-6	Heart rate;
TGCT	cis	rs9527	0.590	rs7089680	chr10:104802071	C/T	cg15744005	chr10:104629667	AS3MT	0.4	4.63	0.38	9.04e-6	Arsenic metabolism;
TGCT	cis	rs4285028	0.948	rs13083557	chr3:121687613	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.77	-6.5	-0.5	1.78e-9	Multiple sclerosis;
TGCT	cis	rs1577917	0.958	rs1545376	chr6:86504582	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.7	5.57	0.45	1.48e-7	Response to antipsychotic treatment;
TGCT	cis	rs12549902	0.800	rs7825494	chr8:41507350	C/T	cg00088007	chr8:41504566	NKX6-3	0.31	4.79	0.39	4.72e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
TGCT	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.18	0.49	8.32e-9	Bipolar disorder;
TGCT	cis	rs1577917	1.000	rs10498958	chr6:86649705	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.65	5.36	0.43	3.86e-7	Response to antipsychotic treatment;
TGCT	cis	rs7216064	0.953	rs11871285	chr17:65840809	G/T	cg12091567	chr17:66097778	LOC651250	-0.83	-6.49	-0.5	1.9e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs7943203	0.568	rs228593	chr11:108141134	G/A	cg04873221	chr11:107992290	ACAT1	-0.61	-4.96	-0.41	2.3e-6	Red blood cell count;Mean corpuscular volume;
TGCT	cis	rs7267979	1.000	rs6050547	chr20:25326012	C/T	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3087591	0.960	rs2952995	chr17:29541061	T/C	cg24425628	chr17:29625626	OMG;NF1	0.45	7.11	0.54	8.22e-11	Hip circumference;
TGCT	cis	rs9527	0.590	rs2148198	chr10:104915310	A/G	cg15744005	chr10:104629667	AS3MT	0.42	4.9	0.4	2.96e-6	Arsenic metabolism;
TGCT	cis	rs3784262	0.631	rs4646560	chr15:58353546	C/G	cg12031962	chr15:58353849	ALDH1A2	-0.42	-6.24	-0.49	6.32e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs7772486	0.686	rs7744014	chr6:146123818	G/A	cg23711669	chr6:146136114	FBXO30	0.86	9.53	0.65	1.74e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg05872129	chr22:39784769	NA	-1.03	-11.23	-0.71	1.28e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs10782582	0.593	rs4638068	chr1:76161663	G/A	cg03433033	chr1:76189801	ACADM	-0.65	-7.41	-0.55	1.67e-11	Daytime sleep phenotypes;
TGCT	cis	rs6089829	0.643	rs6011545	chr20:61660038	G/A	cg03213289	chr20:61660250	NA	0.58	6.8	0.52	4.01e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs80282103	0.618	rs74117849	chr10:1165425	A/G	cg08668510	chr10:1095578	IDI1	1.07	5.04	0.41	1.59e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs8056742	0.643	rs11644003	chr16:85099836	A/G	cg00229868	chr16:85520891	NA	0.38	4.73	0.39	6.13e-6	Amyotrophic lateral sclerosis;
TGCT	cis	rs16867321	1.000	rs16867330	chr2:181446202	T/G	cg23363182	chr2:181467187	NA	-0.39	-5.47	-0.44	2.38e-7	Obesity;
TGCT	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg17054783	chr10:134559939	INPP5A	0.24	4.83	0.4	3.92e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs4664308	1.000	rs4664308	chr2:160917497	A/G	cg03641300	chr2:160917029	PLA2R1	-0.27	-6.58	-0.51	1.2e-9	Idiopathic membranous nephropathy;
TGCT	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.37	-4.91	-0.4	2.78e-6	Menarche (age at onset);
TGCT	cis	rs936229	0.749	rs6495126	chr15:75175026	C/T	cg10253484	chr15:75165896	SCAMP2	0.74	6.26	0.49	5.63e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
TGCT	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg22663859	chr13:21900854	NA	0.36	4.99	0.41	1.97e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	cis	rs2730260	0.537	rs73169246	chr7:158890593	C/T	cg27122614	chr7:157913741	PTPRN2	0.42	4.47	0.37	1.74e-5	Myopia (pathological);
TGCT	cis	rs10782582	0.569	rs2131557	chr1:76388589	A/C	cg05598546	chr1:76251766	SNORD45C;RABGGTB	-0.56	-4.88	-0.4	3.16e-6	Daytime sleep phenotypes;
TGCT	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg20607798	chr8:58055168	NA	0.49	4.52	0.38	1.43e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs4788570	0.538	rs59364668	chr16:71569229	A/T	cg06353428	chr16:71660113	MARVELD3	-1.33	-7.63	-0.57	5.33e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs854765	0.547	rs8069811	chr17:17922280	G/A	cg09796270	chr17:17721594	SREBF1	0.25	5.03	0.41	1.71e-6	Total body bone mineral density;
TGCT	cis	rs16958440	0.867	rs114475395	chr18:44691010	A/G	cg17192377	chr18:44677553	HDHD2	0.63	4.7	0.39	6.74e-6	Sitting height ratio;
TGCT	cis	rs838147	0.563	rs281379	chr19:49214274	C/T	cg04599840	chr19:48886497	KDELR1	0.22	4.59	0.38	1.08e-5	Dietary macronutrient intake;
TGCT	cis	rs7582180	0.701	rs11693044	chr2:100922313	T/C	cg08017756	chr2:100939284	LONRF2	-0.32	-5.31	-0.43	4.86e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg27454412	chr7:1067447	C7orf50	0.6	4.72	0.39	6.32e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs10802346	0.636	rs12047380	chr1:246394817	C/T	cg11377642	chr1:245534889	KIF26B	-0.25	-4.44	-0.37	1.94e-5	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs9419702	0.568	rs11156445	chr10:133542301	T/C	cg04492858	chr10:133558786	NA	0.54	5.81	0.46	4.93e-8	Survival in rectal cancer;
TGCT	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.91	6.41	0.5	2.79e-9	Gut microbiome composition (summer);
TGCT	cis	rs9527	0.637	rs7096169	chr10:104618695	A/G	cg15744005	chr10:104629667	AS3MT	-0.49	-6.32	-0.49	4.34e-9	Arsenic metabolism;
TGCT	cis	rs11096990	0.656	rs4580661	chr4:39296350	T/C	cg20847110	chr4:39482781	LOC401127	-0.16	-4.51	-0.38	1.48e-5	Cognitive function;
TGCT	cis	rs56104184	0.775	rs73063505	chr19:49402765	T/C	cg17863274	chr19:49399704	TULP2	-0.54	-7.43	-0.55	1.58e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	trans	rs208520	0.661	rs207111	chr6:66792513	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-10.77	-0.7	1.66e-19	Exhaled nitric oxide output;
TGCT	cis	rs9486715	0.867	rs4839687	chr6:96951732	C/A	cg06623918	chr6:96969491	KIAA0776	1.1	15.44	0.81	1.17e-30	Headache;
TGCT	cis	rs12142240	0.731	rs6658556	chr1:46844180	A/C	cg00530320	chr1:46809349	NSUN4	0.27	5.55	0.45	1.68e-7	Menopause (age at onset);
TGCT	cis	rs11190604	1.000	rs11190596	chr10:102293238	C/G	cg23241863	chr10:102295624	HIF1AN	0.63	4.63	0.38	9.22e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2439831	0.867	rs3809481	chr15:43662829	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.08	7.96	0.58	9.31e-13	Lung cancer in ever smokers;
TGCT	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	9.52	0.65	1.86e-16	Platelet count;
TGCT	cis	rs7568458	0.709	rs2043675	chr2:85769975	C/T	cg02493740	chr2:85810744	VAMP5	0.28	5.24	0.43	6.55e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs6684514	1.000	rs10908500	chr1:156280671	A/T	cg16558208	chr1:156270281	VHLL	0.48	9.86	0.66	2.71e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs858239	0.704	rs199657	chr7:23337507	G/C	cg05602783	chr7:23145260	KLHL7	0.72	5.72	0.46	7.3900000000000007e-08	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs514406	0.763	rs9988539	chr1:53213884	T/C	cg25767906	chr1:53392781	SCP2	0.48	5.36	0.43	3.95e-7	Monocyte count;
TGCT	cis	rs7772486	0.875	rs10457796	chr6:146416087	T/G	cg05347473	chr6:146136440	FBXO30	0.56	5.1	0.42	1.24e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7666738	0.830	rs59751489	chr4:98933802	A/G	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs950169	0.840	rs12905223	chr15:85114268	T/C	cg11189052	chr15:85197271	WDR73	0.77	6.44	0.5	2.34e-9	Schizophrenia;
TGCT	cis	rs4144743	1.000	rs4144746	chr17:45323355	C/G	cg18085866	chr17:45331354	ITGB3	-0.72	-4.8	-0.4	4.39e-6	Body mass index;
TGCT	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.55	4.92	0.4	2.74e-6	Prudent dietary pattern;
TGCT	cis	rs9611565	0.649	rs4822050	chr22:42177453	C/G	cg13695892	chr22:41940480	POLR3H	-0.79	-7.5	-0.56	1.07e-11	Vitiligo;
TGCT	cis	rs910316	0.935	rs175076	chr14:75505486	A/G	cg11812906	chr14:75593930	NEK9	-0.73	-7.17	-0.54	6.01e-11	Height;
TGCT	cis	rs10791097	0.677	rs11222359	chr11:130730648	A/G	cg14779329	chr11:130786720	SNX19	0.26	4.55	0.38	1.25e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs78487399	0.808	rs13405158	chr2:43705286	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.42	5.56	0.45	1.57e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs28595532	0.688	rs116173135	chr4:119721949	C/T	cg14228332	chr4:119757509	SEC24D	1.38	6.91	0.53	2.21e-10	Cannabis dependence symptom count;
TGCT	cis	rs2463822	1.000	rs2463822	chr11:62103420	T/C	cg23876832	chr11:62092739	NA	0.65	4.56	0.38	1.19e-5	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs28595532	0.920	rs115530096	chr4:119760512	T/G	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs7731657	0.537	rs13355897	chr5:130360622	G/A	cg08523029	chr5:130500466	HINT1	-0.61	-5.08	-0.42	1.34e-6	Fasting plasma glucose;
TGCT	cis	rs7611238	0.560	rs9836665	chr3:195113176	G/A	cg27323046	chr3:195102265	ACAP2	0.39	5.17	0.42	8.93e-7	Body mass index;
TGCT	cis	rs3099143	1.000	rs7172639	chr15:77165288	G/A	cg21673338	chr15:77095150	SCAPER	0.52	5.05	0.41	1.54e-6	Recalcitrant atopic dermatitis;
TGCT	cis	rs9329221	0.772	rs7824675	chr8:10243418	G/T	cg21775007	chr8:11205619	TDH	-0.49	-4.77	-0.39	5.14e-6	Neuroticism;
TGCT	cis	rs9357506	0.905	rs4714927	chr6:46309789	A/T	cg21115430	chr6:46460003	NA	-0.26	-5.16	-0.42	9.6e-7	Body mass index;
TGCT	cis	rs4953076	0.573	rs6544746	chr2:44407985	C/T	cg04920474	chr2:44395004	PPM1B	0.58	5.77	0.46	5.91e-8	Height;
TGCT	cis	rs3733585	0.638	rs6414766	chr4:9956474	G/A	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.7	-0.52	6.62e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7666738	0.962	rs17550217	chr4:98999699	T/A	cg17366294	chr4:99064904	C4orf37	0.76	6.94	0.53	1.91e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg17178900	chr1:205818956	PM20D1	0.58	7.21	0.54	4.81e-11	Menarche (age at onset);
TGCT	cis	rs9902453	0.845	rs7221516	chr17:28232506	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.92	9.1	0.63	1.88e-15	Coffee consumption (cups per day);
TGCT	cis	rs13082711	0.954	rs35523848	chr3:27552800	A/C	cg02860705	chr3:27208620	NA	0.33	4.56	0.38	1.21e-5	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs7133214	0.510	rs4931479	chr12:27948615	A/G	cg12166080	chr12:27706343	PPFIBP1	0.24	5.0	0.41	1.94e-6	Gut microbiota (functional units);
TGCT	cis	rs2832191	0.716	rs8132085	chr21:30501389	G/T	cg24692254	chr21:30365293	RNF160	-0.91	-10.24	-0.68	3.22e-18	Dental caries;
TGCT	cis	rs7674212	0.570	rs2126470	chr4:104061762	T/C	cg16532752	chr4:104119610	CENPE	-0.63	-5.69	-0.45	8.85e-8	Type 2 diabetes;
TGCT	cis	rs425277	0.958	rs262652	chr1:2090816	T/C	cg24578937	chr1:2090814	PRKCZ	0.32	8.03	0.58	6.41e-13	Height;
TGCT	cis	rs7523273	0.565	rs2796251	chr1:207903688	C/G	cg22525895	chr1:207977042	MIR29B2	-0.33	-5.33	-0.43	4.38e-7	Schizophrenia;
TGCT	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg14983838	chr19:29218262	NA	0.83	6.85	0.52	3.07e-10	Methadone dose in opioid dependence;
TGCT	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg01802117	chr1:53393560	SCP2	0.49	5.94	0.47	2.62e-8	Monocyte count;
TGCT	cis	rs9329221	0.905	rs4841329	chr8:10253098	A/G	cg21775007	chr8:11205619	TDH	-0.53	-4.79	-0.4	4.58e-6	Neuroticism;
TGCT	cis	rs11030122	0.702	rs17279635	chr11:3973083	A/C	cg18678763	chr11:4115507	RRM1	0.49	6.13	0.48	1.08e-8	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs931127	0.502	rs1466462	chr11:65419364	C/G	cg17480646	chr11:65405466	SIPA1	0.54	6.84	0.52	3.29e-10	Systemic lupus erythematosus;
TGCT	cis	rs492146	0.765	rs316129	chr6:52848905	C/T	cg06706454	chr6:52930286	FBXO9	-0.53	-4.95	-0.41	2.37e-6	Epilepsy (remission after treatment);
TGCT	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	5.14	0.42	1.03e-6	Height;
TGCT	cis	rs11190604	1.000	rs2495736	chr10:102338410	T/C	cg23241863	chr10:102295624	HIF1AN	0.67	4.9	0.4	2.99e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2070488	0.804	rs13092473	chr3:38458958	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	7.97	0.58	8.75e-13	Electrocardiographic conduction measures;
TGCT	cis	rs4720575	1.000	rs4720575	chr7:47086805	A/G	cg00036614	chr7:47093842	NA	-0.2	-5.08	-0.42	1.35e-6	Angiotensin-converting enzyme inhibitor intolerance;
TGCT	cis	rs651907	0.557	rs2303474	chr3:101371899	G/T	cg11279151	chr3:101281821	RG9MTD1	-0.35	-7.19	-0.54	5.3e-11	Colorectal cancer;
TGCT	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg00475322	chr7:917719	C7orf20	0.5	6.38	0.5	3.17e-9	Perceived unattractiveness to mosquitoes;
TGCT	cis	rs2361718	0.500	rs4889818	chr17:78085228	A/G	cg27614120	chr17:77386099	HRNBP3	0.27	4.77	0.39	5.1e-6	Yeast infection;
TGCT	cis	rs28595532	0.920	rs17258830	chr4:119725543	A/T	cg14228332	chr4:119757509	SEC24D	-1.38	-6.93	-0.53	2.07e-10	Cannabis dependence symptom count;
TGCT	cis	rs10782582	0.546	rs79652169	chr1:76233882	G/A	cg03433033	chr1:76189801	ACADM	-0.55	-6.05	-0.48	1.61e-8	Daytime sleep phenotypes;
TGCT	cis	rs3782455	0.793	rs2290798	chr12:114404143	C/T	cg23502203	chr12:113549970	RASAL1	-0.55	-4.92	-0.4	2.7e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs17741873	0.836	rs57771499	chr10:75605492	T/C	cg07699608	chr10:75541558	CHCHD1	0.71	4.81	0.4	4.26e-6	Paclitaxel disposition in epithelial ovarian cancer;
TGCT	cis	rs13217239	0.646	rs62401067	chr6:27018101	T/A	cg02458000	chr6:26745757	NA	0.49	4.45	0.37	1.92e-5	Schizophrenia;
TGCT	cis	rs7539542	0.556	rs10753928	chr1:202891045	A/C	cg22008490	chr1:202129255	PTPN7	-0.19	-4.48	-0.37	1.66e-5	Mean platelet volume;
TGCT	cis	rs1348850	0.793	rs13000048	chr2:178337089	C/A	cg22681709	chr2:178499509	PDE11A	-0.38	-4.98	-0.41	2.1e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs4789294	0.806	rs7210520	chr17:74450040	C/T	cg17540765	chr17:73631586	RECQL5;LOC643008	0.24	4.43	0.37	2.02e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs1008375	0.966	rs11947836	chr4:17697187	A/G	cg18681998	chr4:17616180	MED28	-0.82	-7.49	-0.56	1.1e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs981844	0.775	rs17299211	chr4:154738284	G/A	cg14289246	chr4:154710475	SFRP2	1.01	8.88	0.62	6.23e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs67385638	1.000	rs2855039	chr11:5271671	C/T	cg12559170	chr11:5275217	HBG2	0.47	9.09	0.63	1.96e-15	Hemoglobin levels;
TGCT	cis	rs9467773	1.000	rs6925895	chr6:26572165	G/T	cg09904177	chr6:26538194	HMGN4	0.69	6.84	0.52	3.23e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs1008375	1.000	rs10939743	chr4:17662731	G/A	cg16339924	chr4:17578868	LAP3	0.55	4.74	0.39	5.88e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2721195	0.845	rs756627	chr8:145737286	G/A	cg15857475	chr8:145742913	RECQL4;LRRC14	0.88	9.27	0.64	7.39e-16	Age at first birth;
TGCT	cis	rs6540559	0.551	rs17389436	chr1:209972297	A/T	cg22029157	chr1:209979665	IRF6	0.81	4.97	0.41	2.19e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs6752107	0.967	rs3792109	chr2:234184417	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.2	4.73	0.39	6.08e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs7226408	0.894	rs11659465	chr18:34375487	A/G	cg06757138	chr18:34340585	FHOD3	0.25	4.56	0.38	1.2e-5	Obesity-related traits;
TGCT	cis	rs735396	0.770	rs1169314	chr12:121443116	A/G	cg15155738	chr12:121454335	C12orf43	0.55	4.79	0.4	4.71e-6	N-glycan levels;
TGCT	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.12	0.54	7.78e-11	Prudent dietary pattern;
TGCT	cis	rs13177918	0.686	rs12654827	chr5:149822090	T/C	cg14059543	chr5:149831962	NA	-0.73	-9.52	-0.65	1.79e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs12989701	0.778	rs7583814	chr2:127863029	C/T	cg08168897	chr2:127865431	BIN1	0.55	6.04	0.48	1.67e-8	Alzheimer's disease (late onset);
TGCT	cis	rs59698941	0.527	rs1032764	chr5:132185419	A/C	cg21474247	chr5:131268130	NA	0.32	4.98	0.41	2.12e-6	Apolipoprotein A-IV levels;
TGCT	cis	rs10782582	0.593	rs12131344	chr1:76136437	C/T	cg03433033	chr1:76189801	ACADM	-0.65	-7.15	-0.54	6.51e-11	Daytime sleep phenotypes;
TGCT	cis	rs1577917	0.958	rs4707236	chr6:86583967	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.16	-0.42	9.71e-7	Response to antipsychotic treatment;
TGCT	cis	rs6815814	0.861	rs12233670	chr4:38787216	C/T	cg02016764	chr4:38805732	TLR1	-0.27	-4.58	-0.38	1.14e-5	Breast cancer;
TGCT	cis	rs7089973	0.584	rs7908665	chr10:116611337	G/A	cg03647239	chr10:116582469	FAM160B1	0.61	5.86	0.47	3.87e-8	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs904251	0.600	rs12211110	chr6:37466232	A/G	cg08126542	chr6:37504118	NA	-0.41	-5.76	-0.46	6.27e-8	Cognitive performance;
TGCT	cis	rs2070488	0.965	rs35553573	chr3:38441439	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.92	9.62	0.65	1.08e-16	Electrocardiographic conduction measures;
TGCT	cis	rs6570726	0.791	rs11155433	chr6:145907831	A/G	cg23711669	chr6:146136114	FBXO30	-0.88	-9.64	-0.65	9.44e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs35883536	0.647	rs10493929	chr1:101043928	A/C	cg14855972	chr1:101004472	GPR88	-0.24	-4.52	-0.38	1.45e-5	Monocyte count;
TGCT	cis	rs617219	0.737	rs2166343	chr5:78484060	A/G	cg05890484	chr5:78407552	BHMT	0.39	5.34	0.43	4.28e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs2354432	0.607	rs4950310	chr1:146659964	A/G	cg25205988	chr1:146714368	CHD1L	1.29	5.46	0.44	2.46e-7	Mitochondrial DNA levels;
TGCT	cis	rs7727544	0.594	rs10479000	chr5:131607402	T/C	cg21474247	chr5:131268130	NA	0.3	4.52	0.38	1.41e-5	Blood metabolite levels;
TGCT	cis	rs7568458	0.905	rs6714709	chr2:85756375	C/G	cg02493740	chr2:85810744	VAMP5	-0.27	-4.84	-0.4	3.72e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg09177884	chr7:1199841	ZFAND2A	0.55	5.35	0.43	4.08e-7	Longevity;Endometriosis;
TGCT	cis	rs137699	0.687	rs4821887	chr22:39756985	C/T	cg24399712	chr22:39784796	NA	-0.74	-6.45	-0.5	2.23e-9	IgG glycosylation;
TGCT	cis	rs35146811	0.657	rs36019559	chr7:99814586	A/G	cg04778012	chr7:99775508	STAG3;GPC2	-0.35	-4.93	-0.41	2.55e-6	Coronary artery disease;
TGCT	cis	rs9527	0.662	rs4919687	chr10:104595248	G/A	cg15744005	chr10:104629667	AS3MT	-0.46	-5.74	-0.46	7e-8	Arsenic metabolism;
TGCT	cis	rs6121246	0.567	rs6120879	chr20:30202961	T/C	cg21427119	chr20:30132790	HM13	-0.43	-6.17	-0.48	8.86e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs933688	1.000	rs12655973	chr5:90736537	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.07	9.6	0.65	1.2e-16	Smoking behavior;
TGCT	cis	rs7772486	0.790	rs6923545	chr6:146244743	A/G	cg23711669	chr6:146136114	FBXO30	-0.89	-10.38	-0.68	1.54e-18	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs3780486	0.718	rs10971418	chr9:33122024	A/C	cg04842962	chr6:43655489	MRPS18A	-1.06	-7.83	-0.58	1.91e-12	IgG glycosylation;
TGCT	cis	rs9811920	0.809	rs13059754	chr3:99678490	C/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	5.36	0.43	3.91e-7	Axial length;
TGCT	cis	rs2227564	0.597	rs12256103	chr10:75545251	A/G	cg19442545	chr10:75533431	FUT11	-0.3	-4.48	-0.37	1.7e-5	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg06618935	chr21:46677482	NA	-0.36	-5.47	-0.44	2.38e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg16423285	chr20:60520624	NA	-0.69	-7.33	-0.55	2.58e-11	Body mass index;
TGCT	cis	rs12477438	0.520	rs13022329	chr2:99731189	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	17.43	0.84	3.73e-35	Chronic sinus infection;
TGCT	cis	rs6770219	0.516	rs7613043	chr3:186134719	A/G	cg20306810	chr3:186501757	SNORD2;EIF4A2	0.73	4.45	0.37	1.89e-5	Cerebrospinal T-tau levels;
TGCT	cis	rs3617	0.625	rs2240915	chr3:52859526	T/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.6	-0.38	1.02e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7412746	0.566	rs2864871	chr1:150766964	T/C	cg04414720	chr1:150670196	GOLPH3L	0.38	4.73	0.39	6.04e-6	Melanoma;
TGCT	cis	rs1129187	0.805	rs1053538	chr6:42903763	C/G	cg17345569	chr6:42928274	GNMT	-0.46	-4.77	-0.39	5.03e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs854765	0.547	rs7209003	chr17:17907393	T/A	cg04398451	chr17:18023971	MYO15A	-0.3	-4.84	-0.4	3.73e-6	Total body bone mineral density;
TGCT	cis	rs9467711	0.606	rs2073530	chr6:26375243	T/C	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12477438	0.765	rs6737257	chr2:99683330	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-4.62	-0.38	9.47e-6	Chronic sinus infection;
TGCT	cis	rs10769945	0.679	rs2137322	chr11:1917354	A/G	cg06503573	chr11:1949039	TNNT3	-0.26	-4.99	-0.41	2e-6	DNA methylation (variation);
TGCT	cis	rs546131	0.928	rs483976	chr11:34840167	C/G	cg06937548	chr11:34938143	PDHX;APIP	0.62	5.61	0.45	1.24e-7	Lung disease severity in cystic fibrosis;
TGCT	cis	rs4961252	0.505	rs6990155	chr8:142098977	C/T	cg09914555	chr8:142094789	NA	0.42	6.53	0.51	1.54e-9	Isovolumetric relaxation time;Response to interferon beta therapy;
TGCT	cis	rs2734839	0.537	rs10891549	chr11:113278447	T/C	cg14159747	chr11:113255604	NA	0.39	4.96	0.41	2.31e-6	Information processing speed;
TGCT	cis	rs1421811	0.532	rs72740626	chr5:32692220	G/C	cg16267343	chr5:32710456	NPR3	0.74	6.53	0.51	1.56e-9	Blood pressure;
TGCT	cis	rs13315871	1.000	rs13071688	chr3:58398730	G/A	cg12435725	chr3:58293450	RPP14	-0.43	-4.47	-0.37	1.71e-5	Cholesterol, total;
TGCT	cis	rs751728	1.000	rs6925273	chr6:33732448	A/G	cg13859433	chr6:33739653	LEMD2	-0.39	-7.36	-0.55	2.26e-11	Crohn's disease;
TGCT	cis	rs7772486	0.686	rs1004752	chr6:146037822	G/A	cg23711669	chr6:146136114	FBXO30	-0.88	-9.77	-0.66	4.64e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs546131	0.928	rs572690	chr11:34833614	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.52	4.58	0.38	1.12e-5	Lung disease severity in cystic fibrosis;
TGCT	cis	rs826838	1.000	rs10880785	chr12:38655405	T/G	cg26384229	chr12:38710491	ALG10B	1.05	10.25	0.68	3.18e-18	Heart rate;
TGCT	cis	rs9611565	0.512	rs139572	chr22:42214532	C/T	cg06481639	chr22:41940642	POLR3H	-0.69	-6.02	-0.48	1.83e-8	Vitiligo;
TGCT	cis	rs13217239	0.646	rs12523820	chr6:27001502	A/G	cg15659132	chr6:26577336	NA	0.54	5.44	0.44	2.78e-7	Schizophrenia;
TGCT	cis	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg18188782	chr20:61659543	NA	0.44	5.37	0.43	3.73e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg05872129	chr22:39784769	NA	-0.99	-11.6	-0.72	1.61e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs7017914	0.652	rs10957533	chr8:71825107	C/T	cg27287166	chr8:71315034	NCOA2	0.48	4.44	0.37	1.94e-5	Bone mineral density;
TGCT	cis	rs2762353	0.639	rs566530	chr6:25878361	T/C	cg07061783	chr6:25882402	NA	-0.48	-5.32	-0.43	4.58e-7	Blood metabolite levels;
TGCT	cis	rs7666738	0.830	rs13145011	chr4:98993410	G/A	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4975616	0.771	rs3816659	chr5:1317820	A/G	cg07493874	chr5:1342172	CLPTM1L	0.26	6.22	0.49	6.98e-9	Lung cancer;
TGCT	cis	rs9311474	1.000	rs2276834	chr3:52325759	A/G	cg10802521	chr3:52805072	NEK4	-0.59	-6.4	-0.5	2.91e-9	Electroencephalogram traits;
TGCT	cis	rs151997	0.671	rs395557	chr5:50215832	G/T	cg06027927	chr5:50259733	NA	0.56	5.64	0.45	1.11e-7	Callous-unemotional behaviour;
TGCT	cis	rs7100689	0.725	rs2487074	chr10:82064104	A/G	cg01528321	chr10:82214614	TSPAN14	0.8	7.91	0.58	1.25e-12	Post bronchodilator FEV1;
TGCT	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.69	-7.06	-0.54	1.07e-10	Prostate cancer;
TGCT	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg23758822	chr17:41437982	NA	0.7	6.6	0.51	1.1e-9	Menopause (age at onset);
TGCT	cis	rs3806843	0.576	rs246021	chr5:140334504	C/A	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7017914	0.934	rs13255152	chr8:71859619	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.07	-0.41	1.39e-6	Bone mineral density;
TGCT	cis	rs6088580	0.608	rs1205342	chr20:32921842	C/T	cg06115741	chr20:33292138	TP53INP2	-0.55	-4.84	-0.4	3.85e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs265548	0.608	rs265544	chr19:17903479	G/C	cg03316864	chr19:17906309	B3GNT3	0.43	4.95	0.41	2.36e-6	Tumor biomarkers;
TGCT	cis	rs7044106	0.718	rs1960421	chr9:123394894	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	4.93	0.4	2.59e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs12291225	0.679	rs1043237	chr11:14289053	A/T	cg19336497	chr11:14380999	RRAS2	-0.38	-5.8	-0.46	5.09e-8	Sense of smell;
TGCT	trans	rs4765905	0.522	rs2283291	chr12:2337460	G/A	cg13866577	chr1:66797481	PDE4B	-0.5	-6.96	-0.53	1.78e-10	Schizophrenia;
TGCT	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg10047753	chr17:41438598	NA	0.96	9.64	0.65	9.37e-17	Menopause (age at onset);
TGCT	cis	rs9581857	0.725	rs1924074	chr13:28015387	C/G	cg22138327	chr13:27999177	GTF3A	-0.79	-5.5	-0.44	2.1e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs1355223	0.583	rs2941043	chr11:34870994	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.77	-8.18	-0.59	2.92e-13	Systemic lupus erythematosus and Systemic sclerosis;
TGCT	cis	rs7568458	0.684	rs67988001	chr2:85787123	C/T	cg17127132	chr2:85788382	GGCX	0.5	4.55	0.38	1.28e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs2153535	0.580	rs9393023	chr6:8469994	T/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs7618915	1.000	rs34569561	chr3:52287293	T/C	cg10802521	chr3:52805072	NEK4	-0.5	-5.3	-0.43	5.02e-7	Bipolar disorder;
TGCT	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg25036284	chr2:26402008	FAM59B	0.54	4.88	0.4	3.15e-6	Gut microbiome composition (summer);
TGCT	cis	rs17376456	1.000	rs13174700	chr5:93554644	G/A	cg25358565	chr5:93447407	FAM172A	0.94	7.65	0.57	4.72e-12	Diabetic retinopathy;
TGCT	trans	rs7819412	0.534	rs11250113	chr8:10907479	C/T	cg15556689	chr8:8085844	FLJ10661	0.72	6.82	0.52	3.6e-10	Triglycerides;
TGCT	cis	rs1472147	0.503	rs58691638	chr7:128433690	A/T	cg00260937	chr7:128520193	KCP	0.43	4.89	0.4	3.09e-6	Calcium levels;
TGCT	cis	rs6495122	0.699	rs1378942	chr15:75077367	A/C	cg10253484	chr15:75165896	SCAMP2	0.68	6.01	0.48	1.87e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
TGCT	cis	rs6788895	0.661	rs60259684	chr3:150494951	A/G	cg07663535	chr3:150480033	SIAH2	0.96	4.49	0.37	1.6e-5	Breast cancer;
TGCT	cis	rs9914988	0.943	rs2043031	chr17:27085564	A/G	cg20469991	chr17:27169893	C17orf63	-0.79	-5.51	-0.44	1.97e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs7666738	0.830	rs2865949	chr4:99039967	A/G	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6121246	0.909	rs6058460	chr20:30363071	G/A	cg13852791	chr20:30311386	BCL2L1	0.8	6.12	0.48	1.15e-8	Mean corpuscular hemoglobin;
TGCT	trans	rs17471911	0.708	rs11189940	chr10:100782356	A/G	cg03484267	chr2:207988651	KLF7	-0.52	-6.7	-0.52	6.49e-10	Neuroticism;
TGCT	cis	rs9400467	0.537	rs584937	chr6:111481577	T/G	cg15721981	chr6:111408429	SLC16A10	0.68	4.48	0.37	1.69e-5	Blood metabolite levels;Amino acid levels;
TGCT	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg06873352	chr17:61820015	STRADA	0.57	6.14	0.48	1.02e-8	Prudent dietary pattern;
TGCT	cis	rs2456568	0.741	rs9633811	chr11:93628327	A/G	cg17595323	chr11:93583763	C11orf90	0.46	6.48	0.5	1.99e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg15556689	chr8:8085844	FLJ10661	-0.79	-7.43	-0.56	1.53e-11	Joint mobility (Beighton score);
TGCT	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg06481639	chr22:41940642	POLR3H	0.74	6.59	0.51	1.11e-9	Vitiligo;
TGCT	cis	rs74181299	0.571	rs71424153	chr2:65280894	G/C	cg05010058	chr2:65284262	CEP68	0.49	5.01	0.41	1.79e-6	Pulse pressure;
TGCT	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg22166914	chr1:53195759	ZYG11B	-0.46	-8.42	-0.6	7.72e-14	Monocyte count;
TGCT	cis	rs7582180	0.602	rs7585582	chr2:100998030	G/C	cg14675211	chr2:100938903	LONRF2	0.47	4.45	0.37	1.89e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7568458	0.684	rs7579147	chr2:85805654	G/A	cg02493740	chr2:85810744	VAMP5	-0.29	-5.51	-0.44	1.94e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs9796	0.866	rs692155	chr15:41407061	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.46	-5.94	-0.47	2.62e-8	Menopause (age at onset);
TGCT	cis	rs910187	0.631	rs62201431	chr20:45810994	G/A	cg27589058	chr20:45804311	EYA2	-0.37	-7.89	-0.58	1.32e-12	Migraine;
TGCT	cis	rs548181	0.736	rs540723	chr11:125489621	A/G	cg03464685	chr11:125439445	EI24	1.12	7.9	0.58	1.27e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs2050392	0.517	rs619864	chr10:30750950	A/G	cg13289132	chr10:30722225	MAP3K8	0.42	5.18	0.42	8.55e-7	Inflammatory bowel disease;
TGCT	trans	rs17684571	0.938	rs13206849	chr6:56566621	T/C	cg14229071	chr15:89282588	NA	0.52	6.82	0.52	3.54e-10	Schizophrenia;
TGCT	cis	rs9534288	0.797	rs9526134	chr13:46618046	G/T	cg15192986	chr13:46630673	CPB2	-0.5	-7.06	-0.54	1.07e-10	Blood protein levels;
TGCT	cis	rs7647973	0.626	rs1996664	chr3:49878395	A/G	cg03034192	chr3:50606346	HEMK1;C3orf18	-0.36	-4.83	-0.4	3.96e-6	Menarche (age at onset);
TGCT	cis	rs9883204	0.904	rs11717195	chr3:123082398	C/T	cg04890266	chr3:123102914	ADCY5	-0.35	-4.88	-0.4	3.2e-6	Birth weight;
TGCT	cis	rs61931739	0.500	rs12146843	chr12:34451738	T/G	cg06521331	chr12:34319734	NA	-0.28	-4.52	-0.38	1.4e-5	Morning vs. evening chronotype;
TGCT	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg13683864	chr3:40499215	RPL14	-1.18	-12.86	-0.76	1.47e-24	Renal cell carcinoma;
TGCT	cis	rs2549003	0.966	rs839	chr5:131819126	C/T	cg00255919	chr5:131827918	IRF1	0.2	4.7	0.39	6.92e-6	Asthma (sex interaction);
TGCT	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.64	0.51	8.85e-10	Bipolar disorder;
TGCT	cis	rs2721195	0.874	rs2721197	chr8:145727705	A/G	cg11211951	chr8:145729740	GPT	0.27	6.49	0.5	1.9e-9	Age at first birth;
TGCT	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg11494091	chr17:61959527	GH2	0.61	14.43	0.79	2.59e-28	Prudent dietary pattern;
TGCT	cis	rs904251	0.861	rs1776456	chr6:37484698	C/G	cg01843034	chr6:37503916	NA	-0.51	-6.24	-0.49	6.23e-9	Cognitive performance;
TGCT	cis	rs2467099	0.504	rs2666005	chr17:73944596	T/G	cg10108402	chr17:73901394	MRPL38	-0.47	-4.61	-0.38	1e-5	Systolic blood pressure;
TGCT	cis	rs514406	0.525	rs269291	chr1:53189297	C/T	cg25767906	chr1:53392781	SCP2	-0.45	-4.89	-0.4	3.09e-6	Monocyte count;
TGCT	cis	rs9517302	0.847	rs9517297	chr13:99094961	A/C	cg22223119	chr13:99095684	FARP1	-0.69	-8.58	-0.61	3.27e-14	Obesity-related traits;
TGCT	cis	rs556990	0.760	rs3024739	chr13:113819948	G/A	cg18105134	chr13:113819100	PROZ	-0.47	-7.85	-0.58	1.64e-12	Blood protein levels;
TGCT	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg11644478	chr21:40555479	PSMG1	0.96	9.3	0.64	6.17e-16	Cognitive function;
TGCT	cis	rs6964587	1.000	rs1859037	chr7:91568272	A/G	cg17063962	chr7:91808500	NA	-0.9	-9.67	-0.66	7.91e-17	Breast cancer;
TGCT	cis	rs2996428	0.667	rs16824230	chr1:3766240	A/G	cg17848003	chr1:3704513	LRRC47	0.2	5.49	0.44	2.21e-7	Red cell distribution width;
TGCT	cis	rs1171582	0.692	rs2671611	chr10:61491646	C/T	cg23572703	chr10:62241191	NA	0.3	4.96	0.41	2.27e-6	Alopecia areata;
TGCT	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg04234412	chr22:24373322	LOC391322	-0.93	-11.97	-0.73	2.05e-22	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1153858	1.000	rs11858495	chr15:45637662	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.47	-5.19	-0.42	8.25e-7	Homoarginine levels;
TGCT	cis	rs4653767	1.000	rs4653767	chr1:226916078	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.46	-4.89	-0.4	3.08e-6	Parkinson's disease;
TGCT	cis	rs12497850	0.931	rs7647813	chr3:48833348	G/T	cg07636037	chr3:49044803	WDR6	0.95	10.74	0.69	2e-19	Parkinson's disease;
TGCT	cis	rs7267979	0.718	rs2983489	chr20:25244120	C/A	cg03522245	chr20:25566470	NINL	0.52	5.4	0.44	3.22e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg16680214	chr1:154839983	KCNN3	-0.42	-9.25	-0.64	8.37e-16	Prostate cancer;
TGCT	cis	rs3008870	1.000	rs975451	chr1:67480060	T/C	cg03991309	chr1:68237761	GNG12	0.27	4.49	0.37	1.6e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs72768842	1.000	rs60449834	chr5:78957986	G/A	cg24834873	chr5:79865402	ANKRD34B	-1.16	-4.61	-0.38	9.84e-6	Post bronchodilator FEV1/FVC ratio in COPD;
TGCT	cis	rs1008375	0.966	rs2010053	chr4:17583806	A/C	cg16339924	chr4:17578868	LAP3	0.8	6.96	0.53	1.73e-10	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs11718455	0.960	rs11921942	chr3:44007957	T/C	cg08738300	chr3:44038990	NA	0.86	6.55	0.51	1.4e-9	Coronary artery disease;
TGCT	cis	rs7918232	0.574	rs10458708	chr10:27455605	C/T	cg14442939	chr10:27389572	ANKRD26	0.98	9.72	0.66	5.87e-17	Breast cancer;
TGCT	cis	rs2235642	0.928	rs56289115	chr16:1608934	A/G	cg11375102	chr16:1583810	IFT140;TMEM204	-0.29	-5.22	-0.42	7.33e-7	Coronary artery disease;
TGCT	cis	rs7917772	0.582	rs4917978	chr10:104366353	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.61	-6.01	-0.47	1.94e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9467773	0.620	rs2451741	chr6:26629404	A/G	cg11502198	chr6:26597334	ABT1	0.54	4.97	0.41	2.14e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1062177	0.756	rs2964591	chr5:151117397	A/G	cg12924095	chr5:151150029	G3BP1	-0.34	-4.59	-0.38	1.08e-5	Preschool internalizing problems;
TGCT	trans	rs7507204	0.530	rs4807469	chr19:3443382	G/C	cg08382705	chr11:45687319	CHST1	-0.79	-7.8	-0.57	2.22e-12	Height;
TGCT	cis	rs9325144	0.555	rs7301258	chr12:38706942	C/T	cg26384229	chr12:38710491	ALG10B	0.69	6.4	0.5	2.84e-9	Morning vs. evening chronotype;
TGCT	cis	rs7017914	0.967	rs34677078	chr8:71617715	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.55	-5.13	-0.42	1.11e-6	Bone mineral density;
TGCT	cis	rs909002	0.849	rs10798881	chr1:32101775	G/C	cg13919466	chr1:32135498	COL16A1	-0.32	-4.46	-0.37	1.8e-5	Intelligence (multi-trait analysis);
TGCT	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg01171360	chr6:293285	DUSP22	-0.78	-7.84	-0.58	1.81e-12	Menopause (age at onset);
TGCT	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg03452623	chr4:187889614	NA	-0.38	-5.7	-0.46	8.09e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6725041	0.846	rs10185271	chr2:213089454	T/G	cg16329650	chr2:213403929	ERBB4	-0.53	-4.52	-0.38	1.44e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs78487399	0.908	rs12474030	chr2:43812317	G/A	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.66	4.67	0.39	7.66e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	trans	rs1075232	0.677	rs72714666	chr15:31492226	T/C	cg27417677	chr7:130130918	MESTIT1;MEST	0.94	6.68	0.51	7.11e-10	Survival in colorectal cancer (non-distant metastatic);
TGCT	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg22166914	chr1:53195759	ZYG11B	0.36	5.96	0.47	2.45e-8	Monocyte count;
TGCT	cis	rs7772486	0.719	rs4391282	chr6:146276780	A/T	cg23711669	chr6:146136114	FBXO30	-0.85	-9.51	-0.65	1.95e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs155076	1.000	rs567166	chr13:21837519	T/C	cg14456004	chr13:21872349	NA	-1.32	-10.82	-0.7	1.25e-19	White matter hyperintensity burden;
TGCT	trans	rs7824557	0.564	rs2572389	chr8:11236392	T/C	cg15556689	chr8:8085844	FLJ10661	-0.74	-6.68	-0.51	7.12e-10	Retinal vascular caliber;
TGCT	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs4953076	0.573	rs920519	chr2:44452344	T/C	cg04920474	chr2:44395004	PPM1B	0.6	6.02	0.48	1.81e-8	Height;
TGCT	cis	rs2013441	1.000	rs2703780	chr17:20143672	A/G	cg18979559	chr17:20280153	CCDC144C	-0.45	-4.67	-0.39	7.61e-6	Obesity-related traits;
TGCT	cis	rs3892630	0.588	rs28787932	chr19:33226229	T/C	cg22980127	chr19:33182716	NUDT19	0.76	6.28	0.49	5.32e-9	Red blood cell traits;
TGCT	cis	rs853679	0.546	rs200995	chr6:27813694	C/T	cg10876282	chr6:28092338	ZSCAN16	-0.74	-4.44	-0.37	1.98e-5	Depression;
TGCT	cis	rs12134133	1.000	rs2564973	chr1:207480104	T/C	cg02152968	chr1:207494213	CD55	0.62	4.89	0.4	3.05e-6	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs1215050	0.605	rs28479339	chr4:98604485	A/G	cg05340658	chr4:99064831	C4orf37	-0.41	-4.96	-0.41	2.3e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs11696501	0.637	rs2093090	chr20:44205464	C/T	cg11783356	chr20:44313418	WFDC10B	-0.33	-4.62	-0.38	9.32e-6	Brain structure;
TGCT	cis	rs7829975	0.846	rs7005216	chr8:8547110	C/G	cg15556689	chr8:8085844	FLJ10661	-0.72	-6.3	-0.49	4.69e-9	Mood instability;
TGCT	cis	rs12477438	0.520	rs13023744	chr2:99738224	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.89	9.0	0.63	3.26e-15	Chronic sinus infection;
TGCT	cis	rs587847	0.737	rs12148150	chr15:37657009	G/T	cg00216138	chr15:37171175	LOC145845	0.31	4.49	0.37	1.59e-5	Intraocular pressure;
TGCT	cis	rs9296092	0.538	rs3916674	chr6:33522975	C/T	cg13560919	chr6:33536144	NA	-0.2	-4.64	-0.38	8.68e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs2404602	0.631	rs9646213	chr15:76807672	G/C	cg26408565	chr15:76604113	ETFA	-0.41	-5.22	-0.42	7.44e-7	Blood metabolite levels;
TGCT	cis	rs4242434	0.699	rs878051	chr8:22483836	T/C	cg03733263	chr8:22462867	KIAA1967	0.98	14.04	0.78	2.12e-27	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs36051895	0.695	rs12352214	chr9:5018041	G/A	cg02405213	chr9:5042618	JAK2	-0.75	-9.96	-0.67	1.62e-17	Pediatric autoimmune diseases;
TGCT	cis	rs514406	0.825	rs12089511	chr1:53436427	A/T	cg27535305	chr1:53392650	SCP2	0.23	4.49	0.37	1.59e-5	Monocyte count;
TGCT	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg05552183	chr6:42928497	GNMT	0.52	4.55	0.38	1.25e-5	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg10802521	chr3:52805072	NEK4	-0.78	-10.0	-0.67	1.26e-17	Electroencephalogram traits;
TGCT	cis	rs7267979	1.000	rs6083844	chr20:25386832	C/T	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9467711	0.606	rs2073531	chr6:26375256	A/G	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs950169	0.887	rs35986397	chr15:84955107	G/A	cg12863693	chr15:85201151	NMB	0.44	4.79	0.4	4.58e-6	Schizophrenia;
TGCT	cis	rs6570726	0.764	rs9386125	chr6:145911677	C/T	cg23711669	chr6:146136114	FBXO30	0.86	9.28	0.64	7.13e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs780096	0.587	rs4665969	chr2:27574953	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.34	-4.43	-0.37	2.01e-5	Total body bone mineral density;
TGCT	cis	rs7119038	0.818	rs56758835	chr11:118615340	G/A	cg19308663	chr11:118741387	NA	0.29	5.39	0.44	3.41e-7	Sjögren's syndrome;
TGCT	cis	rs3796352	1.000	rs113995589	chr3:53132372	A/T	cg07884673	chr3:53033167	SFMBT1	0.54	5.76	0.46	6.2e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs6088590	0.561	rs6087605	chr20:33180624	G/T	cg06115741	chr20:33292138	TP53INP2	0.51	4.47	0.37	1.76e-5	Coronary artery disease;
TGCT	cis	rs12460587	0.587	rs55899235	chr19:52603124	T/C	cg13540795	chr19:52551618	ZNF432	-0.45	-4.8	-0.4	4.52e-6	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.03	0.41	1.68e-6	Prudent dietary pattern;
TGCT	cis	rs35146811	0.735	rs7811662	chr7:99792608	A/G	cg13334819	chr7:99746414	C7orf59	-0.74	-6.31	-0.49	4.4e-9	Coronary artery disease;
TGCT	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.84	0.46	4.23e-8	Alzheimer's disease;
TGCT	cis	rs9972944	0.651	rs8080916	chr17:63816368	G/C	cg01592018	chr17:63456079	NA	0.25	4.43	0.37	2.01e-5	Total body bone mineral density;
TGCT	cis	rs2702888	0.501	rs2741717	chr8:6747886	G/A	cg26795848	chr8:6756730	NA	-0.32	-6.39	-0.5	3.07e-9	Blood pressure;
TGCT	cis	rs9527	0.545	rs7095304	chr10:104954795	G/A	cg04362960	chr10:104952993	NT5C2	0.68	5.73	0.46	7.14e-8	Arsenic metabolism;
TGCT	cis	rs748404	0.587	rs690276	chr15:43704558	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	4.56	0.38	1.21e-5	Lung cancer;
TGCT	cis	rs7666738	0.830	rs10001702	chr4:99065160	T/G	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.44e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs916888	0.610	rs199536	chr17:44820425	T/C	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.58	-4.51	-0.38	1.51e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg08280861	chr8:58055591	NA	0.41	4.63	0.38	8.93e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs11105298	0.891	rs10858869	chr12:89857611	C/T	cg00757033	chr12:89920650	WDR51B	0.34	5.37	0.43	3.75e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs7447593	0.518	rs4074995	chr5:176797343	C/T	cg17509989	chr5:176798049	RGS14	0.77	12.29	0.74	3.49e-23	Urinary electrolytes (magnesium/calcium ratio);
TGCT	cis	rs1801251	1.000	rs7558609	chr2:233700379	C/T	cg08000102	chr2:233561755	GIGYF2	0.64	6.54	0.51	1.44e-9	Coronary artery disease;
TGCT	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg14159672	chr1:205819179	PM20D1	0.57	6.92	0.53	2.09e-10	Monocyte percentage of white cells;
TGCT	cis	rs9682041	0.696	rs16855034	chr3:170097842	C/G	cg11886554	chr3:170076028	SKIL	0.62	4.82	0.4	4.11e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs3806843	0.576	rs251370	chr5:140246287	C/T	cg09824255	chr5:140014002	CD14	-0.26	-4.53	-0.38	1.35e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg18188782	chr20:61659543	NA	0.44	5.38	0.43	3.6e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9467773	0.933	rs35355150	chr6:26526039	G/A	cg09904177	chr6:26538194	HMGN4	0.59	5.76	0.46	6.11e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs4440224	chr4:99044924	G/A	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2242116	0.900	rs4683300	chr3:46934292	C/A	cg23352942	chr3:46931381	PTH1R	-0.37	-5.81	-0.46	5.02e-8	Birth weight;
TGCT	cis	rs950169	0.580	rs11634320	chr15:85172183	A/C	cg17173187	chr15:85201210	NMB	-0.62	-7.09	-0.54	8.99e-11	Schizophrenia;
TGCT	cis	rs1878931	0.501	rs37800	chr16:3423648	T/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.75	-7.06	-0.54	1.05e-10	Body mass index (adult);
TGCT	cis	rs7511006	1.000	rs7364173	chr22:50681029	C/T	cg16473166	chr22:50639996	SELO	-0.58	-5.81	-0.46	4.87e-8	Obesity-related traits;
TGCT	cis	rs2204008	0.805	rs11169513	chr12:37988640	G/A	cg13010199	chr12:38710504	ALG10B	0.65	5.29	0.43	5.47e-7	Bladder cancer;
TGCT	cis	rs7772486	0.790	rs7742333	chr6:146159029	A/G	cg23711669	chr6:146136114	FBXO30	-0.83	-8.94	-0.63	4.63e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6570726	0.526	rs9376928	chr6:145724403	T/G	cg23711669	chr6:146136114	FBXO30	-0.56	-4.99	-0.41	1.96e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6752107	0.901	rs34701569	chr2:234143048	C/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.21	5.01	0.41	1.79e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs1153858	1.000	rs72623915	chr15:45647433	C/T	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.62e-8	Homoarginine levels;
TGCT	cis	rs7523273	1.000	rs7523273	chr1:207977083	A/G	cg22525895	chr1:207977042	MIR29B2	-0.49	-8.9	-0.62	5.71e-15	Schizophrenia;
TGCT	cis	rs1555895	0.544	rs1555897	chr10:853674	A/C	cg02193355	chr10:851439	NA	0.21	4.78	0.39	4.82e-6	Survival in rectal cancer;
TGCT	cis	rs2204008	0.837	rs12370891	chr12:37984531	A/G	cg26384229	chr12:38710491	ALG10B	0.86	7.77	0.57	2.55e-12	Bladder cancer;
TGCT	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg17554472	chr22:41940697	POLR3H	-0.43	-4.56	-0.38	1.22e-5	Vitiligo;
TGCT	cis	rs6912958	0.781	rs9450739	chr6:88268271	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-5.06	-0.41	1.45e-6	Monocyte percentage of white cells;
TGCT	cis	rs7267979	0.866	rs2424699	chr20:25257462	G/A	cg16686733	chr20:25566563	NINL	0.62	6.15	0.48	9.65e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7014346	0.767	rs7837626	chr8:128423341	A/G	cg04263511	chr8:128962092	PVT1	-0.31	-4.5	-0.37	1.54e-5	Colorectal cancer;
TGCT	cis	rs1997103	1.000	rs6948112	chr7:55411302	G/A	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs9916302	0.851	rs612209	chr17:37442713	G/C	cg15445000	chr17:37608096	MED1	-0.31	-4.59	-0.38	1.06e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg24503407	chr1:205819492	PM20D1	0.56	7.64	0.57	5.08e-12	Menarche (age at onset);
TGCT	cis	rs9733	0.565	rs11804276	chr1:150685761	T/A	cg09365446	chr1:150670422	GOLPH3L	0.3	4.52	0.38	1.4e-5	Tonsillectomy;
TGCT	cis	rs910316	0.875	rs12588099	chr14:75594462	A/T	cg08847533	chr14:75593920	NEK9	0.95	10.55	0.69	5.84e-19	Height;
TGCT	cis	rs9611565	0.512	rs2899347	chr22:42158204	T/C	cg06481639	chr22:41940642	POLR3H	0.69	6.02	0.48	1.83e-8	Vitiligo;
TGCT	cis	rs10465746	0.967	rs12748268	chr1:84374438	T/C	cg10977910	chr1:84465055	TTLL7	0.63	6.19	0.49	8.08e-9	Obesity-related traits;
TGCT	cis	rs76419734	0.558	rs10032269	chr4:106525703	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.81	4.6	0.38	1.02e-5	Post bronchodilator FEV1;
TGCT	cis	rs1667284	0.967	rs1667281	chr18:29220756	C/G	cg15259973	chr18:29078565	DSG2	0.53	5.19	0.42	8.27e-7	Problematic alcohol use in trauma-exposed individuals;
TGCT	cis	rs62380364	0.727	rs1671539	chr5:88168395	C/G	cg22951263	chr5:87985283	NA	0.5	5.02	0.41	1.79e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2637266	1.000	rs17384253	chr10:78342391	A/G	cg18941641	chr10:78392320	NA	0.4	5.02	0.41	1.77e-6	Pulmonary function;
TGCT	cis	rs4746818	0.892	rs10823298	chr10:70867083	T/C	cg04149295	chr10:70884716	VPS26A	0.72	4.68	0.39	7.53e-6	Left atrial antero-posterior diameter;
TGCT	cis	rs2197308	0.565	rs12809769	chr12:37909968	C/T	cg13010199	chr12:38710504	ALG10B	0.67	5.38	0.44	3.57e-7	Morning vs. evening chronotype;
TGCT	cis	rs7772486	0.754	rs6937661	chr6:146113299	T/C	cg13319975	chr6:146136371	FBXO30	0.58	5.24	0.43	6.75e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg23982607	chr1:1823379	GNB1	-0.56	-8.49	-0.61	5.45e-14	Body mass index;
TGCT	cis	rs734999	0.967	rs6671426	chr1:2504234	C/A	cg18854424	chr1:2615690	NA	0.44	5.33	0.43	4.39e-7	Ulcerative colitis;
TGCT	cis	rs1005277	0.522	rs289643	chr10:37941494	T/G	cg25427524	chr10:38739819	LOC399744	-0.36	-7.05	-0.54	1.08e-10	Extrinsic epigenetic age acceleration;
TGCT	cis	rs9911578	1.000	rs12952832	chr17:56906254	T/C	cg05425664	chr17:57184151	TRIM37	-0.62	-6.06	-0.48	1.53e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs838147	0.537	rs504963	chr19:49208865	G/A	cg10667338	chr19:49617042	LIN7B	-0.34	-4.65	-0.39	8.39e-6	Dietary macronutrient intake;
TGCT	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.12	-15.83	-0.82	1.5e-31	Prudent dietary pattern;
TGCT	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg25767906	chr1:53392781	SCP2	0.5	5.73	0.46	7.21e-8	Monocyte count;
TGCT	cis	rs240764	0.658	rs1039030	chr6:101198707	G/A	cg09795085	chr6:101329169	ASCC3	-0.51	-4.51	-0.38	1.45e-5	Neuroticism;
TGCT	cis	rs360798	0.532	rs11125942	chr2:62966758	T/C	cg17519650	chr2:63277830	OTX1	-0.61	-5.51	-0.44	2e-7	Coronary artery disease;
TGCT	cis	rs11264213	0.551	rs172081	chr1:36497498	T/G	cg27506609	chr1:36549197	TEKT2	0.45	5.19	0.42	8.31e-7	Schizophrenia;
TGCT	cis	rs6433857	0.657	rs6756509	chr2:181500273	T/C	cg23363182	chr2:181467187	NA	-0.33	-5.08	-0.42	1.33e-6	Body mass index;
TGCT	cis	rs17270561	1.000	rs12211184	chr6:25823774	G/A	cg16482183	chr6:26056742	HIST1H1C	0.79	5.25	0.43	6.49e-7	Iron status biomarkers;
TGCT	cis	rs17221829	0.733	rs11018684	chr11:89364863	A/C	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.65	-0.39	8.43e-6	Anxiety in major depressive disorder;
TGCT	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg11644478	chr21:40555479	PSMG1	1.0	10.69	0.69	2.7e-19	Cognitive function;
TGCT	cis	rs3772130	0.775	rs6769102	chr3:121560722	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.62	0.38	9.48e-6	Cognitive performance;
TGCT	cis	rs7959452	0.605	rs12819406	chr12:69696400	G/T	cg11871910	chr12:69753446	YEATS4	0.63	6.37	0.5	3.34e-9	Blood protein levels;
TGCT	cis	rs11096990	0.964	rs6831700	chr4:39256964	G/T	cg14806045	chr4:39367699	RFC1	-0.58	-4.55	-0.38	1.26e-5	Cognitive function;
TGCT	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg08736216	chr1:53307985	ZYG11A	-0.29	-6.02	-0.48	1.84e-8	Monocyte count;
TGCT	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg22963979	chr7:1858916	MAD1L1	-0.44	-7.28	-0.55	3.29e-11	Schizophrenia;
TGCT	cis	rs9303401	0.614	rs34843288	chr17:57103140	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.58	5.82	0.46	4.69e-8	Cognitive test performance;
TGCT	cis	rs2070433	0.706	rs3788265	chr21:47833789	G/T	cg04277056	chr21:48021941	S100B	0.35	5.02	0.41	1.75e-6	Lymphocyte counts;
TGCT	cis	rs7267979	0.966	rs2482918	chr20:25412135	C/T	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7647973	0.626	rs1463728	chr3:49647404	T/A	cg06212747	chr3:49208901	KLHDC8B	0.59	4.44	0.37	2e-5	Menarche (age at onset);
TGCT	cis	rs910316	1.000	rs4322591	chr14:75600697	C/T	cg11812906	chr14:75593930	NEK9	0.74	7.37	0.55	2.12e-11	Height;
TGCT	cis	rs6840360	0.967	rs1511170	chr4:152701110	A/G	cg22705602	chr4:152727874	NA	-0.25	-4.63	-0.38	9.16e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs12643440	0.538	rs62296726	chr4:17143914	T/C	cg22650099	chr4:17144496	NA	-0.46	-4.7	-0.39	6.79e-6	Metabolite levels (Pyroglutamine);
TGCT	cis	rs6490294	0.904	rs1016078	chr12:112410077	G/T	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Mean platelet volume;
TGCT	cis	rs4862307	0.762	rs28584149	chr4:184996482	C/T	cg06737308	chr4:185021514	ENPP6	0.32	4.58	0.38	1.1e-5	Serum dimethylarginine levels (asymmetric/symetric ratio);
TGCT	cis	rs7772486	0.790	rs9376968	chr6:146180364	T/C	cg23711669	chr6:146136114	FBXO30	0.91	10.41	0.68	1.3e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs61990749	0.597	rs4903643	chr14:78254791	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	0.67	4.73	0.39	6.09e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs11098499	0.863	rs2127823	chr4:120485670	G/T	cg09307838	chr4:120376055	NA	0.74	7.34	0.55	2.49e-11	Corneal astigmatism;
TGCT	cis	rs72949976	0.707	rs10932473	chr2:214039057	C/T	cg08319019	chr2:214017104	IKZF2	-0.75	-6.35	-0.5	3.78e-9	Lung cancer;Squamous cell lung carcinoma;
TGCT	cis	rs9388451	0.868	rs10457467	chr6:126045148	T/A	cg10911889	chr6:126070802	HEY2	0.5	4.91	0.4	2.75e-6	Brugada syndrome;
TGCT	cis	rs10927875	0.541	rs1739844	chr1:16343322	T/C	cg21385522	chr1:16154831	NA	0.46	4.85	0.4	3.64e-6	Dilated cardiomyopathy;
TGCT	cis	rs288326	0.561	rs7595898	chr2:183819892	C/A	cg09997497	chr2:183902928	NCKAP1	1.11	4.95	0.41	2.38e-6	Blood protein levels;
TGCT	cis	rs76419734	0.558	rs11730825	chr4:106527568	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.81	4.63	0.38	9.19e-6	Post bronchodilator FEV1;
TGCT	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg00343986	chr7:65444356	GUSB	0.26	6.03	0.48	1.76e-8	Aortic root size;
TGCT	cis	rs9807989	0.507	rs1035129	chr2:103019785	T/C	cg03938978	chr2:103052716	IL18RAP	0.27	5.41	0.44	3.17e-7	Asthma;
TGCT	cis	rs9467711	0.606	rs71557334	chr6:26365913	G/T	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7582180	0.585	rs12999151	chr2:100939333	G/A	cg08017756	chr2:100939284	LONRF2	-0.3	-4.78	-0.39	4.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9985766	0.793	rs10005992	chr4:150999112	A/T	cg05926478	chr4:151174724	DCLK2	-0.24	-4.64	-0.38	8.63e-6	Coronary artery disease;Myocardial infarction;
TGCT	cis	rs739496	0.947	rs2238154	chr12:111882485	C/A	cg10833066	chr12:111807467	FAM109A	0.36	5.51	0.44	2.01e-7	Platelet count;
TGCT	cis	rs9916302	0.904	rs801420	chr17:37466103	C/G	cg15445000	chr17:37608096	MED1	-0.33	-4.71	-0.39	6.46e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7937682	0.924	rs10891286	chr11:111532691	C/G	cg09085632	chr11:111637200	PPP2R1B	-1.12	-11.81	-0.73	4.86e-22	Primary sclerosing cholangitis;
TGCT	cis	rs3749237	0.595	rs7621003	chr3:49411404	T/C	cg07636037	chr3:49044803	WDR6	0.64	6.04	0.48	1.63e-8	Resting heart rate;
TGCT	trans	rs4650994	1.000	rs10798617	chr1:178515806	T/C	cg05059571	chr16:84539110	KIAA1609	-0.4	-7.43	-0.56	1.52e-11	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	5.99	0.47	2.14e-8	Alzheimer's disease;
TGCT	trans	rs877282	0.891	rs12357999	chr10:796468	A/C	cg22713356	chr15:30763199	NA	1.18	10.55	0.69	5.81e-19	Uric acid levels;
TGCT	cis	rs8103278	0.507	rs2041975	chr19:46238555	T/C	cg14061069	chr19:46274453	DMPK	0.63	10.97	0.7	5.44e-20	Coronary artery disease;
TGCT	cis	rs1520333	0.958	rs13272546	chr8:79350425	G/A	cg16589705	chr8:80226364	NA	-0.3	-4.51	-0.38	1.47e-5	Multiple sclerosis;
TGCT	cis	rs4478858	0.684	rs11579845	chr1:31736248	A/G	cg00250761	chr1:31883323	NA	-0.25	-4.52	-0.38	1.45e-5	Alcohol dependence;
TGCT	cis	rs138249	0.898	rs138232	chr22:50559838	C/G	cg24864161	chr22:50528282	MOV10L1	0.47	5.02	0.41	1.77e-6	Gestational age at birth in labor-initiated deliveries (child effect);
TGCT	cis	rs6570726	0.967	rs6903252	chr6:145922777	A/G	cg23711669	chr6:146136114	FBXO30	0.78	7.91	0.58	1.22e-12	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2445762	0.642	rs8025191	chr15:51623785	A/G	cg00184732	chr15:51633821	GLDN	0.5	5.17	0.42	9.05e-7	Hormone measurements;
TGCT	cis	rs62064224	0.818	rs11080181	chr17:30701210	C/T	cg18200150	chr17:30822561	MYO1D	0.58	7.69	0.57	3.92e-12	Schizophrenia;
TGCT	cis	rs3540	0.597	rs10152221	chr15:91047664	A/G	cg22089800	chr15:90895588	ZNF774	-0.76	-7.77	-0.57	2.55e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs1799949	0.965	rs4792989	chr17:41437552	T/C	cg10047753	chr17:41438598	NA	0.85	7.86	0.58	1.56e-12	Menopause (age at onset);
TGCT	trans	rs7819412	0.745	rs4841498	chr8:10985432	C/T	cg15556689	chr8:8085844	FLJ10661	-0.77	-7.39	-0.55	1.94e-11	Triglycerides;
TGCT	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg03188948	chr7:1209495	NA	0.55	4.56	0.38	1.2e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs3772130	0.962	rs4413346	chr3:121486310	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.53	4.83	0.4	3.97e-6	Cognitive performance;
TGCT	cis	rs7584330	0.554	rs56881028	chr2:238446678	C/G	cg08992911	chr2:238395768	MLPH	0.65	4.47	0.37	1.74e-5	Prostate cancer;
TGCT	cis	rs9818758	0.505	rs67286839	chr3:49265744	C/T	cg07636037	chr3:49044803	WDR6	-1.04	-5.13	-0.42	1.09e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs9560113	1.000	rs9560104	chr13:112174389	A/G	cg14154082	chr13:112174009	NA	0.33	4.44	0.37	1.93e-5	Menarche (age at onset);
TGCT	cis	rs7508	0.511	rs208056	chr8:17822884	C/T	cg01800426	chr8:17659068	MTUS1	-0.67	-5.05	-0.41	1.53e-6	Atrial fibrillation;
TGCT	cis	rs7044106	0.762	rs10760110	chr9:123412563	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.6	-6.29	-0.49	4.9e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs7772486	0.875	rs2224120	chr6:146343280	A/C	cg23711669	chr6:146136114	FBXO30	0.88	9.67	0.66	7.78e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs8078723	0.866	rs11078934	chr17:38189793	C/T	cg17467752	chr17:38218738	THRA	0.69	6.8	0.52	3.94e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs9325144	0.647	rs7487395	chr12:38865660	C/A	cg10518543	chr12:38710700	ALG10B	-0.48	-4.44	-0.37	1.99e-5	Morning vs. evening chronotype;
TGCT	cis	rs7666738	0.830	rs13139078	chr4:99020774	C/T	cg18180107	chr4:99064573	C4orf37	0.54	5.03	0.41	1.7e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11650776	1	rs11650776	chr17:37641402	G/A	cg15445000	chr17:37608096	MED1	0.31	4.57	0.38	1.17e-5	Lung function (FEV1);
TGCT	cis	rs7208859	0.623	rs11651858	chr17:29170718	A/G	cg18442181	chr17:29233375	C17orf42	-0.78	-4.61	-0.38	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs9902453	0.791	rs55655651	chr17:28244286	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.81	7.28	0.55	3.32e-11	Coffee consumption (cups per day);
TGCT	cis	rs7226408	0.894	rs72885207	chr18:34397344	G/C	cg06757138	chr18:34340585	FHOD3	0.26	4.79	0.4	4.62e-6	Obesity-related traits;
TGCT	cis	rs4268898	0.722	rs6723257	chr2:24391129	A/G	cg02683114	chr2:24398427	C2orf84	0.19	4.57	0.38	1.14e-5	Asthma;
TGCT	cis	rs6988636	0.534	rs57815619	chr8:124096724	A/G	cg27053337	chr8:124217698	FAM83A	0.54	4.68	0.39	7.34e-6	Urinary uromodulin levels;
TGCT	cis	rs3026101	0.671	rs11868032	chr17:5283617	A/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	4.53	0.38	1.39e-5	Body mass index;
TGCT	cis	rs2013441	1.000	rs17686798	chr17:20029170	A/C	cg18979559	chr17:20280153	CCDC144C	-0.44	-4.72	-0.39	6.21e-6	Obesity-related traits;
TGCT	cis	rs8103278	0.507	rs8112282	chr19:46265029	C/T	cg14061069	chr19:46274453	DMPK	0.63	10.79	0.7	1.51e-19	Coronary artery disease;
TGCT	trans	rs797680	0.856	rs4847408	chr1:93791437	C/G	cg27528825	chr2:159282178	CCDC148	0.33	6.67	0.51	7.68e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs10465746	0.780	rs1570691	chr1:84370393	A/C	cg10977910	chr1:84465055	TTLL7	0.66	6.65	0.51	8.38e-10	Obesity-related traits;
TGCT	cis	rs10419226	0.604	rs12976741	chr19:18767477	G/A	cg14292368	chr19:18793705	CRTC1	-0.49	-5.42	-0.44	2.98e-7	Barrett's esophagus;Esophageal adenocarcinoma;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs9611565	0.571	rs7364123	chr22:42216326	A/G	cg06634786	chr22:41940651	POLR3H	-0.76	-6.92	-0.53	2.2e-10	Vitiligo;
TGCT	cis	rs1971762	0.563	rs10747678	chr12:54077687	A/C	cg16917193	chr12:54089295	NA	-1.34	-17.66	-0.85	1.17e-35	Height;
TGCT	trans	rs10506458	0.915	rs60094497	chr12:63394838	T/G	cg22491629	chr6:157744540	C6orf35	-0.99	-8.55	-0.61	3.94e-14	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg27266060	chr8:22091797	NA	-0.24	-4.55	-0.38	1.24e-5	Hypertriglyceridemia;
TGCT	cis	rs9894429	0.646	rs9905639	chr17:79614154	A/G	cg18240062	chr17:79603768	NPLOC4	0.56	4.93	0.4	2.58e-6	Eye color traits;
TGCT	cis	rs9330316	0.632	rs28615410	chr2:110334358	C/A	cg25199208	chr2:109402912	CCDC138	-0.42	-4.56	-0.38	1.19e-5	Schizophrenia;
TGCT	cis	rs7772486	0.754	rs2328709	chr6:146106819	A/G	cg23711669	chr6:146136114	FBXO30	-0.93	-10.29	-0.68	2.54e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9467711	0.606	rs2076030	chr6:26426856	G/A	cg10795676	chr6:26370623	BTN3A2	-0.45	-4.56	-0.38	1.23e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6570726	0.526	rs4896805	chr6:145735429	C/A	cg23711669	chr6:146136114	FBXO30	-0.55	-4.82	-0.4	4.15e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9291683	0.610	rs993172	chr4:10324361	G/T	cg11266682	chr4:10021025	SLC2A9	0.51	5.98	0.47	2.2e-8	Bone mineral density;
TGCT	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.06	-9.57	-0.65	1.41e-16	Platelet count;
TGCT	cis	rs700590	0.603	rs304151	chr5:88125853	G/T	cg22951263	chr5:87985283	NA	-0.63	-5.75	-0.46	6.52e-8	Educational attainment (years of education);
TGCT	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg00149659	chr3:10157352	C3orf10	0.94	6.0	0.47	2e-8	Alzheimer's disease;
TGCT	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg08280861	chr8:58055591	NA	0.52	5.97	0.47	2.35e-8	Developmental language disorder (linguistic errors);
TGCT	cis	rs13217239	0.621	rs12527231	chr6:27001288	G/A	cg15659132	chr6:26577336	NA	0.54	5.44	0.44	2.78e-7	Schizophrenia;
TGCT	cis	rs9926296	0.712	rs258332	chr16:89727683	G/A	cg04287289	chr16:89883240	FANCA	-0.54	-5.01	-0.41	1.82e-6	Vitiligo;
TGCT	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.55	4.92	0.4	2.74e-6	Prudent dietary pattern;
TGCT	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg04944784	chr2:26401820	FAM59B	0.72	5.92	0.47	2.93e-8	Gut microbiome composition (summer);
TGCT	cis	rs3733585	0.725	rs10939636	chr4:9972640	T/G	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.72	-0.52	5.74e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg18135555	chr8:22132992	PIWIL2	-0.29	-6.06	-0.48	1.48e-8	Hypertriglyceridemia;
TGCT	cis	rs4566357	1.000	rs7577005	chr2:227921573	A/G	cg11843606	chr2:227700838	RHBDD1	-0.58	-5.31	-0.43	4.92e-7	Coronary artery disease;
TGCT	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg16325326	chr1:53192061	ZYG11B	-0.73	-8.95	-0.63	4.41e-15	Monocyte count;
TGCT	cis	rs7666738	0.791	rs2081621	chr4:98926753	C/A	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4727027	0.704	rs12704073	chr7:148905067	G/A	cg23583168	chr7:148888333	NA	-0.83	-10.97	-0.7	5.54e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs4746818	0.818	rs7076011	chr10:70900430	T/C	cg04149295	chr10:70884716	VPS26A	0.79	5.4	0.44	3.22e-7	Left atrial antero-posterior diameter;
TGCT	cis	rs3809566	0.676	rs11071719	chr15:63329875	C/A	cg00520135	chr15:63333846	TPM1	-0.42	-5.16	-0.42	9.55e-7	Platelet count;
TGCT	cis	rs796364	0.806	rs76568708	chr2:200929531	C/T	cg17644776	chr2:200775616	C2orf69	-0.33	-5.0	-0.41	1.91e-6	Schizophrenia;
TGCT	cis	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg18252515	chr7:66147081	NA	-1.2	-7.83	-0.58	1.89e-12	Diabetic kidney disease;
TGCT	cis	rs7474896	0.515	rs2738208	chr10:38306128	A/G	cg13720705	chr10:37990370	NA	-0.35	-4.73	-0.39	5.99e-6	Obesity (extreme);
TGCT	cis	rs889312	0.500	rs1867731	chr5:56132115	C/G	cg24531977	chr5:56204891	C5orf35	-0.53	-5.5	-0.44	2.07e-7	Breast cancer;Breast cancer (early onset);
TGCT	cis	rs7412746	0.566	rs2864871	chr1:150766964	T/C	cg09365446	chr1:150670422	GOLPH3L	0.36	5.19	0.42	8.25e-7	Melanoma;
TGCT	cis	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg08975724	chr8:8085496	FLJ10661	0.63	5.98	0.47	2.25e-8	Mood instability;
TGCT	cis	rs6570726	0.875	rs368744	chr6:145812622	A/G	cg23711669	chr6:146136114	FBXO30	0.73	6.85	0.52	3e-10	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs901683	0.702	rs78757497	chr10:46161918	T/C	cg03466342	chr12:52753899	KRT85	-0.6	-7.26	-0.55	3.79e-11	Red blood cell traits;Mean corpuscular volume;
TGCT	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg27211696	chr2:191398769	TMEM194B	-0.27	-5.07	-0.41	1.42e-6	Pulse pressure;
TGCT	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg06481639	chr22:41940642	POLR3H	-0.61	-5.49	-0.44	2.17e-7	Vitiligo;
TGCT	cis	rs9419702	0.614	rs4897816	chr10:133533646	G/A	cg20568497	chr10:133558893	NA	0.45	4.73	0.39	6e-6	Survival in rectal cancer;
TGCT	cis	rs10751667	0.666	rs6597962	chr11:976351	C/T	cg06064525	chr11:970664	AP2A2	-0.35	-8.11	-0.59	4.17e-13	Alzheimer's disease (late onset);
TGCT	cis	rs151997	0.671	rs27281	chr5:50200764	C/T	cg06027927	chr5:50259733	NA	0.56	5.64	0.45	1.11e-7	Callous-unemotional behaviour;
TGCT	cis	rs9831754	0.756	rs6548554	chr3:78423185	C/T	cg06138941	chr3:78371609	NA	-0.39	-4.43	-0.37	2.01e-5	Calcium levels;
TGCT	cis	rs13191362	0.872	rs13194619	chr6:163203657	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.11	8.17	0.59	2.98e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs950169	0.922	rs62028133	chr15:84919375	A/C	cg12863693	chr15:85201151	NMB	0.41	4.5	0.38	1.51e-5	Schizophrenia;
TGCT	trans	rs1814175	0.546	rs1614397	chr11:49913384	G/C	cg03929089	chr4:120376271	NA	-0.71	-8.09	-0.59	4.74e-13	Height;
TGCT	cis	rs3741404	0.791	rs11603192	chr11:63927695	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.87	9.54	0.65	1.61e-16	Platelet count;
TGCT	cis	rs7772486	0.686	rs4896833	chr6:145965673	T/G	cg05347473	chr6:146136440	FBXO30	0.48	4.53	0.38	1.38e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg03517284	chr6:25882590	NA	-0.62	-6.45	-0.5	2.23e-9	Blood metabolite levels;
TGCT	cis	rs6988636	1.000	rs28542077	chr8:124190896	T/C	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs11122272	0.735	rs2749714	chr1:231538634	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-6.28	-0.49	5.32e-9	Hemoglobin concentration;
TGCT	cis	rs9796	0.689	rs692153	chr15:41452681	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.5	-6.75	-0.52	5.02e-10	Menopause (age at onset);
TGCT	cis	rs175714	0.845	rs175706	chr14:75976200	G/A	cg01624173	chr14:75981868	NA	0.4	7.44	0.56	1.47e-11	Lymphocyte counts;
TGCT	cis	rs2859741	1.000	rs4653239	chr1:37509872	C/G	cg09363841	chr1:37513479	NA	0.19	4.49	0.37	1.63e-5	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
TGCT	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg12963246	chr6:28129442	ZNF389	0.51	5.02	0.41	1.73e-6	Depression;
TGCT	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg23302884	chr18:44338147	ST8SIA5	0.39	4.52	0.38	1.44e-5	Personality dimensions;
TGCT	trans	rs7824557	0.527	rs2736305	chr8:11237773	T/C	cg15556689	chr8:8085844	FLJ10661	-0.75	-6.65	-0.51	8.2e-10	Retinal vascular caliber;
TGCT	cis	rs826838	0.616	rs11182893	chr12:38627715	C/G	cg26384229	chr12:38710491	ALG10B	-0.54	-4.74	-0.39	5.87e-6	Heart rate;
TGCT	cis	rs13082711	0.522	rs653076	chr3:27343691	T/C	cg02860705	chr3:27208620	NA	0.33	5.45	0.44	2.62e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs477895	0.713	rs7952318	chr11:63961242	G/A	cg04317338	chr11:64019027	PLCB3	0.79	6.65	0.51	8.44e-10	Mean platelet volume;
TGCT	cis	rs9911578	0.874	rs302865	chr17:56756977	A/G	cg12560992	chr17:57184187	TRIM37	0.71	8.43	0.6	7.36e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs4595586	0.870	rs10444553	chr12:39294076	C/G	cg10518543	chr12:38710700	ALG10B	0.46	4.54	0.38	1.29e-5	Morning vs. evening chronotype;
TGCT	cis	rs9357506	1.000	rs12055643	chr6:46306348	C/T	cg21115430	chr6:46460003	NA	-0.26	-5.17	-0.42	9.2e-7	Body mass index;
TGCT	cis	rs75059851	0.756	rs73036087	chr11:133842361	G/A	cg14047540	chr11:133829660	NA	-0.57	-5.69	-0.45	8.72e-8	Schizophrenia;
TGCT	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg21862992	chr11:68658383	NA	0.46	6.54	0.51	1.45e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs12497850	0.931	rs3774628	chr3:48801840	C/T	cg06212747	chr3:49208901	KLHDC8B	0.61	5.73	0.46	7.23e-8	Parkinson's disease;
TGCT	cis	rs826838	1.000	rs826889	chr12:39101076	G/A	cg13010199	chr12:38710504	ALG10B	-0.61	-4.98	-0.41	2.06e-6	Heart rate;
TGCT	cis	rs12643440	0.538	rs4299576	chr4:17140108	G/A	cg22650099	chr4:17144496	NA	-0.45	-4.65	-0.39	8.28e-6	Metabolite levels (Pyroglutamine);
TGCT	cis	rs1857353	1.000	rs4949854	chr1:75912119	G/A	cg11838876	chr1:75668600	SLC44A5	-0.51	-4.81	-0.4	4.23e-6	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs11098499	0.821	rs28665282	chr4:120384186	C/T	cg09307838	chr4:120376055	NA	0.68	6.53	0.51	1.54e-9	Corneal astigmatism;
TGCT	cis	rs6582630	0.555	rs10880520	chr12:38464111	C/T	cg13010199	chr12:38710504	ALG10B	0.58	4.72	0.39	6.16e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.2	0.42	8.14e-7	Menopause (age at onset);
TGCT	cis	rs67460515	0.892	rs1382429	chr3:161015153	T/C	cg03342759	chr3:160939853	NMD3	-0.51	-5.42	-0.44	2.98e-7	Parkinson's disease;
TGCT	cis	rs7786877	0.508	rs11765509	chr7:100310990	T/G	cg20848291	chr7:100343083	ZAN	-0.52	-4.51	-0.38	1.46e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7027203	0.557	rs9299411	chr9:96523104	C/A	cg13679303	chr9:96623674	NA	-0.53	-7.48	-0.56	1.18e-11	DNA methylation (variation);
TGCT	cis	rs2115536	0.967	rs4778734	chr15:80210851	A/G	cg00225070	chr15:80189496	MTHFS	0.58	5.03	0.41	1.66e-6	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs4820539	1.000	rs6003518	chr22:23471533	C/T	cg14186256	chr22:23484241	RTDR1	0.99	12.58	0.75	6.81e-24	Bone mineral density;
TGCT	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg22535103	chr8:58192502	C8orf71	-0.4	-5.06	-0.41	1.44e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg24829409	chr8:58192753	C8orf71	-0.55	-5.17	-0.42	9.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7772486	0.754	rs6922507	chr6:146250155	A/T	cg05347473	chr6:146136440	FBXO30	-0.52	-5.03	-0.41	1.67e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs12510870	0.599	rs12503916	chr4:74451259	C/T	cg05868023	chr4:75230803	EREG	-0.54	-4.75	-0.39	5.61e-6	Iris color (b* coordinate);
TGCT	cis	rs362272	0.545	rs2749785	chr4:3325179	G/C	cg06533319	chr4:3265114	C4orf44	-0.28	-5.69	-0.45	8.71e-8	Serum sulfate level;
TGCT	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg11764359	chr7:65958608	NA	-0.53	-4.7	-0.39	6.81e-6	Aortic root size;
TGCT	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg04772025	chr11:68637568	NA	0.62	6.89	0.53	2.52e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7412746	0.611	rs2864873	chr1:150814174	A/G	cg04414720	chr1:150670196	GOLPH3L	0.41	5.14	0.42	1.06e-6	Melanoma;
TGCT	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.45	-6.78	-0.52	4.41e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs854765	0.583	rs11650649	chr17:17790319	C/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.74	-7.98	-0.58	8.43e-13	Total body bone mineral density;
TGCT	cis	rs1005277	0.505	rs200936	chr10:38134935	T/C	cg25427524	chr10:38739819	LOC399744	-0.37	-7.41	-0.55	1.75e-11	Extrinsic epigenetic age acceleration;
TGCT	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg25767906	chr1:53392781	SCP2	-0.63	-7.64	-0.57	5e-12	Monocyte count;
TGCT	cis	rs6089584	0.927	rs2296081	chr20:60572663	G/T	cg16423285	chr20:60520624	NA	-0.61	-6.89	-0.53	2.44e-10	Body mass index;
TGCT	cis	rs59107033	0.607	rs55925662	chr3:123118699	A/G	cg04890266	chr3:123102914	ADCY5	-0.39	-5.49	-0.44	2.12e-7	Lymphocyte counts;
TGCT	cis	rs1008375	0.797	rs6843530	chr4:17593605	G/T	cg10189774	chr4:17578691	LAP3	0.71	6.05	0.48	1.59e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs79349575	0.749	rs8182364	chr17:47018025	A/G	cg26022315	chr17:47021804	SNF8	0.49	4.9	0.4	2.94e-6	Type 2 diabetes;
TGCT	cis	rs12369179	0.737	rs116896792	chr12:122948907	T/C	cg18578876	chr12:123200353	GPR109B	-0.44	-4.5	-0.37	1.57e-5	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;
TGCT	cis	rs3806843	0.583	rs408652	chr5:140330013	T/G	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.73e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs71435601	0.574	rs1652421	chr2:21383848	A/G	cg25035485	chr2:21266500	APOB	0.51	4.48	0.37	1.64e-5	Cholesterol, total;
TGCT	cis	rs67311347	0.549	rs60249586	chr3:40246659	G/A	cg13683864	chr3:40499215	RPL14	-0.75	-6.94	-0.53	1.93e-10	Renal cell carcinoma;
TGCT	cis	rs9291683	0.517	rs11736479	chr4:10017387	G/C	cg02734326	chr4:10020555	SLC2A9	0.38	4.54	0.38	1.34e-5	Bone mineral density;
TGCT	cis	rs617219	0.710	rs10054122	chr5:78581371	A/T	cg23987322	chr5:78407566	BHMT	-0.37	-5.01	-0.41	1.81e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs2050392	0.687	rs608693	chr10:30734971	G/A	cg18806716	chr10:30721971	MAP3K8	-0.52	-5.91	-0.47	3.06e-8	Inflammatory bowel disease;
TGCT	cis	rs9522267	0.535	rs9515453	chr13:112234612	T/C	cg10483660	chr13:112241077	NA	-0.27	-4.61	-0.38	9.78e-6	Hepatitis;
TGCT	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg24060327	chr5:131705240	SLC22A5	-0.75	-8.11	-0.59	4.12e-13	Breast cancer;
TGCT	cis	rs10197940	0.578	rs2432946	chr2:152306897	G/T	cg19508488	chr2:152266495	RIF1	-0.56	-4.68	-0.39	7.3e-6	Lung cancer;
TGCT	cis	rs11785400	0.793	rs4430071	chr8:143737680	T/C	cg10596483	chr8:143751796	JRK	0.55	5.48	0.44	2.29e-7	Schizophrenia;
TGCT	cis	rs11039216	1	rs11039216	chr11:47406592	C/T	cg20307385	chr11:47447363	PSMC3	0.57	5.59	0.45	1.39e-7	Neuroticism;
TGCT	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg00814883	chr7:100076585	TSC22D4	-0.85	-8.49	-0.61	5.27e-14	Platelet count;
TGCT	cis	rs6586163	0.509	rs2031610	chr10:90754487	T/C	cg03111039	chr10:90751583	FAS;ACTA2	0.6	7.77	0.57	2.59e-12	Chronic lymphocytic leukemia;
TGCT	cis	rs2463822	1.000	rs2246920	chr11:62104937	T/G	cg06239285	chr11:62104954	ASRGL1	0.93	6.71	0.52	6.27e-10	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs5769707	0.904	rs7288869	chr22:50015327	C/T	cg10356904	chr22:49881777	NA	-0.23	-4.54	-0.38	1.3e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs3820068	0.603	rs67349836	chr1:15966176	T/C	cg05660106	chr1:15850417	CASP9	0.79	7.94	0.58	1.04e-12	Systolic blood pressure;
TGCT	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg18876405	chr7:65276391	NA	0.38	5.89	0.47	3.32e-8	Aortic root size;
TGCT	cis	rs7267979	1.000	rs1077889	chr20:25267893	A/G	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3847687	1.000	rs11061291	chr12:131518875	C/T	cg13586425	chr12:131519906	GPR133	-0.31	-4.67	-0.39	7.75e-6	Longevity;
TGCT	cis	rs6430585	0.941	rs7589832	chr2:136504101	A/C	cg07169764	chr2:136633963	MCM6	0.91	8.26	0.6	1.86e-13	Corneal structure;
TGCT	cis	rs7666738	0.830	rs34070283	chr4:98893027	A/T	cg17366294	chr4:99064904	C4orf37	0.68	6.87	0.53	2.72e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg04772025	chr11:68637568	NA	0.6	6.77	0.52	4.63e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs1215050	0.547	rs10008398	chr4:98607327	A/C	cg05340658	chr4:99064831	C4orf37	-0.41	-4.96	-0.41	2.3e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs3087591	0.919	rs2012581	chr17:29560800	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.49	-7.65	-0.57	4.82e-12	Hip circumference;
TGCT	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg05368731	chr17:41323189	NBR1	1.19	13.98	0.78	2.93e-27	Menopause (age at onset);
TGCT	cis	rs9291683	0.507	rs3796837	chr4:10011321	C/G	cg11266682	chr4:10021025	SLC2A9	0.65	8.48	0.61	5.78e-14	Bone mineral density;
TGCT	cis	rs858239	0.896	rs1637192	chr7:23260514	G/A	cg05602783	chr7:23145260	KLHL7	-0.66	-5.55	-0.45	1.68e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs1577917	0.785	rs1885607	chr6:86394905	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.64	5.85	0.47	4.09e-8	Response to antipsychotic treatment;
TGCT	cis	rs6424115	0.830	rs1105	chr1:24200800	T/C	cg15997130	chr1:24165203	NA	0.85	9.25	0.64	8.02e-16	Immature fraction of reticulocytes;
TGCT	cis	rs7829975	0.658	rs2409096	chr8:8692477	T/C	cg15556689	chr8:8085844	FLJ10661	0.67	5.98	0.47	2.2e-8	Mood instability;
TGCT	cis	rs7824557	0.591	rs2060457	chr8:11213250	C/T	cg21775007	chr8:11205619	TDH	0.68	6.46	0.5	2.16e-9	Retinal vascular caliber;
TGCT	cis	rs9926296	0.632	rs4785717	chr16:89801133	A/G	cg03388025	chr16:89894329	SPIRE2	0.32	4.69	0.39	7.03e-6	Vitiligo;
TGCT	cis	rs9915657	0.773	rs9916815	chr17:70105651	A/G	cg06234051	chr17:70120541	SOX9	-0.26	-5.37	-0.43	3.78e-7	Thyroid hormone levels;
TGCT	cis	rs7824557	0.778	rs6601572	chr8:11093337	C/G	cg21775007	chr8:11205619	TDH	-0.5	-4.55	-0.38	1.27e-5	Retinal vascular caliber;
TGCT	cis	rs2204008	0.837	rs11168334	chr12:37961768	A/G	cg13010199	chr12:38710504	ALG10B	0.61	4.94	0.41	2.49e-6	Bladder cancer;
TGCT	cis	rs10276303	0.584	rs2614950	chr7:3581391	A/G	cg05061754	chr7:4254313	SDK1	0.21	4.49	0.37	1.6e-5	Dupuytren's disease;
TGCT	cis	rs4824093	0.610	rs7410534	chr22:50289925	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.12	-6.78	-0.52	4.3e-10	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs2243480	1.000	rs4718317	chr7:65648901	A/G	cg20637647	chr7:64974828	NA	-0.88	-5.12	-0.42	1.13e-6	Diabetic kidney disease;
TGCT	cis	rs11690462	0.926	rs11689086	chr2:26549127	C/T	cg04726446	chr2:26624865	C2orf39	0.43	4.61	0.38	9.87e-6	Coronary artery disease;
TGCT	cis	rs1723838	0.826	rs1670560	chr11:73600167	G/A	cg18195628	chr11:73498948	MRPL48	0.93	4.55	0.38	1.28e-5	Obesity-related traits;
TGCT	cis	rs4851254	0.920	rs11686599	chr2:100753475	A/G	cg04109781	chr2:100722022	AFF3	0.45	4.8	0.4	4.51e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2797160	0.651	rs6569436	chr6:126032104	A/G	cg05901451	chr6:126070800	HEY2	0.71	6.52	0.51	1.57e-9	Endometrial cancer;
TGCT	cis	rs11671005	0.735	rs11667723	chr19:58927489	A/G	cg13877915	chr19:58951672	ZNF132	0.63	4.99	0.41	1.95e-6	Mean platelet volume;
TGCT	cis	rs7666738	0.830	rs62321598	chr4:99014237	C/T	cg18180107	chr4:99064573	C4orf37	0.56	5.28	0.43	5.54e-7	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg27523141	chr10:43048294	ZNF37B	0.74	8.61	0.61	2.7e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg04944784	chr2:26401820	FAM59B	-0.73	-5.95	-0.47	2.61e-8	Gut microbiome composition (summer);
TGCT	cis	rs6674176	0.628	rs4660758	chr1:44424879	A/C	cg13606994	chr1:44402422	ARTN	-0.46	-4.84	-0.4	3.73e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg18402987	chr7:1209562	NA	0.74	6.42	0.5	2.6e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs3091242	0.804	rs631133	chr1:25724146	T/C	cg10117171	chr1:25599238	RHD	-0.36	-5.69	-0.45	8.8e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs11030122	0.673	rs4910590	chr11:4018619	C/T	cg18678763	chr11:4115507	RRM1	-0.48	-5.88	-0.47	3.54e-8	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs739496	0.843	rs610769	chr12:111999570	G/A	cg10833066	chr12:111807467	FAM109A	0.37	5.2	0.42	8.01e-7	Platelet count;
TGCT	cis	rs17767294	0.708	rs72848770	chr6:27919149	A/G	cg08851530	chr6:28072375	NA	1.56	7.22	0.54	4.47e-11	Parkinson's disease;
TGCT	cis	rs7027203	0.964	rs7853688	chr9:96523254	C/A	cg13679303	chr9:96623674	NA	0.64	9.79	0.66	4.09e-17	DNA methylation (variation);
TGCT	cis	rs9467711	0.516	rs1165168	chr6:25859508	A/C	cg03517284	chr6:25882590	NA	-0.73	-4.85	-0.4	3.62e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9467773	0.935	rs4573	chr6:26546808	A/G	cg02458000	chr6:26745757	NA	0.54	5.37	0.43	3.68e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs45509595	0.659	rs390764	chr6:27782535	C/T	cg10876282	chr6:28092338	ZSCAN16	0.78	4.57	0.38	1.17e-5	Breast cancer;
TGCT	cis	rs7208859	0.623	rs79607958	chr17:28934548	T/G	cg13385521	chr17:29058706	SUZ12P	0.81	4.87	0.4	3.39e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7267979	0.844	rs869358	chr20:25374674	A/G	cg14121845	chr20:25566513	NINL	-0.45	-4.6	-0.38	1.02e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs137699	1.000	rs137699	chr22:39748854	A/G	cg05872129	chr22:39784769	NA	-0.56	-4.65	-0.39	8.39e-6	IgG glycosylation;
TGCT	cis	rs149613931	1	rs149613931	chr10:103550281	G/T	cg22630918	chr10:102748988	C10orf2	0.44	4.91	0.4	2.83e-6	Educational attainment (years of education);
TGCT	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg03407747	chr17:6899364	ALOX12	0.53	5.71	0.46	7.9e-8	Tonsillectomy;
TGCT	cis	rs2721195	1.000	rs6599530	chr8:145677418	C/G	cg15320075	chr8:145703422	NA	-0.71	-7.16	-0.54	6.3e-11	Age at first birth;
TGCT	cis	rs17221829	0.965	rs4553368	chr11:89459742	T/C	cg02982614	chr11:89391479	FOLH1B	-0.27	-4.76	-0.39	5.25e-6	Anxiety in major depressive disorder;
TGCT	cis	rs6964587	0.839	rs6952459	chr7:91435820	T/A	cg17063962	chr7:91808500	NA	0.82	8.45	0.6	6.54e-14	Breast cancer;
TGCT	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg23758822	chr17:41437982	NA	0.72	6.81	0.52	3.77e-10	Menopause (age at onset);
TGCT	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg25703541	chr22:24373054	LOC391322	-0.82	-8.68	-0.61	1.87e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7552404	1.000	rs11161510	chr1:76210289	A/G	cg03433033	chr1:76189801	ACADM	-0.83	-9.84	-0.66	3.03e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2147959	0.825	rs12746910	chr1:228658133	G/A	cg22700015	chr1:228743131	NA	0.57	4.54	0.38	1.31e-5	Adult asthma;
TGCT	cis	rs7729723	0.591	rs6870458	chr5:137818916	G/T	cg19169342	chr5:137827400	NA	0.35	5.0	0.41	1.91e-6	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);
TGCT	cis	rs651907	0.557	rs2288272	chr3:101378476	C/T	cg12386194	chr3:101231763	SENP7	0.56	5.44	0.44	2.78e-7	Colorectal cancer;
TGCT	cis	rs11718455	0.582	rs6763436	chr3:43913653	A/G	cg08738300	chr3:44038990	NA	-0.82	-5.49	-0.44	2.16e-7	Coronary artery disease;
TGCT	cis	rs4851254	0.584	rs56935201	chr2:100637788	G/A	cg22139774	chr2:100720529	AFF3	-0.45	-4.9	-0.4	2.94e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs68170813	0.559	rs10953531	chr7:106827867	A/G	cg02696742	chr7:106810147	HBP1	0.74	6.14	0.48	1.05e-8	Coronary artery disease;
TGCT	cis	rs10875746	0.859	rs4760695	chr12:48591848	A/G	cg20731937	chr12:48336164	NA	0.63	5.05	0.41	1.51e-6	Longevity (90 years and older);
TGCT	cis	rs7172809	0.599	rs10519158	chr15:77412457	G/C	cg22256960	chr15:77711686	NA	-0.47	-4.51	-0.38	1.51e-5	Glucose homeostasis traits;
TGCT	cis	rs11578119	0.898	rs7519067	chr1:170395209	T/C	cg09767346	chr1:170501363	GORAB	0.71	5.69	0.46	8.67e-8	Male-pattern baldness;
TGCT	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg22535103	chr8:58192502	C8orf71	-0.37	-4.73	-0.39	6.08e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg07167872	chr1:205819463	PM20D1	0.55	6.95	0.53	1.81e-10	Menarche (age at onset);
TGCT	cis	rs1483890	0.605	rs1483889	chr3:69413324	A/G	cg22125112	chr3:69402811	FRMD4B	0.28	4.75	0.39	5.63e-6	Resting heart rate;
TGCT	cis	rs62244186	0.715	rs13321717	chr3:44667455	C/A	cg21672276	chr3:44754072	ZNF502	-0.46	-5.2	-0.42	8.08e-7	Depressive symptoms;
TGCT	cis	rs2888674	0.933	rs10267707	chr7:150510973	C/G	cg10409299	chr7:150498843	TMEM176B;TMEM176A	0.28	4.8	0.4	4.47e-6	Forced expiratory volume in 1 second (occupational environmental exposures interaction);
TGCT	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg22963979	chr7:1858916	MAD1L1	-0.4	-6.38	-0.5	3.12e-9	Bipolar disorder and schizophrenia;
TGCT	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg08509172	chr19:19383838	TM6SF2	-0.34	-4.52	-0.38	1.4e-5	Tonsillectomy;
TGCT	cis	rs7552404	0.731	rs61770552	chr1:76373050	T/C	cg22875332	chr1:76189707	ACADM	0.69	6.67	0.51	7.46e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs10089	1.000	rs4836368	chr5:127486330	T/A	cg19767477	chr5:127420684	SLC12A2	-0.43	-4.52	-0.38	1.45e-5	Ileal carcinoids;
TGCT	cis	rs4478858	0.684	rs4949372	chr1:31738857	G/A	cg07478791	chr1:31886160	SERINC2	-0.52	-5.02	-0.41	1.73e-6	Alcohol dependence;
TGCT	cis	rs13190036	1.000	rs35535623	chr5:176629296	A/G	cg18465082	chr5:176734745	MXD3	0.32	4.44	0.37	1.95e-5	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
TGCT	cis	rs60843830	0.928	rs55742348	chr2:217563	T/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.77	7.33	0.55	2.57e-11	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs9303401	0.625	rs10515159	chr17:56802693	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.59	5.99	0.47	2.08e-8	Cognitive test performance;
TGCT	cis	rs2847281	0.764	rs2847257	chr18:12776050	G/A	cg23598886	chr18:12777645	NA	0.36	4.54	0.38	1.3e-5	C-reactive protein levels;Esophageal cancer (squamous cell);
TGCT	cis	rs904251	0.861	rs914349	chr6:37484715	A/C	cg25019722	chr6:37503610	NA	-0.48	-6.8	-0.52	3.98e-10	Cognitive performance;
TGCT	cis	rs77972916	0.505	rs1322	chr2:43521167	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.4	-5.72	-0.46	7.48e-8	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs4820539	1.000	rs5759598	chr22:23480962	T/G	cg21100191	chr22:23484243	RTDR1	0.9	10.72	0.69	2.2e-19	Bone mineral density;
TGCT	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg08439880	chr3:133502540	NA	0.35	7.0	0.53	1.43e-10	Iron status biomarkers;
TGCT	cis	rs11190604	1.000	rs1800662	chr10:102289078	C/A	cg16342193	chr10:102329863	NA	-0.42	-5.37	-0.43	3.74e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs700651	0.789	rs10184395	chr2:198894285	G/A	cg00792783	chr2:198669748	PLCL1	0.59	5.34	0.43	4.33e-7	Intracranial aneurysm;
TGCT	cis	rs6988636	1.000	rs6983795	chr8:124185296	T/C	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs67311347	1.000	rs4571217	chr3:40521973	A/G	cg13683864	chr3:40499215	RPL14	-1.21	-13.32	-0.77	1.11e-25	Renal cell carcinoma;
TGCT	cis	rs763014	1.000	rs8054842	chr16:672799	T/C	cg27436995	chr16:743998	FBXL16	-0.48	-5.23	-0.43	6.97e-7	Height;
TGCT	trans	rs1814175	0.817	rs12287396	chr11:49819798	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.35	-0.55	2.38e-11	Height;
TGCT	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.49	-4.79	-0.39	4.76e-6	Longevity;Endometriosis;
TGCT	cis	rs4319547	0.615	rs2341439	chr12:122848096	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.57	-4.62	-0.38	9.55e-6	Body mass index;
TGCT	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg11890956	chr21:40555474	PSMG1	-0.79	-7.82	-0.57	2e-12	Cognitive function;
TGCT	cis	rs2445762	0.518	rs8043240	chr15:51635565	C/T	cg00184732	chr15:51633821	GLDN	0.46	5.17	0.42	8.99e-7	Hormone measurements;
TGCT	trans	rs1814175	0.935	rs10839329	chr11:49694206	G/A	cg03929089	chr4:120376271	NA	-0.63	-7.0	-0.53	1.41e-10	Height;
TGCT	cis	rs12497850	0.897	rs7373778	chr3:48836392	C/G	cg18654377	chr3:49208889	KLHDC8B	-0.42	-5.52	-0.44	1.93e-7	Parkinson's disease;
TGCT	cis	rs617219	0.551	rs2131978	chr5:78613986	G/A	cg23514016	chr5:78407564	BHMT	-0.31	-4.77	-0.39	5.08e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs4455778	0.580	rs9942682	chr7:49077999	G/C	cg26309511	chr7:48887640	NA	0.5	6.47	0.5	2.07e-9	Lung cancer in never smokers;
TGCT	cis	rs11822910	1.000	rs4477456	chr11:57197781	G/A	cg00522883	chr11:57194120	SLC43A3	0.36	4.61	0.38	9.93e-6	Platelet distribution width;
TGCT	cis	rs16958440	0.867	rs2117373	chr18:44671834	C/T	cg17192377	chr18:44677553	HDHD2	0.54	4.51	0.38	1.46e-5	Sitting height ratio;
TGCT	cis	rs9913156	0.793	rs72835644	chr17:4573667	G/A	cg00122941	chr17:4613640	ARRB2	0.89	7.52	0.56	9.78e-12	Lymphocyte counts;
TGCT	cis	rs903263	0.601	rs12404263	chr1:84551736	G/A	cg09664975	chr1:84543551	PRKACB	0.5	4.86	0.4	3.47e-6	Breast cancer (male);
TGCT	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg04287289	chr16:89883240	FANCA	0.94	12.2	0.74	5.63e-23	Vitiligo;
TGCT	cis	rs12477438	0.765	rs6722164	chr2:99561527	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.55	-4.62	-0.38	9.65e-6	Chronic sinus infection;
TGCT	trans	rs8073060	0.586	rs72828038	chr17:33893908	C/A	cg19694781	chr19:47549865	TMEM160	0.59	12.81	0.75	1.88e-24	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg02725872	chr8:58115012	NA	-0.38	-5.16	-0.42	9.32e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9611565	0.918	rs2281333	chr22:41749630	T/C	cg06481639	chr22:41940642	POLR3H	-0.56	-4.92	-0.4	2.64e-6	Vitiligo;
TGCT	cis	rs2439831	0.681	rs28578454	chr15:43603032	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.08	7.95	0.58	9.61e-13	Lung cancer in ever smokers;
TGCT	cis	rs3087591	0.960	rs2018634	chr17:29560678	A/C	cg24425628	chr17:29625626	OMG;NF1	-0.47	-7.49	-0.56	1.11e-11	Hip circumference;
TGCT	cis	rs10927875	0.518	rs1763604	chr1:16339772	C/G	cg21385522	chr1:16154831	NA	0.47	4.87	0.4	3.31e-6	Dilated cardiomyopathy;
TGCT	cis	rs10875746	0.537	rs4760625	chr12:48673743	A/T	cg20731937	chr12:48336164	NA	0.59	4.49	0.37	1.61e-5	Longevity (90 years and older);
TGCT	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg12419862	chr22:24373484	LOC391322	-0.83	-8.85	-0.62	7.63e-15	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6545883	0.894	rs12997538	chr2:61564249	A/C	cg15711740	chr2:61764176	XPO1	0.52	4.54	0.38	1.34e-5	Tuberculosis;
TGCT	cis	rs2115630	1.000	rs11854313	chr15:85304048	G/C	cg11189052	chr15:85197271	WDR73	-0.63	-6.04	-0.48	1.67e-8	P wave terminal force;
TGCT	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg04234412	chr22:24373322	LOC391322	-0.92	-11.98	-0.73	1.94e-22	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	trans	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg17830980	chr10:43048298	ZNF37B	-0.87	-11.11	-0.71	2.53e-20	Extrinsic epigenetic age acceleration;
TGCT	cis	rs796364	0.577	rs7574287	chr2:200680999	C/T	cg17644776	chr2:200775616	C2orf69	0.34	4.84	0.4	3.76e-6	Schizophrenia;
TGCT	cis	rs9357506	1.000	rs9357505	chr6:46316191	T/A	cg21115430	chr6:46460003	NA	-0.26	-5.16	-0.42	9.6e-7	Body mass index;
TGCT	cis	rs7000551	0.700	rs7431	chr8:22398462	G/A	cg12081754	chr8:22256438	SLC39A14	0.27	4.5	0.37	1.54e-5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs56114371	0.777	rs200483	chr6:27774824	C/T	cg08798685	chr6:27730294	NA	-0.32	-4.44	-0.37	1.95e-5	Breast cancer;
TGCT	cis	rs12188164	1.000	rs72717410	chr5:428785	A/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.41	-4.75	-0.39	5.43e-6	Cystic fibrosis severity;
TGCT	cis	rs981844	0.712	rs1456398	chr4:154738266	G/A	cg14289246	chr4:154710475	SFRP2	-1.0	-9.32	-0.64	5.46e-16	Response to statins (LDL cholesterol change);
TGCT	cis	rs78707713	0.511	rs28697194	chr10:71215483	T/C	cg14388049	chr10:71211838	TSPAN15	-0.39	-4.5	-0.37	1.55e-5	Venous thromboembolism;
TGCT	cis	rs12681287	0.752	rs1080170	chr8:87310108	C/T	cg27223183	chr8:87520930	FAM82B	-0.85	-6.4	-0.5	2.9e-9	Caudate activity during reward;
TGCT	cis	rs4285028	0.747	rs77790376	chr3:121492211	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-1.03	-8.75	-0.62	1.26e-14	Multiple sclerosis;
TGCT	cis	rs2458413	0.669	rs1812214	chr8:105344070	A/G	cg23108931	chr8:105342351	NA	-0.35	-6.19	-0.49	7.93e-9	Paget's disease;
TGCT	trans	rs7726839	0.540	rs11750321	chr5:599196	C/T	cg25482853	chr8:67687455	SGK3	1.27	10.56	0.69	5.48e-19	Obesity-related traits;
TGCT	cis	rs7267979	1.000	rs2257991	chr20:25270339	C/T	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs12549902	0.966	rs17659386	chr8:41513531	T/C	cg21772509	chr8:41503840	NKX6-3	0.85	9.62	0.65	1.04e-16	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
TGCT	cis	rs13064411	0.696	rs6766615	chr3:113219342	T/C	cg18753928	chr3:113234510	CCDC52	-0.7	-5.75	-0.46	6.6e-8	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg03388025	chr16:89894329	SPIRE2	0.48	8.35	0.6	1.15e-13	Vitiligo;
TGCT	cis	rs8020441	0.891	rs112124522	chr14:51167502	G/A	cg04730355	chr14:51134070	SAV1	0.73	6.02	0.48	1.81e-8	Cognitive performance;
TGCT	cis	rs2180341	1.000	rs9285460	chr6:127640190	A/G	cg27446573	chr6:127587934	RNF146	1.12	10.11	0.67	6.87e-18	Breast cancer;
TGCT	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg05025164	chr4:1340916	KIAA1530	-0.57	-4.96	-0.41	2.29e-6	Obesity-related traits;
TGCT	cis	rs295140	1.000	rs3769476	chr2:201181428	T/C	cg04283868	chr2:201171347	SPATS2L	0.65	6.66	0.51	7.99e-10	QT interval;
TGCT	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg09359103	chr1:154839909	KCNN3	-0.67	-12.23	-0.74	4.77e-23	Prostate cancer;
TGCT	cis	rs3026101	0.671	rs739766	chr17:5290599	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	4.57	0.38	1.16e-5	Body mass index;
TGCT	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg17554472	chr22:41940697	POLR3H	0.43	4.6	0.38	1.01e-5	Vitiligo;
TGCT	cis	rs7909074	1.000	rs4481983	chr10:45400428	G/T	cg04218760	chr10:45406644	TMEM72	-0.27	-5.31	-0.43	4.88e-7	Mean corpuscular volume;
TGCT	cis	rs10992471	0.603	rs7045572	chr9:95137964	T/C	cg14631576	chr9:95140430	CENPP	-0.33	-4.99	-0.41	2.02e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs950880	0.560	rs11679191	chr2:102926800	A/T	cg09003973	chr2:102972529	NA	-0.54	-4.72	-0.39	6.3e-6	Serum protein levels (sST2);
TGCT	cis	rs2820315	0.867	rs2820321	chr1:201880296	G/C	cg12730843	chr1:201915899	LMOD1	-0.27	-5.08	-0.41	1.37e-6	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
TGCT	cis	rs2862064	0.932	rs1553316	chr5:156479509	A/G	cg12943317	chr5:156479607	HAVCR1	-0.45	-5.97	-0.47	2.31e-8	Platelet count;
TGCT	cis	rs137699	0.559	rs137683	chr22:39738501	G/C	cg24399712	chr22:39784796	NA	-0.68	-5.31	-0.43	4.82e-7	IgG glycosylation;
TGCT	cis	rs9902453	0.817	rs1842026	chr17:28188111	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	7.18	0.54	5.62e-11	Coffee consumption (cups per day);
TGCT	cis	rs1008375	1.000	rs10032326	chr4:17630717	A/T	cg18681998	chr4:17616180	MED28	1.01	11.33	0.71	7.13e-21	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs11190604	0.652	rs76629555	chr10:102191417	T/C	cg16342193	chr10:102329863	NA	-0.38	-5.0	-0.41	1.93e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs610932	0.517	rs621965	chr11:60004828	G/A	cg18570331	chr11:60101691	MS4A6E	0.5	4.49	0.37	1.63e-5	Alzheimer's disease;
TGCT	cis	rs2361718	0.631	rs4889989	chr17:78151860	C/G	cg09238746	chr17:78121135	EIF4A3	0.78	7.15	0.54	6.47e-11	Yeast infection;
TGCT	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	8.39	0.6	9.03e-14	Platelet count;
TGCT	cis	rs9486719	0.790	rs2499790	chr6:96845078	G/A	cg18709589	chr6:96969512	KIAA0776	0.75	5.13	0.42	1.1e-6	Migraine;Coronary artery disease;
TGCT	cis	rs7267979	1.000	rs6115191	chr20:25440478	C/T	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7511006	1.000	rs7290710	chr22:50677454	C/T	cg08875078	chr22:50639485	SELO	0.51	4.81	0.4	4.35e-6	Obesity-related traits;
TGCT	cis	rs4499344	0.587	rs10407420	chr19:33054804	G/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.73	-6.21	-0.49	7.33e-9	Mean platelet volume;
TGCT	cis	rs13256369	1.000	rs10088439	chr8:8576699	T/G	cg17143192	chr8:8559678	CLDN23	0.62	5.83	0.46	4.47e-8	Obesity-related traits;
TGCT	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg22535103	chr8:58192502	C8orf71	-0.36	-4.72	-0.39	6.31e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7811142	0.945	rs34989573	chr7:100097895	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.1	9.08	0.63	2.06e-15	Platelet count;
TGCT	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg03452623	chr4:187889614	NA	-0.33	-4.94	-0.41	2.42e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7267979	1.000	rs2027003	chr20:25350498	A/G	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9818758	0.607	rs73074866	chr3:49626666	C/T	cg07636037	chr3:49044803	WDR6	-0.98	-4.72	-0.39	6.18e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs614226	1.000	rs580016	chr12:120933977	T/C	cg01236616	chr12:121019343	POP5	-1.23	-12.71	-0.75	3.22e-24	Type 1 diabetes nephropathy;
TGCT	cis	rs12681287	0.752	rs4534114	chr8:87271956	A/G	cg27223183	chr8:87520930	FAM82B	-0.82	-5.86	-0.47	3.98e-8	Caudate activity during reward;
TGCT	cis	rs9346649	0.630	rs6913441	chr6:168491271	C/T	cg02770688	chr6:168491649	NA	0.31	5.74	0.46	6.95e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
TGCT	cis	rs2562456	0.917	rs2562466	chr19:21714204	C/T	cg25650185	chr19:21324782	ZNF431	0.61	5.38	0.43	3.6e-7	Pain;
TGCT	cis	rs9296092	0.517	rs56069946	chr6:33511136	G/A	cg13560919	chr6:33536144	NA	-0.2	-4.47	-0.37	1.75e-5	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs9911578	0.835	rs2301867	chr17:56480074	T/A	cg12560992	chr17:57184187	TRIM37	-0.77	-8.97	-0.63	3.76e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs3015497	0.586	rs12587821	chr14:51092554	A/G	cg04730355	chr14:51134070	SAV1	-0.64	-6.04	-0.48	1.64e-8	Mean platelet volume;
TGCT	cis	rs7267979	1.000	rs2424700	chr20:25266513	A/G	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1878931	0.531	rs9635548	chr16:3417156	G/A	cg22508957	chr16:3507546	NAT15	-0.38	-4.98	-0.41	2.1e-6	Body mass index (adult);
TGCT	cis	rs1018836	0.923	rs4735256	chr8:91612145	C/G	cg16814680	chr8:91681699	NA	-0.86	-9.27	-0.64	7.49e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2439831	1.000	rs690002	chr15:43729349	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.01	8.37	0.6	1.02e-13	Lung cancer in ever smokers;
TGCT	cis	rs854765	0.583	rs11078405	chr17:17824978	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.76	7.94	0.58	1.04e-12	Total body bone mineral density;
TGCT	cis	rs2439831	0.850	rs7163245	chr15:43671294	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	6.61	0.51	1e-9	Lung cancer in ever smokers;
TGCT	cis	rs950173	1.000	rs950173	chr2:172570419	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.0	-5.78	-0.46	5.57e-8	Hippocampal volume;
TGCT	cis	rs5769765	0.908	rs9616388	chr22:50313438	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.24	-13.17	-0.76	2.52e-25	Schizophrenia;
TGCT	cis	rs208520	0.690	rs12198745	chr6:66722598	T/C	cg07460842	chr6:66804631	NA	0.95	10.11	0.67	6.77e-18	Exhaled nitric oxide output;
TGCT	cis	rs12048904	0.533	rs1590580	chr1:101292668	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.82	7.42	0.55	1.63e-11	Multiple sclerosis;
TGCT	cis	rs651907	0.535	rs11716558	chr3:101528481	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	4.86	0.4	3.51e-6	Colorectal cancer;
TGCT	cis	rs11098499	0.780	rs12504773	chr4:120562149	G/C	cg09307838	chr4:120376055	NA	0.7	6.52	0.51	1.6e-9	Corneal astigmatism;
TGCT	cis	rs9399137	0.507	rs4896129	chr6:135349845	C/T	cg24558204	chr6:135376177	HBS1L	0.48	4.97	0.41	2.22e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
TGCT	cis	rs7666738	0.822	rs13110418	chr4:99046963	G/A	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3862030	0.839	rs7078679	chr10:104284017	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.53	-5.15	-0.42	9.99e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
TGCT	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg24399712	chr22:39784796	NA	-1.05	-12.52	-0.75	9.61e-24	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs2980439	0.517	rs793753	chr8:8105359	T/G	cg08975724	chr8:8085496	FLJ10661	-0.53	-4.85	-0.4	3.68e-6	Neuroticism;
TGCT	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg06108461	chr20:60628389	TAF4	-0.7	-9.99	-0.67	1.32e-17	Body mass index;
TGCT	cis	rs7843479	0.509	rs3758156	chr8:21770796	A/G	cg17168535	chr8:21777572	XPO7	0.76	7.11	0.54	8.28e-11	Mean corpuscular volume;
TGCT	cis	rs7412746	0.658	rs10888397	chr1:150886752	A/G	cg09365446	chr1:150670422	GOLPH3L	-0.33	-4.85	-0.4	3.58e-6	Melanoma;
TGCT	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	8.0	0.58	7.67e-13	Platelet count;
TGCT	cis	rs1008375	0.932	rs4698627	chr4:17605959	T/C	cg18681998	chr4:17616180	MED28	0.99	10.18	0.67	4.67e-18	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs911263	0.961	rs2208397	chr14:68753287	T/G	cg18825221	chr14:68749962	RAD51L1	0.28	5.31	0.43	4.82e-7	Primary biliary cholangitis;
TGCT	cis	rs2486288	0.656	rs12911186	chr15:45551423	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.46	-5.59	-0.45	1.38e-7	Glomerular filtration rate;
TGCT	cis	rs36051895	0.659	rs7862042	chr9:5268139	G/A	cg02405213	chr9:5042618	JAK2	-0.63	-7.6	-0.56	6.32e-12	Pediatric autoimmune diseases;
TGCT	cis	rs6582630	0.519	rs9738104	chr12:38338459	A/C	cg13010199	chr12:38710504	ALG10B	0.61	4.77	0.39	5.11e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs6543140	0.572	rs17027173	chr2:103057043	G/A	cg09003973	chr2:102972529	NA	0.79	6.45	0.5	2.31e-9	Blood protein levels;
TGCT	cis	rs709400	0.526	rs11622835	chr14:103967504	G/A	cg26031613	chr14:104095156	KLC1	0.7	5.61	0.45	1.25e-7	Body mass index;
TGCT	trans	rs1814175	0.645	rs28538913	chr11:50040718	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.84	-0.7	1.13e-19	Height;
TGCT	cis	rs12497850	0.931	rs9867373	chr3:48960938	A/T	cg05785598	chr3:49045655	WDR6	0.36	4.75	0.39	5.46e-6	Parkinson's disease;
TGCT	cis	rs7568458	0.846	rs1078004	chr2:85769711	C/G	cg02493740	chr2:85810744	VAMP5	-0.29	-5.47	-0.44	2.42e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs7666738	0.830	rs28485415	chr4:99060340	G/A	cg05340658	chr4:99064831	C4orf37	0.52	5.79	0.46	5.32e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10744422	0.858	rs10773627	chr12:123311853	A/G	cg25930673	chr12:123319894	HIP1R	-0.85	-5.01	-0.41	1.86e-6	Schizophrenia;
TGCT	cis	rs2153535	0.580	rs9505458	chr6:8479215	A/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs7909074	0.714	rs10900129	chr10:45398609	G/C	cg05187965	chr10:45406764	TMEM72	-0.24	-4.84	-0.4	3.72e-6	Mean corpuscular volume;
TGCT	cis	rs7639513	0.767	rs9878151	chr3:12703714	G/C	cg23032965	chr3:12705835	RAF1	0.77	8.53	0.61	4.28e-14	Itch intensity from mosquito bite;
TGCT	cis	rs2032447	0.670	rs198801	chr6:26139741	T/C	cg12310025	chr6:25882481	NA	0.5	4.49	0.37	1.58e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs9611565	0.765	rs132905	chr22:41799106	C/A	cg03806693	chr22:41940476	POLR3H	1.01	11.44	0.72	3.94e-21	Vitiligo;
TGCT	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg03517284	chr6:25882590	NA	-0.52	-5.27	-0.43	5.77e-7	Blood metabolite levels;
TGCT	cis	rs73110464	0.505	rs2682296	chr12:53308265	G/A	cg05393297	chr12:53359155	NA	-0.45	-5.08	-0.41	1.37e-6	Cancer (pleiotropy);
TGCT	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg13770153	chr20:60521292	NA	0.6	8.74	0.62	1.36e-14	Obesity-related traits;
TGCT	cis	rs7412746	0.597	rs868751	chr1:150669414	T/G	cg04414720	chr1:150670196	GOLPH3L	0.39	5.04	0.41	1.58e-6	Melanoma;
TGCT	cis	rs7267979	0.966	rs2257712	chr20:25264910	T/C	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3820068	0.608	rs7514858	chr1:16035246	G/A	cg17385448	chr1:15911702	AGMAT	0.36	4.92	0.4	2.67e-6	Systolic blood pressure;
TGCT	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg08859206	chr1:53392774	SCP2	0.39	5.8	0.46	5.07e-8	Monocyte count;
TGCT	trans	rs3780486	0.846	rs10738905	chr9:33123627	A/G	cg20290983	chr6:43655470	MRPS18A	1.21	15.13	0.81	5.99e-30	IgG glycosylation;
TGCT	cis	rs3733585	0.699	rs7683283	chr4:9969974	T/C	cg00071950	chr4:10020882	SLC2A9	-0.57	-6.83	-0.52	3.41e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs17601876	0.814	rs8042086	chr15:51561478	C/T	cg19946085	chr15:51559439	CYP19A1	-0.33	-5.06	-0.41	1.45e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs739496	0.615	rs609230	chr12:112146911	A/G	cg10833066	chr12:111807467	FAM109A	-0.37	-4.79	-0.39	4.76e-6	Platelet count;
TGCT	cis	rs1878931	0.501	rs9921169	chr16:3421261	A/T	cg05754148	chr16:3507555	NAT15	-0.33	-4.46	-0.37	1.82e-5	Body mass index (adult);
TGCT	cis	rs2153535	0.580	rs6913100	chr6:8456855	A/G	cg23788917	chr6:8435910	SLC35B3	0.62	5.62	0.45	1.2e-7	Motion sickness;
TGCT	cis	rs7829975	0.582	rs448231	chr8:8790059	A/T	cg06636001	chr8:8085503	FLJ10661	-0.74	-7.26	-0.55	3.67e-11	Mood instability;
TGCT	cis	rs910316	0.935	rs11159119	chr14:75636967	C/T	cg23033748	chr14:75592666	NEK9	-0.28	-4.77	-0.39	4.98e-6	Height;
TGCT	cis	rs273909	0.514	rs77450473	chr5:131785536	G/A	cg24060327	chr5:131705240	SLC22A5	0.64	4.49	0.37	1.61e-5	Coronary artery disease;
TGCT	cis	rs8031584	0.752	rs34722914	chr15:31191991	G/A	cg08704250	chr15:31115839	NA	-0.42	-6.28	-0.49	5.27e-9	Huntington's disease progression;
TGCT	cis	rs7666738	0.830	rs7672901	chr4:98938781	C/T	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9650657	0.740	rs6980805	chr8:10679842	G/C	cg27411982	chr8:10470053	RP1L1	-0.23	-5.11	-0.42	1.17e-6	Neuroticism;
TGCT	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg11941060	chr3:133502564	NA	-0.26	-5.43	-0.44	2.88e-7	Iron status biomarkers;
TGCT	cis	rs9916302	0.904	rs12452509	chr17:37574722	G/A	cg15445000	chr17:37608096	MED1	0.34	4.8	0.4	4.43e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs2342371	0.701	rs4916498	chr3:196202961	G/C	cg15048948	chr3:196158458	UBXN7	-0.54	-4.62	-0.38	9.56e-6	Fat distribution (HIV);
TGCT	cis	rs7178572	0.524	rs12914128	chr15:77493875	T/C	cg15453836	chr15:77711506	NA	-0.44	-4.91	-0.4	2.86e-6	Type 2 diabetes;
TGCT	cis	rs2832191	0.720	rs7277028	chr21:30494604	T/C	cg24692254	chr21:30365293	RNF160	-0.92	-9.97	-0.67	1.45e-17	Dental caries;
TGCT	cis	rs7267979	1.000	rs6050609	chr20:25411751	A/G	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7000551	0.560	rs4872483	chr8:22255684	C/T	cg12081754	chr8:22256438	SLC39A14	0.32	5.08	0.41	1.36e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs4722166	0.630	rs10950916	chr7:22799667	C/T	cg26061582	chr7:22766209	IL6	0.5	6.49	0.5	1.88e-9	Lung cancer;
TGCT	cis	rs782590	0.967	rs11125581	chr2:55796527	C/G	cg03859395	chr2:55845619	SMEK2	0.9	11.19	0.71	1.64e-20	Metabolic syndrome;
TGCT	cis	rs7017914	0.905	rs2732114	chr8:71928712	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.56	-5.11	-0.42	1.21e-6	Bone mineral density;
TGCT	cis	rs60111824	1	rs60111824	chr7:6774135	A/G	cg11074378	chr7:5938227	C7orf28A	-0.88	-4.53	-0.38	1.36e-5	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2224391	0.628	rs2753239	chr6:5252826	C/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.99	-6.43	-0.5	2.46e-9	Height;
TGCT	cis	rs7192750	0.617	rs9929256	chr16:72040032	A/C	cg06353428	chr16:71660113	MARVELD3	1.01	5.63	0.45	1.14e-7	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs9640161	0.659	rs11975886	chr7:150010362	G/A	cg17279839	chr7:150038598	RARRES2	0.42	4.45	0.37	1.88e-5	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg06896619	chr17:61851486	DDX42;CCDC47	-0.51	-4.96	-0.41	2.24e-6	Prudent dietary pattern;
TGCT	cis	rs10927875	0.541	rs1739842	chr1:16342848	T/G	cg21385522	chr1:16154831	NA	0.46	4.75	0.39	5.5e-6	Dilated cardiomyopathy;
TGCT	cis	rs6543140	0.927	rs917999	chr2:103067869	G/A	cg09003973	chr2:102972529	NA	0.56	4.67	0.39	7.86e-6	Blood protein levels;
TGCT	cis	rs13326165	0.760	rs2335640	chr3:52368387	T/C	cg27565382	chr3:53032988	SFMBT1	0.37	4.9	0.4	2.97e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs6540559	0.673	rs11803382	chr1:209986426	G/A	cg22029157	chr1:209979665	IRF6	0.74	5.53	0.44	1.84e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs79976124	0.879	rs17511467	chr6:66627293	T/C	cg07460842	chr6:66804631	NA	0.58	5.32	0.43	4.77e-7	Type 2 diabetes;
TGCT	cis	rs317689	0.819	rs317685	chr12:69715457	A/G	cg14784868	chr12:69753453	YEATS4	-0.58	-5.01	-0.41	1.79e-6	Response to diuretic therapy;
TGCT	cis	rs8062405	0.824	rs62034324	chr16:28536762	T/C	cg09754948	chr16:28834200	ATXN2L	0.58	4.57	0.38	1.14e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs6964587	1.000	rs13245393	chr7:91641928	A/G	cg22709100	chr7:91322751	NA	0.27	4.48	0.37	1.68e-5	Breast cancer;
TGCT	cis	rs13256369	1.000	rs10110591	chr8:8576608	G/T	cg17143192	chr8:8559678	CLDN23	-0.6	-5.56	-0.45	1.59e-7	Obesity-related traits;
TGCT	cis	rs6831352	0.842	rs1230156	chr4:99989626	C/T	cg12011299	chr4:100065546	ADH4	0.37	4.62	0.38	9.6e-6	Alcohol dependence;
TGCT	cis	rs10791097	0.694	rs4456262	chr11:130755813	C/T	cg05962950	chr11:130786565	SNX19	-0.94	-6.71	-0.52	6.14e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg12310025	chr6:25882481	NA	-0.7	-7.48	-0.56	1.17e-11	Blood metabolite levels;
TGCT	cis	rs763014	0.898	rs1981484	chr16:630710	A/G	cg09263875	chr16:632152	PIGQ	0.3	6.4	0.5	2.88e-9	Height;
TGCT	cis	rs72945132	0.882	rs67529561	chr11:70162055	G/T	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs3213545	0.659	rs2259690	chr12:121457914	T/G	cg02403541	chr12:121454288	C12orf43	0.7	7.9	0.58	1.3e-12	Subjective well-being;Cardiovascular disease risk factors;
TGCT	cis	rs739496	0.563	rs7484754	chr12:112047296	T/A	cg10833066	chr12:111807467	FAM109A	0.36	4.98	0.41	2.1e-6	Platelet count;
TGCT	cis	rs7818688	0.591	rs10098025	chr8:95989583	T/A	cg16049864	chr8:95962084	TP53INP1	0.54	4.64	0.38	8.87e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs2288884	1.000	rs79817140	chr19:52571657	C/T	cg15405931	chr19:52693188	PPP2R1A	-0.69	-4.5	-0.37	1.56e-5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs10507380	0.824	rs75857247	chr13:27926133	A/C	cg25543773	chr13:27185723	WASF3	0.32	4.52	0.38	1.45e-5	Electrocardiographic traits;
TGCT	cis	rs1971762	0.545	rs876252	chr12:54071422	A/G	cg16917193	chr12:54089295	NA	1.15	12.16	0.74	7.16e-23	Height;
TGCT	cis	rs3617	0.591	rs2276823	chr3:52869263	C/A	cg10802521	chr3:52805072	NEK4	0.63	7.34	0.55	2.49e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.51	-4.97	-0.41	2.21e-6	Longevity;Endometriosis;
TGCT	trans	rs629535	0.814	rs558511	chr8:70069908	C/A	cg21567404	chr3:27674614	NA	0.57	9.11	0.63	1.82e-15	Dupuytren's disease;
TGCT	cis	rs9486715	0.964	rs6921480	chr6:97066329	C/G	cg18709589	chr6:96969512	KIAA0776	-0.77	-7.12	-0.54	7.74e-11	Headache;
TGCT	cis	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg15556689	chr8:8085844	FLJ10661	0.67	6.2	0.49	7.84e-9	Mood instability;
TGCT	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	15.93	0.82	8.93e-32	Prudent dietary pattern;
TGCT	cis	rs10165862	0.572	rs11674212	chr2:73911180	C/T	cg07208825	chr2:73871855	ALMS1P	0.23	4.88	0.4	3.15e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9372498	0.505	rs9489462	chr6:118927855	C/T	cg21191810	chr6:118973309	C6orf204	-0.38	-4.97	-0.41	2.14e-6	Diastolic blood pressure;
TGCT	cis	rs7192750	0.562	rs9302632	chr16:71943511	A/G	cg06353428	chr16:71660113	MARVELD3	0.83	7.32	0.55	2.74e-11	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs644799	1.000	rs611020	chr11:95567905	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	7.88	0.58	1.4e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.49	-4.62	-0.38	9.64e-6	Bipolar disorder;
TGCT	cis	rs739496	0.512	rs73422315	chr12:112268299	A/G	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs7949030	0.626	rs72927213	chr11:62351198	G/C	cg11742103	chr11:62369870	EML3;MTA2	0.6	8.63	0.61	2.53e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7659604	0.540	rs9998385	chr4:122676673	C/T	cg19748678	chr4:122722346	EXOSC9	-0.51	-5.0	-0.41	1.89e-6	Type 2 diabetes;
TGCT	cis	rs1055129	0.584	rs9895947	chr17:73908566	A/C	cg10935138	chr17:73851978	WBP2	0.57	4.87	0.4	3.34e-6	White matter hyperintensity burden;
TGCT	cis	rs904251	0.523	rs2776871	chr6:37481759	A/G	cg01843034	chr6:37503916	NA	-0.56	-7.56	-0.56	7.84e-12	Cognitive performance;
TGCT	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg18876405	chr7:65276391	NA	-0.34	-5.09	-0.42	1.27e-6	Aortic root size;
TGCT	cis	rs9300255	0.569	rs1727320	chr12:123700476	T/A	cg00376283	chr12:123451042	ABCB9	0.73	5.67	0.45	9.46e-8	Neutrophil percentage of white cells;
TGCT	cis	rs2153535	0.580	rs1414351	chr6:8476634	T/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs72945132	0.882	rs60780459	chr11:70162468	A/G	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs4478037	0.558	rs55980934	chr3:33081696	C/T	cg19404215	chr3:33155277	CRTAP	1.04	4.95	0.41	2.36e-6	Major depressive disorder;
TGCT	cis	rs3617	0.539	rs11130331	chr3:52956918	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	0.46	4.49	0.37	1.58e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg26338869	chr17:61819248	STRADA	-0.52	-4.75	-0.39	5.48e-6	Prudent dietary pattern;
TGCT	cis	rs854765	0.663	rs6502618	chr17:17746741	A/G	cg09796270	chr17:17721594	SREBF1	-0.24	-4.52	-0.38	1.45e-5	Total body bone mineral density;
TGCT	cis	rs12643440	0.574	rs1581400	chr4:17139504	A/G	cg22650099	chr4:17144496	NA	-0.45	-4.65	-0.39	8.28e-6	Metabolite levels (Pyroglutamine);
TGCT	cis	rs4478858	0.684	rs3737755	chr1:31744168	G/A	cg07478791	chr1:31886160	SERINC2	-0.48	-4.6	-0.38	1.05e-5	Alcohol dependence;
TGCT	cis	rs2658782	0.756	rs3019222	chr11:93079718	C/T	cg18152523	chr11:93063302	CCDC67	-0.67	-5.19	-0.42	8.29e-7	Pulmonary function decline;
TGCT	cis	rs2204008	0.540	rs1283306	chr12:38153778	C/A	cg26384229	chr12:38710491	ALG10B	-0.58	-5.08	-0.42	1.33e-6	Bladder cancer;
TGCT	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg11890956	chr21:40555474	PSMG1	-0.68	-6.67	-0.51	7.62e-10	Menarche (age at onset);
TGCT	cis	rs56235845	0.694	rs11738681	chr5:176761535	A/G	cg16006841	chr5:176797999	RGS14	0.49	7.31	0.55	2.9100000000000002e-11	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs2880765	0.835	rs7161880	chr15:86018746	C/T	cg13263323	chr15:86062960	AKAP13	-0.22	-4.74	-0.39	5.67e-6	Coronary artery disease;
TGCT	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg20203395	chr5:56204925	C5orf35	-0.59	-5.12	-0.42	1.12e-6	Initial pursuit acceleration;
TGCT	cis	rs200810	0.694	rs4839913	chr6:98019234	C/G	cg16511841	chr6:97730490	C6orf167;MIR548H3	-0.71	-4.78	-0.39	4.89e-6	Body mass index;
TGCT	cis	rs11711311	0.910	rs62265549	chr3:113396234	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.8	-7.16	-0.54	6.18e-11	IgG glycosylation;
TGCT	cis	rs73110464	0.609	rs11170348	chr12:53355588	A/G	cg14581129	chr12:53358946	NA	-0.63	-6.78	-0.52	4.39e-10	Cancer (pleiotropy);
TGCT	cis	rs10791323	0.546	rs55801927	chr11:133713094	A/C	cg03690763	chr11:133734501	NA	-0.31	-4.92	-0.4	2.73e-6	Childhood ear infection;
TGCT	cis	rs453301	0.522	rs2929309	chr8:9083771	C/A	cg06636001	chr8:8085503	FLJ10661	-0.55	-4.8	-0.4	4.51e-6	Joint mobility (Beighton score);
TGCT	cis	rs11997175	0.524	rs10954932	chr8:33650176	A/C	ch.8.33884649F	chr8:33765107	NA	0.28	4.54	0.38	1.3e-5	Body mass index;
TGCT	trans	rs10109025	0.670	rs7825690	chr8:10858257	G/T	cg06636001	chr8:8085503	FLJ10661	-0.79	-7.49	-0.56	1.11e-11	Joint mobility (Beighton score);
TGCT	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg06028808	chr11:68637592	NA	0.56	6.93	0.53	2.08e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs11621121	0.556	rs11158588	chr14:65799876	G/A	cg04536575	chr14:65016802	C14orf50	-0.63	-4.49	-0.37	1.61e-5	N-glycan levels;
TGCT	cis	rs7267979	0.966	rs6037103	chr20:25369095	A/G	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs929354	1.000	rs1182410	chr7:157063837	C/T	cg05182265	chr7:156933206	UBE3C	0.3	6.39	0.5	3.05e-9	Body mass index;
TGCT	trans	rs7618501	0.966	rs7372966	chr3:49788969	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-1.03	-13.16	-0.76	2.65e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.753	rs9991512	chr4:99007205	T/C	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1475911	1.000	rs12482477	chr21:43517233	T/A	cg19766460	chr21:43528205	UMODL1;C21orf128	0.51	7.02	0.53	1.3e-10	IgG glycosylation;
TGCT	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg25036284	chr2:26402008	FAM59B	-0.61	-4.89	-0.4	3.1e-6	Gut microbiome composition (summer);
TGCT	trans	rs1814175	0.791	rs7395713	chr11:49877887	A/G	cg15704280	chr7:45808275	SEPT13	-0.71	-7.9	-0.58	1.27e-12	Height;
TGCT	cis	rs9807989	0.801	rs10173193	chr2:102975050	G/A	cg09003973	chr2:102972529	NA	0.67	6.03	0.48	1.75e-8	Asthma;
TGCT	cis	rs1577917	0.958	rs12198971	chr6:86525445	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-5.53	-0.44	1.82e-7	Response to antipsychotic treatment;
TGCT	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg22508957	chr16:3507546	NAT15	0.5	5.79	0.46	5.49e-8	Tuberculosis;
TGCT	cis	rs593982	1.000	rs593982	chr11:65513107	T/C	cg08755490	chr11:65554678	OVOL1	1.42	12.09	0.74	1.03e-22	Atopic dermatitis;
TGCT	cis	rs68170813	0.559	rs6964966	chr7:106933099	C/G	cg02696742	chr7:106810147	HBP1	-0.69	-5.81	-0.46	4.85e-8	Coronary artery disease;
TGCT	cis	rs6088580	0.634	rs6120666	chr20:33090718	A/G	cg08999081	chr20:33150536	PIGU	0.29	5.57	0.45	1.54e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs12908161	0.959	rs2175567	chr15:85200946	C/G	cg12863693	chr15:85201151	NMB	0.46	5.54	0.45	1.73e-7	Schizophrenia;
TGCT	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg26039829	chr8:22132926	PIWIL2	0.27	5.12	0.42	1.14e-6	Hypertriglyceridemia;
TGCT	cis	rs10782582	0.593	rs114421765	chr1:76141802	C/T	cg10523679	chr1:76189770	ACADM	-0.68	-7.06	-0.54	1.03e-10	Daytime sleep phenotypes;
TGCT	cis	rs13242816	1.000	rs62468976	chr7:116126891	C/G	cg02799643	chr7:116139180	CAV2	-0.45	-5.46	-0.44	2.49e-7	P wave duration;
TGCT	cis	rs72945132	0.882	rs11235739	chr11:70132780	C/T	cg00319359	chr11:70116639	PPFIA1	1.01	7.58	0.56	7.09e-12	Coronary artery disease;
TGCT	cis	rs9326248	0.581	rs10892072	chr11:116960313	G/A	cg20608306	chr11:116969690	SIK3	0.4	4.52	0.38	1.4e-5	Blood protein levels;
TGCT	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	7.12	0.54	7.55e-11	Platelet count;
TGCT	cis	rs7809950	0.637	rs2701685	chr7:107299584	A/G	cg23024343	chr7:107201750	COG5	0.41	5.78	0.46	5.71e-8	Coronary artery disease;
TGCT	cis	rs7192750	0.583	rs2550043	chr16:72067491	T/C	cg06353428	chr16:71660113	MARVELD3	0.98	4.87	0.4	3.27e-6	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg03396347	chr1:1875803	NA	-0.37	-6.63	-0.51	9.38e-10	Body mass index;
TGCT	cis	rs4819052	0.808	rs2838825	chr21:46655651	C/T	cg06618935	chr21:46677482	NA	-0.34	-5.29	-0.43	5.26e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.41	-4.88	-0.4	3.13e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg22121687	chr7:65037720	NA	-0.78	-4.7	-0.39	6.74e-6	Diabetic kidney disease;
TGCT	cis	rs3917265	0.602	rs3917290	chr2:102782079	C/T	cg17937070	chr2:102766322	NA	-0.32	-4.48	-0.37	1.66e-5	Atopic dermatitis;
TGCT	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg00814883	chr7:100076585	TSC22D4	-0.92	-9.76	-0.66	4.73e-17	Platelet count;
TGCT	cis	rs2235642	1.000	rs2076438	chr16:1584618	T/C	cg08296037	chr16:1584118	IFT140;TMEM204	-0.3	-5.51	-0.44	2.01e-7	Coronary artery disease;
TGCT	cis	rs2033711	0.840	rs4801590	chr19:58961813	G/C	cg04608855	chr19:58913158	NA	0.53	5.06	0.41	1.49e-6	Uric acid clearance;
TGCT	cis	rs1843834	0.929	rs4674934	chr2:225516468	A/T	cg22455342	chr2:225449267	CUL3	-0.72	-7.29	-0.55	3.15e-11	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs9611519	0.780	rs3171692	chr22:41642212	C/T	cg06634786	chr22:41940651	POLR3H	-0.56	-5.05	-0.41	1.52e-6	Neuroticism;
TGCT	cis	rs727563	0.635	rs713988	chr22:42159072	A/G	cg13695892	chr22:41940480	POLR3H	0.87	8.24	0.59	2.06e-13	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs10883723	0.773	rs11191303	chr10:104255158	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs12142240	0.698	rs17357711	chr1:46829013	A/G	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs2455799	0.614	rs2881211	chr3:15866983	C/T	cg12172478	chr3:16357591	RFTN1	-0.33	-4.86	-0.4	3.47e-6	Mean platelet volume;
TGCT	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg16680214	chr1:154839983	KCNN3	-0.42	-9.08	-0.63	2.15e-15	Prostate cancer;
TGCT	cis	rs838147	0.563	rs2638282	chr19:49213833	G/A	cg13540341	chr19:49222985	MAMSTR	-0.36	-4.66	-0.39	7.98e-6	Dietary macronutrient intake;
TGCT	cis	rs7666738	0.830	rs11735193	chr4:98761900	C/T	cg17366294	chr4:99064904	C4orf37	0.65	6.78	0.52	4.31e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7666738	0.830	rs11097598	chr4:98946057	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6933660	0.745	rs3800272	chr6:151744283	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	-0.56	-5.53	-0.44	1.8e-7	Menarche (age at onset);
TGCT	cis	rs7666738	0.830	rs4699603	chr4:99056172	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.45	0.56	1.4e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs31872	0.521	rs246050	chr5:140326860	T/G	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Visceral adipose tissue adjusted for BMI;
TGCT	trans	rs208520	1.000	rs12191598	chr6:66983962	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.83	7.46	0.56	1.31e-11	Exhaled nitric oxide output;
TGCT	cis	rs13177918	0.677	rs3900644	chr5:149822922	T/A	cg14059543	chr5:149831962	NA	-0.71	-9.45	-0.65	2.77e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs9926296	0.609	rs4785710	chr16:89796756	C/T	cg27121462	chr16:89883253	FANCA	-0.55	-5.27	-0.43	5.81e-7	Vitiligo;
TGCT	trans	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg15556689	chr8:8085844	FLJ10661	0.84	8.16	0.59	3.26e-13	Triglycerides;
TGCT	cis	rs9467773	0.967	rs1535276	chr6:26520941	T/C	cg05738196	chr6:26577821	NA	0.88	12.5	0.75	1.03e-23	Intelligence (multi-trait analysis);
TGCT	trans	rs208515	0.525	rs1484577	chr6:66688397	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.92	10.09	0.67	7.45e-18	Exhaled nitric oxide levels;
TGCT	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg08280861	chr8:58055591	NA	0.4	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2692947	0.673	rs2692894	chr2:96784934	T/G	cg05933789	chr2:97190408	NA	-0.17	-4.87	-0.4	3.39e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs12479064	0.724	rs11885942	chr2:100004165	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.74	-6.33	-0.49	4.06e-9	Chronic sinus infection;
TGCT	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg27286337	chr10:134555280	INPP5A	0.39	4.73	0.39	6.02e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs10892173	0.566	rs111578166	chr11:117666714	G/T	cg21640587	chr11:117668038	DSCAML1	0.65	7.53	0.56	9.06e-12	Myopia;
TGCT	cis	rs4499344	0.589	rs259218	chr19:33138125	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	8.28	0.6	1.68e-13	Mean platelet volume;
TGCT	cis	rs10276381	0.786	rs73089302	chr7:28187134	G/A	cg23620719	chr7:28220237	JAZF1	1.01	5.82	0.46	4.75e-8	Crohn's disease;
TGCT	cis	rs1215050	0.740	rs783945	chr4:99014394	G/A	cg05340658	chr4:99064831	C4orf37	-0.41	-4.99	-0.41	1.95e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7666738	0.830	rs35235971	chr4:98999833	G/T	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs17030434	0.784	rs10032475	chr4:154674748	C/T	cg14289246	chr4:154710475	SFRP2	-0.81	-6.76	-0.52	4.73e-10	Electrocardiographic conduction measures;
TGCT	cis	rs12477438	0.735	rs12474477	chr2:99690408	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-5.85	-0.47	4.06e-8	Chronic sinus infection;
TGCT	cis	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg07424592	chr7:64974309	NA	1.34	8.26	0.6	1.81e-13	Diabetic kidney disease;
TGCT	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg11062466	chr8:58055876	NA	0.46	4.81	0.4	4.29e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs28595532	0.920	rs115738062	chr4:119725490	C/T	cg14228332	chr4:119757509	SEC24D	1.38	6.93	0.53	2.07e-10	Cannabis dependence symptom count;
TGCT	cis	rs941408	1.000	rs2260416	chr19:2796355	G/A	cg06609049	chr19:2785107	THOP1	0.79	7.46	0.56	1.34e-11	Total cholesterol levels;
TGCT	cis	rs910187	0.537	rs1417452	chr20:45763350	T/C	cg27589058	chr20:45804311	EYA2	-0.34	-6.28	-0.49	5.1e-9	Migraine;
TGCT	trans	rs77457752	0.525	rs10961293	chr9:13894250	A/G	cg18948646	chr4:83674694	SCD5;MIR575	0.57	6.94	0.53	1.98e-10	Breast cancer;
TGCT	cis	rs2307449	0.729	rs1006659	chr15:89883672	T/G	cg24365117	chr15:89879190	POLG	0.3	4.47	0.37	1.74e-5	Menopause (age at onset);
TGCT	cis	rs7208859	0.673	rs9895684	chr17:29242600	G/A	cg14008862	chr17:28927542	LRRC37B2	0.73	4.71	0.39	6.49e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs6912958	0.935	rs2179844	chr6:88165773	C/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.63	-6.22	-0.49	7.06e-9	Monocyte percentage of white cells;
TGCT	cis	rs8028182	0.636	rs8023815	chr15:75814704	G/A	cg20655648	chr15:75932815	IMP3	0.59	4.62	0.38	9.55e-6	Sudden cardiac arrest;
TGCT	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg24578937	chr1:2090814	PRKCZ	0.26	6.95	0.53	1.8e-10	Height;
TGCT	cis	rs2956278	0.717	rs2929752	chr12:84677004	G/A	cg25678815	chr12:85673915	ALX1	-0.54	-4.83	-0.4	3.96e-6	Depressive symptoms;Depressive symptoms (multi-trait analysis);
TGCT	trans	rs10504390	0.656	rs79932695	chr8:66547075	T/C	cg26037026	chr7:1641922	NA	-0.64	-6.84	-0.52	3.29e-10	IgG glycosylation;
TGCT	cis	rs10465746	0.905	rs34274953	chr1:84415011	G/A	cg10977910	chr1:84465055	TTLL7	0.65	6.56	0.51	1.31e-9	Obesity-related traits;
TGCT	cis	rs11154851	1.000	rs9321547	chr6:136307525	A/G	cg00082954	chr6:136878319	MAP3K5	0.73	4.49	0.37	1.59e-5	Alzheimer's disease (cognitive decline);
TGCT	cis	rs7267979	0.565	rs6107059	chr20:25592431	C/A	cg14121845	chr20:25566513	NINL	-0.41	-4.48	-0.37	1.7e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg05368731	chr17:41323189	NBR1	1.13	13.37	0.77	8.37e-26	Menopause (age at onset);
TGCT	cis	rs9372253	1.000	rs9386894	chr6:110718853	A/G	cg01119278	chr6:110721349	DDO	-0.37	-5.94	-0.47	2.7e-8	Platelet distribution width;
TGCT	cis	rs2153535	0.563	rs1796687	chr6:8536118	C/G	cg07606381	chr6:8435919	SLC35B3	0.53	4.98	0.41	2.09e-6	Motion sickness;
TGCT	cis	rs9473924	0.505	rs9463664	chr6:50902570	T/A	cg14470998	chr6:50812995	TFAP2B	1.35	8.39	0.6	9.05e-14	Body mass index;
TGCT	cis	rs921968	0.541	rs578450	chr2:219401237	C/T	cg02176678	chr2:219576539	TTLL4	0.48	6.78	0.52	4.32e-10	Mean corpuscular hemoglobin concentration;
TGCT	trans	rs11088226	0.645	rs2833904	chr21:33941089	T/C	cg09050820	chr6:167586206	TCP10L2	0.81	7.3	0.55	2.98e-11	Gastritis;
TGCT	cis	rs11190604	1.000	rs3750633	chr10:102308214	C/T	cg23241863	chr10:102295624	HIF1AN	0.7	5.18	0.42	8.9e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs11190604	1.000	rs79831012	chr10:102237059	T/C	cg16342193	chr10:102329863	NA	-0.4	-5.31	-0.43	4.85e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9816226	0.618	rs1516728	chr3:185829891	A/T	cg00760338	chr3:185826511	ETV5	0.73	6.37	0.5	3.42e-9	Obesity;Body mass index;
TGCT	cis	rs707040	0.961	rs35706065	chr2:155235853	G/T	cg18104148	chr2:154337490	NA	0.19	4.56	0.38	1.2e-5	Sudden cardiac arrest;
TGCT	cis	rs3812831	0.695	rs6560935	chr13:114945867	G/A	cg08824895	chr13:115047677	UPF3A	0.49	4.7	0.39	6.79e-6	Schizophrenia;
TGCT	cis	rs709400	0.663	rs11626787	chr14:103991749	A/G	cg12935359	chr14:103987150	CKB	-0.39	-5.77	-0.46	5.87e-8	Body mass index;
TGCT	cis	rs7312933	0.558	rs2178753	chr12:42732804	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.59	-5.72	-0.46	7.52e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs3784262	1.000	rs12903551	chr15:58268372	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.49	-7.74	-0.57	3.01e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	trans	rs2469997	1.000	rs2470006	chr8:120358591	G/C	cg01792902	chr3:178864926	PIK3CA	0.83	6.77	0.52	4.49e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs911263	0.961	rs3784099	chr14:68749927	A/G	cg18825221	chr14:68749962	RAD51L1	0.25	4.98	0.41	2.05e-6	Primary biliary cholangitis;
TGCT	cis	rs7582180	0.739	rs4851292	chr2:100924761	A/G	cg14675211	chr2:100938903	LONRF2	0.49	4.8	0.4	4.49e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4635969	1.000	rs4635969	chr5:1308552	C/T	cg18250916	chr5:612533	CEP72	0.49	4.51	0.38	1.5e-5	Testicular germ cell tumor;Testicular germ cell cancer;
TGCT	cis	rs7904368	0.568	rs7075036	chr10:16864810	C/T	cg14835575	chr10:16859367	RSU1	0.45	5.33	0.43	4.42e-7	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
TGCT	cis	rs2658782	0.789	rs56091149	chr11:93073640	A/C	cg15737290	chr11:93063684	CCDC67	-0.84	-5.36	-0.43	3.99e-7	Pulmonary function decline;
TGCT	cis	rs35883536	0.647	rs55728953	chr1:101046863	T/C	cg10298815	chr1:101004474	GPR88	-0.25	-4.5	-0.37	1.54e-5	Monocyte count;
TGCT	cis	rs9796	0.621	rs12324159	chr15:41462468	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.54	-7.22	-0.54	4.66e-11	Menopause (age at onset);
TGCT	cis	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg13531842	chr10:38383804	ZNF37A	-0.38	-4.51	-0.38	1.49e-5	Extrinsic epigenetic age acceleration;
TGCT	cis	rs8038465	0.967	rs3935942	chr15:73971361	C/A	cg15420318	chr15:73925796	NPTN	0.7	6.53	0.51	1.56e-9	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs8020441	0.588	rs59096640	chr14:51186392	G/C	cg04730355	chr14:51134070	SAV1	1.04	7.27	0.55	3.55e-11	Cognitive performance;
TGCT	cis	rs9325144	0.555	rs12424003	chr12:38688140	C/T	cg26384229	chr12:38710491	ALG10B	-0.65	-6.01	-0.48	1.9e-8	Morning vs. evening chronotype;
TGCT	cis	rs7647973	0.925	rs4955421	chr3:49218888	G/A	cg07690219	chr3:49449608	TCTA;RHOA	-0.57	-4.79	-0.4	4.63e-6	Menarche (age at onset);
TGCT	cis	rs6725041	0.819	rs13420153	chr2:213083191	C/G	cg16329650	chr2:213403929	ERBB4	-0.54	-4.61	-0.38	9.88e-6	QT interval (ambient particulate matter interaction);
TGCT	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg11644478	chr21:40555479	PSMG1	-0.49	-4.56	-0.38	1.21e-5	Menarche (age at onset);
TGCT	cis	rs4780401	0.609	rs4780399	chr16:11828701	A/T	cg01061890	chr16:11836724	TXNDC11	-0.57	-5.42	-0.44	3.05e-7	Rheumatoid arthritis;
TGCT	cis	rs17221829	0.733	rs11018726	chr11:89413265	T/C	cg02982614	chr11:89391479	FOLH1B	-0.28	-4.66	-0.39	7.94e-6	Anxiety in major depressive disorder;
TGCT	cis	rs9611565	0.559	rs132768	chr22:42013523	C/A	cg03806693	chr22:41940476	POLR3H	1.07	11.4	0.72	4.95e-21	Vitiligo;
TGCT	cis	rs17122693	1.000	rs17122674	chr14:51066429	G/A	cg04730355	chr14:51134070	SAV1	1.15	7.71	0.57	3.48e-12	Cognitive performance;
TGCT	cis	rs4704846	1.000	rs10067589	chr5:156524999	C/T	cg12943317	chr5:156479607	HAVCR1	-0.34	-4.75	-0.39	5.43e-6	Blood protein levels;
TGCT	cis	rs9913156	0.793	rs55974786	chr17:4567564	T/C	cg19197139	chr17:4613644	ARRB2	0.86	7.97	0.58	8.69e-13	Lymphocyte counts;
TGCT	cis	rs79349575	0.715	rs4793997	chr17:47019672	C/A	cg26022315	chr17:47021804	SNF8	0.49	4.9	0.4	2.94e-6	Type 2 diabetes;
TGCT	cis	rs9926296	0.569	rs4785708	chr16:89796569	C/T	cg04287289	chr16:89883240	FANCA	-0.61	-6.02	-0.48	1.85e-8	Vitiligo;
TGCT	cis	rs6714710	0.603	rs34974566	chr2:98552299	C/G	cg26665480	chr2:98280029	ACTR1B	0.63	5.99	0.47	2.13e-8	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs941408	1.000	rs941407	chr19:2812153	A/G	cg06609049	chr19:2785107	THOP1	0.84	8.23	0.59	2.16e-13	Total cholesterol levels;
TGCT	cis	rs8078723	0.738	rs8066582	chr17:38146929	A/G	cg17467752	chr17:38218738	THRA	-0.53	-5.37	-0.43	3.8e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs7017914	0.934	rs3110239	chr8:71916745	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.57	-5.31	-0.43	4.8e-7	Bone mineral density;
TGCT	cis	rs9807989	0.839	rs1362348	chr2:102984624	C/G	cg09003973	chr2:102972529	NA	0.64	5.76	0.46	6.37e-8	Asthma;
TGCT	cis	rs72768842	1.000	rs72768817	chr5:78944371	G/C	cg24834873	chr5:79865402	ANKRD34B	-1.16	-4.61	-0.38	9.84e-6	Post bronchodilator FEV1/FVC ratio in COPD;
TGCT	cis	rs4372836	0.504	rs13025081	chr2:29083850	C/A	cg09522027	chr2:28974177	PPP1CB	-0.57	-5.63	-0.45	1.14e-7	Body mass index;
TGCT	cis	rs34526934	0.566	rs34028621	chr2:177042779	C/T	cg26754761	chr2:177040938	NA	-0.29	-5.39	-0.44	3.35e-7	Obstructive sleep apnea trait (apnea hypopnea index);
TGCT	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	8.39	0.6	9.03e-14	Platelet count;
TGCT	cis	rs12776158	0.901	rs60110374	chr10:71217090	C/T	cg12610070	chr10:71211762	TSPAN15	-0.59	-5.17	-0.42	9.16e-7	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs9733	0.519	rs1336899	chr1:150678910	T/C	cg09365446	chr1:150670422	GOLPH3L	0.3	4.52	0.38	1.4e-5	Tonsillectomy;
TGCT	cis	rs1843834	0.858	rs6731785	chr2:225491143	A/G	cg22455342	chr2:225449267	CUL3	0.8	7.99	0.58	8.11e-13	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs3087591	1.000	rs2952982	chr17:29470646	A/C	cg24425628	chr17:29625626	OMG;NF1	0.48	7.63	0.57	5.39e-12	Hip circumference;
TGCT	cis	rs68170813	0.559	rs79026644	chr7:107031803	A/G	cg02696742	chr7:106810147	HBP1	-0.7	-5.68	-0.45	8.91e-8	Coronary artery disease;
TGCT	cis	rs10504229	0.636	rs77691549	chr8:58055126	G/T	cg02725872	chr8:58115012	NA	-0.38	-4.69	-0.39	7.12e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg14159672	chr1:205819179	PM20D1	-0.58	-7.11	-0.54	8.04e-11	Monocyte percentage of white cells;
TGCT	cis	rs981844	1.000	rs2606327	chr4:154653629	C/T	cg14289246	chr4:154710475	SFRP2	1.02	8.98	0.63	3.61e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs77236434	0.579	rs1671368	chr8:13190714	C/G	cg07307335	chr8:12602187	LONRF1	0.33	4.62	0.38	9.32e-6	Familial hepatitis B virus-related hepatocellular carcinoma;
TGCT	cis	rs9883204	1.000	rs34970607	chr3:123090360	G/A	cg04890266	chr3:123102914	ADCY5	0.36	5.1	0.42	1.26e-6	Birth weight;
TGCT	cis	rs3751972	0.641	rs7212926	chr17:26235226	T/C	cg02948944	chr17:26242737	NA	0.39	5.53	0.44	1.79e-7	Fractional exhaled nitric oxide (childhood);
TGCT	trans	rs901683	0.702	rs74940001	chr10:46144294	G/A	cg03466342	chr12:52753899	KRT85	-0.58	-7.16	-0.54	6.39e-11	Red blood cell traits;Mean corpuscular volume;
TGCT	cis	rs1994135	0.669	rs10844628	chr12:33697065	T/C	cg06521331	chr12:34319734	NA	-0.3	-4.73	-0.39	6.09e-6	Resting heart rate;
TGCT	cis	rs7586879	0.658	rs7563204	chr2:25125075	T/G	cg01884057	chr2:25150051	NA	0.35	6.9	0.53	2.39e-10	Body mass index;
TGCT	cis	rs7727544	0.735	rs272842	chr5:131656517	A/G	cg24060327	chr5:131705240	SLC22A5	-0.55	-6.18	-0.48	8.66e-9	Blood metabolite levels;
TGCT	cis	rs9467773	0.967	rs9467775	chr6:26513435	G/A	cg15659132	chr6:26577336	NA	0.86	12.21	0.74	5.3e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs9952991	0.941	rs2847278	chr18:12778715	C/T	cg09945482	chr18:12777974	NA	0.51	4.86	0.4	3.47e-6	Inflammatory skin disease;
TGCT	cis	rs2486288	0.656	rs8039153	chr15:45579813	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.81	-8.48	-0.61	5.52e-14	Glomerular filtration rate;
TGCT	cis	rs12142240	0.698	rs72677596	chr1:46833930	C/T	cg00530320	chr1:46809349	NSUN4	0.28	5.78	0.46	5.69e-8	Menopause (age at onset);
TGCT	cis	rs9902453	0.791	rs6505141	chr17:27998187	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.84	8.26	0.6	1.9e-13	Coffee consumption (cups per day);
TGCT	cis	rs7666738	0.830	rs7689495	chr4:98920152	T/C	cg18180107	chr4:99064573	C4orf37	0.57	5.23	0.43	6.88e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8056742	0.908	rs55757943	chr16:85094261	A/G	cg00229868	chr16:85520891	NA	0.34	4.98	0.41	2.07e-6	Amyotrophic lateral sclerosis;
TGCT	cis	rs12579753	0.871	rs10862362	chr12:82199383	T/G	cg07988820	chr12:82153109	PPFIA2	-0.59	-6.19	-0.49	7.93e-9	Resting heart rate;
TGCT	cis	rs6693567	0.565	rs35784258	chr1:150405882	T/C	cg09579323	chr1:150459698	TARS2	0.52	4.64	0.38	8.63e-6	Migraine;
TGCT	cis	rs9388451	0.626	rs3799708	chr6:126078530	C/T	cg05901451	chr6:126070800	HEY2	-0.98	-12.53	-0.75	9.05e-24	Brugada syndrome;
TGCT	cis	rs6938	0.563	rs12917376	chr15:75116167	C/T	cg13906792	chr15:75199810	C15orf17	-0.2	-4.54	-0.38	1.34e-5	Breast cancer;
TGCT	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.29	0.55	3.27e-11	Prudent dietary pattern;
TGCT	cis	rs28595532	1.000	rs115706377	chr4:119628481	G/A	cg14228332	chr4:119757509	SEC24D	1.0	5.76	0.46	6.22e-8	Cannabis dependence symptom count;
TGCT	cis	rs1008375	1.000	rs10805357	chr4:17652352	G/A	cg10189774	chr4:17578691	LAP3	0.57	5.15	0.42	9.95e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7833790	0.676	rs7834555	chr8:82697625	A/G	cg27398817	chr8:82754497	SNX16	-0.58	-4.66	-0.39	8.19e-6	Diastolic blood pressure;
TGCT	cis	rs6570726	0.935	rs380433	chr6:145859601	A/T	cg05347473	chr6:146136440	FBXO30	0.49	4.54	0.38	1.29e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7923452	0.507	rs103441	chr10:30778184	C/T	cg18806716	chr10:30721971	MAP3K8	-0.63	-7.2	-0.54	4.97e-11	Itch intensity from mosquito bite;
TGCT	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg06481639	chr22:41940642	POLR3H	-0.72	-6.25	-0.49	6.08e-9	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg25036284	chr2:26402008	FAM59B	-0.57	-4.97	-0.41	2.15e-6	Gut microbiome composition (summer);
TGCT	cis	rs1865760	0.602	rs9467662	chr6:26021327	G/A	cg17042849	chr6:26104293	HIST1H4C	-0.61	-5.13	-0.42	1.07e-6	Height;
TGCT	cis	rs9527	0.662	rs4919686	chr10:104592249	A/C	cg15744005	chr10:104629667	AS3MT	-0.47	-5.6	-0.45	1.33e-7	Arsenic metabolism;
TGCT	cis	rs2034088	0.591	rs4968166	chr17:404537	C/T	cg01214346	chr17:406501	NA	-0.36	-5.48	-0.44	2.25e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs1215050	0.740	rs9994227	chr4:98767094	T/G	cg05340658	chr4:99064831	C4orf37	0.44	5.51	0.44	2.01e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7044106	0.791	rs7043969	chr9:123493989	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	4.77	0.39	4.99e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs6121246	0.559	rs6060599	chr20:30257754	T/G	cg13852791	chr20:30311386	BCL2L1	0.8	7.49	0.56	1.1e-11	Mean corpuscular hemoglobin;
TGCT	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.52	-6.0	-0.47	2.05e-8	Longevity;Endometriosis;
TGCT	cis	rs4372836	0.504	rs13011935	chr2:29014746	C/T	cg09522027	chr2:28974177	PPP1CB	-0.56	-5.68	-0.45	9.2e-8	Body mass index;
TGCT	cis	rs7119038	0.818	rs4936441	chr11:118725660	C/G	cg19308663	chr11:118741387	NA	-0.32	-5.98	-0.47	2.16e-8	Sjögren's syndrome;
TGCT	cis	rs6500602	0.727	rs4786516	chr16:4578641	C/T	cg08645402	chr16:4508243	NA	0.19	5.25	0.43	6.32e-7	Schizophrenia;
TGCT	cis	rs12368653	0.557	rs903067	chr12:58011857	G/A	cg12615879	chr12:58013172	SLC26A10	-0.5	-5.87	-0.47	3.81e-8	Multiple sclerosis;
TGCT	cis	rs13256369	1.000	rs873064	chr8:8572380	G/A	cg18904891	chr8:8559673	CLDN23	0.62	5.7	0.46	8.41e-8	Obesity-related traits;
TGCT	cis	rs111803315	1.000	rs113097743	chr14:60018216	G/A	cg22995959	chr14:59931024	GPR135	0.63	4.56	0.38	1.23e-5	Schizophrenia;
TGCT	trans	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg27523141	chr10:43048294	ZNF37B	0.74	8.66	0.61	2.13e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs9303401	0.659	rs7210432	chr17:56668170	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs416603	0.901	rs149597	chr16:11343942	C/G	cg00044050	chr16:11439710	C16orf75	-0.82	-8.32	-0.6	1.31e-13	Type 1 diabetes;
TGCT	cis	rs9308731	0.644	rs3789064	chr2:111915322	T/C	cg04202892	chr2:111875749	ACOXL	0.55	6.48	0.5	1.98e-9	Chronic lymphocytic leukemia;
TGCT	cis	rs3087591	0.959	rs2051505	chr17:29699859	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.48	-7.22	-0.54	4.67e-11	Hip circumference;
TGCT	trans	rs208520	0.802	rs1342959	chr6:66883329	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-10.21	-0.68	4.02e-18	Exhaled nitric oxide output;
TGCT	cis	rs6088590	0.965	rs6088620	chr20:33412022	A/G	cg06115741	chr20:33292138	TP53INP2	0.65	5.43	0.44	2.82e-7	Coronary artery disease;
TGCT	cis	rs10883723	0.773	rs2296578	chr10:104240974	C/G	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs12134245	0.747	rs17501512	chr1:92012481	C/G	cg07090678	chr1:91966139	CDC7	-0.36	-4.83	-0.4	3.92e-6	Breast cancer;
TGCT	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg17971929	chr21:40555470	PSMG1	0.93	8.98	0.63	3.63e-15	Cognitive function;
TGCT	cis	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg20637647	chr7:64974828	NA	0.89	4.99	0.41	2.01e-6	Diabetic kidney disease;
TGCT	cis	rs2290405	0.527	rs4690332	chr4:910520	C/T	cg04824913	chr4:887549	GAK	-0.37	-5.06	-0.41	1.45e-6	Systemic sclerosis;
TGCT	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg20887711	chr4:1340912	KIAA1530	0.92	8.35	0.6	1.13e-13	Longevity;
TGCT	cis	rs11190604	1.000	rs1800662	chr10:102289078	C/A	cg23241863	chr10:102295624	HIF1AN	0.68	5.17	0.42	9.14e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg00149659	chr3:10157352	C3orf10	1.18	7.44	0.56	1.44e-11	Alzheimer's disease;
TGCT	cis	rs2836974	0.583	rs8132993	chr21:40716410	T/C	cg11644478	chr21:40555479	PSMG1	0.64	6.06	0.48	1.52e-8	Cognitive function;
TGCT	cis	rs2932538	0.961	rs6537746	chr1:113163529	C/T	cg22162597	chr1:113214053	CAPZA1	-0.27	-5.98	-0.47	2.24e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs7584330	0.868	rs7569197	chr2:238383073	A/G	cg14458575	chr2:238380390	NA	0.5	7.89	0.58	1.35e-12	Prostate cancer;
TGCT	cis	rs10791097	0.694	rs876641	chr11:130752040	A/C	cg05962950	chr11:130786565	SNX19	0.91	11.68	0.72	1.01e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs7552404	1.000	rs2133134	chr1:76179587	G/A	cg10523679	chr1:76189770	ACADM	0.91	9.92	0.67	2.01e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs6840360	1.000	rs9995704	chr4:152619069	C/A	cg22705602	chr4:152727874	NA	-0.25	-4.47	-0.37	1.71e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs11209002	0.524	rs2815386	chr1:67541996	A/G	cg02640540	chr1:67518911	SLC35D1	0.53	4.45	0.37	1.86e-5	Crohn's disease;
TGCT	cis	rs7178424	0.742	rs12908081	chr15:62162264	C/T	cg00456672	chr15:62358751	C2CD4A	-0.31	-4.72	-0.39	6.37e-6	Height;
TGCT	cis	rs11723530	0.538	rs12498436	chr4:170796457	C/G	cg16551732	chr4:169799087	PALLD	0.34	4.54	0.38	1.34e-5	Myopia (pathological);
TGCT	trans	rs1814175	0.645	rs28627251	chr11:50048125	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.67	-0.69	2.92e-19	Height;
TGCT	cis	rs6840360	0.593	rs11723227	chr4:152689717	G/A	cg17479576	chr4:152424074	FAM160A1	-0.52	-5.2	-0.42	8.05e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs3749237	1.000	rs1317140	chr3:49878652	G/A	cg07636037	chr3:49044803	WDR6	0.61	5.35	0.43	4.03e-7	Resting heart rate;
TGCT	cis	rs1461503	0.548	rs7114175	chr11:122813983	A/T	cg14473756	chr11:122847823	NA	-0.47	-4.63	-0.38	8.99e-6	Menarche (age at onset);
TGCT	cis	rs10479542	0.806	rs4700835	chr5:178976313	A/G	cg00080972	chr5:178986291	RUFY1	0.44	5.06	0.41	1.45e-6	Lung cancer;
TGCT	cis	rs2486012	0.649	rs246777	chr1:44274434	C/G	cg12908607	chr1:44402522	ARTN	-0.65	-5.46	-0.44	2.55e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg11644478	chr21:40555479	PSMG1	1.02	11.05	0.7	3.46e-20	Cognitive function;
TGCT	cis	rs910316	1.000	rs175492	chr14:75545220	A/C	cg08847533	chr14:75593920	NEK9	0.87	9.19	0.64	1.17e-15	Height;
TGCT	cis	rs7666738	0.830	rs11727612	chr4:99001662	T/C	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9393692	0.645	rs11756673	chr6:26323505	A/G	cg00631329	chr6:26305371	NA	-0.46	-6.91	-0.53	2.23e-10	Educational attainment;
TGCT	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg11494091	chr17:61959527	GH2	0.61	14.34	0.79	4.3e-28	Prudent dietary pattern;
TGCT	cis	rs7017914	0.967	rs2639919	chr8:71875128	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.52	-4.84	-0.4	3.86e-6	Bone mineral density;
TGCT	cis	rs13191362	1.000	rs13201023	chr6:162981381	C/G	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.87	0.4	3.38e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs6840360	0.615	rs9996320	chr4:152610587	T/G	cg22705602	chr4:152727874	NA	-0.36	-5.97	-0.47	2.28e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg01448562	chr3:133502909	NA	0.34	6.92	0.53	2.12e-10	Iron status biomarkers;
TGCT	cis	rs651907	0.557	rs11711079	chr3:101386918	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.03	0.41	1.65e-6	Colorectal cancer;
TGCT	cis	rs7267979	1.000	rs2500432	chr20:25290512	A/C	cg03522245	chr20:25566470	NINL	0.62	6.71	0.52	6.12e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4455778	0.659	rs7792707	chr7:49059566	G/T	cg26309511	chr7:48887640	NA	0.44	5.09	0.42	1.28e-6	Lung cancer in never smokers;
TGCT	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg11247378	chr22:39784982	NA	-0.73	-9.83	-0.66	3.22e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs9467773	0.620	rs2451744	chr6:26633463	G/T	cg26531700	chr6:26746687	NA	0.5	4.68	0.39	7.52e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs67614146	1	rs67614146	chr6:87821827	AC/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.41	-5.26	-0.43	6.16e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs453301	0.686	rs1045527	chr8:8890041	A/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-5.49	-0.44	2.18e-7	Joint mobility (Beighton score);
TGCT	trans	rs7618501	0.669	rs3774758	chr3:49938227	C/G	cg21659725	chr3:3221576	CRBN	0.78	9.49	0.65	2.23e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs4972806	0.849	rs1542180	chr2:177028767	C/T	cg03152288	chr2:177042942	NA	0.59	5.24	0.43	6.67e-7	IgG glycosylation;
TGCT	cis	rs6988636	1.000	rs16898097	chr8:124195034	G/C	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs4268898	0.722	rs11691212	chr2:24404733	A/G	cg05570707	chr2:24270316	C2orf44	0.49	4.84	0.4	3.73e-6	Asthma;
TGCT	cis	rs617219	0.737	rs12659709	chr5:78458257	C/G	cg05890484	chr5:78407552	BHMT	0.38	5.25	0.43	6.28e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs7731657	0.537	rs2189510	chr5:130316231	C/T	cg08523029	chr5:130500466	HINT1	-0.57	-4.54	-0.38	1.33e-5	Fasting plasma glucose;
TGCT	cis	rs35146811	0.735	rs1061230	chr7:99807265	G/A	cg13334819	chr7:99746414	C7orf59	0.74	6.31	0.49	4.4e-9	Coronary artery disease;
TGCT	cis	rs7523273	0.597	rs66532523	chr1:207983745	A/C	cg22525895	chr1:207977042	MIR29B2	-0.44	-6.29	-0.49	4.89e-9	Schizophrenia;
TGCT	cis	rs9486719	1.000	rs9400016	chr6:96940883	G/T	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.86	-0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs11190604	1.000	rs2295772	chr10:102265183	G/A	cg16342193	chr10:102329863	NA	-0.38	-4.89	-0.4	3.06e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2549003	1.000	rs2549003	chr5:131829297	A/G	cg00255919	chr5:131827918	IRF1	0.21	4.94	0.41	2.45e-6	Asthma (sex interaction);
TGCT	cis	rs1971762	0.523	rs7135101	chr12:54080605	G/A	cg16917193	chr12:54089295	NA	1.39	17.73	0.85	8.5000000000000007e-36	Height;
TGCT	cis	rs72781680	1.000	rs7578969	chr2:24168620	T/C	cg08917208	chr2:24149416	ATAD2B	0.73	4.51	0.38	1.48e-5	Lymphocyte counts;
TGCT	cis	rs9318086	0.712	rs3794339	chr13:24434065	A/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.79	8.29	0.6	1.6e-13	Myopia (pathological);
TGCT	cis	rs713587	0.967	rs10182458	chr2:25150641	A/G	cg01884057	chr2:25150051	NA	0.4	8.22	0.59	2.25e-13	Body mass index in non-asthmatics;
TGCT	cis	rs2180341	0.814	rs6940933	chr6:127732740	C/G	cg27446573	chr6:127587934	RNF146	0.87	7.91	0.58	1.21e-12	Breast cancer;
TGCT	cis	rs853679	0.506	rs1150693	chr6:28174590	T/C	cg12963246	chr6:28129442	ZNF389	0.49	4.85	0.4	3.65e-6	Depression;
TGCT	cis	rs4237845	0.837	rs7954591	chr12:58299037	A/G	cg02175503	chr12:58329896	NA	0.52	5.5	0.44	2.09e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs473651	0.935	rs520765	chr2:239354712	C/T	cg08773314	chr2:239334832	ASB1	0.47	8.03	0.58	6.52e-13	Multiple system atrophy;
TGCT	cis	rs858239	0.600	rs6461692	chr7:23139695	G/C	cg05602783	chr7:23145260	KLHL7	-0.62	-5.2	-0.42	7.92e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg08219700	chr8:58056026	NA	0.4	4.78	0.39	4.79e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10504229	1.000	rs79311869	chr8:58195546	T/C	cg24829409	chr8:58192753	C8orf71	-0.55	-4.77	-0.39	5.18e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7613051	0.649	rs6777787	chr3:33057103	A/G	cg19000631	chr3:33138515	GLB1;TMPPE	0.56	4.78	0.39	4.97e-6	Atopic dermatitis;
TGCT	cis	rs7647973	0.593	rs1799844	chr3:49847642	G/A	cg05785598	chr3:49045655	WDR6	-0.44	-5.15	-0.42	9.89e-7	Menarche (age at onset);
TGCT	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg17178900	chr1:205818956	PM20D1	0.61	7.52	0.56	9.65e-12	Menarche (age at onset);
TGCT	cis	rs12220238	0.730	rs10740421	chr10:75941002	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.07	0.54	9.74e-11	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs75059851	1.000	rs73036065	chr11:133830067	G/T	cg14047540	chr11:133829660	NA	-0.52	-5.15	-0.42	1e-6	Schizophrenia;
TGCT	cis	rs7103648	1.000	rs12292911	chr11:47449072	C/T	cg20307385	chr11:47447363	PSMC3	1.05	13.23	0.76	1.9e-25	Diastolic blood pressure;Systolic blood pressure;
TGCT	cis	rs3540	0.597	rs12708583	chr15:91050271	C/T	cg22089800	chr15:90895588	ZNF774	0.74	7.99	0.58	7.81e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg13628971	chr7:2884303	GNA12	0.54	4.64	0.38	8.74e-6	Height;
TGCT	cis	rs10984561	0.881	rs12237206	chr9:122247803	C/G	cg14242995	chr9:122249943	NA	0.75	6.41	0.5	2.7e-9	Pulmonary function decline;
TGCT	cis	rs4988958	0.548	rs6543127	chr2:103028301	A/C	cg03938978	chr2:103052716	IL18RAP	0.27	5.41	0.44	3.17e-7	Asthma (childhood onset);
TGCT	cis	rs13242816	1.000	rs34652384	chr7:116157011	T/C	cg16553024	chr7:116138462	CAV2	-0.45	-5.27	-0.43	5.81e-7	P wave duration;
TGCT	cis	rs7666738	0.830	rs13147768	chr4:98833675	A/T	cg17366294	chr4:99064904	C4orf37	0.72	7.47	0.56	1.23e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg12963246	chr6:28129442	ZNF389	0.52	5.01	0.41	1.85e-6	Depression;
TGCT	cis	rs7267979	0.816	rs390123	chr20:25480105	C/G	cg14121845	chr20:25566513	NINL	0.46	4.76	0.39	5.36e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9467773	0.584	rs1021372	chr6:26632444	T/C	cg05738196	chr6:26577821	NA	0.88	11.22	0.71	1.33e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs7246657	0.722	rs2909098	chr19:38204248	G/A	cg03611452	chr19:38183253	ZNF781	-0.56	-4.63	-0.38	8.97e-6	Coronary artery calcification;
TGCT	cis	rs12497850	0.931	rs10780033	chr3:48891275	T/C	cg18654377	chr3:49208889	KLHDC8B	-0.41	-5.49	-0.44	2.15e-7	Parkinson's disease;
TGCT	cis	rs6964587	1.000	rs4265	chr7:91719608	A/G	cg22709100	chr7:91322751	NA	-0.28	-4.8	-0.4	4.43e-6	Breast cancer;
TGCT	cis	rs9486719	1.000	rs3798295	chr6:97052164	C/T	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.32	-0.6	1.32e-13	Migraine;Coronary artery disease;
TGCT	cis	rs231513	0.681	rs75086002	chr17:42021918	C/T	cg26893861	chr17:41843967	DUSP3	0.71	4.44	0.37	1.97e-5	Cognitive function;
TGCT	cis	rs12950390	0.853	rs8078052	chr17:45859434	A/G	cg06532163	chr17:45867833	NA	0.37	5.96	0.47	2.45e-8	IgG glycosylation;
TGCT	cis	rs2354432	0.607	rs6677679	chr1:146803630	C/T	cg25205988	chr1:146714368	CHD1L	-1.41	-5.83	-0.46	4.57e-8	Mitochondrial DNA levels;
TGCT	cis	rs78487399	0.808	rs7575024	chr2:43666991	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.42	-4.83	-0.4	3.99e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs7178424	0.875	rs28411984	chr15:62221592	A/C	cg00456672	chr15:62358751	C2CD4A	0.31	4.5	0.37	1.57e-5	Height;
TGCT	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg08736216	chr1:53307985	ZYG11A	-0.31	-6.42	-0.5	2.63e-9	Monocyte count;
TGCT	cis	rs1322512	0.959	rs2623985	chr6:152948748	T/C	cg03415253	chr6:152958462	SYNE1	-0.56	-4.91	-0.4	2.8e-6	Tonometry;
TGCT	cis	rs13088281	1.000	rs13088281	chr3:53147576	A/C	cg07884673	chr3:53033167	SFMBT1	-0.6	-6.79	-0.52	4.2e-10	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs7937682	0.632	rs11608193	chr11:111732215	T/C	cg09085632	chr11:111637200	PPP2R1B	0.81	7.14	0.54	6.97e-11	Primary sclerosing cholangitis;
TGCT	cis	rs7769051	0.522	rs11965927	chr6:133101353	T/C	cg07930552	chr6:133119739	C6orf192	1.21	4.81	0.4	4.24e-6	Type 2 diabetes nephropathy;
TGCT	cis	rs12477438	0.520	rs4402818	chr2:99717608	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	16.17	0.82	2.46e-32	Chronic sinus infection;
TGCT	cis	rs904251	0.828	rs1757174	chr6:37486695	G/A	cg01843034	chr6:37503916	NA	-0.52	-6.35	-0.5	3.64e-9	Cognitive performance;
TGCT	cis	rs9325144	0.647	rs870431	chr12:38953073	T/C	cg26384229	chr12:38710491	ALG10B	-0.59	-5.6	-0.45	1.28e-7	Morning vs. evening chronotype;
TGCT	cis	rs2180341	0.814	rs6919082	chr6:127737888	T/G	cg24812749	chr6:127587940	RNF146	0.76	6.23	0.49	6.57e-9	Breast cancer;
TGCT	cis	rs1371867	0.875	rs1660319	chr8:101337530	A/G	cg06636551	chr8:101224915	SPAG1	-0.45	-6.12	-0.48	1.13e-8	Atrioventricular conduction;
TGCT	cis	rs7769051	0.522	rs7738256	chr6:133113066	C/G	cg07930552	chr6:133119739	C6orf192	1.33	5.16	0.42	9.59e-7	Type 2 diabetes nephropathy;
TGCT	cis	rs2456568	0.709	rs1546400	chr11:93639203	G/A	cg16099599	chr11:93583650	C11orf90	0.39	4.75	0.39	5.46e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs2982552	0.815	rs3020349	chr6:152058268	C/A	cg22157087	chr6:152012887	ESR1	0.2	4.89	0.4	3e-6	Bone properties (heel);
TGCT	trans	rs2749592	0.531	rs1208559	chr10:38221370	T/C	cg17830980	chr10:43048298	ZNF37B	0.67	7.08	0.54	9.67e-11	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs6570726	0.599	rs426371	chr6:145886469	A/G	cg23711669	chr6:146136114	FBXO30	-0.71	-6.53	-0.51	1.56e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6988636	1.000	rs62521841	chr8:124194625	G/A	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs13177918	0.629	rs13161261	chr5:149822407	G/A	cg14059543	chr5:149831962	NA	-0.72	-9.49	-0.65	2.17e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs28374715	0.681	rs8037574	chr15:41630770	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.87	-13.45	-0.77	5.4e-26	Ulcerative colitis;
TGCT	cis	rs60871478	0.636	rs4719520	chr7:875216	C/G	cg15782153	chr7:917662	C7orf20	0.52	4.78	0.39	4.84e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs10465746	0.747	rs1952066	chr1:84436456	T/C	cg10977910	chr1:84465055	TTLL7	0.69	7.04	0.53	1.14e-10	Obesity-related traits;
TGCT	cis	rs459571	0.920	rs455073	chr9:136909141	G/C	cg14405625	chr9:136855902	VAV2	-0.3	-4.44	-0.37	1.94e-5	Platelet distribution width;
TGCT	cis	rs9650657	0.769	rs6601527	chr8:10665444	C/A	cg27411982	chr8:10470053	RP1L1	-0.23	-5.32	-0.43	4.63e-7	Neuroticism;
TGCT	cis	rs3008870	1.000	rs3008853	chr1:67385488	C/T	cg11518657	chr1:67396239	MIER1	0.52	4.53	0.38	1.39e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs4805272	0.759	rs1030099	chr19:29343616	C/T	cg15000279	chr19:29285009	NA	0.56	6.38	0.5	3.22e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
TGCT	cis	rs3617	0.625	rs56019197	chr3:52874753	T/C	cg11645453	chr3:52864694	ITIH4	-0.29	-5.58	-0.45	1.41e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2204008	0.748	rs11514352	chr12:38246954	C/T	cg26384229	chr12:38710491	ALG10B	0.86	7.42	0.55	1.6e-11	Bladder cancer;
TGCT	cis	rs4820539	0.966	rs2267000	chr22:23455366	A/G	cg21100191	chr22:23484243	RTDR1	0.93	11.4	0.72	4.8e-21	Bone mineral density;
TGCT	cis	rs7412746	0.658	rs2275235	chr1:150730279	A/G	cg04414720	chr1:150670196	GOLPH3L	0.37	4.63	0.38	9.12e-6	Melanoma;
TGCT	trans	rs3102947	0.929	rs3097276	chr2:8432132	A/G	cg00548009	chr16:12637499	SNX29	0.34	6.68	0.51	7.02e-10	IgE levels;
TGCT	cis	rs13082711	0.595	rs13075389	chr3:27339586	C/T	cg02860705	chr3:27208620	NA	0.48	7.57	0.56	7.46e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs986417	0.748	rs10136486	chr14:60946111	C/T	cg27398547	chr14:60952738	C14orf39	1.39	10.61	0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs950169	0.650	rs12902052	chr15:85125838	A/T	cg11189052	chr15:85197271	WDR73	0.78	6.44	0.5	2.42e-9	Schizophrenia;
TGCT	cis	rs9486719	1.000	rs12208884	chr6:96885572	G/A	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.21	-0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs8067545	0.611	rs8071274	chr17:20216928	T/C	cg13482628	chr17:19912719	NA	-0.52	-4.45	-0.37	1.9e-5	Schizophrenia;
TGCT	cis	rs9858542	0.953	rs9862080	chr3:49674458	A/G	cg03060546	chr3:49711283	APEH	-0.64	-5.7	-0.46	8.18e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs2562456	0.755	rs2562421	chr19:21631304	T/G	cg01304269	chr19:21688519	ZNF429	-0.61	-4.81	-0.4	4.22e-6	Pain;
TGCT	cis	rs3780378	0.967	rs62543876	chr9:5085859	G/C	cg03508284	chr9:4985524	JAK2	-0.48	-4.48	-0.37	1.68e-5	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs3820928	0.839	rs13398103	chr2:227859693	T/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-4.85	-0.4	3.62e-6	Pulmonary function;
TGCT	cis	rs17473412	1.000	rs6880221	chr5:122739993	C/G	cg15125798	chr5:122621645	NA	-0.58	-5.14	-0.42	1.05e-6	Total body bone mineral density;
TGCT	cis	rs3780378	0.875	rs4372063	chr9:5003338	C/T	cg02405213	chr9:5042618	JAK2	-0.54	-6.68	-0.51	7.22e-10	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs10875746	0.669	rs17122812	chr12:48597053	A/G	cg20731937	chr12:48336164	NA	0.59	4.49	0.37	1.61e-5	Longevity (90 years and older);
TGCT	cis	rs7831492	0.564	rs7831530	chr8:41614567	G/A	cg17182837	chr8:41585554	ANK1	-0.17	-4.44	-0.37	1.96e-5	Colorectal cancer;
TGCT	cis	rs1018836	0.884	rs2073640	chr8:91594853	A/G	cg16814680	chr8:91681699	NA	-0.85	-9.12	-0.63	1.68e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg18876405	chr7:65276391	NA	0.31	4.76	0.39	5.33e-6	Aortic root size;
TGCT	cis	rs826838	0.967	rs11168299	chr12:38902028	G/T	cg26384229	chr12:38710491	ALG10B	1.01	9.84	0.66	3.01e-17	Heart rate;
TGCT	cis	rs6714710	0.603	rs2044459	chr2:98447004	T/C	cg26665480	chr2:98280029	ACTR1B	0.66	6.27	0.49	5.45e-9	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg10047753	chr17:41438598	NA	0.94	9.08	0.63	2.11e-15	Menopause (age at onset);
TGCT	cis	rs11122272	0.667	rs2244992	chr1:231537220	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-6.5	-0.5	1.77e-9	Hemoglobin concentration;
TGCT	cis	rs9341808	0.718	rs9448886	chr6:80825901	C/T	cg08355045	chr6:80787529	NA	0.32	5.83	0.46	4.48e-8	Sitting height ratio;
TGCT	cis	rs9914988	0.943	rs1035989	chr17:27143810	T/G	cg20469991	chr17:27169893	C17orf63	-0.72	-5.09	-0.42	1.28e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs56804039	0.573	rs11777722	chr8:8415295	T/C	cg14215082	chr8:9055850	NA	0.5	4.9	0.4	2.91e-6	Cervical cancer;
TGCT	cis	rs7772486	0.875	rs1960885	chr6:146325930	G/T	cg23711669	chr6:146136114	FBXO30	0.84	9.12	0.63	1.72e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1107366	0.618	rs1447657	chr3:125929471	A/G	cg01346077	chr3:125931526	NA	0.39	6.38	0.5	3.26e-9	Metabolite levels;
TGCT	trans	rs12339966	0.615	rs73642444	chr9:11337985	A/T	cg03488587	chr11:64876988	C11orf2	0.32	7.0	0.53	1.42e-10	Systolic blood pressure;
TGCT	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs76419734	0.510	rs6820671	chr4:106613821	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.71	4.66	0.39	7.95e-6	Post bronchodilator FEV1;
TGCT	cis	rs4595586	0.525	rs6580891	chr12:39370127	C/T	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs2692947	0.727	rs893173	chr2:96789787	T/C	cg05933789	chr2:97190408	NA	0.15	4.53	0.38	1.37e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs9364220	0.684	rs9355053	chr6:168493061	G/C	cg02770688	chr6:168491649	NA	-0.3	-5.52	-0.44	1.92e-7	Attention deficit hyperactivity disorder (inattention symptoms);Attention deficit hyperactivity disorder (combined symptoms);
TGCT	cis	rs6484504	0.576	rs208090	chr11:31190992	T/C	cg26647111	chr11:31128758	NA	-0.34	-4.63	-0.38	9.09e-6	Red blood cell count;
TGCT	cis	rs8017423	0.967	rs2277517	chr14:90722778	G/A	cg04374321	chr14:90722782	PSMC1	0.76	7.71	0.57	3.59e-12	Mortality in heart failure;
TGCT	cis	rs6952808	0.792	rs35582663	chr7:1948756	G/A	cg22963979	chr7:1858916	MAD1L1	-0.35	-5.43	-0.44	2.9e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs7666738	0.830	rs890470	chr4:98923435	A/C	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg07424592	chr7:64974309	NA	1.31	8.14	0.59	3.55e-13	Diabetic kidney disease;
TGCT	cis	rs7975161	0.520	rs4502051	chr12:104695569	A/T	cg25273343	chr12:104657179	TXNRD1	-0.36	-5.0	-0.41	1.9e-6	Toenail selenium levels;
TGCT	cis	rs7178572	0.539	rs12594346	chr15:77671966	A/T	cg15453836	chr15:77711506	NA	0.43	4.77	0.39	5.1e-6	Type 2 diabetes;
TGCT	cis	rs13394619	0.936	rs9789414	chr2:11724684	A/G	cg07314298	chr2:11723111	GREB1	-0.29	-5.16	-0.42	9.68e-7	Endometriosis;
TGCT	cis	rs2933343	1.000	rs2630252	chr3:128624772	T/C	cg11901034	chr3:128598214	ACAD9	-0.63	-5.13	-0.42	1.08e-6	IgG glycosylation;
TGCT	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg27588902	chr6:42928151	GNMT	-0.49	-5.93	-0.47	2.85e-8	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs548181	0.611	rs2849225	chr11:125415936	A/G	cg03464685	chr11:125439445	EI24	1.65	11.17	0.71	1.79e-20	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs10883723	0.810	rs7912901	chr10:104277440	T/C	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs7226408	0.857	rs72887045	chr18:34481737	G/A	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs1395	0.778	rs72810794	chr2:27401260	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.65	9.03	0.63	2.73e-15	Blood metabolite levels;
TGCT	cis	rs7267979	1.000	rs3002702	chr20:25268920	T/C	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs2688482	0.512	rs1104760	chr3:195517321	G/A	cg17952111	chr19:54960355	LENG8	0.83	6.82	0.52	3.57e-10	Lung disease severity in cystic fibrosis;
TGCT	cis	rs2730260	0.537	rs73169248	chr7:158891742	T/G	cg02078164	chr7:157982224	PTPRN2	0.41	4.58	0.38	1.11e-5	Myopia (pathological);
TGCT	cis	rs2836950	0.501	rs62223052	chr21:40708702	A/C	cg17971929	chr21:40555470	PSMG1	-0.52	-4.51	-0.38	1.46e-5	Menarche (age at onset);
TGCT	cis	rs11696501	0.739	rs6073835	chr20:44286454	C/T	cg11783356	chr20:44313418	WFDC10B	-0.32	-4.55	-0.38	1.29e-5	Brain structure;
TGCT	cis	rs362296	0.590	rs4690081	chr4:3262105	T/G	cg06533319	chr4:3265114	C4orf44	0.24	4.71	0.39	6.61e-6	Parental longevity (mother's age at death);
TGCT	trans	rs6040399	1.000	rs6040398	chr20:11156550	C/T	cg11320084	chr1:185014181	RNF2	0.34	6.65	0.51	8.45e-10	Response to citalopram treatment;
TGCT	cis	rs786425	0.585	rs10744162	chr12:124243707	T/C	cg10461218	chr12:124144432	GTF2H3	0.22	4.67	0.39	7.73e-6	Pubertal anthropometrics;
TGCT	cis	rs6088580	0.634	rs6141465	chr20:32967314	T/C	cg06115741	chr20:33292138	TP53INP2	-0.53	-4.67	-0.39	7.83e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs739401	0.611	rs494427	chr11:3048140	A/G	cg25174290	chr11:3078921	CARS	0.48	4.68	0.39	7.48e-6	Longevity;
TGCT	cis	rs6840360	0.642	rs7666571	chr4:152443273	C/T	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.82e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs4253772	0.591	rs6520010	chr22:46721223	G/A	cg26492175	chr22:47022658	GRAMD4	0.19	4.5	0.37	1.54e-5	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs4722166	0.573	rs35436671	chr7:22775508	G/A	cg13104385	chr7:22767384	IL6	0.22	4.64	0.38	8.6e-6	Lung cancer;
TGCT	cis	rs4629710	0.592	rs11154622	chr6:131547578	C/T	cg12606694	chr6:131520996	AKAP7	0.39	4.63	0.38	9.14e-6	Multiple myeloma (IgH translocation);
TGCT	cis	rs1997103	1.000	rs6958664	chr7:55404958	T/G	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs1475911	1.000	rs2839465	chr21:43511232	C/T	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.23	-4.75	-0.39	5.58e-6	IgG glycosylation;
TGCT	cis	rs7568458	0.591	rs55971080	chr2:85812746	T/C	cg17127132	chr2:85788382	GGCX	0.69	6.25	0.49	5.98e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs9303401	0.659	rs2072316	chr17:56604813	G/T	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs3806843	0.576	rs251368	chr5:140241027	G/T	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	0.41	4.82	0.4	4.07e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs6840360	0.642	rs7698816	chr4:152352972	C/T	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.83e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs453301	0.598	rs1025395	chr8:8836603	G/C	cg15556689	chr8:8085844	FLJ10661	0.78	6.92	0.53	2.12e-10	Joint mobility (Beighton score);
TGCT	cis	rs9911578	1.000	rs999431	chr17:56854441	A/G	cg05425664	chr17:57184151	TRIM37	-0.61	-5.98	-0.47	2.24e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg23302884	chr18:44338147	ST8SIA5	-0.4	-4.66	-0.39	7.96e-6	Personality dimensions;
TGCT	cis	rs10883723	0.810	rs2281879	chr10:104268877	C/G	cg05855489	chr10:104503620	C10orf26	-0.56	-4.8	-0.4	4.57e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs6121246	0.567	rs2811	chr20:30194248	A/G	cg13852791	chr20:30311386	BCL2L1	0.69	4.54	0.38	1.33e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs17767294	0.614	rs41269285	chr6:28194799	T/C	cg08851530	chr6:28072375	NA	1.46	6.76	0.52	4.79e-10	Parkinson's disease;
TGCT	cis	rs10986311	0.802	rs1330811	chr9:127117346	G/A	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.19	4.75	0.39	5.63e-6	Vitiligo;
TGCT	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg18876405	chr7:65276391	NA	0.35	5.2	0.42	7.81e-7	Aortic root size;
TGCT	cis	rs1401999	0.510	rs2293001	chr3:183700211	C/T	cg01324343	chr3:183735012	ABCC5	0.52	5.66	0.45	9.97e-8	Anterior chamber depth;
TGCT	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg06481639	chr22:41940642	POLR3H	-0.71	-6.26	-0.49	5.75e-9	Vitiligo;
TGCT	cis	rs17401966	0.558	rs4846218	chr1:10452040	G/T	cg19773385	chr1:10388646	KIF1B	-0.22	-5.05	-0.41	1.56e-6	Hepatocellular carcinoma;
TGCT	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	4.74	0.39	5.74e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs1153858	1.000	rs67461176	chr15:45676819	C/T	cg14582100	chr15:45693742	SPATA5L1	0.49	5.73	0.46	7.14e-8	Homoarginine levels;
TGCT	cis	rs35160687	0.871	rs2278105	chr2:86466516	A/G	cg17168863	chr2:85470620	TCF7L1	0.27	4.44	0.37	1.99e-5	Night sleep phenotypes;
TGCT	cis	rs68170813	0.521	rs75035695	chr7:106818731	T/C	cg02696742	chr7:106810147	HBP1	-0.7	-6.05	-0.48	1.59e-8	Coronary artery disease;
TGCT	cis	rs35306767	0.807	rs34527494	chr10:935192	T/C	cg26597838	chr10:835615	NA	0.81	12.42	0.74	1.61e-23	Eosinophil percentage of granulocytes;
TGCT	cis	rs651907	0.557	rs17347644	chr3:101547733	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	4.89	0.4	3e-6	Colorectal cancer;
TGCT	cis	rs13191362	1.000	rs35017019	chr6:162982581	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.68	5.79	0.46	5.33e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg03806693	chr22:41940476	POLR3H	-1.13	-13.26	-0.77	1.59e-25	Vitiligo;
TGCT	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg18402987	chr7:1209562	NA	0.78	6.64	0.51	8.96e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs4478858	0.735	rs4949205	chr1:31800579	A/G	cg07478791	chr1:31886160	SERINC2	-0.51	-4.95	-0.41	2.33e-6	Alcohol dependence;
TGCT	cis	rs1129187	0.805	rs1053539	chr6:42903766	T/G	cg17345569	chr6:42928274	GNMT	-0.47	-4.94	-0.41	2.49e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg03188948	chr7:1209495	NA	0.64	5.76	0.46	6.34e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1801251	0.893	rs11687128	chr2:233608901	T/C	cg08000102	chr2:233561755	GIGYF2	0.64	6.56	0.51	1.34e-9	Coronary artery disease;
TGCT	cis	rs2455799	0.559	rs1447652	chr3:15907128	G/C	cg12172478	chr3:16357591	RFTN1	-0.36	-5.3	-0.43	5.07e-7	Mean platelet volume;
TGCT	cis	rs7681440	0.904	rs2301135	chr4:90758389	G/C	cg20003494	chr4:90757398	SNCA	-0.61	-5.78	-0.46	5.59e-8	Dementia with Lewy bodies;
TGCT	cis	rs2050392	0.767	rs10763786	chr10:30693567	G/C	cg18806716	chr10:30721971	MAP3K8	0.67	8.98	0.63	3.71e-15	Inflammatory bowel disease;
TGCT	cis	rs1371867	0.875	rs1125706	chr8:101326739	T/A	cg06002616	chr8:101225028	SPAG1	-0.56	-6.58	-0.51	1.2e-9	Atrioventricular conduction;
TGCT	cis	rs17387100	1.000	rs17387100	chr4:15995125	A/G	cg13480465	chr4:16795757	LDB2	-0.41	-4.66	-0.39	8e-6	Suicide attempts in depression or bipolar disorder;
TGCT	cis	rs28595532	0.920	rs17324821	chr4:119770716	A/G	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	trans	rs783396	0.685	rs3804344	chr6:107087870	G/A	cg27564810	chr2:201635376	AOX2P	0.5	6.61	0.51	1e-9	Stroke;
TGCT	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.65	-6.51	-0.5	1.68e-9	Prostate cancer;
TGCT	trans	rs208520	0.690	rs207740	chr6:66764132	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	11.29	0.71	9.4e-21	Exhaled nitric oxide output;
TGCT	cis	rs7119	0.717	rs12902896	chr15:77809150	G/T	cg27398640	chr15:77910606	LINGO1	0.25	4.59	0.38	1.06e-5	Type 2 diabetes;
TGCT	cis	rs9326248	0.520	rs74830	chr11:117090558	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.58	-5.3	-0.43	5.01e-7	Blood protein levels;
TGCT	cis	rs11122272	0.732	rs2808605	chr1:231540187	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-6.28	-0.49	5.32e-9	Hemoglobin concentration;
TGCT	cis	rs7568458	0.660	rs6722691	chr2:85758352	C/T	cg02493740	chr2:85810744	VAMP5	-0.29	-5.7	-0.46	8.09e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs7659604	1.000	rs28433617	chr4:122664138	C/A	cg19748678	chr4:122722346	EXOSC9	0.57	5.54	0.45	1.69e-7	Type 2 diabetes;
TGCT	cis	rs4836694	0.574	rs3824542	chr9:132936132	C/T	cg05251000	chr9:132935664	FREQ	0.52	5.53	0.44	1.79e-7	Alzheimer's disease (cognitive decline);
TGCT	cis	rs12484776	0.786	rs17323619	chr22:40538717	C/G	cg07138101	chr22:40742427	ADSL	-0.61	-4.69	-0.39	7.22e-6	Uterine fibroids;
TGCT	cis	rs9640161	0.636	rs3735171	chr7:150033882	A/G	cg17279839	chr7:150038598	RARRES2	0.44	4.65	0.39	8.35e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	5.49	0.44	2.21e-7	Alzheimer's disease;
TGCT	cis	rs1997103	0.954	rs6953004	chr7:55411919	G/A	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg08439880	chr3:133502540	NA	-0.29	-5.42	-0.44	2.93e-7	Iron status biomarkers;
TGCT	cis	rs7267979	0.966	rs8123949	chr20:25388133	C/T	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6912958	0.874	rs2103764	chr6:88157392	T/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.63	-6.22	-0.49	7.06e-9	Monocyte percentage of white cells;
TGCT	cis	rs6088580	0.634	rs6120642	chr20:33012531	A/G	cg06115741	chr20:33292138	TP53INP2	0.55	4.82	0.4	4.15e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs453301	0.512	rs2921381	chr8:8895401	T/A	cg15556689	chr8:8085844	FLJ10661	0.78	7.2	0.54	5.07e-11	Joint mobility (Beighton score);
TGCT	cis	rs9303401	0.573	rs34097494	chr17:57171917	C/T	cg25039879	chr17:56429692	SUPT4H1	0.55	4.9	0.4	2.93e-6	Cognitive test performance;
TGCT	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	4.67	0.39	7.7e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs12479064	0.724	rs2305352	chr2:100015124	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.73	-6.44	-0.5	2.42e-9	Chronic sinus infection;
TGCT	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg24060327	chr5:131705240	SLC22A5	-0.76	-8.4	-0.6	8.54e-14	Breast cancer;
TGCT	cis	rs6570726	0.791	rs9399558	chr6:145911730	T/C	cg13319975	chr6:146136371	FBXO30	-0.54	-4.77	-0.39	5.1e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3008870	0.883	rs2755249	chr1:67493662	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.07	11.4	0.72	5.07e-21	Lymphocyte percentage of white cells;
TGCT	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg01416388	chr22:39784598	NA	-0.7	-6.92	-0.53	2.11e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs3096299	0.642	rs12934829	chr16:89523349	T/A	cg08392591	chr16:89556376	ANKRD11	0.6	5.72	0.46	7.47e-8	Multiple myeloma (IgH translocation);
TGCT	cis	rs12188164	1.000	rs56042615	chr5:437667	G/A	cg21144161	chr5:423903	AHRR	0.26	4.94	0.41	2.49e-6	Cystic fibrosis severity;
TGCT	cis	rs6545883	0.868	rs2441381	chr2:61798829	C/T	cg15711740	chr2:61764176	XPO1	-0.6	-5.66	-0.45	1e-7	Tuberculosis;
TGCT	cis	rs67311347	0.868	rs10865895	chr3:40378677	C/T	cg17264618	chr3:40429014	ENTPD3	0.32	4.65	0.39	8.34e-6	Renal cell carcinoma;
TGCT	cis	rs79349575	0.783	rs4399576	chr17:47009835	G/A	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.52	-0.38	1.44e-5	Type 2 diabetes;
TGCT	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg27170947	chr2:26402098	FAM59B	-0.4	-4.63	-0.38	8.93e-6	Gut microbiome composition (summer);
TGCT	cis	rs1519814	0.915	rs10808507	chr8:121166429	G/A	cg22335954	chr8:121166405	COL14A1	-0.32	-4.59	-0.38	1.09e-5	Breast cancer;
TGCT	cis	rs7666738	0.791	rs1967978	chr4:98966152	T/C	cg18180107	chr4:99064573	C4orf37	0.57	5.19	0.42	8.47e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7666738	0.861	rs28821920	chr4:98962743	T/C	cg05340658	chr4:99064831	C4orf37	0.53	5.93	0.47	2.85e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg16006841	chr5:176797999	RGS14	-0.7	-12.16	-0.74	7.1e-23	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs1018836	0.651	rs2339175	chr8:91565805	A/T	cg16814680	chr8:91681699	NA	-0.87	-9.27	-0.64	7.48e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg11644478	chr21:40555479	PSMG1	1.04	10.72	0.69	2.25e-19	Cognitive function;
TGCT	cis	rs651907	0.557	rs7651721	chr3:101393583	C/A	cg12386194	chr3:101231763	SENP7	0.53	5.13	0.42	1.08e-6	Colorectal cancer;
TGCT	cis	rs7552404	1.000	rs2133134	chr1:76179587	G/A	cg03433033	chr1:76189801	ACADM	0.83	9.91	0.66	2.13e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg02953382	chr22:24373134	LOC391322	0.86	10.12	0.67	6.61e-18	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2276314	1.000	rs2298715	chr18:33552425	T/C	cg19628046	chr18:33552617	C18orf21	0.53	4.5	0.37	1.53e-5	Endometriosis;Drug-induced torsades de pointes;
TGCT	cis	rs637571	0.522	rs550435	chr11:65732651	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.6	6.03	0.48	1.75e-8	Eosinophil percentage of white cells;
TGCT	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg13695892	chr22:41940480	POLR3H	-0.91	-9.07	-0.63	2.18e-15	Vitiligo;
TGCT	trans	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg17830980	chr10:43048298	ZNF37B	-0.82	-10.26	-0.68	2.99e-18	Extrinsic epigenetic age acceleration;
TGCT	cis	rs4891159	0.548	rs609487	chr18:74134382	C/G	cg24786174	chr18:74118243	ZNF516	-0.66	-13.52	-0.77	3.66e-26	Longevity;
TGCT	cis	rs2235642	0.691	rs2281235	chr16:1603535	T/C	cg07341220	chr16:1583899	IFT140;TMEM204	-0.29	-4.56	-0.38	1.23e-5	Coronary artery disease;
TGCT	cis	rs6463523	0.898	rs66892628	chr7:759374	T/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.94	11.59	0.72	1.71e-21	Subjective well-being;
TGCT	cis	rs10838634	0.901	rs16938534	chr11:46887384	T/C	cg18332754	chr11:46939436	LRP4	0.89	4.77	0.39	5.13e-6	Schizophrenia;
TGCT	cis	rs7714584	1.000	rs7724036	chr5:150284808	A/G	cg22134413	chr5:150180641	NA	-0.71	-5.67	-0.45	9.7e-8	Crohn's disease;
TGCT	cis	rs11112613	0.762	rs66754070	chr12:105949779	G/A	cg03607813	chr12:105948248	NA	0.52	6.0	0.47	2.03e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	cis	rs617219	0.591	rs1840805	chr5:78565563	T/A	cg05890484	chr5:78407552	BHMT	-0.36	-4.86	-0.4	3.5e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs3812831	0.695	rs7998546	chr13:114939914	C/G	cg08824895	chr13:115047677	UPF3A	0.48	4.75	0.39	5.59e-6	Schizophrenia;
TGCT	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg18876405	chr7:65276391	NA	0.31	4.78	0.39	4.81e-6	Aortic root size;
TGCT	cis	rs1372520	0.684	rs356188	chr4:90691537	T/C	cg01966878	chr4:90757139	SNCA	0.3	4.82	0.4	4.11e-6	Neuroticism;
TGCT	cis	rs2204008	0.715	rs11525003	chr12:38332359	G/A	cg26384229	chr12:38710491	ALG10B	0.83	7.27	0.55	3.51e-11	Bladder cancer;
TGCT	cis	rs9467773	0.620	rs2504540	chr6:26641626	A/G	cg26531700	chr6:26746687	NA	0.51	4.71	0.39	6.4e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9467711	1.000	rs6908156	chr6:26322861	C/T	cg03264133	chr6:25882463	NA	-0.82	-4.48	-0.37	1.65e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4851266	1.000	rs4851264	chr2:100810188	T/C	cg07810366	chr2:100720526	AFF3	-0.39	-5.62	-0.45	1.2e-7	Educational attainment;
TGCT	cis	rs3091242	0.933	rs61775167	chr1:25780893	A/G	cg23205692	chr1:25664452	TMEM50A	-0.47	-4.97	-0.41	2.22e-6	Erythrocyte sedimentation rate;
TGCT	cis	rs74233809	1.000	rs10883832	chr10:104871279	T/G	cg05855489	chr10:104503620	C10orf26	0.84	4.47	0.37	1.71e-5	Birth weight;
TGCT	cis	rs13256369	1.000	rs13282915	chr8:8570891	T/G	cg06671706	chr8:8559999	CLDN23	0.34	4.57	0.38	1.18e-5	Obesity-related traits;
TGCT	cis	rs4891159	0.526	rs2848961	chr18:74129886	C/G	cg24786174	chr18:74118243	ZNF516	-0.67	-12.97	-0.76	7.68e-25	Longevity;
TGCT	cis	rs11190604	0.767	rs10883481	chr10:102165021	G/A	cg16342193	chr10:102329863	NA	-0.4	-5.06	-0.41	1.5e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9611565	0.722	rs202635	chr22:41809637	C/T	cg06481639	chr22:41940642	POLR3H	0.6	5.48	0.44	2.23e-7	Vitiligo;
TGCT	cis	rs1362404	0.648	rs4784888	chr16:51969082	C/T	cg03955530	chr16:52681474	NA	0.29	4.64	0.38	8.61e-6	Gut microbiota (bacterial taxa);
TGCT	cis	rs2439831	0.850	rs56909447	chr15:44137618	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	6.2	0.49	7.73e-9	Lung cancer in ever smokers;
TGCT	cis	rs78487399	0.808	rs6761129	chr2:43735713	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.53	-0.44	1.79e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs858239	0.899	rs1881203	chr7:23292808	T/C	cg05602783	chr7:23145260	KLHL7	-0.6	-4.77	-0.39	5.09e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs13242816	1.000	rs3807987	chr7:116179834	G/A	cg02799643	chr7:116139180	CAV2	-0.43	-5.29	-0.43	5.24e-7	P wave duration;
TGCT	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg01448562	chr3:133502909	NA	-0.26	-5.06	-0.41	1.49e-6	Iron status biomarkers;
TGCT	cis	rs9818758	0.607	rs73084135	chr3:49272218	A/G	cg00383909	chr3:49044727	WDR6	1.31	6.76	0.52	4.72e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs6831352	0.918	rs29001195	chr4:100054244	G/T	cg12011299	chr4:100065546	ADH4	-0.4	-4.88	-0.4	3.26e-6	Alcohol dependence;
TGCT	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.85	7.0	0.53	1.44e-10	Platelet count;
TGCT	cis	rs72634258	0.554	rs34305100	chr1:7913029	A/G	cg26816564	chr1:7831052	VAMP3	0.64	4.88	0.4	3.16e-6	Inflammatory bowel disease;
TGCT	cis	rs3008870	0.755	rs2815363	chr1:67497221	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.8	-8.48	-0.61	5.61e-14	Lymphocyte percentage of white cells;
TGCT	cis	rs11175492	0.528	rs11175479	chr12:65027421	A/G	cg18624581	chr12:65153313	GNS	-0.85	-4.64	-0.38	8.76e-6	Platelet count;
TGCT	cis	rs3733585	0.648	rs67820465	chr4:9975873	A/G	cg00071950	chr4:10020882	SLC2A9	-0.57	-6.62	-0.51	9.8e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	trans	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg23505145	chr19:12996616	KLF1	0.8	8.19	0.59	2.76e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs986417	1.000	rs1254265	chr14:60840478	T/C	cg27398547	chr14:60952738	C14orf39	-1.36	-8.75	-0.62	1.28e-14	Gut microbiota (bacterial taxa);
TGCT	cis	rs55823223	0.646	rs55868394	chr17:73851113	C/A	cg10935138	chr17:73851978	WBP2	1.01	6.59	0.51	1.12e-9	Psoriasis;
TGCT	cis	rs1552244	0.554	rs3732965	chr3:10048760	A/C	cg00149659	chr3:10157352	C3orf10	0.69	4.99	0.41	2.03e-6	Alzheimer's disease;
TGCT	cis	rs10992471	0.603	rs10116813	chr9:95090360	C/T	cg14631576	chr9:95140430	CENPP	-0.32	-4.71	-0.39	6.43e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs860554	0.921	rs1779300	chr1:201261666	G/A	cg01022117	chr1:201258280	PKP1	0.33	5.26	0.43	6.12e-7	Panic disorder;
TGCT	cis	rs7178572	0.568	rs12908262	chr15:77493256	G/A	cg22256960	chr15:77711686	NA	-0.88	-8.99	-0.63	3.53e-15	Type 2 diabetes;
TGCT	cis	rs36051895	0.632	rs62543560	chr9:5175938	C/T	cg02405213	chr9:5042618	JAK2	-0.71	-9.57	-0.65	1.42e-16	Pediatric autoimmune diseases;
TGCT	cis	rs4746818	0.579	rs118014923	chr10:70932108	T/C	cg11621586	chr10:70884670	VPS26A	-1.23	-5.0	-0.41	1.94e-6	Left atrial antero-posterior diameter;
TGCT	cis	rs11031096	0.542	rs10835337	chr11:3958828	A/G	cg18678763	chr11:4115507	RRM1	0.42	5.14	0.42	1.05e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs7959452	0.590	rs11177643	chr12:69785712	T/G	cg14784868	chr12:69753453	YEATS4	0.83	8.96	0.63	4.14e-15	Blood protein levels;
TGCT	cis	rs4253772	0.550	rs6007823	chr22:46706249	C/T	cg24881330	chr22:46731750	TRMU	1.01	5.42	0.44	3.03e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs6504950	0.566	rs7208403	chr17:53046667	C/A	cg19360675	chr17:53046073	COX11;STXBP4	0.56	5.46	0.44	2.48e-7	Breast cancer;
TGCT	trans	rs7819412	0.775	rs11773990	chr8:10935082	T/C	cg15556689	chr8:8085844	FLJ10661	-0.84	-8.16	-0.59	3.12e-13	Triglycerides;
TGCT	cis	rs13392177	0.647	rs10932761	chr2:219064391	T/A	cg00012203	chr2:219082015	ARPC2	-0.81	-8.14	-0.59	3.48e-13	Pyoderma gangrenosum in inflammatory bowel disease;
TGCT	cis	rs11574514	1.000	rs117017165	chr16:67646311	G/A	cg00545966	chr16:67701244	C16orf86;C16orf48	0.72	4.45	0.37	1.87e-5	Crohn's disease;
TGCT	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg17971929	chr21:40555470	PSMG1	-0.96	-9.39	-0.64	3.88e-16	Cognitive function;
TGCT	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg19010396	chr19:19431384	KIAA0892;SF4	0.54	4.47	0.37	1.77e-5	Tonsillectomy;
TGCT	cis	rs2070488	0.965	rs1065800	chr3:38566480	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.83	-8.19	-0.59	2.71e-13	Electrocardiographic conduction measures;
TGCT	cis	rs56104184	0.779	rs17206686	chr19:49356317	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.79	-9.39	-0.64	3.75e-16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs7588654	0.793	rs16859517	chr2:219949184	A/G	cg06736663	chr2:219754761	WNT10A	0.48	4.79	0.39	4.72e-6	Height;
TGCT	cis	rs9291683	0.588	rs13133766	chr4:10019732	C/T	cg02734326	chr4:10020555	SLC2A9	0.38	4.54	0.38	1.34e-5	Bone mineral density;
TGCT	trans	rs7088591	0.702	rs10491208	chr10:59703352	C/G	cg02584432	chr5:138740366	SPATA24	0.71	6.78	0.52	4.3e-10	Blood pressure;
TGCT	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg03060546	chr3:49711283	APEH	0.51	4.91	0.4	2.84e-6	Menarche (age at onset);
TGCT	cis	rs9303401	0.527	rs7224468	chr17:56749943	C/T	cg25039879	chr17:56429692	SUPT4H1	0.53	4.55	0.38	1.25e-5	Cognitive test performance;
TGCT	cis	rs35883536	0.647	rs34195036	chr1:101040429	C/A	cg10298815	chr1:101004474	GPR88	-0.24	-4.51	-0.38	1.47e-5	Monocyte count;
TGCT	cis	rs9796	0.870	rs1001341	chr15:41261491	T/A	cg18705301	chr15:41695430	NDUFAF1	0.43	5.63	0.45	1.13e-7	Menopause (age at onset);
TGCT	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg06481639	chr22:41940642	POLR3H	-0.71	-6.39	-0.5	3.11e-9	Vitiligo;
TGCT	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.38	-5.03	-0.41	1.69e-6	Menarche (age at onset);
TGCT	cis	rs7560180	1	rs7560180	chr2:113965200	A/T	cg27425262	chr2:113953981	PSD4;LOC440839	0.4	4.67	0.39	7.79e-6	Hemoglobin concentration;
TGCT	cis	rs7089973	0.604	rs11196941	chr10:116596258	A/G	cg03647239	chr10:116582469	FAM160B1	0.59	5.74	0.46	6.72e-8	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs9611565	0.694	rs5758411	chr22:42079734	G/A	cg17554472	chr22:41940697	POLR3H	0.47	5.02	0.41	1.72e-6	Vitiligo;
TGCT	cis	rs7666738	0.927	rs6832373	chr4:99051967	A/G	cg18180107	chr4:99064573	C4orf37	0.58	5.24	0.43	6.54e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg06618935	chr21:46677482	NA	-0.32	-4.98	-0.41	2.06e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs17076896	0.786	rs74570351	chr13:19933722	T/C	cg00777926	chr13:20807375	GJB6	-0.37	-4.53	-0.38	1.36e-5	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs13191362	1.000	rs34192365	chr6:163012382	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs2204008	0.665	rs11179830	chr12:38220966	T/C	cg13010199	chr12:38710504	ALG10B	0.58	4.59	0.38	1.08e-5	Bladder cancer;
TGCT	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg21724239	chr8:58056113	NA	0.39	4.59	0.38	1.07e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs10883723	0.810	rs1409311	chr10:104282160	G/A	cg05855489	chr10:104503620	C10orf26	-0.58	-5.06	-0.41	1.47e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg20607798	chr8:58055168	NA	0.49	4.67	0.39	7.56e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg13732083	chr21:47605072	C21orf56	0.35	4.69	0.39	7.17e-6	Testicular germ cell tumor;
TGCT	cis	rs6854137	0.904	rs13124822	chr4:169737712	G/A	cg20607169	chr4:169750834	PALLD	0.21	4.56	0.38	1.23e-5	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs208520	0.909	rs9453672	chr6:66991431	A/G	cg07460842	chr6:66804631	NA	0.74	6.46	0.5	2.11e-9	Exhaled nitric oxide output;
TGCT	cis	rs9633740	0.578	rs11185982	chr10:82305627	C/T	cg01528321	chr10:82214614	TSPAN14	1.09	6.58	0.51	1.19e-9	Post bronchodilator FEV1;
TGCT	cis	rs6752107	0.967	rs2880080	chr2:234154139	G/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.21	4.98	0.41	2.06e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs12477438	0.798	rs1453562	chr2:99615850	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-8.52	-0.61	4.5e-14	Chronic sinus infection;
TGCT	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg11764359	chr7:65958608	NA	0.61	5.53	0.44	1.79e-7	Aortic root size;
TGCT	cis	rs4654899	0.802	rs2290381	chr1:21213271	C/A	cg01072550	chr1:21505969	NA	-0.47	-7.05	-0.53	1.11e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs2153535	0.580	rs6597326	chr6:8482019	A/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs2762353	0.562	rs1165206	chr6:25867566	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.5	4.78	0.39	4.89e-6	Blood metabolite levels;
TGCT	cis	rs10791097	0.694	rs7107595	chr11:130758556	C/T	cg14779329	chr11:130786720	SNX19	0.28	4.95	0.41	2.36e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs6901250	0.851	rs7760125	chr6:117123391	A/C	cg12892004	chr6:117198278	RFX6	0.54	6.6	0.51	1.05e-9	C-reactive protein levels;
TGCT	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg03188948	chr7:1209495	NA	0.7	6.19	0.49	8.06e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2651899	0.902	rs1736522	chr1:3080940	C/G	cg07622451	chr1:3079886	PRDM16	0.25	4.87	0.4	3.36e-6	Migraine;
TGCT	cis	rs8017423	0.934	rs11159952	chr14:90684874	T/C	cg04374321	chr14:90722782	PSMC1	0.77	7.93	0.58	1.12e-12	Mortality in heart failure;
TGCT	cis	rs1008375	1.000	rs4698200	chr4:17657051	G/A	cg16339924	chr4:17578868	LAP3	0.61	5.19	0.42	8.41e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs644799	0.648	rs1255176	chr11:95471465	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.51	5.17	0.42	9.05e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs2050392	0.792	rs684395	chr10:30719112	C/G	cg18806716	chr10:30721971	MAP3K8	-0.48	-5.52	-0.44	1.94e-7	Inflammatory bowel disease;
TGCT	cis	rs2797160	0.547	rs9388442	chr6:125972608	G/C	cg05901451	chr6:126070800	HEY2	-0.63	-5.35	-0.43	4.14e-7	Endometrial cancer;
TGCT	cis	rs4478858	0.698	rs4949204	chr1:31800415	A/G	cg00250761	chr1:31883323	NA	-0.28	-4.96	-0.41	2.32e-6	Alcohol dependence;
TGCT	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg15595755	chr5:1867978	NA	0.45	5.13	0.42	1.08e-6	Cardiovascular disease risk factors;
TGCT	cis	rs377070	0.816	rs309404	chr4:123617741	A/T	cg10495464	chr4:123653540	BBS12;LOC729338	-0.42	-4.72	-0.39	6.35e-6	Mosquito bite size;
TGCT	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg09517075	chr8:22133004	PIWIL2	0.25	4.95	0.41	2.36e-6	Hypertriglyceridemia;
TGCT	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg06028808	chr11:68637592	NA	0.54	7.03	0.53	1.2e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs514406	0.929	rs12145105	chr1:53340564	T/C	cg27535305	chr1:53392650	SCP2	-0.23	-4.6	-0.38	1.03e-5	Monocyte count;
TGCT	cis	rs11264213	0.591	rs274732	chr1:36488199	T/G	cg27506609	chr1:36549197	TEKT2	-0.47	-5.33	-0.43	4.54e-7	Schizophrenia;
TGCT	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.71	5.14	0.42	1.02e-6	Platelet count;
TGCT	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg13395646	chr4:1353034	KIAA1530	-0.38	-4.72	-0.39	6.28e-6	Obesity-related traits;
TGCT	cis	rs11690935	0.843	rs9784070	chr2:172785007	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.89	-7.98	-0.58	8.45e-13	Schizophrenia;
TGCT	cis	rs9427116	0.531	rs35504625	chr1:154599778	C/G	cg17218026	chr1:154582156	ADAR	0.31	7.77	0.57	2.51e-12	Blood protein levels;
TGCT	cis	rs12780845	0.540	rs2295809	chr10:17199871	A/T	cg01003015	chr10:17271136	VIM	-0.52	-4.71	-0.39	6.42e-6	Homocysteine levels;
TGCT	cis	rs55794721	0.543	rs1293260	chr1:25709104	C/G	cg10117171	chr1:25599238	RHD	-0.36	-5.87	-0.47	3.8e-8	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs10927875	0.541	rs1739844	chr1:16343322	T/C	cg22431228	chr1:16359049	CLCNKA	-0.29	-6.07	-0.48	1.42e-8	Dilated cardiomyopathy;
TGCT	cis	rs3812831	0.669	rs382913	chr13:114928255	G/T	cg08824895	chr13:115047677	UPF3A	0.49	4.73	0.39	5.98e-6	Schizophrenia;
TGCT	cis	rs9457247	1.000	rs422094	chr6:167397033	C/G	cg25258033	chr6:167368657	RNASET2	0.18	4.52	0.38	1.42e-5	Crohn's disease;
TGCT	cis	rs3749237	0.595	rs3870338	chr3:49557051	A/G	cg07636037	chr3:49044803	WDR6	0.61	5.79	0.46	5.4e-8	Resting heart rate;
TGCT	cis	rs11252926	0.599	rs11252213	chr10:454694	C/T	cg20256804	chr10:444983	DIP2C	-0.22	-4.73	-0.39	6.02e-6	Psychosis in Alzheimer's disease;
TGCT	cis	rs12477438	0.765	rs6754843	chr2:99680485	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-4.62	-0.38	9.47e-6	Chronic sinus infection;
TGCT	cis	rs12477438	0.798	rs6542848	chr2:99573732	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.7	-6.22	-0.49	7.15e-9	Chronic sinus infection;
TGCT	cis	rs9916302	0.861	rs4795377	chr17:37669056	C/T	cg15445000	chr17:37608096	MED1	0.32	4.66	0.39	8.18e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.54	-5.22	-0.42	7.39e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs34070283	chr4:98893027	A/T	cg18180107	chr4:99064573	C4orf37	0.53	4.84	0.4	3.83e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6964587	0.967	rs6973896	chr7:91778465	A/G	cg17063962	chr7:91808500	NA	0.93	10.08	0.67	8.03e-18	Breast cancer;
TGCT	cis	rs2224391	0.628	rs6913120	chr6:5260505	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-1.03	-6.43	-0.5	2.47e-9	Height;
TGCT	cis	rs6987853	0.933	rs2974339	chr8:42397529	T/C	cg20539142	chr8:42623718	CHRNA6	-0.21	-5.03	-0.41	1.69e-6	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs611744	0.967	rs591792	chr8:109200446	T/C	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs7568458	0.870	rs6757263	chr2:85803542	A/G	cg17127132	chr2:85788382	GGCX	0.72	6.7	0.52	6.53e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs861020	0.630	rs628300	chr1:209998298	C/T	cg05527609	chr1:210001259	C1orf107	0.9	7.9	0.58	1.31e-12	Orofacial clefts;
TGCT	cis	rs739496	0.615	rs1544396	chr12:112062875	C/T	cg10833066	chr12:111807467	FAM109A	-0.35	-5.01	-0.41	1.86e-6	Platelet count;
TGCT	cis	rs9916302	0.904	rs7501488	chr17:37576417	T/G	cg07936489	chr17:37558343	FBXL20	-0.65	-4.98	-0.41	2.11e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7666738	0.830	rs35865860	chr4:98968822	C/T	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7539409	0.651	rs6576953	chr1:84316946	A/G	cg10977910	chr1:84465055	TTLL7	0.88	5.62	0.45	1.19e-7	Alzheimer's disease;
TGCT	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg00149659	chr3:10157352	C3orf10	-0.96	-6.1	-0.48	1.26e-8	Alzheimer's disease;
TGCT	cis	rs2204008	0.682	rs2320517	chr12:38259239	A/T	cg26384229	chr12:38710491	ALG10B	0.86	7.48	0.56	1.17e-11	Bladder cancer;
TGCT	cis	rs6840360	0.554	rs4643789	chr4:152726691	C/T	cg17479576	chr4:152424074	FAM160A1	-0.49	-5.08	-0.42	1.33e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg03517284	chr6:25882590	NA	-0.62	-6.45	-0.5	2.24e-9	Blood metabolite levels;
TGCT	cis	rs7258465	1.000	rs4808134	chr19:18608579	G/A	cg06462663	chr19:18546047	ISYNA1	0.2	4.67	0.39	7.74e-6	Breast cancer;
TGCT	cis	rs7772486	0.875	rs865913	chr6:146308874	C/T	cg23711669	chr6:146136114	FBXO30	0.89	9.5	0.65	2.02e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4253772	0.591	rs6007795	chr22:46686792	C/G	cg24881330	chr22:46731750	TRMU	0.96	6.38	0.5	3.18e-9	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs854765	0.693	rs4924822	chr17:17748013	A/G	cg09796270	chr17:17721594	SREBF1	-0.25	-4.55	-0.38	1.28e-5	Total body bone mineral density;
TGCT	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg19318889	chr4:1322082	MAEA	0.19	4.51	0.38	1.46e-5	Longevity;
TGCT	cis	rs2153535	0.580	rs718502	chr6:8527400	T/C	cg07606381	chr6:8435919	SLC35B3	0.53	4.97	0.41	2.22e-6	Motion sickness;
TGCT	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg25036284	chr2:26402008	FAM59B	-0.57	-4.99	-0.41	1.99e-6	Gut microbiome composition (summer);
TGCT	cis	rs4148883	0.689	rs1311621	chr4:100014018	T/C	cg13256891	chr4:100009986	ADH5	0.42	4.49	0.37	1.64e-5	Alcohol dependence;
TGCT	cis	rs28595532	0.702	rs72670250	chr4:119337134	T/C	cg21605333	chr4:119757512	SEC24D	0.87	5.49	0.44	2.14e-7	Cannabis dependence symptom count;
TGCT	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg17054783	chr10:134559939	INPP5A	0.23	4.64	0.38	8.89e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg08859206	chr1:53392774	SCP2	-0.47	-7.78	-0.57	2.39e-12	Monocyte count;
TGCT	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.5	5.41	0.44	3.18e-7	Lymphocyte counts;
TGCT	cis	rs7824557	0.734	rs2293856	chr8:11177447	C/T	cg21775007	chr8:11205619	TDH	0.55	5.23	0.43	7.01e-7	Retinal vascular caliber;
TGCT	cis	rs4689388	0.889	rs10026334	chr4:6294607	G/A	cg25554036	chr4:6271136	WFS1	0.54	7.37	0.55	2.11e-11	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs12210905	1.000	rs72843643	chr6:27211247	G/C	cg08851530	chr6:28072375	NA	1.05	5.07	0.41	1.42e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs651907	0.557	rs11925001	chr3:101373966	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.91	10.9	0.7	8.24e-20	Colorectal cancer;
TGCT	cis	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg12570787	chr5:219185	SDHA;CCDC127	0.66	4.48	0.37	1.64e-5	Breast cancer;
TGCT	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg11494091	chr17:61959527	GH2	0.55	11.12	0.71	2.32e-20	Prudent dietary pattern;
TGCT	cis	rs593982	1.000	rs118030231	chr11:65501905	G/A	cg08755490	chr11:65554678	OVOL1	-1.48	-10.77	-0.7	1.68e-19	Atopic dermatitis;
TGCT	cis	rs908922	1.000	rs908922	chr1:152454591	C/T	cg20991723	chr1:152506922	NA	0.39	4.91	0.4	2.77e-6	Hair morphology;
TGCT	cis	rs911555	0.723	rs2023395	chr14:103981971	A/G	cg12935359	chr14:103987150	CKB	0.36	4.87	0.4	3.34e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1008375	0.932	rs13109475	chr4:17677565	C/G	cg10189774	chr4:17578691	LAP3	-0.55	-4.75	-0.39	5.62e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2797160	1.000	rs1777195	chr6:126006861	A/C	cg05901451	chr6:126070800	HEY2	0.74	6.11	0.48	1.18e-8	Endometrial cancer;
TGCT	cis	rs35771425	0.619	rs6689078	chr1:211476423	C/G	cg25617285	chr1:211431773	RCOR3	-0.51	-6.06	-0.48	1.5e-8	Educational attainment (years of education);
TGCT	cis	rs9910055	0.502	rs1684662	chr17:42180822	T/A	cg13607699	chr17:42295918	UBTF	-0.59	-4.85	-0.4	3.63e-6	Total body bone mineral density;
TGCT	cis	rs67460515	0.892	rs11710489	chr3:161093332	G/A	cg03342759	chr3:160939853	NMD3	-0.49	-4.92	-0.4	2.74e-6	Parkinson's disease;
TGCT	cis	rs6088580	0.608	rs1205342	chr20:32921842	C/T	cg08999081	chr20:33150536	PIGU	-0.25	-4.85	-0.4	3.66e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.5	-6.61	-0.51	1.02e-9	Alzheimer's disease;
TGCT	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg14851468	chr5:179071604	C5orf60	0.26	5.43	0.44	2.86e-7	Lung cancer;
TGCT	trans	rs877282	0.898	rs11253353	chr10:766862	C/A	cg22713356	chr15:30763199	NA	1.22	9.83	0.66	3.3e-17	Uric acid levels;
TGCT	cis	rs651907	0.514	rs10936744	chr3:101433440	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	4.73	0.39	5.91e-6	Colorectal cancer;
TGCT	cis	rs9914544	0.933	rs11871889	chr17:18771425	T/C	cg26378065	chr17:18585709	ZNF286B	0.52	4.73	0.39	5.94e-6	Educational attainment (years of education);
TGCT	cis	rs12497850	0.627	rs4974078	chr3:49009386	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.33	-4.75	-0.39	5.62e-6	Parkinson's disease;
TGCT	cis	rs2404602	0.655	rs4886507	chr15:77209694	T/C	cg22467129	chr15:76604101	ETFA	-0.5	-5.63	-0.45	1.12e-7	Blood metabolite levels;
TGCT	cis	rs933688	1.000	rs2839728	chr5:90727412	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.89	8.36	0.6	1.08e-13	Smoking behavior;
TGCT	cis	rs644799	0.635	rs10831428	chr11:95508404	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.29	0.6	1.54e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs6088580	0.634	rs6059880	chr20:33088669	G/A	cg08999081	chr20:33150536	PIGU	0.28	5.57	0.45	1.53e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg00814883	chr7:100076585	TSC22D4	-0.92	-9.76	-0.66	4.73e-17	Platelet count;
TGCT	cis	rs514406	0.505	rs6688064	chr1:53165609	C/T	cg08859206	chr1:53392774	SCP2	-0.34	-4.74	-0.39	5.65e-6	Monocyte count;
TGCT	cis	rs459571	0.959	rs2810491	chr9:136923331	C/T	cg14405625	chr9:136855902	VAV2	0.3	4.57	0.38	1.16e-5	Platelet distribution width;
TGCT	cis	rs7255045	0.752	rs11085822	chr19:12985576	A/G	cg23899408	chr19:12877188	HOOK2	-0.61	-5.01	-0.41	1.79e-6	Mean corpuscular volume;
TGCT	cis	rs2933343	0.553	rs71331686	chr3:128711428	T/A	cg11901034	chr3:128598214	ACAD9	-0.57	-5.31	-0.43	4.92e-7	IgG glycosylation;
TGCT	cis	rs2594989	1.000	rs2606756	chr3:11358181	G/A	cg00170343	chr3:11313890	ATG7	0.66	4.87	0.4	3.39e-6	Circulating chemerin levels;
TGCT	cis	rs10892173	0.765	rs7125694	chr11:117670657	C/T	cg07621104	chr11:117668040	DSCAML1	0.49	5.16	0.42	9.7e-7	Myopia;
TGCT	cis	rs10089	1.000	rs3805606	chr5:127470813	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.77	-7.48	-0.56	1.19e-11	Ileal carcinoids;
TGCT	cis	rs3820928	1.000	rs12615988	chr2:227769000	A/G	cg11843606	chr2:227700838	RHBDD1	-0.51	-4.5	-0.37	1.52e-5	Pulmonary function;
TGCT	cis	rs13256369	0.901	rs12681327	chr8:8566414	G/T	cg17143192	chr8:8559678	CLDN23	0.58	5.55	0.45	1.64e-7	Obesity-related traits;
TGCT	cis	rs7655441	0.964	rs4690132	chr4:80908043	G/C	cg02241357	chr4:80885279	ANTXR2	-0.24	-4.59	-0.38	1.07e-5	Neutrophil percentage of white cells;
TGCT	cis	rs3781663	0.963	rs3781662	chr11:69999501	A/G	cg06393558	chr11:69982916	ANO1	-0.28	-4.45	-0.37	1.86e-5	Survival in rectal cancer;
TGCT	cis	rs8051431	0.876	rs7192750	chr16:72014782	T/C	cg06353428	chr16:71660113	MARVELD3	0.58	4.9	0.4	2.98e-6	LDL cholesterol levels;
TGCT	cis	rs10206020	0.885	rs13388254	chr2:1577209	A/G	cg01028140	chr2:1542097	TPO	-0.28	-4.51	-0.38	1.47e-5	IgG glycosylation;
TGCT	cis	rs1153858	1.000	rs1145091	chr15:45649996	A/G	cg14582100	chr15:45693742	SPATA5L1	0.48	5.69	0.46	8.56e-8	Homoarginine levels;
TGCT	cis	rs7677751	0.806	rs7679903	chr4:55097373	T/C	cg17187183	chr4:55093834	PDGFRA	0.55	7.06	0.54	1.05e-10	Corneal astigmatism;
TGCT	cis	rs2439831	0.681	rs478104	chr15:43594900	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.0	8.18	0.59	2.93e-13	Lung cancer in ever smokers;
TGCT	cis	rs2663905	0.706	rs2683260	chr15:81385552	A/C	cg18837035	chr15:81426597	C15orf26	-0.79	-6.72	-0.52	6e-10	QT interval (drug interaction);
TGCT	cis	rs2456568	0.802	rs1506656	chr11:93639813	G/A	cg26875233	chr11:93583750	C11orf90	-0.48	-6.35	-0.5	3.75e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7772486	0.754	rs12199362	chr6:146118225	A/G	cg05347473	chr6:146136440	FBXO30	0.53	4.99	0.41	2.02e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7772486	0.902	rs2777480	chr6:146309983	T/A	cg05347473	chr6:146136440	FBXO30	0.54	5.15	0.42	9.88e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs68170813	0.599	rs6466162	chr7:106902625	C/T	cg02696742	chr7:106810147	HBP1	-0.69	-5.61	-0.45	1.27e-7	Coronary artery disease;
TGCT	cis	rs1008375	0.931	rs10939734	chr4:17570709	C/T	cg16339924	chr4:17578868	LAP3	0.82	7.13	0.54	7.32e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4808199	0.948	rs7259434	chr19:19428805	A/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.64	4.75	0.39	5.58e-6	Nonalcoholic fatty liver disease;
TGCT	cis	rs3127573	0.843	rs3798156	chr6:160676216	C/T	cg20707008	chr6:160210612	MRPL18;TCP1	0.84	4.58	0.38	1.1e-5	Creatinine levels;
TGCT	cis	rs1105881	0.541	rs2277536	chr15:41857303	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.22	-5.46	-0.44	2.5e-7	Educational attainment;
TGCT	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg11494091	chr17:61959527	GH2	0.6	14.54	0.79	1.46e-28	Prudent dietary pattern;
TGCT	cis	rs2840044	0.534	rs2124246	chr17:33885431	G/A	cg05299278	chr17:33885742	SLFN14	0.22	4.92	0.4	2.7e-6	Response to radiotherapy in cancer (late toxicity);
TGCT	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg11764359	chr7:65958608	NA	0.59	5.28	0.43	5.53e-7	Aortic root size;
TGCT	cis	rs3008870	0.920	rs12132532	chr1:67457015	G/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.1	-11.8	-0.73	5.15e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs13188771	0.651	rs10515312	chr5:100906519	G/T	cg18665594	chr5:101119420	NA	0.44	4.47	0.37	1.74e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs67311347	1.000	rs11706148	chr3:40407243	A/C	cg13409248	chr3:40428643	ENTPD3	0.57	4.62	0.38	9.51e-6	Renal cell carcinoma;
TGCT	cis	rs4891159	0.790	rs660029	chr18:74149668	A/G	cg24786174	chr18:74118243	ZNF516	0.57	8.54	0.61	4.12e-14	Longevity;
TGCT	cis	rs9611565	0.592	rs12484254	chr22:41962003	T/A	cg03806693	chr22:41940476	POLR3H	-1.08	-11.36	-0.71	6.34e-21	Vitiligo;
TGCT	cis	rs7528419	0.927	rs660240	chr1:109817838	T/C	cg00908766	chr1:109817496	CELSR2	0.53	5.37	0.43	3.78e-7	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
TGCT	cis	rs7246657	0.943	rs4803347	chr19:37848017	G/A	cg18154014	chr19:37997991	ZNF793	0.71	5.11	0.42	1.2e-6	Coronary artery calcification;
TGCT	cis	rs7666738	0.830	rs34164616	chr4:99015251	G/A	cg18180107	chr4:99064573	C4orf37	0.54	5.03	0.41	1.7e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2708977	1.000	rs1011040	chr2:97212755	A/G	cg01950434	chr2:97203154	ARID5A	-0.59	-5.62	-0.45	1.19e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs28595532	0.920	rs56322132	chr4:119742496	T/A	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs7681440	0.874	rs7687945	chr4:90764699	C/T	cg26578617	chr4:90757533	SNCA	-0.49	-5.1	-0.42	1.26e-6	Dementia with Lewy bodies;
TGCT	cis	rs2299587	0.698	rs2283113	chr8:17880243	C/A	cg01800426	chr8:17659068	MTUS1	-0.56	-4.77	-0.39	5.17e-6	Economic and political preferences;
TGCT	trans	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg27523141	chr10:43048294	ZNF37B	0.7	8.15	0.59	3.36e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg08219700	chr8:58056026	NA	0.35	4.56	0.38	1.2e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7973719	0.833	rs3825405	chr12:7360143	G/T	cg07052231	chr12:7363540	PEX5	0.37	5.76	0.46	6.19e-8	IgG glycosylation;
TGCT	cis	rs11690935	1.000	rs3795999	chr2:172544483	A/G	cg13550731	chr2:172543902	DYNC1I2	1.21	13.07	0.76	4.43e-25	Schizophrenia;
TGCT	cis	rs6840360	0.571	rs28608620	chr4:152504791	C/T	cg17479576	chr4:152424074	FAM160A1	-0.73	-7.94	-0.58	1.03e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs6840360	0.533	rs4696297	chr4:152725838	T/G	cg22705602	chr4:152727874	NA	0.33	6.0	0.47	2.01e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9916302	0.904	rs2338797	chr17:37548241	G/A	cg07936489	chr17:37558343	FBXL20	0.64	4.94	0.41	2.46e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg10295955	chr4:187884368	NA	-0.99	-15.24	-0.81	3.38e-30	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs79349575	0.681	rs56080003	chr17:47019049	A/T	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.52	-0.38	1.44e-5	Type 2 diabetes;
TGCT	cis	rs41271951	0.512	rs11204765	chr1:151016757	G/A	cg00666978	chr1:150947442	LASS2	0.89	4.64	0.38	8.54e-6	Blood protein levels;
TGCT	cis	rs546131	1.000	rs546131	chr11:34851760	G/C	cg11058730	chr11:34937778	PDHX;APIP	0.57	5.04	0.41	1.63e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs7829975	0.511	rs2948286	chr8:8130160	A/G	cg06636001	chr8:8085503	FLJ10661	0.73	6.42	0.5	2.67e-9	Mood instability;
TGCT	cis	rs1395	0.744	rs1975384	chr2:27542041	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.62	8.02	0.58	6.76e-13	Blood metabolite levels;
TGCT	cis	rs1670533	1.000	rs11247972	chr4:1060550	A/G	cg20887711	chr4:1340912	KIAA1530	0.65	5.07	0.41	1.38e-6	Recombination rate (females);
TGCT	cis	rs6752107	0.901	rs11679791	chr2:234156536	G/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.2	4.86	0.4	3.44e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg16414030	chr3:133502952	NA	-0.61	-9.62	-0.65	1.03e-16	Iron status biomarkers;
TGCT	cis	rs696279	0.869	rs697509	chr7:16700495	G/A	cg08595592	chr7:16780162	NA	0.25	4.78	0.39	4.77e-6	Mean platelet volume;
TGCT	cis	rs55794721	0.543	rs1293260	chr1:25709104	C/G	cg00786635	chr1:25594202	NA	0.6	6.24	0.49	6.44e-9	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs7772486	0.754	rs4566902	chr6:146244128	A/G	cg05347473	chr6:146136440	FBXO30	-0.51	-4.95	-0.41	2.32e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg22920501	chr2:26401640	FAM59B	0.81	6.36	0.5	3.52e-9	Gut microbiome composition (summer);
TGCT	cis	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg02380750	chr20:61661411	NA	-0.3	-5.21	-0.42	7.68e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1059312	0.966	rs12370194	chr12:129277250	A/T	cg09035930	chr12:129282057	SLC15A4	0.6	11.86	0.73	3.65e-22	Systemic lupus erythematosus;
TGCT	cis	rs6427419	0.725	rs7514301	chr1:158057420	A/T	cg07184316	chr1:157669111	FCRL3	-0.24	-4.51	-0.38	1.5e-5	Obesity-related traits;
TGCT	cis	rs854765	0.575	rs7207821	chr17:17891781	A/G	cg04398451	chr17:18023971	MYO15A	-0.33	-5.3	-0.43	5.16e-7	Total body bone mineral density;
TGCT	cis	rs514406	0.505	rs448788	chr1:53161620	A/G	cg25767906	chr1:53392781	SCP2	0.45	4.84	0.4	3.78e-6	Monocyte count;
TGCT	cis	rs4319547	0.695	rs11058034	chr12:122894936	G/T	cg16389456	chr12:123636548	NA	-0.29	-4.93	-0.41	2.53e-6	Body mass index;
TGCT	cis	rs4953076	0.533	rs10173126	chr2:44446492	T/C	cg00619915	chr2:44497795	NA	-0.23	-5.15	-0.42	9.99e-7	Height;
TGCT	trans	rs629535	0.911	rs688612	chr8:70011887	C/T	cg21567404	chr3:27674614	NA	-0.58	-9.2	-0.64	1.1e-15	Dupuytren's disease;
TGCT	cis	rs1801251	1.000	rs6437074	chr2:233712296	C/T	cg08000102	chr2:233561755	GIGYF2	-0.63	-6.42	-0.5	2.64e-9	Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs7662114	chr4:99019985	A/G	cg17366294	chr4:99064904	C4orf37	0.68	7.04	0.53	1.17e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6684514	0.922	rs12037778	chr1:156284864	A/G	cg20302342	chr1:156215951	PAQR6	0.35	4.74	0.39	5.77e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs11249608	0.548	rs17078991	chr5:178459426	A/C	cg23951258	chr5:178450506	ZNF879	0.44	4.56	0.38	1.23e-5	Pubertal anthropometrics;
TGCT	trans	rs842828	0.710	rs296780	chr2:201239485	C/T	cg01425746	chr11:45671369	CHST1	0.66	6.65	0.51	8.36e-10	Urate levels in lean individuals;
TGCT	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg03517284	chr6:25882590	NA	-0.77	-8.05	-0.59	5.9e-13	Blood metabolite levels;
TGCT	cis	rs9325144	0.647	rs870431	chr12:38953073	T/C	cg10518543	chr12:38710700	ALG10B	-0.49	-4.68	-0.39	7.26e-6	Morning vs. evening chronotype;
TGCT	cis	rs7772486	0.597	rs2485631	chr6:146190077	G/C	cg13319975	chr6:146136371	FBXO30	-0.67	-6.02	-0.48	1.84e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9399137	0.507	rs4896128	chr6:135349756	A/G	cg24558204	chr6:135376177	HBS1L	-0.45	-4.74	-0.39	5.74e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
TGCT	cis	rs112591243	0.570	rs17393980	chr21:47971060	C/T	cg10657630	chr21:48055338	PRMT2	1.03	4.98	0.41	2.1e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs7635838	0.819	rs4684072	chr3:11514860	A/G	cg00170343	chr3:11313890	ATG7	0.69	6.67	0.51	7.44e-10	HDL cholesterol;
TGCT	cis	rs11673344	0.543	rs8108429	chr19:37636776	A/C	cg08039142	chr19:36980659	ZNF566	0.52	4.69	0.39	7.06e-6	Obesity-related traits;
TGCT	cis	rs7681440	0.874	rs1372525	chr4:90776165	G/A	cg20003494	chr4:90757398	SNCA	-0.56	-5.35	-0.43	4.11e-7	Dementia with Lewy bodies;
TGCT	cis	rs6570726	0.791	rs6913727	chr6:145899826	A/G	cg13319975	chr6:146136371	FBXO30	-0.5	-4.51	-0.38	1.48e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs78487399	0.808	rs10168889	chr2:43841717	A/C	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.69	5.06	0.41	1.47e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	trans	rs330048	0.509	rs36111783	chr8:9145588	A/G	cg15556689	chr8:8085844	FLJ10661	0.66	6.64	0.51	8.62e-10	Systemic lupus erythematosus;
TGCT	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.51	-5.96	-0.47	2.38e-8	Longevity;Endometriosis;
TGCT	cis	rs35883536	0.647	rs34195036	chr1:101040429	C/A	cg06223162	chr1:101003688	GPR88	-0.42	-8.0	-0.58	7.5e-13	Monocyte count;
TGCT	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg24531977	chr5:56204891	C5orf35	-0.76	-7.34	-0.55	2.45e-11	Initial pursuit acceleration;
TGCT	cis	rs17376456	0.877	rs28637444	chr5:93495548	C/T	cg21475434	chr5:93447410	FAM172A	0.63	4.63	0.38	8.98e-6	Diabetic retinopathy;
TGCT	cis	rs6992820	0.902	rs13274826	chr8:56764794	G/T	cg06880721	chr8:56792545	LYN	-0.68	-5.76	-0.46	6.32e-8	Mean platelet volume;
TGCT	cis	rs9948	0.655	rs62156221	chr2:97410850	A/G	cg01990225	chr2:97406019	LMAN2L	-1.02	-5.19	-0.42	8.43e-7	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs3617	0.625	rs3774364	chr3:52863605	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.52	-0.38	1.4e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7246657	0.550	rs9941475	chr19:38064517	C/T	cg18154014	chr19:37997991	ZNF793	0.69	4.63	0.38	9.25e-6	Coronary artery calcification;
TGCT	cis	rs6700896	0.500	rs4655740	chr1:66084309	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.59	4.56	0.38	1.22e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs7617773	0.539	rs13069884	chr3:48381148	T/A	cg11946769	chr3:48343235	NME6	0.55	4.6	0.38	1.02e-5	Coronary artery disease;
TGCT	trans	rs10435719	0.610	rs76311455	chr8:11790526	C/G	cg15556689	chr8:8085844	FLJ10661	0.75	6.87	0.53	2.77e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs3087591	0.960	rs9303642	chr17:29578360	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.48	-7.56	-0.56	7.74e-12	Hip circumference;
TGCT	cis	rs933688	1.000	rs1363839	chr5:90671274	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.06	10.12	0.67	6.38e-18	Smoking behavior;
TGCT	cis	rs854765	0.583	rs8078583	chr17:17811465	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.76	7.95	0.58	1.01e-12	Total body bone mineral density;
TGCT	cis	rs9611565	0.512	rs132767	chr22:42009520	C/T	cg06634786	chr22:41940651	POLR3H	-0.81	-7.48	-0.56	1.21e-11	Vitiligo;
TGCT	cis	rs1525293	0.646	rs10269409	chr7:70490054	C/T	cg21135135	chr7:70597687	WBSCR17	-0.52	-5.14	-0.42	1.04e-6	Colonoscopy-negative controls vs population controls;Major depressive disorder;
TGCT	cis	rs6484504	0.532	rs7117286	chr11:31283810	T/A	cg26647111	chr11:31128758	NA	-0.35	-4.84	-0.4	3.83e-6	Red blood cell count;
TGCT	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	0.5	4.81	0.4	4.26e-6	Bipolar disorder;
TGCT	cis	rs7677751	0.806	rs1800812	chr4:55094629	G/T	cg17187183	chr4:55093834	PDGFRA	0.55	7.06	0.54	1.05e-10	Corneal astigmatism;
TGCT	cis	rs9583531	0.689	rs9515273	chr13:111383427	G/C	cg24331049	chr13:111365604	ING1	0.87	8.58	0.61	3.25e-14	Coronary artery disease;
TGCT	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg21724239	chr8:58056113	NA	0.4	4.62	0.38	9.57e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2404602	0.647	rs36114653	chr15:77025393	G/A	cg22467129	chr15:76604101	ETFA	0.48	4.77	0.39	5.15e-6	Blood metabolite levels;
TGCT	cis	rs28595532	0.920	rs56283736	chr4:119747268	A/G	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg03709012	chr19:19516395	GATAD2A	0.75	6.16	0.48	9.21e-9	Tonsillectomy;
TGCT	cis	rs6988636	1.000	rs57902736	chr8:124189893	G/A	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs12369635	1.000	rs12369635	chr12:129561356	C/T	cg01909103	chr12:129572610	TMEM132D	-0.64	-4.47	-0.37	1.73e-5	Schizophrenia (inflammation and infection response interaction);
TGCT	cis	rs10927875	0.632	rs7535248	chr1:16129598	C/T	cg21385522	chr1:16154831	NA	-0.96	-15.71	-0.82	2.84e-31	Dilated cardiomyopathy;
TGCT	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg06238570	chr21:40685208	BRWD1	0.82	9.01	0.63	3.07e-15	Cognitive function;
TGCT	cis	rs17102423	0.654	rs8015921	chr14:65523015	G/A	cg11161011	chr14:65562177	MAX	-0.46	-6.17	-0.48	8.9e-9	Obesity-related traits;
TGCT	cis	rs778371	0.834	rs778364	chr2:233777859	A/G	cg08000102	chr2:233561755	GIGYF2	0.49	4.52	0.38	1.44e-5	Schizophrenia;
TGCT	cis	rs4366490	0.534	rs7120661	chr11:62864385	A/G	cg21002970	chr11:62369079	MTA2	0.67	4.7	0.39	6.87e-6	Conotruncal heart defects;
TGCT	cis	rs11577318	0.853	rs17645	chr1:26646730	A/G	cg04990556	chr1:26633338	UBXN11	-0.59	-4.94	-0.41	2.47e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs3935685	0.874	rs34906247	chr15:78004204	A/G	cg03457338	chr15:78040120	NA	-0.21	-5.54	-0.45	1.72e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9443645	0.901	rs9343856	chr6:79678211	G/A	cg05283184	chr6:79620031	NA	-0.21	-4.71	-0.39	6.56e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4849845	0.573	rs33971369	chr2:121024987	A/G	cg24070213	chr2:121070622	NA	0.35	4.8	0.4	4.43e-6	Mean platelet volume;
TGCT	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg04944784	chr2:26401820	FAM59B	-0.68	-6.13	-0.48	1.1e-8	Gut microbiome composition (summer);
TGCT	cis	rs9811920	0.660	rs7619512	chr3:99729132	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.45	5.34	0.43	4.29e-7	Axial length;
TGCT	cis	rs7772486	0.743	rs9376955	chr6:145949404	T/A	cg23711669	chr6:146136114	FBXO30	0.79	8.38	0.6	9.86e-14	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6547741	0.935	rs12714204	chr2:27787540	T/C	cg27432699	chr2:27873401	GPN1	0.18	4.66	0.39	8.09e-6	Oral cavity cancer;
TGCT	cis	rs13190036	1.000	rs13157667	chr5:176613877	C/T	cg18465082	chr5:176734745	MXD3	0.32	4.44	0.37	1.95e-5	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
TGCT	cis	rs2242194	0.844	rs11264295	chr1:154987526	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.26	6.93	0.53	2.02e-10	Schizophrenia;
TGCT	cis	rs6121246	0.954	rs6121245	chr20:30432060	G/A	cg18721089	chr20:30220636	NA	-0.45	-4.98	-0.41	2.12e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg10802521	chr3:52805072	NEK4	-0.78	-10.01	-0.67	1.22e-17	Bipolar disorder;
TGCT	cis	rs11249608	0.600	rs13359570	chr5:178449249	T/G	cg01312482	chr5:178451176	ZNF879	-0.58	-5.77	-0.46	5.94e-8	Pubertal anthropometrics;
TGCT	cis	rs7772486	0.754	rs9399567	chr6:146147295	C/T	cg23711669	chr6:146136114	FBXO30	0.91	10.49	0.69	8.21e-19	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2549003	0.966	rs839	chr5:131819126	C/T	cg02551604	chr5:131831745	NA	-0.89	-11.95	-0.73	2.33e-22	Asthma (sex interaction);
TGCT	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg22166914	chr1:53195759	ZYG11B	-0.46	-8.42	-0.6	7.72e-14	Monocyte count;
TGCT	cis	rs6912958	0.703	rs9362427	chr6:88097634	G/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.4	5.18	0.42	8.73e-7	Monocyte percentage of white cells;
TGCT	cis	rs614226	0.935	rs7137953	chr12:120894685	C/T	cg10072921	chr12:121022843	NA	0.45	4.69	0.39	7.09e-6	Type 1 diabetes nephropathy;
TGCT	cis	rs4851266	1.000	rs893246	chr2:100814917	T/C	cg07810366	chr2:100720526	AFF3	-0.4	-5.75	-0.46	6.53e-8	Educational attainment;
TGCT	cis	rs78487399	0.710	rs17031000	chr2:43758625	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.4	-4.72	-0.39	6.22e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs10193935	0.901	rs12619348	chr2:42625586	C/T	cg27598129	chr2:42591480	NA	-0.35	-5.04	-0.41	1.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7226408	0.948	rs72885224	chr18:34401378	C/T	cg06757138	chr18:34340585	FHOD3	0.26	4.79	0.4	4.62e-6	Obesity-related traits;
TGCT	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg21237687	chr17:6899380	ALOX12	-0.47	-5.19	-0.42	8.42e-7	Tonsillectomy;
TGCT	cis	rs10744422	0.764	rs10773599	chr12:123297419	A/T	cg18912006	chr12:123335444	HIP1R	0.56	4.78	0.39	4.84e-6	Schizophrenia;
TGCT	cis	rs4273100	0.646	rs4924987	chr17:19247075	G/A	cg01534423	chr17:18965556	NA	-0.79	-7.19	-0.54	5.25e-11	Schizophrenia;
TGCT	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs941408	1.000	rs1640271	chr19:2799979	C/T	cg06609049	chr19:2785107	THOP1	0.82	7.73	0.57	3.18e-12	Total cholesterol levels;
TGCT	cis	rs7666738	0.830	rs34273190	chr4:99004568	C/T	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1475911	1.000	rs17114359	chr21:43510437	A/C	cg19766460	chr21:43528205	UMODL1;C21orf128	0.54	7.44	0.56	1.48e-11	IgG glycosylation;
TGCT	cis	rs1008375	1.000	rs10939746	chr4:17684951	A/G	cg10189774	chr4:17578691	LAP3	-0.57	-5.1	-0.42	1.23e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg08280861	chr8:58055591	NA	0.4	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9916302	0.904	rs2303316	chr17:37704217	A/G	cg07936489	chr17:37558343	FBXL20	-0.61	-4.92	-0.4	2.69e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg08048268	chr3:133502702	NA	-0.54	-7.2	-0.54	5.06e-11	Iron status biomarkers;
TGCT	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg00024416	chr22:24240387	NA	-0.24	-4.61	-0.38	9.69e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs911555	0.755	rs1138400	chr14:103956833	A/G	cg12935359	chr14:103987150	CKB	-0.33	-4.59	-0.38	1.07e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs58235267	0.656	rs12713469	chr2:63059927	C/T	cg17519650	chr2:63277830	OTX1	-0.54	-4.97	-0.41	2.2e-6	Prostate-specific antigen levels (conditioned on lead SNPs);
TGCT	cis	rs72781680	0.699	rs72796125	chr2:23919169	C/T	cg08917208	chr2:24149416	ATAD2B	1.0	5.79	0.46	5.41e-8	Lymphocyte counts;
TGCT	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg26668828	chr6:292823	DUSP22	-0.77	-8.12	-0.59	4.02e-13	Menopause (age at onset);
TGCT	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.61	0.38	9.85e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	trans	rs2624839	0.602	rs2526390	chr3:50192760	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.77	6.99	0.53	1.5e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs7542091	0.748	rs2357231	chr1:210028454	A/C	cg06375148	chr1:209958343	C1orf74	-0.25	-4.55	-0.38	1.26e-5	Monobrow;
TGCT	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg11494091	chr17:61959527	GH2	0.6	14.54	0.79	1.46e-28	Prudent dietary pattern;
TGCT	cis	rs9527	0.590	rs726010	chr10:104841977	C/T	cg04362960	chr10:104952993	NT5C2	0.67	5.63	0.45	1.16e-7	Arsenic metabolism;
TGCT	cis	rs9527	0.590	rs763914	chr10:104841587	T/C	cg04362960	chr10:104952993	NT5C2	0.66	5.61	0.45	1.25e-7	Arsenic metabolism;
TGCT	cis	rs1008375	0.932	rs11938710	chr4:17670664	G/C	cg16339924	chr4:17578868	LAP3	-0.59	-4.83	-0.4	3.97e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6060987	1	rs6060987	chr20:30427077	T/A	cg18721089	chr20:30220636	NA	-0.45	-4.98	-0.41	2.12e-6	Mean corpuscular volume;
TGCT	cis	rs478304	0.934	rs1193496	chr11:65537556	C/T	cg27068330	chr11:65405492	SIPA1	-0.76	-7.35	-0.55	2.37e-11	Acne (severe);
TGCT	cis	rs9443645	0.901	rs1572584	chr6:79690290	A/G	cg09184832	chr6:79620586	NA	0.46	4.98	0.41	2.08e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6582630	0.555	rs10785454	chr12:38476260	C/T	cg13010199	chr12:38710504	ALG10B	0.58	4.72	0.39	6.16e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs6570726	0.791	rs4332001	chr6:145934841	T/C	cg23711669	chr6:146136114	FBXO30	0.83	8.67	0.61	2.02e-14	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg10802521	chr3:52805072	NEK4	-0.78	-10.0	-0.67	1.26e-17	Bipolar disorder;
TGCT	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg23758822	chr17:41437982	NA	0.6	6.0	0.47	1.99e-8	Menopause (age at onset);
TGCT	cis	rs72781680	1.000	rs56104215	chr2:24133590	T/C	cg08917208	chr2:24149416	ATAD2B	0.73	4.51	0.38	1.48e-5	Lymphocyte counts;
TGCT	cis	rs11250097	0.549	rs11778177	chr8:11310362	C/T	cg21775007	chr8:11205619	TDH	-0.53	-4.87	-0.4	3.31e-6	Neuroticism;
TGCT	cis	rs904251	1.000	rs904251	chr6:37451696	G/T	cg08126542	chr6:37504118	NA	-0.4	-5.27	-0.43	5.92e-7	Cognitive performance;
TGCT	cis	rs9611565	0.568	rs5758441	chr22:42132888	C/A	cg03806693	chr22:41940476	POLR3H	0.93	9.08	0.63	2.06e-15	Vitiligo;
TGCT	cis	rs79349575	0.783	rs62075852	chr17:47017176	T/C	cg26022315	chr17:47021804	SNF8	0.49	4.9	0.4	2.94e-6	Type 2 diabetes;
TGCT	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg08859206	chr1:53392774	SCP2	-0.43	-6.71	-0.52	6.09e-10	Monocyte count;
TGCT	cis	rs80282103	0.618	rs74117848	chr10:1160974	T/G	cg08668510	chr10:1095578	IDI1	1.06	5.03	0.41	1.7e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs11190604	1.000	rs2495736	chr10:102338410	T/C	cg16342193	chr10:102329863	NA	-0.43	-5.39	-0.44	3.43e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs36051895	0.632	rs10815165	chr9:5149138	T/C	cg02405213	chr9:5042618	JAK2	-0.72	-9.36	-0.64	4.43e-16	Pediatric autoimmune diseases;
TGCT	cis	rs981844	1.000	rs62325085	chr4:154663283	A/G	cg14289246	chr4:154710475	SFRP2	1.01	8.46	0.6	6.31e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs35306767	0.761	rs12359796	chr10:1021479	G/C	cg26597838	chr10:835615	NA	0.58	6.42	0.5	2.64e-9	Eosinophil percentage of granulocytes;
TGCT	cis	rs28595532	0.920	rs116091383	chr4:119635518	A/G	cg11846333	chr4:119757529	SEC24D	0.92	4.59	0.38	1.07e-5	Cannabis dependence symptom count;
TGCT	cis	rs881375	0.678	rs10985102	chr9:123707497	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.44	4.73	0.39	6.09e-6	Rheumatoid arthritis;
TGCT	cis	rs8037137	0.915	rs60290423	chr15:91529452	T/C	cg22570213	chr15:91497863	RCCD1	0.49	4.69	0.39	6.96e-6	Platelet count;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
TGCT	cis	rs4499344	0.730	rs614361	chr19:33106387	C/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	8.74	0.62	1.36e-14	Mean platelet volume;
TGCT	cis	rs8017423	0.967	rs11845329	chr14:90727749	C/T	cg04374321	chr14:90722782	PSMC1	0.78	7.86	0.58	1.59e-12	Mortality in heart failure;
TGCT	cis	rs6429082	0.714	rs704719	chr1:235667170	G/A	cg26050004	chr1:235667680	B3GALNT2	0.6	5.4	0.44	3.32e-7	Adiposity;
TGCT	cis	rs1577917	1.000	rs955227	chr6:86651032	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-5.36	-0.43	3.86e-7	Response to antipsychotic treatment;
TGCT	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg18402987	chr7:1209562	NA	0.88	7.18	0.54	5.54e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs8180040	0.654	rs1466740	chr3:47245883	C/T	cg27129171	chr3:47204927	SETD2	-0.7	-8.35	-0.6	1.13e-13	Colorectal cancer;
TGCT	cis	rs7666738	0.830	rs13112037	chr4:98976986	A/T	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg13615516	chr5:77269221	NA	0.68	8.54	0.61	3.97e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs40363	0.723	rs757269	chr16:3538003	A/G	cg22508957	chr16:3507546	NAT15	-0.51	-4.69	-0.39	7.08e-6	Tuberculosis;
TGCT	cis	rs1008375	0.897	rs6820164	chr4:17630115	G/A	cg16339924	chr4:17578868	LAP3	0.71	5.7	0.46	8.2e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs11098499	0.954	rs10014845	chr4:120301077	T/G	cg09307838	chr4:120376055	NA	0.65	6.39	0.5	3.02e-9	Corneal astigmatism;
TGCT	cis	rs9341808	0.690	rs3805926	chr6:80879280	C/G	cg08355045	chr6:80787529	NA	0.32	5.64	0.45	1.11e-7	Sitting height ratio;
TGCT	cis	rs826838	0.616	rs9668847	chr12:38614669	C/T	cg26384229	chr12:38710491	ALG10B	0.55	5.0	0.41	1.93e-6	Heart rate;
TGCT	cis	rs7666738	0.546	rs13105521	chr4:98734419	C/T	cg17366294	chr4:99064904	C4orf37	0.59	5.57	0.45	1.48e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4699052	0.662	rs1516732	chr4:104251154	A/T	cg16532752	chr4:104119610	CENPE	-0.5	-4.88	-0.4	3.2e-6	Testicular germ cell tumor;
TGCT	cis	rs7208859	0.673	rs9894876	chr17:29182020	G/A	cg18442181	chr17:29233375	C17orf42	-0.78	-4.61	-0.38	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	trans	rs1499614	1.000	rs60326618	chr7:66166358	G/A	cg07424592	chr7:64974309	NA	1.35	8.11	0.59	4.14e-13	Gout;
TGCT	cis	rs4285028	0.948	rs13067270	chr3:121673901	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.77	-6.55	-0.51	1.35e-9	Multiple sclerosis;
TGCT	cis	rs9653442	0.545	rs10496344	chr2:100764125	C/T	cg07810366	chr2:100720526	AFF3	0.37	5.46	0.44	2.45e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs2013441	1.000	rs2189710	chr17:20078964	C/A	cg18979559	chr17:20280153	CCDC144C	-0.44	-4.61	-0.38	9.78e-6	Obesity-related traits;
TGCT	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg06873352	chr17:61820015	STRADA	0.58	6.37	0.5	3.32e-9	Prudent dietary pattern;
TGCT	cis	rs9788682	0.747	rs12910984	chr15:78891627	G/A	cg24631222	chr15:78858424	CHRNA5	-0.83	-6.21	-0.49	7.37e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs9291683	0.525	rs12506455	chr4:10031569	T/A	cg11266682	chr4:10021025	SLC2A9	0.64	8.92	0.63	5e-15	Bone mineral density;
TGCT	cis	rs10791097	0.694	rs2155749	chr11:130751094	G/T	cg12179176	chr11:130786555	SNX19	0.82	10.15	0.67	5.45e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs924607	0.900	rs1697950	chr5:616890	G/A	cg18765565	chr5:669397	TPPP	-0.62	-6.72	-0.52	6e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs7249142	0.562	rs1050544	chr19:19287901	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.48	-4.63	-0.38	9.08e-6	IgG glycosylation;
TGCT	cis	rs2299587	0.637	rs6586677	chr8:17890687	A/G	cg01800426	chr8:17659068	MTUS1	-0.61	-5.17	-0.42	9.09e-7	Economic and political preferences;
TGCT	cis	rs8077889	0.703	rs231531	chr17:41946180	A/C	cg26893861	chr17:41843967	DUSP3	1.04	9.69	0.66	6.95e-17	Triglycerides;
TGCT	cis	rs9814567	0.896	rs6763188	chr3:134349995	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.84	7.7	0.57	3.76e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs3087591	0.708	rs2525569	chr17:29675971	T/A	cg24425628	chr17:29625626	OMG;NF1	0.39	5.52	0.44	1.87e-7	Hip circumference;
TGCT	cis	rs12210905	0.614	rs12199685	chr6:27323486	G/A	cg08851530	chr6:28072375	NA	1.25	5.39	0.44	3.38e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	5.45	0.44	2.66e-7	Height;
TGCT	cis	rs6495122	0.699	rs1378941	chr15:75080150	C/A	cg10253484	chr15:75165896	SCAMP2	-0.68	-6.01	-0.48	1.87e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
TGCT	cis	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg08564027	chr20:61660810	NA	0.37	6.85	0.52	3.1e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs28595532	0.920	rs17324968	chr4:119772316	A/G	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg18305652	chr10:134549665	INPP5A	0.31	5.07	0.41	1.42e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs9948	1.000	rs62152790	chr2:97478579	G/A	cg01990225	chr2:97406019	LMAN2L	-0.83	-4.67	-0.39	7.67e-6	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs6912958	0.514	rs1980792	chr6:87889917	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.44	-0.44	2.74e-7	Monocyte percentage of white cells;
TGCT	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg03709012	chr19:19516395	GATAD2A	0.75	6.16	0.48	9.21e-9	Tonsillectomy;
TGCT	cis	rs6840360	0.533	rs13147021	chr4:152722688	A/C	cg17479576	chr4:152424074	FAM160A1	0.46	4.83	0.4	3.88e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg00024416	chr22:24240387	NA	-0.26	-4.96	-0.41	2.25e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg20637647	chr7:64974828	NA	0.88	5.12	0.42	1.13e-6	Diabetic kidney disease;
TGCT	cis	rs4689388	0.926	rs28420833	chr4:6279504	G/A	cg14416269	chr4:6271139	WFS1	0.38	5.23	0.42	7.12e-7	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs7208859	0.623	rs58089675	chr17:29196764	C/G	cg18442181	chr17:29233375	C17orf42	-0.78	-4.61	-0.38	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg05872129	chr22:39784769	NA	-0.98	-10.82	-0.7	1.27e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs941873	0.803	rs2105461	chr10:81101679	A/G	cg09469691	chr10:81107165	PPIF	-0.57	-5.8	-0.46	5.1e-8	Height;
TGCT	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg00420450	chr8:22132641	PIWIL2	0.23	4.56	0.38	1.19e-5	Hypertriglyceridemia;
TGCT	cis	rs9303401	0.625	rs66508449	chr17:56691034	T/C	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs425277	0.565	rs2480711	chr1:2111376	A/G	cg24578937	chr1:2090814	PRKCZ	0.27	7.01	0.53	1.38e-10	Height;
TGCT	cis	rs2290402	0.536	rs56080039	chr4:886519	G/A	cg11315544	chr4:1222440	CTBP1	0.26	4.46	0.37	1.84e-5	Type 2 diabetes;
TGCT	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	5.53	0.44	1.8e-7	Alzheimer's disease;
TGCT	cis	rs10501293	0.956	rs11037235	chr11:43100381	G/C	cg03447554	chr11:43094025	NA	-0.5	-6.92	-0.53	2.09e-10	Cognitive performance;
TGCT	cis	rs4595586	0.545	rs4254106	chr12:39389342	G/A	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs3858526	0.916	rs11039551	chr11:5930773	C/T	cg13902645	chr11:5959945	NA	-0.44	-4.8	-0.4	4.54e-6	DNA methylation (variation);
TGCT	cis	rs7824557	0.593	rs11774673	chr8:11191537	T/C	cg21775007	chr8:11205619	TDH	0.7	6.86	0.52	2.93e-10	Retinal vascular caliber;
TGCT	cis	rs6835098	1.000	rs1054497	chr4:174089048	A/T	cg08422745	chr4:174089978	GALNT7	0.93	11.26	0.71	1.08e-20	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg20573242	chr4:122745356	CCNA2	0.62	5.48	0.44	2.24e-7	Type 2 diabetes;
TGCT	cis	rs4253772	0.513	rs12171124	chr22:46710693	A/C	cg24881330	chr22:46731750	TRMU	1.04	5.41	0.44	3.12e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs858239	0.601	rs6971002	chr7:23172304	C/G	cg05602783	chr7:23145260	KLHL7	-0.63	-5.24	-0.43	6.57e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs11148252	0.538	rs2897976	chr13:52715944	G/A	cg00495681	chr13:53174319	NA	0.57	5.86	0.47	3.88e-8	Lewy body disease;
TGCT	cis	rs3087591	0.960	rs2940184	chr17:29423119	T/C	cg24425628	chr17:29625626	OMG;NF1	0.47	7.21	0.54	4.89e-11	Hip circumference;
TGCT	cis	rs1670533	1.000	rs34956924	chr4:1047270	T/C	cg20887711	chr4:1340912	KIAA1530	0.72	5.74	0.46	6.72e-8	Recombination rate (females);
TGCT	cis	rs1062177	0.756	rs2964592	chr5:151115688	A/G	cg00977110	chr5:151150581	G3BP1	-0.39	-4.51	-0.38	1.47e-5	Preschool internalizing problems;
TGCT	cis	rs9818758	0.607	rs55873331	chr3:49597055	C/T	cg00383909	chr3:49044727	WDR6	1.31	6.63	0.51	9.3e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs7100689	0.516	rs10887711	chr10:82034842	A/G	cg01528321	chr10:82214614	TSPAN14	0.63	6.15	0.48	9.93e-9	Post bronchodilator FEV1;
TGCT	cis	rs1322512	1.000	rs1407488	chr6:152945777	G/T	cg03415253	chr6:152958462	SYNE1	-0.57	-4.99	-0.41	2e-6	Tonometry;
TGCT	cis	rs9527	0.590	rs7087040	chr10:104799668	G/A	cg04362960	chr10:104952993	NT5C2	0.65	5.59	0.45	1.36e-7	Arsenic metabolism;
TGCT	cis	rs2777491	1.000	rs7177641	chr15:41743426	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.74	-8.89	-0.62	6.08e-15	Ulcerative colitis;
TGCT	cis	rs12893668	0.703	rs34896432	chr14:104027995	C/T	cg26031613	chr14:104095156	KLC1	-0.54	-4.55	-0.38	1.28e-5	Reticulocyte count;
TGCT	cis	rs731174	0.797	rs510208	chr1:38147166	A/G	cg22449745	chr1:38156939	CDCA8;C1orf109	-0.27	-4.56	-0.38	1.22e-5	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1801251	0.727	rs13029336	chr2:233569935	A/G	cg25237894	chr2:233734115	C2orf82	-0.25	-4.71	-0.39	6.51e-6	Coronary artery disease;
TGCT	cis	rs6701037	0.714	rs2285219	chr1:175130983	A/T	cg00321850	chr1:175162397	KIAA0040	-0.42	-5.83	-0.46	4.61e-8	Alcohol dependence;
TGCT	cis	rs10206020	0.885	rs6720923	chr2:1574197	T/C	cg12573674	chr2:1569213	NA	-0.46	-5.2	-0.42	7.88e-7	IgG glycosylation;
TGCT	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg12310025	chr6:25882481	NA	-0.54	-5.47	-0.44	2.39e-7	Blood metabolite levels;
TGCT	cis	rs12540874	0.670	rs3887826	chr7:50544961	G/A	cg18232548	chr7:50535776	DDC	-0.38	-6.7	-0.52	6.66e-10	Systemic sclerosis;
TGCT	cis	rs2274459	0.572	rs116454384	chr6:33646375	C/T	cg00898486	chr6:34006557	GRM4	0.32	4.78	0.39	4.86e-6	Obesity (extreme);
TGCT	cis	rs6138458	0.962	rs6036976	chr20:24901567	T/G	cg26195577	chr20:24973756	C20orf3	-1.2	-12.04	-0.73	1.35e-22	Blood protein levels;
TGCT	cis	rs1949733	0.917	rs10461079	chr4:8392724	G/A	cg13073564	chr4:8508604	NA	0.5	5.43	0.44	2.88e-7	Response to antineoplastic agents;
TGCT	cis	rs1348850	0.634	rs2293471	chr2:178487729	T/G	cg19192590	chr2:178524533	PDE11A	0.5	4.58	0.38	1.1e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs9326248	0.581	rs7120515	chr11:116991926	A/G	cg20608306	chr11:116969690	SIK3	0.39	4.58	0.38	1.12e-5	Blood protein levels;
TGCT	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.53	-6.53	-0.51	1.49e-9	Longevity;Endometriosis;
TGCT	cis	rs1801251	1.000	rs2305137	chr2:233712049	G/A	cg25237894	chr2:233734115	C2orf82	-0.31	-5.42	-0.44	2.98e-7	Coronary artery disease;
TGCT	cis	rs5769765	0.542	rs5770720	chr22:50253101	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.97	6.35	0.5	3.69e-9	Schizophrenia;
TGCT	cis	rs4266144	0.558	rs4680339	chr3:156835419	G/T	cg25506747	chr3:157813810	SHOX2	-0.35	-4.49	-0.37	1.59e-5	Coronary artery disease;
TGCT	cis	rs1018836	0.892	rs1476428	chr8:91555603	G/T	cg16814680	chr8:91681699	NA	-0.74	-7.48	-0.56	1.15e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg20007245	chr22:24372913	LOC391322	-0.72	-7.11	-0.54	8.1e-11	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs10746514	0.833	rs12039526	chr1:232272599	C/T	cg09506761	chr1:232265262	NA	-0.5	-5.09	-0.42	1.28e-6	Response to statin therapy;
TGCT	cis	rs9674544	0.757	rs9896443	chr17:47125982	A/G	cg07075026	chr17:47091521	IGF2BP1	-0.45	-5.28	-0.43	5.68e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
TGCT	cis	rs9611565	0.592	rs57102627	chr22:41987627	T/C	cg06481639	chr22:41940642	POLR3H	-0.62	-5.26	-0.43	6.21e-7	Vitiligo;
TGCT	cis	rs2677744	0.719	rs2002739	chr15:91452106	C/T	cg23684204	chr15:91497937	RCCD1	0.36	5.14	0.42	1.02e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs68170813	0.559	rs2107318	chr7:106845969	A/G	cg02696742	chr7:106810147	HBP1	-0.67	-5.43	-0.44	2.88e-7	Coronary artery disease;
TGCT	cis	rs13082711	0.953	rs35124294	chr3:27539526	A/G	cg02860705	chr3:27208620	NA	0.34	4.64	0.38	8.68e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs2862064	0.872	rs4704734	chr5:156480406	G/A	cg12943317	chr5:156479607	HAVCR1	-0.41	-5.23	-0.43	6.98e-7	Platelet count;
TGCT	cis	rs73198271	0.628	rs11776981	chr8:8589459	C/T	ch.8.214553F	chr8:8189620	PRAGMIN	-0.32	-5.23	-0.42	7.04e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg06238570	chr21:40685208	BRWD1	0.69	6.41	0.5	2.71e-9	Cognitive function;
TGCT	cis	rs6964587	1.000	rs6970277	chr7:91680655	T/C	cg17063962	chr7:91808500	NA	0.88	9.54	0.65	1.69e-16	Breast cancer;
TGCT	cis	rs6540559	0.673	rs6540561	chr1:209982255	C/T	cg23283495	chr1:209979779	IRF6	0.65	5.04	0.41	1.63e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg23262073	chr20:60523788	NA	-0.36	-5.74	-0.46	6.78e-8	Obesity-related traits;
TGCT	cis	rs7223966	1.000	rs7223412	chr17:61808172	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	4.68	0.39	7.5e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg16325326	chr1:53192061	ZYG11B	-0.58	-6.41	-0.5	2.75e-9	Monocyte count;
TGCT	cis	rs6991838	0.593	rs7011464	chr8:66635287	A/T	cg14353373	chr8:66472662	NA	-0.46	-4.63	-0.38	9.25e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs877282	0.945	rs71491303	chr10:772884	G/T	cg17470449	chr10:769945	NA	0.31	4.8	0.4	4.44e-6	Uric acid levels;
TGCT	cis	rs3806843	0.547	rs246048	chr5:140327900	G/A	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2742417	1.000	rs2673037	chr3:45749094	A/T	cg04837898	chr3:45731254	SACM1L	-0.55	-5.72	-0.46	7.45e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs9810089	0.835	rs654237	chr3:136068699	T/C	cg12473912	chr3:136751656	NA	0.35	5.04	0.41	1.59e-6	Gestational age at birth (child effect);
TGCT	cis	rs11249608	0.548	rs2047354	chr5:178455247	T/C	cg21905437	chr5:178450457	ZNF879	0.43	4.5	0.37	1.53e-5	Pubertal anthropometrics;
TGCT	cis	rs8017423	0.967	rs8021881	chr14:90722276	T/C	cg04374321	chr14:90722782	PSMC1	0.76	7.71	0.57	3.59e-12	Mortality in heart failure;
TGCT	cis	rs62244186	0.714	rs2293600	chr3:44599103	G/T	cg15687855	chr3:44754131	ZNF502	0.45	5.36	0.43	3.99e-7	Depressive symptoms;
TGCT	cis	rs12142240	0.698	rs56063031	chr1:46825433	C/T	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs4891159	0.548	rs689902	chr18:74119969	C/T	cg24786174	chr18:74118243	ZNF516	-0.7	-15.58	-0.81	5.53e-31	Longevity;
TGCT	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	14.32	0.79	4.83e-28	Prudent dietary pattern;
TGCT	cis	rs2797160	0.874	rs58305111	chr6:126008386	G/T	cg05901451	chr6:126070800	HEY2	0.75	6.33	0.49	4.14e-9	Endometrial cancer;
TGCT	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg03396347	chr1:1875803	NA	-0.37	-6.68	-0.51	7.07e-10	Body mass index;
TGCT	cis	rs617791	0.508	rs747526	chr11:65776071	C/A	cg09783858	chr11:65769428	EIF1AD;BANF1	0.49	4.49	0.37	1.64e-5	Breast cancer;
TGCT	cis	rs1153858	1.000	rs8032904	chr15:45651309	C/T	cg26924012	chr15:45694286	SPATA5L1	1.09	15.16	0.81	5.15e-30	Homoarginine levels;
TGCT	cis	rs644799	1.000	rs680134	chr11:95559517	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.82	8.63	0.61	2.52e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9926296	0.568	rs417323	chr16:89746277	T/G	cg01097406	chr16:89675127	NA	0.33	5.79	0.46	5.55e-8	Vitiligo;
TGCT	cis	rs1577917	0.958	rs10944144	chr6:86537755	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.46	-0.44	2.47e-7	Response to antipsychotic treatment;
TGCT	cis	rs2439831	0.702	rs7171750	chr15:44025858	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	5.91	0.47	3.05e-8	Lung cancer in ever smokers;
TGCT	cis	rs9467773	0.620	rs6925087	chr6:26592853	T/A	cg11502198	chr6:26597334	ABT1	0.54	4.95	0.41	2.42e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.86	-8.18	-0.59	2.9e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs6088590	0.561	rs3891369	chr20:33161127	C/T	cg08999081	chr20:33150536	PIGU	0.25	4.73	0.39	5.91e-6	Coronary artery disease;
TGCT	cis	rs28374715	0.510	rs28478807	chr15:41558620	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.65	-7.85	-0.58	1.65e-12	Ulcerative colitis;
TGCT	cis	rs910187	0.605	rs6018324	chr20:45810181	G/C	cg27589058	chr20:45804311	EYA2	-0.38	-8.34	-0.6	1.18e-13	Migraine;
TGCT	cis	rs35000415	0.938	rs12539476	chr7:128657483	T/C	cg06242719	chr7:129414860	MIR183;MIR96	-0.31	-4.52	-0.38	1.4e-5	Systemic lupus erythematosus;
TGCT	trans	rs1496653	0.602	rs35314441	chr3:23454217	C/T	cg02770683	chr12:57597238	LRP1	0.38	6.77	0.52	4.52e-10	Type 2 diabetes;
TGCT	cis	rs6589563	0.737	rs11823543	chr11:116649135	G/A	cg20660624	chr11:117307972	DSCAML1	-0.36	-4.7	-0.39	6.66e-6	Eosinophil counts;
TGCT	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.64	5.1	0.42	1.26e-6	Lung function (FEV1/FVC);
TGCT	cis	rs7000551	0.505	rs4872499	chr8:22293306	A/G	cg12081754	chr8:22256438	SLC39A14	-0.39	-5.04	-0.41	1.61e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg04772025	chr11:68637568	NA	0.6	6.7	0.52	6.37e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7727544	0.660	rs2631361	chr5:131707380	C/A	cg24060327	chr5:131705240	SLC22A5	0.62	6.77	0.52	4.69e-10	Blood metabolite levels;
TGCT	cis	rs59104589	0.916	rs62193162	chr2:242268436	T/A	cg21155796	chr2:242212141	HDLBP	0.56	4.77	0.39	5.12e-6	Fibrinogen levels;
TGCT	cis	rs6121246	0.909	rs6058460	chr20:30363071	G/A	cg18721089	chr20:30220636	NA	-0.43	-4.75	-0.39	5.54e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs8062405	1.000	rs7198606	chr16:28875122	T/G	cg09754948	chr16:28834200	ATXN2L	0.59	4.45	0.37	1.91e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg11845111	chr2:191398756	TMEM194B	-0.36	-5.44	-0.44	2.73e-7	Pulse pressure;
TGCT	cis	rs631288	0.557	rs6697092	chr1:146659277	C/G	cg25205988	chr1:146714368	CHD1L	1.34	5.37	0.43	3.79e-7	PR interval in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9993613	0.875	rs1401144	chr4:73506817	G/A	cg15102770	chr4:73434591	ADAMTS3	0.51	4.7	0.39	6.8e-6	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs73001065	0.591	rs57962361	chr19:19425025	C/T	cg03709012	chr19:19516395	GATAD2A	0.87	4.59	0.38	1.09e-5	LDL cholesterol;
TGCT	cis	rs921968	0.643	rs589967	chr2:219445165	T/C	cg02176678	chr2:219576539	TTLL4	0.44	6.33	0.49	4.17e-9	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs752010	0.715	rs4660551	chr1:42099979	T/C	cg06885757	chr1:42089581	HIVEP3	0.28	4.91	0.4	2.79e-6	Lupus nephritis in systemic lupus erythematosus;
TGCT	cis	rs12579753	0.872	rs34415838	chr12:82122078	T/C	cg07988820	chr12:82153109	PPFIA2	-0.67	-7.34	-0.55	2.5e-11	Resting heart rate;
TGCT	cis	rs6746896	1.000	rs6746896	chr2:97410949	C/T	cg26085987	chr2:97230376	NA	-0.18	-4.56	-0.38	1.2e-5	Bipolar disorder;
TGCT	cis	rs57590327	0.503	rs898763	chr3:81513408	T/C	cg07356753	chr3:81810745	GBE1	0.58	4.89	0.4	3.06e-6	Extraversion;
TGCT	cis	rs9325144	0.600	rs7312522	chr12:38730423	A/G	cg26384229	chr12:38710491	ALG10B	0.61	5.58	0.45	1.45e-7	Morning vs. evening chronotype;
TGCT	cis	rs7568458	0.846	rs6738645	chr2:85783128	T/G	cg02493740	chr2:85810744	VAMP5	-0.29	-5.59	-0.45	1.35e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg10819733	chr22:24237672	NA	-0.32	-5.37	-0.43	3.78e-7	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	trans	rs4332037	0.624	rs56256289	chr7:1892529	C/T	cg25206134	chr2:45395956	NA	0.92	7.87	0.58	1.52e-12	Bipolar disorder;
TGCT	cis	rs6938	0.596	rs11630918	chr15:75155896	C/T	cg10253484	chr15:75165896	SCAMP2	-0.61	-5.46	-0.44	2.45e-7	Breast cancer;
TGCT	cis	rs2201728	0.967	rs3749550	chr4:100221503	C/T	cg07219303	chr4:100140905	ADH6	-0.35	-5.14	-0.42	1.04e-6	Cardiac Troponin-T levels;
TGCT	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg11941060	chr3:133502564	NA	0.29	6.25	0.49	6.15e-9	Iron status biomarkers;
TGCT	cis	rs12510870	0.599	rs16849677	chr4:74452188	T/C	cg05868023	chr4:75230803	EREG	-0.55	-4.74	-0.39	5.71e-6	Iris color (b* coordinate);
TGCT	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.54	4.95	0.41	2.35e-6	Prudent dietary pattern;
TGCT	cis	rs6121246	0.697	rs7269866	chr20:30232504	G/A	cg13852791	chr20:30311386	BCL2L1	0.74	4.84	0.4	3.77e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs7666738	0.830	rs957742	chr4:99029409	C/T	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7590720	1.000	rs934154	chr2:216901933	C/T	cg12620499	chr2:216877984	MREG	0.85	8.48	0.61	5.57e-14	Alcohol dependence;
TGCT	cis	rs7727544	0.735	rs272860	chr5:131684175	C/G	cg24060327	chr5:131705240	SLC22A5	-0.56	-6.26	-0.49	5.61e-9	Blood metabolite levels;
TGCT	cis	rs7772486	0.790	rs4280983	chr6:146280790	G/C	cg23711669	chr6:146136114	FBXO30	-0.88	-10.07	-0.67	8.66e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs986417	0.818	rs1955702	chr14:61074301	T/A	cg27398547	chr14:60952738	C14orf39	1.33	9.79	0.66	4e-17	Gut microbiota (bacterial taxa);
TGCT	cis	rs61990749	0.544	rs176979	chr14:78198072	A/C	cg02301378	chr14:78227641	SNW1;C14orf178	0.62	4.58	0.38	1.13e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs6912958	0.677	rs111990232	chr6:88022240	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.53	4.69	0.39	7.17e-6	Monocyte percentage of white cells;
TGCT	cis	rs1577917	0.739	rs2758846	chr6:86349570	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.57	-0.45	1.5e-7	Response to antipsychotic treatment;
TGCT	trans	rs621559	0.636	rs620418	chr1:43671182	A/G	cg19324027	chr2:74699582	MRPL53	0.87	6.75	0.52	5.12e-10	Telomere length;
TGCT	cis	rs9969804	0.846	rs912260	chr9:95493279	C/G	cg13940029	chr9:95239186	CENPP;ASPN	-0.17	-4.48	-0.37	1.67e-5	Height;
TGCT	cis	rs11148252	0.532	rs9536262	chr13:53303074	A/C	cg00495681	chr13:53174319	NA	-0.78	-8.2	-0.59	2.53e-13	Lewy body disease;
TGCT	cis	rs17445774	0.857	rs6435043	chr2:200900974	C/G	cg17644776	chr2:200775616	C2orf69	0.3	4.77	0.39	5.17e-6	LDL cholesterol to HDL cholesterol ratio;
TGCT	cis	rs9393777	0.513	rs1104871	chr6:26665235	T/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.63	-5.84	-0.46	4.22e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs6840360	0.593	rs1877186	chr4:152692418	C/G	cg17479576	chr4:152424074	FAM160A1	-0.53	-5.26	-0.43	5.99e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg05340658	chr4:99064831	C4orf37	0.55	6.07	0.48	1.47e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs67696533	0.957	rs293566	chr20:31097877	T/C	cg25191716	chr20:32077802	CBFA2T2	-0.5	-4.43	-0.37	2.01e-5	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
TGCT	cis	rs362296	0.661	rs3095077	chr4:3265710	A/G	cg06533319	chr4:3265114	C4orf44	-0.25	-5.0	-0.41	1.95e-6	Parental longevity (mother's age at death);
TGCT	cis	rs116095464	0.558	rs56298907	chr5:283280	C/A	cg22857025	chr5:266934	NA	-0.35	-6.87	-0.53	2.7e-10	Breast cancer;
TGCT	cis	rs11754661	1.000	rs78944278	chr6:151207454	C/T	cg11579907	chr6:151412213	MTHFD1L	0.54	4.91	0.4	2.83e-6	Alzheimer's disease (late onset);
TGCT	cis	rs17253792	0.822	rs75437558	chr14:56066798	C/T	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs1629083	0.905	rs17121881	chr11:118081345	A/T	cg16594165	chr11:118135105	MPZL2	-0.33	-4.59	-0.38	1.09e-5	Lung cancer;
TGCT	cis	rs9486719	0.857	rs2971609	chr6:97039665	A/G	cg06623918	chr6:96969491	KIAA0776	-1.04	-10.25	-0.68	3.11e-18	Migraine;Coronary artery disease;
TGCT	cis	rs10504229	0.906	rs2270608	chr8:58194688	T/C	cg21724239	chr8:58056113	NA	0.38	4.7	0.39	6.91e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs3733585	0.726	rs4306953	chr4:9955776	G/A	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.7	-0.52	6.62e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs8084125	0.832	rs62105180	chr18:74951197	C/G	cg07390210	chr18:74961196	GALR1	0.37	4.51	0.38	1.49e-5	Obesity-related traits;
TGCT	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg07870213	chr5:140052090	DND1	0.62	7.4	0.55	1.84e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.51	-4.96	-0.41	2.24e-6	Prudent dietary pattern;
TGCT	cis	rs9291683	0.526	rs7695555	chr4:10001656	T/C	cg00071950	chr4:10020882	SLC2A9	0.68	8.18	0.59	2.85e-13	Bone mineral density;
TGCT	trans	rs7615952	0.800	rs2062773	chr3:125639648	T/C	cg07211511	chr3:129823064	LOC729375	-0.46	-7.9	-0.58	1.26e-12	Blood pressure (smoking interaction);
TGCT	cis	rs1005224	0.654	rs8005753	chr14:76136086	A/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.65	-5.88	-0.47	3.49e-8	Large artery stroke;
TGCT	cis	rs7914558	0.933	rs1538204	chr10:104733893	T/A	cg15744005	chr10:104629667	AS3MT	-0.4	-4.97	-0.41	2.21e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg00343986	chr7:65444356	GUSB	0.26	6.06	0.48	1.48e-8	Aortic root size;
TGCT	cis	rs11673344	0.523	rs2082009	chr19:37530736	T/G	cg08039142	chr19:36980659	ZNF566	0.5	4.65	0.39	8.42e-6	Obesity-related traits;
TGCT	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg04744514	chr10:134541379	INPP5A	0.25	4.49	0.37	1.58e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg11764359	chr7:65958608	NA	-0.55	-4.87	-0.4	3.3e-6	Aortic root size;
TGCT	cis	rs682748	0.782	rs12187273	chr5:17110554	A/G	cg23987134	chr5:17158319	LOC285696	-0.21	-4.9	-0.4	2.87e-6	Hippocampal atrophy;
TGCT	cis	rs26868	1.000	rs26870	chr16:2248229	C/A	cg26873644	chr16:2260806	C16orf79	-0.23	-4.48	-0.37	1.69e-5	Height;
TGCT	cis	rs78487399	0.808	rs7556744	chr2:43672795	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.44	5.24	0.43	6.79e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs6582630	0.574	rs12146797	chr12:38436499	T/C	cg13010199	chr12:38710504	ALG10B	0.59	4.79	0.4	4.67e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs12477438	0.520	rs4851187	chr2:99745860	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.88	-8.83	-0.62	8.54e-15	Chronic sinus infection;
TGCT	cis	rs3733585	0.753	rs12500805	chr4:10017979	C/T	cg11266682	chr4:10021025	SLC2A9	0.72	9.87	0.66	2.54e-17	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs13242816	1.000	rs6968230	chr7:116137049	G/T	cg02799643	chr7:116139180	CAV2	-0.46	-5.92	-0.47	3e-8	P wave duration;
TGCT	cis	rs7267979	0.966	rs2257233	chr20:25265984	A/C	cg03522245	chr20:25566470	NINL	-0.6	-6.31	-0.49	4.42e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs12220898	0.749	rs17009669	chr10:50470109	A/C	cg25968469	chr10:49687287	ARHGAP22	-0.28	-4.51	-0.38	1.51e-5	Inflammatory biomarkers;
TGCT	cis	rs10114408	0.959	rs6415865	chr9:96644692	A/C	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs1865760	0.566	rs2794720	chr6:26087202	G/C	cg16482183	chr6:26056742	HIST1H1C	0.58	4.97	0.41	2.13e-6	Height;
TGCT	cis	rs1008375	0.864	rs4698196	chr4:17574735	T/C	cg16339924	chr4:17578868	LAP3	0.85	7.15	0.54	6.5e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg25767906	chr1:53392781	SCP2	0.47	5.26	0.43	6.03e-7	Monocyte count;
TGCT	cis	rs2070488	0.775	rs13098946	chr3:38517784	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.77	7.53	0.56	9.03e-12	Electrocardiographic conduction measures;
TGCT	cis	rs7822232	0.908	rs4977164	chr8:145144912	T/G	cg06239191	chr8:145163136	KIAA1875	-0.88	-6.45	-0.5	2.26e-9	Blood metabolite levels;
TGCT	cis	rs7020830	0.898	rs308521	chr9:37367094	T/C	cg14294708	chr9:37120828	ZCCHC7	1.06	13.83	0.78	6.89e-27	Schizophrenia;
TGCT	cis	rs7824557	0.569	rs10106207	chr8:11015338	C/T	cg21775007	chr8:11205619	TDH	-0.53	-5.01	-0.41	1.84e-6	Retinal vascular caliber;
TGCT	cis	rs9467773	0.620	rs4368798	chr6:26593471	A/G	cg05738196	chr6:26577821	NA	0.88	11.13	0.71	2.26e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs1903068	0.614	rs9998950	chr4:55996845	C/T	cg01777861	chr4:56023843	NA	0.53	5.81	0.46	4.92e-8	Endometriosis;
TGCT	cis	rs5769765	0.908	rs138864	chr22:50204712	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.06	-10.93	-0.7	6.83e-20	Schizophrenia;
TGCT	cis	rs59698941	0.943	rs67860107	chr5:132276825	G/C	cg27099455	chr5:132201840	GDF9;UQCRQ	0.37	4.47	0.37	1.74e-5	Apolipoprotein A-IV levels;
TGCT	cis	rs17221829	0.673	rs10830334	chr11:89403921	A/G	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.44	-0.37	1.93e-5	Anxiety in major depressive disorder;
TGCT	cis	rs7208859	0.623	rs170051	chr17:28914153	G/A	cg13385521	chr17:29058706	SUZ12P	0.86	5.14	0.42	1.05e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7772486	0.654	rs1011597	chr6:146075672	A/C	cg05347473	chr6:146136440	FBXO30	-0.49	-4.57	-0.38	1.15e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7267979	0.744	rs6050463	chr20:25208990	G/A	cg14121845	chr20:25566513	NINL	0.46	4.67	0.39	7.71e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7267979	0.966	rs2151144	chr20:25414924	G/C	cg16686733	chr20:25566563	NINL	-0.58	-5.86	-0.47	3.93e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3820928	0.874	rs7594505	chr2:227878562	C/G	cg11843606	chr2:227700838	RHBDD1	-0.5	-4.53	-0.38	1.35e-5	Pulmonary function;
TGCT	cis	rs6665290	0.935	rs17600669	chr1:227201871	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.0	-20.66	-0.88	5.7e-42	Myeloid white cell count;
TGCT	cis	rs9388451	0.874	rs9398787	chr6:126090608	A/G	cg05901451	chr6:126070800	HEY2	-1.02	-15.06	-0.8	8.77e-30	Brugada syndrome;
TGCT	cis	rs6121246	0.697	rs8118150	chr20:30436088	G/A	cg13852791	chr20:30311386	BCL2L1	0.84	6.17	0.48	8.77e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs7572733	0.534	rs700680	chr2:198707950	A/T	cg00792783	chr2:198669748	PLCL1	-0.55	-5.12	-0.42	1.13e-6	Dermatomyositis;
TGCT	cis	rs4566357	0.615	rs2272204	chr2:227915601	G/T	cg11843606	chr2:227700838	RHBDD1	-0.55	-5.17	-0.42	8.92e-7	Coronary artery disease;
TGCT	trans	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg17470723	chr8:74884337	TCEB1	0.71	6.77	0.52	4.48e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs929354	0.685	rs1808217	chr7:157002741	T/C	cg05182265	chr7:156933206	UBE3C	-0.39	-8.77	-0.62	1.19e-14	Body mass index;
TGCT	cis	rs35146811	0.844	rs12705070	chr7:99656927	A/G	cg13334819	chr7:99746414	C7orf59	-0.8	-6.87	-0.52	2.81e-10	Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs11944855	chr4:99068258	G/A	cg17366294	chr4:99064904	C4orf37	0.73	7.45	0.56	1.4e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7267979	0.932	rs6132848	chr20:25561645	C/T	cg16686733	chr20:25566563	NINL	0.56	5.69	0.46	8.49e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs981844	1.000	rs55792703	chr4:154668278	C/A	cg14289246	chr4:154710475	SFRP2	1.01	8.67	0.61	2.02e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs7666738	0.830	rs9998582	chr4:98938949	T/C	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg03303774	chr4:1407052	NA	-0.33	-5.06	-0.41	1.46e-6	Obesity-related traits;
TGCT	cis	rs13256369	0.802	rs11249888	chr8:8564934	T/C	cg18904891	chr8:8559673	CLDN23	0.59	5.46	0.44	2.54e-7	Obesity-related traits;
TGCT	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6430585	0.941	rs6708957	chr2:136520043	C/T	cg07169764	chr2:136633963	MCM6	0.89	7.96	0.58	9.17e-13	Corneal structure;
TGCT	cis	rs9921192	0.967	rs233953	chr16:4330570	A/G	cg00021532	chr16:4324280	TFAP4	0.83	9.25	0.64	8.07e-16	Prostate-specific antigen levels;
TGCT	cis	rs9486719	1.000	rs12530462	chr6:97053514	C/T	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.32	-0.6	1.32e-13	Migraine;Coronary artery disease;
TGCT	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg06618935	chr21:46677482	NA	-0.37	-5.81	-0.46	5.06e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs1801251	1.000	rs2044449	chr2:233718808	G/A	cg25237894	chr2:233734115	C2orf82	-0.31	-5.47	-0.44	2.38e-7	Coronary artery disease;
TGCT	cis	rs80282103	0.618	rs74120451	chr10:1126866	T/C	cg18964960	chr10:1102726	WDR37	0.99	4.44	0.37	2.01e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs9467773	0.620	rs2504566	chr6:26660488	G/C	cg05738196	chr6:26577821	NA	0.88	10.63	0.69	3.68e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs362272	0.545	rs2749783	chr4:3326098	A/C	cg06533319	chr4:3265114	C4orf44	-0.26	-5.34	-0.43	4.37e-7	Serum sulfate level;
TGCT	cis	rs67311347	0.544	rs12633295	chr3:40335292	G/T	cg13683864	chr3:40499215	RPL14	0.79	7.54	0.56	8.54e-12	Renal cell carcinoma;
TGCT	cis	rs6964587	1.000	rs2299239	chr7:91654617	C/T	cg17063962	chr7:91808500	NA	0.92	10.19	0.67	4.47e-18	Breast cancer;
TGCT	cis	rs12477438	0.520	rs13009147	chr2:99803998	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	17.43	0.84	3.73e-35	Chronic sinus infection;
TGCT	cis	rs2046867	0.818	rs17010133	chr3:72827987	T/C	cg25664220	chr3:72788482	NA	-0.56	-6.93	-0.53	2.07e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs4862307	0.836	rs6829678	chr4:185001631	C/T	cg06737308	chr4:185021514	ENPP6	-0.35	-5.08	-0.42	1.34e-6	Serum dimethylarginine levels (asymmetric/symetric ratio);
TGCT	cis	rs78456975	1.000	rs6744743	chr2:1558161	C/T	cg01028140	chr2:1542097	TPO	0.32	4.52	0.38	1.41e-5	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs12711979	0.765	rs13028529	chr2:3825467	C/T	cg17052675	chr2:3827356	NA	-0.39	-7.63	-0.57	5.34e-12	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs6969780	0.722	rs4722666	chr7:27197601	C/G	cg04317399	chr7:27170313	HOXA4	-0.44	-4.9	-0.4	2.94e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs7824557	0.591	rs2736282	chr8:11225480	C/T	cg21775007	chr8:11205619	TDH	0.66	6.74	0.52	5.2400000000000005e-10	Retinal vascular caliber;
TGCT	cis	rs9987353	0.544	rs2929469	chr8:9062656	T/G	cg06636001	chr8:8085503	FLJ10661	0.48	4.44	0.37	1.96e-5	Recombination measurement;
TGCT	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg20607798	chr8:58055168	NA	0.49	4.67	0.39	7.56e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs12464483	0.591	rs2602775	chr2:30883012	C/T	cg12454169	chr2:30669597	LCLAT1	0.4	4.68	0.39	7.44e-6	Pre-treatment pain in head and neck squamous cell carcinoma;
TGCT	cis	rs10791323	0.598	rs10750550	chr11:133736083	A/G	cg15485101	chr11:133734466	NA	0.39	5.61	0.45	1.28e-7	Childhood ear infection;
TGCT	cis	rs1568889	0.838	rs7933991	chr11:28059761	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.92	11.21	0.71	1.43e-20	Bipolar disorder;
TGCT	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.65	-6.59	-0.51	1.12e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs1857353	1.000	rs17096887	chr1:75903598	T/C	cg11838876	chr1:75668600	SLC44A5	-0.47	-4.56	-0.38	1.2e-5	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg16423285	chr20:60520624	NA	-0.61	-6.46	-0.5	2.12e-9	Body mass index;
TGCT	cis	rs7914558	1.000	rs10883837	chr10:104896486	G/A	cg04362960	chr10:104952993	NT5C2	0.62	5.55	0.45	1.66e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs67311347	1.000	rs73080165	chr3:40533062	G/T	cg13409248	chr3:40428643	ENTPD3	0.64	4.91	0.4	2.77e-6	Renal cell carcinoma;
TGCT	cis	rs903263	0.965	rs12748859	chr1:84655238	G/A	cg09664975	chr1:84543551	PRKACB	0.48	4.54	0.38	1.31e-5	Breast cancer (male);
TGCT	cis	rs2236918	0.710	rs1776174	chr1:242031839	G/T	cg04158730	chr1:242011433	EXO1	0.56	5.16	0.42	9.55e-7	Menopause (age at onset);
TGCT	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.83	0.4	3.97e-6	Bipolar disorder;
TGCT	cis	rs1008375	1.000	rs10939743	chr4:17662731	G/A	cg18681998	chr4:17616180	MED28	0.93	10.91	0.7	7.68e-20	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1048238	0.506	rs848195	chr1:16286522	A/G	cg22431228	chr1:16359049	CLCNKA	0.23	4.54	0.38	1.33e-5	Systolic blood pressure;
TGCT	cis	rs709400	0.604	rs7158144	chr14:103887615	A/G	cg12935359	chr14:103987150	CKB	-0.36	-5.47	-0.44	2.42e-7	Body mass index;
TGCT	cis	rs10465746	0.967	rs5028806	chr1:84329295	G/A	cg10977910	chr1:84465055	TTLL7	0.63	6.19	0.49	8.08e-9	Obesity-related traits;
TGCT	cis	rs9611565	0.559	rs4822049	chr22:41993496	G/A	cg06634786	chr22:41940651	POLR3H	-0.89	-8.16	-0.59	3.16e-13	Vitiligo;
TGCT	cis	rs4919044	0.808	rs835275	chr10:94796683	T/C	cg05127821	chr10:94822908	CYP26C1	-0.74	-4.83	-0.4	3.95e-6	Coronary artery disease;
TGCT	cis	rs12908161	1.000	rs34900908	chr15:85257599	G/A	cg12863693	chr15:85201151	NMB	0.46	5.51	0.44	1.95e-7	Schizophrenia;
TGCT	cis	rs7666738	0.830	rs1426670	chr4:98923572	A/G	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs798766	1.000	rs798719	chr4:1698183	C/T	cg05874882	chr4:1763078	NA	-0.39	-5.15	-0.42	9.83e-7	Bladder cancer;Urinary bladder cancer;
TGCT	cis	rs7104764	1.000	rs10794302	chr11:234102	T/C	cg18336825	chr11:236787	PSMD13;SIRT3	1.07	11.15	0.71	2.05e-20	Menarche (age at onset);
TGCT	cis	rs10871290	0.881	rs3863439	chr16:74470644	T/C	cg01733217	chr16:74700730	RFWD3	-0.6	-5.66	-0.45	1.02e-7	Breast cancer;
TGCT	cis	rs12908161	0.959	rs61074241	chr15:85333396	C/T	cg12863693	chr15:85201151	NMB	0.38	4.45	0.37	1.9e-5	Schizophrenia;
TGCT	cis	rs301043	0.500	rs301038	chr12:95877796	C/T	cg07805603	chr12:95869602	METAP2	0.41	5.19	0.42	8.35e-7	Immature fraction of reticulocytes;
TGCT	cis	rs7267979	0.586	rs6037057	chr20:25182089	T/C	cg03522245	chr20:25566470	NINL	0.5	5.27	0.43	5.88e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9948	0.655	rs62156228	chr2:97420335	A/G	cg01990225	chr2:97406019	LMAN2L	-1.02	-5.19	-0.42	8.43e-7	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs832540	0.931	rs33318	chr5:56208414	G/T	cg24531977	chr5:56204891	C5orf35	-0.53	-5.49	-0.44	2.15e-7	Coronary artery disease;
TGCT	cis	rs11096990	0.892	rs6815686	chr4:39199791	A/T	ch.4.37949012R	chr4:38272617	NA	-0.38	-4.81	-0.4	4.33e-6	Cognitive function;
TGCT	cis	rs3812049	0.784	rs1560637	chr5:127448066	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	5.87	0.47	3.81e-8	Lymphocyte counts;Red cell distribution width;
TGCT	cis	rs3806843	0.547	rs246010	chr5:140336635	A/T	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs4891159	0.790	rs11872411	chr18:74132051	C/T	cg24786174	chr18:74118243	ZNF516	-0.59	-8.89	-0.62	6.07e-15	Longevity;
TGCT	cis	rs9388451	0.872	rs2008027	chr6:126052359	A/G	cg05901451	chr6:126070800	HEY2	-1.01	-13.73	-0.78	1.17e-26	Brugada syndrome;
TGCT	cis	rs12762955	0.561	rs4880744	chr10:1012026	A/G	cg18964960	chr10:1102726	WDR37	-0.64	-5.66	-0.45	1.01e-7	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs12908161	0.959	rs34028043	chr15:85231585	G/A	cg11189052	chr15:85197271	WDR73	0.75	6.3	0.49	4.8e-9	Schizophrenia;
TGCT	cis	rs6598955	0.543	rs17163720	chr1:26549399	A/G	cg04990556	chr1:26633338	UBXN11	-0.8	-7.3	-0.55	3.01e-11	Obesity-related traits;
TGCT	cis	rs9929218	0.529	rs8060790	chr16:68729112	A/G	cg01251360	chr16:68772225	CDH1	-0.26	-4.87	-0.4	3.33e-6	Colorectal cancer;
TGCT	cis	rs72781680	0.821	rs17045981	chr2:24109316	A/G	cg08917208	chr2:24149416	ATAD2B	0.87	5.33	0.43	4.46e-7	Lymphocyte counts;
TGCT	cis	rs1857353	1.000	rs12405357	chr1:75861616	A/T	cg11838876	chr1:75668600	SLC44A5	-0.47	-4.56	-0.38	1.2e-5	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs7666738	0.518	rs13133925	chr4:98706398	G/T	cg05340658	chr4:99064831	C4orf37	0.52	5.76	0.46	6.27e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7943191	0.805	rs12226821	chr11:62369018	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.55	6.38	0.5	3.12e-9	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg27286337	chr10:134555280	INPP5A	0.39	4.73	0.39	6.02e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg24250549	chr1:154909240	PMVK	0.54	5.08	0.42	1.33e-6	Prostate cancer;
TGCT	cis	rs80282103	0.618	rs74117848	chr10:1160974	T/G	cg18964960	chr10:1102726	WDR37	1.03	4.55	0.38	1.28e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs1030877	0.960	rs3792049	chr2:105901908	A/C	cg02079111	chr2:105885981	TGFBRAP1	-0.18	-5.01	-0.41	1.85e-6	Obesity-related traits;
TGCT	cis	rs4478858	0.709	rs7514640	chr1:31752316	G/A	cg00250761	chr1:31883323	NA	-0.26	-4.55	-0.38	1.28e-5	Alcohol dependence;
TGCT	cis	rs1670533	0.932	rs11731289	chr4:1057773	T/G	cg20887711	chr4:1340912	KIAA1530	0.71	5.7	0.46	8.33e-8	Recombination rate (females);
TGCT	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs4499344	0.730	rs28402742	chr19:33099734	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	8.81	0.62	9.52e-15	Mean platelet volume;
TGCT	cis	rs71597109	0.639	rs4698969	chr4:102725955	A/G	cg14855874	chr4:102712397	BANK1	-0.42	-5.07	-0.41	1.43e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.56	4.56	0.38	1.21e-5	Renal function-related traits (BUN);
TGCT	cis	rs9486719	1.000	rs2499807	chr6:96864053	T/G	cg06623918	chr6:96969491	KIAA0776	1.01	8.86	0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs13191362	1.000	rs13204439	chr6:163015358	A/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.68	-5.79	-0.46	5.33e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs909341	0.537	rs6089971	chr20:62385846	G/A	cg14758556	chr20:62440591	NA	0.4	5.74	0.46	6.9e-8	Atopic dermatitis;
TGCT	cis	rs13082711	0.522	rs537674	chr3:27361901	G/T	cg02860705	chr3:27208620	NA	0.3	4.96	0.41	2.3e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg21862992	chr11:68658383	NA	0.45	6.17	0.48	9.06e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs62244186	0.627	rs12386385	chr3:44457540	A/G	cg02073558	chr3:44770973	ZNF501	0.6	5.79	0.46	5.35e-8	Depressive symptoms;
TGCT	cis	rs7666738	0.830	rs4699577	chr4:98846513	G/A	cg17366294	chr4:99064904	C4orf37	0.72	7.56	0.56	7.78e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7727544	0.716	rs4705926	chr5:131561758	C/T	cg21474247	chr5:131268130	NA	0.32	4.54	0.38	1.32e-5	Blood metabolite levels;
TGCT	cis	rs3008870	0.959	rs2985810	chr1:67376162	T/C	cg03991309	chr1:68237761	GNG12	0.27	4.68	0.39	7.28e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs6964587	0.839	rs6950538	chr7:91417816	T/C	cg17063962	chr7:91808500	NA	0.84	8.25	0.6	1.99e-13	Breast cancer;
TGCT	cis	rs11671005	0.735	rs11878198	chr19:58920302	A/G	cg13877915	chr19:58951672	ZNF132	0.63	4.99	0.41	1.99e-6	Mean platelet volume;
TGCT	cis	rs35146811	0.695	rs1618851	chr7:99810643	T/G	cg22906224	chr7:99728672	NA	-0.49	-4.45	-0.37	1.88e-5	Coronary artery disease;
TGCT	cis	rs11722228	1.000	rs11722228	chr4:9915741	C/T	cg11266682	chr4:10021025	SLC2A9	0.46	5.12	0.42	1.11e-6	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs7666738	0.571	rs7683769	chr4:99091742	T/C	cg18180107	chr4:99064573	C4orf37	0.53	4.75	0.39	5.61e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3806843	0.576	rs246046	chr5:140329264	T/A	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg06873352	chr17:61820015	STRADA	0.55	6.1	0.48	1.26e-8	Prudent dietary pattern;
TGCT	cis	rs2404602	0.611	rs2404734	chr15:76936165	T/C	cg22467129	chr15:76604101	ETFA	0.47	4.61	0.38	9.77e-6	Blood metabolite levels;
TGCT	cis	rs9467773	1.000	rs9467783	chr6:26542894	C/T	cg15659132	chr6:26577336	NA	0.85	12.04	0.73	1.38e-22	Intelligence (multi-trait analysis);
TGCT	cis	rs244731	0.959	rs7724098	chr5:176659570	G/A	cg17509989	chr5:176798049	RGS14	-0.62	-7.54	-0.56	8.56e-12	Urate levels in lean individuals;
TGCT	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg26354017	chr1:205819088	PM20D1	0.54	6.39	0.5	3.1e-9	Menarche (age at onset);
TGCT	cis	rs938554	0.542	rs7678287	chr4:10000501	A/G	cg11266682	chr4:10021025	SLC2A9	0.5	4.53	0.38	1.35e-5	Blood metabolite levels;
TGCT	cis	rs2153535	0.580	rs7341383	chr6:8470634	A/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs6688613	0.545	rs10800270	chr1:166827602	A/T	cg07049167	chr1:166818506	POGK	0.24	5.09	0.42	1.31e-6	Refractive astigmatism;
TGCT	cis	rs7192750	0.652	rs152828	chr16:72123886	T/C	cg06353428	chr16:71660113	MARVELD3	1.03	5.27	0.43	5.78e-7	LDL cholesterol levels;Total cholesterol levels;
TGCT	trans	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.86	9.26	0.64	7.75e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs4345191	chr4:98945408	A/G	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6570726	0.791	rs952406	chr6:145925616	C/A	cg13319975	chr6:146136371	FBXO30	-0.53	-4.79	-0.4	4.6e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3091242	0.933	rs35497030	chr1:25783066	A/G	cg10117171	chr1:25599238	RHD	0.3	4.93	0.4	2.62e-6	Erythrocyte sedimentation rate;
TGCT	cis	rs9560113	1.000	rs9555806	chr13:112179954	G/A	cg14154082	chr13:112174009	NA	0.37	5.07	0.41	1.42e-6	Menarche (age at onset);
TGCT	cis	rs2204008	0.683	rs11522927	chr12:38137537	C/T	cg13010199	chr12:38710504	ALG10B	0.67	5.31	0.43	4.83e-7	Bladder cancer;
TGCT	cis	rs10751667	0.621	rs7394862	chr11:927500	T/C	cg06064525	chr11:970664	AP2A2	-0.35	-8.09	-0.59	4.54e-13	Alzheimer's disease (late onset);
TGCT	cis	rs2249625	0.526	rs17725666	chr6:72889711	G/A	cg08500200	chr6:72892038	RIMS1	0.42	4.58	0.38	1.14e-5	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
TGCT	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg24675658	chr1:53192096	ZYG11B	-0.69	-7.99	-0.58	8.01e-13	Monocyte count;
TGCT	cis	rs4455778	0.538	rs7796590	chr7:49124983	C/T	cg26309511	chr7:48887640	NA	0.51	6.62	0.51	9.97e-10	Lung cancer in never smokers;
TGCT	cis	rs854765	0.647	rs4426402	chr17:17977926	C/T	cg09796270	chr17:17721594	SREBF1	-0.23	-4.68	-0.39	7.33e-6	Total body bone mineral density;
TGCT	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg08280861	chr8:58055591	NA	0.53	5.96	0.47	2.44e-8	Developmental language disorder (linguistic errors);
TGCT	cis	rs2033711	0.503	rs6510141	chr19:58885786	C/G	cg13691442	chr19:58878570	NA	0.19	4.59	0.38	1.09e-5	Uric acid clearance;
TGCT	cis	rs6964587	1.000	rs10236397	chr7:91691601	C/T	cg22709100	chr7:91322751	NA	0.28	4.56	0.38	1.19e-5	Breast cancer;
TGCT	cis	rs858239	0.738	rs13225593	chr7:23260307	A/G	cg05602783	chr7:23145260	KLHL7	-0.66	-5.18	-0.42	8.78e-7	Cerebrospinal fluid biomarker levels;
TGCT	trans	rs2727020	0.563	rs10769582	chr11:49474040	T/C	cg15704280	chr7:45808275	SEPT13	-0.75	-8.76	-0.62	1.24e-14	Coronary artery disease;
TGCT	trans	rs4332037	0.707	rs62435130	chr7:1890002	C/T	cg10840412	chr1:235813424	GNG4	0.86	6.76	0.52	4.92e-10	Bipolar disorder;
TGCT	cis	rs2797160	0.935	rs1739379	chr6:126012593	T/C	cg05901451	chr6:126070800	HEY2	0.74	6.12	0.48	1.15e-8	Endometrial cancer;
TGCT	cis	rs11711311	1.000	rs9851731	chr3:113502651	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.7	6.64	0.51	8.96e-10	IgG glycosylation;
TGCT	cis	rs1062177	0.756	rs2964589	chr5:151118189	G/T	cg12924095	chr5:151150029	G3BP1	-0.34	-4.65	-0.39	8.34e-6	Preschool internalizing problems;
TGCT	cis	rs8038465	0.874	rs3816661	chr15:74005600	C/T	cg15420318	chr15:73925796	NPTN	0.55	5.08	0.42	1.33e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs950169	0.922	rs8037078	chr15:84818871	A/G	cg17173187	chr15:85201210	NMB	-0.54	-5.52	-0.44	1.87e-7	Schizophrenia;
TGCT	cis	rs3617	0.625	rs11719137	chr3:52876389	G/T	cg10802521	chr3:52805072	NEK4	0.62	7.17	0.54	6e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs78456975	0.689	rs13391992	chr2:1542153	G/A	cg01028140	chr2:1542097	TPO	-0.37	-5.3	-0.43	5.13e-7	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs1062177	0.855	rs6892117	chr5:151264985	C/T	cg14319409	chr5:151304409	GLRA1	-0.35	-4.45	-0.37	1.85e-5	Preschool internalizing problems;
TGCT	cis	rs7552404	0.727	rs1144336	chr1:76277421	C/A	cg22875332	chr1:76189707	ACADM	0.63	6.96	0.53	1.71e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	trans	rs2840044	0.711	rs225301	chr17:33922411	T/A	cg19694781	chr19:47549865	TMEM160	-0.42	-8.04	-0.59	6.07e-13	Response to radiotherapy in cancer (late toxicity);
TGCT	trans	rs941408	1.000	rs1076447	chr19:2792128	C/G	cg22153745	chr1:153894579	GATAD2B	-0.64	-7.01	-0.53	1.39e-10	Total cholesterol levels;
TGCT	cis	rs1519814	0.654	rs11986190	chr8:121013325	G/A	cg22335954	chr8:121166405	COL14A1	-0.36	-4.52	-0.38	1.44e-5	Breast cancer;
TGCT	cis	rs8031584	0.678	rs798127	chr15:31117403	T/C	cg14829155	chr15:31115871	NA	0.37	4.93	0.4	2.59e-6	Huntington's disease progression;
TGCT	cis	rs2742417	0.967	rs1883096	chr3:45750015	C/T	cg04837898	chr3:45731254	SACM1L	-0.55	-5.72	-0.46	7.45e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs7582180	0.652	rs11678158	chr2:100932297	T/C	cg08017756	chr2:100939284	LONRF2	-0.3	-4.73	-0.39	6.03e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg10047753	chr17:41438598	NA	0.94	9.23	0.64	9.06e-16	Menopause (age at onset);
TGCT	cis	rs1371867	0.817	rs1660315	chr8:101332956	G/A	cg06636551	chr8:101224915	SPAG1	-0.48	-6.52	-0.51	1.62e-9	Atrioventricular conduction;
TGCT	cis	rs3008870	1.000	rs2985818	chr1:67398916	G/A	cg03991309	chr1:68237761	GNG12	0.27	4.55	0.38	1.26e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs10267417	0.514	rs2072184	chr7:19748883	A/G	cg05791153	chr7:19748676	TWISTNB	1.34	14.14	0.79	1.26e-27	Night sleep phenotypes;
TGCT	cis	rs3784262	0.565	rs1899355	chr15:58286989	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.35	-4.94	-0.41	2.47e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs4788570	0.566	rs72795881	chr16:71500229	A/G	cg06353428	chr16:71660113	MARVELD3	-1.32	-7.86	-0.58	1.6e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs6598955	0.670	rs10902734	chr1:26617923	G/T	cg04990556	chr1:26633338	UBXN11	0.89	11.49	0.72	2.99e-21	Obesity-related traits;
TGCT	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg18230493	chr5:56204884	C5orf35	-0.68	-5.92	-0.47	2.92e-8	Initial pursuit acceleration;
TGCT	cis	rs11098499	0.663	rs9996501	chr4:120238918	C/A	cg09307838	chr4:120376055	NA	0.63	6.22	0.49	7.01e-9	Corneal astigmatism;
TGCT	cis	rs12477438	0.520	rs11678456	chr2:99708237	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	8.52	0.61	4.42e-14	Chronic sinus infection;
TGCT	cis	rs12510870	0.599	rs2091584	chr4:74416512	C/T	cg05868023	chr4:75230803	EREG	-0.55	-5.06	-0.41	1.48e-6	Iris color (b* coordinate);
TGCT	cis	rs79349575	0.783	rs4793998	chr17:47019899	C/T	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.52	-0.38	1.44e-5	Type 2 diabetes;
TGCT	trans	rs28735056	0.967	rs8091497	chr18:77632565	G/A	cg05926928	chr17:57297772	GDPD1	-0.71	-7.6	-0.56	6.2e-12	Schizophrenia;
TGCT	cis	rs6840360	0.530	rs6839802	chr4:152485834	G/A	cg17479576	chr4:152424074	FAM160A1	-0.73	-7.94	-0.58	1.03e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs7824557	0.614	rs2293858	chr8:11213881	G/C	cg21775007	chr8:11205619	TDH	0.68	6.46	0.5	2.16e-9	Retinal vascular caliber;
TGCT	cis	rs9611565	0.592	rs5751139	chr22:42099981	G/C	cg06481639	chr22:41940642	POLR3H	0.71	6.43	0.5	2.56e-9	Vitiligo;
TGCT	cis	rs11030122	0.661	rs10767811	chr11:4066398	G/A	cg18678763	chr11:4115507	RRM1	-0.45	-5.6	-0.45	1.3e-7	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.47	-4.95	-0.41	2.35e-6	Lymphocyte counts;
TGCT	cis	rs11992162	0.569	rs35283519	chr8:11831661	C/T	cg15426459	chr8:11813211	NA	-0.42	-5.42	-0.44	3e-7	Monocyte count;
TGCT	cis	rs2932538	0.922	rs36029940	chr1:113106444	T/G	cg10983938	chr1:113465962	AFARP1;SLC16A1	0.21	4.44	0.37	1.99e-5	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs7267979	1.000	rs2259956	chr20:25282433	A/G	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3796352	1.000	rs13058817	chr3:53024139	C/T	cg15956490	chr3:53032818	SFMBT1	0.62	6.82	0.52	3.6e-10	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs9611565	0.503	rs5751156	chr22:42170025	A/G	cg06634786	chr22:41940651	POLR3H	0.85	8.04	0.59	6.06e-13	Vitiligo;
TGCT	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg11494091	chr17:61959527	GH2	-0.61	-14.04	-0.78	2.15e-27	Prudent dietary pattern;
TGCT	cis	rs9928842	0.882	rs6564241	chr16:75263974	T/C	cg09066997	chr16:75300724	BCAR1	0.28	4.92	0.4	2.72e-6	Alcoholic chronic pancreatitis;
TGCT	cis	rs7267979	0.844	rs6107027	chr20:25288632	A/G	cg16686733	chr20:25566563	NINL	0.52	5.1	0.42	1.24e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2486288	0.656	rs11632752	chr15:45551140	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.72	-7.46	-0.56	1.34e-11	Glomerular filtration rate;
TGCT	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg12756686	chr19:29218302	NA	0.67	6.2	0.49	7.59e-9	Methadone dose in opioid dependence;
TGCT	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg05368731	chr17:41323189	NBR1	1.16	13.7	0.78	1.41e-26	Menopause (age at onset);
TGCT	cis	rs362272	0.505	rs60208975	chr4:3364530	A/G	cg06533319	chr4:3265114	C4orf44	-0.26	-5.29	-0.43	5.35e-7	Serum sulfate level;
TGCT	trans	rs61931739	0.500	rs11053189	chr12:34433455	G/A	cg26384229	chr12:38710491	ALG10B	0.74	6.89	0.53	2.46e-10	Morning vs. evening chronotype;
TGCT	cis	rs11122272	0.735	rs2437148	chr1:231513979	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.14	-0.54	6.86e-11	Hemoglobin concentration;
TGCT	cis	rs16958440	0.867	rs58061761	chr18:44686165	T/C	cg17192377	chr18:44677553	HDHD2	0.63	4.7	0.39	6.74e-6	Sitting height ratio;
TGCT	cis	rs36051895	0.530	rs4425810	chr9:5222208	A/G	cg02405213	chr9:5042618	JAK2	-0.63	-8.03	-0.58	6.5e-13	Pediatric autoimmune diseases;
TGCT	cis	rs6545883	0.831	rs9309336	chr2:61763165	T/C	cg15711740	chr2:61764176	XPO1	-0.57	-5.23	-0.43	6.89e-7	Tuberculosis;
TGCT	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg06636001	chr8:8085503	FLJ10661	0.66	5.59	0.45	1.36e-7	Mood instability;
TGCT	cis	rs7264396	0.635	rs6060688	chr20:34516731	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.28	4.94	0.41	2.44e-6	Total cholesterol levels;
TGCT	cis	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg13531842	chr10:38383804	ZNF37A	-0.38	-4.51	-0.38	1.49e-5	Extrinsic epigenetic age acceleration;
TGCT	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6500602	0.855	rs2304631	chr16:4475868	A/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	6.31	0.49	4.45e-9	Schizophrenia;
TGCT	cis	rs10984561	0.881	rs16908421	chr9:122244896	G/A	cg14242995	chr9:122249943	NA	0.76	6.5	0.5	1.79e-9	Pulmonary function decline;
TGCT	cis	rs1322512	0.848	rs2695247	chr6:152948596	G/T	cg03415253	chr6:152958462	SYNE1	-0.57	-4.99	-0.41	2e-6	Tonometry;
TGCT	cis	rs6684514	1.000	rs2277871	chr1:156246742	A/G	cg16558208	chr1:156270281	VHLL	0.46	9.38	0.64	3.92e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs71597109	0.639	rs34851381	chr4:102729463	T/C	cg14855874	chr4:102712397	BANK1	0.42	4.63	0.38	9.15e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs939658	0.805	rs939661	chr15:79431063	A/G	cg17916960	chr15:79447300	NA	-0.49	-7.59	-0.56	6.76e-12	Refractive error;
TGCT	cis	rs7681440	0.904	rs1372521	chr4:90765223	G/A	cg20003494	chr4:90757398	SNCA	-0.62	-5.93	-0.47	2.74e-8	Dementia with Lewy bodies;
TGCT	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg20891283	chr12:69753455	YEATS4	0.91	10.33	0.68	1.96e-18	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs4730250	0.707	rs3729876	chr7:106786952	T/C	cg02696742	chr7:106810147	HBP1	0.74	6.15	0.48	9.79e-9	Osteoarthritis;
TGCT	cis	rs2997447	0.706	rs61776573	chr1:26429356	A/C	cg03844060	chr1:26490628	NA	0.26	4.44	0.37	1.96e-5	QRS complex (12-leadsum);
TGCT	cis	rs6684514	0.506	rs3762281	chr1:156304782	A/G	cg20302342	chr1:156215951	PAQR6	0.37	5.54	0.45	1.73e-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs17376456	0.825	rs36042718	chr5:93180997	C/T	cg21475434	chr5:93447410	FAM172A	0.69	4.81	0.4	4.36e-6	Diabetic retinopathy;
TGCT	cis	rs13242816	1.000	rs2188243	chr7:116109293	G/A	cg02799643	chr7:116139180	CAV2	-0.48	-5.45	-0.44	2.56e-7	P wave duration;
TGCT	cis	rs68170813	0.599	rs11769901	chr7:106958505	G/A	cg02696742	chr7:106810147	HBP1	-0.69	-5.81	-0.46	4.85e-8	Coronary artery disease;
TGCT	cis	rs7727544	0.526	rs4705908	chr5:131347520	G/A	cg21474247	chr5:131268130	NA	0.36	4.85	0.4	3.68e-6	Blood metabolite levels;
TGCT	cis	rs9399137	0.507	rs7761964	chr6:135314265	T/C	cg24558204	chr6:135376177	HBS1L	0.47	4.78	0.39	4.95e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
TGCT	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.84	0.52	3.14e-10	Electroencephalogram traits;
TGCT	cis	rs9653442	0.777	rs6732141	chr2:100743492	G/C	cg22139774	chr2:100720529	AFF3	-0.44	-7.6	-0.56	6.3e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs523522	0.962	rs3893104	chr12:120903936	G/A	cg12219531	chr12:120966889	COQ5	0.83	7.3	0.55	2.97e-11	High light scatter reticulocyte count;
TGCT	cis	rs6424115	1.000	rs1018396	chr1:24133612	G/A	cg15997130	chr1:24165203	NA	0.89	9.94	0.67	1.81e-17	Immature fraction of reticulocytes;
TGCT	cis	rs9916302	0.904	rs12600751	chr17:37553651	G/C	cg07936489	chr17:37558343	FBXL20	0.64	4.81	0.4	4.3e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs17376456	0.569	rs35878747	chr5:93094070	C/A	cg21475434	chr5:93447410	FAM172A	0.61	4.95	0.41	2.35e-6	Diabetic retinopathy;
TGCT	cis	rs1008375	0.932	rs4698650	chr4:17692878	G/C	cg18681998	chr4:17616180	MED28	0.76	7.28	0.55	3.42e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7264396	0.635	rs6060656	chr20:34466382	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.04	-0.41	1.58e-6	Total cholesterol levels;
TGCT	cis	rs2996428	0.667	rs7545274	chr1:3744261	G/T	cg17848003	chr1:3704513	LRRC47	0.17	4.75	0.39	5.54e-6	Red cell distribution width;
TGCT	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg09436375	chr6:42928200	GNMT	-0.42	-5.41	-0.44	3.16e-7	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs881375	0.967	rs1930780	chr9:123686219	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.4	4.58	0.38	1.12e-5	Rheumatoid arthritis;
TGCT	cis	rs11711311	0.712	rs4682139	chr3:113331859	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.58	-4.74	-0.39	5.66e-6	IgG glycosylation;
TGCT	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg08859206	chr1:53392774	SCP2	0.46	7.05	0.53	1.1e-10	Monocyte count;
TGCT	cis	rs910316	1.000	rs7303	chr14:75520065	T/C	cg08847533	chr14:75593920	NEK9	0.96	10.6	0.69	4.3e-19	Height;
TGCT	cis	rs751728	0.664	rs9394167	chr6:33754396	A/G	cg13859433	chr6:33739653	LEMD2	-0.33	-5.75	-0.46	6.65e-8	Crohn's disease;
TGCT	cis	rs10540	1.000	rs61876339	chr11:495283	T/C	cg03352830	chr11:487213	PTDSS2	0.26	4.46	0.37	1.8e-5	Body mass index;
TGCT	cis	rs8141529	0.748	rs132531	chr22:29297365	C/T	cg02153584	chr22:29168773	CCDC117	-0.64	-5.08	-0.41	1.36e-6	Lymphocyte counts;
TGCT	cis	rs12510870	0.544	rs72647083	chr4:74384981	G/A	cg05868023	chr4:75230803	EREG	-0.55	-4.7	-0.39	6.84e-6	Iris color (b* coordinate);
TGCT	trans	rs7726839	0.540	rs3749615	chr5:601485	C/T	cg25482853	chr8:67687455	SGK3	1.23	10.7	0.69	2.49e-19	Obesity-related traits;
TGCT	cis	rs4919694	0.667	rs75890466	chr10:105076383	C/T	cg04362960	chr10:104952993	NT5C2	0.94	6.15	0.48	9.68e-9	Arsenic metabolism;
TGCT	cis	rs13191362	1.000	rs73035021	chr6:163000716	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs28595532	0.764	rs115986119	chr4:119767785	C/T	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs4727027	0.901	rs7794500	chr7:148819519	C/T	cg23583168	chr7:148888333	NA	0.72	9.17	0.64	1.3e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs259282	0.692	rs35972270	chr19:33128457	C/T	cg26639809	chr19:33781782	NA	0.27	5.74	0.46	6.86e-8	Schizophrenia;
TGCT	cis	rs654950	0.934	rs665223	chr1:42000654	A/T	cg06885757	chr1:42089581	HIVEP3	-0.29	-4.96	-0.41	2.22e-6	Airway imaging phenotypes;
TGCT	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg26338869	chr17:61819248	STRADA	0.54	5.17	0.42	8.94e-7	Prudent dietary pattern;
TGCT	cis	rs7666738	0.791	rs13149968	chr4:99070262	G/T	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.44e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg24846343	chr22:24311635	DDTL	0.23	6.0	0.47	2.01e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs12908161	1.000	rs35960805	chr15:85343980	T/G	cg12863693	chr15:85201151	NMB	0.42	5.06	0.41	1.5e-6	Schizophrenia;
TGCT	cis	rs10754283	0.967	rs4658307	chr1:90117586	G/T	cg03145924	chr1:90228473	NA	-0.4	-4.51	-0.38	1.51e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs1018836	0.527	rs13268721	chr8:91481549	G/A	cg16814680	chr8:91681699	NA	-0.89	-8.99	-0.63	3.52e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs35160687	0.901	rs6714362	chr2:86476588	A/G	cg03171300	chr2:86307199	POLR1A	-0.31	-5.43	-0.44	2.92e-7	Night sleep phenotypes;
TGCT	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg07167872	chr1:205819463	PM20D1	0.71	10.34	0.68	1.9e-18	Menarche (age at onset);
TGCT	cis	rs916888	0.821	rs70602	chr17:44859715	T/C	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.7	-4.82	-0.4	4.1e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs117785887	0.536	rs3811105	chr6:146349751	A/G	cg06708562	chr6:146285465	SHPRH	-0.85	-5.12	-0.42	1.13e-6	Interleukin-17 levels;
TGCT	cis	rs858239	0.539	rs7791200	chr7:23182121	A/T	cg05602783	chr7:23145260	KLHL7	-0.62	-5.03	-0.41	1.67e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs929843	1	rs929843	chr16:70045748	A/C	cg05523882	chr16:70323915	AARS	0.23	4.54	0.38	1.29e-5	Menarche (age at onset);
TGCT	cis	rs6714710	0.603	rs11680321	chr2:98379267	C/T	cg26665480	chr2:98280029	ACTR1B	0.66	6.24	0.49	6.33e-9	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg07061783	chr6:25882402	NA	0.64	6.7	0.52	6.57e-10	Blood metabolite levels;
TGCT	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg17971929	chr21:40555470	PSMG1	-0.72	-6.55	-0.51	1.35e-9	Cognitive function;
TGCT	cis	rs12220898	0.749	rs2377976	chr10:50479493	A/G	cg09603381	chr10:49954066	WDFY4	0.39	4.73	0.39	6.01e-6	Inflammatory biomarkers;
TGCT	cis	rs2404602	0.716	rs3866543	chr15:76629609	T/G	cg22467129	chr15:76604101	ETFA	-0.6	-7.44	-0.56	1.45e-11	Blood metabolite levels;
TGCT	cis	rs10769945	0.679	rs2137322	chr11:1917354	A/G	cg08273750	chr11:2011282	LOC100133545	-0.27	-4.52	-0.38	1.44e-5	DNA methylation (variation);
TGCT	cis	rs7666738	0.791	rs1405766	chr4:98965389	T/C	cg05340658	chr4:99064831	C4orf37	0.53	5.93	0.47	2.85e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs981844	0.775	rs921884	chr4:154753059	G/A	cg14289246	chr4:154710475	SFRP2	-0.96	-8.4	-0.6	8.66e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg08045932	chr20:61659980	NA	0.48	9.16	0.64	1.36e-15	Prostate cancer (SNP x SNP interaction);
TGCT	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg07332563	chr6:291687	DUSP22	-0.75	-7.74	-0.57	3.04e-12	Menopause (age at onset);
TGCT	cis	rs8141529	0.702	rs469990	chr22:29304200	A/T	cg02153584	chr22:29168773	CCDC117	0.59	4.49	0.37	1.6e-5	Lymphocyte counts;
TGCT	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.95	9.75	0.66	5.01e-17	Intelligence (multi-trait analysis);
TGCT	trans	rs17685	0.753	rs4732595	chr7:75755139	A/G	cg19862616	chr7:65841803	NCRNA00174	0.53	9.11	0.63	1.74e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg22857025	chr5:266934	NA	-0.31	-6.32	-0.49	4.33e-9	Breast cancer;
TGCT	cis	rs6424115	1.000	rs12121387	chr1:24166536	T/G	cg15997130	chr1:24165203	NA	-0.92	-10.48	-0.69	8.6e-19	Immature fraction of reticulocytes;
TGCT	cis	rs910187	0.678	rs6018329	chr20:45813184	A/G	cg27589058	chr20:45804311	EYA2	-0.36	-7.88	-0.58	1.44e-12	Migraine;
TGCT	cis	rs4478037	0.818	rs17522946	chr3:33138777	A/G	cg19404215	chr3:33155277	CRTAP	1.03	5.15	0.42	9.76e-7	Major depressive disorder;
TGCT	cis	rs4727027	0.704	rs10952805	chr7:148907849	G/A	cg23583168	chr7:148888333	NA	-0.85	-10.95	-0.7	6.08e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs546131	0.928	rs552868	chr11:34830694	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.53	4.59	0.38	1.08e-5	Lung disease severity in cystic fibrosis;
TGCT	cis	rs6674176	0.569	rs34830883	chr1:44405339	T/C	cg12908607	chr1:44402522	ARTN	-0.75	-9.11	-0.63	1.81e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs35000415	0.938	rs35188261	chr7:128683539	G/A	cg06242719	chr7:129414860	MIR183;MIR96	-0.31	-4.52	-0.38	1.4e-5	Systemic lupus erythematosus;
TGCT	cis	rs3091242	0.904	rs6661533	chr1:25771715	A/G	cg10117171	chr1:25599238	RHD	-0.32	-5.22	-0.42	7.32e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg10207240	chr12:122356781	WDR66	0.35	4.9	0.4	2.97e-6	Mean corpuscular volume;
TGCT	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg00149659	chr3:10157352	C3orf10	0.94	6.0	0.47	2e-8	Alzheimer's disease;
TGCT	cis	rs12368653	0.840	rs3816896	chr12:58195773	C/T	cg12615879	chr12:58013172	SLC26A10	0.5	5.99	0.47	2.16e-8	Multiple sclerosis;
TGCT	cis	rs10479542	0.806	rs4700835	chr5:178976313	A/G	cg19626725	chr5:178986131	RUFY1	0.44	5.46	0.44	2.49e-7	Lung cancer;
TGCT	cis	rs9467773	0.595	rs3846845	chr6:26444915	G/A	cg15659132	chr6:26577336	NA	-0.43	-4.51	-0.38	1.47e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs9611565	0.921	rs8137373	chr22:41729216	A/G	cg06481639	chr22:41940642	POLR3H	0.54	4.72	0.39	6.29e-6	Vitiligo;
TGCT	cis	rs9467711	0.516	rs548987	chr6:25869371	C/G	cg12310025	chr6:25882481	NA	-0.67	-4.47	-0.37	1.74e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs295137	0.836	rs1217456	chr2:201092279	C/T	cg23649088	chr2:200775458	C2orf69	0.35	6.17	0.48	8.75e-9	Asthma (bronchodilator response);
TGCT	trans	rs877282	0.755	rs2486578	chr10:785227	C/T	cg22713356	chr15:30763199	NA	-0.95	-8.2	-0.59	2.51e-13	Uric acid levels;
TGCT	cis	rs8072100	0.745	rs7214410	chr17:45422628	A/G	cg08085267	chr17:45401833	C17orf57	-0.46	-5.19	-0.42	8.36e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs6089829	0.692	rs6122349	chr20:61664096	T/C	cg08564027	chr20:61660810	NA	0.3	4.71	0.39	6.64e-6	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.36	-4.58	-0.38	1.11e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6882046	0.513	rs34316	chr5:88015545	A/C	cg22951263	chr5:87985283	NA	-0.57	-6.08	-0.48	1.38e-8	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs6582630	0.502	rs11520278	chr12:38359642	T/A	cg13010199	chr12:38710504	ALG10B	0.6	4.74	0.39	5.87e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs10791323	0.593	rs2282604	chr11:133714672	A/G	cg03690763	chr11:133734501	NA	-0.32	-5.42	-0.44	2.94e-7	Childhood ear infection;
TGCT	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg17054783	chr10:134559939	INPP5A	0.26	4.93	0.41	2.53e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs73058052	0.597	rs2890072	chr19:50087876	T/C	cg09250473	chr19:50168907	IRF3;BCL2L12	0.67	5.46	0.44	2.53e-7	Fibrinogen levels;
TGCT	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg02725872	chr8:58115012	NA	-0.39	-5.15	-0.42	1.01e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2070488	1.000	rs13079757	chr3:38491444	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	9.66	0.66	8.59e-17	Electrocardiographic conduction measures;
TGCT	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg01416388	chr22:39784598	NA	-0.72	-7.05	-0.53	1.1e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs9611565	0.607	rs132792	chr22:42062822	C/T	cg06634786	chr22:41940651	POLR3H	0.81	7.67	0.57	4.44e-12	Vitiligo;
TGCT	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg06238570	chr21:40685208	BRWD1	0.69	6.47	0.5	2.08e-9	Cognitive function;
TGCT	cis	rs72781680	0.898	rs12620558	chr2:23936022	G/A	cg08917208	chr2:24149416	ATAD2B	0.89	5.41	0.44	3.11e-7	Lymphocyte counts;
TGCT	cis	rs526231	0.578	rs3776870	chr5:102295070	G/A	cg23492399	chr5:102201601	PAM	-0.51	-4.48	-0.37	1.64e-5	Primary biliary cholangitis;
TGCT	cis	rs1215050	0.791	rs165254	chr4:98763564	C/T	cg17366294	chr4:99064904	C4orf37	0.52	5.61	0.45	1.27e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2153535	0.606	rs11243253	chr6:8380193	T/C	cg07606381	chr6:8435919	SLC35B3	-0.54	-5.08	-0.42	1.32e-6	Motion sickness;
TGCT	cis	rs9467773	0.967	rs6932865	chr6:26540166	C/A	cg09904177	chr6:26538194	HMGN4	0.65	6.53	0.51	1.53e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs2180341	1.000	rs4895822	chr6:127642703	T/C	cg24812749	chr6:127587940	RNF146	0.98	7.64	0.57	5.06e-12	Breast cancer;
TGCT	cis	rs933688	1.000	rs12651840	chr5:90729592	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.08	9.6	0.65	1.2e-16	Smoking behavior;
TGCT	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg18230493	chr5:56204884	C5orf35	-0.65	-5.7	-0.46	8.13e-8	Initial pursuit acceleration;
TGCT	trans	rs1814175	0.817	rs1988416	chr11:49932324	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.36	-7.05	-0.53	1.13e-10	Height;
TGCT	cis	rs858239	0.600	rs6978827	chr7:23125544	A/T	cg05602783	chr7:23145260	KLHL7	-0.64	-5.37	-0.43	3.69e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs10206020	0.885	rs13411553	chr2:1574018	A/G	cg01028140	chr2:1542097	TPO	-0.28	-4.45	-0.37	1.88e-5	IgG glycosylation;
TGCT	cis	rs778371	0.697	rs2344613	chr2:233603065	C/G	cg08000102	chr2:233561755	GIGYF2	0.69	7.77	0.57	2.62e-12	Schizophrenia;
TGCT	cis	rs10892173	0.566	rs2298649	chr11:117672225	A/G	cg21014159	chr11:117668035	DSCAML1	0.61	5.86	0.47	3.96e-8	Myopia;
TGCT	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs360798	0.553	rs11682530	chr2:63073194	C/T	cg17519650	chr2:63277830	OTX1	-0.54	-4.69	-0.39	7.09e-6	Coronary artery disease;
TGCT	cis	rs6701037	0.555	rs10912899	chr1:175120715	C/T	cg08873628	chr1:175162347	KIAA0040	0.46	4.75	0.39	5.44e-6	Alcohol dependence;
TGCT	cis	rs7662987	0.517	rs2924580	chr4:100032168	C/G	cg12011299	chr4:100065546	ADH4	0.4	4.85	0.4	3.55e-6	Smoking initiation;
TGCT	cis	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg07424592	chr7:64974309	NA	-1.31	-7.72	-0.57	3.33e-12	Diabetic kidney disease;
TGCT	cis	rs2769264	0.546	rs12071705	chr1:151430504	G/C	cg18801370	chr1:151430492	POGZ	0.72	6.74	0.52	5.31e-10	Blood trace element (Cu levels);
TGCT	cis	rs12477438	0.798	rs6712338	chr2:99585457	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-6.1	-0.48	1.22e-8	Chronic sinus infection;
TGCT	cis	rs9926296	0.572	rs2079671	chr16:89884981	T/C	cg08627397	chr16:89984028	MC1R	-0.31	-4.8	-0.4	4.46e-6	Vitiligo;
TGCT	cis	rs8180040	0.764	rs11716539	chr3:47186503	G/T	cg27129171	chr3:47204927	SETD2	0.77	9.86	0.66	2.77e-17	Colorectal cancer;
TGCT	cis	rs751728	1.000	rs2395449	chr6:33728755	T/A	cg13859433	chr6:33739653	LEMD2	-0.39	-7.29	-0.55	3.17e-11	Crohn's disease;
TGCT	cis	rs6586163	0.546	rs12359362	chr10:90753145	G/C	cg03111039	chr10:90751583	FAS;ACTA2	0.6	7.77	0.57	2.59e-12	Chronic lymphocytic leukemia;
TGCT	cis	rs2032447	0.641	rs442601	chr6:25934524	G/A	cg03517284	chr6:25882590	NA	-0.61	-5.5	-0.44	2.12e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs763121	0.853	rs5750621	chr22:38956166	C/T	cg06022373	chr22:39101656	GTPBP1	0.81	7.86	0.58	1.58e-12	Menopause (age at onset);
TGCT	cis	rs7267979	1.000	rs2424704	chr20:25273929	A/G	cg14121845	chr20:25566513	NINL	0.49	5.23	0.42	7.08e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7666738	0.761	rs13136913	chr4:98998031	C/T	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2153535	0.580	rs1832101	chr6:8460177	A/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs10882165	0.779	rs17382342	chr10:94908144	A/C	cg15980076	chr10:94822747	CYP26C1	0.44	4.77	0.39	5.13e-6	Refractive error;
TGCT	cis	rs7772486	0.875	rs6938972	chr6:146410608	G/A	cg23711669	chr6:146136114	FBXO30	0.91	9.95	0.67	1.67e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs13177918	0.677	rs13160685	chr5:149822331	A/G	cg14059543	chr5:149831962	NA	-0.72	-9.49	-0.65	2.17e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs2836633	0.895	rs2836598	chr21:40024758	C/G	cg05519781	chr21:40033154	ERG	0.68	6.65	0.51	8.34e-10	Coronary artery disease;
TGCT	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg02675527	chr2:114030824	PAX8;LOC440839	-0.5	-6.65	-0.51	8.34e-10	Lymphocyte counts;
TGCT	cis	rs6460942	1.000	rs7796485	chr7:12405676	G/A	cg06484146	chr7:12443880	VWDE	-0.63	-5.65	-0.45	1.04e-7	Coronary artery disease;
TGCT	cis	rs13191362	0.872	rs13215538	chr6:163037975	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.92	7.24	0.55	4.11e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs3780378	0.682	rs7861755	chr9:5273180	C/T	cg02405213	chr9:5042618	JAK2	-0.54	-6.96	-0.53	1.75e-10	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs7607369	0.748	rs662250	chr2:219374117	T/A	cg02176678	chr2:219576539	TTLL4	0.46	6.31	0.49	4.53e-9	Red blood cell count;Amyotrophic lateral sclerosis;
TGCT	cis	rs727505	0.954	rs59673207	chr7:124596982	G/C	cg23710748	chr7:124431027	NA	-0.26	-4.55	-0.38	1.27e-5	Lewy body disease;
TGCT	trans	rs4332037	0.901	rs11767040	chr7:1945468	C/T	cg25206134	chr2:45395956	NA	1.1	9.31	0.64	5.82e-16	Bipolar disorder;
TGCT	cis	rs7267979	0.903	rs6115118	chr20:25246734	G/A	cg03522245	chr20:25566470	NINL	0.6	6.58	0.51	1.21e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.33	0.55	2.59e-11	Prudent dietary pattern;
TGCT	cis	rs68170813	0.605	rs2299428	chr7:107134384	A/G	cg02696742	chr7:106810147	HBP1	-0.64	-5.01	-0.41	1.83e-6	Coronary artery disease;
TGCT	cis	rs4689388	0.824	rs114669221	chr4:6301459	G/A	cg25554036	chr4:6271136	WFS1	0.52	7.07	0.54	9.88e-11	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs72945132	0.882	rs72949078	chr11:70217708	T/C	cg00319359	chr11:70116639	PPFIA1	0.99	7.21	0.54	4.95e-11	Coronary artery disease;
TGCT	cis	rs793571	0.544	rs11638244	chr15:58907151	A/T	cg05156742	chr15:59063176	FAM63B	0.56	5.31	0.43	4.86e-7	Schizophrenia;
TGCT	cis	rs7523273	1.000	rs12123251	chr1:207992546	G/A	cg22525895	chr1:207977042	MIR29B2	-0.49	-8.55	-0.61	3.78e-14	Schizophrenia;
TGCT	cis	rs35146811	0.844	rs13232115	chr7:99670932	T/C	cg13334819	chr7:99746414	C7orf59	-0.74	-6.1	-0.48	1.23e-8	Coronary artery disease;
TGCT	cis	rs9393777	0.778	rs13212921	chr6:27205422	C/T	cg10876282	chr6:28092338	ZSCAN16	0.71	4.62	0.38	9.6e-6	Intelligence (multi-trait analysis);
TGCT	trans	rs4957048	0.577	rs56294732	chr5:568144	T/C	cg25482853	chr8:67687455	SGK3	1.1	8.74	0.62	1.34e-14	Ulcerative colitis;
TGCT	cis	rs4149423	1.000	rs4149423	chr2:108916044	A/G	cg13968390	chr2:108904812	SULT1C2	-0.25	-4.72	-0.39	6.2e-6	Lobe size;
TGCT	cis	rs1538970	0.924	rs12097497	chr1:45880669	C/T	cg05343316	chr1:45956843	TESK2	0.73	5.87	0.47	3.79e-8	Platelet count;
TGCT	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	8.0	0.58	7.67e-13	Platelet count;
TGCT	cis	rs7267979	0.934	rs6037085	chr20:25305202	C/T	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7666738	0.822	rs6815312	chr4:99058220	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.79	0.46	5.32e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9902453	0.740	rs1382391	chr17:28111986	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.84	-8.19	-0.59	2.73e-13	Coffee consumption (cups per day);
TGCT	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg22920501	chr2:26401640	FAM59B	0.81	6.36	0.5	3.52e-9	Gut microbiome composition (summer);
TGCT	cis	rs9611565	0.765	rs132909	chr22:41802031	G/A	cg03806693	chr22:41940476	POLR3H	1.01	11.44	0.72	3.94e-21	Vitiligo;
TGCT	trans	rs12785341	1.000	rs12294479	chr11:110395207	C/T	cg05839347	chr2:3648246	COLEC11	0.43	6.74	0.52	5.25e-10	Renal sinus fat;
TGCT	cis	rs909002	0.962	rs7537646	chr1:32135495	G/A	cg11573219	chr1:32083031	HCRTR1	-0.42	-5.25	-0.43	6.29e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs6940638	0.513	rs4424065	chr6:27036456	C/T	cg15659132	chr6:26577336	NA	-0.57	-5.65	-0.45	1.05e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7918232	0.941	rs1085782	chr10:27440517	G/A	cg14442939	chr10:27389572	ANKRD26	-0.8	-5.32	-0.43	4.7e-7	Breast cancer;
TGCT	cis	rs7546094	0.509	rs7415988	chr1:113159730	G/T	cg10983938	chr1:113465962	AFARP1;SLC16A1	-0.21	-4.44	-0.37	1.99e-5	Platelet distribution width;
TGCT	cis	rs939658	0.776	rs869672	chr15:79430860	G/A	cg17916960	chr15:79447300	NA	-0.49	-7.48	-0.56	1.21e-11	Refractive error;
TGCT	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg10253484	chr15:75165896	SCAMP2	-0.55	-5.08	-0.42	1.32e-6	Breast cancer;
TGCT	cis	rs7805747	0.961	rs55779150	chr7:151406449	A/T	cg17611936	chr7:151411526	PRKAG2	0.51	6.61	0.51	1e-9	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
TGCT	trans	rs9388451	0.626	rs9385383	chr6:126086290	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.84	-10.02	-0.67	1.16e-17	Brugada syndrome;
TGCT	cis	rs9303401	0.614	rs12947982	chr17:57140301	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.58	5.82	0.46	4.8e-8	Cognitive test performance;
TGCT	cis	rs208520	0.955	rs9453664	chr6:66976079	A/C	cg07460842	chr6:66804631	NA	0.77	6.83	0.52	3.34e-10	Exhaled nitric oxide output;
TGCT	cis	rs499368	0.519	rs216247	chr12:310571	C/T	cg23063825	chr12:298151	NA	-0.38	-4.49	-0.37	1.62e-5	Blood metabolite levels;Metabolite levels;
TGCT	cis	rs6815814	0.861	rs10034903	chr4:38784678	C/G	cg02016764	chr4:38805732	TLR1	-0.28	-4.59	-0.38	1.06e-5	Breast cancer;
TGCT	cis	rs7219021	0.770	rs7217007	chr17:46844697	C/T	cg07967210	chr17:47022446	SNF8	0.39	4.78	0.39	4.96e-6	Schizophrenia or bipolar disorder;
TGCT	cis	rs7020830	0.894	rs12337316	chr9:37148105	G/A	cg14294708	chr9:37120828	ZCCHC7	1.18	16.96	0.84	4.1e-34	Schizophrenia;
TGCT	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg20607798	chr8:58055168	NA	0.5	4.66	0.39	8.04e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg18188782	chr20:61659543	NA	0.44	5.37	0.43	3.73e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9611565	0.512	rs132784	chr22:42052363	G/A	cg13695892	chr22:41940480	POLR3H	0.86	7.84	0.58	1.77e-12	Vitiligo;
TGCT	cis	rs3733585	0.673	rs4467564	chr4:9953472	G/T	cg00071950	chr4:10020882	SLC2A9	-0.55	-6.58	-0.51	1.21e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7587476	0.601	rs13021937	chr2:215673937	C/T	cg04004882	chr2:215674386	BARD1	-0.65	-5.13	-0.42	1.09e-6	Neuroblastoma;
TGCT	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg00149659	chr3:10157352	C3orf10	0.91	5.89	0.47	3.32e-8	Alzheimer's disease;
TGCT	cis	rs4242434	0.698	rs10104039	chr8:22538384	A/G	cg03733263	chr8:22462867	KIAA1967	-1.04	-14.26	-0.79	6.7e-28	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs7829975	0.593	rs2979241	chr8:8303353	G/C	cg06636001	chr8:8085503	FLJ10661	0.69	6.31	0.49	4.44e-9	Mood instability;
TGCT	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.94	0.41	2.45e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9399137	0.507	rs13064	chr6:135287533	A/G	cg24558204	chr6:135376177	HBS1L	0.47	4.78	0.39	4.95e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
TGCT	cis	rs6933660	0.800	rs2046371	chr6:151754744	G/A	cg17179660	chr6:151773299	C6orf211;RMND1	-0.55	-4.88	-0.4	3.16e-6	Menarche (age at onset);
TGCT	cis	rs559928	0.548	rs11231713	chr11:63931849	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	4.56	0.38	1.22e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
TGCT	cis	rs1453308	1.000	rs4663225	chr2:237188566	C/T	cg19324714	chr2:237145437	ASB18	0.59	5.21	0.42	7.8e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs7647973	0.626	rs9824435	chr3:49674343	A/G	cg05785598	chr3:49045655	WDR6	-0.42	-5.05	-0.41	1.53e-6	Menarche (age at onset);
TGCT	cis	rs2692947	0.630	rs1168966	chr2:96798510	G/A	cg22654517	chr2:96458247	NA	0.22	5.01	0.41	1.82e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs9807989	0.839	rs10192036	chr2:102968211	C/A	cg09003973	chr2:102972529	NA	0.64	5.7	0.46	8.28e-8	Asthma;
TGCT	cis	rs79349575	0.777	rs28517720	chr17:46976756	C/G	cg26022315	chr17:47021804	SNF8	0.49	4.89	0.4	3.04e-6	Type 2 diabetes;
TGCT	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg06221963	chr1:154839813	KCNN3	-0.76	-13.04	-0.76	5.35e-25	Prostate cancer;
TGCT	cis	rs3087591	0.960	rs2066736	chr17:29559932	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.46	-7.1	-0.54	8.41e-11	Hip circumference;
TGCT	cis	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg18188782	chr20:61659543	NA	0.44	5.37	0.43	3.73e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2278034	0.516	rs9829709	chr3:195616673	G/A	cg16000393	chr3:195602323	TNK2	-0.16	-4.88	-0.4	3.21e-6	Bronchopulmonary dysplasia;
TGCT	cis	rs8062405	0.964	rs62036614	chr16:28824685	T/C	cg09754948	chr16:28834200	ATXN2L	0.6	4.51	0.38	1.5e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs9296092	0.538	rs62405942	chr6:33517346	G/A	cg13560919	chr6:33536144	NA	-0.21	-4.74	-0.39	5.87e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.75	5.41	0.44	3.09e-7	Platelet count;
TGCT	cis	rs11673344	0.523	rs1402468	chr19:37620248	A/T	cg08039142	chr19:36980659	ZNF566	0.52	4.83	0.4	3.89e-6	Obesity-related traits;
TGCT	cis	rs218265	0.841	rs218263	chr4:55408104	C/T	cg20208633	chr4:55405888	NA	-0.55	-4.45	-0.37	1.92e-5	Sum neutrophil eosinophil counts;Myeloid white cell count;High light scatter reticulocyte percentage of red cells;Mean corpuscular volume;Reticulocyte fraction of red cells;Red blood cell count;Immature fraction of reticulocytes;Sum basophil neutrophil counts;Granulocyte count;White blood cell count;Neutrophil count;Mean corpuscular hemoglobin;Plateletcrit;
TGCT	cis	rs208520	0.690	rs851465	chr6:66840293	G/A	cg07460842	chr6:66804631	NA	-0.92	-9.58	-0.65	1.29e-16	Exhaled nitric oxide output;
TGCT	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg27121462	chr16:89883253	FANCA	0.53	4.87	0.4	3.33e-6	Vitiligo;
TGCT	cis	rs12136530	0.593	rs11578302	chr1:19724835	A/G	cg09329407	chr1:19054906	PAX7	-0.24	-4.5	-0.37	1.57e-5	Lead levels in blood;
TGCT	cis	rs903263	0.932	rs6576962	chr1:84604937	C/T	cg09664975	chr1:84543551	PRKACB	0.5	4.87	0.4	3.4e-6	Breast cancer (male);
TGCT	cis	rs7226408	0.948	rs72883565	chr18:34380148	A/G	cg06757138	chr18:34340585	FHOD3	0.25	4.56	0.38	1.21e-5	Obesity-related traits;
TGCT	cis	rs17125944	1.000	rs17125924	chr14:53391680	A/G	cg00686598	chr14:53173677	PSMC6	0.92	4.54	0.38	1.29e-5	Alzheimer's disease (late onset);
TGCT	cis	rs4851266	1.000	rs4851268	chr2:100825864	C/T	cg22139774	chr2:100720529	AFF3	-0.35	-5.19	-0.42	8.51e-7	Educational attainment;
TGCT	cis	rs7937682	0.889	rs1784785	chr11:111483306	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.05	-11.39	-0.72	5.21e-21	Primary sclerosing cholangitis;
TGCT	cis	rs9467773	1.000	rs6903973	chr6:26499942	C/A	cg26531700	chr6:26746687	NA	0.46	4.55	0.38	1.27e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7937682	0.564	rs1944116	chr11:111366792	A/C	cg09085632	chr11:111637200	PPP2R1B	0.55	4.94	0.41	2.52e-6	Primary sclerosing cholangitis;
TGCT	cis	rs478304	0.654	rs10896035	chr11:65461160	G/A	cg27068330	chr11:65405492	SIPA1	-0.99	-11.32	-0.71	7.67e-21	Acne (severe);
TGCT	cis	rs7727544	0.547	rs10076758	chr5:131524299	A/G	cg14196790	chr5:131705035	SLC22A5	0.33	4.49	0.37	1.59e-5	Blood metabolite levels;
TGCT	cis	rs6714788	0.523	rs6542905	chr2:100654707	C/G	cg22139774	chr2:100720529	AFF3	-0.41	-6.5	-0.5	1.74e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs2153535	0.580	rs5001130	chr6:8442298	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.58	0.45	1.42e-7	Motion sickness;
TGCT	cis	rs7666738	0.830	rs1527517	chr4:98931907	C/T	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1801251	1.000	rs2012221	chr2:233566848	T/C	cg08000102	chr2:233561755	GIGYF2	0.64	6.44	0.5	2.36e-9	Coronary artery disease;
TGCT	cis	rs593982	0.920	rs72922791	chr11:65567395	G/A	cg08755490	chr11:65554678	OVOL1	-1.06	-6.73	-0.52	5.74e-10	Atopic dermatitis;
TGCT	cis	rs6424115	0.800	rs4649123	chr1:24197696	A/G	cg15997130	chr1:24165203	NA	0.86	9.63	0.65	1.02e-16	Immature fraction of reticulocytes;
TGCT	cis	rs472402	0.560	rs2303705	chr5:6622017	A/C	cg06614609	chr5:6605060	NSUN2	0.17	4.47	0.37	1.76e-5	Response to amphetamines;
TGCT	cis	rs28489187	0.617	rs233124	chr1:85791658	A/G	cg16011679	chr1:85725395	C1orf52	0.49	4.49	0.37	1.63e-5	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
TGCT	cis	rs6671200	1.000	rs259346	chr1:95728746	G/T	cg03123541	chr1:95699097	RWDD3	0.91	6.4	0.5	2.93e-9	Stearic acid (18:0) levels;
TGCT	cis	rs9325144	0.505	rs7138977	chr12:38642109	G/A	cg26384229	chr12:38710491	ALG10B	0.74	7.25	0.55	3.97e-11	Morning vs. evening chronotype;
TGCT	cis	rs2075165	0.901	rs1043165	chr1:156220056	T/C	cg20302342	chr1:156215951	PAQR6	0.39	5.64	0.45	1.12e-7	Tonsillectomy;
TGCT	cis	rs6089584	0.507	rs6061990	chr20:60628429	T/G	cg13770153	chr20:60521292	NA	-0.43	-5.31	-0.43	4.99e-7	Body mass index;
TGCT	cis	rs9811920	0.609	rs793465	chr3:99627750	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.6	-6.82	-0.52	3.63e-10	Axial length;
TGCT	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg13206674	chr6:150067644	NUP43	0.51	4.45	0.37	1.91e-5	Lung cancer;
TGCT	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg19729930	chr2:74357872	NA	0.62	8.94	0.63	4.63e-15	Gestational age at birth (maternal effect);
TGCT	cis	rs12477438	0.798	rs4622780	chr2:99631760	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.69	-5.87	-0.47	3.64e-8	Chronic sinus infection;
TGCT	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg14820908	chr5:178986412	RUFY1	-0.54	-5.76	-0.46	6.26e-8	Lung cancer;
TGCT	cis	rs9993613	0.875	rs34647859	chr4:73490197	C/T	cg15102770	chr4:73434591	ADAMTS3	0.5	4.59	0.38	1.05e-5	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs2120019	1.000	rs7167285	chr15:75368769	A/G	cg11632617	chr15:75315747	PPCDC	-0.34	-4.82	-0.4	4.18e-6	Blood trace element (Zn levels);
TGCT	cis	rs928736	0.557	rs2834083	chr21:34436973	A/G	cg10915739	chr21:34405733	NA	0.39	4.87	0.4	3.33e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs9303542	0.625	rs17703636	chr17:46566890	C/T	cg25032089	chr17:46643351	HOXB3	-0.5	-5.2	-0.42	8.15e-7	Ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs7312933	0.592	rs1551210	chr12:42865874	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.51	4.9	0.4	2.99e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs12908161	1.000	rs35316992	chr15:85248133	A/G	cg17173187	chr15:85201210	NMB	0.59	6.77	0.52	4.55e-10	Schizophrenia;
TGCT	cis	rs2760061	0.598	rs590657	chr1:228117581	A/C	cg02753203	chr1:228287806	NA	-0.34	-6.57	-0.51	1.24e-9	Diastolic blood pressure;
TGCT	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg25767906	chr1:53392781	SCP2	-0.53	-6.21	-0.49	7.34e-9	Monocyte count;
TGCT	cis	rs826838	1.000	rs11183747	chr12:38822595	A/G	cg26384229	chr12:38710491	ALG10B	-1.02	-10.12	-0.67	6.58e-18	Heart rate;
TGCT	cis	rs10464366	0.746	rs12670510	chr7:39142146	A/G	cg18850127	chr7:39170497	POU6F2	0.27	5.7	0.46	8.11e-8	IgG glycosylation;
TGCT	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg00343986	chr7:65444356	GUSB	0.23	5.14	0.42	1.06e-6	Aortic root size;
TGCT	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.19	-0.42	8.4e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs922182	0.538	rs16947599	chr15:64260944	C/T	cg02919090	chr15:64263738	DAPK2	-0.28	-4.93	-0.41	2.54e-6	Blood protein levels;
TGCT	cis	rs11190604	1.000	rs4919468	chr10:102288343	G/C	cg16342193	chr10:102329863	NA	-0.44	-5.56	-0.45	1.58e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2228479	0.867	rs34604714	chr16:89948985	A/G	cg06558623	chr16:89946397	TCF25	0.56	6.83	0.52	3.38e-10	Skin colour saturation;
TGCT	cis	rs7833790	0.660	rs1451995	chr8:82746123	G/C	cg17211192	chr8:82754475	SNX16	0.95	8.83	0.62	8.45e-15	Diastolic blood pressure;
TGCT	cis	rs524281	0.861	rs6591208	chr11:65949689	A/C	cg00563793	chr11:65837595	PACS1	0.57	4.97	0.41	2.13e-6	Electroencephalogram traits;
TGCT	cis	rs9733	0.628	rs11807409	chr1:150683423	C/T	cg04414720	chr1:150670196	GOLPH3L	0.37	4.91	0.4	2.76e-6	Tonsillectomy;
TGCT	cis	rs17300741	0.509	rs4930195	chr11:64310649	C/T	cg08822897	chr11:64258103	NA	-0.26	-4.46	-0.37	1.79e-5	Uric acid levels;
TGCT	cis	rs7666738	0.830	rs13110410	chr4:98920018	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.51	0.56	1e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1505368	0.789	rs13419353	chr2:213271459	A/T	cg20637307	chr2:213403960	ERBB4	-0.47	-4.51	-0.38	1.48e-5	Symmetrical dimethylarginine levels;
TGCT	cis	rs9581857	0.579	rs9581843	chr13:27980507	T/G	cg22138327	chr13:27999177	GTF3A	0.74	5.46	0.44	2.53e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs2832191	0.791	rs2832178	chr21:30479858	T/G	cg08807101	chr21:30365312	RNF160	-0.64	-6.01	-0.48	1.91e-8	Dental caries;
TGCT	cis	rs7255045	0.711	rs2077544	chr19:12963285	C/T	cg23899408	chr19:12877188	HOOK2	-0.56	-4.44	-0.37	1.96e-5	Mean corpuscular volume;
TGCT	cis	rs1005224	0.853	rs12898082	chr14:76306359	A/C	cg04684003	chr14:76127793	TTLL5;C14orf1	0.56	5.18	0.42	8.54e-7	Large artery stroke;
TGCT	cis	rs931608	0.640	rs2957824	chr19:22579316	T/C	cg08394602	chr19:22123885	NA	0.5	4.47	0.37	1.76e-5	Dental caries;Response to statins (LDL cholesterol change);
TGCT	cis	rs7677751	0.806	rs6836215	chr4:55102741	T/C	cg17187183	chr4:55093834	PDGFRA	0.54	7.0	0.53	1.45e-10	Corneal astigmatism;
TGCT	cis	rs10114408	0.959	rs10992961	chr9:96653239	C/T	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	trans	rs4332037	0.851	rs10268609	chr7:1962163	A/C	cg25206134	chr2:45395956	NA	1.1	9.69	0.66	7.33e-17	Bipolar disorder;
TGCT	cis	rs62244186	0.627	rs3935212	chr3:44460954	G/A	cg17546649	chr3:44802566	KIF15;KIAA1143	-0.37	-4.49	-0.37	1.64e-5	Depressive symptoms;
TGCT	cis	rs7940866	0.774	rs2162059	chr11:130831224	C/T	cg05962950	chr11:130786565	SNX19	0.77	7.84	0.58	1.74e-12	Schizophrenia;
TGCT	cis	rs151997	0.925	rs27287	chr5:50195567	C/A	cg06027927	chr5:50259733	NA	0.48	4.95	0.41	2.41e-6	Callous-unemotional behaviour;
TGCT	cis	rs2637266	0.935	rs7393727	chr10:78365977	T/A	cg18941641	chr10:78392320	NA	0.4	4.73	0.39	6.03e-6	Pulmonary function;
TGCT	cis	rs7714584	1.000	rs11748151	chr5:150226292	C/T	cg22134413	chr5:150180641	NA	0.89	6.96	0.53	1.73e-10	Crohn's disease;
TGCT	trans	rs10506458	1.000	rs12425655	chr12:63434463	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.44	-7.32	-0.55	2.74e-11	Hemostatic factors and hematological phenotypes;
TGCT	trans	rs1496653	0.602	rs34504120	chr3:23369340	G/A	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs1395	0.925	rs1659689	chr2:27393030	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.48	-6.02	-0.48	1.8e-8	Blood metabolite levels;
TGCT	cis	rs7937682	0.924	rs499750	chr11:111513645	T/G	cg09085632	chr11:111637200	PPP2R1B	-1.09	-11.4	-0.72	4.97e-21	Primary sclerosing cholangitis;
TGCT	cis	rs9611565	0.559	rs8139993	chr22:41995335	T/C	cg13695892	chr22:41940480	POLR3H	-0.83	-7.82	-0.57	1.94e-12	Vitiligo;
TGCT	cis	rs7811142	0.945	rs34989573	chr7:100097895	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.05	-9.12	-0.63	1.65e-15	Platelet count;
TGCT	cis	rs1205863	0.607	rs1205850	chr6:11940593	C/G	cg07106625	chr6:11870215	NA	0.44	4.77	0.39	5.18e-6	Disc degeneration (lumbar);
TGCT	cis	rs3027009	0.881	rs12045546	chr1:159132532	A/G	cg03685774	chr1:159870326	CCDC19	0.51	4.72	0.39	6.23e-6	Lean body mass and age at menarche (combined);
TGCT	cis	rs3087591	0.960	rs2071009	chr17:29558082	T/C	cg24425628	chr17:29625626	OMG;NF1	-0.47	-7.33	-0.55	2.62e-11	Hip circumference;
TGCT	cis	rs10392	0.500	rs8118646	chr20:37600887	A/G	cg27552599	chr20:37590471	DHX35	0.37	4.62	0.38	9.29e-6	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
TGCT	trans	rs28735056	1.000	rs28865701	chr18:77620911	A/G	cg05926928	chr17:57297772	GDPD1	-0.67	-7.05	-0.53	1.08e-10	Schizophrenia;
TGCT	cis	rs7659604	0.540	rs67150579	chr4:122704331	T/A	cg19748678	chr4:122722346	EXOSC9	-0.6	-5.85	-0.46	4.14e-8	Type 2 diabetes;
TGCT	cis	rs9291683	0.546	rs10939672	chr4:10052136	A/G	cg00071950	chr4:10020882	SLC2A9	0.54	5.95	0.47	2.56e-8	Bone mineral density;
TGCT	cis	rs200810	0.964	rs28657486	chr6:97769261	T/C	cg17774634	chr6:97730494	C6orf167;MIR548H3	-0.54	-4.69	-0.39	7.07e-6	Body mass index;
TGCT	cis	rs8038465	0.874	rs11072434	chr15:74002854	A/G	cg15420318	chr15:73925796	NPTN	-0.56	-5.02	-0.41	1.73e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1552244	0.554	rs58020561	chr3:10054682	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.33	-4.95	-0.41	2.39e-6	Alzheimer's disease;
TGCT	cis	rs950169	0.881	rs4842852	chr15:84941961	A/G	cg17173187	chr15:85201210	NMB	0.58	5.93	0.47	2.77e-8	Schizophrenia;
TGCT	cis	rs11696501	0.694	rs6124722	chr20:44263264	G/A	cg11783356	chr20:44313418	WFDC10B	-0.32	-4.63	-0.38	9.25e-6	Brain structure;
TGCT	cis	rs9653442	0.622	rs11685341	chr2:100636757	A/G	cg07810366	chr2:100720526	AFF3	0.38	6.09	0.48	1.28e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs2239547	0.522	rs9842974	chr3:53011050	C/A	cg10802521	chr3:52805072	NEK4	-0.59	-5.41	-0.44	3.08e-7	Schizophrenia;
TGCT	cis	rs9611565	0.649	rs6002480	chr22:42176917	A/T	cg06481639	chr22:41940642	POLR3H	-0.52	-4.45	-0.37	1.9e-5	Vitiligo;
TGCT	cis	rs78487399	0.808	rs79271345	chr2:43746094	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.07	-0.41	1.41e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs12142240	0.698	rs6696777	chr1:46810970	A/G	cg00530320	chr1:46809349	NSUN4	0.29	5.88	0.47	3.63e-8	Menopause (age at onset);
TGCT	cis	rs912057	0.601	rs1294413	chr6:6739924	C/A	cg06612196	chr6:6737390	NA	0.5	7.47	0.56	1.24e-11	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs8017423	0.647	rs1958345	chr14:90823770	T/C	cg04374321	chr14:90722782	PSMC1	-0.54	-5.41	-0.44	3.13e-7	Mortality in heart failure;
TGCT	cis	rs62244186	0.566	rs55901755	chr3:44834707	C/T	cg04389838	chr3:44770851	ZNF501	-0.37	-4.76	-0.39	5.25e-6	Depressive symptoms;
TGCT	cis	rs7647973	1.000	rs7648995	chr3:49438803	C/T	cg05785598	chr3:49045655	WDR6	-0.4	-4.67	-0.39	7.57e-6	Menarche (age at onset);
TGCT	cis	rs1949733	1.000	rs2688233	chr4:8491885	T/C	cg11789530	chr4:8429930	ACOX3	0.6	5.49	0.44	2.21e-7	Response to antineoplastic agents;
TGCT	cis	rs7267979	1.000	rs2856	chr20:25433536	T/C	cg16686733	chr20:25566563	NINL	0.58	5.75	0.46	6.46e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2153535	0.580	rs9379206	chr6:8458021	C/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs12510870	0.599	rs1881611	chr4:74403462	G/A	cg05868023	chr4:75230803	EREG	0.54	5.01	0.41	1.83e-6	Iris color (b* coordinate);
TGCT	cis	rs700651	0.821	rs4850812	chr2:198743655	G/T	cg00792783	chr2:198669748	PLCL1	-0.56	-5.08	-0.42	1.35e-6	Intracranial aneurysm;
TGCT	cis	rs7296418	0.883	rs1727312	chr12:123642220	G/T	cg00376283	chr12:123451042	ABCB9	0.84	7.66	0.57	4.68e-12	Platelet count;
TGCT	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg12042659	chr19:58951599	ZNF132	0.51	4.6	0.38	1.05e-5	Uric acid clearance;
TGCT	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg03452623	chr4:187889614	NA	-0.32	-4.84	-0.4	3.77e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7027203	0.828	rs10122041	chr9:96615517	A/G	cg14396892	chr9:96623032	NA	-0.26	-5.46	-0.44	2.51e-7	DNA methylation (variation);
TGCT	cis	rs3796352	1.000	rs11714876	chr3:53101640	C/G	cg27565382	chr3:53032988	SFMBT1	-0.44	-4.74	-0.39	5.86e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs9858542	0.953	rs11922013	chr3:49458355	G/C	cg03060546	chr3:49711283	APEH	-0.61	-5.37	-0.43	3.78e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs62244186	0.566	rs6766221	chr3:44882784	C/T	cg15687855	chr3:44754131	ZNF502	-0.55	-6.8	-0.52	3.89e-10	Depressive symptoms;
TGCT	cis	rs9467773	0.967	rs7753565	chr6:26560012	A/G	cg15659132	chr6:26577336	NA	0.9	13.19	0.76	2.26e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs6088580	0.542	rs6059882	chr20:33090167	T/C	cg08999081	chr20:33150536	PIGU	0.29	5.57	0.45	1.54e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs4319547	0.794	rs61954972	chr12:123074167	T/G	cg23029597	chr12:123009494	RSRC2	-0.3	-4.92	-0.4	2.65e-6	Body mass index;
TGCT	cis	rs9911578	1.000	rs8079774	chr17:56908188	A/G	cg12560992	chr17:57184187	TRIM37	0.75	9.07	0.63	2.26e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs2075371	0.897	rs12667905	chr7:134000812	A/C	cg11752832	chr7:134001865	SLC35B4	0.67	5.91	0.47	3.12e-8	Mean platelet volume;
TGCT	cis	rs28595532	0.920	rs17324807	chr4:119770638	G/A	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs9787249	0.957	rs12239844	chr1:40217258	T/C	cg24920358	chr1:40204285	PPIE	0.58	10.56	0.69	5.56e-19	Blood protein levels;
TGCT	cis	rs752092	0.802	rs2412005	chr15:101767591	T/A	cg25114630	chr15:101792522	CHSY1	0.5	4.73	0.39	6.12e-6	Corneal structure;
TGCT	cis	rs6121246	0.909	rs6119729	chr20:30413163	A/G	cg18721089	chr20:30220636	NA	0.43	4.75	0.39	5.54e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs35883536	0.647	rs12026951	chr1:101046273	C/T	cg10298815	chr1:101004474	GPR88	-0.25	-4.5	-0.37	1.54e-5	Monocyte count;
TGCT	cis	rs6912958	1.000	rs6937823	chr6:88160386	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.39	-5.0	-0.41	1.91e-6	Monocyte percentage of white cells;
TGCT	cis	rs988712	0.672	rs35038967	chr11:27703480	T/A	cg10635145	chr11:27742435	BDNF	-0.43	-5.98	-0.47	2.19e-8	Obesity;
TGCT	cis	rs11722228	1.000	rs4697695	chr4:9915850	C/T	cg11266682	chr4:10021025	SLC2A9	0.52	5.57	0.45	1.53e-7	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs6964587	0.692	rs6970629	chr7:91846599	T/C	cg17063962	chr7:91808500	NA	0.77	7.17	0.54	6.08e-11	Breast cancer;
TGCT	cis	rs7772486	0.536	rs9373467	chr6:145955605	C/T	cg13319975	chr6:146136371	FBXO30	-0.7	-6.39	-0.5	3.04e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg04234412	chr22:24373322	LOC391322	-0.93	-11.15	-0.71	1.99e-20	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs11190604	0.945	rs11190573	chr10:102233172	T/C	cg16342193	chr10:102329863	NA	-0.4	-5.31	-0.43	4.85e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs1372520	0.873	rs2583990	chr4:90771499	A/G	cg01966878	chr4:90757139	SNCA	-0.31	-5.0	-0.41	1.9e-6	Neuroticism;
TGCT	cis	rs36051895	0.659	rs4495487	chr9:5072798	T/C	cg02405213	chr9:5042618	JAK2	-0.76	-9.95	-0.67	1.69e-17	Pediatric autoimmune diseases;
TGCT	cis	rs7091068	0.518	rs9633674	chr10:95455431	C/T	cg20715218	chr10:95462985	C10orf4	0.52	5.5	0.44	2.07e-7	Urinary tract infection frequency;
TGCT	cis	rs1887596	0.639	rs9553873	chr13:27186843	T/C	cg01312412	chr13:27282625	NA	0.3	5.46	0.44	2.45e-7	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs2836633	0.929	rs4514962	chr21:40041753	C/T	cg05519781	chr21:40033154	ERG	0.69	6.82	0.52	3.63e-10	Coronary artery disease;
TGCT	cis	rs62244186	0.748	rs6441861	chr3:44652287	A/G	cg25151919	chr3:44754333	ZNF502	-0.43	-5.02	-0.41	1.75e-6	Depressive symptoms;
TGCT	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg11764359	chr7:65958608	NA	-0.54	-4.9	-0.4	2.89e-6	Aortic root size;
TGCT	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg03517284	chr6:25882590	NA	-0.58	-6.02	-0.48	1.79e-8	Blood metabolite levels;
TGCT	cis	rs6484504	0.553	rs2183484	chr11:31259370	G/A	cg26647111	chr11:31128758	NA	-0.35	-4.85	-0.4	3.58e-6	Red blood cell count;
TGCT	cis	rs9611565	0.592	rs5996037	chr22:41965292	A/G	cg17554472	chr22:41940697	POLR3H	-0.48	-4.94	-0.41	2.47e-6	Vitiligo;
TGCT	cis	rs617219	0.671	rs13165414	chr5:78548873	C/T	cg23514016	chr5:78407564	BHMT	0.32	4.87	0.4	3.38e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs9291683	0.527	rs11727087	chr4:10096020	A/G	cg11266682	chr4:10021025	SLC2A9	0.57	6.74	0.52	5.32e-10	Bone mineral density;
TGCT	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg08280861	chr8:58055591	NA	0.51	5.73	0.46	7.17e-8	Developmental language disorder (linguistic errors);
TGCT	cis	rs3818285	0.655	rs2475277	chr10:111639730	C/T	cg00817464	chr10:111662876	XPNPEP1	0.32	5.56	0.45	1.57e-7	Superior crus of antihelix expression;
TGCT	cis	rs79387448	0.745	rs1523197	chr2:103163732	A/G	cg09003973	chr2:102972529	NA	0.92	5.89	0.47	3.39e-8	Gut microbiota (bacterial taxa);
TGCT	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.48	-0.37	1.66e-5	Bipolar disorder;
TGCT	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg17554472	chr22:41940697	POLR3H	0.49	5.07	0.41	1.38e-6	Vitiligo;
TGCT	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs8072100	0.748	rs9908016	chr17:45551361	G/A	cg08085267	chr17:45401833	C17orf57	-0.48	-5.23	-0.43	6.87e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs12210905	0.688	rs12195783	chr6:27444345	A/G	cg08851530	chr6:28072375	NA	1.34	6.29	0.49	5.02e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs35146811	0.731	rs2257213	chr7:99810113	T/C	cg00553149	chr7:99775558	STAG3;GPC2	-0.32	-4.81	-0.4	4.28e-6	Coronary artery disease;
TGCT	cis	rs1580019	0.523	rs9791770	chr7:32582252	C/A	cg06627557	chr7:32535165	LSM5;AVL9	1.2	15.12	0.81	6.42e-30	Cognitive ability;
TGCT	cis	rs854765	0.583	rs8065563	chr17:17782404	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.76	7.92	0.58	1.17e-12	Total body bone mineral density;
TGCT	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg02725872	chr8:58115012	NA	-0.41	-4.95	-0.41	2.37e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs881375	0.967	rs1860824	chr9:123659339	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	5.2	0.42	8.09e-7	Rheumatoid arthritis;
TGCT	cis	rs77741769	0.571	rs4454799	chr12:121317075	A/C	cg02419362	chr12:121203948	SPPL3	-0.19	-4.49	-0.37	1.63e-5	Mean corpuscular volume;
TGCT	cis	rs3771570	1.000	rs62186400	chr2:242226700	A/G	cg21155796	chr2:242212141	HDLBP	0.98	6.68	0.51	7.29e-10	Prostate cancer;
TGCT	cis	rs7020830	0.931	rs3802422	chr9:37097172	G/A	cg14294708	chr9:37120828	ZCCHC7	1.28	20.28	0.88	3.46e-41	Schizophrenia;
TGCT	cis	rs11718455	0.960	rs4682713	chr3:44013191	G/C	cg08738300	chr3:44038990	NA	0.87	6.63	0.51	9.07e-10	Coronary artery disease;
TGCT	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs981844	0.712	rs4469056	chr4:154745796	A/T	cg14289246	chr4:154710475	SFRP2	0.99	9.12	0.63	1.65e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs4819052	0.851	rs7275468	chr21:46656499	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	5.07	0.41	1.39e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs11190604	1.000	rs3793771	chr10:102222957	C/G	cg23241863	chr10:102295624	HIF1AN	0.62	4.87	0.4	3.27e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7647973	1.000	rs3870339	chr3:49536863	T/A	cg05785598	chr3:49045655	WDR6	0.37	4.52	0.38	1.42e-5	Menarche (age at onset);
TGCT	cis	rs6987853	0.933	rs2974340	chr8:42397731	T/C	cg20539142	chr8:42623718	CHRNA6	-0.21	-5.03	-0.41	1.69e-6	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs1865760	0.508	rs9379820	chr6:26049924	T/C	cg17042849	chr6:26104293	HIST1H4C	-0.62	-5.41	-0.44	3.18e-7	Height;
TGCT	cis	rs11098499	0.738	rs28687057	chr4:120280812	A/G	cg09307838	chr4:120376055	NA	0.58	5.76	0.46	6.16e-8	Corneal astigmatism;
TGCT	cis	rs9650657	0.740	rs2277130	chr8:10677601	G/C	cg27411982	chr8:10470053	RP1L1	-0.23	-5.12	-0.42	1.13e-6	Neuroticism;
TGCT	cis	rs7662987	0.517	rs2034696	chr4:100024322	C/G	cg12011299	chr4:100065546	ADH4	0.4	4.82	0.4	4.07e-6	Smoking initiation;
TGCT	cis	rs17345786	1.000	rs17345528	chr3:101294830	A/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.86	-8.79	-0.62	1.01e-14	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12479064	0.671	rs62155807	chr2:100076579	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.71	-6.02	-0.48	1.85e-8	Chronic sinus infection;
TGCT	cis	rs4711350	0.862	rs652049	chr6:33711420	C/T	cg18005901	chr6:33739558	LEMD2	0.57	5.9	0.47	3.23e-8	Schizophrenia;
TGCT	cis	rs4820539	0.966	rs2267005	chr22:23461723	A/G	cg21100191	chr22:23484243	RTDR1	0.9	11.01	0.7	4.35e-20	Bone mineral density;
TGCT	cis	rs7191439	0.518	rs4238679	chr16:88742688	G/C	cg27087555	chr16:88793112	FAM38A	-0.47	-4.75	-0.39	5.46e-6	Plateletcrit;
TGCT	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg06675483	chr6:26987649	LOC100270746;C6orf41	0.36	4.65	0.39	8.51e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2075371	0.796	rs10954440	chr7:134005657	C/T	cg11752832	chr7:134001865	SLC35B4	0.71	6.37	0.5	3.39e-9	Mean platelet volume;
TGCT	cis	rs6582630	0.599	rs7967598	chr12:38540760	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-4.77	-0.39	5.06e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs62209	0.752	rs1928720	chr10:11014351	T/A	cg26901096	chr10:10994189	LOC254312	0.43	6.99	0.53	1.46e-10	Alzheimer's disease (late onset);
TGCT	cis	rs8014204	0.935	rs4903267	chr14:75360419	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.75	-7.22	-0.54	4.62e-11	Caffeine consumption;
TGCT	cis	rs13091206	1	rs13091206	chr3:49238718	A/G	cg07636037	chr3:49044803	WDR6	0.83	6.33	0.49	4.16e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs1348850	0.750	rs12997716	chr2:178494629	G/A	cg22681709	chr2:178499509	PDE11A	-0.47	-5.62	-0.45	1.18e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs11190604	0.767	rs10786590	chr10:102164604	T/C	cg23241863	chr10:102295624	HIF1AN	0.6	4.57	0.38	1.17e-5	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs12681288	0.676	rs17740799	chr8:1014327	C/T	cg08872321	chr8:1308229	NA	0.24	4.44	0.37	1.94e-5	Schizophrenia;
TGCT	cis	rs6666258	1.000	rs6666258	chr1:154814268	G/C	cg06418219	chr1:154948305	SHC1;CKS1B	0.62	5.04	0.41	1.59e-6	Atrial fibrillation;
TGCT	cis	rs7267979	0.753	rs400357	chr20:25479058	A/G	cg03522245	chr20:25566470	NINL	0.55	5.55	0.45	1.69e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs62244186	0.659	rs9855433	chr3:44468065	C/A	cg10108389	chr3:44770937	ZNF501	-0.47	-4.76	-0.39	5.34e-6	Depressive symptoms;
TGCT	cis	rs4919694	1.000	rs4919694	chr10:104698978	T/C	cg04362960	chr10:104952993	NT5C2	1.02	6.9	0.53	2.41e-10	Arsenic metabolism;
TGCT	cis	rs2862064	1.000	rs1910052	chr5:156429154	T/C	cg12943317	chr5:156479607	HAVCR1	-0.45	-5.92	-0.47	2.96e-8	Platelet count;
TGCT	cis	rs968451	0.762	rs5757618	chr22:39724551	A/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.85	8.61	0.61	2.85e-14	Primary biliary cholangitis;
TGCT	cis	rs4788570	0.615	rs10852503	chr16:71652227	G/C	cg06353428	chr16:71660113	MARVELD3	1.55	12.96	0.76	8.29e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs12220238	1.000	rs10824088	chr10:75921490	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.06	0.54	1.05e-10	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs9911578	1.000	rs8079774	chr17:56908188	A/G	cg05425664	chr17:57184151	TRIM37	-0.62	-6.06	-0.48	1.53e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg23131131	chr22:24373011	LOC391322	-0.66	-6.75	-0.52	5.03e-10	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6750047	0.566	rs1157184	chr2:38285774	C/G	cg07380506	chr2:38303506	CYP1B1	0.68	6.34	0.49	3.98e-9	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs12220898	0.749	rs10857456	chr10:50474756	A/G	cg06072769	chr10:50146962	WDFY4	0.36	4.67	0.39	7.64e-6	Inflammatory biomarkers;
TGCT	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg20607798	chr8:58055168	NA	0.45	4.62	0.38	9.54e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2072499	0.750	rs55675376	chr1:156165881	C/T	cg24450063	chr1:156163899	SLC25A44	1.13	10.64	0.69	3.48e-19	Testicular germ cell tumor;
TGCT	cis	rs7959452	0.535	rs1350166	chr12:69636314	G/T	cg14784868	chr12:69753453	YEATS4	0.69	7.0	0.53	1.39e-10	Blood protein levels;
TGCT	cis	rs11098499	0.909	rs2127821	chr4:120394535	T/C	cg09307838	chr4:120376055	NA	0.68	6.37	0.5	3.41e-9	Corneal astigmatism;
TGCT	cis	rs8017423	0.967	rs11627429	chr14:90689232	G/A	cg04374321	chr14:90722782	PSMC1	-0.76	-7.83	-0.58	1.9e-12	Mortality in heart failure;
TGCT	cis	rs3796352	1.000	rs13069006	chr3:52973305	G/C	cg07884673	chr3:53033167	SFMBT1	0.63	5.74	0.46	6.83e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg24675658	chr1:53192096	ZYG11B	0.89	11.91	0.73	2.9e-22	Monocyte count;
TGCT	cis	rs2115630	0.902	rs8023276	chr15:85219638	C/T	cg12501888	chr15:85177176	SCAND2	-0.49	-4.77	-0.39	5.18e-6	P wave terminal force;
TGCT	cis	rs7714584	0.793	rs2161363	chr5:150182079	G/C	cg22134413	chr5:150180641	NA	1.17	8.69	0.62	1.76e-14	Crohn's disease;
TGCT	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg21963583	chr11:68658836	MRPL21	0.36	6.17	0.48	9.01e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs4919669	0.623	rs2298278	chr10:104390303	A/G	cg05855489	chr10:104503620	C10orf26	0.73	4.67	0.39	7.6e-6	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs9653442	0.511	rs6739695	chr2:100859622	A/G	cg22139774	chr2:100720529	AFF3	-0.38	-6.19	-0.49	8.08e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs1163251	0.902	rs640195	chr1:120217650	T/A	cg19096424	chr1:120255104	PHGDH	0.56	5.29	0.43	5.46e-7	Blood metabolite levels;
TGCT	cis	rs939658	1.000	rs8031019	chr15:79458512	C/T	cg17916960	chr15:79447300	NA	-0.53	-8.43	-0.6	7.39e-14	Refractive error;
TGCT	cis	rs13064411	0.696	rs2129434	chr3:113138763	A/C	cg10517650	chr3:113235015	CCDC52	-0.35	-4.82	-0.4	4.2e-6	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs9868809	0.881	rs13096357	chr3:48675856	C/A	cg00383909	chr3:49044727	WDR6	0.93	4.92	0.4	2.68e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs922182	0.663	rs55929105	chr15:64265804	C/T	cg02919090	chr15:64263738	DAPK2	0.38	7.06	0.54	1.03e-10	Blood protein levels;
TGCT	cis	rs791888	0.929	rs2755431	chr10:89415104	C/T	cg13926569	chr10:89418898	PAPSS2	-0.35	-4.74	-0.39	5.67e-6	Magnesium levels;
TGCT	cis	rs7829975	0.582	rs6983150	chr8:8792426	A/G	cg06636001	chr8:8085503	FLJ10661	-0.72	-6.69	-0.52	6.68e-10	Mood instability;
TGCT	cis	rs981844	0.816	rs62325145	chr4:154725687	G/C	cg14289246	chr4:154710475	SFRP2	1.03	9.03	0.63	2.72e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs7542091	0.704	rs12022221	chr1:210046178	A/C	cg23283495	chr1:209979779	IRF6	0.52	5.25	0.43	6.36e-7	Monobrow;
TGCT	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg08736216	chr1:53307985	ZYG11A	0.25	4.93	0.4	2.59e-6	Monocyte count;
TGCT	cis	rs2120019	0.938	rs8028632	chr15:75321262	T/C	cg17294928	chr15:75287854	SCAMP5	-0.79	-6.27	-0.49	5.46e-9	Blood trace element (Zn levels);
TGCT	cis	rs7772486	0.686	rs857880	chr6:145971115	T/C	cg13319975	chr6:146136371	FBXO30	0.54	4.98	0.41	2.09e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs763121	0.853	rs2267395	chr22:39113903	C/T	cg06022373	chr22:39101656	GTPBP1	0.74	7.33	0.55	2.53e-11	Menopause (age at onset);
TGCT	cis	rs7226408	0.857	rs72885273	chr18:34438538	T/C	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs7647973	0.592	rs6774202	chr3:49687779	T/G	cg03060546	chr3:49711283	APEH	0.63	5.63	0.45	1.12e-7	Menarche (age at onset);
TGCT	cis	rs7772486	0.774	rs6930181	chr6:146180974	A/T	cg05347473	chr6:146136440	FBXO30	-0.5	-4.5	-0.37	1.53e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2657888	1.000	rs17540509	chr12:56943840	T/C	cg23932658	chr12:57637574	STAC3	-0.52	-4.74	-0.39	5.78e-6	Adiponectin levels;
TGCT	cis	rs9611565	0.559	rs132761	chr22:42004371	C/T	cg17554472	chr22:41940697	POLR3H	0.5	5.35	0.43	4.07e-7	Vitiligo;
TGCT	cis	rs4372836	0.576	rs6547880	chr2:29018889	T/C	cg09522027	chr2:28974177	PPP1CB	-0.69	-7.27	-0.55	3.54e-11	Body mass index;
TGCT	cis	rs12497850	0.897	rs9850134	chr3:48957147	A/G	cg06212747	chr3:49208901	KLHDC8B	0.61	5.62	0.45	1.2e-7	Parkinson's disease;
TGCT	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.0	7.42	0.55	1.64e-11	Gut microbiome composition (summer);
TGCT	cis	rs13256369	0.950	rs13255655	chr8:8577736	C/T	cg18904891	chr8:8559673	CLDN23	0.62	5.39	0.44	3.41e-7	Obesity-related traits;
TGCT	cis	rs72781680	0.756	rs2551337	chr2:24006886	C/T	cg08917208	chr2:24149416	ATAD2B	0.79	4.94	0.41	2.51e-6	Lymphocyte counts;
TGCT	cis	rs933688	0.938	rs1477348	chr5:90707823	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.96	8.06	0.59	5.53e-13	Smoking behavior;
TGCT	cis	rs4499344	0.693	rs8106502	chr19:33097796	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.83	8.7	0.62	1.68e-14	Mean platelet volume;
TGCT	cis	rs59107033	0.607	rs9851257	chr3:123125711	T/A	cg04890266	chr3:123102914	ADCY5	-0.37	-5.78	-0.46	5.69e-8	Lymphocyte counts;
TGCT	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg08280861	chr8:58055591	NA	0.49	5.47	0.44	2.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs4727027	0.727	rs1568944	chr7:148873497	A/T	cg23583168	chr7:148888333	NA	-0.68	-8.19	-0.59	2.74e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs11673344	0.523	rs8101392	chr19:37515318	A/G	cg08039142	chr19:36980659	ZNF566	0.5	4.72	0.39	6.26e-6	Obesity-related traits;
TGCT	trans	rs2760061	0.819	rs708114	chr1:228197496	G/A	cg16006296	chr10:38738647	LOC399744	-0.31	-7.08	-0.54	9.57e-11	Diastolic blood pressure;
TGCT	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg16325326	chr1:53192061	ZYG11B	-0.71	-8.82	-0.62	8.9e-15	Monocyte count;
TGCT	cis	rs644799	0.965	rs687529	chr11:95545587	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	10.57	0.69	5.17e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9399135	1.000	rs11754265	chr6:135356216	C/G	cg24558204	chr6:135376177	HBS1L	0.46	4.59	0.38	1.09e-5	Red blood cell count;
TGCT	cis	rs9911578	1.000	rs302854	chr17:56683612	G/A	cg05425664	chr17:57184151	TRIM37	-0.63	-6.24	-0.49	6.44e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs10056811	0.538	rs2035191	chr5:74413713	T/C	cg00601450	chr5:74908170	NA	0.46	4.5	0.37	1.57e-5	Coronary artery disease;
TGCT	trans	rs9354352	0.935	rs7766730	chr6:66697003	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	7.89	0.58	1.33e-12	Initial pursuit acceleration in psychotic disorders;
TGCT	cis	rs981844	0.712	rs1037654	chr4:154750300	C/G	cg14289246	chr4:154710475	SFRP2	-0.99	-9.12	-0.63	1.65e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs2180341	0.960	rs6913424	chr6:127707010	A/C	cg27446573	chr6:127587934	RNF146	1.1	10.08	0.67	8.12e-18	Breast cancer;
TGCT	cis	rs1949733	0.701	rs2631754	chr4:8449233	A/G	cg11789530	chr4:8429930	ACOX3	0.53	4.99	0.41	2e-6	Response to antineoplastic agents;
TGCT	cis	rs4727027	0.866	rs2373438	chr7:148780287	C/A	cg23583168	chr7:148888333	NA	-0.69	-8.76	-0.62	1.23e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs12701220	0.817	rs7798459	chr7:1087965	C/T	cg27454412	chr7:1067447	C7orf50	-0.48	-4.45	-0.37	1.87e-5	Bronchopulmonary dysplasia;
TGCT	cis	rs79387448	0.745	rs7575867	chr2:103120179	C/T	cg09003973	chr2:102972529	NA	0.85	5.65	0.45	1.03e-7	Gut microbiota (bacterial taxa);
TGCT	cis	rs12188164	0.930	rs11743825	chr5:475463	C/T	cg26850624	chr5:429559	AHRR	-0.2	-4.85	-0.4	3.59e-6	Cystic fibrosis severity;
TGCT	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.46	-6.43	-0.5	2.53e-9	Alzheimer's disease;
TGCT	cis	rs7809950	0.678	rs62483641	chr7:106901741	T/C	cg23024343	chr7:107201750	COG5	-0.43	-5.81	-0.46	4.86e-8	Coronary artery disease;
TGCT	cis	rs7119	0.717	rs12901732	chr15:77818933	G/T	cg27398640	chr15:77910606	LINGO1	-0.25	-4.61	-0.38	9.81e-6	Type 2 diabetes;
TGCT	cis	rs896854	0.654	rs13278601	chr8:95972974	G/C	cg23172400	chr8:95962367	TP53INP1	-0.39	-6.52	-0.51	1.57e-9	Type 2 diabetes;
TGCT	cis	rs3902035	0.964	rs62423994	chr6:119011597	G/A	cg07617317	chr6:118971624	C6orf204	0.43	5.01	0.41	1.79e-6	QT interval;
TGCT	cis	rs586688	0.625	rs481966	chr1:201655746	A/G	cg14168733	chr1:201708718	NAV1	-0.55	-4.44	-0.37	1.93e-5	Obesity-related traits;
TGCT	cis	rs17076896	0.708	rs61956079	chr13:19932611	A/G	cg00777926	chr13:20807375	GJB6	-0.37	-4.53	-0.38	1.36e-5	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.73	-7.05	-0.54	1.09e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs977747	0.872	rs6658125	chr1:47677015	C/T	cg03885399	chr1:47691550	TAL1	-0.42	-5.48	-0.44	2.27e-7	Body mass index;
TGCT	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs41271951	0.542	rs12138787	chr1:150246070	T/C	cg18798344	chr1:149336151	NA	0.56	4.5	0.37	1.52e-5	Blood protein levels;
TGCT	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg11494091	chr17:61959527	GH2	0.61	14.81	0.8	3.37e-29	Prudent dietary pattern;
TGCT	cis	rs3087591	0.683	rs757375	chr17:29717879	C/G	cg24425628	chr17:29625626	OMG;NF1	0.4	5.87	0.47	3.67e-8	Hip circumference;
TGCT	trans	rs561341	1.000	rs56903735	chr17:30254393	T/A	cg20587970	chr11:113659929	NA	-1.03	-11.15	-0.71	2.03e-20	Hip circumference adjusted for BMI;
TGCT	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg03806693	chr22:41940476	POLR3H	-1.13	-13.26	-0.77	1.59e-25	Vitiligo;
TGCT	cis	rs713587	0.967	rs6752378	chr2:25150116	C/A	cg15423357	chr2:25149977	NA	0.63	6.47	0.5	2.01e-9	Body mass index in non-asthmatics;
TGCT	cis	rs10751667	0.643	rs7394436	chr11:970373	G/C	cg06064525	chr11:970664	AP2A2	-0.36	-8.28	-0.6	1.67e-13	Alzheimer's disease (late onset);
TGCT	cis	rs933688	0.938	rs7705465	chr5:90680949	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.99	8.15	0.59	3.39e-13	Smoking behavior;
TGCT	cis	rs8068544	0.606	rs77681389	chr17:40154419	T/C	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.07	-5.1	-0.42	1.26e-6	Reticulocyte fraction of red cells;Reticulocyte count;
TGCT	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7666738	0.830	rs7694889	chr4:98855596	T/C	cg18180107	chr4:99064573	C4orf37	0.55	5.14	0.42	1.03e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9549367	0.789	rs34989271	chr13:113894766	G/A	cg18105134	chr13:113819100	PROZ	-0.34	-5.58	-0.45	1.41e-7	Platelet distribution width;
TGCT	cis	rs7119	0.667	rs907392	chr15:77903393	T/C	cg27398640	chr15:77910606	LINGO1	0.32	6.76	0.52	4.86e-10	Type 2 diabetes;
TGCT	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg08280861	chr8:58055591	NA	0.39	4.76	0.39	5.35e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs60843830	1.000	rs4497901	chr2:239969	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.75	7.58	0.56	6.94e-12	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs2832191	0.632	rs2246777	chr21:30309586	T/C	cg24692254	chr21:30365293	RNF160	-0.94	-10.37	-0.68	1.6e-18	Dental caries;
TGCT	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg00343986	chr7:65444356	GUSB	0.23	5.14	0.42	1.06e-6	Aortic root size;
TGCT	cis	rs6138458	1.000	rs227627	chr20:24912107	T/C	cg26195577	chr20:24973756	C20orf3	1.2	12.04	0.73	1.35e-22	Blood protein levels;
TGCT	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg15242686	chr22:24348715	GSTTP1	0.42	5.66	0.45	1.01e-7	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1008375	0.897	rs3733577	chr4:17649233	T/G	cg16339924	chr4:17578868	LAP3	0.67	5.48	0.44	2.23e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7729723	0.533	rs219277	chr5:137833766	C/T	cg19169342	chr5:137827400	NA	0.33	4.53	0.38	1.37e-5	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);
TGCT	cis	rs7582180	0.629	rs13031508	chr2:100952757	A/G	cg08017756	chr2:100939284	LONRF2	-0.3	-4.82	-0.4	4.16e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2404602	0.710	rs2469541	chr15:76562118	C/T	cg22467129	chr15:76604101	ETFA	0.69	8.66	0.61	2.1e-14	Blood metabolite levels;
TGCT	cis	rs12579753	0.917	rs12372724	chr12:82193628	C/T	cg07988820	chr12:82153109	PPFIA2	-0.59	-6.19	-0.49	7.93e-9	Resting heart rate;
TGCT	cis	rs231513	0.911	rs231515	chr17:41964083	A/G	cg26893861	chr17:41843967	DUSP3	-0.71	-5.21	-0.42	7.57e-7	Cognitive function;
TGCT	cis	rs1371867	0.875	rs1660344	chr8:101324659	A/G	cg06636551	chr8:101224915	SPAG1	-0.48	-6.52	-0.51	1.62e-9	Atrioventricular conduction;
TGCT	cis	rs939658	0.683	rs8038464	chr15:79463036	A/T	cg17916960	chr15:79447300	NA	-0.42	-6.64	-0.51	8.59e-10	Refractive error;
TGCT	trans	rs208520	0.661	rs7747492	chr6:66857788	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-10.43	-0.68	1.13e-18	Exhaled nitric oxide output;
TGCT	cis	rs804280	0.662	rs11784693	chr8:11610674	C/T	cg26752888	chr8:11627280	NEIL2	0.69	5.48	0.44	2.32e-7	Myopia (pathological);
TGCT	cis	rs11249608	0.636	rs6868893	chr5:178449826	C/A	cg01312482	chr5:178451176	ZNF879	-0.57	-5.6	-0.45	1.34e-7	Pubertal anthropometrics;
TGCT	cis	rs4273100	0.688	rs12939947	chr17:19204531	A/T	cg03910582	chr17:19030146	GRAPL	0.53	6.46	0.5	2.11e-9	Schizophrenia;
TGCT	cis	rs7523050	0.643	rs36047249	chr1:109401499	T/C	cg08274380	chr1:109419600	GPSM2	1.3	6.39	0.5	2.99e-9	Fat distribution (HIV);
TGCT	cis	rs3091242	0.933	rs3093584	chr1:25668714	T/C	cg23205692	chr1:25664452	TMEM50A	-0.51	-5.22	-0.42	7.26e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs3087591	0.708	rs3815154	chr17:29654974	G/A	cg24425628	chr17:29625626	OMG;NF1	0.39	5.46	0.44	2.45e-7	Hip circumference;
TGCT	cis	rs12693043	0.727	rs6748959	chr2:175424127	C/T	cg11778734	chr2:175439522	WIPF1	-0.37	-4.82	-0.4	4.09e-6	Urate levels (BMI interaction);
TGCT	cis	rs6840360	0.642	rs7658169	chr4:152353414	G/A	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.83e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs694739	0.892	rs647152	chr11:64109118	T/G	cg02228329	chr11:64053129	BAD;GPR137	0.72	7.0	0.53	1.43e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs6912958	0.703	rs6903219	chr6:88096498	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.62	6.12	0.48	1.13e-8	Monocyte percentage of white cells;
TGCT	cis	rs17331151	0.573	rs4687556	chr3:52890475	T/C	cg15956490	chr3:53032818	SFMBT1	-0.47	-5.9	-0.47	3.27e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs3858526	0.883	rs7481882	chr11:5944221	A/G	cg05234568	chr11:5960015	NA	-0.46	-4.51	-0.38	1.45e-5	DNA methylation (variation);
TGCT	cis	rs4144743	1.000	rs4144743	chr17:45323125	A/G	cg18085866	chr17:45331354	ITGB3	-0.72	-4.88	-0.4	3.15e-6	Body mass index;
TGCT	cis	rs12549902	0.933	rs17659428	chr8:41513809	T/C	cg21772509	chr8:41503840	NKX6-3	0.85	9.62	0.65	1.04e-16	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
TGCT	cis	rs5769707	0.605	rs9616702	chr22:50025938	A/G	cg06623630	chr22:50017776	C22orf34	-0.27	-4.65	-0.39	8.38e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs6582630	0.599	rs12309369	chr12:38419683	C/G	cg26384229	chr12:38710491	ALG10B	-0.54	-4.81	-0.4	4.32e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs12477438	0.520	rs13010904	chr2:99754289	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.85	8.37	0.6	1.02e-13	Chronic sinus infection;
TGCT	cis	rs2239547	0.657	rs4687554	chr3:52864135	T/C	cg11645453	chr3:52864694	ITIH4	0.34	5.69	0.46	8.61e-8	Schizophrenia;
TGCT	cis	rs11648796	0.718	rs62032512	chr16:764826	C/T	cg07343612	chr16:622815	PIGQ	-0.36	-5.0	-0.41	1.89e-6	Height;
TGCT	cis	rs910187	0.605	rs3787239	chr20:45802729	T/C	cg27589058	chr20:45804311	EYA2	-0.4	-8.74	-0.62	1.37e-14	Migraine;
TGCT	cis	rs62380364	0.602	rs589544	chr5:88064462	T/C	cg24804195	chr5:87968844	LOC645323	-0.55	-5.34	-0.43	4.23e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs892961	0.720	rs103458	chr17:75416031	A/G	cg05865280	chr17:75406074	SEPT9	0.29	6.83	0.52	3.46e-10	Airflow obstruction;
TGCT	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg13770153	chr20:60521292	NA	-0.54	-7.12	-0.54	7.73e-11	Body mass index;
TGCT	cis	rs2562456	0.833	rs2681388	chr19:21732253	G/C	cg01304269	chr19:21688519	ZNF429	0.57	4.74	0.39	5.86e-6	Pain;
TGCT	cis	rs12210905	1.000	rs12205921	chr6:27113540	G/T	cg08851530	chr6:28072375	NA	1.05	5.16	0.42	9.42e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg05785598	chr3:49045655	WDR6	0.38	5.12	0.42	1.14e-6	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs7568458	0.709	rs1446669	chr2:85762209	T/C	cg17127132	chr2:85788382	GGCX	0.52	4.77	0.39	5.12e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs12549902	0.966	rs6990613	chr8:41515130	A/G	cg21772509	chr8:41503840	NKX6-3	0.86	9.58	0.65	1.35e-16	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
TGCT	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg08736216	chr1:53307985	ZYG11A	0.25	4.93	0.4	2.59e-6	Monocyte count;
TGCT	cis	rs763121	0.925	rs4821797	chr22:39016182	T/C	cg06022373	chr22:39101656	GTPBP1	0.79	7.98	0.58	8.44e-13	Menopause (age at onset);
TGCT	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg20203395	chr5:56204925	C5orf35	-0.58	-4.87	-0.4	3.34e-6	Initial pursuit acceleration;
TGCT	cis	rs8017423	0.935	rs7158410	chr14:90704370	T/C	cg04374321	chr14:90722782	PSMC1	0.77	8.04	0.59	6.19e-13	Mortality in heart failure;
TGCT	cis	rs6669919	0.967	rs7513031	chr1:211671900	C/T	cg26515805	chr1:211431828	RCOR3	0.4	4.66	0.39	7.93e-6	Intelligence (multi-trait analysis);
TGCT	trans	rs1814175	0.817	rs4405313	chr11:50013636	G/A	cg15704280	chr7:45808275	SEPT13	-0.72	-8.47	-0.61	6.02e-14	Height;
TGCT	cis	rs62244186	0.748	rs2888410	chr3:44655476	A/C	cg10263370	chr3:44754102	ZNF502	-0.44	-5.26	-0.43	6.2e-7	Depressive symptoms;
TGCT	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg08048268	chr3:133502702	NA	-0.67	-10.27	-0.68	2.75e-18	Iron status biomarkers;
TGCT	cis	rs9549367	0.713	rs9549356	chr13:113851633	A/G	cg00898013	chr13:113819073	PROZ	-0.53	-6.94	-0.53	1.89e-10	Platelet distribution width;
TGCT	cis	rs9486719	1.000	rs2179126	chr6:96871350	A/G	cg18709589	chr6:96969512	KIAA0776	0.71	5.21	0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs9308731	0.583	rs10211562	chr2:111930796	G/T	cg04202892	chr2:111875749	ACOXL	0.45	5.11	0.42	1.21e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs7953249	0.656	rs6489786	chr12:121397875	A/G	cg02403541	chr12:121454288	C12orf43	-0.62	-5.3	-0.43	5.11e-7	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs1215050	0.755	rs811479	chr4:98727398	A/T	cg17366294	chr4:99064904	C4orf37	0.52	5.61	0.45	1.27e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs4727027	0.870	rs1534196	chr7:148790591	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	4.9	0.4	2.96e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs977747	0.815	rs11211480	chr1:47693220	A/G	cg03885399	chr1:47691550	TAL1	-0.39	-5.12	-0.42	1.11e-6	Body mass index;
TGCT	cis	rs1903068	0.853	rs12331471	chr4:56001509	T/C	cg16572876	chr4:56024045	NA	0.43	4.94	0.41	2.43e-6	Endometriosis;
TGCT	cis	rs9814567	1.000	rs9851441	chr3:134315091	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.91	-8.78	-0.62	1.1e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs950169	1.000	rs62026530	chr15:84775840	G/T	cg11189052	chr15:85197271	WDR73	0.69	5.91	0.47	3.07e-8	Schizophrenia;
TGCT	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg14456004	chr13:21872349	NA	1.25	12.41	0.74	1.76e-23	White matter hyperintensity burden;
TGCT	cis	rs4746818	1.000	rs4746818	chr10:70884687	G/T	cg11621586	chr10:70884670	VPS26A	1.19	11.41	0.72	4.59e-21	Left atrial antero-posterior diameter;
TGCT	cis	rs2463822	0.920	rs11828383	chr11:62067818	C/T	cg06239285	chr11:62104954	ASRGL1	-0.89	-5.48	-0.44	2.32e-7	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs473651	0.837	rs563458	chr2:239345613	T/A	cg08773314	chr2:239334832	ASB1	0.45	7.45	0.56	1.38e-11	Multiple system atrophy;
TGCT	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg12564285	chr5:131593104	PDLIM4	0.38	4.64	0.38	8.61e-6	Acylcarnitine levels;
TGCT	cis	rs2153535	0.580	rs9406164	chr6:8470048	C/T	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs6543140	0.964	rs10169192	chr2:103072211	A/G	cg09003973	chr2:102972529	NA	0.55	4.67	0.39	7.71e-6	Blood protein levels;
TGCT	cis	rs1865760	0.566	rs2032445	chr6:26044812	T/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.77	7.31	0.55	2.87e-11	Height;
TGCT	cis	rs4711350	0.862	rs530614	chr6:33714781	G/A	cg00334056	chr6:33755658	LEMD2	0.31	4.77	0.39	5.04e-6	Schizophrenia;
TGCT	cis	rs11627546	0.615	rs61980616	chr14:70366459	C/T	cg10496350	chr14:71275911	MAP3K9	-0.94	-4.44	-0.37	1.96e-5	Red blood cell traits;
TGCT	cis	rs67311347	0.544	rs6762121	chr3:40355313	G/A	cg13683864	chr3:40499215	RPL14	-0.84	-7.85	-0.58	1.71e-12	Renal cell carcinoma;
TGCT	cis	rs2404602	1.000	rs2120107	chr15:76869789	A/G	cg26408565	chr15:76604113	ETFA	-0.35	-4.56	-0.38	1.22e-5	Blood metabolite levels;
TGCT	cis	rs2041840	0.960	rs2058716	chr2:37510013	C/G	cg22629987	chr2:37571677	QPCT	0.46	4.5	0.37	1.54e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs3091242	0.933	rs28633797	chr1:25741629	C/A	cg09222892	chr1:25734099	RHCE	-0.44	-7.02	-0.53	1.3100000000000001e-10	Erythrocyte sedimentation rate;
TGCT	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-8.44	-0.6	6.87e-14	Platelet count;
TGCT	cis	rs7100689	0.784	rs10736342	chr10:82130005	A/G	cg01528321	chr10:82214614	TSPAN14	0.88	8.48	0.61	5.61e-14	Post bronchodilator FEV1;
TGCT	cis	rs2404602	0.692	rs12904198	chr15:77146978	G/A	cg22467129	chr15:76604101	ETFA	-0.47	-5.4	-0.44	3.28e-7	Blood metabolite levels;
TGCT	cis	rs2742234	0.955	rs2075913	chr10:43622368	T/A	cg02780029	chr10:43622663	RET	-0.25	-4.91	-0.4	2.87e-6	Hirschsprung disease;
TGCT	cis	rs7647973	0.593	rs62262730	chr3:49808274	T/G	cg03060546	chr3:49711283	APEH	-0.63	-5.33	-0.43	4.5e-7	Menarche (age at onset);
TGCT	cis	rs10791097	0.694	rs4459316	chr11:130756176	T/C	cg12179176	chr11:130786555	SNX19	0.83	9.92	0.67	1.94e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs3749237	0.964	rs10865959	chr3:49891002	G/C	cg07636037	chr3:49044803	WDR6	0.56	4.68	0.39	7.52e-6	Resting heart rate;
TGCT	cis	rs10832963	0.924	rs10500834	chr11:18638712	A/T	cg20219074	chr11:18656078	SPTY2D1	1.0	9.93	0.67	1.85e-17	Breast cancer;
TGCT	cis	rs7267979	0.966	rs6037083	chr20:25290543	T/C	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs35306767	0.903	rs11813210	chr10:919796	G/A	cg26597838	chr10:835615	NA	0.75	10.54	0.69	6.3e-19	Eosinophil percentage of granulocytes;
TGCT	cis	rs7927592	0.763	rs10896326	chr11:68234571	T/C	cg16797656	chr11:68205561	LRP5	0.26	4.54	0.38	1.29e-5	Total body bone mineral density;
TGCT	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg24503407	chr1:205819492	PM20D1	0.58	8.13	0.59	3.84e-13	Menarche (age at onset);
TGCT	cis	rs7666738	0.830	rs11940273	chr4:98979965	T/A	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12711979	0.509	rs10205540	chr2:3827839	A/G	cg17052675	chr2:3827356	NA	-0.56	-13.37	-0.77	8.42e-26	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg00149659	chr3:10157352	C3orf10	0.91	5.89	0.47	3.32e-8	Alzheimer's disease;
TGCT	cis	rs7666738	0.830	rs2903150	chr4:99027184	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg10802521	chr3:52805072	NEK4	-0.71	-8.72	-0.62	1.51e-14	Bipolar disorder;
TGCT	cis	rs2153535	0.541	rs9379207	chr6:8458186	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs4851266	0.966	rs13026283	chr2:100842638	C/T	cg22139774	chr2:100720529	AFF3	-0.34	-4.99	-0.41	2.01e-6	Educational attainment;
TGCT	trans	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg25482853	chr8:67687455	SGK3	1.21	10.33	0.68	2.02e-18	Lung disease severity in cystic fibrosis;
TGCT	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg22920501	chr2:26401640	FAM59B	0.72	6.19	0.49	8.23e-9	Gut microbiome composition (summer);
TGCT	cis	rs6693567	0.545	rs11205375	chr1:150412474	C/T	cg09579323	chr1:150459698	TARS2	0.52	4.62	0.38	9.56e-6	Migraine;
TGCT	cis	rs9581857	0.547	rs17753763	chr13:28077734	A/G	cg22138327	chr13:27999177	GTF3A	0.73	4.54	0.38	1.34e-5	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg01802117	chr1:53393560	SCP2	-0.44	-5.21	-0.42	7.54e-7	Monocyte count;
TGCT	cis	rs12791968	0.765	rs12794846	chr11:44998943	C/T	cg11846598	chr11:44996168	LOC221122	0.33	4.89	0.4	3.09e-6	Inhibitory control;
TGCT	cis	rs524281	0.861	rs12226649	chr11:65842047	T/C	cg00563793	chr11:65837595	PACS1	0.6	5.26	0.43	6.11e-7	Electroencephalogram traits;
TGCT	cis	rs854765	0.647	rs854763	chr17:18010095	C/G	cg04398451	chr17:18023971	MYO15A	-0.37	-6.46	-0.5	2.14e-9	Total body bone mineral density;
TGCT	cis	rs360798	0.512	rs2539978	chr2:63195179	T/C	cg17519650	chr2:63277830	OTX1	0.62	5.73	0.46	7.22e-8	Coronary artery disease;
TGCT	cis	rs3796352	0.764	rs11714902	chr3:53101544	G/C	cg07884673	chr3:53033167	SFMBT1	0.61	6.28	0.49	5.2e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs6831352	0.879	rs4699716	chr4:100066125	G/A	cg12011299	chr4:100065546	ADH4	-0.43	-5.07	-0.41	1.44e-6	Alcohol dependence;
TGCT	cis	rs72949976	1.000	rs6747328	chr2:214032156	C/G	cg08319019	chr2:214017104	IKZF2	-0.83	-7.74	-0.57	2.99e-12	Lung cancer;Squamous cell lung carcinoma;
TGCT	cis	rs7727544	0.709	rs272852	chr5:131688767	G/A	cg24060327	chr5:131705240	SLC22A5	-0.57	-6.39	-0.5	3.11e-9	Blood metabolite levels;
TGCT	cis	rs6570726	0.837	rs419991	chr6:145864212	C/T	cg23711669	chr6:146136114	FBXO30	0.71	7.03	0.53	1.25e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs8135665	0.600	rs6519097	chr22:38451465	C/T	cg13116946	chr22:38479732	SLC16A8	0.3	5.77	0.46	5.94e-8	Advanced age-related macular degeneration;Age-related macular degeneration;
TGCT	cis	rs71636778	0.509	rs12742376	chr1:27285195	C/T	cg23921621	chr1:27994728	IFI6	-0.43	-4.61	-0.38	9.92e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
TGCT	cis	rs1401999	1.000	rs6443924	chr3:183679532	A/G	cg01324343	chr3:183735012	ABCC5	0.82	10.97	0.7	5.41e-20	Anterior chamber depth;
TGCT	cis	rs8070740	1.000	rs8066928	chr17:5328155	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	4.55	0.38	1.27e-5	Menopause (age at onset);
TGCT	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg03161606	chr19:29218774	NA	0.59	5.71	0.46	7.95e-8	Methadone dose in opioid dependence;
TGCT	cis	rs28595532	0.920	rs17257039	chr4:119603703	G/A	cg11846333	chr4:119757529	SEC24D	0.95	4.68	0.39	7.54e-6	Cannabis dependence symptom count;
TGCT	cis	rs17376456	0.542	rs10476588	chr5:93208330	C/T	cg21475434	chr5:93447410	FAM172A	-0.68	-5.22	-0.42	7.16e-7	Diabetic retinopathy;
TGCT	cis	rs10782582	0.609	rs5745485	chr1:76349534	C/G	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.52	4.53	0.38	1.37e-5	Daytime sleep phenotypes;
TGCT	cis	rs1799949	0.794	rs116409325	chr17:41445460	C/A	cg23758822	chr17:41437982	NA	0.7	6.59	0.51	1.14e-9	Menopause (age at onset);
TGCT	cis	rs10876993	0.890	rs812304	chr12:58074853	A/C	cg15848620	chr12:58087721	OS9	-0.72	-5.83	-0.46	4.52e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs79387448	0.638	rs11465670	chr2:103034440	A/G	cg09003973	chr2:102972529	NA	1.27	9.82	0.66	3.37e-17	Gut microbiota (bacterial taxa);
TGCT	cis	rs7829975	0.582	rs11783950	chr8:8597831	A/C	cg15556689	chr8:8085844	FLJ10661	-0.54	-4.62	-0.38	9.37e-6	Mood instability;
TGCT	cis	rs1691799	0.899	rs4762091	chr12:66747863	A/G	cg16791601	chr12:66731901	HELB	-0.29	-6.17	-0.48	8.77e-9	White blood cell count (basophil);
TGCT	cis	rs2439831	0.867	rs2920781	chr15:43924682	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	4.95	0.41	2.38e-6	Lung cancer in ever smokers;
TGCT	cis	rs3087591	0.636	rs736598	chr17:29720470	T/C	cg24425628	chr17:29625626	OMG;NF1	0.4	5.87	0.47	3.67e-8	Hip circumference;
TGCT	cis	rs4478858	0.735	rs7547897	chr1:31797593	G/A	cg00250761	chr1:31883323	NA	-0.28	-4.96	-0.41	2.32e-6	Alcohol dependence;
TGCT	cis	rs79976124	0.879	rs77185357	chr6:66629070	G/A	cg07460842	chr6:66804631	NA	0.57	5.23	0.43	6.84e-7	Type 2 diabetes;
TGCT	cis	rs2996428	0.536	rs12126653	chr1:3773815	C/G	cg17848003	chr1:3704513	LRRC47	0.17	4.98	0.41	2.1e-6	Red cell distribution width;
TGCT	cis	rs12478296	0.681	rs6598999	chr2:242994405	C/A	cg06360820	chr2:242988706	NA	-0.62	-5.33	-0.43	4.43e-7	Obesity-related traits;
TGCT	cis	rs10851411	0.862	rs1900921	chr15:42787144	C/A	cg23803468	chr15:43513504	EPB42	0.28	5.15	0.42	1.01e-6	Glucose homeostasis traits;
TGCT	cis	rs2730245	0.563	rs2709857	chr7:158685257	T/C	cg24397884	chr7:158709396	WDR60	0.34	4.45	0.37	1.9e-5	Height;
TGCT	cis	rs4786125	0.636	rs9932626	chr16:6917014	C/G	cg03623568	chr16:6915990	A2BP1	-0.43	-6.34	-0.49	3.9e-9	Heart rate variability traits (SDNN);
TGCT	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg20203395	chr5:56204925	C5orf35	0.53	4.89	0.4	3.03e-6	Initial pursuit acceleration;
TGCT	cis	rs12681287	0.752	rs10100235	chr8:87249294	A/G	cg27223183	chr8:87520930	FAM82B	-0.81	-5.89	-0.47	3.47e-8	Caudate activity during reward;
TGCT	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg16680214	chr1:154839983	KCNN3	-0.4	-8.92	-0.63	5e-15	Prostate cancer;
TGCT	cis	rs7647973	0.516	rs4955418	chr3:49200627	A/G	cg03060546	chr3:49711283	APEH	0.5	4.7	0.39	6.82e-6	Menarche (age at onset);
TGCT	cis	rs860554	0.705	rs832166	chr1:201255692	C/T	cg01022117	chr1:201258280	PKP1	0.34	5.05	0.41	1.52e-6	Panic disorder;
TGCT	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.5	-4.81	-0.4	4.26e-6	Bipolar disorder;
TGCT	cis	rs10504229	0.636	rs77691549	chr8:58055126	G/T	cg20607798	chr8:58055168	NA	0.59	4.95	0.41	2.38e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg11905131	chr22:24372483	LOC391322	0.87	10.07	0.67	8.4e-18	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs10992471	0.603	rs10820974	chr9:95211876	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.53	-4.99	-0.41	2.03e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs4273100	0.688	rs1533034	chr17:19153175	G/C	cg03910582	chr17:19030146	GRAPL	0.47	5.45	0.44	2.63e-7	Schizophrenia;
TGCT	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg12311346	chr5:56204834	C5orf35	-0.66	-6.67	-0.51	7.55e-10	Initial pursuit acceleration;
TGCT	cis	rs7845219	0.544	rs10956932	chr8:95948202	C/T	cg16049864	chr8:95962084	TP53INP1	0.48	5.31	0.43	5e-7	Type 2 diabetes;
TGCT	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg21862992	chr11:68658383	NA	0.49	6.62	0.51	9.71e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs4148883	0.898	rs4699726	chr4:100099513	T/C	cg12011299	chr4:100065546	ADH4	0.35	5.14	0.42	1.03e-6	Alcohol dependence;
TGCT	trans	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.8	8.32	0.6	1.31e-13	Body mass index;
TGCT	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg02953382	chr22:24373134	LOC391322	-0.82	-9.0	-0.63	3.34e-15	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs17030434	0.822	rs28367474	chr4:154718642	A/G	cg14289246	chr4:154710475	SFRP2	-0.92	-7.76	-0.57	2.76e-12	Electrocardiographic conduction measures;
TGCT	cis	rs79349575	0.783	rs17635252	chr17:47006950	T/C	cg07967210	chr17:47022446	SNF8	0.44	6.13	0.48	1.1e-8	Type 2 diabetes;
TGCT	cis	rs4506170	1.000	rs72712310	chr8:128333565	G/A	cg07795030	chr8:128802207	NA	-0.21	-4.56	-0.38	1.23e-5	Prostate cancer;
TGCT	cis	rs67311347	0.866	rs3214006	chr3:40352134	C/T	cg13683864	chr3:40499215	RPL14	-0.91	-8.78	-0.62	1.08e-14	Renal cell carcinoma;
TGCT	cis	rs7727544	0.716	rs6863213	chr5:131575932	C/T	cg21474247	chr5:131268130	NA	0.31	4.59	0.38	1.07e-5	Blood metabolite levels;
TGCT	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg06873352	chr17:61820015	STRADA	0.56	6.22	0.49	7.1e-9	Prudent dietary pattern;
TGCT	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg26668828	chr6:292823	DUSP22	-0.82	-8.5	-0.61	5.15e-14	Menopause (age at onset);
TGCT	cis	rs9902453	0.780	rs57037139	chr17:28173283	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	7.17	0.54	5.79e-11	Coffee consumption (cups per day);
TGCT	cis	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg00343986	chr7:65444356	GUSB	0.25	5.49	0.44	2.18e-7	Aortic root size;
TGCT	cis	rs4851266	0.966	rs1465800	chr2:100834777	T/C	cg22139774	chr2:100720529	AFF3	-0.35	-5.41	-0.44	3.1e-7	Educational attainment;
TGCT	cis	rs295140	1.000	rs7580924	chr2:201172628	G/C	cg04283868	chr2:201171347	SPATS2L	0.63	6.43	0.5	2.46e-9	QT interval;
TGCT	cis	rs9914988	0.619	rs9898529	chr17:27318861	A/T	cg17523868	chr17:27313033	SEZ6	-0.57	-4.84	-0.4	3.82e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs12477438	0.520	rs11123764	chr2:99750677	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	8.52	0.61	4.42e-14	Chronic sinus infection;
TGCT	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg12310025	chr6:25882481	NA	0.79	8.09	0.59	4.59e-13	Blood metabolite levels;
TGCT	cis	rs611744	1.000	rs611744	chr8:109228008	A/G	cg21045802	chr8:109455806	TTC35	0.52	4.72	0.39	6.21e-6	Dupuytren's disease;
TGCT	cis	rs739496	0.615	rs77684561	chr12:112061723	C/T	cg10833066	chr12:111807467	FAM109A	0.37	4.88	0.4	3.26e-6	Platelet count;
TGCT	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg00149659	chr3:10157352	C3orf10	0.91	5.89	0.47	3.32e-8	Alzheimer's disease;
TGCT	cis	rs2836633	0.929	rs58120977	chr21:40037346	C/T	cg12884169	chr21:40033163	ERG	0.45	4.98	0.41	2.13e-6	Coronary artery disease;
TGCT	cis	rs4851254	0.961	rs11680586	chr2:100746207	G/T	cg23118464	chr2:100721844	AFF3	0.69	5.08	0.42	1.34e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9467773	0.526	rs9348710	chr6:26360486	A/C	cg15659132	chr6:26577336	NA	-0.53	-5.47	-0.44	2.37e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs1813251	chr4:98921170	A/G	cg18180107	chr4:99064573	C4orf37	0.57	5.18	0.42	8.79e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6540559	0.611	rs61747285	chr1:210004332	G/A	cg23283495	chr1:209979779	IRF6	0.6	4.5	0.37	1.54e-5	Cleft lip with or without cleft palate;
TGCT	cis	rs7829975	0.744	rs2409092	chr8:8682192	A/T	cg06636001	chr8:8085503	FLJ10661	0.69	6.25	0.49	6.14e-9	Mood instability;
TGCT	cis	rs11098499	0.644	rs6855918	chr4:120546299	C/T	cg09307838	chr4:120376055	NA	0.62	5.86	0.47	3.86e-8	Corneal astigmatism;
TGCT	cis	rs2836633	0.929	rs62217518	chr21:40033189	T/G	cg12884169	chr21:40033163	ERG	0.43	4.69	0.39	7.03e-6	Coronary artery disease;
TGCT	cis	rs13188771	0.651	rs59109546	chr5:100879961	G/A	cg18665594	chr5:101119420	NA	0.44	4.47	0.37	1.74e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs13108904	0.517	rs7671242	chr4:1339875	G/A	cg00684032	chr4:1343700	KIAA1530	0.23	4.77	0.39	4.98e-6	Obesity-related traits;
TGCT	cis	rs3087591	0.708	rs7503922	chr17:29641935	C/A	cg24425628	chr17:29625626	OMG;NF1	0.39	5.76	0.46	6.19e-8	Hip circumference;
TGCT	cis	rs9303401	0.659	rs62083410	chr17:56964386	T/C	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs2856321	1.000	rs11054424	chr12:11860170	C/G	cg26373351	chr12:12031304	ETV6	0.21	4.43	0.37	2.01e-5	Height;
TGCT	cis	rs7959452	0.684	rs11177615	chr12:69754189	G/A	cg11871910	chr12:69753446	YEATS4	0.82	8.68	0.61	1.93e-14	Blood protein levels;
TGCT	cis	rs2288278	0.580	rs2036764	chr17:46588331	C/T	cg25032089	chr17:46643351	HOXB3	-0.42	-5.03	-0.41	1.68e-6	Hand grip strength;
TGCT	trans	rs797680	0.796	rs797661	chr1:93687091	G/T	cg27528825	chr2:159282178	CCDC148	0.35	6.88	0.53	2.65e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs7714584	1.000	rs4958843	chr5:150224924	T/C	cg22134413	chr5:150180641	NA	0.89	6.96	0.53	1.73e-10	Crohn's disease;
TGCT	trans	rs4650994	0.525	rs10913567	chr1:178511941	A/C	cg05059571	chr16:84539110	KIAA1609	-0.55	-11.45	-0.72	3.74e-21	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.64	0.51	8.82e-10	Electroencephalogram traits;
TGCT	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.3	-4.65	-0.39	8.4e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs35883536	1.000	rs17403857	chr1:101105216	A/C	cg06223162	chr1:101003688	GPR88	0.28	4.5	0.37	1.53e-5	Monocyte count;
TGCT	cis	rs2235642	1.000	rs2235642	chr16:1584866	T/C	cg10465839	chr16:1584050	IFT140;TMEM204	-0.3	-5.09	-0.42	1.31e-6	Coronary artery disease;
TGCT	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.1	0.54	8.35e-11	Prudent dietary pattern;
TGCT	cis	rs763014	0.865	rs8909	chr16:633851	T/C	cg09263875	chr16:632152	PIGQ	0.3	6.4	0.5	2.88e-9	Height;
TGCT	cis	rs514406	0.584	rs12095247	chr1:53193796	A/C	cg08859206	chr1:53392774	SCP2	0.35	4.98	0.41	2.11e-6	Monocyte count;
TGCT	cis	rs6723226	0.804	rs17428810	chr2:32736043	T/C	cg02381751	chr2:32503542	YIPF4	-0.55	-4.92	-0.4	2.74e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10206020	0.921	rs72778005	chr2:1573122	C/G	cg12573674	chr2:1569213	NA	-0.49	-5.29	-0.43	5.44e-7	IgG glycosylation;
TGCT	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.07	0.48	1.47e-8	Bipolar disorder;
TGCT	cis	rs7223966	1.000	rs8078862	chr17:61854068	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	4.68	0.39	7.5e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs16952006	0.568	rs55815331	chr17:1945694	C/T	cg22998033	chr17:1394477	MYO1C	-0.61	-4.46	-0.37	1.8e-5	Breast cancer;
TGCT	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg02725872	chr8:58115012	NA	-0.39	-4.83	-0.4	3.9e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9910055	0.664	rs433610	chr17:42197281	A/G	cg19774624	chr17:42201019	HDAC5	0.8	8.3	0.6	1.53e-13	Total body bone mineral density;
TGCT	cis	rs2239908	0.718	rs241776	chr17:26644308	C/T	cg10494684	chr17:26645200	TMEM97	0.46	4.96	0.41	2.32e-6	Blood protein levels;
TGCT	cis	rs763121	0.853	rs9622833	chr22:39000397	G/A	cg06022373	chr22:39101656	GTPBP1	0.78	7.44	0.56	1.48e-11	Menopause (age at onset);
TGCT	cis	rs796364	0.906	rs281784	chr2:200749749	T/A	cg17644776	chr2:200775616	C2orf69	0.31	4.83	0.4	3.99e-6	Schizophrenia;
TGCT	cis	rs3812831	0.695	rs7983872	chr13:114944781	T/G	cg06611532	chr13:114900021	NA	0.35	6.45	0.5	2.24e-9	Schizophrenia;
TGCT	cis	rs12908161	0.959	rs2175567	chr15:85200946	C/G	cg11189052	chr15:85197271	WDR73	0.74	6.09	0.48	1.3e-8	Schizophrenia;
TGCT	cis	rs56399783	0.901	rs11971014	chr7:2778444	C/T	cg19731401	chr7:2775893	GNA12	0.33	4.75	0.39	5.57e-6	Childhood ear infection;
TGCT	cis	rs79387448	0.745	rs57942521	chr2:103139849	A/G	cg09003973	chr2:102972529	NA	0.89	5.92	0.47	2.99e-8	Gut microbiota (bacterial taxa);
TGCT	trans	rs629535	0.590	rs55988608	chr8:70133619	A/G	cg21567404	chr3:27674614	NA	-0.52	-7.76	-0.57	2.74e-12	Dupuytren's disease;
TGCT	cis	rs7267979	1.000	rs6050631	chr20:25431749	C/T	cg16686733	chr20:25566563	NINL	0.6	6.04	0.48	1.62e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs941764	0.965	rs747159	chr14:91841030	A/C	cg10511902	chr14:91842949	CCDC88C	-0.28	-4.79	-0.4	4.64e-6	Breast cancer;
TGCT	cis	rs3087591	1.000	rs8082020	chr17:29694795	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.47	-7.01	-0.53	1.38e-10	Hip circumference;
TGCT	cis	rs1401999	1.000	rs6443927	chr3:183718864	A/G	cg01324343	chr3:183735012	ABCC5	0.83	11.23	0.71	1.3e-20	Anterior chamber depth;
TGCT	cis	rs1950500	0.550	rs7148384	chr14:24828814	C/T	cg07162820	chr14:24837146	NFATC4	0.5	5.76	0.46	6.13e-8	Height;
TGCT	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg23982607	chr1:1823379	GNB1	-0.55	-8.47	-0.61	5.97e-14	Body mass index;
TGCT	cis	rs151997	0.671	rs27845	chr5:50197420	A/C	cg06027927	chr5:50259733	NA	0.56	5.78	0.46	5.72e-8	Callous-unemotional behaviour;
TGCT	cis	rs7772486	0.875	rs2814876	chr6:146304030	C/T	cg05347473	chr6:146136440	FBXO30	0.55	5.11	0.42	1.2e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4509693	0.843	rs4403743	chr10:102496740	A/C	cg24127310	chr10:102502104	NA	0.7	5.86	0.47	3.84e-8	Alzheimer's disease;
TGCT	cis	rs7095607	0.785	rs10997957	chr10:69916441	G/A	cg18986048	chr10:69913749	MYPN	0.45	5.03	0.41	1.68e-6	Lung function (FVC);
TGCT	cis	rs2456568	0.570	rs1518579	chr11:93656821	A/G	cg26875233	chr11:93583750	C11orf90	-0.46	-5.7	-0.46	8.27e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg13695892	chr22:41940480	POLR3H	0.92	9.08	0.63	2.08e-15	Vitiligo;
TGCT	cis	rs9527	0.551	rs28606370	chr10:104670832	C/A	cg04362960	chr10:104952993	NT5C2	0.56	4.81	0.4	4.27e-6	Arsenic metabolism;
TGCT	cis	rs9311474	0.607	rs2015971	chr3:52546820	C/T	cg10802521	chr3:52805072	NEK4	-0.72	-8.73	-0.62	1.44e-14	Electroencephalogram traits;
TGCT	cis	rs4843747	0.671	rs74729706	chr16:88104159	C/T	cg06915872	chr16:87998081	BANP	-0.3	-4.55	-0.38	1.25e-5	Menopause (age at onset);
TGCT	cis	rs1505368	0.836	rs10201067	chr2:213284411	A/G	cg20637307	chr2:213403960	ERBB4	-0.49	-4.79	-0.4	4.62e-6	Symmetrical dimethylarginine levels;
TGCT	cis	rs7043114	0.525	rs7863406	chr9:95053381	T/C	cg14631576	chr9:95140430	CENPP	-0.28	-4.65	-0.39	8.23e-6	Height;
TGCT	cis	rs9611565	0.729	rs505533	chr22:41864216	A/C	cg06481639	chr22:41940642	POLR3H	0.59	5.12	0.42	1.12e-6	Vitiligo;
TGCT	cis	rs2153535	0.580	rs2184585	chr6:8474168	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs1505368	0.562	rs7569142	chr2:213294557	C/T	cg20637307	chr2:213403960	ERBB4	0.55	4.99	0.41	2e-6	Symmetrical dimethylarginine levels;
TGCT	cis	rs7833790	0.963	rs28823280	chr8:82777716	G/A	cg06027949	chr8:82754900	SNX16	0.64	4.54	0.38	1.32e-5	Diastolic blood pressure;
TGCT	cis	rs492146	0.740	rs1032418	chr6:52834957	A/T	cg24393602	chr6:52860404	GSTA4	0.48	4.51	0.38	1.47e-5	Epilepsy (remission after treatment);
TGCT	cis	rs6840360	0.615	rs4696094	chr4:152465501	C/T	cg17479576	chr4:152424074	FAM160A1	-0.71	-7.74	-0.57	2.95e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs2637266	0.729	rs846618	chr10:78545455	G/A	cg18941641	chr10:78392320	NA	0.38	4.54	0.38	1.3e-5	Pulmonary function;
TGCT	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg10117171	chr1:25599238	RHD	-0.35	-5.64	-0.45	1.1e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs6089829	0.962	rs6089826	chr20:61668595	G/A	cg08045932	chr20:61659980	NA	0.48	9.09	0.63	2.04e-15	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg08045932	chr20:61659980	NA	0.48	9.28	0.64	7.07e-16	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs736408	0.812	rs4687654	chr3:52827566	G/A	cg10802521	chr3:52805072	NEK4	-0.63	-7.07	-0.54	9.9e-11	Bipolar disorder;
TGCT	cis	rs10501293	0.746	rs10742663	chr11:43032810	C/G	cg03447554	chr11:43094025	NA	0.44	6.29	0.49	5.05e-9	Cognitive performance;
TGCT	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg18876405	chr7:65276391	NA	0.35	5.66	0.45	1.01e-7	Calcium levels;
TGCT	cis	rs12950390	0.893	rs4239166	chr17:45847329	A/G	cg06532163	chr17:45867833	NA	0.34	5.31	0.43	4.82e-7	IgG glycosylation;
TGCT	cis	rs910316	0.839	rs35977276	chr14:75637359	A/C	cg11812906	chr14:75593930	NEK9	-0.74	-7.3	-0.55	3.1e-11	Height;
TGCT	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg22968622	chr17:43663579	NA	1.0	9.57	0.65	1.41e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7772486	0.776	rs4316025	chr6:146238032	C/T	cg05347473	chr6:146136440	FBXO30	-0.52	-5.16	-0.42	9.33e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11031096	0.542	rs10835390	chr11:3981488	A/G	cg18678763	chr11:4115507	RRM1	-0.41	-5.09	-0.42	1.27e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs9341808	0.718	rs2322636	chr6:80897436	C/T	cg08355045	chr6:80787529	NA	0.32	5.6	0.45	1.29e-7	Sitting height ratio;
TGCT	cis	rs10875746	0.903	rs725454	chr12:48502100	A/G	cg20731937	chr12:48336164	NA	0.62	4.94	0.41	2.46e-6	Longevity (90 years and older);
TGCT	cis	rs1997103	1.000	rs9642578	chr7:55400320	A/G	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9818758	0.607	rs35283189	chr3:49113668	T/C	cg00383909	chr3:49044727	WDR6	1.3	6.73	0.52	5.74e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs1986116	0.773	rs12881395	chr14:77507925	C/G	cg00956679	chr14:77462606	NA	0.32	4.44	0.37	1.95e-5	Sleep quality;
TGCT	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs1401999	1.000	rs9858774	chr3:183652736	G/A	cg01324343	chr3:183735012	ABCC5	0.85	11.41	0.72	4.7e-21	Anterior chamber depth;
TGCT	cis	rs6598955	0.671	rs11247901	chr1:26612693	T/A	cg04990556	chr1:26633338	UBXN11	0.64	4.91	0.4	2.78e-6	Obesity-related traits;
TGCT	cis	rs7635838	0.573	rs73019547	chr3:11493323	A/C	cg00170343	chr3:11313890	ATG7	0.71	6.62	0.51	9.86e-10	HDL cholesterol;
TGCT	cis	rs2456568	0.805	rs55784864	chr11:93682887	G/A	cg17595323	chr11:93583763	C11orf90	-0.46	-6.01	-0.47	1.92e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs62244186	0.541	rs3804583	chr3:44884647	G/T	cg15687855	chr3:44754131	ZNF502	-0.54	-6.68	-0.51	7.35e-10	Depressive symptoms;
TGCT	cis	rs447921	0.861	rs12949638	chr17:74444758	C/T	cg09812376	chr17:74270190	QRICH2	-0.47	-4.97	-0.41	2.17e-6	Mitochondrial DNA levels;
TGCT	cis	rs926938	0.527	rs360681	chr1:115496741	C/G	cg12756093	chr1:115239321	AMPD1	0.34	4.97	0.41	2.19e-6	Autism;
TGCT	cis	rs1348850	1.000	rs1348850	chr2:178418575	A/G	cg22681709	chr2:178499509	PDE11A	-0.4	-5.41	-0.44	3.17e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs12134133	1.000	rs28371614	chr1:207505274	C/T	cg02152968	chr1:207494213	CD55	0.6	4.8	0.4	4.42e-6	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs2506889	0.553	rs7548453	chr1:10589836	A/G	cg17425144	chr1:10567563	PEX14	0.52	7.41	0.55	1.68e-11	Breast cancer;
TGCT	cis	rs7772486	0.846	rs7755440	chr6:146375906	T/C	cg05347473	chr6:146136440	FBXO30	0.56	5.22	0.42	7.31e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10465746	0.780	rs7551787	chr1:84419297	A/G	cg10977910	chr1:84465055	TTLL7	0.68	7.2	0.54	5.06e-11	Obesity-related traits;
TGCT	cis	rs71435601	0.600	rs501863	chr2:21390000	G/A	cg25035485	chr2:21266500	APOB	0.51	4.48	0.37	1.64e-5	Cholesterol, total;
TGCT	cis	rs7568458	0.684	rs6731700	chr2:85760991	C/G	cg02493740	chr2:85810744	VAMP5	-0.28	-5.37	-0.43	3.67e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs208520	0.661	rs7747492	chr6:66857788	A/T	cg07460842	chr6:66804631	NA	-0.92	-9.58	-0.65	1.29e-16	Exhaled nitric oxide output;
TGCT	cis	rs1577917	0.916	rs12206726	chr6:86499716	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-5.53	-0.44	1.82e-7	Response to antipsychotic treatment;
TGCT	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg03388025	chr16:89894329	SPIRE2	0.5	8.7	0.62	1.73e-14	Vitiligo;
TGCT	cis	rs3820068	0.580	rs7512308	chr1:16006604	C/A	cg05660106	chr1:15850417	CASP9	0.58	5.38	0.43	3.64e-7	Systolic blood pressure;
TGCT	cis	rs9650657	0.562	rs10090444	chr8:10745469	C/G	cg27411982	chr8:10470053	RP1L1	0.21	4.64	0.38	8.87e-6	Neuroticism;
TGCT	cis	rs13326165	0.760	rs123602	chr3:52442354	C/G	cg07884673	chr3:53033167	SFMBT1	0.39	4.69	0.39	7e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs344364	0.552	rs388928	chr16:1909657	G/C	cg01422476	chr16:1922425	C16orf73	-0.47	-4.57	-0.38	1.16e-5	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs35146811	0.586	rs1076237	chr7:99585441	A/C	cg13334819	chr7:99746414	C7orf59	-0.65	-5.74	-0.46	6.78e-8	Coronary artery disease;
TGCT	cis	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg18188782	chr20:61659543	NA	0.44	5.37	0.43	3.73e-7	Prostate cancer (SNP x SNP interaction);
TGCT	trans	rs2243480	1.000	rs1796220	chr7:66062100	C/T	cg07424592	chr7:64974309	NA	1.3	8.23	0.59	2.19e-13	Diabetic kidney disease;
TGCT	cis	rs1949733	0.666	rs3103070	chr4:8508825	A/G	cg11789530	chr4:8429930	ACOX3	-0.61	-5.69	-0.46	8.62e-8	Response to antineoplastic agents;
TGCT	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg22105103	chr4:187893119	NA	0.33	4.62	0.38	9.41e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs12712073	0.845	rs1370353	chr2:100764824	G/C	cg07810366	chr2:100720526	AFF3	-0.36	-5.31	-0.43	4.95e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9300255	0.602	rs2695479	chr12:123689386	T/C	cg00376283	chr12:123451042	ABCB9	0.72	4.99	0.41	2e-6	Neutrophil percentage of white cells;
TGCT	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.42	6.05	0.48	1.57e-8	Lymphocyte counts;
TGCT	cis	rs35146811	0.735	rs1727138	chr7:99815247	A/G	cg13334819	chr7:99746414	C7orf59	0.74	6.31	0.49	4.4e-9	Coronary artery disease;
TGCT	cis	rs11748023	0.605	rs155948	chr5:139519181	A/G	cg01081189	chr5:139537190	NA	-0.25	-4.46	-0.37	1.83e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs2439831	0.850	rs8042868	chr15:43939642	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.91	6.47	0.5	2.04e-9	Lung cancer in ever smokers;
TGCT	cis	rs651907	0.535	rs17412601	chr3:101499275	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.31	-6.52	-0.51	1.56e-9	Colorectal cancer;
TGCT	cis	rs921968	0.541	rs6720403	chr2:219294258	A/C	cg02176678	chr2:219576539	TTLL4	-0.45	-6.45	-0.5	2.25e-9	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs739496	0.615	rs4767939	chr12:112206895	A/G	cg10833066	chr12:111807467	FAM109A	0.37	5.02	0.41	1.74e-6	Platelet count;
TGCT	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg11890956	chr21:40555474	PSMG1	-0.68	-6.75	-0.52	5.1e-10	Menarche (age at onset);
TGCT	cis	rs4851254	0.961	rs11682173	chr2:100759810	C/T	cg23118464	chr2:100721844	AFF3	0.68	5.01	0.41	1.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7523273	0.597	rs56075814	chr1:207975949	T/C	cg22525895	chr1:207977042	MIR29B2	-0.45	-6.64	-0.51	8.76e-10	Schizophrenia;
TGCT	cis	rs7666738	0.830	rs17027058	chr4:98864671	G/A	cg18180107	chr4:99064573	C4orf37	0.58	5.38	0.43	3.58e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9640161	0.750	rs1047586	chr7:150035459	T/G	cg10018233	chr7:150070692	REPIN1	0.31	4.45	0.37	1.88e-5	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs912057	0.526	rs746453	chr6:6734221	C/A	cg06612196	chr6:6737390	NA	0.48	6.93	0.53	2.05e-10	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg22857025	chr5:266934	NA	-0.34	-6.7	-0.52	6.65e-10	Breast cancer;
TGCT	cis	rs11924390	0.789	rs822366	chr3:186452490	A/G	cg12454167	chr3:186435060	KNG1	0.44	6.91	0.53	2.24e-10	Adiponectin levels;
TGCT	cis	rs62064224	0.614	rs4794923	chr17:30763009	G/A	cg18200150	chr17:30822561	MYO1D	0.43	5.31	0.43	4.86e-7	Schizophrenia;
TGCT	cis	rs7010267	0.740	rs7464496	chr8:119954842	T/C	cg17171407	chr8:119960777	TNFRSF11B	0.25	4.45	0.37	1.86e-5	Total body bone mineral density (age 45-60);
TGCT	cis	rs7681440	0.904	rs28777703	chr4:90769924	A/G	cg01966878	chr4:90757139	SNCA	0.25	4.5	0.37	1.54e-5	Dementia with Lewy bodies;
TGCT	cis	rs7582180	0.739	rs11123824	chr2:100924029	G/A	cg08017756	chr2:100939284	LONRF2	-0.32	-5.26	-0.43	6.1e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7772486	0.790	rs2249386	chr6:146186611	G/A	cg05347473	chr6:146136440	FBXO30	0.54	5.06	0.41	1.47e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3806843	0.576	rs550475	chr5:140273528	G/C	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.42	-5.05	-0.41	1.52e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs28595532	0.920	rs114547492	chr4:119773078	G/C	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs4819052	1.000	rs4819052	chr21:46699777	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.97	7.98	0.58	8.44e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs3820068	0.705	rs57238793	chr1:15890029	A/G	cg05660106	chr1:15850417	CASP9	1.13	13.14	0.76	3.06e-25	Systolic blood pressure;
TGCT	cis	rs7267979	1.000	rs2424713	chr20:25418482	C/T	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9914988	0.565	rs34039488	chr17:27320232	G/A	cg16968985	chr17:27313254	SEZ6	-0.35	-4.47	-0.37	1.75e-5	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs7819412	0.642	rs11250117	chr8:10972740	C/A	cg03192020	chr8:11204681	TDH	-0.5	-4.57	-0.38	1.17e-5	Triglycerides;
TGCT	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg06238570	chr21:40685208	BRWD1	0.69	6.41	0.5	2.81e-9	Cognitive function;
TGCT	cis	rs26868	0.816	rs26872	chr16:2247644	C/T	cg26873644	chr16:2260806	C16orf79	-0.24	-4.81	-0.4	4.36e-6	Height;
TGCT	cis	rs1552244	0.554	rs6762594	chr3:9995516	G/A	cg00149659	chr3:10157352	C3orf10	0.66	4.89	0.4	3.04e-6	Alzheimer's disease;
TGCT	cis	rs2224391	0.628	rs1609808	chr6:5246333	C/A	cg09085698	chr6:5261316	LYRM4;FARS2	-1.04	-6.69	-0.51	6.87e-10	Height;
TGCT	cis	rs1348850	0.519	rs1544002	chr2:178529534	C/T	cg22681709	chr2:178499509	PDE11A	-0.47	-5.96	-0.47	2.43e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg23172400	chr8:95962367	TP53INP1	-0.4	-6.65	-0.51	8.46e-10	Type 2 diabetes;
TGCT	cis	rs4727027	0.870	rs1105261	chr7:148794442	T/G	cg23583168	chr7:148888333	NA	-0.71	-8.93	-0.63	4.74e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs25422	0.938	rs62424176	chr6:118798602	T/C	cg07617317	chr6:118971624	C6orf204	0.51	5.52	0.44	1.92e-7	Renal cell carcinoma;
TGCT	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg20891283	chr12:69753455	YEATS4	0.91	10.46	0.68	9.81e-19	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg00024416	chr22:24240387	NA	0.24	4.6	0.38	1.02e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6558530	0.931	rs4639549	chr8:1708044	A/G	cg09410841	chr8:1729607	CLN8	0.91	10.31	0.68	2.23e-18	Systolic blood pressure;
TGCT	cis	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg20637647	chr7:64974828	NA	0.91	5.37	0.43	3.74e-7	Diabetic kidney disease;
TGCT	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg07157834	chr1:205819609	PM20D1	0.49	8.25	0.6	1.92e-13	Menarche (age at onset);
TGCT	cis	rs2180341	0.618	rs4502958	chr6:127593113	G/A	cg24812749	chr6:127587940	RNF146	0.63	5.33	0.43	4.51e-7	Breast cancer;
TGCT	cis	rs447735	0.565	rs10852626	chr16:89914633	T/G	cg27121462	chr16:89883253	FANCA	0.56	5.02	0.41	1.77e-6	Hemoglobin concentration;
TGCT	cis	rs10892173	0.818	rs7947524	chr11:117671091	C/T	cg07621104	chr11:117668040	DSCAML1	0.46	4.81	0.4	4.21e-6	Myopia;
TGCT	cis	rs7103648	0.966	rs10769263	chr11:47417183	A/C	cg20307385	chr11:47447363	PSMC3	1.0	11.81	0.73	4.88e-22	Diastolic blood pressure;Systolic blood pressure;
TGCT	cis	rs12620999	0.774	rs7584900	chr2:237957112	T/G	cg23555395	chr2:238036564	NA	0.27	4.76	0.39	5.37e-6	Systemic lupus erythematosus;
TGCT	cis	rs68170813	0.559	rs7981	chr7:106843133	G/C	cg02696742	chr7:106810147	HBP1	-0.69	-5.73	-0.46	7.17e-8	Coronary artery disease;
TGCT	cis	rs8031584	0.652	rs2691683	chr15:31135060	A/G	cg08109568	chr15:31115862	NA	0.38	5.03	0.41	1.67e-6	Huntington's disease progression;
TGCT	cis	rs9914988	0.673	rs9890212	chr17:27169890	G/C	cg20469991	chr17:27169893	C17orf63	-0.71	-4.99	-0.41	2.02e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs2439831	0.867	rs28729853	chr15:43673680	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.04	8.35	0.6	1.16e-13	Lung cancer in ever smokers;
TGCT	cis	rs929354	1.000	rs1182378	chr7:157048322	T/C	cg05182265	chr7:156933206	UBE3C	0.31	6.45	0.5	2.23e-9	Body mass index;
TGCT	cis	rs611744	0.967	rs645241	chr8:109190963	C/T	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg12000995	chr2:27665139	KRTCAP3	-0.36	-4.44	-0.37	1.98e-5	Total body bone mineral density;
TGCT	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.62	-8.26	-0.6	1.9e-13	Longevity;Endometriosis;
TGCT	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	5.03	0.41	1.69e-6	Prudent dietary pattern;
TGCT	cis	rs2361718	0.521	rs2361724	chr17:78099114	G/A	cg21238619	chr17:78079768	GAA	-0.37	-4.74	-0.39	5.86e-6	Yeast infection;
TGCT	cis	rs12497850	0.931	rs4974079	chr3:48906469	T/G	cg05785598	chr3:49045655	WDR6	0.36	4.75	0.39	5.46e-6	Parkinson's disease;
TGCT	cis	rs6770219	0.516	rs6794762	chr3:186136514	G/T	cg20306810	chr3:186501757	SNORD2;EIF4A2	0.73	4.45	0.37	1.89e-5	Cerebrospinal T-tau levels;
TGCT	cis	rs2797160	1.000	rs1935774	chr6:125996661	A/G	cg05901451	chr6:126070800	HEY2	0.74	6.67	0.51	7.64e-10	Endometrial cancer;
TGCT	cis	rs4961252	0.545	rs1107258	chr8:142104071	G/A	cg09914555	chr8:142094789	NA	-0.38	-5.67	-0.45	9.51e-8	Isovolumetric relaxation time;Response to interferon beta therapy;
TGCT	cis	rs12681288	0.550	rs73176529	chr8:962283	G/C	cg04851639	chr8:1020857	NA	-0.3	-5.08	-0.41	1.36e-6	Schizophrenia;
TGCT	cis	rs2249625	0.504	rs2496508	chr6:72891398	A/G	cg08500200	chr6:72892038	RIMS1	-0.43	-4.59	-0.38	1.07e-5	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
TGCT	cis	rs1461503	0.512	rs4293126	chr11:122804133	A/G	cg14473756	chr11:122847823	NA	0.44	4.69	0.39	7.1e-6	Menarche (age at onset);
TGCT	cis	rs354033	1.000	rs354043	chr7:149297332	C/T	cg24335155	chr7:149193227	ZNF746	0.32	4.56	0.38	1.19e-5	Multiple sclerosis;
TGCT	cis	rs7714584	1.000	rs1428554	chr5:150257616	A/G	cg22134413	chr5:150180641	NA	0.83	6.53	0.51	1.54e-9	Crohn's disease;
TGCT	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.86	8.45	0.6	6.61e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg04608855	chr19:58913158	NA	-0.5	-4.73	-0.39	6.09e-6	Uric acid clearance;
TGCT	cis	rs12620999	0.941	rs58678188	chr2:237971036	C/A	cg23555395	chr2:238036564	NA	0.28	4.82	0.4	4.13e-6	Systemic lupus erythematosus;
TGCT	cis	rs4780401	0.539	rs62040604	chr16:11803641	G/A	cg01061890	chr16:11836724	TXNDC11	-0.57	-5.41	-0.44	3.06e-7	Rheumatoid arthritis;
TGCT	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg10802521	chr3:52805072	NEK4	-0.7	-8.53	-0.61	4.33e-14	Cognitive function;
TGCT	cis	rs9500256	0.655	rs12210275	chr6:58331759	C/T	cg16251399	chr6:58287822	GUSBL2	0.56	4.74	0.39	5.76e-6	Eosinophilic esophagitis (pediatric);
TGCT	cis	rs10504229	0.906	rs28447218	chr8:58170813	T/G	cg22535103	chr8:58192502	C8orf71	-0.39	-5.19	-0.42	8.44e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs941408	1.000	rs1736181	chr19:2797703	C/T	cg06609049	chr19:2785107	THOP1	0.8	7.68	0.57	4.14e-12	Total cholesterol levels;
TGCT	cis	rs17331151	0.541	rs4687676	chr3:52890418	C/T	cg12962167	chr3:53033115	SFMBT1	-0.42	-4.78	-0.39	4.81e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs3125734	0.633	rs3765002	chr10:64006124	G/T	cg05499367	chr10:63213510	TMEM26	-0.33	-4.46	-0.37	1.78e-5	Rheumatoid arthritis;
TGCT	cis	rs896854	0.654	rs10429443	chr8:95971164	A/G	cg09323728	chr8:95962352	TP53INP1	-0.52	-6.6	-0.51	1.07e-9	Type 2 diabetes;
TGCT	cis	rs35306767	0.669	rs2101051	chr10:1158791	G/T	cg18964960	chr10:1102726	WDR37	0.66	4.51	0.38	1.46e-5	Eosinophil percentage of granulocytes;
TGCT	cis	rs6060960	0.502	rs15817	chr20:30193538	A/G	cg10886678	chr20:30946050	ASXL1	-0.71	-4.8	-0.4	4.42e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
TGCT	cis	rs494003	1.000	rs578056	chr11:65514874	C/T	cg04293602	chr11:65553660	OVOL1	0.36	4.62	0.38	9.28e-6	Systemic lupus erythematosus;
TGCT	cis	rs7824557	0.628	rs17797894	chr8:11212081	A/G	cg21775007	chr8:11205619	TDH	0.73	7.03	0.53	1.23e-10	Retinal vascular caliber;
TGCT	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg12034118	chr1:209979487	IRF6	0.72	8.01	0.58	7.19e-13	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
TGCT	cis	rs218265	0.764	rs218237	chr4:55394172	C/T	cg20208633	chr4:55405888	NA	-0.56	-4.6	-0.38	1.03e-5	Sum neutrophil eosinophil counts;Myeloid white cell count;High light scatter reticulocyte percentage of red cells;Mean corpuscular volume;Reticulocyte fraction of red cells;Red blood cell count;Immature fraction of reticulocytes;Sum basophil neutrophil counts;Granulocyte count;White blood cell count;Neutrophil count;Mean corpuscular hemoglobin;Plateletcrit;
TGCT	cis	rs453301	0.624	rs6987558	chr8:8862521	C/G	cg06636001	chr8:8085503	FLJ10661	0.76	6.73	0.52	5.5e-10	Joint mobility (Beighton score);
TGCT	cis	rs734999	0.545	rs9970196	chr1:2574078	T/C	cg18854424	chr1:2615690	NA	-0.46	-5.31	-0.43	4.97e-7	Ulcerative colitis;
TGCT	cis	rs4851266	0.966	rs10496345	chr2:100817619	T/G	cg22139774	chr2:100720529	AFF3	-0.36	-5.38	-0.44	3.55e-7	Educational attainment;
TGCT	cis	rs8077889	0.917	rs8081646	chr17:41893360	T/C	cg26893861	chr17:41843967	DUSP3	1.11	13.17	0.76	2.53e-25	Triglycerides;
TGCT	cis	rs28374715	0.528	rs7181982	chr15:41623020	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.9	-14.93	-0.8	1.76e-29	Ulcerative colitis;
TGCT	cis	rs2688608	0.592	rs11000757	chr10:75486815	T/C	cg04320760	chr10:75533139	FUT11	-0.4	-6.25	-0.49	6.11e-9	Inflammatory bowel disease;
TGCT	cis	rs1008375	1.000	rs7697889	chr4:17617961	G/T	cg16339924	chr4:17578868	LAP3	0.6	4.97	0.41	2.14e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7582180	0.629	rs4851297	chr2:100949571	G/A	cg08017756	chr2:100939284	LONRF2	-0.3	-4.87	-0.4	3.27e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2486288	0.656	rs6493144	chr15:45573489	C/G	cg14582100	chr15:45693742	SPATA5L1	0.47	5.65	0.45	1.04e-7	Glomerular filtration rate;
TGCT	cis	rs2224391	1.000	rs2753247	chr6:5261987	A/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.79	-6.05	-0.48	1.61e-8	Height;
TGCT	cis	rs62064224	0.589	rs6505295	chr17:30687522	G/C	cg18200150	chr17:30822561	MYO1D	0.39	4.7	0.39	6.66e-6	Schizophrenia;
TGCT	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg23758822	chr17:41437982	NA	0.71	6.83	0.52	3.46e-10	Menopause (age at onset);
TGCT	cis	rs9611565	0.765	rs727563	chr22:41867377	C/T	cg17554472	chr22:41940697	POLR3H	0.47	5.07	0.41	1.43e-6	Vitiligo;
TGCT	cis	rs1865760	0.663	rs9467656	chr6:25993559	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.7	6.91	0.53	2.26e-10	Height;
TGCT	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg02975922	chr3:195473998	MUC4	-0.24	-5.74	-0.46	6.87e-8	Pancreatic cancer;
TGCT	cis	rs763121	0.853	rs6001188	chr22:39062194	T/C	cg06022373	chr22:39101656	GTPBP1	0.77	7.51	0.56	9.9e-12	Menopause (age at onset);
TGCT	cis	rs1153858	0.943	rs4774580	chr15:45652086	G/A	cg26924012	chr15:45694286	SPATA5L1	1.09	15.16	0.81	5.15e-30	Homoarginine levels;
TGCT	cis	rs7044106	0.537	rs4434680	chr9:123489688	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	5.55	0.45	1.62e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs6582630	0.555	rs35284307	chr12:38509999	T/G	cg26384229	chr12:38710491	ALG10B	0.85	7.86	0.58	1.55e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg07424592	chr7:64974309	NA	-1.27	-7.84	-0.58	1.8e-12	Diabetic kidney disease;
TGCT	cis	rs360798	0.532	rs7573756	chr2:62990637	G/A	cg17519650	chr2:63277830	OTX1	-0.58	-5.06	-0.41	1.48e-6	Coronary artery disease;
TGCT	cis	rs9916302	0.904	rs4795357	chr17:37569551	T/C	cg15445000	chr17:37608096	MED1	0.35	5.05	0.41	1.53e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg20637647	chr7:64974828	NA	1.0	5.59	0.45	1.4e-7	Diabetic kidney disease;
TGCT	cis	rs2243480	1.000	rs4718269	chr7:65200778	C/G	cg18252515	chr7:66147081	NA	1.17	7.17	0.54	5.94e-11	Diabetic kidney disease;
TGCT	cis	rs7678296	0.649	rs77896458	chr4:37237843	A/G	cg06805348	chr4:37245195	KIAA1239	0.57	4.78	0.39	4.81e-6	3-hydroxypropylmercapturic acid levels in smokers;
TGCT	cis	rs28595532	0.841	rs55744948	chr4:119769243	T/C	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs896854	0.654	rs2011566	chr8:95971921	G/A	cg23172400	chr8:95962367	TP53INP1	-0.36	-6.15	-0.48	9.57e-9	Type 2 diabetes;
TGCT	trans	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg21659725	chr3:3221576	CRBN	0.76	9.35	0.64	4.85e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs75686122	0.892	rs74869978	chr8:104678453	T/C	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs7043114	0.525	rs710162	chr9:95059790	A/T	cg13798575	chr9:95087839	CENPP;NOL8	0.54	5.38	0.43	3.6e-7	Height;
TGCT	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs10746514	0.833	rs867844	chr1:232266278	A/T	cg09506761	chr1:232265262	NA	0.5	5.11	0.42	1.17e-6	Response to statin therapy;
TGCT	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.93	7.44	0.56	1.44e-11	Platelet count;
TGCT	cis	rs4722585	0.533	rs6964215	chr7:26196819	G/A	cg07876897	chr7:26191696	NFE2L3	0.39	5.2	0.42	8.14e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
TGCT	cis	rs422249	0.512	rs174578	chr11:61605499	T/A	cg20584555	chr11:61717780	BEST1	-0.23	-4.46	-0.37	1.82e-5	Trans fatty acid levels;
TGCT	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg13206674	chr6:150067644	NUP43	0.52	4.46	0.37	1.78e-5	Lung cancer;
TGCT	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg11494091	chr17:61959527	GH2	0.61	14.8	0.8	3.65e-29	Prudent dietary pattern;
TGCT	cis	rs8044995	0.563	rs56220628	chr16:68384837	G/A	cg05110241	chr16:68378359	PRMT7	-0.35	-4.44	-0.37	1.94e-5	Schizophrenia;
TGCT	cis	rs10276381	1.000	rs10263857	chr7:28187284	C/G	cg23620719	chr7:28220237	JAZF1	1.01	5.82	0.46	4.75e-8	Crohn's disease;
TGCT	cis	rs1901167	0.908	rs1061443	chr5:40982622	G/T	cg02441090	chr5:41871058	OXCT1	-0.31	-4.61	-0.38	9.86e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs4824093	0.610	rs13340054	chr22:50311726	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.07	-5.93	-0.47	2.87e-8	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.43	6.28	0.49	5.19e-9	Schizophrenia;
TGCT	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg11764359	chr7:65958608	NA	0.61	5.53	0.44	1.79e-7	Aortic root size;
TGCT	cis	rs13405699	1	rs13405699	chr2:174605633	A/C	cg04180623	chr2:174057774	ZAK	-0.32	-4.56	-0.38	1.2e-5	Male-pattern baldness;
TGCT	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg03303774	chr4:1407052	NA	0.38	5.9	0.47	3.24e-8	Obesity-related traits;
TGCT	cis	rs9611565	0.877	rs3817999	chr22:41747717	A/G	cg06634786	chr22:41940651	POLR3H	0.81	7.97	0.58	8.93e-13	Vitiligo;
TGCT	cis	rs9527	0.615	rs10883804	chr10:104706520	G/A	cg04362960	chr10:104952993	NT5C2	0.64	5.4	0.44	3.33e-7	Arsenic metabolism;
TGCT	cis	rs4595586	0.545	rs969468	chr12:39367278	A/C	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg03609598	chr5:56110824	MAP3K1	-0.58	-4.7	-0.39	6.72e-6	Initial pursuit acceleration;
TGCT	cis	rs473651	0.904	rs10929275	chr2:239323169	A/G	cg08773314	chr2:239334832	ASB1	0.47	7.86	0.58	1.62e-12	Multiple system atrophy;
TGCT	cis	rs6940638	0.662	rs6915678	chr6:27235866	T/G	cg15659132	chr6:26577336	NA	-0.59	-5.52	-0.44	1.87e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9942416	0.660	rs194137	chr5:74978857	G/A	cg19683494	chr5:74908142	NA	-0.59	-6.29	-0.49	4.99e-9	Age-related disease endophenotypes;
TGCT	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	5.08	0.42	1.35e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs35150201	1.000	rs35150201	chr7:135346262	T/G	cg23117316	chr7:135346802	PL-5283	-0.45	-4.74	-0.39	5.77e-6	Plateletcrit;Mean corpuscular hemoglobin;Mean platelet volume;
TGCT	cis	rs7428	0.545	rs4832163	chr2:85541083	T/C	cg24342717	chr2:85555507	TGOLN2	-0.48	-8.35	-0.6	1.15e-13	Ear protrusion;
TGCT	cis	rs9467773	0.595	rs2451736	chr6:26620544	G/A	cg09904177	chr6:26538194	HMGN4	0.66	6.33	0.49	3.99e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs3820928	0.935	rs12151597	chr2:227859224	A/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-4.63	-0.38	9.03e-6	Pulmonary function;
TGCT	cis	rs9296092	0.538	rs75082458	chr6:33524792	C/T	cg13560919	chr6:33536144	NA	-0.22	-4.83	-0.4	3.97e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs6500602	0.653	rs3747579	chr16:4445327	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.27	-4.54	-0.38	1.29e-5	Schizophrenia;
TGCT	cis	rs9560113	1.000	rs11620313	chr13:112179363	G/A	cg14154082	chr13:112174009	NA	0.37	4.96	0.41	2.28e-6	Menarche (age at onset);
TGCT	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.0	0.41	1.89e-6	Menopause (age at onset);
TGCT	cis	rs2742234	0.955	rs1272142	chr10:43695484	G/T	cg02780029	chr10:43622663	RET	-0.26	-5.09	-0.42	1.28e-6	Hirschsprung disease;
TGCT	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg08859206	chr1:53392774	SCP2	0.4	5.96	0.47	2.46e-8	Monocyte count;
TGCT	cis	rs514406	0.525	rs269291	chr1:53189297	C/T	cg04995860	chr1:53192072	ZYG11B	-0.4	-4.49	-0.37	1.59e-5	Monocyte count;
TGCT	cis	rs3806843	0.548	rs246057	chr5:140325583	A/G	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs1903068	0.886	rs1551644	chr4:55994266	A/T	cg01777861	chr4:56023843	NA	0.56	6.43	0.5	2.54e-9	Endometriosis;
TGCT	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg20203395	chr5:56204925	C5orf35	-0.58	-4.87	-0.4	3.34e-6	Initial pursuit acceleration;
TGCT	cis	rs3849570	0.643	rs11705789	chr3:81969196	G/T	cg07356753	chr3:81810745	GBE1	-0.72	-6.75	-0.52	5e-10	Waist circumference;Body mass index;
TGCT	cis	rs35146811	0.735	rs858512	chr7:99824453	A/G	cg04778012	chr7:99775508	STAG3;GPC2	-0.36	-5.1	-0.42	1.22e-6	Coronary artery disease;
TGCT	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg03732007	chr1:2071316	PRKCZ	-0.27	-6.02	-0.48	1.81e-8	Height;
TGCT	cis	rs394563	0.726	rs6906384	chr6:149664540	G/A	cg03678062	chr6:149772716	ZC3H12D	0.44	5.79	0.46	5.49e-8	Dupuytren's disease;
TGCT	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg18538332	chr22:24372958	LOC391322	-0.96	-10.62	-0.69	3.95e-19	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	trans	rs1496653	0.602	rs35218978	chr3:23429585	T/C	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs7412746	0.658	rs11582281	chr1:150826831	T/C	cg04414720	chr1:150670196	GOLPH3L	0.39	4.75	0.39	5.55e-6	Melanoma;
TGCT	cis	rs546131	0.642	rs566798	chr11:34852277	A/G	cg06937548	chr11:34938143	PDHX;APIP	-0.54	-4.63	-0.38	9.24e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs11249608	0.548	rs11951738	chr5:178491228	G/A	cg01312482	chr5:178451176	ZNF879	-0.49	-4.8	-0.4	4.4e-6	Pubertal anthropometrics;
TGCT	trans	rs12145833	1.000	rs76473275	chr1:243460555	T/C	cg15780870	chr12:130953802	RIMBP2	0.48	6.73	0.52	5.57e-10	Obesity (early onset extreme);
TGCT	cis	rs6901004	0.803	rs1322214	chr6:111480045	T/A	cg15721981	chr6:111408429	SLC16A10	-0.51	-4.53	-0.38	1.35e-5	Blood metabolite levels;
TGCT	cis	rs4951018	0.821	rs11240547	chr1:205632932	A/G	cg07167872	chr1:205819463	PM20D1	0.39	4.61	0.38	9.91e-6	Prostate-specific antigen levels;
TGCT	cis	rs10464059	0.575	rs6601110	chr5:179759928	T/C	cg25959792	chr5:179775488	GFPT2	0.3	4.48	0.37	1.65e-5	Parkinson's disease;
TGCT	trans	rs459571	1.000	rs2810489	chr9:136922700	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.82	-8.78	-0.62	1.08e-14	Platelet distribution width;
TGCT	cis	rs8072100	0.727	rs4794052	chr17:45769236	T/C	cg08085267	chr17:45401833	C17orf57	-0.43	-4.82	-0.4	4.04e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs926938	0.584	rs360606	chr1:115391769	C/T	cg12756093	chr1:115239321	AMPD1	0.41	5.87	0.47	3.69e-8	Autism;
TGCT	cis	rs17376456	0.825	rs17372725	chr5:93135588	C/A	cg25358565	chr5:93447407	FAM172A	0.91	8.17	0.59	2.97e-13	Diabetic retinopathy;
TGCT	trans	rs6069325	0.529	rs6024210	chr20:54139554	A/G	cg26869512	chr4:8389770	ACOX3	0.47	6.92	0.53	2.12e-10	Motion sickness;
TGCT	cis	rs10794720	0.748	rs11250275	chr10:1171823	A/G	cg08668510	chr10:1095578	IDI1	-1.14	-5.18	-0.42	8.73e-7	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;
TGCT	cis	rs7617773	0.743	rs6804986	chr3:48363595	A/G	cg11946769	chr3:48343235	NME6	0.79	6.83	0.52	3.32e-10	Coronary artery disease;
TGCT	cis	rs1153858	0.943	rs8038342	chr15:45651537	T/C	cg26924012	chr15:45694286	SPATA5L1	1.09	15.16	0.81	5.15e-30	Homoarginine levels;
TGCT	cis	rs8062405	0.965	rs56040780	chr16:28861881	C/T	cg09754948	chr16:28834200	ATXN2L	0.59	4.45	0.37	1.91e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs78487399	0.808	rs75934770	chr2:43659694	C/G	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.74	4.69	0.39	7.08e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs2463822	0.858	rs2513037	chr11:62084822	A/T	cg23876832	chr11:62092739	NA	-0.63	-4.63	-0.38	8.94e-6	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg10802521	chr3:52805072	NEK4	-0.72	-9.11	-0.63	1.82e-15	Bipolar disorder;
TGCT	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg08219700	chr8:58056026	NA	0.3	4.64	0.38	8.89e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6570726	0.846	rs6899900	chr6:145883873	T/G	cg05347473	chr6:146136440	FBXO30	0.51	4.78	0.39	4.8e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs12451471	0.529	rs2278620	chr17:78083565	G/A	cg06718696	chr17:78121285	EIF4A3	0.71	5.89	0.47	3.42e-8	Plateletcrit;Mean corpuscular hemoglobin concentration;
TGCT	cis	rs877282	0.853	rs11253332	chr10:755262	G/C	cg17470449	chr10:769945	NA	0.32	4.91	0.4	2.76e-6	Uric acid levels;
TGCT	cis	rs7830933	0.955	rs1550280	chr8:23601830	C/T	cg04349084	chr8:23602677	NA	0.25	4.9	0.4	2.96e-6	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
TGCT	cis	rs4851266	1.000	rs1122231	chr2:100834546	C/T	cg07810366	chr2:100720526	AFF3	-0.39	-5.73	-0.46	7.19e-8	Educational attainment;
TGCT	cis	rs2721195	0.845	rs4244611	chr8:145739924	G/A	cg11211951	chr8:145729740	GPT	0.27	6.58	0.51	1.16e-9	Age at first birth;
TGCT	cis	rs9330316	0.632	rs34557890	chr2:110316208	G/A	cg25199208	chr2:109402912	CCDC138	-0.42	-4.56	-0.38	1.19e-5	Schizophrenia;
TGCT	cis	rs9560113	0.573	rs1888304	chr13:112242454	A/G	cg10483660	chr13:112241077	NA	0.36	5.51	0.44	1.97e-7	Menarche (age at onset);
TGCT	cis	rs858239	0.539	rs6956828	chr7:23187347	A/G	cg05602783	chr7:23145260	KLHL7	-0.62	-5.03	-0.41	1.67e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs9914988	0.943	rs4795459	chr17:27113726	G/C	cg20469991	chr17:27169893	C17orf63	-0.72	-5.04	-0.41	1.58e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs10193935	0.901	rs62142561	chr2:42477808	G/C	cg27598129	chr2:42591480	NA	-0.39	-5.43	-0.44	2.86e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1322512	0.760	rs818451	chr6:152924673	T/G	cg03415253	chr6:152958462	SYNE1	-0.56	-5.28	-0.43	5.72e-7	Tonometry;
TGCT	cis	rs7829975	0.617	rs4841071	chr8:8791144	G/T	cg00184457	chr8:8946301	NA	0.22	4.47	0.37	1.76e-5	Mood instability;
TGCT	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg08736216	chr1:53307985	ZYG11A	0.25	4.93	0.41	2.55e-6	Monocyte count;
TGCT	cis	rs1153858	1.000	rs16942568	chr15:45677390	T/C	cg26924012	chr15:45694286	SPATA5L1	1.09	15.16	0.81	5.15e-30	Homoarginine levels;
TGCT	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg24531977	chr5:56204891	C5orf35	0.97	9.1	0.63	1.92e-15	Initial pursuit acceleration;
TGCT	cis	rs3734905	1.000	rs3734905	chr6:169958982	G/A	cg20469989	chr6:170102314	C6orf120;WDR27	-0.88	-4.67	-0.39	7.59e-6	HIV-1 control;
TGCT	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg11905131	chr22:24372483	LOC391322	-0.93	-10.65	-0.69	3.41e-19	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9303401	0.659	rs35928756	chr17:56702652	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs6121246	0.529	rs73235789	chr20:30196148	T/C	cg10886678	chr20:30946050	ASXL1	-0.71	-4.8	-0.4	4.39e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs7336332	0.600	rs9579083	chr13:28017270	G/C	cg22138327	chr13:27999177	GTF3A	0.83	6.64	0.51	9e-10	Weight;
TGCT	cis	rs7043114	0.525	rs6479419	chr9:95110002	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-5.54	-0.45	1.72e-7	Height;
TGCT	cis	rs9443189	0.570	rs6931578	chr6:76272310	C/T	cg01950844	chr6:76311363	SENP6	0.98	6.08	0.48	1.35e-8	Prostate cancer;
TGCT	cis	rs1903068	0.719	rs73236106	chr4:55996712	C/T	cg01777861	chr4:56023843	NA	0.53	6.16	0.48	9.28e-9	Endometriosis;
TGCT	cis	rs9883204	0.855	rs11719201	chr3:123068744	C/T	cg04890266	chr3:123102914	ADCY5	0.37	4.99	0.41	1.98e-6	Birth weight;
TGCT	cis	rs2120019	0.608	rs8042558	chr15:75320433	G/T	cg17294928	chr15:75287854	SCAMP5	-0.92	-7.8	-0.57	2.22e-12	Blood trace element (Zn levels);
TGCT	cis	rs5769765	0.874	rs11703411	chr22:50258751	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.4	-6.01	-0.48	1.89e-8	Schizophrenia;
TGCT	cis	rs7178424	0.516	rs11635621	chr15:62322646	T/C	cg00456672	chr15:62358751	C2CD4A	-0.29	-4.46	-0.37	1.84e-5	Height;
TGCT	cis	rs11190604	0.767	rs10736150	chr10:102195341	G/A	cg16342193	chr10:102329863	NA	0.4	4.99	0.41	2.04e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9653442	0.900	rs10194635	chr2:100834217	T/A	cg22139774	chr2:100720529	AFF3	-0.39	-6.27	-0.49	5.59e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs10411936	1.000	rs873636	chr19:16514771	C/T	cg19006008	chr19:16999768	F2RL3	0.27	4.66	0.39	8.03e-6	White blood cell count;Multiple sclerosis;
TGCT	cis	rs11098499	0.863	rs1480936	chr4:120462861	C/T	cg09307838	chr4:120376055	NA	0.7	6.6	0.51	1.06e-9	Corneal astigmatism;
TGCT	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg24060327	chr5:131705240	SLC22A5	0.62	6.34	0.49	3.83e-9	Acylcarnitine levels;
TGCT	cis	rs9985766	0.958	rs4259040	chr4:151002847	T/G	cg05926478	chr4:151174724	DCLK2	-0.24	-4.72	-0.39	6.32e-6	Coronary artery disease;Myocardial infarction;
TGCT	cis	rs2228479	0.867	rs12930606	chr16:89946682	A/G	cg04013166	chr16:89971882	TCF25	0.32	4.46	0.37	1.84e-5	Skin colour saturation;
TGCT	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg08125733	chr17:73851984	WBP2	1.17	12.85	0.76	1.47e-24	Psoriasis;
TGCT	cis	rs9329289	0.510	rs9733402	chr10:2551532	G/A	cg07014206	chr10:2547000	NA	-0.28	-4.64	-0.38	8.6e-6	Age-related hearing impairment;
TGCT	cis	rs539096	0.500	rs2527776	chr1:44345292	G/A	cg12908607	chr1:44402522	ARTN	-0.7	-8.79	-0.62	1.01e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs941408	0.515	rs12610096	chr19:2778129	C/T	cg06609049	chr19:2785107	THOP1	1.17	13.17	0.76	2.56e-25	Total cholesterol levels;
TGCT	cis	rs7582180	0.663	rs6542944	chr2:100988038	T/C	cg14675211	chr2:100938903	LONRF2	0.48	4.6	0.38	1.01e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg04944784	chr2:26401820	FAM59B	-0.66	-5.93	-0.47	2.85e-8	Gut microbiome composition (summer);
TGCT	cis	rs9733	0.596	rs12403255	chr1:150660412	C/T	cg04414720	chr1:150670196	GOLPH3L	0.38	5.02	0.41	1.77e-6	Tonsillectomy;
TGCT	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg20203395	chr5:56204925	C5orf35	0.57	4.89	0.4	3.08e-6	Initial pursuit acceleration;
TGCT	cis	rs13064447	0.967	rs12637499	chr3:12756946	C/T	cg20675869	chr3:12750130	NA	0.19	4.9	0.4	2.97e-6	Major depression and alcohol dependence;
TGCT	cis	rs67478160	0.643	rs4906369	chr14:104242458	T/C	cg26031613	chr14:104095156	KLC1	-0.63	-6.57	-0.51	1.25e-9	Schizophrenia;
TGCT	cis	rs28595532	0.920	rs116366070	chr4:119764180	A/T	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs700651	0.685	rs976180	chr2:198880443	C/T	cg00792783	chr2:198669748	PLCL1	-0.58	-5.04	-0.41	1.64e-6	Intracranial aneurysm;
TGCT	cis	rs6990255	0.681	rs1495236	chr8:34119750	G/T	cg19906737	chr8:33370681	C8orf41	0.75	4.61	0.38	9.76e-6	Bipolar disorder;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs17473412	0.609	rs74841787	chr5:122870294	G/A	cg15125798	chr5:122621645	NA	-0.54	-4.86	-0.4	3.42e-6	Total body bone mineral density;
TGCT	cis	rs3820068	0.705	rs11587541	chr1:15899478	T/C	cg05660106	chr1:15850417	CASP9	1.17	14.8	0.8	3.47e-29	Systolic blood pressure;
TGCT	cis	rs10114408	0.959	rs10123414	chr9:96646136	T/A	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs9549367	0.789	rs2287250	chr13:113889474	C/T	cg00898013	chr13:113819073	PROZ	0.41	5.12	0.42	1.12e-6	Platelet distribution width;
TGCT	cis	rs11098499	0.690	rs34818745	chr4:120257055	T/C	cg09307838	chr4:120376055	NA	0.68	6.49	0.5	1.88e-9	Corneal astigmatism;
TGCT	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg07507251	chr3:52567010	NT5DC2	0.47	6.64	0.51	8.85e-10	Electroencephalogram traits;
TGCT	cis	rs17253792	0.822	rs78826571	chr14:56048906	G/A	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs3733585	0.699	rs7677710	chr4:9969517	T/G	cg11266682	chr4:10021025	SLC2A9	-0.59	-7.85	-0.58	1.7e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7291412	0.662	rs12159707	chr22:46449891	G/A	cg05468064	chr22:46423449	NA	0.48	4.58	0.38	1.12e-5	Dupuytren's disease;Subjective well-being;
TGCT	cis	rs1153858	0.945	rs16943246	chr15:45720597	G/A	cg26924012	chr15:45694286	SPATA5L1	1.04	13.15	0.76	2.81e-25	Homoarginine levels;
TGCT	cis	rs6545883	0.929	rs13413337	chr2:61747123	A/G	cg15711740	chr2:61764176	XPO1	-0.52	-4.78	-0.39	4.78e-6	Tuberculosis;
TGCT	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg25036284	chr2:26402008	FAM59B	-0.58	-4.61	-0.38	1.01e-5	Gut microbiome composition (summer);
TGCT	cis	rs4767364	0.922	rs7300252	chr12:112430346	C/T	cg10833066	chr12:111807467	FAM109A	0.32	5.05	0.41	1.52e-6	Oral cavity and pharyngeal cancer;
TGCT	cis	rs11578119	0.866	rs12133110	chr1:170353436	G/A	cg09767346	chr1:170501363	GORAB	0.61	4.61	0.38	9.8e-6	Male-pattern baldness;
TGCT	cis	rs981844	0.857	rs62325142	chr4:154717790	A/G	cg14289246	chr4:154710475	SFRP2	1.01	8.9	0.62	5.71e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg20203395	chr5:56204925	C5orf35	-0.56	-4.67	-0.39	7.83e-6	Initial pursuit acceleration;
TGCT	trans	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg11887960	chr12:57824829	NA	1.14	9.3	0.64	6.29e-16	Lung disease severity in cystic fibrosis;
TGCT	cis	rs10791323	0.569	rs10750541	chr11:133713189	A/C	cg15485101	chr11:133734466	NA	-0.42	-5.52	-0.44	1.86e-7	Childhood ear infection;
TGCT	cis	rs12497850	0.931	rs7643368	chr3:48992855	T/G	cg07636037	chr3:49044803	WDR6	0.96	10.39	0.68	1.45e-18	Parkinson's disease;
TGCT	cis	rs1865760	1.000	rs6905887	chr6:25912103	T/C	cg16482183	chr6:26056742	HIST1H1C	0.55	4.97	0.41	2.19e-6	Height;
TGCT	cis	rs4242434	0.927	rs13271626	chr8:22467760	C/G	cg03733263	chr8:22462867	KIAA1967	1.15	20.1	0.87	7.99e-41	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs7226408	1.000	rs72883560	chr18:34372280	G/A	cg06757138	chr18:34340585	FHOD3	0.27	4.59	0.38	1.08e-5	Obesity-related traits;
TGCT	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg12310025	chr6:25882481	NA	-0.63	-5.76	-0.46	6.4e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs3733585	0.699	rs57574512	chr4:9960182	T/C	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.67	-0.51	7.44e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg00908189	chr16:619842	PIGQ	0.87	10.7	0.69	2.47e-19	Height;
TGCT	cis	rs713587	0.713	rs12466350	chr2:25239969	A/G	cg15423357	chr2:25149977	NA	0.58	5.91	0.47	3.05e-8	Body mass index in non-asthmatics;
TGCT	cis	rs9297145	0.678	rs62473048	chr7:98775511	T/C	cg05967295	chr7:98741636	SMURF1	0.98	12.45	0.75	1.39e-23	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg14820908	chr5:178986412	RUFY1	0.49	4.95	0.41	2.41e-6	Lung cancer;
TGCT	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg13877915	chr19:58951672	ZNF132	0.89	11.13	0.71	2.22e-20	Uric acid clearance;
TGCT	cis	rs1129187	0.782	rs9462860	chr6:42947013	G/C	cg21280719	chr6:42927975	GNMT	-0.38	-4.62	-0.38	9.57e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs4285028	0.948	rs12488851	chr3:121687192	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.77	-6.5	-0.5	1.78e-9	Multiple sclerosis;
TGCT	cis	rs2295359	0.892	rs11209004	chr1:67613932	G/A	cg12940439	chr1:67600707	NA	0.63	6.47	0.5	2.06e-9	Psoriasis;
TGCT	cis	rs394563	0.559	rs7753269	chr6:149671360	G/A	cg11245181	chr6:149772854	ZC3H12D	0.28	4.5	0.37	1.57e-5	Dupuytren's disease;
TGCT	cis	rs7666738	0.830	rs9996098	chr4:98867740	T/C	cg17366294	chr4:99064904	C4orf37	0.7	7.27	0.55	3.62e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12477438	0.501	rs17759607	chr2:99737005	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	14.89	0.8	2.21e-29	Chronic sinus infection;
TGCT	cis	rs7267979	0.873	rs6132822	chr20:25228695	C/T	cg03522245	chr20:25566470	NINL	0.56	5.71	0.46	7.78e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1045529	0.524	rs34251783	chr8:8891376	T/C	cg15556689	chr8:8085844	FLJ10661	-0.62	-5.24	-0.43	6.69e-7	Myopia;Myopia (pathological);
TGCT	cis	rs8072100	0.713	rs4968318	chr17:45451894	G/A	cg08085267	chr17:45401833	C17orf57	-0.51	-5.58	-0.45	1.47e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg22857025	chr5:266934	NA	-0.34	-6.7	-0.52	6.65e-10	Breast cancer;
TGCT	cis	rs35306767	0.715	rs17293580	chr10:1034895	T/C	cg18964960	chr10:1102726	WDR37	0.79	5.5	0.44	2.04e-7	Eosinophil percentage of granulocytes;
TGCT	cis	rs9443645	0.901	rs7742431	chr6:79679577	A/G	cg09184832	chr6:79620586	NA	-0.49	-5.42	-0.44	2.98e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs3852122	chr4:98697400	T/C	cg17366294	chr4:99064904	C4orf37	0.65	6.78	0.52	4.31e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9911578	0.933	rs2531726	chr17:56522533	C/T	cg05425664	chr17:57184151	TRIM37	0.59	6.07	0.48	1.47e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs1478897	0.510	rs11786148	chr8:11423781	C/G	cg21175976	chr8:11421337	BLK	-0.36	-4.62	-0.38	9.65e-6	Systemic lupus erythematosus;
TGCT	cis	rs7819412	0.511	rs2409797	chr8:11433780	T/C	cg27411982	chr8:10470053	RP1L1	-0.21	-4.54	-0.38	1.31e-5	Triglycerides;
TGCT	cis	rs62244186	0.520	rs2372828	chr3:44784949	A/G	cg21672276	chr3:44754072	ZNF502	0.54	6.25	0.49	5.94e-9	Depressive symptoms;
TGCT	cis	rs1887596	0.624	rs9553860	chr13:27139814	C/T	cg01312412	chr13:27282625	NA	-0.26	-4.69	-0.39	6.97e-6	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs7666738	0.830	rs6852015	chr4:99054373	C/A	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg20637647	chr7:64974828	NA	0.95	5.8	0.46	5.3e-8	Diabetic kidney disease;
TGCT	trans	rs74910095	0.656	rs73761386	chr5:62932251	A/G	cg02938449	chr2:220419364	OBSL1	0.8	6.75	0.52	4.95e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7267979	0.586	rs6050445	chr20:25195394	C/T	cg03522245	chr20:25566470	NINL	0.52	5.43	0.44	2.83e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs17331151	0.573	rs79664140	chr3:52866936	A/G	cg12962167	chr3:53033115	SFMBT1	0.44	4.96	0.41	2.28e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs2760061	0.583	rs708121	chr1:228208257	A/G	cg18477163	chr1:228402036	OBSCN	0.35	7.11	0.54	8.02e-11	Diastolic blood pressure;
TGCT	cis	rs10493773	0.510	rs11161645	chr1:86092872	T/C	cg17807903	chr1:86174739	ZNHIT6	0.4	5.06	0.41	1.45e-6	Urate levels in overweight individuals;
TGCT	cis	rs5769765	0.671	rs138844	chr22:50184484	T/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.96	-8.65	-0.61	2.28e-14	Schizophrenia;
TGCT	cis	rs1451375	0.756	rs11761683	chr7:50542879	C/T	cg18232548	chr7:50535776	DDC	-0.44	-6.46	-0.5	2.14e-9	Malaria;
TGCT	cis	rs637571	0.512	rs660118	chr11:65735174	G/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.68	6.71	0.52	6.09e-10	Eosinophil percentage of white cells;
TGCT	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.75	5.41	0.44	3.09e-7	Platelet count;
TGCT	cis	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg20637647	chr7:64974828	NA	-0.95	-5.3	-0.43	5.09e-7	Diabetic kidney disease;
TGCT	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.94	7.92	0.58	1.17e-12	Platelet count;
TGCT	cis	rs7267979	0.789	rs6083841	chr20:25384564	C/T	cg16686733	chr20:25566563	NINL	-0.49	-4.61	-0.38	9.76e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs12497850	0.931	rs9311433	chr3:48863835	T/C	cg06212747	chr3:49208901	KLHDC8B	0.62	5.83	0.46	4.42e-8	Parkinson's disease;
TGCT	cis	rs7191439	0.858	rs11076702	chr16:88774569	A/C	cg27087555	chr16:88793112	FAM38A	-0.49	-5.63	-0.45	1.15e-7	Plateletcrit;
TGCT	cis	rs7552404	0.924	rs114752222	chr1:76180878	C/T	cg03433033	chr1:76189801	ACADM	0.82	9.89	0.66	2.31e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs950169	1.000	rs35297609	chr15:84772896	A/G	cg17173187	chr15:85201210	NMB	0.47	5.23	0.43	7.01e-7	Schizophrenia;
TGCT	trans	rs4332037	0.707	rs73046323	chr7:1882795	G/A	cg25206134	chr2:45395956	NA	0.93	7.88	0.58	1.43e-12	Bipolar disorder;
TGCT	trans	rs2727020	0.704	rs2988340	chr11:49176057	C/T	cg03929089	chr4:120376271	NA	-0.61	-6.7	-0.52	6.41e-10	Coronary artery disease;
TGCT	cis	rs1395	1.000	rs7593448	chr2:27449293	C/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.51	6.69	0.52	6.74e-10	Blood metabolite levels;
TGCT	cis	rs8032315	0.895	rs4932370	chr15:91404705	A/G	cg04510874	chr15:91427884	FES	-0.49	-5.36	-0.43	3.89e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs682748	1.000	rs612378	chr5:17159362	C/T	cg23987134	chr5:17158319	LOC285696	-0.23	-5.38	-0.44	3.56e-7	Hippocampal atrophy;
TGCT	cis	rs7809950	0.817	rs62483725	chr7:107201575	G/A	cg23024343	chr7:107201750	COG5	-0.47	-6.81	-0.52	3.74e-10	Coronary artery disease;
TGCT	cis	rs1348850	0.519	rs4144275	chr2:178523368	C/T	cg22681709	chr2:178499509	PDE11A	-0.48	-6.09	-0.48	1.3e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs9419702	0.614	rs4897816	chr10:133533646	G/A	cg04492858	chr10:133558786	NA	0.55	5.71	0.46	7.96e-8	Survival in rectal cancer;
TGCT	cis	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg25427524	chr10:38739819	LOC399744	0.4	8.22	0.59	2.34e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs35160687	1.000	rs35160687	chr2:86472114	C/T	cg12542933	chr2:85804724	VAMP8	0.41	4.88	0.4	3.25e-6	Night sleep phenotypes;
TGCT	cis	rs8177253	0.665	rs8177178	chr3:133463272	G/A	cg01448562	chr3:133502909	NA	-0.26	-4.74	-0.39	5.8e-6	Iron status biomarkers;
TGCT	cis	rs12188164	0.965	rs72717435	chr5:448202	G/A	cg21144161	chr5:423903	AHRR	0.25	4.69	0.39	7.08e-6	Cystic fibrosis severity;
TGCT	cis	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg18252515	chr7:66147081	NA	-1.31	-8.18	-0.59	2.87e-13	Diabetic kidney disease;
TGCT	cis	rs7552404	0.731	rs10873788	chr1:76367857	A/C	cg22875332	chr1:76189707	ACADM	0.63	6.06	0.48	1.53e-8	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs28595532	0.841	rs114363775	chr4:119765587	G/A	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs28595532	0.920	rs116023902	chr4:119725131	A/G	cg21605333	chr4:119757512	SEC24D	1.72	8.96	0.63	3.99e-15	Cannabis dependence symptom count;
TGCT	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg03388025	chr16:89894329	SPIRE2	0.48	8.4	0.6	8.77e-14	Vitiligo;
TGCT	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg00343986	chr7:65444356	GUSB	-0.2	-4.51	-0.38	1.51e-5	Aortic root size;
TGCT	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg00738919	chr7:1100172	C7orf50	0.4	4.5	0.37	1.54e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7647973	0.826	rs9834535	chr3:49378797	A/T	cg06212747	chr3:49208901	KLHDC8B	0.6	4.73	0.39	6.08e-6	Menarche (age at onset);
TGCT	cis	rs35306767	0.903	rs17159950	chr10:875287	T/G	cg20503657	chr10:835505	NA	0.7	9.83	0.66	3.22e-17	Eosinophil percentage of granulocytes;
TGCT	cis	rs9372498	0.536	rs1319988	chr6:118782379	G/A	cg07617317	chr6:118971624	C6orf204	0.5	5.39	0.44	3.37e-7	Diastolic blood pressure;
TGCT	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg04234412	chr22:24373322	LOC391322	-0.91	-10.67	-0.69	2.98e-19	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg03352830	chr11:487213	PTDSS2	0.26	4.58	0.38	1.12e-5	Body mass index;
TGCT	cis	rs7119	0.635	rs938090	chr15:77879975	A/G	cg27398640	chr15:77910606	LINGO1	0.31	6.19	0.49	8.26e-9	Type 2 diabetes;
TGCT	cis	rs992157	1.000	rs2168704	chr2:219142492	G/A	cg00012203	chr2:219082015	ARPC2	0.78	8.39	0.6	9.39e-14	Colorectal cancer;
TGCT	trans	rs10435719	0.867	rs34583868	chr8:11791383	G/T	cg15556689	chr8:8085844	FLJ10661	0.75	7.26	0.55	3.66e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs7666738	0.830	rs7687315	chr4:98900613	A/G	cg18180107	chr4:99064573	C4orf37	0.53	4.81	0.4	4.23e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg06675538	chr2:114033490	PAX8;LOC440839	0.44	4.81	0.4	4.22e-6	Lymphocyte counts;
TGCT	cis	rs4924935	0.851	rs12936834	chr17:18807078	A/G	cg26378065	chr17:18585709	ZNF286B	0.58	4.87	0.4	3.39e-6	Pancreatic cancer;
TGCT	cis	rs2191566	1.000	rs390369	chr19:44506984	C/T	cg03039196	chr19:44506973	ZNF230	-0.54	-4.75	-0.39	5.52e-6	Acute lymphoblastic leukemia (childhood);
TGCT	cis	rs7546668	0.640	rs4661634	chr1:15808289	C/T	cg17657618	chr1:15427654	KIAA1026	-0.25	-4.63	-0.38	9.03e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs6866344	0.568	rs4626352	chr5:178096777	G/A	cg10224037	chr5:178157518	ZNF354A	0.6	5.06	0.41	1.5e-6	Neutrophil percentage of white cells;
TGCT	trans	rs1814175	0.817	rs4405313	chr11:50013636	G/A	cg03929089	chr4:120376271	NA	-0.72	-8.55	-0.61	3.8e-14	Height;
TGCT	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs10501293	0.746	rs4755184	chr11:43009790	T/C	cg03447554	chr11:43094025	NA	0.43	6.1	0.48	1.26e-8	Cognitive performance;
TGCT	cis	rs1044826	0.518	rs295488	chr3:139239323	C/T	cg00490450	chr3:139108681	COPB2	0.51	4.76	0.39	5.19e-6	Obesity-related traits;
TGCT	cis	rs2439831	0.717	rs9806227	chr15:43680115	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	8.14	0.59	3.58e-13	Lung cancer in ever smokers;
TGCT	cis	rs7267979	0.933	rs2424708	chr20:25281398	C/T	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg24250549	chr1:154909240	PMVK	0.63	6.25	0.49	6.03e-9	Prostate cancer;
TGCT	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg10802521	chr3:52805072	NEK4	-0.78	-10.01	-0.67	1.22e-17	Bipolar disorder;
TGCT	cis	rs13256369	0.802	rs11781257	chr8:8559663	A/T	cg17143192	chr8:8559678	CLDN23	0.53	4.82	0.4	4.03e-6	Obesity-related traits;
TGCT	cis	rs28595532	0.841	rs116329146	chr4:119733438	G/A	cg21605333	chr4:119757512	SEC24D	1.66	8.33	0.6	1.28e-13	Cannabis dependence symptom count;
TGCT	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg06634786	chr22:41940651	POLR3H	-0.85	-7.8	-0.57	2.16e-12	Vitiligo;
TGCT	cis	rs2688608	0.967	rs2675663	chr10:75660270	T/G	cg04320760	chr10:75533139	FUT11	-0.3	-4.57	-0.38	1.18e-5	Inflammatory bowel disease;
TGCT	cis	rs933688	0.938	rs7708782	chr5:90718517	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.02	8.42	0.6	7.65e-14	Smoking behavior;
TGCT	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg13695892	chr22:41940480	POLR3H	-0.89	-8.48	-0.61	5.62e-14	Vitiligo;
TGCT	cis	rs614226	1.000	rs7174	chr12:121017171	A/G	cg01236616	chr12:121019343	POP5	1.28	13.92	0.78	4.09e-27	Type 1 diabetes nephropathy;
TGCT	trans	rs1499614	0.522	rs13247442	chr7:66188858	T/C	cg07424592	chr7:64974309	NA	1.52	8.51	0.61	4.72e-14	Gout;
TGCT	cis	rs2980439	0.525	rs1850511	chr8:8170329	T/A	cg06636001	chr8:8085503	FLJ10661	0.72	6.22	0.49	7.12e-9	Neuroticism;
TGCT	cis	rs3820928	0.904	rs4439949	chr2:227764954	T/G	cg11843606	chr2:227700838	RHBDD1	-0.53	-4.68	-0.39	7.37e-6	Pulmonary function;
TGCT	cis	rs2235649	0.552	rs8056773	chr16:1959432	G/A	cg02432467	chr16:1963432	HS3ST6	-0.31	-4.61	-0.38	9.71e-6	Blood metabolite levels;
TGCT	cis	rs986417	1.000	rs4243618	chr14:61067022	T/C	cg27398547	chr14:60952738	C14orf39	1.41	8.4	0.6	8.74e-14	Gut microbiota (bacterial taxa);
TGCT	cis	rs3008870	1.000	rs58680688	chr1:67443751	C/G	cg03991309	chr1:68237761	GNG12	-0.27	-4.53	-0.38	1.36e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs644799	0.965	rs1944080	chr11:95503636	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	8.46	0.6	6.27e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs514406	0.893	rs6588445	chr1:53424928	T/C	cg27535305	chr1:53392650	SCP2	0.23	4.53	0.38	1.38e-5	Monocyte count;
TGCT	cis	rs2046867	0.818	rs11929144	chr3:72868234	T/C	cg25664220	chr3:72788482	NA	-0.53	-6.73	-0.52	5.6e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs1568889	0.838	rs7943538	chr11:28288955	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.91	10.83	0.7	1.23e-19	Bipolar disorder;
TGCT	cis	rs7940866	0.845	rs2324314	chr11:130834589	A/C	cg12179176	chr11:130786555	SNX19	0.55	5.4	0.44	3.32e-7	Schizophrenia;
TGCT	cis	rs8014204	0.804	rs2241274	chr14:75251331	G/A	cg06637938	chr14:75390232	RPS6KL1	0.7	6.75	0.52	5.06e-10	Caffeine consumption;
TGCT	cis	rs6582630	0.598	rs12823134	chr12:38514347	T/A	cg26384229	chr12:38710491	ALG10B	-0.54	-4.79	-0.4	4.57e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs10791097	0.720	rs6590517	chr11:130733505	C/T	cg12179176	chr11:130786555	SNX19	0.83	9.97	0.67	1.52e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9952991	0.883	rs2542147	chr18:12775851	G/T	cg23598886	chr18:12777645	NA	0.62	5.78	0.46	5.63e-8	Inflammatory skin disease;
TGCT	cis	rs727505	1.000	rs720614	chr7:124452790	T/C	cg23710748	chr7:124431027	NA	-0.27	-4.63	-0.38	9.07e-6	Lewy body disease;
TGCT	cis	rs9916302	0.706	rs8078599	chr17:37518660	C/T	cg07936489	chr17:37558343	FBXL20	0.88	6.28	0.49	5.31e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs2594989	0.887	rs2447604	chr3:11574297	G/A	cg26283222	chr3:11613257	VGLL4	0.23	4.66	0.39	7.97e-6	Circulating chemerin levels;
TGCT	cis	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg18252515	chr7:66147081	NA	-1.31	-8.18	-0.59	2.87e-13	Diabetic kidney disease;
TGCT	cis	rs1371867	0.875	rs28595052	chr8:101327553	G/A	cg00191853	chr8:101177733	SPAG1	-0.22	-4.47	-0.37	1.75e-5	Atrioventricular conduction;
TGCT	cis	rs9486719	0.947	rs72932805	chr6:96902933	T/G	cg18709589	chr6:96969512	KIAA0776	-0.72	-5.24	-0.43	6.58e-7	Migraine;Coronary artery disease;
TGCT	cis	rs2243480	1.000	rs160633	chr7:65528228	T/C	cg20637647	chr7:64974828	NA	0.95	5.8	0.46	5.3e-8	Diabetic kidney disease;
TGCT	cis	rs4523957	0.620	rs9906467	chr17:2069003	C/T	cg16513277	chr17:2031491	SMG6	-0.2	-4.46	-0.37	1.8e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs5769765	0.954	rs5769762	chr22:50264042	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.41	-6.13	-0.48	1.08e-8	Schizophrenia;
TGCT	cis	rs28595532	0.920	rs56042726	chr4:119751777	T/A	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs6815814	0.851	rs10023850	chr4:38763693	G/A	cg02016764	chr4:38805732	TLR1	-0.32	-5.08	-0.42	1.35e-6	Breast cancer;
TGCT	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg04944784	chr2:26401820	FAM59B	-0.76	-6.24	-0.49	6.46e-9	Gut microbiome composition (summer);
TGCT	cis	rs10927875	0.619	rs28537253	chr1:16148600	A/C	cg21385522	chr1:16154831	NA	-0.75	-9.3	-0.64	6.17e-16	Dilated cardiomyopathy;
TGCT	cis	rs2153535	0.580	rs6910742	chr6:8448328	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.76	0.46	6.39e-8	Motion sickness;
TGCT	cis	rs9916302	0.653	rs4239223	chr17:37717004	T/C	cg07936489	chr17:37558343	FBXL20	-0.84	-6.16	-0.48	9.13e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs1371867	0.817	rs1788208	chr8:101312515	T/C	cg06636551	chr8:101224915	SPAG1	-0.48	-6.52	-0.51	1.62e-9	Atrioventricular conduction;
TGCT	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg13752114	chr3:195489708	MUC4	-0.33	-4.81	-0.4	4.33e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg18735214	chr6:43276756	CRIP3	-0.51	-4.8	-0.4	4.52e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	5.12	0.42	1.11e-6	Alzheimer's disease;
TGCT	cis	rs727505	1.000	rs10228201	chr7:124449895	A/G	cg23710748	chr7:124431027	NA	-0.27	-4.65	-0.39	8.35e-6	Lewy body disease;
TGCT	cis	rs9419702	0.639	rs9419624	chr10:133534822	G/A	cg23460707	chr10:133558971	NA	0.42	4.84	0.4	3.8e-6	Survival in rectal cancer;
TGCT	cis	rs6121246	0.954	rs7266148	chr20:30431070	G/T	cg13852791	chr20:30311386	BCL2L1	0.8	6.12	0.48	1.15e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs8077577	0.895	rs62073615	chr17:18080329	T/A	cg09161412	chr17:18057145	MYO15A	-0.66	-5.36	-0.43	3.94e-7	Obesity-related traits;
TGCT	cis	rs6740322	0.748	rs6544635	chr2:43486704	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.4	-6.29	-0.49	4.92e-9	Coronary artery disease;
TGCT	trans	rs877282	1.000	rs71491304	chr10:772982	C/T	cg22713356	chr15:30763199	NA	1.16	10.02	0.67	1.16e-17	Uric acid levels;
TGCT	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg13206674	chr6:150067644	NUP43	0.52	4.51	0.38	1.5e-5	Lung cancer;
TGCT	cis	rs2299587	0.554	rs11778309	chr8:17747433	T/C	cg04898035	chr8:17640624	MTUS1	-0.21	-4.7	-0.39	6.92e-6	Economic and political preferences;
TGCT	trans	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg17830980	chr10:43048298	ZNF37B	-0.86	-11.18	-0.71	1.68e-20	Extrinsic epigenetic age acceleration;
TGCT	trans	rs9467711	1.000	rs6903015	chr6:26322526	A/G	cg20516262	chr7:155325649	CNPY1	0.54	6.63	0.51	9.34e-10	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1865760	0.532	rs2794719	chr6:26088890	T/G	cg17042849	chr6:26104293	HIST1H4C	-0.66	-5.6	-0.45	1.33e-7	Height;
TGCT	cis	rs4654899	0.772	rs10916892	chr1:21201325	A/G	cg01072550	chr1:21505969	NA	-0.47	-5.8	-0.46	5.17e-8	Superior frontal gyrus grey matter volume;
TGCT	cis	rs11209185	0.503	rs4655573	chr1:68438778	C/T	cg22082780	chr1:68452167	NA	-0.31	-4.67	-0.39	7.56e-6	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs7216064	0.953	rs80135947	chr17:65836001	A/C	cg12091567	chr17:66097778	LOC651250	-0.83	-6.49	-0.5	1.9e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg06221963	chr1:154839813	KCNN3	-0.79	-15.15	-0.81	5.4e-30	Prostate cancer;
TGCT	cis	rs2980439	0.607	rs2980419	chr8:8114141	A/T	cg06636001	chr8:8085503	FLJ10661	0.86	8.26	0.6	1.91e-13	Neuroticism;
TGCT	cis	rs6569992	0.636	rs61593090	chr6:135488083	G/A	cg22676075	chr6:135203613	NA	0.74	5.03	0.41	1.69e-6	Red blood cell traits;
TGCT	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg00684032	chr4:1343700	KIAA1530	0.22	4.82	0.4	4.11e-6	Obesity-related traits;
TGCT	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg11764359	chr7:65958608	NA	0.61	5.53	0.44	1.79e-7	Aortic root size;
TGCT	cis	rs4455778	0.500	rs7783586	chr7:49057244	C/A	cg26309511	chr7:48887640	NA	0.52	6.8	0.52	3.99e-10	Lung cancer in never smokers;
TGCT	cis	rs3087591	0.708	rs2854311	chr17:29671327	C/T	cg24425628	chr17:29625626	OMG;NF1	0.39	5.56	0.45	1.57e-7	Hip circumference;
TGCT	cis	rs11190604	0.767	rs4919458	chr10:102177728	G/A	cg16005271	chr10:102321736	NA	-0.43	-4.45	-0.37	1.86e-5	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs6840360	0.642	rs2709825	chr4:152365563	C/A	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.83e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs6570726	0.791	rs1280275	chr6:145892402	C/T	cg05347473	chr6:146136440	FBXO30	0.52	4.95	0.41	2.33e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7267979	0.873	rs7453	chr20:25207074	A/G	cg03522245	chr20:25566470	NINL	0.57	6.17	0.48	8.89e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7267979	1.000	rs6037121	chr20:25428311	G/A	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10193935	0.892	rs13413028	chr2:42394865	C/G	cg27598129	chr2:42591480	NA	-0.39	-5.14	-0.42	1.05e-6	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg20587970	chr11:113659929	NA	-1.03	-12.23	-0.74	4.82e-23	Hip circumference adjusted for BMI;
TGCT	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg06481639	chr22:41940642	POLR3H	0.75	6.66	0.51	8.03e-10	Vitiligo;
TGCT	trans	rs28735056	0.935	rs72980082	chr18:77630170	G/T	cg05926928	chr17:57297772	GDPD1	-0.71	-7.6	-0.56	6.2e-12	Schizophrenia;
TGCT	trans	rs877282	0.898	rs11253339	chr10:759640	C/T	cg22713356	chr15:30763199	NA	1.17	9.15	0.63	1.44e-15	Uric acid levels;
TGCT	trans	rs1814175	0.647	rs61306292	chr11:49856040	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.38	-7.3	-0.55	2.99e-11	Height;
TGCT	cis	rs8020441	0.588	rs4534750	chr14:51188124	C/T	cg04730355	chr14:51134070	SAV1	0.97	6.98	0.53	1.61e-10	Cognitive performance;
TGCT	cis	rs5769765	0.671	rs138841	chr22:50181960	C/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.94	-8.72	-0.62	1.56e-14	Schizophrenia;
TGCT	cis	rs10791097	0.765	rs4622274	chr11:130729486	C/T	cg12179176	chr11:130786555	SNX19	0.73	8.59	0.61	3.08e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs1577917	1.000	rs7771342	chr6:86631936	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.54	-0.45	1.73e-7	Response to antipsychotic treatment;
TGCT	cis	rs12477438	0.953	rs3851334	chr2:99794704	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-5.46	-0.44	2.5e-7	Chronic sinus infection;
TGCT	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg03303774	chr4:1407052	NA	0.31	4.87	0.4	3.31e-6	Obesity-related traits;
TGCT	cis	rs67311347	0.955	rs2123999	chr3:40378738	C/T	cg13683864	chr3:40499215	RPL14	-1.03	-10.79	-0.7	1.51e-19	Renal cell carcinoma;
TGCT	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg18876405	chr7:65276391	NA	-0.36	-5.41	-0.44	3.12e-7	Aortic root size;
TGCT	cis	rs7666738	0.710	rs7674407	chr4:98838522	A/G	cg17366294	chr4:99064904	C4orf37	0.72	7.5	0.56	1.07e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2469997	0.925	rs2447173	chr8:120359513	C/T	cg00681363	chr8:120844660	TAF2	0.69	4.48	0.37	1.64e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs2594989	0.831	rs7356051	chr3:11566288	A/C	cg00170343	chr3:11313890	ATG7	-0.65	-4.82	-0.4	4.08e-6	Circulating chemerin levels;
TGCT	cis	rs6570726	0.791	rs7765675	chr6:145915077	A/C	cg05347473	chr6:146136440	FBXO30	0.53	4.92	0.4	2.74e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2243480	0.522	rs778717	chr7:65848151	G/C	cg07424592	chr7:64974309	NA	1.42	8.46	0.6	6.25e-14	Diabetic kidney disease;
TGCT	cis	rs7621025	0.500	rs1965107	chr3:136648643	T/A	cg15507776	chr3:136538369	TMEM22	0.67	6.26	0.49	5.69e-9	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
TGCT	cis	rs34526934	0.566	rs9141	chr2:177037970	T/C	cg26754761	chr2:177040938	NA	-0.3	-5.57	-0.45	1.49e-7	Obstructive sleep apnea trait (apnea hypopnea index);
TGCT	cis	rs28595532	0.841	rs55823625	chr4:119780600	T/A	cg21605333	chr4:119757512	SEC24D	1.53	8.87	0.62	6.71e-15	Cannabis dependence symptom count;
TGCT	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg06618935	chr21:46677482	NA	-0.36	-5.71	-0.46	7.76e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.61	-5.07	-0.41	1.42e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2486288	0.656	rs7162022	chr15:45565253	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.43	-4.9	-0.4	2.91e-6	Glomerular filtration rate;
TGCT	cis	rs453301	0.571	rs2929453	chr8:9084341	A/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-4.8	-0.4	4.42e-6	Joint mobility (Beighton score);
TGCT	cis	rs12497850	0.931	rs9876848	chr3:48844059	G/A	cg06212747	chr3:49208901	KLHDC8B	0.61	5.62	0.45	1.2e-7	Parkinson's disease;
TGCT	cis	rs7104764	0.507	rs6598054	chr11:254010	C/T	cg18336825	chr11:236787	PSMD13;SIRT3	-0.67	-5.04	-0.41	1.6e-6	Menarche (age at onset);
TGCT	cis	rs3784262	0.528	rs6493979	chr15:58338052	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.43	-6.46	-0.5	2.19e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.61	5.06	0.41	1.5e-6	Tonsillectomy;
TGCT	cis	rs4851254	0.961	rs11677607	chr2:100751150	C/T	cg23118464	chr2:100721844	AFF3	0.74	5.52	0.44	1.86e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2147959	0.766	rs35724040	chr1:228782519	A/T	cg22700015	chr1:228743131	NA	0.58	5.02	0.41	1.71e-6	Adult asthma;
TGCT	cis	rs6921919	0.583	rs11755942	chr6:28369537	A/G	cg18815343	chr6:28367644	ZSCAN12	-0.56	-5.27	-0.43	5.78e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9921338	0.961	rs7626	chr16:11445596	C/T	cg00044050	chr16:11439710	C16orf75	-0.73	-5.69	-0.45	8.72e-8	Vein graft stenosis in coronary artery bypass grafting;
TGCT	trans	rs2727020	0.894	rs11040333	chr11:49346332	G/A	cg03929089	chr4:120376271	NA	-0.64	-6.74	-0.52	5.34e-10	Coronary artery disease;
TGCT	cis	rs7824557	0.767	rs2164273	chr8:11168499	A/G	cg21775007	chr8:11205619	TDH	0.58	5.46	0.44	2.46e-7	Retinal vascular caliber;
TGCT	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg24675658	chr1:53192096	ZYG11B	0.7	7.98	0.58	8.59e-13	Monocyte count;
TGCT	cis	rs60843830	1.000	rs10193373	chr2:281886	T/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.7	6.56	0.51	1.33e-9	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs854765	0.647	rs62073573	chr17:17976354	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	7.42	0.55	1.6e-11	Total body bone mineral density;
TGCT	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.69	-7.06	-0.54	1.07e-10	Prostate cancer;
TGCT	cis	rs694739	0.628	rs538147	chr11:64129722	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.69	6.61	0.51	1.03e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs7666738	0.830	rs10001479	chr4:98918764	A/G	cg05340658	chr4:99064831	C4orf37	-0.57	-6.6	-0.51	1.1e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs950169	0.922	rs4338765	chr15:84916836	G/T	cg12863693	chr15:85201151	NMB	0.41	4.5	0.38	1.51e-5	Schizophrenia;
TGCT	cis	rs11586313	0.935	rs4845496	chr1:152888178	A/G	cg07796016	chr1:152779584	LCE1C	-0.48	-5.61	-0.45	1.27e-7	Vitamin D levels;
TGCT	cis	rs7917772	0.536	rs3961456	chr10:104425304	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.82	-8.16	-0.59	3.15e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9611565	0.605	rs202638	chr22:41855458	A/G	cg03806693	chr22:41940476	POLR3H	1.08	11.92	0.73	2.64e-22	Vitiligo;
TGCT	cis	rs10193935	0.901	rs59890734	chr2:42595662	G/A	cg27598129	chr2:42591480	NA	-0.4	-5.53	-0.44	1.83e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg04632378	chr13:21900426	NA	0.43	5.04	0.41	1.6e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	trans	rs4332037	0.539	rs56305291	chr7:2048706	A/G	cg25206134	chr2:45395956	NA	0.96	7.24	0.55	4.07e-11	Bipolar disorder;
TGCT	cis	rs7178572	0.568	rs4886862	chr15:77652368	T/C	cg22256960	chr15:77711686	NA	-0.85	-8.73	-0.62	1.4e-14	Type 2 diabetes;
TGCT	cis	rs9430161	0.579	rs7542354	chr1:11040385	G/A	cg27631724	chr1:11040367	C1orf127	0.55	6.58	0.51	1.2e-9	Ewing sarcoma;
TGCT	cis	rs7169223	0.615	rs8038189	chr15:79099026	G/C	cg21242079	chr15:79101063	ADAMTS7	0.36	5.74	0.46	6.73e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
TGCT	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.42	-7.04	-0.53	1.16e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg03934478	chr11:495069	RNH1	-0.34	-5.91	-0.47	3.07e-8	Body mass index;
TGCT	cis	rs3849046	0.781	rs4835691	chr5:137938573	G/T	cg24064279	chr5:137839461	NA	-0.28	-4.47	-0.37	1.77e-5	Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs8031584	0.752	rs34722914	chr15:31191991	G/A	cg08109568	chr15:31115862	NA	-0.35	-4.79	-0.4	4.66e-6	Huntington's disease progression;
TGCT	cis	rs7666738	0.515	rs13118898	chr4:98792893	T/A	cg18180107	chr4:99064573	C4orf37	0.52	4.58	0.38	1.13e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs17376456	0.877	rs10070390	chr5:93452345	G/A	cg25358565	chr5:93447407	FAM172A	0.92	8.38	0.6	9.58e-14	Diabetic retinopathy;
TGCT	cis	rs2241685	0.850	rs7565890	chr2:1942959	G/A	cg21862353	chr2:1801628	MYT1L	-0.52	-4.77	-0.39	5.05e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs3617	0.652	rs60332615	chr3:52867595	C/A	cg11645453	chr3:52864694	ITIH4	-0.29	-5.71	-0.46	7.84e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs79349575	0.715	rs1058018	chr17:47000251	C/T	cg07967210	chr17:47022446	SNF8	0.37	5.07	0.41	1.43e-6	Type 2 diabetes;
TGCT	cis	rs250677	0.641	rs2915807	chr5:148450950	A/G	cg23229984	chr5:148520753	ABLIM3	0.23	5.1	0.42	1.25e-6	Breast cancer;
TGCT	cis	rs9915657	0.933	rs17246133	chr17:70140485	A/G	cg06234051	chr17:70120541	SOX9	-0.24	-4.7	-0.39	6.93e-6	Thyroid hormone levels;
TGCT	cis	rs2456568	0.900	rs2000960	chr11:93682348	C/T	cg16099599	chr11:93583650	C11orf90	-0.39	-4.69	-0.39	7.11e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs2640806	0.505	rs7012725	chr8:97361834	C/T	cg04026948	chr8:97953330	PGCP	-0.25	-4.5	-0.37	1.55e-5	Obesity-related traits;
TGCT	cis	rs4372836	0.504	rs7601413	chr2:29032238	C/T	cg09522027	chr2:28974177	PPP1CB	-0.56	-5.58	-0.45	1.42e-7	Body mass index;
TGCT	cis	rs6500602	0.701	rs8129	chr16:4562351	A/G	cg08645402	chr16:4508243	NA	0.2	5.04	0.41	1.58e-6	Schizophrenia;
TGCT	cis	rs2535633	0.588	rs2564930	chr3:53017307	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.49	-4.48	-0.37	1.66e-5	Body mass index;
TGCT	cis	rs514406	0.505	rs387436	chr1:53179376	C/T	cg22166914	chr1:53195759	ZYG11B	-0.45	-8.14	-0.59	3.47e-13	Monocyte count;
TGCT	cis	rs11711311	1.000	rs7633832	chr3:113472292	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.79	-7.32	-0.55	2.75e-11	IgG glycosylation;
TGCT	cis	rs7267979	1.000	rs1888998	chr20:25291826	A/G	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9473924	0.580	rs66462826	chr6:50814877	C/A	cg14470998	chr6:50812995	TFAP2B	1.36	8.61	0.61	2.74e-14	Body mass index;
TGCT	cis	rs849898	1	rs849898	chr1:228153917	A/G	cg02753203	chr1:228287806	NA	-0.4	-8.18	-0.59	2.91e-13	Parkinson's disease;
TGCT	cis	rs35306767	0.855	rs61830900	chr10:871481	C/G	cg26597838	chr10:835615	NA	0.8	12.11	0.74	9.26e-23	Eosinophil percentage of granulocytes;
TGCT	cis	rs478304	0.593	rs4645927	chr11:65482827	C/T	cg12758867	chr11:65354231	EHBP1L1	0.26	4.48	0.37	1.67e-5	Acne (severe);
TGCT	cis	rs514406	0.505	rs416968	chr1:53183513	A/G	cg08859206	chr1:53392774	SCP2	-0.33	-4.74	-0.39	5.64e-6	Monocyte count;
TGCT	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg04025307	chr7:1156635	C7orf50	0.23	5.38	0.44	3.52e-7	Longevity;Endometriosis;
TGCT	cis	rs4901869	0.966	rs4901868	chr14:59333792	C/T	cg02291164	chr14:59296302	NA	-0.25	-4.94	-0.41	2.51e-6	Panic disorder;
TGCT	cis	rs9393692	0.905	rs9366649	chr6:26329103	A/T	cg05868516	chr6:26286170	HIST1H4H	-0.55	-5.23	-0.43	6.92e-7	Educational attainment;
TGCT	cis	rs7959452	0.718	rs10878963	chr12:69717166	T/G	cg14784868	chr12:69753453	YEATS4	0.58	5.59	0.45	1.35e-7	Blood protein levels;
TGCT	cis	rs2282802	0.677	rs9686454	chr5:139627813	T/C	cg01081189	chr5:139537190	NA	0.29	5.22	0.42	7.24e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs6671200	0.790	rs259357	chr1:95711478	G/T	cg20701556	chr1:95698924	RWDD3	-0.67	-5.63	-0.45	1.13e-7	Stearic acid (18:0) levels;
TGCT	cis	rs79387448	0.638	rs74731686	chr2:103043981	G/A	cg09003973	chr2:102972529	NA	1.27	9.82	0.66	3.37e-17	Gut microbiota (bacterial taxa);
TGCT	cis	rs4788570	0.615	rs4788550	chr16:71720523	C/T	cg06353428	chr16:71660113	MARVELD3	1.56	12.54	0.75	8.54e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs763121	0.853	rs5750627	chr22:38982321	A/G	cg06022373	chr22:39101656	GTPBP1	0.82	8.37	0.6	1.05e-13	Menopause (age at onset);
TGCT	cis	rs2120019	0.938	rs8030089	chr15:75290377	C/T	cg09165964	chr15:75287851	SCAMP5	-1.14	-9.98	-0.67	1.43e-17	Blood trace element (Zn levels);
TGCT	cis	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg22857025	chr5:266934	NA	-0.34	-6.7	-0.52	6.65e-10	Breast cancer;
TGCT	cis	rs9611565	0.568	rs2413656	chr22:42129357	G/T	cg17554472	chr22:41940697	POLR3H	0.44	4.62	0.38	9.38e-6	Vitiligo;
TGCT	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg16325326	chr1:53192061	ZYG11B	-0.64	-7.19	-0.54	5.26e-11	Monocyte count;
TGCT	cis	rs17376456	0.809	rs13177800	chr5:93307350	T/C	cg25358565	chr5:93447407	FAM172A	0.99	8.37	0.6	1.02e-13	Diabetic retinopathy;
TGCT	cis	rs9393692	0.905	rs4412192	chr6:26290377	A/G	cg13736514	chr6:26305472	NA	0.37	5.42	0.44	3.01e-7	Educational attainment;
TGCT	cis	rs9807989	0.507	rs2287033	chr2:103011237	C/T	cg03938978	chr2:103052716	IL18RAP	-0.27	-5.54	-0.45	1.71e-7	Asthma;
TGCT	cis	rs9914544	1.000	rs59682951	chr17:18800766	G/T	cg26306683	chr17:18585705	ZNF286B	0.56	4.97	0.41	2.18e-6	Educational attainment (years of education);
TGCT	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg24060327	chr5:131705240	SLC22A5	-0.53	-5.42	-0.44	2.97e-7	Breast cancer;
TGCT	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg24060327	chr5:131705240	SLC22A5	-0.56	-5.6	-0.45	1.34e-7	Breast cancer;
TGCT	cis	rs981844	0.712	rs4538465	chr4:154746763	T/C	cg14289246	chr4:154710475	SFRP2	-0.99	-9.12	-0.63	1.65e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg11764359	chr7:65958608	NA	0.59	5.29	0.43	5.45e-7	Aortic root size;
TGCT	cis	rs9814567	0.896	rs4435682	chr3:134344182	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.85	7.73	0.57	3.19e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs6061231	0.544	rs2427314	chr20:60973666	C/T	cg22633769	chr20:60982531	CABLES2	0.59	4.85	0.4	3.63e-6	Colorectal cancer;
TGCT	cis	rs12291225	0.645	rs3763950	chr11:14278049	T/A	cg19336497	chr11:14380999	RRAS2	-0.39	-6.09	-0.48	1.31e-8	Sense of smell;
TGCT	cis	rs2204008	0.606	rs1581358	chr12:38391582	G/T	cg26384229	chr12:38710491	ALG10B	0.84	7.3	0.55	2.97e-11	Bladder cancer;
TGCT	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg10047753	chr17:41438598	NA	0.95	9.0	0.63	3.2e-15	Menopause (age at onset);
TGCT	cis	rs42648	0.738	rs13247172	chr7:89889204	A/C	cg25739043	chr7:89950458	NA	-0.53	-4.69	-0.39	7.14e-6	Homocysteine levels;
TGCT	cis	rs2361718	0.522	rs11867921	chr17:78121170	G/T	cg09238746	chr17:78121135	EIF4A3	-1.15	-11.72	-0.73	8.12e-22	Yeast infection;
TGCT	cis	rs10746514	0.833	rs1888601	chr1:232266922	C/T	cg09506761	chr1:232265262	NA	-0.49	-5.01	-0.41	1.79e-6	Response to statin therapy;
TGCT	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.94	7.92	0.58	1.17e-12	Platelet count;
TGCT	cis	rs147858478	1	rs147858478	chr5:131682785	CCTGAGTT/C	cg24060327	chr5:131705240	SLC22A5	-0.56	-6.26	-0.49	5.61e-9	High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs12472274	0.941	rs36066920	chr2:239074480	T/G	cg17459225	chr2:239074497	NA	0.31	4.57	0.38	1.15e-5	Phospholipid levels (plasma);
TGCT	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg08392591	chr16:89556376	ANKRD11	0.59	5.48	0.44	2.32e-7	Multiple myeloma (IgH translocation);
TGCT	cis	rs60843830	1.000	rs56167434	chr2:282137	G/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.7	6.41	0.5	2.81e-9	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs7582180	0.629	rs4851298	chr2:100949827	G/A	cg14675211	chr2:100938903	LONRF2	0.5	4.78	0.39	4.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7769051	1.000	rs9493454	chr6:133144629	G/T	cg22852734	chr6:133119734	C6orf192	-1.3	-7.33	-0.55	2.6e-11	Type 2 diabetes nephropathy;
TGCT	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	5.94	0.47	2.67e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9611519	0.929	rs12484477	chr22:41429084	G/A	cg03806693	chr22:41940476	POLR3H	-0.7	-6.22	-0.49	6.88e-9	Neuroticism;
TGCT	cis	rs9383153	0.793	rs2016498	chr6:16344914	C/T	cg23850913	chr6:15505452	JARID2	0.87	5.22	0.42	7.32e-7	Gambling;
TGCT	cis	rs7103648	0.864	rs10769264	chr11:47423340	C/T	cg20307385	chr11:47447363	PSMC3	1.0	12.09	0.74	1.06e-22	Diastolic blood pressure;Systolic blood pressure;
TGCT	cis	rs7236492	0.688	rs9709477	chr18:77202786	C/A	cg15644404	chr18:77186268	NFATC1	-0.35	-4.64	-0.38	8.67e-6	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg13699009	chr12:122356056	WDR66	0.29	5.7	0.46	8.3e-8	Mean corpuscular volume;
TGCT	cis	rs4699052	0.739	rs11936824	chr4:104238003	T/G	cg16532752	chr4:104119610	CENPE	-0.54	-5.48	-0.44	2.23e-7	Testicular germ cell tumor;
TGCT	cis	rs8072100	0.790	rs11079783	chr17:45686016	C/T	cg08085267	chr17:45401833	C17orf57	0.46	5.01	0.41	1.82e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs513349	0.964	rs210139	chr6:33543409	A/C	cg24505687	chr6:33548425	BAK1	0.51	6.46	0.5	2.2e-9	Platelet count;
TGCT	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg04772025	chr11:68637568	NA	0.62	6.54	0.51	1.42e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs6121246	0.529	rs56153385	chr20:30187609	C/T	cg13852791	chr20:30311386	BCL2L1	0.69	4.65	0.39	8.44e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg23302884	chr18:44338147	ST8SIA5	0.4	4.7	0.39	6.77e-6	Personality dimensions;
TGCT	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg25036284	chr2:26402008	FAM59B	-0.65	-5.19	-0.42	8.36e-7	Gut microbiome composition (summer);
TGCT	cis	rs11122272	0.735	rs2486737	chr1:231520523	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.13	-0.54	7.33e-11	Hemoglobin concentration;
TGCT	cis	rs11209002	0.567	rs2815385	chr1:67542083	A/G	cg02640540	chr1:67518911	SLC35D1	0.53	4.45	0.37	1.86e-5	Crohn's disease;
TGCT	cis	rs765787	0.530	rs11636395	chr15:45535684	G/C	cg24006582	chr15:45444508	DUOX1	-0.25	-5.59	-0.45	1.37e-7	Uric acid levels;
TGCT	cis	rs9467711	0.606	rs66823108	chr6:26377939	G/A	cg16898833	chr6:26189333	HIST1H4D	1.1	5.3	0.43	5.01e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs922182	0.613	rs8028927	chr15:64232281	A/G	cg02919090	chr15:64263738	DAPK2	-0.33	-6.14	-0.48	1.05e-8	Blood protein levels;
TGCT	cis	rs4654899	0.931	rs1152998	chr1:21124290	C/T	cg01072550	chr1:21505969	NA	-0.48	-7.65	-0.57	4.72e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs7267979	0.833	rs6138556	chr20:25243310	C/T	cg03522245	chr20:25566470	NINL	0.58	6.25	0.49	6.16e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1062177	1.000	rs2347596	chr5:151179199	T/C	cg12924095	chr5:151150029	G3BP1	0.35	5.08	0.42	1.34e-6	Preschool internalizing problems;
TGCT	cis	rs62244186	0.659	rs4431151	chr3:44510906	G/C	cg02073558	chr3:44770973	ZNF501	0.61	5.79	0.46	5.39e-8	Depressive symptoms;
TGCT	cis	rs9916302	0.851	rs6503518	chr17:37660469	A/G	cg07936489	chr17:37558343	FBXL20	-0.62	-4.91	-0.4	2.85e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs3617	0.572	rs2256332	chr3:52855865	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	0.5	4.85	0.4	3.62e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7598759	0.527	rs12987949	chr2:232367511	A/G	cg19187155	chr2:232395269	NMUR1	0.52	6.18	0.49	8.55e-9	Noise-induced hearing loss;
TGCT	cis	rs4824093	0.541	rs8142132	chr22:50211294	C/T	cg20569369	chr22:51173646	NA	0.34	5.34	0.43	4.22e-7	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs55962025	0.855	rs4498089	chr4:3080199	A/G	cg06533319	chr4:3265114	C4orf44	0.23	4.61	0.38	9.86e-6	Parental longevity (mother's age at death);
TGCT	cis	rs36051895	0.559	rs1590268	chr9:5209433	T/A	cg02405213	chr9:5042618	JAK2	-0.67	-8.47	-0.61	5.81e-14	Pediatric autoimmune diseases;
TGCT	trans	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg25482853	chr8:67687455	SGK3	1.16	10.5	0.69	7.91e-19	Lung disease severity in cystic fibrosis;
TGCT	cis	rs6570726	0.935	rs454370	chr6:145846729	T/G	cg23711669	chr6:146136114	FBXO30	0.68	6.67	0.51	7.58e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10256972	0.758	rs7789093	chr7:1002981	T/C	cg07930192	chr7:1003750	NA	0.3	4.72	0.39	6.33e-6	Longevity;Endometriosis;
TGCT	cis	rs7666738	0.830	rs7659006	chr4:98934529	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4824093	0.610	rs73441787	chr22:50269646	A/G	cg14114931	chr22:50943910	LMF2	0.37	4.58	0.38	1.11e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs7666738	0.791	rs1896155	chr4:99020948	C/A	cg17366294	chr4:99064904	C4orf37	0.68	7.04	0.53	1.17e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs36051895	0.659	rs12339666	chr9:5063296	A/C	cg02405213	chr9:5042618	JAK2	0.79	11.45	0.72	3.74e-21	Pediatric autoimmune diseases;
TGCT	cis	rs644799	0.862	rs1150361	chr11:95633805	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	7.37	0.55	2.05e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9911578	1.000	rs9915935	chr17:56843048	A/G	cg05425664	chr17:57184151	TRIM37	-0.63	-6.26	-0.49	5.86e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs4746818	1.000	rs7899844	chr10:70949694	A/G	cg04149295	chr10:70884716	VPS26A	0.78	5.32	0.43	4.7e-7	Left atrial antero-posterior diameter;
TGCT	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg00814883	chr7:100076585	TSC22D4	-0.9	-9.56	-0.65	1.5e-16	Platelet count;
TGCT	cis	rs72717009	0.825	rs9427399	chr1:161476533	T/C	cg23840854	chr1:161414152	NA	-0.98	-5.86	-0.47	3.95e-8	Rheumatoid arthritis;
TGCT	cis	rs4937076	1.000	rs4937076	chr11:125826702	G/A	cg17967973	chr11:126139042	FOXRED1;SRPR	-0.4	-4.66	-0.39	8.05e-6	Primary tooth development (time to first tooth eruption);
TGCT	cis	rs4076764	0.846	rs7525724	chr1:163426372	G/A	cg24596788	chr1:163392923	NA	-0.17	-4.88	-0.4	3.17e-6	Motion sickness;
TGCT	cis	rs28735056	1.000	rs28865701	chr18:77620911	A/G	cg20368463	chr18:77673604	PQLC1	-0.45	-5.66	-0.45	9.83e-8	Schizophrenia;
TGCT	cis	rs7980687	0.678	rs7132277	chr12:123593382	C/T	cg00376283	chr12:123451042	ABCB9	-0.69	-4.73	-0.39	5.98e-6	Height;Educational attainment;Head circumference (infant);
TGCT	cis	rs9911578	0.867	rs4793941	chr17:56472366	G/A	cg12560992	chr17:57184187	TRIM37	-0.76	-8.94	-0.63	4.6e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs6163	0.588	rs3818708	chr10:104503584	C/T	cg05855489	chr10:104503620	C10orf26	0.98	12.41	0.74	1.75e-23	Waist circumference;Hip circumference;
TGCT	cis	rs4803468	1.000	rs10417311	chr19:41902038	G/A	cg09537434	chr19:41945824	ATP5SL	-0.89	-10.04	-0.67	9.93e-18	Height;
TGCT	cis	rs796364	1.000	rs281774	chr2:200814572	C/T	cg17644776	chr2:200775616	C2orf69	0.31	4.85	0.4	3.58e-6	Schizophrenia;
TGCT	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg19901468	chr14:105411992	AHNAK2	-0.27	-6.17	-0.48	9.09e-9	Rheumatoid arthritis;
TGCT	cis	rs9611519	0.780	rs9611546	chr22:41698542	C/G	cg03806693	chr22:41940476	POLR3H	-0.84	-8.39	-0.6	9.17e-14	Neuroticism;
TGCT	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg11644478	chr21:40555479	PSMG1	0.61	5.71	0.46	7.78e-8	Cognitive function;
TGCT	cis	rs7226408	0.857	rs57901563	chr18:34453207	A/G	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs453301	0.686	rs4840389	chr8:8884503	G/C	cg15556689	chr8:8085844	FLJ10661	-0.66	-5.4	-0.44	3.27e-7	Joint mobility (Beighton score);
TGCT	cis	rs916888	0.821	rs199507	chr17:44858855	A/G	cg01570182	chr17:44337453	NA	-1.01	-9.1	-0.63	1.83e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs4253772	0.530	rs28528366	chr22:46680696	G/A	cg24881330	chr22:46731750	TRMU	1.0	4.88	0.4	3.25e-6	LDL cholesterol;Cholesterol, total;
TGCT	trans	rs8073060	0.545	rs3859282	chr17:34006111	T/C	cg19694781	chr19:47549865	TMEM160	-0.6	-13.37	-0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.43	6.28	0.49	5.32e-9	Schizophrenia;
TGCT	cis	rs7098414	0.531	rs3844126	chr10:82019997	T/G	cg01528321	chr10:82214614	TSPAN14	0.63	5.66	0.45	9.73e-8	Post bronchodilator FEV1;
TGCT	cis	rs62244186	0.545	rs725866	chr3:44765533	A/G	cg11003573	chr3:44754125	ZNF502	-0.45	-5.08	-0.42	1.32e-6	Depressive symptoms;
TGCT	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg06873352	chr17:61820015	STRADA	0.55	6.13	0.48	1.09e-8	Prudent dietary pattern;
TGCT	cis	rs9326248	1.000	rs7107152	chr11:117056080	C/T	cg16524733	chr11:117070046	TAGLN	-0.33	-5.2	-0.42	7.82e-7	Blood protein levels;
TGCT	cis	rs3008870	1.000	rs12132068	chr1:67451924	G/T	cg03991309	chr1:68237761	GNG12	-0.27	-4.55	-0.38	1.25e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs6582630	0.593	rs11182590	chr12:38574274	A/T	cg26384229	chr12:38710491	ALG10B	0.61	5.74	0.46	6.87e-8	Drug-induced liver injury (flucloxacillin);
TGCT	trans	rs2727020	0.523	rs4115783	chr11:49556026	G/A	cg11707556	chr5:10655725	ANKRD33B	0.42	8.63	0.61	2.5e-14	Coronary artery disease;
TGCT	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg27121462	chr16:89883253	FANCA	0.82	8.95	0.63	4.3e-15	Vitiligo;
TGCT	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs2276314	0.857	rs4799409	chr18:33592602	C/T	cg19628046	chr18:33552617	C18orf21	0.51	4.46	0.37	1.79e-5	Endometriosis;Drug-induced torsades de pointes;
TGCT	cis	rs601339	0.536	rs575171	chr12:123194635	C/T	cg11919336	chr12:123188078	GPR109A	0.65	7.82	0.57	1.96e-12	Adiponectin levels;
TGCT	trans	rs877282	0.898	rs11253349	chr10:765897	C/G	cg22713356	chr15:30763199	NA	1.2	9.39	0.64	3.76e-16	Uric acid levels;
TGCT	cis	rs56104184	0.775	rs17272700	chr19:49391770	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.73	-9.15	-0.63	1.47e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs9467773	0.901	rs1407045	chr6:26476155	A/G	cg26531700	chr6:26746687	NA	0.57	5.51	0.44	1.98e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7824557	0.628	rs11777746	chr8:11204755	T/C	cg21775007	chr8:11205619	TDH	0.72	7.0	0.53	1.45e-10	Retinal vascular caliber;
TGCT	cis	rs12983728	0.536	rs34380569	chr19:58648528	A/G	cg07378217	chr19:58662286	ZNF329	-0.63	-4.69	-0.39	7.1e-6	Cholesterol, total;
TGCT	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.73	-7.31	-0.55	2.95e-11	Prudent dietary pattern;
TGCT	cis	rs11190604	1.000	rs2495742	chr10:102331364	C/T	cg23241863	chr10:102295624	HIF1AN	0.66	4.87	0.4	3.37e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7590720	0.788	rs4674050	chr2:216907322	G/T	cg12620499	chr2:216877984	MREG	0.91	10.36	0.68	1.66e-18	Alcohol dependence;
TGCT	cis	rs2235642	0.893	rs2076442	chr16:1591112	G/T	cg07639376	chr16:1584516	IFT140;TMEM204	-0.33	-5.79	-0.46	5.54e-8	Coronary artery disease;
TGCT	cis	rs2354432	0.607	rs10453880	chr1:146693689	T/C	cg25205988	chr1:146714368	CHD1L	1.33	6.35	0.5	3.68e-9	Mitochondrial DNA levels;
TGCT	cis	rs7809950	0.768	rs62482493	chr7:106951579	T/C	cg23024343	chr7:107201750	COG5	-0.41	-5.58	-0.45	1.43e-7	Coronary artery disease;
TGCT	cis	rs6546537	0.714	rs17036759	chr2:69767029	C/T	cg10773587	chr2:69614142	GFPT1	-0.88	-9.03	-0.63	2.79e-15	Serum thyroid-stimulating hormone levels;
TGCT	cis	rs7192750	0.562	rs9921412	chr16:71988106	C/T	cg06353428	chr16:71660113	MARVELD3	0.74	6.6	0.51	1.09e-9	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs7772486	0.754	rs702318	chr6:146005873	G/T	cg13319975	chr6:146136371	FBXO30	0.52	4.68	0.39	7.31e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.54	4.95	0.41	2.35e-6	Prudent dietary pattern;
TGCT	cis	rs208520	0.874	rs208469	chr6:66915891	T/C	cg07460842	chr6:66804631	NA	-0.9	-9.16	-0.64	1.34e-15	Exhaled nitric oxide output;
TGCT	cis	rs477895	1.000	rs41294396	chr11:64078581	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	5.19	0.42	8.41e-7	Mean platelet volume;
TGCT	cis	rs66573146	1.000	rs73202122	chr4:7005594	G/A	cg01220768	chr4:7056774	TADA2B	0.41	4.88	0.4	3.16e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg27170947	chr2:26402098	FAM59B	-0.39	-4.46	-0.37	1.8e-5	Gut microbiome composition (summer);
TGCT	cis	rs7267979	0.966	rs2261785	chr20:25262403	C/T	cg16686733	chr20:25566563	NINL	0.61	6.1	0.48	1.23e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs72781680	0.821	rs11894756	chr2:24170214	A/G	cg08917208	chr2:24149416	ATAD2B	-0.74	-4.66	-0.39	7.9e-6	Lymphocyte counts;
TGCT	cis	rs909002	0.925	rs10798882	chr1:32108547	C/G	cg11573219	chr1:32083031	HCRTR1	0.48	6.2	0.49	7.79e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7927592	0.513	rs607887	chr11:68196961	C/T	cg16797656	chr11:68205561	LRP5	0.28	5.13	0.42	1.1e-6	Total body bone mineral density;
TGCT	cis	rs910316	1.000	rs8017642	chr14:75590822	G/A	cg08847533	chr14:75593920	NEK9	0.95	10.55	0.69	5.83e-19	Height;
TGCT	cis	rs6912958	0.559	rs446851	chr6:88043640	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.73	7.68	0.57	4.16e-12	Monocyte percentage of white cells;
TGCT	cis	rs7552404	0.731	rs10873808	chr1:76406767	T/C	cg22875332	chr1:76189707	ACADM	0.68	6.54	0.51	1.43e-9	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2075371	0.829	rs11770764	chr7:134003308	T/C	cg11752832	chr7:134001865	SLC35B4	0.74	6.69	0.51	6.91e-10	Mean platelet volume;
TGCT	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg20607798	chr8:58055168	NA	0.45	4.62	0.38	9.54e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2034088	0.507	rs11650424	chr17:435896	C/T	cg01214346	chr17:406501	NA	-0.39	-5.0	-0.41	1.88e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs67311347	0.568	rs57287242	chr3:40335538	T/C	cg13683864	chr3:40499215	RPL14	-0.78	-7.5	-0.56	1.06e-11	Renal cell carcinoma;
TGCT	cis	rs9300255	0.510	rs1790086	chr12:123672518	A/G	cg00376283	chr12:123451042	ABCB9	0.73	5.69	0.46	8.5e-8	Neutrophil percentage of white cells;
TGCT	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	5.71	0.46	8.05e-8	Alzheimer's disease;
TGCT	cis	rs3087591	1.000	rs6505235	chr17:29688603	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.48	-7.22	-0.54	4.48e-11	Hip circumference;
TGCT	cis	rs9911578	0.967	rs2429369	chr17:56501420	A/G	cg12560992	chr17:57184187	TRIM37	0.76	9.26	0.64	7.61e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs4268898	0.760	rs11125535	chr2:24528114	T/C	cg02683114	chr2:24398427	C2orf84	0.2	4.95	0.41	2.42e-6	Asthma;
TGCT	cis	rs1008375	1.000	rs1008374	chr4:17683219	G/A	cg16339924	chr4:17578868	LAP3	0.52	4.56	0.38	1.19e-5	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6570726	0.846	rs6914304	chr6:145921017	T/C	cg13319975	chr6:146136371	FBXO30	-0.51	-4.5	-0.37	1.53e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs17384381	1.000	rs12138852	chr1:85878208	C/T	cg16011679	chr1:85725395	C1orf52	0.8	6.44	0.5	2.39e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg11644478	chr21:40555479	PSMG1	-0.54	-5.12	-0.42	1.15e-6	Menarche (age at onset);
TGCT	cis	rs4824093	0.535	rs9627797	chr22:50317569	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.17	-4.53	-0.38	1.34e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg13395646	chr4:1353034	KIAA1530	-0.58	-7.81	-0.57	2.08e-12	Obesity-related traits;
TGCT	cis	rs17376456	0.825	rs28534784	chr5:93063332	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.68	5.05	0.41	1.51e-6	Diabetic retinopathy;
TGCT	cis	rs7264396	0.690	rs2425165	chr20:34438059	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.04	-0.41	1.58e-6	Total cholesterol levels;
TGCT	cis	rs10088262	0.629	rs7828192	chr8:124804669	C/T	cg20713898	chr8:124780851	FAM91A1	-0.84	-7.19	-0.54	5.3e-11	Pancreatic cancer;
TGCT	cis	rs68170813	0.617	rs76923959	chr7:107182915	T/C	cg02696742	chr7:106810147	HBP1	-0.58	-4.47	-0.37	1.74e-5	Coronary artery disease;
TGCT	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg10802521	chr3:52805072	NEK4	-0.72	-9.1	-0.63	1.91e-15	Bipolar disorder;
TGCT	cis	rs2380220	0.541	rs72928277	chr6:96079745	G/T	cg04719120	chr6:96025338	MANEA	-0.74	-5.48	-0.44	2.25e-7	Behavioural disinhibition (generation interaction);
TGCT	cis	rs2242116	0.727	rs10865943	chr3:46969970	T/C	cg27129171	chr3:47204927	SETD2	0.66	6.63	0.51	9.04e-10	Birth weight;
TGCT	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg02353165	chr6:42928485	GNMT	0.97	9.95	0.67	1.66e-17	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs9916302	0.904	rs9905432	chr17:37555918	C/A	cg07936489	chr17:37558343	FBXL20	0.65	4.98	0.41	2.11e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs792975	0.666	rs710109	chr5:172272571	G/A	cg15947959	chr5:172261155	ERGIC1	-0.62	-4.44	-0.37	1.95e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);
TGCT	cis	rs28595532	0.920	rs55794497	chr4:119764664	A/G	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs7296418	0.738	rs1568428	chr12:123738876	A/G	cg00376283	chr12:123451042	ABCB9	-0.71	-6.89	-0.53	2.51e-10	Platelet count;
TGCT	cis	rs3020736	0.500	rs8138678	chr22:42516229	A/G	cg15557168	chr22:42548783	NA	0.22	5.58	0.45	1.47e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs231513	0.636	rs34239920	chr17:42013076	G/T	cg26893861	chr17:41843967	DUSP3	0.76	4.64	0.38	8.65e-6	Cognitive function;
TGCT	cis	rs7781977	0.960	rs4917017	chr7:50335232	A/G	cg14216940	chr7:50343131	IKZF1	-0.38	-4.48	-0.37	1.66e-5	IgG glycosylation;
TGCT	cis	rs59107033	0.509	rs60496964	chr3:123102795	T/C	cg04890266	chr3:123102914	ADCY5	-0.49	-7.91	-0.58	1.23e-12	Lymphocyte counts;
TGCT	cis	rs60843830	1.000	rs3791223	chr2:222336	T/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.77	7.44	0.56	1.47e-11	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg19729930	chr2:74357872	NA	0.58	7.04	0.53	1.14e-10	Gestational age at birth (maternal effect);
TGCT	trans	rs877282	0.898	rs10904547	chr10:766283	C/T	cg22713356	chr15:30763199	NA	1.2	9.39	0.64	3.76e-16	Uric acid levels;
TGCT	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg03934478	chr11:495069	RNH1	0.35	5.88	0.47	3.51e-8	Body mass index;
TGCT	cis	rs36051895	0.632	rs10974969	chr9:5125336	G/A	cg02405213	chr9:5042618	JAK2	-0.71	-9.55	-0.65	1.57e-16	Pediatric autoimmune diseases;
TGCT	cis	rs548987	0.529	rs9467618	chr6:25824809	C/T	cg03264133	chr6:25882463	NA	-0.54	-4.44	-0.37	1.99e-5	Homocysteine levels;
TGCT	cis	rs7208859	0.623	rs12103440	chr17:29086657	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg04025307	chr7:1156635	C7orf50	0.23	5.23	0.43	6.91e-7	Longevity;Endometriosis;
TGCT	cis	rs12479064	0.671	rs4851207	chr2:100105775	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.71	-6.02	-0.48	1.85e-8	Chronic sinus infection;
TGCT	cis	rs4700695	0.614	rs2561241	chr5:65206565	C/T	cg21114390	chr5:65439923	SFRS12	0.77	5.42	0.44	3e-7	Facial morphology (factor 19);
TGCT	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg01802117	chr1:53393560	SCP2	0.43	5.12	0.42	1.14e-6	Monocyte count;
TGCT	cis	rs11098499	1.000	rs28374891	chr4:120183550	G/A	cg24670566	chr4:120433619	PDE5A	0.23	4.58	0.38	1.1e-5	Corneal astigmatism;
TGCT	cis	rs9300255	0.512	rs2851436	chr12:123667354	G/T	cg00376283	chr12:123451042	ABCB9	0.73	5.69	0.46	8.5e-8	Neutrophil percentage of white cells;
TGCT	cis	rs9868809	0.772	rs9812977	chr3:48720303	G/A	cg15315015	chr3:49131774	QRICH1	0.95	4.54	0.38	1.31e-5	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg11764359	chr7:65958608	NA	-0.61	-5.36	-0.43	3.96e-7	Aortic root size;
TGCT	cis	rs1981331	0.867	rs76188425	chr21:48002207	C/T	cg23283320	chr21:48055893	PRMT2	1.29	6.09	0.48	1.31e-8	Cerebrospinal fluid t-tau:AB1-42 ratio;
TGCT	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg06873352	chr17:61820015	STRADA	0.56	6.22	0.49	7.1e-9	Prudent dietary pattern;
TGCT	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg03188948	chr7:1209495	NA	0.71	6.04	0.48	1.68e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg10295955	chr4:187884368	NA	0.93	13.29	0.77	1.35e-25	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs344364	0.511	rs2906912	chr16:1953151	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.46	-5.31	-0.43	4.97e-7	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs7633770	0.769	rs2385858	chr3:46660436	T/C	cg11219411	chr3:46661640	NA	0.36	5.27	0.43	5.86e-7	Coronary artery disease;
TGCT	cis	rs295140	1.000	rs12618057	chr2:201171355	T/C	cg04283868	chr2:201171347	SPATS2L	0.63	6.39	0.5	3.03e-9	QT interval;
TGCT	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg22963979	chr7:1858916	MAD1L1	-0.39	-6.24	-0.49	6.33e-9	Bipolar disorder and schizophrenia;
TGCT	cis	rs9393692	0.905	rs7769028	chr6:26267568	C/T	cg05868516	chr6:26286170	HIST1H4H	0.63	5.94	0.47	2.72e-8	Educational attainment;
TGCT	cis	rs7086627	0.515	rs11202959	chr10:82209672	A/G	cg01528321	chr10:82214614	TSPAN14	0.65	6.21	0.49	7.21e-9	Post bronchodilator FEV1;
TGCT	cis	rs6840360	0.571	rs4696110	chr4:152671325	G/A	cg22705602	chr4:152727874	NA	-0.34	-5.83	-0.46	4.43e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg20203395	chr5:56204925	C5orf35	0.53	4.92	0.4	2.67e-6	Initial pursuit acceleration;
TGCT	cis	rs3749237	0.964	rs62260719	chr3:49852419	G/A	cg10152585	chr3:50297680	NA	0.53	5.02	0.41	1.75e-6	Resting heart rate;
TGCT	cis	rs17122693	0.786	rs72679588	chr14:51092687	A/C	cg04730355	chr14:51134070	SAV1	1.24	8.74	0.62	1.38e-14	Cognitive performance;
TGCT	cis	rs4788570	0.545	rs8044144	chr16:71783121	T/C	cg06353428	chr16:71660113	MARVELD3	1.56	12.67	0.75	4.05e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg21724239	chr8:58056113	NA	-0.39	-4.59	-0.38	1.07e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7605378	1.000	rs769958	chr2:200695901	G/A	cg23649088	chr2:200775458	C2orf69	0.35	5.73	0.46	7.15e-8	Osteoporosis;
TGCT	trans	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg17830980	chr10:43048298	ZNF37B	-0.84	-10.94	-0.7	6.62e-20	Extrinsic epigenetic age acceleration;
TGCT	cis	rs4730250	0.707	rs257378	chr7:106801395	C/G	cg02696742	chr7:106810147	HBP1	-0.71	-5.89	-0.47	3.42e-8	Osteoarthritis;
TGCT	cis	rs7914558	1.000	rs4917994	chr10:104811699	C/T	cg04362960	chr10:104952993	NT5C2	0.61	5.46	0.44	2.44e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs2295359	0.892	rs12401432	chr1:67656931	C/G	cg08029281	chr1:67600428	NA	0.4	4.72	0.39	6.15e-6	Psoriasis;
TGCT	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg10047753	chr17:41438598	NA	0.95	8.81	0.62	9.26e-15	Menopause (age at onset);
TGCT	cis	rs9467773	0.620	rs2101582	chr6:26622734	C/T	cg15659132	chr6:26577336	NA	0.84	10.89	0.7	8.44e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs709400	0.663	rs17679475	chr14:103916958	A/G	cg12935359	chr14:103987150	CKB	-0.35	-5.28	-0.43	5.51e-7	Body mass index;
TGCT	cis	rs7666738	0.830	rs10009206	chr4:99056900	A/C	cg18180107	chr4:99064573	C4orf37	-0.58	-5.37	-0.43	3.77e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs727563	0.635	rs713988	chr22:42159072	A/G	cg06634786	chr22:41940651	POLR3H	0.86	8.01	0.58	7.16e-13	Crohn's disease;Inflammatory bowel disease;
TGCT	trans	rs208520	0.560	rs2351880	chr6:66863707	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-10.43	-0.68	1.13e-18	Exhaled nitric oxide output;
TGCT	cis	rs9549260	0.755	rs17061450	chr13:41183716	G/A	cg21288729	chr13:41239152	FOXO1	1.02	10.32	0.68	2.17e-18	Red blood cell count;
TGCT	cis	rs986417	0.901	rs7150630	chr14:61019458	T/A	cg27398547	chr14:60952738	C14orf39	1.49	10.43	0.68	1.12e-18	Gut microbiota (bacterial taxa);
TGCT	cis	rs7666738	0.791	rs2081621	chr4:98926753	C/A	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1538970	0.962	rs7544178	chr1:45819069	C/T	cg05343316	chr1:45956843	TESK2	0.64	5.1	0.42	1.26e-6	Platelet count;
TGCT	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg24503407	chr1:205819492	PM20D1	-0.51	-7.05	-0.53	1.11e-10	Monocyte percentage of white cells;
TGCT	cis	rs2180341	0.597	rs11154397	chr6:127646649	G/C	cg24812749	chr6:127587940	RNF146	0.63	5.33	0.43	4.51e-7	Breast cancer;
TGCT	cis	rs3749237	0.576	rs4241406	chr3:49600426	C/T	cg03060546	chr3:49711283	APEH	0.78	8.87	0.62	6.79e-15	Resting heart rate;
TGCT	cis	rs12142240	0.698	rs72677599	chr1:46834251	G/A	cg00530320	chr1:46809349	NSUN4	0.29	6.03	0.48	1.71e-8	Menopause (age at onset);
TGCT	cis	rs4478858	0.735	rs4949382	chr1:31776731	A/G	cg07478791	chr1:31886160	SERINC2	-0.48	-4.61	-0.38	1e-5	Alcohol dependence;
TGCT	cis	rs7523273	0.606	rs2488255	chr1:207941741	C/T	cg22525895	chr1:207977042	MIR29B2	0.53	8.71	0.62	1.62e-14	Schizophrenia;
TGCT	cis	rs1215050	0.791	rs592053	chr4:98732220	C/T	cg17366294	chr4:99064904	C4orf37	0.52	5.61	0.45	1.27e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg03709012	chr19:19516395	GATAD2A	-0.66	-5.7	-0.46	8.46e-8	Tonsillectomy;
TGCT	cis	rs3796352	1.000	rs2336541	chr3:52974630	G/C	cg15956490	chr3:53032818	SFMBT1	0.59	6.04	0.48	1.65e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	trans	rs17834679	0.957	rs59546961	chr19:52270210	G/C	cg13034837	chr18:32924525	ZNF24	0.86	6.69	0.51	6.93e-10	Alopecia areata;
TGCT	cis	rs6671200	0.920	rs7555236	chr1:95631314	G/A	cg26537280	chr1:95699037	RWDD3	0.68	5.49	0.44	2.15e-7	Stearic acid (18:0) levels;
TGCT	cis	rs9814567	1.000	rs7429866	chr3:134236306	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.96	9.11	0.63	1.79e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs57221529	0.766	rs72706608	chr5:559203	C/T	cg09021430	chr5:549028	NA	-0.4	-5.46	-0.44	2.44e-7	Lung disease severity in cystic fibrosis;
TGCT	cis	rs7267979	1.000	rs422424	chr20:25445446	G/C	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11690935	0.959	rs973889	chr2:172579954	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.18	-12.58	-0.75	6.59e-24	Schizophrenia;
TGCT	cis	rs854765	0.929	rs2955360	chr17:17974887	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.66	-6.3	-0.49	4.75e-9	Total body bone mineral density;
TGCT	trans	rs7180079	0.502	rs6494466	chr15:64508763	A/G	cg06219821	chr1:12290367	VPS13D	-0.68	-6.75	-0.52	4.94e-10	Monocyte count;
TGCT	cis	rs7666738	0.830	rs2865989	chr4:99067532	G/A	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.44e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11673344	0.504	rs4806409	chr19:37588825	A/G	cg08039142	chr19:36980659	ZNF566	0.49	4.48	0.37	1.68e-5	Obesity-related traits;
TGCT	cis	rs13191362	0.872	rs35672319	chr6:163245464	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.67	4.66	0.39	8.09e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg17971929	chr21:40555470	PSMG1	-0.72	-6.06	-0.48	1.5e-8	Cognitive function;
TGCT	cis	rs636291	0.517	rs670666	chr1:10549380	C/T	cg17425144	chr1:10567563	PEX14	-0.53	-7.41	-0.55	1.73e-11	Prostate cancer;
TGCT	trans	rs3780486	1.000	rs12342831	chr9:33124872	A/G	cg04842962	chr6:43655489	MRPS18A	1.13	11.53	0.72	2.42e-21	IgG glycosylation;
TGCT	cis	rs10114408	0.959	rs10992953	chr9:96646988	C/T	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs2688608	0.592	rs12253482	chr10:75496130	G/A	cg15838173	chr10:75533400	FUT11	-0.31	-5.08	-0.42	1.33e-6	Inflammatory bowel disease;
TGCT	cis	rs9467773	0.549	rs9467805	chr6:26583366	C/T	cg11502198	chr6:26597334	ABT1	0.54	4.94	0.41	2.49e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9914544	0.602	rs4924929	chr17:18714241	G/A	cg26306683	chr17:18585705	ZNF286B	0.52	4.83	0.4	4.01e-6	Educational attainment (years of education);
TGCT	cis	rs933688	1.000	rs12188467	chr5:90765632	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.97	9.16	0.64	1.38e-15	Smoking behavior;
TGCT	cis	rs7447593	0.666	rs10866705	chr5:176801131	G/T	cg17509989	chr5:176798049	RGS14	-0.69	-8.58	-0.61	3.29e-14	Urinary electrolytes (magnesium/calcium ratio);
TGCT	cis	rs17401966	0.838	rs35257796	chr1:10267390	T/A	cg19773385	chr1:10388646	KIF1B	-0.21	-4.57	-0.38	1.18e-5	Hepatocellular carcinoma;
TGCT	cis	rs1997103	1.000	rs10252413	chr7:55396740	C/G	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs2072499	0.966	rs6427304	chr1:156156789	A/G	cg24450063	chr1:156163899	SLC25A44	1.15	15.99	0.82	6.37e-32	Testicular germ cell tumor;
TGCT	cis	rs9993613	0.875	rs12642941	chr4:73513158	A/G	cg15102770	chr4:73434591	ADAMTS3	0.5	4.62	0.38	9.58e-6	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.94	7.92	0.58	1.17e-12	Platelet count;
TGCT	cis	rs12497850	0.897	rs9681717	chr3:48872998	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.41	-5.47	-0.44	2.41e-7	Parkinson's disease;
TGCT	cis	rs4653767	0.573	rs708772	chr1:226912891	A/G	cg11238820	chr1:226410871	MIXL1	0.32	4.55	0.38	1.24e-5	Parkinson's disease;
TGCT	cis	rs1371867	0.810	rs2860518	chr8:101238120	G/T	cg06002616	chr8:101225028	SPAG1	0.51	5.86	0.47	3.95e-8	Atrioventricular conduction;
TGCT	cis	rs9611565	0.765	rs132914	chr22:41805749	T/C	cg03806693	chr22:41940476	POLR3H	1.01	11.44	0.72	3.94e-21	Vitiligo;
TGCT	cis	rs35160687	0.901	rs12472390	chr2:86475083	T/C	cg04877910	chr2:85804641	VAMP8	0.34	4.48	0.37	1.67e-5	Night sleep phenotypes;
TGCT	cis	rs7772486	0.790	rs2254288	chr6:146204470	G/A	cg05347473	chr6:146136440	FBXO30	0.5	4.9	0.4	2.92e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs4555082	0.874	rs56263609	chr14:105756944	C/T	cg01266790	chr14:105781312	PACS2	0.59	4.86	0.4	3.45e-6	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs1670533	0.932	rs13140571	chr4:1054358	T/C	cg27284194	chr4:1044797	NA	0.69	5.71	0.46	7.76e-8	Recombination rate (females);
TGCT	cis	rs362272	0.524	rs881816	chr4:3365366	A/G	cg06533319	chr4:3265114	C4orf44	-0.28	-5.69	-0.46	8.58e-8	Serum sulfate level;
TGCT	cis	rs16867321	1.000	rs1358520	chr2:181440081	C/T	cg23363182	chr2:181467187	NA	-0.38	-5.39	-0.44	3.41e-7	Obesity;
TGCT	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg16414030	chr3:133502952	NA	-0.5	-7.01	-0.53	1.39e-10	Iron status biomarkers;
TGCT	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg22920501	chr2:26401640	FAM59B	-0.74	-6.4	-0.5	2.86e-9	Gut microbiome composition (summer);
TGCT	cis	rs4319547	0.741	rs4758644	chr12:122943915	A/C	cg05707623	chr12:122985044	ZCCHC8	-0.58	-4.64	-0.38	8.72e-6	Body mass index;
TGCT	cis	rs7267979	1.000	rs2184000	chr20:25395878	G/A	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg25036284	chr2:26402008	FAM59B	-0.57	-4.99	-0.41	2e-6	Gut microbiome composition (summer);
TGCT	cis	rs10197940	0.571	rs13393021	chr2:152413258	A/C	cg19508488	chr2:152266495	RIF1	0.7	6.39	0.5	2.98e-9	Lung cancer;
TGCT	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg09436375	chr6:42928200	GNMT	-0.4	-5.2	-0.42	8.08e-7	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs6088590	1.000	rs2180276	chr20:33360785	T/A	cg24642439	chr20:33292090	TP53INP2	0.69	6.17	0.48	8.94e-9	Coronary artery disease;
TGCT	cis	rs12615966	1.000	rs6543268	chr2:105370105	G/C	cg16465502	chr2:105461796	NA	0.77	4.56	0.38	1.19e-5	Pancreatic cancer;
TGCT	cis	rs12210905	1.000	rs858975	chr6:27155623	G/A	cg22243996	chr6:26757644	NA	-0.62	-4.65	-0.39	8.47e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg25036284	chr2:26402008	FAM59B	-0.54	-4.7	-0.39	6.93e-6	Gut microbiome composition (summer);
TGCT	cis	rs7246657	0.722	rs10403173	chr19:38078680	G/A	cg03611452	chr19:38183253	ZNF781	0.58	4.64	0.38	8.62e-6	Coronary artery calcification;
TGCT	cis	rs2797160	0.967	rs2797162	chr6:126011381	G/T	cg05901451	chr6:126070800	HEY2	0.72	6.11	0.48	1.18e-8	Endometrial cancer;
TGCT	cis	rs6138458	1.000	rs6114988	chr20:24977586	C/T	cg26195577	chr20:24973756	C20orf3	1.22	12.1	0.74	9.98e-23	Blood protein levels;
TGCT	cis	rs3820928	0.874	rs10166456	chr2:227900113	G/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-4.96	-0.41	2.29e-6	Pulmonary function;
TGCT	cis	rs644799	1.000	rs560854	chr11:95584905	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.85	9.0	0.63	3.27e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs56309584	0.673	rs12451139	chr17:8119626	G/T	cg08322244	chr17:8066669	VAMP2	-0.56	-5.2	-0.42	7.95e-7	Initial pursuit acceleration;
TGCT	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg18230493	chr5:56204884	C5orf35	-0.67	-5.71	-0.46	8e-8	Initial pursuit acceleration;
TGCT	cis	rs9814567	1.000	rs9813774	chr3:134227100	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.95	-9.62	-0.65	1.04e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs6671200	0.607	rs7528790	chr1:95709074	A/G	cg06440946	chr1:95699313	RWDD3	-0.62	-5.3	-0.43	5.09e-7	Stearic acid (18:0) levels;
TGCT	cis	rs899997	1.000	rs11072800	chr15:79045857	C/T	cg00061860	chr15:78953028	NA	0.27	5.04	0.41	1.6e-6	Coronary artery disease or large artery stroke;
TGCT	cis	rs6910741	1.000	rs6910741	chr6:25895575	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.91	6.53	0.51	1.5e-9	Blood pressure;
TGCT	cis	rs10057188	1.000	rs13436853	chr5:77870977	A/C	cg06873401	chr5:77792105	LHFPL2	-0.22	-4.44	-0.37	1.94e-5	Pulse pressure;
TGCT	cis	rs155076	1.000	rs261404	chr13:21858162	T/G	cg07022442	chr13:21864356	NA	0.31	4.81	0.4	4.31e-6	White matter hyperintensity burden;
TGCT	cis	rs7246657	0.679	rs12461113	chr19:38083188	G/A	cg18154014	chr19:37997991	ZNF793	0.69	4.63	0.38	9.25e-6	Coronary artery calcification;
TGCT	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg16497277	chr3:49208875	KLHDC8B	0.53	5.13	0.42	1.09e-6	Menarche (age at onset);
TGCT	cis	rs12048904	0.595	rs2295280	chr1:101342497	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.66	6.92	0.53	2.11e-10	Multiple sclerosis;
TGCT	cis	rs3935685	0.874	rs56370262	chr15:77996708	G/C	cg25212270	chr15:78015279	NA	0.26	5.58	0.45	1.47e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7909074	1.000	rs4948927	chr10:45397071	G/A	cg04218760	chr10:45406644	TMEM72	-0.27	-5.33	-0.43	4.38e-7	Mean corpuscular volume;
TGCT	cis	rs12142240	0.845	rs4313342	chr1:46801904	T/C	cg00530320	chr1:46809349	NSUN4	0.27	5.42	0.44	3.03e-7	Menopause (age at onset);
TGCT	cis	rs1971762	0.966	rs11170631	chr12:54041192	T/C	cg16917193	chr12:54089295	NA	0.55	4.57	0.38	1.18e-5	Height;
TGCT	cis	rs9902453	0.904	rs12103671	chr17:28408217	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.84	-7.98	-0.58	8.19e-13	Coffee consumption (cups per day);
TGCT	cis	rs7904368	0.754	rs7076779	chr10:16852667	C/T	cg14835575	chr10:16859367	RSU1	0.67	7.67	0.57	4.27e-12	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
TGCT	cis	rs3617	0.625	rs7652667	chr3:52866535	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	-0.48	-4.53	-0.38	1.35e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	trans	rs877282	0.853	rs10904544	chr10:756966	A/G	cg22713356	chr15:30763199	NA	1.13	8.3	0.6	1.52e-13	Uric acid levels;
TGCT	cis	rs7100689	0.646	rs1934692	chr10:82125734	C/A	cg01528321	chr10:82214614	TSPAN14	0.8	7.76	0.57	2.7e-12	Post bronchodilator FEV1;
TGCT	cis	rs394563	0.619	rs4895787	chr6:149646500	G/A	cg16235748	chr6:149772707	ZC3H12D	0.43	4.98	0.41	2.05e-6	Dupuytren's disease;
TGCT	cis	rs7178572	0.568	rs8037561	chr15:77680462	A/G	cg15453836	chr15:77711506	NA	-0.42	-4.78	-0.39	4.92e-6	Type 2 diabetes;
TGCT	cis	rs941873	0.868	rs12780295	chr10:81115438	G/A	cg09469691	chr10:81107165	PPIF	0.55	5.42	0.44	2.93e-7	Height;
TGCT	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg08859206	chr1:53392774	SCP2	-0.43	-6.41	-0.5	2.76e-9	Monocyte count;
TGCT	cis	rs9388451	0.505	rs6920965	chr6:126179111	G/A	cg05901451	chr6:126070800	HEY2	-0.73	-7.38	-0.55	2.05e-11	Brugada syndrome;
TGCT	cis	rs860295	0.580	rs867550	chr1:155880391	T/C	cg05700447	chr1:155978627	NA	0.23	4.72	0.39	6.14e-6	Body mass index;
TGCT	cis	rs7017914	0.934	rs17689585	chr8:71818801	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.03	-0.41	1.69e-6	Bone mineral density;
TGCT	cis	rs7639513	0.767	rs6784168	chr3:12702847	T/G	cg23032965	chr3:12705835	RAF1	0.77	8.53	0.61	4.28e-14	Itch intensity from mosquito bite;
TGCT	cis	rs7312933	0.558	rs3747560	chr12:42719890	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.59	-5.7	-0.46	8.16e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs6430585	0.527	rs76380759	chr2:136438517	G/A	cg07169764	chr2:136633963	MCM6	0.97	8.66	0.61	2.06e-14	Corneal structure;
TGCT	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg22166914	chr1:53195759	ZYG11B	-0.47	-8.65	-0.61	2.18e-14	Monocyte count;
TGCT	cis	rs12477438	0.834	rs10179043	chr2:99687490	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.68	-5.88	-0.47	3.51e-8	Chronic sinus infection;
TGCT	cis	rs6785206	0.527	rs35216064	chr3:128643155	C/T	cg25356066	chr3:128598488	ACAD9	-0.71	-4.45	-0.37	1.85e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs10986311	0.681	rs10986291	chr9:127016271	A/T	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.2	-4.47	-0.37	1.73e-5	Vitiligo;
TGCT	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg11764359	chr7:65958608	NA	-0.56	-5.09	-0.42	1.31e-6	Aortic root size;
TGCT	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg05896524	chr21:47604654	C21orf56	-0.46	-4.93	-0.4	2.6e-6	Testicular germ cell tumor;
TGCT	cis	rs28595532	0.841	rs116329146	chr4:119733438	G/A	cg14228332	chr4:119757509	SEC24D	1.32	6.38	0.5	3.2e-9	Cannabis dependence symptom count;
TGCT	cis	rs319204	0.959	rs319194	chr5:146268717	C/T	cg25021259	chr5:146258546	PPP2R2B	0.37	4.66	0.39	8.02e-6	Schizophrenia;
TGCT	cis	rs295140	1.000	rs11888462	chr2:201160499	G/T	cg04283868	chr2:201171347	SPATS2L	0.63	6.36	0.5	3.56e-9	QT interval;
TGCT	cis	rs2228479	0.850	rs11648689	chr16:89806732	G/A	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs7226408	0.857	rs61044601	chr18:34440179	C/T	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs806215	1.000	rs327511	chr7:127257261	G/T	cg25922125	chr7:127225783	GCC1	0.47	4.79	0.4	4.62e-6	Type 2 diabetes;
TGCT	cis	rs9611565	0.649	rs2064189	chr22:42127999	A/G	cg06481639	chr22:41940642	POLR3H	0.56	4.78	0.39	4.79e-6	Vitiligo;
TGCT	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg11494091	chr17:61959527	GH2	0.61	14.46	0.79	2.18e-28	Prudent dietary pattern;
TGCT	cis	rs2153535	0.580	rs2143356	chr6:8517675	C/T	cg07606381	chr6:8435919	SLC35B3	0.54	5.01	0.41	1.86e-6	Motion sickness;
TGCT	cis	rs9814567	0.806	rs2293294	chr3:134322814	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.78	7.26	0.55	3.68e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.5	-4.65	-0.39	8.45e-6	Prudent dietary pattern;
TGCT	trans	rs941408	1.000	rs1640271	chr19:2799979	C/T	cg19676328	chr12:49525230	TUBA1B	-0.78	-7.55	-0.56	8.09e-12	Total cholesterol levels;
TGCT	cis	rs8103278	1.000	rs9807819	chr19:46239598	C/T	cg11657440	chr19:46296263	DMWD	-0.53	-5.08	-0.42	1.34e-6	Coronary artery disease;
TGCT	cis	rs9467711	0.606	rs12174639	chr6:26373121	G/A	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6500550	0.636	rs2158443	chr16:3685782	C/G	cg07396092	chr16:3662230	BTBD12	0.5	4.44	0.37	2e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;White blood cell count;Neutrophil count;
TGCT	cis	rs6582630	0.519	rs7305570	chr12:38349285	G/A	cg26384229	chr12:38710491	ALG10B	0.83	7.23	0.54	4.33e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs7666738	0.800	rs7683737	chr4:99070880	A/T	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.44e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4986172	0.655	rs1044977	chr17:43227214	T/C	cg10701640	chr17:43249399	NA	0.55	6.58	0.51	1.18e-9	Height;
TGCT	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.18	0.49	8.32e-9	Electroencephalogram traits;
TGCT	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.51	5.37	0.43	3.71e-7	Menopause (age at onset);
TGCT	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg02725872	chr8:58115012	NA	-0.4	-4.83	-0.4	3.92e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6484504	0.532	rs11031330	chr11:31275073	G/A	cg26647111	chr11:31128758	NA	-0.35	-4.85	-0.4	3.58e-6	Red blood cell count;
TGCT	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.72	-6.47	-0.5	2.04e-9	Tonsillectomy;
TGCT	cis	rs10431058	1.000	rs10431058	chr11:107481518	A/G	cg18204760	chr11:107461044	ELMOD1;LOC643923	-0.66	-6.36	-0.5	3.47e-9	Common traits (Other);
TGCT	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg12140144	chr1:2984275	FLJ42875;PRDM16	-0.32	-4.46	-0.37	1.81e-5	Height;
TGCT	cis	rs7267979	0.780	rs6050679	chr20:25537827	A/T	cg03522245	chr20:25566470	NINL	0.58	6.02	0.48	1.85e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9291683	0.546	rs12504565	chr4:10045145	G/A	cg11266682	chr4:10021025	SLC2A9	0.6	7.52	0.56	9.49e-12	Bone mineral density;
TGCT	cis	rs35306767	0.903	rs12244253	chr10:889320	G/T	cg20503657	chr10:835505	NA	0.7	9.83	0.66	3.22e-17	Eosinophil percentage of granulocytes;
TGCT	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.32	-5.13	-0.42	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg00149659	chr3:10157352	C3orf10	0.97	5.98	0.47	2.19e-8	Alzheimer's disease;
TGCT	cis	rs2730245	1.000	rs2730245	chr7:158724789	G/C	cg24397884	chr7:158709396	WDR60	-0.4	-5.3	-0.43	5.05e-7	Height;
TGCT	cis	rs6087990	0.899	rs998382	chr20:31384136	C/T	cg13636640	chr20:31349939	DNMT3B	-1.06	-15.55	-0.81	6.6e-31	Ulcerative colitis;
TGCT	cis	rs7659604	0.605	rs1507994	chr4:122749541	C/T	cg20573242	chr4:122745356	CCNA2	0.59	5.41	0.44	3.11e-7	Type 2 diabetes;
TGCT	cis	rs7909074	0.898	rs10793565	chr10:45388231	G/C	cg05187965	chr10:45406764	TMEM72	-0.25	-5.31	-0.43	4.96e-7	Mean corpuscular volume;
TGCT	cis	rs7020830	0.931	rs9775431	chr9:37130433	G/A	cg14294708	chr9:37120828	ZCCHC7	1.22	18.16	0.85	9.64e-37	Schizophrenia;
TGCT	cis	rs910316	0.737	rs175045	chr14:75475275	A/C	cg11812906	chr14:75593930	NEK9	-0.59	-5.25	-0.43	6.35e-7	Height;
TGCT	cis	rs7267979	1.000	rs11100	chr20:25281184	G/C	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs877282	0.853	rs7092805	chr10:756246	G/A	cg22713356	chr15:30763199	NA	1.12	8.58	0.61	3.29e-14	Uric acid levels;
TGCT	cis	rs926938	0.618	rs1286555	chr1:115361896	C/T	cg12756093	chr1:115239321	AMPD1	-0.42	-6.06	-0.48	1.53e-8	Autism;
TGCT	cis	rs877282	0.891	rs12767062	chr10:797961	C/T	cg17470449	chr10:769945	NA	0.3	4.72	0.39	6.34e-6	Uric acid levels;
TGCT	cis	rs2806561	0.765	rs1612905	chr1:23510023	G/T	cg12483005	chr1:23474871	LUZP1	0.37	4.76	0.39	5.23e-6	Height;
TGCT	cis	rs10504229	0.906	rs2270609	chr8:58194684	G/A	cg22535103	chr8:58192502	C8orf71	-0.39	-4.5	-0.37	1.54e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9393777	0.513	rs9393737	chr6:26617306	A/G	cg15659132	chr6:26577336	NA	0.72	5.29	0.43	5.24e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2404602	0.692	rs4442773	chr15:77031633	T/C	cg22467129	chr15:76604101	ETFA	-0.44	-4.93	-0.4	2.62e-6	Blood metabolite levels;
TGCT	cis	rs8037137	0.915	rs76119208	chr15:91535329	G/T	cg22570213	chr15:91497863	RCCD1	0.5	4.65	0.39	8.27e-6	Platelet count;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
TGCT	cis	rs9814567	0.727	rs7641798	chr3:134345719	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-5.95	-0.47	2.58e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs6921919	0.583	rs16894060	chr6:28362471	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.56	-5.27	-0.43	5.78e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs72843506	1.000	rs7223910	chr17:19982768	G/A	cg21163262	chr17:19349762	NA	0.23	4.51	0.38	1.51e-5	Schizophrenia;
TGCT	cis	rs492146	0.765	rs367836	chr6:52843131	G/T	cg06706454	chr6:52930286	FBXO9	-0.51	-4.66	-0.39	8.12e-6	Epilepsy (remission after treatment);
TGCT	cis	rs11249608	0.600	rs13359570	chr5:178449249	T/G	cg21905437	chr5:178450457	ZNF879	0.45	4.48	0.37	1.67e-5	Pubertal anthropometrics;
TGCT	cis	rs7772486	0.692	rs2265915	chr6:146194332	A/T	cg05347473	chr6:146136440	FBXO30	0.54	5.06	0.41	1.47e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2075371	0.933	rs1833475	chr7:133958263	C/T	cg11752832	chr7:134001865	SLC35B4	0.68	5.89	0.47	3.32e-8	Mean platelet volume;
TGCT	cis	rs1865760	1.000	rs7739966	chr6:25906040	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.65	6.24	0.49	6.27e-9	Height;
TGCT	cis	rs2762353	0.546	rs2205936	chr6:25685492	G/C	cg17042849	chr6:26104293	HIST1H4C	-0.56	-4.97	-0.41	2.14e-6	Blood metabolite levels;
TGCT	cis	rs2439831	0.850	rs2957637	chr15:43951118	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.72	4.64	0.38	8.81e-6	Lung cancer in ever smokers;
TGCT	cis	rs7192750	0.586	rs2288031	chr16:71902142	C/A	cg06353428	chr16:71660113	MARVELD3	0.8	7.26	0.55	3.8e-11	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs2404602	1.000	rs12594541	chr15:76834368	G/A	cg26408565	chr15:76604113	ETFA	-0.41	-5.19	-0.42	8.3e-7	Blood metabolite levels;
TGCT	cis	rs9399135	0.967	rs4896119	chr6:135293391	C/T	cg24558204	chr6:135376177	HBS1L	0.48	4.75	0.39	5.5e-6	Red blood cell count;
TGCT	cis	rs55823223	0.564	rs1463485	chr17:73851791	C/G	cg08125733	chr17:73851984	WBP2	0.87	8.8	0.62	1e-14	Psoriasis;
TGCT	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-1.12	-14.29	-0.79	5.53e-28	Height;
TGCT	cis	rs2816062	0.775	rs2745315	chr1:18897118	G/A	cg18795169	chr1:18902165	NA	-0.58	-13.28	-0.77	1.36e-25	Urate levels in lean individuals;
TGCT	cis	rs12477438	0.765	rs12612688	chr2:99613091	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-7.56	-0.56	7.93e-12	Chronic sinus infection;
TGCT	cis	rs72945132	0.825	rs7941965	chr11:70213182	T/C	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs12477438	0.501	rs11685756	chr2:99766215	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	8.52	0.61	4.42e-14	Chronic sinus infection;
TGCT	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg11890956	chr21:40555474	PSMG1	-0.72	-6.51	-0.5	1.67e-9	Cognitive function;
TGCT	cis	rs5769765	0.955	rs9616366	chr22:50301178	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.09	-10.56	-0.69	5.6e-19	Schizophrenia;
TGCT	cis	rs1156327	0.655	rs179235	chr16:19324733	G/A	cg02978544	chr16:19716338	NA	0.44	4.62	0.38	9.3e-6	Periodontal disease-related phenotypes;
TGCT	cis	rs4273100	1.000	rs16960499	chr17:19203032	A/G	cg01534423	chr17:18965556	NA	0.92	5.96	0.47	2.42e-8	Schizophrenia;
TGCT	cis	rs7954584	0.531	rs6486781	chr12:122318985	A/C	cg22168489	chr12:122356033	WDR66	0.19	4.61	0.38	9.95e-6	Mean corpuscular volume;
TGCT	cis	rs13191362	0.507	rs1954806	chr6:163051858	G/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.61	-5.48	-0.44	2.27e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg21724239	chr8:58056113	NA	0.41	4.87	0.4	3.33e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7772486	0.817	rs2748491	chr6:146327759	T/C	cg13319975	chr6:146136371	FBXO30	-0.5	-4.48	-0.37	1.67e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2637266	0.630	rs7095225	chr10:78452623	G/T	cg18941641	chr10:78392320	NA	0.4	4.8	0.4	4.51e-6	Pulmonary function;
TGCT	cis	rs3091242	0.933	rs35403885	chr1:25784551	G/A	cg23205692	chr1:25664452	TMEM50A	-0.47	-4.97	-0.41	2.22e-6	Erythrocyte sedimentation rate;
TGCT	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.91	0.4	2.83e-6	Height;
TGCT	cis	rs7917772	0.560	rs729023	chr10:104341887	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.61	-6.01	-0.47	1.94e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg04267008	chr7:1944627	MAD1L1	-0.35	-4.51	-0.38	1.5e-5	Bipolar disorder and schizophrenia;
TGCT	cis	rs9467711	0.591	rs13202688	chr6:25993469	A/G	cg16898833	chr6:26189333	HIST1H4D	1.36	6.0	0.47	2.05e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4845570	0.850	rs4504897	chr1:151766851	T/A	cg07092448	chr1:151763213	TDRKH	1.06	9.06	0.63	2.36e-15	Coronary artery disease;
TGCT	cis	rs9486719	0.843	rs2499787	chr6:96841762	G/C	cg18709589	chr6:96969512	KIAA0776	0.77	5.12	0.42	1.16e-6	Migraine;Coronary artery disease;
TGCT	cis	rs11190604	1.000	rs11190592	chr10:102291059	T/C	cg23241863	chr10:102295624	HIF1AN	0.68	5.17	0.42	9.14e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs904251	0.523	rs2776870	chr6:37481364	C/A	cg25019722	chr6:37503610	NA	-0.53	-8.19	-0.59	2.75e-13	Cognitive performance;
TGCT	cis	rs1865760	1.000	rs12209482	chr6:25909229	T/G	cg17042849	chr6:26104293	HIST1H4C	-0.52	-4.68	-0.39	7.33e-6	Height;
TGCT	cis	rs13217239	0.646	rs10946888	chr6:26951678	A/G	cg15659132	chr6:26577336	NA	0.54	5.45	0.44	2.61e-7	Schizophrenia;
TGCT	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg23708337	chr7:1209742	NA	0.56	5.09	0.42	1.31e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs12681287	0.752	rs7846635	chr8:87304281	G/A	cg27223183	chr8:87520930	FAM82B	-0.82	-5.79	-0.46	5.37e-8	Caudate activity during reward;
TGCT	cis	rs1843834	0.539	rs12694643	chr2:225446603	A/G	cg22455342	chr2:225449267	CUL3	1.05	10.96	0.7	5.87e-20	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs9611565	0.592	rs5996038	chr22:41965300	T/C	cg03806693	chr22:41940476	POLR3H	-1.08	-11.36	-0.71	6.34e-21	Vitiligo;
TGCT	cis	rs992157	0.697	rs13384682	chr2:219069137	G/A	cg00012203	chr2:219082015	ARPC2	0.81	10.19	0.68	4.34e-18	Colorectal cancer;
TGCT	cis	rs7611238	0.560	rs62287069	chr3:195027645	T/C	cg27323046	chr3:195102265	ACAP2	0.36	4.9	0.4	2.94e-6	Body mass index;
TGCT	cis	rs2075371	0.796	rs35336643	chr7:134010640	G/A	cg11752832	chr7:134001865	SLC35B4	0.7	5.97	0.47	2.27e-8	Mean platelet volume;
TGCT	cis	rs360798	0.512	rs7562149	chr2:63008414	A/G	cg17519650	chr2:63277830	OTX1	-0.67	-6.26	-0.49	5.8e-9	Coronary artery disease;
TGCT	cis	rs3849570	0.615	rs6778265	chr3:81985745	C/T	cg07356753	chr3:81810745	GBE1	0.58	5.09	0.42	1.3e-6	Waist circumference;Body mass index;
TGCT	trans	rs7824557	0.564	rs2736302	chr8:11236419	T/C	cg15556689	chr8:8085844	FLJ10661	-0.74	-6.68	-0.51	7.12e-10	Retinal vascular caliber;
TGCT	cis	rs10464366	0.510	rs62442212	chr7:39146896	A/C	cg18850127	chr7:39170497	POU6F2	0.28	6.61	0.51	1.03e-9	IgG glycosylation;
TGCT	cis	rs10992471	0.528	rs3739606	chr9:95237222	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.53	-4.94	-0.41	2.47e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs9811920	0.683	rs16841874	chr3:99720564	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.44	5.28	0.43	5.61e-7	Axial length;
TGCT	cis	rs10875595	0.775	rs66998469	chr5:140659960	T/C	cg24830062	chr5:140700576	TAF7	-0.6	-5.07	-0.41	1.42e-6	Pulmonary function decline;
TGCT	cis	rs1461503	0.838	rs7107012	chr11:122829813	G/A	cg27398637	chr11:122830231	C11orf63	-0.41	-4.77	-0.39	5.14e-6	Menarche (age at onset);
TGCT	cis	rs9467773	0.549	rs9461273	chr6:26584526	A/G	cg09904177	chr6:26538194	HMGN4	-0.68	-6.55	-0.51	1.41e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs10949834	0.529	rs150861	chr7:73524901	T/C	cg07137043	chr7:73588983	EIF4H	0.7	5.44	0.44	2.71e-7	Verbal memory performance (residualized delayed recall change);
TGCT	trans	rs1496653	0.602	rs71322171	chr3:23369360	C/T	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs6840360	0.571	rs62327278	chr4:152558790	G/C	cg17479576	chr4:152424074	FAM160A1	-0.71	-7.72	-0.57	3.41e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs12142240	0.738	rs10489769	chr1:46806703	A/G	cg14993813	chr1:46806288	NSUN4	-0.58	-4.78	-0.39	4.78e-6	Menopause (age at onset);
TGCT	cis	rs9388451	0.839	rs4897157	chr6:126102981	A/T	cg10911889	chr6:126070802	HEY2	0.51	5.33	0.43	4.47e-7	Brugada syndrome;
TGCT	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg11941060	chr3:133502564	NA	-0.29	-6.15	-0.48	9.6e-9	Iron status biomarkers;
TGCT	cis	rs9549367	0.713	rs3024745	chr13:113821598	A/G	cg00898013	chr13:113819073	PROZ	-0.51	-6.11	-0.48	1.2e-8	Platelet distribution width;
TGCT	cis	rs6893807	0.623	rs112862634	chr5:87970352	G/C	cg24804195	chr5:87968844	LOC645323	0.77	4.58	0.38	1.11e-5	Body mass index;
TGCT	cis	rs6433857	0.657	rs2368178	chr2:181501938	T/C	cg23363182	chr2:181467187	NA	-0.34	-5.16	-0.42	9.57e-7	Body mass index;
TGCT	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg06238570	chr21:40685208	BRWD1	-0.82	-8.86	-0.62	7.17e-15	Cognitive function;
TGCT	cis	rs1878931	0.696	rs35984213	chr16:3451030	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.98	12.11	0.74	9.25e-23	Body mass index (adult);
TGCT	cis	rs9682041	0.877	rs12489967	chr3:170073339	A/C	cg07589077	chr3:170072950	NA	0.29	5.01	0.41	1.82e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs346785	1.000	rs164106	chr17:74290566	C/A	cg09812376	chr17:74270190	QRICH2	-0.39	-5.96	-0.47	2.43e-8	White matter hyperintensities in ischemic stroke;
TGCT	cis	rs2242116	1.000	rs1138518	chr3:46944274	T/C	cg27129171	chr3:47204927	SETD2	0.61	5.84	0.46	4.25e-8	Birth weight;
TGCT	cis	rs12615966	0.584	rs72830474	chr2:105414217	C/T	cg16465502	chr2:105461796	NA	0.85	5.6	0.45	1.34e-7	Pancreatic cancer;
TGCT	cis	rs751728	0.664	rs943478	chr6:33750940	T/A	cg13859433	chr6:33739653	LEMD2	-0.32	-5.68	-0.45	8.97e-8	Crohn's disease;
TGCT	cis	rs2469997	0.843	rs2470013	chr8:120360758	G/C	cg00681363	chr8:120844660	TAF2	0.69	4.48	0.37	1.64e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs3091242	0.900	rs35345536	chr1:25766488	A/G	cg09222892	chr1:25734099	RHCE	-0.42	-6.88	-0.53	2.58e-10	Erythrocyte sedimentation rate;
TGCT	cis	rs2486012	1.000	rs2231283	chr1:44450737	C/G	cg12908607	chr1:44402522	ARTN	0.73	5.95	0.47	2.6e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg22535103	chr8:58192502	C8orf71	-0.46	-5.16	-0.42	9.68e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7666738	0.830	rs115279324	chr4:99042114	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.49	0.56	1.11e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12908161	1.000	rs12903134	chr15:85337699	T/A	cg17173187	chr15:85201210	NMB	0.57	6.39	0.5	3.07e-9	Schizophrenia;
TGCT	cis	rs7528419	0.895	rs599839	chr1:109822166	A/G	cg00908766	chr1:109817496	CELSR2	-0.45	-4.69	-0.39	7.1e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
TGCT	cis	rs7267979	1.000	rs6050566	chr20:25351071	G/A	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg24250549	chr1:154909240	PMVK	0.57	5.48	0.44	2.28e-7	Prostate cancer;
TGCT	cis	rs1008375	1.000	rs1558378	chr4:17650351	T/C	cg16339924	chr4:17578868	LAP3	0.67	5.55	0.45	1.68e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4563143	0.502	rs73029061	chr19:29283980	T/A	cg12667521	chr19:29218732	NA	0.55	5.9	0.47	3.29e-8	Methadone dose in opioid dependence;
TGCT	cis	rs9443189	0.615	rs618239	chr6:76350038	A/G	cg01950844	chr6:76311363	SENP6	1.0	6.26	0.49	5.74e-9	Prostate cancer;
TGCT	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg25767906	chr1:53392781	SCP2	-0.53	-6.21	-0.49	7.34e-9	Monocyte count;
TGCT	cis	rs10493773	0.609	rs11161656	chr1:86182414	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.52	-8.15	-0.59	3.45e-13	Urate levels in overweight individuals;
TGCT	cis	rs7772486	0.641	rs2777485	chr6:146334377	G/A	cg05347473	chr6:146136440	FBXO30	0.56	5.22	0.42	7.2e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7666738	0.830	rs6532724	chr4:99060993	C/T	cg17366294	chr4:99064904	C4orf37	0.73	7.45	0.56	1.4e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg02353165	chr6:42928485	GNMT	0.94	9.65	0.66	8.78e-17	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs936229	0.813	rs3784790	chr15:75081745	G/C	cg10253484	chr15:75165896	SCAMP2	-0.67	-5.38	-0.43	3.64e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
TGCT	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg11764359	chr7:65958608	NA	-0.55	-4.99	-0.41	1.98e-6	Aortic root size;
TGCT	cis	rs7666738	0.830	rs11721726	chr4:98996314	T/C	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9921338	0.961	rs12934968	chr16:11414066	C/A	cg00044050	chr16:11439710	C16orf75	0.95	7.39	0.55	1.92e-11	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs4901869	0.897	rs12878587	chr14:59339378	C/G	cg02291164	chr14:59296302	NA	0.24	4.7	0.39	6.86e-6	Panic disorder;
TGCT	cis	rs72945132	0.882	rs1061328	chr11:70185325	C/T	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs1670533	1.000	rs2045069	chr4:1052206	T/C	cg20887711	chr4:1340912	KIAA1530	0.73	5.74	0.46	6.77e-8	Recombination rate (females);
TGCT	trans	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg20587970	chr11:113659929	NA	-1.09	-13.5	-0.77	4.23e-26	Hip circumference adjusted for BMI;
TGCT	cis	rs453301	0.653	rs2956244	chr8:8885166	A/G	cg06636001	chr8:8085503	FLJ10661	0.81	7.06	0.54	1.06e-10	Joint mobility (Beighton score);
TGCT	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg00343986	chr7:65444356	GUSB	-0.23	-5.16	-0.42	9.66e-7	Aortic root size;
TGCT	cis	rs4074961	0.669	rs4652964	chr1:38078300	A/G	cg17933807	chr1:38061675	GNL2	0.96	11.42	0.72	4.35e-21	Axial length;
TGCT	cis	rs11623869	0.553	rs11627567	chr14:103851775	C/T	cg26031613	chr14:104095156	KLC1	0.68	5.41	0.44	3.11e-7	Bone mineral density;
TGCT	cis	rs2066819	1.000	rs79101914	chr12:56729739	A/G	cg26714650	chr12:56694279	CS	-1.36	-6.06	-0.48	1.54e-8	Psoriasis vulgaris;
TGCT	cis	rs8062405	0.573	rs8045689	chr16:28988269	C/T	cg01117621	chr16:28073818	GSG1L	-0.37	-4.73	-0.39	6.11e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs2288884	0.943	rs12611112	chr19:52574939	G/A	cg15405931	chr19:52693188	PPP2R1A	-0.69	-4.5	-0.37	1.56e-5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs4242434	0.597	rs1877675	chr8:22533947	C/T	cg03733263	chr8:22462867	KIAA1967	-1.02	-13.72	-0.78	1.25e-26	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs1729951	0.514	rs75977	chr3:136700549	C/A	cg21827317	chr3:136751795	NA	0.4	5.61	0.45	1.28e-7	Neuroticism;
TGCT	cis	rs259282	0.583	rs3760938	chr19:33106907	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.6	5.34	0.43	4.25e-7	Schizophrenia;
TGCT	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.68	4.89	0.4	3e-6	Platelet count;
TGCT	cis	rs7772486	0.597	rs9386136	chr6:146158300	A/T	cg13319975	chr6:146136371	FBXO30	-0.67	-6.06	-0.48	1.53e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6545883	1.000	rs778758	chr2:61782161	T/C	cg15711740	chr2:61764176	XPO1	-0.56	-5.08	-0.42	1.35e-6	Tuberculosis;
TGCT	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg03264133	chr6:25882463	NA	-0.61	-6.51	-0.5	1.68e-9	Blood metabolite levels;
TGCT	cis	rs11696501	0.739	rs4812938	chr20:44249919	T/A	cg11783356	chr20:44313418	WFDC10B	-0.32	-4.63	-0.38	9.25e-6	Brain structure;
TGCT	cis	rs7945705	0.902	rs2012696	chr11:8995818	A/C	cg21881798	chr11:8931708	C11orf17;ST5	0.47	5.37	0.43	3.7e-7	Hemoglobin concentration;
TGCT	cis	rs10465746	0.967	rs11163876	chr1:84440605	T/C	cg10977910	chr1:84465055	TTLL7	0.65	6.54	0.51	1.44e-9	Obesity-related traits;
TGCT	cis	rs10992471	0.580	rs7847534	chr9:95282653	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.6	-5.63	-0.45	1.13e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs7824557	0.602	rs7828711	chr8:11205665	G/C	cg21775007	chr8:11205619	TDH	0.71	6.7	0.52	6.36e-10	Retinal vascular caliber;
TGCT	cis	rs6558174	1.000	rs6558174	chr8:22492129	A/G	cg03733263	chr8:22462867	KIAA1967	0.63	4.88	0.4	3.17e-6	Breast cancer;
TGCT	cis	rs826838	1.000	rs826851	chr12:39112639	A/G	cg26384229	chr12:38710491	ALG10B	-0.92	-8.47	-0.61	5.96e-14	Heart rate;
TGCT	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg03806693	chr22:41940476	POLR3H	1.16	13.41	0.77	7.02e-26	Vitiligo;
TGCT	cis	rs17102423	0.755	rs11158572	chr14:65577411	C/T	cg11161011	chr14:65562177	MAX	-0.54	-7.49	-0.56	1.15e-11	Obesity-related traits;
TGCT	cis	rs13191362	0.938	rs59067610	chr6:163030440	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.65	5.32	0.43	4.7e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7172809	0.573	rs4886865	chr15:77686876	C/T	cg22256960	chr15:77711686	NA	-0.5	-4.74	-0.39	5.82e-6	Glucose homeostasis traits;
TGCT	cis	rs910316	0.967	rs4899545	chr14:75568138	A/G	cg11812906	chr14:75593930	NEK9	0.74	7.38	0.55	1.97e-11	Height;
TGCT	cis	rs13326165	0.760	rs9861879	chr3:52424001	A/G	cg27565382	chr3:53032988	SFMBT1	0.38	5.06	0.41	1.5e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs116095464	0.558	rs60251075	chr5:245292	T/C	cg22857025	chr5:266934	NA	-0.34	-6.72	-0.52	5.96e-10	Breast cancer;
TGCT	trans	rs941408	0.928	rs2260414	chr19:2796316	G/A	cg19676328	chr12:49525230	TUBA1B	-0.75	-7.31	-0.55	2.84e-11	Total cholesterol levels;
TGCT	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg11764359	chr7:65958608	NA	0.61	5.54	0.45	1.76e-7	Aortic root size;
TGCT	cis	rs1729951	0.514	rs75977	chr3:136700549	C/A	cg12473912	chr3:136751656	NA	0.39	6.18	0.49	8.36e-9	Neuroticism;
TGCT	trans	rs324780	0.544	rs2220575	chr12:83906245	G/A	cg27144766	chr5:150604977	CCDC69	0.24	6.63	0.51	9.42e-10	Vertical cup-disc ratio;
TGCT	cis	rs60843830	1.000	rs4497901	chr2:239969	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.72	6.82	0.52	3.58e-10	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs858239	0.899	rs10085838	chr7:23298415	C/A	cg05602783	chr7:23145260	KLHL7	-0.67	-5.24	-0.43	6.72e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs140365914	1	rs140365914	chr7:155106570	C/T	cg14927855	chr7:155151427	NA	0.49	6.82	0.52	3.51e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7226408	0.802	rs72894332	chr18:34717721	T/C	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs6582630	0.555	rs10880602	chr12:38505660	T/C	cg26384229	chr12:38710491	ALG10B	0.83	7.75	0.57	2.83e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs7119	0.717	rs7180732	chr15:77829921	G/A	cg27398640	chr15:77910606	LINGO1	-0.26	-4.73	-0.39	6.02e-6	Type 2 diabetes;
TGCT	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg04267008	chr7:1944627	MAD1L1	-0.36	-4.82	-0.4	4.05e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs1372520	0.684	rs356191	chr4:90688120	G/A	cg15133208	chr4:90757351	SNCA	0.47	5.58	0.45	1.43e-7	Neuroticism;
TGCT	cis	rs3820068	0.705	rs927206	chr1:15893338	C/T	cg05660106	chr1:15850417	CASP9	1.17	14.8	0.8	3.47e-29	Systolic blood pressure;
TGCT	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9325144	0.600	rs10785615	chr12:38733627	G/C	cg26384229	chr12:38710491	ALG10B	0.62	5.66	0.45	1e-7	Morning vs. evening chronotype;
TGCT	cis	rs79149102	0.579	rs8033125	chr15:75374970	G/C	cg09165964	chr15:75287851	SCAMP5	-1.0	-5.42	-0.44	3.02e-7	Lung cancer;
TGCT	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg01448562	chr3:133502909	NA	-0.33	-6.67	-0.51	7.6e-10	Iron status biomarkers;
TGCT	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg22963979	chr7:1858916	MAD1L1	-0.45	-7.41	-0.55	1.74e-11	Bipolar disorder and schizophrenia;
TGCT	cis	rs9913156	0.517	rs2326118	chr17:4611851	C/T	cg19197139	chr17:4613644	ARRB2	0.64	5.78	0.46	5.58e-8	Lymphocyte counts;
TGCT	trans	rs9383153	1.000	rs9370888	chr6:16335544	A/G	cg19822892	chr17:4507469	SMTNL2	0.8	7.15	0.54	6.58e-11	Gambling;
TGCT	cis	rs17826219	0.568	rs11658027	chr17:29094882	A/G	cg13385521	chr17:29058706	SUZ12P	-0.84	-4.89	-0.4	3.06e-6	Body mass index;
TGCT	cis	rs2637266	1.000	rs2395384	chr10:78335329	G/A	cg18941641	chr10:78392320	NA	0.42	4.99	0.41	2e-6	Pulmonary function;
TGCT	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg12000995	chr2:27665139	KRTCAP3	-0.37	-4.74	-0.39	5.83e-6	Total body bone mineral density;
TGCT	cis	rs478304	0.934	rs12801731	chr11:65549606	T/C	cg27068330	chr11:65405492	SIPA1	0.74	7.34	0.55	2.48e-11	Acne (severe);
TGCT	cis	rs2842992	0.714	rs2495278	chr6:160123674	G/A	cg11366901	chr6:160182831	ACAT2	1.0	6.51	0.5	1.64e-9	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs6831352	0.729	rs4699718	chr4:100067791	G/A	cg12011299	chr4:100065546	ADH4	-0.43	-5.07	-0.41	1.44e-6	Alcohol dependence;
TGCT	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg10047753	chr17:41438598	NA	0.84	7.61	0.56	5.9e-12	Menopause (age at onset);
TGCT	cis	rs9659323	1.000	rs6700415	chr1:119516174	A/T	cg07961512	chr1:119535619	NA	0.44	5.07	0.41	1.4e-6	Body mass index;
TGCT	cis	rs6904897	0.563	rs4896117	chr6:135229400	T/C	cg22676075	chr6:135203613	NA	-0.62	-6.66	-0.51	7.82e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs11098499	0.874	rs12502503	chr4:120116255	C/T	cg09307838	chr4:120376055	NA	0.5	4.64	0.38	8.86e-6	Corneal astigmatism;
TGCT	cis	rs6460942	1.000	rs2053378	chr7:12405564	C/G	cg06484146	chr7:12443880	VWDE	-0.63	-5.65	-0.45	1.04e-7	Coronary artery disease;
TGCT	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg13695892	chr22:41940480	POLR3H	-0.86	-8.12	-0.59	3.89e-13	Vitiligo;
TGCT	cis	rs6714710	0.603	rs11692010	chr2:98397301	C/T	cg26665480	chr2:98280029	ACTR1B	0.67	6.22	0.49	7.05e-9	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.12	0.42	1.15e-6	Prudent dietary pattern;
TGCT	cis	rs9902453	0.845	rs7501472	chr17:28010628	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	7.19	0.54	5.48e-11	Coffee consumption (cups per day);
TGCT	cis	rs6433895	1.000	rs35543145	chr2:182018115	A/G	cg16904960	chr2:182549928	NA	0.34	4.47	0.37	1.77e-5	Lymphocyte counts;
TGCT	cis	rs6671200	0.573	rs6666528	chr1:95697490	C/A	cg20701556	chr1:95698924	RWDD3	-0.52	-5.34	-0.43	4.26e-7	Stearic acid (18:0) levels;
TGCT	cis	rs644799	0.710	rs522536	chr11:95528714	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	8.5	0.61	5.03e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs240764	0.658	rs11155635	chr6:101199367	C/T	cg09795085	chr6:101329169	ASCC3	-0.51	-4.51	-0.38	1.45e-5	Neuroticism;
TGCT	cis	rs2841277	0.676	rs10438246	chr14:105410183	T/C	cg19901468	chr14:105411992	AHNAK2	-0.27	-5.88	-0.47	3.63e-8	Rheumatoid arthritis;
TGCT	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.66	0.39	8.18e-6	Prudent dietary pattern;
TGCT	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg20607798	chr8:58055168	NA	0.59	5.37	0.43	3.72e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs1018836	0.575	rs17635255	chr8:91518135	A/T	cg16814680	chr8:91681699	NA	-0.81	-6.34	-0.49	3.95e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg20887711	chr4:1340912	KIAA1530	0.54	4.71	0.39	6.4e-6	Longevity;
TGCT	cis	rs2268241	0.938	rs7283827	chr21:34769904	A/G	cg14850771	chr21:34775459	IFNGR2	0.6	5.15	0.42	1.01e-6	Obesity-related traits;
TGCT	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg05665937	chr4:1216051	CTBP1	0.22	4.5	0.37	1.53e-5	Obesity-related traits;
TGCT	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.4	7.02	0.53	1.32e-10	Schizophrenia;
TGCT	cis	rs12643440	0.538	rs2041441	chr4:17136036	C/T	cg22650099	chr4:17144496	NA	-0.45	-4.61	-0.38	9.97e-6	Metabolite levels (Pyroglutamine);
TGCT	cis	rs3820928	0.874	rs1320407	chr2:227867385	G/T	cg11843606	chr2:227700838	RHBDD1	-0.52	-4.63	-0.38	9.03e-6	Pulmonary function;
TGCT	cis	rs9911578	0.967	rs2611781	chr17:56703124	C/G	cg12560992	chr17:57184187	TRIM37	0.75	9.21	0.64	1.04e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs7611238	0.560	rs11709417	chr3:195004216	A/C	cg27323046	chr3:195102265	ACAP2	0.35	4.69	0.39	6.99e-6	Body mass index;
TGCT	cis	rs60843830	1.000	rs36216559	chr2:262335	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.76	7.69	0.57	3.87e-12	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs763121	0.925	rs17032	chr22:39130843	C/G	cg06022373	chr22:39101656	GTPBP1	0.8	7.96	0.58	9.56e-13	Menopause (age at onset);
TGCT	cis	rs2721811	0.701	rs2721808	chr7:24744309	C/A	cg17569154	chr7:24781545	DFNA5	0.22	4.56	0.38	1.2e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs2865978	chr4:99017946	G/T	cg17366294	chr4:99064904	C4orf37	0.68	7.04	0.53	1.17e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8033133	0.602	rs4906699	chr15:25321029	A/G	cg14481604	chr15:25334117	SNORD116-22	0.24	5.17	0.42	9.26e-7	Blood osmolality (transformed sodium);
TGCT	cis	rs3820068	0.603	rs7516453	chr1:15972558	C/G	cg05660106	chr1:15850417	CASP9	0.83	7.73	0.57	3.15e-12	Systolic blood pressure;
TGCT	cis	rs2580764	0.516	rs2860453	chr2:55270485	T/G	cg09592903	chr2:55203963	RTN4	0.27	6.06	0.48	1.51e-8	Mean platelet volume;
TGCT	cis	rs79149102	0.579	rs8031545	chr15:75290496	T/C	cg09165964	chr15:75287851	SCAMP5	-1.06	-5.82	-0.46	4.83e-8	Lung cancer;
TGCT	cis	rs9653442	0.547	rs1062143	chr2:100659796	A/G	cg22139774	chr2:100720529	AFF3	-0.41	-7.32	-0.55	2.67e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs939658	0.683	rs8041222	chr15:79465549	A/G	cg17916960	chr15:79447300	NA	-0.42	-6.58	-0.51	1.19e-9	Refractive error;
TGCT	cis	rs3796352	0.881	rs13100714	chr3:53074824	T/G	cg15956490	chr3:53032818	SFMBT1	0.59	6.75	0.52	5.19e-10	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs7254827	0.589	rs2305758	chr19:17163661	A/G	cg22949562	chr19:17951967	JAK3	0.27	4.79	0.4	4.66e-6	Mean platelet volume;
TGCT	cis	rs797680	0.786	rs12133576	chr1:93816400	C/T	cg17826107	chr1:92977322	EVI5	0.24	5.62	0.45	1.19e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs6088580	0.634	rs6088498	chr20:33020446	A/G	cg06115741	chr20:33292138	TP53INP2	0.52	4.58	0.38	1.12e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs13082711	0.595	rs6778612	chr3:27370789	T/C	cg02860705	chr3:27208620	NA	-0.37	-5.47	-0.44	2.35e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs7830371	0.512	rs2978543	chr8:62140844	C/A	cg09941713	chr8:61705332	CHD7	0.26	4.45	0.37	1.91e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs11785400	0.793	rs2976399	chr8:143746050	C/T	cg10596483	chr8:143751796	JRK	0.53	5.24	0.43	6.63e-7	Schizophrenia;
TGCT	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.18	0.49	8.42e-9	Bipolar disorder;
TGCT	cis	rs9359856	0.623	rs7742602	chr6:90327385	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.45	-4.88	-0.4	3.15e-6	Bipolar disorder;
TGCT	cis	rs1563304	1	rs1563304	chr17:44874453	C/T	cg17911788	chr17:44343683	NA	-0.56	-5.02	-0.41	1.76e-6	Neuroticism;
TGCT	cis	rs7017697	0.642	rs3927029	chr8:19681933	G/A	cg03894339	chr8:19674705	INTS10	-0.61	-4.75	-0.39	5.58e-6	Breast cancer;
TGCT	cis	rs35883536	0.609	rs1577513	chr1:101044402	C/A	cg06223162	chr1:101003688	GPR88	0.42	7.84	0.58	1.77e-12	Monocyte count;
TGCT	cis	rs3749237	0.555	rs2117939	chr3:49415179	C/A	cg03060546	chr3:49711283	APEH	0.77	8.87	0.62	6.79e-15	Resting heart rate;
TGCT	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg11062466	chr8:58055876	NA	0.38	4.62	0.38	9.5e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs881375	0.702	rs3761847	chr9:123690239	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	5.37	0.43	3.76e-7	Rheumatoid arthritis;
TGCT	trans	rs208515	0.525	rs12214310	chr6:66666308	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.9	9.56	0.65	1.46e-16	Exhaled nitric oxide levels;
TGCT	cis	rs7666738	0.830	rs7691864	chr4:98971376	G/C	cg05340658	chr4:99064831	C4orf37	0.5	5.84	0.46	4.35e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7044106	0.734	rs12553070	chr9:123485266	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.19	4.51	0.38	1.5e-5	Hip circumference adjusted for BMI;
TGCT	cis	rs1008375	0.966	rs3775925	chr4:17588437	A/G	cg10189774	chr4:17578691	LAP3	0.64	5.61	0.45	1.28e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1215050	0.740	rs783916	chr4:99026264	A/C	cg17366294	chr4:99064904	C4orf37	-0.59	-6.35	-0.5	3.73e-9	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7474896	0.537	rs2749586	chr10:38270214	G/C	cg13720705	chr10:37990370	NA	-0.35	-4.73	-0.39	5.99e-6	Obesity (extreme);
TGCT	cis	rs7647973	1.000	rs10155014	chr3:49432321	C/T	cg07690219	chr3:49449608	TCTA;RHOA	-0.56	-4.58	-0.38	1.11e-5	Menarche (age at onset);
TGCT	cis	rs36051895	0.623	rs10815148	chr9:5057284	T/A	cg02405213	chr9:5042618	JAK2	-0.8	-10.54	-0.69	6.06e-19	Pediatric autoimmune diseases;
TGCT	cis	rs9916302	0.861	rs11078896	chr17:37415544	C/T	cg15445000	chr17:37608096	MED1	0.33	4.84	0.4	3.8e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg21963583	chr11:68658836	MRPL21	0.36	6.17	0.48	9.01e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs367943	1.000	rs348952	chr5:112821990	G/T	cg12552261	chr5:112820674	MCC	-0.24	-4.91	-0.4	2.81e-6	Type 2 diabetes;
TGCT	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.07	0.82	4.17e-32	Prudent dietary pattern;
TGCT	cis	rs1801251	0.778	rs2592115	chr2:233736349	C/T	cg25237894	chr2:233734115	C2orf82	-0.29	-5.63	-0.45	1.14e-7	Coronary artery disease;
TGCT	cis	rs17270561	0.779	rs12210620	chr6:25884785	T/C	cg16482183	chr6:26056742	HIST1H1C	0.89	6.63	0.51	9.23e-10	Iron status biomarkers;
TGCT	cis	rs10779751	0.690	rs28729193	chr1:11180151	T/C	cg08854313	chr1:11322531	MTOR	-0.82	-6.58	-0.51	1.17e-9	Body mass index;
TGCT	cis	rs72945132	0.882	rs7943840	chr11:70228615	C/A	cg00319359	chr11:70116639	PPFIA1	1.03	7.86	0.58	1.59e-12	Coronary artery disease;
TGCT	cis	rs4730779	0.545	rs3808184	chr7:117214125	T/C	cg10524701	chr7:117356490	CTTNBP2	0.23	4.87	0.4	3.4e-6	Waist circumference;
TGCT	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg09365446	chr1:150670422	GOLPH3L	0.31	4.64	0.38	8.7e-6	Tonsillectomy;
TGCT	cis	rs6570726	0.791	rs436156	chr6:145874873	A/G	cg13319975	chr6:146136371	FBXO30	-0.51	-4.6	-0.38	1.01e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7091068	0.802	rs10786121	chr10:95419796	G/A	cg20715218	chr10:95462985	C10orf4	0.55	5.16	0.42	9.49e-7	Urinary tract infection frequency;
TGCT	cis	rs6582630	0.599	rs1589392	chr12:38418535	G/C	cg26384229	chr12:38710491	ALG10B	-0.54	-4.81	-0.4	4.32e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg11871910	chr12:69753446	YEATS4	0.87	10.07	0.67	8.72e-18	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs6534347	0.573	rs2221903	chr4:123538912	C/T	cg10583651	chr4:123538969	IL21	-0.31	-4.51	-0.38	1.49e-5	Type 1 diabetes;
TGCT	cis	rs7918232	0.882	rs2149413	chr10:27430311	C/T	cg14442939	chr10:27389572	ANKRD26	-0.72	-5.35	-0.43	4.16e-7	Breast cancer;
TGCT	trans	rs9650657	0.515	rs6601560	chr8:10950866	T/C	cg06636001	chr8:8085503	FLJ10661	-0.77	-7.0	-0.53	1.45e-10	Neuroticism;
TGCT	cis	rs10791097	0.720	rs6590518	chr11:130733530	C/T	cg12179176	chr11:130786555	SNX19	0.83	10.11	0.67	6.98e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs7666738	0.830	rs28515641	chr4:98726419	G/A	cg05340658	chr4:99064831	C4orf37	0.49	5.77	0.46	6.02e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2562152	0.706	rs216596	chr16:105320	A/G	cg08083976	chr16:432219	LOC100134368;TMEM8A	-0.65	-4.88	-0.4	3.25e-6	Glioblastoma;
TGCT	cis	rs1062177	1.000	rs2964578	chr5:151147198	T/A	cg00977110	chr5:151150581	G3BP1	0.41	4.62	0.38	9.52e-6	Preschool internalizing problems;
TGCT	cis	rs4975616	0.710	rs27996	chr5:1345474	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.25	-6.07	-0.48	1.45e-8	Lung cancer;
TGCT	cis	rs763014	0.898	rs916416	chr16:632198	T/A	cg07343612	chr16:622815	PIGQ	-0.41	-7.87	-0.58	1.52e-12	Height;
TGCT	cis	rs631288	0.793	rs1530337	chr1:146683319	C/A	cg25205988	chr1:146714368	CHD1L	1.33	5.39	0.44	3.4e-7	PR interval in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7100689	0.646	rs11202721	chr10:82135762	G/A	cg01528321	chr10:82214614	TSPAN14	0.8	7.72	0.57	3.42e-12	Post bronchodilator FEV1;
TGCT	cis	rs7216064	0.954	rs8079291	chr17:65887622	A/G	cg12091567	chr17:66097778	LOC651250	-0.83	-6.49	-0.5	1.9e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs4689388	0.929	rs1046320	chr4:6304344	C/T	cg00701064	chr4:6280414	WFS1	0.41	5.24	0.43	6.7e-7	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs17221829	0.733	rs11018725	chr11:89413251	C/T	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.44	-0.37	1.96e-5	Anxiety in major depressive disorder;
TGCT	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg10802521	chr3:52805072	NEK4	-0.72	-9.1	-0.63	1.91e-15	Bipolar disorder;
TGCT	cis	rs3096299	0.632	rs4399533	chr16:89539382	G/C	cg06640241	chr16:89574553	SPG7	0.79	8.98	0.63	3.73e-15	Multiple myeloma (IgH translocation);
TGCT	cis	rs11148252	0.774	rs6561666	chr13:52930045	A/G	cg00495681	chr13:53174319	NA	0.57	5.58	0.45	1.45e-7	Lewy body disease;
TGCT	trans	rs1814175	0.645	rs10839456	chr11:49964093	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.67	-0.69	2.92e-19	Height;
TGCT	cis	rs8084125	0.832	rs62105174	chr18:74948324	G/A	cg07390210	chr18:74961196	GALR1	0.36	4.46	0.37	1.85e-5	Obesity-related traits;
TGCT	cis	rs6500602	0.702	rs3761680	chr16:4524060	C/A	cg08645402	chr16:4508243	NA	0.18	4.97	0.41	2.21e-6	Schizophrenia;
TGCT	cis	rs2721195	0.845	rs4244611	chr8:145739924	G/A	cg17328964	chr8:145687451	CYHR1	-0.44	-6.22	-0.49	6.83e-9	Age at first birth;
TGCT	cis	rs12478296	1.000	rs73007138	chr2:243007041	C/T	cg06360820	chr2:242988706	NA	-0.88	-5.78	-0.46	5.76e-8	Obesity-related traits;
TGCT	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg06873352	chr17:61820015	STRADA	0.58	6.42	0.5	2.65e-9	Prudent dietary pattern;
TGCT	cis	rs5757676	0.858	rs6001585	chr22:39812986	G/T	cg05872129	chr22:39784769	NA	-0.92	-7.75	-0.57	2.88e-12	IgG glycosylation;
TGCT	cis	rs9308731	0.644	rs60286362	chr2:111877493	G/C	cg04202892	chr2:111875749	ACOXL	0.54	6.25	0.49	6.1e-9	Chronic lymphocytic leukemia;
TGCT	cis	rs2730260	0.537	rs3793224	chr7:158876573	G/A	cg09066883	chr7:157932951	PTPRN2	0.42	4.66	0.39	8.09e-6	Myopia (pathological);
TGCT	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg07157834	chr1:205819609	PM20D1	0.45	7.36	0.55	2.21e-11	Menarche (age at onset);
TGCT	cis	rs2832191	0.720	rs4643617	chr21:30485278	T/C	cg24692254	chr21:30365293	RNF160	-0.94	-10.58	-0.69	4.78e-19	Dental caries;
TGCT	cis	rs1577917	1.000	rs6936048	chr6:86702608	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.54	-0.45	1.73e-7	Response to antipsychotic treatment;
TGCT	trans	rs4824093	0.610	rs4824113	chr22:50284974	C/T	cg09872104	chr7:134855509	C7orf49	-1.01	-8.43	-0.6	7.42e-14	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs79387448	0.745	rs6742433	chr2:103175360	C/T	cg09003973	chr2:102972529	NA	0.97	6.32	0.49	4.33e-9	Gut microbiota (bacterial taxa);
TGCT	cis	rs6952808	0.792	rs12537914	chr7:1948359	C/T	cg22963979	chr7:1858916	MAD1L1	-0.35	-5.43	-0.44	2.9e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs1580019	0.961	rs6949851	chr7:32493807	T/G	cg06627557	chr7:32535165	LSM5;AVL9	0.77	7.07	0.54	1.01e-10	Cognitive ability;
TGCT	cis	rs4372836	0.681	rs6419696	chr2:29010339	G/A	cg09522027	chr2:28974177	PPP1CB	-0.69	-7.27	-0.55	3.54e-11	Body mass index;
TGCT	cis	rs12188164	0.686	rs56279338	chr5:416118	G/A	cg26850624	chr5:429559	AHRR	-0.22	-5.08	-0.41	1.36e-6	Cystic fibrosis severity;
TGCT	cis	rs11096990	0.551	rs2060005	chr4:39162521	A/G	cg20847110	chr4:39482781	LOC401127	0.17	4.86	0.4	3.49e-6	Cognitive function;
TGCT	cis	rs3862435	0.571	rs2589950	chr15:90957179	C/T	cg14166756	chr15:90894880	ZNF774	-0.29	-4.76	-0.39	5.19e-6	Response to exercise (triglyceride level interaction);
TGCT	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg25036284	chr2:26402008	FAM59B	-0.61	-4.9	-0.4	2.92e-6	Gut microbiome composition (summer);
TGCT	cis	rs1799899	0.826	rs1800277	chr3:133466155	A/G	cg18342939	chr3:134203408	ANAPC13;CEP63	-0.48	-4.91	-0.4	2.85e-6	Alcohol consumption (transferrin glycosylation);
TGCT	cis	rs2739330	0.576	rs2858912	chr22:24297197	A/G	cg10150615	chr22:24372951	LOC391322	-0.97	-12.67	-0.75	4.14e-24	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7829975	0.508	rs4841006	chr8:8501474	T/C	cg15556689	chr8:8085844	FLJ10661	-0.54	-5.14	-0.42	1.04e-6	Mood instability;
TGCT	cis	rs6840360	0.809	rs6846809	chr4:152730201	A/G	cg22705602	chr4:152727874	NA	0.27	4.82	0.4	4.09e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.71	5.95	0.47	2.57e-8	Tonsillectomy;
TGCT	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg22166914	chr1:53195759	ZYG11B	0.3	4.88	0.4	3.23e-6	Monocyte count;
TGCT	cis	rs3803170	0.513	rs4766573	chr12:111830809	C/A	cg10833066	chr12:111807467	FAM109A	0.36	5.41	0.44	3.09e-7	Mean corpuscular hemoglobin;
TGCT	cis	rs736408	0.812	rs2239699	chr3:52827915	C/T	cg07507251	chr3:52567010	NT5DC2	0.41	5.46	0.44	2.46e-7	Bipolar disorder;
TGCT	cis	rs35306767	0.623	rs72760943	chr10:1143104	G/A	cg20503657	chr10:835505	NA	0.51	5.41	0.44	3.18e-7	Eosinophil percentage of granulocytes;
TGCT	cis	rs7147624	0.572	rs72714498	chr14:66037734	C/T	cg03016385	chr14:66212404	NA	0.59	6.26	0.49	5.7e-9	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs11648796	0.721	rs3169403	chr16:769247	G/A	cg07343612	chr16:622815	PIGQ	-0.38	-5.24	-0.43	6.6e-7	Height;
TGCT	cis	rs78487399	0.731	rs6722104	chr2:43752346	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.02	-0.41	1.75e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs10411936	0.924	rs8110761	chr19:16501005	A/G	cg14704714	chr19:15740395	CYP4F8	0.25	4.45	0.37	1.86e-5	White blood cell count;Multiple sclerosis;
TGCT	cis	rs2594989	0.806	rs2606746	chr3:11375120	A/G	cg00170343	chr3:11313890	ATG7	0.64	5.14	0.42	1.05e-6	Circulating chemerin levels;
TGCT	cis	rs2486288	0.656	rs62026703	chr15:45569929	G/T	cg14582100	chr15:45693742	SPATA5L1	-0.43	-4.86	-0.4	3.48e-6	Glomerular filtration rate;
TGCT	cis	rs35883536	0.609	rs12747197	chr1:101036831	A/C	cg06223162	chr1:101003688	GPR88	-0.42	-8.0	-0.58	7.38e-13	Monocyte count;
TGCT	cis	rs9611565	0.500	rs2011053	chr22:42121278	G/A	cg17554472	chr22:41940697	POLR3H	0.45	4.84	0.4	3.72e-6	Vitiligo;
TGCT	cis	rs4711350	0.765	rs2395446	chr6:33743264	C/T	cg18005901	chr6:33739558	LEMD2	-0.6	-6.9	-0.53	2.42e-10	Schizophrenia;
TGCT	cis	rs2932538	0.922	rs2273369	chr1:113072477	A/G	cg22162597	chr1:113214053	CAPZA1	0.28	5.98	0.47	2.26e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	trans	rs1814175	0.587	rs7937757	chr11:49978342	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.67	-0.69	2.92e-19	Height;
TGCT	cis	rs7267979	1.000	rs6037105	chr20:25374199	C/A	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs12477438	1.000	rs12053372	chr2:99810055	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-5.97	-0.47	2.3e-8	Chronic sinus infection;
TGCT	cis	rs56309584	0.715	rs77224069	chr17:8124268	G/C	cg08322244	chr17:8066669	VAMP2	-0.57	-5.26	-0.43	6.21e-7	Initial pursuit acceleration;
TGCT	cis	rs2242116	0.734	rs4683294	chr3:46979013	C/G	cg27129171	chr3:47204927	SETD2	-0.64	-6.41	-0.5	2.76e-9	Birth weight;
TGCT	cis	rs9368481	0.729	rs10946881	chr6:26914611	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.47	5.0	0.41	1.89e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2235642	0.821	rs2281236	chr16:1603576	G/A	cg07341220	chr16:1583899	IFT140;TMEM204	-0.29	-4.56	-0.38	1.23e-5	Coronary artery disease;
TGCT	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg06238570	chr21:40685208	BRWD1	-0.78	-8.67	-0.61	2.02e-14	Cognitive function;
TGCT	cis	rs12681287	0.571	rs10097450	chr8:87358677	G/A	cg27223183	chr8:87520930	FAM82B	0.9	6.71	0.52	6.12e-10	Caudate activity during reward;
TGCT	cis	rs317689	0.690	rs618470	chr12:69672060	A/G	cg14784868	chr12:69753453	YEATS4	0.53	4.51	0.38	1.48e-5	Response to diuretic therapy;
TGCT	cis	rs7949030	0.626	rs35587183	chr11:62318656	C/T	cg22862634	chr11:62369728	EML3;MTA2	0.62	6.29	0.49	4.86e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9467773	0.844	rs2393669	chr6:26503873	C/T	cg05738196	chr6:26577821	NA	0.88	12.49	0.75	1.09e-23	Intelligence (multi-trait analysis);
TGCT	trans	rs208520	0.690	rs851458	chr6:66813279	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.97	-10.61	-0.69	4.11e-19	Exhaled nitric oxide output;
TGCT	cis	rs6671200	0.607	rs10874908	chr1:95704151	C/G	cg03123541	chr1:95699097	RWDD3	-0.81	-7.26	-0.55	3.81e-11	Stearic acid (18:0) levels;
TGCT	cis	rs10791323	0.604	rs2250025	chr11:133710914	G/A	cg15485101	chr11:133734466	NA	0.39	5.12	0.42	1.15e-6	Childhood ear infection;
TGCT	cis	rs4383453	0.539	rs2009176	chr3:123100976	C/T	cg04890266	chr3:123102914	ADCY5	-0.5	-8.19	-0.59	2.68e-13	Gestational age at birth (maternal effect);
TGCT	cis	rs3008870	0.755	rs10789219	chr1:67417742	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.82	8.49	0.61	5.37e-14	Lymphocyte percentage of white cells;
TGCT	cis	rs28595532	1.000	rs115706377	chr4:119628481	G/A	cg21605333	chr4:119757512	SEC24D	1.33	8.02	0.58	6.93e-13	Cannabis dependence symptom count;
TGCT	cis	rs189218934	1	rs189218934	chr15:78903987	T/C	cg24631222	chr15:78858424	CHRNA5	-0.88	-6.66	-0.51	7.79e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs28595532	0.920	rs115085630	chr4:119741765	T/C	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs8070740	0.617	rs1058115	chr17:5323269	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	-0.64	-6.33	-0.49	4.08e-9	Menopause (age at onset);
TGCT	cis	rs2153535	0.580	rs1832100	chr6:8446956	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.76	0.46	6.39e-8	Motion sickness;
TGCT	cis	rs17376456	0.825	rs10052662	chr5:93271385	A/G	cg25358565	chr5:93447407	FAM172A	1.02	8.11	0.59	4.23e-13	Diabetic retinopathy;
TGCT	cis	rs394563	0.591	rs237026	chr6:149720681	G/A	cg16235748	chr6:149772707	ZC3H12D	-0.44	-5.06	-0.41	1.46e-6	Dupuytren's disease;
TGCT	cis	rs68170813	0.559	rs12540475	chr7:106886295	C/T	cg02696742	chr7:106810147	HBP1	-0.69	-5.61	-0.45	1.27e-7	Coronary artery disease;
TGCT	cis	rs2549003	0.933	rs3846731	chr5:131814264	T/C	cg00255919	chr5:131827918	IRF1	0.22	5.15	0.42	1.01e-6	Asthma (sex interaction);
TGCT	cis	rs11122272	0.668	rs2472261	chr1:231505701	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-6.93	-0.53	1.99e-10	Hemoglobin concentration;
TGCT	cis	rs1030877	0.960	rs3792047	chr2:105901553	A/G	cg02079111	chr2:105885981	TGFBRAP1	-0.17	-4.74	-0.39	5.87e-6	Obesity-related traits;
TGCT	cis	rs28595532	0.844	rs115573749	chr4:119756848	T/A	cg21605333	chr4:119757512	SEC24D	1.62	7.73	0.57	3.22e-12	Cannabis dependence symptom count;
TGCT	cis	rs2688608	0.592	rs7076585	chr10:75503692	T/C	cg19442545	chr10:75533431	FUT11	-0.36	-5.66	-0.45	9.76e-8	Inflammatory bowel disease;
TGCT	cis	rs9325144	0.671	rs12818797	chr12:39019409	A/G	cg10518543	chr12:38710700	ALG10B	-0.5	-4.8	-0.4	4.45e-6	Morning vs. evening chronotype;
TGCT	cis	rs5769765	0.818	rs138850	chr22:50193337	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.88	8.8	0.62	9.76e-15	Schizophrenia;
TGCT	cis	rs6450176	1.000	rs6450175	chr5:53297824	C/T	ch.5.1024479R	chr5:53302184	ARL15	-0.53	-5.12	-0.42	1.15e-6	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs6714788	0.503	rs11681737	chr2:100679024	T/C	cg07810366	chr2:100720526	AFF3	-0.38	-5.2	-0.42	7.95e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs12620999	0.887	rs10929214	chr2:238037436	C/G	cg23555395	chr2:238036564	NA	-0.3	-5.19	-0.42	8.25e-7	Systemic lupus erythematosus;
TGCT	cis	rs5769707	0.967	rs739248	chr22:50025205	T/C	cg10356904	chr22:49881777	NA	-0.22	-4.52	-0.38	1.4e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs36051895	0.659	rs7045342	chr9:5183892	T/C	cg02405213	chr9:5042618	JAK2	-0.69	-8.71	-0.62	1.6e-14	Pediatric autoimmune diseases;
TGCT	cis	rs4808199	0.948	rs1859287	chr19:19422187	T/C	cg03709012	chr19:19516395	GATAD2A	0.81	6.55	0.51	1.4e-9	Nonalcoholic fatty liver disease;
TGCT	cis	rs4273100	0.607	rs1043809	chr17:19239432	C/T	cg03910582	chr17:19030146	GRAPL	-0.51	-6.21	-0.49	7.47e-9	Schizophrenia;
TGCT	cis	rs2841233	0.520	rs77494727	chr14:105348018	A/G	cg03469805	chr14:105330648	KIAA0284	-0.45	-5.0	-0.41	1.93e-6	IgG glycosylation;
TGCT	cis	rs941408	1.000	rs1624295	chr19:2792034	G/A	cg06609049	chr19:2785107	THOP1	0.77	7.55	0.56	8.09e-12	Total cholesterol levels;
TGCT	trans	rs1908814	0.504	rs7830734	chr8:11795639	C/T	cg15556689	chr8:8085844	FLJ10661	0.75	7.26	0.55	3.72e-11	Neuroticism;
TGCT	cis	rs4073582	0.595	rs2508657	chr11:66043898	G/A	cg16950941	chr11:66035639	RAB1B	0.58	5.44	0.44	2.67e-7	Gout;
TGCT	cis	rs9611565	0.512	rs7291736	chr22:42124874	C/A	cg06634786	chr22:41940651	POLR3H	0.89	8.81	0.62	9.46e-15	Vitiligo;
TGCT	cis	rs2980439	0.783	rs2948305	chr8:8098577	G/A	cg08975724	chr8:8085496	FLJ10661	0.56	5.1	0.42	1.24e-6	Neuroticism;
TGCT	cis	rs6882046	0.513	rs454214	chr5:88003403	A/G	cg24804195	chr5:87968844	LOC645323	0.58	5.64	0.45	1.1e-7	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg17971929	chr21:40555470	PSMG1	0.97	9.54	0.65	1.67e-16	Cognitive function;
TGCT	cis	rs6490294	0.799	rs73424286	chr12:112327142	G/A	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Mean platelet volume;
TGCT	cis	rs12510870	0.634	rs4618279	chr4:74382503	A/G	cg05868023	chr4:75230803	EREG	0.56	5.07	0.41	1.42e-6	Iris color (b* coordinate);
TGCT	cis	rs6540559	0.673	rs2357230	chr1:210019498	G/A	cg21951975	chr1:209979733	IRF6	0.64	4.82	0.4	4.12e-6	Cleft lip with or without cleft palate;
TGCT	trans	rs561341	0.700	rs8079471	chr17:30218317	A/G	cg20587970	chr11:113659929	NA	-0.59	-8.85	-0.62	7.64e-15	Hip circumference adjusted for BMI;
TGCT	cis	rs7822232	0.908	rs56138570	chr8:145142206	G/A	cg14631276	chr8:145163102	KIAA1875	-0.56	-5.05	-0.41	1.55e-6	Blood metabolite levels;
TGCT	cis	rs2153535	0.580	rs2184584	chr6:8468407	T/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs3820928	0.874	rs7563644	chr2:227846932	A/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-4.59	-0.38	1.05e-5	Pulmonary function;
TGCT	cis	rs2871473	1.000	rs2871473	chr2:103107280	A/C	cg09003973	chr2:102972529	NA	0.64	4.52	0.38	1.4e-5	Blood protein levels;
TGCT	cis	rs6121246	0.954	rs6121245	chr20:30432060	G/A	cg13852791	chr20:30311386	BCL2L1	0.76	5.67	0.45	9.7e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs826838	0.900	rs11169301	chr12:39128497	C/A	cg26384229	chr12:38710491	ALG10B	0.95	8.73	0.62	1.41e-14	Heart rate;
TGCT	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs4680	0.737	rs4646312	chr22:19948337	C/T	cg23601416	chr22:19950040	COMT	0.38	5.09	0.42	1.29e-6	Blood metabolite levels;
TGCT	cis	rs7772486	0.641	rs2253757	chr6:146199686	C/T	cg05347473	chr6:146136440	FBXO30	0.67	6.27	0.49	5.48e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs933688	1.000	rs61612071	chr5:90741470	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.0	8.47	0.61	6.09e-14	Smoking behavior;
TGCT	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg20203395	chr5:56204925	C5orf35	0.51	4.74	0.39	5.72e-6	Initial pursuit acceleration;
TGCT	cis	rs6867032	1.000	rs28392808	chr5:2013477	A/G	cg26168224	chr5:2018326	NA	0.46	8.36	0.6	1.08e-13	Gut microbiome composition (winter);
TGCT	cis	rs910316	0.967	rs2268619	chr14:75640354	C/G	cg23033748	chr14:75592666	NEK9	-0.28	-4.64	-0.38	8.72e-6	Height;
TGCT	cis	rs317689	0.680	rs315140	chr12:69790780	A/T	cg20891283	chr12:69753455	YEATS4	0.55	4.62	0.38	9.53e-6	Response to diuretic therapy;
TGCT	cis	rs9467773	0.572	rs13213953	chr6:26594534	T/A	cg09904177	chr6:26538194	HMGN4	0.63	5.71	0.46	7.78e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs12893668	0.663	rs12889731	chr14:104087482	C/T	cg26031613	chr14:104095156	KLC1	-0.55	-4.64	-0.38	8.81e-6	Reticulocyte count;
TGCT	cis	rs7582180	0.606	rs10174145	chr2:100932488	T/C	cg14675211	chr2:100938903	LONRF2	0.53	5.24	0.43	6.82e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs12908161	0.959	rs17598603	chr15:85200211	C/G	cg17173187	chr15:85201210	NMB	-0.57	-6.53	-0.51	1.52e-9	Schizophrenia;
TGCT	cis	rs2172802	0.576	rs7656189	chr4:62411676	A/G	cg04118610	chr4:62707027	LPHN3	-0.4	-4.91	-0.4	2.86e-6	Partial epilepsies;
TGCT	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg13944838	chr5:179740914	GFPT2	-0.4	-6.32	-0.49	4.35e-9	Height;
TGCT	trans	rs3780486	0.846	rs7036812	chr9:33143822	T/C	cg04842962	chr6:43655489	MRPS18A	1.21	14.37	0.79	3.68e-28	IgG glycosylation;
TGCT	cis	rs4478858	0.684	rs10798837	chr1:31719340	C/T	cg00250761	chr1:31883323	NA	-0.26	-4.74	-0.39	5.75e-6	Alcohol dependence;
TGCT	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg07061783	chr6:25882402	NA	-0.45	-4.82	-0.4	4.15e-6	Blood metabolite levels;
TGCT	cis	rs1451375	0.755	rs3829897	chr7:50629764	G/T	cg18232548	chr7:50535776	DDC	0.44	7.03	0.53	1.22e-10	Malaria;
TGCT	cis	rs9911578	0.935	rs6503878	chr17:56884581	T/G	cg12560992	chr17:57184187	TRIM37	0.76	9.34	0.64	4.88e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs922182	0.599	rs34409256	chr15:64270314	G/T	cg02919090	chr15:64263738	DAPK2	-0.29	-5.21	-0.42	7.69e-7	Blood protein levels;
TGCT	cis	rs2617583	0.530	rs1478435	chr5:1454612	T/C	cg13982541	chr5:1466431	LPCAT1	0.2	4.86	0.4	3.45e-6	Breast cancer;
TGCT	cis	rs17376456	0.569	rs1349711	chr5:93179032	C/T	cg25358565	chr5:93447407	FAM172A	-0.84	-6.67	-0.51	7.58e-10	Diabetic retinopathy;
TGCT	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	5.53	0.44	1.79e-7	Height;
TGCT	cis	rs4466137	0.953	rs1420654	chr5:82975793	G/A	cg16102102	chr5:83017553	HAPLN1	-0.93	-10.85	-0.7	1.06e-19	Prostate cancer;
TGCT	cis	rs2370759	1.000	rs2370759	chr10:32634972	G/A	cg01819863	chr10:32635814	EPC1	1.0	9.52	0.65	1.8e-16	Sexual dysfunction (female);
TGCT	cis	rs319204	0.851	rs319190	chr5:146270241	A/G	cg25021259	chr5:146258546	PPP2R2B	0.35	4.49	0.37	1.63e-5	Schizophrenia;
TGCT	cis	rs57221529	0.766	rs12519469	chr5:581772	A/G	cg16624210	chr5:671434	TPPP	0.37	4.44	0.37	1.99e-5	Lung disease severity in cystic fibrosis;
TGCT	cis	rs1008375	0.966	rs12509962	chr4:17680292	G/A	cg10189774	chr4:17578691	LAP3	0.52	4.89	0.4	3.1e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	trans	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg11887960	chr12:57824829	NA	1.12	9.54	0.65	1.68e-16	Obesity-related traits;
TGCT	cis	rs7267979	0.966	rs2424714	chr20:25418681	T/G	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.99	-10.88	-0.7	8.97e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs67311347	1.000	rs56303661	chr3:40520778	C/G	cg17264618	chr3:40429014	ENTPD3	0.32	4.45	0.37	1.88e-5	Renal cell carcinoma;
TGCT	cis	rs11578119	0.866	rs10919379	chr1:170354577	T/C	cg09767346	chr1:170501363	GORAB	0.61	4.61	0.38	9.8e-6	Male-pattern baldness;
TGCT	cis	rs6582630	0.513	rs11181246	chr12:38302670	C/T	cg26384229	chr12:38710491	ALG10B	0.82	7.14	0.54	6.78e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs7681440	0.647	rs1442136	chr4:90819026	C/T	cg20003494	chr4:90757398	SNCA	0.53	4.7	0.39	6.88e-6	Dementia with Lewy bodies;
TGCT	cis	rs1971762	0.527	rs9737721	chr12:54074696	A/T	cg16917193	chr12:54089295	NA	1.33	16.62	0.83	2.36e-33	Height;
TGCT	cis	rs112591243	0.570	rs4819254	chr21:47887462	T/A	cg10657630	chr21:48055338	PRMT2	1.06	5.21	0.42	7.69e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg04267008	chr7:1944627	MAD1L1	0.36	4.59	0.38	1.05e-5	Bipolar disorder and schizophrenia;
TGCT	cis	rs911555	0.815	rs2756118	chr14:103992473	C/T	cg12935359	chr14:103987150	CKB	0.38	5.37	0.43	3.7e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9328448	1.000	rs7744601	chr6:7988910	T/C	cg13863638	chr6:7199401	RREB1	0.19	4.46	0.37	1.79e-5	Coronary artery calcification;
TGCT	cis	rs79349575	0.783	rs62075820	chr17:46983171	G/C	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.44	-0.37	1.95e-5	Type 2 diabetes;
TGCT	cis	rs76419734	0.510	rs7659526	chr4:106621643	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.71	4.66	0.39	7.95e-6	Post bronchodilator FEV1;
TGCT	cis	rs6570726	0.967	rs373704	chr6:145860618	C/A	cg05347473	chr6:146136440	FBXO30	0.5	4.46	0.37	1.82e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs12464483	0.591	rs72800120	chr2:30897122	G/A	cg12454169	chr2:30669597	LCLAT1	0.52	5.58	0.45	1.42e-7	Pre-treatment pain in head and neck squamous cell carcinoma;
TGCT	cis	rs1005224	0.889	rs12717566	chr14:76147507	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.66	-5.8	-0.46	5.13e-8	Large artery stroke;
TGCT	cis	rs3820928	0.874	rs13423714	chr2:227896652	C/G	cg11843606	chr2:227700838	RHBDD1	0.56	5.04	0.41	1.63e-6	Pulmonary function;
TGCT	cis	rs3772130	0.603	rs35489993	chr3:121411876	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.72	0.39	6.14e-6	Cognitive performance;
TGCT	cis	rs7267979	0.816	rs404775	chr20:25481117	A/G	cg14121845	chr20:25566513	NINL	0.46	4.76	0.39	5.36e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9443645	0.901	rs1890229	chr6:79695029	C/T	cg09184832	chr6:79620586	NA	-0.48	-5.34	-0.43	4.21e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1670533	0.872	rs935969	chr4:1062588	A/G	cg27284194	chr4:1044797	NA	0.7	6.09	0.48	1.28e-8	Recombination rate (females);
TGCT	cis	rs9341808	0.644	rs59371711	chr6:80942027	G/T	cg08355045	chr6:80787529	NA	-0.28	-4.52	-0.38	1.45e-5	Sitting height ratio;
TGCT	cis	rs1475911	1.000	rs34421316	chr21:43513989	C/T	cg19766460	chr21:43528205	UMODL1;C21orf128	0.52	6.85	0.52	3e-10	IgG glycosylation;
TGCT	cis	rs1799949	1.000	rs4793236	chr17:41436440	T/C	cg05368731	chr17:41323189	NBR1	1.19	13.98	0.78	3.03e-27	Menopause (age at onset);
TGCT	cis	rs2304725	0.526	rs2600091	chr3:10826905	C/A	cg15914589	chr3:10206523	IRAK2	0.46	4.47	0.37	1.74e-5	Pulmonary function in asthmatics;
TGCT	cis	rs6121246	0.567	rs6060263	chr20:30193110	T/C	cg13852791	chr20:30311386	BCL2L1	0.69	4.54	0.38	1.33e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg20276088	chr3:133502917	NA	0.24	5.26	0.43	6.13e-7	Iron status biomarkers;
TGCT	cis	rs6598955	0.502	rs6683157	chr1:26545865	G/A	cg04990556	chr1:26633338	UBXN11	0.8	7.36	0.55	2.19e-11	Obesity-related traits;
TGCT	cis	rs9796	0.662	rs8033435	chr15:41436479	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.53	-6.86	-0.52	2.97e-10	Menopause (age at onset);
TGCT	cis	rs208515	0.525	rs12204706	chr6:66669930	A/G	cg07460842	chr6:66804631	NA	-0.86	-8.95	-0.63	4.31e-15	Exhaled nitric oxide levels;
TGCT	cis	rs9303401	0.659	rs66514313	chr17:56714057	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs3008870	1.000	rs975451	chr1:67480060	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.08	11.47	0.72	3.32e-21	Lymphocyte percentage of white cells;
TGCT	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.48	-0.37	1.66e-5	Bipolar disorder;
TGCT	cis	rs1466788	1.000	rs3754439	chr1:110615094	A/G	cg11787288	chr1:111506544	C1orf103	0.49	4.5	0.38	1.51e-5	Blood metabolite levels;
TGCT	cis	rs6669384	0.737	rs882198	chr1:208036509	A/G	cg22525895	chr1:207977042	MIR29B2	0.37	5.08	0.42	1.32e-6	Immune response to measles vaccine (measles-specific neutralising antibody titre);
TGCT	cis	rs1997103	0.906	rs6593231	chr7:55402914	T/A	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs3806843	1.000	rs1030164	chr5:140185272	A/G	cg19875535	chr5:140030758	IK	0.35	5.85	0.47	4.01e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2562456	0.833	rs2562416	chr19:21613411	A/G	cg25650185	chr19:21324782	ZNF431	-0.56	-4.45	-0.37	1.88e-5	Pain;
TGCT	cis	rs789852	0.867	rs1675938	chr3:194327370	T/A	cg18000598	chr3:194342907	TMEM44	-0.81	-5.19	-0.42	8.35e-7	QT interval;
TGCT	cis	rs7412746	0.658	rs17660092	chr1:150797748	T/C	cg09365446	chr1:150670422	GOLPH3L	0.35	5.13	0.42	1.1e-6	Melanoma;
TGCT	cis	rs7819412	0.668	rs2409714	chr8:11010118	A/G	cg21775007	chr8:11205619	TDH	-0.61	-5.97	-0.47	2.3e-8	Triglycerides;
TGCT	cis	rs7104764	0.507	rs6598056	chr11:252283	A/G	cg18336825	chr11:236787	PSMD13;SIRT3	-0.71	-5.37	-0.43	3.67e-7	Menarche (age at onset);
TGCT	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg03709012	chr19:19516395	GATAD2A	0.67	5.74	0.46	6.83e-8	Tonsillectomy;
TGCT	cis	rs7824557	0.564	rs2572400	chr8:11234367	T/G	cg21775007	chr8:11205619	TDH	-0.64	-6.27	-0.49	5.48e-9	Retinal vascular caliber;
TGCT	cis	rs651907	0.557	rs13069443	chr3:101373305	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.35	-7.28	-0.55	3.4e-11	Colorectal cancer;
TGCT	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg24675658	chr1:53192096	ZYG11B	-0.75	-6.34	-0.49	3.84e-9	Monocyte count;
TGCT	cis	rs4285028	0.747	rs58367397	chr3:121451700	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.92	-7.3	-0.55	3.03e-11	Multiple sclerosis;
TGCT	cis	rs1514658	0.903	rs13124454	chr4:119279431	G/A	cg21605333	chr4:119757512	SEC24D	-0.5	-4.5	-0.37	1.56e-5	Congenital heart disease (maternal effect);
TGCT	cis	rs4808199	0.948	rs757000	chr19:19448301	A/G	cg03709012	chr19:19516395	GATAD2A	0.81	6.32	0.49	4.32e-9	Nonalcoholic fatty liver disease;
TGCT	cis	rs28735056	0.967	rs56328473	chr18:77636101	C/T	cg20368463	chr18:77673604	PQLC1	-0.44	-5.46	-0.44	2.44e-7	Schizophrenia;
TGCT	cis	rs6754311	0.593	rs2034276	chr2:136422171	A/T	cg07169764	chr2:136633963	MCM6	0.65	5.87	0.47	3.74e-8	Mosquito bite size;
TGCT	cis	rs5769765	0.955	rs4075330	chr22:50303249	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.17	-11.54	-0.72	2.25e-21	Schizophrenia;
TGCT	cis	rs1903068	1.000	rs1903068	chr4:56008477	A/G	cg09978860	chr4:56023921	NA	0.58	6.61	0.51	1.02e-9	Endometriosis;
TGCT	cis	rs7119038	0.818	rs715412	chr11:118684610	G/A	cg19308663	chr11:118741387	NA	0.29	5.76	0.46	6.25e-8	Sjögren's syndrome;
TGCT	cis	rs2456568	0.802	rs1506656	chr11:93639813	G/A	cg16099599	chr11:93583650	C11orf90	-0.39	-4.77	-0.39	5.02e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs11578119	0.933	rs1412890	chr1:170413406	C/T	cg09767346	chr1:170501363	GORAB	0.71	5.69	0.46	8.66e-8	Male-pattern baldness;
TGCT	cis	rs10507380	0.766	rs78172194	chr13:27919689	A/C	cg25543773	chr13:27185723	WASF3	0.34	4.83	0.4	3.97e-6	Electrocardiographic traits;
TGCT	cis	rs11252926	0.598	rs4881256	chr10:453831	T/A	cg20256804	chr10:444983	DIP2C	-0.21	-4.45	-0.37	1.9e-5	Psychosis in Alzheimer's disease;
TGCT	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg10802521	chr3:52805072	NEK4	-0.74	-9.21	-0.64	1.02e-15	Electroencephalogram traits;
TGCT	cis	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg09021430	chr5:549028	NA	-0.4	-5.48	-0.44	2.24e-7	Lung disease severity in cystic fibrosis;
TGCT	cis	rs1372520	0.684	rs2572318	chr4:90718719	C/T	cg15133208	chr4:90757351	SNCA	-0.5	-5.09	-0.42	1.28e-6	Neuroticism;
TGCT	cis	rs9467773	0.836	rs1624440	chr6:26433329	G/A	cg09904177	chr6:26538194	HMGN4	-0.51	-4.68	-0.39	7.5e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9926296	0.569	rs4785708	chr16:89796569	C/T	cg27121462	chr16:89883253	FANCA	-0.5	-4.67	-0.39	7.64e-6	Vitiligo;
TGCT	cis	rs9913156	0.793	rs9916135	chr17:4568115	A/C	cg23387401	chr17:4582204	PELP1	-0.31	-4.63	-0.38	8.97e-6	Lymphocyte counts;
TGCT	cis	rs4455778	0.519	rs34062689	chr7:49035022	G/T	cg26309511	chr7:48887640	NA	0.52	6.9	0.53	2.36e-10	Lung cancer in never smokers;
TGCT	cis	rs10114408	0.879	rs10821244	chr9:96638449	A/G	cg13679303	chr9:96623674	NA	-0.36	-4.69	-0.39	6.98e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs9549367	0.826	rs9549713	chr13:113905308	G/T	cg00898013	chr13:113819073	PROZ	-0.4	-5.03	-0.41	1.64e-6	Platelet distribution width;
TGCT	cis	rs9611565	0.921	rs2143695	chr22:41728620	A/G	cg03806693	chr22:41940476	POLR3H	-0.83	-8.68	-0.61	1.93e-14	Vitiligo;
TGCT	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg18305652	chr10:134549665	INPP5A	0.35	5.93	0.47	2.87e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs9486715	0.867	rs6568428	chr6:96903604	A/G	cg06623918	chr6:96969491	KIAA0776	1.11	16.47	0.83	5.28e-33	Headache;
TGCT	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg00684032	chr4:1343700	KIAA1530	-0.22	-4.72	-0.39	6.18e-6	Obesity-related traits;
TGCT	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg16049864	chr8:95962084	TP53INP1	-0.75	-10.28	-0.68	2.7e-18	Type 2 diabetes;
TGCT	cis	rs7568458	0.870	rs1972297	chr2:85808573	T/C	cg17127132	chr2:85788382	GGCX	0.67	6.24	0.49	6.43e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs4969178	0.560	rs4969182	chr17:76393030	T/C	cg05887092	chr17:76393375	PGS1	0.21	4.49	0.37	1.58e-5	HDL cholesterol levels;
TGCT	cis	rs67311347	0.911	rs58282210	chr3:40417943	C/T	cg13683864	chr3:40499215	RPL14	-1.12	-11.9	-0.73	2.94e-22	Renal cell carcinoma;
TGCT	cis	rs7584330	0.666	rs7600317	chr2:238353513	C/T	cg14458575	chr2:238380390	NA	0.53	7.82	0.57	1.99e-12	Prostate cancer;
TGCT	cis	rs11098499	0.779	rs7674500	chr4:120303593	C/T	cg09307838	chr4:120376055	NA	0.65	6.39	0.5	3.02e-9	Corneal astigmatism;
TGCT	cis	rs7267979	0.844	rs6083845	chr20:25388090	G/C	cg14121845	chr20:25566513	NINL	-0.45	-4.6	-0.38	1.02e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs629535	0.783	rs658407	chr8:70035247	T/C	cg21567404	chr3:27674614	NA	0.58	9.18	0.64	1.22e-15	Dupuytren's disease;
TGCT	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg21724239	chr8:58056113	NA	0.47	5.1	0.42	1.22e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs3782455	1.000	rs75235459	chr12:114400776	C/T	cg10631684	chr12:113795897	PLBD2	-0.7	-4.61	-0.38	1e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs6433895	1.000	rs55900432	chr2:182017904	G/A	cg16904960	chr2:182549928	NA	0.34	4.47	0.37	1.77e-5	Lymphocyte counts;
TGCT	cis	rs60843830	0.633	rs1078763	chr2:113763	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	-0.59	-5.32	-0.43	4.61e-7	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs853679	0.546	rs200981	chr6:27833174	A/G	cg08798685	chr6:27730294	NA	-0.34	-4.69	-0.39	7.2e-6	Depression;
TGCT	cis	rs2153535	0.580	rs9379222	chr6:8514788	T/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.01	0.41	1.86e-6	Motion sickness;
TGCT	cis	rs34734847	1.000	rs10431385	chr12:121128882	T/C	cg21892295	chr12:121157589	UNC119B	-0.23	-5.49	-0.44	2.17e-7	Mean corpuscular volume;
TGCT	cis	rs524281	0.861	rs1862005	chr11:65863402	T/C	cg00563793	chr11:65837595	PACS1	0.55	4.62	0.38	9.44e-6	Electroencephalogram traits;
TGCT	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.93	7.44	0.56	1.44e-11	Platelet count;
TGCT	cis	rs896854	0.654	rs10429443	chr8:95971164	A/G	cg13393036	chr8:95962371	TP53INP1	-0.63	-8.52	-0.61	4.51e-14	Type 2 diabetes;
TGCT	cis	rs611744	0.752	rs609197	chr8:109234035	G/A	cg21045802	chr8:109455806	TTC35	0.52	4.72	0.39	6.21e-6	Dupuytren's disease;
TGCT	trans	rs208520	0.545	rs6899712	chr6:66749670	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.04	14.26	0.79	6.57e-28	Exhaled nitric oxide output;
TGCT	cis	rs6456156	0.792	rs2039321	chr6:167516299	C/T	cg07741184	chr6:167504864	NA	0.22	4.44	0.37	2e-5	Primary biliary cholangitis;
TGCT	cis	rs12615966	1.000	rs17030308	chr2:105385872	T/C	cg16465502	chr2:105461796	NA	0.78	5.03	0.41	1.66e-6	Pancreatic cancer;
TGCT	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg27588902	chr6:42928151	GNMT	-0.56	-6.93	-0.53	2.08e-10	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs9300255	0.602	rs1716177	chr12:123655457	C/T	cg00376283	chr12:123451042	ABCB9	0.66	4.85	0.4	3.59e-6	Neutrophil percentage of white cells;
TGCT	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg16414030	chr3:133502952	NA	-0.5	-7.01	-0.53	1.39e-10	Iron status biomarkers;
TGCT	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg23172400	chr8:95962367	TP53INP1	-0.4	-6.56	-0.51	1.33e-9	Type 2 diabetes;
TGCT	cis	rs2013441	1.000	rs9905493	chr17:20188581	C/G	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.63	-0.38	9.19e-6	Obesity-related traits;
TGCT	cis	rs7098414	0.530	rs10749572	chr10:82136664	G/T	cg01528321	chr10:82214614	TSPAN14	0.51	4.45	0.37	1.91e-5	Post bronchodilator FEV1;
TGCT	cis	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg18188782	chr20:61659543	NA	0.44	5.48	0.44	2.24e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs4642101	0.561	rs7638333	chr3:12806142	T/C	cg04715183	chr3:11886989	C3orf31	-0.17	-4.44	-0.37	2e-5	QRS complex (12-leadsum);
TGCT	cis	rs2180341	0.618	rs4502958	chr6:127593113	G/A	cg27446573	chr6:127587934	RNF146	0.65	5.79	0.46	5.52e-8	Breast cancer;
TGCT	cis	rs1451375	1.000	rs2329342	chr7:50624971	A/G	cg18232548	chr7:50535776	DDC	-0.41	-6.34	-0.49	3.85e-9	Malaria;
TGCT	cis	rs981844	0.826	rs4585278	chr4:154684145	A/G	cg14289246	chr4:154710475	SFRP2	1.06	9.98	0.67	1.4e-17	Response to statins (LDL cholesterol change);
TGCT	cis	rs3796352	1.000	rs35737577	chr3:53002557	G/C	cg15956490	chr3:53032818	SFMBT1	0.61	6.76	0.52	4.92e-10	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	5.53	0.44	1.8e-7	Alzheimer's disease;
TGCT	cis	rs2847281	0.761	rs8087237	chr18:12834359	G/T	cg23598886	chr18:12777645	NA	0.39	4.69	0.39	6.96e-6	C-reactive protein levels;Esophageal cancer (squamous cell);
TGCT	cis	rs506338	0.517	rs1207179	chr11:64450795	C/T	cg19395706	chr11:64412079	NRXN2	0.5	6.05	0.48	1.58e-8	Body mass index;Urate levels;
TGCT	cis	rs11105298	0.891	rs10858852	chr12:89833338	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.67	-4.74	-0.39	5.67e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs6088580	0.634	rs6088508	chr20:33060081	A/G	cg08999081	chr20:33150536	PIGU	0.29	5.66	0.45	9.97e-8	Glomerular filtration rate (creatinine);
TGCT	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg27436995	chr16:743998	FBXL16	-0.48	-5.09	-0.42	1.29e-6	Height;
TGCT	cis	rs7104764	1.000	rs1128322	chr11:244197	C/T	cg18336825	chr11:236787	PSMD13;SIRT3	-1.07	-11.19	-0.71	1.61e-20	Menarche (age at onset);
TGCT	cis	rs10489202	0.634	rs11582396	chr1:168077636	C/T	cg24449463	chr1:168025552	DCAF6	-0.49	-5.06	-0.41	1.49e-6	Schizophrenia;
TGCT	cis	rs7027203	1.000	rs34624092	chr9:96523092	G/A	cg14396892	chr9:96623032	NA	0.23	4.6	0.38	1.03e-5	DNA methylation (variation);
TGCT	cis	rs427394	0.735	rs416689	chr5:6740855	C/T	cg10857441	chr5:6722123	POLS	-0.32	-7.93	-0.58	1.08e-12	Menopause (age at onset);
TGCT	cis	rs2033711	0.811	rs9304814	chr19:58951811	C/A	cg12042659	chr19:58951599	ZNF132	0.53	4.64	0.38	8.82e-6	Uric acid clearance;
TGCT	cis	rs950027	0.787	rs1153845	chr15:45724729	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.65	-7.04	-0.53	1.17e-10	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg11494091	chr17:61959527	GH2	0.61	14.8	0.8	3.65e-29	Prudent dietary pattern;
TGCT	trans	rs783396	0.685	rs60992370	chr6:107085676	A/C	cg27564810	chr2:201635376	AOX2P	0.5	6.61	0.51	1e-9	Stroke;
TGCT	cis	rs7226408	0.640	rs1968334	chr18:34343634	A/G	cg06757138	chr18:34340585	FHOD3	0.29	4.97	0.41	2.14e-6	Obesity-related traits;
TGCT	cis	rs1971762	0.762	rs7976793	chr12:54073069	G/T	cg09709951	chr12:54017699	ATF7	0.35	5.38	0.44	3.52e-7	Height;
TGCT	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg08439880	chr3:133502540	NA	-0.27	-4.96	-0.41	2.32e-6	Iron status biomarkers;
TGCT	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg09165964	chr15:75287851	SCAMP5	0.51	4.65	0.39	8.33e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
TGCT	cis	rs236907	0.859	rs6656852	chr1:171752373	A/G	cg20598894	chr1:171756153	METTL13	-0.19	-4.47	-0.37	1.72e-5	Mean platelet volume;
TGCT	trans	rs4650994	0.544	rs11579513	chr1:178496092	T/C	cg05059571	chr16:84539110	KIAA1609	-0.54	-11.23	-0.71	1.27e-20	HDL cholesterol levels;HDL cholesterol;
TGCT	trans	rs1974653	0.672	rs9606256	chr22:20108500	G/A	cg08822737	chr17:71088851	SLC39A11	-0.93	-7.65	-0.57	4.76e-12	Schizophrenia;
TGCT	cis	rs1153858	0.887	rs28569043	chr15:45730926	A/T	cg14582100	chr15:45693742	SPATA5L1	0.41	4.74	0.39	5.78e-6	Homoarginine levels;
TGCT	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg05368731	chr17:41323189	NBR1	1.21	14.63	0.8	8.89e-29	Menopause (age at onset);
TGCT	cis	rs7131987	0.903	rs67150462	chr12:29393325	T/C	cg09582351	chr12:29534625	ERGIC2	-0.23	-4.54	-0.38	1.33e-5	QT interval;
TGCT	cis	rs7647973	0.626	rs9824435	chr3:49674343	A/G	cg03060546	chr3:49711283	APEH	-0.64	-5.48	-0.44	2.25e-7	Menarche (age at onset);
TGCT	cis	rs250677	0.687	rs2915809	chr5:148452111	A/T	cg23229984	chr5:148520753	ABLIM3	0.21	4.89	0.4	3.11e-6	Breast cancer;
TGCT	cis	rs9911578	0.934	rs8081967	chr17:57072701	T/C	cg12560992	chr17:57184187	TRIM37	0.78	9.58	0.65	1.35e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs250677	0.687	rs36048	chr5:148441713	G/C	cg18129178	chr5:148520854	ABLIM3	-0.43	-6.29	-0.49	5.05e-9	Breast cancer;
TGCT	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg11764359	chr7:65958608	NA	0.61	5.53	0.44	1.84e-7	Aortic root size;
TGCT	cis	rs7043114	0.525	rs7853859	chr9:95151377	A/G	cg14631576	chr9:95140430	CENPP	-0.26	-4.57	-0.38	1.14e-5	Height;
TGCT	cis	rs7666738	0.830	rs17484890	chr4:99013778	T/C	cg18180107	chr4:99064573	C4orf37	0.52	4.85	0.4	3.57e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6681544	0.760	rs1475395	chr1:82411947	C/T	cg04226724	chr1:82268649	LPHN2	0.48	4.95	0.41	2.42e-6	Metabolite levels  (X-11787);
TGCT	cis	rs9467773	0.620	rs4368798	chr6:26593471	A/G	cg09904177	chr6:26538194	HMGN4	0.67	6.32	0.49	4.25e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs12549025	0.530	rs34297248	chr8:23364378	G/A	cg00472375	chr8:23315376	ENTPD4	0.62	5.37	0.43	3.72e-7	Reticulocyte fraction of red cells;
TGCT	cis	rs189918	1	rs189918	chr1:6737212	T/C	cg06778853	chr1:6672620	PHF13	-0.16	-4.46	-0.37	1.81e-5	Schizophrenia;
TGCT	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg11965913	chr1:205819406	PM20D1	0.53	7.56	0.56	7.72e-12	Menarche (age at onset);
TGCT	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg19318889	chr4:1322082	MAEA	0.27	6.56	0.51	1.28e-9	Longevity;
TGCT	cis	rs4242434	0.699	rs878053	chr8:22483849	T/C	cg03733263	chr8:22462867	KIAA1967	0.98	14.04	0.78	2.12e-27	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs7824557	0.564	rs12550129	chr8:11233917	C/T	cg21775007	chr8:11205619	TDH	-0.67	-6.55	-0.51	1.35e-9	Retinal vascular caliber;
TGCT	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg10047753	chr17:41438598	NA	0.91	8.44	0.6	6.86e-14	Menopause (age at onset);
TGCT	cis	rs4455778	0.743	rs28867851	chr7:49097556	A/G	cg26309511	chr7:48887640	NA	0.49	5.49	0.44	2.21e-7	Lung cancer in never smokers;
TGCT	cis	rs854765	0.647	rs2955366	chr17:18024013	A/G	cg04398451	chr17:18023971	MYO15A	-0.39	-6.89	-0.53	2.53e-10	Total body bone mineral density;
TGCT	trans	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg13615516	chr5:77269221	NA	0.68	8.54	0.61	3.97e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9467711	0.591	rs76091509	chr6:26706602	T/A	cg12315302	chr6:26189340	HIST1H4D	1.24	4.96	0.41	2.3e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12220898	0.749	rs11101076	chr10:50486539	G/A	cg06072769	chr10:50146962	WDFY4	0.38	5.07	0.41	1.38e-6	Inflammatory biomarkers;
TGCT	cis	rs62244186	0.659	rs9819766	chr3:44520980	G/C	cg15687855	chr3:44754131	ZNF502	-0.44	-5.18	-0.42	8.84e-7	Depressive symptoms;
TGCT	cis	rs6570726	0.934	rs430003	chr6:145819506	C/T	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9467773	1.000	rs9393728	chr6:26509330	C/G	cg15659132	chr6:26577336	NA	0.86	12.18	0.74	6.14e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs2153535	0.560	rs2210798	chr6:8481522	C/T	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs3741404	0.560	rs12362602	chr11:63908660	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.76	-7.29	-0.55	3.23e-11	Platelet count;
TGCT	cis	rs12497850	0.931	rs9840684	chr3:48893780	T/C	cg05785598	chr3:49045655	WDR6	0.36	4.75	0.39	5.46e-6	Parkinson's disease;
TGCT	trans	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg13615516	chr5:77269221	NA	-0.68	-8.11	-0.59	4.22e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs6450176	1.000	rs12521454	chr5:53297304	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.53	-5.12	-0.42	1.15e-6	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs9467773	0.620	rs2451737	chr6:26619041	T/C	cg02458000	chr6:26745757	NA	0.55	5.25	0.43	6.28e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2739330	0.964	rs2739338	chr22:24297130	T/C	cg04234412	chr22:24373322	LOC391322	-0.87	-10.27	-0.68	2.84e-18	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs617219	0.710	rs6874525	chr5:78574237	C/T	cg05890484	chr5:78407552	BHMT	-0.34	-4.63	-0.38	9.24e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs7264396	0.790	rs6060565	chr20:34285442	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.3	-5.31	-0.43	4.96e-7	Total cholesterol levels;
TGCT	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg10802521	chr3:52805072	NEK4	-0.78	-10.0	-0.67	1.26e-17	Bipolar disorder;
TGCT	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg13395646	chr4:1353034	KIAA1530	-0.36	-4.61	-0.38	9.75e-6	Obesity-related traits;
TGCT	cis	rs9911578	0.902	rs12948746	chr17:57071892	A/G	cg12560992	chr17:57184187	TRIM37	0.78	9.61	0.65	1.1e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg13695892	chr22:41940480	POLR3H	-0.9	-9.05	-0.63	2.43e-15	Vitiligo;
TGCT	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg27170947	chr2:26402098	FAM59B	-0.4	-4.58	-0.38	1.1e-5	Gut microbiome composition (summer);
TGCT	cis	rs79724016	1.000	rs11801716	chr1:42143899	C/T	cg14093106	chr1:42503579	NA	-0.66	-4.91	-0.4	2.78e-6	Breast cancer;
TGCT	cis	rs56104184	0.775	rs17272707	chr19:49404535	T/G	cg17863274	chr19:49399704	TULP2	-0.54	-7.43	-0.55	1.58e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs6121246	0.909	rs6060793	chr20:30288830	T/G	cg18721089	chr20:30220636	NA	-0.42	-4.65	-0.39	8.2e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs6840360	0.571	rs4696272	chr4:152528229	A/G	cg17479576	chr4:152424074	FAM160A1	-0.73	-7.94	-0.58	1.03e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs78487399	0.808	rs13396401	chr2:43701213	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-5.4	-0.44	3.21e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs2463822	0.920	rs72923207	chr11:62117959	A/G	cg06239285	chr11:62104954	ASRGL1	-0.94	-6.59	-0.51	1.15e-9	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg17554472	chr22:41940697	POLR3H	-0.47	-4.79	-0.4	4.68e-6	Vitiligo;
TGCT	cis	rs2963155	0.590	rs258757	chr5:142620736	A/G	cg17617527	chr5:142782415	NR3C1	-0.74	-5.9	-0.47	3.29e-8	Breast cancer;
TGCT	cis	rs11249608	0.548	rs17078991	chr5:178459426	A/C	cg01312482	chr5:178451176	ZNF879	-0.49	-4.85	-0.4	3.62e-6	Pubertal anthropometrics;
TGCT	cis	rs6542838	0.611	rs1976766	chr2:99522754	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.57	-5.46	-0.44	2.52e-7	Fear of minor pain;
TGCT	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.11	-7.29	-0.55	3.13e-11	Gut microbiome composition (summer);
TGCT	cis	rs9302001	0.883	rs1209118	chr13:95455315	C/G	cg07483244	chr13:95358924	NA	0.35	4.47	0.37	1.72e-5	Panic disorder;
TGCT	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.31	0.43	4.9e-7	Prudent dietary pattern;
TGCT	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg16680214	chr1:154839983	KCNN3	-0.36	-7.26	-0.55	3.81e-11	Prostate cancer;
TGCT	cis	rs7809950	0.953	rs1468336	chr7:107208250	T/C	cg23024343	chr7:107201750	COG5	0.35	5.32	0.43	4.76e-7	Coronary artery disease;
TGCT	cis	rs4700695	0.719	rs27085	chr5:65435063	C/T	cg21114390	chr5:65439923	SFRS12	0.85	7.52	0.56	9.85e-12	Facial morphology (factor 19);
TGCT	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	5.24	0.43	6.73e-7	Menopause (age at onset);
TGCT	cis	rs10509586	0.522	rs28719637	chr10:91689096	T/A	cg25278353	chr10:91717815	NA	0.43	5.13	0.42	1.08e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
TGCT	cis	rs1943345	0.642	rs11233500	chr11:82881407	C/T	cg07047830	chr11:82868014	PCF11	-0.52	-5.28	-0.43	5.68e-7	Obesity-related traits;
TGCT	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg06634786	chr22:41940651	POLR3H	0.86	8.19	0.59	2.71e-13	Vitiligo;
TGCT	cis	rs9916302	0.904	rs1077715	chr17:37683548	A/T	cg07936489	chr17:37558343	FBXL20	-0.61	-4.92	-0.4	2.69e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg23982607	chr1:1823379	GNB1	-0.56	-8.56	-0.61	3.65e-14	Body mass index;
TGCT	cis	rs6920965	0.583	rs9388456	chr6:126147197	C/T	cg05901451	chr6:126070800	HEY2	-0.62	-6.72	-0.52	5.97e-10	High light scatter reticulocyte count;
TGCT	cis	rs4851266	1.000	rs2871344	chr2:100839430	A/G	cg22139774	chr2:100720529	AFF3	-0.33	-5.03	-0.41	1.67e-6	Educational attainment;
TGCT	trans	rs656319	0.629	rs10111315	chr8:9865588	G/A	cg15556689	chr8:8085844	FLJ10661	-0.71	-6.62	-0.51	9.63e-10	Myopia (pathological);
TGCT	cis	rs17376456	0.932	rs3940842	chr5:93534858	C/A	cg25358565	chr5:93447407	FAM172A	0.93	7.91	0.58	1.22e-12	Diabetic retinopathy;
TGCT	cis	rs7666738	0.791	rs1896156	chr4:99020882	C/G	cg18180107	chr4:99064573	C4orf37	0.54	5.03	0.41	1.7e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8180040	0.587	rs62246398	chr3:47066203	A/C	cg27129171	chr3:47204927	SETD2	-0.71	-8.51	-0.61	4.8e-14	Colorectal cancer;
TGCT	cis	rs10791323	0.572	rs10894755	chr11:133739685	C/T	cg15485101	chr11:133734466	NA	-0.41	-5.92	-0.47	2.96e-8	Childhood ear infection;
TGCT	cis	rs9902453	0.817	rs55758314	chr17:28173978	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	7.17	0.54	5.79e-11	Coffee consumption (cups per day);
TGCT	cis	rs12210905	1.000	rs12214930	chr6:27093715	C/T	cg08851530	chr6:28072375	NA	1.21	5.58	0.45	1.43e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs9527	0.615	rs10883781	chr10:104581130	A/G	cg15744005	chr10:104629667	AS3MT	-0.5	-5.81	-0.46	4.91e-8	Arsenic metabolism;
TGCT	cis	rs7917772	0.503	rs7914389	chr10:104295402	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs6087771	0.926	rs6058431	chr20:30297133	C/T	cg13852791	chr20:30311386	BCL2L1	0.82	7.74	0.57	3.03e-12	Subcortical brain region volumes;Putamen volume;
TGCT	trans	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.88	-9.5	-0.65	2.02e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs2469997	1.000	rs2447179	chr8:120355775	A/G	cg00681363	chr8:120844660	TAF2	0.65	4.52	0.38	1.45e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg10047753	chr17:41438598	NA	0.92	8.71	0.62	1.57e-14	Menopause (age at onset);
TGCT	cis	rs7666738	0.830	rs921523	chr4:98841659	C/T	cg18180107	chr4:99064573	C4orf37	0.5	4.47	0.37	1.72e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs56399783	0.803	rs17132665	chr7:2802173	T/C	cg19731401	chr7:2775893	GNA12	0.35	5.07	0.41	1.38e-6	Childhood ear infection;
TGCT	cis	rs28595532	0.920	rs115860303	chr4:119734526	T/C	cg14228332	chr4:119757509	SEC24D	1.32	6.38	0.5	3.2e-9	Cannabis dependence symptom count;
TGCT	cis	rs7302981	0.967	rs7972842	chr12:50516323	G/T	cg23855989	chr12:50355821	AQP5	-0.3	-4.44	-0.37	2e-5	Systolic blood pressure;
TGCT	cis	rs9368481	0.700	rs6911401	chr6:26913214	C/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.47	4.92	0.4	2.72e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg24799795	chr11:5959658	NA	0.38	4.55	0.38	1.24e-5	DNA methylation (variation);
TGCT	cis	rs7621025	0.586	rs34553037	chr3:136379413	T/C	cg15507776	chr3:136538369	TMEM22	-0.51	-4.44	-0.37	2e-5	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
TGCT	cis	rs7044106	0.791	rs7036766	chr9:123479621	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	4.85	0.4	3.57e-6	Hip circumference adjusted for BMI;
TGCT	trans	rs208520	0.690	rs1233103	chr6:66855943	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-10.43	-0.68	1.13e-18	Exhaled nitric oxide output;
TGCT	cis	rs1949733	1.000	rs3103071	chr4:8508579	C/G	cg13073564	chr4:8508604	NA	0.46	4.83	0.4	3.89e-6	Response to antineoplastic agents;
TGCT	cis	rs10488031	0.867	rs17170841	chr7:37073212	G/C	cg06458904	chr7:36312573	EEPD1	0.51	4.5	0.37	1.54e-5	QT interval;
TGCT	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg04772025	chr11:68637568	NA	0.6	6.75	0.52	5.08e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs11948739	0.610	rs1363695	chr5:130378027	C/T	cg08523029	chr5:130500466	HINT1	-0.6	-4.91	-0.4	2.82e-6	Pediatric bone mineral content (hip);
TGCT	trans	rs2469997	0.858	rs1551785	chr8:120352397	T/A	cg01792902	chr3:178864926	PIK3CA	0.8	6.91	0.53	2.21e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs8017423	0.967	rs12889636	chr14:90689953	A/C	cg04374321	chr14:90722782	PSMC1	-0.76	-7.83	-0.58	1.9e-12	Mortality in heart failure;
TGCT	cis	rs894734	0.535	rs10783613	chr12:54321966	G/T	cg17708016	chr12:54321992	NA	0.69	5.69	0.46	8.48e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
TGCT	cis	rs727505	1.000	rs67939974	chr7:124554364	C/T	cg23710748	chr7:124431027	NA	-0.26	-4.49	-0.37	1.6e-5	Lewy body disease;
TGCT	cis	rs2346177	0.846	rs62138876	chr2:46650672	C/A	cg26688816	chr2:46740690	ATP6V1E2	-0.43	-4.79	-0.39	4.75e-6	HDL cholesterol;
TGCT	cis	rs11098499	0.604	rs17051352	chr4:120581427	G/A	cg09307838	chr4:120376055	NA	0.62	5.8	0.46	5.24e-8	Corneal astigmatism;
TGCT	cis	rs10791097	0.967	rs10894268	chr11:130717153	C/T	cg12179176	chr11:130786555	SNX19	0.65	6.88	0.53	2.63e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg19626725	chr5:178986131	RUFY1	-0.44	-5.61	-0.45	1.26e-7	Lung cancer;
TGCT	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg11764359	chr7:65958608	NA	-0.57	-5.25	-0.43	6.43e-7	Aortic root size;
TGCT	cis	rs17122693	0.748	rs72681636	chr14:51145871	G/T	cg04730355	chr14:51134070	SAV1	1.33	12.04	0.73	1.37e-22	Cognitive performance;
TGCT	cis	rs13064411	0.696	rs13325046	chr3:113104444	C/T	cg18753928	chr3:113234510	CCDC52	-0.73	-5.54	-0.45	1.72e-7	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs473651	0.935	rs477041	chr2:239355995	C/G	cg08773314	chr2:239334832	ASB1	-0.48	-8.19	-0.59	2.68e-13	Multiple system atrophy;
TGCT	cis	rs3020736	0.500	rs6002603	chr22:42492362	C/G	cg15557168	chr22:42548783	NA	0.22	5.47	0.44	2.34e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7267979	1.000	rs2027004	chr20:25350618	C/T	cg16686733	chr20:25566563	NINL	-0.59	-6.07	-0.48	1.42e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3008870	1.000	rs12039172	chr1:67447450	A/G	cg11518657	chr1:67396239	MIER1	-0.54	-4.61	-0.38	9.72e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs950169	0.580	rs17532346	chr15:85171495	A/C	cg11189052	chr15:85197271	WDR73	0.73	6.1	0.48	1.27e-8	Schizophrenia;
TGCT	cis	rs526231	0.819	rs26234	chr5:102597156	G/A	cg05225461	chr5:102596755	C5orf30	0.22	4.49	0.37	1.64e-5	Primary biliary cholangitis;
TGCT	cis	rs61990749	0.597	rs3783980	chr14:78219807	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	0.6	4.45	0.37	1.88e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs8064299	0.636	rs9915279	chr17:72772848	T/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.91	10.11	0.67	6.76e-18	Monocyte count;
TGCT	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg16145915	chr7:1198662	ZFAND2A	-0.42	-4.89	-0.4	3.08e-6	Longevity;Endometriosis;
TGCT	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg01570182	chr17:44337453	NA	1.09	10.0	0.67	1.26e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs929354	0.772	rs2023977	chr7:156996022	C/G	cg05182265	chr7:156933206	UBE3C	-0.39	-8.79	-0.62	1.03e-14	Body mass index;
TGCT	cis	rs637571	0.522	rs542332	chr11:65744421	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.65	6.4	0.5	2.96e-9	Eosinophil percentage of white cells;
TGCT	cis	rs11096990	0.634	rs6531706	chr4:39296167	T/C	cg20847110	chr4:39482781	LOC401127	-0.16	-4.51	-0.38	1.48e-5	Cognitive function;
TGCT	cis	rs9527	0.590	rs4917992	chr10:104786313	G/A	cg15744005	chr10:104629667	AS3MT	-0.42	-4.7	-0.39	6.75e-6	Arsenic metabolism;
TGCT	cis	rs9560113	0.960	rs950891	chr13:112173992	G/A	cg10483660	chr13:112241077	NA	-0.33	-4.77	-0.39	5.11e-6	Menarche (age at onset);
TGCT	cis	rs1059312	0.771	rs11059922	chr12:129290418	C/T	cg09035930	chr12:129282057	SLC15A4	0.55	10.73	0.69	2.06e-19	Systemic lupus erythematosus;
TGCT	cis	rs9486719	1.000	rs12207570	chr6:96987884	A/C	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.43	-0.44	2.89e-7	Migraine;Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs3907020	chr4:99038583	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.94	0.47	2.68e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2836950	0.520	rs2836966	chr21:40637521	A/G	cg11644478	chr21:40555479	PSMG1	-0.56	-5.22	-0.42	7.38e-7	Menarche (age at onset);
TGCT	cis	rs911555	0.713	rs2765051	chr14:103972379	T/C	cg23461800	chr14:103021989	NA	-0.35	-4.51	-0.38	1.5e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs9467773	0.620	rs1027203	chr6:26639332	G/C	cg26531700	chr6:26746687	NA	0.61	5.84	0.46	4.23e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7937682	0.632	rs4936834	chr11:111764017	T/A	cg09085632	chr11:111637200	PPP2R1B	0.83	7.15	0.54	6.45e-11	Primary sclerosing cholangitis;
TGCT	trans	rs797680	0.861	rs612037	chr1:93682878	G/A	cg27528825	chr2:159282178	CCDC148	0.34	6.7	0.52	6.63e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs1385374	0.858	rs959989	chr12:129292708	A/T	cg09035930	chr12:129282057	SLC15A4	-0.55	-4.76	-0.39	5.27e-6	Systemic lupus erythematosus;
TGCT	cis	rs6978712	1.000	rs6962032	chr7:127151489	G/A	cg01017541	chr7:127776461	NA	0.76	4.6	0.38	1.01e-5	Medication adherence in chronic diseases;
TGCT	cis	rs921968	0.509	rs556468	chr2:219355794	G/A	cg02176678	chr2:219576539	TTLL4	0.48	6.78	0.52	4.32e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs4478858	0.735	rs7523509	chr1:31788329	A/G	cg00250761	chr1:31883323	NA	-0.27	-4.76	-0.39	5.29e-6	Alcohol dependence;
TGCT	cis	rs9457247	1.000	rs1794693	chr6:167405670	T/C	cg23791538	chr6:167370224	RNASET2	-0.49	-4.96	-0.41	2.26e-6	Crohn's disease;
TGCT	cis	rs7586879	1.000	rs12713419	chr2:25121853	G/A	cg01884057	chr2:25150051	NA	0.29	5.15	0.42	9.75e-7	Body mass index;
TGCT	cis	rs9611565	1.000	rs5758314	chr22:41762523	T/G	cg17554472	chr22:41940697	POLR3H	-0.4	-4.47	-0.37	1.73e-5	Vitiligo;
TGCT	cis	rs896854	0.818	rs13262110	chr8:95926890	C/T	cg13393036	chr8:95962371	TP53INP1	-0.59	-7.96	-0.58	9.23e-13	Type 2 diabetes;
TGCT	cis	rs8017423	0.967	rs7154683	chr14:90700692	A/G	cg04374321	chr14:90722782	PSMC1	0.77	8.05	0.59	5.68e-13	Mortality in heart failure;
TGCT	cis	rs79349575	0.783	rs59270107	chr17:47026185	A/T	cg26022315	chr17:47021804	SNF8	0.49	4.9	0.4	2.94e-6	Type 2 diabetes;
TGCT	cis	rs6121246	0.529	rs112367115	chr20:30178627	G/A	cg13852791	chr20:30311386	BCL2L1	0.71	4.54	0.38	1.31e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs2243480	1.000	rs4718269	chr7:65200778	C/G	cg07424592	chr7:64974309	NA	-1.33	-7.99	-0.58	7.81e-13	Diabetic kidney disease;
TGCT	cis	rs2439831	0.867	rs2412778	chr15:43660982	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	8.65	0.61	2.26e-14	Lung cancer in ever smokers;
TGCT	cis	rs7731657	0.537	rs10066004	chr5:130304689	G/A	cg08523029	chr5:130500466	HINT1	-0.59	-4.8	-0.4	4.4e-6	Fasting plasma glucose;
TGCT	cis	rs459571	0.629	rs441233	chr9:136876021	A/G	cg14405625	chr9:136855902	VAV2	0.33	4.87	0.4	3.34e-6	Platelet distribution width;
TGCT	cis	rs13188771	0.651	rs10515312	chr5:100906519	G/T	cg10455971	chr5:101119566	NA	0.44	4.45	0.37	1.87e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs3849570	0.732	rs11715625	chr3:81875938	A/T	cg07356753	chr3:81810745	GBE1	-0.6	-5.31	-0.43	4.92e-7	Waist circumference;Body mass index;
TGCT	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg20007245	chr22:24372913	LOC391322	-0.72	-7.42	-0.55	1.64e-11	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7666738	0.830	rs7672127	chr4:98938477	A/G	cg17366294	chr4:99064904	C4orf37	0.74	7.58	0.56	7.02e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7772486	0.688	rs1884364	chr6:146337817	C/G	cg23711669	chr6:146136114	FBXO30	0.66	6.24	0.49	6.25e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2120019	0.567	rs28844983	chr15:75178088	T/A	cg09165964	chr15:75287851	SCAMP5	-0.88	-7.07	-0.54	9.73e-11	Blood trace element (Zn levels);
TGCT	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg00484396	chr16:3507460	NAT15	0.41	6.02	0.48	1.82e-8	Tuberculosis;
TGCT	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg06028605	chr16:24865363	SLC5A11	-0.41	-4.58	-0.38	1.13e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg13665807	chr20:60559372	TAF4	-0.46	-4.9	-0.4	2.87e-6	Body mass index;
TGCT	trans	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg17830980	chr10:43048298	ZNF37B	-0.84	-10.72	-0.69	2.25e-19	Extrinsic epigenetic age acceleration;
TGCT	cis	rs12188164	0.515	rs11744936	chr5:412112	C/T	cg22025206	chr5:502436	SLC9A3	-0.28	-4.9	-0.4	2.96e-6	Cystic fibrosis severity;
TGCT	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg21237687	chr17:6899380	ALOX12	0.52	5.78	0.46	5.57e-8	Tonsillectomy;
TGCT	cis	rs2239547	0.657	rs6445538	chr3:52874288	T/C	cg11645453	chr3:52864694	ITIH4	0.35	5.88	0.47	3.57e-8	Schizophrenia;
TGCT	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg09359103	chr1:154839909	KCNN3	-0.64	-12.27	-0.74	3.87e-23	Prostate cancer;
TGCT	cis	rs6087990	0.806	rs1474738	chr20:31380309	G/A	cg13636640	chr20:31349939	DNMT3B	1.01	13.26	0.77	1.6e-25	Ulcerative colitis;
TGCT	trans	rs117132860	0.661	rs4329181	chr7:17108209	G/T	cg25519926	chr7:130132360	MEST;MESTIT1	0.95	6.9	0.53	2.32e-10	Cutaneous squamous cell carcinoma;
TGCT	cis	rs7000551	0.725	rs2443496	chr8:22365788	G/A	cg12081754	chr8:22256438	SLC39A14	0.28	4.48	0.37	1.68e-5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs9611565	0.559	rs5751160	chr22:42175695	A/G	cg06481639	chr22:41940642	POLR3H	0.69	6.05	0.48	1.59e-8	Vitiligo;
TGCT	cis	rs7666738	0.546	rs17546687	chr4:98769266	T/A	cg05340658	chr4:99064831	C4orf37	0.52	5.7	0.46	8.44e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9399135	0.967	rs9389261	chr6:135371148	C/G	cg24558204	chr6:135376177	HBS1L	0.46	4.55	0.38	1.24e-5	Red blood cell count;
TGCT	cis	rs4319547	0.698	rs4039670	chr12:122822655	A/G	cg08088222	chr12:122070432	ORAI1	0.26	4.66	0.39	8.01e-6	Body mass index;
TGCT	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg25767906	chr1:53392781	SCP2	-0.6	-7.71	-0.57	3.49e-12	Monocyte count;
TGCT	cis	rs7666738	0.546	rs3911415	chr4:98692401	T/A	cg05340658	chr4:99064831	C4orf37	0.52	5.75	0.46	6.63e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9902453	0.845	rs2259855	chr17:28097860	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-7.19	-0.54	5.27e-11	Coffee consumption (cups per day);
TGCT	cis	rs1005277	0.505	rs200939	chr10:38139483	T/C	cg13531842	chr10:38383804	ZNF37A	-0.39	-4.59	-0.38	1.07e-5	Extrinsic epigenetic age acceleration;
TGCT	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg03709012	chr19:19516395	GATAD2A	0.76	6.42	0.5	2.64e-9	Tonsillectomy;
TGCT	cis	rs3806843	0.576	rs246027	chr5:140333601	A/G	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs3820068	0.581	rs72645874	chr1:15926238	C/G	cg05660106	chr1:15850417	CASP9	0.82	8.02	0.58	6.63e-13	Systolic blood pressure;
TGCT	cis	rs1488864	1.000	rs1973312	chr11:6352121	G/A	cg12755421	chr11:6342214	PRKCDBP	-0.6	-4.51	-0.38	1.47e-5	Smooth-surface caries;
TGCT	cis	rs881375	0.678	rs2269060	chr9:123683569	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	4.96	0.41	2.3e-6	Rheumatoid arthritis;
TGCT	cis	rs41271951	0.512	rs7537292	chr1:151071038	C/G	cg00666978	chr1:150947442	LASS2	0.89	4.64	0.38	8.54e-6	Blood protein levels;
TGCT	cis	rs9611565	0.572	rs139569	chr22:42211141	A/G	cg13695892	chr22:41940480	POLR3H	-0.79	-7.5	-0.56	1.04e-11	Vitiligo;
TGCT	cis	rs7829975	0.514	rs2979139	chr8:8268313	A/G	cg06636001	chr8:8085503	FLJ10661	0.72	6.28	0.49	5.23e-9	Mood instability;
TGCT	cis	rs13191362	0.810	rs13200053	chr6:163011443	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	trans	rs561341	1.000	rs506766	chr17:30289659	T/C	cg20587970	chr11:113659929	NA	-1.03	-10.74	-0.69	1.99e-19	Hip circumference adjusted for BMI;
TGCT	cis	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg04013166	chr16:89971882	TCF25	0.32	4.72	0.39	6.22e-6	Skin colour saturation;
TGCT	cis	rs1865760	0.516	rs9393684	chr6:26075531	G/C	cg16482183	chr6:26056742	HIST1H1C	0.57	4.99	0.41	1.96e-6	Height;
TGCT	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg04944784	chr2:26401820	FAM59B	-0.68	-6.07	-0.48	1.45e-8	Gut microbiome composition (summer);
TGCT	cis	rs68170813	0.559	rs6946036	chr7:106853659	G/A	cg02696742	chr7:106810147	HBP1	-0.69	-5.61	-0.45	1.27e-7	Coronary artery disease;
TGCT	cis	rs2153535	0.542	rs9505465	chr6:8510846	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.49e-8	Motion sickness;
TGCT	cis	rs4285028	0.948	rs12497349	chr3:121708517	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.77	-6.5	-0.5	1.78e-9	Multiple sclerosis;
TGCT	cis	rs6570726	0.846	rs409553	chr6:145886963	C/T	cg05347473	chr6:146136440	FBXO30	0.51	4.78	0.39	4.8e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3008870	0.959	rs2985826	chr1:67412918	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.1	11.91	0.73	2.83e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs151997	0.629	rs27288	chr5:50194920	T/A	cg06027927	chr5:50259733	NA	0.56	5.78	0.46	5.72e-8	Callous-unemotional behaviour;
TGCT	cis	rs12579753	1.000	rs12367791	chr12:82237278	C/T	cg07988820	chr12:82153109	PPFIA2	-0.61	-6.52	-0.51	1.62e-9	Resting heart rate;
TGCT	cis	rs6500602	0.787	rs7204624	chr16:4459834	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	6.34	0.49	3.97e-9	Schizophrenia;
TGCT	cis	rs62244186	0.545	rs9284880	chr3:44759389	C/T	cg04389838	chr3:44770851	ZNF501	-0.38	-4.83	-0.4	4.01e-6	Depressive symptoms;
TGCT	cis	rs11673344	0.542	rs826325	chr19:37494482	A/G	cg08039142	chr19:36980659	ZNF566	0.57	5.36	0.43	3.88e-7	Obesity-related traits;
TGCT	cis	rs12220238	1.000	rs10824101	chr10:75947438	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.28	0.55	3.4e-11	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs7772486	0.719	rs702307	chr6:145993454	C/G	cg05347473	chr6:146136440	FBXO30	-0.53	-4.97	-0.41	2.18e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs34754277	0.636	rs1627787	chr1:118165973	C/T	cg11819305	chr1:117910798	MAN1A2	-0.5	-4.46	-0.37	1.8e-5	Immature fraction of reticulocytes;
TGCT	cis	rs1577917	1.000	rs34106666	chr6:86676258	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.16	-0.42	9.39e-7	Response to antipsychotic treatment;
TGCT	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs35883536	0.551	rs6666607	chr1:101032368	A/G	cg06223162	chr1:101003688	GPR88	-0.42	-7.96	-0.58	9.26e-13	Monocyte count;
TGCT	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs8044995	0.563	rs55968019	chr16:68398111	G/A	cg05110241	chr16:68378359	PRMT7	-0.36	-4.46	-0.37	1.84e-5	Schizophrenia;
TGCT	cis	rs17345786	0.861	rs11711808	chr3:101235101	T/C	cg12386194	chr3:101231763	SENP7	0.64	5.97	0.47	2.28e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7027203	0.576	rs4415381	chr9:96554603	A/G	cg13679303	chr9:96623674	NA	0.53	7.61	0.56	6.13e-12	DNA methylation (variation);
TGCT	cis	rs9788721	0.836	rs17483548	chr15:78730313	G/A	cg18825076	chr15:78729989	IREB2	-0.35	-5.22	-0.42	7.15e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
TGCT	cis	rs754133	0.535	rs7315495	chr12:54440445	A/T	cg16264616	chr12:54390824	NA	0.37	5.19	0.42	8.34e-7	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;
TGCT	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg23758822	chr17:41437982	NA	0.73	7.14	0.54	6.88e-11	Menopause (age at onset);
TGCT	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg04744514	chr10:134541379	INPP5A	-0.25	-4.63	-0.38	9.09e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	9.51	0.65	1.99e-16	Platelet count;
TGCT	cis	rs853679	0.527	rs9461443	chr6:28194629	A/T	cg12963246	chr6:28129442	ZNF389	0.46	4.52	0.38	1.43e-5	Depression;
TGCT	cis	rs9393777	0.513	rs7759969	chr6:26663096	T/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.59	-4.66	-0.39	8.03e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs5769707	0.967	rs9616713	chr22:50049109	G/A	cg05373962	chr22:49881684	NA	-0.31	-6.31	-0.49	4.55e-9	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg06238570	chr21:40685208	BRWD1	0.7	6.46	0.5	2.16e-9	Cognitive function;
TGCT	cis	rs7666738	0.830	rs28867087	chr4:98880349	T/A	cg17366294	chr4:99064904	C4orf37	0.74	7.62	0.56	5.55e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs57506017	0.585	rs5011439	chr7:12268811	G/C	cg07541786	chr7:12610355	SCIN	0.45	4.58	0.38	1.12e-5	Neuroticism;
TGCT	cis	rs13082711	0.558	rs640912	chr3:27364092	C/A	cg02860705	chr3:27208620	NA	0.29	4.66	0.39	8.01e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs7617773	0.780	rs36075665	chr3:48343087	C/T	cg11946769	chr3:48343235	NME6	0.82	7.09	0.54	9.1e-11	Coronary artery disease;
TGCT	cis	rs9914988	0.778	rs9907185	chr17:27122414	C/T	cg20469991	chr17:27169893	C17orf63	-0.72	-5.04	-0.41	1.58e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs1406084	0.636	rs12693840	chr2:154724799	A/G	cg25703346	chr2:154729189	GALNT13	0.77	4.6	0.38	1.03e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12188164	1.000	rs56042615	chr5:437667	G/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.4	-4.76	-0.39	5.33e-6	Cystic fibrosis severity;
TGCT	cis	rs1865760	0.963	rs1540273	chr6:25924158	T/C	cg16482183	chr6:26056742	HIST1H1C	0.51	4.59	0.38	1.06e-5	Height;
TGCT	cis	rs2404602	0.692	rs56193230	chr15:76934472	C/T	cg22467129	chr15:76604101	ETFA	-0.45	-5.11	-0.42	1.18e-6	Blood metabolite levels;
TGCT	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg08280861	chr8:58055591	NA	-0.37	-4.8	-0.4	4.41e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10875746	0.729	rs11168355	chr12:48410978	A/G	cg20731937	chr12:48336164	NA	-0.63	-5.34	-0.43	4.25e-7	Longevity (90 years and older);
TGCT	cis	rs4253772	0.591	rs8143066	chr22:46656607	C/T	cg09491104	chr22:46646882	C22orf40	-0.63	-6.39	-0.5	3.05e-9	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs556990	0.760	rs3024739	chr13:113819948	G/A	cg00898013	chr13:113819073	PROZ	-0.51	-6.13	-0.48	1.06e-8	Blood protein levels;
TGCT	cis	rs17059066	0.764	rs11962398	chr6:130622609	C/T	cg25049486	chr6:130544510	SAMD3	0.38	4.52	0.38	1.41e-5	Mosquito bite size;
TGCT	cis	rs11792861	0.591	rs2275641	chr9:111696389	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.67	7.67	0.57	4.34e-12	Menarche (age at onset);
TGCT	cis	rs1887596	0.672	rs4771002	chr13:27201568	A/G	cg01312412	chr13:27282625	NA	0.3	5.31	0.43	4.89e-7	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs6684514	1.000	rs2277870	chr1:156246792	C/T	cg20302342	chr1:156215951	PAQR6	0.34	4.6	0.38	1.01e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs826838	0.967	rs1719856	chr12:39127201	C/T	cg26384229	chr12:38710491	ALG10B	-0.86	-7.72	-0.57	3.37e-12	Heart rate;
TGCT	cis	rs56104184	0.775	rs56146968	chr19:49398847	A/G	cg21252483	chr19:49399788	TULP2	-0.42	-5.89	-0.47	3.47e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs909674	0.818	rs5757680	chr22:39844793	C/T	cg01416388	chr22:39784598	NA	0.69	6.32	0.49	4.37e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg20276088	chr3:133502917	NA	0.28	6.07	0.48	1.42e-8	Iron status biomarkers;
TGCT	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg18876405	chr7:65276391	NA	0.36	5.36	0.43	3.97e-7	Aortic root size;
TGCT	cis	rs3540	0.512	rs3862434	chr15:91080387	C/T	cg22089800	chr15:90895588	ZNF774	0.76	7.91	0.58	1.21e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs10927875	0.541	rs1048237	chr1:16341733	T/C	cg22431228	chr1:16359049	CLCNKA	-0.29	-6.07	-0.48	1.42e-8	Dilated cardiomyopathy;
TGCT	cis	rs1532993	0.518	rs1508469	chr4:98575375	T/C	cg05340658	chr4:99064831	C4orf37	-0.42	-5.05	-0.41	1.57e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs7917772	0.582	rs10786684	chr10:104323028	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.59	-5.73	-0.46	7.1e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs55883249	1.000	rs55883249	chr2:9741535	C/A	cg23886495	chr2:9695866	ADAM17	0.82	5.01	0.41	1.86e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs7635838	0.718	rs2594991	chr3:11362704	G/A	cg00170343	chr3:11313890	ATG7	0.62	6.09	0.48	1.28e-8	HDL cholesterol;
TGCT	cis	rs4794202	0.534	rs8078688	chr17:45919869	T/C	cg02219949	chr17:45927392	SP6	0.37	4.47	0.37	1.76e-5	Alzheimer's disease (cognitive decline);
TGCT	cis	rs10504229	0.679	rs1442125	chr8:58036258	A/C	cg08280861	chr8:58055591	NA	-0.34	-5.01	-0.41	1.81e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs539096	0.602	rs1143702	chr1:44086831	C/T	cg12908607	chr1:44402522	ARTN	-0.43	-4.8	-0.4	4.43e-6	Intelligence (multi-trait analysis);
TGCT	trans	rs4332037	0.539	rs11764590	chr7:2032803	C/T	cg25206134	chr2:45395956	NA	0.97	7.33	0.55	2.6e-11	Bipolar disorder;
TGCT	cis	rs892961	0.932	rs11657961	chr17:75405407	C/T	cg05865280	chr17:75406074	SEPT9	0.29	6.76	0.52	4.91e-10	Airflow obstruction;
TGCT	trans	rs62103177	0.513	rs9945153	chr18:77598450	C/T	cg05926928	chr17:57297772	GDPD1	1.22	11.62	0.72	1.41e-21	Opioid sensitivity;
TGCT	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	8.99	0.63	3.48e-15	Platelet count;
TGCT	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg11644478	chr21:40555479	PSMG1	-0.56	-5.22	-0.42	7.38e-7	Menarche (age at onset);
TGCT	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg01341218	chr17:43662625	NA	1.11	9.15	0.63	1.43e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs6723226	0.803	rs176415	chr2:32649778	G/A	cg02381751	chr2:32503542	YIPF4	-0.57	-5.13	-0.42	1.09e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg25811766	chr13:21894605	NA	0.26	5.27	0.43	5.79e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	cis	rs4455778	0.659	rs12673347	chr7:49025613	C/G	cg26309511	chr7:48887640	NA	0.44	5.31	0.43	4.87e-7	Lung cancer in never smokers;
TGCT	cis	rs2439831	0.867	rs4075674	chr15:43650230	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	8.65	0.61	2.26e-14	Lung cancer in ever smokers;
TGCT	cis	rs6674970	0.501	rs6691701	chr1:151001583	G/A	cg00666978	chr1:150947442	LASS2	-0.56	-4.46	-0.37	1.78e-5	Childhood ear infection;
TGCT	cis	rs7100689	0.646	rs10466235	chr10:82149655	C/T	cg01528321	chr10:82214614	TSPAN14	-0.69	-7.02	-0.53	1.27e-10	Post bronchodilator FEV1;
TGCT	cis	rs36051895	0.623	rs7847811	chr9:5237081	T/C	cg02405213	chr9:5042618	JAK2	-0.68	-8.01	-0.58	7.18e-13	Pediatric autoimmune diseases;
TGCT	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg01802117	chr1:53393560	SCP2	-0.44	-5.23	-0.43	6.9e-7	Monocyte count;
TGCT	cis	rs7666738	0.753	rs13122897	chr4:98936185	C/A	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7666738	0.830	rs13138063	chr4:99050438	A/C	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1008375	0.898	rs4698620	chr4:17587361	C/T	cg10189774	chr4:17578691	LAP3	0.64	5.61	0.45	1.28e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	trans	rs2727020	0.729	rs4315497	chr11:49214499	G/A	cg15704280	chr7:45808275	SEPT13	0.7	7.71	0.57	3.59e-12	Coronary artery disease;
TGCT	cis	rs11078884	0.527	rs2760748	chr17:2001604	T/A	cg21733020	chr17:2599052	KIAA0664	0.33	4.76	0.39	5.4e-6	Metabolite levels (5-HIAA);
TGCT	trans	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg23505145	chr19:12996616	KLF1	0.78	8.12	0.59	4.03e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg24250549	chr1:154909240	PMVK	0.62	6.21	0.49	7.36e-9	Prostate cancer;
TGCT	cis	rs4699052	0.507	rs7662107	chr4:104258396	C/T	cg16532752	chr4:104119610	CENPE	-0.7	-6.07	-0.48	1.45e-8	Testicular germ cell tumor;
TGCT	cis	rs9916302	0.706	rs4488484	chr17:37717377	A/T	cg03321784	chr17:37729644	NA	-0.44	-4.49	-0.37	1.6e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs7178572	0.568	rs11632941	chr15:77533888	A/G	cg22256960	chr15:77711686	NA	-0.85	-8.73	-0.62	1.4e-14	Type 2 diabetes;
TGCT	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg25767906	chr1:53392781	SCP2	-0.51	-6.21	-0.49	7.42e-9	Monocyte count;
TGCT	cis	rs6693567	0.565	rs12739706	chr1:150261653	C/G	cg09579323	chr1:150459698	TARS2	-0.53	-4.81	-0.4	4.38e-6	Migraine;
TGCT	cis	rs9611565	0.592	rs5758405	chr22:42076381	C/A	cg06634786	chr22:41940651	POLR3H	0.9	9.03	0.63	2.7e-15	Vitiligo;
TGCT	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg10047753	chr17:41438598	NA	0.92	8.63	0.61	2.49e-14	Menopause (age at onset);
TGCT	cis	rs611744	0.503	rs13282220	chr8:109263043	T/C	cg21045802	chr8:109455806	TTC35	0.7	6.88	0.53	2.63e-10	Dupuytren's disease;
TGCT	cis	rs9325144	0.647	rs4616077	chr12:39092364	T/C	cg10518543	chr12:38710700	ALG10B	-0.49	-4.58	-0.38	1.11e-5	Morning vs. evening chronotype;
TGCT	cis	rs17162190	0.590	rs4659374	chr1:26779270	C/T	cg02450742	chr1:26856648	RPS6KA1	-0.56	-4.68	-0.39	7.47e-6	Mean corpuscular volume;
TGCT	cis	rs9926296	0.682	rs645019	chr16:89716883	C/T	cg03388025	chr16:89894329	SPIRE2	-0.35	-5.19	-0.42	8.38e-7	Vitiligo;
TGCT	cis	rs7666738	0.830	rs7691864	chr4:98971376	G/C	cg18180107	chr4:99064573	C4orf37	0.53	4.89	0.4	3.01e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7607369	0.791	rs72965151	chr2:219344165	G/T	cg02176678	chr2:219576539	TTLL4	-0.48	-6.79	-0.52	4.17e-10	Red blood cell count;Amyotrophic lateral sclerosis;
TGCT	cis	rs473651	0.503	rs515342	chr2:239367296	A/G	cg18131467	chr2:239335373	ASB1	-0.86	-7.24	-0.55	4.1e-11	Multiple system atrophy;
TGCT	cis	rs514406	0.505	rs431427	chr1:53179094	C/A	cg16325326	chr1:53192061	ZYG11B	0.85	12.13	0.74	8.13e-23	Monocyte count;
TGCT	cis	rs11085466	1.000	rs73552479	chr19:21778816	G/T	cg02997983	chr19:21646781	NA	-0.6	-4.6	-0.38	1.03e-5	Colorectal or endometrial cancer;
TGCT	cis	rs7940866	0.845	rs1991899	chr11:130801649	C/T	cg12179176	chr11:130786555	SNX19	-0.56	-5.64	-0.45	1.1e-7	Schizophrenia;
TGCT	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg04025307	chr7:1156635	C7orf50	0.23	5.55	0.45	1.64e-7	Longevity;Endometriosis;
TGCT	cis	rs10484885	0.775	rs17584945	chr6:90512776	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.47	-4.51	-0.38	1.46e-5	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs2898290	0.617	rs13273172	chr8:11461111	A/G	cg21775007	chr8:11205619	TDH	-0.47	-4.52	-0.38	1.41e-5	Systolic blood pressure;
TGCT	cis	rs7590720	1.000	rs4674051	chr2:216907512	G/C	cg12620499	chr2:216877984	MREG	0.88	8.99	0.63	3.55e-15	Alcohol dependence;
TGCT	cis	rs4727027	0.866	rs7778766	chr7:148806729	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	4.6	0.38	1.04e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs2274273	0.622	rs11846809	chr14:55401782	T/C	cg01923255	chr14:55878535	KIAA0831	0.53	4.53	0.38	1.36e-5	Protein biomarker;
TGCT	cis	rs826838	0.802	rs10785619	chr12:38742897	T/A	cg13010199	chr12:38710504	ALG10B	0.68	5.53	0.44	1.79e-7	Heart rate;
TGCT	cis	rs7043114	0.563	rs7848391	chr9:95337520	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.53	-5.23	-0.42	7.08e-7	Height;
TGCT	cis	rs7208859	0.673	rs57432042	chr17:29241038	T/C	cg18442181	chr17:29233375	C17orf42	-0.77	-4.49	-0.37	1.6e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7542091	0.669	rs11119357	chr1:210042382	C/T	cg22029157	chr1:209979665	IRF6	0.65	6.27	0.49	5.56e-9	Monobrow;
TGCT	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg25703541	chr22:24373054	LOC391322	0.85	7.26	0.55	3.8e-11	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs7698623	0.850	rs1381958	chr4:88796785	T/C	cg27387453	chr4:88533842	DSPP	-0.61	-4.6	-0.38	1.03e-5	Cardiovascular disease risk factors;
TGCT	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg23758822	chr17:41437982	NA	0.72	6.96	0.53	1.79e-10	Menopause (age at onset);
TGCT	cis	rs2797160	0.905	rs1418641	chr6:125999854	C/T	cg05901451	chr6:126070800	HEY2	-0.74	-6.48	-0.5	1.96e-9	Endometrial cancer;
TGCT	cis	rs877282	0.891	rs11253355	chr10:768367	C/G	cg17470449	chr10:769945	NA	0.34	5.15	0.42	9.77e-7	Uric acid levels;
TGCT	cis	rs2797160	0.967	rs1739355	chr6:126018114	A/G	cg05901451	chr6:126070800	HEY2	0.73	6.29	0.49	5.01e-9	Endometrial cancer;
TGCT	cis	rs2456568	0.867	rs1827931	chr11:93663170	T/C	cg17595323	chr11:93583763	C11orf90	-0.46	-5.85	-0.47	4e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7666738	0.716	rs2865982	chr4:99031661	T/G	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2836974	0.583	rs2776306	chr21:40713754	A/G	cg17971929	chr21:40555470	PSMG1	0.61	5.62	0.45	1.22e-7	Cognitive function;
TGCT	cis	rs910316	0.737	rs175499	chr14:75535927	G/A	cg11812906	chr14:75593930	NEK9	-0.62	-5.7	-0.46	8.15e-8	Height;
TGCT	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg03452623	chr4:187889614	NA	-0.38	-5.66	-0.45	9.76e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1371867	1.000	rs1371867	chr8:101330209	A/C	cg06002616	chr8:101225028	SPAG1	-0.48	-5.6	-0.45	1.29e-7	Atrioventricular conduction;
TGCT	cis	rs7010267	0.596	rs6996754	chr8:120034870	T/C	cg17171407	chr8:119960777	TNFRSF11B	0.26	4.59	0.38	1.06e-5	Total body bone mineral density (age 45-60);
TGCT	cis	rs617219	0.698	rs12189248	chr5:78517143	A/G	cg09550809	chr5:78407562	BHMT	-0.43	-5.95	-0.47	2.51e-8	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs7412746	0.622	rs72704654	chr1:150826410	G/A	cg04414720	chr1:150670196	GOLPH3L	0.39	4.75	0.39	5.55e-6	Melanoma;
TGCT	cis	rs2066819	1.000	rs77131854	chr12:56664231	C/T	cg26714650	chr12:56694279	CS	-1.36	-6.06	-0.48	1.54e-8	Psoriasis vulgaris;
TGCT	cis	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg20637647	chr7:64974828	NA	0.89	4.99	0.41	2.01e-6	Diabetic kidney disease;
TGCT	cis	rs9814567	0.963	rs9844537	chr3:134238341	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.92	-9.2	-0.64	1.11e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs736408	0.812	rs2071506	chr3:52826276	T/C	cg07507251	chr3:52567010	NT5DC2	0.45	5.99	0.47	2.1e-8	Bipolar disorder;
TGCT	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg04414720	chr1:150670196	GOLPH3L	0.39	5.04	0.41	1.59e-6	Tonsillectomy;
TGCT	cis	rs10206020	0.885	rs11887527	chr2:1578080	A/G	cg01028140	chr2:1542097	TPO	-0.28	-4.51	-0.38	1.47e-5	IgG glycosylation;
TGCT	cis	rs9467773	0.620	rs1490488	chr6:26614808	T/C	cg11502198	chr6:26597334	ABT1	0.53	4.93	0.41	2.53e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2486012	0.826	rs2993621	chr1:44372291	T/C	cg12908607	chr1:44402522	ARTN	0.71	5.86	0.47	3.87e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2299587	0.543	rs12546204	chr8:17796871	A/C	cg01800426	chr8:17659068	MTUS1	-0.63	-5.39	-0.44	3.41e-7	Economic and political preferences;
TGCT	cis	rs12142240	0.698	rs41293273	chr1:46806393	T/C	cg14993813	chr1:46806288	NSUN4	-0.58	-4.78	-0.39	4.78e-6	Menopause (age at onset);
TGCT	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg00684032	chr4:1343700	KIAA1530	0.24	4.93	0.41	2.53e-6	Obesity-related traits;
TGCT	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg21862992	chr11:68658383	NA	0.44	6.01	0.47	1.93e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs6540559	0.673	rs4556361	chr1:210019654	C/G	cg21951975	chr1:209979733	IRF6	-0.6	-4.61	-0.38	9.67e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs1372520	0.684	rs2619347	chr4:90745770	G/A	cg20003494	chr4:90757398	SNCA	-0.63	-5.09	-0.42	1.3e-6	Neuroticism;
TGCT	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg19901468	chr14:105411992	AHNAK2	-0.28	-6.09	-0.48	1.31e-8	Rheumatoid arthritis;
TGCT	cis	rs2847281	0.614	rs888269	chr18:12774860	G/C	cg23598886	chr18:12777645	NA	0.37	4.69	0.39	7.07e-6	C-reactive protein levels;Esophageal cancer (squamous cell);
TGCT	cis	rs7208859	0.623	rs122898	chr17:28905254	C/T	cg13385521	chr17:29058706	SUZ12P	-0.8	-4.89	-0.4	3.12e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg06221963	chr1:154839813	KCNN3	-0.75	-12.65	-0.75	4.66e-24	Prostate cancer;
TGCT	cis	rs4700695	0.614	rs930066	chr5:65207836	G/A	cg21114390	chr5:65439923	SFRS12	0.67	4.69	0.39	7.07e-6	Facial morphology (factor 19);
TGCT	cis	rs4776059	1.000	rs12914047	chr15:52970993	G/A	cg25063058	chr15:52860530	ARPP19	0.53	4.76	0.39	5.35e-6	Schizophrenia;
TGCT	cis	rs3960554	0.808	rs867973	chr7:75686007	G/A	cg17325771	chr7:75508891	RHBDD2	-0.54	-4.63	-0.38	8.97e-6	Eotaxin levels;
TGCT	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg11494091	chr17:61959527	GH2	0.61	14.78	0.8	4.02e-29	Prudent dietary pattern;
TGCT	cis	rs7674212	0.581	rs13150953	chr4:103942498	A/G	cg16532752	chr4:104119610	CENPE	-0.56	-4.92	-0.4	2.64e-6	Type 2 diabetes;
TGCT	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.6	-5.26	-0.43	6.18e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs62244186	0.683	rs6766334	chr3:44567065	T/C	cg11003573	chr3:44754125	ZNF502	-0.41	-4.67	-0.39	7.57e-6	Depressive symptoms;
TGCT	cis	rs7267979	0.816	rs3746337	chr20:25208272	C/T	cg16686733	chr20:25566563	NINL	0.51	4.81	0.4	4.25e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg24829409	chr8:58192753	C8orf71	-0.55	-5.2	-0.42	7.84e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.51	5.69	0.46	8.51e-8	Lymphocyte counts;
TGCT	cis	rs72781680	1.000	rs17711825	chr2:24124578	A/G	cg08917208	chr2:24149416	ATAD2B	0.73	4.51	0.38	1.48e-5	Lymphocyte counts;
TGCT	cis	rs13392177	0.647	rs6718220	chr2:219066518	T/C	cg00012203	chr2:219082015	ARPC2	-0.75	-7.53	-0.56	8.88e-12	Pyoderma gangrenosum in inflammatory bowel disease;
TGCT	cis	rs6964587	0.626	rs7785941	chr7:91531024	T/C	cg17063962	chr7:91808500	NA	-0.73	-6.94	-0.53	1.98e-10	Breast cancer;
TGCT	cis	rs7772486	0.754	rs9399561	chr6:145955687	C/G	cg13319975	chr6:146136371	FBXO30	-0.56	-5.06	-0.41	1.46e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1891275	0.515	rs7092884	chr10:93483872	A/C	cg07889827	chr10:93443413	NA	0.31	6.27	0.49	5.47e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs950776	0.684	rs61012457	chr15:78865694	C/G	cg06917634	chr15:78832804	PSMA4	0.69	5.43	0.44	2.84e-7	Sudden cardiac arrest;
TGCT	cis	rs1580019	0.523	rs9791770	chr7:32582252	C/A	cg07520158	chr7:32535189	LSM5;AVL9	0.6	4.95	0.41	2.39e-6	Cognitive ability;
TGCT	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	15.48	0.81	9.24e-31	Prudent dietary pattern;
TGCT	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg07507251	chr3:52567010	NT5DC2	0.47	6.64	0.51	8.85e-10	Electroencephalogram traits;
TGCT	cis	rs9372253	0.678	rs9372251	chr6:110700656	A/G	cg19196401	chr6:110721138	DDO	-0.43	-5.95	-0.47	2.53e-8	Platelet distribution width;
TGCT	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg14159672	chr1:205819179	PM20D1	0.75	10.73	0.69	2.11e-19	Menarche (age at onset);
TGCT	cis	rs6988636	1.000	rs62521841	chr8:124194625	G/A	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg13395646	chr4:1353034	KIAA1530	-0.47	-6.15	-0.48	9.8e-9	Obesity-related traits;
TGCT	cis	rs78456975	0.527	rs72776299	chr2:1570300	G/C	cg01028140	chr2:1542097	TPO	-0.33	-5.09	-0.42	1.26e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	trans	rs1814175	0.529	rs1988417	chr11:49932430	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.41	-8.7	-0.62	1.69e-14	Height;
TGCT	cis	rs6060960	0.502	rs15817	chr20:30193538	A/G	cg18721089	chr20:30220636	NA	-0.57	-6.22	-0.49	6.83e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
TGCT	cis	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg11764359	chr7:65958608	NA	0.54	4.85	0.4	3.67e-6	Aortic root size;
TGCT	cis	rs9926296	0.569	rs4785708	chr16:89796569	C/T	cg08627397	chr16:89984028	MC1R	0.3	4.85	0.4	3.69e-6	Vitiligo;
TGCT	trans	rs6089829	0.888	rs4809467	chr20:61671688	A/G	cg23505145	chr19:12996616	KLF1	0.96	9.99	0.67	1.36e-17	Prostate cancer (SNP x SNP interaction);
TGCT	trans	rs1974653	0.672	rs113307754	chr22:20089271	A/G	cg08822737	chr17:71088851	SLC39A11	-0.93	-7.61	-0.56	5.97e-12	Schizophrenia;
TGCT	cis	rs7552404	1.000	rs4949872	chr1:76131392	C/G	cg22875332	chr1:76189707	ACADM	0.8	9.91	0.66	2.06e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs344364	0.511	rs12599337	chr16:1946751	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	0.42	4.66	0.39	8.15e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs79349575	0.811	rs80032154	chr17:47014992	C/A	cg07967210	chr17:47022446	SNF8	0.44	6.13	0.48	1.06e-8	Type 2 diabetes;
TGCT	cis	rs6582630	0.638	rs11182428	chr12:38526387	T/C	cg26384229	chr12:38710491	ALG10B	-0.55	-4.89	-0.4	3.05e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs3947	0.950	rs1692811	chr8:11703048	C/G	cg02840367	chr8:11660030	FDFT1	0.91	6.66	0.51	7.98e-10	Blood protein levels;
TGCT	cis	rs425277	0.958	rs626479	chr1:2110260	A/G	cg24578937	chr1:2090814	PRKCZ	-0.28	-6.99	-0.53	1.52e-10	Height;
TGCT	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg19774624	chr17:42201019	HDAC5	-0.87	-10.75	-0.69	1.84e-19	Total body bone mineral density;
TGCT	trans	rs3107575	0.572	rs73169366	chr3:165320307	C/T	cg04140596	chr1:228404239	OBSCN	0.72	6.63	0.51	9.27e-10	Morning vs. evening chronotype;
TGCT	cis	rs3733585	0.699	rs7658170	chr4:9966593	C/T	cg00071950	chr4:10020882	SLC2A9	0.54	6.46	0.5	2.2e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs9398235	0.929	rs2073211	chr6:110729270	A/G	cg00083206	chr6:110721305	DDO	0.44	4.46	0.37	1.79e-5	Systemic lupus erythematosus;
TGCT	cis	rs612683	0.694	rs6688364	chr1:101000874	G/A	cg06223162	chr1:101003688	GPR88	0.34	5.72	0.46	7.52e-8	Breast cancer;
TGCT	cis	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg20637647	chr7:64974828	NA	-0.9	-5.31	-0.43	4.87e-7	Diabetic kidney disease;
TGCT	cis	rs2688608	0.592	rs10762563	chr10:75524802	C/A	cg19442545	chr10:75533431	FUT11	-0.36	-5.73	-0.46	7.17e-8	Inflammatory bowel disease;
TGCT	cis	rs3733585	0.534	rs7375642	chr4:9955236	A/G	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.73	-0.57	3.25e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs854765	0.520	rs7219324	chr17:17909775	C/T	cg04398451	chr17:18023971	MYO15A	0.31	4.8	0.4	4.4e-6	Total body bone mineral density;
TGCT	cis	rs7914558	0.966	rs11191518	chr10:104782853	C/G	cg04362960	chr10:104952993	NT5C2	0.61	5.46	0.44	2.44e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs11122272	0.735	rs11122279	chr1:231519804	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.13	-0.54	7.33e-11	Hemoglobin concentration;
TGCT	cis	rs425277	1.000	rs12401379	chr1:2058580	G/C	cg24578937	chr1:2090814	PRKCZ	0.32	7.65	0.57	4.86e-12	Height;
TGCT	cis	rs6582630	0.555	rs10748382	chr12:38504529	C/T	cg26384229	chr12:38710491	ALG10B	0.87	8.29	0.6	1.5700000000000001e-13	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs13326165	0.760	rs55965068	chr3:52354432	A/G	cg07884673	chr3:53033167	SFMBT1	0.39	4.69	0.39	7e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs735396	0.770	rs2257764	chr12:121446446	T/A	cg15155738	chr12:121454335	C12orf43	-0.55	-4.76	-0.39	5.4e-6	N-glycan levels;
TGCT	cis	rs2230307	0.536	rs56215716	chr1:100447486	G/A	cg24955406	chr1:100503596	HIAT1	0.72	4.68	0.39	7.51e-6	Carotid intima media thickness;
TGCT	cis	rs4319547	0.695	rs10846699	chr12:122853073	A/G	cg05707623	chr12:122985044	ZCCHC8	0.63	5.02	0.41	1.74e-6	Body mass index;
TGCT	cis	rs3862435	0.666	rs2601202	chr15:90958089	G/A	cg14166756	chr15:90894880	ZNF774	-0.29	-4.76	-0.39	5.2e-6	Response to exercise (triglyceride level interaction);
TGCT	cis	rs2303745	0.589	rs11882562	chr19:17395055	C/G	cg02221750	chr19:17393354	ANKLE1	0.51	6.93	0.53	2.08e-10	Systemic lupus erythematosus;
TGCT	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg07061783	chr6:25882402	NA	0.58	5.57	0.45	1.48e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7017914	0.905	rs2732110	chr8:71926811	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.56	-5.11	-0.42	1.21e-6	Bone mineral density;
TGCT	cis	rs7104764	1.000	rs6598062	chr11:243712	A/G	cg18336825	chr11:236787	PSMD13;SIRT3	1.07	11.19	0.71	1.61e-20	Menarche (age at onset);
TGCT	cis	rs6500602	0.647	rs1641868	chr16:4594503	G/C	cg08645402	chr16:4508243	NA	0.18	5.04	0.41	1.58e-6	Schizophrenia;
TGCT	cis	rs79349575	0.783	rs28409394	chr17:46998118	T/C	cg26022315	chr17:47021804	SNF8	0.49	4.89	0.4	3.03e-6	Type 2 diabetes;
TGCT	cis	rs2797160	1.000	rs1739363	chr6:126020980	G/A	cg05901451	chr6:126070800	HEY2	0.75	6.66	0.51	8e-10	Endometrial cancer;
TGCT	cis	rs7666738	0.830	rs28497822	chr4:98906873	C/T	cg05340658	chr4:99064831	C4orf37	0.53	6.32	0.49	4.21e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg06618935	chr21:46677482	NA	-0.37	-5.81	-0.46	5.06e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs514406	0.893	rs1242315	chr1:53417181	A/G	cg24675658	chr1:53192096	ZYG11B	-0.69	-8.0	-0.58	7.54e-13	Monocyte count;
TGCT	cis	rs9906944	0.707	rs11655950	chr17:47129121	C/T	cg07075026	chr17:47091521	IGF2BP1	-0.47	-5.06	-0.41	1.46e-6	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs9611565	0.765	rs132915	chr22:41805782	T/C	cg17554472	chr22:41940697	POLR3H	0.43	4.79	0.39	4.73e-6	Vitiligo;
TGCT	cis	rs12291225	0.546	rs12291662	chr11:14342949	T/C	cg19336497	chr11:14380999	RRAS2	-0.45	-7.25	-0.55	3.87e-11	Sense of smell;
TGCT	cis	rs763121	0.853	rs138716	chr22:39146527	C/T	cg06022373	chr22:39101656	GTPBP1	0.8	7.56	0.56	7.77e-12	Menopause (age at onset);
TGCT	cis	rs13190036	1.000	rs71601344	chr5:176633493	G/A	cg18465082	chr5:176734745	MXD3	0.32	4.46	0.37	1.78e-5	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
TGCT	cis	rs3087591	0.708	rs2854305	chr17:29647003	G/A	cg24425628	chr17:29625626	OMG;NF1	0.4	5.63	0.45	1.14e-7	Hip circumference;
TGCT	cis	rs10423674	0.526	rs12462498	chr19:18832950	A/G	cg20185461	chr19:18899082	COMP	0.5	4.86	0.4	3.49e-6	Menarche (age at onset);
TGCT	cis	rs116095464	0.558	rs7708515	chr5:234989	C/G	cg22857025	chr5:266934	NA	-0.33	-6.73	-0.52	5.7e-10	Breast cancer;
TGCT	cis	rs727563	0.635	rs5751141	chr22:42107745	A/G	cg06634786	chr22:41940651	POLR3H	0.9	8.74	0.62	1.35e-14	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs11651000	0.761	rs11079788	chr17:45820723	C/T	cg06532163	chr17:45867833	NA	0.33	4.82	0.4	4.05e-6	IgG glycosylation;
TGCT	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg04234412	chr22:24373322	LOC391322	-0.91	-10.78	-0.7	1.62e-19	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7267979	1.000	rs2387881	chr20:25378172	A/G	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg11965913	chr1:205819406	PM20D1	0.53	7.51	0.56	1.01e-11	Menarche (age at onset);
TGCT	cis	rs9915657	0.773	rs9912974	chr17:70095963	C/T	cg06234051	chr17:70120541	SOX9	-0.27	-5.68	-0.45	9.25e-8	Thyroid hormone levels;
TGCT	cis	rs28595532	1.000	rs11931194	chr4:119631160	C/T	cg11846333	chr4:119757529	SEC24D	0.9	4.52	0.38	1.42e-5	Cannabis dependence symptom count;
TGCT	cis	rs10858047	0.783	rs6692475	chr1:115209142	C/T	cg12756093	chr1:115239321	AMPD1	-0.47	-4.96	-0.41	2.27e-6	Autism;
TGCT	cis	rs7937682	0.921	rs4534611	chr11:111440425	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.86	-7.29	-0.55	3.21e-11	Primary sclerosing cholangitis;
TGCT	trans	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg11887960	chr12:57824829	NA	1.06	9.28	0.64	6.78e-16	Lung disease severity in cystic fibrosis;
TGCT	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	7.55	0.56	8.19e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs12142240	0.698	rs1475388	chr1:46816465	G/A	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs2268241	0.938	rs11088251	chr21:34770810	A/C	cg14850771	chr21:34775459	IFNGR2	0.64	5.13	0.42	1.08e-6	Obesity-related traits;
TGCT	cis	rs12497850	0.931	rs10780033	chr3:48891275	T/C	cg05785598	chr3:49045655	WDR6	0.35	4.72	0.39	6.35e-6	Parkinson's disease;
TGCT	cis	rs13177918	0.798	rs13182116	chr5:149845526	A/T	cg14059543	chr5:149831962	NA	0.53	5.56	0.45	1.58e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs7914558	0.966	rs7085598	chr10:104650128	T/C	cg04362960	chr10:104952993	NT5C2	0.58	5.16	0.42	9.65e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs68170813	0.599	rs12532514	chr7:107000952	C/T	cg02696742	chr7:106810147	HBP1	-0.7	-5.7	-0.46	8.16e-8	Coronary artery disease;
TGCT	trans	rs853410	0.516	rs6421941	chr6:3998448	C/T	cg13911294	chr9:88951310	ZCCHC6	-0.64	-6.66	-0.51	8.02e-10	Night sleep phenotypes;
TGCT	trans	rs10506458	0.834	rs12426893	chr12:63388120	G/T	cg22491629	chr6:157744540	C6orf35	-0.99	-8.5	-0.61	5.08e-14	Hemostatic factors and hematological phenotypes;
TGCT	trans	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.86	-9.4	-0.65	3.49e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs9733	0.596	rs17658705	chr1:150678071	A/C	cg09365446	chr1:150670422	GOLPH3L	-0.31	-4.64	-0.38	8.7e-6	Tonsillectomy;
TGCT	cis	rs7818688	0.654	rs75680386	chr8:95986148	A/G	cg16049864	chr8:95962084	TP53INP1	0.54	4.64	0.38	8.87e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs12530845	1.000	rs4291212	chr7:135335465	C/T	cg23117316	chr7:135346802	PL-5283	-0.51	-4.82	-0.4	4.1e-6	Red blood cell traits;
TGCT	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg08280861	chr8:58055591	NA	0.52	5.97	0.47	2.35e-8	Developmental language disorder (linguistic errors);
TGCT	cis	rs904251	0.600	rs1874736	chr6:37447994	C/G	cg08126542	chr6:37504118	NA	-0.4	-5.72	-0.46	7.64e-8	Cognitive performance;
TGCT	cis	rs13272623	0.502	rs268628	chr8:71560505	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.61	-5.12	-0.42	1.12e-6	IgG glycosylation;
TGCT	cis	rs1466788	0.965	rs6674413	chr1:110625110	C/T	cg11787288	chr1:111506544	C1orf103	0.5	4.5	0.37	1.52e-5	Blood metabolite levels;
TGCT	cis	rs6582630	0.638	rs35864536	chr12:38472255	T/A	cg26384229	chr12:38710491	ALG10B	-0.54	-4.83	-0.4	4.03e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	8.0	0.58	7.67e-13	Platelet count;
TGCT	cis	rs12210905	0.688	rs12191373	chr6:27484330	C/T	cg08851530	chr6:28072375	NA	1.34	6.29	0.49	5.02e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.52	4.44	0.37	1.96e-5	Renal function-related traits (BUN);
TGCT	cis	rs9303401	0.573	rs34717648	chr17:56886624	T/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs28595532	0.920	rs114963870	chr4:119758099	T/C	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs616402	0.527	rs604369	chr1:10567208	C/A	cg17425144	chr1:10567563	PEX14	0.57	8.21	0.59	2.43e-13	Breast size;
TGCT	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg04944784	chr2:26401820	FAM59B	-0.68	-6.04	-0.48	1.7e-8	Gut microbiome composition (summer);
TGCT	cis	rs6163	0.588	rs67506723	chr10:104509064	G/T	cg05855489	chr10:104503620	C10orf26	0.98	12.37	0.74	2.13e-23	Waist circumference;Hip circumference;
TGCT	cis	rs35883536	0.647	rs17402665	chr1:101046940	C/T	cg10298815	chr1:101004474	GPR88	-0.25	-4.5	-0.37	1.54e-5	Monocyte count;
TGCT	cis	rs6687430	0.562	rs12139169	chr1:10635328	C/T	cg17425144	chr1:10567563	PEX14	0.48	5.18	0.42	8.88e-7	Hand grip strength;
TGCT	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg21963583	chr11:68658836	MRPL21	0.36	5.96	0.47	2.44e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg06238570	chr21:40685208	BRWD1	0.69	6.47	0.5	2.08e-9	Cognitive function;
TGCT	cis	rs2742234	0.955	rs2503865	chr10:43659536	C/T	cg02780029	chr10:43622663	RET	-0.26	-4.98	-0.41	2.07e-6	Hirschsprung disease;
TGCT	cis	rs7424096	0.613	rs17332671	chr2:37244124	C/G	cg14987922	chr2:37194071	STRN	0.52	4.65	0.39	8.4e-6	High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg09021430	chr5:549028	NA	-0.4	-5.63	-0.45	1.16e-7	Obesity-related traits;
TGCT	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg13395646	chr4:1353034	KIAA1530	-0.39	-4.98	-0.41	2.13e-6	Obesity-related traits;
TGCT	cis	rs473651	0.935	rs35080527	chr2:239351387	T/C	cg18131467	chr2:239335373	ASB1	1.02	15.09	0.8	7.51e-30	Multiple system atrophy;
TGCT	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg24250549	chr1:154909240	PMVK	0.63	6.25	0.49	6.03e-9	Prostate cancer;
TGCT	cis	rs9640161	0.789	rs4554381	chr7:150025567	G/A	cg10018233	chr7:150070692	REPIN1	0.32	4.63	0.38	9.08e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs67073037	0.955	rs12053141	chr2:29134743	A/G	cg09522027	chr2:28974177	PPP1CB	0.57	4.49	0.37	1.59e-5	Breast cancer;Breast cancer (estrogen-receptor negative);
TGCT	cis	rs9818758	0.607	rs13087930	chr3:48961726	A/G	cg00383909	chr3:49044727	WDR6	1.26	6.52	0.51	1.58e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	5.06	0.41	1.46e-6	Menopause (age at onset);
TGCT	cis	rs11122272	0.735	rs10489610	chr1:231517765	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.13	-0.54	7.33e-11	Hemoglobin concentration;
TGCT	cis	rs4820539	0.966	rs5759600	chr22:23483769	C/A	cg21100191	chr22:23484243	RTDR1	0.93	11.16	0.71	1.91e-20	Bone mineral density;
TGCT	cis	rs3733585	0.699	rs6823361	chr4:9963127	A/G	cg00071950	chr4:10020882	SLC2A9	-0.55	-6.55	-0.51	1.41e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg24531977	chr5:56204891	C5orf35	-0.65	-6.39	-0.5	3.1e-9	Coronary artery disease;
TGCT	cis	rs933688	0.818	rs10052492	chr5:90759930	T/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.88	8.16	0.59	3.2e-13	Smoking behavior;
TGCT	cis	rs2066819	1.000	rs111885088	chr12:56657216	A/C	cg26714650	chr12:56694279	CS	-1.36	-6.06	-0.48	1.54e-8	Psoriasis vulgaris;
TGCT	cis	rs9457247	0.967	rs2149084	chr6:167370988	G/C	cg23791538	chr6:167370224	RNASET2	0.51	4.98	0.41	2.09e-6	Crohn's disease;
TGCT	cis	rs4664308	1.000	rs6759924	chr2:160912747	G/A	cg03641300	chr2:160917029	PLA2R1	-0.26	-6.35	-0.5	3.77e-9	Idiopathic membranous nephropathy;
TGCT	cis	rs2072499	0.833	rs2251636	chr1:156202809	G/C	cg24450063	chr1:156163899	SLC25A44	1.01	12.65	0.75	4.62e-24	Testicular germ cell tumor;
TGCT	cis	rs6665290	0.901	rs2104860	chr1:227208637	G/C	cg10327440	chr1:227177885	CDC42BPA	-0.9	-16.17	-0.82	2.56e-32	Myeloid white cell count;
TGCT	cis	rs2239547	0.657	rs6445539	chr3:52874296	G/A	cg10802521	chr3:52805072	NEK4	-0.65	-6.12	-0.48	1.16e-8	Schizophrenia;
TGCT	cis	rs910316	1.000	rs7147118	chr14:75610170	G/C	cg23033748	chr14:75592666	NEK9	0.28	4.79	0.39	4.73e-6	Height;
TGCT	cis	rs9330316	0.611	rs56402128	chr2:110321071	C/T	cg25199208	chr2:109402912	CCDC138	-0.42	-4.56	-0.38	1.19e-5	Schizophrenia;
TGCT	cis	rs9486715	0.838	rs9386576	chr6:96954717	C/T	cg06623918	chr6:96969491	KIAA0776	1.1	15.44	0.81	1.17e-30	Headache;
TGCT	cis	rs208515	0.525	rs12193560	chr6:66690457	A/T	cg07460842	chr6:66804631	NA	0.88	9.35	0.64	4.63e-16	Exhaled nitric oxide levels;
TGCT	cis	rs6542838	0.641	rs6741166	chr2:99534926	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.55	-4.96	-0.41	2.29e-6	Fear of minor pain;
TGCT	cis	rs926938	0.527	rs2335954	chr1:115534151	C/T	cg12756093	chr1:115239321	AMPD1	-0.32	-4.67	-0.39	7.82e-6	Autism;
TGCT	cis	rs763014	0.931	rs2071981	chr16:630025	C/G	cg07343612	chr16:622815	PIGQ	-0.41	-7.87	-0.58	1.52e-12	Height;
TGCT	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg11965913	chr1:205819406	PM20D1	0.61	9.63	0.65	1.01e-16	Menarche (age at onset);
TGCT	trans	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg21659725	chr3:3221576	CRBN	-0.74	-8.33	-0.6	1.3e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs7619708	1	rs7619708	chr3:195810187	T/C	cg16824377	chr3:195164118	ACAP2	-0.6	-4.56	-0.38	1.22e-5	Red cell distribution width;
TGCT	cis	rs8051431	0.876	rs12443563	chr16:72018099	C/T	cg06353428	chr16:71660113	MARVELD3	0.57	4.54	0.38	1.31e-5	LDL cholesterol levels;
TGCT	cis	rs11585357	0.895	rs72633828	chr1:17632251	G/A	cg08277548	chr1:17600880	PADI3	-0.95	-9.6	-0.65	1.15e-16	Hair shape;
TGCT	cis	rs61990749	0.597	rs7147516	chr14:78153980	T/C	cg23188588	chr14:78226832	SNW1;C14orf178	-0.66	-4.69	-0.39	7.04e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs2153535	0.580	rs915350	chr6:8443486	A/G	cg07606381	chr6:8435919	SLC35B3	0.58	5.38	0.44	3.54e-7	Motion sickness;
TGCT	cis	rs2760061	0.626	rs634106	chr1:228121548	C/T	cg02753203	chr1:228287806	NA	-0.34	-6.68	-0.51	7.2e-10	Diastolic blood pressure;
TGCT	cis	rs12681287	0.640	rs4490816	chr8:87384938	T/C	cg27223183	chr8:87520930	FAM82B	0.89	6.61	0.51	1.04e-9	Caudate activity during reward;
TGCT	trans	rs459571	0.916	rs109536	chr9:136889987	G/C	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.75	-8.21	-0.59	2.47e-13	Platelet distribution width;
TGCT	cis	rs56104184	0.779	rs17272666	chr19:49356294	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.76	-8.95	-0.63	4.37e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs8072100	0.666	rs6503804	chr17:45772447	G/A	cg08085267	chr17:45401833	C17orf57	-0.43	-4.82	-0.4	4.04e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg03188948	chr7:1209495	NA	0.48	6.81	0.52	3.76e-10	Longevity;Endometriosis;
TGCT	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg22166914	chr1:53195759	ZYG11B	-0.42	-7.46	-0.56	1.29e-11	Monocyte count;
TGCT	cis	rs1887596	0.672	rs9553875	chr13:27210925	G/A	cg01312412	chr13:27282625	NA	0.29	5.13	0.42	1.1e-6	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs2180341	1.000	rs4897207	chr6:127605898	C/T	cg24812749	chr6:127587940	RNF146	0.99	7.72	0.57	3.33e-12	Breast cancer;
TGCT	cis	rs11971779	0.666	rs7786851	chr7:139007020	C/G	cg07862535	chr7:139043722	LUC7L2	-0.65	-5.22	-0.42	7.26e-7	Diisocyanate-induced asthma;
TGCT	cis	rs1372520	1.000	rs1372520	chr4:90757505	T/C	cg14346243	chr4:90757452	SNCA	-0.65	-5.32	-0.43	4.78e-7	Neuroticism;
TGCT	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg11494091	chr17:61959527	GH2	0.61	14.8	0.8	3.65e-29	Prudent dietary pattern;
TGCT	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg22105103	chr4:187893119	NA	0.33	4.53	0.38	1.35e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9640161	0.711	rs3800781	chr7:150027324	T/A	cg17279839	chr7:150038598	RARRES2	0.43	4.54	0.38	1.29e-5	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs10791323	0.660	rs2156681	chr11:133731644	G/T	cg03690763	chr11:133734501	NA	-0.28	-4.46	-0.37	1.83e-5	Childhood ear infection;
TGCT	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg01516881	chr6:292596	DUSP22	-0.78	-8.17	-0.59	2.99e-13	Menopause (age at onset);
TGCT	cis	rs4803468	1.000	rs2241711	chr19:41911980	T/C	cg09537434	chr19:41945824	ATP5SL	-0.92	-10.69	-0.69	2.72e-19	Height;
TGCT	cis	rs7949030	0.653	rs2516634	chr11:62367186	G/A	cg11742103	chr11:62369870	EML3;MTA2	-0.61	-9.07	-0.63	2.25e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9952991	0.941	rs2542149	chr18:12779018	G/A	cg09945482	chr18:12777974	NA	0.51	4.86	0.4	3.47e-6	Inflammatory skin disease;
TGCT	cis	rs9549367	0.713	rs3024764	chr13:113824314	A/G	cg00898013	chr13:113819073	PROZ	-0.55	-7.27	-0.55	3.47e-11	Platelet distribution width;
TGCT	cis	rs28595532	0.920	rs55671478	chr4:119753811	A/G	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs5769765	0.954	rs1569954	chr22:50244071	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	1.08	11.84	0.73	4.29e-22	Schizophrenia;
TGCT	cis	rs1008375	0.932	rs4698630	chr4:17614692	C/G	cg10189774	chr4:17578691	LAP3	0.65	5.49	0.44	2.22e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	trans	rs17685	0.753	rs4728550	chr7:75670988	C/A	cg19862616	chr7:65841803	NCRNA00174	-0.52	-8.84	-0.62	7.72e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs7666738	0.830	rs115712871	chr4:98954535	A/T	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7647973	0.593	rs62262730	chr3:49808274	T/G	cg03034192	chr3:50606346	HEMK1;C3orf18	-0.37	-4.8	-0.4	4.56e-6	Menarche (age at onset);
TGCT	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg08923669	chr16:420230	MRPL28	-0.61	-6.31	-0.49	4.44e-9	Bone mineral density (spine);Bone mineral density;
TGCT	trans	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg27523141	chr10:43048294	ZNF37B	0.73	8.58	0.61	3.32e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs910316	0.967	rs11159116	chr14:75550584	G/T	cg11812906	chr14:75593930	NEK9	0.74	7.38	0.55	1.97e-11	Height;
TGCT	cis	rs36051895	0.632	rs62541944	chr9:5159318	G/T	cg02405213	chr9:5042618	JAK2	-0.71	-9.01	-0.63	3.02e-15	Pediatric autoimmune diseases;
TGCT	cis	rs4780401	0.609	rs8063099	chr16:11806714	T/G	cg01061890	chr16:11836724	TXNDC11	-0.6	-5.82	-0.46	4.74e-8	Rheumatoid arthritis;
TGCT	cis	rs9906944	0.933	rs9906710	chr17:47091283	C/A	cg07075026	chr17:47091521	IGF2BP1	-0.44	-4.84	-0.4	3.78e-6	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs9388451	0.772	rs1268064	chr6:126042578	G/A	cg10911889	chr6:126070802	HEY2	-0.52	-5.26	-0.43	6.17e-7	Brugada syndrome;
TGCT	cis	rs2243480	1.000	rs781157	chr7:65478311	G/A	cg07424592	chr7:64974309	NA	1.4	8.42	0.6	7.87e-14	Diabetic kidney disease;
TGCT	cis	rs2271316	0.587	rs11078659	chr17:6903944	G/A	cg21237687	chr17:6899380	ALOX12	0.42	4.59	0.38	1.06e-5	Blood metabolite levels;
TGCT	cis	rs929354	1.000	rs1182391	chr7:157038368	T/C	cg05182265	chr7:156933206	UBE3C	0.33	6.75	0.52	4.96e-10	Body mass index;
TGCT	cis	rs9300255	0.544	rs1716157	chr12:123670473	T/C	cg00376283	chr12:123451042	ABCB9	0.73	5.69	0.46	8.5e-8	Neutrophil percentage of white cells;
TGCT	cis	rs7267979	0.844	rs6083851	chr20:25401235	G/A	cg16686733	chr20:25566563	NINL	-0.52	-4.93	-0.4	2.61e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs62103177	0.525	rs4283293	chr18:77759582	A/G	cg07235805	chr18:78004237	PARD6G	-0.45	-4.47	-0.37	1.75e-5	Opioid sensitivity;
TGCT	cis	rs10927875	0.632	rs6699394	chr1:16145143	C/A	cg14742211	chr1:16348397	CLCNKA	-0.2	-4.77	-0.39	4.99e-6	Dilated cardiomyopathy;
TGCT	cis	rs2239547	0.618	rs1573815	chr3:52870132	A/G	cg10802521	chr3:52805072	NEK4	0.57	5.54	0.45	1.75e-7	Schizophrenia;
TGCT	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg03609598	chr5:56110824	MAP3K1	-0.58	-4.7	-0.39	6.72e-6	Initial pursuit acceleration;
TGCT	cis	rs6582630	0.502	rs11614397	chr12:38328163	C/T	cg13010199	chr12:38710504	ALG10B	0.58	4.55	0.38	1.26e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs9916302	0.808	rs12948906	chr17:37644854	C/T	cg07936489	chr17:37558343	FBXL20	-0.62	-4.91	-0.4	2.85e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7731657	0.538	rs2107335	chr5:130292853	C/A	cg08523029	chr5:130500466	HINT1	-0.58	-4.84	-0.4	3.8e-6	Fasting plasma glucose;
TGCT	cis	rs9291683	0.530	rs13115193	chr4:9982191	C/T	cg11266682	chr4:10021025	SLC2A9	0.62	8.63	0.61	2.51e-14	Bone mineral density;
TGCT	cis	rs806215	0.826	rs712699	chr7:127250597	G/A	cg25922125	chr7:127225783	GCC1	0.58	5.87	0.47	3.69e-8	Type 2 diabetes;
TGCT	cis	rs367615	0.679	rs4259216	chr5:108841817	A/G	cg17395555	chr5:108820864	NA	0.31	5.86	0.47	3.94e-8	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs7666738	0.606	rs6852813	chr4:99084671	G/A	cg05340658	chr4:99064831	C4orf37	0.44	4.8	0.4	4.5e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2404602	1.000	rs12148786	chr15:76800362	A/G	cg26408565	chr15:76604113	ETFA	-0.38	-4.87	-0.4	3.28e-6	Blood metabolite levels;
TGCT	cis	rs10037670	0.557	rs972595	chr5:153824214	G/T	cg21964928	chr5:153872958	NA	0.28	5.1	0.42	1.22e-6	Behavioural disinhibition (generation interaction);
TGCT	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg04156016	chr5:1868137	NA	0.34	4.79	0.4	4.64e-6	Cardiovascular disease risk factors;
TGCT	cis	rs3924048	0.574	rs3923904	chr1:12616535	T/C	cg00291366	chr1:12616550	NA	0.33	5.14	0.42	1.05e-6	Optic cup area;
TGCT	trans	rs7819412	0.774	rs34208825	chr8:11014616	T/G	cg06636001	chr8:8085503	FLJ10661	-0.77	-6.62	-0.51	9.84e-10	Triglycerides;
TGCT	cis	rs12220898	0.749	rs7068959	chr10:50468696	A/C	cg06072769	chr10:50146962	WDFY4	0.38	5.01	0.41	1.82e-6	Inflammatory biomarkers;
TGCT	cis	rs28595532	0.920	rs28797314	chr4:119783044	A/G	cg21605333	chr4:119757512	SEC24D	1.44	8.24	0.6	2.03e-13	Cannabis dependence symptom count;
TGCT	cis	rs13256369	0.951	rs13259955	chr8:8565885	C/G	cg17143192	chr8:8559678	CLDN23	0.58	5.55	0.45	1.64e-7	Obesity-related traits;
TGCT	cis	rs3806843	0.576	rs246059	chr5:140325010	G/T	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg04944784	chr2:26401820	FAM59B	-0.77	-6.48	-0.5	1.97e-9	Gut microbiome composition (summer);
TGCT	cis	rs9394169	0.613	rs2395399	chr6:33777432	T/C	cg18005901	chr6:33739558	LEMD2	-0.52	-6.18	-0.49	8.57e-9	Essential tremor;
TGCT	cis	rs9300255	0.602	rs1402274	chr12:123686224	T/C	cg00376283	chr12:123451042	ABCB9	0.71	5.59	0.45	1.41e-7	Neutrophil percentage of white cells;
TGCT	cis	rs6933660	0.760	rs6904364	chr6:151754273	T/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.52	-4.66	-0.39	8.03e-6	Menarche (age at onset);
TGCT	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg03517284	chr6:25882590	NA	-0.49	-5.07	-0.41	1.4e-6	Height;
TGCT	cis	rs8062405	1.000	rs4788101	chr16:28867804	C/T	cg09754948	chr16:28834200	ATXN2L	0.59	4.45	0.37	1.91e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs9913156	0.793	rs7210953	chr17:4608870	C/T	cg23387401	chr17:4582204	PELP1	0.31	4.68	0.39	7.44e-6	Lymphocyte counts;
TGCT	cis	rs54211	1.000	rs137580	chr22:39677741	C/T	cg00820535	chr22:39852281	MGAT3	0.35	5.21	0.42	7.69e-7	Sudden cardiac arrest;
TGCT	cis	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg09021430	chr5:549028	NA	-0.4	-5.48	-0.44	2.24e-7	Lung disease severity in cystic fibrosis;
TGCT	cis	rs3749237	0.595	rs4855873	chr3:49459114	A/C	cg07636037	chr3:49044803	WDR6	0.63	5.98	0.47	2.26e-8	Resting heart rate;
TGCT	cis	rs2806561	0.704	rs7532266	chr1:23551623	A/C	cg12483005	chr1:23474871	LUZP1	-0.4	-4.95	-0.41	2.33e-6	Height;
TGCT	cis	rs896854	0.654	rs13278601	chr8:95972974	G/C	cg13393036	chr8:95962371	TP53INP1	-0.63	-8.52	-0.61	4.51e-14	Type 2 diabetes;
TGCT	cis	rs2299587	0.545	rs12543739	chr8:17756229	C/T	cg01800426	chr8:17659068	MTUS1	-0.56	-5.02	-0.41	1.73e-6	Economic and political preferences;
TGCT	cis	rs67311347	1.000	rs17078941	chr3:40450888	A/G	cg13683864	chr3:40499215	RPL14	1.15	12.87	0.76	1.32e-24	Renal cell carcinoma;
TGCT	cis	rs4319547	0.695	rs10773103	chr12:122856532	A/G	cg08088222	chr12:122070432	ORAI1	-0.25	-4.49	-0.37	1.58e-5	Body mass index;
TGCT	cis	rs4891159	0.505	rs680253	chr18:74167427	A/C	cg24786174	chr18:74118243	ZNF516	-0.63	-10.94	-0.7	6.53e-20	Longevity;
TGCT	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg22166914	chr1:53195759	ZYG11B	-0.43	-7.49	-0.56	1.13e-11	Monocyte count;
TGCT	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg13342137	chr4:2252803	MXD4	0.16	4.46	0.37	1.79e-5	Obesity-related traits;
TGCT	cis	rs7666738	0.791	rs6532725	chr4:99061479	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.79	0.46	5.32e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4711350	0.678	rs680608	chr6:33713169	C/T	cg00334056	chr6:33755658	LEMD2	0.34	4.61	0.38	9.78e-6	Schizophrenia;
TGCT	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg08859206	chr1:53392774	SCP2	0.39	5.8	0.46	5.07e-8	Monocyte count;
TGCT	cis	rs7552404	0.731	rs11161857	chr1:76370228	G/C	cg22875332	chr1:76189707	ACADM	0.68	6.57	0.51	1.26e-9	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs644799	1.000	rs593665	chr11:95574302	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	8.19	0.59	2.72e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9653442	0.564	rs7590378	chr2:100789877	A/G	cg07810366	chr2:100720526	AFF3	-0.35	-5.26	-0.43	6e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg13866156	chr1:1669148	SLC35E2	0.24	5.55	0.45	1.63e-7	Body mass index;
TGCT	cis	rs11578119	0.933	rs11584810	chr1:170471343	C/T	cg09767346	chr1:170501363	GORAB	0.66	5.29	0.43	5.27e-7	Male-pattern baldness;
TGCT	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg05785598	chr3:49045655	WDR6	0.36	4.78	0.39	4.78e-6	Menarche (age at onset);
TGCT	trans	rs13064411	0.542	rs9874747	chr3:113221258	G/A	cg00307254	chr3:126706825	PLXNA1	0.34	6.72	0.52	5.79e-10	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg20276088	chr3:133502917	NA	-0.23	-4.44	-0.37	1.96e-5	Iron status biomarkers;
TGCT	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg13395646	chr4:1353034	KIAA1530	-0.39	-4.97	-0.41	2.2e-6	Obesity-related traits;
TGCT	cis	rs2455799	0.517	rs9835592	chr3:15936942	A/G	cg12172478	chr3:16357591	RFTN1	-0.33	-4.81	-0.4	4.31e-6	Mean platelet volume;
TGCT	cis	rs7914558	0.966	rs12766205	chr10:104893568	A/G	cg15744005	chr10:104629667	AS3MT	-0.42	-5.24	-0.43	6.69e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs7617773	0.815	rs9825637	chr3:48372282	T/C	cg11946769	chr3:48343235	NME6	0.8	6.88	0.53	2.61e-10	Coronary artery disease;
TGCT	cis	rs9638182	1.000	rs35659126	chr7:72988069	C/T	cg14087351	chr7:73037990	MLXIPL	-0.56	-4.73	-0.39	6.08e-6	Triglycerides;
TGCT	cis	rs2797160	1.000	rs2797161	chr6:126010789	A/G	cg05901451	chr6:126070800	HEY2	0.73	6.3	0.49	4.83e-9	Endometrial cancer;
TGCT	cis	rs77372450	0.591	rs11740603	chr5:157098756	G/T	cg12606933	chr5:157078573	SOX30	-0.42	-4.72	-0.39	6.3e-6	Bipolar disorder (body mass index interaction);
TGCT	cis	rs2657888	1.000	rs73118833	chr12:56941734	C/A	cg23932658	chr12:57637574	STAC3	-0.51	-4.73	-0.39	5.9e-6	Adiponectin levels;
TGCT	cis	rs13392177	0.672	rs4674270	chr2:219053141	G/T	cg00012203	chr2:219082015	ARPC2	-0.77	-7.94	-0.58	1.04e-12	Pyoderma gangrenosum in inflammatory bowel disease;
TGCT	cis	rs514406	0.621	rs2003250	chr1:53196666	T/C	cg16325326	chr1:53192061	ZYG11B	-0.89	-13.12	-0.76	3.31e-25	Monocyte count;
TGCT	cis	rs1894292	0.527	rs34468776	chr4:74362504	T/A	cg05868023	chr4:75230803	EREG	0.53	4.52	0.38	1.43e-5	Prostate cancer;
TGCT	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg18876405	chr7:65276391	NA	-0.31	-4.82	-0.4	4.12e-6	Aortic root size;
TGCT	cis	rs3820068	0.581	rs72645890	chr1:15930602	A/G	cg05660106	chr1:15850417	CASP9	0.82	8.02	0.58	6.63e-13	Systolic blood pressure;
TGCT	cis	rs473651	1.000	rs473651	chr2:239335401	A/C	cg18131467	chr2:239335373	ASB1	1.01	14.5	0.79	1.78e-28	Multiple system atrophy;
TGCT	cis	rs1670533	1.000	rs11735663	chr4:1051845	C/T	cg20887711	chr4:1340912	KIAA1530	0.72	5.73	0.46	7.16e-8	Recombination rate (females);
TGCT	cis	rs2742417	1.000	rs2742397	chr3:45758946	C/G	cg04837898	chr3:45731254	SACM1L	0.5	5.16	0.42	9.55e-7	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs524281	0.861	rs535395	chr11:65906534	A/G	cg00563793	chr11:65837595	PACS1	-0.56	-4.83	-0.4	3.9e-6	Electroencephalogram traits;
TGCT	cis	rs13424612	0.965	rs58652766	chr2:240904884	G/A	cg26363272	chr2:240904871	NDUFA10	0.3	4.97	0.41	2.15e-6	Odorant perception (isobutyraldehyde);
TGCT	cis	rs1008375	0.966	rs6825133	chr4:17577776	C/T	cg10189774	chr4:17578691	LAP3	0.64	5.61	0.45	1.28e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs62244186	0.659	rs56231820	chr3:44530329	C/T	cg04389838	chr3:44770851	ZNF501	-0.41	-5.72	-0.46	7.49e-8	Depressive symptoms;
TGCT	cis	rs367943	1.000	rs348929	chr5:112814883	T/A	cg12552261	chr5:112820674	MCC	-0.24	-4.91	-0.4	2.81e-6	Type 2 diabetes;
TGCT	cis	rs12579753	0.956	rs7965168	chr12:82184467	C/A	cg07988820	chr12:82153109	PPFIA2	-0.65	-6.79	-0.52	4.09e-10	Resting heart rate;
TGCT	cis	rs17030434	0.822	rs4696492	chr4:154679981	T/A	cg14289246	chr4:154710475	SFRP2	0.9	7.0	0.53	1.41e-10	Electrocardiographic conduction measures;
TGCT	cis	rs9467711	0.606	rs2073527	chr6:26374978	T/C	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9916302	0.851	rs12947620	chr17:37605364	T/C	cg15445000	chr17:37608096	MED1	0.31	4.59	0.38	1.06e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs2153535	0.580	rs1120392	chr6:8487053	C/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs17102423	0.755	rs7161394	chr14:65563309	G/T	cg11161011	chr14:65562177	MAX	-0.55	-7.7	-0.57	3.74e-12	Obesity-related traits;
TGCT	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg13395646	chr4:1353034	KIAA1530	-0.4	-5.0	-0.41	1.93e-6	Obesity-related traits;
TGCT	cis	rs4653767	1.000	rs708775	chr1:226923264	G/A	cg10327440	chr1:227177885	CDC42BPA	-0.47	-5.22	-0.42	7.27e-7	Parkinson's disease;
TGCT	cis	rs4808199	0.948	rs2301668	chr19:19452249	G/A	cg03709012	chr19:19516395	GATAD2A	0.81	6.32	0.49	4.32e-9	Nonalcoholic fatty liver disease;
TGCT	cis	rs58722170	0.659	rs61776209	chr1:38090323	C/T	cg17933807	chr1:38061675	GNL2	-0.87	-8.9	-0.62	5.71e-15	High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs7552404	0.883	rs7513363	chr1:76143443	A/G	cg10523679	chr1:76189770	ACADM	0.9	9.92	0.67	2e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs6728642	0.908	rs9973669	chr2:97679094	T/C	cg26665480	chr2:98280029	ACTR1B	-0.95	-5.88	-0.47	3.52e-8	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	cis	rs7523050	0.643	rs34114412	chr1:109402866	C/T	cg08274380	chr1:109419600	GPSM2	1.3	6.39	0.5	2.99e-9	Fat distribution (HIV);
TGCT	cis	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg20637647	chr7:64974828	NA	-0.9	-5.31	-0.43	4.87e-7	Diabetic kidney disease;
TGCT	cis	rs2327429	0.767	rs12190287	chr6:134214525	C/G	cg08368617	chr6:134217040	NA	-0.45	-4.57	-0.38	1.17e-5	Coronary artery disease;
TGCT	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg11905131	chr22:24372483	LOC391322	0.88	8.52	0.61	4.62e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6598955	0.671	rs12145403	chr1:26597189	C/T	cg14788334	chr1:26606110	SH3BGRL3	0.24	4.61	0.38	9.71e-6	Obesity-related traits;
TGCT	cis	rs3806843	0.735	rs3776129	chr5:140072292	G/A	cg19875535	chr5:140030758	IK	-0.37	-6.23	-0.49	6.51e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs11098499	0.954	rs10034623	chr4:120397829	G/A	cg09307838	chr4:120376055	NA	0.72	7.08	0.54	9.22e-11	Corneal astigmatism;
TGCT	cis	rs9926296	0.643	rs12596429	chr16:89841374	T/C	cg26513180	chr16:89883248	FANCA	0.72	7.03	0.53	1.24e-10	Vitiligo;
TGCT	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg18876405	chr7:65276391	NA	0.32	4.89	0.4	3.1e-6	Aortic root size;
TGCT	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg07061783	chr6:25882402	NA	-0.66	-6.91	-0.53	2.2e-10	Blood metabolite levels;
TGCT	cis	rs3812831	0.630	rs9562129	chr13:114917152	A/G	cg06611532	chr13:114900021	NA	0.34	6.0	0.47	2.04e-8	Schizophrenia;
TGCT	cis	rs13191362	1.000	rs35723993	chr6:163008197	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs57590327	0.503	rs9880844	chr3:81507217	C/T	cg07356753	chr3:81810745	GBE1	0.58	4.89	0.4	3.06e-6	Extraversion;
TGCT	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	5.02	0.41	1.78e-6	Prudent dietary pattern;
TGCT	cis	rs6725041	0.819	rs1521660	chr2:213082960	C/T	cg16329650	chr2:213403929	ERBB4	-0.54	-4.64	-0.38	8.57e-6	QT interval (ambient particulate matter interaction);
TGCT	cis	rs2629540	0.737	rs10901821	chr10:126480556	T/C	cg08799069	chr10:126477246	METTL10	-0.3	-4.83	-0.4	4e-6	Cocaine dependence;
TGCT	cis	rs6582630	0.533	rs11504406	chr12:38334580	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-4.51	-0.38	1.5e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs7819412	0.775	rs4841489	chr8:10936811	A/G	cg21775007	chr8:11205619	TDH	-0.5	-4.61	-0.38	9.83e-6	Triglycerides;
TGCT	cis	rs6545977	0.692	rs58235267	chr2:63277843	C/G	cg17519650	chr2:63277830	OTX1	0.73	8.01	0.58	7.03e-13	Prostate cancer;
TGCT	cis	rs7572733	0.555	rs7561950	chr2:198754244	C/T	cg00792783	chr2:198669748	PLCL1	0.57	5.11	0.42	1.2e-6	Dermatomyositis;
TGCT	cis	rs9914544	0.545	rs3803835	chr17:18793061	C/T	cg26378065	chr17:18585709	ZNF286B	0.53	4.63	0.38	9.01e-6	Educational attainment (years of education);
TGCT	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg11764359	chr7:65958608	NA	-0.61	-5.52	-0.44	1.93e-7	Aortic root size;
TGCT	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg01416388	chr22:39784598	NA	-0.72	-7.15	-0.54	6.43e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs9467711	0.790	rs13195402	chr6:26463575	G/T	cg16898833	chr6:26189333	HIST1H4D	1.37	6.2	0.49	7.83e-9	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs789852	0.764	rs2794668	chr3:194316895	C/T	cg18000598	chr3:194342907	TMEM44	-0.76	-5.09	-0.42	1.31e-6	QT interval;
TGCT	cis	rs2639990	1.000	rs609303	chr18:72895242	C/T	cg02750262	chr18:72916776	ZADH2	0.87	6.6	0.51	1.08e-9	Vascular endothelial growth factor levels;
TGCT	cis	rs7917772	0.636	rs7894154	chr10:104524647	G/A	cg05855489	chr10:104503620	C10orf26	0.67	5.32	0.43	4.77e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1538970	1.000	rs4520450	chr1:45834773	A/G	cg05343316	chr1:45956843	TESK2	0.64	5.06	0.41	1.47e-6	Platelet count;
TGCT	cis	rs7267979	0.744	rs6050464	chr20:25209299	C/A	cg03522245	chr20:25566470	NINL	0.56	5.63	0.45	1.13e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7267979	0.932	rs449703	chr20:25458559	C/T	cg14121845	chr20:25566513	NINL	0.49	5.36	0.43	3.83e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs17206232	0.534	rs6877731	chr5:64695717	C/T	cg12806353	chr3:119315532	PLA1A	0.45	6.98	0.53	1.58e-10	Schizophrenia;
TGCT	trans	rs208520	0.690	rs10455595	chr6:66738034	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	10.83	0.7	1.19e-19	Exhaled nitric oxide output;
TGCT	cis	rs9300255	0.537	rs2695482	chr12:123623174	C/T	cg00376283	chr12:123451042	ABCB9	0.71	5.54	0.45	1.7e-7	Neutrophil percentage of white cells;
TGCT	cis	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg07424592	chr7:64974309	NA	1.4	8.42	0.6	7.87e-14	Diabetic kidney disease;
TGCT	cis	rs35828350	1	rs35828350	chr15:85355841	G/A	cg11189052	chr15:85197271	WDR73	0.71	5.88	0.47	3.62e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9859260	0.744	rs492349	chr3:195784192	G/A	cg22891161	chr3:195456627	MUC20	0.23	4.6	0.38	1.04e-5	Mean corpuscular volume;
TGCT	cis	rs9300255	0.596	rs4460848	chr12:123677810	A/G	cg00376283	chr12:123451042	ABCB9	0.79	6.75	0.52	5e-10	Neutrophil percentage of white cells;
TGCT	cis	rs7607369	0.580	rs17573731	chr2:219652153	T/C	cg02176678	chr2:219576539	TTLL4	-0.45	-5.86	-0.47	3.89e-8	Red blood cell count;Amyotrophic lateral sclerosis;
TGCT	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg03264133	chr6:25882463	NA	0.74	7.71	0.57	3.43e-12	Blood metabolite levels;
TGCT	cis	rs9894429	1.000	rs7503679	chr17:79583843	G/C	cg21028142	chr17:79581711	NPLOC4	0.29	6.81	0.52	3.83e-10	Eye color traits;
TGCT	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg00908189	chr16:619842	PIGQ	0.87	10.65	0.69	3.27e-19	Height;
TGCT	cis	rs5769765	0.778	rs8137331	chr22:50313358	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.19	-12.02	-0.73	1.56e-22	Schizophrenia;
TGCT	cis	rs10779751	0.770	rs6674994	chr1:11239515	T/C	cg08854313	chr1:11322531	MTOR	0.84	8.09	0.59	4.52e-13	Body mass index;
TGCT	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2235642	0.717	rs9937922	chr16:1658154	C/G	cg07639376	chr16:1584516	IFT140;TMEM204	-0.29	-4.95	-0.41	2.38e-6	Coronary artery disease;
TGCT	cis	rs910316	0.967	rs12147532	chr14:75651858	T/G	cg08847533	chr14:75593920	NEK9	-0.91	-9.56	-0.65	1.46e-16	Height;
TGCT	cis	rs9640161	0.830	rs13307276	chr7:150061525	T/C	cg21361702	chr7:150065534	REPIN1	0.49	4.47	0.37	1.75e-5	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg08392591	chr16:89556376	ANKRD11	0.61	5.78	0.46	5.71e-8	Multiple myeloma (IgH translocation);
TGCT	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	16.1	0.82	3.69e-32	Prudent dietary pattern;
TGCT	trans	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg13565492	chr6:43139072	SRF	-0.82	-7.72	-0.57	3.43e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.03	0.41	1.68e-6	Prudent dietary pattern;
TGCT	cis	rs9325144	0.600	rs34138871	chr12:38735261	A/G	cg26384229	chr12:38710491	ALG10B	0.61	5.65	0.45	1.05e-7	Morning vs. evening chronotype;
TGCT	cis	rs11098499	0.863	rs10018280	chr4:120478139	T/G	cg09307838	chr4:120376055	NA	0.74	7.34	0.55	2.49e-11	Corneal astigmatism;
TGCT	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg27425262	chr2:113953981	PSD4;LOC440839	-0.47	-6.82	-0.52	3.64e-10	Lymphocyte counts;
TGCT	cis	rs748404	0.578	rs2278856	chr15:43631356	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.46	4.44	0.37	1.98e-5	Lung cancer;
TGCT	cis	rs9549260	0.755	rs7338669	chr13:41200091	C/T	cg21288729	chr13:41239152	FOXO1	-0.98	-10.52	-0.69	6.96e-19	Red blood cell count;
TGCT	cis	rs6543140	0.964	rs13383602	chr2:103085962	C/T	cg09003973	chr2:102972529	NA	0.54	4.46	0.37	1.83e-5	Blood protein levels;
TGCT	cis	rs9527	0.590	rs943039	chr10:104825132	C/T	cg15744005	chr10:104629667	AS3MT	-0.42	-4.87	-0.4	3.29e-6	Arsenic metabolism;
TGCT	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	6.11	0.48	1.17e-8	Alzheimer's disease;
TGCT	cis	rs6940638	1.000	rs12215241	chr6:27023081	G/A	cg16898833	chr6:26189333	HIST1H4D	0.77	5.68	0.45	8.91e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs73198271	0.628	rs56188408	chr8:8592158	G/C	ch.8.214553F	chr8:8189620	PRAGMIN	-0.32	-5.23	-0.42	7.04e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg24531977	chr5:56204891	C5orf35	-0.77	-7.61	-0.56	5.83e-12	Initial pursuit acceleration;
TGCT	cis	rs3813567	0.702	rs7164665	chr15:78953919	T/C	cg24631222	chr15:78858424	CHRNA5	0.68	4.72	0.39	6.35e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
TGCT	cis	rs9604529	0.557	rs74406200	chr13:114741208	C/T	cg13259177	chr13:114761607	RASA3	-0.27	-4.54	-0.38	1.32e-5	Response to tocilizumab in rheumatoid arthritis;
TGCT	cis	rs6500602	0.727	rs2160567	chr16:4535557	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.29	5.35	0.43	4.12e-7	Schizophrenia;
TGCT	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-5.1	-0.42	1.23e-6	Electroencephalogram traits;
TGCT	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg12311346	chr5:56204834	C5orf35	-0.67	-6.77	-0.52	4.59e-10	Initial pursuit acceleration;
TGCT	cis	rs7617773	0.710	rs36064160	chr3:48243101	C/G	cg11946769	chr3:48343235	NME6	0.76	6.53	0.51	1.54e-9	Coronary artery disease;
TGCT	cis	rs9902453	0.967	rs7212741	chr17:28322941	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.75	6.55	0.51	1.36e-9	Coffee consumption (cups per day);
TGCT	cis	rs5760092	0.755	rs3884794	chr22:24251766	C/A	cg04234412	chr22:24373322	LOC391322	-0.88	-8.35	-0.6	1.17e-13	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs7044106	0.762	rs1158553	chr9:123400974	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	4.87	0.4	3.3e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg00149659	chr3:10157352	C3orf10	0.91	5.89	0.47	3.32e-8	Alzheimer's disease;
TGCT	cis	rs6964587	1.000	rs6979085	chr7:91673623	C/T	cg17063962	chr7:91808500	NA	0.88	9.65	0.66	8.73e-17	Breast cancer;
TGCT	cis	rs9467773	0.549	rs9467805	chr6:26583366	C/T	cg05738196	chr6:26577821	NA	0.87	11.1	0.71	2.65e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg03806693	chr22:41940476	POLR3H	1.14	12.91	0.76	1.07e-24	Vitiligo;
TGCT	cis	rs1697139	0.583	rs11960733	chr5:66538715	C/T	cg11553311	chr5:66541588	NA	0.3	6.4	0.5	2.84e-9	Breast cancer;
TGCT	cis	rs2456568	0.803	rs10831142	chr11:93640781	A/G	cg16099599	chr11:93583650	C11orf90	0.42	5.4	0.44	3.24e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.12	0.54	7.78e-11	Prudent dietary pattern;
TGCT	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg24549020	chr5:56110836	MAP3K1	0.67	5.73	0.46	7.1e-8	Type 2 diabetes;
TGCT	cis	rs11098499	0.955	rs1551	chr4:120158500	T/G	cg24670566	chr4:120433619	PDE5A	0.23	4.45	0.37	1.89e-5	Corneal astigmatism;
TGCT	cis	rs4285028	0.747	rs9808981	chr3:121429561	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.92	-7.3	-0.55	3.03e-11	Multiple sclerosis;
TGCT	cis	rs7582180	0.629	rs6716636	chr2:100940067	C/G	cg08017756	chr2:100939284	LONRF2	-0.3	-4.78	-0.39	4.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	5.38	0.44	3.58e-7	Alzheimer's disease;
TGCT	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg08219700	chr8:58056026	NA	0.38	4.69	0.39	6.95e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9467773	0.967	rs1535276	chr6:26520941	T/C	cg26531700	chr6:26746687	NA	0.47	4.57	0.38	1.14e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs765787	0.530	rs1648285	chr15:45517505	C/G	cg24006582	chr15:45444508	DUOX1	-0.26	-5.7	-0.46	8.11e-8	Uric acid levels;
TGCT	cis	rs3741404	1.000	rs3741404	chr11:63999240	G/C	cg03236948	chr11:63997492	DNAJC4	0.37	4.67	0.39	7.66e-6	Platelet count;
TGCT	cis	rs910316	1.000	rs4899544	chr14:75546556	C/T	cg08847533	chr14:75593920	NEK9	0.96	10.6	0.69	4.3e-19	Height;
TGCT	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg13699009	chr12:122356056	WDR66	0.28	6.14	0.48	1.05e-8	Mean corpuscular volume;
TGCT	cis	rs4654899	0.965	rs4654907	chr1:21521094	C/T	cg01072550	chr1:21505969	NA	-0.5	-8.03	-0.59	6.27e-13	Superior frontal gyrus grey matter volume;
TGCT	cis	rs2242194	0.816	rs11264296	chr1:154994750	T/C	cg12436631	chr1:155007014	DCST1;DCST2	0.26	7.04	0.53	1.16e-10	Schizophrenia;
TGCT	cis	rs11098499	0.691	rs9996644	chr4:120238877	G/T	cg09307838	chr4:120376055	NA	0.63	6.14	0.48	1.01e-8	Corneal astigmatism;
TGCT	cis	rs17345786	0.628	rs11718446	chr3:101552553	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.36	-7.75	-0.57	2.86e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9467711	0.606	rs12174623	chr6:26373086	C/T	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs13191362	1.000	rs73035023	chr6:163000927	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg20891558	chr2:74357851	NA	0.59	8.97	0.63	3.96e-15	Gestational age at birth (maternal effect);
TGCT	cis	rs2456568	0.803	rs10765641	chr11:93640312	T/C	cg26875233	chr11:93583750	C11orf90	-0.48	-6.35	-0.5	3.73e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg12667521	chr19:29218732	NA	0.53	6.34	0.49	3.83e-9	Methadone dose in opioid dependence;
TGCT	cis	rs12478296	1.000	rs73007129	chr2:243000555	T/C	cg06360820	chr2:242988706	NA	-0.79	-5.2	-0.42	7.9e-7	Obesity-related traits;
TGCT	cis	rs78487399	0.808	rs111812200	chr2:43674278	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-5.09	-0.42	1.3e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs3096299	0.933	rs889576	chr16:89429653	A/G	cg06640241	chr16:89574553	SPG7	-0.57	-5.62	-0.45	1.21e-7	Multiple myeloma (IgH translocation);
TGCT	cis	rs7547997	0.615	rs34591069	chr1:158316990	G/C	cg03528325	chr1:158223921	CD1A	0.33	4.81	0.4	4.38e-6	QRS duration;
TGCT	cis	rs10851411	0.908	rs12324717	chr15:42846553	C/A	cg23803468	chr15:43513504	EPB42	0.27	5.16	0.42	9.47e-7	Glucose homeostasis traits;
TGCT	cis	rs56235845	0.964	rs11746443	chr5:176798306	G/A	cg06060754	chr5:176797920	RGS14	0.62	10.78	0.7	1.58e-19	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg24675658	chr1:53192096	ZYG11B	-0.69	-8.17	-0.59	3.05e-13	Monocyte count;
TGCT	cis	rs35146811	0.735	rs1061230	chr7:99807265	G/A	cg00553149	chr7:99775558	STAG3;GPC2	-0.31	-4.61	-0.38	9.75e-6	Coronary artery disease;
TGCT	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg21016266	chr12:122356598	WDR66	0.43	5.65	0.45	1.03e-7	Mean corpuscular volume;
TGCT	cis	rs9659323	0.931	rs113197996	chr1:119522426	G/A	cg07961512	chr1:119535619	NA	0.44	4.99	0.41	2.01e-6	Body mass index;
TGCT	cis	rs2688608	0.592	rs3933085	chr10:75483331	C/T	cg04320760	chr10:75533139	FUT11	-0.4	-6.25	-0.49	6.11e-9	Inflammatory bowel disease;
TGCT	cis	rs17152411	0.947	rs17152408	chr10:126649007	C/T	cg07906193	chr10:126599966	NA	0.37	4.72	0.39	6.35e-6	Height;
TGCT	cis	rs2224391	0.578	rs766339	chr6:5243506	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-1.04	-6.69	-0.51	6.87e-10	Height;
TGCT	cis	rs929354	0.713	rs1034785	chr7:157002383	T/C	cg05182265	chr7:156933206	UBE3C	-0.38	-8.68	-0.61	1.92e-14	Body mass index;
TGCT	cis	rs782590	0.537	rs12619903	chr2:55884106	T/A	cg03859395	chr2:55845619	SMEK2	-0.64	-5.17	-0.42	9.11e-7	Metabolic syndrome;
TGCT	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg17554472	chr22:41940697	POLR3H	-0.47	-4.89	-0.4	3.06e-6	Vitiligo;
TGCT	cis	rs1008375	1.000	rs6849704	chr4:17652031	G/C	cg10189774	chr4:17578691	LAP3	0.57	5.15	0.42	9.95e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7104764	0.957	rs519592	chr11:236811	G/A	cg18336825	chr11:236787	PSMD13;SIRT3	1.13	13.04	0.76	5.36e-25	Menarche (age at onset);
TGCT	cis	rs2251381	0.750	rs2255055	chr21:30537045	C/T	cg24692254	chr21:30365293	RNF160	0.71	6.98	0.53	1.56e-10	Selective IgA deficiency;
TGCT	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg11890956	chr21:40555474	PSMG1	-0.69	-6.81	-0.52	3.7e-10	Menarche (age at onset);
TGCT	cis	rs709400	0.663	rs3742458	chr14:103950368	A/G	cg12935359	chr14:103987150	CKB	-0.36	-5.64	-0.45	1.11e-7	Body mass index;
TGCT	cis	rs1532993	0.518	rs10513769	chr4:98595395	G/C	cg05340658	chr4:99064831	C4orf37	-0.38	-4.49	-0.37	1.59e-5	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs986417	0.818	rs767602	chr14:61098624	G/T	cg27398547	chr14:60952738	C14orf39	1.48	8.31	0.6	1.44e-13	Gut microbiota (bacterial taxa);
TGCT	cis	rs933688	1.000	rs2059208	chr5:90732065	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.05	10.44	0.68	1.07e-18	Smoking behavior;
TGCT	cis	rs7824557	0.670	rs2736381	chr8:11132766	A/T	cg21775007	chr8:11205619	TDH	-0.5	-4.51	-0.38	1.48e-5	Retinal vascular caliber;
TGCT	cis	rs13082711	0.519	rs13091109	chr3:27229125	G/A	cg02860705	chr3:27208620	NA	0.43	6.88	0.53	2.58e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs9467773	1.000	rs2224380	chr6:26553943	G/A	cg15659132	chr6:26577336	NA	0.89	13.14	0.76	3.05e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs57920188	0.703	rs3813810	chr1:4088339	G/T	cg20703997	chr1:4087676	NA	0.46	4.98	0.41	2.09e-6	Interleukin-17 levels;
TGCT	cis	rs2442825	0.508	rs2648545	chr3:9389223	C/T	cg24633833	chr3:10029261	TMEM111	-0.53	-5.16	-0.42	9.7e-7	Cerebrospinal fluid clusterin levels;
TGCT	cis	rs3008870	0.583	rs2815369	chr1:67500894	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.97	8.09	0.59	4.6e-13	Lymphocyte percentage of white cells;
TGCT	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg22920501	chr2:26401640	FAM59B	-0.78	-6.16	-0.48	9.43e-9	Gut microbiome composition (summer);
TGCT	cis	rs586688	1.000	rs492563	chr1:201631471	C/T	cg14168733	chr1:201708718	NAV1	-0.54	-4.52	-0.38	1.43e-5	Obesity-related traits;
TGCT	trans	rs7726839	0.540	rs58599998	chr5:596087	A/G	cg11887960	chr12:57824829	NA	1.2	9.56	0.65	1.47e-16	Obesity-related traits;
TGCT	cis	rs7945705	0.935	rs2653593	chr11:8877317	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-5.62	-0.45	1.21e-7	Hemoglobin concentration;
TGCT	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs116975820	0.698	rs11181497	chr12:42814962	A/G	cg19980929	chr12:42632907	YAF2	0.6	4.82	0.4	4.14e-6	PR interval in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7264396	0.790	rs3787166	chr20:34229072	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.28	-4.52	-0.38	1.44e-5	Total cholesterol levels;
TGCT	cis	rs2535633	0.631	rs11915851	chr3:53096047	C/T	cg11645453	chr3:52864694	ITIH4	0.27	5.19	0.42	8.41e-7	Body mass index;
TGCT	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg21951975	chr1:209979733	IRF6	0.66	5.69	0.45	8.77e-8	Cleft lip with or without cleft palate;
TGCT	cis	rs9902453	0.791	rs3115086	chr17:28025949	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.85	8.57	0.61	3.4e-14	Coffee consumption (cups per day);
TGCT	cis	rs2303745	0.589	rs8103523	chr19:17398269	A/G	cg04248312	chr19:17393744	ANKLE1	-0.34	-5.59	-0.45	1.35e-7	Systemic lupus erythematosus;
TGCT	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg19318889	chr4:1322082	MAEA	0.29	6.6	0.51	1.06e-9	Longevity;
TGCT	cis	rs12497850	0.931	rs4974082	chr3:48999323	G/A	cg18654377	chr3:49208889	KLHDC8B	-0.42	-5.46	-0.44	2.48e-7	Parkinson's disease;
TGCT	cis	rs1580019	0.510	rs4723162	chr7:32543804	C/A	cg06627557	chr7:32535165	LSM5;AVL9	1.13	14.11	0.79	1.45e-27	Cognitive ability;
TGCT	cis	rs10114408	0.918	rs10992952	chr9:96645436	T/A	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	trans	rs561341	0.843	rs879945	chr17:30242796	G/A	cg20587970	chr11:113659929	NA	-0.86	-11.09	-0.71	2.74e-20	Hip circumference adjusted for BMI;
TGCT	trans	rs7698623	0.850	rs4693891	chr4:88787834	C/T	cg01186725	chr1:53905612	FLJ40434	-0.48	-6.63	-0.51	9.21e-10	Cardiovascular disease risk factors;
TGCT	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg08736216	chr1:53307985	ZYG11A	-0.3	-6.06	-0.48	1.48e-8	Monocyte count;
TGCT	cis	rs7027203	0.828	rs10821229	chr9:96595136	A/C	cg13679303	chr9:96623674	NA	-0.66	-10.78	-0.7	1.64e-19	DNA methylation (variation);
TGCT	cis	rs9650657	0.645	rs11774552	chr8:10515679	C/T	cg27411982	chr8:10470053	RP1L1	-0.23	-4.93	-0.4	2.62e-6	Neuroticism;
TGCT	cis	rs1525293	0.714	rs12698979	chr7:70506630	A/T	cg21135135	chr7:70597687	WBSCR17	-0.47	-4.66	-0.39	7.9e-6	Colonoscopy-negative controls vs population controls;Major depressive disorder;
TGCT	cis	rs7412746	0.611	rs1889741	chr1:150869045	T/C	cg04414720	chr1:150670196	GOLPH3L	0.37	4.46	0.37	1.81e-5	Melanoma;
TGCT	cis	rs6845621	0.840	rs6816238	chr4:18918968	T/C	cg12196642	chr4:18937545	NA	-0.24	-4.45	-0.37	1.91e-5	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
TGCT	cis	rs1577917	0.917	rs1838959	chr6:86556804	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.29	-0.43	5.34e-7	Response to antipsychotic treatment;
TGCT	cis	rs7582180	0.629	rs11686649	chr2:100946701	T/C	cg14675211	chr2:100938903	LONRF2	0.5	4.78	0.39	4.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7829975	0.572	rs28446104	chr8:8795901	C/G	cg15556689	chr8:8085844	FLJ10661	-0.68	-5.91	-0.47	3.04e-8	Mood instability;
TGCT	cis	rs8017423	0.967	rs7147809	chr14:90715025	A/G	cg04374321	chr14:90722782	PSMC1	0.74	7.74	0.57	2.98e-12	Mortality in heart failure;
TGCT	cis	rs939658	0.728	rs8031638	chr15:79422726	C/T	cg17916960	chr15:79447300	NA	-0.48	-6.69	-0.52	6.71e-10	Refractive error;
TGCT	cis	rs17739794	0.677	rs17739674	chr8:801584	G/T	cg20652464	chr8:752313	NA	-0.24	-4.59	-0.38	1.08e-5	Clozapine-induced cytotoxicity;
TGCT	cis	rs644799	0.710	rs10831427	chr11:95508383	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.81	9.02	0.63	2.92e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs231513	1.000	rs231518	chr17:41961451	C/T	cg26893861	chr17:41843967	DUSP3	0.72	5.31	0.43	4.91e-7	Cognitive function;
TGCT	cis	rs2439831	0.850	rs7169988	chr15:44060435	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	5.93	0.47	2.78e-8	Lung cancer in ever smokers;
TGCT	cis	rs2486288	0.656	rs7171312	chr15:45570225	C/G	cg14582100	chr15:45693742	SPATA5L1	-0.43	-4.86	-0.4	3.48e-6	Glomerular filtration rate;
TGCT	cis	rs9653442	0.527	rs2118280	chr2:100746395	G/A	cg22139774	chr2:100720529	AFF3	-0.37	-5.48	-0.44	2.24e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg21862992	chr11:68658383	NA	0.47	6.54	0.51	1.42e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs950169	0.881	rs62029599	chr15:84956565	A/C	cg11189052	chr15:85197271	WDR73	0.81	6.22	0.49	6.89e-9	Schizophrenia;
TGCT	trans	rs1496653	0.602	rs13082311	chr3:23600011	A/G	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs9486719	1.000	rs1303852	chr6:96864523	C/T	cg18709589	chr6:96969512	KIAA0776	0.71	5.21	0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs6964587	0.967	rs7783414	chr7:91785957	C/T	cg17063962	chr7:91808500	NA	0.89	9.55	0.65	1.53e-16	Breast cancer;
TGCT	cis	rs981844	0.735	rs111822747	chr4:154734629	G/C	cg14289246	chr4:154710475	SFRP2	1.01	8.88	0.62	6.23e-15	Response to statins (LDL cholesterol change);
TGCT	trans	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg17470723	chr8:74884337	TCEB1	0.72	6.94	0.53	1.91e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9303401	0.614	rs3887355	chr17:56538639	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.77	0.52	4.6e-10	Cognitive test performance;
TGCT	cis	rs3026101	0.624	rs1058400	chr17:5288794	G/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.49	4.92	0.4	2.73e-6	Body mass index;
TGCT	cis	rs4746818	1.000	rs10823301	chr10:70885875	G/A	cg11621586	chr10:70884670	VPS26A	1.16	10.93	0.7	6.81e-20	Left atrial antero-posterior diameter;
TGCT	cis	rs12210905	0.688	rs12209905	chr6:27404592	C/G	cg08851530	chr6:28072375	NA	1.34	6.07	0.48	1.44e-8	Hip circumference adjusted for BMI;
TGCT	cis	rs11690935	0.843	rs9784123	chr2:172785005	T/A	cg13550731	chr2:172543902	DYNC1I2	-0.86	-7.68	-0.57	4.12e-12	Schizophrenia;
TGCT	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg11764359	chr7:65958608	NA	-0.63	-5.8	-0.46	5.13e-8	Aortic root size;
TGCT	cis	rs806215	0.526	rs12673293	chr7:127520162	T/G	cg11539674	chr7:127291444	SND1	-0.36	-4.65	-0.39	8.46e-6	Type 2 diabetes;
TGCT	cis	rs1953600	1.000	rs2789679	chr10:81907884	A/T	cg04850286	chr10:81895943	PLAC9	-0.4	-4.72	-0.39	6.32e-6	Sarcoidosis;
TGCT	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.45	4.71	0.39	6.41e-6	Lymphocyte counts;
TGCT	cis	rs7647973	0.626	rs4855833	chr3:49657441	A/G	cg05785598	chr3:49045655	WDR6	0.42	5.24	0.43	6.67e-7	Menarche (age at onset);
TGCT	cis	rs12477438	0.501	rs12992218	chr2:99753834	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.82	0.62	8.67e-15	Chronic sinus infection;
TGCT	cis	rs7216064	0.911	rs12449442	chr17:65947640	G/A	cg12091567	chr17:66097778	LOC651250	-0.82	-6.18	-0.49	8.44e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs9902453	0.808	rs10445400	chr17:28183059	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.75	6.96	0.53	1.75e-10	Coffee consumption (cups per day);
TGCT	cis	rs13185784	0.667	rs4700728	chr5:179647551	T/G	cg04734276	chr5:178882605	NA	0.29	4.46	0.37	1.79e-5	TRAIL levels;
TGCT	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg22963979	chr7:1858916	MAD1L1	-0.34	-5.03	-0.41	1.7e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs7552404	0.731	rs10873788	chr1:76367857	A/C	cg03433033	chr1:76189801	ACADM	0.69	6.46	0.5	2.1e-9	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg00343986	chr7:65444356	GUSB	0.22	5.38	0.44	3.58e-7	Calcium levels;
TGCT	cis	rs7917772	0.636	rs2486757	chr10:104535145	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.58	4.77	0.39	5.02e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2735413	0.564	rs1882595	chr16:78100684	G/A	cg09132178	chr16:78079569	NA	0.36	4.85	0.4	3.64e-6	Systolic blood pressure (alcohol consumption interaction);
TGCT	cis	rs13326165	0.760	rs34762015	chr3:52366044	G/A	cg07884673	chr3:53033167	SFMBT1	0.38	4.65	0.39	8.2e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs6754311	0.593	rs313524	chr2:136444123	C/T	cg07169764	chr2:136633963	MCM6	0.69	6.28	0.49	5.13e-9	Mosquito bite size;
TGCT	cis	rs7666738	0.519	rs11732209	chr4:98801643	A/G	cg17366294	chr4:99064904	C4orf37	0.61	5.71	0.46	8.05e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6831352	0.918	rs7694646	chr4:100059732	T/A	cg12011299	chr4:100065546	ADH4	-0.41	-4.97	-0.41	2.21e-6	Alcohol dependence;
TGCT	cis	rs651907	0.557	rs13081846	chr3:101383321	T/C	cg12386194	chr3:101231763	SENP7	0.53	5.13	0.42	1.08e-6	Colorectal cancer;
TGCT	cis	rs9611565	0.592	rs4481089	chr22:41980892	T/C	cg17554472	chr22:41940697	POLR3H	-0.49	-5.15	-0.42	9.88e-7	Vitiligo;
TGCT	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.6	6.44	0.5	2.39e-9	Height;
TGCT	cis	rs12519773	0.501	rs4293897	chr5:92500822	T/G	cg04854328	chr5:92914828	FLJ42709	-0.3	-4.55	-0.38	1.24e-5	Migraine;
TGCT	cis	rs3091242	0.967	rs3093614	chr1:25677844	T/A	cg09222892	chr1:25734099	RHCE	0.44	7.12	0.54	7.87e-11	Erythrocyte sedimentation rate;
TGCT	cis	rs3751972	0.668	rs4796228	chr17:26222810	A/G	cg02948944	chr17:26242737	NA	-0.35	-5.14	-0.42	1.05e-6	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs11190604	1.000	rs2495752	chr10:102326115	T/C	cg23241863	chr10:102295624	HIF1AN	0.68	5.17	0.42	9.18e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs73198271	0.694	rs115037021	chr8:8647080	A/C	cg06671706	chr8:8559999	CLDN23	-0.35	-4.5	-0.37	1.52e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs2227564	0.620	rs10740418	chr10:75519322	T/C	cg04320760	chr10:75533139	FUT11	-0.32	-4.55	-0.38	1.28e-5	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs9457247	1.000	rs239935	chr6:167411788	G/A	cg23791538	chr6:167370224	RNASET2	-0.52	-5.15	-0.42	1e-6	Crohn's disease;
TGCT	cis	rs11623869	0.614	rs11627052	chr14:103863476	A/G	cg12935359	chr14:103987150	CKB	0.45	5.95	0.47	2.55e-8	Bone mineral density;
TGCT	cis	rs7666738	0.830	rs28417577	chr4:99053007	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12472274	0.941	rs12616232	chr2:239080093	C/T	cg17459225	chr2:239074497	NA	0.32	4.61	0.38	9.9e-6	Phospholipid levels (plasma);
TGCT	cis	rs11671005	0.570	rs73062110	chr19:58936642	G/T	cg13877915	chr19:58951672	ZNF132	0.64	5.12	0.42	1.13e-6	Mean platelet volume;
TGCT	cis	rs13256369	0.755	rs12550057	chr8:8562268	G/A	cg17143192	chr8:8559678	CLDN23	0.54	5.06	0.41	1.47e-6	Obesity-related traits;
TGCT	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg12963246	chr6:28129442	ZNF389	0.52	5.1	0.42	1.23e-6	Depression;
TGCT	cis	rs2147959	0.824	rs1925730	chr1:228666410	G/A	cg22700015	chr1:228743131	NA	-0.62	-4.67	-0.39	7.73e-6	Adult asthma;
TGCT	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg05025164	chr4:1340916	KIAA1530	0.51	4.58	0.38	1.12e-5	Longevity;
TGCT	cis	rs1784581	0.588	rs6415086	chr6:162418147	C/T	cg17173639	chr6:162384350	PARK2	0.4	6.6	0.51	1.08e-9	Itch intensity from mosquito bite;
TGCT	cis	rs72634258	0.554	rs4908699	chr1:7905274	G/A	cg26816564	chr1:7831052	VAMP3	0.87	6.44	0.5	2.34e-9	Inflammatory bowel disease;
TGCT	cis	rs10791097	0.694	rs1054869	chr11:130742630	G/A	cg14779329	chr11:130786720	SNX19	0.28	4.82	0.4	4.09e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs7647973	0.925	rs4384984	chr3:49289878	T/G	cg05785598	chr3:49045655	WDR6	0.39	4.61	0.38	9.91e-6	Menarche (age at onset);
TGCT	cis	rs9534288	0.833	rs56813530	chr13:46622039	A/C	cg15192986	chr13:46630673	CPB2	-0.49	-6.18	-0.49	8.64e-9	Blood protein levels;
TGCT	cis	rs1577917	0.958	rs12213343	chr6:86443019	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.17	-0.42	9.02e-7	Response to antipsychotic treatment;
TGCT	cis	rs7824557	0.736	rs10107010	chr8:11132712	C/A	cg21775007	chr8:11205619	TDH	-0.6	-5.74	-0.46	6.84e-8	Retinal vascular caliber;
TGCT	cis	rs12681288	0.862	rs7015529	chr8:1020249	A/G	cg04851639	chr8:1020857	NA	-0.37	-6.83	-0.52	3.45e-10	Schizophrenia;
TGCT	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.92	-6.8	-0.52	3.96e-10	Gut microbiome composition (summer);
TGCT	cis	rs4851266	0.865	rs11123818	chr2:100867308	G/A	cg22139774	chr2:100720529	AFF3	-0.32	-4.66	-0.39	7.89e-6	Educational attainment;
TGCT	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg06618935	chr21:46677482	NA	-0.37	-5.83	-0.46	4.48e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs62244186	0.748	rs2888410	chr3:44655476	A/C	cg21672276	chr3:44754072	ZNF502	-0.46	-5.2	-0.42	8.15e-7	Depressive symptoms;
TGCT	cis	rs3960554	0.808	rs111714534	chr7:75748896	C/T	cg17325771	chr7:75508891	RHBDD2	-0.54	-4.63	-0.38	8.97e-6	Eotaxin levels;
TGCT	cis	rs1062177	0.826	rs2915873	chr5:151156658	G/A	cg12924095	chr5:151150029	G3BP1	0.35	4.99	0.41	2.03e-6	Preschool internalizing problems;
TGCT	cis	rs6582630	0.638	rs12425531	chr12:38550387	A/G	cg26384229	chr12:38710491	ALG10B	-0.53	-4.77	-0.39	5.12e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs79387448	0.745	rs1403549	chr2:103110745	G/C	cg09003973	chr2:102972529	NA	0.85	5.65	0.45	1.03e-7	Gut microbiota (bacterial taxa);
TGCT	cis	rs6490294	0.748	rs7963329	chr12:112403931	A/G	cg10833066	chr12:111807467	FAM109A	0.37	5.45	0.44	2.57e-7	Mean platelet volume;
TGCT	cis	rs73058052	0.542	rs10414643	chr19:50097784	T/C	cg09250473	chr19:50168907	IRF3;BCL2L12	0.65	5.15	0.42	1.01e-6	Fibrinogen levels;
TGCT	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg09365446	chr1:150670422	GOLPH3L	0.3	4.49	0.37	1.63e-5	Tonsillectomy;
TGCT	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg22968622	chr17:43663579	NA	-0.99	-9.47	-0.65	2.39e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg04772025	chr11:68637568	NA	0.58	6.69	0.52	6.78e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs4073582	0.595	rs3016319	chr11:65981846	C/T	cg16950941	chr11:66035639	RAB1B	0.56	5.21	0.42	7.62e-7	Gout;
TGCT	cis	rs72627509	0.629	rs1277313	chr4:57903948	A/C	cg26694713	chr4:57773883	REST	-0.59	-5.14	-0.42	1.04e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg20203395	chr5:56204925	C5orf35	0.51	4.73	0.39	5.91e-6	Initial pursuit acceleration;
TGCT	cis	rs2439831	0.681	rs3742971	chr15:43622916	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.99	-8.47	-0.61	5.98e-14	Lung cancer in ever smokers;
TGCT	cis	rs2739330	0.615	rs2858911	chr22:24297195	G/T	cg24846343	chr22:24311635	DDTL	0.22	5.68	0.45	9.16e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1008375	0.900	rs7658447	chr4:17579415	T/C	cg10189774	chr4:17578691	LAP3	0.61	5.15	0.42	9.88e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9325144	0.560	rs10876005	chr12:39126149	C/G	cg13010199	chr12:38710504	ALG10B	-0.56	-5.01	-0.41	1.82e-6	Morning vs. evening chronotype;
TGCT	cis	rs9393777	0.513	rs9368451	chr6:26654333	A/G	cg15659132	chr6:26577336	NA	-0.75	-5.25	-0.43	6.33e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1215050	0.791	rs13114823	chr4:98671119	G/A	cg05340658	chr4:99064831	C4orf37	-0.43	-5.4	-0.44	3.2e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs250677	0.687	rs171636	chr5:148434545	G/A	cg23229984	chr5:148520753	ABLIM3	0.23	5.1	0.42	1.25e-6	Breast cancer;
TGCT	cis	rs2075371	1.000	rs2241335	chr7:133979368	C/T	cg11752832	chr7:134001865	SLC35B4	0.68	6.35	0.5	3.76e-9	Mean platelet volume;
TGCT	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	5.28	0.43	5.67e-7	Bipolar disorder;
TGCT	cis	rs7208859	0.673	rs9891179	chr17:29208160	G/T	cg14008862	chr17:28927542	LRRC37B2	0.72	4.66	0.39	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7929679	0.875	rs11032876	chr11:34813868	C/A	cg18414381	chr11:34642885	EHF	-0.23	-4.51	-0.38	1.47e-5	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
TGCT	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg17971929	chr21:40555470	PSMG1	-0.68	-5.96	-0.47	2.42e-8	Cognitive function;
TGCT	cis	rs2948294	0.524	rs13270062	chr8:8112650	C/A	cg06636001	chr8:8085503	FLJ10661	0.82	7.16	0.54	6.3e-11	Red cell distribution width;
TGCT	cis	rs1385374	0.858	rs3765107	chr12:129278310	A/G	cg09035930	chr12:129282057	SLC15A4	-0.55	-4.76	-0.39	5.27e-6	Systemic lupus erythematosus;
TGCT	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg08280861	chr8:58055591	NA	0.4	5.48	0.44	2.3e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6912958	0.559	rs376633	chr6:88042785	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.73	7.63	0.57	5.25e-12	Monocyte percentage of white cells;
TGCT	cis	rs2717559	0.504	rs2585130	chr8:143868977	T/C	cg07661805	chr8:143867942	LY6D	0.23	4.47	0.37	1.77e-5	Urinary tract infection frequency;
TGCT	cis	rs5167	0.781	rs11672748	chr19:45490192	A/G	cg13119609	chr19:45449297	APOC2	0.23	4.73	0.39	5.98e-6	Blood protein levels;
TGCT	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg07343612	chr16:622815	PIGQ	-0.42	-8.45	-0.6	6.8e-14	Height;
TGCT	cis	rs634534	0.591	rs688862	chr11:65733393	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.58	5.46	0.44	2.55e-7	Sum eosinophil basophil counts;Eosinophil counts;
TGCT	cis	rs916888	0.610	rs199442	chr17:44820122	G/A	cg17911788	chr17:44343683	NA	-0.5	-5.73	-0.46	7.23e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs4389656	0.806	rs897710	chr5:6762770	C/T	cg12187999	chr5:6845652	NA	0.32	4.45	0.37	1.85e-5	Coronary artery disease;
TGCT	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg03188948	chr7:1209495	NA	0.55	4.56	0.38	1.2e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.12	0.42	1.15e-6	Prudent dietary pattern;
TGCT	cis	rs10927875	0.688	rs2009371	chr1:16348083	A/T	cg21385522	chr1:16154831	NA	0.62	6.41	0.5	2.76e-9	Dilated cardiomyopathy;
TGCT	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg04154034	chr17:28927549	LRRC37B2	-0.77	-4.81	-0.4	4.37e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs5769765	1.000	rs8138941	chr22:50290678	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.4	6.02	0.48	1.81e-8	Schizophrenia;
TGCT	cis	rs2562456	0.874	rs9304986	chr19:21682062	G/A	cg25650185	chr19:21324782	ZNF431	0.61	5.38	0.43	3.6e-7	Pain;
TGCT	cis	rs1371867	0.846	rs1692007	chr8:101268343	T/C	cg06636551	chr8:101224915	SPAG1	0.43	5.95	0.47	2.58e-8	Atrioventricular conduction;
TGCT	cis	rs7772486	0.754	rs6915718	chr6:146100676	A/G	cg05347473	chr6:146136440	FBXO30	-0.54	-5.1	-0.42	1.25e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2224391	0.540	rs1570085	chr6:5253063	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.99	-6.43	-0.5	2.46e-9	Height;
TGCT	cis	rs6674970	0.933	rs12134957	chr1:151045419	A/G	cg00003202	chr1:151319512	RFX5	-0.53	-4.62	-0.38	9.6e-6	Childhood ear infection;
TGCT	cis	rs7843479	0.582	rs13439690	chr8:21778082	T/C	cg17168535	chr8:21777572	XPO7	0.82	8.19	0.59	2.68e-13	Mean corpuscular volume;
TGCT	cis	rs2288884	0.767	rs3450	chr19:52552999	T/C	cg15405931	chr19:52693188	PPP2R1A	-0.64	-4.5	-0.38	1.51e-5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs981844	0.775	rs17299519	chr4:154762123	C/T	cg14289246	chr4:154710475	SFRP2	1.01	8.89	0.62	5.85e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs3772130	0.962	rs13065245	chr3:121566729	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.62	0.38	9.48e-6	Cognitive performance;
TGCT	cis	rs858239	0.571	rs2390755	chr7:23190716	A/T	cg05602783	chr7:23145260	KLHL7	-0.63	-4.98	-0.41	2.09e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs7226408	0.842	rs62083182	chr18:34339924	A/C	cg06757138	chr18:34340585	FHOD3	0.29	4.76	0.39	5.37e-6	Obesity-related traits;
TGCT	cis	rs7568458	1.000	rs7568458	chr2:85788175	T/A	cg17127132	chr2:85788382	GGCX	0.77	7.4	0.55	1.79e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs910316	1.000	rs10143132	chr14:75525850	G/A	cg11812906	chr14:75593930	NEK9	0.74	7.25	0.55	3.9e-11	Height;
TGCT	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg15782153	chr7:917662	C7orf20	0.5	5.84	0.46	4.24e-8	Perceived unattractiveness to mosquitoes;
TGCT	cis	rs6088590	1.000	rs1998028	chr20:33344595	A/T	cg24642439	chr20:33292090	TP53INP2	0.69	6.17	0.48	8.94e-9	Coronary artery disease;
TGCT	cis	rs78487399	0.808	rs79271345	chr2:43746094	C/T	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.76	4.68	0.39	7.27e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	trans	rs2469997	1.000	rs2447178	chr8:120356188	C/T	cg01792902	chr3:178864926	PIK3CA	0.78	6.66	0.51	7.93e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs6693567	0.565	rs10888578	chr1:150260993	A/G	cg09579323	chr1:150459698	TARS2	-0.55	-5.2	-0.42	7.92e-7	Migraine;
TGCT	cis	rs6969780	0.722	rs3823764	chr7:27187753	C/T	cg11410718	chr7:27170412	HOXA4	-0.47	-4.68	-0.39	7.38e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs6540559	0.546	rs7551944	chr1:210029430	G/C	cg23283495	chr1:209979779	IRF6	0.67	5.05	0.41	1.55e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs208520	0.661	rs207099	chr6:66796373	A/C	cg07460842	chr6:66804631	NA	-0.94	-9.86	-0.66	2.74e-17	Exhaled nitric oxide output;
TGCT	cis	rs9926296	0.609	rs4785710	chr16:89796756	C/T	cg26513180	chr16:89883248	FANCA	-0.68	-6.7	-0.52	6.6e-10	Vitiligo;
TGCT	cis	rs838147	0.537	rs485073	chr19:49207255	A/G	cg04599840	chr19:48886497	KDELR1	0.23	4.67	0.39	7.81e-6	Dietary macronutrient intake;
TGCT	cis	rs28595532	1.000	rs55634130	chr4:119655093	C/T	cg14228332	chr4:119757509	SEC24D	1.02	5.37	0.43	3.75e-7	Cannabis dependence symptom count;
TGCT	cis	rs12497850	1.000	rs6788650	chr3:48749543	T/C	cg16497277	chr3:49208875	KLHDC8B	-0.5	-4.78	-0.39	4.87e-6	Parkinson's disease;
TGCT	cis	rs875971	1.000	rs1144894	chr7:65542894	A/G	cg11764359	chr7:65958608	NA	-0.56	-4.7	-0.39	6.74e-6	Aortic root size;
TGCT	cis	rs12950390	0.853	rs11658511	chr17:45856918	T/C	cg24803719	chr17:45855879	NA	-0.5	-5.12	-0.42	1.15e-6	IgG glycosylation;
TGCT	cis	rs1371867	0.775	rs6511	chr8:101252680	T/C	cg06636551	chr8:101224915	SPAG1	0.48	6.46	0.5	2.11e-9	Atrioventricular conduction;
TGCT	cis	rs34779708	0.966	rs12782948	chr10:35450607	G/A	cg04310649	chr10:35416472	CREM	-0.53	-4.71	-0.39	6.66e-6	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs11718455	1.000	rs1524885	chr3:44031847	G/A	cg08738300	chr3:44038990	NA	0.85	6.49	0.5	1.87e-9	Coronary artery disease;
TGCT	cis	rs1971762	0.509	rs784567	chr12:53894465	C/T	cg16917193	chr12:54089295	NA	-0.96	-9.81	-0.66	3.62e-17	Height;
TGCT	cis	rs7980687	0.662	rs585522	chr12:123550813	A/G	cg00376283	chr12:123451042	ABCB9	0.73	5.61	0.45	1.25e-7	Height;Educational attainment;Head circumference (infant);
TGCT	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg12310025	chr6:25882481	NA	-0.69	-7.5	-0.56	1.08e-11	Blood metabolite levels;
TGCT	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs11250098	0.583	rs36030755	chr8:10816771	G/C	cg21775007	chr8:11205619	TDH	-0.58	-5.47	-0.44	2.43e-7	Morning vs. evening chronotype;
TGCT	trans	rs6762477	0.748	rs11714286	chr3:50185508	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.75	-7.39	-0.55	1.88e-11	Menarche (age at onset);
TGCT	cis	rs8103278	0.507	rs10415988	chr19:46246704	C/T	cg11657440	chr19:46296263	DMWD	0.75	7.74	0.57	3.02e-12	Coronary artery disease;
TGCT	cis	rs9853921	0.894	rs9855363	chr3:117954415	T/A	cg15509235	chr3:117715573	NA	0.53	4.48	0.37	1.65e-5	JT interval (sulfonylurea treatment interaction);
TGCT	cis	rs3617	0.573	rs9810807	chr3:52924227	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.5	-4.68	-0.39	7.35e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs112591243	0.685	rs2839282	chr21:47902822	C/G	cg10657630	chr21:48055338	PRMT2	-1.06	-5.21	-0.42	7.69e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs950169	0.887	rs12903946	chr15:84954430	T/C	cg12863693	chr15:85201151	NMB	0.45	4.96	0.41	2.28e-6	Schizophrenia;
TGCT	cis	rs4786125	0.801	rs8057091	chr16:6902148	A/G	cg03623568	chr16:6915990	A2BP1	-0.4	-5.61	-0.45	1.26e-7	Heart rate variability traits (SDNN);
TGCT	cis	rs2836974	0.831	rs4375956	chr21:40521788	G/A	cg17971929	chr21:40555470	PSMG1	0.98	9.32	0.64	5.67e-16	Cognitive function;
TGCT	cis	rs950169	0.881	rs4081123	chr15:84956235	A/G	cg11189052	chr15:85197271	WDR73	0.81	6.22	0.49	6.89e-9	Schizophrenia;
TGCT	cis	rs4906332	1.000	rs12879663	chr14:103874215	A/G	cg26031613	chr14:104095156	KLC1	-0.51	-4.62	-0.38	9.61e-6	Coronary artery disease;
TGCT	cis	rs7772486	0.840	rs11155451	chr6:146422524	A/G	cg23711669	chr6:146136114	FBXO30	0.89	9.8	0.66	3.86e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs918629	0.679	rs72656689	chr5:95270872	A/G	cg16656078	chr5:95278638	ELL2	-0.28	-4.8	-0.4	4.47e-6	IgG glycosylation;
TGCT	cis	rs2153535	0.580	rs6597327	chr6:8482157	G/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg11062466	chr8:58055876	NA	0.38	4.62	0.38	9.5e-6	Developmental language disorder (linguistic errors);
TGCT	trans	rs28735056	0.967	rs61090726	chr18:77631219	A/G	cg05926928	chr17:57297772	GDPD1	-0.71	-7.6	-0.56	6.2e-12	Schizophrenia;
TGCT	cis	rs3784262	0.669	rs4646564	chr15:58351797	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.42	-6.24	-0.49	6.32e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs6424115	0.830	rs3003335	chr1:24200052	A/G	cg15997130	chr1:24165203	NA	0.85	9.25	0.64	8.02e-16	Immature fraction of reticulocytes;
TGCT	cis	rs10992471	0.756	rs11792342	chr9:95143668	G/A	cg14631576	chr9:95140430	CENPP	-0.3	-4.97	-0.41	2.21e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs2204008	0.837	rs11612397	chr12:38357455	T/C	cg26384229	chr12:38710491	ALG10B	0.83	7.27	0.55	3.51e-11	Bladder cancer;
TGCT	cis	rs1483890	0.723	rs2007578	chr3:69408982	T/A	cg22125112	chr3:69402811	FRMD4B	0.29	4.74	0.39	5.85e-6	Resting heart rate;
TGCT	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg02493798	chr17:6899577	ALOX12	0.43	4.74	0.39	5.83e-6	Tonsillectomy;
TGCT	cis	rs3806843	0.733	rs801181	chr5:140092814	C/T	cg19875535	chr5:140030758	IK	-0.35	-5.95	-0.47	2.61e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs16854884	0.586	rs4616638	chr3:143735423	A/T	cg06585982	chr3:143692056	C3orf58	-0.57	-4.61	-0.38	9.92e-6	Economic and political preferences (feminism/equality);
TGCT	cis	rs7959452	0.649	rs4761239	chr12:69776886	T/A	cg20891283	chr12:69753455	YEATS4	0.86	8.81	0.62	9.49e-15	Blood protein levels;
TGCT	cis	rs7666738	0.830	rs13328042	chr4:99055406	A/G	cg17366294	chr4:99064904	C4orf37	0.73	7.45	0.56	1.4e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6831352	0.840	rs34634551	chr4:100067362	C/A	cg12011299	chr4:100065546	ADH4	-0.46	-5.22	-0.42	7.38e-7	Alcohol dependence;
TGCT	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg03452623	chr4:187889614	NA	-0.34	-5.18	-0.42	8.8e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7552404	0.960	rs12134854	chr1:76137606	A/G	cg03433033	chr1:76189801	ACADM	0.83	10.12	0.67	6.52e-18	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs483180	0.512	rs677277	chr1:120202298	C/T	cg19096424	chr1:120255104	PHGDH	-0.57	-5.19	-0.42	8.35e-7	Macular telangiectasia type 2;
TGCT	cis	rs13191362	1.000	rs34591938	chr6:163087003	C/G	cg06582575	chr6:163149167	PACRG;PARK2	0.98	7.63	0.57	5.48e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4478858	0.735	rs11582342	chr1:31810681	A/G	cg07478791	chr1:31886160	SERINC2	-0.51	-4.95	-0.41	2.33e-6	Alcohol dependence;
TGCT	cis	rs3091242	0.902	rs36003018	chr1:25784318	A/G	cg10117171	chr1:25599238	RHD	0.3	4.92	0.4	2.69e-6	Erythrocyte sedimentation rate;
TGCT	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg21724239	chr8:58056113	NA	0.42	5.04	0.41	1.59e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs13022357	1.000	rs2042495	chr2:160084263	A/G	cg00168785	chr2:160142643	WDSUB1	0.46	4.6	0.38	1.04e-5	Sudden cardiac arrest;
TGCT	cis	rs694739	0.628	rs475032	chr11:64140737	G/C	cg23796481	chr11:64053134	BAD;GPR137	-0.63	-6.54	-0.51	1.44e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs72945132	0.882	rs56368270	chr11:70162590	A/G	cg00319359	chr11:70116639	PPFIA1	0.98	7.13	0.54	7.33e-11	Coronary artery disease;
TGCT	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg07167872	chr1:205819463	PM20D1	-0.54	-7.05	-0.53	1.1e-10	Menarche (age at onset);
TGCT	cis	rs9796	0.727	rs12101934	chr15:41353079	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.49	-6.18	-0.49	8.53e-9	Menopause (age at onset);
TGCT	cis	rs7647973	0.925	rs6446256	chr3:49224210	A/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.57	-4.79	-0.4	4.63e-6	Menarche (age at onset);
TGCT	cis	rs2050392	0.858	rs2250569	chr10:30698914	G/C	cg18806716	chr10:30721971	MAP3K8	-0.46	-5.37	-0.43	3.74e-7	Inflammatory bowel disease;
TGCT	cis	rs116095464	0.558	rs73029475	chr5:206969	T/C	cg22857025	chr5:266934	NA	-0.34	-6.71	-0.52	6.3e-10	Breast cancer;
TGCT	cis	rs12540874	0.698	rs3823674	chr7:50571996	C/T	cg18232548	chr7:50535776	DDC	-0.37	-6.43	-0.5	2.45e-9	Systemic sclerosis;
TGCT	cis	rs986417	0.901	rs1955692	chr14:61008408	C/A	cg27398547	chr14:60952738	C14orf39	1.42	8.85	0.62	7.38e-15	Gut microbiota (bacterial taxa);
TGCT	cis	rs78487399	0.808	rs6544664	chr2:43729108	T/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-4.82	-0.4	4.03e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs6582630	0.638	rs7963994	chr12:38555535	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-4.62	-0.38	9.6e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs12908161	0.920	rs12904605	chr15:85201419	T/C	cg12863693	chr15:85201151	NMB	0.46	5.54	0.45	1.73e-7	Schizophrenia;
TGCT	cis	rs78487399	0.808	rs13413856	chr2:43764825	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.42	-5.13	-0.42	1.06e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs6011674	0.808	rs56946612	chr20:61849265	T/G	cg06763829	chr20:61885236	FLJ16779;NKAIN4	0.85	4.55	0.38	1.28e-5	Response to cytadine analogues (cytosine arabinoside);
TGCT	cis	rs9325144	0.624	rs7979541	chr12:39129679	T/C	cg10518543	chr12:38710700	ALG10B	-0.48	-4.44	-0.37	1.97e-5	Morning vs. evening chronotype;
TGCT	cis	rs8177179	0.967	rs6439436	chr3:133453779	C/T	cg24879335	chr3:133465180	TF	-0.36	-5.04	-0.41	1.63e-6	Iron status biomarkers (transferrin levels);
TGCT	cis	rs6121246	0.567	rs6058189	chr20:30192389	A/G	cg21427119	chr20:30132790	HM13	-0.38	-5.63	-0.45	1.14e-7	Mean corpuscular hemoglobin;
TGCT	cis	rs7826238	0.594	rs2948285	chr8:8130538	A/T	cg06636001	chr8:8085503	FLJ10661	0.73	6.42	0.5	2.56e-9	Systolic blood pressure;
TGCT	cis	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg20637647	chr7:64974828	NA	0.92	5.36	0.43	3.87e-7	Diabetic kidney disease;
TGCT	cis	rs2549003	0.933	rs3846731	chr5:131814264	T/C	cg21138405	chr5:131827807	IRF1	0.2	5.08	0.41	1.36e-6	Asthma (sex interaction);
TGCT	cis	rs4822044	0.560	rs7284839	chr22:42010902	C/T	cg06481639	chr22:41940642	POLR3H	0.74	6.64	0.51	8.88e-10	Cannabis dependence symptom count;
TGCT	cis	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg07424592	chr7:64974309	NA	1.31	8.14	0.59	3.55e-13	Diabetic kidney disease;
TGCT	cis	rs6540559	0.808	rs11119358	chr1:210042456	T/C	cg12034118	chr1:209979487	IRF6	0.67	5.07	0.41	1.43e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg17747265	chr1:1875780	NA	-0.41	-7.72	-0.57	3.38e-12	Body mass index;
TGCT	cis	rs7772486	0.658	rs4895683	chr6:146113654	T/A	cg13319975	chr6:146136371	FBXO30	0.5	4.62	0.38	9.6e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3806843	0.900	rs2531340	chr5:140131046	C/T	cg19875535	chr5:140030758	IK	-0.35	-5.97	-0.47	2.27e-8	Depressive symptoms (multi-trait analysis);
TGCT	trans	rs9388451	0.839	rs11154331	chr6:126111429	A/T	cg05039488	chr6:79577232	IRAK1BP1	-0.72	-8.03	-0.58	6.54e-13	Brugada syndrome;
TGCT	cis	rs7611238	0.560	rs4461369	chr3:195000811	G/A	cg27323046	chr3:195102265	ACAP2	0.35	4.69	0.39	6.99e-6	Body mass index;
TGCT	cis	rs7607369	0.648	rs55983650	chr2:219654932	T/C	cg02176678	chr2:219576539	TTLL4	-0.48	-6.11	-0.48	1.17e-8	Red blood cell count;Amyotrophic lateral sclerosis;
TGCT	cis	rs797680	0.856	rs7553465	chr1:93644410	C/T	cg17826107	chr1:92977322	EVI5	-0.24	-5.27	-0.43	5.93e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs7666738	0.830	rs4699591	chr4:98974171	A/G	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12477438	1.000	rs57846982	chr2:99921574	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.79	-5.86	-0.47	3.88e-8	Chronic sinus infection;
TGCT	cis	rs9993613	0.875	rs719381	chr4:73453998	C/T	cg15102770	chr4:73434591	ADAMTS3	-0.51	-4.8	-0.4	4.47e-6	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs2594989	0.943	rs9836824	chr3:11463517	G/A	cg00170343	chr3:11313890	ATG7	0.72	5.37	0.43	3.8e-7	Circulating chemerin levels;
TGCT	trans	rs17685	0.735	rs11763339	chr7:75761541	T/C	cg19862616	chr7:65841803	NCRNA00174	0.52	9.01	0.63	3.02e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs6977660	0.652	rs2072187	chr7:19747915	A/G	cg05791153	chr7:19748676	TWISTNB	1.04	6.33	0.49	4.03e-9	Thyroid stimulating hormone;
TGCT	trans	rs7618501	0.699	rs3733135	chr3:49939587	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.87	9.3	0.64	6.15e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs10832963	0.594	rs1550869	chr11:18613498	G/T	cg15824435	chr11:18617206	NA	0.34	5.67	0.45	9.61e-8	Breast cancer;
TGCT	cis	rs11577318	0.579	rs11247936	chr1:26698884	A/G	cg12733254	chr1:26682999	NA	0.22	4.47	0.37	1.72e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs225245	0.755	rs226432	chr17:34043825	G/A	cg05299278	chr17:33885742	SLFN14	-0.21	-4.52	-0.38	1.42e-5	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs1775715	1.000	rs1775715	chr10:32309005	A/G	cg14930904	chr10:32216787	ARHGAP12	-0.5	-4.63	-0.38	8.96e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs2153535	0.580	rs6921964	chr6:8446395	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.65	0.45	1.02e-7	Motion sickness;
TGCT	cis	rs9611565	0.921	rs2281332	chr22:41746212	T/C	cg13695892	chr22:41940480	POLR3H	-0.72	-7.37	-0.55	2.15e-11	Vitiligo;
TGCT	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg02725872	chr8:58115012	NA	-0.38	-5.16	-0.42	9.32e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs11167764	1.000	rs6580220	chr5:141480558	G/A	cg02659431	chr5:141694439	SPRY4	-0.22	-4.72	-0.39	6.31e-6	Crohn's disease;
TGCT	cis	rs7917772	0.582	rs7091252	chr10:104328859	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	5.36	0.43	3.84e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs3617	0.573	rs62253582	chr3:52928333	G/A	cg11645453	chr3:52864694	ITIH4	-0.27	-5.14	-0.42	1.05e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9457247	1.000	rs404222	chr6:167402150	G/A	cg23791538	chr6:167370224	RNASET2	-0.52	-5.16	-0.42	9.46e-7	Crohn's disease;
TGCT	cis	rs6565180	0.791	rs4247355	chr16:30392099	A/G	cg17640201	chr16:30407289	ZNF48	0.96	9.09	0.63	1.94e-15	Tonsillectomy;
TGCT	cis	rs9913156	0.793	rs72835633	chr17:4562643	C/T	cg00122941	chr17:4613640	ARRB2	0.87	7.38	0.55	1.95e-11	Lymphocyte counts;
TGCT	cis	rs76473307	1.000	rs6015381	chr20:57393614	G/C	cg06163629	chr20:57414884	GNASAS;GNAS	-0.67	-4.53	-0.38	1.34e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs2153535	0.580	rs986060	chr6:8465428	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs6840360	0.571	rs1822346	chr4:152525303	G/C	cg17479576	chr4:152424074	FAM160A1	-0.73	-7.94	-0.58	1.03e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs250677	0.687	rs36048	chr5:148441713	G/C	cg23229984	chr5:148520753	ABLIM3	0.21	4.89	0.4	3.11e-6	Breast cancer;
TGCT	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg08736216	chr1:53307985	ZYG11A	-0.24	-4.74	-0.39	5.75e-6	Monocyte count;
TGCT	cis	rs3749237	0.595	rs35701831	chr3:49515000	A/C	cg02487422	chr3:49467188	NICN1	0.58	5.92	0.47	3e-8	Resting heart rate;
TGCT	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg22535103	chr8:58192502	C8orf71	-0.41	-4.81	-0.4	4.27e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs11718455	1.000	rs17076273	chr3:44020113	A/G	cg08738300	chr3:44038990	NA	0.88	6.65	0.51	8.52e-10	Coronary artery disease;
TGCT	cis	rs7119038	0.774	rs73005426	chr11:118681083	A/G	cg19308663	chr11:118741387	NA	0.27	5.5	0.44	2.11e-7	Sjögren's syndrome;
TGCT	cis	rs10875595	0.836	rs57396973	chr5:140659106	T/A	cg24830062	chr5:140700576	TAF7	-0.6	-5.07	-0.41	1.42e-6	Pulmonary function decline;
TGCT	cis	rs1395	0.744	rs11126936	chr2:27483101	A/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.61	-7.75	-0.57	2.92e-12	Blood metabolite levels;
TGCT	cis	rs1670533	0.932	rs13137819	chr4:1042115	T/C	cg27284194	chr4:1044797	NA	0.67	5.29	0.43	5.34e-7	Recombination rate (females);
TGCT	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg11644478	chr21:40555479	PSMG1	-0.57	-4.9	-0.4	2.9e-6	Cognitive function;
TGCT	trans	rs1496653	0.602	rs13095737	chr3:23524494	A/G	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs1278769	0.786	rs7998551	chr13:113540649	G/T	cg17842918	chr13:113540400	ATP11A	-0.32	-4.48	-0.37	1.67e-5	Interstitial lung disease;
TGCT	cis	rs1395	0.767	rs1821986	chr2:27405835	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.5	-6.75	-0.52	5.06e-10	Blood metabolite levels;
TGCT	cis	rs68170813	0.523	rs79619227	chr7:107025335	T/C	cg02696742	chr7:106810147	HBP1	-0.68	-5.44	-0.44	2.69e-7	Coronary artery disease;
TGCT	cis	rs7104764	1.000	rs9795476	chr11:235894	T/G	cg18336825	chr11:236787	PSMD13;SIRT3	1.07	11.15	0.71	2.05e-20	Menarche (age at onset);
TGCT	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg26338869	chr17:61819248	STRADA	-0.53	-4.94	-0.41	2.48e-6	Prudent dietary pattern;
TGCT	cis	rs6921919	0.609	rs36018474	chr6:28385529	C/G	cg18815343	chr6:28367644	ZSCAN12	-0.54	-5.25	-0.43	6.29e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1532993	0.518	rs13142828	chr4:98628307	T/C	cg05340658	chr4:99064831	C4orf37	-0.41	-4.96	-0.41	2.3e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg13695892	chr22:41940480	POLR3H	-0.91	-9.07	-0.63	2.18e-15	Vitiligo;
TGCT	cis	rs2832191	0.791	rs2832187	chr21:30485543	T/C	cg24692254	chr21:30365293	RNF160	-0.94	-10.58	-0.69	4.78e-19	Dental caries;
TGCT	cis	rs1975974	0.511	rs66766425	chr17:21755307	G/T	cg18423549	chr17:21743878	NA	-0.67	-6.07	-0.48	1.41e-8	Psoriasis;
TGCT	cis	rs4699052	0.928	rs2169511	chr4:104192580	G/A	cg16532752	chr4:104119610	CENPE	-0.55	-4.97	-0.41	2.19e-6	Testicular germ cell tumor;
TGCT	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg01416388	chr22:39784598	NA	-0.72	-7.57	-0.56	7.35e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs910316	1.000	rs876402	chr14:75601862	C/T	cg08847533	chr14:75593920	NEK9	-0.95	-11.03	-0.7	4.03e-20	Height;
TGCT	cis	rs4689592	0.503	rs2292461	chr4:7058473	C/T	cg25660036	chr4:7070649	GRPEL1	-0.62	-5.13	-0.42	1.09e-6	Monocyte percentage of white cells;
TGCT	cis	rs17376456	0.825	rs12716453	chr5:93271697	T/C	cg25358565	chr5:93447407	FAM172A	1.02	8.11	0.59	4.23e-13	Diabetic retinopathy;
TGCT	cis	rs539096	0.872	rs3791137	chr1:44050004	G/A	cg12908607	chr1:44402522	ARTN	-0.48	-4.94	-0.41	2.46e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10832169	0.967	rs1406355	chr11:14067894	C/T	cg04547675	chr11:13986162	SPON1	0.51	4.51	0.38	1.49e-5	Blood protein levels;
TGCT	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.55	-5.11	-0.42	1.2e-6	Prudent dietary pattern;
TGCT	cis	rs3091242	0.836	rs34997029	chr1:25783823	A/G	cg10117171	chr1:25599238	RHD	0.32	5.17	0.42	9.25e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs12519773	0.597	rs17360518	chr5:92457899	A/C	cg18783429	chr5:92414398	NA	0.31	4.61	0.38	9.91e-6	Migraine;
TGCT	cis	rs362272	0.525	rs910568	chr4:3307373	A/G	cg06533319	chr4:3265114	C4orf44	-0.26	-5.24	-0.43	6.75e-7	Serum sulfate level;
TGCT	cis	rs3020736	0.500	rs6002614	chr22:42501802	G/A	cg15557168	chr22:42548783	NA	0.22	5.58	0.45	1.47e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7216064	0.773	rs11867618	chr17:65875587	G/A	cg12091567	chr17:66097778	LOC651250	-0.72	-4.94	-0.41	2.49e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.43	-5.17	-0.42	9.15e-7	Longevity;Endometriosis;
TGCT	cis	rs6430585	0.583	rs61253125	chr2:136618178	T/C	cg07169764	chr2:136633963	MCM6	1.22	12.03	0.73	1.46e-22	Corneal structure;
TGCT	cis	rs3809822	0.617	rs66687178	chr17:7254602	T/G	cg02676175	chr17:7253720	KCTD11;ACAP1	-0.53	-5.09	-0.42	1.31e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
TGCT	cis	rs36051895	0.632	rs12336875	chr9:5138404	C/A	cg02405213	chr9:5042618	JAK2	-0.75	-10.48	-0.69	8.58e-19	Pediatric autoimmune diseases;
TGCT	cis	rs10791097	0.694	rs10160281	chr11:130742788	T/C	cg05962950	chr11:130786565	SNX19	0.92	11.55	0.72	2.13e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs2153535	0.580	rs6902001	chr6:8477055	T/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs7296418	0.630	rs7974099	chr12:123771475	A/G	cg00376283	chr12:123451042	ABCB9	0.67	5.81	0.46	4.87e-8	Platelet count;
TGCT	cis	rs1577917	0.958	rs12215265	chr6:86443969	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.17	-0.42	9.02e-7	Response to antipsychotic treatment;
TGCT	cis	rs2486288	0.656	rs12915314	chr15:45551491	C/G	cg14582100	chr15:45693742	SPATA5L1	-0.46	-5.59	-0.45	1.38e-7	Glomerular filtration rate;
TGCT	cis	rs6460942	0.915	rs62448602	chr7:12457145	T/G	cg06484146	chr7:12443880	VWDE	-0.57	-5.52	-0.44	1.92e-7	Coronary artery disease;
TGCT	cis	rs2180341	0.960	rs7773484	chr6:127670779	T/C	cg24812749	chr6:127587940	RNF146	1.01	7.62	0.56	5.59e-12	Breast cancer;
TGCT	cis	rs9581857	0.615	rs9581849	chr13:28005782	G/T	cg22138327	chr13:27999177	GTF3A	0.81	5.61	0.45	1.26e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs6121246	0.520	rs6060425	chr20:30224355	C/T	cg18721089	chr20:30220636	NA	-0.6	-6.12	-0.48	1.12e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs7698623	0.850	rs1381960	chr4:88801652	A/T	cg02735620	chr4:88950514	PKD2	-0.37	-4.44	-0.37	1.98e-5	Cardiovascular disease risk factors;
TGCT	cis	rs3020736	0.500	rs6002601	chr22:42489058	A/T	cg05082376	chr22:42548792	NA	0.23	5.38	0.44	3.52e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9814567	1.000	rs6790466	chr3:134197740	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.97	-9.24	-0.64	8.89e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs7772486	0.743	rs2092262	chr6:146037105	C/T	cg05347473	chr6:146136440	FBXO30	-0.5	-4.75	-0.39	5.58e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9902453	0.933	rs9898353	chr17:28451865	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	5.41	0.44	3.13e-7	Coffee consumption (cups per day);
TGCT	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/A	cg05738196	chr6:26577821	NA	0.85	10.41	0.68	1.31e-18	Intelligence (multi-trait analysis);
TGCT	cis	rs2677744	0.688	rs2072078	chr15:91449015	A/G	cg23684204	chr15:91497937	RCCD1	0.34	4.89	0.4	3.05e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs9467603	0.547	rs9295661	chr6:25450026	A/C	cg16898833	chr6:26189333	HIST1H4D	1.08	4.53	0.38	1.37e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7027203	0.688	rs4075733	chr9:96624645	C/T	cg14396892	chr9:96623032	NA	-0.28	-5.71	-0.46	7.98e-8	DNA methylation (variation);
TGCT	cis	rs669446	0.561	rs568639	chr1:44086080	T/C	cg12908607	chr1:44402522	ARTN	-0.54	-5.68	-0.45	8.9e-8	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs7668190	0.924	rs4864504	chr4:55097835	G/C	cg17187183	chr4:55093834	PDGFRA	0.44	6.04	0.48	1.63e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4455778	0.561	rs28742972	chr7:48995176	A/G	cg26309511	chr7:48887640	NA	-0.55	-7.09	-0.54	8.88e-11	Lung cancer in never smokers;
TGCT	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	5.56	0.45	1.58e-7	Height;
TGCT	trans	rs208520	1.000	rs208527	chr6:66957209	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.88	-8.21	-0.59	2.37e-13	Exhaled nitric oxide output;
TGCT	cis	rs881375	0.967	rs7875829	chr9:123660398	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	5.08	0.42	1.34e-6	Rheumatoid arthritis;
TGCT	cis	rs2562456	0.874	rs2562417	chr19:21711202	T/C	cg25650185	chr19:21324782	ZNF431	0.61	5.38	0.43	3.6e-7	Pain;
TGCT	cis	rs13188771	0.690	rs350561	chr5:100857159	G/A	cg10455971	chr5:101119566	NA	-0.44	-4.52	-0.38	1.44e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs7918232	0.830	rs10764672	chr10:27392541	A/C	cg14442939	chr10:27389572	ANKRD26	-0.79	-6.94	-0.53	1.91e-10	Breast cancer;
TGCT	cis	rs2836950	0.501	rs2836984	chr21:40700949	A/C	cg11890956	chr21:40555474	PSMG1	-0.64	-5.97	-0.47	2.38e-8	Menarche (age at onset);
TGCT	cis	rs1497406	0.744	rs4537547	chr1:16510798	C/T	cg20430773	chr1:16534157	ARHGEF19	-0.56	-6.53	-0.51	1.53e-9	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9486719	1.000	rs2273622	chr6:97058567	A/G	cg06623918	chr6:96969491	KIAA0776	-1.02	-8.33	-0.6	1.28e-13	Migraine;Coronary artery disease;
TGCT	cis	rs4808199	0.894	rs10418051	chr19:19397789	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.65	4.89	0.4	3.05e-6	Nonalcoholic fatty liver disease;
TGCT	cis	rs10165862	0.537	rs17009372	chr2:73955571	A/G	cg07208825	chr2:73871855	ALMS1P	-0.23	-4.96	-0.41	2.24e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs67311347	1.000	rs9827461	chr3:40489351	T/A	cg13683864	chr3:40499215	RPL14	-1.19	-13.81	-0.78	7.61e-27	Renal cell carcinoma;
TGCT	cis	rs9522267	0.624	rs1182786	chr13:112196412	A/G	cg10483660	chr13:112241077	NA	-0.28	-4.45	-0.37	1.92e-5	Hepatitis;
TGCT	cis	rs4660261	0.526	rs810680	chr1:44347856	C/T	cg13606994	chr1:44402422	ARTN	-0.41	-4.46	-0.37	1.82e-5	Intelligence (multi-trait analysis);
TGCT	trans	rs6740731	0.518	rs35766785	chr2:145295628	C/T	cg03855592	chr7:113034122	NA	0.42	6.83	0.52	3.31e-10	Coronary artery disease;
TGCT	cis	rs2295359	1.000	rs4655683	chr1:67611613	C/T	cg12940439	chr1:67600707	NA	0.57	5.97	0.47	2.27e-8	Psoriasis;
TGCT	cis	rs9291683	0.655	rs55941493	chr4:10100341	G/A	cg00071950	chr4:10020882	SLC2A9	-0.49	-5.12	-0.42	1.13e-6	Bone mineral density;
TGCT	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.95	-11.06	-0.7	3.42e-20	Menarche (age at onset);
TGCT	cis	rs7923609	0.967	rs10761752	chr10:65160321	T/C	cg08743896	chr10:65200160	JMJD1C	-0.34	-4.57	-0.38	1.15e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2797160	1.000	rs2211418	chr6:125995503	G/A	cg05901451	chr6:126070800	HEY2	-0.73	-6.6	-0.51	1.09e-9	Endometrial cancer;
TGCT	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg27535305	chr1:53392650	SCP2	0.26	5.13	0.42	1.09e-6	Monocyte count;
TGCT	cis	rs3015497	0.753	rs12881776	chr14:51136330	T/G	cg04730355	chr14:51134070	SAV1	-0.61	-5.86	-0.47	3.95e-8	Mean platelet volume;
TGCT	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg25767906	chr1:53392781	SCP2	-0.51	-6.22	-0.49	6.83e-9	Monocyte count;
TGCT	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg17054783	chr10:134559939	INPP5A	0.24	4.65	0.39	8.27e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs12477438	0.798	rs6759354	chr2:99632195	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-5.87	-0.47	3.74e-8	Chronic sinus infection;
TGCT	cis	rs10114408	0.959	rs1890378	chr9:96665229	G/A	cg13679303	chr9:96623674	NA	-0.36	-4.66	-0.39	8e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs73198271	0.583	rs11781985	chr8:8589783	C/T	cg06636001	chr8:8085503	FLJ10661	0.68	4.75	0.39	5.42e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs9985766	0.958	rs60160057	chr4:151000830	G/A	cg05926478	chr4:151174724	DCLK2	-0.24	-4.72	-0.39	6.32e-6	Coronary artery disease;Myocardial infarction;
TGCT	cis	rs9467773	0.873	rs9295698	chr6:26566099	T/A	cg15659132	chr6:26577336	NA	0.9	13.19	0.76	2.26e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs9517313	0.897	rs4772087	chr13:99115041	A/G	cg20487152	chr13:99095054	FARP1	0.25	5.1	0.42	1.24e-6	Neuroticism;
TGCT	cis	rs909002	0.849	rs10798879	chr1:32096815	T/C	cg11573219	chr1:32083031	HCRTR1	-0.49	-6.44	-0.5	2.36e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs10940138	0.830	rs10447112	chr5:67219761	G/A	ch.5.1281357F	chr5:67228439	NA	0.44	4.98	0.41	2.05e-6	Menarche (age at onset);
TGCT	cis	rs9372498	0.536	rs62422236	chr6:118972633	G/T	cg07617317	chr6:118971624	C6orf204	0.47	4.92	0.4	2.71e-6	Diastolic blood pressure;
TGCT	cis	rs57590327	0.503	rs9852235	chr3:81508355	A/G	cg07356753	chr3:81810745	GBE1	0.58	4.89	0.4	3.06e-6	Extraversion;
TGCT	cis	rs933688	1.000	rs2367353	chr5:90686568	G/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.05	10.14	0.67	5.91e-18	Smoking behavior;
TGCT	cis	rs7666738	0.830	rs28810677	chr4:99043193	C/T	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1552244	0.554	rs6796411	chr3:10010681	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.31	-4.74	-0.39	5.86e-6	Alzheimer's disease;
TGCT	cis	rs17253792	0.822	rs17683614	chr14:56041058	G/A	cg01858014	chr14:56050164	KTN1	-0.36	-4.57	-0.38	1.15e-5	Putamen volume;
TGCT	trans	rs9951602	1.000	rs9951602	chr18:76657779	C/T	cg02800362	chr5:177631904	HNRNPAB	0.97	6.69	0.51	6.89e-10	Obesity-related traits;
TGCT	cis	rs4780401	0.588	rs1050068	chr16:11769948	C/T	cg01061890	chr16:11836724	TXNDC11	-0.46	-4.52	-0.38	1.45e-5	Rheumatoid arthritis;
TGCT	cis	rs7014346	0.736	rs11985829	chr8:128409232	C/T	cg04263511	chr8:128962092	PVT1	0.36	4.7	0.39	6.72e-6	Colorectal cancer;
TGCT	cis	rs7264396	0.635	rs6088971	chr20:34535373	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.04	-0.41	1.58e-6	Total cholesterol levels;
TGCT	cis	rs6964587	0.967	rs28615927	chr7:91600648	C/A	cg17063962	chr7:91808500	NA	0.91	9.99	0.67	1.32e-17	Breast cancer;
TGCT	cis	rs2180341	0.960	rs7751865	chr6:127683040	G/A	cg27446573	chr6:127587934	RNF146	1.14	10.91	0.7	7.51e-20	Breast cancer;
TGCT	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg03709012	chr19:19516395	GATAD2A	-0.69	-5.76	-0.46	6.23e-8	Tonsillectomy;
TGCT	cis	rs2072499	0.554	rs1052067	chr1:156206121	C/T	cg24450063	chr1:156163899	SLC25A44	0.7	5.69	0.45	8.83e-8	Testicular germ cell tumor;
TGCT	cis	rs9926296	0.546	rs9935541	chr16:89905925	G/C	cg27121462	chr16:89883253	FANCA	0.63	5.93	0.47	2.74e-8	Vitiligo;
TGCT	cis	rs11731606	0.508	rs57403425	chr4:95312411	G/T	cg00507259	chr4:95128692	SMARCAD1	0.66	4.85	0.4	3.58e-6	Mean platelet volume;
TGCT	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg23758822	chr17:41437982	NA	0.72	6.81	0.52	3.77e-10	Menopause (age at onset);
TGCT	cis	rs3617	0.559	rs11915546	chr3:52866845	A/C	cg10802521	chr3:52805072	NEK4	0.62	7.17	0.54	6e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7809950	1.000	rs2520265	chr7:107181231	A/G	cg23024343	chr7:107201750	COG5	-0.35	-5.43	-0.44	2.88e-7	Coronary artery disease;
TGCT	cis	rs950169	0.920	rs12915390	chr15:84792069	T/C	cg11189052	chr15:85197271	WDR73	0.73	6.13	0.48	1.06e-8	Schizophrenia;
TGCT	cis	rs4788570	0.697	rs2334877	chr16:71833332	C/T	cg06353428	chr16:71660113	MARVELD3	1.52	12.72	0.75	3.08e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs1670533	1.000	rs10007978	chr4:1060984	A/T	cg20887711	chr4:1340912	KIAA1530	0.65	5.07	0.41	1.38e-6	Recombination rate (females);
TGCT	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.73	-0.39	5.93e-6	Prudent dietary pattern;
TGCT	cis	rs7180079	0.514	rs7402386	chr15:65003054	C/T	cg03791955	chr15:65024147	NA	-0.28	-5.43	-0.44	2.85e-7	Monocyte count;
TGCT	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg24399712	chr22:39784796	NA	-1.07	-13.1	-0.76	3.73e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs514406	0.505	rs425520	chr1:53179805	C/G	cg24675658	chr1:53192096	ZYG11B	-0.79	-9.71	-0.66	6.32e-17	Monocyte count;
TGCT	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg23758822	chr17:41437982	NA	0.68	6.76	0.52	4.84e-10	Menopause (age at onset);
TGCT	cis	rs79387448	0.745	rs72995658	chr2:103176773	A/G	cg09003973	chr2:102972529	NA	0.97	6.32	0.49	4.33e-9	Gut microbiota (bacterial taxa);
TGCT	cis	rs9859260	0.701	rs9872347	chr3:195831237	T/C	cg02975922	chr3:195473998	MUC4	-0.25	-4.97	-0.41	2.2e-6	Mean corpuscular volume;
TGCT	cis	rs68170813	0.652	rs11532774	chr7:107201579	T/C	cg02696742	chr7:106810147	HBP1	-0.59	-4.71	-0.39	6.61e-6	Coronary artery disease;
TGCT	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg02038168	chr22:39784481	NA	-0.76	-6.36	-0.5	3.47e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs10791323	0.569	rs546381	chr11:133760651	T/G	cg03690763	chr11:133734501	NA	-0.31	-5.24	-0.43	6.73e-7	Childhood ear infection;
TGCT	cis	rs12549902	0.966	rs12544241	chr8:41514888	G/A	cg21772509	chr8:41503840	NKX6-3	0.85	9.62	0.65	1.04e-16	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
TGCT	cis	rs4689388	0.890	rs6446481	chr4:6295583	C/A	cg25554036	chr4:6271136	WFS1	0.55	7.28	0.55	3.28e-11	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs2463822	1.000	rs2513071	chr11:62098387	A/C	cg06239285	chr11:62104954	ASRGL1	0.93	6.71	0.52	6.27e-10	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs9611565	0.512	rs5758436	chr22:42124265	C/T	cg06481639	chr22:41940642	POLR3H	0.71	6.43	0.5	2.56e-9	Vitiligo;
TGCT	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg22166914	chr1:53195759	ZYG11B	0.3	4.87	0.4	3.29e-6	Monocyte count;
TGCT	cis	rs9486715	0.867	rs1127175	chr6:96999725	C/T	cg06623918	chr6:96969491	KIAA0776	-1.1	-13.97	-0.78	3.18e-27	Headache;
TGCT	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg06238570	chr21:40685208	BRWD1	-0.82	-8.52	-0.61	4.53e-14	Cognitive function;
TGCT	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg04025307	chr7:1156635	C7orf50	0.21	4.95	0.41	2.39e-6	Longevity;Endometriosis;
TGCT	cis	rs1005277	0.505	rs200935	chr10:38132810	T/A	cg13531842	chr10:38383804	ZNF37A	-0.39	-4.59	-0.38	1.07e-5	Extrinsic epigenetic age acceleration;
TGCT	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg17054783	chr10:134559939	INPP5A	0.28	5.64	0.45	1.07e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs28595532	0.920	rs115878132	chr4:119756239	T/A	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs6920965	0.545	rs614031	chr6:126165720	A/C	cg05901451	chr6:126070800	HEY2	-0.56	-5.05	-0.41	1.56e-6	High light scatter reticulocyte count;
TGCT	cis	rs1062177	1.000	rs2915869	chr5:151171509	C/T	cg12924095	chr5:151150029	G3BP1	0.35	5.09	0.42	1.31e-6	Preschool internalizing problems;
TGCT	cis	rs477895	0.838	rs2001003	chr11:64018687	C/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.83	6.93	0.53	2.04e-10	Mean platelet volume;
TGCT	cis	rs1729951	0.575	rs361239	chr3:136701295	G/T	cg21827317	chr3:136751795	NA	0.4	5.61	0.45	1.28e-7	Neuroticism;
TGCT	cis	rs526231	0.578	rs35100629	chr5:102246085	C/G	cg23492399	chr5:102201601	PAM	-0.51	-4.49	-0.37	1.62e-5	Primary biliary cholangitis;
TGCT	cis	rs7572733	0.534	rs1401092	chr2:198792320	C/A	cg00792783	chr2:198669748	PLCL1	-0.57	-5.14	-0.42	1.03e-6	Dermatomyositis;
TGCT	cis	rs56011263	0.687	rs4690187	chr4:703813	C/T	cg17689763	chr4:710664	PCGF3	-0.24	-7.23	-0.54	4.25e-11	White blood cell count;
TGCT	cis	rs2594989	0.721	rs9860504	chr3:11573615	G/T	cg00170343	chr3:11313890	ATG7	-0.64	-4.77	-0.39	5.18e-6	Circulating chemerin levels;
TGCT	cis	rs8180040	0.701	rs11917474	chr3:47010491	G/A	cg27129171	chr3:47204927	SETD2	0.73	9.42	0.65	3.15e-16	Colorectal cancer;
TGCT	cis	rs2180341	0.814	rs7768435	chr6:127737038	A/C	cg24812749	chr6:127587940	RNF146	0.76	6.22	0.49	7.07e-9	Breast cancer;
TGCT	cis	rs12220898	0.749	rs7913006	chr10:50483043	G/T	cg06072769	chr10:50146962	WDFY4	0.38	5.07	0.41	1.38e-6	Inflammatory biomarkers;
TGCT	trans	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.86	-9.4	-0.65	3.49e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs35160687	0.901	rs10520415	chr2:86498738	C/T	cg04877910	chr2:85804641	VAMP8	-0.34	-4.48	-0.37	1.67e-5	Night sleep phenotypes;
TGCT	cis	rs9549260	0.564	rs4943808	chr13:41293950	C/T	cg21288729	chr13:41239152	FOXO1	0.94	9.08	0.63	2.07e-15	Red blood cell count;
TGCT	cis	rs9790314	0.503	rs6441374	chr3:161064540	A/T	cg03342759	chr3:160939853	NMD3	-0.46	-4.85	-0.4	3.7e-6	Morning vs. evening chronotype;
TGCT	cis	rs9902453	1.000	rs6505158	chr17:28403348	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.76	-6.77	-0.52	4.47e-10	Coffee consumption (cups per day);
TGCT	cis	rs9291683	0.588	rs13121211	chr4:9999539	A/G	cg11266682	chr4:10021025	SLC2A9	0.66	8.94	0.63	4.5e-15	Bone mineral density;
TGCT	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg22963979	chr7:1858916	MAD1L1	-0.42	-6.58	-0.51	1.19e-9	Bipolar disorder and schizophrenia;
TGCT	cis	rs2243480	1.000	rs2707844	chr7:66059509	G/A	cg18252515	chr7:66147081	NA	-1.22	-8.04	-0.59	6.02e-13	Diabetic kidney disease;
TGCT	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.49	-4.76	-0.39	5.34e-6	Bipolar disorder;
TGCT	cis	rs12477438	0.798	rs13414153	chr2:99624748	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-5.43	-0.44	2.89e-7	Chronic sinus infection;
TGCT	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg16325326	chr1:53192061	ZYG11B	-0.84	-11.96	-0.73	2.15e-22	Monocyte count;
TGCT	trans	rs73310256	0.536	rs7078606	chr10:92165861	G/T	cg19882243	chr17:80877520	TBCD	0.7	6.65	0.51	8.23e-10	Alzheimer disease and age of onset;
TGCT	cis	rs6448317	0.954	rs35276311	chr4:24923493	C/T	cg21108841	chr4:24914750	CCDC149	-0.63	-4.98	-0.41	2.1e-6	Heschl's gyrus morphology;
TGCT	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg10802521	chr3:52805072	NEK4	0.72	9.05	0.63	2.45e-15	Bipolar disorder;
TGCT	cis	rs453301	0.624	rs2979265	chr8:8858717	G/C	cg06636001	chr8:8085503	FLJ10661	0.8	7.09	0.54	8.97e-11	Joint mobility (Beighton score);
TGCT	cis	rs1568889	0.838	rs10767708	chr11:28294847	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.93	10.99	0.7	4.8e-20	Bipolar disorder;
TGCT	cis	rs10464366	0.544	rs6952466	chr7:39155032	A/T	cg18850127	chr7:39170497	POU6F2	0.33	7.46	0.56	1.34e-11	IgG glycosylation;
TGCT	cis	rs4499344	0.657	rs259238	chr19:33140381	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.8	8.04	0.59	5.95e-13	Mean platelet volume;
TGCT	cis	rs17270561	0.525	rs10484432	chr6:26008876	G/A	cg17691542	chr6:26056736	HIST1H1C	1.0	7.07	0.54	9.94e-11	Iron status biomarkers;
TGCT	cis	rs10507380	0.824	rs9512620	chr13:27903333	A/T	cg25543773	chr13:27185723	WASF3	0.31	4.49	0.37	1.6e-5	Electrocardiographic traits;
TGCT	cis	rs8180040	0.715	rs6772670	chr3:47191349	G/A	cg27129171	chr3:47204927	SETD2	0.75	9.86	0.66	2.82e-17	Colorectal cancer;
TGCT	cis	rs4319547	1.000	rs1392236	chr12:123074890	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.68	-5.41	-0.44	3.16e-7	Body mass index;
TGCT	cis	rs2933343	0.700	rs789233	chr3:128603150	G/T	cg11901034	chr3:128598214	ACAD9	-0.63	-5.96	-0.47	2.38e-8	IgG glycosylation;
TGCT	cis	rs10193935	0.901	rs13022188	chr2:42704423	A/C	cg27598129	chr2:42591480	NA	0.39	5.23	0.43	6.87e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2688608	0.592	rs10762560	chr10:75495405	T/G	cg15838173	chr10:75533400	FUT11	-0.31	-5.02	-0.41	1.73e-6	Inflammatory bowel disease;
TGCT	cis	rs78456975	0.506	rs10167704	chr2:1571037	G/C	cg12573674	chr2:1569213	NA	-0.48	-5.21	-0.42	7.78e-7	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs4081724	0.565	rs73026209	chr19:33806610	G/A	cg18823272	chr19:34111733	CHST8	0.42	4.7	0.39	6.85e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1215050	0.874	rs17545594	chr4:98652689	A/G	cg17366294	chr4:99064904	C4orf37	-0.46	-4.51	-0.38	1.46e-5	Waist-to-hip ratio adjusted for body mass index;
TGCT	trans	rs7819412	0.807	rs4840542	chr8:10944809	G/T	cg06636001	chr8:8085503	FLJ10661	-0.8	-7.43	-0.56	1.56e-11	Triglycerides;
TGCT	cis	rs7267979	0.932	rs6138600	chr20:25521346	A/T	cg14121845	chr20:25566513	NINL	0.49	5.36	0.43	3.83e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11105298	0.891	rs11105309	chr12:89909850	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.7	-5.02	-0.41	1.79e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs13326165	0.715	rs11705963	chr3:52371991	T/G	cg27565382	chr3:53032988	SFMBT1	0.38	5.06	0.41	1.5e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs3733585	0.648	rs28513781	chr4:9959334	G/C	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.7	-0.57	3.69e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs887829	0.569	rs4663333	chr2:234655303	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.26	-4.61	-0.38	9.85e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
TGCT	cis	rs9611519	0.929	rs13055800	chr22:41440424	G/A	cg03806693	chr22:41940476	POLR3H	-0.68	-6.1	-0.48	1.25e-8	Neuroticism;
TGCT	cis	rs8082590	1	rs8082590	chr17:17958402	G/A	cg09796270	chr17:17721594	SREBF1	-0.26	-5.17	-0.42	9.05e-7	Schizophrenia;
TGCT	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.85	-9.07	-0.63	2.22e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg11890956	chr21:40555474	PSMG1	1.11	12.17	0.74	6.69e-23	Cognitive function;
TGCT	cis	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg20637647	chr7:64974828	NA	0.9	5.31	0.43	4.87e-7	Diabetic kidney disease;
TGCT	cis	rs3780378	0.967	rs12339774	chr9:5045916	C/T	cg02405213	chr9:5042618	JAK2	-0.58	-7.5	-0.56	1.09e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs12220238	1.000	rs6480723	chr10:75966366	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.78	0.57	2.42e-12	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs11098499	0.909	rs28668716	chr4:120309875	T/C	cg09307838	chr4:120376055	NA	0.65	6.39	0.5	3.02e-9	Corneal astigmatism;
TGCT	cis	rs28595532	0.841	rs114385163	chr4:119737058	C/T	cg11846333	chr4:119757529	SEC24D	0.93	4.44	0.37	2e-5	Cannabis dependence symptom count;
TGCT	cis	rs617219	0.671	rs2591392	chr5:78546293	G/A	cg05890484	chr5:78407552	BHMT	0.37	5.02	0.41	1.73e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs7552404	0.690	rs11161620	chr1:76255228	A/G	cg10523679	chr1:76189770	ACADM	-0.74	-7.23	-0.54	4.46e-11	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg06238570	chr21:40685208	BRWD1	0.67	6.29	0.49	4.97e-9	Cognitive function;
TGCT	cis	rs2066819	0.792	rs1274496	chr12:56625693	C/A	cg26714650	chr12:56694279	CS	1.54	7.77	0.57	2.59e-12	Psoriasis vulgaris;
TGCT	cis	rs12142240	0.667	rs66990604	chr1:46822073	G/A	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs28595532	0.920	rs115688334	chr4:119770805	C/T	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs2276314	0.600	rs28729782	chr18:33590529	A/G	cg19628046	chr18:33552617	C18orf21	0.51	4.6	0.38	1.04e-5	Endometriosis;Drug-induced torsades de pointes;
TGCT	cis	rs11190604	0.607	rs12220970	chr10:102175269	G/A	cg16005271	chr10:102321736	NA	0.45	4.48	0.37	1.7e-5	Palmitoleic acid (16:1n-7) levels;
TGCT	trans	rs57221529	0.766	rs17497684	chr5:558307	T/C	cg11887960	chr12:57824829	NA	1.15	9.35	0.64	4.71e-16	Lung disease severity in cystic fibrosis;
TGCT	cis	rs6920965	0.507	rs4285341	chr6:126205589	T/G	cg05901451	chr6:126070800	HEY2	-0.66	-6.5	-0.5	1.74e-9	High light scatter reticulocyte count;
TGCT	cis	rs8111998	0.826	rs4932776	chr19:22766697	T/C	cg19914732	chr19:22715077	NA	-0.56	-4.51	-0.38	1.46e-5	Corneal structure;
TGCT	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg04772025	chr11:68637568	NA	0.61	6.52	0.51	1.61e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs4676380	0.855	rs1583261	chr2:241644740	T/C	cg21930842	chr2:241631663	AQP12A	0.3	5.49	0.44	2.13e-7	Response to metformin (IC50);
TGCT	cis	rs7714584	1.000	rs4958422	chr5:150186734	T/G	cg22134413	chr5:150180641	NA	1.13	8.18	0.59	2.91e-13	Crohn's disease;
TGCT	cis	rs9443189	0.570	rs529383	chr6:76297847	T/G	cg01950844	chr6:76311363	SENP6	1.01	6.36	0.5	3.47e-9	Prostate cancer;
TGCT	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg24503407	chr1:205819492	PM20D1	0.6	8.49	0.61	5.35e-14	Menarche (age at onset);
TGCT	cis	rs9372498	0.572	rs56082110	chr6:118909480	A/G	cg21191810	chr6:118973309	C6orf204	-0.39	-5.14	-0.42	1.02e-6	Diastolic blood pressure;
TGCT	cis	rs250677	0.687	rs40523	chr5:148444186	A/T	cg18129178	chr5:148520854	ABLIM3	0.43	6.17	0.48	9.09e-9	Breast cancer;
TGCT	cis	rs9611519	0.894	rs8136923	chr22:41470522	G/A	cg03806693	chr22:41940476	POLR3H	-0.66	-5.98	-0.47	2.25e-8	Neuroticism;
TGCT	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg22535103	chr8:58192502	C8orf71	-0.46	-5.16	-0.42	9.68e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg04944784	chr2:26401820	FAM59B	-0.67	-6.16	-0.48	9.54e-9	Gut microbiome composition (summer);
TGCT	cis	rs889312	0.500	rs832577	chr5:56163787	G/A	cg12311346	chr5:56204834	C5orf35	-0.46	-5.0	-0.41	1.87e-6	Breast cancer;Breast cancer (early onset);
TGCT	cis	rs3821902	0.502	rs17718748	chr3:64038816	A/T	cg22134162	chr3:63841271	THOC7	0.33	4.54	0.38	1.29e-5	Breast cancer;
TGCT	cis	rs7582180	0.629	rs11685250	chr2:100955137	C/T	cg08017756	chr2:100939284	LONRF2	-0.3	-4.87	-0.4	3.27e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7220711	1.000	rs9897313	chr17:41787558	G/A	cg26893861	chr17:41843967	DUSP3	0.52	4.51	0.38	1.47e-5	Bone mineral density (spine);Bone mineral density (hip);
TGCT	cis	rs9399135	0.967	rs952674	chr6:135349157	A/G	cg24558204	chr6:135376177	HBS1L	0.5	5.0	0.41	1.89e-6	Red blood cell count;
TGCT	cis	rs7403037	0.583	rs60600106	chr15:24651180	T/A	cg08449389	chr15:24672285	NA	0.43	4.6	0.38	1.04e-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
TGCT	cis	rs4631830	0.747	rs745180	chr10:51504493	A/C	cg10326726	chr10:51549505	MSMB	0.23	4.54	0.38	1.33e-5	Prostate-specific antigen levels;
TGCT	cis	rs12908161	0.960	rs17599989	chr15:85285536	A/G	cg17173187	chr15:85201210	NMB	0.56	6.38	0.5	3.18e-9	Schizophrenia;
TGCT	cis	rs60012524	1	rs60012524	chr2:99559117	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.91	-7.46	-0.56	1.34e-11	Chronic sinus infection;
TGCT	cis	rs6867913	0.709	rs2338874	chr5:141466926	G/A	cg24830494	chr5:140474986	PCDHB2	-0.4	-4.45	-0.37	1.9e-5	Asthma;
TGCT	cis	rs9682041	0.932	rs7631221	chr3:170069893	A/G	cg11886554	chr3:170076028	SKIL	0.83	5.6	0.45	1.3e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs10782582	0.593	rs74968421	chr1:76233496	T/C	cg03433033	chr1:76189801	ACADM	-0.55	-6.1	-0.48	1.25e-8	Daytime sleep phenotypes;
TGCT	cis	rs137603	0.644	rs137635	chr22:39720656	G/C	cg17798944	chr22:39715225	SNORD43;RPL3	-0.68	-7.25	-0.55	3.85e-11	Primary biliary cholangitis;
TGCT	cis	rs8062405	1.000	rs61737565	chr16:28855522	G/C	cg09754948	chr16:28834200	ATXN2L	0.59	4.45	0.37	1.91e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs12541335	0.579	rs59283125	chr8:22212311	G/A	cg09517075	chr8:22133004	PIWIL2	0.26	5.04	0.41	1.62e-6	Hypertriglyceridemia;
TGCT	cis	rs2050392	0.767	rs10763787	chr10:30700753	G/A	cg12408189	chr10:30722286	MAP3K8	0.44	4.46	0.37	1.84e-5	Inflammatory bowel disease;
TGCT	cis	rs4689388	0.856	rs10016157	chr4:6294414	T/C	cg25554036	chr4:6271136	WFS1	0.54	7.37	0.55	2.11e-11	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs3015497	0.616	rs7154131	chr14:51046526	G/C	cg04730355	chr14:51134070	SAV1	-0.62	-6.09	-0.48	1.3e-8	Mean platelet volume;
TGCT	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg04944784	chr2:26401820	FAM59B	-0.69	-6.5	-0.5	1.8e-9	Gut microbiome composition (summer);
TGCT	cis	rs17030434	0.784	rs4696486	chr4:154651354	T/C	cg14289246	chr4:154710475	SFRP2	-0.86	-7.33	-0.55	2.59e-11	Electrocardiographic conduction measures;
TGCT	cis	rs208520	0.690	rs1100981	chr6:66852052	T/C	cg07460842	chr6:66804631	NA	-0.92	-9.58	-0.65	1.29e-16	Exhaled nitric oxide output;
TGCT	trans	rs9990220	0.608	rs1317243	chr3:112053246	C/T	cg09134205	chr7:154003215	DPP6	0.36	6.72	0.52	5.93e-10	Eosinophil percentage of white cells;
TGCT	cis	rs1062177	1.000	rs2964585	chr5:151141895	C/T	cg12924095	chr5:151150029	G3BP1	0.35	5.04	0.41	1.6e-6	Preschool internalizing problems;
TGCT	cis	rs2836950	0.520	rs2836966	chr21:40637521	A/G	cg11890956	chr21:40555474	PSMG1	-0.7	-6.76	-0.52	4.9e-10	Menarche (age at onset);
TGCT	cis	rs1949733	1.000	rs2688223	chr4:8471398	T/C	cg11789530	chr4:8429930	ACOX3	0.64	5.99	0.47	2.14e-8	Response to antineoplastic agents;
TGCT	trans	rs7726839	0.561	rs72703050	chr5:582917	A/C	cg11887960	chr12:57824829	NA	0.98	7.81	0.57	2.09e-12	Obesity-related traits;
TGCT	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg19774624	chr17:42201019	HDAC5	0.88	10.92	0.7	7.5e-20	Total body bone mineral density;
TGCT	cis	rs3733585	0.699	rs17245723	chr4:9962218	A/T	cg11266682	chr4:10021025	SLC2A9	-0.57	-7.21	-0.54	4.78e-11	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg24060327	chr5:131705240	SLC22A5	-0.73	-7.83	-0.58	1.83e-12	Breast cancer;
TGCT	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg23034840	chr1:205782522	SLC41A1	0.7	6.31	0.49	4.59e-9	Prostate-specific antigen levels;
TGCT	cis	rs17345786	0.520	rs12638134	chr3:101334609	G/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.52	5.49	0.44	2.2e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs13401104	0.587	rs56146026	chr2:237145629	A/G	cg19324714	chr2:237145437	ASB18	0.48	5.03	0.41	1.67e-6	Educational attainment;
TGCT	cis	rs10465746	0.780	rs6703493	chr1:84435812	G/A	cg10977910	chr1:84465055	TTLL7	0.69	7.1	0.54	8.56e-11	Obesity-related traits;
TGCT	trans	rs12339966	0.615	rs4333706	chr9:11357040	G/A	cg03488587	chr11:64876988	C11orf2	0.3	6.92	0.53	2.12e-10	Systolic blood pressure;
TGCT	cis	rs629922	0.642	rs531831	chr11:114071814	A/G	cg01914181	chr11:114070210	ZBTB16	-0.27	-5.14	-0.42	1.05e-6	Paneth cell defects in Crohn's disease;
TGCT	cis	rs2439831	0.850	rs3825783	chr15:44102309	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	6.27	0.49	5.48e-9	Lung cancer in ever smokers;
TGCT	cis	rs12477438	0.520	rs2516835	chr2:99779131	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.75	7.25	0.55	3.92e-11	Chronic sinus infection;
TGCT	cis	rs797680	0.820	rs11164879	chr1:93655522	G/A	cg17826107	chr1:92977322	EVI5	-0.24	-5.23	-0.43	6.89e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs6570726	0.791	rs6912079	chr6:145894949	G/A	cg13319975	chr6:146136371	FBXO30	-0.51	-4.58	-0.38	1.13e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7208859	0.673	rs1347359	chr17:28914529	T/C	cg14008862	chr17:28927542	LRRC37B2	0.73	4.7	0.39	6.84e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7267979	0.816	rs374701	chr20:25483616	A/G	cg16686733	chr20:25566563	NINL	0.52	5.05	0.41	1.52e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7954584	0.531	rs6486781	chr12:122318985	A/C	cg13699009	chr12:122356056	WDR66	0.3	6.65	0.51	8.41e-10	Mean corpuscular volume;
TGCT	cis	rs61008539	0.821	rs10950789	chr7:897492	A/G	cg00475322	chr7:917719	C7orf20	0.52	7.34	0.55	2.4e-11	Perceived unattractiveness to mosquitoes;
TGCT	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg11764359	chr7:65958608	NA	0.62	5.57	0.45	1.51e-7	Aortic root size;
TGCT	cis	rs1018836	0.564	rs7821994	chr8:91700916	C/T	cg16814680	chr8:91681699	NA	-1.05	-14.68	-0.8	6.61e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg25036284	chr2:26402008	FAM59B	-0.53	-4.71	-0.39	6.62e-6	Gut microbiome composition (summer);
TGCT	cis	rs3764563	0.735	rs62106282	chr19:15727124	T/C	cg20725493	chr19:15740067	CYP4F8	-0.44	-4.46	-0.37	1.85e-5	Inflammatory biomarkers;
TGCT	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg19318889	chr4:1322082	MAEA	0.19	4.53	0.38	1.35e-5	Longevity;
TGCT	cis	rs6089584	1.000	rs3787424	chr20:60559219	G/A	cg06108461	chr20:60628389	TAF4	-0.57	-8.01	-0.58	7.25e-13	Body mass index;
TGCT	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg08280861	chr8:58055591	NA	0.39	4.86	0.4	3.45e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs12477438	0.700	rs10190421	chr2:99670711	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-5.87	-0.47	3.74e-8	Chronic sinus infection;
TGCT	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg11644478	chr21:40555479	PSMG1	1.01	10.47	0.69	8.99e-19	Cognitive function;
TGCT	cis	rs9911578	1.000	rs302859	chr17:56693132	C/T	cg05425664	chr17:57184151	TRIM37	-0.64	-6.48	-0.5	1.99e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs11096990	0.634	rs4975001	chr4:39266464	T/C	cg20847110	chr4:39482781	LOC401127	-0.16	-4.53	-0.38	1.38e-5	Cognitive function;
TGCT	cis	rs3087591	0.922	rs2953013	chr17:29496343	A/C	cg24425628	chr17:29625626	OMG;NF1	-0.42	-6.17	-0.48	8.91e-9	Hip circumference;
TGCT	cis	rs2115630	1.000	rs2115630	chr15:85364516	C/T	cg12501888	chr15:85177176	SCAND2	-0.49	-4.56	-0.38	1.2e-5	P wave terminal force;
TGCT	cis	rs1801251	0.778	rs709934	chr2:233733352	A/G	cg25237894	chr2:233734115	C2orf82	-0.32	-6.23	-0.49	6.73e-9	Coronary artery disease;
TGCT	cis	rs10464366	0.957	rs11765705	chr7:39106942	G/T	cg18850127	chr7:39170497	POU6F2	0.21	4.5	0.37	1.55e-5	IgG glycosylation;
TGCT	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg09359103	chr1:154839909	KCNN3	-0.66	-12.15	-0.74	7.27e-23	Prostate cancer;
TGCT	cis	rs9486719	0.895	rs4486019	chr6:96883814	T/C	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.86	-0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg19748678	chr4:122722346	EXOSC9	0.9	9.34	0.64	4.9e-16	Type 2 diabetes;
TGCT	cis	rs7772486	0.875	rs1331640	chr6:146427250	G/A	cg13319975	chr6:146136371	FBXO30	-0.51	-4.5	-0.37	1.56e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs68170813	0.641	rs61511581	chr7:106948091	T/A	cg02696742	chr7:106810147	HBP1	-0.72	-6.05	-0.48	1.61e-8	Coronary artery disease;
TGCT	cis	rs1371867	0.846	rs1788180	chr8:101333368	A/G	cg06002616	chr8:101225028	SPAG1	-0.53	-6.21	-0.49	7.16e-9	Atrioventricular conduction;
TGCT	cis	rs911186	0.786	rs13211901	chr6:27187612	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.55	-4.81	-0.4	4.35e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs17401966	0.838	rs12127604	chr1:10352800	T/G	cg19773385	chr1:10388646	KIF1B	-0.21	-4.57	-0.38	1.17e-5	Hepatocellular carcinoma;
TGCT	cis	rs727563	0.635	rs5758444	chr22:42133921	T/A	cg06481639	chr22:41940642	POLR3H	0.7	6.1	0.48	1.24e-8	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs1153858	0.895	rs12593402	chr15:45617392	G/A	cg26924012	chr15:45694286	SPATA5L1	1.05	13.95	0.78	3.56e-27	Homoarginine levels;
TGCT	cis	rs72781680	0.752	rs56343114	chr2:23900629	C/G	cg08917208	chr2:24149416	ATAD2B	0.84	4.63	0.38	8.91e-6	Lymphocyte counts;
TGCT	trans	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg20587970	chr11:113659929	NA	-1.03	-10.98	-0.7	5.21e-20	Hip circumference adjusted for BMI;
TGCT	cis	rs478304	0.651	rs948494	chr11:65552118	G/A	cg10518572	chr11:65560635	OVOL1	-0.24	-4.44	-0.37	1.98e-5	Acne (severe);
TGCT	cis	rs9914988	0.778	rs9907192	chr17:27122426	C/G	cg20469991	chr17:27169893	C17orf63	-0.72	-5.04	-0.41	1.58e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs9341808	0.558	rs2490234	chr6:80816966	G/C	cg08355045	chr6:80787529	NA	0.32	5.2	0.42	8.09e-7	Sitting height ratio;
TGCT	cis	rs12136530	0.774	rs10442642	chr1:19773818	A/G	cg18923740	chr1:19971790	NBL1	0.37	4.52	0.38	1.44e-5	Lead levels in blood;
TGCT	cis	rs4455778	0.659	rs12718315	chr7:49026733	G/A	cg26309511	chr7:48887640	NA	-0.44	-5.22	-0.42	7.26e-7	Lung cancer in never smokers;
TGCT	cis	rs13408808	0.641	rs10199851	chr2:168583046	T/A	cg25427580	chr2:168675357	B3GALT1	0.39	4.52	0.38	1.45e-5	Obesity-related traits;
TGCT	cis	rs2243480	0.522	rs1638736	chr7:66092308	A/T	cg18252515	chr7:66147081	NA	-0.99	-5.97	-0.47	2.34e-8	Diabetic kidney disease;
TGCT	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg12311346	chr5:56204834	C5orf35	-0.67	-6.82	-0.52	3.63e-10	Initial pursuit acceleration;
TGCT	cis	rs7923609	0.811	rs3847325	chr10:65331511	G/C	cg08743896	chr10:65200160	JMJD1C	0.32	4.46	0.37	1.82e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11190604	0.747	rs11190516	chr10:102173525	G/A	cg16342193	chr10:102329863	NA	-0.4	-5.06	-0.41	1.5e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7666738	0.830	rs28852677	chr4:99039509	T/G	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs265548	0.538	rs36688	chr19:17911212	A/C	cg16744531	chr19:17905626	B3GNT3	0.42	5.34	0.43	4.26e-7	Tumor biomarkers;
TGCT	cis	rs9807989	0.839	rs10192157	chr2:102968356	C/T	cg09003973	chr2:102972529	NA	0.64	5.7	0.46	8.28e-8	Asthma;
TGCT	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg01516881	chr6:292596	DUSP22	-0.78	-8.17	-0.59	2.99e-13	Menopause (age at onset);
TGCT	cis	rs7267979	1.000	rs6115146	chr20:25304507	G/A	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs912057	0.932	rs1294406	chr6:6737737	A/G	cg06612196	chr6:6737390	NA	0.39	4.97	0.41	2.17e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs6500602	0.727	rs4786509	chr16:4568769	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.32	-5.97	-0.47	2.35e-8	Schizophrenia;
TGCT	cis	rs7103648	0.569	rs11039266	chr11:47532395	T/G	cg20307385	chr11:47447363	PSMC3	0.89	8.35	0.6	1.15e-13	Diastolic blood pressure;Systolic blood pressure;
TGCT	cis	rs2013441	1.000	rs2526484	chr17:20103760	A/G	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.61	-0.38	9.96e-6	Obesity-related traits;
TGCT	cis	rs4242434	0.672	rs900266	chr8:22485295	A/T	cg03733263	chr8:22462867	KIAA1967	0.98	13.14	0.76	2.97e-25	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs933688	1.000	rs10059163	chr5:90742444	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.0	8.64	0.61	2.4e-14	Smoking behavior;
TGCT	trans	rs854624	0.681	rs12451192	chr17:34337246	C/T	cg25044186	chr6:170494475	NA	0.75	6.73	0.52	5.7e-10	Blood protein levels;
TGCT	cis	rs9303401	0.659	rs36093395	chr17:56957357	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	trans	rs9388451	0.874	rs13209968	chr6:126089285	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.74	-8.38	-0.6	9.81e-14	Brugada syndrome;
TGCT	cis	rs7829975	0.577	rs940030	chr8:8546928	A/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-5.09	-0.42	1.3e-6	Mood instability;
TGCT	cis	rs11731606	0.508	rs7696494	chr4:95285174	G/A	cg00507259	chr4:95128692	SMARCAD1	0.63	4.72	0.39	6.18e-6	Mean platelet volume;
TGCT	cis	rs11969893	0.850	rs9386260	chr6:101329428	G/A	cg12253828	chr6:101329408	ASCC3	1.36	6.32	0.49	4.33e-9	Economic and political preferences (immigration/crime);
TGCT	cis	rs3812831	0.543	rs389108	chr13:114925389	A/G	cg15513719	chr13:114904418	NA	0.37	4.56	0.38	1.22e-5	Schizophrenia;
TGCT	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs854765	0.693	rs9915776	chr17:17749056	A/G	cg04398451	chr17:18023971	MYO15A	0.31	4.67	0.39	7.57e-6	Total body bone mineral density;
TGCT	cis	rs826838	0.933	rs1906263	chr12:38653362	T/C	cg13010199	chr12:38710504	ALG10B	0.77	6.31	0.49	4.59e-9	Heart rate;
TGCT	cis	rs2730245	0.510	rs2788474	chr7:158649005	T/C	cg11984989	chr7:158649758	WDR60	1.06	9.85	0.66	2.94e-17	Height;
TGCT	cis	rs7772486	0.790	rs9403755	chr6:146231470	C/A	cg05347473	chr6:146136440	FBXO30	-0.51	-4.95	-0.41	2.32e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4727027	0.835	rs11767810	chr7:148774433	T/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	4.99	0.41	2.02e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs734999	0.549	rs2764840	chr1:2529437	C/T	cg18854424	chr1:2615690	NA	-0.5	-5.9	-0.47	3.25e-8	Ulcerative colitis;
TGCT	trans	rs7698623	0.850	rs1477604	chr4:88771060	C/T	cg07071417	chr3:65365250	MAGI1	-0.71	-6.86	-0.52	2.98e-10	Cardiovascular disease risk factors;
TGCT	cis	rs7582180	0.764	rs1530028	chr2:100927910	A/C	cg14675211	chr2:100938903	LONRF2	0.52	4.98	0.41	2.1e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs17376456	0.825	rs10058331	chr5:93279115	T/G	cg25358565	chr5:93447407	FAM172A	1.03	8.1	0.59	4.5e-13	Diabetic retinopathy;
TGCT	cis	rs9486719	0.802	rs2983896	chr6:97029871	G/A	cg18709589	chr6:96969512	KIAA0776	-0.79	-6.36	-0.5	3.44e-9	Migraine;Coronary artery disease;
TGCT	cis	rs7180079	0.502	rs6494466	chr15:64508763	A/G	cg13401987	chr15:63569418	APH1B	-0.53	-4.62	-0.38	9.39e-6	Monocyte count;
TGCT	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.73	-7.39	-0.55	1.92e-11	Prudent dietary pattern;
TGCT	cis	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg26116260	chr4:7069785	GRPEL1	-0.85	-6.51	-0.5	1.72e-9	Monocyte percentage of white cells;
TGCT	cis	rs5769765	0.773	rs9616751	chr22:50222236	T/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.34	4.77	0.39	5.01e-6	Schizophrenia;
TGCT	cis	rs1577917	0.958	rs13207173	chr6:86457522	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.27	-0.43	5.96e-7	Response to antipsychotic treatment;
TGCT	cis	rs9393777	0.513	rs9368450	chr6:26652489	A/C	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.53	-4.88	-0.4	3.19e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg03351412	chr1:154909251	PMVK	0.51	4.88	0.4	3.26e-6	Prostate cancer;
TGCT	cis	rs919433	0.679	rs67492914	chr2:198523402	T/G	cg00792783	chr2:198669748	PLCL1	0.55	4.88	0.4	3.24e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs17376456	0.569	rs10050364	chr5:93064127	T/C	cg21475434	chr5:93447410	FAM172A	0.61	4.95	0.41	2.35e-6	Diabetic retinopathy;
TGCT	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg05368731	chr17:41323189	NBR1	1.19	14.18	0.79	9.89e-28	Menopause (age at onset);
TGCT	cis	rs1008375	0.931	rs6837181	chr4:17701253	A/C	cg18681998	chr4:17616180	MED28	0.77	7.29	0.55	3.15e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9467711	0.722	rs13201782	chr6:26651053	T/A	cg12315302	chr6:26189340	HIST1H4D	0.99	4.44	0.37	1.93e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2153535	0.562	rs10458225	chr6:8386004	G/A	cg07606381	chr6:8435919	SLC35B3	-0.54	-5.07	-0.41	1.39e-6	Motion sickness;
TGCT	trans	rs916888	0.647	rs199524	chr17:44848438	G/T	cg01341218	chr17:43662625	NA	-0.86	-7.5	-0.56	1.06e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs1552244	0.816	rs9847657	chr3:10173492	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.38	-5.63	-0.45	1.15e-7	Alzheimer's disease;
TGCT	cis	rs210138	1.000	rs210138	chr6:33542538	C/T	cg07679836	chr6:33548423	BAK1	-0.41	-5.77	-0.46	5.88e-8	Testicular germ cell tumor;
TGCT	cis	rs7213347	0.780	rs1555568	chr17:2149505	T/C	cg20777128	chr17:1945076	DPH1;OVCA2	-0.5	-4.46	-0.37	1.84e-5	Total body bone mineral density;
TGCT	cis	rs6840360	0.904	rs6813516	chr4:152594407	C/G	cg17479576	chr4:152424074	FAM160A1	-0.56	-6.11	-0.48	1.17e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs13008689	0.875	rs55776708	chr2:8520167	A/C	cg21129864	chr2:9369739	ASAP2	-0.2	-4.63	-0.38	8.94e-6	Longevity;
TGCT	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg13206674	chr6:150067644	NUP43	0.52	4.46	0.37	1.78e-5	Lung cancer;
TGCT	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg01448562	chr3:133502909	NA	0.32	6.58	0.51	1.16e-9	Iron status biomarkers;
TGCT	cis	rs7666738	0.830	rs7667796	chr4:99071415	G/T	cg05340658	chr4:99064831	C4orf37	-0.53	-5.88	-0.47	3.62e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs78487399	0.808	rs76851696	chr2:43746062	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.07	-0.41	1.41e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs7666738	0.830	rs11723283	chr4:99001617	C/T	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1362404	0.648	rs7187733	chr16:51993069	C/T	cg00216305	chr16:51625890	NA	-0.29	-4.71	-0.39	6.6e-6	Gut microbiota (bacterial taxa);
TGCT	cis	rs2237234	0.813	rs34565965	chr6:26350810	T/A	cg15659132	chr6:26577336	NA	-0.68	-5.21	-0.42	7.75e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs950169	1.000	rs34751999	chr15:84758419	T/C	cg11189052	chr15:85197271	WDR73	0.69	5.91	0.47	3.07e-8	Schizophrenia;
TGCT	cis	rs3796352	1.000	rs13078971	chr3:53103645	G/C	cg15956490	chr3:53032818	SFMBT1	0.59	6.6	0.51	1.07e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs6061231	0.583	rs2427313	chr20:60970675	G/A	cg15674680	chr20:60982522	CABLES2	0.72	5.97	0.47	2.29e-8	Colorectal cancer;
TGCT	cis	rs669446	0.561	rs517849	chr1:44081873	A/C	cg12908607	chr1:44402522	ARTN	-0.55	-5.9	-0.47	3.25e-8	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs3020736	0.500	rs6002618	chr22:42507859	G/C	cg15557168	chr22:42548783	NA	0.22	5.58	0.45	1.47e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1008375	0.900	rs12650220	chr4:17595365	A/T	cg18681998	chr4:17616180	MED28	1.0	9.95	0.67	1.69e-17	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6912958	0.703	rs12207825	chr6:88098292	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.62	6.09	0.48	1.29e-8	Monocyte percentage of white cells;
TGCT	cis	rs7940866	0.770	rs10750456	chr11:130819634	A/G	cg12179176	chr11:130786555	SNX19	0.62	5.96	0.47	2.43e-8	Schizophrenia;
TGCT	cis	rs6815814	0.898	rs17582830	chr4:38867427	A/G	cg02016764	chr4:38805732	TLR1	-0.36	-5.61	-0.45	1.24e-7	Breast cancer;
TGCT	trans	rs1814175	0.619	rs847644	chr11:49918418	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.51	-0.69	7.2e-19	Height;
TGCT	cis	rs6918586	0.658	rs198854	chr6:26104057	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.7	-6.6	-0.51	1.09e-9	Schizophrenia;
TGCT	trans	rs208520	1.000	rs12212063	chr6:66985148	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.8	7.11	0.54	7.9e-11	Exhaled nitric oxide output;
TGCT	cis	rs1008375	1.000	rs13149474	chr4:17688582	G/A	cg18681998	chr4:17616180	MED28	-0.91	-8.98	-0.63	3.58e-15	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	trans	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg27523141	chr10:43048294	ZNF37B	-0.69	-8.08	-0.59	4.93e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg15556689	chr8:8085844	FLJ10661	0.67	6.2	0.49	7.84e-9	Mood instability;
TGCT	cis	rs71636778	0.509	rs35108146	chr1:27248440	C/T	cg23921621	chr1:27994728	IFI6	-0.43	-4.61	-0.38	9.95e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
TGCT	cis	rs554111	0.656	rs10916891	chr1:21199974	A/C	cg01072550	chr1:21505969	NA	0.35	5.4	0.44	3.32e-7	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs10114408	0.959	rs7852025	chr9:96647865	G/A	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs12681287	0.604	rs6471316	chr8:87403587	G/C	cg27223183	chr8:87520930	FAM82B	0.87	6.39	0.5	3e-9	Caudate activity during reward;
TGCT	cis	rs8084125	0.832	rs7238522	chr18:74948730	A/C	cg05528293	chr18:74961138	GALR1	-0.51	-5.07	-0.41	1.4e-6	Obesity-related traits;
TGCT	trans	rs1814175	0.817	rs10769618	chr11:49822336	A/G	cg03929089	chr4:120376271	NA	-0.72	-8.26	-0.6	1.84e-13	Height;
TGCT	cis	rs1670533	0.685	rs56019586	chr4:1059842	C/G	cg27284194	chr4:1044797	NA	0.67	5.79	0.46	5.37e-8	Recombination rate (females);
TGCT	cis	rs80282103	0.764	rs12244052	chr10:1103266	G/A	cg08668510	chr10:1095578	IDI1	1.01	4.51	0.38	1.48e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs7119	0.689	rs12901765	chr15:77819103	C/A	cg27398640	chr15:77910606	LINGO1	-0.26	-4.66	-0.39	7.98e-6	Type 2 diabetes;
TGCT	cis	rs1127311	1.000	rs9427094	chr1:154557685	C/T	cg17218026	chr1:154582156	ADAR	0.29	7.29	0.55	3.13e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs1215050	0.740	rs11097580	chr4:98767255	C/A	cg17366294	chr4:99064904	C4orf37	0.52	5.59	0.45	1.4e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	trans	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg21659725	chr3:3221576	CRBN	-0.76	-9.03	-0.63	2.74e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs7772486	0.790	rs1062068	chr6:146207465	A/G	cg23711669	chr6:146136114	FBXO30	0.91	10.68	0.69	2.77e-19	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.31	0.43	4.9e-7	Prudent dietary pattern;
TGCT	cis	rs7192750	0.586	rs6499551	chr16:71943107	T/C	cg06353428	chr16:71660113	MARVELD3	0.83	7.32	0.55	2.74e-11	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs259282	0.524	rs3760941	chr19:33130866	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.51	4.69	0.39	7e-6	Schizophrenia;
TGCT	cis	rs2758596	0.850	rs2495270	chr1:156181530	A/G	cg25208724	chr1:156163844	SLC25A44	0.99	5.48	0.44	2.3e-7	Paclitaxel disposition in epithelial ovarian cancer;
TGCT	cis	rs2637266	0.935	rs7900900	chr10:78367383	A/T	cg18941641	chr10:78392320	NA	0.4	4.73	0.39	6.03e-6	Pulmonary function;
TGCT	cis	rs7833790	0.660	rs67666182	chr8:82772037	A/G	cg27398817	chr8:82754497	SNX16	0.69	5.52	0.44	1.9e-7	Diastolic blood pressure;
TGCT	cis	rs561341	0.739	rs4795663	chr17:30214542	T/C	cg13647721	chr17:30228624	UTP6	-0.59	-5.21	-0.42	7.66e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs11190604	1.000	rs2495755	chr10:102324649	A/C	cg23241863	chr10:102295624	HIF1AN	0.66	4.87	0.4	3.37e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9921338	0.961	rs4781069	chr16:11428762	G/A	cg00044050	chr16:11439710	C16orf75	-0.88	-6.75	-0.52	5.08e-10	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs6121246	0.580	rs6121016	chr20:30245239	C/T	cg13852791	chr20:30311386	BCL2L1	0.72	4.78	0.39	4.95e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs3780378	0.935	rs2230724	chr9:5081780	G/A	cg02405213	chr9:5042618	JAK2	-0.62	-8.3	-0.6	1.48e-13	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs9436747	0.641	rs12239395	chr1:66046013	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.52	4.65	0.39	8.37e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs12477438	0.501	rs9941561	chr2:99753829	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	12.84	0.76	1.57e-24	Chronic sinus infection;
TGCT	cis	rs4886920	0.563	rs4886915	chr15:78075023	A/G	cg03457338	chr15:78040120	NA	0.18	4.51	0.38	1.48e-5	Neuroticism;
TGCT	cis	rs7772486	0.719	rs702317	chr6:146005010	C/T	cg05347473	chr6:146136440	FBXO30	-0.51	-4.8	-0.4	4.44e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs68170813	0.559	rs78064065	chr7:106967440	G/A	cg02696742	chr7:106810147	HBP1	-0.68	-5.64	-0.45	1.09e-7	Coronary artery disease;
TGCT	cis	rs7267979	1.000	rs2424716	chr20:25423538	G/A	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7949030	0.626	rs11231144	chr11:62328038	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.62	8.88	0.62	6.35e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs11674184	0.659	rs59129126	chr2:11728388	T/C	cg07314298	chr2:11723111	GREB1	-0.4	-7.53	-0.56	8.9e-12	Endometriosis;
TGCT	cis	rs11578119	0.866	rs12408130	chr1:170375663	A/G	cg09767346	chr1:170501363	GORAB	0.64	4.89	0.4	3.02e-6	Male-pattern baldness;
TGCT	cis	rs644799	0.542	rs10831415	chr11:95466159	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.57	5.72	0.46	7.43e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg01341218	chr17:43662625	NA	-1.09	-8.99	-0.63	3.46e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7769051	1.000	rs9493446	chr6:133125643	C/T	cg22852734	chr6:133119734	C6orf192	1.22	7.01	0.53	1.38e-10	Type 2 diabetes nephropathy;
TGCT	cis	rs62380364	0.774	rs7730255	chr5:88158146	G/C	cg22951263	chr5:87985283	NA	-0.52	-5.03	-0.41	1.65e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs752010	0.714	rs7552928	chr1:42086664	C/T	cg06885757	chr1:42089581	HIVEP3	0.25	4.56	0.38	1.23e-5	Lupus nephritis in systemic lupus erythematosus;
TGCT	cis	rs2067615	0.524	rs1882543	chr12:107067160	A/G	cg15890332	chr12:107067104	RFX4	-0.29	-5.71	-0.46	7.83e-8	Heart rate;
TGCT	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg23302884	chr18:44338147	ST8SIA5	0.41	4.81	0.4	4.33e-6	Personality dimensions;
TGCT	cis	rs7169223	0.615	rs11630027	chr15:79096983	C/A	cg21242079	chr15:79101063	ADAMTS7	0.3	5.02	0.41	1.75e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
TGCT	cis	rs427394	0.632	rs2279656	chr5:6737576	G/A	cg10857441	chr5:6722123	POLS	-0.28	-6.08	-0.48	1.38e-8	Menopause (age at onset);
TGCT	cis	rs17601876	0.814	rs28637352	chr15:51559666	C/A	cg19946085	chr15:51559439	CYP19A1	-0.33	-5.06	-0.41	1.45e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	trans	rs10506458	1.000	rs1495013	chr12:63428188	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.47	-7.61	-0.56	5.88e-12	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs3741151	1.000	rs1892856	chr11:73017971	G/C	cg17517138	chr11:73019481	ARHGEF17	1.16	5.5	0.44	2.11e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
TGCT	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg08859206	chr1:53392774	SCP2	-0.43	-6.47	-0.5	2.07e-9	Monocyte count;
TGCT	cis	rs6500602	0.598	rs3859155	chr16:4593741	A/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.29	-5.44	-0.44	2.77e-7	Schizophrenia;
TGCT	trans	rs877282	0.945	rs11253396	chr10:789754	C/T	cg22713356	chr15:30763199	NA	1.18	10.55	0.69	5.81e-19	Uric acid levels;
TGCT	cis	rs1997103	1.000	rs7779040	chr7:55412947	T/C	cg17469321	chr7:55412551	NA	0.65	6.75	0.52	5.08e-10	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs7666738	0.546	rs13148080	chr4:98680947	A/G	cg05340658	chr4:99064831	C4orf37	0.49	5.29	0.43	5.45e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs36051895	0.560	rs10975009	chr9:5220397	T/G	cg02405213	chr9:5042618	JAK2	-0.68	-8.59	-0.61	3.09e-14	Pediatric autoimmune diseases;
TGCT	cis	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg02380750	chr20:61661411	NA	0.34	6.02	0.48	1.86e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs3793917	0.948	rs11200632	chr10:124211536	A/G	cg25576655	chr10:124402963	DMBT1	0.29	4.46	0.37	1.84e-5	Age-related macular degeneration;
TGCT	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg12140144	chr1:2984275	FLJ42875;PRDM16	-0.32	-4.46	-0.37	1.81e-5	Height;
TGCT	cis	rs838147	0.505	rs1688264	chr19:49209560	T/G	cg04599840	chr19:48886497	KDELR1	0.21	4.44	0.37	1.98e-5	Dietary macronutrient intake;
TGCT	cis	rs6988636	0.710	rs62521799	chr8:124134987	G/A	cg22384356	chr8:124195192	FAM83A	-0.49	-4.72	-0.39	6.35e-6	Urinary uromodulin levels;
TGCT	cis	rs6815814	0.950	rs55903115	chr4:38786474	C/A	cg02016764	chr4:38805732	TLR1	-0.36	-5.46	-0.44	2.53e-7	Breast cancer;
TGCT	cis	rs1801251	0.727	rs6437071	chr2:233568793	G/A	cg25237894	chr2:233734115	C2orf82	0.25	4.67	0.39	7.56e-6	Coronary artery disease;
TGCT	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg20891283	chr12:69753455	YEATS4	0.9	10.24	0.68	3.28e-18	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs12477438	0.798	rs4324365	chr2:99623845	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-6.1	-0.48	1.22e-8	Chronic sinus infection;
TGCT	cis	rs67311347	0.544	rs60329764	chr3:40334621	C/T	cg13683864	chr3:40499215	RPL14	0.8	7.65	0.57	4.79e-12	Renal cell carcinoma;
TGCT	cis	rs9467773	0.935	rs9461270	chr6:26544110	A/G	cg26531700	chr6:26746687	NA	0.47	4.56	0.38	1.19e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7523273	0.627	rs2724389	chr1:207933648	T/C	cg22525895	chr1:207977042	MIR29B2	0.52	8.49	0.61	5.2e-14	Schizophrenia;
TGCT	cis	rs3796352	1.000	rs13072818	chr3:53074263	C/T	cg15956490	chr3:53032818	SFMBT1	0.59	6.75	0.52	5.19e-10	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs9911578	1.000	rs2333332	chr17:56631054	A/G	cg05425664	chr17:57184151	TRIM37	0.63	6.26	0.49	5.86e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg13395646	chr4:1353034	KIAA1530	-0.37	-4.56	-0.38	1.19e-5	Longevity;
TGCT	cis	rs9467711	0.606	rs13190739	chr6:26587373	G/T	cg16898833	chr6:26189333	HIST1H4D	1.26	5.95	0.47	2.59e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9346649	0.616	rs7740995	chr6:168492221	G/A	cg02770688	chr6:168491649	NA	0.32	5.58	0.45	1.47e-7	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
TGCT	cis	rs9430161	0.611	rs12081181	chr1:11034165	T/G	cg27631724	chr1:11040367	C1orf127	0.53	6.05	0.48	1.58e-8	Ewing sarcoma;
TGCT	cis	rs9993613	0.875	rs35100429	chr4:73482344	A/C	cg15102770	chr4:73434591	ADAMTS3	0.52	4.89	0.4	3.07e-6	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg25660036	chr4:7070649	GRPEL1	-0.59	-4.6	-0.38	1.01e-5	Monocyte percentage of white cells;
TGCT	cis	rs4788570	0.538	rs16973286	chr16:71552257	C/A	cg06353428	chr16:71660113	MARVELD3	-1.32	-7.58	-0.56	6.9e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.7	-0.39	6.79e-6	Prudent dietary pattern;
TGCT	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.12	0.54	7.78e-11	Prudent dietary pattern;
TGCT	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg26531700	chr6:26746687	NA	-0.57	-5.21	-0.42	7.62e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1801251	1.000	rs7578299	chr2:233573469	G/T	cg08000102	chr2:233561755	GIGYF2	0.66	6.8	0.52	3.88e-10	Coronary artery disease;
TGCT	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg05368731	chr17:41323189	NBR1	1.21	14.63	0.8	8.89e-29	Menopause (age at onset);
TGCT	trans	rs1814175	0.904	rs7924371	chr11:49620595	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.34	-6.67	-0.51	7.47e-10	Height;
TGCT	cis	rs3806843	0.612	rs246075	chr5:140300557	T/C	cg09824255	chr5:140014002	CD14	0.26	4.58	0.38	1.13e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2956278	0.717	rs2929744	chr12:84690201	G/A	cg25678815	chr12:85673915	ALX1	-0.53	-4.76	-0.39	5.4e-6	Depressive symptoms;Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2013441	1.000	rs2034109	chr17:20196633	C/T	cg18979559	chr17:20280153	CCDC144C	-0.49	-5.04	-0.41	1.59e-6	Obesity-related traits;
TGCT	cis	rs933688	0.938	rs10942634	chr5:90658392	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.06	10.12	0.67	6.38e-18	Smoking behavior;
TGCT	trans	rs525455	0.966	rs1659844	chr10:13102104	T/G	cg21721093	chr17:8906386	NA	0.63	6.62	0.51	9.7e-10	Platelet aggregation;
TGCT	cis	rs9581857	0.685	rs17808758	chr13:28036412	C/T	cg22138327	chr13:27999177	GTF3A	0.77	5.24	0.43	6.8e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs968567	0.817	rs61896141	chr11:61556039	A/C	cg19610905	chr11:61596333	FADS2	-0.81	-5.14	-0.42	1.04e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
TGCT	cis	rs2239547	0.525	rs2246556	chr3:53027983	T/C	cg11645453	chr3:52864694	ITIH4	-0.28	-5.27	-0.43	5.73e-7	Schizophrenia;
TGCT	cis	rs259282	0.605	rs3760939	chr19:33106911	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.56	5.12	0.42	1.11e-6	Schizophrenia;
TGCT	cis	rs67366981	0.720	rs4396457	chr14:77685379	G/A	cg22824376	chr14:77648248	TMEM63C	0.74	4.75	0.39	5.58e-6	Obsessive-compulsive symptoms;
TGCT	cis	rs7264396	0.635	rs6058351	chr20:34486093	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.04	-0.41	1.58e-6	Total cholesterol levels;
TGCT	cis	rs854765	0.624	rs9899634	chr17:17727943	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.69	-6.55	-0.51	1.36e-9	Total body bone mineral density;
TGCT	cis	rs924607	0.898	rs1697990	chr5:626278	A/G	cg18765565	chr5:669397	TPPP	-0.64	-7.05	-0.54	1.08e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs3087591	0.708	rs7505	chr17:29644852	G/A	cg24425628	chr17:29625626	OMG;NF1	0.4	5.63	0.45	1.14e-7	Hip circumference;
TGCT	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg05025164	chr4:1340916	KIAA1530	-0.57	-5.03	-0.41	1.69e-6	Obesity-related traits;
TGCT	cis	rs2046867	0.862	rs7648954	chr3:72838756	C/A	cg25664220	chr3:72788482	NA	-0.52	-6.64	-0.51	8.92e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs17221829	0.574	rs2773245	chr11:89372626	G/A	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.63	-0.38	9.04e-6	Anxiety in major depressive disorder;
TGCT	cis	rs4325129	1.000	rs12141291	chr1:159460871	C/T	cg20944283	chr1:159172620	CADM3	-0.28	-4.44	-0.37	1.96e-5	Obesity-related traits;
TGCT	cis	rs7267979	1.000	rs398036	chr20:25439850	C/T	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2762353	0.574	rs9467574	chr6:25705718	C/G	cg03517284	chr6:25882590	NA	0.88	8.68	0.61	1.88e-14	Blood metabolite levels;
TGCT	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.63	0.38	9.2e-6	Prudent dietary pattern;
TGCT	cis	rs7772486	0.622	rs1292333	chr6:145982344	C/T	cg05347473	chr6:146136440	FBXO30	-0.48	-4.56	-0.38	1.22e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs910316	0.737	rs175084	chr14:75519175	C/T	cg08847533	chr14:75593920	NEK9	-0.85	-8.45	-0.6	6.56e-14	Height;
TGCT	cis	rs2224391	0.628	rs2773316	chr6:5254448	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.99	-6.43	-0.5	2.46e-9	Height;
TGCT	cis	rs523522	0.962	rs10849754	chr12:120940418	A/C	cg27279351	chr12:120934652	DYNLL1	0.76	6.59	0.51	1.15e-9	High light scatter reticulocyte count;
TGCT	cis	rs7833790	0.660	rs10091077	chr8:82705464	A/G	cg06027949	chr8:82754900	SNX16	-0.62	-4.74	-0.39	5.73e-6	Diastolic blood pressure;
TGCT	cis	rs12510870	0.674	rs10019320	chr4:74453878	G/A	cg05868023	chr4:75230803	EREG	-0.55	-4.73	-0.39	5.96e-6	Iris color (b* coordinate);
TGCT	cis	rs9914544	0.545	rs9914914	chr17:18787780	G/A	cg26378065	chr17:18585709	ZNF286B	0.53	4.63	0.38	9.01e-6	Educational attainment (years of education);
TGCT	cis	rs9911578	1.000	rs304270	chr17:56802141	A/G	cg12560992	chr17:57184187	TRIM37	-0.77	-9.56	-0.65	1.45e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs6121246	0.559	rs12479491	chr20:30265450	T/C	cg13852791	chr20:30311386	BCL2L1	0.82	8.0	0.58	7.65e-13	Mean corpuscular hemoglobin;
TGCT	cis	rs11785400	0.793	rs2976399	chr8:143746050	C/T	cg24634471	chr8:143751801	JRK	0.54	5.29	0.43	5.35e-7	Schizophrenia;
TGCT	cis	rs11172134	0.508	rs1800174	chr12:57559809	G/A	cg19258868	chr12:57585184	LRP1	-0.33	-6.06	-0.48	1.48e-8	Urate levels in overweight individuals;
TGCT	cis	rs12579753	0.917	rs12366599	chr12:82212112	C/T	cg07988820	chr12:82153109	PPFIA2	-0.59	-6.23	-0.49	6.65e-9	Resting heart rate;
TGCT	cis	rs4805272	0.632	rs7249919	chr19:29335362	C/A	cg15000279	chr19:29285009	NA	0.57	6.33	0.49	4.02e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
TGCT	cis	rs317689	0.600	rs478863	chr12:69639207	G/A	cg11871910	chr12:69753446	YEATS4	0.54	4.47	0.37	1.72e-5	Response to diuretic therapy;
TGCT	cis	rs10089	1.000	rs59484271	chr5:127503781	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.81	7.36	0.55	2.17e-11	Ileal carcinoids;
TGCT	cis	rs3820928	0.904	rs60906902	chr2:227760034	C/T	cg11843606	chr2:227700838	RHBDD1	-0.57	-5.13	-0.42	1.08e-6	Pulmonary function;
TGCT	cis	rs6074578	0.679	rs12480529	chr20:137454	T/G	cg16931068	chr20:139680	DEFB127	0.27	4.8	0.4	4.52e-6	Hirschsprung disease;
TGCT	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg07167872	chr1:205819463	PM20D1	0.41	4.77	0.39	4.98e-6	Menarche (age at onset);
TGCT	cis	rs9796	0.689	rs9888710	chr15:41446153	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.53	-6.83	-0.52	3.38e-10	Menopause (age at onset);
TGCT	cis	rs12579753	0.956	rs34747993	chr12:82217777	C/T	cg07988820	chr12:82153109	PPFIA2	-0.65	-6.81	-0.52	3.72e-10	Resting heart rate;
TGCT	cis	rs28714278	0.644	rs34754163	chr15:40308161	A/C	cg21830797	chr15:40226279	EIF2AK4	-0.54	-4.88	-0.4	3.19e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs6969780	0.722	rs983185	chr7:27188607	G/A	cg04317399	chr7:27170313	HOXA4	-0.46	-5.04	-0.41	1.6e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs514406	0.505	rs395169	chr1:53174071	G/A	cg24675658	chr1:53192096	ZYG11B	-0.78	-9.23	-0.64	9e-16	Monocyte count;
TGCT	cis	rs909002	0.800	rs6703093	chr1:32093561	C/T	cg11573219	chr1:32083031	HCRTR1	-0.4	-5.12	-0.42	1.12e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg08280861	chr8:58055591	NA	0.39	4.86	0.4	3.45e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs17345786	0.798	rs1609159	chr3:101275902	A/C	cg11279151	chr3:101281821	RG9MTD1	-0.44	-9.82	-0.66	3.38e-17	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.09	-16.1	-0.82	3.69e-32	Prudent dietary pattern;
TGCT	cis	rs9916302	0.904	rs3964723	chr17:37403979	C/T	cg07936489	chr17:37558343	FBXL20	-0.63	-5.06	-0.41	1.46e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs2663905	1.000	rs2663905	chr15:81359137	G/A	cg27045999	chr15:81426544	C15orf26	-0.54	-5.49	-0.44	2.12e-7	QT interval (drug interaction);
TGCT	cis	rs75686122	0.892	rs4734077	chr8:104600186	G/A	cg04852977	chr8:104510831	NA	0.59	4.45	0.37	1.92e-5	Cocaine dependence;
TGCT	cis	rs1371867	0.846	rs1613453	chr8:101244215	G/T	cg06002616	chr8:101225028	SPAG1	0.53	6.07	0.48	1.45e-8	Atrioventricular conduction;
TGCT	cis	rs832540	0.931	rs832534	chr5:56213672	G/A	cg24531977	chr5:56204891	C5orf35	-0.52	-5.18	-0.42	8.65e-7	Coronary artery disease;
TGCT	cis	rs2645424	0.530	rs1293303	chr8:11720227	C/G	cg21281001	chr8:11725306	CTSB	-0.56	-4.8	-0.4	4.4e-6	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
TGCT	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.55	-6.35	-0.5	3.74e-9	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg26818010	chr10:134567672	INPP5A	-0.36	-4.95	-0.41	2.33e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs2760061	0.626	rs672907	chr1:228120345	G/A	cg02753203	chr1:228287806	NA	-0.34	-6.63	-0.51	9.15e-10	Diastolic blood pressure;
TGCT	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	15.25	0.81	3.21e-30	Prudent dietary pattern;
TGCT	cis	rs6921919	0.583	rs6928773	chr6:28375210	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.53	-5.13	-0.42	1.09e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1005277	0.505	rs719569	chr10:38154415	T/G	cg13531842	chr10:38383804	ZNF37A	0.38	4.55	0.38	1.24e-5	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2439831	0.867	rs2927072	chr15:43922398	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	4.95	0.41	2.38e-6	Lung cancer in ever smokers;
TGCT	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg03806693	chr22:41940476	POLR3H	1.16	13.52	0.77	3.78e-26	Vitiligo;
TGCT	cis	rs1395	0.710	rs58965570	chr2:27481460	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.65	8.48	0.61	5.54e-14	Blood metabolite levels;
TGCT	cis	rs2288073	0.965	rs10469924	chr2:24416230	G/A	cg05570707	chr2:24270316	C2orf44	-0.5	-4.47	-0.37	1.72e-5	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs2115630	0.936	rs11073663	chr15:85260268	A/G	cg11189052	chr15:85197271	WDR73	-0.65	-6.41	-0.5	2.71e-9	P wave terminal force;
TGCT	cis	rs1018836	0.828	rs7816023	chr8:91567398	T/C	cg16814680	chr8:91681699	NA	-0.75	-7.85	-0.58	1.71e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg22166914	chr1:53195759	ZYG11B	0.34	5.71	0.46	7.92e-8	Monocyte count;
TGCT	cis	rs1476029	0.800	rs105161	chr22:36530428	G/A	cg00323501	chr22:37464839	TMPRSS6	-0.53	-4.73	-0.39	6.09e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
TGCT	cis	rs10197940	0.624	rs13393122	chr2:152413315	A/G	cg06191203	chr2:152266755	RIF1	-0.75	-7.11	-0.54	8.21e-11	Lung cancer;
TGCT	cis	rs739496	0.793	rs76604970	chr12:111967155	A/T	cg10833066	chr12:111807467	FAM109A	0.37	5.16	0.42	9.31e-7	Platelet count;
TGCT	cis	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg04055107	chr11:65626734	MUS81;CFL1	0.45	4.47	0.37	1.73e-5	Sum eosinophil basophil counts;Eosinophil counts;
TGCT	cis	rs7000551	0.751	rs2469775	chr8:22373238	T/C	cg12081754	chr8:22256438	SLC39A14	0.3	4.72	0.39	6.19e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs394563	0.591	rs237035	chr6:149710848	C/T	cg16235748	chr6:149772707	ZC3H12D	-0.44	-4.9	-0.4	2.87e-6	Dupuytren's disease;
TGCT	cis	rs7666738	0.830	rs9992391	chr4:98916052	G/A	cg05340658	chr4:99064831	C4orf37	0.54	6.51	0.5	1.7e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10823500	0.604	rs10740329	chr10:71941253	A/T	cg02100629	chr10:71892760	AIFM2	0.37	4.45	0.37	1.89e-5	Blood protein levels;
TGCT	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg13395646	chr4:1353034	KIAA1530	-0.36	-4.61	-0.38	9.75e-6	Obesity-related traits;
TGCT	cis	rs35883536	0.647	rs17402630	chr1:101046587	C/T	cg10298815	chr1:101004474	GPR88	-0.25	-4.5	-0.37	1.54e-5	Monocyte count;
TGCT	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg04013166	chr16:89971882	TCF25	-0.34	-5.16	-0.42	9.42e-7	Skin colour saturation;
TGCT	cis	rs9911578	0.967	rs302842	chr17:56728102	C/G	cg12560992	chr17:57184187	TRIM37	0.75	9.21	0.64	1.04e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs4900538	0.821	rs7012	chr14:102814945	C/T	cg18135206	chr14:102964638	TECPR2	-0.19	-4.8	-0.4	4.56e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs7119	0.717	rs12904584	chr15:77815991	C/T	cg27398640	chr15:77910606	LINGO1	-0.25	-4.6	-0.38	1.05e-5	Type 2 diabetes;
TGCT	cis	rs6121246	0.909	rs6119729	chr20:30413163	A/G	cg13852791	chr20:30311386	BCL2L1	-0.8	-6.12	-0.48	1.15e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs10992471	0.603	rs747628	chr9:95289532	A/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.6	-5.63	-0.45	1.13e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs6051080	1	rs6051080	chr20:25975674	A/G	cg03522245	chr20:25566470	NINL	0.52	5.72	0.46	7.43e-8	Colorectal or endometrial cancer;
TGCT	cis	rs12935418	0.583	rs62054240	chr16:81003096	G/C	cg07676361	chr16:80966860	NA	-0.33	-4.8	-0.4	4.5e-6	Mean corpuscular volume;
TGCT	cis	rs2204008	0.743	rs11182052	chr12:38450421	T/C	cg13010199	chr12:38710504	ALG10B	0.57	4.66	0.39	7.88e-6	Bladder cancer;
TGCT	trans	rs4576506	0.536	rs36043162	chr9:31506156	A/C	cg11445191	chr5:140227765	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA5;PCDHA9;PCDHA3;PCDHA4;PCDHA8	0.98	6.69	0.51	6.76e-10	Psychosis and Alzheimer's disease;
TGCT	cis	rs36051895	0.623	rs2208685	chr9:5251758	T/C	cg02405213	chr9:5042618	JAK2	-0.7	-8.27	-0.6	1.78e-13	Pediatric autoimmune diseases;
TGCT	cis	rs5167	0.533	rs11083755	chr19:45490065	C/T	cg09555818	chr19:45449301	APOC2	0.23	4.62	0.38	9.53e-6	Blood protein levels;
TGCT	cis	rs2580764	0.598	rs2580772	chr2:55218805	G/T	cg09592903	chr2:55203963	RTN4	0.25	5.63	0.45	1.12e-7	Mean platelet volume;
TGCT	cis	rs7552404	0.731	rs61770556	chr1:76421902	T/C	cg10523679	chr1:76189770	ACADM	0.8	6.76	0.52	4.91e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs13108904	0.846	rs9631804	chr4:1283032	A/T	cg03303774	chr4:1407052	NA	-0.33	-4.94	-0.41	2.51e-6	Obesity-related traits;
TGCT	cis	rs2730245	0.851	rs2657333	chr7:158728743	G/A	cg24397884	chr7:158709396	WDR60	-0.4	-5.3	-0.43	5.05e-7	Height;
TGCT	cis	rs2841277	0.645	rs28380382	chr14:105410827	C/T	cg21017887	chr14:105400489	NA	0.35	4.87	0.4	3.38e-6	Rheumatoid arthritis;
TGCT	cis	rs6570726	0.791	rs400329	chr6:145879442	A/T	cg13319975	chr6:146136371	FBXO30	-0.51	-4.6	-0.38	1.01e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6540559	0.673	rs6698154	chr1:210007777	A/G	cg22029157	chr1:209979665	IRF6	0.71	5.09	0.42	1.3e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs12899618	0.688	rs2165489	chr15:71673778	C/T	cg16778903	chr15:72612567	BRUNOL6	0.6	4.67	0.39	7.6e-6	Pulmonary function (smoking interaction);Pulmonary function;
TGCT	cis	rs1153858	1.000	rs10444821	chr15:45647236	C/T	cg26924012	chr15:45694286	SPATA5L1	1.09	15.16	0.81	5.15e-30	Homoarginine levels;
TGCT	cis	rs7681440	0.904	rs1822217	chr4:90765052	C/T	cg26578617	chr4:90757533	SNCA	-0.47	-4.87	-0.4	3.34e-6	Dementia with Lewy bodies;
TGCT	cis	rs1577917	0.740	rs9353327	chr6:86394066	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-4.63	-0.38	9.26e-6	Response to antipsychotic treatment;
TGCT	cis	rs1729951	0.575	rs361239	chr3:136701295	G/T	cg12473912	chr3:136751656	NA	0.39	6.18	0.49	8.36e-9	Neuroticism;
TGCT	cis	rs2070488	0.965	rs6802071	chr3:38574237	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.8	-7.82	-0.57	1.91e-12	Electrocardiographic conduction measures;
TGCT	cis	rs9467773	1.000	rs6940188	chr6:26562029	G/C	cg15659132	chr6:26577336	NA	0.9	13.19	0.76	2.26e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs1552244	0.515	rs28853661	chr3:10177659	A/G	cg00149659	chr3:10157352	C3orf10	0.98	6.97	0.53	1.68e-10	Alzheimer's disease;
TGCT	cis	rs10791097	0.694	rs4457753	chr11:130755575	A/G	cg14779329	chr11:130786720	SNX19	0.29	5.0	0.41	1.9e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs4409675	0.576	rs7536088	chr1:28234325	A/G	cg23691781	chr1:28212827	C1orf38	0.25	5.12	0.42	1.11e-6	Corneal astigmatism;
TGCT	cis	rs11785400	0.793	rs4457308	chr8:143733922	G/A	cg24634471	chr8:143751801	JRK	0.55	5.53	0.44	1.85e-7	Schizophrenia;
TGCT	cis	rs7264396	0.690	rs2425164	chr20:34434916	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.28	-4.83	-0.4	3.89e-6	Total cholesterol levels;
TGCT	cis	rs59107033	0.607	rs17295401	chr3:123128413	C/T	cg04890266	chr3:123102914	ADCY5	0.37	5.28	0.43	5.53e-7	Lymphocyte counts;
TGCT	cis	rs763121	0.853	rs8142098	chr22:39058757	T/G	cg06022373	chr22:39101656	GTPBP1	0.77	7.51	0.56	9.9e-12	Menopause (age at onset);
TGCT	cis	rs35306767	0.761	rs12359796	chr10:1021479	G/C	cg20503657	chr10:835505	NA	0.58	6.48	0.5	1.92e-9	Eosinophil percentage of granulocytes;
TGCT	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg00343986	chr7:65444356	GUSB	0.26	6.14	0.48	1.02e-8	Aortic root size;
TGCT	cis	rs873946	0.564	rs2803991	chr10:134557068	A/G	cg27286337	chr10:134555280	INPP5A	0.43	5.41	0.44	3.06e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs4253772	0.591	rs7291444	chr22:46656246	T/G	cg09491104	chr22:46646882	C22orf40	-0.66	-6.63	-0.51	9.44e-10	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs7552404	1.000	rs9662166	chr1:76235906	C/A	cg22875332	chr1:76189707	ACADM	0.76	8.83	0.62	8.53e-15	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7267979	0.866	rs6138609	chr20:25570985	T/A	cg03522245	chr20:25566470	NINL	0.6	6.43	0.5	2.48e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2354432	0.556	rs7520661	chr1:146793149	A/G	cg25205988	chr1:146714368	CHD1L	-1.36	-6.36	-0.5	3.58e-9	Mitochondrial DNA levels;
TGCT	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg04944784	chr2:26401820	FAM59B	0.76	6.24	0.49	6.46e-9	Gut microbiome composition (summer);
TGCT	cis	rs2070433	0.539	rs721131	chr21:47957767	T/C	cg12379764	chr21:47803548	PCNT	0.53	5.38	0.43	3.6e-7	Lymphocyte counts;
TGCT	cis	rs5769765	0.955	rs1321	chr22:50297435	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.4	6.02	0.48	1.81e-8	Schizophrenia;
TGCT	cis	rs155076	1.000	rs195570	chr13:21867580	T/G	cg11317459	chr13:21872234	NA	-1.3	-11.64	-0.72	1.26e-21	White matter hyperintensity burden;
TGCT	cis	rs4566357	1.000	rs12612535	chr2:227926998	T/C	cg11843606	chr2:227700838	RHBDD1	-0.5	-4.49	-0.37	1.59e-5	Coronary artery disease;
TGCT	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg07061783	chr6:25882402	NA	-0.57	-5.44	-0.44	2.74e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7582180	0.614	rs9973737	chr2:100942296	T/C	cg08017756	chr2:100939284	LONRF2	-0.3	-5.0	-0.41	1.93e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9303401	0.615	rs35288118	chr17:56600748	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs950776	0.593	rs6495306	chr15:78865893	C/T	cg06917634	chr15:78832804	PSMA4	-0.65	-5.35	-0.43	4.11e-7	Sudden cardiac arrest;
TGCT	cis	rs6901250	0.655	rs9384990	chr6:117126941	A/G	cg12892004	chr6:117198278	RFX6	0.45	5.65	0.45	1.05e-7	C-reactive protein levels;
TGCT	cis	rs9928842	0.882	rs3169330	chr16:75269267	A/G	cg09066997	chr16:75300724	BCAR1	0.28	5.09	0.42	1.29e-6	Alcoholic chronic pancreatitis;
TGCT	trans	rs7613875	0.543	rs34034116	chr3:49959156	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.8	8.21	0.59	2.46e-13	Body mass index;
TGCT	cis	rs10791097	0.739	rs12279359	chr11:130730544	G/A	cg14779329	chr11:130786720	SNX19	0.25	4.44	0.37	1.96e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs6540559	0.546	rs59435160	chr1:210030730	C/A	cg21951975	chr1:209979733	IRF6	0.76	5.87	0.47	3.66e-8	Cleft lip with or without cleft palate;
TGCT	cis	rs9993613	1.000	rs28627296	chr4:73487092	G/A	cg15102770	chr4:73434591	ADAMTS3	-0.52	-4.89	-0.4	3.1e-6	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs16939607	0.818	rs56080040	chr8:79009063	T/C	cg21244580	chr8:79934476	NA	0.47	4.68	0.39	7.33e-6	White blood cell count;
TGCT	cis	rs17376456	0.569	rs7701114	chr5:93096028	T/C	cg21475434	chr5:93447410	FAM172A	0.6	4.9	0.4	2.92e-6	Diabetic retinopathy;
TGCT	trans	rs9650657	0.504	rs10109167	chr8:11033525	C/T	cg15556689	chr8:8085844	FLJ10661	-0.74	-6.81	-0.52	3.65e-10	Neuroticism;
TGCT	cis	rs9467711	0.790	rs34158769	chr6:26336572	G/A	cg05948654	chr6:25930507	SLC17A2	0.34	4.54	0.38	1.29e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6921919	0.583	rs1416918	chr6:28358335	G/C	cg18815343	chr6:28367644	ZSCAN12	-0.56	-5.32	-0.43	4.76e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2637266	1.000	rs11001835	chr10:78364770	A/G	cg18941641	chr10:78392320	NA	0.4	4.73	0.39	6.03e-6	Pulmonary function;
TGCT	cis	rs4072980	0.524	rs28477803	chr1:38398694	C/T	cg26398791	chr1:38455867	SF3A3	-0.57	-4.55	-0.38	1.27e-5	Coronary artery disease;
TGCT	cis	rs11190604	1.000	rs7071271	chr10:102264824	G/A	cg16342193	chr10:102329863	NA	-0.38	-4.89	-0.4	3.06e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9921338	0.961	rs72773832	chr16:11413123	G/A	cg00044050	chr16:11439710	C16orf75	-0.93	-6.96	-0.53	1.7e-10	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs704	0.585	rs1007398	chr17:26665648	A/G	cg10342447	chr17:26645325	TMEM97	-0.61	-6.14	-0.48	1.02e-8	Osteoprotegerin levels;
TGCT	cis	rs9952991	0.883	rs2847293	chr18:12782448	A/T	cg09945482	chr18:12777974	NA	0.5	4.75	0.39	5.61e-6	Inflammatory skin disease;
TGCT	cis	rs7572733	0.534	rs700687	chr2:198721560	A/T	cg00792783	chr2:198669748	PLCL1	0.56	5.08	0.42	1.35e-6	Dermatomyositis;
TGCT	cis	rs1030877	0.889	rs2576746	chr2:105909559	G/A	cg02079111	chr2:105885981	TGFBRAP1	0.2	5.94	0.47	2.71e-8	Obesity-related traits;
TGCT	cis	rs9457247	1.000	rs422780	chr6:167406209	A/G	cg23791538	chr6:167370224	RNASET2	-0.49	-4.96	-0.41	2.26e-6	Crohn's disease;
TGCT	cis	rs17102423	0.740	rs35520739	chr14:65577612	T/C	cg11161011	chr14:65562177	MAX	0.44	5.82	0.46	4.63e-8	Obesity-related traits;
TGCT	cis	rs17221829	0.965	rs12292340	chr11:89461273	C/A	cg02982614	chr11:89391479	FOLH1B	-0.3	-5.15	-0.42	9.89e-7	Anxiety in major depressive disorder;
TGCT	cis	rs12478296	1.000	rs55717005	chr2:243041071	T/A	cg06360820	chr2:242988706	NA	-0.61	-4.66	-0.39	8.13e-6	Obesity-related traits;
TGCT	cis	rs12438659	1	rs12438659	chr15:78824924	G/A	cg24631222	chr15:78858424	CHRNA5	0.93	7.96	0.58	9.55e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	trans	rs208520	0.690	rs851464	chr6:66839802	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-10.43	-0.68	1.13e-18	Exhaled nitric oxide output;
TGCT	cis	rs9611565	0.512	rs4512	chr22:42206084	G/C	cg13695892	chr22:41940480	POLR3H	-0.87	-8.24	-0.59	2.06e-13	Vitiligo;
TGCT	cis	rs896854	0.530	rs10956934	chr8:95992473	C/A	cg09323728	chr8:95962352	TP53INP1	-0.44	-5.07	-0.41	1.44e-6	Type 2 diabetes;
TGCT	cis	rs727563	0.636	rs2413653	chr22:42106996	T/C	cg06481639	chr22:41940642	POLR3H	0.71	6.43	0.5	2.56e-9	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs208520	0.674	rs207103	chr6:66795568	G/T	cg07460842	chr6:66804631	NA	-0.94	-9.86	-0.66	2.74e-17	Exhaled nitric oxide output;
TGCT	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg18876405	chr7:65276391	NA	-0.36	-5.41	-0.44	3.12e-7	Aortic root size;
TGCT	cis	rs3771570	1.000	rs1984598	chr2:242284824	G/A	cg21155796	chr2:242212141	HDLBP	0.85	6.44	0.5	2.41e-9	Prostate cancer;
TGCT	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg12310025	chr6:25882481	NA	-0.66	-6.01	-0.48	1.88e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg12963246	chr6:28129442	ZNF389	0.51	4.97	0.41	2.19e-6	Depression;
TGCT	cis	rs68170813	0.559	rs12536491	chr7:106978024	T/G	cg02696742	chr7:106810147	HBP1	-0.68	-5.64	-0.45	1.09e-7	Coronary artery disease;
TGCT	cis	rs1691799	0.867	rs1168344	chr12:66758213	G/A	cg16791601	chr12:66731901	HELB	-0.29	-6.18	-0.49	8.39e-9	White blood cell count (basophil);
TGCT	cis	rs7568458	0.846	rs6547621	chr2:85774676	G/A	cg17127132	chr2:85788382	GGCX	0.68	6.59	0.51	1.12e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs7714584	1.000	rs931058	chr5:150333698	A/T	cg22134413	chr5:150180641	NA	1.01	5.68	0.45	9.02e-8	Crohn's disease;
TGCT	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg13342137	chr4:2252803	MXD4	0.17	4.51	0.38	1.5e-5	Obesity-related traits;
TGCT	cis	rs8072100	0.790	rs6505048	chr17:45674998	G/A	cg08085267	chr17:45401833	C17orf57	0.46	5.01	0.41	1.82e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs6570726	0.764	rs9403731	chr6:145907937	G/A	cg23711669	chr6:146136114	FBXO30	0.85	8.98	0.63	3.55e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11858159	0.565	rs8038318	chr15:24807060	T/C	cg08449389	chr15:24672285	NA	0.44	4.67	0.39	7.76e-6	Platelet thrombus formation;
TGCT	cis	rs10782582	0.609	rs5745545	chr1:76377356	A/G	cg10523679	chr1:76189770	ACADM	-0.58	-5.18	-0.42	8.57e-7	Daytime sleep phenotypes;
TGCT	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg08736216	chr1:53307985	ZYG11A	-0.27	-5.27	-0.43	5.79e-7	Monocyte count;
TGCT	trans	rs2727020	0.734	rs1164663	chr11:49294723	A/T	cg03929089	chr4:120376271	NA	0.67	6.89	0.53	2.44e-10	Coronary artery disease;
TGCT	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg25036284	chr2:26402008	FAM59B	0.65	5.18	0.42	8.59e-7	Gut microbiome composition (summer);
TGCT	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg21016266	chr12:122356598	WDR66	0.51	7.28	0.55	3.42e-11	Mean corpuscular volume;
TGCT	cis	rs7714584	1.000	rs11957134	chr5:150230950	A/G	cg22134413	chr5:150180641	NA	-1.11	-8.06	-0.59	5.42e-13	Crohn's disease;
TGCT	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9303401	1.000	rs7218362	chr17:56888299	A/G	cg12560992	chr17:57184187	TRIM37	0.54	5.61	0.45	1.26e-7	Cognitive test performance;
TGCT	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg17554472	chr22:41940697	POLR3H	-0.49	-5.26	-0.43	6.14e-7	Vitiligo;
TGCT	cis	rs3008870	1.000	rs3008848	chr1:67379284	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.1	12.08	0.74	1.11e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs8031584	0.678	rs4779497	chr15:31151365	T/A	cg08109568	chr15:31115862	NA	-0.38	-5.03	-0.41	1.67e-6	Huntington's disease progression;
TGCT	cis	rs2224391	0.628	rs11752747	chr6:5272671	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-1.06	-6.44	-0.5	2.44e-9	Height;
TGCT	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg02725872	chr8:58115012	NA	-0.38	-5.16	-0.42	9.32e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6430585	0.583	rs79633114	chr2:136586825	C/T	cg07169764	chr2:136633963	MCM6	1.22	11.81	0.73	4.95e-22	Corneal structure;
TGCT	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg02975922	chr3:195473998	MUC4	0.24	5.51	0.44	2.02e-7	Pancreatic cancer;
TGCT	cis	rs4699052	0.625	rs1400365	chr4:104289396	C/G	cg16532752	chr4:104119610	CENPE	-0.51	-4.86	-0.4	3.49e-6	Testicular germ cell tumor;
TGCT	cis	rs651907	0.514	rs55654108	chr3:101425703	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	5.0	0.41	1.91e-6	Colorectal cancer;
TGCT	cis	rs9314614	1.000	rs2978894	chr8:6693629	G/C	cg27319216	chr8:6693540	XKR5	-0.29	-4.92	-0.4	2.66e-6	IgA nephropathy;White blood cell count (basophil);
TGCT	cis	rs6912958	0.547	rs451089	chr6:88041859	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.73	7.63	0.57	5.25e-12	Monocyte percentage of white cells;
TGCT	cis	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg02380750	chr20:61661411	NA	0.33	5.96	0.47	2.4e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs610932	0.517	rs666555	chr11:59970984	G/A	cg18570331	chr11:60101691	MS4A6E	0.52	4.73	0.39	6.07e-6	Alzheimer's disease;
TGCT	cis	rs9372498	0.908	rs72967573	chr6:118696532	C/T	cg21191810	chr6:118973309	C6orf204	-0.5	-4.61	-0.38	9.92e-6	Diastolic blood pressure;
TGCT	cis	rs782590	0.694	rs2627775	chr2:55877113	C/T	cg18811423	chr2:55921094	PNPT1	0.54	5.51	0.44	1.97e-7	Metabolic syndrome;
TGCT	cis	rs4455778	0.536	rs38769	chr7:48940934	C/T	cg26309511	chr7:48887640	NA	0.46	5.48	0.44	2.28e-7	Lung cancer in never smokers;
TGCT	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg12963246	chr6:28129442	ZNF389	0.51	5.02	0.41	1.73e-6	Depression;
TGCT	cis	rs2243480	0.908	rs313822	chr7:65573939	G/A	cg07424592	chr7:64974309	NA	1.22	7.36	0.55	2.2e-11	Diabetic kidney disease;
TGCT	cis	rs6500602	0.702	rs11076834	chr16:4549583	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.32	5.95	0.47	2.54e-8	Schizophrenia;
TGCT	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.33	0.43	4.5e-7	Prudent dietary pattern;
TGCT	cis	rs17376456	0.597	rs6869110	chr5:93355531	G/A	cg21475434	chr5:93447410	FAM172A	-0.62	-5.93	-0.47	2.77e-8	Diabetic retinopathy;
TGCT	cis	rs2692947	0.673	rs4907299	chr2:96780122	G/T	cg22654517	chr2:96458247	NA	0.24	5.08	0.41	1.36e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs986417	0.818	rs965455	chr14:60960314	A/C	cg27398547	chr14:60952738	C14orf39	1.39	10.61	0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs7302981	0.967	rs7297421	chr12:50518926	C/T	cg23855989	chr12:50355821	AQP5	-0.3	-4.44	-0.37	2e-5	Systolic blood pressure;
TGCT	cis	rs7809950	1.000	rs7793613	chr7:107250484	C/T	cg23024343	chr7:107201750	COG5	-0.33	-5.21	-0.42	7.63e-7	Coronary artery disease;
TGCT	cis	rs6977660	0.598	rs72591445	chr7:19773035	G/A	cg05791153	chr7:19748676	TWISTNB	1.17	7.73	0.57	3.22e-12	Thyroid stimulating hormone;
TGCT	cis	rs7267979	1.000	rs4813566	chr20:25386465	G/T	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs763121	0.853	rs5757203	chr22:39044152	G/C	cg06022373	chr22:39101656	GTPBP1	0.77	7.46	0.56	1.35e-11	Menopause (age at onset);
TGCT	trans	rs561341	0.769	rs559228	chr17:30294527	T/C	cg20587970	chr11:113659929	NA	-1.03	-10.98	-0.7	5.21e-20	Hip circumference adjusted for BMI;
TGCT	cis	rs78487399	0.808	rs111783562	chr2:43759381	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.42	-4.75	-0.39	5.47e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs637571	0.544	rs617791	chr11:65702523	C/G	cg04055107	chr11:65626734	MUS81;CFL1	0.51	5.14	0.42	1.03e-6	Eosinophil percentage of white cells;
TGCT	cis	rs7698623	0.850	rs7684659	chr4:88769571	G/A	cg27387453	chr4:88533842	DSPP	-0.61	-4.6	-0.38	1.03e-5	Cardiovascular disease risk factors;
TGCT	cis	rs155076	0.938	rs9509633	chr13:21844482	G/C	cg14456004	chr13:21872349	NA	-1.32	-10.82	-0.7	1.25e-19	White matter hyperintensity burden;
TGCT	cis	rs1372520	0.564	rs356186	chr4:90705364	A/G	cg15133208	chr4:90757351	SNCA	-0.49	-5.68	-0.45	9.08e-8	Neuroticism;
TGCT	cis	rs8180040	0.966	rs59586735	chr3:47518325	C/T	cg27129171	chr3:47204927	SETD2	-0.65	-7.68	-0.57	4.2e-12	Colorectal cancer;
TGCT	cis	rs10982256	0.567	rs11791072	chr9:117238655	C/T	cg13965272	chr9:117993982	DEC1	-0.23	-4.62	-0.38	9.5e-6	Bipolar disorder;
TGCT	cis	rs9419702	0.568	rs7920966	chr10:133555185	G/T	cg20568497	chr10:133558893	NA	0.43	4.85	0.4	3.56e-6	Survival in rectal cancer;
TGCT	cis	rs10871290	0.881	rs3863436	chr16:74468038	T/C	cg01733217	chr16:74700730	RFWD3	-0.61	-5.8	-0.46	5.1e-8	Breast cancer;
TGCT	cis	rs1691799	0.867	rs1168316	chr12:66746239	A/G	cg16791601	chr12:66731901	HELB	-0.28	-6.18	-0.49	8.52e-9	White blood cell count (basophil);
TGCT	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg03517284	chr6:25882590	NA	-0.53	-5.43	-0.44	2.88e-7	Blood metabolite levels;
TGCT	cis	rs6912958	0.781	rs4707376	chr6:88270947	A/G	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.91	-0.4	2.78e-6	Monocyte percentage of white cells;
TGCT	cis	rs2840044	1.000	rs17637907	chr17:33891386	A/G	cg05299278	chr17:33885742	SLFN14	-0.24	-5.58	-0.45	1.43e-7	Response to radiotherapy in cancer (late toxicity);
TGCT	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg16414030	chr3:133502952	NA	-0.61	-9.65	-0.66	8.74e-17	Iron status biomarkers;
TGCT	cis	rs7809950	0.678	rs2237665	chr7:106906998	T/C	cg23024343	chr7:107201750	COG5	-0.43	-5.81	-0.46	4.86e-8	Coronary artery disease;
TGCT	cis	rs9549367	0.789	rs3764125	chr13:113897648	A/G	cg00898013	chr13:113819073	PROZ	0.37	4.65	0.39	8.35e-6	Platelet distribution width;
TGCT	cis	rs9911578	1.000	rs9898626	chr17:56698219	C/G	cg05425664	chr17:57184151	TRIM37	-0.64	-6.48	-0.5	1.99e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs6674176	0.932	rs4660761	chr1:44440146	G/A	cg12908607	chr1:44402522	ARTN	-0.74	-8.47	-0.61	5.88e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg18188782	chr20:61659543	NA	0.44	5.38	0.43	3.6e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs709400	0.659	rs3825566	chr14:103852725	C/T	cg26031613	chr14:104095156	KLC1	-0.84	-9.12	-0.63	1.71e-15	Body mass index;
TGCT	cis	rs8031584	0.678	rs35098644	chr15:31145440	A/G	cg08704250	chr15:31115839	NA	-0.42	-5.82	-0.46	4.74e-8	Huntington's disease progression;
TGCT	cis	rs7659604	0.502	rs13104233	chr4:122672473	T/C	cg19748678	chr4:122722346	EXOSC9	-0.51	-5.01	-0.41	1.84e-6	Type 2 diabetes;
TGCT	trans	rs208520	0.690	rs12197578	chr6:66725905	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	11.06	0.7	3.28e-20	Exhaled nitric oxide output;
TGCT	cis	rs7412746	0.658	rs12068264	chr1:150727329	C/T	cg04414720	chr1:150670196	GOLPH3L	0.37	4.57	0.38	1.15e-5	Melanoma;
TGCT	cis	rs200810	0.694	rs71562340	chr6:98031290	G/A	cg16511841	chr6:97730490	C6orf167;MIR548H3	-0.65	-4.44	-0.37	1.94e-5	Body mass index;
TGCT	cis	rs1997103	1.000	rs6973337	chr7:55411534	T/C	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs8072100	0.640	rs3851808	chr17:45425144	C/T	cg08085267	chr17:45401833	C17orf57	-0.46	-5.03	-0.41	1.68e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs60843830	0.964	rs17713568	chr2:242132	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.75	7.63	0.57	5.51e-12	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs9467711	0.606	rs9393715	chr6:26375645	G/A	cg10795676	chr6:26370623	BTN3A2	-0.47	-4.77	-0.39	5e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs476633	0.708	rs28629856	chr15:41446950	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.66	-8.77	-0.62	1.18e-14	Glomerular filtration rate (creatinine);
TGCT	cis	rs3812831	0.643	rs7322339	chr13:114929726	C/A	cg15513719	chr13:114904418	NA	0.39	4.73	0.39	6.05e-6	Schizophrenia;
TGCT	cis	rs7923609	0.783	rs4746203	chr10:65323997	G/T	cg08743896	chr10:65200160	JMJD1C	0.32	4.47	0.37	1.73e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2735413	0.564	rs7192226	chr16:78120260	T/A	cg09132178	chr16:78079569	NA	0.35	4.51	0.38	1.47e-5	Systolic blood pressure (alcohol consumption interaction);
TGCT	cis	rs35306767	0.715	rs1871622	chr10:1049309	T/G	cg26597838	chr10:835615	NA	0.6	6.63	0.51	9.45e-10	Eosinophil percentage of granulocytes;
TGCT	cis	rs11190604	0.945	rs2495735	chr10:102338609	G/A	cg23241863	chr10:102295624	HIF1AN	0.71	5.39	0.44	3.39e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	trans	rs629535	0.911	rs490165	chr8:70014976	A/G	cg21567404	chr3:27674614	NA	-0.58	-9.46	-0.65	2.51e-16	Dupuytren's disease;
TGCT	cis	rs950169	0.763	rs35372971	chr15:84941795	G/A	cg17173187	chr15:85201210	NMB	0.58	5.93	0.47	2.77e-8	Schizophrenia;
TGCT	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.36	0.55	2.25e-11	Prudent dietary pattern;
TGCT	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg04013166	chr16:89971882	TCF25	0.32	4.61	0.38	9.93e-6	Skin colour saturation;
TGCT	cis	rs526231	0.819	rs411648	chr5:102602902	A/T	cg05225461	chr5:102596755	C5orf30	0.23	4.62	0.38	9.51e-6	Primary biliary cholangitis;
TGCT	cis	rs66561647	0.634	rs10097497	chr8:128932363	A/G	cg05480350	chr8:128972681	MIR1205;PVT1	0.21	4.45	0.37	1.88e-5	Hemoglobin concentration;
TGCT	cis	rs7017914	0.905	rs2639956	chr8:71924091	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.56	-5.11	-0.42	1.2e-6	Bone mineral density;
TGCT	cis	rs9517320	0.534	rs9556962	chr13:99156648	C/T	cg07423050	chr13:99094983	FARP1	-0.29	-5.81	-0.46	5.02e-8	Longevity;
TGCT	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg16423285	chr20:60520624	NA	-0.61	-6.57	-0.51	1.23e-9	Body mass index;
TGCT	cis	rs9303401	0.580	rs34076823	chr17:57114497	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.56	5.59	0.45	1.4e-7	Cognitive test performance;
TGCT	cis	rs11578119	0.933	rs7512094	chr1:170408985	A/C	cg09767346	chr1:170501363	GORAB	0.71	5.66	0.45	9.92e-8	Male-pattern baldness;
TGCT	cis	rs10791097	0.694	rs2155752	chr11:130755998	C/T	cg12179176	chr11:130786555	SNX19	0.83	9.92	0.67	1.94e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs7412746	0.571	rs12402939	chr1:150615094	A/C	cg04414720	chr1:150670196	GOLPH3L	0.4	4.97	0.41	2.19e-6	Melanoma;
TGCT	cis	rs986417	1.000	rs1254292	chr14:60863636	T/C	cg27398547	chr14:60952738	C14orf39	-1.39	-10.61	-0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs9814567	1.000	rs35718987	chr3:134272783	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.96	9.11	0.63	1.79e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs950169	0.656	rs748455	chr15:85149575	T/C	cg11189052	chr15:85197271	WDR73	0.78	6.71	0.52	6.11e-10	Schizophrenia;
TGCT	cis	rs7824557	0.614	rs5029571	chr8:11213389	C/T	cg21775007	chr8:11205619	TDH	0.68	6.46	0.5	2.16e-9	Retinal vascular caliber;
TGCT	cis	rs9486719	0.552	rs9399923	chr6:96850379	G/A	cg06623918	chr6:96969491	KIAA0776	0.87	7.0	0.53	1.41e-10	Migraine;Coronary artery disease;
TGCT	cis	rs6964587	0.967	rs12671991	chr7:91559481	T/C	cg17063962	chr7:91808500	NA	-0.9	-9.67	-0.66	7.91e-17	Breast cancer;
TGCT	cis	rs933688	0.938	rs7705465	chr5:90680949	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.96	8.05	0.59	5.84e-13	Smoking behavior;
TGCT	cis	rs1050631	1.000	rs11081934	chr18:33705304	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.49	4.84	0.4	3.76e-6	Esophageal squamous cell cancer (length of survival);
TGCT	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.73	-0.39	5.93e-6	Prudent dietary pattern;
TGCT	cis	rs6121246	0.529	rs6058196	chr20:30194714	A/T	cg21427119	chr20:30132790	HM13	-0.42	-6.17	-0.48	8.75e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs6565180	0.888	rs8060853	chr16:30403858	A/G	cg17640201	chr16:30407289	ZNF48	0.94	8.64	0.61	2.29e-14	Tonsillectomy;
TGCT	cis	rs7394190	0.748	rs2306325	chr10:75506674	T/C	cg07699608	chr10:75541558	CHCHD1	0.77	4.86	0.4	3.48e-6	Incident atrial fibrillation;
TGCT	cis	rs9522267	0.535	rs7326875	chr13:112236231	C/T	cg10483660	chr13:112241077	NA	-0.27	-4.61	-0.38	9.78e-6	Hepatitis;
TGCT	cis	rs2274273	0.712	rs17832311	chr14:55534466	A/G	cg01923255	chr14:55878535	KIAA0831	0.57	4.89	0.4	3.03e-6	Protein biomarker;
TGCT	cis	rs7584330	0.822	rs13390494	chr2:238388792	G/A	cg14458575	chr2:238380390	NA	0.48	7.42	0.55	1.66e-11	Prostate cancer;
TGCT	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg06238570	chr21:40685208	BRWD1	0.73	6.66	0.51	8.12e-10	Cognitive function;
TGCT	cis	rs4595586	0.870	rs1400285	chr12:39277867	T/C	cg10518543	chr12:38710700	ALG10B	-0.47	-4.67	-0.39	7.64e-6	Morning vs. evening chronotype;
TGCT	cis	rs28595532	0.920	rs114165587	chr4:119779525	C/T	cg21605333	chr4:119757512	SEC24D	1.53	8.87	0.62	6.71e-15	Cannabis dependence symptom count;
TGCT	cis	rs1153858	1.000	rs7402650	chr15:45701895	C/T	cg26924012	chr15:45694286	SPATA5L1	1.1	15.34	0.81	2.01e-30	Homoarginine levels;
TGCT	cis	rs6912958	0.781	rs2268993	chr6:88184111	G/A	cg06598631	chr6:88300029	RARS2;ORC3L	-0.53	-4.85	-0.4	3.69e-6	Monocyte percentage of white cells;
TGCT	cis	rs7772486	0.875	rs2748497	chr6:146319417	C/T	cg05347473	chr6:146136440	FBXO30	0.49	4.47	0.37	1.74e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2239547	0.522	rs6771610	chr3:53026104	T/C	cg11645453	chr3:52864694	ITIH4	0.33	5.28	0.43	5.48e-7	Schizophrenia;
TGCT	cis	rs11122272	0.735	rs2572252	chr1:231513653	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.14	-0.54	6.86e-11	Hemoglobin concentration;
TGCT	cis	rs9611565	0.512	rs139562	chr22:42196684	G/C	cg06481639	chr22:41940642	POLR3H	-0.67	-5.86	-0.47	3.97e-8	Vitiligo;
TGCT	cis	rs9522267	0.535	rs9522291	chr13:112233761	T/C	cg10483660	chr13:112241077	NA	-0.27	-4.61	-0.38	9.78e-6	Hepatitis;
TGCT	cis	rs7772486	0.790	rs2254283	chr6:146204289	T/C	cg23711669	chr6:146136114	FBXO30	0.89	10.18	0.67	4.61e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2302045	1.000	rs34777851	chr2:242047530	G/T	cg04553960	chr2:241721320	KIF1A	-0.7	-4.68	-0.39	7.4e-6	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio);
TGCT	cis	rs10501293	0.746	rs7104602	chr11:43018295	C/T	cg03447554	chr11:43094025	NA	0.44	6.32	0.49	4.2e-9	Cognitive performance;
TGCT	trans	rs1814175	0.684	rs1827015	chr11:49585241	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.4	-9.03	-0.63	2.77e-15	Height;
TGCT	cis	rs28595532	0.541	rs56055826	chr4:119789424	T/A	cg14228332	chr4:119757509	SEC24D	1.3	6.62	0.51	9.62e-10	Cannabis dependence symptom count;
TGCT	cis	rs7769051	1.000	rs7765224	chr6:133101624	T/C	cg07930552	chr6:133119739	C6orf192	0.93	5.0	0.41	1.87e-6	Type 2 diabetes nephropathy;
TGCT	cis	rs7829975	0.744	rs2409092	chr8:8682192	A/T	cg08975724	chr8:8085496	FLJ10661	0.53	4.82	0.4	4.03e-6	Mood instability;
TGCT	cis	rs4319547	1.000	rs9705654	chr12:123083508	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.69	-5.44	-0.44	2.68e-7	Body mass index;
TGCT	cis	rs2014572	0.967	rs8100154	chr19:57765432	A/G	cg24459738	chr19:57751996	ZNF805	-0.58	-5.7	-0.46	8.38e-8	Hyperactive-impulsive symptoms;
TGCT	cis	rs796364	0.806	rs11694236	chr2:200916230	T/C	cg17644776	chr2:200775616	C2orf69	-0.33	-5.0	-0.41	1.91e-6	Schizophrenia;
TGCT	cis	rs7267979	0.903	rs6115101	chr20:25229564	C/A	cg14121845	chr20:25566513	NINL	0.5	5.51	0.44	1.95e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg04944784	chr2:26401820	FAM59B	-0.73	-5.95	-0.47	2.61e-8	Gut microbiome composition (summer);
TGCT	cis	rs2562456	0.833	rs516519	chr19:21481532	C/G	cg25650185	chr19:21324782	ZNF431	0.54	4.52	0.38	1.41e-5	Pain;
TGCT	cis	rs7119	0.717	rs11636529	chr15:77816220	T/C	cg27398640	chr15:77910606	LINGO1	-0.25	-4.6	-0.38	1.05e-5	Type 2 diabetes;
TGCT	cis	rs2836974	0.831	rs4375956	chr21:40521788	G/A	cg06238570	chr21:40685208	BRWD1	0.69	6.28	0.49	5.3300000000000004e-09	Cognitive function;
TGCT	cis	rs2046867	0.862	rs35178407	chr3:72799703	C/T	cg25664220	chr3:72788482	NA	-0.55	-6.81	-0.52	3.66e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs3820068	0.581	rs6666373	chr1:15939884	A/T	cg05660106	chr1:15850417	CASP9	0.83	8.16	0.59	3.26e-13	Systolic blood pressure;
TGCT	cis	rs514406	0.505	rs6703127	chr1:53180565	C/T	cg08859206	chr1:53392774	SCP2	-0.36	-5.22	-0.42	7.32e-7	Monocyte count;
TGCT	cis	rs6088580	0.634	rs4911153	chr20:32961547	C/T	cg08999081	chr20:33150536	PIGU	-0.25	-4.86	-0.4	3.46e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7769051	0.522	rs7761207	chr6:133110430	G/A	cg22852734	chr6:133119734	C6orf192	1.22	4.65	0.39	8.32e-6	Type 2 diabetes nephropathy;
TGCT	cis	rs7666738	0.830	rs6839203	chr4:98839814	C/G	cg05340658	chr4:99064831	C4orf37	0.53	6.17	0.48	8.71e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7845219	0.544	rs7017487	chr8:95922752	A/G	cg16049864	chr8:95962084	TP53INP1	0.48	5.3	0.43	5.23e-7	Type 2 diabetes;
TGCT	cis	rs73198271	0.628	rs11777908	chr8:8590437	C/T	ch.8.214553F	chr8:8189620	PRAGMIN	-0.32	-5.23	-0.42	7.04e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs12497850	0.931	rs7627404	chr3:48819668	A/C	cg05785598	chr3:49045655	WDR6	0.36	4.75	0.39	5.46e-6	Parkinson's disease;
TGCT	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg04025307	chr7:1156635	C7orf50	0.21	5.15	0.42	9.79e-7	Longevity;Endometriosis;
TGCT	cis	rs981844	1.000	rs2606332	chr4:154655372	G/A	cg14289246	chr4:154710475	SFRP2	1.05	8.74	0.62	1.39e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg21963583	chr11:68658836	MRPL21	-0.36	-6.03	-0.48	1.71e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9303401	0.538	rs3785493	chr17:56472119	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.69	-6.1	-0.48	1.23e-8	Cognitive test performance;
TGCT	cis	rs2075671	0.855	rs62483567	chr7:100286435	G/A	cg20848291	chr7:100343083	ZAN	-0.52	-4.52	-0.38	1.44e-5	Other erythrocyte phenotypes;
TGCT	cis	rs1008375	0.898	rs10008445	chr4:17593978	G/T	cg18681998	chr4:17616180	MED28	1.0	10.01	0.67	1.2e-17	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs11122272	0.675	rs1416913	chr1:231533206	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-6.53	-0.51	1.55e-9	Hemoglobin concentration;
TGCT	cis	rs9894429	0.816	rs7406040	chr17:79597583	A/C	cg21028142	chr17:79581711	NPLOC4	0.3	7.03	0.53	1.2e-10	Eye color traits;
TGCT	cis	rs2033711	0.905	rs893186	chr19:58969179	C/A	cg03735888	chr19:58951602	ZNF132	0.55	4.86	0.4	3.42e-6	Uric acid clearance;
TGCT	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg11644478	chr21:40555479	PSMG1	1.02	11.05	0.7	3.46e-20	Cognitive function;
TGCT	cis	rs2012796	0.661	rs59969857	chr14:81841579	A/G	cg02996355	chr14:81879375	NA	0.53	5.28	0.43	5.55e-7	Night sleep phenotypes;
TGCT	cis	rs11105298	0.891	rs11105313	chr12:89923376	A/T	cg00757033	chr12:89920650	WDR51B	-0.31	-4.91	-0.4	2.82e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs17741873	0.836	rs11000797	chr10:75628224	A/G	cg07699608	chr10:75541558	CHCHD1	0.79	5.64	0.45	1.07e-7	Paclitaxel disposition in epithelial ovarian cancer;
TGCT	cis	rs7681440	0.904	rs6532193	chr4:90764188	G/A	cg20003494	chr4:90757398	SNCA	-0.63	-6.09	-0.48	1.3e-8	Dementia with Lewy bodies;
TGCT	cis	rs4700695	1.000	rs111338	chr5:65420393	G/A	cg21114390	chr5:65439923	SFRS12	-0.65	-5.02	-0.41	1.76e-6	Facial morphology (factor 19);
TGCT	cis	rs854765	0.547	rs4925135	chr17:17952868	T/C	cg09796270	chr17:17721594	SREBF1	-0.24	-4.7	-0.39	6.8e-6	Total body bone mineral density;
TGCT	cis	rs25645	0.830	rs3935281	chr17:38188419	C/T	cg17467752	chr17:38218738	THRA	-0.56	-5.08	-0.41	1.36e-6	Myeloid white cell count;
TGCT	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-4.88	-0.4	3.2e-6	Bipolar disorder;
TGCT	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg06873352	chr17:61820015	STRADA	0.55	6.13	0.48	1.09e-8	Prudent dietary pattern;
TGCT	cis	rs7119	0.666	rs2516302	chr15:77879842	C/G	cg27398640	chr15:77910606	LINGO1	0.3	6.22	0.49	7.06e-9	Type 2 diabetes;
TGCT	cis	rs910316	0.763	rs4556	chr14:75476071	G/C	cg11812906	chr14:75593930	NEK9	0.58	5.56	0.45	1.6e-7	Height;
TGCT	trans	rs1814175	0.791	rs10219223	chr11:49791468	A/T	cg03929089	chr4:120376271	NA	-0.7	-8.19	-0.59	2.72e-13	Height;
TGCT	cis	rs72945132	0.882	rs6592522	chr11:70128271	G/A	cg00319359	chr11:70116639	PPFIA1	0.97	7.07	0.54	1.01e-10	Coronary artery disease;
TGCT	cis	rs34014631	0.748	rs61874116	chr10:103611191	A/G	cg22630918	chr10:102748988	C10orf2	0.34	4.56	0.38	1.21e-5	Coronary artery calcification;
TGCT	cis	rs6906287	0.647	rs11753128	chr6:118853514	C/T	cg21191810	chr6:118973309	C6orf204	0.26	4.49	0.37	1.58e-5	Electrocardiographic conduction measures;
TGCT	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg19901468	chr14:105411992	AHNAK2	-0.27	-5.86	-0.47	3.84e-8	Rheumatoid arthritis;
TGCT	cis	rs7975161	0.572	rs4964226	chr12:104570489	A/G	cg25273343	chr12:104657179	TXNRD1	-0.31	-4.56	-0.38	1.22e-5	Toenail selenium levels;
TGCT	cis	rs9467773	0.933	rs35355150	chr6:26526039	G/A	cg15659132	chr6:26577336	NA	0.81	10.8	0.7	1.45e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs6500602	0.727	rs11644481	chr16:4581002	T/G	cg09549813	chr16:4587862	C16orf5	-0.28	-4.5	-0.37	1.52e-5	Schizophrenia;
TGCT	cis	rs1577917	0.958	rs12209259	chr6:86502348	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-5.53	-0.44	1.82e-7	Response to antipsychotic treatment;
TGCT	cis	rs56114371	0.568	rs200468	chr6:27757855	C/G	cg10876282	chr6:28092338	ZSCAN16	0.57	4.54	0.38	1.32e-5	Breast cancer;
TGCT	cis	rs4699052	1.000	rs7694190	chr4:104168017	A/G	cg16532752	chr4:104119610	CENPE	-0.62	-5.75	-0.46	6.64e-8	Testicular germ cell tumor;
TGCT	cis	rs1577917	1.000	rs12208493	chr6:86662267	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.13	-0.42	1.07e-6	Response to antipsychotic treatment;
TGCT	cis	rs709400	0.633	rs1951391	chr14:103898313	T/C	cg26031613	chr14:104095156	KLC1	0.84	9.31	0.64	5.77e-16	Body mass index;
TGCT	cis	rs28595532	0.844	rs55845920	chr4:119490085	C/T	cg11846333	chr4:119757529	SEC24D	0.93	5.08	0.42	1.32e-6	Cannabis dependence symptom count;
TGCT	cis	rs2058350	1.000	rs7980501	chr12:3912972	C/T	cg08553284	chr12:4381997	CCND2	-0.53	-4.44	-0.37	1.93e-5	Cognitive performance;
TGCT	cis	rs1971762	0.563	rs10219725	chr12:54080865	T/G	cg16917193	chr12:54089295	NA	1.39	17.73	0.85	8.5000000000000007e-36	Height;
TGCT	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg04287289	chr16:89883240	FANCA	-0.94	-12.0	-0.73	1.7e-22	Vitiligo;
TGCT	cis	rs12693043	0.727	rs10172858	chr2:175417011	C/T	cg11778734	chr2:175439522	WIPF1	0.39	5.1	0.42	1.24e-6	Urate levels (BMI interaction);
TGCT	cis	rs79349575	0.749	rs957557	chr17:47003221	G/T	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.51	-0.38	1.48e-5	Type 2 diabetes;
TGCT	cis	rs28595532	0.920	rs114649974	chr4:119735341	T/C	cg14228332	chr4:119757509	SEC24D	1.32	6.38	0.5	3.2e-9	Cannabis dependence symptom count;
TGCT	cis	rs7267979	1.000	rs2258135	chr20:25272323	C/A	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2282802	0.685	rs62385161	chr5:139635747	T/C	cg01081189	chr5:139537190	NA	0.29	5.24	0.43	6.57e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7727544	0.545	rs10074490	chr5:131340032	C/T	cg21474247	chr5:131268130	NA	0.34	4.6	0.38	1.05e-5	Blood metabolite levels;
TGCT	cis	rs36405	1.000	rs36403	chr14:72358612	C/T	cg10066683	chr14:71515513	PCNX	-0.25	-4.84	-0.4	3.72e-6	Yang-deficiency constitution;
TGCT	cis	rs9650657	0.738	rs11250078	chr8:10666581	G/A	cg27411982	chr8:10470053	RP1L1	-0.23	-5.17	-0.42	9.17e-7	Neuroticism;
TGCT	cis	rs546131	0.963	rs539044	chr11:34841542	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.5	4.52	0.38	1.42e-5	Lung disease severity in cystic fibrosis;
TGCT	cis	rs2862064	0.745	rs4704733	chr5:156480104	T/G	cg12943317	chr5:156479607	HAVCR1	-0.41	-5.32	-0.43	4.59e-7	Platelet count;
TGCT	cis	rs9910055	0.529	rs228746	chr17:42173752	T/C	cg19774624	chr17:42201019	HDAC5	0.65	5.87	0.47	3.67e-8	Total body bone mineral density;
TGCT	cis	rs12118280	0.959	rs61799377	chr1:108741774	T/A	cg11967332	chr1:108735228	SLC25A24	0.39	5.44	0.44	2.74e-7	Myeloid white cell count;
TGCT	cis	rs854765	0.647	rs1008135	chr17:18027143	A/G	cg04398451	chr17:18023971	MYO15A	-0.39	-6.73	-0.52	5.54e-10	Total body bone mineral density;
TGCT	cis	rs11785400	1.000	rs4557682	chr8:143738182	T/C	cg10596483	chr8:143751796	JRK	0.56	6.05	0.48	1.61e-8	Schizophrenia;
TGCT	cis	rs5769765	0.955	rs8138687	chr22:50291869	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.09	-11.86	-0.73	3.71e-22	Schizophrenia;
TGCT	cis	rs7523050	0.643	rs35438081	chr1:109402831	G/T	cg08274380	chr1:109419600	GPSM2	1.3	6.39	0.5	2.99e-9	Fat distribution (HIV);
TGCT	trans	rs551517	0.541	rs494605	chr9:113644930	C/T	cg18410444	chr5:89825535	LYSMD3	0.68	6.98	0.53	1.56e-10	Post bronchodilator FEV1 in COPD;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
TGCT	cis	rs7666738	0.791	rs13125277	chr4:99009922	T/G	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12681287	0.752	rs13277670	chr8:87259920	T/G	cg27223183	chr8:87520930	FAM82B	-0.81	-5.66	-0.45	9.9e-8	Caudate activity during reward;
TGCT	cis	rs6733011	0.506	rs11123755	chr2:99507948	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.51	-4.78	-0.39	4.87e-6	Bipolar disorder;
TGCT	cis	rs7772486	0.686	rs1292334	chr6:145968288	A/G	cg13319975	chr6:146136371	FBXO30	-0.56	-5.13	-0.42	1.1e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7829975	0.686	rs907180	chr8:8702827	A/G	cg06636001	chr8:8085503	FLJ10661	0.71	6.69	0.52	6.76e-10	Mood instability;
TGCT	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg20637647	chr7:64974828	NA	0.92	5.09	0.42	1.26e-6	Diabetic kidney disease;
TGCT	cis	rs2749592	0.550	rs9733309	chr10:37882405	G/A	cg25427524	chr10:38739819	LOC399744	0.3	5.53	0.44	1.79e-7	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs59197085	0.636	rs9791702	chr7:128440185	T/C	cg00260937	chr7:128520193	KCP	0.48	5.02	0.41	1.77e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
TGCT	cis	rs9372498	0.536	rs9489447	chr6:118900846	G/A	cg07617317	chr6:118971624	C6orf204	0.5	5.32	0.43	4.71e-7	Diastolic blood pressure;
TGCT	cis	rs12478296	1.000	rs6743297	chr2:243013814	A/G	cg06360820	chr2:242988706	NA	-0.59	-4.77	-0.39	4.99e-6	Obesity-related traits;
TGCT	cis	rs71435601	0.600	rs1652422	chr2:21383841	A/G	cg25035485	chr2:21266500	APOB	0.51	4.48	0.37	1.64e-5	Cholesterol, total;
TGCT	cis	rs6558530	0.692	rs12335115	chr8:1699852	C/G	cg09410841	chr8:1729607	CLN8	0.72	6.48	0.5	1.98e-9	Systolic blood pressure;
TGCT	cis	rs4824093	0.610	rs58671506	chr22:50288983	G/A	cg14114931	chr22:50943910	LMF2	0.37	4.58	0.38	1.11e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs11650494	0.908	rs74830554	chr17:47431950	G/A	cg08112188	chr17:47440006	ZNF652	1.04	5.34	0.43	4.3e-7	Prostate cancer;
TGCT	cis	rs36051895	0.664	rs11793659	chr9:5109707	A/G	cg02405213	chr9:5042618	JAK2	-0.72	-9.48	-0.65	2.31e-16	Pediatric autoimmune diseases;
TGCT	cis	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg25427524	chr10:38739819	LOC399744	-0.4	-8.2	-0.59	2.5e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs1682825	1.000	rs73812286	chr3:10769921	C/G	cg23512531	chr3:10780469	NA	0.69	4.75	0.39	5.43e-6	Economic and political preferences (feminism/equality);
TGCT	cis	rs858239	0.932	rs199355	chr7:23296533	C/T	cg05602783	chr7:23145260	KLHL7	-0.62	-5.06	-0.41	1.45e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs17741873	0.779	rs58125091	chr10:75605420	A/T	cg07699608	chr10:75541558	CHCHD1	0.71	4.81	0.4	4.26e-6	Paclitaxel disposition in epithelial ovarian cancer;
TGCT	cis	rs68170813	0.559	rs114221457	chr7:107019913	C/G	cg02696742	chr7:106810147	HBP1	-0.7	-5.7	-0.46	8.16e-8	Coronary artery disease;
TGCT	cis	rs7715806	0.500	rs17563974	chr5:75004175	G/A	cg19683494	chr5:74908142	NA	0.57	5.02	0.41	1.76e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs861020	0.630	rs657861	chr1:210006884	C/G	cg05527609	chr1:210001259	C1orf107	0.86	7.54	0.56	8.69e-12	Orofacial clefts;
TGCT	cis	rs9914544	0.505	rs4924774	chr17:18794920	A/C	cg26378065	chr17:18585709	ZNF286B	0.55	4.86	0.4	3.53e-6	Educational attainment (years of education);
TGCT	cis	rs1887596	0.705	rs665816	chr13:27228538	T/C	cg01312412	chr13:27282625	NA	0.28	4.99	0.41	1.96e-6	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg20203395	chr5:56204925	C5orf35	-0.58	-4.87	-0.4	3.34e-6	Initial pursuit acceleration;
TGCT	cis	rs6430585	0.583	rs2304370	chr2:136561735	G/A	cg07169764	chr2:136633963	MCM6	1.05	10.03	0.67	1.09e-17	Corneal structure;
TGCT	cis	rs910316	0.763	rs175044	chr14:75472109	G/A	cg08847533	chr14:75593920	NEK9	-0.84	-8.92	-0.63	5.19e-15	Height;
TGCT	cis	rs10986311	0.832	rs10818951	chr9:127131062	C/T	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.2	4.71	0.39	6.55e-6	Vitiligo;
TGCT	cis	rs78487399	0.808	rs13419380	chr2:43739184	T/G	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.76	4.68	0.39	7.27e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	trans	rs561341	1.000	rs55959993	chr17:30254771	C/G	cg20587970	chr11:113659929	NA	-1.03	-10.94	-0.7	6.67e-20	Hip circumference adjusted for BMI;
TGCT	cis	rs6714710	0.603	rs1875699	chr2:98580724	G/T	cg26665480	chr2:98280029	ACTR1B	0.63	5.98	0.47	2.19e-8	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs7940866	0.804	rs6590540	chr11:130805444	T/C	cg05962950	chr11:130786565	SNX19	0.67	6.64	0.51	8.71e-10	Schizophrenia;
TGCT	cis	rs7818688	0.697	rs11781397	chr8:95974506	G/T	cg16049864	chr8:95962084	TP53INP1	0.54	4.64	0.38	8.87e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs854765	0.618	rs9908017	chr17:17774422	C/T	cg09796270	chr17:17721594	SREBF1	-0.24	-4.78	-0.39	4.77e-6	Total body bone mineral density;
TGCT	cis	rs9473924	0.542	rs9473925	chr6:50834565	T/C	cg14470998	chr6:50812995	TFAP2B	1.35	8.39	0.6	9.05e-14	Body mass index;
TGCT	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg11764359	chr7:65958608	NA	-0.55	-5.08	-0.42	1.34e-6	Aortic root size;
TGCT	cis	rs2013441	0.965	rs6587063	chr17:20193940	T/C	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.63	-0.38	9.19e-6	Obesity-related traits;
TGCT	cis	rs2832191	0.716	rs7509628	chr21:30454252	C/T	cg08807101	chr21:30365312	RNF160	0.65	6.14	0.48	1.03e-8	Dental caries;
TGCT	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs10791097	0.694	rs7106973	chr11:130758113	G/A	cg12179176	chr11:130786555	SNX19	0.87	10.65	0.69	3.29e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs79057730	0.599	rs35928068	chr7:805363	G/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.76	5.84	0.46	4.31e-8	Initial pursuit acceleration;
TGCT	cis	rs4555082	0.874	rs3000075	chr14:105713219	C/T	cg01266790	chr14:105781312	PACS2	-0.53	-4.49	-0.37	1.6e-5	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg10802521	chr3:52805072	NEK4	-0.78	-10.0	-0.67	1.28e-17	Electroencephalogram traits;
TGCT	cis	rs9393692	0.645	rs2179152	chr6:26325888	T/C	cg13736514	chr6:26305472	NA	-0.45	-6.67	-0.51	7.52e-10	Educational attainment;
TGCT	cis	rs8072100	0.905	rs9895274	chr17:45539117	C/T	cg08085267	chr17:45401833	C17orf57	-0.46	-4.99	-0.41	1.98e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	trans	rs62295889	1.000	rs62293733	chr4:12594002	T/C	cg01948047	chr22:19724501	NA	0.69	7.25	0.55	4.03e-11	Obesity-related traits;
TGCT	cis	rs1971762	0.523	rs3852562	chr12:54085750	T/C	cg16917193	chr12:54089295	NA	1.38	18.38	0.86	3.23e-37	Height;
TGCT	cis	rs9534288	0.730	rs2148412	chr13:46595849	C/T	cg15192986	chr13:46630673	CPB2	-0.49	-6.92	-0.53	2.11e-10	Blood protein levels;
TGCT	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg07507251	chr3:52567010	NT5DC2	0.48	6.95	0.53	1.82e-10	Bipolar disorder;
TGCT	cis	rs8031584	0.678	rs8035703	chr15:31168472	T/C	cg08704250	chr15:31115839	NA	-0.43	-6.31	-0.49	4.47e-9	Huntington's disease progression;
TGCT	cis	rs7072216	0.763	rs7909822	chr10:100172035	A/C	cg26618903	chr10:100175079	PYROXD2	-0.4	-4.49	-0.37	1.64e-5	Metabolite levels;
TGCT	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg04546413	chr19:29218101	NA	0.83	6.74	0.52	5.35e-10	Methadone dose in opioid dependence;
TGCT	cis	rs3096299	0.967	rs2965932	chr16:89477051	C/T	cg06640241	chr16:89574553	SPG7	-0.65	-6.28	-0.49	5.18e-9	Multiple myeloma (IgH translocation);
TGCT	cis	rs7178424	0.606	rs17271151	chr15:62140189	A/C	cg00456672	chr15:62358751	C2CD4A	-0.29	-4.5	-0.37	1.56e-5	Height;
TGCT	cis	rs12210905	0.610	rs80328528	chr6:27595604	T/A	cg08851530	chr6:28072375	NA	1.33	6.25	0.49	6.17e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs137699	1.000	rs2413588	chr22:39755175	A/G	cg24399712	chr22:39784796	NA	-0.63	-5.63	-0.45	1.16e-7	IgG glycosylation;
TGCT	cis	rs8180040	0.966	rs11130128	chr3:47486632	T/C	cg27129171	chr3:47204927	SETD2	-0.65	-7.68	-0.57	4.2e-12	Colorectal cancer;
TGCT	cis	rs1395	1.000	rs1659685	chr2:27420690	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.49	-6.62	-0.51	9.77e-10	Blood metabolite levels;
TGCT	cis	rs12142240	0.698	rs1475390	chr1:46816340	A/G	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs709400	0.628	rs10150072	chr14:103977605	C/T	cg12935359	chr14:103987150	CKB	-0.38	-5.7	-0.46	8.3e-8	Body mass index;
TGCT	trans	rs7819412	0.806	rs2898256	chr8:10932695	G/C	cg06636001	chr8:8085503	FLJ10661	-0.77	-7.04	-0.53	1.14e-10	Triglycerides;
TGCT	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg06238570	chr21:40685208	BRWD1	-0.61	-6.3	-0.49	4.75e-9	Menarche (age at onset);
TGCT	cis	rs35160687	0.901	rs34048420	chr2:86529748	A/G	cg04877910	chr2:85804641	VAMP8	0.34	4.51	0.38	1.49e-5	Night sleep phenotypes;
TGCT	cis	rs933688	1.000	rs10073657	chr5:90689749	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	9.43	0.65	2.97e-16	Smoking behavior;
TGCT	cis	rs7552404	0.961	rs1061337	chr1:76227022	A/G	cg22875332	chr1:76189707	ACADM	0.77	8.97	0.63	3.96e-15	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs3806843	0.606	rs251377	chr5:140255792	C/A	cg07102913	chr5:140593443	PCDHB13	0.49	4.71	0.39	6.4e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9911578	0.967	rs9907940	chr17:56663842	A/G	cg05425664	chr17:57184151	TRIM37	-0.63	-6.26	-0.49	5.86e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7223966	1.000	rs7209435	chr17:61712964	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	4.76	0.39	5.24e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs62244186	0.627	rs3935212	chr3:44460954	G/A	cg15687855	chr3:44754131	ZNF502	-0.42	-5.06	-0.41	1.46e-6	Depressive symptoms;
TGCT	trans	rs210152	0.531	rs3130023	chr6:33448862	A/G	cg08795360	chr21:41033440	B3GALT5	-0.45	-7.17	-0.54	5.98e-11	Schizophrenia;
TGCT	cis	rs28595532	0.748	rs17594978	chr4:119336398	T/C	cg21605333	chr4:119757512	SEC24D	0.87	5.49	0.44	2.14e-7	Cannabis dependence symptom count;
TGCT	cis	rs2456568	0.564	rs6483270	chr11:93624380	C/T	cg16099599	chr11:93583650	C11orf90	-0.38	-4.44	-0.37	1.99e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs910316	0.737	rs175077	chr14:75506875	G/A	cg11812906	chr14:75593930	NEK9	-0.63	-5.85	-0.47	4.1e-8	Height;
TGCT	cis	rs7666738	0.830	rs10007261	chr4:98926155	C/T	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs77106637	0.932	rs74439784	chr11:72649396	A/T	cg03713592	chr11:72463424	ARAP1	0.87	5.87	0.47	3.74e-8	Type 2 diabetes;
TGCT	cis	rs9517313	0.591	rs17574543	chr13:99172893	G/A	cg07423050	chr13:99094983	FARP1	-0.31	-5.98	-0.47	2.26e-8	Neuroticism;
TGCT	cis	rs9527	0.615	rs1556960	chr10:104726673	A/G	cg04362960	chr10:104952993	NT5C2	0.66	5.64	0.45	1.1e-7	Arsenic metabolism;
TGCT	cis	rs1059312	0.808	rs2306683	chr12:129299675	C/G	cg09035930	chr12:129282057	SLC15A4	0.56	9.95	0.67	1.71e-17	Systemic lupus erythematosus;
TGCT	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg14004847	chr7:1930337	MAD1L1	-0.28	-4.71	-0.39	6.44e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs12765878	1.000	rs34300861	chr10:105643332	A/C	cg11005552	chr10:105648138	OBFC1	0.44	7.6	0.56	6.24e-12	Coronary artery disease;
TGCT	cis	rs669446	0.533	rs28833034	chr1:44212942	A/G	cg12908607	chr1:44402522	ARTN	-0.63	-7.43	-0.56	1.52e-11	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs6940638	1.000	rs6940638	chr6:27046250	A/G	cg16898833	chr6:26189333	HIST1H4D	0.75	5.77	0.46	5.93e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7843479	1.000	rs13248727	chr8:21842063	T/C	cg17168535	chr8:21777572	XPO7	0.63	5.73	0.46	7.05e-8	Mean corpuscular volume;
TGCT	cis	rs7937612	1.000	rs7104639	chr11:120239456	C/G	cg24566217	chr11:120254723	ARHGEF12	-0.29	-4.7	-0.39	6.76e-6	Intraocular pressure;
TGCT	cis	rs7917772	0.636	rs7897384	chr10:104529042	T/G	cg05855489	chr10:104503620	C10orf26	0.61	4.92	0.4	2.71e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg17971929	chr21:40555470	PSMG1	-0.7	-6.53	-0.51	1.55e-9	Cognitive function;
TGCT	cis	rs7727544	0.735	rs274559	chr5:131720070	A/G	cg14196790	chr5:131705035	SLC22A5	-0.32	-4.51	-0.38	1.46e-5	Blood metabolite levels;
TGCT	cis	rs2115630	0.691	rs2292462	chr15:85200754	G/T	cg11189052	chr15:85197271	WDR73	-0.69	-6.58	-0.51	1.2e-9	P wave terminal force;
TGCT	cis	rs4718428	0.705	rs3800817	chr7:66263550	T/A	cg18252515	chr7:66147081	NA	-0.59	-4.52	-0.38	1.44e-5	Corneal structure;
TGCT	cis	rs752010	0.655	rs10890145	chr1:42086290	A/G	cg06885757	chr1:42089581	HIVEP3	0.25	4.56	0.38	1.23e-5	Lupus nephritis in systemic lupus erythematosus;
TGCT	cis	rs3008870	1.000	rs1925412	chr1:67405057	G/A	cg08660285	chr1:67390436	MIER1;WDR78	1.1	11.97	0.73	2.07e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs9372498	0.536	rs9489467	chr6:118935206	C/T	cg07617317	chr6:118971624	C6orf204	0.48	5.08	0.42	1.32e-6	Diastolic blood pressure;
TGCT	cis	rs2404602	0.692	rs3110382	chr15:77148688	G/A	cg26408565	chr15:76604113	ETFA	0.36	4.56	0.38	1.23e-5	Blood metabolite levels;
TGCT	cis	rs3008870	1.000	rs3008854	chr1:67385951	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.1	12.09	0.74	1.01e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs910316	0.935	rs2268620	chr14:75640403	G/A	cg08847533	chr14:75593920	NEK9	-0.93	-10.14	-0.67	5.65e-18	Height;
TGCT	cis	rs2228479	0.850	rs17233664	chr16:89810628	C/T	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs34779708	0.931	rs4934709	chr10:35339324	A/C	cg05301181	chr10:35379533	CUL2	-0.53	-4.69	-0.39	7.06e-6	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs1949733	0.628	rs1543246	chr4:8504909	A/T	cg11789530	chr4:8429930	ACOX3	0.47	4.58	0.38	1.11e-5	Response to antineoplastic agents;
TGCT	cis	rs7923609	0.967	rs4454603	chr10:65012750	C/T	cg08743896	chr10:65200160	JMJD1C	-0.34	-4.54	-0.38	1.32e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs208520	1.000	rs72884017	chr6:66992513	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.83	7.46	0.56	1.31e-11	Exhaled nitric oxide output;
TGCT	cis	rs7829975	0.840	rs555617	chr8:8592845	C/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-4.61	-0.38	9.79e-6	Mood instability;
TGCT	cis	rs909674	0.818	rs8137426	chr22:39844350	T/G	cg02038168	chr22:39784481	NA	-0.73	-5.59	-0.45	1.39e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs651907	0.557	rs7651404	chr3:101393294	C/A	cg11279151	chr3:101281821	RG9MTD1	-0.35	-7.28	-0.55	3.4e-11	Colorectal cancer;
TGCT	cis	rs7523273	0.564	rs1570565	chr1:207881256	G/A	cg22525895	chr1:207977042	MIR29B2	0.29	4.48	0.37	1.69e-5	Schizophrenia;
TGCT	cis	rs12620999	0.941	rs13005377	chr2:238037759	T/C	cg23555395	chr2:238036564	NA	-0.31	-5.51	-0.44	2.02e-7	Systemic lupus erythematosus;
TGCT	cis	rs896854	0.552	rs2515236	chr8:95934907	A/G	cg09323728	chr8:95962352	TP53INP1	0.42	4.8	0.4	4.49e-6	Type 2 diabetes;
TGCT	cis	rs7044106	0.762	rs7849566	chr9:123460769	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	4.57	0.38	1.16e-5	Hip circumference adjusted for BMI;
TGCT	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs6547741	0.788	rs7595739	chr2:27874563	G/T	cg27432699	chr2:27873401	GPN1	-0.24	-6.14	-0.48	1.04e-8	Oral cavity cancer;
TGCT	cis	rs1971256	0.500	rs3912291	chr6:151818210	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.8	-4.77	-0.39	5.14e-6	Endometriosis;
TGCT	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg17554472	chr22:41940697	POLR3H	-0.49	-5.27	-0.43	5.9e-7	Vitiligo;
TGCT	cis	rs8077577	0.895	rs1563373	chr17:18114228	G/A	cg09161412	chr17:18057145	MYO15A	-0.6	-4.79	-0.4	4.61e-6	Obesity-related traits;
TGCT	trans	rs1005277	0.522	rs11011343	chr10:38002698	A/G	cg17830980	chr10:43048298	ZNF37B	-0.65	-7.34	-0.55	2.4e-11	Extrinsic epigenetic age acceleration;
TGCT	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg08048268	chr3:133502702	NA	-0.65	-9.77	-0.66	4.57e-17	Iron status biomarkers;
TGCT	cis	rs9527	0.590	rs1926029	chr10:104855670	C/T	cg15744005	chr10:104629667	AS3MT	-0.44	-5.08	-0.42	1.33e-6	Arsenic metabolism;
TGCT	cis	rs344364	0.518	rs1657129	chr16:1945826	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.45	-5.08	-0.42	1.35e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs9914988	1.000	rs9895443	chr17:27182944	A/G	cg20469991	chr17:27169893	C17orf63	-0.69	-5.05	-0.41	1.51e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs2404602	1.000	rs4886818	chr15:76880939	G/A	cg26408565	chr15:76604113	ETFA	-0.38	-4.82	-0.4	4.03e-6	Blood metabolite levels;
TGCT	cis	rs9902453	1.000	rs12600993	chr17:28291222	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.76	6.61	0.51	1.01e-9	Coffee consumption (cups per day);
TGCT	trans	rs7819412	0.740	rs28633434	chr8:11053922	G/A	cg15556689	chr8:8085844	FLJ10661	-0.76	-7.32	-0.55	2.7e-11	Triglycerides;
TGCT	cis	rs2921036	0.529	rs2979192	chr8:8338147	C/T	cg15556689	chr8:8085844	FLJ10661	0.62	5.5	0.44	2.04e-7	Neuroticism;
TGCT	cis	rs10751667	0.621	rs10794348	chr11:939941	G/A	cg06064525	chr11:970664	AP2A2	-0.35	-8.09	-0.59	4.54e-13	Alzheimer's disease (late onset);
TGCT	trans	rs1814175	0.817	rs1851860	chr11:49861310	A/C	cg03929089	chr4:120376271	NA	-0.7	-8.05	-0.59	5.64e-13	Height;
TGCT	cis	rs854765	0.552	rs11078407	chr17:17841083	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.74	7.72	0.57	3.31e-12	Total body bone mineral density;
TGCT	cis	rs908922	0.676	rs908927	chr1:152513338	C/G	cg20991723	chr1:152506922	NA	0.45	6.16	0.48	9.53e-9	Hair morphology;
TGCT	cis	rs2404602	0.647	rs11855296	chr15:77092962	C/T	cg22467129	chr15:76604101	ETFA	0.48	4.71	0.39	6.51e-6	Blood metabolite levels;
TGCT	cis	rs826838	0.874	rs10880943	chr12:38734317	C/T	cg26384229	chr12:38710491	ALG10B	1.08	10.88	0.7	9.18e-20	Heart rate;
TGCT	cis	rs651907	0.557	rs7612283	chr3:101434919	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	4.73	0.39	5.91e-6	Colorectal cancer;
TGCT	cis	rs7246657	0.943	rs1015848	chr19:37945274	A/C	cg18154014	chr19:37997991	ZNF793	0.95	6.63	0.51	9.39e-10	Coronary artery calcification;
TGCT	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg17971929	chr21:40555470	PSMG1	0.95	9.07	0.63	2.19e-15	Cognitive function;
TGCT	cis	rs6089584	0.586	rs2296087	chr20:60584328	T/A	cg06108461	chr20:60628389	TAF4	-0.42	-5.2	-0.42	8.11e-7	Body mass index;
TGCT	cis	rs698813	0.604	rs7606004	chr2:44479983	G/A	cg00619915	chr2:44497795	NA	-0.24	-5.62	-0.45	1.19e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
TGCT	cis	rs9419702	0.538	rs4074772	chr10:133540006	A/T	cg23460707	chr10:133558971	NA	0.44	4.94	0.41	2.46e-6	Survival in rectal cancer;
TGCT	cis	rs2230307	0.505	rs482873	chr1:100589757	C/T	cg24955406	chr1:100503596	HIAT1	-0.75	-5.11	-0.42	1.2e-6	Carotid intima media thickness;
TGCT	cis	rs1568889	1.000	rs35697240	chr11:28287342	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	8.8	0.62	9.95e-15	Bipolar disorder;
TGCT	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg06618935	chr21:46677482	NA	-0.37	-4.97	-0.41	2.13e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9650657	0.589	rs12542037	chr8:10758496	G/A	cg21775007	chr8:11205619	TDH	0.49	4.46	0.37	1.84e-5	Neuroticism;
TGCT	cis	rs7226408	0.857	rs72887029	chr18:34471969	A/T	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs2197308	0.565	rs12809769	chr12:37909968	C/T	cg26384229	chr12:38710491	ALG10B	0.89	7.98	0.58	8.43e-13	Morning vs. evening chronotype;
TGCT	cis	rs2456568	0.867	rs2462744	chr11:93682913	G/A	cg14065697	chr11:93583672	C11orf90	-0.38	-4.58	-0.38	1.13e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7655441	0.964	rs6534693	chr4:80906214	T/A	cg02241357	chr4:80885279	ANTXR2	-0.24	-4.59	-0.38	1.07e-5	Neutrophil percentage of white cells;
TGCT	cis	rs2295359	1.000	rs11209007	chr1:67619345	C/G	cg03340356	chr1:67600835	NA	0.36	4.55	0.38	1.24e-5	Psoriasis;
TGCT	cis	rs7731657	0.537	rs4705851	chr5:130220592	A/G	cg08523029	chr5:130500466	HINT1	0.61	5.07	0.41	1.4e-6	Fasting plasma glucose;
TGCT	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg18402987	chr7:1209562	NA	0.78	6.64	0.51	8.96e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs11190604	0.767	rs7916904	chr10:102186778	C/G	cg23241863	chr10:102295624	HIF1AN	0.62	4.79	0.4	4.69e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs881375	0.933	rs2239657	chr9:123671520	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.49	-5.5	-0.44	2.09e-7	Rheumatoid arthritis;
TGCT	cis	rs10892173	0.678	rs4537790	chr11:117661356	A/G	cg07621104	chr11:117668040	DSCAML1	0.54	5.55	0.45	1.65e-7	Myopia;
TGCT	cis	rs9611565	0.592	rs5751129	chr22:42015765	C/T	cg06634786	chr22:41940651	POLR3H	0.83	7.91	0.58	1.2e-12	Vitiligo;
TGCT	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg22433210	chr17:43662623	NA	0.96	7.94	0.58	1.03e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg06634786	chr22:41940651	POLR3H	-0.91	-8.85	-0.62	7.39e-15	Vitiligo;
TGCT	cis	rs2637266	1.000	rs7477433	chr10:78358116	C/T	cg18941641	chr10:78392320	NA	0.4	5.01	0.41	1.81e-6	Pulmonary function;
TGCT	cis	rs10838634	1.000	rs56331152	chr11:46885016	C/T	cg18332754	chr11:46939436	LRP4	0.89	4.77	0.39	5.13e-6	Schizophrenia;
TGCT	cis	rs6088590	0.965	rs6058108	chr20:33288655	A/G	cg08999081	chr20:33150536	PIGU	0.26	4.6	0.38	1.03e-5	Coronary artery disease;
TGCT	cis	rs1723838	0.702	rs1623476	chr11:73581224	C/T	cg18195628	chr11:73498948	MRPL48	0.92	5.05	0.41	1.57e-6	Obesity-related traits;
TGCT	cis	rs40363	0.951	rs72778117	chr16:3531827	T/C	cg22508957	chr16:3507546	NAT15	0.54	5.04	0.41	1.59e-6	Tuberculosis;
TGCT	cis	rs6754311	0.564	rs1960171	chr2:136815388	C/T	cg07169764	chr2:136633963	MCM6	0.58	5.23	0.43	7.03e-7	Mosquito bite size;
TGCT	cis	rs2235642	0.928	rs1057610	chr16:1605537	T/C	cg11375102	chr16:1583810	IFT140;TMEM204	-0.3	-5.26	-0.43	6.24e-7	Coronary artery disease;
TGCT	cis	rs78707713	0.592	rs3829182	chr10:71251384	A/G	cg12610070	chr10:71211762	TSPAN15	-0.62	-7.39	-0.55	1.91e-11	Venous thromboembolism;
TGCT	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg11764359	chr7:65958608	NA	-0.55	-5.0	-0.41	1.94e-6	Aortic root size;
TGCT	cis	rs7959452	0.535	rs11615712	chr12:69619736	A/T	cg14784868	chr12:69753453	YEATS4	-0.67	-6.7	-0.52	6.61e-10	Blood protein levels;
TGCT	cis	rs10782582	0.593	rs11163915	chr1:76130199	C/T	cg03433033	chr1:76189801	ACADM	-0.63	-7.25	-0.55	3.83e-11	Daytime sleep phenotypes;
TGCT	cis	rs929354	0.772	rs1182364	chr7:157017912	T/C	cg05182265	chr7:156933206	UBE3C	0.4	9.08	0.63	2.11e-15	Body mass index;
TGCT	cis	rs55883249	1.000	rs57234614	chr2:9756379	T/C	cg23886495	chr2:9695866	ADAM17	0.8	4.72	0.39	6.38e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs854765	0.547	rs7209003	chr17:17907393	T/A	cg09796270	chr17:17721594	SREBF1	0.24	4.83	0.4	4.03e-6	Total body bone mineral density;
TGCT	cis	rs9534288	0.830	rs2296641	chr13:46632226	A/C	cg15192986	chr13:46630673	CPB2	-0.5	-6.23	-0.49	6.66e-9	Blood protein levels;
TGCT	cis	rs10788264	0.518	rs1028632	chr10:124044657	C/G	cg09507567	chr10:124027408	NA	0.33	4.72	0.39	6.3e-6	Total body bone mineral density;
TGCT	cis	rs7654585	1.000	rs4692025	chr4:25949759	A/C	cg10409131	chr4:25915609	C4orf52	-0.69	-7.03	-0.53	1.23e-10	Obesity-related traits;
TGCT	cis	rs910316	0.810	rs77939209	chr14:75670070	A/G	cg11812906	chr14:75593930	NEK9	-0.66	-6.46	-0.5	2.17e-9	Height;
TGCT	cis	rs6570726	0.791	rs6912079	chr6:145894949	G/A	cg23711669	chr6:146136114	FBXO30	0.89	9.85	0.66	2.95e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3540	1.000	rs6496678	chr15:91034456	A/G	cg22089800	chr15:90895588	ZNF774	0.78	7.9	0.58	1.27e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs2952156	0.883	rs1495100	chr17:37832279	C/T	cg20243544	chr17:37824526	PNMT	0.51	4.47	0.37	1.74e-5	Asthma;
TGCT	cis	rs7772486	0.875	rs9322043	chr6:146352690	A/G	cg05347473	chr6:146136440	FBXO30	0.55	5.23	0.43	6.86e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4851254	0.618	rs7572939	chr2:100654914	A/G	cg07810366	chr2:100720526	AFF3	-0.47	-4.75	-0.39	5.46e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs11030122	0.547	rs10767721	chr11:3953411	G/C	cg18678763	chr11:4115507	RRM1	-0.39	-4.76	-0.39	5.24e-6	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs2067615	0.524	rs9804754	chr12:107083031	G/A	cg15890332	chr12:107067104	RFX4	0.29	5.77	0.46	5.9e-8	Heart rate;
TGCT	cis	rs9291683	0.605	rs73224439	chr4:10331818	C/A	cg11266682	chr4:10021025	SLC2A9	-0.5	-5.75	-0.46	6.44e-8	Bone mineral density;
TGCT	cis	rs902774	0.585	rs7399070	chr12:53355678	G/T	cg05393297	chr12:53359155	NA	-0.85	-5.44	-0.44	2.73e-7	Prostate cancer;
TGCT	cis	rs7715806	0.500	rs72633986	chr5:75006449	T/A	cg19683494	chr5:74908142	NA	0.57	5.02	0.41	1.76e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs9486719	1.000	rs2273622	chr6:97058567	A/G	cg18709589	chr6:96969512	KIAA0776	-0.78	-5.55	-0.45	1.63e-7	Migraine;Coronary artery disease;
TGCT	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg19774624	chr17:42201019	HDAC5	-0.87	-10.64	-0.69	3.48e-19	Total body bone mineral density;
TGCT	cis	rs877282	0.945	rs12767287	chr10:787310	A/G	cg17470449	chr10:769945	NA	0.3	4.71	0.39	6.53e-6	Uric acid levels;
TGCT	cis	rs2797160	0.714	rs1777220	chr6:126022602	G/T	cg05901451	chr6:126070800	HEY2	0.73	6.29	0.49	5.07e-9	Endometrial cancer;
TGCT	cis	rs765787	0.530	rs2413785	chr15:45530381	T/C	cg24006582	chr15:45444508	DUOX1	-0.25	-5.53	-0.44	1.82e-7	Uric acid levels;
TGCT	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg22168489	chr12:122356033	WDR66	0.2	4.7	0.39	6.72e-6	Mean corpuscular volume;
TGCT	cis	rs2120019	0.938	rs5020842	chr15:75322310	T/C	cg17294928	chr15:75287854	SCAMP5	-0.89	-6.84	-0.52	3.22e-10	Blood trace element (Zn levels);
TGCT	cis	rs7267979	1.000	rs6050565	chr20:25347563	A/C	cg16686733	chr20:25566563	NINL	-0.59	-6.08	-0.48	1.39e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs950169	0.840	rs62019457	chr15:85102142	T/C	cg12863693	chr15:85201151	NMB	0.41	4.63	0.38	9.27e-6	Schizophrenia;
TGCT	cis	rs6964587	0.967	rs6465341	chr7:91596121	G/C	cg17063962	chr7:91808500	NA	0.91	9.99	0.67	1.32e-17	Breast cancer;
TGCT	cis	rs7772486	0.655	rs2142981	chr6:146071695	G/C	cg13319975	chr6:146136371	FBXO30	0.56	4.93	0.4	2.56e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11614913	0.509	rs12300425	chr12:54395082	G/T	cg25285794	chr12:54402699	HOXC8	-0.64	-5.49	-0.44	2.16e-7	Waist circumference adjusted for body mass index;
TGCT	cis	rs1865760	0.786	rs2164487	chr6:25950800	A/C	cg16482183	chr6:26056742	HIST1H1C	0.53	4.88	0.4	3.14e-6	Height;
TGCT	cis	rs2982552	0.873	rs3020303	chr6:152064454	T/C	cg22157087	chr6:152012887	ESR1	0.21	4.92	0.4	2.65e-6	Bone properties (heel);
TGCT	cis	rs9549260	0.755	rs2755216	chr13:41156938	G/A	cg21288729	chr13:41239152	FOXO1	1.02	10.62	0.69	3.83e-19	Red blood cell count;
TGCT	cis	rs6088580	0.634	rs6088508	chr20:33060081	A/G	cg06115741	chr20:33292138	TP53INP2	0.52	4.47	0.37	1.75e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs7809950	1.000	rs17154104	chr7:107090698	C/T	cg23024343	chr7:107201750	COG5	-0.34	-5.37	-0.43	3.73e-7	Coronary artery disease;
TGCT	cis	rs7208859	0.673	rs1347359	chr17:28914529	T/C	cg13385521	chr17:29058706	SUZ12P	0.7	4.48	0.37	1.69e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs34816374	1	rs34816374	chr6:26949672	A/G	cg12315302	chr6:26189340	HIST1H4D	0.93	4.48	0.37	1.71e-5	Lung cancer in ever smokers;
TGCT	cis	rs9300255	0.663	rs7953929	chr12:123758235	C/G	cg00376283	chr12:123451042	ABCB9	0.63	4.59	0.38	1.09e-5	Neutrophil percentage of white cells;
TGCT	cis	rs7043114	0.525	rs1053441	chr9:95147840	T/A	cg14631576	chr9:95140430	CENPP	-0.29	-4.79	-0.39	4.76e-6	Height;
TGCT	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg27436995	chr16:743998	FBXL16	-0.47	-5.12	-0.42	1.12e-6	Height;
TGCT	trans	rs2727020	0.553	rs4103567	chr11:49255389	C/T	cg03929089	chr4:120376271	NA	-0.6	-6.75	-0.52	5.08e-10	Coronary artery disease;
TGCT	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg10802521	chr3:52805072	NEK4	-0.7	-8.67	-0.61	2.04e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg03303774	chr4:1407052	NA	0.31	4.93	0.4	2.58e-6	Obesity-related traits;
TGCT	cis	rs2084881	0.521	rs1022088	chr17:46579790	T/A	cg25732028	chr17:46619313	NA	-0.31	-4.54	-0.38	1.34e-5	Ovarian cancer;
TGCT	cis	rs7924176	0.668	rs7895133	chr10:76007455	A/T	cg19889307	chr10:75911429	ADK;AP3M1	-0.47	-4.56	-0.38	1.22e-5	Primary tooth development (time to first tooth eruption);Permanent tooth development;Primary tooth development (number of teeth);
TGCT	cis	rs2760061	0.655	rs686533	chr1:228119604	A/G	cg18477163	chr1:228402036	OBSCN	-0.32	-6.44	-0.5	2.38e-9	Diastolic blood pressure;
TGCT	cis	rs9467711	0.591	rs9461219	chr6:25836927	C/G	cg16898833	chr6:26189333	HIST1H4D	-1.21	-5.94	-0.47	2.64e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg21862992	chr11:68658383	NA	0.46	6.37	0.5	3.37e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs12477438	0.501	rs2516833	chr2:99777405	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	14.89	0.8	2.21e-29	Chronic sinus infection;
TGCT	cis	rs2839186	0.681	rs13047198	chr21:47701835	T/C	cg12516959	chr21:47718080	NA	-0.32	-4.64	-0.38	8.8e-6	Testicular germ cell tumor;
TGCT	cis	rs3087591	0.960	rs2285812	chr17:29533871	A/G	cg24425628	chr17:29625626	OMG;NF1	0.46	7.04	0.53	1.17e-10	Hip circumference;
TGCT	cis	rs617219	0.698	rs72764988	chr5:78533584	G/C	cg05890484	chr5:78407552	BHMT	0.38	5.17	0.42	9.01e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs4689388	0.926	rs5018648	chr4:6292818	C/G	cg14416269	chr4:6271139	WFS1	-0.36	-4.8	-0.4	4.5e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs57994353	0.568	rs10747043	chr9:139318310	G/A	cg13741927	chr9:139327495	INPP5E	-0.24	-5.59	-0.45	1.37e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg20999797	chr1:1681921	NA	0.19	5.06	0.41	1.5e-6	Body mass index;
TGCT	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg11494091	chr17:61959527	GH2	0.61	14.49	0.79	1.92e-28	Prudent dietary pattern;
TGCT	cis	rs2243480	1.000	rs4718269	chr7:65200778	C/G	cg20637647	chr7:64974828	NA	-0.9	-5.06	-0.41	1.45e-6	Diabetic kidney disease;
TGCT	cis	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg18188782	chr20:61659543	NA	0.44	5.38	0.43	3.6e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs858239	0.601	rs764534	chr7:23153935	C/T	cg05602783	chr7:23145260	KLHL7	-0.71	-6.11	-0.48	1.2e-8	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs10927875	0.619	rs2102664	chr1:16130169	A/G	cg21385522	chr1:16154831	NA	-0.74	-8.95	-0.63	4.33e-15	Dilated cardiomyopathy;
TGCT	cis	rs9467773	0.620	rs2504540	chr6:26641626	A/G	cg09904177	chr6:26538194	HMGN4	0.68	6.36	0.5	3.55e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs116095464	0.558	rs62346506	chr5:201594	T/C	cg12570787	chr5:219185	SDHA;CCDC127	0.73	4.63	0.38	9.01e-6	Breast cancer;
TGCT	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.62	4.82	0.4	4.1e-6	Lung function (FEV1/FVC);
TGCT	cis	rs2228479	0.850	rs34033205	chr16:89922959	G/T	cg06558623	chr16:89946397	TCF25	0.55	4.83	0.4	3.89e-6	Skin colour saturation;
TGCT	cis	rs513349	1.000	rs513349	chr6:33541719	A/G	cg07679836	chr6:33548423	BAK1	0.32	4.77	0.39	4.98e-6	Platelet count;
TGCT	cis	rs12893668	0.572	rs7148857	chr14:104143237	C/G	cg26031613	chr14:104095156	KLC1	-0.6	-5.09	-0.42	1.32e-6	Reticulocyte count;
TGCT	cis	rs10927875	0.832	rs4661342	chr1:16160773	C/G	cg14742211	chr1:16348397	CLCNKA	-0.2	-4.5	-0.37	1.55e-5	Dilated cardiomyopathy;
TGCT	cis	rs7267979	0.714	rs1555329	chr20:25231858	G/A	cg03522245	chr20:25566470	NINL	0.48	4.59	0.38	1.06e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3087591	0.960	rs4559963	chr17:29438558	G/A	cg24425628	chr17:29625626	OMG;NF1	0.47	7.3	0.55	3.03e-11	Hip circumference;
TGCT	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.06	-9.57	-0.65	1.41e-16	Platelet count;
TGCT	cis	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg07424592	chr7:64974309	NA	-1.27	-7.84	-0.58	1.8e-12	Diabetic kidney disease;
TGCT	trans	rs4650994	0.525	rs4650996	chr1:178517365	A/G	cg05059571	chr16:84539110	KIAA1609	-0.54	-11.05	-0.7	3.43e-20	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs34638657	0.732	rs61111557	chr16:82201102	A/C	cg09439754	chr16:82129088	HSD17B2	-0.24	-4.53	-0.38	1.37e-5	Lung adenocarcinoma;
TGCT	cis	rs1801251	1.000	rs1022330	chr2:233577330	G/A	cg08000102	chr2:233561755	GIGYF2	0.66	6.73	0.52	5.67e-10	Coronary artery disease;
TGCT	cis	rs3008870	0.959	rs2985810	chr1:67376162	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.1	12.08	0.74	1.11e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs227917	1.000	rs10269243	chr7:23686785	A/G	cg12601843	chr7:23510954	IGF2BP3	0.64	4.97	0.41	2.18e-6	Common carotid intima-media thickness in HIV negative individuals;
TGCT	cis	rs7681440	0.904	rs7698219	chr4:90771351	C/A	cg20003494	chr4:90757398	SNCA	-0.59	-5.52	-0.44	1.9e-7	Dementia with Lewy bodies;
TGCT	cis	rs3813359	0.614	rs12202427	chr6:130703231	G/T	cg25049486	chr6:130544510	SAMD3	0.39	4.66	0.39	7.91e-6	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg22683308	chr4:1340831	KIAA1530	-0.65	-6.09	-0.48	1.32e-8	Longevity;
TGCT	cis	rs751728	0.605	rs1535950	chr6:33785827	A/G	cg13859433	chr6:33739653	LEMD2	-0.31	-5.45	-0.44	2.61e-7	Crohn's disease;
TGCT	cis	rs854765	0.663	rs3744113	chr17:17748645	T/C	cg09796270	chr17:17721594	SREBF1	-0.28	-5.43	-0.44	2.91e-7	Total body bone mineral density;
TGCT	cis	rs931127	0.658	rs7926512	chr11:65464487	T/A	cg17480646	chr11:65405466	SIPA1	-0.42	-5.36	-0.43	3.9e-7	Systemic lupus erythematosus;
TGCT	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg07061783	chr6:25882402	NA	-0.57	-5.59	-0.45	1.37e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7647973	1.000	rs4241407	chr3:49600319	C/T	cg05785598	chr3:49045655	WDR6	0.38	4.6	0.38	1.02e-5	Menarche (age at onset);
TGCT	cis	rs7590720	0.704	rs7603645	chr2:216876949	C/G	cg12620499	chr2:216877984	MREG	0.92	12.08	0.74	1.12e-22	Alcohol dependence;
TGCT	cis	rs4494114	0.967	rs1925677	chr1:39346905	T/G	cg25970120	chr1:39325951	RRAGC	-0.54	-5.55	-0.45	1.65e-7	Blood protein levels;
TGCT	cis	rs55794721	0.509	rs6699896	chr1:25762902	A/T	cg09222892	chr1:25734099	RHCE	-0.41	-6.72	-0.52	5.98e-10	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs3617	0.625	rs11922961	chr3:52868610	T/C	cg10802521	chr3:52805072	NEK4	0.62	7.17	0.54	6e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs3784262	0.565	rs4646606	chr15:58287526	A/G	cg12031962	chr15:58353849	ALDH1A2	0.37	5.24	0.43	6.8e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs9473924	0.542	rs35546156	chr6:50829785	C/T	cg14470998	chr6:50812995	TFAP2B	1.33	7.94	0.58	1.05e-12	Body mass index;
TGCT	cis	rs9921338	0.961	rs7198849	chr16:11373301	C/T	cg00044050	chr16:11439710	C16orf75	-0.76	-5.61	-0.45	1.24e-7	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.18	0.49	8.32e-9	Electroencephalogram traits;
TGCT	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg08859206	chr1:53392774	SCP2	-0.41	-6.12	-0.48	1.11e-8	Monocyte count;
TGCT	cis	rs2072499	0.966	rs887953	chr1:156191149	T/C	cg24450063	chr1:156163899	SLC25A44	1.2	14.13	0.79	1.31e-27	Testicular germ cell tumor;
TGCT	cis	rs2562456	0.876	rs62110202	chr19:21754601	C/T	cg25650185	chr19:21324782	ZNF431	-0.62	-5.13	-0.42	1.1e-6	Pain;
TGCT	cis	rs483180	0.855	rs562038	chr1:120254545	G/C	cg19096424	chr1:120255104	PHGDH	0.6	5.57	0.45	1.48e-7	Macular telangiectasia type 2;
TGCT	cis	rs8031584	0.723	rs11632229	chr15:31179534	A/G	cg14829155	chr15:31115871	NA	0.36	4.69	0.39	7.16e-6	Huntington's disease progression;
TGCT	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg07636037	chr3:49044803	WDR6	0.85	8.88	0.62	6.21e-15	Menarche (age at onset);
TGCT	cis	rs492146	0.765	rs419427	chr6:52844886	T/A	cg06706454	chr6:52930286	FBXO9	-0.51	-4.66	-0.39	8.12e-6	Epilepsy (remission after treatment);
TGCT	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.06	-9.57	-0.65	1.41e-16	Platelet count;
TGCT	cis	rs8078723	0.738	rs3816472	chr17:38142677	A/C	cg17467752	chr17:38218738	THRA	-0.53	-5.37	-0.43	3.69e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs250677	0.652	rs36045	chr5:148441184	A/G	cg23229984	chr5:148520753	ABLIM3	-0.22	-4.97	-0.41	2.14e-6	Breast cancer;
TGCT	trans	rs10802346	0.545	rs4607841	chr1:246373295	T/C	cg13514129	chr1:39547527	MACF1	0.87	7.87	0.58	1.51e-12	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs7726839	0.540	rs72703095	chr5:601789	T/C	cg09021430	chr5:549028	NA	-0.43	-5.77	-0.46	5.99e-8	Obesity-related traits;
TGCT	cis	rs12711979	0.509	rs10200764	chr2:3827772	C/G	cg17052675	chr2:3827356	NA	-0.56	-13.37	-0.77	8.42e-26	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs7267979	1.000	rs8125868	chr20:25324410	A/G	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs826838	0.967	rs7299170	chr12:38789536	G/A	cg26384229	chr12:38710491	ALG10B	1.06	10.68	0.69	2.84e-19	Heart rate;
TGCT	cis	rs8017423	0.904	rs11159963	chr14:90805358	C/T	cg04374321	chr14:90722782	PSMC1	-0.73	-6.95	-0.53	1.82e-10	Mortality in heart failure;
TGCT	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs5769707	0.554	rs10854876	chr22:50010570	T/C	cg05373962	chr22:49881684	NA	-0.3	-5.09	-0.42	1.31e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs11785400	1.000	rs6997670	chr8:143737915	G/A	cg24634471	chr8:143751801	JRK	0.57	6.12	0.48	1.11e-8	Schizophrenia;
TGCT	cis	rs7010267	0.596	rs4354338	chr8:120016060	A/C	cg17171407	chr8:119960777	TNFRSF11B	0.26	4.59	0.38	1.06e-5	Total body bone mineral density (age 45-60);
TGCT	cis	rs7584330	0.554	rs6744807	chr2:238424684	A/G	cg08992911	chr2:238395768	MLPH	0.66	4.73	0.39	5.91e-6	Prostate cancer;
TGCT	cis	rs9486719	0.690	rs2092094	chr6:96844123	G/C	cg18709589	chr6:96969512	KIAA0776	0.75	5.13	0.42	1.1e-6	Migraine;Coronary artery disease;
TGCT	cis	rs854765	0.583	rs8075965	chr17:17853180	A/T	cg09796270	chr17:17721594	SREBF1	0.23	4.55	0.38	1.27e-5	Total body bone mineral density;
TGCT	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg12311346	chr5:56204834	C5orf35	0.57	6.16	0.48	9.36e-9	Initial pursuit acceleration;
TGCT	cis	rs12575480	0.901	rs6578977	chr11:2101804	C/T	cg15541987	chr11:2077307	NA	-0.39	-4.73	-0.39	6.13e-6	Pursuit maintenance gain;
TGCT	cis	rs2721195	0.845	rs3816732	chr8:145724275	T/C	cg17328964	chr8:145687451	CYHR1	-0.42	-5.71	-0.46	7.81e-8	Age at first birth;
TGCT	trans	rs1974653	0.672	rs9606251	chr22:20092777	C/A	cg08822737	chr17:71088851	SLC39A11	-0.93	-7.61	-0.56	5.97e-12	Schizophrenia;
TGCT	cis	rs4252435	0.614	rs4987568	chr7:142590737	C/T	cg09833174	chr7:143059591	FAM131B	-0.95	-4.49	-0.37	1.58e-5	Cancer;
TGCT	cis	rs950776	0.507	rs12912673	chr15:78810216	T/C	cg06917634	chr15:78832804	PSMA4	0.97	9.62	0.65	1.05e-16	Sudden cardiac arrest;
TGCT	cis	rs2730260	0.537	rs55864635	chr7:158859744	C/T	cg02078164	chr7:157982224	PTPRN2	0.42	4.67	0.39	7.79e-6	Myopia (pathological);
TGCT	cis	rs523522	0.923	rs2235217	chr12:120884328	C/T	cg27279351	chr12:120934652	DYNLL1	0.74	6.4	0.5	2.95e-9	High light scatter reticulocyte count;
TGCT	cis	rs9303401	0.659	rs17822908	chr17:56801778	T/C	cg25039879	chr17:56429692	SUPT4H1	0.52	4.62	0.38	9.48e-6	Cognitive test performance;
TGCT	cis	rs7659604	0.676	rs6534323	chr4:122695888	G/A	cg19748678	chr4:122722346	EXOSC9	0.87	9.36	0.64	4.56e-16	Type 2 diabetes;
TGCT	cis	rs9972944	0.756	rs12600343	chr17:63764721	G/A	cg07283582	chr17:63770753	CCDC46	-0.26	-5.3	-0.43	5.02e-7	Total body bone mineral density;
TGCT	cis	rs61990749	0.544	rs2544567	chr14:78181739	T/C	cg23188588	chr14:78226832	SNW1;C14orf178	0.66	4.65	0.39	8.45e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs1857353	1.000	rs116774684	chr1:75873384	C/T	cg11838876	chr1:75668600	SLC44A5	-0.47	-4.62	-0.38	9.64e-6	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg00149659	chr3:10157352	C3orf10	0.79	4.96	0.41	2.27e-6	Alzheimer's disease;
TGCT	trans	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg21659725	chr3:3221576	CRBN	0.77	9.12	0.63	1.67e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs910316	0.967	rs175505	chr14:75529619	C/T	cg08847533	chr14:75593920	NEK9	-0.92	-9.64	-0.65	9.33e-17	Height;
TGCT	cis	rs4242434	0.597	rs4066629	chr8:22529073	A/C	cg21658235	chr8:22456391	C8orf58	-0.46	-4.96	-0.41	2.31e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg01802117	chr1:53393560	SCP2	0.46	5.63	0.45	1.13e-7	Monocyte count;
TGCT	cis	rs4563143	0.514	rs73029081	chr19:29295583	C/G	cg04546413	chr19:29218101	NA	0.73	5.38	0.43	3.65e-7	Methadone dose in opioid dependence;
TGCT	cis	rs826838	0.933	rs1906263	chr12:38653362	T/C	cg26384229	chr12:38710491	ALG10B	1.05	10.25	0.68	3.18e-18	Heart rate;
TGCT	cis	rs4891159	0.548	rs948646	chr18:74118168	G/A	cg24786174	chr18:74118243	ZNF516	0.7	15.05	0.8	9.51e-30	Longevity;
TGCT	cis	rs11677370	0.603	rs11675498	chr2:3850943	G/T	cg17052675	chr2:3827356	NA	-0.42	-7.13	-0.54	7.31e-11	Type 2 diabetes;
TGCT	cis	rs2458413	1.000	rs2458413	chr8:105359432	C/T	cg23108931	chr8:105342351	NA	0.36	6.01	0.48	1.91e-8	Paget's disease;
TGCT	cis	rs9837602	0.507	rs793453	chr3:99529095	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.59	6.91	0.53	2.27e-10	Breast cancer;
TGCT	cis	rs13191362	0.935	rs67673890	chr6:163107647	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.99	8.17	0.59	3.08e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs28595532	1.000	rs115915387	chr4:119640854	C/T	cg14228332	chr4:119757509	SEC24D	1.02	5.37	0.43	3.75e-7	Cannabis dependence symptom count;
TGCT	cis	rs478304	0.817	rs524475	chr11:65518065	T/A	cg27068330	chr11:65405492	SIPA1	0.74	7.41	0.55	1.67e-11	Acne (severe);
TGCT	cis	rs4746818	0.711	rs4745976	chr10:70845181	A/G	cg11621586	chr10:70884670	VPS26A	1.05	7.01	0.53	1.34e-10	Left atrial antero-posterior diameter;
TGCT	cis	rs12134245	0.776	rs12122066	chr1:92005140	C/T	cg02896835	chr1:92012615	NA	-0.28	-4.74	-0.39	5.75e-6	Breast cancer;
TGCT	cis	rs6725041	0.547	rs4672645	chr2:213204955	C/T	cg20637307	chr2:213403960	ERBB4	-0.53	-4.53	-0.38	1.37e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs6534347	0.512	rs6534354	chr4:123552125	T/A	cg10583651	chr4:123538969	IL21	-0.31	-4.47	-0.37	1.73e-5	Type 1 diabetes;
TGCT	cis	rs7954584	0.546	rs10840630	chr12:122352445	C/T	cg22618164	chr12:122356400	WDR66	0.69	6.52	0.51	1.6e-9	Mean corpuscular volume;
TGCT	cis	rs7937682	0.883	rs486038	chr11:111465963	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.99	-10.02	-0.67	1.16e-17	Primary sclerosing cholangitis;
TGCT	cis	rs6121246	0.909	rs6087778	chr20:30354142	G/A	cg13852791	chr20:30311386	BCL2L1	0.8	6.12	0.48	1.15e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs7843479	0.601	rs2306646	chr8:21846586	C/G	cg17168535	chr8:21777572	XPO7	0.8	7.93	0.58	1.11e-12	Mean corpuscular volume;
TGCT	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg23758822	chr17:41437982	NA	0.68	6.78	0.52	4.4e-10	Menopause (age at onset);
TGCT	cis	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg20637647	chr7:64974828	NA	0.89	4.99	0.41	2.01e-6	Diabetic kidney disease;
TGCT	cis	rs2070488	0.965	rs2126534	chr3:38445165	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.92	9.73	0.66	5.78e-17	Electrocardiographic conduction measures;
TGCT	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg19318889	chr4:1322082	MAEA	0.27	6.46	0.5	2.1e-9	Longevity;
TGCT	cis	rs319204	1.000	rs319234	chr5:146241232	A/G	cg25021259	chr5:146258546	PPP2R2B	0.36	4.53	0.38	1.37e-5	Schizophrenia;
TGCT	cis	rs7432375	1.000	rs10935186	chr3:136346206	T/C	cg12473912	chr3:136751656	NA	0.35	5.05	0.41	1.56e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg25036284	chr2:26402008	FAM59B	0.65	5.19	0.42	8.36e-7	Gut microbiome composition (summer);
TGCT	cis	rs4499344	0.633	rs259258	chr19:33152523	A/G	cg26639809	chr19:33781782	NA	0.22	4.47	0.37	1.75e-5	Mean platelet volume;
TGCT	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg22166914	chr1:53195759	ZYG11B	-0.5	-9.4	-0.64	3.65e-16	Monocyte count;
TGCT	cis	rs16958440	0.867	rs77599321	chr18:44689642	T/C	cg17192377	chr18:44677553	HDHD2	0.63	4.7	0.39	6.74e-6	Sitting height ratio;
TGCT	cis	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg18252515	chr7:66147081	NA	-1.31	-8.18	-0.59	2.87e-13	Diabetic kidney disease;
TGCT	trans	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg17830980	chr10:43048298	ZNF37B	-0.81	-10.14	-0.67	5.73e-18	Extrinsic epigenetic age acceleration;
TGCT	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs1670533	0.746	rs688008	chr4:1082829	T/C	cg27284194	chr4:1044797	NA	0.69	5.93	0.47	2.78e-8	Recombination rate (females);
TGCT	cis	rs1865760	0.827	rs9461227	chr6:25960815	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.64	6.29	0.49	4.91e-9	Height;
TGCT	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg05754148	chr16:3507555	NAT15	0.41	4.93	0.4	2.63e-6	Tuberculosis;
TGCT	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg23758822	chr17:41437982	NA	0.7	6.75	0.52	5.19e-10	Menopause (age at onset);
TGCT	cis	rs228769	0.543	rs170634	chr17:42175821	C/A	cg19774624	chr17:42201019	HDAC5	0.7	6.71	0.52	6.31e-10	Bone mineral density (hip);Bone mineral density (spine);
TGCT	cis	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg18252515	chr7:66147081	NA	-1.09	-6.4	-0.5	2.88e-9	Diabetic kidney disease;
TGCT	cis	rs11642862	1.000	rs11642466	chr16:30781942	A/G	cg02466173	chr16:30829666	NA	-0.39	-4.68	-0.39	7.24e-6	Tonsillectomy;
TGCT	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg03517284	chr6:25882590	NA	-0.68	-6.25	-0.49	6.06e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs2456568	0.835	rs7936182	chr11:93665532	T/A	cg26875233	chr11:93583750	C11orf90	-0.46	-5.74	-0.46	6.93e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg21644426	chr2:191273491	MFSD6	-0.6	-5.91	-0.47	3.12e-8	Pulse pressure;
TGCT	cis	rs79057730	0.527	rs35316052	chr7:802954	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.65	5.41	0.44	3.16e-7	Initial pursuit acceleration;
TGCT	cis	rs8067545	1.000	rs28807825	chr17:19942850	G/A	cg13482628	chr17:19912719	NA	0.53	4.48	0.37	1.66e-5	Schizophrenia;
TGCT	cis	rs1865760	0.865	rs10946800	chr6:25957773	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.64	6.29	0.49	4.91e-9	Height;
TGCT	cis	rs8062405	0.789	rs1968751	chr16:28631759	T/C	cg09754948	chr16:28834200	ATXN2L	-0.59	-4.78	-0.39	4.82e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs7249142	0.562	rs2314035	chr19:19284920	T/C	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.45	-4.5	-0.37	1.56e-5	IgG glycosylation;
TGCT	cis	rs7246657	0.598	rs10405372	chr19:37668775	A/C	cg24025825	chr19:37761650	NA	-0.32	-5.02	-0.41	1.79e-6	Coronary artery calcification;
TGCT	cis	rs17767294	0.708	rs9380018	chr6:27740646	A/G	cg08851530	chr6:28072375	NA	0.93	4.57	0.38	1.19e-5	Parkinson's disease;
TGCT	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg02953382	chr22:24373134	LOC391322	-0.75	-7.44	-0.56	1.45e-11	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs12220238	1.000	rs2279648	chr10:75867193	G/T	cg19889307	chr10:75911429	ADK;AP3M1	0.86	6.75	0.52	5.16e-10	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs11931598	0.509	rs10937771	chr4:6940034	C/T	cg02503808	chr4:7069936	GRPEL1	0.54	4.92	0.4	2.67e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs2404602	0.967	rs7167613	chr15:77041192	C/A	cg22467129	chr15:76604101	ETFA	-0.46	-5.04	-0.41	1.61e-6	Blood metabolite levels;
TGCT	cis	rs56399783	0.901	rs79932907	chr7:2827901	C/G	cg19731401	chr7:2775893	GNA12	0.37	5.15	0.42	1e-6	Childhood ear infection;
TGCT	cis	rs9486719	1.000	rs11757063	chr6:96884886	C/T	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.69	-0.62	1.76e-14	Migraine;Coronary artery disease;
TGCT	cis	rs7552404	0.727	rs1144336	chr1:76277421	C/A	cg10523679	chr1:76189770	ACADM	0.74	7.2	0.54	5.04e-11	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs854765	0.654	rs11078400	chr17:17757728	A/G	cg09796270	chr17:17721594	SREBF1	-0.24	-4.8	-0.4	4.56e-6	Total body bone mineral density;
TGCT	cis	rs1348850	0.914	rs12693120	chr2:178283288	A/G	cg22681709	chr2:178499509	PDE11A	-0.35	-4.6	-0.38	1.03e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs739496	0.947	rs2339816	chr12:111912188	T/C	cg10833066	chr12:111807467	FAM109A	0.37	5.2	0.42	8.1e-7	Platelet count;
TGCT	cis	rs7731657	0.575	rs12513465	chr5:130364503	A/G	cg08523029	chr5:130500466	HINT1	-0.61	-5.08	-0.42	1.34e-6	Fasting plasma glucose;
TGCT	cis	rs881375	0.654	rs10760126	chr9:123662618	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	5.31	0.43	4.92e-7	Rheumatoid arthritis;
TGCT	cis	rs11690935	0.731	rs10930491	chr2:172569824	A/G	cg13550731	chr2:172543902	DYNC1I2	0.68	5.97	0.47	2.38e-8	Schizophrenia;
TGCT	cis	rs7727544	0.716	rs11955347	chr5:131567924	G/A	cg24060327	chr5:131705240	SLC22A5	-0.57	-5.23	-0.43	6.84e-7	Blood metabolite levels;
TGCT	cis	rs7432375	0.901	rs1729951	chr3:136500733	T/G	cg12473912	chr3:136751656	NA	-0.35	-5.04	-0.41	1.62e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs10779751	1.000	rs11121703	chr1:11293792	G/T	cg08854313	chr1:11322531	MTOR	-0.99	-10.58	-0.69	4.78e-19	Body mass index;
TGCT	cis	rs7172809	0.643	rs11855272	chr15:77840790	G/A	cg22256960	chr15:77711686	NA	-0.47	-4.73	-0.39	6.05e-6	Glucose homeostasis traits;
TGCT	trans	rs4332037	0.901	rs7791899	chr7:1935988	T/C	cg25206134	chr2:45395956	NA	1.1	9.34	0.64	5.11e-16	Bipolar disorder;
TGCT	cis	rs1018836	0.631	rs2205158	chr8:91472515	C/T	cg16814680	chr8:91681699	NA	-0.77	-7.57	-0.56	7.42e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4478858	0.684	rs2062951	chr1:31762981	T/C	cg00250761	chr1:31883323	NA	-0.26	-4.55	-0.38	1.28e-5	Alcohol dependence;
TGCT	cis	rs6725041	0.819	rs1996763	chr2:213082269	T/C	cg20637307	chr2:213403960	ERBB4	-0.51	-4.48	-0.37	1.68e-5	QT interval (ambient particulate matter interaction);
TGCT	trans	rs7824557	0.569	rs10106207	chr8:11015338	C/T	cg06636001	chr8:8085503	FLJ10661	-0.8	-7.49	-0.56	1.13e-11	Retinal vascular caliber;
TGCT	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.71	6.36	0.5	3.53e-9	Tonsillectomy;
TGCT	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg08859206	chr1:53392774	SCP2	0.39	5.8	0.46	5.07e-8	Monocyte count;
TGCT	cis	rs7666738	0.830	rs13110498	chr4:98959150	G/A	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs981844	0.712	rs4571310	chr4:154746832	T/C	cg14289246	chr4:154710475	SFRP2	-0.99	-9.12	-0.63	1.65e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs66573146	1.000	rs66519732	chr4:6990569	C/G	cg05069807	chr4:6945702	TBC1D14	0.35	4.94	0.41	2.43e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs12134133	1.000	rs6540893	chr1:207435727	G/A	cg02152968	chr1:207494213	CD55	0.61	4.66	0.39	7.94e-6	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs11098499	0.866	rs10518329	chr4:120401835	A/G	cg09307838	chr4:120376055	NA	0.62	5.96	0.47	2.44e-8	Corneal astigmatism;
TGCT	cis	rs12477438	0.798	rs6740267	chr2:99561867	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-6.02	-0.48	1.86e-8	Chronic sinus infection;
TGCT	cis	rs1950500	0.545	rs724165	chr14:24806229	G/A	cg22990158	chr14:24802150	ADCY4	-0.55	-4.84	-0.4	3.83e-6	Height;
TGCT	cis	rs55794721	0.509	rs12027110	chr1:25775682	A/T	cg09222892	chr1:25734099	RHCE	-0.42	-7.1	-0.54	8.43e-11	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs911263	0.603	rs60593979	chr14:68773298	C/G	cg18825221	chr14:68749962	RAD51L1	0.22	4.44	0.37	1.97e-5	Primary biliary cholangitis;
TGCT	cis	rs4595586	0.545	rs2388177	chr12:39364403	T/C	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs9611565	0.765	rs132915	chr22:41805782	T/C	cg06634786	chr22:41940651	POLR3H	0.7	6.65	0.51	8.51e-10	Vitiligo;
TGCT	cis	rs2629540	0.765	rs7097254	chr10:126512248	A/C	cg08799069	chr10:126477246	METTL10	-0.28	-4.69	-0.39	7e-6	Cocaine dependence;
TGCT	cis	rs6964587	0.839	rs10808086	chr7:91447515	T/C	cg17063962	chr7:91808500	NA	0.82	8.31	0.6	1.43e-13	Breast cancer;
TGCT	cis	rs473651	0.935	rs477041	chr2:239355995	C/G	cg21699342	chr2:239360505	ASB1	-0.17	-4.74	-0.39	5.7e-6	Multiple system atrophy;
TGCT	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.7	-5.5	-0.44	2.07e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs1008375	0.800	rs10008598	chr4:17607323	T/C	cg16339924	chr4:17578868	LAP3	0.74	5.92	0.47	3e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2710642	0.962	rs6545972	chr2:63084682	G/A	cg17519650	chr2:63277830	OTX1	0.63	5.72	0.46	7.55e-8	LDL cholesterol levels;LDL cholesterol;
TGCT	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg00814883	chr7:100076585	TSC22D4	0.92	9.69	0.66	7.12e-17	Platelet count;
TGCT	cis	rs11083475	0.557	rs2368519	chr19:39259241	C/T	cg17759274	chr19:39260954	NA	0.39	5.35	0.43	4.01e-7	Heart rate;
TGCT	cis	rs1406084	0.636	rs7591244	chr2:154710717	C/T	cg25703346	chr2:154729189	GALNT13	0.77	4.6	0.38	1.03e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9911578	0.967	rs686425	chr17:56776730	A/G	cg12560992	chr17:57184187	TRIM37	0.76	9.34	0.64	4.88e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs6598955	0.627	rs3924324	chr1:26616280	G/A	cg04990556	chr1:26633338	UBXN11	0.64	4.91	0.4	2.78e-6	Obesity-related traits;
TGCT	trans	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg17830980	chr10:43048298	ZNF37B	0.87	11.26	0.71	1.1e-20	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2216164	1.000	rs2216164	chr12:68534340	C/T	cg17065850	chr12:67807625	NA	-0.23	-4.44	-0.37	1.93e-5	Alopecia areata;
TGCT	cis	rs13256369	0.760	rs7839473	chr8:8575836	C/T	cg18904891	chr8:8559673	CLDN23	0.64	5.89	0.47	3.36e-8	Obesity-related traits;
TGCT	cis	rs61990749	0.500	rs8011337	chr14:78272626	T/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.6	4.45	0.37	1.88e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs8141529	0.719	rs5762825	chr22:29223642	A/G	cg02153584	chr22:29168773	CCDC117	0.67	5.69	0.45	8.82e-8	Lymphocyte counts;
TGCT	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg03060546	chr3:49711283	APEH	0.53	5.14	0.42	1.05e-6	Menarche (age at onset);
TGCT	cis	rs1005277	0.505	rs10827835	chr10:38150709	G/A	cg25427524	chr10:38739819	LOC399744	0.37	7.47	0.56	1.24e-11	Extrinsic epigenetic age acceleration;
TGCT	cis	rs587847	0.737	rs4924142	chr15:37621265	T/G	cg00216138	chr15:37171175	LOC145845	0.31	4.57	0.38	1.15e-5	Intraocular pressure;
TGCT	cis	rs2549003	0.966	rs2070730	chr5:131819800	G/A	cg00255919	chr5:131827918	IRF1	0.2	4.7	0.39	6.92e-6	Asthma (sex interaction);
TGCT	cis	rs13256369	1.000	rs4841017	chr8:8577093	A/G	cg18904891	chr8:8559673	CLDN23	0.63	5.82	0.46	4.83e-8	Obesity-related traits;
TGCT	cis	rs1843834	0.624	rs2396110	chr2:225560219	A/G	cg22455342	chr2:225449267	CUL3	0.61	5.45	0.44	2.58e-7	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs1519814	0.659	rs7387672	chr8:121024511	A/G	cg22335954	chr8:121166405	COL14A1	-0.37	-4.73	-0.39	6.06e-6	Breast cancer;
TGCT	trans	rs77457752	0.562	rs7874765	chr9:13899199	G/C	cg25510823	chr7:47085976	NA	0.45	6.68	0.51	7.21e-10	Breast cancer;
TGCT	cis	rs15676	0.783	rs6478851	chr9:131561110	G/A	cg14578146	chr9:130637464	AK1	0.25	4.56	0.38	1.23e-5	Blood metabolite levels;
TGCT	cis	rs829883	0.763	rs249843	chr12:98870987	G/A	cg25150519	chr12:98850993	NA	0.64	7.84	0.58	1.8e-12	Colorectal adenoma (advanced);
TGCT	cis	rs710216	0.957	rs841570	chr1:43435571	C/G	cg03128534	chr1:43423976	SLC2A1	0.6	4.56	0.38	1.23e-5	Red cell distribution width;
TGCT	cis	rs4077468	1.000	rs4077468	chr1:205914757	A/G	cg07157834	chr1:205819609	PM20D1	-0.31	-4.43	-0.37	2.01e-5	Cystic fibrosis-related diabetes;
TGCT	cis	rs114540395	1.000	rs114540395	chr10:103479062	C/T	cg18276125	chr10:102749041	C10orf2	0.42	5.27	0.43	5.96e-7	Schizophrenia;
TGCT	cis	rs6964587	1.000	rs10488512	chr7:91753579	C/T	cg22709100	chr7:91322751	NA	0.28	4.52	0.38	1.45e-5	Breast cancer;
TGCT	cis	rs735396	0.770	rs1169315	chr12:121443753	T/G	cg15155738	chr12:121454335	C12orf43	0.55	4.81	0.4	4.38e-6	N-glycan levels;
TGCT	cis	rs9611565	0.608	rs202652	chr22:41838792	A/G	cg06481639	chr22:41940642	POLR3H	0.69	5.92	0.47	2.95e-8	Vitiligo;
TGCT	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.5	-4.87	-0.4	3.34e-6	Bipolar disorder;
TGCT	cis	rs46522	0.585	rs79049364	chr17:47014991	T/A	cg27201301	chr17:47039149	GIP	0.26	4.58	0.38	1.12e-5	Coronary heart disease;
TGCT	cis	rs832540	0.629	rs10940512	chr5:56082094	G/C	cg24531977	chr5:56204891	C5orf35	-0.55	-5.42	-0.44	2.92e-7	Coronary artery disease;
TGCT	cis	rs10875746	0.810	rs10875732	chr12:48442105	A/C	cg20731937	chr12:48336164	NA	0.63	4.96	0.41	2.31e-6	Longevity (90 years and older);
TGCT	cis	rs7647973	0.593	rs7620848	chr3:49828021	G/C	cg03034192	chr3:50606346	HEMK1;C3orf18	-0.36	-4.75	-0.39	5.61e-6	Menarche (age at onset);
TGCT	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.87	8.62	0.61	2.69e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs4808199	0.948	rs11085261	chr19:19462606	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.69	5.48	0.44	2.24e-7	Nonalcoholic fatty liver disease;
TGCT	cis	rs797680	0.786	rs9432465	chr1:93780591	G/A	cg17826107	chr1:92977322	EVI5	-0.22	-5.05	-0.41	1.53e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs7647973	0.925	rs4955439	chr3:49245645	G/T	cg07636037	chr3:49044803	WDR6	-0.63	-5.12	-0.42	1.11e-6	Menarche (age at onset);
TGCT	cis	rs7666738	0.830	rs34244876	chr4:99031336	G/A	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6831352	1.000	rs1126673	chr4:100045616	C/T	cg12011299	chr4:100065546	ADH4	0.41	5.01	0.41	1.81e-6	Alcohol dependence;
TGCT	cis	rs9906944	0.707	rs11655950	chr17:47129121	C/T	cg10950924	chr17:47092072	IGF2BP1	-0.34	-4.55	-0.38	1.26e-5	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs4148883	0.689	rs1311621	chr4:100014018	T/C	cg12011299	chr4:100065546	ADH4	0.38	5.72	0.46	7.41e-8	Alcohol dependence;
TGCT	cis	rs10984561	0.881	rs58163718	chr9:122251146	A/C	cg14242995	chr9:122249943	NA	0.73	5.96	0.47	2.46e-8	Pulmonary function decline;
TGCT	cis	rs1843834	0.505	rs3820763	chr2:225347270	A/G	cg22455342	chr2:225449267	CUL3	-1.03	-10.95	-0.7	6.27e-20	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs9549367	0.789	rs57747440	chr13:113894750	C/A	cg00898013	chr13:113819073	PROZ	-0.4	-4.98	-0.41	2.13e-6	Platelet distribution width;
TGCT	cis	rs6598955	0.671	rs12086573	chr1:26574330	G/A	cg04990556	chr1:26633338	UBXN11	0.62	4.73	0.39	6.12e-6	Obesity-related traits;
TGCT	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg19010396	chr19:19431384	KIAA0892;SF4	-0.54	-4.54	-0.38	1.3e-5	Tonsillectomy;
TGCT	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg11494091	chr17:61959527	GH2	0.6	14.51	0.79	1.71e-28	Prudent dietary pattern;
TGCT	cis	rs7829975	0.511	rs1401390	chr8:8136410	C/T	cg15462221	chr8:8086144	FLJ10661	-0.51	-4.44	-0.37	1.94e-5	Mood instability;
TGCT	cis	rs138171347	1	rs138171347	chr17:5183203	AAAAT/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.47	4.71	0.39	6.58e-6	White blood cell count;
TGCT	cis	rs7172809	0.573	rs13379686	chr15:77436191	T/C	cg22256960	chr15:77711686	NA	-0.48	-4.63	-0.38	9.17e-6	Glucose homeostasis traits;
TGCT	cis	rs7246657	0.943	rs3760825	chr19:37945601	C/T	cg18154014	chr19:37997991	ZNF793	0.73	5.38	0.44	3.53e-7	Coronary artery calcification;
TGCT	cis	rs3749237	0.964	rs2352975	chr3:49891885	T/C	cg03060546	chr3:49711283	APEH	0.7	6.71	0.52	6.05e-10	Resting heart rate;
TGCT	cis	rs910316	1.000	rs10142626	chr14:75555636	A/T	cg23033748	chr14:75592666	NEK9	0.27	4.57	0.38	1.16e-5	Height;
TGCT	cis	rs61990749	0.597	rs28534379	chr14:78172140	G/A	cg23188588	chr14:78226832	SNW1;C14orf178	-0.66	-4.65	-0.39	8.45e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg02380750	chr20:61661411	NA	0.33	5.96	0.47	2.4e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs367615	0.918	rs10055528	chr5:108861129	G/T	cg17395555	chr5:108820864	NA	0.31	5.01	0.41	1.85e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs4851266	0.966	rs1160545	chr2:100832269	C/T	cg22139774	chr2:100720529	AFF3	-0.35	-5.19	-0.42	8.51e-7	Educational attainment;
TGCT	cis	rs1692580	0.682	rs12045693	chr1:2205581	A/C	cg21194808	chr1:2205498	SKI	-0.27	-5.54	-0.45	1.71e-7	Coronary artery disease;
TGCT	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg08859206	chr1:53392774	SCP2	-0.38	-5.71	-0.46	8.07e-8	Monocyte count;
TGCT	cis	rs765787	0.530	rs2413782	chr15:45538490	A/C	cg24006582	chr15:45444508	DUOX1	-0.25	-5.54	-0.45	1.76e-7	Uric acid levels;
TGCT	cis	rs68170813	0.652	rs76924513	chr7:107205887	T/C	cg02696742	chr7:106810147	HBP1	-0.59	-4.71	-0.39	6.61e-6	Coronary artery disease;
TGCT	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg11764359	chr7:65958608	NA	0.62	5.57	0.45	1.51e-7	Aortic root size;
TGCT	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg11301795	chr4:187892539	NA	-0.3	-4.48	-0.37	1.69e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6570726	0.764	rs366673	chr6:145814628	T/A	cg05347473	chr6:146136440	FBXO30	0.53	4.96	0.41	2.26e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2299587	0.637	rs7832527	chr8:17889343	C/A	cg04898035	chr8:17640624	MTUS1	-0.22	-4.75	-0.39	5.59e-6	Economic and political preferences;
TGCT	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg06634786	chr22:41940651	POLR3H	0.88	8.31	0.6	1.42e-13	Vitiligo;
TGCT	cis	rs6866344	0.697	rs62392831	chr5:178134365	A/G	cg03877680	chr5:178157825	ZNF354A	0.75	6.1	0.48	1.25e-8	Neutrophil percentage of white cells;
TGCT	trans	rs208520	0.690	rs207077	chr6:66769855	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-11.22	-0.71	1.34e-20	Exhaled nitric oxide output;
TGCT	cis	rs9926296	0.572	rs2376878	chr16:89885161	G/A	cg27121462	chr16:89883253	FANCA	0.54	5.07	0.41	1.41e-6	Vitiligo;
TGCT	cis	rs9640161	0.789	rs1464752	chr7:150021284	C/T	cg10018233	chr7:150070692	REPIN1	0.32	4.63	0.38	8.94e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs2521263	1.000	rs2651829	chr11:2308304	A/C	cg10151367	chr11:2847642	KCNQ1	0.47	4.53	0.38	1.36e-5	Obesity-related traits;
TGCT	cis	rs6087990	0.735	rs2424913	chr20:31374259	C/T	cg13636640	chr20:31349939	DNMT3B	0.94	12.09	0.74	1.03e-22	Ulcerative colitis;
TGCT	cis	rs7605378	0.688	rs769961	chr2:200712141	C/A	cg17644776	chr2:200775616	C2orf69	0.34	6.79	0.52	4.07e-10	Osteoporosis;
TGCT	cis	rs7674212	0.570	rs2711898	chr4:104063071	C/T	cg16532752	chr4:104119610	CENPE	-0.61	-5.64	-0.45	1.09e-7	Type 2 diabetes;
TGCT	cis	rs73001065	0.901	rs73004926	chr19:19671266	C/T	cg03709012	chr19:19516395	GATAD2A	1.03	5.03	0.41	1.65e-6	LDL cholesterol;
TGCT	cis	rs1215050	0.791	rs700738	chr4:98907909	C/A	cg17366294	chr4:99064904	C4orf37	-0.53	-5.69	-0.45	8.67e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9584850	0.874	rs7988959	chr13:99104004	T/C	cg15168958	chr13:99100528	FARP1	-0.25	-4.51	-0.38	1.46e-5	Neuroticism;
TGCT	cis	rs2013441	1.000	rs9900166	chr17:20192969	G/A	cg18979559	chr17:20280153	CCDC144C	-0.45	-4.67	-0.39	7.61e-6	Obesity-related traits;
TGCT	cis	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg08564027	chr20:61660810	NA	0.37	6.85	0.52	3.1e-10	Prostate cancer (SNP x SNP interaction);
TGCT	trans	rs208520	0.661	rs4710566	chr6:66848538	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-10.43	-0.68	1.13e-18	Exhaled nitric oxide output;
TGCT	cis	rs4660261	0.545	rs803682	chr1:44362623	G/A	cg12908607	chr1:44402522	ARTN	-0.7	-8.79	-0.62	1.01e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg24829409	chr8:58192753	C8orf71	-0.56	-5.31	-0.43	4.86e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs73001065	0.818	rs73004975	chr19:19727152	A/G	cg03709012	chr19:19516395	GATAD2A	1.06	5.2	0.42	8.02e-7	LDL cholesterol;
TGCT	trans	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.86	9.4	0.65	3.49e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs2742417	0.603	rs2531755	chr3:45772742	T/C	cg04837898	chr3:45731254	SACM1L	-0.67	-7.3	-0.55	3.06e-11	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs7949030	0.626	rs11231154	chr11:62362293	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.61	8.75	0.62	1.29e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	trans	rs9383153	1.000	rs9370888	chr6:16335544	A/G	cg11826961	chr17:38221639	THRA	0.59	6.65	0.51	8.31e-10	Gambling;
TGCT	cis	rs6578985	1.000	rs116226565	chr11:2148166	C/G	cg25742037	chr11:2171694	INS-IGF2;IGF2	0.24	4.66	0.39	8.07e-6	Femoral neck bone geometry and menarche (age at onset);
TGCT	cis	rs950027	0.620	rs1145089	chr15:45652054	G/C	cg14582100	chr15:45693742	SPATA5L1	0.47	6.02	0.48	1.8e-8	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg21285383	chr16:89894308	SPIRE2	0.46	7.19	0.54	5.44e-11	Vitiligo;
TGCT	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg11764359	chr7:65958608	NA	0.55	5.08	0.42	1.34e-6	Aortic root size;
TGCT	cis	rs912057	1.000	rs912057	chr6:6736931	C/T	cg06612196	chr6:6737390	NA	-0.38	-4.89	-0.4	3.02e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg05368731	chr17:41323189	NBR1	1.15	13.39	0.77	7.57e-26	Menopause (age at onset);
TGCT	cis	rs3733585	0.638	rs7377625	chr4:9953099	T/C	cg00071950	chr4:10020882	SLC2A9	-0.55	-6.58	-0.51	1.21e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg16680214	chr1:154839983	KCNN3	-0.36	-7.26	-0.55	3.81e-11	Prostate cancer;
TGCT	cis	rs16957091	0.602	rs7178248	chr15:43199519	C/T	cg17935677	chr15:44119062	WDR76	0.52	4.71	0.39	6.44e-6	MGMT methylation in smokers;
TGCT	cis	rs2439831	0.681	rs1549525	chr15:43627855	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.04	8.86	0.62	7.03e-15	Lung cancer in ever smokers;
TGCT	cis	rs921968	0.643	rs586374	chr2:219383003	A/C	cg02176678	chr2:219576539	TTLL4	0.44	6.33	0.49	4.17e-9	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs858239	0.539	rs10254544	chr7:23220235	T/C	cg05602783	chr7:23145260	KLHL7	-0.68	-5.31	-0.43	4.98e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs1153858	1.000	rs1153858	chr15:45652703	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.49	-5.75	-0.46	6.63e-8	Homoarginine levels;
TGCT	cis	rs11098499	0.644	rs10009566	chr4:120558608	A/G	cg24670566	chr4:120433619	PDE5A	0.23	4.46	0.37	1.85e-5	Corneal astigmatism;
TGCT	cis	rs6671200	1.000	rs71654418	chr1:95662658	G/T	cg26537280	chr1:95699037	RWDD3	0.68	5.49	0.44	2.15e-7	Stearic acid (18:0) levels;
TGCT	cis	rs10751667	0.600	rs10751665	chr11:941300	G/A	cg06064525	chr11:970664	AP2A2	-0.35	-8.09	-0.59	4.54e-13	Alzheimer's disease (late onset);
TGCT	cis	rs6684514	1.000	rs12117947	chr1:156244058	A/T	cg20302342	chr1:156215951	PAQR6	0.34	4.6	0.38	1.01e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs17270561	0.514	rs10946805	chr6:26077891	C/T	cg16482183	chr6:26056742	HIST1H1C	1.0	7.6	0.56	6.14e-12	Iron status biomarkers;
TGCT	cis	rs694739	0.628	rs10897487	chr11:64140704	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.7	6.8	0.52	4.02e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg22433210	chr17:43662623	NA	-1.0	-7.13	-0.54	7.26e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	8.27	0.6	1.72e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs12510870	0.565	rs7687216	chr4:74411253	T/C	cg05868023	chr4:75230803	EREG	0.53	4.63	0.38	9.08e-6	Iris color (b* coordinate);
TGCT	cis	rs7662987	0.517	rs2602873	chr4:100039032	G/C	cg12011299	chr4:100065546	ADH4	0.39	4.81	0.4	4.36e-6	Smoking initiation;
TGCT	cis	rs910316	0.935	rs175422	chr14:75627319	T/A	cg08847533	chr14:75593920	NEK9	-0.92	-9.96	-0.67	1.6e-17	Height;
TGCT	cis	rs7809950	0.593	rs62482503	chr7:106987988	A/G	cg23024343	chr7:107201750	COG5	-0.43	-5.85	-0.47	4.12e-8	Coronary artery disease;
TGCT	cis	rs1568889	0.712	rs4567438	chr11:28380051	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	5.5	0.44	2.1e-7	Bipolar disorder;
TGCT	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg21862992	chr11:68658383	NA	0.46	6.57	0.51	1.25e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7586879	0.789	rs67221599	chr2:25131948	T/C	cg01884057	chr2:25150051	NA	0.27	4.83	0.4	3.94e-6	Body mass index;
TGCT	cis	rs28493229	0.786	rs73546894	chr19:41189203	C/T	cg11601297	chr19:41224147	ITPKC;ADCK4	0.57	5.49	0.44	2.18e-7	Kawasaki disease;
TGCT	cis	rs4478858	0.698	rs11802155	chr1:31805012	T/C	cg00250761	chr1:31883323	NA	-0.28	-4.96	-0.41	2.32e-6	Alcohol dependence;
TGCT	cis	rs79349575	0.749	rs58838744	chr17:46998902	A/G	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.51	-0.38	1.48e-5	Type 2 diabetes;
TGCT	cis	rs9486719	1.000	rs2064947	chr6:97052754	C/T	cg18709589	chr6:96969512	KIAA0776	-0.74	-5.21	-0.42	7.5e-7	Migraine;Coronary artery disease;
TGCT	cis	rs3749237	1.000	rs4768	chr3:49758764	A/G	cg10152585	chr3:50297680	NA	0.49	4.47	0.37	1.77e-5	Resting heart rate;
TGCT	cis	rs68170813	0.559	rs6971774	chr7:106834139	A/G	cg02696742	chr7:106810147	HBP1	-0.66	-5.58	-0.45	1.41e-7	Coronary artery disease;
TGCT	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs782590	0.774	rs782637	chr2:55894247	T/C	cg03859395	chr2:55845619	SMEK2	0.85	9.64	0.65	9.63e-17	Metabolic syndrome;
TGCT	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg05872129	chr22:39784769	NA	-1.01	-11.09	-0.71	2.82e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs9902453	1.000	rs62070312	chr17:28438877	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.74	6.6	0.51	1.07e-9	Coffee consumption (cups per day);
TGCT	cis	rs752092	1.000	rs11247277	chr15:101784664	A/G	cg25114630	chr15:101792522	CHSY1	0.56	5.36	0.43	3.88e-7	Corneal structure;
TGCT	cis	rs8072100	0.713	rs11651643	chr17:45483229	A/G	cg08085267	chr17:45401833	C17orf57	-0.52	-5.75	-0.46	6.48e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs10927875	0.541	rs761759	chr1:16342350	A/T	cg22431228	chr1:16359049	CLCNKA	-0.29	-6.07	-0.48	1.42e-8	Dilated cardiomyopathy;
TGCT	cis	rs6809651	0.524	rs4686728	chr3:185795333	C/T	cg00760338	chr3:185826511	ETV5	0.75	6.04	0.48	1.64e-8	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
TGCT	cis	rs6938	0.534	rs4886636	chr15:75196176	G/A	cg09165964	chr15:75287851	SCAMP5	0.55	5.32	0.43	4.67e-7	Breast cancer;
TGCT	cis	rs4680	0.737	rs6269	chr22:19949952	A/G	cg22546130	chr22:19950026	COMT	-0.35	-5.26	-0.43	6.21e-7	Blood metabolite levels;
TGCT	cis	rs1045714	0.895	rs73043182	chr7:2646005	C/T	cg17215154	chr7:2644645	IQCE	0.28	4.92	0.4	2.75e-6	Urate levels in lean individuals;
TGCT	cis	rs362296	0.511	rs2857861	chr4:3323767	C/T	cg06533319	chr4:3265114	C4orf44	-0.21	-4.63	-0.38	9.27e-6	Parental longevity (mother's age at death);
TGCT	cis	rs10256972	0.647	rs10233430	chr7:1051664	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.47	-5.47	-0.44	2.35e-7	Longevity;Endometriosis;
TGCT	cis	rs41271951	0.512	rs12074309	chr1:151087827	T/C	cg00666978	chr1:150947442	LASS2	0.89	4.64	0.38	8.54e-6	Blood protein levels;
TGCT	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.01	8.32	0.6	1.34e-13	Platelet count;
TGCT	cis	rs617791	0.678	rs551659	chr11:65749645	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.69	6.77	0.52	4.5e-10	Breast cancer;
TGCT	cis	rs2404602	0.692	rs58973160	chr15:77000342	T/C	cg22467129	chr15:76604101	ETFA	-0.45	-5.11	-0.42	1.19e-6	Blood metabolite levels;
TGCT	cis	rs1371867	0.839	rs1788186	chr8:101335686	T/C	cg00191853	chr8:101177733	SPAG1	-0.23	-4.76	-0.39	5.2e-6	Atrioventricular conduction;
TGCT	cis	rs7246657	0.943	rs3745765	chr19:37854235	G/T	cg03233940	chr19:37894644	NA	-0.34	-4.49	-0.37	1.59e-5	Coronary artery calcification;
TGCT	cis	rs11190604	1.000	rs3750627	chr10:102275642	G/T	cg16342193	chr10:102329863	NA	-0.42	-5.45	-0.44	2.6e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9549367	0.789	rs9549718	chr13:113909822	A/G	cg00898013	chr13:113819073	PROZ	-0.41	-5.09	-0.42	1.31e-6	Platelet distribution width;
TGCT	cis	rs17539620	0.534	rs7768635	chr6:154827861	C/T	cg20019720	chr6:154832845	CNKSR3	0.46	4.46	0.37	1.79e-5	Lipoprotein (a) levels;
TGCT	cis	rs9902453	0.967	rs17825877	chr17:28515188	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	6.3	0.49	4.72e-9	Coffee consumption (cups per day);
TGCT	cis	rs910316	0.699	rs175039	chr14:75468950	G/C	cg08847533	chr14:75593920	NEK9	-0.84	-8.91	-0.62	5.45e-15	Height;
TGCT	cis	rs950169	0.887	rs71395453	chr15:85113490	G/C	cg11189052	chr15:85197271	WDR73	0.77	6.44	0.5	2.34e-9	Schizophrenia;
TGCT	cis	rs7582180	0.764	rs11683121	chr2:100920705	C/T	cg14675211	chr2:100938903	LONRF2	0.49	4.8	0.4	4.45e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2153535	0.580	rs1932275	chr6:8442333	T/A	cg07606381	chr6:8435919	SLC35B3	0.57	5.25	0.43	6.46e-7	Motion sickness;
TGCT	cis	rs350251	0.837	rs1641850	chr16:12188433	C/G	cg01574788	chr16:12184133	SNX29	0.36	4.74	0.39	5.87e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6671200	1.000	rs35179427	chr1:95670888	G/A	cg03123541	chr1:95699097	RWDD3	0.87	6.17	0.48	8.81e-9	Stearic acid (18:0) levels;
TGCT	trans	rs4332037	1.000	rs10240470	chr7:1949971	G/T	cg25206134	chr2:45395956	NA	-1.12	-9.49	-0.65	2.13e-16	Bipolar disorder;
TGCT	cis	rs4449834	0.851	rs6982898	chr8:61704083	C/T	cg12485212	chr8:61565947	NA	-0.59	-4.61	-0.38	9.88e-6	Sum eosinophil basophil counts;
TGCT	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg13695892	chr22:41940480	POLR3H	-0.9	-9.01	-0.63	3.17e-15	Vitiligo;
TGCT	cis	rs3096299	0.632	rs4399533	chr16:89539382	G/C	cg02187348	chr16:89574699	SPG7	0.62	6.66	0.51	7.91e-10	Multiple myeloma (IgH translocation);
TGCT	cis	rs7103648	0.966	rs1534576	chr11:47419663	A/C	cg20307385	chr11:47447363	PSMC3	-1.04	-12.01	-0.73	1.65e-22	Diastolic blood pressure;Systolic blood pressure;
TGCT	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.66	6.16	0.48	9.18e-9	Bipolar disorder;
TGCT	cis	rs7226408	0.857	rs72885278	chr18:34441154	T/C	cg06757138	chr18:34340585	FHOD3	0.25	4.74	0.39	5.85e-6	Obesity-related traits;
TGCT	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg11764359	chr7:65958608	NA	0.58	5.33	0.43	4.47e-7	Aortic root size;
TGCT	cis	rs782590	1.000	rs782590	chr2:55843413	C/T	cg18811423	chr2:55921094	PNPT1	0.65	6.77	0.52	4.64e-10	Metabolic syndrome;
TGCT	cis	rs910316	0.967	rs11159116	chr14:75550584	G/T	cg08847533	chr14:75593920	NEK9	0.96	10.9	0.7	8.37e-20	Height;
TGCT	cis	rs13191362	1.000	rs34773528	chr6:163088796	G/C	cg06582575	chr6:163149167	PACRG;PARK2	0.98	7.66	0.57	4.67e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs9647570	0.668	rs11134473	chr5:167270818	G/A	cg11091196	chr5:167285540	ODZ2	0.32	4.71	0.39	6.62e-6	Menarche (age at onset);
TGCT	cis	rs2288073	0.965	rs10469924	chr2:24416230	G/A	cg02683114	chr2:24398427	C2orf84	-0.25	-5.67	-0.45	9.72e-8	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs9398235	1.000	rs9398235	chr6:110732116	A/G	cg00083206	chr6:110721305	DDO	-0.45	-4.72	-0.39	6.22e-6	Systemic lupus erythematosus;
TGCT	trans	rs12339966	0.581	rs56080329	chr9:11330372	A/G	cg03488587	chr11:64876988	C11orf2	0.32	7.03	0.53	1.19e-10	Systolic blood pressure;
TGCT	cis	rs514406	0.893	rs1242315	chr1:53417181	A/G	cg22166914	chr1:53195759	ZYG11B	0.37	6.34	0.5	3.81e-9	Monocyte count;
TGCT	cis	rs10875595	0.691	rs1076361	chr5:140674609	C/T	cg20560182	chr5:140700478	TAF7	-0.65	-4.68	-0.39	7.3e-6	Pulmonary function decline;
TGCT	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg13607699	chr17:42295918	UBTF	0.59	5.46	0.44	2.53e-7	Total body bone mineral density;
TGCT	cis	rs362272	0.505	rs60208975	chr4:3364530	A/G	cg22655196	chr4:3374909	RGS12	0.24	4.91	0.4	2.8e-6	Serum sulfate level;
TGCT	cis	rs6500602	0.563	rs917305	chr16:4440593	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.38	5.56	0.45	1.55e-7	Schizophrenia;
TGCT	cis	rs595982	0.559	rs117227130	chr19:49367959	A/G	cg21252483	chr19:49399788	TULP2	-0.42	-6.39	-0.5	3.02e-9	Red cell distribution width;
TGCT	cis	rs7267979	1.000	rs2500443	chr20:25331442	C/T	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11779988	0.545	rs208763	chr8:17806482	G/A	cg01800426	chr8:17659068	MTUS1	-0.64	-4.99	-0.41	2.02e-6	Breast cancer;
TGCT	cis	rs10992471	0.528	rs1924243	chr9:95224847	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.52	-4.91	-0.4	2.8e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs2075371	0.933	rs432336	chr7:133949064	A/G	cg11752832	chr7:134001865	SLC35B4	0.68	5.88	0.47	3.48e-8	Mean platelet volume;
TGCT	cis	rs910316	1.000	rs12589376	chr14:75561152	C/T	cg08847533	chr14:75593920	NEK9	0.96	10.6	0.69	4.3e-19	Height;
TGCT	cis	rs3617	0.573	rs13072537	chr3:52896032	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	4.61	0.38	9.76e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs17401966	0.540	rs10864452	chr1:10395683	G/T	cg19773385	chr1:10388646	KIF1B	-0.21	-5.07	-0.41	1.44e-6	Hepatocellular carcinoma;
TGCT	cis	rs1372520	0.684	rs2619355	chr4:90748374	A/C	cg01966878	chr4:90757139	SNCA	-0.3	-4.76	-0.39	5.2e-6	Neuroticism;
TGCT	cis	rs6558530	0.692	rs7818406	chr8:1701250	C/T	cg09410841	chr8:1729607	CLN8	0.72	6.49	0.5	1.87e-9	Systolic blood pressure;
TGCT	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg13395646	chr4:1353034	KIAA1530	-0.39	-4.82	-0.4	4.08e-6	Longevity;
TGCT	cis	rs10875746	0.669	rs10875772	chr12:48609553	C/T	cg20731937	chr12:48336164	NA	0.65	4.96	0.41	2.31e-6	Longevity (90 years and older);
TGCT	cis	rs13256369	0.802	rs12680019	chr8:8561698	A/G	cg18904891	chr8:8559673	CLDN23	0.57	5.27	0.43	5.87e-7	Obesity-related traits;
TGCT	cis	rs1008375	0.646	rs4235387	chr4:17569327	T/G	cg10189774	chr4:17578691	LAP3	0.65	5.5	0.44	2.1e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs933688	1.000	rs6865495	chr5:90746424	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	9.32	0.64	5.66e-16	Smoking behavior;
TGCT	cis	rs9972944	0.702	rs987930	chr17:63765862	C/T	cg07283582	chr17:63770753	CCDC46	-0.26	-5.3	-0.43	5.02e-7	Total body bone mineral density;
TGCT	cis	rs57920188	0.585	rs6703106	chr1:4068337	C/T	cg20703997	chr1:4087676	NA	0.48	5.91	0.47	3.14e-8	Interleukin-17 levels;
TGCT	cis	rs11673344	0.523	rs7260488	chr19:37549785	G/A	cg08039142	chr19:36980659	ZNF566	0.5	4.64	0.38	8.58e-6	Obesity-related traits;
TGCT	cis	rs12497850	0.931	rs10780033	chr3:48891275	T/C	cg07636037	chr3:49044803	WDR6	0.95	10.74	0.69	2e-19	Parkinson's disease;
TGCT	cis	rs9400467	0.537	rs12214886	chr6:111500081	C/T	cg15721981	chr6:111408429	SLC16A10	0.7	4.48	0.37	1.66e-5	Blood metabolite levels;Amino acid levels;
TGCT	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg22166914	chr1:53195759	ZYG11B	0.3	4.87	0.4	3.29e-6	Monocyte count;
TGCT	cis	rs112591243	0.614	rs78654337	chr21:47824372	A/G	cg10657630	chr21:48055338	PRMT2	1.06	5.27	0.43	5.79e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs858239	0.669	rs1618339	chr7:23229774	T/C	cg05602783	chr7:23145260	KLHL7	-0.55	-4.54	-0.38	1.32e-5	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs4455778	0.538	rs7786675	chr7:49123150	C/T	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs4252435	0.614	rs8176036	chr7:142640596	T/G	cg09833174	chr7:143059591	FAM131B	-1.02	-4.65	-0.39	8.26e-6	Cancer;
TGCT	cis	rs950169	0.922	rs4842941	chr15:84831312	G/C	cg11189052	chr15:85197271	WDR73	-0.81	-6.5	-0.5	1.78e-9	Schizophrenia;
TGCT	cis	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg18188782	chr20:61659543	NA	0.44	5.38	0.43	3.6e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7552404	0.889	rs2211080	chr1:76243438	G/A	cg10523679	chr1:76189770	ACADM	0.77	7.43	0.56	1.52e-11	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg13397359	chr6:42928475	GNMT	0.73	6.81	0.52	3.7e-10	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs921968	0.541	rs3731867	chr2:219472734	G/A	cg02176678	chr2:219576539	TTLL4	-0.49	-6.85	-0.52	3.03e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs597480	0.853	rs475380	chr11:85446708	T/A	cg11817631	chr11:85522609	SYTL2	-0.48	-4.81	-0.4	4.23e-6	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);
TGCT	cis	rs10851411	0.908	rs10851410	chr15:42844788	A/G	cg23803468	chr15:43513504	EPB42	0.27	5.16	0.42	9.47e-7	Glucose homeostasis traits;
TGCT	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs2070488	0.699	rs6599205	chr3:38529440	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.69	6.13	0.48	1.09e-8	Electrocardiographic conduction measures;
TGCT	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg17971929	chr21:40555470	PSMG1	0.97	8.85	0.62	7.27e-15	Cognitive function;
TGCT	cis	rs4824093	0.610	rs4141437	chr22:50243719	C/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.45	-4.65	-0.39	8.43e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs4786125	0.512	rs55694271	chr16:6930378	G/A	cg03623568	chr16:6915990	A2BP1	-0.41	-5.71	-0.46	7.91e-8	Heart rate variability traits (SDNN);
TGCT	cis	rs669446	0.531	rs673485	chr1:44087496	C/T	cg12908607	chr1:44402522	ARTN	-0.44	-4.58	-0.38	1.11e-5	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs3087591	0.879	rs59015798	chr17:29580882	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.43	-6.43	-0.5	2.53e-9	Hip circumference;
TGCT	trans	rs1814175	0.817	rs10769648	chr11:50013992	T/C	cg03929089	chr4:120376271	NA	-0.72	-8.55	-0.61	3.8e-14	Height;
TGCT	cis	rs6582630	0.537	rs11520294	chr12:38402705	C/A	cg26384229	chr12:38710491	ALG10B	0.84	7.42	0.55	1.62e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs35306767	0.903	rs35637113	chr10:874149	G/C	cg26597838	chr10:835615	NA	0.71	10.12	0.67	6.47e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs13242816	1.000	rs17138747	chr7:116132670	G/A	cg16553024	chr7:116138462	CAV2	-0.45	-5.04	-0.41	1.57e-6	P wave duration;
TGCT	cis	rs7312933	0.524	rs11181465	chr12:42765098	T/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.54	5.14	0.42	1.03e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs9487051	0.714	rs7757347	chr6:109633815	G/A	cg01475377	chr6:109611718	NA	-0.31	-4.73	-0.39	6.12e-6	Reticulocyte fraction of red cells;
TGCT	cis	rs6669384	0.737	rs12145290	chr1:208037821	C/T	cg22525895	chr1:207977042	MIR29B2	-0.4	-5.53	-0.44	1.8e-7	Immune response to measles vaccine (measles-specific neutralising antibody titre);
TGCT	cis	rs8062405	1.000	rs9972693	chr16:28859802	A/G	cg09754948	chr16:28834200	ATXN2L	0.59	4.45	0.37	1.91e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs7552404	0.961	rs17587071	chr1:76225083	A/C	cg03433033	chr1:76189801	ACADM	0.84	9.57	0.65	1.38e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2795502	0.873	rs1891324	chr10:43399581	A/G	cg20628663	chr10:43360327	NA	0.36	5.45	0.44	2.66e-7	Blood protein levels;
TGCT	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg05368731	chr17:41323189	NBR1	1.16	13.76	0.78	1.03e-26	Menopause (age at onset);
TGCT	cis	rs9611565	0.694	rs79008	chr22:41850500	C/T	cg13695892	chr22:41940480	POLR3H	-0.91	-8.81	-0.62	9.48e-15	Vitiligo;
TGCT	cis	rs6500602	0.893	rs4785962	chr16:4484328	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.29	4.9	0.4	2.99e-6	Schizophrenia;
TGCT	cis	rs9443645	0.901	rs9341754	chr6:79584973	A/C	cg09184832	chr6:79620586	NA	-0.49	-5.29	-0.43	5.29e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7927771	0.832	rs935914	chr11:47387599	C/T	cg21462715	chr11:47870315	NUP160	-0.56	-4.63	-0.38	9.16e-6	Subjective well-being;
TGCT	cis	rs832540	0.656	rs832573	chr5:56159578	T/C	cg24531977	chr5:56204891	C5orf35	-0.51	-4.94	-0.41	2.43e-6	Coronary artery disease;
TGCT	cis	rs1153858	1.000	rs1719247	chr15:45620985	C/T	cg14582100	chr15:45693742	SPATA5L1	0.49	5.82	0.46	4.77e-8	Homoarginine levels;
TGCT	cis	rs2688608	0.617	rs6480709	chr10:75479125	T/C	cg04320760	chr10:75533139	FUT11	-0.39	-6.01	-0.48	1.89e-8	Inflammatory bowel disease;
TGCT	cis	rs17125944	0.505	rs75296244	chr14:53233218	G/A	cg00686598	chr14:53173677	PSMC6	1.08	6.32	0.49	4.37e-9	Alzheimer's disease (late onset);
TGCT	cis	rs6459788	0.585	rs6950818	chr7:157235364	C/G	cg06271696	chr7:157225062	NA	-0.37	-7.01	-0.53	1.34e-10	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs11190604	0.767	rs11190509	chr10:102156208	G/A	cg23241863	chr10:102295624	HIF1AN	0.61	4.58	0.38	1.12e-5	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs6671200	0.607	rs3767313	chr1:95712797	G/A	cg26537280	chr1:95699037	RWDD3	-0.51	-4.9	-0.4	2.94e-6	Stearic acid (18:0) levels;
TGCT	cis	rs2016266	0.784	rs7308162	chr12:53654956	G/A	cg16917193	chr12:54089295	NA	0.67	4.89	0.4	3.05e-6	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg20637647	chr7:64974828	NA	-0.95	-5.3	-0.43	5.09e-7	Diabetic kidney disease;
TGCT	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg04944784	chr2:26401820	FAM59B	-0.81	-6.87	-0.52	2.82e-10	Gut microbiome composition (summer);
TGCT	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg17971929	chr21:40555470	PSMG1	-0.52	-4.71	-0.39	6.45e-6	Menarche (age at onset);
TGCT	cis	rs6088590	1.000	rs6119516	chr20:33328024	C/T	cg24642439	chr20:33292090	TP53INP2	0.69	6.02	0.48	1.85e-8	Coronary artery disease;
TGCT	cis	rs59107033	0.607	rs6771700	chr3:123117488	C/T	cg04890266	chr3:123102914	ADCY5	-0.37	-5.12	-0.42	1.13e-6	Lymphocyte counts;
TGCT	cis	rs6570726	0.791	rs11155435	chr6:145938545	T/C	cg23711669	chr6:146136114	FBXO30	0.89	9.69	0.66	7.3e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg16049864	chr8:95962084	TP53INP1	-0.73	-10.22	-0.68	3.63e-18	Type 2 diabetes;
TGCT	cis	rs35883536	0.647	rs2783693	chr1:101045040	C/T	cg06223162	chr1:101003688	GPR88	0.42	7.84	0.58	1.77e-12	Monocyte count;
TGCT	cis	rs57590327	0.679	rs17019030	chr3:81552062	C/T	cg07356753	chr3:81810745	GBE1	-0.55	-4.54	-0.38	1.3e-5	Extraversion;
TGCT	cis	rs713587	0.563	rs10865315	chr2:25100738	C/A	cg01884057	chr2:25150051	NA	0.31	5.82	0.46	4.63e-8	Body mass index in non-asthmatics;
TGCT	cis	rs968567	0.539	rs174560	chr11:61581764	T/C	cg19610905	chr11:61596333	FADS2	-1.07	-11.78	-0.73	5.92e-22	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
TGCT	cis	rs4689388	0.926	rs3889821	chr4:6282596	C/T	cg25554036	chr4:6271136	WFS1	0.55	8.09	0.59	4.65e-13	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs2742417	1.000	rs2742423	chr3:45733430	A/G	cg04837898	chr3:45731254	SACM1L	-0.56	-5.92	-0.47	2.89e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs9362426	0.895	rs242292	chr6:88078074	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.44	5.07	0.41	1.43e-6	Depressive episodes in bipolar disorder;
TGCT	cis	rs12950390	0.893	rs12325760	chr17:45840886	C/T	cg06532163	chr17:45867833	NA	0.34	5.31	0.43	4.82e-7	IgG glycosylation;
TGCT	cis	rs1997103	0.906	rs4618644	chr7:55402037	T/G	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs5760092	0.755	rs3884794	chr22:24251766	C/A	cg25703541	chr22:24373054	LOC391322	-0.78	-6.8	-0.52	3.94e-10	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs1555895	0.576	rs12413763	chr10:849454	A/G	cg02193355	chr10:851439	NA	0.22	4.96	0.41	2.28e-6	Survival in rectal cancer;
TGCT	cis	rs17767294	0.708	rs72848763	chr6:27902488	A/G	cg08851530	chr6:28072375	NA	1.56	7.22	0.54	4.47e-11	Parkinson's disease;
TGCT	cis	rs7666738	0.546	rs10007424	chr4:98885450	C/T	cg05340658	chr4:99064831	C4orf37	0.58	6.18	0.49	8.3e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs35000415	0.688	rs13222044	chr7:128716525	C/T	cg06242719	chr7:129414860	MIR183;MIR96	-0.3	-4.58	-0.38	1.1e-5	Systemic lupus erythematosus;
TGCT	cis	rs2786098	0.577	rs10922304	chr1:197820945	C/A	cg00114966	chr1:197893920	LHX9	0.38	4.62	0.38	9.45e-6	Asthma;
TGCT	cis	rs4727027	0.870	rs1568945	chr7:148874112	T/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	4.77	0.39	5.16e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs7824557	0.737	rs2293855	chr8:11177410	G/A	cg21775007	chr8:11205619	TDH	0.52	4.97	0.41	2.22e-6	Retinal vascular caliber;
TGCT	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg06238570	chr21:40685208	BRWD1	-0.84	-9.31	-0.64	6.01e-16	Cognitive function;
TGCT	cis	rs950169	0.840	rs4842854	chr15:84942339	T/G	cg12863693	chr15:85201151	NMB	0.45	4.96	0.41	2.28e-6	Schizophrenia;
TGCT	cis	rs6977660	0.507	rs72591449	chr7:19775443	T/C	cg07541023	chr7:19748670	TWISTNB	1.01	6.55	0.51	1.39e-9	Thyroid stimulating hormone;
TGCT	cis	rs2014572	0.967	rs7248000	chr19:57762139	C/T	cg24459738	chr19:57751996	ZNF805	-0.58	-5.69	-0.46	8.5e-8	Hyperactive-impulsive symptoms;
TGCT	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg13206674	chr6:150067644	NUP43	0.53	4.56	0.38	1.23e-5	Lung cancer;
TGCT	cis	rs2153535	0.580	rs2327057	chr6:8443319	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.58	0.45	1.42e-7	Motion sickness;
TGCT	cis	rs7659604	1.000	rs28640980	chr4:122664284	T/C	cg19748678	chr4:122722346	EXOSC9	0.57	5.54	0.45	1.69e-7	Type 2 diabetes;
TGCT	cis	rs7267979	1.000	rs2258879	chr20:25279213	T/C	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7552404	0.727	rs7521344	chr1:76318325	C/T	cg22875332	chr1:76189707	ACADM	-0.58	-6.24	-0.49	6.18e-9	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9972944	0.756	rs7220733	chr17:63764890	A/T	cg07283582	chr17:63770753	CCDC46	-0.23	-4.89	-0.4	3.03e-6	Total body bone mineral density;
TGCT	cis	rs13191362	0.810	rs13209784	chr6:162961274	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.66	5.11	0.42	1.17e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs9300255	0.602	rs1716164	chr12:123663660	G/A	cg00376283	chr12:123451042	ABCB9	0.72	5.61	0.45	1.27e-7	Neutrophil percentage of white cells;
TGCT	cis	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg13531842	chr10:38383804	ZNF37A	-0.39	-4.64	-0.38	8.78e-6	Extrinsic epigenetic age acceleration;
TGCT	cis	rs9611565	0.525	rs1883827	chr22:41703579	A/G	cg13695892	chr22:41940480	POLR3H	-0.64	-6.03	-0.48	1.78e-8	Vitiligo;
TGCT	cis	rs1008375	0.932	rs9884565	chr4:17655096	A/G	cg10189774	chr4:17578691	LAP3	0.58	4.99	0.41	1.96e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg24250549	chr1:154909240	PMVK	0.66	6.5	0.5	1.73e-9	Prostate cancer;
TGCT	cis	rs427394	0.659	rs187295	chr5:6734326	C/T	cg10857441	chr5:6722123	POLS	-0.27	-5.7	-0.46	8.2e-8	Menopause (age at onset);
TGCT	cis	rs11578119	0.933	rs10919417	chr1:170442454	A/C	cg09767346	chr1:170501363	GORAB	0.71	5.68	0.45	9.07e-8	Male-pattern baldness;
TGCT	cis	rs72615157	0.645	rs11771660	chr7:99851269	T/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.61	4.72	0.39	6.31e-6	Lung function (FEV1/FVC);
TGCT	cis	rs669446	0.561	rs641365	chr1:44083507	A/G	cg12908607	chr1:44402522	ARTN	-0.57	-6.2	-0.49	7.8e-9	Amyotrophic lateral sclerosis (age of onset);
TGCT	trans	rs11722228	0.508	rs61335146	chr4:10130793	G/C	cg26043149	chr18:55253948	FECH	1.24	14.45	0.79	2.36e-28	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs11249608	0.548	rs7733072	chr5:178456007	A/G	cg23951258	chr5:178450506	ZNF879	0.44	4.54	0.38	1.32e-5	Pubertal anthropometrics;
TGCT	cis	rs9929218	0.551	rs9888942	chr16:68727572	A/G	cg01251360	chr16:68772225	CDH1	-0.28	-5.31	-0.43	4.95e-7	Colorectal cancer;
TGCT	cis	rs9831754	0.906	rs9869812	chr3:78385679	G/A	cg06138941	chr3:78371609	NA	-0.49	-5.4	-0.44	3.25e-7	Calcium levels;
TGCT	cis	rs11098499	0.954	rs17009122	chr4:120362403	G/A	cg09307838	chr4:120376055	NA	0.68	6.53	0.51	1.54e-9	Corneal astigmatism;
TGCT	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg16497277	chr3:49208875	KLHDC8B	0.53	5.13	0.42	1.09e-6	Menarche (age at onset);
TGCT	cis	rs67311347	1.000	rs6801185	chr3:40505060	C/T	cg17264618	chr3:40429014	ENTPD3	-0.33	-4.85	-0.4	3.66e-6	Renal cell carcinoma;
TGCT	cis	rs2017387	0.572	rs157548	chr19:50540237	A/G	cg19230443	chr19:49950584	PIH1D1	-0.29	-4.69	-0.39	7.22e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
TGCT	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg06238570	chr21:40685208	BRWD1	0.72	6.58	0.51	1.16e-9	Cognitive function;
TGCT	cis	rs1784581	0.588	rs9355971	chr6:162421242	A/G	cg17173639	chr6:162384350	PARK2	0.39	6.5	0.5	1.73e-9	Itch intensity from mosquito bite;
TGCT	cis	rs6138458	1.000	rs227629	chr20:24913551	G/T	cg26195577	chr20:24973756	C20orf3	1.2	12.04	0.73	1.35e-22	Blood protein levels;
TGCT	cis	rs7819412	0.745	rs28464654	chr8:11080665	T/A	cg21775007	chr8:11205619	TDH	-0.56	-5.15	-0.42	9.93e-7	Triglycerides;
TGCT	cis	rs7666738	0.830	rs28810677	chr4:99043193	C/T	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	8.16	0.59	3.1400000000000003e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs804292	1.000	rs804292	chr8:11643915	C/T	cg26752888	chr8:11627280	NEIL2	-1.03	-12.0	-0.73	1.72e-22	Alcohol dependence;Nicotine use;
TGCT	cis	rs4450131	1.000	rs10901799	chr10:126348274	A/G	cg20435097	chr10:126320824	FAM53B	-0.18	-4.59	-0.38	1.09e-5	White blood cell count (basophil);
TGCT	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg03517284	chr6:25882590	NA	0.89	9.12	0.63	1.72e-15	Blood metabolite levels;
TGCT	cis	rs40363	1.000	rs1690443	chr16:3517787	C/G	cg00484396	chr16:3507460	NAT15	0.42	5.05	0.41	1.51e-6	Tuberculosis;
TGCT	cis	rs227584	0.501	rs62078931	chr17:42198059	A/C	cg19774624	chr17:42201019	HDAC5	0.6	6.31	0.49	4.5e-9	Bone mineral density (hip);Bone mineral density;
TGCT	cis	rs2050392	0.590	rs685319	chr10:30719331	G/A	cg18806716	chr10:30721971	MAP3K8	-0.7	-9.39	-0.64	3.84e-16	Inflammatory bowel disease;
TGCT	cis	rs6722750	0.967	rs17754672	chr2:64400608	A/G	cg22352474	chr2:64371530	PELI1	-0.61	-5.34	-0.43	4.19e-7	Neuroticism;
TGCT	cis	rs910316	1.000	rs12435391	chr14:75601737	A/G	cg23033748	chr14:75592666	NEK9	0.28	4.81	0.4	4.24e-6	Height;
TGCT	cis	rs11148252	0.574	rs73186430	chr13:53232891	T/C	cg00495681	chr13:53174319	NA	0.72	7.5	0.56	1.07e-11	Lewy body disease;
TGCT	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg24250549	chr1:154909240	PMVK	0.66	6.56	0.51	1.31e-9	Prostate cancer;
TGCT	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg06618935	chr21:46677482	NA	-0.37	-5.01	-0.41	1.86e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2535633	0.661	rs4515041	chr3:52996032	T/A	cg10802521	chr3:52805072	NEK4	0.56	6.02	0.48	1.86e-8	Body mass index;
TGCT	cis	rs911555	0.755	rs11620897	chr14:103944861	T/G	cg12935359	chr14:103987150	CKB	-0.33	-4.59	-0.38	1.07e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs9905704	0.647	rs2036730	chr17:57038282	A/G	cg12560992	chr17:57184187	TRIM37	0.58	5.05	0.41	1.52e-6	Testicular germ cell tumor;
TGCT	cis	rs2354432	0.607	rs7537279	chr1:146673642	A/G	cg25205988	chr1:146714368	CHD1L	1.33	6.35	0.5	3.68e-9	Mitochondrial DNA levels;
TGCT	cis	rs826838	1.000	rs10880914	chr12:38720543	C/T	cg13010199	chr12:38710504	ALG10B	0.83	6.83	0.52	3.43e-10	Heart rate;
TGCT	cis	rs9486715	0.867	rs4240553	chr6:96965324	T/C	cg06623918	chr6:96969491	KIAA0776	1.1	15.44	0.81	1.17e-30	Headache;
TGCT	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.84	7.5	0.56	1.08e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2692947	0.726	rs13019188	chr2:96774199	A/G	cg22654517	chr2:96458247	NA	-0.22	-4.83	-0.4	3.96e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs9303401	0.614	rs2333409	chr17:57139134	G/A	cg25039879	chr17:56429692	SUPT4H1	0.54	4.84	0.4	3.85e-6	Cognitive test performance;
TGCT	cis	rs2997447	0.761	rs56299762	chr1:26441638	G/A	cg03844060	chr1:26490628	NA	0.28	4.55	0.38	1.27e-5	QRS complex (12-leadsum);
TGCT	cis	rs7095607	0.785	rs7081820	chr10:69914009	C/T	cg18986048	chr10:69913749	MYPN	0.43	4.87	0.4	3.29e-6	Lung function (FVC);
TGCT	cis	rs5758659	0.714	rs133373	chr22:42465788	G/A	cg15557168	chr22:42548783	NA	-0.18	-4.63	-0.38	9.08e-6	Cognitive function;
TGCT	cis	rs709400	1.000	rs8018979	chr14:104109087	G/A	cg26031613	chr14:104095156	KLC1	1.14	17.16	0.84	1.53e-34	Body mass index;
TGCT	trans	rs1814175	0.740	rs10839439	chr11:49918240	C/T	cg03929089	chr4:120376271	NA	-0.71	-8.09	-0.59	4.74e-13	Height;
TGCT	cis	rs8031584	0.958	rs11637469	chr15:31238783	T/C	cg08704250	chr15:31115839	NA	-0.36	-4.96	-0.41	2.29e-6	Huntington's disease progression;
TGCT	cis	rs3096299	0.869	rs748941	chr16:89440754	T/A	cg05504729	chr16:89399490	ANKRD11	-0.22	-4.44	-0.37	2e-5	Multiple myeloma (IgH translocation);
TGCT	cis	rs11190604	1.000	rs1054399	chr10:102312565	C/T	cg23241863	chr10:102295624	HIF1AN	0.68	5.13	0.42	1.08e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9858542	0.953	rs11715915	chr3:49455330	A/G	cg03060546	chr3:49711283	APEH	0.59	5.3	0.43	5.08e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.0	8.11	0.59	4.07e-13	Platelet count;
TGCT	cis	rs7100689	0.577	rs2282367	chr10:82040346	A/G	cg01528321	chr10:82214614	TSPAN14	0.69	6.64	0.51	8.59e-10	Post bronchodilator FEV1;
TGCT	cis	rs9457247	0.967	rs1590257	chr6:167377782	G/T	cg25258033	chr6:167368657	RNASET2	-0.18	-4.48	-0.37	1.64e-5	Crohn's disease;
TGCT	cis	rs236907	0.859	rs2294718	chr1:171750854	C/G	cg20598894	chr1:171756153	METTL13	-0.2	-4.54	-0.38	1.31e-5	Mean platelet volume;
TGCT	cis	rs28595532	0.920	rs17259173	chr4:119777232	T/C	cg14228332	chr4:119757509	SEC24D	1.26	7.08	0.54	9.26e-11	Cannabis dependence symptom count;
TGCT	cis	rs10795061	0.576	rs12219804	chr10:3710626	C/T	cg13668419	chr10:3197757	PITRM1	-0.18	-4.72	-0.39	6.14e-6	Subjective well-being;
TGCT	cis	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg07424592	chr7:64974309	NA	1.34	8.08	0.59	4.95e-13	Diabetic kidney disease;
TGCT	cis	rs3733585	0.579	rs4235353	chr4:10122934	C/T	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.45	-0.5	2.28e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs9674544	0.757	rs9896443	chr17:47125982	A/G	cg10950924	chr17:47092072	IGF2BP1	-0.31	-4.51	-0.38	1.48e-5	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
TGCT	cis	rs7552404	0.727	rs61770533	chr1:76306490	C/G	cg22875332	chr1:76189707	ACADM	0.63	6.74	0.52	5.33e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs6570726	0.935	rs390252	chr6:145856896	A/G	cg05347473	chr6:146136440	FBXO30	0.49	4.54	0.38	1.29e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7264396	0.676	rs6060727	chr20:34556000	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.04	-0.41	1.58e-6	Total cholesterol levels;
TGCT	cis	rs6671200	0.920	rs11165339	chr1:95674064	T/C	cg03123541	chr1:95699097	RWDD3	-0.87	-6.17	-0.48	8.81e-9	Stearic acid (18:0) levels;
TGCT	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg24846343	chr22:24311635	DDTL	0.23	5.79	0.46	5.54e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2463822	1.000	rs2513076	chr11:62103711	A/G	cg23876832	chr11:62092739	NA	0.67	4.91	0.4	2.82e-6	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs11779988	0.543	rs410445	chr8:17882304	C/T	cg01800426	chr8:17659068	MTUS1	-0.69	-5.59	-0.45	1.35e-7	Breast cancer;
TGCT	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg20607798	chr8:58055168	NA	-0.48	-4.78	-0.39	4.93e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9372498	0.536	rs62422220	chr6:118923731	G/A	cg07617317	chr6:118971624	C6orf204	0.49	5.22	0.42	7.37e-7	Diastolic blood pressure;
TGCT	cis	rs61612642	0.537	rs6915565	chr6:42192582	G/A	cg01092361	chr6:42185687	MRPS10	0.98	7.15	0.54	6.56e-11	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
TGCT	cis	rs7845219	0.544	rs7001535	chr8:95921090	C/G	cg16049864	chr8:95962084	TP53INP1	-0.48	-5.3	-0.43	5.23e-7	Type 2 diabetes;
TGCT	cis	rs10493773	0.609	rs11161664	chr1:86185379	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.52	-8.15	-0.59	3.45e-13	Urate levels in overweight individuals;
TGCT	cis	rs2486012	0.737	rs4660749	chr1:44250301	T/G	cg12908607	chr1:44402522	ARTN	-0.71	-5.61	-0.45	1.26e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs17102423	0.594	rs1998688	chr14:65562306	C/G	cg11161011	chr14:65562177	MAX	0.47	6.56	0.51	1.32e-9	Obesity-related traits;
TGCT	cis	rs4944092	0.855	rs608747	chr11:75916477	A/G	cg04588336	chr11:75916460	WNT11	-0.43	-5.89	-0.47	3.41e-8	PR interval;
TGCT	cis	rs10031466	1.000	rs2279550	chr4:189012728	G/C	cg14506195	chr4:188913931	NA	-0.25	-4.78	-0.39	4.86e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs10782582	0.609	rs11588643	chr1:76255613	A/G	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.52	4.54	0.38	1.31e-5	Daytime sleep phenotypes;
TGCT	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg22963979	chr7:1858916	MAD1L1	-0.34	-5.14	-0.42	1.05e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs7681440	0.874	rs1372522	chr4:90765280	A/G	cg14346243	chr4:90757452	SNCA	-0.57	-5.6	-0.45	1.31e-7	Dementia with Lewy bodies;
TGCT	cis	rs2046867	0.818	rs67355490	chr3:72830935	T/C	cg25664220	chr3:72788482	NA	-0.58	-7.21	-0.54	4.9e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs981844	0.601	rs62323856	chr4:154623149	T/C	cg14289246	chr4:154710475	SFRP2	1.0	8.1	0.59	4.42e-13	Response to statins (LDL cholesterol change);
TGCT	cis	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg20362242	chr5:692897	TPPP	0.48	4.51	0.38	1.47e-5	Lung disease severity in cystic fibrosis;
TGCT	cis	rs7666738	0.830	rs10012271	chr4:99065154	A/C	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.44e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1451375	0.657	rs12665904	chr7:50635399	A/G	cg18232548	chr7:50535776	DDC	0.46	7.1	0.54	8.31e-11	Malaria;
TGCT	cis	rs11696501	0.739	rs6104250	chr20:44251479	C/T	cg11783356	chr20:44313418	WFDC10B	-0.32	-4.63	-0.38	9.25e-6	Brain structure;
TGCT	cis	rs8177253	0.696	rs4459901	chr3:133465699	T/C	cg11941060	chr3:133502564	NA	-0.26	-5.19	-0.42	8.21e-7	Iron status biomarkers;
TGCT	cis	rs11214589	0.774	rs877137	chr11:113256330	C/T	cg14159747	chr11:113255604	NA	0.37	4.54	0.38	1.3e-5	Neuroticism;
TGCT	cis	rs36051895	0.623	rs10975024	chr9:5246403	A/T	cg02405213	chr9:5042618	JAK2	-0.72	-9.35	-0.64	4.76e-16	Pediatric autoimmune diseases;
TGCT	cis	rs1042445	1.000	rs1863622	chr3:186396616	C/T	cg13908232	chr3:186371902	NA	-0.42	-4.72	-0.39	6.38e-6	Blood protein levels;
TGCT	cis	rs6840360	0.550	rs7675818	chr4:152690777	C/G	cg22705602	chr4:152727874	NA	-0.34	-5.91	-0.47	3.06e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg03806693	chr22:41940476	POLR3H	1.11	12.05	0.73	1.3e-22	Vitiligo;
TGCT	cis	rs71636778	0.509	rs34473788	chr1:27271519	A/G	cg23921621	chr1:27994728	IFI6	-0.43	-4.61	-0.38	9.92e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
TGCT	cis	rs9372498	0.536	rs62424198	chr6:118827247	A/G	cg21191810	chr6:118973309	C6orf204	-0.36	-4.77	-0.39	5.1e-6	Diastolic blood pressure;
TGCT	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg08280861	chr8:58055591	NA	0.34	4.62	0.38	9.41e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs12989701	0.877	rs36085158	chr2:127869982	C/T	cg08168897	chr2:127865431	BIN1	0.5	5.34	0.43	4.28e-7	Alzheimer's disease (late onset);
TGCT	cis	rs6542838	0.702	rs4851167	chr2:99496303	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-4.67	-0.39	7.81e-6	Fear of minor pain;
TGCT	cis	rs782590	0.774	rs782632	chr2:55898290	C/G	cg03859395	chr2:55845619	SMEK2	0.85	9.64	0.65	9.63e-17	Metabolic syndrome;
TGCT	cis	rs10510102	0.872	rs75831447	chr10:123713478	A/G	cg23691251	chr10:123688108	ATE1	-0.59	-4.7	-0.39	6.75e-6	Breast cancer;
TGCT	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg12311346	chr5:56204834	C5orf35	-0.67	-6.82	-0.52	3.63e-10	Initial pursuit acceleration;
TGCT	cis	rs8072100	0.840	rs11079774	chr17:45479706	C/G	cg08085267	chr17:45401833	C17orf57	-0.5	-5.69	-0.46	8.6e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg04944784	chr2:26401820	FAM59B	0.65	6.07	0.48	1.45e-8	Gut microbiome composition (summer);
TGCT	cis	rs9926296	0.546	rs9935541	chr16:89905925	G/C	cg03388025	chr16:89894329	SPIRE2	0.36	5.32	0.43	4.75e-7	Vitiligo;
TGCT	cis	rs422249	0.896	rs174449	chr11:61640379	A/G	cg01500311	chr11:61656094	FADS3	-0.4	-7.91	-0.58	1.24e-12	Trans fatty acid levels;
TGCT	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg16423285	chr20:60520624	NA	-0.6	-6.41	-0.5	2.76e-9	Body mass index;
TGCT	cis	rs624899	0.522	rs645584	chr19:11612466	A/G	cg01045132	chr19:11649571	CNN1	0.6	7.22	0.54	4.59e-11	Presence of antiphospholipid antibodies;
TGCT	cis	rs7829975	0.501	rs2980769	chr8:8320291	G/A	cg06636001	chr8:8085503	FLJ10661	0.79	7.36	0.55	2.24e-11	Mood instability;
TGCT	cis	rs7904368	0.806	rs7899853	chr10:16857603	A/T	cg14835575	chr10:16859367	RSU1	0.72	7.76	0.57	2.67e-12	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
TGCT	cis	rs9467711	0.790	rs13195401	chr6:26463574	G/T	cg12315302	chr6:26189340	HIST1H4D	0.99	4.44	0.37	1.93e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4919694	0.901	rs74376228	chr10:104677662	G/C	cg04362960	chr10:104952993	NT5C2	1.05	6.9	0.53	2.39e-10	Arsenic metabolism;
TGCT	cis	rs9858542	0.903	rs11917431	chr3:49644012	C/T	cg03060546	chr3:49711283	APEH	-0.63	-5.48	-0.44	2.28e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs7681440	0.904	rs1442153	chr4:90775719	T/G	cg20003494	chr4:90757398	SNCA	-0.56	-5.35	-0.43	4.11e-7	Dementia with Lewy bodies;
TGCT	cis	rs1215050	0.818	rs165238	chr4:98712138	G/T	cg17366294	chr4:99064904	C4orf37	0.52	5.57	0.45	1.54e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	5.84	0.46	4.3e-8	Bipolar disorder;
TGCT	cis	rs16866061	1.000	rs17480230	chr2:225399864	G/A	cg12698349	chr2:225449008	CUL3	1.0	9.83	0.66	3.23e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	cis	rs13191362	1.000	rs13204013	chr6:163002480	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg09177884	chr7:1199841	ZFAND2A	-0.72	-4.47	-0.37	1.72e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg03934478	chr11:495069	RNH1	0.35	5.89	0.47	3.34e-8	Body mass index;
TGCT	cis	rs12497850	0.931	rs7430501	chr3:48890119	C/T	cg05785598	chr3:49045655	WDR6	0.35	4.72	0.39	6.35e-6	Parkinson's disease;
TGCT	cis	rs2888674	1.000	rs1006581	chr7:150511923	A/G	cg10409299	chr7:150498843	TMEM176B;TMEM176A	-0.26	-4.52	-0.38	1.44e-5	Forced expiratory volume in 1 second (occupational environmental exposures interaction);
TGCT	cis	rs7552404	1.000	rs1498316	chr1:76159198	G/A	cg10523679	chr1:76189770	ACADM	0.91	9.92	0.67	2.01e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	trans	rs561341	0.629	rs7216107	chr17:30224419	G/A	cg20587970	chr11:113659929	NA	-0.53	-7.67	-0.57	4.47e-12	Hip circumference adjusted for BMI;
TGCT	cis	rs1568889	1.000	rs33937991	chr11:28045260	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	8.86	0.62	7.07e-15	Bipolar disorder;
TGCT	cis	rs1865760	0.534	rs72834629	chr6:26023032	C/T	cg17042849	chr6:26104293	HIST1H4C	-0.82	-6.93	-0.53	2.04e-10	Height;
TGCT	cis	rs6500602	0.627	rs863501	chr16:4588394	G/C	cg08645402	chr16:4508243	NA	-0.21	-5.57	-0.45	1.53e-7	Schizophrenia;
TGCT	cis	rs933688	1.000	rs332544	chr5:90778848	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.04	10.45	0.68	1.02e-18	Smoking behavior;
TGCT	cis	rs372883	0.648	rs1003772	chr21:30736145	A/T	cg24692254	chr21:30365293	RNF160	0.51	4.57	0.38	1.14e-5	Pancreatic cancer;
TGCT	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg06618935	chr21:46677482	NA	-0.37	-5.44	-0.44	2.69e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs8082590	1	rs8082590	chr17:17958402	G/A	cg04398451	chr17:18023971	MYO15A	0.33	5.39	0.44	3.47e-7	Schizophrenia;
TGCT	cis	rs2862064	1.000	rs7731951	chr5:156449685	A/T	cg12943317	chr5:156479607	HAVCR1	0.44	5.66	0.45	9.9e-8	Platelet count;
TGCT	cis	rs864745	0.967	rs849135	chr7:28196413	G/A	cg23620719	chr7:28220237	JAZF1	-0.48	-4.45	-0.37	1.92e-5	Crohn's disease;Type 2 diabetes;
TGCT	cis	rs7552404	0.690	rs12723575	chr1:76335203	T/C	cg10523679	chr1:76189770	ACADM	-0.67	-6.27	-0.49	5.47e-9	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9467773	1.000	rs9461259	chr6:26504835	C/A	cg09904177	chr6:26538194	HMGN4	0.65	6.53	0.51	1.5e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs74544699	1.000	rs11574450	chr4:74847111	A/C	cg16072462	chr4:74847758	PF4	1.02	5.45	0.44	2.56e-7	Growth-regulated protein alpha levels;
TGCT	cis	rs11671005	0.735	rs56292587	chr19:58919066	A/T	cg13877915	chr19:58951672	ZNF132	0.63	4.99	0.41	1.99e-6	Mean platelet volume;
TGCT	cis	rs12479064	0.724	rs112900993	chr2:99948805	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.57	-4.47	-0.37	1.71e-5	Chronic sinus infection;
TGCT	cis	rs10507380	0.824	rs117389279	chr13:27923547	C/T	cg25543773	chr13:27185723	WASF3	0.34	4.83	0.4	3.97e-6	Electrocardiographic traits;
TGCT	cis	rs7824557	0.527	rs10109537	chr8:11239640	C/T	cg21775007	chr8:11205619	TDH	-0.67	-6.56	-0.51	1.28e-9	Retinal vascular caliber;
TGCT	cis	rs6714710	0.603	rs17489454	chr2:98407350	C/T	cg26665480	chr2:98280029	ACTR1B	0.64	6.06	0.48	1.53e-8	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs11696501	0.688	rs6073842	chr20:44293841	G/C	cg11783356	chr20:44313418	WFDC10B	-0.32	-4.63	-0.38	9.25e-6	Brain structure;
TGCT	cis	rs11252926	0.527	rs10904093	chr10:436848	A/G	cg18196295	chr10:418757	DIP2C	-0.3	-5.2	-0.42	7.99e-7	Psychosis in Alzheimer's disease;
TGCT	cis	rs7666738	0.830	rs9998803	chr4:99002519	C/T	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1998418	0.736	rs1006368	chr10:126346603	C/T	cg03585084	chr10:126284563	LHPP	0.25	4.46	0.37	1.8e-5	Mean platelet volume;
TGCT	cis	rs7829975	0.573	rs7842359	chr8:8797078	T/G	cg06636001	chr8:8085503	FLJ10661	-0.7	-6.19	-0.49	8.23e-9	Mood instability;
TGCT	cis	rs9393777	0.513	rs9368447	chr6:26646674	A/C	cg15659132	chr6:26577336	NA	-0.75	-5.25	-0.43	6.33e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7089973	0.872	rs7918388	chr10:116614563	T/C	cg03647239	chr10:116582469	FAM160B1	0.52	4.64	0.38	8.75e-6	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs79349575	0.715	rs9894220	chr17:46989154	C/T	cg07967210	chr17:47022446	SNF8	0.41	5.41	0.44	3.18e-7	Type 2 diabetes;
TGCT	cis	rs9467711	0.606	rs9393705	chr6:26361011	G/A	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs13102973	0.720	rs13137300	chr4:135889460	G/A	cg14419869	chr4:135874104	NA	0.26	4.6	0.38	1.03e-5	Subjective well-being;
TGCT	cis	rs6570726	1.000	rs386678	chr6:145869010	A/G	cg05347473	chr6:146136440	FBXO30	0.53	4.74	0.39	5.75e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4073582	0.576	rs556595	chr11:66058082	T/G	cg16950941	chr11:66035639	RAB1B	0.57	5.15	0.42	9.9e-7	Gout;
TGCT	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg07507251	chr3:52567010	NT5DC2	-0.41	-5.65	-0.45	1.07e-7	Bipolar disorder;
TGCT	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg17971929	chr21:40555470	PSMG1	0.98	9.57	0.65	1.43e-16	Cognitive function;
TGCT	cis	rs2439831	0.867	rs2255042	chr15:43834318	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.84	-5.79	-0.46	5.33e-8	Lung cancer in ever smokers;
TGCT	cis	rs950027	0.572	rs12910764	chr15:45609360	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.47	-5.89	-0.47	3.46e-8	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs7647973	0.593	rs7620848	chr3:49828021	G/C	cg03060546	chr3:49711283	APEH	-0.63	-5.63	-0.45	1.12e-7	Menarche (age at onset);
TGCT	cis	rs909674	0.731	rs6001594	chr22:39837472	C/T	cg24399712	chr22:39784796	NA	-1.07	-11.03	-0.7	4.05e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs713587	0.967	rs10182458	chr2:25150641	A/G	cg15423357	chr2:25149977	NA	0.63	6.46	0.5	2.15e-9	Body mass index in non-asthmatics;
TGCT	cis	rs739496	0.579	rs7980569	chr12:112281384	G/A	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs7666738	0.830	rs1813251	chr4:98921170	A/G	cg17366294	chr4:99064904	C4orf37	0.73	7.49	0.56	1.1e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg23708337	chr7:1209742	NA	0.6	5.57	0.45	1.53e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs17197710	0.673	rs61896051	chr11:47313569	C/T	cg13308137	chr11:47528955	CUGBP1	0.41	5.82	0.46	4.71e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs6912958	1.000	rs6454630	chr6:88171357	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.58	5.45	0.44	2.59e-7	Monocyte percentage of white cells;
TGCT	cis	rs9914544	0.545	rs12600851	chr17:18767518	T/A	cg26378065	chr17:18585709	ZNF286B	0.52	4.5	0.37	1.56e-5	Educational attainment (years of education);
TGCT	cis	rs7954584	0.616	rs10743186	chr12:122356436	C/T	cg22168489	chr12:122356033	WDR66	0.23	5.55	0.45	1.63e-7	Mean corpuscular volume;
TGCT	cis	rs17345786	0.906	rs72944107	chr3:101197190	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.4	-8.36	-0.6	1.09e-13	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs651907	0.557	rs3094297	chr3:101399260	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.89	11.66	0.72	1.13e-21	Colorectal cancer;
TGCT	cis	rs9638182	0.778	rs35332062	chr7:73012042	G/A	cg14087351	chr7:73037990	MLXIPL	-0.65	-5.07	-0.41	1.43e-6	Triglycerides;
TGCT	cis	rs6988636	1.000	rs62521826	chr8:124186668	C/T	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs57590327	0.527	rs11917558	chr3:81610805	G/A	cg07356753	chr3:81810745	GBE1	-0.59	-4.96	-0.41	2.23e-6	Extraversion;
TGCT	cis	rs7647973	1.000	rs11710434	chr3:49346130	T/C	cg07636037	chr3:49044803	WDR6	0.72	5.84	0.46	4.25e-8	Menarche (age at onset);
TGCT	cis	rs7264396	0.790	rs6060526	chr20:34225302	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.28	4.74	0.39	5.75e-6	Total cholesterol levels;
TGCT	cis	rs7267979	0.966	rs2261720	chr20:25260641	T/G	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg18402987	chr7:1209562	NA	0.56	5.07	0.41	1.4e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs10507380	0.824	rs9512636	chr13:27920494	G/T	cg25543773	chr13:27185723	WASF3	0.34	4.83	0.4	3.97e-6	Electrocardiographic traits;
TGCT	cis	rs5750830	0.594	rs5757647	chr22:39775047	C/A	cg02038168	chr22:39784481	NA	-0.64	-5.48	-0.44	2.32e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.57	-4.53	-0.38	1.35e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs950027	0.620	rs2461700	chr15:45640627	T/C	cg14582100	chr15:45693742	SPATA5L1	0.47	6.05	0.48	1.59e-8	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.88	9.59	0.65	1.28e-16	Platelet count;
TGCT	cis	rs2739330	0.615	rs2858911	chr22:24297195	G/T	cg11905131	chr22:24372483	LOC391322	-0.98	-12.41	-0.74	1.79e-23	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	5.3	0.43	5.06e-7	Height;
TGCT	cis	rs7805747	0.961	rs10224210	chr7:151413194	T/C	cg17611936	chr7:151411526	PRKAG2	0.56	6.64	0.51	8.81e-10	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
TGCT	cis	rs7954584	0.520	rs1169095	chr12:122465738	G/A	cg22168489	chr12:122356033	WDR66	-0.19	-4.52	-0.38	1.42e-5	Mean corpuscular volume;
TGCT	cis	rs4689388	0.926	rs10937717	chr4:6295087	T/A	cg25554036	chr4:6271136	WFS1	0.55	7.69	0.57	3.85e-12	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.91	0.4	2.83e-6	Height;
TGCT	cis	rs7119	0.604	rs2667781	chr15:77858619	A/C	cg27398640	chr15:77910606	LINGO1	0.27	4.96	0.41	2.23e-6	Type 2 diabetes;
TGCT	cis	rs11190604	0.943	rs9420792	chr10:102258439	C/T	cg16342193	chr10:102329863	NA	-0.4	-5.12	-0.42	1.12e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs1371867	0.875	rs2439456	chr8:101336874	C/T	cg06636551	chr8:101224915	SPAG1	-0.45	-6.05	-0.48	1.55e-8	Atrioventricular conduction;
TGCT	trans	rs17685	0.623	rs7782808	chr7:75768645	C/T	cg19862616	chr7:65841803	NCRNA00174	0.52	9.01	0.63	3.02e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg03934478	chr11:495069	RNH1	0.35	5.77	0.46	6.03e-8	Body mass index;
TGCT	cis	rs644799	0.526	rs534973	chr11:95633624	A/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.52	4.96	0.41	2.3e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs394563	0.591	rs11964335	chr6:149658101	A/T	cg11245181	chr6:149772854	ZC3H12D	0.28	4.5	0.37	1.57e-5	Dupuytren's disease;
TGCT	cis	rs9972944	0.729	rs7224482	chr17:63777949	C/A	cg07283582	chr17:63770753	CCDC46	0.26	5.05	0.41	1.53e-6	Total body bone mineral density;
TGCT	cis	rs7552404	0.824	rs1251079	chr1:76189445	C/T	cg03433033	chr1:76189801	ACADM	0.92	14.93	0.8	1.79e-29	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs11105298	0.891	rs10858879	chr12:89886578	A/T	cg08166232	chr12:89918718	WDR51B;GALNT4	0.7	5.02	0.41	1.79e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs459571	0.959	rs467379	chr9:136905474	C/T	cg13789015	chr9:136890014	NCRNA00094	0.36	6.43	0.5	2.53e-9	Platelet distribution width;
TGCT	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg07507251	chr3:52567010	NT5DC2	0.49	7.04	0.53	1.14e-10	Electroencephalogram traits;
TGCT	cis	rs7666738	0.753	rs10004827	chr4:99037953	A/C	cg18180107	chr4:99064573	C4orf37	0.57	5.23	0.42	7.1e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9900497	0.569	rs2072327	chr17:19651482	G/T	cg15323506	chr17:19619410	SLC47A2	-0.22	-5.62	-0.45	1.17e-7	Response to paliperidone in schizophrenia (CGI-S score);
TGCT	cis	rs10875595	0.836	rs7703869	chr5:140666494	C/T	cg20560182	chr5:140700478	TAF7	-0.66	-5.07	-0.41	1.42e-6	Pulmonary function decline;
TGCT	cis	rs2046867	0.908	rs67967166	chr3:72794198	A/G	cg25664220	chr3:72788482	NA	-0.55	-6.95	-0.53	1.83e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7582180	0.663	rs2053263	chr2:100971407	A/G	cg14675211	chr2:100938903	LONRF2	0.47	4.56	0.38	1.22e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.79	6.34	0.49	3.93e-9	Mean platelet volume;
TGCT	cis	rs12908161	0.959	rs3748376	chr15:85328352	C/T	cg11189052	chr15:85197271	WDR73	0.71	5.82	0.46	4.75e-8	Schizophrenia;
TGCT	cis	rs853679	0.546	rs200950	chr6:27835772	A/G	cg08798685	chr6:27730294	NA	-0.34	-4.69	-0.39	7.2e-6	Depression;
TGCT	cis	rs7513165	0.932	rs11240694	chr1:204157973	C/T	cg04791601	chr1:204159016	NA	0.26	5.06	0.41	1.47e-6	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
TGCT	cis	rs1031925	0.687	rs6778196	chr3:51770429	C/T	cg10583097	chr3:51429234	RBM15B	-0.57	-4.94	-0.41	2.5e-6	Melanoma;
TGCT	cis	rs259282	0.538	rs62124303	chr19:33113042	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.5	4.56	0.38	1.21e-5	Schizophrenia;
TGCT	cis	rs4468007	0.505	rs4836866	chr9:124620787	G/A	cg01549227	chr9:124980074	LHX6	-0.3	-4.55	-0.38	1.24e-5	Educational attainment;
TGCT	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg11871910	chr12:69753446	YEATS4	0.87	10.07	0.67	8.72e-18	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs6125597	1.000	rs6125597	chr20:47840772	T/C	cg11220565	chr20:47934802	NA	-0.3	-4.58	-0.38	1.13e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs72781680	0.898	rs72786288	chr2:24075416	G/T	cg08917208	chr2:24149416	ATAD2B	0.77	4.69	0.39	7.06e-6	Lymphocyte counts;
TGCT	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg22963979	chr7:1858916	MAD1L1	-0.45	-7.65	-0.57	4.91e-12	Schizophrenia;
TGCT	cis	rs939658	0.805	rs35230534	chr15:79441093	T/C	cg17916960	chr15:79447300	NA	-0.49	-7.41	-0.55	1.73e-11	Refractive error;
TGCT	cis	rs10927875	0.619	rs2013019	chr1:16129320	T/C	cg21385522	chr1:16154831	NA	-0.74	-8.83	-0.62	8.18e-15	Dilated cardiomyopathy;
TGCT	cis	rs77372450	0.551	rs6892478	chr5:157106968	C/T	cg12606933	chr5:157078573	SOX30	-0.42	-4.75	-0.39	5.51e-6	Bipolar disorder (body mass index interaction);
TGCT	cis	rs3741151	1.000	rs79038783	chr11:73038746	C/G	cg17517138	chr11:73019481	ARHGEF17	1.12	5.41	0.44	3.11e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
TGCT	cis	rs6725041	0.792	rs10048750	chr2:213090883	C/T	cg16329650	chr2:213403929	ERBB4	-0.53	-4.58	-0.38	1.12e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.54	4.52	0.38	1.44e-5	Tonsillectomy;
TGCT	cis	rs909674	0.818	rs5757681	chr22:39845547	A/G	cg05872129	chr22:39784769	NA	-1.0	-9.92	-0.67	1.94e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs2832191	0.791	rs57721945	chr21:30498744	T/C	cg08807101	chr21:30365312	RNF160	-0.62	-5.8	-0.46	5.14e-8	Dental caries;
TGCT	cis	rs137603	0.644	rs470082	chr22:39715140	C/T	cg01093212	chr22:39715156	SNORD43;RPL3	-0.51	-4.95	-0.41	2.41e-6	Primary biliary cholangitis;
TGCT	cis	rs7959452	0.535	rs10784771	chr12:69621264	A/G	cg14784868	chr12:69753453	YEATS4	0.68	6.68	0.51	7.27e-10	Blood protein levels;
TGCT	cis	rs860554	0.705	rs832170	chr1:201257016	G/A	cg01022117	chr1:201258280	PKP1	0.34	5.01	0.41	1.87e-6	Panic disorder;
TGCT	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg21724239	chr8:58056113	NA	-0.37	-4.53	-0.38	1.39e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs10927875	0.619	rs1806991	chr1:16129441	T/C	cg21385522	chr1:16154831	NA	-0.74	-8.95	-0.63	4.33e-15	Dilated cardiomyopathy;
TGCT	cis	rs6840360	0.593	rs867800	chr4:152691470	T/C	cg22705602	chr4:152727874	NA	-0.34	-5.9	-0.47	3.24e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs4851254	1.000	rs4851254	chr2:100762937	C/G	cg23118464	chr2:100721844	AFF3	0.69	5.19	0.42	8.17e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7772486	0.686	rs9390357	chr6:146129347	A/G	cg05347473	chr6:146136440	FBXO30	0.47	4.48	0.37	1.65e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2172802	0.924	rs12715703	chr4:62432010	C/T	cg04118610	chr4:62707027	LPHN3	-0.43	-4.68	-0.39	7.28e-6	Partial epilepsies;
TGCT	cis	rs7617773	0.539	rs2017858	chr3:48382282	G/T	cg11946769	chr3:48343235	NME6	0.55	4.6	0.38	1.02e-5	Coronary artery disease;
TGCT	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7914558	1.000	rs67908413	chr10:104764989	T/C	cg04362960	chr10:104952993	NT5C2	0.6	5.39	0.44	3.41e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg10150615	chr22:24372951	LOC391322	-1.01	-13.23	-0.77	1.86e-25	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs4460629	0.650	rs11264319	chr1:155083942	T/C	cg23973274	chr1:155060172	NA	-0.26	-4.72	-0.39	6.25e-6	Serum magnesium levels;
TGCT	cis	rs1552244	0.832	rs73024591	chr3:10203194	A/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.11	6.29	0.49	4.85e-9	Alzheimer's disease;
TGCT	cis	rs3772130	0.962	rs11707504	chr3:121496734	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.72	0.39	6.25e-6	Cognitive performance;
TGCT	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg01416388	chr22:39784598	NA	0.71	7.2	0.54	5.14e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs35146811	0.695	rs858509	chr7:99821470	A/G	cg13334819	chr7:99746414	C7orf59	0.74	6.41	0.5	2.82e-9	Coronary artery disease;
TGCT	cis	rs12477438	0.765	rs6737257	chr2:99683330	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-7.6	-0.56	6.47e-12	Chronic sinus infection;
TGCT	cis	rs35146811	0.660	rs3779046	chr7:99779243	A/G	cg22906224	chr7:99728672	NA	0.49	4.45	0.37	1.88e-5	Coronary artery disease;
TGCT	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg27454412	chr7:1067447	C7orf50	0.57	4.48	0.37	1.71e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg03188948	chr7:1209495	NA	0.46	6.38	0.5	3.24e-9	Longevity;Endometriosis;
TGCT	cis	rs1372520	0.684	rs2619368	chr4:90729747	T/G	cg01966878	chr4:90757139	SNCA	-0.31	-4.84	-0.4	3.8e-6	Neuroticism;
TGCT	cis	rs514406	0.763	rs6685599	chr1:53213172	G/A	cg01802117	chr1:53393560	SCP2	0.44	5.26	0.43	6.2e-7	Monocyte count;
TGCT	cis	rs1552244	0.766	rs34232505	chr3:10186216	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.03	5.95	0.47	2.58e-8	Alzheimer's disease;
TGCT	cis	rs6088580	0.660	rs6087592	chr20:33114503	A/G	cg08999081	chr20:33150536	PIGU	0.29	5.54	0.45	1.75e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs921943	0.554	rs163132	chr5:78285921	A/G	cg17845680	chr5:78281827	ARSB	0.37	4.99	0.41	1.98e-6	Blood and toenail selenium levels;Blood trace element (Se levels);
TGCT	cis	rs476633	0.708	rs8031159	chr15:41445199	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.66	-8.77	-0.62	1.18e-14	Glomerular filtration rate (creatinine);
TGCT	cis	rs17253792	0.642	rs10483648	chr14:56104278	T/C	cg01858014	chr14:56050164	KTN1	-0.35	-4.5	-0.37	1.53e-5	Putamen volume;
TGCT	cis	rs425277	0.628	rs3107147	chr1:2048729	G/A	cg24578937	chr1:2090814	PRKCZ	-0.25	-6.0	-0.47	2.01e-8	Height;
TGCT	cis	rs9394841	0.692	rs9369312	chr6:41841535	A/T	cg08135965	chr6:41755394	TOMM6	0.57	5.17	0.42	9.15e-7	Mean corpuscular hemoglobin;Red cell distribution width;
TGCT	cis	rs686320	1.000	rs686320	chr11:65244538	G/C	cg21890820	chr11:65308645	LTBP3	0.59	4.51	0.38	1.49e-5	Hip circumference adjusted for BMI;
TGCT	cis	rs6912958	0.754	rs4707374	chr6:88255438	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-5.06	-0.41	1.45e-6	Monocyte percentage of white cells;
TGCT	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg07061783	chr6:25882402	NA	-0.66	-6.43	-0.5	2.45e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7511006	0.893	rs5771104	chr22:50651839	C/T	cg16473166	chr22:50639996	SELO	0.63	6.12	0.48	1.14e-8	Obesity-related traits;
TGCT	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg20887711	chr4:1340912	KIAA1530	0.92	8.12	0.59	3.93e-13	Longevity;
TGCT	cis	rs9911578	1.000	rs302848	chr17:56686454	C/T	cg05425664	chr17:57184151	TRIM37	-0.57	-5.96	-0.47	2.47e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7647973	0.506	rs11920251	chr3:49356671	C/T	cg07636037	chr3:49044803	WDR6	0.74	6.83	0.52	3.45e-10	Menarche (age at onset);
TGCT	cis	rs208520	0.874	rs208514	chr6:66945520	G/A	cg07460842	chr6:66804631	NA	-0.9	-9.15	-0.63	1.45e-15	Exhaled nitric oxide output;
TGCT	trans	rs66573146	0.831	rs68111914	chr4:6986677	C/T	cg07817883	chr1:32538562	TMEM39B	1.3	6.83	0.52	3.41e-10	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg08859206	chr1:53392774	SCP2	0.46	7.05	0.53	1.1e-10	Monocyte count;
TGCT	cis	rs7104764	0.778	rs7930823	chr11:206767	C/T	cg18336825	chr11:236787	PSMD13;SIRT3	-0.88	-9.3	-0.64	6.2e-16	Menarche (age at onset);
TGCT	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.66	0.39	8.18e-6	Prudent dietary pattern;
TGCT	cis	rs1023500	0.573	rs133370	chr22:42465260	T/C	cg15557168	chr22:42548783	NA	-0.22	-5.54	-0.45	1.76e-7	Schizophrenia;
TGCT	cis	rs6484504	0.532	rs2150212	chr11:31255935	G/A	cg26647111	chr11:31128758	NA	-0.35	-4.85	-0.4	3.58e-6	Red blood cell count;
TGCT	cis	rs7267979	0.934	rs2500399	chr20:25354694	T/G	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9303401	0.659	rs12940212	chr17:56674474	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs12220238	0.818	rs10430521	chr10:75913590	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.06	0.54	1.05e-10	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg06896619	chr17:61851486	DDX42;CCDC47	-0.51	-4.97	-0.41	2.18e-6	Prudent dietary pattern;
TGCT	cis	rs61867294	0.553	rs6584646	chr10:106709239	C/T	cg08000847	chr10:105880925	C10orf78	0.47	4.48	0.37	1.64e-5	Schizophrenia;
TGCT	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg27454412	chr7:1067447	C7orf50	0.62	4.68	0.39	7.54e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg24060327	chr5:131705240	SLC22A5	0.57	5.65	0.45	1.03e-7	Breast cancer;
TGCT	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg15691649	chr6:25882328	NA	-0.36	-4.71	-0.39	6.5e-6	Blood metabolite levels;
TGCT	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg24829409	chr8:58192753	C8orf71	-0.57	-4.72	-0.39	6.14e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2594989	0.943	rs4684780	chr3:11478960	C/T	cg00170343	chr3:11313890	ATG7	0.63	4.96	0.41	2.27e-6	Circulating chemerin levels;
TGCT	trans	rs208520	0.909	rs9453672	chr6:66991431	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.79	7.05	0.53	1.12e-10	Exhaled nitric oxide output;
TGCT	cis	rs936229	0.749	rs6495127	chr15:75194490	C/T	cg10253484	chr15:75165896	SCAMP2	-0.77	-6.52	-0.51	1.56e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
TGCT	cis	rs7772486	0.743	rs2092262	chr6:146037105	C/T	cg23711669	chr6:146136114	FBXO30	-0.83	-8.95	-0.63	4.23e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs8056742	0.642	rs12927887	chr16:85031784	G/A	cg00229868	chr16:85520891	NA	0.37	4.64	0.38	8.75e-6	Amyotrophic lateral sclerosis;
TGCT	cis	rs28595532	0.920	rs114584210	chr4:119773363	G/A	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs2760061	0.626	rs594916	chr1:228133544	C/A	cg18477163	chr1:228402036	OBSCN	-0.32	-6.34	-0.49	3.86e-9	Diastolic blood pressure;
TGCT	cis	rs6665290	0.836	rs56029302	chr1:227203390	G/A	cg10327440	chr1:227177885	CDC42BPA	-0.92	-16.13	-0.82	3.09e-32	Myeloid white cell count;
TGCT	cis	rs7248779	0.512	rs7250002	chr19:2413188	A/G	cg22729335	chr19:2427816	TIMM13	1.13	13.41	0.77	6.73e-26	Cortisol levels (saliva);
TGCT	cis	rs7523273	1.000	rs12184327	chr1:207978780	A/G	cg22525895	chr1:207977042	MIR29B2	-0.49	-8.61	-0.61	2.78e-14	Schizophrenia;
TGCT	cis	rs3820068	0.603	rs72647138	chr1:15980929	C/T	cg05660106	chr1:15850417	CASP9	0.79	7.46	0.56	1.29e-11	Systolic blood pressure;
TGCT	cis	rs921968	0.607	rs2465100	chr2:219551044	A/T	cg02176678	chr2:219576539	TTLL4	-0.33	-4.45	-0.37	1.92e-5	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs9467773	1.000	rs6456733	chr6:26566804	C/T	cg15659132	chr6:26577336	NA	0.88	12.27	0.74	3.83e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs7100689	0.646	rs7077712	chr10:82134894	A/G	cg01528321	chr10:82214614	TSPAN14	0.8	7.72	0.57	3.42e-12	Post bronchodilator FEV1;
TGCT	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg03188948	chr7:1209495	NA	0.42	5.57	0.45	1.51e-7	Longevity;Endometriosis;
TGCT	cis	rs36051895	0.659	rs12337134	chr9:5061578	G/A	cg02405213	chr9:5042618	JAK2	-0.73	-9.89	-0.66	2.38e-17	Pediatric autoimmune diseases;
TGCT	cis	rs6424115	0.708	rs34570472	chr1:24191720	A/G	cg15997130	chr1:24165203	NA	-0.68	-6.62	-0.51	9.92e-10	Immature fraction of reticulocytes;
TGCT	cis	rs9910055	0.636	rs7089	chr17:42269017	T/C	cg13607699	chr17:42295918	UBTF	0.6	5.48	0.44	2.23e-7	Total body bone mineral density;
TGCT	cis	rs12477438	0.520	rs4347885	chr2:99804007	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.75	7.25	0.55	3.92e-11	Chronic sinus infection;
TGCT	cis	rs9303401	0.659	rs11079357	chr17:56902778	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs250677	1.000	rs250677	chr5:148433549	T/C	cg23229984	chr5:148520753	ABLIM3	0.21	4.81	0.4	4.23e-6	Breast cancer;
TGCT	cis	rs35771425	0.626	rs6677230	chr1:211652902	A/C	cg10512769	chr1:211675356	NA	-0.25	-4.49	-0.37	1.59e-5	Educational attainment (years of education);
TGCT	cis	rs72781680	0.716	rs2712071	chr2:23990419	A/G	cg08917208	chr2:24149416	ATAD2B	0.79	4.94	0.41	2.51e-6	Lymphocyte counts;
TGCT	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg24250549	chr1:154909240	PMVK	0.62	6.28	0.49	5.29e-9	Prostate cancer;
TGCT	cis	rs12541335	0.579	rs59283125	chr8:22212311	G/A	cg02788857	chr8:22132959	PIWIL2	0.3	5.45	0.44	2.62e-7	Hypertriglyceridemia;
TGCT	cis	rs1981331	0.609	rs57896262	chr21:48028188	C/T	cg17243659	chr21:48055224	PRMT2	1.13	6.28	0.49	5.15e-9	Cerebrospinal fluid t-tau:AB1-42 ratio;
TGCT	cis	rs2249625	0.545	rs9791273	chr6:72891016	G/T	cg08500200	chr6:72892038	RIMS1	0.42	4.58	0.38	1.14e-5	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
TGCT	cis	rs2760061	0.599	rs644794	chr1:228148670	T/C	cg02753203	chr1:228287806	NA	-0.34	-6.55	-0.51	1.4e-9	Diastolic blood pressure;
TGCT	cis	rs710216	1.000	rs710216	chr1:43428757	A/G	cg03128534	chr1:43423976	SLC2A1	0.59	4.55	0.38	1.28e-5	Red cell distribution width;
TGCT	cis	rs514406	0.584	rs7524702	chr1:53197830	G/A	cg24675658	chr1:53192096	ZYG11B	0.84	10.42	0.68	1.22e-18	Monocyte count;
TGCT	cis	rs4073582	0.595	rs801741	chr11:65917084	A/G	cg16950941	chr11:66035639	RAB1B	0.55	5.38	0.43	3.59e-7	Gout;
TGCT	cis	rs2242116	0.796	rs7645278	chr3:46974100	A/C	cg27129171	chr3:47204927	SETD2	0.65	6.44	0.5	2.43e-9	Birth weight;
TGCT	cis	rs9549367	0.756	rs2302756	chr13:113900197	G/A	cg18105134	chr13:113819100	PROZ	0.34	5.6	0.45	1.3e-7	Platelet distribution width;
TGCT	cis	rs9549260	0.727	rs4603422	chr13:41148353	T/C	cg21288729	chr13:41239152	FOXO1	1.0	10.37	0.68	1.61e-18	Red blood cell count;
TGCT	cis	rs6570726	0.935	rs397418	chr6:145842362	C/T	cg23711669	chr6:146136114	FBXO30	0.7	6.83	0.52	3.42e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs13424612	0.896	rs12467120	chr2:240894275	A/G	cg26363272	chr2:240904871	NDUFA10	-0.31	-5.15	-0.42	1e-6	Odorant perception (isobutyraldehyde);
TGCT	cis	rs4851254	0.660	rs60697219	chr2:100699507	G/A	cg04109781	chr2:100722022	AFF3	0.46	4.59	0.38	1.08e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs11096990	0.819	rs4974991	chr4:39194767	T/A	cg20847110	chr4:39482781	LOC401127	-0.17	-4.5	-0.37	1.53e-5	Cognitive function;
TGCT	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.84	7.5	0.56	1.08e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7940866	0.845	rs10894294	chr11:130830748	G/T	cg05962950	chr11:130786565	SNX19	0.67	5.48	0.44	2.31e-7	Schizophrenia;
TGCT	cis	rs433598	0.765	rs163265	chr16:20661809	A/G	cg16616769	chr16:19727142	IQCK;C16orf88	-0.21	-4.68	-0.39	7.35e-6	Schizophrenia;
TGCT	cis	rs67072384	0.818	rs1872127	chr11:72465085	G/A	cg03713592	chr11:72463424	ARAP1	-0.88	-4.77	-0.39	5.04e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs11249608	0.548	rs7704565	chr5:178473923	G/C	cg01312482	chr5:178451176	ZNF879	-0.5	-4.93	-0.41	2.55e-6	Pubertal anthropometrics;
TGCT	trans	rs877282	0.898	rs2004478	chr10:770709	C/A	cg22713356	chr15:30763199	NA	1.21	10.47	0.69	8.99e-19	Uric acid levels;
TGCT	cis	rs7666738	0.830	rs1426667	chr4:98949772	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg23708337	chr7:1209742	NA	0.56	5.09	0.42	1.31e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs75686122	0.772	rs76370225	chr8:104520027	A/T	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs2880765	0.835	rs7162502	chr15:86044473	G/T	cg13263323	chr15:86062960	AKAP13	-0.23	-4.82	-0.4	4.1e-6	Coronary artery disease;
TGCT	cis	rs12681287	0.609	rs13281414	chr8:87495254	A/C	cg27223183	chr8:87520930	FAM82B	-0.92	-6.79	-0.52	4.12e-10	Caudate activity during reward;
TGCT	cis	rs7584330	0.955	rs13432426	chr2:238388631	T/G	cg14458575	chr2:238380390	NA	0.48	7.42	0.55	1.66e-11	Prostate cancer;
TGCT	cis	rs904251	0.523	rs1776455	chr6:37482923	A/T	cg08126542	chr6:37504118	NA	-0.41	-6.05	-0.48	1.57e-8	Cognitive performance;
TGCT	cis	rs7216064	1.000	rs8067892	chr17:65837983	A/G	cg12091567	chr17:66097778	LOC651250	-0.87	-6.85	-0.52	3.1e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs77372450	0.551	rs77213903	chr5:157106186	C/G	cg12606933	chr5:157078573	SOX30	-0.42	-4.75	-0.39	5.51e-6	Bipolar disorder (body mass index interaction);
TGCT	cis	rs1857353	0.803	rs17645210	chr1:75898049	T/C	cg11838876	chr1:75668600	SLC44A5	-0.51	-4.81	-0.4	4.23e-6	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg27535305	chr1:53392650	SCP2	-0.24	-4.73	-0.39	5.98e-6	Monocyte count;
TGCT	cis	rs6088590	0.931	rs6088624	chr20:33436852	T/A	cg24642439	chr20:33292090	TP53INP2	0.69	6.21	0.49	7.16e-9	Coronary artery disease;
TGCT	cis	rs806795	0.605	rs6935954	chr6:26255451	A/G	cg13736514	chr6:26305472	NA	-0.31	-4.67	-0.39	7.58e-6	Mosquito bite size;
TGCT	cis	rs77741769	0.529	rs12579868	chr12:121207147	C/T	cg02419362	chr12:121203948	SPPL3	0.19	4.5	0.37	1.54e-5	Mean corpuscular volume;
TGCT	cis	rs7607369	0.572	rs629177	chr2:219454801	T/G	cg02176678	chr2:219576539	TTLL4	0.48	6.78	0.52	4.32e-10	Red blood cell count;Amyotrophic lateral sclerosis;
TGCT	cis	rs6430585	0.583	rs4988201	chr2:136618507	A/G	cg07169764	chr2:136633963	MCM6	1.22	12.03	0.73	1.46e-22	Corneal structure;
TGCT	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg08219700	chr8:58056026	NA	0.3	4.55	0.38	1.25e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg09359103	chr1:154839909	KCNN3	-0.71	-14.31	-0.79	4.89e-28	Prostate cancer;
TGCT	cis	rs11673344	0.504	rs6510592	chr19:37624332	G/C	cg08039142	chr19:36980659	ZNF566	0.51	4.65	0.39	8.51e-6	Obesity-related traits;
TGCT	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.96	-12.29	-0.74	3.32e-23	Prudent dietary pattern;
TGCT	cis	rs9860250	0.537	rs1449317	chr3:100761838	C/T	cg05801080	chr3:100119813	LNP1;TOMM70A	0.54	4.44	0.37	1.96e-5	Optic disc area;
TGCT	cis	rs882300	0.900	rs12691875	chr2:136915698	C/A	cg05194412	chr2:137003533	NA	0.25	4.73	0.39	6.09e-6	Multiple sclerosis;Electrocardiographic traits;
TGCT	cis	rs1008375	0.898	rs2079892	chr4:17577163	G/A	cg16339924	chr4:17578868	LAP3	0.8	6.96	0.53	1.73e-10	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7552404	0.731	rs11161845	chr1:76367559	T/C	cg03433033	chr1:76189801	ACADM	0.77	7.43	0.56	1.5e-11	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg02725872	chr8:58115012	NA	-0.38	-4.76	-0.39	5.39e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7072216	0.763	rs10736129	chr10:100171571	C/T	cg26618903	chr10:100175079	PYROXD2	0.4	4.49	0.37	1.64e-5	Metabolite levels;
TGCT	cis	rs922182	0.617	rs17777266	chr15:64241242	A/G	cg02919090	chr15:64263738	DAPK2	0.37	7.01	0.53	1.33e-10	Blood protein levels;
TGCT	cis	rs2412459	0.611	rs4924402	chr15:40245754	C/T	cg25407064	chr15:40226267	EIF2AK4	-0.72	-4.7	-0.39	6.72e-6	Response to haloperidol in psychosis;
TGCT	cis	rs854765	0.604	rs12948749	chr17:17949802	G/A	cg04398451	chr17:18023971	MYO15A	0.31	4.84	0.4	3.76e-6	Total body bone mineral density;
TGCT	cis	rs7208859	0.623	rs8081299	chr17:29104296	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	4.71	0.39	6.51e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs4561483	0.549	rs33659	chr16:11963361	A/G	cg08843971	chr16:11963173	GSPT1	-0.32	-6.3	-0.49	4.78e-9	Testicular germ cell tumor;
TGCT	cis	rs644799	0.648	rs1255178	chr11:95471908	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.51	5.17	0.42	9.05e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	trans	rs4332037	0.539	rs11763750	chr7:2080114	G/A	cg25206134	chr2:45395956	NA	0.97	7.28	0.55	3.36e-11	Bipolar disorder;
TGCT	cis	rs17384381	0.953	rs11161599	chr1:85795965	A/G	cg16011679	chr1:85725395	C1orf52	-0.72	-6.12	-0.48	1.14e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs265548	0.595	rs265543	chr19:17904260	T/G	cg21960279	chr19:17905606	B3GNT3	0.49	5.48	0.44	2.3e-7	Tumor biomarkers;
TGCT	cis	rs1129187	0.755	rs2296804	chr6:42931261	C/G	cg27588902	chr6:42928151	GNMT	-0.57	-6.87	-0.53	2.76e-10	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs56104184	0.779	rs73061627	chr19:49360418	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.77	-8.88	-0.62	6.4e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs6952808	0.636	rs6461005	chr7:1947687	A/G	cg22963979	chr7:1858916	MAD1L1	-0.36	-5.49	-0.44	2.18e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs72634258	0.519	rs35197830	chr1:7930983	A/G	cg26816564	chr1:7831052	VAMP3	0.62	4.99	0.41	1.98e-6	Inflammatory bowel disease;
TGCT	cis	rs7772486	0.764	rs7762562	chr6:146158994	T/C	cg23711669	chr6:146136114	FBXO30	0.89	10.01	0.67	1.2e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg20007245	chr22:24372913	LOC391322	0.79	8.72	0.62	1.55e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9814567	0.806	rs12637301	chr3:134317966	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.76	-7.11	-0.54	8.15e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	trans	rs9951602	0.512	rs73494176	chr18:76644895	T/C	cg02800362	chr5:177631904	HNRNPAB	1.14	13.02	0.76	6.04e-25	Obesity-related traits;
TGCT	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg12963246	chr6:28129442	ZNF389	0.52	5.1	0.42	1.23e-6	Depression;
TGCT	cis	rs7412746	0.622	rs11552229	chr1:150783985	T/C	cg09365446	chr1:150670422	GOLPH3L	0.37	5.41	0.44	3.07e-7	Melanoma;
TGCT	cis	rs669446	0.562	rs10890275	chr1:44194216	T/G	cg12908607	chr1:44402522	ARTN	-0.62	-7.25	-0.55	3.99e-11	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs1348850	1.000	rs3927978	chr2:178443854	A/G	cg22681709	chr2:178499509	PDE11A	0.37	4.81	0.4	4.23e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs7714584	1.000	rs7734778	chr5:150256556	G/A	cg22134413	chr5:150180641	NA	0.83	6.53	0.51	1.54e-9	Crohn's disease;
TGCT	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg17971929	chr21:40555470	PSMG1	0.69	6.15	0.48	9.7e-9	Cognitive function;
TGCT	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.4	-4.5	-0.37	1.55e-5	Height;
TGCT	cis	rs9486715	0.867	rs9386500	chr6:96889845	A/C	cg18709589	chr6:96969512	KIAA0776	0.79	7.77	0.57	2.5e-12	Headache;
TGCT	cis	rs3809566	0.676	rs4775607	chr15:63328007	C/T	cg00520135	chr15:63333846	TPM1	-0.42	-5.32	-0.43	4.75e-7	Platelet count;
TGCT	cis	rs9467773	1.000	rs12526680	chr6:26550954	A/G	cg09904177	chr6:26538194	HMGN4	0.65	6.55	0.51	1.36e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7582180	0.577	rs6542942	chr2:100985378	G/T	cg14675211	chr2:100938903	LONRF2	0.49	4.69	0.39	7.2e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg07424592	chr7:64974309	NA	1.34	8.08	0.59	4.95e-13	Diabetic kidney disease;
TGCT	cis	rs1865760	0.963	rs9356991	chr6:25901758	C/A	cg17042849	chr6:26104293	HIST1H4C	-0.52	-4.68	-0.39	7.33e-6	Height;
TGCT	cis	rs1008375	0.932	rs12500947	chr4:17603424	C/T	cg18681998	chr4:17616180	MED28	0.99	9.69	0.66	7.08e-17	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs12477438	0.501	rs7608938	chr2:99782226	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	14.89	0.8	2.21e-29	Chronic sinus infection;
TGCT	cis	rs1371867	0.875	rs1788184	chr8:101335106	A/G	cg06002616	chr8:101225028	SPAG1	-0.53	-6.21	-0.49	7.16e-9	Atrioventricular conduction;
TGCT	cis	rs3820068	0.603	rs7531396	chr1:15969870	G/C	cg05660106	chr1:15850417	CASP9	0.83	8.16	0.59	3.25e-13	Systolic blood pressure;
TGCT	cis	rs4713118	0.513	rs149959	chr6:28013854	T/C	cg10876282	chr6:28092338	ZSCAN16	0.51	4.75	0.39	5.48e-6	Parkinson's disease;
TGCT	cis	rs4654899	1.000	rs72865329	chr1:21517567	G/A	cg01072550	chr1:21505969	NA	-0.5	-8.03	-0.59	6.27e-13	Superior frontal gyrus grey matter volume;
TGCT	cis	rs1008375	1.000	rs28501187	chr4:17643620	G/A	cg18681998	chr4:17616180	MED28	1.0	11.93	0.73	2.54e-22	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg03806693	chr22:41940476	POLR3H	1.14	12.74	0.75	2.72e-24	Vitiligo;
TGCT	cis	rs61656020	1	rs61656020	chr16:1882221	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.43	-4.67	-0.39	7.61e-6	Ankle injury;
TGCT	cis	rs9388451	0.626	rs1268074	chr6:126107791	G/C	cg05901451	chr6:126070800	HEY2	-0.94	-11.88	-0.73	3.44e-22	Brugada syndrome;
TGCT	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg03709012	chr19:19516395	GATAD2A	0.67	5.75	0.46	6.45e-8	Tonsillectomy;
TGCT	cis	rs9486719	1.000	rs12191653	chr6:96903898	T/C	cg06623918	chr6:96969491	KIAA0776	-0.98	-8.77	-0.62	1.15e-14	Migraine;Coronary artery disease;
TGCT	cis	rs7095607	0.730	rs1900012	chr10:69953942	G/A	cg18986048	chr10:69913749	MYPN	0.58	6.79	0.52	4.14e-10	Lung function (FVC);
TGCT	cis	rs1538970	0.774	rs67683090	chr1:45977803	T/G	cg05343316	chr1:45956843	TESK2	0.82	6.69	0.51	6.98e-10	Platelet count;
TGCT	cis	rs12048904	0.964	rs8888	chr1:101338324	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.55	5.09	0.42	1.31e-6	Multiple sclerosis;
TGCT	cis	rs17221829	0.673	rs11018700	chr11:89382066	A/C	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.63	-0.38	8.95e-6	Anxiety in major depressive disorder;
TGCT	cis	rs7917772	0.503	rs10883732	chr10:104293461	G/A	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs73110464	0.609	rs727266	chr12:53356411	C/T	cg25025879	chr12:53359317	NA	-0.52	-5.7	-0.46	8.29e-8	Cancer (pleiotropy);
TGCT	cis	rs10501293	0.703	rs10768909	chr11:43020427	G/A	cg03447554	chr11:43094025	NA	0.44	6.29	0.49	4.97e-9	Cognitive performance;
TGCT	cis	rs6845621	0.727	rs10020540	chr4:18908628	T/C	cg12196642	chr4:18937545	NA	-0.25	-4.5	-0.37	1.53e-5	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
TGCT	cis	rs1371867	0.846	rs1788191	chr8:101260844	C/T	cg00191853	chr8:101177733	SPAG1	0.22	4.5	0.37	1.53e-5	Atrioventricular conduction;
TGCT	cis	rs736408	1.000	rs736408	chr3:52835354	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	4.74	0.39	5.77e-6	Bipolar disorder;
TGCT	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	16.04	0.82	5e-32	Prudent dietary pattern;
TGCT	cis	rs922182	0.613	rs6494454	chr15:64233563	C/A	cg02919090	chr15:64263738	DAPK2	-0.33	-6.14	-0.48	1.05e-8	Blood protein levels;
TGCT	cis	rs5769707	0.967	rs2071904	chr22:50034477	C/T	cg10356904	chr22:49881777	NA	-0.22	-4.52	-0.38	1.4e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs61990749	0.597	rs176955	chr14:78181220	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	0.67	4.73	0.39	6.09e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs7829975	0.653	rs13259070	chr8:8690787	C/T	cg08975724	chr8:8085496	FLJ10661	0.58	5.13	0.42	1.1e-6	Mood instability;
TGCT	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg20887711	chr4:1340912	KIAA1530	-0.58	-4.97	-0.41	2.17e-6	Obesity-related traits;
TGCT	cis	rs12477438	0.501	rs6753063	chr2:99801469	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.82	0.62	8.67e-15	Chronic sinus infection;
TGCT	cis	rs9308731	0.863	rs616582	chr2:111941995	T/C	cg04202892	chr2:111875749	ACOXL	0.45	4.83	0.4	3.9e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs9928842	0.824	rs889515	chr16:75251299	T/C	cg09066997	chr16:75300724	BCAR1	0.26	4.52	0.38	1.41e-5	Alcoholic chronic pancreatitis;
TGCT	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg24829409	chr8:58192753	C8orf71	-0.59	-4.97	-0.41	2.17e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2486288	0.656	rs11632724	chr15:45550791	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.72	-7.46	-0.56	1.34e-11	Glomerular filtration rate;
TGCT	cis	rs6684514	1.000	rs10908499	chr1:156279176	G/C	cg16558208	chr1:156270281	VHLL	0.48	9.61	0.65	1.13e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs7223966	1.000	rs7222060	chr17:61868279	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	4.68	0.39	7.5e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs7312933	0.531	rs1796380	chr12:42791543	T/G	cg19980929	chr12:42632907	YAF2	-0.41	-5.8	-0.46	5.14e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs16966142	1.000	rs3890534	chr16:89835289	A/G	cg04287289	chr16:89883240	FANCA	-0.79	-4.9	-0.4	2.93e-6	Caffeine consumption;
TGCT	cis	rs2295359	1.000	rs2295359	chr1:67635950	G/A	cg12940439	chr1:67600707	NA	0.54	5.66	0.45	9.77e-8	Psoriasis;
TGCT	cis	rs4319547	0.656	rs10161534	chr12:122873864	T/C	cg08088222	chr12:122070432	ORAI1	0.25	4.45	0.37	1.89e-5	Body mass index;
TGCT	cis	rs12693043	0.727	rs9789707	chr2:175412112	G/C	cg11778734	chr2:175439522	WIPF1	-0.4	-5.15	-0.42	9.9e-7	Urate levels (BMI interaction);
TGCT	cis	rs35146811	0.586	rs6964754	chr7:99589404	G/A	cg13334819	chr7:99746414	C7orf59	-0.65	-5.74	-0.46	6.78e-8	Coronary artery disease;
TGCT	cis	rs7246657	0.943	rs10415937	chr19:37830064	T/G	cg03233940	chr19:37894644	NA	-0.34	-4.53	-0.38	1.34e-5	Coronary artery calcification;
TGCT	cis	rs3733585	0.699	rs6449157	chr4:9960442	G/A	cg00071950	chr4:10020882	SLC2A9	-0.55	-6.55	-0.51	1.41e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs2153535	0.580	rs4960411	chr6:8438231	C/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.58	0.45	1.42e-7	Motion sickness;
TGCT	cis	rs2688608	0.620	rs11000767	chr10:75516626	G/T	cg04320760	chr10:75533139	FUT11	-0.36	-5.66	-0.45	9.83e-8	Inflammatory bowel disease;
TGCT	cis	rs813218	0.523	rs652026	chr3:99442809	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.42	5.04	0.41	1.59e-6	Orofacial clefts;
TGCT	cis	rs76878669	0.561	rs10791872	chr11:66138434	C/G	cg18002602	chr11:66138449	SLC29A2	-0.53	-6.49	-0.5	1.89e-9	Educational attainment (years of education);
TGCT	cis	rs7727544	0.716	rs7720230	chr5:131592405	T/G	cg21474247	chr5:131268130	NA	0.31	4.63	0.38	9.21e-6	Blood metabolite levels;
TGCT	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg18876405	chr7:65276391	NA	0.31	4.78	0.39	4.81e-6	Aortic root size;
TGCT	cis	rs877282	0.945	rs10904550	chr10:774177	C/T	cg17470449	chr10:769945	NA	0.3	4.77	0.39	5.05e-6	Uric acid levels;
TGCT	cis	rs4919669	0.668	rs17114808	chr10:104391285	C/T	cg05855489	chr10:104503620	C10orf26	0.81	4.83	0.4	3.99e-6	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs910316	0.789	rs12894419	chr14:75471802	C/T	cg08847533	chr14:75593920	NEK9	0.83	8.89	0.62	5.99e-15	Height;
TGCT	cis	rs763121	0.889	rs2267390	chr22:38889657	C/T	cg06022373	chr22:39101656	GTPBP1	0.76	7.43	0.55	1.56e-11	Menopause (age at onset);
TGCT	cis	rs11031096	0.655	rs1822289	chr11:4212184	T/C	cg18678763	chr11:4115507	RRM1	-0.44	-5.69	-0.46	8.66e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs9534288	0.762	rs3934247	chr13:46549137	C/T	cg15192986	chr13:46630673	CPB2	-0.53	-7.68	-0.57	4.13e-12	Blood protein levels;
TGCT	cis	rs58722170	0.610	rs55884510	chr1:38068943	G/A	cg17933807	chr1:38061675	GNL2	-0.84	-8.39	-0.6	9.28e-14	High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs9457247	0.935	rs2149093	chr6:167373045	T/C	cg23791538	chr6:167370224	RNASET2	0.53	5.07	0.41	1.39e-6	Crohn's disease;
TGCT	cis	rs7267979	1.000	rs6050590	chr20:25384994	G/A	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9902453	0.904	rs11654983	chr17:28370042	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.84	-7.96	-0.58	9.19e-13	Coffee consumption (cups per day);
TGCT	cis	rs57590327	0.555	rs3943556	chr3:81738892	G/C	cg07356753	chr3:81810745	GBE1	-0.78	-7.36	-0.55	2.18e-11	Extraversion;
TGCT	cis	rs7635838	0.963	rs35834806	chr3:11414100	C/T	cg00170343	chr3:11313890	ATG7	0.61	5.91	0.47	3.14e-8	HDL cholesterol;
TGCT	cis	rs6546537	0.550	rs72837959	chr2:69780762	C/T	cg10773587	chr2:69614142	GFPT1	-0.65	-5.94	-0.47	2.7e-8	Serum thyroid-stimulating hormone levels;
TGCT	cis	rs7180079	0.563	rs6494486	chr15:64996193	G/A	cg03791955	chr15:65024147	NA	0.28	5.45	0.44	2.61e-7	Monocyte count;
TGCT	cis	rs7586879	1.000	rs7586879	chr2:25116977	C/T	cg01884057	chr2:25150051	NA	0.29	5.07	0.41	1.38e-6	Body mass index;
TGCT	cis	rs7611238	0.538	rs4677842	chr3:195137216	C/T	cg27323046	chr3:195102265	ACAP2	0.38	5.13	0.42	1.09e-6	Body mass index;
TGCT	cis	rs2242116	0.727	rs6442040	chr3:46963035	C/A	cg02527881	chr3:46936655	PTH1R	-0.31	-5.77	-0.46	5.88e-8	Birth weight;
TGCT	cis	rs11711311	1.000	rs7622515	chr3:113472538	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.72	-6.74	-0.52	5.36e-10	IgG glycosylation;
TGCT	cis	rs225245	0.791	rs2285742	chr17:34018682	C/T	cg05299278	chr17:33885742	SLFN14	0.22	4.7	0.39	6.92e-6	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs11671005	0.735	rs11084543	chr19:58932701	T/C	cg13877915	chr19:58951672	ZNF132	0.65	5.14	0.42	1.04e-6	Mean platelet volume;
TGCT	cis	rs2797160	1.000	rs1739380	chr6:126012858	T/C	cg05901451	chr6:126070800	HEY2	0.74	6.12	0.48	1.15e-8	Endometrial cancer;
TGCT	cis	rs8084125	0.765	rs72981157	chr18:74944238	A/G	cg05528293	chr18:74961138	GALR1	0.49	4.84	0.4	3.74e-6	Obesity-related traits;
TGCT	cis	rs9611565	0.625	rs2076199	chr22:41903743	G/T	cg03806693	chr22:41940476	POLR3H	-0.98	-10.44	-0.68	1.11e-18	Vitiligo;
TGCT	cis	rs7103648	0.808	rs7103835	chr11:47461693	G/A	cg20307385	chr11:47447363	PSMC3	0.96	10.27	0.68	2.85e-18	Diastolic blood pressure;Systolic blood pressure;
TGCT	cis	rs6500602	0.727	rs4786515	chr16:4578133	T/A	cg08645402	chr16:4508243	NA	0.19	5.25	0.43	6.32e-7	Schizophrenia;
TGCT	cis	rs28595532	0.920	rs114019902	chr4:119755564	G/A	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs3796352	1.000	rs34313969	chr3:52995166	A/G	cg15956490	chr3:53032818	SFMBT1	0.59	6.04	0.48	1.65e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs8014204	0.566	rs11629369	chr14:75162021	G/A	cg06637938	chr14:75390232	RPS6KL1	0.61	5.51	0.44	1.98e-7	Caffeine consumption;
TGCT	trans	rs9388451	0.839	rs4897155	chr6:126095144	C/A	cg05039488	chr6:79577232	IRAK1BP1	-0.74	-8.38	-0.6	9.89e-14	Brugada syndrome;
TGCT	cis	rs1865760	0.566	rs9467663	chr6:26021456	C/G	cg17042849	chr6:26104293	HIST1H4C	-0.61	-5.13	-0.42	1.07e-6	Height;
TGCT	cis	rs13191362	1.000	rs34052221	chr6:163160803	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.14	9.38	0.64	4.1e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7666738	0.830	rs28802909	chr4:99039410	G/A	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10779751	1.000	rs2076655	chr1:11289161	A/G	cg08854313	chr1:11322531	MTOR	-0.92	-10.07	-0.67	8.5e-18	Body mass index;
TGCT	cis	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg09021430	chr5:549028	NA	-0.37	-5.16	-0.42	9.7e-7	Lung disease severity in cystic fibrosis;
TGCT	cis	rs2836950	0.502	rs12627205	chr21:40630027	C/T	cg06238570	chr21:40685208	BRWD1	-0.61	-6.2	-0.49	7.81e-9	Menarche (age at onset);
TGCT	cis	rs1005224	0.963	rs11623813	chr14:76138194	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.63	-5.66	-0.45	1.01e-7	Large artery stroke;
TGCT	cis	rs858239	0.601	rs987257	chr7:23147840	G/A	cg05602783	chr7:23145260	KLHL7	-0.66	-5.62	-0.45	1.2e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs3008870	1.000	rs1137656	chr1:67451602	A/C	cg11518657	chr1:67396239	MIER1	-0.54	-4.61	-0.38	9.72e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs7586879	0.616	rs6545813	chr2:25131287	C/T	cg15423357	chr2:25149977	NA	0.52	5.03	0.41	1.65e-6	Body mass index;
TGCT	cis	rs3008870	0.583	rs11208985	chr1:67464666	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-0.97	-8.16	-0.59	3.17e-13	Lymphocyte percentage of white cells;
TGCT	cis	rs751728	1.000	rs3793079	chr6:33767788	T/A	cg00334056	chr6:33755658	LEMD2	-0.25	-4.52	-0.38	1.44e-5	Crohn's disease;
TGCT	cis	rs7772486	0.846	rs866473	chr6:146353414	A/C	cg23711669	chr6:146136114	FBXO30	0.89	10.0	0.67	1.25e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6912958	0.500	rs2025486	chr6:87796886	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.73	-7.35	-0.55	2.37e-11	Monocyte percentage of white cells;
TGCT	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg13770153	chr20:60521292	NA	-0.6	-7.67	-0.57	4.3e-12	Body mass index;
TGCT	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg01171360	chr6:293285	DUSP22	-0.78	-7.98	-0.58	8.31e-13	Menopause (age at onset);
TGCT	cis	rs9653442	0.545	rs11123810	chr2:100759285	T/C	cg07810366	chr2:100720526	AFF3	-0.35	-5.06	-0.41	1.48e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg21862992	chr11:68658383	NA	-0.43	-5.96	-0.47	2.4e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs12510870	0.599	rs7695792	chr4:74453064	T/C	cg05868023	chr4:75230803	EREG	-0.55	-4.74	-0.39	5.71e-6	Iris color (b* coordinate);
TGCT	cis	rs28595532	0.841	rs10019311	chr4:119785458	G/A	cg00700008	chr4:120138107	USP53	0.49	4.48	0.37	1.71e-5	Cannabis dependence symptom count;
TGCT	cis	rs3862435	0.764	rs2589948	chr15:90952232	G/A	cg14166756	chr15:90894880	ZNF774	-0.29	-4.68	-0.39	7.31e-6	Response to exercise (triglyceride level interaction);
TGCT	cis	rs9928842	0.765	rs6564221	chr16:75224971	C/T	cg09066997	chr16:75300724	BCAR1	0.29	5.13	0.42	1.09e-6	Alcoholic chronic pancreatitis;
TGCT	trans	rs4332037	1.000	rs6947019	chr7:1950337	G/A	cg10840412	chr1:235813424	GNG4	1.05	8.28	0.6	1.71e-13	Bipolar disorder;
TGCT	cis	rs6089829	0.589	rs73921629	chr20:61676036	G/C	cg03213289	chr20:61660250	NA	-0.55	-5.49	-0.44	2.18e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2013441	0.965	rs8068720	chr17:20214171	G/T	cg18979559	chr17:20280153	CCDC144C	-0.47	-4.93	-0.4	2.63e-6	Obesity-related traits;
TGCT	cis	rs7843479	0.601	rs11135764	chr8:21814004	A/G	cg17168535	chr8:21777572	XPO7	0.81	8.33	0.6	1.25e-13	Mean corpuscular volume;
TGCT	cis	rs10089	0.953	rs1432615	chr5:127395371	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	6.93	0.53	2e-10	Ileal carcinoids;
TGCT	cis	rs2439831	0.702	rs2467402	chr15:44024490	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.76	-5.34	-0.43	4.36e-7	Lung cancer in ever smokers;
TGCT	cis	rs12579753	0.879	rs1986537	chr12:82156475	G/C	cg07988820	chr12:82153109	PPFIA2	-0.67	-7.45	-0.56	1.4e-11	Resting heart rate;
TGCT	cis	rs9430161	0.579	rs11121669	chr1:11039567	T/C	cg27631724	chr1:11040367	C1orf127	0.55	6.58	0.51	1.2e-9	Ewing sarcoma;
TGCT	cis	rs7523050	0.643	rs67091034	chr1:109402567	C/G	cg08274380	chr1:109419600	GPSM2	1.3	6.39	0.5	2.99e-9	Fat distribution (HIV);
TGCT	cis	rs7829975	0.542	rs7844374	chr8:8798684	A/G	cg06636001	chr8:8085503	FLJ10661	-0.76	-6.71	-0.52	6.14e-10	Mood instability;
TGCT	cis	rs79057730	0.527	rs34519158	chr7:811114	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.64	5.23	0.43	6.91e-7	Initial pursuit acceleration;
TGCT	trans	rs17685	0.558	rs60787921	chr7:75792844	C/A	cg19862616	chr7:65841803	NCRNA00174	0.51	8.88	0.62	6.28e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs55962025	0.842	rs362271	chr4:3235518	C/T	cg06533319	chr4:3265114	C4orf44	0.24	4.87	0.4	3.26e-6	Parental longevity (mother's age at death);
TGCT	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg06112835	chr11:68658793	MRPL21	-0.43	-7.19	-0.54	5.3e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9467711	0.516	rs555460	chr6:25870655	C/T	cg12310025	chr6:25882481	NA	-0.76	-5.11	-0.42	1.18e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs11148252	0.774	rs56033750	chr13:52747278	A/C	cg00495681	chr13:53174319	NA	0.51	4.87	0.4	3.39e-6	Lewy body disease;
TGCT	cis	rs13217239	0.572	rs9379958	chr6:27066163	A/C	cg02458000	chr6:26745757	NA	-0.51	-4.57	-0.38	1.18e-5	Schizophrenia;
TGCT	cis	rs72634258	0.554	rs7556518	chr1:7847846	G/A	cg26816564	chr1:7831052	VAMP3	0.95	6.95	0.53	1.88e-10	Inflammatory bowel disease;
TGCT	cis	rs79349575	0.783	rs4794003	chr17:47029904	C/T	cg07967210	chr17:47022446	SNF8	0.44	6.13	0.48	1.1e-8	Type 2 diabetes;
TGCT	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg05785598	chr3:49045655	WDR6	0.36	4.89	0.4	3e-6	Menarche (age at onset);
TGCT	cis	rs2334880	0.678	rs16973190	chr16:71508501	T/C	cg06353428	chr16:71660113	MARVELD3	-1.33	-7.82	-0.57	2.01e-12	Malaria;
TGCT	cis	rs2072499	0.966	rs2842857	chr1:156168736	T/C	cg24450063	chr1:156163899	SLC25A44	1.2	18.21	0.85	7.43e-37	Testicular germ cell tumor;
TGCT	cis	rs4665630	0.522	rs75866363	chr2:24046426	G/A	cg08063864	chr2:24346004	PFN4;LOC375190	1.18	5.08	0.41	1.35e-6	Hypertension;
TGCT	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg23806715	chr17:73775811	H3F3B	0.55	4.55	0.38	1.26e-5	Psoriasis;
TGCT	cis	rs1538970	0.816	rs4633317	chr1:45985157	T/C	cg05343316	chr1:45956843	TESK2	0.79	6.48	0.5	1.99e-9	Platelet count;
TGCT	cis	rs4478858	0.652	rs6672056	chr1:31688111	T/C	cg00250761	chr1:31883323	NA	0.29	5.03	0.41	1.7e-6	Alcohol dependence;
TGCT	cis	rs76419734	0.558	rs7696836	chr4:106583826	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.65	4.82	0.4	4.09e-6	Post bronchodilator FEV1;
TGCT	cis	rs2243480	1.000	rs316331	chr7:65604622	A/G	cg18252515	chr7:66147081	NA	1.18	7.7	0.57	3.8e-12	Diabetic kidney disease;
TGCT	cis	rs4919694	0.536	rs12414777	chr10:104697781	C/T	cg04362960	chr10:104952993	NT5C2	0.68	5.4	0.44	3.21e-7	Arsenic metabolism;
TGCT	cis	rs6754311	0.731	rs309134	chr2:136755684	A/G	cg07169764	chr2:136633963	MCM6	-0.69	-6.41	-0.5	2.82e-9	Mosquito bite size;
TGCT	cis	rs9467711	0.523	rs9379853	chr6:26357635	A/G	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2730245	0.618	rs859781	chr7:158661758	G/A	cg11984989	chr7:158649758	WDR60	1.07	9.74	0.66	5.49e-17	Height;
TGCT	cis	rs7666738	0.830	rs7659593	chr4:98934823	T/C	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12510870	0.599	rs7674913	chr4:74449470	G/A	cg05868023	chr4:75230803	EREG	-0.54	-4.76	-0.39	5.33e-6	Iris color (b* coordinate);
TGCT	cis	rs9330316	0.632	rs6594037	chr2:110341585	C/G	cg25199208	chr2:109402912	CCDC138	-0.41	-4.44	-0.37	1.99e-5	Schizophrenia;
TGCT	cis	rs9467773	1.000	rs6932156	chr6:26571506	T/G	cg26531700	chr6:26746687	NA	0.5	4.85	0.4	3.64e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9467773	0.620	rs2498351	chr6:26659642	C/T	cg02458000	chr6:26745757	NA	0.51	4.59	0.38	1.08e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs17443541	0.507	rs971325	chr2:200450294	A/G	cg00055341	chr2:200446845	NA	-0.33	-4.61	-0.38	9.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9682041	0.627	rs34392658	chr3:170091584	C/T	cg07589077	chr3:170072950	NA	0.26	4.53	0.38	1.36e-5	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs7085104	0.700	rs7096183	chr10:104609466	T/C	cg04362960	chr10:104952993	NT5C2	0.58	5.14	0.42	1.04e-6	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg00814883	chr7:100076585	TSC22D4	-0.9	-9.56	-0.65	1.5e-16	Platelet count;
TGCT	cis	rs1215050	0.755	rs783958	chr4:98893836	A/T	cg05340658	chr4:99064831	C4orf37	-0.46	-5.82	-0.46	4.74e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs68170813	0.559	rs76167266	chr7:106900664	C/T	cg02696742	chr7:106810147	HBP1	-0.69	-5.61	-0.45	1.27e-7	Coronary artery disease;
TGCT	cis	rs651907	0.535	rs12631513	chr3:101517476	A/C	cg11279151	chr3:101281821	RG9MTD1	-0.31	-6.4	-0.5	2.91e-9	Colorectal cancer;
TGCT	cis	rs155076	1.000	rs484365	chr13:21845944	G/T	cg11317459	chr13:21872234	NA	-1.42	-12.02	-0.73	1.53e-22	White matter hyperintensity burden;
TGCT	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.4	7.13	0.54	7.33e-11	Schizophrenia;
TGCT	cis	rs9611565	0.571	rs7364123	chr22:42216326	A/G	cg03806693	chr22:41940476	POLR3H	-0.86	-7.93	-0.58	1.09e-12	Vitiligo;
TGCT	cis	rs62380364	0.542	rs2247885	chr5:88047999	T/C	cg22951263	chr5:87985283	NA	-0.58	-6.12	-0.48	1.12e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs10791097	0.739	rs11222358	chr11:130730497	G/A	cg14779329	chr11:130786720	SNX19	0.25	4.44	0.37	1.96e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	trans	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg21659725	chr3:3221576	CRBN	-0.98	-15.33	-0.81	2.1000000000000002e-30	Intelligence (multi-trait analysis);
TGCT	cis	rs317865	0.867	rs7668729	chr4:16180391	A/C	cg04764131	chr4:16228633	TAPT1;FLJ39653	-0.68	-4.53	-0.38	1.35e-5	Kidney disease (early stage) in type 1 diabetes;
TGCT	cis	rs1129187	0.755	rs2296804	chr6:42931261	C/G	cg10862848	chr6:42927986	GNMT	-0.37	-4.47	-0.37	1.75e-5	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs12477438	0.798	rs2309524	chr2:99659510	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-6.1	-0.48	1.22e-8	Chronic sinus infection;
TGCT	cis	rs7267979	0.816	rs8115257	chr20:25207931	A/G	cg16686733	chr20:25566563	NINL	0.48	4.5	0.37	1.52e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7178424	0.649	rs17271158	chr15:62143664	C/T	cg00456672	chr15:62358751	C2CD4A	-0.31	-4.47	-0.37	1.75e-5	Height;
TGCT	cis	rs919433	0.617	rs10931793	chr2:198577585	G/A	cg00792783	chr2:198669748	PLCL1	-0.55	-5.04	-0.41	1.62e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs208520	0.690	rs2126120	chr6:66742754	A/G	cg07460842	chr6:66804631	NA	0.94	9.91	0.66	2.15e-17	Exhaled nitric oxide output;
TGCT	cis	rs1129187	0.935	rs9462859	chr6:42946943	G/A	cg09436375	chr6:42928200	GNMT	-0.4	-5.13	-0.42	1.06e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	trans	rs10504390	0.656	rs75002270	chr8:66474587	T/C	cg26037026	chr7:1641922	NA	-0.64	-6.84	-0.52	3.26e-10	IgG glycosylation;
TGCT	cis	rs3015497	1.000	rs3015495	chr14:51114703	C/T	cg04730355	chr14:51134070	SAV1	-0.54	-4.74	-0.39	5.8e-6	Mean platelet volume;
TGCT	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	7.12	0.54	7.55e-11	Platelet count;
TGCT	cis	rs7666738	0.546	rs10026181	chr4:98814118	C/T	cg05340658	chr4:99064831	C4orf37	-0.56	-5.96	-0.47	2.4e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9858542	0.537	rs9864406	chr3:49352619	A/G	cg08550065	chr3:50336684	HYAL3;NAT6	0.64	4.57	0.38	1.17e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs13401104	0.680	rs72620813	chr2:237146225	C/T	cg26422059	chr2:237146110	ASB18	0.57	4.62	0.38	9.62e-6	Educational attainment;
TGCT	cis	rs60843830	1.000	rs62114548	chr2:274672	C/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.73	7.33	0.55	2.65e-11	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs12142240	0.698	rs1057535	chr1:46815898	T/C	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs228437	0.526	rs2474924	chr6:134907563	A/T	cg09872934	chr6:134495829	SGK1	0.61	5.33	0.43	4.57e-7	Melanoma;
TGCT	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.94	7.92	0.58	1.17e-12	Platelet count;
TGCT	cis	rs7552404	0.690	rs7549863	chr1:76327923	T/C	cg22875332	chr1:76189707	ACADM	-0.57	-6.14	-0.48	1.05e-8	Blood metabolite levels;Acylcarnitine levels;
TGCT	trans	rs1496653	0.602	rs34928966	chr3:23450757	C/G	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs4808199	0.947	rs2099333	chr19:19605963	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.72	5.15	0.42	9.94e-7	Nonalcoholic fatty liver disease;
TGCT	trans	rs1814175	0.645	rs847635	chr11:49923323	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.51	-0.69	7.2e-19	Height;
TGCT	cis	rs11792861	0.851	rs4542004	chr9:111814478	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.47	4.64	0.38	8.84e-6	Menarche (age at onset);
TGCT	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg23131131	chr22:24373011	LOC391322	-0.83	-9.34	-0.64	5e-16	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs4891159	0.790	rs11150953	chr18:74145491	G/A	cg24786174	chr18:74118243	ZNF516	-0.54	-7.19	-0.54	5.41e-11	Longevity;
TGCT	cis	rs58799304	0.644	rs11578696	chr1:156056968	A/G	cg25208724	chr1:156163844	SLC25A44	0.85	4.79	0.4	4.58e-6	Ischemic stroke;
TGCT	cis	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg07424592	chr7:64974309	NA	1.4	8.37	0.6	1.04e-13	Diabetic kidney disease;
TGCT	cis	rs807669	0.548	rs723414	chr22:19185736	G/A	cg02655711	chr22:19163373	SLC25A1	0.31	6.38	0.5	3.25e-9	Metabolite levels;
TGCT	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg06238570	chr21:40685208	BRWD1	-0.61	-6.31	-0.49	4.43e-9	Menarche (age at onset);
TGCT	cis	rs2153535	0.580	rs2327053	chr6:8443127	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.58	0.45	1.42e-7	Motion sickness;
TGCT	cis	rs244731	0.959	rs6872021	chr5:176610012	G/A	cg17509989	chr5:176798049	RGS14	-0.6	-7.32	-0.55	2.69e-11	Urate levels in lean individuals;
TGCT	cis	rs9467711	0.659	rs72844462	chr6:26563864	A/C	cg16898833	chr6:26189333	HIST1H4D	1.25	5.86	0.47	3.88e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7614311	0.681	rs73130565	chr3:63887135	T/C	cg22134162	chr3:63841271	THOC7	-0.4	-5.16	-0.42	9.41e-7	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg03264133	chr6:25882463	NA	0.52	4.82	0.4	4.2e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9486715	1.000	rs2273621	chr6:97058553	A/G	cg06623918	chr6:96969491	KIAA0776	-1.11	-14.98	-0.8	1.36e-29	Headache;
TGCT	cis	rs887829	0.569	rs4663963	chr2:234650193	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.26	-4.56	-0.38	1.22e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
TGCT	cis	rs950169	0.595	rs11631921	chr15:85143277	G/A	cg12863693	chr15:85201151	NMB	0.39	4.46	0.37	1.81e-5	Schizophrenia;
TGCT	cis	rs10465746	0.725	rs4907188	chr1:84361608	C/T	cg10977910	chr1:84465055	TTLL7	0.69	6.73	0.52	5.74e-10	Obesity-related traits;
TGCT	cis	rs11080466	0.964	rs12455464	chr18:10901807	C/T	cg02393756	chr18:9912783	VAPA	0.26	4.73	0.39	6.09e-6	Non-small cell lung cancer;
TGCT	cis	rs6918586	0.636	rs198857	chr6:26102417	G/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.7	-6.6	-0.51	1.09e-9	Schizophrenia;
TGCT	cis	rs67311347	0.955	rs73080163	chr3:40533061	G/T	cg13683864	chr3:40499215	RPL14	-1.17	-11.19	-0.71	1.56e-20	Renal cell carcinoma;
TGCT	cis	rs13394619	0.875	rs9287734	chr2:11724475	A/G	cg07314298	chr2:11723111	GREB1	-0.28	-4.95	-0.41	2.32e-6	Endometriosis;
TGCT	cis	rs7804356	0.651	rs11980739	chr7:26818164	A/G	cg03456212	chr7:26904342	SKAP2	-0.54	-4.54	-0.38	1.3e-5	Type 1 diabetes;
TGCT	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg18876405	chr7:65276391	NA	-0.32	-4.92	-0.4	2.72e-6	Aortic root size;
TGCT	cis	rs9611519	0.780	rs9611528	chr22:41648502	T/C	cg06634786	chr22:41940651	POLR3H	-0.54	-4.87	-0.4	3.37e-6	Neuroticism;
TGCT	cis	rs9400467	0.537	rs1150081	chr6:111479016	A/G	cg15721981	chr6:111408429	SLC16A10	0.68	4.48	0.37	1.69e-5	Blood metabolite levels;Amino acid levels;
TGCT	cis	rs35883536	0.587	rs2809812	chr1:101032087	G/T	cg10298815	chr1:101004474	GPR88	0.24	4.58	0.38	1.12e-5	Monocyte count;
TGCT	cis	rs9341808	0.617	rs9294170	chr6:80814080	A/G	cg08355045	chr6:80787529	NA	0.34	6.03	0.48	1.7e-8	Sitting height ratio;
TGCT	cis	rs35883536	0.528	rs1855800	chr1:101030641	G/A	cg06223162	chr1:101003688	GPR88	0.43	8.41	0.6	8.23e-14	Monocyte count;
TGCT	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg07507251	chr3:52567010	NT5DC2	0.47	6.74	0.52	5.33e-10	Electroencephalogram traits;
TGCT	cis	rs12477438	0.765	rs7571390	chr2:99626593	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-4.56	-0.38	1.21e-5	Chronic sinus infection;
TGCT	cis	rs3796352	0.568	rs11713376	chr3:52958927	A/G	cg11137980	chr3:52469226	SEMA3G	0.3	4.8	0.4	4.45e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg06618935	chr21:46677482	NA	-0.36	-5.71	-0.46	7.76e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs644799	0.662	rs35793328	chr11:95490896	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.78	7.75	0.57	2.9e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7312774	0.609	rs2374655	chr12:107380162	T/C	cg16260113	chr12:107380972	MTERFD3	1.58	6.82	0.52	3.48e-10	Severe influenza A (H1N1) infection;
TGCT	trans	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg13615516	chr5:77269221	NA	0.67	8.36	0.6	1.09e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7666738	0.830	rs13137859	chr4:99050319	A/G	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg07061783	chr6:25882402	NA	-0.89	-10.69	-0.69	2.63e-19	Urate levels;
TGCT	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg22166914	chr1:53195759	ZYG11B	0.3	4.85	0.4	3.62e-6	Monocyte count;
TGCT	cis	rs2836950	0.501	rs62223052	chr21:40708702	A/C	cg06238570	chr21:40685208	BRWD1	-0.62	-6.26	-0.49	5.66e-9	Menarche (age at onset);
TGCT	cis	rs6964587	1.000	rs36021614	chr7:91717490	C/G	cg17063962	chr7:91808500	NA	0.86	9.47	0.65	2.39e-16	Breast cancer;
TGCT	cis	rs4273100	0.646	rs11652784	chr17:19217261	C/T	cg03910582	chr17:19030146	GRAPL	-0.51	-6.2	-0.49	7.86e-9	Schizophrenia;
TGCT	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg02725872	chr8:58115012	NA	-0.39	-4.74	-0.39	5.77e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2932538	0.922	rs7551933	chr1:113086706	C/T	cg22162597	chr1:113214053	CAPZA1	-0.27	-5.98	-0.47	2.24e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs1538970	0.924	rs4660851	chr1:45843810	A/T	cg05343316	chr1:45956843	TESK2	0.64	5.05	0.41	1.51e-6	Platelet count;
TGCT	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg06238570	chr21:40685208	BRWD1	0.69	6.47	0.5	2.08e-9	Cognitive function;
TGCT	cis	rs72781680	0.898	rs12612492	chr2:24093756	C/T	cg08917208	chr2:24149416	ATAD2B	0.82	5.58	0.45	1.43e-7	Lymphocyte counts;
TGCT	cis	rs1056107	0.931	rs10759536	chr9:114991502	C/T	cg02332936	chr9:115140584	NA	-0.25	-4.45	-0.37	1.89e-5	Colorectal cancer;
TGCT	cis	rs2153535	0.580	rs7755284	chr6:8457479	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg10862848	chr6:42927986	GNMT	-0.36	-4.45	-0.37	1.9e-5	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs9325144	0.555	rs7955128	chr12:38684121	A/T	cg13010199	chr12:38710504	ALG10B	0.53	4.72	0.39	6.36e-6	Morning vs. evening chronotype;
TGCT	cis	rs10193935	0.901	rs2286701	chr2:42555636	T/C	cg27598129	chr2:42591480	NA	-0.41	-5.68	-0.45	9.25e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs36051895	0.623	rs3780383	chr9:5232409	G/C	cg02405213	chr9:5042618	JAK2	-0.69	-7.96	-0.58	9.22e-13	Pediatric autoimmune diseases;
TGCT	cis	rs2544527	0.563	rs6728667	chr2:15904705	G/A	cg26669897	chr2:15909070	NA	0.39	4.88	0.4	3.24e-6	Pulmonary function (smoking interaction);Pulmonary function;
TGCT	cis	rs9473924	0.542	rs2817378	chr6:50789197	G/A	cg14470998	chr6:50812995	TFAP2B	1.33	7.94	0.58	1.03e-12	Body mass index;
TGCT	cis	rs1008375	0.966	rs4235391	chr4:17696409	A/G	cg18681998	chr4:17616180	MED28	0.78	7.35	0.55	2.35e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6088590	0.502	rs6059861	chr20:33068563	A/T	cg08999081	chr20:33150536	PIGU	0.29	5.66	0.45	9.97e-8	Coronary artery disease;
TGCT	cis	rs9894429	0.690	rs11869779	chr17:79570067	C/T	cg21028142	chr17:79581711	NPLOC4	-0.3	-7.03	-0.53	1.2e-10	Eye color traits;
TGCT	cis	rs68170813	0.521	rs61673847	chr7:106892431	A/G	cg02696742	chr7:106810147	HBP1	-0.69	-5.61	-0.45	1.27e-7	Coronary artery disease;
TGCT	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg07636037	chr3:49044803	WDR6	0.84	8.59	0.61	3.04e-14	Menarche (age at onset);
TGCT	cis	rs4455778	0.659	rs28683492	chr7:49014741	G/A	cg26309511	chr7:48887640	NA	-0.45	-5.47	-0.44	2.36e-7	Lung cancer in never smokers;
TGCT	cis	rs13256369	0.708	rs11249886	chr8:8562021	T/A	cg17143192	chr8:8559678	CLDN23	0.55	5.1	0.42	1.25e-6	Obesity-related traits;
TGCT	cis	rs11696501	0.688	rs6073850	chr20:44301084	C/T	cg11783356	chr20:44313418	WFDC10B	-0.33	-4.79	-0.4	4.67e-6	Brain structure;
TGCT	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg22166914	chr1:53195759	ZYG11B	-0.4	-6.85	-0.52	2.99e-10	Monocyte count;
TGCT	cis	rs9972944	0.756	rs9894010	chr17:63760156	T/G	cg07283582	chr17:63770753	CCDC46	-0.26	-5.11	-0.42	1.18e-6	Total body bone mineral density;
TGCT	cis	rs6570726	0.791	rs365747	chr6:145866784	C/T	cg05347473	chr6:146136440	FBXO30	0.54	5.15	0.42	1.01e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs79387448	0.745	rs1523196	chr2:103163700	T/G	cg09003973	chr2:102972529	NA	0.92	5.89	0.47	3.39e-8	Gut microbiota (bacterial taxa);
TGCT	cis	rs1903068	0.719	rs73236106	chr4:55996712	C/T	cg09978860	chr4:56023921	NA	0.55	6.09	0.48	1.31e-8	Endometriosis;
TGCT	cis	rs453301	0.686	rs6748	chr8:8890802	C/T	cg06636001	chr8:8085503	FLJ10661	-0.66	-5.58	-0.45	1.42e-7	Joint mobility (Beighton score);
TGCT	cis	rs9303401	0.580	rs12946396	chr17:57164195	T/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.64	5.87	0.47	3.79e-8	Cognitive test performance;
TGCT	cis	rs2074977	0.500	rs10153493	chr19:3447745	C/T	cg08380311	chr19:3435252	NFIC	-0.74	-6.92	-0.53	2.1e-10	Height;
TGCT	cis	rs6750047	0.573	rs149148	chr2:38318640	G/A	cg07380506	chr2:38303506	CYP1B1	0.59	5.47	0.44	2.37e-7	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs13082711	0.595	rs4973762	chr3:27364789	A/T	cg02860705	chr3:27208620	NA	0.44	6.65	0.51	8.54e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs2742417	1.000	rs2251954	chr3:45731784	A/G	cg04837898	chr3:45731254	SACM1L	-0.56	-5.92	-0.47	2.89e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg06636001	chr8:8085503	FLJ10661	0.61	5.46	0.44	2.47e-7	Mood instability;
TGCT	cis	rs765787	0.530	rs28756676	chr15:45540360	G/A	cg24006582	chr15:45444508	DUOX1	-0.25	-5.54	-0.45	1.76e-7	Uric acid levels;
TGCT	cis	rs2997447	0.846	rs12067677	chr1:26411971	C/T	cg03844060	chr1:26490628	NA	0.28	4.57	0.38	1.16e-5	QRS complex (12-leadsum);
TGCT	cis	rs9858542	0.953	rs7633271	chr3:49555963	T/C	cg03060546	chr3:49711283	APEH	-0.61	-5.37	-0.43	3.78e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs11098499	0.909	rs28632018	chr4:120386730	T/C	cg09307838	chr4:120376055	NA	0.68	6.51	0.5	1.66e-9	Corneal astigmatism;
TGCT	cis	rs12908161	0.959	rs12906348	chr15:85329421	A/C	cg12863693	chr15:85201151	NMB	0.41	4.86	0.4	3.54e-6	Schizophrenia;
TGCT	cis	rs12477438	0.798	rs6759354	chr2:99632195	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-6.1	-0.48	1.22e-8	Chronic sinus infection;
TGCT	cis	rs7772486	0.875	rs10872582	chr6:146373061	G/A	cg05347473	chr6:146136440	FBXO30	0.51	4.83	0.4	3.87e-6	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs1864729	1.000	rs1864729	chr8:98282189	G/A	cg08679828	chr8:102218111	ZNF706	-0.98	-6.67	-0.51	7.76e-10	Estradiol plasma levels (breast cancer);
TGCT	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	4.92	0.4	2.68e-6	Menopause (age at onset);
TGCT	cis	rs4727027	0.737	rs10278971	chr7:148780659	A/T	cg23583168	chr7:148888333	NA	-0.67	-8.47	-0.61	6e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs1499614	1.000	rs2707840	chr7:66158015	C/T	cg18252515	chr7:66147081	NA	-1.26	-7.85	-0.58	1.69e-12	Gout;
TGCT	cis	rs7666738	0.830	rs35822567	chr4:98654138	G/A	cg18180107	chr4:99064573	C4orf37	0.53	5.07	0.41	1.41e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4499344	0.633	rs259251	chr19:33149768	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.85	9.09	0.63	2.01e-15	Mean platelet volume;
TGCT	cis	rs3087591	0.887	rs1013946	chr17:29530350	A/C	cg24425628	chr17:29625626	OMG;NF1	0.47	7.35	0.55	2.32e-11	Hip circumference;
TGCT	cis	rs6545883	0.895	rs7588814	chr2:61695589	A/T	cg15711740	chr2:61764176	XPO1	-0.54	-4.81	-0.4	4.29e-6	Tuberculosis;
TGCT	cis	rs9653442	0.932	rs893245	chr2:100814893	C/T	cg22139774	chr2:100720529	AFF3	-0.39	-6.25	-0.49	5.95e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs3099143	1.000	rs4886831	chr15:77106801	T/C	cg21673338	chr15:77095150	SCAPER	0.51	4.88	0.4	3.17e-6	Recalcitrant atopic dermatitis;
TGCT	cis	rs3096299	0.509	rs4785691	chr16:89597221	A/G	cg02187348	chr16:89574699	SPG7	0.68	7.78	0.57	2.39e-12	Multiple myeloma (IgH translocation);
TGCT	cis	rs6964587	1.000	rs6967256	chr7:91643219	G/A	cg17063962	chr7:91808500	NA	0.91	9.97	0.67	1.53e-17	Breast cancer;
TGCT	trans	rs1814175	0.754	rs10839453	chr11:49955815	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.38	-7.38	-0.55	2e-11	Height;
TGCT	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.2	0.42	8.14e-7	Menopause (age at onset);
TGCT	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg20607798	chr8:58055168	NA	0.45	4.66	0.39	7.88e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs28595532	0.920	rs115317002	chr4:119722809	T/C	cg14228332	chr4:119757509	SEC24D	1.38	6.91	0.53	2.21e-10	Cannabis dependence symptom count;
TGCT	cis	rs62064224	0.589	rs9904964	chr17:30662832	A/G	cg18200150	chr17:30822561	MYO1D	-0.4	-4.77	-0.39	5.03e-6	Schizophrenia;
TGCT	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg01017244	chr2:74357527	NA	0.43	5.87	0.47	3.8e-8	Gestational age at birth (maternal effect);
TGCT	cis	rs78456975	0.527	rs10184112	chr2:1571112	A/G	cg01028140	chr2:1542097	TPO	-0.32	-4.99	-0.41	1.97e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	trans	rs1973993	0.691	rs1989141	chr1:96898520	C/T	cg10631902	chr5:14652156	NA	0.4	10.92	0.7	7.19e-20	Weight;
TGCT	cis	rs6500602	0.673	rs4786512	chr16:4573040	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.44	6.44	0.5	2.38e-9	Schizophrenia;
TGCT	cis	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg25427524	chr10:38739819	LOC399744	-0.39	-8.06	-0.59	5.59e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs919433	0.679	rs1598469	chr2:198515658	T/C	cg00792783	chr2:198669748	PLCL1	0.54	4.8	0.4	4.55e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs367615	0.959	rs2201016	chr5:108947287	T/C	cg17395555	chr5:108820864	NA	0.3	4.81	0.4	4.38e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs7568458	0.811	rs3755015	chr2:85764041	G/A	cg17127132	chr2:85788382	GGCX	0.68	6.58	0.51	1.2e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs4319547	0.656	rs10734918	chr12:122921512	A/C	cg08088222	chr12:122070432	ORAI1	0.26	4.46	0.37	1.84e-5	Body mass index;
TGCT	cis	rs35000415	0.938	rs12531054	chr7:128644251	A/C	cg06242719	chr7:129414860	MIR183;MIR96	0.31	4.52	0.38	1.4e-5	Systemic lupus erythematosus;
TGCT	cis	rs6840360	0.642	rs2709822	chr4:152351500	A/G	cg17479576	chr4:152424074	FAM160A1	-0.57	-6.02	-0.48	1.84e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs453301	0.571	rs2929453	chr8:9084341	A/G	cg15556689	chr8:8085844	FLJ10661	-0.64	-6.03	-0.48	1.71e-8	Joint mobility (Beighton score);
TGCT	cis	rs1532993	0.518	rs28670002	chr4:98625759	A/G	cg05340658	chr4:99064831	C4orf37	-0.41	-4.96	-0.41	2.3e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg13944838	chr5:179740914	GFPT2	-0.4	-6.42	-0.5	2.66e-9	Height;
TGCT	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg18876405	chr7:65276391	NA	0.32	4.89	0.4	3.1e-6	Aortic root size;
TGCT	cis	rs245880	0.740	rs245888	chr7:29190414	C/T	cg17163760	chr7:29186267	CPVL	-0.44	-5.54	-0.45	1.73e-7	Warfarin maintenance dose;
TGCT	cis	rs1167827	0.680	rs1167796	chr7:75173180	C/T	cg04681579	chr7:75027559	TRIM73;TRIM74	0.39	4.5	0.37	1.55e-5	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs1008375	1.000	rs9991307	chr4:17662408	A/G	cg16339924	chr4:17578868	LAP3	0.56	4.86	0.4	3.51e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs360798	0.532	rs12994674	chr2:62996645	G/A	cg17519650	chr2:63277830	OTX1	-0.56	-4.65	-0.39	8.2e-6	Coronary artery disease;
TGCT	cis	rs68092024	0.704	rs704575	chr3:99486075	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.5	5.94	0.47	2.64e-8	Cleft lip with or without cleft palate;
TGCT	cis	rs12497850	0.931	rs7623023	chr3:48914238	G/A	cg06212747	chr3:49208901	KLHDC8B	0.62	5.83	0.46	4.42e-8	Parkinson's disease;
TGCT	cis	rs155076	1.000	rs261427	chr13:21860998	G/A	cg11317459	chr13:21872234	NA	-1.32	-10.89	-0.7	8.4e-20	White matter hyperintensity burden;
TGCT	cis	rs11098499	0.908	rs11729050	chr4:120300066	T/C	cg09307838	chr4:120376055	NA	0.65	6.39	0.5	3.02e-9	Corneal astigmatism;
TGCT	cis	rs9611519	0.929	rs9611469	chr22:41433319	T/C	cg13695892	chr22:41940480	POLR3H	-0.53	-4.62	-0.38	9.54e-6	Neuroticism;
TGCT	cis	rs9910055	0.529	rs228749	chr17:42174570	A/G	cg19774624	chr17:42201019	HDAC5	0.66	6.02	0.48	1.84e-8	Total body bone mineral density;
TGCT	cis	rs7267979	1.000	rs6050565	chr20:25347563	A/C	cg14121845	chr20:25566513	NINL	-0.5	-5.49	-0.44	2.13e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs372883	0.554	rs10154065	chr21:30749480	G/C	cg24692254	chr21:30365293	RNF160	0.51	4.63	0.38	9.14e-6	Pancreatic cancer;
TGCT	cis	rs9916302	0.904	rs10221223	chr17:37489100	T/G	cg07936489	chr17:37558343	FBXL20	0.63	4.91	0.4	2.83e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs250677	1.000	rs28173	chr5:148423573	C/T	cg18129178	chr5:148520854	ABLIM3	-0.43	-6.48	-0.5	1.96e-9	Breast cancer;
TGCT	cis	rs9549260	0.755	rs9549236	chr13:41147158	C/T	cg21288729	chr13:41239152	FOXO1	-0.97	-10.34	-0.68	1.9e-18	Red blood cell count;
TGCT	cis	rs116095464	0.558	rs113796397	chr5:246503	A/G	cg22857025	chr5:266934	NA	-0.34	-6.72	-0.52	5.96e-10	Breast cancer;
TGCT	cis	rs7172971	0.701	rs7172081	chr15:42345272	G/A	cg05886115	chr15:42349113	NA	0.32	5.1	0.42	1.25e-6	3-hydroxypropylmercapturic acid levels in smokers;
TGCT	trans	rs28735056	0.935	rs537962	chr18:77592660	C/G	cg05926928	chr17:57297772	GDPD1	0.71	7.61	0.56	6.04e-12	Schizophrenia;
TGCT	cis	rs11112613	0.713	rs73184083	chr12:105952593	T/A	cg03607813	chr12:105948248	NA	0.47	5.72	0.46	7.49e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	cis	rs782590	0.694	rs2627775	chr2:55877113	C/T	cg03859395	chr2:55845619	SMEK2	0.77	8.69	0.62	1.75e-14	Metabolic syndrome;
TGCT	cis	rs1577917	0.958	rs1838958	chr6:86563968	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.29	-0.43	5.34e-7	Response to antipsychotic treatment;
TGCT	cis	rs4689388	0.856	rs3200	chr4:6304878	C/T	cg00701064	chr4:6280414	WFS1	0.45	5.89	0.47	3.47e-8	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs7666738	0.830	rs13119913	chr4:98977983	G/T	cg17366294	chr4:99064904	C4orf37	0.68	6.94	0.53	1.95e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28595532	0.920	rs114207133	chr4:119755140	T/C	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs2964802	0.505	rs6897847	chr5:10831632	T/C	cg14521931	chr5:10832172	NA	-0.27	-4.49	-0.37	1.59e-5	Major depressive disorder;Recurrent major depressive disorder;
TGCT	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7246657	0.943	rs35540940	chr19:38008235	G/A	cg18154014	chr19:37997991	ZNF793	0.93	6.54	0.51	1.48e-9	Coronary artery calcification;
TGCT	cis	rs6554196	0.644	rs7694444	chr4:55498515	G/T	cg02821500	chr4:54931072	CHIC2	0.5	4.94	0.41	2.47e-6	Monocyte count;
TGCT	cis	rs2180341	0.538	rs4392733	chr6:127712603	T/C	cg24812749	chr6:127587940	RNF146	0.61	5.39	0.44	3.45e-7	Breast cancer;
TGCT	cis	rs6582630	0.538	rs12305104	chr12:38336353	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-4.51	-0.38	1.5e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs7267979	0.932	rs6132848	chr20:25561645	C/T	cg14121845	chr20:25566513	NINL	0.49	5.36	0.43	3.83e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7172809	0.643	rs16953967	chr15:77836521	C/T	cg22256960	chr15:77711686	NA	-0.5	-5.03	-0.41	1.68e-6	Glucose homeostasis traits;
TGCT	cis	rs6752107	1.000	rs2289474	chr2:234181848	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.2	4.81	0.4	4.36e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs4699052	0.590	rs2138593	chr4:104238721	T/A	cg16532752	chr4:104119610	CENPE	-0.58	-5.86	-0.47	3.96e-8	Testicular germ cell tumor;
TGCT	cis	rs877426	0.515	rs57506460	chr13:114767789	G/A	cg23466769	chr13:114801307	RASA3	0.18	4.54	0.38	1.31e-5	Facial morphology (factor 14, intercanthal width);
TGCT	cis	rs7681440	0.904	rs10004413	chr4:90769479	T/C	cg14346243	chr4:90757452	SNCA	-0.55	-5.4	-0.44	3.34e-7	Dementia with Lewy bodies;
TGCT	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg27286337	chr10:134555280	INPP5A	0.45	5.35	0.43	4.02e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg24549020	chr5:56110836	MAP3K1	0.67	5.78	0.46	5.74e-8	Initial pursuit acceleration;
TGCT	cis	rs28595532	0.764	rs56309519	chr4:119754158	C/T	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs66573146	0.831	rs56081162	chr4:6989718	C/T	cg00086871	chr4:6988644	TBC1D14	0.94	4.62	0.38	9.61e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs9486715	0.867	rs9384585	chr6:96875664	C/T	cg06623918	chr6:96969491	KIAA0776	1.11	16.62	0.83	2.35e-33	Headache;
TGCT	cis	rs1577917	0.958	rs2197648	chr6:86543887	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.47	-0.44	2.33e-7	Response to antipsychotic treatment;
TGCT	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg22166914	chr1:53195759	ZYG11B	-0.42	-7.46	-0.56	1.33e-11	Monocyte count;
TGCT	cis	rs1691799	0.899	rs1183272	chr12:66735421	T/C	cg16791601	chr12:66731901	HELB	-0.28	-6.17	-0.48	8.87e-9	White blood cell count (basophil);
TGCT	cis	rs12142240	0.698	rs17357635	chr1:46808668	G/A	cg00530320	chr1:46809349	NSUN4	0.29	5.88	0.47	3.63e-8	Menopause (age at onset);
TGCT	trans	rs1814175	0.904	rs7924371	chr11:49620595	C/T	cg15704280	chr7:45808275	SEPT13	-0.61	-6.8	-0.52	4.02e-10	Height;
TGCT	cis	rs524023	0.957	rs561193	chr11:64353029	A/G	cg07733098	chr11:64478343	NRXN2	-0.3	-4.44	-0.37	1.99e-5	Urate levels in obese individuals;
TGCT	cis	rs7769051	0.522	rs10457596	chr6:133169974	T/G	cg22852734	chr6:133119734	C6orf192	1.15	5.47	0.44	2.39e-7	Type 2 diabetes nephropathy;
TGCT	cis	rs921968	0.643	rs526134	chr2:219402371	G/A	cg02176678	chr2:219576539	TTLL4	0.44	6.34	0.49	3.92e-9	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.3	0.55	3.02e-11	Prudent dietary pattern;
TGCT	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg06112835	chr11:68658793	MRPL21	0.46	7.65	0.57	4.92e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs11190604	0.767	rs79106148	chr10:102184732	G/A	cg16342193	chr10:102329863	NA	-0.4	-5.02	-0.41	1.74e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs72615157	0.634	rs11762932	chr7:99792666	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	0.62	5.1	0.42	1.22e-6	Lung function (FEV1/FVC);
TGCT	cis	rs2050392	0.517	rs302423	chr10:30772513	A/G	cg13289132	chr10:30722225	MAP3K8	-0.38	-4.48	-0.37	1.71e-5	Inflammatory bowel disease;
TGCT	trans	rs2727020	0.681	rs1976901	chr11:49378697	T/C	cg15704280	chr7:45808275	SEPT13	-0.73	-8.33	-0.6	1.3e-13	Coronary artery disease;
TGCT	cis	rs9467711	0.790	rs35400317	chr6:26593275	C/T	cg16898833	chr6:26189333	HIST1H4D	1.37	6.2	0.49	7.83e-9	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6546537	0.550	rs4241252	chr2:69777065	C/A	cg10773587	chr2:69614142	GFPT1	-0.69	-6.26	-0.49	5.87e-9	Serum thyroid-stimulating hormone levels;
TGCT	cis	rs7769051	0.614	rs6912936	chr6:133102664	A/G	cg22852734	chr6:133119734	C6orf192	1.22	7.01	0.53	1.38e-10	Type 2 diabetes nephropathy;
TGCT	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg08280861	chr8:58055591	NA	0.36	4.93	0.4	2.61e-6	Developmental language disorder (linguistic errors);
TGCT	trans	rs208520	0.954	rs72884027	chr6:66995044	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.84	7.59	0.56	6.69e-12	Exhaled nitric oxide output;
TGCT	cis	rs62103177	0.525	rs9949598	chr18:77753037	G/A	cg07235805	chr18:78004237	PARD6G	-0.46	-4.61	-0.38	1e-5	Opioid sensitivity;
TGCT	cis	rs1372520	0.577	rs2737021	chr4:90739992	T/A	cg01966878	chr4:90757139	SNCA	-0.31	-4.76	-0.39	5.27e-6	Neuroticism;
TGCT	cis	rs9300255	0.537	rs1618679	chr12:123650714	A/G	cg00376283	chr12:123451042	ABCB9	0.72	5.55	0.45	1.65e-7	Neutrophil percentage of white cells;
TGCT	cis	rs1878931	0.501	rs4785934	chr16:3419934	G/T	cg22508957	chr16:3507546	NAT15	-0.38	-4.98	-0.41	2.1e-6	Body mass index (adult);
TGCT	trans	rs9354352	0.967	rs9354351	chr6:66696271	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	7.89	0.58	1.33e-12	Initial pursuit acceleration in psychotic disorders;
TGCT	cis	rs950776	0.518	rs12914694	chr15:78814444	G/A	cg06917634	chr15:78832804	PSMA4	0.96	9.71	0.66	6.43e-17	Sudden cardiac arrest;
TGCT	cis	rs35160687	0.901	rs10200186	chr2:86527423	C/T	cg03171300	chr2:86307199	POLR1A	0.32	5.57	0.45	1.48e-7	Night sleep phenotypes;
TGCT	cis	rs6912958	0.781	rs3918467	chr6:88180388	C/G	cg06598631	chr6:88300029	RARS2;ORC3L	-0.53	-4.85	-0.4	3.69e-6	Monocyte percentage of white cells;
TGCT	cis	rs3733589	0.590	rs12499734	chr4:10051761	A/G	cg02734326	chr4:10020555	SLC2A9	1.03	5.02	0.41	1.75e-6	Renal overload gout;
TGCT	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg13866156	chr1:1669148	SLC35E2	-0.24	-5.87	-0.47	3.74e-8	Body mass index;
TGCT	cis	rs9303401	0.614	rs56284918	chr17:57178838	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.64	5.87	0.47	3.79e-8	Cognitive test performance;
TGCT	cis	rs10779751	0.959	rs2092642	chr1:11317320	C/T	cg08854313	chr1:11322531	MTOR	0.94	10.5	0.69	7.65e-19	Body mass index;
TGCT	cis	rs56399783	0.901	rs73047387	chr7:2774125	G/A	cg19731401	chr7:2775893	GNA12	0.36	5.07	0.41	1.4e-6	Childhood ear infection;
TGCT	cis	rs4285028	0.948	rs34478505	chr3:121694071	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.77	-6.5	-0.5	1.78e-9	Multiple sclerosis;
TGCT	cis	rs5769707	0.967	rs17182154	chr22:49990470	A/G	cg20744362	chr22:50050164	C22orf34	0.27	4.57	0.38	1.16e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs614226	1.000	rs7174	chr12:121017171	A/G	cg10072921	chr12:121022843	NA	-0.43	-4.59	-0.38	1.08e-5	Type 1 diabetes nephropathy;
TGCT	cis	rs1555895	0.576	rs752375	chr10:863329	C/T	cg02193355	chr10:851439	NA	0.21	4.9	0.4	2.94e-6	Survival in rectal cancer;
TGCT	cis	rs1997103	0.906	rs2177806	chr7:55402609	A/T	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs7666738	0.830	rs17027216	chr4:99009152	G/C	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs208520	0.802	rs208516	chr6:66946119	T/C	cg07460842	chr6:66804631	NA	-0.9	-9.15	-0.63	1.45e-15	Exhaled nitric oxide output;
TGCT	cis	rs2354432	0.943	rs6660219	chr1:146691404	A/T	cg25205988	chr1:146714368	CHD1L	1.32	7.66	0.57	4.54e-12	Mitochondrial DNA levels;
TGCT	cis	rs4727027	0.651	rs12704068	chr7:148856153	T/C	cg23583168	chr7:148888333	NA	-0.69	-7.8	-0.57	2.21e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg27454412	chr7:1067447	C7orf50	0.6	4.7	0.39	6.76e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs231513	0.556	rs7221263	chr17:42011695	A/G	cg26893861	chr17:41843967	DUSP3	0.58	4.51	0.38	1.5e-5	Cognitive function;
TGCT	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg06108461	chr20:60628389	TAF4	-0.36	-4.52	-0.38	1.4e-5	Obesity-related traits;
TGCT	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg06112835	chr11:68658793	MRPL21	0.47	7.96	0.58	9.28e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs514406	0.800	rs4926930	chr1:53217335	A/G	cg16325326	chr1:53192061	ZYG11B	-0.74	-9.11	-0.63	1.79e-15	Monocyte count;
TGCT	cis	rs42648	0.693	rs2106274	chr7:89880548	C/T	cg25739043	chr7:89950458	NA	-0.54	-5.04	-0.41	1.61e-6	Homocysteine levels;
TGCT	cis	rs7552404	0.727	rs5745427	chr1:76332637	C/A	cg10523679	chr1:76189770	ACADM	-0.67	-6.27	-0.49	5.47e-9	Blood metabolite levels;Acylcarnitine levels;
TGCT	trans	rs6948404	0.737	rs73344647	chr7:36623259	A/C	cg00810939	chr1:24463749	IL22RA1	0.68	7.04	0.53	1.17e-10	HIV-1 viral setpoint;
TGCT	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg11890956	chr21:40555474	PSMG1	-0.72	-6.41	-0.5	2.76e-9	Cognitive function;
TGCT	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg05368731	chr17:41323189	NBR1	1.15	13.14	0.76	2.96e-25	Menopause (age at onset);
TGCT	cis	rs3924048	0.574	rs61776783	chr1:12612657	T/C	cg00291366	chr1:12616550	NA	0.33	4.93	0.4	2.6e-6	Optic cup area;
TGCT	cis	rs2239547	0.657	rs13072536	chr3:52861211	A/T	cg10802521	chr3:52805072	NEK4	-0.62	-5.85	-0.47	4.1e-8	Schizophrenia;
TGCT	cis	rs12681288	0.782	rs2600500	chr8:1029031	G/C	cg04851639	chr8:1020857	NA	-0.34	-6.11	-0.48	1.18e-8	Schizophrenia;
TGCT	cis	rs4409675	0.576	rs2815707	chr1:28238880	T/C	cg23691781	chr1:28212827	C1orf38	0.26	5.44	0.44	2.76e-7	Corneal astigmatism;
TGCT	cis	rs2075371	0.863	rs1646638	chr7:134008706	T/C	cg11752832	chr7:134001865	SLC35B4	0.79	7.31	0.55	2.89e-11	Mean platelet volume;
TGCT	trans	rs629535	0.767	rs72654073	chr8:70081231	G/A	cg21567404	chr3:27674614	NA	-0.57	-8.99	-0.63	3.38e-15	Dupuytren's disease;
TGCT	cis	rs13242816	0.881	rs12672038	chr7:116187106	G/A	cg16553024	chr7:116138462	CAV2	-0.44	-5.26	-0.43	6.11e-7	P wave duration;
TGCT	cis	rs986417	0.901	rs10483726	chr14:61039476	A/G	cg18240143	chr14:60952599	C14orf39	0.83	4.52	0.38	1.41e-5	Gut microbiota (bacterial taxa);
TGCT	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs17345786	1.000	rs55641278	chr3:101290577	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.85	8.63	0.61	2.42e-14	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs208520	0.690	rs12209753	chr6:66703951	A/G	cg07460842	chr6:66804631	NA	0.96	10.26	0.68	2.92e-18	Exhaled nitric oxide output;
TGCT	cis	rs78456975	1.000	rs78456975	chr2:1554190	T/G	cg01028140	chr2:1542097	TPO	-0.35	-4.57	-0.38	1.17e-5	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg00343986	chr7:65444356	GUSB	-0.23	-5.16	-0.42	9.66e-7	Aortic root size;
TGCT	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg13695892	chr22:41940480	POLR3H	0.92	9.06	0.63	2.36e-15	Vitiligo;
TGCT	cis	rs2836974	0.965	rs8134733	chr21:40683459	C/T	cg11890956	chr21:40555474	PSMG1	1.12	11.29	0.71	9.26e-21	Cognitive function;
TGCT	cis	rs2204008	0.840	rs7136347	chr12:38453531	G/A	cg13010199	chr12:38710504	ALG10B	0.64	5.09	0.42	1.27e-6	Bladder cancer;
TGCT	trans	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg17830980	chr10:43048298	ZNF37B	-0.8	-10.01	-0.67	1.19e-17	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2882667	0.931	rs10074461	chr5:138319815	G/T	cg04439458	chr5:138467593	SIL1	-0.3	-4.71	-0.39	6.62e-6	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs9902453	0.904	rs4567782	chr17:28268800	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.87	8.26	0.6	1.9e-13	Coffee consumption (cups per day);
TGCT	cis	rs4654899	0.758	rs6426665	chr1:21382205	T/C	cg01072550	chr1:21505969	NA	-0.57	-9.39	-0.64	3.77e-16	Superior frontal gyrus grey matter volume;
TGCT	cis	rs9682041	0.740	rs2111826	chr3:170140846	A/G	cg11886554	chr3:170076028	SKIL	0.93	6.25	0.49	5.93e-9	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs6490294	0.659	rs642898	chr12:112141233	A/G	cg10833066	chr12:111807467	FAM109A	0.31	4.88	0.4	3.25e-6	Mean platelet volume;
TGCT	cis	rs9611565	0.546	rs5758431	chr22:42109917	A/G	cg13695892	chr22:41940480	POLR3H	0.89	9.04	0.63	2.55e-15	Vitiligo;
TGCT	cis	rs1008375	1.000	rs10939740	chr4:17617490	T/C	cg10189774	chr4:17578691	LAP3	0.58	5.05	0.41	1.57e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2404602	0.716	rs7164060	chr15:76707694	T/C	cg26408565	chr15:76604113	ETFA	-0.42	-5.43	-0.44	2.8e-7	Blood metabolite levels;
TGCT	cis	rs4711350	1.000	rs2395447	chr6:33743174	T/C	cg18005901	chr6:33739558	LEMD2	-0.55	-5.91	-0.47	3.13e-8	Schizophrenia;
TGCT	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.85	-9.06	-0.63	2.37e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs12477438	0.520	rs2969379	chr2:99776686	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.9	9.33	0.64	5.15e-16	Chronic sinus infection;
TGCT	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg05025164	chr4:1340916	KIAA1530	0.69	5.7	0.46	8.34e-8	Longevity;
TGCT	cis	rs6500602	0.701	rs6500614	chr16:4573938	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.43	7.58	0.56	7.17e-12	Schizophrenia;
TGCT	trans	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg23505145	chr19:12996616	KLF1	0.78	8.12	0.59	4.03e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs514406	0.547	rs377808	chr1:53190359	T/G	cg24675658	chr1:53192096	ZYG11B	-0.86	-11.02	-0.7	4.2e-20	Monocyte count;
TGCT	cis	rs7582180	0.629	rs11694642	chr2:100957813	A/G	cg08017756	chr2:100939284	LONRF2	-0.3	-4.87	-0.4	3.27e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7715806	0.500	rs17563700	chr5:74986045	A/G	cg19683494	chr5:74908142	NA	0.57	4.93	0.4	2.57e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs6591182	0.504	rs7116712	chr11:65372518	A/G	cg27068330	chr11:65405492	SIPA1	-0.95	-10.67	-0.69	3.04e-19	Non-alcoholic fatty liver disease histology (lobular);
TGCT	cis	rs7826238	0.653	rs2979202	chr8:8344127	T/C	cg08975724	chr8:8085496	FLJ10661	0.57	5.49	0.44	2.14e-7	Systolic blood pressure;
TGCT	cis	rs7412746	0.611	rs1889740	chr1:150799755	C/T	cg09365446	chr1:150670422	GOLPH3L	0.32	4.55	0.38	1.25e-5	Melanoma;
TGCT	cis	rs612683	0.664	rs6702766	chr1:100997635	A/G	cg06223162	chr1:101003688	GPR88	-0.31	-5.18	-0.42	8.71e-7	Breast cancer;
TGCT	trans	rs877282	0.947	rs7923867	chr10:768094	G/A	cg22713356	chr15:30763199	NA	1.19	9.85	0.66	2.99e-17	Uric acid levels;
TGCT	cis	rs11719291	0.584	rs13080725	chr3:49076092	G/A	cg00383909	chr3:49044727	WDR6	1.3	6.73	0.52	5.74e-10	Cognitive function;
TGCT	cis	rs4325129	1.000	rs61821536	chr1:159461308	C/T	cg07417683	chr1:159440267	NA	-0.45	-4.63	-0.38	9.16e-6	Obesity-related traits;
TGCT	cis	rs9926296	0.744	rs154656	chr16:89708003	T/A	cg26513180	chr16:89883248	FANCA	-0.6	-5.7	-0.46	8.2e-8	Vitiligo;
TGCT	cis	rs7698623	0.850	rs6532020	chr4:88768928	C/T	cg27387453	chr4:88533842	DSPP	-0.61	-4.6	-0.38	1.03e-5	Cardiovascular disease risk factors;
TGCT	cis	rs4642101	0.765	rs6791647	chr3:12826425	C/T	cg05775895	chr3:12838266	CAND2	-0.8	-9.14	-0.63	1.52e-15	QRS complex (12-leadsum);
TGCT	trans	rs114540395	0.858	rs78446856	chr10:103119815	T/A	cg10198749	chr1:39920707	MACF1	0.52	7.12	0.54	7.77e-11	Schizophrenia;
TGCT	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg03303774	chr4:1407052	NA	0.32	4.9	0.4	2.9e-6	Obesity-related traits;
TGCT	cis	rs67460515	0.926	rs11715591	chr3:161043137	C/T	cg03342759	chr3:160939853	NMD3	-0.51	-5.42	-0.44	2.98e-7	Parkinson's disease;
TGCT	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg17971929	chr21:40555470	PSMG1	-0.7	-6.66	-0.51	7.99e-10	Cognitive function;
TGCT	cis	rs7943191	0.768	rs34065644	chr11:62371938	C/T	cg22862634	chr11:62369728	EML3;MTA2	0.6	6.0	0.47	2.04e-8	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs6089829	0.926	rs6011552	chr20:61667894	T/C	cg03213289	chr20:61660250	NA	0.66	9.28	0.64	6.93e-16	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7027203	0.797	rs7870672	chr9:96606693	A/C	cg14396892	chr9:96623032	NA	-0.26	-5.46	-0.44	2.51e-7	DNA methylation (variation);
TGCT	cis	rs11792861	0.855	rs72607165	chr9:111814498	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.49	4.52	0.38	1.44e-5	Menarche (age at onset);
TGCT	cis	rs1692580	0.807	rs10910036	chr1:2183754	C/G	cg24578937	chr1:2090814	PRKCZ	0.2	4.56	0.38	1.22e-5	Coronary artery disease;
TGCT	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg08509172	chr19:19383838	TM6SF2	-0.35	-4.6	-0.38	1.02e-5	Tonsillectomy;
TGCT	cis	rs9346649	0.591	rs1873338	chr6:168492087	T/C	cg02770688	chr6:168491649	NA	0.34	6.06	0.48	1.48e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
TGCT	cis	rs7246657	0.943	rs1035479	chr19:37893300	G/T	cg18154014	chr19:37997991	ZNF793	-0.73	-5.38	-0.44	3.53e-7	Coronary artery calcification;
TGCT	trans	rs4332037	0.826	rs4721188	chr7:1953615	G/A	cg25206134	chr2:45395956	NA	-1.06	-9.11	-0.63	1.78e-15	Bipolar disorder;
TGCT	cis	rs3935685	0.874	rs35761651	chr15:78003069	G/T	cg25212270	chr15:78015279	NA	0.27	5.66	0.45	9.87e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs1536827	0.841	rs10857733	chr10:135332803	G/A	cg12448312	chr10:135032219	KNDC1	-0.45	-4.76	-0.39	5.27e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs514406	0.621	rs2003250	chr1:53196666	T/C	cg08859206	chr1:53392774	SCP2	0.34	4.82	0.4	4.1e-6	Monocyte count;
TGCT	cis	rs9910055	0.530	rs2269907	chr17:42294215	G/A	cg13607699	chr17:42295918	UBTF	0.96	11.07	0.7	3.21e-20	Total body bone mineral density;
TGCT	cis	rs11190604	1.000	rs2489050	chr10:102350898	T/A	cg16342193	chr10:102329863	NA	-0.43	-5.43	-0.44	2.79e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7772486	0.754	rs6570703	chr6:145957052	C/T	cg05347473	chr6:146136440	FBXO30	0.48	4.53	0.38	1.38e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7582180	0.629	rs13025184	chr2:100944842	A/G	cg08017756	chr2:100939284	LONRF2	-0.3	-4.87	-0.4	3.27e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9427116	0.502	rs9426829	chr1:154592201	T/C	cg17218026	chr1:154582156	ADAR	0.31	7.83	0.58	1.89e-12	Blood protein levels;
TGCT	cis	rs11711311	1.000	rs2603793	chr3:113496418	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.76	-7.16	-0.54	6.29e-11	IgG glycosylation;
TGCT	cis	rs17270561	0.525	rs12201678	chr6:25978993	C/T	cg17691542	chr6:26056736	HIST1H1C	1.02	7.17	0.54	5.89e-11	Iron status biomarkers;
TGCT	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg07507251	chr3:52567010	NT5DC2	0.48	6.91	0.53	2.24e-10	Bipolar disorder;
TGCT	cis	rs9969804	0.747	rs7021624	chr9:95531220	C/G	cg13940029	chr9:95239186	CENPP;ASPN	-0.17	-4.54	-0.38	1.29e-5	Height;
TGCT	cis	rs12220238	0.915	rs1908334	chr10:75991721	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.78	0.57	2.42e-12	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs7681440	0.869	rs7680557	chr4:90763360	C/A	cg14346243	chr4:90757452	SNCA	-0.59	-5.74	-0.46	6.82e-8	Dementia with Lewy bodies;
TGCT	cis	rs28595532	0.920	rs115006522	chr4:119732499	A/G	cg14228332	chr4:119757509	SEC24D	1.32	6.38	0.5	3.2e-9	Cannabis dependence symptom count;
TGCT	cis	rs8056742	0.730	rs11649284	chr16:85099251	C/T	cg00229868	chr16:85520891	NA	-0.32	-4.66	-0.39	8.11e-6	Amyotrophic lateral sclerosis;
TGCT	cis	rs2242194	0.844	rs11264295	chr1:154987526	C/T	cg09359103	chr1:154839909	KCNN3	-0.47	-6.53	-0.51	1.51e-9	Schizophrenia;
TGCT	cis	rs4595586	1.000	rs4384412	chr12:39218113	T/C	cg10518543	chr12:38710700	ALG10B	-0.49	-4.93	-0.4	2.59e-6	Morning vs. evening chronotype;
TGCT	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg08736216	chr1:53307985	ZYG11A	-0.27	-5.04	-0.41	1.64e-6	Monocyte count;
TGCT	cis	rs8013055	0.846	rs10151805	chr14:105974781	T/C	cg23356831	chr14:105996513	TMEM121	0.41	6.33	0.49	4.01e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs2797160	1.000	rs6904992	chr6:126016003	G/A	cg05901451	chr6:126070800	HEY2	0.73	6.29	0.49	5.01e-9	Endometrial cancer;
TGCT	cis	rs10972341	0.904	rs10972353	chr9:35151594	A/T	cg00812861	chr9:35114699	KIAA1539	0.33	5.06	0.41	1.44e-6	Weight;
TGCT	cis	rs644799	0.932	rs523934	chr11:95641775	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.77	9.09	0.63	2.04e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs17221829	0.733	rs10830337	chr11:89407049	C/T	cg02982614	chr11:89391479	FOLH1B	-0.27	-4.56	-0.38	1.19e-5	Anxiety in major depressive disorder;
TGCT	cis	rs9653442	0.527	rs4850923	chr2:100782256	A/C	cg07810366	chr2:100720526	AFF3	-0.34	-4.96	-0.41	2.27e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg12310025	chr6:25882481	NA	-0.66	-5.95	-0.47	2.57e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs36051895	0.632	rs7849717	chr9:5170080	G/A	cg02405213	chr9:5042618	JAK2	-0.72	-9.46	-0.65	2.63e-16	Pediatric autoimmune diseases;
TGCT	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg03732007	chr1:2071316	PRKCZ	-0.26	-5.89	-0.47	3.45e-8	Height;
TGCT	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg00080972	chr5:178986291	RUFY1	0.46	5.38	0.44	3.55e-7	Lung cancer;
TGCT	cis	rs906628	0.541	rs113946880	chr11:134706712	C/T	cg25999867	chr11:134145940	GLB1L3	0.87	4.54	0.38	1.33e-5	Tooth agenesis (mandibular third molar);
TGCT	cis	rs9611565	0.512	rs7291736	chr22:42124874	C/A	cg17554472	chr22:41940697	POLR3H	0.47	5.04	0.41	1.63e-6	Vitiligo;
TGCT	cis	rs3091242	1.000	rs646867	chr1:25709258	A/C	cg09222892	chr1:25734099	RHCE	-0.44	-7.12	-0.54	7.52e-11	Erythrocyte sedimentation rate;
TGCT	cis	rs10256972	0.721	rs10435145	chr7:1065988	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.5	-4.7	-0.39	6.84e-6	Longevity;Endometriosis;
TGCT	cis	rs11098499	0.909	rs10017335	chr4:120381523	C/G	cg09307838	chr4:120376055	NA	-0.7	-6.43	-0.5	2.56e-9	Corneal astigmatism;
TGCT	cis	rs1008375	1.000	rs1121090	chr4:17676437	C/G	cg18681998	chr4:17616180	MED28	0.89	10.2	0.68	4.06e-18	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4746818	1.000	rs4342912	chr10:70959282	T/C	cg11621586	chr10:70884670	VPS26A	1.21	10.5	0.69	7.7e-19	Left atrial antero-posterior diameter;
TGCT	cis	rs4478858	0.735	rs11576603	chr1:31774031	C/T	cg07478791	chr1:31886160	SERINC2	-0.48	-4.61	-0.38	1e-5	Alcohol dependence;
TGCT	cis	rs7917772	0.582	rs4917975	chr10:104358407	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	5.36	0.43	3.84e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs763014	0.865	rs4006748	chr16:632225	T/C	cg27436995	chr16:743998	FBXL16	-0.45	-4.82	-0.4	4.17e-6	Height;
TGCT	trans	rs941408	0.963	rs2537855	chr19:2806574	A/G	cg19676328	chr12:49525230	TUBA1B	-0.85	-7.52	-0.56	9.73e-12	Total cholesterol levels;
TGCT	trans	rs7824557	0.547	rs4512344	chr8:11078781	A/C	cg06636001	chr8:8085503	FLJ10661	-0.77	-7.0	-0.53	1.44e-10	Retinal vascular caliber;
TGCT	cis	rs6840360	0.967	rs6841204	chr4:152598603	C/T	cg17479576	chr4:152424074	FAM160A1	-0.5	-5.4	-0.44	3.26e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg03709012	chr19:19516395	GATAD2A	0.75	6.51	0.5	1.71e-9	Tonsillectomy;
TGCT	cis	rs5760092	0.842	rs5751763	chr22:24247793	T/C	cg00024416	chr22:24240387	NA	-0.38	-6.58	-0.51	1.16e-9	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg05215272	chr17:6899095	ALOX12	0.53	6.55	0.51	1.37e-9	Tonsillectomy;
TGCT	cis	rs2231884	0.697	rs11227332	chr11:65623739	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.68	5.8	0.46	5.25e-8	Inflammatory bowel disease;
TGCT	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.48	-5.65	-0.45	1.06e-7	Longevity;Endometriosis;
TGCT	cis	rs2797160	1.000	rs1739352	chr6:126005310	T/C	cg05901451	chr6:126070800	HEY2	-0.74	-6.3	-0.49	4.62e-9	Endometrial cancer;
TGCT	cis	rs6582630	0.519	rs8189561	chr12:38296178	G/A	cg13010199	chr12:38710504	ALG10B	0.57	4.45	0.37	1.89e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg27436995	chr16:743998	FBXL16	-0.47	-5.12	-0.42	1.15e-6	Height;
TGCT	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg14773178	chr5:1868261	NA	0.33	5.79	0.46	5.47e-8	Cardiovascular disease risk factors;
TGCT	cis	rs826838	0.620	rs11614695	chr12:39331847	C/T	cg26384229	chr12:38710491	ALG10B	0.86	7.28	0.55	3.35e-11	Heart rate;
TGCT	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg05368731	chr17:41323189	NBR1	1.21	14.63	0.8	8.89e-29	Menopause (age at onset);
TGCT	cis	rs66887589	0.616	rs1052633	chr4:120215314	A/G	cg24670566	chr4:120433619	PDE5A	0.21	4.57	0.38	1.16e-5	Diastolic blood pressure;
TGCT	cis	rs17102423	0.594	rs1953232	chr14:65570386	A/C	cg11161011	chr14:65562177	MAX	0.47	6.48	0.5	1.94e-9	Obesity-related traits;
TGCT	cis	rs7226408	0.790	rs9946701	chr18:34340486	C/G	cg06757138	chr18:34340585	FHOD3	0.3	5.02	0.41	1.75e-6	Obesity-related traits;
TGCT	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg13695892	chr22:41940480	POLR3H	0.93	9.1	0.63	1.91e-15	Vitiligo;
TGCT	cis	rs78487399	0.808	rs28700209	chr2:43667465	T/C	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.72	4.62	0.38	9.53e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs67311347	0.544	rs9868700	chr3:40345408	G/A	cg13683864	chr3:40499215	RPL14	-0.79	-7.57	-0.56	7.26e-12	Renal cell carcinoma;
TGCT	cis	rs16867321	0.950	rs1919148	chr2:181501758	G/A	cg23363182	chr2:181467187	NA	-0.4	-5.7	-0.46	8.41e-8	Obesity;
TGCT	cis	rs9814567	1.000	rs6769885	chr3:134286913	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.91	-8.45	-0.6	6.55e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs72634258	0.519	rs35267144	chr1:7934258	G/A	cg26816564	chr1:7831052	VAMP3	0.64	4.9	0.4	2.97e-6	Inflammatory bowel disease;
TGCT	cis	rs12142240	0.698	rs72886911	chr1:46814352	G/A	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg17971929	chr21:40555470	PSMG1	-0.7	-6.32	-0.49	4.38e-9	Cognitive function;
TGCT	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.64	5.04	0.41	1.63e-6	Lung function (FEV1/FVC);
TGCT	cis	rs11252926	0.537	rs4881255	chr10:453638	T/C	cg20256804	chr10:444983	DIP2C	-0.21	-4.45	-0.37	1.88e-5	Psychosis in Alzheimer's disease;
TGCT	cis	rs523522	0.962	rs1050187	chr12:120902111	A/G	cg27279351	chr12:120934652	DYNLL1	-0.76	-6.58	-0.51	1.19e-9	High light scatter reticulocyte count;
TGCT	cis	rs514406	0.548	rs6670871	chr1:53212082	A/C	cg22166914	chr1:53195759	ZYG11B	-0.5	-9.19	-0.64	1.16e-15	Monocyte count;
TGCT	cis	rs7647973	1.000	rs2177268	chr3:49439725	A/T	cg05785598	chr3:49045655	WDR6	-0.4	-4.67	-0.39	7.57e-6	Menarche (age at onset);
TGCT	cis	rs9303401	0.592	rs12936771	chr17:56725052	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs2013441	1.000	rs2703794	chr17:20073338	T/C	cg18979559	chr17:20280153	CCDC144C	0.44	4.61	0.38	9.78e-6	Obesity-related traits;
TGCT	cis	rs11209185	0.672	rs1926278	chr1:68453859	C/T	cg22082780	chr1:68452167	NA	0.29	4.98	0.41	2.09e-6	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs6570726	0.967	rs9403707	chr6:145800010	A/G	cg23711669	chr6:146136114	FBXO30	0.62	5.84	0.46	4.3e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9467773	0.620	rs2504571	chr6:26643435	C/T	cg26531700	chr6:26746687	NA	0.52	4.85	0.4	3.65e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg09033563	chr22:24373618	LOC391322	-0.47	-4.49	-0.37	1.59e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs12421382	0.507	rs10890995	chr11:109327622	A/G	cg16359550	chr11:109292809	C11orf87	-0.72	-8.08	-0.59	4.95e-13	Schizophrenia;
TGCT	cis	rs2242116	0.796	rs9852082	chr3:46972377	T/C	cg02527881	chr3:46936655	PTH1R	-0.33	-5.89	-0.47	3.34e-8	Birth weight;
TGCT	cis	rs2455799	0.613	rs7633542	chr3:15816326	C/T	cg16303742	chr3:15540471	COLQ	-0.25	-4.74	-0.39	5.76e-6	Mean platelet volume;
TGCT	cis	rs7949030	0.653	rs2516634	chr11:62367186	G/A	cg22862634	chr11:62369728	EML3;MTA2	-0.7	-9.07	-0.63	2.22e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs6582630	0.555	rs10748382	chr12:38504529	C/T	cg13010199	chr12:38710504	ALG10B	0.66	5.65	0.45	1.06e-7	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs9467773	0.620	rs2451741	chr6:26629404	A/G	cg02458000	chr6:26745757	NA	0.53	5.02	0.41	1.76e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4654899	1.000	rs6702110	chr1:21515906	A/G	cg01072550	chr1:21505969	NA	-0.51	-8.23	-0.59	2.15e-13	Superior frontal gyrus grey matter volume;
TGCT	cis	rs4629710	0.563	rs9483238	chr6:131567196	A/T	cg12606694	chr6:131520996	AKAP7	0.39	4.61	0.38	9.76e-6	Multiple myeloma (IgH translocation);
TGCT	cis	rs1215050	0.791	rs984940	chr4:98811756	T/A	cg05340658	chr4:99064831	C4orf37	0.44	5.57	0.45	1.53e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs57994353	0.861	rs34302850	chr9:139327064	A/G	cg13741927	chr9:139327495	INPP5E	-0.27	-6.2	-0.49	7.7e-9	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs137887	0.817	rs137888	chr22:50464496	G/A	cg17558497	chr22:50464837	TTLL8	0.2	4.56	0.38	1.21e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
TGCT	cis	rs68170813	0.652	rs4730250	chr7:107207695	A/G	cg02696742	chr7:106810147	HBP1	-0.59	-4.71	-0.39	6.61e-6	Coronary artery disease;
TGCT	cis	rs1153858	1.000	rs2114501	chr15:45670316	G/A	cg26924012	chr15:45694286	SPATA5L1	1.09	15.08	0.8	7.99e-30	Homoarginine levels;
TGCT	cis	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg08045932	chr20:61659980	NA	0.49	9.25	0.64	8.4e-16	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs4595586	0.545	rs11610886	chr12:39390613	C/G	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs713587	0.626	rs62140636	chr2:25233811	T/C	cg01884057	chr2:25150051	NA	-0.38	-7.59	-0.56	6.56e-12	Body mass index in non-asthmatics;
TGCT	cis	rs6964587	1.000	rs7805077	chr7:91644553	A/G	cg17063962	chr7:91808500	NA	0.91	9.99	0.67	1.32e-17	Breast cancer;
TGCT	cis	rs10791097	0.694	rs4264159	chr11:130755784	G/T	cg12179176	chr11:130786555	SNX19	0.83	9.92	0.67	1.94e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs61990749	0.597	rs2364584	chr14:78152286	T/C	cg23188588	chr14:78226832	SNW1;C14orf178	-0.66	-4.62	-0.38	9.57e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg06481639	chr22:41940642	POLR3H	0.74	6.58	0.51	1.2e-9	Vitiligo;
TGCT	cis	rs7635838	0.892	rs2880897	chr3:11494544	A/G	cg00170343	chr3:11313890	ATG7	0.63	5.54	0.45	1.72e-7	HDL cholesterol;
TGCT	cis	rs7267979	0.844	rs4815413	chr20:25359229	G/T	cg03522245	chr20:25566470	NINL	-0.55	-5.55	-0.45	1.68e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs36051895	0.593	rs12340379	chr9:5176352	C/T	cg02405213	chr9:5042618	JAK2	-0.77	-10.92	-0.7	7.2e-20	Pediatric autoimmune diseases;
TGCT	cis	rs6570726	1.000	rs404229	chr6:145868200	G/A	cg05347473	chr6:146136440	FBXO30	0.5	4.46	0.37	1.82e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10037670	1.000	rs10037670	chr5:153811490	C/T	cg21964928	chr5:153872958	NA	-0.26	-5.17	-0.42	9.21e-7	Behavioural disinhibition (generation interaction);
TGCT	cis	rs9899728	0.572	rs4365317	chr17:73059820	C/G	cg27626185	chr17:73056755	KCTD2	-0.46	-4.49	-0.37	1.59e-5	Alzheimer's disease or small vessel stroke;
TGCT	cis	rs1532993	0.518	rs7442272	chr4:98583775	C/T	cg05340658	chr4:99064831	C4orf37	-0.38	-4.49	-0.37	1.58e-5	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs782590	0.764	rs935177	chr2:55826761	C/G	cg03859395	chr2:55845619	SMEK2	0.84	10.09	0.67	7.69e-18	Metabolic syndrome;
TGCT	cis	rs9653442	0.564	rs4851253	chr2:100762786	T/G	cg22139774	chr2:100720529	AFF3	-0.38	-5.97	-0.47	2.35e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg06634786	chr22:41940651	POLR3H	-0.88	-8.48	-0.61	5.74e-14	Vitiligo;
TGCT	cis	rs644799	0.526	rs530914	chr11:95632156	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.49	4.84	0.4	3.82e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7927771	0.864	rs112060627	chr11:47426956	G/A	cg10139015	chr11:47448256	PSMC3	0.52	4.44	0.37	1.97e-5	Subjective well-being;
TGCT	cis	rs12893668	0.637	rs12892038	chr14:104068629	G/A	cg26031613	chr14:104095156	KLC1	-0.55	-4.64	-0.38	8.81e-6	Reticulocyte count;
TGCT	trans	rs17685	0.712	rs6954569	chr7:75738885	T/A	cg19862616	chr7:65841803	NCRNA00174	0.52	9.01	0.63	3.02e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg10047753	chr17:41438598	NA	0.96	9.54	0.65	1.61e-16	Menopause (age at onset);
TGCT	cis	rs425277	1.000	rs262651	chr1:2091397	A/G	cg03732007	chr1:2071316	PRKCZ	0.26	5.44	0.44	2.77e-7	Height;
TGCT	cis	rs9325144	0.560	rs13377717	chr12:38639474	T/A	cg13010199	chr12:38710504	ALG10B	-0.51	-4.52	-0.38	1.45e-5	Morning vs. evening chronotype;
TGCT	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg22166914	chr1:53195759	ZYG11B	-0.42	-7.36	-0.55	2.26e-11	Monocyte count;
TGCT	cis	rs6543140	0.964	rs6543138	chr2:103066132	G/A	cg09003973	chr2:102972529	NA	0.56	4.67	0.39	7.86e-6	Blood protein levels;
TGCT	cis	rs11031096	0.563	rs12289940	chr11:4224589	T/A	cg18678763	chr11:4115507	RRM1	-0.39	-4.91	-0.4	2.82e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	trans	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg23505145	chr19:12996616	KLF1	0.78	8.12	0.59	4.03e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg23302884	chr18:44338147	ST8SIA5	-0.41	-4.79	-0.4	4.61e-6	Personality dimensions;
TGCT	cis	rs7267979	1.000	rs7020	chr20:25278600	G/A	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11648796	0.718	rs62032512	chr16:764826	C/T	cg27144592	chr16:783916	NARFL	0.39	5.42	0.44	2.92e-7	Height;
TGCT	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg22963979	chr7:1858916	MAD1L1	-0.4	-6.17	-0.48	8.79e-9	Bipolar disorder and schizophrenia;
TGCT	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg00684032	chr4:1343700	KIAA1530	0.22	4.73	0.39	5.89e-6	Obesity-related traits;
TGCT	cis	rs5769707	0.521	rs739244	chr22:50060158	A/G	cg05373962	chr22:49881684	NA	-0.32	-5.42	-0.44	3e-7	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs8180040	1.000	rs1024037	chr3:47318449	C/A	cg27129171	chr3:47204927	SETD2	-0.69	-8.17	-0.59	2.94e-13	Colorectal cancer;
TGCT	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg08645402	chr16:4508243	NA	0.21	5.03	0.41	1.65e-6	Schizophrenia;
TGCT	cis	rs60154123	0.772	rs701944	chr1:210417098	G/A	cg22029157	chr1:209979665	IRF6	0.64	4.52	0.38	1.43e-5	Coronary artery disease;
TGCT	cis	rs12711979	0.584	rs11694096	chr2:3868113	G/A	cg17052675	chr2:3827356	NA	-0.4	-7.24	-0.54	4.24e-11	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs4319547	1.000	rs7295397	chr12:123116209	C/T	cg23029597	chr12:123009494	RSRC2	-0.31	-5.16	-0.42	9.31e-7	Body mass index;
TGCT	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg10053473	chr17:62856997	LRRC37A3	0.41	7.06	0.54	1.03e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2692947	0.644	rs1724125	chr2:96831355	G/A	cg22654517	chr2:96458247	NA	0.23	4.83	0.4	4e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs9549367	0.789	rs912012	chr13:113886152	G/A	cg00898013	chr13:113819073	PROZ	-0.4	-4.88	-0.4	3.18e-6	Platelet distribution width;
TGCT	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg13607699	chr17:42295918	UBTF	0.82	7.53	0.56	9.29e-12	Total body bone mineral density;
TGCT	cis	rs2730260	0.537	rs56023468	chr7:158875329	T/C	cg02078164	chr7:157982224	PTPRN2	0.41	4.58	0.38	1.11e-5	Myopia (pathological);
TGCT	cis	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg20637647	chr7:64974828	NA	0.89	4.95	0.41	2.37e-6	Diabetic kidney disease;
TGCT	cis	rs10484885	0.715	rs2585013	chr6:90553402	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.55	-6.6	-0.51	1.09e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.6	-6.13	-0.48	1.09e-8	Longevity;Endometriosis;
TGCT	cis	rs7819412	0.806	rs2409689	chr8:10932868	A/G	cg21775007	chr8:11205619	TDH	-0.5	-4.62	-0.38	9.28e-6	Triglycerides;
TGCT	cis	rs3796352	0.892	rs11718388	chr3:53076415	G/A	cg15956490	chr3:53032818	SFMBT1	0.59	6.75	0.52	5.19e-10	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg06873352	chr17:61820015	STRADA	0.56	6.22	0.49	7.1e-9	Prudent dietary pattern;
TGCT	cis	rs9303401	0.580	rs2013166	chr17:56637630	C/T	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs7917772	0.560	rs35095897	chr10:104377759	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-5.46	-0.44	2.51e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2742417	1.000	rs2673047	chr3:45743113	A/G	cg04837898	chr3:45731254	SACM1L	-0.55	-5.68	-0.45	9.22e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs4862750	0.881	rs6813866	chr4:187872161	T/G	cg10295955	chr4:187884368	NA	-0.93	-12.52	-0.75	9.29e-24	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9894429	0.789	rs7219915	chr17:79591813	C/T	cg18240062	chr17:79603768	NPLOC4	0.84	9.67	0.66	8.03e-17	Eye color traits;
TGCT	cis	rs4769475	0.957	rs7327409	chr13:26730668	A/G	cg19000612	chr13:26506281	ATP8A2	0.3	4.48	0.37	1.66e-5	Response to Homoharringtonine (cytotoxicity);
TGCT	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.59	-5.58	-0.45	1.42e-7	Longevity;Endometriosis;
TGCT	cis	rs9611519	0.761	rs35445172	chr22:41660301	G/A	cg06634786	chr22:41940651	POLR3H	-0.55	-4.98	-0.41	2.04e-6	Neuroticism;
TGCT	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.71	5.14	0.42	1.02e-6	Platelet count;
TGCT	cis	rs78545713	1.000	rs114970164	chr6:26241993	G/C	cg12260798	chr6:26240519	HIST1H4F	-0.58	-4.89	-0.4	3.06e-6	Iron status biomarkers (total iron binding capacity);
TGCT	cis	rs3796352	1.000	rs34933390	chr3:53006265	T/G	cg07884673	chr3:53033167	SFMBT1	0.62	6.19	0.49	8.26e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs9467711	0.539	rs34436535	chr6:26370365	G/C	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs916888	0.647	rs199523	chr17:44848517	C/A	cg01570182	chr17:44337453	NA	-0.84	-8.15	-0.59	3.41e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg00343986	chr7:65444356	GUSB	0.25	5.81	0.46	4.88e-8	Aortic root size;
TGCT	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7246657	0.882	rs13345148	chr19:37819631	A/G	cg18154014	chr19:37997991	ZNF793	0.74	5.08	0.42	1.34e-6	Coronary artery calcification;
TGCT	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg08280861	chr8:58055591	NA	0.39	4.86	0.4	3.45e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6866344	0.570	rs56236920	chr5:178144617	C/T	cg10224037	chr5:178157518	ZNF354A	0.98	9.34	0.64	5.07e-16	Neutrophil percentage of white cells;
TGCT	cis	rs981844	0.775	rs55986083	chr4:154765640	A/C	cg14289246	chr4:154710475	SFRP2	1.0	8.87	0.62	6.69e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs1865760	0.566	rs2032443	chr6:26046802	A/G	cg17042849	chr6:26104293	HIST1H4C	-0.6	-5.17	-0.42	8.99e-7	Height;
TGCT	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.61	5.06	0.41	1.5e-6	Tonsillectomy;
TGCT	cis	rs10858047	0.883	rs761755	chr1:115222434	G/A	cg12756093	chr1:115239321	AMPD1	-0.49	-5.17	-0.42	9.05e-7	Autism;
TGCT	cis	rs12765878	0.541	rs7091346	chr10:105608824	C/T	cg11005552	chr10:105648138	OBFC1	-0.38	-6.06	-0.48	1.49e-8	Coronary artery disease;
TGCT	cis	rs2404602	0.716	rs12441550	chr15:76863682	A/T	cg22467129	chr15:76604101	ETFA	-0.44	-5.05	-0.41	1.51e-6	Blood metabolite levels;
TGCT	cis	rs763121	0.853	rs2281021	chr22:39064667	T/C	cg06022373	chr22:39101656	GTPBP1	0.77	7.57	0.56	7.47e-12	Menopause (age at onset);
TGCT	cis	rs3008870	1.000	rs3008858	chr1:67390416	G/C	cg03991309	chr1:68237761	GNG12	0.27	4.56	0.38	1.23e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs4664308	1.000	rs62175517	chr2:160911575	C/T	cg03641300	chr2:160917029	PLA2R1	-0.26	-6.53	-0.51	1.49e-9	Idiopathic membranous nephropathy;
TGCT	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg16414030	chr3:133502952	NA	0.57	8.59	0.61	3.07e-14	Iron status biomarkers;
TGCT	cis	rs10791097	0.667	rs12363163	chr11:130744509	A/G	cg05962950	chr11:130786565	SNX19	0.92	11.55	0.72	2.13e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs789852	0.867	rs6437391	chr3:194316826	C/T	cg18000598	chr3:194342907	TMEM44	-0.76	-5.09	-0.42	1.31e-6	QT interval;
TGCT	cis	rs4285028	0.948	rs1920309	chr3:121665479	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.77	-6.5	-0.5	1.78e-9	Multiple sclerosis;
TGCT	cis	rs7586879	0.593	rs6733224	chr2:25130907	C/T	cg01884057	chr2:25150051	NA	-0.35	-6.86	-0.52	2.97e-10	Body mass index;
TGCT	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg18402987	chr7:1209562	NA	0.78	6.64	0.51	8.96e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	trans	rs1864729	1.000	rs2451113	chr8:98273448	G/A	cg08679828	chr8:102218111	ZNF706	-1.07	-7.39	-0.55	1.87e-11	Estradiol plasma levels (breast cancer);
TGCT	cis	rs3818285	0.544	rs9787456	chr10:111711822	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.3	-4.87	-0.4	3.4e-6	Superior crus of antihelix expression;
TGCT	cis	rs3806843	0.966	rs2563262	chr5:140137712	C/G	cg19875535	chr5:140030758	IK	-0.36	-6.17	-0.48	8.74e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7927771	0.864	rs3781627	chr11:47441472	T/A	cg10139015	chr11:47448256	PSMC3	-0.57	-4.65	-0.39	8.31e-6	Subjective well-being;
TGCT	cis	rs11098499	0.866	rs11098506	chr4:120284971	A/G	cg09307838	chr4:120376055	NA	0.58	5.76	0.46	6.16e-8	Corneal astigmatism;
TGCT	cis	rs13191362	0.938	rs59067610	chr6:163030440	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.56	4.64	0.38	8.87e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs1865760	1.000	rs2071299	chr6:25914801	G/A	cg16482183	chr6:26056742	HIST1H1C	0.52	4.6	0.38	1.04e-5	Height;
TGCT	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg22535103	chr8:58192502	C8orf71	-0.42	-5.41	-0.44	3.19e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs1018836	0.828	rs9297871	chr8:91572731	G/A	cg16814680	chr8:91681699	NA	-0.75	-7.85	-0.58	1.71e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9633740	0.842	rs1870140	chr10:82246749	A/G	cg01528321	chr10:82214614	TSPAN14	0.9	6.44	0.5	2.37e-9	Post bronchodilator FEV1;
TGCT	cis	rs3617	0.573	rs56383738	chr3:52908398	T/C	cg11645453	chr3:52864694	ITIH4	-0.28	-5.48	-0.44	2.24e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs11605924	0.792	rs10838524	chr11:45870177	A/G	ch.11.939596F	chr11:45881766	CRY2	-0.36	-4.52	-0.38	1.43e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);
TGCT	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.66	0.39	8.18e-6	Prudent dietary pattern;
TGCT	cis	rs2820292	0.583	rs651103	chr1:201764737	G/T	cg07139329	chr1:201708558	NAV1	0.35	4.6	0.38	1.03e-5	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
TGCT	cis	rs6964587	1.000	rs10225892	chr7:91671020	A/G	cg17063962	chr7:91808500	NA	0.88	9.63	0.65	9.8e-17	Breast cancer;
TGCT	cis	rs700651	0.789	rs1978889	chr2:198889366	G/A	cg00792783	chr2:198669748	PLCL1	0.59	5.34	0.43	4.33e-7	Intracranial aneurysm;
TGCT	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg12288994	chr5:1860383	NA	0.24	4.47	0.37	1.78e-5	Cardiovascular disease risk factors;
TGCT	trans	rs1814175	0.817	rs6486044	chr11:49982718	C/T	cg03929089	chr4:120376271	NA	-0.72	-8.53	-0.61	4.24e-14	Height;
TGCT	cis	rs593982	0.777	rs534414	chr11:65475515	A/G	cg08755490	chr11:65554678	OVOL1	1.3	7.59	0.56	6.8e-12	Atopic dermatitis;
TGCT	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs2832077	0.527	rs11088095	chr21:30223188	A/T	cg24692254	chr21:30365293	RNF160	-0.59	-5.05	-0.41	1.53e-6	Cognitive test performance;
TGCT	cis	rs1729951	0.545	rs1097288	chr3:136693721	C/T	cg21827317	chr3:136751795	NA	0.4	5.61	0.45	1.28e-7	Neuroticism;
TGCT	cis	rs2070433	0.752	rs11700468	chr21:47776391	C/T	cg12379764	chr21:47803548	PCNT	0.66	5.61	0.45	1.25e-7	Lymphocyte counts;
TGCT	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg04944784	chr2:26401820	FAM59B	0.69	5.74	0.46	6.71e-8	Gut microbiome composition (summer);
TGCT	cis	rs1371867	0.846	rs1788205	chr8:101306546	G/C	cg06002616	chr8:101225028	SPAG1	-0.56	-6.58	-0.51	1.2e-9	Atrioventricular conduction;
TGCT	cis	rs826838	0.935	rs4583043	chr12:38645147	T/G	cg26384229	chr12:38710491	ALG10B	0.99	9.34	0.64	4.97e-16	Heart rate;
TGCT	cis	rs6062496	0.631	rs6062300	chr20:62303794	G/A	cg27236539	chr20:62289627	RTEL1	0.69	6.52	0.51	1.59e-9	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs9914988	0.673	rs12325788	chr17:27080049	G/A	cg20469991	chr17:27169893	C17orf63	-0.66	-5.03	-0.41	1.65e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs3812831	0.695	rs6560936	chr13:114945972	C/T	cg08824895	chr13:115047677	UPF3A	-0.49	-4.74	-0.39	5.83e-6	Schizophrenia;
TGCT	cis	rs2404602	0.735	rs12903874	chr15:76693318	A/T	cg22467129	chr15:76604101	ETFA	0.49	5.06	0.41	1.5e-6	Blood metabolite levels;
TGCT	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg22764044	chr5:178986830	RUFY1	0.5	5.57	0.45	1.49e-7	Lung cancer;
TGCT	cis	rs4455778	0.692	rs7800120	chr7:49012977	C/T	cg26309511	chr7:48887640	NA	-0.47	-5.84	-0.46	4.38e-8	Lung cancer in never smokers;
TGCT	cis	rs4242434	0.927	rs7843828	chr8:22463623	C/T	cg21658235	chr8:22456391	C8orf58	0.43	4.53	0.38	1.36e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs3733585	0.699	rs6852441	chr4:9973744	C/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.72	-0.52	5.74e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs13242816	1.000	rs62468973	chr7:116125834	G/T	cg16553024	chr7:116138462	CAV2	-0.43	-4.88	-0.4	3.26e-6	P wave duration;
TGCT	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg12311346	chr5:56204834	C5orf35	0.59	6.35	0.5	3.68e-9	Initial pursuit acceleration;
TGCT	trans	rs11992162	0.548	rs4841631	chr8:11781668	C/T	cg15556689	chr8:8085844	FLJ10661	-0.81	-6.99	-0.53	1.48e-10	Monocyte count;
TGCT	cis	rs67311347	0.955	rs1129200	chr3:40532257	T/C	cg13409248	chr3:40428643	ENTPD3	0.63	4.92	0.4	2.72e-6	Renal cell carcinoma;
TGCT	cis	rs12711979	0.904	rs12329356	chr2:3868533	G/C	cg17052675	chr2:3827356	NA	-0.32	-5.85	-0.46	4.12e-8	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg02725872	chr8:58115012	NA	-0.41	-5.38	-0.44	3.5e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9467773	0.596	rs2451751	chr6:26646714	T/C	cg15659132	chr6:26577336	NA	0.87	10.72	0.69	2.19e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg18230493	chr5:56204884	C5orf35	-0.83	-6.76	-0.52	4.9e-10	Initial pursuit acceleration;
TGCT	cis	rs7267979	1.000	rs6115146	chr20:25304507	G/A	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg00814883	chr7:100076585	TSC22D4	-0.85	-8.49	-0.61	5.27e-14	Platelet count;
TGCT	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg18876405	chr7:65276391	NA	0.32	4.89	0.4	3.1e-6	Aortic root size;
TGCT	cis	rs11098499	0.954	rs10518331	chr4:120323595	C/T	cg09307838	chr4:120376055	NA	0.68	6.53	0.51	1.54e-9	Corneal astigmatism;
TGCT	cis	rs7744392	0.557	rs9658100	chr6:35356640	G/T	cg06087101	chr6:35551932	FKBP5	-0.61	-4.56	-0.38	1.21e-5	Cataracts in type 2 diabetes;
TGCT	cis	rs79349575	0.783	rs62075838	chr17:46996432	C/T	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.51	-0.38	1.48e-5	Type 2 diabetes;
TGCT	cis	rs3757318	0.686	rs17688135	chr6:151849040	G/A	cg18745416	chr6:152011399	ESR1	0.52	4.84	0.4	3.82e-6	Breast cancer (estrogen-receptor negative, progesterone-receptor negative, and human epidermal growth factor-receptor negative);Breast cancer;
TGCT	cis	rs250677	0.652	rs36042	chr5:148439782	G/T	cg18129178	chr5:148520854	ABLIM3	-0.42	-5.74	-0.46	6.77e-8	Breast cancer;
TGCT	cis	rs2820315	1.000	rs2132363	chr1:201826482	C/T	cg12730843	chr1:201915899	LMOD1	-0.27	-4.8	-0.4	4.44e-6	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
TGCT	cis	rs9788682	0.591	rs7170068	chr15:78912943	G/A	cg24631222	chr15:78858424	CHRNA5	0.93	6.27	0.49	5.43e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.7	6.33	0.49	4.02e-9	Tonsillectomy;
TGCT	cis	rs6582630	0.572	rs7315897	chr12:38449081	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-4.79	-0.4	4.57e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg25036284	chr2:26402008	FAM59B	0.65	5.18	0.42	8.59e-7	Gut microbiome composition (summer);
TGCT	cis	rs62012628	0.527	rs12438008	chr15:79084680	C/T	cg00639195	chr15:79103007	ADAMTS7	0.5	4.68	0.39	7.26e-6	Diastolic blood pressure;
TGCT	cis	rs58904263	1	rs58904263	chr20:30401406	A/AG	cg13852791	chr20:30311386	BCL2L1	0.76	5.71	0.46	8.02e-8	Monocyte count;
TGCT	cis	rs6540559	0.546	rs59435160	chr1:210030730	C/A	cg12034118	chr1:209979487	IRF6	0.68	4.83	0.4	3.94e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs877282	0.891	rs12357999	chr10:796468	A/C	cg17470449	chr10:769945	NA	0.3	4.82	0.4	4.14e-6	Uric acid levels;
TGCT	cis	rs57590327	0.555	rs13084107	chr3:81833577	T/C	cg07356753	chr3:81810745	GBE1	-0.73	-6.73	-0.52	5.57e-10	Extraversion;
TGCT	cis	rs11674184	0.714	rs16857668	chr2:11723110	G/A	cg07314298	chr2:11723111	GREB1	-0.43	-7.85	-0.58	1.7e-12	Endometriosis;
TGCT	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.67	-0.39	7.73e-6	Prudent dietary pattern;
TGCT	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg07636037	chr3:49044803	WDR6	-0.85	-8.91	-0.62	5.44e-15	Menarche (age at onset);
TGCT	cis	rs17253792	0.822	rs77250916	chr14:56042208	A/G	cg01858014	chr14:56050164	KTN1	-0.36	-4.57	-0.38	1.15e-5	Putamen volume;
TGCT	cis	rs7917772	0.503	rs56397707	chr10:104302693	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	8.36	0.6	1.1e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs17473412	0.864	rs17408694	chr5:122729230	T/A	cg15125798	chr5:122621645	NA	-0.55	-4.9	-0.4	2.9e-6	Total body bone mineral density;
TGCT	cis	rs7582180	0.652	rs11694700	chr2:100936637	C/T	cg14675211	chr2:100938903	LONRF2	0.51	4.95	0.41	2.32e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4780401	0.609	rs9924522	chr16:11816852	C/A	cg01061890	chr16:11836724	TXNDC11	-0.6	-5.82	-0.46	4.74e-8	Rheumatoid arthritis;
TGCT	cis	rs259282	0.605	rs17692992	chr19:33099430	T/G	cg26639809	chr19:33781782	NA	0.24	4.76	0.39	5.3e-6	Schizophrenia;
TGCT	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg06873352	chr17:61820015	STRADA	0.58	6.42	0.5	2.65e-9	Prudent dietary pattern;
TGCT	cis	rs9902453	0.868	rs9902340	chr17:28476458	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-6.9	-0.53	2.37e-10	Coffee consumption (cups per day);
TGCT	cis	rs4972806	0.849	rs2857541	chr2:177029086	C/T	cg13092806	chr2:177043255	NA	0.56	4.84	0.4	3.77e-6	IgG glycosylation;
TGCT	cis	rs9467773	0.584	rs1021372	chr6:26632444	T/C	cg15659132	chr6:26577336	NA	0.86	11.04	0.7	3.71e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg27286337	chr10:134555280	INPP5A	0.37	4.52	0.38	1.4e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs9534288	0.797	rs4337200	chr13:46531749	G/A	cg15192986	chr13:46630673	CPB2	-0.51	-7.21	-0.54	4.75e-11	Blood protein levels;
TGCT	cis	rs6978712	1.000	rs56040865	chr7:127152442	C/G	cg01017541	chr7:127776461	NA	0.76	4.6	0.38	1.01e-5	Medication adherence in chronic diseases;
TGCT	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.31	-4.82	-0.4	4.12e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1218582	0.651	rs4845396	chr1:154828409	A/G	cg06221963	chr1:154839813	KCNN3	0.53	6.89	0.53	2.54e-10	Prostate cancer;
TGCT	cis	rs12458462	1.000	rs12458462	chr18:77472436	C/A	cg11879182	chr18:77439856	CTDP1	0.67	7.52	0.56	9.5e-12	Monocyte count;
TGCT	cis	rs9560113	0.573	rs7988040	chr13:112226534	C/G	cg10483660	chr13:112241077	NA	0.31	4.96	0.41	2.27e-6	Menarche (age at onset);
TGCT	cis	rs3749237	0.615	rs6792911	chr3:49429856	C/T	cg02487422	chr3:49467188	NICN1	0.61	6.37	0.5	3.31e-9	Resting heart rate;
TGCT	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg18876405	chr7:65276391	NA	-0.33	-5.05	-0.41	1.55e-6	Aortic root size;
TGCT	cis	rs2243480	0.901	rs13237344	chr7:66022256	T/A	cg18252515	chr7:66147081	NA	-1.22	-8.04	-0.59	6.02e-13	Diabetic kidney disease;
TGCT	cis	rs6840360	0.533	rs4696295	chr4:152717430	T/C	cg22705602	chr4:152727874	NA	0.34	5.91	0.47	3.03e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs4072705	0.967	rs4144630	chr9:127439200	A/G	cg13476313	chr9:127244764	NR5A1	0.3	4.88	0.4	3.15e-6	Menarche (age at onset);
TGCT	cis	rs9309473	0.615	rs74523560	chr2:73764185	C/T	cg07208825	chr2:73871855	ALMS1P	0.25	4.76	0.39	5.37e-6	Metabolite levels;
TGCT	cis	rs7666738	0.830	rs10034619	chr4:98970067	G/C	cg18180107	chr4:99064573	C4orf37	0.53	4.89	0.4	3.01e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg25036284	chr2:26402008	FAM59B	0.65	5.18	0.42	8.59e-7	Gut microbiome composition (summer);
TGCT	cis	rs9972944	0.902	rs9972947	chr17:63771088	G/A	cg07283582	chr17:63770753	CCDC46	0.28	5.89	0.47	3.36e-8	Total body bone mineral density;
TGCT	cis	rs2839186	0.656	rs4819226	chr21:47712412	A/G	cg12516959	chr21:47718080	NA	-0.31	-4.51	-0.38	1.47e-5	Testicular germ cell tumor;
TGCT	cis	rs514406	0.825	rs12089511	chr1:53436427	A/T	cg01802117	chr1:53393560	SCP2	0.39	4.67	0.39	7.55e-6	Monocyte count;
TGCT	cis	rs17122693	0.710	rs8011413	chr14:51160245	A/G	cg04730355	chr14:51134070	SAV1	1.15	8.47	0.61	5.79e-14	Cognitive performance;
TGCT	trans	rs9388451	0.839	rs3799711	chr6:126075313	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.73	8.44	0.6	6.92e-14	Brugada syndrome;
TGCT	cis	rs694739	1.000	rs499425	chr11:64105929	A/G	cg23796481	chr11:64053134	BAD;GPR137	-0.69	-7.23	-0.54	4.44e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	8.0	0.58	7.67e-13	Platelet count;
TGCT	cis	rs9660992	0.539	rs113699533	chr1:205122895	G/A	cg00857998	chr1:205179979	DSTYK	0.48	4.48	0.37	1.68e-5	Mean corpuscular volume;Mean platelet volume;
TGCT	cis	rs10779751	0.734	rs2261217	chr1:11127764	C/A	cg08854313	chr1:11322531	MTOR	0.82	7.04	0.53	1.19e-10	Body mass index;
TGCT	cis	rs61931739	0.517	rs7958755	chr12:34294699	T/C	cg06521331	chr12:34319734	NA	-0.3	-4.55	-0.38	1.28e-5	Morning vs. evening chronotype;
TGCT	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg16325326	chr1:53192061	ZYG11B	0.6	6.77	0.52	4.62e-10	Monocyte count;
TGCT	cis	rs910316	0.737	rs175080	chr14:75513828	G/A	cg08847533	chr14:75593920	NEK9	-0.85	-8.45	-0.6	6.56e-14	Height;
TGCT	cis	rs2235642	0.750	rs2974845	chr16:1648162	T/C	cg07639376	chr16:1584516	IFT140;TMEM204	-0.28	-4.81	-0.4	4.25e-6	Coronary artery disease;
TGCT	cis	rs9513627	0.573	rs4771336	chr13:100210610	T/G	cg25919922	chr13:100150906	NA	0.71	5.66	0.45	1e-7	Obesity-related traits;
TGCT	cis	rs3087591	1.000	rs9902427	chr17:29625430	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.48	-7.29	-0.55	3.12e-11	Hip circumference;
TGCT	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg02725872	chr8:58115012	NA	-0.38	-4.99	-0.41	1.98e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs151997	1.000	rs251043	chr5:50215997	A/G	cg06027927	chr5:50259733	NA	0.47	4.83	0.4	3.9e-6	Callous-unemotional behaviour;
TGCT	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg00814883	chr7:100076585	TSC22D4	-0.92	-9.68	-0.66	7.64e-17	Platelet count;
TGCT	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.54	-5.1	-0.42	1.22e-6	Electroencephalogram traits;
TGCT	cis	rs5750830	0.645	rs756640	chr22:39779300	G/A	cg11247378	chr22:39784982	NA	-0.74	-10.6	-0.69	4.31e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs6893300	0.524	rs12522926	chr5:179214818	G/A	cg14593053	chr5:179126677	CANX	0.49	5.66	0.45	1.01e-7	Resting heart rate;
TGCT	cis	rs904251	0.523	rs9349039	chr6:37480392	A/G	cg08126542	chr6:37504118	NA	-0.46	-6.46	-0.5	2.11e-9	Cognitive performance;
TGCT	cis	rs709400	0.663	rs8015918	chr14:103942991	A/G	cg26031613	chr14:104095156	KLC1	0.85	9.72	0.66	5.87e-17	Body mass index;
TGCT	cis	rs1005224	0.889	rs2059382	chr14:76158916	T/C	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.54	-4.67	-0.39	7.82e-6	Large artery stroke;
TGCT	trans	rs10802346	0.514	rs5024440	chr1:246372608	G/C	cg13514129	chr1:39547527	MACF1	0.83	7.31	0.55	2.94e-11	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg13770153	chr20:60521292	NA	-0.61	-8.97	-0.63	3.88e-15	Obesity-related traits;
TGCT	cis	rs72781680	1.000	rs17712391	chr2:24245659	C/T	cg08917208	chr2:24149416	ATAD2B	0.85	5.13	0.42	1.08e-6	Lymphocyte counts;
TGCT	cis	rs9486719	1.000	rs35487471	chr6:96879715	C/T	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.21	-0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs7246657	0.722	rs2927746	chr19:38156570	G/A	cg18154014	chr19:37997991	ZNF793	-0.67	-4.69	-0.39	6.96e-6	Coronary artery calcification;
TGCT	cis	rs9916302	0.904	rs10491128	chr17:37551988	G/A	cg15445000	chr17:37608096	MED1	-0.35	-5.04	-0.41	1.61e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7786808	0.712	rs2335170	chr7:158207101	G/A	cg01191920	chr7:158217561	PTPRN2	-0.44	-6.74	-0.52	5.44e-10	Obesity-related traits;
TGCT	cis	rs453301	0.686	rs6601281	chr8:8911004	A/G	cg06636001	chr8:8085503	FLJ10661	-0.72	-6.0	-0.47	2.04e-8	Joint mobility (Beighton score);
TGCT	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg12667521	chr19:29218732	NA	0.54	5.72	0.46	7.65e-8	Methadone dose in opioid dependence;
TGCT	cis	rs763121	0.853	rs3747174	chr22:39069181	T/C	cg06022373	chr22:39101656	GTPBP1	0.77	7.46	0.56	1.35e-11	Menopause (age at onset);
TGCT	cis	rs7809950	0.954	rs2894466	chr7:107242909	G/A	cg23024343	chr7:107201750	COG5	0.33	5.29	0.43	5.36e-7	Coronary artery disease;
TGCT	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg06108461	chr20:60628389	TAF4	-0.61	-8.86	-0.62	6.96e-15	Body mass index;
TGCT	cis	rs4319547	0.728	rs61954974	chr12:123074169	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.68	-5.38	-0.44	3.5e-7	Body mass index;
TGCT	cis	rs6598955	0.671	rs11579354	chr1:26604071	T/G	cg04990556	chr1:26633338	UBXN11	0.66	5.0	0.41	1.88e-6	Obesity-related traits;
TGCT	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.45	-5.37	-0.43	3.72e-7	Alzheimer's disease;
TGCT	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg12963246	chr6:28129442	ZNF389	0.51	5.02	0.41	1.73e-6	Depression;
TGCT	cis	rs67311347	0.869	rs6790495	chr3:40366770	C/T	cg13683864	chr3:40499215	RPL14	-1.05	-10.95	-0.7	6.12e-20	Renal cell carcinoma;
TGCT	cis	rs9324022	0.626	rs10873520	chr14:101175967	G/A	cg18089426	chr14:101175970	NA	0.63	5.96	0.47	2.38e-8	Plateletcrit;
TGCT	cis	rs9611565	1.000	rs5751086	chr22:41768862	C/T	cg13695892	chr22:41940480	POLR3H	-0.73	-7.41	-0.55	1.69e-11	Vitiligo;
TGCT	cis	rs9926296	0.632	rs7206546	chr16:89799079	C/T	cg08627397	chr16:89984028	MC1R	0.31	4.99	0.41	2.02e-6	Vitiligo;
TGCT	cis	rs6754311	0.731	rs3754686	chr2:136603276	T/C	cg07169764	chr2:136633963	MCM6	-0.66	-6.05	-0.48	1.6e-8	Mosquito bite size;
TGCT	cis	rs8072100	0.840	rs12452796	chr17:45479733	G/T	cg08085267	chr17:45401833	C17orf57	0.5	5.69	0.46	8.53e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs483180	0.512	rs606312	chr1:120222582	G/A	cg19096424	chr1:120255104	PHGDH	0.55	5.1	0.42	1.23e-6	Macular telangiectasia type 2;
TGCT	cis	rs727563	0.562	rs5758458	chr22:42154132	G/A	cg06481639	chr22:41940642	POLR3H	0.69	6.02	0.48	1.83e-8	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs36051895	0.632	rs7850484	chr9:5147817	C/T	cg02405213	chr9:5042618	JAK2	-0.76	-9.88	-0.66	2.47e-17	Pediatric autoimmune diseases;
TGCT	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	5.8	0.46	5.19e-8	Alzheimer's disease;
TGCT	cis	rs6460942	1.000	rs75333414	chr7:12303829	T/A	cg06484146	chr7:12443880	VWDE	-0.53	-4.73	-0.39	6.07e-6	Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs28594127	chr4:99001121	T/G	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6088580	0.609	rs6059844	chr20:33036482	A/G	cg06115741	chr20:33292138	TP53INP2	0.52	4.71	0.39	6.55e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs9467711	1.000	rs34569761	chr6:26334306	A/G	cg16898833	chr6:26189333	HIST1H4D	1.04	5.41	0.44	3.12e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9527	0.615	rs36045108	chr10:104697929	G/A	cg04362960	chr10:104952993	NT5C2	0.64	5.4	0.44	3.33e-7	Arsenic metabolism;
TGCT	cis	rs2180341	0.618	rs11154396	chr6:127638911	C/T	cg27446573	chr6:127587934	RNF146	0.65	5.79	0.46	5.52e-8	Breast cancer;
TGCT	cis	rs4699052	0.963	rs7657390	chr4:104213114	T/A	cg16532752	chr4:104119610	CENPE	-0.56	-5.05	-0.41	1.57e-6	Testicular germ cell tumor;
TGCT	cis	rs954108	0.772	rs9508154	chr13:29370726	A/G	cg11788234	chr13:29393811	NA	-0.41	-5.17	-0.42	9.07e-7	Obesity-related traits;
TGCT	cis	rs1843834	0.505	rs3820763	chr2:225347270	A/G	cg12698349	chr2:225449008	CUL3	-0.76	-6.38	-0.5	3.26e-9	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs936229	0.511	rs12591513	chr15:75102714	G/A	cg10253484	chr15:75165896	SCAMP2	-0.68	-6.04	-0.48	1.63e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
TGCT	cis	rs9611565	0.694	rs4822032	chr22:41925535	T/C	cg17554472	chr22:41940697	POLR3H	-0.45	-5.1	-0.42	1.22e-6	Vitiligo;
TGCT	cis	rs2997447	0.761	rs17257107	chr1:26448447	A/G	cg03844060	chr1:26490628	NA	0.28	4.56	0.38	1.19e-5	QRS complex (12-leadsum);
TGCT	trans	rs28735056	0.592	rs12455965	chr18:77688830	G/C	cg05926928	chr17:57297772	GDPD1	-0.68	-6.75	-0.52	5.1e-10	Schizophrenia;
TGCT	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg03161606	chr19:29218774	NA	0.6	5.84	0.46	4.28e-8	Methadone dose in opioid dependence;
TGCT	cis	rs904251	0.600	rs1874736	chr6:37447994	C/G	cg25019722	chr6:37503610	NA	-0.48	-6.92	-0.53	2.1e-10	Cognitive performance;
TGCT	cis	rs3857536	0.544	rs208453	chr6:66906841	A/T	cg07460842	chr6:66804631	NA	-0.68	-6.73	-0.52	5.5e-10	Blood trace element (Cu levels);
TGCT	cis	rs7647973	0.593	rs7620848	chr3:49828021	G/C	cg05785598	chr3:49045655	WDR6	-0.42	-5.24	-0.43	6.67e-7	Menarche (age at onset);
TGCT	cis	rs1568889	1.000	rs16917735	chr11:28119980	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.84	-8.78	-0.62	1.09e-14	Bipolar disorder;
TGCT	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg03806693	chr22:41940476	POLR3H	-1.13	-13.26	-0.77	1.59e-25	Vitiligo;
TGCT	cis	rs412000	0.554	rs2680700	chr17:56440542	G/T	cg25039879	chr17:56429692	SUPT4H1	0.62	5.94	0.47	2.63e-8	Primary tooth development (time to first tooth eruption);
TGCT	cis	rs4689388	0.926	rs10010131	chr4:6292915	A/G	cg00701064	chr4:6280414	WFS1	0.37	4.72	0.39	6.3e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg12963246	chr6:28129442	ZNF389	0.52	5.1	0.42	1.23e-6	Depression;
TGCT	cis	rs6912958	0.684	rs4707382	chr6:88320641	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-4.57	-0.38	1.16e-5	Monocyte percentage of white cells;
TGCT	cis	rs9308731	0.644	rs1821968	chr2:111880623	C/T	cg04202892	chr2:111875749	ACOXL	0.54	6.25	0.49	6.1e-9	Chronic lymphocytic leukemia;
TGCT	cis	rs10089	1.000	rs10478796	chr5:127436187	A/G	cg19767477	chr5:127420684	SLC12A2	-0.43	-4.52	-0.38	1.43e-5	Ileal carcinoids;
TGCT	cis	rs951366	0.677	rs1775140	chr1:205672107	C/A	cg17178900	chr1:205818956	PM20D1	0.58	6.97	0.53	1.66e-10	Menarche (age at onset);
TGCT	cis	rs13082711	0.522	rs674303	chr3:27332177	T/C	cg02860705	chr3:27208620	NA	0.34	5.58	0.45	1.43e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs6840360	0.593	rs6855883	chr4:152688997	A/G	cg17479576	chr4:152424074	FAM160A1	-0.52	-5.16	-0.42	9.49e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs853679	0.546	rs200948	chr6:27835272	T/C	cg10876282	chr6:28092338	ZSCAN16	0.75	4.45	0.37	1.88e-5	Depression;
TGCT	cis	rs11578119	0.864	rs6667728	chr1:170493407	A/G	cg09767346	chr1:170501363	GORAB	0.66	5.2	0.42	7.84e-7	Male-pattern baldness;
TGCT	cis	rs4631830	0.900	rs7075009	chr10:51544143	T/G	cg10326726	chr10:51549505	MSMB	-0.26	-5.28	-0.43	5.5e-7	Prostate-specific antigen levels;
TGCT	cis	rs7769051	0.522	rs62424539	chr6:133173272	C/T	cg22852734	chr6:133119734	C6orf192	1.1	5.45	0.44	2.61e-7	Type 2 diabetes nephropathy;
TGCT	trans	rs12339966	0.653	rs7037356	chr9:11300688	G/A	cg07173112	chr1:1114698	TTLL10	-0.34	-6.8	-0.52	4.02e-10	Systolic blood pressure;
TGCT	cis	rs896854	0.714	rs6471503	chr8:95990283	G/A	cg16049864	chr8:95962084	TP53INP1	-0.7	-9.94	-0.67	1.76e-17	Type 2 diabetes;
TGCT	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg23302884	chr18:44338147	ST8SIA5	-0.4	-4.58	-0.38	1.11e-5	Personality dimensions;
TGCT	cis	rs11719291	0.833	rs11713694	chr3:48833615	G/T	cg00383909	chr3:49044727	WDR6	1.26	6.52	0.51	1.58e-9	Cognitive function;
TGCT	cis	rs6570726	1.000	rs450076	chr6:145847655	G/T	cg23711669	chr6:146136114	FBXO30	0.68	6.26	0.49	5.81e-9	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs7726839	0.507	rs72703100	chr5:614291	C/T	cg11887960	chr12:57824829	NA	1.19	9.29	0.64	6.45e-16	Obesity-related traits;
TGCT	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg21963583	chr11:68658836	MRPL21	0.38	6.43	0.5	2.51e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs453301	0.522	rs2929309	chr8:9083771	C/A	cg15556689	chr8:8085844	FLJ10661	-0.61	-5.63	-0.45	1.14e-7	Joint mobility (Beighton score);
TGCT	cis	rs9341808	0.739	rs4706831	chr6:81007699	T/C	cg08355045	chr6:80787529	NA	0.28	4.75	0.39	5.54e-6	Sitting height ratio;
TGCT	cis	rs7000551	0.715	rs1879792	chr8:22314029	C/A	cg12081754	chr8:22256438	SLC39A14	0.31	5.17	0.42	9.19e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg01802117	chr1:53393560	SCP2	-0.39	-4.61	-0.38	1e-5	Monocyte count;
TGCT	cis	rs9733	0.650	rs1971378	chr1:150597261	C/T	cg13175981	chr1:150552382	MCL1	0.47	5.29	0.43	5.27e-7	Tonsillectomy;
TGCT	cis	rs3806843	1.000	rs13184940	chr5:140172918	T/C	cg19875535	chr5:140030758	IK	0.37	6.34	0.49	3.89e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs4808199	0.894	rs10418051	chr19:19397789	C/T	cg03709012	chr19:19516395	GATAD2A	0.81	6.55	0.51	1.41e-9	Nonalcoholic fatty liver disease;
TGCT	cis	rs4478858	0.735	rs11590120	chr1:31792324	A/G	cg00250761	chr1:31883323	NA	-0.27	-4.78	-0.39	4.86e-6	Alcohol dependence;
TGCT	cis	rs250677	0.687	rs250673	chr5:148445798	C/T	cg18129178	chr5:148520854	ABLIM3	-0.43	-6.29	-0.49	5.05e-9	Breast cancer;
TGCT	cis	rs10883723	0.810	rs1056857	chr10:104240003	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	8.36	0.6	1.1e-13	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs807669	0.807	rs698422	chr22:19205826	A/T	cg02655711	chr22:19163373	SLC25A1	0.33	7.25	0.55	3.9e-11	Metabolite levels;
TGCT	cis	rs28595532	0.920	rs116717907	chr4:119762568	A/G	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs8072100	0.967	rs12452315	chr17:45479446	G/T	cg08085267	chr17:45401833	C17orf57	0.48	5.41	0.44	3.12e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg10207240	chr12:122356781	WDR66	0.33	4.54	0.38	1.31e-5	Mean corpuscular volume;
TGCT	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6582630	0.537	rs7310749	chr12:38400472	C/T	cg13010199	chr12:38710504	ALG10B	0.59	4.68	0.39	7.35e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs2836974	0.583	rs9981884	chr21:40585633	G/A	cg11644478	chr21:40555479	PSMG1	0.71	7.25	0.55	3.94e-11	Cognitive function;
TGCT	cis	rs7666738	0.512	rs165251	chr4:98758490	C/G	cg05340658	chr4:99064831	C4orf37	0.44	5.52	0.44	1.85e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7267979	1.000	rs4815404	chr20:25301845	T/G	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1555895	0.633	rs7913077	chr10:845969	T/C	cg02193355	chr10:851439	NA	0.22	4.71	0.39	6.6e-6	Survival in rectal cancer;
TGCT	cis	rs56309584	0.715	rs74506939	chr17:8139463	G/A	cg08322244	chr17:8066669	VAMP2	-0.57	-5.26	-0.43	6.01e-7	Initial pursuit acceleration;
TGCT	cis	rs9649213	0.586	rs55648546	chr7:97960800	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.93	-8.48	-0.61	5.64e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs838147	0.507	rs1704773	chr19:49209566	A/G	cg04599840	chr19:48886497	KDELR1	0.21	4.44	0.37	1.98e-5	Dietary macronutrient intake;
TGCT	cis	rs2072499	0.932	rs3001790	chr1:156165290	T/G	cg25208724	chr1:156163844	SLC25A44	1.14	16.93	0.84	4.87e-34	Testicular germ cell tumor;
TGCT	cis	rs6429082	0.818	rs291341	chr1:235663174	G/T	cg26050004	chr1:235667680	B3GALNT2	0.59	5.16	0.42	9.52e-7	Adiposity;
TGCT	cis	rs11098499	0.754	rs1511025	chr4:120240238	T/C	cg09307838	chr4:120376055	NA	0.61	5.91	0.47	3.14e-8	Corneal astigmatism;
TGCT	cis	rs12935418	0.583	rs80181133	chr16:80967950	G/T	cg07676361	chr16:80966860	NA	-0.34	-4.54	-0.38	1.31e-5	Mean corpuscular volume;
TGCT	cis	rs79349575	0.715	rs11657238	chr17:46985634	A/G	cg07967210	chr17:47022446	SNF8	0.41	5.44	0.44	2.69e-7	Type 2 diabetes;
TGCT	cis	rs10992471	0.756	rs2516568	chr9:95187380	A/T	cg14631576	chr9:95140430	CENPP	-0.3	-4.97	-0.41	2.21e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs6121246	0.909	rs4518038	chr20:30419051	A/G	cg13852791	chr20:30311386	BCL2L1	0.67	4.63	0.38	9.04e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg22166914	chr1:53195759	ZYG11B	0.34	5.71	0.46	7.92e-8	Monocyte count;
TGCT	cis	rs9383153	1.000	rs9370888	chr6:16335544	A/G	cg13189271	chr6:15365693	JARID2	0.99	5.2	0.42	7.9e-7	Gambling;
TGCT	cis	rs2334880	0.836	rs9934715	chr16:71757387	C/G	cg06353428	chr16:71660113	MARVELD3	1.49	12.95	0.76	8.56e-25	Malaria;
TGCT	cis	rs7586879	0.616	rs6545814	chr2:25131316	A/G	cg15423357	chr2:25149977	NA	0.48	4.62	0.38	9.44e-6	Body mass index;
TGCT	cis	rs6460942	0.749	rs74834695	chr7:12464779	G/A	cg06484146	chr7:12443880	VWDE	-0.57	-5.54	-0.45	1.71e-7	Coronary artery disease;
TGCT	cis	rs9443645	0.869	rs1567168	chr6:79536455	G/T	cg05283184	chr6:79620031	NA	-0.21	-4.64	-0.38	8.56e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs55882075	0.765	rs34329357	chr5:179130408	G/C	cg14593053	chr5:179126677	CANX	0.52	5.69	0.46	8.52e-8	Monocyte percentage of white cells;
TGCT	cis	rs9611565	0.545	rs5758432	chr22:42111693	T/C	cg17554472	chr22:41940697	POLR3H	0.48	5.06	0.41	1.5e-6	Vitiligo;
TGCT	cis	rs9814567	0.752	rs1880378	chr3:134330709	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-6.41	-0.5	2.8e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs3782455	0.793	rs2290800	chr12:114404383	T/G	cg10631684	chr12:113795897	PLBD2	-0.7	-4.61	-0.38	1e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs7772486	0.790	rs2265469	chr6:146219049	T/C	cg05347473	chr6:146136440	FBXO30	0.52	5.0	0.41	1.89e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7666738	0.753	rs28463863	chr4:98844444	T/C	cg05340658	chr4:99064831	C4orf37	0.52	6.05	0.48	1.6e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11190604	1.000	rs4917901	chr10:102201773	A/C	cg16342193	chr10:102329863	NA	-0.4	-5.31	-0.43	4.85e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs17376456	0.825	rs12153021	chr5:93073913	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	4.43	0.37	2.01e-5	Diabetic retinopathy;
TGCT	cis	rs8111998	0.702	rs16999400	chr19:22768608	A/G	cg19914732	chr19:22715077	NA	-0.56	-4.51	-0.38	1.46e-5	Corneal structure;
TGCT	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg18305652	chr10:134549665	INPP5A	0.35	5.64	0.45	1.1e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs7772486	0.875	rs1125461	chr6:146417653	C/T	cg05347473	chr6:146136440	FBXO30	0.52	4.72	0.39	6.35e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6424115	0.830	rs2502992	chr1:24201919	T/C	cg15997130	chr1:24165203	NA	0.85	9.25	0.64	8.02e-16	Immature fraction of reticulocytes;
TGCT	cis	rs986417	1.000	rs1254302	chr14:60885343	A/C	cg27398547	chr14:60952738	C14orf39	-1.42	-8.68	-0.61	1.89e-14	Gut microbiota (bacterial taxa);
TGCT	cis	rs7246657	0.943	rs1559229	chr19:37876197	T/C	cg03233940	chr19:37894644	NA	-0.35	-4.54	-0.38	1.3e-5	Coronary artery calcification;
TGCT	cis	rs2857078	1.000	rs2857078	chr17:42330171	A/C	cg13607699	chr17:42295918	UBTF	-0.89	-8.56	-0.61	3.65e-14	Red cell distribution width;Reticulocyte count;
TGCT	cis	rs11587682	0.785	rs72694993	chr1:150242604	A/C	cg18798344	chr1:149336151	NA	0.56	4.48	0.37	1.7e-5	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs10927875	0.518	rs945416	chr1:16344402	G/A	cg22431228	chr1:16359049	CLCNKA	-0.29	-5.94	-0.47	2.68e-8	Dilated cardiomyopathy;
TGCT	cis	rs9443189	0.570	rs9341532	chr6:76403674	A/G	cg01950844	chr6:76311363	SENP6	1.0	6.24	0.49	6.35e-9	Prostate cancer;
TGCT	cis	rs11718455	0.883	rs2372579	chr3:44034003	A/T	cg08738300	chr3:44038990	NA	0.86	6.57	0.51	1.23e-9	Coronary artery disease;
TGCT	cis	rs651907	0.588	rs1707613	chr3:101637189	A/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.5	4.79	0.4	4.65e-6	Colorectal cancer;
TGCT	cis	rs79387448	0.745	rs7587856	chr2:103144305	C/A	cg09003973	chr2:102972529	NA	0.98	6.36	0.5	3.57e-9	Gut microbiota (bacterial taxa);
TGCT	cis	rs1865760	0.865	rs1115920	chr6:25954027	A/G	cg17042849	chr6:26104293	HIST1H4C	-0.52	-4.78	-0.39	4.88e-6	Height;
TGCT	trans	rs1814175	0.592	rs1794161	chr11:49898825	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.58	-0.69	4.9e-19	Height;
TGCT	cis	rs2549003	1.000	rs6894655	chr5:131818649	T/C	cg00255919	chr5:131827918	IRF1	0.22	5.15	0.42	1.01e-6	Asthma (sex interaction);
TGCT	cis	rs1799949	0.931	rs9891977	chr17:41437398	A/G	cg05368731	chr17:41323189	NBR1	1.05	11.03	0.7	3.86e-20	Menopause (age at onset);
TGCT	cis	rs10489202	0.683	rs202260	chr1:167956167	G/T	cg24449463	chr1:168025552	DCAF6	-0.59	-7.11	-0.54	8.22e-11	Schizophrenia;
TGCT	cis	rs2153535	0.580	rs9505454	chr6:8478532	T/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs17253792	0.822	rs28831725	chr14:56087569	C/T	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.41	-6.76	-0.52	4.9e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2112347	0.502	rs34339	chr5:74931333	G/T	cg19683494	chr5:74908142	NA	-0.65	-6.25	-0.49	6.16e-9	Body mass index (joint analysis main effects and smoking interaction);Waist circumference;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Hip circumference;Body mass index;Body mass index in physically active individuals;Obesity;
TGCT	cis	rs9831754	0.906	rs9840031	chr3:78396140	C/T	cg06138941	chr3:78371609	NA	0.49	5.4	0.44	3.25e-7	Calcium levels;
TGCT	cis	rs35306767	0.953	rs10904583	chr10:983498	T/C	cg18964960	chr10:1102726	WDR37	0.56	4.58	0.38	1.12e-5	Eosinophil percentage of granulocytes;
TGCT	cis	rs2836633	0.894	rs55955614	chr21:40037330	T/G	cg12884169	chr21:40033163	ERG	0.45	4.98	0.41	2.13e-6	Coronary artery disease;
TGCT	cis	rs3796352	1.000	rs35174175	chr3:53041509	T/C	cg07884673	chr3:53033167	SFMBT1	0.64	6.39	0.5	3.03e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs459571	0.920	rs433402	chr9:136898627	A/G	cg13789015	chr9:136890014	NCRNA00094	0.41	7.73	0.57	3.16e-12	Platelet distribution width;
TGCT	cis	rs3540	0.597	rs4620932	chr15:91036569	G/A	cg22089800	chr15:90895588	ZNF774	0.76	7.77	0.57	2.62e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs11098499	0.863	rs3775845	chr4:120432447	T/C	cg09307838	chr4:120376055	NA	0.69	6.53	0.51	1.49e-9	Corneal astigmatism;
TGCT	cis	rs9611565	0.506	rs4822020	chr22:41700203	C/T	cg06634786	chr22:41940651	POLR3H	-0.63	-5.66	-0.45	1.01e-7	Vitiligo;
TGCT	cis	rs7213347	0.707	rs2038677	chr17:2178092	C/G	cg13315690	chr17:1944831	OVCA2;DPH1	-0.37	-4.7	-0.39	6.76e-6	Total body bone mineral density;
TGCT	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.51	-4.99	-0.41	2e-6	Bipolar disorder;
TGCT	cis	rs10871290	0.551	rs3863435	chr16:74465396	C/G	cg01733217	chr16:74700730	RFWD3	-0.66	-6.71	-0.52	6.2e-10	Breast cancer;
TGCT	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/A	cg13877915	chr19:58951672	ZNF132	0.64	5.05	0.41	1.51e-6	Mean platelet volume;
TGCT	cis	rs2562456	0.917	rs2650793	chr19:21676115	C/G	cg25650185	chr19:21324782	ZNF431	0.57	5.03	0.41	1.67e-6	Pain;
TGCT	cis	rs36051895	0.623	rs6476952	chr9:5236924	T/C	cg02405213	chr9:5042618	JAK2	-0.69	-8.52	-0.61	4.64e-14	Pediatric autoimmune diseases;
TGCT	cis	rs3796352	1.000	rs11712653	chr3:53070875	A/C	cg24616795	chr3:53032891	SFMBT1	-0.38	-4.73	-0.39	5.99e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs1577917	0.958	rs66807489	chr6:86440702	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.4	-0.44	3.28e-7	Response to antipsychotic treatment;
TGCT	cis	rs4566357	0.595	rs10201538	chr2:227914449	A/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-5.24	-0.43	6.55e-7	Coronary artery disease;
TGCT	trans	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg17470723	chr8:74884337	TCEB1	0.72	6.87	0.53	2.78e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7412746	0.646	rs10399947	chr1:150861960	G/A	cg04414720	chr1:150670196	GOLPH3L	0.39	4.64	0.38	8.63e-6	Melanoma;
TGCT	cis	rs7607369	0.626	rs4672892	chr2:219278630	A/G	cg02176678	chr2:219576539	TTLL4	-0.49	-6.24	-0.49	6.26e-9	Red blood cell count;Amyotrophic lateral sclerosis;
TGCT	cis	rs7833790	1.000	rs1463259	chr8:82737745	A/G	cg17211192	chr8:82754475	SNX16	-1.08	-8.89	-0.62	6.01e-15	Diastolic blood pressure;
TGCT	cis	rs8017423	0.935	rs11628952	chr14:90734953	T/C	cg04374321	chr14:90722782	PSMC1	-0.75	-7.32	-0.55	2.75e-11	Mortality in heart failure;
TGCT	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.51	5.37	0.43	3.71e-7	Menopause (age at onset);
TGCT	cis	rs9388451	0.626	rs1739384	chr6:126099246	C/A	cg05901451	chr6:126070800	HEY2	-0.92	-11.38	-0.71	5.49e-21	Brugada syndrome;
TGCT	cis	rs6840360	0.615	rs12641441	chr4:152607623	A/G	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.13	-0.48	1.1e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs881375	0.678	rs4836834	chr9:123665901	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	5.31	0.43	4.92e-7	Rheumatoid arthritis;
TGCT	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg23172400	chr8:95962367	TP53INP1	-0.39	-6.48	-0.5	1.99e-9	Type 2 diabetes;
TGCT	cis	rs17376456	0.569	rs11135394	chr5:93187135	C/T	cg25358565	chr5:93447407	FAM172A	-0.6	-5.47	-0.44	2.38e-7	Diabetic retinopathy;
TGCT	cis	rs79349575	0.655	rs62078384	chr17:47044463	C/T	cg26022315	chr17:47021804	SNF8	0.47	4.56	0.38	1.2e-5	Type 2 diabetes;
TGCT	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg25703541	chr22:24373054	LOC391322	0.86	8.27	0.6	1.72e-13	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9807989	0.839	rs3771166	chr2:102986222	G/A	cg09003973	chr2:102972529	NA	0.67	6.03	0.48	1.75e-8	Asthma;
TGCT	cis	rs4975616	0.804	rs456366	chr5:1337070	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.28	-6.85	-0.52	3.06e-10	Lung cancer;
TGCT	cis	rs35306767	0.953	rs1539174	chr10:974870	C/G	cg20503657	chr10:835505	NA	0.56	7.77	0.57	2.63e-12	Eosinophil percentage of granulocytes;
TGCT	trans	rs57221529	0.655	rs11948381	chr5:568413	A/T	cg25482853	chr8:67687455	SGK3	1.11	8.76	0.62	1.19e-14	Lung disease severity in cystic fibrosis;
TGCT	cis	rs11098499	0.874	rs17839089	chr4:120111069	A/G	cg09307838	chr4:120376055	NA	0.5	4.64	0.38	8.86e-6	Corneal astigmatism;
TGCT	cis	rs12477438	0.520	rs2516829	chr2:99773201	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.1	15.5	0.81	8.29e-31	Chronic sinus infection;
TGCT	cis	rs3540	0.512	rs11633872	chr15:91080512	G/A	cg22089800	chr15:90895588	ZNF774	-0.74	-7.57	-0.56	7.35e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs2228479	0.850	rs3785279	chr16:89824562	G/C	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs600550	0.927	rs603568	chr11:59981619	T/C	cg18570331	chr11:60101691	MS4A6E	0.52	4.84	0.4	3.79e-6	Lipoprotein-associated phospholipase A2 activity and mass;
TGCT	cis	rs13256369	1.000	rs10110591	chr8:8576608	G/T	cg06671706	chr8:8559999	CLDN23	-0.35	-4.62	-0.38	9.33e-6	Obesity-related traits;
TGCT	cis	rs10791323	0.536	rs4937842	chr11:133734542	C/G	cg15485101	chr11:133734466	NA	-0.42	-5.94	-0.47	2.71e-8	Childhood ear infection;
TGCT	cis	rs896854	0.738	rs2515226	chr8:95965743	G/A	cg09323728	chr8:95962352	TP53INP1	0.45	5.26	0.43	6.17e-7	Type 2 diabetes;
TGCT	cis	rs7000551	0.751	rs1116085	chr8:22394920	A/G	cg12081754	chr8:22256438	SLC39A14	0.29	4.61	0.38	1e-5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs4924935	1.000	rs2158100	chr17:18811479	A/G	cg26378065	chr17:18585709	ZNF286B	-0.56	-4.71	-0.39	6.6e-6	Pancreatic cancer;
TGCT	cis	rs9467773	1.000	rs6930120	chr6:26555484	A/G	cg05738196	chr6:26577821	NA	0.91	13.19	0.76	2.28e-25	Intelligence (multi-trait analysis);
TGCT	trans	rs6089829	0.962	rs6089825	chr20:61668447	C/T	cg13615516	chr5:77269221	NA	0.72	9.11	0.63	1.74e-15	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1008375	0.966	rs1476836	chr4:17585014	G/C	cg16339924	chr4:17578868	LAP3	0.8	6.96	0.53	1.73e-10	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7584330	0.910	rs12465081	chr2:238401784	A/G	cg16989719	chr2:238392110	NA	-0.27	-4.89	-0.4	3.06e-6	Prostate cancer;
TGCT	cis	rs2735413	0.564	rs11863846	chr16:78119557	C/G	cg09132178	chr16:78079569	NA	0.35	4.51	0.38	1.47e-5	Systolic blood pressure (alcohol consumption interaction);
TGCT	cis	rs9902453	0.967	rs61240589	chr17:28449035	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	6.51	0.5	1.66e-9	Coffee consumption (cups per day);
TGCT	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg01802117	chr1:53393560	SCP2	-0.48	-5.77	-0.46	6.09e-8	Monocyte count;
TGCT	cis	rs2932538	0.922	rs6658555	chr1:113098534	C/T	cg22162597	chr1:113214053	CAPZA1	0.29	6.34	0.49	3.95e-9	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs67460515	0.892	rs4856769	chr3:161004549	C/A	cg03342759	chr3:160939853	NMD3	-0.55	-5.82	-0.46	4.68e-8	Parkinson's disease;
TGCT	cis	rs9814567	0.928	rs6768323	chr3:134268737	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.96	9.11	0.63	1.79e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs1865760	0.613	rs9379805	chr6:25938764	T/A	cg03517284	chr6:25882590	NA	-0.48	-4.78	-0.39	4.78e-6	Height;
TGCT	cis	rs813218	0.584	rs1718240	chr3:99536937	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.48	5.36	0.43	3.97e-7	Orofacial clefts;
TGCT	cis	rs10791097	0.694	rs4264159	chr11:130755784	G/T	cg14779329	chr11:130786720	SNX19	0.29	4.94	0.41	2.45e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg06896619	chr17:61851486	DDX42;CCDC47	-0.51	-4.96	-0.41	2.24e-6	Prudent dietary pattern;
TGCT	cis	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg20637647	chr7:64974828	NA	0.89	4.95	0.41	2.37e-6	Diabetic kidney disease;
TGCT	cis	rs2710642	0.962	rs4671051	chr2:63032696	A/T	cg17519650	chr2:63277830	OTX1	-0.64	-5.83	-0.46	4.47e-8	LDL cholesterol levels;LDL cholesterol;
TGCT	cis	rs77551289	0.512	rs4987853	chr18:60793655	A/G	cg14455307	chr18:60987429	BCL2	-0.57	-4.48	-0.37	1.69e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs1894292	0.527	rs2178290	chr4:74376846	C/T	cg05868023	chr4:75230803	EREG	0.56	5.07	0.41	1.42e-6	Prostate cancer;
TGCT	cis	rs74417235	0.684	rs7723312	chr5:154053249	A/G	cg08754654	chr5:154026448	NA	-0.58	-5.53	-0.44	1.84e-7	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
TGCT	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg12923728	chr3:195709715	SDHAP1	-0.36	-7.57	-0.56	7.39e-12	Pancreatic cancer;
TGCT	cis	rs4727027	0.631	rs62507511	chr7:148796080	C/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	4.6	0.38	1.05e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs3806843	0.548	rs246052	chr5:140326413	G/A	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg06112835	chr11:68658793	MRPL21	0.47	8.03	0.59	6.25e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs1555895	0.656	rs1536338	chr10:838378	C/T	cg02193355	chr10:851439	NA	-0.23	-5.04	-0.41	1.6e-6	Survival in rectal cancer;
TGCT	cis	rs2468186	0.583	rs2450069	chr8:120095828	A/G	cg02248809	chr8:120845432	TAF2	-0.45	-4.83	-0.4	3.99e-6	Osteoprotegerin levels;
TGCT	cis	rs295140	0.507	rs13019821	chr2:201106815	C/G	cg23649088	chr2:200775458	C2orf69	-0.34	-5.87	-0.47	3.76e-8	QT interval;
TGCT	cis	rs10992471	0.603	rs7873397	chr9:95205928	G/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.62	-5.74	-0.46	6.79e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg04944784	chr2:26401820	FAM59B	0.79	5.45	0.44	2.58e-7	Gut microbiome composition (summer);
TGCT	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg03264133	chr6:25882463	NA	-0.64	-5.74	-0.46	6.9e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg15242686	chr22:24348715	GSTTP1	0.5	7.46	0.56	1.34e-11	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7095607	0.967	rs12785105	chr10:69964794	C/T	cg18986048	chr10:69913749	MYPN	0.42	4.49	0.37	1.62e-5	Lung function (FVC);
TGCT	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs270601	0.909	rs2569265	chr5:131704519	T/C	cg24060327	chr5:131705240	SLC22A5	0.78	8.62	0.61	2.62e-14	Acylcarnitine levels;
TGCT	cis	rs7959452	0.590	rs10878974	chr12:69781528	C/G	cg11871910	chr12:69753446	YEATS4	0.82	8.95	0.63	4.38e-15	Blood protein levels;
TGCT	cis	rs10892173	0.566	rs12364667	chr11:117675286	A/C	cg07621104	chr11:117668040	DSCAML1	0.74	8.11	0.59	4.06e-13	Myopia;
TGCT	cis	rs9486719	0.843	rs2499796	chr6:96848364	A/G	cg06623918	chr6:96969491	KIAA0776	0.93	7.08	0.54	9.59e-11	Migraine;Coronary artery disease;
TGCT	cis	rs7226408	0.857	rs72887084	chr18:34503982	G/A	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs910187	0.605	rs6066224	chr20:45806632	T/A	cg27589058	chr20:45804311	EYA2	-0.38	-8.27	-0.6	1.74e-13	Migraine;
TGCT	cis	rs2404602	0.692	rs2304920	chr15:76993867	T/C	cg22467129	chr15:76604101	ETFA	-0.45	-5.11	-0.42	1.2e-6	Blood metabolite levels;
TGCT	cis	rs9814567	1.000	rs6772896	chr3:134203347	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.97	-9.24	-0.64	8.89e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs3820068	0.581	rs16851876	chr1:15950628	A/T	cg05660106	chr1:15850417	CASP9	-0.79	-7.66	-0.57	4.64e-12	Systolic blood pressure;
TGCT	cis	rs5760092	0.755	rs11090298	chr22:24262061	G/A	cg07205460	chr22:24236375	MIF	0.57	4.46	0.37	1.78e-5	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs12048904	0.505	rs10493936	chr1:101213335	A/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.64	-5.46	-0.44	2.54e-7	Multiple sclerosis;
TGCT	trans	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg25482853	chr8:67687455	SGK3	1.22	10.56	0.69	5.48e-19	Lung disease severity in cystic fibrosis;
TGCT	cis	rs8078723	0.714	rs2241245	chr17:38151014	C/T	cg17467752	chr17:38218738	THRA	-0.53	-5.37	-0.43	3.8e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg03806693	chr22:41940476	POLR3H	1.02	11.39	0.72	5.21e-21	Vitiligo;
TGCT	cis	rs7412746	0.611	rs10888391	chr1:150729983	G/A	cg04414720	chr1:150670196	GOLPH3L	0.37	4.57	0.38	1.15e-5	Melanoma;
TGCT	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	7.26	0.55	3.73e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs13401104	0.587	rs6731967	chr2:237145606	G/C	cg19324714	chr2:237145437	ASB18	0.55	6.17	0.48	8.81e-9	Educational attainment;
TGCT	cis	rs9787249	0.957	rs7518431	chr1:40214944	C/T	cg19912559	chr1:40204330	PPIE	-0.45	-5.33	-0.43	4.49e-7	Blood protein levels;
TGCT	cis	rs1555895	0.576	rs4881537	chr10:848059	A/T	cg02193355	chr10:851439	NA	0.23	5.23	0.43	6.88e-7	Survival in rectal cancer;
TGCT	cis	rs2243480	1.000	rs160639	chr7:65579987	C/G	cg20637647	chr7:64974828	NA	0.84	4.85	0.4	3.63e-6	Diabetic kidney disease;
TGCT	cis	rs74233809	1.000	rs10883815	chr10:104739179	T/C	cg05855489	chr10:104503620	C10orf26	0.74	4.44	0.37	1.96e-5	Birth weight;
TGCT	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg07507251	chr3:52567010	NT5DC2	0.43	5.86	0.47	3.94e-8	Bipolar disorder;
TGCT	cis	rs473651	0.777	rs550890	chr2:239332555	G/A	cg18131467	chr2:239335373	ASB1	0.99	10.74	0.69	1.96e-19	Multiple system atrophy;
TGCT	cis	rs7192750	0.563	rs7184486	chr16:71886530	T/A	cg06353428	chr16:71660113	MARVELD3	0.8	7.29	0.55	3.15e-11	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg24531977	chr5:56204891	C5orf35	-0.76	-7.34	-0.55	2.45e-11	Initial pursuit acceleration;
TGCT	cis	rs78487399	0.710	rs76857293	chr2:43591676	C/T	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.76	4.68	0.39	7.27e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs4478858	0.624	rs10914333	chr1:31701491	A/G	cg00250761	chr1:31883323	NA	-0.28	-4.67	-0.39	7.77e-6	Alcohol dependence;
TGCT	cis	rs2836950	0.501	rs4818019	chr21:40694456	T/A	cg06238570	chr21:40685208	BRWD1	-0.63	-6.47	-0.5	2.02e-9	Menarche (age at onset);
TGCT	cis	rs704	0.605	rs2227736	chr17:26693231	G/C	cg10494684	chr17:26645200	TMEM97	-0.46	-4.95	-0.41	2.33e-6	Osteoprotegerin levels;
TGCT	cis	rs7666738	0.830	rs4334758	chr4:98971875	A/G	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2710642	0.566	rs2710651	chr2:63166379	G/A	cg17519650	chr2:63277830	OTX1	0.69	6.61	0.51	1.04e-9	LDL cholesterol levels;LDL cholesterol;
TGCT	cis	rs2933343	0.533	rs13086121	chr3:128704290	A/T	cg11901034	chr3:128598214	ACAD9	-0.56	-5.26	-0.43	6.23e-7	IgG glycosylation;
TGCT	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg05368731	chr17:41323189	NBR1	1.08	11.0	0.7	4.76e-20	Menopause (age at onset);
TGCT	cis	rs6570726	0.791	rs6918814	chr6:145906028	G/A	cg23711669	chr6:146136114	FBXO30	0.73	7.32	0.55	2.77e-11	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4654899	0.680	rs6704421	chr1:21220674	A/C	cg01072550	chr1:21505969	NA	0.55	8.94	0.63	4.56e-15	Superior frontal gyrus grey matter volume;
TGCT	cis	rs3741151	1.000	rs75114310	chr11:73042047	C/T	cg17517138	chr11:73019481	ARHGEF17	1.22	6.25	0.49	5.95e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
TGCT	cis	rs10411936	1.000	rs1870071	chr19:16505106	A/G	cg14704714	chr19:15740395	CYP4F8	-0.25	-4.44	-0.37	2e-5	White blood cell count;Multiple sclerosis;
TGCT	cis	rs1505368	0.837	rs10167244	chr2:213281310	A/G	cg16329650	chr2:213403929	ERBB4	0.61	6.14	0.48	1.04e-8	Symmetrical dimethylarginine levels;
TGCT	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg12963246	chr6:28129442	ZNF389	0.48	4.74	0.39	5.69e-6	Depression;
TGCT	cis	rs9911578	0.765	rs66954617	chr17:56999427	A/G	cg05425664	chr17:57184151	TRIM37	-0.62	-6.18	-0.49	8.33e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7267979	0.933	rs6138571	chr20:25435388	A/G	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2472297	1.000	rs2472297	chr15:75027880	A/G	cg10253484	chr15:75165896	SCAMP2	0.67	4.76	0.39	5.25e-6	Caffeine metabolism (plasma 1,3,7-trimethylxanthine (caffeine) level);Coffee consumption (cups per day);Coffee consumption;Caffeine metabolism (plasma 1,3-dimethylxanthine (theophylline) level);Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
TGCT	cis	rs7246657	0.943	rs3745765	chr19:37854235	G/T	cg18154014	chr19:37997991	ZNF793	0.72	5.19	0.42	8.3e-7	Coronary artery calcification;
TGCT	cis	rs9611565	0.729	rs203319	chr22:41914593	C/T	cg17554472	chr22:41940697	POLR3H	-0.47	-5.27	-0.43	5.92e-7	Vitiligo;
TGCT	cis	rs9436747	0.667	rs4655518	chr1:66039858	G/T	cg14976592	chr1:65886160	LEPROT;LEPR	-0.58	-5.47	-0.44	2.33e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs477895	1.000	rs34292685	chr11:64049021	C/T	cg23719950	chr11:63933701	MACROD1	-0.57	-4.49	-0.37	1.63e-5	Mean platelet volume;
TGCT	cis	rs11122272	0.735	rs2572263	chr1:231509408	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.14	-0.54	6.86e-11	Hemoglobin concentration;
TGCT	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg10047753	chr17:41438598	NA	0.96	9.54	0.65	1.61e-16	Menopause (age at onset);
TGCT	cis	rs66573146	0.539	rs56659624	chr4:7069377	G/C	cg26116260	chr4:7069785	GRPEL1	-0.92	-4.45	-0.37	1.87e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs6938	0.618	rs12911254	chr15:75166335	G/A	cg10253484	chr15:75165896	SCAMP2	-0.6	-5.5	-0.44	2.06e-7	Breast cancer;
TGCT	cis	rs2637266	1.000	rs12414151	chr10:78359041	T/G	cg18941641	chr10:78392320	NA	0.39	4.88	0.4	3.24e-6	Pulmonary function;
TGCT	cis	rs904251	0.523	rs2797799	chr6:37483620	T/G	cg25019722	chr6:37503610	NA	-0.51	-7.89	-0.58	1.39e-12	Cognitive performance;
TGCT	cis	rs62244186	0.659	rs4431151	chr3:44510906	G/C	cg04389838	chr3:44770851	ZNF501	-0.38	-4.94	-0.41	2.5e-6	Depressive symptoms;
TGCT	cis	rs77741769	0.571	rs7969140	chr12:121303626	T/C	cg02419362	chr12:121203948	SPPL3	0.19	4.49	0.37	1.63e-5	Mean corpuscular volume;
TGCT	cis	rs7677751	0.806	rs7673027	chr4:55096180	T/A	cg17187183	chr4:55093834	PDGFRA	0.55	7.06	0.54	1.05e-10	Corneal astigmatism;
TGCT	cis	rs7312933	0.558	rs1796381	chr12:42842475	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.59	5.87	0.47	3.79e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs4455778	0.538	rs34820160	chr7:49115948	C/A	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs9611565	0.559	rs739136	chr22:42100275	C/T	cg06634786	chr22:41940651	POLR3H	-0.89	-8.81	-0.62	9.46e-15	Vitiligo;
TGCT	cis	rs3806843	0.576	rs246020	chr5:140334771	G/A	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7786808	0.712	rs2335167	chr7:158213948	A/C	cg01191920	chr7:158217561	PTPRN2	-0.42	-6.67	-0.51	7.44e-10	Obesity-related traits;
TGCT	cis	rs9403317	0.573	rs4896550	chr6:142029174	T/C	cg15052665	chr6:141804349	NA	-0.24	-4.46	-0.37	1.85e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9858542	0.903	rs17080528	chr3:49389842	C/T	cg03060546	chr3:49711283	APEH	-0.63	-5.47	-0.44	2.39e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs6840360	0.557	rs4696261	chr4:152322659	C/G	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.35	-0.5	3.68e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7523273	0.548	rs2724381	chr1:207949017	T/C	cg22525895	chr1:207977042	MIR29B2	0.53	8.71	0.62	1.62e-14	Schizophrenia;
TGCT	cis	rs4242434	0.672	rs6993302	chr8:22527457	T/C	cg21658235	chr8:22456391	C8orf58	-0.45	-4.81	-0.4	4.37e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	trans	rs1814175	0.586	rs10769603	chr11:49688837	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.41	-9.51	-0.65	1.93e-16	Height;
TGCT	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.71	-0.39	6.54e-6	Prudent dietary pattern;
TGCT	cis	rs3087591	0.879	rs4795591	chr17:29612410	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.47	-7.21	-0.54	4.8e-11	Hip circumference;
TGCT	cis	rs7617773	0.780	rs3731489	chr3:48228906	C/A	cg11946769	chr3:48343235	NME6	0.77	6.73	0.52	5.53e-10	Coronary artery disease;
TGCT	cis	rs765787	0.530	rs4238376	chr15:45541887	T/C	cg24006582	chr15:45444508	DUOX1	-0.25	-5.54	-0.45	1.76e-7	Uric acid levels;
TGCT	cis	rs1580019	0.961	rs3801328	chr7:32496930	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.8	7.59	0.56	6.75e-12	Cognitive ability;
TGCT	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg11644478	chr21:40555479	PSMG1	1.04	10.81	0.7	1.38e-19	Cognitive function;
TGCT	trans	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-1.03	-13.16	-0.76	2.65e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs13256369	1.000	rs10095733	chr8:8574646	A/G	cg17143192	chr8:8559678	CLDN23	0.63	5.93	0.47	2.8e-8	Obesity-related traits;
TGCT	trans	rs7819412	0.623	rs7833435	chr8:10801137	A/G	cg15556689	chr8:8085844	FLJ10661	-0.83	-7.45	-0.56	1.37e-11	Triglycerides;
TGCT	cis	rs7727544	0.547	rs10076758	chr5:131524299	A/G	cg24060327	chr5:131705240	SLC22A5	-0.44	-4.5	-0.37	1.56e-5	Blood metabolite levels;
TGCT	trans	rs561341	1.000	rs693116	chr17:30246124	C/T	cg20587970	chr11:113659929	NA	-1.04	-12.51	-0.75	9.9e-24	Hip circumference adjusted for BMI;
TGCT	cis	rs710216	0.957	rs710215	chr1:43429105	T/C	cg03128534	chr1:43423976	SLC2A1	0.59	4.55	0.38	1.28e-5	Red cell distribution width;
TGCT	cis	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg18252515	chr7:66147081	NA	1.22	7.33	0.55	2.53e-11	Diabetic kidney disease;
TGCT	cis	rs9860250	0.554	rs9825968	chr3:100790788	C/T	cg05801080	chr3:100119813	LNP1;TOMM70A	0.54	4.45	0.37	1.89e-5	Optic disc area;
TGCT	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	8.55	0.61	3.84e-14	Platelet count;
TGCT	cis	rs9467711	0.606	rs9358932	chr6:26362705	A/G	cg16898833	chr6:26189333	HIST1H4D	-1.09	-5.35	-0.43	4.15e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1857353	1.000	rs74089258	chr1:75925610	G/A	cg11838876	chr1:75668600	SLC44A5	-0.51	-4.81	-0.4	4.23e-6	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg23758822	chr17:41437982	NA	0.71	6.77	0.52	4.56e-10	Menopause (age at onset);
TGCT	cis	rs28489187	0.597	rs506082	chr1:85899215	A/C	cg16011679	chr1:85725395	C1orf52	-0.49	-4.49	-0.37	1.61e-5	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
TGCT	cis	rs748404	0.631	rs4296223	chr15:43645246	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	4.72	0.39	6.3e-6	Lung cancer;
TGCT	cis	rs709400	0.633	rs2296484	chr14:104003094	C/T	cg12935359	chr14:103987150	CKB	-0.37	-5.54	-0.45	1.73e-7	Body mass index;
TGCT	cis	rs7439150	0.954	rs2227423	chr4:155492249	T/C	cg22130008	chr4:155548532	NA	-0.53	-6.61	-0.51	1e-9	Fibrinogen levels;
TGCT	cis	rs1990950	0.716	rs6890442	chr5:156832251	A/G	cg25387487	chr5:157003181	ADAM19	0.3	4.66	0.39	7.98e-6	Lung function (FEV1/FVC);
TGCT	cis	rs6545883	0.965	rs6545872	chr2:61724568	G/A	cg15711740	chr2:61764176	XPO1	-0.54	-4.95	-0.41	2.39e-6	Tuberculosis;
TGCT	cis	rs9549367	0.577	rs3024718	chr13:113813853	C/T	cg00898013	chr13:113819073	PROZ	0.55	6.65	0.51	8.31e-10	Platelet distribution width;
TGCT	cis	rs1505368	0.543	rs13413590	chr2:213292329	C/T	cg16329650	chr2:213403929	ERBB4	0.65	6.24	0.49	6.44e-9	Symmetrical dimethylarginine levels;
TGCT	cis	rs7582180	0.629	rs2309798	chr2:100956949	G/A	cg14675211	chr2:100938903	LONRF2	0.53	5.16	0.42	9.36e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs12497850	0.829	rs12636030	chr3:49182237	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.5	-4.55	-0.38	1.25e-5	Parkinson's disease;
TGCT	cis	rs17221829	0.703	rs17818747	chr11:89373690	T/C	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.63	-0.38	9.04e-6	Anxiety in major depressive disorder;
TGCT	cis	rs7666738	0.609	rs35214820	chr4:98864692	G/A	cg18180107	chr4:99064573	C4orf37	0.56	4.7	0.39	6.68e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2439831	1.000	rs2439841	chr15:43734749	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.8	5.7	0.46	8.33e-8	Lung cancer in ever smokers;
TGCT	cis	rs9467711	0.606	rs34878490	chr6:26370572	C/T	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7829975	0.774	rs11249893	chr8:8700851	C/T	cg08975724	chr8:8085496	FLJ10661	0.55	5.01	0.41	1.8e-6	Mood instability;
TGCT	cis	rs7975161	0.521	rs4447242	chr12:104720708	T/G	cg25273343	chr12:104657179	TXNRD1	-0.36	-5.0	-0.41	1.9e-6	Toenail selenium levels;
TGCT	cis	rs7940866	0.834	rs10791108	chr11:130849354	T/A	cg12179176	chr11:130786555	SNX19	0.62	5.92	0.47	2.9e-8	Schizophrenia;
TGCT	cis	rs12049351	0.774	rs6668018	chr1:229629053	T/C	cg12130225	chr1:229698885	NA	0.39	4.59	0.38	1.06e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs473651	0.935	rs520765	chr2:239354712	C/T	cg21699342	chr2:239360505	ASB1	0.18	4.94	0.41	2.49e-6	Multiple system atrophy;
TGCT	cis	rs7917772	0.582	rs10883736	chr10:104320029	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	5.36	0.43	3.84e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs17253792	0.822	rs75509578	chr14:56133493	G/A	cg01858014	chr14:56050164	KTN1	-0.35	-4.65	-0.39	8.23e-6	Putamen volume;
TGCT	cis	rs6684514	1.000	rs12024813	chr1:156224529	C/A	cg16558208	chr1:156270281	VHLL	0.46	8.4	0.6	8.73e-14	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg09323728	chr8:95962352	TP53INP1	-0.51	-6.49	-0.5	1.89e-9	Type 2 diabetes;
TGCT	cis	rs2066819	0.892	rs117305040	chr12:56657888	A/G	cg26714650	chr12:56694279	CS	-1.36	-6.06	-0.48	1.54e-8	Psoriasis vulgaris;
TGCT	cis	rs13082711	0.595	rs17681498	chr3:27331258	T/C	cg02860705	chr3:27208620	NA	0.48	7.4	0.55	1.83e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs7829975	0.606	rs11776838	chr8:8794801	C/T	cg00184457	chr8:8946301	NA	-0.25	-4.85	-0.4	3.64e-6	Mood instability;
TGCT	cis	rs244731	0.959	rs10037110	chr5:176658066	A/T	cg06060754	chr5:176797920	RGS14	-0.45	-6.34	-0.49	3.93e-9	Urate levels in lean individuals;
TGCT	cis	rs2243480	1.000	rs2243480	chr7:65599196	C/T	cg07424592	chr7:64974309	NA	1.21	6.64	0.51	8.78e-10	Diabetic kidney disease;
TGCT	cis	rs11578119	0.866	rs12129359	chr1:170358043	A/G	cg09767346	chr1:170501363	GORAB	0.61	4.58	0.38	1.1e-5	Male-pattern baldness;
TGCT	cis	rs9549260	0.816	rs7334318	chr13:41217410	C/G	cg21288729	chr13:41239152	FOXO1	0.99	10.37	0.68	1.56e-18	Red blood cell count;
TGCT	cis	rs524023	0.957	rs538737	chr11:64355772	C/G	cg07733098	chr11:64478343	NRXN2	-0.31	-4.7	-0.39	6.79e-6	Urate levels in obese individuals;
TGCT	cis	rs9296092	0.560	rs9469506	chr6:33527897	A/G	cg13560919	chr6:33536144	NA	-0.23	-5.06	-0.41	1.49e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs3020736	0.500	rs5996110	chr22:42493767	A/G	cg05082376	chr22:42548792	NA	0.23	5.43	0.44	2.83e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs986417	0.818	rs7156107	chr14:61059153	C/G	cg27398547	chr14:60952738	C14orf39	-1.0	-8.02	-0.58	6.72e-13	Gut microbiota (bacterial taxa);
TGCT	cis	rs7267979	0.903	rs2500423	chr20:25374882	G/A	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6840360	0.571	rs62327269	chr4:152527973	G/C	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.0	-0.58	7.69e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs1215050	0.740	rs13134479	chr4:99067723	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.15	0.48	9.93e-9	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs12286929	0.637	rs3802858	chr11:115078492	T/C	cg04017736	chr11:115827165	NA	0.2	4.96	0.41	2.25e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs2050392	0.965	rs2480279	chr10:30700032	C/T	cg18806716	chr10:30721971	MAP3K8	-0.46	-5.37	-0.43	3.74e-7	Inflammatory bowel disease;
TGCT	cis	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg22963979	chr7:1858916	MAD1L1	-0.35	-5.12	-0.42	1.14e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs9814567	1.000	rs9871305	chr3:134213538	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.96	-9.19	-0.64	1.16e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs9549367	0.713	rs9549357	chr13:113860121	C/T	cg00898013	chr13:113819073	PROZ	-0.52	-6.98	-0.53	1.6e-10	Platelet distribution width;
TGCT	cis	rs9467773	1.000	rs6456733	chr6:26566804	C/T	cg09904177	chr6:26538194	HMGN4	0.69	6.84	0.52	3.23e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs8177179	0.967	rs9820225	chr3:133449189	A/G	cg24879335	chr3:133465180	TF	0.37	5.02	0.41	1.72e-6	Iron status biomarkers (transferrin levels);
TGCT	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg19626725	chr5:178986131	RUFY1	0.5	6.38	0.5	3.15e-9	Lung cancer;
TGCT	cis	rs1552244	0.554	rs6443275	chr3:10008819	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.3	-4.7	-0.39	6.82e-6	Alzheimer's disease;
TGCT	cis	rs8013055	0.846	rs10152050	chr14:105984145	C/G	cg19700328	chr14:106028568	NA	-0.48	-5.12	-0.42	1.14e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs950169	0.959	rs12902070	chr15:84793558	T/C	cg17173187	chr15:85201210	NMB	0.5	5.56	0.45	1.61e-7	Schizophrenia;
TGCT	cis	rs7819412	0.703	rs2409713	chr8:11009797	C/T	cg21775007	chr8:11205619	TDH	-0.59	-5.35	-0.43	4.12e-7	Triglycerides;
TGCT	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	8.55	0.61	3.84e-14	Platelet count;
TGCT	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg22891161	chr3:195456627	MUC20	-0.23	-5.23	-0.43	6.89e-7	Pancreatic cancer;
TGCT	cis	rs853679	0.513	rs13437444	chr6:28070998	C/T	cg12963246	chr6:28129442	ZNF389	0.52	4.49	0.37	1.63e-5	Depression;
TGCT	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9430161	0.611	rs35033941	chr1:11034382	C/T	cg27631724	chr1:11040367	C1orf127	0.53	6.05	0.48	1.58e-8	Ewing sarcoma;
TGCT	cis	rs208520	0.690	rs207107	chr6:66794385	T/C	cg07460842	chr6:66804631	NA	-0.94	-9.86	-0.66	2.74e-17	Exhaled nitric oxide output;
TGCT	cis	rs2594989	0.778	rs6801721	chr3:11470267	T/C	cg00170343	chr3:11313890	ATG7	0.79	5.8	0.46	5.18e-8	Circulating chemerin levels;
TGCT	cis	rs6570726	0.791	rs6900040	chr6:145893134	C/T	cg13319975	chr6:146136371	FBXO30	-0.5	-4.51	-0.38	1.48e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2637266	0.739	rs2439580	chr10:78423214	T/G	cg18941641	chr10:78392320	NA	0.38	4.57	0.38	1.15e-5	Pulmonary function;
TGCT	cis	rs2456568	0.802	rs1108910	chr11:93629677	C/T	cg26875233	chr11:93583750	C11orf90	0.49	6.25	0.49	6.16e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg11890956	chr21:40555474	PSMG1	-0.98	-9.91	-0.66	2.08e-17	Cognitive function;
TGCT	cis	rs1371867	0.875	rs1962901	chr8:101326428	A/G	cg00191853	chr8:101177733	SPAG1	-0.23	-4.76	-0.39	5.2e-6	Atrioventricular conduction;
TGCT	trans	rs7618501	0.932	rs4855850	chr3:49761571	G/A	cg21659725	chr3:3221576	CRBN	-0.98	-15.33	-0.81	2.1000000000000002e-30	Intelligence (multi-trait analysis);
TGCT	cis	rs7027203	0.576	rs4424329	chr9:96560806	G/C	cg14598338	chr9:96623480	NA	0.49	7.16	0.54	6.37e-11	DNA methylation (variation);
TGCT	cis	rs7586879	0.639	rs2033653	chr2:25103446	C/T	cg01884057	chr2:25150051	NA	-0.32	-6.07	-0.48	1.46e-8	Body mass index;
TGCT	cis	rs9810089	0.835	rs655836	chr3:136097576	T/C	cg12473912	chr3:136751656	NA	0.35	4.98	0.41	2.11e-6	Gestational age at birth (child effect);
TGCT	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.45	-4.86	-0.4	3.52e-6	Longevity;Endometriosis;
TGCT	cis	rs1451375	0.669	rs10274172	chr7:50637575	G/A	cg18232548	chr7:50535776	DDC	-0.46	-7.1	-0.54	8.31e-11	Malaria;
TGCT	trans	rs17780086	0.529	rs7406406	chr17:30220153	T/G	cg20587970	chr11:113659929	NA	-0.59	-8.98	-0.63	3.73e-15	Height;
TGCT	cis	rs11874712	1.000	rs11872985	chr18:43686578	A/G	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	5.15	0.42	1.01e-6	Migraine - clinic-based;
TGCT	cis	rs4788815	0.562	rs12926041	chr16:71978645	G/C	cg06353428	chr16:71660113	MARVELD3	0.75	6.74	0.52	5.43e-10	Metabolite levels;
TGCT	cis	rs7584330	0.666	rs72620819	chr2:238354982	C/T	cg14458575	chr2:238380390	NA	0.56	8.18	0.59	2.85e-13	Prostate cancer;
TGCT	cis	rs36051895	0.659	rs62541556	chr9:5049092	G/T	cg02405213	chr9:5042618	JAK2	-0.74	-9.85	-0.66	2.89e-17	Pediatric autoimmune diseases;
TGCT	cis	rs6542838	0.588	rs4851175	chr2:99530118	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.56	-5.24	-0.43	6.76e-7	Fear of minor pain;
TGCT	cis	rs2742417	1.000	rs2673038	chr3:45748632	A/G	cg04837898	chr3:45731254	SACM1L	-0.55	-5.68	-0.45	9.22e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs4911259	0.513	rs6057665	chr20:31463460	A/G	cg13636640	chr20:31349939	DNMT3B	-0.89	-9.83	-0.66	3.33e-17	Inflammatory bowel disease;
TGCT	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.54	4.87	0.4	3.38e-6	Prudent dietary pattern;
TGCT	cis	rs295140	0.605	rs3739119	chr2:201194279	C/A	cg23649088	chr2:200775458	C2orf69	-0.27	-4.49	-0.37	1.62e-5	QT interval;
TGCT	cis	rs9467711	0.651	rs16891261	chr6:26062631	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.6	-4.67	-0.39	7.83e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2204008	0.692	rs11613378	chr12:38213138	T/A	cg26384229	chr12:38710491	ALG10B	0.84	7.43	0.56	1.51e-11	Bladder cancer;
TGCT	cis	rs7191700	1.000	rs7191700	chr16:11406803	C/T	cg00044050	chr16:11439710	C16orf75	0.74	6.7	0.52	6.59e-10	Multiple sclerosis;
TGCT	cis	rs782590	0.774	rs782630	chr2:55899425	T/C	cg03859395	chr2:55845619	SMEK2	0.85	9.64	0.65	9.63e-17	Metabolic syndrome;
TGCT	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg08280861	chr8:58055591	NA	0.34	4.62	0.38	9.41e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs3008870	0.959	rs2815353	chr1:67483372	A/G	cg03991309	chr1:68237761	GNG12	0.27	4.49	0.37	1.6e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs433598	0.828	rs163270	chr16:20675829	G/A	cg08248577	chr16:19727447	IQCK;C16orf88	-0.22	-5.29	-0.43	5.36e-7	Schizophrenia;
TGCT	cis	rs7681440	0.904	rs6817001	chr4:90766019	C/T	cg01966878	chr4:90757139	SNCA	-0.25	-4.56	-0.38	1.2e-5	Dementia with Lewy bodies;
TGCT	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg13393036	chr8:95962371	TP53INP1	-0.65	-8.88	-0.62	6.27e-15	Type 2 diabetes;
TGCT	cis	rs644799	0.932	rs523934	chr11:95641775	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.71	7.54	0.56	8.81e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs4727027	0.870	rs62507485	chr7:148764182	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	4.97	0.41	2.22e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs2456568	0.867	rs2462744	chr11:93682913	G/A	cg16099599	chr11:93583650	C11orf90	-0.39	-4.69	-0.39	7.11e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs1215050	0.740	rs783941	chr4:99008235	T/C	cg05340658	chr4:99064831	C4orf37	-0.41	-5.03	-0.41	1.69e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7412746	0.658	rs7528773	chr1:150915875	G/A	cg04414720	chr1:150670196	GOLPH3L	0.37	4.46	0.37	1.81e-5	Melanoma;
TGCT	cis	rs2288884	0.806	rs17779439	chr19:52583991	G/T	cg13540795	chr19:52551618	ZNF432	-0.61	-5.28	-0.43	5.48e-7	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs17331151	0.573	rs2276818	chr3:52864635	A/G	cg07884673	chr3:53033167	SFMBT1	0.49	5.66	0.45	1.01e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs849210	0.517	rs13022810	chr2:206181237	A/G	cg11793701	chr2:206547163	NRP2	-0.54	-4.49	-0.37	1.62e-5	Tonsillectomy;
TGCT	cis	rs7917772	0.604	rs10883756	chr10:104400112	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-5.26	-0.43	6.16e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg22907277	chr7:1156413	C7orf50	0.19	4.5	0.37	1.55e-5	Longevity;Endometriosis;
TGCT	cis	rs7523273	0.626	rs2466572	chr1:207934487	A/C	cg22525895	chr1:207977042	MIR29B2	0.46	6.75	0.52	5.11e-10	Schizophrenia;
TGCT	cis	rs9467711	0.606	rs9393706	chr6:26361500	G/A	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4711350	0.723	rs549652	chr6:33686103	G/A	cg00334056	chr6:33755658	LEMD2	0.34	4.57	0.38	1.19e-5	Schizophrenia;
TGCT	trans	rs7618501	0.966	rs13085679	chr3:49869631	G/A	cg21659725	chr3:3221576	CRBN	0.98	15.33	0.81	2.08e-30	Intelligence (multi-trait analysis);
TGCT	cis	rs4566357	0.595	rs6707286	chr2:227911400	A/G	cg11843606	chr2:227700838	RHBDD1	-0.55	-5.17	-0.42	8.92e-7	Coronary artery disease;
TGCT	cis	rs854765	0.551	rs8070748	chr17:17859421	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	7.69	0.57	3.98e-12	Total body bone mineral density;
TGCT	cis	rs7258465	1.000	rs271623	chr19:18628947	A/G	cg06462663	chr19:18546047	ISYNA1	0.21	5.01	0.41	1.82e-6	Breast cancer;
TGCT	cis	rs1691799	0.899	rs1168327	chr12:66728842	G/A	cg16791601	chr12:66731901	HELB	-0.28	-6.17	-0.48	8.77e-9	White blood cell count (basophil);
TGCT	cis	rs2153535	0.601	rs9328487	chr6:8529378	G/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.01	0.41	1.86e-6	Motion sickness;
TGCT	cis	rs9905704	0.647	rs12943705	chr17:57097047	T/C	cg12560992	chr17:57184187	TRIM37	-0.62	-5.52	-0.44	1.9e-7	Testicular germ cell tumor;
TGCT	cis	rs751728	1.000	rs751728	chr6:33764033	C/T	cg00334056	chr6:33755658	LEMD2	-0.25	-4.52	-0.38	1.45e-5	Crohn's disease;
TGCT	cis	rs9905704	0.647	rs6503892	chr17:57067086	G/A	cg12560992	chr17:57184187	TRIM37	0.58	5.03	0.41	1.68e-6	Testicular germ cell tumor;
TGCT	cis	rs7086627	0.515	rs10887894	chr10:82209952	A/G	cg01528321	chr10:82214614	TSPAN14	0.65	6.21	0.49	7.21e-9	Post bronchodilator FEV1;
TGCT	cis	rs9868809	0.772	rs73078349	chr3:48688114	G/A	cg07636037	chr3:49044803	WDR6	-0.99	-4.44	-0.37	1.96e-5	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs67311347	1.000	rs12633431	chr3:40505740	C/T	cg13683864	chr3:40499215	RPL14	1.17	13.19	0.76	2.34e-25	Renal cell carcinoma;
TGCT	cis	rs734999	0.588	rs3001837	chr1:2532506	G/A	cg18854424	chr1:2615690	NA	-0.46	-5.28	-0.43	5.53e-7	Ulcerative colitis;
TGCT	cis	rs9583531	0.891	rs3742182	chr13:111375132	C/T	cg24331049	chr13:111365604	ING1	0.77	5.42	0.44	3.05e-7	Coronary artery disease;
TGCT	cis	rs1894292	0.527	rs12504448	chr4:74369406	G/A	cg05868023	chr4:75230803	EREG	-0.52	-4.64	-0.38	8.72e-6	Prostate cancer;
TGCT	trans	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg13615516	chr5:77269221	NA	0.67	8.36	0.6	1.09e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs523522	0.926	rs10774555	chr12:120971978	G/A	cg12219531	chr12:120966889	COQ5	0.83	7.27	0.55	3.46e-11	High light scatter reticulocyte count;
TGCT	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg08280861	chr8:58055591	NA	0.42	4.82	0.4	4.15e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs459571	0.959	rs461462	chr9:136911272	C/T	cg13789015	chr9:136890014	NCRNA00094	0.39	6.81	0.52	3.72e-10	Platelet distribution width;
TGCT	cis	rs7267979	0.966	rs4815425	chr20:25398876	G/C	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs473651	0.935	rs508483	chr2:239339709	T/C	cg21699342	chr2:239360505	ASB1	0.18	4.78	0.39	4.79e-6	Multiple system atrophy;
TGCT	cis	rs72781680	1.000	rs963725	chr2:24148231	T/C	cg08917208	chr2:24149416	ATAD2B	0.85	5.28	0.43	5.53e-7	Lymphocyte counts;
TGCT	cis	rs7674212	0.541	rs11727498	chr4:104100987	C/T	cg16532752	chr4:104119610	CENPE	-0.58	-5.37	-0.43	3.66e-7	Type 2 diabetes;
TGCT	cis	rs11190604	1.000	rs2495737	chr10:102338344	T/C	cg23241863	chr10:102295624	HIF1AN	0.67	4.96	0.41	2.29e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9913156	0.793	rs9436	chr17:4574751	T/A	cg00122941	chr17:4613640	ARRB2	0.88	7.51	0.56	1.03e-11	Lymphocyte counts;
TGCT	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg22166914	chr1:53195759	ZYG11B	0.4	5.03	0.41	1.69e-6	Monocyte count;
TGCT	cis	rs79349575	0.783	rs12601858	chr17:47017477	T/C	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.52	-0.38	1.44e-5	Type 2 diabetes;
TGCT	trans	rs10506458	0.834	rs58821476	chr12:63389425	T/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.47	-7.54	-0.56	8.62e-12	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs2760061	0.598	rs590657	chr1:228117581	A/C	cg18477163	chr1:228402036	OBSCN	-0.32	-6.37	-0.5	3.31e-9	Diastolic blood pressure;
TGCT	cis	rs2560966	1.000	rs1171098	chr19:48531518	G/T	cg17660703	chr19:48964810	KCNJ14	-0.35	-4.52	-0.38	1.41e-5	Intelligence;
TGCT	cis	rs2153535	0.580	rs5001324	chr6:8451604	A/T	cg07606381	chr6:8435919	SLC35B3	0.53	5.02	0.41	1.79e-6	Motion sickness;
TGCT	cis	rs1348850	0.914	rs9789582	chr2:178330173	C/G	cg22681709	chr2:178499509	PDE11A	-0.36	-4.75	-0.39	5.6e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs13102973	0.899	rs4479760	chr4:135867474	T/C	cg14419869	chr4:135874104	NA	0.24	4.46	0.37	1.83e-5	Subjective well-being;
TGCT	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-6.74	-0.52	5.26e-10	Alzheimer's disease;
TGCT	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs11785400	0.762	rs1137522	chr8:143739020	A/C	cg24634471	chr8:143751801	JRK	0.55	5.51	0.44	1.99e-7	Schizophrenia;
TGCT	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg00684032	chr4:1343700	KIAA1530	0.22	4.85	0.4	3.69e-6	Obesity-related traits;
TGCT	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg05368731	chr17:41323189	NBR1	1.17	13.8	0.78	7.84e-27	Menopause (age at onset);
TGCT	cis	rs9611565	0.608	rs2003816	chr22:42095140	T/G	cg03806693	chr22:41940476	POLR3H	0.96	9.69	0.66	7.24e-17	Vitiligo;
TGCT	cis	rs1568889	1.000	rs7102106	chr11:28343953	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	8.8	0.62	9.95e-15	Bipolar disorder;
TGCT	cis	rs854765	0.663	rs6502618	chr17:17746741	A/G	cg04398451	chr17:18023971	MYO15A	0.3	4.6	0.38	1.04e-5	Total body bone mineral density;
TGCT	cis	rs2721195	0.719	rs4925812	chr8:145808035	C/T	cg11211951	chr8:145729740	GPT	0.25	5.55	0.45	1.65e-7	Age at first birth;
TGCT	cis	rs7178572	0.568	rs11858641	chr15:77585820	C/T	cg15453836	chr15:77711506	NA	-0.42	-4.79	-0.4	4.68e-6	Type 2 diabetes;
TGCT	cis	rs6912958	0.559	rs242280	chr6:88048714	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.4	4.71	0.39	6.65e-6	Monocyte percentage of white cells;
TGCT	cis	rs7027203	0.576	rs4415381	chr9:96554603	A/G	cg14598338	chr9:96623480	NA	0.49	7.16	0.54	6.37e-11	DNA methylation (variation);
TGCT	cis	rs9372498	0.505	rs62422248	chr6:118987610	T/C	cg07617317	chr6:118971624	C6orf204	0.49	5.14	0.42	1.02e-6	Diastolic blood pressure;
TGCT	cis	rs1670533	1.000	rs6599279	chr4:1058833	G/A	cg27284194	chr4:1044797	NA	0.68	5.88	0.47	3.56e-8	Recombination rate (females);
TGCT	cis	rs10751667	0.666	rs11246358	chr11:967349	G/A	cg06064525	chr11:970664	AP2A2	-0.35	-8.11	-0.59	4.15e-13	Alzheimer's disease (late onset);
TGCT	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs3617	0.599	rs12487379	chr3:52895785	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	4.68	0.39	7.45e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9868809	0.772	rs9812200	chr3:48695667	A/G	cg00383909	chr3:49044727	WDR6	-0.77	-4.84	-0.4	3.75e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs7621025	0.500	rs4678275	chr3:136653683	C/T	cg15507776	chr3:136538369	TMEM22	0.63	5.91	0.47	3.1e-8	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
TGCT	cis	rs9818758	0.607	rs13087930	chr3:48961726	A/G	cg07636037	chr3:49044803	WDR6	-1.0	-4.98	-0.41	2.11e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs611744	0.967	rs653633	chr8:109196151	T/G	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg11764359	chr7:65958608	NA	-0.58	-5.22	-0.42	7.37e-7	Aortic root size;
TGCT	cis	rs6835098	0.816	rs13111572	chr4:174159788	G/A	cg08422745	chr4:174089978	GALNT7	0.93	10.32	0.68	2.06e-18	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs1008375	0.806	rs13139898	chr4:17706928	T/G	cg10189774	chr4:17578691	LAP3	-0.53	-4.7	-0.39	6.86e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs66573146	0.831	rs67315413	chr4:6987910	T/C	cg05069807	chr4:6945702	TBC1D14	0.31	4.83	0.4	3.91e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs524281	0.861	rs7937281	chr11:65950074	T/C	cg00563793	chr11:65837595	PACS1	0.57	5.03	0.41	1.68e-6	Electroencephalogram traits;
TGCT	cis	rs909002	0.800	rs10914459	chr1:32096918	T/C	cg11573219	chr1:32083031	HCRTR1	-0.43	-5.6	-0.45	1.33e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs826838	0.935	rs3886109	chr12:39189243	C/T	cg13010199	chr12:38710504	ALG10B	0.77	6.09	0.48	1.31e-8	Heart rate;
TGCT	cis	rs7412746	0.658	rs8444	chr1:150938571	G/A	cg09365446	chr1:150670422	GOLPH3L	0.35	4.81	0.4	4.36e-6	Melanoma;
TGCT	cis	rs4891159	0.757	rs11665518	chr18:74147054	C/T	cg24786174	chr18:74118243	ZNF516	-0.54	-7.25	-0.55	4.01e-11	Longevity;
TGCT	cis	rs9534288	0.763	rs9534273	chr13:46566988	A/G	cg15192986	chr13:46630673	CPB2	-0.53	-7.63	-0.57	5.32e-12	Blood protein levels;
TGCT	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg23708337	chr7:1209742	NA	0.51	4.46	0.37	1.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2692947	0.589	rs810057	chr2:97015073	T/C	cg23100626	chr2:96804247	ASTL	0.44	5.47	0.44	2.42e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs7223966	1.000	rs6504170	chr17:61709168	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	4.59	0.38	1.05e-5	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs9400467	0.537	rs449308	chr6:111480395	A/C	cg15721981	chr6:111408429	SLC16A10	-0.71	-4.6	-0.38	1.03e-5	Blood metabolite levels;Amino acid levels;
TGCT	cis	rs317689	0.680	rs315140	chr12:69790780	A/T	cg11871910	chr12:69753446	YEATS4	0.54	4.6	0.38	1.02e-5	Response to diuretic therapy;
TGCT	cis	rs11650494	0.901	rs74659133	chr17:47336931	C/T	cg08112188	chr17:47440006	ZNF652	1.06	5.45	0.44	2.65e-7	Prostate cancer;
TGCT	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg11890956	chr21:40555474	PSMG1	-1.03	-11.93	-0.73	2.49e-22	Cognitive function;
TGCT	cis	rs782590	0.967	rs782592	chr2:55843875	T/A	cg18811423	chr2:55921094	PNPT1	0.62	5.71	0.46	7.82e-8	Metabolic syndrome;
TGCT	cis	rs77741769	0.571	rs11065282	chr12:121264415	G/T	cg02419362	chr12:121203948	SPPL3	0.19	4.5	0.37	1.58e-5	Mean corpuscular volume;
TGCT	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg13695892	chr22:41940480	POLR3H	-0.91	-9.07	-0.63	2.18e-15	Vitiligo;
TGCT	cis	rs7647973	0.626	rs6809879	chr3:49834571	A/G	cg03060546	chr3:49711283	APEH	-0.63	-5.63	-0.45	1.12e-7	Menarche (age at onset);
TGCT	cis	rs7447593	0.666	rs10866705	chr5:176801131	G/T	cg16006841	chr5:176797999	RGS14	-0.65	-9.0	-0.63	3.34e-15	Urinary electrolytes (magnesium/calcium ratio);
TGCT	cis	rs7192750	0.586	rs4788585	chr16:71993638	A/G	cg06353428	chr16:71660113	MARVELD3	0.78	6.37	0.5	3.42e-9	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs62244186	0.748	rs12635624	chr3:44678498	G/A	cg21672276	chr3:44754072	ZNF502	-0.45	-4.96	-0.41	2.25e-6	Depressive symptoms;
TGCT	cis	rs6912958	0.559	rs242267	chr6:88061837	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.43	-5.7	-0.46	8.46e-8	Monocyte percentage of white cells;
TGCT	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg00149659	chr3:10157352	C3orf10	0.73	4.72	0.39	6.17e-6	Alzheimer's disease;
TGCT	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg19318889	chr4:1322082	MAEA	0.19	5.08	0.41	1.37e-6	Obesity-related traits;
TGCT	trans	rs2727020	0.553	rs10839295	chr11:49527345	A/C	cg15704280	chr7:45808275	SEPT13	-0.61	-6.81	-0.52	3.77e-10	Coronary artery disease;
TGCT	cis	rs459571	1.000	rs459571	chr9:136912626	C/T	cg14405625	chr9:136855902	VAV2	-0.32	-4.68	-0.39	7.28e-6	Platelet distribution width;
TGCT	cis	rs9926296	0.656	rs4522419	chr16:89853307	T/C	cg04287289	chr16:89883240	FANCA	0.68	6.75	0.52	5.13e-10	Vitiligo;
TGCT	cis	rs68170813	0.559	rs12537730	chr7:106844281	T/C	cg02696742	chr7:106810147	HBP1	-0.67	-5.39	-0.44	3.44e-7	Coronary artery disease;
TGCT	cis	rs67460515	0.892	rs11711413	chr3:160998910	C/G	cg03342759	chr3:160939853	NMD3	-0.49	-5.3	-0.43	5.16e-7	Parkinson's disease;
TGCT	trans	rs2727020	0.658	rs7120136	chr11:49384358	A/C	cg15704280	chr7:45808275	SEPT13	-0.74	-8.29	-0.6	1.55e-13	Coronary artery disease;
TGCT	cis	rs12477438	0.798	rs10167015	chr2:99570707	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.81	-7.88	-0.58	1.46e-12	Chronic sinus infection;
TGCT	cis	rs66573146	1.000	rs73202122	chr4:7005594	G/A	cg05069807	chr4:6945702	TBC1D14	0.38	5.12	0.42	1.11e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs6088580	0.634	rs6120644	chr20:33023810	G/A	cg24642439	chr20:33292090	TP53INP2	0.49	4.5	0.37	1.55e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs35306767	0.761	rs1871621	chr10:1049596	C/T	cg20503657	chr10:835505	NA	0.61	6.71	0.52	6.11e-10	Eosinophil percentage of granulocytes;
TGCT	cis	rs711245	0.572	rs3821150	chr2:36795233	G/A	cg10546459	chr2:36825355	FEZ2	0.58	4.91	0.4	2.76e-6	Height;
TGCT	cis	rs7100689	0.598	rs35353819	chr10:82135737	A/G	cg01528321	chr10:82214614	TSPAN14	0.79	7.51	0.56	1.02e-11	Post bronchodilator FEV1;
TGCT	cis	rs12887734	0.524	rs4900599	chr14:104283444	G/T	cg26031613	chr14:104095156	KLC1	-0.72	-6.2	-0.49	7.61e-9	Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9952991	0.883	rs11663253	chr18:12789556	A/G	cg23544223	chr18:12777786	NA	-0.6	-5.33	-0.43	4.57e-7	Inflammatory skin disease;
TGCT	cis	rs11599315	0.507	rs12220555	chr10:1341858	C/T	cg27336068	chr10:1336103	ADARB2	-0.34	-5.47	-0.44	2.41e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	cis	rs7246657	0.663	rs10408619	chr19:38070474	C/T	cg03611452	chr19:38183253	ZNF781	0.58	4.64	0.38	8.62e-6	Coronary artery calcification;
TGCT	cis	rs13326165	0.760	rs3752819	chr3:52400740	G/C	cg07884673	chr3:53033167	SFMBT1	0.38	4.65	0.39	8.36e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg07061783	chr6:25882402	NA	-0.55	-5.19	-0.42	8.38e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs6088590	1.000	rs6120748	chr20:33458284	T/G	cg24642439	chr20:33292090	TP53INP2	0.7	5.98	0.47	2.17e-8	Coronary artery disease;
TGCT	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg03264133	chr6:25882463	NA	-0.65	-6.05	-0.48	1.58e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2153535	0.541	rs1414352	chr6:8485547	A/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	trans	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg20587970	chr11:113659929	NA	-1.03	-10.98	-0.7	5.21e-20	Hip circumference adjusted for BMI;
TGCT	cis	rs1865760	1.000	rs6910174	chr6:25904414	C/T	cg17042849	chr6:26104293	HIST1H4C	-0.52	-4.68	-0.39	7.33e-6	Height;
TGCT	cis	rs7607369	0.609	rs13391398	chr2:219282429	A/G	cg02176678	chr2:219576539	TTLL4	0.47	6.46	0.5	2.19e-9	Red blood cell count;Amyotrophic lateral sclerosis;
TGCT	cis	rs2677744	1.000	rs2677744	chr15:91450441	A/G	cg23684204	chr15:91497937	RCCD1	-0.33	-4.86	-0.4	3.52e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs2658782	1.000	rs2658778	chr11:93148948	C/G	cg15737290	chr11:93063684	CCDC67	0.85	5.67	0.45	9.66e-8	Pulmonary function decline;
TGCT	cis	rs2228479	0.850	rs62056066	chr16:89906563	G/A	cg06558623	chr16:89946397	TCF25	0.55	4.86	0.4	3.55e-6	Skin colour saturation;
TGCT	cis	rs7944584	0.879	rs11039182	chr11:47346723	T/C	cg20307385	chr11:47447363	PSMC3	0.78	7.39	0.55	1.87e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
TGCT	cis	rs992157	1.000	rs13003334	chr2:219124921	T/A	cg00012203	chr2:219082015	ARPC2	0.77	8.2	0.59	2.56e-13	Colorectal cancer;
TGCT	cis	rs7819412	0.595	rs4841500	chr8:10988275	A/G	cg21775007	chr8:11205619	TDH	-0.54	-5.0	-0.41	1.87e-6	Triglycerides;
TGCT	cis	rs3771570	0.901	rs869943	chr2:242431585	C/G	cg21155796	chr2:242212141	HDLBP	0.92	6.63	0.51	9.25e-10	Prostate cancer;
TGCT	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg10802521	chr3:52805072	NEK4	-0.78	-10.01	-0.67	1.23e-17	Electroencephalogram traits;
TGCT	cis	rs10927875	0.722	rs6696912	chr1:16338474	T/C	cg22431228	chr1:16359049	CLCNKA	-0.26	-4.91	-0.4	2.79e-6	Dilated cardiomyopathy;
TGCT	cis	rs1488864	1.000	rs1488864	chr11:6342329	T/G	cg12755421	chr11:6342214	PRKCDBP	-0.57	-4.6	-0.38	1.02e-5	Smooth-surface caries;
TGCT	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.7	-0.39	6.79e-6	Prudent dietary pattern;
TGCT	cis	rs1153858	1.000	rs67744121	chr15:45677237	C/G	cg26924012	chr15:45694286	SPATA5L1	1.09	15.16	0.81	5.15e-30	Homoarginine levels;
TGCT	cis	rs9291683	0.595	rs10939665	chr4:10037628	T/C	cg00071950	chr4:10020882	SLC2A9	0.68	8.83	0.62	8.22e-15	Bone mineral density;
TGCT	cis	rs12477438	0.572	rs10170063	chr2:99655639	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-7.6	-0.56	6.47e-12	Chronic sinus infection;
TGCT	cis	rs2455799	0.573	rs2455831	chr3:15751583	T/A	cg16303742	chr3:15540471	COLQ	-0.25	-4.68	-0.39	7.43e-6	Mean platelet volume;
TGCT	cis	rs9611565	0.512	rs5751148	chr22:42139078	A/G	cg06481639	chr22:41940642	POLR3H	0.7	6.1	0.48	1.24e-8	Vitiligo;
TGCT	trans	rs2727020	0.704	rs2988340	chr11:49176057	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.38	-7.66	-0.57	4.66e-12	Coronary artery disease;
TGCT	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg08439880	chr3:133502540	NA	-0.35	-6.94	-0.53	1.93e-10	Iron status biomarkers;
TGCT	cis	rs1568889	0.941	rs35357280	chr11:28322745	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.81	6.53	0.51	1.55e-9	Bipolar disorder;
TGCT	cis	rs6594499	0.872	rs10038058	chr5:110443281	A/G	cg04022379	chr5:110408740	TSLP	0.44	4.74	0.39	5.65e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs7909074	0.865	rs10900123	chr10:45376574	C/T	cg05187965	chr10:45406764	TMEM72	-0.28	-5.9	-0.47	3.3e-8	Mean corpuscular volume;
TGCT	cis	rs12950390	0.853	rs55745341	chr17:45855778	G/C	cg24803719	chr17:45855879	NA	-0.46	-4.75	-0.39	5.56e-6	IgG glycosylation;
TGCT	cis	rs7178424	0.711	rs11635569	chr15:62213597	G/A	cg00456672	chr15:62358751	C2CD4A	-0.3	-4.47	-0.37	1.71e-5	Height;
TGCT	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.09	0.54	8.96e-11	Prudent dietary pattern;
TGCT	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg13395646	chr4:1353034	KIAA1530	-0.42	-5.36	-0.43	3.92e-7	Obesity-related traits;
TGCT	cis	rs12451471	0.559	rs1042396	chr17:78084769	G/A	cg06718696	chr17:78121285	EIF4A3	0.71	5.89	0.47	3.42e-8	Plateletcrit;Mean corpuscular hemoglobin concentration;
TGCT	cis	rs7552404	0.727	rs1159214	chr1:76317910	G/T	cg22875332	chr1:76189707	ACADM	-0.58	-6.24	-0.49	6.18e-9	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs3849570	0.576	rs4425286	chr3:81992365	G/A	cg07356753	chr3:81810745	GBE1	-0.56	-4.67	-0.39	7.67e-6	Waist circumference;Body mass index;
TGCT	cis	rs1059312	1.000	rs7302634	chr12:129279931	C/T	cg09035930	chr12:129282057	SLC15A4	0.6	10.93	0.7	6.81e-20	Systemic lupus erythematosus;
TGCT	cis	rs6714710	0.603	rs13008968	chr2:98435982	C/T	cg26665480	chr2:98280029	ACTR1B	0.66	6.24	0.49	6.33e-9	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs7666738	0.861	rs28821920	chr4:98962743	T/C	cg17366294	chr4:99064904	C4orf37	0.74	7.56	0.56	7.89e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3806843	0.518	rs173471	chr5:140335226	A/G	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7208859	0.673	rs56146117	chr17:29153325	C/T	cg14008862	chr17:28927542	LRRC37B2	0.75	5.06	0.41	1.5e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7336332	0.941	rs9579097	chr13:28084337	C/T	cg22138327	chr13:27999177	GTF3A	0.73	4.54	0.38	1.34e-5	Weight;
TGCT	cis	rs524281	0.861	rs10896095	chr11:65962560	A/G	cg00563793	chr11:65837595	PACS1	0.54	4.74	0.39	5.86e-6	Electroencephalogram traits;
TGCT	cis	rs514406	0.621	rs2003250	chr1:53196666	T/C	cg22166914	chr1:53195759	ZYG11B	-0.5	-9.42	-0.65	3.19e-16	Monocyte count;
TGCT	cis	rs10782582	0.609	rs1689270	chr1:76390937	A/G	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.56	4.84	0.4	3.71e-6	Daytime sleep phenotypes;
TGCT	cis	rs763014	0.898	rs1045277	chr16:633125	T/C	cg00908189	chr16:619842	PIGQ	0.87	10.5	0.69	7.53e-19	Height;
TGCT	cis	rs909002	0.849	rs2271933	chr1:32092525	C/T	cg11573219	chr1:32083031	HCRTR1	0.47	6.08	0.48	1.37e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2153535	0.580	rs4587214	chr6:8454119	T/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.31e-6	Motion sickness;
TGCT	cis	rs6754311	0.593	rs6755383	chr2:136416941	C/T	cg07169764	chr2:136633963	MCM6	0.67	6.1	0.48	1.24e-8	Mosquito bite size;
TGCT	cis	rs12367572	0.965	rs1506678	chr12:45249492	A/G	cg04608330	chr12:45269318	NELL2	-0.61	-6.39	-0.5	2.98e-9	Gut microbiome composition (summer);
TGCT	cis	rs96067	0.711	rs795047	chr1:36637708	C/T	cg07093915	chr1:36184400	C1orf216	0.43	4.46	0.37	1.81e-5	Corneal structure;
TGCT	cis	rs7267979	0.714	rs6132825	chr20:25238309	A/T	cg03522245	chr20:25566470	NINL	0.51	4.89	0.4	3.08e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg11905131	chr22:24372483	LOC391322	-0.95	-11.13	-0.71	2.26e-20	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2404602	0.647	rs4886837	chr15:77156417	A/G	cg23625390	chr15:77176239	SCAPER	-0.39	-5.04	-0.41	1.6e-6	Blood metabolite levels;
TGCT	cis	rs2997447	0.723	rs56241003	chr1:26435919	C/T	cg03844060	chr1:26490628	NA	0.28	4.56	0.38	1.19e-5	QRS complex (12-leadsum);
TGCT	cis	rs10751667	1.000	rs10794349	chr11:945678	T/C	cg06064525	chr11:970664	AP2A2	-0.33	-6.65	-0.51	8.39e-10	Alzheimer's disease (late onset);
TGCT	cis	rs858239	0.601	rs28673077	chr7:23250854	C/T	cg05602783	chr7:23145260	KLHL7	-0.73	-5.73	-0.46	7.15e-8	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg27121462	chr16:89883253	FANCA	0.78	8.41	0.6	8.42e-14	Vitiligo;
TGCT	cis	rs6964587	0.900	rs11984136	chr7:91766953	T/C	cg17063962	chr7:91808500	NA	0.91	9.8	0.66	3.89e-17	Breast cancer;
TGCT	cis	rs858239	0.601	rs2141307	chr7:23191424	G/C	cg05602783	chr7:23145260	KLHL7	-0.69	-5.78	-0.46	5.68e-8	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs9902453	0.967	rs4473252	chr17:28454423	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	6.39	0.5	3.03e-9	Coffee consumption (cups per day);
TGCT	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.57	-4.76	-0.39	5.35e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2233152	0.572	rs10403040	chr19:41296046	A/T	cg23743927	chr19:41304969	EGLN2	0.65	4.54	0.38	1.34e-5	Kawasaki disease;
TGCT	cis	rs651907	0.535	rs4342086	chr3:101503765	G/A	cg12386194	chr3:101231763	SENP7	0.48	4.81	0.4	4.36e-6	Colorectal cancer;
TGCT	cis	rs941408	0.515	rs4624312	chr19:2774460	T/C	cg06609049	chr19:2785107	THOP1	1.12	12.98	0.76	7.39e-25	Total cholesterol levels;
TGCT	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg06028808	chr11:68637592	NA	-0.52	-6.89	-0.53	2.46e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs6074578	0.679	rs2298109	chr20:138148	C/T	cg16931068	chr20:139680	DEFB127	0.29	5.06	0.41	1.46e-6	Hirschsprung disease;
TGCT	cis	rs12971120	0.947	rs8084410	chr18:72168486	T/C	cg26446133	chr18:72167187	CNDP2	-0.39	-7.53	-0.56	9.3e-12	Refractive error;
TGCT	cis	rs6534347	0.551	rs10032644	chr4:123544074	T/A	cg10583651	chr4:123538969	IL21	-0.32	-4.5	-0.37	1.54e-5	Type 1 diabetes;
TGCT	cis	rs2721195	0.626	rs59464125	chr8:145857786	G/A	cg15320075	chr8:145703422	NA	-0.61	-5.66	-0.45	9.8e-8	Age at first birth;
TGCT	cis	rs4747241	0.515	rs4554797	chr10:73988264	A/G	cg09661010	chr10:73848153	SPOCK2	-0.41	-5.24	-0.43	6.81e-7	Heschl's gyrus morphology;
TGCT	cis	rs12477438	0.501	rs7608938	chr2:99782226	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.75	7.25	0.55	3.92e-11	Chronic sinus infection;
TGCT	cis	rs9902453	0.817	rs12051834	chr17:28192785	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	7.18	0.54	5.62e-11	Coffee consumption (cups per day);
TGCT	cis	rs17331151	0.505	rs7614424	chr3:52566354	C/T	cg15956490	chr3:53032818	SFMBT1	0.7	5.14	0.42	1.02e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs8078723	0.690	rs3785549	chr17:38149724	T/C	cg17467752	chr17:38218738	THRA	-0.53	-5.37	-0.43	3.8e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs1205863	1.000	rs1205875	chr6:11945509	C/T	cg07106625	chr6:11870215	NA	0.51	5.05	0.41	1.51e-6	Disc degeneration (lumbar);
TGCT	cis	rs2467099	0.504	rs2608881	chr17:73936653	C/G	cg10108402	chr17:73901394	MRPL38	-0.47	-4.6	-0.38	1.02e-5	Systolic blood pressure;
TGCT	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg25036284	chr2:26402008	FAM59B	0.65	5.19	0.42	8.36e-7	Gut microbiome composition (summer);
TGCT	cis	rs6988636	1.000	rs28694222	chr8:124195017	C/T	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs12908161	0.960	rs11633450	chr15:85307287	C/T	cg17173187	chr15:85201210	NMB	0.61	6.23	0.49	6.75e-9	Schizophrenia;
TGCT	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg14893161	chr1:205819251	PM20D1	0.66	10.91	0.7	7.77e-20	Menarche (age at onset);
TGCT	cis	rs7772486	0.701	rs11155438	chr6:145950112	C/G	cg23711669	chr6:146136114	FBXO30	0.92	10.45	0.68	1.03e-18	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs1814175	0.645	rs1851849	chr11:50012164	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.84	-0.7	1.13e-19	Height;
TGCT	cis	rs11098499	0.722	rs10025925	chr4:120271744	A/T	cg09307838	chr4:120376055	NA	0.56	5.48	0.44	2.26e-7	Corneal astigmatism;
TGCT	cis	rs6570726	1.000	rs386678	chr6:145869010	A/G	cg23711669	chr6:146136114	FBXO30	0.71	6.55	0.51	1.4e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6460942	0.558	rs4330594	chr7:12278615	G/A	cg06484146	chr7:12443880	VWDE	-0.53	-4.65	-0.39	8.3e-6	Coronary artery disease;
TGCT	cis	rs7010267	0.668	rs4876876	chr8:119986235	T/C	cg17171407	chr8:119960777	TNFRSF11B	0.32	6.05	0.48	1.62e-8	Total body bone mineral density (age 45-60);
TGCT	cis	rs2456568	0.709	rs1546400	chr11:93639203	G/A	cg26875233	chr11:93583750	C11orf90	0.47	6.01	0.48	1.9e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs2046867	0.628	rs1393584	chr3:72917193	G/T	cg25664220	chr3:72788482	NA	-0.41	-5.61	-0.45	1.26e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg00024416	chr22:24240387	NA	-0.25	-4.79	-0.39	4.74e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7017914	0.967	rs1838393	chr8:71702591	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.52	-4.8	-0.4	4.53e-6	Bone mineral density;
TGCT	cis	rs9682041	1.000	rs57508070	chr3:170074374	C/A	cg07589077	chr3:170072950	NA	0.32	4.83	0.4	3.88e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg22963979	chr7:1858916	MAD1L1	-0.33	-5.38	-0.44	3.53e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs9816226	0.618	rs869399	chr3:185826764	C/T	cg00760338	chr3:185826511	ETV5	0.71	6.24	0.49	6.28e-9	Obesity;Body mass index;
TGCT	cis	rs10875746	0.855	rs10875730	chr12:48427875	A/T	cg20731937	chr12:48336164	NA	0.68	5.29	0.43	5.3e-7	Longevity (90 years and older);
TGCT	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg26818010	chr10:134567672	INPP5A	-0.39	-5.36	-0.43	3.97e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs9831754	0.906	rs1588650	chr3:78410750	T/G	cg06138941	chr3:78371609	NA	-0.47	-5.01	-0.41	1.87e-6	Calcium levels;
TGCT	cis	rs7769051	1.000	rs7769051	chr6:133146796	G/T	cg07930552	chr6:133119739	C6orf192	0.94	4.99	0.41	1.98e-6	Type 2 diabetes nephropathy;
TGCT	cis	rs7044106	0.791	rs10739572	chr9:123489815	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	7.55	0.56	8.22e-12	Hip circumference adjusted for BMI;
TGCT	cis	rs7552404	0.696	rs10782602	chr1:76464261	T/C	cg03433033	chr1:76189801	ACADM	0.76	7.05	0.54	1.09e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2251381	0.640	rs2183568	chr21:30484782	A/T	cg08807101	chr21:30365312	RNF160	-0.51	-4.49	-0.37	1.6e-5	Selective IgA deficiency;
TGCT	cis	rs10782582	0.593	rs11576534	chr1:76112751	C/T	cg22875332	chr1:76189707	ACADM	-0.52	-6.05	-0.48	1.56e-8	Daytime sleep phenotypes;
TGCT	cis	rs7809950	0.817	rs17154091	chr7:107084790	T/C	cg23024343	chr7:107201750	COG5	-0.48	-7.05	-0.54	1.08e-10	Coronary artery disease;
TGCT	cis	rs1008375	0.932	rs2302389	chr4:17661889	T/C	cg10189774	chr4:17578691	LAP3	0.49	4.44	0.37	2e-5	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2228479	0.717	rs12917681	chr16:89810941	C/A	cg26513180	chr16:89883248	FANCA	0.78	4.54	0.38	1.32e-5	Skin colour saturation;
TGCT	cis	rs9549260	0.753	rs9549243	chr13:41217205	G/A	cg21288729	chr13:41239152	FOXO1	0.65	4.59	0.38	1.09e-5	Red blood cell count;
TGCT	cis	rs9393777	0.513	rs9368447	chr6:26646674	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.63	-5.75	-0.46	6.58e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9916302	0.904	rs2338797	chr17:37548241	G/A	cg15445000	chr17:37608096	MED1	-0.33	-4.7	-0.39	6.85e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs344364	0.511	rs56077812	chr16:1948870	T/G	cg26617929	chr16:1858877	NA	-0.27	-4.9	-0.4	2.99e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs8177179	0.967	rs4443173	chr3:133439378	A/G	cg24879335	chr3:133465180	TF	0.36	4.82	0.4	4.13e-6	Iron status biomarkers (transferrin levels);
TGCT	cis	rs1018836	0.818	rs2285232	chr8:91546162	C/G	cg16814680	chr8:91681699	NA	-0.75	-7.78	-0.57	2.41e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs56104184	0.668	rs73063523	chr19:49408943	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.73	-9.15	-0.63	1.47e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs4455778	0.543	rs4132419	chr7:49066633	A/G	cg26309511	chr7:48887640	NA	0.51	6.63	0.51	9.47e-10	Lung cancer in never smokers;
TGCT	cis	rs3733585	0.605	rs4697708	chr4:10121189	A/G	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.5	-0.5	1.76e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs3821902	0.646	rs58627691	chr3:64015548	T/C	cg22134162	chr3:63841271	THOC7	-0.32	-4.85	-0.4	3.7e-6	Breast cancer;
TGCT	trans	rs2727020	0.823	rs7102374	chr11:49261795	G/A	cg15704280	chr7:45808275	SEPT13	0.73	8.14	0.59	3.47e-13	Coronary artery disease;
TGCT	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg22598563	chr5:131563921	P4HA2	0.27	4.5	0.37	1.56e-5	Acylcarnitine levels;
TGCT	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs12681287	0.752	rs10112123	chr8:87302328	T/C	cg27223183	chr8:87520930	FAM82B	-0.82	-5.86	-0.47	3.98e-8	Caudate activity during reward;
TGCT	cis	rs9796	0.558	rs8043253	chr15:41503730	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.52	-7.27	-0.55	3.55e-11	Menopause (age at onset);
TGCT	cis	rs314370	0.855	rs17883557	chr7:100494949	G/T	cg10426581	chr7:100472382	SRRT	1.0	10.93	0.7	6.98e-20	Resting heart rate;
TGCT	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg02617428	chr7:158030585	PTPRN2	0.35	5.31	0.43	4.85e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7929679	0.846	rs1858169	chr11:34813187	G/T	cg18414381	chr11:34642885	EHF	-0.23	-4.51	-0.38	1.47e-5	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
TGCT	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg22535103	chr8:58192502	C8orf71	-0.41	-5.24	-0.43	6.57e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs514406	0.505	rs405208	chr1:53176674	C/T	cg24675658	chr1:53192096	ZYG11B	-0.78	-9.29	-0.64	6.63e-16	Monocyte count;
TGCT	cis	rs908922	0.676	rs2282296	chr1:152487979	C/T	cg20991723	chr1:152506922	NA	0.47	6.71	0.52	6.16e-10	Hair morphology;
TGCT	cis	rs4478858	0.684	rs4949369	chr1:31723845	T/A	cg00250761	chr1:31883323	NA	-0.27	-4.96	-0.41	2.28e-6	Alcohol dependence;
TGCT	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg03517284	chr6:25882590	NA	-0.46	-4.62	-0.38	9.63e-6	Height;
TGCT	cis	rs2153535	0.580	rs6597330	chr6:8492076	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs9467711	1.000	rs9467704	chr6:26319486	A/G	cg02458000	chr6:26745757	NA	1.1	6.09	0.48	1.29e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg10802521	chr3:52805072	NEK4	-0.78	-10.0	-0.67	1.26e-17	Electroencephalogram traits;
TGCT	cis	rs2718812	0.766	rs2589269	chr3:133409977	C/T	cg08048268	chr3:133502702	NA	0.39	4.83	0.4	3.99e-6	Iron status biomarkers;
TGCT	cis	rs9894429	0.624	rs9910935	chr17:79613949	T/C	cg21028142	chr17:79581711	NPLOC4	0.28	6.12	0.48	1.13e-8	Eye color traits;
TGCT	cis	rs904251	0.600	rs9380673	chr6:37415125	T/C	cg08126542	chr6:37504118	NA	-0.4	-5.72	-0.46	7.68e-8	Cognitive performance;
TGCT	cis	rs9527	0.590	rs11191540	chr10:104822809	G/C	cg04362960	chr10:104952993	NT5C2	0.66	5.55	0.45	1.62e-7	Arsenic metabolism;
TGCT	cis	rs12530845	0.945	rs7799891	chr7:135322853	T/C	cg23117316	chr7:135346802	PL-5283	-0.51	-4.83	-0.4	3.98e-6	Red blood cell traits;
TGCT	cis	rs12681287	0.547	rs9942793	chr8:87509091	C/T	cg27223183	chr8:87520930	FAM82B	-0.95	-6.95	-0.53	1.81e-10	Caudate activity during reward;
TGCT	cis	rs4478858	0.735	rs10798845	chr1:31822636	A/G	cg07478791	chr1:31886160	SERINC2	0.48	4.84	0.4	3.72e-6	Alcohol dependence;
TGCT	cis	rs453301	0.686	rs1045527	chr8:8890041	A/G	cg15556689	chr8:8085844	FLJ10661	-0.62	-5.28	-0.43	5.57e-7	Joint mobility (Beighton score);
TGCT	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg23758822	chr17:41437982	NA	0.61	5.86	0.47	3.83e-8	Menopause (age at onset);
TGCT	cis	rs12142240	0.698	rs72677593	chr1:46824363	T/C	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs4788570	0.697	rs2173702	chr16:71812671	G/A	cg06353428	chr16:71660113	MARVELD3	1.53	12.59	0.75	6.48e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs9486719	0.857	rs2983897	chr6:97033780	C/T	cg18709589	chr6:96969512	KIAA0776	-0.73	-6.07	-0.48	1.43e-8	Migraine;Coronary artery disease;
TGCT	cis	rs10193935	0.901	rs6544549	chr2:42693056	C/T	cg27598129	chr2:42591480	NA	0.38	5.14	0.42	1.05e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6088580	0.634	rs6059905	chr20:33126946	T/C	cg08999081	chr20:33150536	PIGU	0.28	5.55	0.45	1.66e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs6940638	0.531	rs12211984	chr6:26986054	G/C	cg05738196	chr6:26577821	NA	0.49	4.77	0.39	4.98e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg22535103	chr8:58192502	C8orf71	0.4	4.71	0.39	6.66e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2404602	0.647	rs55778276	chr15:77136590	T/A	cg22467129	chr15:76604101	ETFA	0.46	4.64	0.38	8.6e-6	Blood metabolite levels;
TGCT	cis	rs35306767	0.668	rs72760914	chr10:1070952	A/G	cg20503657	chr10:835505	NA	0.49	5.66	0.45	9.87e-8	Eosinophil percentage of granulocytes;
TGCT	cis	rs362272	0.524	rs3129334	chr4:3368526	T/C	cg22655196	chr4:3374909	RGS12	0.22	4.49	0.37	1.58e-5	Serum sulfate level;
TGCT	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	16.1	0.82	3.69e-32	Prudent dietary pattern;
TGCT	cis	rs9467711	0.559	rs13208916	chr6:26601940	G/A	cg16898833	chr6:26189333	HIST1H4D	1.01	5.36	0.43	3.91e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg20362242	chr5:692897	TPPP	0.51	4.66	0.39	8.06e-6	Obesity-related traits;
TGCT	cis	rs2562456	1.000	rs2562456	chr19:21666210	A/G	cg01304269	chr19:21688519	ZNF429	0.57	4.76	0.39	5.32e-6	Pain;
TGCT	cis	rs4631830	0.720	rs12412140	chr10:51503977	T/C	cg10326726	chr10:51549505	MSMB	0.23	4.54	0.38	1.33e-5	Prostate-specific antigen levels;
TGCT	cis	rs2456568	0.803	rs10765641	chr11:93640312	T/C	cg16099599	chr11:93583650	C11orf90	-0.39	-4.78	-0.39	4.97e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	4.55	0.38	1.25e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs1153858	1.000	rs66528868	chr15:45668547	A/C	cg26924012	chr15:45694286	SPATA5L1	1.09	15.08	0.8	7.99e-30	Homoarginine levels;
TGCT	trans	rs1814175	0.712	rs9665784	chr11:50030617	C/T	cg03929089	chr4:120376271	NA	-0.72	-8.55	-0.61	3.8e-14	Height;
TGCT	cis	rs7586879	0.598	rs6724772	chr2:25128730	T/C	cg01884057	chr2:25150051	NA	0.35	6.9	0.53	2.39e-10	Body mass index;
TGCT	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg07343612	chr16:622815	PIGQ	-0.42	-8.45	-0.6	6.8e-14	Height;
TGCT	cis	rs11264213	0.591	rs274745	chr1:36538282	G/A	cg27506609	chr1:36549197	TEKT2	-0.41	-4.7	-0.39	6.71e-6	Schizophrenia;
TGCT	cis	rs2236918	0.710	rs1776159	chr1:242018583	C/G	cg04158730	chr1:242011433	EXO1	0.59	5.53	0.44	1.78e-7	Menopause (age at onset);
TGCT	cis	rs7539409	0.651	rs910182	chr1:84297117	A/G	cg10977910	chr1:84465055	TTLL7	0.91	5.53	0.45	1.78e-7	Alzheimer's disease;
TGCT	cis	rs42648	0.935	rs42651	chr7:89978590	A/G	cg25739043	chr7:89950458	NA	-0.67	-6.69	-0.52	6.69e-10	Homocysteine levels;
TGCT	cis	rs6867032	1.000	rs4975796	chr5:2015520	A/T	cg26168224	chr5:2018326	NA	-0.43	-7.52	-0.56	9.44e-12	Gut microbiome composition (winter);
TGCT	cis	rs11650494	0.908	rs8076023	chr17:47399633	C/G	cg08112188	chr17:47440006	ZNF652	1.04	5.35	0.43	4.09e-7	Prostate cancer;
TGCT	cis	rs16966142	0.786	rs2238533	chr16:89871344	T/C	cg26513180	chr16:89883248	FANCA	0.89	5.45	0.44	2.62e-7	Caffeine consumption;
TGCT	cis	rs2228479	0.850	rs17227057	chr16:89816333	C/T	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs4879913	0.801	rs7047816	chr9:35591632	G/T	cg18130437	chr9:35658183	CCDC107;RMRP	-0.5	-4.95	-0.41	2.38e-6	Electroencephalogram traits;
TGCT	cis	rs10791097	0.694	rs2155749	chr11:130751094	G/T	cg05962950	chr11:130786565	SNX19	0.91	11.68	0.72	1.01e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs28785552	0.897	rs7259466	chr19:53239369	G/A	cg22067481	chr19:53234126	ZNF611	-0.49	-7.16	-0.54	6.29e-11	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs6964587	0.967	rs6465340	chr7:91588664	G/A	cg17063962	chr7:91808500	NA	0.88	9.63	0.65	1.02e-16	Breast cancer;
TGCT	cis	rs7267979	1.000	rs6050631	chr20:25431749	C/T	cg03522245	chr20:25566470	NINL	0.63	6.82	0.52	3.55e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2549003	1.000	rs2070728	chr5:131819977	C/T	cg21138405	chr5:131827807	IRF1	0.19	4.79	0.4	4.64e-6	Asthma (sex interaction);
TGCT	cis	rs548181	0.668	rs540555	chr11:125486848	T/C	cg03464685	chr11:125439445	EI24	1.12	7.9	0.58	1.27e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs7647973	0.593	rs28535523	chr3:49848414	C/T	cg05785598	chr3:49045655	WDR6	-0.43	-5.28	-0.43	5.5e-7	Menarche (age at onset);
TGCT	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg06418219	chr1:154948305	SHC1;CKS1B	-0.69	-6.95	-0.53	1.82e-10	Prostate cancer;
TGCT	cis	rs4788570	0.537	rs12149254	chr16:71458851	G/A	cg06353428	chr16:71660113	MARVELD3	-1.25	-8.03	-0.58	6.54e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg17971929	chr21:40555470	PSMG1	0.98	9.57	0.65	1.43e-16	Cognitive function;
TGCT	cis	rs4595586	0.525	rs2892450	chr12:39363678	G/A	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	trans	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-1.03	-13.16	-0.76	2.65e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs8072100	0.967	rs7221548	chr17:45582952	T/C	cg08085267	chr17:45401833	C17orf57	0.44	4.63	0.38	8.96e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs344364	0.511	rs2982455	chr16:1950498	T/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.45	-5.11	-0.42	1.17e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg00149659	chr3:10157352	C3orf10	1.13	7.38	0.55	2e-11	Alzheimer's disease;
TGCT	trans	rs561341	0.769	rs12941700	chr17:30185022	A/G	cg20587970	chr11:113659929	NA	0.84	8.42	0.6	7.76e-14	Hip circumference adjusted for BMI;
TGCT	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg16680214	chr1:154839983	KCNN3	-0.36	-7.26	-0.55	3.81e-11	Prostate cancer;
TGCT	cis	rs4629710	0.592	rs1885641	chr6:131553986	A/G	cg12606694	chr6:131520996	AKAP7	0.4	4.76	0.39	5.26e-6	Multiple myeloma (IgH translocation);
TGCT	trans	rs4332037	0.539	rs11762545	chr7:2060775	C/T	cg10840412	chr1:235813424	GNG4	0.94	6.84	0.52	3.21e-10	Bipolar disorder;
TGCT	cis	rs7819412	0.838	rs4840544	chr8:10960572	C/T	cg27411982	chr8:10470053	RP1L1	-0.22	-4.81	-0.4	4.38e-6	Triglycerides;
TGCT	cis	rs9487051	0.872	rs1111865	chr6:109610863	A/G	cg01475377	chr6:109611718	NA	0.29	4.57	0.38	1.14e-5	Reticulocyte fraction of red cells;
TGCT	cis	rs9473924	0.542	rs13195969	chr6:50814627	C/A	cg14470998	chr6:50812995	TFAP2B	1.36	8.61	0.61	2.74e-14	Body mass index;
TGCT	cis	rs4689388	0.816	rs13147655	chr4:6293474	A/G	cg25554036	chr4:6271136	WFS1	0.52	7.12	0.54	7.56e-11	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs7833790	0.632	rs6415653	chr8:82702536	A/G	cg17211192	chr8:82754475	SNX16	-0.9	-7.85	-0.58	1.71e-12	Diastolic blood pressure;
TGCT	cis	rs13256369	0.802	rs12681326	chr8:8566389	G/A	cg17143192	chr8:8559678	CLDN23	0.57	5.4	0.44	3.2e-7	Obesity-related traits;
TGCT	cis	rs6690583	0.623	rs74689037	chr1:85439268	C/T	cg20280350	chr1:85513789	MCOLN3	-0.67	-4.5	-0.37	1.52e-5	Serum sulfate level;
TGCT	cis	rs6988636	0.710	rs17316158	chr8:124157607	A/C	cg23067535	chr8:124195133	FAM83A	-0.35	-4.71	-0.39	6.44e-6	Urinary uromodulin levels;
TGCT	cis	rs4700695	0.719	rs27080	chr5:65442271	A/G	cg21114390	chr5:65439923	SFRS12	-0.83	-7.19	-0.54	5.27e-11	Facial morphology (factor 19);
TGCT	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs75229567	0.618	rs75389984	chr12:70212879	A/G	cg10114359	chr12:70132523	RAB3IP	1.38	6.71	0.52	6.19e-10	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
TGCT	cis	rs17331151	0.573	rs77223362	chr3:52865125	G/A	cg27565382	chr3:53032988	SFMBT1	0.47	5.96	0.47	2.42e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs10986311	0.649	rs10818936	chr9:127006346	C/G	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.2	-4.54	-0.38	1.3e-5	Vitiligo;
TGCT	cis	rs1062177	0.756	rs2915817	chr5:151115517	T/C	cg12924095	chr5:151150029	G3BP1	-0.34	-4.87	-0.4	3.3e-6	Preschool internalizing problems;
TGCT	cis	rs9910055	0.509	rs9916444	chr17:42313512	C/G	cg19774624	chr17:42201019	HDAC5	-0.69	-7.14	-0.54	6.91e-11	Total body bone mineral density;
TGCT	cis	rs12134133	1.000	rs6684804	chr1:207439015	C/T	cg02152968	chr1:207494213	CD55	0.61	4.66	0.39	7.94e-6	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg02675527	chr2:114030824	PAX8;LOC440839	-0.47	-5.71	-0.46	7.9e-8	Lymphocyte counts;
TGCT	cis	rs11031096	0.502	rs720571	chr11:4001328	G/T	cg18678763	chr11:4115507	RRM1	-0.49	-6.13	-0.48	1.08e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs992157	0.798	rs10932772	chr2:219177148	C/T	cg00012203	chr2:219082015	ARPC2	0.76	7.6	0.56	6.44e-12	Colorectal cancer;
TGCT	cis	rs7959452	0.558	rs1478464	chr12:69779789	G/C	cg11871910	chr12:69753446	YEATS4	0.83	9.03	0.63	2.79e-15	Blood protein levels;
TGCT	cis	rs2456568	0.709	rs12806128	chr11:93634972	C/T	cg17595323	chr11:93583763	C11orf90	0.47	6.22	0.49	6.86e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	trans	rs3780486	0.801	rs10971424	chr9:33138775	T/C	cg04842962	chr6:43655489	MRPS18A	1.24	15.76	0.82	2.18e-31	IgG glycosylation;
TGCT	trans	rs2727020	0.563	rs10769582	chr11:49474040	T/C	cg03929089	chr4:120376271	NA	-0.77	-9.19	-0.64	1.15e-15	Coronary artery disease;
TGCT	cis	rs60843830	0.964	rs62114538	chr2:256116	G/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.67	6.32	0.49	4.25e-9	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs2120019	1.000	rs7173833	chr15:75369618	C/T	cg17294928	chr15:75287854	SCAMP5	-0.93	-7.16	-0.54	6.33e-11	Blood trace element (Zn levels);
TGCT	cis	rs7044106	0.718	rs1981021	chr9:123388393	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.62	6.58	0.51	1.19e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg10802521	chr3:52805072	NEK4	-0.7	-8.52	-0.61	4.47e-14	Bipolar disorder;
TGCT	cis	rs1865760	0.566	rs9379825	chr6:26083871	C/A	cg17042849	chr6:26104293	HIST1H4C	-0.63	-5.47	-0.44	2.43e-7	Height;
TGCT	cis	rs11910985	1.000	rs11910985	chr21:48042766	C/T	cg17243659	chr21:48055224	PRMT2	1.26	6.43	0.5	2.45e-9	Cerebrospinal fluid t-tau:AB1-42 ratio;
TGCT	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg16414030	chr3:133502952	NA	-0.61	-9.83	-0.66	3.35e-17	Iron status biomarkers;
TGCT	cis	rs1696756	1.000	rs1696756	chr17:77827973	C/T	cg00646381	chr17:77835854	NA	0.44	7.51	0.56	1.02e-11	Glucocorticoid-induced osteonecrosis (age 10 years and older);
TGCT	cis	rs6866344	0.697	rs11748497	chr5:178130012	C/G	cg10224037	chr5:178157518	ZNF354A	0.93	8.22	0.59	2.25e-13	Neutrophil percentage of white cells;
TGCT	cis	rs7178572	0.568	rs1823100	chr15:77402744	C/T	cg15453836	chr15:77711506	NA	-0.4	-4.52	-0.38	1.45e-5	Type 2 diabetes;
TGCT	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg25036284	chr2:26402008	FAM59B	0.72	5.06	0.41	1.44e-6	Gut microbiome composition (summer);
TGCT	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg11235426	chr6:292522	DUSP22	-0.69	-6.94	-0.53	1.93e-10	Menopause (age at onset);
TGCT	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg24675658	chr1:53192096	ZYG11B	-0.69	-8.17	-0.59	3.05e-13	Monocyte count;
TGCT	trans	rs28595532	0.748	rs67928655	chr4:119336525	C/A	cg26518628	chr1:97050305	NA	-0.56	-6.79	-0.52	4.19e-10	Cannabis dependence symptom count;
TGCT	cis	rs9549260	0.753	rs9549246	chr13:41220755	G/A	cg21288729	chr13:41239152	FOXO1	0.67	4.68	0.39	7.31e-6	Red blood cell count;
TGCT	cis	rs1991651	0.578	rs13259086	chr8:10490218	G/C	cg27411982	chr8:10470053	RP1L1	0.22	5.03	0.41	1.66e-6	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
TGCT	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg04414720	chr1:150670196	GOLPH3L	0.39	5.04	0.41	1.59e-6	Tonsillectomy;
TGCT	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg06028808	chr11:68637592	NA	0.55	6.88	0.53	2.61e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg08509172	chr19:19383838	TM6SF2	-0.35	-4.49	-0.37	1.62e-5	Tonsillectomy;
TGCT	cis	rs7829975	0.560	rs17154599	chr8:8551418	C/T	cg17143192	chr8:8559678	CLDN23	-0.5	-5.18	-0.42	8.74e-7	Mood instability;
TGCT	cis	rs12908161	1.000	rs36033486	chr15:85319692	A/G	cg11189052	chr15:85197271	WDR73	0.71	5.85	0.47	4.04e-8	Schizophrenia;
TGCT	cis	rs7666738	0.753	rs7659724	chr4:98944063	C/T	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9913156	0.589	rs7213481	chr17:4547906	C/T	cg23387401	chr17:4582204	PELP1	0.32	4.75	0.39	5.42e-6	Lymphocyte counts;
TGCT	cis	rs2447097	0.904	rs2447098	chr17:2277720	C/A	cg27406664	chr17:2294951	MNT	0.26	5.22	0.42	7.44e-7	Autism spectrum disorder;
TGCT	cis	rs16867321	0.639	rs12466864	chr2:181441417	C/G	cg23363182	chr2:181467187	NA	0.42	6.22	0.49	7.03e-9	Obesity;
TGCT	cis	rs7647973	1.000	rs7619789	chr3:49476263	T/C	cg07636037	chr3:49044803	WDR6	0.64	5.26	0.43	6.12e-7	Menarche (age at onset);
TGCT	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.66	-6.62	-0.51	9.87e-10	Longevity;Endometriosis;
TGCT	cis	rs35883536	0.647	rs2809790	chr1:101040461	C/T	cg06223162	chr1:101003688	GPR88	0.42	8.0	0.58	7.5e-13	Monocyte count;
TGCT	cis	rs11648796	0.721	rs3169403	chr16:769247	G/A	cg27144592	chr16:783916	NARFL	0.43	5.82	0.46	4.73e-8	Height;
TGCT	cis	rs11676348	0.811	rs4674255	chr2:218987325	C/T	cg00012203	chr2:219082015	ARPC2	-0.51	-4.85	-0.4	3.6e-6	Ulcerative colitis;
TGCT	cis	rs422249	0.512	rs174583	chr11:61609750	A/G	cg19610905	chr11:61596333	FADS2	0.87	8.05	0.59	5.89e-13	Trans fatty acid levels;
TGCT	trans	rs1814175	0.565	rs4881721	chr11:49761851	G/A	cg15704280	chr7:45808275	SEPT13	-0.58	-6.7	-0.52	6.48e-10	Height;
TGCT	cis	rs9517320	0.534	rs9556963	chr13:99157026	G/A	cg20487152	chr13:99095054	FARP1	-0.24	-4.64	-0.38	8.83e-6	Longevity;
TGCT	cis	rs73198271	0.960	rs73198290	chr8:8616009	A/T	ch.8.214553F	chr8:8189620	PRAGMIN	-0.27	-4.79	-0.39	4.72e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs13040088	1.000	rs13040088	chr20:61549202	A/G	cg23096297	chr20:61557774	DIDO1	1.19	9.82	0.66	3.46e-17	Menopause (age at onset);
TGCT	cis	rs114540395	0.777	rs17760556	chr10:103138615	G/A	cg18276125	chr10:102749041	C10orf2	0.38	4.6	0.38	1.05e-5	Schizophrenia;
TGCT	cis	rs6860806	0.531	rs270612	chr5:131637338	G/A	cg24060327	chr5:131705240	SLC22A5	-0.73	-7.65	-0.57	4.87e-12	Breast cancer;
TGCT	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.67	5.45	0.44	2.66e-7	Tonsillectomy;
TGCT	cis	rs2760061	0.819	rs708111	chr1:228191365	G/A	cg02753203	chr1:228287806	NA	0.3	5.71	0.46	7.95e-8	Diastolic blood pressure;
TGCT	cis	rs79149102	0.579	rs6495142	chr15:75320166	C/T	cg09165964	chr15:75287851	SCAMP5	-1.05	-5.73	-0.46	7.26e-8	Lung cancer;
TGCT	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg00814883	chr7:100076585	TSC22D4	-0.9	-9.56	-0.65	1.5e-16	Platelet count;
TGCT	trans	rs1499614	1.000	rs1638731	chr7:66144679	C/T	cg07424592	chr7:64974309	NA	1.35	8.11	0.59	4.14e-13	Gout;
TGCT	cis	rs9513593	1.000	rs35912802	chr13:99886236	A/C	cg21788972	chr13:99853209	UBAC2	0.59	4.73	0.39	6.13e-6	Psoriasis;
TGCT	cis	rs10791097	0.703	rs11222360	chr11:130730871	C/T	cg12179176	chr11:130786555	SNX19	0.76	9.14	0.63	1.54e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs11674184	0.525	rs4669755	chr2:11748585	A/C	cg07314298	chr2:11723111	GREB1	0.36	6.44	0.5	2.34e-9	Endometriosis;
TGCT	cis	rs12049351	0.665	rs12035203	chr1:229642517	T/C	cg12130225	chr1:229698885	NA	0.39	4.59	0.38	1.06e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs2346177	0.875	rs1447565	chr2:46643682	T/A	cg26688816	chr2:46740690	ATP6V1E2	-0.41	-4.53	-0.38	1.38e-5	HDL cholesterol;
TGCT	cis	rs815815	0.608	rs6751198	chr2:47396274	C/T	cg27223769	chr2:47403360	CALM2	-0.58	-5.25	-0.43	6.34e-7	Dialysis-related mortality;
TGCT	cis	rs9611565	0.545	rs5758432	chr22:42111693	T/C	cg03806693	chr22:41940476	POLR3H	1.08	11.98	0.73	1.9e-22	Vitiligo;
TGCT	cis	rs11623869	0.772	rs12587310	chr14:103907286	G/A	cg12935359	chr14:103987150	CKB	0.34	4.9	0.4	2.92e-6	Bone mineral density;
TGCT	cis	rs360798	0.532	rs360800	chr2:62954326	C/T	cg17519650	chr2:63277830	OTX1	-0.55	-4.49	-0.37	1.63e-5	Coronary artery disease;
TGCT	cis	rs16867321	0.639	rs13028421	chr2:181444035	G/T	cg23363182	chr2:181467187	NA	0.41	6.04	0.48	1.69e-8	Obesity;
TGCT	cis	rs17102423	0.731	rs1957949	chr14:65542607	C/T	cg11161011	chr14:65562177	MAX	-0.43	-5.92	-0.47	2.97e-8	Obesity-related traits;
TGCT	cis	rs3099143	1.000	rs901008	chr15:77097018	C/A	cg21673338	chr15:77095150	SCAPER	-0.51	-4.88	-0.4	3.17e-6	Recalcitrant atopic dermatitis;
TGCT	cis	rs10927875	0.726	rs1763603	chr1:16339809	T/C	cg21385522	chr1:16154831	NA	0.6	6.29	0.49	4.95e-9	Dilated cardiomyopathy;
TGCT	cis	rs7572733	0.576	rs6734781	chr2:198759973	G/A	cg00792783	chr2:198669748	PLCL1	0.57	5.21	0.42	7.75e-7	Dermatomyositis;
TGCT	cis	rs7829975	0.846	rs7005216	chr8:8547110	C/G	cg06636001	chr8:8085503	FLJ10661	-0.61	-5.05	-0.41	1.57e-6	Mood instability;
TGCT	cis	rs7727544	0.735	rs272879	chr5:131670546	C/G	cg24060327	chr5:131705240	SLC22A5	-0.56	-6.31	-0.49	4.43e-9	Blood metabolite levels;
TGCT	cis	rs9326248	1.000	rs4938354	chr11:117051165	A/G	cg26566898	chr11:117069891	TAGLN	0.33	4.67	0.39	7.55e-6	Blood protein levels;
TGCT	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg13342137	chr4:2252803	MXD4	0.17	4.56	0.38	1.23e-5	Obesity-related traits;
TGCT	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg27588902	chr6:42928151	GNMT	-0.57	-7.05	-0.54	1.07e-10	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs35883536	0.626	rs80052576	chr1:101039229	A/G	cg10298815	chr1:101004474	GPR88	-0.24	-4.5	-0.37	1.57e-5	Monocyte count;
TGCT	cis	rs7552404	0.920	rs1612097	chr1:76218875	C/T	cg03433033	chr1:76189801	ACADM	0.76	9.01	0.63	3.15e-15	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs6969780	0.722	rs983185	chr7:27188607	G/A	cg22997113	chr7:27170241	HOXA4	-0.45	-4.45	-0.37	1.85e-5	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs988712	0.662	rs11030100	chr11:27677586	G/T	cg10635145	chr11:27742435	BDNF	-0.39	-5.49	-0.44	2.2e-7	Obesity;
TGCT	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg11764359	chr7:65958608	NA	0.58	5.34	0.43	4.22e-7	Aortic root size;
TGCT	cis	rs425277	1.000	rs262667	chr1:2082722	T/C	cg24578937	chr1:2090814	PRKCZ	0.32	8.19	0.59	2.64e-13	Height;
TGCT	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg04287289	chr16:89883240	FANCA	-0.87	-10.91	-0.7	7.5599999999999994e-20	Vitiligo;
TGCT	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg06238570	chr21:40685208	BRWD1	-0.63	-5.79	-0.46	5.47e-8	Cognitive function;
TGCT	cis	rs6688613	1.000	rs6665341	chr1:166947018	A/G	cg07049167	chr1:166818506	POGK	0.21	4.53	0.38	1.36e-5	Refractive astigmatism;
TGCT	cis	rs4077515	0.743	rs3812571	chr9:139275294	G/C	cg13741927	chr9:139327495	INPP5E	-0.19	-4.59	-0.38	1.05e-5	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs11249608	0.636	rs6888567	chr5:178449074	C/T	cg23951258	chr5:178450506	ZNF879	-0.46	-4.49	-0.37	1.58e-5	Pubertal anthropometrics;
TGCT	cis	rs9948	0.655	rs62156213	chr2:97399100	T/C	cg01990225	chr2:97406019	LMAN2L	-1.02	-5.19	-0.42	8.43e-7	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs7542091	1.000	rs7542091	chr1:210031948	G/C	cg21951975	chr1:209979733	IRF6	0.54	5.56	0.45	1.56e-7	Monobrow;
TGCT	cis	rs10791097	0.667	rs4937585	chr11:130741940	A/G	cg05962950	chr11:130786565	SNX19	0.92	11.55	0.72	2.13e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs6598955	0.585	rs11577098	chr1:26602525	C/T	cg04990556	chr1:26633338	UBXN11	0.66	5.0	0.41	1.88e-6	Obesity-related traits;
TGCT	cis	rs9419702	0.639	rs9419624	chr10:133534822	G/A	cg20568497	chr10:133558893	NA	0.44	4.87	0.4	3.4e-6	Survival in rectal cancer;
TGCT	cis	rs9467773	0.804	rs2073526	chr6:26374658	C/T	cg05738196	chr6:26577821	NA	-0.6	-6.2	-0.49	7.53e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs2730260	0.537	rs73169238	chr7:158883818	G/A	cg27122614	chr7:157913741	PTPRN2	0.42	4.47	0.37	1.74e-5	Myopia (pathological);
TGCT	cis	rs1801251	1.000	rs11676216	chr2:233706368	C/T	cg08000102	chr2:233561755	GIGYF2	-0.63	-6.46	-0.5	2.2e-9	Coronary artery disease;
TGCT	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg13770153	chr20:60521292	NA	-0.54	-7.04	-0.53	1.15e-10	Body mass index;
TGCT	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg12419862	chr22:24373484	LOC391322	0.89	7.86	0.58	1.55e-12	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg25427524	chr10:38739819	LOC399744	-0.38	-7.77	-0.57	2.54e-12	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg03264133	chr6:25882463	NA	-0.61	-6.51	-0.5	1.68e-9	Blood metabolite levels;
TGCT	trans	rs1814175	0.817	rs7109440	chr11:49966296	C/T	cg03929089	chr4:120376271	NA	-0.72	-8.53	-0.61	4.24e-14	Height;
TGCT	cis	rs7412746	0.658	rs12068264	chr1:150727329	C/T	cg09365446	chr1:150670422	GOLPH3L	0.33	4.78	0.39	4.8e-6	Melanoma;
TGCT	cis	rs1451375	1.000	rs10247443	chr7:50620586	G/A	cg18232548	chr7:50535776	DDC	0.43	6.65	0.51	8.19e-10	Malaria;
TGCT	cis	rs709400	0.628	rs2273699	chr14:103923475	A/G	cg26031613	chr14:104095156	KLC1	0.85	9.49	0.65	2.17e-16	Body mass index;
TGCT	cis	rs28493229	0.708	rs4803352	chr19:41159193	C/T	cg11601297	chr19:41224147	ITPKC;ADCK4	-0.55	-5.15	-0.42	9.8e-7	Kawasaki disease;
TGCT	cis	rs10114408	0.959	rs7868037	chr9:96647901	A/G	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs3820068	0.608	rs12091644	chr1:16044945	G/A	cg05660106	chr1:15850417	CASP9	0.73	6.78	0.52	4.41e-10	Systolic blood pressure;
TGCT	cis	rs2115630	1.000	rs6496441	chr15:85363348	A/G	cg09876464	chr15:85330779	ZNF592	0.19	4.46	0.37	1.78e-5	P wave terminal force;
TGCT	cis	rs10089	0.953	rs2190797	chr5:127352875	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	6.75	0.52	5e-10	Ileal carcinoids;
TGCT	cis	rs7089973	0.624	rs10885613	chr10:116589400	G/A	cg03647239	chr10:116582469	FAM160B1	0.59	5.75	0.46	6.46e-8	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg20203395	chr5:56204925	C5orf35	-0.78	-6.46	-0.5	2.17e-9	Initial pursuit acceleration;
TGCT	cis	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg25427524	chr10:38739819	LOC399744	-0.38	-7.92	-0.58	1.17e-12	Extrinsic epigenetic age acceleration;
TGCT	cis	rs696279	0.967	rs697511	chr7:16700648	C/A	cg08595592	chr7:16780162	NA	0.24	4.74	0.39	5.67e-6	Mean platelet volume;
TGCT	cis	rs9467773	0.620	rs6925087	chr6:26592853	T/A	cg09904177	chr6:26538194	HMGN4	0.67	6.32	0.49	4.25e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs6121246	0.909	rs6060929	chr20:30345914	C/T	cg18721089	chr20:30220636	NA	-0.43	-4.75	-0.39	5.54e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs17384381	0.861	rs34561661	chr1:85777250	C/T	cg16011679	chr1:85725395	C1orf52	0.86	6.19	0.49	8.17e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9549260	0.683	rs35594717	chr13:41240783	G/A	cg21288729	chr13:41239152	FOXO1	0.7	4.94	0.41	2.51e-6	Red blood cell count;
TGCT	cis	rs7095607	0.606	rs10998014	chr10:69959567	C/A	cg18986048	chr10:69913749	MYPN	0.52	5.29	0.43	5.35e-7	Lung function (FVC);
TGCT	cis	rs829883	0.664	rs1096148	chr12:98851005	A/G	cg25150519	chr12:98850993	NA	0.64	7.54	0.56	8.56e-12	Colorectal adenoma (advanced);
TGCT	cis	rs7582180	0.591	rs1030902	chr2:101007178	T/G	cg14675211	chr2:100938903	LONRF2	0.49	4.7	0.39	6.74e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs35306767	0.715	rs12777801	chr10:1036285	T/A	cg18964960	chr10:1102726	WDR37	0.78	5.45	0.44	2.58e-7	Eosinophil percentage of granulocytes;
TGCT	cis	rs1801251	1.000	rs3816334	chr2:233708806	A/G	cg08000102	chr2:233561755	GIGYF2	-0.63	-6.46	-0.5	2.2e-9	Coronary artery disease;
TGCT	cis	rs968451	1.000	rs971964	chr22:39702473	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.87	7.8	0.57	2.23e-12	Primary biliary cholangitis;
TGCT	cis	rs514406	0.679	rs11206006	chr1:53218380	A/G	cg22166914	chr1:53195759	ZYG11B	-0.37	-5.99	-0.47	2.15e-8	Monocyte count;
TGCT	cis	rs6570726	0.846	rs4896824	chr6:145927048	C/T	cg23711669	chr6:146136114	FBXO30	0.83	8.64	0.61	2.4e-14	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs61884328	0.852	rs60335739	chr11:47148728	C/T	cg13308137	chr11:47528955	CUGBP1	0.38	4.47	0.37	1.76e-5	Total body bone mineral density (age over 60);
TGCT	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.36	0.55	2.25e-11	Prudent dietary pattern;
TGCT	cis	rs3091242	0.933	rs34933589	chr1:25788198	T/C	cg00786635	chr1:25594202	NA	-0.51	-5.32	-0.43	4.67e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs7666738	0.753	rs6826709	chr4:98714553	C/G	cg18180107	chr4:99064573	C4orf37	0.55	5.17	0.42	8.93e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7647973	1.000	rs974495	chr3:49400482	T/C	cg07636037	chr3:49044803	WDR6	0.66	5.33	0.43	4.45e-7	Menarche (age at onset);
TGCT	cis	rs4295623	0.556	rs10903343	chr8:11695872	T/C	cg02840367	chr8:11660030	FDFT1	-0.67	-5.67	-0.45	9.68e-8	Morning vs. evening chronotype;
TGCT	cis	rs6500602	0.727	rs3761681	chr16:4566857	C/T	cg08645402	chr16:4508243	NA	0.19	5.3	0.43	5.08e-7	Schizophrenia;
TGCT	cis	rs13191362	1.000	rs13207239	chr6:163008772	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs33794	0.729	rs33783	chr3:45291959	G/T	cg18645101	chr3:44551900	NA	0.5	4.48	0.37	1.7e-5	Lung function (forced expiratory volume in 1 second);
TGCT	cis	rs6866344	0.697	rs6873150	chr5:178125704	G/A	cg03877680	chr5:178157825	ZNF354A	0.73	5.73	0.46	7.07e-8	Neutrophil percentage of white cells;
TGCT	cis	rs79349575	0.783	rs9747646	chr17:47016882	C/T	cg07967210	chr17:47022446	SNF8	0.44	6.13	0.48	1.1e-8	Type 2 diabetes;
TGCT	cis	rs11673344	0.504	rs7259332	chr19:37634291	G/T	cg08039142	chr19:36980659	ZNF566	0.51	4.69	0.39	6.97e-6	Obesity-related traits;
TGCT	cis	rs765787	0.530	rs12440321	chr15:45529385	G/A	cg24006582	chr15:45444508	DUOX1	0.24	5.3	0.43	5.17e-7	Uric acid levels;
TGCT	cis	rs12900413	0.603	rs12905689	chr15:90301343	G/A	cg24249390	chr15:90295951	MESP1	-0.3	-5.23	-0.42	7.05e-7	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs3858526	0.642	rs55732658	chr11:5894602	A/C	cg13902645	chr11:5959945	NA	-0.41	-4.49	-0.37	1.6e-5	DNA methylation (variation);
TGCT	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg00343986	chr7:65444356	GUSB	-0.23	-5.16	-0.42	9.66e-7	Aortic root size;
TGCT	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg03188948	chr7:1209495	NA	0.67	5.62	0.45	1.18e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs6740322	0.748	rs1549723	chr2:43460514	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.39	-6.02	-0.48	1.86e-8	Coronary artery disease;
TGCT	cis	rs727505	0.721	rs11536526	chr7:124749441	G/A	cg23710748	chr7:124431027	NA	-0.26	-4.56	-0.38	1.2e-5	Lewy body disease;
TGCT	cis	rs4372836	1.000	rs72782294	chr2:28953390	C/G	cg09522027	chr2:28974177	PPP1CB	0.59	5.14	0.42	1.03e-6	Body mass index;
TGCT	cis	rs1395	0.778	rs11693001	chr2:27412744	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.64	8.74	0.62	1.37e-14	Blood metabolite levels;
TGCT	trans	rs2970818	0.831	rs7304949	chr12:4609625	A/G	cg21748317	chr7:158073589	PTPRN2	0.45	7.16	0.54	6.14e-11	Phosphorus levels;
TGCT	cis	rs3806843	0.576	rs246011	chr5:140336405	G/C	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2832191	1.000	rs2832190	chr21:30488226	G/A	cg08807101	chr21:30365312	RNF160	-0.49	-4.48	-0.37	1.65e-5	Dental caries;
TGCT	cis	rs9911578	0.935	rs34523895	chr17:57034095	T/C	cg05425664	chr17:57184151	TRIM37	-0.56	-5.42	-0.44	2.99e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg11644478	chr21:40555479	PSMG1	-1.03	-11.03	-0.7	3.93e-20	Cognitive function;
TGCT	cis	rs4713118	0.866	rs2179094	chr6:27741825	T/C	cg02458000	chr6:26745757	NA	-0.57	-4.97	-0.41	2.18e-6	Parkinson's disease;
TGCT	cis	rs9535307	0.769	rs9535306	chr13:50290817	A/G	cg03651054	chr13:50194643	NA	0.37	4.49	0.37	1.61e-5	Obesity-related traits;
TGCT	cis	rs12477438	0.798	rs17708218	chr2:99696284	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-8.74	-0.62	1.36e-14	Chronic sinus infection;
TGCT	cis	rs644799	1.000	rs518919	chr11:95623313	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	7.25	0.55	3.87e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs854765	0.547	rs6502633	chr17:17941037	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.79	8.26	0.6	1.86e-13	Total body bone mineral density;
TGCT	cis	rs67073037	0.955	rs12472068	chr2:29136685	C/T	cg09522027	chr2:28974177	PPP1CB	0.57	4.49	0.37	1.59e-5	Breast cancer;Breast cancer (estrogen-receptor negative);
TGCT	cis	rs17712049	0.908	rs62447151	chr7:48199772	C/G	cg16849860	chr7:48352531	ABCA13	0.32	5.26	0.43	6.19e-7	Refractive astigmatism;
TGCT	cis	rs7584330	0.554	rs729389	chr2:238425118	G/A	cg08992911	chr2:238395768	MLPH	0.73	4.95	0.41	2.37e-6	Prostate cancer;
TGCT	cis	rs7781977	0.920	rs62447179	chr7:50339609	G/A	cg01139861	chr7:50343298	IKZF1	0.53	5.63	0.45	1.12e-7	IgG glycosylation;
TGCT	trans	rs114540395	0.698	rs7098584	chr10:103209336	G/A	cg10198749	chr1:39920707	MACF1	0.55	7.11	0.54	8.11e-11	Schizophrenia;
TGCT	cis	rs881375	1.000	rs1609810	chr9:123642351	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.39	4.5	0.37	1.52e-5	Rheumatoid arthritis;
TGCT	cis	rs16925187	1.000	rs7850439	chr9:7042390	A/C	cg00667760	chr9:6757146	KDM4C	-1.07	-5.09	-0.42	1.3e-6	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg18876405	chr7:65276391	NA	0.35	5.2	0.42	7.81e-7	Aortic root size;
TGCT	cis	rs4253772	0.530	rs55653327	chr22:46682976	C/T	cg24881330	chr22:46731750	TRMU	1.01	4.95	0.41	2.35e-6	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs9926296	0.706	rs2159115	chr16:89831819	A/G	cg26513180	chr16:89883248	FANCA	0.67	6.44	0.5	2.41e-9	Vitiligo;
TGCT	cis	rs1691799	0.867	rs1168347	chr12:66757303	T/C	cg16791601	chr12:66731901	HELB	-0.28	-5.99	-0.47	2.14e-8	White blood cell count (basophil);
TGCT	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs9303401	0.573	rs35104446	chr17:57180234	A/C	cg25039879	chr17:56429692	SUPT4H1	0.55	4.9	0.4	2.93e-6	Cognitive test performance;
TGCT	cis	rs7584330	0.666	rs72620817	chr2:238353661	C/T	cg14458575	chr2:238380390	NA	0.55	8.09	0.59	4.56e-13	Prostate cancer;
TGCT	cis	rs7267979	0.932	rs6115214	chr20:25557426	C/T	cg14121845	chr20:25566513	NINL	-0.48	-5.24	-0.43	6.68e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11031096	0.678	rs4606468	chr11:4183643	G/T	cg18678763	chr11:4115507	RRM1	-0.44	-5.75	-0.46	6.48e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs17102423	0.594	rs1957948	chr14:65542629	A/G	cg11161011	chr14:65562177	MAX	0.48	6.78	0.52	4.29e-10	Obesity-related traits;
TGCT	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg00684032	chr4:1343700	KIAA1530	0.23	5.02	0.41	1.73e-6	Obesity-related traits;
TGCT	cis	rs2463822	0.669	rs72919496	chr11:62052730	T/C	cg06239285	chr11:62104954	ASRGL1	-0.91	-5.82	-0.46	4.7e-8	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg18230493	chr5:56204884	C5orf35	-0.69	-6.07	-0.48	1.44e-8	Initial pursuit acceleration;
TGCT	cis	rs6969780	1.000	rs929249	chr7:27167537	T/C	cg04321618	chr7:27170880	HOXA4	0.51	4.48	0.37	1.67e-5	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs2255336	0.938	rs1382264	chr12:10543339	A/G	cg16084090	chr12:10586130	KLRC2	-0.28	-4.67	-0.39	7.56e-6	Blood protein levels;
TGCT	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg16414030	chr3:133502952	NA	-0.5	-7.01	-0.53	1.32e-10	Iron status biomarkers;
TGCT	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.48	-4.65	-0.39	8.42e-6	Prudent dietary pattern;
TGCT	cis	rs9467711	0.606	rs9379851	chr6:26354780	A/C	cg16898833	chr6:26189333	HIST1H4D	1.03	5.35	0.43	4.02e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4499344	0.730	rs10410888	chr19:33103328	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.83	8.63	0.61	2.53e-14	Mean platelet volume;
TGCT	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg07507251	chr3:52567010	NT5DC2	0.45	6.17	0.48	8.78e-9	Bipolar disorder;
TGCT	cis	rs2153535	0.580	rs9328486	chr6:8528008	T/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.01	0.41	1.86e-6	Motion sickness;
TGCT	cis	rs1629083	0.902	rs57495164	chr11:118095148	T/C	cg16594165	chr11:118135105	MPZL2	-0.33	-4.7	-0.39	6.73e-6	Lung cancer;
TGCT	cis	rs916888	0.738	rs199515	chr17:44856641	C/G	cg16520312	chr17:43971471	MAPT;LOC100128977	0.56	4.81	0.4	4.28e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2742417	1.000	rs2742390	chr3:45756722	A/G	cg04837898	chr3:45731254	SACM1L	0.56	5.97	0.47	2.3e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg07167872	chr1:205819463	PM20D1	0.45	4.48	0.37	1.7e-5	Parkinson's disease;
TGCT	cis	rs10832169	0.967	rs1528639	chr11:14070459	G/C	cg04547675	chr11:13986162	SPON1	0.51	4.51	0.38	1.49e-5	Blood protein levels;
TGCT	cis	rs62244186	0.566	rs55852922	chr3:44826188	A/G	cg10263370	chr3:44754102	ZNF502	-0.47	-5.67	-0.45	9.48e-8	Depressive symptoms;
TGCT	cis	rs12421382	0.659	rs1439518	chr11:109382921	T/G	cg16359550	chr11:109292809	C11orf87	0.4	4.48	0.37	1.65e-5	Schizophrenia;
TGCT	cis	rs4820539	1.000	rs4822358	chr22:23474795	A/G	cg21100191	chr22:23484243	RTDR1	0.89	10.58	0.69	5.04e-19	Bone mineral density;
TGCT	cis	rs7819412	0.635	rs4841501	chr8:11000976	T/C	cg21775007	chr8:11205619	TDH	-0.57	-5.41	-0.44	3.18e-7	Triglycerides;
TGCT	cis	rs9818758	0.556	rs9835439	chr3:49220330	G/C	cg07636037	chr3:49044803	WDR6	-1.03	-5.02	-0.41	1.77e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg25036284	chr2:26402008	FAM59B	0.65	5.19	0.42	8.36e-7	Gut microbiome composition (summer);
TGCT	cis	rs7582180	0.629	rs12989897	chr2:100940998	A/G	cg14675211	chr2:100938903	LONRF2	0.5	4.78	0.39	4.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2456568	0.571	rs1105114	chr11:93693511	C/T	cg26875233	chr11:93583750	C11orf90	0.43	5.16	0.42	9.71e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	trans	rs1814175	0.817	rs1319547	chr11:49916705	C/T	cg03929089	chr4:120376271	NA	-0.71	-8.09	-0.59	4.74e-13	Height;
TGCT	cis	rs2188554	0.711	rs213947	chr7:117192608	A/G	cg08576598	chr7:116962626	WNT2	-0.36	-4.56	-0.38	1.23e-5	Esophageal adenocarcinoma;
TGCT	cis	rs7772486	0.875	rs2748482	chr6:146336532	T/C	cg23711669	chr6:146136114	FBXO30	0.88	9.67	0.66	7.78e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1843834	0.898	rs4674936	chr2:225553731	C/T	cg22455342	chr2:225449267	CUL3	0.75	7.37	0.55	2.15e-11	IgE levels in asthmatics (D.p. specific);
TGCT	trans	rs9383153	0.625	rs1886349	chr6:16320320	G/A	cg19402885	chr12:15475236	PTPRO	1.0	6.71	0.52	6.22e-10	Gambling;
TGCT	cis	rs7017914	0.967	rs2639901	chr8:71917751	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.57	-5.31	-0.43	4.8e-7	Bone mineral density;
TGCT	cis	rs17376456	1.000	rs13174700	chr5:93554644	G/A	cg21475434	chr5:93447410	FAM172A	0.65	4.66	0.39	7.92e-6	Diabetic retinopathy;
TGCT	cis	rs9682041	0.696	rs6798399	chr3:170086482	G/A	cg11886554	chr3:170076028	SKIL	0.6	4.76	0.39	5.35e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs7727544	0.606	rs200838	chr5:131710399	A/C	cg14196790	chr5:131705035	SLC22A5	-0.37	-5.2	-0.42	8.01e-7	Blood metabolite levels;
TGCT	cis	rs9611565	0.592	rs9611612	chr22:41961189	T/C	cg17554472	chr22:41940697	POLR3H	-0.47	-4.91	-0.4	2.79e-6	Vitiligo;
TGCT	cis	rs250677	0.687	rs250673	chr5:148445798	C/T	cg23229984	chr5:148520753	ABLIM3	0.21	4.89	0.4	3.11e-6	Breast cancer;
TGCT	cis	rs10788264	0.621	rs9633733	chr10:124056546	A/G	cg09507567	chr10:124027408	NA	-0.37	-5.32	-0.43	4.71e-7	Total body bone mineral density;
TGCT	cis	rs208515	0.556	rs12206707	chr6:66697182	A/G	cg07460842	chr6:66804631	NA	0.88	9.36	0.64	4.39e-16	Exhaled nitric oxide levels;
TGCT	cis	rs17376456	0.542	rs17083380	chr5:93170476	C/G	cg21475434	chr5:93447410	FAM172A	-0.59	-5.58	-0.45	1.44e-7	Diabetic retinopathy;
TGCT	cis	rs3784262	0.669	rs6493981	chr15:58352923	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.42	-6.24	-0.49	6.32e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs66573146	0.808	rs73202120	chr4:7005588	A/G	cg00086871	chr4:6988644	TBC1D14	0.96	4.85	0.4	3.57e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs2224391	0.628	rs9405261	chr6:5249702	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-1.04	-6.69	-0.51	6.87e-10	Height;
TGCT	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg27286337	chr10:134555280	INPP5A	0.37	4.54	0.38	1.3e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg22920501	chr2:26401640	FAM59B	0.81	6.36	0.5	3.52e-9	Gut microbiome composition (summer);
TGCT	cis	rs4820539	1.000	rs2157710	chr22:23457486	C/T	cg21100191	chr22:23484243	RTDR1	0.93	11.2	0.71	1.54e-20	Bone mineral density;
TGCT	cis	rs9905704	0.647	rs7221274	chr17:57008128	A/G	cg12560992	chr17:57184187	TRIM37	0.58	4.93	0.4	2.57e-6	Testicular germ cell tumor;
TGCT	cis	rs8056742	0.730	rs78274149	chr16:85084293	G/A	cg00229868	chr16:85520891	NA	0.36	4.83	0.4	3.96e-6	Amyotrophic lateral sclerosis;
TGCT	cis	rs7819412	0.744	rs6601562	chr8:10962929	G/C	cg27411982	chr8:10470053	RP1L1	-0.2	-4.44	-0.37	1.94e-5	Triglycerides;
TGCT	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg06634786	chr22:41940651	POLR3H	-0.87	-8.2	-0.59	2.56e-13	Vitiligo;
TGCT	cis	rs4891159	0.527	rs689642	chr18:74119120	A/C	cg24786174	chr18:74118243	ZNF516	0.71	15.66	0.82	3.6e-31	Longevity;
TGCT	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg11141652	chr22:24348549	GSTTP1	-0.34	-4.82	-0.4	4.17e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs508618	0.731	rs11805033	chr1:231546452	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.62	5.11	0.42	1.18e-6	Red blood cell count;
TGCT	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg22920501	chr2:26401640	FAM59B	-0.74	-6.4	-0.5	2.86e-9	Gut microbiome composition (summer);
TGCT	cis	rs919433	0.679	rs7564924	chr2:198513877	C/T	cg00792783	chr2:198669748	PLCL1	0.55	4.97	0.41	2.15e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs11761231	1.000	rs11761231	chr7:131370039	A/G	cg08326674	chr7:132266446	PLXNA4	0.23	4.59	0.38	1.09e-5	Rheumatoid arthritis;
TGCT	cis	rs7412746	0.611	rs36008098	chr1:150856806	G/A	cg04414720	chr1:150670196	GOLPH3L	0.4	4.82	0.4	4.06e-6	Melanoma;
TGCT	cis	rs12497850	1.000	rs4858831	chr3:48735558	C/T	cg06212747	chr3:49208901	KLHDC8B	0.62	5.93	0.47	2.75e-8	Parkinson's disease;
TGCT	cis	rs13217239	0.646	rs10456351	chr6:26986792	C/T	cg05738196	chr6:26577821	NA	0.49	4.77	0.39	4.98e-6	Schizophrenia;
TGCT	cis	rs1971762	0.563	rs3897117	chr12:54077407	T/G	cg16917193	chr12:54089295	NA	1.37	17.65	0.85	1.25e-35	Height;
TGCT	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg01416388	chr22:39784598	NA	-0.72	-7.15	-0.54	6.43e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs4771122	0.728	rs1475221	chr13:28037566	C/T	cg22138327	chr13:27999177	GTF3A	-0.7	-5.65	-0.45	1.02e-7	Body mass index;
TGCT	cis	rs2795502	1.000	rs2795503	chr10:43347224	T/A	cg20628663	chr10:43360327	NA	-0.45	-6.41	-0.5	2.71e-9	Blood protein levels;
TGCT	cis	rs514406	0.505	rs269289	chr1:53167151	A/C	cg25767906	chr1:53392781	SCP2	-0.47	-5.13	-0.42	1.09e-6	Monocyte count;
TGCT	cis	rs986417	1.000	rs12147690	chr14:60924009	A/G	cg27398547	chr14:60952738	C14orf39	1.39	10.61	0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs1729951	0.575	rs1654925	chr3:136690391	C/T	cg21827317	chr3:136751795	NA	-0.4	-5.61	-0.45	1.28e-7	Neuroticism;
TGCT	cis	rs797680	0.856	rs7547244	chr1:93781768	A/G	cg17826107	chr1:92977322	EVI5	-0.22	-5.05	-0.41	1.53e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7666738	0.791	rs1896156	chr4:99020882	C/G	cg17366294	chr4:99064904	C4orf37	0.68	7.04	0.53	1.17e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg01448562	chr3:133502909	NA	0.3	6.0	0.47	2.04e-8	Iron status biomarkers;
TGCT	cis	rs910316	1.000	rs175436	chr14:75608683	C/G	cg08847533	chr14:75593920	NEK9	-0.95	-10.23	-0.68	3.53e-18	Height;
TGCT	cis	rs2050392	0.517	rs302423	chr10:30772513	A/G	cg18806716	chr10:30721971	MAP3K8	-0.5	-5.82	-0.46	4.68e-8	Inflammatory bowel disease;
TGCT	cis	rs7267979	0.868	rs6138546	chr20:25216534	G/A	cg16686733	chr20:25566563	NINL	0.59	6.04	0.48	1.64e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs13191362	0.507	rs2155506	chr6:163035342	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.61	-5.84	-0.46	4.3e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs858239	0.601	rs1558313	chr7:23156079	G/A	cg05602783	chr7:23145260	KLHL7	-0.65	-5.52	-0.44	1.93e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs9419702	0.568	rs10782366	chr10:133557866	G/A	cg23460707	chr10:133558971	NA	0.44	4.84	0.4	3.72e-6	Survival in rectal cancer;
TGCT	cis	rs12681288	0.550	rs12674921	chr8:957969	A/C	cg04851639	chr8:1020857	NA	-0.27	-4.45	-0.37	1.85e-5	Schizophrenia;
TGCT	cis	rs2242116	0.793	rs9855938	chr3:46957298	G/A	cg02527881	chr3:46936655	PTH1R	-0.29	-5.47	-0.44	2.36e-7	Birth weight;
TGCT	cis	rs3796352	0.764	rs34872575	chr3:52986277	G/A	cg07884673	chr3:53033167	SFMBT1	0.63	5.74	0.46	6.83e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs9486715	0.758	rs9386528	chr6:96928514	G/A	cg18709589	chr6:96969512	KIAA0776	-0.71	-6.14	-0.48	1.01e-8	Headache;
TGCT	cis	rs796364	1.000	rs769949	chr2:200729558	A/G	cg17644776	chr2:200775616	C2orf69	0.31	4.83	0.4	3.99e-6	Schizophrenia;
TGCT	cis	rs10782582	0.609	rs2029682	chr1:76341619	T/C	cg10523679	chr1:76189770	ACADM	-0.59	-5.42	-0.44	2.94e-7	Daytime sleep phenotypes;
TGCT	cis	rs4822044	0.617	rs13054514	chr22:42130383	A/G	cg03806693	chr22:41940476	POLR3H	0.93	9.08	0.63	2.06e-15	Cannabis dependence symptom count;
TGCT	cis	rs17253792	0.822	rs17253716	chr14:56153661	G/C	cg01858014	chr14:56050164	KTN1	-0.35	-4.62	-0.38	9.37e-6	Putamen volume;
TGCT	cis	rs2404602	0.716	rs12907805	chr15:76690606	C/T	cg26408565	chr15:76604113	ETFA	-0.42	-5.44	-0.44	2.76e-7	Blood metabolite levels;
TGCT	cis	rs936229	0.749	rs7497201	chr15:75190690	A/G	cg10253484	chr15:75165896	SCAMP2	-0.77	-6.49	-0.5	1.85e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
TGCT	cis	rs7666738	0.830	rs6854594	chr4:99065312	A/T	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.44e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1153858	1.000	rs9788780	chr15:45685487	T/A	cg26924012	chr15:45694286	SPATA5L1	1.09	15.16	0.81	5.15e-30	Homoarginine levels;
TGCT	cis	rs4319547	0.695	rs4758645	chr12:122946487	G/A	cg23029597	chr12:123009494	RSRC2	-0.28	-4.52	-0.38	1.43e-5	Body mass index;
TGCT	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg13770153	chr20:60521292	NA	-0.59	-8.39	-0.6	9.32e-14	Obesity-related traits;
TGCT	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7714584	0.793	rs11955174	chr5:150254391	T/G	cg22134413	chr5:150180641	NA	0.83	6.53	0.51	1.54e-9	Crohn's disease;
TGCT	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg06481639	chr22:41940642	POLR3H	0.63	5.66	0.45	1.02e-7	Vitiligo;
TGCT	cis	rs17387100	0.551	rs2677782	chr4:16020824	C/G	cg13480465	chr4:16795757	LDB2	-0.42	-5.33	-0.43	4.56e-7	Suicide attempts in depression or bipolar disorder;
TGCT	cis	rs6688613	1.000	rs2296837	chr1:166958601	T/C	cg07049167	chr1:166818506	POGK	0.21	4.5	0.37	1.57e-5	Refractive astigmatism;
TGCT	cis	rs748404	0.631	rs6493084	chr15:43647627	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	4.72	0.39	6.3e-6	Lung cancer;
TGCT	cis	rs13202913	0.748	rs2859823	chr6:151815864	G/A	cg03627880	chr6:151815985	C6orf97	-0.62	-5.75	-0.46	6.43e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	trans	rs1814175	0.935	rs1827017	chr11:49632592	C/G	cg15704280	chr7:45808275	SEPT13	-0.61	-6.8	-0.52	4.02e-10	Height;
TGCT	cis	rs35306767	0.714	rs67205460	chr10:1090366	C/T	cg18964960	chr10:1102726	WDR37	0.68	4.77	0.39	5.02e-6	Eosinophil percentage of granulocytes;
TGCT	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	9.52	0.65	1.86e-16	Platelet count;
TGCT	cis	rs2115630	0.645	rs4842978	chr15:85197253	T/C	cg17173187	chr15:85201210	NMB	-0.48	-5.75	-0.46	6.41e-8	P wave terminal force;
TGCT	cis	rs7949030	0.626	rs7124057	chr11:62334096	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.64	9.42	0.65	3.17e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs6754311	0.638	rs2322659	chr2:136555659	A/G	cg07169764	chr2:136633963	MCM6	-0.68	-6.19	-0.49	7.9e-9	Mosquito bite size;
TGCT	cis	rs10791097	0.694	rs4457753	chr11:130755575	A/G	cg05962950	chr11:130786565	SNX19	0.91	11.78	0.73	5.8e-22	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs4273100	0.512	rs973650	chr17:19291785	A/G	cg03910582	chr17:19030146	GRAPL	-0.45	-6.22	-0.49	6.97e-9	Schizophrenia;
TGCT	trans	rs74910095	0.786	rs7726154	chr5:62941736	T/C	cg02938449	chr2:220419364	OBSL1	0.8	6.75	0.52	4.95e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6598955	0.670	rs6663950	chr1:26560131	T/C	cg04990556	chr1:26633338	UBXN11	-0.91	-11.87	-0.73	3.59e-22	Obesity-related traits;
TGCT	cis	rs7552404	0.807	rs2066183	chr1:76153745	A/G	cg22875332	chr1:76189707	ACADM	0.78	9.74	0.66	5.53e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9653442	0.545	rs12712067	chr2:100763900	A/C	cg07810366	chr2:100720526	AFF3	0.36	5.45	0.44	2.59e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs6815814	0.950	rs113465719	chr4:38808045	A/T	cg02016764	chr4:38805732	TLR1	-0.35	-5.65	-0.45	1.04e-7	Breast cancer;
TGCT	cis	rs9309473	0.615	rs11680965	chr2:73725916	G/T	cg07208825	chr2:73871855	ALMS1P	0.24	4.62	0.38	9.64e-6	Metabolite levels;
TGCT	cis	rs7666738	0.800	rs2865987	chr4:99067852	A/C	cg18180107	chr4:99064573	C4orf37	0.59	5.32	0.43	4.76e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11676348	0.818	rs4674256	chr2:218987893	A/T	cg00012203	chr2:219082015	ARPC2	-0.52	-4.98	-0.41	2.08e-6	Ulcerative colitis;
TGCT	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.31	0.43	4.9e-7	Prudent dietary pattern;
TGCT	cis	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg07424592	chr7:64974309	NA	1.36	8.08	0.59	4.97e-13	Diabetic kidney disease;
TGCT	cis	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg20637647	chr7:64974828	NA	-0.95	-5.3	-0.43	5.09e-7	Diabetic kidney disease;
TGCT	cis	rs6545883	0.759	rs777585	chr2:61412559	A/G	cg15711740	chr2:61764176	XPO1	0.52	4.6	0.38	1.02e-5	Tuberculosis;
TGCT	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs1401999	1.000	rs2872249	chr3:183636273	T/A	cg01324343	chr3:183735012	ABCC5	0.85	11.47	0.72	3.33e-21	Anterior chamber depth;
TGCT	cis	rs1971762	0.583	rs1527068	chr12:54088688	A/G	cg16917193	chr12:54089295	NA	1.34	17.42	0.84	4.03e-35	Height;
TGCT	cis	rs7949030	0.725	rs12808829	chr11:62378660	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.63	9.19	0.64	1.12e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs208520	0.754	rs1100989	chr6:66880532	G/A	cg07460842	chr6:66804631	NA	-0.91	-9.43	-0.65	2.99e-16	Exhaled nitric oxide output;
TGCT	cis	rs12711979	0.740	rs6715434	chr2:3820862	T/G	cg17052675	chr2:3827356	NA	-0.4	-7.82	-0.57	2.02e-12	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs7824557	0.569	rs2409718	chr8:11012977	C/T	cg27411982	chr8:10470053	RP1L1	-0.21	-4.67	-0.39	7.77e-6	Retinal vascular caliber;
TGCT	cis	rs1878931	0.501	rs28735976	chr16:3418419	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.76	7.12	0.54	7.59e-11	Body mass index (adult);
TGCT	cis	rs3858526	1.000	rs3858526	chr11:5959757	A/C	cg13902645	chr11:5959945	NA	-0.43	-4.65	-0.39	8.43e-6	DNA methylation (variation);
TGCT	cis	rs6121246	0.567	rs6058189	chr20:30192389	A/G	cg18721089	chr20:30220636	NA	-0.57	-6.22	-0.49	6.83e-9	Mean corpuscular hemoglobin;
TGCT	trans	rs9467711	1.000	rs9467707	chr6:26327905	G/C	cg20516262	chr7:155325649	CNPY1	0.54	6.63	0.51	9.34e-10	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4372836	0.504	rs2045886	chr2:29010517	A/G	cg09522027	chr2:28974177	PPP1CB	-0.56	-5.68	-0.45	9.2e-8	Body mass index;
TGCT	trans	rs877282	0.898	rs71489279	chr10:760510	T/C	cg22713356	chr15:30763199	NA	1.17	9.15	0.63	1.44e-15	Uric acid levels;
TGCT	cis	rs7904368	1.000	rs7904368	chr10:16858587	C/T	cg23933602	chr10:16859644	RSU1	0.64	4.99	0.41	1.97e-6	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
TGCT	cis	rs367615	0.661	rs9326773	chr5:108833523	C/T	cg17395555	chr5:108820864	NA	0.31	5.86	0.47	3.94e-8	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg03732007	chr1:2071316	PRKCZ	-0.28	-6.56	-0.51	1.31e-9	Height;
TGCT	cis	rs739496	0.579	rs75080921	chr12:112298972	T/G	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg01416388	chr22:39784598	NA	-0.7	-6.94	-0.53	1.9e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg22683308	chr4:1340831	KIAA1530	-0.64	-5.93	-0.47	2.76e-8	Longevity;
TGCT	cis	rs4654899	0.895	rs7515590	chr1:21216664	T/C	cg01072550	chr1:21505969	NA	0.49	7.7	0.57	3.76e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs295140	0.502	rs3769456	chr2:201239002	C/T	cg04283868	chr2:201171347	SPATS2L	0.52	4.98	0.41	2.06e-6	QT interval;
TGCT	cis	rs11792861	0.926	rs7855282	chr9:111802614	T/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.47	4.46	0.37	1.79e-5	Menarche (age at onset);
TGCT	cis	rs2836950	0.520	rs2836966	chr21:40637521	A/G	cg06238570	chr21:40685208	BRWD1	-0.61	-6.19	-0.49	7.89e-9	Menarche (age at onset);
TGCT	cis	rs9650657	0.707	rs11250076	chr8:10647823	A/G	cg27411982	chr8:10470053	RP1L1	-0.24	-5.05	-0.41	1.54e-6	Neuroticism;
TGCT	cis	rs2288884	1.000	rs79817140	chr19:52571657	C/T	cg13540795	chr19:52551618	ZNF432	-0.59	-5.02	-0.41	1.79e-6	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs1116547	0.684	rs2091803	chr5:112578543	C/T	cg04138046	chr5:112608004	MCC	-0.46	-4.65	-0.39	8.46e-6	Cerebral amyloid angiopathy;
TGCT	cis	rs644799	0.544	rs1622515	chr11:95523433	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.56	5.76	0.46	6.32e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7655841	0.704	rs1757936	chr4:130011891	G/A	cg26347359	chr4:129759716	PHF17	-0.45	-5.2	-0.42	7.86e-7	Chronic obstructive pulmonary disease (moderate to severe);
TGCT	cis	rs34245846	0.769	rs12058931	chr1:154825093	C/A	cg06418219	chr1:154948305	SHC1;CKS1B	0.74	5.93	0.47	2.84e-8	Atrial fibrillation;
TGCT	cis	rs6912958	0.712	rs2814712	chr6:88396322	A/C	cg06598631	chr6:88300029	RARS2;ORC3L	0.49	4.72	0.39	6.37e-6	Monocyte percentage of white cells;
TGCT	cis	rs3806843	0.705	rs35614340	chr5:140043618	C/G	cg19875535	chr5:140030758	IK	-0.36	-6.15	-0.48	9.57e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9942416	0.660	rs2307113	chr5:74998264	C/T	cg02573091	chr5:74908125	NA	0.38	4.51	0.38	1.47e-5	Age-related disease endophenotypes;
TGCT	cis	rs10871290	0.881	rs4099290	chr16:74468889	A/G	cg01733217	chr16:74700730	RFWD3	-0.61	-5.8	-0.46	5.1e-8	Breast cancer;
TGCT	cis	rs2120019	1.000	rs2415255	chr15:75332412	A/G	cg09165964	chr15:75287851	SCAMP5	-1.14	-10.22	-0.68	3.76e-18	Blood trace element (Zn levels);
TGCT	cis	rs9733	0.596	rs11582840	chr1:150688487	A/G	cg09365446	chr1:150670422	GOLPH3L	0.3	4.52	0.38	1.4e-5	Tonsillectomy;
TGCT	cis	rs7582180	0.629	rs4851295	chr2:100945605	T/C	cg08017756	chr2:100939284	LONRF2	-0.3	-4.87	-0.4	3.27e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6988636	1.000	rs13259806	chr8:124190103	A/T	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs2239785	0.727	rs136156	chr22:36656442	C/A	cg15716373	chr22:36655542	APOL1	-0.43	-5.37	-0.43	3.8e-7	Glomerulosclerosis;
TGCT	cis	rs6089584	0.507	rs6061989	chr20:60627893	C/T	cg13770153	chr20:60521292	NA	-0.43	-5.15	-0.42	9.9e-7	Body mass index;
TGCT	cis	rs2153535	0.580	rs6597325	chr6:8461053	A/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs763121	0.853	rs2064088	chr22:39053382	A/G	cg06022373	chr22:39101656	GTPBP1	0.77	7.46	0.56	1.35e-11	Menopause (age at onset);
TGCT	cis	rs3741404	0.620	rs2236648	chr11:63964657	C/T	cg00022866	chr11:64108440	CCDC88B	0.24	4.51	0.38	1.47e-5	Platelet count;
TGCT	cis	rs3820068	0.705	rs4646083	chr1:15825564	G/A	cg05660106	chr1:15850417	CASP9	1.18	13.63	0.77	2.04e-26	Systolic blood pressure;
TGCT	cis	rs631288	0.793	rs10900331	chr1:146733128	C/G	cg25205988	chr1:146714368	CHD1L	1.25	6.03	0.48	1.7e-8	PR interval in Tripanosoma cruzi seropositivity;
TGCT	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.12	0.42	1.15e-6	Prudent dietary pattern;
TGCT	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg18230493	chr5:56204884	C5orf35	-0.68	-5.39	-0.44	3.35e-7	Initial pursuit acceleration;
TGCT	cis	rs10880689	1	rs10880689	chr12:37930102	A/G	cg26384229	chr12:38710491	ALG10B	0.85	7.82	0.57	1.94e-12	Resting heart rate;
TGCT	cis	rs12681288	0.676	rs35389636	chr8:1010613	G/T	cg04851639	chr8:1020857	NA	-0.28	-4.62	-0.38	9.42e-6	Schizophrenia;
TGCT	cis	rs9473924	0.505	rs9473938	chr6:50874050	C/T	cg14470998	chr6:50812995	TFAP2B	1.35	8.39	0.6	9.05e-14	Body mass index;
TGCT	cis	rs981844	0.816	rs62325148	chr4:154727993	A/G	cg14289246	chr4:154710475	SFRP2	1.03	9.04	0.63	2.61e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs7267979	0.932	rs6138600	chr20:25521346	A/T	cg16686733	chr20:25566563	NINL	0.56	5.69	0.46	8.49e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7655441	0.964	rs6824433	chr4:80857151	C/A	cg02241357	chr4:80885279	ANTXR2	-0.23	-4.46	-0.37	1.81e-5	Neutrophil percentage of white cells;
TGCT	cis	rs1857353	1.000	rs17584397	chr1:75894453	A/G	cg11838876	chr1:75668600	SLC44A5	-0.51	-4.81	-0.4	4.23e-6	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.48	-0.37	1.66e-5	Bipolar disorder;
TGCT	cis	rs7666738	0.791	rs7660866	chr4:98961335	G/A	cg17366294	chr4:99064904	C4orf37	0.74	7.56	0.56	7.89e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1729951	0.575	rs16844325	chr3:136678161	C/G	cg21827317	chr3:136751795	NA	0.4	5.61	0.45	1.28e-7	Neuroticism;
TGCT	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg11494091	chr17:61959527	GH2	0.42	6.96	0.53	1.76e-10	Height;
TGCT	trans	rs1814175	0.645	rs7103554	chr11:50027612	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.84	-0.7	1.13e-19	Height;
TGCT	cis	rs1629083	0.902	rs10892226	chr11:118096618	G/A	cg16594165	chr11:118135105	MPZL2	-0.33	-4.62	-0.38	9.3e-6	Lung cancer;
TGCT	cis	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.65	6.4	0.5	2.96e-9	Breast cancer;
TGCT	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg14983838	chr19:29218262	NA	0.83	6.76	0.52	4.75e-10	Methadone dose in opioid dependence;
TGCT	cis	rs11935103	0.569	rs7656763	chr4:187294858	C/G	cg16785698	chr4:186456103	PDLIM3	-0.46	-4.68	-0.39	7.45e-6	Response to citalopram treatment;
TGCT	cis	rs4727027	0.754	rs11764892	chr7:148858916	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.55	4.65	0.39	8.37e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs3733585	0.699	rs7437120	chr4:9967683	T/A	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.72	-0.52	5.82e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs6582630	0.537	rs12823925	chr12:38409323	C/T	cg26384229	chr12:38710491	ALG10B	0.84	7.51	0.56	1e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs1395	0.778	rs34618115	chr2:27418289	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.66	9.16	0.64	1.39e-15	Blood metabolite levels;
TGCT	cis	rs9858542	0.953	rs11711485	chr3:49491983	G/T	cg03060546	chr3:49711283	APEH	-0.62	-5.46	-0.44	2.52e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs7937840	0.501	rs4963459	chr11:61877137	G/A	cg05871569	chr11:61891931	INCENP	0.77	8.36	0.6	1.11e-13	Breast cancer;
TGCT	cis	rs7100689	0.646	rs11202725	chr10:82136276	A/G	cg01528321	chr10:82214614	TSPAN14	0.8	7.72	0.57	3.42e-12	Post bronchodilator FEV1;
TGCT	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg11764359	chr7:65958608	NA	0.59	5.28	0.43	5.53e-7	Aortic root size;
TGCT	cis	rs3020736	0.500	rs2839708	chr22:42500745	A/G	cg05082376	chr22:42548792	NA	0.23	5.43	0.44	2.83e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs694739	0.894	rs887314	chr11:64053157	T/G	cg02228329	chr11:64053129	BAD;GPR137	0.75	7.5	0.56	1.08e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs17076896	0.881	rs61956064	chr13:19928890	G/T	cg00777926	chr13:20807375	GJB6	-0.37	-4.51	-0.38	1.5e-5	Coronary artery aneurysm in Kawasaki disease;
TGCT	trans	rs2760061	0.819	rs1745417	chr1:228204279	C/T	cg16006296	chr10:38738647	LOC399744	-0.31	-7.21	-0.54	4.89e-11	Diastolic blood pressure;
TGCT	cis	rs950169	0.580	rs11633762	chr15:85187152	T/C	cg11189052	chr15:85197271	WDR73	0.75	6.21	0.49	7.32e-9	Schizophrenia;
TGCT	cis	rs4713675	0.553	rs943465	chr6:33731663	G/A	cg18005901	chr6:33739558	LEMD2	-0.51	-5.65	-0.45	1.05e-7	Plateletcrit;
TGCT	cis	rs1580019	0.563	rs896137	chr7:32579345	G/T	cg06627557	chr7:32535165	LSM5;AVL9	1.2	15.12	0.81	6.42e-30	Cognitive ability;
TGCT	cis	rs1215050	0.791	rs984940	chr4:98811756	T/A	cg17366294	chr4:99064904	C4orf37	0.54	5.79	0.46	5.38e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs6484504	0.532	rs12222329	chr11:31274340	T/C	cg26647111	chr11:31128758	NA	-0.35	-4.86	-0.4	3.44e-6	Red blood cell count;
TGCT	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg01341218	chr17:43662625	NA	-0.83	-7.37	-0.55	2.14e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2535633	0.631	rs2245424	chr3:53003021	G/C	cg05573699	chr3:52720067	GNL3;PBRM1	0.53	5.12	0.42	1.15e-6	Body mass index;
TGCT	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg10047753	chr17:41438598	NA	0.96	9.1	0.63	1.9e-15	Menopause (age at onset);
TGCT	cis	rs9807989	0.811	rs67088699	chr2:102968751	C/T	cg09003973	chr2:102972529	NA	0.64	5.7	0.46	8.28e-8	Asthma;
TGCT	cis	rs17376456	0.825	rs10038828	chr5:93124056	C/T	cg25358565	chr5:93447407	FAM172A	0.9	7.65	0.57	4.86e-12	Diabetic retinopathy;
TGCT	cis	rs7621025	0.500	rs9845460	chr3:136587117	A/G	cg15507776	chr3:136538369	TMEM22	0.67	6.26	0.49	5.69e-9	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
TGCT	cis	rs4566357	0.615	rs12328878	chr2:227918962	G/A	cg11843606	chr2:227700838	RHBDD1	-0.55	-5.26	-0.43	6.22e-7	Coronary artery disease;
TGCT	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg06108461	chr20:60628389	TAF4	-0.69	-10.64	-0.69	3.59e-19	Body mass index;
TGCT	cis	rs9653442	0.527	rs10185059	chr2:100790172	C/T	cg07810366	chr2:100720526	AFF3	-0.36	-5.25	-0.43	6.45e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs56309584	0.596	rs8075078	chr17:8186096	C/T	cg08322244	chr17:8066669	VAMP2	-0.57	-5.31	-0.43	4.95e-7	Initial pursuit acceleration;
TGCT	cis	rs4911253	0.527	rs853859	chr20:31402269	A/G	cg13636640	chr20:31349939	DNMT3B	0.8	8.49	0.61	5.39e-14	Lymphocyte counts;
TGCT	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg13770153	chr20:60521292	NA	-0.47	-6.01	-0.48	1.9e-8	Body mass index;
TGCT	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.7	-0.39	6.79e-6	Prudent dietary pattern;
TGCT	cis	rs1153858	0.945	rs2467854	chr15:45701597	A/G	cg26924012	chr15:45694286	SPATA5L1	0.99	12.38	0.74	2.11e-23	Homoarginine levels;
TGCT	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	8.13	0.59	3.82e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	trans	rs1908814	0.516	rs10112958	chr8:11793140	A/G	cg15556689	chr8:8085844	FLJ10661	0.77	7.37	0.55	2.13e-11	Neuroticism;
TGCT	trans	rs1814175	0.645	rs7952104	chr11:49964180	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.67	-0.69	2.92e-19	Height;
TGCT	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg16049864	chr8:95962084	TP53INP1	-0.75	-10.28	-0.68	2.7e-18	Type 2 diabetes;
TGCT	cis	rs6500602	0.727	rs4786515	chr16:4578133	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.32	5.95	0.47	2.54e-8	Schizophrenia;
TGCT	cis	rs2014572	0.933	rs8109882	chr19:57755618	C/G	cg24459738	chr19:57751996	ZNF805	-0.54	-5.4	-0.44	3.21e-7	Hyperactive-impulsive symptoms;
TGCT	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg22920501	chr2:26401640	FAM59B	0.72	6.38	0.5	3.19e-9	Gut microbiome composition (summer);
TGCT	cis	rs8180040	0.615	rs13062681	chr3:47021124	A/G	cg27129171	chr3:47204927	SETD2	0.73	9.42	0.65	3.15e-16	Colorectal cancer;
TGCT	cis	rs548181	0.545	rs1054997	chr11:125618813	G/A	cg03464685	chr11:125439445	EI24	-1.31	-7.78	-0.57	2.47e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs13191362	0.872	rs35443919	chr6:163055804	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.91	6.86	0.52	2.88e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs941873	0.868	rs7898	chr10:81114959	C/T	cg09469691	chr10:81107165	PPIF	0.55	5.42	0.44	2.93e-7	Height;
TGCT	cis	rs3087591	0.960	rs11870097	chr17:29448097	C/T	cg24425628	chr17:29625626	OMG;NF1	0.47	7.3	0.55	3.03e-11	Hip circumference;
TGCT	cis	rs7666738	0.830	rs1426669	chr4:98945534	C/T	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28493229	0.521	rs2604878	chr19:41191971	G/C	cg11601297	chr19:41224147	ITPKC;ADCK4	0.48	4.62	0.38	9.44e-6	Kawasaki disease;
TGCT	cis	rs12908161	1.000	rs56864281	chr15:85357649	C/A	cg17173187	chr15:85201210	NMB	0.57	6.35	0.5	3.63e-9	Schizophrenia;
TGCT	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg04414720	chr1:150670196	GOLPH3L	0.39	5.04	0.41	1.58e-6	Tonsillectomy;
TGCT	cis	rs3741151	1.000	rs57893472	chr11:73042826	C/T	cg17517138	chr11:73019481	ARHGEF17	0.97	4.96	0.41	2.28e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
TGCT	cis	rs3733585	0.699	rs4515163	chr4:9959603	C/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.67	-0.51	7.44e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs9443645	0.901	rs6937465	chr6:79570345	G/T	cg05283184	chr6:79620031	NA	-0.22	-4.98	-0.41	2.11e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4383453	0.539	rs56712020	chr3:123099368	G/A	cg04890266	chr3:123102914	ADCY5	-0.5	-8.34	-0.6	1.2e-13	Gestational age at birth (maternal effect);
TGCT	cis	rs7178572	0.568	rs7166927	chr15:77673459	A/G	cg22256960	chr15:77711686	NA	0.88	9.16	0.64	1.32e-15	Type 2 diabetes;
TGCT	cis	rs6665290	0.669	rs3768424	chr1:227177444	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.91	-15.21	-0.81	4.04e-30	Myeloid white cell count;
TGCT	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg21862992	chr11:68658383	NA	0.47	6.45	0.5	2.29e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs11785400	0.793	rs4587307	chr8:143738529	G/A	cg10596483	chr8:143751796	JRK	0.55	5.48	0.44	2.29e-7	Schizophrenia;
TGCT	cis	rs765787	0.530	rs4270107	chr15:45535350	A/G	cg24006582	chr15:45444508	DUOX1	-0.25	-5.54	-0.45	1.76e-7	Uric acid levels;
TGCT	cis	rs12220238	0.841	rs10824146	chr10:76076779	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.87	6.44	0.5	2.37e-9	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs57590327	0.679	rs62265397	chr3:81543883	A/T	cg07356753	chr3:81810745	GBE1	-0.55	-4.54	-0.38	1.3e-5	Extraversion;
TGCT	cis	rs1215050	0.740	rs185468	chr4:98756242	C/T	cg17366294	chr4:99064904	C4orf37	0.52	5.61	0.45	1.27e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs6722750	0.783	rs11125991	chr2:64387765	A/G	cg22352474	chr2:64371530	PELI1	0.67	6.33	0.49	4e-9	Neuroticism;
TGCT	cis	rs62244186	0.566	rs55852922	chr3:44826188	A/G	cg11003573	chr3:44754125	ZNF502	-0.47	-5.44	-0.44	2.75e-7	Depressive symptoms;
TGCT	cis	rs9443645	0.901	rs2050662	chr6:79753073	G/C	cg09184832	chr6:79620586	NA	-0.48	-5.34	-0.43	4.21e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7726839	0.540	rs3749615	chr5:601485	C/T	cg20362242	chr5:692897	TPPP	0.51	4.54	0.38	1.33e-5	Obesity-related traits;
TGCT	cis	rs1153858	1.000	rs1719247	chr15:45620985	C/T	cg26924012	chr15:45694286	SPATA5L1	0.97	11.56	0.72	2.03e-21	Homoarginine levels;
TGCT	cis	rs9811920	0.535	rs792833	chr3:99475268	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.39	-4.6	-0.38	1.04e-5	Axial length;
TGCT	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.39	-0.5	3.02e-9	Alzheimer's disease;
TGCT	cis	rs1153858	1.000	rs67831559	chr15:45649307	G/T	cg26924012	chr15:45694286	SPATA5L1	1.09	15.16	0.81	5.15e-30	Homoarginine levels;
TGCT	cis	rs2180341	1.000	rs6904520	chr6:127629802	T/C	cg27446573	chr6:127587934	RNF146	1.12	10.11	0.67	6.87e-18	Breast cancer;
TGCT	cis	rs2075371	0.673	rs35290398	chr7:134011773	C/T	cg11752832	chr7:134001865	SLC35B4	0.62	5.18	0.42	8.84e-7	Mean platelet volume;
TGCT	cis	rs2549003	1.000	rs2548999	chr5:131831058	G/T	cg00255919	chr5:131827918	IRF1	-0.2	-4.71	-0.39	6.59e-6	Asthma (sex interaction);
TGCT	cis	rs12791968	1.000	rs11038237	chr11:45001880	C/T	cg11846598	chr11:44996168	LOC221122	-0.35	-6.65	-0.51	8.24e-10	Inhibitory control;
TGCT	cis	rs950776	0.518	rs56007453	chr15:78826239	T/C	cg06917634	chr15:78832804	PSMA4	0.95	9.52	0.65	1.81e-16	Sudden cardiac arrest;
TGCT	cis	rs1838472	0.607	rs11929003	chr3:123979321	A/G	cg19008133	chr3:123124015	ADCY5	-0.19	-4.84	-0.4	3.74e-6	Schizophrenia;
TGCT	cis	rs9640161	0.789	rs1464753	chr7:150021350	G/C	cg10018233	chr7:150070692	REPIN1	0.32	4.63	0.38	8.94e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs1865760	1.000	rs3830057	chr6:25918510	G/T	cg16482183	chr6:26056742	HIST1H1C	0.51	4.55	0.38	1.25e-5	Height;
TGCT	cis	rs3796352	1.000	rs11720191	chr3:53013839	T/C	cg07884673	chr3:53033167	SFMBT1	0.62	6.19	0.49	8.26e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg07157834	chr1:205819609	PM20D1	0.34	5.06	0.41	1.46e-6	Menarche (age at onset);
TGCT	cis	rs7818688	0.697	rs60003497	chr8:95983423	A/T	cg16049864	chr8:95962084	TP53INP1	0.54	4.64	0.38	8.87e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs6725041	0.792	rs1546719	chr2:213088582	G/C	cg20637307	chr2:213403960	ERBB4	-0.52	-4.47	-0.37	1.72e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs858239	0.539	rs28624974	chr7:23188936	T/C	cg05602783	chr7:23145260	KLHL7	-0.62	-5.03	-0.41	1.67e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs2028414	0.512	rs752265	chr14:105361934	T/C	cg16576083	chr14:105354267	KIAA0284	0.3	4.72	0.39	6.29e-6	IgG glycosylation;
TGCT	cis	rs2033711	0.936	rs882609	chr19:58991479	G/A	cg04608855	chr19:58913158	NA	0.51	4.68	0.39	7.5e-6	Uric acid clearance;
TGCT	cis	rs4711350	0.953	rs1547668	chr6:33775446	A/G	cg00334056	chr6:33755658	LEMD2	-0.3	-4.93	-0.41	2.54e-6	Schizophrenia;
TGCT	cis	rs2439831	0.850	rs28707214	chr15:44131623	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.9	6.3	0.49	4.62e-9	Lung cancer in ever smokers;
TGCT	cis	rs6582630	0.555	rs10880611	chr12:38509316	C/G	cg13010199	chr12:38710504	ALG10B	0.6	4.88	0.4	3.15e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs2840044	1.000	rs225262	chr17:33959697	A/G	cg05299278	chr17:33885742	SLFN14	0.22	4.98	0.41	2.07e-6	Response to radiotherapy in cancer (late toxicity);
TGCT	cis	rs8017423	0.967	rs6575117	chr14:90715412	G/A	cg04374321	chr14:90722782	PSMC1	0.74	7.74	0.57	2.98e-12	Mortality in heart failure;
TGCT	cis	rs2074977	0.530	rs10401784	chr19:3445721	A/C	cg08380311	chr19:3435252	NFIC	0.72	6.74	0.52	5.35e-10	Height;
TGCT	cis	rs78366141	0.649	rs78114325	chr4:89682189	T/C	cg01026744	chr4:89619053	NAP1L5;HERC3	1.15	5.23	0.43	6.86e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
TGCT	cis	rs732765	0.819	rs2058920	chr14:75311329	C/T	cg06637938	chr14:75390232	RPS6KL1	0.6	5.2	0.42	7.87e-7	Non-small cell lung cancer;
TGCT	cis	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg20637647	chr7:64974828	NA	0.89	4.99	0.41	2.01e-6	Diabetic kidney disease;
TGCT	cis	rs7786808	0.530	rs7780796	chr7:158183330	C/T	cg01191920	chr7:158217561	PTPRN2	0.35	4.96	0.41	2.26e-6	Obesity-related traits;
TGCT	cis	rs4727027	0.901	rs1534198	chr7:148772323	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	4.99	0.41	2.02e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs1483890	0.723	rs34184121	chr3:69411426	A/T	cg22125112	chr3:69402811	FRMD4B	0.29	4.74	0.39	5.85e-6	Resting heart rate;
TGCT	cis	rs3796352	1.000	rs34979715	chr3:53048960	G/A	cg15956490	chr3:53032818	SFMBT1	0.62	6.82	0.52	3.6e-10	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs4901869	0.902	rs2162491	chr14:59296247	C/T	cg02291164	chr14:59296302	NA	0.27	5.19	0.42	8.43e-7	Panic disorder;
TGCT	cis	rs7918232	1.000	rs7918232	chr10:27369162	A/G	cg14442939	chr10:27389572	ANKRD26	0.74	5.47	0.44	2.35e-7	Breast cancer;
TGCT	cis	rs4819852	1.000	rs1034566	chr22:19984277	C/T	cg07821417	chr22:19972146	ARVCF	0.2	5.08	0.41	1.36e-6	Pulse pressure;
TGCT	cis	rs2073300	1.000	rs17830565	chr20:23444805	G/A	cg09953122	chr20:23471693	CST8	-0.64	-4.56	-0.38	1.19e-5	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs9611565	0.512	rs4820446	chr22:42215684	C/T	cg13695892	chr22:41940480	POLR3H	-0.85	-8.05	-0.59	5.63e-13	Vitiligo;
TGCT	cis	rs9341808	0.935	rs942381	chr6:80880150	T/G	cg08355045	chr6:80787529	NA	0.27	4.69	0.39	6.96e-6	Sitting height ratio;
TGCT	cis	rs7590720	1.000	rs6435930	chr2:216885852	A/G	cg12620499	chr2:216877984	MREG	0.85	9.27	0.64	7.33e-16	Alcohol dependence;
TGCT	cis	rs763121	0.853	rs2267393	chr22:39101619	G/C	cg06022373	chr22:39101656	GTPBP1	0.78	8.1	0.59	4.34e-13	Menopause (age at onset);
TGCT	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6460942	0.908	rs6978367	chr7:12232347	A/G	cg06484146	chr7:12443880	VWDE	-0.53	-4.6	-0.38	1.03e-5	Coronary artery disease;
TGCT	cis	rs60843830	1.000	rs60484953	chr2:221560	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.73	6.57	0.51	1.28e-9	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs2153535	0.580	rs9406158	chr6:8464152	C/T	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	trans	rs7824557	0.545	rs2736303	chr8:11236850	C/T	cg15556689	chr8:8085844	FLJ10661	-0.74	-6.68	-0.51	7.12e-10	Retinal vascular caliber;
TGCT	cis	rs61990749	0.597	rs1978416	chr14:78227901	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.62	4.58	0.38	1.13e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs6598955	0.670	rs7520517	chr1:26556385	A/C	cg04990556	chr1:26633338	UBXN11	-0.91	-11.87	-0.73	3.59e-22	Obesity-related traits;
TGCT	cis	rs2842992	0.915	rs2758350	chr6:160118056	A/G	cg11366901	chr6:160182831	ACAT2	0.94	6.18	0.49	8.48e-9	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs6430585	0.527	rs2304366	chr2:136467119	C/T	cg07169764	chr2:136633963	MCM6	1.01	9.32	0.64	5.68e-16	Corneal structure;
TGCT	cis	rs68170813	0.559	rs76843318	chr7:106863173	A/G	cg02696742	chr7:106810147	HBP1	-0.69	-5.61	-0.45	1.27e-7	Coronary artery disease;
TGCT	cis	rs6121246	0.821	rs115585940	chr20:30317902	T/C	cg13852791	chr20:30311386	BCL2L1	0.66	4.55	0.38	1.25e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs1475911	1.000	rs2839466	chr21:43512324	A/G	cg19766460	chr21:43528205	UMODL1;C21orf128	-0.57	-7.85	-0.58	1.67e-12	IgG glycosylation;
TGCT	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg11494091	chr17:61959527	GH2	0.6	14.54	0.79	1.46e-28	Prudent dietary pattern;
TGCT	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.09	13.28	0.77	1.38e-25	Height;
TGCT	cis	rs17376456	0.877	rs13185660	chr5:93336500	G/A	cg21475434	chr5:93447410	FAM172A	0.63	4.77	0.39	5.14e-6	Diabetic retinopathy;
TGCT	cis	rs9911578	1.000	rs368186	chr17:56736659	A/G	cg05425664	chr17:57184151	TRIM37	-0.64	-6.48	-0.5	1.99e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs4566357	0.964	rs6436648	chr2:227923004	C/A	cg11843606	chr2:227700838	RHBDD1	-0.58	-5.31	-0.43	4.92e-7	Coronary artery disease;
TGCT	cis	rs13256369	0.901	rs13251887	chr8:8568678	G/A	cg06671706	chr8:8559999	CLDN23	0.34	4.57	0.38	1.18e-5	Obesity-related traits;
TGCT	cis	rs3806843	0.547	rs246033	chr5:140332115	A/C	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2777491	0.957	rs7163788	chr15:41704789	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.75	-10.9	-0.7	8.27e-20	Ulcerative colitis;
TGCT	cis	rs6074578	0.649	rs1935387	chr20:137127	A/G	cg16931068	chr20:139680	DEFB127	-0.27	-4.88	-0.4	3.26e-6	Hirschsprung disease;
TGCT	cis	rs6430585	0.583	rs2322813	chr2:136582809	A/G	cg07169764	chr2:136633963	MCM6	1.22	11.84	0.73	4.08e-22	Corneal structure;
TGCT	cis	rs7647973	0.922	rs7620024	chr3:49451691	G/A	cg07636037	chr3:49044803	WDR6	-0.69	-5.67	-0.45	9.43e-8	Menarche (age at onset);
TGCT	cis	rs35160687	0.901	rs12478653	chr2:86535394	A/C	cg03171300	chr2:86307199	POLR1A	-0.28	-4.81	-0.4	4.33e-6	Night sleep phenotypes;
TGCT	cis	rs1008375	1.000	rs10805358	chr4:17652450	A/C	cg10189774	chr4:17578691	LAP3	0.57	5.24	0.43	6.8e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4499344	0.696	rs398990	chr19:33104244	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	8.81	0.62	9.52e-15	Mean platelet volume;
TGCT	cis	rs1401999	1.000	rs13317532	chr3:183641669	G/C	cg01324343	chr3:183735012	ABCC5	0.85	11.45	0.72	3.69e-21	Anterior chamber depth;
TGCT	trans	rs1814175	0.645	rs11040703	chr11:50024961	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.84	-0.7	1.13e-19	Height;
TGCT	cis	rs2013441	1.000	rs2703789	chr17:20162923	G/A	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.63	-0.38	9.19e-6	Obesity-related traits;
TGCT	cis	rs11671005	0.693	rs11666928	chr19:58914231	A/G	cg13877915	chr19:58951672	ZNF132	0.66	4.9	0.4	2.94e-6	Mean platelet volume;
TGCT	cis	rs36051895	0.632	rs10121316	chr9:5147539	C/T	cg02405213	chr9:5042618	JAK2	0.73	10.1	0.67	7.06e-18	Pediatric autoimmune diseases;
TGCT	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.46	-5.47	-0.44	2.33e-7	Longevity;Endometriosis;
TGCT	cis	rs3796352	0.881	rs35384050	chr3:53008769	G/T	cg15956490	chr3:53032818	SFMBT1	0.61	6.76	0.52	4.92e-10	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs9926296	0.744	rs164749	chr16:89708224	A/C	cg01097406	chr16:89675127	NA	0.33	6.27	0.49	5.37e-9	Vitiligo;
TGCT	cis	rs3796352	0.881	rs34238610	chr3:53026480	A/T	cg27565382	chr3:53032988	SFMBT1	0.45	4.58	0.38	1.14e-5	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs10501293	0.746	rs7952577	chr11:43017703	G/A	cg03447554	chr11:43094025	NA	0.43	6.14	0.48	1.03e-8	Cognitive performance;
TGCT	cis	rs858239	0.600	rs4409314	chr7:23127952	T/C	cg05602783	chr7:23145260	KLHL7	-0.7	-6.08	-0.48	1.37e-8	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs9308731	0.644	rs4627572	chr2:111873378	T/C	cg04202892	chr2:111875749	ACOXL	0.55	6.29	0.49	4.97e-9	Chronic lymphocytic leukemia;
TGCT	cis	rs12908161	0.959	rs34784022	chr15:85231906	T/C	cg17173187	chr15:85201210	NMB	0.59	6.74	0.52	5.44e-10	Schizophrenia;
TGCT	cis	rs4727027	0.870	rs62507512	chr7:148799338	C/T	cg23583168	chr7:148888333	NA	-0.72	-9.11	-0.63	1.8e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs67311347	0.955	rs11719205	chr3:40417258	G/A	cg13683864	chr3:40499215	RPL14	-1.04	-10.79	-0.7	1.54e-19	Renal cell carcinoma;
TGCT	cis	rs933688	0.941	rs6452954	chr5:90735692	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.07	10.69	0.69	2.68e-19	Smoking behavior;
TGCT	cis	rs6460942	0.915	rs75158182	chr7:12456059	C/T	cg06484146	chr7:12443880	VWDE	-0.57	-5.52	-0.44	1.92e-7	Coronary artery disease;
TGCT	trans	rs77457752	0.523	rs9696661	chr9:13901539	T/C	cg25510823	chr7:47085976	NA	0.45	6.68	0.51	7.04e-10	Breast cancer;
TGCT	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg18402987	chr7:1209562	NA	0.7	5.67	0.45	9.66e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7681440	0.669	rs6814481	chr4:90805660	C/T	cg20003494	chr4:90757398	SNCA	-0.54	-4.76	-0.39	5.34e-6	Dementia with Lewy bodies;
TGCT	cis	rs62244186	0.520	rs2372828	chr3:44784949	A/G	cg04389838	chr3:44770851	ZNF501	0.37	4.83	0.4	4.02e-6	Depressive symptoms;
TGCT	cis	rs7586879	0.593	rs10200566	chr2:25130462	G/T	cg01884057	chr2:25150051	NA	-0.33	-6.28	-0.49	5.26e-9	Body mass index;
TGCT	cis	rs1113500	0.547	rs12076264	chr1:108557108	G/A	cg22161131	chr1:109420278	GPSM2	-0.6	-5.83	-0.46	4.49e-8	Growth-regulated protein alpha levels;
TGCT	trans	rs2688608	0.592	rs7908825	chr10:75554541	C/G	cg13918328	chr10:52500089	ASAH2B	-0.68	-6.78	-0.52	4.3e-10	Inflammatory bowel disease;
TGCT	cis	rs739401	0.611	rs2071104	chr11:3036933	G/T	cg05729581	chr11:3078854	CARS	-0.54	-5.13	-0.42	1.07e-6	Longevity;
TGCT	cis	rs2832191	0.646	rs2832214	chr21:30517127	C/T	cg24692254	chr21:30365293	RNF160	-0.61	-5.31	-0.43	4.91e-7	Dental caries;
TGCT	cis	rs6582630	0.537	rs7299661	chr12:38527713	C/T	cg26384229	chr12:38710491	ALG10B	0.85	7.84	0.58	1.81e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs7666738	0.830	rs60007031	chr4:98824753	G/C	cg05340658	chr4:99064831	C4orf37	0.51	6.03	0.48	1.76e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7267979	1.000	rs6083809	chr20:25329309	A/G	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6815814	0.851	rs4129009	chr4:38774889	T/C	cg02016764	chr4:38805732	TLR1	-0.35	-5.55	-0.45	1.69e-7	Breast cancer;
TGCT	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg01874867	chr7:94954059	PON1	0.33	4.87	0.4	3.37e-6	Paraoxonase activity;
TGCT	cis	rs626457	0.883	rs682479	chr1:57375718	C/A	cg14377849	chr1:56539619	NA	-0.35	-4.43	-0.37	2.01e-5	Blood protein levels;
TGCT	cis	rs1878931	0.517	rs17685105	chr16:3413749	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.82	-8.95	-0.63	4.33e-15	Body mass index (adult);
TGCT	cis	rs61990749	0.597	rs6574402	chr14:78267950	C/A	cg02301378	chr14:78227641	SNW1;C14orf178	0.6	4.45	0.37	1.88e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg17554472	chr22:41940697	POLR3H	-0.5	-5.36	-0.43	3.95e-7	Vitiligo;
TGCT	cis	rs3796352	1.000	rs34943350	chr3:53012888	C/T	cg27565382	chr3:53032988	SFMBT1	0.45	4.58	0.38	1.14e-5	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs2836974	0.545	rs3167757	chr21:40714478	C/T	cg11890956	chr21:40555474	PSMG1	0.75	7.46	0.56	1.29e-11	Cognitive function;
TGCT	cis	rs10501293	0.625	rs7944433	chr11:42999452	A/T	cg03447554	chr11:43094025	NA	-0.42	-6.09	-0.48	1.31e-8	Cognitive performance;
TGCT	cis	rs4253772	0.591	rs11704586	chr22:46685274	T/C	cg24881330	chr22:46731750	TRMU	1.04	5.38	0.44	3.54e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs11719291	0.833	rs13074318	chr3:48816725	C/T	cg07636037	chr3:49044803	WDR6	-1.0	-4.9	-0.4	2.93e-6	Cognitive function;
TGCT	cis	rs3617	0.539	rs12629687	chr3:52950659	T/C	cg11645453	chr3:52864694	ITIH4	-0.26	-5.01	-0.41	1.81e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg12311346	chr5:56204834	C5orf35	0.57	6.09	0.48	1.28e-8	Initial pursuit acceleration;
TGCT	cis	rs8017423	0.845	rs114583024	chr14:90727628	T/C	cg04374321	chr14:90722782	PSMC1	0.76	7.63	0.57	5.3e-12	Mortality in heart failure;
TGCT	cis	rs6496667	0.632	rs6496658	chr15:90884105	A/G	cg22089800	chr15:90895588	ZNF774	0.62	5.3	0.43	5.2e-7	Rheumatoid arthritis;
TGCT	cis	rs9467711	0.606	rs66823108	chr6:26377939	G/A	cg10795676	chr6:26370623	BTN3A2	-0.47	-4.77	-0.39	5.18e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4711336	0.935	rs754404	chr6:33664730	T/C	cg14003231	chr6:33640908	ITPR3	0.28	4.58	0.38	1.13e-5	Height;
TGCT	cis	rs4478858	0.735	rs7523509	chr1:31788329	A/G	cg07478791	chr1:31886160	SERINC2	-0.47	-4.51	-0.38	1.47e-5	Alcohol dependence;
TGCT	trans	rs28735056	0.967	rs56328473	chr18:77636101	C/T	cg05926928	chr17:57297772	GDPD1	-0.71	-7.64	-0.57	5e-12	Schizophrenia;
TGCT	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.18	0.49	8.46e-9	Electroencephalogram traits;
TGCT	cis	rs916888	0.821	rs199504	chr17:44861003	C/T	cg15921436	chr17:44337874	NA	-0.51	-6.92	-0.53	2.11e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs12477438	0.501	rs6751927	chr2:99740175	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.89	9.0	0.63	3.26e-15	Chronic sinus infection;
TGCT	cis	rs909674	0.818	rs8136980	chr22:39844574	G/A	cg05872129	chr22:39784769	NA	-0.98	-10.17	-0.67	4.81e-18	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs8033133	0.647	rs1124767	chr15:25326173	T/C	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	-0.25	-4.95	-0.41	2.37e-6	Blood osmolality (transformed sodium);
TGCT	cis	rs6500602	0.702	rs56895104	chr16:4548132	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.31	5.65	0.45	1.02e-7	Schizophrenia;
TGCT	cis	rs806215	0.901	rs989100	chr7:127220918	T/C	cg25922125	chr7:127225783	GCC1	-0.6	-6.2	-0.49	7.6e-9	Type 2 diabetes;
TGCT	cis	rs4478858	0.662	rs6425735	chr1:31783945	T/C	cg07478791	chr1:31886160	SERINC2	-0.48	-4.61	-0.38	1e-5	Alcohol dependence;
TGCT	cis	rs2066819	1.000	rs2629447	chr12:56700809	G/A	cg26714650	chr12:56694279	CS	1.53	8.28	0.6	1.67e-13	Psoriasis vulgaris;
TGCT	cis	rs7809950	1.000	rs12668402	chr7:107173020	G/A	cg23024343	chr7:107201750	COG5	-0.35	-5.55	-0.45	1.67e-7	Coronary artery disease;
TGCT	cis	rs35306767	0.715	rs17221456	chr10:1037234	T/C	cg26597838	chr10:835615	NA	0.63	7.0	0.53	1.45e-10	Eosinophil percentage of granulocytes;
TGCT	cis	rs2455799	0.545	rs9815740	chr3:15867632	A/G	cg12172478	chr3:16357591	RFTN1	-0.31	-4.74	-0.39	5.64e-6	Mean platelet volume;
TGCT	cis	rs4900538	0.821	rs8016191	chr14:102825340	G/A	cg18135206	chr14:102964638	TECPR2	-0.2	-4.86	-0.4	3.45e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs8038465	0.622	rs56712926	chr15:73886849	G/T	cg15420318	chr15:73925796	NPTN	0.67	7.07	0.54	9.91e-11	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6570726	0.791	rs12205752	chr6:145896118	A/G	cg23711669	chr6:146136114	FBXO30	0.86	9.54	0.65	1.64e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2485376	0.813	rs56238324	chr10:104149814	C/G	cg26089160	chr10:104170217	PSD	0.52	5.09	0.42	1.3e-6	QT interval;
TGCT	cis	rs6570726	0.935	rs454614	chr6:145832633	C/T	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg17554472	chr22:41940697	POLR3H	-0.47	-4.89	-0.4	3.06e-6	Vitiligo;
TGCT	trans	rs7726839	0.718	rs6887972	chr5:597274	C/G	cg25482853	chr8:67687455	SGK3	0.97	7.64	0.57	5.1e-12	Obesity-related traits;
TGCT	cis	rs9911578	0.967	rs4932693	chr17:57110327	T/C	cg05425664	chr17:57184151	TRIM37	0.66	6.48	0.5	1.92e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs17376456	0.825	rs55724660	chr5:93276636	A/G	cg25358565	chr5:93447407	FAM172A	1.02	8.11	0.59	4.23e-13	Diabetic retinopathy;
TGCT	cis	rs6570726	0.935	rs415590	chr6:145851244	T/C	cg23711669	chr6:146136114	FBXO30	0.68	6.67	0.51	7.58e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg06112835	chr11:68658793	MRPL21	-0.47	-8.29	-0.6	1.58e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	trans	rs561341	0.714	rs473535	chr17:30312365	A/G	cg20587970	chr11:113659929	NA	-1.03	-12.33	-0.74	2.79e-23	Hip circumference adjusted for BMI;
TGCT	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg24829409	chr8:58192753	C8orf71	-0.57	-5.35	-0.43	4.14e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7666738	0.830	rs28516388	chr4:98987449	A/G	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs858239	0.676	rs3807459	chr7:23389751	T/C	cg05602783	chr7:23145260	KLHL7	-0.6	-5.07	-0.41	1.43e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg20007245	chr22:24372913	LOC391322	-0.69	-6.87	-0.52	2.81e-10	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9906944	0.707	rs8068981	chr17:47122525	T/C	cg20966754	chr17:47091339	IGF2BP1	-0.45	-5.17	-0.42	9.27e-7	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs477895	0.838	rs2001003	chr11:64018687	C/A	cg23719950	chr11:63933701	MACROD1	-0.69	-5.74	-0.46	6.94e-8	Mean platelet volume;
TGCT	cis	rs1801251	1.000	rs13003675	chr2:233584109	C/T	cg25237894	chr2:233734115	C2orf82	0.32	5.81	0.46	5.01e-8	Coronary artery disease;
TGCT	cis	rs10492096	0.947	rs10849483	chr12:6635374	G/A	cg00459232	chr12:6309025	CD9	0.36	4.47	0.37	1.77e-5	Hip geometry;
TGCT	cis	rs2933343	0.649	rs789216	chr3:128594503	A/C	cg11901034	chr3:128598214	ACAD9	-0.63	-5.98	-0.47	2.23e-8	IgG glycosylation;
TGCT	cis	rs2204008	0.805	rs3863360	chr12:37966432	C/T	cg13010199	chr12:38710504	ALG10B	0.61	4.89	0.4	3.05e-6	Bladder cancer;
TGCT	cis	rs3770081	1.000	rs1561328	chr2:86272758	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.18	-4.81	-0.4	4.33e-6	Facial emotion recognition (sad faces);
TGCT	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg15556689	chr8:8085844	FLJ10661	0.65	5.94	0.47	2.72e-8	Mood instability;
TGCT	cis	rs1153858	0.887	rs7164139	chr15:45670851	G/A	cg14582100	chr15:45693742	SPATA5L1	0.49	5.73	0.46	7.14e-8	Homoarginine levels;
TGCT	cis	rs7659604	0.676	rs6534323	chr4:122695888	G/A	cg06713675	chr4:122721982	EXOSC9	-0.6	-8.14	-0.59	3.6e-13	Type 2 diabetes;
TGCT	cis	rs9443645	0.901	rs9352666	chr6:79572184	C/G	cg09184832	chr6:79620586	NA	-0.48	-5.17	-0.42	9.23e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.41	5.66	0.45	1.01e-7	Lymphocyte counts;
TGCT	cis	rs586688	1.000	rs1736448	chr1:201644091	C/G	cg05779441	chr1:201574716	NA	0.29	4.69	0.39	7.05e-6	Obesity-related traits;
TGCT	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg24531977	chr5:56204891	C5orf35	0.97	9.1	0.63	1.86e-15	Initial pursuit acceleration;
TGCT	cis	rs1577917	0.958	rs11752180	chr6:86573165	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.47	-0.44	2.33e-7	Response to antipsychotic treatment;
TGCT	cis	rs231513	0.954	rs231500	chr17:41973374	T/C	cg26893861	chr17:41843967	DUSP3	-0.71	-5.33	-0.43	4.45e-7	Cognitive function;
TGCT	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.61	4.9	0.4	2.91e-6	Lung function (FEV1/FVC);
TGCT	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg07507251	chr3:52567010	NT5DC2	0.49	6.7	0.52	6.38e-10	Bipolar disorder;
TGCT	cis	rs8180040	0.966	rs807932	chr3:47354241	C/T	cg27129171	chr3:47204927	SETD2	0.7	8.88	0.62	6.43e-15	Colorectal cancer;
TGCT	cis	rs986417	0.540	rs10144415	chr14:61112667	G/C	cg27398547	chr14:60952738	C14orf39	1.55	10.36	0.68	1.66e-18	Gut microbiota (bacterial taxa);
TGCT	cis	rs6543140	0.964	rs1523205	chr2:103070176	G/T	cg09003973	chr2:102972529	NA	0.55	4.67	0.39	7.71e-6	Blood protein levels;
TGCT	cis	rs7617773	0.780	rs13082158	chr3:48372470	T/C	cg11946769	chr3:48343235	NME6	0.81	6.96	0.53	1.71e-10	Coronary artery disease;
TGCT	cis	rs10032931	1.000	rs10032931	chr4:96458433	T/C	cg17031751	chr4:96469067	UNC5C	-0.42	-5.12	-0.42	1.14e-6	Optic nerve measurement (cup-to-disc ratio);
TGCT	cis	rs16854884	0.657	rs16854819	chr3:143736126	C/T	cg06585982	chr3:143692056	C3orf58	-0.56	-4.53	-0.38	1.37e-5	Economic and political preferences (feminism/equality);
TGCT	cis	rs1008375	1.000	rs7688682	chr4:17693794	A/G	cg18681998	chr4:17616180	MED28	-0.76	-7.12	-0.54	7.85e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg06618935	chr21:46677482	NA	-0.38	-5.69	-0.45	8.75e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7412746	0.611	rs752376	chr1:150941381	C/T	cg04414720	chr1:150670196	GOLPH3L	0.38	4.5	0.37	1.52e-5	Melanoma;
TGCT	cis	rs1163251	0.729	rs686362	chr1:120221011	T/C	cg19096424	chr1:120255104	PHGDH	0.6	6.12	0.48	1.16e-8	Blood metabolite levels;
TGCT	cis	rs9389248	0.690	rs2064101	chr6:135250530	G/A	cg22676075	chr6:135203613	NA	-0.51	-5.11	-0.42	1.17e-6	High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs3125734	0.633	rs7088891	chr10:64034019	G/T	cg09941381	chr10:64027924	RTKN2	-0.37	-5.65	-0.45	1.04e-7	Rheumatoid arthritis;
TGCT	cis	rs4499344	0.556	rs259225	chr19:33135458	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.82	8.26	0.6	1.84e-13	Mean platelet volume;
TGCT	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg19723775	chr5:179050963	HNRNPH1	0.52	5.33	0.43	4.51e-7	Lung cancer;
TGCT	cis	rs986417	1.000	rs1956875	chr14:60846212	T/C	cg27398547	chr14:60952738	C14orf39	-1.45	-10.38	-0.68	1.52e-18	Gut microbiota (bacterial taxa);
TGCT	cis	rs2806561	0.734	rs1952527	chr1:23400969	T/C	cg12483005	chr1:23474871	LUZP1	0.41	5.19	0.42	8.21e-7	Height;
TGCT	cis	rs612683	0.621	rs508020	chr1:100955532	T/C	cg06223162	chr1:101003688	GPR88	-0.35	-6.31	-0.49	4.4e-9	Breast cancer;
TGCT	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg00814883	chr7:100076585	TSC22D4	-0.92	-9.76	-0.66	4.73e-17	Platelet count;
TGCT	cis	rs4654899	0.865	rs6426674	chr1:21483906	C/T	cg01072550	chr1:21505969	NA	-0.48	-7.14	-0.54	7.03e-11	Superior frontal gyrus grey matter volume;
TGCT	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg06618935	chr21:46677482	NA	-0.35	-5.28	-0.43	5.6e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs3820068	0.581	rs16851841	chr1:15922713	A/G	cg05660106	chr1:15850417	CASP9	0.83	8.29	0.6	1.58e-13	Systolic blood pressure;
TGCT	cis	rs478304	0.651	rs11600918	chr11:65511965	A/G	cg17480646	chr11:65405466	SIPA1	-0.56	-6.95	-0.53	1.84e-10	Acne (severe);
TGCT	cis	rs11690935	0.788	rs6715929	chr2:172877507	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.81	-7.3	-0.55	3.05e-11	Schizophrenia;
TGCT	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg11301795	chr4:187892539	NA	-0.33	-5.11	-0.42	1.2e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7219021	0.705	rs28635466	chr17:46983820	G/A	cg26022315	chr17:47021804	SNF8	-0.53	-4.73	-0.39	5.96e-6	Schizophrenia or bipolar disorder;
TGCT	cis	rs2293052	0.697	rs549040	chr12:117754348	A/G	cg02962597	chr12:117799749	NOS1	0.27	4.65	0.39	8.28e-6	Schizophrenia;
TGCT	cis	rs4595586	0.546	rs2056159	chr12:39270417	C/G	cg26384229	chr12:38710491	ALG10B	0.66	5.38	0.43	3.64e-7	Morning vs. evening chronotype;
TGCT	cis	rs10464366	0.517	rs13231075	chr7:39174806	G/T	cg15212455	chr7:39170539	POU6F2	0.3	6.73	0.52	5.66e-10	IgG glycosylation;
TGCT	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg13395646	chr4:1353034	KIAA1530	-0.39	-4.97	-0.41	2.2e-6	Obesity-related traits;
TGCT	cis	rs4555082	0.834	rs2975217	chr14:105710238	A/C	cg01266790	chr14:105781312	PACS2	0.54	4.44	0.37	1.95e-5	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.49	-6.64	-0.51	8.8e-10	Alzheimer's disease;
TGCT	cis	rs790123	1.000	rs810976	chr3:122381683	T/C	cg22896480	chr3:122379438	NA	0.2	5.27	0.43	5.82e-7	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs17345786	1.000	rs17345786	chr3:101318318	A/C	cg12386194	chr3:101231763	SENP7	-0.58	-5.55	-0.45	1.64e-7	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs1814175	0.817	rs7947286	chr11:49874657	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.35	-0.55	2.38e-11	Height;
TGCT	cis	rs1008375	0.966	rs10939735	chr4:17578891	A/G	cg10189774	chr4:17578691	LAP3	0.61	5.28	0.43	5.6e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9527	0.590	rs7897663	chr10:104905604	T/C	cg04362960	chr10:104952993	NT5C2	0.67	5.64	0.45	1.09e-7	Arsenic metabolism;
TGCT	cis	rs1903068	0.853	rs10012589	chr4:56002689	A/T	cg16572876	chr4:56024045	NA	0.42	4.79	0.39	4.75e-6	Endometriosis;
TGCT	cis	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg20637647	chr7:64974828	NA	0.87	5.31	0.43	4.99e-7	Diabetic kidney disease;
TGCT	cis	rs6463523	0.864	rs73047957	chr7:759373	A/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.87	11.91	0.73	2.85e-22	Subjective well-being;
TGCT	cis	rs57994353	0.897	rs67220311	chr9:139376668	T/C	cg13741927	chr9:139327495	INPP5E	-0.23	-5.16	-0.42	9.54e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	trans	rs28735056	0.903	rs56185453	chr18:77638297	A/G	cg05926928	chr17:57297772	GDPD1	-0.83	-9.62	-0.65	1.05e-16	Schizophrenia;
TGCT	cis	rs1532993	0.518	rs1508470	chr4:98575319	C/T	cg05340658	chr4:99064831	C4orf37	0.41	5.0	0.41	1.92e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs35306767	0.953	rs11253517	chr10:970524	A/G	cg26597838	chr10:835615	NA	-0.61	-8.36	-0.6	1.08e-13	Eosinophil percentage of granulocytes;
TGCT	cis	rs62103177	0.608	rs613847	chr18:77845644	A/G	cg07235805	chr18:78004237	PARD6G	-0.51	-4.98	-0.41	2.11e-6	Opioid sensitivity;
TGCT	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg06112835	chr11:68658793	MRPL21	0.46	8.12	0.59	3.91e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg11494091	chr17:61959527	GH2	0.61	14.81	0.8	3.35e-29	Prudent dietary pattern;
TGCT	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg00149659	chr3:10157352	C3orf10	0.96	6.1	0.48	1.26e-8	Alzheimer's disease;
TGCT	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg00149659	chr3:10157352	C3orf10	1.18	7.44	0.56	1.44e-11	Alzheimer's disease;
TGCT	cis	rs4478037	1.000	rs59229836	chr3:33162622	T/C	cg19404215	chr3:33155277	CRTAP	1.33	8.79	0.62	1.04e-14	Major depressive disorder;
TGCT	cis	rs10833905	0.680	rs10833892	chr11:23027429	A/G	cg06387204	chr11:22647648	FANCF	-0.55	-5.07	-0.41	1.44e-6	Sudden cardiac arrest;
TGCT	cis	rs2070488	0.965	rs6805386	chr3:38557921	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.83	-8.45	-0.6	6.78e-14	Electrocardiographic conduction measures;
TGCT	cis	rs910187	0.641	rs3818010	chr20:45816562	A/G	cg27589058	chr20:45804311	EYA2	-0.35	-7.6	-0.56	6.23e-12	Migraine;
TGCT	cis	rs7178572	0.568	rs10152181	chr15:77678346	A/G	cg22256960	chr15:77711686	NA	-0.88	-9.16	-0.64	1.32e-15	Type 2 diabetes;
TGCT	trans	rs57221529	0.766	rs12522303	chr5:555564	A/C	cg11887960	chr12:57824829	NA	1.15	9.35	0.64	4.71e-16	Lung disease severity in cystic fibrosis;
TGCT	cis	rs6121246	0.567	rs7361893	chr20:30200751	C/T	cg18721089	chr20:30220636	NA	-0.57	-6.19	-0.49	7.9e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs9814567	0.806	rs2888670	chr3:134326684	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-7.21	-0.54	4.87e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs6988636	1.000	rs62521826	chr8:124186668	C/T	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs62380364	0.870	rs11749060	chr5:88152574	A/C	cg22951263	chr5:87985283	NA	0.47	4.54	0.38	1.31e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs6831352	0.589	rs1133483	chr4:100023923	G/C	cg13256891	chr4:100009986	ADH5	0.45	4.68	0.39	7.47e-6	Alcohol dependence;
TGCT	cis	rs9296661	0.522	rs1326575	chr6:51667498	C/A	cg20180370	chr6:50691003	TFAP2D	-0.49	-4.65	-0.39	8.46e-6	Weight loss (gastric bypass surgery);
TGCT	cis	rs11190604	1.000	rs2489037	chr10:102319918	A/G	cg23241863	chr10:102295624	HIF1AN	-0.67	-4.9	-0.4	2.99e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7017914	0.934	rs56043721	chr8:71630427	A/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.55	-5.13	-0.42	1.11e-6	Bone mineral density;
TGCT	cis	rs12421382	0.543	rs11213094	chr11:109357926	G/A	cg27471124	chr11:109292789	C11orf87	0.53	6.26	0.49	5.73e-9	Schizophrenia;
TGCT	cis	rs3924048	0.559	rs6541039	chr1:12626261	T/C	cg00291366	chr1:12616550	NA	0.31	4.88	0.4	3.17e-6	Optic cup area;
TGCT	cis	rs7178424	0.653	rs3886246	chr15:62140034	G/A	cg00456672	chr15:62358751	C2CD4A	-0.31	-4.67	-0.39	7.7e-6	Height;
TGCT	cis	rs78707713	0.560	rs2394563	chr10:71238618	G/A	cg12610070	chr10:71211762	TSPAN15	-0.62	-7.31	-0.55	2.83e-11	Venous thromboembolism;
TGCT	cis	rs2594714	1.000	rs12162265	chr19:13955161	G/A	cg18576835	chr19:13944261	NA	-0.46	-5.06	-0.41	1.47e-6	Breast cancer;
TGCT	cis	rs4808199	0.901	rs11669516	chr19:19532682	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.69	4.99	0.41	1.98e-6	Nonalcoholic fatty liver disease;
TGCT	cis	rs6121246	0.529	rs6060118	chr20:30171209	T/C	cg21427119	chr20:30132790	HM13	-0.39	-5.81	-0.46	4.97e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg06221963	chr1:154839813	KCNN3	-0.73	-11.82	-0.73	4.65e-22	Prostate cancer;
TGCT	cis	rs12477438	0.666	rs10179910	chr2:99658503	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.68	-6.44	-0.5	2.32e-9	Chronic sinus infection;
TGCT	cis	rs7666738	0.830	rs13134819	chr4:98919885	G/C	cg18180107	chr4:99064573	C4orf37	0.57	5.23	0.43	6.88e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2370759	0.945	rs74625866	chr10:32597618	A/T	cg01819863	chr10:32635814	EPC1	1.03	10.03	0.67	1.05e-17	Sexual dysfunction (female);
TGCT	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg24675658	chr1:53192096	ZYG11B	-0.69	-8.17	-0.59	3.05e-13	Monocyte count;
TGCT	cis	rs1008375	0.872	rs6831115	chr4:17640463	A/G	cg16339924	chr4:17578868	LAP3	0.64	5.47	0.44	2.42e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs8072100	0.805	rs67919208	chr17:45771873	T/C	cg08085267	chr17:45401833	C17orf57	-0.4	-4.64	-0.38	8.84e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	trans	rs17471911	0.708	rs11189943	chr10:100785546	T/C	cg03484267	chr2:207988651	KLF7	-0.52	-6.7	-0.52	6.49e-10	Neuroticism;
TGCT	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg26354017	chr1:205819088	PM20D1	0.55	6.43	0.5	2.46e-9	Menarche (age at onset);
TGCT	cis	rs360798	0.512	rs6739804	chr2:63269604	T/C	cg17519650	chr2:63277830	OTX1	0.62	5.71	0.46	7.87e-8	Coronary artery disease;
TGCT	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg16325326	chr1:53192061	ZYG11B	-0.71	-8.81	-0.62	9.22e-15	Monocyte count;
TGCT	cis	rs13326165	0.760	rs55965068	chr3:52354432	A/G	cg27565382	chr3:53032988	SFMBT1	0.37	4.9	0.4	2.97e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs9296092	0.517	rs56043172	chr6:33522363	T/G	cg13560919	chr6:33536144	NA	-0.21	-4.75	-0.39	5.5e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg20999797	chr1:1681921	NA	0.18	4.51	0.38	1.5e-5	Body mass index;
TGCT	cis	rs7264396	0.635	rs6060660	chr20:34476649	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.04	-0.41	1.58e-6	Total cholesterol levels;
TGCT	cis	rs3935685	0.874	rs4477663	chr15:78007254	A/G	cg03457338	chr15:78040120	NA	0.22	5.82	0.46	4.77e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs12887734	0.546	rs4906376	chr14:104272165	A/C	cg26031613	chr14:104095156	KLC1	-0.69	-5.83	-0.46	4.49e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs8013055	0.846	rs12717698	chr14:105979015	G/A	cg19700328	chr14:106028568	NA	-0.56	-5.88	-0.47	3.48e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs2115630	1.000	rs8037423	chr15:85355494	C/T	cg12501888	chr15:85177176	SCAND2	-0.48	-4.49	-0.37	1.62e-5	P wave terminal force;
TGCT	cis	rs9914544	1.000	rs7223231	chr17:18811846	C/T	cg26378065	chr17:18585709	ZNF286B	0.52	4.65	0.38	8.54e-6	Educational attainment (years of education);
TGCT	cis	rs17270561	1.000	rs79867288	chr6:25828416	A/G	cg17691542	chr6:26056736	HIST1H1C	0.78	4.78	0.39	4.87e-6	Iron status biomarkers;
TGCT	trans	rs9329221	0.741	rs9650622	chr8:9804292	G/T	cg06636001	chr8:8085503	FLJ10661	-0.77	-6.92	-0.53	2.12e-10	Neuroticism;
TGCT	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg03517284	chr6:25882590	NA	-0.52	-5.27	-0.43	5.77e-7	Blood metabolite levels;
TGCT	cis	rs17376456	0.809	rs13177800	chr5:93307350	T/C	cg21475434	chr5:93447410	FAM172A	0.66	4.81	0.4	4.26e-6	Diabetic retinopathy;
TGCT	cis	rs7647973	0.925	rs6769821	chr3:49244657	G/A	cg07636037	chr3:49044803	WDR6	0.64	5.13	0.42	1.09e-6	Menarche (age at onset);
TGCT	cis	rs9467773	0.596	rs2494693	chr6:26619226	T/C	cg15659132	chr6:26577336	NA	0.84	10.91	0.7	7.83e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs6978712	1.000	rs56060721	chr7:127148448	A/G	cg01017541	chr7:127776461	NA	0.76	4.6	0.38	1.01e-5	Medication adherence in chronic diseases;
TGCT	cis	rs10425738	0.536	rs10426903	chr19:41417719	T/C	cg19493303	chr19:41414353	NA	0.44	5.51	0.44	1.94e-7	nicotine metabolite ratio in current smokers;Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
TGCT	cis	rs67311347	0.544	rs1454492	chr3:40352884	C/T	cg13683864	chr3:40499215	RPL14	-0.8	-7.5	-0.56	1.06e-11	Renal cell carcinoma;
TGCT	cis	rs13242816	1.000	rs17138750	chr7:116134170	A/G	cg16553024	chr7:116138462	CAV2	-0.45	-5.04	-0.41	1.57e-6	P wave duration;
TGCT	cis	rs2456568	0.778	rs7940973	chr11:93682045	C/G	cg16099599	chr11:93583650	C11orf90	0.39	4.8	0.4	4.39e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs72781680	1.000	rs17762782	chr2:24126493	A/G	cg08917208	chr2:24149416	ATAD2B	0.73	4.51	0.38	1.48e-5	Lymphocyte counts;
TGCT	cis	rs9902453	0.740	rs2254414	chr17:28061130	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.84	-8.39	-0.6	9.14e-14	Coffee consumption (cups per day);
TGCT	cis	rs3784262	0.692	rs1441819	chr15:58243204	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.43	-6.19	-0.49	8.09e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs1577917	0.876	rs12212808	chr6:86533972	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-5.53	-0.44	1.82e-7	Response to antipsychotic treatment;
TGCT	cis	rs1865760	0.865	rs9467648	chr6:25957933	T/A	cg16482183	chr6:26056742	HIST1H1C	0.52	4.84	0.4	3.78e-6	Height;
TGCT	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg24675658	chr1:53192096	ZYG11B	-0.84	-10.28	-0.68	2.58e-18	Monocyte count;
TGCT	cis	rs854765	0.647	rs4426402	chr17:17977926	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.68	-6.99	-0.53	1.51e-10	Total body bone mineral density;
TGCT	cis	rs2688608	0.592	rs7076585	chr10:75503692	T/C	cg23231163	chr10:75533350	FUT11	-0.28	-4.73	-0.39	5.98e-6	Inflammatory bowel disease;
TGCT	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	9.52	0.65	1.86e-16	Platelet count;
TGCT	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg11644478	chr21:40555479	PSMG1	1.03	11.1	0.71	2.61e-20	Cognitive function;
TGCT	cis	rs28595532	0.920	rs115076001	chr4:119764346	T/G	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg24060327	chr5:131705240	SLC22A5	-0.66	-6.96	-0.53	1.78e-10	Acylcarnitine levels;
TGCT	cis	rs6977955	0.838	rs917115	chr7:28172586	T/C	cg23620719	chr7:28220237	JAZF1	0.58	4.66	0.39	8.03e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs3816788	0.792	rs729180	chr8:21817245	C/T	cg17168535	chr8:21777572	XPO7	0.81	8.33	0.6	1.25e-13	Lung cancer in ever smokers;
TGCT	cis	rs425277	1.000	rs809912	chr1:2078385	C/T	cg03732007	chr1:2071316	PRKCZ	0.26	5.44	0.44	2.77e-7	Height;
TGCT	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg12288994	chr5:1860383	NA	0.24	4.72	0.39	6.2e-6	Cardiovascular disease risk factors;
TGCT	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.63	-0.51	9.04e-10	Alzheimer's disease;
TGCT	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg23708337	chr7:1209742	NA	0.6	5.57	0.45	1.53e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs896854	0.517	rs1011796	chr8:95951273	A/G	cg09323728	chr8:95962352	TP53INP1	0.44	5.06	0.41	1.47e-6	Type 2 diabetes;
TGCT	cis	rs478304	0.627	rs11604568	chr11:65511336	G/A	cg17480646	chr11:65405466	SIPA1	-0.57	-6.93	-0.53	2.03e-10	Acne (severe);
TGCT	cis	rs36051895	0.659	rs3780367	chr9:5068755	T/G	cg02405213	chr9:5042618	JAK2	-0.74	-9.81	-0.66	3.67e-17	Pediatric autoimmune diseases;
TGCT	cis	rs12210905	0.688	rs114188783	chr6:27449604	T/C	cg08851530	chr6:28072375	NA	1.34	6.29	0.49	5.02e-9	Hip circumference adjusted for BMI;
TGCT	trans	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg25482853	chr8:67687455	SGK3	1.22	10.53	0.69	6.33e-19	Obesity-related traits;
TGCT	cis	rs3020736	0.500	rs9620026	chr22:42498578	C/T	cg05082376	chr22:42548792	NA	0.23	5.43	0.44	2.83e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.52	-5.04	-0.41	1.63e-6	Longevity;Endometriosis;
TGCT	cis	rs2797160	1.000	rs1832980	chr6:125997444	T/G	cg05901451	chr6:126070800	HEY2	-0.74	-6.49	-0.5	1.84e-9	Endometrial cancer;
TGCT	cis	rs910316	0.967	rs175498	chr14:75536369	G/A	cg23033748	chr14:75592666	NEK9	-0.28	-4.7	-0.39	6.7e-6	Height;
TGCT	cis	rs2224391	0.704	rs9504371	chr6:5261608	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.8	-6.12	-0.48	1.13e-8	Height;
TGCT	cis	rs2760061	0.659	rs708107	chr1:228189495	C/T	cg02753203	chr1:228287806	NA	0.31	5.79	0.46	5.54e-8	Diastolic blood pressure;
TGCT	cis	rs6540559	0.808	rs11119358	chr1:210042456	T/C	cg23283495	chr1:209979779	IRF6	0.66	5.36	0.43	3.86e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs9393777	0.513	rs9379907	chr6:26654318	C/T	cg15659132	chr6:26577336	NA	-0.75	-5.25	-0.43	6.33e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9611565	0.649	rs6002480	chr22:42176917	A/T	cg03806693	chr22:41940476	POLR3H	-0.89	-8.61	-0.61	2.72e-14	Vitiligo;
TGCT	cis	rs55665837	0.524	rs2882128	chr11:14414634	A/C	cg19336497	chr11:14380999	RRAS2	-0.3	-4.64	-0.38	8.58e-6	Vitamin D levels;
TGCT	cis	rs11690935	0.610	rs59844139	chr2:172731983	C/A	cg13550731	chr2:172543902	DYNC1I2	0.57	4.62	0.38	9.5e-6	Schizophrenia;
TGCT	cis	rs35883536	0.647	rs10875316	chr1:101044150	G/A	cg10298815	chr1:101004474	GPR88	-0.24	-4.44	-0.37	1.95e-5	Monocyte count;
TGCT	cis	rs7772486	0.875	rs854148	chr6:146310979	G/C	cg05347473	chr6:146136440	FBXO30	0.54	5.0	0.41	1.91e-6	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg27523141	chr10:43048294	ZNF37B	0.71	8.32	0.6	1.35e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs11734570	0.581	rs73808504	chr4:38600593	T/C	cg18361445	chr4:38666374	KLF3;FLJ13197	0.69	5.66	0.45	9.9e-8	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs10193935	0.901	rs62142596	chr2:42529339	C/T	cg27598129	chr2:42591480	NA	-0.38	-5.17	-0.42	9.27e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1129187	0.805	rs1053539	chr6:42903766	T/G	cg27588902	chr6:42928151	GNMT	-0.49	-5.95	-0.47	2.53e-8	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg08280861	chr8:58055591	NA	0.49	5.38	0.43	3.64e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg04772025	chr11:68637568	NA	0.6	6.78	0.52	4.26e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs11031096	0.782	rs2284450	chr11:4149214	A/T	cg18678763	chr11:4115507	RRM1	-0.51	-6.59	-0.51	1.14e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs12497850	0.931	rs9835307	chr3:48857805	T/C	cg07636037	chr3:49044803	WDR6	0.94	10.39	0.68	1.46e-18	Parkinson's disease;
TGCT	cis	rs7666738	0.830	rs28878289	chr4:98855181	C/T	cg18180107	chr4:99064573	C4orf37	0.55	5.14	0.42	1.03e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg16414030	chr3:133502952	NA	-0.52	-7.29	-0.55	3.17e-11	Iron status biomarkers;
TGCT	cis	rs1801251	1.000	rs283477	chr2:233649427	A/G	cg08000102	chr2:233561755	GIGYF2	0.64	6.41	0.5	2.78e-9	Coronary artery disease;
TGCT	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg23708337	chr7:1209742	NA	0.64	5.94	0.47	2.63e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs45509595	0.749	rs401763	chr6:27782528	T/C	cg10876282	chr6:28092338	ZSCAN16	0.78	4.57	0.38	1.17e-5	Breast cancer;
TGCT	cis	rs7666738	0.830	rs17550610	chr4:99008273	T/C	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2204008	0.775	rs12369238	chr12:38176051	A/G	cg26384229	chr12:38710491	ALG10B	0.85	7.68	0.57	4.21e-12	Bladder cancer;
TGCT	cis	rs4455778	0.580	rs7777309	chr7:49085524	C/T	cg26309511	chr7:48887640	NA	0.5	6.47	0.5	2.03e-9	Lung cancer in never smokers;
TGCT	cis	rs7617480	0.648	rs9848268	chr3:48762271	C/T	cg07636037	chr3:49044803	WDR6	0.74	5.88	0.47	3.51e-8	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs11711311	0.747	rs9882193	chr3:113349451	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.72	6.11	0.48	1.17e-8	IgG glycosylation;
TGCT	cis	rs4654899	0.897	rs6670897	chr1:21066376	T/C	cg01072550	chr1:21505969	NA	-0.49	-7.85	-0.58	1.67e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs2797160	1.000	rs2747724	chr6:126004935	G/A	cg05901451	chr6:126070800	HEY2	-0.74	-6.3	-0.49	4.62e-9	Endometrial cancer;
TGCT	cis	rs68170813	0.641	rs1978085	chr7:107095216	T/C	cg02696742	chr7:106810147	HBP1	-0.65	-5.15	-0.42	1.01e-6	Coronary artery disease;
TGCT	cis	rs28374715	0.627	rs28516832	chr15:41367036	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.75	-9.77	-0.66	4.5e-17	Ulcerative colitis;
TGCT	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg18402987	chr7:1209562	NA	0.7	5.67	0.45	9.66e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs4788570	0.584	rs9934301	chr16:71756845	C/G	cg06353428	chr16:71660113	MARVELD3	1.49	12.95	0.76	8.56e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs9560113	1.000	rs9560110	chr13:112181233	C/T	cg14154082	chr13:112174009	NA	0.38	5.01	0.41	1.83e-6	Menarche (age at onset);
TGCT	cis	rs9650657	0.770	rs9969626	chr8:10670801	A/C	cg27411982	chr8:10470053	RP1L1	-0.21	-4.66	-0.39	7.97e-6	Neuroticism;
TGCT	cis	rs17376456	0.825	rs6877030	chr5:93201841	C/A	cg21475434	chr5:93447410	FAM172A	0.69	4.81	0.4	4.36e-6	Diabetic retinopathy;
TGCT	cis	rs950169	0.580	rs2271431	chr15:85189464	A/C	cg12863693	chr15:85201151	NMB	0.44	5.2	0.42	7.97e-7	Schizophrenia;
TGCT	cis	rs68170813	0.652	rs76742243	chr7:107144202	G/A	cg02696742	chr7:106810147	HBP1	-0.58	-4.47	-0.37	1.74e-5	Coronary artery disease;
TGCT	cis	rs2153535	0.553	rs2984099	chr6:8637274	C/T	cg23788917	chr6:8435910	SLC35B3	-0.88	-6.83	-0.52	3.43e-10	Motion sickness;
TGCT	cis	rs9910055	0.529	rs575798	chr17:42181796	A/C	cg19774624	chr17:42201019	HDAC5	0.65	5.98	0.47	2.23e-8	Total body bone mineral density;
TGCT	cis	rs6570726	0.791	rs392612	chr6:145881586	C/G	cg05347473	chr6:146136440	FBXO30	-0.54	-5.15	-0.42	1.01e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.55	-5.12	-0.42	1.15e-6	Prudent dietary pattern;
TGCT	cis	rs9811920	0.609	rs793462	chr3:99616461	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.6	-6.82	-0.52	3.63e-10	Axial length;
TGCT	cis	rs7829975	0.514	rs2976926	chr8:8261624	T/C	cg06636001	chr8:8085503	FLJ10661	0.7	6.18	0.49	8.28e-9	Mood instability;
TGCT	cis	rs2354432	0.607	rs2297752	chr1:146765454	C/G	cg25205988	chr1:146714368	CHD1L	-1.18	-7.03	-0.53	1.24e-10	Mitochondrial DNA levels;
TGCT	cis	rs9325144	0.555	rs4882284	chr12:38710459	C/T	cg26384229	chr12:38710491	ALG10B	-0.68	-6.28	-0.49	5.18e-9	Morning vs. evening chronotype;
TGCT	cis	rs7226408	0.802	rs11665058	chr18:34469552	C/A	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs2820315	1.000	rs903678	chr1:201809918	G/A	cg12730843	chr1:201915899	LMOD1	-0.27	-4.82	-0.4	4.09e-6	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
TGCT	cis	rs7666738	0.830	rs1869897	chr4:98730997	C/T	cg05340658	chr4:99064831	C4orf37	0.49	5.77	0.46	6.02e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg09021430	chr5:549028	NA	-0.37	-5.16	-0.42	9.7e-7	Lung disease severity in cystic fibrosis;
TGCT	cis	rs7296418	0.663	rs28450974	chr12:123861420	G/A	cg00376283	chr12:123451042	ABCB9	0.63	5.42	0.44	3.02e-7	Platelet count;
TGCT	cis	rs12497850	1.000	rs1352420	chr3:48757291	A/G	cg07636037	chr3:49044803	WDR6	0.93	9.94	0.67	1.8e-17	Parkinson's disease;
TGCT	cis	rs17152411	0.947	rs61873270	chr10:126595923	C/A	cg07906193	chr10:126599966	NA	0.42	5.28	0.43	5.6e-7	Height;
TGCT	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg19774624	chr17:42201019	HDAC5	-0.83	-8.49	-0.61	5.19e-14	Total body bone mineral density;
TGCT	cis	rs2249625	0.564	rs2463734	chr6:72882558	C/T	cg08500200	chr6:72892038	RIMS1	-0.42	-4.54	-0.38	1.33e-5	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
TGCT	trans	rs1496653	0.602	rs13076527	chr3:23385877	G/A	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs9653442	0.564	rs10185510	chr2:100790581	C/T	cg07810366	chr2:100720526	AFF3	-0.36	-5.25	-0.43	6.45e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs6938	0.618	rs11857695	chr15:75165751	G/T	cg09165964	chr15:75287851	SCAMP5	0.53	5.08	0.42	1.33e-6	Breast cancer;
TGCT	cis	rs7017914	0.967	rs34508469	chr8:71628463	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.55	-5.13	-0.42	1.11e-6	Bone mineral density;
TGCT	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.84	7.5	0.56	1.08e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7727544	0.606	rs200838	chr5:131710399	A/C	cg24060327	chr5:131705240	SLC22A5	0.51	5.44	0.44	2.73e-7	Blood metabolite levels;
TGCT	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.36	-4.45	-0.37	1.9e-5	Total body bone mineral density;
TGCT	trans	rs941408	1.000	rs1624295	chr19:2792034	G/A	cg19676328	chr12:49525230	TUBA1B	-0.76	-7.72	-0.57	3.34e-12	Total cholesterol levels;
TGCT	cis	rs2114646	0.697	rs1863694	chr2:170633728	A/G	cg01268571	chr2:170624998	NA	0.46	4.56	0.38	1.23e-5	Obesity-related traits;
TGCT	cis	rs7666738	0.677	rs13120306	chr4:99036099	A/T	cg05340658	chr4:99064831	C4orf37	0.51	5.69	0.45	8.74e-8	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs208520	0.690	rs10455194	chr6:66743356	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	10.83	0.7	1.19e-19	Exhaled nitric oxide output;
TGCT	cis	rs554111	0.613	rs1567128	chr1:21404653	G/A	cg01072550	chr1:21505969	NA	0.35	5.34	0.43	4.23e-7	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs12220238	1.000	rs12355771	chr10:75894404	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.06	0.54	1.05e-10	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs8141529	0.764	rs5752809	chr22:29225500	G/A	cg02153584	chr22:29168773	CCDC117	0.67	5.69	0.45	8.82e-8	Lymphocyte counts;
TGCT	cis	rs7824557	0.806	rs6601573	chr8:11094751	A/G	cg21775007	chr8:11205619	TDH	-0.5	-4.55	-0.38	1.27e-5	Retinal vascular caliber;
TGCT	cis	rs1018836	0.851	rs10808620	chr8:91622940	T/C	cg16814680	chr8:91681699	NA	-0.82	-8.6	-0.61	2.86e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2404602	0.647	rs10152247	chr15:76942252	T/G	cg23625390	chr15:77176239	SCAPER	-0.37	-4.67	-0.39	7.71e-6	Blood metabolite levels;
TGCT	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg00024416	chr22:24240387	NA	-0.26	-4.97	-0.41	2.15e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6570726	0.643	rs9403735	chr6:145936591	C/T	cg13319975	chr6:146136371	FBXO30	-0.53	-4.75	-0.39	5.62e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11679640	0.610	rs55687681	chr2:43114582	T/C	cg00484711	chr2:42331922	NA	-0.2	-4.54	-0.38	1.33e-5	White matter hyperintensity burden;
TGCT	cis	rs13191362	1.000	rs34594856	chr6:163051845	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.07	8.5	0.61	5.17e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs17767294	0.708	rs72847355	chr6:27825176	G/A	cg08851530	chr6:28072375	NA	1.54	7.3	0.55	3.1e-11	Parkinson's disease;
TGCT	cis	rs6430585	0.583	rs3769001	chr2:136626078	A/G	cg07169764	chr2:136633963	MCM6	1.24	12.25	0.74	4.19e-23	Corneal structure;
TGCT	cis	rs75686122	0.892	rs17234965	chr8:104729139	C/G	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs6684514	1.000	rs12122180	chr1:156244559	G/A	cg16558208	chr1:156270281	VHLL	0.46	9.38	0.64	3.92e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg05552183	chr6:42928497	GNMT	0.54	4.75	0.39	5.47e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs6429082	0.783	rs291385	chr1:235646613	T/C	cg26050004	chr1:235667680	B3GALNT2	0.59	5.26	0.43	6.02e-7	Adiposity;
TGCT	cis	rs6815814	0.950	rs11727978	chr4:38811051	T/A	cg02016764	chr4:38805732	TLR1	-0.37	-5.85	-0.47	4.08e-8	Breast cancer;
TGCT	cis	rs459571	0.959	rs467379	chr9:136905474	C/T	cg14405625	chr9:136855902	VAV2	-0.33	-5.16	-0.42	9.42e-7	Platelet distribution width;
TGCT	cis	rs9858542	0.537	rs67882627	chr3:49380441	A/T	cg00383909	chr3:49044727	WDR6	0.7	4.75	0.39	5.48e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs10464366	0.544	rs2280667	chr7:39172228	A/C	cg08835956	chr7:39171034	POU6F2	0.25	4.67	0.39	7.79e-6	IgG glycosylation;
TGCT	cis	rs6582630	0.519	rs8189599	chr12:38280748	A/G	cg26384229	chr12:38710491	ALG10B	0.87	7.54	0.56	8.43e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs3806843	0.546	rs246023	chr5:140333990	G/T	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2204008	0.603	rs4397954	chr12:38089157	T/C	cg26384229	chr12:38710491	ALG10B	0.85	7.57	0.56	7.57e-12	Bladder cancer;
TGCT	cis	rs7044106	0.500	rs56725168	chr9:123492576	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.49	5.54	0.45	1.69e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs10276381	1.000	rs7796417	chr7:28186119	G/C	cg23620719	chr7:28220237	JAZF1	1.01	5.82	0.46	4.75e-8	Crohn's disease;
TGCT	cis	rs7178572	0.568	rs1125617	chr15:77532711	A/G	cg22256960	chr15:77711686	NA	-0.85	-8.73	-0.62	1.4e-14	Type 2 diabetes;
TGCT	cis	rs11190604	1.000	rs2495739	chr10:102335507	C/T	cg16342193	chr10:102329863	NA	-0.43	-5.39	-0.44	3.43e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs904251	0.734	rs2797790	chr6:37447075	A/G	cg25019722	chr6:37503610	NA	0.38	4.51	0.38	1.51e-5	Cognitive performance;
TGCT	cis	rs2594989	0.837	rs2922348	chr3:11309784	T/C	cg00170343	chr3:11313890	ATG7	0.7	4.97	0.41	2.21e-6	Circulating chemerin levels;
TGCT	cis	rs669446	0.533	rs3862228	chr1:44196945	C/T	cg12908607	chr1:44402522	ARTN	-0.62	-7.25	-0.55	3.99e-11	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs4319547	0.910	rs6416298	chr12:123002143	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.65	-4.8	-0.4	4.55e-6	Body mass index;
TGCT	cis	rs10984561	0.881	rs1331594	chr9:122254439	T/C	cg14242995	chr9:122249943	NA	0.72	5.82	0.46	4.75e-8	Pulmonary function decline;
TGCT	trans	rs6762477	0.748	rs9831967	chr3:50217234	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.9	-9.91	-0.66	2.05e-17	Menarche (age at onset);
TGCT	cis	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg18252515	chr7:66147081	NA	-1.13	-6.81	-0.52	3.7e-10	Diabetic kidney disease;
TGCT	cis	rs7959452	0.535	rs7308481	chr12:69659299	A/G	cg14784868	chr12:69753453	YEATS4	0.69	7.03	0.53	1.23e-10	Blood protein levels;
TGCT	cis	rs3784262	0.565	rs4646549	chr15:58358607	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.37	-5.11	-0.42	1.17e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs1461503	0.966	rs7110154	chr11:122843300	A/G	cg27398637	chr11:122830231	C11orf63	-0.43	-5.31	-0.43	5e-7	Menarche (age at onset);
TGCT	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg20891283	chr12:69753455	YEATS4	0.91	10.33	0.68	1.96e-18	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs6867032	0.527	rs4975777	chr5:1973324	G/T	cg05184729	chr5:1962311	NA	0.27	4.54	0.38	1.32e-5	Gut microbiome composition (winter);
TGCT	cis	rs2404602	0.709	rs11072591	chr15:76649562	A/G	cg26408565	chr15:76604113	ETFA	-0.4	-4.83	-0.4	4.01e-6	Blood metabolite levels;
TGCT	cis	rs9512730	0.553	rs1040986	chr13:28051352	G/T	cg04070771	chr13:27998621	GTF3A	0.55	4.8	0.4	4.44e-6	Schizophrenia;
TGCT	cis	rs1577917	0.958	rs7382798	chr6:86559834	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.29	-0.43	5.34e-7	Response to antipsychotic treatment;
TGCT	cis	rs7100689	0.622	rs7897994	chr10:82133304	T/G	cg01528321	chr10:82214614	TSPAN14	0.8	7.76	0.57	2.7e-12	Post bronchodilator FEV1;
TGCT	cis	rs7824557	0.603	rs2736278	chr8:11219781	C/T	cg21775007	chr8:11205619	TDH	0.64	5.93	0.47	2.83e-8	Retinal vascular caliber;
TGCT	cis	rs17221829	0.733	rs12421371	chr11:89381008	T/G	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.63	-0.38	9.04e-6	Anxiety in major depressive disorder;
TGCT	cis	rs34734847	1.000	rs56179458	chr12:121157535	G/A	cg21892295	chr12:121157589	UNC119B	-0.24	-5.71	-0.46	7.99e-8	Mean corpuscular volume;
TGCT	cis	rs5769765	0.671	rs138841	chr22:50181960	C/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.33	4.69	0.39	7e-6	Schizophrenia;
TGCT	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg20203395	chr5:56204925	C5orf35	-0.61	-5.3	-0.43	5.19e-7	Initial pursuit acceleration;
TGCT	trans	rs4919669	0.546	rs4919647	chr10:104250754	A/C	cg19053889	chr7:1098703	C7orf50;GPR146	0.51	6.77	0.52	4.63e-10	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs7845219	0.544	rs4735331	chr8:95917958	C/T	cg13393036	chr8:95962371	TP53INP1	-0.44	-5.14	-0.42	1.05e-6	Type 2 diabetes;
TGCT	cis	rs7772486	0.790	rs7753696	chr6:146279098	G/T	cg05347473	chr6:146136440	FBXO30	-0.55	-5.3	-0.43	5.08e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.52	-4.98	-0.41	2.04e-6	Bipolar disorder;
TGCT	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg13877915	chr19:58951672	ZNF132	0.91	11.55	0.72	2.15e-21	Uric acid clearance;
TGCT	cis	rs2204008	0.678	rs61929520	chr12:38446800	T/C	cg26384229	chr12:38710491	ALG10B	-0.54	-4.81	-0.4	4.32e-6	Bladder cancer;
TGCT	cis	rs9814567	1.000	rs9819532	chr3:134288644	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.94	-9.18	-0.64	1.2e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs2033711	0.870	rs1051500	chr19:58944402	A/G	cg13877915	chr19:58951672	ZNF132	0.89	11.28	0.71	9.7e-21	Uric acid clearance;
TGCT	cis	rs797680	0.930	rs1474927	chr1:93570368	C/T	cg17826107	chr1:92977322	EVI5	-0.22	-5.21	-0.42	7.58e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs7666738	0.830	rs13118892	chr4:98968497	T/C	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs367615	0.918	rs10067984	chr5:108872684	C/T	cg17395555	chr5:108820864	NA	0.31	5.01	0.41	1.85e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs7666738	0.830	rs35560671	chr4:99069095	G/A	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.44e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8084125	0.765	rs72981159	chr18:74945042	A/G	cg05528293	chr18:74961138	GALR1	0.5	4.93	0.4	2.61e-6	Obesity-related traits;
TGCT	cis	rs9393777	0.513	rs9379905	chr6:26630990	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.59	-5.33	-0.43	4.44e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs981844	0.712	rs1563461	chr4:154751913	C/T	cg14289246	chr4:154710475	SFRP2	-0.99	-9.12	-0.63	1.65e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs2795502	1.000	rs3121278	chr10:43375646	G/T	cg20628663	chr10:43360327	NA	0.48	5.6	0.45	1.33e-7	Blood protein levels;
TGCT	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg07507251	chr3:52567010	NT5DC2	0.47	6.64	0.51	8.85e-10	Bipolar disorder;
TGCT	cis	rs7208859	0.623	rs11652358	chr17:29205480	T/C	cg18442181	chr17:29233375	C17orf42	-0.78	-4.61	-0.38	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs4722166	0.597	rs1554606	chr7:22768707	T/G	cg26061582	chr7:22766209	IL6	0.58	7.49	0.56	1.1e-11	Lung cancer;
TGCT	cis	rs734999	0.967	rs10910090	chr1:2496214	C/T	cg18854424	chr1:2615690	NA	0.47	5.7	0.46	8.17e-8	Ulcerative colitis;
TGCT	cis	rs9915657	0.834	rs2287131	chr17:70106227	T/C	cg06234051	chr17:70120541	SOX9	-0.26	-5.37	-0.43	3.78e-7	Thyroid hormone levels;
TGCT	cis	rs6933660	0.512	rs13202634	chr6:151800630	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.73	-4.52	-0.38	1.44e-5	Menarche (age at onset);
TGCT	cis	rs617219	0.698	rs13177470	chr5:78495899	T/C	cg05890484	chr5:78407552	BHMT	0.38	5.2	0.42	8.14e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs35306767	0.761	rs11253540	chr10:1011958	C/T	cg20503657	chr10:835505	NA	-0.57	-6.65	-0.51	8.44e-10	Eosinophil percentage of granulocytes;
TGCT	cis	rs7575873	1	rs7575873	chr2:23962647	A/G	cg08917208	chr2:24149416	ATAD2B	0.95	6.09	0.48	1.28e-8	Birth weight;
TGCT	cis	rs7647973	0.848	rs4292260	chr3:49148890	T/C	cg07636037	chr3:49044803	WDR6	0.77	6.08	0.48	1.34e-8	Menarche (age at onset);
TGCT	cis	rs72843506	0.722	rs3764436	chr17:20013802	G/A	cg18979559	chr17:20280153	CCDC144C	-0.64	-4.8	-0.4	4.54e-6	Schizophrenia;
TGCT	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.92	7.56	0.56	7.89e-12	Platelet count;
TGCT	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.62	-5.63	-0.45	1.13e-7	Height;
TGCT	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg18876405	chr7:65276391	NA	0.33	4.97	0.41	2.13e-6	Aortic root size;
TGCT	cis	rs3617	0.539	rs9985365	chr3:52953844	A/G	cg11645453	chr3:52864694	ITIH4	-0.28	-5.67	-0.45	9.6e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9393692	0.905	rs7761298	chr6:26278436	C/T	cg00631329	chr6:26305371	NA	-0.41	-6.09	-0.48	1.34e-8	Educational attainment;
TGCT	cis	rs12579753	0.810	rs10862350	chr12:82156202	G/A	cg07988820	chr12:82153109	PPFIA2	-0.62	-7.12	-0.54	7.57e-11	Resting heart rate;
TGCT	cis	rs10089	1.000	rs10463838	chr5:127518305	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.79	7.56	0.56	7.96e-12	Ileal carcinoids;
TGCT	trans	rs2727020	0.576	rs1814175	chr11:49559172	T/C	cg15704280	chr7:45808275	SEPT13	-0.61	-6.78	-0.52	4.26e-10	Coronary artery disease;
TGCT	cis	rs2841277	0.741	rs9672139	chr14:105408182	T/G	cg19901468	chr14:105411992	AHNAK2	-0.27	-6.07	-0.48	1.47e-8	Rheumatoid arthritis;
TGCT	cis	rs4638749	1.000	rs12477202	chr2:108867112	G/A	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.69	-0.39	6.95e-6	Blood pressure;
TGCT	cis	rs7091068	0.616	rs7084701	chr10:95482249	A/G	cg20715218	chr10:95462985	C10orf4	0.56	5.29	0.43	5.36e-7	Urinary tract infection frequency;
TGCT	cis	rs7843479	0.511	rs4379446	chr8:21777595	C/G	cg17168535	chr8:21777572	XPO7	0.76	7.55	0.56	8.38e-12	Mean corpuscular volume;
TGCT	cis	rs6490294	0.808	rs7137270	chr12:112263402	G/A	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Mean platelet volume;
TGCT	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg05665937	chr4:1216051	CTBP1	0.25	4.75	0.39	5.64e-6	Obesity-related traits;
TGCT	trans	rs7726839	0.540	rs57306627	chr5:597643	T/C	cg11887960	chr12:57824829	NA	1.2	9.56	0.65	1.47e-16	Obesity-related traits;
TGCT	cis	rs4851254	0.618	rs35300735	chr2:100667829	G/A	cg07810366	chr2:100720526	AFF3	-0.49	-5.09	-0.42	1.28e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs66569888	0.754	rs6719028	chr2:106895212	T/C	cg16099169	chr2:106886729	NA	0.43	4.81	0.4	4.32e-6	Facial morphology (factor 23);
TGCT	cis	rs763014	0.932	rs7204439	chr16:661335	T/C	cg09263875	chr16:632152	PIGQ	0.31	6.78	0.52	4.46e-10	Height;
TGCT	cis	rs2120019	0.638	rs34492112	chr15:75294917	G/A	cg09165964	chr15:75287851	SCAMP5	1.12	11.73	0.73	7.76e-22	Blood trace element (Zn levels);
TGCT	trans	rs6089829	0.851	rs6089827	chr20:61668845	C/T	cg23505145	chr19:12996616	KLF1	0.89	9.9	0.66	2.21e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs4555082	0.874	rs78923231	chr14:105754033	C/T	cg01266790	chr14:105781312	PACS2	0.57	4.65	0.39	8.29e-6	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs3796352	1.000	rs59583591	chr3:53119581	T/C	cg15956490	chr3:53032818	SFMBT1	0.49	5.58	0.45	1.41e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs59197085	0.636	rs60389668	chr7:128452556	T/G	cg00260937	chr7:128520193	KCP	0.47	4.9	0.4	2.92e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
TGCT	cis	rs7666738	0.830	rs6855393	chr4:99056534	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.45	0.56	1.4e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg22857025	chr5:266934	NA	-0.32	-6.58	-0.51	1.18e-9	Breast cancer;
TGCT	cis	rs1580019	0.713	rs2167274	chr7:32524844	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.02	10.57	0.69	5.23e-19	Cognitive ability;
TGCT	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7824557	0.872	rs2572417	chr8:11111462	A/T	cg21775007	chr8:11205619	TDH	-0.52	-4.92	-0.4	2.64e-6	Retinal vascular caliber;
TGCT	cis	rs12142240	0.698	rs66972124	chr1:46807445	A/G	cg00530320	chr1:46809349	NSUN4	0.29	5.88	0.47	3.63e-8	Menopause (age at onset);
TGCT	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg23758822	chr17:41437982	NA	-0.67	-6.73	-0.52	5.47e-10	Menopause (age at onset);
TGCT	cis	rs9393777	0.513	rs6936555	chr6:26640886	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.59	-5.33	-0.43	4.44e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs6570726	0.818	rs437978	chr6:145809134	A/G	cg23711669	chr6:146136114	FBXO30	0.76	7.57	0.56	7.21e-12	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs8064299	0.597	rs2016126	chr17:72784932	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.88	10.14	0.67	5.78e-18	Monocyte count;
TGCT	cis	rs921968	0.541	rs576901	chr2:219424364	A/G	cg02176678	chr2:219576539	TTLL4	0.48	6.78	0.52	4.32e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg20276088	chr3:133502917	NA	0.24	4.98	0.41	2.07e-6	Iron status biomarkers;
TGCT	cis	rs6964587	1.000	rs1063243	chr7:91726927	A/C	cg17063962	chr7:91808500	NA	0.86	9.47	0.65	2.39e-16	Breast cancer;
TGCT	cis	rs1865760	0.551	rs9461230	chr6:26019240	G/C	cg17042849	chr6:26104293	HIST1H4C	-0.66	-5.91	-0.47	3.15e-8	Height;
TGCT	cis	rs736408	0.812	rs746694	chr3:52826620	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.49	-4.49	-0.37	1.58e-5	Bipolar disorder;
TGCT	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.48	-0.37	1.66e-5	Bipolar disorder;
TGCT	cis	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg20637647	chr7:64974828	NA	-0.9	-5.31	-0.43	4.87e-7	Diabetic kidney disease;
TGCT	cis	rs2439831	1.000	rs561863	chr15:43761352	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.8	5.7	0.46	8.33e-8	Lung cancer in ever smokers;
TGCT	cis	rs9914988	0.943	rs7224870	chr17:27102620	A/G	cg20469991	chr17:27169893	C17orf63	-0.66	-5.03	-0.41	1.65e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs1215050	0.740	rs2555390	chr4:98999112	A/G	cg17366294	chr4:99064904	C4orf37	-0.54	-5.81	-0.46	4.85e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2204008	0.775	rs12369238	chr12:38176051	A/G	cg13010199	chr12:38710504	ALG10B	0.6	4.8	0.4	4.57e-6	Bladder cancer;
TGCT	cis	rs7909074	0.831	rs2065466	chr10:45384047	T/C	cg05187965	chr10:45406764	TMEM72	-0.27	-5.76	-0.46	6.14e-8	Mean corpuscular volume;
TGCT	cis	rs1372520	0.748	rs1471484	chr4:90754313	C/T	cg15133208	chr4:90757351	SNCA	-0.46	-5.2	-0.42	8.04e-7	Neuroticism;
TGCT	cis	rs7172809	0.561	rs74026925	chr15:77798709	A/G	cg22256960	chr15:77711686	NA	-0.51	-4.84	-0.4	3.83e-6	Glucose homeostasis traits;
TGCT	cis	rs8017423	0.967	rs2401875	chr14:90688451	A/G	cg04374321	chr14:90722782	PSMC1	0.77	8.02	0.58	6.73e-13	Mortality in heart failure;
TGCT	cis	rs12210905	0.688	rs9368509	chr6:27379422	A/G	cg08851530	chr6:28072375	NA	-1.38	-6.42	-0.5	2.57e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs2730245	0.851	rs2657333	chr7:158728743	G/A	cg11984989	chr7:158649758	WDR60	-0.95	-8.47	-0.61	5.89e-14	Height;
TGCT	cis	rs2836950	0.527	rs2836948	chr21:40599677	T/C	cg17971929	chr21:40555470	PSMG1	-0.51	-4.64	-0.38	8.88e-6	Menarche (age at onset);
TGCT	cis	rs9905704	0.671	rs28709536	chr17:57008912	C/A	cg05425664	chr17:57184151	TRIM37	-0.57	-4.44	-0.37	1.97e-5	Testicular germ cell tumor;
TGCT	cis	rs7267979	1.000	rs2257432	chr20:25271086	T/C	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1949733	0.958	rs2631731	chr4:8429817	A/G	cg11789530	chr4:8429930	ACOX3	0.63	5.72	0.46	7.58e-8	Response to antineoplastic agents;
TGCT	cis	rs9653442	0.545	rs1821827	chr2:100764717	T/C	cg07810366	chr2:100720526	AFF3	-0.38	-5.62	-0.45	1.21e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	trans	rs7726839	0.540	rs61731455	chr5:665295	A/G	cg11887960	chr12:57824829	NA	1.15	9.91	0.66	2.07e-17	Obesity-related traits;
TGCT	cis	rs9303401	0.659	rs16943326	chr17:57050365	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.6	6.14	0.48	1.01e-8	Cognitive test performance;
TGCT	cis	rs6750795	0.502	rs11685196	chr2:232381298	A/G	cg12810212	chr2:232379626	C2orf52	0.45	4.92	0.4	2.72e-6	Height;
TGCT	cis	rs523522	0.924	rs11065150	chr12:120958875	T/G	cg12219531	chr12:120966889	COQ5	0.83	7.36	0.55	2.24e-11	High light scatter reticulocyte count;
TGCT	cis	rs60871478	0.636	rs4721834	chr7:896142	C/T	cg15782153	chr7:917662	C7orf20	0.54	4.92	0.4	2.74e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs968451	0.951	rs5757622	chr22:39728861	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.91	8.88	0.62	6.32e-15	Primary biliary cholangitis;
TGCT	cis	rs9926296	0.593	rs6500456	chr16:89888341	T/C	cg26513180	chr16:89883248	FANCA	0.75	7.39	0.55	1.92e-11	Vitiligo;
TGCT	cis	rs4727027	0.933	rs10238826	chr7:148830888	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	4.58	0.38	1.13e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	trans	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg15556689	chr8:8085844	FLJ10661	-0.85	-8.31	-0.6	1.39e-13	Retinal vascular caliber;
TGCT	cis	rs477895	0.838	rs35090903	chr11:64000598	C/T	cg23719950	chr11:63933701	MACROD1	-0.68	-5.65	-0.45	1.07e-7	Mean platelet volume;
TGCT	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg03303774	chr4:1407052	NA	-0.29	-5.08	-0.41	1.37e-6	Obesity-related traits;
TGCT	cis	rs2153535	0.580	rs6918391	chr6:8461178	A/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs9468199	0.510	rs72851161	chr6:28071123	A/G	cg08851530	chr6:28072375	NA	1.56	7.21	0.54	4.9e-11	Parkinson's disease;
TGCT	cis	rs4788570	0.566	rs8053992	chr16:71505495	G/A	cg06353428	chr16:71660113	MARVELD3	-1.19	-7.71	-0.57	3.49e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs2463822	1.000	rs1406384	chr11:62083530	A/G	cg06239285	chr11:62104954	ASRGL1	-0.93	-6.73	-0.52	5.56e-10	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs6570726	0.875	rs12524077	chr6:145866333	G/C	cg23711669	chr6:146136114	FBXO30	0.71	7.03	0.53	1.25e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9303401	0.527	rs34835800	chr17:56764990	G/A	cg25039879	chr17:56429692	SUPT4H1	0.53	4.55	0.38	1.25e-5	Cognitive test performance;
TGCT	cis	rs12497850	0.865	rs7649458	chr3:48920127	C/T	cg05785598	chr3:49045655	WDR6	0.35	4.72	0.39	6.35e-6	Parkinson's disease;
TGCT	cis	rs7681440	0.904	rs12331318	chr4:90770255	A/G	cg26578617	chr4:90757533	SNCA	-0.47	-4.78	-0.39	4.95e-6	Dementia with Lewy bodies;
TGCT	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs912057	0.833	rs1294436	chr6:6746166	G/C	cg06612196	chr6:6737390	NA	0.37	4.7	0.39	6.75e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs61990749	0.597	rs12896026	chr14:78244436	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.61	4.52	0.38	1.43e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs6095298	0.595	rs35567324	chr20:47453054	T/C	cg12307787	chr20:48099359	KCNB1	0.42	4.51	0.38	1.51e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs6684514	1.000	rs12045339	chr1:156294211	C/T	cg16558208	chr1:156270281	VHLL	0.48	9.6	0.65	1.19e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs1371867	0.875	rs1788187	chr8:101336099	A/G	cg00191853	chr8:101177733	SPAG1	-0.23	-4.76	-0.39	5.2e-6	Atrioventricular conduction;
TGCT	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg24250549	chr1:154909240	PMVK	0.66	6.5	0.5	1.73e-9	Prostate cancer;
TGCT	cis	rs4824093	0.610	rs3761496	chr22:50246466	T/C	cg20569369	chr22:51173646	NA	0.28	4.58	0.38	1.13e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs6964587	0.933	rs10271174	chr7:91785970	A/G	cg17063962	chr7:91808500	NA	0.89	9.55	0.65	1.55e-16	Breast cancer;
TGCT	cis	rs813218	0.565	rs2449106	chr3:99602087	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-5.49	-0.44	2.19e-7	Orofacial clefts;
TGCT	cis	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg20637647	chr7:64974828	NA	-0.9	-5.31	-0.43	4.87e-7	Diabetic kidney disease;
TGCT	cis	rs35883536	0.626	rs12135243	chr1:101092955	G/A	cg06223162	chr1:101003688	GPR88	-0.4	-7.07	-0.54	1.01e-10	Monocyte count;
TGCT	cis	rs992157	0.835	rs4674282	chr2:219144230	A/T	cg00012203	chr2:219082015	ARPC2	-0.79	-7.91	-0.58	1.22e-12	Colorectal cancer;
TGCT	cis	rs10782582	0.609	rs1628063	chr1:76391646	A/G	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.53	4.66	0.39	7.96e-6	Daytime sleep phenotypes;
TGCT	cis	rs12497850	0.797	rs61583136	chr3:49189195	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.49	-4.47	-0.37	1.72e-5	Parkinson's disease;
TGCT	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg03161606	chr19:29218774	NA	0.6	5.79	0.46	5.33e-8	Methadone dose in opioid dependence;
TGCT	cis	rs60843830	0.661	rs7588043	chr2:104979	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.54	4.51	0.38	1.45e-5	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg13206674	chr6:150067644	NUP43	0.52	4.51	0.38	1.5e-5	Lung cancer;
TGCT	cis	rs751728	0.965	rs9394168	chr6:33759701	T/A	cg00334056	chr6:33755658	LEMD2	-0.25	-4.52	-0.38	1.44e-5	Crohn's disease;
TGCT	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg04944784	chr2:26401820	FAM59B	-0.72	-5.92	-0.47	2.93e-8	Gut microbiome composition (summer);
TGCT	cis	rs3008870	1.000	rs12740884	chr1:67459855	C/A	cg03991309	chr1:68237761	GNG12	-0.27	-4.53	-0.38	1.36e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs9457247	1.000	rs397713	chr6:167386714	G/A	cg23791538	chr6:167370224	RNASET2	-0.5	-4.98	-0.41	2.08e-6	Crohn's disease;
TGCT	cis	rs6582630	0.555	rs12372536	chr12:38400864	C/G	cg26384229	chr12:38710491	ALG10B	0.83	7.39	0.55	1.92e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs9311474	0.713	rs352171	chr3:52234203	A/G	cg10802521	chr3:52805072	NEK4	-0.56	-6.01	-0.48	1.9e-8	Electroencephalogram traits;
TGCT	cis	rs763121	0.853	rs1043441	chr22:39130964	C/T	cg06022373	chr22:39101656	GTPBP1	0.79	7.32	0.55	2.68e-11	Menopause (age at onset);
TGCT	cis	rs7714584	1.000	rs11748158	chr5:150226345	C/T	cg22134413	chr5:150180641	NA	0.89	6.96	0.53	1.73e-10	Crohn's disease;
TGCT	cis	rs6952808	0.609	rs6970033	chr7:1948087	G/A	cg22963979	chr7:1858916	MAD1L1	-0.37	-5.62	-0.45	1.22e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs9549367	0.713	rs553316	chr13:113838015	A/G	cg00898013	chr13:113819073	PROZ	0.53	7.2	0.54	5.17e-11	Platelet distribution width;
TGCT	cis	rs670523	0.804	rs2364400	chr1:155997173	T/C	cg05700447	chr1:155978627	NA	-0.19	-4.62	-0.38	9.36e-6	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs7666738	0.830	rs1426664	chr4:98988264	A/C	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9902453	0.791	rs2628166	chr17:28113123	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-6.81	-0.52	3.65e-10	Coffee consumption (cups per day);
TGCT	cis	rs4372836	0.930	rs7589860	chr2:28967648	A/T	cg09522027	chr2:28974177	PPP1CB	-0.59	-5.15	-0.42	1e-6	Body mass index;
TGCT	trans	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg13615516	chr5:77269221	NA	0.7	8.72	0.62	1.53e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.0	-7.42	-0.55	1.64e-11	Gut microbiome composition (summer);
TGCT	cis	rs17539620	0.624	rs62432739	chr6:154835926	A/G	cg20019720	chr6:154832845	CNKSR3	0.57	5.02	0.41	1.72e-6	Lipoprotein (a) levels;
TGCT	cis	rs6540559	1.000	rs6696825	chr1:209982372	A/G	cg23283495	chr1:209979779	IRF6	0.67	5.59	0.45	1.35e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs6032067	0.516	rs57047308	chr20:43899974	T/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.38	-5.96	-0.47	2.38e-8	Blood protein levels;
TGCT	cis	rs1018836	0.892	rs11776824	chr8:91553256	T/C	cg16814680	chr8:91681699	NA	-0.77	-8.22	-0.59	2.3e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs713587	0.713	rs11682135	chr2:25205377	G/A	cg15423357	chr2:25149977	NA	-0.58	-5.9	-0.47	3.16e-8	Body mass index in non-asthmatics;
TGCT	cis	rs508618	1.000	rs508618	chr1:231532312	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-5.46	-0.44	2.46e-7	Red blood cell count;
TGCT	cis	rs2228479	0.850	rs17226973	chr16:89825248	T/C	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs999943	0.846	rs9366826	chr6:33619184	C/G	cg14003231	chr6:33640908	ITPR3	0.37	4.61	0.38	9.72e-6	Obesity (extreme);
TGCT	cis	rs9383153	1.000	rs2237223	chr6:16329741	G/A	cg03173502	chr6:15505345	JARID2	0.83	4.59	0.38	1.06e-5	Gambling;
TGCT	cis	rs6459804	0.588	rs2109303	chr7:157506846	G/A	cg14168080	chr7:157504135	PTPRN2	-0.4	-4.49	-0.37	1.58e-5	Bipolar disorder and schizophrenia;
TGCT	cis	rs360798	0.512	rs360801	chr2:62955387	C/T	cg17519650	chr2:63277830	OTX1	0.61	4.81	0.4	4.24e-6	Coronary artery disease;
TGCT	cis	rs12497850	0.931	rs4974087	chr3:48919232	A/G	cg06212747	chr3:49208901	KLHDC8B	0.61	5.62	0.45	1.2e-7	Parkinson's disease;
TGCT	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg20887711	chr4:1340912	KIAA1530	0.76	6.31	0.49	4.41e-9	Longevity;
TGCT	cis	rs7523273	0.606	rs2796268	chr1:207925192	G/A	cg22525895	chr1:207977042	MIR29B2	0.54	9.18	0.64	1.18e-15	Schizophrenia;
TGCT	cis	rs9393692	0.905	rs9379838	chr6:26277133	C/T	cg05868516	chr6:26286170	HIST1H4H	0.56	5.35	0.43	4.01e-7	Educational attainment;
TGCT	cis	rs9916302	0.904	rs8068427	chr17:37511517	G/A	cg15445000	chr17:37608096	MED1	-0.35	-5.05	-0.41	1.53e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs12712073	0.512	rs6710355	chr2:100699994	T/C	cg22139774	chr2:100720529	AFF3	-0.4	-6.29	-0.49	4.87e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs250677	0.522	rs919730	chr5:148352401	T/C	cg18129178	chr5:148520854	ABLIM3	0.4	5.14	0.42	1.04e-6	Breast cancer;
TGCT	cis	rs6540559	1.000	rs6696825	chr1:209982372	A/G	cg21951975	chr1:209979733	IRF6	0.71	5.98	0.47	2.21e-8	Cleft lip with or without cleft palate;
TGCT	cis	rs57221529	0.766	rs72703075	chr5:592819	C/T	cg16624210	chr5:671434	TPPP	0.45	4.9	0.4	2.9e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg22105103	chr4:187893119	NA	0.34	4.62	0.38	9.32e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9640161	0.742	rs2108854	chr7:150017408	C/T	cg10018233	chr7:150070692	REPIN1	-0.33	-4.68	-0.39	7.25e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs9303401	0.659	rs12935851	chr17:56600244	C/A	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs67478160	0.655	rs4900598	chr14:104281541	T/C	cg26031613	chr14:104095156	KLC1	-0.63	-6.52	-0.51	1.61e-9	Schizophrenia;
TGCT	trans	rs7824557	0.564	rs7834572	chr8:11236685	C/T	cg15556689	chr8:8085844	FLJ10661	-0.74	-6.68	-0.51	7.12e-10	Retinal vascular caliber;
TGCT	cis	rs9911578	1.000	rs9892062	chr17:56976981	G/A	cg05425664	chr17:57184151	TRIM37	-0.62	-6.18	-0.49	8.33e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs1215050	0.740	rs2555390	chr4:98999112	A/G	cg05340658	chr4:99064831	C4orf37	-0.41	-5.03	-0.41	1.69e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7666738	0.830	rs1426662	chr4:98990319	C/T	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28595532	0.920	rs115154263	chr4:119765307	G/A	cg21605333	chr4:119757512	SEC24D	1.57	8.38	0.6	9.59e-14	Cannabis dependence symptom count;
TGCT	cis	rs1865760	0.623	rs12216125	chr6:25997458	C/T	cg17042849	chr6:26104293	HIST1H4C	-0.72	-6.45	-0.5	2.28e-9	Height;
TGCT	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg13206674	chr6:150067644	NUP43	0.52	4.51	0.38	1.5e-5	Lung cancer;
TGCT	cis	rs3784262	0.739	rs1550574	chr15:58213368	G/T	cg12031962	chr15:58353849	ALDH1A2	-0.54	-7.79	-0.57	2.3e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg16145915	chr7:1198662	ZFAND2A	-0.4	-4.78	-0.39	4.86e-6	Longevity;Endometriosis;
TGCT	cis	rs72945132	0.882	rs55758686	chr11:70172204	C/T	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg12570787	chr5:219185	SDHA;CCDC127	0.66	4.48	0.37	1.64e-5	Breast cancer;
TGCT	cis	rs1766786	1.000	rs1766792	chr1:119465681	A/T	cg03855857	chr1:119029635	NA	-0.43	-4.47	-0.37	1.72e-5	Chin dimples;
TGCT	cis	rs3772130	0.962	rs11707518	chr3:121496568	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.72	0.39	6.25e-6	Cognitive performance;
TGCT	cis	rs314370	0.951	rs13226502	chr7:100506381	C/T	cg10426581	chr7:100472382	SRRT	1.02	11.08	0.71	2.94e-20	Resting heart rate;
TGCT	cis	rs9291683	0.595	rs11731110	chr4:10037346	T/C	cg11266682	chr4:10021025	SLC2A9	0.64	8.91	0.62	5.31e-15	Bone mineral density;
TGCT	cis	rs10114408	0.959	rs7030088	chr9:96663432	A/C	cg13679303	chr9:96623674	NA	-0.36	-4.63	-0.38	9.04e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs875971	0.577	rs34888281	chr7:65585771	C/T	cg18876405	chr7:65276391	NA	-0.4	-6.01	-0.48	1.89e-8	Aortic root size;
TGCT	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg16145915	chr7:1198662	ZFAND2A	0.39	4.71	0.39	6.54e-6	Longevity;Endometriosis;
TGCT	cis	rs11148252	0.774	rs9596649	chr13:52934610	A/G	cg00495681	chr13:53174319	NA	-0.58	-5.69	-0.45	8.79e-8	Lewy body disease;
TGCT	cis	rs3796352	1.000	rs11713859	chr3:53042080	C/A	cg27565382	chr3:53032988	SFMBT1	0.45	4.58	0.38	1.14e-5	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs17331151	0.573	rs3755801	chr3:52865798	G/A	cg07884673	chr3:53033167	SFMBT1	0.48	5.54	0.45	1.76e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs10466239	0.614	rs56214316	chr10:43861106	G/A	cg08951903	chr10:44070173	ZNF239	-0.76	-4.46	-0.37	1.84e-5	Telomere length;
TGCT	cis	rs9443645	0.901	rs4421161	chr6:79564219	A/G	cg05283184	chr6:79620031	NA	0.21	4.7	0.39	6.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	6.12	0.48	1.11e-8	Bipolar disorder;
TGCT	cis	rs11577318	0.853	rs7416513	chr1:26647949	G/C	cg04990556	chr1:26633338	UBXN11	-0.6	-4.96	-0.41	2.28e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg25767906	chr1:53392781	SCP2	-0.52	-6.19	-0.49	8.06e-9	Monocyte count;
TGCT	cis	rs9457247	1.000	rs400063	chr6:167386592	C/T	cg25258033	chr6:167368657	RNASET2	0.18	4.49	0.37	1.63e-5	Crohn's disease;
TGCT	cis	rs3020736	0.500	rs6002618	chr22:42507859	G/C	cg05082376	chr22:42548792	NA	0.23	5.43	0.44	2.83e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1568889	1.000	rs12802157	chr11:28060285	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	8.86	0.62	7.07e-15	Bipolar disorder;
TGCT	cis	rs7267979	0.844	rs6115188	chr20:25432170	G/T	cg16686733	chr20:25566563	NINL	0.52	4.93	0.4	2.62e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9399135	0.967	rs6925424	chr6:135313948	T/A	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.36e-6	Red blood cell count;
TGCT	cis	rs7104764	1.000	rs1128320	chr11:244167	C/T	cg18336825	chr11:236787	PSMD13;SIRT3	1.07	11.19	0.71	1.61e-20	Menarche (age at onset);
TGCT	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg19774624	chr17:42201019	HDAC5	0.84	8.43	0.6	7.41e-14	Total body bone mineral density;
TGCT	cis	rs17152411	1.000	rs11245423	chr10:126588435	C/A	cg07906193	chr10:126599966	NA	0.41	5.05	0.41	1.52e-6	Height;
TGCT	cis	rs7103648	0.669	rs11039332	chr11:47695840	G/A	cg20307385	chr11:47447363	PSMC3	0.83	7.81	0.57	2.1e-12	Diastolic blood pressure;Systolic blood pressure;
TGCT	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg10295955	chr4:187884368	NA	-0.97	-14.62	-0.8	9.35e-29	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11098499	0.866	rs13125526	chr4:120288019	G/A	cg09307838	chr4:120376055	NA	0.58	5.76	0.46	6.16e-8	Corneal astigmatism;
TGCT	cis	rs10791097	0.694	rs12361892	chr11:130744490	T/G	cg14779329	chr11:130786720	SNX19	0.28	4.82	0.4	4.09e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs7208859	0.623	rs1061343	chr17:29114276	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs1878931	0.501	rs9302871	chr16:3415512	T/C	cg22508957	chr16:3507546	NAT15	-0.38	-4.98	-0.41	2.1e-6	Body mass index (adult);
TGCT	cis	rs250677	0.652	rs250680	chr5:148436024	T/C	cg23229984	chr5:148520753	ABLIM3	0.21	4.89	0.4	3.11e-6	Breast cancer;
TGCT	cis	rs7103648	0.545	rs6485795	chr11:47929846	G/A	cg20307385	chr11:47447363	PSMC3	0.74	6.87	0.52	2.82e-10	Diastolic blood pressure;Systolic blood pressure;
TGCT	cis	rs4076943	0.500	rs4909973	chr11:11273949	C/T	cg21653586	chr11:10530636	NA	-0.49	-4.91	-0.4	2.76e-6	Post bronchodilator FEV1;
TGCT	cis	rs1008375	1.000	rs2315561	chr4:17679695	C/T	cg18681998	chr4:17616180	MED28	0.91	10.53	0.69	6.55e-19	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs13102973	0.682	rs7691622	chr4:135889689	T/C	cg14419869	chr4:135874104	NA	0.26	4.6	0.38	1.03e-5	Subjective well-being;
TGCT	cis	rs7659604	0.540	rs7699289	chr4:122671553	G/A	cg19748678	chr4:122722346	EXOSC9	-0.51	-4.93	-0.4	2.61e-6	Type 2 diabetes;
TGCT	cis	rs600231	0.665	rs1621277	chr11:65221954	A/G	cg17120908	chr11:65337727	SSSCA1	0.5	4.81	0.4	4.36e-6	Bone mineral density;
TGCT	cis	rs9549260	0.755	rs2721044	chr13:41162225	C/T	cg21288729	chr13:41239152	FOXO1	1.0	10.34	0.68	1.84e-18	Red blood cell count;
TGCT	cis	rs7772486	0.701	rs697056	chr6:146003897	C/T	cg23711669	chr6:146136114	FBXO30	-0.93	-10.83	-0.7	1.24e-19	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9457247	1.000	rs405553	chr6:167395058	A/G	cg25258033	chr6:167368657	RNASET2	0.18	4.49	0.37	1.63e-5	Crohn's disease;
TGCT	cis	rs617219	0.698	rs7706045	chr5:78507910	T/G	cg09550809	chr5:78407562	BHMT	0.4	5.71	0.46	7.79e-8	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs7226408	0.901	rs72885252	chr18:34429398	T/C	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs7666738	0.791	rs13111960	chr4:98976851	C/T	cg05340658	chr4:99064831	C4orf37	0.5	5.84	0.46	4.35e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7786808	0.552	rs12539355	chr7:158187565	C/T	cg01191920	chr7:158217561	PTPRN2	-0.37	-5.44	-0.44	2.67e-7	Obesity-related traits;
TGCT	cis	rs7659604	0.502	rs13128434	chr4:122672461	A/C	cg19748678	chr4:122722346	EXOSC9	-0.51	-5.01	-0.41	1.86e-6	Type 2 diabetes;
TGCT	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg03303774	chr4:1407052	NA	-0.32	-4.92	-0.4	2.7e-6	Obesity-related traits;
TGCT	cis	rs210152	0.531	rs3130023	chr6:33448862	A/G	cg16739976	chr6:34101401	GRM4	-0.58	-4.75	-0.39	5.47e-6	Schizophrenia;
TGCT	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg05368731	chr17:41323189	NBR1	1.16	13.7	0.78	1.41e-26	Menopause (age at onset);
TGCT	cis	rs9611565	0.877	rs3817999	chr22:41747717	A/G	cg13695892	chr22:41940480	POLR3H	0.91	9.67	0.66	8.18e-17	Vitiligo;
TGCT	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg18876405	chr7:65276391	NA	-0.35	-5.31	-0.43	4.85e-7	Aortic root size;
TGCT	cis	rs6121246	0.954	rs6058470	chr20:30416827	A/T	cg18721089	chr20:30220636	NA	-0.43	-4.75	-0.39	5.54e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs4595586	0.545	rs7980848	chr12:39375166	G/C	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs782590	0.805	rs782578	chr2:55915904	A/C	cg03859395	chr2:55845619	SMEK2	0.82	9.59	0.65	1.22e-16	Metabolic syndrome;
TGCT	cis	rs752092	0.925	rs8032007	chr15:101790817	C/T	cg19997662	chr15:101784653	CHSY1	0.27	5.04	0.41	1.58e-6	Corneal structure;
TGCT	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg11062466	chr8:58055876	NA	0.4	4.62	0.38	9.62e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg03396347	chr1:1875803	NA	-0.36	-6.51	-0.5	1.68e-9	Body mass index;
TGCT	cis	rs6570726	0.738	rs6917199	chr6:145918320	G/A	cg13319975	chr6:146136371	FBXO30	-0.54	-4.77	-0.39	5.1e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs12220238	1.000	rs11000909	chr10:75944828	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.28	0.55	3.4e-11	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs3087591	0.922	rs11867284	chr17:29597464	G/A	cg24425628	chr17:29625626	OMG;NF1	0.49	7.55	0.56	8.21e-12	Hip circumference;
TGCT	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.26	4.81	0.4	4.35e-6	Schizophrenia;
TGCT	cis	rs8072100	0.967	rs11871606	chr17:45732774	G/T	cg08085267	chr17:45401833	C17orf57	0.43	4.81	0.4	4.28e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	trans	rs1814175	0.817	rs10769613	chr11:49769692	G/A	cg03929089	chr4:120376271	NA	-0.69	-8.17	-0.59	3.03e-13	Height;
TGCT	cis	rs881375	0.715	rs10985073	chr9:123643855	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	5.31	0.43	4.82e-7	Rheumatoid arthritis;
TGCT	cis	rs651907	0.535	rs34263427	chr3:101507805	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	4.85	0.4	3.68e-6	Colorectal cancer;
TGCT	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg08219700	chr8:58056026	NA	0.41	4.94	0.41	2.47e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9926296	0.609	rs4785714	chr16:89798404	G/T	cg04287289	chr16:89883240	FANCA	-0.61	-6.06	-0.48	1.54e-8	Vitiligo;
TGCT	cis	rs3617	0.503	rs9866243	chr3:52915219	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.48	-4.52	-0.38	1.41e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs308403	0.600	rs13129352	chr4:123633736	G/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.72	6.52	0.51	1.57e-9	Blood protein levels;
TGCT	cis	rs1577917	1.000	rs12201741	chr6:86602619	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-5.27	-0.43	5.73e-7	Response to antipsychotic treatment;
TGCT	trans	rs696279	1.000	rs696279	chr7:16700798	A/G	cg14841483	chr5:131310671	ACSL6	-0.38	-6.7	-0.52	6.51e-10	Mean platelet volume;
TGCT	cis	rs4654899	0.965	rs6692244	chr1:21396886	C/A	cg01072550	chr1:21505969	NA	-0.49	-7.88	-0.58	1.41e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg06238570	chr21:40685208	BRWD1	0.73	6.66	0.51	8.12e-10	Cognitive function;
TGCT	cis	rs9303401	0.527	rs2116450	chr17:56745561	C/T	cg25039879	chr17:56429692	SUPT4H1	0.53	4.55	0.38	1.25e-5	Cognitive test performance;
TGCT	cis	rs896854	0.654	rs13278601	chr8:95972974	G/C	cg09323728	chr8:95962352	TP53INP1	-0.52	-6.6	-0.51	1.07e-9	Type 2 diabetes;
TGCT	cis	rs2046867	0.908	rs68142603	chr3:72790220	A/C	cg25664220	chr3:72788482	NA	-0.56	-7.15	-0.54	6.59e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs1355223	0.583	rs1828298	chr11:34870439	A/G	cg24088639	chr11:34937564	PDHX;APIP	-0.51	-4.54	-0.38	1.31e-5	Systemic lupus erythematosus and Systemic sclerosis;
TGCT	cis	rs7804356	1.000	rs12536560	chr7:26822876	G/C	cg03456212	chr7:26904342	SKAP2	-0.64	-4.88	-0.4	3.16e-6	Type 1 diabetes;
TGCT	cis	rs2230307	0.536	rs560659	chr1:100523536	A/G	cg24955406	chr1:100503596	HIAT1	-0.72	-4.64	-0.38	8.69e-6	Carotid intima media thickness;
TGCT	cis	rs2688482	0.512	rs3103954	chr3:195516630	G/T	cg13752114	chr3:195489708	MUC4	0.34	4.98	0.41	2.07e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs9302001	0.881	rs12583303	chr13:95469027	C/T	cg07483244	chr13:95358924	NA	0.37	4.84	0.4	3.86e-6	Panic disorder;
TGCT	cis	rs9372498	0.505	rs9481789	chr6:118734320	A/C	cg07617317	chr6:118971624	C6orf204	0.5	5.39	0.44	3.37e-7	Diastolic blood pressure;
TGCT	cis	rs7552404	0.924	rs1498317	chr1:76171984	A/C	cg03433033	chr1:76189801	ACADM	0.82	9.89	0.66	2.31e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7584330	0.744	rs72620822	chr2:238379582	C/T	cg14458575	chr2:238380390	NA	0.61	9.25	0.64	8.25e-16	Prostate cancer;
TGCT	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.63	-6.31	-0.49	4.49e-9	Prostate cancer;
TGCT	cis	rs7119	0.689	rs12916833	chr15:77819778	G/A	cg27398640	chr15:77910606	LINGO1	-0.26	-4.66	-0.39	7.98e-6	Type 2 diabetes;
TGCT	cis	rs6815814	0.904	rs2101521	chr4:38811551	C/T	cg02016764	chr4:38805732	TLR1	-0.29	-4.76	-0.39	5.31e-6	Breast cancer;
TGCT	cis	rs1868673	0.545	rs9855441	chr3:150099659	C/A	cg24290546	chr3:150134309	TSC22D2	-0.3	-4.75	-0.39	5.42e-6	Waist circumference;
TGCT	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg26119090	chr2:26468346	HADHA;HADHB	0.96	5.78	0.46	5.81e-8	Gut microbiome composition (summer);
TGCT	cis	rs7178572	0.568	rs12909924	chr15:77551445	T/G	cg15453836	chr15:77711506	NA	-0.42	-4.79	-0.4	4.68e-6	Type 2 diabetes;
TGCT	cis	rs6701037	0.512	rs4650716	chr1:175128711	C/A	cg08873628	chr1:175162347	KIAA0040	0.48	4.57	0.38	1.15e-5	Alcohol dependence;
TGCT	cis	rs9929218	0.551	rs2274240	chr16:68725486	A/G	cg01251360	chr16:68772225	CDH1	-0.27	-5.02	-0.41	1.75e-6	Colorectal cancer;
TGCT	cis	rs7394190	0.748	rs1057410	chr10:75574079	G/A	cg07699608	chr10:75541558	CHCHD1	0.81	5.6	0.45	1.33e-7	Incident atrial fibrillation;
TGCT	cis	rs1572072	0.545	rs765606	chr13:24163339	A/G	cg06150803	chr13:24144257	TNFRSF19	-0.38	-4.48	-0.37	1.66e-5	Nasopharyngeal carcinoma;
TGCT	cis	rs6570726	0.764	rs451108	chr6:145844309	T/C	cg23711669	chr6:146136114	FBXO30	0.88	9.55	0.65	1.54e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9916302	0.904	rs4511574	chr17:37532916	A/G	cg07936489	chr17:37558343	FBXL20	-0.62	-4.71	-0.39	6.66e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs9916302	0.851	rs11078904	chr17:37650569	G/A	cg07936489	chr17:37558343	FBXL20	-0.62	-4.91	-0.4	2.85e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs28595532	1.000	rs116030177	chr4:119650768	T/C	cg14228332	chr4:119757509	SEC24D	1.02	5.37	0.43	3.75e-7	Cannabis dependence symptom count;
TGCT	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg26338869	chr17:61819248	STRADA	-0.53	-4.85	-0.4	3.68e-6	Prudent dietary pattern;
TGCT	cis	rs67460515	0.892	rs11929238	chr3:161045937	A/T	cg03342759	chr3:160939853	NMD3	-0.48	-5.16	-0.42	9.65e-7	Parkinson's disease;
TGCT	cis	rs17253792	0.822	rs17685078	chr14:56127202	T/C	cg01858014	chr14:56050164	KTN1	-0.35	-4.65	-0.39	8.23e-6	Putamen volume;
TGCT	trans	rs4819388	0.709	rs2329712	chr21:45639245	C/T	cg17383793	chr5:52405638	MOCS2	-0.71	-6.73	-0.52	5.65e-10	Celiac disease;
TGCT	cis	rs11690935	0.632	rs34531723	chr2:172564094	A/C	cg13550731	chr2:172543902	DYNC1I2	0.68	5.99	0.47	2.13e-8	Schizophrenia;
TGCT	cis	rs12220238	0.822	rs7919517	chr10:76111355	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.9	6.17	0.48	9.08e-9	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs3806843	0.576	rs155360	chr5:140309016	C/T	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.43	-5.34	-0.43	4.19e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs3771570	1.000	rs73020143	chr2:242261240	T/A	cg21155796	chr2:242212141	HDLBP	0.98	6.68	0.51	7.29e-10	Prostate cancer;
TGCT	cis	rs13401104	0.716	rs10204147	chr2:237130344	A/C	cg19324714	chr2:237145437	ASB18	0.46	5.03	0.41	1.69e-6	Educational attainment;
TGCT	cis	rs2235642	0.717	rs2236269	chr16:1652614	T/A	cg11375102	chr16:1583810	IFT140;TMEM204	-0.27	-4.66	-0.39	7.98e-6	Coronary artery disease;
TGCT	cis	rs6964587	0.843	rs56075286	chr7:91731518	G/A	cg17063962	chr7:91808500	NA	0.88	9.59	0.65	1.26e-16	Breast cancer;
TGCT	cis	rs7552404	1.000	rs6672180	chr1:76123973	C/G	cg22875332	chr1:76189707	ACADM	0.8	9.87	0.66	2.65e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2970818	0.764	rs11063182	chr12:4581371	A/G	cg21129006	chr12:4023078	NA	0.3	4.67	0.39	7.76e-6	Phosphorus levels;
TGCT	cis	rs7666738	1.000	rs13116475	chr4:99054843	C/T	cg17366294	chr4:99064904	C4orf37	-0.76	-6.93	-0.53	1.99e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg10295955	chr4:187884368	NA	-0.96	-13.98	-0.78	3.07e-27	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6912958	0.781	rs4464759	chr6:88282621	A/C	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.91	-0.4	2.78e-6	Monocyte percentage of white cells;
TGCT	cis	rs896854	0.516	rs12679044	chr8:95891356	C/A	cg13393036	chr8:95962371	TP53INP1	-0.51	-6.29	-0.49	5e-9	Type 2 diabetes;
TGCT	cis	rs9926296	1.000	rs9926296	chr16:89818089	A/G	cg27121462	chr16:89883253	FANCA	0.71	7.27	0.55	3.46e-11	Vitiligo;
TGCT	cis	rs2235642	0.859	rs12599207	chr16:1606445	A/G	cg07639376	chr16:1584516	IFT140;TMEM204	-0.32	-5.63	-0.45	1.16e-7	Coronary artery disease;
TGCT	cis	rs7772486	0.754	rs9386134	chr6:146145508	G/A	cg13319975	chr6:146136371	FBXO30	-0.53	-4.76	-0.39	5.37e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2456568	0.802	rs11020585	chr11:93638493	A/C	cg17595323	chr11:93583763	C11orf90	0.46	6.36	0.5	3.59e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs9291683	0.655	rs3822242	chr4:10094904	T/C	cg00071950	chr4:10020882	SLC2A9	-0.51	-5.66	-0.45	9.86e-8	Bone mineral density;
TGCT	cis	rs2228479	0.867	rs34604714	chr16:89948985	A/G	cg19635926	chr16:89946313	TCF25	0.28	4.8	0.4	4.47e-6	Skin colour saturation;
TGCT	cis	rs5769765	0.955	rs8139758	chr22:50261123	G/T	cg15316289	chr22:50310904	ALG12;CRELD2	-0.41	-6.13	-0.48	1.08e-8	Schizophrenia;
TGCT	cis	rs9549260	0.755	rs7989711	chr13:41215696	C/T	cg21288729	chr13:41239152	FOXO1	0.97	10.09	0.67	7.57e-18	Red blood cell count;
TGCT	cis	rs1008375	0.932	rs6835077	chr4:17653285	A/T	cg16339924	chr4:17578868	LAP3	0.66	5.52	0.44	1.89e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7208859	0.623	rs59447372	chr17:29057585	C/T	cg13385521	chr17:29058706	SUZ12P	0.79	4.77	0.39	5.16e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs3806843	0.576	rs155358	chr5:140297032	A/T	cg09824255	chr5:140014002	CD14	0.25	4.48	0.37	1.69e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs11722228	0.964	rs10939614	chr4:9926613	T/C	cg11266682	chr4:10021025	SLC2A9	-0.51	-5.76	-0.46	6.17e-8	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg12963246	chr6:28129442	ZNF389	0.51	5.02	0.41	1.73e-6	Depression;
TGCT	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg11764359	chr7:65958608	NA	0.59	5.29	0.43	5.45e-7	Aortic root size;
TGCT	cis	rs9611565	0.608	rs2003816	chr22:42095140	T/G	cg06481639	chr22:41940642	POLR3H	0.57	4.86	0.4	3.51e-6	Vitiligo;
TGCT	cis	rs6089829	0.888	rs4809467	chr20:61671688	A/G	cg08564027	chr20:61660810	NA	0.37	5.98	0.47	2.26e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs922182	0.595	rs9302232	chr15:64205358	C/T	cg02919090	chr15:64263738	DAPK2	0.37	6.9	0.53	2.35e-10	Blood protein levels;
TGCT	cis	rs9911578	0.935	rs2567912	chr17:56731270	T/C	cg12560992	chr17:57184187	TRIM37	0.75	9.21	0.64	1.04e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs2380220	0.576	rs7751219	chr6:96018915	G/A	cg04719120	chr6:96025338	MANEA	0.73	5.45	0.44	2.66e-7	Behavioural disinhibition (generation interaction);
TGCT	cis	rs12142240	0.698	rs12385696	chr1:46818836	A/G	cg00530320	chr1:46809349	NSUN4	0.3	6.29	0.49	5.07e-9	Menopause (age at onset);
TGCT	cis	rs9467773	0.620	rs2494694	chr6:26619328	A/T	cg02458000	chr6:26745757	NA	0.55	5.25	0.43	6.28e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs12908161	0.959	rs17598603	chr15:85200211	C/G	cg12863693	chr15:85201151	NMB	-0.44	-5.38	-0.44	3.5e-7	Schizophrenia;
TGCT	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg19774624	chr17:42201019	HDAC5	-0.88	-10.92	-0.7	7.5e-20	Total body bone mineral density;
TGCT	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg18402987	chr7:1209562	NA	0.47	4.68	0.39	7.37e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs68170813	0.652	rs74374590	chr7:107172470	G/A	cg02696742	chr7:106810147	HBP1	-0.58	-4.47	-0.37	1.74e-5	Coronary artery disease;
TGCT	cis	rs9560113	0.573	rs9560133	chr13:112240013	C/A	cg10483660	chr13:112241077	NA	0.36	5.67	0.45	9.63e-8	Menarche (age at onset);
TGCT	cis	rs6840360	1.000	rs6849050	chr4:152599902	C/T	cg17479576	chr4:152424074	FAM160A1	-0.5	-5.25	-0.43	6.5e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs804280	0.662	rs7826055	chr8:11611723	G/C	cg26752888	chr8:11627280	NEIL2	0.6	4.92	0.4	2.66e-6	Myopia (pathological);
TGCT	cis	rs11190604	0.945	rs11190573	chr10:102233172	T/C	cg23241863	chr10:102295624	HIF1AN	0.62	4.87	0.4	3.27e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg07507251	chr3:52567010	NT5DC2	0.47	6.55	0.51	1.36e-9	Bipolar disorder;
TGCT	cis	rs2456568	0.503	rs4254038	chr11:93666978	T/C	cg17595323	chr11:93583763	C11orf90	-0.47	-5.84	-0.46	4.28e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg23758822	chr17:41437982	NA	0.78	7.29	0.55	3.14e-11	Menopause (age at onset);
TGCT	cis	rs9660180	0.967	rs12040325	chr1:1702436	G/A	cg23982607	chr1:1823379	GNB1	-0.55	-8.56	-0.61	3.62e-14	Body mass index;
TGCT	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg17971929	chr21:40555470	PSMG1	0.68	6.1	0.48	1.28e-8	Cognitive function;
TGCT	cis	rs1552244	0.554	rs34883592	chr3:10046165	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.33	-4.95	-0.41	2.39e-6	Alzheimer's disease;
TGCT	cis	rs4713118	0.662	rs9468275	chr6:28026136	G/T	cg12963246	chr6:28129442	ZNF389	0.45	4.55	0.38	1.27e-5	Parkinson's disease;
TGCT	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs12477438	0.765	rs7605734	chr2:99644068	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-7.6	-0.56	6.47e-12	Chronic sinus infection;
TGCT	cis	rs11673344	0.542	rs826324	chr19:37505245	A/T	cg08039142	chr19:36980659	ZNF566	0.52	4.84	0.4	3.71e-6	Obesity-related traits;
TGCT	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg11247378	chr22:39784982	NA	-0.72	-10.08	-0.67	8.19e-18	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs1023500	0.551	rs2301521	chr22:42423110	G/C	cg15557168	chr22:42548783	NA	-0.19	-4.82	-0.4	4.12e-6	Schizophrenia;
TGCT	cis	rs185694	1.000	rs202101	chr13:30897337	A/G	cg07600127	chr13:30881527	KATNAL1	-0.81	-6.53	-0.51	1.53e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
TGCT	cis	rs6582630	0.537	rs1829579	chr12:38420555	A/G	cg26384229	chr12:38710491	ALG10B	0.84	7.7	0.57	3.77e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs2797160	1.000	rs1739367	chr6:126004720	G/T	cg05901451	chr6:126070800	HEY2	-0.74	-6.3	-0.49	4.62e-9	Endometrial cancer;
TGCT	cis	rs4383453	0.539	rs4678018	chr3:123102044	G/A	cg04890266	chr3:123102914	ADCY5	-0.49	-7.91	-0.58	1.23e-12	Gestational age at birth (maternal effect);
TGCT	cis	rs1865760	0.622	rs9295685	chr6:26071725	G/C	cg16482183	chr6:26056742	HIST1H1C	0.58	4.96	0.41	2.25e-6	Height;
TGCT	cis	rs36051895	0.632	rs7871515	chr9:5175288	A/G	cg02405213	chr9:5042618	JAK2	0.75	10.62	0.69	3.84e-19	Pediatric autoimmune diseases;
TGCT	cis	rs12681287	0.517	rs7462883	chr8:87526790	G/A	cg27223183	chr8:87520930	FAM82B	-0.96	-7.03	-0.53	1.21e-10	Caudate activity during reward;
TGCT	cis	rs826838	0.967	rs11183022	chr12:38652519	G/A	cg26384229	chr12:38710491	ALG10B	1.05	10.25	0.68	3.18e-18	Heart rate;
TGCT	cis	rs9611565	0.512	rs9607842	chr22:42192722	G/A	cg03806693	chr22:41940476	POLR3H	-1.0	-10.21	-0.68	3.92e-18	Vitiligo;
TGCT	cis	rs595982	0.527	rs55706579	chr19:49382969	G/A	cg21252483	chr19:49399788	TULP2	-0.46	-6.92	-0.53	2.12e-10	Red cell distribution width;
TGCT	cis	rs11252926	0.537	rs61836851	chr10:447231	T/C	cg13477178	chr10:375248	DIP2C	-0.24	-4.47	-0.37	1.71e-5	Psychosis in Alzheimer's disease;
TGCT	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs1158570	0.843	rs3057	chr8:131329837	C/T	cg16277922	chr8:131349729	ASAP1	0.48	7.21	0.54	4.89e-11	Platelet count;
TGCT	cis	rs2721195	0.845	rs1063739	chr8:145729727	C/A	cg15857475	chr8:145742913	RECQL4;LRRC14	0.87	9.17	0.64	1.26e-15	Age at first birth;
TGCT	cis	rs74233809	1.000	rs11191543	chr10:104824387	G/A	cg05855489	chr10:104503620	C10orf26	0.82	4.61	0.38	9.67e-6	Birth weight;
TGCT	cis	rs4851266	0.901	rs4851271	chr2:100833058	T/C	cg22139774	chr2:100720529	AFF3	-0.34	-5.09	-0.42	1.28e-6	Educational attainment;
TGCT	cis	rs7267979	1.000	rs2424712	chr20:25416942	T/C	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9467773	0.869	rs742090	chr6:26415637	A/C	cg15659132	chr6:26577336	NA	-0.53	-5.58	-0.45	1.46e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs6663390	0.510	rs2267895	chr1:208081063	C/T	cg03990033	chr1:208084030	CD34	0.73	6.41	0.5	2.77e-9	Facial morphology (factor 18);
TGCT	cis	rs231513	0.655	rs231446	chr17:42005193	G/A	cg26893861	chr17:41843967	DUSP3	-0.61	-5.11	-0.42	1.18e-6	Cognitive function;
TGCT	cis	rs6450176	1.000	rs1445887	chr5:53299376	A/T	ch.5.1024479R	chr5:53302184	ARL15	-0.53	-5.1	-0.42	1.23e-6	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg08280861	chr8:58055591	NA	0.36	4.97	0.41	2.17e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9868809	0.656	rs73078362	chr3:48703917	G/C	cg07636037	chr3:49044803	WDR6	-1.0	-4.6	-0.38	1.04e-5	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs7156960	0.540	rs4903393	chr14:76734188	A/C	cg13981132	chr14:76734493	NA	-0.36	-5.63	-0.45	1.13e-7	Acute lymphoblastic leukemia (childhood);
TGCT	cis	rs3806843	1.000	rs2240692	chr5:140183585	A/G	cg19875535	chr5:140030758	IK	0.35	5.85	0.47	4.01e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2290405	0.527	rs6829987	chr4:932974	C/G	cg04824913	chr4:887549	GAK	-0.36	-4.56	-0.38	1.23e-5	Systemic sclerosis;
TGCT	cis	rs4273100	0.688	rs12938803	chr17:19204432	A/C	cg01534423	chr17:18965556	NA	-0.81	-6.87	-0.52	2.78e-10	Schizophrenia;
TGCT	cis	rs9534288	0.830	rs1126364	chr13:46633394	C/G	cg15192986	chr13:46630673	CPB2	-0.5	-6.23	-0.49	6.66e-9	Blood protein levels;
TGCT	cis	rs78707713	0.592	rs3829182	chr10:71251384	A/G	cg14388049	chr10:71211838	TSPAN15	-0.4	-4.77	-0.39	5.01e-6	Venous thromboembolism;
TGCT	cis	rs9929218	0.529	rs17715450	chr16:68729785	C/A	cg01251360	chr16:68772225	CDH1	-0.26	-4.76	-0.39	5.4e-6	Colorectal cancer;
TGCT	cis	rs500492	0.542	rs421245	chr16:1074458	G/C	cg01366354	chr16:1075121	NA	0.36	5.23	0.43	6.99e-7	Polycystic ovary syndrome;
TGCT	cis	rs10022260	1	rs10022260	chr4:83793921	C/T	cg00595051	chr4:83955429	COPS4	-0.41	-5.25	-0.43	6.43e-7	Adult asthma;
TGCT	cis	rs8180040	0.726	rs6774733	chr3:46991241	G/A	cg27129171	chr3:47204927	SETD2	0.73	9.44	0.65	2.94e-16	Colorectal cancer;
TGCT	cis	rs1570884	0.516	rs9316462	chr13:50176321	A/G	cg08779649	chr13:50194554	NA	0.37	5.84	0.46	4.24e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
TGCT	cis	rs9467773	1.000	rs9393728	chr6:26509330	C/G	cg05738196	chr6:26577821	NA	0.88	12.49	0.75	1.09e-23	Intelligence (multi-trait analysis);
TGCT	trans	rs7726839	0.561	rs4957049	chr5:579080	C/A	cg25482853	chr8:67687455	SGK3	1.05	9.29	0.64	6.67e-16	Obesity-related traits;
TGCT	cis	rs71435601	0.628	rs540897	chr2:21383982	A/G	cg25035485	chr2:21266500	APOB	0.51	4.48	0.37	1.64e-5	Cholesterol, total;
TGCT	cis	rs7809950	0.906	rs2395907	chr7:107253304	A/G	cg23024343	chr7:107201750	COG5	0.35	5.57	0.45	1.48e-7	Coronary artery disease;
TGCT	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg07507251	chr3:52567010	NT5DC2	0.47	6.7	0.52	6.49e-10	Bipolar disorder;
TGCT	cis	rs2439831	0.850	rs3742982	chr15:44176681	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	5.75	0.46	6.66e-8	Lung cancer in ever smokers;
TGCT	cis	rs6700896	0.500	rs11208688	chr1:66081355	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.59	4.56	0.38	1.22e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs8103278	0.826	rs11669442	chr19:46374557	A/G	cg14061069	chr19:46274453	DMPK	-0.43	-5.82	-0.46	4.69e-8	Coronary artery disease;
TGCT	cis	rs1538970	0.781	rs34768551	chr1:46020408	G/A	cg05343316	chr1:45956843	TESK2	0.67	5.15	0.42	9.98e-7	Platelet count;
TGCT	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg12140144	chr1:2984275	FLJ42875;PRDM16	-0.32	-4.46	-0.37	1.81e-5	Height;
TGCT	cis	rs7829975	0.517	rs12542733	chr8:8824858	G/T	cg06636001	chr8:8085503	FLJ10661	-0.78	-7.01	-0.53	1.34e-10	Mood instability;
TGCT	cis	rs10984561	0.881	rs59720051	chr9:122251073	G/T	cg14242995	chr9:122249943	NA	0.73	5.96	0.47	2.46e-8	Pulmonary function decline;
TGCT	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg04414720	chr1:150670196	GOLPH3L	0.39	5.04	0.41	1.58e-6	Tonsillectomy;
TGCT	cis	rs28595532	0.841	rs115918392	chr4:119610356	T/A	cg21605333	chr4:119757512	SEC24D	1.36	7.24	0.55	4.12e-11	Cannabis dependence symptom count;
TGCT	cis	rs12421382	0.659	rs1837397	chr11:109389803	A/C	cg16359550	chr11:109292809	C11orf87	0.41	4.57	0.38	1.17e-5	Schizophrenia;
TGCT	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg25767906	chr1:53392781	SCP2	-0.54	-6.16	-0.48	9.25e-9	Monocyte count;
TGCT	cis	rs6121246	0.697	rs6088864	chr20:30228157	G/A	cg21427119	chr20:30132790	HM13	-0.37	-5.19	-0.42	8.51e-7	Mean corpuscular hemoglobin;
TGCT	cis	rs1048238	0.506	rs10927866	chr1:16175317	C/T	cg21385522	chr1:16154831	NA	0.61	7.01	0.53	1.34e-10	Systolic blood pressure;
TGCT	cis	rs79349575	0.749	rs519537	chr17:46971140	G/A	cg26022315	chr17:47021804	SNF8	0.47	4.55	0.38	1.28e-5	Type 2 diabetes;
TGCT	cis	rs2836974	0.965	rs8134733	chr21:40683459	C/T	cg06238570	chr21:40685208	BRWD1	0.74	6.54	0.51	1.45e-9	Cognitive function;
TGCT	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg06634786	chr22:41940651	POLR3H	-0.9	-8.72	-0.62	1.55e-14	Vitiligo;
TGCT	cis	rs7666738	0.830	rs880470	chr4:98922522	A/T	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12220898	0.749	rs10732631	chr10:50485910	T/C	cg06072769	chr10:50146962	WDFY4	0.38	5.07	0.41	1.38e-6	Inflammatory biomarkers;
TGCT	cis	rs1580019	0.665	rs34147895	chr7:32531796	G/C	cg06627557	chr7:32535165	LSM5;AVL9	1.03	10.62	0.69	3.91e-19	Cognitive ability;
TGCT	cis	rs2033711	0.840	rs4801590	chr19:58961813	G/C	cg13877915	chr19:58951672	ZNF132	0.92	11.68	0.72	1.01e-21	Uric acid clearance;
TGCT	cis	rs13191362	0.507	rs2510207	chr6:163086592	T/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.6	-5.54	-0.45	1.75e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs12497850	0.897	rs9681717	chr3:48872998	A/G	cg05785598	chr3:49045655	WDR6	0.36	4.84	0.4	3.73e-6	Parkinson's disease;
TGCT	cis	rs9915657	0.715	rs12952178	chr17:70107622	G/T	cg06234051	chr17:70120541	SOX9	-0.24	-5.14	-0.42	1.03e-6	Thyroid hormone levels;
TGCT	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg13665807	chr20:60559372	TAF4	-0.53	-5.39	-0.44	3.47e-7	Body mass index;
TGCT	cis	rs1577917	1.000	rs6454513	chr6:86720049	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.64	5.14	0.42	1.06e-6	Response to antipsychotic treatment;
TGCT	cis	rs7100689	0.577	rs2342813	chr10:82046302	T/G	cg01528321	chr10:82214614	TSPAN14	0.67	6.45	0.5	2.31e-9	Post bronchodilator FEV1;
TGCT	cis	rs3096299	0.933	rs747485	chr16:89474094	T/C	cg02187348	chr16:89574699	SPG7	0.49	4.72	0.39	6.35e-6	Multiple myeloma (IgH translocation);
TGCT	cis	rs2544523	0.511	rs10929387	chr2:15912926	A/G	cg26669897	chr2:15909070	NA	0.37	4.7	0.39	6.89e-6	Asthma or chronic obstructive pulmonary disease;
TGCT	cis	rs3091242	0.933	rs10903130	chr1:25769221	A/T	cg23205692	chr1:25664452	TMEM50A	0.47	4.97	0.41	2.22e-6	Erythrocyte sedimentation rate;
TGCT	cis	rs11578119	0.898	rs10919424	chr1:170481571	G/A	cg09767346	chr1:170501363	GORAB	0.66	5.29	0.43	5.27e-7	Male-pattern baldness;
TGCT	cis	rs16939607	1.000	rs16939607	chr8:79013333	A/G	cg21244580	chr8:79934476	NA	-0.47	-4.68	-0.39	7.33e-6	White blood cell count;
TGCT	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	16.07	0.82	4.21e-32	Prudent dietary pattern;
TGCT	cis	rs10927875	0.541	rs1739841	chr1:16342727	A/G	cg21385522	chr1:16154831	NA	0.46	4.75	0.39	5.5e-6	Dilated cardiomyopathy;
TGCT	cis	rs9549367	0.737	rs71446680	chr13:113894846	C/T	cg00898013	chr13:113819073	PROZ	-0.4	-5.03	-0.41	1.64e-6	Platelet distribution width;
TGCT	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs734999	0.566	rs10797435	chr1:2534801	G/C	cg18854424	chr1:2615690	NA	0.43	4.96	0.41	2.31e-6	Ulcerative colitis;
TGCT	cis	rs1997103	0.911	rs17777	chr7:55380765	T/C	cg17469321	chr7:55412551	NA	0.63	6.37	0.5	3.41e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg08859206	chr1:53392774	SCP2	0.46	7.11	0.54	8.24e-11	Monocyte count;
TGCT	cis	rs10986311	0.775	rs7857897	chr9:127118550	G/A	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.2	4.87	0.4	3.36e-6	Vitiligo;
TGCT	cis	rs4087296	0.671	rs11150459	chr16:82379577	A/G	cg05453434	chr16:83371223	CDH13	0.31	4.44	0.37	1.93e-5	Bone mineral density;
TGCT	cis	rs71435601	0.600	rs544655	chr2:21384441	G/T	cg25035485	chr2:21266500	APOB	0.51	4.48	0.37	1.64e-5	Cholesterol, total;
TGCT	cis	rs903263	0.601	rs72711192	chr1:84562805	A/G	cg09664975	chr1:84543551	PRKACB	0.5	4.87	0.4	3.36e-6	Breast cancer (male);
TGCT	cis	rs1018836	0.923	rs2105967	chr8:91587522	A/G	cg16814680	chr8:91681699	NA	-0.81	-8.26	-0.6	1.84e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9457247	1.000	rs429083	chr6:167383972	T/C	cg25258033	chr6:167368657	RNASET2	0.18	4.49	0.37	1.63e-5	Crohn's disease;
TGCT	cis	rs3617	0.625	rs7612624	chr3:52893426	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	0.49	4.79	0.4	4.67e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg18876405	chr7:65276391	NA	-0.32	-4.92	-0.4	2.69e-6	Aortic root size;
TGCT	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg11890956	chr21:40555474	PSMG1	1.11	12.43	0.74	1.56e-23	Cognitive function;
TGCT	cis	rs3785574	0.650	rs7406102	chr17:62004749	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.55	-4.87	-0.4	3.36e-6	Height;
TGCT	cis	rs9611565	0.625	rs2076199	chr22:41903743	G/T	cg06634786	chr22:41940651	POLR3H	-0.76	-7.16	-0.54	6.31e-11	Vitiligo;
TGCT	cis	rs4654899	0.931	rs2275468	chr1:21220375	T/G	cg01072550	chr1:21505969	NA	0.49	7.73	0.57	3.2e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs7439150	1.000	rs2042642	chr4:155487221	G/C	cg22130008	chr4:155548532	NA	-0.48	-5.99	-0.47	2.07e-8	Fibrinogen levels;
TGCT	cis	rs739496	0.615	rs59905228	chr12:112181226	C/T	cg10833066	chr12:111807467	FAM109A	0.36	4.67	0.39	7.74e-6	Platelet count;
TGCT	cis	rs6570726	0.791	rs365869	chr6:145884751	C/T	cg13319975	chr6:146136371	FBXO30	-0.51	-4.6	-0.38	1.01e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6701037	0.566	rs10753091	chr1:175134571	T/C	cg00321850	chr1:175162397	KIAA0040	0.38	5.04	0.41	1.61e-6	Alcohol dependence;
TGCT	cis	rs9379850	0.730	rs9393738	chr6:26620658	G/A	cg15659132	chr6:26577336	NA	-0.72	-5.29	-0.43	5.24e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs924607	1.000	rs11746907	chr5:598224	G/A	cg04476341	chr5:669733	TPPP	-0.26	-4.59	-0.38	1.05e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs2070488	1.000	rs762317	chr3:38497659	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	9.66	0.66	8.59e-17	Electrocardiographic conduction measures;
TGCT	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2996428	0.667	rs11576900	chr1:3770914	A/G	cg13057898	chr1:3703894	LRRC47	0.21	4.64	0.38	8.81e-6	Red cell distribution width;
TGCT	cis	rs72700829	0.518	rs11548267	chr1:150238699	T/C	cg18798344	chr1:149336151	NA	0.56	4.5	0.37	1.52e-5	Schizophrenia;
TGCT	trans	rs7618501	0.572	rs7428430	chr3:50174184	C/T	cg21659725	chr3:3221576	CRBN	-0.66	-7.3	-0.55	3.08e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs6688613	0.685	rs4657613	chr1:166870878	A/G	cg07049167	chr1:166818506	POGK	0.25	5.39	0.44	3.45e-7	Refractive astigmatism;
TGCT	cis	rs2658782	0.547	rs3020065	chr11:93059899	A/G	cg15737290	chr11:93063684	CCDC67	1.05	11.65	0.72	1.24e-21	Pulmonary function decline;
TGCT	cis	rs11671005	0.651	rs35117909	chr19:58912906	G/A	cg13877915	chr19:58951672	ZNF132	0.66	4.9	0.4	2.94e-6	Mean platelet volume;
TGCT	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg07157834	chr1:205819609	PM20D1	0.45	7.32	0.55	2.76e-11	Menarche (age at onset);
TGCT	cis	rs711245	0.573	rs11899523	chr2:36800918	T/C	cg09467607	chr2:36825704	FEZ2	0.33	4.67	0.39	7.72e-6	Height;
TGCT	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg12288994	chr5:1860383	NA	0.24	4.65	0.39	8.46e-6	Cardiovascular disease risk factors;
TGCT	trans	rs7726839	0.540	rs7558	chr5:660491	C/T	cg25482853	chr8:67687455	SGK3	1.19	9.73	0.66	5.75e-17	Obesity-related traits;
TGCT	cis	rs921968	0.541	rs7574429	chr2:219498759	T/G	cg02176678	chr2:219576539	TTLL4	0.48	6.73	0.52	5.53e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg20887711	chr4:1340912	KIAA1530	0.54	5.03	0.41	1.69e-6	Longevity;
TGCT	cis	rs587847	0.522	rs582122	chr15:37687805	A/T	cg22444584	chr15:37174661	LOC145845	-0.31	-4.61	-0.38	1e-5	Intraocular pressure;
TGCT	cis	rs1062177	0.724	rs2915828	chr5:151118121	G/A	cg12924095	chr5:151150029	G3BP1	-0.34	-4.97	-0.41	2.17e-6	Preschool internalizing problems;
TGCT	cis	rs10464366	0.912	rs6979668	chr7:39104228	G/A	cg18850127	chr7:39170497	POU6F2	0.21	4.5	0.37	1.55e-5	IgG glycosylation;
TGCT	cis	rs9902453	0.689	rs56788338	chr17:28186557	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.87	8.54	0.61	4.08e-14	Coffee consumption (cups per day);
TGCT	cis	rs13256369	0.951	rs12679360	chr8:8566269	G/T	cg17143192	chr8:8559678	CLDN23	-0.55	-5.52	-0.44	1.88e-7	Obesity-related traits;
TGCT	cis	rs739496	0.615	rs847895	chr12:112118576	T/C	cg10833066	chr12:111807467	FAM109A	0.37	4.79	0.39	4.76e-6	Platelet count;
TGCT	cis	rs7617773	0.963	rs9822496	chr3:48181333	T/C	cg11946769	chr3:48343235	NME6	0.59	5.3	0.43	5.19e-7	Coronary artery disease;
TGCT	cis	rs17376456	0.542	rs2084916	chr5:93194961	A/T	cg21475434	chr5:93447410	FAM172A	-0.7	-5.15	-0.42	1.02e-6	Diabetic retinopathy;
TGCT	cis	rs2760061	0.583	rs708110	chr1:228190805	T/A	cg18477163	chr1:228402036	OBSCN	0.35	7.06	0.54	1.03e-10	Diastolic blood pressure;
TGCT	cis	rs317865	0.867	rs56106162	chr4:16159062	G/A	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.67	4.62	0.38	9.31e-6	Kidney disease (early stage) in type 1 diabetes;
TGCT	cis	rs11785400	0.793	rs4403386	chr8:143736770	C/G	cg10596483	chr8:143751796	JRK	0.54	5.44	0.44	2.7e-7	Schizophrenia;
TGCT	cis	rs2239547	0.562	rs35380116	chr3:52979178	A/G	cg11645453	chr3:52864694	ITIH4	-0.32	-5.28	-0.43	5.48e-7	Schizophrenia;
TGCT	trans	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg13615516	chr5:77269221	NA	0.67	8.36	0.6	1.09e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs6429082	0.683	rs868815	chr1:235584543	C/G	cg26050004	chr1:235667680	B3GALNT2	-0.56	-4.95	-0.41	2.41e-6	Adiposity;
TGCT	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg23758822	chr17:41437982	NA	0.72	6.77	0.52	4.51e-10	Menopause (age at onset);
TGCT	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg07507251	chr3:52567010	NT5DC2	0.48	7.06	0.54	1.05e-10	Bipolar disorder;
TGCT	cis	rs151997	0.962	rs27936	chr5:50181418	T/A	cg06027927	chr5:50259733	NA	0.46	4.61	0.38	9.69e-6	Callous-unemotional behaviour;
TGCT	cis	rs9325144	0.647	rs34311455	chr12:39060889	C/T	cg10518543	chr12:38710700	ALG10B	-0.48	-4.47	-0.37	1.77e-5	Morning vs. evening chronotype;
TGCT	cis	rs9814567	0.752	rs6764764	chr3:134331167	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.78	6.94	0.53	1.91e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	trans	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg11887960	chr12:57824829	NA	1.16	9.59	0.65	1.25e-16	Lung disease severity in cystic fibrosis;
TGCT	cis	rs2072499	0.966	rs1137703	chr1:156184458	T/C	cg06970220	chr1:156163860	SLC25A44	0.67	5.98	0.47	2.22e-8	Testicular germ cell tumor;
TGCT	cis	rs2657888	0.529	rs11171862	chr12:56871314	C/T	cg23002907	chr12:56915593	RBMS2	-0.42	-5.69	-0.45	8.68e-8	Adiponectin levels;
TGCT	cis	rs950169	1.000	rs62026530	chr15:84775840	G/T	cg17173187	chr15:85201210	NMB	0.47	5.23	0.43	7.01e-7	Schizophrenia;
TGCT	cis	rs11785400	0.793	rs4457308	chr8:143733922	G/A	cg10596483	chr8:143751796	JRK	0.55	5.47	0.44	2.41e-7	Schizophrenia;
TGCT	cis	rs7772486	0.875	rs2748498	chr6:146319166	C/G	cg23711669	chr6:146136114	FBXO30	0.87	9.38	0.64	4.09e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg27170947	chr2:26402098	FAM59B	-0.4	-4.66	-0.39	8.04e-6	Gut microbiome composition (summer);
TGCT	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg16325326	chr1:53192061	ZYG11B	0.59	6.41	0.5	2.81e-9	Monocyte count;
TGCT	cis	rs10986311	0.802	rs2416	chr9:127113660	A/G	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.19	4.72	0.39	6.24e-6	Vitiligo;
TGCT	cis	rs2228479	0.850	rs62054638	chr16:89821131	G/C	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs9858542	1.000	rs34762726	chr3:49689210	G/A	cg03060546	chr3:49711283	APEH	-0.67	-6.09	-0.48	1.28e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs12286929	0.576	rs2275997	chr11:115100186	A/G	cg16269184	chr11:114127960	NA	-0.2	-4.86	-0.4	3.55e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs12142240	0.738	rs10489769	chr1:46806703	A/G	cg00530320	chr1:46809349	NSUN4	0.29	5.95	0.47	2.58e-8	Menopause (age at onset);
TGCT	cis	rs2964802	0.505	rs7447014	chr5:10814212	T/C	cg14521931	chr5:10832172	NA	-0.28	-4.61	-0.38	9.72e-6	Major depressive disorder;Recurrent major depressive disorder;
TGCT	trans	rs208520	0.874	rs208473	chr6:66917265	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.95	-9.95	-0.67	1.64e-17	Exhaled nitric oxide output;
TGCT	cis	rs1691799	0.899	rs1168318	chr12:66745269	A/G	cg16791601	chr12:66731901	HELB	0.28	5.98	0.47	2.19e-8	White blood cell count (basophil);
TGCT	cis	rs9929218	0.954	rs17715799	chr16:68830511	A/T	cg03880890	chr16:69439245	NA	-0.22	-4.47	-0.37	1.73e-5	Colorectal cancer;
TGCT	cis	rs7681440	0.647	rs1442133	chr4:90819195	C/T	cg20003494	chr4:90757398	SNCA	-0.53	-4.73	-0.39	5.98e-6	Dementia with Lewy bodies;
TGCT	cis	rs2562456	0.917	rs11085463	chr19:21751302	G/T	cg25650185	chr19:21324782	ZNF431	-0.63	-5.58	-0.45	1.43e-7	Pain;
TGCT	cis	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg18252515	chr7:66147081	NA	-1.31	-8.17	-0.59	2.99e-13	Diabetic kidney disease;
TGCT	trans	rs561341	1.000	rs564714	chr17:30318404	C/T	cg20587970	chr11:113659929	NA	-1.04	-12.57	-0.75	6.97e-24	Hip circumference adjusted for BMI;
TGCT	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg17971929	chr21:40555470	PSMG1	-0.51	-4.64	-0.38	8.79e-6	Menarche (age at onset);
TGCT	cis	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg20362242	chr5:692897	TPPP	0.53	4.56	0.38	1.22e-5	Obesity-related traits;
TGCT	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg03517284	chr6:25882590	NA	-0.6	-5.33	-0.43	4.57e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs11096990	0.593	rs6531700	chr4:39270885	T/G	cg20847110	chr4:39482781	LOC401127	-0.16	-4.53	-0.38	1.36e-5	Cognitive function;
TGCT	cis	rs4076943	0.603	rs7941021	chr11:11271212	T/C	cg21653586	chr11:10530636	NA	0.5	5.07	0.41	1.43e-6	Post bronchodilator FEV1;
TGCT	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg11965913	chr1:205819406	PM20D1	0.48	6.6	0.51	1.07e-9	Menarche (age at onset);
TGCT	cis	rs4808199	0.901	rs12973258	chr19:19488718	T/C	cg03709012	chr19:19516395	GATAD2A	1.0	7.84	0.58	1.77e-12	Nonalcoholic fatty liver disease;
TGCT	cis	rs651907	0.557	rs59596156	chr3:101394217	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.92	11.52	0.72	2.52e-21	Colorectal cancer;
TGCT	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg06481639	chr22:41940642	POLR3H	-0.74	-6.74	-0.52	5.38e-10	Vitiligo;
TGCT	cis	rs921968	0.591	rs13421421	chr2:219519286	A/G	cg02176678	chr2:219576539	TTLL4	0.43	6.07	0.48	1.44e-8	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs12477438	0.765	rs62156363	chr2:99693324	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-4.62	-0.38	9.47e-6	Chronic sinus infection;
TGCT	cis	rs7395581	0.918	rs7124955	chr11:47315274	A/T	cg20307385	chr11:47447363	PSMC3	-0.53	-4.46	-0.37	1.83e-5	HDL cholesterol;
TGCT	cis	rs1215050	0.655	rs3974902	chr4:98644254	C/T	cg05340658	chr4:99064831	C4orf37	-0.44	-5.25	-0.43	6.25e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1577917	0.958	rs2100109	chr6:86544926	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.29	-0.43	5.34e-7	Response to antipsychotic treatment;
TGCT	cis	rs7091068	0.532	rs554062	chr10:95399535	T/A	cg20715218	chr10:95462985	C10orf4	-0.49	-6.01	-0.47	1.96e-8	Urinary tract infection frequency;
TGCT	cis	rs6424115	0.800	rs2229581	chr1:24201094	G/C	cg15997130	chr1:24165203	NA	0.85	9.25	0.64	8.02e-16	Immature fraction of reticulocytes;
TGCT	cis	rs9435341	0.930	rs2232015	chr1:107599258	A/T	cg09367891	chr1:107599246	PRMT6	0.64	5.58	0.45	1.43e-7	Facial morphology (factor 21, depth of nasal alae);
TGCT	cis	rs208520	0.661	rs150263	chr6:66777620	T/C	cg07460842	chr6:66804631	NA	-0.95	-9.97	-0.67	1.53e-17	Exhaled nitric oxide output;
TGCT	cis	rs2224391	1.000	rs2773320	chr6:5261681	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.8	-6.12	-0.48	1.13e-8	Height;
TGCT	cis	rs4383453	0.539	rs12631979	chr3:123097710	A/G	cg04890266	chr3:123102914	ADCY5	-0.5	-8.34	-0.6	1.2e-13	Gestational age at birth (maternal effect);
TGCT	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg06634786	chr22:41940651	POLR3H	-0.88	-8.54	-0.61	3.98e-14	Vitiligo;
TGCT	cis	rs2688608	0.560	rs10128354	chr10:75470045	T/C	cg04320760	chr10:75533139	FUT11	-0.38	-5.86	-0.47	3.9e-8	Inflammatory bowel disease;
TGCT	cis	rs904251	0.861	rs1757173	chr6:37486952	A/C	cg01843034	chr6:37503916	NA	-0.52	-6.29	-0.49	4.88e-9	Cognitive performance;
TGCT	cis	rs9796	0.774	rs28866311	chr15:41442195	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.51	-6.56	-0.51	1.33e-9	Menopause (age at onset);
TGCT	cis	rs2594989	0.733	rs9876898	chr3:11567961	T/C	cg00170343	chr3:11313890	ATG7	-0.66	-5.26	-0.43	6.1e-7	Circulating chemerin levels;
TGCT	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg03213289	chr20:61660250	NA	0.69	10.06	0.67	9.06e-18	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg04267008	chr7:1944627	MAD1L1	-0.35	-4.72	-0.39	6.16e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs7017914	0.905	rs2732095	chr8:71919946	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.55	-5.1	-0.42	1.24e-6	Bone mineral density;
TGCT	cis	rs7666738	0.830	rs17558151	chr4:99048699	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.94	0.47	2.68e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6570726	0.791	rs621382	chr6:145799144	T/C	cg23711669	chr6:146136114	FBXO30	0.89	9.84	0.66	3.1e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7100689	0.622	rs4536152	chr10:82119242	C/T	cg01528321	chr10:82214614	TSPAN14	0.81	7.75	0.57	2.9e-12	Post bronchodilator FEV1;
TGCT	cis	rs6831352	0.918	rs17218560	chr4:100060794	C/T	cg12011299	chr4:100065546	ADH4	0.4	4.75	0.39	5.55e-6	Alcohol dependence;
TGCT	cis	rs7772486	0.754	rs857881	chr6:145970793	C/A	cg05347473	chr6:146136440	FBXO30	-0.5	-4.61	-0.38	9.92e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9560113	1.000	rs9555811	chr13:112181532	A/C	cg14154082	chr13:112174009	NA	0.38	5.01	0.41	1.83e-6	Menarche (age at onset);
TGCT	cis	rs7017914	0.840	rs2732099	chr8:71921050	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.55	-5.05	-0.41	1.52e-6	Bone mineral density;
TGCT	cis	rs7980687	0.550	rs1727324	chr12:123698603	A/T	cg00376283	chr12:123451042	ABCB9	0.73	5.1	0.42	1.26e-6	Height;Educational attainment;Head circumference (infant);
TGCT	cis	rs6430585	0.702	rs746857	chr2:136554890	G/A	cg07169764	chr2:136633963	MCM6	-1.18	-10.81	-0.7	1.33e-19	Corneal structure;
TGCT	cis	rs3761847	0.622	rs10435888	chr9:123819603	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.43	4.52	0.38	1.42e-5	Rheumatoid arthritis;
TGCT	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg16325326	chr1:53192061	ZYG11B	0.63	7.34	0.55	2.51e-11	Monocyte count;
TGCT	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg09365446	chr1:150670422	GOLPH3L	0.31	4.66	0.39	8.17e-6	Tonsillectomy;
TGCT	cis	rs62103177	0.608	rs4442895	chr18:77826399	C/G	cg20368463	chr18:77673604	PQLC1	-0.45	-4.65	-0.39	8.28e-6	Opioid sensitivity;
TGCT	trans	rs208520	0.802	rs4710315	chr6:66887594	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.95	-10.37	-0.68	1.58e-18	Exhaled nitric oxide output;
TGCT	cis	rs7552404	0.924	rs7550974	chr1:76204185	A/G	cg03433033	chr1:76189801	ACADM	0.82	9.91	0.66	2.05e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs1670533	1.000	rs7673898	chr4:1056569	C/A	cg20887711	chr4:1340912	KIAA1530	0.71	5.7	0.46	8.33e-8	Recombination rate (females);
TGCT	cis	rs7584330	0.955	rs7581882	chr2:238390745	T/C	cg14458575	chr2:238380390	NA	0.48	7.42	0.55	1.66e-11	Prostate cancer;
TGCT	cis	rs12950390	0.853	rs66471233	chr17:45867086	C/T	cg06532163	chr17:45867833	NA	0.37	5.96	0.47	2.45e-8	IgG glycosylation;
TGCT	cis	rs4727027	0.833	rs2107846	chr7:148832774	G/A	cg23583168	chr7:148888333	NA	-0.72	-9.18	-0.64	1.18e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs3733585	0.699	rs7657340	chr4:9966772	A/T	cg11266682	chr4:10021025	SLC2A9	-0.59	-7.87	-0.58	1.53e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs6988636	1.000	rs16898084	chr8:124190377	A/T	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs858239	0.632	rs6952947	chr7:23121042	C/G	cg05602783	chr7:23145260	KLHL7	0.6	5.02	0.41	1.76e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs12188164	0.965	rs11739543	chr5:443676	G/A	cg21144161	chr5:423903	AHRR	0.25	4.79	0.4	4.59e-6	Cystic fibrosis severity;
TGCT	cis	rs7772486	0.558	rs9497403	chr6:146054695	T/G	cg05347473	chr6:146136440	FBXO30	-0.65	-5.89	-0.47	3.34e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1385374	0.502	rs923077	chr12:129276708	C/A	cg09035930	chr12:129282057	SLC15A4	0.55	4.76	0.39	5.27e-6	Systemic lupus erythematosus;
TGCT	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs4851266	1.000	rs11686372	chr2:100827907	C/A	cg22139774	chr2:100720529	AFF3	-0.35	-5.19	-0.42	8.51e-7	Educational attainment;
TGCT	cis	rs651907	0.557	rs1031710	chr3:101463895	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.33	-6.78	-0.52	4.35e-10	Colorectal cancer;
TGCT	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg03264133	chr6:25882463	NA	0.48	5.13	0.42	1.1e-6	Blood metabolite levels;
TGCT	cis	rs838147	0.563	rs2638282	chr19:49213833	G/A	cg00822241	chr19:49201468	FUT2	0.29	4.59	0.38	1.08e-5	Dietary macronutrient intake;
TGCT	cis	rs950169	0.922	rs4842946	chr15:84942331	G/A	cg11189052	chr15:85197271	WDR73	0.81	6.22	0.49	6.89e-9	Schizophrenia;
TGCT	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg06873352	chr17:61820015	STRADA	-0.53	-6.18	-0.49	8.61e-9	Prudent dietary pattern;
TGCT	cis	rs2549003	1.000	rs3846732	chr5:131816087	T/C	cg02551604	chr5:131831745	NA	-0.89	-11.77	-0.73	6.36e-22	Asthma (sex interaction);
TGCT	cis	rs4766566	0.704	rs10774617	chr12:111755178	T/C	cg10833066	chr12:111807467	FAM109A	0.36	6.36	0.5	3.44e-9	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
TGCT	cis	rs763121	0.853	rs35522482	chr22:39063015	C/A	cg06022373	chr22:39101656	GTPBP1	0.77	7.57	0.56	7.47e-12	Menopause (age at onset);
TGCT	cis	rs7044106	0.734	rs12553070	chr9:123485266	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	4.91	0.4	2.84e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs2033711	0.936	rs882609	chr19:58991479	G/A	cg13877915	chr19:58951672	ZNF132	0.79	8.3	0.6	1.5e-13	Uric acid clearance;
TGCT	cis	rs1371867	0.846	rs1613453	chr8:101244215	G/T	cg06636551	chr8:101224915	SPAG1	0.49	6.63	0.51	9.45e-10	Atrioventricular conduction;
TGCT	cis	rs12497850	1.000	rs10865952	chr3:48744484	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.44	-6.06	-0.48	1.52e-8	Parkinson's disease;
TGCT	cis	rs2153535	0.601	rs1928183	chr6:8530018	A/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.01	0.41	1.86e-6	Motion sickness;
TGCT	cis	rs28493229	0.522	rs2233152	chr19:41281016	C/T	cg23743927	chr19:41304969	EGLN2	-0.74	-4.67	-0.39	7.7e-6	Kawasaki disease;
TGCT	cis	rs78487399	0.808	rs74608713	chr2:43763539	T/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.4	-4.66	-0.39	8.17e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs742320	0.756	rs4984925	chr16:839996	T/C	cg03433313	chr16:819064	MIR662	-0.52	-7.15	-0.54	6.46e-11	Mean corpuscular volume;
TGCT	trans	rs10506458	0.915	rs1009540	chr12:63414872	C/A	cg22491629	chr6:157744540	C6orf35	-0.99	-8.57	-0.61	3.45e-14	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs739401	0.611	rs2239900	chr11:3030992	C/T	cg05729581	chr11:3078854	CARS	-0.54	-5.12	-0.42	1.13e-6	Longevity;
TGCT	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg06873352	chr17:61820015	STRADA	0.58	6.37	0.5	3.32e-9	Prudent dietary pattern;
TGCT	cis	rs7772486	0.774	rs2247571	chr6:146219533	T/A	cg05347473	chr6:146136440	FBXO30	0.5	4.58	0.38	1.1e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1552244	0.554	rs58020561	chr3:10054682	A/G	cg00149659	chr3:10157352	C3orf10	0.69	4.99	0.41	2.03e-6	Alzheimer's disease;
TGCT	cis	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg08564027	chr20:61660810	NA	0.38	7.08	0.54	9.36e-11	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9522267	0.535	rs9522299	chr13:112236013	C/A	cg10483660	chr13:112241077	NA	-0.27	-4.61	-0.38	9.78e-6	Hepatitis;
TGCT	cis	rs3125734	0.607	rs7923556	chr10:64024648	A/G	cg19640130	chr10:64028056	RTKN2	-0.4	-5.17	-0.42	9.02e-7	Rheumatoid arthritis;
TGCT	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg24531977	chr5:56204891	C5orf35	0.68	7.22	0.54	4.65e-11	Initial pursuit acceleration;
TGCT	cis	rs9910055	0.529	rs228765	chr17:42186422	C/T	cg19774624	chr17:42201019	HDAC5	0.75	7.12	0.54	7.85e-11	Total body bone mineral density;
TGCT	cis	rs3772130	0.886	rs9825248	chr3:121568711	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.5	4.48	0.37	1.65e-5	Cognitive performance;
TGCT	cis	rs4972806	0.849	rs1542180	chr2:177028767	C/T	cg14324370	chr2:177042789	NA	0.73	6.98	0.53	1.59e-10	IgG glycosylation;
TGCT	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	6.05	0.48	1.59e-8	Alzheimer's disease;
TGCT	trans	rs1974653	0.672	rs7284918	chr22:20086737	T/C	cg08822737	chr17:71088851	SLC39A11	-0.93	-7.61	-0.56	5.97e-12	Schizophrenia;
TGCT	cis	rs9467773	0.620	rs9467810	chr6:26608261	A/C	cg02458000	chr6:26745757	NA	0.51	4.73	0.39	5.91e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs3796352	1.000	rs7645611	chr3:53125297	G/C	cg27565382	chr3:53032988	SFMBT1	0.41	4.63	0.38	9.1e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs7044106	0.762	rs10739570	chr9:123381222	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	6.06	0.48	1.53e-8	Hip circumference adjusted for BMI;
TGCT	cis	rs1801251	1.000	rs4973053	chr2:233670099	G/A	cg25237894	chr2:233734115	C2orf82	-0.31	-5.49	-0.44	2.17e-7	Coronary artery disease;
TGCT	cis	rs116095464	0.558	rs10068203	chr5:206618	C/T	cg22857025	chr5:266934	NA	-0.35	-6.63	-0.51	9.12e-10	Breast cancer;
TGCT	cis	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg12570787	chr5:219185	SDHA;CCDC127	0.66	4.48	0.37	1.64e-5	Breast cancer;
TGCT	cis	rs7119	0.700	rs57471224	chr15:77888169	A/G	cg27398640	chr15:77910606	LINGO1	0.33	6.85	0.52	3.09e-10	Type 2 diabetes;
TGCT	cis	rs9899728	0.706	rs7210092	chr17:73021600	A/G	cg00012762	chr17:72744649	SLC9A3R1	-1.0	-4.48	-0.37	1.67e-5	Alzheimer's disease or small vessel stroke;
TGCT	cis	rs1008375	0.966	rs10939735	chr4:17578891	A/G	cg18681998	chr4:17616180	MED28	0.85	8.18	0.59	2.86e-13	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	trans	rs208515	0.525	rs12204706	chr6:66669930	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.9	-9.83	-0.66	3.19e-17	Exhaled nitric oxide levels;
TGCT	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg11494091	chr17:61959527	GH2	0.61	14.8	0.8	3.65e-29	Prudent dietary pattern;
TGCT	cis	rs1843834	0.574	rs6436499	chr2:225456551	A/T	cg22455342	chr2:225449267	CUL3	1.01	10.65	0.69	3.37e-19	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs1008375	1.000	rs11724495	chr4:17621310	G/A	cg18681998	chr4:17616180	MED28	1.0	11.31	0.71	8.26e-21	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs11264213	0.901	rs72661628	chr1:36406547	A/G	cg27506609	chr1:36549197	TEKT2	0.42	4.72	0.39	6.2e-6	Schizophrenia;
TGCT	trans	rs17685	0.712	rs10235086	chr7:75833138	G/T	cg19862616	chr7:65841803	NCRNA00174	0.48	8.22	0.59	2.25e-13	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs3820068	0.608	rs7516683	chr1:16020502	A/G	cg05660106	chr1:15850417	CASP9	-0.65	-5.99	-0.47	2.09e-8	Systolic blood pressure;
TGCT	cis	rs9325144	0.581	rs2730929	chr12:38942739	T/C	cg13010199	chr12:38710504	ALG10B	-0.58	-5.46	-0.44	2.46e-7	Morning vs. evening chronotype;
TGCT	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.62	-6.91	-0.53	2.28e-10	Blood metabolite levels;
TGCT	cis	rs9436747	0.615	rs6676495	chr1:66052117	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.56	5.04	0.41	1.59e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs1524927	0.966	rs12704871	chr7:96334274	C/T	cg03808172	chr7:96339361	SHFM1	-0.49	-5.08	-0.41	1.36e-6	Total body bone mineral density;
TGCT	cis	rs6669384	0.774	rs12141901	chr1:208031234	G/A	cg22525895	chr1:207977042	MIR29B2	-0.38	-5.35	-0.43	4.04e-7	Immune response to measles vaccine (measles-specific neutralising antibody titre);
TGCT	cis	rs1475911	0.708	rs11701371	chr21:43523972	C/G	cg19766460	chr21:43528205	UMODL1;C21orf128	0.65	9.67	0.66	8.13e-17	IgG glycosylation;
TGCT	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg16049864	chr8:95962084	TP53INP1	-0.76	-11.14	-0.71	2.13e-20	Type 2 diabetes;
TGCT	cis	rs9527	0.590	rs10509764	chr10:104776475	G/A	cg15744005	chr10:104629667	AS3MT	-0.42	-4.92	-0.4	2.74e-6	Arsenic metabolism;
TGCT	cis	rs28595532	0.920	rs56042726	chr4:119751777	T/A	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs12967678	1	rs12967678	chr18:12805388	G/A	cg23598886	chr18:12777645	NA	-0.64	-5.03	-0.41	1.67e-6	Selective IgA deficiency;
TGCT	cis	rs10504229	0.906	rs2270609	chr8:58194684	G/A	cg08280861	chr8:58055591	NA	0.35	4.47	0.37	1.72e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs12681287	0.640	rs6992287	chr8:87418960	G/A	cg27223183	chr8:87520930	FAM82B	0.89	6.36	0.5	3.45e-9	Caudate activity during reward;
TGCT	cis	rs9611565	0.649	rs738422	chr22:42123399	C/T	cg13695892	chr22:41940480	POLR3H	0.83	8.18	0.59	2.79e-13	Vitiligo;
TGCT	cis	rs7666738	0.800	rs2865988	chr4:99067807	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.79	0.46	5.32e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2288884	1.000	rs17779301	chr19:52539243	A/G	cg15405931	chr19:52693188	PPP2R1A	0.68	4.7	0.39	6.9e-6	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs10875746	0.624	rs11168498	chr12:48655088	A/G	cg20731937	chr12:48336164	NA	0.59	4.49	0.37	1.61e-5	Longevity (90 years and older);
TGCT	cis	rs2404602	0.622	rs4886506	chr15:77207277	G/T	cg23625390	chr15:77176239	SCAPER	0.36	4.47	0.37	1.72e-5	Blood metabolite levels;
TGCT	cis	rs7914558	0.899	rs7913682	chr10:104684392	T/A	cg04362960	chr10:104952993	NT5C2	0.61	5.41	0.44	3.14e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs9790314	0.502	rs2404342	chr3:161092562	C/T	cg03342759	chr3:160939853	NMD3	-0.52	-5.38	-0.44	3.56e-7	Morning vs. evening chronotype;
TGCT	cis	rs67478160	0.619	rs12897150	chr14:104319530	A/T	cg26031613	chr14:104095156	KLC1	-0.68	-6.98	-0.53	1.61e-10	Schizophrenia;
TGCT	cis	rs7523273	0.597	rs4844390	chr1:207934849	A/G	cg22525895	chr1:207977042	MIR29B2	-0.46	-6.64	-0.51	8.7e-10	Schizophrenia;
TGCT	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.74	5.21	0.42	7.56e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.66	0.39	8.18e-6	Prudent dietary pattern;
TGCT	trans	rs853410	0.516	rs1886334	chr6:4003364	T/C	cg13911294	chr9:88951310	ZCCHC6	-0.67	-6.96	-0.53	1.75e-10	Night sleep phenotypes;
TGCT	cis	rs2720460	0.502	rs223374	chr4:103758301	T/C	cg16532752	chr4:104119610	CENPE	-0.61	-5.43	-0.44	2.85e-7	Testicular germ cell tumor;
TGCT	cis	rs9467711	1.000	rs9467708	chr6:26327956	T/C	cg02458000	chr6:26745757	NA	-1.05	-5.8	-0.46	5.29e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1534166	0.647	rs1464937	chr3:133536655	C/G	cg08048268	chr3:133502702	NA	0.42	5.15	0.42	9.87e-7	Alcohol consumption (transferrin glycosylation);
TGCT	cis	rs7617773	0.817	rs34225441	chr3:48308891	T/A	cg11946769	chr3:48343235	NME6	0.76	6.64	0.51	8.76e-10	Coronary artery disease;
TGCT	cis	rs9611565	0.592	rs9611613	chr22:41961831	T/C	cg03806693	chr22:41940476	POLR3H	-1.08	-11.36	-0.71	6.34e-21	Vitiligo;
TGCT	cis	rs3096299	0.933	rs2965823	chr16:89454924	G/A	cg02187348	chr16:89574699	SPG7	0.46	4.45	0.37	1.88e-5	Multiple myeloma (IgH translocation);
TGCT	cis	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg22857025	chr5:266934	NA	-0.34	-6.7	-0.52	6.65e-10	Breast cancer;
TGCT	cis	rs12908161	1.000	rs62019464	chr15:85294469	T/A	cg17173187	chr15:85201210	NMB	0.56	6.32	0.49	4.2e-9	Schizophrenia;
TGCT	cis	rs4733781	0.933	rs1118887	chr8:131202021	A/T	cg16277922	chr8:131349729	ASAP1	0.43	5.4	0.44	3.23e-7	Tuberculosis;
TGCT	cis	rs6840360	1.000	rs3749562	chr4:152596540	T/C	cg17479576	chr4:152424074	FAM160A1	-0.5	-5.26	-0.43	6.16e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7542091	0.669	rs7540534	chr1:210044824	A/T	cg23283495	chr1:209979779	IRF6	0.55	5.47	0.44	2.34e-7	Monobrow;
TGCT	trans	rs3107575	0.572	rs73169365	chr3:165319778	T/C	cg03961853	chr1:230384989	GALNT2	0.64	6.9	0.53	2.41e-10	Morning vs. evening chronotype;
TGCT	cis	rs2832191	0.740	rs2012645	chr21:30445961	G/A	cg08807101	chr21:30365312	RNF160	0.65	6.14	0.48	1.03e-8	Dental caries;
TGCT	cis	rs1577917	1.000	rs68171315	chr6:86707400	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.13	-0.42	1.07e-6	Response to antipsychotic treatment;
TGCT	cis	rs1215050	0.740	rs6855827	chr4:99065706	G/A	cg05340658	chr4:99064831	C4orf37	0.44	5.3	0.43	5.03e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs476633	0.708	rs3986303	chr15:41443179	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.66	-8.77	-0.62	1.13e-14	Glomerular filtration rate (creatinine);
TGCT	cis	rs17741873	0.830	rs11000801	chr10:75647491	A/C	cg07699608	chr10:75541558	CHCHD1	0.66	5.06	0.41	1.49e-6	Paclitaxel disposition in epithelial ovarian cancer;
TGCT	cis	rs910316	0.967	rs12890371	chr14:75593839	T/C	cg08847533	chr14:75593920	NEK9	0.96	10.86	0.7	1.05e-19	Height;
TGCT	cis	rs7552404	1.000	rs6593585	chr1:76140273	G/A	cg03433033	chr1:76189801	ACADM	0.83	9.91	0.66	2.13e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	trans	rs7819412	0.745	rs28464654	chr8:11080665	T/A	cg06636001	chr8:8085503	FLJ10661	-0.77	-6.86	-0.52	2.93e-10	Triglycerides;
TGCT	cis	rs9583531	0.843	rs7999702	chr13:111382264	A/C	cg24331049	chr13:111365604	ING1	-0.75	-5.43	-0.44	2.89e-7	Coronary artery disease;
TGCT	cis	rs3796352	1.000	rs33999310	chr3:52883332	G/A	cg15956490	chr3:53032818	SFMBT1	0.57	5.25	0.43	6.25e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs7917772	0.636	rs4919674	chr10:104522226	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.56	-4.59	-0.38	1.07e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7662987	0.517	rs2924580	chr4:100032168	C/G	cg13256891	chr4:100009986	ADH5	0.52	4.58	0.38	1.12e-5	Smoking initiation;
TGCT	trans	rs2727020	0.521	rs7101761	chr11:49598178	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.4	-7.69	-0.57	3.92e-12	Coronary artery disease;
TGCT	cis	rs739401	0.527	rs418832	chr11:3072236	C/T	cg25174290	chr11:3078921	CARS	0.51	4.96	0.41	2.23e-6	Longevity;
TGCT	cis	rs1941023	0.584	rs2197236	chr11:60168859	T/C	cg08716584	chr11:60157161	MS4A7	-0.31	-4.69	-0.39	7.18e-6	Congenital heart disease (maternal effect);
TGCT	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg06873352	chr17:61820015	STRADA	0.56	6.22	0.49	6.93e-9	Prudent dietary pattern;
TGCT	trans	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg21659725	chr3:3221576	CRBN	-0.74	-8.78	-0.62	1.08e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg18876405	chr7:65276391	NA	0.32	4.93	0.4	2.61e-6	Aortic root size;
TGCT	trans	rs7819412	0.806	rs17723229	chr8:10930069	A/C	cg15556689	chr8:8085844	FLJ10661	-0.84	-8.17	-0.59	2.99e-13	Triglycerides;
TGCT	cis	rs17125944	0.505	rs76219229	chr14:53178346	G/A	cg00686598	chr14:53173677	PSMC6	1.2	6.43	0.5	2.51e-9	Alzheimer's disease (late onset);
TGCT	cis	rs2594989	0.790	rs2443716	chr3:11523670	A/G	cg00170343	chr3:11313890	ATG7	0.68	5.46	0.44	2.49e-7	Circulating chemerin levels;
TGCT	cis	rs4820539	1.000	rs5759598	chr22:23480962	T/G	cg14186256	chr22:23484241	RTDR1	0.99	12.69	0.75	3.59e-24	Bone mineral density;
TGCT	cis	rs281408	0.559	rs281386	chr19:49217305	A/G	cg13540341	chr19:49222985	MAMSTR	0.46	6.76	0.52	4.92e-10	Urinary metabolites (H-NMR features);
TGCT	cis	rs2439831	1.000	rs2467739	chr15:43740196	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.01	8.37	0.6	1.02e-13	Lung cancer in ever smokers;
TGCT	cis	rs73198271	0.960	rs17154702	chr8:8609880	C/T	cg06636001	chr8:8085503	FLJ10661	-0.63	-4.59	-0.38	1.08e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs9611565	0.729	rs169362	chr22:41827589	G/C	cg06481639	chr22:41940642	POLR3H	0.59	5.12	0.42	1.12e-6	Vitiligo;
TGCT	cis	rs16866061	1.000	rs10933068	chr2:225418360	G/A	cg12698349	chr2:225449008	CUL3	1.0	10.02	0.67	1.14e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	cis	rs3784262	1.000	rs12908953	chr15:58277812	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.49	-7.7	-0.57	3.76e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs9911578	1.000	rs8071916	chr17:56660279	A/G	cg12560992	chr17:57184187	TRIM37	0.75	9.11	0.63	1.79e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs595982	0.559	rs73061632	chr19:49361663	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.71	-9.68	-0.66	7.61e-17	Red cell distribution width;
TGCT	cis	rs3821902	0.646	rs17344716	chr3:64019744	T/A	cg22134162	chr3:63841271	THOC7	-0.33	-4.89	-0.4	3.1e-6	Breast cancer;
TGCT	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg03806693	chr22:41940476	POLR3H	-0.96	-9.51	-0.65	1.96e-16	Vitiligo;
TGCT	cis	rs950169	0.544	rs2036949	chr15:85163605	T/C	cg17173187	chr15:85201210	NMB	0.58	6.62	0.51	9.59e-10	Schizophrenia;
TGCT	cis	rs832540	0.593	rs96844	chr5:56196604	G/A	cg12311346	chr5:56204834	C5orf35	-0.5	-4.79	-0.4	4.68e-6	Coronary artery disease;
TGCT	cis	rs6667605	0.527	rs6673993	chr1:2552071	T/C	cg18854424	chr1:2615690	NA	0.5	5.95	0.47	2.54e-8	Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs9916302	0.660	rs4795379	chr17:37674683	T/G	cg07936489	chr17:37558343	FBXL20	-0.87	-6.27	-0.49	5.47e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs4237845	0.780	rs3751331	chr12:58290278	G/A	cg02175503	chr12:58329896	NA	0.52	4.86	0.4	3.52e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs8056742	0.642	rs12934305	chr16:85027718	C/G	cg00229868	chr16:85520891	NA	-0.37	-4.64	-0.38	8.75e-6	Amyotrophic lateral sclerosis;
TGCT	cis	rs546131	0.928	rs516228	chr11:34838823	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.51	4.54	0.38	1.34e-5	Lung disease severity in cystic fibrosis;
TGCT	cis	rs17376456	0.597	rs10866760	chr5:93338335	G/A	cg21475434	chr5:93447410	FAM172A	-0.64	-5.91	-0.47	3.04e-8	Diabetic retinopathy;
TGCT	cis	rs977747	1.000	rs7664	chr1:47682017	T/G	cg03885399	chr1:47691550	TAL1	-0.39	-4.69	-0.39	7.14e-6	Body mass index;
TGCT	cis	rs4906332	1.000	rs78316803	chr14:103942863	A/G	cg26031613	chr14:104095156	KLC1	-0.52	-4.72	-0.39	6.31e-6	Coronary artery disease;
TGCT	cis	rs1799949	0.794	rs116409325	chr17:41445460	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	5.31	0.43	4.88e-7	Menopause (age at onset);
TGCT	cis	rs13242816	1.000	rs12668226	chr7:116187690	A/C	cg02799643	chr7:116139180	CAV2	-0.45	-5.55	-0.45	1.66e-7	P wave duration;
TGCT	cis	rs6733011	0.578	rs1581251	chr2:99500867	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-4.67	-0.39	7.81e-6	Bipolar disorder;
TGCT	cis	rs208520	0.690	rs12194057	chr6:66745616	A/G	cg07460842	chr6:66804631	NA	0.94	9.91	0.66	2.15e-17	Exhaled nitric oxide output;
TGCT	cis	rs732765	0.734	rs28470774	chr14:75186907	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.55	-4.48	-0.37	1.71e-5	Non-small cell lung cancer;
TGCT	cis	rs2439831	0.850	rs3816792	chr15:44116986	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.89	-6.27	-0.49	5.48e-9	Lung cancer in ever smokers;
TGCT	cis	rs7772486	0.597	rs6570732	chr6:146245151	G/A	cg05347473	chr6:146136440	FBXO30	-0.64	-6.06	-0.48	1.48e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9837602	0.529	rs793494	chr3:99508768	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.56	6.42	0.5	2.56e-9	Breast cancer;
TGCT	cis	rs793571	0.522	rs11071398	chr15:59120077	A/G	cg05156742	chr15:59063176	FAM63B	0.54	5.07	0.41	1.38e-6	Schizophrenia;
TGCT	cis	rs7017914	0.870	rs3098883	chr8:71943567	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-4.93	-0.4	2.62e-6	Bone mineral density;
TGCT	trans	rs208520	0.754	rs12204635	chr6:66740779	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	10.83	0.7	1.19e-19	Exhaled nitric oxide output;
TGCT	cis	rs10791323	0.628	rs2851118	chr11:133705995	A/C	cg03690763	chr11:133734501	NA	-0.35	-5.39	-0.44	3.39e-7	Childhood ear infection;
TGCT	cis	rs7937682	0.632	rs10891294	chr11:111699224	C/T	cg09085632	chr11:111637200	PPP2R1B	0.81	7.03	0.53	1.23e-10	Primary sclerosing cholangitis;
TGCT	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg04025307	chr7:1156635	C7orf50	0.24	5.46	0.44	2.51e-7	Longevity;Endometriosis;
TGCT	cis	rs919433	0.680	rs1563340	chr2:198414713	A/T	cg00792783	chr2:198669748	PLCL1	0.5	4.55	0.38	1.28e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs6921919	0.583	rs2041230	chr6:28365515	A/G	cg18815343	chr6:28367644	ZSCAN12	-0.53	-5.06	-0.41	1.47e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9894429	0.505	rs35570626	chr17:79611084	A/G	cg21028142	chr17:79581711	NPLOC4	0.28	5.87	0.47	3.73e-8	Eye color traits;
TGCT	cis	rs2677744	1.000	rs1550636	chr15:91477461	A/G	cg23684204	chr15:91497937	RCCD1	0.35	5.14	0.42	1.06e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs732765	0.734	rs11844127	chr14:75139936	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.57	-4.94	-0.41	2.43e-6	Non-small cell lung cancer;
TGCT	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg14851468	chr5:179071604	C5orf60	0.27	5.58	0.45	1.42e-7	Lung cancer;
TGCT	cis	rs7336332	0.598	rs76249173	chr13:28010445	A/G	cg22138327	chr13:27999177	GTF3A	0.8	5.97	0.47	2.35e-8	Weight;
TGCT	cis	rs6500602	0.793	rs4785964	chr16:4484613	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.39	5.85	0.46	4.14e-8	Schizophrenia;
TGCT	cis	rs796364	1.000	rs11680723	chr2:200810957	C/G	cg17644776	chr2:200775616	C2orf69	-0.31	-4.83	-0.4	3.99e-6	Schizophrenia;
TGCT	cis	rs13064411	0.735	rs722392	chr3:113228294	A/G	cg18753928	chr3:113234510	CCDC52	-0.7	-5.68	-0.45	9.16e-8	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs3849570	1.000	rs78242412	chr3:81747219	A/G	cg07356753	chr3:81810745	GBE1	-0.82	-7.89	-0.58	1.37e-12	Waist circumference;Body mass index;
TGCT	cis	rs6671200	1.000	rs35179427	chr1:95670888	G/A	cg20701556	chr1:95698924	RWDD3	0.65	5.58	0.45	1.43e-7	Stearic acid (18:0) levels;
TGCT	cis	rs4383453	0.539	rs4678016	chr3:123101981	C/T	cg04890266	chr3:123102914	ADCY5	-0.49	-7.91	-0.58	1.23e-12	Gestational age at birth (maternal effect);
TGCT	cis	rs7523273	0.597	rs11118580	chr1:207959070	T/C	cg22525895	chr1:207977042	MIR29B2	-0.46	-6.64	-0.51	9e-10	Schizophrenia;
TGCT	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.48	-0.37	1.66e-5	Bipolar disorder;
TGCT	cis	rs6988636	1.000	rs13259806	chr8:124190103	A/T	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs9467773	1.000	rs6925895	chr6:26572165	G/T	cg26531700	chr6:26746687	NA	0.5	4.85	0.4	3.64e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10876993	0.928	rs2928053	chr12:58063475	T/C	cg15848620	chr12:58087721	OS9	-0.73	-6.02	-0.48	1.8e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs17376456	1.000	rs61132622	chr5:93539684	G/A	cg25358565	chr5:93447407	FAM172A	0.94	7.65	0.57	4.96e-12	Diabetic retinopathy;
TGCT	trans	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg25482853	chr8:67687455	SGK3	1.2	10.12	0.67	6.42e-18	Lung disease severity in cystic fibrosis;
TGCT	cis	rs2730260	0.537	rs73169238	chr7:158883818	G/A	cg02078164	chr7:157982224	PTPRN2	0.41	4.58	0.38	1.11e-5	Myopia (pathological);
TGCT	trans	rs9388451	0.839	rs3799709	chr6:126078361	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.74	-8.58	-0.61	3.3e-14	Brugada syndrome;
TGCT	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg12963246	chr6:28129442	ZNF389	0.51	5.02	0.41	1.73e-6	Parkinson's disease;
TGCT	cis	rs832540	0.931	rs2591960	chr5:56238811	A/T	cg12311346	chr5:56204834	C5orf35	0.53	5.23	0.43	6.91e-7	Coronary artery disease;
TGCT	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.29	-4.49	-0.37	1.64e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs12681287	0.517	rs34367154	chr8:87508749	A/T	cg19078186	chr8:87526527	CPNE3	-0.37	-4.57	-0.38	1.15e-5	Caudate activity during reward;
TGCT	cis	rs4242434	0.819	rs2306518	chr8:22470308	A/G	cg03733263	chr8:22462867	KIAA1967	1.09	17.22	0.84	1.13e-34	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs7246657	0.722	rs2909105	chr19:38167906	A/G	cg18154014	chr19:37997991	ZNF793	-0.67	-4.69	-0.39	6.96e-6	Coronary artery calcification;
TGCT	cis	rs926938	0.618	rs516985	chr1:115495011	G/A	cg12756093	chr1:115239321	AMPD1	0.39	5.78	0.46	5.69e-8	Autism;
TGCT	cis	rs360798	0.512	rs34104251	chr2:62995183	A/G	cg17519650	chr2:63277830	OTX1	-0.6	-5.32	-0.43	4.76e-7	Coronary artery disease;
TGCT	cis	rs7336332	0.598	rs74563672	chr13:28010660	A/G	cg22138327	chr13:27999177	GTF3A	0.8	5.97	0.47	2.35e-8	Weight;
TGCT	cis	rs12681288	0.862	rs34510005	chr8:1018943	T/C	cg08872321	chr8:1308229	NA	-0.26	-4.65	-0.39	8.45e-6	Schizophrenia;
TGCT	cis	rs601339	1.000	rs635400	chr12:123171089	A/G	cg11919336	chr12:123188078	GPR109A	0.66	7.7	0.57	3.69e-12	Adiponectin levels;
TGCT	cis	rs67311347	1.000	rs1004655	chr3:40490009	G/A	cg13683864	chr3:40499215	RPL14	-1.19	-13.31	-0.77	1.2e-25	Renal cell carcinoma;
TGCT	cis	rs9486719	0.843	rs1009597	chr6:96843540	A/T	cg18709589	chr6:96969512	KIAA0776	0.75	5.13	0.42	1.1e-6	Migraine;Coronary artery disease;
TGCT	cis	rs1062177	0.826	rs2915879	chr5:151147442	A/G	cg12924095	chr5:151150029	G3BP1	0.34	5.0	0.41	1.9e-6	Preschool internalizing problems;
TGCT	cis	rs4819052	0.851	rs2255774	chr21:46683851	A/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	7.09	0.54	9.14e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7178572	0.568	rs1446312	chr15:77412189	G/C	cg15453836	chr15:77711506	NA	-0.42	-4.68	-0.39	7.31e-6	Type 2 diabetes;
TGCT	cis	rs9952991	0.622	rs8091566	chr18:12826385	G/A	cg23598886	chr18:12777645	NA	0.54	4.76	0.39	5.29e-6	Inflammatory skin disease;
TGCT	cis	rs7267979	1.000	rs4815406	chr20:25341316	C/G	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.29	-4.49	-0.37	1.64e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs8016982	0.698	rs8011097	chr14:81702736	T/C	cg01989461	chr14:81687754	GTF2A1	0.77	7.18	0.54	5.7e-11	Schizophrenia;
TGCT	cis	rs2153535	0.580	rs7753192	chr6:8482637	G/A	cg23788917	chr6:8435910	SLC35B3	0.62	5.59	0.45	1.37e-7	Motion sickness;
TGCT	cis	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg06636001	chr8:8085503	FLJ10661	0.67	5.75	0.46	6.61e-8	Mood instability;
TGCT	cis	rs6669384	0.774	rs4844623	chr1:208035434	T/A	cg22525895	chr1:207977042	MIR29B2	-0.39	-5.53	-0.44	1.82e-7	Immune response to measles vaccine (measles-specific neutralising antibody titre);
TGCT	cis	rs2075371	0.501	rs1643043	chr7:134013902	C/T	cg11752832	chr7:134001865	SLC35B4	0.58	4.78	0.39	4.95e-6	Mean platelet volume;
TGCT	cis	rs9814567	1.000	rs6800862	chr3:134228628	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.93	-9.27	-0.64	7.51e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs7614311	0.731	rs3774721	chr3:63954649	A/G	cg22134162	chr3:63841271	THOC7	-0.45	-5.73	-0.46	7.3e-8	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs3540	0.576	rs12907587	chr15:91045851	G/C	cg22089800	chr15:90895588	ZNF774	-0.75	-7.59	-0.56	6.74e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs1451375	0.959	rs6962356	chr7:50621941	T/C	cg18232548	chr7:50535776	DDC	0.44	6.76	0.52	4.7e-10	Malaria;
TGCT	cis	rs3087591	0.922	rs12939969	chr17:29463577	A/G	cg24425628	chr17:29625626	OMG;NF1	0.49	7.61	0.56	6.09e-12	Hip circumference;
TGCT	cis	rs678347	0.961	rs601897	chr8:102469182	C/T	cg26560785	chr8:103251167	RRM2B	0.55	4.46	0.37	1.83e-5	Rheumatoid arthritis;
TGCT	cis	rs6089584	1.000	rs6089580	chr20:60558976	G/A	cg06108461	chr20:60628389	TAF4	-0.57	-8.01	-0.58	7.25e-13	Body mass index;
TGCT	cis	rs17767294	0.708	rs72847342	chr6:27789270	A/G	cg08851530	chr6:28072375	NA	1.54	7.3	0.55	3.1e-11	Parkinson's disease;
TGCT	cis	rs3733585	0.673	rs6840802	chr4:9965633	C/G	cg00071950	chr4:10020882	SLC2A9	0.54	6.38	0.5	3.14e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg08280861	chr8:58055591	NA	0.36	4.98	0.41	2.08e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7822232	0.908	rs6558297	chr8:145143934	C/T	cg06495924	chr8:145149574	CYC1	-1.04	-4.49	-0.37	1.6e-5	Blood metabolite levels;
TGCT	cis	rs28595532	0.844	rs115411027	chr4:119490685	T/C	cg21605333	chr4:119757512	SEC24D	1.33	8.01	0.58	7.07e-13	Cannabis dependence symptom count;
TGCT	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg03517284	chr6:25882590	NA	-0.66	-5.95	-0.47	2.55e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs4790312	0.513	rs9912609	chr17:1967620	A/G	cg24156229	chr17:1948635	NA	-0.34	-5.33	-0.43	4.49e-7	Left atrial antero-posterior diameter;
TGCT	cis	rs9443645	0.901	rs2174742	chr6:79610101	G/T	cg09184832	chr6:79620586	NA	-0.48	-5.17	-0.42	9.23e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs6690583	0.562	rs6688354	chr1:85520854	A/G	cg20280350	chr1:85513789	MCOLN3	-0.82	-5.27	-0.43	5.92e-7	Serum sulfate level;
TGCT	cis	rs4727027	0.901	rs4727018	chr7:148822247	G/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	4.58	0.38	1.13e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs11577318	0.812	rs3795683	chr1:26632831	C/A	cg04990556	chr1:26633338	UBXN11	-0.63	-5.77	-0.46	6.01e-8	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs10479542	0.896	rs10078712	chr5:178978805	C/T	cg19723775	chr5:179050963	HNRNPH1	-0.54	-5.34	-0.43	4.24e-7	Lung cancer;
TGCT	cis	rs11785400	1.000	rs10099892	chr8:143734608	C/T	cg24634471	chr8:143751801	JRK	0.56	6.12	0.48	1.12e-8	Schizophrenia;
TGCT	cis	rs9611565	0.802	rs9611571	chr22:41784867	G/A	cg17554472	chr22:41940697	POLR3H	-0.42	-4.56	-0.38	1.19e-5	Vitiligo;
TGCT	cis	rs10927875	0.864	rs1976402	chr1:16143779	G/A	cg14742211	chr1:16348397	CLCNKA	-0.2	-4.52	-0.38	1.44e-5	Dilated cardiomyopathy;
TGCT	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg21171335	chr12:122356390	WDR66	0.71	7.5	0.56	1.06e-11	Mean corpuscular volume;
TGCT	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.48	-4.52	-0.38	1.43e-5	Electroencephalogram traits;
TGCT	trans	rs877282	0.786	rs10904558	chr10:797509	C/T	cg22713356	chr15:30763199	NA	1.16	10.39	0.68	1.44e-18	Uric acid levels;
TGCT	cis	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg07424592	chr7:64974309	NA	1.26	7.79	0.57	2.25e-12	Diabetic kidney disease;
TGCT	cis	rs11190604	1.000	rs10883501	chr10:102238326	A/G	cg16342193	chr10:102329863	NA	-0.4	-5.34	-0.43	4.36e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9303401	0.659	rs34818467	chr17:56643109	C/T	cg25039879	chr17:56429692	SUPT4H1	-0.52	-4.68	-0.39	7.47e-6	Cognitive test performance;
TGCT	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg09323728	chr8:95962352	TP53INP1	-0.55	-7.07	-0.54	9.72e-11	Type 2 diabetes;
TGCT	cis	rs13082711	0.522	rs6551192	chr3:27343376	C/T	cg02860705	chr3:27208620	NA	0.32	5.24	0.43	6.54e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	trans	rs1973993	0.507	rs2759670	chr1:97002864	A/G	cg10631902	chr5:14652156	NA	0.37	9.46	0.65	2.54e-16	Weight;
TGCT	cis	rs9796	0.870	rs2927061	chr15:41302219	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.41	-5.3	-0.43	5.07e-7	Menopause (age at onset);
TGCT	cis	rs9929218	0.906	rs9932679	chr16:68751904	A/G	cg01251360	chr16:68772225	CDH1	0.3	5.0	0.41	1.88e-6	Colorectal cancer;
TGCT	cis	rs1008375	1.000	rs2315560	chr4:17677305	C/G	cg16339924	chr4:17578868	LAP3	0.53	4.62	0.38	9.53e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	trans	rs459571	0.883	rs2520096	chr9:136919416	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.8	-8.66	-0.61	2.13e-14	Platelet distribution width;
TGCT	cis	rs13188771	0.578	rs67960514	chr5:100905390	G/A	cg18665594	chr5:101119420	NA	0.44	4.47	0.37	1.74e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs7727544	0.716	rs3844312	chr5:131582356	C/T	cg22598563	chr5:131563921	P4HA2	-0.29	-4.66	-0.39	7.88e-6	Blood metabolite levels;
TGCT	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg05872129	chr22:39784769	NA	-0.98	-10.82	-0.7	1.27e-19	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs4699052	0.625	rs1516740	chr4:104295787	C/T	cg16532752	chr4:104119610	CENPE	0.49	4.74	0.39	5.82e-6	Testicular germ cell tumor;
TGCT	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg00290607	chr11:67383545	NA	-0.32	-5.21	-0.42	7.5e-7	Mean corpuscular volume;
TGCT	cis	rs3091242	0.933	rs9645452	chr1:25668326	C/T	cg23205692	chr1:25664452	TMEM50A	-0.52	-5.38	-0.43	3.61e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs2455799	0.613	rs7620787	chr3:15882826	G/A	cg16303742	chr3:15540471	COLQ	-0.25	-4.8	-0.4	4.53e-6	Mean platelet volume;
TGCT	trans	rs11662586	0.517	rs11663082	chr18:77713494	C/T	cg05926928	chr17:57297772	GDPD1	0.76	7.2	0.54	5.06e-11	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
TGCT	cis	rs1322512	1.000	rs1727054	chr6:152947742	A/G	cg03415253	chr6:152958462	SYNE1	-0.57	-4.99	-0.41	2e-6	Tonometry;
TGCT	cis	rs7607369	0.526	rs4674322	chr2:219513782	C/T	cg02176678	chr2:219576539	TTLL4	0.51	5.94	0.47	2.7e-8	Red blood cell count;Amyotrophic lateral sclerosis;
TGCT	cis	rs3091242	0.806	rs35189848	chr1:25788422	A/G	cg23205692	chr1:25664452	TMEM50A	-0.49	-5.1	-0.42	1.26e-6	Erythrocyte sedimentation rate;
TGCT	trans	rs1814175	0.935	rs7482690	chr11:49648814	C/T	cg03929089	chr4:120376271	NA	-0.65	-7.45	-0.56	1.35e-11	Height;
TGCT	cis	rs6740322	0.895	rs10196095	chr2:43571885	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.39	-6.18	-0.49	8.32e-9	Coronary artery disease;
TGCT	cis	rs3806843	0.778	rs2531346	chr5:140126139	T/G	cg19875535	chr5:140030758	IK	-0.34	-5.68	-0.45	9.12e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs11785400	0.642	rs4256574	chr8:143725705	C/T	cg24634471	chr8:143751801	JRK	0.53	5.33	0.43	4.41e-7	Schizophrenia;
TGCT	cis	rs7681423	1.000	rs2066865	chr4:155525276	G/A	cg20735720	chr4:155535218	FGG	-0.46	-6.8	-0.52	4e-10	Fibrinogen;
TGCT	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg10047753	chr17:41438598	NA	0.97	9.94	0.67	1.73e-17	Menopause (age at onset);
TGCT	cis	rs10751667	0.643	rs6597969	chr11:928843	C/T	cg06064525	chr11:970664	AP2A2	-0.35	-8.09	-0.59	4.54e-13	Alzheimer's disease (late onset);
TGCT	cis	rs13064411	0.696	rs13066742	chr3:113208423	T/C	cg18753928	chr3:113234510	CCDC52	-0.7	-5.64	-0.45	1.08e-7	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs57221529	0.766	rs17497684	chr5:558307	T/C	cg09021430	chr5:549028	NA	-0.4	-5.46	-0.44	2.44e-7	Lung disease severity in cystic fibrosis;
TGCT	cis	rs2354432	0.556	rs885305	chr1:146786080	G/A	cg25205988	chr1:146714368	CHD1L	-1.34	-6.07	-0.48	1.44e-8	Mitochondrial DNA levels;
TGCT	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg27286337	chr10:134555280	INPP5A	0.39	4.73	0.39	6.02e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs68170813	0.559	rs17349904	chr7:106897237	A/C	cg02696742	chr7:106810147	HBP1	-0.68	-5.64	-0.45	1.09e-7	Coronary artery disease;
TGCT	cis	rs11031096	0.676	rs7120125	chr11:3941264	C/T	cg18678763	chr11:4115507	RRM1	0.39	5.25	0.43	6.38e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs2549003	1.000	rs7734334	chr5:131815004	C/A	cg21138405	chr5:131827807	IRF1	0.2	5.08	0.41	1.36e-6	Asthma (sex interaction);
TGCT	cis	rs2242194	0.816	rs11264296	chr1:154994750	T/C	cg16680214	chr1:154839983	KCNN3	-0.31	-5.81	-0.46	4.84e-8	Schizophrenia;
TGCT	cis	rs17253792	0.822	rs58569951	chr14:56152245	T/C	cg01858014	chr14:56050164	KTN1	-0.33	-4.54	-0.38	1.33e-5	Putamen volume;
TGCT	cis	rs807669	0.548	rs762522	chr22:19180575	C/T	cg02655711	chr22:19163373	SLC25A1	0.33	6.83	0.52	3.41e-10	Metabolite levels;
TGCT	cis	rs9303401	0.614	rs68100606	chr17:56500898	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.68	6.75	0.52	5.15e-10	Cognitive test performance;
TGCT	cis	rs13191362	0.935	rs116735807	chr6:163010615	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs10791097	0.694	rs10894273	chr11:130742155	G/T	cg14779329	chr11:130786720	SNX19	0.28	4.82	0.4	4.09e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs45430	0.665	rs431563	chr21:42740949	C/T	cg22778903	chr21:42741698	MX2	0.3	4.86	0.4	3.43e-6	Melanoma;
TGCT	cis	rs2070488	0.775	rs1132064	chr3:38566519	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.71	-6.89	-0.53	2.46e-10	Electrocardiographic conduction measures;
TGCT	cis	rs617219	0.710	rs2607142	chr5:78557948	T/C	cg09550809	chr5:78407562	BHMT	0.37	5.24	0.43	6.65e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs208520	0.690	rs207740	chr6:66764132	T/G	cg07460842	chr6:66804631	NA	0.96	10.32	0.68	2.1e-18	Exhaled nitric oxide output;
TGCT	cis	rs12188164	1.000	rs72717410	chr5:428785	A/T	cg22025206	chr5:502436	SLC9A3	-0.25	-4.47	-0.37	1.71e-5	Cystic fibrosis severity;
TGCT	cis	rs7980687	0.574	rs10744149	chr12:123708490	T/A	cg00376283	chr12:123451042	ABCB9	0.73	5.67	0.45	9.46e-8	Height;Educational attainment;Head circumference (infant);
TGCT	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.52	-4.99	-0.41	2.02e-6	Longevity;Endometriosis;
TGCT	cis	rs11169225	0.906	rs399023	chr12:50338952	A/C	cg04450003	chr12:50355995	AQP5	0.29	4.73	0.39	5.89e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs56104184	0.775	rs55981795	chr19:49401952	A/C	cg15549821	chr19:49342101	PLEKHA4	-0.73	-9.15	-0.63	1.47e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs2535633	0.661	rs4515041	chr3:52996032	T/A	cg11645453	chr3:52864694	ITIH4	-0.28	-5.13	-0.42	1.1e-6	Body mass index;
TGCT	cis	rs4509693	1.000	rs4244340	chr10:102499268	G/C	cg24127310	chr10:102502104	NA	0.7	5.86	0.47	3.84e-8	Alzheimer's disease;
TGCT	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs916888	0.610	rs199452	chr17:44801340	C/T	cg17911788	chr17:44343683	NA	-0.48	-5.66	-0.45	9.83e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs8177253	0.696	rs4459901	chr3:133465699	T/C	cg08439880	chr3:133502540	NA	-0.27	-4.87	-0.4	3.28e-6	Iron status biomarkers;
TGCT	cis	rs10114408	0.959	rs4354373	chr9:96650369	A/G	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs1887596	0.663	rs1298079	chr13:27246261	A/G	cg01312412	chr13:27282625	NA	0.28	5.01	0.41	1.79e-6	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs3849570	1.000	rs2290081	chr3:81810725	C/T	cg07356753	chr3:81810745	GBE1	-0.84	-7.89	-0.58	1.35e-12	Waist circumference;Body mass index;
TGCT	cis	rs7726839	0.507	rs72703100	chr5:614291	C/T	cg20362242	chr5:692897	TPPP	0.52	4.48	0.37	1.68e-5	Obesity-related traits;
TGCT	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg04234412	chr22:24373322	LOC391322	0.92	10.83	0.7	1.2e-19	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9467773	0.620	rs1027203	chr6:26639332	G/C	cg09904177	chr6:26538194	HMGN4	0.64	5.95	0.47	2.56e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs66573146	1.000	rs9942188	chr4:6984181	C/T	cg05069807	chr4:6945702	TBC1D14	0.35	4.94	0.41	2.51e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs9303542	0.625	rs8073963	chr17:46609918	G/A	cg25032089	chr17:46643351	HOXB3	-0.53	-5.54	-0.45	1.76e-7	Ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs11874712	1.000	rs8088881	chr18:43664970	T/C	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	5.23	0.42	7.11e-7	Migraine - clinic-based;
TGCT	cis	rs12477438	0.834	rs1563107	chr2:99701276	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.88	9.09	0.63	1.97e-15	Chronic sinus infection;
TGCT	cis	rs3806843	1.000	rs3733710	chr5:140167463	C/T	cg19875535	chr5:140030758	IK	0.37	6.33	0.49	4.17e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7819412	0.740	rs28633434	chr8:11053922	G/A	cg21775007	chr8:11205619	TDH	-0.48	-4.58	-0.38	1.1e-5	Triglycerides;
TGCT	cis	rs6964587	0.732	rs12539523	chr7:91710836	G/A	cg17063962	chr7:91808500	NA	0.88	9.54	0.65	1.69e-16	Breast cancer;
TGCT	cis	rs425277	0.628	rs3107145	chr1:2047547	G/A	cg24578937	chr1:2090814	PRKCZ	-0.26	-6.1	-0.48	1.23e-8	Height;
TGCT	cis	rs6547741	1.000	rs1528404	chr2:27846603	C/T	cg27432699	chr2:27873401	GPN1	-0.18	-4.56	-0.38	1.2e-5	Oral cavity cancer;
TGCT	cis	rs72945132	0.882	rs7932431	chr11:70166059	A/T	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs732765	0.644	rs2268613	chr14:75408500	G/A	cg06637938	chr14:75390232	RPS6KL1	0.65	5.36	0.43	3.85e-7	Non-small cell lung cancer;
TGCT	cis	rs9318086	0.624	rs9510909	chr13:24436760	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.79	8.37	0.6	1.05e-13	Myopia (pathological);
TGCT	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg11764359	chr7:65958608	NA	-0.55	-4.98	-0.41	2.1e-6	Aortic root size;
TGCT	cis	rs62244186	0.748	rs4682987	chr3:44674996	C/T	cg11003573	chr3:44754125	ZNF502	-0.4	-4.53	-0.38	1.35e-5	Depressive symptoms;
TGCT	cis	rs244731	0.959	rs7721671	chr5:176630984	A/G	cg06060754	chr5:176797920	RGS14	-0.44	-6.2	-0.49	7.79e-9	Urate levels in lean individuals;
TGCT	cis	rs79387448	0.701	rs10515921	chr2:102981018	T/G	cg09003973	chr2:102972529	NA	1.47	10.36	0.68	1.69e-18	Gut microbiota (bacterial taxa);
TGCT	cis	rs514406	0.505	rs448788	chr1:53161620	A/G	cg01802117	chr1:53393560	SCP2	0.43	4.89	0.4	3.08e-6	Monocyte count;
TGCT	cis	rs7666738	0.606	rs4577589	chr4:99087858	A/G	cg18180107	chr4:99064573	C4orf37	0.53	4.67	0.39	7.61e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2050392	0.517	rs687036	chr10:30761249	G/A	cg13289132	chr10:30722225	MAP3K8	-0.39	-4.8	-0.4	4.53e-6	Inflammatory bowel disease;
TGCT	cis	rs6940638	0.956	rs13207365	chr6:27030980	T/C	cg16898833	chr6:26189333	HIST1H4D	0.71	5.34	0.43	4.2e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs66561647	1.000	rs66561647	chr8:128971861	C/T	cg05480350	chr8:128972681	MIR1205;PVT1	0.22	4.46	0.37	1.79e-5	Hemoglobin concentration;
TGCT	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg10819733	chr22:24237672	NA	-0.29	-4.9	-0.4	2.99e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg17971929	chr21:40555470	PSMG1	-0.68	-5.95	-0.47	2.6e-8	Cognitive function;
TGCT	cis	rs797680	0.856	rs4847408	chr1:93791437	C/G	cg17826107	chr1:92977322	EVI5	0.22	5.05	0.41	1.53e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs3820068	0.705	rs59502343	chr1:15872617	T/C	cg05660106	chr1:15850417	CASP9	1.16	14.82	0.8	3.11e-29	Systolic blood pressure;
TGCT	trans	rs1496653	0.602	rs71322200	chr3:23614390	C/A	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs4455778	0.658	rs111468777	chr7:49117642	A/G	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs881375	1.000	rs10760118	chr9:123641616	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.39	4.57	0.38	1.18e-5	Rheumatoid arthritis;
TGCT	trans	rs10506458	1.000	rs73128779	chr12:63441852	T/G	cg22491629	chr6:157744540	C6orf35	-0.96	-8.34	-0.6	1.21e-13	Hemostatic factors and hematological phenotypes;
TGCT	trans	rs11671005	0.610	rs4756	chr19:59074653	T/C	cg22037779	chr5:139682734	PFDN1	-0.85	-6.91	-0.53	2.25e-10	Mean platelet volume;
TGCT	cis	rs17767294	0.614	rs116152083	chr6:28541959	A/G	cg08851530	chr6:28072375	NA	1.52	6.87	0.52	2.83e-10	Parkinson's disease;
TGCT	cis	rs9383153	1.000	rs2237223	chr6:16329741	G/A	cg10975897	chr6:15504844	JARID2	0.8	4.45	0.37	1.88e-5	Gambling;
TGCT	cis	rs2721195	0.626	rs59464125	chr8:145857786	G/A	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.89	-9.47	-0.65	2.42e-16	Age at first birth;
TGCT	cis	rs6671200	0.607	rs3767313	chr1:95712797	G/A	cg20701556	chr1:95698924	RWDD3	-0.52	-5.34	-0.43	4.26e-7	Stearic acid (18:0) levels;
TGCT	cis	rs155076	0.711	rs4770131	chr13:21897468	A/G	cg14456004	chr13:21872349	NA	1.29	11.07	0.71	3.11e-20	White matter hyperintensity burden;
TGCT	cis	rs916888	0.610	rs199536	chr17:44820425	T/C	cg17911788	chr17:44343683	NA	0.48	5.67	0.45	9.45e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs17433780	0.612	rs7911	chr1:89518120	A/G	cg09516651	chr1:89888402	LOC400759	0.23	4.63	0.38	9.11e-6	Carotid intima media thickness;
TGCT	cis	rs35306767	0.953	rs11253509	chr10:964306	C/T	cg26597838	chr10:835615	NA	0.63	9.1	0.63	1.93e-15	Eosinophil percentage of granulocytes;
TGCT	cis	rs4851266	1.000	rs2871344	chr2:100839430	A/G	cg07810366	chr2:100720526	AFF3	-0.37	-5.33	-0.43	4.39e-7	Educational attainment;
TGCT	cis	rs10514758	0.744	rs4831110	chr3:114939276	A/G	cg05943254	chr3:114009756	NA	-0.76	-4.53	-0.38	1.39e-5	Urate levels in obese individuals;
TGCT	cis	rs7091068	0.518	rs726817	chr10:95459817	C/T	cg20715218	chr10:95462985	C10orf4	0.52	5.51	0.44	1.99e-7	Urinary tract infection frequency;
TGCT	cis	rs9902453	0.753	rs3097118	chr17:27978466	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.84	8.48	0.61	5.74e-14	Coffee consumption (cups per day);
TGCT	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg20607798	chr8:58055168	NA	0.5	4.66	0.39	8.04e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs12042938	0.935	rs823167	chr1:231767230	G/A	cg04892437	chr1:231737901	TSNAX-DISC1	0.44	4.52	0.38	1.4e-5	Neuranatomic and neurocognitive phenotypes;
TGCT	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	7.12	0.54	7.55e-11	Platelet count;
TGCT	trans	rs1814175	0.645	rs28549248	chr11:50042740	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.84	-0.7	1.13e-19	Height;
TGCT	cis	rs12188164	1.000	rs34847072	chr5:437862	G/C	cg26850624	chr5:429559	AHRR	-0.2	-4.73	-0.39	6.01e-6	Cystic fibrosis severity;
TGCT	cis	rs2239547	0.603	rs34230854	chr3:53078590	C/A	cg11645453	chr3:52864694	ITIH4	0.29	4.62	0.38	9.33e-6	Schizophrenia;
TGCT	cis	rs12681288	0.748	rs2701935	chr8:1028618	T/A	cg04851639	chr8:1020857	NA	-0.34	-6.11	-0.48	1.18e-8	Schizophrenia;
TGCT	cis	rs4950928	0.823	rs2494277	chr1:203168092	A/G	cg17014757	chr1:203156097	CHI3L1	-0.4	-4.97	-0.41	2.15e-6	YKL-40 levels;
TGCT	cis	rs938554	0.571	rs12509955	chr4:10024303	C/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.92	-0.4	2.67e-6	Blood metabolite levels;
TGCT	cis	rs7772486	0.875	rs2207785	chr6:146332784	T/G	cg23711669	chr6:146136114	FBXO30	0.86	9.55	0.65	1.57e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs524281	0.861	rs918299	chr11:65927607	C/T	cg00563793	chr11:65837595	PACS1	0.56	4.74	0.39	5.69e-6	Electroencephalogram traits;
TGCT	cis	rs7226408	0.857	rs8099124	chr18:34593676	C/T	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg06753367	chr22:24256600	NA	-0.25	-4.73	-0.39	5.98e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9914988	0.943	rs9303621	chr17:27161138	A/G	cg20469991	chr17:27169893	C17orf63	-0.72	-5.09	-0.42	1.28e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	5.81	0.46	4.91e-8	Bipolar disorder;
TGCT	cis	rs7617773	0.815	rs7624450	chr3:48350375	A/G	cg11946769	chr3:48343235	NME6	0.82	7.09	0.54	9.1e-11	Coronary artery disease;
TGCT	cis	rs9584850	0.834	rs7334078	chr13:99120484	C/T	cg15168958	chr13:99100528	FARP1	0.23	4.51	0.38	1.5e-5	Neuroticism;
TGCT	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg10802521	chr3:52805072	NEK4	-0.72	-8.93	-0.63	4.86e-15	Bipolar disorder;
TGCT	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg16414030	chr3:133502952	NA	-0.61	-9.62	-0.65	1.06e-16	Iron status biomarkers;
TGCT	cis	rs2439831	0.867	rs8039638	chr15:43634405	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	6.61	0.51	1e-9	Lung cancer in ever smokers;
TGCT	cis	rs5760092	0.755	rs3884794	chr22:24251766	C/A	cg11905131	chr22:24372483	LOC391322	-0.56	-4.44	-0.37	1.93e-5	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs2243480	1.000	rs160643	chr7:65558222	C/T	cg07424592	chr7:64974309	NA	1.14	7.5	0.56	1.07e-11	Diabetic kidney disease;
TGCT	cis	rs3008870	1.000	rs2985817	chr1:67398607	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.1	11.97	0.73	2.07e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs611744	0.538	rs2298605	chr8:109272006	T/C	cg21045802	chr8:109455806	TTC35	0.82	8.65	0.61	2.19e-14	Dupuytren's disease;
TGCT	cis	rs6088590	0.931	rs6088617	chr20:33408036	G/A	cg24642439	chr20:33292090	TP53INP2	0.68	6.09	0.48	1.32e-8	Coronary artery disease;
TGCT	cis	rs2439831	1.000	rs2439831	chr15:43784475	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	5.25	0.43	6.46e-7	Lung cancer in ever smokers;
TGCT	cis	rs12681287	0.640	rs8635	chr8:87479810	C/T	cg27223183	chr8:87520930	FAM82B	-0.89	-6.41	-0.5	2.8e-9	Caudate activity during reward;
TGCT	cis	rs66561647	0.661	rs35851359	chr8:128935626	G/C	cg05480350	chr8:128972681	MIR1205;PVT1	0.22	4.57	0.38	1.18e-5	Hemoglobin concentration;
TGCT	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg03517284	chr6:25882590	NA	-0.62	-6.45	-0.5	2.23e-9	Blood metabolite levels;
TGCT	cis	rs9549260	0.755	rs59308928	chr13:41245079	C/T	cg21288729	chr13:41239152	FOXO1	1.0	10.25	0.68	3.06e-18	Red blood cell count;
TGCT	cis	rs617219	0.684	rs2896766	chr5:78586493	A/G	cg23987322	chr5:78407566	BHMT	-0.35	-4.7	-0.39	6.68e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs2692947	0.644	rs772154	chr2:97021664	G/T	cg22654517	chr2:96458247	NA	0.21	4.6	0.38	1.01e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs6138458	1.000	rs7269416	chr20:24976196	T/G	cg26195577	chr20:24973756	C20orf3	1.22	12.1	0.74	9.98e-23	Blood protein levels;
TGCT	cis	rs8030485	0.756	rs1521624	chr15:79412399	C/A	cg17916960	chr15:79447300	NA	0.35	4.87	0.4	3.29e-6	Left ventricle wall thickness;
TGCT	cis	rs1362404	0.649	rs34129201	chr16:51956358	G/A	cg00216305	chr16:51625890	NA	-0.27	-4.52	-0.38	1.41e-5	Gut microbiota (bacterial taxa);
TGCT	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg06896619	chr17:61851486	DDX42;CCDC47	0.51	4.96	0.41	2.24e-6	Prudent dietary pattern;
TGCT	cis	rs3087591	0.960	rs2905878	chr17:29511199	T/C	cg24425628	chr17:29625626	OMG;NF1	0.45	6.95	0.53	1.84e-10	Hip circumference;
TGCT	cis	rs2404618	0.624	rs4457358	chr8:1477213	C/A	cg13402656	chr8:1511478	DLGAP2	-0.38	-6.36	-0.5	3.52e-9	Lung cancer;
TGCT	cis	rs12210905	1.000	rs12213361	chr6:27138387	T/C	cg08851530	chr6:28072375	NA	1.12	5.43	0.44	2.82e-7	Hip circumference adjusted for BMI;
TGCT	trans	rs1814175	0.817	rs1996982	chr11:49972619	G/T	cg15704280	chr7:45808275	SEPT13	-0.73	-8.48	-0.61	5.58e-14	Height;
TGCT	cis	rs4499344	0.921	rs4805776	chr19:33087759	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.73	-6.6	-0.51	1.07e-9	Mean platelet volume;
TGCT	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg13409248	chr3:40428643	ENTPD3	0.57	4.53	0.38	1.37e-5	Renal cell carcinoma;
TGCT	cis	rs1552244	0.554	rs17050705	chr3:10046398	G/C	cg00149659	chr3:10157352	C3orf10	0.69	4.99	0.41	2.03e-6	Alzheimer's disease;
TGCT	cis	rs7267979	0.565	rs6107059	chr20:25592431	C/A	cg03522245	chr20:25566470	NINL	-0.45	-4.69	-0.39	6.99e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7336332	0.574	rs9512699	chr13:28029896	G/A	cg22138327	chr13:27999177	GTF3A	-0.73	-5.85	-0.47	4.11e-8	Weight;
TGCT	cis	rs28595532	0.688	rs116580819	chr4:119767362	T/A	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs7666738	0.515	rs13131874	chr4:98779183	A/G	cg18180107	chr4:99064573	C4orf37	0.54	4.74	0.39	5.8e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9810089	0.903	rs10935185	chr3:136290529	C/G	cg12473912	chr3:136751656	NA	0.34	4.83	0.4	3.9e-6	Gestational age at birth (child effect);
TGCT	cis	rs10779751	0.734	rs2791647	chr1:11132801	G/A	cg08854313	chr1:11322531	MTOR	0.82	7.04	0.53	1.19e-10	Body mass index;
TGCT	cis	rs200810	0.694	rs4527719	chr6:98020739	C/T	cg16511841	chr6:97730490	C6orf167;MIR548H3	-0.64	-4.45	-0.37	1.91e-5	Body mass index;
TGCT	cis	rs7647973	0.516	rs12490393	chr3:49196132	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.38	-4.92	-0.4	2.69e-6	Menarche (age at onset);
TGCT	cis	rs2442825	0.513	rs2648539	chr3:9400424	T/C	cg24633833	chr3:10029261	TMEM111	0.5	5.01	0.41	1.83e-6	Cerebrospinal fluid clusterin levels;
TGCT	cis	rs1891275	0.508	rs7099557	chr10:93445364	C/G	cg07889827	chr10:93443413	NA	-0.33	-6.99	-0.53	1.53e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg06028808	chr11:68637592	NA	-0.51	-6.53	-0.51	1.53e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs60843830	1.000	rs60149603	chr2:285421	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.72	7.02	0.53	1.3100000000000001e-10	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs9522267	0.535	rs9522302	chr13:112236874	C/T	cg10483660	chr13:112241077	NA	-0.27	-4.61	-0.38	9.78e-6	Hepatitis;
TGCT	cis	rs2046867	0.862	rs28632160	chr3:72800690	T/C	cg25664220	chr3:72788482	NA	-0.57	-7.12	-0.54	7.61e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg13732083	chr21:47605072	C21orf56	0.34	4.48	0.37	1.68e-5	Testicular germ cell tumor;
TGCT	cis	rs763121	0.853	rs9306329	chr22:39072454	C/T	cg06022373	chr22:39101656	GTPBP1	0.77	7.46	0.56	1.35e-11	Menopause (age at onset);
TGCT	cis	rs4383453	0.511	rs6803100	chr3:123103246	T/C	cg04890266	chr3:123102914	ADCY5	-0.49	-7.9	-0.58	1.28e-12	Gestational age at birth (maternal effect);
TGCT	cis	rs7666738	0.715	rs3857216	chr4:99032129	G/T	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2797160	1.000	rs1777226	chr6:126017691	C/A	cg05901451	chr6:126070800	HEY2	0.73	6.29	0.49	5.01e-9	Endometrial cancer;
TGCT	cis	rs7599312	0.534	rs10207878	chr2:213409337	A/G	cg20637307	chr2:213403960	ERBB4	0.92	11.42	0.72	4.43e-21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs9467773	1.000	rs9467787	chr6:26556769	G/T	cg09904177	chr6:26538194	HMGN4	0.66	6.6	0.51	1.05e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7647973	0.961	rs11130187	chr3:49307872	T/C	cg07636037	chr3:49044803	WDR6	0.67	5.41	0.44	3.15e-7	Menarche (age at onset);
TGCT	cis	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg08975724	chr8:8085496	FLJ10661	-0.59	-5.63	-0.45	1.16e-7	Mood instability;
TGCT	cis	rs62244186	1.000	rs62244186	chr3:44739783	G/A	cg18722847	chr3:44754129	ZNF502	-0.39	-4.45	-0.37	1.9e-5	Depressive symptoms;
TGCT	cis	rs2364543	0.624	rs61774752	chr1:41847024	T/C	cg01193554	chr1:41846683	NA	-0.41	-5.01	-0.41	1.86e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs713587	0.806	rs6737082	chr2:25138040	A/C	cg01884057	chr2:25150051	NA	0.27	5.33	0.43	4.41e-7	Body mass index in non-asthmatics;
TGCT	cis	rs854765	0.547	rs9894138	chr17:17964345	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.81	-8.63	-0.61	2.55e-14	Total body bone mineral density;
TGCT	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.47	0.56	1.28e-11	Prudent dietary pattern;
TGCT	cis	rs644799	1.000	rs481630	chr11:95582447	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.85	8.64	0.61	2.34e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs67311347	0.955	rs1129200	chr3:40532257	T/C	cg13683864	chr3:40499215	RPL14	-1.14	-11.17	-0.71	1.81e-20	Renal cell carcinoma;
TGCT	cis	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg13531842	chr10:38383804	ZNF37A	-0.38	-4.55	-0.38	1.25e-5	Extrinsic epigenetic age acceleration;
TGCT	cis	rs10114408	0.959	rs10821252	chr9:96652906	G/T	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs13256369	0.865	rs13277708	chr8:8573936	T/C	cg18904891	chr8:8559673	CLDN23	0.6	5.49	0.44	2.19e-7	Obesity-related traits;
TGCT	cis	rs7666738	0.791	rs1593571	chr4:98963763	T/C	cg17366294	chr4:99064904	C4orf37	0.74	7.56	0.56	7.89e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2651899	0.934	rs1627080	chr1:3081309	T/C	cg07622451	chr1:3079886	PRDM16	0.28	5.51	0.44	1.99e-7	Migraine;
TGCT	cis	rs12950390	0.853	rs12450733	chr17:45855404	A/G	cg06532163	chr17:45867833	NA	0.35	5.43	0.44	2.83e-7	IgG glycosylation;
TGCT	cis	rs13242816	1.000	rs13247015	chr7:116095623	A/C	cg02799643	chr7:116139180	CAV2	-0.44	-5.22	-0.42	7.16e-7	P wave duration;
TGCT	cis	rs478304	0.903	rs495961	chr11:65540886	C/T	cg27068330	chr11:65405492	SIPA1	0.74	7.41	0.55	1.67e-11	Acne (severe);
TGCT	cis	rs7714584	1.000	rs10058943	chr5:150226586	A/G	cg22134413	chr5:150180641	NA	0.87	6.89	0.53	2.52e-10	Crohn's disease;
TGCT	cis	rs2486288	0.656	rs8039540	chr15:45551842	C/G	cg26924012	chr15:45694286	SPATA5L1	-0.72	-7.46	-0.56	1.34e-11	Glomerular filtration rate;
TGCT	cis	rs12142240	0.698	rs17413694	chr1:46818416	A/C	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs6840360	0.574	rs2709844	chr4:152368212	C/T	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.83e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs1538970	0.924	rs11211108	chr1:45891152	C/T	cg05343316	chr1:45956843	TESK2	0.76	6.19	0.49	7.93e-9	Platelet count;
TGCT	cis	rs208520	1.000	rs12199876	chr6:66989469	A/G	cg07460842	chr6:66804631	NA	0.78	6.82	0.52	3.61e-10	Exhaled nitric oxide output;
TGCT	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg25036284	chr2:26402008	FAM59B	-0.54	-4.7	-0.39	6.93e-6	Gut microbiome composition (summer);
TGCT	cis	rs1153858	1.000	rs11070453	chr15:45645154	C/G	cg26924012	chr15:45694286	SPATA5L1	1.09	15.16	0.81	5.15e-30	Homoarginine levels;
TGCT	cis	rs7615952	0.932	rs13065725	chr3:125632289	C/A	cg05084668	chr3:125655381	ALG1L	-0.63	-4.58	-0.38	1.13e-5	Blood pressure (smoking interaction);
TGCT	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg22618164	chr12:122356400	WDR66	0.69	6.52	0.51	1.6e-9	Mean corpuscular volume;
TGCT	cis	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg18252515	chr7:66147081	NA	-1.12	-6.49	-0.5	1.83e-9	Diabetic kidney disease;
TGCT	cis	rs2032447	0.677	rs199737	chr6:25933538	A/T	cg03517284	chr6:25882590	NA	-0.73	-6.67	-0.51	7.4e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs4851266	0.966	rs13017207	chr2:100841235	G/A	cg22139774	chr2:100720529	AFF3	-0.35	-5.18	-0.42	8.68e-7	Educational attainment;
TGCT	cis	rs3091242	0.866	rs11249249	chr1:25758134	A/G	cg23205692	chr1:25664452	TMEM50A	0.51	5.31	0.43	4.88e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs877282	0.853	rs7079450	chr10:755932	T/A	cg17470449	chr10:769945	NA	0.32	4.91	0.4	2.76e-6	Uric acid levels;
TGCT	cis	rs4654899	0.772	rs12145203	chr1:21086127	C/T	cg01072550	chr1:21505969	NA	-0.48	-7.17	-0.54	6.05e-11	Superior frontal gyrus grey matter volume;
TGCT	cis	rs13191362	1.000	rs66789102	chr6:163104432	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.11	9.41	0.65	3.38e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs6815814	0.808	rs3860069	chr4:38862121	A/C	cg02016764	chr4:38805732	TLR1	-0.33	-5.35	-0.43	4.13e-7	Breast cancer;
TGCT	trans	rs7726839	0.507	rs111707179	chr5:593308	T/A	cg11887960	chr12:57824829	NA	1.2	9.65	0.65	8.99e-17	Obesity-related traits;
TGCT	cis	rs7851660	0.527	rs7859751	chr9:100575888	C/T	cg13688889	chr9:100608707	NA	-0.23	-4.63	-0.38	9.01e-6	Strep throat;
TGCT	cis	rs1023500	0.596	rs133350	chr22:42429049	A/G	cg05082376	chr22:42548792	NA	-0.22	-5.3	-0.43	5.09e-7	Schizophrenia;
TGCT	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs17376456	0.825	rs17372615	chr5:93124768	C/T	cg25358565	chr5:93447407	FAM172A	0.91	8.22	0.59	2.27e-13	Diabetic retinopathy;
TGCT	cis	rs4851254	0.660	rs17023468	chr2:100694091	A/G	cg22139774	chr2:100720529	AFF3	-0.42	-4.71	-0.39	6.55e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg24829409	chr8:58192753	C8orf71	-0.59	-4.97	-0.41	2.17e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg24060327	chr5:131705240	SLC22A5	-0.65	-6.56	-0.51	1.32e-9	Acylcarnitine levels;
TGCT	cis	rs7666738	0.791	rs6840669	chr4:99016020	G/T	cg05340658	chr4:99064831	C4orf37	0.48	5.43	0.44	2.92e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs72781680	0.848	rs72780199	chr2:24016269	A/C	cg08917208	chr2:24149416	ATAD2B	0.81	5.01	0.41	1.8e-6	Lymphocyte counts;
TGCT	cis	rs7805747	0.922	rs73728279	chr7:151411494	G/T	cg17611936	chr7:151411526	PRKAG2	0.56	6.64	0.51	8.81e-10	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
TGCT	cis	rs12477438	0.501	rs2632284	chr2:99775865	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.05	13.31	0.77	1.16e-25	Chronic sinus infection;
TGCT	cis	rs9549367	0.789	rs9549701	chr13:113881752	G/C	cg00898013	chr13:113819073	PROZ	-0.4	-4.88	-0.4	3.18e-6	Platelet distribution width;
TGCT	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg11301795	chr4:187892539	NA	-0.34	-5.11	-0.42	1.17e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg08280861	chr8:58055591	NA	0.4	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg22618164	chr12:122356400	WDR66	0.69	6.43	0.5	2.52e-9	Mean corpuscular volume;
TGCT	cis	rs12477438	0.520	rs11695751	chr2:99708247	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.89	9.0	0.63	3.26e-15	Chronic sinus infection;
TGCT	cis	rs11578119	0.933	rs12126472	chr1:170530053	G/T	cg09767346	chr1:170501363	GORAB	0.58	4.56	0.38	1.19e-5	Male-pattern baldness;
TGCT	cis	rs6089829	0.962	rs2314131	chr20:61665225	A/G	cg08564027	chr20:61660810	NA	0.3	4.78	0.39	4.9e-6	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9467773	0.549	rs9461273	chr6:26584526	A/G	cg26531700	chr6:26746687	NA	-0.5	-4.71	-0.39	6.45e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7714584	1.000	rs75774363	chr5:150223722	C/T	cg22134413	chr5:150180641	NA	0.99	7.43	0.56	1.51e-11	Crohn's disease;
TGCT	trans	rs4650994	1.000	rs17276513	chr1:178520604	A/T	cg05059571	chr16:84539110	KIAA1609	0.39	7.24	0.55	4.23e-11	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs12477438	0.765	rs10181344	chr2:99692829	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-4.62	-0.38	9.47e-6	Chronic sinus infection;
TGCT	cis	rs6545883	0.894	rs7566035	chr2:61520815	C/T	cg15711740	chr2:61764176	XPO1	0.56	4.76	0.39	5.36e-6	Tuberculosis;
TGCT	cis	rs2637266	0.739	rs727902	chr10:78436425	A/C	cg18941641	chr10:78392320	NA	0.4	4.88	0.4	3.24e-6	Pulmonary function;
TGCT	cis	rs10754283	0.756	rs17441836	chr1:90135433	C/T	cg03145924	chr1:90228473	NA	-0.36	-4.51	-0.38	1.51e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	trans	rs4332037	0.707	rs4721096	chr7:1877311	T/C	cg25206134	chr2:45395956	NA	-0.85	-6.62	-0.51	9.68e-10	Bipolar disorder;
TGCT	cis	rs709400	0.663	rs1467561	chr14:103994961	T/C	cg26031613	chr14:104095156	KLC1	0.86	9.53	0.65	1.7e-16	Body mass index;
TGCT	cis	rs73036520	0.560	rs346750	chr19:45737218	G/T	cg20198684	chr19:45742032	NA	-0.24	-4.57	-0.38	1.15e-5	Monocyte percentage of white cells;
TGCT	trans	rs7726839	0.540	rs4957083	chr5:659343	T/C	cg11887960	chr12:57824829	NA	1.16	9.4	0.65	3.51e-16	Obesity-related traits;
TGCT	cis	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg08975724	chr8:8085496	FLJ10661	-0.58	-5.4	-0.44	3.31e-7	Mood instability;
TGCT	cis	rs10193935	0.901	rs222468	chr2:42642531	C/T	cg27598129	chr2:42591480	NA	-0.33	-4.83	-0.4	4.02e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9400180	1.000	rs6568529	chr6:108396166	C/T	cg08494708	chr6:108881870	FOXO3	0.51	4.44	0.37	1.93e-5	Major depressive disorder;
TGCT	cis	rs317689	0.718	rs645026	chr12:69757931	G/A	cg11871910	chr12:69753446	YEATS4	0.55	4.72	0.39	6.38e-6	Response to diuretic therapy;
TGCT	cis	rs1153858	1.000	rs2066090	chr15:45650018	T/C	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.62e-8	Homoarginine levels;
TGCT	cis	rs12291225	0.535	rs12806025	chr11:14413817	G/A	cg19336497	chr11:14380999	RRAS2	-0.3	-4.64	-0.38	8.58e-6	Sense of smell;
TGCT	cis	rs2404602	0.716	rs12441247	chr15:76812316	T/C	cg26408565	chr15:76604113	ETFA	-0.4	-5.24	-0.43	6.54e-7	Blood metabolite levels;
TGCT	cis	rs7568458	0.527	rs35416445	chr2:85773659	A/G	cg17127132	chr2:85788382	GGCX	0.52	4.63	0.38	9.25e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs28595532	0.920	rs114223775	chr4:119775091	C/T	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs5769707	0.521	rs9616715	chr22:50058582	C/T	cg05373962	chr22:49881684	NA	-0.32	-5.46	-0.44	2.46e-7	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs72945132	0.769	rs11235754	chr11:70136092	C/T	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	trans	rs7615952	1.000	rs9289275	chr3:125648659	A/T	cg07211511	chr3:129823064	LOC729375	-0.45	-7.63	-0.57	5.35e-12	Blood pressure (smoking interaction);
TGCT	cis	rs9928842	0.771	rs8059190	chr16:75260797	T/A	cg09066997	chr16:75300724	BCAR1	0.28	4.96	0.41	2.3e-6	Alcoholic chronic pancreatitis;
TGCT	trans	rs208520	0.731	rs12206488	chr6:66999917	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.84	7.22	0.54	4.62e-11	Exhaled nitric oxide output;
TGCT	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg08048268	chr3:133502702	NA	-0.64	-9.75	-0.66	4.97e-17	Iron status biomarkers;
TGCT	cis	rs76473307	1.000	rs6026555	chr20:57418329	G/T	cg06163629	chr20:57414884	GNASAS;GNAS	-0.64	-4.5	-0.37	1.54e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs1420338	0.967	rs10224203	chr7:34149593	C/T	cg01275685	chr7:34179230	BMPER	-0.27	-5.11	-0.42	1.17e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs12142240	0.698	rs79490411	chr1:46813568	G/A	cg14993813	chr1:46806288	NSUN4	-0.59	-4.74	-0.39	5.85e-6	Menopause (age at onset);
TGCT	cis	rs7412746	0.658	rs3843843	chr1:150918084	C/T	cg09365446	chr1:150670422	GOLPH3L	0.35	4.83	0.4	3.87e-6	Melanoma;
TGCT	cis	rs4499344	0.622	rs4805767	chr19:33049056	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.73	-6.37	-0.5	3.35e-9	Mean platelet volume;
TGCT	cis	rs2070433	0.539	rs2839314	chr21:47961067	A/G	cg12379764	chr21:47803548	PCNT	0.53	5.38	0.43	3.6e-7	Lymphocyte counts;
TGCT	cis	rs7312933	0.526	rs1669892	chr12:42811305	G/A	cg19980929	chr12:42632907	YAF2	-0.4	-5.7	-0.46	8.24e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs7582180	0.764	rs12712075	chr2:100924129	T/C	cg14675211	chr2:100938903	LONRF2	0.51	4.93	0.4	2.61e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6840360	0.517	rs4399967	chr4:152729312	T/A	cg22705602	chr4:152727874	NA	0.37	6.54	0.51	1.47e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg27436995	chr16:743998	FBXL16	-0.47	-5.13	-0.42	1.07e-6	Height;
TGCT	cis	rs9527	0.590	rs2182348	chr10:104872684	A/G	cg15744005	chr10:104629667	AS3MT	-0.43	-4.9	-0.4	2.89e-6	Arsenic metabolism;
TGCT	cis	rs1008375	0.863	rs7680984	chr4:17600884	A/G	cg16339924	chr4:17578868	LAP3	0.82	6.6	0.51	1.09e-9	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg15691649	chr6:25882328	NA	-0.42	-5.35	-0.43	4.11e-7	Blood metabolite levels;
TGCT	cis	rs2544527	0.586	rs6728750	chr2:15904734	C/T	cg26669897	chr2:15909070	NA	0.37	4.65	0.39	8.39e-6	Pulmonary function (smoking interaction);Pulmonary function;
TGCT	cis	rs7659604	0.540	rs10004284	chr4:122699222	A/T	cg19748678	chr4:122722346	EXOSC9	-0.6	-5.97	-0.47	2.35e-8	Type 2 diabetes;
TGCT	cis	rs1865760	1.000	rs3830057	chr6:25918510	G/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.65	6.11	0.48	1.17e-8	Height;
TGCT	cis	rs4577244	0.505	rs12616009	chr2:29123191	C/G	cg09522027	chr2:28974177	PPP1CB	0.57	4.49	0.37	1.59e-5	Breast cancer (estrogen-receptor negative);
TGCT	cis	rs6429082	0.738	rs2131921	chr1:235705157	C/T	cg26050004	chr1:235667680	B3GALNT2	0.59	5.42	0.44	2.97e-7	Adiposity;
TGCT	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.15	0.82	2.71e-32	Prudent dietary pattern;
TGCT	cis	rs72781680	0.752	rs55801864	chr2:23922325	C/T	cg08917208	chr2:24149416	ATAD2B	1.0	5.79	0.46	5.41e-8	Lymphocyte counts;
TGCT	cis	rs6754311	0.593	rs12619365	chr2:136398174	C/T	cg07169764	chr2:136633963	MCM6	0.68	5.86	0.47	4e-8	Mosquito bite size;
TGCT	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg05785598	chr3:49045655	WDR6	0.36	4.81	0.4	4.24e-6	Menarche (age at onset);
TGCT	cis	rs75059851	0.756	rs11223655	chr11:133842707	G/A	cg14047540	chr11:133829660	NA	-0.57	-5.69	-0.45	8.72e-8	Schizophrenia;
TGCT	cis	rs1153858	1.000	rs11070453	chr15:45645154	C/G	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.62e-8	Homoarginine levels;
TGCT	cis	rs60843830	1.000	rs17714252	chr2:285471	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.74	7.26	0.55	3.77e-11	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs2070488	0.766	rs6808093	chr3:38498160	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	7.9	0.58	1.3e-12	Electrocardiographic conduction measures;
TGCT	cis	rs7267979	1.000	rs6107045	chr20:25441936	G/A	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9611565	0.532	rs4401299	chr22:42156517	A/G	cg06481639	chr22:41940642	POLR3H	0.54	4.49	0.37	1.61e-5	Vitiligo;
TGCT	cis	rs12579753	0.719	rs4384447	chr12:82268069	G/C	cg07988820	chr12:82153109	PPFIA2	-0.42	-4.44	-0.37	1.97e-5	Resting heart rate;
TGCT	cis	rs3749237	0.595	rs4855839	chr3:49507847	G/A	cg07636037	chr3:49044803	WDR6	0.63	5.98	0.47	2.26e-8	Resting heart rate;
TGCT	cis	rs55823223	0.564	rs1463485	chr17:73851791	C/G	cg10935138	chr17:73851978	WBP2	0.82	7.59	0.56	6.81e-12	Psoriasis;
TGCT	cis	rs2153535	0.580	rs4960422	chr6:8459309	T/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs2708977	0.933	rs2464914	chr2:97179828	A/G	cg01950434	chr2:97203154	ARID5A	-0.69	-6.37	-0.5	3.27e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs870825	0.585	rs2696039	chr4:185610899	T/C	cg14471096	chr4:185570637	CCDC111;CASP3	-0.67	-4.62	-0.38	9.41e-6	Blood protein levels;
TGCT	cis	rs465969	1.000	rs459888	chr6:111651156	A/T	cg00587628	chr6:111584033	KIAA1919	-0.55	-5.43	-0.44	2.91e-7	Psoriasis;
TGCT	cis	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg25660036	chr4:7070649	GRPEL1	-0.67	-5.81	-0.46	4.85e-8	Monocyte percentage of white cells;
TGCT	cis	rs6770219	0.516	rs73182267	chr3:186135453	G/A	cg20306810	chr3:186501757	SNORD2;EIF4A2	0.73	4.45	0.37	1.89e-5	Cerebrospinal T-tau levels;
TGCT	cis	rs10972341	0.933	rs10972339	chr9:35138810	C/T	cg00812861	chr9:35114699	KIAA1539	-0.31	-4.54	-0.38	1.33e-5	Weight;
TGCT	cis	rs3617	0.625	rs6769789	chr3:52874446	C/T	cg11645453	chr3:52864694	ITIH4	-0.29	-5.71	-0.46	7.84e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9372498	0.536	rs9489458	chr6:118920503	G/A	cg07617317	chr6:118971624	C6orf204	0.49	5.22	0.42	7.37e-7	Diastolic blood pressure;
TGCT	cis	rs1443512	0.773	rs2366146	chr12:54331002	G/A	cg17708016	chr12:54321992	NA	0.57	4.67	0.39	7.84e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
TGCT	cis	rs72901758	0.768	rs11655421	chr17:76251518	T/A	cg25512537	chr17:76250053	NA	0.25	4.51	0.38	1.49e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs7772486	0.686	rs9376961	chr6:146048737	C/T	cg05347473	chr6:146136440	FBXO30	0.46	4.48	0.37	1.65e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2439831	0.850	rs28524541	chr15:44124831	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.9	6.3	0.49	4.62e-9	Lung cancer in ever smokers;
TGCT	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg03934478	chr11:495069	RNH1	0.35	5.82	0.46	4.66e-8	Body mass index;
TGCT	cis	rs2299587	0.560	rs12718385	chr8:17781257	T/C	cg01800426	chr8:17659068	MTUS1	-0.65	-5.78	-0.46	5.68e-8	Economic and political preferences;
TGCT	cis	rs651907	0.557	rs3806654	chr3:101396529	G/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.91	11.43	0.72	4.08e-21	Colorectal cancer;
TGCT	cis	rs60843830	1.000	rs3791221	chr2:226933	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.72	6.81	0.52	3.78e-10	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs7647973	0.626	rs9829155	chr3:49817450	T/C	cg03034192	chr3:50606346	HEMK1;C3orf18	-0.36	-4.75	-0.39	5.61e-6	Menarche (age at onset);
TGCT	cis	rs2239547	0.522	rs6792578	chr3:53004604	G/A	cg11645453	chr3:52864694	ITIH4	0.34	5.51	0.44	2.02e-7	Schizophrenia;
TGCT	cis	rs11690935	0.959	rs11897196	chr2:172585595	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.18	-12.58	-0.75	6.59e-24	Schizophrenia;
TGCT	cis	rs3782455	1.000	rs75596675	chr12:114401944	A/G	cg10631684	chr12:113795897	PLBD2	-0.7	-4.61	-0.38	1e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs9291683	0.509	rs998676	chr4:9948564	T/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-8.05	-0.59	5.87e-13	Bone mineral density;
TGCT	cis	rs941873	0.772	rs1892498	chr10:81103862	A/G	cg09469691	chr10:81107165	PPIF	0.57	5.7	0.46	8.35e-8	Height;
TGCT	cis	rs5769765	1.000	rs2295409	chr22:50261060	G/C	cg15316289	chr22:50310904	ALG12;CRELD2	-0.41	-6.07	-0.48	1.47e-8	Schizophrenia;
TGCT	cis	rs700590	0.532	rs10462335	chr5:88088204	G/A	cg22951263	chr5:87985283	NA	-0.55	-5.64	-0.45	1.09e-7	Educational attainment (years of education);
TGCT	cis	rs6700896	0.522	rs6664534	chr1:66160075	T/A	cg14976592	chr1:65886160	LEPROT;LEPR	-0.54	-4.44	-0.37	1.98e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs2463822	0.583	rs72919472	chr11:62040655	C/T	cg06239285	chr11:62104954	ASRGL1	-0.88	-5.49	-0.44	2.15e-7	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs17331151	0.573	rs11718060	chr3:52875546	G/A	cg11137980	chr3:52469226	SEMA3G	0.27	4.67	0.39	7.79e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs11098499	0.722	rs7673476	chr4:120248683	C/T	cg09307838	chr4:120376055	NA	0.62	6.09	0.48	1.31e-8	Corneal astigmatism;
TGCT	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg22963979	chr7:1858916	MAD1L1	-0.4	-6.44	-0.5	2.44e-9	Bipolar disorder and schizophrenia;
TGCT	cis	rs9858542	0.537	rs34514189	chr3:49373045	A/G	cg00383909	chr3:49044727	WDR6	0.68	4.6	0.38	1.02e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs7267979	1.000	rs2500443	chr20:25331442	C/T	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4699052	1.000	rs4699055	chr4:104154500	T/C	cg16532752	chr4:104119610	CENPE	-0.58	-5.46	-0.44	2.43e-7	Testicular germ cell tumor;
TGCT	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg17911788	chr17:44343683	NA	-0.67	-6.98	-0.53	1.62e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg05785598	chr3:49045655	WDR6	-0.36	-4.86	-0.4	3.41e-6	Menarche (age at onset);
TGCT	cis	rs6728642	0.572	rs1320147	chr2:97600626	A/C	cg26665480	chr2:98280029	ACTR1B	0.9	6.85	0.52	3.09e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	cis	rs9581857	0.547	rs1235848	chr13:28111559	G/T	cg22138327	chr13:27999177	GTF3A	-0.7	-4.81	-0.4	4.22e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	trans	rs1814175	0.817	rs12295885	chr11:50036762	T/G	cg15704280	chr7:45808275	SEPT13	-0.72	-8.47	-0.61	6.02e-14	Height;
TGCT	cis	rs2469997	1.000	rs2447168	chr8:120365613	A/T	cg00681363	chr8:120844660	TAF2	0.66	4.47	0.37	1.72e-5	Hypertension (SNP x SNP interaction);
TGCT	trans	rs208520	0.661	rs7740835	chr6:66865548	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-10.43	-0.68	1.13e-18	Exhaled nitric oxide output;
TGCT	cis	rs2153535	0.541	rs9392222	chr6:8467649	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs910316	1.000	rs4899546	chr14:75594946	G/C	cg23033748	chr14:75592666	NEK9	0.28	4.79	0.39	4.73e-6	Height;
TGCT	cis	rs6460942	0.818	rs7780083	chr7:12233647	C/T	cg06484146	chr7:12443880	VWDE	-0.54	-4.76	-0.39	5.21e-6	Coronary artery disease;
TGCT	cis	rs9297145	0.724	rs6954584	chr7:98766930	G/A	cg05967295	chr7:98741636	SMURF1	0.99	12.81	0.75	1.84e-24	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs2120019	0.938	rs8028632	chr15:75321262	T/C	cg09165964	chr15:75287851	SCAMP5	-1.14	-10.33	-0.68	2.05e-18	Blood trace element (Zn levels);
TGCT	cis	rs7674212	0.539	rs7676041	chr4:104126421	T/A	cg16532752	chr4:104119610	CENPE	-0.57	-5.15	-0.42	9.78e-7	Type 2 diabetes;
TGCT	cis	rs17376456	0.696	rs6860390	chr5:93494731	G/T	cg21475434	chr5:93447410	FAM172A	-0.58	-5.35	-0.43	4.16e-7	Diabetic retinopathy;
TGCT	cis	rs617219	0.765	rs10053349	chr5:78475423	T/C	cg23514016	chr5:78407564	BHMT	0.35	5.53	0.44	1.82e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs7584330	0.554	rs9646713	chr2:238443542	T/C	cg08992911	chr2:238395768	MLPH	0.64	4.49	0.37	1.63e-5	Prostate cancer;
TGCT	cis	rs2742417	1.000	rs2673067	chr3:45770087	A/C	cg04837898	chr3:45731254	SACM1L	-0.47	-4.82	-0.4	4.03e-6	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs7072216	0.763	rs3750601	chr10:100174561	C/A	cg26618903	chr10:100175079	PYROXD2	-0.4	-4.49	-0.37	1.64e-5	Metabolite levels;
TGCT	cis	rs9913156	0.793	rs9916135	chr17:4568115	A/C	cg00122941	chr17:4613640	ARRB2	-0.89	-7.56	-0.56	7.65e-12	Lymphocyte counts;
TGCT	trans	rs7819412	0.775	rs2001329	chr8:10986859	C/T	cg15556689	chr8:8085844	FLJ10661	-0.8	-7.58	-0.56	7.01e-12	Triglycerides;
TGCT	cis	rs1008375	0.966	rs11733730	chr4:17625209	G/C	cg16339924	chr4:17578868	LAP3	0.71	5.77	0.46	6.04e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2836974	0.583	rs2776306	chr21:40713754	A/G	cg11890956	chr21:40555474	PSMG1	0.76	7.6	0.56	6.28e-12	Cognitive function;
TGCT	cis	rs2862064	1.000	rs7715467	chr5:156468654	C/G	cg12943317	chr5:156479607	HAVCR1	-0.45	-5.29	-0.43	5.36e-7	Platelet count;
TGCT	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg10047753	chr17:41438598	NA	0.87	8.58	0.61	3.31e-14	Menopause (age at onset);
TGCT	cis	rs10193935	0.748	rs12467253	chr2:42697588	A/C	cg27598129	chr2:42591480	NA	0.38	5.14	0.42	1.05e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9325144	0.555	rs10748433	chr12:38696352	C/G	cg26384229	chr12:38710491	ALG10B	0.66	6.16	0.48	9.33e-9	Morning vs. evening chronotype;
TGCT	cis	rs7267979	1.000	rs447722	chr20:25443510	C/T	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs854765	0.583	rs4257260	chr17:17857003	A/G	cg09796270	chr17:17721594	SREBF1	0.23	4.55	0.38	1.27e-5	Total body bone mineral density;
TGCT	cis	rs2239547	0.522	rs6770957	chr3:52995416	T/C	cg10802521	chr3:52805072	NEK4	-0.61	-5.9	-0.47	3.2e-8	Schizophrenia;
TGCT	cis	rs6952808	0.609	rs6970034	chr7:1948088	G/A	cg22963979	chr7:1858916	MAD1L1	-0.37	-5.62	-0.45	1.22e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs6582630	0.594	rs7308707	chr12:38450428	G/C	cg26384229	chr12:38710491	ALG10B	-0.54	-4.79	-0.4	4.57e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs2797160	0.547	rs9401837	chr6:125956853	T/C	cg05901451	chr6:126070800	HEY2	-0.62	-5.17	-0.42	9.25e-7	Endometrial cancer;
TGCT	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg00149659	chr3:10157352	C3orf10	0.94	6.04	0.48	1.63e-8	Alzheimer's disease;
TGCT	cis	rs1371867	0.875	rs1788169	chr8:101326314	C/T	cg06002616	chr8:101225028	SPAG1	-0.56	-6.58	-0.51	1.2e-9	Atrioventricular conduction;
TGCT	cis	rs10992471	0.756	rs10115222	chr9:95128149	C/T	cg14631576	chr9:95140430	CENPP	0.29	4.82	0.4	4.17e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs3741404	0.609	rs651855	chr11:63870810	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	7.46	0.56	1.34e-11	Platelet count;
TGCT	cis	rs7666738	0.677	rs13120306	chr4:99036099	A/T	cg17366294	chr4:99064904	C4orf37	0.74	7.59	0.56	6.7e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7937682	0.961	rs17113227	chr11:111620491	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.13	-12.51	-0.75	1.02e-23	Primary sclerosing cholangitis;
TGCT	cis	rs66731853	0.771	rs541244	chr1:20889380	G/A	cg04087271	chr1:20915334	CDA	-0.55	-6.64	-0.51	8.88e-10	Mean corpuscular volume;
TGCT	cis	rs8067545	0.640	rs17759083	chr17:19963605	T/A	cg18979559	chr17:20280153	CCDC144C	0.47	4.89	0.4	3e-6	Schizophrenia;
TGCT	cis	rs66573146	0.803	rs59809420	chr4:6969928	G/T	cg01220768	chr4:7056774	TADA2B	0.36	4.55	0.38	1.27e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs2229238	0.911	rs73023331	chr1:154508210	G/A	cg13067139	chr1:155221277	FAM189B	0.2	4.51	0.38	1.47e-5	Coronary heart disease;
TGCT	cis	rs9682041	0.877	rs12489967	chr3:170073339	A/C	cg11886554	chr3:170076028	SKIL	0.59	4.7	0.39	6.84e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs877529	0.530	rs1005300	chr22:39547891	C/G	cg18708252	chr22:39545030	CBX7	-0.35	-5.18	-0.42	8.84e-7	Multiple myeloma;
TGCT	cis	rs595982	0.726	rs607356	chr19:49371241	T/C	cg17863274	chr19:49399704	TULP2	-0.29	-4.48	-0.37	1.67e-5	Red cell distribution width;
TGCT	cis	rs2354432	0.607	rs58941651	chr1:146784919	T/C	cg25205988	chr1:146714368	CHD1L	-1.34	-6.07	-0.48	1.44e-8	Mitochondrial DNA levels;
TGCT	cis	rs9911578	1.000	rs9902994	chr17:56948722	T/A	cg12560992	chr17:57184187	TRIM37	0.76	9.21	0.64	1.03e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs904251	0.772	rs2776906	chr6:37431757	A/G	cg01843034	chr6:37503916	NA	-0.43	-4.45	-0.37	1.87e-5	Cognitive performance;
TGCT	trans	rs2727020	0.734	rs1164663	chr11:49294723	A/T	cg15704280	chr7:45808275	SEPT13	0.67	6.8	0.52	4.02e-10	Coronary artery disease;
TGCT	cis	rs909674	0.690	rs5750825	chr22:39831278	A/G	cg05872129	chr22:39784769	NA	-0.99	-9.57	-0.65	1.36e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs6912958	0.712	rs2814712	chr6:88396322	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.49	4.88	0.4	3.14e-6	Monocyte percentage of white cells;
TGCT	cis	rs1903068	0.657	rs41408948	chr4:55992025	G/A	cg01777861	chr4:56023843	NA	0.52	5.58	0.45	1.44e-7	Endometriosis;
TGCT	cis	rs6121246	0.567	rs6060249	chr20:30190944	G/A	cg21427119	chr20:30132790	HM13	-0.42	-6.17	-0.48	8.75e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs9486719	1.000	rs11152969	chr6:96908712	A/C	cg06623918	chr6:96969491	KIAA0776	-0.98	-8.77	-0.62	1.15e-14	Migraine;Coronary artery disease;
TGCT	cis	rs13242816	1.000	rs13221364	chr7:116083544	C/T	cg16553024	chr7:116138462	CAV2	-0.47	-4.72	-0.39	6.27e-6	P wave duration;
TGCT	cis	rs7786808	0.705	rs1377373	chr7:158215549	A/C	cg01191920	chr7:158217561	PTPRN2	0.43	6.65	0.51	8.33e-10	Obesity-related traits;
TGCT	cis	rs12497850	0.931	rs9840050	chr3:49133310	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.41	-5.4	-0.44	3.33e-7	Parkinson's disease;
TGCT	cis	rs9443645	0.901	rs9341754	chr6:79584973	A/C	cg05283184	chr6:79620031	NA	-0.21	-4.71	-0.39	6.61e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs11614913	0.551	rs1867297	chr12:54396971	A/G	cg25285794	chr12:54402699	HOXC8	-0.65	-5.42	-0.44	3.04e-7	Waist circumference adjusted for body mass index;
TGCT	cis	rs7666738	0.830	rs6532721	chr4:99048015	G/A	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg20891283	chr12:69753455	YEATS4	-0.91	-10.46	-0.68	9.81e-19	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs2354432	0.607	rs3820130	chr1:146724003	A/G	cg25205988	chr1:146714368	CHD1L	-1.34	-6.07	-0.48	1.44e-8	Mitochondrial DNA levels;
TGCT	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.62	-6.45	-0.5	2.24e-9	Longevity;Endometriosis;
TGCT	cis	rs34891900	0.507	rs5992088	chr22:18135912	C/T	cg19898043	chr22:18121309	BCL2L13	-0.54	-4.55	-0.38	1.26e-5	Sum neutrophil eosinophil counts;
TGCT	cis	rs8017423	0.569	rs10141476	chr14:90823351	C/T	cg04374321	chr14:90722782	PSMC1	-0.54	-5.41	-0.44	3.13e-7	Mortality in heart failure;
TGCT	cis	rs13191362	0.507	rs2849518	chr6:163134248	T/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.57	-5.44	-0.44	2.72e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs9921338	0.961	rs8048768	chr16:11396840	T/C	cg00044050	chr16:11439710	C16orf75	-0.97	-7.11	-0.54	8.2e-11	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs2688608	0.592	rs11000760	chr10:75493734	G/A	cg15838173	chr10:75533400	FUT11	-0.31	-5.02	-0.41	1.73e-6	Inflammatory bowel disease;
TGCT	cis	rs2075371	0.932	rs2544215	chr7:133987896	T/C	cg11752832	chr7:134001865	SLC35B4	0.69	6.32	0.49	4.25e-9	Mean platelet volume;
TGCT	cis	rs2288073	0.965	rs36101491	chr2:24387532	C/T	cg02683114	chr2:24398427	C2orf84	-0.23	-4.94	-0.41	2.52e-6	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs7666738	0.830	rs1593573	chr4:98925293	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9611519	0.929	rs2064560	chr22:41530040	A/G	cg03806693	chr22:41940476	POLR3H	-0.66	-5.97	-0.47	2.28e-8	Neuroticism;
TGCT	cis	rs6074578	0.679	rs6077246	chr20:136454	T/C	cg16931068	chr20:139680	DEFB127	0.29	4.94	0.41	2.48e-6	Hirschsprung disease;
TGCT	cis	rs7809950	0.862	rs62482502	chr7:106987810	A/C	cg23024343	chr7:107201750	COG5	-0.31	-4.64	-0.38	8.63e-6	Coronary artery disease;
TGCT	cis	rs7772486	0.875	rs13198450	chr6:146370524	C/A	cg23711669	chr6:146136114	FBXO30	0.89	10.0	0.67	1.25e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg14827481	chr10:134361889	INPP5A	0.29	4.66	0.39	8.11e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs9549367	0.569	rs3024719	chr13:113814225	G/A	cg18105134	chr13:113819100	PROZ	-0.46	-7.35	-0.55	2.29e-11	Platelet distribution width;
TGCT	cis	rs916888	0.821	rs199506	chr17:44859031	A/G	cg15921436	chr17:44337874	NA	-0.51	-6.96	-0.53	1.77e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	16.05	0.82	4.59e-32	Prudent dietary pattern;
TGCT	cis	rs939658	0.683	rs1434459	chr15:79465210	T/C	cg17916960	chr15:79447300	NA	-0.42	-6.64	-0.51	8.59e-10	Refractive error;
TGCT	cis	rs2251381	0.722	rs2251278	chr21:30529234	A/G	cg08807101	chr21:30365312	RNF160	0.52	4.49	0.37	1.59e-5	Selective IgA deficiency;
TGCT	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg22963979	chr7:1858916	MAD1L1	-0.44	-6.93	-0.53	2.01e-10	Bipolar disorder and schizophrenia;
TGCT	cis	rs1218582	0.772	rs2061690	chr1:154919080	C/T	cg03351412	chr1:154909251	PMVK	0.5	4.68	0.39	7.52e-6	Prostate cancer;
TGCT	cis	rs12620999	0.555	rs4073396	chr2:238111471	A/C	cg23555395	chr2:238036564	NA	0.27	4.75	0.39	5.57e-6	Systemic lupus erythematosus;
TGCT	cis	rs9913156	0.802	rs4538065	chr17:4566015	G/A	cg23387401	chr17:4582204	PELP1	-0.31	-4.63	-0.38	8.97e-6	Lymphocyte counts;
TGCT	cis	rs6545883	0.929	rs7606167	chr2:61742654	C/G	cg15711740	chr2:61764176	XPO1	-0.57	-5.23	-0.42	7.06e-7	Tuberculosis;
TGCT	cis	rs72945132	0.882	rs59398290	chr11:70134819	G/A	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs295140	0.535	rs1369841	chr2:201227060	A/G	cg04283868	chr2:201171347	SPATS2L	0.52	5.1	0.42	1.25e-6	QT interval;
TGCT	cis	rs10791097	0.694	rs12361892	chr11:130744490	T/G	cg12179176	chr11:130786555	SNX19	0.84	10.17	0.67	4.95e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	trans	rs9951602	0.541	rs12454297	chr18:76654445	A/G	cg02800362	chr5:177631904	HNRNPAB	1.13	12.84	0.76	1.57e-24	Obesity-related traits;
TGCT	cis	rs1990950	1.000	rs1990950	chr5:156920756	G/T	cg25387487	chr5:157003181	ADAM19	0.32	4.82	0.4	4.12e-6	Lung function (FEV1/FVC);
TGCT	cis	rs9902453	0.904	rs4077465	chr17:28300144	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.82	7.63	0.57	5.3e-12	Coffee consumption (cups per day);
TGCT	cis	rs12042938	0.905	rs823160	chr1:231776636	A/G	cg04892437	chr1:231737901	TSNAX-DISC1	0.44	4.66	0.39	8.13e-6	Neuranatomic and neurocognitive phenotypes;
TGCT	cis	rs806215	0.547	rs11772303	chr7:127398962	G/T	cg11539674	chr7:127291444	SND1	-0.37	-4.72	-0.39	6.35e-6	Type 2 diabetes;
TGCT	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg04317338	chr11:64019027	PLCB3	0.75	6.15	0.48	1e-8	Mean platelet volume;
TGCT	cis	rs2299587	0.553	rs2299580	chr8:17734567	C/A	cg01800426	chr8:17659068	MTUS1	-0.53	-4.77	-0.39	5.14e-6	Economic and political preferences;
TGCT	cis	rs2997447	0.601	rs61776577	chr1:26431931	T/C	cg03844060	chr1:26490628	NA	0.28	4.56	0.38	1.19e-5	QRS complex (12-leadsum);
TGCT	cis	rs7568458	0.660	rs55692129	chr2:85792404	A/T	cg02493740	chr2:85810744	VAMP5	-0.31	-5.81	-0.46	4.94e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs9560113	1.000	rs4773387	chr13:112180955	T/C	cg14154082	chr13:112174009	NA	0.37	5.07	0.41	1.42e-6	Menarche (age at onset);
TGCT	cis	rs7246657	1.000	rs1823061	chr19:37800626	G/A	cg18154014	chr19:37997991	ZNF793	0.81	5.56	0.45	1.61e-7	Coronary artery calcification;
TGCT	cis	rs7959452	0.640	rs4761233	chr12:69722880	T/C	cg14784868	chr12:69753453	YEATS4	0.67	6.96	0.53	1.79e-10	Blood protein levels;
TGCT	cis	rs11098499	0.615	rs59867181	chr4:120556467	C/T	cg09307838	chr4:120376055	NA	-0.57	-5.3	-0.43	5.13e-7	Corneal astigmatism;
TGCT	cis	rs4953076	0.533	rs1551315	chr2:44407618	G/A	cg04920474	chr2:44395004	PPM1B	0.59	5.88	0.47	3.58e-8	Height;
TGCT	cis	rs2180341	0.960	rs9398840	chr6:127669744	G/A	cg27446573	chr6:127587934	RNF146	1.21	10.87	0.7	9.57e-20	Breast cancer;
TGCT	cis	rs7193541	0.929	rs12933037	chr16:74660174	G/A	cg01733217	chr16:74700730	RFWD3	0.83	7.95	0.58	1e-12	Multiple myeloma;
TGCT	cis	rs7824557	0.564	rs2572392	chr8:11235605	T/G	cg21775007	chr8:11205619	TDH	-0.65	-6.4	-0.5	2.95e-9	Retinal vascular caliber;
TGCT	cis	rs7914558	0.966	rs10786719	chr10:104637992	C/T	cg05855489	chr10:104503620	C10orf26	-0.51	-4.6	-0.38	1.02e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg04287289	chr16:89883240	FANCA	0.94	12.19	0.74	5.77e-23	Vitiligo;
TGCT	cis	rs62244186	0.711	rs6778410	chr3:44743993	C/T	cg18722847	chr3:44754129	ZNF502	-0.4	-4.63	-0.38	9.18e-6	Depressive symptoms;
TGCT	cis	rs7954584	0.546	rs10840630	chr12:122352445	C/T	cg21016266	chr12:122356598	WDR66	0.53	6.61	0.51	1.04e-9	Mean corpuscular volume;
TGCT	cis	rs155076	0.666	rs4638420	chr13:21872348	A/G	cg14456004	chr13:21872349	NA	1.36	12.09	0.74	1.05e-22	White matter hyperintensity burden;
TGCT	cis	rs4499344	0.633	rs259239	chr19:33141090	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.85	9.38	0.64	3.96e-16	Mean platelet volume;
TGCT	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	4.93	0.4	2.6e-6	Menopause (age at onset);
TGCT	trans	rs1814175	0.645	rs12364337	chr11:49942580	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.51	-0.69	7.2e-19	Height;
TGCT	cis	rs3820928	0.874	rs13413235	chr2:227893863	C/T	cg11843606	chr2:227700838	RHBDD1	-0.54	-4.96	-0.41	2.29e-6	Pulmonary function;
TGCT	cis	rs67073037	0.955	rs12611829	chr2:29144456	T/C	cg09522027	chr2:28974177	PPP1CB	0.57	4.49	0.37	1.59e-5	Breast cancer;Breast cancer (estrogen-receptor negative);
TGCT	cis	rs548987	0.507	rs1408268	chr6:25826986	T/A	cg03517284	chr6:25882590	NA	-0.55	-4.44	-0.37	1.93e-5	Homocysteine levels;
TGCT	cis	rs8056742	0.558	rs11644136	chr16:85100034	C/T	cg00229868	chr16:85520891	NA	0.38	4.76	0.39	5.34e-6	Amyotrophic lateral sclerosis;
TGCT	cis	rs10032931	0.926	rs17024152	chr4:96456402	T/A	cg17031751	chr4:96469067	UNC5C	-0.37	-4.66	-0.39	7.98e-6	Optic nerve measurement (cup-to-disc ratio);
TGCT	cis	rs12188164	1.000	rs55842567	chr5:437586	G/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.4	-4.76	-0.39	5.33e-6	Cystic fibrosis severity;
TGCT	cis	rs7267979	1.000	rs2482930	chr20:25334115	G/C	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7246657	0.943	rs4803460	chr19:37885228	T/C	cg18154014	chr19:37997991	ZNF793	0.75	5.34	0.43	4.18e-7	Coronary artery calcification;
TGCT	cis	rs7267979	1.000	rs2258617	chr20:25274318	C/T	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2404602	0.692	rs35498563	chr15:76958868	C/T	cg22467129	chr15:76604101	ETFA	-0.45	-5.11	-0.42	1.2e-6	Blood metabolite levels;
TGCT	cis	rs36051895	0.632	rs72701654	chr9:5161453	T/C	cg02405213	chr9:5042618	JAK2	-0.71	-9.01	-0.63	3.02e-15	Pediatric autoimmune diseases;
TGCT	cis	rs12188164	1.000	rs72717414	chr5:429818	C/G	cg21144161	chr5:423903	AHRR	0.26	4.93	0.4	2.59e-6	Cystic fibrosis severity;
TGCT	cis	rs9929218	0.551	rs7201437	chr16:68727130	A/C	cg01251360	chr16:68772225	CDH1	-0.28	-5.23	-0.43	6.96e-7	Colorectal cancer;
TGCT	cis	rs7215564	0.818	rs34756632	chr17:78618859	C/T	cg23263226	chr17:78226839	SLC26A11	0.45	4.55	0.38	1.26e-5	Myopia (pathological);
TGCT	cis	rs6912958	0.712	rs9444525	chr6:88324142	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-4.57	-0.38	1.16e-5	Monocyte percentage of white cells;
TGCT	cis	rs4780401	0.587	rs9931332	chr16:11807517	G/C	cg01061890	chr16:11836724	TXNDC11	-0.6	-5.82	-0.46	4.74e-8	Rheumatoid arthritis;
TGCT	cis	rs7010267	0.681	rs7842942	chr8:120008587	T/C	cg17171407	chr8:119960777	TNFRSF11B	0.27	5.0	0.41	1.9e-6	Total body bone mineral density (age 45-60);
TGCT	cis	rs7010267	0.570	rs10090576	chr8:120037816	T/C	cg17171407	chr8:119960777	TNFRSF11B	0.26	4.59	0.38	1.06e-5	Total body bone mineral density (age 45-60);
TGCT	cis	rs12908161	1.000	rs34570071	chr15:85280212	T/A	cg11189052	chr15:85197271	WDR73	0.7	5.71	0.46	7.73e-8	Schizophrenia;
TGCT	cis	rs4728071	0.568	rs3735643	chr7:127224193	A/G	cg11539674	chr7:127291444	SND1	-0.4	-4.71	-0.39	6.45e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs236907	0.859	rs3891278	chr1:171756248	A/C	cg20598894	chr1:171756153	METTL13	-0.19	-4.47	-0.37	1.72e-5	Mean platelet volume;
TGCT	cis	rs904251	0.600	rs2270687	chr6:37418263	A/G	cg08126542	chr6:37504118	NA	-0.41	-5.74	-0.46	6.94e-8	Cognitive performance;
TGCT	cis	rs7772486	0.875	rs2777484	chr6:146334162	A/G	cg05347473	chr6:146136440	FBXO30	0.55	5.19	0.42	8.36e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg04944784	chr2:26401820	FAM59B	-0.73	-6.04	-0.48	1.65e-8	Gut microbiome composition (summer);
TGCT	cis	rs10504229	1.000	rs10504229	chr8:58196495	A/G	cg21724239	chr8:58056113	NA	0.38	4.75	0.39	5.6e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4808199	0.895	rs4808196	chr19:19476520	G/A	cg03709012	chr19:19516395	GATAD2A	0.99	7.6	0.56	6.46e-12	Nonalcoholic fatty liver disease;
TGCT	cis	rs10193935	0.792	rs2053349	chr2:42516205	G/A	cg27598129	chr2:42591480	NA	-0.39	-5.37	-0.43	3.72e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs926938	0.584	rs869990	chr1:115379614	A/G	cg12756093	chr1:115239321	AMPD1	-0.41	-6.02	-0.48	1.79e-8	Autism;
TGCT	cis	rs2456568	0.802	rs1108910	chr11:93629677	C/T	cg17595323	chr11:93583763	C11orf90	0.49	6.44	0.5	2.42e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs3749237	0.615	rs11130202	chr3:49566715	C/T	cg02487422	chr3:49467188	NICN1	0.6	6.2	0.49	7.76e-9	Resting heart rate;
TGCT	cis	rs7829975	0.564	rs2921057	chr8:8318667	C/T	cg06636001	chr8:8085503	FLJ10661	0.8	7.81	0.57	2.09e-12	Mood instability;
TGCT	cis	rs56235845	0.685	rs35630910	chr5:176757841	A/C	cg17509989	chr5:176798049	RGS14	0.59	7.97	0.58	8.7e-13	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs5769765	0.955	rs6520066	chr22:50294988	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.11	-11.96	-0.73	2.2e-22	Schizophrenia;
TGCT	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.14	0.42	1.06e-6	Prudent dietary pattern;
TGCT	cis	rs904251	0.523	rs1757191	chr6:37482871	C/T	cg08126542	chr6:37504118	NA	-0.43	-6.28	-0.49	5.34e-9	Cognitive performance;
TGCT	cis	rs28785552	0.800	rs10853854	chr19:53232128	A/G	cg22067481	chr19:53234126	ZNF611	0.45	6.71	0.52	6.32e-10	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs3617	0.625	rs6769789	chr3:52874446	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.48	-4.53	-0.38	1.35e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7208859	0.623	rs11657369	chr17:29136468	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs3741151	1.000	rs75109191	chr11:73023532	T/C	cg17517138	chr11:73019481	ARHGEF17	1.12	5.41	0.44	3.11e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
TGCT	cis	rs992157	0.735	rs13388024	chr2:219097773	A/G	cg00012203	chr2:219082015	ARPC2	0.81	10.19	0.68	4.34e-18	Colorectal cancer;
TGCT	cis	rs13188771	0.651	rs3912803	chr5:100881268	T/G	cg10455971	chr5:101119566	NA	0.44	4.45	0.37	1.87e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs1903068	0.853	rs12331597	chr4:55997914	T/C	cg01777861	chr4:56023843	NA	0.57	6.65	0.51	8.32e-10	Endometriosis;
TGCT	cis	rs950027	0.620	rs1145089	chr15:45652054	G/C	cg26924012	chr15:45694286	SPATA5L1	0.79	8.86	0.62	6.92e-15	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs7772486	0.846	rs1474871	chr6:146406294	G/A	cg05347473	chr6:146136440	FBXO30	0.53	5.03	0.41	1.71e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3806843	0.545	rs251375	chr5:140252960	T/G	cg07102913	chr5:140593443	PCDHB13	0.49	4.71	0.39	6.4e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs735396	1.000	rs2259852	chr12:121434833	G/A	cg02403541	chr12:121454288	C12orf43	0.66	6.42	0.5	2.59e-9	N-glycan levels;
TGCT	cis	rs7582180	0.663	rs2309794	chr2:100954270	G/A	cg08017756	chr2:100939284	LONRF2	-0.3	-5.01	-0.41	1.79e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs62380364	0.626	rs618741	chr5:88064012	C/T	cg24804195	chr5:87968844	LOC645323	-0.55	-5.34	-0.43	4.23e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg27121462	chr16:89883253	FANCA	0.76	8.07	0.59	5.3e-13	Vitiligo;
TGCT	cis	rs994533	0.586	rs17804901	chr2:218262876	C/G	cg25097514	chr2:219157373	TMBIM1;PNKD	-0.35	-4.5	-0.37	1.52e-5	Height;
TGCT	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg18876405	chr7:65276391	NA	0.33	4.97	0.41	2.13e-6	Aortic root size;
TGCT	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg10047753	chr17:41438598	NA	0.84	7.61	0.56	5.9e-12	Menopause (age at onset);
TGCT	cis	rs6964587	0.967	rs10429103	chr7:91598443	T/A	cg17063962	chr7:91808500	NA	0.91	9.99	0.67	1.32e-17	Breast cancer;
TGCT	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg08048268	chr3:133502702	NA	0.64	9.73	0.66	5.78e-17	Iron status biomarkers;
TGCT	cis	rs60843830	0.928	rs62114494	chr2:211317	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.61	5.14	0.42	1.02e-6	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs10992471	0.729	rs6479418	chr9:95064762	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.61	-6.26	-0.49	5.87e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs854765	0.693	rs8080061	chr17:17776389	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.75	-7.78	-0.57	2.42e-12	Total body bone mineral density;
TGCT	cis	rs12946454	0.621	rs11651809	chr17:43255681	C/G	cg10701640	chr17:43249399	NA	0.53	7.14	0.54	6.83e-11	Systolic blood pressure;
TGCT	cis	rs3892630	0.620	rs10413279	chr19:33182746	A/G	cg22980127	chr19:33182716	NUDT19	0.8	6.61	0.51	1.04e-9	Red blood cell traits;
TGCT	cis	rs921968	0.643	rs2278530	chr2:219501133	G/A	cg02176678	chr2:219576539	TTLL4	0.43	6.12	0.48	1.13e-8	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs9993613	0.875	rs1878759	chr4:73514262	A/G	cg15102770	chr4:73434591	ADAMTS3	0.51	4.76	0.39	5.25e-6	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs7178424	0.875	rs7172967	chr15:62218568	A/C	cg00456672	chr15:62358751	C2CD4A	0.32	4.87	0.4	3.29e-6	Height;
TGCT	cis	rs2887571	0.955	rs11061819	chr12:1637239	A/C	cg01940102	chr12:1095972	NA	0.25	4.66	0.39	8.17e-6	Bone mineral density;
TGCT	cis	rs9527	0.640	rs7089061	chr10:104723015	C/A	cg04362960	chr10:104952993	NT5C2	0.66	5.55	0.45	1.66e-7	Arsenic metabolism;
TGCT	cis	rs922182	0.579	rs11856257	chr15:64239941	T/C	cg02919090	chr15:64263738	DAPK2	0.37	7.01	0.53	1.35e-10	Blood protein levels;
TGCT	cis	rs523522	0.962	rs509445	chr12:121017243	A/C	cg12219531	chr12:120966889	COQ5	0.77	6.52	0.51	1.57e-9	High light scatter reticulocyte count;
TGCT	cis	rs10892173	0.566	rs111578166	chr11:117666714	G/T	cg21014159	chr11:117668035	DSCAML1	0.61	6.05	0.48	1.61e-8	Myopia;
TGCT	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg11890956	chr21:40555474	PSMG1	-0.72	-6.51	-0.5	1.67e-9	Cognitive function;
TGCT	cis	rs612683	0.536	rs12042531	chr1:100965942	G/A	cg06223162	chr1:101003688	GPR88	-0.32	-5.28	-0.43	5.51e-7	Breast cancer;
TGCT	cis	rs1971762	0.583	rs7979659	chr12:54086579	A/G	cg16917193	chr12:54089295	NA	1.37	18.11	0.85	1.24e-36	Height;
TGCT	cis	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg18252515	chr7:66147081	NA	1.17	7.17	0.54	5.94e-11	Diabetic kidney disease;
TGCT	cis	rs2637266	0.846	rs2583051	chr10:78403542	T/C	cg18941641	chr10:78392320	NA	0.43	5.58	0.45	1.46e-7	Pulmonary function;
TGCT	cis	rs3135071	1.000	rs3135071	chr4:2406321	C/T	cg01601518	chr4:2404284	ZFYVE28	0.53	5.42	0.44	3.04e-7	Influenza A (H1N1) severity;
TGCT	cis	rs8051431	0.876	rs1559398	chr16:72011450	G/A	cg06353428	chr16:71660113	MARVELD3	0.59	5.02	0.41	1.73e-6	LDL cholesterol levels;
TGCT	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg05721485	chr17:44071124	MAPT	0.26	4.59	0.38	1.06e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs4642101	0.662	rs1969154	chr3:12829156	A/G	cg05775895	chr3:12838266	CAND2	0.78	8.9	0.62	5.77e-15	QRS complex (12-leadsum);
TGCT	cis	rs17345786	0.511	rs1138818	chr3:101399583	C/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.91	10.9	0.7	8.24e-20	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs78487399	0.665	rs6753942	chr2:43749436	T/G	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.69	4.58	0.38	1.1e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	trans	rs1814175	0.546	rs1614397	chr11:49913384	G/C	cg15704280	chr7:45808275	SEPT13	-0.71	-8.0	-0.58	7.45e-13	Height;
TGCT	cis	rs7707921	0.522	rs12374541	chr5:81491408	A/G	cg15871215	chr5:81402204	ATG10	0.25	4.97	0.41	2.22e-6	Breast cancer;
TGCT	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg03303774	chr4:1407052	NA	0.33	5.21	0.42	7.7300000000000005e-07	Obesity-related traits;
TGCT	cis	rs28595532	0.920	rs115271785	chr4:119735748	A/T	cg21605333	chr4:119757512	SEC24D	1.61	8.95	0.63	4.36e-15	Cannabis dependence symptom count;
TGCT	cis	rs36051895	0.632	rs62541899	chr9:5143291	C/T	cg02405213	chr9:5042618	JAK2	-0.7	-9.44	-0.65	2.91e-16	Pediatric autoimmune diseases;
TGCT	cis	rs854765	0.619	rs4561528	chr17:17979099	C/T	cg04398451	chr17:18023971	MYO15A	-0.36	-6.24	-0.49	6.25e-9	Total body bone mineral density;
TGCT	cis	rs68170813	0.559	rs12536574	chr7:106810997	A/T	cg02696742	chr7:106810147	HBP1	-0.69	-5.92	-0.47	2.9e-8	Coronary artery disease;
TGCT	cis	rs362296	0.698	rs3095073	chr4:3263138	C/T	cg06533319	chr4:3265114	C4orf44	0.23	4.66	0.39	8.03e-6	Parental longevity (mother's age at death);
TGCT	cis	rs909674	0.818	rs5750833	chr22:39843091	C/A	cg01416388	chr22:39784598	NA	-0.68	-6.2	-0.49	7.58e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg14893161	chr1:205819251	PM20D1	0.48	5.26	0.43	6.05e-7	Parkinson's disease;
TGCT	cis	rs56104184	0.830	rs17272658	chr19:49355405	C/T	cg17863274	chr19:49399704	TULP2	-0.5	-6.03	-0.48	1.76e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs6500602	0.647	rs4785967	chr16:4523208	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.31	5.6	0.45	1.28e-7	Schizophrenia;
TGCT	cis	rs9393777	0.513	rs9368450	chr6:26652489	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.63	-5.75	-0.46	6.58e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs3845702	0.736	rs2367990	chr2:180843126	C/T	cg01881094	chr2:180872142	CWC22	-1.08	-6.92	-0.53	2.19e-10	Schizophrenia;
TGCT	cis	rs9653442	1.000	rs9653442	chr2:100825367	A/G	cg07810366	chr2:100720526	AFF3	0.45	7.6	0.56	6.15e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs968567	0.906	rs61897793	chr11:61599347	G/A	cg19610905	chr11:61596333	FADS2	-0.79	-5.45	-0.44	2.66e-7	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
TGCT	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg27121462	chr16:89883253	FANCA	0.78	8.31	0.6	1.39e-13	Vitiligo;
TGCT	cis	rs9929218	1.000	rs35069703	chr16:68789445	G/A	cg01251360	chr16:68772225	CDH1	0.29	4.89	0.4	3.01e-6	Colorectal cancer;
TGCT	cis	rs478304	0.654	rs11227260	chr11:65461158	G/T	cg17480646	chr11:65405466	SIPA1	-0.6	-7.95	-0.58	9.79e-13	Acne (severe);
TGCT	cis	rs28595532	0.920	rs17324884	chr4:119771477	C/T	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	trans	rs1814175	0.791	rs11040472	chr11:49703116	C/T	cg03929089	chr4:120376271	NA	-0.71	-8.36	-0.6	1.09e-13	Height;
TGCT	cis	rs78761021	0.502	rs12150273	chr17:9765514	G/C	cg15743799	chr17:9805578	RCVRN	-0.25	-5.32	-0.43	4.6e-7	Type 2 diabetes;
TGCT	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg26338869	chr17:61819248	STRADA	-0.53	-4.87	-0.4	3.31e-6	Prudent dietary pattern;
TGCT	cis	rs6964587	0.626	rs10266424	chr7:91503228	C/T	cg17063962	chr7:91808500	NA	-0.79	-7.38	-0.55	1.96e-11	Breast cancer;
TGCT	cis	rs7017914	0.902	rs34856835	chr8:71970611	C/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.57	-5.28	-0.43	5.57e-7	Bone mineral density;
TGCT	cis	rs9952991	0.943	rs9952753	chr18:12780463	A/C	cg09945482	chr18:12777974	NA	0.5	4.75	0.39	5.61e-6	Inflammatory skin disease;
TGCT	cis	rs4970988	0.501	rs11204713	chr1:150694623	T/A	cg04414720	chr1:150670196	GOLPH3L	0.37	4.91	0.4	2.76e-6	Urate levels;
TGCT	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg03161606	chr19:29218774	NA	0.6	5.84	0.46	4.28e-8	Methadone dose in opioid dependence;
TGCT	cis	rs1050631	1.000	rs1785914	chr18:33700796	A/G	cg25426722	chr18:33708991	SLC39A6;ELP2	-0.5	-4.9	-0.4	2.91e-6	Esophageal squamous cell cancer (length of survival);
TGCT	trans	rs629535	0.814	rs62513371	chr8:70077779	T/A	cg21567404	chr3:27674614	NA	-0.57	-8.99	-0.63	3.38e-15	Dupuytren's disease;
TGCT	cis	rs36051895	0.632	rs11793886	chr9:5125469	A/G	cg02405213	chr9:5042618	JAK2	-0.71	-9.55	-0.65	1.57e-16	Pediatric autoimmune diseases;
TGCT	cis	rs3847687	1.000	rs78233646	chr12:131520170	G/T	cg25772418	chr12:131519998	GPR133	-0.33	-6.1	-0.48	1.26e-8	Longevity;
TGCT	trans	rs8073060	0.559	rs10438814	chr17:34007065	A/G	cg19694781	chr19:47549865	TMEM160	-0.6	-13.37	-0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs9457247	1.000	rs421214	chr6:167396629	A/G	cg23791538	chr6:167370224	RNASET2	-0.49	-4.88	-0.4	3.17e-6	Crohn's disease;
TGCT	cis	rs2404602	0.735	rs11857015	chr15:76649390	T/C	cg22467129	chr15:76604101	ETFA	0.51	5.32	0.43	4.58e-7	Blood metabolite levels;
TGCT	cis	rs539096	0.500	rs803678	chr1:44350898	G/T	cg13606994	chr1:44402422	ARTN	-0.42	-4.52	-0.38	1.44e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg12310025	chr6:25882481	NA	-0.62	-6.42	-0.5	2.62e-9	Blood metabolite levels;
TGCT	cis	rs8017423	0.967	rs2149655	chr14:90707246	T/C	cg04374321	chr14:90722782	PSMC1	0.77	8.05	0.59	5.68e-13	Mortality in heart failure;
TGCT	cis	rs4891159	0.790	rs56077581	chr18:74116865	T/G	cg24786174	chr18:74118243	ZNF516	-0.62	-9.41	-0.65	3.36e-16	Longevity;
TGCT	cis	rs68170813	0.641	rs12534124	chr7:107119047	G/A	cg02696742	chr7:106810147	HBP1	-0.65	-5.15	-0.42	9.98e-7	Coronary artery disease;
TGCT	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg01448562	chr3:133502909	NA	-0.27	-5.09	-0.42	1.3e-6	Iron status biomarkers;
TGCT	cis	rs950169	0.544	rs2036949	chr15:85163605	T/C	cg11189052	chr15:85197271	WDR73	0.75	6.38	0.5	3.2e-9	Schizophrenia;
TGCT	cis	rs11931598	0.509	rs10937771	chr4:6940034	C/T	cg26116260	chr4:7069785	GRPEL1	0.64	5.88	0.47	3.61e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs425277	1.000	rs1401138	chr1:2063149	C/T	cg03732007	chr1:2071316	PRKCZ	0.25	5.0	0.41	1.92e-6	Height;
TGCT	cis	rs1949733	0.523	rs56053534	chr4:8542876	G/A	cg13073564	chr4:8508604	NA	0.5	4.9	0.4	2.96e-6	Response to antineoplastic agents;
TGCT	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs12510870	0.635	rs1528915	chr4:74452337	A/T	cg05868023	chr4:75230803	EREG	-0.55	-4.74	-0.39	5.71e-6	Iris color (b* coordinate);
TGCT	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg10935138	chr17:73851978	WBP2	1.05	9.62	0.65	1.08e-16	Psoriasis;
TGCT	cis	rs9486715	0.867	rs9373907	chr6:96981189	G/A	cg06623918	chr6:96969491	KIAA0776	1.08	14.94	0.8	1.69e-29	Headache;
TGCT	cis	rs12971120	0.891	rs71359051	chr18:72169723	G/A	cg26446133	chr18:72167187	CNDP2	-0.37	-6.33	-0.49	4.13e-9	Refractive error;
TGCT	cis	rs9638182	1.000	rs9638180	chr7:72998952	A/G	cg14087351	chr7:73037990	MLXIPL	-0.56	-4.73	-0.39	6.08e-6	Triglycerides;
TGCT	cis	rs10056811	0.556	rs55810502	chr5:74380959	A/G	cg19683494	chr5:74908142	NA	0.62	5.47	0.44	2.39e-7	Coronary artery disease;
TGCT	cis	rs2153535	0.563	rs1737585	chr6:8536594	A/G	cg23788917	chr6:8435910	SLC35B3	-0.6	-5.43	-0.44	2.88e-7	Motion sickness;
TGCT	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg23758822	chr17:41437982	NA	0.72	6.81	0.52	3.77e-10	Menopause (age at onset);
TGCT	cis	rs2535633	0.820	rs7626551	chr3:52938092	C/G	cg10802521	chr3:52805072	NEK4	0.58	6.45	0.5	2.27e-9	Body mass index;
TGCT	cis	rs2073300	1.000	rs114718317	chr20:23442620	T/C	cg09953122	chr20:23471693	CST8	-0.64	-4.56	-0.38	1.19e-5	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs4906332	1.000	rs12896919	chr14:103956713	T/C	cg26031613	chr14:104095156	KLC1	-0.51	-4.51	-0.38	1.48e-5	Coronary artery disease;
TGCT	cis	rs10992471	0.603	rs7850528	chr9:95208992	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.59	-5.36	-0.43	3.84e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs10465746	0.967	rs6670658	chr1:84461268	A/G	cg10977910	chr1:84465055	TTLL7	0.67	6.78	0.52	4.26e-10	Obesity-related traits;
TGCT	cis	rs7267979	0.932	rs449370	chr20:25451180	A/G	cg16686733	chr20:25566563	NINL	-0.58	-5.85	-0.47	4.09e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7611238	0.560	rs10439949	chr3:195080491	T/C	cg27323046	chr3:195102265	ACAP2	0.37	5.01	0.41	1.86e-6	Body mass index;
TGCT	cis	rs6540559	0.673	rs6540561	chr1:209982255	C/T	cg04352962	chr1:209979756	IRF6	0.65	4.6	0.38	1.05e-5	Cleft lip with or without cleft palate;
TGCT	cis	rs12478296	1.000	rs55814222	chr2:243041166	C/T	cg06360820	chr2:242988706	NA	-0.61	-4.66	-0.39	8.13e-6	Obesity-related traits;
TGCT	cis	rs981844	0.712	rs4616729	chr4:154746900	T/G	cg14289246	chr4:154710475	SFRP2	-0.99	-9.12	-0.63	1.65e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs910316	0.737	rs108621	chr14:75480637	T/C	cg08847533	chr14:75593920	NEK9	-0.84	-8.67	-0.61	2.03e-14	Height;
TGCT	cis	rs6598955	0.543	rs6698557	chr1:26561220	G/C	cg04990556	chr1:26633338	UBXN11	0.83	8.1	0.59	4.29e-13	Obesity-related traits;
TGCT	cis	rs1525293	0.965	rs6944601	chr7:70489980	A/T	cg21135135	chr7:70597687	WBSCR17	0.48	4.78	0.39	4.89e-6	Colonoscopy-negative controls vs population controls;Major depressive disorder;
TGCT	cis	rs12681287	0.752	rs67615966	chr8:87255203	C/A	cg27223183	chr8:87520930	FAM82B	-0.81	-5.66	-0.45	9.9e-8	Caudate activity during reward;
TGCT	cis	rs1577917	0.958	rs34795473	chr6:86461799	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-5.59	-0.45	1.39e-7	Response to antipsychotic treatment;
TGCT	trans	rs208520	1.000	rs72882100	chr6:66981495	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.83	7.46	0.56	1.31e-11	Exhaled nitric oxide output;
TGCT	cis	rs896854	0.714	rs6471503	chr8:95990283	G/A	cg23172400	chr8:95962367	TP53INP1	-0.36	-6.07	-0.48	1.44e-8	Type 2 diabetes;
TGCT	cis	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg00646381	chr17:77835854	NA	0.37	5.56	0.45	1.61e-7	Electroencephalogram traits;
TGCT	cis	rs12620999	0.627	rs7570274	chr2:238103614	G/C	cg23555395	chr2:238036564	NA	-0.28	-4.95	-0.41	2.4e-6	Systemic lupus erythematosus;
TGCT	cis	rs3008870	1.000	rs2985822	chr1:67404910	T/G	cg08660285	chr1:67390436	MIER1;WDR78	1.1	11.97	0.73	2.07e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs1801251	1.000	rs6724117	chr2:233593660	T/G	cg25237894	chr2:233734115	C2orf82	0.32	5.81	0.46	4.94e-8	Coronary artery disease;
TGCT	cis	rs7085104	0.684	rs7092690	chr10:104609365	T/C	cg05855489	chr10:104503620	C10orf26	0.51	4.54	0.38	1.34e-5	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs7909074	0.831	rs7903412	chr10:45382361	C/T	cg05187965	chr10:45406764	TMEM72	-0.27	-5.76	-0.46	6.14e-8	Mean corpuscular volume;
TGCT	cis	rs7914558	1.000	rs10509757	chr10:104752960	C/T	cg04362960	chr10:104952993	NT5C2	0.59	5.19	0.42	8.49e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg18252515	chr7:66147081	NA	-1.31	-8.18	-0.59	2.87e-13	Diabetic kidney disease;
TGCT	cis	rs7727544	0.735	rs270605	chr5:131651811	C/T	cg14196790	chr5:131705035	SLC22A5	0.32	4.44	0.37	1.94e-5	Blood metabolite levels;
TGCT	cis	rs9611565	0.802	rs132916	chr22:41806768	C/G	cg13695892	chr22:41940480	POLR3H	0.78	7.93	0.58	1.07e-12	Vitiligo;
TGCT	cis	rs10501293	1.000	rs4495880	chr11:43133626	A/C	cg03447554	chr11:43094025	NA	-0.48	-6.72	-0.52	5.89e-10	Cognitive performance;
TGCT	cis	rs174601	0.615	rs174534	chr11:61549458	C/T	cg01500311	chr11:61656094	FADS3	0.26	4.77	0.39	5.07e-6	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
TGCT	cis	rs6688613	0.721	rs2312675	chr1:166922533	T/C	cg07049167	chr1:166818506	POGK	0.23	4.94	0.41	2.49e-6	Refractive astigmatism;
TGCT	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.48	6.49	0.5	1.83e-9	Alzheimer's disease;
TGCT	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg22920501	chr2:26401640	FAM59B	-0.81	-6.36	-0.5	3.52e-9	Gut microbiome composition (summer);
TGCT	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg13695892	chr22:41940480	POLR3H	-0.9	-9.03	-0.63	2.7e-15	Vitiligo;
TGCT	cis	rs61990749	0.597	rs6574391	chr14:78208121	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	0.6	4.45	0.37	1.88e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg07424592	chr7:64974309	NA	1.36	8.15	0.59	3.36e-13	Diabetic kidney disease;
TGCT	cis	rs11785400	1.000	rs4557682	chr8:143738182	T/C	cg24634471	chr8:143751801	JRK	0.57	6.12	0.48	1.11e-8	Schizophrenia;
TGCT	cis	rs10782582	0.593	rs17848068	chr1:76190216	G/A	cg22875332	chr1:76189707	ACADM	-0.5	-5.71	-0.46	7.83e-8	Daytime sleep phenotypes;
TGCT	cis	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg07636037	chr3:49044803	WDR6	0.62	5.51	0.44	2.02e-7	Resting heart rate;
TGCT	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg15782153	chr7:917662	C7orf20	0.46	5.4	0.44	3.33e-7	Perceived unattractiveness to mosquitoes;
TGCT	cis	rs9894429	0.934	rs35868252	chr17:79575472	C/G	cg18240062	chr17:79603768	NPLOC4	-0.67	-6.84	-0.52	3.23e-10	Eye color traits;
TGCT	cis	rs1153858	1.000	rs56669689	chr15:45637729	A/C	cg26924012	chr15:45694286	SPATA5L1	1.07	14.56	0.79	1.32e-28	Homoarginine levels;
TGCT	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg03517284	chr6:25882590	NA	-0.62	-6.45	-0.5	2.24e-9	Blood metabolite levels;
TGCT	cis	rs9611565	0.512	rs9611667	chr22:42187015	C/T	cg13695892	chr22:41940480	POLR3H	-0.84	-7.96	-0.58	9.47e-13	Vitiligo;
TGCT	cis	rs651907	0.557	rs34457525	chr3:101435225	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	4.73	0.39	5.91e-6	Colorectal cancer;
TGCT	cis	rs4891159	0.756	rs3892540	chr18:74118058	C/T	cg24786174	chr18:74118243	ZNF516	-0.62	-9.38	-0.64	3.96e-16	Longevity;
TGCT	cis	rs7680126	0.596	rs4637402	chr4:10045430	C/T	cg11266682	chr4:10021025	SLC2A9	0.5	4.78	0.39	4.89e-6	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
TGCT	cis	rs4808199	0.948	rs968525	chr19:19459215	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.67	5.27	0.43	5.81e-7	Nonalcoholic fatty liver disease;
TGCT	cis	rs453301	0.512	rs2921381	chr8:8895401	T/A	cg06636001	chr8:8085503	FLJ10661	0.71	6.23	0.49	6.75e-9	Joint mobility (Beighton score);
TGCT	cis	rs1018836	0.668	rs9297857	chr8:91480964	A/C	cg16814680	chr8:91681699	NA	-0.78	-8.02	-0.58	6.64e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs11249608	0.548	rs10516150	chr5:178459169	G/C	cg23951258	chr5:178450506	ZNF879	0.44	4.56	0.38	1.23e-5	Pubertal anthropometrics;
TGCT	cis	rs11690935	0.655	rs12052995	chr2:172537212	A/G	cg13550731	chr2:172543902	DYNC1I2	0.69	6.07	0.48	1.45e-8	Schizophrenia;
TGCT	cis	rs10504229	0.593	rs7000752	chr8:58026980	C/G	cg08280861	chr8:58055591	NA	0.32	4.57	0.38	1.15e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7072216	0.763	rs2274246	chr10:100175060	C/T	cg26618903	chr10:100175079	PYROXD2	-0.4	-4.49	-0.37	1.64e-5	Metabolite levels;
TGCT	cis	rs9468199	0.510	rs77576207	chr6:27842155	G/T	cg08851530	chr6:28072375	NA	1.58	7.16	0.54	6.15e-11	Parkinson's disease;
TGCT	cis	rs28735056	1.000	rs59183289	chr18:77631198	A/G	cg20368463	chr18:77673604	PQLC1	-0.47	-5.84	-0.46	4.22e-8	Schizophrenia;
TGCT	cis	rs72781680	0.821	rs72796401	chr2:24180078	T/A	cg08917208	chr2:24149416	ATAD2B	0.77	4.77	0.39	5.02e-6	Lymphocyte counts;
TGCT	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg20276088	chr3:133502917	NA	-0.24	-4.96	-0.41	2.28e-6	Iron status biomarkers;
TGCT	cis	rs651907	1.000	rs651907	chr3:101600724	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.46	4.64	0.38	8.78e-6	Colorectal cancer;
TGCT	trans	rs4824093	0.610	rs60036544	chr22:50264019	C/T	cg09872104	chr7:134855509	C7orf49	-0.94	-7.68	-0.57	4.2e-12	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg13732083	chr21:47605072	C21orf56	0.37	4.87	0.4	3.31e-6	Testicular germ cell tumor;
TGCT	cis	rs4889911	0.544	rs1294081	chr17:77829864	T/C	cg00646381	chr17:77835854	NA	0.44	6.6	0.51	1.06e-9	Electroencephalogram traits;
TGCT	cis	rs1865760	0.622	rs9968910	chr6:26072095	A/C	cg17042849	chr6:26104293	HIST1H4C	-0.85	-7.52	-0.56	9.57e-12	Height;
TGCT	cis	rs12693043	0.727	rs3087907	chr2:175424779	T/G	cg11778734	chr2:175439522	WIPF1	-0.38	-4.89	-0.4	3.05e-6	Urate levels (BMI interaction);
TGCT	trans	rs1814175	0.817	rs10769641	chr11:49960141	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.36	-7.14	-0.54	6.88e-11	Height;
TGCT	cis	rs7208859	0.673	rs11080138	chr17:29224542	A/G	cg14008862	chr17:28927542	LRRC37B2	0.72	4.66	0.39	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs1552244	0.554	rs55847233	chr3:9991101	C/G	cg00149659	chr3:10157352	C3orf10	0.67	4.94	0.41	2.48e-6	Alzheimer's disease;
TGCT	cis	rs9443645	0.901	rs4147183	chr6:79557046	C/G	cg09184832	chr6:79620586	NA	-0.48	-5.35	-0.43	4.01e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2305707	0.867	rs1054984	chr15:51551127	T/A	cg19946085	chr15:51559439	CYP19A1	0.49	5.15	0.42	9.79e-7	Height;
TGCT	cis	rs3617	0.573	rs62253583	chr3:52928334	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	-0.5	-4.67	-0.39	7.82e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7772486	0.790	rs2253768	chr6:146199922	A/G	cg23711669	chr6:146136114	FBXO30	0.95	10.8	0.7	1.46e-19	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs826838	0.834	rs826874	chr12:39122599	C/A	cg26384229	chr12:38710491	ALG10B	-0.87	-7.93	-0.58	1.08e-12	Heart rate;
TGCT	trans	rs1814175	0.817	rs1621090	chr11:49895868	C/A	cg15704280	chr7:45808275	SEPT13	-0.72	-8.14	-0.59	3.63e-13	Height;
TGCT	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg11062466	chr8:58055876	NA	0.38	4.62	0.38	9.5e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6725041	0.819	rs11677623	chr2:213082372	A/G	cg16329650	chr2:213403929	ERBB4	-0.54	-4.61	-0.38	9.88e-6	QT interval (ambient particulate matter interaction);
TGCT	cis	rs1218582	0.741	rs705094	chr1:154917314	G/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.64	-6.53	-0.51	1.52e-9	Prostate cancer;
TGCT	cis	rs5769765	0.908	rs138889	chr22:50226673	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.05	-11.2	-0.71	1.49e-20	Schizophrenia;
TGCT	cis	rs9902453	0.838	rs3110495	chr17:27978455	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-6.41	-0.5	2.74e-9	Coffee consumption (cups per day);
TGCT	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.0	-7.42	-0.55	1.64e-11	Gut microbiome composition (summer);
TGCT	cis	rs7312933	0.558	rs1669936	chr12:42813509	C/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.58	-5.69	-0.46	8.61e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs523522	0.962	rs670568	chr12:121021206	C/T	cg12219531	chr12:120966889	COQ5	0.82	7.38	0.55	2.05e-11	High light scatter reticulocyte count;
TGCT	cis	rs7584330	0.554	rs75918156	chr2:238426287	G/A	cg08992911	chr2:238395768	MLPH	0.7	4.72	0.39	6.32e-6	Prostate cancer;
TGCT	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-6.74	-0.52	5.26e-10	Alzheimer's disease;
TGCT	cis	rs9611565	0.592	rs1811113	chr22:42073134	C/T	cg03806693	chr22:41940476	POLR3H	1.08	11.79	0.73	5.53e-22	Vitiligo;
TGCT	cis	rs1511802	0.614	rs12507156	chr4:187116832	C/T	cg19358738	chr4:186734530	SORBS2	0.18	4.59	0.38	1.09e-5	Blood protein levels;
TGCT	cis	rs3796352	0.686	rs1560333	chr3:53138254	T/C	cg27565382	chr3:53032988	SFMBT1	-0.38	-4.54	-0.38	1.33e-5	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs7586879	0.964	rs4077679	chr2:25122852	T/C	cg01884057	chr2:25150051	NA	0.28	5.03	0.41	1.69e-6	Body mass index;
TGCT	cis	rs9611565	0.918	rs9611562	chr22:41760172	T/G	cg13695892	chr22:41940480	POLR3H	-0.92	-9.08	-0.63	2.06e-15	Vitiligo;
TGCT	cis	rs7104764	1.000	rs6598061	chr11:243853	G/A	cg18336825	chr11:236787	PSMD13;SIRT3	1.07	11.19	0.71	1.61e-20	Menarche (age at onset);
TGCT	cis	rs11676348	0.846	rs3890158	chr2:218990292	G/A	cg00012203	chr2:219082015	ARPC2	-0.51	-4.85	-0.4	3.59e-6	Ulcerative colitis;
TGCT	cis	rs595982	0.559	rs17206700	chr19:49361255	A/G	cg17863274	chr19:49399704	TULP2	-0.47	-6.71	-0.52	6.21e-10	Red cell distribution width;
TGCT	cis	rs7267979	0.586	rs11087505	chr20:25196520	T/A	cg16686733	chr20:25566563	NINL	0.51	5.12	0.42	1.16e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg20637647	chr7:64974828	NA	1.0	5.59	0.45	1.4e-7	Diabetic kidney disease;
TGCT	cis	rs1008375	0.931	rs6813374	chr4:17649494	T/C	cg10189774	chr4:17578691	LAP3	0.6	5.29	0.43	5.23e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs67311347	1.000	rs10510708	chr3:40404770	A/G	cg17264618	chr3:40429014	ENTPD3	0.31	4.65	0.39	8.38e-6	Renal cell carcinoma;
TGCT	cis	rs78487399	0.808	rs17030818	chr2:43680318	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.24	-0.43	6.79e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs6558530	0.965	rs6558529	chr8:1706206	C/T	cg09410841	chr8:1729607	CLN8	0.87	9.5	0.65	2e-16	Systolic blood pressure;
TGCT	cis	rs11577318	0.853	rs12743998	chr1:26629882	G/A	cg04990556	chr1:26633338	UBXN11	-0.63	-5.83	-0.46	4.58e-8	Granulocyte percentage of myeloid white cells;
TGCT	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.47	-6.89	-0.53	2.48e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs4780355	0.918	rs243323	chr16:11361202	A/G	cg00044050	chr16:11439710	C16orf75	0.54	4.77	0.39	5.01e-6	Crohn's disease and psoriasis;
TGCT	cis	rs2820315	1.000	rs2820295	chr1:201800868	G/A	cg12730843	chr1:201915899	LMOD1	-0.27	-4.81	-0.4	4.22e-6	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
TGCT	cis	rs10782582	0.593	rs114421765	chr1:76141802	C/T	cg22875332	chr1:76189707	ACADM	-0.54	-6.17	-0.48	8.76e-9	Daytime sleep phenotypes;
TGCT	cis	rs7312933	0.558	rs1796382	chr12:42840955	C/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.58	-5.7	-0.46	8.41e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs28595532	0.764	rs116158926	chr4:119730572	C/T	cg21605333	chr4:119757512	SEC24D	1.66	8.33	0.6	1.28e-13	Cannabis dependence symptom count;
TGCT	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg07061783	chr6:25882402	NA	0.72	7.4	0.55	1.8e-11	Blood metabolite levels;
TGCT	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.68	5.6	0.45	1.31e-7	Tonsillectomy;
TGCT	cis	rs4727027	0.933	rs9718383	chr7:148857624	A/T	cg23583168	chr7:148888333	NA	0.77	10.15	0.67	5.62e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs9788682	0.948	rs59683676	chr15:78833453	T/C	cg06917634	chr15:78832804	PSMA4	-0.7	-4.86	-0.4	3.47e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs6546537	0.824	rs13011186	chr2:69778558	C/T	cg10773587	chr2:69614142	GFPT1	-0.81	-8.18	-0.59	2.84e-13	Serum thyroid-stimulating hormone levels;
TGCT	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg09359103	chr1:154839909	KCNN3	-0.7	-14.59	-0.79	1.13e-28	Prostate cancer;
TGCT	cis	rs7542091	0.704	rs7550330	chr1:210044587	G/A	cg21951975	chr1:209979733	IRF6	0.6	6.1	0.48	1.24e-8	Monobrow;
TGCT	cis	rs10927875	0.562	rs10803401	chr1:16147377	G/A	cg14742211	chr1:16348397	CLCNKA	-0.2	-4.79	-0.39	4.75e-6	Dilated cardiomyopathy;
TGCT	cis	rs208515	0.556	rs1872309	chr6:66660432	A/C	cg07460842	chr6:66804631	NA	0.73	7.21	0.54	4.72e-11	Exhaled nitric oxide levels;
TGCT	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg06028808	chr11:68637592	NA	0.51	6.66	0.51	7.87e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg06873352	chr17:61820015	STRADA	0.59	6.56	0.51	1.31e-9	Prudent dietary pattern;
TGCT	cis	rs748404	0.660	rs2439846	chr15:43740970	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	4.75	0.39	5.51e-6	Lung cancer;
TGCT	cis	rs7302981	0.934	rs7294548	chr12:50543201	A/G	cg23855989	chr12:50355821	AQP5	-0.3	-4.5	-0.38	1.52e-5	Systolic blood pressure;
TGCT	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg10802521	chr3:52805072	NEK4	-0.78	-10.09	-0.67	7.59e-18	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.791	rs6851549	chr4:99029827	G/A	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12971120	0.891	rs12605820	chr18:72167802	G/A	cg25817165	chr18:72167213	CNDP2	-0.29	-4.98	-0.41	2.05e-6	Refractive error;
TGCT	cis	rs9549260	0.755	rs7317254	chr13:41217849	A/G	cg21288729	chr13:41239152	FOXO1	0.99	10.37	0.68	1.56e-18	Red blood cell count;
TGCT	cis	rs16867321	0.614	rs10204086	chr2:181449668	G/T	cg23363182	chr2:181467187	NA	-0.41	-6.04	-0.48	1.69e-8	Obesity;
TGCT	cis	rs7772486	0.875	rs6930975	chr6:146387111	C/T	cg23711669	chr6:146136114	FBXO30	0.89	9.59	0.65	1.22e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs17270561	0.562	rs12199626	chr6:26013604	G/A	cg16482183	chr6:26056742	HIST1H1C	0.98	7.33	0.55	2.6e-11	Iron status biomarkers;
TGCT	cis	rs7208859	0.623	rs609063	chr17:28951513	A/G	cg14008862	chr17:28927542	LRRC37B2	0.88	5.32	0.43	4.75e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs9883204	0.817	rs10934647	chr3:123130684	C/T	cg04890266	chr3:123102914	ADCY5	0.36	5.08	0.42	1.34e-6	Birth weight;
TGCT	cis	rs483180	0.859	rs478093	chr1:120255126	C/T	cg19096424	chr1:120255104	PHGDH	-0.57	-5.27	-0.43	5.95e-7	Macular telangiectasia type 2;
TGCT	cis	rs12908161	1.000	rs11632465	chr15:85282045	A/T	cg17173187	chr15:85201210	NMB	0.57	6.38	0.5	3.25e-9	Schizophrenia;
TGCT	cis	rs6867032	0.876	rs1552435	chr5:2018378	A/G	cg26168224	chr5:2018326	NA	0.44	8.03	0.59	6.26e-13	Gut microbiome composition (winter);
TGCT	cis	rs78456975	0.506	rs10167704	chr2:1571037	G/C	cg01028140	chr2:1542097	TPO	-0.33	-5.02	-0.41	1.77e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs12497850	0.931	rs4974082	chr3:48999323	G/A	cg05785598	chr3:49045655	WDR6	0.37	4.83	0.4	3.91e-6	Parkinson's disease;
TGCT	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg11494091	chr17:61959527	GH2	0.61	14.81	0.8	3.37e-29	Prudent dietary pattern;
TGCT	cis	rs7698623	0.702	rs4693884	chr4:88770229	C/T	cg27387453	chr4:88533842	DSPP	0.61	4.6	0.38	1.03e-5	Cardiovascular disease risk factors;
TGCT	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg23708337	chr7:1209742	NA	0.6	5.57	0.45	1.53e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs33794	0.901	rs33774	chr3:45286107	C/T	cg18645101	chr3:44551900	NA	0.54	4.67	0.39	7.71e-6	Lung function (forced expiratory volume in 1 second);
TGCT	cis	rs7729723	0.533	rs11242429	chr5:137821271	T/C	cg19169342	chr5:137827400	NA	0.32	4.46	0.37	1.78e-5	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);
TGCT	cis	rs6545883	0.965	rs1562308	chr2:61768421	A/C	cg15711740	chr2:61764176	XPO1	-0.57	-5.23	-0.43	6.89e-7	Tuberculosis;
TGCT	cis	rs2115630	0.645	rs3825878	chr15:85174755	C/T	cg12863693	chr15:85201151	NMB	-0.39	-5.11	-0.42	1.19e-6	P wave terminal force;
TGCT	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg09359103	chr1:154839909	KCNN3	-0.66	-12.15	-0.74	7.27e-23	Prostate cancer;
TGCT	cis	rs8072100	0.582	rs3826536	chr17:45501967	T/A	cg08085267	chr17:45401833	C17orf57	-0.52	-5.75	-0.46	6.48e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg11644478	chr21:40555479	PSMG1	1.07	10.81	0.7	1.32e-19	Cognitive function;
TGCT	cis	rs3617	0.573	rs13072537	chr3:52896032	C/A	cg10802521	chr3:52805072	NEK4	-0.57	-6.58	-0.51	1.21e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9467711	0.790	rs13195401	chr6:26463574	G/T	cg16898833	chr6:26189333	HIST1H4D	1.37	6.2	0.49	7.83e-9	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2486012	1.000	rs2906456	chr1:44340920	C/T	cg12908607	chr1:44402522	ARTN	0.67	5.42	0.44	2.93e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg01802117	chr1:53393560	SCP2	-0.4	-4.72	-0.39	6.33e-6	Monocyte count;
TGCT	cis	rs1035144	0.505	rs2268459	chr14:81463041	A/G	cg06600135	chr14:81408086	NA	-0.48	-4.48	-0.37	1.64e-5	Male sexual orientation;
TGCT	cis	rs1395	0.710	rs1992291	chr2:27504312	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.58	7.24	0.55	4.04e-11	Blood metabolite levels;
TGCT	cis	rs9972944	0.656	rs10083855	chr17:63773139	T/C	cg07283582	chr17:63770753	CCDC46	0.26	5.05	0.41	1.53e-6	Total body bone mineral density;
TGCT	cis	rs514475	0.526	rs9688555	chr6:137956470	A/G	cg02673417	chr6:137105249	MAP3K5	-0.29	-4.44	-0.37	1.98e-5	Inflammatory skin disease;
TGCT	cis	rs4242434	1.000	rs4242434	chr8:22501830	C/A	cg03733263	chr8:22462867	KIAA1967	1.16	17.73	0.85	8.57e-36	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs4849845	0.637	rs11688038	chr2:121026582	A/G	cg24070213	chr2:121070622	NA	0.35	4.8	0.4	4.43e-6	Mean platelet volume;
TGCT	cis	rs55823223	0.564	rs936396	chr17:73846829	C/G	cg10935138	chr17:73851978	WBP2	0.82	7.57	0.56	7.35e-12	Psoriasis;
TGCT	cis	rs4631830	0.720	rs2843560	chr10:51512129	C/G	cg10326726	chr10:51549505	MSMB	0.23	4.5	0.37	1.54e-5	Prostate-specific antigen levels;
TGCT	cis	rs9486719	1.000	rs11153058	chr6:97012746	C/T	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.0	-0.41	1.9e-6	Migraine;Coronary artery disease;
TGCT	cis	rs11098499	0.866	rs7665125	chr4:120402079	G/T	cg09307838	chr4:120376055	NA	0.62	6.1	0.48	1.24e-8	Corneal astigmatism;
TGCT	trans	rs9388451	0.807	rs1268070	chr6:126041164	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.74	-7.47	-0.56	1.24e-11	Brugada syndrome;
TGCT	cis	rs1008375	1.000	rs6848360	chr4:17634442	G/T	cg16339924	chr4:17578868	LAP3	0.71	5.75	0.46	6.46e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4888262	0.545	rs12716768	chr16:74556486	A/G	cg01733217	chr16:74700730	RFWD3	-0.69	-6.62	-0.51	9.96e-10	Testicular germ cell tumor;
TGCT	cis	rs4711350	0.765	rs2182658	chr6:33748831	G/T	cg18005901	chr6:33739558	LEMD2	0.59	6.65	0.51	8.49e-10	Schizophrenia;
TGCT	cis	rs2204008	0.683	rs11519834	chr12:38053575	T/A	cg13010199	chr12:38710504	ALG10B	0.65	5.29	0.43	5.47e-7	Bladder cancer;
TGCT	trans	rs1814175	0.645	rs10128563	chr11:50023681	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.84	-0.7	1.13e-19	Height;
TGCT	cis	rs2458413	0.771	rs7010076	chr8:105342827	C/G	cg23108931	chr8:105342351	NA	-0.36	-6.26	-0.49	5.85e-9	Paget's disease;
TGCT	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	15.94	0.82	8.5e-32	Prudent dietary pattern;
TGCT	cis	rs7666738	0.753	rs10033138	chr4:98981922	A/C	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg25036284	chr2:26402008	FAM59B	-0.55	-4.76	-0.39	5.33e-6	Gut microbiome composition (summer);
TGCT	cis	rs7772486	0.686	rs1011596	chr6:146076433	A/G	cg05347473	chr6:146136440	FBXO30	0.51	4.69	0.39	7.21e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6545883	1.000	rs778762	chr2:61782921	G/T	cg15711740	chr2:61764176	XPO1	-0.56	-5.14	-0.42	1.06e-6	Tuberculosis;
TGCT	cis	rs796364	0.951	rs281776	chr2:200834282	T/G	cg17644776	chr2:200775616	C2orf69	0.31	4.85	0.4	3.58e-6	Schizophrenia;
TGCT	cis	rs2749592	0.918	rs1208653	chr10:38253826	C/G	cg25427524	chr10:38739819	LOC399744	0.33	4.95	0.41	2.38e-6	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs4319547	0.661	rs10846830	chr12:122897220	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.63	-4.94	-0.41	2.46e-6	Body mass index;
TGCT	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg20007245	chr22:24372913	LOC391322	-0.76	-7.82	-0.57	1.93e-12	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs3733585	0.604	rs73215003	chr4:10126317	C/G	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.23	-0.49	6.59e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs71636778	0.509	rs11538549	chr1:27248283	C/G	cg23921621	chr1:27994728	IFI6	-0.43	-4.61	-0.38	9.95e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
TGCT	cis	rs7267979	0.657	rs6107073	chr20:25716363	T/C	cg21995068	chr20:25989032	LOC100134868	-0.41	-5.11	-0.42	1.18e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg00343986	chr7:65444356	GUSB	0.26	6.07	0.48	1.42e-8	Calcium levels;
TGCT	cis	rs17376456	0.597	rs10866760	chr5:93338335	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.54	-4.58	-0.38	1.11e-5	Diabetic retinopathy;
TGCT	cis	rs2404602	0.583	rs2456076	chr15:76557553	T/G	cg26408565	chr15:76604113	ETFA	0.47	6.51	0.5	1.65e-9	Blood metabolite levels;
TGCT	cis	rs427394	0.802	rs274712	chr5:6723950	G/A	cg10857441	chr5:6722123	POLS	-0.32	-7.93	-0.58	1.08e-12	Menopause (age at onset);
TGCT	cis	rs10510102	0.872	rs116521083	chr10:123710126	A/C	cg23691251	chr10:123688108	ATE1	-0.59	-4.7	-0.39	6.75e-6	Breast cancer;
TGCT	cis	rs368123	0.686	rs2774226	chr6:160700386	G/A	cg19643109	chr6:160697625	NA	-0.2	-4.82	-0.4	4.06e-6	Waist circumference;
TGCT	cis	rs1552244	0.554	rs3732963	chr3:10048885	G/T	cg00149659	chr3:10157352	C3orf10	0.69	4.99	0.41	2.03e-6	Alzheimer's disease;
TGCT	cis	rs10876993	1.000	rs10876993	chr12:58062667	C/T	cg15848620	chr12:58087721	OS9	-0.7	-5.61	-0.45	1.28e-7	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs6163	0.588	rs11191392	chr10:104526951	C/A	cg05855489	chr10:104503620	C10orf26	1.02	12.83	0.76	1.7e-24	Waist circumference;Hip circumference;
TGCT	cis	rs11264213	0.901	rs72661613	chr1:36364781	A/G	cg26235710	chr1:36184717	C1orf216	1.06	4.47	0.37	1.72e-5	Schizophrenia;
TGCT	cis	rs7193541	0.965	rs28616016	chr16:74676964	T/C	cg01733217	chr16:74700730	RFWD3	0.8	7.74	0.57	2.95e-12	Multiple myeloma;
TGCT	cis	rs11122272	0.735	rs11122281	chr1:231519842	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.13	-0.54	7.33e-11	Hemoglobin concentration;
TGCT	cis	rs116095464	0.558	rs1968374	chr5:249025	A/C	cg12570787	chr5:219185	SDHA;CCDC127	0.73	4.64	0.38	8.88e-6	Breast cancer;
TGCT	cis	rs394563	0.591	rs6570964	chr6:149691859	G/A	cg03678062	chr6:149772716	ZC3H12D	0.38	4.8	0.4	4.4e-6	Dupuytren's disease;
TGCT	cis	rs6690583	0.623	rs12042160	chr1:85504516	A/G	cg20280350	chr1:85513789	MCOLN3	-0.71	-4.58	-0.38	1.1e-5	Serum sulfate level;
TGCT	cis	rs4494114	0.967	rs6663796	chr1:39312887	T/C	cg25970120	chr1:39325951	RRAGC	-0.6	-6.43	-0.5	2.52e-9	Blood protein levels;
TGCT	cis	rs11105298	0.891	rs11105325	chr12:89938590	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.74	-5.27	-0.43	5.75e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs6752107	0.935	rs11690131	chr2:234148383	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.2	4.91	0.4	2.8e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs797680	0.786	rs4847240	chr1:93817946	A/G	cg17826107	chr1:92977322	EVI5	-0.24	-5.65	-0.45	1.05e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs910316	0.875	rs12588099	chr14:75594462	A/T	cg11812906	chr14:75593930	NEK9	0.73	7.23	0.54	4.33e-11	Height;
TGCT	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg16325326	chr1:53192061	ZYG11B	0.59	7.1	0.54	8.48e-11	Monocyte count;
TGCT	cis	rs67311347	1.000	rs56291770	chr3:40515370	T/C	cg13409248	chr3:40428643	ENTPD3	0.56	4.45	0.37	1.91e-5	Renal cell carcinoma;
TGCT	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs8103278	1.000	rs17571725	chr19:46290822	C/T	cg14061069	chr19:46274453	DMPK	-0.43	-6.14	-0.48	1.04e-8	Coronary artery disease;
TGCT	cis	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg07424592	chr7:64974309	NA	1.38	8.17	0.59	3.04e-13	Diabetic kidney disease;
TGCT	cis	rs3885907	0.542	rs9315046	chr13:31320543	G/A	cg22282089	chr13:30686841	NA	-0.22	-4.57	-0.38	1.16e-5	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU);
TGCT	cis	rs9868809	0.772	rs9812977	chr3:48720303	G/A	cg00383909	chr3:49044727	WDR6	1.36	6.75	0.52	5.01e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs9910055	0.530	rs7222349	chr17:42304644	C/T	cg19774624	chr17:42201019	HDAC5	-0.7	-7.42	-0.55	1.61e-11	Total body bone mineral density;
TGCT	cis	rs2013441	1.000	rs2058971	chr17:20219508	T/A	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.63	-0.38	9.19e-6	Obesity-related traits;
TGCT	trans	rs61931739	0.500	rs11513287	chr12:34584351	G/A	cg26384229	chr12:38710491	ALG10B	0.72	6.67	0.51	7.67e-10	Morning vs. evening chronotype;
TGCT	cis	rs9993613	0.778	rs13105983	chr4:73420634	G/A	cg15102770	chr4:73434591	ADAMTS3	0.52	4.63	0.38	9.11e-6	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs7829975	0.539	rs940031	chr8:8546848	C/T	cg17143192	chr8:8559678	CLDN23	-0.52	-5.25	-0.43	6.37e-7	Mood instability;
TGCT	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg18876405	chr7:65276391	NA	-0.33	-4.99	-0.41	1.97e-6	Aortic root size;
TGCT	cis	rs10779751	0.734	rs1130683	chr1:11132217	G/A	cg08854313	chr1:11322531	MTOR	0.82	7.04	0.53	1.19e-10	Body mass index;
TGCT	cis	rs933688	1.000	rs1035477	chr5:90743325	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.96	8.25	0.6	1.91e-13	Smoking behavior;
TGCT	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg00814883	chr7:100076585	TSC22D4	-0.55	-5.42	-0.44	3.01e-7	Lung function (FEV1/FVC);
TGCT	cis	rs10904908	0.931	rs7903137	chr10:17259567	C/T	cg01003015	chr10:17271136	VIM	-0.52	-4.52	-0.38	1.44e-5	Total cholesterol levels;Cholesterol, total;
TGCT	cis	rs8180040	0.902	rs73081205	chr3:47517670	A/C	cg27129171	chr3:47204927	SETD2	-0.66	-7.84	-0.58	1.75e-12	Colorectal cancer;
TGCT	cis	rs782590	0.807	rs782572	chr2:55912120	T/C	cg18811423	chr2:55921094	PNPT1	0.72	8.16	0.59	3.21e-13	Metabolic syndrome;
TGCT	cis	rs76419734	0.850	rs17331332	chr4:106808107	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	-1.01	-4.61	-0.38	9.71e-6	Post bronchodilator FEV1;
TGCT	cis	rs939658	1.000	rs939658	chr15:79451869	A/G	cg17916960	chr15:79447300	NA	0.53	8.37	0.6	1.04e-13	Refractive error;
TGCT	cis	rs6095298	0.595	rs11905558	chr20:47452577	G/A	cg12307787	chr20:48099359	KCNB1	0.42	4.51	0.38	1.51e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs9467773	0.587	rs10946813	chr6:26345141	A/G	cg15659132	chr6:26577336	NA	0.52	5.36	0.43	3.98e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7312933	0.669	rs7974476	chr12:42542484	C/A	cg19980929	chr12:42632907	YAF2	0.45	6.21	0.49	7.43e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs35306767	0.903	rs11253467	chr10:901244	A/G	cg26597838	chr10:835615	NA	0.75	10.61	0.69	4.13e-19	Eosinophil percentage of granulocytes;
TGCT	cis	rs2657888	0.529	rs71459376	chr12:56889139	C/G	cg23002907	chr12:56915593	RBMS2	-0.37	-4.66	-0.39	7.9e-6	Adiponectin levels;
TGCT	cis	rs7412746	0.658	rs12410394	chr1:150860186	G/A	cg04414720	chr1:150670196	GOLPH3L	0.4	4.82	0.4	4.06e-6	Melanoma;
TGCT	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg11890956	chr21:40555474	PSMG1	0.75	7.38	0.55	1.98e-11	Cognitive function;
TGCT	cis	rs6463523	0.864	rs73047957	chr7:759373	A/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.74	10.68	0.69	2.83e-19	Subjective well-being;
TGCT	cis	rs2239815	0.515	rs9625600	chr22:29244395	T/C	cg02153584	chr22:29168773	CCDC117	0.67	4.57	0.38	1.17e-5	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
TGCT	trans	rs629535	0.862	rs2178955	chr8:70045303	C/T	cg21567404	chr3:27674614	NA	0.58	9.18	0.64	1.22e-15	Dupuytren's disease;
TGCT	cis	rs9486719	0.947	rs12208556	chr6:96903486	C/T	cg06623918	chr6:96969491	KIAA0776	-0.97	-9.2	-0.64	1.06e-15	Migraine;Coronary artery disease;
TGCT	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg01585852	chr22:24235823	MIF	0.22	4.69	0.39	7.13e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs854765	0.693	rs8079418	chr17:17924060	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.67	6.42	0.5	2.61e-9	Total body bone mineral density;
TGCT	cis	rs7611238	0.560	rs6437373	chr3:195062395	A/G	cg27323046	chr3:195102265	ACAP2	0.35	4.75	0.39	5.5e-6	Body mass index;
TGCT	cis	rs2153535	0.580	rs9406174	chr6:8516764	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.55e-8	Motion sickness;
TGCT	cis	rs4808199	0.947	rs754255	chr19:19578890	T/C	cg03709012	chr19:19516395	GATAD2A	0.97	7.53	0.56	9.28e-12	Nonalcoholic fatty liver disease;
TGCT	trans	rs77457752	0.525	rs10961293	chr9:13894250	A/G	cg13808641	chr9:96006533	WNK2	0.49	7.13	0.54	7.4e-11	Breast cancer;
TGCT	cis	rs868036	0.718	rs16951275	chr15:68077168	T/C	cg05925327	chr15:68127851	NA	-0.51	-4.94	-0.41	2.52e-6	Restless legs syndrome;
TGCT	cis	rs9308731	1.000	rs2015454	chr2:111872148	A/G	cg04202892	chr2:111875749	ACOXL	0.43	4.59	0.38	1.05e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs67460515	0.892	rs7610985	chr3:161062848	G/A	cg03342759	chr3:160939853	NMD3	-0.51	-5.49	-0.44	2.14e-7	Parkinson's disease;
TGCT	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg24675658	chr1:53192096	ZYG11B	0.86	11.3	0.71	8.54e-21	Monocyte count;
TGCT	cis	rs7772486	0.782	rs7747576	chr6:146277827	C/T	cg05347473	chr6:146136440	FBXO30	-0.54	-5.22	-0.42	7.38e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs36051895	0.623	rs10118434	chr9:5238460	A/G	cg02405213	chr9:5042618	JAK2	-0.67	-8.15	-0.59	3.34e-13	Pediatric autoimmune diseases;
TGCT	cis	rs8072100	1.000	rs3809868	chr17:45750596	G/A	cg08085267	chr17:45401833	C17orf57	0.47	5.13	0.42	1.07e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg06634786	chr22:41940651	POLR3H	-0.88	-8.54	-0.61	3.98e-14	Vitiligo;
TGCT	cis	rs1129187	0.805	rs1053538	chr6:42903763	C/G	cg09436375	chr6:42928200	GNMT	-0.38	-4.9	-0.4	2.95e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs17376456	0.569	rs6881815	chr5:93105666	A/G	cg21475434	chr5:93447410	FAM172A	0.6	4.9	0.4	2.92e-6	Diabetic retinopathy;
TGCT	cis	rs9611519	0.565	rs8135524	chr22:41436442	T/C	cg03806693	chr22:41940476	POLR3H	-0.62	-5.7	-0.46	8.35e-8	Neuroticism;
TGCT	cis	rs6901004	0.803	rs354544	chr6:111531159	T/C	cg15721981	chr6:111408429	SLC16A10	-0.54	-4.71	-0.39	6.51e-6	Blood metabolite levels;
TGCT	cis	rs35146811	0.700	rs7788301	chr7:99782753	C/G	cg22906224	chr7:99728672	NA	0.49	4.45	0.37	1.88e-5	Coronary artery disease;
TGCT	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg03188948	chr7:1209495	NA	0.56	4.61	0.38	9.68e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	trans	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg21659725	chr3:3221576	CRBN	-0.76	-9.35	-0.64	4.6e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs4886920	0.601	rs4589520	chr15:78079434	C/G	cg25212270	chr15:78015279	NA	-0.23	-4.87	-0.4	3.37e-6	Neuroticism;
TGCT	cis	rs12134245	0.776	rs61548854	chr1:92001536	C/T	cg02896835	chr1:92012615	NA	-0.27	-4.59	-0.38	1.08e-5	Breast cancer;
TGCT	cis	rs4383453	0.539	rs3845913	chr3:123100606	T/A	cg04890266	chr3:123102914	ADCY5	0.49	8.18	0.59	2.82e-13	Gestational age at birth (maternal effect);
TGCT	cis	rs938554	0.657	rs9994216	chr4:9984541	G/T	cg00071950	chr4:10020882	SLC2A9	0.49	4.65	0.39	8.39e-6	Blood metabolite levels;
TGCT	cis	rs751728	0.643	rs12173787	chr6:33735471	G/C	cg13859433	chr6:33739653	LEMD2	-0.33	-6.0	-0.47	1.99e-8	Crohn's disease;
TGCT	cis	rs950169	0.922	rs4842939	chr15:84827966	C/T	cg12863693	chr15:85201151	NMB	-0.4	-4.52	-0.38	1.41e-5	Schizophrenia;
TGCT	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.31	-4.76	-0.39	5.36e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs739496	0.843	rs642536	chr12:111997023	G/A	cg10833066	chr12:111807467	FAM109A	0.37	5.2	0.42	8.01e-7	Platelet count;
TGCT	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg21724239	chr8:58056113	NA	0.42	5.04	0.41	1.59e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7264396	0.635	rs6060692	chr20:34517925	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.29	5.04	0.41	1.58e-6	Total cholesterol levels;
TGCT	cis	rs9682041	0.935	rs11923053	chr3:170095281	T/C	cg07589077	chr3:170072950	NA	0.3	4.54	0.38	1.3e-5	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs7264396	0.733	rs2425105	chr20:34312834	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.3	-5.31	-0.43	4.96e-7	Total cholesterol levels;
TGCT	cis	rs7666738	0.830	rs1834645	chr4:98979593	T/A	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9640161	0.830	rs7800196	chr7:150061534	C/G	cg10018233	chr7:150070692	REPIN1	0.37	5.89	0.47	3.39e-8	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg10047753	chr17:41438598	NA	0.96	9.64	0.65	9.37e-17	Menopause (age at onset);
TGCT	cis	rs41271473	0.519	rs9660783	chr1:228886880	C/T	cg18025438	chr1:228756789	NA	0.57	4.73	0.39	5.88e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs79839061	0.610	rs2279182	chr4:882625	T/G	cg15843217	chr4:699224	PCGF3	-0.56	-4.52	-0.38	1.42e-5	Intelligence (multi-trait analysis);
TGCT	trans	rs629535	0.814	rs674429	chr8:70069942	G/A	cg21567404	chr3:27674614	NA	0.57	9.11	0.63	1.82e-15	Dupuytren's disease;
TGCT	cis	rs7607369	0.637	rs3731866	chr2:219288899	C/T	cg02176678	chr2:219576539	TTLL4	-0.5	-6.37	-0.5	3.41e-9	Red blood cell count;Amyotrophic lateral sclerosis;
TGCT	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg12756686	chr19:29218302	NA	0.68	6.47	0.5	2e-9	Methadone dose in opioid dependence;
TGCT	cis	rs711245	0.518	rs11886145	chr2:36825716	C/G	cg10546459	chr2:36825355	FEZ2	0.58	5.65	0.45	1.06e-7	Height;
TGCT	cis	rs75059851	0.756	rs11223652	chr11:133841207	A/G	cg14047540	chr11:133829660	NA	-0.57	-5.69	-0.45	8.72e-8	Schizophrenia;
TGCT	cis	rs7465272	0.515	rs34087536	chr8:143720876	G/A	cg10596483	chr8:143751796	JRK	0.53	5.12	0.42	1.14e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs11783469	0.519	rs13250356	chr8:23359831	G/T	cg00472375	chr8:23315376	ENTPD4	0.62	5.3	0.43	5.16e-7	Reticulocyte count;
TGCT	cis	rs2224391	0.628	rs9504364	chr6:5256072	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-1.0	-6.14	-0.48	1.01e-8	Height;
TGCT	cis	rs4455778	0.659	rs7796789	chr7:49057671	C/T	cg26309511	chr7:48887640	NA	0.44	5.12	0.42	1.13e-6	Lung cancer in never smokers;
TGCT	cis	rs35883536	0.647	rs2783702	chr1:101040836	G/A	cg10298815	chr1:101004474	GPR88	0.24	4.51	0.38	1.47e-5	Monocyte count;
TGCT	cis	rs4631830	0.720	rs2611471	chr10:51503559	G/C	cg10326726	chr10:51549505	MSMB	-0.23	-4.68	-0.39	7.43e-6	Prostate-specific antigen levels;
TGCT	trans	rs2624839	0.704	rs11919418	chr3:50233215	T/G	cg21659725	chr3:3221576	CRBN	0.66	6.67	0.51	7.61e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs10751667	0.666	rs4074234	chr11:977715	C/G	cg06064525	chr11:970664	AP2A2	-0.36	-8.28	-0.6	1.67e-13	Alzheimer's disease (late onset);
TGCT	cis	rs12959333	0.772	rs12953612	chr18:33301227	G/A	cg18885387	chr18:32820922	ZNF397	0.95	4.44	0.37	1.97e-5	Post bronchodilator FEV1;
TGCT	cis	rs7565124	1.000	rs7608391	chr2:20261167	T/C	cg00462460	chr2:20212509	MATN3	-0.43	-4.64	-0.38	8.69e-6	Major depressive disorder;
TGCT	cis	rs346785	0.692	rs8074821	chr17:74293099	A/G	cg09812376	chr17:74270190	QRICH2	-0.36	-5.34	-0.43	4.22e-7	White matter hyperintensities in ischemic stroke;
TGCT	cis	rs7845219	0.544	rs34293080	chr8:95908078	G/T	cg13393036	chr8:95962371	TP53INP1	-0.45	-5.16	-0.42	9.7e-7	Type 2 diabetes;
TGCT	cis	rs2070488	0.965	rs2284819	chr3:38557161	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.78	7.82	0.57	1.97e-12	Electrocardiographic conduction measures;
TGCT	cis	rs826838	1.000	rs4768328	chr12:39129315	C/T	cg13010199	chr12:38710504	ALG10B	-0.63	-5.06	-0.41	1.46e-6	Heart rate;
TGCT	trans	rs2469997	1.000	rs2470014	chr8:120360820	C/G	cg01792902	chr3:178864926	PIK3CA	0.83	6.77	0.52	4.49e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg06618935	chr21:46677482	NA	-0.37	-5.81	-0.46	5.06e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs79387448	0.745	rs7601773	chr2:103120483	G/T	cg09003973	chr2:102972529	NA	0.85	5.65	0.45	1.03e-7	Gut microbiota (bacterial taxa);
TGCT	cis	rs651907	0.535	rs34743741	chr3:101532448	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	4.87	0.4	3.32e-6	Colorectal cancer;
TGCT	cis	rs11690935	0.851	rs10930502	chr2:172890588	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.02	-9.72	-0.66	6.05e-17	Schizophrenia;
TGCT	cis	rs7772486	0.597	rs6570732	chr6:146245151	G/A	cg23711669	chr6:146136114	FBXO30	-0.74	-6.96	-0.53	1.75e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7086627	0.515	rs10887903	chr10:82210641	C/T	cg00277334	chr10:82204260	NA	-0.54	-8.44	-0.6	7.03e-14	Post bronchodilator FEV1;
TGCT	cis	rs4851254	0.550	rs13402299	chr2:100659409	C/T	cg07810366	chr2:100720526	AFF3	-0.46	-4.91	-0.4	2.76e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10892173	0.935	rs7108548	chr11:117674072	A/T	cg07621104	chr11:117668040	DSCAML1	0.47	4.81	0.4	4.31e-6	Myopia;
TGCT	cis	rs4654899	0.897	rs611658	chr1:21089133	T/G	cg01072550	chr1:21505969	NA	-0.5	-8.03	-0.59	6.32e-13	Superior frontal gyrus grey matter volume;
TGCT	trans	rs208520	0.874	rs208470	chr6:66916402	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.95	-9.95	-0.67	1.64e-17	Exhaled nitric oxide output;
TGCT	cis	rs6061231	0.597	rs624313	chr20:60927412	G/A	cg24112000	chr20:60950667	NA	0.34	4.76	0.39	5.24e-6	Colorectal cancer;
TGCT	cis	rs9611565	0.559	rs5751160	chr22:42175695	A/G	cg06634786	chr22:41940651	POLR3H	0.85	8.15	0.59	3.41e-13	Vitiligo;
TGCT	cis	rs7666738	0.830	rs7672720	chr4:98938760	A/T	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7617773	0.746	rs6796343	chr3:48282021	C/A	cg11946769	chr3:48343235	NME6	0.76	6.67	0.51	7.6e-10	Coronary artery disease;
TGCT	cis	rs259282	0.646	rs34182086	chr19:33125823	A/C	cg26639809	chr19:33781782	NA	0.26	5.48	0.44	2.24e-7	Schizophrenia;
TGCT	cis	rs11098499	0.754	rs7689729	chr4:120256192	A/G	cg09307838	chr4:120376055	NA	0.63	6.07	0.48	1.44e-8	Corneal astigmatism;
TGCT	cis	rs9534288	0.699	rs7139571	chr13:46662584	G/A	cg15192986	chr13:46630673	CPB2	-0.51	-6.01	-0.47	1.92e-8	Blood protein levels;
TGCT	cis	rs9486719	1.000	rs12213426	chr6:96896035	T/C	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.21	-0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs7809950	0.817	rs2237678	chr7:107203265	T/G	cg23024343	chr7:107201750	COG5	-0.47	-6.81	-0.52	3.74e-10	Coronary artery disease;
TGCT	trans	rs853356	0.947	rs853383	chr6:14180705	C/T	cg14262035	chr17:42019790	PPY	0.51	6.72	0.52	5.86e-10	Height;
TGCT	cis	rs7727102	0.660	rs1909992	chr5:4711281	G/T	cg13287621	chr5:3853654	NA	0.37	4.46	0.37	1.78e-5	Bipolar disorder and schizophrenia;
TGCT	cis	rs1075232	1.000	rs9672214	chr15:31677775	A/T	cg01030201	chr15:31746330	NA	-1.1	-5.4	-0.44	3.27e-7	Survival in colorectal cancer (non-distant metastatic);
TGCT	cis	rs11955175	1.000	rs113120818	chr5:40642896	T/A	cg17351974	chr5:40835760	RPL37	0.76	4.75	0.39	5.46e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs6964587	0.626	rs6951795	chr7:91543764	T/C	cg17063962	chr7:91808500	NA	-0.77	-7.32	-0.55	2.77e-11	Breast cancer;
TGCT	cis	rs7810240	1.000	rs2888633	chr7:150083370	G/T	cg24650120	chr7:150096722	NA	-0.74	-9.86	-0.66	2.79e-17	Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
TGCT	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg02725872	chr8:58115012	NA	-0.39	-4.74	-0.39	5.77e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9457247	1.000	rs239935	chr6:167411788	G/A	cg25258033	chr6:167368657	RNASET2	0.19	4.51	0.38	1.51e-5	Crohn's disease;
TGCT	cis	rs3784262	0.512	rs4646571	chr15:58343137	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.51	-7.68	-0.57	4.14e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs8084125	0.832	rs62105179	chr18:74950858	A/G	cg05528293	chr18:74961138	GALR1	0.52	5.18	0.42	8.65e-7	Obesity-related traits;
TGCT	cis	rs7917772	0.636	rs2249845	chr10:104512095	A/G	cg05855489	chr10:104503620	C10orf26	0.64	5.03	0.41	1.7e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	trans	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg13615516	chr5:77269221	NA	0.67	8.36	0.6	1.09e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg24829409	chr8:58192753	C8orf71	-0.55	-5.06	-0.41	1.46e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.42	0.44	3.02e-7	Bipolar disorder;
TGCT	trans	rs2624839	0.639	rs2526389	chr3:50192826	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.75	7.43	0.56	1.56e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs17270561	0.525	rs12201678	chr6:25978993	C/T	cg17042849	chr6:26104293	HIST1H4C	-0.84	-5.82	-0.46	4.7e-8	Iron status biomarkers;
TGCT	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg01416388	chr22:39784598	NA	-0.65	-6.28	-0.49	5.1e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs1008375	0.931	rs7435102	chr4:17571480	C/G	cg18681998	chr4:17616180	MED28	0.94	9.51	0.65	1.93e-16	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg03188948	chr7:1209495	NA	0.43	5.67	0.45	9.5e-8	Longevity;Endometriosis;
TGCT	cis	rs10875746	0.903	rs12301339	chr12:48475233	T/C	cg20731937	chr12:48336164	NA	0.62	4.95	0.41	2.36e-6	Longevity (90 years and older);
TGCT	cis	rs79387448	0.655	rs3771167	chr2:102986188	A/G	cg09003973	chr2:102972529	NA	1.39	11.37	0.71	5.75e-21	Gut microbiota (bacterial taxa);
TGCT	cis	rs4523957	0.583	rs8077597	chr17:2043818	C/T	cg16513277	chr17:2031491	SMG6	-0.2	-4.58	-0.38	1.13e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs7100689	0.754	rs1934695	chr10:82125230	T/C	cg01528321	chr10:82214614	TSPAN14	0.88	8.48	0.61	5.61e-14	Post bronchodilator FEV1;
TGCT	cis	rs9354352	0.935	rs9345749	chr6:66699892	G/T	cg07460842	chr6:66804631	NA	-0.57	-4.6	-0.38	1.02e-5	Initial pursuit acceleration in psychotic disorders;
TGCT	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	8.99	0.63	3.48e-15	Platelet count;
TGCT	cis	rs651907	0.557	rs11720745	chr3:101441690	G/A	cg12386194	chr3:101231763	SENP7	0.48	4.63	0.38	9.23e-6	Colorectal cancer;
TGCT	cis	rs3806843	0.735	rs2530235	chr5:140072647	G/T	cg19875535	chr5:140030758	IK	-0.38	-6.33	-0.49	4.09e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs6912958	0.781	rs9444512	chr6:88223397	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-5.06	-0.41	1.45e-6	Monocyte percentage of white cells;
TGCT	cis	rs9527	0.590	rs7917650	chr10:104937100	G/C	cg15744005	chr10:104629667	AS3MT	-0.4	-4.63	-0.38	9.04e-6	Arsenic metabolism;
TGCT	cis	rs2836950	0.501	rs2836980	chr21:40687618	G/T	cg06238570	chr21:40685208	BRWD1	-0.63	-6.44	-0.5	2.42e-9	Menarche (age at onset);
TGCT	cis	rs56011263	0.687	rs4690292	chr4:703712	A/G	cg17689763	chr4:710664	PCGF3	-0.24	-6.85	-0.52	3.02e-10	White blood cell count;
TGCT	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg21724239	chr8:58056113	NA	0.47	5.14	0.42	1.05e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4689388	0.679	rs1046316	chr4:6304087	A/G	cg14416269	chr4:6271139	WFS1	0.48	6.05	0.48	1.58e-8	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs12681287	0.640	rs13251006	chr8:87469105	C/T	cg27223183	chr8:87520930	FAM82B	-0.89	-6.43	-0.5	2.54e-9	Caudate activity during reward;
TGCT	cis	rs968567	0.705	rs174575	chr11:61602003	C/G	cg19610905	chr11:61596333	FADS2	-0.85	-7.4	-0.55	1.76e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
TGCT	cis	rs9899728	0.539	rs57813751	chr17:73053512	C/T	cg27626185	chr17:73056755	KCTD2	-0.92	-8.01	-0.58	7.17e-13	Alzheimer's disease or small vessel stroke;
TGCT	cis	rs763121	0.962	rs6001193	chr22:39074737	A/G	cg06022373	chr22:39101656	GTPBP1	0.73	7.14	0.54	7.12e-11	Menopause (age at onset);
TGCT	cis	rs7959452	0.530	rs12811632	chr12:69755003	G/A	cg11871910	chr12:69753446	YEATS4	0.83	8.9	0.62	5.55e-15	Blood protein levels;
TGCT	cis	rs113601626	1	rs113601626	chr2:24239189	T/TCCTGGC	cg08917208	chr2:24149416	ATAD2B	0.83	5.08	0.42	1.35e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs1215050	0.791	rs260893	chr4:98744785	A/C	cg05340658	chr4:99064831	C4orf37	0.44	5.52	0.44	1.85e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs8177179	0.967	rs6439434	chr3:133450371	T/G	cg16262614	chr3:133464971	TF	0.35	4.72	0.39	6.28e-6	Iron status biomarkers (transferrin levels);
TGCT	cis	rs7223966	1.000	rs112143304	chr17:61822401	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	4.72	0.39	6.31e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs2455799	0.559	rs6770404	chr3:15911428	G/C	cg12172478	chr3:16357591	RFTN1	-0.36	-5.3	-0.43	5.07e-7	Mean platelet volume;
TGCT	cis	rs1008375	0.606	rs6828925	chr4:17561139	C/T	cg10189774	chr4:17578691	LAP3	0.6	5.65	0.45	1.05e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9859260	0.744	rs492349	chr3:195784192	G/A	cg02975922	chr3:195473998	MUC4	0.25	5.1	0.42	1.24e-6	Mean corpuscular volume;
TGCT	cis	rs2836950	0.501	rs2836983	chr21:40689336	G/A	cg11890956	chr21:40555474	PSMG1	-0.66	-6.24	-0.49	6.47e-9	Menarche (age at onset);
TGCT	cis	rs2180341	0.814	rs6919277	chr6:127738050	T/C	cg27446573	chr6:127587934	RNF146	0.87	7.79	0.57	2.37e-12	Breast cancer;
TGCT	cis	rs9443645	0.868	rs9443643	chr6:79798838	A/G	cg05283184	chr6:79620031	NA	-0.2	-4.45	-0.37	1.85e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs10214930	0.561	rs6961731	chr7:27925158	A/G	cg05786569	chr7:27702416	HIBADH	-0.73	-5.24	-0.43	6.74e-7	Hypospadias;
TGCT	cis	rs8180040	0.966	rs62260711	chr3:47564491	G/C	cg27129171	chr3:47204927	SETD2	-0.64	-7.34	-0.55	2.41e-11	Colorectal cancer;
TGCT	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs11190604	1.000	rs2495742	chr10:102331364	C/T	cg16342193	chr10:102329863	NA	-0.42	-5.26	-0.43	5.99e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs10507380	0.824	rs9512635	chr13:27920468	C/A	cg25543773	chr13:27185723	WASF3	0.34	4.83	0.4	3.97e-6	Electrocardiographic traits;
TGCT	cis	rs6674176	0.932	rs12410334	chr1:44442521	A/C	cg12908607	chr1:44402522	ARTN	-0.74	-8.47	-0.61	5.88e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs6087990	0.806	rs910084	chr20:31379665	C/T	cg13636640	chr20:31349939	DNMT3B	1.08	14.64	0.8	8.49e-29	Ulcerative colitis;
TGCT	cis	rs4253772	0.637	rs9627350	chr22:46663017	A/G	cg09491104	chr22:46646882	C22orf40	-0.67	-6.65	-0.51	8.56e-10	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg06636001	chr8:8085503	FLJ10661	-0.77	-7.73	-0.57	3.17e-12	Mood instability;
TGCT	cis	rs986417	1.000	rs1955686	chr14:61093560	C/T	cg27398547	chr14:60952738	C14orf39	1.56	8.73	0.62	1.45e-14	Gut microbiota (bacterial taxa);
TGCT	cis	rs1784581	0.851	rs1784591	chr6:162388893	C/G	cg17173639	chr6:162384350	PARK2	-0.5	-9.35	-0.64	4.63e-16	Itch intensity from mosquito bite;
TGCT	trans	rs11764590	0.950	rs11514731	chr7:2051503	C/G	cg25206134	chr2:45395956	NA	1.0	7.57	0.56	7.46e-12	Neuroticism;
TGCT	cis	rs7264396	0.790	rs6060582	chr20:34313297	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.29	5.25	0.43	6.33e-7	Total cholesterol levels;
TGCT	cis	rs11190604	1.000	rs35106985	chr10:102307542	T/C	cg23241863	chr10:102295624	HIF1AN	0.68	5.15	0.42	9.74e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs12541335	0.507	rs9644047	chr8:22158670	T/A	cg09517075	chr8:22133004	PIWIL2	0.23	4.45	0.37	1.91e-5	Hypertriglyceridemia;
TGCT	cis	rs7590720	0.851	rs13006614	chr2:216876204	C/T	cg12620499	chr2:216877984	MREG	0.9	10.93	0.7	6.95e-20	Alcohol dependence;
TGCT	cis	rs7017914	0.967	rs35960437	chr8:71661960	C/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.03	-0.41	1.69e-6	Bone mineral density;
TGCT	cis	rs4642101	0.793	rs13086170	chr3:12832604	G/C	cg05775895	chr3:12838266	CAND2	0.78	8.9	0.62	5.77e-15	QRS complex (12-leadsum);
TGCT	cis	rs7909074	0.966	rs879074	chr10:45400053	G/A	cg05187965	chr10:45406764	TMEM72	-0.23	-4.88	-0.4	3.25e-6	Mean corpuscular volume;
TGCT	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg05368731	chr17:41323189	NBR1	0.91	7.94	0.58	1.03e-12	Menopause (age at onset);
TGCT	cis	rs7666738	0.606	rs10006454	chr4:99080361	G/A	cg18180107	chr4:99064573	C4orf37	0.53	4.67	0.39	7.61e-6	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs4650994	0.935	rs4652306	chr1:178528206	T/C	cg05059571	chr16:84539110	KIAA1609	-0.4	-7.43	-0.56	1.54e-11	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs2197308	0.692	rs67352173	chr12:37906912	A/T	cg26384229	chr12:38710491	ALG10B	0.85	7.82	0.57	1.94e-12	Morning vs. evening chronotype;
TGCT	cis	rs7017914	0.934	rs35214141	chr8:71574564	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.53	-4.9	-0.4	2.87e-6	Bone mineral density;
TGCT	cis	rs6121246	0.559	rs6060933	chr20:30351903	C/T	cg13852791	chr20:30311386	BCL2L1	0.82	8.0	0.58	7.65e-13	Mean corpuscular hemoglobin;
TGCT	cis	rs7208859	0.623	rs7219712	chr17:29080570	G/T	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs6746896	0.959	rs72809820	chr2:97360079	C/T	cg26085987	chr2:97230376	NA	0.19	4.69	0.39	7.16e-6	Bipolar disorder;
TGCT	cis	rs13217239	0.646	rs10946897	chr6:26995251	A/C	cg02458000	chr6:26745757	NA	0.5	4.61	0.38	1e-5	Schizophrenia;
TGCT	cis	rs6582630	0.563	rs923281	chr12:38590241	G/A	cg26384229	chr12:38710491	ALG10B	-0.54	-4.75	-0.39	5.62e-6	Drug-induced liver injury (flucloxacillin);
TGCT	trans	rs629535	0.814	rs72654071	chr8:70079484	A/G	cg21567404	chr3:27674614	NA	-0.57	-8.99	-0.63	3.38e-15	Dupuytren's disease;
TGCT	trans	rs4650994	0.967	rs6681043	chr1:178525957	A/G	cg05059571	chr16:84539110	KIAA1609	-0.41	-7.67	-0.57	4.37e-12	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs860295	0.529	rs10908486	chr1:155978544	C/G	cg05700447	chr1:155978627	NA	-0.19	-4.75	-0.39	5.57e-6	Body mass index;
TGCT	cis	rs6121246	0.529	rs6060145	chr20:30178631	T/C	cg18721089	chr20:30220636	NA	-0.63	-6.68	-0.51	7.29e-10	Mean corpuscular hemoglobin;
TGCT	trans	rs4332037	0.539	rs4470910	chr7:2071723	C/T	cg25206134	chr2:45395956	NA	0.98	7.42	0.55	1.63e-11	Bipolar disorder;
TGCT	cis	rs7917772	0.582	rs10786691	chr10:104364652	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	5.36	0.43	3.84e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9818758	0.607	rs11552724	chr3:49156473	C/G	cg00383909	chr3:49044727	WDR6	1.3	6.72	0.52	5.87e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs422249	0.512	rs99780	chr11:61596633	C/T	cg01500311	chr11:61656094	FADS3	-0.32	-5.71	-0.46	8.04e-8	Trans fatty acid levels;
TGCT	cis	rs2562456	0.652	rs4809145	chr19:21780709	A/C	cg13978929	chr19:21580086	ZNF493	-0.58	-4.73	-0.39	6.04e-6	Pain;
TGCT	trans	rs561341	0.609	rs739800	chr17:30190083	T/A	cg20587970	chr11:113659929	NA	0.67	8.22	0.59	2.35e-13	Hip circumference adjusted for BMI;
TGCT	cis	rs10109025	0.701	rs10101292	chr8:10856474	T/C	cg21775007	chr8:11205619	TDH	-0.49	-4.44	-0.37	1.94e-5	Joint mobility (Beighton score);
TGCT	cis	rs2469997	1.000	rs2447172	chr8:120360863	A/T	cg00681363	chr8:120844660	TAF2	0.69	4.48	0.37	1.64e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs250677	0.916	rs17109279	chr5:148416581	A/G	cg18129178	chr5:148520854	ABLIM3	-0.4	-5.63	-0.45	1.17e-7	Breast cancer;
TGCT	cis	rs10791097	0.667	rs12363163	chr11:130744509	A/G	cg12179176	chr11:130786555	SNX19	0.84	10.17	0.67	4.95e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs13108904	0.604	rs11946375	chr4:1313488	T/C	cg13395646	chr4:1353034	KIAA1530	-0.48	-6.95	-0.53	1.82e-10	Obesity-related traits;
TGCT	cis	rs7113874	0.589	rs10840051	chr11:8475180	G/C	cg14521421	chr11:8862019	ST5	0.28	4.44	0.37	1.94e-5	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	trans	rs1814175	0.935	rs7479914	chr11:49661351	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.34	-6.67	-0.51	7.74e-10	Height;
TGCT	cis	rs9913156	0.793	rs4346260	chr17:4567215	A/G	cg19197139	chr17:4613644	ARRB2	-0.87	-8.05	-0.59	5.79e-13	Lymphocyte counts;
TGCT	cis	rs7647973	1.000	rs11710434	chr3:49346130	T/C	cg05785598	chr3:49045655	WDR6	0.39	4.62	0.38	9.58e-6	Menarche (age at onset);
TGCT	trans	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg23505145	chr19:12996616	KLF1	0.77	7.97	0.58	8.9e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs4149423	1.000	rs4149420	chr2:108913090	G/T	cg13968390	chr2:108904812	SULT1C2	-0.27	-5.16	-0.42	9.57e-7	Lobe size;
TGCT	cis	rs7209700	0.600	rs7218632	chr17:45365153	A/G	cg21624342	chr17:45890973	OSBPL7	0.16	4.46	0.37	1.85e-5	IgG glycosylation;
TGCT	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg12310025	chr6:25882481	NA	-0.59	-5.17	-0.42	8.92e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs739496	0.843	rs598710	chr12:111973141	A/C	cg10833066	chr12:111807467	FAM109A	0.35	4.58	0.38	1.13e-5	Platelet count;
TGCT	cis	rs7727544	0.654	rs4705849	chr5:131559199	T/A	cg21474247	chr5:131268130	NA	0.31	4.49	0.37	1.59e-5	Blood metabolite levels;
TGCT	cis	rs7681440	0.605	rs1372509	chr4:90817311	A/G	cg10208370	chr4:90758469	SNCA	-0.57	-5.41	-0.44	3.05e-7	Dementia with Lewy bodies;
TGCT	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg22433210	chr17:43662623	NA	-1.0	-7.13	-0.54	7.26e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2070488	0.965	rs6796845	chr3:38567771	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.83	-8.45	-0.6	6.78e-14	Electrocardiographic conduction measures;
TGCT	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg08280861	chr8:58055591	NA	0.42	4.82	0.4	4.15e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs295140	0.743	rs1729412	chr2:201083598	T/C	cg04283868	chr2:201171347	SPATS2L	-0.53	-5.25	-0.43	6.53e-7	QT interval;
TGCT	cis	rs11650494	1.000	rs11650494	chr17:47345186	G/A	cg08112188	chr17:47440006	ZNF652	1.06	5.44	0.44	2.68e-7	Prostate cancer;
TGCT	trans	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg11887960	chr12:57824829	NA	1.1	9.44	0.65	2.89e-16	Lung disease severity in cystic fibrosis;
TGCT	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg03806693	chr22:41940476	POLR3H	1.16	13.41	0.77	7.02e-26	Vitiligo;
TGCT	cis	rs10540	0.841	rs35601764	chr11:532923	A/C	cg03934478	chr11:495069	RNH1	0.32	4.55	0.38	1.28e-5	Body mass index;
TGCT	cis	rs6988636	1.000	rs59601467	chr8:124193488	C/T	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs2204008	0.774	rs11520237	chr12:38266978	G/A	cg13010199	chr12:38710504	ALG10B	0.61	4.67	0.39	7.69e-6	Bladder cancer;
TGCT	cis	rs4273100	0.688	rs28760541	chr17:19172505	A/G	cg03910582	chr17:19030146	GRAPL	0.51	6.15	0.48	9.7e-9	Schizophrenia;
TGCT	cis	rs1801251	1.000	rs7587309	chr2:233705702	G/T	cg25237894	chr2:233734115	C2orf82	-0.31	-5.49	-0.44	2.19e-7	Coronary artery disease;
TGCT	cis	rs2153535	0.542	rs9505465	chr6:8510846	C/T	cg07606381	chr6:8435919	SLC35B3	0.53	4.97	0.41	2.22e-6	Motion sickness;
TGCT	cis	rs6087771	0.821	rs6058444	chr20:30315137	A/G	cg13852791	chr20:30311386	BCL2L1	0.79	7.13	0.54	7.48e-11	Subcortical brain region volumes;Putamen volume;
TGCT	cis	rs9611565	0.512	rs715498	chr22:42148467	G/A	cg06481639	chr22:41940642	POLR3H	0.69	6.05	0.48	1.59e-8	Vitiligo;
TGCT	cis	rs7666738	0.830	rs34892904	chr4:98938097	T/C	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7178572	0.568	rs7176302	chr15:77671216	C/G	cg22256960	chr15:77711686	NA	-0.88	-9.16	-0.64	1.32e-15	Type 2 diabetes;
TGCT	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg16414030	chr3:133502952	NA	-0.5	-7.01	-0.53	1.39e-10	Iron status biomarkers;
TGCT	cis	rs4319547	0.737	rs4758646	chr12:122946507	G/A	cg23029597	chr12:123009494	RSRC2	-0.28	-4.52	-0.38	1.43e-5	Body mass index;
TGCT	cis	rs9837602	0.529	rs793495	chr3:99507934	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.5	-5.66	-0.45	9.93e-8	Breast cancer;
TGCT	cis	rs9611565	0.729	rs12165508	chr22:41819960	T/C	cg06634786	chr22:41940651	POLR3H	0.81	7.71	0.57	3.43e-12	Vitiligo;
TGCT	cis	rs79349575	0.729	rs62075824	chr17:46986679	A/G	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.44	-0.37	1.95e-5	Type 2 diabetes;
TGCT	cis	rs6484504	0.532	rs10835756	chr11:31267622	C/T	cg26647111	chr11:31128758	NA	-0.35	-4.85	-0.4	3.58e-6	Red blood cell count;
TGCT	cis	rs12519773	0.562	rs6557066	chr5:92499467	T/A	cg04854328	chr5:92914828	FLJ42709	-0.3	-4.55	-0.38	1.24e-5	Migraine;
TGCT	cis	rs6540559	0.611	rs926347	chr1:209965193	T/C	cg22029157	chr1:209979665	IRF6	0.75	5.58	0.45	1.45e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg10802521	chr3:52805072	NEK4	-0.78	-10.01	-0.67	1.22e-17	Bipolar disorder;
TGCT	cis	rs2153535	0.580	rs1119690	chr6:8460660	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs7552404	0.731	rs7523573	chr1:76372020	G/T	cg22875332	chr1:76189707	ACADM	0.67	6.46	0.5	2.16e-9	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9486719	1.000	rs4839837	chr6:96908706	G/A	cg06623918	chr6:96969491	KIAA0776	0.96	9.44	0.65	2.83e-16	Migraine;Coronary artery disease;
TGCT	cis	rs986417	0.901	rs9743622	chr14:61037163	A/T	cg27398547	chr14:60952738	C14orf39	1.44	8.71	0.62	1.57e-14	Gut microbiota (bacterial taxa);
TGCT	cis	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg18252515	chr7:66147081	NA	1.22	7.33	0.55	2.53e-11	Diabetic kidney disease;
TGCT	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg08736216	chr1:53307985	ZYG11A	-0.3	-6.06	-0.48	1.48e-8	Monocyte count;
TGCT	cis	rs17761864	0.675	rs72815344	chr17:2046947	T/C	cg02171503	chr17:1588363	PRPF8	-0.5	-4.79	-0.4	4.7e-6	Esophageal cancer (squamous cell);
TGCT	cis	rs9549367	0.826	rs1885688	chr13:113894236	G/T	cg00898013	chr13:113819073	PROZ	-0.43	-5.5	-0.44	2.11e-7	Platelet distribution width;
TGCT	cis	rs6424115	0.830	rs4649124	chr1:24201357	A/G	cg15997130	chr1:24165203	NA	0.85	9.25	0.64	8.02e-16	Immature fraction of reticulocytes;
TGCT	cis	rs28595532	0.920	rs56046676	chr4:119766733	A/G	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs9913156	0.789	rs72824966	chr17:4596679	T/C	cg00122941	chr17:4613640	ARRB2	0.88	7.63	0.57	5.46e-12	Lymphocyte counts;
TGCT	cis	rs17384381	1.000	rs12743049	chr1:85897386	G/A	cg16011679	chr1:85725395	C1orf52	0.8	6.44	0.5	2.39e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs739401	0.611	rs2301140	chr11:3022629	C/T	cg25174290	chr11:3078921	CARS	0.47	4.6	0.38	1.04e-5	Longevity;
TGCT	cis	rs2739330	1.000	rs2739330	chr22:24295286	T/C	cg00024416	chr22:24240387	NA	-0.25	-4.9	-0.4	2.91e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs826838	0.967	rs11183622	chr12:38792849	T/C	cg13010199	chr12:38710504	ALG10B	0.82	6.85	0.52	3e-10	Heart rate;
TGCT	cis	rs950776	0.593	rs588765	chr15:78865425	T/C	cg06917634	chr15:78832804	PSMA4	-0.65	-5.32	-0.43	4.65e-7	Sudden cardiac arrest;
TGCT	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg00343986	chr7:65444356	GUSB	0.23	5.14	0.42	1.06e-6	Aortic root size;
TGCT	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.1	-8.45	-0.6	6.56e-14	Platelet count;
TGCT	cis	rs10782582	0.609	rs11584577	chr1:76242378	A/G	cg10523679	chr1:76189770	ACADM	-0.53	-4.98	-0.41	2.04e-6	Daytime sleep phenotypes;
TGCT	cis	rs3733585	0.673	rs4235347	chr4:9951956	C/T	cg00071950	chr4:10020882	SLC2A9	-0.55	-6.63	-0.51	9.3e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs9346649	0.967	rs6907103	chr6:168490016	C/T	cg02770688	chr6:168491649	NA	-0.27	-5.08	-0.41	1.36e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
TGCT	cis	rs6684514	0.961	rs10908501	chr1:156285513	G/T	cg16558208	chr1:156270281	VHLL	0.48	9.6	0.65	1.19e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs644799	0.601	rs662168	chr11:95586982	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.67	6.59	0.51	1.13e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs902774	0.585	rs7399070	chr12:53355678	G/C	cg07115879	chr12:52695515	KRT86	-0.47	-4.9	-0.4	2.89e-6	Prostate cancer;
TGCT	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg07507251	chr3:52567010	NT5DC2	0.48	6.91	0.53	2.24e-10	Bipolar disorder;
TGCT	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg23283495	chr1:209979779	IRF6	0.67	5.7	0.46	8.12e-8	Cleft lip with or without cleft palate;
TGCT	cis	rs2046867	0.908	rs868336	chr3:72818165	A/C	cg25664220	chr3:72788482	NA	-0.53	-6.88	-0.53	2.65e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg00814883	chr7:100076585	TSC22D4	-0.9	-9.56	-0.65	1.5e-16	Platelet count;
TGCT	cis	rs13177918	0.750	rs59354956	chr5:149822020	G/A	cg14059543	chr5:149831962	NA	-0.71	-9.32	-0.64	5.69e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg21963583	chr11:68658836	MRPL21	0.35	6.02	0.48	1.8e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	trans	rs57221529	0.766	rs17497684	chr5:558307	T/C	cg25482853	chr8:67687455	SGK3	1.2	10.16	0.67	5.25e-18	Lung disease severity in cystic fibrosis;
TGCT	cis	rs778371	0.723	rs6704763	chr2:233592487	C/T	cg08000102	chr2:233561755	GIGYF2	0.7	8.43	0.6	7.33e-14	Schizophrenia;
TGCT	cis	rs7267979	0.844	rs6107027	chr20:25288632	A/G	cg14121845	chr20:25566513	NINL	0.49	5.19	0.42	8.42e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3008870	0.755	rs2815360	chr1:67494458	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.78	8.22	0.59	2.32e-13	Lymphocyte percentage of white cells;
TGCT	cis	rs9814567	0.964	rs9820425	chr3:134223018	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.96	-9.19	-0.64	1.16e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	trans	rs561341	1.000	rs7210970	chr17:30262169	G/A	cg20587970	chr11:113659929	NA	-0.83	-7.97	-0.58	8.86e-13	Hip circumference adjusted for BMI;
TGCT	cis	rs2549003	0.966	rs10213701	chr5:131824064	T/A	cg21138405	chr5:131827807	IRF1	0.18	4.49	0.37	1.63e-5	Asthma (sex interaction);
TGCT	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg21724239	chr8:58056113	NA	0.39	5.24	0.43	6.73e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6683383	1.000	rs17464408	chr1:203101073	T/A	cg04395153	chr1:203052423	MYOG	-0.29	-4.74	-0.39	5.76e-6	Asthma;
TGCT	cis	rs79349575	0.756	rs2643361	chr17:46977462	T/G	cg07967210	chr17:47022446	SNF8	0.43	6.08	0.48	1.4e-8	Type 2 diabetes;
TGCT	cis	rs713587	0.563	rs7591460	chr2:25103967	A/C	cg01884057	chr2:25150051	NA	0.31	5.77	0.46	5.94e-8	Body mass index in non-asthmatics;
TGCT	cis	rs9894429	1.000	rs7209180	chr17:79581519	C/A	cg21028142	chr17:79581711	NPLOC4	0.29	6.81	0.52	3.83e-10	Eye color traits;
TGCT	cis	rs35160687	0.901	rs12478575	chr2:86535314	C/G	cg12542933	chr2:85804724	VAMP8	0.41	4.9	0.4	2.97e-6	Night sleep phenotypes;
TGCT	cis	rs6964587	0.743	rs33993294	chr7:91998655	A/C	cg17063962	chr7:91808500	NA	0.83	8.04	0.59	6.09e-13	Breast cancer;
TGCT	cis	rs61774743	0.681	rs10889959	chr1:41849735	T/C	cg01193554	chr1:41846683	NA	-0.44	-5.49	-0.44	2.13e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.36	-4.45	-0.37	1.9e-5	Total body bone mineral density;
TGCT	cis	rs1371867	0.875	rs1619759	chr8:101337560	T/C	cg06002616	chr8:101225028	SPAG1	-0.56	-6.52	-0.51	1.64e-9	Atrioventricular conduction;
TGCT	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg08280861	chr8:58055591	NA	-0.39	-4.86	-0.4	3.45e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2228479	0.850	rs62054611	chr16:89817017	T/C	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs7666738	0.546	rs34621463	chr4:98793357	G/C	cg17366294	chr4:99064904	C4orf37	0.61	5.69	0.46	8.47e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs13217239	0.646	rs62401067	chr6:27018101	T/A	cg15659132	chr6:26577336	NA	0.54	5.34	0.43	4.37e-7	Schizophrenia;
TGCT	cis	rs1371867	0.846	rs1788181	chr8:101334068	C/T	cg06002616	chr8:101225028	SPAG1	-0.53	-6.21	-0.49	7.16e-9	Atrioventricular conduction;
TGCT	cis	rs67311347	1.000	rs9874006	chr3:40471596	G/A	cg17264618	chr3:40429014	ENTPD3	0.32	4.76	0.39	5.36e-6	Renal cell carcinoma;
TGCT	cis	rs9916302	0.904	rs11654018	chr17:37703740	C/T	cg07936489	chr17:37558343	FBXL20	0.64	5.02	0.41	1.79e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg21285383	chr16:89894308	SPIRE2	-0.43	-6.59	-0.51	1.14e-9	Vitiligo;
TGCT	cis	rs35000415	0.938	rs17339836	chr7:128681062	C/T	cg06242719	chr7:129414860	MIR183;MIR96	-0.31	-4.52	-0.38	1.4e-5	Systemic lupus erythematosus;
TGCT	cis	rs11662586	0.517	rs11662894	chr18:77713591	G/A	cg20368463	chr18:77673604	PQLC1	0.6	7.0	0.53	1.39e-10	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
TGCT	cis	rs9674544	0.740	rs11870560	chr17:47114033	T/C	cg20966754	chr17:47091339	IGF2BP1	-0.46	-4.99	-0.41	2e-6	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
TGCT	cis	rs6840360	0.573	rs2407171	chr4:152256782	A/G	cg17479576	chr4:152424074	FAM160A1	-0.44	-4.66	-0.39	8.03e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2404602	0.647	rs12910820	chr15:77022825	T/C	cg23625390	chr15:77176239	SCAPER	-0.37	-4.67	-0.39	7.76e-6	Blood metabolite levels;
TGCT	cis	rs116095464	0.558	rs9312957	chr5:202194	C/T	cg22857025	chr5:266934	NA	-0.35	-6.52	-0.51	1.63e-9	Breast cancer;
TGCT	cis	rs8070740	0.898	rs9896735	chr17:5325808	G/T	cg25236894	chr17:5323110	RPAIN;NUP88	-0.49	-4.88	-0.4	3.15e-6	Menopause (age at onset);
TGCT	cis	rs6003958	1	rs6003958	chr22:24264089	T/G	cg20007245	chr22:24372913	LOC391322	0.8	6.8	0.52	3.87e-10	S-phenylmercapturic acid levels in smokers;
TGCT	cis	rs7617773	0.779	rs3731487	chr3:48229624	C/T	cg11946769	chr3:48343235	NME6	0.76	6.67	0.51	7.6e-10	Coronary artery disease;
TGCT	cis	rs929354	0.742	rs2107863	chr7:156963731	T/C	cg05182265	chr7:156933206	UBE3C	-0.39	-8.79	-0.62	1.03e-14	Body mass index;
TGCT	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	7.35	0.55	2.39e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7666738	0.830	rs28465658	chr4:99035866	T/C	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs13191362	1.000	rs73035012	chr6:162997279	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7677751	0.806	rs7678144	chr4:55102425	T/C	cg17187183	chr4:55093834	PDGFRA	0.56	7.13	0.54	7.37e-11	Corneal astigmatism;
TGCT	cis	rs11690935	0.851	rs7573003	chr2:172741415	T/A	cg13550731	chr2:172543902	DYNC1I2	-0.92	-8.46	-0.61	6.2e-14	Schizophrenia;
TGCT	cis	rs9911578	1.000	rs2567905	chr17:56782297	T/C	cg12560992	chr17:57184187	TRIM37	0.76	9.34	0.64	4.88e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs2361718	0.500	rs8068856	chr17:78100731	A/G	cg27614120	chr17:77386099	HRNBP3	0.29	5.02	0.41	1.72e-6	Yeast infection;
TGCT	cis	rs7666738	0.830	rs1869082	chr4:98841254	T/A	cg18180107	chr4:99064573	C4orf37	0.56	5.17	0.42	9.04e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9650657	0.740	rs34653170	chr8:10676542	G/T	cg27411982	chr8:10470053	RP1L1	-0.23	-5.19	-0.42	8.48e-7	Neuroticism;
TGCT	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg25036284	chr2:26402008	FAM59B	-0.57	-5.04	-0.41	1.63e-6	Gut microbiome composition (summer);
TGCT	cis	rs6121246	0.529	rs6088814	chr20:30218172	C/T	cg18721089	chr20:30220636	NA	-0.64	-6.86	-0.52	2.84e-10	Mean corpuscular hemoglobin;
TGCT	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.42	6.15	0.48	9.72e-9	Schizophrenia;
TGCT	cis	rs4727027	0.704	rs13221837	chr7:148903597	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	4.64	0.38	8.83e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs3096299	0.754	rs2965942	chr16:89510327	G/A	cg08392591	chr16:89556376	ANKRD11	0.58	5.36	0.43	3.88e-7	Multiple myeloma (IgH translocation);
TGCT	cis	rs34734847	1.000	rs34734847	chr12:121154221	T/C	cg21892295	chr12:121157589	UNC119B	-0.24	-5.71	-0.46	7.99e-8	Mean corpuscular volume;
TGCT	cis	rs3820928	1.000	rs11692572	chr2:227774503	C/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-4.64	-0.38	8.58e-6	Pulmonary function;
TGCT	cis	rs17826219	0.500	rs57005940	chr17:29066329	C/G	cg14008862	chr17:28927542	LRRC37B2	0.76	4.52	0.38	1.42e-5	Body mass index;
TGCT	cis	rs2153535	0.580	rs9379216	chr6:8481235	G/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs7635838	0.859	rs9869423	chr3:11459156	G/T	cg00170343	chr3:11313890	ATG7	0.64	6.16	0.48	9.46e-9	HDL cholesterol;
TGCT	cis	rs7666738	0.830	rs4323111	chr4:98952276	A/G	cg17366294	chr4:99064904	C4orf37	0.72	7.39	0.55	1.87e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1055129	0.516	rs7218498	chr17:73931847	C/G	cg08125733	chr17:73851984	WBP2	0.57	5.24	0.43	6.72e-7	White matter hyperintensity burden;
TGCT	cis	rs6840360	0.642	rs11932398	chr4:152397554	T/G	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.82e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7246967	0.611	rs73030508	chr19:22826032	T/C	cg05241461	chr19:22816980	ZNF492	0.67	4.51	0.38	1.47e-5	Bronchopulmonary dysplasia;
TGCT	cis	rs910316	0.839	rs35977276	chr14:75637359	A/C	cg08847533	chr14:75593920	NEK9	-0.93	-10.14	-0.67	5.65e-18	Height;
TGCT	cis	rs7666738	0.830	rs10001479	chr4:98918764	A/G	cg17366294	chr4:99064904	C4orf37	-0.72	-7.33	-0.55	2.64e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12477438	1.000	rs17760953	chr2:99859863	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.97	-8.87	-0.62	6.77e-15	Chronic sinus infection;
TGCT	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg03303774	chr4:1407052	NA	0.32	4.88	0.4	3.16e-6	Obesity-related traits;
TGCT	cis	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg07424592	chr7:64974309	NA	1.34	8.08	0.59	4.95e-13	Diabetic kidney disease;
TGCT	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	8.55	0.61	3.84e-14	Platelet count;
TGCT	cis	rs3096299	0.504	rs4785574	chr16:89568875	A/G	cg06640241	chr16:89574553	SPG7	0.72	7.85	0.58	1.68e-12	Multiple myeloma (IgH translocation);
TGCT	cis	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg07424592	chr7:64974309	NA	1.4	8.42	0.6	7.87e-14	Diabetic kidney disease;
TGCT	trans	rs797680	1.000	rs797680	chr1:93716974	G/T	cg27528825	chr2:159282178	CCDC148	0.36	6.95	0.53	1.82e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs11785400	0.793	rs4581034	chr8:143736968	G/A	cg24634471	chr8:143751801	JRK	0.55	5.52	0.44	1.87e-7	Schizophrenia;
TGCT	cis	rs9443645	0.901	rs9343860	chr6:79739010	G/A	cg09184832	chr6:79620586	NA	-0.48	-5.34	-0.43	4.21e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9894429	0.634	rs9709130	chr17:79583948	C/T	cg18240062	chr17:79603768	NPLOC4	0.56	4.92	0.4	2.67e-6	Eye color traits;
TGCT	cis	rs7666738	0.791	rs10010438	chr4:99022177	C/T	cg18180107	chr4:99064573	C4orf37	0.54	5.03	0.41	1.7e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs60871478	0.947	rs4074610	chr7:791755	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.45	4.49	0.37	1.6e-5	Cerebrospinal P-tau181p levels;
TGCT	cis	rs7914558	0.932	rs4307650	chr10:104959852	C/A	cg04362960	chr10:104952993	NT5C2	0.62	5.55	0.45	1.67e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs1023500	0.505	rs134889	chr22:42674350	A/T	cg05082376	chr22:42548792	NA	-0.21	-4.47	-0.37	1.76e-5	Schizophrenia;
TGCT	cis	rs8192284	1.000	rs2228145	chr1:154426970	A/C	cg00791854	chr1:154392070	IL6R	0.29	4.64	0.38	8.85e-6	Fibrinogen;C-reactive protein;Fibrinogen levels;
TGCT	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg17971929	chr21:40555470	PSMG1	-0.51	-4.6	-0.38	1.02e-5	Menarche (age at onset);
TGCT	cis	rs10986311	0.775	rs3780198	chr9:127175598	G/C	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.21	-4.87	-0.4	3.37e-6	Vitiligo;
TGCT	cis	rs13242816	1.000	rs62468976	chr7:116126891	C/G	cg16553024	chr7:116138462	CAV2	-0.43	-4.88	-0.4	3.26e-6	P wave duration;
TGCT	trans	rs1814175	0.717	rs11040450	chr11:49650638	G/A	cg15704280	chr7:45808275	SEPT13	-0.61	-6.8	-0.52	4.02e-10	Height;
TGCT	cis	rs9811920	0.638	rs10936008	chr3:99686665	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.6	-6.87	-0.52	2.82e-10	Axial length;
TGCT	cis	rs6671200	1.000	rs10747468	chr1:95686291	C/T	cg26537280	chr1:95699037	RWDD3	0.64	5.39	0.44	3.37e-7	Stearic acid (18:0) levels;
TGCT	cis	rs7172809	0.599	rs2864840	chr15:77732001	C/T	cg22256960	chr15:77711686	NA	-0.51	-4.87	-0.4	3.32e-6	Glucose homeostasis traits;
TGCT	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg12419862	chr22:24373484	LOC391322	-0.85	-9.99	-0.67	1.3e-17	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9303401	0.659	rs34275691	chr17:56736640	A/T	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs7666738	0.830	rs4699600	chr4:99019429	C/G	cg18180107	chr4:99064573	C4orf37	0.54	5.03	0.41	1.7e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs644799	0.965	rs11021313	chr11:95506907	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	8.46	0.6	6.27e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs62244186	0.541	rs62244226	chr3:44831831	G/A	cg25151919	chr3:44754333	ZNF502	-0.47	-5.46	-0.44	2.49e-7	Depressive symptoms;
TGCT	cis	rs7267979	1.000	rs6138572	chr20:25435934	G/C	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs854765	0.583	rs7207043	chr17:17819188	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.74	7.69	0.57	3.91e-12	Total body bone mineral density;
TGCT	cis	rs829661	0.947	rs829665	chr2:30724701	T/A	cg17749961	chr2:30669863	LCLAT1	1.13	8.03	0.58	6.45e-13	Midgestational circulating levels of PBDEs (fetal genetic effect);
TGCT	cis	rs4072705	0.586	rs7023736	chr9:127247946	G/A	cg13476313	chr9:127244764	NR5A1	0.3	5.1	0.42	1.25e-6	Menarche (age at onset);
TGCT	cis	rs6964587	1.000	rs10263309	chr7:91645265	A/G	cg17063962	chr7:91808500	NA	0.91	9.99	0.67	1.32e-17	Breast cancer;
TGCT	cis	rs7119	0.700	rs4886519	chr15:77893885	A/G	cg27398640	chr15:77910606	LINGO1	0.33	6.83	0.52	3.3e-10	Type 2 diabetes;
TGCT	cis	rs9359856	0.510	rs74437492	chr6:90338728	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.43	-4.44	-0.37	1.96e-5	Bipolar disorder;
TGCT	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.44	-5.79	-0.46	5.42e-8	Alzheimer's disease;
TGCT	cis	rs72781680	0.784	rs12616678	chr2:24181159	G/T	cg08917208	chr2:24149416	ATAD2B	0.72	4.5	0.37	1.56e-5	Lymphocyte counts;
TGCT	cis	rs4494114	1.000	rs12127091	chr1:39339449	C/T	cg25970120	chr1:39325951	RRAGC	-0.6	-6.23	-0.49	6.58e-9	Blood protein levels;
TGCT	cis	rs9910055	0.659	rs8079310	chr17:42270291	A/G	cg19774624	chr17:42201019	HDAC5	-0.88	-11.23	-0.71	1.27e-20	Total body bone mineral density;
TGCT	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg02038168	chr22:39784481	NA	0.68	5.75	0.46	6.42e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9952991	0.941	rs2542149	chr18:12779018	G/A	cg23598886	chr18:12777645	NA	0.62	5.9	0.47	3.25e-8	Inflammatory skin disease;
TGCT	cis	rs10751667	0.580	rs11246363	chr11:971667	T/C	cg06064525	chr11:970664	AP2A2	-0.36	-8.28	-0.6	1.66e-13	Alzheimer's disease (late onset);
TGCT	cis	rs1865760	0.516	rs9393684	chr6:26075531	G/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.77	7.38	0.55	2.03e-11	Height;
TGCT	cis	rs3796352	1.000	rs3097417	chr3:53088601	C/G	cg15956490	chr3:53032818	SFMBT1	-0.55	-6.56	-0.51	1.32e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs9325144	0.600	rs12297194	chr12:38735803	A/G	cg13010199	chr12:38710504	ALG10B	-0.53	-4.83	-0.4	4.02e-6	Morning vs. evening chronotype;
TGCT	cis	rs3806843	0.518	rs2563310	chr5:140015741	A/G	cg19875535	chr5:140030758	IK	-0.33	-5.26	-0.43	6.05e-7	Depressive symptoms (multi-trait analysis);
TGCT	trans	rs877282	1.000	rs11253367	chr10:773389	G/A	cg22713356	chr15:30763199	NA	1.15	10.1	0.67	7.07e-18	Uric acid levels;
TGCT	cis	rs12477438	0.765	rs6754843	chr2:99680485	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-7.6	-0.56	6.47e-12	Chronic sinus infection;
TGCT	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg17775962	chr7:1200435	ZFAND2A	0.28	4.88	0.4	3.13e-6	Longevity;Endometriosis;
TGCT	cis	rs6554196	0.606	rs7663318	chr4:55538880	T/C	cg26039058	chr4:54931064	CHIC2	0.54	4.62	0.38	9.28e-6	Monocyte count;
TGCT	cis	rs8028182	0.577	rs8023268	chr15:75814672	A/T	cg20655648	chr15:75932815	IMP3	0.59	4.62	0.38	9.55e-6	Sudden cardiac arrest;
TGCT	cis	rs968567	0.501	rs174553	chr11:61575158	A/G	cg01500311	chr11:61656094	FADS3	-0.3	-5.25	-0.43	6.42e-7	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
TGCT	cis	rs713587	0.935	rs11676272	chr2:25141538	A/G	cg15423357	chr2:25149977	NA	0.64	6.83	0.52	3.41e-10	Body mass index in non-asthmatics;
TGCT	cis	rs2075371	0.932	rs2241333	chr7:133970750	C/T	cg11752832	chr7:134001865	SLC35B4	0.66	6.11	0.48	1.19e-8	Mean platelet volume;
TGCT	cis	rs2178146	0.535	rs17181663	chr16:86449076	C/T	cg11165158	chr16:86613094	FOXL1	0.34	4.59	0.38	1.05e-5	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Esophageal adenocarcinoma;
TGCT	trans	rs208520	0.690	rs12194057	chr6:66745616	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	10.83	0.7	1.19e-19	Exhaled nitric oxide output;
TGCT	trans	rs11082438	0.786	rs11660485	chr18:42866471	A/C	cg11115673	chr10:50224628	C10orf72	-0.83	-7.11	-0.54	8.21e-11	Follicular lymphoma;
TGCT	cis	rs8010715	1.000	rs2236352	chr14:24610733	T/C	cg23112188	chr14:24563095	PCK2	-0.41	-4.84	-0.4	3.8e-6	IgG glycosylation;
TGCT	cis	rs1008375	0.931	rs10939733	chr4:17570658	T/C	cg18681998	chr4:17616180	MED28	0.94	9.51	0.65	1.93e-16	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs477895	0.713	rs3802933	chr11:63988102	C/T	cg23719950	chr11:63933701	MACROD1	-0.72	-6.04	-0.48	1.63e-8	Mean platelet volume;
TGCT	cis	rs208520	0.609	rs208436	chr6:66897470	G/A	cg07460842	chr6:66804631	NA	-0.67	-6.69	-0.52	6.82e-10	Exhaled nitric oxide output;
TGCT	cis	rs67478160	0.595	rs12889993	chr14:104274294	A/G	cg26031613	chr14:104095156	KLC1	-0.64	-6.57	-0.51	1.23e-9	Schizophrenia;
TGCT	cis	rs858239	0.511	rs10256996	chr7:23145295	G/T	cg05602783	chr7:23145260	KLHL7	0.7	6.76	0.52	4.71e-10	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.61	5.06	0.41	1.45e-6	Tonsillectomy;
TGCT	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg11644478	chr21:40555479	PSMG1	0.98	10.28	0.68	2.68e-18	Cognitive function;
TGCT	cis	rs763121	0.853	rs5750673	chr22:39110124	G/A	cg06022373	chr22:39101656	GTPBP1	0.71	6.59	0.51	1.14e-9	Menopause (age at onset);
TGCT	cis	rs2120019	1.000	rs7167285	chr15:75368769	A/G	cg17294928	chr15:75287854	SCAMP5	-0.85	-6.5	-0.5	1.78e-9	Blood trace element (Zn levels);
TGCT	cis	rs2033711	0.783	rs8113810	chr19:58932106	A/G	cg04608855	chr19:58913158	NA	0.57	5.66	0.45	1.02e-7	Uric acid clearance;
TGCT	cis	rs3806843	0.576	rs251376	chr5:140253689	A/G	cg09824255	chr5:140014002	CD14	-0.26	-4.64	-0.38	8.87e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7945705	0.967	rs10769970	chr11:8917937	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.46	5.19	0.42	8.23e-7	Hemoglobin concentration;
TGCT	cis	rs9611565	0.512	rs139560	chr22:42194962	A/G	cg13695892	chr22:41940480	POLR3H	-0.8	-7.6	-0.56	6.36e-12	Vitiligo;
TGCT	cis	rs10858047	0.883	rs6537839	chr1:115188908	G/T	cg12756093	chr1:115239321	AMPD1	0.47	4.96	0.41	2.27e-6	Autism;
TGCT	cis	rs5769765	0.837	rs4824110	chr22:50271631	T/A	cg22709217	chr22:50311962	ALG12;CRELD2	1.11	11.76	0.73	6.5e-22	Schizophrenia;
TGCT	cis	rs2692947	0.644	rs3821051	chr2:96912787	A/G	cg22654517	chr2:96458247	NA	-0.21	-4.85	-0.4	3.61e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs910316	1.000	rs3742778	chr14:75538217	A/C	cg08847533	chr14:75593920	NEK9	-0.97	-10.82	-0.7	1.28e-19	Height;
TGCT	trans	rs7819412	0.775	rs4841489	chr8:10936811	A/G	cg15556689	chr8:8085844	FLJ10661	-0.84	-8.16	-0.59	3.26e-13	Triglycerides;
TGCT	cis	rs7208859	0.623	rs73267858	chr17:29059737	A/G	cg14008862	chr17:28927542	LRRC37B2	0.77	4.59	0.38	1.08e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg05368731	chr17:41323189	NBR1	1.21	14.63	0.8	8.89e-29	Menopause (age at onset);
TGCT	cis	rs10746514	0.833	rs11122428	chr1:232261417	A/G	cg09506761	chr1:232265262	NA	-0.5	-5.17	-0.42	9.3e-7	Response to statin therapy;
TGCT	cis	rs748404	0.578	rs576557	chr15:43597737	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	4.56	0.38	1.19e-5	Lung cancer;
TGCT	cis	rs2075165	0.901	rs7542045	chr1:156246473	G/C	cg20302342	chr1:156215951	PAQR6	0.36	5.38	0.44	3.56e-7	Tonsillectomy;
TGCT	cis	rs7432375	0.804	rs6764567	chr3:136425514	A/C	cg12473912	chr3:136751656	NA	-0.36	-5.06	-0.41	1.5e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	trans	rs11785693	0.909	rs62489558	chr8:4968620	G/A	cg21607066	chr6:79787807	PHIP	0.92	6.84	0.52	3.18e-10	Neuroticism (multi-trait analysis);Neuroticism;
TGCT	cis	rs13082711	0.522	rs653886	chr3:27343549	C/T	cg02860705	chr3:27208620	NA	0.33	5.45	0.44	2.62e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs9467711	1.000	rs9467701	chr6:26312170	G/C	cg16898833	chr6:26189333	HIST1H4D	1.04	5.51	0.44	1.97e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2658782	0.547	rs4344448	chr11:93047047	T/C	cg15737290	chr11:93063684	CCDC67	1.0	10.37	0.68	1.58e-18	Pulmonary function decline;
TGCT	cis	rs908922	0.651	rs4845444	chr1:152530125	G/A	cg20991723	chr1:152506922	NA	0.44	5.98	0.47	2.2e-8	Hair morphology;
TGCT	cis	rs4788815	0.552	rs7187129	chr16:71861444	T/C	cg06353428	chr16:71660113	MARVELD3	0.81	7.32	0.55	2.79e-11	Metabolite levels;
TGCT	cis	rs12135894	0.562	rs6688969	chr1:3743391	C/T	cg10555106	chr1:3691387	LOC388588	0.31	4.88	0.4	3.21e-6	Mean corpuscular volume;
TGCT	cis	rs7647973	0.731	rs13084037	chr3:49214066	G/A	cg05785598	chr3:49045655	WDR6	0.44	5.04	0.41	1.6e-6	Menarche (age at onset);
TGCT	cis	rs6740322	0.843	rs6727237	chr2:43562000	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.38	-6.32	-0.49	4.21e-9	Coronary artery disease;
TGCT	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg05368731	chr17:41323189	NBR1	1.19	13.98	0.78	2.93e-27	Menopause (age at onset);
TGCT	cis	rs10875595	0.723	rs62378371	chr5:140680211	G/A	cg24830062	chr5:140700576	TAF7	-0.69	-5.38	-0.43	3.6e-7	Pulmonary function decline;
TGCT	cis	rs500492	0.508	rs449566	chr16:1074581	C/T	cg01366354	chr16:1075121	NA	0.36	5.23	0.43	6.99e-7	Polycystic ovary syndrome;
TGCT	cis	rs35306767	0.953	rs11253520	chr10:975961	C/G	cg18964960	chr10:1102726	WDR37	-0.53	-4.63	-0.38	9e-6	Eosinophil percentage of granulocytes;
TGCT	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg04013166	chr16:89971882	TCF25	0.33	4.86	0.4	3.47e-6	Skin colour saturation;
TGCT	cis	rs10927875	0.722	rs1763606	chr1:16338282	A/G	cg21385522	chr1:16154831	NA	0.6	6.38	0.5	3.14e-9	Dilated cardiomyopathy;
TGCT	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg23708337	chr7:1209742	NA	0.56	5.09	0.42	1.31e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs806215	0.547	rs9791922	chr7:127559133	T/C	cg11539674	chr7:127291444	SND1	-0.35	-4.52	-0.38	1.43e-5	Type 2 diabetes;
TGCT	cis	rs8077577	0.945	rs8065026	chr17:18046290	A/G	cg09161412	chr17:18057145	MYO15A	-0.63	-5.2	-0.42	7.87e-7	Obesity-related traits;
TGCT	cis	rs2982552	0.787	rs11155810	chr6:152056081	T/C	cg22157087	chr6:152012887	ESR1	0.21	5.17	0.42	8.93e-7	Bone properties (heel);
TGCT	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg23708337	chr7:1209742	NA	0.44	4.97	0.41	2.13e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	trans	rs877282	0.891	rs12767043	chr10:797943	C/T	cg22713356	chr15:30763199	NA	1.16	10.18	0.67	4.53e-18	Uric acid levels;
TGCT	cis	rs9913156	0.789	rs72824966	chr17:4596679	T/C	cg19197139	chr17:4613644	ARRB2	0.83	7.74	0.57	3.03e-12	Lymphocyte counts;
TGCT	cis	rs933688	0.877	rs1477349	chr5:90707773	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.96	8.06	0.59	5.53e-13	Smoking behavior;
TGCT	cis	rs709400	0.930	rs10149249	chr14:104047757	C/T	cg26031613	chr14:104095156	KLC1	1.14	15.35	0.81	1.87e-30	Body mass index;
TGCT	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg26513180	chr16:89883248	FANCA	1.03	14.55	0.79	1.35e-28	Vitiligo;
TGCT	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.7	6.26	0.49	5.64e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs11122272	0.735	rs2739509	chr1:231526765	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-6.3	-0.49	4.72e-9	Hemoglobin concentration;
TGCT	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	-0.53	-5.06	-0.41	1.48e-6	Menarche (age at onset);
TGCT	cis	rs12484776	0.786	rs73165039	chr22:40535152	A/G	cg07138101	chr22:40742427	ADSL	0.61	4.65	0.39	8.24e-6	Uterine fibroids;
TGCT	cis	rs17133449	0.718	rs7905751	chr10:4752837	A/T	cg04530666	chr10:3759553	NA	-0.31	-5.22	-0.42	7.34e-7	Major depressive disorder;
TGCT	cis	rs6867032	1.000	rs6867032	chr5:2015103	G/T	cg26168224	chr5:2018326	NA	-0.44	-8.11	-0.59	4.08e-13	Gut microbiome composition (winter);
TGCT	cis	rs9467711	0.720	rs35627490	chr6:26462104	C/T	cg16898833	chr6:26189333	HIST1H4D	1.26	5.95	0.47	2.59e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs806795	0.605	rs809871	chr6:26256526	C/G	cg00631329	chr6:26305371	NA	0.34	5.32	0.43	4.59e-7	Mosquito bite size;
TGCT	cis	rs10193935	0.792	rs72794590	chr2:42378392	G/A	cg27598129	chr2:42591480	NA	-0.42	-5.44	-0.44	2.74e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9297145	0.585	rs13235218	chr7:98785080	C/T	cg05967295	chr7:98741636	SMURF1	-0.68	-8.29	-0.6	1.54e-13	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs7246657	0.882	rs6508716	chr19:37819010	T/C	cg18154014	chr19:37997991	ZNF793	0.74	5.08	0.42	1.34e-6	Coronary artery calcification;
TGCT	cis	rs1552244	0.554	rs6762397	chr3:10007840	C/T	cg00149659	chr3:10157352	C3orf10	0.63	4.65	0.39	8.35e-6	Alzheimer's disease;
TGCT	cis	rs6087771	0.682	rs2038397	chr20:30217759	A/G	cg21427119	chr20:30132790	HM13	-0.3	-5.11	-0.42	1.18e-6	Subcortical brain region volumes;Putamen volume;
TGCT	cis	rs6570726	0.967	rs441364	chr6:145853662	G/C	cg05347473	chr6:146136440	FBXO30	0.49	4.45	0.37	1.88e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2637266	0.905	rs1907313	chr10:78338072	A/G	cg18941641	chr10:78392320	NA	0.42	5.45	0.44	2.62e-7	Pulmonary function;
TGCT	cis	rs1577917	1.000	rs7747824	chr6:86647106	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.05	-0.41	1.57e-6	Response to antipsychotic treatment;
TGCT	cis	rs700651	0.752	rs1850631	chr2:198829468	T/G	cg00792783	chr2:198669748	PLCL1	0.57	5.23	0.43	6.99e-7	Intracranial aneurysm;
TGCT	cis	rs1215050	0.791	rs6838628	chr4:98809574	A/G	cg17366294	chr4:99064904	C4orf37	0.51	5.55	0.45	1.67e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs40363	1.000	rs28401	chr16:3515354	C/G	cg22508957	chr16:3507546	NAT15	0.57	5.15	0.42	1.01e-6	Tuberculosis;
TGCT	cis	rs651907	0.557	rs56291106	chr3:101377474	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.03	0.41	1.65e-6	Colorectal cancer;
TGCT	cis	rs9611519	0.929	rs2064560	chr22:41530040	A/G	cg13695892	chr22:41940480	POLR3H	-0.51	-4.48	-0.37	1.69e-5	Neuroticism;
TGCT	cis	rs453301	0.658	rs6983877	chr8:8904639	T/C	cg06636001	chr8:8085503	FLJ10661	-0.69	-5.59	-0.45	1.37e-7	Joint mobility (Beighton score);
TGCT	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg17178900	chr1:205818956	PM20D1	0.56	7.03	0.53	1.2e-10	Menarche (age at onset);
TGCT	cis	rs2688608	0.592	rs10762559	chr10:75486453	G/C	cg19442545	chr10:75533431	FUT11	-0.37	-5.77	-0.46	5.93e-8	Inflammatory bowel disease;
TGCT	cis	rs2013441	1.000	rs2703816	chr17:20118887	A/G	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.61	-0.38	9.96e-6	Obesity-related traits;
TGCT	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg12311346	chr5:56204834	C5orf35	-0.67	-6.82	-0.52	3.63e-10	Initial pursuit acceleration;
TGCT	cis	rs10858047	0.883	rs72698011	chr1:115093654	T/C	cg12756093	chr1:115239321	AMPD1	0.45	4.63	0.38	9.24e-6	Autism;
TGCT	cis	rs62244186	0.541	rs3804583	chr3:44884647	G/T	cg21672276	chr3:44754072	ZNF502	-0.55	-6.37	-0.5	3.41e-9	Depressive symptoms;
TGCT	cis	rs854765	0.647	rs721669	chr17:18005073	A/G	cg04398451	chr17:18023971	MYO15A	-0.37	-6.46	-0.5	2.14e-9	Total body bone mineral density;
TGCT	cis	rs9457247	0.967	rs1794696	chr6:167396174	T/C	cg25258033	chr6:167368657	RNASET2	0.2	4.82	0.4	4.09e-6	Crohn's disease;
TGCT	cis	rs4074961	0.527	rs10908355	chr1:38035286	G/T	cg17933807	chr1:38061675	GNL2	1.05	15.81	0.82	1.69e-31	Axial length;
TGCT	cis	rs9325144	0.647	rs11168741	chr12:38989120	C/T	cg10518543	chr12:38710700	ALG10B	-0.48	-4.57	-0.38	1.17e-5	Morning vs. evening chronotype;
TGCT	cis	rs3751972	0.697	rs4063521	chr17:26220355	G/T	cg02948944	chr17:26242737	NA	0.33	4.79	0.4	4.63e-6	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs8072100	0.688	rs7221224	chr17:45419061	T/G	cg08085267	chr17:45401833	C17orf57	0.46	5.05	0.41	1.51e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs4850410	0.626	rs7582411	chr2:197912886	A/G	cg19149314	chr2:197065128	HECW2	0.22	4.53	0.38	1.37e-5	Interferon alpha levels in systemic lupus erythematosus;
TGCT	cis	rs2289583	0.517	rs2004278	chr15:75264363	C/T	cg10253484	chr15:75165896	SCAMP2	0.56	5.0	0.41	1.87e-6	Systemic lupus erythematosus;
TGCT	trans	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg17830980	chr10:43048298	ZNF37B	-0.87	-11.3	-0.71	8.72e-21	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7681440	0.728	rs974711	chr4:90737327	G/A	cg14346243	chr4:90757452	SNCA	-0.54	-5.1	-0.42	1.24e-6	Dementia with Lewy bodies;
TGCT	cis	rs3960554	0.808	rs11983987	chr7:75657850	A/G	cg17325771	chr7:75508891	RHBDD2	-0.51	-4.74	-0.39	5.87e-6	Eotaxin levels;
TGCT	cis	rs6540559	0.673	rs17015330	chr1:210012795	T/G	cg22029157	chr1:209979665	IRF6	0.71	5.09	0.42	1.3e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.01	8.32	0.6	1.34e-13	Platelet count;
TGCT	cis	rs7542091	0.813	rs2049999	chr1:210031331	A/G	cg23283495	chr1:209979779	IRF6	0.47	4.76	0.39	5.32e-6	Monobrow;
TGCT	cis	rs2404602	0.684	rs62026898	chr15:76944371	C/A	cg23625390	chr15:77176239	SCAPER	-0.36	-4.62	-0.38	9.3e-6	Blood metabolite levels;
TGCT	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2439831	1.000	rs527921	chr15:43770416	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	-1.0	-7.35	-0.55	2.38e-11	Lung cancer in ever smokers;
TGCT	cis	rs7647973	1.000	rs7647973	chr3:49510931	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.59	-4.67	-0.39	7.6e-6	Menarche (age at onset);
TGCT	cis	rs72781680	0.898	rs72782117	chr2:24026921	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	5.84	0.46	4.22e-8	Lymphocyte counts;
TGCT	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg05368731	chr17:41323189	NBR1	1.07	12.07	0.73	1.17e-22	Menopause (age at onset);
TGCT	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg18402987	chr7:1209562	NA	0.65	5.32	0.43	4.65e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs67478160	0.643	rs11624184	chr14:104240998	A/G	cg26031613	chr14:104095156	KLC1	-0.61	-6.28	-0.49	5.19e-9	Schizophrenia;
TGCT	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg03517284	chr6:25882590	NA	-0.52	-5.28	-0.43	5.67e-7	Blood metabolite levels;
TGCT	cis	rs6570726	0.764	rs9399553	chr6:145873664	A/T	cg13319975	chr6:146136371	FBXO30	-0.51	-4.6	-0.38	1.01e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9486719	0.948	rs2472881	chr6:96862562	C/T	cg18709589	chr6:96969512	KIAA0776	0.71	5.21	0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs11931598	0.513	rs3857170	chr4:7003366	A/T	cg26116260	chr4:7069785	GRPEL1	0.59	5.48	0.44	2.32e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs4319547	0.956	rs7397990	chr12:123119472	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.66	-5.32	-0.43	4.62e-7	Body mass index;
TGCT	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg17971929	chr21:40555470	PSMG1	0.98	9.47	0.65	2.42e-16	Cognitive function;
TGCT	cis	rs6906287	0.625	rs7764280	chr6:118692514	A/G	cg21191810	chr6:118973309	C6orf204	0.26	4.47	0.37	1.74e-5	Electrocardiographic conduction measures;
TGCT	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg24549020	chr5:56110836	MAP3K1	0.67	5.78	0.46	5.74e-8	Initial pursuit acceleration;
TGCT	cis	rs9443189	0.570	rs485906	chr6:76300550	A/C	cg01950844	chr6:76311363	SENP6	0.95	5.98	0.47	2.16e-8	Prostate cancer;
TGCT	cis	rs1372520	0.577	rs1811443	chr4:90747883	G/C	cg15133208	chr4:90757351	SNCA	-0.5	-5.86	-0.47	4e-8	Neuroticism;
TGCT	cis	rs1008375	0.932	rs6841784	chr4:17626418	G/A	cg18681998	chr4:17616180	MED28	1.0	10.26	0.68	2.93e-18	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7044106	0.762	rs10818471	chr9:123394045	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	5.08	0.41	1.37e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs1949733	0.701	rs940134	chr4:8454870	C/T	cg13073564	chr4:8508604	NA	-0.42	-4.61	-0.38	9.77e-6	Response to antineoplastic agents;
TGCT	cis	rs35374984	0.920	rs7897595	chr10:30234930	C/T	cg22629853	chr10:30638455	MTPAP	-0.58	-5.36	-0.43	3.99e-7	Emphysema distribution in smoking;
TGCT	cis	rs12950390	0.853	rs17773010	chr17:45858297	C/T	cg24803719	chr17:45855879	NA	-0.5	-5.12	-0.42	1.15e-6	IgG glycosylation;
TGCT	cis	rs3008870	0.755	rs10749766	chr1:67376921	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.8	8.46	0.61	6.24e-14	Lymphocyte percentage of white cells;
TGCT	cis	rs28595532	0.920	rs55901549	chr4:119770172	T/A	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs9527	0.615	rs7899622	chr10:104727333	C/T	cg04362960	chr10:104952993	NT5C2	0.66	5.55	0.45	1.66e-7	Arsenic metabolism;
TGCT	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg13397359	chr6:42928475	GNMT	0.82	7.87	0.58	1.5e-12	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs4727027	0.901	rs11760293	chr7:148811725	A/G	cg23583168	chr7:148888333	NA	-0.72	-9.16	-0.64	1.34e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs950027	0.787	rs1547487	chr15:45723983	A/G	cg14582100	chr15:45693742	SPATA5L1	0.39	4.89	0.4	3.01e-6	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs981844	0.857	rs62325141	chr4:154716407	A/G	cg14289246	chr4:154710475	SFRP2	1.05	8.88	0.62	6.23e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs6500602	0.653	rs4786488	chr16:4442527	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.28	4.51	0.38	1.49e-5	Schizophrenia;
TGCT	cis	rs3125734	0.571	rs7100401	chr10:64024417	C/G	cg05499367	chr10:63213510	TMEM26	-0.33	-4.47	-0.37	1.77e-5	Rheumatoid arthritis;
TGCT	cis	rs7605378	1.000	rs7577763	chr2:200681753	C/T	cg23649088	chr2:200775458	C2orf69	0.35	5.83	0.46	4.53e-8	Osteoporosis;
TGCT	cis	rs9467773	0.620	rs9461276	chr6:26595168	T/C	cg09904177	chr6:26538194	HMGN4	0.67	6.32	0.49	4.25e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs4819852	0.958	rs2238786	chr22:19975444	A/G	cg07821417	chr22:19972146	ARVCF	0.19	4.79	0.4	4.7e-6	Pulse pressure;
TGCT	cis	rs4654899	0.571	rs34530426	chr1:21085204	C/T	cg01072550	chr1:21505969	NA	-0.54	-8.85	-0.62	7.34e-15	Superior frontal gyrus grey matter volume;
TGCT	cis	rs7824557	0.564	rs13260727	chr8:11232860	A/G	cg21775007	chr8:11205619	TDH	0.52	4.94	0.41	2.5e-6	Retinal vascular caliber;
TGCT	cis	rs9467711	0.516	rs1324088	chr6:25841122	C/T	cg03517284	chr6:25882590	NA	-0.7	-4.65	-0.39	8.22e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1497406	0.744	rs12057175	chr1:16508375	A/G	cg20430773	chr1:16534157	ARHGEF19	0.54	6.27	0.49	5.36e-9	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1629083	0.935	rs1715453	chr11:118125077	T/C	cg16594165	chr11:118135105	MPZL2	-0.33	-4.62	-0.38	9.6e-6	Lung cancer;
TGCT	cis	rs6674176	0.660	rs3791112	chr1:44379248	T/G	cg13606994	chr1:44402422	ARTN	-0.49	-5.4	-0.44	3.22e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs1799899	1.000	rs1799899	chr3:133475812	G/A	cg18342939	chr3:134203408	ANAPC13;CEP63	0.5	4.56	0.38	1.22e-5	Alcohol consumption (transferrin glycosylation);
TGCT	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	5.87	0.47	3.72e-8	Bipolar disorder;
TGCT	cis	rs3947	0.906	rs1692821	chr8:11699988	C/T	cg02840367	chr8:11660030	FDFT1	1.0	8.13	0.59	3.82e-13	Blood protein levels;
TGCT	cis	rs7412746	0.611	rs66847267	chr1:150875173	C/A	cg09365446	chr1:150670422	GOLPH3L	0.34	4.71	0.39	6.58e-6	Melanoma;
TGCT	cis	rs7192750	0.586	rs2335714	chr16:71897926	A/G	cg06353428	chr16:71660113	MARVELD3	0.7	6.23	0.49	6.71e-9	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs3096299	0.685	rs3803682	chr16:89544636	C/T	cg06640241	chr16:89574553	SPG7	0.8	9.11	0.63	1.79e-15	Multiple myeloma (IgH translocation);
TGCT	cis	rs12142240	0.698	rs1135460	chr1:46815970	T/C	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs6500602	0.701	rs1362626	chr16:4549226	C/G	cg08645402	chr16:4508243	NA	0.21	5.31	0.43	4.99e-7	Schizophrenia;
TGCT	cis	rs2016266	0.859	rs2886129	chr12:53731984	G/A	cg16917193	chr12:54089295	NA	0.68	4.55	0.38	1.25e-5	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs7917772	0.503	rs11191342	chr10:104344450	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.8	8.21	0.59	2.44e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs881375	0.900	rs1008383	chr9:123683579	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	5.43	0.44	2.89e-7	Rheumatoid arthritis;
TGCT	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	8.0	0.58	7.67e-13	Platelet count;
TGCT	cis	rs933688	1.000	rs10041402	chr5:90738948	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.0	8.64	0.61	2.4e-14	Smoking behavior;
TGCT	cis	rs7927592	0.546	rs683978	chr11:68192421	T/C	cg16797656	chr11:68205561	LRP5	0.29	4.97	0.41	2.16e-6	Total body bone mineral density;
TGCT	trans	rs2727020	0.554	rs7111711	chr11:49557880	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.42	-8.63	-0.61	2.5e-14	Coronary artery disease;
TGCT	cis	rs9788682	1.000	rs7164594	chr15:78803057	C/T	cg06917634	chr15:78832804	PSMA4	-0.68	-4.98	-0.41	2.11e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs6088580	0.668	rs1205337	chr20:32926041	T/A	cg08999081	chr20:33150536	PIGU	-0.25	-4.85	-0.4	3.66e-6	Glomerular filtration rate (creatinine);
TGCT	trans	rs9830388	0.625	rs4241512	chr3:23379199	T/A	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	RR interval (tricyclic/tetracyclic antidepressant use interaction);
TGCT	cis	rs9611565	0.559	rs8139993	chr22:41995335	T/C	cg06481639	chr22:41940642	POLR3H	-0.62	-5.26	-0.43	6.21e-7	Vitiligo;
TGCT	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg19901468	chr14:105411992	AHNAK2	-0.25	-5.89	-0.47	3.45e-8	Rheumatoid arthritis;
TGCT	cis	rs4319547	0.697	rs7974262	chr12:122896385	C/T	cg05707623	chr12:122985044	ZCCHC8	0.63	4.94	0.41	2.46e-6	Body mass index;
TGCT	cis	rs854765	0.583	rs4925126	chr17:17798633	C/T	cg09796270	chr17:17721594	SREBF1	0.24	4.7	0.39	6.94e-6	Total body bone mineral density;
TGCT	cis	rs7647973	1.000	rs13322887	chr3:49555583	G/A	cg05785598	chr3:49045655	WDR6	-0.38	-4.6	-0.38	1.02e-5	Menarche (age at onset);
TGCT	trans	rs3780486	0.846	rs7849148	chr9:33138352	A/T	cg20290983	chr6:43655470	MRPS18A	1.2	14.83	0.8	3.07e-29	IgG glycosylation;
TGCT	cis	rs6540559	0.546	rs735693	chr1:210033988	A/C	cg22029157	chr1:209979665	IRF6	0.85	6.39	0.5	3.1e-9	Cleft lip with or without cleft palate;
TGCT	cis	rs9926296	0.581	rs12598477	chr16:89902482	T/C	cg03388025	chr16:89894329	SPIRE2	0.35	5.21	0.42	7.63e-7	Vitiligo;
TGCT	cis	rs12477438	0.520	rs6717723	chr2:99756930	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.06	13.28	0.77	1.43e-25	Chronic sinus infection;
TGCT	cis	rs7829975	0.514	rs2979151	chr8:8258019	A/G	cg08975724	chr8:8085496	FLJ10661	-0.55	-5.06	-0.41	1.47e-6	Mood instability;
TGCT	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg08509172	chr19:19383838	TM6SF2	0.34	4.52	0.38	1.4e-5	Tonsillectomy;
TGCT	cis	rs28595532	0.920	rs55668908	chr4:119769799	C/T	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg18230493	chr5:56204884	C5orf35	-0.67	-5.88	-0.47	3.5e-8	Initial pursuit acceleration;
TGCT	cis	rs2766692	0.956	rs35696661	chr14:100742355	G/C	cg14866419	chr14:100704911	YY1	0.59	4.68	0.39	7.52e-6	Electroencephalographic traits in alcoholism;
TGCT	cis	rs6831352	0.734	rs2851259	chr4:100033986	C/T	cg12011299	chr4:100065546	ADH4	0.39	5.2	0.42	8.04e-7	Alcohol dependence;
TGCT	cis	rs3617	0.539	rs9985365	chr3:52953844	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	0.47	4.63	0.38	9.24e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs3793917	0.948	rs3750848	chr10:124215315	A/C	cg09507567	chr10:124027408	NA	0.38	4.71	0.39	6.62e-6	Age-related macular degeneration;
TGCT	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg19748678	chr4:122722346	EXOSC9	0.9	9.1	0.63	1.85e-15	Type 2 diabetes;
TGCT	cis	rs1215050	0.782	rs6853916	chr4:98653387	C/T	cg17366294	chr4:99064904	C4orf37	-0.52	-5.51	-0.44	1.97e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7824557	0.527	rs2736305	chr8:11237773	T/C	cg21775007	chr8:11205619	TDH	-0.7	-6.8	-0.52	3.92e-10	Retinal vascular caliber;
TGCT	cis	rs6570726	0.577	rs403345	chr6:145845171	T/C	cg05347473	chr6:146136440	FBXO30	0.61	5.63	0.45	1.15e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9457247	1.000	rs408040	chr6:167398903	A/T	cg23791538	chr6:167370224	RNASET2	-0.49	-4.96	-0.41	2.26e-6	Crohn's disease;
TGCT	cis	rs8180040	0.966	rs11914795	chr3:47557722	G/A	cg27129171	chr3:47204927	SETD2	0.62	7.36	0.55	2.26e-11	Colorectal cancer;
TGCT	cis	rs1865760	0.964	rs6932113	chr6:25913098	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.65	6.24	0.49	6.27e-9	Height;
TGCT	cis	rs6912958	0.558	rs9444530	chr6:88343318	C/T	cg06598631	chr6:88300029	RARS2;ORC3L	0.57	5.04	0.41	1.6e-6	Monocyte percentage of white cells;
TGCT	cis	rs2066819	1.000	rs80317430	chr12:56727705	G/A	cg26714650	chr12:56694279	CS	-1.36	-6.06	-0.48	1.54e-8	Psoriasis vulgaris;
TGCT	trans	rs17685	0.753	rs12531559	chr7:75631697	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.5	-8.43	-0.6	7.38e-14	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs6582630	0.502	rs2204008	chr12:38439203	C/T	cg13010199	chr12:38710504	ALG10B	0.57	4.46	0.37	1.79e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs11190604	1.000	rs7090431	chr10:102261753	A/G	cg23241863	chr10:102295624	HIF1AN	0.7	5.38	0.43	3.59e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2562456	0.876	rs2681395	chr19:21738140	T/C	cg25650185	chr19:21324782	ZNF431	-0.64	-5.73	-0.46	7.12e-8	Pain;
TGCT	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg03806693	chr22:41940476	POLR3H	1.15	13.16	0.76	2.69e-25	Vitiligo;
TGCT	cis	rs344364	0.511	rs1742395	chr16:1955965	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.47	-5.43	-0.44	2.8e-7	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs9549367	0.756	rs2302756	chr13:113900197	G/A	cg00898013	chr13:113819073	PROZ	0.4	4.94	0.41	2.48e-6	Platelet distribution width;
TGCT	cis	rs17376456	0.825	rs13156202	chr5:93157721	C/T	cg25358565	chr5:93447407	FAM172A	-0.9	-8.07	-0.59	5.24e-13	Diabetic retinopathy;
TGCT	cis	rs6754311	0.517	rs60453613	chr2:136527120	G/C	cg07169764	chr2:136633963	MCM6	0.89	7.96	0.58	9.17e-13	Mosquito bite size;
TGCT	cis	rs12210905	0.688	rs72845027	chr6:27528199	T/C	cg08851530	chr6:28072375	NA	1.34	6.29	0.49	5.02e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs758129	0.501	rs2238297	chr15:89875066	G/A	cg24365117	chr15:89879190	POLG	0.33	4.63	0.38	8.94e-6	Schizophrenia;
TGCT	cis	rs61990749	0.597	rs2267768	chr14:78216014	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.62	4.58	0.38	1.13e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs11190604	1.000	rs11190604	chr10:102302457	A/G	cg16342193	chr10:102329863	NA	-0.43	-5.32	-0.43	4.69e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9291683	0.588	rs17247314	chr4:10004743	C/G	cg11266682	chr4:10021025	SLC2A9	0.66	9.71	0.66	6.54e-17	Bone mineral density;
TGCT	cis	rs2458413	0.563	rs2458422	chr8:105332817	C/T	cg13045555	chr8:105342365	NA	-0.39	-6.6	-0.51	1.05e-9	Paget's disease;
TGCT	cis	rs9394841	0.667	rs10807268	chr6:41777591	A/T	cg08135965	chr6:41755394	TOMM6	0.55	5.15	0.42	9.77e-7	Mean corpuscular hemoglobin;Red cell distribution width;
TGCT	cis	rs9649213	0.614	rs59120980	chr7:98017730	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.94	-8.9	-0.62	5.66e-15	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs17076896	0.786	rs61956073	chr13:19931292	C/T	cg00777926	chr13:20807375	GJB6	-0.37	-4.51	-0.38	1.5e-5	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs7647973	0.593	rs4855885	chr3:49690199	G/A	cg03034192	chr3:50606346	HEMK1;C3orf18	0.37	4.81	0.4	4.32e-6	Menarche (age at onset);
TGCT	cis	rs782590	0.643	rs13009906	chr2:55739434	A/G	cg18811423	chr2:55921094	PNPT1	-0.61	-6.3	-0.49	4.71e-9	Metabolic syndrome;
TGCT	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs4523957	0.651	rs4790316	chr17:2074977	T/C	cg16513277	chr17:2031491	SMG6	-0.2	-4.62	-0.38	9.44e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs1635	0.655	rs723476	chr6:28305104	C/T	cg15743358	chr6:28303923	ZNF323	-1.29	-6.5	-0.5	1.73e-9	Schizophrenia;
TGCT	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg11494091	chr17:61959527	GH2	0.44	7.34	0.55	2.52e-11	Height;
TGCT	cis	rs1577917	0.837	rs806529	chr6:86467121	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-5.18	-0.42	8.84e-7	Response to antipsychotic treatment;
TGCT	cis	rs36051895	0.589	rs17492549	chr9:5202830	A/C	cg02405213	chr9:5042618	JAK2	-0.7	-8.49	-0.61	5.46e-14	Pediatric autoimmune diseases;
TGCT	trans	rs941408	0.963	rs2537855	chr19:2806574	A/G	cg22153745	chr1:153894579	GATAD2B	-0.71	-6.9	-0.53	2.37e-10	Total cholesterol levels;
TGCT	cis	rs11031096	0.683	rs10835729	chr11:4210847	T/C	cg18678763	chr11:4115507	RRM1	-0.45	-5.77	-0.46	6.11e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs9399135	0.967	rs1854865	chr6:135360300	C/G	cg24558204	chr6:135376177	HBS1L	0.46	4.56	0.38	1.23e-5	Red blood cell count;
TGCT	cis	rs3008870	0.920	rs3008860	chr1:67391003	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.1	12.09	0.74	1.01e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs7044106	0.762	rs966397	chr9:123453312	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	6.34	0.49	3.94e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg03517284	chr6:25882590	NA	-0.53	-5.43	-0.44	2.88e-7	Blood metabolite levels;
TGCT	trans	rs10504390	0.656	rs78912269	chr8:66511446	C/T	cg07799219	chr22:43901523	MPPED1	-0.71	-6.88	-0.53	2.67e-10	IgG glycosylation;
TGCT	cis	rs9393777	0.513	rs9368448	chr6:26649355	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.63	-5.75	-0.46	6.58e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs709400	0.663	rs72710714	chr14:103981849	T/G	cg26031613	chr14:104095156	KLC1	0.87	9.32	0.64	5.5e-16	Body mass index;
TGCT	cis	rs8070740	0.617	rs9908179	chr17:5323631	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.64	6.22	0.49	7.1e-9	Menopause (age at onset);
TGCT	trans	rs4332037	0.851	rs10268609	chr7:1962163	A/C	cg10840412	chr1:235813424	GNG4	1.07	8.91	0.62	5.31e-15	Bipolar disorder;
TGCT	cis	rs12134245	0.776	rs61548854	chr1:92001536	C/T	cg25838465	chr1:92012736	NA	-0.41	-6.57	-0.51	1.23e-9	Breast cancer;
TGCT	cis	rs3862435	0.518	rs2601170	chr15:90914209	C/T	cg14166756	chr15:90894880	ZNF774	-0.32	-5.07	-0.41	1.4e-6	Response to exercise (triglyceride level interaction);
TGCT	cis	rs4851266	1.000	rs12619178	chr2:100838157	C/T	cg22139774	chr2:100720529	AFF3	-0.34	-5.09	-0.42	1.28e-6	Educational attainment;
TGCT	cis	rs6088590	0.561	rs2295444	chr20:33173883	C/T	cg08999081	chr20:33150536	PIGU	0.25	4.99	0.41	1.97e-6	Coronary artery disease;
TGCT	cis	rs2836950	0.501	rs2836985	chr21:40701169	A/G	cg11890956	chr21:40555474	PSMG1	-0.64	-5.97	-0.47	2.38e-8	Menarche (age at onset);
TGCT	cis	rs9400467	0.537	rs73530951	chr6:111484814	G/A	cg15721981	chr6:111408429	SLC16A10	0.69	4.5	0.37	1.56e-5	Blood metabolite levels;Amino acid levels;
TGCT	cis	rs7017914	1.000	rs13253842	chr8:71625503	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.55	-5.13	-0.42	1.11e-6	Bone mineral density;
TGCT	cis	rs6545883	0.929	rs1186707	chr2:61673520	C/A	cg15711740	chr2:61764176	XPO1	-0.51	-4.62	-0.38	9.42e-6	Tuberculosis;
TGCT	cis	rs3540	0.960	rs8040585	chr15:91026477	T/C	cg22089800	chr15:90895588	ZNF774	0.77	7.25	0.55	4.02e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs9916302	0.904	rs600010	chr17:37433517	T/C	cg15445000	chr17:37608096	MED1	0.32	4.69	0.39	7.11e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs35306767	0.622	rs66462130	chr10:1022108	C/T	cg20503657	chr10:835505	NA	0.58	6.48	0.5	1.92e-9	Eosinophil percentage of granulocytes;
TGCT	cis	rs10186029	0.676	rs35922168	chr2:213949018	T/C	cg08319019	chr2:214017104	IKZF2	0.62	5.76	0.46	6.13e-8	Systemic sclerosis;
TGCT	cis	rs1797081	1.000	rs2603807	chr10:16872797	A/G	cg14835575	chr10:16859367	RSU1	0.4	4.61	0.38	9.76e-6	Platelet distribution width;
TGCT	cis	rs7666738	0.830	rs11097608	chr4:99011693	T/C	cg17366294	chr4:99064904	C4orf37	0.71	7.17	0.54	5.92e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg02725872	chr8:58115012	NA	-0.38	-5.16	-0.42	9.32e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs908922	0.651	rs4845442	chr1:152485545	G/A	cg20991723	chr1:152506922	NA	0.48	6.68	0.51	7.04e-10	Hair morphology;
TGCT	cis	rs7246657	0.722	rs10409605	chr19:38123137	T/G	cg18154014	chr19:37997991	ZNF793	0.69	4.67	0.39	7.7e-6	Coronary artery calcification;
TGCT	cis	rs3771570	1.000	rs62193171	chr2:242276523	C/A	cg21155796	chr2:242212141	HDLBP	0.98	6.68	0.51	7.29e-10	Prostate cancer;
TGCT	cis	rs72781680	0.948	rs72796385	chr2:24170360	T/A	cg08917208	chr2:24149416	ATAD2B	0.73	4.51	0.38	1.48e-5	Lymphocyte counts;
TGCT	cis	rs2180341	0.814	rs9401959	chr6:127736464	T/C	cg24812749	chr6:127587940	RNF146	0.76	6.22	0.49	7.07e-9	Breast cancer;
TGCT	cis	rs801193	0.548	rs2659904	chr7:66178602	C/A	cg18876405	chr7:65276391	NA	0.34	4.92	0.4	2.7e-6	Aortic root size;
TGCT	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg08280861	chr8:58055591	NA	0.36	4.8	0.4	4.43e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg01802117	chr1:53393560	SCP2	-0.42	-5.25	-0.43	6.33e-7	Monocyte count;
TGCT	cis	rs3858526	0.959	rs1840179	chr11:5949148	A/G	cg05234568	chr11:5960015	NA	-0.48	-4.77	-0.39	5.08e-6	DNA methylation (variation);
TGCT	cis	rs7209700	0.962	rs56327427	chr17:45354746	C/T	cg21624342	chr17:45890973	OSBPL7	0.18	5.1	0.42	1.25e-6	IgG glycosylation;
TGCT	cis	rs7246657	1.000	rs1529957	chr19:37739801	A/G	cg18154014	chr19:37997991	ZNF793	0.68	4.69	0.39	6.97e-6	Coronary artery calcification;
TGCT	cis	rs9447004	0.557	rs2173854	chr6:74426775	T/A	cg23004174	chr6:74404879	CD109	0.21	4.53	0.38	1.37e-5	Blood protein levels;Calcium levels;
TGCT	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg12756686	chr19:29218302	NA	0.69	6.7	0.52	6.51e-10	Methadone dose in opioid dependence;
TGCT	cis	rs1008375	0.932	rs6449321	chr4:17644472	A/G	cg18681998	chr4:17616180	MED28	1.05	12.0	0.73	1.69e-22	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2268241	0.938	rs2268242	chr21:34781104	C/T	cg14850771	chr21:34775459	IFNGR2	0.61	5.23	0.43	6.88e-7	Obesity-related traits;
TGCT	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg02353165	chr6:42928485	GNMT	0.94	9.64	0.65	9.69e-17	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs9926296	0.715	rs2115401	chr16:89740609	A/G	cg04287289	chr16:89883240	FANCA	0.51	4.96	0.41	2.29e-6	Vitiligo;
TGCT	cis	rs902774	0.597	rs7299694	chr12:53352572	A/C	cg14581129	chr12:53358946	NA	-0.56	-6.14	-0.48	1.05e-8	Prostate cancer;
TGCT	cis	rs826838	1.000	rs11514441	chr12:38775190	C/T	cg26384229	chr12:38710491	ALG10B	1.08	10.86	0.7	1.01e-19	Heart rate;
TGCT	cis	rs6121246	0.559	rs6060621	chr20:30261562	G/C	cg13852791	chr20:30311386	BCL2L1	0.82	8.0	0.58	7.65e-13	Mean corpuscular hemoglobin;
TGCT	cis	rs2228479	0.618	rs72477006	chr16:89950299	G/C	cg19635926	chr16:89946313	TCF25	0.29	4.81	0.4	4.3e-6	Skin colour saturation;
TGCT	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.49	-5.66	-0.45	9.81e-8	Longevity;Endometriosis;
TGCT	cis	rs7216064	0.906	rs78452260	chr17:65848522	G/T	cg12091567	chr17:66097778	LOC651250	-0.83	-6.49	-0.5	1.9e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg27454412	chr7:1067447	C7orf50	-0.48	-4.45	-0.37	1.91e-5	Bronchopulmonary dysplasia;
TGCT	cis	rs6087990	0.863	rs1569686	chr20:31367079	G/T	cg13636640	chr20:31349939	DNMT3B	1.08	14.22	0.79	8.35e-28	Ulcerative colitis;
TGCT	cis	rs1577917	0.958	rs7739241	chr6:86575796	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.16	-0.42	9.71e-7	Response to antipsychotic treatment;
TGCT	cis	rs2806561	0.514	rs7519093	chr1:23541078	A/T	cg19743168	chr1:23544995	NA	-0.47	-7.79	-0.57	2.32e-12	Height;
TGCT	cis	rs2980439	0.556	rs2921059	chr8:8317887	G/T	cg15556689	chr8:8085844	FLJ10661	0.7	6.45	0.5	2.3e-9	Neuroticism;
TGCT	cis	rs9911578	1.000	rs4482353	chr17:56896834	A/G	cg12560992	chr17:57184187	TRIM37	0.76	9.34	0.64	4.88e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs7752195	0.643	rs6940230	chr6:25247120	G/T	cg16898833	chr6:26189333	HIST1H4D	0.97	4.58	0.38	1.1e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12210905	1.000	rs1062834	chr6:27222539	A/G	cg08851530	chr6:28072375	NA	1.06	5.05	0.41	1.55e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs3806843	1.000	rs3756339	chr5:140180537	A/G	cg19875535	chr5:140030758	IK	0.37	6.34	0.49	3.89e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2404602	0.583	rs12907668	chr15:76589767	A/T	cg22467129	chr15:76604101	ETFA	-0.61	-7.93	-0.58	1.09e-12	Blood metabolite levels;
TGCT	cis	rs7949030	1.000	rs7949030	chr11:62394881	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.51	6.88	0.53	2.64e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2120019	0.935	rs8043181	chr15:75380424	T/C	cg17294928	chr15:75287854	SCAMP5	-0.87	-6.62	-0.51	9.65e-10	Blood trace element (Zn levels);
TGCT	cis	rs4372836	0.504	rs13009357	chr2:29041877	T/C	cg09522027	chr2:28974177	PPP1CB	-0.56	-5.68	-0.45	9.2e-8	Body mass index;
TGCT	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg03264133	chr6:25882463	NA	-0.73	-7.73	-0.57	3.2e-12	Blood metabolite levels;
TGCT	cis	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg18252515	chr7:66147081	NA	1.2	7.83	0.58	1.89e-12	Diabetic kidney disease;
TGCT	cis	rs17270561	0.541	rs12192932	chr6:25911502	A/G	cg17042849	chr6:26104293	HIST1H4C	-0.79	-5.76	-0.46	6.33e-8	Iron status biomarkers;
TGCT	cis	rs9633740	0.578	rs7084416	chr10:82304297	G/A	cg01528321	chr10:82214614	TSPAN14	-0.85	-5.28	-0.43	5.6e-7	Post bronchodilator FEV1;
TGCT	cis	rs265548	0.646	rs36692	chr19:17906839	C/T	cg16744531	chr19:17905626	B3GNT3	0.41	5.07	0.41	1.41e-6	Tumor biomarkers;
TGCT	cis	rs6433857	0.627	rs6741769	chr2:181500545	G/A	cg23363182	chr2:181467187	NA	-0.33	-5.08	-0.42	1.33e-6	Body mass index;
TGCT	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.29	-4.56	-0.38	1.19e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs3096299	0.658	rs34590044	chr16:89543157	A/C	cg06640241	chr16:89574553	SPG7	0.78	9.07	0.63	2.2e-15	Multiple myeloma (IgH translocation);
TGCT	cis	rs7617773	0.817	rs745116	chr3:48272536	T/G	cg11946769	chr3:48343235	NME6	0.72	6.23	0.49	6.77e-9	Coronary artery disease;
TGCT	cis	rs4700695	0.668	rs27961	chr5:65443352	A/C	cg21114390	chr5:65439923	SFRS12	-0.76	-6.52	-0.51	1.62e-9	Facial morphology (factor 19);
TGCT	trans	rs3780486	0.846	rs3780487	chr9:33139237	T/C	cg20290983	chr6:43655470	MRPS18A	1.2	14.83	0.8	3.07e-29	IgG glycosylation;
TGCT	cis	rs7267979	0.702	rs449801	chr20:25491847	C/T	cg16686733	chr20:25566563	NINL	0.49	4.74	0.39	5.84e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs546131	0.928	rs552627	chr11:34826680	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.66	6.03	0.48	1.74e-8	Lung disease severity in cystic fibrosis;
TGCT	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg08859206	chr1:53392774	SCP2	0.4	5.97	0.47	2.38e-8	Monocyte count;
TGCT	cis	rs2721195	0.816	rs4251689	chr8:145741130	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.88	9.57	0.65	1.4e-16	Age at first birth;
TGCT	cis	rs5769765	0.862	rs56377703	chr22:50306940	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.44	6.33	0.49	4.16e-9	Schizophrenia;
TGCT	cis	rs709400	0.628	rs2273699	chr14:103923475	A/G	cg12935359	chr14:103987150	CKB	-0.35	-5.38	-0.44	3.5e-7	Body mass index;
TGCT	cis	rs7020830	0.898	rs2047010	chr9:37077947	A/G	cg14294708	chr9:37120828	ZCCHC7	1.28	19.85	0.87	2.54e-40	Schizophrenia;
TGCT	cis	rs7772486	0.875	rs2777477	chr6:146305491	A/G	cg23711669	chr6:146136114	FBXO30	0.84	8.85	0.62	7.33e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9467773	1.000	rs10484442	chr6:26555879	A/G	cg15659132	chr6:26577336	NA	0.9	12.92	0.76	1.04e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs3741404	0.609	rs641430	chr11:63869531	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.72	-7.26	-0.55	3.77e-11	Platelet count;
TGCT	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg21017887	chr14:105400489	NA	0.36	5.14	0.42	1.04e-6	Rheumatoid arthritis;
TGCT	cis	rs68170813	0.559	rs77671232	chr7:106939202	A/G	cg02696742	chr7:106810147	HBP1	-0.69	-5.95	-0.47	2.61e-8	Coronary artery disease;
TGCT	cis	rs854624	0.892	rs1719194	chr17:34336054	C/G	cg02022384	chr17:34097390	MMP28	-0.45	-4.47	-0.37	1.73e-5	Blood protein levels;
TGCT	cis	rs12540874	0.698	rs13234331	chr7:50560314	G/T	cg18232548	chr7:50535776	DDC	-0.38	-6.53	-0.51	1.55e-9	Systemic sclerosis;
TGCT	cis	rs7584330	0.541	rs10202181	chr2:238352099	A/G	cg14458575	chr2:238380390	NA	0.51	7.51	0.56	1e-11	Prostate cancer;
TGCT	trans	rs459571	0.635	rs379471	chr9:136890649	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.72	-7.83	-0.58	1.87e-12	Platelet distribution width;
TGCT	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg23708337	chr7:1209742	NA	0.64	5.94	0.47	2.63e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2692947	0.537	rs1345917	chr2:96200603	A/C	cg23100626	chr2:96804247	ASTL	0.45	5.34	0.43	4.21e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg13607699	chr17:42295918	UBTF	0.59	5.4	0.44	3.23e-7	Total body bone mineral density;
TGCT	cis	rs2718812	0.792	rs1006098	chr3:133411605	G/T	cg16414030	chr3:133502952	NA	0.39	5.05	0.41	1.56e-6	Iron status biomarkers;
TGCT	cis	rs10883723	0.737	rs7074444	chr10:104249922	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs11153730	0.503	rs369383	chr6:118618400	T/A	cg21191810	chr6:118973309	C6orf204	0.27	4.55	0.38	1.27e-5	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
TGCT	cis	rs7523050	0.643	rs12741194	chr1:109400390	T/C	cg08274380	chr1:109419600	GPSM2	1.3	6.39	0.5	2.99e-9	Fat distribution (HIV);
TGCT	cis	rs10174077	0.687	rs10172023	chr2:152476028	C/G	cg19508488	chr2:152266495	RIF1	0.62	5.83	0.46	4.59e-8	Squamous cell lung carcinoma;
TGCT	cis	rs614226	0.872	rs12307148	chr12:120903179	T/C	cg01236616	chr12:121019343	POP5	-1.23	-12.24	-0.74	4.57e-23	Type 1 diabetes nephropathy;
TGCT	cis	rs3026101	0.671	rs3026109	chr17:5284480	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	-0.48	-4.71	-0.39	6.61e-6	Body mass index;
TGCT	cis	rs7666738	0.830	rs13108871	chr4:98803872	T/C	cg18180107	chr4:99064573	C4orf37	0.55	5.3	0.43	5e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7027203	0.828	rs3957506	chr9:96588133	C/T	cg14598338	chr9:96623480	NA	-0.62	-9.7	-0.66	6.89e-17	DNA methylation (variation);
TGCT	cis	rs4455778	0.580	rs4560745	chr7:49115412	G/T	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs7772486	0.875	rs7767660	chr6:146436550	T/C	cg23711669	chr6:146136114	FBXO30	0.87	9.27	0.64	7.2e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7666738	0.830	rs7662389	chr4:99019892	G/A	cg05340658	chr4:99064831	C4orf37	0.47	5.16	0.42	9.68e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4722166	0.597	rs2069845	chr7:22770149	G/A	cg05265849	chr7:22767390	IL6	0.23	4.54	0.38	1.32e-5	Lung cancer;
TGCT	cis	rs9733	0.650	rs3738485	chr1:150552392	C/G	cg13175981	chr1:150552382	MCL1	0.52	5.75	0.46	6.55e-8	Tonsillectomy;
TGCT	cis	rs7666738	0.830	rs2865977	chr4:99017916	C/T	cg18180107	chr4:99064573	C4orf37	0.54	5.03	0.41	1.71e-6	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs17685	0.672	rs56343450	chr7:75796235	C/T	cg19862616	chr7:65841803	NCRNA00174	0.51	8.88	0.62	6.28e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs7714584	0.793	rs11958146	chr5:150254158	A/G	cg22134413	chr5:150180641	NA	0.83	6.53	0.51	1.54e-9	Crohn's disease;
TGCT	cis	rs6582630	0.531	rs3850000	chr12:38483752	T/C	cg26384229	chr12:38710491	ALG10B	0.83	7.6	0.56	6.18e-12	Drug-induced liver injury (flucloxacillin);
TGCT	trans	rs1814175	0.817	rs6486044	chr11:49982718	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.36	-7.14	-0.54	6.88e-11	Height;
TGCT	cis	rs367943	1.000	rs1057827	chr5:112823768	T/C	cg12552261	chr5:112820674	MCC	0.24	4.91	0.4	2.81e-6	Type 2 diabetes;
TGCT	cis	rs4455778	0.580	rs34230450	chr7:49118157	T/C	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs7975161	0.565	rs4545635	chr12:104636844	A/C	cg25273343	chr12:104657179	TXNRD1	-0.35	-4.76	-0.39	5.28e-6	Toenail selenium levels;
TGCT	cis	rs644799	0.965	rs602512	chr11:95561682	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	10.66	0.69	3.18e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs12762955	0.561	rs1904671	chr10:1014603	G/A	cg26597838	chr10:835615	NA	-0.45	-6.15	-0.48	9.6e-9	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs10992471	0.528	rs7031567	chr9:95241363	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.53	-4.94	-0.41	2.47e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.54	-0.38	1.33e-5	Bipolar disorder;
TGCT	cis	rs72945132	0.882	rs58039907	chr11:70183336	C/T	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs7611238	0.560	rs2275518	chr3:195102787	T/C	cg27323046	chr3:195102265	ACAP2	0.37	5.01	0.41	1.81e-6	Body mass index;
TGCT	cis	rs6089829	0.888	rs4809465	chr20:61671156	G/C	cg18188782	chr20:61659543	NA	0.44	4.88	0.4	3.17e-6	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs910316	0.967	rs10246	chr14:75544470	T/A	cg11812906	chr14:75593930	NEK9	0.74	7.18	0.54	5.58e-11	Height;
TGCT	cis	rs36051895	0.664	rs12344629	chr9:5109208	C/T	cg02405213	chr9:5042618	JAK2	-0.71	-9.43	-0.65	3.07e-16	Pediatric autoimmune diseases;
TGCT	cis	rs1371867	0.846	rs1660330	chr8:101305015	T/A	cg06636551	chr8:101224915	SPAG1	-0.48	-6.52	-0.51	1.62e-9	Atrioventricular conduction;
TGCT	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg23708337	chr7:1209742	NA	0.56	5.1	0.42	1.25e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2147959	0.824	rs12542	chr1:228682330	C/G	cg22700015	chr1:228743131	NA	-0.63	-4.82	-0.4	4.2e-6	Adult asthma;
TGCT	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg11494091	chr17:61959527	GH2	-0.59	-16.13	-0.82	3.12e-32	Prudent dietary pattern;
TGCT	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg25036284	chr2:26402008	FAM59B	-0.57	-4.97	-0.41	2.15e-6	Gut microbiome composition (summer);
TGCT	cis	rs3540	0.618	rs11636089	chr15:91039527	C/T	cg22089800	chr15:90895588	ZNF774	0.75	7.58	0.56	7.16e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs2120019	0.608	rs4886414	chr15:75308650	C/T	cg09165964	chr15:75287851	SCAMP5	1.13	11.71	0.72	8.48e-22	Blood trace element (Zn levels);
TGCT	cis	rs644148	0.704	rs2686761	chr19:44989752	T/C	cg15540054	chr19:45004280	ZNF180	-0.6	-4.56	-0.38	1.23e-5	Personality dimensions;
TGCT	cis	rs60843830	0.661	rs11674325	chr2:105517	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.54	4.51	0.38	1.45e-5	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs2652822	0.530	rs7165016	chr15:63439590	T/A	cg12855773	chr15:63363890	TPM1	-0.19	-5.11	-0.42	1.16e-6	Metabolic traits;
TGCT	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg19748678	chr4:122722346	EXOSC9	0.87	9.24	0.64	8.52e-16	Type 2 diabetes;
TGCT	cis	rs7010267	0.596	rs4307369	chr8:120036953	A/G	cg17171407	chr8:119960777	TNFRSF11B	0.26	4.59	0.38	1.06e-5	Total body bone mineral density (age 45-60);
TGCT	cis	rs3020736	0.500	rs764481	chr22:42518426	G/A	cg05082376	chr22:42548792	NA	0.23	5.43	0.44	2.83e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs8017423	0.900	rs11625870	chr14:90693396	C/T	cg04374321	chr14:90722782	PSMC1	-0.76	-7.83	-0.58	1.9e-12	Mortality in heart failure;
TGCT	cis	rs9394438	0.628	rs2153947	chr6:37544930	A/G	cg00985040	chr6:37553208	NA	-0.25	-4.97	-0.41	2.18e-6	IgG glycosylation;
TGCT	cis	rs7267979	1.000	rs4815406	chr20:25341316	C/G	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg03303774	chr4:1407052	NA	0.38	6.07	0.48	1.45e-8	Obesity-related traits;
TGCT	cis	rs1903068	0.853	rs28411232	chr4:56000009	A/T	cg09978860	chr4:56023921	NA	0.57	6.47	0.5	2.1e-9	Endometriosis;
TGCT	cis	rs1878931	0.580	rs4785932	chr16:3410456	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.93	10.42	0.68	1.18e-18	Body mass index (adult);
TGCT	cis	rs10782582	0.609	rs2029680	chr1:76363505	A/C	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.52	4.48	0.37	1.66e-5	Daytime sleep phenotypes;
TGCT	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg24250549	chr1:154909240	PMVK	0.65	6.49	0.5	1.84e-9	Prostate cancer;
TGCT	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.56	-0.51	1.31e-9	Alzheimer's disease;
TGCT	cis	rs7523273	0.565	rs11118453	chr1:207887996	A/C	cg22525895	chr1:207977042	MIR29B2	0.35	5.75	0.46	6.66e-8	Schizophrenia;
TGCT	cis	rs9807989	0.507	rs10208196	chr2:102996345	G/A	cg03938978	chr2:103052716	IL18RAP	0.26	5.22	0.42	7.15e-7	Asthma;
TGCT	cis	rs4595586	0.505	rs12827467	chr12:39374014	A/G	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg16423285	chr20:60520624	NA	0.68	7.07	0.54	1.02e-10	Body mass index;
TGCT	trans	rs629535	0.773	rs569064	chr8:70065967	A/G	cg21567404	chr3:27674614	NA	0.57	9.11	0.63	1.82e-15	Dupuytren's disease;
TGCT	cis	rs7586879	0.681	rs6723803	chr2:25120713	G/C	cg01884057	chr2:25150051	NA	0.35	6.9	0.53	2.39e-10	Body mass index;
TGCT	cis	rs7959452	0.557	rs899224	chr12:69784774	A/G	cg20891283	chr12:69753455	YEATS4	0.83	8.7	0.62	1.68e-14	Blood protein levels;
TGCT	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg11941060	chr3:133502564	NA	-0.29	-6.21	-0.49	7.41e-9	Iron status biomarkers;
TGCT	cis	rs10791323	0.604	rs2853115	chr11:133707908	C/T	cg15485101	chr11:133734466	NA	-0.4	-5.2	-0.42	7.81e-7	Childhood ear infection;
TGCT	cis	rs854765	0.624	rs4925116	chr17:17731200	A/G	cg09796270	chr17:17721594	SREBF1	-0.24	-4.52	-0.38	1.42e-5	Total body bone mineral density;
TGCT	cis	rs6988636	1.000	rs57165742	chr8:124184559	G/A	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs6582630	0.519	rs2387812	chr12:38381480	A/G	cg26384229	chr12:38710491	ALG10B	0.81	7.13	0.54	7.23e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg13607699	chr17:42295918	UBTF	0.6	5.46	0.44	2.47e-7	Total body bone mineral density;
TGCT	cis	rs7829975	0.509	rs2945269	chr8:8115578	G/C	cg15556689	chr8:8085844	FLJ10661	0.68	6.42	0.5	2.65e-9	Mood instability;
TGCT	cis	rs1568889	0.838	rs1483858	chr11:28189639	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.92	10.94	0.7	6.46e-20	Bipolar disorder;
TGCT	cis	rs724767	1.000	rs724767	chr3:193722330	C/T	cg19410732	chr3:194305082	NA	-0.59	-4.58	-0.38	1.13e-5	Estradiol plasma levels (breast cancer);
TGCT	cis	rs9534288	0.699	rs9534320	chr13:46665572	A/G	cg15192986	chr13:46630673	CPB2	-0.51	-6.11	-0.48	1.19e-8	Blood protein levels;
TGCT	cis	rs9807989	0.507	rs3732124	chr2:103018052	A/G	cg03938978	chr2:103052716	IL18RAP	-0.26	-5.23	-0.42	7.11e-7	Asthma;
TGCT	cis	rs9914544	0.545	rs34417974	chr17:18773636	T/C	cg26378065	chr17:18585709	ZNF286B	0.53	4.63	0.38	9.02e-6	Educational attainment (years of education);
TGCT	cis	rs896854	0.738	rs2515226	chr8:95965743	G/A	cg23172400	chr8:95962367	TP53INP1	0.36	5.6	0.45	1.33e-7	Type 2 diabetes;
TGCT	cis	rs7119	0.651	rs12909292	chr15:77837982	G/T	cg27398640	chr15:77910606	LINGO1	-0.28	-5.12	-0.42	1.12e-6	Type 2 diabetes;
TGCT	cis	rs7824557	0.564	rs7821459	chr8:11236681	T/G	cg21775007	chr8:11205619	TDH	-0.65	-6.39	-0.5	3.07e-9	Retinal vascular caliber;
TGCT	cis	rs11098499	0.954	rs6838814	chr4:120392443	G/A	cg09307838	chr4:120376055	NA	0.69	6.56	0.51	1.31e-9	Corneal astigmatism;
TGCT	cis	rs10256972	0.514	rs2140578	chr7:1214003	T/C	cg17775962	chr7:1200435	ZFAND2A	0.31	5.2	0.42	8.11e-7	Longevity;Endometriosis;
TGCT	cis	rs589249	1.000	rs218989	chr1:37166715	G/T	cg04012535	chr1:37176647	NA	-0.31	-4.96	-0.41	2.28e-6	Neuroticism (multi-trait analysis);Schizophrenia;
TGCT	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg19774624	chr17:42201019	HDAC5	-0.89	-11.07	-0.7	3.17e-20	Total body bone mineral density;
TGCT	cis	rs10791323	0.660	rs10791330	chr11:133727535	C/T	cg15485101	chr11:133734466	NA	0.35	4.59	0.38	1.09e-5	Childhood ear infection;
TGCT	cis	rs2075371	1.000	rs2504	chr7:133979545	A/T	cg11752832	chr7:134001865	SLC35B4	0.69	6.32	0.49	4.19e-9	Mean platelet volume;
TGCT	cis	rs422249	0.547	rs174535	chr11:61551356	T/C	cg01500311	chr11:61656094	FADS3	-0.34	-5.66	-0.45	9.97e-8	Trans fatty acid levels;
TGCT	cis	rs9914988	0.887	rs11656272	chr17:27091153	A/G	cg20469991	chr17:27169893	C17orf63	-0.72	-5.04	-0.41	1.58e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs12971120	0.891	rs3794953	chr18:72180519	C/T	cg25817165	chr18:72167213	CNDP2	-0.27	-4.66	-0.39	7.94e-6	Refractive error;
TGCT	cis	rs849210	0.517	rs12468794	chr2:206190721	A/G	cg11793701	chr2:206547163	NRP2	-0.56	-4.5	-0.37	1.54e-5	Tonsillectomy;
TGCT	cis	rs6489785	0.509	rs4767937	chr12:121223244	G/C	cg02419362	chr12:121203948	SPPL3	0.19	4.47	0.37	1.74e-5	Longevity;Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs929596	0.614	rs10929302	chr2:234665782	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.34	-5.49	-0.44	2.13e-7	Total bilirubin levels in HIV-1 infection;
TGCT	cis	rs4242434	0.672	rs7830206	chr8:22485375	C/T	cg03733263	chr8:22462867	KIAA1967	0.98	12.7	0.75	3.48e-24	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs3812831	0.695	rs7995986	chr13:114938802	A/G	cg15513719	chr13:114904418	NA	0.36	4.51	0.38	1.46e-5	Schizophrenia;
TGCT	cis	rs12950390	0.853	rs11655336	chr17:45858836	A/G	cg06532163	chr17:45867833	NA	-0.36	-5.76	-0.46	6.14e-8	IgG glycosylation;
TGCT	cis	rs2562456	0.833	rs2968078	chr19:21641744	A/G	cg01304269	chr19:21688519	ZNF429	-0.6	-4.89	-0.4	3.07e-6	Pain;
TGCT	cis	rs7246657	0.722	rs2927746	chr19:38156570	G/A	cg03611452	chr19:38183253	ZNF781	-0.57	-4.79	-0.39	4.72e-6	Coronary artery calcification;
TGCT	cis	rs3125734	0.608	rs7094950	chr10:64019744	T/C	cg19640130	chr10:64028056	RTKN2	-0.4	-5.11	-0.42	1.17e-6	Rheumatoid arthritis;
TGCT	cis	rs10832169	0.967	rs4534565	chr11:14065598	C/T	cg04547675	chr11:13986162	SPON1	0.51	4.51	0.38	1.49e-5	Blood protein levels;
TGCT	trans	rs2243480	1.000	rs1618893	chr7:66096119	C/T	cg07424592	chr7:64974309	NA	1.37	7.99	0.58	7.88e-13	Diabetic kidney disease;
TGCT	cis	rs7216064	0.954	rs4790973	chr17:65951133	C/T	cg12091567	chr17:66097778	LOC651250	-0.82	-6.2	-0.49	7.54e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs739401	0.572	rs389285	chr11:3062673	G/A	cg25174290	chr11:3078921	CARS	0.47	4.51	0.38	1.49e-5	Longevity;
TGCT	cis	rs2645424	0.671	rs2294138	chr8:11705139	C/T	cg12568669	chr8:11666485	FDFT1	-0.35	-4.5	-0.37	1.52e-5	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
TGCT	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg23172400	chr8:95962367	TP53INP1	-0.38	-6.49	-0.5	1.84e-9	Type 2 diabetes;
TGCT	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.55	5.39	0.44	3.47e-7	Menarche (age at onset);
TGCT	cis	rs1059312	0.808	rs4760537	chr12:129301299	C/A	cg09035930	chr12:129282057	SLC15A4	0.56	10.49	0.69	8.05e-19	Systemic lupus erythematosus;
TGCT	cis	rs7833790	0.927	rs61020899	chr8:82757090	C/T	cg27398817	chr8:82754497	SNX16	0.84	6.06	0.48	1.52e-8	Diastolic blood pressure;
TGCT	cis	rs6429082	0.783	rs291365	chr1:235688043	A/G	cg26050004	chr1:235667680	B3GALNT2	0.64	5.99	0.47	2.13e-8	Adiposity;
TGCT	cis	rs832540	0.898	rs252890	chr5:56226410	T/C	cg12311346	chr5:56204834	C5orf35	-0.43	-4.58	-0.38	1.11e-5	Coronary artery disease;
TGCT	cis	rs4478037	0.822	rs9826234	chr3:33123832	A/C	cg19404215	chr3:33155277	CRTAP	0.98	5.13	0.42	1.1e-6	Major depressive disorder;
TGCT	cis	rs9910055	1.000	rs9910055	chr17:42283037	C/T	cg13607699	chr17:42295918	UBTF	0.82	7.0	0.53	1.41e-10	Total body bone mineral density;
TGCT	cis	rs9659323	1.000	rs10923715	chr1:119535334	A/T	cg07961512	chr1:119535619	NA	-0.44	-4.93	-0.4	2.57e-6	Body mass index;
TGCT	cis	rs11696501	0.688	rs6065866	chr20:44323440	G/A	cg11783356	chr20:44313418	WFDC10B	-0.33	-4.49	-0.37	1.6e-5	Brain structure;
TGCT	cis	rs10782582	0.593	rs11163967	chr1:76154185	T/C	cg10523679	chr1:76189770	ACADM	-0.69	-7.19	-0.54	5.26e-11	Daytime sleep phenotypes;
TGCT	cis	rs7659604	0.521	rs4833773	chr4:122689245	C/T	cg19748678	chr4:122722346	EXOSC9	-0.56	-5.53	-0.44	1.79e-7	Type 2 diabetes;
TGCT	cis	rs10751667	0.643	rs10902234	chr11:935578	A/G	cg06064525	chr11:970664	AP2A2	-0.35	-8.28	-0.6	1.65e-13	Alzheimer's disease (late onset);
TGCT	cis	rs3733585	0.673	rs4467564	chr4:9953472	G/T	cg11266682	chr4:10021025	SLC2A9	-0.57	-7.6	-0.56	6.21e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg24250549	chr1:154909240	PMVK	0.64	6.48	0.5	1.95e-9	Prostate cancer;
TGCT	trans	rs57221529	0.766	rs56278696	chr5:582669	A/G	cg25482853	chr8:67687455	SGK3	1.2	10.12	0.67	6.42e-18	Lung disease severity in cystic fibrosis;
TGCT	cis	rs12497850	0.931	rs6446253	chr3:48911443	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.41	-5.49	-0.44	2.15e-7	Parkinson's disease;
TGCT	cis	rs751728	0.664	rs943474	chr6:33749834	G/C	cg13859433	chr6:33739653	LEMD2	-0.32	-5.67	-0.45	9.47e-8	Crohn's disease;
TGCT	cis	rs9787249	0.957	rs7548120	chr1:40204424	A/T	cg20968010	chr1:40505947	CAP1	-0.53	-5.0	-0.41	1.91e-6	Blood protein levels;
TGCT	cis	rs12477438	0.765	rs12470471	chr2:99689141	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.74	7.5	0.56	1.04e-11	Chronic sinus infection;
TGCT	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg06618935	chr21:46677482	NA	-0.38	-4.86	-0.4	3.44e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs860295	0.529	rs1475766	chr1:155981489	C/G	cg05700447	chr1:155978627	NA	-0.19	-4.75	-0.39	5.44e-6	Body mass index;
TGCT	cis	rs9611565	0.546	rs2092274	chr22:42123737	A/G	cg06481639	chr22:41940642	POLR3H	0.71	6.48	0.5	1.95e-9	Vitiligo;
TGCT	cis	rs11718455	0.618	rs35351588	chr3:43926386	C/G	cg08738300	chr3:44038990	NA	0.8	5.29	0.43	5.45e-7	Coronary artery disease;
TGCT	cis	rs2204008	0.837	rs7301679	chr12:37989629	T/C	cg26384229	chr12:38710491	ALG10B	-0.7	-6.12	-0.48	1.11e-8	Bladder cancer;
TGCT	cis	rs593531	0.571	rs11236088	chr11:74094343	A/G	cg25592907	chr11:73676012	DNAJB13	0.35	4.94	0.41	2.48e-6	Neuroticism;
TGCT	cis	rs11586313	0.649	rs61815701	chr1:152887412	G/A	cg07796016	chr1:152779584	LCE1C	-0.46	-5.14	-0.42	1.06e-6	Vitamin D levels;
TGCT	cis	rs7666738	0.791	rs13120773	chr4:98972589	C/T	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg18188782	chr20:61659543	NA	0.44	5.37	0.43	3.73e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg11494091	chr17:61959527	GH2	0.43	7.37	0.55	2.07e-11	Height;
TGCT	cis	rs739496	0.579	rs10774640	chr12:112295190	T/C	cg10833066	chr12:111807467	FAM109A	0.41	6.14	0.48	1.02e-8	Platelet count;
TGCT	cis	rs5769765	1.000	rs5770755	chr22:50280136	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	-0.39	-5.79	-0.46	5.34e-8	Schizophrenia;
TGCT	cis	rs6484504	0.532	rs10835757	chr11:31281902	C/T	cg14844989	chr11:31128820	NA	-0.26	-5.0	-0.41	1.9e-6	Red blood cell count;
TGCT	cis	rs1406084	0.636	rs12476730	chr2:154719309	C/T	cg25703346	chr2:154729189	GALNT13	0.77	4.6	0.38	1.03e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4664293	0.836	rs13421392	chr2:160658296	G/A	cg00829656	chr2:159791884	NA	0.24	4.53	0.38	1.37e-5	Monocyte percentage of white cells;
TGCT	trans	rs3848445	1.000	rs7214411	chr17:14288990	C/T	cg07670188	chr12:124066860	NA	0.98	7.16	0.54	6.35e-11	Protein quantitative trait loci;
TGCT	cis	rs6752107	0.901	rs11687982	chr2:234149039	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.2	4.79	0.4	4.61e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs55692411	0.537	rs71326904	chr3:49991060	C/T	cg14019146	chr3:50243930	SLC38A3	-0.21	-4.44	-0.37	1.98e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.753	rs7659724	chr4:98944063	C/T	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6964587	0.967	rs28399886	chr7:91638451	A/G	cg22709100	chr7:91322751	NA	0.27	4.48	0.37	1.68e-5	Breast cancer;
TGCT	cis	rs9467773	1.000	rs4713008	chr6:26538268	T/C	cg15659132	chr6:26577336	NA	0.86	12.21	0.74	5.3e-23	Intelligence (multi-trait analysis);
TGCT	trans	rs1499614	1.000	rs2141924	chr7:66186246	C/T	cg07424592	chr7:64974309	NA	1.35	8.11	0.59	4.14e-13	Gout;
TGCT	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg03517284	chr6:25882590	NA	-0.62	-5.65	-0.45	1.03e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs13064411	0.696	rs7613546	chr3:113228019	G/A	cg10517650	chr3:113235015	CCDC52	-0.32	-4.45	-0.37	1.85e-5	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg12310025	chr6:25882481	NA	-0.61	-5.39	-0.44	3.38e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs17473412	0.864	rs1864046	chr5:122740921	G/T	cg15125798	chr5:122621645	NA	-0.55	-4.9	-0.4	2.9e-6	Total body bone mineral density;
TGCT	cis	rs2204008	0.744	rs11168870	chr12:37973333	A/G	cg13010199	chr12:38710504	ALG10B	0.65	5.29	0.43	5.47e-7	Bladder cancer;
TGCT	cis	rs7552404	0.889	rs1250874	chr1:76190978	A/G	cg10523679	chr1:76189770	ACADM	0.85	9.49	0.65	2.17e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs12643440	0.538	rs2041444	chr4:17138005	A/C	cg22650099	chr4:17144496	NA	-0.46	-4.66	-0.39	8.14e-6	Metabolite levels (Pyroglutamine);
TGCT	cis	rs6964587	1.000	rs9691325	chr7:91731047	G/A	cg22709100	chr7:91322751	NA	0.29	4.81	0.4	4.28e-6	Breast cancer;
TGCT	cis	rs881375	1.000	rs10760118	chr9:123641616	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	5.52	0.44	1.92e-7	Rheumatoid arthritis;
TGCT	cis	rs2948294	0.588	rs12544596	chr8:8116346	A/T	cg15556689	chr8:8085844	FLJ10661	0.75	6.41	0.5	2.81e-9	Red cell distribution width;
TGCT	cis	rs2404602	0.583	rs2456076	chr15:76557553	T/G	cg22467129	chr15:76604101	ETFA	0.64	8.34	0.6	1.2e-13	Blood metabolite levels;
TGCT	cis	rs739496	0.579	rs7296199	chr12:112291844	T/C	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs9443645	0.869	rs11754419	chr6:79729648	A/G	cg09184832	chr6:79620586	NA	-0.48	-5.34	-0.43	4.21e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs28785552	0.897	rs10424736	chr19:53239176	G/A	cg04754360	chr19:53238445	ZNF611	-0.71	-5.64	-0.45	1.11e-7	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg22963979	chr7:1858916	MAD1L1	-0.31	-4.78	-0.39	4.9e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs2836950	0.527	rs2836948	chr21:40599677	T/C	cg06238570	chr21:40685208	BRWD1	-0.6	-6.21	-0.49	7.27e-9	Menarche (age at onset);
TGCT	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg00149659	chr3:10157352	C3orf10	0.92	5.88	0.47	3.58e-8	Alzheimer's disease;
TGCT	cis	rs2404602	0.692	rs58361452	chr15:76973372	T/C	cg22467129	chr15:76604101	ETFA	-0.45	-5.11	-0.42	1.2e-6	Blood metabolite levels;
TGCT	cis	rs13191362	1.000	rs36042757	chr6:163004744	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.57	4.94	0.41	2.45e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs1670533	1.000	rs12645644	chr4:1054159	C/T	cg27284194	chr4:1044797	NA	0.65	5.96	0.47	2.41e-8	Recombination rate (females);
TGCT	cis	rs1577917	0.771	rs2842609	chr6:86296788	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.58	-0.45	1.43e-7	Response to antipsychotic treatment;
TGCT	cis	rs4930561	0.714	rs11228151	chr11:67949371	C/G	cg04465784	chr11:67976953	SUV420H1	-0.38	-5.47	-0.44	2.37e-7	Breast cancer in childhood cancer survivors;IgG glycosylation;
TGCT	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg10802521	chr3:52805072	NEK4	-0.71	-8.81	-0.62	9.29e-15	Bipolar disorder;
TGCT	cis	rs231513	0.813	rs231495	chr17:41976748	G/C	cg26893861	chr17:41843967	DUSP3	-0.71	-5.33	-0.43	4.45e-7	Cognitive function;
TGCT	cis	rs2361710	0.668	rs4889830	chr17:78114528	G/A	cg09238746	chr17:78121135	EIF4A3	-0.76	-7.24	-0.55	4.14e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
TGCT	cis	rs713587	0.525	rs11675457	chr2:25079770	C/T	cg01884057	chr2:25150051	NA	0.3	5.78	0.46	5.69e-8	Body mass index in non-asthmatics;
TGCT	trans	rs2688608	0.530	rs71507081	chr10:75493136	G/A	cg13918328	chr10:52500089	ASAH2B	0.68	6.7	0.52	6.48e-10	Inflammatory bowel disease;
TGCT	cis	rs78487399	0.764	rs12473987	chr2:43812180	G/A	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.66	4.67	0.39	7.66e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs4819852	0.958	rs758374	chr22:19971552	T/C	cg07821417	chr22:19972146	ARVCF	0.21	5.37	0.43	3.81e-7	Pulse pressure;
TGCT	cis	rs11718455	0.920	rs4682927	chr3:44033299	C/A	cg08738300	chr3:44038990	NA	0.86	6.57	0.51	1.23e-9	Coronary artery disease;
TGCT	cis	rs17345786	1.000	rs997739	chr3:101313940	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.56	4.81	0.4	4.21e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9325144	0.647	rs1875609	chr12:39018259	C/T	cg10518543	chr12:38710700	ALG10B	-0.5	-4.8	-0.4	4.45e-6	Morning vs. evening chronotype;
TGCT	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg27121462	chr16:89883253	FANCA	0.78	8.52	0.61	4.57e-14	Vitiligo;
TGCT	cis	rs4824093	0.610	rs73443906	chr22:50274293	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.48	4.97	0.41	2.17e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs7980687	0.506	rs1611973	chr12:123622731	C/G	cg00376283	chr12:123451042	ABCB9	0.84	7.66	0.57	4.68e-12	Height;Educational attainment;Head circumference (infant);
TGCT	cis	rs7945705	0.714	rs2653570	chr11:8987823	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.43	-4.79	-0.4	4.65e-6	Hemoglobin concentration;
TGCT	cis	rs1401999	0.966	rs2292998	chr3:183663833	T/C	cg01324343	chr3:183735012	ABCC5	0.82	10.97	0.7	5.56e-20	Anterior chamber depth;
TGCT	cis	rs7843479	0.582	rs11135743	chr8:21803008	A/G	cg17168535	chr8:21777572	XPO7	0.8	7.91	0.58	1.23e-12	Mean corpuscular volume;
TGCT	cis	rs7513165	0.935	rs2510	chr1:204161591	T/C	cg04791601	chr1:204159016	NA	0.26	5.21	0.42	7.78e-7	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
TGCT	cis	rs2120019	0.938	rs2304903	chr15:75315778	A/G	cg09165964	chr15:75287851	SCAMP5	-1.14	-10.33	-0.68	2.05e-18	Blood trace element (Zn levels);
TGCT	cis	rs35883536	0.647	rs1995142	chr1:101041174	G/A	cg10298815	chr1:101004474	GPR88	0.25	4.66	0.39	8.05e-6	Monocyte count;
TGCT	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg18538332	chr22:24372958	LOC391322	-1.02	-13.27	-0.77	1.51e-25	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs10782582	0.609	rs5745331	chr1:76273313	A/G	cg03433033	chr1:76189801	ACADM	-0.5	-4.95	-0.41	2.39e-6	Daytime sleep phenotypes;
TGCT	cis	rs2996428	0.667	rs16824230	chr1:3766240	A/G	cg13057898	chr1:3703894	LRRC47	0.21	4.61	0.38	9.9e-6	Red cell distribution width;
TGCT	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9807989	0.839	rs13392100	chr2:102982094	C/A	cg09003973	chr2:102972529	NA	0.67	6.03	0.48	1.75e-8	Asthma;
TGCT	cis	rs1691799	0.867	rs1168343	chr12:66758581	C/T	cg16791601	chr12:66731901	HELB	-0.29	-6.18	-0.49	8.39e-9	White blood cell count (basophil);
TGCT	cis	rs10883723	0.669	rs2001595	chr10:104395085	C/T	cg05855489	chr10:104503620	C10orf26	-0.57	-4.69	-0.39	7.15e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs75686122	0.772	rs78303485	chr8:104552916	G/A	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs4478037	1.000	rs59622575	chr3:33162249	A/C	cg19404215	chr3:33155277	CRTAP	1.33	8.79	0.62	1.04e-14	Major depressive disorder;
TGCT	cis	rs2228479	0.867	rs62056110	chr16:89946388	A/C	cg04013166	chr16:89971882	TCF25	0.32	4.46	0.37	1.84e-5	Skin colour saturation;
TGCT	cis	rs7647973	0.626	rs9829155	chr3:49817450	T/C	cg03060546	chr3:49711283	APEH	-0.63	-5.63	-0.45	1.12e-7	Menarche (age at onset);
TGCT	trans	rs7615952	0.736	rs13063122	chr3:125643860	G/A	cg07211511	chr3:129823064	LOC729375	-0.48	-8.0	-0.58	7.7e-13	Blood pressure (smoking interaction);
TGCT	cis	rs6754311	0.731	rs2236783	chr2:136594158	G/A	cg07169764	chr2:136633963	MCM6	-0.61	-5.57	-0.45	1.53e-7	Mosquito bite size;
TGCT	cis	rs7666738	0.861	rs28829607	chr4:98964325	G/C	cg05340658	chr4:99064831	C4orf37	0.53	5.93	0.47	2.85e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3733585	0.673	rs4467563	chr4:9953460	A/T	cg11266682	chr4:10021025	SLC2A9	-0.57	-7.6	-0.56	6.21e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-1.06	-14.78	-0.8	3.86e-29	Menarche (age at onset);
TGCT	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg19626725	chr5:178986131	RUFY1	0.55	7.64	0.57	5.16e-12	Lung cancer;
TGCT	cis	rs56104184	0.775	rs17272707	chr19:49404535	T/G	cg21252483	chr19:49399788	TULP2	-0.42	-5.89	-0.47	3.47e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg01874867	chr7:94954059	PON1	-0.34	-4.98	-0.41	2.05e-6	Paraoxonase activity;
TGCT	cis	rs7666738	0.830	rs34916200	chr4:98851593	C/T	cg18180107	chr4:99064573	C4orf37	0.55	5.14	0.42	1.03e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9302065	0.681	rs9524903	chr13:95963565	A/G	cg26751094	chr13:95954534	ABCC4	-0.34	-5.38	-0.44	3.57e-7	Blood metabolite levels;
TGCT	cis	rs80282103	0.867	rs11819178	chr10:1098417	A/G	cg08668510	chr10:1095578	IDI1	1.12	4.65	0.39	8.28e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs3617	0.652	rs7630552	chr3:52891570	G/C	cg10802521	chr3:52805072	NEK4	0.62	7.17	0.54	6.08e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4746818	1.000	rs6480383	chr10:70890482	C/T	cg04149295	chr10:70884716	VPS26A	0.79	5.4	0.44	3.22e-7	Left atrial antero-posterior diameter;
TGCT	cis	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg08045932	chr20:61659980	NA	0.48	9.16	0.64	1.36e-15	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs78487399	0.908	rs17031116	chr2:43833013	A/G	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.66	4.69	0.39	7.06e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs7943191	0.768	rs34065644	chr11:62371938	C/T	cg11742103	chr11:62369870	EML3;MTA2	0.55	6.35	0.5	3.71e-9	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs9818758	0.607	rs67060340	chr3:48915321	C/T	cg00383909	chr3:49044727	WDR6	1.26	6.52	0.51	1.58e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs1215050	0.791	rs783969	chr4:98906504	C/T	cg17366294	chr4:99064904	C4orf37	0.53	5.65	0.45	1.03e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg26668828	chr6:292823	DUSP22	-0.83	-8.57	-0.61	3.38e-14	Menopause (age at onset);
TGCT	cis	rs7772486	0.875	rs6909827	chr6:146365738	A/G	cg05347473	chr6:146136440	FBXO30	0.52	4.93	0.41	2.54e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1460583	1.000	rs34311536	chr8:106105905	A/G	cg13963735	chr8:106810858	ZFPM2	0.27	4.5	0.37	1.53e-5	Schizophrenia;
TGCT	cis	rs7909074	0.831	rs7903412	chr10:45382361	C/T	cg04218760	chr10:45406644	TMEM72	-0.29	-5.63	-0.45	1.15e-7	Mean corpuscular volume;
TGCT	cis	rs11031096	0.655	rs12293706	chr11:4211581	C/G	cg18678763	chr11:4115507	RRM1	-0.45	-5.77	-0.46	6.11e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs2857078	0.720	rs9901595	chr17:42305699	G/A	cg13607699	chr17:42295918	UBTF	0.96	10.81	0.7	1.38e-19	Red cell distribution width;Reticulocyte count;
TGCT	cis	rs2456568	0.802	rs10831139	chr11:93640537	G/A	cg26875233	chr11:93583750	C11orf90	-0.48	-6.35	-0.5	3.73e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs916888	0.610	rs199444	chr17:44818276	T/C	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.64	4.91	0.4	2.82e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg13342137	chr4:2252803	MXD4	0.17	4.47	0.37	1.71e-5	Obesity-related traits;
TGCT	cis	rs911186	0.679	rs67330695	chr6:27103654	G/A	cg16898833	chr6:26189333	HIST1H4D	0.79	4.76	0.39	5.31e-6	Autism spectrum disorder or schizophrenia;
TGCT	trans	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg17830980	chr10:43048298	ZNF37B	-0.83	-10.39	-0.68	1.4e-18	Extrinsic epigenetic age acceleration;
TGCT	cis	rs6586163	0.872	rs7914490	chr10:90747447	A/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.38	-4.78	-0.39	4.79e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs9355610	0.727	rs2247315	chr6:167370211	A/C	cg23791538	chr6:167370224	RNASET2	0.63	6.04	0.48	1.64e-8	Graves' disease;
TGCT	cis	rs950027	0.620	rs1145076	chr15:45684508	G/T	cg14582100	chr15:45693742	SPATA5L1	0.46	5.9	0.47	3.31e-8	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs6988636	1.000	rs16898084	chr8:124190377	A/T	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	trans	rs1864729	1.000	rs2567769	chr8:98297848	G/A	cg08679828	chr8:102218111	ZNF706	-1.05	-7.0	-0.53	1.44e-10	Estradiol plasma levels (breast cancer);
TGCT	cis	rs7027203	0.521	rs9299412	chr9:96523268	G/T	cg14598338	chr9:96623480	NA	-0.49	-7.04	-0.53	1.18e-10	DNA methylation (variation);
TGCT	cis	rs988712	0.705	rs879048	chr11:27638934	A/C	cg10635145	chr11:27742435	BDNF	-0.35	-4.81	-0.4	4.34e-6	Obesity;
TGCT	cis	rs79349575	0.783	rs318090	chr17:46991752	G/A	cg26022315	chr17:47021804	SNF8	0.49	4.89	0.4	3.03e-6	Type 2 diabetes;
TGCT	cis	rs4906332	0.966	rs59858038	chr14:103867102	C/T	cg26031613	chr14:104095156	KLC1	-0.51	-4.65	-0.39	8.49e-6	Coronary artery disease;
TGCT	cis	rs7572733	0.576	rs4850441	chr2:198913413	A/G	cg00792783	chr2:198669748	PLCL1	-0.59	-5.15	-0.42	1.01e-6	Dermatomyositis;
TGCT	cis	rs28830936	0.510	rs12440605	chr15:42102285	A/G	cg17847044	chr15:42102381	MAPKBP1	0.18	5.12	0.42	1.13e-6	Diastolic blood pressure;
TGCT	cis	rs3796352	1.000	rs13072395	chr3:52980573	T/C	cg15956490	chr3:53032818	SFMBT1	0.61	6.11	0.48	1.17e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs6088590	0.930	rs6087618	chr20:33288407	C/T	cg24642439	chr20:33292090	TP53INP2	0.68	6.23	0.49	6.81e-9	Coronary artery disease;
TGCT	cis	rs74233809	1.000	rs17115213	chr10:104681143	A/G	cg05855489	chr10:104503620	C10orf26	0.74	4.45	0.37	1.87e-5	Birth weight;
TGCT	cis	rs72634258	0.945	rs12740409	chr1:8027830	A/C	cg23986158	chr1:8847014	RERE	0.29	4.63	0.38	9.17e-6	Inflammatory bowel disease;
TGCT	cis	rs1205863	1.000	rs1205864	chr6:11943595	A/G	cg07106625	chr6:11870215	NA	0.51	5.05	0.41	1.51e-6	Disc degeneration (lumbar);
TGCT	cis	rs933688	0.938	rs10063683	chr5:90714595	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.02	8.35	0.6	1.17e-13	Smoking behavior;
TGCT	cis	rs2404602	0.716	rs17363713	chr15:76746128	G/C	cg22467129	chr15:76604101	ETFA	-0.57	-6.83	-0.52	3.31e-10	Blood metabolite levels;
TGCT	cis	rs6570726	0.967	rs7772286	chr6:145930423	A/T	cg05347473	chr6:146136440	FBXO30	-0.53	-4.86	-0.4	3.45e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7917772	0.582	rs10883738	chr10:104321721	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	5.36	0.43	3.84e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg02953382	chr22:24373134	LOC391322	-0.79	-8.29	-0.6	1.55e-13	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7662987	0.517	rs2851256	chr4:100039549	G/A	cg12011299	chr4:100065546	ADH4	0.39	4.81	0.4	4.36e-6	Smoking initiation;
TGCT	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg04944784	chr2:26401820	FAM59B	0.76	6.24	0.49	6.46e-9	Gut microbiome composition (summer);
TGCT	cis	rs112591243	0.685	rs74671132	chr21:47963485	T/C	cg10657630	chr21:48055338	PRMT2	1.03	4.64	0.38	8.57e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs9381040	0.610	rs6940356	chr6:41020360	C/T	cg03526776	chr6:41159608	TREML2	0.27	5.27	0.43	5.78e-7	Alzheimer's disease (late onset);
TGCT	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	0.45	5.49	0.44	2.22e-7	Alzheimer's disease;
TGCT	cis	rs7772486	0.720	rs9403757	chr6:146261271	C/T	cg05347473	chr6:146136440	FBXO30	-0.51	-4.95	-0.41	2.32e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs13190036	1.000	rs13167431	chr5:176621075	G/C	cg18465082	chr5:176734745	MXD3	0.32	4.44	0.37	1.95e-5	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
TGCT	cis	rs17122693	0.818	rs72681645	chr14:51155209	G/A	cg04730355	chr14:51134070	SAV1	1.18	8.37	0.6	1.02e-13	Cognitive performance;
TGCT	cis	rs765787	0.505	rs4439707	chr15:45524216	G/A	cg24006582	chr15:45444508	DUOX1	0.24	5.29	0.43	5.3e-7	Uric acid levels;
TGCT	cis	rs2242116	0.796	rs7623898	chr3:46974172	C/T	cg27129171	chr3:47204927	SETD2	-0.65	-6.37	-0.5	3.28e-9	Birth weight;
TGCT	trans	rs2688608	0.672	rs2633321	chr10:75693695	C/T	cg13918328	chr10:52500089	ASAH2B	0.7	7.15	0.54	6.73e-11	Inflammatory bowel disease;
TGCT	cis	rs6809651	0.524	rs79262908	chr3:185803594	C/T	cg00760338	chr3:185826511	ETV5	-0.79	-6.45	-0.5	2.23e-9	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
TGCT	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg10802521	chr3:52805072	NEK4	-0.78	-10.0	-0.67	1.26e-17	Electroencephalogram traits;
TGCT	cis	rs11711311	0.955	rs78029398	chr3:113421321	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.68	-6.01	-0.48	1.89e-8	IgG glycosylation;
TGCT	cis	rs1372520	0.684	rs1811442	chr4:90747751	C/T	cg01966878	chr4:90757139	SNCA	-0.3	-4.76	-0.39	5.2e-6	Neuroticism;
TGCT	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	5.8	0.46	5.19e-8	Alzheimer's disease;
TGCT	cis	rs10540	1.000	rs12421457	chr11:505780	T/C	cg03934478	chr11:495069	RNH1	0.35	5.77	0.46	6.03e-8	Body mass index;
TGCT	cis	rs10493773	0.630	rs3753790	chr1:86174772	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.52	-8.15	-0.59	3.45e-13	Urate levels in overweight individuals;
TGCT	cis	rs67340775	0.541	rs200966	chr6:27862152	T/C	cg26587870	chr6:27730563	NA	-0.31	-4.48	-0.37	1.67e-5	Lung cancer in ever smokers;
TGCT	cis	rs9859260	0.744	rs539816	chr3:195784076	T/A	cg02975922	chr3:195473998	MUC4	0.25	5.1	0.42	1.24e-6	Mean corpuscular volume;
TGCT	cis	rs2204008	0.630	rs1283300	chr12:38150227	C/T	cg26384229	chr12:38710491	ALG10B	-0.58	-5.08	-0.42	1.33e-6	Bladder cancer;
TGCT	cis	rs10875595	0.836	rs7703869	chr5:140666494	C/T	cg24830062	chr5:140700576	TAF7	-0.6	-5.08	-0.42	1.34e-6	Pulmonary function decline;
TGCT	cis	rs11690462	0.963	rs6748996	chr2:26590084	T/G	cg04726446	chr2:26624865	C2orf39	0.44	4.73	0.39	5.97e-6	Coronary artery disease;
TGCT	cis	rs2718812	0.766	rs10935071	chr3:133394159	T/C	cg08048268	chr3:133502702	NA	-0.38	-4.7	-0.39	6.68e-6	Iron status biomarkers;
TGCT	cis	rs4372836	0.729	rs6547873	chr2:28981983	G/A	cg09522027	chr2:28974177	PPP1CB	-0.68	-6.93	-0.53	2e-10	Body mass index;
TGCT	cis	rs7267979	0.966	rs2227892	chr20:25264814	T/C	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7674212	0.556	rs6533039	chr4:103859538	A/G	cg16532752	chr4:104119610	CENPE	-0.6	-5.31	-0.43	4.86e-7	Type 2 diabetes;
TGCT	cis	rs8179	0.593	rs7804722	chr7:92288106	C/T	cg15732164	chr7:92237376	CDK6	0.27	4.77	0.39	5e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
TGCT	cis	rs9911578	0.813	rs12452313	chr17:57129882	C/A	cg12560992	chr17:57184187	TRIM37	-0.79	-8.78	-0.62	1.1e-14	Intelligence (multi-trait analysis);
TGCT	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg15383120	chr6:291909	DUSP22	-0.67	-6.91	-0.53	2.3e-10	Menopause (age at onset);
TGCT	cis	rs4808199	1.000	rs12977524	chr19:19568244	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.72	5.15	0.42	9.94e-7	Nonalcoholic fatty liver disease;
TGCT	cis	rs611744	0.967	rs641820	chr8:109190717	T/C	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs308447	0.516	rs732676	chr4:123717476	T/C	cg10495464	chr4:123653540	BBS12;LOC729338	0.63	5.93	0.47	2.78e-8	Perceived unattractiveness to mosquitoes;
TGCT	cis	rs9549367	0.789	rs2302757	chr13:113909339	A/G	cg18105134	chr13:113819100	PROZ	-0.34	-5.58	-0.45	1.41e-7	Platelet distribution width;
TGCT	cis	rs9436747	0.641	rs3790424	chr1:66044013	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.52	4.65	0.39	8.37e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs3020736	0.500	rs2413669	chr22:42507748	A/C	cg15557168	chr22:42548783	NA	0.22	5.58	0.45	1.47e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9916302	0.808	rs6503515	chr17:37606433	G/T	cg07936489	chr17:37558343	FBXL20	-0.62	-4.91	-0.4	2.85e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs367943	1.000	rs348944	chr5:112822925	C/T	cg12552261	chr5:112820674	MCC	-0.24	-4.91	-0.4	2.81e-6	Type 2 diabetes;
TGCT	cis	rs9303542	0.559	rs12602539	chr17:46617459	T/A	cg25032089	chr17:46643351	HOXB3	0.56	5.34	0.43	4.22e-7	Ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs6500602	0.826	rs9932461	chr16:4454170	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.43	6.47	0.5	2.03e-9	Schizophrenia;
TGCT	cis	rs6121246	0.609	rs2376998	chr20:30340663	T/C	cg13852791	chr20:30311386	BCL2L1	0.84	8.15	0.59	3.38e-13	Mean corpuscular hemoglobin;
TGCT	cis	rs62064224	0.702	rs2302277	chr17:30791509	C/G	cg25809561	chr17:30822961	MYO1D	0.3	5.2	0.42	7.96e-7	Schizophrenia;
TGCT	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg26818010	chr10:134567672	INPP5A	-0.35	-4.94	-0.41	2.48e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs2579519	0.547	rs11683523	chr2:96544855	T/C	cg13655245	chr2:97463316	CNNM4	0.15	4.51	0.38	1.51e-5	Diastolic blood pressure;
TGCT	cis	rs3026101	0.671	rs8081480	chr17:5282761	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.47	4.52	0.38	1.41e-5	Body mass index;
TGCT	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg04608855	chr19:58913158	NA	0.58	5.69	0.46	8.64e-8	Uric acid clearance;
TGCT	cis	rs1371867	0.817	rs1660315	chr8:101332956	G/A	cg06002616	chr8:101225028	SPAG1	-0.56	-6.58	-0.51	1.2e-9	Atrioventricular conduction;
TGCT	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg25036284	chr2:26402008	FAM59B	-0.56	-4.88	-0.4	3.2e-6	Gut microbiome composition (summer);
TGCT	cis	rs9443189	0.570	rs504446	chr6:76326939	T/C	cg01950844	chr6:76311363	SENP6	0.99	6.27	0.49	5.49e-9	Prostate cancer;
TGCT	cis	rs367615	0.704	rs72802966	chr5:108846754	T/G	cg17395555	chr5:108820864	NA	0.31	5.72	0.46	7.47e-8	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs12291225	0.679	rs7934671	chr11:14305101	C/T	cg19336497	chr11:14380999	RRAS2	-0.38	-5.9	-0.47	3.23e-8	Sense of smell;
TGCT	cis	rs7819412	0.564	rs10503415	chr8:10983921	C/G	cg21775007	chr8:11205619	TDH	-0.59	-5.58	-0.45	1.45e-7	Triglycerides;
TGCT	cis	rs651907	0.513	rs34963630	chr3:101504817	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.31	-6.4	-0.5	2.91e-9	Colorectal cancer;
TGCT	cis	rs6540559	1.000	rs1044516	chr1:209959614	G/T	cg22029157	chr1:209979665	IRF6	0.77	6.34	0.5	3.81e-9	Cleft lip with or without cleft palate;
TGCT	cis	rs3845702	0.736	rs3845701	chr2:180826781	A/G	cg01881094	chr2:180872142	CWC22	-1.05	-6.78	-0.52	4.27e-10	Schizophrenia;
TGCT	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9682041	0.800	rs7643085	chr3:170070371	A/G	cg11886554	chr3:170076028	SKIL	0.71	5.62	0.45	1.2e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs7100689	0.598	rs2342815	chr10:82086532	T/C	cg01528321	chr10:82214614	TSPAN14	0.75	7.49	0.56	1.15e-11	Post bronchodilator FEV1;
TGCT	cis	rs1552244	0.688	rs9875667	chr3:10180041	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.36	-5.46	-0.44	2.54e-7	Alzheimer's disease;
TGCT	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.68	5.62	0.45	1.18e-7	Tonsillectomy;
TGCT	cis	rs9915657	0.660	rs2241170	chr17:70070989	G/C	cg06234051	chr17:70120541	SOX9	-0.25	-5.3	-0.43	5.03e-7	Thyroid hormone levels;
TGCT	cis	rs56104184	0.779	rs73061627	chr19:49360418	C/T	cg21252483	chr19:49399788	TULP2	-0.39	-4.94	-0.41	2.43e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs12142240	0.698	rs17361950	chr1:46864150	C/T	cg14993813	chr1:46806288	NSUN4	-0.61	-4.99	-0.41	1.97e-6	Menopause (age at onset);
TGCT	cis	rs933688	1.000	rs11948075	chr5:90680579	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.02	8.42	0.6	7.91e-14	Smoking behavior;
TGCT	cis	rs6688613	0.840	rs6695609	chr1:166953866	A/C	cg07049167	chr1:166818506	POGK	-0.26	-5.18	-0.42	8.56e-7	Refractive astigmatism;
TGCT	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.1	0.42	1.24e-6	Menopause (age at onset);
TGCT	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.33	-5.2	-0.42	7.9e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs4953076	0.573	rs2054005	chr2:44401843	C/T	cg00619915	chr2:44497795	NA	-0.22	-4.97	-0.41	2.16e-6	Height;
TGCT	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg20007245	chr22:24372913	LOC391322	0.76	6.29	0.49	4.92e-9	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs17221829	0.899	rs10160328	chr11:89462164	A/G	cg02982614	chr11:89391479	FOLH1B	-0.3	-5.29	-0.43	5.47e-7	Anxiety in major depressive disorder;
TGCT	cis	rs11648796	0.757	rs763206	chr16:770103	C/G	cg27144592	chr16:783916	NARFL	0.38	5.42	0.44	3.03e-7	Height;
TGCT	cis	rs2153535	0.505	rs9405395	chr6:8468622	T/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.12	0.42	1.12e-6	Motion sickness;
TGCT	cis	rs6121246	0.559	rs6121172	chr20:30296095	A/C	cg13852791	chr20:30311386	BCL2L1	0.8	7.42	0.55	1.61e-11	Mean corpuscular hemoglobin;
TGCT	cis	rs7336332	0.662	rs9581862	chr13:28039993	T/G	cg22138327	chr13:27999177	GTF3A	0.73	5.63	0.45	1.13e-7	Weight;
TGCT	cis	rs2404602	0.679	rs12899871	chr15:76757347	T/C	cg26408565	chr15:76604113	ETFA	-0.4	-5.26	-0.43	6.23e-7	Blood metabolite levels;
TGCT	cis	rs9916302	0.904	rs7503705	chr17:37669704	A/G	cg15445000	chr17:37608096	MED1	0.32	4.66	0.39	8.18e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs35146811	0.735	rs2528900	chr7:99805319	A/G	cg04778012	chr7:99775508	STAG3;GPC2	-0.35	-4.93	-0.41	2.55e-6	Coronary artery disease;
TGCT	cis	rs600231	0.708	rs661403	chr11:65242478	A/G	cg17120908	chr11:65337727	SSSCA1	-0.55	-5.14	-0.42	1.03e-6	Bone mineral density;
TGCT	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg00343986	chr7:65444356	GUSB	0.24	5.4	0.44	3.32e-7	Aortic root size;
TGCT	cis	rs5769707	0.935	rs9616332	chr22:50047678	C/G	cg20744362	chr22:50050164	C22orf34	0.29	4.82	0.4	4.12e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs2295359	0.892	rs6688383	chr1:67655954	C/T	cg12940439	chr1:67600707	NA	-0.61	-6.3	-0.49	4.68e-9	Psoriasis;
TGCT	cis	rs11031096	0.774	rs1867133	chr11:4205956	A/G	cg18678763	chr11:4115507	RRM1	-0.4	-5.52	-0.44	1.9e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs9929218	0.529	rs2296404	chr16:68729525	C/T	cg01251360	chr16:68772225	CDH1	-0.26	-4.83	-0.4	3.87e-6	Colorectal cancer;
TGCT	cis	rs57920188	0.658	rs7548273	chr1:4078945	G/C	cg20703997	chr1:4087676	NA	0.46	5.72	0.46	7.63e-8	Interleukin-17 levels;
TGCT	cis	rs7937612	1.000	rs2305010	chr11:120330149	C/G	cg24566217	chr11:120254723	ARHGEF12	0.3	4.67	0.39	7.84e-6	Intraocular pressure;
TGCT	cis	rs6815814	0.851	rs17582921	chr4:38892649	T/C	cg02016764	chr4:38805732	TLR1	-0.34	-5.18	-0.42	8.61e-7	Breast cancer;
TGCT	cis	rs7917772	0.502	rs10748827	chr10:104368336	G/T	cg05855489	chr10:104503620	C10orf26	-0.61	-5.41	-0.44	3.16e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9467773	0.587	rs10946812	chr6:26344975	G/C	cg15659132	chr6:26577336	NA	-0.52	-5.32	-0.43	4.77e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs6121246	0.567	rs6060263	chr20:30193110	T/C	cg18721089	chr20:30220636	NA	-0.63	-6.88	-0.53	2.67e-10	Mean corpuscular hemoglobin;
TGCT	cis	rs12458462	0.787	rs56006341	chr18:77439844	G/T	cg11879182	chr18:77439856	CTDP1	0.67	7.67	0.57	4.44e-12	Monocyte count;
TGCT	cis	rs11785400	1.000	rs4327844	chr8:143733540	C/T	cg24634471	chr8:143751801	JRK	-0.53	-5.77	-0.46	5.94e-8	Schizophrenia;
TGCT	trans	rs564343	0.583	rs2430978	chr11:65816656	G/C	cg26701943	chr11:108369231	KDELC2	-0.71	-6.7	-0.52	6.5e-10	Obesity (early onset extreme);
TGCT	cis	rs889312	0.500	rs702688	chr5:56190986	A/G	cg24531977	chr5:56204891	C5orf35	-0.5	-5.04	-0.41	1.57e-6	Breast cancer;Breast cancer (early onset);
TGCT	cis	rs7819412	0.594	rs17724226	chr8:10968926	C/T	cg21775007	chr8:11205619	TDH	-0.49	-4.94	-0.41	2.5e-6	Triglycerides;
TGCT	cis	rs4808199	0.895	rs12981405	chr19:19651577	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.73	4.89	0.4	3.05e-6	Nonalcoholic fatty liver disease;
TGCT	cis	rs899997	1.000	rs11072793	chr15:79006442	C/T	cg04896959	chr15:78267971	NA	0.33	5.12	0.42	1.13e-6	Coronary artery disease or large artery stroke;
TGCT	cis	rs9902453	0.874	rs7213517	chr17:28401740	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.82	-7.84	-0.58	1.8e-12	Coffee consumption (cups per day);
TGCT	cis	rs4499344	0.921	rs752718	chr19:33086262	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.73	-6.6	-0.51	1.07e-9	Mean platelet volume;
TGCT	cis	rs3845702	0.673	rs12468986	chr2:180862320	T/G	cg01881094	chr2:180872142	CWC22	1.06	6.66	0.51	8.12e-10	Schizophrenia;
TGCT	cis	rs6088580	0.634	rs6059890	chr20:33101653	G/C	cg08999081	chr20:33150536	PIGU	0.29	5.57	0.45	1.54e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs2242194	0.816	rs2242193	chr1:154995503	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	0.51	4.72	0.39	6.37e-6	Schizophrenia;
TGCT	cis	rs12188164	0.965	rs11745789	chr5:450777	T/C	cg21144161	chr5:423903	AHRR	0.25	4.79	0.4	4.59e-6	Cystic fibrosis severity;
TGCT	cis	rs765787	0.530	rs28414644	chr15:45536721	G/C	cg24006582	chr15:45444508	DUOX1	-0.25	-5.54	-0.45	1.76e-7	Uric acid levels;
TGCT	cis	rs77633900	0.614	rs2439993	chr15:76861532	G/A	cg21673338	chr15:77095150	SCAPER	-0.5	-4.68	-0.39	7.27e-6	Non-glioblastoma glioma;Glioma;
TGCT	cis	rs17376456	0.877	rs12153788	chr5:93405437	A/G	cg21475434	chr5:93447410	FAM172A	0.59	4.66	0.39	8.09e-6	Diabetic retinopathy;
TGCT	cis	rs6121246	0.909	rs6089058	chr20:30326338	T/G	cg13852791	chr20:30311386	BCL2L1	0.8	6.12	0.48	1.15e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs295140	0.903	rs3820888	chr2:201180023	T/C	cg04283868	chr2:201171347	SPATS2L	0.62	6.15	0.48	1e-8	QT interval;
TGCT	cis	rs882300	0.934	rs2102895	chr2:136906692	G/A	cg05194412	chr2:137003533	NA	0.24	4.59	0.38	1.06e-5	Multiple sclerosis;Electrocardiographic traits;
TGCT	cis	rs6490294	0.861	rs2106956	chr12:112418918	C/T	cg10833066	chr12:111807467	FAM109A	0.36	5.33	0.43	4.4e-7	Mean platelet volume;
TGCT	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg04944784	chr2:26401820	FAM59B	-0.78	-6.56	-0.51	1.34e-9	Gut microbiome composition (summer);
TGCT	cis	rs34638657	0.500	rs1056675	chr16:82181934	T/C	cg09439754	chr16:82129088	HSD17B2	-0.22	-4.59	-0.38	1.08e-5	Lung adenocarcinoma;
TGCT	cis	rs4273100	0.688	rs4143829	chr17:19241505	G/A	cg01534423	chr17:18965556	NA	-0.79	-7.19	-0.54	5.25e-11	Schizophrenia;
TGCT	cis	rs4808199	0.948	rs2301671	chr19:19466269	C/T	cg03709012	chr19:19516395	GATAD2A	0.81	6.55	0.51	1.4e-9	Nonalcoholic fatty liver disease;
TGCT	cis	rs9926296	0.586	rs1800359	chr16:89805261	A/G	cg27121462	chr16:89883253	FANCA	0.57	5.32	0.43	4.64e-7	Vitiligo;
TGCT	cis	rs7666738	0.830	rs10010698	chr4:98981594	C/T	cg18180107	chr4:99064573	C4orf37	0.53	4.89	0.4	3.01e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg26338869	chr17:61819248	STRADA	-0.55	-5.08	-0.42	1.34e-6	Prudent dietary pattern;
TGCT	cis	rs7267979	1.000	rs2482911	chr20:25395528	T/C	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7786808	0.707	rs62479983	chr7:158227613	G/A	cg01191920	chr7:158217561	PTPRN2	-0.43	-6.3	-0.49	4.68e-9	Obesity-related traits;
TGCT	cis	rs12142240	0.730	rs56030283	chr1:46823093	C/G	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs727563	0.648	rs6002406	chr22:41965237	A/T	cg03806693	chr22:41940476	POLR3H	-1.12	-12.12	-0.74	8.54e-23	Crohn's disease;Inflammatory bowel disease;
TGCT	trans	rs2688608	0.752	rs1916341	chr10:75671162	G/T	cg13918328	chr10:52500089	ASAH2B	0.67	6.77	0.52	4.64e-10	Inflammatory bowel disease;
TGCT	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg18876405	chr7:65276391	NA	0.32	4.87	0.4	3.29e-6	Aortic root size;
TGCT	cis	rs35306767	0.953	rs1106064	chr10:957211	G/A	cg26597838	chr10:835615	NA	0.66	9.01	0.63	3.04e-15	Eosinophil percentage of granulocytes;
TGCT	cis	rs11105298	0.891	rs3825330	chr12:89933710	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.67	-4.85	-0.4	3.63e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs9300255	0.568	rs1621194	chr12:123651018	T/C	cg00376283	chr12:123451042	ABCB9	0.72	5.55	0.45	1.65e-7	Neutrophil percentage of white cells;
TGCT	cis	rs7017914	0.967	rs2732087	chr8:71860439	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.53	-5.02	-0.41	1.72e-6	Bone mineral density;
TGCT	cis	rs7584330	0.554	rs77180399	chr2:238442951	G/A	cg14458575	chr2:238380390	NA	0.43	4.55	0.38	1.25e-5	Prostate cancer;
TGCT	cis	rs950776	0.752	rs62010328	chr15:78894971	C/T	cg06917634	chr15:78832804	PSMA4	0.68	5.37	0.43	3.7e-7	Sudden cardiac arrest;
TGCT	cis	rs704	0.585	rs1007398	chr17:26665648	A/G	cg10494684	chr17:26645200	TMEM97	-0.45	-4.89	-0.4	3.03e-6	Osteoprotegerin levels;
TGCT	cis	rs7552404	0.924	rs1146581	chr1:76213024	T/G	cg03433033	chr1:76189801	ACADM	0.77	9.25	0.64	8.26e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs4906332	0.933	rs34606394	chr14:103915636	G/A	cg26031613	chr14:104095156	KLC1	-0.53	-4.72	-0.39	6.2e-6	Coronary artery disease;
TGCT	cis	rs7216064	1.000	rs9912084	chr17:65868035	A/C	cg12091567	chr17:66097778	LOC651250	-0.87	-6.85	-0.52	3.1e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs7568458	0.811	rs3755014	chr2:85764006	C/T	cg17127132	chr2:85788382	GGCX	0.68	6.58	0.51	1.18e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs6500602	0.673	rs1861652	chr16:4505331	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.33	4.77	0.39	5.17e-6	Schizophrenia;
TGCT	cis	rs2730260	0.537	rs3793224	chr7:158876573	G/A	cg02078164	chr7:157982224	PTPRN2	0.41	4.58	0.38	1.11e-5	Myopia (pathological);
TGCT	cis	rs62103177	0.810	rs62103195	chr18:77629693	T/C	cg12964065	chr18:77638022	KCNG2	0.38	4.76	0.39	5.2e-6	Opioid sensitivity;
TGCT	cis	rs11577318	0.853	rs12728971	chr1:26626612	C/T	cg04990556	chr1:26633338	UBXN11	-0.63	-5.83	-0.46	4.58e-8	Granulocyte percentage of myeloid white cells;
TGCT	trans	rs1814175	0.647	rs2903409	chr11:49953612	C/G	cg03929089	chr4:120376271	NA	-0.62	-7.26	-0.55	3.76e-11	Height;
TGCT	cis	rs2227564	0.620	rs11000787	chr10:75584383	T/C	cg19442545	chr10:75533431	FUT11	-0.31	-4.47	-0.37	1.72e-5	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs7582180	0.676	rs10048665	chr2:100933085	A/G	cg08017756	chr2:100939284	LONRF2	-0.3	-4.98	-0.41	2.11e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7412746	0.658	rs7528773	chr1:150915875	G/A	cg09365446	chr1:150670422	GOLPH3L	0.34	4.71	0.39	6.58e-6	Melanoma;
TGCT	cis	rs2760061	0.626	rs635563	chr1:228136834	C/T	cg02753203	chr1:228287806	NA	-0.35	-6.84	-0.52	3.14e-10	Diastolic blood pressure;
TGCT	cis	rs7020830	0.858	rs13293465	chr9:37127678	C/T	cg14294708	chr9:37120828	ZCCHC7	1.26	17.63	0.85	1.37e-35	Schizophrenia;
TGCT	cis	rs3824867	0.770	rs11820680	chr11:47452744	C/T	cg20307385	chr11:47447363	PSMC3	-0.68	-5.78	-0.46	5.79e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs9435341	0.965	rs6669831	chr1:107608607	G/A	cg09367891	chr1:107599246	PRMT6	-0.63	-5.48	-0.44	2.24e-7	Facial morphology (factor 21, depth of nasal alae);
TGCT	cis	rs1697139	0.583	rs11739587	chr5:66540481	A/C	cg11553311	chr5:66541588	NA	-0.28	-5.96	-0.47	2.4e-8	Breast cancer;
TGCT	cis	rs12142240	0.698	rs17361936	chr1:46862893	C/T	cg14993813	chr1:46806288	NSUN4	-0.59	-4.86	-0.4	3.45e-6	Menopause (age at onset);
TGCT	cis	rs13064411	0.542	rs13082603	chr3:113223362	T/C	cg18753928	chr3:113234510	CCDC52	-0.56	-4.72	-0.39	6.3e-6	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs7089973	0.604	rs17095662	chr10:116596071	A/C	cg03647239	chr10:116582469	FAM160B1	0.58	5.66	0.45	9.75e-8	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs2180341	0.960	rs1543432	chr6:127698018	T/C	cg24812749	chr6:127587940	RNF146	0.99	7.63	0.57	5.24e-12	Breast cancer;
TGCT	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg11644478	chr21:40555479	PSMG1	1.04	10.81	0.7	1.38e-19	Cognitive function;
TGCT	cis	rs7666738	0.791	rs34437628	chr4:99029232	C/G	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs36051895	0.659	rs62541538	chr9:5038164	G/A	cg02405213	chr9:5042618	JAK2	-0.77	-10.51	-0.69	7.18e-19	Pediatric autoimmune diseases;
TGCT	cis	rs36022378	0.504	rs4688688	chr3:50042690	C/G	cg03060546	chr3:49711283	APEH	-0.57	-4.53	-0.38	1.37e-5	Diastolic blood pressure;
TGCT	cis	rs7552404	0.690	rs2029681	chr1:76333846	G/A	cg03433033	chr1:76189801	ACADM	-0.59	-5.97	-0.47	2.34e-8	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs13256369	1.000	rs10103769	chr8:8573036	G/T	cg17143192	chr8:8559678	CLDN23	0.62	5.82	0.46	4.82e-8	Obesity-related traits;
TGCT	cis	rs13191362	0.935	rs35100164	chr6:162963003	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.66	5.11	0.42	1.17e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs8056742	0.818	rs9939283	chr16:85090195	C/G	cg00229868	chr16:85520891	NA	0.34	5.07	0.41	1.42e-6	Amyotrophic lateral sclerosis;
TGCT	trans	rs1814175	0.817	rs11518158	chr11:49985633	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.36	-7.14	-0.54	6.89e-11	Height;
TGCT	cis	rs7267979	0.816	rs6037158	chr20:25595466	C/A	cg03522245	chr20:25566470	NINL	0.56	5.74	0.46	6.77e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2404602	1.000	rs12898430	chr15:76874923	G/A	cg26408565	chr15:76604113	ETFA	-0.38	-4.82	-0.4	4.03e-6	Blood metabolite levels;
TGCT	cis	rs8077577	1.000	rs62073606	chr17:18069142	G/A	cg09161412	chr17:18057145	MYO15A	-0.67	-5.44	-0.44	2.69e-7	Obesity-related traits;
TGCT	cis	rs67311347	1.000	rs2085115	chr3:40497540	G/T	cg13409248	chr3:40428643	ENTPD3	0.56	4.45	0.37	1.91e-5	Renal cell carcinoma;
TGCT	cis	rs17197710	0.608	rs41304347	chr11:47330991	A/G	cg13308137	chr11:47528955	CUGBP1	0.41	5.82	0.46	4.71e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg15595755	chr5:1867978	NA	0.46	5.36	0.43	3.94e-7	Cardiovascular disease risk factors;
TGCT	cis	rs6964587	0.692	rs10227225	chr7:91571074	A/G	cg17063962	chr7:91808500	NA	-0.75	-7.1	-0.54	8.63e-11	Breast cancer;
TGCT	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg13695892	chr22:41940480	POLR3H	0.92	9.29	0.64	6.61e-16	Vitiligo;
TGCT	trans	rs2469997	0.843	rs2470030	chr8:120368991	T/C	cg01792902	chr3:178864926	PIK3CA	0.83	6.77	0.52	4.49e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs12142240	0.698	rs41534051	chr1:46828734	A/G	cg14993813	chr1:46806288	NSUN4	-0.58	-4.79	-0.4	4.69e-6	Menopause (age at onset);
TGCT	cis	rs17331151	0.573	rs2276818	chr3:52864635	A/G	cg12962167	chr3:53033115	SFMBT1	0.44	4.96	0.41	2.28e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg10047753	chr17:41438598	NA	0.77	7.29	0.55	3.18e-11	Menopause (age at onset);
TGCT	cis	rs12049351	0.524	rs4925495	chr1:229624424	C/T	cg12130225	chr1:229698885	NA	0.39	4.55	0.38	1.24e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs7727544	0.735	rs272884	chr5:131668654	G/C	cg24060327	chr5:131705240	SLC22A5	-0.56	-6.31	-0.49	4.43e-9	Blood metabolite levels;
TGCT	cis	rs8062405	1.000	rs8055982	chr16:28881202	A/C	cg09754948	chr16:28834200	ATXN2L	0.6	4.46	0.37	1.79e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs10114408	0.918	rs10992944	chr9:96640702	A/G	cg13679303	chr9:96623674	NA	-0.36	-4.69	-0.39	6.98e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs9906944	0.933	rs35051752	chr17:47089908	G/A	cg07075026	chr17:47091521	IGF2BP1	-0.43	-4.8	-0.4	4.47e-6	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs6540559	0.673	rs11803382	chr1:209986426	G/A	cg04352962	chr1:209979756	IRF6	0.65	4.6	0.38	1.05e-5	Cleft lip with or without cleft palate;
TGCT	cis	rs10875746	0.903	rs11168418	chr12:48515754	C/A	cg20731937	chr12:48336164	NA	0.62	4.94	0.41	2.46e-6	Longevity (90 years and older);
TGCT	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg24846343	chr22:24311635	DDTL	0.23	5.79	0.46	5.37e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	5.02	0.41	1.78e-6	Prudent dietary pattern;
TGCT	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg02038168	chr22:39784481	NA	-0.76	-6.33	-0.49	4.13e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs10838634	1.000	rs11824327	chr11:46864705	T/C	cg18332754	chr11:46939436	LRP4	0.91	4.61	0.38	9.98e-6	Schizophrenia;
TGCT	cis	rs1008375	0.932	rs4698630	chr4:17614692	C/G	cg16339924	chr4:17578868	LAP3	0.74	5.88	0.47	3.64e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs3806843	0.966	rs11958868	chr5:140201420	T/C	cg19875535	chr5:140030758	IK	0.36	5.84	0.46	4.29e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs17253792	0.822	rs77599953	chr14:56058905	C/T	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs2439831	0.867	rs3213991	chr15:43670280	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	6.61	0.51	1e-9	Lung cancer in ever smokers;
TGCT	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg13732083	chr21:47605072	C21orf56	-0.35	-4.51	-0.38	1.5e-5	Testicular germ cell tumor;
TGCT	cis	rs2455799	0.613	rs1393969	chr3:15730257	G/A	cg16303742	chr3:15540471	COLQ	-0.25	-4.74	-0.39	5.65e-6	Mean platelet volume;
TGCT	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg26513180	chr16:89883248	FANCA	1.07	14.72	0.8	5.42e-29	Vitiligo;
TGCT	cis	rs10114408	0.959	rs7857898	chr9:96642275	C/T	cg13679303	chr9:96623674	NA	-0.35	-4.45	-0.37	1.85e-5	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs881375	0.933	rs7028641	chr9:123691141	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	4.99	0.41	2.03e-6	Rheumatoid arthritis;
TGCT	cis	rs4786125	0.636	rs7192853	chr16:6918241	G/C	cg03623568	chr16:6915990	A2BP1	-0.45	-6.66	-0.51	7.78e-10	Heart rate variability traits (SDNN);
TGCT	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg06634786	chr22:41940651	POLR3H	0.89	8.4	0.6	8.56e-14	Vitiligo;
TGCT	cis	rs7582180	0.629	rs4851308	chr2:100971865	C/A	cg08017756	chr2:100939284	LONRF2	-0.3	-4.87	-0.4	3.38e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs918629	0.679	rs12055287	chr5:95272428	G/C	cg16656078	chr5:95278638	ELL2	-0.32	-5.06	-0.41	1.49e-6	IgG glycosylation;
TGCT	cis	rs72781680	0.768	rs56339558	chr2:24125234	G/A	cg08917208	chr2:24149416	ATAD2B	0.74	4.66	0.39	7.9e-6	Lymphocyte counts;
TGCT	cis	rs7611238	0.560	rs62288364	chr3:195110699	C/A	cg27323046	chr3:195102265	ACAP2	0.38	5.06	0.41	1.5e-6	Body mass index;
TGCT	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg01802117	chr1:53393560	SCP2	-0.42	-5.25	-0.43	6.33e-7	Monocyte count;
TGCT	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg01084871	chr4:1340883	KIAA1530	0.59	4.62	0.38	9.57e-6	Longevity;
TGCT	cis	rs10465746	0.747	rs10493741	chr1:84388118	G/C	cg10977910	chr1:84465055	TTLL7	0.71	7.15	0.54	6.64e-11	Obesity-related traits;
TGCT	trans	rs9383153	0.590	rs2072736	chr6:16328068	T/C	cg19402885	chr12:15475236	PTPRO	0.99	6.81	0.52	3.76e-10	Gambling;
TGCT	cis	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg13531842	chr10:38383804	ZNF37A	-0.39	-4.65	-0.39	8.25e-6	Extrinsic epigenetic age acceleration;
TGCT	trans	rs208520	0.690	rs1351867	chr6:66760995	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	11.29	0.71	9.4e-21	Exhaled nitric oxide output;
TGCT	cis	rs79349575	0.783	rs11079844	chr17:47028334	G/A	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.52	-0.38	1.44e-5	Type 2 diabetes;
TGCT	cis	rs17152411	0.895	rs7080330	chr10:126585673	A/G	cg07906193	chr10:126599966	NA	0.41	5.05	0.41	1.52e-6	Height;
TGCT	cis	rs4654899	0.833	rs3816454	chr1:21191416	T/G	cg01072550	chr1:21505969	NA	0.46	6.86	0.52	2.89e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg12963246	chr6:28129442	ZNF389	0.52	5.1	0.42	1.23e-6	Depression;
TGCT	cis	rs7829975	0.684	rs474892	chr8:8596731	G/T	cg15556689	chr8:8085844	FLJ10661	-0.62	-5.28	-0.43	5.55e-7	Mood instability;
TGCT	cis	rs9911578	1.000	rs9898916	chr17:57048660	C/T	cg05425664	chr17:57184151	TRIM37	-0.63	-6.25	-0.49	6.03e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs62244186	0.715	rs11130032	chr3:44704083	G/A	cg15687855	chr3:44754131	ZNF502	-0.41	-4.78	-0.39	4.93e-6	Depressive symptoms;
TGCT	cis	rs2188554	0.740	rs213944	chr7:117190066	C/T	cg09181792	chr7:117119393	CFTR	0.47	4.47	0.37	1.77e-5	Esophageal adenocarcinoma;
TGCT	cis	rs908922	0.962	rs4240882	chr1:152456358	G/C	cg20991723	chr1:152506922	NA	0.42	5.35	0.43	4.14e-7	Hair morphology;
TGCT	cis	rs3809863	0.602	rs7225700	chr17:45391804	T/C	cg08085267	chr17:45401833	C17orf57	-0.66	-7.62	-0.56	5.77e-12	Glaucoma (primary open-angle);
TGCT	cis	rs2730245	0.527	rs842693	chr7:158660491	C/T	cg11984989	chr7:158649758	WDR60	1.01	7.8	0.57	2.2e-12	Height;
TGCT	cis	rs6815814	0.950	rs67206233	chr4:38807853	T/C	cg02016764	chr4:38805732	TLR1	-0.35	-5.65	-0.45	1.04e-7	Breast cancer;
TGCT	cis	rs13108904	0.846	rs9631804	chr4:1283032	A/T	cg13395646	chr4:1353034	KIAA1530	0.38	4.58	0.38	1.1e-5	Obesity-related traits;
TGCT	cis	rs763121	0.962	rs138703	chr22:39132748	C/T	cg06022373	chr22:39101656	GTPBP1	0.7	6.69	0.51	7e-10	Menopause (age at onset);
TGCT	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg11764359	chr7:65958608	NA	0.57	5.12	0.42	1.12e-6	Aortic root size;
TGCT	cis	rs2932538	0.961	rs3795820	chr1:113163042	C/A	cg10983938	chr1:113465962	AFARP1;SLC16A1	-0.21	-4.5	-0.37	1.52e-5	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg21644426	chr2:191273491	MFSD6	-0.6	-5.91	-0.47	3.12e-8	Pulse pressure;
TGCT	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	0.59	6.16	0.48	9.39e-9	Prostate cancer;
TGCT	cis	rs17376456	0.877	rs10065056	chr5:93380123	G/T	cg25358565	chr5:93447407	FAM172A	0.92	8.38	0.6	9.58e-14	Diabetic retinopathy;
TGCT	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg11301795	chr4:187892539	NA	-0.36	-5.38	-0.43	3.61e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2721195	1.000	rs750472	chr8:145701453	A/C	cg17328964	chr8:145687451	CYHR1	0.44	6.29	0.49	5.08e-9	Age at first birth;
TGCT	cis	rs12478296	1.000	rs11899408	chr2:243014630	A/G	cg06360820	chr2:242988706	NA	-0.85	-6.23	-0.49	6.61e-9	Obesity-related traits;
TGCT	cis	rs72945132	0.825	rs57871058	chr11:70192344	T/C	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg11905131	chr22:24372483	LOC391322	-0.95	-11.15	-0.71	2.06e-20	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9926296	0.712	rs258332	chr16:89727683	G/A	cg03388025	chr16:89894329	SPIRE2	-0.35	-5.09	-0.42	1.28e-6	Vitiligo;
TGCT	cis	rs727505	0.954	rs68102397	chr7:124685315	C/T	cg23710748	chr7:124431027	NA	-0.27	-4.59	-0.38	1.08e-5	Lewy body disease;
TGCT	cis	rs17270561	0.579	rs10456326	chr6:25919662	G/A	cg17691542	chr6:26056736	HIST1H1C	0.89	6.28	0.49	5.3e-9	Iron status biomarkers;
TGCT	cis	rs4975616	0.843	rs4975615	chr5:1315343	C/T	cg07493874	chr5:1342172	CLPTM1L	0.25	6.05	0.48	1.58e-8	Lung cancer;
TGCT	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg18876405	chr7:65276391	NA	0.33	5.05	0.41	1.55e-6	Aortic root size;
TGCT	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	5.8	0.46	5.19e-8	Alzheimer's disease;
TGCT	cis	rs9894429	0.789	rs6565611	chr17:79598319	T/C	cg18240062	chr17:79603768	NPLOC4	0.84	9.67	0.66	8.03e-17	Eye color traits;
TGCT	cis	rs11105306	1	rs11105306	chr12:89897388	C/T	cg00757033	chr12:89920650	WDR51B	0.34	5.37	0.43	3.75e-7	NT-proBNP levels in acute coronary syndrome;
TGCT	cis	rs7220401	0.789	rs4794859	chr17:27962393	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.81	-7.15	-0.54	6.61e-11	Coronary artery disease;
TGCT	cis	rs6988636	1.000	rs58177772	chr8:124188067	T/C	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs12510870	0.566	rs6837506	chr4:74462267	C/T	cg05868023	chr4:75230803	EREG	0.56	5.01	0.41	1.83e-6	Iris color (b* coordinate);
TGCT	cis	rs138249	0.505	rs138218	chr22:50547558	T/C	cg24864161	chr22:50528282	MOV10L1	0.5	4.45	0.37	1.91e-5	Gestational age at birth in labor-initiated deliveries (child effect);
TGCT	trans	rs1814175	0.727	rs2140597	chr11:49873946	G/A	cg15704280	chr7:45808275	SEPT13	-0.72	-8.14	-0.59	3.61e-13	Height;
TGCT	cis	rs9467773	1.000	rs9467791	chr6:26562486	A/G	cg15659132	chr6:26577336	NA	-0.88	-12.86	-0.76	1.43e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs2354432	0.607	rs6683243	chr1:146733422	A/T	cg25205988	chr1:146714368	CHD1L	-1.34	-6.07	-0.48	1.44e-8	Mitochondrial DNA levels;
TGCT	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.34	0.43	4.23e-7	Prudent dietary pattern;
TGCT	cis	rs477895	1.000	rs34292685	chr11:64049021	C/T	cg04317338	chr11:64019027	PLCB3	0.7	5.65	0.45	1.05e-7	Mean platelet volume;
TGCT	cis	rs909002	0.962	rs1474181	chr1:32136610	C/G	cg11573219	chr1:32083031	HCRTR1	-0.36	-4.56	-0.38	1.2e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs12477438	0.501	rs6751927	chr2:99740175	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.06	13.26	0.77	1.59e-25	Chronic sinus infection;
TGCT	cis	rs8103278	0.507	rs10415988	chr19:46246704	C/T	cg14061069	chr19:46274453	DMPK	0.62	10.19	0.68	4.35e-18	Coronary artery disease;
TGCT	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.06	-9.57	-0.65	1.41e-16	Platelet count;
TGCT	cis	rs17030434	0.954	rs6847810	chr4:154752789	C/T	cg14289246	chr4:154710475	SFRP2	-0.9	-7.03	-0.53	1.2e-10	Electrocardiographic conduction measures;
TGCT	cis	rs2463822	0.844	rs2513737	chr11:62119495	G/C	cg06239285	chr11:62104954	ASRGL1	0.92	6.75	0.52	5.06e-10	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg10802521	chr3:52805072	NEK4	-0.71	-8.79	-0.62	1.04e-14	Bipolar disorder;
TGCT	cis	rs734999	0.566	rs4648658	chr1:2560882	G/A	cg18854424	chr1:2615690	NA	-0.5	-5.95	-0.47	2.54e-8	Ulcerative colitis;
TGCT	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg07507251	chr3:52567010	NT5DC2	0.47	6.74	0.52	5.29e-10	Electroencephalogram traits;
TGCT	cis	rs6988636	1.000	rs13261100	chr8:124190312	G/A	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs826838	0.967	rs4768330	chr12:39129399	T/C	cg13010199	chr12:38710504	ALG10B	-0.64	-5.11	-0.42	1.19e-6	Heart rate;
TGCT	cis	rs9810089	0.711	rs711972	chr3:136110018	C/T	cg12473912	chr3:136751656	NA	0.35	5.16	0.42	9.38e-7	Gestational age at birth (child effect);
TGCT	cis	rs3771570	0.901	rs55764424	chr2:242407467	C/T	cg21155796	chr2:242212141	HDLBP	0.92	6.63	0.51	9.25e-10	Prostate cancer;
TGCT	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg24060327	chr5:131705240	SLC22A5	-0.66	-6.85	-0.52	3.07e-10	Acylcarnitine levels;
TGCT	cis	rs587847	0.597	rs28896807	chr15:37764378	A/G	cg00216138	chr15:37171175	LOC145845	0.31	4.55	0.38	1.24e-5	Intraocular pressure;
TGCT	cis	rs7267979	0.966	rs416745	chr20:25438868	T/C	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs12368653	0.591	rs1552842	chr12:58012163	A/G	cg00700412	chr12:58011837	NA	-0.23	-4.62	-0.38	9.42e-6	Multiple sclerosis;
TGCT	cis	rs2180341	0.695	rs6569487	chr6:127726196	C/T	cg24812749	chr6:127587940	RNF146	-0.64	-5.82	-0.46	4.81e-8	Breast cancer;
TGCT	cis	rs2255336	0.938	rs2733840	chr12:10545925	C/T	cg16084090	chr12:10586130	KLRC2	0.28	4.62	0.38	9.32e-6	Blood protein levels;
TGCT	cis	rs11673344	0.523	rs7245453	chr19:37534349	G/T	cg08039142	chr19:36980659	ZNF566	0.51	4.69	0.39	6.99e-6	Obesity-related traits;
TGCT	cis	rs2657888	1.000	rs28697089	chr12:56938703	A/G	cg23002907	chr12:56915593	RBMS2	-0.45	-6.07	-0.48	1.44e-8	Adiponectin levels;
TGCT	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg01802117	chr1:53393560	SCP2	-0.45	-5.73	-0.46	7.03e-8	Monocyte count;
TGCT	cis	rs9291683	0.609	rs34709913	chr4:10028955	T/C	cg00071950	chr4:10020882	SLC2A9	0.7	9.43	0.65	3.06e-16	Bone mineral density;
TGCT	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.07	-9.63	-0.65	1.01e-16	Platelet count;
TGCT	cis	rs6089584	0.821	rs2273990	chr20:60579149	G/T	cg06108461	chr20:60628389	TAF4	-0.59	-8.58	-0.61	3.35e-14	Body mass index;
TGCT	trans	rs208520	1.000	rs72880045	chr6:66965232	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	8.21	0.59	2.37e-13	Exhaled nitric oxide output;
TGCT	cis	rs9486719	1.000	rs67996804	chr6:96884387	C/T	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.86	-0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs79349575	0.783	rs318090	chr17:46991752	G/A	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.51	-0.38	1.48e-5	Type 2 diabetes;
TGCT	cis	rs77741769	0.529	rs3901854	chr12:121225526	C/T	cg02419362	chr12:121203948	SPPL3	0.19	4.46	0.37	1.83e-5	Mean corpuscular volume;
TGCT	cis	rs4950928	0.823	rs2153101	chr1:203168474	A/T	cg17014757	chr1:203156097	CHI3L1	-0.36	-4.59	-0.38	1.09e-5	YKL-40 levels;
TGCT	cis	rs737008	0.586	rs7195820	chr16:11403855	A/T	cg00044050	chr16:11439710	C16orf75	0.62	4.44	0.37	1.93e-5	Obesity-related traits;
TGCT	cis	rs10411936	1.000	rs873636	chr19:16514771	C/T	cg14704714	chr19:15740395	CYP4F8	0.26	4.65	0.39	8.3e-6	White blood cell count;Multiple sclerosis;
TGCT	cis	rs5758659	0.504	rs133367	chr22:42463366	A/G	cg15557168	chr22:42548783	NA	0.22	5.74	0.46	6.78e-8	Cognitive function;
TGCT	cis	rs4372836	0.964	rs55721532	chr2:28938968	A/G	cg09522027	chr2:28974177	PPP1CB	0.59	5.01	0.41	1.86e-6	Body mass index;
TGCT	cis	rs9325144	0.647	rs12424190	chr12:39111206	A/T	cg10518543	chr12:38710700	ALG10B	-0.48	-4.5	-0.37	1.52e-5	Morning vs. evening chronotype;
TGCT	cis	rs1635	0.655	rs2281041	chr6:28303845	G/C	cg15743358	chr6:28303923	ZNF323	-1.28	-6.27	-0.49	5.57e-9	Schizophrenia;
TGCT	cis	rs2046867	0.862	rs57396880	chr3:72844785	G/A	cg25664220	chr3:72788482	NA	-0.56	-7.05	-0.53	1.1e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg08859206	chr1:53392774	SCP2	-0.43	-6.56	-0.51	1.31e-9	Monocyte count;
TGCT	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg08439880	chr3:133502540	NA	0.31	5.86	0.47	4e-8	Iron status biomarkers;
TGCT	cis	rs62103177	0.733	rs62103193	chr18:77629217	C/T	cg12964065	chr18:77638022	KCNG2	0.37	4.76	0.39	5.4e-6	Opioid sensitivity;
TGCT	cis	rs295137	0.725	rs1729413	chr2:201086663	T/G	cg23649088	chr2:200775458	C2orf69	0.29	5.16	0.42	9.7e-7	Asthma (bronchodilator response);
TGCT	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg13683864	chr3:40499215	RPL14	-1.18	-13.68	-0.78	1.54e-26	Renal cell carcinoma;
TGCT	cis	rs17270561	0.779	rs78589800	chr6:25883500	C/G	cg17691542	chr6:26056736	HIST1H1C	0.87	6.0	0.47	2.02e-8	Iron status biomarkers;
TGCT	cis	rs11690935	0.632	rs12052246	chr2:172895606	G/T	cg13550731	chr2:172543902	DYNC1I2	0.6	5.28	0.43	5.59e-7	Schizophrenia;
TGCT	trans	rs7086803	1.000	rs7086803	chr10:114498476	A/G	cg12515325	chr1:110008909	SYPL2	-1.13	-6.73	-0.52	5.65e-10	Lung cancer;
TGCT	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.97	0.41	2.15e-6	Height;
TGCT	cis	rs3771570	1.000	rs62190370	chr2:242384194	C/G	cg21155796	chr2:242212141	HDLBP	0.93	6.6	0.51	1.08e-9	Prostate cancer;
TGCT	cis	rs4808199	0.948	rs7250368	chr19:19452763	G/A	cg03709012	chr19:19516395	GATAD2A	0.81	6.55	0.51	1.4e-9	Nonalcoholic fatty liver disease;
TGCT	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg07298985	chr8:22133076	PIWIL2	0.31	4.77	0.39	5.06e-6	Hypertriglyceridemia;
TGCT	cis	rs3008870	0.677	rs2815354	chr1:67483642	A/T	cg11518657	chr1:67396239	MIER1	0.61	4.81	0.4	4.26e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs11783469	0.524	rs4872139	chr8:23346641	A/G	cg00472375	chr8:23315376	ENTPD4	0.75	5.72	0.46	7.44e-8	Reticulocyte count;
TGCT	cis	rs586688	1.000	rs589855	chr1:201631649	C/A	cg05779441	chr1:201574716	NA	0.28	4.6	0.38	1.03e-5	Obesity-related traits;
TGCT	cis	rs17345786	1.000	rs55641278	chr3:101290577	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.45	-9.8	-0.66	3.86e-17	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7267979	0.816	rs6076358	chr20:25519403	G/T	cg14121845	chr20:25566513	NINL	-0.46	-4.76	-0.39	5.36e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6831352	0.918	rs13112176	chr4:100055825	G/A	cg12011299	chr4:100065546	ADH4	-0.4	-4.88	-0.4	3.26e-6	Alcohol dependence;
TGCT	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	4.93	0.4	2.6e-6	Menopause (age at onset);
TGCT	cis	rs2204008	0.539	rs2703682	chr12:38107969	A/G	cg26384229	chr12:38710491	ALG10B	0.59	5.11	0.42	1.17e-6	Bladder cancer;
TGCT	cis	rs9640161	0.702	rs3735175	chr7:150020457	C/T	cg10018233	chr7:150070692	REPIN1	0.32	4.63	0.38	8.98e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg16680214	chr1:154839983	KCNN3	-0.36	-7.17	-0.54	6.05e-11	Prostate cancer;
TGCT	cis	rs17376456	1.000	rs34013242	chr5:93507947	C/T	cg25358565	chr5:93447407	FAM172A	0.95	7.97	0.58	8.71e-13	Diabetic retinopathy;
TGCT	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg04234412	chr22:24373322	LOC391322	-0.9	-10.31	-0.68	2.18e-18	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9311474	1.000	rs6445358	chr3:52308845	C/G	cg10802521	chr3:52805072	NEK4	-0.58	-6.43	-0.5	2.45e-9	Electroencephalogram traits;
TGCT	cis	rs35146811	0.735	rs2528900	chr7:99805319	A/G	cg13334819	chr7:99746414	C7orf59	0.74	6.31	0.49	4.4e-9	Coronary artery disease;
TGCT	cis	rs6952809	0.884	rs60383982	chr7:2464394	T/G	cg23289794	chr7:2394357	EIF3B	-0.59	-4.78	-0.39	4.82e-6	Multiple sclerosis;
TGCT	cis	rs10411936	0.962	rs2607278	chr19:16568197	C/T	cg19006008	chr19:16999768	F2RL3	-0.27	-4.69	-0.39	7.07e-6	White blood cell count;Multiple sclerosis;
TGCT	cis	rs7914558	0.966	rs10748835	chr10:104660256	C/T	cg04362960	chr10:104952993	NT5C2	0.56	5.14	0.42	1.04e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs2032447	0.613	rs6456708	chr6:26032847	G/C	cg12310025	chr6:25882481	NA	-0.49	-4.8	-0.4	4.53e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9303401	0.659	rs17822807	chr17:56687190	A/C	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs2742417	0.603	rs2742370	chr3:45782098	T/C	cg04837898	chr3:45731254	SACM1L	-0.67	-7.3	-0.55	3.06e-11	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs80282103	0.618	rs7100114	chr10:1110231	A/G	cg08668510	chr10:1095578	IDI1	1.07	5.29	0.43	5.38e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs1552244	0.515	rs7613004	chr3:9999913	A/C	cg00149659	chr3:10157352	C3orf10	0.65	4.8	0.4	4.49e-6	Alzheimer's disease;
TGCT	cis	rs9486719	1.000	rs3906199	chr6:97049899	C/A	cg18709589	chr6:96969512	KIAA0776	-0.74	-5.21	-0.42	7.5e-7	Migraine;Coronary artery disease;
TGCT	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.71	-0.39	6.54e-6	Prudent dietary pattern;
TGCT	cis	rs8013055	0.796	rs35592422	chr14:105996593	G/C	cg23356831	chr14:105996513	TMEM121	0.36	5.6	0.45	1.31e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs1215050	0.791	rs1669745	chr4:98842047	G/A	cg05340658	chr4:99064831	C4orf37	-0.47	-5.9	-0.47	3.22e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs4148883	0.689	rs1869458	chr4:100024728	C/G	cg12011299	chr4:100065546	ADH4	0.37	5.69	0.46	8.58e-8	Alcohol dependence;
TGCT	cis	rs7246967	0.673	rs12978964	chr19:22819244	G/A	cg05241461	chr19:22816980	ZNF492	0.71	4.79	0.4	4.6e-6	Bronchopulmonary dysplasia;
TGCT	cis	rs9467773	1.000	rs9467797	chr6:26568473	A/T	cg05738196	chr6:26577821	NA	0.9	12.48	0.75	1.16e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs317689	0.819	rs317683	chr12:69713630	T/G	cg14784868	chr12:69753453	YEATS4	0.58	4.96	0.41	2.25e-6	Response to diuretic therapy;
TGCT	cis	rs7264396	0.635	rs2024854	chr20:34511189	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.04	-0.41	1.58e-6	Total cholesterol levels;
TGCT	cis	rs9811920	0.666	rs793456	chr3:99525631	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.44	4.98	0.41	2.08e-6	Axial length;
TGCT	cis	rs4631830	0.720	rs7090326	chr10:51503375	A/T	cg10326726	chr10:51549505	MSMB	-0.23	-4.51	-0.38	1.46e-5	Prostate-specific antigen levels;
TGCT	cis	rs9372253	1.000	rs11153232	chr6:110716252	G/T	cg00083206	chr6:110721305	DDO	0.43	6.46	0.5	2.2e-9	Platelet distribution width;
TGCT	cis	rs6570726	1.000	rs455109	chr6:145872665	C/T	cg23711669	chr6:146136114	FBXO30	0.71	6.66	0.51	7.78e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9486719	0.843	rs2205754	chr6:96843134	T/C	cg06623918	chr6:96969491	KIAA0776	0.93	7.08	0.54	9.59e-11	Migraine;Coronary artery disease;
TGCT	cis	rs28595532	0.920	rs114165587	chr4:119779525	C/T	cg11846333	chr4:119757529	SEC24D	0.92	4.64	0.38	8.74e-6	Cannabis dependence symptom count;
TGCT	cis	rs950027	0.620	rs2486274	chr15:45666228	G/T	cg26924012	chr15:45694286	SPATA5L1	0.8	8.99	0.63	3.48e-15	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs7945705	0.818	rs2742552	chr11:8876852	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.42	-4.64	-0.38	8.82e-6	Hemoglobin concentration;
TGCT	cis	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg13531842	chr10:38383804	ZNF37A	-0.38	-4.51	-0.38	1.49e-5	Extrinsic epigenetic age acceleration;
TGCT	cis	rs9926296	0.712	rs459920	chr16:89730827	T/C	cg27121462	chr16:89883253	FANCA	-0.54	-5.01	-0.41	1.83e-6	Vitiligo;
TGCT	cis	rs2046867	0.774	rs9820293	chr3:72876237	T/A	cg25664220	chr3:72788482	NA	-0.52	-5.95	-0.47	2.54e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs548987	0.529	rs6456703	chr6:25826119	C/T	cg12310025	chr6:25882481	NA	-0.57	-4.61	-0.38	9.67e-6	Homocysteine levels;
TGCT	cis	rs8051431	0.876	rs8056712	chr16:72015406	A/G	cg06353428	chr16:71660113	MARVELD3	0.55	4.76	0.39	5.3e-6	LDL cholesterol levels;
TGCT	cis	rs4566357	0.557	rs6707158	chr2:227911269	A/G	cg11843606	chr2:227700838	RHBDD1	-0.55	-5.17	-0.42	8.92e-7	Coronary artery disease;
TGCT	cis	rs6490294	0.583	rs7314282	chr12:112502438	A/G	cg10833066	chr12:111807467	FAM109A	0.33	5.03	0.41	1.65e-6	Mean platelet volume;
TGCT	cis	rs2836974	0.549	rs34160989	chr21:40554118	C/G	cg11890956	chr21:40555474	PSMG1	0.95	7.14	0.54	6.84e-11	Cognitive function;
TGCT	cis	rs9443645	0.901	rs1538235	chr6:79689450	C/T	cg09184832	chr6:79620586	NA	-0.48	-5.34	-0.43	4.21e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs10501293	0.703	rs4267059	chr11:42988930	T/G	cg03447554	chr11:43094025	NA	0.44	6.45	0.5	2.25e-9	Cognitive performance;
TGCT	cis	rs9500256	0.967	rs1012500	chr6:58304669	G/A	cg16251399	chr6:58287822	GUSBL2	0.67	6.0	0.47	2.03e-8	Eosinophilic esophagitis (pediatric);
TGCT	cis	rs7267979	0.899	rs2104734	chr20:25526668	A/G	cg16686733	chr20:25566563	NINL	0.56	5.69	0.46	8.49e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg03303774	chr4:1407052	NA	0.28	4.58	0.38	1.12e-5	Obesity-related traits;
TGCT	cis	rs7267979	0.844	rs4423675	chr20:25402778	A/G	cg14121845	chr20:25566513	NINL	-0.45	-4.6	-0.38	1.02e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6121246	0.697	rs6088857	chr20:30226764	G/C	cg18721089	chr20:30220636	NA	-0.53	-5.43	-0.44	2.86e-7	Mean corpuscular hemoglobin;
TGCT	cis	rs2760061	0.819	rs1745417	chr1:228204279	C/T	cg18477163	chr1:228402036	OBSCN	0.34	7.22	0.54	4.65e-11	Diastolic blood pressure;
TGCT	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg04772025	chr11:68637568	NA	0.59	6.69	0.52	6.73e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg11890956	chr21:40555474	PSMG1	0.75	7.66	0.57	4.67e-12	Cognitive function;
TGCT	cis	rs7552404	0.727	rs4949677	chr1:76266662	T/A	cg03433033	chr1:76189801	ACADM	0.66	6.75	0.52	5.17e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9467773	0.620	rs2130657	chr6:26650826	C/T	cg09904177	chr6:26538194	HMGN4	0.68	6.27	0.49	5.41e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs1541995	0.964	rs34992592	chr15:96380753	G/A	cg00882281	chr15:96346592	NA	0.28	4.6	0.38	1.02e-5	Photic sneeze reflex;
TGCT	cis	rs12477438	0.520	rs6741773	chr2:99738962	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	17.16	0.84	1.49e-34	Chronic sinus infection;
TGCT	cis	rs3617	0.503	rs9866243	chr3:52915219	C/T	cg11645453	chr3:52864694	ITIH4	-0.26	-5.07	-0.41	1.39e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1729951	0.575	rs747843	chr3:136703130	G/C	cg21827317	chr3:136751795	NA	0.4	5.61	0.45	1.28e-7	Neuroticism;
TGCT	cis	rs4148883	0.645	rs2851264	chr4:100029715	C/T	cg12011299	chr4:100065546	ADH4	0.38	5.74	0.46	6.75e-8	Alcohol dependence;
TGCT	cis	rs7017914	0.934	rs2639921	chr8:71874834	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.52	-4.84	-0.4	3.86e-6	Bone mineral density;
TGCT	cis	rs877529	0.605	rs79504	chr22:39551555	T/C	cg18708252	chr22:39545030	CBX7	-0.4	-5.85	-0.46	4.13e-8	Multiple myeloma;
TGCT	cis	rs7027203	0.828	rs10761287	chr9:96609150	A/G	cg13679303	chr9:96623674	NA	-0.66	-10.78	-0.7	1.64e-19	DNA methylation (variation);
TGCT	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg13206674	chr6:150067644	NUP43	0.52	4.51	0.38	1.5e-5	Lung cancer;
TGCT	cis	rs9560113	0.580	rs9560115	chr13:112193619	G/A	cg10483660	chr13:112241077	NA	0.32	4.64	0.38	8.8e-6	Menarche (age at onset);
TGCT	cis	rs10254284	1.000	rs1985152	chr7:28166534	G/A	cg23620719	chr7:28220237	JAZF1	-0.56	-4.87	-0.4	3.28e-6	Lymphocyte percentage of white cells;Systemic lupus erythematosus;
TGCT	cis	rs4654899	0.643	rs589755	chr1:21099846	A/G	cg01072550	chr1:21505969	NA	-0.54	-8.85	-0.62	7.62e-15	Superior frontal gyrus grey matter volume;
TGCT	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg00343986	chr7:65444356	GUSB	-0.22	-5.27	-0.43	5.79e-7	Calcium levels;
TGCT	cis	rs892961	0.899	rs72896162	chr17:75412521	A/G	cg05865280	chr17:75406074	SEPT9	0.28	6.86	0.52	2.9e-10	Airflow obstruction;
TGCT	cis	rs9948	0.786	rs62156225	chr2:97414118	T/C	cg01990225	chr2:97406019	LMAN2L	-0.88	-4.81	-0.4	4.37e-6	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs12048904	0.541	rs1571046	chr1:101299216	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.87	7.77	0.57	2.6e-12	Multiple sclerosis;
TGCT	cis	rs9811920	0.683	rs7650727	chr3:99688976	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.43	5.12	0.42	1.14e-6	Axial length;
TGCT	cis	rs1008375	0.800	rs28754811	chr4:17612312	C/T	cg10189774	chr4:17578691	LAP3	0.59	5.07	0.41	1.43e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	trans	rs7726839	0.540	rs12520279	chr5:657291	T/C	cg25482853	chr8:67687455	SGK3	1.2	10.13	0.67	6.02e-18	Obesity-related traits;
TGCT	cis	rs7617773	1.000	rs7617773	chr3:48193515	C/T	cg11946769	chr3:48343235	NME6	-0.59	-5.25	-0.43	6.49e-7	Coronary artery disease;
TGCT	cis	rs3796352	0.881	rs35385050	chr3:52997945	C/A	cg15956490	chr3:53032818	SFMBT1	0.61	6.11	0.48	1.17e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	6.13	0.48	1.06e-8	Bipolar disorder;
TGCT	cis	rs7647973	1.000	rs7647973	chr3:49510931	G/A	cg07636037	chr3:49044803	WDR6	-0.73	-5.87	-0.47	3.65e-8	Menarche (age at onset);
TGCT	cis	rs4319547	0.585	rs7953007	chr12:122816977	A/C	cg05707623	chr12:122985044	ZCCHC8	-0.59	-4.53	-0.38	1.35e-5	Body mass index;
TGCT	cis	rs10791097	0.748	rs2282579	chr11:130735482	C/T	cg05962950	chr11:130786565	SNX19	0.89	11.4	0.72	4.96e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs7666738	0.830	rs11944107	chr4:98931638	G/C	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg25036284	chr2:26402008	FAM59B	0.57	4.97	0.41	2.15e-6	Gut microbiome composition (summer);
TGCT	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg22920501	chr2:26401640	FAM59B	0.88	6.09	0.48	1.32e-8	Gut microbiome composition (summer);
TGCT	cis	rs13185784	0.667	rs4441844	chr5:179645386	C/T	cg04734276	chr5:178882605	NA	0.29	4.46	0.37	1.81e-5	TRAIL levels;
TGCT	cis	rs6570726	0.764	rs448258	chr6:145869145	C/A	cg13319975	chr6:146136371	FBXO30	-0.51	-4.6	-0.38	1.01e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6589563	0.737	rs57200947	chr11:116623674	C/T	cg20660624	chr11:117307972	DSCAML1	-0.38	-4.99	-0.41	2.02e-6	Eosinophil counts;
TGCT	cis	rs7681440	0.904	rs1442153	chr4:90775719	T/G	cg14346243	chr4:90757452	SNCA	-0.56	-5.47	-0.44	2.41e-7	Dementia with Lewy bodies;
TGCT	cis	rs10510102	0.872	rs12244199	chr10:123724632	C/G	cg23691251	chr10:123688108	ATE1	-0.67	-5.33	-0.43	4.38e-7	Breast cancer;
TGCT	cis	rs9972944	0.902	rs9972956	chr17:63771092	T/C	cg07283582	chr17:63770753	CCDC46	0.28	5.89	0.47	3.36e-8	Total body bone mineral density;
TGCT	cis	rs739496	0.649	rs616513	chr12:112003383	G/T	cg10833066	chr12:111807467	FAM109A	0.37	5.59	0.45	1.4e-7	Platelet count;
TGCT	trans	rs3780486	0.718	rs73645257	chr9:33132354	C/T	cg04842962	chr6:43655489	MRPS18A	0.99	7.15	0.54	6.6e-11	IgG glycosylation;
TGCT	cis	rs1348850	0.632	rs11682717	chr2:178499240	C/G	cg22681709	chr2:178499509	PDE11A	-0.51	-6.43	-0.5	2.47e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs67311347	1.000	rs56992941	chr3:40472434	A/T	cg17264618	chr3:40429014	ENTPD3	0.32	4.76	0.39	5.36e-6	Renal cell carcinoma;
TGCT	cis	rs12971120	0.838	rs2241510	chr18:72180739	G/A	cg26446133	chr18:72167187	CNDP2	-0.35	-5.95	-0.47	2.59e-8	Refractive error;
TGCT	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.09	0.82	3.7e-32	Prudent dietary pattern;
TGCT	cis	rs78487399	0.808	rs112387154	chr2:43763231	G/A	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.79	4.82	0.4	4.14e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs10791097	0.547	rs11222371	chr11:130745719	C/T	cg14779329	chr11:130786720	SNX19	0.29	4.79	0.4	4.58e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs926938	0.520	rs6663115	chr1:115272254	G/A	cg12756093	chr1:115239321	AMPD1	-0.41	-4.93	-0.4	2.62e-6	Autism;
TGCT	cis	rs11098499	1.000	rs28374891	chr4:120183550	G/A	cg09307838	chr4:120376055	NA	0.49	4.52	0.38	1.43e-5	Corneal astigmatism;
TGCT	cis	rs6815814	0.731	rs11096956	chr4:38776180	G/T	cg02016764	chr4:38805732	TLR1	-0.29	-5.02	-0.41	1.73e-6	Breast cancer;
TGCT	cis	rs259282	0.851	rs174083	chr19:33141180	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.88	9.84	0.66	3.09e-17	Schizophrenia;
TGCT	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg09359103	chr1:154839909	KCNN3	-0.67	-12.98	-0.76	7.41e-25	Prostate cancer;
TGCT	cis	rs2862064	0.818	rs1979870	chr5:156481383	T/C	cg12943317	chr5:156479607	HAVCR1	-0.47	-5.98	-0.47	2.2e-8	Platelet count;
TGCT	cis	rs911555	1.000	rs911552	chr14:103999508	A/G	cg12935359	chr14:103987150	CKB	0.35	4.99	0.41	2.03e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4886920	0.563	rs4509984	chr15:78079267	C/G	cg03457338	chr15:78040120	NA	0.18	4.51	0.38	1.48e-5	Neuroticism;
TGCT	cis	rs3008870	0.629	rs12742428	chr1:67426487	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.82	8.51	0.61	4.75e-14	Lymphocyte percentage of white cells;
TGCT	cis	rs11098499	0.604	rs34278750	chr4:120571136	G/A	cg09307838	chr4:120376055	NA	0.64	6.23	0.49	6.81e-9	Corneal astigmatism;
TGCT	cis	rs7208859	0.623	rs8068645	chr17:29104342	T/A	cg13385521	chr17:29058706	SUZ12P	0.8	4.71	0.39	6.51e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	trans	rs804280	0.542	rs36100659	chr8:11791653	A/T	cg15556689	chr8:8085844	FLJ10661	0.75	7.26	0.55	3.66e-11	Myopia (pathological);
TGCT	cis	rs2070433	0.800	rs11700596	chr21:47874054	G/C	cg12379764	chr21:47803548	PCNT	0.56	4.78	0.39	4.83e-6	Lymphocyte counts;
TGCT	cis	rs28595532	0.920	rs17257039	chr4:119603703	G/A	cg14228332	chr4:119757509	SEC24D	1.04	5.37	0.43	3.66e-7	Cannabis dependence symptom count;
TGCT	cis	rs7647973	0.626	rs1491985	chr3:49739507	G/C	cg03034192	chr3:50606346	HEMK1;C3orf18	0.36	4.75	0.39	5.61e-6	Menarche (age at onset);
TGCT	cis	rs548181	0.545	rs4486648	chr11:125610589	T/A	cg03464685	chr11:125439445	EI24	-1.31	-7.98	-0.58	8.17e-13	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs904251	0.797	rs2776878	chr6:37487273	G/A	cg08126542	chr6:37504118	NA	-0.44	-5.94	-0.47	2.73e-8	Cognitive performance;
TGCT	cis	rs9807989	0.507	rs1592458	chr2:103031749	A/T	cg03938978	chr2:103052716	IL18RAP	0.27	5.41	0.44	3.17e-7	Asthma;
TGCT	cis	rs1215050	0.605	rs4092341	chr4:98614252	C/T	cg05340658	chr4:99064831	C4orf37	-0.41	-4.96	-0.41	2.3e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs6500602	0.819	rs3747580	chr16:4455675	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.44	6.7	0.52	6.58e-10	Schizophrenia;
TGCT	cis	rs11971779	0.680	rs4728467	chr7:139120562	G/A	cg07862535	chr7:139043722	LUC7L2	0.69	5.41	0.44	3.1e-7	Diisocyanate-induced asthma;
TGCT	cis	rs78487399	0.808	rs17039131	chr2:43652398	A/C	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.74	4.69	0.39	7.08e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs2404602	0.692	rs12595586	chr15:77172210	A/G	cg22467129	chr15:76604101	ETFA	-0.47	-5.39	-0.44	3.44e-7	Blood metabolite levels;
TGCT	cis	rs9611565	0.681	rs5751094	chr22:41803279	C/T	cg06481639	chr22:41940642	POLR3H	0.6	5.48	0.44	2.23e-7	Vitiligo;
TGCT	cis	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg27286337	chr10:134555280	INPP5A	0.45	5.43	0.44	2.8e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs9611565	0.694	rs5758324	chr22:41787950	G/T	cg06481639	chr22:41940642	POLR3H	-0.58	-5.03	-0.41	1.67e-6	Vitiligo;
TGCT	cis	rs10782582	0.609	rs2881785	chr1:76318096	T/C	cg03433033	chr1:76189801	ACADM	-0.52	-5.16	-0.42	9.66e-7	Daytime sleep phenotypes;
TGCT	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg20607798	chr8:58055168	NA	0.5	4.66	0.39	8.04e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs78487399	0.808	rs7561287	chr2:43689071	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.42	-4.77	-0.39	4.98e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs9393692	0.905	rs7747133	chr6:26293470	C/T	cg05868516	chr6:26286170	HIST1H4H	0.63	5.93	0.47	2.76e-8	Educational attainment;
TGCT	cis	rs4911259	0.552	rs11700082	chr20:31460244	A/G	cg13636640	chr20:31349939	DNMT3B	-0.89	-9.82	-0.66	3.4e-17	Inflammatory bowel disease;
TGCT	cis	rs13392177	0.684	rs62185965	chr2:219073779	T/C	cg00012203	chr2:219082015	ARPC2	-0.79	-8.02	-0.58	6.73e-13	Pyoderma gangrenosum in inflammatory bowel disease;
TGCT	cis	rs7923609	0.811	rs3847326	chr10:65331859	A/G	cg08743896	chr10:65200160	JMJD1C	0.32	4.44	0.37	1.99e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2439831	0.850	rs3759790	chr15:44121030	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.44	0.37	1.99e-5	Lung cancer in ever smokers;
TGCT	cis	rs593982	1.000	rs72922786	chr11:65562852	G/C	cg08755490	chr11:65554678	OVOL1	-1.09	-7.12	-0.54	7.54e-11	Atopic dermatitis;
TGCT	cis	rs79996792	0.578	rs77427002	chr2:162285739	T/C	cg22496339	chr2:162101262	NA	0.54	4.46	0.37	1.81e-5	Neuroticism;
TGCT	cis	rs6540559	0.673	rs58637469	chr1:209971480	T/A	cg22029157	chr1:209979665	IRF6	0.74	5.53	0.44	1.84e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs7524258	0.835	rs7521425	chr1:7306543	C/T	cg07173049	chr1:7289937	CAMTA1	0.29	4.72	0.39	6.23e-6	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs7412746	0.622	rs11552229	chr1:150783985	T/C	cg04414720	chr1:150670196	GOLPH3L	0.42	5.25	0.43	6.37e-7	Melanoma;
TGCT	cis	rs10984561	0.881	rs59676902	chr9:122252850	A/C	cg14242995	chr9:122249943	NA	0.73	5.96	0.47	2.46e-8	Pulmonary function decline;
TGCT	cis	rs2295359	0.892	rs72676069	chr1:67658954	T/C	cg08029281	chr1:67600428	NA	0.4	4.68	0.39	7.36e-6	Psoriasis;
TGCT	cis	rs4478858	0.647	rs7524117	chr1:31738416	A/G	cg07478791	chr1:31886160	SERINC2	-0.49	-4.91	-0.4	2.82e-6	Alcohol dependence;
TGCT	cis	rs9467711	0.516	rs1165163	chr6:25863487	G/C	cg12310025	chr6:25882481	NA	-0.72	-4.77	-0.39	5.17e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4888262	0.545	rs4888270	chr16:74698576	A/G	cg01733217	chr16:74700730	RFWD3	0.75	7.65	0.57	4.96e-12	Testicular germ cell tumor;
TGCT	cis	rs7659604	0.539	rs11098645	chr4:122729251	G/A	cg20573242	chr4:122745356	CCNA2	0.62	5.48	0.44	2.23e-7	Type 2 diabetes;
TGCT	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.61	5.06	0.41	1.5e-6	Tonsillectomy;
TGCT	cis	rs7617773	0.780	rs7645425	chr3:48362369	A/T	cg11946769	chr3:48343235	NME6	0.8	6.91	0.53	2.26e-10	Coronary artery disease;
TGCT	cis	rs1784581	0.631	rs3016544	chr6:162393065	T/C	cg17173639	chr6:162384350	PARK2	-0.46	-8.18	-0.59	2.92e-13	Itch intensity from mosquito bite;
TGCT	cis	rs6882046	0.513	rs676096	chr5:88035887	C/T	cg22951263	chr5:87985283	NA	-0.55	-5.94	-0.47	2.74e-8	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs2153535	0.580	rs9392223	chr6:8468650	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.8	0.46	5.19e-8	Motion sickness;
TGCT	trans	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg21659725	chr3:3221576	CRBN	-0.76	-9.03	-0.63	2.74e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs3733585	0.624	rs76574510	chr4:9953252	T/A	cg11266682	chr4:10021025	SLC2A9	-0.57	-7.6	-0.56	6.21e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs8014204	0.816	rs10083386	chr14:75347585	C/A	cg06637938	chr14:75390232	RPS6KL1	-0.53	-4.58	-0.38	1.12e-5	Caffeine consumption;
TGCT	cis	rs7267979	1.000	rs6083809	chr20:25329309	A/G	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg11247378	chr22:39784982	NA	-0.74	-9.64	-0.65	9.38e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs8180040	0.676	rs7633698	chr3:47013452	A/T	cg27129171	chr3:47204927	SETD2	0.73	9.4	0.65	3.57e-16	Colorectal cancer;
TGCT	cis	rs9467711	0.606	rs71557334	chr6:26365913	G/T	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs295140	0.837	rs12474914	chr2:201130210	A/G	cg04283868	chr2:201171347	SPATS2L	0.52	5.2	0.42	8.14e-7	QT interval;
TGCT	cis	rs12477438	0.765	rs13390672	chr2:99589829	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-4.62	-0.38	9.47e-6	Chronic sinus infection;
TGCT	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg06618935	chr21:46677482	NA	-0.36	-5.58	-0.45	1.46e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2120019	1.000	rs12898259	chr15:75369780	G/A	cg11632617	chr15:75315747	PPCDC	-0.33	-4.78	-0.39	4.82e-6	Blood trace element (Zn levels);
TGCT	cis	rs7666738	0.830	rs13112131	chr4:98976784	G/A	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7772486	0.764	rs7745696	chr6:146162829	T/C	cg13319975	chr6:146136371	FBXO30	-0.5	-4.49	-0.37	1.61e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs17539620	0.519	rs871071	chr6:154837667	T/C	cg20019720	chr6:154832845	CNKSR3	0.63	5.72	0.46	7.47e-8	Lipoprotein (a) levels;
TGCT	cis	rs6988636	0.710	rs62521806	chr8:124161054	C/T	cg23067535	chr8:124195133	FAM83A	-0.35	-4.75	-0.39	5.61e-6	Urinary uromodulin levels;
TGCT	cis	rs9549260	0.753	rs9549254	chr13:41234763	G/A	cg21288729	chr13:41239152	FOXO1	0.67	4.78	0.39	4.78e-6	Red blood cell count;
TGCT	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.04	0.53	1.16e-10	Prudent dietary pattern;
TGCT	cis	rs4788570	0.566	rs10468265	chr16:71476943	T/C	cg06353428	chr16:71660113	MARVELD3	-1.32	-7.86	-0.58	1.6e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs12643440	0.538	rs1581402	chr4:17139877	T/A	cg22650099	chr4:17144496	NA	-0.45	-4.65	-0.39	8.28e-6	Metabolite levels (Pyroglutamine);
TGCT	cis	rs172166	0.694	rs2791332	chr6:28108788	C/T	cg10876282	chr6:28092338	ZSCAN16	0.49	4.44	0.37	1.98e-5	Cardiac Troponin-T levels;
TGCT	cis	rs7772486	0.686	rs4896833	chr6:145965673	T/G	cg23711669	chr6:146136114	FBXO30	0.84	9.16	0.64	1.36e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7043114	0.525	rs7863406	chr9:95053381	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-5.57	-0.45	1.53e-7	Height;
TGCT	cis	rs6088580	0.602	rs6059834	chr20:33019299	A/G	cg06115741	chr20:33292138	TP53INP2	0.55	4.81	0.4	4.24e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs17601876	0.814	rs749292	chr15:51558731	A/G	cg19946085	chr15:51559439	CYP19A1	0.33	5.04	0.41	1.6e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs1903068	0.925	rs1551645	chr4:55994314	T/G	cg16572876	chr4:56024045	NA	0.45	5.08	0.42	1.34e-6	Endometriosis;
TGCT	cis	rs1466788	0.965	rs1390954	chr1:110615668	C/T	cg11787288	chr1:111506544	C1orf103	0.49	4.5	0.38	1.51e-5	Blood metabolite levels;
TGCT	cis	rs9814567	0.806	rs9857242	chr3:134316378	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.76	7.2	0.54	5.12e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs6901004	0.712	rs367734	chr6:111512378	C/G	cg15721981	chr6:111408429	SLC16A10	-0.52	-4.6	-0.38	1.03e-5	Blood metabolite levels;
TGCT	cis	rs2153535	0.541	rs1414347	chr6:8471831	T/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.07	0.41	1.43e-6	Motion sickness;
TGCT	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	8.0	0.58	7.67e-13	Platelet count;
TGCT	cis	rs941408	1.000	rs941408	chr19:2814181	C/T	cg06609049	chr19:2785107	THOP1	0.82	7.25	0.55	3.85e-11	Total cholesterol levels;
TGCT	cis	rs1670533	1.000	rs7669622	chr4:1058659	A/G	cg27284194	chr4:1044797	NA	0.66	5.69	0.45	8.85e-8	Recombination rate (females);
TGCT	cis	rs137699	0.652	rs137707	chr22:39751401	T/C	cg01416388	chr22:39784598	NA	-0.59	-4.73	-0.39	6.08e-6	IgG glycosylation;
TGCT	cis	rs62244186	0.715	rs10212378	chr3:44667286	C/G	cg21672276	chr3:44754072	ZNF502	-0.43	-4.8	-0.4	4.44e-6	Depressive symptoms;
TGCT	cis	rs7909074	1.000	rs7909074	chr10:45395839	G/A	cg04218760	chr10:45406644	TMEM72	-0.27	-5.33	-0.43	4.38e-7	Mean corpuscular volume;
TGCT	cis	rs9325144	0.560	rs10785573	chr12:38654166	G/A	cg26384229	chr12:38710491	ALG10B	-0.66	-6.0	-0.47	2.06e-8	Morning vs. evening chronotype;
TGCT	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg11247378	chr22:39784982	NA	0.66	8.83	0.62	8.17e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs1451375	0.527	rs6950777	chr7:50597056	G/A	cg18232548	chr7:50535776	DDC	0.35	4.64	0.38	8.75e-6	Malaria;
TGCT	cis	rs2594989	0.622	rs2442794	chr3:11551001	A/G	cg00170343	chr3:11313890	ATG7	0.62	4.46	0.37	1.79e-5	Circulating chemerin levels;
TGCT	cis	rs6430585	0.591	rs61187091	chr2:136468238	G/A	cg07169764	chr2:136633963	MCM6	1.12	10.49	0.69	8.04e-19	Corneal structure;
TGCT	cis	rs10893109	1.000	rs10893109	chr11:123804419	A/C	cg14126608	chr11:122846540	NA	-0.28	-4.58	-0.38	1.12e-5	Facial morphology (factor 13, vertical position of alar curvature relative to upper lip);
TGCT	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg11764359	chr7:65958608	NA	0.59	5.06	0.41	1.5e-6	Aortic root size;
TGCT	cis	rs6484504	0.576	rs2150213	chr11:31244634	A/G	cg14844989	chr11:31128820	NA	-0.23	-4.44	-0.37	1.97e-5	Red blood cell count;
TGCT	cis	rs17221829	0.627	rs12421880	chr11:89391713	C/T	cg02982614	chr11:89391479	FOLH1B	-0.25	-4.46	-0.37	1.8e-5	Anxiety in major depressive disorder;
TGCT	cis	rs7618915	0.501	rs55678971	chr3:52717229	T/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.48	-4.47	-0.37	1.76e-5	Bipolar disorder;
TGCT	cis	rs56011263	0.687	rs4690188	chr4:703930	G/C	cg20735989	chr4:730612	PCGF3	-0.25	-5.45	-0.44	2.63e-7	White blood cell count;
TGCT	cis	rs6088590	1.000	rs2378256	chr20:33292127	G/C	cg24642439	chr20:33292090	TP53INP2	0.7	6.41	0.5	2.75e-9	Coronary artery disease;
TGCT	cis	rs9814567	1.000	rs9850015	chr3:134269541	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.98	-9.89	-0.66	2.32e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs6815814	0.950	rs73236618	chr4:38794041	T/C	cg02016764	chr4:38805732	TLR1	-0.32	-4.95	-0.41	2.35e-6	Breast cancer;
TGCT	cis	rs9291683	0.605	rs73224439	chr4:10331818	C/A	cg00071950	chr4:10020882	SLC2A9	-0.44	-4.53	-0.38	1.35e-5	Bone mineral density;
TGCT	cis	rs9549367	0.826	rs2302755	chr13:113898418	C/T	cg00898013	chr13:113819073	PROZ	-0.43	-5.47	-0.44	2.37e-7	Platelet distribution width;
TGCT	cis	rs35306767	0.855	rs34318754	chr10:890714	G/A	cg20503657	chr10:835505	NA	0.77	11.34	0.71	6.95e-21	Eosinophil percentage of granulocytes;
TGCT	cis	rs651907	0.557	rs17411983	chr3:101399126	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.91	-10.9	-0.7	8.24e-20	Colorectal cancer;
TGCT	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg07870213	chr5:140052090	DND1	-0.62	-7.4	-0.55	1.84e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg01448562	chr3:133502909	NA	-0.33	-6.71	-0.52	6.3e-10	Iron status biomarkers;
TGCT	cis	rs4566357	0.576	rs3769644	chr2:227917240	C/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-5.24	-0.43	6.55e-7	Coronary artery disease;
TGCT	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg04267008	chr7:1944627	MAD1L1	-0.36	-4.76	-0.39	5.32e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg04267008	chr7:1944627	MAD1L1	-0.4	-5.46	-0.44	2.5e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg26338869	chr17:61819248	STRADA	-0.53	-4.94	-0.41	2.48e-6	Prudent dietary pattern;
TGCT	cis	rs6840360	1.000	rs6838966	chr4:152603475	C/T	cg17479576	chr4:152424074	FAM160A1	-0.49	-5.15	-0.42	9.73e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs793571	0.523	rs7163162	chr15:58983588	T/A	cg05156742	chr15:59063176	FAM63B	0.48	4.46	0.37	1.83e-5	Schizophrenia;
TGCT	cis	rs2334880	0.678	rs12919092	chr16:71446490	T/C	cg06353428	chr16:71660113	MARVELD3	-1.23	-7.7	-0.57	3.78e-12	Malaria;
TGCT	cis	rs7937682	0.924	rs875258	chr11:111530607	C/A	cg09085632	chr11:111637200	PPP2R1B	-1.12	-11.81	-0.73	4.86e-22	Primary sclerosing cholangitis;
TGCT	trans	rs1814175	0.781	rs2866734	chr11:49886338	A/G	cg03929089	chr4:120376271	NA	-0.72	-8.26	-0.6	1.84e-13	Height;
TGCT	cis	rs2224391	0.590	rs2145372	chr6:5245070	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.98	-6.21	-0.49	7.43e-9	Height;
TGCT	cis	rs12681288	0.862	rs2701899	chr8:1019581	G/A	cg04851639	chr8:1020857	NA	-0.4	-7.59	-0.56	6.62e-12	Schizophrenia;
TGCT	cis	rs3087591	0.960	rs4795587	chr17:29587917	A/C	cg24425628	chr17:29625626	OMG;NF1	-0.49	-7.37	-0.55	2.06e-11	Hip circumference;
TGCT	cis	rs9902453	0.808	rs56088359	chr17:28173659	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	7.17	0.54	5.79e-11	Coffee consumption (cups per day);
TGCT	cis	rs896854	0.654	rs896846	chr8:95972453	G/A	cg09323728	chr8:95962352	TP53INP1	-0.52	-6.6	-0.51	1.07e-9	Type 2 diabetes;
TGCT	cis	rs7666738	0.800	rs2839836	chr4:98970512	A/G	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7027203	0.828	rs3957506	chr9:96588133	C/T	cg13679303	chr9:96623674	NA	-0.68	-10.87	-0.7	9.9e-20	DNA methylation (variation);
TGCT	cis	rs7267979	0.789	rs9927	chr20:25277244	A/G	cg16686733	chr20:25566563	NINL	0.57	5.45	0.44	2.6e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs561341	1.000	rs546519	chr17:30297682	T/G	cg20587970	chr11:113659929	NA	-1.03	-10.98	-0.7	5.21e-20	Hip circumference adjusted for BMI;
TGCT	cis	rs2797160	1.000	rs1418948	chr6:126007018	C/T	cg05901451	chr6:126070800	HEY2	0.74	6.3	0.49	4.62e-9	Endometrial cancer;
TGCT	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg04267008	chr7:1944627	MAD1L1	-0.4	-5.28	-0.43	5.67e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs2692947	0.696	rs2969490	chr2:96803904	A/G	cg22654517	chr2:96458247	NA	0.22	5.01	0.41	1.82e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs2762353	0.904	rs13197514	chr6:25785991	C/T	cg03264133	chr6:25882463	NA	0.5	5.29	0.43	5.3e-7	Blood metabolite levels;
TGCT	cis	rs2506155	0.752	rs61843160	chr10:33515868	C/G	cg25928881	chr10:32632685	EPC1	0.31	4.69	0.39	7.08e-6	Migraine;
TGCT	cis	rs35146811	0.555	rs1981550	chr7:99541952	G/A	cg13334819	chr7:99746414	C7orf59	-0.6	-5.1	-0.42	1.26e-6	Coronary artery disease;
TGCT	cis	rs910316	1.000	rs4903284	chr14:75592483	G/C	cg11812906	chr14:75593930	NEK9	0.73	7.23	0.54	4.36e-11	Height;
TGCT	cis	rs6684514	1.000	rs2296375	chr1:156309372	G/C	cg16558208	chr1:156270281	VHLL	0.48	9.38	0.64	4.04e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs3733631	0.696	rs7672658	chr4:104631530	G/A	cg24090629	chr4:104641072	TACR3	-0.73	-5.81	-0.46	4.96e-8	Menarche (age at onset);
TGCT	cis	rs34014631	1.000	rs78134907	chr10:103652875	T/G	cg22630918	chr10:102748988	C10orf2	0.42	4.82	0.4	4.15e-6	Coronary artery calcification;
TGCT	cis	rs6840360	0.554	rs62329088	chr4:152471289	C/T	cg17479576	chr4:152424074	FAM160A1	-0.72	-7.98	-0.58	8.25e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs6879260	1.000	rs1035411	chr5:179729519	A/G	cg13944838	chr5:179740914	GFPT2	-0.41	-6.61	-0.51	1.03e-9	Height;
TGCT	cis	rs35934224	0.783	rs35969236	chr22:19860355	T/G	cg11182965	chr22:19864308	TXNRD2	-0.38	-5.3	-0.43	5.04e-7	Glaucoma (primary open-angle);
TGCT	cis	rs4072705	0.869	rs2416951	chr9:127550603	C/G	cg13476313	chr9:127244764	NR5A1	0.29	4.79	0.4	4.63e-6	Menarche (age at onset);
TGCT	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg02725872	chr8:58115012	NA	-0.41	-5.42	-0.44	3.01e-7	Developmental language disorder (linguistic errors);
TGCT	trans	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.86	-9.41	-0.65	3.39e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs12134133	1.000	rs7532664	chr1:207426943	C/T	cg02152968	chr1:207494213	CD55	0.61	4.83	0.4	3.92e-6	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.81	9.15	0.63	1.44e-15	Menarche (age at onset);
TGCT	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg11890956	chr21:40555474	PSMG1	-0.73	-7.16	-0.54	6.37e-11	Cognitive function;
TGCT	cis	rs3806843	0.838	rs2563289	chr5:140122766	T/A	cg19875535	chr5:140030758	IK	-0.35	-5.92	-0.47	2.89e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg00343986	chr7:65444356	GUSB	0.23	5.16	0.42	9.66e-7	Aortic root size;
TGCT	cis	rs10992471	0.631	rs2296667	chr9:95274338	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.54	-5.4	-0.44	3.31e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs10883723	0.773	rs2296578	chr10:104240974	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs7615952	0.866	rs11922276	chr3:125631326	G/T	cg05084668	chr3:125655381	ALG1L	-0.74	-6.05	-0.48	1.6e-8	Blood pressure (smoking interaction);
TGCT	cis	rs9372498	0.536	rs25422	chr6:118807847	A/G	cg07617317	chr6:118971624	C6orf204	-0.49	-5.1	-0.42	1.26e-6	Diastolic blood pressure;
TGCT	cis	rs10193935	0.901	rs7570083	chr2:42517859	G/A	cg27598129	chr2:42591480	NA	-0.39	-5.37	-0.43	3.72e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg18402987	chr7:1209562	NA	0.74	6.21	0.49	7.23e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs877282	1.000	rs71491304	chr10:772982	C/T	cg17470449	chr10:769945	NA	0.31	4.8	0.4	4.44e-6	Uric acid levels;
TGCT	cis	rs9325144	0.671	rs35817541	chr12:38975001	T/C	cg26384229	chr12:38710491	ALG10B	-0.59	-5.6	-0.45	1.28e-7	Morning vs. evening chronotype;
TGCT	cis	rs9916302	0.904	rs4239222	chr17:37696235	A/C	cg15445000	chr17:37608096	MED1	-0.36	-5.21	-0.42	7.58e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs7666738	0.546	rs13141117	chr4:98892798	G/A	cg05340658	chr4:99064831	C4orf37	0.59	6.33	0.49	4.05e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7582180	0.764	rs11682748	chr2:100925934	C/A	cg08017756	chr2:100939284	LONRF2	-0.32	-5.31	-0.43	4.86e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9858542	0.953	rs9827708	chr3:49649989	C/G	cg03060546	chr3:49711283	APEH	-0.63	-5.51	-0.44	1.96e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg12963246	chr6:28129442	ZNF389	0.52	5.01	0.41	1.85e-6	Depression;
TGCT	cis	rs2153535	0.580	rs7747306	chr6:8453663	C/G	cg23788917	chr6:8435910	SLC35B3	-0.62	-5.66	-0.45	9.91e-8	Motion sickness;
TGCT	cis	rs28595532	0.668	rs72670237	chr4:119320937	T/C	cg21605333	chr4:119757512	SEC24D	0.84	4.92	0.4	2.74e-6	Cannabis dependence symptom count;
TGCT	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg11764359	chr7:65958608	NA	-0.55	-5.0	-0.41	1.94e-6	Aortic root size;
TGCT	cis	rs2836633	0.895	rs2836597	chr21:40024424	A/G	cg05519781	chr21:40033154	ERG	0.69	6.7	0.52	6.55e-10	Coronary artery disease;
TGCT	cis	rs4455778	0.600	rs12718312	chr7:49024757	C/T	cg26309511	chr7:48887640	NA	-0.43	-5.07	-0.41	1.4e-6	Lung cancer in never smokers;
TGCT	cis	rs78545713	1.000	rs16891484	chr6:26242930	G/A	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.66	-4.71	-0.39	6.57e-6	Iron status biomarkers (total iron binding capacity);
TGCT	cis	rs35264875	0.950	rs72928659	chr11:68852358	C/T	cg02660097	chr11:68866761	NA	0.32	4.96	0.41	2.3e-6	Blond vs. brown hair color;
TGCT	cis	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg05590025	chr7:65112418	INTS4L2	-0.77	-4.5	-0.37	1.52e-5	Diabetic kidney disease;
TGCT	cis	rs511515	1	rs511515	chr6:33541507	A/G	cg24505687	chr6:33548425	BAK1	0.55	6.24	0.49	6.3e-9	Eosinophil counts;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
TGCT	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg19901468	chr14:105411992	AHNAK2	-0.27	-5.86	-0.47	3.84e-8	Rheumatoid arthritis;
TGCT	cis	rs9393692	0.905	rs9379843	chr6:26289435	A/G	cg05868516	chr6:26286170	HIST1H4H	0.63	5.88	0.47	3.57e-8	Educational attainment;
TGCT	trans	rs7342694	0.965	rs12102309	chr16:81907046	T/C	cg04928372	chr6:27720905	NA	0.7	6.79	0.52	4.18e-10	Coronary artery disease;
TGCT	cis	rs7542091	0.669	rs7540534	chr1:210044824	A/T	cg22029157	chr1:209979665	IRF6	0.64	6.1	0.48	1.23e-8	Monobrow;
TGCT	cis	rs3008870	0.755	rs11208974	chr1:67398119	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.78	8.29	0.6	1.59e-13	Lymphocyte percentage of white cells;
TGCT	cis	rs7726839	0.540	rs74553517	chr5:665671	C/T	cg20362242	chr5:692897	TPPP	0.51	4.66	0.39	8.11e-6	Obesity-related traits;
TGCT	cis	rs9911578	0.817	rs304264	chr17:56749628	A/G	cg12560992	chr17:57184187	TRIM37	0.71	8.43	0.6	7.36e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs2180341	1.000	rs9285460	chr6:127640190	A/G	cg24812749	chr6:127587940	RNF146	0.98	7.64	0.57	5.06e-12	Breast cancer;
TGCT	cis	rs4938534	0.785	rs1944926	chr11:111287287	T/G	cg01212326	chr11:111250286	POU2AF1	-0.23	-4.83	-0.4	3.94e-6	Primary biliary cholangitis;
TGCT	cis	rs763121	0.657	rs5995603	chr22:39040733	G/A	cg06022373	chr22:39101656	GTPBP1	0.73	6.34	0.49	3.9e-9	Menopause (age at onset);
TGCT	cis	rs4805272	0.512	rs66830923	chr19:29321277	C/T	cg03161606	chr19:29218774	NA	0.54	4.48	0.37	1.68e-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
TGCT	cis	rs6754311	0.678	rs309181	chr2:136614813	C/G	cg07169764	chr2:136633963	MCM6	-0.62	-5.74	-0.46	7e-8	Mosquito bite size;
TGCT	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg15595755	chr5:1867978	NA	0.48	5.68	0.45	9.07e-8	Cardiovascular disease risk factors;
TGCT	trans	rs62103177	0.561	rs891489	chr18:77637493	G/A	cg05926928	chr17:57297772	GDPD1	-0.99	-9.29	-0.64	6.5e-16	Opioid sensitivity;
TGCT	cis	rs2637266	1.000	rs2579747	chr10:78327759	C/T	cg18941641	chr10:78392320	NA	0.39	4.97	0.41	2.16e-6	Pulmonary function;
TGCT	cis	rs732765	0.734	rs12897105	chr14:75188122	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.55	-4.48	-0.37	1.71e-5	Non-small cell lung cancer;
TGCT	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg20573242	chr4:122745356	CCNA2	0.62	5.48	0.44	2.24e-7	Type 2 diabetes;
TGCT	cis	rs2677744	1.000	rs4773	chr15:91463842	G/A	cg22288577	chr15:91498497	RCCD1	0.47	4.86	0.4	3.45e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg04267008	chr7:1944627	MAD1L1	-0.35	-4.72	-0.39	6.16e-6	Schizophrenia;
TGCT	cis	rs611744	0.967	rs598477	chr8:109187874	G/T	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs514475	0.526	rs12201688	chr6:137956658	T/G	cg02673417	chr6:137105249	MAP3K5	0.29	4.45	0.37	1.88e-5	Inflammatory skin disease;
TGCT	cis	rs9346649	0.606	rs6940383	chr6:168491688	G/A	cg02770688	chr6:168491649	NA	0.32	5.58	0.45	1.41e-7	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
TGCT	cis	rs826838	0.967	rs1684414	chr12:39129553	A/G	cg13010199	chr12:38710504	ALG10B	-0.63	-5.06	-0.41	1.46e-6	Heart rate;
TGCT	cis	rs2762353	0.639	rs566530	chr6:25878361	T/C	cg03517284	chr6:25882590	NA	-0.63	-6.91	-0.53	2.21e-10	Blood metabolite levels;
TGCT	cis	rs8026198	0.734	rs7163986	chr15:42696158	A/T	cg23803468	chr15:43513504	EPB42	0.28	4.57	0.38	1.16e-5	Fibrinogen levels;
TGCT	cis	rs7833790	0.963	rs1451997	chr8:82774053	A/T	cg06027949	chr8:82754900	SNX16	0.65	4.49	0.37	1.59e-5	Diastolic blood pressure;
TGCT	cis	rs2439831	0.681	rs7168940	chr15:43633334	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	9.01	0.63	3.09e-15	Lung cancer in ever smokers;
TGCT	cis	rs4918072	0.917	rs17573075	chr10:105649940	C/G	cg11005552	chr10:105648138	OBFC1	0.42	5.41	0.44	3.17e-7	Coronary artery disease;
TGCT	cis	rs5769707	0.935	rs1109320	chr22:49989106	G/A	cg20744362	chr22:50050164	C22orf34	0.28	4.59	0.38	1.06e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs28785552	0.931	rs8112235	chr19:53239010	C/G	cg10871876	chr19:53194124	ZNF83	0.6	8.52	0.61	4.57e-14	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs9611565	0.879	rs4820437	chr22:41761290	T/C	cg17554472	chr22:41940697	POLR3H	-0.45	-4.91	-0.4	2.84e-6	Vitiligo;
TGCT	cis	rs7917772	0.636	rs7897384	chr10:104529042	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.57	-4.71	-0.39	6.53e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2228479	0.850	rs2286393	chr16:89809548	C/A	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs4969178	0.645	rs4490057	chr17:76375095	C/T	cg05887092	chr17:76393375	PGS1	-0.22	-4.85	-0.4	3.7e-6	HDL cholesterol levels;
TGCT	cis	rs782590	0.967	rs58003472	chr2:55797507	T/C	cg03859395	chr2:55845619	SMEK2	0.92	11.37	0.71	5.88e-21	Metabolic syndrome;
TGCT	cis	rs6570726	0.738	rs7746330	chr6:145899257	A/C	cg13319975	chr6:146136371	FBXO30	-0.51	-4.58	-0.38	1.13e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7772486	0.875	rs2073287	chr6:146350264	T/C	cg23711669	chr6:146136114	FBXO30	0.85	9.44	0.65	2.92e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs478222	1.000	rs478222	chr2:25301755	A/T	cg01884057	chr2:25150051	NA	-0.25	-4.64	-0.38	8.56e-6	Type 1 diabetes;
TGCT	cis	rs75686122	0.772	rs78015094	chr8:104587409	C/T	cg04852977	chr8:104510831	NA	0.59	4.45	0.37	1.92e-5	Cocaine dependence;
TGCT	cis	rs4654899	0.627	rs667071	chr1:21045726	T/C	cg01072550	chr1:21505969	NA	-0.4	-5.96	-0.47	2.45e-8	Superior frontal gyrus grey matter volume;
TGCT	cis	rs854765	0.534	rs7207461	chr17:17949789	T/G	cg04398451	chr17:18023971	MYO15A	0.34	5.49	0.44	2.21e-7	Total body bone mineral density;
TGCT	cis	rs7552404	1.000	rs28602663	chr1:76235355	C/T	cg03433033	chr1:76189801	ACADM	0.82	9.39	0.64	3.73e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs1215050	0.740	rs783932	chr4:98973936	C/G	cg17366294	chr4:99064904	C4orf37	-0.55	-5.8	-0.46	5.23e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7523273	0.606	rs7144	chr1:207967719	A/G	cg22525895	chr1:207977042	MIR29B2	-0.57	-10.0	-0.67	1.3e-17	Schizophrenia;
TGCT	cis	rs10411936	1.000	rs16995422	chr19:16519045	A/G	cg14704714	chr19:15740395	CYP4F8	-0.26	-4.57	-0.38	1.16e-5	White blood cell count;Multiple sclerosis;
TGCT	cis	rs62380364	0.754	rs4518438	chr5:88157552	T/C	cg22951263	chr5:87985283	NA	-0.51	-5.01	-0.41	1.85e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10875746	0.903	rs11168414	chr12:48512331	C/T	cg20731937	chr12:48336164	NA	0.62	4.94	0.41	2.46e-6	Longevity (90 years and older);
TGCT	cis	rs10804591	0.848	rs4579013	chr3:129316019	G/C	cg07730360	chr3:128845626	NA	-0.2	-4.53	-0.38	1.37e-5	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Hip circumference adjusted for BMI;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9457247	1.000	rs2769354	chr6:167379771	G/T	cg25258033	chr6:167368657	RNASET2	-0.18	-4.49	-0.37	1.63e-5	Crohn's disease;
TGCT	cis	rs2282802	0.651	rs10060071	chr5:139599097	T/C	cg01081189	chr5:139537190	NA	0.29	5.41	0.44	3.07e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg23708337	chr7:1209742	NA	0.55	5.47	0.44	2.34e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg23719950	chr11:63933701	MACROD1	-0.72	-5.98	-0.47	2.24e-8	Mean platelet volume;
TGCT	cis	rs6912958	0.678	rs9450733	chr6:88250081	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-5.06	-0.41	1.45e-6	Monocyte percentage of white cells;
TGCT	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg09737314	chr17:6899359	ALOX12	0.49	5.23	0.42	7.07e-7	Tonsillectomy;
TGCT	cis	rs7666738	0.753	rs11932536	chr4:98930105	A/G	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg04944784	chr2:26401820	FAM59B	-0.68	-6.13	-0.48	1.1e-8	Gut microbiome composition (summer);
TGCT	cis	rs681343	1.000	rs492602	chr19:49206417	A/G	cg13540341	chr19:49222985	MAMSTR	-0.33	-4.48	-0.37	1.69e-5	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
TGCT	cis	rs7192750	0.586	rs2335710	chr16:71923181	C/G	cg06353428	chr16:71660113	MARVELD3	-0.83	-7.22	-0.54	4.68e-11	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	-0.97	-8.16	-0.59	3.11e-13	Platelet count;
TGCT	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	5.98	0.47	2.23e-8	Alzheimer's disease;
TGCT	cis	rs12549902	0.932	rs6981607	chr8:41508168	A/C	cg21772509	chr8:41503840	NKX6-3	0.89	10.58	0.69	4.81e-19	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
TGCT	cis	rs7264396	0.709	rs2425073	chr20:34293699	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.3	-5.31	-0.43	4.96e-7	Total cholesterol levels;
TGCT	cis	rs4372836	1.000	rs6707848	chr2:28988083	T/C	cg09522027	chr2:28974177	PPP1CB	-0.62	-5.48	-0.44	2.24e-7	Body mass index;
TGCT	cis	rs62380364	0.602	rs588282	chr5:88032651	G/T	cg22951263	chr5:87985283	NA	-0.55	-5.94	-0.47	2.74e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9467773	1.000	rs9986382	chr6:26550619	T/C	cg26531700	chr6:26746687	NA	0.48	4.69	0.39	7.1e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs13064447	0.753	rs9811396	chr3:12747915	A/G	cg20675869	chr3:12750130	NA	0.19	4.57	0.38	1.18e-5	Major depression and alcohol dependence;
TGCT	cis	rs7647973	1.000	rs13096474	chr3:49443081	C/T	cg07636037	chr3:49044803	WDR6	-0.6	-4.78	-0.39	4.83e-6	Menarche (age at onset);
TGCT	cis	rs7647973	0.516	rs4499638	chr3:49202782	C/G	cg06212747	chr3:49208901	KLHDC8B	0.66	6.18	0.49	8.29e-9	Menarche (age at onset);
TGCT	cis	rs6912958	0.712	rs6454640	chr6:88370352	G/T	cg06598631	chr6:88300029	RARS2;ORC3L	0.49	4.5	0.37	1.53e-5	Monocyte percentage of white cells;
TGCT	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg17554472	chr22:41940697	POLR3H	-0.48	-5.15	-0.42	9.89e-7	Vitiligo;
TGCT	cis	rs782590	0.805	rs782578	chr2:55915904	A/C	cg18811423	chr2:55921094	PNPT1	0.71	7.98	0.58	8.2e-13	Metabolic syndrome;
TGCT	cis	rs2832191	0.692	rs2254872	chr21:30414724	C/T	cg24692254	chr21:30365293	RNF160	0.99	11.43	0.72	4.08e-21	Dental caries;
TGCT	cis	rs9399135	0.844	rs13209789	chr6:135367916	A/G	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.21e-6	Red blood cell count;
TGCT	cis	rs2692947	0.832	rs2692954	chr2:96683378	T/G	cg13655245	chr2:97463316	CNNM4	0.16	4.54	0.38	1.29e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs610932	0.517	rs584469	chr11:59988862	T/C	cg18570331	chr11:60101691	MS4A6E	0.5	4.55	0.38	1.28e-5	Alzheimer's disease;
TGCT	trans	rs1814175	0.817	rs7927373	chr11:49957640	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.36	-7.14	-0.54	6.88e-11	Height;
TGCT	cis	rs9952991	0.941	rs60735058	chr18:12795470	T/A	cg23544223	chr18:12777786	NA	-0.6	-5.36	-0.43	3.89e-7	Inflammatory skin disease;
TGCT	cis	rs797680	0.856	rs4847235	chr1:93627727	T/C	cg17826107	chr1:92977322	EVI5	-0.23	-5.0	-0.41	1.88e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs2458413	0.669	rs1812214	chr8:105344070	A/G	cg13045555	chr8:105342365	NA	-0.4	-6.63	-0.51	9.03e-10	Paget's disease;
TGCT	cis	rs13242816	1.000	rs17138750	chr7:116134170	A/G	cg02799643	chr7:116139180	CAV2	-0.46	-5.53	-0.44	1.78e-7	P wave duration;
TGCT	cis	rs67385638	0.855	rs3759074	chr11:5257778	C/T	cg12559170	chr11:5275217	HBG2	0.47	8.72	0.62	1.48e-14	Hemoglobin levels;
TGCT	cis	rs60843830	0.662	rs6721594	chr2:305203	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	-0.59	-5.91	-0.47	3.12e-8	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs9914988	0.943	rs9890377	chr17:27111111	A/G	cg20469991	chr17:27169893	C17orf63	-0.72	-5.04	-0.41	1.58e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs17401966	0.931	rs1555849	chr1:10400602	G/T	cg19773385	chr1:10388646	KIF1B	0.23	5.43	0.44	2.8e-7	Hepatocellular carcinoma;
TGCT	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.71	0.39	6.53e-6	Prudent dietary pattern;
TGCT	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg04944784	chr2:26401820	FAM59B	-0.7	-6.49	-0.5	1.89e-9	Gut microbiome composition (summer);
TGCT	cis	rs2404618	0.509	rs13271550	chr8:1488891	C/G	cg13402656	chr8:1511478	DLGAP2	-0.36	-6.38	-0.5	3.13e-9	Lung cancer;
TGCT	cis	rs12497850	0.805	rs11130176	chr3:48844077	A/G	cg07636037	chr3:49044803	WDR6	0.95	10.74	0.69	2e-19	Parkinson's disease;
TGCT	cis	rs9296661	0.522	rs1326568	chr6:51665345	G/A	cg20180370	chr6:50691003	TFAP2D	-0.48	-4.67	-0.39	7.68e-6	Weight loss (gastric bypass surgery);
TGCT	cis	rs4654899	0.758	rs7556221	chr1:21455559	C/G	cg01072550	chr1:21505969	NA	-0.55	-9.05	-0.63	2.44e-15	Superior frontal gyrus grey matter volume;
TGCT	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.34	0.43	4.23e-7	Prudent dietary pattern;
TGCT	cis	rs6543140	0.890	rs61122764	chr2:102999520	A/G	cg09003973	chr2:102972529	NA	0.56	4.64	0.38	8.7e-6	Blood protein levels;
TGCT	cis	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg08564027	chr20:61660810	NA	0.38	7.08	0.54	9.36e-11	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9883204	0.951	rs7614016	chr3:123070426	G/A	cg04890266	chr3:123102914	ADCY5	0.37	5.0	0.41	1.92e-6	Birth weight;
TGCT	cis	rs826838	0.967	rs7136593	chr12:39128265	C/T	cg13010199	chr12:38710504	ALG10B	-0.63	-5.06	-0.41	1.46e-6	Heart rate;
TGCT	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg23758822	chr17:41437982	NA	0.7	6.6	0.51	1.1e-9	Menopause (age at onset);
TGCT	cis	rs797680	0.897	rs6658257	chr1:93820684	A/G	cg17826107	chr1:92977322	EVI5	-0.24	-5.74	-0.46	6.97e-8	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs854765	0.575	rs7207821	chr17:17891781	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.79	8.13	0.59	3.81e-13	Total body bone mineral density;
TGCT	cis	rs9467603	0.548	rs34991172	chr6:25480328	T/G	cg16898833	chr6:26189333	HIST1H4D	1.33	5.64	0.45	1.07e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg17971929	chr21:40555470	PSMG1	0.96	8.86	0.62	6.96e-15	Cognitive function;
TGCT	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg18538332	chr22:24372958	LOC391322	0.76	6.33	0.49	4e-9	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	trans	rs1814175	0.645	rs1851844	chr11:50021773	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.84	-0.7	1.13e-19	Height;
TGCT	cis	rs1387259	0.698	rs4579969	chr12:48779562	C/T	cg04545296	chr12:48745243	ZNF641	-0.33	-4.62	-0.38	9.3e-6	Obstructive sleep apnea trait (apnea hypopnea index);
TGCT	cis	rs2836950	0.501	rs2070865	chr21:40715519	C/T	cg06238570	chr21:40685208	BRWD1	-0.6	-6.07	-0.48	1.45e-8	Menarche (age at onset);
TGCT	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg26354017	chr1:205819088	PM20D1	0.56	6.81	0.52	3.75e-10	Menarche (age at onset);
TGCT	cis	rs1372520	0.627	rs2583964	chr4:90727218	A/G	cg01966878	chr4:90757139	SNCA	-0.31	-4.84	-0.4	3.8e-6	Neuroticism;
TGCT	trans	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg27523141	chr10:43048294	ZNF37B	0.73	8.58	0.61	3.32e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs231513	0.911	rs537165	chr17:41976736	C/T	cg26893861	chr17:41843967	DUSP3	-0.71	-5.33	-0.43	4.45e-7	Cognitive function;
TGCT	cis	rs6978712	1.000	rs55748686	chr7:127148595	T/C	cg01017541	chr7:127776461	NA	0.76	4.6	0.38	1.01e-5	Medication adherence in chronic diseases;
TGCT	cis	rs75686122	0.764	rs80100464	chr8:104646434	C/G	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs2072499	0.966	rs2244144	chr1:156184598	G/A	cg25208724	chr1:156163844	SLC25A44	1.11	12.73	0.75	2.98e-24	Testicular germ cell tumor;
TGCT	cis	rs7523273	0.548	rs3109808	chr1:207948477	C/A	cg22525895	chr1:207977042	MIR29B2	0.55	9.45	0.65	2.72e-16	Schizophrenia;
TGCT	cis	rs2688608	0.592	rs7908825	chr10:75554541	C/G	cg15838173	chr10:75533400	FUT11	0.3	4.89	0.4	3.12e-6	Inflammatory bowel disease;
TGCT	cis	rs10927875	0.541	rs1763596	chr1:16343835	C/T	cg21385522	chr1:16154831	NA	0.46	4.79	0.4	4.62e-6	Dilated cardiomyopathy;
TGCT	cis	rs10751667	0.666	rs7394992	chr11:980690	G/C	cg06064525	chr11:970664	AP2A2	-0.36	-8.02	-0.58	6.65e-13	Alzheimer's disease (late onset);
TGCT	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg16423285	chr20:60520624	NA	-0.69	-7.11	-0.54	7.98e-11	Body mass index;
TGCT	cis	rs13326165	0.760	rs13076890	chr3:52407933	T/C	cg27565382	chr3:53032988	SFMBT1	0.37	4.9	0.4	2.97e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg08280861	chr8:58055591	NA	0.39	4.86	0.4	3.45e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs595982	0.702	rs626974	chr19:49375900	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.37	-5.07	-0.41	1.4e-6	Red cell distribution width;
TGCT	cis	rs12142240	0.698	rs68012736	chr1:46839510	A/G	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs7267979	0.932	rs6115215	chr20:25562500	C/T	cg16686733	chr20:25566563	NINL	0.56	5.69	0.46	8.49e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2456568	0.802	rs7115629	chr11:93635477	G/A	cg26875233	chr11:93583750	C11orf90	-0.48	-6.47	-0.5	2.07e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs14978	0.605	rs4721064	chr7:12284378	G/A	cg07541786	chr7:12610355	SCIN	0.47	4.79	0.39	4.75e-6	Response to amphetamines;
TGCT	cis	rs7412746	0.658	rs2230061	chr1:150727539	G/A	cg09365446	chr1:150670422	GOLPH3L	0.33	4.78	0.39	4.8e-6	Melanoma;
TGCT	cis	rs7267979	1.000	rs2257982	chr20:25269630	A/G	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs916888	0.821	rs199514	chr17:44856881	G/A	cg17911788	chr17:44343683	NA	0.61	6.44	0.5	2.42e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2153535	0.606	rs11243253	chr6:8380193	T/C	cg23788917	chr6:8435910	SLC35B3	-0.65	-5.93	-0.47	2.87e-8	Motion sickness;
TGCT	trans	rs9929218	0.551	rs1886697	chr16:68716179	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.63	8.21	0.59	2.47e-13	Colorectal cancer;
TGCT	cis	rs7714584	1.000	rs7709464	chr5:150269441	C/A	cg22134413	chr5:150180641	NA	0.78	6.12	0.48	1.16e-8	Crohn's disease;
TGCT	cis	rs11754661	1.000	rs11754661	chr6:151207078	G/A	cg01354656	chr6:151411710	MTHFD1L	0.45	4.53	0.38	1.37e-5	Alzheimer's disease (late onset);
TGCT	cis	rs2070488	0.932	rs1841776	chr3:38480727	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	9.66	0.66	8.59e-17	Electrocardiographic conduction measures;
TGCT	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg20887711	chr4:1340912	KIAA1530	-0.68	-6.0	-0.47	1.99e-8	Obesity-related traits;
TGCT	cis	rs2204008	0.807	rs4123933	chr12:37973539	G/A	cg13010199	chr12:38710504	ALG10B	0.65	5.29	0.43	5.47e-7	Bladder cancer;
TGCT	cis	rs9341808	0.718	rs6910201	chr6:80904938	G/C	cg08355045	chr6:80787529	NA	0.32	5.6	0.45	1.29e-7	Sitting height ratio;
TGCT	trans	rs3780486	0.718	rs3818593	chr9:33120706	A/G	cg04842962	chr6:43655489	MRPS18A	0.98	7.28	0.55	3.36e-11	IgG glycosylation;
TGCT	cis	rs67311347	1.000	rs9834052	chr3:40399060	G/A	cg17264618	chr3:40429014	ENTPD3	0.31	4.65	0.39	8.38e-6	Renal cell carcinoma;
TGCT	cis	rs2762353	0.902	rs3799344	chr6:25786993	C/T	cg12310025	chr6:25882481	NA	0.49	5.0	0.41	1.92e-6	Blood metabolite levels;
TGCT	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg03709012	chr19:19516395	GATAD2A	0.67	5.74	0.46	6.83e-8	Tonsillectomy;
TGCT	cis	rs939658	0.805	rs34222382	chr15:79440748	C/T	cg17916960	chr15:79447300	NA	-0.49	-7.59	-0.56	6.76e-12	Refractive error;
TGCT	cis	rs9902453	0.934	rs34433787	chr17:28496780	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	6.39	0.5	3.03e-9	Coffee consumption (cups per day);
TGCT	cis	rs2153535	0.563	rs4428546	chr6:8490376	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs9467773	0.572	rs13213953	chr6:26594534	T/A	cg26531700	chr6:26746687	NA	0.67	6.47	0.5	2.09e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs2486288	0.656	rs12911861	chr15:45566718	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.45	-5.07	-0.41	1.41e-6	Glomerular filtration rate;
TGCT	cis	rs7584330	0.554	rs6736468	chr2:238422228	A/G	cg08992911	chr2:238395768	MLPH	0.69	4.77	0.39	5e-6	Prostate cancer;
TGCT	trans	rs7819412	0.775	rs6601564	chr8:10982051	A/G	cg15556689	chr8:8085844	FLJ10661	-0.82	-8.06	-0.59	5.57e-13	Triglycerides;
TGCT	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.69	-0.39	7e-6	Prudent dietary pattern;
TGCT	cis	rs56104184	0.830	rs45589039	chr19:49355385	C/T	cg21252483	chr19:49399788	TULP2	-0.41	-5.21	-0.42	7.47e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs709400	0.628	rs7150317	chr14:103921691	C/G	cg12935359	chr14:103987150	CKB	-0.35	-5.33	-0.43	4.54e-7	Body mass index;
TGCT	cis	rs7829975	0.540	rs2976909	chr8:8346690	C/T	cg08975724	chr8:8085496	FLJ10661	-0.52	-5.35	-0.43	4.06e-7	Mood instability;
TGCT	cis	rs9549260	0.592	rs9315783	chr13:41289164	T/C	cg21288729	chr13:41239152	FOXO1	0.87	7.86	0.58	1.59e-12	Red blood cell count;
TGCT	cis	rs7246657	0.722	rs10406379	chr19:38036725	G/A	cg03611452	chr19:38183253	ZNF781	0.58	4.64	0.38	8.62e-6	Coronary artery calcification;
TGCT	cis	rs6089584	0.508	rs6061988	chr20:60626300	C/T	cg13770153	chr20:60521292	NA	-0.42	-4.95	-0.41	2.37e-6	Body mass index;
TGCT	cis	rs473651	0.904	rs501333	chr2:239336045	G/A	cg18131467	chr2:239335373	ASB1	1.02	15.09	0.8	7.51e-30	Multiple system atrophy;
TGCT	cis	rs2236918	0.687	rs2797601	chr1:242029249	C/G	cg04158730	chr1:242011433	EXO1	0.56	5.2	0.42	8.05e-7	Menopause (age at onset);
TGCT	cis	rs6121246	0.567	rs6058203	chr20:30198979	C/T	cg21427119	chr20:30132790	HM13	-0.43	-6.17	-0.48	8.86e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs9325144	0.577	rs10876008	chr12:39126750	T/C	cg26384229	chr12:38710491	ALG10B	-0.61	-5.7	-0.46	8.45e-8	Morning vs. evening chronotype;
TGCT	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	6.09	0.48	1.32e-8	Attention deficit hyperactivity disorder;
TGCT	cis	rs1045714	0.895	rs4721866	chr7:2643341	G/A	cg17215154	chr7:2644645	IQCE	0.28	4.92	0.4	2.75e-6	Urate levels in lean individuals;
TGCT	cis	rs7666738	0.645	rs10013290	chr4:99082799	G/A	cg18180107	chr4:99064573	C4orf37	0.57	5.01	0.41	1.83e-6	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs10506458	0.915	rs79133015	chr12:63396838	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.47	-7.58	-0.56	6.97e-12	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs4975709	0.569	rs2353583	chr5:1858834	G/C	cg07747251	chr5:1868357	NA	0.38	5.31	0.43	4.95e-7	Cardiovascular disease risk factors;
TGCT	cis	rs7208859	0.614	rs4794874	chr17:28841318	C/T	cg13385521	chr17:29058706	SUZ12P	-0.69	-4.57	-0.38	1.18e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs1801251	0.963	rs35395584	chr2:233573698	G/C	cg08000102	chr2:233561755	GIGYF2	0.66	6.84	0.52	3.29e-10	Coronary artery disease;
TGCT	cis	rs17108533	0.588	rs12897337	chr14:71302994	A/G	cg23900759	chr14:71108106	TTC9	-1.15	-4.79	-0.39	4.73e-6	Response to antipsychotic treatment in schizophrenia (reasoning);
TGCT	cis	rs7523273	0.927	rs1891423	chr1:207931913	G/A	cg22525895	chr1:207977042	MIR29B2	0.47	8.1	0.59	4.31e-13	Schizophrenia;
TGCT	cis	rs858239	0.539	rs2103281	chr7:23194231	A/G	cg05602783	chr7:23145260	KLHL7	-0.67	-5.47	-0.44	2.37e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs17345786	0.911	rs10936707	chr3:101324063	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.56	4.81	0.4	4.21e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4523957	0.583	rs923863	chr17:2031387	A/G	cg16513277	chr17:2031491	SMG6	-0.2	-4.58	-0.38	1.13e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9814567	0.806	rs9824185	chr3:134324024	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-7.21	-0.54	4.87e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs11785400	1.000	rs3802232	chr8:143746701	A/G	cg24634471	chr8:143751801	JRK	0.57	6.12	0.48	1.11e-8	Schizophrenia;
TGCT	cis	rs514406	0.505	rs12726160	chr1:53175099	A/G	cg01802117	chr1:53393560	SCP2	-0.44	-5.18	-0.42	8.57e-7	Monocyte count;
TGCT	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg06634786	chr22:41940651	POLR3H	-0.89	-8.69	-0.62	1.79e-14	Vitiligo;
TGCT	cis	rs7829975	0.658	rs907181	chr8:8702875	T/C	cg15556689	chr8:8085844	FLJ10661	0.67	6.28	0.49	5.11e-9	Mood instability;
TGCT	cis	rs2963155	0.518	rs712189	chr5:142631258	C/T	cg17617527	chr5:142782415	NR3C1	0.85	6.29	0.49	4.9e-9	Breast cancer;
TGCT	cis	rs727563	0.593	rs5758461	chr22:42162189	G/C	cg03806693	chr22:41940476	POLR3H	1.02	10.49	0.69	7.92e-19	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs453301	0.686	rs6748	chr8:8890802	C/T	cg15556689	chr8:8085844	FLJ10661	-0.62	-5.24	-0.43	6.69e-7	Joint mobility (Beighton score);
TGCT	cis	rs9733	0.596	rs1415148	chr1:150705755	G/A	cg09365446	chr1:150670422	GOLPH3L	0.3	4.52	0.38	1.4e-5	Tonsillectomy;
TGCT	cis	rs7221109	0.522	rs2462970	chr17:38871049	A/G	cg07480653	chr17:39868082	GAST	-0.24	-5.14	-0.42	1.04e-6	Type 1 diabetes;
TGCT	cis	rs6912958	0.500	rs2025486	chr6:87796886	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.37	-4.54	-0.38	1.33e-5	Monocyte percentage of white cells;
TGCT	cis	rs916888	0.821	rs199509	chr17:44858728	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.7	-4.82	-0.4	4.1e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs9467773	0.583	rs1021373	chr6:26632457	G/A	cg11502198	chr6:26597334	ABT1	0.54	4.97	0.41	2.14e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg08280861	chr8:58055591	NA	0.36	4.82	0.4	4.2e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9807989	0.507	rs2293224	chr2:103035779	T/C	cg03938978	chr2:103052716	IL18RAP	0.27	5.4	0.44	3.31e-7	Asthma;
TGCT	cis	rs4523957	0.620	rs898749	chr17:2085185	G/A	cg16513277	chr17:2031491	SMG6	-0.2	-4.64	-0.38	8.83e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs2299587	0.607	rs2237848	chr8:17874604	A/C	cg04898035	chr8:17640624	MTUS1	-0.21	-4.56	-0.38	1.19e-5	Economic and political preferences;
TGCT	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg13732083	chr21:47605072	C21orf56	-0.34	-4.59	-0.38	1.07e-5	Testicular germ cell tumor;
TGCT	cis	rs7085104	0.700	rs10883785	chr10:104603588	A/G	cg04362960	chr10:104952993	NT5C2	0.57	5.05	0.41	1.54e-6	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs9814567	0.806	rs11927540	chr3:134319455	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.76	-7.11	-0.54	8.15e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg20607798	chr8:58055168	NA	0.66	5.87	0.47	3.66e-8	Developmental language disorder (linguistic errors);
TGCT	cis	rs2562456	0.682	rs11085464	chr19:21751778	C/G	cg01304269	chr19:21688519	ZNF429	0.58	4.74	0.39	5.78e-6	Pain;
TGCT	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg11890956	chr21:40555474	PSMG1	1.1	12.28	0.74	3.66e-23	Cognitive function;
TGCT	cis	rs5750830	0.594	rs5757648	chr22:39775156	G/A	cg11247378	chr22:39784982	NA	-0.64	-8.48	-0.61	5.71e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs2243480	0.706	rs34466769	chr7:65453292	A/C	cg07424592	chr7:64974309	NA	0.96	6.03	0.48	1.78e-8	Diabetic kidney disease;
TGCT	cis	rs6500602	0.929	rs9926114	chr16:4478322	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.3	5.16	0.42	9.6e-7	Schizophrenia;
TGCT	cis	rs9527	0.590	rs12775302	chr10:104911356	A/G	cg04362960	chr10:104952993	NT5C2	0.67	5.64	0.45	1.09e-7	Arsenic metabolism;
TGCT	cis	rs3020333	0.721	rs1293936	chr6:152017691	T/G	cg22157087	chr6:152012887	ESR1	0.23	5.59	0.45	1.36e-7	Total body bone mineral density;
TGCT	cis	rs904251	0.522	rs882322	chr6:37484103	A/G	cg01843034	chr6:37503916	NA	-0.54	-7.33	-0.55	2.57e-11	Cognitive performance;
TGCT	cis	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg18252515	chr7:66147081	NA	-1.22	-7.98	-0.58	8.46e-13	Diabetic kidney disease;
TGCT	cis	rs1008375	0.966	rs6833808	chr4:17652526	T/A	cg16339924	chr4:17578868	LAP3	0.68	5.61	0.45	1.26e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6964587	1.000	rs36120033	chr7:91679298	G/A	cg22709100	chr7:91322751	NA	0.28	4.56	0.38	1.19e-5	Breast cancer;
TGCT	cis	rs1577917	0.545	rs1832070	chr6:86483172	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.6	4.94	0.41	2.47e-6	Response to antipsychotic treatment;
TGCT	cis	rs611744	0.647	rs1379336	chr8:109276606	G/T	cg21045802	chr8:109455806	TTC35	0.72	7.39	0.55	1.92e-11	Dupuytren's disease;
TGCT	cis	rs4478858	0.602	rs6425723	chr1:31715204	T/C	cg00250761	chr1:31883323	NA	-0.27	-4.89	-0.4	3.11e-6	Alcohol dependence;
TGCT	cis	rs617219	0.698	rs13177470	chr5:78495899	T/C	cg23514016	chr5:78407564	BHMT	0.35	5.44	0.44	2.78e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs9325144	0.560	rs2387923	chr12:38662677	G/A	cg26384229	chr12:38710491	ALG10B	-0.63	-5.92	-0.47	2.9e-8	Morning vs. evening chronotype;
TGCT	cis	rs6964587	0.773	rs12740	chr7:92029302	A/G	cg17063962	chr7:91808500	NA	0.84	7.84	0.58	1.75e-12	Breast cancer;
TGCT	cis	rs12893668	0.703	rs4906335	chr14:104021141	C/A	cg26031613	chr14:104095156	KLC1	-0.54	-4.55	-0.38	1.28e-5	Reticulocyte count;
TGCT	cis	rs1997103	0.954	rs6593236	chr7:55410992	C/T	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs651907	0.535	rs11714444	chr3:101513682	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.31	-6.4	-0.5	2.91e-9	Colorectal cancer;
TGCT	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg01802117	chr1:53393560	SCP2	0.48	5.82	0.46	4.82e-8	Monocyte count;
TGCT	cis	rs6586111	1.000	rs4934372	chr10:82372981	A/G	cg03086067	chr10:82368399	SH2D4B	0.24	4.7	0.39	6.84e-6	Capecitabine sensitivity;
TGCT	cis	rs9300255	0.639	rs941306	chr12:123715113	C/T	cg00376283	chr12:123451042	ABCB9	0.67	5.26	0.43	6.13e-7	Neutrophil percentage of white cells;
TGCT	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg04772025	chr11:68637568	NA	0.6	6.79	0.52	4.07e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs903263	0.932	rs1565823	chr1:84576620	G/A	cg09664975	chr1:84543551	PRKACB	0.49	4.55	0.38	1.24e-5	Breast cancer (male);
TGCT	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg13395646	chr4:1353034	KIAA1530	-0.48	-6.1	-0.48	1.28e-8	Obesity-related traits;
TGCT	cis	rs73198271	0.595	rs55874147	chr8:8591954	T/C	ch.8.214553F	chr8:8189620	PRAGMIN	-0.32	-5.23	-0.42	7.04e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs17102423	0.594	rs1124752	chr14:65567515	G/T	cg11161011	chr14:65562177	MAX	-0.47	-6.42	-0.5	2.57e-9	Obesity-related traits;
TGCT	trans	rs9388451	1.000	rs9388451	chr6:126090377	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.77	-8.56	-0.61	3.6e-14	Brugada syndrome;
TGCT	cis	rs6866344	0.561	rs55974982	chr5:178141421	G/A	cg03877680	chr5:178157825	ZNF354A	0.77	6.78	0.52	4.28e-10	Neutrophil percentage of white cells;
TGCT	cis	rs2404602	0.647	rs11072612	chr15:76960984	A/T	cg22467129	chr15:76604101	ETFA	0.47	4.65	0.39	8.48e-6	Blood metabolite levels;
TGCT	cis	rs9902453	0.704	rs1972305	chr17:28533880	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	5.96	0.47	2.43e-8	Coffee consumption (cups per day);
TGCT	cis	rs2072499	0.778	rs2247476	chr1:156190280	C/A	cg24450063	chr1:156163899	SLC25A44	1.03	9.7	0.66	6.62e-17	Testicular germ cell tumor;
TGCT	cis	rs8033133	0.602	rs1549477	chr15:25332118	C/T	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	-0.24	-4.58	-0.38	1.1e-5	Blood osmolality (transformed sodium);
TGCT	cis	rs10782582	0.617	rs1846233	chr1:76159354	C/T	cg22875332	chr1:76189707	ACADM	-0.55	-6.35	-0.5	3.77e-9	Daytime sleep phenotypes;
TGCT	cis	rs7267979	1.000	rs6083828	chr20:25369918	T/C	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs1005277	0.540	rs289638	chr10:37923731	G/A	cg17830980	chr10:43048298	ZNF37B	-0.67	-7.5	-0.56	1.05e-11	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2046867	0.866	rs2244246	chr3:72789191	G/A	cg25664220	chr3:72788482	NA	0.55	6.96	0.53	1.75e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs763121	0.752	rs6001190	chr22:39073811	T/C	cg06022373	chr22:39101656	GTPBP1	0.77	7.43	0.56	1.54e-11	Menopause (age at onset);
TGCT	cis	rs12549902	0.966	rs716199	chr8:41515531	A/G	cg00088007	chr8:41504566	NKX6-3	0.34	5.31	0.43	4.93e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
TGCT	trans	rs1496653	0.602	rs71322184	chr3:23439190	G/A	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	5.8	0.46	5.19e-8	Alzheimer's disease;
TGCT	cis	rs2836633	0.895	rs61085980	chr21:40032140	C/T	cg05519781	chr21:40033154	ERG	0.66	6.38	0.5	3.15e-9	Coronary artery disease;
TGCT	cis	rs2811893	1.000	rs232775	chr1:59124546	A/G	cg26196860	chr1:59745563	NA	0.25	4.68	0.39	7.49e-6	Diabetic retinopathy;
TGCT	cis	rs4794202	0.534	rs9895764	chr17:45927961	C/G	cg02219949	chr17:45927392	SP6	0.38	4.55	0.38	1.24e-5	Alzheimer's disease (cognitive decline);
TGCT	cis	rs9859260	0.744	rs419059	chr3:195782184	C/T	cg22891161	chr3:195456627	MUC20	0.23	4.6	0.38	1.04e-5	Mean corpuscular volume;
TGCT	cis	rs473651	0.904	rs62196716	chr2:239356977	C/G	cg21699342	chr2:239360505	ASB1	0.17	4.74	0.39	5.66e-6	Multiple system atrophy;
TGCT	cis	rs1538970	0.816	rs11211124	chr1:45962409	T/C	cg05343316	chr1:45956843	TESK2	0.81	6.64	0.51	8.93e-10	Platelet count;
TGCT	cis	rs727563	0.594	rs5758408	chr22:42077737	A/C	cg06634786	chr22:41940651	POLR3H	0.9	8.74	0.62	1.34e-14	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs13242816	1.000	rs35800921	chr7:116124041	G/A	cg02799643	chr7:116139180	CAV2	-0.49	-5.53	-0.45	1.78e-7	P wave duration;
TGCT	cis	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg22857025	chr5:266934	NA	-0.32	-6.58	-0.51	1.18e-9	Breast cancer;
TGCT	cis	rs77741769	0.529	rs7137504	chr12:121221628	C/T	cg02419362	chr12:121203948	SPPL3	0.19	4.47	0.37	1.74e-5	Mean corpuscular volume;
TGCT	cis	rs1055129	0.560	rs2305913	chr17:73922941	T/C	cg08125733	chr17:73851984	WBP2	0.57	5.22	0.42	7.14e-7	White matter hyperintensity burden;
TGCT	cis	rs826838	0.967	rs11183514	chr12:38760744	A/T	cg13010199	chr12:38710504	ALG10B	0.82	6.86	0.52	2.91e-10	Heart rate;
TGCT	cis	rs7809950	0.724	rs1858888	chr7:107046062	T/A	cg23024343	chr7:107201750	COG5	-0.48	-6.3	-0.49	4.82e-9	Coronary artery disease;
TGCT	cis	rs6141769	0.542	rs6058821	chr20:31304713	C/T	cg13636640	chr20:31349939	DNMT3B	-0.51	-4.48	-0.37	1.68e-5	Subjective well-being;
TGCT	cis	rs10791097	0.694	rs10894275	chr11:130756251	C/T	cg14779329	chr11:130786720	SNX19	0.29	4.94	0.41	2.45e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs651907	0.557	rs62284199	chr3:101478531	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	4.69	0.39	7.06e-6	Colorectal cancer;
TGCT	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg16414030	chr3:133502952	NA	-0.61	-9.53	-0.65	1.78e-16	Iron status biomarkers;
TGCT	cis	rs7731657	0.537	rs4637539	chr5:130311944	T/C	cg08523029	chr5:130500466	HINT1	-0.57	-4.54	-0.38	1.33e-5	Fasting plasma glucose;
TGCT	cis	rs28785552	0.765	rs28850924	chr19:53234323	T/G	cg22067481	chr19:53234126	ZNF611	-0.48	-6.8	-0.52	3.98e-10	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs6121246	0.529	rs750144	chr20:30179027	C/T	cg13852791	chr20:30311386	BCL2L1	-0.69	-4.53	-0.38	1.36e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs7552404	0.924	rs7546641	chr1:76158035	T/C	cg10523679	chr1:76189770	ACADM	0.9	9.92	0.67	2e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg08859206	chr1:53392774	SCP2	-0.49	-7.71	-0.57	3.61e-12	Monocyte count;
TGCT	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg07205460	chr22:24236375	MIF	0.59	4.65	0.39	8.26e-6	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs17767294	0.708	rs72848755	chr6:27878553	T/C	cg08851530	chr6:28072375	NA	1.53	7.17	0.54	6.02e-11	Parkinson's disease;
TGCT	cis	rs10206020	0.921	rs6605278	chr2:1547230	C/T	cg12573674	chr2:1569213	NA	-0.49	-4.95	-0.41	2.41e-6	IgG glycosylation;
TGCT	cis	rs7010267	0.570	rs2326193	chr8:120029709	A/C	cg17171407	chr8:119960777	TNFRSF11B	0.26	4.69	0.39	7.07e-6	Total body bone mineral density (age 45-60);
TGCT	cis	rs6933660	0.683	rs8180642	chr6:151756612	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.49	4.49	0.37	1.58e-5	Menarche (age at onset);
TGCT	cis	rs4631830	0.863	rs4935162	chr10:51525699	C/G	cg10326726	chr10:51549505	MSMB	-0.25	-4.87	-0.4	3.4e-6	Prostate-specific antigen levels;
TGCT	cis	rs17376456	0.825	rs55947981	chr5:93278104	G/T	cg21475434	chr5:93447410	FAM172A	0.65	4.47	0.37	1.72e-5	Diabetic retinopathy;
TGCT	cis	rs7208859	0.673	rs28588622	chr17:29245699	G/A	cg14008862	chr17:28927542	LRRC37B2	0.71	4.67	0.39	7.67e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg13944838	chr5:179740914	GFPT2	-0.4	-6.27	-0.49	5.56e-9	Height;
TGCT	cis	rs3741151	1.000	rs111882289	chr11:73053714	T/C	cg17517138	chr11:73019481	ARHGEF17	1.06	5.6	0.45	1.3e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
TGCT	cis	rs8044995	0.563	rs57434514	chr16:68402649	G/A	cg05110241	chr16:68378359	PRMT7	-0.36	-4.46	-0.37	1.84e-5	Schizophrenia;
TGCT	cis	rs7428	0.545	rs7572750	chr2:85552186	C/A	cg03728395	chr2:85555865	TGOLN2	-0.31	-5.17	-0.42	8.93e-7	Ear protrusion;
TGCT	cis	rs7267979	0.789	rs4815429	chr20:25521611	T/C	cg16686733	chr20:25566563	NINL	-0.52	-5.05	-0.41	1.52e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg18876405	chr7:65276391	NA	0.32	4.89	0.4	3.11e-6	Aortic root size;
TGCT	cis	rs7975161	0.630	rs7138317	chr12:104650271	G/A	cg25273343	chr12:104657179	TXNRD1	-0.35	-4.83	-0.4	3.87e-6	Toenail selenium levels;
TGCT	cis	rs10838634	1.000	rs60940896	chr11:46870593	T/C	cg18332754	chr11:46939436	LRP4	0.91	4.61	0.38	9.98e-6	Schizophrenia;
TGCT	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg06713675	chr4:122721982	EXOSC9	-0.69	-9.69	-0.66	7.11e-17	Type 2 diabetes;
TGCT	cis	rs6674176	0.628	rs3791116	chr1:44414156	T/A	cg13606994	chr1:44402422	ARTN	-0.46	-4.95	-0.41	2.36e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs35306767	0.579	rs7091502	chr10:1154979	C/T	cg18964960	chr10:1102726	WDR37	0.65	4.45	0.37	1.93e-5	Eosinophil percentage of granulocytes;
TGCT	cis	rs4689388	0.926	rs10012946	chr4:6293350	C/T	cg14416269	chr4:6271139	WFS1	-0.44	-5.39	-0.44	3.46e-7	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg07507251	chr3:52567010	NT5DC2	0.47	6.75	0.52	5.11e-10	Bipolar disorder;
TGCT	cis	rs748404	0.560	rs2255663	chr15:43829008	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.46	-4.49	-0.37	1.63e-5	Lung cancer;
TGCT	cis	rs72627509	0.680	rs56162812	chr4:57740667	G/A	cg26694713	chr4:57773883	REST	0.82	6.68	0.51	7.07e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.07	15.03	0.8	1.05e-29	Prudent dietary pattern;
TGCT	cis	rs9549367	0.713	rs9549682	chr13:113830181	C/T	cg00898013	chr13:113819073	PROZ	-0.55	-7.05	-0.53	1.12e-10	Platelet distribution width;
TGCT	cis	rs1525293	0.714	rs12698976	chr7:70501199	C/T	cg21135135	chr7:70597687	WBSCR17	-0.54	-4.97	-0.41	2.13e-6	Colonoscopy-negative controls vs population controls;Major depressive disorder;
TGCT	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg27121462	chr16:89883253	FANCA	0.78	8.21	0.59	2.48e-13	Vitiligo;
TGCT	cis	rs9894429	1.000	rs4074916	chr17:79579248	G/A	cg21028142	chr17:79581711	NPLOC4	-0.29	-6.7	-0.52	6.64e-10	Eye color traits;
TGCT	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.68	5.62	0.45	1.18e-7	Tonsillectomy;
TGCT	cis	rs7843479	0.601	rs10101881	chr8:21830158	A/G	cg17168535	chr8:21777572	XPO7	0.8	7.93	0.58	1.07e-12	Mean corpuscular volume;
TGCT	cis	rs9473924	0.505	rs55653665	chr6:50812984	T/C	cg14470998	chr6:50812995	TFAP2B	1.36	8.61	0.61	2.74e-14	Body mass index;
TGCT	cis	rs17331151	0.505	rs71299613	chr3:52698805	G/A	cg15956490	chr3:53032818	SFMBT1	0.7	5.71	0.46	7.8e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs1691799	0.899	rs1168293	chr12:66733904	G/A	cg16791601	chr12:66731901	HELB	-0.28	-5.95	-0.47	2.5e-8	White blood cell count (basophil);
TGCT	cis	rs6933660	0.800	rs6930557	chr6:151755806	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.7	7.16	0.54	6.38e-11	Menarche (age at onset);
TGCT	cis	rs9318086	0.753	rs9553094	chr13:24474613	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.7	-7.21	-0.54	4.85e-11	Myopia (pathological);
TGCT	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.01	8.32	0.6	1.34e-13	Platelet count;
TGCT	cis	rs1153858	1.000	rs7169818	chr15:45640191	G/A	cg26924012	chr15:45694286	SPATA5L1	0.97	11.83	0.73	4.55e-22	Homoarginine levels;
TGCT	cis	rs4253772	0.513	rs11090863	chr22:46705407	C/T	cg24881330	chr22:46731750	TRMU	1.05	5.46	0.44	2.5e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg25427524	chr10:38739819	LOC399744	-0.4	-8.24	-0.59	2.07e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2242194	0.816	rs6671688	chr1:154994265	T/C	cg16680214	chr1:154839983	KCNN3	-0.31	-5.76	-0.46	6.3e-8	Schizophrenia;
TGCT	cis	rs9611565	0.512	rs8141103	chr22:42136930	T/C	cg17554472	chr22:41940697	POLR3H	0.46	4.72	0.39	6.36e-6	Vitiligo;
TGCT	cis	rs4478858	0.746	rs6703593	chr1:31689284	A/C	cg00250761	chr1:31883323	NA	0.29	4.78	0.39	4.9e-6	Alcohol dependence;
TGCT	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg10047753	chr17:41438598	NA	0.84	7.61	0.56	5.9e-12	Menopause (age at onset);
TGCT	cis	rs2456568	0.867	rs72962810	chr11:93663619	A/G	cg26875233	chr11:93583750	C11orf90	-0.46	-5.76	-0.46	6.28e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs6456156	0.792	rs4710181	chr6:167513998	T/C	cg07741184	chr6:167504864	NA	0.22	4.51	0.38	1.48e-5	Primary biliary cholangitis;
TGCT	cis	rs1538970	0.962	rs2298018	chr1:45813441	T/C	cg05343316	chr1:45956843	TESK2	0.64	5.13	0.42	1.08e-6	Platelet count;
TGCT	cis	rs10088262	0.527	rs3911939	chr8:124793744	T/G	cg02993010	chr8:124780839	FAM91A1	-0.64	-4.58	-0.38	1.1e-5	Pancreatic cancer;
TGCT	cis	rs1797081	0.967	rs811912	chr10:16859618	G/C	cg14835575	chr10:16859367	RSU1	0.41	4.85	0.4	3.61e-6	Platelet distribution width;
TGCT	cis	rs1670533	0.872	rs13108222	chr4:1054256	C/A	cg27284194	chr4:1044797	NA	0.67	5.79	0.46	5.37e-8	Recombination rate (females);
TGCT	cis	rs7208859	0.623	rs8079891	chr17:29058863	G/A	cg13385521	chr17:29058706	SUZ12P	0.79	4.77	0.39	5.16e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs752010	0.715	rs11807117	chr1:42101206	C/T	cg06885757	chr1:42089581	HIVEP3	0.28	4.91	0.4	2.79e-6	Lupus nephritis in systemic lupus erythematosus;
TGCT	cis	rs9393777	0.513	rs9368448	chr6:26649355	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.59	-4.66	-0.39	8.03e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs473651	0.935	rs540636	chr2:239358341	T/C	cg18131467	chr2:239335373	ASB1	1.01	14.8	0.8	3.56e-29	Multiple system atrophy;
TGCT	cis	rs6589563	0.737	rs11825181	chr11:116626258	G/A	cg20660624	chr11:117307972	DSCAML1	-0.38	-4.99	-0.41	2.02e-6	Eosinophil counts;
TGCT	cis	rs28595532	0.920	rs114966881	chr4:119761078	C/G	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg23131131	chr22:24373011	LOC391322	0.7	7.28	0.55	3.34e-11	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6866344	0.697	rs17184281	chr5:178127563	G/A	cg10224037	chr5:178157518	ZNF354A	0.93	7.9	0.58	1.26e-12	Neutrophil percentage of white cells;
TGCT	cis	rs3008870	1.000	rs2985794	chr1:67425311	T/G	cg11518657	chr1:67396239	MIER1	0.54	4.61	0.38	9.72e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs7659604	0.846	rs60340409	chr4:122666355	G/C	cg19748678	chr4:122722346	EXOSC9	0.55	5.31	0.43	4.92e-7	Type 2 diabetes;
TGCT	cis	rs8070740	0.731	rs1071648	chr17:5326089	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.49	4.88	0.4	3.15e-6	Menopause (age at onset);
TGCT	cis	rs4595586	0.545	rs12816776	chr12:39375817	A/G	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs2862064	1.000	rs11747316	chr5:156422948	A/G	cg12943317	chr5:156479607	HAVCR1	-0.43	-5.67	-0.45	9.29e-8	Platelet count;
TGCT	trans	rs9383153	0.793	rs2016498	chr6:16344914	C/T	cg19895197	chr17:37887061	C17orf37	-0.96	-7.23	-0.54	4.28e-11	Gambling;
TGCT	cis	rs709400	0.628	rs7146506	chr14:103924477	A/G	cg26031613	chr14:104095156	KLC1	0.85	9.49	0.65	2.17e-16	Body mass index;
TGCT	cis	rs9859260	0.710	rs41298097	chr3:195779155	C/T	cg02975922	chr3:195473998	MUC4	0.25	5.1	0.42	1.24e-6	Mean corpuscular volume;
TGCT	cis	rs4765905	0.500	rs2239030	chr12:2335941	A/G	cg07807026	chr12:2041581	NA	0.25	4.59	0.38	1.06e-5	Schizophrenia;
TGCT	cis	rs9296092	0.538	rs9469487	chr6:33516943	G/T	cg13560919	chr6:33536144	NA	-0.21	-4.74	-0.39	5.87e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.69	-0.39	7e-6	Prudent dietary pattern;
TGCT	cis	rs651907	0.514	rs10936744	chr3:101433440	C/T	cg12386194	chr3:101231763	SENP7	0.51	4.9	0.4	2.89e-6	Colorectal cancer;
TGCT	cis	rs6912958	0.781	rs3918467	chr6:88180388	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.54	-5.23	-0.43	7.03e-7	Monocyte percentage of white cells;
TGCT	cis	rs2430386	1.000	rs2430386	chr2:63178111	C/T	cg17519650	chr2:63277830	OTX1	0.7	6.93	0.53	2.01e-10	Prostate cancer;
TGCT	cis	rs1969363	0.531	rs11495331	chr12:38110702	A/G	cg26384229	chr12:38710491	ALG10B	0.59	5.12	0.42	1.16e-6	Morning vs. evening chronotype;
TGCT	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg11764359	chr7:65958608	NA	0.59	5.28	0.43	5.53e-7	Aortic root size;
TGCT	cis	rs6125597	0.967	rs6067025	chr20:47854020	T/C	cg11220565	chr20:47934802	NA	-0.3	-4.6	-0.38	1.02e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs4722166	0.541	rs1800795	chr7:22766645	C/G	cg26061582	chr7:22766209	IL6	0.47	6.32	0.49	4.29e-9	Lung cancer;
TGCT	cis	rs2072499	0.966	rs1060604	chr1:156184268	T/C	cg06970220	chr1:156163860	SLC25A44	0.74	5.91	0.47	3.05e-8	Testicular germ cell tumor;
TGCT	cis	rs9837602	0.529	rs793458	chr3:99520169	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.58	6.71	0.52	6.1e-10	Breast cancer;
TGCT	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs644799	0.687	rs11021318	chr11:95522996	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.79	8.65	0.61	2.18e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg22920501	chr2:26401640	FAM59B	-0.74	-6.4	-0.5	2.86e-9	Gut microbiome composition (summer);
TGCT	cis	rs2718812	0.766	rs2589269	chr3:133409977	C/T	cg16414030	chr3:133502952	NA	0.41	5.55	0.45	1.64e-7	Iron status biomarkers;
TGCT	cis	rs10883723	0.810	rs10786671	chr10:104271303	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs7666738	0.791	rs13146909	chr4:98934198	C/T	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.57	-5.6	-0.45	1.31e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9611519	0.580	rs8138349	chr22:41412723	C/T	cg13695892	chr22:41940480	POLR3H	-0.54	-5.1	-0.42	1.21e-6	Neuroticism;
TGCT	cis	rs7097610	1	rs7097610	chr10:82304162	C/T	cg01528321	chr10:82214614	TSPAN14	-0.85	-5.28	-0.43	5.6e-7	Post bronchodilator FEV1;
TGCT	cis	rs72945132	0.882	rs55905028	chr11:70127750	G/A	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs9926296	0.632	rs72807526	chr16:89775946	A/G	cg04287289	chr16:89883240	FANCA	-0.57	-5.05	-0.41	1.55e-6	Vitiligo;
TGCT	cis	rs7681440	0.647	rs6824979	chr4:90819407	C/G	cg10208370	chr4:90758469	SNCA	0.57	5.37	0.43	3.69e-7	Dementia with Lewy bodies;
TGCT	cis	rs1395	1.000	rs1275528	chr2:27430781	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.49	-6.62	-0.51	9.77e-10	Blood metabolite levels;
TGCT	cis	rs3125734	0.633	rs10821968	chr10:63993905	C/T	cg09941381	chr10:64027924	RTKN2	0.34	5.31	0.43	4.98e-7	Rheumatoid arthritis;
TGCT	cis	rs6061231	0.583	rs2427313	chr20:60970675	G/A	cg24112000	chr20:60950667	NA	-0.37	-4.89	-0.4	3.06e-6	Colorectal cancer;
TGCT	cis	rs910316	0.967	rs4899551	chr14:75660246	C/G	cg11812906	chr14:75593930	NEK9	-0.72	-6.93	-0.53	2.01e-10	Height;
TGCT	cis	rs4713118	0.506	rs9366697	chr6:27633018	T/C	cg10876282	chr6:28092338	ZSCAN16	0.49	4.89	0.4	3.08e-6	Parkinson's disease;
TGCT	cis	rs6076065	0.548	rs6048742	chr20:23327584	T/C	cg11657817	chr20:23433608	CST11	0.28	4.92	0.4	2.68e-6	Facial morphology (factor 15, philtrum width);
TGCT	cis	rs36051895	0.632	rs10974993	chr9:5182159	C/T	cg02405213	chr9:5042618	JAK2	-0.76	-10.76	-0.69	1.8e-19	Pediatric autoimmune diseases;
TGCT	cis	rs7940866	0.801	rs2113929	chr11:130835974	G/A	cg05962950	chr11:130786565	SNX19	0.74	7.18	0.54	5.63e-11	Schizophrenia;
TGCT	cis	rs56309584	0.715	rs3027234	chr17:8136092	C/T	cg08322244	chr17:8066669	VAMP2	-0.57	-5.19	-0.42	8.26e-7	Initial pursuit acceleration;
TGCT	cis	rs2832191	0.791	rs2832202	chr21:30501342	G/A	cg24692254	chr21:30365293	RNF160	-0.89	-9.49	-0.65	2.2e-16	Dental caries;
TGCT	cis	rs651907	0.535	rs34648996	chr3:101511202	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.86	10.4	0.68	1.35e-18	Colorectal cancer;
TGCT	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs739496	0.579	rs11066077	chr12:112346661	C/T	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs7617773	0.780	rs13066044	chr3:48377276	C/T	cg11946769	chr3:48343235	NME6	0.82	6.99	0.53	1.49e-10	Coronary artery disease;
TGCT	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs16867321	0.671	rs6712709	chr2:181492933	G/A	cg23363182	chr2:181467187	NA	-0.45	-4.79	-0.4	4.59e-6	Obesity;
TGCT	cis	rs7104764	0.917	rs6598068	chr11:243092	A/C	cg18336825	chr11:236787	PSMD13;SIRT3	1.07	11.19	0.71	1.61e-20	Menarche (age at onset);
TGCT	cis	rs13168506	0.538	rs12521857	chr5:135440364	G/A	cg00308130	chr5:135415190	NA	-0.32	-4.52	-0.38	1.44e-5	Stroke;
TGCT	cis	rs9467773	0.572	rs2076029	chr6:26390830	T/C	cg05738196	chr6:26577821	NA	-0.5	-5.19	-0.42	8.47e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1797081	0.967	rs780633	chr10:16863161	C/T	cg23933602	chr10:16859644	RSU1	1.04	13.03	0.76	5.47e-25	Platelet distribution width;
TGCT	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg17747265	chr1:1875780	NA	-0.39	-7.23	-0.54	4.29e-11	Body mass index;
TGCT	cis	rs1008375	0.931	rs3796814	chr4:17602033	G/C	cg18681998	chr4:17616180	MED28	0.98	10.43	0.68	1.17e-18	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10782582	0.593	rs2147039	chr1:76143166	C/T	cg22875332	chr1:76189707	ACADM	-0.56	-6.44	-0.5	2.43e-9	Daytime sleep phenotypes;
TGCT	cis	rs6815814	0.851	rs11466645	chr4:38778203	A/T	cg02016764	chr4:38805732	TLR1	-0.35	-5.51	-0.44	1.96e-7	Breast cancer;
TGCT	cis	rs3796352	1.000	rs35576914	chr3:53092270	G/A	cg15956490	chr3:53032818	SFMBT1	0.6	6.78	0.52	4.31e-10	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs9291683	0.552	rs10939656	chr4:10014646	A/C	cg00071950	chr4:10020882	SLC2A9	0.76	10.25	0.68	3.14e-18	Bone mineral density;
TGCT	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg03303774	chr4:1407052	NA	0.31	4.87	0.4	3.31e-6	Obesity-related traits;
TGCT	cis	rs67478160	0.595	rs67768834	chr14:104221085	C/G	cg26031613	chr14:104095156	KLC1	-0.63	-6.53	-0.51	1.56e-9	Schizophrenia;
TGCT	cis	rs2758596	1.000	rs2842866	chr1:156159721	G/A	cg25208724	chr1:156163844	SLC25A44	0.84	5.09	0.42	1.27e-6	Paclitaxel disposition in epithelial ovarian cancer;
TGCT	cis	rs1046896	0.553	rs2292965	chr17:80900645	G/A	cg03160526	chr17:80928410	B3GNTL1	0.33	4.44	0.37	1.95e-5	Glycated hemoglobin levels;
TGCT	cis	rs4268898	0.722	rs7564420	chr2:24414002	C/T	cg05570707	chr2:24270316	C2orf44	-0.47	-4.63	-0.38	9.07e-6	Asthma;
TGCT	cis	rs259282	0.605	rs55687317	chr19:33109191	G/A	cg26639809	chr19:33781782	NA	0.25	5.04	0.41	1.6e-6	Schizophrenia;
TGCT	cis	rs4273100	0.688	rs1533034	chr17:19153175	G/C	cg01534423	chr17:18965556	NA	0.78	6.78	0.52	4.25e-10	Schizophrenia;
TGCT	cis	rs11690935	1.000	rs35549875	chr2:172532392	A/G	cg13550731	chr2:172543902	DYNC1I2	1.2	12.91	0.76	1.08e-24	Schizophrenia;
TGCT	cis	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg20637647	chr7:64974828	NA	0.94	5.16	0.42	9.35e-7	Diabetic kidney disease;
TGCT	cis	rs10465746	0.752	rs10874426	chr1:84451820	A/G	cg10977910	chr1:84465055	TTLL7	0.63	6.13	0.48	1.07e-8	Obesity-related traits;
TGCT	cis	rs4242434	0.854	rs11782130	chr8:22452357	G/T	cg03733263	chr8:22462867	KIAA1967	1.1	17.29	0.84	7.63e-35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs634534	0.622	rs624273	chr11:65712413	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.54	5.17	0.42	9.27e-7	Sum eosinophil basophil counts;Eosinophil counts;
TGCT	cis	rs651907	0.557	rs7645391	chr3:101361506	C/G	cg11279151	chr3:101281821	RG9MTD1	-0.35	-7.33	-0.55	2.65e-11	Colorectal cancer;
TGCT	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.56	-4.66	-0.39	8.14e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs11677370	0.603	rs10164826	chr2:3849951	G/C	cg17052675	chr2:3827356	NA	-0.42	-7.13	-0.54	7.31e-11	Type 2 diabetes;
TGCT	cis	rs6831352	0.959	rs4699710	chr4:100051819	C/T	cg12011299	chr4:100065546	ADH4	0.41	5.2	0.42	8.11e-7	Alcohol dependence;
TGCT	cis	rs9311474	1.000	rs7629072	chr3:52305633	C/T	cg07507251	chr3:52567010	NT5DC2	0.44	5.99	0.47	2.09e-8	Electroencephalogram traits;
TGCT	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg21644426	chr2:191273491	MFSD6	0.62	6.15	0.48	9.57e-9	Pulse pressure;
TGCT	cis	rs3008870	1.000	rs2985795	chr1:67426223	A/G	cg03991309	chr1:68237761	GNG12	0.27	4.53	0.38	1.36e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs9677476	0.515	rs2303353	chr2:231944373	A/T	cg07929768	chr2:232055508	NA	0.34	5.31	0.43	4.92e-7	Food antigen IgG levels;
TGCT	cis	rs4851254	0.626	rs13001783	chr2:100689652	A/T	cg22139774	chr2:100720529	AFF3	-0.45	-4.91	-0.4	2.75e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs12711979	0.765	rs6705742	chr2:3820672	C/T	cg17052675	chr2:3827356	NA	-0.4	-7.82	-0.57	2.02e-12	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg25767906	chr1:53392781	SCP2	-0.53	-6.11	-0.48	1.2e-8	Monocyte count;
TGCT	cis	rs2486012	1.000	rs2245439	chr1:44389959	C/T	cg12908607	chr1:44402522	ARTN	0.73	5.63	0.45	1.13e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	5.93	0.47	2.76e-8	Alzheimer's disease;
TGCT	cis	rs2840044	0.534	rs167691	chr17:33885826	G/A	cg05299278	chr17:33885742	SLFN14	0.22	4.92	0.4	2.7e-6	Response to radiotherapy in cancer (late toxicity);
TGCT	cis	rs2075371	0.933	rs431306	chr7:133955974	A/T	cg11752832	chr7:134001865	SLC35B4	0.68	5.89	0.47	3.32e-8	Mean platelet volume;
TGCT	cis	rs7312933	0.612	rs10785334	chr12:42620377	A/G	cg19980929	chr12:42632907	YAF2	-0.48	-5.99	-0.47	2.11e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs9326248	0.911	rs474339	chr11:117059552	G/A	cg26566898	chr11:117069891	TAGLN	0.34	5.05	0.41	1.56e-6	Blood protein levels;
TGCT	cis	rs12681287	0.608	rs13270090	chr8:87553297	T/A	cg27223183	chr8:87520930	FAM82B	0.84	6.08	0.48	1.41e-8	Caudate activity during reward;
TGCT	cis	rs13191362	1.000	rs35723993	chr6:163008197	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7727544	0.684	rs2516788	chr5:131715565	G/C	cg24060327	chr5:131705240	SLC22A5	0.61	6.7	0.52	6.54e-10	Blood metabolite levels;
TGCT	cis	rs854765	0.663	rs2236513	chr17:17747366	A/C	cg09796270	chr17:17721594	SREBF1	-0.24	-4.52	-0.38	1.43e-5	Total body bone mineral density;
TGCT	cis	rs9457247	1.000	rs430477	chr6:167389851	T/C	cg23791538	chr6:167370224	RNASET2	-0.5	-4.98	-0.41	2.08e-6	Crohn's disease;
TGCT	trans	rs208520	0.837	rs208486	chr6:66926255	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.97	-10.05	-0.67	9.41e-18	Exhaled nitric oxide output;
TGCT	cis	rs858239	0.862	rs1728292	chr7:23263474	C/G	cg05602783	chr7:23145260	KLHL7	-0.62	-4.93	-0.41	2.53e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs9611565	0.802	rs132916	chr22:41806768	C/G	cg03806693	chr22:41940476	POLR3H	0.97	10.86	0.7	9.98e-20	Vitiligo;
TGCT	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg04267008	chr7:1944627	MAD1L1	-0.37	-4.98	-0.41	2.09e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs6912958	0.559	rs373646	chr6:88056896	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.44	5.82	0.46	4.73e-8	Monocyte percentage of white cells;
TGCT	cis	rs617219	0.737	rs12659709	chr5:78458257	C/G	cg23514016	chr5:78407564	BHMT	0.35	5.49	0.44	2.2e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs4700695	0.841	rs417152	chr5:65316205	G/A	cg21114390	chr5:65439923	SFRS12	0.6	4.47	0.37	1.74e-5	Facial morphology (factor 19);
TGCT	trans	rs9329221	0.905	rs10283145	chr8:10241411	C/T	cg15556689	chr8:8085844	FLJ10661	-0.77	-7.17	-0.54	5.9e-11	Neuroticism;
TGCT	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg04944784	chr2:26401820	FAM59B	0.72	5.92	0.47	2.93e-8	Gut microbiome composition (summer);
TGCT	cis	rs908922	0.636	rs474086	chr1:152513431	C/T	cg20991723	chr1:152506922	NA	0.46	6.18	0.48	8.66e-9	Hair morphology;
TGCT	cis	rs7119	0.667	rs907390	chr15:77902419	T/C	cg27398640	chr15:77910606	LINGO1	0.32	6.72	0.52	5.98e-10	Type 2 diabetes;
TGCT	trans	rs7618501	1.000	rs9872864	chr3:49792023	A/G	cg21659725	chr3:3221576	CRBN	-0.98	-15.33	-0.81	2.1000000000000002e-30	Intelligence (multi-trait analysis);
TGCT	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.63	0.38	9.2e-6	Prudent dietary pattern;
TGCT	cis	rs4788570	0.667	rs9302630	chr16:71789529	A/C	cg06353428	chr16:71660113	MARVELD3	1.53	11.94	0.73	2.45e-22	Intelligence (multi-trait analysis);
TGCT	cis	rs637571	0.557	rs1204649	chr11:65702776	A/C	cg04055107	chr11:65626734	MUS81;CFL1	0.46	4.65	0.39	8.2e-6	Eosinophil percentage of white cells;
TGCT	cis	rs4722166	0.630	rs1581497	chr7:22779503	C/A	cg26061582	chr7:22766209	IL6	0.56	7.17	0.54	5.89e-11	Lung cancer;
TGCT	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg06212747	chr3:49208901	KLHDC8B	0.67	6.36	0.5	3.57e-9	Menarche (age at onset);
TGCT	cis	rs713587	0.719	rs58048722	chr2:25187825	C/T	cg15423357	chr2:25149977	NA	-0.58	-5.9	-0.47	3.22e-8	Body mass index in non-asthmatics;
TGCT	cis	rs739496	0.579	rs7297760	chr12:112313688	A/C	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs617219	0.597	rs10474581	chr5:78578884	G/A	cg05890484	chr5:78407552	BHMT	-0.38	-5.17	-0.42	9.01e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs9217	0.870	rs3853821	chr17:7396327	G/T	cg17892169	chr17:7452644	TNFSF12;TNFSF12-TNFSF13	-0.23	-4.44	-0.37	1.99e-5	Height;
TGCT	cis	rs2440129	0.611	rs10852889	chr17:6900845	C/T	cg03407747	chr17:6899364	ALOX12	0.53	5.91	0.47	3.11e-8	Tonsillectomy;
TGCT	cis	rs17767294	0.708	rs72848786	chr6:27980017	G/A	cg08851530	chr6:28072375	NA	1.56	7.22	0.54	4.47e-11	Parkinson's disease;
TGCT	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg18876405	chr7:65276391	NA	0.31	4.79	0.4	4.58e-6	Aortic root size;
TGCT	cis	rs1670533	1.000	rs13107058	chr4:1054379	G/A	cg20887711	chr4:1340912	KIAA1530	0.72	5.55	0.45	1.64e-7	Recombination rate (females);
TGCT	cis	rs3806843	0.576	rs246032	chr5:140332547	C/A	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs806215	0.526	rs58106688	chr7:127483211	T/C	cg11539674	chr7:127291444	SND1	-0.36	-4.67	-0.39	7.77e-6	Type 2 diabetes;
TGCT	cis	rs4689592	0.546	rs907523	chr4:7052777	A/G	cg26116260	chr4:7069785	GRPEL1	1.13	10.56	0.69	5.46e-19	Monocyte percentage of white cells;
TGCT	cis	rs1887596	0.705	rs1697223	chr13:27216940	A/T	cg01312412	chr13:27282625	NA	-0.3	-5.35	-0.43	4.01e-7	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs10876993	0.821	rs1629032	chr12:58038686	C/T	cg15848620	chr12:58087721	OS9	-0.72	-5.78	-0.46	5.57e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs7647973	1.000	rs10155014	chr3:49432321	C/T	cg07636037	chr3:49044803	WDR6	0.67	5.36	0.43	3.92e-7	Menarche (age at onset);
TGCT	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg17554472	chr22:41940697	POLR3H	-0.49	-5.27	-0.43	5.9e-7	Vitiligo;
TGCT	cis	rs2758596	0.850	rs2495270	chr1:156181530	A/G	cg24450063	chr1:156163899	SLC25A44	0.9	4.67	0.39	7.64e-6	Paclitaxel disposition in epithelial ovarian cancer;
TGCT	cis	rs6788895	0.661	rs57869178	chr3:150492826	G/C	cg07663535	chr3:150480033	SIAH2	0.99	4.55	0.38	1.24e-5	Breast cancer;
TGCT	cis	rs11105298	0.891	rs11105302	chr12:89891366	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	0.72	5.06	0.41	1.46e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	trans	rs11764590	0.715	rs9639202	chr7:2087315	G/A	cg25206134	chr2:45395956	NA	0.97	6.72	0.52	5.86e-10	Neuroticism;
TGCT	cis	rs13217239	0.646	rs6937880	chr6:27000236	C/T	cg02458000	chr6:26745757	NA	0.5	4.61	0.38	1e-5	Schizophrenia;
TGCT	cis	rs240110	0.539	rs6919745	chr6:101338978	T/C	cg09795085	chr6:101329169	ASCC3	0.56	4.45	0.37	1.85e-5	Neuroticism;
TGCT	cis	rs1878931	0.559	rs1968055	chr16:3392053	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.71	6.76	0.52	4.79e-10	Body mass index (adult);
TGCT	cis	rs7726839	0.507	rs56282020	chr5:596701	T/C	cg16624210	chr5:671434	TPPP	0.44	4.83	0.4	3.89e-6	Obesity-related traits;
TGCT	cis	rs11969893	0.649	rs9498408	chr6:101292340	C/T	cg12253828	chr6:101329408	ASCC3	1.22	5.92	0.47	2.93e-8	Economic and political preferences (immigration/crime);
TGCT	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg10819733	chr22:24237672	NA	0.29	4.89	0.4	3.01e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg00343986	chr7:65444356	GUSB	0.26	5.95	0.47	2.56e-8	Calcium levels;
TGCT	cis	rs9549260	0.753	rs1986649	chr13:41178824	C/T	cg21288729	chr13:41239152	FOXO1	0.67	4.68	0.39	7.31e-6	Red blood cell count;
TGCT	cis	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg26566898	chr11:117069891	TAGLN	0.35	5.09	0.42	1.27e-6	Blood protein levels;
TGCT	trans	rs621559	0.636	rs602629	chr1:43670248	A/T	cg19324027	chr2:74699582	MRPL53	0.87	6.75	0.52	5.12e-10	Telomere length;
TGCT	cis	rs6554196	0.644	rs7655709	chr4:55499386	C/G	cg02821500	chr4:54931072	CHIC2	0.48	4.71	0.39	6.54e-6	Monocyte count;
TGCT	cis	rs896854	0.684	rs2340534	chr8:95992330	G/A	cg16049864	chr8:95962084	TP53INP1	-0.7	-9.93	-0.67	1.84e-17	Type 2 diabetes;
TGCT	cis	rs7267979	1.000	rs2500405	chr20:25360826	A/G	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2016266	0.819	rs1976938	chr12:53661925	C/T	cg16917193	chr12:54089295	NA	0.67	5.1	0.42	1.25e-6	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs10197940	0.662	rs4335940	chr2:152275304	A/G	cg06191203	chr2:152266755	RIF1	0.71	6.28	0.49	5.14e-9	Lung cancer;
TGCT	cis	rs7119	0.667	rs907393	chr15:77903447	T/C	cg27398640	chr15:77910606	LINGO1	0.32	6.76	0.52	4.86e-10	Type 2 diabetes;
TGCT	cis	rs2797160	1.000	rs1777183	chr6:126011995	A/C	cg05901451	chr6:126070800	HEY2	0.72	5.91	0.47	3.15e-8	Endometrial cancer;
TGCT	cis	rs7568458	0.846	rs6705839	chr2:85761279	A/T	cg02493740	chr2:85810744	VAMP5	-0.26	-5.04	-0.41	1.59e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs4076764	1.000	rs7525643	chr1:163426283	G/A	cg24596788	chr1:163392923	NA	-0.17	-4.75	-0.39	5.46e-6	Motion sickness;
TGCT	trans	rs7726839	0.526	rs55647623	chr5:567747	T/C	cg11887960	chr12:57824829	NA	1.02	7.74	0.57	3.07e-12	Obesity-related traits;
TGCT	cis	rs6840360	0.615	rs62329085	chr4:152470237	G/A	cg17479576	chr4:152424074	FAM160A1	-0.71	-7.74	-0.57	2.95e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs11718455	0.960	rs3843372	chr3:43997666	C/T	cg08738300	chr3:44038990	NA	0.81	6.02	0.48	1.8e-8	Coronary artery disease;
TGCT	cis	rs10089	1.000	rs10478803	chr5:127488855	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	7.27	0.55	3.56e-11	Ileal carcinoids;
TGCT	cis	rs7402982	0.625	rs4966008	chr15:99203445	A/G	cg03437748	chr15:99193247	IGF1R	-0.47	-4.5	-0.37	1.56e-5	Birth weight;
TGCT	cis	rs10193935	1.000	rs12622910	chr2:42398918	C/A	cg27598129	chr2:42591480	NA	-0.39	-5.14	-0.42	1.05e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg11644478	chr21:40555479	PSMG1	-0.58	-5.1	-0.42	1.23e-6	Cognitive function;
TGCT	cis	rs651907	0.557	rs35850993	chr3:101437433	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.33	-6.69	-0.51	7.01e-10	Colorectal cancer;
TGCT	cis	rs10197940	0.624	rs6724796	chr2:152412813	C/T	cg19508488	chr2:152266495	RIF1	0.7	6.39	0.5	2.98e-9	Lung cancer;
TGCT	cis	rs9682041	0.935	rs11923053	chr3:170095281	T/C	cg11886554	chr3:170076028	SKIL	0.83	6.37	0.5	3.41e-9	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg02675527	chr2:114030824	PAX8;LOC440839	-0.5	-6.65	-0.51	8.34e-10	Lymphocyte counts;
TGCT	cis	rs7552404	0.731	rs5745445	chr1:76344332	G/A	cg22875332	chr1:76189707	ACADM	0.7	7.11	0.54	8.18e-11	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs6089584	0.507	rs6061989	chr20:60627893	C/T	cg06108461	chr20:60628389	TAF4	-0.43	-5.2	-0.42	7.98e-7	Body mass index;
TGCT	cis	rs2243480	1.000	rs313832	chr7:65550891	G/T	cg18252515	chr7:66147081	NA	-1.1	-7.23	-0.54	4.36e-11	Diabetic kidney disease;
TGCT	cis	rs2797160	1.000	rs6910933	chr6:126017155	C/G	cg05901451	chr6:126070800	HEY2	0.73	6.29	0.49	5.01e-9	Endometrial cancer;
TGCT	cis	rs6582630	0.519	rs11519914	chr12:38287014	A/G	cg26384229	chr12:38710491	ALG10B	0.78	7.01	0.53	1.36e-10	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs10507380	0.824	rs9512632	chr13:27919034	C/G	cg25543773	chr13:27185723	WASF3	0.34	4.83	0.4	3.97e-6	Electrocardiographic traits;
TGCT	cis	rs854765	0.693	rs9907287	chr17:17774118	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.74	-7.65	-0.57	4.87e-12	Total body bone mineral density;
TGCT	cis	rs908922	0.651	rs1988805	chr1:152531495	T/G	cg20991723	chr1:152506922	NA	0.45	6.05	0.48	1.6e-8	Hair morphology;
TGCT	cis	rs2204008	0.728	rs11495375	chr12:38282631	G/A	cg13010199	chr12:38710504	ALG10B	0.64	4.97	0.41	2.15e-6	Bladder cancer;
TGCT	cis	rs4455778	0.536	rs38771	chr7:48940564	C/A	cg26309511	chr7:48887640	NA	0.46	5.51	0.44	1.98e-7	Lung cancer in never smokers;
TGCT	cis	rs62380364	0.565	rs13158247	chr5:88030670	C/T	cg22951263	chr5:87985283	NA	-0.55	-5.96	-0.47	2.46e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs11190604	0.943	rs11190574	chr10:102234331	T/C	cg16005271	chr10:102321736	NA	0.46	4.69	0.39	6.96e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg22764044	chr5:178986830	RUFY1	-0.41	-4.49	-0.37	1.58e-5	Lung cancer;
TGCT	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg13395646	chr4:1353034	KIAA1530	-0.4	-5.0	-0.41	1.93e-6	Obesity-related traits;
TGCT	cis	rs7267979	1.000	rs2500432	chr20:25290512	A/C	cg14121845	chr20:25566513	NINL	0.52	5.61	0.45	1.28e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs950776	0.518	rs28438420	chr15:78836288	A/T	cg06917634	chr15:78832804	PSMA4	-0.88	-8.51	-0.61	4.66e-14	Sudden cardiac arrest;
TGCT	cis	rs56104184	0.775	rs73061689	chr19:49397214	C/T	cg17863274	chr19:49399704	TULP2	-0.54	-7.43	-0.55	1.58e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs1371867	0.846	rs1660330	chr8:101305015	T/A	cg00191853	chr8:101177733	SPAG1	-0.22	-4.47	-0.37	1.75e-5	Atrioventricular conduction;
TGCT	cis	rs35146811	0.735	rs1727140	chr7:99815399	T/A	cg13334819	chr7:99746414	C7orf59	0.74	6.31	0.49	4.4e-9	Coronary artery disease;
TGCT	cis	rs912057	1.000	rs1294407	chr6:6738103	C/G	cg06612196	chr6:6737390	NA	0.39	4.91	0.4	2.85e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs17384381	1.000	rs36110608	chr1:85852936	A/C	cg16011679	chr1:85725395	C1orf52	0.84	6.52	0.51	1.6e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs950169	0.922	rs4842941	chr15:84831312	G/C	cg17173187	chr15:85201210	NMB	-0.54	-5.52	-0.44	1.87e-7	Schizophrenia;
TGCT	trans	rs2832077	0.527	rs1048546	chr21:30244877	G/T	cg14791747	chr16:20752902	THUMPD1	1.01	10.53	0.69	6.61e-19	Cognitive test performance;
TGCT	cis	rs7014346	0.767	rs7837328	chr8:128423127	A/G	cg04263511	chr8:128962092	PVT1	-0.31	-4.5	-0.37	1.54e-5	Colorectal cancer;
TGCT	cis	rs2197308	0.605	rs2387437	chr12:37919367	T/C	cg26384229	chr12:38710491	ALG10B	0.85	7.82	0.57	1.94e-12	Morning vs. evening chronotype;
TGCT	cis	rs2486288	0.656	rs11639349	chr15:45568260	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.43	-4.71	-0.39	6.43e-6	Glomerular filtration rate;
TGCT	cis	rs11690935	1.000	rs312924	chr2:172564021	A/T	cg13550731	chr2:172543902	DYNC1I2	1.05	10.38	0.68	1.48e-18	Schizophrenia;
TGCT	cis	rs9611565	0.512	rs5758450	chr22:42141640	G/A	cg17554472	chr22:41940697	POLR3H	0.47	4.9	0.4	2.89e-6	Vitiligo;
TGCT	cis	rs4631830	0.863	rs2843549	chr10:51521247	C/A	cg10326726	chr10:51549505	MSMB	-0.25	-4.87	-0.4	3.38e-6	Prostate-specific antigen levels;
TGCT	cis	rs6967385	0.560	rs7790370	chr7:12353523	G/C	cg20607287	chr7:12443886	VWDE	0.41	4.5	0.37	1.57e-5	Response to taxane treatment (placlitaxel);
TGCT	cis	rs4900538	0.927	rs1190547	chr14:102905087	G/C	cg18135206	chr14:102964638	TECPR2	-0.22	-5.31	-0.43	4.81e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.52	-6.67	-0.51	7.62e-10	Lymphocyte counts;
TGCT	cis	rs11098499	0.698	rs4422403	chr4:120258194	C/T	cg09307838	chr4:120376055	NA	0.55	5.33	0.43	4.45e-7	Corneal astigmatism;
TGCT	cis	rs10088262	0.629	rs9918907	chr8:124816862	A/G	cg20713898	chr8:124780851	FAM91A1	-0.88	-7.29	-0.55	3.13e-11	Pancreatic cancer;
TGCT	cis	rs11098499	0.954	rs13113483	chr4:120309039	C/T	cg09307838	chr4:120376055	NA	0.65	6.39	0.5	3.02e-9	Corneal astigmatism;
TGCT	cis	rs9300255	0.739	rs4759417	chr12:123746510	C/T	cg00376283	chr12:123451042	ABCB9	0.72	5.54	0.45	1.76e-7	Neutrophil percentage of white cells;
TGCT	cis	rs644799	1.000	rs596277	chr11:95566886	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.88	9.59	0.65	1.24e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg01341218	chr17:43662625	NA	-1.11	-9.34	-0.64	5.11e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg18402987	chr7:1209562	NA	0.47	4.68	0.39	7.37e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9328448	1.000	rs9502672	chr6:7991435	A/G	cg13863638	chr6:7199401	RREB1	0.19	4.57	0.38	1.15e-5	Coronary artery calcification;
TGCT	cis	rs1568889	1.000	rs58502944	chr11:28060943	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	8.59	0.61	3.18e-14	Bipolar disorder;
TGCT	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg16680214	chr1:154839983	KCNN3	-0.43	-9.49	-0.65	2.21e-16	Prostate cancer;
TGCT	cis	rs6912958	0.712	rs2246113	chr6:88410050	C/T	cg06598631	chr6:88300029	RARS2;ORC3L	-0.51	-4.93	-0.4	2.55e-6	Monocyte percentage of white cells;
TGCT	cis	rs514406	0.536	rs878957	chr1:53197559	C/T	cg01802117	chr1:53393560	SCP2	0.45	5.33	0.43	4.41e-7	Monocyte count;
TGCT	cis	rs3820928	0.839	rs12151848	chr2:227859326	G/A	cg11843606	chr2:227700838	RHBDD1	-0.52	-4.63	-0.38	9.03e-6	Pulmonary function;
TGCT	cis	rs9549367	0.713	rs4907599	chr13:113861441	C/T	cg00898013	chr13:113819073	PROZ	0.5	6.73	0.52	5.71e-10	Platelet distribution width;
TGCT	cis	rs3806843	1.000	rs6898939	chr5:140169355	C/A	cg19875535	chr5:140030758	IK	0.37	6.17	0.48	8.88e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs612683	0.536	rs1855797	chr1:101027126	A/G	cg06223162	chr1:101003688	GPR88	0.33	5.59	0.45	1.39e-7	Breast cancer;
TGCT	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.06	-9.6	-0.65	1.15e-16	Platelet count;
TGCT	cis	rs3091242	1.000	rs646867	chr1:25709258	A/C	cg10117171	chr1:25599238	RHD	-0.35	-5.72	-0.46	7.42e-8	Erythrocyte sedimentation rate;
TGCT	trans	rs4332037	1.000	rs10240470	chr7:1949971	G/T	cg10840412	chr1:235813424	GNG4	-1.06	-8.34	-0.6	1.21e-13	Bipolar disorder;
TGCT	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg21724239	chr8:58056113	NA	0.47	5.14	0.42	1.05e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6728642	0.808	rs114192053	chr2:97871906	G/A	cg26665480	chr2:98280029	ACTR1B	-0.97	-4.85	-0.4	3.69e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	cis	rs4478858	0.735	rs4949205	chr1:31800579	A/G	cg00250761	chr1:31883323	NA	-0.28	-4.96	-0.41	2.32e-6	Alcohol dependence;
TGCT	cis	rs4566357	0.615	rs10178260	chr2:227914458	G/T	cg11843606	chr2:227700838	RHBDD1	-0.54	-5.24	-0.43	6.55e-7	Coronary artery disease;
TGCT	cis	rs7605378	0.528	rs281787	chr2:200784238	C/T	cg19045956	chr2:200819837	C2orf60;C2orf47	-0.54	-5.82	-0.46	4.81e-8	Osteoporosis;
TGCT	cis	rs1059312	0.966	rs35907548	chr12:129282180	T/C	cg09035930	chr12:129282057	SLC15A4	0.59	11.59	0.72	1.72e-21	Systemic lupus erythematosus;
TGCT	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg01802117	chr1:53393560	SCP2	-0.43	-5.2	-0.42	8.03e-7	Monocyte count;
TGCT	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg20607798	chr8:58055168	NA	0.61	5.06	0.41	1.5e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs57590327	0.503	rs13079104	chr3:81886039	A/T	cg07356753	chr3:81810745	GBE1	-0.69	-6.34	-0.49	3.87e-9	Extraversion;
TGCT	cis	rs10186029	0.667	rs6734174	chr2:213981428	A/C	cg08319019	chr2:214017104	IKZF2	-0.52	-4.87	-0.4	3.39e-6	Systemic sclerosis;
TGCT	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg06618935	chr21:46677482	NA	-0.37	-5.83	-0.46	4.48e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs75229567	0.618	rs1599745	chr12:70186029	A/G	cg10114359	chr12:70132523	RAB3IP	1.26	6.41	0.5	2.71e-9	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
TGCT	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg14827481	chr10:134361889	INPP5A	0.31	4.99	0.41	1.99e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs4689388	0.926	rs10937720	chr4:6295451	A/G	cg00701064	chr4:6280414	WFS1	0.37	4.7	0.39	6.72e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs259282	0.692	rs35972270	chr19:33128457	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.62	5.84	0.46	4.38e-8	Schizophrenia;
TGCT	cis	rs9644630	0.696	rs7828025	chr8:19314693	A/G	cg06699216	chr8:19333253	CSGALNACT1	-0.25	-4.44	-0.37	1.95e-5	Oropharynx cancer;
TGCT	cis	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg25427524	chr10:38739819	LOC399744	-0.39	-8.05	-0.59	5.9e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg08280861	chr8:58055591	NA	0.38	4.81	0.4	4.36e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs362272	0.545	rs3129308	chr4:3309272	C/T	cg06533319	chr4:3265114	C4orf44	-0.25	-4.87	-0.4	3.4e-6	Serum sulfate level;
TGCT	cis	rs11190604	1.000	rs11190551	chr10:102204734	A/G	cg23241863	chr10:102295624	HIF1AN	0.62	4.87	0.4	3.27e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs12048904	0.964	rs17123467	chr1:101331760	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.48	4.62	0.38	9.44e-6	Multiple sclerosis;
TGCT	cis	rs12477438	0.501	rs11683107	chr2:99759235	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	14.86	0.8	2.64e-29	Chronic sinus infection;
TGCT	cis	rs3008870	1.000	rs2985797	chr1:67431499	C/T	cg03991309	chr1:68237761	GNG12	-0.27	-4.45	-0.37	1.9e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs7666738	0.830	rs7689495	chr4:98920152	T/C	cg05340658	chr4:99064831	C4orf37	0.53	6.11	0.48	1.21e-8	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs28735056	0.904	rs12962619	chr18:77628832	T/C	cg05926928	chr17:57297772	GDPD1	0.65	6.74	0.52	5.44e-10	Schizophrenia;
TGCT	cis	rs7000551	0.751	rs2449329	chr8:22374794	G/T	cg12081754	chr8:22256438	SLC39A14	0.31	5.0	0.41	1.9e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs4803468	1.000	rs4803468	chr19:41922352	A/G	cg09537434	chr19:41945824	ATP5SL	-0.92	-10.71	-0.69	2.31e-19	Height;
TGCT	cis	rs8017423	0.647	rs4900037	chr14:90821478	A/G	cg04374321	chr14:90722782	PSMC1	0.51	5.05	0.41	1.52e-6	Mortality in heart failure;
TGCT	cis	rs7264396	0.635	rs6060681	chr20:34506147	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.01	-0.41	1.85e-6	Total cholesterol levels;
TGCT	cis	rs2404602	0.669	rs9788684	chr15:77194838	A/T	cg26408565	chr15:76604113	ETFA	-0.36	-4.68	-0.39	7.46e-6	Blood metabolite levels;
TGCT	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg21171335	chr12:122356390	WDR66	0.69	6.97	0.53	1.69e-10	Mean corpuscular volume;
TGCT	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.65	0.39	8.47e-6	Prudent dietary pattern;
TGCT	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	4.77	0.39	5.14e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg22963979	chr7:1858916	MAD1L1	-0.41	-6.4	-0.5	2.83e-9	Bipolar disorder and schizophrenia;
TGCT	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg03264133	chr6:25882463	NA	0.86	8.95	0.63	4.38e-15	Blood metabolite levels;
TGCT	cis	rs7208859	0.673	rs9913782	chr17:29237384	A/G	cg14008862	chr17:28927542	LRRC37B2	0.72	4.66	0.39	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs2562456	0.917	rs2650804	chr19:21680184	A/G	cg01304269	chr19:21688519	ZNF429	0.6	4.94	0.41	2.44e-6	Pain;
TGCT	cis	rs651907	0.554	rs10470501	chr3:101630497	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.53	5.01	0.41	1.83e-6	Colorectal cancer;
TGCT	cis	rs910316	0.763	rs175044	chr14:75472109	G/A	cg11812906	chr14:75593930	NEK9	-0.59	-5.59	-0.45	1.38e-7	Height;
TGCT	cis	rs6558530	0.692	rs6558525	chr8:1702523	A/G	cg09410841	chr8:1729607	CLN8	0.72	6.49	0.5	1.87e-9	Systolic blood pressure;
TGCT	cis	rs17376456	0.778	rs72786662	chr5:93137630	C/T	cg25358565	chr5:93447407	FAM172A	0.9	7.6	0.56	6.43e-12	Diabetic retinopathy;
TGCT	cis	rs7647973	0.626	rs12715437	chr3:49751856	T/C	cg05785598	chr3:49045655	WDR6	0.42	5.24	0.43	6.67e-7	Menarche (age at onset);
TGCT	cis	rs896854	0.684	rs10098778	chr8:95992020	C/T	cg09323728	chr8:95962352	TP53INP1	-0.47	-6.18	-0.49	8.62e-9	Type 2 diabetes;
TGCT	cis	rs7666738	0.830	rs13144771	chr4:99026935	G/C	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg11062466	chr8:58055876	NA	0.38	4.5	0.37	1.56e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs42648	0.596	rs194523	chr7:89860574	A/T	cg25739043	chr7:89950458	NA	-0.5	-4.83	-0.4	3.91e-6	Homocysteine levels;
TGCT	cis	rs4325129	1.000	rs12133664	chr1:159460890	C/T	cg07417683	chr1:159440267	NA	-0.44	-4.54	-0.38	1.33e-5	Obesity-related traits;
TGCT	cis	rs7666738	0.716	rs7656233	chr4:99079237	G/A	cg05340658	chr4:99064831	C4orf37	0.52	5.64	0.45	1.08e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4843185	0.576	rs1868871	chr16:85728651	A/G	cg26571870	chr16:85723150	GINS2	0.34	4.74	0.39	5.8e-6	Platelet distribution width;
TGCT	cis	rs798766	1.000	rs3752749	chr4:1737262	T/C	cg05874882	chr4:1763078	NA	-0.35	-4.45	-0.37	1.86e-5	Bladder cancer;Urinary bladder cancer;
TGCT	cis	rs6693567	0.565	rs698917	chr1:150319884	G/A	cg09579323	chr1:150459698	TARS2	0.54	4.79	0.4	4.59e-6	Migraine;
TGCT	cis	rs13217239	0.608	rs6930508	chr6:27053142	T/C	cg02458000	chr6:26745757	NA	-0.5	-4.55	-0.38	1.25e-5	Schizophrenia;
TGCT	cis	rs1008375	0.966	rs4698638	chr4:17632988	G/C	cg18681998	chr4:17616180	MED28	1.01	11.55	0.72	2.15e-21	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-8.44	-0.6	6.87e-14	Platelet count;
TGCT	cis	rs2862064	0.649	rs1995377	chr5:156436679	T/A	cg12943317	chr5:156479607	HAVCR1	-0.45	-5.77	-0.46	5.83e-8	Platelet count;
TGCT	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg13695892	chr22:41940480	POLR3H	0.92	9.08	0.63	2.08e-15	Vitiligo;
TGCT	cis	rs889312	0.500	rs33323	chr5:56175566	C/G	cg12311346	chr5:56204834	C5orf35	-0.46	-4.97	-0.41	2.14e-6	Breast cancer;Breast cancer (early onset);
TGCT	cis	rs6882076	1.000	rs6882076	chr5:156390297	T/C	cg12943317	chr5:156479607	HAVCR1	-0.29	-5.6	-0.45	1.3e-7	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
TGCT	cis	rs3008870	1.000	rs1925412	chr1:67405057	G/A	cg03991309	chr1:68237761	GNG12	0.27	4.55	0.38	1.26e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs936229	0.813	rs4886629	chr15:75072558	G/C	cg10253484	chr15:75165896	SCAMP2	-0.69	-5.59	-0.45	1.4e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
TGCT	cis	rs12908161	1.000	rs4643294	chr15:85250253	C/T	cg12863693	chr15:85201151	NMB	0.46	5.51	0.44	1.95e-7	Schizophrenia;
TGCT	cis	rs7666738	0.606	rs28625338	chr4:99076996	A/G	cg18180107	chr4:99064573	C4orf37	0.51	4.56	0.38	1.21e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9309473	0.687	rs12465867	chr2:73612102	C/T	cg20560298	chr2:73613845	ALMS1	-0.48	-5.37	-0.43	3.68e-7	Metabolite levels;
TGCT	cis	rs2742417	1.000	rs9829631	chr3:45740558	T/C	cg04837898	chr3:45731254	SACM1L	-0.55	-5.68	-0.45	9.14e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs7312933	0.703	rs12371615	chr12:42563989	C/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	5.07	0.41	1.42e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs868036	0.609	rs16951304	chr15:68089618	T/C	cg27219399	chr15:67835830	MAP2K5	0.34	4.49	0.37	1.6e-5	Restless legs syndrome;
TGCT	cis	rs7945705	0.967	rs10840148	chr11:8923528	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.46	5.19	0.42	8.23e-7	Hemoglobin concentration;
TGCT	cis	rs2204008	0.805	rs11169513	chr12:37988640	G/A	cg26384229	chr12:38710491	ALG10B	0.86	7.77	0.57	2.55e-12	Bladder cancer;
TGCT	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg07507251	chr3:52567010	NT5DC2	0.47	6.7	0.52	6.47e-10	Bipolar disorder;
TGCT	cis	rs11098499	0.535	rs7671759	chr4:120248094	A/C	cg09307838	chr4:120376055	NA	0.61	5.78	0.46	5.57e-8	Corneal astigmatism;
TGCT	cis	rs9814567	0.929	rs13316205	chr3:134223563	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.95	-9.62	-0.65	1.04e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs7552404	0.924	rs1694419	chr1:76219801	C/T	cg22875332	chr1:76189707	ACADM	0.61	6.28	0.49	5.17e-9	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs42648	0.667	rs2157793	chr7:89880354	C/G	cg25739043	chr7:89950458	NA	-0.54	-5.04	-0.41	1.61e-6	Homocysteine levels;
TGCT	cis	rs2228479	0.681	rs11642428	chr16:89971909	A/T	cg06558623	chr16:89946397	TCF25	0.37	4.81	0.4	4.33e-6	Skin colour saturation;
TGCT	cis	rs35306767	0.953	rs11253509	chr10:964306	C/T	cg20503657	chr10:835505	NA	0.65	9.54	0.65	1.66e-16	Eosinophil percentage of granulocytes;
TGCT	cis	rs2677744	0.688	rs3784779	chr15:91453131	C/T	cg23684204	chr15:91497937	RCCD1	0.33	5.04	0.41	1.62e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs2072499	1.000	rs2253809	chr1:156172125	T/C	cg06970220	chr1:156163860	SLC25A44	0.67	5.9	0.47	3.22e-8	Testicular germ cell tumor;
TGCT	cis	rs8180040	0.620	rs11707736	chr3:47069504	G/T	cg27129171	chr3:47204927	SETD2	-0.7	-8.34	-0.6	1.22e-13	Colorectal cancer;
TGCT	cis	rs12118280	0.581	rs545593	chr1:108720242	G/A	cg11967332	chr1:108735228	SLC25A24	-0.36	-5.17	-0.42	9.18e-7	Myeloid white cell count;
TGCT	cis	rs7552404	1.000	rs11161511	chr1:76210477	A/G	cg10523679	chr1:76189770	ACADM	-0.86	-9.2	-0.64	1.06e-15	Blood metabolite levels;Acylcarnitine levels;
TGCT	trans	rs1005277	0.540	rs2145487	chr10:38010077	A/G	cg17830980	chr10:43048298	ZNF37B	-0.65	-7.34	-0.55	2.4e-11	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7552404	0.960	rs12085123	chr1:76149749	G/A	cg10523679	chr1:76189770	ACADM	0.91	9.92	0.67	2.01e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2836974	0.545	rs2776311	chr21:40716885	A/G	cg11890956	chr21:40555474	PSMG1	0.76	7.42	0.55	1.63e-11	Cognitive function;
TGCT	cis	rs704	0.585	rs2227735	chr17:26693258	C/T	cg10342447	chr17:26645325	TMEM97	-0.6	-6.02	-0.48	1.8e-8	Osteoprotegerin levels;
TGCT	cis	rs2760061	0.626	rs591582	chr1:228117360	C/A	cg02753203	chr1:228287806	NA	-0.34	-6.63	-0.51	9.12e-10	Diastolic blood pressure;
TGCT	cis	rs9443645	0.901	rs2174739	chr6:79659170	C/T	cg09184832	chr6:79620586	NA	0.49	5.3	0.43	5.1e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs72781680	0.716	rs2551343	chr2:24027002	C/G	cg08917208	chr2:24149416	ATAD2B	0.79	4.94	0.41	2.51e-6	Lymphocyte counts;
TGCT	cis	rs6570726	0.791	rs9373463	chr6:145894762	C/T	cg23711669	chr6:146136114	FBXO30	0.86	9.54	0.65	1.64e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs644799	0.544	rs1527450	chr11:95467777	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.6	5.83	0.46	4.5e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg10047753	chr17:41438598	NA	0.84	7.61	0.56	5.9e-12	Menopause (age at onset);
TGCT	cis	rs9486715	0.867	rs211159	chr6:97023026	G/A	cg06623918	chr6:96969491	KIAA0776	-1.08	-13.6	-0.77	2.39e-26	Headache;
TGCT	cis	rs9677476	1.000	rs12621567	chr2:232118813	T/C	cg07929768	chr2:232055508	NA	0.3	4.44	0.37	1.97e-5	Food antigen IgG levels;
TGCT	cis	rs57920188	0.535	rs7412438	chr1:4095581	C/G	cg20703997	chr1:4087676	NA	0.48	5.77	0.46	5.97e-8	Interleukin-17 levels;
TGCT	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg27541892	chr1:1571801	CDK11B	0.35	4.65	0.39	8.39e-6	Body mass index;
TGCT	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg00908189	chr16:619842	PIGQ	0.87	10.61	0.69	4.21e-19	Height;
TGCT	cis	rs17401966	0.838	rs10864449	chr1:10296922	A/T	cg19773385	chr1:10388646	KIF1B	-0.21	-4.57	-0.38	1.14e-5	Hepatocellular carcinoma;
TGCT	cis	rs4273100	0.688	rs4924980	chr17:19204863	T/C	cg03910582	chr17:19030146	GRAPL	-0.51	-6.28	-0.49	5.18e-9	Schizophrenia;
TGCT	cis	rs921968	0.613	rs2710250	chr2:219543277	A/G	cg02176678	chr2:219576539	TTLL4	-0.33	-4.45	-0.37	1.91e-5	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs6750047	0.546	rs985257	chr2:38283228	A/T	cg07380506	chr2:38303506	CYP1B1	-0.7	-6.64	-0.51	8.88e-10	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs4742903	0.967	rs10820610	chr9:106907819	G/A	cg21169611	chr9:106856078	SMC2	0.49	4.53	0.38	1.34e-5	High-grade serous ovarian cancer;Breast cancer;
TGCT	cis	rs1865760	0.963	rs3846838	chr6:25911775	T/C	cg16482183	chr6:26056742	HIST1H1C	0.55	4.97	0.41	2.19e-6	Height;
TGCT	cis	rs9486719	0.843	rs2499793	chr6:96846402	A/C	cg06623918	chr6:96969491	KIAA0776	0.93	7.08	0.54	9.59e-11	Migraine;Coronary artery disease;
TGCT	cis	rs28595532	0.764	rs115986119	chr4:119767785	C/T	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs6671200	1.000	rs71654419	chr1:95664497	C/G	cg20701556	chr1:95698924	RWDD3	0.65	5.58	0.45	1.43e-7	Stearic acid (18:0) levels;
TGCT	cis	rs13392177	0.660	rs12988046	chr2:219073804	A/G	cg00012203	chr2:219082015	ARPC2	-0.79	-8.02	-0.58	6.73e-13	Pyoderma gangrenosum in inflammatory bowel disease;
TGCT	cis	rs9517313	0.770	rs9517301	chr13:99095088	A/G	cg20487152	chr13:99095054	FARP1	-0.26	-5.14	-0.42	1.06e-6	Neuroticism;
TGCT	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg06481639	chr22:41940642	POLR3H	0.62	5.59	0.45	1.4e-7	Vitiligo;
TGCT	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg24675658	chr1:53192096	ZYG11B	0.66	7.2	0.54	4.97e-11	Monocyte count;
TGCT	cis	rs4499344	0.519	rs259226	chr19:33134965	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.82	8.26	0.6	1.84e-13	Mean platelet volume;
TGCT	cis	rs17534004	1.000	rs35955426	chr13:31471381	A/G	cg13251181	chr13:31481184	C13orf33	0.37	4.79	0.39	4.76e-6	3-hydroxypropylmercapturic acid levels in smokers;
TGCT	cis	rs2361718	0.500	rs12451697	chr17:78100690	T/A	cg21238619	chr17:78079768	GAA	-0.33	-4.59	-0.38	1.06e-5	Yeast infection;
TGCT	cis	rs17253792	0.822	rs79398217	chr14:56067350	C/T	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs4144743	1.000	rs34492688	chr17:45321622	C/A	cg18085866	chr17:45331354	ITGB3	-0.7	-4.62	-0.38	9.41e-6	Body mass index;
TGCT	cis	rs9894429	0.700	rs113915083	chr17:79552696	G/C	cg21984481	chr17:79567631	NPLOC4	0.26	4.83	0.4	3.98e-6	Eye color traits;
TGCT	cis	rs6921919	0.583	rs4254981	chr6:28371402	A/C	cg18815343	chr6:28367644	ZSCAN12	-0.54	-5.25	-0.43	6.29e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7666738	0.753	rs7657644	chr4:99057734	T/A	cg17366294	chr4:99064904	C4orf37	0.73	7.45	0.56	1.4e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9952991	0.941	rs60735058	chr18:12795470	T/A	cg23598886	chr18:12777645	NA	-0.62	-5.55	-0.45	1.64e-7	Inflammatory skin disease;
TGCT	cis	rs473651	0.967	rs483042	chr2:239335320	A/G	cg21699342	chr2:239360505	ASB1	0.17	4.79	0.4	4.69e-6	Multiple system atrophy;
TGCT	cis	rs763121	0.853	rs5750671	chr22:39094619	A/C	cg06022373	chr22:39101656	GTPBP1	0.78	8.1	0.59	4.34e-13	Menopause (age at onset);
TGCT	cis	rs2115630	0.967	rs7171167	chr15:85239123	A/T	cg12863693	chr15:85201151	NMB	-0.34	-4.64	-0.38	8.76e-6	P wave terminal force;
TGCT	cis	rs60012524	1	rs60012524	chr2:99559117	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-4.67	-0.39	7.59e-6	Chronic sinus infection;
TGCT	cis	rs35264875	1.000	rs72928644	chr11:68849845	A/G	cg02660097	chr11:68866761	NA	0.32	4.96	0.41	2.3e-6	Blond vs. brown hair color;
TGCT	cis	rs3091242	0.781	rs71652378	chr1:25721457	G/C	cg00786635	chr1:25594202	NA	0.57	5.87	0.47	3.72e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs10507380	0.943	rs41485749	chr13:27890560	C/T	cg25543773	chr13:27185723	WASF3	-0.34	-4.77	-0.39	5.14e-6	Electrocardiographic traits;
TGCT	cis	rs9457247	0.534	rs9355610	chr6:167383075	G/A	cg23791538	chr6:167370224	RNASET2	0.6	5.75	0.46	6.56e-8	Crohn's disease;
TGCT	cis	rs910187	0.605	rs2235907	chr20:45809652	A/G	cg27589058	chr20:45804311	EYA2	-0.38	-8.33	-0.6	1.3e-13	Migraine;
TGCT	cis	rs4851266	0.865	rs11695996	chr2:100854336	C/T	cg07810366	chr2:100720526	AFF3	-0.36	-5.21	-0.42	7.59e-7	Educational attainment;
TGCT	cis	rs12210905	1.000	rs72843640	chr6:27202093	T/A	cg08851530	chr6:28072375	NA	1.05	5.07	0.41	1.42e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg22857025	chr5:266934	NA	0.32	6.12	0.48	1.16e-8	Breast cancer;
TGCT	cis	rs1372520	0.935	rs1442152	chr4:90775649	C/A	cg14346243	chr4:90757452	SNCA	-0.62	-5.26	-0.43	6.17e-7	Neuroticism;
TGCT	cis	rs11122272	0.735	rs2250749	chr1:231485763	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.13	-0.54	7.37e-11	Hemoglobin concentration;
TGCT	cis	rs12780845	0.522	rs7900703	chr10:17237617	T/C	cg01003015	chr10:17271136	VIM	-0.58	-5.45	-0.44	2.63e-7	Homocysteine levels;
TGCT	cis	rs1062177	1.000	rs1062177	chr5:151184701	C/T	cg12924095	chr5:151150029	G3BP1	0.35	4.97	0.41	2.16e-6	Preschool internalizing problems;
TGCT	cis	rs9906944	0.707	rs9899931	chr17:47108282	G/A	cg20966754	chr17:47091339	IGF2BP1	-0.45	-5.17	-0.42	9.27e-7	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs7949030	0.590	rs12225213	chr11:62350248	T/A	cg13298116	chr11:62369859	EML3;MTA2	0.64	9.36	0.64	4.54e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7191700	0.583	rs243314	chr16:11385104	G/C	cg00044050	chr16:11439710	C16orf75	1.0	13.95	0.78	3.58e-27	Multiple sclerosis;
TGCT	cis	rs6912958	0.525	rs242262	chr6:88018057	A/C	cg10393598	chr6:87862264	NA	-0.31	-4.44	-0.37	2e-5	Monocyte percentage of white cells;
TGCT	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-8.64	-0.61	2.39e-14	Platelet count;
TGCT	cis	rs3540	0.597	rs1978150	chr15:91037041	A/G	cg22089800	chr15:90895588	ZNF774	-0.76	-7.8	-0.57	2.15e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs425277	0.917	rs262656	chr1:2088754	A/C	cg24578937	chr1:2090814	PRKCZ	0.32	8.03	0.58	6.43e-13	Height;
TGCT	cis	rs295140	0.706	rs3769483	chr2:201173048	A/G	cg04283868	chr2:201171347	SPATS2L	0.6	5.68	0.45	9.27e-8	QT interval;
TGCT	cis	rs10489525	0.599	rs910622	chr1:115600424	A/G	cg12756093	chr1:115239321	AMPD1	0.4	5.56	0.45	1.57e-7	Autism;
TGCT	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg00684032	chr4:1343700	KIAA1530	0.22	4.73	0.39	5.89e-6	Obesity-related traits;
TGCT	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg04944784	chr2:26401820	FAM59B	0.79	5.54	0.45	1.76e-7	Gut microbiome composition (summer);
TGCT	cis	rs9611565	0.921	rs5751080	chr22:41736267	A/G	cg03806693	chr22:41940476	POLR3H	-0.87	-9.3	-0.64	6.07e-16	Vitiligo;
TGCT	cis	rs11098499	0.863	rs10030660	chr4:120436704	G/A	cg09307838	chr4:120376055	NA	0.69	6.53	0.51	1.49e-9	Corneal astigmatism;
TGCT	cis	rs9467711	1.000	rs6908156	chr6:26322861	C/T	cg02458000	chr6:26745757	NA	-1.05	-5.8	-0.46	5.29e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs151997	0.569	rs10035173	chr5:50276059	C/G	cg06027927	chr5:50259733	NA	0.56	5.5	0.44	2.07e-7	Callous-unemotional behaviour;
TGCT	cis	rs13256369	0.950	rs13248096	chr8:8577476	C/T	cg18904891	chr8:8559673	CLDN23	0.63	5.9	0.47	3.31e-8	Obesity-related traits;
TGCT	cis	rs6977660	0.652	rs10486362	chr7:19755224	A/G	cg07541023	chr7:19748670	TWISTNB	-1.15	-7.28	-0.55	3.33e-11	Thyroid stimulating hormone;
TGCT	cis	rs3087591	1.000	rs12948444	chr17:29443614	A/G	cg24425628	chr17:29625626	OMG;NF1	0.47	7.58	0.56	7.13e-12	Hip circumference;
TGCT	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.68	-5.79	-0.46	5.47e-8	Tonsillectomy;
TGCT	cis	rs669446	0.558	rs609171	chr1:44110216	A/C	cg12908607	chr1:44402522	ARTN	-0.55	-5.9	-0.47	3.25e-8	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs8078723	0.866	rs3935280	chr17:38189055	A/G	cg17467752	chr17:38218738	THRA	-0.62	-6.06	-0.48	1.49e-8	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs25422	0.938	rs62421538	chr6:118729703	A/T	cg07617317	chr6:118971624	C6orf204	0.5	5.39	0.44	3.37e-7	Renal cell carcinoma;
TGCT	cis	rs709400	0.633	rs45441198	chr14:104002611	T/C	cg26031613	chr14:104095156	KLC1	0.86	9.6	0.65	1.19e-16	Body mass index;
TGCT	cis	rs12681288	0.862	rs2701899	chr8:1019581	G/A	cg06709756	chr8:1339049	NA	-0.23	-4.57	-0.38	1.15e-5	Schizophrenia;
TGCT	cis	rs200810	0.694	rs4839913	chr6:98019234	C/G	cg17774634	chr6:97730494	C6orf167;MIR548H3	-0.67	-4.54	-0.38	1.32e-5	Body mass index;
TGCT	cis	rs6912958	1.000	rs2223880	chr6:88167897	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.64	-6.31	-0.49	4.58e-9	Monocyte percentage of white cells;
TGCT	cis	rs7666738	0.830	rs6831219	chr4:98993576	C/A	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7945705	0.935	rs10769971	chr11:8925276	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.46	5.1	0.42	1.24e-6	Hemoglobin concentration;
TGCT	cis	rs9653442	0.805	rs7608424	chr2:100796543	G/T	cg22139774	chr2:100720529	AFF3	-0.43	-7.48	-0.56	1.16e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.36	0.55	2.25e-11	Prudent dietary pattern;
TGCT	cis	rs6671200	0.573	rs3738171	chr1:95699594	A/G	cg03123541	chr1:95699097	RWDD3	-0.83	-7.18	-0.54	5.78e-11	Stearic acid (18:0) levels;
TGCT	cis	rs78545713	1.000	rs114970164	chr6:26241993	G/C	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.72	-4.67	-0.39	7.66e-6	Iron status biomarkers (total iron binding capacity);
TGCT	cis	rs11690462	0.963	rs34436433	chr2:26592534	T/G	cg04726446	chr2:26624865	C2orf39	0.42	4.59	0.38	1.06e-5	Coronary artery disease;
TGCT	cis	rs9682041	0.740	rs6444929	chr3:170150076	C/T	cg07589077	chr3:170072950	NA	0.32	4.6	0.38	1.02e-5	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.53	4.55	0.38	1.26e-5	Urate levels;
TGCT	cis	rs763121	0.813	rs2179143	chr22:39037984	A/G	cg06022373	chr22:39101656	GTPBP1	0.74	7.32	0.55	2.74e-11	Menopause (age at onset);
TGCT	cis	rs155076	1.000	rs261431	chr13:21865738	A/G	cg07022442	chr13:21864356	NA	-0.29	-4.58	-0.38	1.13e-5	White matter hyperintensity burden;
TGCT	cis	rs3809566	1.000	rs4774471	chr15:63332645	A/T	cg08198488	chr15:63333792	TPM1	0.34	4.95	0.41	2.41e-6	Platelet count;
TGCT	cis	rs694739	0.536	rs11231740	chr11:64046641	C/T	cg23796481	chr11:64053134	BAD;GPR137	-0.55	-5.34	-0.43	4.33e-7	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs2243480	1.000	rs6964530	chr7:65718851	G/C	cg18252515	chr7:66147081	NA	1.18	7.05	0.53	1.11e-10	Diabetic kidney disease;
TGCT	cis	rs4900538	0.963	rs4906205	chr14:102932447	A/G	cg18135206	chr14:102964638	TECPR2	0.22	5.62	0.45	1.22e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs2120019	0.938	rs13056	chr15:75312187	A/G	cg09165964	chr15:75287851	SCAMP5	-1.14	-10.33	-0.68	2.05e-18	Blood trace element (Zn levels);
TGCT	cis	rs1903068	0.657	rs41408948	chr4:55992025	G/A	cg09978860	chr4:56023921	NA	0.54	5.48	0.44	2.26e-7	Endometriosis;
TGCT	cis	rs394563	0.591	rs237026	chr6:149720681	G/A	cg11245181	chr6:149772854	ZC3H12D	-0.28	-4.52	-0.38	1.43e-5	Dupuytren's disease;
TGCT	cis	rs6430585	0.528	rs12476127	chr2:136763242	A/G	cg07169764	chr2:136633963	MCM6	1.27	12.64	0.75	4.76e-24	Corneal structure;
TGCT	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg11764359	chr7:65958608	NA	-0.54	-4.9	-0.4	2.89e-6	Aortic root size;
TGCT	cis	rs4321325	0.733	rs13421996	chr2:127934812	G/T	cg09760422	chr2:128146352	NA	0.44	4.55	0.38	1.26e-5	Protein C levels;
TGCT	cis	rs2980439	0.517	rs17594065	chr8:8105405	T/C	cg08975724	chr8:8085496	FLJ10661	-0.54	-4.84	-0.4	3.84e-6	Neuroticism;
TGCT	cis	rs12681288	0.676	rs1562925	chr8:1010894	A/G	cg04851639	chr8:1020857	NA	-0.27	-4.51	-0.38	1.48e-5	Schizophrenia;
TGCT	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	8.39	0.6	9.13e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs1008375	0.932	rs6844593	chr4:17659039	T/C	cg18681998	chr4:17616180	MED28	0.98	10.79	0.7	1.49e-19	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1008375	1.000	rs2286771	chr4:17643848	G/A	cg18681998	chr4:17616180	MED28	1.01	11.89	0.73	3.17e-22	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6558530	0.932	rs6558531	chr8:1707566	A/G	cg09410841	chr8:1729607	CLN8	0.91	10.27	0.68	2.86e-18	Systolic blood pressure;
TGCT	cis	rs9926296	0.706	rs2159115	chr16:89831819	A/G	cg27121462	chr16:89883253	FANCA	0.56	5.33	0.43	4.54e-7	Vitiligo;
TGCT	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg03517284	chr6:25882590	NA	-0.58	-6.03	-0.48	1.76e-8	Blood metabolite levels;
TGCT	cis	rs9348729	1	rs9348729	chr6:26664268	T/C	cg15659132	chr6:26577336	NA	-0.73	-5.25	-0.43	6.5e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs116095464	0.850	rs10055295	chr5:243749	G/A	cg22857025	chr5:266934	NA	-0.34	-6.72	-0.52	5.96e-10	Breast cancer;
TGCT	cis	rs73099903	0.611	rs7306523	chr12:53393964	A/G	cg24505307	chr12:53448429	TENC1	0.37	4.92	0.4	2.7e-6	Systolic blood pressure;
TGCT	cis	rs7666738	0.800	rs13107147	chr4:99028753	C/T	cg17366294	chr4:99064904	C4orf37	0.72	7.54	0.56	8.52e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28595532	0.920	rs56117870	chr4:119766583	T/C	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg04944784	chr2:26401820	FAM59B	-0.67	-6.09	-0.48	1.32e-8	Gut microbiome composition (summer);
TGCT	cis	rs79349575	0.655	rs62078384	chr17:47044463	C/T	cg07967210	chr17:47022446	SNF8	0.45	6.27	0.49	5.37e-9	Type 2 diabetes;
TGCT	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg12042659	chr19:58951599	ZNF132	0.52	4.66	0.39	7.87e-6	Uric acid clearance;
TGCT	cis	rs7772486	0.754	rs6570708	chr6:145989428	C/T	cg23711669	chr6:146136114	FBXO30	-0.92	-10.52	-0.69	6.88e-19	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg10047753	chr17:41438598	NA	0.97	10.04	0.67	1.04e-17	Menopause (age at onset);
TGCT	cis	rs7772486	0.806	rs7740785	chr6:146171299	C/A	cg23711669	chr6:146136114	FBXO30	0.87	9.51	0.65	1.93e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs950169	0.763	rs35372971	chr15:84941795	G/A	cg12863693	chr15:85201151	NMB	0.45	4.96	0.41	2.28e-6	Schizophrenia;
TGCT	cis	rs2013441	0.965	rs2703808	chr17:20109665	A/C	cg18979559	chr17:20280153	CCDC144C	-0.44	-4.61	-0.38	9.78e-6	Obesity-related traits;
TGCT	cis	rs236907	0.859	rs56365362	chr1:171752193	G/A	cg20598894	chr1:171756153	METTL13	-0.19	-4.47	-0.37	1.72e-5	Mean platelet volume;
TGCT	cis	rs3806843	0.933	rs2337987	chr5:140188383	T/G	cg19875535	chr5:140030758	IK	0.35	5.85	0.47	4.01e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs10876993	0.890	rs12302351	chr12:58062590	T/C	cg15848620	chr12:58087721	OS9	-0.71	-5.63	-0.45	1.13e-7	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs3845702	0.736	rs72962517	chr2:180861452	G/A	cg01881094	chr2:180872142	CWC22	1.06	6.66	0.51	8.12e-10	Schizophrenia;
TGCT	cis	rs3796352	0.892	rs9756317	chr3:53088815	T/C	cg27565382	chr3:53032988	SFMBT1	-0.42	-4.79	-0.4	4.61e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs682748	0.846	rs12186747	chr5:17155432	G/A	cg23987134	chr5:17158319	LOC285696	-0.23	-5.48	-0.44	2.22e-7	Hippocampal atrophy;
TGCT	cis	rs3806843	0.900	rs2261651	chr5:140136804	A/C	cg19875535	chr5:140030758	IK	-0.36	-6.17	-0.48	9.04e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg05368731	chr17:41323189	NBR1	1.21	14.53	0.79	1.5e-28	Menopause (age at onset);
TGCT	cis	rs12615966	0.932	rs72830462	chr2:105394600	C/T	cg16465502	chr2:105461796	NA	0.8	5.14	0.42	1.06e-6	Pancreatic cancer;
TGCT	cis	rs1059312	0.522	rs3825181	chr12:129279264	G/A	cg09035930	chr12:129282057	SLC15A4	-0.49	-6.99	-0.53	1.54e-10	Systemic lupus erythematosus;
TGCT	cis	rs858239	0.899	rs7794684	chr7:23310805	A/G	cg05602783	chr7:23145260	KLHL7	-0.66	-5.26	-0.43	6.04e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg24531977	chr5:56204891	C5orf35	-0.75	-7.31	-0.55	2.87e-11	Initial pursuit acceleration;
TGCT	cis	rs806215	0.547	rs59140894	chr7:127430797	C/T	cg11539674	chr7:127291444	SND1	-0.36	-4.6	-0.38	1.02e-5	Type 2 diabetes;
TGCT	cis	rs10883723	0.810	rs913025	chr10:104276043	C/T	cg05855489	chr10:104503620	C10orf26	-0.58	-5.06	-0.41	1.47e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs9646954	0.560	rs4149507	chr2:101032745	C/T	cg08017756	chr2:100939284	LONRF2	-0.29	-4.58	-0.38	1.11e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs4631830	0.720	rs898343	chr10:51505403	A/G	cg10326726	chr10:51549505	MSMB	0.23	4.53	0.38	1.35e-5	Prostate-specific antigen levels;
TGCT	cis	rs6671200	0.573	rs6666528	chr1:95697490	C/A	cg26537280	chr1:95699037	RWDD3	-0.51	-4.9	-0.4	2.94e-6	Stearic acid (18:0) levels;
TGCT	cis	rs17253792	0.822	rs76918910	chr14:56058762	T/C	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs17433780	0.836	rs61798917	chr1:89506093	G/A	cg09516651	chr1:89888402	LOC400759	0.25	4.99	0.41	2.01e-6	Carotid intima media thickness;
TGCT	cis	rs7267979	0.549	rs6138536	chr20:25182648	A/G	cg16686733	chr20:25566563	NINL	0.53	5.39	0.44	3.48e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6882046	0.513	rs42850	chr5:88019474	G/A	cg24804195	chr5:87968844	LOC645323	-0.57	-5.57	-0.45	1.5e-7	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs2710642	0.927	rs6705798	chr2:63259881	C/T	cg17519650	chr2:63277830	OTX1	0.66	5.73	0.46	7.17e-8	LDL cholesterol levels;LDL cholesterol;
TGCT	cis	rs1505368	0.817	rs6435701	chr2:213283512	A/G	cg16329650	chr2:213403929	ERBB4	0.66	6.59	0.51	1.11e-9	Symmetrical dimethylarginine levels;
TGCT	cis	rs739401	0.572	rs410820	chr11:3080102	G/A	cg25174290	chr11:3078921	CARS	0.54	5.22	0.42	7.36e-7	Longevity;
TGCT	cis	rs7714584	1.000	rs2344180	chr5:150267357	T/A	cg22134413	chr5:150180641	NA	0.78	6.12	0.48	1.16e-8	Crohn's disease;
TGCT	cis	rs9928842	0.765	rs2870467	chr16:75223881	A/G	cg09066997	chr16:75300724	BCAR1	0.26	4.61	0.38	9.91e-6	Alcoholic chronic pancreatitis;
TGCT	cis	rs35306767	0.623	rs34034003	chr10:1143435	G/A	cg26597838	chr10:835615	NA	0.47	4.95	0.41	2.37e-6	Eosinophil percentage of granulocytes;
TGCT	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg11494091	chr17:61959527	GH2	0.43	7.52	0.56	9.81e-12	Height;
TGCT	cis	rs2760061	0.819	rs964941	chr1:228193857	G/A	cg02753203	chr1:228287806	NA	0.3	5.71	0.46	7.95e-8	Diastolic blood pressure;
TGCT	cis	rs7647973	0.696	rs3087866	chr3:49054692	A/G	cg07636037	chr3:49044803	WDR6	0.8	6.66	0.51	8.03e-10	Menarche (age at onset);
TGCT	cis	rs3091242	0.933	rs34006994	chr1:25780668	C/T	cg09222892	chr1:25734099	RHCE	0.42	7.15	0.54	6.72e-11	Erythrocyte sedimentation rate;
TGCT	cis	rs877282	0.898	rs12357016	chr10:765675	C/T	cg17470449	chr10:769945	NA	0.37	5.59	0.45	1.37e-7	Uric acid levels;
TGCT	cis	rs7017914	0.905	rs2732106	chr8:71923839	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.56	-5.11	-0.42	1.2e-6	Bone mineral density;
TGCT	cis	rs6424115	0.594	rs10799802	chr1:24009544	C/T	cg15997130	chr1:24165203	NA	0.55	5.08	0.42	1.34e-6	Immature fraction of reticulocytes;
TGCT	cis	rs9948	0.655	rs3731940	chr2:97377883	A/G	cg01990225	chr2:97406019	LMAN2L	1.01	5.13	0.42	1.08e-6	Erectile dysfunction and prostate cancer treatment;
TGCT	trans	rs7726839	0.561	rs11955068	chr5:582324	C/T	cg25482853	chr8:67687455	SGK3	1.07	8.9	0.62	5.55e-15	Obesity-related traits;
TGCT	cis	rs61160187	0.582	rs17332824	chr5:60166187	C/G	cg02684056	chr5:59996105	DEPDC1B	-0.47	-4.44	-0.37	1.99e-5	Educational attainment (years of education);Educational attainment (college completion);
TGCT	cis	rs2832191	0.791	rs2832196	chr21:30497412	G/A	cg24692254	chr21:30365293	RNF160	-0.86	-9.11	-0.63	1.83e-15	Dental caries;
TGCT	cis	rs7819412	0.807	rs10105315	chr8:10932203	G/C	cg21775007	chr8:11205619	TDH	-0.51	-4.78	-0.39	4.86e-6	Triglycerides;
TGCT	cis	rs9549260	0.564	rs4943812	chr13:41335816	T/C	cg21288729	chr13:41239152	FOXO1	0.95	9.2	0.64	1.08e-15	Red blood cell count;
TGCT	cis	rs1062177	0.826	rs2915873	chr5:151156658	G/A	cg00977110	chr5:151150581	G3BP1	0.4	4.62	0.38	9.49e-6	Preschool internalizing problems;
TGCT	cis	rs2836974	0.583	rs8132993	chr21:40716410	T/C	cg17971929	chr21:40555470	PSMG1	0.62	5.52	0.44	1.92e-7	Cognitive function;
TGCT	cis	rs7927592	0.513	rs531163	chr11:68194496	A/G	cg16797656	chr11:68205561	LRP5	0.28	5.07	0.41	1.44e-6	Total body bone mineral density;
TGCT	cis	rs854765	0.547	rs2955383	chr17:17941364	A/G	cg09796270	chr17:17721594	SREBF1	0.26	5.15	0.42	9.93e-7	Total body bone mineral density;
TGCT	cis	rs17826219	0.636	rs79565452	chr17:29142841	T/C	cg13385521	chr17:29058706	SUZ12P	0.79	4.8	0.4	4.47e-6	Body mass index;
TGCT	cis	rs950027	0.620	rs2486274	chr15:45666228	G/T	cg14582100	chr15:45693742	SPATA5L1	0.48	6.07	0.48	1.44e-8	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs7666738	0.830	rs3911282	chr4:99037602	T/A	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7727544	0.901	rs55633655	chr5:131598756	T/G	cg24060327	chr5:131705240	SLC22A5	-0.6	-6.4	-0.5	2.92e-9	Blood metabolite levels;
TGCT	cis	rs11190604	1.000	rs11190599	chr10:102295420	C/T	cg23241863	chr10:102295624	HIF1AN	0.67	5.12	0.42	1.12e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2933343	0.729	rs1680781	chr3:128612830	C/A	cg11901034	chr3:128598214	ACAD9	-0.67	-6.55	-0.51	1.35e-9	IgG glycosylation;
TGCT	cis	rs10114408	0.959	rs10739963	chr9:96650907	G/A	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs3008870	0.583	rs3008861	chr1:67396222	T/G	cg08660285	chr1:67390436	MIER1;WDR78	0.98	8.3	0.6	1.46e-13	Lymphocyte percentage of white cells;
TGCT	cis	rs644799	0.965	rs1944080	chr11:95503636	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	10.82	0.7	1.31e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9611565	0.649	rs5758434	chr22:42116163	G/A	cg13695892	chr22:41940480	POLR3H	0.83	8.18	0.59	2.79e-13	Vitiligo;
TGCT	cis	rs9527	0.590	rs10883834	chr10:104881402	T/C	cg15744005	chr10:104629667	AS3MT	-0.43	-4.9	-0.4	2.89e-6	Arsenic metabolism;
TGCT	cis	rs9527	0.590	rs3861984	chr10:104916980	T/C	cg04362960	chr10:104952993	NT5C2	0.67	5.64	0.45	1.09e-7	Arsenic metabolism;
TGCT	cis	rs12291225	0.545	rs11023187	chr11:14345559	T/G	cg19336497	chr11:14380999	RRAS2	-0.45	-7.25	-0.55	3.87e-11	Sense of smell;
TGCT	cis	rs6988636	1.000	rs58189203	chr8:124184739	G/T	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs1555895	0.566	rs1057304	chr10:853106	T/C	cg02193355	chr10:851439	NA	0.24	5.33	0.43	4.45e-7	Survival in rectal cancer;
TGCT	trans	rs10504390	0.656	rs74675840	chr8:66485845	G/A	cg26037026	chr7:1641922	NA	-0.64	-6.84	-0.52	3.26e-10	IgG glycosylation;
TGCT	cis	rs752092	1.000	rs11636578	chr15:101787969	T/C	cg19997662	chr15:101784653	CHSY1	-0.3	-5.72	-0.46	7.64e-8	Corneal structure;
TGCT	trans	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg27523141	chr10:43048294	ZNF37B	0.73	8.58	0.61	3.32e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs5167	0.566	rs2075620	chr19:45480037	C/T	cg13119609	chr19:45449297	APOC2	-0.23	-4.65	-0.39	8.26e-6	Blood protein levels;
TGCT	cis	rs2730260	0.500	rs73169244	chr7:158887293	T/C	cg02078164	chr7:157982224	PTPRN2	0.41	4.58	0.38	1.11e-5	Myopia (pathological);
TGCT	cis	rs4803468	0.967	rs3213860	chr19:41920211	T/C	cg09537434	chr19:41945824	ATP5SL	-0.9	-10.59	-0.69	4.65e-19	Height;
TGCT	cis	rs709400	0.550	rs11626905	chr14:104016066	C/T	cg12935359	chr14:103987150	CKB	-0.46	-6.02	-0.48	1.87e-8	Body mass index;
TGCT	cis	rs7829975	0.871	rs777709	chr8:8583872	T/C	cg06636001	chr8:8085503	FLJ10661	-0.59	-4.91	-0.4	2.78e-6	Mood instability;
TGCT	cis	rs903263	0.901	rs12750691	chr1:84595520	C/T	cg09664975	chr1:84543551	PRKACB	0.5	4.75	0.39	5.62e-6	Breast cancer (male);
TGCT	cis	rs9487051	0.714	rs6930733	chr6:109631587	T/C	cg01475377	chr6:109611718	NA	-0.31	-4.73	-0.39	6.12e-6	Reticulocyte fraction of red cells;
TGCT	cis	rs826838	0.933	rs980573	chr12:39127811	T/C	cg26384229	chr12:38710491	ALG10B	-0.86	-7.7	-0.57	3.65e-12	Heart rate;
TGCT	cis	rs12134245	1.000	rs12134245	chr1:92021464	C/T	cg25838465	chr1:92012736	NA	-0.41	-6.63	-0.51	9.27e-10	Breast cancer;
TGCT	cis	rs6703348	0.560	rs863018	chr1:159215326	C/T	cg07961479	chr1:159825173	VSIG8;C1orf204	0.25	4.85	0.4	3.61e-6	Monocyte chemoattractant protein-1 levels;
TGCT	cis	rs62103177	0.714	rs7227962	chr18:77603283	T/G	cg12964065	chr18:77638022	KCNG2	0.33	4.63	0.38	9.06e-6	Opioid sensitivity;
TGCT	cis	rs10782582	0.593	rs74090712	chr1:76189098	A/G	cg22875332	chr1:76189707	ACADM	-0.51	-5.75	-0.46	6.54e-8	Daytime sleep phenotypes;
TGCT	cis	rs9814567	0.762	rs13093893	chr3:134292131	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.8	6.08	0.48	1.38e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg22963979	chr7:1858916	MAD1L1	-0.32	-4.78	-0.39	4.9e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs7523273	0.526	rs2724375	chr1:207997973	C/A	cg22525895	chr1:207977042	MIR29B2	-0.53	-9.19	-0.64	1.14e-15	Schizophrenia;
TGCT	cis	rs3733585	0.579	rs4235353	chr4:10122934	C/T	cg00071950	chr4:10020882	SLC2A9	-0.51	-5.29	-0.43	5.33e-7	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs1971762	0.563	rs11170645	chr12:54079080	G/T	cg16917193	chr12:54089295	NA	1.37	17.65	0.85	1.25e-35	Height;
TGCT	cis	rs4727027	0.704	rs1123992	chr7:148907201	C/G	cg23583168	chr7:148888333	NA	-0.78	-9.9	-0.66	2.24e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs11098499	0.863	rs13140391	chr4:120503437	A/G	cg09307838	chr4:120376055	NA	0.69	6.53	0.51	1.49e-9	Corneal astigmatism;
TGCT	cis	rs7937682	0.889	rs11213971	chr11:111529829	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.1	-11.66	-0.72	1.13e-21	Primary sclerosing cholangitis;
TGCT	cis	rs12950390	0.853	rs4793647	chr17:45854090	G/C	cg06532163	chr17:45867833	NA	0.37	5.87	0.47	3.74e-8	IgG glycosylation;
TGCT	cis	rs17030434	0.784	rs8180349	chr4:154657038	T/C	cg14289246	chr4:154710475	SFRP2	-0.85	-7.21	-0.54	4.87e-11	Electrocardiographic conduction measures;
TGCT	cis	rs11785400	0.793	rs35985277	chr8:143736137	C/T	cg10596483	chr8:143751796	JRK	0.53	5.27	0.43	5.89e-7	Schizophrenia;
TGCT	cis	rs4478858	0.735	rs6687819	chr1:31801112	G/A	cg00250761	chr1:31883323	NA	-0.28	-4.96	-0.41	2.32e-6	Alcohol dependence;
TGCT	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg27588902	chr6:42928151	GNMT	-0.56	-6.86	-0.52	2.94e-10	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs1971762	0.583	rs10876485	chr12:54087648	C/T	cg16917193	chr12:54089295	NA	-1.27	-17.05	-0.84	2.6e-34	Height;
TGCT	cis	rs7085104	0.632	rs6162	chr10:104596981	G/A	cg15744005	chr10:104629667	AS3MT	-0.43	-5.37	-0.43	3.77e-7	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs9611565	0.559	rs5758397	chr22:42019251	C/T	cg03806693	chr22:41940476	POLR3H	1.06	11.19	0.71	1.58e-20	Vitiligo;
TGCT	cis	rs904251	0.797	rs1776460	chr6:37485484	A/G	cg25019722	chr6:37503610	NA	-0.48	-6.63	-0.51	9.26e-10	Cognitive performance;
TGCT	cis	rs11030122	0.645	rs11493482	chr11:4034772	A/G	cg18678763	chr11:4115507	RRM1	-0.49	-6.13	-0.48	1.08e-8	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs67180937	0.553	rs3008629	chr1:222835930	T/C	cg09820183	chr1:222886073	C1orf58;AIDA	0.73	4.47	0.37	1.77e-5	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
TGCT	cis	rs36051895	0.632	rs10217652	chr9:5119939	A/G	cg02405213	chr9:5042618	JAK2	-0.74	-10.47	-0.68	9.14e-19	Pediatric autoimmune diseases;
TGCT	cis	rs7607369	0.596	rs10165754	chr2:219287370	A/G	cg02176678	chr2:219576539	TTLL4	-0.5	-6.37	-0.5	3.41e-9	Red blood cell count;Amyotrophic lateral sclerosis;
TGCT	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.93	7.44	0.56	1.44e-11	Platelet count;
TGCT	cis	rs9911578	0.900	rs4793593	chr17:56892699	C/G	cg12560992	chr17:57184187	TRIM37	-0.76	-9.34	-0.64	4.88e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs3540	0.960	rs11857092	chr15:90960115	T/C	cg22089800	chr15:90895588	ZNF774	0.73	6.81	0.52	3.77e-10	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs514475	0.526	rs12194668	chr6:137956734	C/T	cg02673417	chr6:137105249	MAP3K5	0.29	4.45	0.37	1.88e-5	Inflammatory skin disease;
TGCT	cis	rs4803468	1.000	rs11670668	chr19:41920454	G/C	cg09537434	chr19:41945824	ATP5SL	-0.9	-10.59	-0.69	4.65e-19	Height;
TGCT	cis	rs7666738	0.830	rs1813251	chr4:98921170	A/G	cg05340658	chr4:99064831	C4orf37	0.53	6.11	0.48	1.17e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8032315	0.965	rs12906125	chr15:91427612	G/A	cg03209642	chr15:91427605	FES	0.52	4.92	0.4	2.67e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2721195	0.967	rs1985022	chr8:145684031	C/T	cg11211951	chr8:145729740	GPT	0.23	5.38	0.43	3.64e-7	Age at first birth;
TGCT	cis	rs2439831	0.681	rs11858152	chr15:43634196	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	6.89	0.53	2.52e-10	Lung cancer in ever smokers;
TGCT	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg21016266	chr12:122356598	WDR66	0.47	5.97	0.47	2.36e-8	Mean platelet volume;
TGCT	cis	rs4711350	0.765	rs2395446	chr6:33743264	C/T	cg13859433	chr6:33739653	LEMD2	-0.34	-5.22	-0.42	7.46e-7	Schizophrenia;
TGCT	cis	rs739496	0.947	rs587914	chr12:111943004	T/C	cg10833066	chr12:111807467	FAM109A	0.37	5.59	0.45	1.4e-7	Platelet count;
TGCT	cis	rs2073300	1.000	rs6132625	chr20:23444671	C/T	cg09953122	chr20:23471693	CST8	-0.64	-4.56	-0.38	1.19e-5	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs7640424	0.826	rs7635063	chr3:107818777	C/T	cg09227934	chr3:107805635	CD47	-0.23	-4.45	-0.37	1.87e-5	Body mass index;
TGCT	cis	rs2228479	0.850	rs2239358	chr16:89827330	C/G	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs9952991	0.566	rs579052	chr18:12858610	T/C	cg23544223	chr18:12777786	NA	0.55	4.88	0.4	3.22e-6	Inflammatory skin disease;
TGCT	cis	rs301043	0.500	rs301010	chr12:95870154	A/G	cg07805603	chr12:95869602	METAP2	0.41	5.19	0.42	8.35e-7	Immature fraction of reticulocytes;
TGCT	cis	rs9467773	0.620	rs9467810	chr6:26608261	A/C	cg15659132	chr6:26577336	NA	0.86	10.87	0.7	9.57e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs709400	0.770	rs7142883	chr14:104066645	G/A	cg26031613	chr14:104095156	KLC1	1.15	16.05	0.82	4.72e-32	Body mass index;
TGCT	cis	rs17221829	0.733	rs1873083	chr11:89396810	G/A	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.57	-0.38	1.18e-5	Anxiety in major depressive disorder;
TGCT	cis	rs2535633	0.631	rs2581827	chr3:52966558	C/T	cg11645453	chr3:52864694	ITIH4	-0.29	-5.21	-0.42	7.57e-7	Body mass index;
TGCT	cis	rs7264396	0.790	rs6060541	chr20:34248066	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.25	-0.43	6.33e-7	Total cholesterol levels;
TGCT	cis	rs3820928	1.000	rs10204368	chr2:227774244	G/C	cg11843606	chr2:227700838	RHBDD1	-0.54	-4.82	-0.4	4.12e-6	Pulmonary function;
TGCT	cis	rs12497850	0.931	rs11924597	chr3:48937790	T/C	cg07636037	chr3:49044803	WDR6	0.94	10.39	0.68	1.46e-18	Parkinson's disease;
TGCT	cis	rs7772486	0.754	rs702306	chr6:145991029	T/C	cg13319975	chr6:146136371	FBXO30	0.55	4.99	0.41	2.03e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs950027	0.549	rs1719250	chr15:45609773	A/G	cg14582100	chr15:45693742	SPATA5L1	0.45	5.55	0.45	1.68e-7	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs11030122	0.702	rs1013351	chr11:3952303	A/T	cg18678763	chr11:4115507	RRM1	-0.49	-6.14	-0.48	1.01e-8	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs9549367	0.713	rs1323315	chr13:113859658	T/C	cg18105134	chr13:113819100	PROZ	0.46	8.76	0.62	1.2e-14	Platelet distribution width;
TGCT	cis	rs6940638	0.513	rs4424065	chr6:27036456	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.42	-4.62	-0.38	9.3e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs11098499	0.954	rs10005644	chr4:120298477	T/C	cg09307838	chr4:120376055	NA	0.65	6.39	0.5	3.02e-9	Corneal astigmatism;
TGCT	cis	rs9443645	0.901	rs9448580	chr6:79551812	C/G	cg05283184	chr6:79620031	NA	-0.2	-4.67	-0.39	7.71e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs644799	0.509	rs580181	chr11:95643040	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.49	4.97	0.41	2.17e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg05368731	chr17:41323189	NBR1	1.2	14.48	0.79	1.98e-28	Menopause (age at onset);
TGCT	cis	rs9430161	0.579	rs7542354	chr1:11040385	G/A	cg02454025	chr1:11042201	C1orf127	0.97	12.71	0.75	3.27e-24	Ewing sarcoma;
TGCT	cis	rs11249608	0.548	rs6880315	chr5:178452502	G/A	cg01312482	chr5:178451176	ZNF879	-0.56	-5.5	-0.44	2.09e-7	Pubertal anthropometrics;
TGCT	cis	rs10751667	0.643	rs10902238	chr11:944810	G/A	cg06064525	chr11:970664	AP2A2	-0.35	-8.09	-0.59	4.54e-13	Alzheimer's disease (late onset);
TGCT	cis	rs2742417	0.603	rs2064063	chr3:45759924	T/A	cg04837898	chr3:45731254	SACM1L	-0.66	-7.02	-0.53	1.27e-10	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs6582630	0.502	rs11181475	chr12:38348922	G/A	cg26384229	chr12:38710491	ALG10B	0.78	6.94	0.53	1.91e-10	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs832540	0.552	rs252924	chr5:56205643	A/G	cg24531977	chr5:56204891	C5orf35	-0.6	-5.74	-0.46	6.92e-8	Coronary artery disease;
TGCT	cis	rs13191362	0.507	rs6936804	chr6:163069424	A/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.59	-5.37	-0.43	3.66e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs12579753	0.879	rs11115008	chr12:82164859	C/T	cg07988820	chr12:82153109	PPFIA2	-0.69	-7.56	-0.56	7.78e-12	Resting heart rate;
TGCT	cis	rs453301	0.686	rs3989373	chr8:8911308	G/T	cg06636001	chr8:8085503	FLJ10661	-0.7	-5.94	-0.47	2.74e-8	Joint mobility (Beighton score);
TGCT	cis	rs9611565	0.879	rs5758311	chr22:41759375	G/T	cg13695892	chr22:41940480	POLR3H	-0.85	-8.45	-0.6	6.59e-14	Vitiligo;
TGCT	cis	rs7772486	0.806	rs4075695	chr6:146250959	A/G	cg05347473	chr6:146136440	FBXO30	-0.52	-5.16	-0.42	9.33e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6674176	0.597	rs3762422	chr1:44400532	T/A	cg12908607	chr1:44402522	ARTN	-0.74	-9.33	-0.64	5.3e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs2204008	0.571	rs8175738	chr12:38311234	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-4.7	-0.39	6.68e-6	Bladder cancer;
TGCT	cis	rs11098499	0.708	rs1546506	chr4:120241240	T/C	cg09307838	chr4:120376055	NA	0.61	5.89	0.47	3.33e-8	Corneal astigmatism;
TGCT	cis	rs66573146	1.000	rs7686186	chr4:6986094	C/T	cg05069807	chr4:6945702	TBC1D14	0.35	4.94	0.41	2.51e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs4635969	1.000	rs4635969	chr5:1308552	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.25	-4.78	-0.39	4.9e-6	Testicular germ cell tumor;Testicular germ cell cancer;
TGCT	cis	rs72781680	0.716	rs6731314	chr2:24048338	C/T	cg08917208	chr2:24149416	ATAD2B	-0.78	-4.85	-0.4	3.62e-6	Lymphocyte counts;
TGCT	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg00484396	chr16:3507460	NAT15	0.43	6.62	0.51	9.89e-10	Tuberculosis;
TGCT	trans	rs7824557	0.689	rs10481454	chr8:11109303	C/G	cg06636001	chr8:8085503	FLJ10661	-0.83	-6.89	-0.53	2.46e-10	Retinal vascular caliber;
TGCT	cis	rs2282802	0.660	rs7726176	chr5:139547971	T/A	cg01081189	chr5:139537190	NA	-0.3	-5.37	-0.43	3.82e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg16325326	chr1:53192061	ZYG11B	-0.58	-6.4	-0.5	2.86e-9	Monocyte count;
TGCT	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg18230493	chr5:56204884	C5orf35	-0.68	-5.92	-0.47	2.92e-8	Initial pursuit acceleration;
TGCT	cis	rs9926296	0.656	rs2376882	chr16:89827002	T/C	cg26513180	chr16:89883248	FANCA	0.69	6.79	0.52	4.23e-10	Vitiligo;
TGCT	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg13866156	chr1:1669148	SLC35E2	-0.22	-5.16	-0.42	9.35e-7	Body mass index;
TGCT	cis	rs2361718	0.967	rs2361719	chr17:78103403	A/G	cg09238746	chr17:78121135	EIF4A3	0.51	4.58	0.38	1.12e-5	Yeast infection;
TGCT	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.59	-5.45	-0.44	2.58e-7	Height;
TGCT	cis	rs9326248	0.520	rs236919	chr11:117095361	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.58	5.35	0.43	4.05e-7	Blood protein levels;
TGCT	cis	rs7552404	0.731	rs2029683	chr1:76341643	T/G	cg03433033	chr1:76189801	ACADM	-0.76	-7.76	-0.57	2.66e-12	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7666738	0.962	rs2865986	chr4:99067907	A/G	cg18180107	chr4:99064573	C4orf37	0.56	4.54	0.38	1.33e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3790515	1.000	rs3790515	chr1:151786372	A/G	cg07092448	chr1:151763213	TDRKH	1.0	4.5	0.37	1.54e-5	Depressive symptoms (SSRI exposure interaction);
TGCT	cis	rs6062496	0.609	rs67311561	chr20:62304762	A/G	cg27236539	chr20:62289627	RTEL1	0.69	6.5	0.5	1.73e-9	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.62	4.95	0.41	2.34e-6	Lung function (FEV1/FVC);
TGCT	cis	rs7772486	0.686	rs9399564	chr6:146078907	C/T	cg23711669	chr6:146136114	FBXO30	-0.9	-10.29	-0.68	2.52e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs17401966	0.838	rs17034643	chr1:10332102	A/G	cg19773385	chr1:10388646	KIF1B	0.21	4.55	0.38	1.25e-5	Hepatocellular carcinoma;
TGCT	cis	rs7829975	0.573	rs7842359	chr8:8797078	T/G	cg15556689	chr8:8085844	FLJ10661	-0.69	-6.14	-0.48	1.01e-8	Mood instability;
TGCT	cis	rs4242434	0.927	rs746011	chr8:22457804	C/T	cg03733263	chr8:22462867	KIAA1967	1.16	19.41	0.87	2.12e-39	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs6028335	0.502	rs7265661	chr20:37586842	G/T	cg27552599	chr20:37590471	DHX35	0.37	4.47	0.37	1.72e-5	Alcohol and nicotine co-dependence;
TGCT	cis	rs4631830	0.900	rs10763534	chr10:51534920	C/T	cg10326726	chr10:51549505	MSMB	-0.27	-5.46	-0.44	2.54e-7	Prostate-specific antigen levels;
TGCT	cis	rs4319547	1.000	rs7309390	chr12:123110422	A/G	cg23029597	chr12:123009494	RSRC2	-0.3	-4.82	-0.4	4.14e-6	Body mass index;
TGCT	cis	rs6840360	0.593	rs10222925	chr4:152690215	A/G	cg22705602	chr4:152727874	NA	-0.35	-5.94	-0.47	2.62e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs8031584	0.678	rs36047941	chr15:31159235	A/G	cg14829155	chr15:31115871	NA	-0.36	-4.72	-0.39	6.14e-6	Huntington's disease progression;
TGCT	cis	rs12142240	0.698	rs66516678	chr1:46810112	G/T	cg14993813	chr1:46806288	NSUN4	-0.58	-4.81	-0.4	4.34e-6	Menopause (age at onset);
TGCT	cis	rs7611238	0.560	rs9859902	chr3:195065255	T/C	cg27323046	chr3:195102265	ACAP2	0.35	4.75	0.39	5.5e-6	Body mass index;
TGCT	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	4.55	0.38	1.26e-5	Height;
TGCT	cis	rs62244186	0.659	rs9855433	chr3:44468065	C/A	cg15687855	chr3:44754131	ZNF502	-0.44	-5.27	-0.43	5.84e-7	Depressive symptoms;
TGCT	trans	rs1814175	0.765	rs1721990	chr11:49912154	G/C	cg15704280	chr7:45808275	SEPT13	-0.71	-8.0	-0.58	7.36e-13	Height;
TGCT	cis	rs8017423	0.765	rs8017170	chr14:90721849	T/A	cg04374321	chr14:90722782	PSMC1	0.76	7.71	0.57	3.59e-12	Mortality in heart failure;
TGCT	cis	rs10946940	0.864	rs13201411	chr6:27498217	G/C	cg10876282	chr6:28092338	ZSCAN16	-0.46	-4.6	-0.38	1.04e-5	Systemic lupus erythematosus;
TGCT	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg24675658	chr1:53192096	ZYG11B	0.89	11.87	0.73	3.58e-22	Monocyte count;
TGCT	cis	rs6582630	0.519	rs11181294	chr12:38312787	C/T	cg26384229	chr12:38710491	ALG10B	0.82	7.18	0.54	5.6e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs9300255	0.602	rs2695476	chr12:123694206	T/C	cg00376283	chr12:123451042	ABCB9	0.73	5.1	0.42	1.26e-6	Neutrophil percentage of white cells;
TGCT	cis	rs10984561	0.881	rs7019298	chr9:122251256	A/G	cg14242995	chr9:122249943	NA	0.73	5.96	0.47	2.46e-8	Pulmonary function decline;
TGCT	cis	rs4563143	0.514	rs55727361	chr19:29300415	A/T	cg14983838	chr19:29218262	NA	0.71	5.19	0.42	8.21e-7	Methadone dose in opioid dependence;
TGCT	cis	rs12950390	0.530	rs16947058	chr17:45825186	A/G	cg06532163	chr17:45867833	NA	-0.27	-4.65	-0.39	8.33e-6	IgG glycosylation;
TGCT	cis	rs1568889	0.667	rs7123947	chr11:28399908	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	5.57	0.45	1.5e-7	Bipolar disorder;
TGCT	cis	rs10193935	0.681	rs13396880	chr2:42374700	G/T	cg27598129	chr2:42591480	NA	-0.39	-4.88	-0.4	3.21e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2439831	0.850	rs7179388	chr15:44123945	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	6.01	0.48	1.9e-8	Lung cancer in ever smokers;
TGCT	trans	rs1814175	0.558	rs5025146	chr11:49795724	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.45	-11.32	-0.71	7.95e-21	Height;
TGCT	cis	rs2153535	0.580	rs3938660	chr6:8443335	G/A	cg07606381	chr6:8435919	SLC35B3	0.57	5.25	0.43	6.46e-7	Motion sickness;
TGCT	trans	rs17685	0.725	rs6947068	chr7:75662056	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.5	-8.42	-0.6	7.75e-14	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs7772486	0.790	rs9390365	chr6:146235626	A/G	cg05347473	chr6:146136440	FBXO30	-0.52	-5.03	-0.41	1.67e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9911578	0.835	rs1476596	chr17:56485358	C/T	cg12560992	chr17:57184187	TRIM37	0.78	9.1	0.63	1.88e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg03188948	chr7:1209495	NA	0.59	4.82	0.4	4.06e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg11764359	chr7:65958608	NA	-0.55	-5.08	-0.42	1.34e-6	Aortic root size;
TGCT	cis	rs4710191	0.510	rs2180713	chr6:167615010	G/A	cg07560741	chr6:167734054	NA	0.28	5.66	0.45	1.01e-7	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs34891900	0.507	rs2535679	chr22:18202850	A/G	cg19898043	chr22:18121309	BCL2L13	0.55	4.74	0.39	5.77e-6	Sum neutrophil eosinophil counts;
TGCT	trans	rs2688608	0.592	rs10762563	chr10:75524802	C/A	cg13918328	chr10:52500089	ASAH2B	0.68	6.83	0.52	3.38e-10	Inflammatory bowel disease;
TGCT	cis	rs8180040	0.620	rs11917361	chr3:47070497	G/T	cg27129171	chr3:47204927	SETD2	-0.73	-9.16	-0.64	1.38e-15	Colorectal cancer;
TGCT	cis	rs1843834	0.721	rs6715655	chr2:225582284	C/T	cg22455342	chr2:225449267	CUL3	-0.59	-5.54	-0.45	1.77e-7	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg07138768	chr7:917805	C7orf20	0.37	4.5	0.37	1.56e-5	Perceived unattractiveness to mosquitoes;
TGCT	cis	rs6570726	0.791	rs10872577	chr6:145900560	G/T	cg13319975	chr6:146136371	FBXO30	-0.5	-4.51	-0.38	1.48e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4654899	0.965	rs4654898	chr1:21376383	T/C	cg01072550	chr1:21505969	NA	-0.51	-8.27	-0.6	1.76e-13	Superior frontal gyrus grey matter volume;
TGCT	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg21017887	chr14:105400489	NA	0.39	5.52	0.44	1.93e-7	Rheumatoid arthritis;
TGCT	trans	rs3780486	0.522	rs10217770	chr9:33146393	C/A	cg20290983	chr6:43655470	MRPS18A	0.76	8.2	0.59	2.63e-13	IgG glycosylation;
TGCT	cis	rs12477438	0.765	rs7607578	chr2:99669771	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-4.62	-0.38	9.47e-6	Chronic sinus infection;
TGCT	cis	rs12579753	0.797	rs1922561	chr12:82152640	C/A	cg21231944	chr12:82153410	PPFIA2	-0.35	-4.61	-0.38	9.96e-6	Resting heart rate;
TGCT	cis	rs7666738	0.830	rs6819177	chr4:99040907	T/C	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28595532	1.000	rs28595532	chr4:119716950	A/C	cg14228332	chr4:119757509	SEC24D	0.94	5.55	0.45	1.67e-7	Cannabis dependence symptom count;
TGCT	cis	rs7172809	0.599	rs17471480	chr15:77755550	A/G	cg22256960	chr15:77711686	NA	0.52	5.0	0.41	1.93e-6	Glucose homeostasis traits;
TGCT	cis	rs3015497	0.789	rs3015496	chr14:51114051	T/C	cg04730355	chr14:51134070	SAV1	-0.68	-6.57	-0.51	1.26e-9	Mean platelet volume;
TGCT	cis	rs6988636	0.901	rs16898076	chr8:124187721	T/C	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs3096299	0.967	rs2965932	chr16:89477051	C/T	cg02187348	chr16:89574699	SPG7	-0.47	-4.54	-0.38	1.32e-5	Multiple myeloma (IgH translocation);
TGCT	cis	rs926938	0.527	rs360594	chr1:115472401	G/A	cg12756093	chr1:115239321	AMPD1	0.34	4.97	0.41	2.19e-6	Autism;
TGCT	cis	rs7267979	1.000	rs4813563	chr20:25365340	T/C	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10791097	0.547	rs12365680	chr11:130749059	C/T	cg12179176	chr11:130786555	SNX19	0.86	10.85	0.7	1.1e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs2820315	0.867	rs2819349	chr1:201885026	C/T	cg12730843	chr1:201915899	LMOD1	-0.27	-4.86	-0.4	3.46e-6	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
TGCT	cis	rs9611565	0.559	rs5751160	chr22:42175695	A/G	cg13695892	chr22:41940480	POLR3H	0.85	8.06	0.59	5.4e-13	Vitiligo;
TGCT	cis	rs1395	0.744	rs11126934	chr2:27476613	T/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.62	7.72	0.57	3.38e-12	Blood metabolite levels;
TGCT	cis	rs10992471	0.564	rs10491804	chr9:95487407	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.53	-4.56	-0.38	1.21e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs1670533	1.000	rs633556	chr4:1092405	A/G	cg20887711	chr4:1340912	KIAA1530	0.65	5.12	0.42	1.12e-6	Recombination rate (females);
TGCT	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg00024416	chr22:24240387	NA	-0.28	-5.41	-0.44	3.16e-7	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2204008	0.713	rs2320522	chr12:38251438	C/T	cg13010199	chr12:38710504	ALG10B	0.64	4.97	0.41	2.15e-6	Bladder cancer;
TGCT	cis	rs394563	0.775	rs448420	chr6:149785802	T/C	cg03678062	chr6:149772716	ZC3H12D	-0.36	-4.45	-0.37	1.87e-5	Dupuytren's disease;
TGCT	cis	rs737008	0.959	rs11865598	chr16:11403432	T/C	cg00044050	chr16:11439710	C16orf75	0.79	8.37	0.6	1.05e-13	Obesity-related traits;
TGCT	cis	rs11969893	0.850	rs3734351	chr6:101307131	C/T	cg12253828	chr6:101329408	ASCC3	1.36	6.32	0.49	4.33e-9	Economic and political preferences (immigration/crime);
TGCT	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg13699009	chr12:122356056	WDR66	-0.29	-5.95	-0.47	2.6e-8	Mean corpuscular volume;
TGCT	cis	rs789859	0.965	rs789858	chr3:194405966	C/T	cg21106136	chr3:194405973	FAM43A	-0.35	-5.06	-0.41	1.46e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
TGCT	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg09263875	chr16:632152	PIGQ	0.31	6.91	0.53	2.25e-10	Height;
TGCT	cis	rs826838	1.000	rs10880914	chr12:38720543	C/T	cg26384229	chr12:38710491	ALG10B	1.1	11.12	0.71	2.32e-20	Heart rate;
TGCT	cis	rs7909074	1.000	rs7079573	chr10:45400406	G/A	cg05187965	chr10:45406764	TMEM72	-0.24	-5.02	-0.41	1.73e-6	Mean corpuscular volume;
TGCT	cis	rs4285028	0.747	rs10049060	chr3:121358448	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.92	7.3	0.55	3.03e-11	Multiple sclerosis;
TGCT	cis	rs9299	0.778	rs11079830	chr17:46682630	A/G	cg25032089	chr17:46643351	HOXB3	0.45	5.74	0.46	6.97e-8	Obesity;
TGCT	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg17554472	chr22:41940697	POLR3H	0.46	4.71	0.39	6.63e-6	Cannabis dependence symptom count;
TGCT	cis	rs17076896	0.786	rs7325441	chr13:19934252	A/G	cg00777926	chr13:20807375	GJB6	-0.37	-4.53	-0.38	1.36e-5	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs7677751	0.806	rs6554163	chr4:55102559	A/T	cg17187183	chr4:55093834	PDGFRA	0.56	7.19	0.54	5.34e-11	Corneal astigmatism;
TGCT	cis	rs7043114	0.563	rs10820990	chr9:95323297	C/T	cg13798575	chr9:95087839	CENPP;NOL8	0.54	5.37	0.43	3.78e-7	Height;
TGCT	cis	rs5167	0.743	rs8111069	chr19:45483438	A/C	cg13119609	chr19:45449297	APOC2	0.23	4.73	0.39	5.98e-6	Blood protein levels;
TGCT	cis	rs10493389	0.591	rs10889587	chr1:66281473	T/C	cg08716655	chr1:66257732	PDE4B	-0.45	-4.62	-0.38	9.34e-6	Echocardiographic traits;
TGCT	cis	rs4319547	0.695	rs113841747	chr12:122886088	G/T	cg05707623	chr12:122985044	ZCCHC8	0.62	4.88	0.4	3.17e-6	Body mass index;
TGCT	cis	rs28595532	0.920	rs115372254	chr4:119771735	T/C	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg20999797	chr1:1681921	NA	0.18	4.78	0.39	4.93e-6	Body mass index;
TGCT	cis	rs8180040	0.903	rs2276854	chr3:47276968	C/T	cg27129171	chr3:47204927	SETD2	0.71	8.58	0.61	3.22e-14	Colorectal cancer;
TGCT	cis	rs3796352	1.000	rs2336541	chr3:52974630	G/C	cg07884673	chr3:53033167	SFMBT1	0.6	5.53	0.44	1.82e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs7659604	0.605	rs67772833	chr4:122723106	G/A	cg20573242	chr4:122745356	CCNA2	0.57	5.25	0.43	6.28e-7	Type 2 diabetes;
TGCT	cis	rs200810	0.634	rs62422095	chr6:97991825	T/A	cg16511841	chr6:97730490	C6orf167;MIR548H3	-0.68	-4.65	-0.39	8.37e-6	Body mass index;
TGCT	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg03396347	chr1:1875803	NA	0.37	6.79	0.52	4.1e-10	Body mass index;
TGCT	cis	rs13223928	0.536	rs12700594	chr7:3156701	G/A	cg19214707	chr7:3157722	NA	0.46	6.97	0.53	1.64e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
TGCT	cis	rs79149102	0.579	rs28394281	chr15:75326754	C/G	cg09165964	chr15:75287851	SCAMP5	-1.07	-5.81	-0.46	4.93e-8	Lung cancer;
TGCT	cis	rs2229238	0.780	rs61698846	chr1:154504854	C/T	cg13067139	chr1:155221277	FAM189B	0.2	4.51	0.38	1.47e-5	Coronary heart disease;
TGCT	cis	rs6089584	1.000	rs6089584	chr20:60564086	G/C	cg16423285	chr20:60520624	NA	-0.52	-5.62	-0.45	1.18e-7	Body mass index;
TGCT	trans	rs208520	1.000	rs9453671	chr6:66991208	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.79	7.05	0.53	1.12e-10	Exhaled nitric oxide output;
TGCT	cis	rs1505368	0.781	rs4673664	chr2:213277649	T/C	cg20637307	chr2:213403960	ERBB4	0.48	4.67	0.39	7.82e-6	Symmetrical dimethylarginine levels;
TGCT	cis	rs492146	0.765	rs316141	chr6:52846158	A/G	cg06706454	chr6:52930286	FBXO9	-0.51	-4.66	-0.39	8.12e-6	Epilepsy (remission after treatment);
TGCT	cis	rs7267979	0.586	rs6050429	chr20:25183058	G/A	cg16686733	chr20:25566563	NINL	0.53	5.43	0.44	2.9e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs473651	0.716	rs548179	chr2:239320505	G/A	cg08773314	chr2:239334832	ASB1	0.48	8.01	0.58	7.01e-13	Multiple system atrophy;
TGCT	cis	rs11105298	0.891	rs12369685	chr12:89928905	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.7	-5.08	-0.42	1.35e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg03709012	chr19:19516395	GATAD2A	0.67	5.75	0.46	6.45e-8	Tonsillectomy;
TGCT	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.67	-0.39	7.73e-6	Prudent dietary pattern;
TGCT	cis	rs4253772	0.530	rs9615955	chr22:46743931	A/G	cg24881330	chr22:46731750	TRMU	1.09	5.61	0.45	1.28e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs8072100	0.935	rs4793978	chr17:45698175	G/A	cg08085267	chr17:45401833	C17orf57	0.43	4.64	0.38	8.8e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs617219	0.591	rs1840805	chr5:78565563	T/A	cg09550809	chr5:78407562	BHMT	-0.38	-5.28	-0.43	5.63e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs9807989	0.507	rs6755905	chr2:103048207	C/A	cg03938978	chr2:103052716	IL18RAP	0.27	5.41	0.44	3.17e-7	Asthma;
TGCT	cis	rs826838	0.967	rs1684411	chr12:39128494	C/T	cg26384229	chr12:38710491	ALG10B	-0.83	-7.31	-0.55	2.88e-11	Heart rate;
TGCT	cis	rs72949976	0.584	rs4673729	chr2:214023810	A/G	cg08319019	chr2:214017104	IKZF2	0.84	8.38	0.6	9.58e-14	Lung cancer;Squamous cell lung carcinoma;
TGCT	cis	rs7772486	0.686	rs9376956	chr6:145949844	T/C	cg23711669	chr6:146136114	FBXO30	0.84	9.16	0.64	1.36e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2299587	0.623	rs12718384	chr8:17781112	T/C	cg01800426	chr8:17659068	MTUS1	-0.65	-5.61	-0.45	1.26e-7	Economic and political preferences;
TGCT	cis	rs3806843	0.608	rs155364	chr5:140346468	T/A	cg07102913	chr5:140593443	PCDHB13	-0.48	-4.81	-0.4	4.33e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7000551	0.532	rs55726237	chr8:22252985	C/T	cg12081754	chr8:22256438	SLC39A14	0.35	4.99	0.41	1.98e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs6912958	0.547	rs451089	chr6:88041859	A/G	cg10393598	chr6:87862264	NA	-0.31	-4.5	-0.37	1.55e-5	Monocyte percentage of white cells;
TGCT	cis	rs2235642	1.000	rs2235642	chr16:1584866	T/C	cg07341220	chr16:1583899	IFT140;TMEM204	-0.29	-4.64	-0.38	8.66e-6	Coronary artery disease;
TGCT	cis	rs7959452	0.605	rs12819406	chr12:69696400	G/T	cg14784868	chr12:69753453	YEATS4	0.68	6.95	0.53	1.81e-10	Blood protein levels;
TGCT	cis	rs9913156	0.793	rs7210953	chr17:4608870	C/T	cg00122941	chr17:4613640	ARRB2	0.88	7.63	0.57	5.46e-12	Lymphocyte counts;
TGCT	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg08048268	chr3:133502702	NA	-0.66	-9.83	-0.66	3.36e-17	Iron status biomarkers;
TGCT	cis	rs1577917	0.959	rs34258068	chr6:86679449	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.48	-0.44	2.27e-7	Response to antipsychotic treatment;
TGCT	cis	rs12477438	0.765	rs9710648	chr2:99673129	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-7.6	-0.56	6.47e-12	Chronic sinus infection;
TGCT	cis	rs11785400	0.762	rs4401833	chr8:143739731	A/T	cg10596483	chr8:143751796	JRK	0.55	5.48	0.44	2.29e-7	Schizophrenia;
TGCT	cis	rs13217239	0.646	rs6937880	chr6:27000236	C/T	cg26531700	chr6:26746687	NA	0.68	6.86	0.52	2.83e-10	Schizophrenia;
TGCT	cis	rs55882075	0.730	rs10794700	chr5:179148335	C/G	cg14593053	chr5:179126677	CANX	0.48	5.4	0.44	3.23e-7	Monocyte percentage of white cells;
TGCT	cis	rs9394169	0.818	rs1547671	chr6:33777260	C/T	cg13859433	chr6:33739653	LEMD2	-0.28	-4.99	-0.41	2.02e-6	Essential tremor;
TGCT	cis	rs62244186	0.627	rs12386385	chr3:44457540	A/G	cg04389838	chr3:44770851	ZNF501	-0.4	-5.3	-0.43	5.22e-7	Depressive symptoms;
TGCT	cis	rs1375194	0.606	rs13393407	chr2:33818198	C/T	cg04131969	chr2:33951647	MYADML	-0.53	-4.51	-0.38	1.49e-5	Response to antidepressants in depression;
TGCT	cis	rs2458413	0.521	rs2458427	chr8:105339594	G/T	cg23108931	chr8:105342351	NA	-0.36	-6.39	-0.5	3.05e-9	Paget's disease;
TGCT	cis	rs5769765	0.955	rs2295406	chr22:50260169	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	1.11	11.71	0.72	8.52e-22	Schizophrenia;
TGCT	cis	rs4699052	0.590	rs1156669	chr4:104288204	A/C	cg16532752	chr4:104119610	CENPE	-0.5	-4.75	-0.39	5.48e-6	Testicular germ cell tumor;
TGCT	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg25036284	chr2:26402008	FAM59B	-0.56	-4.88	-0.4	3.2e-6	Gut microbiome composition (summer);
TGCT	cis	rs7746199	0.736	rs6904596	chr6:27491299	G/A	cg26587870	chr6:27730563	NA	-0.48	-4.82	-0.4	4.1e-6	Gait speed in old age;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs3087591	0.762	rs7502029	chr17:29590791	T/A	cg24425628	chr17:29625626	OMG;NF1	0.46	6.82	0.52	3.53e-10	Hip circumference;
TGCT	cis	rs739496	0.843	rs619010	chr12:111974823	A/G	cg10833066	chr12:111807467	FAM109A	0.37	5.41	0.44	3.1e-7	Platelet count;
TGCT	cis	rs290268	1.000	rs290268	chr9:93552450	A/G	cg02608019	chr9:93564028	SYK	0.48	4.82	0.4	4.19e-6	Platelet count;
TGCT	cis	rs514406	0.505	rs146750	chr1:53183447	C/G	cg25767906	chr1:53392781	SCP2	-0.47	-5.41	-0.44	3.17e-7	Monocyte count;
TGCT	cis	rs13102973	0.931	rs12499856	chr4:135868573	C/T	cg14419869	chr4:135874104	NA	0.24	4.46	0.37	1.83e-5	Subjective well-being;
TGCT	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg25767906	chr1:53392781	SCP2	-0.52	-6.02	-0.48	1.82e-8	Monocyte count;
TGCT	cis	rs2249625	0.545	rs2496487	chr6:72875226	G/C	cg08500200	chr6:72892038	RIMS1	-0.42	-4.54	-0.38	1.33e-5	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
TGCT	cis	rs11711311	1.000	rs12695295	chr3:113474866	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.72	-6.74	-0.52	5.36e-10	IgG glycosylation;
TGCT	cis	rs9902453	0.740	rs2729446	chr17:28102499	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.84	-8.19	-0.59	2.73e-13	Coffee consumption (cups per day);
TGCT	cis	rs6490294	0.748	rs6489820	chr12:112328503	T/C	cg10833066	chr12:111807467	FAM109A	0.38	5.61	0.45	1.24e-7	Mean platelet volume;
TGCT	cis	rs7523273	0.565	rs2488248	chr1:207899682	C/T	cg22525895	chr1:207977042	MIR29B2	-0.33	-5.31	-0.43	4.83e-7	Schizophrenia;
TGCT	cis	rs9611565	0.765	rs132906	chr22:41799767	G/C	cg06634786	chr22:41940651	POLR3H	0.65	6.2	0.49	7.8e-9	Vitiligo;
TGCT	cis	rs2153535	0.601	rs9505472	chr6:8538765	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.67	0.45	9.45e-8	Motion sickness;
TGCT	cis	rs910316	0.737	rs398896	chr14:75482827	C/A	cg08847533	chr14:75593920	NEK9	-0.87	-9.09	-0.63	1.95e-15	Height;
TGCT	cis	rs10465746	0.901	rs17475760	chr1:84398435	A/T	cg10977910	chr1:84465055	TTLL7	0.63	6.25	0.49	5.95e-9	Obesity-related traits;
TGCT	cis	rs9467711	0.606	rs12174602	chr6:26372827	C/T	cg10795676	chr6:26370623	BTN3A2	-0.51	-5.27	-0.43	5.97e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4689388	0.610	rs4328980	chr4:6281756	A/G	cg25554036	chr4:6271136	WFS1	0.53	6.84	0.52	3.27e-10	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs6671200	1.000	rs60929805	chr1:95646386	C/T	cg26537280	chr1:95699037	RWDD3	0.68	5.49	0.44	2.15e-7	Stearic acid (18:0) levels;
TGCT	cis	rs904251	0.523	rs9369005	chr6:37483109	A/G	cg01843034	chr6:37503916	NA	-0.53	-7.14	-0.54	7.06e-11	Cognitive performance;
TGCT	cis	rs3809566	1.000	rs10851721	chr15:63332383	T/C	cg05507819	chr15:63340323	TPM1	0.48	4.52	0.38	1.4e-5	Platelet count;
TGCT	cis	rs2404602	0.692	rs35170561	chr15:77130695	C/T	cg22467129	chr15:76604101	ETFA	-0.45	-5.11	-0.42	1.21e-6	Blood metabolite levels;
TGCT	cis	rs9972944	0.729	rs10083877	chr17:63773623	T/C	cg07283582	chr17:63770753	CCDC46	0.26	5.05	0.41	1.53e-6	Total body bone mineral density;
TGCT	cis	rs7666738	0.546	rs1456207	chr4:98676911	G/A	cg18180107	chr4:99064573	C4orf37	0.54	4.73	0.39	5.89e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9443189	0.615	rs6453829	chr6:76268509	C/T	cg01950844	chr6:76311363	SENP6	0.95	5.82	0.46	4.69e-8	Prostate cancer;
TGCT	cis	rs10193935	1.000	rs10210866	chr2:42387879	A/G	cg27598129	chr2:42591480	NA	-0.39	-5.14	-0.42	1.05e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9357506	0.967	rs9381443	chr6:46316567	A/G	cg21115430	chr6:46460003	NA	-0.25	-4.8	-0.4	4.49e-6	Body mass index;
TGCT	cis	rs711245	0.572	rs3821150	chr2:36795233	G/A	cg15105969	chr2:36825350	FEZ2	0.56	4.76	0.39	5.3e-6	Height;
TGCT	cis	rs6546537	0.910	rs10779953	chr2:69886757	A/G	cg10773587	chr2:69614142	GFPT1	-0.72	-6.53	-0.51	1.5e-9	Serum thyroid-stimulating hormone levels;
TGCT	cis	rs11621121	0.556	rs2127870	chr14:65796846	C/G	cg04536575	chr14:65016802	C14orf50	-0.64	-4.46	-0.37	1.84e-5	N-glycan levels;
TGCT	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg09359103	chr1:154839909	KCNN3	-0.64	-11.6	-0.72	1.58e-21	Prostate cancer;
TGCT	cis	rs7605378	0.528	rs7592587	chr2:200786516	C/G	cg23649088	chr2:200775458	C2orf69	0.48	10.23	0.68	3.47e-18	Osteoporosis;
TGCT	cis	rs3008870	0.755	rs2815381	chr1:67514591	G/A	cg02640540	chr1:67518911	SLC35D1	0.69	6.17	0.48	8.93e-9	Lymphocyte percentage of white cells;
TGCT	cis	rs986417	1.000	rs1951114	chr14:60922005	C/G	cg27398547	chr14:60952738	C14orf39	-1.39	-10.61	-0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs172166	0.694	rs203892	chr6:28067196	T/C	cg10876282	chr6:28092338	ZSCAN16	0.51	4.79	0.39	4.75e-6	Cardiac Troponin-T levels;
TGCT	cis	rs9534288	0.619	rs9526143	chr13:46675991	C/T	cg15192986	chr13:46630673	CPB2	-0.5	-6.04	-0.48	1.65e-8	Blood protein levels;
TGCT	cis	rs597539	0.521	rs7943745	chr11:68605828	A/G	cg06112835	chr11:68658793	MRPL21	-0.33	-5.58	-0.45	1.47e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs921968	0.541	rs485975	chr2:219374250	C/T	cg02176678	chr2:219576539	TTLL4	0.48	6.78	0.52	4.32e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs6840360	0.642	rs2709833	chr4:152377622	A/G	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.83e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs2964802	0.505	rs11133627	chr5:10830474	T/G	cg14521931	chr5:10832172	NA	-0.26	-4.46	-0.37	1.78e-5	Major depressive disorder;Recurrent major depressive disorder;
TGCT	cis	rs3733585	0.699	rs11724510	chr4:9958583	C/T	cg11266682	chr4:10021025	SLC2A9	-0.57	-7.47	-0.56	1.23e-11	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs17076896	0.786	rs17080342	chr13:19926967	C/T	cg00777926	chr13:20807375	GJB6	-0.37	-4.51	-0.38	1.5e-5	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs9583531	0.660	rs61971611	chr13:111335319	C/T	cg15747390	chr13:111297551	CARS2	0.88	5.97	0.47	2.32e-8	Coronary artery disease;
TGCT	cis	rs2251381	0.750	rs2251087	chr21:30527999	C/T	cg24692254	chr21:30365293	RNF160	0.74	7.03	0.53	1.23e-10	Selective IgA deficiency;
TGCT	cis	rs854765	0.583	rs4925123	chr17:17784374	A/G	cg09796270	chr17:17721594	SREBF1	-0.27	-5.63	-0.45	1.16e-7	Total body bone mineral density;
TGCT	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.72	-7.13	-0.54	7.39e-11	Prudent dietary pattern;
TGCT	cis	rs2153535	0.580	rs1577472	chr6:8486215	G/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs13326165	0.760	rs35133416	chr3:52359040	C/T	cg27565382	chr3:53032988	SFMBT1	0.37	4.9	0.4	2.97e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs7586879	1.000	rs10207698	chr2:25117672	C/T	cg01884057	chr2:25150051	NA	0.28	5.03	0.41	1.69e-6	Body mass index;
TGCT	cis	rs868036	0.681	rs4776981	chr15:68109474	G/A	cg05925327	chr15:68127851	NA	-0.5	-4.85	-0.4	3.57e-6	Restless legs syndrome;
TGCT	cis	rs12477438	0.520	rs2632277	chr2:99778985	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.05	13.57	0.77	2.9e-26	Chronic sinus infection;
TGCT	cis	rs9486719	0.843	rs2103539	chr6:96844342	T/A	cg18709589	chr6:96969512	KIAA0776	0.75	5.13	0.42	1.1e-6	Migraine;Coronary artery disease;
TGCT	cis	rs7605378	0.528	rs7592587	chr2:200786516	C/G	cg17644776	chr2:200775616	C2orf69	0.33	7.36	0.55	2.18e-11	Osteoporosis;
TGCT	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg26119090	chr2:26468346	HADHA;HADHB	0.91	6.41	0.5	2.79e-9	Gut microbiome composition (summer);
TGCT	cis	rs1949733	0.523	rs16842557	chr4:8543985	C/T	cg13073564	chr4:8508604	NA	0.5	4.94	0.41	2.46e-6	Response to antineoplastic agents;
TGCT	cis	rs11696501	0.688	rs6073834	chr20:44279989	C/A	cg11783356	chr20:44313418	WFDC10B	-0.32	-4.63	-0.38	9.25e-6	Brain structure;
TGCT	cis	rs17376456	0.778	rs10440717	chr5:93424852	C/A	cg21475434	chr5:93447410	FAM172A	0.59	4.66	0.39	8.09e-6	Diabetic retinopathy;
TGCT	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg21016266	chr12:122356598	WDR66	0.53	6.58	0.51	1.19e-9	Mean corpuscular volume;
TGCT	cis	rs9811920	0.638	rs793440	chr3:99643176	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.6	-6.92	-0.53	2.1e-10	Axial length;
TGCT	cis	rs6074578	0.679	rs11087789	chr20:139173	A/G	cg16931068	chr20:139680	DEFB127	0.27	4.54	0.38	1.33e-5	Hirschsprung disease;
TGCT	cis	rs10858047	0.883	rs6537843	chr1:115210578	C/A	cg12756093	chr1:115239321	AMPD1	-0.47	-4.96	-0.41	2.27e-6	Autism;
TGCT	cis	rs548987	0.529	rs9467618	chr6:25824809	C/T	cg12310025	chr6:25882481	NA	-0.57	-4.61	-0.38	9.67e-6	Homocysteine levels;
TGCT	trans	rs877282	0.733	rs11253342	chr10:765072	A/G	cg22713356	chr15:30763199	NA	1.2	9.39	0.64	3.76e-16	Uric acid levels;
TGCT	cis	rs2204008	0.777	rs114096617	chr12:38342557	A/C	cg13010199	chr12:38710504	ALG10B	0.59	4.63	0.38	9.17e-6	Bladder cancer;
TGCT	cis	rs4253772	0.626	rs9615960	chr22:46752307	G/A	cg24881330	chr22:46731750	TRMU	0.94	4.43	0.37	2.01e-5	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg22535103	chr8:58192502	C8orf71	-0.42	-4.79	-0.4	4.7e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs55794721	0.509	rs4649085	chr1:25778832	G/A	cg23205692	chr1:25664452	TMEM50A	0.48	5.07	0.41	1.42e-6	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs7615952	0.800	rs11914298	chr3:125643772	G/A	cg05084668	chr3:125655381	ALG1L	-0.76	-6.17	-0.48	8.82e-9	Blood pressure (smoking interaction);
TGCT	cis	rs933688	0.532	rs28693622	chr5:90538722	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.54	-4.82	-0.4	4.09e-6	Smoking behavior;
TGCT	cis	rs2197308	0.765	rs12230545	chr12:37927114	C/T	cg26384229	chr12:38710491	ALG10B	-0.71	-6.31	-0.49	4.42e-9	Morning vs. evening chronotype;
TGCT	cis	rs3806843	0.766	rs6848	chr5:140086062	A/T	cg19875535	chr5:140030758	IK	-0.35	-6.02	-0.48	1.85e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs1218582	0.651	rs4845396	chr1:154828409	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	0.55	5.15	0.42	1.01e-6	Prostate cancer;
TGCT	cis	rs6684514	1.000	rs3806408	chr1:156252137	C/A	cg20302342	chr1:156215951	PAQR6	0.34	4.6	0.38	1.01e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs9296092	0.517	rs11751684	chr6:33528739	G/T	cg13560919	chr6:33536144	NA	-0.23	-4.95	-0.41	2.4e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs9303401	0.659	rs34351230	chr17:56782555	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.67	6.3	0.49	4.7e-9	Cognitive test performance;
TGCT	cis	rs8077889	0.917	rs60335331	chr17:41907509	A/G	cg26893861	chr17:41843967	DUSP3	1.09	13.08	0.76	4.26e-25	Triglycerides;
TGCT	cis	rs4727027	0.804	rs13231262	chr7:148886058	C/T	cg23583168	chr7:148888333	NA	-0.77	-9.95	-0.67	1.63e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg10802521	chr3:52805072	NEK4	-0.73	-9.14	-0.63	1.51e-15	Bipolar disorder;
TGCT	trans	rs2727020	0.704	rs4144700	chr11:49370834	C/A	cg03929089	chr4:120376271	NA	-0.74	-8.68	-0.61	1.87e-14	Coronary artery disease;
TGCT	cis	rs76419734	0.558	rs10030620	chr4:106574536	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.71	4.56	0.38	1.22e-5	Post bronchodilator FEV1;
TGCT	cis	rs1784581	0.588	rs7752870	chr6:162422510	T/C	cg17173639	chr6:162384350	PARK2	0.4	6.6	0.51	1.08e-9	Itch intensity from mosquito bite;
TGCT	cis	rs826838	0.900	rs9739128	chr12:38948960	A/T	cg13010199	chr12:38710504	ALG10B	0.8	6.74	0.52	5.43e-10	Heart rate;
TGCT	cis	rs700651	0.754	rs1518367	chr2:198807015	T/A	cg00792783	chr2:198669748	PLCL1	0.57	5.23	0.43	6.99e-7	Intracranial aneurysm;
TGCT	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg05368731	chr17:41323189	NBR1	1.02	11.3	0.71	8.52e-21	Menopause (age at onset);
TGCT	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg19901468	chr14:105411992	AHNAK2	-0.28	-5.86	-0.47	3.96e-8	Rheumatoid arthritis;
TGCT	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg00024416	chr22:24240387	NA	-0.25	-4.84	-0.4	3.86e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs3806843	0.932	rs2563256	chr5:140141779	G/T	cg19875535	chr5:140030758	IK	-0.36	-6.17	-0.48	8.74e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9457247	1.000	rs408080	chr6:167392522	T/C	cg23791538	chr6:167370224	RNASET2	-0.53	-5.18	-0.42	8.72e-7	Crohn's disease;
TGCT	cis	rs11711311	0.955	rs9881563	chr3:113414031	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.79	7.05	0.53	1.11e-10	IgG glycosylation;
TGCT	cis	rs7772486	0.686	rs1045820	chr6:145947080	C/T	cg05347473	chr6:146136440	FBXO30	0.48	4.53	0.38	1.38e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7552404	0.727	rs7521344	chr1:76318325	C/T	cg10523679	chr1:76189770	ACADM	-0.67	-6.36	-0.5	3.5e-9	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9486719	1.000	rs2472887	chr6:96865437	A/G	cg06623918	chr6:96969491	KIAA0776	1.01	8.86	0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs80033912	0.640	rs6785832	chr3:49224316	C/T	cg07690219	chr3:49449608	TCTA;RHOA	-0.47	-4.51	-0.38	1.49e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs25422	0.938	rs114309775	chr6:118838782	G/A	cg21191810	chr6:118973309	C6orf204	-0.37	-4.79	-0.39	4.73e-6	Renal cell carcinoma;
TGCT	cis	rs17376456	0.877	rs10070390	chr5:93452345	G/A	cg21475434	chr5:93447410	FAM172A	0.59	4.66	0.39	8.09e-6	Diabetic retinopathy;
TGCT	cis	rs76878669	0.561	rs11227465	chr11:66115879	T/A	cg18002602	chr11:66138449	SLC29A2	-0.53	-6.3	-0.49	4.69e-9	Educational attainment (years of education);
TGCT	cis	rs2469997	1.000	rs2470016	chr8:120361220	T/G	cg00681363	chr8:120844660	TAF2	0.69	4.48	0.37	1.64e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs9467711	0.606	rs34878490	chr6:26370572	C/T	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs73001065	0.591	rs2285626	chr19:19467545	C/T	cg03709012	chr19:19516395	GATAD2A	0.85	5.39	0.44	3.4e-7	LDL cholesterol;
TGCT	cis	rs2066819	1.000	rs41392645	chr12:56696742	A/G	cg26714650	chr12:56694279	CS	-1.36	-6.06	-0.48	1.54e-8	Psoriasis vulgaris;
TGCT	cis	rs9303401	0.659	rs56162835	chr17:56687315	A/G	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs11098499	0.604	rs2389882	chr4:120566733	A/C	cg09307838	chr4:120376055	NA	0.64	6.05	0.48	1.57e-8	Corneal astigmatism;
TGCT	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg18402987	chr7:1209562	NA	0.81	6.94	0.53	1.9e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs6598955	0.543	rs112752634	chr1:26534217	G/A	cg04990556	chr1:26633338	UBXN11	0.81	7.32	0.55	2.76e-11	Obesity-related traits;
TGCT	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg06238570	chr21:40685208	BRWD1	0.58	5.2	0.42	7.95e-7	Cognitive function;
TGCT	cis	rs2016266	0.752	rs10783562	chr12:53657467	G/A	cg16917193	chr12:54089295	NA	0.65	4.82	0.4	4.19e-6	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs4660306	0.961	rs2152077	chr1:45986670	G/T	cg15605315	chr1:45957053	TESK2	0.47	4.47	0.37	1.72e-5	Homocysteine levels;
TGCT	cis	rs11167764	0.945	rs7720832	chr5:141473097	T/G	cg23435118	chr5:141488016	NDFIP1	-0.28	-4.58	-0.38	1.1e-5	Crohn's disease;
TGCT	cis	rs1348850	0.914	rs11893448	chr2:178280013	T/C	cg22681709	chr2:178499509	PDE11A	-0.34	-4.47	-0.37	1.74e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg13695892	chr22:41940480	POLR3H	-0.91	-9.07	-0.63	2.18e-15	Vitiligo;
TGCT	cis	rs4148883	0.675	rs28762430	chr4:100119257	C/A	cg12011299	chr4:100065546	ADH4	0.39	5.88	0.47	3.53e-8	Alcohol dependence;
TGCT	cis	rs6938	0.618	rs12911254	chr15:75166335	G/A	cg09165964	chr15:75287851	SCAMP5	0.58	5.33	0.43	4.45e-7	Breast cancer;
TGCT	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg03303774	chr4:1407052	NA	0.29	4.65	0.39	8.26e-6	Obesity-related traits;
TGCT	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg03264133	chr6:25882463	NA	-0.51	-5.36	-0.43	3.84e-7	Blood metabolite levels;
TGCT	cis	rs11190604	1.000	rs11190596	chr10:102293238	C/G	cg16342193	chr10:102329863	NA	-0.46	-5.86	-0.47	3.89e-8	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs6582630	0.502	rs12815350	chr12:38439921	A/T	cg13010199	chr12:38710504	ALG10B	0.56	4.44	0.37	2e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.31	-4.82	-0.4	4.17e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9549367	0.773	rs9549717	chr13:113908826	A/G	cg00898013	chr13:113819073	PROZ	-0.43	-5.55	-0.45	1.68e-7	Platelet distribution width;
TGCT	trans	rs7726839	0.526	rs11960159	chr5:568685	C/T	cg11887960	chr12:57824829	NA	1.03	7.93	0.58	1.11e-12	Obesity-related traits;
TGCT	cis	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg07424592	chr7:64974309	NA	1.33	8.82	0.62	8.94e-15	Diabetic kidney disease;
TGCT	cis	rs9611519	0.964	rs5995992	chr22:41487218	T/C	cg13695892	chr22:41940480	POLR3H	-0.5	-4.53	-0.38	1.39e-5	Neuroticism;
TGCT	cis	rs614226	1.000	rs1614223	chr12:120964043	T/C	cg01236616	chr12:121019343	POP5	1.26	13.2	0.76	2.23e-25	Type 1 diabetes nephropathy;
TGCT	trans	rs17685	0.753	rs1637039	chr7:75693009	C/T	cg19862616	chr7:65841803	NCRNA00174	0.51	8.73	0.62	1.42e-14	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs35306767	0.761	rs11253560	chr10:1047226	T/G	cg26597838	chr10:835615	NA	0.6	6.63	0.51	9.45e-10	Eosinophil percentage of granulocytes;
TGCT	cis	rs2153535	0.580	rs7743418	chr6:8438128	A/C	cg07606381	chr6:8435919	SLC35B3	0.57	5.25	0.43	6.46e-7	Motion sickness;
TGCT	cis	rs9911578	0.967	rs2611781	chr17:56703124	C/G	cg05425664	chr17:57184151	TRIM37	-0.64	-6.48	-0.5	1.99e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs9291683	0.546	rs13139055	chr4:10038924	G/T	cg00071950	chr4:10020882	SLC2A9	0.6	6.89	0.53	2.49e-10	Bone mineral density;
TGCT	cis	rs7246657	0.943	rs12709813	chr19:37844983	G/A	cg18154014	chr19:37997991	ZNF793	0.72	5.19	0.42	8.3e-7	Coronary artery calcification;
TGCT	cis	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg08045932	chr20:61659980	NA	0.48	9.28	0.64	7.07e-16	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1561288	0.553	rs12233134	chr2:25329016	C/T	cg15423357	chr2:25149977	NA	-0.5	-4.51	-0.38	1.49e-5	Body mass index;
TGCT	cis	rs4268898	0.697	rs10445892	chr2:24406958	T/C	cg02683114	chr2:24398427	C2orf84	0.19	4.76	0.39	5.37e-6	Asthma;
TGCT	cis	rs739496	0.563	rs61547643	chr12:112266624	G/C	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs7267979	1.000	rs2257420	chr20:25275890	C/A	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7225537	0.507	rs2292530	chr17:17075318	A/G	cg26176665	chr17:16994978	MPRIP	0.23	5.35	0.43	4.18e-7	Mean platelet volume;
TGCT	cis	rs752590	0.650	rs6751201	chr2:113952699	C/G	cg27425262	chr2:113953981	PSD4;LOC440839	-0.39	-4.62	-0.38	9.44e-6	Mucinous ovarian carcinoma;
TGCT	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg00343986	chr7:65444356	GUSB	0.25	5.63	0.45	1.15e-7	Aortic root size;
TGCT	cis	rs896854	0.654	rs1453377	chr8:95969947	C/T	cg16049864	chr8:95962084	TP53INP1	-0.71	-9.68	-0.66	7.71e-17	Type 2 diabetes;
TGCT	cis	rs7666738	0.830	rs10014284	chr4:98681951	G/C	cg17366294	chr4:99064904	C4orf37	0.62	6.4	0.5	2.94e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7666738	0.606	rs3846447	chr4:99099907	G/A	cg18180107	chr4:99064573	C4orf37	0.51	4.58	0.38	1.09e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3749237	0.964	rs35210174	chr3:49812606	C/T	cg03060546	chr3:49711283	APEH	0.72	7.38	0.55	2.02e-11	Resting heart rate;
TGCT	trans	rs877282	0.797	rs7079164	chr10:756363	A/G	cg22713356	chr15:30763199	NA	1.07	8.27	0.6	1.75e-13	Uric acid levels;
TGCT	cis	rs595982	0.661	rs657008	chr19:49373632	A/G	cg21252483	chr19:49399788	TULP2	-0.26	-4.57	-0.38	1.18e-5	Red cell distribution width;
TGCT	cis	rs67311347	0.640	rs7434088	chr3:40297288	T/C	cg13683864	chr3:40499215	RPL14	-0.74	-6.79	-0.52	4.2e-10	Renal cell carcinoma;
TGCT	trans	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg23505145	chr19:12996616	KLF1	0.78	8.12	0.59	4.03e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1577917	0.696	rs10806334	chr6:86439329	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-5.16	-0.42	9.69e-7	Response to antipsychotic treatment;
TGCT	cis	rs10791097	0.967	rs10791099	chr11:130718813	G/C	cg05962950	chr11:130786565	SNX19	0.75	8.13	0.59	3.73e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	trans	rs17471911	0.643	rs11189947	chr10:100797203	A/G	cg03484267	chr2:207988651	KLF7	-0.52	-6.79	-0.52	4.17e-10	Neuroticism;
TGCT	cis	rs3733585	0.673	rs4519796	chr4:9955936	A/G	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.7	-0.52	6.62e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.68	-6.37	-0.5	3.34e-9	Menarche (age at onset);
TGCT	cis	rs7267979	0.932	rs6132848	chr20:25561645	C/T	cg03522245	chr20:25566470	NINL	0.6	6.46	0.5	2.14e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs62103177	0.565	rs473119	chr18:77849459	T/G	cg07235805	chr18:78004237	PARD6G	-0.52	-5.04	-0.41	1.57e-6	Opioid sensitivity;
TGCT	cis	rs9372498	0.536	rs9489450	chr6:118904385	G/A	cg21191810	chr6:118973309	C6orf204	-0.39	-5.04	-0.41	1.59e-6	Diastolic blood pressure;
TGCT	cis	rs896854	0.738	rs2515226	chr8:95965743	G/A	cg13393036	chr8:95962371	TP53INP1	0.56	6.85	0.52	3.02e-10	Type 2 diabetes;
TGCT	cis	rs12477438	0.501	rs12995473	chr2:99764884	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	16.87	0.83	6.81e-34	Chronic sinus infection;
TGCT	cis	rs9638182	0.673	rs79862839	chr7:72921609	T/C	cg14087351	chr7:73037990	MLXIPL	-0.61	-4.81	-0.4	4.34e-6	Triglycerides;
TGCT	cis	rs7592578	0.766	rs12472081	chr2:191398545	G/A	cg11845111	chr2:191398756	TMEM194B	-0.42	-4.48	-0.37	1.69e-5	Diastolic blood pressure;
TGCT	cis	rs28595532	0.920	rs10025640	chr4:119787451	G/A	cg00700008	chr4:120138107	USP53	0.49	4.48	0.37	1.71e-5	Cannabis dependence symptom count;
TGCT	cis	rs6940638	1.000	rs12215773	chr6:27039233	T/C	cg16898833	chr6:26189333	HIST1H4D	0.76	5.61	0.45	1.27e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs11031096	0.803	rs10082689	chr11:4172575	A/G	cg18678763	chr11:4115507	RRM1	0.39	5.28	0.43	5.52e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs2295359	1.000	rs963427	chr1:67609347	A/G	cg12940439	chr1:67600707	NA	0.58	6.21	0.49	7.19e-9	Psoriasis;
TGCT	cis	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg25427524	chr10:38739819	LOC399744	0.39	7.85	0.58	1.67e-12	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2115630	0.967	rs7171167	chr15:85239123	A/T	cg24513567	chr15:85260248	SEC11A	-0.35	-4.57	-0.38	1.15e-5	P wave terminal force;
TGCT	cis	rs7617773	0.817	rs13094727	chr3:48323489	G/A	cg11946769	chr3:48343235	NME6	0.76	6.57	0.51	1.23e-9	Coronary artery disease;
TGCT	trans	rs12339966	0.615	rs73642474	chr9:11368518	G/A	cg03488587	chr11:64876988	C11orf2	0.29	6.8	0.52	4.04e-10	Systolic blood pressure;
TGCT	cis	rs5757676	1.000	rs5757676	chr22:39841700	T/C	cg02038168	chr22:39784481	NA	-0.76	-5.2	-0.42	7.93e-7	IgG glycosylation;
TGCT	cis	rs12893668	0.572	rs12590968	chr14:104136633	G/C	cg26031613	chr14:104095156	KLC1	-0.59	-5.08	-0.42	1.34e-6	Reticulocyte count;
TGCT	cis	rs2239547	0.522	rs6770957	chr3:52995416	T/C	cg11645453	chr3:52864694	ITIH4	0.32	5.27	0.43	5.93e-7	Schizophrenia;
TGCT	cis	rs9942416	0.660	rs61173369	chr5:74997995	A/G	cg02573091	chr5:74908125	NA	0.38	4.51	0.38	1.47e-5	Age-related disease endophenotypes;
TGCT	cis	rs17331151	0.573	rs13080929	chr3:52885112	A/C	cg11137980	chr3:52469226	SEMA3G	0.29	5.12	0.42	1.13e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs17384381	1.000	rs12758237	chr1:85870783	G/A	cg16011679	chr1:85725395	C1orf52	0.78	6.1	0.48	1.27e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs858239	0.508	rs7805071	chr7:23190212	C/T	cg05602783	chr7:23145260	KLHL7	-0.68	-5.62	-0.45	1.2e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg01802117	chr1:53393560	SCP2	-0.39	-4.55	-0.38	1.27e-5	Monocyte count;
TGCT	cis	rs61867294	0.553	rs7090254	chr10:106730404	C/T	cg08000847	chr10:105880925	C10orf78	0.48	4.46	0.37	1.81e-5	Schizophrenia;
TGCT	cis	rs7572733	0.515	rs6724526	chr2:198858401	A/G	cg00792783	chr2:198669748	PLCL1	0.57	5.1	0.42	1.24e-6	Dermatomyositis;
TGCT	cis	rs6988636	1.000	rs13261066	chr8:124190276	G/A	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs7937682	0.855	rs7934922	chr11:111500026	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.11	-11.7	-0.72	9.24e-22	Primary sclerosing cholangitis;
TGCT	cis	rs4689388	0.926	rs5018648	chr4:6292818	C/G	cg00701064	chr4:6280414	WFS1	-0.37	-4.73	-0.39	5.98e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs9807989	0.507	rs13021177	chr2:103056493	A/G	cg03938978	chr2:103052716	IL18RAP	0.26	5.28	0.43	5.56e-7	Asthma;
TGCT	cis	rs2721195	1.000	rs11542372	chr8:145677089	G/A	cg15320075	chr8:145703422	NA	-0.71	-7.16	-0.54	6.3e-11	Age at first birth;
TGCT	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg24829409	chr8:58192753	C8orf71	-0.64	-5.31	-0.43	4.89e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9902453	0.967	rs11080121	chr17:28528842	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	6.37	0.5	3.28e-9	Coffee consumption (cups per day);
TGCT	cis	rs910316	0.712	rs175037	chr14:75465038	T/C	cg08847533	chr14:75593920	NEK9	-0.84	-9.15	-0.64	1.4e-15	Height;
TGCT	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg00738919	chr7:1100172	C7orf50	0.47	4.6	0.38	1.04e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7246657	0.663	rs4803287	chr19:38079435	A/G	cg18154014	chr19:37997991	ZNF793	0.69	4.63	0.38	9.25e-6	Coronary artery calcification;
TGCT	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg22963979	chr7:1858916	MAD1L1	-0.47	-7.55	-0.56	8.09e-12	Bipolar disorder and schizophrenia;
TGCT	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	6.89	0.53	2.53e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs11690935	0.921	rs7594711	chr2:172895637	T/G	cg13550731	chr2:172543902	DYNC1I2	-1.14	-11.28	-0.71	9.47e-21	Schizophrenia;
TGCT	cis	rs11673344	0.523	rs2562609	chr19:37527157	C/T	cg08039142	chr19:36980659	ZNF566	0.51	4.72	0.39	6.16e-6	Obesity-related traits;
TGCT	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg25703541	chr22:24373054	LOC391322	-0.93	-10.97	-0.7	5.66e-20	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs250677	0.522	rs1007400	chr5:148382635	C/T	cg18129178	chr5:148520854	ABLIM3	0.36	4.7	0.39	6.92e-6	Breast cancer;
TGCT	cis	rs6500602	0.627	rs3848372	chr16:4587875	C/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.39	6.85	0.52	3e-10	Schizophrenia;
TGCT	cis	rs2639990	0.744	rs640261	chr18:72905808	C/T	cg02750262	chr18:72916776	ZADH2	0.88	6.43	0.5	2.49e-9	Vascular endothelial growth factor levels;
TGCT	cis	rs9818758	0.545	rs9853352	chr3:49813258	C/T	cg07636037	chr3:49044803	WDR6	1.01	4.93	0.4	2.63e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs11169225	0.906	rs399023	chr12:50338952	A/C	cg23855989	chr12:50355821	AQP5	0.41	4.92	0.4	2.74e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg20203395	chr5:56204925	C5orf35	-0.58	-4.87	-0.4	3.34e-6	Initial pursuit acceleration;
TGCT	cis	rs1005224	0.889	rs10132250	chr14:76124380	C/A	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.53	-4.8	-0.4	4.48e-6	Large artery stroke;
TGCT	cis	rs7818688	0.654	rs896848	chr8:95981810	G/A	cg16049864	chr8:95962084	TP53INP1	0.5	4.52	0.38	1.44e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs13185784	0.667	rs4309929	chr5:179650988	A/C	cg04734276	chr5:178882605	NA	0.29	4.51	0.38	1.5e-5	TRAIL levels;
TGCT	cis	rs4891159	0.790	rs1787448	chr18:74113179	T/C	cg24786174	chr18:74118243	ZNF516	0.63	9.91	0.66	2.07e-17	Longevity;
TGCT	cis	rs7095607	1.000	rs7094660	chr10:69956912	A/G	cg18986048	chr10:69913749	MYPN	0.46	4.93	0.41	2.54e-6	Lung function (FVC);
TGCT	cis	rs11874712	0.965	rs8083998	chr18:43673144	A/C	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	5.23	0.42	7.11e-7	Migraine - clinic-based;
TGCT	cis	rs7659604	1.000	rs34952897	chr4:122664409	C/T	cg19748678	chr4:122722346	EXOSC9	0.57	5.54	0.45	1.69e-7	Type 2 diabetes;
TGCT	cis	rs67311347	0.544	rs4974040	chr3:40331059	G/A	cg13683864	chr3:40499215	RPL14	-0.78	-7.45	-0.56	1.42e-11	Renal cell carcinoma;
TGCT	trans	rs9951602	0.512	rs7232551	chr18:76650702	G/A	cg02800362	chr5:177631904	HNRNPAB	1.15	13.03	0.76	5.64e-25	Obesity-related traits;
TGCT	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg17971929	chr21:40555470	PSMG1	0.98	9.57	0.65	1.43e-16	Cognitive function;
TGCT	cis	rs7845219	0.544	rs4570121	chr8:95917088	C/T	cg13393036	chr8:95962371	TP53INP1	-0.44	-5.14	-0.42	1.05e-6	Type 2 diabetes;
TGCT	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg08280861	chr8:58055591	NA	0.55	6.23	0.49	6.59e-9	Developmental language disorder (linguistic errors);
TGCT	cis	rs11122272	0.735	rs2486735	chr1:231521778	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-6.94	-0.53	1.98e-10	Hemoglobin concentration;
TGCT	cis	rs9902453	1.000	rs4350617	chr17:28423088	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.74	6.52	0.51	1.63e-9	Coffee consumption (cups per day);
TGCT	cis	rs6969780	1.000	rs73071550	chr7:27149099	T/C	cg04317399	chr7:27170313	HOXA4	0.48	4.46	0.37	1.81e-5	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs16867321	0.853	rs73023563	chr2:181502830	C/T	cg23363182	chr2:181467187	NA	-0.4	-5.7	-0.46	8.41e-8	Obesity;
TGCT	trans	rs459571	0.796	rs10993894	chr9:136884511	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.76	-8.27	-0.6	1.79e-13	Platelet distribution width;
TGCT	cis	rs688020	1.000	rs688020	chr7:4228553	C/T	cg24441899	chr7:4244372	SDK1	0.41	5.3	0.43	5.21e-7	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;
TGCT	cis	rs7267979	1.000	rs6050629	chr20:25430680	G/A	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10875746	0.903	rs12304476	chr12:48482153	T/C	cg20731937	chr12:48336164	NA	0.62	4.95	0.41	2.36e-6	Longevity (90 years and older);
TGCT	cis	rs2456568	0.900	rs2511376	chr11:93670388	C/T	cg17595323	chr11:93583763	C11orf90	-0.46	-5.86	-0.47	3.97e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	trans	rs57221529	0.655	rs11948381	chr5:568413	A/T	cg11887960	chr12:57824829	NA	1.02	7.66	0.57	4.52e-12	Lung disease severity in cystic fibrosis;
TGCT	cis	rs12477438	0.561	rs2084988	chr2:99655755	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-7.6	-0.56	6.47e-12	Chronic sinus infection;
TGCT	cis	rs11696501	0.694	rs6073827	chr20:44265556	T/C	cg11783356	chr20:44313418	WFDC10B	-0.32	-4.63	-0.38	9.25e-6	Brain structure;
TGCT	cis	rs2153535	0.580	rs9406171	chr6:8515362	T/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.01	0.41	1.86e-6	Motion sickness;
TGCT	cis	rs1801251	1.000	rs283468	chr2:233658309	C/T	cg08000102	chr2:233561755	GIGYF2	0.62	6.15	0.48	9.79e-9	Coronary artery disease;
TGCT	cis	rs7104764	0.957	rs10794301	chr11:220401	C/T	cg18336825	chr11:236787	PSMD13;SIRT3	1.05	10.74	0.69	2e-19	Menarche (age at onset);
TGCT	cis	rs916888	0.610	rs199446	chr17:44813169	G/A	cg01570182	chr17:44337453	NA	-0.78	-7.51	-0.56	1.01e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs12210905	0.688	rs12213533	chr6:27346021	C/T	cg08851530	chr6:28072375	NA	1.25	5.39	0.44	3.38e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs9611565	0.532	rs4401299	chr22:42156517	A/G	cg06634786	chr22:41940651	POLR3H	0.78	7.17	0.54	5.91e-11	Vitiligo;
TGCT	cis	rs3818285	0.515	rs4918471	chr10:111660500	C/A	cg00817464	chr10:111662876	XPNPEP1	-0.29	-4.94	-0.41	2.51e-6	Superior crus of antihelix expression;
TGCT	cis	rs3087591	0.683	rs12602834	chr17:29637308	G/A	cg24425628	chr17:29625626	OMG;NF1	0.41	6.01	0.47	1.93e-8	Hip circumference;
TGCT	cis	rs7552404	0.924	rs3818855	chr1:76198785	C/T	cg03433033	chr1:76189801	ACADM	0.82	9.87	0.66	2.55e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs1008375	1.000	rs28480159	chr4:17685707	A/C	cg10189774	chr4:17578691	LAP3	0.52	4.74	0.39	5.82e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg04944784	chr2:26401820	FAM59B	0.72	5.92	0.47	2.93e-8	Gut microbiome composition (summer);
TGCT	cis	rs9913156	0.707	rs72835625	chr17:4560274	G/A	cg23387401	chr17:4582204	PELP1	0.31	4.57	0.38	1.14e-5	Lymphocyte counts;
TGCT	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg17971929	chr21:40555470	PSMG1	-0.67	-6.15	-0.48	9.72e-9	Cognitive function;
TGCT	cis	rs8177179	0.505	rs1405023	chr3:133481128	T/C	cg08048268	chr3:133502702	NA	0.44	5.16	0.42	9.47e-7	Iron status biomarkers (transferrin levels);
TGCT	cis	rs4273100	0.564	rs10445411	chr17:19265797	C/T	cg03910582	chr17:19030146	GRAPL	-0.51	-6.67	-0.51	7.46e-10	Schizophrenia;
TGCT	cis	rs939563	0.894	rs2302460	chr17:1444702	C/T	cg04957132	chr17:1395371	MYO1C	0.28	4.49	0.37	1.61e-5	Mean platelet volume;
TGCT	cis	rs2985684	0.948	rs4900925	chr14:50012325	A/G	cg04989706	chr14:50066350	PPIL5	0.57	4.86	0.4	3.47e-6	Carotid intima media thickness;
TGCT	cis	rs9611519	0.828	rs4822008	chr22:41539206	C/G	cg03806693	chr22:41940476	POLR3H	-0.67	-6.23	-0.49	6.64e-9	Neuroticism;
TGCT	cis	rs6089584	1.000	rs6142910	chr20:60562181	C/A	cg13770153	chr20:60521292	NA	-0.44	-5.62	-0.45	1.21e-7	Body mass index;
TGCT	cis	rs9650657	0.615	rs11986935	chr8:10691549	T/A	cg16664915	chr8:10907788	XKR6	-0.29	-4.68	-0.39	7.26e-6	Neuroticism;
TGCT	cis	rs9560113	1.000	rs914026	chr13:112182029	G/A	cg14154082	chr13:112174009	NA	0.38	5.01	0.41	1.83e-6	Menarche (age at onset);
TGCT	cis	rs6582630	0.519	rs8189461	chr12:38374870	G/T	cg26384229	chr12:38710491	ALG10B	0.83	7.27	0.55	3.51e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs28735056	0.563	rs12968139	chr18:77685520	A/G	cg20368463	chr18:77673604	PQLC1	-0.47	-5.52	-0.44	1.86e-7	Schizophrenia;
TGCT	cis	rs548987	0.529	rs651578	chr6:25873883	T/C	cg03517284	chr6:25882590	NA	-0.64	-5.44	-0.44	2.77e-7	Homocysteine levels;
TGCT	cis	rs6088580	0.634	rs6142157	chr20:32984172	C/G	cg08999081	chr20:33150536	PIGU	-0.28	-5.51	-0.44	1.96e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs9534288	0.699	rs9567621	chr13:46665814	A/G	cg15192986	chr13:46630673	CPB2	-0.49	-5.83	-0.46	4.48e-8	Blood protein levels;
TGCT	cis	rs9527	0.615	rs17725614	chr10:104685493	G/C	cg15744005	chr10:104629667	AS3MT	-0.45	-5.31	-0.43	4.9e-7	Arsenic metabolism;
TGCT	cis	rs433598	0.894	rs180149	chr16:20676969	G/A	cg16616769	chr16:19727142	IQCK;C16orf88	-0.2	-4.47	-0.37	1.71e-5	Schizophrenia;
TGCT	cis	rs79976124	0.837	rs11751145	chr6:66642039	T/C	cg07460842	chr6:66804631	NA	0.59	5.31	0.43	4.8e-7	Type 2 diabetes;
TGCT	cis	rs7523273	0.568	rs55935450	chr1:208018779	T/A	cg22525895	chr1:207977042	MIR29B2	-0.44	-6.18	-0.49	8.56e-9	Schizophrenia;
TGCT	cis	rs9818758	0.556	rs9814987	chr3:49207849	T/C	cg00383909	chr3:49044727	WDR6	1.28	6.68	0.51	7.04e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs4294134	0.608	rs35357843	chr7:135245068	T/C	cg08396481	chr7:135194601	CNOT4	-0.62	-4.81	-0.4	4.25e-6	Paget's disease;
TGCT	cis	rs60843830	1.000	rs7605824	chr2:280819	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	-0.69	-6.52	-0.51	1.61e-9	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs896854	0.552	rs2515236	chr8:95934907	A/G	cg13393036	chr8:95962371	TP53INP1	0.53	6.41	0.5	2.73e-9	Type 2 diabetes;
TGCT	cis	rs4808199	0.793	rs12459676	chr19:19425141	A/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.75	5.3	0.43	5.06e-7	Nonalcoholic fatty liver disease;
TGCT	cis	rs11621121	0.637	rs4902388	chr14:65792852	A/G	cg04536575	chr14:65016802	C14orf50	-0.64	-4.53	-0.38	1.36e-5	N-glycan levels;
TGCT	cis	rs428668	0.681	rs192193	chr5:150692590	A/G	cg11125805	chr5:150678162	SLC36A3	0.27	6.08	0.48	1.35e-8	Skin aging (microtopography measurement);
TGCT	cis	rs10791097	0.547	rs10791101	chr11:130739133	C/T	cg05962950	chr11:130786565	SNX19	0.93	11.63	0.72	1.37e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9581857	0.512	rs2057523	chr13:28073816	T/C	cg22138327	chr13:27999177	GTF3A	0.85	6.02	0.48	1.87e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs910316	0.737	rs175055	chr14:75488946	T/G	cg11812906	chr14:75593930	NEK9	-0.59	-5.59	-0.45	1.36e-7	Height;
TGCT	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg23188684	chr11:67383651	NA	0.31	4.73	0.39	5.95e-6	Mean corpuscular volume;
TGCT	cis	rs7666738	0.791	rs1559860	chr4:99024422	C/T	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7666738	0.830	rs13113899	chr4:99050422	T/C	cg18180107	chr4:99064573	C4orf37	0.56	5.08	0.41	1.37e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg09323728	chr8:95962352	TP53INP1	-0.54	-6.92	-0.53	2.17e-10	Type 2 diabetes;
TGCT	cis	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs75686122	0.892	rs79348688	chr8:104594128	G/A	cg04852977	chr8:104510831	NA	0.59	4.45	0.37	1.92e-5	Cocaine dependence;
TGCT	cis	rs8177253	0.511	rs9830001	chr3:133433470	A/G	cg08439880	chr3:133502540	NA	0.25	4.49	0.37	1.58e-5	Iron status biomarkers;
TGCT	cis	rs6484504	0.576	rs158136	chr11:31220712	C/T	cg26647111	chr11:31128758	NA	-0.34	-4.62	-0.38	9.36e-6	Red blood cell count;
TGCT	cis	rs6565180	0.507	rs4471699	chr16:30320307	G/T	cg17640201	chr16:30407289	ZNF48	-0.69	-7.07	-0.54	9.81e-11	Tonsillectomy;
TGCT	cis	rs2070433	1.000	rs2070433	chr21:47961386	G/A	cg12379764	chr21:47803548	PCNT	0.53	4.5	0.37	1.54e-5	Lymphocyte counts;
TGCT	cis	rs7666738	0.791	rs7684521	chr4:99071219	A/G	cg18180107	chr4:99064573	C4orf37	0.56	5.0	0.41	1.9e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2153535	0.580	rs915352	chr6:8442766	G/A	cg07606381	chr6:8435919	SLC35B3	0.57	5.25	0.43	6.46e-7	Motion sickness;
TGCT	trans	rs1814175	0.817	rs1794164	chr11:49899610	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.04	-0.53	1.16e-10	Height;
TGCT	cis	rs12530845	0.767	rs7784162	chr7:135305886	G/T	cg23117316	chr7:135346802	PL-5283	-0.55	-5.3	-0.43	5.04e-7	Red blood cell traits;
TGCT	cis	rs950776	0.518	rs12907169	chr15:78825498	G/C	cg06917634	chr15:78832804	PSMA4	0.95	9.52	0.65	1.81e-16	Sudden cardiac arrest;
TGCT	cis	rs1878931	0.507	rs11648783	chr16:3406626	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.64	4.89	0.4	3.01e-6	Body mass index (adult);
TGCT	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg11845111	chr2:191398756	TMEM194B	0.37	5.65	0.45	1.03e-7	Pulse pressure;
TGCT	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg04944784	chr2:26401820	FAM59B	-0.77	-6.49	-0.5	1.84e-9	Gut microbiome composition (summer);
TGCT	cis	rs9486719	0.947	rs2472893	chr6:96870048	G/C	cg06623918	chr6:96969491	KIAA0776	1.01	8.86	0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs7267979	1.000	rs6132835	chr20:25434667	A/G	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7772486	0.790	rs11760	chr6:146205973	G/T	cg05347473	chr6:146136440	FBXO30	0.52	5.0	0.41	1.87e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6121246	0.909	rs6060929	chr20:30345914	C/T	cg13852791	chr20:30311386	BCL2L1	0.8	6.12	0.48	1.15e-8	Mean corpuscular hemoglobin;
TGCT	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg01341218	chr17:43662625	NA	1.09	8.7	0.62	1.73e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs380904	0.926	rs7842979	chr8:144601896	T/G	cg22012530	chr8:144635309	GSDMD	0.47	4.68	0.39	7.27e-6	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs62244186	0.748	rs13319803	chr3:44635461	G/A	cg11003573	chr3:44754125	ZNF502	-0.4	-4.55	-0.38	1.28e-5	Depressive symptoms;
TGCT	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg13683864	chr3:40499215	RPL14	-1.19	-13.2	-0.76	2.17e-25	Renal cell carcinoma;
TGCT	cis	rs617219	0.710	rs10805925	chr5:78539399	A/G	cg09550809	chr5:78407562	BHMT	0.36	4.99	0.41	2.03e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs7647973	0.710	rs9869120	chr3:49624065	T/C	cg05785598	chr3:49045655	WDR6	0.41	4.66	0.39	8.03e-6	Menarche (age at onset);
TGCT	cis	rs11785400	0.793	rs34875149	chr8:143736131	G/A	cg24634471	chr8:143751801	JRK	0.54	5.33	0.43	4.51e-7	Schizophrenia;
TGCT	cis	rs9486719	1.000	rs4262195	chr6:96929475	T/C	cg18709589	chr6:96969512	KIAA0776	-0.72	-5.24	-0.43	6.58e-7	Migraine;Coronary artery disease;
TGCT	cis	rs12497850	0.931	rs1134591	chr3:48972892	C/T	cg07636037	chr3:49044803	WDR6	0.99	10.32	0.68	2.16e-18	Parkinson's disease;
TGCT	cis	rs11785693	0.862	rs73189843	chr8:5000915	C/T	cg26367366	chr8:4980734	NA	0.58	4.59	0.38	1.06e-5	Neuroticism (multi-trait analysis);Neuroticism;
TGCT	cis	rs11722228	1.000	rs6825187	chr4:9915325	T/C	cg00071950	chr4:10020882	SLC2A9	-0.45	-4.58	-0.38	1.11e-5	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs826838	0.967	rs1684415	chr12:39130099	T/C	cg26384229	chr12:38710491	ALG10B	-0.86	-7.7	-0.57	3.65e-12	Heart rate;
TGCT	cis	rs4148883	0.615	rs2187483	chr4:100134103	G/T	cg12011299	chr4:100065546	ADH4	-0.33	-4.89	-0.4	3.06e-6	Alcohol dependence;
TGCT	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg06634786	chr22:41940651	POLR3H	0.85	8.04	0.59	6.2e-13	Vitiligo;
TGCT	cis	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg15556689	chr8:8085844	FLJ10661	0.86	9.14	0.63	1.49e-15	Neuroticism;
TGCT	cis	rs10031466	0.935	rs902909	chr4:189021465	A/G	cg14506195	chr4:188913931	NA	0.24	4.51	0.38	1.49e-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs8020441	0.838	rs72681662	chr14:51163884	G/A	cg04730355	chr14:51134070	SAV1	0.73	6.01	0.47	1.96e-8	Cognitive performance;
TGCT	cis	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg18252515	chr7:66147081	NA	-1.14	-6.81	-0.52	3.76e-10	Diabetic kidney disease;
TGCT	cis	rs12643440	0.538	rs1522079	chr4:17134960	A/G	cg22650099	chr4:17144496	NA	-0.46	-4.66	-0.39	8.14e-6	Metabolite levels (Pyroglutamine);
TGCT	cis	rs7666738	0.830	rs28587201	chr4:98991733	C/T	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs737008	0.960	rs34764020	chr16:11378359	C/T	cg00044050	chr16:11439710	C16orf75	-0.72	-7.32	-0.55	2.69e-11	Obesity-related traits;
TGCT	cis	rs4776059	1.000	rs35372377	chr15:52882281	G/A	cg25063058	chr15:52860530	ARPP19	0.52	4.68	0.39	7.54e-6	Schizophrenia;
TGCT	cis	rs10779751	0.726	rs1205593	chr1:11252716	T/C	cg08854313	chr1:11322531	MTOR	0.87	6.93	0.53	2.02e-10	Body mass index;
TGCT	cis	rs6459788	0.720	rs11768765	chr7:157253133	C/T	cg03453431	chr7:157225567	NA	-0.39	-5.91	-0.47	3.16e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs7178572	0.568	rs12908262	chr15:77493256	G/A	cg15453836	chr15:77711506	NA	-0.44	-4.91	-0.4	2.86e-6	Type 2 diabetes;
TGCT	trans	rs7726839	0.540	rs61731455	chr5:665295	A/G	cg25482853	chr8:67687455	SGK3	1.19	10.53	0.69	6.56e-19	Obesity-related traits;
TGCT	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg11764359	chr7:65958608	NA	-0.55	-4.99	-0.41	1.98e-6	Aortic root size;
TGCT	cis	rs9291683	0.530	rs882223	chr4:9981625	A/C	cg11266682	chr4:10021025	SLC2A9	0.62	8.63	0.61	2.51e-14	Bone mineral density;
TGCT	cis	rs617791	0.508	rs1047464	chr11:65769456	A/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.49	4.49	0.37	1.64e-5	Breast cancer;
TGCT	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg14624950	chr17:62577106	SMURF2	-0.19	-4.46	-0.37	1.81e-5	Prudent dietary pattern;
TGCT	cis	rs6912958	0.712	rs6454638	chr6:88329427	C/T	cg06598631	chr6:88300029	RARS2;ORC3L	0.53	4.87	0.4	3.38e-6	Monocyte percentage of white cells;
TGCT	cis	rs1023500	0.506	rs6002625	chr22:42517689	A/G	cg15557168	chr22:42548783	NA	0.21	5.32	0.43	4.7e-7	Schizophrenia;
TGCT	cis	rs933688	0.639	rs332530	chr5:90789810	G/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.95	8.24	0.59	2.11e-13	Smoking behavior;
TGCT	cis	rs76473307	1.000	rs116642297	chr20:57409750	T/C	cg06163629	chr20:57414884	GNASAS;GNAS	-0.64	-4.5	-0.37	1.54e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs6558174	0.930	rs1038311	chr8:22489247	T/C	cg03733263	chr8:22462867	KIAA1967	0.68	5.47	0.44	2.42e-7	Breast cancer;
TGCT	cis	rs6770219	0.516	rs11926434	chr3:186135861	A/G	cg20306810	chr3:186501757	SNORD2;EIF4A2	0.73	4.45	0.37	1.89e-5	Cerebrospinal T-tau levels;
TGCT	cis	rs11992186	0.570	rs17628941	chr8:8587534	G/C	cg17143192	chr8:8559678	CLDN23	-0.51	-5.01	-0.41	1.82e-6	Neuroticism;
TGCT	cis	rs8180040	0.966	rs11716763	chr3:47518266	C/T	cg27129171	chr3:47204927	SETD2	-0.65	-7.68	-0.57	4.2e-12	Colorectal cancer;
TGCT	cis	rs3824867	0.920	rs9734013	chr11:47451517	G/T	cg20307385	chr11:47447363	PSMC3	-0.69	-5.86	-0.47	3.99e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs7786808	0.508	rs896765	chr7:158182809	G/A	cg01191920	chr7:158217561	PTPRN2	0.35	4.96	0.41	2.26e-6	Obesity-related traits;
TGCT	cis	rs7119	0.604	rs2682921	chr15:77865459	C/T	cg27398640	chr15:77910606	LINGO1	0.27	4.78	0.39	4.92e-6	Type 2 diabetes;
TGCT	cis	rs17767294	0.708	rs72851160	chr6:28067841	T/G	cg08851530	chr6:28072375	NA	1.56	7.21	0.54	4.9e-11	Parkinson's disease;
TGCT	cis	rs4808199	0.948	rs2074300	chr19:19380996	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.69	5.22	0.42	7.2e-7	Nonalcoholic fatty liver disease;
TGCT	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg12311346	chr5:56204834	C5orf35	0.57	6.09	0.48	1.28e-8	Initial pursuit acceleration;
TGCT	cis	rs61931739	0.500	rs6488218	chr12:34452587	T/C	cg06521331	chr12:34319734	NA	-0.28	-4.44	-0.37	1.94e-5	Morning vs. evening chronotype;
TGCT	cis	rs7178572	0.568	rs12909924	chr15:77551445	T/G	cg22256960	chr15:77711686	NA	-0.85	-8.73	-0.62	1.4e-14	Type 2 diabetes;
TGCT	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg11494091	chr17:61959527	GH2	0.6	14.54	0.79	1.46e-28	Prudent dietary pattern;
TGCT	cis	rs909002	0.849	rs1464306	chr1:32076261	T/C	cg11573219	chr1:32083031	HCRTR1	-0.49	-6.41	-0.5	2.73e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs523522	0.962	rs9788155	chr12:120938408	G/A	cg27279351	chr12:120934652	DYNLL1	0.76	6.59	0.51	1.15e-9	High light scatter reticulocyte count;
TGCT	cis	rs617219	0.659	rs13182512	chr5:78573790	A/T	cg23987322	chr5:78407566	BHMT	-0.35	-4.69	-0.39	7.07e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs9902453	0.791	rs3098950	chr17:27998385	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.84	8.29	0.6	1.61e-13	Coffee consumption (cups per day);
TGCT	cis	rs13401104	0.587	rs55801537	chr2:237145481	C/T	cg26422059	chr2:237146110	ASB18	0.57	4.56	0.38	1.19e-5	Educational attainment;
TGCT	cis	rs2050392	0.517	rs619864	chr10:30750950	A/G	cg18806716	chr10:30721971	MAP3K8	0.57	6.95	0.53	1.88e-10	Inflammatory bowel disease;
TGCT	cis	rs9383153	1.000	rs2073518	chr6:16332730	T/C	cg03173502	chr6:15505345	JARID2	0.9	5.41	0.44	3.17e-7	Gambling;
TGCT	cis	rs7914558	1.000	rs4917996	chr10:104925829	A/C	cg04362960	chr10:104952993	NT5C2	0.61	5.45	0.44	2.6e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg02975922	chr3:195473998	MUC4	-0.24	-5.44	-0.44	2.69e-7	Pancreatic cancer;
TGCT	cis	rs2463822	0.669	rs72919475	chr11:62042361	T/A	cg06239285	chr11:62104954	ASRGL1	-0.84	-5.17	-0.42	9.26e-7	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	trans	rs1499614	1.000	rs2707830	chr7:66167645	T/C	cg07424592	chr7:64974309	NA	1.35	8.11	0.59	4.14e-13	Gout;
TGCT	cis	rs797680	0.856	rs687394	chr1:93713917	G/A	cg17826107	chr1:92977322	EVI5	0.24	5.29	0.43	5.47e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs6988636	1.000	rs11988157	chr8:124194740	A/G	cg27053337	chr8:124217698	FAM83A	-0.61	-5.17	-0.42	9.04e-7	Urinary uromodulin levels;
TGCT	cis	rs9302065	0.565	rs2992910	chr13:95962216	T/A	cg26751094	chr13:95954534	ABCC4	-0.4	-6.74	-0.52	5.33e-10	Blood metabolite levels;
TGCT	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg07061783	chr6:25882402	NA	0.72	7.44	0.56	1.44e-11	Blood metabolite levels;
TGCT	cis	rs9810089	0.934	rs1153877	chr3:136004925	C/T	cg12473912	chr3:136751656	NA	0.35	4.98	0.41	2.05e-6	Gestational age at birth (child effect);
TGCT	cis	rs8020441	0.686	rs6572687	chr14:51165438	G/C	cg04730355	chr14:51134070	SAV1	0.7	5.79	0.46	5.45e-8	Cognitive performance;
TGCT	cis	rs225245	0.782	rs321601	chr17:33892087	A/C	cg05299278	chr17:33885742	SLFN14	-0.21	-4.73	-0.39	6.08e-6	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
TGCT	trans	rs208520	0.661	rs150263	chr6:66777620	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-10.86	-0.7	1.03e-19	Exhaled nitric oxide output;
TGCT	trans	rs4824093	0.610	rs3761496	chr22:50246466	T/C	cg09872104	chr7:134855509	C7orf49	-0.96	-7.87	-0.58	1.49e-12	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg20607798	chr8:58055168	NA	0.5	4.66	0.39	8.04e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2688608	0.967	rs9971038	chr10:75661149	C/T	cg02947784	chr10:75434997	AGAP5	0.16	4.51	0.38	1.46e-5	Inflammatory bowel disease;
TGCT	cis	rs10206020	0.921	rs72776300	chr2:1571152	A/G	cg12573674	chr2:1569213	NA	-0.49	-5.3	-0.43	5.1e-7	IgG glycosylation;
TGCT	cis	rs7615952	0.736	rs9866347	chr3:125669925	C/T	cg05084668	chr3:125655381	ALG1L	-0.77	-5.24	-0.43	6.74e-7	Blood pressure (smoking interaction);
TGCT	cis	rs10510102	0.872	rs11200268	chr10:123692176	C/T	cg23691251	chr10:123688108	ATE1	-0.58	-4.58	-0.38	1.11e-5	Breast cancer;
TGCT	cis	rs2832077	0.506	rs2832093	chr21:30164855	C/T	cg24692254	chr21:30365293	RNF160	-0.59	-5.22	-0.42	7.35e-7	Cognitive test performance;
TGCT	cis	rs9583531	0.527	rs2391866	chr13:111363294	A/T	cg24331049	chr13:111365604	ING1	0.77	7.3	0.55	2.96e-11	Coronary artery disease;
TGCT	cis	rs28595532	0.920	rs114696063	chr4:119760624	T/A	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs8180040	0.966	rs56351005	chr3:47430186	G/T	cg27129171	chr3:47204927	SETD2	-0.64	-7.39	-0.55	1.89e-11	Colorectal cancer;
TGCT	cis	rs35146811	0.735	rs1138417	chr7:99807146	C/G	cg04778012	chr7:99775508	STAG3;GPC2	-0.33	-4.76	-0.39	5.35e-6	Coronary artery disease;
TGCT	cis	rs3741404	0.620	rs2236647	chr11:63964605	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.75	-7.6	-0.56	6.31e-12	Platelet count;
TGCT	trans	rs1814175	0.817	rs10769618	chr11:49822336	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.35	-0.55	2.38e-11	Height;
TGCT	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg13395646	chr4:1353034	KIAA1530	-0.38	-4.71	-0.39	6.41e-6	Longevity;
TGCT	cis	rs9467773	1.000	rs9467773	chr6:26498426	A/G	cg15659132	chr6:26577336	NA	0.84	11.93	0.73	2.59e-22	Intelligence (multi-trait analysis);
TGCT	cis	rs2749592	0.550	rs4934881	chr10:37914346	A/C	cg25427524	chr10:38739819	LOC399744	0.32	5.79	0.46	5.38e-8	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs4711350	0.906	rs10947446	chr6:33791998	G/A	cg18005901	chr6:33739558	LEMD2	-0.56	-5.47	-0.44	2.43e-7	Schizophrenia;
TGCT	cis	rs617219	0.737	rs12659709	chr5:78458257	C/G	cg09550809	chr5:78407562	BHMT	0.4	5.67	0.45	9.51e-8	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg18876405	chr7:65276391	NA	-0.33	-4.99	-0.41	1.98e-6	Aortic root size;
TGCT	cis	rs7819412	0.645	rs10156356	chr8:11046209	T/C	cg21775007	chr8:11205619	TDH	-0.52	-4.73	-0.39	5.92e-6	Triglycerides;
TGCT	cis	rs908922	0.676	rs6674451	chr1:152531054	C/T	cg20991723	chr1:152506922	NA	0.45	6.05	0.48	1.6e-8	Hair morphology;
TGCT	cis	rs10751667	0.666	rs7105477	chr11:964271	C/G	cg06064525	chr11:970664	AP2A2	-0.35	-8.12	-0.59	3.98e-13	Alzheimer's disease (late onset);
TGCT	cis	rs1797081	0.967	rs780632	chr10:16861400	A/G	cg23933602	chr10:16859644	RSU1	-1.03	-12.13	-0.74	8.13e-23	Platelet distribution width;
TGCT	cis	rs3816788	0.837	rs6557640	chr8:21771731	A/T	cg17168535	chr8:21777572	XPO7	0.77	7.4	0.55	1.81e-11	Lung cancer in ever smokers;
TGCT	cis	rs12497850	1.000	rs12497850	chr3:48748989	G/T	cg06212747	chr3:49208901	KLHDC8B	0.62	5.94	0.47	2.65e-8	Parkinson's disease;
TGCT	trans	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg06636001	chr8:8085503	FLJ10661	0.8	7.32	0.55	2.69e-11	Retinal vascular caliber;
TGCT	trans	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg21659725	chr3:3221576	CRBN	0.76	9.03	0.63	2.74e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs951366	0.870	rs3747973	chr1:205677148	A/G	cg14159672	chr1:205819179	PM20D1	0.43	4.56	0.38	1.19e-5	Menarche (age at onset);
TGCT	cis	rs6684514	1.000	rs12038481	chr1:156284815	T/C	cg20302342	chr1:156215951	PAQR6	0.35	4.74	0.39	5.77e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs7940866	0.834	rs10894302	chr11:130861994	C/T	cg05962950	chr11:130786565	SNX19	0.73	7.02	0.53	1.27e-10	Schizophrenia;
TGCT	cis	rs758129	0.501	rs2351002	chr15:89869329	C/G	cg24365117	chr15:89879190	POLG	0.34	4.46	0.37	1.81e-5	Schizophrenia;
TGCT	cis	rs11895698	1	rs11895698	chr2:239338495	C/T	cg08773314	chr2:239334832	ASB1	-0.46	-4.49	-0.37	1.64e-5	Chronotype;
TGCT	cis	rs9858542	1.000	rs9822268	chr3:49719729	G/A	cg03060546	chr3:49711283	APEH	-0.67	-6.09	-0.48	1.28e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs6964587	1.000	rs7781066	chr7:91691946	G/T	cg22709100	chr7:91322751	NA	0.28	4.56	0.38	1.19e-5	Breast cancer;
TGCT	cis	rs854765	0.583	rs7213225	chr17:17869111	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	7.69	0.57	3.98e-12	Total body bone mineral density;
TGCT	cis	rs7772486	0.597	rs2485631	chr6:146190077	G/C	cg05347473	chr6:146136440	FBXO30	0.67	6.25	0.49	6.04e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10986311	0.962	rs2068165	chr9:127088350	G/A	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.19	-4.44	-0.37	1.97e-5	Vitiligo;
TGCT	cis	rs3947	0.950	rs1293331	chr8:11698436	C/T	cg02840367	chr8:11660030	FDFT1	0.91	6.65	0.51	8.45e-10	Blood protein levels;
TGCT	cis	rs7666738	0.830	rs10034619	chr4:98970067	G/C	cg05340658	chr4:99064831	C4orf37	0.5	5.84	0.46	4.35e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs911263	0.961	rs1950897	chr14:68760141	C/T	cg18825221	chr14:68749962	RAD51L1	0.28	5.47	0.44	2.36e-7	Primary biliary cholangitis;
TGCT	cis	rs6121246	0.909	rs6060979	chr20:30417522	C/T	cg18721089	chr20:30220636	NA	-0.45	-5.04	-0.41	1.63e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs1981331	0.609	rs7282611	chr21:48043297	C/A	cg23283320	chr21:48055893	PRMT2	1.35	6.43	0.5	2.51e-9	Cerebrospinal fluid t-tau:AB1-42 ratio;
TGCT	cis	rs933688	1.000	rs2367353	chr5:90686568	G/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.0	9.55	0.65	1.57e-16	Smoking behavior;
TGCT	cis	rs7267979	1.000	rs6050630	chr20:25430745	A/G	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg27523141	chr10:43048294	ZNF37B	0.74	8.34	0.6	1.22e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs12478296	1.000	rs55732177	chr2:243040006	C/T	cg06360820	chr2:242988706	NA	-0.61	-4.66	-0.39	8.13e-6	Obesity-related traits;
TGCT	cis	rs4851266	1.000	rs11687241	chr2:100824595	A/G	cg22139774	chr2:100720529	AFF3	-0.36	-5.4	-0.44	3.26e-7	Educational attainment;
TGCT	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg17971929	chr21:40555470	PSMG1	-0.7	-6.32	-0.49	4.38e-9	Cognitive function;
TGCT	cis	rs644799	0.930	rs631099	chr11:95563482	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.82	8.63	0.61	2.52e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs17376456	0.877	rs17374627	chr5:93296306	C/T	cg21475434	chr5:93447410	FAM172A	0.64	4.66	0.39	8.1e-6	Diabetic retinopathy;
TGCT	cis	rs2836950	0.502	rs12627205	chr21:40630027	C/T	cg11890956	chr21:40555474	PSMG1	-0.71	-6.94	-0.53	1.94e-10	Menarche (age at onset);
TGCT	cis	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg06636001	chr8:8085503	FLJ10661	0.78	7.3	0.55	3.04e-11	Mood instability;
TGCT	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg11905131	chr22:24372483	LOC391322	-0.95	-11.1	-0.71	2.66e-20	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs644799	1.000	rs534497	chr11:95562868	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.82	8.63	0.61	2.52e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs950776	0.616	rs3743077	chr15:78894896	C/T	cg06917634	chr15:78832804	PSMA4	0.65	5.29	0.43	5.28e-7	Sudden cardiac arrest;
TGCT	cis	rs9549367	0.789	rs6577034	chr13:113879900	T/C	cg18105134	chr13:113819100	PROZ	-0.34	-5.67	-0.45	9.36e-8	Platelet distribution width;
TGCT	cis	rs67072384	1.000	rs7122017	chr11:72448558	C/G	cg03713592	chr11:72463424	ARAP1	-0.94	-4.8	-0.4	4.41e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs9928842	0.823	rs889514	chr16:75272512	A/G	cg09066997	chr16:75300724	BCAR1	0.27	4.86	0.4	3.45e-6	Alcoholic chronic pancreatitis;
TGCT	cis	rs208520	0.661	rs4710566	chr6:66848538	G/A	cg07460842	chr6:66804631	NA	-0.92	-9.58	-0.65	1.29e-16	Exhaled nitric oxide output;
TGCT	cis	rs71435601	0.628	rs560522	chr2:21382363	A/C	cg25035485	chr2:21266500	APOB	0.51	4.48	0.37	1.64e-5	Cholesterol, total;
TGCT	cis	rs902774	0.597	rs7299694	chr12:53352572	A/C	cg25025879	chr12:53359317	NA	-0.44	-4.87	-0.4	3.39e-6	Prostate cancer;
TGCT	cis	rs7432375	0.579	rs10935199	chr3:136563535	G/C	cg12473912	chr3:136751656	NA	0.33	4.6	0.38	1.01e-5	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4862307	0.733	rs28631204	chr4:184996363	T/G	cg06737308	chr4:185021514	ENPP6	0.32	4.55	0.38	1.28e-5	Serum dimethylarginine levels (asymmetric/symetric ratio);
TGCT	cis	rs1371867	0.846	rs1660316	chr8:101333049	T/C	cg06636551	chr8:101224915	SPAG1	-0.48	-6.52	-0.51	1.62e-9	Atrioventricular conduction;
TGCT	cis	rs4523957	0.620	rs8064309	chr17:2059961	T/C	cg16513277	chr17:2031491	SMG6	-0.2	-4.64	-0.38	8.83e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs3540	0.960	rs2238325	chr15:91011262	C/T	cg22089800	chr15:90895588	ZNF774	-0.76	-7.03	-0.53	1.21e-10	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs3784262	0.740	rs12917536	chr15:58288247	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.42	-5.95	-0.47	2.58e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs9787249	0.957	rs7547787	chr1:40220806	C/T	cg19912559	chr1:40204330	PPIE	0.49	5.61	0.45	1.26e-7	Blood protein levels;
TGCT	cis	rs6582630	0.560	rs4882325	chr12:38510037	C/T	cg26384229	chr12:38710491	ALG10B	-0.55	-4.91	-0.4	2.86e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs2066819	1.000	rs57137641	chr12:56741228	G/A	cg26714650	chr12:56694279	CS	-1.36	-5.95	-0.47	2.56e-8	Psoriasis vulgaris;
TGCT	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	15.93	0.82	8.93e-32	Prudent dietary pattern;
TGCT	cis	rs12908161	0.920	rs35758837	chr15:85311382	C/T	cg11189052	chr15:85197271	WDR73	0.71	5.85	0.47	4.04e-8	Schizophrenia;
TGCT	trans	rs9929218	0.551	rs3785134	chr16:68728938	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.57	7.45	0.56	1.41e-11	Colorectal cancer;
TGCT	cis	rs2486288	0.656	rs11632752	chr15:45551140	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.46	-5.59	-0.45	1.38e-7	Glomerular filtration rate;
TGCT	cis	rs916888	0.821	rs415430	chr17:44859144	C/T	cg16520312	chr17:43971471	MAPT;LOC100128977	0.57	4.86	0.4	3.45e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs9467773	0.836	rs1624440	chr6:26433329	G/A	cg26531700	chr6:26746687	NA	-0.5	-4.89	-0.4	3e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs11578119	0.866	rs10919375	chr1:170349137	A/G	cg09767346	chr1:170501363	GORAB	0.61	4.57	0.38	1.16e-5	Male-pattern baldness;
TGCT	cis	rs9818758	0.607	rs35108630	chr3:49088356	T/A	cg07636037	chr3:49044803	WDR6	-1.04	-5.16	-0.42	9.65e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs17376456	0.877	rs10076052	chr5:93317762	C/T	cg25358565	chr5:93447407	FAM172A	0.98	8.39	0.6	9.01e-14	Diabetic retinopathy;
TGCT	cis	rs116095464	0.558	rs34629844	chr5:200829	A/G	cg22857025	chr5:266934	NA	-0.33	-6.25	-0.49	6.09e-9	Breast cancer;
TGCT	cis	rs514406	0.505	rs395169	chr1:53174071	G/A	cg08859206	chr1:53392774	SCP2	-0.35	-4.99	-0.41	2.03e-6	Monocyte count;
TGCT	cis	rs62244186	0.541	rs9859879	chr3:44840166	G/A	cg02073558	chr3:44770973	ZNF501	0.69	7.01	0.53	1.37e-10	Depressive symptoms;
TGCT	cis	rs10057188	1.000	rs12697889	chr5:77870700	G/A	cg06873401	chr5:77792105	LHFPL2	-0.22	-4.46	-0.37	1.79e-5	Pulse pressure;
TGCT	cis	rs3617	0.625	rs11922961	chr3:52868610	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	0.49	4.77	0.39	5.04e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7267979	0.833	rs4619688	chr20:25244101	C/G	cg03522245	chr20:25566470	NINL	0.6	6.58	0.51	1.21e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11190604	1.000	rs4919470	chr10:102298920	C/T	cg23241863	chr10:102295624	HIF1AN	0.67	4.8	0.4	4.46e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg08048268	chr3:133502702	NA	-0.65	-9.83	-0.66	3.21e-17	Iron status biomarkers;
TGCT	cis	rs916888	0.821	rs70602	chr17:44859715	T/C	cg15921436	chr17:44337874	NA	-0.51	-6.96	-0.53	1.77e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	trans	rs1005277	0.522	rs7090858	chr10:38003670	A/C	cg17830980	chr10:43048298	ZNF37B	0.67	7.5	0.56	1.06e-11	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7589728	0.563	rs12479338	chr2:88444513	C/T	cg04511125	chr2:88470314	THNSL2	0.79	6.55	0.51	1.37e-9	Plasma clusterin levels;
TGCT	cis	rs877282	0.891	rs11253406	chr10:796297	G/A	cg17470449	chr10:769945	NA	0.3	4.82	0.4	4.14e-6	Uric acid levels;
TGCT	cis	rs4862750	0.914	rs10027250	chr4:187873460	T/C	cg11301795	chr4:187892539	NA	-0.34	-5.14	-0.42	1.06e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7552404	1.000	rs7534754	chr1:76185308	G/A	cg22875332	chr1:76189707	ACADM	0.79	9.69	0.66	7.25e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9527	0.590	rs1935323	chr10:104877035	T/C	cg04362960	chr10:104952993	NT5C2	0.68	5.82	0.46	4.81e-8	Arsenic metabolism;
TGCT	cis	rs854765	0.547	rs4365348	chr17:17912548	C/T	cg09796270	chr17:17721594	SREBF1	0.25	5.03	0.41	1.71e-6	Total body bone mineral density;
TGCT	cis	rs713587	0.691	rs754536	chr2:25176200	C/T	cg15423357	chr2:25149977	NA	-0.46	-4.52	-0.38	1.41e-5	Body mass index in non-asthmatics;
TGCT	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7727544	0.660	rs272886	chr5:131665840	T/C	cg14196790	chr5:131705035	SLC22A5	0.32	4.53	0.38	1.34e-5	Blood metabolite levels;
TGCT	cis	rs1670533	1.000	rs10084889	chr4:1053815	G/A	cg27284194	chr4:1044797	NA	0.67	5.77	0.46	5.9e-8	Recombination rate (females);
TGCT	cis	rs9457247	1.000	rs389946	chr6:167407268	T/C	cg23791538	chr6:167370224	RNASET2	-0.49	-4.96	-0.41	2.26e-6	Crohn's disease;
TGCT	cis	rs8103278	0.507	rs10401971	chr19:46261982	C/T	cg14061069	chr19:46274453	DMPK	0.63	10.79	0.7	1.51e-19	Coronary artery disease;
TGCT	cis	rs6964587	1.000	rs10234071	chr7:91645152	C/G	cg17063962	chr7:91808500	NA	-0.92	-10.29	-0.68	2.52e-18	Breast cancer;
TGCT	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg07507251	chr3:52567010	NT5DC2	0.48	6.95	0.53	1.82e-10	Bipolar disorder;
TGCT	cis	rs1538970	0.924	rs4660858	chr1:45936351	G/A	cg05343316	chr1:45956843	TESK2	0.74	6.09	0.48	1.28e-8	Platelet count;
TGCT	cis	rs589448	0.535	rs12423794	chr12:69713018	G/A	cg14784868	chr12:69753453	YEATS4	0.75	8.07	0.59	5.17e-13	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.34	0.43	4.23e-7	Prudent dietary pattern;
TGCT	cis	rs992157	1.000	rs992157	chr2:219154781	A/G	cg00012203	chr2:219082015	ARPC2	-0.74	-7.91	-0.58	1.23e-12	Colorectal cancer;
TGCT	cis	rs8028182	0.525	rs9920028	chr15:75927717	G/A	cg20655648	chr15:75932815	IMP3	0.54	4.44	0.37	1.99e-5	Sudden cardiac arrest;
TGCT	cis	rs7937682	0.883	rs553632	chr11:111462897	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.99	-10.02	-0.67	1.16e-17	Primary sclerosing cholangitis;
TGCT	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.65	-6.34	-0.49	3.92e-9	Prostate cancer;
TGCT	cis	rs7635838	0.785	rs904475	chr3:11535417	G/A	cg00170343	chr3:11313890	ATG7	0.69	6.42	0.5	2.58e-9	HDL cholesterol;
TGCT	cis	rs35160687	0.901	rs12620833	chr2:86472870	T/C	cg12542933	chr2:85804724	VAMP8	0.41	4.88	0.4	3.25e-6	Night sleep phenotypes;
TGCT	cis	rs9318086	0.712	rs9510916	chr13:24442789	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.77	8.28	0.6	1.69e-13	Myopia (pathological);
TGCT	cis	rs2239547	0.563	rs4687699	chr3:53101224	C/T	cg10802521	chr3:52805072	NEK4	-0.59	-5.46	-0.44	2.45e-7	Schizophrenia;
TGCT	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg13393036	chr8:95962371	TP53INP1	-0.62	-8.55	-0.61	3.83e-14	Type 2 diabetes;
TGCT	cis	rs3617	0.625	rs6445541	chr3:52880128	G/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.48	-4.69	-0.39	7.05e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2658782	0.901	rs7116173	chr11:93222311	C/T	cg26827247	chr11:93063208	CCDC67	0.57	4.45	0.37	1.9e-5	Pulmonary function decline;
TGCT	cis	rs3796352	0.892	rs2581807	chr3:53088844	G/A	cg07884673	chr3:53033167	SFMBT1	-0.58	-6.25	-0.49	5.99e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg08219700	chr8:58056026	NA	0.29	4.44	0.37	1.93e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs28595532	0.702	rs72670252	chr4:119337546	A/C	cg11846333	chr4:119757529	SEC24D	0.72	4.51	0.38	1.48e-5	Cannabis dependence symptom count;
TGCT	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg06873352	chr17:61820015	STRADA	-0.49	-5.47	-0.44	2.33e-7	Prudent dietary pattern;
TGCT	cis	rs909674	0.514	rs7423	chr22:39781429	C/T	cg01416388	chr22:39784598	NA	-0.64	-6.48	-0.5	1.95e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg11890956	chr21:40555474	PSMG1	-0.78	-7.37	-0.55	2.08e-11	Cognitive function;
TGCT	cis	rs6714710	0.603	rs2278700	chr2:98427382	T/C	cg26665480	chr2:98280029	ACTR1B	0.66	6.24	0.49	6.33e-9	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs11578119	0.933	rs10919423	chr1:170480531	C/T	cg09767346	chr1:170501363	GORAB	0.66	5.29	0.43	5.27e-7	Male-pattern baldness;
TGCT	cis	rs6964587	0.933	rs6465350	chr7:91768615	G/A	cg22709100	chr7:91322751	NA	0.29	4.68	0.39	7.29e-6	Breast cancer;
TGCT	cis	rs9911578	1.000	rs12453049	chr17:56611372	C/T	cg05425664	chr17:57184151	TRIM37	0.63	6.26	0.49	5.86e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs6921919	0.583	rs2071965	chr6:28403225	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.53	-5.12	-0.42	1.15e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.36	0.55	2.25e-11	Prudent dietary pattern;
TGCT	cis	rs611744	0.868	rs612722	chr8:109194850	C/T	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg11494091	chr17:61959527	GH2	-0.61	-16.1	-0.82	3.53e-32	Prudent dietary pattern;
TGCT	cis	rs7095607	0.813	rs4584466	chr10:69933132	C/G	cg18986048	chr10:69913749	MYPN	0.44	5.02	0.41	1.73e-6	Lung function (FVC);
TGCT	cis	rs362296	0.698	rs3095083	chr4:3263499	G/A	cg06533319	chr4:3265114	C4orf44	0.23	4.64	0.38	8.9e-6	Parental longevity (mother's age at death);
TGCT	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg23758822	chr17:41437982	NA	0.73	7.03	0.53	1.2e-10	Menopause (age at onset);
TGCT	cis	rs12900413	0.603	rs4448912	chr15:90299690	G/A	cg24249390	chr15:90295951	MESP1	-0.3	-5.2	-0.42	8.04e-7	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs250677	0.687	rs36044	chr5:148441128	T/C	cg18129178	chr5:148520854	ABLIM3	-0.43	-6.29	-0.49	5.05e-9	Breast cancer;
TGCT	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg03609598	chr5:56110824	MAP3K1	-0.58	-4.7	-0.39	6.72e-6	Initial pursuit acceleration;
TGCT	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg27588902	chr6:42928151	GNMT	0.56	6.93	0.53	2.08e-10	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs4780401	0.632	rs7192366	chr16:11835209	C/G	cg01061890	chr16:11836724	TXNDC11	-0.63	-6.09	-0.48	1.32e-8	Rheumatoid arthritis;
TGCT	cis	rs7666738	0.830	rs10025174	chr4:98914172	A/G	cg05340658	chr4:99064831	C4orf37	0.54	6.51	0.5	1.7e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2832191	0.935	rs67287920	chr21:30523519	C/A	cg08807101	chr21:30365312	RNF160	-0.52	-4.87	-0.4	3.27e-6	Dental caries;
TGCT	cis	rs9916302	0.861	rs2338801	chr17:37490780	G/T	cg07936489	chr17:37558343	FBXL20	0.65	5.08	0.41	1.36e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs2739330	1.000	rs2739330	chr22:24295286	T/C	cg15242686	chr22:24348715	GSTTP1	0.43	5.95	0.47	2.57e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs17767294	0.708	rs72851105	chr6:28036408	G/T	cg08851530	chr6:28072375	NA	1.56	7.22	0.54	4.47e-11	Parkinson's disease;
TGCT	cis	rs56334439	0.665	rs28716988	chr3:60108414	G/C	cg17894779	chr3:60066405	FHIT	-0.37	-4.94	-0.41	2.48e-6	Myringotomy;
TGCT	cis	rs36051895	0.664	rs9695933	chr9:5153104	C/T	cg02405213	chr9:5042618	JAK2	-0.73	-9.46	-0.65	2.54e-16	Pediatric autoimmune diseases;
TGCT	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg12310025	chr6:25882481	NA	-0.64	-6.66	-0.51	7.99e-10	Blood metabolite levels;
TGCT	cis	rs909674	0.775	rs4821896	chr22:39833437	T/C	cg02038168	chr22:39784481	NA	-0.74	-5.58	-0.45	1.41e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	trans	rs7819412	0.668	rs2409721	chr8:11038244	A/T	cg15556689	chr8:8085844	FLJ10661	-0.74	-6.67	-0.51	7.51e-10	Triglycerides;
TGCT	cis	rs9682041	0.660	rs13089074	chr3:170113481	G/A	cg11886554	chr3:170076028	SKIL	0.62	4.82	0.4	4.11e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg03806693	chr22:41940476	POLR3H	-1.13	-13.26	-0.77	1.59e-25	Vitiligo;
TGCT	cis	rs9329289	0.926	rs10903784	chr10:2541943	G/T	cg15501526	chr10:2543763	NA	-0.42	-5.27	-0.43	5.91e-7	Age-related hearing impairment;
TGCT	trans	rs7618501	0.699	rs9862795	chr3:49915506	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.89	9.83	0.66	3.23e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs3809566	1.000	rs4774471	chr15:63332645	A/T	cg00520135	chr15:63333846	TPM1	0.45	5.55	0.45	1.65e-7	Platelet count;
TGCT	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	1.01	12.49	0.75	1.1e-23	Menarche (age at onset);
TGCT	cis	rs12497850	0.865	rs13072911	chr3:48962128	T/G	cg05785598	chr3:49045655	WDR6	0.36	4.75	0.39	5.46e-6	Parkinson's disease;
TGCT	cis	rs1865760	0.865	rs9393678	chr6:25945819	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.64	6.31	0.49	4.56e-9	Height;
TGCT	cis	rs4727027	0.866	rs10435245	chr7:148816081	C/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	4.64	0.38	8.88e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs12681288	0.862	rs2600487	chr8:1016903	C/T	cg06709756	chr8:1339049	NA	-0.23	-4.54	-0.38	1.3e-5	Schizophrenia;
TGCT	cis	rs77861329	1.000	rs9811707	chr3:52190657	G/A	cg08692210	chr3:52188851	WDR51A	0.83	4.64	0.38	8.71e-6	Macrophage inflammatory protein 1b levels;
TGCT	cis	rs4242434	0.889	rs11785755	chr8:22453223	C/A	cg03733263	chr8:22462867	KIAA1967	1.1	17.97	0.85	2.57e-36	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs9952991	0.941	rs9952749	chr18:12780456	A/G	cg09945482	chr18:12777974	NA	0.5	4.75	0.39	5.61e-6	Inflammatory skin disease;
TGCT	cis	rs79149102	0.579	rs7172989	chr15:75295905	C/T	cg09165964	chr15:75287851	SCAMP5	-1.04	-5.71	-0.46	7.93e-8	Lung cancer;
TGCT	cis	rs7586879	0.616	rs10203386	chr2:25136866	T/A	cg01884057	chr2:25150051	NA	0.35	6.95	0.53	1.81e-10	Body mass index;
TGCT	cis	rs6912958	0.525	rs586771	chr6:88064971	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.68	6.88	0.53	2.68e-10	Monocyte percentage of white cells;
TGCT	cis	rs1990950	0.654	rs2161398	chr5:156838886	C/A	cg25387487	chr5:157003181	ADAM19	0.29	4.54	0.38	1.29e-5	Lung function (FEV1/FVC);
TGCT	cis	rs79349575	0.721	rs2291725	chr17:47039132	T/C	cg00947319	chr17:47005597	UBE2Z	-0.2	-4.5	-0.37	1.53e-5	Type 2 diabetes;
TGCT	cis	rs1371867	0.846	rs1660351	chr8:101275034	C/T	cg06636551	chr8:101224915	SPAG1	-0.49	-6.83	-0.52	3.32e-10	Atrioventricular conduction;
TGCT	trans	rs2727020	0.595	rs11040416	chr11:49566429	C/T	cg03929089	chr4:120376271	NA	-0.77	-9.31	-0.64	5.96e-16	Coronary artery disease;
TGCT	cis	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg18252515	chr7:66147081	NA	1.25	7.75	0.57	2.92e-12	Diabetic kidney disease;
TGCT	cis	rs56104184	0.725	rs1466896	chr19:49385253	C/G	cg15549821	chr19:49342101	PLEKHA4	-0.73	-9.15	-0.63	1.47e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	trans	rs9388451	0.872	rs2008027	chr6:126052359	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.74	-8.1	-0.59	4.31e-13	Brugada syndrome;
TGCT	cis	rs1865760	0.786	rs2164487	chr6:25950800	A/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.64	6.31	0.49	4.56e-9	Height;
TGCT	cis	rs1691799	0.899	rs1177555	chr12:66727568	A/G	cg16791601	chr12:66731901	HELB	-0.28	-6.17	-0.48	8.77e-9	White blood cell count (basophil);
TGCT	cis	rs2075371	1.000	rs2598285	chr7:133971153	A/T	cg11752832	chr7:134001865	SLC35B4	0.66	6.11	0.48	1.19e-8	Mean platelet volume;
TGCT	cis	rs35306767	0.761	rs11253560	chr10:1047226	T/G	cg18964960	chr10:1102726	WDR37	0.78	5.46	0.44	2.45e-7	Eosinophil percentage of granulocytes;
TGCT	cis	rs1577917	0.958	rs1838955	chr6:86565449	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.29	-0.43	5.34e-7	Response to antipsychotic treatment;
TGCT	cis	rs2739330	1.000	rs2739330	chr22:24295286	T/C	cg24846343	chr22:24311635	DDTL	0.22	5.66	0.45	1e-7	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6714710	0.603	rs7583868	chr2:98588372	C/A	cg26665480	chr2:98280029	ACTR1B	0.63	5.98	0.47	2.19e-8	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs644799	0.526	rs693172	chr11:95636618	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.49	4.93	0.4	2.63e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs3008870	1.000	rs3008858	chr1:67390416	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.1	12.09	0.74	1.01e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs2075371	0.897	rs1643033	chr7:134004662	T/C	cg11752832	chr7:134001865	SLC35B4	0.81	7.72	0.57	3.33e-12	Mean platelet volume;
TGCT	cis	rs4851254	0.618	rs12996621	chr2:100646137	A/G	cg22139774	chr2:100720529	AFF3	-0.47	-5.18	-0.42	8.65e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs3008870	0.958	rs34367328	chr1:67445321	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-1.1	-11.8	-0.73	5.15e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs9467773	1.000	rs4713006	chr6:26519872	A/G	cg05738196	chr6:26577821	NA	0.88	12.5	0.75	1.03e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs17433780	0.860	rs10922545	chr1:89492201	C/T	cg09516651	chr1:89888402	LOC400759	0.26	4.48	0.37	1.67e-5	Carotid intima media thickness;
TGCT	cis	rs9929218	0.508	rs1559366	chr16:68799611	A/G	cg01251360	chr16:68772225	CDH1	-0.25	-4.5	-0.37	1.53e-5	Colorectal cancer;
TGCT	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg15595755	chr5:1867978	NA	0.45	5.28	0.43	5.66e-7	Cardiovascular disease risk factors;
TGCT	cis	rs7511006	1.000	rs7511006	chr22:50676259	T/C	cg08875078	chr22:50639485	SELO	0.51	4.81	0.4	4.23e-6	Obesity-related traits;
TGCT	cis	rs9611565	0.512	rs4820446	chr22:42215684	C/T	cg17554472	chr22:41940697	POLR3H	-0.45	-4.67	-0.39	7.81e-6	Vitiligo;
TGCT	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg07507251	chr3:52567010	NT5DC2	0.47	6.6	0.51	1.05e-9	Bipolar disorder;
TGCT	cis	rs4654899	0.802	rs4654724	chr1:21177210	C/T	cg01072550	chr1:21505969	NA	-0.45	-6.76	-0.52	4.8e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs4319547	0.661	rs10773172	chr12:122939655	G/A	cg23029597	chr12:123009494	RSRC2	-0.27	-4.44	-0.37	1.99e-5	Body mass index;
TGCT	cis	rs3796352	1.000	rs13078971	chr3:53103645	G/C	cg27565382	chr3:53032988	SFMBT1	0.45	4.76	0.39	5.2e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs6450176	0.638	rs16881969	chr5:53300748	A/G	ch.5.1024479R	chr5:53302184	ARL15	0.63	4.68	0.39	7.44e-6	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs682748	0.846	rs60388951	chr5:17134319	C/G	cg23987134	chr5:17158319	LOC285696	-0.21	-5.11	-0.42	1.17e-6	Hippocampal atrophy;
TGCT	cis	rs8013055	0.796	rs28662250	chr14:105996341	C/G	cg19700328	chr14:106028568	NA	-0.48	-5.13	-0.42	1.09e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.32	-0.43	4.69e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs75557865	1	rs75557865	chr3:121652141	G/A	cg20356878	chr3:121714668	ILDR1	0.51	6.56	0.51	1.33e-9	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs2535633	0.631	rs2245424	chr3:53003021	G/C	cg11645453	chr3:52864694	ITIH4	-0.27	-5.03	-0.41	1.68e-6	Body mass index;
TGCT	cis	rs35883536	1.000	rs12239531	chr1:101085661	A/G	cg06223162	chr1:101003688	GPR88	0.31	4.89	0.4	3.07e-6	Monocyte count;
TGCT	cis	rs595982	0.559	rs117227130	chr19:49367959	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.69	-9.25	-0.64	8.09e-16	Red cell distribution width;
TGCT	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg06896619	chr17:61851486	DDX42;CCDC47	-0.51	-4.96	-0.41	2.24e-6	Prudent dietary pattern;
TGCT	cis	rs881375	1.000	rs10117059	chr9:123653477	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	5.43	0.44	2.9e-7	Rheumatoid arthritis;
TGCT	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	16.07	0.82	4.21e-32	Prudent dietary pattern;
TGCT	cis	rs11264213	0.551	rs11263852	chr1:36554442	G/C	cg27506609	chr1:36549197	TEKT2	-0.37	-5.96	-0.47	2.42e-8	Schizophrenia;
TGCT	cis	rs7617773	0.817	rs3937	chr3:48312402	T/C	cg11946769	chr3:48343235	NME6	0.72	6.2	0.49	7.83e-9	Coronary artery disease;
TGCT	cis	rs1865760	0.568	rs2032450	chr6:25993114	C/G	cg16482183	chr6:26056742	HIST1H1C	0.54	4.77	0.39	5.15e-6	Height;
TGCT	cis	rs9611565	0.559	rs132765	chr22:42008068	A/G	cg13695892	chr22:41940480	POLR3H	0.88	8.46	0.6	6.38e-14	Vitiligo;
TGCT	cis	rs55962025	0.883	rs362275	chr4:3224602	C/T	cg06533319	chr4:3265114	C4orf44	0.24	4.7	0.39	6.87e-6	Parental longevity (mother's age at death);
TGCT	cis	rs10791097	0.694	rs3190331	chr11:130748131	C/T	cg14779329	chr11:130786720	SNX19	-0.29	-5.11	-0.42	1.19e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg18188782	chr20:61659543	NA	0.44	5.37	0.43	3.73e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9811920	0.609	rs6440938	chr3:99652092	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.59	6.77	0.52	4.51e-10	Axial length;
TGCT	cis	rs6500602	0.727	rs2058811	chr16:4575162	C/T	cg08645402	chr16:4508243	NA	0.19	5.25	0.43	6.37e-7	Schizophrenia;
TGCT	cis	rs8179	0.700	rs42039	chr7:92244422	A/G	cg15732164	chr7:92237376	CDK6	0.28	4.89	0.4	3.11e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
TGCT	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.1	0.48	1.25e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs4654899	1.000	rs6682368	chr1:21506914	G/A	cg01072550	chr1:21505969	NA	-0.5	-8.08	-0.59	4.94e-13	Superior frontal gyrus grey matter volume;
TGCT	cis	rs72945132	0.882	rs12294540	chr11:70118973	A/T	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs7617773	0.817	rs13072018	chr3:48320332	G/A	cg11946769	chr3:48343235	NME6	0.76	6.57	0.51	1.23e-9	Coronary artery disease;
TGCT	cis	rs2730260	0.578	rs56375711	chr7:158854935	G/A	cg02078164	chr7:157982224	PTPRN2	0.41	4.48	0.37	1.66e-5	Myopia (pathological);
TGCT	trans	rs11158198	0.582	rs34548381	chr14:58621716	C/T	cg18792904	chr6:83074812	TPBG	0.74	6.74	0.52	5.38e-10	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs739401	0.611	rs7130841	chr11:3043658	A/G	cg05729581	chr11:3078854	CARS	-0.54	-5.13	-0.42	1.07e-6	Longevity;
TGCT	cis	rs1532993	0.518	rs9654187	chr4:98630909	G/T	cg05340658	chr4:99064831	C4orf37	-0.4	-4.91	-0.4	2.77e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg11764359	chr7:65958608	NA	0.59	5.12	0.42	1.14e-6	Aortic root size;
TGCT	cis	rs11098499	0.731	rs10015579	chr4:120271802	T/C	cg09307838	chr4:120376055	NA	0.55	5.46	0.44	2.5e-7	Corneal astigmatism;
TGCT	cis	rs317689	0.581	rs160829	chr12:69769538	G/C	cg19645103	chr12:69753606	YEATS4	-0.57	-4.8	-0.4	4.5e-6	Response to diuretic therapy;
TGCT	cis	rs2115630	0.846	rs8024538	chr15:85368419	A/T	cg17173187	chr15:85201210	NMB	-0.49	-5.99	-0.47	2.14e-8	P wave terminal force;
TGCT	cis	rs10927875	0.541	rs1763599	chr1:16342602	C/T	cg22431228	chr1:16359049	CLCNKA	-0.29	-6.02	-0.48	1.8e-8	Dilated cardiomyopathy;
TGCT	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	trans	rs4650994	0.625	rs6681354	chr1:178526279	A/G	cg05059571	chr16:84539110	KIAA1609	-0.41	-7.67	-0.57	4.37e-12	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs7819412	0.669	rs4840549	chr8:10998955	A/G	cg03192020	chr8:11204681	TDH	-0.52	-4.5	-0.37	1.53e-5	Triglycerides;
TGCT	cis	rs28735056	0.967	rs11660941	chr18:77630600	G/C	cg20368463	chr18:77673604	PQLC1	-0.45	-5.55	-0.45	1.65e-7	Schizophrenia;
TGCT	cis	rs6714788	0.503	rs2309748	chr2:100681449	A/T	cg07810366	chr2:100720526	AFF3	-0.37	-5.29	-0.43	5.31e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs10791323	0.628	rs1893850	chr11:133705356	T/C	cg15485101	chr11:133734466	NA	0.4	5.08	0.42	1.34e-6	Childhood ear infection;
TGCT	trans	rs6089829	0.888	rs4809268	chr20:61675249	C/G	cg17470723	chr8:74884337	TCEB1	0.78	6.83	0.52	3.42e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs533581	0.866	rs502258	chr16:88968547	G/A	cg05579598	chr16:88989069	CBFA2T3	0.36	4.45	0.37	1.88e-5	Social autistic-like traits;
TGCT	cis	rs861020	0.959	rs641348	chr1:209992043	A/G	cg05527609	chr1:210001259	C1orf107	0.95	7.67	0.57	4.35e-12	Orofacial clefts;
TGCT	cis	rs12497850	1.000	rs12493578	chr3:48730116	C/T	cg16497277	chr3:49208875	KLHDC8B	0.51	4.84	0.4	3.81e-6	Parkinson's disease;
TGCT	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg20607798	chr8:58055168	NA	0.49	4.56	0.38	1.2e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2455799	0.613	rs13071730	chr3:15891035	C/T	cg16303742	chr3:15540471	COLQ	-0.25	-4.68	-0.39	7.4e-6	Mean platelet volume;
TGCT	trans	rs17685	0.712	rs4732578	chr7:75721532	A/G	cg19862616	chr7:65841803	NCRNA00174	0.51	8.3	0.6	1.51e-13	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs6684514	1.000	rs3806407	chr1:156251742	T/C	cg20302342	chr1:156215951	PAQR6	0.34	4.6	0.38	1.01e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs11190604	0.767	rs77769532	chr10:102193646	T/C	cg16005271	chr10:102321736	NA	0.46	4.69	0.39	6.99e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs12142240	0.667	rs66990604	chr1:46822073	G/A	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg14983838	chr19:29218262	NA	0.83	6.85	0.52	3.07e-10	Methadone dose in opioid dependence;
TGCT	cis	rs10045504	0.502	rs17456482	chr5:38737783	G/C	cg15396434	chr5:38725168	NA	-0.35	-4.47	-0.37	1.78e-5	Night sleep phenotypes;
TGCT	cis	rs11785400	0.731	rs4644221	chr8:143736984	C/T	cg24634471	chr8:143751801	JRK	-0.54	-5.51	-0.44	1.95e-7	Schizophrenia;
TGCT	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	6.14	0.48	1.04e-8	Bipolar disorder;
TGCT	cis	rs9467773	0.620	rs2504567	chr6:26662920	C/G	cg26531700	chr6:26746687	NA	0.51	4.64	0.38	8.75e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg25036284	chr2:26402008	FAM59B	0.65	5.19	0.42	8.36e-7	Gut microbiome composition (summer);
TGCT	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg07636037	chr3:49044803	WDR6	0.96	10.5	0.69	7.74e-19	Parkinson's disease;
TGCT	cis	rs9291683	0.588	rs4280729	chr4:10013861	C/T	cg00071950	chr4:10020882	SLC2A9	0.76	10.25	0.68	3.14e-18	Bone mineral density;
TGCT	cis	rs877282	0.853	rs7092805	chr10:756246	G/A	cg17470449	chr10:769945	NA	0.34	5.11	0.42	1.16e-6	Uric acid levels;
TGCT	cis	rs3796352	0.527	rs11715498	chr3:52943551	G/C	cg11137980	chr3:52469226	SEMA3G	0.28	4.65	0.39	8.22e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs2239547	0.522	rs2336162	chr3:52951519	C/T	cg11645453	chr3:52864694	ITIH4	-0.36	-6.24	-0.49	6.31e-9	Schizophrenia;
TGCT	cis	rs45509595	0.841	rs2747054	chr6:27783359	A/G	cg10876282	chr6:28092338	ZSCAN16	0.78	4.57	0.38	1.17e-5	Breast cancer;
TGCT	cis	rs7772486	0.686	rs4896828	chr6:145953339	A/C	cg05347473	chr6:146136440	FBXO30	0.48	4.56	0.38	1.19e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs854765	0.655	rs4470201	chr17:17844870	G/A	cg09796270	chr17:17721594	SREBF1	0.24	4.77	0.39	5.16e-6	Total body bone mineral density;
TGCT	cis	rs1023500	0.573	rs133377	chr22:42466950	C/T	cg05082376	chr22:42548792	NA	-0.23	-5.43	-0.44	2.83e-7	Schizophrenia;
TGCT	cis	rs8042680	0.554	rs8036115	chr15:91528961	G/A	cg22570213	chr15:91497863	RCCD1	0.43	4.46	0.37	1.78e-5	Type 2 diabetes;
TGCT	cis	rs734999	0.549	rs60733400	chr1:2516781	G/A	cg18854424	chr1:2615690	NA	0.47	5.23	0.42	7.09e-7	Ulcerative colitis;
TGCT	cis	rs9527	0.545	rs11191602	chr10:104954219	C/T	cg04362960	chr10:104952993	NT5C2	0.68	5.73	0.46	7.14e-8	Arsenic metabolism;
TGCT	cis	rs2242194	0.816	rs2242193	chr1:154995503	A/G	cg09359103	chr1:154839909	KCNN3	0.44	6.1	0.48	1.22e-8	Schizophrenia;
TGCT	cis	rs9467711	1.000	rs6923139	chr6:26313348	C/T	cg03517284	chr6:25882590	NA	-0.86	-4.67	-0.39	7.69e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs854765	0.647	rs854790	chr17:18028318	C/G	cg04398451	chr17:18023971	MYO15A	-0.4	-6.86	-0.52	2.96e-10	Total body bone mineral density;
TGCT	cis	rs10992471	0.603	rs1121978	chr9:95140351	T/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.61	-5.59	-0.45	1.36e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs11626933	1.000	rs6575122	chr14:90753556	A/G	cg14092571	chr14:90743983	NA	-0.3	-6.13	-0.48	1.06e-8	Gut microbiota (bacterial taxa);
TGCT	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg03517284	chr6:25882590	NA	-1.01	-11.7	-0.72	9.25e-22	Uric acid levels;
TGCT	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg07507251	chr3:52567010	NT5DC2	0.48	6.91	0.53	2.24e-10	Bipolar disorder;
TGCT	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg06112835	chr11:68658793	MRPL21	0.46	8.12	0.59	3.91e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2982552	0.708	rs1124674	chr6:152080735	A/C	cg22157087	chr6:152012887	ESR1	0.2	4.98	0.41	2.07e-6	Bone properties (heel);
TGCT	trans	rs1814175	0.538	rs1684260	chr11:49224231	G/A	cg03929089	chr4:120376271	NA	0.71	7.86	0.58	1.61e-12	Height;
TGCT	cis	rs644799	0.526	rs693792	chr11:95622200	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.49	4.84	0.4	3.75e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs924607	0.966	rs1621827	chr5:635074	A/G	cg18765565	chr5:669397	TPPP	0.58	6.07	0.48	1.45e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg18252515	chr7:66147081	NA	-1.09	-6.4	-0.5	2.88e-9	Diabetic kidney disease;
TGCT	cis	rs12549025	0.536	rs9644075	chr8:23359961	C/G	cg00472375	chr8:23315376	ENTPD4	0.66	5.2	0.42	8.06e-7	Reticulocyte fraction of red cells;
TGCT	cis	rs909002	0.886	rs11807225	chr1:32083193	G/C	cg11573219	chr1:32083031	HCRTR1	-0.49	-6.49	-0.5	1.82e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs9638182	0.725	rs13232120	chr7:72983310	A/T	cg14087351	chr7:73037990	MLXIPL	-0.64	-4.98	-0.41	2.09e-6	Triglycerides;
TGCT	cis	rs1031261	0.749	rs73922775	chr2:32906594	T/A	cg02381751	chr2:32503542	YIPF4	-0.73	-4.47	-0.37	1.72e-5	Hippocampal atrophy;
TGCT	cis	rs1691799	0.899	rs903589	chr12:66745835	C/T	cg16791601	chr12:66731901	HELB	-0.27	-5.81	-0.46	4.89e-8	White blood cell count (basophil);
TGCT	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg17264618	chr3:40429014	ENTPD3	0.32	4.57	0.38	1.18e-5	Renal cell carcinoma;
TGCT	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg21724239	chr8:58056113	NA	0.37	4.95	0.41	2.38e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9911578	0.935	rs12948039	chr17:57045184	C/T	cg05425664	chr17:57184151	TRIM37	-0.56	-5.42	-0.44	2.99e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7552404	0.924	rs7546641	chr1:76158035	T/C	cg22875332	chr1:76189707	ACADM	0.78	9.74	0.66	5.53e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7824557	0.707	rs2572419	chr8:11137820	C/T	cg21775007	chr8:11205619	TDH	-0.59	-5.69	-0.46	8.5e-8	Retinal vascular caliber;
TGCT	cis	rs7017914	0.905	rs2639899	chr8:71919462	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.55	-5.1	-0.42	1.24e-6	Bone mineral density;
TGCT	cis	rs778371	0.723	rs737027	chr2:233641083	G/C	cg08000102	chr2:233561755	GIGYF2	0.72	8.68	0.61	1.91e-14	Schizophrenia;
TGCT	cis	rs11239930	0.538	rs3011810	chr1:146553628	A/C	cg00044796	chr1:146552390	NA	-0.34	-4.46	-0.37	1.84e-5	AIDS progression;
TGCT	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg08509172	chr19:19383838	TM6SF2	-0.35	-4.63	-0.38	9.18e-6	Tonsillectomy;
TGCT	cis	rs13191362	0.872	rs67712738	chr6:163245768	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.67	4.66	0.39	8.09e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs6840360	1.000	rs1877187	chr4:152605621	C/T	cg17479576	chr4:152424074	FAM160A1	-0.46	-4.9	-0.4	2.95e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7172809	0.615	rs76499944	chr15:77804814	A/G	cg22256960	chr15:77711686	NA	-0.5	-4.75	-0.39	5.62e-6	Glucose homeostasis traits;
TGCT	cis	rs314370	0.818	rs13245899	chr7:100497131	A/G	cg10426581	chr7:100472382	SRRT	0.96	11.37	0.71	5.95e-21	Resting heart rate;
TGCT	cis	rs3096299	0.719	rs12934708	chr16:89523790	C/T	cg08392591	chr16:89556376	ANKRD11	0.6	5.64	0.45	1.09e-7	Multiple myeloma (IgH translocation);
TGCT	cis	rs4372836	0.729	rs67410623	chr2:29057440	G/A	cg09522027	chr2:28974177	PPP1CB	0.66	6.77	0.52	4.53e-10	Body mass index;
TGCT	cis	rs3796352	0.667	rs3755805	chr3:52866299	G/A	cg27565382	chr3:53032988	SFMBT1	0.49	4.47	0.37	1.75e-5	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs1577917	0.771	rs2758844	chr6:86330115	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.58	-0.45	1.43e-7	Response to antipsychotic treatment;
TGCT	cis	rs6570726	0.620	rs12201226	chr6:145913419	A/T	cg13319975	chr6:146136371	FBXO30	-0.68	-6.23	-0.49	6.81e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4888262	0.526	rs7201105	chr16:74590603	A/G	cg01733217	chr16:74700730	RFWD3	0.71	7.11	0.54	7.94e-11	Testicular germ cell tumor;
TGCT	cis	rs2227564	0.649	rs2688626	chr10:75611090	G/A	cg19442545	chr10:75533431	FUT11	-0.33	-4.72	-0.39	6.29e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.0	7.42	0.55	1.64e-11	Gut microbiome composition (summer);
TGCT	cis	rs9926296	0.609	rs4785710	chr16:89796756	C/T	cg08627397	chr16:89984028	MC1R	0.31	4.95	0.41	2.33e-6	Vitiligo;
TGCT	cis	rs2404602	0.669	rs12148877	chr15:76919959	T/G	cg22467129	chr15:76604101	ETFA	-0.44	-4.98	-0.41	2.07e-6	Blood metabolite levels;
TGCT	cis	rs2463822	0.925	rs74692811	chr11:62156572	G/A	cg06239285	chr11:62104954	ASRGL1	-0.92	-6.75	-0.52	5.06e-10	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs7818688	0.697	rs74861094	chr8:95981385	A/G	cg16049864	chr8:95962084	TP53INP1	0.54	4.64	0.38	8.87e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs7666738	0.830	rs62321598	chr4:99014237	C/T	cg05340658	chr4:99064831	C4orf37	0.47	5.33	0.43	4.51e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7772486	0.875	rs11755334	chr6:146399297	T/C	cg05347473	chr6:146136440	FBXO30	0.55	5.14	0.42	1.05e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg23156509	chr2:114033830	PAX8;LOC440839	-0.32	-4.93	-0.4	2.58e-6	Lymphocyte counts;
TGCT	cis	rs7917772	0.636	rs2486757	chr10:104535145	C/T	cg05855489	chr10:104503620	C10orf26	-0.63	-5.05	-0.41	1.54e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs4499344	0.805	rs116855540	chr19:33083830	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.74	-6.49	-0.5	1.87e-9	Mean platelet volume;
TGCT	cis	rs6570726	0.935	rs447818	chr6:145868996	C/T	cg23711669	chr6:146136114	FBXO30	0.7	6.78	0.52	4.39e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9653442	0.777	rs6732141	chr2:100743492	G/C	cg07810366	chr2:100720526	AFF3	-0.47	-7.82	-0.57	1.99e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs12142240	0.698	rs1053627	chr1:46827728	A/C	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs67311347	1.000	rs7633809	chr3:40517737	A/G	cg17264618	chr3:40429014	ENTPD3	-0.32	-4.64	-0.38	8.57e-6	Renal cell carcinoma;
TGCT	cis	rs9467711	0.606	rs67234939	chr6:26530419	A/G	cg16898833	chr6:26189333	HIST1H4D	1.04	5.4	0.44	3.34e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs5771225	0.563	rs1129880	chr22:50694297	A/G	cg16473166	chr22:50639996	SELO	0.69	5.69	0.45	8.74e-8	Late-onset Alzheimer's disease;
TGCT	cis	rs6540559	0.611	rs76766079	chr1:209997731	C/T	cg22029157	chr1:209979665	IRF6	0.71	5.04	0.41	1.61e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs9549367	0.789	rs3764124	chr13:113897320	C/T	cg00898013	chr13:113819073	PROZ	-0.4	-5.07	-0.41	1.42e-6	Platelet distribution width;
TGCT	cis	rs6500602	0.826	rs9925719	chr16:4461861	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.44	6.71	0.52	6.09e-10	Schizophrenia;
TGCT	cis	rs11105298	0.891	rs11105312	chr12:89920733	C/T	cg00757033	chr12:89920650	WDR51B	0.32	5.13	0.42	1.11e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs4851266	1.000	rs11689201	chr2:100820431	A/G	cg07810366	chr2:100720526	AFF3	-0.39	-5.64	-0.45	1.11e-7	Educational attainment;
TGCT	cis	rs7681440	0.904	rs28415623	chr4:90767110	C/T	cg14346243	chr4:90757452	SNCA	-0.57	-5.6	-0.45	1.31e-7	Dementia with Lewy bodies;
TGCT	cis	rs12497850	0.864	rs7431857	chr3:48900347	G/A	cg06212747	chr3:49208901	KLHDC8B	0.62	5.83	0.46	4.42e-8	Parkinson's disease;
TGCT	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg06618935	chr21:46677482	NA	-0.37	-5.55	-0.45	1.65e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs12477438	0.798	rs6761570	chr2:99577276	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-5.97	-0.47	2.3e-8	Chronic sinus infection;
TGCT	cis	rs7772486	0.713	rs1986729	chr6:146194831	G/A	cg23711669	chr6:146136114	FBXO30	0.97	11.27	0.71	1.01e-20	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs274567	0.602	rs272853	chr5:131688561	A/G	cg24060327	chr5:131705240	SLC22A5	-0.73	-7.94	-0.58	1.01e-12	Blood metabolite levels;
TGCT	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg11905131	chr22:24372483	LOC391322	-1.03	-13.21	-0.76	2.1e-25	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg00684032	chr4:1343700	KIAA1530	0.23	5.01	0.41	1.79e-6	Obesity-related traits;
TGCT	cis	rs739496	0.515	rs66480035	chr12:112052651	T/C	cg10833066	chr12:111807467	FAM109A	0.35	5.25	0.43	6.5e-7	Platelet count;
TGCT	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg22920501	chr2:26401640	FAM59B	0.81	6.36	0.5	3.52e-9	Gut microbiome composition (summer);
TGCT	trans	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg17830980	chr10:43048298	ZNF37B	-0.83	-10.39	-0.68	1.4e-18	Extrinsic epigenetic age acceleration;
TGCT	cis	rs1215050	0.740	rs1648568	chr4:98957619	A/G	cg17366294	chr4:99064904	C4orf37	-0.57	-6.12	-0.48	1.12e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg27411982	chr8:10470053	RP1L1	0.22	4.82	0.4	4.13e-6	Retinal vascular caliber;
TGCT	cis	rs10892173	0.566	rs10892174	chr11:117672565	A/C	cg21014159	chr11:117668035	DSCAML1	0.61	5.86	0.47	3.96e-8	Myopia;
TGCT	cis	rs1865760	0.663	rs9379815	chr6:25980116	T/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.7	6.91	0.53	2.26e-10	Height;
TGCT	cis	rs7264396	0.676	rs1341603	chr20:34556216	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.04	-0.41	1.58e-6	Total cholesterol levels;
TGCT	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg10295955	chr4:187884368	NA	-1.0	-14.26	-0.79	6.69e-28	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs250677	0.917	rs36066	chr5:148419771	A/G	cg18129178	chr5:148520854	ABLIM3	-0.4	-5.58	-0.45	1.42e-7	Breast cancer;
TGCT	cis	rs736408	0.812	rs2071506	chr3:52826276	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.49	-4.49	-0.37	1.58e-5	Bipolar disorder;
TGCT	cis	rs7731657	0.537	rs9327578	chr5:130181064	C/T	cg08523029	chr5:130500466	HINT1	-0.59	-4.95	-0.41	2.41e-6	Fasting plasma glucose;
TGCT	cis	rs10540	1.000	rs12801271	chr11:508720	C/T	cg03934478	chr11:495069	RNH1	0.32	4.83	0.4	3.94e-6	Body mass index;
TGCT	cis	rs2295359	0.824	rs4655679	chr1:67599657	A/G	cg03340356	chr1:67600835	NA	-0.41	-4.95	-0.41	2.37e-6	Psoriasis;
TGCT	trans	rs9383153	1.000	rs9370888	chr6:16335544	A/G	cg12405048	chr12:112074086	NA	0.67	6.8	0.52	3.88e-10	Gambling;
TGCT	cis	rs78456975	1.000	rs13414537	chr2:1556330	C/T	cg01028140	chr2:1542097	TPO	-0.33	-4.53	-0.38	1.37e-5	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs11249608	0.548	rs13161528	chr5:178452958	C/G	cg23951258	chr5:178450506	ZNF879	0.45	4.61	0.38	9.7e-6	Pubertal anthropometrics;
TGCT	cis	rs28595532	0.764	rs115298416	chr4:119565383	C/T	cg11846333	chr4:119757529	SEC24D	0.96	4.75	0.39	5.58e-6	Cannabis dependence symptom count;
TGCT	cis	rs910316	1.000	rs12889472	chr14:75543979	A/G	cg11812906	chr14:75593930	NEK9	0.74	7.19	0.54	5.49e-11	Height;
TGCT	cis	rs9457247	1.000	rs415890	chr6:167406633	C/G	cg23791538	chr6:167370224	RNASET2	0.51	5.06	0.41	1.45e-6	Crohn's disease;
TGCT	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	5.06	0.41	1.47e-6	Electroencephalogram traits;
TGCT	cis	rs35306767	0.903	rs35968821	chr10:910225	A/G	cg26597838	chr10:835615	NA	0.75	10.54	0.69	6.3e-19	Eosinophil percentage of granulocytes;
TGCT	cis	rs2228479	0.850	rs11640209	chr16:89807828	C/A	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs6459788	0.934	rs10237947	chr7:157258109	G/T	cg03453431	chr7:157225567	NA	0.34	5.29	0.43	5.43e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs559555	0.626	rs499362	chr2:31811572	A/C	cg02381751	chr2:32503542	YIPF4	0.46	4.46	0.37	1.8e-5	Blood metabolite ratios;Blood metabolite levels;
TGCT	cis	rs74233809	1.000	rs12221064	chr10:104677126	C/T	cg05855489	chr10:104503620	C10orf26	0.74	4.45	0.37	1.87e-5	Birth weight;
TGCT	cis	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg25427524	chr10:38739819	LOC399744	-0.39	-8.05	-0.59	5.9e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg11301795	chr4:187892539	NA	-0.34	-5.13	-0.42	1.08e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7917772	0.502	rs2296584	chr10:104244323	T/A	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs4665630	0.708	rs4078753	chr2:23896727	C/T	cg08063864	chr2:24346004	PFN4;LOC375190	-1.0	-4.97	-0.41	2.17e-6	Hypertension;
TGCT	cis	rs13242816	1.000	rs55833477	chr7:116110375	C/G	cg02799643	chr7:116139180	CAV2	-0.48	-5.52	-0.44	1.87e-7	P wave duration;
TGCT	cis	rs2016266	0.819	rs10747662	chr12:53669821	A/T	cg16917193	chr12:54089295	NA	0.66	4.96	0.41	2.22e-6	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.72	-6.47	-0.5	2.04e-9	Tonsillectomy;
TGCT	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg04267008	chr7:1944627	MAD1L1	-0.41	-5.4	-0.44	3.34e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs2594989	0.943	rs901865	chr3:11300707	T/C	cg00170343	chr3:11313890	ATG7	0.65	4.73	0.39	6.09e-6	Circulating chemerin levels;
TGCT	cis	rs4901869	0.966	rs60800733	chr14:59337778	A/G	cg02291164	chr14:59296302	NA	0.25	4.73	0.39	5.99e-6	Panic disorder;
TGCT	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs1008375	1.000	rs3933453	chr4:17636319	A/C	cg18681998	chr4:17616180	MED28	1.02	11.55	0.72	2.14e-21	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1008375	0.966	rs6832962	chr4:17652133	T/C	cg16339924	chr4:17578868	LAP3	0.66	5.52	0.44	1.89e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	8.0	0.58	7.67e-13	Platelet count;
TGCT	cis	rs9486719	0.947	rs11755945	chr6:96908038	G/C	cg18709589	chr6:96969512	KIAA0776	-0.68	-5.05	-0.41	1.55e-6	Migraine;Coronary artery disease;
TGCT	cis	rs3812831	0.661	rs2987458	chr13:114919835	A/G	cg06611532	chr13:114900021	NA	0.34	6.02	0.48	1.82e-8	Schizophrenia;
TGCT	cis	rs78707713	0.512	rs12772559	chr10:71184356	C/G	cg12610070	chr10:71211762	TSPAN15	-0.58	-6.53	-0.51	1.49e-9	Venous thromboembolism;
TGCT	cis	rs7246657	0.722	rs4802029	chr19:38055612	A/T	cg18154014	chr19:37997991	ZNF793	0.69	4.63	0.38	9.25e-6	Coronary artery calcification;
TGCT	cis	rs2535633	0.588	rs2564930	chr3:53017307	T/C	cg10802521	chr3:52805072	NEK4	0.55	5.88	0.47	3.48e-8	Body mass index;
TGCT	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	5.27	0.43	5.81e-7	Electroencephalogram traits;
TGCT	cis	rs6815814	1.000	rs6815814	chr4:38816338	A/C	cg02016764	chr4:38805732	TLR1	-0.29	-4.83	-0.4	3.95e-6	Breast cancer;
TGCT	cis	rs61990749	0.544	rs11628888	chr14:78161506	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	-0.6	-4.44	-0.37	2.01e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs6684514	0.922	rs11264475	chr1:156306918	G/A	cg16558208	chr1:156270281	VHLL	0.48	9.6	0.65	1.19e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs4919694	0.572	rs4917995	chr10:104845443	A/T	cg04362960	chr10:104952993	NT5C2	-0.99	-6.74	-0.52	5.39e-10	Arsenic metabolism;
TGCT	cis	rs1670533	1.000	rs2014318	chr4:1068778	C/T	cg20887711	chr4:1340912	KIAA1530	-0.69	-5.54	-0.45	1.72e-7	Recombination rate (females);
TGCT	cis	rs28595532	0.623	rs34082100	chr4:119220563	C/T	cg21605333	chr4:119757512	SEC24D	0.78	4.84	0.4	3.75e-6	Cannabis dependence symptom count;
TGCT	cis	rs7552404	0.924	rs2275378	chr1:76198436	T/C	cg22875332	chr1:76189707	ACADM	0.76	9.33	0.64	5.34e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs17125944	0.615	rs12589020	chr14:53312002	C/T	cg00686598	chr14:53173677	PSMC6	0.86	4.54	0.38	1.32e-5	Alzheimer's disease (late onset);
TGCT	cis	rs7666738	0.688	rs4632667	chr4:98748299	A/G	cg17366294	chr4:99064904	C4orf37	0.69	5.38	0.43	3.62e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4713118	0.955	rs9468204	chr6:27688809	C/T	cg10876282	chr6:28092338	ZSCAN16	0.5	4.67	0.39	7.86e-6	Parkinson's disease;
TGCT	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg27425262	chr2:113953981	PSD4;LOC440839	-0.52	-8.2	-0.59	2.52e-13	Lymphocyte counts;
TGCT	cis	rs4727027	0.865	rs62505077	chr7:148849656	T/A	cg23583168	chr7:148888333	NA	-0.77	-10.1	-0.67	7.35e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs2153535	0.504	rs5001323	chr6:8451605	C/T	cg07606381	chr6:8435919	SLC35B3	0.53	5.03	0.41	1.71e-6	Motion sickness;
TGCT	cis	rs6882076	1.000	rs12517431	chr5:156392248	C/T	cg12943317	chr5:156479607	HAVCR1	-0.31	-6.09	-0.48	1.31e-8	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
TGCT	cis	rs4689388	0.819	rs12649341	chr4:6294759	G/A	cg00701064	chr4:6280414	WFS1	0.37	4.72	0.39	6.3e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs7824557	0.569	rs35418978	chr8:11186453	T/C	cg21775007	chr8:11205619	TDH	0.69	6.62	0.51	9.52e-10	Retinal vascular caliber;
TGCT	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg02953382	chr22:24373134	LOC391322	-0.79	-8.27	-0.6	1.72e-13	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9443645	0.835	rs1044309	chr6:79646575	A/G	cg05283184	chr6:79620031	NA	-0.21	-4.71	-0.39	6.61e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2658782	0.547	rs3020054	chr11:93055556	C/T	cg15737290	chr11:93063684	CCDC67	1.11	11.61	0.72	1.5e-21	Pulmonary function decline;
TGCT	cis	rs9534288	0.742	rs1022952	chr13:46649348	C/T	cg15192986	chr13:46630673	CPB2	0.52	6.39	0.5	2.97e-9	Blood protein levels;
TGCT	cis	rs763121	0.815	rs12168758	chr22:38997269	C/G	cg06022373	chr22:39101656	GTPBP1	0.73	7.02	0.53	1.26e-10	Menopause (age at onset);
TGCT	cis	rs9486715	1.000	rs6902835	chr6:97063005	C/G	cg06623918	chr6:96969491	KIAA0776	-1.07	-13.0	-0.76	6.68e-25	Headache;
TGCT	cis	rs9818758	0.607	rs61729488	chr3:49067904	T/C	cg07636037	chr3:49044803	WDR6	-1.0	-4.82	-0.4	4.15e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs911263	0.603	rs11158729	chr14:68776060	T/C	cg18825221	chr14:68749962	RAD51L1	0.22	4.48	0.37	1.64e-5	Primary biliary cholangitis;
TGCT	cis	rs950027	0.620	rs872192	chr15:45614502	A/G	cg14582100	chr15:45693742	SPATA5L1	0.48	6.08	0.48	1.35e-8	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs9810089	0.843	rs650326	chr3:136037707	G/A	cg12473912	chr3:136751656	NA	0.36	5.15	0.42	9.88e-7	Gestational age at birth (child effect);
TGCT	cis	rs7267979	1.000	rs6076345	chr20:25381895	T/G	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs5769765	0.908	rs138866	chr22:50205903	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.98	10.24	0.68	3.32e-18	Schizophrenia;
TGCT	cis	rs611744	0.934	rs604698	chr8:109238721	G/A	cg21045802	chr8:109455806	TTC35	0.52	4.72	0.39	6.21e-6	Dupuytren's disease;
TGCT	cis	rs939658	0.967	rs7171067	chr15:79452727	G/T	cg17916960	chr15:79447300	NA	0.52	8.15	0.59	3.36e-13	Refractive error;
TGCT	cis	rs7255045	0.788	rs8110185	chr19:12959827	T/A	cg06537894	chr19:12978706	MAST1	-0.49	-4.48	-0.37	1.69e-5	Mean corpuscular volume;
TGCT	cis	rs644799	0.965	rs11021310	chr11:95502106	A/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	10.82	0.7	1.31e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs2456568	0.802	rs10831139	chr11:93640537	G/A	cg17595323	chr11:93583763	C11orf90	-0.46	-6.24	-0.49	6.46e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs2629540	0.765	rs7097177	chr10:126539839	A/G	cg08799069	chr10:126477246	METTL10	-0.28	-4.58	-0.38	1.12e-5	Cocaine dependence;
TGCT	cis	rs2688608	0.618	rs28718766	chr10:75489844	C/A	cg23231163	chr10:75533350	FUT11	-0.29	-4.87	-0.4	3.37e-6	Inflammatory bowel disease;
TGCT	trans	rs2727020	0.729	rs10839283	chr11:49490943	T/C	cg03929089	chr4:120376271	NA	0.73	8.36	0.6	1.08e-13	Coronary artery disease;
TGCT	cis	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg22857025	chr5:266934	NA	-0.31	-6.32	-0.49	4.33e-9	Breast cancer;
TGCT	cis	rs146201400	1	rs146201400	chr1:26645955	G/GA	cg04990556	chr1:26633338	UBXN11	-0.62	-5.46	-0.44	2.45e-7	Monocyte percentage of white cells;
TGCT	cis	rs10751667	0.666	rs7123912	chr11:963936	T/C	cg06064525	chr11:970664	AP2A2	-0.35	-8.23	-0.59	2.17e-13	Alzheimer's disease (late onset);
TGCT	cis	rs7552404	0.727	rs61770533	chr1:76306490	C/G	cg03433033	chr1:76189801	ACADM	0.65	6.73	0.52	5.56e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs35000415	0.938	rs35234849	chr7:128648953	T/C	cg06242719	chr7:129414860	MIR183;MIR96	-0.31	-4.52	-0.38	1.4e-5	Systemic lupus erythematosus;
TGCT	cis	rs7666738	0.830	rs4699590	chr4:98974030	A/C	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7572733	0.534	rs700664	chr2:198671145	C/T	cg00792783	chr2:198669748	PLCL1	0.56	5.08	0.42	1.35e-6	Dermatomyositis;
TGCT	cis	rs3091242	0.900	rs1883427	chr1:25744468	C/T	cg10117171	chr1:25599238	RHD	-0.36	-5.89	-0.47	3.47e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs4654899	1.000	rs61117207	chr1:21394374	A/C	cg01072550	chr1:21505969	NA	-0.49	-7.88	-0.58	1.41e-12	Superior frontal gyrus grey matter volume;
TGCT	trans	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.82	8.47	0.61	6.11e-14	Intelligence (multi-trait analysis);
TGCT	trans	rs11722228	0.521	rs12501336	chr4:10137351	G/A	cg26043149	chr18:55253948	FECH	1.09	13.01	0.76	6.33e-25	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs9796	0.870	rs7162992	chr15:41290861	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.41	-5.42	-0.44	3.01e-7	Menopause (age at onset);
TGCT	cis	rs7944584	1.000	rs7944584	chr11:47336320	A/T	cg20307385	chr11:47447363	PSMC3	0.78	7.41	0.55	1.75e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
TGCT	cis	rs694739	0.964	rs2510066	chr11:64052447	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.75	7.5	0.56	1.08e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg17971929	chr21:40555470	PSMG1	-0.52	-4.69	-0.39	7.17e-6	Menarche (age at onset);
TGCT	cis	rs7772486	0.719	rs702307	chr6:145993454	C/G	cg23711669	chr6:146136114	FBXO30	-0.93	-10.56	-0.69	5.5e-19	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2692947	0.770	rs11689832	chr2:96554851	A/C	cg13655245	chr2:97463316	CNNM4	0.15	4.51	0.38	1.51e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	5.02	0.41	1.78e-6	Prudent dietary pattern;
TGCT	cis	rs6671200	1.000	rs259359	chr1:95709039	A/G	cg03123541	chr1:95699097	RWDD3	-0.87	-6.13	-0.48	1.09e-8	Stearic acid (18:0) levels;
TGCT	cis	rs4845570	0.764	rs12122917	chr1:151716712	C/A	cg07092448	chr1:151763213	TDRKH	-1.03	-7.53	-0.56	8.99e-12	Coronary artery disease;
TGCT	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg03452623	chr4:187889614	NA	-0.36	-5.3	-0.43	5.01e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs79349575	0.749	rs2270574	chr17:47022270	C/T	cg07967210	chr17:47022446	SNF8	0.44	6.13	0.48	1.1e-8	Type 2 diabetes;
TGCT	cis	rs7267979	0.932	rs417110	chr20:25458297	T/C	cg03522245	chr20:25566470	NINL	0.6	6.46	0.5	2.14e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs62244186	0.659	rs9850129	chr3:44532047	C/T	cg10108389	chr3:44770937	ZNF501	-0.48	-4.96	-0.41	2.31e-6	Depressive symptoms;
TGCT	cis	rs7216064	1.000	rs7209675	chr17:65831258	A/T	cg12091567	chr17:66097778	LOC651250	-0.9	-6.83	-0.52	3.43e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs9653442	0.675	rs7605430	chr2:100647552	C/G	cg07810366	chr2:100720526	AFF3	0.39	6.44	0.5	2.42e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs72945132	1.000	rs56913804	chr11:70114673	G/A	cg00319359	chr11:70116639	PPFIA1	0.98	7.07	0.54	9.95e-11	Coronary artery disease;
TGCT	cis	rs55794721	0.509	rs2982358	chr1:25745204	G/T	cg09222892	chr1:25734099	RHCE	-0.44	-7.02	-0.53	1.3100000000000001e-10	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs7666738	0.830	rs1405767	chr4:98965295	T/C	cg18180107	chr4:99064573	C4orf37	0.57	5.18	0.42	8.63e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg10802521	chr3:52805072	NEK4	-0.65	-7.63	-0.57	5.37e-12	Electroencephalogram traits;
TGCT	cis	rs2033711	0.936	rs3794968	chr19:58986799	G/C	cg04608855	chr19:58913158	NA	0.54	5.07	0.41	1.42e-6	Uric acid clearance;
TGCT	cis	rs6940638	0.615	rs9393801	chr6:27242681	A/G	cg05738196	chr6:26577821	NA	-0.53	-4.76	-0.39	5.38e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs3796352	0.892	rs3821872	chr3:53080555	C/G	cg15956490	chr3:53032818	SFMBT1	-0.53	-6.29	-0.49	4.97e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg25767906	chr1:53392781	SCP2	-0.52	-6.19	-0.49	8.06e-9	Monocyte count;
TGCT	cis	rs6831352	0.840	rs17817868	chr4:100060623	C/T	cg12011299	chr4:100065546	ADH4	-0.41	-4.97	-0.41	2.21e-6	Alcohol dependence;
TGCT	cis	rs709400	0.520	rs28583452	chr14:103938664	C/A	cg12935359	chr14:103987150	CKB	-0.36	-5.55	-0.45	1.67e-7	Body mass index;
TGCT	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg02725872	chr8:58115012	NA	-0.38	-5.16	-0.42	9.32e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6582630	0.519	rs11182457	chr12:38538331	G/A	cg13010199	chr12:38710504	ALG10B	0.65	5.18	0.42	8.78e-7	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs13082711	0.689	rs34641383	chr3:27320210	G/A	cg02860705	chr3:27208620	NA	0.58	8.58	0.61	3.32e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg06238570	chr21:40685208	BRWD1	0.59	5.29	0.43	5.26e-7	Cognitive function;
TGCT	cis	rs9914544	0.545	rs12937933	chr17:18770283	C/G	cg26378065	chr17:18585709	ZNF286B	0.52	4.5	0.37	1.56e-5	Educational attainment (years of education);
TGCT	cis	rs6121246	0.909	rs1994250	chr20:30287494	A/G	cg13852791	chr20:30311386	BCL2L1	0.78	5.8	0.46	5.15e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs514406	0.698	rs1672913	chr1:53408326	A/T	cg24675658	chr1:53192096	ZYG11B	-0.74	-9.03	-0.63	2.84e-15	Monocyte count;
TGCT	cis	rs9952991	0.941	rs2014857	chr18:12774326	C/T	cg24737193	chr18:12778029	NA	0.53	5.93	0.47	2.8e-8	Inflammatory skin disease;
TGCT	cis	rs6840360	0.571	rs1978955	chr4:152509509	G/A	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.0	-0.58	7.69e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs2338224	1.000	rs10068109	chr5:71744199	C/T	cg01187920	chr5:71015162	CARTPT	0.5	4.47	0.37	1.74e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Granulocyte count;Myeloid white cell count;
TGCT	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg11494091	chr17:61959527	GH2	0.43	7.34	0.55	2.45e-11	Height;
TGCT	cis	rs902774	0.515	rs2363635	chr12:53354622	T/C	cg05393297	chr12:53359155	NA	-0.75	-8.33	-0.6	1.27e-13	Prostate cancer;
TGCT	cis	rs727563	0.520	rs132773	chr22:42031768	T/A	cg17554472	chr22:41940697	POLR3H	0.5	5.26	0.43	6.02e-7	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs2153535	0.541	rs6938688	chr6:8521629	G/T	cg07606381	chr6:8435919	SLC35B3	0.54	5.01	0.41	1.86e-6	Motion sickness;
TGCT	cis	rs9660992	0.573	rs12144980	chr1:205185104	C/T	cg00857998	chr1:205179979	DSTYK	0.51	4.75	0.39	5.63e-6	Mean corpuscular volume;Mean platelet volume;
TGCT	cis	rs9291683	0.620	rs11722946	chr4:10125990	A/G	cg11266682	chr4:10021025	SLC2A9	-0.43	-5.15	-0.42	9.84e-7	Bone mineral density;
TGCT	cis	rs17345786	1.000	rs11715368	chr3:101336380	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.89	9.49	0.65	2.23e-16	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9929218	0.953	rs12920562	chr16:68737512	C/T	cg01251360	chr16:68772225	CDH1	0.3	4.81	0.4	4.35e-6	Colorectal cancer;
TGCT	cis	rs7582180	0.606	rs11684004	chr2:100954783	C/T	cg08017756	chr2:100939284	LONRF2	-0.3	-4.87	-0.4	3.27e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7937682	1.000	rs7121011	chr11:111568681	C/T	cg09085632	chr11:111637200	PPP2R1B	1.04	9.55	0.65	1.58e-16	Primary sclerosing cholangitis;
TGCT	cis	rs4455778	0.628	rs11185623	chr7:49027187	T/C	cg26309511	chr7:48887640	NA	-0.44	-5.22	-0.42	7.26e-7	Lung cancer in never smokers;
TGCT	cis	rs2688608	0.592	rs10762559	chr10:75486453	G/C	cg04320760	chr10:75533139	FUT11	-0.4	-6.24	-0.49	6.28e-9	Inflammatory bowel disease;
TGCT	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg22920501	chr2:26401640	FAM59B	-0.7	-6.05	-0.48	1.59e-8	Gut microbiome composition (summer);
TGCT	cis	rs2019216	0.500	rs6565385	chr17:21897646	C/A	cg22648282	chr17:21454238	C17orf51	-0.56	-5.51	-0.44	1.97e-7	Pelvic organ prolapse;
TGCT	cis	rs7586879	0.616	rs6545809	chr2:25126715	C/T	cg01884057	chr2:25150051	NA	0.35	6.9	0.53	2.39e-10	Body mass index;
TGCT	cis	rs6570726	0.764	rs9399553	chr6:145873664	A/T	cg05347473	chr6:146136440	FBXO30	0.54	5.15	0.42	1.01e-6	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.88	9.9	0.66	2.18e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs1372520	0.627	rs2737025	chr4:90719192	A/G	cg15133208	chr4:90757351	SNCA	-0.52	-6.07	-0.48	1.44e-8	Neuroticism;
TGCT	cis	rs56104184	0.723	rs1058483	chr19:49407660	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.73	-9.15	-0.63	1.47e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	8.04	0.59	5.91e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs290268	0.874	rs772407	chr9:93560850	A/C	cg02608019	chr9:93564028	SYK	0.44	4.44	0.37	1.94e-5	Platelet count;
TGCT	cis	rs10256972	0.680	rs7784708	chr7:1003049	A/G	cg07930192	chr7:1003750	NA	0.3	4.72	0.39	6.33e-6	Longevity;Endometriosis;
TGCT	cis	rs377070	0.816	rs309406	chr4:123618707	G/A	cg10495464	chr4:123653540	BBS12;LOC729338	0.44	4.85	0.4	3.66e-6	Mosquito bite size;
TGCT	cis	rs453301	0.658	rs3855900	chr8:8901921	A/G	cg06636001	chr8:8085503	FLJ10661	-0.68	-5.5	-0.44	2.1e-7	Joint mobility (Beighton score);
TGCT	cis	rs10883723	0.810	rs10748823	chr10:104274465	C/G	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs8100891	0.734	rs4804990	chr19:32837429	C/G	cg16662424	chr19:32837316	ZNF507	-0.46	-5.58	-0.45	1.44e-7	Neuroticism;
TGCT	cis	rs9300255	0.602	rs1790098	chr12:123655481	A/C	cg00376283	chr12:123451042	ABCB9	0.66	4.85	0.4	3.59e-6	Neutrophil percentage of white cells;
TGCT	cis	rs11696501	0.694	rs6073825	chr20:44258217	T/C	cg11783356	chr20:44313418	WFDC10B	-0.33	-4.66	-0.39	7.91e-6	Brain structure;
TGCT	cis	rs34779708	0.931	rs35317849	chr10:35285721	C/A	cg04310649	chr10:35416472	CREM	-0.51	-4.55	-0.38	1.24e-5	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs9443189	0.527	rs775059	chr6:76370130	G/T	cg01950844	chr6:76311363	SENP6	1.0	6.24	0.49	6.35e-9	Prostate cancer;
TGCT	cis	rs807669	0.807	rs807431	chr22:19242361	G/A	cg02655711	chr22:19163373	SLC25A1	0.34	7.5	0.56	1.09e-11	Metabolite levels;
TGCT	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg03188948	chr7:1209495	NA	0.59	4.82	0.4	4.06e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs17376456	0.504	rs7702649	chr5:93065149	C/A	cg25358565	chr5:93447407	FAM172A	0.74	6.42	0.5	2.66e-9	Diabetic retinopathy;
TGCT	trans	rs1814175	0.817	rs10128730	chr11:50023369	G/T	cg03929089	chr4:120376271	NA	-0.72	-8.55	-0.61	3.8e-14	Height;
TGCT	cis	rs7552404	0.727	rs2172507	chr1:76331320	A/G	cg03433033	chr1:76189801	ACADM	-0.6	-6.01	-0.48	1.9e-8	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs832540	0.966	rs252923	chr5:56205662	T/G	cg24531977	chr5:56204891	C5orf35	-0.55	-5.75	-0.46	6.44e-8	Coronary artery disease;
TGCT	trans	rs7618501	0.572	rs7428430	chr3:50174184	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.85	-9.03	-0.63	2.77e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs1420338	0.967	rs4720151	chr7:34160523	G/A	cg01275685	chr7:34179230	BMPER	-0.25	-4.56	-0.38	1.23e-5	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs2915864	0.628	rs6580216	chr5:141433075	C/T	cg19884223	chr5:140554610	PCDHB7	-0.64	-4.45	-0.37	1.88e-5	Facial morphology (factor 20);
TGCT	cis	rs9467773	1.000	rs1884949	chr6:26568067	G/A	cg26531700	chr6:26746687	NA	0.5	4.85	0.4	3.64e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs587847	0.767	rs4924155	chr15:37666501	T/C	cg00216138	chr15:37171175	LOC145845	0.31	4.45	0.37	1.91e-5	Intraocular pressure;
TGCT	cis	rs1153858	1.000	rs66939267	chr15:45676902	T/A	cg26924012	chr15:45694286	SPATA5L1	1.09	15.08	0.8	7.99e-30	Homoarginine levels;
TGCT	cis	rs11190604	0.945	rs2495735	chr10:102338609	G/A	cg16342193	chr10:102329863	NA	-0.4	-5.08	-0.42	1.32e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7927592	0.546	rs599083	chr11:68192346	T/G	cg16797656	chr11:68205561	LRP5	0.29	4.97	0.41	2.16e-6	Total body bone mineral density;
TGCT	cis	rs3734905	1.000	rs2075978	chr6:169812588	A/G	cg05229362	chr6:169789120	NA	0.48	4.44	0.37	1.94e-5	HIV-1 control;
TGCT	cis	rs909341	0.678	rs2738778	chr20:62291830	C/T	cg03999872	chr20:62272968	STMN3	-0.36	-4.71	-0.39	6.53e-6	Atopic dermatitis;
TGCT	cis	rs7586879	0.719	rs7565468	chr2:25130092	C/T	cg01884057	chr2:25150051	NA	0.27	4.83	0.4	3.87e-6	Body mass index;
TGCT	cis	rs916888	0.610	rs199436	chr17:44789285	C/T	cg15921436	chr17:44337874	NA	-0.41	-6.58	-0.51	1.21e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2463822	1.000	rs2513747	chr11:62098735	T/C	cg06239285	chr11:62104954	ASRGL1	0.93	6.71	0.52	6.27e-10	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs12142240	0.698	rs112089006	chr1:46812360	C/T	cg14993813	chr1:46806288	NSUN4	-0.58	-4.79	-0.4	4.68e-6	Menopause (age at onset);
TGCT	trans	rs6695400	0.610	rs9433784	chr1:101784340	A/C	cg17848389	chr13:114886717	RASA3	-0.37	-7.12	-0.54	7.76e-11	Initial pursuit acceleration;
TGCT	cis	rs36051895	0.664	rs3780374	chr9:5099677	G/A	cg02405213	chr9:5042618	JAK2	-0.71	-9.43	-0.65	3.07e-16	Pediatric autoimmune diseases;
TGCT	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg17264618	chr3:40429014	ENTPD3	0.32	4.57	0.38	1.18e-5	Renal cell carcinoma;
TGCT	cis	rs7091068	0.671	rs514120	chr10:95404400	G/A	cg20715218	chr10:95462985	C10orf4	-0.54	-5.15	-0.42	9.95e-7	Urinary tract infection frequency;
TGCT	cis	rs2404602	0.569	rs2469249	chr15:76772062	C/T	cg26408565	chr15:76604113	ETFA	0.4	4.56	0.38	1.19e-5	Blood metabolite levels;
TGCT	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	9.11	0.63	1.81e-15	Platelet count;
TGCT	cis	rs4663969	0.733	rs6741669	chr2:234653192	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.26	-4.61	-0.38	9.83e-6	Total bilirubin levels in HIV-1 infection;
TGCT	trans	rs804280	0.509	rs4841639	chr8:11796093	A/T	cg15556689	chr8:8085844	FLJ10661	0.75	7.26	0.55	3.66e-11	Myopia (pathological);
TGCT	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg04944784	chr2:26401820	FAM59B	-0.67	-6.16	-0.48	9.54e-9	Gut microbiome composition (summer);
TGCT	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.71	6.36	0.5	3.53e-9	Tonsillectomy;
TGCT	cis	rs7917772	0.582	rs10786687	chr10:104336994	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	5.36	0.43	3.84e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs13191362	1.000	rs73035021	chr6:163000716	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7666738	0.830	rs1967980	chr4:98966426	C/G	cg17366294	chr4:99064904	C4orf37	0.74	7.54	0.56	8.74e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9611565	0.802	rs4822028	chr22:41789408	A/G	cg03806693	chr22:41940476	POLR3H	-1.01	-11.18	-0.71	1.71e-20	Vitiligo;
TGCT	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg19729930	chr2:74357872	NA	0.57	6.9	0.53	2.39e-10	Gestational age at birth (maternal effect);
TGCT	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg07507251	chr3:52567010	NT5DC2	0.47	6.75	0.52	5.14e-10	Bipolar disorder;
TGCT	cis	rs11098499	0.697	rs4373140	chr4:120307698	A/G	cg09307838	chr4:120376055	NA	0.65	6.39	0.5	3.02e-9	Corneal astigmatism;
TGCT	cis	rs13191362	1.000	rs1333963	chr6:163192571	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.11	8.17	0.59	2.98e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg06558623	chr16:89946397	TCF25	0.56	7.51	0.56	1.04e-11	Skin colour saturation;
TGCT	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg04944784	chr2:26401820	FAM59B	0.71	6.24	0.49	6.24e-9	Gut microbiome composition (summer);
TGCT	cis	rs9372498	0.536	rs9489447	chr6:118900846	G/A	cg21191810	chr6:118973309	C6orf204	-0.39	-5.04	-0.41	1.59e-6	Diastolic blood pressure;
TGCT	trans	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.86	9.41	0.65	3.39e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg11644478	chr21:40555479	PSMG1	1.01	10.47	0.69	8.99e-19	Cognitive function;
TGCT	cis	rs9467773	0.620	rs9461276	chr6:26595168	T/C	cg11502198	chr6:26597334	ABT1	0.54	4.95	0.41	2.42e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg27411982	chr8:10470053	RP1L1	-0.22	-4.81	-0.4	4.3e-6	Retinal vascular caliber;
TGCT	cis	rs9372498	0.706	rs9489396	chr6:118761703	A/C	cg07617317	chr6:118971624	C6orf204	0.5	5.39	0.44	3.37e-7	Diastolic blood pressure;
TGCT	cis	rs6988636	0.818	rs10111810	chr8:124169565	G/A	cg27053337	chr8:124217698	FAM83A	0.67	4.77	0.39	5.15e-6	Urinary uromodulin levels;
TGCT	cis	rs7786808	0.504	rs10949725	chr7:158196003	C/T	cg01191920	chr7:158217561	PTPRN2	0.36	5.27	0.43	5.86e-7	Obesity-related traits;
TGCT	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	16.07	0.82	4.16e-32	Prudent dietary pattern;
TGCT	trans	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg17470723	chr8:74884337	TCEB1	0.72	6.94	0.53	1.91e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg26338869	chr17:61819248	STRADA	-0.53	-4.9	-0.4	2.95e-6	Prudent dietary pattern;
TGCT	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6121246	0.909	rs6119725	chr20:30385557	G/T	cg13852791	chr20:30311386	BCL2L1	0.8	6.12	0.48	1.15e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs7412746	0.587	rs11204722	chr1:150730184	A/C	cg09365446	chr1:150670422	GOLPH3L	-0.33	-4.84	-0.4	3.75e-6	Melanoma;
TGCT	cis	rs9807989	0.507	rs11465721	chr2:103063240	T/G	cg03938978	chr2:103052716	IL18RAP	0.27	5.4	0.44	3.21e-7	Asthma;
TGCT	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg07507251	chr3:52567010	NT5DC2	0.47	6.6	0.51	1.05e-9	Bipolar disorder;
TGCT	cis	rs7666738	0.830	rs3852123	chr4:98697586	A/G	cg05340658	chr4:99064831	C4orf37	0.52	6.13	0.48	1.06e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs208520	1.000	rs72882079	chr6:66973878	T/C	cg07460842	chr6:66804631	NA	0.81	7.16	0.54	6.31e-11	Exhaled nitric oxide output;
TGCT	cis	rs6121246	0.529	rs6060291	chr20:30198043	T/G	cg21427119	chr20:30132790	HM13	-0.43	-6.17	-0.48	8.86e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg06618935	chr21:46677482	NA	-0.37	-5.83	-0.46	4.48e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6545883	0.868	rs7608483	chr2:61836235	A/C	cg15711740	chr2:61764176	XPO1	-0.59	-5.52	-0.44	1.9e-7	Tuberculosis;
TGCT	cis	rs939574	1.000	rs11689596	chr2:220093423	T/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-1.06	-6.52	-0.51	1.6e-9	Platelet distribution width;
TGCT	cis	rs10791097	0.739	rs11222358	chr11:130730497	G/A	cg12179176	chr11:130786555	SNX19	0.73	8.6	0.61	2.98e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs12477438	0.501	rs13008171	chr2:99743419	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	14.89	0.8	2.21e-29	Chronic sinus infection;
TGCT	cis	rs477895	0.713	rs12575642	chr11:63979643	G/T	cg04317338	chr11:64019027	PLCB3	0.81	7.03	0.53	1.23e-10	Mean platelet volume;
TGCT	cis	rs2075371	0.637	rs2544165	chr7:133920443	A/G	cg11752832	chr7:134001865	SLC35B4	-0.64	-5.68	-0.45	9.07e-8	Mean platelet volume;
TGCT	cis	rs7100689	0.646	rs1290317	chr10:82062531	C/A	cg01528321	chr10:82214614	TSPAN14	0.75	7.46	0.56	1.32e-11	Post bronchodilator FEV1;
TGCT	cis	rs727505	0.954	rs66871687	chr7:124670475	A/G	cg23710748	chr7:124431027	NA	-0.27	-4.62	-0.38	9.56e-6	Lewy body disease;
TGCT	cis	rs10193935	0.901	rs10179237	chr2:42515501	C/T	cg27598129	chr2:42591480	NA	-0.39	-5.37	-0.43	3.72e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4468007	0.550	rs4837904	chr9:124620480	T/C	cg01549227	chr9:124980074	LHX6	-0.3	-4.55	-0.38	1.24e-5	Educational attainment;
TGCT	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg25036284	chr2:26402008	FAM59B	0.65	5.19	0.42	8.36e-7	Gut microbiome composition (summer);
TGCT	cis	rs12142240	0.698	rs6695043	chr1:46844530	A/G	cg14993813	chr1:46806288	NSUN4	0.61	5.01	0.41	1.83e-6	Menopause (age at onset);
TGCT	cis	rs7572733	0.534	rs700682	chr2:198712310	C/A	cg00792783	chr2:198669748	PLCL1	0.56	5.08	0.42	1.35e-6	Dermatomyositis;
TGCT	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg13695892	chr22:41940480	POLR3H	-0.9	-8.66	-0.61	2.17e-14	Vitiligo;
TGCT	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg04944784	chr2:26401820	FAM59B	0.76	6.24	0.49	6.46e-9	Gut microbiome composition (summer);
TGCT	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg11494091	chr17:61959527	GH2	0.61	14.34	0.79	4.3e-28	Prudent dietary pattern;
TGCT	cis	rs12291225	0.679	rs10832240	chr11:14304744	C/T	cg19336497	chr11:14380999	RRAS2	-0.38	-5.9	-0.47	3.19e-8	Sense of smell;
TGCT	cis	rs593982	0.764	rs55796623	chr11:65411714	G/A	cg08755490	chr11:65554678	OVOL1	-1.14	-6.29	-0.49	4.98e-9	Atopic dermatitis;
TGCT	cis	rs34734847	1.000	rs56273049	chr12:121156041	A/T	cg21892295	chr12:121157589	UNC119B	-0.24	-5.71	-0.46	7.99e-8	Mean corpuscular volume;
TGCT	cis	rs2730245	0.510	rs2788471	chr7:158649786	G/T	cg24397884	chr7:158709396	WDR60	0.35	4.44	0.37	2e-5	Height;
TGCT	trans	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg21659725	chr3:3221576	CRBN	0.76	9.03	0.63	2.74e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs6964587	0.934	rs2961019	chr7:91572749	T/G	cg17063962	chr7:91808500	NA	-0.88	-9.17	-0.64	1.26e-15	Breast cancer;
TGCT	cis	rs7178572	1.000	rs8024485	chr15:77718368	C/A	cg15453836	chr15:77711506	NA	-0.4	-4.56	-0.38	1.22e-5	Type 2 diabetes;
TGCT	cis	rs9341808	0.683	rs7771449	chr6:80919977	C/T	cg08355045	chr6:80787529	NA	0.32	5.6	0.45	1.29e-7	Sitting height ratio;
TGCT	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.18	0.49	8.32e-9	Bipolar disorder;
TGCT	cis	rs2204008	0.774	rs8186954	chr12:38318566	C/A	cg26384229	chr12:38710491	ALG10B	0.79	6.97	0.53	1.67e-10	Bladder cancer;
TGCT	cis	rs1865760	0.532	rs9295687	chr6:26082710	T/C	cg17042849	chr6:26104293	HIST1H4C	-0.63	-5.47	-0.44	2.43e-7	Height;
TGCT	cis	rs950169	0.580	rs17598114	chr15:85171317	C/T	cg17173187	chr15:85201210	NMB	0.61	6.95	0.53	1.84e-10	Schizophrenia;
TGCT	cis	rs68170813	0.641	rs79434636	chr7:107105656	A/C	cg02696742	chr7:106810147	HBP1	-0.63	-4.92	-0.4	2.68e-6	Coronary artery disease;
TGCT	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg11494091	chr17:61959527	GH2	0.43	7.51	0.56	9.88e-12	Height;
TGCT	cis	rs8016982	0.657	rs8021125	chr14:81704787	C/T	cg01989461	chr14:81687754	GTF2A1	-0.8	-7.86	-0.58	1.61e-12	Schizophrenia;
TGCT	cis	rs12541335	0.639	rs3923433	chr8:22169798	A/T	cg18135555	chr8:22132992	PIWIL2	0.3	6.14	0.48	1.02e-8	Hypertriglyceridemia;
TGCT	cis	rs981844	1.000	rs2251639	chr4:154656410	T/C	cg14289246	chr4:154710475	SFRP2	1.04	8.19	0.59	2.74e-13	Response to statins (LDL cholesterol change);
TGCT	cis	rs11887277	0.707	rs4513249	chr2:27058451	G/T	cg14949065	chr2:27373128	TCF23	0.19	4.49	0.37	1.62e-5	Obesity-related traits;
TGCT	cis	rs10782582	0.593	rs11163904	chr1:76121208	A/G	cg03433033	chr1:76189801	ACADM	0.62	7.18	0.54	5.71e-11	Daytime sleep phenotypes;
TGCT	cis	rs4746818	1.000	rs10762263	chr10:70970178	A/G	cg04149295	chr10:70884716	VPS26A	0.8	5.39	0.44	3.38e-7	Left atrial antero-posterior diameter;
TGCT	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg01448562	chr3:133502909	NA	-0.33	-6.58	-0.51	1.16e-9	Iron status biomarkers;
TGCT	cis	rs2361718	0.500	rs8068856	chr17:78100731	A/G	cg21238619	chr17:78079768	GAA	-0.37	-4.65	-0.39	8.52e-6	Yeast infection;
TGCT	cis	rs2290416	0.688	rs34892354	chr8:144690648	G/C	cg08017634	chr8:144659831	NAPRT1	0.51	4.68	0.39	7.36e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs10927875	0.631	rs28579893	chr1:16347534	A/G	cg21385522	chr1:16154831	NA	0.61	6.27	0.49	5.37e-9	Dilated cardiomyopathy;
TGCT	cis	rs7586879	0.616	rs6726199	chr2:25126328	G/C	cg15423357	chr2:25149977	NA	0.5	4.89	0.4	3.06e-6	Body mass index;
TGCT	cis	rs4252435	0.614	rs73460471	chr7:142600094	A/G	cg09833174	chr7:143059591	FAM131B	-0.96	-4.52	-0.38	1.41e-5	Cancer;
TGCT	cis	rs4455778	0.724	rs10227744	chr7:49007522	A/G	cg26309511	chr7:48887640	NA	-0.49	-5.87	-0.47	3.75e-8	Lung cancer in never smokers;
TGCT	cis	rs6750047	0.585	rs4670234	chr2:38272477	C/T	cg07380506	chr2:38303506	CYP1B1	0.59	5.36	0.43	3.84e-7	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs36051895	0.587	rs11999802	chr9:5189773	T/G	cg02405213	chr9:5042618	JAK2	-0.66	-7.81	-0.57	2.13e-12	Pediatric autoimmune diseases;
TGCT	cis	rs896854	0.846	rs13254283	chr8:95914103	G/T	cg16049864	chr8:95962084	TP53INP1	-0.71	-9.83	-0.66	3.32e-17	Type 2 diabetes;
TGCT	cis	rs806215	0.547	rs10487497	chr7:127400667	C/T	cg11539674	chr7:127291444	SND1	0.36	4.76	0.39	5.32e-6	Type 2 diabetes;
TGCT	cis	rs2072499	0.868	rs2758600	chr1:156195205	C/T	cg25208724	chr1:156163844	SLC25A44	1.11	12.68	0.75	3.79e-24	Testicular germ cell tumor;
TGCT	cis	rs7264396	0.747	rs2425151	chr20:34394541	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.3	-5.25	-0.43	6.36e-7	Total cholesterol levels;
TGCT	cis	rs2180341	1.000	rs6937287	chr6:127645719	T/A	cg27446573	chr6:127587934	RNF146	1.12	10.11	0.67	6.87e-18	Breast cancer;
TGCT	cis	rs6555855	0.868	rs1592818	chr5:168741524	G/T	cg26492514	chr5:168728236	SLIT3	-0.28	-4.48	-0.37	1.66e-5	Menarche (age at onset);
TGCT	cis	rs66887589	0.592	rs11731571	chr4:120221185	G/A	cg24670566	chr4:120433619	PDE5A	0.21	4.52	0.38	1.43e-5	Diastolic blood pressure;
TGCT	cis	rs67311347	1.000	rs17078916	chr3:40445438	C/T	cg13683864	chr3:40499215	RPL14	-1.19	-13.2	-0.76	2.17e-25	Renal cell carcinoma;
TGCT	cis	rs11025559	1.000	rs11025559	chr11:20443875	A/G	cg19653624	chr11:20408972	PRMT3	0.61	4.72	0.39	6.3e-6	Pursuit maintenance gain;
TGCT	cis	rs8064299	0.597	rs7210318	chr17:72783385	T/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.88	9.97	0.67	1.49e-17	Monocyte count;
TGCT	cis	rs2204008	0.605	rs4608149	chr12:38132057	G/C	cg13010199	chr12:38710504	ALG10B	0.64	5.16	0.42	9.41e-7	Bladder cancer;
TGCT	cis	rs8014204	0.753	rs6574199	chr14:75356103	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.75	-7.25	-0.55	4e-11	Caffeine consumption;
TGCT	cis	rs2046867	0.818	rs2208	chr3:72871773	A/G	cg25664220	chr3:72788482	NA	0.52	6.66	0.51	8.01e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs394563	0.726	rs6922130	chr6:149672375	C/G	cg11245181	chr6:149772854	ZC3H12D	0.28	4.6	0.38	1.01e-5	Dupuytren's disease;
TGCT	cis	rs11673344	0.542	rs1667380	chr19:37492750	C/T	cg08039142	chr19:36980659	ZNF566	0.58	5.61	0.45	1.25e-7	Obesity-related traits;
TGCT	cis	rs2964802	0.505	rs1438714	chr5:10811422	G/A	cg14521931	chr5:10832172	NA	-0.28	-4.59	-0.38	1.09e-5	Major depressive disorder;Recurrent major depressive disorder;
TGCT	cis	rs4319547	0.760	rs61954973	chr12:123074168	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.68	-5.38	-0.44	3.5e-7	Body mass index;
TGCT	cis	rs2153535	0.580	rs1414348	chr6:8471940	A/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs904251	0.523	rs2797798	chr6:37481437	C/T	cg08126542	chr6:37504118	NA	-0.44	-6.51	-0.5	1.71e-9	Cognitive performance;
TGCT	cis	rs1451375	0.698	rs11489736	chr7:50645372	G/A	cg18232548	chr7:50535776	DDC	0.44	6.72	0.52	5.81e-10	Malaria;
TGCT	cis	rs559928	0.576	rs750830	chr11:64163446	G/A	cg12453748	chr11:64085041	PRDX5;TRMT112	0.57	4.95	0.41	2.36e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
TGCT	cis	rs459571	1.000	rs456207	chr9:136911140	G/A	cg14405625	chr9:136855902	VAV2	-0.3	-4.54	-0.38	1.3e-5	Platelet distribution width;
TGCT	cis	rs9902453	0.933	rs7224199	chr17:28523726	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	5.35	0.43	4.09e-7	Coffee consumption (cups per day);
TGCT	cis	rs9914988	0.887	rs2070265	chr17:27075423	A/G	cg20469991	chr17:27169893	C17orf63	0.72	5.04	0.41	1.58e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs3820068	0.656	rs72645829	chr1:15889748	A/G	cg05660106	chr1:15850417	CASP9	1.17	14.8	0.8	3.47e-29	Systolic blood pressure;
TGCT	cis	rs7843479	0.601	rs4872204	chr8:21841396	T/C	cg17168535	chr8:21777572	XPO7	0.8	7.93	0.58	1.08e-12	Mean corpuscular volume;
TGCT	cis	rs11779988	0.545	rs438873	chr8:17786516	G/A	cg01800426	chr8:17659068	MTUS1	-0.7	-5.46	-0.44	2.5e-7	Breast cancer;
TGCT	cis	rs7312933	0.584	rs6582391	chr12:42634686	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.54	5.16	0.42	9.61e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs2980439	0.556	rs2921059	chr8:8317887	G/T	cg06636001	chr8:8085503	FLJ10661	0.77	7.11	0.54	8.23e-11	Neuroticism;
TGCT	cis	rs4366490	0.687	rs1939752	chr11:62910214	G/A	cg21002970	chr11:62369079	MTA2	0.71	5.03	0.41	1.66e-6	Conotruncal heart defects;
TGCT	cis	rs2230307	0.536	rs580678	chr1:100483009	C/A	cg24955406	chr1:100503596	HIAT1	0.74	4.83	0.4	4e-6	Carotid intima media thickness;
TGCT	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg10047753	chr17:41438598	NA	0.96	9.6	0.65	1.16e-16	Menopause (age at onset);
TGCT	cis	rs2404602	0.532	rs206205	chr15:76736091	T/G	cg22467129	chr15:76604101	ETFA	-0.42	-4.72	-0.39	6.24e-6	Blood metabolite levels;
TGCT	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg02018176	chr4:1364513	KIAA1530	0.26	4.44	0.37	1.93e-5	Longevity;
TGCT	cis	rs3806933	0.522	rs11241100	chr5:110460958	C/T	cg04022379	chr5:110408740	TSLP	0.59	6.11	0.48	1.18e-8	Eosinophilic esophagitis;
TGCT	cis	rs11190604	1.000	rs10883497	chr10:102228519	A/G	cg23241863	chr10:102295624	HIF1AN	0.61	4.76	0.39	5.24e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg06221963	chr1:154839813	KCNN3	-0.77	-12.94	-0.76	9.36e-25	Prostate cancer;
TGCT	cis	rs2153535	0.580	rs2143357	chr6:8497196	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs34526934	0.608	rs34720456	chr2:177027292	G/A	cg00278547	chr2:177037212	HOXD3	-0.4	-4.98	-0.41	2.09e-6	Obstructive sleep apnea trait (apnea hypopnea index);
TGCT	cis	rs7647973	0.731	rs9831648	chr3:49214303	G/T	cg07690219	chr3:49449608	TCTA;RHOA	-0.58	-4.54	-0.38	1.29e-5	Menarche (age at onset);
TGCT	cis	rs7927592	0.546	rs554734	chr11:68192518	T/G	cg16797656	chr11:68205561	LRP5	0.29	4.97	0.41	2.16e-6	Total body bone mineral density;
TGCT	cis	rs4664308	0.967	rs62175559	chr2:160955833	G/A	cg03641300	chr2:160917029	PLA2R1	-0.28	-6.84	-0.52	3.28e-10	Idiopathic membranous nephropathy;
TGCT	cis	rs992157	0.643	rs10191283	chr2:219056755	G/A	cg00012203	chr2:219082015	ARPC2	0.83	10.68	0.69	2.77e-19	Colorectal cancer;
TGCT	trans	rs561341	0.831	rs11658469	chr17:30206426	T/C	cg20587970	chr11:113659929	NA	0.8	9.45	0.65	2.65e-16	Hip circumference adjusted for BMI;
TGCT	cis	rs6570726	0.791	rs11759979	chr6:145918881	C/T	cg05347473	chr6:146136440	FBXO30	0.53	4.92	0.4	2.74e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2730245	0.510	rs2788474	chr7:158649005	T/C	cg24397884	chr7:158709396	WDR60	0.36	4.58	0.38	1.11e-5	Height;
TGCT	cis	rs17376456	0.825	rs10476590	chr5:93244884	A/T	cg25358565	chr5:93447407	FAM172A	1.01	7.9	0.58	1.29e-12	Diabetic retinopathy;
TGCT	cis	rs7020830	0.825	rs13297152	chr9:37075623	C/T	cg14294708	chr9:37120828	ZCCHC7	1.29	18.67	0.86	7.91e-38	Schizophrenia;
TGCT	cis	rs2067615	0.524	rs4275715	chr12:107062246	C/T	cg15890332	chr12:107067104	RFX4	0.28	5.56	0.45	1.59e-7	Heart rate;
TGCT	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	6.02	0.48	1.81e-8	Alzheimer's disease;
TGCT	cis	rs7926906	1.000	rs12291122	chr11:90531578	A/C	cg22332266	chr11:89956777	CHORDC1	-0.43	-4.5	-0.37	1.55e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs8141529	0.702	rs8137262	chr22:29292135	C/T	cg02153584	chr22:29168773	CCDC117	0.64	4.91	0.4	2.87e-6	Lymphocyte counts;
TGCT	cis	rs6089584	0.606	rs2273989	chr20:60579138	G/A	cg13770153	chr20:60521292	NA	-0.41	-5.12	-0.42	1.15e-6	Body mass index;
TGCT	cis	rs11264213	0.591	rs408986	chr1:36551895	C/T	cg27506609	chr1:36549197	TEKT2	0.47	5.52	0.44	1.9e-7	Schizophrenia;
TGCT	cis	rs1218582	0.741	rs705094	chr1:154917314	G/A	cg16680214	chr1:154839983	KCNN3	-0.37	-7.66	-0.57	4.71e-12	Prostate cancer;
TGCT	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg01570182	chr17:44337453	NA	1.03	9.28	0.64	6.84e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs17221829	0.614	rs10765236	chr11:89450030	G/A	cg02982614	chr11:89391479	FOLH1B	-0.29	-5.09	-0.42	1.3e-6	Anxiety in major depressive disorder;
TGCT	cis	rs2370759	1.000	rs11594963	chr10:32625736	G/A	cg01819863	chr10:32635814	EPC1	1.02	9.91	0.66	2.11e-17	Sexual dysfunction (female);
TGCT	cis	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg25427524	chr10:38739819	LOC399744	-0.39	-8.04	-0.59	5.95e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs910316	0.763	rs175047	chr14:75479039	C/G	cg11812906	chr14:75593930	NEK9	-0.59	-5.69	-0.45	8.86e-8	Height;
TGCT	cis	rs12142240	0.698	rs68012736	chr1:46839510	A/G	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs12765878	0.603	rs2475213	chr10:105664459	A/T	cg11005552	chr10:105648138	OBFC1	0.41	6.46	0.5	2.15e-9	Coronary artery disease;
TGCT	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg26338869	chr17:61819248	STRADA	-0.53	-4.87	-0.4	3.29e-6	Prudent dietary pattern;
TGCT	cis	rs9467711	0.606	rs9366655	chr6:26377385	C/G	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs28595532	0.920	rs115797971	chr4:119779620	A/G	cg21605333	chr4:119757512	SEC24D	1.53	8.87	0.62	6.71e-15	Cannabis dependence symptom count;
TGCT	cis	rs6500602	0.701	rs8129	chr16:4562351	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.4	7.29	0.55	3.2e-11	Schizophrenia;
TGCT	cis	rs6586111	1.000	rs4934371	chr10:82372795	A/G	cg03086067	chr10:82368399	SH2D4B	0.24	4.48	0.37	1.68e-5	Capecitabine sensitivity;
TGCT	cis	rs6690583	0.623	rs12042910	chr1:85452580	G/A	cg20280350	chr1:85513789	MCOLN3	-0.74	-5.11	-0.42	1.2e-6	Serum sulfate level;
TGCT	cis	rs17473412	0.926	rs115796963	chr5:122654779	A/G	cg15125798	chr5:122621645	NA	-0.66	-5.97	-0.47	2.29e-8	Total body bone mineral density;
TGCT	cis	rs3796352	1.000	rs116616340	chr3:53132371	C/G	cg07884673	chr3:53033167	SFMBT1	0.54	5.76	0.46	6.2e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs734999	0.967	rs6672381	chr1:2502834	A/G	cg18854424	chr1:2615690	NA	0.47	5.92	0.47	3.01e-8	Ulcerative colitis;
TGCT	cis	rs860554	0.510	rs2071960	chr1:201291066	C/T	cg01022117	chr1:201258280	PKP1	-0.27	-4.91	-0.4	2.77e-6	Panic disorder;
TGCT	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg16325326	chr1:53192061	ZYG11B	-0.89	-12.84	-0.76	1.58e-24	Monocyte count;
TGCT	cis	rs736408	0.924	rs2535629	chr3:52833219	C/T	cg07507251	chr3:52567010	NT5DC2	0.47	6.24	0.49	6.45e-9	Bipolar disorder;
TGCT	cis	rs62244186	0.659	rs9855433	chr3:44468065	C/A	cg02073558	chr3:44770973	ZNF501	0.58	5.6	0.45	1.28e-7	Depressive symptoms;
TGCT	cis	rs17331151	0.505	rs7614424	chr3:52566354	C/T	cg07884673	chr3:53033167	SFMBT1	0.74	4.99	0.41	1.98e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs2721195	0.577	rs4532636	chr8:145904423	A/C	cg15320075	chr8:145703422	NA	-0.63	-5.63	-0.45	1.14e-7	Age at first birth;
TGCT	cis	rs9807989	0.507	rs6710528	chr2:103016142	A/G	cg03938978	chr2:103052716	IL18RAP	-0.28	-5.59	-0.45	1.39e-7	Asthma;
TGCT	cis	rs7584330	0.910	rs6757376	chr2:238400036	G/C	cg16989719	chr2:238392110	NA	-0.29	-4.89	-0.4	3.01e-6	Prostate cancer;
TGCT	cis	rs7267979	0.844	rs6083845	chr20:25388090	G/C	cg16686733	chr20:25566563	NINL	-0.52	-4.93	-0.4	2.61e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs8037137	0.915	rs2290202	chr15:91512267	G/T	cg22570213	chr15:91497863	RCCD1	0.49	4.72	0.39	6.18e-6	Platelet count;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
TGCT	cis	rs4240897	0.935	rs3766744	chr1:12043717	G/A	cg05523254	chr1:12040215	MFN2	0.47	4.51	0.38	1.5e-5	Tuberculosis;
TGCT	cis	rs2307449	0.704	rs758131	chr15:89884301	T/A	cg01877814	chr15:89879097	POLG	0.29	4.46	0.37	1.83e-5	Menopause (age at onset);
TGCT	cis	rs12368653	1.000	rs12371356	chr12:58135420	T/C	cg12615879	chr12:58013172	SLC26A10	0.46	5.72	0.46	7.65e-8	Multiple sclerosis;
TGCT	cis	rs4631830	0.900	rs4630241	chr10:51532751	G/A	cg10326726	chr10:51549505	MSMB	-0.27	-5.38	-0.43	3.6e-7	Prostate-specific antigen levels;
TGCT	cis	rs999943	0.846	rs999942	chr6:33624902	G/C	cg14003231	chr6:33640908	ITPR3	0.4	4.86	0.4	3.48e-6	Obesity (extreme);
TGCT	cis	rs595982	0.661	rs657008	chr19:49373632	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.37	-5.05	-0.41	1.56e-6	Red cell distribution width;
TGCT	cis	rs11190604	0.725	rs9420796	chr10:102323092	G/C	cg16342193	chr10:102329863	NA	-0.4	-5.08	-0.42	1.32e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2836950	0.509	rs4816618	chr21:40599529	G/A	cg11644478	chr21:40555479	PSMG1	-0.54	-5.1	-0.42	1.25e-6	Menarche (age at onset);
TGCT	cis	rs7666738	0.830	rs6829567	chr4:99047340	T/C	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9911578	1.000	rs12602346	chr17:56901713	T/C	cg12560992	chr17:57184187	TRIM37	0.76	9.21	0.64	1.03e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs7726839	1.000	rs7726839	chr5:618586	A/G	cg09021430	chr5:549028	NA	-0.38	-5.52	-0.44	1.93e-7	Obesity-related traits;
TGCT	cis	rs7044106	0.537	rs10818474	chr9:123489964	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.48	5.22	0.42	7.39e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs7267979	0.844	rs6107017	chr20:25232300	A/G	cg16686733	chr20:25566563	NINL	0.52	4.9	0.4	2.98e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9611565	0.592	rs5751139	chr22:42099981	G/C	cg06634786	chr22:41940651	POLR3H	0.89	8.81	0.62	9.46e-15	Vitiligo;
TGCT	cis	rs559928	0.556	rs11607903	chr11:63932140	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	4.56	0.38	1.22e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
TGCT	cis	rs4665630	0.708	rs115460150	chr2:23896434	C/A	cg08063864	chr2:24346004	PFN4;LOC375190	1.0	4.97	0.41	2.17e-6	Hypertension;
TGCT	cis	rs12681287	0.547	rs13267858	chr8:87510871	G/A	cg19078186	chr8:87526527	CPNE3	-0.37	-4.57	-0.38	1.15e-5	Caudate activity during reward;
TGCT	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg06636001	chr8:8085503	FLJ10661	0.76	6.8	0.52	3.97e-10	Systolic blood pressure;
TGCT	cis	rs6582630	0.555	rs11182217	chr12:38480030	G/A	cg13010199	chr12:38710504	ALG10B	0.61	4.81	0.4	4.34e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs79387448	0.745	rs7582378	chr2:103162263	C/A	cg09003973	chr2:102972529	NA	0.92	5.89	0.47	3.39e-8	Gut microbiota (bacterial taxa);
TGCT	trans	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg27523141	chr10:43048294	ZNF37B	0.7	8.15	0.59	3.36e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs568617	0.768	rs12225345	chr11:65647105	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.67	5.7	0.46	8.36e-8	Crohn's disease;
TGCT	cis	rs7666738	0.830	rs7673385	chr4:99024922	T/G	cg05340658	chr4:99064831	C4orf37	0.51	5.82	0.46	4.75e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg11247378	chr22:39784982	NA	-0.75	-9.73	-0.66	5.69e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs7659604	0.540	rs4075065	chr4:122683906	A/G	cg19748678	chr4:122722346	EXOSC9	-0.48	-4.86	-0.4	3.54e-6	Type 2 diabetes;
TGCT	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.64	-5.57	-0.45	1.53e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs9916302	0.851	rs9909064	chr17:37500434	G/T	cg07936489	chr17:37558343	FBXL20	0.65	5.08	0.41	1.36e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg03264133	chr6:25882463	NA	0.86	8.88	0.62	6.24e-15	Blood metabolite levels;
TGCT	cis	rs910316	0.935	rs175422	chr14:75627319	T/A	cg23033748	chr14:75592666	NEK9	-0.28	-4.84	-0.4	3.84e-6	Height;
TGCT	cis	rs66569888	0.507	rs67196165	chr2:106886496	C/G	cg15412446	chr2:106886593	NA	-0.53	-6.76	-0.52	4.9e-10	Facial morphology (factor 23);
TGCT	cis	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg07424592	chr7:64974309	NA	1.27	7.84	0.58	1.8e-12	Diabetic kidney disease;
TGCT	cis	rs4919694	0.808	rs112574306	chr10:104971159	C/T	cg04362960	chr10:104952993	NT5C2	1.09	6.67	0.51	7.46e-10	Arsenic metabolism;
TGCT	cis	rs9733	0.650	rs11204680	chr1:150587140	T/G	cg13175981	chr1:150552382	MCL1	0.54	6.13	0.48	1.09e-8	Tonsillectomy;
TGCT	cis	rs9303401	0.703	rs9911583	chr17:57210721	A/G	cg12560992	chr17:57184187	TRIM37	-0.47	-4.55	-0.38	1.28e-5	Cognitive test performance;
TGCT	cis	rs6586163	0.872	rs7910825	chr10:90743341	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.38	-4.7	-0.39	6.86e-6	Chronic lymphocytic leukemia;
TGCT	trans	rs941408	1.000	rs1640274	chr19:2807375	G/A	cg22153745	chr1:153894579	GATAD2B	-0.7	-6.98	-0.53	1.57e-10	Total cholesterol levels;
TGCT	cis	rs2153535	0.580	rs1119690	chr6:8460660	G/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs548987	0.507	rs1408268	chr6:25826986	T/A	cg03264133	chr6:25882463	NA	-0.54	-4.44	-0.37	1.99e-5	Homocysteine levels;
TGCT	cis	rs826838	0.586	rs10880753	chr12:38628147	C/A	cg26384229	chr12:38710491	ALG10B	-0.54	-4.74	-0.39	5.87e-6	Heart rate;
TGCT	cis	rs117785887	0.536	rs12205195	chr6:146364300	G/A	cg06708562	chr6:146285465	SHPRH	-0.8	-4.81	-0.4	4.23e-6	Interleukin-17 levels;
TGCT	cis	rs67311347	1.000	rs7648952	chr3:40457038	C/T	cg17264618	chr3:40429014	ENTPD3	-0.32	-4.76	-0.39	5.36e-6	Renal cell carcinoma;
TGCT	cis	rs1467026	0.691	rs9985266	chr3:12803162	C/T	cg05775895	chr3:12838266	CAND2	-0.55	-5.25	-0.43	6.5e-7	P wave duration;
TGCT	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg13695892	chr22:41940480	POLR3H	-0.91	-9.07	-0.63	2.18e-15	Vitiligo;
TGCT	cis	rs1023500	0.573	rs1807494	chr22:42474138	C/G	cg15557168	chr22:42548783	NA	0.22	5.58	0.45	1.47e-7	Schizophrenia;
TGCT	cis	rs921968	0.541	rs620596	chr2:219462419	G/A	cg02176678	chr2:219576539	TTLL4	0.48	6.78	0.52	4.32e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg08509172	chr19:19383838	TM6SF2	0.33	4.46	0.37	1.83e-5	Tonsillectomy;
TGCT	cis	rs10838634	1.000	rs7112060	chr11:46891901	C/T	cg18332754	chr11:46939436	LRP4	0.89	4.77	0.39	5.13e-6	Schizophrenia;
TGCT	cis	rs2153535	0.580	rs7341383	chr6:8470634	A/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs2735413	0.564	rs74316728	chr16:78099653	C/T	cg09132178	chr16:78079569	NA	0.36	4.5	0.37	1.55e-5	Systolic blood pressure (alcohol consumption interaction);
TGCT	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.59	-8.2	-0.59	2.64e-13	Longevity;Endometriosis;
TGCT	cis	rs12530134	1.000	rs12530134	chr6:170919470	G/A	cg02645993	chr6:170674463	FAM120B	0.36	4.53	0.38	1.35e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg19626725	chr5:178986131	RUFY1	0.49	6.09	0.48	1.31e-8	Lung cancer;
TGCT	cis	rs981844	1.000	rs62325105	chr4:154673846	T/C	cg14289246	chr4:154710475	SFRP2	1.01	8.67	0.61	2.02e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs7267979	1.000	rs2482941	chr20:25361216	T/C	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1577917	0.771	rs2842602	chr6:86331887	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.57	-0.45	1.5e-7	Response to antipsychotic treatment;
TGCT	cis	rs77741769	0.571	rs1542859	chr12:121336766	A/G	cg02419362	chr12:121203948	SPPL3	0.19	4.5	0.37	1.56e-5	Mean corpuscular volume;
TGCT	cis	rs9368481	0.594	rs2636425	chr6:26799460	A/G	cg02458000	chr6:26745757	NA	0.59	5.14	0.42	1.03e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg24399712	chr22:39784796	NA	0.96	11.54	0.72	2.26e-21	IgG glycosylation;
TGCT	cis	rs968567	0.539	rs174555	chr11:61579760	T/C	cg19610905	chr11:61596333	FADS2	-1.05	-11.51	-0.72	2.6e-21	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
TGCT	cis	rs11030122	0.702	rs10767702	chr11:3934132	T/C	cg18678763	chr11:4115507	RRM1	-0.52	-6.41	-0.5	2.8e-9	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs36051895	0.695	rs4527935	chr9:5016455	A/T	cg02405213	chr9:5042618	JAK2	-0.72	-9.35	-0.64	4.65e-16	Pediatric autoimmune diseases;
TGCT	cis	rs4293393	1.000	rs13333226	chr16:20365654	A/G	cg26923810	chr16:20935690	LYRM1	0.2	4.44	0.37	2e-5	Chronic kidney disease and serum creatinine levels;
TGCT	cis	rs9911578	0.839	rs1871751	chr17:57190368	A/G	cg05425664	chr17:57184151	TRIM37	-0.65	-6.5	-0.5	1.77e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg13770153	chr20:60521292	NA	0.56	6.96	0.53	1.71e-10	Body mass index;
TGCT	cis	rs6060960	0.502	rs6057968	chr20:30082779	A/T	cg21427119	chr20:30132790	HM13	-0.39	-5.56	-0.45	1.58e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
TGCT	cis	rs204693	0.547	rs205894	chr20:543616	T/C	cg15180867	chr20:591076	TCF15	-0.65	-4.48	-0.37	1.69e-5	Pursuit maintenance gain;
TGCT	cis	rs7568458	0.777	rs12473819	chr2:85773061	A/G	cg17127132	chr2:85788382	GGCX	0.7	6.64	0.51	8.96e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs713587	0.934	rs6728219	chr2:25159172	T/C	cg01884057	chr2:25150051	NA	0.4	8.24	0.59	2.03e-13	Body mass index in non-asthmatics;
TGCT	cis	rs2806561	0.765	rs1757046	chr1:23511821	T/C	cg12483005	chr1:23474871	LUZP1	0.38	4.72	0.39	6.25e-6	Height;
TGCT	cis	rs1005224	0.926	rs7143743	chr14:76127805	G/C	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.55	-4.94	-0.41	2.42e-6	Large artery stroke;
TGCT	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg05985448	chr10:134359359	INPP5A	0.23	4.99	0.41	2.01e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs1568889	1.000	rs12794100	chr11:28332785	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	8.8	0.62	9.95e-15	Bipolar disorder;
TGCT	cis	rs7666738	0.830	rs13102652	chr4:99006737	T/G	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg22535103	chr8:58192502	C8orf71	-0.42	-4.79	-0.4	4.7e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1532993	0.518	rs6822369	chr4:98643888	A/T	cg05340658	chr4:99064831	C4orf37	-0.4	-4.87	-0.4	3.32e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs8177253	0.514	rs6790668	chr3:133442481	T/A	cg24879335	chr3:133465180	TF	0.37	5.0	0.41	1.93e-6	Iron status biomarkers;
TGCT	cis	rs7100689	0.646	rs10788586	chr10:82117435	A/G	cg01528321	chr10:82214614	TSPAN14	0.8	7.76	0.57	2.7e-12	Post bronchodilator FEV1;
TGCT	cis	rs1362404	0.648	rs4784889	chr16:51969854	C/A	cg03955530	chr16:52681474	NA	0.28	4.5	0.37	1.56e-5	Gut microbiota (bacterial taxa);
TGCT	cis	rs7772486	0.875	rs2073287	chr6:146350264	T/C	cg05347473	chr6:146136440	FBXO30	0.52	4.93	0.41	2.54e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6964587	0.867	rs12704637	chr7:91874686	C/T	cg17063962	chr7:91808500	NA	0.86	8.63	0.61	2.53e-14	Breast cancer;
TGCT	cis	rs11212617	1.000	rs228591	chr11:108097333	A/G	cg16693212	chr11:108093249	ATM;NPAT	0.48	4.54	0.38	1.33e-5	Response to metformin in type 2 diabetes (glycemic);
TGCT	cis	rs922182	0.617	rs2899697	chr15:64240436	T/C	cg02919090	chr15:64263738	DAPK2	0.37	7.01	0.53	1.35e-10	Blood protein levels;
TGCT	cis	rs35146811	0.735	rs2272344	chr7:99786819	C/T	cg00553149	chr7:99775558	STAG3;GPC2	0.31	4.61	0.38	9.75e-6	Coronary artery disease;
TGCT	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg11764359	chr7:65958608	NA	-0.55	-4.98	-0.41	2.1e-6	Aortic root size;
TGCT	cis	rs28493229	0.522	rs2287692	chr19:41289756	G/A	cg23743927	chr19:41304969	EGLN2	-0.74	-4.67	-0.39	7.7e-6	Kawasaki disease;
TGCT	cis	rs13064447	0.967	rs9873195	chr3:12767936	A/G	cg20675869	chr3:12750130	NA	0.19	4.81	0.4	4.3e-6	Major depression and alcohol dependence;
TGCT	cis	rs6500602	0.702	rs2270366	chr16:4558615	A/G	cg08645402	chr16:4508243	NA	-0.18	-4.91	-0.4	2.83e-6	Schizophrenia;
TGCT	cis	rs6964587	1.000	rs3753107	chr7:91629151	C/T	cg17063962	chr7:91808500	NA	-0.89	-9.88	-0.66	2.44e-17	Breast cancer;
TGCT	cis	rs11696501	0.739	rs6104257	chr20:44262100	G/T	cg11783356	chr20:44313418	WFDC10B	-0.33	-4.69	-0.39	7.08e-6	Brain structure;
TGCT	cis	rs9972944	0.756	rs8072765	chr17:63763508	T/C	cg07283582	chr17:63770753	CCDC46	-0.26	-5.29	-0.43	5.45e-7	Total body bone mineral density;
TGCT	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg11871910	chr12:69753446	YEATS4	-0.88	-10.58	-0.69	4.98e-19	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs9383153	0.793	rs6937740	chr6:16348080	C/T	cg14009473	chr6:15502099	JARID2	0.62	4.94	0.41	2.5e-6	Gambling;
TGCT	cis	rs9549367	0.789	rs9549365	chr13:113907391	C/T	cg00898013	chr13:113819073	PROZ	0.42	5.41	0.44	3.19e-7	Platelet distribution width;
TGCT	cis	rs2180341	0.924	rs6930849	chr6:127630963	A/T	cg27446573	chr6:127587934	RNF146	1.12	10.11	0.67	6.87e-18	Breast cancer;
TGCT	cis	rs8014204	0.806	rs11159104	chr14:75293374	A/G	cg06637938	chr14:75390232	RPS6KL1	0.7	6.74	0.52	5.37e-10	Caffeine consumption;
TGCT	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/A	cg04287289	chr16:89883240	FANCA	0.72	6.72	0.52	5.84e-10	Vitiligo;
TGCT	cis	rs6912958	0.559	rs242281	chr6:88048916	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.72	7.53	0.56	9.05e-12	Monocyte percentage of white cells;
TGCT	cis	rs4629710	0.592	rs4310080	chr6:131538377	T/G	cg12606694	chr6:131520996	AKAP7	0.39	4.57	0.38	1.17e-5	Multiple myeloma (IgH translocation);
TGCT	cis	rs9486715	1.000	rs11153082	chr6:97059666	A/G	cg06623918	chr6:96969491	KIAA0776	-1.12	-15.49	-0.81	8.72e-31	Headache;
TGCT	cis	rs11025559	0.773	rs10833334	chr11:20498640	T/C	cg19653624	chr11:20408972	PRMT3	-0.64	-4.85	-0.4	3.59e-6	Pursuit maintenance gain;
TGCT	cis	rs7635838	0.892	rs6792718	chr3:11434380	A/G	cg00170343	chr3:11313890	ATG7	0.65	6.23	0.49	6.56e-9	HDL cholesterol;
TGCT	cis	rs72781680	0.821	rs72781644	chr2:24209348	T/C	cg08917208	chr2:24149416	ATAD2B	0.72	4.5	0.37	1.56e-5	Lymphocyte counts;
TGCT	cis	rs2380220	0.541	rs72928273	chr6:96079360	C/T	cg04719120	chr6:96025338	MANEA	-0.7	-5.13	-0.42	1.08e-6	Behavioural disinhibition (generation interaction);
TGCT	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.12	0.54	7.78e-11	Prudent dietary pattern;
TGCT	cis	rs228437	0.586	rs9494012	chr6:134964646	A/G	cg09872934	chr6:134495829	SGK1	-0.58	-4.74	-0.39	5.66e-6	Melanoma;
TGCT	cis	rs7017914	0.905	rs3098868	chr8:71929692	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.56	-5.11	-0.42	1.21e-6	Bone mineral density;
TGCT	cis	rs2153535	0.580	rs2184586	chr6:8474182	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	5.03	0.41	1.66e-6	Height;
TGCT	cis	rs3008870	0.755	rs1024230	chr1:67512920	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.79	7.31	0.55	2.83e-11	Lymphocyte percentage of white cells;
TGCT	cis	rs11190604	0.767	rs79106148	chr10:102184732	G/A	cg16005271	chr10:102321736	NA	0.46	4.67	0.39	7.62e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs1669338	0.507	rs4685609	chr3:3202279	T/C	cg16797762	chr3:3221439	CRBN	-0.89	-5.67	-0.45	9.6e-8	White matter integrity;
TGCT	trans	rs17685	0.753	rs2868203	chr7:75680026	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.52	-8.84	-0.62	7.72e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg00149659	chr3:10157352	C3orf10	0.73	4.72	0.39	6.17e-6	Alzheimer's disease;
TGCT	cis	rs7267979	0.903	rs6115101	chr20:25229564	C/A	cg16686733	chr20:25566563	NINL	0.59	6.06	0.48	1.53e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2657888	0.931	rs7301093	chr12:56933244	G/T	cg23002907	chr12:56915593	RBMS2	0.44	6.14	0.48	1.03e-8	Adiponectin levels;
TGCT	cis	rs829883	0.664	rs865509	chr12:98854444	T/A	cg25150519	chr12:98850993	NA	0.64	7.54	0.56	8.56e-12	Colorectal adenoma (advanced);
TGCT	cis	rs28374715	0.662	rs8038983	chr15:41473316	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.81	-11.5	-0.72	2.84e-21	Ulcerative colitis;
TGCT	cis	rs6840360	0.642	rs1443090	chr4:152451819	T/C	cg17479576	chr4:152424074	FAM160A1	-0.62	-6.7	-0.52	6.64e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs6495367	1.000	rs28412916	chr15:79378167	A/C	cg17916960	chr15:79447300	NA	0.36	5.21	0.42	7.56e-7	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs1215050	0.791	rs13114823	chr4:98671119	G/A	cg17366294	chr4:99064904	C4orf37	-0.52	-5.51	-0.44	1.97e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs910316	0.935	rs175448	chr14:75591071	G/A	cg08847533	chr14:75593920	NEK9	-0.94	-10.33	-0.68	2.03e-18	Height;
TGCT	cis	rs8177253	0.665	rs8177178	chr3:133463272	G/A	cg08048268	chr3:133502702	NA	-0.54	-7.08	-0.54	9.62e-11	Iron status biomarkers;
TGCT	cis	rs6684514	0.961	rs10908497	chr1:156274740	G/A	cg16558208	chr1:156270281	VHLL	0.46	9.38	0.64	3.92e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs6714710	0.603	rs11690687	chr2:98461821	C/T	cg26665480	chr2:98280029	ACTR1B	0.64	6.1	0.48	1.26e-8	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs28785552	0.589	rs11669056	chr19:53244443	G/A	cg04754360	chr19:53238445	ZNF611	-0.62	-4.89	-0.4	3.09e-6	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg03934478	chr11:495069	RNH1	0.32	4.96	0.41	2.28e-6	Body mass index;
TGCT	cis	rs6964587	0.782	rs13221571	chr7:91500236	C/T	cg17063962	chr7:91808500	NA	-0.86	-9.21	-0.64	1.02e-15	Breast cancer;
TGCT	cis	rs910316	0.737	rs175499	chr14:75535927	G/A	cg08847533	chr14:75593920	NEK9	-0.84	-8.46	-0.6	6.38e-14	Height;
TGCT	cis	rs611744	0.647	rs674391	chr8:109242803	A/T	cg21045802	chr8:109455806	TTC35	0.69	6.96	0.53	1.73e-10	Dupuytren's disease;
TGCT	cis	rs4654899	0.865	rs72988025	chr1:21351441	A/G	cg01072550	chr1:21505969	NA	-0.46	-6.95	-0.53	1.88e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs752010	0.631	rs1073197	chr1:42059822	C/T	cg06885757	chr1:42089581	HIVEP3	-0.29	-5.21	-0.42	7.78e-7	Lupus nephritis in systemic lupus erythematosus;
TGCT	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg19774624	chr17:42201019	HDAC5	-0.89	-10.87	-0.7	9.7e-20	Total body bone mineral density;
TGCT	cis	rs9467711	0.659	rs35277236	chr6:26562269	G/T	cg16898833	chr6:26189333	HIST1H4D	1.25	5.86	0.47	3.88e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6882046	0.513	rs447801	chr5:88002653	T/C	cg22951263	chr5:87985283	NA	-0.61	-6.53	-0.51	1.49e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	trans	rs28735056	0.935	rs552957	chr18:77595748	G/A	cg05926928	chr17:57297772	GDPD1	-0.68	-6.88	-0.53	2.61e-10	Schizophrenia;
TGCT	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg13877915	chr19:58951672	ZNF132	0.88	10.81	0.7	1.36e-19	Uric acid clearance;
TGCT	cis	rs1371867	0.846	rs1616833	chr8:101271821	C/T	cg00191853	chr8:101177733	SPAG1	0.23	4.8	0.4	4.44e-6	Atrioventricular conduction;
TGCT	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg12310025	chr6:25882481	NA	-0.66	-5.74	-0.46	6.73e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9467773	0.620	rs9461275	chr6:26590801	C/T	cg26531700	chr6:26746687	NA	0.5	4.65	0.39	8.29e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs12477438	0.520	rs13012481	chr2:99754290	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.15	17.85	0.85	4.6e-36	Chronic sinus infection;
TGCT	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg01341218	chr17:43662625	NA	0.85	7.42	0.55	1.63e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs5769765	1.000	rs1033665	chr22:50252127	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.09	-11.87	-0.73	3.47e-22	Schizophrenia;
TGCT	cis	rs6728642	0.908	rs7588921	chr2:98021001	C/T	cg26665480	chr2:98280029	ACTR1B	-0.96	-5.21	-0.42	7.79e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	cis	rs2880765	0.835	rs4843062	chr15:86040137	A/G	cg13263323	chr15:86062960	AKAP13	-0.22	-4.83	-0.4	3.97e-6	Coronary artery disease;
TGCT	cis	rs9318086	0.712	rs9318100	chr13:24442482	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.77	-8.22	-0.59	2.29e-13	Myopia (pathological);
TGCT	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9583531	0.689	rs4773244	chr13:111383937	A/T	cg24331049	chr13:111365604	ING1	-0.88	-8.92	-0.63	5.11e-15	Coronary artery disease;
TGCT	cis	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg13531842	chr10:38383804	ZNF37A	-0.38	-4.51	-0.38	1.49e-5	Extrinsic epigenetic age acceleration;
TGCT	cis	rs4727027	0.933	rs12532104	chr7:148864233	A/C	cg23583168	chr7:148888333	NA	-0.76	-10.09	-0.67	7.46e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs2153535	0.623	rs2152346	chr6:8454652	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg18252515	chr7:66147081	NA	-1.13	-7.39	-0.55	1.94e-11	Diabetic kidney disease;
TGCT	cis	rs7772486	0.790	rs7753696	chr6:146279098	G/T	cg23711669	chr6:146136114	FBXO30	-0.89	-10.17	-0.67	4.95e-18	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs10506458	0.915	rs12426308	chr12:63405778	C/T	cg22491629	chr6:157744540	C6orf35	-1.0	-8.59	-0.61	3.09e-14	Hemostatic factors and hematological phenotypes;
TGCT	trans	rs2688482	0.512	rs2177336	chr3:195516878	T/C	cg17952111	chr19:54960355	LENG8	0.84	6.88	0.53	2.64e-10	Lung disease severity in cystic fibrosis;
TGCT	cis	rs376008	0.526	rs2305742	chr19:18191441	A/C	cg15085805	chr19:18433592	LSM4	0.52	4.74	0.39	5.79e-6	Blood protein levels;
TGCT	cis	rs929354	0.772	rs1002389	chr7:156968323	C/G	cg05182265	chr7:156933206	UBE3C	-0.39	-8.79	-0.62	1.03e-14	Body mass index;
TGCT	cis	rs807669	0.903	rs807667	chr22:19161327	A/G	cg02655711	chr22:19163373	SLC25A1	-0.42	-10.06	-0.67	8.99e-18	Metabolite levels;
TGCT	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.98	7.97	0.58	8.82e-13	Platelet count;
TGCT	cis	rs10510102	0.872	rs7916380	chr10:123703288	C/A	cg23691251	chr10:123688108	ATE1	-0.58	-4.58	-0.38	1.11e-5	Breast cancer;
TGCT	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg11905131	chr22:24372483	LOC391322	-0.95	-11.08	-0.71	2.91e-20	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg12140144	chr1:2984275	FLJ42875;PRDM16	-0.32	-4.54	-0.38	1.34e-5	Height;
TGCT	cis	rs2204008	0.744	rs2222344	chr12:38406832	T/G	cg26384229	chr12:38710491	ALG10B	0.83	7.58	0.56	6.92e-12	Bladder cancer;
TGCT	cis	rs10992471	0.580	rs1535756	chr9:95202032	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.6	-5.67	-0.45	9.42e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs3617	0.598	rs56214994	chr3:52878600	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.48	-4.53	-0.38	1.35e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2180341	1.000	rs2326567	chr6:127606160	G/A	cg27446573	chr6:127587934	RNF146	1.13	10.12	0.67	6.64e-18	Breast cancer;
TGCT	cis	rs7192750	0.563	rs11649672	chr16:71952614	G/C	cg06353428	chr16:71660113	MARVELD3	0.82	7.26	0.55	3.65e-11	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs1670533	1.000	rs2045065	chr4:1052488	A/G	cg27284194	chr4:1044797	NA	0.66	5.49	0.44	2.22e-7	Recombination rate (females);
TGCT	trans	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg17830980	chr10:43048298	ZNF37B	-0.82	-10.26	-0.68	2.99e-18	Extrinsic epigenetic age acceleration;
TGCT	cis	rs79976124	0.842	rs7760550	chr6:66628788	T/C	cg07460842	chr6:66804631	NA	0.59	5.34	0.43	4.3e-7	Type 2 diabetes;
TGCT	cis	rs12188164	0.930	rs72717436	chr5:448291	C/A	cg26850624	chr5:429559	AHRR	-0.2	-4.84	-0.4	3.78e-6	Cystic fibrosis severity;
TGCT	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg00684032	chr4:1343700	KIAA1530	-0.22	-4.73	-0.39	6.06e-6	Obesity-related traits;
TGCT	cis	rs826838	0.967	rs11168985	chr12:39045983	A/C	cg26384229	chr12:38710491	ALG10B	-0.84	-6.91	-0.53	2.3e-10	Heart rate;
TGCT	cis	rs6543140	0.964	rs11903551	chr2:103084181	C/G	cg09003973	chr2:102972529	NA	0.54	4.46	0.37	1.83e-5	Blood protein levels;
TGCT	cis	rs28374715	0.681	rs28712264	chr15:41588797	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.86	-12.43	-0.74	1.54e-23	Ulcerative colitis;
TGCT	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg06112835	chr11:68658793	MRPL21	0.47	8.18	0.59	2.86e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.47	-4.88	-0.4	3.15e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4688759	0.609	rs113176147	chr3:49534439	G/T	cg08550065	chr3:50336684	HYAL3;NAT6	1.22	4.93	0.4	2.58e-6	Blood protein levels;
TGCT	cis	rs10193935	0.901	rs62142639	chr2:42600019	C/G	cg27598129	chr2:42591480	NA	-0.4	-5.44	-0.44	2.71e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4704846	0.904	rs11741184	chr5:156515406	C/G	cg12943317	chr5:156479607	HAVCR1	0.32	4.73	0.39	6.1e-6	Blood protein levels;
TGCT	cis	rs826838	0.616	rs2387921	chr12:38624767	T/C	cg26384229	chr12:38710491	ALG10B	-0.54	-4.74	-0.39	5.87e-6	Heart rate;
TGCT	cis	rs1005224	0.864	rs11625011	chr14:76144828	G/A	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.62	-5.75	-0.46	6.6e-8	Large artery stroke;
TGCT	cis	rs2072499	0.554	rs1052067	chr1:156206121	C/T	cg25208724	chr1:156163844	SLC25A44	0.65	5.51	0.44	1.96e-7	Testicular germ cell tumor;
TGCT	cis	rs5750830	0.645	rs4821890	chr22:39777523	G/A	cg02038168	chr22:39784481	NA	-0.68	-6.13	-0.48	1.05e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs78487399	0.808	rs75934770	chr2:43659694	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.45	-5.35	-0.43	4.03e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs1215050	0.791	rs1025201	chr4:98902938	A/G	cg17366294	chr4:99064904	C4orf37	-0.53	-5.69	-0.45	8.67e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7917772	0.582	rs12782153	chr10:104368294	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-5.46	-0.44	2.51e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs554111	0.613	rs10753510	chr1:21412248	G/A	cg01072550	chr1:21505969	NA	0.36	5.46	0.44	2.51e-7	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs838147	0.507	rs1704773	chr19:49209566	A/G	cg05248581	chr19:49925731	PTH2	0.41	4.51	0.38	1.5e-5	Dietary macronutrient intake;
TGCT	cis	rs80282103	0.867	rs7098169	chr10:1078601	G/A	cg08668510	chr10:1095578	IDI1	1.12	4.67	0.39	7.72e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg09359103	chr1:154839909	KCNN3	-0.74	-15.86	-0.82	1.26e-31	Prostate cancer;
TGCT	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg25036284	chr2:26402008	FAM59B	-0.57	-4.99	-0.41	2e-6	Gut microbiome composition (summer);
TGCT	cis	rs7681440	0.869	rs7680557	chr4:90763360	C/A	cg26578617	chr4:90757533	SNCA	-0.49	-5.1	-0.42	1.26e-6	Dementia with Lewy bodies;
TGCT	cis	rs3885907	0.542	rs9315047	chr13:31321289	T/A	cg22282089	chr13:30686841	NA	-0.22	-4.6	-0.38	1.03e-5	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU);
TGCT	cis	rs494003	1.000	rs494003	chr11:65542298	G/A	cg04293602	chr11:65553660	OVOL1	0.36	4.65	0.39	8.51e-6	Systemic lupus erythematosus;
TGCT	cis	rs7666738	0.830	rs7678250	chr4:98922109	G/A	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12497850	0.897	rs7432989	chr3:49105136	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.42	-5.42	-0.44	3e-7	Parkinson's disease;
TGCT	cis	rs9926296	0.624	rs1110331	chr16:89774396	A/G	cg26513180	chr16:89883248	FANCA	-0.56	-4.93	-0.4	2.62e-6	Vitiligo;
TGCT	cis	rs7674212	0.541	rs2720460	chr4:104054686	C/T	cg16532752	chr4:104119610	CENPE	0.56	4.9	0.4	2.93e-6	Type 2 diabetes;
TGCT	cis	rs11031096	0.542	rs6578424	chr11:3973140	G/A	cg08557956	chr11:4115526	RRM1	-0.49	-4.44	-0.37	1.97e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs1215050	0.791	rs155019	chr4:98759126	G/A	cg05340658	chr4:99064831	C4orf37	0.44	5.52	0.44	1.85e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2688608	0.933	rs2633307	chr10:75653881	G/A	cg19442545	chr10:75533431	FUT11	-0.29	-4.63	-0.38	8.99e-6	Inflammatory bowel disease;
TGCT	cis	rs6879260	1.000	rs10903252	chr5:179733934	T/C	cg02891314	chr5:179741120	GFPT2	-0.41	-7.16	-0.54	6.21e-11	Height;
TGCT	cis	rs11025559	0.796	rs10833317	chr11:20412277	A/T	cg19653624	chr11:20408972	PRMT3	-0.62	-4.84	-0.4	3.73e-6	Pursuit maintenance gain;
TGCT	cis	rs4808199	0.948	rs11085261	chr19:19462606	G/A	cg03709012	chr19:19516395	GATAD2A	0.81	6.55	0.51	1.4e-9	Nonalcoholic fatty liver disease;
TGCT	cis	rs17331151	0.512	rs9637477	chr3:52891426	G/C	cg15956490	chr3:53032818	SFMBT1	-0.47	-5.9	-0.47	3.27e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs7432375	0.800	rs1280622	chr3:136508008	C/A	cg12473912	chr3:136751656	NA	-0.34	-4.77	-0.39	5.06e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12989701	0.877	rs35860453	chr2:127866047	C/T	cg08168897	chr2:127865431	BIN1	0.53	5.77	0.46	6.05e-8	Alzheimer's disease (late onset);
TGCT	cis	rs13242816	0.892	rs34205980	chr7:116078406	T/A	cg02799643	chr7:116139180	CAV2	-0.43	-5.08	-0.42	1.33e-6	P wave duration;
TGCT	cis	rs208520	0.837	rs208498	chr6:66931560	G/A	cg07460842	chr6:66804631	NA	-0.9	-9.15	-0.63	1.45e-15	Exhaled nitric oxide output;
TGCT	cis	rs12142240	0.698	rs68191463	chr1:46808695	T/C	cg14993813	chr1:46806288	NSUN4	-0.58	-4.81	-0.4	4.34e-6	Menopause (age at onset);
TGCT	cis	rs3096299	0.900	rs2911258	chr16:89480760	A/G	cg06640241	chr16:89574553	SPG7	0.65	6.33	0.49	4.05e-9	Multiple myeloma (IgH translocation);
TGCT	cis	rs539096	0.872	rs2478978	chr1:44031657	C/T	cg12908607	chr1:44402522	ARTN	0.49	5.19	0.42	8.41e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs3809566	0.613	rs16946330	chr15:63324501	C/G	cg00520135	chr15:63333846	TPM1	0.4	4.81	0.4	4.25e-6	Platelet count;
TGCT	cis	rs9527	1.000	rs9527	chr10:104623578	C/T	cg04362960	chr10:104952993	NT5C2	0.64	5.24	0.43	6.75e-7	Arsenic metabolism;
TGCT	cis	rs9325144	0.560	rs6582539	chr12:38630097	C/T	cg26384229	chr12:38710491	ALG10B	-0.67	-5.95	-0.47	2.55e-8	Morning vs. evening chronotype;
TGCT	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg07636037	chr3:49044803	WDR6	0.86	8.45	0.6	6.53e-14	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs1348850	0.914	rs4341974	chr2:178324879	A/C	cg22681709	chr2:178499509	PDE11A	-0.37	-4.89	-0.4	3.01e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs9611565	0.918	rs2281333	chr22:41749630	T/C	cg02107564	chr22:41488750	EP300	-0.54	-4.44	-0.37	1.96e-5	Vitiligo;
TGCT	cis	rs9611565	0.765	rs132915	chr22:41805782	T/C	cg06481639	chr22:41940642	POLR3H	0.6	5.48	0.44	2.23e-7	Vitiligo;
TGCT	cis	rs7523050	0.643	rs34572569	chr1:109401856	A/T	cg08274380	chr1:109419600	GPSM2	1.3	6.39	0.5	2.99e-9	Fat distribution (HIV);
TGCT	cis	rs3733585	0.683	rs13112015	chr4:9933796	C/T	cg11266682	chr4:10021025	SLC2A9	-0.57	-7.3	-0.55	3.08e-11	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg00343986	chr7:65444356	GUSB	0.24	5.41	0.44	3.13e-7	Calcium levels;
TGCT	cis	rs4788570	0.510	rs9931074	chr16:71667680	C/T	cg06353428	chr16:71660113	MARVELD3	1.54	12.33	0.74	2.73e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs3764400	0.567	rs4995899	chr17:46150730	G/A	cg02340556	chr17:46797764	NA	0.41	4.47	0.37	1.72e-5	Body mass index;
TGCT	cis	rs7191439	0.858	rs7205626	chr16:88780472	T/C	cg27087555	chr16:88793112	FAM38A	-0.43	-4.87	-0.4	3.4e-6	Plateletcrit;
TGCT	cis	rs2046867	0.862	rs58538718	chr3:72800563	C/A	cg25664220	chr3:72788482	NA	-0.57	-7.05	-0.53	1.13e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7267979	1.000	rs2500404	chr20:25359758	A/C	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1801251	1.000	rs2012221	chr2:233566848	T/C	cg25237894	chr2:233734115	C2orf82	0.32	5.58	0.45	1.45e-7	Coronary artery disease;
TGCT	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg03303774	chr4:1407052	NA	0.33	4.96	0.41	2.31e-6	Obesity-related traits;
TGCT	cis	rs2562456	0.876	rs11085468	chr19:21751889	C/T	cg25650185	chr19:21324782	ZNF431	-0.64	-5.7	-0.46	8.24e-8	Pain;
TGCT	cis	rs3733585	0.699	rs28613263	chr4:9964880	C/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.68	-0.51	7.36e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs6892003	0.857	rs10071232	chr5:174180140	G/T	cg06056415	chr5:174162510	NA	0.44	4.62	0.38	9.46e-6	Clopidogrel active metabolite levels;
TGCT	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg27535305	chr1:53392650	SCP2	-0.25	-5.06	-0.41	1.47e-6	Monocyte count;
TGCT	cis	rs13242816	0.881	rs55930206	chr7:116172850	C/T	cg16553024	chr7:116138462	CAV2	-0.44	-5.26	-0.43	6.11e-7	P wave duration;
TGCT	cis	rs3617	0.573	rs2336667	chr3:52916363	C/T	cg11645453	chr3:52864694	ITIH4	-0.27	-5.17	-0.42	9.18e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2013441	1.000	rs8074047	chr17:20176703	G/A	cg18979559	chr17:20280153	CCDC144C	-0.45	-4.66	-0.39	8.02e-6	Obesity-related traits;
TGCT	cis	rs9393692	0.840	rs9358915	chr6:26277268	G/A	cg05868516	chr6:26286170	HIST1H4H	0.56	5.35	0.43	4.01e-7	Educational attainment;
TGCT	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.72	5.19	0.42	8.33e-7	Platelet count;
TGCT	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg21862992	chr11:68658383	NA	0.47	6.54	0.51	1.42e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs826838	0.802	rs10785619	chr12:38742897	T/A	cg26384229	chr12:38710491	ALG10B	0.89	8.19	0.59	2.66e-13	Heart rate;
TGCT	cis	rs7917772	0.503	rs7915589	chr10:104299264	G/A	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2153535	0.601	rs9505473	chr6:8538777	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.67	0.45	9.45e-8	Motion sickness;
TGCT	cis	rs1153858	1.000	rs7164602	chr15:45671325	A/G	cg26924012	chr15:45694286	SPATA5L1	1.09	15.16	0.81	5.15e-30	Homoarginine levels;
TGCT	cis	rs524281	0.731	rs2452682	chr11:65812609	C/T	cg00563793	chr11:65837595	PACS1	0.61	4.46	0.37	1.85e-5	Electroencephalogram traits;
TGCT	cis	rs2242116	0.796	rs9852082	chr3:46972377	T/C	cg27129171	chr3:47204927	SETD2	0.66	6.23	0.49	6.52e-9	Birth weight;
TGCT	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg14008862	chr17:28927542	LRRC37B2	-0.73	-4.7	-0.39	6.84e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg17971929	chr21:40555470	PSMG1	0.97	9.51	0.65	1.95e-16	Cognitive function;
TGCT	cis	rs6586163	0.872	rs7082720	chr10:90742049	C/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.36	-4.47	-0.37	1.76e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs9549367	0.789	rs9577218	chr13:113894911	A/G	cg18105134	chr13:113819100	PROZ	-0.35	-5.94	-0.47	2.68e-8	Platelet distribution width;
TGCT	cis	rs9314614	0.899	rs2977802	chr8:6694845	C/G	cg27319216	chr8:6693540	XKR5	0.27	4.64	0.38	8.77e-6	IgA nephropathy;White blood cell count (basophil);
TGCT	trans	rs208520	0.661	rs851466	chr6:66840476	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-10.43	-0.68	1.13e-18	Exhaled nitric oxide output;
TGCT	trans	rs12339966	0.580	rs2171664	chr9:11292003	T/C	cg07173112	chr1:1114698	TTLL10	-0.34	-6.77	-0.52	4.66e-10	Systolic blood pressure;
TGCT	cis	rs10193935	1.000	rs13386385	chr2:42436928	G/T	cg27598129	chr2:42591480	NA	-0.39	-5.14	-0.42	1.05e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2014572	0.967	rs10427146	chr19:57755998	T/C	cg24459738	chr19:57751996	ZNF805	-0.55	-5.5	-0.44	2.1e-7	Hyperactive-impulsive symptoms;
TGCT	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg12419862	chr22:24373484	LOC391322	-0.63	-6.16	-0.48	9.46e-9	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7666738	0.791	rs10033211	chr4:98995624	T/A	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12497850	0.931	rs7430198	chr3:48988760	T/C	cg06212747	chr3:49208901	KLHDC8B	0.61	5.5	0.44	2.06e-7	Parkinson's disease;
TGCT	cis	rs250677	0.652	rs36045	chr5:148441184	A/G	cg18129178	chr5:148520854	ABLIM3	0.42	5.7	0.46	8.4e-8	Breast cancer;
TGCT	cis	rs28595532	0.920	rs56162974	chr4:119742333	T/C	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs7772486	0.875	rs13204280	chr6:146415368	T/C	cg23711669	chr6:146136114	FBXO30	0.89	9.47	0.65	2.36e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7267979	1.000	rs6132835	chr20:25434667	A/G	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2645424	0.530	rs1293303	chr8:11720227	C/G	cg18999641	chr8:11876646	NA	-0.21	-4.48	-0.37	1.71e-5	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
TGCT	cis	rs4233949	0.535	rs11125534	chr2:54620866	G/T	cg14634210	chr2:54682758	SPTBN1	0.5	4.54	0.38	1.34e-5	Bone mineral density;
TGCT	cis	rs2224391	0.628	rs2753236	chr6:5252214	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-1.04	-6.74	-0.52	5.44e-10	Height;
TGCT	cis	rs8070740	0.898	rs11078562	chr17:5326857	A/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.49	4.88	0.4	3.15e-6	Menopause (age at onset);
TGCT	cis	rs6424115	1.000	rs7521961	chr1:24157634	C/T	cg15997130	chr1:24165203	NA	-0.92	-10.61	-0.69	4.13e-19	Immature fraction of reticulocytes;
TGCT	cis	rs17376456	0.825	rs28705226	chr5:93233135	T/C	cg21475434	chr5:93447410	FAM172A	0.7	4.9	0.4	2.96e-6	Diabetic retinopathy;
TGCT	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg07167872	chr1:205819463	PM20D1	0.68	9.98	0.67	1.4e-17	Menarche (age at onset);
TGCT	cis	rs9581857	0.519	rs9581880	chr13:28105850	C/A	cg22138327	chr13:27999177	GTF3A	0.72	4.75	0.39	5.45e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs6088590	1.000	rs6120750	chr20:33465289	A/C	cg06115741	chr20:33292138	TP53INP2	0.64	5.1	0.42	1.25e-6	Coronary artery disease;
TGCT	cis	rs4820539	0.966	rs2267005	chr22:23461723	A/G	cg14186256	chr22:23484241	RTDR1	0.93	11.47	0.72	3.32e-21	Bone mineral density;
TGCT	cis	rs10875746	0.903	rs12313404	chr12:48492048	T/A	cg20731937	chr12:48336164	NA	0.63	4.96	0.41	2.24e-6	Longevity (90 years and older);
TGCT	cis	rs7914558	0.933	rs10883814	chr10:104737404	T/C	cg15744005	chr10:104629667	AS3MT	-0.41	-5.08	-0.42	1.33e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs6700896	0.500	rs4655555	chr1:66080269	T/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.59	4.56	0.38	1.22e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs886126	0.950	rs6490025	chr12:111691081	T/C	cg10833066	chr12:111807467	FAM109A	0.33	5.64	0.45	1.07e-7	Coronary heart disease;
TGCT	cis	rs362272	0.505	rs13104157	chr4:3366950	T/C	cg22655196	chr4:3374909	RGS12	0.24	4.85	0.4	3.63e-6	Serum sulfate level;
TGCT	cis	rs5769765	0.955	rs5770750	chr22:50276828	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.4	-6.07	-0.48	1.46e-8	Schizophrenia;
TGCT	cis	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg22857025	chr5:266934	NA	-0.32	-6.53	-0.51	1.5e-9	Breast cancer;
TGCT	cis	rs7681440	0.728	rs1812923	chr4:90739539	C/A	cg14346243	chr4:90757452	SNCA	-0.54	-5.1	-0.42	1.24e-6	Dementia with Lewy bodies;
TGCT	cis	rs7659604	0.502	rs4075066	chr4:122684283	T/C	cg19748678	chr4:122722346	EXOSC9	-0.52	-5.27	-0.43	5.91e-7	Type 2 diabetes;
TGCT	cis	rs6669384	0.547	rs2745979	chr1:208018219	G/C	cg22525895	chr1:207977042	MIR29B2	-0.41	-6.04	-0.48	1.68e-8	Immune response to measles vaccine (measles-specific neutralising antibody titre);
TGCT	cis	rs7208859	0.673	rs3764420	chr17:29164154	A/G	cg18442181	chr17:29233375	C17orf42	-0.77	-4.54	-0.38	1.32e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs2073300	1.000	rs6106656	chr20:23444301	A/G	cg09953122	chr20:23471693	CST8	-0.61	-4.45	-0.37	1.9e-5	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs9894429	0.621	rs9747119	chr17:79607017	A/G	cg18240062	chr17:79603768	NPLOC4	0.56	4.92	0.4	2.67e-6	Eye color traits;
TGCT	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg18402987	chr7:1209562	NA	0.38	4.82	0.4	4.05e-6	Longevity;Endometriosis;
TGCT	cis	rs28595532	0.920	rs55640619	chr4:119761999	C/T	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg06238570	chr21:40685208	BRWD1	-0.79	-8.74	-0.62	1.36e-14	Cognitive function;
TGCT	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg24531977	chr5:56204891	C5orf35	0.77	7.61	0.56	5.83e-12	Initial pursuit acceleration;
TGCT	cis	rs62244186	0.541	rs3804583	chr3:44884647	G/T	cg25151919	chr3:44754333	ZNF502	-0.46	-5.31	-0.43	4.79e-7	Depressive symptoms;
TGCT	cis	rs968451	0.813	rs5757614	chr22:39717554	G/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.84	8.54	0.61	4.02e-14	Primary biliary cholangitis;
TGCT	cis	rs7267979	1.000	rs6132835	chr20:25434667	A/G	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3780378	1.000	rs10815158	chr9:5112844	G/A	cg02405213	chr9:5042618	JAK2	-0.65	-8.86	-0.62	7.07e-15	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs9926296	0.609	rs4785709	chr16:89796665	G/A	cg04287289	chr16:89883240	FANCA	-0.65	-6.47	-0.5	2.04e-9	Vitiligo;
TGCT	cis	rs11971779	0.680	rs6962186	chr7:139034806	T/C	cg07862535	chr7:139043722	LUC7L2	0.57	4.55	0.38	1.24e-5	Diisocyanate-induced asthma;
TGCT	cis	rs9341808	0.667	rs1408292	chr6:80883906	G/T	cg08355045	chr6:80787529	NA	0.31	5.1	0.42	1.26e-6	Sitting height ratio;
TGCT	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg04944784	chr2:26401820	FAM59B	-0.69	-6.18	-0.49	8.53e-9	Gut microbiome composition (summer);
TGCT	cis	rs9303401	0.659	rs12602389	chr17:56779778	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.59	5.99	0.47	2.08e-8	Cognitive test performance;
TGCT	cis	rs10193935	0.901	rs10169411	chr2:42637749	G/A	cg27598129	chr2:42591480	NA	-0.37	-5.23	-0.42	7.1e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg20637647	chr7:64974828	NA	0.89	4.99	0.41	2.01e-6	Diabetic kidney disease;
TGCT	cis	rs12142240	0.659	rs111723629	chr1:46853361	G/T	cg00530320	chr1:46809349	NSUN4	0.29	5.79	0.46	5.34e-8	Menopause (age at onset);
TGCT	cis	rs7267979	0.932	rs449370	chr20:25451180	A/G	cg03522245	chr20:25566470	NINL	-0.63	-6.77	-0.52	4.49e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg27535305	chr1:53392650	SCP2	-0.28	-5.36	-0.43	3.92e-7	Monocyte count;
TGCT	trans	rs9951602	0.512	rs1599635	chr18:76643819	G/A	cg02800362	chr5:177631904	HNRNPAB	1.13	12.94	0.76	9.39e-25	Obesity-related traits;
TGCT	cis	rs4595586	0.525	rs12818844	chr12:39423806	A/G	cg10518543	chr12:38710700	ALG10B	0.54	4.5	0.37	1.56e-5	Morning vs. evening chronotype;
TGCT	cis	rs523522	0.962	rs2235218	chr12:120888619	A/C	cg12219531	chr12:120966889	COQ5	0.79	6.99	0.53	1.47e-10	High light scatter reticulocyte count;
TGCT	cis	rs6815814	0.898	rs6848423	chr4:38887933	C/T	cg02016764	chr4:38805732	TLR1	-0.35	-5.39	-0.44	3.35e-7	Breast cancer;
TGCT	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg10876282	chr6:28092338	ZSCAN16	0.5	4.6	0.38	1.01e-5	Parkinson's disease;
TGCT	cis	rs7089973	0.624	rs1359080	chr10:116582419	C/A	cg03647239	chr10:116582469	FAM160B1	0.58	5.63	0.45	1.16e-7	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg11494091	chr17:61959527	GH2	0.6	14.54	0.79	1.46e-28	Prudent dietary pattern;
TGCT	cis	rs3741404	1.000	rs3741404	chr11:63999240	G/C	cg19570321	chr11:63258214	HRASLS5	0.46	5.25	0.43	6.52e-7	Platelet count;
TGCT	cis	rs6547741	1.000	rs11127071	chr2:27838058	C/A	cg27432699	chr2:27873401	GPN1	0.18	4.56	0.38	1.19e-5	Oral cavity cancer;
TGCT	cis	rs3540	0.574	rs2657946	chr15:90967513	G/C	cg22089800	chr15:90895588	ZNF774	0.76	8.15	0.59	3.29e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs7209700	0.788	rs12949936	chr17:45372422	A/G	cg21624342	chr17:45890973	OSBPL7	0.19	5.16	0.42	9.53e-7	IgG glycosylation;
TGCT	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg22963979	chr7:1858916	MAD1L1	-0.35	-5.31	-0.43	4.8e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs6690583	0.623	rs898036	chr1:85521904	A/T	cg20280350	chr1:85513789	MCOLN3	-0.82	-5.27	-0.43	5.92e-7	Serum sulfate level;
TGCT	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg16325326	chr1:53192061	ZYG11B	0.5	5.56	0.45	1.56e-7	Monocyte count;
TGCT	cis	rs12142240	0.667	rs41293287	chr1:46808852	C/T	cg00530320	chr1:46809349	NSUN4	0.29	5.88	0.47	3.63e-8	Menopause (age at onset);
TGCT	cis	rs7666738	0.761	rs13136913	chr4:98998031	C/T	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs826838	0.935	rs11168761	chr12:38997211	C/A	cg26384229	chr12:38710491	ALG10B	1.04	10.61	0.69	4.07e-19	Heart rate;
TGCT	cis	rs7191439	0.858	rs8044367	chr16:88783374	A/G	cg27087555	chr16:88793112	FAM38A	-0.54	-5.86	-0.47	3.88e-8	Plateletcrit;
TGCT	cis	rs7172809	0.615	rs78021430	chr15:77846082	G/T	cg22256960	chr15:77711686	NA	-0.45	-4.44	-0.37	1.96e-5	Glucose homeostasis traits;
TGCT	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg07157834	chr1:205819609	PM20D1	-0.33	-4.61	-0.38	9.98e-6	Menarche (age at onset);
TGCT	cis	rs7727544	0.735	rs274568	chr5:131713578	C/T	cg24060327	chr5:131705240	SLC22A5	0.58	6.47	0.5	2.02e-9	Blood metabolite levels;
TGCT	cis	rs2996428	0.628	rs6667526	chr1:3774603	G/A	cg17848003	chr1:3704513	LRRC47	0.18	4.91	0.4	2.81e-6	Red cell distribution width;
TGCT	cis	rs3784262	0.934	rs4646611	chr15:58265083	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.49	-7.45	-0.56	1.41e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs4237845	0.537	rs59401446	chr12:58259564	G/A	cg23860436	chr12:58378763	NA	0.34	4.54	0.38	1.31e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs2762353	0.603	rs10946798	chr6:25781853	T/G	cg03517284	chr6:25882590	NA	0.51	5.11	0.42	1.18e-6	Blood metabolite levels;
TGCT	cis	rs6977660	0.714	rs10486365	chr7:19801364	A/G	cg05791153	chr7:19748676	TWISTNB	0.74	4.45	0.37	1.9e-5	Thyroid stimulating hormone;
TGCT	cis	rs1949733	0.958	rs3103069	chr4:8509451	T/G	cg11789530	chr4:8429930	ACOX3	-0.65	-5.95	-0.47	2.58e-8	Response to antineoplastic agents;
TGCT	cis	rs7824557	0.806	rs6601574	chr8:11094885	G/A	cg21775007	chr8:11205619	TDH	-0.5	-4.55	-0.38	1.27e-5	Retinal vascular caliber;
TGCT	cis	rs1008375	1.000	rs4698641	chr4:17642630	C/T	cg18681998	chr4:17616180	MED28	1.02	12.01	0.73	1.65e-22	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9902453	0.874	rs11653805	chr17:28378276	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.81	-7.67	-0.57	4.37e-12	Coffee consumption (cups per day);
TGCT	cis	rs9467773	0.620	rs2451711	chr6:26663110	A/G	cg02458000	chr6:26745757	NA	0.51	4.66	0.39	8.19e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6121246	0.559	rs6060857	chr20:30300222	A/G	cg13852791	chr20:30311386	BCL2L1	0.8	7.42	0.55	1.61e-11	Mean corpuscular hemoglobin;
TGCT	cis	rs7668190	0.924	rs28622224	chr4:55088093	C/T	cg17187183	chr4:55093834	PDGFRA	0.43	6.2	0.49	7.85e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2404602	0.647	rs12440511	chr15:76993135	A/G	cg22467129	chr15:76604101	ETFA	0.46	4.6	0.38	1.05e-5	Blood metabolite levels;
TGCT	cis	rs12042938	0.600	rs1865225	chr1:231763004	A/G	cg04892437	chr1:231737901	TSNAX-DISC1	-0.45	-4.68	-0.39	7.42e-6	Neuranatomic and neurocognitive phenotypes;
TGCT	cis	rs11264213	0.686	rs625306	chr1:36454016	T/C	cg07093915	chr1:36184400	C1orf216	0.65	4.47	0.37	1.77e-5	Schizophrenia;
TGCT	cis	rs9486719	0.948	rs2499817	chr6:96878321	C/T	cg18709589	chr6:96969512	KIAA0776	0.71	5.21	0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs17221829	0.645	rs9804648	chr11:89375840	A/G	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.63	-0.38	9.04e-6	Anxiety in major depressive disorder;
TGCT	cis	rs2933343	0.621	rs728838	chr3:128589013	A/G	cg11901034	chr3:128598214	ACAD9	-0.63	-6.2	-0.49	7.62e-9	IgG glycosylation;
TGCT	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9303401	0.538	rs3785493	chr17:56472119	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.56	-5.11	-0.42	1.21e-6	Cognitive test performance;
TGCT	cis	rs2730245	0.527	rs2527202	chr7:158738849	T/C	cg11984989	chr7:158649758	WDR60	-0.96	-6.98	-0.53	1.61e-10	Height;
TGCT	cis	rs1997103	1.000	rs9642580	chr7:55400359	G/A	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	9.52	0.65	1.86e-16	Platelet count;
TGCT	cis	rs10507380	0.766	rs79754516	chr13:27925487	G/T	cg25543773	chr13:27185723	WASF3	0.32	4.52	0.38	1.45e-5	Electrocardiographic traits;
TGCT	cis	rs12360000	0.832	rs12761504	chr10:1907561	C/A	cg26364871	chr10:1889757	NA	0.41	4.63	0.38	9.26e-6	Metabolite levels (Dihydroxy docosatrienoic acid);
TGCT	cis	rs4455778	0.600	rs4404870	chr7:49078959	G/A	cg26309511	chr7:48887640	NA	0.5	6.47	0.5	2.03e-9	Lung cancer in never smokers;
TGCT	cis	rs478304	0.651	rs11227299	chr11:65549570	C/G	cg27068330	chr11:65405492	SIPA1	-0.95	-9.33	-0.64	5.13e-16	Acne (severe);
TGCT	cis	rs514406	0.683	rs10157120	chr1:53210888	A/G	cg01802117	chr1:53393560	SCP2	-0.42	-5.01	-0.41	1.87e-6	Monocyte count;
TGCT	cis	rs5769707	0.642	rs4824070	chr22:50031521	T/C	cg06623630	chr22:50017776	C22orf34	-0.27	-4.56	-0.38	1.22e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs9309473	0.615	rs62153183	chr2:73763366	A/G	cg07208825	chr2:73871855	ALMS1P	0.26	4.87	0.4	3.31e-6	Metabolite levels;
TGCT	cis	rs6671200	0.607	rs3767315	chr1:95705972	A/G	cg26537280	chr1:95699037	RWDD3	-0.51	-4.9	-0.4	2.94e-6	Stearic acid (18:0) levels;
TGCT	trans	rs1814175	0.645	rs4411280	chr11:49962750	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.67	-0.69	2.92e-19	Height;
TGCT	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg14893161	chr1:205819251	PM20D1	0.37	4.54	0.38	1.31e-5	Menarche (age at onset);
TGCT	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg20607798	chr8:58055168	NA	0.61	5.06	0.41	1.5e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7726839	0.540	rs74553517	chr5:665671	C/T	cg09021430	chr5:549028	NA	-0.4	-5.64	-0.45	1.08e-7	Obesity-related traits;
TGCT	cis	rs12220898	0.749	rs4297382	chr10:50471555	G/A	cg25968469	chr10:49687287	ARHGAP22	-0.28	-4.51	-0.38	1.51e-5	Inflammatory biomarkers;
TGCT	cis	rs7017914	0.934	rs6992879	chr8:71699283	A/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.53	-4.98	-0.41	2.09e-6	Bone mineral density;
TGCT	cis	rs2688608	0.592	rs11000760	chr10:75493734	G/A	cg19442545	chr10:75533431	FUT11	-0.37	-5.77	-0.46	5.89e-8	Inflammatory bowel disease;
TGCT	cis	rs11031096	0.679	rs12292515	chr11:4206385	T/G	cg18678763	chr11:4115507	RRM1	-0.45	-5.84	-0.46	4.31e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs12497850	0.764	rs6784111	chr3:49178846	T/C	cg06212747	chr3:49208901	KLHDC8B	0.61	5.4	0.44	3.31e-7	Parkinson's disease;
TGCT	cis	rs4642101	0.640	rs12629398	chr3:12826799	A/G	cg05775895	chr3:12838266	CAND2	0.92	11.28	0.71	9.6e-21	QRS complex (12-leadsum);
TGCT	cis	rs8078723	1.000	rs4795416	chr17:38158133	C/T	cg17467752	chr17:38218738	THRA	0.55	5.34	0.43	4.24e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg01448562	chr3:133502909	NA	-0.33	-6.79	-0.52	4.13e-10	Iron status biomarkers;
TGCT	cis	rs7223966	1.000	rs9747164	chr17:61864787	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	4.62	0.38	9.63e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg19318889	chr4:1322082	MAEA	0.19	4.58	0.38	1.13e-5	Longevity;
TGCT	cis	rs262150	0.837	rs2657404	chr7:158783155	C/T	cg19418458	chr7:158789849	NA	-0.45	-4.69	-0.39	7.16e-6	Facial morphology (factor 20);
TGCT	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg06238570	chr21:40685208	BRWD1	-0.8	-9.02	-0.63	2.92e-15	Cognitive function;
TGCT	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-1.04	-14.28	-0.79	5.95e-28	Menarche (age at onset);
TGCT	cis	rs6998277	1.000	rs16869658	chr8:103633762	C/T	cg10187029	chr8:103597600	NA	0.43	5.44	0.44	2.76e-7	Migraine;
TGCT	cis	rs9650657	0.615	rs7818181	chr8:10696515	C/T	cg16664915	chr8:10907788	XKR6	-0.29	-4.69	-0.39	7.01e-6	Neuroticism;
TGCT	cis	rs7659604	0.840	rs6821305	chr4:122713863	A/C	cg06713675	chr4:122721982	EXOSC9	-0.48	-6.12	-0.48	1.14e-8	Type 2 diabetes;
TGCT	cis	rs9911578	0.967	rs405684	chr17:56777148	T/C	cg12560992	chr17:57184187	TRIM37	0.76	9.34	0.64	4.88e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs7940866	1.000	rs7940866	chr11:130817579	A/T	cg12179176	chr11:130786555	SNX19	-0.59	-5.53	-0.44	1.81e-7	Schizophrenia;
TGCT	cis	rs185694	1.000	rs202098	chr13:30896774	G/T	cg07600127	chr13:30881527	KATNAL1	-0.82	-6.64	-0.51	8.92e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
TGCT	cis	rs7312933	0.618	rs7315968	chr12:42637086	G/A	cg19980929	chr12:42632907	YAF2	0.41	5.86	0.47	3.85e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs116095464	1.000	rs28416084	chr5:217640	G/A	cg12570787	chr5:219185	SDHA;CCDC127	0.71	4.75	0.39	5.44e-6	Breast cancer;
TGCT	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg24675658	chr1:53192096	ZYG11B	-0.78	-9.21	-0.64	1.01e-15	Monocyte count;
TGCT	cis	rs10782582	0.609	rs5745410	chr1:76314356	C/A	cg10523679	chr1:76189770	ACADM	-0.59	-5.42	-0.44	2.94e-7	Daytime sleep phenotypes;
TGCT	cis	rs12681288	0.862	rs7814231	chr8:1021103	A/G	cg04851639	chr8:1020857	NA	-0.37	-6.84	-0.52	3.27e-10	Schizophrenia;
TGCT	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg11890956	chr21:40555474	PSMG1	1.1	11.97	0.73	2e-22	Cognitive function;
TGCT	cis	rs7666738	0.830	rs7674095	chr4:99048158	T/A	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs911555	0.504	rs745079	chr14:104073551	G/A	cg26031613	chr14:104095156	KLC1	0.61	5.6	0.45	1.34e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs8072100	0.837	rs62074055	chr17:45771933	G/C	cg08085267	chr17:45401833	C17orf57	-0.44	-5.16	-0.42	9.69e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs7833790	0.700	rs7825180	chr8:82723991	T/A	cg23324259	chr8:82754387	SNX16	-0.61	-4.71	-0.39	6.42e-6	Diastolic blood pressure;
TGCT	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs5769765	0.818	rs8140681	chr22:50292081	C/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.09	-11.86	-0.73	3.71e-22	Schizophrenia;
TGCT	cis	rs9682041	0.877	rs10804841	chr3:170072031	T/A	cg07589077	chr3:170072950	NA	0.29	5.15	0.42	1e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs6496667	0.533	rs2074584	chr15:91009381	C/T	cg22089800	chr15:90895588	ZNF774	0.51	4.44	0.37	1.97e-5	Rheumatoid arthritis;
TGCT	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg25767906	chr1:53392781	SCP2	0.48	5.55	0.45	1.62e-7	Monocyte count;
TGCT	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.84	10.12	0.67	6.47e-18	Prudent dietary pattern;
TGCT	cis	rs896854	0.654	rs13278601	chr8:95972974	G/C	cg16049864	chr8:95962084	TP53INP1	-0.75	-10.47	-0.69	9.05e-19	Type 2 diabetes;
TGCT	cis	rs7246657	1.000	rs7246657	chr19:37747108	C/T	cg03233940	chr19:37894644	NA	0.37	4.79	0.39	4.73e-6	Coronary artery calcification;
TGCT	cis	rs9300255	0.537	rs1790101	chr12:123704844	T/C	cg00376283	chr12:123451042	ABCB9	0.73	5.67	0.45	9.46e-8	Neutrophil percentage of white cells;
TGCT	cis	rs9368481	0.761	rs4358615	chr6:26998567	A/G	cg26531700	chr6:26746687	NA	0.55	5.18	0.42	8.89e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2797160	0.904	rs2326292	chr6:125999674	G/A	cg05901451	chr6:126070800	HEY2	-0.78	-6.85	-0.52	3.01e-10	Endometrial cancer;
TGCT	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg18305652	chr10:134549665	INPP5A	0.35	5.69	0.45	8.83e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs2880765	0.835	rs4842884	chr15:86035174	T/C	cg13263323	chr15:86062960	AKAP13	-0.22	-4.79	-0.4	4.68e-6	Coronary artery disease;
TGCT	cis	rs11696501	0.688	rs6130894	chr20:44322673	G/A	cg11783356	chr20:44313418	WFDC10B	-0.33	-4.49	-0.37	1.6e-5	Brain structure;
TGCT	cis	rs12477438	0.501	rs12992218	chr2:99753834	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	17.43	0.84	3.73e-35	Chronic sinus infection;
TGCT	cis	rs10892173	0.566	rs10892175	chr11:117674355	G/A	cg21640587	chr11:117668038	DSCAML1	0.71	8.19	0.59	2.74e-13	Myopia;
TGCT	cis	rs916888	0.821	rs199504	chr17:44861003	C/T	cg17911788	chr17:44343683	NA	0.58	6.01	0.47	1.93e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs9467773	0.620	rs2504565	chr6:26656890	G/A	cg02458000	chr6:26745757	NA	0.5	4.52	0.38	1.4e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7226408	0.817	rs55766643	chr18:34448069	T/G	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs908922	0.651	rs1337341	chr1:152508259	A/C	cg20991723	chr1:152506922	NA	0.46	6.08	0.48	1.36e-8	Hair morphology;
TGCT	cis	rs5769707	0.521	rs6009810	chr22:50059540	A/G	cg05373962	chr22:49881684	NA	-0.32	-5.41	-0.44	3.16e-7	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs10489202	0.632	rs413168	chr1:168005789	C/G	cg24449463	chr1:168025552	DCAF6	-0.6	-7.13	-0.54	7.21e-11	Schizophrenia;
TGCT	cis	rs12200560	0.505	rs211178	chr6:97074094	T/A	cg06623918	chr6:96969491	KIAA0776	0.59	5.03	0.41	1.71e-6	Coronary heart disease;
TGCT	cis	rs7833790	0.963	rs28823280	chr8:82777716	G/A	cg27398817	chr8:82754497	SNX16	0.8	6.08	0.48	1.39e-8	Diastolic blood pressure;
TGCT	cis	rs3733631	0.947	rs1351623	chr4:104587977	C/T	cg24090629	chr4:104641072	TACR3	-0.71	-5.56	-0.45	1.55e-7	Menarche (age at onset);
TGCT	cis	rs2228479	0.681	rs7196840	chr16:89959647	A/G	cg06558623	chr16:89946397	TCF25	0.42	5.07	0.41	1.38e-6	Skin colour saturation;
TGCT	cis	rs9952991	0.941	rs34920518	chr18:12783086	A/G	cg24737193	chr18:12778029	NA	-0.52	-5.57	-0.45	1.51e-7	Inflammatory skin disease;
TGCT	trans	rs10953454	1.000	rs12705282	chr7:104488143	G/A	cg04208666	chr6:19734707	NA	-0.57	-6.89	-0.53	2.52e-10	Obesity;
TGCT	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg06618935	chr21:46677482	NA	-0.38	-4.94	-0.41	2.51e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2120019	0.938	rs8040169	chr15:75370958	C/A	cg11632617	chr15:75315747	PPCDC	-0.33	-4.78	-0.39	4.82e-6	Blood trace element (Zn levels);
TGCT	cis	rs10504229	0.679	rs12679920	chr8:58051710	G/T	cg08280861	chr8:58055591	NA	0.39	5.61	0.45	1.26e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6088580	0.634	rs6088512	chr20:33095891	G/A	cg06115741	chr20:33292138	TP53INP2	0.53	4.65	0.39	8.41e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7715806	0.500	rs58968428	chr5:75004107	A/G	cg19683494	chr5:74908142	NA	0.57	5.02	0.41	1.76e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs79387448	0.745	rs74560841	chr2:103149210	G/A	cg09003973	chr2:102972529	NA	1.1	7.22	0.54	4.67e-11	Gut microbiota (bacterial taxa);
TGCT	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg25036284	chr2:26402008	FAM59B	-0.57	-4.97	-0.41	2.15e-6	Gut microbiome composition (summer);
TGCT	cis	rs9640161	0.663	rs56402329	chr7:149998426	A/G	cg10018233	chr7:150070692	REPIN1	0.33	4.52	0.38	1.43e-5	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs11247915	0.600	rs61775118	chr1:26659692	C/T	cg01414934	chr1:26605969	SH3BGRL3	0.21	4.51	0.38	1.48e-5	Obesity-related traits;
TGCT	cis	rs1153858	1.000	rs1980288	chr15:45620612	T/C	cg26924012	chr15:45694286	SPATA5L1	1.07	14.49	0.79	1.89e-28	Homoarginine levels;
TGCT	cis	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg18876405	chr7:65276391	NA	-0.37	-5.58	-0.45	1.47e-7	Aortic root size;
TGCT	cis	rs12971120	0.947	rs8084109	chr18:72168312	T/A	cg25817165	chr18:72167213	CNDP2	-0.29	-5.54	-0.45	1.71e-7	Refractive error;
TGCT	cis	rs56309584	0.715	rs74252612	chr17:8142100	G/A	cg08322244	chr17:8066669	VAMP2	-0.57	-5.26	-0.43	6.01e-7	Initial pursuit acceleration;
TGCT	cis	rs6988636	1.000	rs11992152	chr8:124189455	T/A	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs67478160	0.643	rs2295145	chr14:104202304	G/A	cg26031613	chr14:104095156	KLC1	-0.67	-7.15	-0.54	6.67e-11	Schizophrenia;
TGCT	cis	rs4727027	0.933	rs62505074	chr7:148834780	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	4.58	0.38	1.13e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs1577917	0.916	rs4142546	chr6:86505311	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-5.53	-0.44	1.82e-7	Response to antipsychotic treatment;
TGCT	cis	rs79839061	0.732	rs73207773	chr4:827249	G/A	cg07828340	chr4:882639	GAK	0.4	5.03	0.41	1.71e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs3782089	1.000	rs3782089	chr11:65336819	C/T	cg21890820	chr11:65308645	LTBP3	0.89	5.38	0.43	3.6e-7	Height;
TGCT	cis	rs7654585	0.645	rs6828416	chr4:25933273	C/T	cg10409131	chr4:25915609	C4orf52	0.75	7.02	0.53	1.27e-10	Obesity-related traits;
TGCT	cis	rs7017914	0.902	rs35893260	chr8:71620073	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.55	-5.13	-0.42	1.11e-6	Bone mineral density;
TGCT	cis	rs6840360	0.533	rs11099829	chr4:152727299	A/G	cg22705602	chr4:152727874	NA	0.33	5.99	0.47	2.13e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs3771570	0.892	rs55751610	chr2:242346057	C/T	cg21155796	chr2:242212141	HDLBP	0.94	6.69	0.51	6.97e-10	Prostate cancer;
TGCT	cis	rs67072384	1.000	rs12271961	chr11:72453596	G/A	cg03713592	chr11:72463424	ARAP1	-0.93	-4.66	-0.39	7.89e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs1843834	0.539	rs3912999	chr2:225390089	C/T	cg12698349	chr2:225449008	CUL3	0.81	6.81	0.52	3.78e-10	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs3784262	0.740	rs4646596	chr15:58300895	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.42	-6.28	-0.49	5.12e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs10170846	0.626	rs9288575	chr2:223495133	A/C	cg25565276	chr2:223520875	FARSB	1.04	8.17	0.59	2.94e-13	Schizophrenia (inflammation and infection response interaction);
TGCT	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg06221963	chr1:154839813	KCNN3	-0.74	-13.38	-0.77	7.94e-26	Prostate cancer;
TGCT	cis	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg18252515	chr7:66147081	NA	-1.31	-8.18	-0.59	2.87e-13	Diabetic kidney disease;
TGCT	cis	rs2832191	0.720	rs2832200	chr21:30499165	G/A	cg24692254	chr21:30365293	RNF160	-0.86	-9.11	-0.63	1.83e-15	Dental caries;
TGCT	cis	rs3812831	0.629	rs7318527	chr13:114946956	C/T	cg08824895	chr13:115047677	UPF3A	0.49	4.73	0.39	5.98e-6	Schizophrenia;
TGCT	cis	rs1800469	0.965	rs11668109	chr19:41863777	A/C	cg09537434	chr19:41945824	ATP5SL	-0.53	-4.76	-0.39	5.23e-6	Colorectal cancer;
TGCT	cis	rs9300255	0.620	rs7313483	chr12:123726834	C/T	cg00376283	chr12:123451042	ABCB9	0.72	5.52	0.44	1.88e-7	Neutrophil percentage of white cells;
TGCT	cis	rs7582180	0.564	rs2309795	chr2:100954290	G/A	cg14675211	chr2:100938903	LONRF2	0.53	5.16	0.42	9.36e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs617219	0.671	rs1062326	chr5:78617534	A/C	cg23987322	chr5:78407566	BHMT	-0.35	-4.51	-0.38	1.49e-5	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs425277	1.000	rs262651	chr1:2091397	A/G	cg24578937	chr1:2090814	PRKCZ	0.32	8.03	0.58	6.41e-13	Height;
TGCT	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg18230493	chr5:56204884	C5orf35	-0.68	-5.85	-0.46	4.13e-8	Initial pursuit acceleration;
TGCT	cis	rs6933660	0.745	rs9322320	chr6:151751908	C/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.64	6.4	0.5	2.87e-9	Menarche (age at onset);
TGCT	cis	rs2742417	1.000	rs1969626	chr3:45746836	A/G	cg04837898	chr3:45731254	SACM1L	-0.55	-5.68	-0.45	9.22e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	-0.52	-6.89	-0.53	2.52e-10	Lymphocyte counts;
TGCT	cis	rs709400	0.633	rs2296484	chr14:104003094	C/T	cg26031613	chr14:104095156	KLC1	0.89	9.8	0.66	3.77e-17	Body mass index;
TGCT	cis	rs12220238	0.841	rs10824163	chr10:76136589	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.87	6.32	0.49	4.31e-9	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs3617	0.573	rs9860296	chr3:52913781	A/G	cg11645453	chr3:52864694	ITIH4	0.28	5.35	0.43	4.08e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9291683	0.551	rs2276961	chr4:10022981	C/T	cg00071950	chr4:10020882	SLC2A9	0.7	9.52	0.65	1.86e-16	Bone mineral density;
TGCT	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg00343986	chr7:65444356	GUSB	-0.25	-5.81	-0.46	4.89e-8	Aortic root size;
TGCT	cis	rs433598	0.704	rs163267	chr16:20660957	T/A	cg08248577	chr16:19727447	IQCK;C16orf88	-0.22	-5.08	-0.42	1.34e-6	Schizophrenia;
TGCT	cis	rs12477438	0.765	rs1115756	chr2:99659845	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-4.62	-0.38	9.47e-6	Chronic sinus infection;
TGCT	cis	rs1555895	0.566	rs1000278	chr10:852629	C/T	cg02193355	chr10:851439	NA	0.25	5.6	0.45	1.3e-7	Survival in rectal cancer;
TGCT	cis	rs1018836	0.608	rs6992512	chr8:91477936	C/A	cg16814680	chr8:91681699	NA	-0.71	-7.14	-0.54	6.85e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4642101	0.640	rs3901666	chr3:12824363	G/T	cg05775895	chr3:12838266	CAND2	-0.67	-6.96	-0.53	1.77e-10	QRS complex (12-leadsum);
TGCT	cis	rs12220898	0.679	rs4838483	chr10:50481870	G/A	cg06072769	chr10:50146962	WDFY4	0.38	4.98	0.41	2.07e-6	Inflammatory biomarkers;
TGCT	cis	rs7772486	0.688	rs1884364	chr6:146337817	C/G	cg13319975	chr6:146136371	FBXO30	-0.65	-6.07	-0.48	1.47e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11690935	0.959	rs76324055	chr2:172620150	T/A	cg13550731	chr2:172543902	DYNC1I2	-1.2	-12.28	-0.74	3.49e-23	Schizophrenia;
TGCT	cis	rs10276381	1.000	rs10280937	chr7:28182306	T/C	cg23620719	chr7:28220237	JAZF1	0.99	5.75	0.46	6.58e-8	Crohn's disease;
TGCT	trans	rs1005277	0.505	rs200935	chr10:38132810	T/A	cg17830980	chr10:43048298	ZNF37B	-0.72	-8.22	-0.59	2.33e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs854765	0.647	rs2955365	chr17:18023897	G/A	cg04398451	chr17:18023971	MYO15A	-0.39	-6.89	-0.53	2.53e-10	Total body bone mineral density;
TGCT	cis	rs2562456	0.917	rs2681376	chr19:21715525	T/G	cg25650185	chr19:21324782	ZNF431	0.61	5.38	0.43	3.6e-7	Pain;
TGCT	cis	rs739496	0.947	rs739497	chr12:111858086	C/T	cg10833066	chr12:111807467	FAM109A	0.37	5.2	0.42	8.01e-7	Platelet count;
TGCT	cis	rs548987	0.507	rs35875210	chr6:25827484	A/G	cg03264133	chr6:25882463	NA	-0.54	-4.44	-0.37	1.99e-5	Homocysteine levels;
TGCT	cis	rs7264396	0.790	rs2207889	chr20:34224898	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.28	-4.68	-0.39	7.38e-6	Total cholesterol levels;
TGCT	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg11764359	chr7:65958608	NA	-0.56	-5.04	-0.41	1.61e-6	Aortic root size;
TGCT	cis	rs2832191	0.720	rs2832200	chr21:30499165	G/A	cg08807101	chr21:30365312	RNF160	-0.62	-5.8	-0.46	5.14e-8	Dental caries;
TGCT	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.52	-5.85	-0.47	4.02e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg08975724	chr8:8085496	FLJ10661	-0.55	-5.04	-0.41	1.59e-6	Mood instability;
TGCT	cis	rs1784581	0.588	rs1784583	chr6:162410132	C/T	cg17173639	chr6:162384350	PARK2	-0.4	-6.67	-0.51	7.39e-10	Itch intensity from mosquito bite;
TGCT	cis	rs11098499	0.954	rs12510138	chr4:120423935	C/G	cg09307838	chr4:120376055	NA	0.67	6.34	0.49	3.87e-9	Corneal astigmatism;
TGCT	cis	rs72949976	1.000	rs62186569	chr2:214034151	C/T	cg08319019	chr2:214017104	IKZF2	-0.79	-7.3	-0.55	2.97e-11	Lung cancer;Squamous cell lung carcinoma;
TGCT	cis	rs78487399	0.808	rs17030998	chr2:43758199	A/G	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.76	4.68	0.39	7.27e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs9467773	0.838	rs3734540	chr6:26463321	A/C	cg26531700	chr6:26746687	NA	0.55	5.47	0.44	2.34e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.822	rs28367231	chr4:98845726	G/T	cg05340658	chr4:99064831	C4orf37	0.52	6.02	0.48	1.79e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1008375	1.000	rs2215450	chr4:17675394	T/G	cg10189774	chr4:17578691	LAP3	0.57	5.25	0.43	6.37e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	8.99	0.63	3.48e-15	Platelet count;
TGCT	cis	rs17253792	0.822	rs111467375	chr14:56046159	T/G	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs933688	1.000	rs12655973	chr5:90736537	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.98	8.79	0.62	1.02e-14	Smoking behavior;
TGCT	cis	rs11874712	0.965	rs12954944	chr18:43664115	T/C	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	5.23	0.42	7.11e-7	Migraine - clinic-based;
TGCT	cis	rs2046867	0.818	rs1502757	chr3:72864161	C/T	cg25664220	chr3:72788482	NA	-0.56	-7.03	-0.53	1.24e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	trans	rs17685	0.712	rs1859792	chr7:75789264	T/C	cg19862616	chr7:65841803	NCRNA00174	0.53	9.13	0.63	1.6e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg27302301	chr7:1268188	NA	0.3	4.54	0.38	1.32e-5	Subjective well-being;
TGCT	cis	rs4820539	1.000	rs4822357	chr22:23473231	A/G	cg21100191	chr22:23484243	RTDR1	0.94	8.9	0.62	5.74e-15	Bone mineral density;
TGCT	cis	rs7412746	0.611	rs111905669	chr1:150777565	T/C	cg04414720	chr1:150670196	GOLPH3L	0.41	5.07	0.41	1.41e-6	Melanoma;
TGCT	trans	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg13615516	chr5:77269221	NA	0.68	8.54	0.61	3.97e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs6089829	0.926	rs6011552	chr20:61667894	T/C	cg08045932	chr20:61659980	NA	0.47	8.81	0.62	9.31e-15	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg22920501	chr2:26401640	FAM59B	-0.74	-6.45	-0.5	2.32e-9	Gut microbiome composition (summer);
TGCT	cis	rs10489202	0.632	rs149912	chr1:167957803	A/T	cg24449463	chr1:168025552	DCAF6	-0.58	-6.83	-0.52	3.35e-10	Schizophrenia;
TGCT	cis	rs10501293	0.709	rs7943878	chr11:43006269	T/C	cg03447554	chr11:43094025	NA	0.44	6.28	0.49	5.2e-9	Cognitive performance;
TGCT	cis	rs2580764	0.598	rs6755468	chr2:55240026	A/C	cg09592903	chr2:55203963	RTN4	-0.27	-5.92	-0.47	3e-8	Mean platelet volume;
TGCT	cis	rs9814567	1.000	rs55913793	chr3:134285968	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.94	-9.18	-0.64	1.2e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs1670533	1.000	rs6858612	chr4:1053353	C/T	cg27284194	chr4:1044797	NA	0.67	5.97	0.47	2.29e-8	Recombination rate (females);
TGCT	cis	rs9640161	0.830	rs36069544	chr7:150061538	G/A	cg21361702	chr7:150065534	REPIN1	0.5	4.56	0.38	1.2e-5	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs10904908	0.733	rs7080366	chr10:17254832	C/T	cg01003015	chr10:17271136	VIM	-0.55	-4.8	-0.4	4.39e-6	Total cholesterol levels;Cholesterol, total;
TGCT	cis	rs7647973	1.000	rs7613491	chr3:49508976	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.59	-4.67	-0.39	7.6e-6	Menarche (age at onset);
TGCT	cis	rs1008375	0.966	rs7675735	chr4:17587137	T/A	cg10189774	chr4:17578691	LAP3	0.64	5.61	0.45	1.28e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	trans	rs17685	0.712	rs10275521	chr7:75770972	T/C	cg19862616	chr7:65841803	NCRNA00174	0.52	9.01	0.63	3.02e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs5769707	0.681	rs1107514	chr22:50042383	T/C	cg05373962	chr22:49881684	NA	-0.34	-5.66	-0.45	1.01e-7	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	5.71	0.46	8.05e-8	Alzheimer's disease;
TGCT	cis	rs1018836	0.923	rs2157607	chr8:91600268	A/G	cg16814680	chr8:91681699	NA	-0.83	-8.74	-0.62	1.33e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg10802521	chr3:52805072	NEK4	-0.62	-7.17	-0.54	5.94e-11	Electroencephalogram traits;
TGCT	cis	rs7666738	0.830	rs6839203	chr4:98839814	C/G	cg17366294	chr4:99064904	C4orf37	0.72	7.5	0.56	1.07e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9611565	0.802	rs9611577	chr22:41793090	T/G	cg06481639	chr22:41940642	POLR3H	-0.61	-5.49	-0.44	2.17e-7	Vitiligo;
TGCT	cis	rs9677476	0.863	rs12478335	chr2:232064967	C/A	cg07929768	chr2:232055508	NA	0.31	4.49	0.37	1.61e-5	Food antigen IgG levels;
TGCT	cis	rs5167	0.533	rs11083755	chr19:45490065	C/T	cg13119609	chr19:45449297	APOC2	0.23	4.65	0.39	8.26e-6	Blood protein levels;
TGCT	cis	rs28595532	0.920	rs114243409	chr4:119756585	C/A	cg21605333	chr4:119757512	SEC24D	1.62	7.73	0.57	3.22e-12	Cannabis dependence symptom count;
TGCT	cis	rs9467773	1.000	rs28558133	chr6:26531433	G/C	cg26531700	chr6:26746687	NA	0.47	4.57	0.38	1.14e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs13064447	0.967	rs55668390	chr3:12766020	C/G	cg20675869	chr3:12750130	NA	-0.19	-4.81	-0.4	4.28e-6	Major depression and alcohol dependence;
TGCT	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	5.06	0.41	1.46e-6	Menopause (age at onset);
TGCT	cis	rs7216064	1.000	rs73352808	chr17:65875157	G/A	cg12091567	chr17:66097778	LOC651250	-0.87	-6.85	-0.52	3.1e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs1046896	0.552	rs12602280	chr17:80805421	G/C	cg03160526	chr17:80928410	B3GNTL1	0.33	4.57	0.38	1.18e-5	Glycated hemoglobin levels;
TGCT	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg11062466	chr8:58055876	NA	0.38	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.93	7.44	0.56	1.44e-11	Platelet count;
TGCT	cis	rs6740322	0.895	rs6710656	chr2:43566941	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.39	-6.43	-0.5	2.44e-9	Coronary artery disease;
TGCT	cis	rs7178572	0.568	rs4886515	chr15:77686886	G/A	cg22256960	chr15:77711686	NA	-0.88	-9.16	-0.64	1.32e-15	Type 2 diabetes;
TGCT	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg25036284	chr2:26402008	FAM59B	-0.57	-4.99	-0.41	1.99e-6	Gut microbiome composition (summer);
TGCT	cis	rs9910055	0.540	rs609292	chr17:42180436	G/A	cg13607699	chr17:42295918	UBTF	-0.61	-5.09	-0.42	1.32e-6	Total body bone mineral density;
TGCT	cis	rs308403	0.600	rs309366	chr4:123661408	C/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.73	6.85	0.52	3e-10	Blood protein levels;
TGCT	cis	rs2832191	0.740	rs2832177	chr21:30478353	G/A	cg24692254	chr21:30365293	RNF160	-1.01	-11.59	-0.72	1.73e-21	Dental caries;
TGCT	cis	rs7107174	0.681	rs11237443	chr11:78005089	C/A	cg12700464	chr11:78128424	GAB2	-0.67	-4.63	-0.38	8.98e-6	Testicular germ cell tumor;
TGCT	cis	rs36051895	0.588	rs12340895	chr9:5076691	C/G	cg02405213	chr9:5042618	JAK2	0.73	9.28	0.64	6.85e-16	Pediatric autoimmune diseases;
TGCT	cis	rs9952991	0.608	rs9960807	chr18:12770851	A/G	cg23544223	chr18:12777786	NA	-0.61	-4.64	-0.38	8.63e-6	Inflammatory skin disease;
TGCT	cis	rs394563	0.591	rs11155641	chr6:149648595	G/A	cg11245181	chr6:149772854	ZC3H12D	0.28	4.64	0.38	8.68e-6	Dupuytren's disease;
TGCT	cis	rs7552404	0.731	rs11588578	chr1:76400539	T/G	cg10523679	chr1:76189770	ACADM	0.82	7.13	0.54	7.47e-11	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9611565	0.765	rs132906	chr22:41799767	G/C	cg13695892	chr22:41940480	POLR3H	0.74	7.39	0.55	1.92e-11	Vitiligo;
TGCT	cis	rs644148	0.770	rs2571113	chr19:44999814	A/G	cg15540054	chr19:45004280	ZNF180	-0.65	-5.33	-0.43	4.48e-7	Personality dimensions;
TGCT	cis	rs138880	0.505	rs56248708	chr22:50306969	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.2	-7.39	-0.55	1.9e-11	Schizophrenia;
TGCT	trans	rs4295623	0.504	rs11250160	chr8:11592717	G/A	cg15556689	chr8:8085844	FLJ10661	-0.74	-6.76	-0.52	4.93e-10	Morning vs. evening chronotype;
TGCT	cis	rs36051895	0.623	rs1555476	chr9:5233054	T/C	cg02405213	chr9:5042618	JAK2	-0.67	-7.85	-0.58	1.66e-12	Pediatric autoimmune diseases;
TGCT	cis	rs1903068	0.853	rs9997685	chr4:56022903	A/T	cg09978860	chr4:56023921	NA	0.56	5.9	0.47	3.18e-8	Endometriosis;
TGCT	cis	rs3540	0.597	rs1978149	chr15:91036976	A/G	cg22089800	chr15:90895588	ZNF774	0.76	7.77	0.57	2.62e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs2033711	0.783	rs8113810	chr19:58932106	A/G	cg12042659	chr19:58951599	ZNF132	0.52	4.81	0.4	4.31e-6	Uric acid clearance;
TGCT	cis	rs477895	1.000	rs66968227	chr11:64070930	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.65	4.96	0.41	2.29e-6	Mean platelet volume;
TGCT	cis	rs4601821	0.858	rs7945132	chr11:113262473	A/T	cg14159747	chr11:113255604	NA	0.38	4.48	0.37	1.67e-5	Alcoholic chronic pancreatitis;
TGCT	cis	rs11792861	0.781	rs874864	chr9:111728718	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.5	4.79	0.4	4.69e-6	Menarche (age at onset);
TGCT	cis	rs112217694	1.000	rs75065217	chr4:104653578	C/T	cg24090629	chr4:104641072	TACR3	-0.97	-4.81	-0.4	4.25e-6	Menarche (age at onset);
TGCT	cis	rs56309584	0.560	rs72479723	chr17:8076741	A/G	cg08322244	chr17:8066669	VAMP2	-0.52	-4.89	-0.4	3.04e-6	Initial pursuit acceleration;
TGCT	cis	rs6570726	0.818	rs398812	chr6:145817271	T/C	cg05347473	chr6:146136440	FBXO30	0.51	4.61	0.38	9.83e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2075371	1.000	rs2244694	chr7:133987093	C/T	cg11752832	chr7:134001865	SLC35B4	0.69	6.32	0.49	4.19e-9	Mean platelet volume;
TGCT	cis	rs12188164	0.762	rs11745923	chr5:475408	T/G	cg26850624	chr5:429559	AHRR	-0.2	-4.76	-0.39	5.33e-6	Cystic fibrosis severity;
TGCT	cis	rs2235642	0.893	rs2076440	chr16:1587322	G/A	cg08296037	chr16:1584118	IFT140;TMEM204	-0.31	-5.43	-0.44	2.89e-7	Coronary artery disease;
TGCT	cis	rs10992471	0.603	rs4744137	chr9:95288352	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.6	-5.63	-0.45	1.13e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs6882046	0.513	rs651666	chr5:88048767	A/G	cg22951263	chr5:87985283	NA	-0.58	-6.12	-0.48	1.12e-8	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs904251	0.861	rs1757169	chr6:37487076	G/T	cg08126542	chr6:37504118	NA	-0.44	-5.92	-0.47	2.96e-8	Cognitive performance;
TGCT	trans	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg13615516	chr5:77269221	NA	0.67	8.36	0.6	1.09e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs11690935	0.694	rs312921	chr2:172567225	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.19	-12.75	-0.75	2.7e-24	Schizophrenia;
TGCT	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg05368731	chr17:41323189	NBR1	0.9	8.95	0.63	4.4e-15	Menopause (age at onset);
TGCT	cis	rs709400	0.567	rs1961600	chr14:103862144	G/A	cg12935359	chr14:103987150	CKB	-0.36	-5.38	-0.43	3.63e-7	Body mass index;
TGCT	cis	rs9921192	1.000	rs2892165	chr16:4324293	A/T	cg00021532	chr16:4324280	TFAP4	0.82	9.35	0.64	4.71e-16	Prostate-specific antigen levels;
TGCT	cis	rs6840360	0.615	rs3828546	chr4:152679816	A/G	cg17479576	chr4:152424074	FAM160A1	-0.52	-5.16	-0.42	9.49e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs6678914	0.738	rs721559	chr1:202188119	T/C	cg08883485	chr1:201619787	NAV1	-0.38	-4.52	-0.38	1.44e-5	Breast cancer (estrogen-receptor negative);Breast cancer;
TGCT	cis	rs6484504	0.576	rs438578	chr11:31222579	A/G	cg26647111	chr11:31128758	NA	0.32	4.66	0.39	8e-6	Red blood cell count;
TGCT	cis	rs67478160	0.634	rs941475	chr14:104240618	A/C	cg26031613	chr14:104095156	KLC1	-0.64	-6.6	-0.51	1.07e-9	Schizophrenia;
TGCT	cis	rs35306767	0.807	rs12768348	chr10:899224	T/G	cg26597838	chr10:835615	NA	0.8	12.11	0.74	9.26e-23	Eosinophil percentage of granulocytes;
TGCT	cis	rs3749237	0.595	rs10865955	chr3:49499829	G/A	cg03060546	chr3:49711283	APEH	0.76	8.69	0.62	1.77e-14	Resting heart rate;
TGCT	cis	rs6460942	0.908	rs117451929	chr7:12265149	A/T	cg06484146	chr7:12443880	VWDE	-0.55	-4.63	-0.38	9.11e-6	Coronary artery disease;
TGCT	cis	rs1215050	0.791	rs1215049	chr4:98848280	C/T	cg05340658	chr4:99064831	C4orf37	0.45	5.49	0.44	2.2e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1894292	0.527	rs10212657	chr4:74361254	T/C	cg05868023	chr4:75230803	EREG	0.53	4.55	0.38	1.25e-5	Prostate cancer;
TGCT	cis	rs13256369	0.950	rs13270006	chr8:8574197	C/A	cg18904891	chr8:8559673	CLDN23	0.64	5.89	0.47	3.36e-8	Obesity-related traits;
TGCT	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg22920501	chr2:26401640	FAM59B	0.8	6.34	0.49	3.84e-9	Gut microbiome composition (summer);
TGCT	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	5.11	0.42	1.18e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2268241	0.938	rs2300373	chr21:34788739	A/T	cg14850771	chr21:34775459	IFNGR2	0.61	4.9	0.4	2.93e-6	Obesity-related traits;
TGCT	cis	rs7539409	0.604	rs6689821	chr1:84316605	A/G	cg10977910	chr1:84465055	TTLL7	0.88	5.62	0.45	1.19e-7	Alzheimer's disease;
TGCT	cis	rs6545883	0.894	rs2600660	chr2:61549600	G/T	cg15711740	chr2:61764176	XPO1	0.55	4.72	0.39	6.38e-6	Tuberculosis;
TGCT	cis	rs208520	0.909	rs9345809	chr6:67017543	T/C	cg07460842	chr6:66804631	NA	0.73	5.91	0.47	3.07e-8	Exhaled nitric oxide output;
TGCT	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg10047753	chr17:41438598	NA	0.97	9.91	0.66	2.09e-17	Menopause (age at onset);
TGCT	cis	rs74233809	1.000	rs77180047	chr10:104666757	G/A	cg05855489	chr10:104503620	C10orf26	0.74	4.45	0.37	1.87e-5	Birth weight;
TGCT	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg25036284	chr2:26402008	FAM59B	-0.55	-4.76	-0.39	5.33e-6	Gut microbiome composition (summer);
TGCT	cis	rs1541995	0.898	rs12901540	chr15:96332408	T/A	cg00882281	chr15:96346592	NA	0.27	4.45	0.37	1.86e-5	Photic sneeze reflex;
TGCT	cis	rs593982	0.843	rs680948	chr11:65472394	C/G	cg08755490	chr11:65554678	OVOL1	1.29	7.51	0.56	1.02e-11	Atopic dermatitis;
TGCT	cis	rs5769707	0.542	rs739242	chr22:50057116	A/G	cg05373962	chr22:49881684	NA	-0.32	-5.46	-0.44	2.46e-7	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs6750047	0.756	rs4670233	chr2:38272342	A/G	cg07380506	chr2:38303506	CYP1B1	0.58	5.34	0.43	4.24e-7	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs9733	0.519	rs11807450	chr1:150677719	C/T	cg04414720	chr1:150670196	GOLPH3L	0.37	4.89	0.4	3.05e-6	Tonsillectomy;
TGCT	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg07507251	chr3:52567010	NT5DC2	0.47	6.74	0.52	5.28e-10	Electroencephalogram traits;
TGCT	cis	rs6570726	0.818	rs9390338	chr6:145908265	A/G	cg13319975	chr6:146136371	FBXO30	-0.52	-4.68	-0.39	7.45e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9902453	0.967	rs12450956	chr17:28529025	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	5.4	0.44	3.24e-7	Coffee consumption (cups per day);
TGCT	cis	rs9581857	0.685	rs60787915	chr13:28022298	C/T	cg22138327	chr13:27999177	GTF3A	0.68	4.9	0.4	2.87e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs6977660	0.714	rs10249635	chr7:19787090	A/G	cg05791153	chr7:19748676	TWISTNB	0.84	4.73	0.39	5.91e-6	Thyroid stimulating hormone;
TGCT	trans	rs9650657	0.571	rs4240673	chr8:10787612	T/C	cg15556689	chr8:8085844	FLJ10661	-0.78	-6.94	-0.53	1.94e-10	Neuroticism;
TGCT	cis	rs79839061	0.520	rs2279187	chr4:875529	C/T	cg15843217	chr4:699224	PCGF3	-0.63	-4.5	-0.37	1.55e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg19723775	chr5:179050963	HNRNPH1	0.53	5.29	0.43	5.29e-7	Lung cancer;
TGCT	cis	rs10493773	0.775	rs2069208	chr1:86117583	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.44	-6.34	-0.49	3.83e-9	Urate levels in overweight individuals;
TGCT	cis	rs34042186	1	rs34042186	chr3:46462909	G/A	cg15561453	chr3:47459664	SCAP	0.31	4.52	0.38	1.41e-5	Monocyte percentage of white cells;
TGCT	cis	rs7824557	0.547	rs2409749	chr8:11078949	G/A	cg21775007	chr8:11205619	TDH	-0.49	-4.48	-0.37	1.66e-5	Retinal vascular caliber;
TGCT	cis	rs739496	0.527	rs2269803	chr12:112326145	T/C	cg10833066	chr12:111807467	FAM109A	0.38	5.67	0.45	9.69e-8	Platelet count;
TGCT	cis	rs10193935	0.901	rs10171643	chr2:42532912	C/T	cg27598129	chr2:42591480	NA	-0.42	-6.05	-0.48	1.61e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12200560	0.505	rs211176	chr6:97073821	G/A	cg06623918	chr6:96969491	KIAA0776	0.59	5.03	0.41	1.71e-6	Coronary heart disease;
TGCT	cis	rs11711311	1.000	rs9830975	chr3:113486019	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.79	-7.32	-0.55	2.75e-11	IgG glycosylation;
TGCT	cis	rs4783244	0.862	rs4782721	chr16:82656995	A/G	cg09415485	chr16:82663111	CDH13	0.24	4.61	0.38	9.73e-6	Adiponectin levels;
TGCT	cis	rs682748	1.000	rs587006	chr5:17148502	G/A	cg23987134	chr5:17158319	LOC285696	-0.23	-5.42	-0.44	2.93e-7	Hippocampal atrophy;
TGCT	cis	rs899997	1.000	rs7182993	chr15:79045014	G/A	cg00061860	chr15:78953028	NA	-0.27	-4.67	-0.39	7.62e-6	Coronary artery disease or large artery stroke;
TGCT	cis	rs72843506	0.722	rs76309839	chr17:20175460	T/C	cg18979559	chr17:20280153	CCDC144C	-0.65	-4.88	-0.4	3.2e-6	Schizophrenia;
TGCT	cis	rs896854	0.654	rs16893776	chr8:95973604	C/T	cg09323728	chr8:95962352	TP53INP1	-0.51	-6.5	-0.5	1.74e-9	Type 2 diabetes;
TGCT	cis	rs7100689	0.646	rs7903701	chr10:82129268	T/C	cg01528321	chr10:82214614	TSPAN14	0.8	7.76	0.57	2.7e-12	Post bronchodilator FEV1;
TGCT	cis	rs9300255	0.596	rs10773002	chr12:123746961	A/T	cg00376283	chr12:123451042	ABCB9	-0.72	-5.77	-0.46	6.1e-8	Neutrophil percentage of white cells;
TGCT	cis	rs62244186	0.659	rs9311358	chr3:44538748	C/G	cg04389838	chr3:44770851	ZNF501	-0.38	-4.92	-0.4	2.66e-6	Depressive symptoms;
TGCT	cis	rs10267417	0.544	rs2072185	chr7:19748700	G/A	cg07541023	chr7:19748670	TWISTNB	1.21	11.01	0.7	4.36e-20	Night sleep phenotypes;
TGCT	cis	rs651907	0.557	rs3806653	chr3:101396972	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.91	10.9	0.7	8.24e-20	Colorectal cancer;
TGCT	cis	rs9611565	0.559	rs6002408	chr22:41967870	C/T	cg06481639	chr22:41940642	POLR3H	-0.66	-5.64	-0.45	1.12e-7	Vitiligo;
TGCT	cis	rs7584330	0.737	rs1497127	chr2:238369282	A/G	cg14458575	chr2:238380390	NA	0.46	7.42	0.55	1.64e-11	Prostate cancer;
TGCT	cis	rs9916302	0.706	rs4516267	chr17:37471482	G/T	cg07936489	chr17:37558343	FBXL20	0.84	6.23	0.49	6.68e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs12497850	0.864	rs4521268	chr3:49137904	G/T	cg02487422	chr3:49467188	NICN1	0.5	4.55	0.38	1.24e-5	Parkinson's disease;
TGCT	cis	rs877282	0.898	rs11253341	chr10:765008	G/C	cg17470449	chr10:769945	NA	0.37	5.59	0.45	1.37e-7	Uric acid levels;
TGCT	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg06108461	chr20:60628389	TAF4	-0.71	-10.51	-0.69	7.47e-19	Body mass index;
TGCT	cis	rs8038465	0.622	rs17185294	chr15:73858415	C/T	cg15420318	chr15:73925796	NPTN	-0.62	-6.42	-0.5	2.62e-9	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs317865	0.737	rs16893153	chr4:16181798	T/C	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.68	4.49	0.37	1.6e-5	Kidney disease (early stage) in type 1 diabetes;
TGCT	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.73	-0.39	5.93e-6	Prudent dietary pattern;
TGCT	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg01802117	chr1:53393560	SCP2	0.43	5.13	0.42	1.1e-6	Monocyte count;
TGCT	cis	rs17345786	0.906	rs72944107	chr3:101197190	C/T	cg12386194	chr3:101231763	SENP7	0.65	6.39	0.5	3.06e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7681440	0.904	rs3756063	chr4:90757394	G/C	cg14346243	chr4:90757452	SNCA	-0.59	-5.74	-0.46	6.91e-8	Dementia with Lewy bodies;
TGCT	cis	rs11690935	1.000	rs6433311	chr2:172549248	A/G	cg13550731	chr2:172543902	DYNC1I2	1.21	13.07	0.76	4.43e-25	Schizophrenia;
TGCT	cis	rs4455778	0.659	rs10278618	chr7:49040616	A/C	cg26309511	chr7:48887640	NA	0.42	4.98	0.41	2.08e-6	Lung cancer in never smokers;
TGCT	cis	rs1385374	0.858	rs10847696	chr12:129297153	G/A	cg09035930	chr12:129282057	SLC15A4	-0.55	-4.76	-0.39	5.27e-6	Systemic lupus erythematosus;
TGCT	cis	rs7072216	0.727	rs6584199	chr10:100169983	A/G	cg26618903	chr10:100175079	PYROXD2	-0.4	-4.49	-0.37	1.64e-5	Metabolite levels;
TGCT	cis	rs7819412	0.522	rs4841497	chr8:10985140	A/G	cg21775007	chr8:11205619	TDH	-0.58	-5.38	-0.43	3.64e-7	Triglycerides;
TGCT	cis	rs4919687	0.679	rs12762176	chr10:104499232	A/T	cg05855489	chr10:104503620	C10orf26	0.57	4.55	0.38	1.27e-5	Colorectal cancer;
TGCT	cis	rs7666738	0.830	rs35915560	chr4:98978649	C/T	cg18180107	chr4:99064573	C4orf37	0.55	5.06	0.41	1.5e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs72781680	0.752	rs72796119	chr2:23917179	C/T	cg08917208	chr2:24149416	ATAD2B	1.0	5.79	0.46	5.41e-8	Lymphocyte counts;
TGCT	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7772486	0.597	rs2485631	chr6:146190077	G/C	cg23711669	chr6:146136114	FBXO30	0.76	7.14	0.54	6.99e-11	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg14416726	chr6:151773293	C6orf211;RMND1	-1.05	-14.4	-0.79	3.16e-28	Menarche (age at onset);
TGCT	cis	rs7647973	0.769	rs11130181	chr3:49109919	G/A	cg07636037	chr3:49044803	WDR6	0.79	6.56	0.51	1.32e-9	Menarche (age at onset);
TGCT	cis	rs62392365	0.686	rs115989354	chr6:25208585	C/T	cg16898833	chr6:26189333	HIST1H4D	0.95	4.59	0.38	1.06e-5	Schizophrenia;Intelligence (multi-trait analysis);
TGCT	cis	rs9916302	0.784	rs4795361	chr17:37573446	G/A	cg15445000	chr17:37608096	MED1	0.34	4.8	0.4	4.43e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs716804	0.608	rs7944706	chr11:10331311	A/G	cg17061862	chr11:9590431	NA	-0.37	-4.55	-0.38	1.27e-5	Neuroticism;
TGCT	cis	rs4595586	0.505	rs11611321	chr12:39390803	C/T	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs4242434	0.889	rs7817772	chr8:22539316	A/G	cg03733263	chr8:22462867	KIAA1967	-1.13	-15.54	-0.81	6.82e-31	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs5758659	0.657	rs5758587	chr22:42517636	C/G	cg15557168	chr22:42548783	NA	0.18	4.63	0.38	9.14e-6	Cognitive function;
TGCT	cis	rs10892173	0.765	rs7125693	chr11:117670651	C/T	cg07621104	chr11:117668040	DSCAML1	0.5	5.29	0.43	5.36e-7	Myopia;
TGCT	cis	rs2836974	0.583	rs2735307	chr21:40713358	C/T	cg11890956	chr21:40555474	PSMG1	0.77	7.68	0.57	4.22e-12	Cognitive function;
TGCT	cis	rs9560113	1.000	rs9560109	chr13:112180468	C/T	cg14154082	chr13:112174009	NA	0.37	5.07	0.41	1.42e-6	Menarche (age at onset);
TGCT	cis	rs9527	0.590	rs11191572	chr10:104893137	A/G	cg04362960	chr10:104952993	NT5C2	0.69	5.82	0.46	4.78e-8	Arsenic metabolism;
TGCT	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg13206674	chr6:150067644	NUP43	0.52	4.51	0.38	1.5e-5	Lung cancer;
TGCT	cis	rs1577917	0.665	rs4304137	chr6:86217448	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.59	5.15	0.42	1.01e-6	Response to antipsychotic treatment;
TGCT	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9467711	0.606	rs72836482	chr6:26359241	A/T	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2439831	0.557	rs13329084	chr15:44151063	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.68	-4.44	-0.37	1.99e-5	Lung cancer in ever smokers;
TGCT	cis	rs76419734	0.510	rs961472	chr4:106535062	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.78	4.74	0.39	5.87e-6	Post bronchodilator FEV1;
TGCT	cis	rs13191362	0.935	rs34934114	chr6:163082480	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.07	8.36	0.6	1.07e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	trans	rs114540395	0.858	rs17767748	chr10:103285900	A/G	cg10198749	chr1:39920707	MACF1	-0.6	-7.64	-0.57	5.03e-12	Schizophrenia;
TGCT	cis	rs6582630	0.615	rs12821226	chr12:38546406	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-4.77	-0.39	5.12e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs8180040	0.903	rs13094438	chr3:47277885	G/A	cg27129171	chr3:47204927	SETD2	0.69	8.59	0.61	3.04e-14	Colorectal cancer;
TGCT	cis	rs6684514	0.961	rs12126696	chr1:156241348	C/T	cg16558208	chr1:156270281	VHLL	0.48	9.46	0.65	2.55e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs11731606	0.567	rs17377951	chr4:95321099	C/T	cg00507259	chr4:95128692	SMARCAD1	0.7	5.09	0.42	1.3e-6	Mean platelet volume;
TGCT	cis	rs6463523	0.898	rs66892628	chr7:759374	T/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.87	11.91	0.73	2.85e-22	Subjective well-being;
TGCT	cis	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg20637647	chr7:64974828	NA	0.96	5.59	0.45	1.41e-7	Diabetic kidney disease;
TGCT	cis	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg08564027	chr20:61660810	NA	0.37	6.88	0.53	2.69e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1008375	0.932	rs12500912	chr4:17603318	C/T	cg18681998	chr4:17616180	MED28	0.99	9.69	0.66	7.08e-17	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9682041	0.808	rs9875109	chr3:170064776	A/G	cg11886554	chr3:170076028	SKIL	-0.57	-4.74	-0.39	5.65e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs12049351	0.719	rs10916493	chr1:229634397	G/T	cg12130225	chr1:229698885	NA	0.39	4.59	0.38	1.06e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs3820928	0.874	rs13403281	chr2:227880769	G/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-4.94	-0.41	2.51e-6	Pulmonary function;
TGCT	cis	rs4319547	0.695	rs1803290	chr12:122865029	T/C	cg08088222	chr12:122070432	ORAI1	-0.25	-4.49	-0.37	1.58e-5	Body mass index;
TGCT	cis	rs259282	0.538	rs8100917	chr19:33114702	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.5	4.56	0.38	1.2e-5	Schizophrenia;
TGCT	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg10802521	chr3:52805072	NEK4	-0.78	-10.0	-0.67	1.26e-17	Bipolar disorder;
TGCT	cis	rs7264396	0.790	rs2425125	chr20:34330954	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.29	5.25	0.43	6.33e-7	Total cholesterol levels;
TGCT	cis	rs17221829	0.899	rs10830356	chr11:89443939	C/A	cg02982614	chr11:89391479	FOLH1B	-0.29	-5.08	-0.41	1.36e-6	Anxiety in major depressive disorder;
TGCT	cis	rs907683	0.584	rs1058284	chr2:220286142	G/A	cg15015639	chr2:220282977	DES	-0.39	-4.83	-0.4	3.88e-6	Resting heart rate;
TGCT	cis	rs3752962	0.630	rs11078793	chr17:1951364	T/A	cg24156229	chr17:1948635	NA	-0.38	-7.4	-0.55	1.8e-11	Itch intensity from mosquito bite;
TGCT	cis	rs611744	0.550	rs57045491	chr8:109279120	A/C	cg21045802	chr8:109455806	TTC35	0.72	7.43	0.56	1.53e-11	Dupuytren's disease;
TGCT	cis	rs9372498	0.732	rs17080124	chr6:118717814	A/G	cg21191810	chr6:118973309	C6orf204	-0.45	-4.76	-0.39	5.38e-6	Diastolic blood pressure;
TGCT	cis	rs7666738	0.887	rs34509663	chr4:98982531	C/T	cg18180107	chr4:99064573	C4orf37	0.56	4.54	0.38	1.3e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12497850	0.931	rs9840050	chr3:49133310	A/G	cg05785598	chr3:49045655	WDR6	0.36	4.77	0.39	5.17e-6	Parkinson's disease;
TGCT	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg08439880	chr3:133502540	NA	-0.3	-5.52	-0.44	1.88e-7	Iron status biomarkers;
TGCT	cis	rs797680	0.964	rs2152358	chr1:93634009	G/A	cg17826107	chr1:92977322	EVI5	-0.24	-5.27	-0.43	5.78e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs7000551	0.689	rs6997299	chr8:22324268	T/C	cg12081754	chr8:22256438	SLC39A14	0.28	4.52	0.38	1.45e-5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs13064411	0.597	rs2291905	chr3:113010466	C/T	cg18753928	chr3:113234510	CCDC52	-0.52	-4.61	-0.38	9.96e-6	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs11085466	0.615	rs76695906	chr19:21766710	G/A	cg23026602	chr19:21646605	NA	-0.57	-4.59	-0.38	1.05e-5	Colorectal or endometrial cancer;
TGCT	cis	rs5769765	1.000	rs4824112	chr22:50284345	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.18	-13.1	-0.76	3.8e-25	Schizophrenia;
TGCT	cis	rs11748684	1.000	rs72754922	chr5:42547714	G/A	cg01169772	chr5:41904236	C5orf51	-0.9	-4.5	-0.37	1.57e-5	Response to taxane treatment (docetaxel);
TGCT	cis	rs7100689	0.784	rs11202699	chr10:82131453	A/G	cg01528321	chr10:82214614	TSPAN14	0.88	8.48	0.61	5.61e-14	Post bronchodilator FEV1;
TGCT	cis	rs3806843	0.520	rs265312	chr5:140296272	T/G	cg07102913	chr5:140593443	PCDHB13	-0.49	-4.73	-0.39	5.98e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg03452623	chr4:187889614	NA	-0.36	-5.66	-0.45	9.75e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs72781680	0.678	rs2551341	chr2:24014778	G/T	cg08917208	chr2:24149416	ATAD2B	0.79	4.94	0.41	2.51e-6	Lymphocyte counts;
TGCT	cis	rs8013055	0.846	rs35723046	chr14:105970548	C/T	cg23356831	chr14:105996513	TMEM121	0.41	6.24	0.49	6.39e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs9534288	0.699	rs2146884	chr13:46660392	T/C	cg15192986	chr13:46630673	CPB2	-0.53	-6.41	-0.5	2.75e-9	Blood protein levels;
TGCT	cis	rs796364	1.000	rs281771	chr2:200812202	A/C	cg17644776	chr2:200775616	C2orf69	-0.31	-4.89	-0.4	3.12e-6	Schizophrenia;
TGCT	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg11494091	chr17:61959527	GH2	0.61	14.18	0.79	1.01e-27	Prudent dietary pattern;
TGCT	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg06753367	chr22:24256600	NA	-0.24	-4.56	-0.38	1.22e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2456568	0.741	rs10831137	chr11:93636912	C/T	cg17595323	chr11:93583763	C11orf90	-0.47	-6.52	-0.51	1.58e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg17971929	chr21:40555470	PSMG1	-0.67	-6.27	-0.49	5.46e-9	Cognitive function;
TGCT	trans	rs57221529	0.766	rs12519763	chr5:559145	C/T	cg25482853	chr8:67687455	SGK3	1.2	10.16	0.67	5.25e-18	Lung disease severity in cystic fibrosis;
TGCT	cis	rs1894292	0.527	rs4235119	chr4:74372801	C/G	cg05868023	chr4:75230803	EREG	-0.55	-5.01	-0.41	1.85e-6	Prostate cancer;
TGCT	cis	rs12200560	0.505	rs172425	chr6:97075299	A/T	cg06623918	chr6:96969491	KIAA0776	0.59	5.03	0.41	1.71e-6	Coronary heart disease;
TGCT	cis	rs12765878	1.000	rs2067832	chr10:105643134	G/A	cg11005552	chr10:105648138	OBFC1	0.44	7.6	0.56	6.24e-12	Coronary artery disease;
TGCT	cis	rs587847	0.737	rs17540662	chr15:37665328	C/T	cg00216138	chr15:37171175	LOC145845	0.31	4.45	0.37	1.91e-5	Intraocular pressure;
TGCT	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	5.65	0.45	1.06e-7	Alzheimer's disease;
TGCT	cis	rs593982	0.925	rs585272	chr11:65505289	A/G	cg08755490	chr11:65554678	OVOL1	1.36	11.08	0.71	2.98e-20	Atopic dermatitis;
TGCT	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg08280861	chr8:58055591	NA	0.4	4.73	0.39	5.97e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10193935	0.901	rs222469	chr2:42640235	T/C	cg27598129	chr2:42591480	NA	-0.39	-5.52	-0.44	1.93e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1215050	0.791	rs7688942	chr4:98832048	T/C	cg05340658	chr4:99064831	C4orf37	0.47	5.9	0.47	3.2e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg06481639	chr22:41940642	POLR3H	-0.74	-6.74	-0.52	5.38e-10	Vitiligo;
TGCT	cis	rs3806843	0.547	rs246065	chr5:140323638	A/G	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9388451	0.874	rs3734634	chr6:126111800	G/A	cg05901451	chr6:126070800	HEY2	-1.0	-14.26	-0.79	6.67e-28	Brugada syndrome;
TGCT	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg17554472	chr22:41940697	POLR3H	0.43	4.6	0.38	1.01e-5	Vitiligo;
TGCT	cis	rs1784581	0.651	rs3016568	chr6:162388158	G/A	cg17173639	chr6:162384350	PARK2	-0.47	-8.16	-0.59	3.15e-13	Itch intensity from mosquito bite;
TGCT	cis	rs7772486	0.790	rs6570723	chr6:146151230	A/T	cg23711669	chr6:146136114	FBXO30	0.89	10.12	0.67	6.38e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2230307	0.572	rs512999	chr1:100563330	A/G	cg24955406	chr1:100503596	HIAT1	0.75	5.13	0.42	1.1e-6	Carotid intima media thickness;
TGCT	cis	rs2486012	1.000	rs3011230	chr1:44340655	A/C	cg12908607	chr1:44402522	ARTN	0.72	5.68	0.45	8.89e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs1008375	0.966	rs4235392	chr4:17696422	A/G	cg18681998	chr4:17616180	MED28	0.78	7.29	0.55	3.14e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9814567	0.896	rs6794258	chr3:134344505	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-7.29	-0.55	3.14e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs7119038	0.730	rs10790269	chr11:118729456	C/T	cg19308663	chr11:118741387	NA	-0.32	-5.88	-0.47	3.6e-8	Sjögren's syndrome;
TGCT	cis	rs28595532	0.764	rs55913633	chr4:119747444	C/A	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg11301795	chr4:187892539	NA	-0.35	-5.28	-0.43	5.58e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg24503407	chr1:205819492	PM20D1	0.67	10.78	0.7	1.61e-19	Menarche (age at onset);
TGCT	cis	rs1577917	0.958	rs12195776	chr6:86488599	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-5.63	-0.45	1.16e-7	Response to antipsychotic treatment;
TGCT	cis	rs3087591	0.659	rs2214538	chr17:29636570	C/T	cg24425628	chr17:29625626	OMG;NF1	0.41	6.01	0.47	1.93e-8	Hip circumference;
TGCT	cis	rs9300255	0.596	rs11057207	chr12:123730891	T/G	cg00376283	chr12:123451042	ABCB9	0.79	6.72	0.52	6e-10	Neutrophil percentage of white cells;
TGCT	cis	rs9329221	0.905	rs6601451	chr8:10243681	C/G	cg27411982	chr8:10470053	RP1L1	-0.23	-4.9	-0.4	2.95e-6	Neuroticism;
TGCT	cis	rs17345786	1.000	rs17345786	chr3:101318318	A/C	cg11279151	chr3:101281821	RG9MTD1	0.43	9.38	0.64	4.06e-16	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs4650994	0.935	rs2811289	chr1:178572693	G/A	cg05059571	chr16:84539110	KIAA1609	0.39	7.01	0.53	1.33e-10	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs11718455	0.960	rs3843373	chr3:44011053	C/T	cg08738300	chr3:44038990	NA	-0.86	-6.55	-0.51	1.4e-9	Coronary artery disease;
TGCT	cis	rs12971120	0.685	rs34780792	chr18:72173278	G/A	cg25817165	chr18:72167213	CNDP2	-0.28	-4.84	-0.4	3.71e-6	Refractive error;
TGCT	cis	rs8017423	0.967	rs61996919	chr14:90701803	A/C	cg04374321	chr14:90722782	PSMC1	0.77	8.04	0.59	6.19e-13	Mortality in heart failure;
TGCT	cis	rs68170813	0.641	rs77487103	chr7:107078793	T/C	cg02696742	chr7:106810147	HBP1	-0.65	-5.15	-0.42	1.01e-6	Coronary artery disease;
TGCT	cis	rs478304	0.651	rs4014195	chr11:65506822	C/G	cg10518572	chr11:65560635	OVOL1	0.23	4.49	0.37	1.62e-5	Acne (severe);
TGCT	cis	rs8062405	0.964	rs72793809	chr16:28832382	C/T	cg09754948	chr16:28834200	ATXN2L	0.61	4.54	0.38	1.34e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg11941060	chr3:133502564	NA	-0.29	-5.93	-0.47	2.84e-8	Iron status biomarkers;
TGCT	cis	rs9814567	1.000	rs3932818	chr3:134206069	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.93	-9.27	-0.64	7.51e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs17221829	0.627	rs10830315	chr11:89375574	G/T	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.63	-0.38	9.04e-6	Anxiety in major depressive disorder;
TGCT	cis	rs72781680	0.898	rs72780118	chr2:23994431	G/A	cg08917208	chr2:24149416	ATAD2B	0.81	5.01	0.41	1.8e-6	Lymphocyte counts;
TGCT	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg00786635	chr1:25594202	NA	0.6	6.25	0.49	6.15e-9	Erythrocyte sedimentation rate;
TGCT	cis	rs12711979	0.740	rs6711964	chr2:3820916	A/T	cg17052675	chr2:3827356	NA	-0.4	-7.82	-0.57	2.02e-12	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs2013441	1.000	rs11871827	chr17:20215905	C/G	cg18979559	chr17:20280153	CCDC144C	-0.43	-4.56	-0.38	1.21e-5	Obesity-related traits;
TGCT	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.66	0.39	8.18e-6	Prudent dietary pattern;
TGCT	cis	rs9527	0.590	rs7898770	chr10:104756636	A/G	cg15744005	chr10:104629667	AS3MT	0.45	5.29	0.43	5.38e-7	Arsenic metabolism;
TGCT	cis	rs9309473	0.579	rs6728128	chr2:73595982	T/C	cg20560298	chr2:73613845	ALMS1	-0.41	-4.54	-0.38	1.31e-5	Metabolite levels;
TGCT	cis	rs68170813	0.559	rs76859341	chr7:107070146	C/G	cg02696742	chr7:106810147	HBP1	-0.71	-5.77	-0.46	5.86e-8	Coronary artery disease;
TGCT	cis	rs11105298	0.891	rs11105314	chr12:89924559	C/T	cg00757033	chr12:89920650	WDR51B	0.32	5.13	0.42	1.11e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs2153535	0.580	rs1577467	chr6:8444241	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.58	0.45	1.42e-7	Motion sickness;
TGCT	cis	rs10832963	0.847	rs4237722	chr11:18639363	T/C	cg09201001	chr11:18656081	SPTY2D1	1.01	10.56	0.69	5.45e-19	Breast cancer;
TGCT	cis	rs273218	0.573	rs10513033	chr5:53333477	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.58	-4.79	-0.4	4.61e-6	Migraine;
TGCT	cis	rs62380364	0.727	rs188582	chr5:88167740	G/C	cg22951263	chr5:87985283	NA	0.5	5.02	0.41	1.79e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg22166914	chr1:53195759	ZYG11B	-0.42	-7.46	-0.56	1.29e-11	Monocyte count;
TGCT	cis	rs9814567	1.000	rs9985341	chr3:134232840	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.74	-5.61	-0.45	1.24e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs4253772	0.678	rs1055659	chr22:46638298	C/T	cg09491104	chr22:46646882	C22orf40	-0.48	-4.81	-0.4	4.37e-6	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs17681684	0.565	rs12150167	chr17:9764244	C/A	cg15743799	chr17:9805578	RCVRN	-0.27	-5.89	-0.47	3.45e-8	GIP levels in response to oral glucose tolerance test (fasting);
TGCT	cis	rs9300255	0.602	rs1727306	chr12:123665695	A/G	cg00376283	chr12:123451042	ABCB9	0.73	5.69	0.46	8.5e-8	Neutrophil percentage of white cells;
TGCT	cis	rs7659604	0.702	rs6815790	chr4:122695385	A/C	cg19748678	chr4:122722346	EXOSC9	0.83	8.81	0.62	9.19e-15	Type 2 diabetes;
TGCT	trans	rs4332037	0.539	rs56016347	chr7:2060126	C/T	cg10840412	chr1:235813424	GNG4	0.94	6.84	0.52	3.21e-10	Bipolar disorder;
TGCT	cis	rs2862064	0.613	rs2862060	chr5:156443895	A/C	cg12943317	chr5:156479607	HAVCR1	-0.38	-5.2	-0.42	8.06e-7	Platelet count;
TGCT	cis	rs12479064	0.724	rs11885942	chr2:100004165	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.57	-4.47	-0.37	1.71e-5	Chronic sinus infection;
TGCT	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs832540	0.931	rs832536	chr5:56212595	C/T	cg24531977	chr5:56204891	C5orf35	-0.52	-5.18	-0.42	8.65e-7	Coronary artery disease;
TGCT	cis	rs7312933	0.618	rs7954523	chr12:42681508	A/G	cg19980929	chr12:42632907	YAF2	0.41	5.61	0.45	1.26e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs7572733	0.555	rs11903129	chr2:198918591	A/T	cg00792783	chr2:198669748	PLCL1	0.59	5.15	0.42	1.01e-6	Dermatomyositis;
TGCT	cis	rs7666738	0.546	rs1863602	chr4:98909304	T/C	cg05340658	chr4:99064831	C4orf37	0.59	6.4	0.5	2.86e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7937682	0.889	rs1784786	chr11:111486043	A/G	cg09085632	chr11:111637200	PPP2R1B	1.15	10.17	0.67	4.84e-18	Primary sclerosing cholangitis;
TGCT	cis	rs9549367	0.789	rs7999579	chr13:113879357	T/C	cg18105134	chr13:113819100	PROZ	-0.33	-5.38	-0.43	3.61e-7	Platelet distribution width;
TGCT	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg10802521	chr3:52805072	NEK4	-0.73	-8.95	-0.63	4.39e-15	Electroencephalogram traits;
TGCT	cis	rs174601	0.861	rs174581	chr11:61606683	G/A	cg01500311	chr11:61656094	FADS3	-0.33	-5.8	-0.46	5.23e-8	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
TGCT	cis	rs79387448	0.745	rs7572284	chr2:103119423	C/A	cg09003973	chr2:102972529	NA	0.86	5.72	0.46	7.67e-8	Gut microbiota (bacterial taxa);
TGCT	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-8.32	-0.6	1.35e-13	Platelet count;
TGCT	cis	rs933688	0.877	rs10474352	chr5:90732225	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.03	8.68	0.61	1.89e-14	Smoking behavior;
TGCT	cis	rs17826219	0.636	rs7221463	chr17:29080551	A/C	cg13385521	chr17:29058706	SUZ12P	0.8	4.87	0.4	3.38e-6	Body mass index;
TGCT	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	4.89	0.4	3e-6	Menopause (age at onset);
TGCT	cis	rs11250097	0.549	rs11778177	chr8:11310362	C/T	cg01383082	chr8:11323474	FAM167A	0.28	4.54	0.38	1.3e-5	Neuroticism;
TGCT	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg22535103	chr8:58192502	C8orf71	-0.42	-4.79	-0.4	4.7e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs617219	0.551	rs2131978	chr5:78613986	G/A	cg05890484	chr5:78407552	BHMT	-0.34	-4.62	-0.38	9.35e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs11098499	0.754	rs1546503	chr4:120241167	T/C	cg09307838	chr4:120376055	NA	0.61	5.89	0.47	3.33e-8	Corneal astigmatism;
TGCT	cis	rs7267979	1.000	rs2297496	chr20:25295787	T/C	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg16647868	chr5:131706066	SLC22A5	-0.3	-4.47	-0.37	1.77e-5	Breast cancer;
TGCT	cis	rs7552404	0.824	rs1251079	chr1:76189445	C/T	cg22875332	chr1:76189707	ACADM	0.83	12.87	0.76	1.38e-24	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs4663866	0.803	rs71426511	chr2:239180200	G/A	cg17283117	chr2:239148619	HES6	0.99	4.57	0.38	1.15e-5	Irritable bowel syndrome;
TGCT	trans	rs4819388	0.789	rs4568033	chr21:45649778	A/G	cg17383793	chr5:52405638	MOCS2	0.69	6.94	0.53	1.92e-10	Celiac disease;
TGCT	cis	rs6089584	0.566	rs2146852	chr20:60616492	T/G	cg06108461	chr20:60628389	TAF4	-0.44	-5.58	-0.45	1.44e-7	Body mass index;
TGCT	cis	rs6598955	0.671	rs11247900	chr1:26612460	G/A	cg04990556	chr1:26633338	UBXN11	0.64	4.91	0.4	2.78e-6	Obesity-related traits;
TGCT	cis	rs7312933	0.618	rs7315968	chr12:42637086	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.54	5.16	0.42	9.61e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	trans	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.9	10.11	0.67	6.82e-18	Intelligence (multi-trait analysis);
TGCT	trans	rs9383153	1.000	rs2237223	chr6:16329741	G/A	cg19402885	chr12:15475236	PTPRO	0.99	6.81	0.52	3.76e-10	Gambling;
TGCT	cis	rs35306767	0.855	rs11253499	chr10:944090	A/C	cg26597838	chr10:835615	NA	0.76	10.69	0.69	2.61e-19	Eosinophil percentage of granulocytes;
TGCT	cis	rs4805272	0.539	rs1075733	chr19:29324460	C/T	cg03161606	chr19:29218774	NA	0.54	4.48	0.37	1.68e-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
TGCT	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	7.24	0.55	4.17e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg03395511	chr6:291903	DUSP22	-0.7	-7.2	-0.54	4.99e-11	Menopause (age at onset);
TGCT	cis	rs1472147	0.503	rs62479604	chr7:128433964	T/C	cg00260937	chr7:128520193	KCP	0.43	4.89	0.4	3.09e-6	Calcium levels;
TGCT	cis	rs7635838	0.619	rs346087	chr3:11274354	A/G	cg00170343	chr3:11313890	ATG7	0.65	6.1	0.48	1.25e-8	HDL cholesterol;
TGCT	cis	rs6088590	0.648	rs6059991	chr20:33280836	C/T	cg06115741	chr20:33292138	TP53INP2	0.57	4.86	0.4	3.51e-6	Coronary artery disease;
TGCT	cis	rs1775715	0.769	rs2808102	chr10:32117749	A/T	cg14930904	chr10:32216787	ARHGAP12	0.5	4.85	0.4	3.62e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs775227	0.574	rs79709668	chr3:113161265	G/A	cg18753928	chr3:113234510	CCDC52	-0.66	-4.53	-0.38	1.39e-5	Dental caries;
TGCT	cis	rs2288073	0.965	rs10185445	chr2:24410976	A/C	cg05570707	chr2:24270316	C2orf44	0.5	4.49	0.37	1.58e-5	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs9858542	0.537	rs115753735	chr3:49355005	T/C	cg00383909	chr3:49044727	WDR6	0.7	4.85	0.4	3.64e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs59197085	0.636	rs3807133	chr7:128469760	G/A	cg00260937	chr7:128520193	KCP	0.47	4.89	0.4	3.03e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
TGCT	cis	rs77372450	0.551	rs7728747	chr5:157083635	C/T	cg12606933	chr5:157078573	SOX30	-0.42	-4.75	-0.39	5.48e-6	Bipolar disorder (body mass index interaction);
TGCT	cis	rs10174077	0.874	rs10186656	chr2:152475938	T/G	cg19508488	chr2:152266495	RIF1	0.7	6.53	0.51	1.54e-9	Squamous cell lung carcinoma;
TGCT	cis	rs6121246	0.567	rs6060261	chr20:30192948	C/G	cg21427119	chr20:30132790	HM13	-0.42	-6.17	-0.48	8.75e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs7824557	0.602	rs7819395	chr8:11211068	T/C	cg21775007	chr8:11205619	TDH	0.73	7.03	0.53	1.23e-10	Retinal vascular caliber;
TGCT	cis	rs2468186	0.583	rs2450067	chr8:120096533	C/T	cg02248809	chr8:120845432	TAF2	-0.45	-4.83	-0.4	3.99e-6	Osteoprotegerin levels;
TGCT	cis	rs9611565	0.568	rs5758441	chr22:42132888	C/A	cg06634786	chr22:41940651	POLR3H	0.79	7.29	0.55	3.13e-11	Vitiligo;
TGCT	cis	rs35160687	0.862	rs13023154	chr2:86516984	A/G	cg03171300	chr2:86307199	POLR1A	-0.27	-5.03	-0.41	1.69e-6	Night sleep phenotypes;
TGCT	cis	rs1577917	0.739	rs9450318	chr6:86427177	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.59	5.07	0.41	1.42e-6	Response to antipsychotic treatment;
TGCT	cis	rs244731	1.000	rs244729	chr5:176539018	C/G	cg16006841	chr5:176797999	RGS14	0.51	6.47	0.5	2.01e-9	Urate levels in lean individuals;
TGCT	cis	rs3821902	0.646	rs10510901	chr3:64013062	A/G	cg22134162	chr3:63841271	THOC7	-0.31	-4.85	-0.4	3.58e-6	Breast cancer;
TGCT	trans	rs2688608	0.839	rs2633310	chr10:75594050	G/T	cg13918328	chr10:52500089	ASAH2B	-0.69	-6.73	-0.52	5.47e-10	Inflammatory bowel disease;
TGCT	cis	rs12134133	0.962	rs7526658	chr1:207413443	A/G	cg02152968	chr1:207494213	CD55	0.6	4.65	0.39	8.43e-6	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs1008375	0.866	rs12233712	chr4:17570063	T/A	cg18681998	chr4:17616180	MED28	0.88	8.97	0.63	3.94e-15	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7666738	0.512	rs165251	chr4:98758490	C/G	cg17366294	chr4:99064904	C4orf37	0.52	5.61	0.45	1.27e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs589249	0.963	rs11263940	chr1:37182486	C/T	cg04012535	chr1:37176647	NA	0.32	5.18	0.42	8.63e-7	Neuroticism (multi-trait analysis);Schizophrenia;
TGCT	cis	rs73058052	1.000	rs12462756	chr19:50098423	G/A	cg09250473	chr19:50168907	IRF3;BCL2L12	0.87	6.6	0.51	1.06e-9	Fibrinogen levels;
TGCT	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg17911788	chr17:44343683	NA	-0.68	-7.21	-0.54	4.72e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs10510102	0.872	rs10887032	chr10:123715402	C/T	cg23691251	chr10:123688108	ATE1	0.55	4.5	0.37	1.55e-5	Breast cancer;
TGCT	cis	rs9372498	0.536	rs72954806	chr6:118899965	C/G	cg07617317	chr6:118971624	C6orf204	0.49	5.19	0.42	8.37e-7	Diastolic blood pressure;
TGCT	cis	rs514406	0.893	rs6588446	chr1:53425260	G/A	cg22166914	chr1:53195759	ZYG11B	-0.35	-5.75	-0.46	6.65e-8	Monocyte count;
TGCT	cis	rs2235642	1.000	rs2235642	chr16:1584866	T/C	cg08296037	chr16:1584118	IFT140;TMEM204	-0.3	-5.51	-0.44	2.01e-7	Coronary artery disease;
TGCT	cis	rs3780378	0.875	rs10115312	chr9:5003973	G/T	cg02405213	chr9:5042618	JAK2	-0.6	-7.79	-0.57	2.26e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs950169	0.922	rs11630760	chr15:85113337	G/T	cg12863693	chr15:85201151	NMB	0.39	4.44	0.37	1.99e-5	Schizophrenia;
TGCT	cis	rs61935443	0.720	rs892493	chr12:95283943	T/C	cg21533806	chr12:95267307	NA	0.52	4.49	0.37	1.61e-5	Schizophrenia;
TGCT	cis	rs7017914	0.967	rs13256250	chr8:71596193	G/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.03	-0.41	1.69e-6	Bone mineral density;
TGCT	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	5.23	0.43	6.92e-7	Menopause (age at onset);
TGCT	cis	rs2456568	0.709	rs12806128	chr11:93634972	C/T	cg26875233	chr11:93583750	C11orf90	0.47	6.04	0.48	1.65e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs17253792	0.822	rs77197405	chr14:56159662	T/A	cg01858014	chr14:56050164	KTN1	-0.35	-4.62	-0.38	9.37e-6	Putamen volume;
TGCT	cis	rs7635838	0.892	rs34830847	chr3:11437798	A/C	cg00170343	chr3:11313890	ATG7	0.65	6.23	0.49	6.56e-9	HDL cholesterol;
TGCT	cis	rs4819052	0.851	rs2838866	chr21:46713014	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	4.57	0.38	1.17e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7178572	0.568	rs12901739	chr15:77395491	C/T	cg15453836	chr15:77711506	NA	-0.4	-4.52	-0.38	1.45e-5	Type 2 diabetes;
TGCT	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.07	-9.63	-0.65	1.01e-16	Platelet count;
TGCT	cis	rs7582180	0.764	rs1967341	chr2:100924559	T/C	cg08017756	chr2:100939284	LONRF2	-0.32	-5.26	-0.43	6.1e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs739496	0.615	rs617044	chr12:112132875	T/C	cg10833066	chr12:111807467	FAM109A	0.37	4.79	0.39	4.76e-6	Platelet count;
TGCT	cis	rs7647973	1.000	rs9842132	chr3:49427933	G/A	cg05785598	chr3:49045655	WDR6	-0.4	-4.67	-0.39	7.57e-6	Menarche (age at onset);
TGCT	cis	rs35306767	0.855	rs11253459	chr10:886402	C/T	cg20503657	chr10:835505	NA	0.7	9.83	0.66	3.22e-17	Eosinophil percentage of granulocytes;
TGCT	cis	rs765787	0.530	rs28526629	chr15:45540462	C/T	cg24006582	chr15:45444508	DUOX1	-0.24	-5.29	-0.43	5.34e-7	Uric acid levels;
TGCT	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg23708337	chr7:1209742	NA	0.56	5.09	0.42	1.31e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs10751667	0.666	rs4074235	chr11:977511	C/G	cg06064525	chr11:970664	AP2A2	-0.36	-8.28	-0.6	1.67e-13	Alzheimer's disease (late onset);
TGCT	cis	rs11887277	0.676	rs9646996	chr2:27044097	A/G	cg14949065	chr2:27373128	TCF23	0.19	4.46	0.37	1.8e-5	Obesity-related traits;
TGCT	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs17376456	1.000	rs13185608	chr5:93509688	T/G	cg25358565	chr5:93447407	FAM172A	0.95	7.97	0.58	8.71e-13	Diabetic retinopathy;
TGCT	cis	rs9902453	0.967	rs4429345	chr17:28458105	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-6.39	-0.5	3.03e-9	Coffee consumption (cups per day);
TGCT	cis	rs2239908	0.718	rs241776	chr17:26644308	C/T	cg10342447	chr17:26645325	TMEM97	0.62	6.26	0.49	5.78e-9	Blood protein levels;
TGCT	cis	rs1580019	0.562	rs4720064	chr7:32559638	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.56	4.8	0.4	4.53e-6	Cognitive ability;
TGCT	cis	rs9611565	0.503	rs5996062	chr22:42167464	C/G	cg17554472	chr22:41940697	POLR3H	0.46	4.8	0.4	4.46e-6	Vitiligo;
TGCT	cis	rs12220238	1.000	rs12252705	chr10:75984863	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.78	0.57	2.42e-12	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs7528684	0.752	rs6427402	chr1:157749544	C/T	cg17134153	chr1:157670328	FCRL3	-0.28	-5.13	-0.42	1.08e-6	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;
TGCT	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs4900538	0.963	rs942023	chr14:102972170	T/C	cg18135206	chr14:102964638	TECPR2	0.21	5.0	0.41	1.95e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs10088262	0.629	rs7827665	chr8:124804190	G/A	cg02993010	chr8:124780839	FAM91A1	-0.63	-5.13	-0.42	1.08e-6	Pancreatic cancer;
TGCT	cis	rs3806843	0.608	rs246042	chr5:140330967	G/A	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	trans	rs797680	0.789	rs7539307	chr1:93652703	G/A	cg27528825	chr2:159282178	CCDC148	-0.35	-6.81	-0.52	3.79e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs910316	0.763	rs1548807	chr14:75479582	T/G	cg11812906	chr14:75593930	NEK9	0.58	5.56	0.45	1.6e-7	Height;
TGCT	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg13393036	chr8:95962371	TP53INP1	-0.65	-8.88	-0.62	6.27e-15	Type 2 diabetes;
TGCT	cis	rs137699	1.000	rs760742	chr22:39755190	G/T	cg11247378	chr22:39784982	NA	-0.46	-5.09	-0.42	1.28e-6	IgG glycosylation;
TGCT	cis	rs7208859	0.673	rs1347360	chr17:28914532	T/C	cg04154034	chr17:28927549	LRRC37B2	0.85	5.03	0.41	1.68e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs12477438	0.798	rs10196680	chr2:99628617	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-6.1	-0.48	1.22e-8	Chronic sinus infection;
TGCT	cis	rs9467773	0.595	rs13207371	chr6:26591074	G/A	cg09904177	chr6:26538194	HMGN4	0.64	5.78	0.46	5.73e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs3733585	0.673	rs6449156	chr4:9956712	G/C	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.73	-0.57	3.12e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7666738	0.830	rs28619044	chr4:98789814	G/C	cg18180107	chr4:99064573	C4orf37	0.53	5.05	0.41	1.51e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6669919	0.540	rs11579048	chr1:211681919	C/G	cg10512769	chr1:211675356	NA	-0.25	-4.49	-0.37	1.61e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs4975616	0.869	rs421284	chr5:1325590	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.29	-6.99	-0.53	1.49e-10	Lung cancer;
TGCT	cis	rs9383153	0.590	rs2072736	chr6:16328068	T/C	cg14009473	chr6:15502099	JARID2	0.67	5.16	0.42	9.52e-7	Gambling;
TGCT	cis	rs1245541	0.720	rs1668157	chr10:73906150	A/G	cg09661010	chr10:73848153	SPOCK2	-0.37	-4.53	-0.38	1.39e-5	Insulin-like growth factors;
TGCT	cis	rs782590	0.934	rs62165184	chr2:55788253	G/C	cg03859395	chr2:55845619	SMEK2	0.93	11.51	0.72	2.61e-21	Metabolic syndrome;
TGCT	cis	rs7666738	0.830	rs7663661	chr4:99014761	A/G	cg05340658	chr4:99064831	C4orf37	0.48	5.43	0.44	2.92e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs67478160	0.619	rs28698555	chr14:104316486	C/A	cg26031613	chr14:104095156	KLC1	0.68	6.98	0.53	1.59e-10	Schizophrenia;
TGCT	cis	rs1577917	0.958	rs10455448	chr6:86533611	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-5.53	-0.44	1.82e-7	Response to antipsychotic treatment;
TGCT	cis	rs727563	0.594	rs5758408	chr22:42077737	A/C	cg06481639	chr22:41940642	POLR3H	0.73	6.57	0.51	1.27e-9	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs72781680	0.800	rs6718635	chr2:24066183	A/C	cg08917208	chr2:24149416	ATAD2B	0.9	5.6	0.45	1.29e-7	Lymphocyte counts;
TGCT	cis	rs921968	0.643	rs711186	chr2:219346102	A/G	cg02176678	chr2:219576539	TTLL4	-0.43	-6.44	-0.5	2.37e-9	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs782590	0.818	rs2627782	chr2:55825352	A/G	cg18811423	chr2:55921094	PNPT1	0.55	5.72	0.46	7.65e-8	Metabolic syndrome;
TGCT	cis	rs2735413	0.599	rs73562710	chr16:78124606	T/C	cg09132178	chr16:78079569	NA	0.35	4.49	0.37	1.63e-5	Systolic blood pressure (alcohol consumption interaction);
TGCT	cis	rs6912958	0.525	rs59322	chr6:88020521	C/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.46	5.94	0.47	2.69e-8	Monocyte percentage of white cells;
TGCT	cis	rs4253772	0.530	rs6008623	chr22:46710024	G/A	cg24881330	chr22:46731750	TRMU	1.04	5.41	0.44	3.12e-7	LDL cholesterol;Cholesterol, total;
TGCT	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg03395511	chr6:291903	DUSP22	-0.71	-7.28	-0.55	3.36e-11	Menopause (age at onset);
TGCT	cis	rs7432375	0.933	rs6791142	chr3:136377377	C/T	cg12473912	chr3:136751656	NA	0.36	5.06	0.41	1.5e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs796364	0.806	rs74771155	chr2:200913743	C/T	cg17644776	chr2:200775616	C2orf69	-0.33	-5.0	-0.41	1.91e-6	Schizophrenia;
TGCT	cis	rs35771425	0.642	rs3767380	chr1:211452845	A/G	cg26515805	chr1:211431828	RCOR3	-0.44	-4.65	-0.39	8.52e-6	Educational attainment (years of education);
TGCT	cis	rs7178424	0.742	rs12916268	chr15:62175642	G/A	cg00456672	chr15:62358751	C2CD4A	-0.31	-4.73	-0.39	6e-6	Height;
TGCT	cis	rs3008870	1.000	rs3008856	chr1:67387901	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.1	12.09	0.74	1.01e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs524281	0.861	rs4013917	chr11:65926185	A/G	cg00563793	chr11:65837595	PACS1	0.58	4.92	0.4	2.66e-6	Electroencephalogram traits;
TGCT	cis	rs2549003	0.870	rs61175929	chr5:131821548	C/G	cg00255919	chr5:131827918	IRF1	0.2	4.64	0.38	8.73e-6	Asthma (sex interaction);
TGCT	cis	rs4253772	0.591	rs6007727	chr22:46650959	G/A	cg09491104	chr22:46646882	C22orf40	-0.62	-6.49	-0.5	1.87e-9	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs28595532	0.668	rs58467651	chr4:119349011	T/G	cg14228332	chr4:119757509	SEC24D	0.74	4.53	0.38	1.39e-5	Cannabis dependence symptom count;
TGCT	cis	rs9677476	0.608	rs6437005	chr2:232055735	A/G	cg27665808	chr2:232055229	NA	0.35	4.5	0.37	1.52e-5	Food antigen IgG levels;
TGCT	cis	rs10823500	0.777	rs2184335	chr10:72006891	C/T	cg04118878	chr10:71993077	PPA1	0.57	5.11	0.42	1.16e-6	Blood protein levels;
TGCT	cis	rs7267979	0.744	rs6050464	chr20:25209299	C/A	cg16686733	chr20:25566563	NINL	0.53	4.95	0.41	2.37e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs13242816	1.000	rs56063232	chr7:116172808	G/T	cg16553024	chr7:116138462	CAV2	-0.44	-5.26	-0.43	6.11e-7	P wave duration;
TGCT	cis	rs9926296	1.000	rs9926296	chr16:89818089	A/G	cg26513180	chr16:89883248	FANCA	0.89	10.24	0.68	3.28e-18	Vitiligo;
TGCT	cis	rs6088590	1.000	rs6088595	chr20:33358499	T/A	cg06115741	chr20:33292138	TP53INP2	0.64	5.34	0.43	4.29e-7	Coronary artery disease;
TGCT	cis	rs80282103	0.618	rs17155886	chr10:1145182	A/G	cg08668510	chr10:1095578	IDI1	1.05	5.31	0.43	4.8e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg00343986	chr7:65444356	GUSB	-0.23	-5.16	-0.42	9.66e-7	Aortic root size;
TGCT	cis	rs4938534	0.716	rs7947229	chr11:111289354	T/G	cg24049888	chr11:111250129	POU2AF1	-0.25	-4.44	-0.37	1.98e-5	Primary biliary cholangitis;
TGCT	cis	rs6582630	0.519	rs7305545	chr12:38349223	G/A	cg26384229	chr12:38710491	ALG10B	0.83	7.23	0.54	4.33e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs1150668	0.799	rs1150705	chr6:28193786	T/G	cg13525197	chr6:28411240	ZSCAN23	-0.47	-4.61	-0.38	9.84e-6	Pubertal anthropometrics;
TGCT	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg27535305	chr1:53392650	SCP2	-0.26	-5.07	-0.41	1.43e-6	Monocyte count;
TGCT	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.75	0.52	5.11e-10	Bipolar disorder;
TGCT	cis	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg22857025	chr5:266934	NA	-0.34	-6.67	-0.51	7.72e-10	Breast cancer;
TGCT	cis	rs3820928	0.874	rs10202239	chr2:227901819	C/T	cg11843606	chr2:227700838	RHBDD1	-0.54	-4.96	-0.41	2.29e-6	Pulmonary function;
TGCT	cis	rs2072499	0.750	rs909269	chr1:156192028	C/T	cg25208724	chr1:156163844	SLC25A44	0.94	8.7	0.62	1.73e-14	Testicular germ cell tumor;
TGCT	cis	rs10464366	0.746	rs17171537	chr7:39145647	C/T	cg15212455	chr7:39170539	POU6F2	0.26	5.9	0.47	3.21e-8	IgG glycosylation;
TGCT	cis	rs832540	0.656	rs832573	chr5:56159578	T/C	cg12311346	chr5:56204834	C5orf35	-0.48	-4.91	-0.4	2.78e-6	Coronary artery disease;
TGCT	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg04944784	chr2:26401820	FAM59B	0.76	6.24	0.49	6.46e-9	Gut microbiome composition (summer);
TGCT	cis	rs763014	0.966	rs4144003	chr16:645968	C/T	cg00908189	chr16:619842	PIGQ	0.85	10.14	0.67	5.88e-18	Height;
TGCT	cis	rs7666738	0.606	rs6852813	chr4:99084671	G/A	cg18180107	chr4:99064573	C4orf37	0.53	4.67	0.39	7.61e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	7.32	0.55	2.74e-11	Platelet count;
TGCT	cis	rs12530845	0.832	rs56306315	chr7:135329107	C/T	cg23117316	chr7:135346802	PL-5283	-0.51	-4.83	-0.4	3.98e-6	Red blood cell traits;
TGCT	cis	rs56011263	0.687	rs4690187	chr4:703813	C/T	cg20735989	chr4:730612	PCGF3	-0.24	-5.43	-0.44	2.86e-7	White blood cell count;
TGCT	cis	rs2439831	0.867	rs2251844	chr15:43836478	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.84	5.79	0.46	5.33e-8	Lung cancer in ever smokers;
TGCT	cis	rs9302001	0.960	rs9302000	chr13:95460995	C/G	cg07483244	chr13:95358924	NA	0.37	4.81	0.4	4.22e-6	Panic disorder;
TGCT	cis	rs6586111	1.000	rs6586109	chr10:82375514	A/G	cg03086067	chr10:82368399	SH2D4B	-0.23	-4.54	-0.38	1.33e-5	Capecitabine sensitivity;
TGCT	cis	rs2153535	0.580	rs6921036	chr6:8455400	G/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs8020441	0.945	rs57182174	chr14:51167938	A/T	cg04730355	chr14:51134070	SAV1	0.71	5.83	0.46	4.42e-8	Cognitive performance;
TGCT	cis	rs12142240	0.621	rs66828173	chr1:46818166	G/A	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	trans	rs629535	0.783	rs538832	chr8:70033817	A/G	cg21567404	chr3:27674614	NA	0.58	9.18	0.64	1.22e-15	Dupuytren's disease;
TGCT	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg06873352	chr17:61820015	STRADA	0.55	5.69	0.46	8.57e-8	Prudent dietary pattern;
TGCT	cis	rs1322512	1.000	rs1405694	chr6:152946561	C/T	cg03415253	chr6:152958462	SYNE1	-0.49	-4.45	-0.37	1.93e-5	Tonometry;
TGCT	cis	rs2072499	0.966	rs2842869	chr1:156160696	A/G	cg25208724	chr1:156163844	SLC25A44	1.14	16.72	0.83	1.43e-33	Testicular germ cell tumor;
TGCT	cis	rs2115536	0.967	rs3826008	chr15:80189805	G/T	cg00225070	chr15:80189496	MTHFS	0.61	5.53	0.44	1.82e-7	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs7255045	0.788	rs6511843	chr19:12955544	A/C	cg23899408	chr19:12877188	HOOK2	-0.59	-4.93	-0.41	2.55e-6	Mean corpuscular volume;
TGCT	cis	rs7246657	0.943	rs1373991	chr19:37838911	T/C	cg03233940	chr19:37894644	NA	-0.34	-4.49	-0.37	1.59e-5	Coronary artery calcification;
TGCT	cis	rs9814567	0.896	rs6790338	chr3:134208167	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.96	-9.19	-0.64	1.16e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs9399135	1.000	rs4896130	chr6:135355118	C/T	cg24558204	chr6:135376177	HBS1L	0.46	4.6	0.38	1.03e-5	Red blood cell count;
TGCT	cis	rs12421382	0.659	rs1371330	chr11:109382692	G/T	cg16359550	chr11:109292809	C11orf87	0.4	4.5	0.37	1.54e-5	Schizophrenia;
TGCT	cis	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg03213289	chr20:61660250	NA	0.67	9.59	0.65	1.22e-16	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs422249	0.504	rs174538	chr11:61560081	G/A	cg19610905	chr11:61596333	FADS2	-0.98	-9.07	-0.63	2.23e-15	Trans fatty acid levels;
TGCT	cis	rs7027203	0.576	rs7862149	chr9:96546778	A/G	cg13679303	chr9:96623674	NA	0.53	7.61	0.56	6.13e-12	DNA methylation (variation);
TGCT	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg03609598	chr5:56110824	MAP3K1	-0.58	-4.7	-0.39	6.72e-6	Initial pursuit acceleration;
TGCT	cis	rs2440129	0.611	rs10852889	chr17:6900845	C/T	cg03760483	chr17:6899297	ALOX12	0.47	5.47	0.44	2.33e-7	Tonsillectomy;
TGCT	cis	rs6570726	0.967	rs413880	chr6:145804822	G/A	cg23711669	chr6:146136114	FBXO30	0.66	6.08	0.48	1.37e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.08	0.48	1.37e-8	Bipolar disorder;
TGCT	cis	rs2370759	1.000	rs16933243	chr10:32615135	T/C	cg01819863	chr10:32635814	EPC1	1.03	10.07	0.67	8.33e-18	Sexual dysfunction (female);
TGCT	cis	rs765787	0.530	rs10851423	chr15:45515950	G/A	cg24006582	chr15:45444508	DUOX1	0.25	5.33	0.43	4.46e-7	Uric acid levels;
TGCT	cis	rs7178572	1.000	rs1565756	chr15:77741640	G/A	cg15453836	chr15:77711506	NA	-0.41	-4.71	-0.39	6.5e-6	Type 2 diabetes;
TGCT	cis	rs72627509	0.904	rs17081933	chr4:57822869	T/A	cg26694713	chr4:57773883	REST	0.71	6.26	0.49	5.63e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs826838	0.967	rs826870	chr12:39120250	G/A	cg26384229	chr12:38710491	ALG10B	-0.86	-7.76	-0.57	2.68e-12	Heart rate;
TGCT	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	4.67	0.39	7.7e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2637266	0.846	rs2637260	chr10:78320346	C/T	cg18941641	chr10:78392320	NA	-0.37	-4.48	-0.37	1.67e-5	Pulmonary function;
TGCT	cis	rs13088645	0.729	rs7620040	chr3:134163082	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.65	-6.64	-0.51	8.92e-10	Coronary artery disease;
TGCT	cis	rs524281	0.692	rs11227395	chr11:65829637	A/C	cg00563793	chr11:65837595	PACS1	0.53	4.75	0.39	5.6e-6	Electroencephalogram traits;
TGCT	trans	rs8073060	0.586	rs225298	chr17:33923946	T/G	cg19694781	chr19:47549865	TMEM160	-0.61	-13.7	-0.78	1.39e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs6570726	0.764	rs376257	chr6:145862949	G/A	cg23711669	chr6:146136114	FBXO30	0.89	9.93	0.67	1.82e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs17384381	0.953	rs12139958	chr1:85842112	A/G	cg16011679	chr1:85725395	C1orf52	0.84	6.52	0.51	1.6e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg07507251	chr3:52567010	NT5DC2	0.46	6.51	0.5	1.66e-9	Bipolar disorder;
TGCT	cis	rs7027930	0.517	rs17344772	chr9:549845	A/G	cg13877502	chr9:707387	KANK1	0.5	4.55	0.38	1.28e-5	Pulmonary function decline;
TGCT	cis	rs2455799	0.613	rs6802048	chr3:15883933	A/G	cg16303742	chr3:15540471	COLQ	-0.24	-4.44	-0.37	1.99e-5	Mean platelet volume;
TGCT	cis	rs2688608	0.839	rs2675662	chr10:75599127	A/G	cg19442545	chr10:75533431	FUT11	0.31	4.56	0.38	1.23e-5	Inflammatory bowel disease;
TGCT	cis	rs12682352	0.602	rs6988939	chr8:8666916	C/T	cg06636001	chr8:8085503	FLJ10661	0.61	5.1	0.42	1.26e-6	Neuroticism;
TGCT	cis	rs12477438	1.000	rs1922624	chr2:99909958	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.82	-6.44	-0.5	2.4e-9	Chronic sinus infection;
TGCT	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg08219700	chr8:58056026	NA	0.4	4.92	0.4	2.67e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2637266	0.935	rs1907323	chr10:78336015	C/T	cg18941641	chr10:78392320	NA	0.41	5.21	0.42	7.76e-7	Pulmonary function;
TGCT	cis	rs3820068	0.603	rs72647120	chr1:15956769	G/T	cg05660106	chr1:15850417	CASP9	0.84	8.28	0.6	1.64e-13	Systolic blood pressure;
TGCT	cis	rs2439831	0.850	rs558656	chr15:43723514	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.8	5.7	0.46	8.33e-8	Lung cancer in ever smokers;
TGCT	cis	rs546131	0.642	rs473848	chr11:34851977	A/C	cg06937548	chr11:34938143	PDHX;APIP	0.52	4.55	0.38	1.28e-5	Lung disease severity in cystic fibrosis;
TGCT	cis	rs61990749	0.597	rs2299930	chr14:78163722	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	-0.67	-4.73	-0.39	6.09e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs2594989	0.943	rs77630528	chr3:11314041	A/G	cg00170343	chr3:11313890	ATG7	0.66	4.75	0.39	5.58e-6	Circulating chemerin levels;
TGCT	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg16423285	chr20:60520624	NA	-0.61	-6.57	-0.51	1.23e-9	Body mass index;
TGCT	cis	rs11252926	0.537	rs4554800	chr10:458477	G/T	cg20256804	chr10:444983	DIP2C	0.21	4.7	0.39	6.83e-6	Psychosis in Alzheimer's disease;
TGCT	cis	rs7772486	0.790	rs2256998	chr6:146207657	A/C	cg23711669	chr6:146136114	FBXO30	0.89	10.18	0.67	4.61e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg05590025	chr7:65112418	INTS4L2	-0.77	-4.5	-0.37	1.52e-5	Diabetic kidney disease;
TGCT	cis	rs10501293	0.703	rs4237640	chr11:42990542	G/A	cg03447554	chr11:43094025	NA	0.44	6.45	0.5	2.25e-9	Cognitive performance;
TGCT	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg00343986	chr7:65444356	GUSB	0.24	5.25	0.43	6.3e-7	Aortic root size;
TGCT	cis	rs7666738	0.570	rs10032272	chr4:99095601	T/C	cg18180107	chr4:99064573	C4orf37	0.51	4.58	0.38	1.09e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7582180	0.739	rs11687352	chr2:100919888	A/C	cg14675211	chr2:100938903	LONRF2	0.49	4.8	0.4	4.45e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs8016982	1.000	rs12147118	chr14:81652975	A/C	cg01989461	chr14:81687754	GTF2A1	-0.62	-5.14	-0.42	1.03e-6	Schizophrenia;
TGCT	cis	rs7547997	0.517	rs6687405	chr1:158240757	T/G	cg07950803	chr1:158223934	CD1A	0.31	4.69	0.39	7.1e-6	QRS duration;
TGCT	cis	rs9733	0.596	rs72702570	chr1:150688196	C/T	cg09365446	chr1:150670422	GOLPH3L	0.3	4.52	0.38	1.4e-5	Tonsillectomy;
TGCT	cis	rs2072499	0.778	rs2247476	chr1:156190280	C/A	cg25208724	chr1:156163844	SLC25A44	0.94	8.7	0.62	1.73e-14	Testicular germ cell tumor;
TGCT	cis	rs6424115	0.793	rs2502998	chr1:24198327	T/A	cg15997130	chr1:24165203	NA	0.86	9.53	0.65	1.76e-16	Immature fraction of reticulocytes;
TGCT	cis	rs2820315	1.000	rs2820313	chr1:201870221	A/G	cg12730843	chr1:201915899	LMOD1	-0.27	-4.85	-0.4	3.64e-6	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
TGCT	trans	rs4332037	0.802	rs12113633	chr7:1932936	G/A	cg10840412	chr1:235813424	GNG4	1.04	8.16	0.59	3.22e-13	Bipolar disorder;
TGCT	cis	rs17030434	1.000	rs6853522	chr4:154706220	A/C	cg14289246	chr4:154710475	SFRP2	1.03	8.07	0.59	5.05e-13	Electrocardiographic conduction measures;
TGCT	cis	rs7582180	0.764	rs1946799	chr2:100921136	C/A	cg08017756	chr2:100939284	LONRF2	-0.32	-5.26	-0.43	6.1e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2075371	0.796	rs1646645	chr7:134012232	G/T	cg11752832	chr7:134001865	SLC35B4	-0.72	-6.22	-0.49	6.92e-9	Mean platelet volume;
TGCT	cis	rs9308731	0.583	rs7567184	chr2:111931072	C/G	cg04202892	chr2:111875749	ACOXL	0.45	5.11	0.42	1.21e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs208520	0.690	rs12213581	chr6:66735818	T/C	cg07460842	chr6:66804631	NA	0.95	10.11	0.67	6.77e-18	Exhaled nitric oxide output;
TGCT	cis	rs637571	0.557	rs1204649	chr11:65702776	A/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.62	6.32	0.49	4.22e-9	Eosinophil percentage of white cells;
TGCT	cis	rs7582180	0.739	rs10195793	chr2:100925803	A/G	cg14675211	chr2:100938903	LONRF2	0.51	4.93	0.4	2.61e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.43	-4.64	-0.38	8.8e-6	Longevity;Endometriosis;
TGCT	cis	rs10744422	0.841	rs10847742	chr12:123289395	A/G	cg18912006	chr12:123335444	HIP1R	0.56	4.78	0.39	4.84e-6	Schizophrenia;
TGCT	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg11062466	chr8:58055876	NA	0.37	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs3806843	0.607	rs246044	chr5:140330656	C/T	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.11e-5	Depressive symptoms (multi-trait analysis);
TGCT	trans	rs4650994	0.525	rs2493865	chr1:178545016	G/A	cg05059571	chr16:84539110	KIAA1609	0.53	10.7	0.69	2.54e-19	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg16414030	chr3:133502952	NA	0.63	10.04	0.67	1.02e-17	Iron status biomarkers;
TGCT	cis	rs10779751	1.000	rs4845858	chr1:11304720	C/T	cg08854313	chr1:11322531	MTOR	0.94	10.52	0.69	6.72e-19	Body mass index;
TGCT	cis	rs9814567	1.000	rs7645295	chr3:134307734	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.91	-8.83	-0.62	8.17e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg06221963	chr1:154839813	KCNN3	-0.8	-14.7	-0.8	6.11e-29	Prostate cancer;
TGCT	cis	rs1538970	0.924	rs11211118	chr1:45930270	A/C	cg05343316	chr1:45956843	TESK2	0.75	6.27	0.49	5.48e-9	Platelet count;
TGCT	cis	rs7698623	0.717	rs4693193	chr4:88797992	T/C	cg27387453	chr4:88533842	DSPP	-0.61	-4.6	-0.38	1.03e-5	Cardiovascular disease risk factors;
TGCT	cis	rs494562	0.730	rs9450270	chr6:86114766	A/G	cg27039625	chr6:86159096	NT5E	0.53	4.55	0.38	1.24e-5	Blood metabolite levels;Metabolic traits;
TGCT	cis	rs17125944	0.505	rs75194546	chr14:53212069	A/C	cg00686598	chr14:53173677	PSMC6	1.08	6.32	0.49	4.37e-9	Alzheimer's disease (late onset);
TGCT	cis	rs6681544	0.512	rs17472472	chr1:82479318	T/C	cg04226724	chr1:82268649	LPHN2	0.48	5.21	0.42	7.77e-7	Metabolite levels  (X-11787);
TGCT	cis	rs3820068	0.581	rs111699992	chr1:15927158	G/A	cg05660106	chr1:15850417	CASP9	0.82	8.02	0.58	6.63e-13	Systolic blood pressure;
TGCT	cis	rs2228479	1.000	rs117406136	chr16:89974605	C/T	cg06558623	chr16:89946397	TCF25	0.58	6.67	0.51	7.45e-10	Skin colour saturation;
TGCT	cis	rs763014	0.865	rs710924	chr16:633353	T/C	cg00908189	chr16:619842	PIGQ	0.87	10.2	0.68	4.14e-18	Height;
TGCT	cis	rs7829975	0.577	rs7816329	chr8:8543843	G/A	cg08975724	chr8:8085496	FLJ10661	-0.51	-4.44	-0.37	1.96e-5	Mood instability;
TGCT	cis	rs7428	0.527	rs7607284	chr2:85547376	C/G	cg24342717	chr2:85555507	TGOLN2	-0.49	-7.81	-0.57	2.04e-12	Ear protrusion;
TGCT	cis	rs7209700	0.547	rs61131650	chr17:45344327	G/A	cg21624342	chr17:45890973	OSBPL7	0.19	4.71	0.39	6.52e-6	IgG glycosylation;
TGCT	cis	rs72843506	0.722	rs74255392	chr17:20329052	A/G	cg18052601	chr17:19850474	AKAP10	0.28	4.6	0.38	1.02e-5	Schizophrenia;
TGCT	cis	rs28595532	0.920	rs114792862	chr4:119759938	G/A	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs7666738	0.830	rs114722517	chr4:99042061	G/A	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2857078	0.745	rs4793085	chr17:42320732	A/C	cg13607699	chr17:42295918	UBTF	-0.97	-10.63	-0.69	3.63e-19	Red cell distribution width;Reticulocyte count;
TGCT	cis	rs6582630	0.554	rs7299735	chr12:38450890	A/C	cg26384229	chr12:38710491	ALG10B	-0.54	-4.79	-0.4	4.57e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg10802521	chr3:52805072	NEK4	-0.71	-8.8	-0.62	9.55e-15	Bipolar disorder;
TGCT	cis	rs7760949	0.963	rs9367699	chr6:13894635	A/C	cg27413430	chr6:13925136	RNF182	0.54	5.01	0.41	1.85e-6	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs727563	0.635	rs5751141	chr22:42107745	A/G	cg13695892	chr22:41940480	POLR3H	0.88	8.57	0.61	3.38e-14	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs6570726	0.791	rs11155433	chr6:145907831	A/G	cg13319975	chr6:146136371	FBXO30	0.53	4.76	0.39	5.36e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1960156	1.000	rs1960156	chr16:12404016	C/T	cg08104224	chr16:11588532	NA	0.25	4.48	0.37	1.67e-5	Subjective well-being;
TGCT	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg18305652	chr10:134549665	INPP5A	0.35	5.55	0.45	1.66e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs6543140	1.000	rs6543140	chr2:103074274	G/T	cg09003973	chr2:102972529	NA	0.55	4.67	0.39	7.71e-6	Blood protein levels;
TGCT	cis	rs4242434	0.927	rs2291234	chr8:22464390	T/C	cg03733263	chr8:22462867	KIAA1967	1.13	20.13	0.88	6.96e-41	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs8072100	0.713	rs8075058	chr17:45482857	A/G	cg08085267	chr17:45401833	C17orf57	-0.52	-5.78	-0.46	5.78e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs611744	0.647	rs7016198	chr8:109262752	G/A	cg21045802	chr8:109455806	TTC35	0.7	7.05	0.54	1.07e-10	Dupuytren's disease;
TGCT	cis	rs7044106	0.791	rs2416798	chr9:123480603	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	7.1	0.54	8.41e-11	Hip circumference adjusted for BMI;
TGCT	cis	rs2762353	0.603	rs4145221	chr6:25763192	A/G	cg03264133	chr6:25882463	NA	0.49	4.87	0.4	3.28e-6	Blood metabolite levels;
TGCT	cis	rs7119	0.717	rs12912386	chr15:77817640	T/C	cg27398640	chr15:77910606	LINGO1	-0.25	-4.6	-0.38	1.05e-5	Type 2 diabetes;
TGCT	cis	rs11122272	0.735	rs973253	chr1:231520874	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-6.94	-0.53	1.98e-10	Hemoglobin concentration;
TGCT	cis	rs17376456	0.809	rs10476602	chr5:93445255	T/C	cg21475434	chr5:93447410	FAM172A	0.58	4.57	0.38	1.16e-5	Diabetic retinopathy;
TGCT	cis	rs72615157	0.716	rs75779608	chr7:99768957	C/T	cg00814883	chr7:100076585	TSC22D4	-0.56	-5.22	-0.42	7.46e-7	Lung function (FEV1/FVC);
TGCT	cis	rs9942416	0.601	rs40059	chr5:74964582	A/G	cg19683494	chr5:74908142	NA	-0.62	-6.9	-0.53	2.32e-10	Age-related disease endophenotypes;
TGCT	trans	rs1814175	0.817	rs7929173	chr11:49944007	T/C	cg03929089	chr4:120376271	NA	-0.7	-7.87	-0.58	1.51e-12	Height;
TGCT	cis	rs2235642	0.893	rs2076445	chr16:1592266	A/T	cg10465839	chr16:1584050	IFT140;TMEM204	-0.31	-5.2	-0.42	8.13e-7	Coronary artery disease;
TGCT	cis	rs6540559	0.543	rs650728	chr1:210433351	C/T	cg22029157	chr1:209979665	IRF6	0.62	4.45	0.37	1.92e-5	Cleft lip with or without cleft palate;
TGCT	cis	rs13256369	0.901	rs12681298	chr8:8566235	A/G	cg06671706	chr8:8559999	CLDN23	-0.34	-4.61	-0.38	9.76e-6	Obesity-related traits;
TGCT	cis	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg20637647	chr7:64974828	NA	0.88	5.12	0.42	1.13e-6	Diabetic kidney disease;
TGCT	cis	rs7666738	0.791	rs1426661	chr4:98874303	C/G	cg05340658	chr4:99064831	C4orf37	0.52	6.0	0.47	1.98e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs17401966	0.931	rs10492972	chr1:10353112	A/G	cg19773385	chr1:10388646	KIF1B	-0.2	-4.44	-0.37	1.94e-5	Hepatocellular carcinoma;
TGCT	cis	rs2361718	0.500	rs8068856	chr17:78100731	A/G	cg09238746	chr17:78121135	EIF4A3	-1.09	-10.19	-0.68	4.3e-18	Yeast infection;
TGCT	cis	rs7635838	0.859	rs6768611	chr3:11434465	G/A	cg00170343	chr3:11313890	ATG7	0.63	6.18	0.49	8.64e-9	HDL cholesterol;
TGCT	cis	rs4886920	0.640	rs11072674	chr15:78081658	A/G	cg25212270	chr15:78015279	NA	0.24	4.97	0.41	2.14e-6	Neuroticism;
TGCT	cis	rs7618915	1.000	rs59565798	chr3:52307169	G/A	cg07507251	chr3:52567010	NT5DC2	0.46	6.2	0.49	7.59e-9	Bipolar disorder;
TGCT	cis	rs7617773	0.539	rs12486935	chr3:48390164	C/T	cg11946769	chr3:48343235	NME6	0.57	4.89	0.4	3.05e-6	Coronary artery disease;
TGCT	cis	rs3741404	1.000	rs3741404	chr11:63999240	G/C	cg01727686	chr11:63997306	NUDT22;DNAJC4	0.22	4.57	0.38	1.14e-5	Platelet count;
TGCT	cis	rs11203032	0.831	rs7076185	chr10:90923524	G/A	cg16672925	chr10:90967113	CH25H	0.73	4.5	0.37	1.55e-5	Heart failure;
TGCT	cis	rs7043114	0.525	rs2516567	chr9:95187418	C/T	cg14631576	chr9:95140430	CENPP	-0.27	-4.56	-0.38	1.22e-5	Height;
TGCT	cis	rs6831352	0.918	rs4699714	chr4:100060538	A/G	cg12011299	chr4:100065546	ADH4	-0.41	-4.97	-0.41	2.21e-6	Alcohol dependence;
TGCT	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg23719950	chr11:63933701	MACROD1	-0.71	-5.93	-0.47	2.77e-8	Attention deficit hyperactivity disorder;
TGCT	cis	rs35306767	0.761	rs34480046	chr10:1027440	A/G	cg18964960	chr10:1102726	WDR37	0.74	5.31	0.43	4.97e-7	Eosinophil percentage of granulocytes;
TGCT	cis	rs7647973	0.710	rs6446285	chr3:49626306	G/A	cg03060546	chr3:49711283	APEH	0.62	4.83	0.4	4e-6	Menarche (age at onset);
TGCT	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg10802521	chr3:52805072	NEK4	-0.66	-7.8	-0.57	2.22e-12	Bipolar disorder;
TGCT	cis	rs11190604	0.767	rs11190534	chr10:102190930	G/A	cg16005271	chr10:102321736	NA	0.45	4.7	0.39	6.81e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7918232	0.882	rs6415983	chr10:27357211	A/G	cg14442939	chr10:27389572	ANKRD26	0.68	4.72	0.39	6.38e-6	Breast cancer;
TGCT	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg05368731	chr17:41323189	NBR1	1.06	11.61	0.72	1.55e-21	Menopause (age at onset);
TGCT	cis	rs11209002	0.545	rs2093332	chr1:67531974	G/A	cg02640540	chr1:67518911	SLC35D1	0.53	4.45	0.37	1.86e-5	Crohn's disease;
TGCT	cis	rs858239	0.699	rs1881201	chr7:23194013	C/T	cg05407003	chr7:23246146	NA	0.27	4.59	0.38	1.07e-5	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs10892173	0.765	rs1892902	chr11:117669794	T/G	cg07621104	chr11:117668040	DSCAML1	0.5	5.39	0.44	3.47e-7	Myopia;
TGCT	cis	rs10992471	0.528	rs1535754	chr9:95201917	T/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.52	-4.91	-0.4	2.8e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs968567	0.559	rs174544	chr11:61567753	C/A	cg19610905	chr11:61596333	FADS2	-1.07	-11.36	-0.71	6.23e-21	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
TGCT	cis	rs11190604	0.666	rs7084768	chr10:102200497	T/C	cg23241863	chr10:102295624	HIF1AN	-0.65	-4.9	-0.4	2.9e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs12134133	0.962	rs7516416	chr1:207414395	G/A	cg02152968	chr1:207494213	CD55	0.6	4.65	0.39	8.43e-6	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs13064447	0.870	rs7631468	chr3:12754997	A/G	cg20675869	chr3:12750130	NA	0.19	4.7	0.39	6.7e-6	Major depression and alcohol dependence;
TGCT	cis	rs7010267	0.746	rs13250753	chr8:119906692	C/G	cg17171407	chr8:119960777	TNFRSF11B	-0.29	-5.04	-0.41	1.59e-6	Total body bone mineral density (age 45-60);
TGCT	cis	rs1577917	1.000	rs12201880	chr6:86627007	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.54	-0.45	1.73e-7	Response to antipsychotic treatment;
TGCT	cis	rs8038465	0.874	rs11574497	chr15:74004557	A/T	cg15420318	chr15:73925796	NPTN	0.55	4.92	0.4	2.69e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7714584	1.000	rs4560537	chr5:150262586	G/A	cg22134413	chr5:150180641	NA	0.78	6.12	0.48	1.16e-8	Crohn's disease;
TGCT	cis	rs8051149	0.688	rs12444533	chr16:87869711	C/T	cg01412419	chr16:87856264	NA	0.5	6.07	0.48	1.43e-8	Blood metabolite levels;
TGCT	cis	rs6504950	0.566	rs12937360	chr17:53046298	C/T	cg19360675	chr17:53046073	COX11;STXBP4	0.56	5.41	0.44	3.06e-7	Breast cancer;
TGCT	cis	rs2562456	0.876	rs62110202	chr19:21754601	C/T	cg01304269	chr19:21688519	ZNF429	0.57	4.45	0.37	1.88e-5	Pain;
TGCT	cis	rs2153535	0.580	rs9505457	chr6:8479142	C/T	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs5758659	0.714	rs7245	chr22:42481849	G/A	cg15557168	chr22:42548783	NA	0.17	4.46	0.37	1.82e-5	Cognitive function;
TGCT	cis	rs7786808	0.741	rs11767875	chr7:158228923	A/G	cg01191920	chr7:158217561	PTPRN2	-0.44	-6.64	-0.51	8.76e-10	Obesity-related traits;
TGCT	cis	rs7772486	0.790	rs2250387	chr6:146205233	C/T	cg05347473	chr6:146136440	FBXO30	0.52	5.0	0.41	1.87e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9910055	0.529	rs425038	chr17:42182028	T/C	cg13607699	chr17:42295918	UBTF	-0.65	-5.55	-0.45	1.64e-7	Total body bone mineral density;
TGCT	cis	rs9303401	0.659	rs7210700	chr17:56668186	G/A	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs4460629	0.742	rs11264314	chr1:155078423	C/G	cg23973274	chr1:155060172	NA	-0.26	-4.66	-0.39	8.1e-6	Serum magnesium levels;
TGCT	cis	rs7552404	0.961	rs1767458	chr1:76219155	A/G	cg10523679	chr1:76189770	ACADM	0.82	8.79	0.62	1.05e-14	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs523522	0.923	rs2235217	chr12:120884328	C/T	cg12219531	chr12:120966889	COQ5	0.79	6.99	0.53	1.47e-10	High light scatter reticulocyte count;
TGCT	cis	rs4805272	0.512	rs11879141	chr19:29320335	G/A	cg12756686	chr19:29218302	NA	0.63	4.53	0.38	1.34e-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
TGCT	cis	rs7552404	1.000	rs7513559	chr1:76173744	A/G	cg10523679	chr1:76189770	ACADM	0.91	9.92	0.67	2.01e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs797680	0.856	rs2031225	chr1:93786714	A/G	cg17826107	chr1:92977322	EVI5	0.22	5.05	0.41	1.53e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs6964587	1.000	rs6952671	chr7:91597934	C/A	cg22709100	chr7:91322751	NA	0.27	4.48	0.37	1.68e-5	Breast cancer;
TGCT	cis	rs9296661	0.680	rs6923760	chr6:51685228	G/T	cg00593404	chr6:52377740	TRAM2	0.27	4.56	0.38	1.22e-5	Weight loss (gastric bypass surgery);
TGCT	cis	rs12188164	0.965	rs11743639	chr5:450710	C/T	cg21144161	chr5:423903	AHRR	0.25	4.79	0.4	4.59e-6	Cystic fibrosis severity;
TGCT	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg06634786	chr22:41940651	POLR3H	-0.9	-8.58	-0.61	3.3e-14	Vitiligo;
TGCT	cis	rs763121	0.853	rs5757196	chr22:39039855	G/C	cg06022373	chr22:39101656	GTPBP1	0.77	7.46	0.56	1.35e-11	Menopause (age at onset);
TGCT	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg03760483	chr17:6899297	ALOX12	0.47	5.38	0.44	3.53e-7	Tonsillectomy;
TGCT	cis	rs225245	0.817	rs1476553	chr17:33994566	C/T	cg05299278	chr17:33885742	SLFN14	0.21	4.52	0.38	1.44e-5	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs453301	0.631	rs13250781	chr8:8793343	T/G	cg06636001	chr8:8085503	FLJ10661	-0.69	-5.92	-0.47	2.97e-8	Joint mobility (Beighton score);
TGCT	cis	rs7043114	0.563	rs10820988	chr9:95317008	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.54	-5.26	-0.43	6.11e-7	Height;
TGCT	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg27121462	chr16:89883253	FANCA	0.75	8.07	0.59	5.21e-13	Vitiligo;
TGCT	cis	rs611744	0.573	rs674580	chr8:109251690	C/G	cg21045802	chr8:109455806	TTC35	0.83	8.71	0.62	1.57e-14	Dupuytren's disease;
TGCT	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg21724239	chr8:58056113	NA	0.48	5.17	0.42	9.18e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs1903068	0.785	rs12331538	chr4:55998086	A/C	cg09978860	chr4:56023921	NA	0.56	6.24	0.49	6.22e-9	Endometriosis;
TGCT	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg03161606	chr19:29218774	NA	0.56	6.1	0.48	1.26e-8	Methadone dose in opioid dependence;
TGCT	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg26338869	chr17:61819248	STRADA	-0.55	-5.08	-0.42	1.34e-6	Prudent dietary pattern;
TGCT	cis	rs7552404	1.000	rs7552404	chr1:76135946	A/G	cg22875332	chr1:76189707	ACADM	0.79	9.9	0.66	2.25e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7666738	0.830	rs28887893	chr4:98963006	G/A	cg05340658	chr4:99064831	C4orf37	0.53	5.93	0.47	2.85e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs367615	0.704	rs4320313	chr5:108828687	A/G	cg17395555	chr5:108820864	NA	0.32	6.11	0.48	1.16e-8	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs6912958	0.781	rs9444512	chr6:88223397	G/A	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.91	-0.4	2.78e-6	Monocyte percentage of white cells;
TGCT	cis	rs950169	0.810	rs62029594	chr15:84955252	T/C	cg17173187	chr15:85201210	NMB	0.58	5.93	0.47	2.77e-8	Schizophrenia;
TGCT	cis	rs6723226	0.881	rs10181198	chr2:32686582	A/G	cg02381751	chr2:32503542	YIPF4	0.54	4.95	0.41	2.36e-6	Intelligence (multi-trait analysis);
TGCT	trans	rs9929218	0.551	rs2274240	chr16:68725486	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.97	0.58	8.72e-13	Colorectal cancer;
TGCT	cis	rs76419734	0.510	rs2553461	chr4:106731410	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	-0.7	-4.57	-0.38	1.18e-5	Post bronchodilator FEV1;
TGCT	cis	rs6921919	0.583	rs6922169	chr6:28382932	G/A	cg18815343	chr6:28367644	ZSCAN12	-0.54	-5.25	-0.43	6.29e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs8014252	0.708	rs8010473	chr14:70988993	G/C	cg11204974	chr14:71022665	NA	-0.53	-4.46	-0.37	1.79e-5	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
TGCT	cis	rs137603	0.644	rs137619	chr22:39706360	A/C	cg01093212	chr22:39715156	SNORD43;RPL3	-0.55	-5.07	-0.41	1.41e-6	Primary biliary cholangitis;
TGCT	cis	rs67311347	0.911	rs58282210	chr3:40417943	C/T	cg13409248	chr3:40428643	ENTPD3	0.55	4.49	0.37	1.61e-5	Renal cell carcinoma;
TGCT	cis	rs6840360	0.550	rs6853955	chr4:152510806	G/A	cg17479576	chr4:152424074	FAM160A1	-0.71	-7.72	-0.57	3.41e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs9346649	0.654	rs35453512	chr6:168491906	C/G	cg02770688	chr6:168491649	NA	0.34	6.06	0.48	1.53e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
TGCT	cis	rs9318086	0.712	rs1886970	chr13:24440498	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.77	8.12	0.59	3.92e-13	Myopia (pathological);
TGCT	trans	rs365060	0.908	rs260692	chr2:109581319	T/C	cg13735819	chr19:2253850	JSRP1	-0.7	-6.64	-0.51	8.83e-10	Beard thickness;
TGCT	cis	rs12291225	0.679	rs34238445	chr11:14315915	C/T	cg19336497	chr11:14380999	RRAS2	-0.38	-5.9	-0.47	3.23e-8	Sense of smell;
TGCT	cis	rs9660180	0.967	rs12040325	chr1:1702436	G/A	cg17747265	chr1:1875780	NA	-0.38	-7.18	-0.54	5.61e-11	Body mass index;
TGCT	cis	rs56104184	0.775	rs73061689	chr19:49397214	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.73	-9.15	-0.63	1.47e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs17376456	0.877	rs13165147	chr5:93422214	G/A	cg25358565	chr5:93447407	FAM172A	0.92	8.38	0.6	9.58e-14	Diabetic retinopathy;
TGCT	cis	rs7607369	0.648	rs7599984	chr2:219656713	T/G	cg02176678	chr2:219576539	TTLL4	-0.47	-6.0	-0.47	1.98e-8	Red blood cell count;Amyotrophic lateral sclerosis;
TGCT	cis	rs698813	0.604	rs12712916	chr2:44482099	A/C	cg00619915	chr2:44497795	NA	-0.21	-4.98	-0.41	2.12e-6	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
TGCT	cis	rs9811920	0.683	rs793502	chr3:99588417	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.43	-5.13	-0.42	1.1e-6	Axial length;
TGCT	trans	rs7819412	0.703	rs2409713	chr8:11009797	C/T	cg15556689	chr8:8085844	FLJ10661	-0.79	-7.01	-0.53	1.33e-10	Triglycerides;
TGCT	cis	rs6866344	0.697	rs11743893	chr5:178125194	C/T	cg03877680	chr5:178157825	ZNF354A	0.78	5.91	0.47	3.06e-8	Neutrophil percentage of white cells;
TGCT	cis	rs2440129	0.632	rs13396	chr17:6905624	T/C	cg02493798	chr17:6899577	ALOX12	0.43	4.65	0.39	8.35e-6	Tonsillectomy;
TGCT	trans	rs629535	0.862	rs655028	chr8:70049047	T/C	cg21567404	chr3:27674614	NA	0.58	9.18	0.64	1.22e-15	Dupuytren's disease;
TGCT	cis	rs904251	0.861	rs1757180	chr6:37486145	T/C	cg08126542	chr6:37504118	NA	-0.43	-5.78	-0.46	5.59e-8	Cognitive performance;
TGCT	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.71	5.14	0.42	1.02e-6	Platelet count;
TGCT	cis	rs6570726	0.791	rs6923074	chr6:145893332	T/C	cg05347473	chr6:146136440	FBXO30	0.52	4.95	0.41	2.33e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2013441	1.000	rs2703772	chr17:20131453	C/A	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.61	-0.38	9.96e-6	Obesity-related traits;
TGCT	cis	rs12477438	0.520	rs720229	chr2:99704273	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.76	7.27	0.55	3.46e-11	Chronic sinus infection;
TGCT	cis	rs7017914	0.905	rs3110254	chr8:71937862	A/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-4.97	-0.41	2.16e-6	Bone mineral density;
TGCT	cis	rs9467773	0.838	rs3734540	chr6:26463321	A/C	cg09904177	chr6:26538194	HMGN4	0.56	5.33	0.43	4.39e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.08	0.48	1.37e-8	Bipolar disorder;
TGCT	cis	rs7552404	0.807	rs2066183	chr1:76153745	A/G	cg10523679	chr1:76189770	ACADM	0.9	9.92	0.67	2e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2067615	0.579	rs1073261	chr12:107135942	A/G	cg15890332	chr12:107067104	RFX4	0.3	5.93	0.47	2.85e-8	Heart rate;
TGCT	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2404602	0.716	rs56216512	chr15:76686936	T/C	cg26408565	chr15:76604113	ETFA	-0.42	-5.43	-0.44	2.85e-7	Blood metabolite levels;
TGCT	cis	rs911555	0.504	rs4906340	chr14:104076645	G/A	cg26031613	chr14:104095156	KLC1	-0.63	-5.88	-0.47	3.62e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs1256061	0.654	rs1256040	chr14:64738394	G/A	cg21174375	chr14:64681225	SYNE2	0.2	4.43	0.37	2.01e-5	Hemoglobin concentration;Red blood cell count;Hematocrit;
TGCT	cis	rs5760092	0.842	rs5760103	chr22:24248781	A/G	cg15242686	chr22:24348715	GSTTP1	0.47	5.24	0.43	6.8e-7	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs4919694	1.000	rs80327774	chr10:104656671	T/C	cg04362960	chr10:104952993	NT5C2	1.06	7.07	0.54	9.73e-11	Arsenic metabolism;
TGCT	cis	rs8103278	0.507	rs3745802	chr19:46271177	G/T	cg11657440	chr19:46296263	DMWD	0.75	7.96	0.58	9.31e-13	Coronary artery disease;
TGCT	cis	rs2228479	0.850	rs17226498	chr16:89840631	T/C	cg06558623	chr16:89946397	TCF25	0.45	4.52	0.38	1.42e-5	Skin colour saturation;
TGCT	trans	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg17830980	chr10:43048298	ZNF37B	-0.87	-11.11	-0.71	2.53e-20	Extrinsic epigenetic age acceleration;
TGCT	trans	rs1814175	0.645	rs1721995	chr11:49915488	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.51	-0.69	7.2e-19	Height;
TGCT	trans	rs9990220	0.586	rs12106673	chr3:112061731	G/A	cg09134205	chr7:154003215	DPP6	-0.41	-7.52	-0.56	9.7e-12	Eosinophil percentage of white cells;
TGCT	cis	rs644799	0.511	rs12791736	chr11:95475399	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.65	6.24	0.49	6.21e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs2760061	0.583	rs708121	chr1:228208257	A/G	cg02753203	chr1:228287806	NA	0.39	7.81	0.57	2.08e-12	Diastolic blood pressure;
TGCT	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs921968	0.643	rs4674305	chr2:219293326	C/T	cg02176678	chr2:219576539	TTLL4	0.38	5.52	0.44	1.88e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs7267979	1.000	rs2482911	chr20:25395528	T/C	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs8017423	0.904	rs11623741	chr14:90804474	C/T	cg04374321	chr14:90722782	PSMC1	0.74	7.17	0.54	5.87e-11	Mortality in heart failure;
TGCT	cis	rs78487399	0.710	rs6731998	chr2:43677273	G/C	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.72	4.62	0.38	9.53e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	trans	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg13565492	chr6:43139072	SRF	-0.81	-7.56	-0.56	7.76e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9911578	1.000	rs302859	chr17:56693132	C/T	cg12560992	chr17:57184187	TRIM37	0.75	9.21	0.64	1.04e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs634534	0.622	rs552130	chr11:65732800	T/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.54	5.18	0.42	8.63e-7	Sum eosinophil basophil counts;Eosinophil counts;
TGCT	cis	rs17473412	1.000	rs11748094	chr5:122698695	T/A	cg15125798	chr5:122621645	NA	-0.57	-5.16	-0.42	9.64e-7	Total body bone mineral density;
TGCT	cis	rs11122272	0.735	rs2486736	chr1:231521478	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.62	5.69	0.45	8.78e-8	Hemoglobin concentration;
TGCT	cis	rs6840360	0.550	rs11723438	chr4:152531801	C/T	cg17479576	chr4:152424074	FAM160A1	0.74	7.96	0.58	9.36e-13	Intelligence (multi-trait analysis);
TGCT	trans	rs7824557	0.569	rs2409718	chr8:11012977	C/T	cg15556689	chr8:8085844	FLJ10661	-0.86	-8.59	-0.61	3.03e-14	Retinal vascular caliber;
TGCT	cis	rs7833790	0.700	rs7825180	chr8:82723991	T/A	cg27398817	chr8:82754497	SNX16	-0.67	-5.34	-0.43	4.27e-7	Diastolic blood pressure;
TGCT	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg00343986	chr7:65444356	GUSB	0.26	6.06	0.48	1.48e-8	Aortic root size;
TGCT	cis	rs459571	0.959	rs392134	chr9:136909008	G/A	cg13789015	chr9:136890014	NCRNA00094	0.42	7.78	0.57	2.44e-12	Platelet distribution width;
TGCT	cis	rs2204008	0.840	rs11181795	chr12:38401129	A/G	cg13010199	chr12:38710504	ALG10B	0.59	4.68	0.39	7.35e-6	Bladder cancer;
TGCT	cis	rs6500602	0.701	rs8053770	chr16:4539030	T/A	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.26	4.74	0.39	5.8e-6	Schizophrenia;
TGCT	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg24829409	chr8:58192753	C8orf71	-0.55	-5.17	-0.42	9.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7681440	0.904	rs3806789	chr4:90759556	C/T	cg20003494	chr4:90757398	SNCA	-0.61	-5.78	-0.46	5.59e-8	Dementia with Lewy bodies;
TGCT	cis	rs2486288	0.656	rs62026703	chr15:45569929	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.78	-7.55	-0.56	8e-12	Glomerular filtration rate;
TGCT	trans	rs208515	0.525	rs12204452	chr6:66680325	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.93	10.3	0.68	2.34e-18	Exhaled nitric oxide levels;
TGCT	cis	rs939658	0.935	rs34859518	chr15:79450422	A/G	cg17916960	chr15:79447300	NA	-0.52	-8.31	-0.6	1.45e-13	Refractive error;
TGCT	cis	rs7666738	0.830	rs13148913	chr4:99009732	C/T	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10779751	1.000	rs718206	chr1:11294474	T/A	cg08854313	chr1:11322531	MTOR	0.98	9.12	0.63	1.65e-15	Body mass index;
TGCT	cis	rs2721173	0.619	rs997258	chr8:145903077	C/A	cg11211951	chr8:145729740	GPT	-0.23	-5.11	-0.42	1.2e-6	Educational attainment;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
TGCT	cis	rs617219	0.710	rs10805925	chr5:78539399	A/G	cg23514016	chr5:78407564	BHMT	0.3	4.58	0.38	1.1e-5	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg20637647	chr7:64974828	NA	-0.9	-5.31	-0.43	4.87e-7	Diabetic kidney disease;
TGCT	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg03264133	chr6:25882463	NA	0.49	4.55	0.38	1.24e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs73815153	0.744	rs28369005	chr5:180459580	A/G	cg00299286	chr5:180478185	BTNL9	0.87	4.98	0.41	2.08e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
TGCT	cis	rs344364	0.602	rs12719796	chr16:1921197	A/G	cg07677296	chr16:1877182	HAGH;FAHD1	0.52	4.44	0.37	1.99e-5	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs2439831	1.000	rs2467739	chr15:43740196	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.8	5.7	0.46	8.33e-8	Lung cancer in ever smokers;
TGCT	cis	rs12148488	0.763	rs4886648	chr15:75308837	G/A	cg10253484	chr15:75165896	SCAMP2	-0.6	-5.24	-0.43	6.58e-7	Caffeine consumption;
TGCT	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	5.98	0.47	2.23e-8	Alzheimer's disease;
TGCT	cis	rs10465746	0.935	rs11807807	chr1:84424071	C/T	cg10977910	chr1:84465055	TTLL7	0.63	6.25	0.49	5.95e-9	Obesity-related traits;
TGCT	cis	rs7943203	0.568	rs170548	chr11:108234836	A/C	cg04873221	chr11:107992290	ACAT1	-0.59	-5.0	-0.41	1.87e-6	Red blood cell count;Mean corpuscular volume;
TGCT	cis	rs9733	0.519	rs72704603	chr1:150707992	C/T	cg09365446	chr1:150670422	GOLPH3L	0.3	4.59	0.38	1.05e-5	Tonsillectomy;
TGCT	cis	rs6121246	0.529	rs7261354	chr20:30202414	T/C	cg21427119	chr20:30132790	HM13	-0.39	-5.61	-0.45	1.25e-7	Mean corpuscular hemoglobin;
TGCT	cis	rs6754311	0.551	rs10928545	chr2:136501840	A/G	cg07169764	chr2:136633963	MCM6	-0.71	-6.37	-0.5	3.33e-9	Mosquito bite size;
TGCT	cis	rs7267979	1.000	rs2259926	chr20:25281733	T/C	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs789852	0.867	rs789846	chr3:194322999	T/C	cg18000598	chr3:194342907	TMEM44	-0.81	-5.31	-0.43	4.83e-7	QT interval;
TGCT	cis	rs7264396	0.790	rs6060518	chr20:34217309	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.28	-4.67	-0.39	7.62e-6	Total cholesterol levels;
TGCT	cis	rs6964587	0.900	rs62467794	chr7:91850578	C/T	cg17063962	chr7:91808500	NA	0.86	8.48	0.61	5.67e-14	Breast cancer;
TGCT	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg22920501	chr2:26401640	FAM59B	-0.81	-6.36	-0.5	3.52e-9	Gut microbiome composition (summer);
TGCT	cis	rs4689388	0.890	rs13130845	chr4:6297646	A/C	cg14416269	chr4:6271139	WFS1	0.38	4.94	0.41	2.47e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	trans	rs877282	0.853	rs7079299	chr10:756455	A/G	cg22713356	chr15:30763199	NA	1.07	8.27	0.6	1.75e-13	Uric acid levels;
TGCT	cis	rs11098499	0.863	rs7669520	chr4:120515278	T/C	cg09307838	chr4:120376055	NA	0.69	6.53	0.51	1.49e-9	Corneal astigmatism;
TGCT	cis	rs1420338	0.933	rs731844	chr7:34150264	C/T	cg01275685	chr7:34179230	BMPER	-0.26	-4.84	-0.4	3.75e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg23131131	chr22:24373011	LOC391322	-0.73	-7.0	-0.53	1.46e-10	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7927592	0.763	rs624003	chr11:68231240	C/T	cg16797656	chr11:68205561	LRP5	0.26	4.54	0.38	1.29e-5	Total body bone mineral density;
TGCT	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg25036284	chr2:26402008	FAM59B	-0.56	-4.85	-0.4	3.62e-6	Gut microbiome composition (summer);
TGCT	cis	rs6992820	0.592	rs3808391	chr8:56790649	A/G	cg06880721	chr8:56792545	LYN	-0.72	-6.44	-0.5	2.42e-9	Mean platelet volume;
TGCT	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg24675658	chr1:53192096	ZYG11B	0.74	8.68	0.61	1.87e-14	Monocyte count;
TGCT	cis	rs9810089	0.843	rs834304	chr3:136111658	G/T	cg12473912	chr3:136751656	NA	0.37	5.15	0.42	9.8e-7	Gestational age at birth (child effect);
TGCT	cis	rs7666738	0.830	rs35939134	chr4:98980311	A/G	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg03806693	chr22:41940476	POLR3H	1.11	12.56	0.75	7.44e-24	Vitiligo;
TGCT	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg03188948	chr7:1209495	NA	0.47	5.83	0.46	4.5e-8	Longevity;Endometriosis;
TGCT	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg08280861	chr8:58055591	NA	0.38	5.01	0.41	1.86e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4742903	0.967	rs10512325	chr9:106861191	C/T	cg21169611	chr9:106856078	SMC2	0.49	4.6	0.38	1.03e-5	High-grade serous ovarian cancer;Breast cancer;
TGCT	cis	rs7267979	0.966	rs2257705	chr20:25264664	T/C	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3749237	0.595	rs11130196	chr3:49490149	A/C	cg03060546	chr3:49711283	APEH	0.77	8.86	0.62	6.92e-15	Resting heart rate;
TGCT	cis	rs1395	0.925	rs1275541	chr2:27389195	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.51	-6.73	-0.52	5.72e-10	Blood metabolite levels;
TGCT	cis	rs7219021	0.705	rs67174000	chr17:46982380	G/A	cg26022315	chr17:47021804	SNF8	-0.53	-4.73	-0.39	5.96e-6	Schizophrenia or bipolar disorder;
TGCT	cis	rs7043114	0.507	rs2007837	chr9:95189767	A/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.56	-5.59	-0.45	1.39e-7	Height;
TGCT	cis	rs981844	0.712	rs878911	chr4:154755615	A/G	cg14289246	chr4:154710475	SFRP2	-0.96	-8.97	-0.63	3.91e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs6909430	0.539	rs17058417	chr6:98795332	G/A	cg20000812	chr6:99276697	NA	-0.52	-4.6	-0.38	1.03e-5	Quantitative traits;
TGCT	cis	rs9309473	0.687	rs11693531	chr2:73608614	C/G	cg20560298	chr2:73613845	ALMS1	-0.45	-4.96	-0.41	2.28e-6	Metabolite levels;
TGCT	trans	rs1814175	0.817	rs1794162	chr11:49899506	A/C	cg03929089	chr4:120376271	NA	-0.71	-8.06	-0.59	5.34e-13	Height;
TGCT	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.57	-7.46	-0.56	1.34e-11	Longevity;Endometriosis;
TGCT	cis	rs9467773	1.000	rs6456734	chr6:26566965	G/T	cg05738196	chr6:26577821	NA	0.9	12.48	0.75	1.16e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs601339	0.878	rs7956284	chr12:123183017	G/A	cg11919336	chr12:123188078	GPR109A	0.64	7.74	0.57	3.07e-12	Adiponectin levels;
TGCT	cis	rs8014204	0.806	rs11159105	chr14:75298052	C/T	cg06637938	chr14:75390232	RPS6KL1	0.7	6.74	0.52	5.37e-10	Caffeine consumption;
TGCT	cis	rs12477438	0.520	rs11123766	chr2:99780915	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.82	0.62	8.67e-15	Chronic sinus infection;
TGCT	cis	rs4478858	0.735	rs4531329	chr1:31817810	A/T	cg07478791	chr1:31886160	SERINC2	-0.51	-4.95	-0.41	2.33e-6	Alcohol dependence;
TGCT	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg27170947	chr2:26402098	FAM59B	-0.39	-4.46	-0.37	1.8e-5	Gut microbiome composition (summer);
TGCT	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg03806693	chr22:41940476	POLR3H	-1.12	-13.03	-0.76	5.66e-25	Vitiligo;
TGCT	cis	rs727563	0.636	rs2413653	chr22:42106996	T/C	cg06634786	chr22:41940651	POLR3H	0.89	8.81	0.62	9.46e-15	Crohn's disease;Inflammatory bowel disease;
TGCT	trans	rs3780486	0.846	rs7865745	chr9:33140976	A/G	cg04842962	chr6:43655489	MRPS18A	-1.15	-14.87	-0.8	2.43e-29	IgG glycosylation;
TGCT	cis	rs68170813	0.605	rs74632724	chr7:107136759	A/G	cg02696742	chr7:106810147	HBP1	-0.59	-4.57	-0.38	1.14e-5	Coronary artery disease;
TGCT	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg13393036	chr8:95962371	TP53INP1	-0.63	-8.63	-0.61	2.46e-14	Type 2 diabetes;
TGCT	cis	rs651907	0.557	rs34947019	chr3:101532235	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.86	10.43	0.68	1.13e-18	Colorectal cancer;
TGCT	cis	rs1008375	0.931	rs10939734	chr4:17570709	C/T	cg10189774	chr4:17578691	LAP3	0.67	5.87	0.47	3.77e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs8103278	1.000	rs11671524	chr19:46327166	G/A	cg11657440	chr19:46296263	DMWD	-0.6	-5.7	-0.46	8.16e-8	Coronary artery disease;
TGCT	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg24549020	chr5:56110836	MAP3K1	-0.7	-6.01	-0.48	1.88e-8	Initial pursuit acceleration;
TGCT	cis	rs1577917	1.000	rs10944163	chr6:86658693	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-5.36	-0.43	3.86e-7	Response to antipsychotic treatment;
TGCT	cis	rs11650494	0.908	rs77247327	chr17:47411493	T/C	cg08112188	chr17:47440006	ZNF652	1.04	5.34	0.43	4.3e-7	Prostate cancer;
TGCT	cis	rs17401966	0.540	rs1536262	chr1:10438687	C/T	cg19773385	chr1:10388646	KIF1B	-0.22	-5.27	-0.43	5.96e-7	Hepatocellular carcinoma;
TGCT	cis	rs7666738	0.800	rs2865987	chr4:99067852	A/C	cg17366294	chr4:99064904	C4orf37	0.76	7.74	0.57	3e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9611565	0.592	rs28750375	chr22:41990644	A/C	cg06481639	chr22:41940642	POLR3H	-0.62	-5.26	-0.43	6.21e-7	Vitiligo;
TGCT	cis	rs56104184	0.830	rs55966626	chr19:49342396	G/T	cg15549821	chr19:49342101	PLEKHA4	-0.87	-11.91	-0.73	2.81e-22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs7010267	0.596	rs4336637	chr8:120016636	C/T	cg17171407	chr8:119960777	TNFRSF11B	0.26	4.59	0.38	1.06e-5	Total body bone mineral density (age 45-60);
TGCT	cis	rs7617773	0.780	rs35411187	chr3:48360017	C/G	cg11946769	chr3:48343235	NME6	0.82	7.08	0.54	9.69e-11	Coronary artery disease;
TGCT	cis	rs9394841	0.692	rs56215622	chr6:41892457	G/A	cg08135965	chr6:41755394	TOMM6	0.58	5.2	0.42	8.14e-7	Mean corpuscular hemoglobin;Red cell distribution width;
TGCT	cis	rs921968	0.541	rs636723	chr2:219373197	A/G	cg02176678	chr2:219576539	TTLL4	0.48	6.78	0.52	4.32e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs59197085	0.515	rs17165121	chr7:128442479	A/G	cg00260937	chr7:128520193	KCP	0.47	5.21	0.42	7.54e-7	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
TGCT	cis	rs9911578	0.967	rs11079368	chr17:57086473	C/T	cg12560992	chr17:57184187	TRIM37	-0.79	-9.71	-0.66	6.56e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs2282802	0.685	rs10051345	chr5:139670932	C/G	cg01081189	chr5:139537190	NA	-0.28	-5.08	-0.42	1.34e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs77236434	0.571	rs1349960	chr8:13190377	G/T	cg07307335	chr8:12602187	LONRF1	0.33	4.62	0.38	9.32e-6	Familial hepatitis B virus-related hepatocellular carcinoma;
TGCT	cis	rs763014	0.931	rs7191939	chr16:630089	C/T	cg07343612	chr16:622815	PIGQ	-0.41	-7.87	-0.58	1.52e-12	Height;
TGCT	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg26338869	chr17:61819248	STRADA	-0.53	-4.94	-0.41	2.48e-6	Prudent dietary pattern;
TGCT	cis	rs6733011	0.508	rs13004700	chr2:99527568	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.55	-5.19	-0.42	8.26e-7	Bipolar disorder;
TGCT	cis	rs4951018	0.821	rs7529037	chr1:205637501	C/G	cg07167872	chr1:205819463	PM20D1	-0.38	-4.6	-0.38	1.03e-5	Prostate-specific antigen levels;
TGCT	trans	rs8073060	0.586	rs8077826	chr17:34001139	G/A	cg19694781	chr19:47549865	TMEM160	-0.6	-13.37	-0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs11148252	0.532	rs9536185	chr13:53179801	G/A	cg00495681	chr13:53174319	NA	0.9	9.93	0.67	1.87e-17	Lewy body disease;
TGCT	cis	rs7829975	0.514	rs2976929	chr8:8258712	T/C	cg08975724	chr8:8085496	FLJ10661	0.56	5.01	0.41	1.82e-6	Mood instability;
TGCT	cis	rs7824557	0.872	rs1347410	chr8:11111242	G/A	cg21775007	chr8:11205619	TDH	-0.49	-4.71	-0.39	6.43e-6	Retinal vascular caliber;
TGCT	cis	rs7681440	0.874	rs1442154	chr4:90775761	C/G	cg26578617	chr4:90757533	SNCA	-0.44	-4.54	-0.38	1.31e-5	Dementia with Lewy bodies;
TGCT	cis	rs56104184	0.690	rs56312501	chr19:49395933	T/C	cg17863274	chr19:49399704	TULP2	-0.31	-4.54	-0.38	1.33e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs610932	0.517	rs678384	chr11:60002192	T/G	cg18570331	chr11:60101691	MS4A6E	0.5	4.45	0.37	1.89e-5	Alzheimer's disease;
TGCT	cis	rs78456975	1.000	rs13413096	chr2:1553588	G/A	cg01028140	chr2:1542097	TPO	-0.35	-4.57	-0.38	1.17e-5	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs9443645	0.901	rs9448590	chr6:79606429	C/G	cg05283184	chr6:79620031	NA	-0.21	-4.71	-0.39	6.61e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs62244186	0.566	rs6766221	chr3:44882784	C/T	cg04389838	chr3:44770851	ZNF501	-0.37	-4.76	-0.39	5.23e-6	Depressive symptoms;
TGCT	trans	rs3780486	1.000	rs10813957	chr9:33153527	G/T	cg20290983	chr6:43655470	MRPS18A	1.22	10.5	0.69	7.76e-19	IgG glycosylation;
TGCT	cis	rs112591243	1.000	rs112591243	chr21:47718796	G/A	cg10657630	chr21:48055338	PRMT2	1.06	5.76	0.46	6.31e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs9399135	0.967	rs9389253	chr6:135329755	T/C	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.36e-6	Red blood cell count;
TGCT	cis	rs651907	0.535	rs17347156	chr3:101504674	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	4.61	0.38	1.01e-5	Colorectal cancer;
TGCT	cis	rs514406	0.893	rs1242317	chr1:53414766	T/C	cg27535305	chr1:53392650	SCP2	-0.23	-4.53	-0.38	1.38e-5	Monocyte count;
TGCT	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg03452623	chr4:187889614	NA	0.36	5.26	0.43	6.19e-7	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg07870213	chr5:140052090	DND1	-0.62	-7.4	-0.55	1.84e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs687432	0.774	rs12805812	chr11:57910378	G/A	cg04811534	chr11:57115016	P2RX3	0.18	4.48	0.37	1.66e-5	Parkinson's disease;
TGCT	cis	rs7572733	0.555	rs6729473	chr2:198763928	G/A	cg00792783	chr2:198669748	PLCL1	0.56	5.11	0.42	1.21e-6	Dermatomyositis;
TGCT	cis	rs9914544	0.762	rs4322727	chr17:18798573	A/T	cg26378065	chr17:18585709	ZNF286B	-0.53	-4.97	-0.41	2.19e-6	Educational attainment (years of education);
TGCT	cis	rs77372450	0.551	rs10866685	chr5:157104711	G/A	cg12606933	chr5:157078573	SOX30	-0.42	-4.75	-0.39	5.51e-6	Bipolar disorder (body mass index interaction);
TGCT	cis	rs981844	0.775	rs17371274	chr4:154738713	A/G	cg14289246	chr4:154710475	SFRP2	1.01	8.79	0.62	1.03e-14	Response to statins (LDL cholesterol change);
TGCT	trans	rs7819412	0.838	rs4840544	chr8:10960572	C/T	cg15556689	chr8:8085844	FLJ10661	-0.79	-7.7	-0.57	3.72e-12	Triglycerides;
TGCT	cis	rs2657888	0.965	rs2657902	chr12:56933651	G/A	cg23932658	chr12:57637574	STAC3	0.48	4.57	0.38	1.18e-5	Adiponectin levels;
TGCT	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg15691649	chr6:25882328	NA	-0.56	-7.3	-0.55	3.04e-11	Urate levels;
TGCT	cis	rs9400467	0.506	rs12207199	chr6:111525906	G/A	cg15721981	chr6:111408429	SLC16A10	0.73	4.79	0.4	4.71e-6	Blood metabolite levels;Amino acid levels;
TGCT	cis	rs2153535	0.580	rs7761937	chr6:8459434	A/T	cg07606381	chr6:8435919	SLC35B3	0.57	5.26	0.43	6.05e-7	Motion sickness;
TGCT	cis	rs6831352	0.879	rs7672728	chr4:100055173	A/G	cg12011299	chr4:100065546	ADH4	-0.4	-4.88	-0.4	3.26e-6	Alcohol dependence;
TGCT	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.54	4.91	0.4	2.84e-6	Prudent dietary pattern;
TGCT	trans	rs77457752	0.525	rs10120720	chr9:13897929	G/C	cg25510823	chr7:47085976	NA	0.45	6.68	0.51	7.21e-10	Breast cancer;
TGCT	cis	rs317689	0.876	rs547332	chr12:69743639	C/G	cg14784868	chr12:69753453	YEATS4	0.55	4.69	0.39	7.18e-6	Response to diuretic therapy;
TGCT	cis	rs78545713	1.000	rs41266821	chr6:26247198	A/G	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.72	-4.67	-0.39	7.66e-6	Iron status biomarkers (total iron binding capacity);
TGCT	cis	rs12142240	0.628	rs56126529	chr1:46808860	C/T	cg14993813	chr1:46806288	NSUN4	-0.58	-4.81	-0.4	4.34e-6	Menopause (age at onset);
TGCT	cis	rs2050392	1.000	rs7077496	chr10:30692028	G/A	cg13289132	chr10:30722225	MAP3K8	0.36	4.58	0.38	1.13e-5	Inflammatory bowel disease;
TGCT	cis	rs6424115	1.000	rs35385477	chr1:24155924	G/A	cg15997130	chr1:24165203	NA	0.89	9.78	0.66	4.4e-17	Immature fraction of reticulocytes;
TGCT	cis	rs9486715	0.964	rs6921480	chr6:97066329	C/G	cg06623918	chr6:96969491	KIAA0776	-1.08	-13.52	-0.77	3.67e-26	Headache;
TGCT	cis	rs9611565	0.608	rs202652	chr22:41838792	A/G	cg13695892	chr22:41940480	POLR3H	0.89	8.48	0.61	5.62e-14	Vitiligo;
TGCT	cis	rs892864	0.614	rs10057855	chr5:127676365	A/G	cg01939274	chr5:127874478	FBN2	-0.95	-4.56	-0.38	1.21e-5	Multiple system atrophy;
TGCT	cis	rs1008375	0.966	rs6832962	chr4:17652133	T/C	cg18681998	chr4:17616180	MED28	0.96	10.38	0.68	1.51e-18	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7542091	0.704	rs1108628	chr1:210041150	A/G	cg21951975	chr1:209979733	IRF6	0.61	6.19	0.49	8.21e-9	Monobrow;
TGCT	cis	rs137699	0.959	rs5757633	chr22:39756270	A/G	cg11247378	chr22:39784982	NA	-0.46	-4.99	-0.41	2.03e-6	IgG glycosylation;
TGCT	cis	rs4927850	0.529	rs6800500	chr3:195833507	T/C	cg06252355	chr3:195477915	MUC4	-0.2	-4.53	-0.38	1.34e-5	Pancreatic cancer;
TGCT	cis	rs7829975	0.501	rs2980769	chr8:8320291	G/A	cg15556689	chr8:8085844	FLJ10661	0.7	6.37	0.5	3.43e-9	Mood instability;
TGCT	cis	rs6089584	0.893	rs6089305	chr20:60571817	T/C	cg06108461	chr20:60628389	TAF4	-0.59	-8.38	-0.6	9.49e-14	Body mass index;
TGCT	cis	rs9926296	0.609	rs4785709	chr16:89796665	G/A	cg26513180	chr16:89883248	FANCA	-0.69	-6.67	-0.51	7.61e-10	Vitiligo;
TGCT	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg20607798	chr8:58055168	NA	0.45	4.61	0.38	9.8e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs11711311	1.000	rs7649590	chr3:113447267	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.71	-6.58	-0.51	1.19e-9	IgG glycosylation;
TGCT	cis	rs1421811	0.606	rs10057069	chr5:32716589	A/G	cg16267343	chr5:32710456	NPR3	0.76	6.44	0.5	2.32e-9	Blood pressure;
TGCT	cis	rs6785206	0.614	rs61292315	chr3:128542609	C/T	cg25356066	chr3:128598488	ACAD9	-0.93	-4.8	-0.4	4.53e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs10782582	0.609	rs1796810	chr1:76403305	C/T	cg10523679	chr1:76189770	ACADM	-0.57	-5.14	-0.42	1.04e-6	Daytime sleep phenotypes;
TGCT	cis	rs7666738	0.830	rs3907020	chr4:99038583	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.49	0.56	1.11e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs853679	0.546	rs34295134	chr6:27828151	T/A	cg08798685	chr6:27730294	NA	-0.34	-4.69	-0.39	7.2e-6	Depression;
TGCT	cis	rs8180040	0.934	rs4858811	chr3:47480524	G/C	cg27129171	chr3:47204927	SETD2	-0.65	-7.68	-0.57	4.2e-12	Colorectal cancer;
TGCT	cis	rs2228479	0.717	rs1800358	chr16:89809319	T/C	cg27121462	chr16:89883253	FANCA	0.77	4.61	0.38	9.93e-6	Skin colour saturation;
TGCT	cis	rs1008375	1.000	rs10012335	chr4:17628630	C/G	cg18681998	chr4:17616180	MED28	1.02	11.4	0.72	4.89e-21	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9921192	1.000	rs233950	chr16:4327397	A/G	cg00021532	chr16:4324280	TFAP4	0.83	9.34	0.64	4.86e-16	Prostate-specific antigen levels;
TGCT	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg18305652	chr10:134549665	INPP5A	0.35	5.55	0.45	1.66e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs17102423	0.594	rs942628	chr14:65539463	C/G	cg11161011	chr14:65562177	MAX	-0.45	-6.33	-0.49	4.07e-9	Obesity-related traits;
TGCT	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg22166914	chr1:53195759	ZYG11B	0.37	5.81	0.46	4.92e-8	Monocyte count;
TGCT	cis	rs9549367	0.636	rs486407	chr13:113833499	G/A	cg18105134	chr13:113819100	PROZ	0.47	8.56	0.61	3.67e-14	Platelet distribution width;
TGCT	cis	rs6882046	0.513	rs618298	chr5:88038390	A/G	cg22951263	chr5:87985283	NA	-0.56	-5.82	-0.46	4.73e-8	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs6433857	0.536	rs12464424	chr2:181349137	A/G	cg23363182	chr2:181467187	NA	-0.32	-4.85	-0.4	3.56e-6	Body mass index;
TGCT	cis	rs6750795	0.502	rs11685196	chr2:232381298	A/G	cg19187155	chr2:232395269	NMUR1	0.45	5.15	0.42	1.02e-6	Height;
TGCT	cis	rs7267979	1.000	rs12428	chr20:25433821	G/T	cg03522245	chr20:25566470	NINL	-0.56	-6.04	-0.48	1.69e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6459680	0.516	rs1534008	chr7:156259583	C/T	cg02321112	chr7:156810523	NA	-0.38	-4.64	-0.38	8.89e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7103648	0.695	rs6485758	chr11:47530024	G/A	cg20307385	chr11:47447363	PSMC3	0.87	8.49	0.61	5.4e-14	Diastolic blood pressure;Systolic blood pressure;
TGCT	trans	rs2288327	0.557	rs7588593	chr2:179352450	T/C	cg14011486	chr1:26737247	LIN28	1.03	7.28	0.55	3.41e-11	Atrial fibrillation;
TGCT	cis	rs7666738	0.830	rs11944035	chr4:98931618	C/T	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg17264618	chr3:40429014	ENTPD3	0.34	4.94	0.41	2.52e-6	Renal cell carcinoma;
TGCT	cis	rs910316	0.663	rs175034	chr14:75463687	T/G	cg11812906	chr14:75593930	NEK9	-0.59	-5.59	-0.45	1.37e-7	Height;
TGCT	cis	rs1801251	0.896	rs921054	chr2:233694673	G/A	cg25237894	chr2:233734115	C2orf82	-0.27	-5.01	-0.41	1.83e-6	Coronary artery disease;
TGCT	cis	rs12477438	0.798	rs1453562	chr2:99615850	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-6.1	-0.48	1.22e-8	Chronic sinus infection;
TGCT	cis	rs1505368	0.534	rs10185241	chr2:213244124	C/T	cg16329650	chr2:213403929	ERBB4	0.59	5.18	0.42	8.57e-7	Symmetrical dimethylarginine levels;
TGCT	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg06238570	chr21:40685208	BRWD1	0.68	6.36	0.5	3.5e-9	Cognitive function;
TGCT	cis	rs10949834	0.824	rs3801461	chr7:73536368	C/G	cg07137043	chr7:73588983	EIF4H	-0.74	-4.53	-0.38	1.38e-5	Verbal memory performance (residualized delayed recall change);
TGCT	cis	rs7819412	0.511	rs7464263	chr8:11434176	A/T	cg21775007	chr8:11205619	TDH	-0.54	-5.07	-0.41	1.41e-6	Triglycerides;
TGCT	cis	rs1008375	0.966	rs7658240	chr4:17588950	A/G	cg18681998	chr4:17616180	MED28	-0.86	-8.25	-0.6	1.93e-13	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6831352	0.918	rs7670241	chr4:100059619	G/T	cg12011299	chr4:100065546	ADH4	-0.4	-4.88	-0.4	3.26e-6	Alcohol dependence;
TGCT	cis	rs4242434	0.757	rs7005025	chr8:22519815	G/T	cg21658235	chr8:22456391	C8orf58	0.43	4.56	0.38	1.22e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs453301	0.624	rs4841083	chr8:8870428	A/G	cg15556689	chr8:8085844	FLJ10661	0.76	6.59	0.51	1.13e-9	Joint mobility (Beighton score);
TGCT	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg14983838	chr19:29218262	NA	0.83	6.85	0.52	3.07e-10	Methadone dose in opioid dependence;
TGCT	cis	rs4924935	1.000	rs6502674	chr17:18776897	A/G	cg26378065	chr17:18585709	ZNF286B	0.6	5.18	0.42	8.82e-7	Pancreatic cancer;
TGCT	cis	rs9467711	1.000	rs6908156	chr6:26322861	C/T	cg16898833	chr6:26189333	HIST1H4D	1.04	5.51	0.44	1.97e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1552244	0.515	rs6768768	chr3:10177653	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.34	-4.9	-0.4	2.93e-6	Alzheimer's disease;
TGCT	cis	rs921968	0.608	rs11678428	chr2:219352598	C/T	cg02176678	chr2:219576539	TTLL4	0.39	5.66	0.45	1e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg22963979	chr7:1858916	MAD1L1	0.44	7.19	0.54	5.26e-11	Bipolar disorder and schizophrenia;
TGCT	cis	rs57590327	0.679	rs1907880	chr3:81567861	C/T	cg07356753	chr3:81810745	GBE1	-0.55	-4.54	-0.38	1.3e-5	Extraversion;
TGCT	cis	rs637571	0.544	rs56239996	chr11:65730003	A/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.63	6.33	0.49	4.02e-9	Eosinophil percentage of white cells;
TGCT	cis	rs6964587	0.967	rs7786031	chr7:91649001	T/G	cg22709100	chr7:91322751	NA	0.27	4.48	0.37	1.68e-5	Breast cancer;
TGCT	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg01448562	chr3:133502909	NA	-0.26	-4.9	-0.4	2.98e-6	Iron status biomarkers;
TGCT	cis	rs727563	0.648	rs6002406	chr22:41965237	A/T	cg06634786	chr22:41940651	POLR3H	-0.88	-8.23	-0.59	2.17e-13	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs2836633	0.965	rs2836615	chr21:40048039	C/T	cg05519781	chr21:40033154	ERG	0.68	6.76	0.52	4.7e-10	Coronary artery disease;
TGCT	cis	rs9467773	1.000	rs10946834	chr6:26533664	G/C	cg05738196	chr6:26577821	NA	0.88	12.5	0.75	1.03e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs2758596	0.850	rs2842879	chr1:156163695	G/T	cg24450063	chr1:156163899	SLC25A44	0.79	4.58	0.38	1.11e-5	Paclitaxel disposition in epithelial ovarian cancer;
TGCT	cis	rs7552404	1.000	rs211718	chr1:76106675	C/T	cg03433033	chr1:76189801	ACADM	0.83	9.8	0.66	3.81e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2637266	0.967	rs6480826	chr10:78356154	A/G	cg18941641	chr10:78392320	NA	0.4	5.01	0.41	1.81e-6	Pulmonary function;
TGCT	cis	rs79387448	0.701	rs3752659	chr2:103001598	A/G	cg09003973	chr2:102972529	NA	1.19	9.18	0.64	1.2e-15	Gut microbiota (bacterial taxa);
TGCT	cis	rs2242116	0.796	rs7645278	chr3:46974100	A/C	cg23352942	chr3:46931381	PTH1R	-0.31	-4.51	-0.38	1.5e-5	Birth weight;
TGCT	cis	rs13242816	1.000	rs62468978	chr7:116127099	A/G	cg16553024	chr7:116138462	CAV2	-0.43	-4.88	-0.4	3.26e-6	P wave duration;
TGCT	cis	rs3796352	0.667	rs9831977	chr3:52854140	T/G	cg15956490	chr3:53032818	SFMBT1	0.57	5.02	0.41	1.79e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg16405210	chr4:1374714	KIAA1530	0.25	4.62	0.38	9.42e-6	Longevity;
TGCT	cis	rs4851266	1.000	rs4303732	chr2:100830040	T/C	cg22139774	chr2:100720529	AFF3	-0.35	-5.19	-0.42	8.51e-7	Educational attainment;
TGCT	cis	rs1568889	0.838	rs11030220	chr11:28145769	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.92	11.24	0.71	1.22e-20	Bipolar disorder;
TGCT	cis	rs9788721	0.836	rs2656052	chr15:78740932	A/C	cg18825076	chr15:78729989	IREB2	-0.33	-5.32	-0.43	4.68e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
TGCT	cis	rs611744	0.967	rs681099	chr8:109218892	T/C	cg21045802	chr8:109455806	TTC35	0.52	4.72	0.39	6.21e-6	Dupuytren's disease;
TGCT	cis	rs10186029	0.616	rs12616255	chr2:213978895	T/A	cg08319019	chr2:214017104	IKZF2	0.62	5.73	0.46	7.14e-8	Systemic sclerosis;
TGCT	cis	rs6570726	0.935	rs411641	chr6:145827532	G/A	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.57	-5.48	-0.44	2.29e-7	Prudent dietary pattern;
TGCT	cis	rs6931421	0.800	rs12662365	chr6:80905389	T/A	cg08355045	chr6:80787529	NA	0.3	4.82	0.4	4.14e-6	Sitting height ratio;
TGCT	cis	rs7586879	0.828	rs4077677	chr2:25122798	G/C	cg01884057	chr2:25150051	NA	0.27	4.81	0.4	4.36e-6	Body mass index;
TGCT	cis	rs7100689	0.646	rs6585946	chr10:82118292	G/T	cg01528321	chr10:82214614	TSPAN14	0.8	7.76	0.57	2.7e-12	Post bronchodilator FEV1;
TGCT	cis	rs11785400	0.793	rs2280879	chr8:143722228	T/C	cg24634471	chr8:143751801	JRK	0.53	5.24	0.43	6.7e-7	Schizophrenia;
TGCT	cis	rs7937682	0.711	rs4938792	chr11:111420936	T/C	cg09085632	chr11:111637200	PPP2R1B	0.79	8.0	0.58	7.49e-13	Primary sclerosing cholangitis;
TGCT	cis	rs2228479	0.850	rs1800344	chr16:89816367	T/G	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs1577917	1.000	rs955196	chr6:86729951	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.62	4.93	0.4	2.57e-6	Response to antipsychotic treatment;
TGCT	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg22920501	chr2:26401640	FAM59B	-0.79	-6.35	-0.5	3.68e-9	Gut microbiome composition (summer);
TGCT	cis	rs12681287	0.577	rs13257414	chr8:87494138	C/T	cg27223183	chr8:87520930	FAM82B	-0.92	-6.79	-0.52	4.12e-10	Caudate activity during reward;
TGCT	cis	rs981844	0.775	rs72733610	chr4:154732336	A/G	cg14289246	chr4:154710475	SFRP2	1.01	8.88	0.62	6.23e-15	Response to statins (LDL cholesterol change);
TGCT	trans	rs4919669	0.546	rs2145307	chr10:104280664	G/A	cg19053889	chr7:1098703	C7orf50;GPR146	0.51	6.73	0.52	5.65e-10	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs2191566	0.922	rs7245749	chr19:44513932	G/A	cg03039196	chr19:44506973	ZNF230	0.53	4.47	0.37	1.73e-5	Acute lymphoblastic leukemia (childhood);
TGCT	trans	rs9383153	1.000	rs9370888	chr6:16335544	A/G	cg00634968	chr6:51707133	PKHD1	0.71	6.73	0.52	5.72e-10	Gambling;
TGCT	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg26338869	chr17:61819248	STRADA	-0.53	-4.87	-0.4	3.29e-6	Prudent dietary pattern;
TGCT	cis	rs3087591	0.879	rs12103564	chr17:29607243	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.45	-6.52	-0.51	1.62e-9	Hip circumference;
TGCT	cis	rs78487399	0.831	rs17031142	chr2:43847646	G/A	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.68	4.59	0.38	1.08e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs8103278	0.507	rs522769	chr19:46284520	G/A	cg11657440	chr19:46296263	DMWD	0.78	8.46	0.61	6.22e-14	Coronary artery disease;
TGCT	cis	rs9814567	0.806	rs9857995	chr3:134316706	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.76	7.1	0.54	8.54e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs11098499	0.820	rs28578366	chr4:120536905	A/G	cg09307838	chr4:120376055	NA	-0.68	-6.51	-0.5	1.69e-9	Corneal astigmatism;
TGCT	cis	rs2063714	0.967	rs1012534	chr6:157209663	A/G	cg23222435	chr6:157204239	ARID1B	-0.3	-5.0	-0.41	1.93e-6	Sitting height ratio;
TGCT	cis	rs950169	0.922	rs11639244	chr15:84832650	G/A	cg11189052	chr15:85197271	WDR73	0.81	6.52	0.51	1.61e-9	Schizophrenia;
TGCT	cis	rs6667605	0.527	rs4422947	chr1:2539590	C/T	cg18854424	chr1:2615690	NA	0.46	5.36	0.43	4e-7	Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs587847	0.708	rs4924150	chr15:37633302	T/C	cg00216138	chr15:37171175	LOC145845	0.32	4.74	0.39	5.71e-6	Intraocular pressure;
TGCT	cis	rs7666738	0.830	rs17027102	chr4:98919221	A/G	cg18180107	chr4:99064573	C4orf37	-0.57	-5.19	-0.42	8.25e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7666738	0.830	rs13144564	chr4:98939276	A/G	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6570726	0.720	rs412623	chr6:145883257	C/A	cg05347473	chr6:146136440	FBXO30	0.53	4.87	0.4	3.31e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7211079	0.879	rs72852522	chr17:78131490	C/T	cg09238746	chr17:78121135	EIF4A3	-0.72	-5.83	-0.46	4.5e-8	Myocardial infarction;
TGCT	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	6.05	0.48	1.59e-8	Alzheimer's disease;
TGCT	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg03806693	chr22:41940476	POLR3H	-1.16	-13.37	-0.77	8.59e-26	Vitiligo;
TGCT	cis	rs2486288	0.656	rs11637920	chr15:45550905	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.46	-5.59	-0.45	1.38e-7	Glomerular filtration rate;
TGCT	cis	rs10744422	0.764	rs4759391	chr12:123297718	T/A	cg18912006	chr12:123335444	HIP1R	0.56	4.78	0.39	4.84e-6	Schizophrenia;
TGCT	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg24829409	chr8:58192753	C8orf71	-0.59	-4.97	-0.41	2.17e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs28595532	0.920	rs56150431	chr4:119764786	T/C	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg15242686	chr22:24348715	GSTTP1	-0.53	-6.39	-0.5	3.06e-9	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.68	-7.04	-0.53	1.15e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs4727027	0.866	rs2373437	chr7:148779032	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	4.99	0.41	2.02e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs2115630	0.805	rs8042926	chr15:85205454	T/A	cg12501888	chr15:85177176	SCAND2	-0.46	-4.46	-0.37	1.83e-5	P wave terminal force;
TGCT	cis	rs4892230	1	rs4892230	chr18:72155572	G/A	cg26446133	chr18:72167187	CNDP2	-0.26	-4.66	-0.39	8.07e-6	Mononucleosis;
TGCT	cis	rs61990749	0.597	rs7142390	chr14:78232880	T/C	cg23188588	chr14:78226832	SNW1;C14orf178	0.67	4.48	0.37	1.7e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs10484885	0.690	rs292236	chr6:90528422	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.49	-5.17	-0.42	8.96e-7	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs7447593	0.626	rs3812036	chr5:176813404	C/T	cg16006841	chr5:176797999	RGS14	0.6	8.33	0.6	1.24e-13	Urinary electrolytes (magnesium/calcium ratio);
TGCT	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg06618935	chr21:46677482	NA	-0.37	-5.81	-0.46	5.06e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs11118844	0.793	rs7516292	chr1:221942413	C/T	cg04222084	chr1:221915650	DUSP10	-0.79	-5.51	-0.44	2.01e-7	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
TGCT	cis	rs7681440	0.647	rs6814221	chr4:90805501	C/T	cg10208370	chr4:90758469	SNCA	-0.56	-5.27	-0.43	5.93e-7	Dementia with Lewy bodies;
TGCT	cis	rs3110496	1.000	rs3110496	chr17:27917771	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	4.58	0.38	1.11e-5	Height;
TGCT	cis	rs4455778	0.580	rs4467894	chr7:49116541	G/T	cg26309511	chr7:48887640	NA	-0.51	-6.64	-0.51	8.83e-10	Lung cancer in never smokers;
TGCT	cis	rs151997	0.720	rs152096	chr5:50213850	A/G	cg06027927	chr5:50259733	NA	0.56	5.64	0.45	1.11e-7	Callous-unemotional behaviour;
TGCT	cis	rs10832963	1.000	rs10832963	chr11:18664241	T/G	cg09201001	chr11:18656081	SPTY2D1	1.03	11.49	0.72	2.92e-21	Breast cancer;
TGCT	cis	rs911555	0.755	rs10144051	chr14:103885931	A/C	cg23461800	chr14:103021989	NA	0.33	4.46	0.37	1.83e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.2	0.42	8.14e-7	Menopause (age at onset);
TGCT	cis	rs8070740	0.838	rs35491297	chr17:5327481	T/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	4.55	0.38	1.27e-5	Menopause (age at onset);
TGCT	cis	rs4455778	0.580	rs4270913	chr7:49112389	T/C	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.9e-9	Lung cancer in never smokers;
TGCT	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg06873352	chr17:61820015	STRADA	0.58	6.48	0.5	1.93e-9	Prudent dietary pattern;
TGCT	cis	rs2455799	0.613	rs11712323	chr3:15891360	T/C	cg16303742	chr3:15540471	COLQ	-0.25	-4.68	-0.39	7.4e-6	Mean platelet volume;
TGCT	cis	rs2456568	0.802	rs10765639	chr11:93636194	G/A	cg26875233	chr11:93583750	C11orf90	-0.48	-6.47	-0.5	2.07e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs13223928	0.541	rs66883350	chr7:3136548	T/A	cg19214707	chr7:3157722	NA	-0.4	-5.29	-0.43	5.27e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
TGCT	cis	rs7772486	0.902	rs2748500	chr6:146314852	C/A	cg05347473	chr6:146136440	FBXO30	0.54	5.15	0.42	9.88e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg24549020	chr5:56110836	MAP3K1	0.67	5.78	0.46	5.74e-8	Initial pursuit acceleration;
TGCT	cis	rs2455799	0.634	rs11128764	chr3:15902836	G/C	cg16303742	chr3:15540471	COLQ	-0.24	-4.64	-0.38	8.68e-6	Mean platelet volume;
TGCT	cis	rs35306767	0.714	rs12777800	chr10:1070361	G/A	cg18964960	chr10:1102726	WDR37	0.69	4.9	0.4	2.99e-6	Eosinophil percentage of granulocytes;
TGCT	cis	rs12210905	0.688	rs12189640	chr6:27474657	T/C	cg08851530	chr6:28072375	NA	1.34	6.29	0.49	5.02e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs6988636	1.000	rs57165742	chr8:124184559	G/A	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs9487051	0.604	rs9320282	chr6:109619377	A/G	cg01475377	chr6:109611718	NA	-0.29	-4.52	-0.38	1.4e-5	Reticulocyte fraction of red cells;
TGCT	cis	rs7584330	0.910	rs66509917	chr2:238395394	T/G	cg14458575	chr2:238380390	NA	0.42	6.42	0.5	2.57e-9	Prostate cancer;
TGCT	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg24250549	chr1:154909240	PMVK	0.56	5.42	0.44	2.92e-7	Prostate cancer;
TGCT	cis	rs12142240	0.698	rs7525309	chr1:46809025	G/T	cg00530320	chr1:46809349	NSUN4	0.29	5.88	0.47	3.63e-8	Menopause (age at onset);
TGCT	cis	rs4824093	0.610	rs73443906	chr22:50274293	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.11	-6.79	-0.52	4.13e-10	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs2230307	0.536	rs6577152	chr1:100434610	A/G	cg24955406	chr1:100503596	HIAT1	0.72	4.64	0.38	8.82e-6	Carotid intima media thickness;
TGCT	cis	rs73110464	0.609	rs11170348	chr12:53355588	A/G	cg05393297	chr12:53359155	NA	-0.79	-8.43	-0.6	7.2e-14	Cancer (pleiotropy);
TGCT	cis	rs10832963	0.924	rs10832950	chr11:18635815	A/G	cg20219074	chr11:18656078	SPTY2D1	1.0	9.93	0.67	1.85e-17	Breast cancer;
TGCT	cis	rs9583531	0.689	rs1061386	chr13:111373368	G/C	cg24331049	chr13:111365604	ING1	0.82	7.16	0.54	6.19e-11	Coronary artery disease;
TGCT	cis	rs13242816	1.000	rs2024209	chr7:116135336	T/C	cg16553024	chr7:116138462	CAV2	-0.45	-5.06	-0.41	1.49e-6	P wave duration;
TGCT	cis	rs1218582	0.772	rs2061690	chr1:154919080	C/T	cg06221963	chr1:154839813	KCNN3	-0.73	-12.51	-0.75	1.01e-23	Prostate cancer;
TGCT	cis	rs9902453	0.817	rs7217961	chr17:28403112	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.82	-7.84	-0.58	1.8e-12	Coffee consumption (cups per day);
TGCT	cis	rs2456568	0.778	rs7940973	chr11:93682045	C/G	cg14065697	chr11:93583672	C11orf90	0.37	4.56	0.38	1.22e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg23758822	chr17:41437982	NA	0.72	6.81	0.52	3.77e-10	Menopause (age at onset);
TGCT	cis	rs7552167	0.852	rs10794647	chr1:24509133	C/T	cg01960748	chr1:24522592	NA	-0.49	-5.47	-0.44	2.38e-7	Psoriasis vulgaris;
TGCT	cis	rs6582630	0.555	rs10880624	chr12:38526316	C/T	cg26384229	chr12:38710491	ALG10B	0.86	7.78	0.57	2.47e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs2549003	1.000	rs13170412	chr5:131823519	A/G	cg21138405	chr5:131827807	IRF1	0.18	4.49	0.37	1.63e-5	Asthma (sex interaction);
TGCT	trans	rs7726839	0.574	rs72705017	chr5:623733	G/A	cg25482853	chr8:67687455	SGK3	1.23	9.86	0.66	2.81e-17	Obesity-related traits;
TGCT	cis	rs2956278	0.717	rs2956290	chr12:84682272	A/C	cg25678815	chr12:85673915	ALX1	-0.54	-4.86	-0.4	3.48e-6	Depressive symptoms;Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9419702	0.639	rs9419624	chr10:133534822	G/A	cg04492858	chr10:133558786	NA	0.53	5.74	0.46	6.85e-8	Survival in rectal cancer;
TGCT	cis	rs2729354	0.817	rs2848626	chr11:57283988	C/T	cg24343310	chr11:57249947	NA	0.3	5.01	0.41	1.85e-6	Blood protein levels;
TGCT	cis	rs1185460	0.967	rs1177563	chr11:118949083	C/T	cg01677386	chr11:118938358	VPS11	-0.55	-4.74	-0.39	5.83e-6	Coronary artery disease;
TGCT	trans	rs17471911	0.581	rs10883245	chr10:100760306	A/T	cg03484267	chr2:207988651	KLF7	-0.52	-6.7	-0.52	6.49e-10	Neuroticism;
TGCT	cis	rs57244997	1.000	rs57244997	chr6:162397506	G/A	cg17173639	chr6:162384350	PARK2	-0.52	-5.43	-0.44	2.85e-7	Mosquito bite size;
TGCT	trans	rs17685	0.753	rs6464999	chr7:75787315	T/C	cg19862616	chr7:65841803	NCRNA00174	0.52	9.01	0.63	3.02e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs2204008	0.902	rs11520218	chr12:38223227	G/A	cg26384229	chr12:38710491	ALG10B	0.84	7.38	0.55	2e-11	Bladder cancer;
TGCT	cis	rs6582630	0.519	rs8189618	chr12:38276281	A/C	cg13010199	chr12:38710504	ALG10B	0.61	4.67	0.39	7.69e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs1903068	1.000	rs1903068	chr4:56008477	A/G	cg01777861	chr4:56023843	NA	0.55	6.49	0.5	1.86e-9	Endometriosis;
TGCT	cis	rs7208859	0.573	rs79505916	chr17:29062326	C/T	cg13385521	chr17:29058706	SUZ12P	0.79	4.78	0.39	4.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs9372253	1.000	rs2235989	chr6:110714584	A/T	cg00083206	chr6:110721305	DDO	-0.41	-6.25	-0.49	5.94e-9	Platelet distribution width;
TGCT	cis	rs2295359	1.000	rs11465754	chr1:67631431	A/G	cg12940439	chr1:67600707	NA	0.54	5.78	0.46	5.78e-8	Psoriasis;
TGCT	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg22920501	chr2:26401640	FAM59B	0.81	6.36	0.5	3.52e-9	Gut microbiome composition (summer);
TGCT	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg18230493	chr5:56204884	C5orf35	-0.67	-5.88	-0.47	3.5e-8	Initial pursuit acceleration;
TGCT	cis	rs2455799	0.573	rs2654648	chr3:15775425	T/C	cg16303742	chr3:15540471	COLQ	-0.25	-4.88	-0.4	3.18e-6	Mean platelet volume;
TGCT	cis	rs11785400	0.793	rs4736364	chr8:143742113	C/T	cg10596483	chr8:143751796	JRK	0.55	5.48	0.44	2.29e-7	Schizophrenia;
TGCT	cis	rs2228479	0.867	rs34272502	chr16:89949000	G/C	cg19635926	chr16:89946313	TCF25	0.28	4.8	0.4	4.47e-6	Skin colour saturation;
TGCT	cis	rs796364	1.000	rs166845	chr2:200823360	T/A	cg17644776	chr2:200775616	C2orf69	0.31	4.85	0.4	3.58e-6	Schizophrenia;
TGCT	cis	rs2120019	0.638	rs12050628	chr15:75333494	G/A	cg17294928	chr15:75287854	SCAMP5	0.93	8.84	0.62	8.02e-15	Blood trace element (Zn levels);
TGCT	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg11644478	chr21:40555479	PSMG1	1.03	11.02	0.7	4.14e-20	Cognitive function;
TGCT	cis	rs3754214	0.823	rs10888579	chr1:150261925	C/T	cg09579323	chr1:150459698	TARS2	-0.53	-4.81	-0.4	4.38e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg09021430	chr5:549028	NA	0.39	5.37	0.43	3.77e-7	Obesity-related traits;
TGCT	trans	rs208520	0.526	rs9354370	chr6:66808209	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.08	16.81	0.83	9.08e-34	Exhaled nitric oxide output;
TGCT	cis	rs926938	0.505	rs360593	chr1:115472265	T/G	cg12756093	chr1:115239321	AMPD1	0.34	4.97	0.41	2.19e-6	Autism;
TGCT	cis	rs3008870	0.583	rs2031495	chr1:67421714	G/T	cg11518657	chr1:67396239	MIER1	0.6	4.76	0.39	5.32e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs933688	1.000	rs12656350	chr5:90751343	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.95	8.12	0.59	3.93e-13	Smoking behavior;
TGCT	cis	rs8016982	0.698	rs8021385	chr14:81704682	G/A	cg01989461	chr14:81687754	GTF2A1	0.77	7.16	0.54	6.37e-11	Schizophrenia;
TGCT	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg25767906	chr1:53392781	SCP2	0.46	5.11	0.42	1.19e-6	Monocyte count;
TGCT	cis	rs7208859	0.623	rs11650271	chr17:29213943	C/T	cg18442181	chr17:29233375	C17orf42	-0.78	-4.61	-0.38	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs61990749	0.597	rs1008988	chr14:78260795	A/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.67	4.73	0.39	6.09e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg03609598	chr5:56110824	MAP3K1	-0.58	-4.7	-0.39	6.72e-6	Initial pursuit acceleration;
TGCT	cis	rs13242816	1.000	rs2024209	chr7:116135336	T/C	cg02799643	chr7:116139180	CAV2	-0.46	-5.52	-0.44	1.87e-7	P wave duration;
TGCT	cis	rs10751667	0.666	rs7395321	chr11:940280	C/T	cg06064525	chr11:970664	AP2A2	-0.35	-8.28	-0.6	1.65e-13	Alzheimer's disease (late onset);
TGCT	cis	rs611744	0.967	rs636399	chr8:109235569	G/A	cg21045802	chr8:109455806	TTC35	0.52	4.72	0.39	6.21e-6	Dupuytren's disease;
TGCT	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg05872129	chr22:39784769	NA	-1.01	-11.09	-0.71	2.82e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs6665290	0.935	rs17528667	chr1:227201770	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.0	-20.66	-0.88	5.7e-42	Myeloid white cell count;
TGCT	cis	rs9303401	0.614	rs8081058	chr17:57160513	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.58	5.74	0.46	6.76e-8	Cognitive test performance;
TGCT	cis	rs3099143	1.000	rs4243043	chr15:77178540	A/G	cg21673338	chr15:77095150	SCAPER	0.52	5.05	0.41	1.54e-6	Recalcitrant atopic dermatitis;
TGCT	cis	rs4345303	0.962	rs7702760	chr5:78739087	A/C	cg16405876	chr5:78317871	DMGDH	0.57	4.52	0.38	1.43e-5	Interleukin-10 levels;
TGCT	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg17554472	chr22:41940697	POLR3H	0.42	4.64	0.38	8.64e-6	Vitiligo;
TGCT	cis	rs7020830	0.894	rs28766572	chr9:37093872	G/T	cg14294708	chr9:37120828	ZCCHC7	1.19	18.22	0.85	7.36e-37	Schizophrenia;
TGCT	cis	rs11640734	0.609	rs11647746	chr16:89806343	C/A	cg04287289	chr16:89883240	FANCA	0.74	4.47	0.37	1.75e-5	Interleukin-17 levels;
TGCT	cis	rs7666738	0.830	rs7697315	chr4:98938764	T/C	cg18180107	chr4:99064573	C4orf37	0.55	4.98	0.41	2.05e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1514658	0.903	rs1113677	chr4:119280513	T/C	cg21605333	chr4:119757512	SEC24D	-0.51	-4.52	-0.38	1.43e-5	Congenital heart disease (maternal effect);
TGCT	cis	rs1670533	0.932	rs10902753	chr4:1056223	G/A	cg27284194	chr4:1044797	NA	0.68	5.88	0.47	3.56e-8	Recombination rate (females);
TGCT	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg11764359	chr7:65958608	NA	0.57	5.28	0.43	5.64e-7	Aortic root size;
TGCT	cis	rs10114408	0.918	rs7035672	chr9:96668153	C/G	cg13679303	chr9:96623674	NA	-0.36	-4.55	-0.38	1.25e-5	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs2777491	0.957	rs8027626	chr15:41711514	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.75	-11.01	-0.7	4.47e-20	Ulcerative colitis;
TGCT	cis	rs7043114	0.525	rs10761153	chr9:95130769	A/G	cg14631576	chr9:95140430	CENPP	-0.28	-4.69	-0.39	6.98e-6	Height;
TGCT	cis	rs4689388	0.926	rs4234730	chr4:6296343	A/G	cg00701064	chr4:6280414	WFS1	0.38	4.78	0.39	4.96e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs12497850	0.765	rs12487580	chr3:49182932	G/A	cg16497277	chr3:49208875	KLHDC8B	-0.49	-4.47	-0.37	1.72e-5	Parkinson's disease;
TGCT	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg02725872	chr8:58115012	NA	-0.38	-4.99	-0.41	1.98e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg05368731	chr17:41323189	NBR1	1.06	11.69	0.72	9.65e-22	Menopause (age at onset);
TGCT	trans	rs117132860	0.661	rs62444471	chr7:17100425	T/A	cg25519926	chr7:130132360	MEST;MESTIT1	0.95	6.9	0.53	2.32e-10	Cutaneous squamous cell carcinoma;
TGCT	cis	rs6964587	0.967	rs12535601	chr7:91718346	A/G	cg22709100	chr7:91322751	NA	0.29	4.8	0.4	4.45e-6	Breast cancer;
TGCT	cis	rs11190604	0.767	rs7916904	chr10:102186778	C/G	cg16342193	chr10:102329863	NA	-0.38	-5.0	-0.41	1.93e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9611565	0.921	rs761366	chr22:41744022	C/G	cg03806693	chr22:41940476	POLR3H	-0.99	-11.08	-0.71	2.91e-20	Vitiligo;
TGCT	cis	rs114540395	0.925	rs115878498	chr10:103447267	G/A	cg18276125	chr10:102749041	C10orf2	0.39	4.88	0.4	3.14e-6	Schizophrenia;
TGCT	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg12963246	chr6:28129442	ZNF389	0.52	5.1	0.42	1.23e-6	Depression;
TGCT	cis	rs57920188	0.535	rs4520388	chr1:4092671	T/G	cg20703997	chr1:4087676	NA	0.48	5.7	0.46	8.27e-8	Interleukin-17 levels;
TGCT	trans	rs877282	0.733	rs7092976	chr10:756358	G/A	cg22713356	chr15:30763199	NA	1.07	8.27	0.6	1.75e-13	Uric acid levels;
TGCT	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg11301795	chr4:187892539	NA	-0.33	-5.06	-0.41	1.5e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7098414	0.511	rs7071752	chr10:82159539	C/A	cg00277334	chr10:82204260	NA	-0.38	-4.98	-0.41	2.11e-6	Post bronchodilator FEV1;
TGCT	cis	rs7225537	0.559	rs3744137	chr17:17046024	C/A	cg26176665	chr17:16994978	MPRIP	0.25	5.87	0.47	3.65e-8	Mean platelet volume;
TGCT	cis	rs941873	0.868	rs1483733	chr10:81130036	A/G	cg09469691	chr10:81107165	PPIF	0.55	5.45	0.44	2.66e-7	Height;
TGCT	cis	rs1878931	0.501	rs9635547	chr16:3416664	C/T	cg22508957	chr16:3507546	NAT15	-0.39	-5.06	-0.41	1.49e-6	Body mass index (adult);
TGCT	cis	rs17384381	1.000	rs12118950	chr1:85864519	T/C	cg16011679	chr1:85725395	C1orf52	0.78	6.1	0.48	1.27e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs35883536	0.647	rs10875317	chr1:101045438	G/T	cg10298815	chr1:101004474	GPR88	-0.25	-4.5	-0.37	1.54e-5	Monocyte count;
TGCT	cis	rs7474896	0.537	rs2749589	chr10:38266870	C/T	cg13720705	chr10:37990370	NA	-0.33	-4.5	-0.37	1.56e-5	Obesity (extreme);
TGCT	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg12311346	chr5:56204834	C5orf35	-0.67	-6.82	-0.52	3.63e-10	Initial pursuit acceleration;
TGCT	cis	rs7826238	0.601	rs2976907	chr8:8345168	C/T	cg06636001	chr8:8085503	FLJ10661	0.64	5.96	0.47	2.41e-8	Systolic blood pressure;
TGCT	cis	rs10088262	0.629	rs12541177	chr8:124800273	G/T	cg02993010	chr8:124780839	FAM91A1	-0.63	-5.13	-0.42	1.08e-6	Pancreatic cancer;
TGCT	cis	rs3138083	0.645	rs2039767	chr9:35638955	C/T	cg07116010	chr9:35646325	NA	0.82	10.15	0.67	5.33e-18	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);
TGCT	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg10047753	chr17:41438598	NA	0.96	9.6	0.65	1.16e-16	Menopause (age at onset);
TGCT	cis	rs7103648	0.742	rs34937994	chr11:47389638	C/T	cg20307385	chr11:47447363	PSMC3	1.0	11.33	0.71	7.42e-21	Diastolic blood pressure;Systolic blood pressure;
TGCT	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg06238570	chr21:40685208	BRWD1	0.7	6.45	0.5	2.3e-9	Cognitive function;
TGCT	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg05785598	chr3:49045655	WDR6	0.36	4.78	0.39	4.78e-6	Menarche (age at onset);
TGCT	cis	rs6893807	0.667	rs1477290	chr5:87988934	T/C	cg24804195	chr5:87968844	LOC645323	0.71	4.84	0.4	3.71e-6	Body mass index;
TGCT	cis	rs9915657	0.870	rs720244	chr17:70131643	G/T	cg06234051	chr17:70120541	SOX9	-0.24	-4.92	-0.4	2.75e-6	Thyroid hormone levels;
TGCT	cis	rs9549260	0.591	rs9577108	chr13:41271764	G/A	cg21288729	chr13:41239152	FOXO1	0.94	9.32	0.64	5.56e-16	Red blood cell count;
TGCT	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg18876405	chr7:65276391	NA	-0.32	-4.93	-0.4	2.63e-6	Aortic root size;
TGCT	cis	rs950169	0.656	rs11632395	chr15:85145793	C/A	cg12863693	chr15:85201151	NMB	0.4	4.7	0.39	6.79e-6	Schizophrenia;
TGCT	cis	rs2688482	0.512	rs2177336	chr3:195516878	T/C	cg13752114	chr3:195489708	MUC4	0.33	4.82	0.4	4.06e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg03264133	chr6:25882463	NA	-0.67	-6.04	-0.48	1.67e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs12681287	0.640	rs13282351	chr8:87484669	C/T	cg27223183	chr8:87520930	FAM82B	-0.89	-6.41	-0.5	2.8e-9	Caudate activity during reward;
TGCT	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.52	5.12	0.42	1.13e-6	Menarche (age at onset);
TGCT	cis	rs2637266	0.935	rs2637265	chr10:78326104	A/G	cg18941641	chr10:78392320	NA	0.42	5.38	0.43	3.6e-7	Pulmonary function;
TGCT	cis	rs2404602	0.716	rs7169394	chr15:76913274	G/A	cg22467129	chr15:76604101	ETFA	-0.44	-4.98	-0.41	2.07e-6	Blood metabolite levels;
TGCT	cis	rs7666738	0.830	rs7696715	chr4:98938486	T/C	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs514406	0.547	rs377808	chr1:53190359	T/G	cg22166914	chr1:53195759	ZYG11B	0.51	9.63	0.65	1.01e-16	Monocyte count;
TGCT	cis	rs7769051	0.522	rs7759524	chr6:133109574	A/G	cg07930552	chr6:133119739	C6orf192	1.28	5.03	0.41	1.69e-6	Type 2 diabetes nephropathy;
TGCT	cis	rs6782228	1.000	rs12635488	chr3:128352378	C/T	cg15113803	chr3:129247119	RHO	0.18	4.64	0.38	8.78e-6	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
TGCT	cis	rs9814567	1.000	rs934093	chr3:134195885	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.99	-10.02	-0.67	1.12e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs11098499	0.754	rs12513083	chr4:120249612	A/T	cg09307838	chr4:120376055	NA	0.61	5.91	0.47	3.14e-8	Corneal astigmatism;
TGCT	cis	rs9810089	0.706	rs521746	chr3:136103920	C/T	cg12473912	chr3:136751656	NA	-0.35	-4.97	-0.41	2.13e-6	Gestational age at birth (child effect);
TGCT	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg03264133	chr6:25882463	NA	0.86	8.95	0.63	4.38e-15	Blood metabolite levels;
TGCT	cis	rs9318086	0.600	rs9507185	chr13:24473734	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.82	8.98	0.63	3.58e-15	Myopia (pathological);
TGCT	cis	rs73198271	0.628	rs74433718	chr8:8591546	A/C	ch.8.214553F	chr8:8189620	PRAGMIN	-0.32	-5.23	-0.42	7.04e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs981844	0.740	rs10024619	chr4:154684441	A/T	cg14289246	chr4:154710475	SFRP2	-0.91	-8.31	-0.6	1.38e-13	Response to statins (LDL cholesterol change);
TGCT	cis	rs2070488	0.965	rs7372849	chr3:38524328	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.89	9.01	0.63	3.09e-15	Electrocardiographic conduction measures;
TGCT	trans	rs561341	0.714	rs55925849	chr17:30253085	C/T	cg20587970	chr11:113659929	NA	-1.03	-10.94	-0.7	6.67e-20	Hip circumference adjusted for BMI;
TGCT	cis	rs2439831	0.867	rs28729853	chr15:43673680	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	5.95	0.47	2.53e-8	Lung cancer in ever smokers;
TGCT	cis	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg07424592	chr7:64974309	NA	1.26	7.79	0.57	2.25e-12	Diabetic kidney disease;
TGCT	cis	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg18252515	chr7:66147081	NA	-1.13	-6.81	-0.52	3.7e-10	Diabetic kidney disease;
TGCT	cis	rs644799	0.526	rs693792	chr11:95622200	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.49	5.08	0.41	1.38e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs546131	0.928	rs546521	chr11:34824773	G/C	cg06937548	chr11:34938143	PDHX;APIP	0.66	6.03	0.48	1.74e-8	Lung disease severity in cystic fibrosis;
TGCT	cis	rs2147959	0.831	rs7555386	chr1:228630589	C/G	cg22700015	chr1:228743131	NA	-0.57	-4.53	-0.38	1.35e-5	Adult asthma;
TGCT	cis	rs12908161	1.000	rs11638290	chr15:85227636	C/T	cg17173187	chr15:85201210	NMB	0.59	6.74	0.52	5.44e-10	Schizophrenia;
TGCT	cis	rs2456568	0.802	rs8181567	chr11:93637209	C/T	cg17595323	chr11:93583763	C11orf90	-0.47	-6.52	-0.51	1.58e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7552404	0.727	rs12093623	chr1:76256232	T/G	cg10523679	chr1:76189770	ACADM	0.74	6.98	0.53	1.61e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs611744	0.967	rs636904	chr8:109197565	T/C	cg21045802	chr8:109455806	TTC35	0.5	4.5	0.37	1.53e-5	Dupuytren's disease;
TGCT	cis	rs4273100	0.831	rs59571799	chr17:19178892	C/A	cg01534423	chr17:18965556	NA	0.88	5.59	0.45	1.4e-7	Schizophrenia;
TGCT	cis	rs7091068	0.671	rs620890	chr10:95405424	G/A	cg20715218	chr10:95462985	C10orf4	-0.54	-5.15	-0.42	9.95e-7	Urinary tract infection frequency;
TGCT	cis	rs968451	0.865	rs5757611	chr22:39708357	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.86	8.55	0.61	3.83e-14	Primary biliary cholangitis;
TGCT	cis	rs8141529	0.748	rs6519766	chr22:29269991	A/G	cg02153584	chr22:29168773	CCDC117	-0.62	-4.77	-0.39	4.98e-6	Lymphocyte counts;
TGCT	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg24675658	chr1:53192096	ZYG11B	0.73	8.46	0.6	6.33e-14	Monocyte count;
TGCT	cis	rs11264213	0.686	rs12041193	chr1:36412760	C/T	cg07093915	chr1:36184400	C1orf216	0.65	4.47	0.37	1.77e-5	Schizophrenia;
TGCT	cis	rs7811142	0.945	rs6974282	chr7:100098295	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.05	-9.12	-0.63	1.65e-15	Platelet count;
TGCT	cis	rs12142240	0.698	rs17361887	chr1:46834775	A/G	cg00530320	chr1:46809349	NSUN4	0.28	5.63	0.45	1.12e-7	Menopause (age at onset);
TGCT	cis	rs13242816	0.892	rs34645128	chr7:116078382	T/A	cg02799643	chr7:116139180	CAV2	-0.43	-5.08	-0.42	1.33e-6	P wave duration;
TGCT	cis	rs4746818	1.000	rs7901617	chr10:70904063	C/T	cg11621586	chr10:70884670	VPS26A	1.19	10.76	0.69	1.83e-19	Left atrial antero-posterior diameter;
TGCT	cis	rs514406	0.800	rs4926930	chr1:53217335	A/G	cg24675658	chr1:53192096	ZYG11B	0.71	7.96	0.58	9.48e-13	Monocyte count;
TGCT	cis	rs7666738	0.830	rs11097608	chr4:99011693	T/C	cg18180107	chr4:99064573	C4orf37	0.57	5.19	0.42	8.45e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs36051895	0.659	rs7045491	chr9:5045658	G/A	cg02405213	chr9:5042618	JAK2	-0.78	-10.94	-0.7	6.34e-20	Pediatric autoimmune diseases;
TGCT	cis	rs9291683	0.552	rs17187075	chr4:9990328	G/C	cg11266682	chr4:10021025	SLC2A9	0.67	9.62	0.65	1.07e-16	Bone mineral density;
TGCT	cis	rs910316	0.763	rs12588981	chr14:75460561	A/G	cg08847533	chr14:75593920	NEK9	0.83	8.89	0.62	5.99e-15	Height;
TGCT	cis	rs12477438	0.765	rs6749059	chr2:99591021	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-6.18	-0.49	8.51e-9	Chronic sinus infection;
TGCT	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg07507251	chr3:52567010	NT5DC2	0.48	6.95	0.53	1.86e-10	Electroencephalogram traits;
TGCT	trans	rs1974653	0.672	rs8139107	chr22:20093288	C/T	cg08822737	chr17:71088851	SLC39A11	-0.93	-7.61	-0.56	5.97e-12	Schizophrenia;
TGCT	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg22963979	chr7:1858916	MAD1L1	-0.35	-5.5	-0.44	2.05e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs10782582	0.609	rs5745485	chr1:76349534	C/G	cg03433033	chr1:76189801	ACADM	-0.5	-4.98	-0.41	2.11e-6	Daytime sleep phenotypes;
TGCT	cis	rs12931792	0.875	rs58175255	chr16:30155290	C/A	cg17640201	chr16:30407289	ZNF48	0.65	5.8	0.46	5.29e-8	Tonsillectomy;
TGCT	cis	rs263156	0.967	rs263155	chr6:142906405	G/A	cg18419694	chr6:143832440	FUCA2	-0.4	-4.65	-0.39	8.22e-6	Ear morphology;Lobe size;Lobe attachment;
TGCT	cis	rs709400	0.628	rs10141120	chr14:103923008	T/C	cg26031613	chr14:104095156	KLC1	0.84	9.43	0.65	2.98e-16	Body mass index;
TGCT	cis	rs9611519	0.929	rs71327107	chr22:41418229	T/G	cg03806693	chr22:41940476	POLR3H	-0.7	-6.07	-0.48	1.41e-8	Neuroticism;
TGCT	cis	rs61897795	0.628	rs174585	chr11:61611694	G/A	cg19610905	chr11:61596333	FADS2	-0.79	-6.01	-0.47	1.92e-8	Neutrophil count;Sum basophil neutrophil counts;
TGCT	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg21951975	chr1:209979733	IRF6	0.69	5.92	0.47	2.98e-8	Cleft lip with or without cleft palate;
TGCT	cis	rs7681440	0.835	rs1899389	chr4:90802998	G/A	cg20003494	chr4:90757398	SNCA	-0.62	-5.94	-0.47	2.7e-8	Dementia with Lewy bodies;
TGCT	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg16423285	chr20:60520624	NA	-0.61	-6.43	-0.5	2.45e-9	Body mass index;
TGCT	cis	rs3733585	0.699	rs12498150	chr4:9950537	C/T	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.47	-0.56	1.25e-11	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg18252515	chr7:66147081	NA	-1.2	-7.76	-0.57	2.75e-12	Diabetic kidney disease;
TGCT	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg22166914	chr1:53195759	ZYG11B	0.32	5.27	0.43	5.95e-7	Monocyte count;
TGCT	trans	rs459571	0.959	rs461462	chr9:136911272	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.75	-8.02	-0.58	6.93e-13	Platelet distribution width;
TGCT	cis	rs9341808	0.754	rs6916405	chr6:81024188	C/T	cg08355045	chr6:80787529	NA	0.26	4.48	0.37	1.64e-5	Sitting height ratio;
TGCT	cis	rs7772486	0.686	rs1337841	chr6:146059487	A/G	cg23711669	chr6:146136114	FBXO30	-0.88	-9.9	-0.66	2.22e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs478304	0.580	rs11606947	chr11:65508237	A/C	cg27068330	chr11:65405492	SIPA1	-0.95	-9.75	-0.66	4.99e-17	Acne (severe);
TGCT	cis	rs12188164	0.965	rs1056465	chr5:442438	T/A	cg21144161	chr5:423903	AHRR	0.25	4.79	0.4	4.59e-6	Cystic fibrosis severity;
TGCT	cis	rs40363	0.857	rs55989968	chr16:3530658	C/G	cg05754148	chr16:3507555	NAT15	0.47	4.64	0.38	8.58e-6	Tuberculosis;
TGCT	cis	rs6570726	0.791	rs435671	chr6:145881215	A/G	cg13319975	chr6:146136371	FBXO30	-0.51	-4.6	-0.38	1.01e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs78487399	0.808	rs6726643	chr2:43753746	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.07	-0.41	1.41e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs9443645	0.869	rs9361489	chr6:79816785	T/C	cg09184832	chr6:79620586	NA	-0.47	-5.03	-0.41	1.65e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7772486	0.754	rs4896832	chr6:145964151	G/A	cg05347473	chr6:146136440	FBXO30	0.5	4.71	0.39	6.65e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11574514	1.000	rs10775302	chr16:67792439	C/T	cg26449586	chr16:67701378	C16orf86;C16orf48	0.76	4.44	0.37	1.93e-5	Crohn's disease;
TGCT	cis	rs34014631	1.000	rs34014631	chr10:103698705	C/T	cg22630918	chr10:102748988	C10orf2	0.42	4.78	0.39	4.86e-6	Coronary artery calcification;
TGCT	cis	rs4478037	0.556	rs55680612	chr3:33100948	C/T	cg19404215	chr3:33155277	CRTAP	1.14	4.71	0.39	6.48e-6	Major depressive disorder;
TGCT	cis	rs7523273	0.586	rs7518047	chr1:207899332	T/C	cg22525895	chr1:207977042	MIR29B2	-0.33	-5.31	-0.43	4.83e-7	Schizophrenia;
TGCT	cis	rs1670533	1.000	rs11247972	chr4:1060550	A/G	cg27284194	chr4:1044797	NA	0.7	6.04	0.48	1.63e-8	Recombination rate (females);
TGCT	cis	rs2840044	1.000	rs2840044	chr17:33892068	A/G	cg05299278	chr17:33885742	SLFN14	-0.23	-5.17	-0.42	8.95e-7	Response to radiotherapy in cancer (late toxicity);
TGCT	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg12311346	chr5:56204834	C5orf35	-0.56	-5.99	-0.47	2.11e-8	Initial pursuit acceleration;
TGCT	cis	rs28493229	0.786	rs3815912	chr19:41190726	G/A	cg11601297	chr19:41224147	ITPKC;ADCK4	0.54	5.24	0.43	6.57e-7	Kawasaki disease;
TGCT	cis	rs6835098	0.962	rs6851632	chr4:174109611	A/G	cg08422745	chr4:174089978	GALNT7	-0.9	-10.08	-0.67	7.91e-18	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg17775962	chr7:1200435	ZFAND2A	0.28	4.86	0.4	3.46e-6	Longevity;Endometriosis;
TGCT	cis	rs3008870	1.000	rs3008888	chr1:67368965	C/T	cg11518657	chr1:67396239	MIER1	0.53	4.72	0.39	6.16e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs2439831	0.850	rs3862142	chr15:44064806	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	5.91	0.47	3.05e-8	Lung cancer in ever smokers;
TGCT	cis	rs2153535	0.542	rs6905925	chr6:8440030	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.58	0.45	1.42e-7	Motion sickness;
TGCT	cis	rs12780845	0.540	rs6602178	chr10:17180169	A/C	cg01003015	chr10:17271136	VIM	-0.59	-5.48	-0.44	2.32e-7	Homocysteine levels;
TGCT	cis	rs7226408	0.901	rs72887101	chr18:34513774	G/T	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs12615966	1.000	rs17030292	chr2:105383596	C/G	cg16465502	chr2:105461796	NA	0.78	5.03	0.41	1.66e-6	Pancreatic cancer;
TGCT	cis	rs908922	0.676	rs525960	chr1:152497866	T/A	cg20991723	chr1:152506922	NA	0.46	6.28	0.49	5.26e-9	Hair morphology;
TGCT	cis	rs7923609	0.936	rs10822160	chr10:65112796	T/G	cg08743896	chr10:65200160	JMJD1C	-0.34	-4.46	-0.37	1.78e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2012796	0.956	rs7147254	chr14:81820503	G/A	cg02996355	chr14:81879375	NA	0.47	4.61	0.38	9.68e-6	Night sleep phenotypes;
TGCT	cis	rs8044995	0.563	rs73613962	chr16:68361974	T/G	cg05110241	chr16:68378359	PRMT7	-0.36	-4.45	-0.37	1.87e-5	Schizophrenia;
TGCT	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.64	0.51	8.85e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs4073582	0.595	rs10896104	chr11:66001869	C/T	cg16950941	chr11:66035639	RAB1B	0.58	5.44	0.44	2.67e-7	Gout;
TGCT	cis	rs9534288	0.830	rs1548325	chr13:46635101	A/G	cg15192986	chr13:46630673	CPB2	-0.5	-6.23	-0.49	6.66e-9	Blood protein levels;
TGCT	cis	rs1059312	0.808	rs10847694	chr12:129292457	C/A	cg09035930	chr12:129282057	SLC15A4	0.55	10.73	0.69	2.06e-19	Systemic lupus erythematosus;
TGCT	cis	rs6860806	0.507	rs2631371	chr5:131703691	G/A	cg24060327	chr5:131705240	SLC22A5	0.78	8.48	0.61	5.6e-14	Breast cancer;
TGCT	cis	rs9583531	0.689	rs2165418	chr13:111379365	G/T	cg24331049	chr13:111365604	ING1	-0.91	-9.19	-0.64	1.17e-15	Coronary artery disease;
TGCT	cis	rs12898370	0.561	rs11630770	chr15:77469643	A/G	cg27398640	chr15:77910606	LINGO1	0.34	4.53	0.38	1.35e-5	Risky sexual behaviors (alcohol dependence interaction);
TGCT	cis	rs7809950	0.817	rs34325395	chr7:107113808	C/G	cg23024343	chr7:107201750	COG5	-0.46	-6.76	-0.52	4.89e-10	Coronary artery disease;
TGCT	cis	rs9911578	0.967	rs7214892	chr17:57065401	G/A	cg05425664	chr17:57184151	TRIM37	-0.63	-6.03	-0.48	1.71e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs854765	0.663	rs3744113	chr17:17748645	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.72	-6.85	-0.52	3e-10	Total body bone mineral density;
TGCT	cis	rs5769765	0.955	rs4075330	chr22:50303249	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.42	5.93	0.47	2.83e-8	Schizophrenia;
TGCT	cis	rs1215050	0.791	rs260902	chr4:98764694	G/A	cg05340658	chr4:99064831	C4orf37	0.44	5.52	0.44	1.85e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7617480	0.648	rs4974083	chr3:49000626	A/G	cg07636037	chr3:49044803	WDR6	0.82	6.59	0.51	1.12e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs7100689	0.622	rs1340373	chr10:82129250	G/A	cg01528321	chr10:82214614	TSPAN14	0.8	7.76	0.57	2.7e-12	Post bronchodilator FEV1;
TGCT	cis	rs11098499	0.580	rs12509234	chr4:120319434	T/C	cg09307838	chr4:120376055	NA	0.65	6.17	0.48	8.93e-9	Corneal astigmatism;
TGCT	cis	rs986417	0.901	rs3759688	chr14:60975579	A/C	cg27398547	chr14:60952738	C14orf39	1.42	8.68	0.61	1.89e-14	Gut microbiota (bacterial taxa);
TGCT	cis	rs2797160	1.000	rs9321050	chr6:126001568	A/G	cg05901451	chr6:126070800	HEY2	-0.73	-6.27	-0.49	5.51e-9	Endometrial cancer;
TGCT	trans	rs57221529	0.766	rs72703026	chr5:572383	G/A	cg25482853	chr8:67687455	SGK3	1.2	10.25	0.68	3.07e-18	Lung disease severity in cystic fibrosis;
TGCT	trans	rs208520	1.000	rs72882102	chr6:66983408	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.83	7.46	0.56	1.31e-11	Exhaled nitric oxide output;
TGCT	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg20203395	chr5:56204925	C5orf35	0.53	4.89	0.4	3.03e-6	Initial pursuit acceleration;
TGCT	cis	rs12210905	0.688	rs72845008	chr6:27492961	C/G	cg08851530	chr6:28072375	NA	1.34	6.29	0.49	5.02e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs7552404	0.924	rs7544117	chr1:76158246	A/G	cg22875332	chr1:76189707	ACADM	0.78	9.74	0.66	5.53e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9325144	0.560	rs7314632	chr12:38636979	C/T	cg26384229	chr12:38710491	ALG10B	-0.64	-6.09	-0.48	1.29e-8	Morning vs. evening chronotype;
TGCT	cis	rs6750047	0.548	rs162327	chr2:38318350	G/A	cg07380506	chr2:38303506	CYP1B1	0.58	5.49	0.44	2.16e-7	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs12148488	0.763	rs2304902	chr15:75340727	G/T	cg09165964	chr15:75287851	SCAMP5	0.52	4.56	0.38	1.23e-5	Caffeine consumption;
TGCT	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg21963583	chr11:68658836	MRPL21	0.36	6.17	0.48	9.01e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs904251	0.861	rs914349	chr6:37484715	A/C	cg08126542	chr6:37504118	NA	-0.42	-5.81	-0.46	5e-8	Cognitive performance;
TGCT	cis	rs1865760	0.566	rs1971509	chr6:26085777	T/C	cg16482183	chr6:26056742	HIST1H1C	0.58	4.97	0.41	2.13e-6	Height;
TGCT	cis	rs13256369	1.000	rs10088439	chr8:8576699	T/G	cg06671706	chr8:8559999	CLDN23	0.35	4.69	0.39	6.95e-6	Obesity-related traits;
TGCT	cis	rs7524258	0.868	rs4243825	chr1:7308264	T/C	cg07173049	chr1:7289937	CAMTA1	0.28	4.6	0.38	1.04e-5	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs7044106	0.791	rs2416799	chr9:123480866	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	4.97	0.41	2.13e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs7010267	0.692	rs3134063	chr8:119959657	C/T	cg17171407	chr8:119960777	TNFRSF11B	0.28	5.1	0.42	1.25e-6	Total body bone mineral density (age 45-60);
TGCT	cis	rs13191362	1.000	rs13220181	chr6:163004401	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.68	5.79	0.46	5.33e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg27535305	chr1:53392650	SCP2	-0.23	-4.59	-0.38	1.06e-5	Monocyte count;
TGCT	cis	rs7666738	0.830	rs7663438	chr4:99014582	C/T	cg05340658	chr4:99064831	C4orf37	0.46	5.19	0.42	8.17e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7246657	0.722	rs2909102	chr19:38167364	C/T	cg03611452	chr19:38183253	ZNF781	-0.57	-4.79	-0.39	4.72e-6	Coronary artery calcification;
TGCT	cis	rs9653442	0.564	rs4851261	chr2:100786717	A/G	cg07810366	chr2:100720526	AFF3	-0.36	-5.26	-0.43	6.14e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs6426558	0.524	rs2813948	chr1:227459621	A/T	cg10327440	chr1:227177885	CDC42BPA	0.58	6.76	0.52	4.75e-10	Neutrophil percentage of white cells;
TGCT	cis	rs9650657	0.538	rs11250093	chr8:10798828	C/T	cg27411982	chr8:10470053	RP1L1	0.22	4.74	0.39	5.79e-6	Neuroticism;
TGCT	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg24675658	chr1:53192096	ZYG11B	0.86	11.3	0.71	8.54e-21	Monocyte count;
TGCT	cis	rs7804356	1.000	rs1327989	chr7:26833563	C/T	cg03456212	chr7:26904342	SKAP2	-0.62	-4.73	-0.39	6.1e-6	Type 1 diabetes;
TGCT	cis	rs2404618	0.593	rs7829532	chr8:1485190	C/A	cg13402656	chr8:1511478	DLGAP2	-0.37	-6.0	-0.47	1.99e-8	Lung cancer;
TGCT	cis	rs62380364	0.727	rs12054920	chr5:88161417	T/C	cg22951263	chr5:87985283	NA	-0.52	-5.32	-0.43	4.77e-7	Intelligence (multi-trait analysis);
TGCT	trans	rs1814175	0.645	rs10839448	chr11:49938930	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.51	-0.69	7.2e-19	Height;
TGCT	cis	rs1784581	0.674	rs1789996	chr6:162391895	T/C	cg17173639	chr6:162384350	PARK2	-0.47	-8.16	-0.59	3.15e-13	Itch intensity from mosquito bite;
TGCT	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg14500267	chr11:67383377	NA	0.32	4.98	0.41	2.04e-6	Mean corpuscular volume;
TGCT	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg08048268	chr3:133502702	NA	-0.54	-7.2	-0.54	5.06e-11	Iron status biomarkers;
TGCT	cis	rs42648	0.633	rs11563909	chr7:89935704	A/G	cg25739043	chr7:89950458	NA	-0.62	-6.03	-0.48	1.73e-8	Homocysteine levels;
TGCT	cis	rs4699052	0.662	rs6533083	chr4:104241267	C/T	cg16532752	chr4:104119610	CENPE	-0.55	-5.37	-0.43	3.75e-7	Testicular germ cell tumor;
TGCT	cis	rs4595586	1.000	rs4595586	chr12:39225991	A/T	cg10518543	chr12:38710700	ALG10B	-0.46	-4.51	-0.38	1.48e-5	Morning vs. evening chronotype;
TGCT	cis	rs67478160	0.619	rs10083370	chr14:104314182	G/A	cg26031613	chr14:104095156	KLC1	0.69	6.98	0.53	1.59e-10	Schizophrenia;
TGCT	cis	rs72615157	0.634	rs7789890	chr7:99800559	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.61	4.99	0.41	1.98e-6	Lung function (FEV1/FVC);
TGCT	cis	rs2760061	0.603	rs697761	chr1:228192397	G/A	cg18477163	chr1:228402036	OBSCN	0.36	7.17	0.54	5.84e-11	Diastolic blood pressure;
TGCT	cis	rs7178572	0.568	rs4243045	chr15:77455914	A/C	cg15453836	chr15:77711506	NA	-0.45	-4.99	-0.41	2.02e-6	Type 2 diabetes;
TGCT	cis	rs72949976	0.934	rs1441172	chr2:214037703	C/T	cg08319019	chr2:214017104	IKZF2	-0.69	-6.01	-0.48	1.9e-8	Lung cancer;Squamous cell lung carcinoma;
TGCT	cis	rs7746199	0.668	rs34864796	chr6:27459923	G/A	cg10876282	chr6:28092338	ZSCAN16	0.88	4.52	0.38	1.44e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4919044	0.756	rs2478239	chr10:94806370	A/T	cg05127821	chr10:94822908	CYP26C1	-0.8	-5.15	-0.42	9.92e-7	Coronary artery disease;
TGCT	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg17971929	chr21:40555470	PSMG1	0.96	8.47	0.61	6.08e-14	Cognitive function;
TGCT	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg25036284	chr2:26402008	FAM59B	-0.65	-5.18	-0.42	8.8e-7	Gut microbiome composition (summer);
TGCT	cis	rs12579753	0.879	rs11115010	chr12:82165895	G/T	cg21231944	chr12:82153410	PPFIA2	-0.34	-4.62	-0.38	9.52e-6	Resting heart rate;
TGCT	trans	rs1814175	0.765	rs11493326	chr11:50018063	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.36	-6.98	-0.53	1.55e-10	Height;
TGCT	cis	rs11148252	0.538	rs2296348	chr13:52710136	T/G	cg00495681	chr13:53174319	NA	0.57	5.86	0.47	3.84e-8	Lewy body disease;
TGCT	cis	rs1059312	1.000	rs1059312	chr12:129278864	A/G	cg09035930	chr12:129282057	SLC15A4	-0.57	-11.5	-0.72	2.76e-21	Systemic lupus erythematosus;
TGCT	cis	rs12712073	0.845	rs1370353	chr2:100764824	G/C	cg22139774	chr2:100720529	AFF3	-0.36	-5.65	-0.45	1.04e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1371867	0.846	rs1788196	chr8:101290088	C/T	cg00191853	chr8:101177733	SPAG1	-0.23	-4.76	-0.39	5.2e-6	Atrioventricular conduction;
TGCT	cis	rs6964587	1.000	rs2106171	chr7:91750450	A/G	cg22709100	chr7:91322751	NA	0.29	4.66	0.39	8e-6	Breast cancer;
TGCT	cis	rs17376456	0.825	rs17314797	chr5:93234845	T/A	cg25358565	chr5:93447407	FAM172A	1.01	8.13	0.59	3.77e-13	Diabetic retinopathy;
TGCT	cis	rs929354	0.772	rs6971896	chr7:156978412	C/T	cg05182265	chr7:156933206	UBE3C	-0.39	-8.79	-0.62	1.03e-14	Body mass index;
TGCT	trans	rs77457752	0.690	rs12349345	chr9:13912075	T/C	cg23609682	chr1:3070786	PRDM16	0.51	7.14	0.54	6.89e-11	Breast cancer;
TGCT	cis	rs2486288	0.656	rs7166580	chr15:45571209	C/G	cg26924012	chr15:45694286	SPATA5L1	-0.79	-7.87	-0.58	1.53e-12	Glomerular filtration rate;
TGCT	cis	rs3935685	0.874	rs4595768	chr15:78006290	C/T	cg25212270	chr15:78015279	NA	0.27	5.66	0.45	9.91e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs6840360	0.554	rs13108359	chr4:152727852	T/C	cg17479576	chr4:152424074	FAM160A1	0.51	5.21	0.42	7.5e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9291683	0.567	rs12499857	chr4:9995376	G/A	cg11266682	chr4:10021025	SLC2A9	0.67	8.95	0.63	4.3e-15	Bone mineral density;
TGCT	cis	rs807669	0.903	rs807668	chr22:19162686	A/G	cg02655711	chr22:19163373	SLC25A1	0.42	10.06	0.67	8.99e-18	Metabolite levels;
TGCT	cis	rs7044106	0.791	rs7043969	chr9:123493989	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	7.24	0.54	4.22e-11	Hip circumference adjusted for BMI;
TGCT	cis	rs2204008	0.563	rs2320512	chr12:38266913	G/A	cg26384229	chr12:38710491	ALG10B	-0.54	-4.7	-0.39	6.68e-6	Bladder cancer;
TGCT	cis	rs7833790	0.724	rs6473311	chr8:82726682	G/A	cg23324259	chr8:82754387	SNX16	-0.61	-4.71	-0.39	6.42e-6	Diastolic blood pressure;
TGCT	cis	rs909341	1.000	rs909341	chr20:62328742	C/T	cg14758556	chr20:62440591	NA	0.3	4.56	0.38	1.23e-5	Atopic dermatitis;
TGCT	cis	rs2594989	0.639	rs2442781	chr3:11483769	A/G	cg00170343	chr3:11313890	ATG7	-0.6	-4.45	-0.37	1.9e-5	Circulating chemerin levels;
TGCT	cis	rs12477438	0.520	rs13004491	chr2:99738008	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	13.05	0.76	4.93e-25	Chronic sinus infection;
TGCT	cis	rs35883536	0.588	rs17403878	chr1:101105310	C/T	cg06223162	chr1:101003688	GPR88	0.33	5.54	0.45	1.7e-7	Monocyte count;
TGCT	cis	rs9486719	1.000	rs13208422	chr6:96892119	C/T	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.86	-0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs9486719	1.000	rs2472888	chr6:96865501	T/C	cg06623918	chr6:96969491	KIAA0776	1.01	8.86	0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg16325326	chr1:53192061	ZYG11B	-0.7	-8.6	-0.61	2.87e-14	Monocyte count;
TGCT	cis	rs908922	0.676	rs533917	chr1:152518294	A/G	cg20991723	chr1:152506922	NA	0.46	6.18	0.49	8.64e-9	Hair morphology;
TGCT	cis	rs4919694	1.000	rs10509758	chr10:104681710	T/C	cg04362960	chr10:104952993	NT5C2	1.02	6.9	0.53	2.41e-10	Arsenic metabolism;
TGCT	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg08280861	chr8:58055591	NA	0.38	4.81	0.4	4.36e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7727544	0.684	rs272849	chr5:131690241	A/G	cg24060327	chr5:131705240	SLC22A5	-0.59	-6.54	-0.51	1.43e-9	Blood metabolite levels;
TGCT	cis	rs7715806	0.500	rs4703676	chr5:74979866	G/C	cg19683494	chr5:74908142	NA	0.57	4.95	0.41	2.35e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg13395646	chr4:1353034	KIAA1530	-0.36	-4.61	-0.38	9.75e-6	Obesity-related traits;
TGCT	cis	rs4325129	1.000	rs12141291	chr1:159460871	C/T	cg07417683	chr1:159440267	NA	-0.44	-4.54	-0.38	1.33e-5	Obesity-related traits;
TGCT	cis	rs7714584	1.000	rs1428555	chr5:150257391	A/G	cg22134413	chr5:150180641	NA	-0.91	-7.16	-0.54	6.18e-11	Crohn's disease;
TGCT	cis	rs9467773	0.595	rs6907924	chr6:26438817	T/G	cg05738196	chr6:26577821	NA	-0.52	-5.49	-0.44	2.18e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs17376456	0.877	rs17083460	chr5:93462354	A/G	cg25358565	chr5:93447407	FAM172A	0.92	8.38	0.6	9.58e-14	Diabetic retinopathy;
TGCT	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg24250549	chr1:154909240	PMVK	0.63	6.25	0.49	6.03e-9	Prostate cancer;
TGCT	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	5.24	0.43	6.73e-7	Menopause (age at onset);
TGCT	trans	rs1814175	0.645	rs1851857	chr11:49855589	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.45	-11.09	-0.71	2.8e-20	Height;
TGCT	cis	rs727505	0.954	rs66691367	chr7:124654217	G/T	cg23710748	chr7:124431027	NA	-0.26	-4.55	-0.38	1.27e-5	Lewy body disease;
TGCT	cis	rs62244186	0.516	rs11922470	chr3:44777795	C/T	cg10263370	chr3:44754102	ZNF502	-0.4	-4.46	-0.37	1.81e-5	Depressive symptoms;
TGCT	cis	rs4919044	0.808	rs1222605	chr10:94804200	T/C	cg05127821	chr10:94822908	CYP26C1	-0.75	-4.85	-0.4	3.67e-6	Coronary artery disease;
TGCT	cis	rs9581857	0.547	rs9581872	chr13:28086058	C/T	cg22138327	chr13:27999177	GTF3A	0.72	4.51	0.38	1.46e-5	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs6547741	1.000	rs6756238	chr2:27841305	G/A	cg27432699	chr2:27873401	GPN1	0.18	4.56	0.38	1.19e-5	Oral cavity cancer;
TGCT	cis	rs4851266	0.898	rs12994592	chr2:100857984	T/C	cg07810366	chr2:100720526	AFF3	-0.36	-5.21	-0.42	7.59e-7	Educational attainment;
TGCT	cis	rs7599312	0.534	rs7596285	chr2:213406961	G/A	cg16329650	chr2:213403929	ERBB4	1.07	16.1	0.82	3.53e-32	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs6725041	0.819	rs1521660	chr2:213082960	C/T	cg20637307	chr2:213403960	ERBB4	-0.52	-4.5	-0.37	1.54e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs9611565	0.729	rs203319	chr22:41914593	C/T	cg03806693	chr22:41940476	POLR3H	-1.0	-11.18	-0.71	1.68e-20	Vitiligo;
TGCT	cis	rs9467711	0.659	rs13216828	chr6:26373507	G/A	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12791968	0.765	rs12226848	chr11:45009204	C/T	cg11846598	chr11:44996168	LOC221122	-0.32	-5.01	-0.41	1.83e-6	Inhibitory control;
TGCT	cis	rs637571	0.544	rs12361552	chr11:65701204	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.51	-5.13	-0.42	1.07e-6	Eosinophil percentage of white cells;
TGCT	cis	rs651907	0.535	rs4342086	chr3:101503765	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	4.85	0.4	3.68e-6	Colorectal cancer;
TGCT	cis	rs7100689	0.725	rs2185425	chr10:82139941	T/C	cg01528321	chr10:82214614	TSPAN14	0.89	8.97	0.63	3.94e-15	Post bronchodilator FEV1;
TGCT	cis	rs10504229	0.679	rs6474100	chr8:58031161	G/A	cg08280861	chr8:58055591	NA	0.35	5.07	0.41	1.43e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs5744897	1.000	rs5744897	chr12:133226831	C/T	cg17341477	chr12:133246679	POLE	0.35	4.74	0.39	5.78e-6	Urate levels in overweight individuals;
TGCT	cis	rs9467711	0.538	rs35942482	chr6:26444938	T/A	cg16898833	chr6:26189333	HIST1H4D	1.12	5.36	0.43	3.91e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7191439	0.657	rs3826076	chr16:88780518	C/T	cg27087555	chr16:88793112	FAM38A	0.44	5.13	0.42	1.1e-6	Plateletcrit;
TGCT	cis	rs7681440	0.967	rs920624	chr4:90748195	T/A	cg20003494	chr4:90757398	SNCA	-0.54	-5.05	-0.41	1.56e-6	Dementia with Lewy bodies;
TGCT	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.47	-0.37	1.72e-5	Bipolar disorder;
TGCT	cis	rs7677751	0.806	rs73252942	chr4:55104604	T/C	cg17187183	chr4:55093834	PDGFRA	0.54	7.0	0.53	1.45e-10	Corneal astigmatism;
TGCT	cis	rs12134133	1.000	rs2782851	chr1:207465062	C/T	cg02152968	chr1:207494213	CD55	0.57	4.47	0.37	1.74e-5	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs11098499	0.863	rs13140409	chr4:120503460	A/G	cg09307838	chr4:120376055	NA	0.69	6.53	0.51	1.49e-9	Corneal astigmatism;
TGCT	cis	rs9341808	0.714	rs4256394	chr6:80882142	C/T	cg08355045	chr6:80787529	NA	0.28	4.76	0.39	5.39e-6	Sitting height ratio;
TGCT	cis	rs12497850	0.897	rs9884022	chr3:48956862	G/C	cg05785598	chr3:49045655	WDR6	0.36	4.76	0.39	5.34e-6	Parkinson's disease;
TGCT	cis	rs7539409	0.651	rs7521788	chr1:84309320	G/T	cg10977910	chr1:84465055	TTLL7	0.88	5.62	0.45	1.19e-7	Alzheimer's disease;
TGCT	cis	rs9467773	0.620	rs2101582	chr6:26622734	C/T	cg02458000	chr6:26745757	NA	0.58	5.75	0.46	6.43e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs35084382	1.000	rs2431663	chr5:172196711	A/C	cg19801141	chr5:172198162	DUSP1	0.94	5.35	0.43	4.02e-7	Optic cup area;
TGCT	cis	rs62244186	0.659	rs9873072	chr3:44516496	G/A	cg04389838	chr3:44770851	ZNF501	-0.42	-5.72	-0.46	7.66e-8	Depressive symptoms;
TGCT	cis	rs1568889	1.000	rs12791341	chr11:28335452	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	8.75	0.62	1.27e-14	Bipolar disorder;
TGCT	cis	rs2486288	0.656	rs11639349	chr15:45568260	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.82	-8.09	-0.59	4.62e-13	Glomerular filtration rate;
TGCT	cis	rs2932538	0.922	rs17438324	chr1:113100573	C/T	cg22162597	chr1:113214053	CAPZA1	0.27	5.89	0.47	3.46e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg05368731	chr17:41323189	NBR1	1.2	14.2	0.79	8.98e-28	Menopause (age at onset);
TGCT	trans	rs2727020	0.729	rs2204366	chr11:49349367	A/C	cg03929089	chr4:120376271	NA	0.73	8.36	0.6	1.1e-13	Coronary artery disease;
TGCT	cis	rs13326165	0.671	rs6794675	chr3:52374889	T/A	cg27565382	chr3:53032988	SFMBT1	0.37	4.93	0.41	2.55e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg18252515	chr7:66147081	NA	1.22	7.33	0.55	2.53e-11	Diabetic kidney disease;
TGCT	cis	rs12971120	0.504	rs11665154	chr18:72147006	A/C	cg26446133	chr18:72167187	CNDP2	-0.27	-5.25	-0.43	6.25e-7	Refractive error;
TGCT	cis	rs922182	0.967	rs17788704	chr15:64277097	A/G	cg02919090	chr15:64263738	DAPK2	-0.29	-5.48	-0.44	2.27e-7	Blood protein levels;
TGCT	cis	rs7223966	0.960	rs8082651	chr17:61675292	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.23	0.43	6.88e-7	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs1395	0.778	rs4665959	chr2:27443256	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.7	9.42	0.65	3.12e-16	Blood metabolite levels;
TGCT	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg07507251	chr3:52567010	NT5DC2	0.48	6.95	0.53	1.82e-10	Bipolar disorder;
TGCT	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.92	-6.8	-0.52	3.96e-10	Gut microbiome composition (summer);
TGCT	trans	rs7618501	0.521	rs11709573	chr3:49956628	C/T	cg21659725	chr3:3221576	CRBN	0.68	7.55	0.56	8.1e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs2652822	0.550	rs11853804	chr15:63528256	C/A	cg12855773	chr15:63363890	TPM1	-0.17	-5.21	-0.42	7.77e-7	Metabolic traits;
TGCT	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6088590	0.561	rs6059926	chr20:33164804	C/T	cg06115741	chr20:33292138	TP53INP2	0.51	4.47	0.37	1.76e-5	Coronary artery disease;
TGCT	cis	rs7635838	0.859	rs2443708	chr3:11545719	T/C	cg00170343	chr3:11313890	ATG7	0.61	5.28	0.43	5.69e-7	HDL cholesterol;
TGCT	cis	rs7666738	0.830	rs6532723	chr4:99052147	A/T	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6969780	0.915	rs7341470	chr7:27184842	T/C	cg04317399	chr7:27170313	HOXA4	-0.45	-4.53	-0.38	1.35e-5	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs2562456	1.000	rs2359155	chr19:21671869	C/A	cg01304269	chr19:21688519	ZNF429	-0.58	-4.78	-0.39	4.79e-6	Pain;
TGCT	cis	rs6840360	0.571	rs4696274	chr4:152528478	C/A	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.0	-0.58	7.69e-13	Intelligence (multi-trait analysis);
TGCT	trans	rs1974653	0.672	rs9606238	chr22:20070171	T/C	cg08822737	chr17:71088851	SLC39A11	-0.93	-7.61	-0.56	5.97e-12	Schizophrenia;
TGCT	cis	rs11190604	1.000	rs7088512	chr10:102303498	G/T	cg23241863	chr10:102295624	HIF1AN	0.73	5.38	0.43	3.6e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs617219	0.726	rs1962002	chr5:78430689	T/C	cg23987322	chr5:78407566	BHMT	0.35	4.58	0.38	1.14e-5	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs7772486	0.686	rs7739735	chr6:146123536	G/A	cg23711669	chr6:146136114	FBXO30	0.86	9.53	0.65	1.74e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg20607798	chr8:58055168	NA	0.68	5.66	0.45	1e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs67072384	1.000	rs72964181	chr11:72440124	C/G	cg03713592	chr11:72463424	ARAP1	-0.92	-4.61	-0.38	9.81e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs17376456	0.877	rs9314101	chr5:93461593	A/T	cg25358565	chr5:93447407	FAM172A	0.92	8.38	0.6	9.58e-14	Diabetic retinopathy;
TGCT	cis	rs2204008	0.576	rs11519979	chr12:37999413	C/T	cg13010199	chr12:38710504	ALG10B	0.65	5.29	0.43	5.47e-7	Bladder cancer;
TGCT	cis	rs36051895	0.589	rs7848312	chr9:5237442	T/C	cg02405213	chr9:5042618	JAK2	-0.68	-8.01	-0.58	7.18e-13	Pediatric autoimmune diseases;
TGCT	cis	rs3818285	0.504	rs4917547	chr10:111652285	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.29	-4.94	-0.41	2.46e-6	Superior crus of antihelix expression;
TGCT	cis	rs155076	1.000	rs58519241	chr13:21845006	C/A	cg14456004	chr13:21872349	NA	-1.32	-10.82	-0.7	1.25e-19	White matter hyperintensity burden;
TGCT	cis	rs1371867	0.875	rs962452	chr8:101331369	G/A	cg06636551	chr8:101224915	SPAG1	-0.42	-5.65	-0.45	1.06e-7	Atrioventricular conduction;
TGCT	cis	rs868036	0.718	rs8030456	chr15:68076856	C/T	cg05925327	chr15:68127851	NA	-0.51	-4.94	-0.41	2.52e-6	Restless legs syndrome;
TGCT	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.31	0.43	4.9e-7	Prudent dietary pattern;
TGCT	cis	rs7582180	0.676	rs1437969	chr2:100983482	A/C	cg08017756	chr2:100939284	LONRF2	-0.3	-4.97	-0.41	2.16e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs12188164	1.000	rs34453673	chr5:434722	G/C	cg26850624	chr5:429559	AHRR	-0.19	-4.74	-0.39	5.87e-6	Cystic fibrosis severity;
TGCT	cis	rs2816958	0.803	rs2816956	chr1:200103564	T/C	cg07971716	chr1:199773294	NA	0.43	4.48	0.37	1.7e-5	Ulcerative colitis;Inflammatory bowel disease;
TGCT	cis	rs9611565	0.506	rs1883825	chr22:41703408	A/G	cg06634786	chr22:41940651	POLR3H	-0.58	-5.28	-0.43	5.62e-7	Vitiligo;
TGCT	cis	rs10791097	0.653	rs11222362	chr11:130731425	T/C	cg05962950	chr11:130786565	SNX19	0.84	10.71	0.69	2.4e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg06618935	chr21:46677482	NA	-0.39	-5.85	-0.47	4.12e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg11494091	chr17:61959527	GH2	0.61	14.81	0.8	3.37e-29	Prudent dietary pattern;
TGCT	trans	rs9329221	0.618	rs73197281	chr8:10263282	T/C	cg15556689	chr8:8085844	FLJ10661	-0.74	-6.64	-0.51	9.01e-10	Neuroticism;
TGCT	cis	rs7926906	0.840	rs7926034	chr11:90514796	A/G	cg22332266	chr11:89956777	CHORDC1	-0.43	-4.55	-0.38	1.26e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs1031925	0.640	rs6445958	chr3:51772297	A/G	cg10583097	chr3:51429234	RBM15B	-0.52	-4.96	-0.41	2.26e-6	Melanoma;
TGCT	cis	rs9467773	0.935	rs1884947	chr6:26553273	G/T	cg15659132	chr6:26577336	NA	0.85	11.54	0.72	2.22e-21	Intelligence (multi-trait analysis);
TGCT	cis	rs7582180	0.629	rs74177696	chr2:100938481	C/G	cg08017756	chr2:100939284	LONRF2	-0.3	-4.87	-0.4	3.37e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs8062405	0.823	rs7202948	chr16:28558289	T/A	cg09754948	chr16:28834200	ATXN2L	0.63	4.97	0.41	2.19e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs67079557	1	rs67079557	chr15:75930300	ATAATAAG/A	cg20655648	chr15:75932815	IMP3	0.61	4.88	0.4	3.24e-6	Breast cancer;
TGCT	cis	rs17030434	1.000	rs952211	chr4:154717816	A/G	cg14289246	chr4:154710475	SFRP2	-0.84	-5.35	-0.43	4.05e-7	Electrocardiographic conduction measures;
TGCT	cis	rs7474896	0.515	rs2738203	chr10:38277596	G/A	cg13720705	chr10:37990370	NA	-0.42	-5.36	-0.43	3.95e-7	Obesity (extreme);
TGCT	cis	rs4888262	0.526	rs4887777	chr16:74637821	A/G	cg01733217	chr16:74700730	RFWD3	0.74	7.3	0.55	2.97e-11	Testicular germ cell tumor;
TGCT	cis	rs2677744	1.000	rs2677744	chr15:91450441	A/G	cg22288577	chr15:91498497	RCCD1	-0.44	-4.51	-0.38	1.49e-5	Attention deficit hyperactivity disorder;
TGCT	cis	rs7267979	1.000	rs6050632	chr20:25432601	A/G	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9611519	0.808	rs5751074	chr22:41665722	G/A	cg06634786	chr22:41940651	POLR3H	-0.58	-5.32	-0.43	4.72e-7	Neuroticism;
TGCT	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg03351412	chr1:154909251	PMVK	0.52	4.91	0.4	2.77e-6	Prostate cancer;
TGCT	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg01416388	chr22:39784598	NA	-0.72	-7.15	-0.54	6.43e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs933688	1.000	rs1895448	chr5:90743854	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	9.32	0.64	5.46e-16	Smoking behavior;
TGCT	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg00814883	chr7:100076585	TSC22D4	-0.89	-9.26	-0.64	7.79e-16	Platelet count;
TGCT	cis	rs1577917	0.696	rs2842603	chr6:86336337	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-4.65	-0.39	8.52e-6	Response to antipsychotic treatment;
TGCT	cis	rs13064411	0.696	rs9808893	chr3:113228444	G/A	cg18753928	chr3:113234510	CCDC52	-0.71	-5.78	-0.46	5.63e-8	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs3782455	0.793	rs2290800	chr12:114404383	T/G	cg23502203	chr12:113549970	RASAL1	-0.55	-4.92	-0.4	2.7e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs9527	0.590	rs7906754	chr10:104782557	T/C	cg15744005	chr10:104629667	AS3MT	-0.42	-4.92	-0.4	2.74e-6	Arsenic metabolism;
TGCT	trans	rs459571	0.959	rs410876	chr9:136893867	C/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.73	-8.01	-0.58	7.15e-13	Platelet distribution width;
TGCT	cis	rs2204008	0.905	rs8189449	chr12:38437377	C/A	cg26384229	chr12:38710491	ALG10B	0.83	7.46	0.56	1.32e-11	Bladder cancer;
TGCT	cis	rs4074961	0.586	rs10908360	chr1:38058693	T/C	cg17933807	chr1:38061675	GNL2	0.94	10.45	0.68	1e-18	Axial length;
TGCT	cis	rs68170813	0.559	rs74387778	chr7:106963213	T/C	cg02696742	chr7:106810147	HBP1	-0.69	-5.61	-0.45	1.27e-7	Coronary artery disease;
TGCT	cis	rs1023500	0.573	rs13057094	chr22:42470317	T/C	cg05082376	chr22:42548792	NA	-0.22	-5.37	-0.43	3.69e-7	Schizophrenia;
TGCT	cis	rs709400	1.000	rs3783404	chr14:104118498	A/G	cg26031613	chr14:104095156	KLC1	1.14	17.16	0.84	1.53e-34	Body mass index;
TGCT	cis	rs12908161	0.959	rs35557864	chr15:85331629	A/G	cg17173187	chr15:85201210	NMB	0.55	6.11	0.48	1.17e-8	Schizophrenia;
TGCT	cis	rs6912958	0.781	rs9450755	chr6:88303702	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-4.57	-0.38	1.14e-5	Monocyte percentage of white cells;
TGCT	cis	rs68170813	0.559	rs75007274	chr7:106814543	G/A	cg02696742	chr7:106810147	HBP1	-0.7	-6.05	-0.48	1.59e-8	Coronary artery disease;
TGCT	cis	rs10791323	0.569	rs2298738	chr11:133715153	G/C	cg15485101	chr11:133734466	NA	0.4	5.02	0.41	1.78e-6	Childhood ear infection;
TGCT	cis	rs16958440	0.867	rs77149690	chr18:44697143	T/C	cg17192377	chr18:44677553	HDHD2	0.63	4.7	0.39	6.74e-6	Sitting height ratio;
TGCT	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.08	0.48	1.39e-8	Bipolar disorder;
TGCT	cis	rs62380364	0.542	rs601499	chr5:88052687	A/C	cg22951263	chr5:87985283	NA	-0.59	-6.32	-0.49	4.34e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs2114425	chr4:99023967	T/C	cg17366294	chr4:99064904	C4orf37	0.74	7.62	0.56	5.53e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs765787	0.530	rs28396110	chr15:45536909	A/G	cg24006582	chr15:45444508	DUOX1	-0.25	-5.54	-0.45	1.76e-7	Uric acid levels;
TGCT	cis	rs2742417	0.603	rs2742398	chr3:45759036	A/G	cg04837898	chr3:45731254	SACM1L	-0.66	-7.02	-0.53	1.27e-10	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs11711311	1.000	rs9865965	chr3:113450495	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.78	-7.13	-0.54	7.14e-11	IgG glycosylation;
TGCT	cis	rs4665630	0.614	rs6739646	chr2:23946840	A/C	cg08063864	chr2:24346004	PFN4;LOC375190	-1.23	-5.86	-0.47	3.98e-8	Hypertension;
TGCT	cis	rs11096990	0.656	rs3796513	chr4:39291082	G/A	cg20847110	chr4:39482781	LOC401127	-0.16	-4.51	-0.38	1.48e-5	Cognitive function;
TGCT	cis	rs9303401	0.659	rs34913878	chr17:56897094	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs2549003	1.000	rs2070724	chr5:131822072	A/G	cg21138405	chr5:131827807	IRF1	0.19	4.79	0.39	4.76e-6	Asthma (sex interaction);
TGCT	cis	rs12220238	0.908	rs10824086	chr10:75912668	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.06	0.54	1.05e-10	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs1371867	0.817	rs1660314	chr8:101332953	C/T	cg06636551	chr8:101224915	SPAG1	-0.48	-6.52	-0.51	1.62e-9	Atrioventricular conduction;
TGCT	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg06675538	chr2:114033490	PAX8;LOC440839	-0.42	-4.65	-0.39	8.23e-6	Lymphocyte counts;
TGCT	cis	rs4973397	0.774	rs12998237	chr2:232276651	T/C	cg09339159	chr2:232260559	B3GNT7	0.53	4.53	0.38	1.36e-5	Anti-saccade response;
TGCT	cis	rs9611565	0.649	rs2413659	chr22:42164862	A/G	cg06634786	chr22:41940651	POLR3H	0.78	7.34	0.55	2.49e-11	Vitiligo;
TGCT	cis	rs5769765	1.000	rs4597652	chr22:50270570	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.41	-6.13	-0.48	1.08e-8	Schizophrenia;
TGCT	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg10802521	chr3:52805072	NEK4	-0.72	-9.11	-0.63	1.82e-15	Bipolar disorder;
TGCT	cis	rs11779988	0.503	rs411173	chr8:17768264	G/A	cg01800426	chr8:17659068	MTUS1	-0.73	-5.71	-0.46	7.76e-8	Breast cancer;
TGCT	cis	rs36051895	0.589	rs10122037	chr9:5192874	A/G	cg02405213	chr9:5042618	JAK2	0.66	8.36	0.6	1.08e-13	Pediatric autoimmune diseases;
TGCT	cis	rs56176327	0.583	rs7613603	chr3:49812866	C/T	cg03034192	chr3:50606346	HEMK1;C3orf18	-0.36	-4.75	-0.39	5.61e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg21724239	chr8:58056113	NA	0.47	5.14	0.42	1.05e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7191439	0.522	rs4597303	chr16:88763561	T/C	cg27087555	chr16:88793112	FAM38A	-0.51	-4.57	-0.38	1.15e-5	Plateletcrit;
TGCT	cis	rs9457247	1.000	rs429083	chr6:167383972	T/C	cg23791538	chr6:167370224	RNASET2	-0.5	-4.98	-0.41	2.08e-6	Crohn's disease;
TGCT	cis	rs2204008	0.837	rs73112346	chr12:38357606	C/T	cg13010199	chr12:38710504	ALG10B	0.6	4.74	0.39	5.87e-6	Bladder cancer;
TGCT	cis	rs1577917	1.000	rs12665321	chr6:86769289	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.43	-0.44	2.86e-7	Response to antipsychotic treatment;
TGCT	cis	rs111332265	1	rs111332265	chr5:150393107	A/G	cg22134413	chr5:150180641	NA	0.82	5.07	0.41	1.43e-6	Tumor necrosis factor alpha levels;
TGCT	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.25	-4.45	-0.37	1.88e-5	Total body bone mineral density;
TGCT	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.72	5.14	0.42	1.06e-6	Platelet count;
TGCT	trans	rs931812	0.757	rs4734014	chr8:101908844	A/G	cg20993868	chr7:22813445	NA	0.32	6.68	0.51	7.28e-10	Attention deficit hyperactivity disorder and conduct disorder;
TGCT	cis	rs9372498	0.505	rs62424202	chr6:118851027	T/C	cg07617317	chr6:118971624	C6orf204	0.51	5.42	0.44	3e-7	Diastolic blood pressure;
TGCT	cis	rs7772486	0.875	rs6914813	chr6:146397798	A/G	cg05347473	chr6:146136440	FBXO30	0.52	4.8	0.4	4.41e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg11764359	chr7:65958608	NA	-0.61	-5.51	-0.44	1.96e-7	Aortic root size;
TGCT	trans	rs1814175	0.817	rs4405313	chr11:50013636	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.26	-0.55	3.77e-11	Height;
TGCT	cis	rs1395	0.626	rs72817537	chr2:27497549	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.62	8.02	0.58	6.76e-13	Blood metabolite levels;
TGCT	cis	rs425277	1.000	rs262647	chr1:2095699	C/T	cg03732007	chr1:2071316	PRKCZ	0.26	5.52	0.44	1.89e-7	Height;
TGCT	cis	rs12681287	0.640	rs4961193	chr8:87486168	C/T	cg19078186	chr8:87526527	CPNE3	0.36	4.63	0.38	9.24e-6	Caudate activity during reward;
TGCT	cis	rs11785400	0.793	rs35985277	chr8:143736137	C/T	cg24634471	chr8:143751801	JRK	0.54	5.33	0.43	4.51e-7	Schizophrenia;
TGCT	cis	rs11190604	1.000	rs2495752	chr10:102326115	T/C	cg16342193	chr10:102329863	NA	-0.4	-5.08	-0.42	1.32e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs10791323	0.604	rs2723607	chr11:133711018	C/G	cg15485101	chr11:133734466	NA	0.39	5.12	0.42	1.15e-6	Childhood ear infection;
TGCT	cis	rs1971762	0.563	rs7975862	chr12:54078427	A/C	cg16917193	chr12:54089295	NA	-1.33	-18.03	-0.85	1.9e-36	Height;
TGCT	cis	rs7666738	0.546	rs13149516	chr4:98913030	T/A	cg17366294	chr4:99064904	C4orf37	0.64	5.88	0.47	3.54e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg02725872	chr8:58115012	NA	-0.4	-5.09	-0.42	1.31e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs68170813	0.559	rs6967745	chr7:106850548	G/T	cg02696742	chr7:106810147	HBP1	-0.69	-5.61	-0.45	1.27e-7	Coronary artery disease;
TGCT	cis	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg25427524	chr10:38739819	LOC399744	-0.41	-8.54	-0.61	4.04e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg06697600	chr4:7070879	GRPEL1	-0.45	-4.74	-0.39	5.72e-6	Monocyte percentage of white cells;
TGCT	cis	rs992157	0.932	rs1870125	chr2:219187901	C/T	cg00012203	chr2:219082015	ARPC2	0.7	6.92	0.53	2.19e-10	Colorectal cancer;
TGCT	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg11965913	chr1:205819406	PM20D1	0.52	7.21	0.54	4.73e-11	Menarche (age at onset);
TGCT	cis	rs7582180	0.568	rs10186134	chr2:100939501	T/A	cg14675211	chr2:100938903	LONRF2	0.47	4.57	0.38	1.16e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7772486	0.875	rs854148	chr6:146310979	G/C	cg13319975	chr6:146136371	FBXO30	-0.53	-4.68	-0.39	7.44e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg22121687	chr7:65037720	NA	-0.78	-4.7	-0.39	6.74e-6	Diabetic kidney disease;
TGCT	cis	rs3847687	1.000	rs3847688	chr12:131525310	C/T	cg13586425	chr12:131519906	GPR133	-0.33	-5.26	-0.43	6.17e-7	Longevity;
TGCT	cis	rs7267979	0.966	rs2482918	chr20:25412135	C/T	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7523273	0.606	rs2488253	chr1:207938709	C/A	cg22525895	chr1:207977042	MIR29B2	0.53	8.71	0.62	1.62e-14	Schizophrenia;
TGCT	cis	rs13256369	0.851	rs13258283	chr8:8563630	T/C	cg17143192	chr8:8559678	CLDN23	0.57	5.35	0.43	4.09e-7	Obesity-related traits;
TGCT	cis	rs79387448	0.638	rs76255660	chr2:103091028	T/C	cg09003973	chr2:102972529	NA	1.32	9.88	0.66	2.54e-17	Gut microbiota (bacterial taxa);
TGCT	cis	rs2637266	0.678	rs1660918	chr10:78511674	T/A	cg18941641	chr10:78392320	NA	0.4	4.79	0.4	4.63e-6	Pulmonary function;
TGCT	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.31	-4.76	-0.39	5.36e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg06028808	chr11:68637592	NA	0.52	6.76	0.52	4.92e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs636291	0.517	rs2781233	chr1:10529194	T/C	cg17425144	chr1:10567563	PEX14	0.53	7.44	0.56	1.43e-11	Prostate cancer;
TGCT	trans	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg25482853	chr8:67687455	SGK3	1.16	10.5	0.69	7.91e-19	Lung disease severity in cystic fibrosis;
TGCT	cis	rs9611519	0.579	rs8136274	chr22:41415311	T/C	cg13695892	chr22:41940480	POLR3H	-0.54	-5.1	-0.42	1.21e-6	Neuroticism;
TGCT	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/A	cg09904177	chr6:26538194	HMGN4	0.65	6.02	0.48	1.8e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2404602	0.647	rs11634266	chr15:77093461	A/G	cg23625390	chr15:77176239	SCAPER	-0.38	-4.83	-0.4	4.01e-6	Blood metabolite levels;
TGCT	cis	rs2016266	0.784	rs6421176	chr12:53654052	A/G	cg16917193	chr12:54089295	NA	0.65	4.74	0.39	5.67e-6	Bone mineral density (spine);Bone mineral density;
TGCT	trans	rs5770872	0.511	rs56168974	chr22:50831338	A/G	cg09860653	chr1:19970708	NBL1	-0.75	-6.81	-0.52	3.82e-10	Tonsillectomy;
TGCT	cis	rs9914988	0.943	rs3181215	chr17:27077331	C/T	cg20469991	chr17:27169893	C17orf63	0.63	4.73	0.39	5.92e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs36051895	0.623	rs2381215	chr9:5262607	C/T	cg02405213	chr9:5042618	JAK2	-0.61	-7.38	-0.55	2.05e-11	Pediatric autoimmune diseases;
TGCT	cis	rs4919694	0.536	rs12256506	chr10:104963618	T/A	cg04362960	chr10:104952993	NT5C2	0.96	6.68	0.51	7.03e-10	Arsenic metabolism;
TGCT	cis	rs7909074	1.000	rs4948926	chr10:45392604	G/C	cg04218760	chr10:45406644	TMEM72	-0.27	-5.55	-0.45	1.64e-7	Mean corpuscular volume;
TGCT	cis	rs9921192	1.000	rs12444637	chr16:4345448	T/C	cg00021532	chr16:4324280	TFAP4	0.83	9.25	0.64	8.33e-16	Prostate-specific antigen levels;
TGCT	cis	rs2880765	0.566	rs12911430	chr15:86011264	A/T	cg13263323	chr15:86062960	AKAP13	-0.22	-4.85	-0.4	3.66e-6	Coronary artery disease;
TGCT	cis	rs9640161	0.659	rs11974980	chr7:150009838	C/T	cg17279839	chr7:150038598	RARRES2	0.42	4.45	0.37	1.88e-5	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs9894429	1.000	rs12948099	chr17:79600799	C/G	cg21028142	chr17:79581711	NPLOC4	0.3	6.98	0.53	1.57e-10	Eye color traits;
TGCT	cis	rs10089	0.904	rs3087889	chr5:127524944	T/A	cg19767477	chr5:127420684	SLC12A2	-0.44	-4.68	-0.39	7.35e-6	Ileal carcinoids;
TGCT	cis	rs9583531	0.527	rs9515274	chr13:111390429	A/G	cg24331049	chr13:111365604	ING1	0.75	7.38	0.55	1.97e-11	Coronary artery disease;
TGCT	cis	rs68170813	0.559	rs74906766	chr7:106885236	T/A	cg02696742	chr7:106810147	HBP1	-0.65	-5.38	-0.43	3.63e-7	Coronary artery disease;
TGCT	cis	rs2153535	0.580	rs3938660	chr6:8443335	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.58	0.45	1.42e-7	Motion sickness;
TGCT	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg23708337	chr7:1209742	NA	0.6	5.57	0.45	1.53e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg02725872	chr8:58115012	NA	-0.39	-5.15	-0.42	1.01e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10751667	0.961	rs7480178	chr11:927108	T/C	cg06064525	chr11:970664	AP2A2	-0.31	-6.11	-0.48	1.19e-8	Alzheimer's disease (late onset);
TGCT	cis	rs2013441	0.669	rs62066947	chr17:20351458	G/A	cg18979559	chr17:20280153	CCDC144C	0.55	5.73	0.46	7.29e-8	Obesity-related traits;
TGCT	cis	rs13191362	1.000	rs35818596	chr6:163001874	C/G	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs797680	0.964	rs2296558	chr1:93736555	C/T	cg17826107	chr1:92977322	EVI5	0.23	5.15	0.42	9.77e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	trans	rs561341	0.681	rs56064462	chr17:30235116	G/A	cg20587970	chr11:113659929	NA	-0.69	-9.4	-0.65	3.52e-16	Hip circumference adjusted for BMI;
TGCT	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg18765753	chr7:1198926	ZFAND2A	-0.53	-6.72	-0.52	6.02e-10	Longevity;Endometriosis;
TGCT	cis	rs9952991	0.941	rs2014857	chr18:12774326	C/T	cg09945482	chr18:12777974	NA	0.5	4.75	0.39	5.61e-6	Inflammatory skin disease;
TGCT	cis	rs10789491	1.000	rs4660956	chr1:47158486	A/G	cg15501359	chr1:47185051	KIAA0494	0.82	7.78	0.57	2.38e-12	Response to hepatitis C treatment;
TGCT	cis	rs13082711	0.522	rs514668	chr3:27330972	A/G	cg02860705	chr3:27208620	NA	0.34	5.58	0.45	1.43e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs6598955	0.724	rs10902731	chr1:26600793	A/G	cg04990556	chr1:26633338	UBXN11	-0.9	-11.22	-0.71	1.34e-20	Obesity-related traits;
TGCT	cis	rs317865	0.737	rs28483204	chr4:16205098	A/G	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.77	5.08	0.42	1.32e-6	Kidney disease (early stage) in type 1 diabetes;
TGCT	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6893807	0.778	rs13174131	chr5:87959538	T/G	cg24804195	chr5:87968844	LOC645323	0.82	5.1	0.42	1.24e-6	Body mass index;
TGCT	cis	rs910316	1.000	rs7156328	chr14:75532941	T/C	cg11812906	chr14:75593930	NEK9	0.74	7.25	0.55	3.9e-11	Height;
TGCT	cis	rs2840044	1.000	rs225243	chr17:33947212	A/G	cg05299278	chr17:33885742	SLFN14	0.23	5.07	0.41	1.39e-6	Response to radiotherapy in cancer (late toxicity);
TGCT	cis	rs58688157	0.924	rs35865896	chr11:584591	A/G	cg16486109	chr11:613632	IRF7	0.35	5.08	0.42	1.34e-6	Systemic lupus erythematosus;
TGCT	cis	rs13256369	0.950	rs1522839	chr8:8580453	C/T	cg18904891	chr8:8559673	CLDN23	0.63	5.47	0.44	2.36e-7	Obesity-related traits;
TGCT	cis	rs6748734	0.543	rs73012754	chr2:241754034	G/A	cg04034577	chr2:241836375	C2orf54	0.32	5.12	0.42	1.15e-6	Urinary metabolites;
TGCT	cis	rs17539620	0.506	rs62432749	chr6:154839219	G/A	cg20019720	chr6:154832845	CNKSR3	0.57	4.99	0.41	2.02e-6	Lipoprotein (a) levels;
TGCT	cis	rs778371	0.723	rs12619195	chr2:233678326	G/A	cg08000102	chr2:233561755	GIGYF2	-0.72	-8.68	-0.61	1.91e-14	Schizophrenia;
TGCT	cis	rs17376456	0.932	rs3940842	chr5:93534858	C/A	cg21475434	chr5:93447410	FAM172A	0.61	4.51	0.38	1.47e-5	Diabetic retinopathy;
TGCT	cis	rs3820928	0.874	rs2229813	chr2:227892720	C/T	cg11843606	chr2:227700838	RHBDD1	-0.54	-4.96	-0.41	2.29e-6	Pulmonary function;
TGCT	cis	rs10791097	0.720	rs6590515	chr11:130733365	A/G	cg14779329	chr11:130786720	SNX19	-0.29	-5.1	-0.42	1.24e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs11148252	0.564	rs2296350	chr13:52710044	T/C	cg00495681	chr13:53174319	NA	0.57	5.86	0.47	3.84e-8	Lewy body disease;
TGCT	cis	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg06636001	chr8:8085503	FLJ10661	0.67	6.12	0.48	1.13e-8	Mood instability;
TGCT	cis	rs2013441	1.000	rs1561974	chr17:20196144	G/A	cg23224458	chr17:20280056	CCDC144C	-0.42	-4.91	-0.4	2.82e-6	Obesity-related traits;
TGCT	cis	rs7617773	0.676	rs13060020	chr3:48372646	C/T	cg11946769	chr3:48343235	NME6	0.81	6.96	0.53	1.71e-10	Coronary artery disease;
TGCT	cis	rs10791097	0.694	rs2155751	chr11:130755240	G/A	cg12179176	chr11:130786555	SNX19	0.82	10.15	0.67	5.45e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9611565	0.694	rs11090056	chr22:42095904	A/C	cg06481639	chr22:41940642	POLR3H	0.57	4.86	0.4	3.51e-6	Vitiligo;
TGCT	cis	rs7674212	0.570	rs12501621	chr4:104095505	T/G	cg16532752	chr4:104119610	CENPE	-0.61	-5.67	-0.45	9.45e-8	Type 2 diabetes;
TGCT	cis	rs1061377	1.000	rs10027813	chr4:39121438	T/A	cg24403649	chr4:39172243	NA	0.18	4.44	0.37	1.99e-5	Uric acid levels;
TGCT	cis	rs12210905	0.688	rs12212348	chr6:27361242	T/C	cg08851530	chr6:28072375	NA	1.32	5.79	0.46	5.48e-8	Hip circumference adjusted for BMI;
TGCT	cis	rs6558174	0.863	rs17746902	chr8:22491980	A/C	cg03733263	chr8:22462867	KIAA1967	-0.57	-4.88	-0.4	3.14e-6	Breast cancer;
TGCT	cis	rs2115630	0.691	rs2292462	chr15:85200754	G/T	cg12863693	chr15:85201151	NMB	-0.42	-5.7	-0.46	8.25e-8	P wave terminal force;
TGCT	cis	rs9859260	0.744	rs419059	chr3:195782184	C/T	cg02975922	chr3:195473998	MUC4	0.25	5.1	0.42	1.24e-6	Mean corpuscular volume;
TGCT	cis	rs7666738	0.830	rs1426672	chr4:98923984	T/C	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs909341	0.537	rs4809334	chr20:62384972	G/A	cg14758556	chr20:62440591	NA	0.38	5.44	0.44	2.7e-7	Atopic dermatitis;
TGCT	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	12.73	0.75	2.98e-24	Prudent dietary pattern;
TGCT	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg08280861	chr8:58055591	NA	0.38	4.81	0.4	4.36e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs832540	0.830	rs252907	chr5:56120646	G/A	cg24531977	chr5:56204891	C5orf35	-0.52	-5.39	-0.44	3.44e-7	Coronary artery disease;
TGCT	cis	rs11030122	0.661	rs10835561	chr11:4087594	C/T	cg18678763	chr11:4115507	RRM1	-0.46	-5.67	-0.45	9.61e-8	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs2469997	0.858	rs2470031	chr8:120370390	T/A	cg00681363	chr8:120844660	TAF2	0.69	4.48	0.37	1.64e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs6770219	0.516	rs57506565	chr3:186139358	T/C	cg20306810	chr3:186501757	SNORD2;EIF4A2	0.73	4.45	0.37	1.89e-5	Cerebrospinal T-tau levels;
TGCT	cis	rs2806561	0.765	rs652706	chr1:23514246	G/A	cg12483005	chr1:23474871	LUZP1	0.38	4.73	0.39	5.93e-6	Height;
TGCT	cis	rs2921073	0.604	rs2979140	chr8:8267202	T/A	cg06636001	chr8:8085503	FLJ10661	0.55	4.72	0.39	6.21e-6	Parkinson's disease;
TGCT	cis	rs4727027	0.901	rs4727017	chr7:148822062	A/G	cg23583168	chr7:148888333	NA	-0.72	-9.18	-0.64	1.18e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs2439831	0.717	rs7165471	chr15:43644788	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	6.61	0.51	1e-9	Lung cancer in ever smokers;
TGCT	cis	rs909674	0.731	rs4821897	chr22:39835587	A/G	cg02038168	chr22:39784481	NA	-0.74	-5.59	-0.45	1.35e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs9393692	0.905	rs989134	chr6:26336224	A/C	cg13736514	chr6:26305472	NA	-0.36	-5.11	-0.42	1.21e-6	Educational attainment;
TGCT	cis	rs6840360	0.642	rs1443089	chr4:152450300	A/G	cg17479576	chr4:152424074	FAM160A1	-0.62	-6.73	-0.52	5.67e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs911555	0.755	rs2756135	chr14:103962579	G/A	cg12935359	chr14:103987150	CKB	0.32	4.5	0.37	1.57e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs9296092	0.517	rs7743445	chr6:33470600	G/T	cg13560919	chr6:33536144	NA	-0.22	-4.49	-0.37	1.6e-5	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.49	-5.52	-0.44	1.87e-7	Longevity;Endometriosis;
TGCT	cis	rs16870629	0.541	rs2334955	chr5:1062444	A/G	cg00278107	chr5:1061253	SLC12A7	-0.35	-7.67	-0.57	4.42e-12	QT interval;
TGCT	cis	rs7824557	0.564	rs34389419	chr8:11229319	C/G	cg21775007	chr8:11205619	TDH	-0.6	-5.61	-0.45	1.27e-7	Retinal vascular caliber;
TGCT	cis	rs9296092	0.538	rs78061112	chr6:33526587	T/G	cg13560919	chr6:33536144	NA	-0.23	-5.06	-0.41	1.49e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs11096990	0.551	rs11724855	chr4:39164999	G/A	cg20847110	chr4:39482781	LOC401127	0.17	4.86	0.4	3.49e-6	Cognitive function;
TGCT	cis	rs6988636	1.000	rs13260775	chr8:124190167	G/A	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs6665290	0.839	rs6699400	chr1:227190497	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.01	-21.05	-0.88	9.26e-43	Myeloid white cell count;
TGCT	cis	rs6665290	0.870	rs17600725	chr1:227204231	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.92	-16.67	-0.83	1.9e-33	Myeloid white cell count;
TGCT	cis	rs6484504	0.532	rs12788257	chr11:31255045	T/C	cg14844989	chr11:31128820	NA	-0.25	-4.89	-0.4	3e-6	Red blood cell count;
TGCT	cis	rs2832191	1.000	rs2832183	chr21:30482150	G/A	cg08807101	chr21:30365312	RNF160	-0.49	-4.48	-0.37	1.65e-5	Dental caries;
TGCT	cis	rs2204008	0.774	rs11520237	chr12:38266978	G/A	cg26384229	chr12:38710491	ALG10B	0.86	7.48	0.56	1.19e-11	Bladder cancer;
TGCT	cis	rs644799	0.965	rs549695	chr11:95617788	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	9.93	0.67	1.91e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs1697139	0.563	rs6859520	chr5:66529020	C/T	cg11553311	chr5:66541588	NA	0.3	6.37	0.5	3.36e-9	Breast cancer;
TGCT	cis	rs751728	1.000	rs2296747	chr6:33744882	C/G	cg00334056	chr6:33755658	LEMD2	-0.26	-4.72	-0.39	6.25e-6	Crohn's disease;
TGCT	cis	rs3027009	0.881	rs56184975	chr1:159149253	G/T	cg24432768	chr1:158149974	CD1D	-0.55	-4.76	-0.39	5.41e-6	Lean body mass and age at menarche (combined);
TGCT	cis	rs514406	0.893	rs1242317	chr1:53414766	T/C	cg08859206	chr1:53392774	SCP2	-0.41	-6.31	-0.49	4.48e-9	Monocyte count;
TGCT	cis	rs941873	0.772	rs2000404	chr10:81109708	T/C	cg09469691	chr10:81107165	PPIF	0.5	4.96	0.41	2.27e-6	Height;
TGCT	cis	rs3617	0.573	rs13072537	chr3:52896032	C/A	cg11645453	chr3:52864694	ITIH4	0.26	4.96	0.41	2.24e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4460629	0.680	rs10796938	chr1:155072055	C/A	cg23973274	chr1:155060172	NA	-0.26	-4.66	-0.39	7.99e-6	Serum magnesium levels;
TGCT	cis	rs6674176	0.561	rs12127226	chr1:44395309	C/T	cg13606994	chr1:44402422	ARTN	-0.5	-5.48	-0.44	2.3e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	4.62	0.38	9.36e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs1580019	0.587	rs6951955	chr7:32548761	A/T	cg07520158	chr7:32535189	LSM5;AVL9	0.58	4.96	0.41	2.25e-6	Cognitive ability;
TGCT	cis	rs10484885	0.887	rs2273246	chr6:90453263	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.45	-4.66	-0.39	7.9e-6	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs17122693	0.748	rs76141309	chr14:51110947	A/C	cg04730355	chr14:51134070	SAV1	1.04	6.2	0.49	7.67e-9	Cognitive performance;
TGCT	cis	rs7267979	0.789	rs6083810	chr20:25329759	T/A	cg16686733	chr20:25566563	NINL	-0.49	-4.62	-0.38	9.44e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs12220238	0.822	rs10824193	chr10:76261759	G/T	cg19889307	chr10:75911429	ADK;AP3M1	0.89	5.7	0.46	8.36e-8	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs896854	0.684	rs2340534	chr8:95992330	G/A	cg09323728	chr8:95962352	TP53INP1	-0.48	-6.19	-0.49	7.95e-9	Type 2 diabetes;
TGCT	cis	rs7226408	0.948	rs11665141	chr18:34374865	A/G	cg06757138	chr18:34340585	FHOD3	0.25	4.56	0.38	1.2e-5	Obesity-related traits;
TGCT	cis	rs3780378	0.935	rs6476939	chr9:5084837	T/A	cg02405213	chr9:5042618	JAK2	-0.62	-8.18	-0.59	2.86e-13	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs9309473	0.660	rs11679594	chr2:73779507	G/A	cg07208825	chr2:73871855	ALMS1P	0.23	4.48	0.37	1.65e-5	Metabolite levels;
TGCT	cis	rs6450176	1.000	rs3776705	chr5:53304955	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.49	-4.6	-0.38	1.03e-5	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs11690935	0.655	rs12997093	chr2:172564438	A/G	cg13550731	chr2:172543902	DYNC1I2	0.67	5.86	0.47	3.89e-8	Schizophrenia;
TGCT	cis	rs911263	0.961	rs7148882	chr14:68740924	A/G	cg18825221	chr14:68749962	RAD51L1	-0.28	-5.47	-0.44	2.41e-7	Primary biliary cholangitis;
TGCT	cis	rs453301	0.686	rs7814328	chr8:8876229	T/C	cg11995313	chr8:8860691	ERI1	0.53	4.63	0.38	8.93e-6	Joint mobility (Beighton score);
TGCT	cis	rs79349575	0.783	rs15563	chr17:47005193	A/G	cg00947319	chr17:47005597	UBE2Z	-0.21	-4.88	-0.4	3.21e-6	Type 2 diabetes;
TGCT	cis	rs1215050	0.791	rs503863	chr4:98707663	T/C	cg17366294	chr4:99064904	C4orf37	0.52	5.61	0.45	1.27e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs12477438	0.834	rs1563108	chr2:99701153	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-6.12	-0.48	1.13e-8	Chronic sinus infection;
TGCT	cis	rs4988958	0.527	rs3771155	chr2:103037826	A/G	cg03938978	chr2:103052716	IL18RAP	0.27	5.4	0.44	3.31e-7	Asthma (childhood onset);
TGCT	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg11494091	chr17:61959527	GH2	0.61	14.43	0.79	2.59e-28	Prudent dietary pattern;
TGCT	cis	rs35306767	0.953	rs35693858	chr10:979813	C/T	cg18964960	chr10:1102726	WDR37	0.56	4.47	0.37	1.74e-5	Eosinophil percentage of granulocytes;
TGCT	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.41	4.6	0.38	1.03e-5	Blood metabolite levels;
TGCT	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg14004847	chr7:1930337	MAD1L1	-0.26	-4.46	-0.37	1.83e-5	Schizophrenia;
TGCT	cis	rs8062405	1.000	rs4788102	chr16:28873398	G/A	cg09754948	chr16:28834200	ATXN2L	0.59	4.45	0.37	1.91e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs7568458	0.709	rs762684	chr2:85782023	G/A	cg02493740	chr2:85810744	VAMP5	-0.28	-5.37	-0.43	3.67e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs10875746	0.669	rs10467101	chr12:48607737	T/C	cg20731937	chr12:48336164	NA	0.59	4.52	0.38	1.45e-5	Longevity (90 years and older);
TGCT	trans	rs1814175	0.904	rs1846289	chr11:49620253	G/A	cg15704280	chr7:45808275	SEPT13	-0.61	-6.8	-0.52	4.02e-10	Height;
TGCT	cis	rs2354432	0.607	rs11587707	chr1:146707186	T/C	cg25205988	chr1:146714368	CHD1L	-1.15	-4.8	-0.4	4.49e-6	Mitochondrial DNA levels;
TGCT	cis	rs1982963	1.000	rs753051	chr14:52505360	A/G	cg10843707	chr14:52510701	NID2	-0.43	-6.6	-0.51	1.09e-9	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2295359	1.000	rs10889661	chr1:67625309	T/A	cg12940439	chr1:67600707	NA	0.54	5.72	0.46	7.49e-8	Psoriasis;
TGCT	cis	rs7666738	0.830	rs7659420	chr4:98878714	G/C	cg17366294	chr4:99064904	C4orf37	0.74	7.62	0.56	5.55e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2013441	1.000	rs2703780	chr17:20143672	A/G	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.63	-0.38	9.19e-6	Obesity-related traits;
TGCT	cis	rs9372498	0.505	rs62422248	chr6:118987610	T/C	cg21191810	chr6:118973309	C6orf204	-0.38	-4.95	-0.41	2.39e-6	Diastolic blood pressure;
TGCT	cis	rs2836950	0.502	rs12627205	chr21:40630027	C/T	cg11644478	chr21:40555479	PSMG1	-0.55	-5.18	-0.42	8.7e-7	Menarche (age at onset);
TGCT	cis	rs12477438	0.834	rs1563107	chr2:99701276	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.66	5.78	0.46	5.58e-8	Chronic sinus infection;
TGCT	cis	rs9427116	0.502	rs903323	chr1:154572228	A/G	cg17218026	chr1:154582156	ADAR	-0.3	-7.91	-0.58	1.21e-12	Blood protein levels;
TGCT	cis	rs9325144	0.555	rs2387855	chr12:38687964	T/G	cg26384229	chr12:38710491	ALG10B	0.66	6.12	0.48	1.11e-8	Morning vs. evening chronotype;
TGCT	cis	rs477895	1.000	rs7947143	chr11:64090422	G/A	cg23719950	chr11:63933701	MACROD1	-0.59	-4.6	-0.38	1.01e-5	Mean platelet volume;
TGCT	cis	rs710216	0.571	rs11210772	chr1:43448499	A/G	cg03128534	chr1:43423976	SLC2A1	-0.55	-4.68	-0.39	7.25e-6	Red cell distribution width;
TGCT	cis	rs9894429	0.789	rs7502346	chr17:79603741	T/C	cg21028142	chr17:79581711	NPLOC4	0.3	7.03	0.53	1.2e-10	Eye color traits;
TGCT	cis	rs1580019	0.522	rs10951340	chr7:32562408	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.57	4.86	0.4	3.43e-6	Cognitive ability;
TGCT	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg22920501	chr2:26401640	FAM59B	-0.78	-6.16	-0.48	9.43e-9	Gut microbiome composition (summer);
TGCT	cis	rs3733585	0.699	rs6852441	chr4:9973744	C/T	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.68	-0.57	4.13e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs9291683	0.632	rs11734786	chr4:10041499	A/C	cg00071950	chr4:10020882	SLC2A9	0.68	8.73	0.62	1.45e-14	Bone mineral density;
TGCT	cis	rs514406	0.758	rs532242	chr1:53308665	C/G	cg01802117	chr1:53393560	SCP2	-0.42	-4.93	-0.41	2.54e-6	Monocyte count;
TGCT	cis	rs1403694	0.515	rs1648697	chr3:186449194	A/G	cg12454167	chr3:186435060	KNG1	0.46	7.19	0.54	5.47e-11	Blood protein levels;
TGCT	cis	rs644799	1.000	rs12291986	chr11:95523030	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	8.74	0.62	1.39e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs13147768	chr4:98833675	A/T	cg18180107	chr4:99064573	C4orf37	0.56	5.18	0.42	8.78e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs858239	0.899	rs28635122	chr7:23310181	C/T	cg05602783	chr7:23145260	KLHL7	-0.66	-5.26	-0.43	6.04e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs9796	0.621	rs2578655	chr15:41462809	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.54	-7.22	-0.54	4.66e-11	Menopause (age at onset);
TGCT	cis	rs2380220	0.576	rs4368819	chr6:96031109	T/G	cg04719120	chr6:96025338	MANEA	0.73	5.48	0.44	2.31e-7	Behavioural disinhibition (generation interaction);
TGCT	cis	rs9611565	0.592	rs5996039	chr22:41981957	A/G	cg03806693	chr22:41940476	POLR3H	-1.01	-10.2	-0.68	4.07e-18	Vitiligo;
TGCT	cis	rs950027	0.596	rs2467853	chr15:45698793	T/G	cg26924012	chr15:45694286	SPATA5L1	0.8	9.1	0.63	1.83e-15	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs7267979	0.565	rs13040726	chr20:25559881	T/G	cg03522245	chr20:25566470	NINL	-0.44	-4.59	-0.38	1.06e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs651907	0.557	rs13069443	chr3:101373305	C/T	cg12386194	chr3:101231763	SENP7	0.53	5.13	0.42	1.08e-6	Colorectal cancer;
TGCT	cis	rs41271473	0.526	rs10916344	chr1:228737489	C/T	cg16512390	chr1:228756714	NA	0.72	4.44	0.37	1.96e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs1568079	0.516	rs1571424	chr10:125220311	G/A	cg04278168	chr10:124578263	NA	-0.42	-4.62	-0.38	9.35e-6	Body mass index;
TGCT	cis	rs854765	0.583	rs8065970	chr17:17858771	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	7.69	0.57	3.98e-12	Total body bone mineral density;
TGCT	cis	rs7191439	0.522	rs745326	chr16:88755245	C/G	cg26511997	chr16:89237975	CDH15	0.82	4.44	0.37	1.98e-5	Plateletcrit;
TGCT	cis	rs7246657	0.653	rs10401525	chr19:37658979	C/G	cg24025825	chr19:37761650	NA	-0.33	-5.06	-0.41	1.49e-6	Coronary artery calcification;
TGCT	cis	rs7772486	0.840	rs2474355	chr6:146312540	C/G	cg23711669	chr6:146136114	FBXO30	0.84	9.07	0.63	2.25e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2228479	0.572	rs62054252	chr16:89896834	G/A	cg06558623	chr16:89946397	TCF25	0.55	4.77	0.39	5.13e-6	Skin colour saturation;
TGCT	trans	rs2727020	0.658	rs4980440	chr11:49386017	C/T	cg15704280	chr7:45808275	SEPT13	-0.74	-8.21	-0.59	2.38e-13	Coronary artery disease;
TGCT	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg24549020	chr5:56110836	MAP3K1	0.67	5.78	0.46	5.74e-8	Initial pursuit acceleration;
TGCT	cis	rs3099143	1.000	rs10431768	chr15:77162158	A/G	cg21673338	chr15:77095150	SCAPER	0.54	5.15	0.42	1.01e-6	Recalcitrant atopic dermatitis;
TGCT	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg13732083	chr21:47605072	C21orf56	0.34	4.52	0.38	1.44e-5	Testicular germ cell tumor;
TGCT	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg21433313	chr16:3507492	NAT15	0.39	5.08	0.41	1.36e-6	Tuberculosis;
TGCT	cis	rs11677416	1.000	rs1040193	chr2:113530099	C/T	cg27083787	chr2:113543245	IL1A	0.18	4.5	0.37	1.53e-5	Response to antipsychotic treatment in schizophrenia (working memory);
TGCT	cis	rs8103278	0.826	rs11669442	chr19:46374557	A/G	cg11657440	chr19:46296263	DMWD	-0.63	-6.05	-0.48	1.62e-8	Coronary artery disease;
TGCT	cis	rs1577917	0.958	rs114467802	chr6:86572350	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.29	-0.43	5.34e-7	Response to antipsychotic treatment;
TGCT	cis	rs362272	0.505	rs10155132	chr4:3369500	A/G	cg06533319	chr4:3265114	C4orf44	-0.27	-5.6	-0.45	1.3e-7	Serum sulfate level;
TGCT	cis	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.88	9.59	0.65	1.28e-16	Platelet count;
TGCT	cis	rs4730250	0.655	rs4727671	chr7:106876045	A/G	cg02696742	chr7:106810147	HBP1	-0.66	-5.51	-0.44	1.94e-7	Osteoarthritis;
TGCT	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg08280861	chr8:58055591	NA	0.39	4.86	0.4	3.45e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs12210905	0.688	rs72839471	chr6:27316959	C/T	cg08851530	chr6:28072375	NA	1.25	5.39	0.44	3.38e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs10225163	0.590	rs10266923	chr7:27918229	C/T	cg05786569	chr7:27702416	HIBADH	-0.55	-5.22	-0.42	7.2e-7	Gout;
TGCT	cis	rs13102973	0.965	rs13126242	chr4:135860948	T/C	cg14419869	chr4:135874104	NA	0.24	4.49	0.37	1.6e-5	Subjective well-being;
TGCT	trans	rs11082438	0.786	rs11660485	chr18:42866471	A/C	cg11883238	chr10:62676418	RHOBTB1	-0.7	-6.8	-0.52	4.03e-10	Follicular lymphoma;
TGCT	cis	rs3540	0.576	rs10152871	chr15:91047469	G/A	cg22089800	chr15:90895588	ZNF774	-0.74	-7.48	-0.56	1.17e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs2739330	0.615	rs2858911	chr22:24297195	G/T	cg18538332	chr22:24372958	LOC391322	-0.99	-12.8	-0.75	2e-24	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs539096	0.872	rs3791138	chr1:44050027	A/C	cg12908607	chr1:44402522	ARTN	-0.48	-4.94	-0.41	2.46e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6684514	1.000	rs2273832	chr1:156233143	A/G	cg16558208	chr1:156270281	VHLL	0.48	9.29	0.64	6.47e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg09222892	chr1:25734099	RHCE	-0.42	-6.7	-0.52	6.56e-10	Erythrocyte sedimentation rate;
TGCT	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg23758822	chr17:41437982	NA	0.78	7.29	0.55	3.14e-11	Menopause (age at onset);
TGCT	cis	rs8038465	0.592	rs899981	chr15:73935329	G/A	cg15420318	chr15:73925796	NPTN	0.67	6.96	0.53	1.75e-10	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7666738	0.830	rs10856936	chr4:99011319	T/C	cg05340658	chr4:99064831	C4orf37	0.48	5.53	0.44	1.79e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1008375	1.000	rs3846357	chr4:17635887	A/T	cg10189774	chr4:17578691	LAP3	0.62	5.5	0.44	2.08e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4711350	0.734	rs4713676	chr6:33722098	G/T	cg18005901	chr6:33739558	LEMD2	0.5	5.72	0.46	7.42e-8	Schizophrenia;
TGCT	cis	rs42648	0.935	rs2188232	chr7:89958314	A/C	cg25739043	chr7:89950458	NA	-0.77	-7.39	-0.55	1.93e-11	Homocysteine levels;
TGCT	cis	rs9653442	0.564	rs12712071	chr2:100793876	G/A	cg22139774	chr2:100720529	AFF3	-0.35	-5.35	-0.43	4.16e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs4786125	0.622	rs1492372	chr16:6920965	C/T	cg03623568	chr16:6915990	A2BP1	-0.43	-5.88	-0.47	3.49e-8	Heart rate variability traits (SDNN);
TGCT	cis	rs3806843	0.547	rs246054	chr5:140326159	G/A	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs3806843	0.551	rs184996	chr5:140323773	T/A	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs6728642	1.000	rs17037402	chr2:98014883	C/T	cg26665480	chr2:98280029	ACTR1B	-0.98	-4.98	-0.41	2.09e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg11890956	chr21:40555474	PSMG1	-0.72	-6.51	-0.5	1.67e-9	Cognitive function;
TGCT	cis	rs5769765	0.624	rs138843	chr22:50183162	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.33	4.66	0.39	7.9e-6	Schizophrenia;
TGCT	cis	rs2797160	1.000	rs1739376	chr6:126012084	C/G	cg05901451	chr6:126070800	HEY2	0.59	4.65	0.39	8.23e-6	Endometrial cancer;
TGCT	cis	rs2463822	1.000	rs2513052	chr11:62108248	C/G	cg23876832	chr11:62092739	NA	0.67	4.91	0.4	2.82e-6	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs67311347	1.000	rs73080165	chr3:40533062	G/T	cg02782426	chr3:40428986	ENTPD3	0.44	4.74	0.39	5.88e-6	Renal cell carcinoma;
TGCT	cis	rs7599312	0.534	rs7596285	chr2:213406961	G/A	cg20637307	chr2:213403960	ERBB4	0.91	11.42	0.72	4.5e-21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs3812049	0.784	rs2617617	chr5:127455008	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	5.87	0.47	3.81e-8	Lymphocyte counts;Red cell distribution width;
TGCT	cis	rs79149102	0.579	rs3816261	chr15:75336173	T/A	cg09165964	chr15:75287851	SCAMP5	-1.05	-5.56	-0.45	1.59e-7	Lung cancer;
TGCT	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg12667521	chr19:29218732	NA	0.49	5.8	0.46	5.2100000000000003e-08	Methadone dose in opioid dependence;
TGCT	cis	rs7772486	0.875	rs2207785	chr6:146332784	T/G	cg05347473	chr6:146136440	FBXO30	0.52	4.98	0.41	2.12e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11578119	0.933	rs12124354	chr1:170415362	G/C	cg09767346	chr1:170501363	GORAB	0.71	5.69	0.46	8.66e-8	Male-pattern baldness;
TGCT	cis	rs250677	0.958	rs36070	chr5:148417240	T/C	cg23229984	chr5:148520753	ABLIM3	0.21	4.81	0.4	4.35e-6	Breast cancer;
TGCT	cis	rs8013055	0.846	rs12893999	chr14:105970842	C/G	cg25008857	chr14:105974488	NA	0.28	4.65	0.39	8.41e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg04944784	chr2:26401820	FAM59B	-0.76	-6.24	-0.49	6.46e-9	Gut microbiome composition (summer);
TGCT	cis	rs12510870	0.634	rs11728915	chr4:74410237	G/A	cg05868023	chr4:75230803	EREG	0.56	5.14	0.42	1.06e-6	Iris color (b* coordinate);
TGCT	cis	rs9303401	0.659	rs12602808	chr17:56698420	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs6088580	0.608	rs2105109	chr20:32971932	A/G	cg24642439	chr20:33292090	TP53INP2	-0.49	-4.49	-0.37	1.59e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs4919044	0.808	rs2486680	chr10:94805529	C/T	cg05127821	chr10:94822908	CYP26C1	-0.74	-4.83	-0.4	3.95e-6	Coronary artery disease;
TGCT	cis	rs7666738	0.546	rs11727151	chr4:98837353	A/C	cg05340658	chr4:99064831	C4orf37	0.54	5.87	0.47	3.68e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7666738	0.830	rs17486413	chr4:99060544	G/T	cg18180107	chr4:99064573	C4orf37	0.57	5.17	0.42	9.06e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs904251	0.828	rs1757174	chr6:37486695	G/A	cg08126542	chr6:37504118	NA	-0.45	-6.02	-0.48	1.79e-8	Cognitive performance;
TGCT	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg06873352	chr17:61820015	STRADA	0.59	6.44	0.5	2.37e-9	Prudent dietary pattern;
TGCT	cis	rs9894429	0.646	rs8079963	chr17:79603285	C/T	cg18240062	chr17:79603768	NPLOC4	0.56	4.92	0.4	2.67e-6	Eye color traits;
TGCT	cis	rs1865760	0.827	rs9295680	chr6:25944103	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.65	6.39	0.5	3.02e-9	Height;
TGCT	cis	rs1401999	1.000	rs4148571	chr3:183720576	A/C	cg01324343	chr3:183735012	ABCC5	0.83	11.15	0.71	2.01e-20	Anterior chamber depth;
TGCT	cis	rs394563	0.589	rs1900300	chr6:149641627	T/C	cg03678062	chr6:149772716	ZC3H12D	0.37	4.75	0.39	5.59e-6	Dupuytren's disease;
TGCT	cis	rs1008375	0.966	rs2286773	chr4:17616214	C/A	cg18681998	chr4:17616180	MED28	1.07	12.29	0.74	3.39e-23	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.97	-7.19	-0.54	5.48e-11	Gut microbiome composition (summer);
TGCT	cis	rs7829975	0.572	rs7005000	chr8:8796602	A/G	cg06636001	chr8:8085503	FLJ10661	-0.73	-6.58	-0.51	1.21e-9	Mood instability;
TGCT	cis	rs6088590	0.561	rs764597	chr20:33161225	C/T	cg08999081	chr20:33150536	PIGU	0.25	4.99	0.41	1.97e-6	Coronary artery disease;
TGCT	trans	rs853410	0.516	rs4959915	chr6:4001020	T/C	cg13911294	chr9:88951310	ZCCHC6	-0.64	-6.66	-0.51	8.02e-10	Night sleep phenotypes;
TGCT	cis	rs7937682	0.774	rs59921976	chr11:111473088	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.07	-11.36	-0.71	6.1e-21	Primary sclerosing cholangitis;
TGCT	cis	rs7973719	1.000	rs12828040	chr12:7326541	T/C	cg07052231	chr12:7363540	PEX5	0.33	5.08	0.42	1.32e-6	IgG glycosylation;
TGCT	cis	rs672889	0.525	rs558130	chr2:21381689	T/G	cg25035485	chr2:21266500	APOB	0.51	4.48	0.37	1.66e-5	Cholesterol, total;
TGCT	cis	rs6725041	0.819	rs1546718	chr2:213088329	A/G	cg20637307	chr2:213403960	ERBB4	-0.52	-4.47	-0.37	1.72e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs10782582	0.593	rs17585530	chr1:76134990	G/A	cg03433033	chr1:76189801	ACADM	-0.64	-7.32	-0.55	2.78e-11	Daytime sleep phenotypes;
TGCT	cis	rs4722166	0.695	rs7793125	chr7:22809160	A/G	cg26061582	chr7:22766209	IL6	0.48	6.02	0.48	1.8e-8	Lung cancer;
TGCT	cis	rs1971762	0.563	rs7958775	chr12:54077556	T/C	cg16917193	chr12:54089295	NA	1.37	17.65	0.85	1.25e-35	Height;
TGCT	cis	rs77741769	0.571	rs61946382	chr12:121344574	A/T	cg02419362	chr12:121203948	SPPL3	0.19	4.49	0.37	1.63e-5	Mean corpuscular volume;
TGCT	cis	rs7819412	0.594	rs7460507	chr8:10969075	C/T	cg21775007	chr8:11205619	TDH	-0.5	-5.02	-0.41	1.78e-6	Triglycerides;
TGCT	cis	rs921968	0.509	rs72963905	chr2:219547027	T/G	cg02176678	chr2:219576539	TTLL4	-0.5	-6.93	-0.53	2.02e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs11792861	0.926	rs7856626	chr9:111775502	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.49	4.5	0.37	1.56e-5	Menarche (age at onset);
TGCT	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg00684032	chr4:1343700	KIAA1530	0.21	4.53	0.38	1.36e-5	Obesity-related traits;
TGCT	cis	rs10174077	0.874	rs11892439	chr2:152469858	T/A	cg06191203	chr2:152266755	RIF1	-0.7	-6.65	-0.51	8.38e-10	Squamous cell lung carcinoma;
TGCT	cis	rs7394190	0.748	rs3781216	chr10:75522404	G/A	cg07699608	chr10:75541558	CHCHD1	0.77	4.86	0.4	3.48e-6	Incident atrial fibrillation;
TGCT	cis	rs9915657	0.933	rs8075603	chr17:70136833	G/T	cg06234051	chr17:70120541	SOX9	-0.25	-4.74	-0.39	5.83e-6	Thyroid hormone levels;
TGCT	cis	rs7172809	0.573	rs13380202	chr15:77659982	G/A	cg22256960	chr15:77711686	NA	-0.51	-4.79	-0.4	4.65e-6	Glucose homeostasis traits;
TGCT	cis	rs7666738	0.830	rs880470	chr4:98922522	A/T	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg26513180	chr16:89883248	FANCA	1.04	14.53	0.79	1.53e-28	Vitiligo;
TGCT	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg18230493	chr5:56204884	C5orf35	-0.69	-6.02	-0.48	1.83e-8	Type 2 diabetes;
TGCT	cis	rs8056742	1.000	rs8056742	chr16:85092748	C/T	cg00229868	chr16:85520891	NA	-0.31	-4.67	-0.39	7.76e-6	Amyotrophic lateral sclerosis;
TGCT	cis	rs6977940	0.818	rs11770710	chr7:2896123	A/G	cg19731401	chr7:2775893	GNA12	0.4	4.81	0.4	4.22e-6	White matter integrity;
TGCT	cis	rs6840360	0.533	rs13145446	chr4:152729035	G/A	cg22705602	chr4:152727874	NA	0.34	6.14	0.48	1.02e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7909074	1.000	rs10751360	chr10:45396971	G/A	cg05187965	chr10:45406764	TMEM72	-0.24	-5.23	-0.42	7.12e-7	Mean corpuscular volume;
TGCT	cis	rs3960554	0.529	rs1859795	chr7:75877354	A/G	cg19105122	chr7:75896889	SRRM3	0.55	4.59	0.38	1.08e-5	Eotaxin levels;
TGCT	cis	rs933688	0.877	rs10474352	chr5:90732225	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.96	8.27	0.6	1.74e-13	Smoking behavior;
TGCT	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg08280861	chr8:58055591	NA	0.37	5.03	0.41	1.66e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9900497	0.536	rs4646785	chr17:19651902	A/G	cg12799818	chr17:19450343	SLC47A1	-0.3	-4.88	-0.4	3.22e-6	Response to paliperidone in schizophrenia (CGI-S score);
TGCT	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg10819733	chr22:24237672	NA	-0.28	-4.59	-0.38	1.06e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7666738	0.830	rs13108422	chr4:99059267	G/A	cg05340658	chr4:99064831	C4orf37	0.52	5.92	0.47	2.91e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3617	0.573	rs4687682	chr3:52916939	T/C	cg10802521	chr3:52805072	NEK4	0.58	6.69	0.51	6.96e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs3796352	1.000	rs1346719	chr3:53077372	A/G	cg15956490	chr3:53032818	SFMBT1	0.57	6.24	0.49	6.28e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs7819412	0.608	rs28417109	chr8:10975081	T/A	cg21775007	chr8:11205619	TDH	-0.51	-4.91	-0.4	2.87e-6	Triglycerides;
TGCT	cis	rs6076065	0.775	rs761723	chr20:23330720	A/G	cg11657817	chr20:23433608	CST11	0.31	5.29	0.43	5.46e-7	Facial morphology (factor 15, philtrum width);
TGCT	cis	rs6665290	0.669	rs3768421	chr1:227177193	G/A	cg10327440	chr1:227177885	CDC42BPA	-0.9	-14.92	-0.8	1.86e-29	Myeloid white cell count;
TGCT	cis	rs13102973	0.645	rs6535055	chr4:135886101	A/C	cg14419869	chr4:135874104	NA	0.26	4.6	0.38	1.03e-5	Subjective well-being;
TGCT	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg02725872	chr8:58115012	NA	-0.41	-5.42	-0.44	3.01e-7	Developmental language disorder (linguistic errors);
TGCT	trans	rs17685	0.753	rs6976532	chr7:75681094	A/G	cg19862616	chr7:65841803	NCRNA00174	0.47	8.17	0.59	2.99e-13	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs611744	0.967	rs610452	chr8:109188263	T/C	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs13064411	0.542	rs4396864	chr3:113212562	C/T	cg18753928	chr3:113234510	CCDC52	-0.54	-4.58	-0.38	1.12e-5	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs10032931	0.962	rs1385670	chr4:96456167	T/A	cg17031751	chr4:96469067	UNC5C	-0.37	-4.82	-0.4	4.16e-6	Optic nerve measurement (cup-to-disc ratio);
TGCT	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg07747251	chr5:1868357	NA	0.37	5.06	0.41	1.45e-6	Cardiovascular disease risk factors;
TGCT	cis	rs751728	1.000	rs943477	chr6:33750931	T/C	cg13859433	chr6:33739653	LEMD2	-0.39	-7.23	-0.54	4.25e-11	Crohn's disease;
TGCT	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg25036284	chr2:26402008	FAM59B	-0.64	-5.06	-0.41	1.44e-6	Gut microbiome composition (summer);
TGCT	cis	rs3806843	0.966	rs12659129	chr5:140147248	T/C	cg19875535	chr5:140030758	IK	0.36	6.17	0.48	8.74e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs6867032	1.000	rs2129472	chr5:2016247	G/A	cg26168224	chr5:2018326	NA	0.43	7.96	0.58	9.31e-13	Gut microbiome composition (winter);
TGCT	cis	rs4713118	0.911	rs9461406	chr6:27719764	C/T	cg20933634	chr6:27740509	NA	-0.35	-5.0	-0.41	1.92e-6	Parkinson's disease;
TGCT	cis	rs832540	0.931	rs2591960	chr5:56238811	A/T	cg24531977	chr5:56204891	C5orf35	0.58	5.44	0.44	2.76e-7	Coronary artery disease;
TGCT	cis	rs62244186	0.659	rs4682745	chr3:44508967	T/C	cg02073558	chr3:44770973	ZNF501	0.58	5.68	0.45	8.89e-8	Depressive symptoms;
TGCT	cis	rs9818758	0.607	rs11710247	chr3:49249800	G/T	cg00383909	chr3:49044727	WDR6	1.28	6.57	0.51	1.23e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg18402987	chr7:1209562	NA	0.39	4.85	0.4	3.57e-6	Longevity;Endometriosis;
TGCT	cis	rs2663905	0.611	rs2663920	chr15:81396404	A/G	cg18028999	chr15:81426610	C15orf26	-0.5	-4.7	-0.39	6.77e-6	QT interval (drug interaction);
TGCT	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.64	5.1	0.42	1.26e-6	Lung function (FEV1/FVC);
TGCT	cis	rs7819412	0.669	rs4840549	chr8:10998955	A/G	cg21775007	chr8:11205619	TDH	-0.55	-5.05	-0.41	1.53e-6	Triglycerides;
TGCT	cis	rs3099143	0.901	rs1813479	chr15:77168646	T/C	cg21673338	chr15:77095150	SCAPER	0.52	5.05	0.41	1.54e-6	Recalcitrant atopic dermatitis;
TGCT	cis	rs17169807	1.000	rs73313138	chr7:33350809	G/A	cg06206957	chr7:33080615	NT5C3	0.32	4.44	0.37	1.97e-5	Smooth-surface caries;
TGCT	cis	rs1395	0.922	rs11693052	chr2:27484620	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.51	6.69	0.51	6.91e-10	Blood metabolite levels;
TGCT	cis	rs539096	0.715	rs6665014	chr1:44226004	G/T	cg12908607	chr1:44402522	ARTN	0.65	6.68	0.51	7.03e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg12000995	chr2:27665139	KRTCAP3	-0.36	-4.45	-0.37	1.9e-5	Total body bone mineral density;
TGCT	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg06108461	chr20:60628389	TAF4	-0.69	-10.56	-0.69	5.46e-19	Body mass index;
TGCT	cis	rs9443645	0.901	rs9352683	chr6:79718795	T/G	cg09184832	chr6:79620586	NA	-0.48	-5.34	-0.43	4.21e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1372520	0.684	rs356162	chr4:90697157	T/C	cg20003494	chr4:90757398	SNCA	0.56	4.46	0.37	1.83e-5	Neuroticism;
TGCT	cis	rs6570726	0.791	rs9399558	chr6:145911730	T/C	cg23711669	chr6:146136114	FBXO30	0.89	9.62	0.65	1.06e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9291683	0.620	rs4444830	chr4:10124819	A/G	cg11266682	chr4:10021025	SLC2A9	-0.44	-5.24	-0.43	6.65e-7	Bone mineral density;
TGCT	cis	rs12497850	0.931	rs11705888	chr3:48817289	T/C	cg06212747	chr3:49208901	KLHDC8B	0.62	5.83	0.46	4.42e-8	Parkinson's disease;
TGCT	cis	rs9467773	1.000	rs9393731	chr6:26529374	C/T	cg26531700	chr6:26746687	NA	0.47	4.57	0.38	1.14e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs12681287	0.511	rs7839601	chr8:87503839	G/C	cg19078186	chr8:87526527	CPNE3	-0.37	-4.57	-0.38	1.15e-5	Caudate activity during reward;
TGCT	cis	rs12893668	0.703	rs4906336	chr14:104033265	C/G	cg26031613	chr14:104095156	KLC1	-0.54	-4.45	-0.37	1.88e-5	Reticulocyte count;
TGCT	cis	rs1018836	0.923	rs7833025	chr8:91568470	G/C	cg16814680	chr8:91681699	NA	-0.9	-9.91	-0.66	2.06e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10088262	0.629	rs6990565	chr8:124785645	C/A	cg02993010	chr8:124780839	FAM91A1	-0.63	-4.87	-0.4	3.28e-6	Pancreatic cancer;
TGCT	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	7.12	0.54	7.55e-11	Platelet count;
TGCT	cis	rs7964899	0.750	rs7358578	chr12:14630856	G/A	cg10925082	chr12:15114703	ARHGDIB	0.22	4.5	0.37	1.53e-5	Educational attainment (years of education);
TGCT	cis	rs7949030	0.688	rs2849031	chr11:62365665	G/A	cg13298116	chr11:62369859	EML3;MTA2	-0.62	-9.24	-0.64	8.81e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs8180040	0.691	rs12489211	chr3:47221451	T/A	cg27129171	chr3:47204927	SETD2	0.75	9.86	0.66	2.82e-17	Colorectal cancer;
TGCT	cis	rs7681440	0.904	rs7672979	chr4:90767873	A/G	cg01966878	chr4:90757139	SNCA	-0.25	-4.56	-0.38	1.2e-5	Dementia with Lewy bodies;
TGCT	cis	rs7552404	1.000	rs11163924	chr1:76132070	A/C	cg22875332	chr1:76189707	ACADM	-0.79	-10.12	-0.67	6.33e-18	Blood metabolite levels;Acylcarnitine levels;
TGCT	trans	rs17685	0.753	rs13240967	chr7:75658197	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.52	-8.84	-0.62	7.72e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs4700695	0.614	rs1864042	chr5:65206722	G/A	cg21114390	chr5:65439923	SFRS12	0.67	4.7	0.39	6.91e-6	Facial morphology (factor 19);
TGCT	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg07636037	chr3:49044803	WDR6	0.85	8.88	0.62	6.21e-15	Menarche (age at onset);
TGCT	cis	rs35000415	0.688	rs12536719	chr7:128717740	C/T	cg06242719	chr7:129414860	MIR183;MIR96	-0.3	-4.58	-0.38	1.1e-5	Systemic lupus erythematosus;
TGCT	trans	rs7819412	0.775	rs2898257	chr8:10935368	A/C	cg15556689	chr8:8085844	FLJ10661	-0.84	-8.16	-0.59	3.12e-13	Triglycerides;
TGCT	cis	rs910316	0.967	rs10142770	chr14:75525449	G/A	cg23033748	chr14:75592666	NEK9	0.27	4.53	0.38	1.34e-5	Height;
TGCT	cis	rs1801251	1.000	rs6745879	chr2:233590007	A/G	cg08000102	chr2:233561755	GIGYF2	0.63	6.53	0.51	1.51e-9	Coronary artery disease;
TGCT	cis	rs7924176	0.564	rs6480727	chr10:76003073	C/T	cg19889307	chr10:75911429	ADK;AP3M1	-0.45	-4.49	-0.37	1.59e-5	Primary tooth development (time to first tooth eruption);Permanent tooth development;Primary tooth development (number of teeth);
TGCT	cis	rs9486719	1.000	rs2142653	chr6:96871520	C/A	cg18709589	chr6:96969512	KIAA0776	0.71	5.21	0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	trans	rs7726839	1.000	rs7726839	chr5:618586	A/G	cg11887960	chr12:57824829	NA	0.85	6.69	0.51	6.9e-10	Obesity-related traits;
TGCT	cis	rs228437	0.586	rs6920152	chr6:134947520	G/T	cg09872934	chr6:134495829	SGK1	0.52	4.56	0.38	1.21e-5	Melanoma;
TGCT	cis	rs13191362	1.000	rs55822577	chr6:163069710	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.89	6.39	0.5	3.1e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg15242686	chr22:24348715	GSTTP1	0.41	5.67	0.45	9.33e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs903263	1.000	rs11163911	chr1:84639626	A/G	cg09664975	chr1:84543551	PRKACB	0.47	4.48	0.37	1.65e-5	Breast cancer (male);
TGCT	cis	rs4081724	0.565	rs12150908	chr19:33808145	C/A	cg18823272	chr19:34111733	CHST8	0.42	4.69	0.39	7.17e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs10992471	0.605	rs7872375	chr9:95064843	C/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-5.57	-0.45	1.53e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs3820928	0.605	rs13410141	chr2:227805529	A/G	cg11843606	chr2:227700838	RHBDD1	-0.51	-4.82	-0.4	4.1e-6	Pulmonary function;
TGCT	cis	rs9916302	0.706	rs3744349	chr17:37414842	C/T	cg07936489	chr17:37558343	FBXL20	-0.88	-6.3	-0.49	4.71e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg18305652	chr10:134549665	INPP5A	0.31	5.26	0.43	6.05e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs13326165	0.511	rs1011063	chr3:52506848	A/G	cg27565382	chr3:53032988	SFMBT1	0.38	5.15	0.42	9.78e-7	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs7542091	0.739	rs10863793	chr1:210037420	G/A	cg21951975	chr1:209979733	IRF6	0.53	5.33	0.43	4.43e-7	Monobrow;
TGCT	cis	rs7100689	0.622	rs7082093	chr10:82134954	T/G	cg01528321	chr10:82214614	TSPAN14	0.83	7.87	0.58	1.5e-12	Post bronchodilator FEV1;
TGCT	cis	rs1355223	0.583	rs1396881	chr11:34870506	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.78	8.67	0.61	2.03e-14	Systemic lupus erythematosus and Systemic sclerosis;
TGCT	cis	rs61990749	0.597	rs1549119	chr14:78219812	A/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.62	4.58	0.38	1.13e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg25767906	chr1:53392781	SCP2	-0.55	-6.64	-0.51	8.87e-10	Monocyte count;
TGCT	cis	rs17253792	0.822	rs17253730	chr14:56157911	A/G	cg01858014	chr14:56050164	KTN1	-0.35	-4.62	-0.38	9.37e-6	Putamen volume;
TGCT	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.68	7.22	0.54	4.62e-11	Blood metabolite levels;
TGCT	cis	rs12477438	0.501	rs2632260	chr2:99771590	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.06	13.28	0.77	1.43e-25	Chronic sinus infection;
TGCT	cis	rs1475911	0.708	rs56109792	chr21:43520060	A/G	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.27	-5.3	-0.43	5.04e-7	IgG glycosylation;
TGCT	cis	rs62244186	0.541	rs62244226	chr3:44831831	G/A	cg21672276	chr3:44754072	ZNF502	-0.54	-6.25	-0.49	6.16e-9	Depressive symptoms;
TGCT	cis	rs881375	0.967	rs876445	chr9:123677102	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	4.99	0.41	2.02e-6	Rheumatoid arthritis;
TGCT	cis	rs3733585	0.673	rs7376948	chr4:9954708	G/A	cg11266682	chr4:10021025	SLC2A9	-0.57	-7.44	-0.56	1.45e-11	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs11690935	0.959	rs6745143	chr2:172650382	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.19	-12.78	-0.75	2.24e-24	Schizophrenia;
TGCT	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg23131131	chr22:24373011	LOC391322	-0.81	-8.71	-0.62	1.56e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg04944784	chr2:26401820	FAM59B	-0.71	-6.56	-0.51	1.34e-9	Gut microbiome composition (summer);
TGCT	cis	rs2180341	0.680	rs9388554	chr6:127576234	C/G	cg24812749	chr6:127587940	RNF146	0.79	6.6	0.51	1.09e-9	Breast cancer;
TGCT	cis	rs13217239	0.646	rs6937880	chr6:27000236	C/T	cg15659132	chr6:26577336	NA	0.54	5.44	0.44	2.78e-7	Schizophrenia;
TGCT	trans	rs3780486	0.846	rs10813948	chr9:33121570	G/A	cg04842962	chr6:43655489	MRPS18A	1.23	15.36	0.81	1.81e-30	IgG glycosylation;
TGCT	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg22920501	chr2:26401640	FAM59B	-0.74	-6.4	-0.5	2.86e-9	Gut microbiome composition (summer);
TGCT	cis	rs10193935	0.901	rs222464	chr2:42643889	C/T	cg27598129	chr2:42591480	NA	-0.37	-5.32	-0.43	4.69e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7914558	0.966	rs3977751	chr10:104920232	A/G	cg04362960	chr10:104952993	NT5C2	0.62	5.48	0.44	2.32e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs17076896	0.786	rs61956088	chr13:19937911	G/A	cg00777926	chr13:20807375	GJB6	-0.41	-4.82	-0.4	4.03e-6	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs6714710	0.603	rs11123974	chr2:98605982	A/G	cg26665480	chr2:98280029	ACTR1B	0.63	6.03	0.48	1.75e-8	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs4664308	1.000	rs1511218	chr2:160906390	T/C	cg03641300	chr2:160917029	PLA2R1	-0.26	-6.53	-0.51	1.49e-9	Idiopathic membranous nephropathy;
TGCT	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg11764359	chr7:65958608	NA	0.59	5.28	0.43	5.64e-7	Aortic root size;
TGCT	cis	rs7249142	0.562	rs10417796	chr19:19287072	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.33	-4.51	-0.38	1.5e-5	IgG glycosylation;
TGCT	trans	rs2469997	1.000	rs2447183	chr8:120352978	A/G	cg01792902	chr3:178864926	PIK3CA	0.78	6.66	0.51	7.93e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs1784581	1.000	rs1618170	chr6:162400337	C/T	cg17173639	chr6:162384350	PARK2	-0.5	-9.17	-0.64	1.26e-15	Itch intensity from mosquito bite;
TGCT	cis	rs1865760	1.000	rs2071298	chr6:25914901	G/A	cg16482183	chr6:26056742	HIST1H1C	0.52	4.6	0.38	1.04e-5	Height;
TGCT	cis	rs2404602	0.583	rs3759853	chr15:76587777	C/T	cg22467129	chr15:76604101	ETFA	-0.61	-7.93	-0.58	1.07e-12	Blood metabolite levels;
TGCT	cis	rs611744	0.870	rs613261	chr8:109165949	A/G	cg21045802	chr8:109455806	TTC35	0.69	6.06	0.48	1.51e-8	Dupuytren's disease;
TGCT	cis	rs6933660	0.745	rs6557138	chr6:151732017	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.5	4.62	0.38	9.63e-6	Menarche (age at onset);
TGCT	cis	rs9611565	0.512	rs5996063	chr22:42168767	G/A	cg06634786	chr22:41940651	POLR3H	0.85	8.15	0.59	3.41e-13	Vitiligo;
TGCT	cis	rs2857078	0.654	rs4793083	chr17:42312973	C/T	cg19774624	chr17:42201019	HDAC5	0.75	7.6	0.56	6.45e-12	Red cell distribution width;Reticulocyte count;
TGCT	cis	rs3617	0.625	rs7620690	chr3:52891707	A/G	cg10802521	chr3:52805072	NEK4	0.62	7.17	0.54	6.08e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs76419734	0.510	rs2553456	chr4:106751028	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	-0.7	-4.52	-0.38	1.43e-5	Post bronchodilator FEV1;
TGCT	cis	rs1018836	0.595	rs2223010	chr8:91480068	A/G	cg16814680	chr8:91681699	NA	-0.81	-8.27	-0.6	1.8e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7226408	0.948	rs11665609	chr18:34387348	C/T	cg06757138	chr18:34340585	FHOD3	0.26	4.79	0.4	4.62e-6	Obesity-related traits;
TGCT	cis	rs782590	0.935	rs6739513	chr2:55749902	G/A	cg03859395	chr2:55845619	SMEK2	0.93	11.51	0.72	2.7e-21	Metabolic syndrome;
TGCT	cis	rs3008870	1.000	rs12039172	chr1:67447450	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.1	-11.8	-0.73	5.15e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs6500602	0.627	rs3848372	chr16:4587875	C/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.34	4.92	0.4	2.68e-6	Schizophrenia;
TGCT	cis	rs2486012	1.000	rs2428954	chr1:44442930	A/G	cg12908607	chr1:44402522	ARTN	0.67	5.9	0.47	3.17e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs12368653	0.583	rs7952989	chr12:58095989	T/C	cg12615879	chr12:58013172	SLC26A10	0.49	5.9	0.47	3.27e-8	Multiple sclerosis;
TGCT	cis	rs7188861	0.603	rs2113260	chr16:11455993	C/T	cg00044050	chr16:11439710	C16orf75	0.61	5.43	0.44	2.89e-7	HDL cholesterol;
TGCT	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg17971929	chr21:40555470	PSMG1	-0.7	-6.5	-0.5	1.8e-9	Cognitive function;
TGCT	cis	rs1997103	1.000	rs2177804	chr7:55410302	G/A	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs2836950	0.501	rs1474490	chr21:40716136	C/A	cg11890956	chr21:40555474	PSMG1	-0.6	-5.49	-0.44	2.2e-7	Menarche (age at onset);
TGCT	cis	rs9807989	0.801	rs72823663	chr2:102968738	G/C	cg09003973	chr2:102972529	NA	0.64	5.7	0.46	8.28e-8	Asthma;
TGCT	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg01448562	chr3:133502909	NA	-0.34	-6.9	-0.53	2.37e-10	Iron status biomarkers;
TGCT	cis	rs473651	0.904	rs508274	chr2:239337723	G/A	cg18131467	chr2:239335373	ASB1	1.03	15.25	0.81	3.21e-30	Multiple system atrophy;
TGCT	cis	rs10782582	0.586	rs11161902	chr1:76392498	C/G	cg03433033	chr1:76189801	ACADM	-0.49	-4.81	-0.4	4.29e-6	Daytime sleep phenotypes;
TGCT	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg02725872	chr8:58115012	NA	-0.38	-5.05	-0.41	1.55e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg08564027	chr20:61660810	NA	0.37	6.64	0.51	8.85e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs8033133	0.560	rs12441340	chr15:25323964	G/T	cg14481604	chr15:25334117	SNORD116-22	-0.21	-4.54	-0.38	1.33e-5	Blood osmolality (transformed sodium);
TGCT	cis	rs28408315	0.958	rs3129	chr15:79214215	A/G	cg15822222	chr15:79164806	MORF4L1	-0.49	-5.42	-0.44	2.95e-7	Lung cancer;Lung cancer in ever smokers;Lung adenocarcinoma;
TGCT	cis	rs3806843	0.576	rs246002	chr5:140341104	A/G	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7666738	1.000	rs7666738	chr4:98968077	C/T	cg05340658	chr4:99064831	C4orf37	0.49	4.87	0.4	3.4e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7824557	0.510	rs4841524	chr8:11243126	C/G	cg27411982	chr8:10470053	RP1L1	-0.22	-4.84	-0.4	3.74e-6	Retinal vascular caliber;
TGCT	cis	rs2617583	0.509	rs2937650	chr5:1458018	C/T	cg13982541	chr5:1466431	LPCAT1	-0.2	-4.86	-0.4	3.53e-6	Breast cancer;
TGCT	cis	rs2795502	0.882	rs3123754	chr10:43339011	G/A	cg20628663	chr10:43360327	NA	-0.44	-6.37	-0.5	3.4e-9	Blood protein levels;
TGCT	cis	rs7178572	0.568	rs7166927	chr15:77673459	A/G	cg15453836	chr15:77711506	NA	0.42	4.78	0.39	4.92e-6	Type 2 diabetes;
TGCT	cis	rs1669338	0.588	rs7629889	chr3:3187643	C/T	cg16797762	chr3:3221439	CRBN	-0.86	-5.26	-0.43	6.24e-7	White matter integrity;
TGCT	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg24829409	chr8:58192753	C8orf71	-0.57	-4.82	-0.4	4.19e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1372520	0.935	rs1442152	chr4:90775649	C/A	cg01966878	chr4:90757139	SNCA	-0.3	-4.71	-0.39	6.55e-6	Neuroticism;
TGCT	cis	rs3008870	1.000	rs58680688	chr1:67443751	C/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.1	-11.8	-0.73	5.15e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs78487399	0.710	rs6544665	chr2:43729212	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-4.82	-0.4	4.03e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-6.74	-0.52	5.26e-10	Alzheimer's disease;
TGCT	cis	rs2594989	0.895	rs2442789	chr3:11540188	C/T	cg26283222	chr3:11613257	VGLL4	-0.22	-4.69	-0.39	7.11e-6	Circulating chemerin levels;
TGCT	trans	rs4332037	0.575	rs55952733	chr7:2070680	G/A	cg25206134	chr2:45395956	NA	0.97	7.42	0.55	1.6e-11	Bipolar disorder;
TGCT	cis	rs7666738	0.791	rs34152299	chr4:98929862	G/C	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9311474	1.000	rs1060330	chr3:52288945	T/C	cg10802521	chr3:52805072	NEK4	-0.56	-6.25	-0.49	6.16e-9	Electroencephalogram traits;
TGCT	cis	rs12220238	0.841	rs11000952	chr10:76037336	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.88	5.98	0.47	2.22e-8	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs7617480	0.648	rs9859473	chr3:48837182	A/G	cg06212747	chr3:49208901	KLHDC8B	0.58	4.58	0.38	1.1e-5	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs6754311	0.731	rs2164210	chr2:136580287	T/C	cg07169764	chr2:136633963	MCM6	-0.61	-5.61	-0.45	1.25e-7	Mosquito bite size;
TGCT	cis	rs7937682	0.558	rs7113067	chr11:111692182	G/A	cg09085632	chr11:111637200	PPP2R1B	0.81	6.94	0.53	1.92e-10	Primary sclerosing cholangitis;
TGCT	cis	rs2702888	0.622	rs2702933	chr8:6760142	A/G	cg26795848	chr8:6756730	NA	-0.28	-5.96	-0.47	2.39e-8	Blood pressure;
TGCT	cis	rs6693567	0.565	rs7513182	chr1:150442612	A/G	cg09579323	chr1:150459698	TARS2	-0.52	-4.62	-0.38	9.55e-6	Migraine;
TGCT	cis	rs2692947	0.770	rs62153678	chr2:96558346	C/T	cg23100626	chr2:96804247	ASTL	0.37	4.49	0.37	1.62e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs11098499	0.863	rs11731756	chr4:120478696	T/G	cg09307838	chr4:120376055	NA	0.72	6.9	0.53	2.41e-10	Corneal astigmatism;
TGCT	cis	rs42648	0.935	rs42621	chr7:89956484	A/G	cg25739043	chr7:89950458	NA	-0.75	-7.62	-0.56	5.63e-12	Homocysteine levels;
TGCT	cis	rs1023500	0.573	rs4822088	chr22:42470589	G/C	cg05082376	chr22:42548792	NA	-0.23	-5.43	-0.44	2.83e-7	Schizophrenia;
TGCT	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg04944784	chr2:26401820	FAM59B	-0.67	-5.98	-0.47	2.23e-8	Gut microbiome composition (summer);
TGCT	cis	rs3091242	0.836	rs34997029	chr1:25783823	A/G	cg09222892	chr1:25734099	RHCE	0.42	6.97	0.53	1.68e-10	Erythrocyte sedimentation rate;
TGCT	cis	rs7193541	0.825	rs4411525	chr16:74595502	A/C	cg01733217	chr16:74700730	RFWD3	0.76	6.89	0.53	2.45e-10	Multiple myeloma;
TGCT	cis	rs35883536	0.647	rs7535762	chr1:101047534	A/G	cg10298815	chr1:101004474	GPR88	-0.25	-4.5	-0.37	1.54e-5	Monocyte count;
TGCT	cis	rs9810089	0.900	rs480162	chr3:136068695	A/T	cg12473912	chr3:136751656	NA	0.35	5.04	0.41	1.59e-6	Gestational age at birth (child effect);
TGCT	cis	rs6688613	0.729	rs41269702	chr1:166958937	G/T	cg07049167	chr1:166818506	POGK	0.23	4.72	0.39	6.21e-6	Refractive astigmatism;
TGCT	cis	rs7394190	0.630	rs4746150	chr10:75565935	A/G	cg07699608	chr10:75541558	CHCHD1	0.8	4.77	0.39	5.18e-6	Incident atrial fibrillation;
TGCT	cis	rs28493229	0.522	rs17713068	chr19:41270055	A/C	cg23743927	chr19:41304969	EGLN2	-0.74	-4.67	-0.39	7.7e-6	Kawasaki disease;
TGCT	cis	rs12950390	0.853	rs11079791	chr17:45859099	C/T	cg06532163	chr17:45867833	NA	0.37	5.96	0.47	2.45e-8	IgG glycosylation;
TGCT	cis	rs7729723	0.533	rs219278	chr5:137834091	G/A	cg19169342	chr5:137827400	NA	0.33	4.53	0.38	1.37e-5	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);
TGCT	cis	rs7666738	0.830	rs34671152	chr4:98978177	C/T	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs916888	0.821	rs415430	chr17:44859144	C/T	cg15921436	chr17:44337874	NA	-0.51	-6.96	-0.53	1.77e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs1670533	1.000	rs6822863	chr4:1055606	G/A	cg27284194	chr4:1044797	NA	0.68	5.88	0.47	3.56e-8	Recombination rate (females);
TGCT	cis	rs11209185	0.509	rs12142271	chr1:68446837	A/G	cg22082780	chr1:68452167	NA	0.31	4.84	0.4	3.86e-6	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.62	5.22	0.42	7.25e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs42648	0.837	rs10262472	chr7:89900383	T/C	cg25739043	chr7:89950458	NA	-0.74	-7.33	-0.55	2.64e-11	Homocysteine levels;
TGCT	cis	rs6988636	0.818	rs1713733	chr8:124199458	A/G	cg22384356	chr8:124195192	FAM83A	0.34	4.44	0.37	1.98e-5	Urinary uromodulin levels;
TGCT	cis	rs1011108	0.518	rs935172	chr2:26804247	A/G	cg18742855	chr2:26800399	C2orf70	-0.23	-5.21	-0.42	7.7300000000000005e-07	Periodontal microbiota;
TGCT	cis	rs514406	0.861	rs11206026	chr1:53281708	G/A	cg08736216	chr1:53307985	ZYG11A	-0.23	-4.5	-0.37	1.55e-5	Monocyte count;
TGCT	cis	rs939574	1.000	rs79013471	chr2:220096122	C/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.06	6.52	0.51	1.6e-9	Platelet distribution width;
TGCT	cis	rs9928842	0.941	rs8057145	chr16:75256251	A/G	cg09066997	chr16:75300724	BCAR1	0.25	4.58	0.38	1.14e-5	Alcoholic chronic pancreatitis;
TGCT	cis	rs2832191	0.765	rs2832162	chr21:30461808	G/A	cg24692254	chr21:30365293	RNF160	0.91	9.85	0.66	2.96e-17	Dental caries;
TGCT	cis	rs806215	0.526	rs806174	chr7:127291072	C/A	cg11539674	chr7:127291444	SND1	0.38	4.72	0.39	6.23e-6	Type 2 diabetes;
TGCT	cis	rs5769765	1.000	rs738711	chr22:50282603	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.4	-6.07	-0.48	1.46e-8	Schizophrenia;
TGCT	cis	rs7617773	0.539	rs1471217	chr3:48384895	A/C	cg11946769	chr3:48343235	NME6	0.57	4.83	0.4	4.01e-6	Coronary artery disease;
TGCT	cis	rs854765	0.547	rs2955359	chr17:17946730	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.79	-8.27	-0.6	1.76e-13	Total body bone mineral density;
TGCT	cis	rs4268898	0.722	rs35520052	chr2:24415277	C/T	cg05570707	chr2:24270316	C2orf44	0.47	4.62	0.38	9.59e-6	Asthma;
TGCT	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg11941060	chr3:133502564	NA	-0.29	-6.15	-0.48	9.6e-9	Iron status biomarkers;
TGCT	cis	rs62244186	0.659	rs9819766	chr3:44520980	G/C	cg10263370	chr3:44754102	ZNF502	-0.38	-4.45	-0.37	1.86e-5	Depressive symptoms;
TGCT	cis	rs2832191	0.647	rs11170	chr21:30378090	C/T	cg24692254	chr21:30365293	RNF160	0.9	10.54	0.69	6.03e-19	Dental caries;
TGCT	cis	rs12477438	1.000	rs73963398	chr2:99887025	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.8	-6.4	-0.5	2.92e-9	Chronic sinus infection;
TGCT	cis	rs6714788	0.503	rs11681737	chr2:100679024	T/C	cg22139774	chr2:100720529	AFF3	-0.41	-5.99	-0.47	2.16e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs11711311	1.000	rs9855613	chr3:113448455	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.71	-6.58	-0.51	1.19e-9	IgG glycosylation;
TGCT	cis	rs2073300	1.000	rs115730610	chr20:23442621	G/A	cg09953122	chr20:23471693	CST8	-0.64	-4.56	-0.38	1.19e-5	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs3733585	0.682	rs13124563	chr4:9927553	A/G	cg00071950	chr4:10020882	SLC2A9	0.61	7.3	0.55	3.11e-11	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	7.06	0.54	1.07e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs10782582	0.569	rs4549990	chr1:76125075	A/G	cg03433033	chr1:76189801	ACADM	-0.63	-7.27	-0.55	3.6e-11	Daytime sleep phenotypes;
TGCT	cis	rs2066819	1.000	rs57870697	chr12:56752874	A/G	cg26714650	chr12:56694279	CS	-1.36	-5.89	-0.47	3.4e-8	Psoriasis vulgaris;
TGCT	cis	rs9420907	0.579	rs34547036	chr10:105637026	C/T	cg26719024	chr10:105156444	PDCD11;USMG5	-0.85	-4.66	-0.39	8.08e-6	Telomere length;
TGCT	cis	rs3820068	0.532	rs78917815	chr1:15920821	A/G	cg05660106	chr1:15850417	CASP9	0.84	8.27	0.6	1.8e-13	Systolic blood pressure;
TGCT	cis	rs13256369	0.950	rs13270006	chr8:8574197	C/A	cg06671706	chr8:8559999	CLDN23	0.35	4.62	0.38	9.35e-6	Obesity-related traits;
TGCT	cis	rs137603	0.966	rs137616	chr22:39703883	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	-0.54	-5.12	-0.42	1.15e-6	Primary biliary cholangitis;
TGCT	cis	rs7681423	1.000	rs2066854	chr4:155535181	T/A	cg20735720	chr4:155535218	FGG	-0.46	-6.71	-0.52	6.24e-10	Fibrinogen;
TGCT	cis	rs11190604	0.943	rs3750631	chr10:102279294	A/G	cg23241863	chr10:102295624	HIF1AN	0.68	5.17	0.42	9.14e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs3125734	0.633	rs6479791	chr10:63980341	T/C	cg05499367	chr10:63213510	TMEM26	-0.33	-4.52	-0.38	1.4e-5	Rheumatoid arthritis;
TGCT	cis	rs2562456	0.917	rs2562468	chr19:21714850	G/A	cg25650185	chr19:21324782	ZNF431	0.61	5.38	0.43	3.6e-7	Pain;
TGCT	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg10819733	chr22:24237672	NA	-0.28	-4.55	-0.38	1.26e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2637266	1.000	rs12252604	chr10:78352591	T/C	cg18941641	chr10:78392320	NA	0.41	5.05	0.41	1.56e-6	Pulmonary function;
TGCT	cis	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg20637647	chr7:64974828	NA	0.89	4.95	0.41	2.37e-6	Diabetic kidney disease;
TGCT	cis	rs9341808	0.667	rs2490251	chr6:80895164	A/G	cg08355045	chr6:80787529	NA	0.3	5.09	0.42	1.27e-6	Sitting height ratio;
TGCT	cis	rs11671005	0.735	rs1122955	chr19:58946203	C/T	cg13877915	chr19:58951672	ZNF132	0.63	5.0	0.41	1.95e-6	Mean platelet volume;
TGCT	cis	rs6430585	0.583	rs78364332	chr2:136640101	T/C	cg07169764	chr2:136633963	MCM6	1.23	11.98	0.73	1.9e-22	Corneal structure;
TGCT	cis	rs2742417	0.587	rs2742375	chr3:45784602	G/A	cg04837898	chr3:45731254	SACM1L	-0.67	-7.3	-0.55	3.06e-11	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs2594989	0.895	rs2606759	chr3:11349494	T/C	cg00170343	chr3:11313890	ATG7	0.61	4.58	0.38	1.11e-5	Circulating chemerin levels;
TGCT	cis	rs3796619	1.000	rs11939380	chr4:1086871	C/T	cg27284194	chr4:1044797	NA	-0.46	-4.53	-0.38	1.36e-5	Recombination rate (males);
TGCT	cis	rs4565302	0.539	rs62397056	chr6:38445982	G/A	cg08650320	chr6:39083032	C6orf64	0.72	4.76	0.39	5.27e-6	Mammographic density;
TGCT	cis	rs7666738	0.927	rs6832373	chr4:99051967	A/G	cg17366294	chr4:99064904	C4orf37	0.74	7.59	0.56	6.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3796352	1.000	rs9874517	chr3:53128371	A/G	cg07884673	chr3:53033167	SFMBT1	0.49	5.11	0.42	1.16e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs2237234	0.813	rs34565965	chr6:26350810	T/A	cg16898833	chr6:26189333	HIST1H4D	0.65	4.46	0.37	1.79e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7267979	0.844	rs6076343	chr20:25376663	C/T	cg03522245	chr20:25566470	NINL	-0.55	-5.55	-0.45	1.68e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs67311347	0.866	rs11712426	chr3:40330322	G/A	cg13683864	chr3:40499215	RPL14	-0.89	-8.61	-0.61	2.81e-14	Renal cell carcinoma;
TGCT	cis	rs12908161	1.000	rs62019464	chr15:85294469	T/A	cg11189052	chr15:85197271	WDR73	0.71	5.83	0.46	4.47e-8	Schizophrenia;
TGCT	cis	rs2013441	1.000	rs2703778	chr17:20138900	T/C	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.63	-0.38	9.19e-6	Obesity-related traits;
TGCT	cis	rs1062177	0.724	rs2915828	chr5:151118121	G/A	cg00977110	chr5:151150581	G3BP1	-0.4	-4.67	-0.39	7.7e-6	Preschool internalizing problems;
TGCT	cis	rs3796352	1.000	rs35174175	chr3:53041509	T/C	cg27565382	chr3:53032988	SFMBT1	0.45	4.58	0.38	1.14e-5	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs112217694	1.000	rs55703794	chr4:104650272	G/A	cg24090629	chr4:104641072	TACR3	-1.0	-5.19	-0.42	8.44e-7	Menarche (age at onset);
TGCT	cis	rs797680	0.856	rs12124011	chr1:93652544	C/A	cg17826107	chr1:92977322	EVI5	-0.24	-5.23	-0.43	6.89e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs986417	1.000	rs12895784	chr14:60980116	G/T	cg27398547	chr14:60952738	C14orf39	1.48	11.21	0.71	1.46e-20	Gut microbiota (bacterial taxa);
TGCT	cis	rs9357506	0.967	rs9395173	chr6:46311493	T/C	cg21115430	chr6:46460003	NA	-0.26	-5.16	-0.42	9.6e-7	Body mass index;
TGCT	cis	rs11098499	0.865	rs10213221	chr4:120255926	G/A	cg09307838	chr4:120376055	NA	0.63	6.07	0.48	1.44e-8	Corneal astigmatism;
TGCT	cis	rs921968	0.643	rs3845836	chr2:219504955	C/T	cg02176678	chr2:219576539	TTLL4	0.44	6.16	0.48	9.35e-9	Mean corpuscular hemoglobin concentration;
TGCT	trans	rs6089829	0.851	rs10854168	chr20:61669550	A/G	cg23505145	chr19:12996616	KLF1	0.96	9.99	0.67	1.36e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9534288	0.552	rs2840241	chr13:46658903	T/G	cg15192986	chr13:46630673	CPB2	-0.53	-6.39	-0.5	3.01e-9	Blood protein levels;
TGCT	cis	rs7666738	0.800	rs2865988	chr4:99067807	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.45	0.56	1.4e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg24250549	chr1:154909240	PMVK	0.63	6.25	0.49	6.03e-9	Prostate cancer;
TGCT	cis	rs912057	0.671	rs1294427	chr6:6744546	T/G	cg06612196	chr6:6737390	NA	0.48	6.95	0.53	1.82e-10	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs9928842	0.664	rs8053265	chr16:75221851	C/T	cg09066997	chr16:75300724	BCAR1	0.24	4.56	0.38	1.22e-5	Alcoholic chronic pancreatitis;
TGCT	cis	rs67311347	1.000	rs9874499	chr3:40441908	C/T	cg13409248	chr3:40428643	ENTPD3	0.55	4.46	0.37	1.78e-5	Renal cell carcinoma;
TGCT	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg20276088	chr3:133502917	NA	-0.24	-4.98	-0.41	2.04e-6	Iron status biomarkers;
TGCT	cis	rs7267979	0.966	rs2261784	chr20:25262396	G/C	cg16686733	chr20:25566563	NINL	0.61	6.1	0.48	1.23e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs12681287	0.547	rs13261956	chr8:87478765	G/A	cg27223183	chr8:87520930	FAM82B	-0.89	-6.34	-0.49	3.84e-9	Caudate activity during reward;
TGCT	cis	rs4919694	1.000	rs11191545	chr10:104829793	C/T	cg04362960	chr10:104952993	NT5C2	1.01	6.66	0.51	7.9e-10	Arsenic metabolism;
TGCT	cis	rs4631830	0.737	rs7071471	chr10:51503335	C/T	cg10326726	chr10:51549505	MSMB	0.27	5.24	0.43	6.7e-7	Prostate-specific antigen levels;
TGCT	cis	rs9303401	0.615	rs35288118	chr17:56600748	A/C	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs1629083	0.935	rs1793151	chr11:118126920	C/T	cg16594165	chr11:118135105	MPZL2	-0.33	-4.62	-0.38	9.51e-6	Lung cancer;
TGCT	cis	rs2295359	0.892	rs11209005	chr1:67618678	A/G	cg12940439	chr1:67600707	NA	0.62	6.45	0.5	2.29e-9	Psoriasis;
TGCT	cis	rs9611565	0.506	rs7364221	chr22:41650190	C/A	cg06634786	chr22:41940651	POLR3H	-0.57	-5.15	-0.42	1.01e-6	Vitiligo;
TGCT	cis	rs9952991	0.566	rs7234029	chr18:12877060	C/T	cg23544223	chr18:12777786	NA	0.54	4.86	0.4	3.42e-6	Inflammatory skin disease;
TGCT	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg22920501	chr2:26401640	FAM59B	-0.74	-6.45	-0.5	2.32e-9	Gut microbiome composition (summer);
TGCT	cis	rs4566357	0.615	rs2272200	chr2:227912331	G/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-5.25	-0.43	6.53e-7	Coronary artery disease;
TGCT	cis	rs9311474	0.713	rs352165	chr3:52242902	A/G	cg07507251	chr3:52567010	NT5DC2	0.43	5.63	0.45	1.16e-7	Electroencephalogram traits;
TGCT	cis	rs10851411	0.826	rs2617237	chr15:42765624	C/T	cg12711755	chr15:41779622	NA	-0.2	-4.91	-0.4	2.86e-6	Glucose homeostasis traits;
TGCT	cis	rs34734847	0.787	rs695949	chr12:121149736	A/G	cg21892295	chr12:121157589	UNC119B	-0.2	-4.72	-0.39	6.18e-6	Mean corpuscular volume;
TGCT	cis	rs4072705	0.615	rs7869829	chr9:127247177	G/A	cg13476313	chr9:127244764	NR5A1	-0.29	-4.91	-0.4	2.86e-6	Menarche (age at onset);
TGCT	cis	rs9486715	0.790	rs2971602	chr6:97022468	C/T	cg18709589	chr6:96969512	KIAA0776	-0.87	-8.46	-0.61	6.16e-14	Headache;
TGCT	trans	rs28735056	0.933	rs499260	chr18:77589689	G/A	cg05926928	chr17:57297772	GDPD1	-0.71	-7.64	-0.57	5.03e-12	Schizophrenia;
TGCT	cis	rs709400	0.691	rs12888077	chr14:103872553	G/T	cg26031613	chr14:104095156	KLC1	-0.8	-8.72	-0.62	1.49e-14	Body mass index;
TGCT	cis	rs11690935	0.959	rs10184866	chr2:172608956	T/G	cg13550731	chr2:172543902	DYNC1I2	-1.18	-12.5	-0.75	1.05e-23	Schizophrenia;
TGCT	cis	rs2688608	0.620	rs7098444	chr10:75580042	C/T	cg23231163	chr10:75533350	FUT11	-0.27	-4.64	-0.38	8.56e-6	Inflammatory bowel disease;
TGCT	cis	rs6906287	0.625	rs9320648	chr6:118690014	A/C	cg21191810	chr6:118973309	C6orf204	0.27	4.58	0.38	1.11e-5	Electrocardiographic conduction measures;
TGCT	cis	rs9419702	0.538	rs9419625	chr10:133534954	T/G	cg04492858	chr10:133558786	NA	0.57	6.07	0.48	1.44e-8	Survival in rectal cancer;
TGCT	cis	rs6430585	0.583	rs3769012	chr2:136556480	C/T	cg07169764	chr2:136633963	MCM6	1.23	12.14	0.74	8.06e-23	Corneal structure;
TGCT	cis	rs9952991	0.941	rs45450798	chr18:12792940	C/G	cg23544223	chr18:12777786	NA	-0.6	-5.3	-0.43	5.22e-7	Inflammatory skin disease;
TGCT	cis	rs7208859	0.623	rs8067338	chr17:29102345	T/C	cg13385521	chr17:29058706	SUZ12P	0.82	4.86	0.4	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs739496	0.947	rs10849949	chr12:111893537	C/T	cg10833066	chr12:111807467	FAM109A	-0.35	-5.4	-0.44	3.2e-7	Platelet count;
TGCT	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg06481639	chr22:41940642	POLR3H	-0.62	-5.61	-0.45	1.27e-7	Vitiligo;
TGCT	cis	rs6964587	0.967	rs34574955	chr7:91847550	A/C	cg17063962	chr7:91808500	NA	0.91	9.8	0.66	3.82e-17	Breast cancer;
TGCT	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.78	7.49	0.56	1.12e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs61008539	0.821	rs10950789	chr7:897492	A/G	cg07138768	chr7:917805	C7orf20	0.45	5.85	0.47	4.01e-8	Perceived unattractiveness to mosquitoes;
TGCT	cis	rs3809566	0.963	rs12148057	chr15:63331509	A/T	cg05507819	chr15:63340323	TPM1	0.48	4.52	0.38	1.4e-5	Platelet count;
TGCT	cis	rs4631830	0.900	rs10763546	chr10:51536399	C/G	cg10326726	chr10:51549505	MSMB	-0.25	-5.27	-0.43	5.89e-7	Prostate-specific antigen levels;
TGCT	cis	rs10114408	0.837	rs10115198	chr9:96632030	A/G	cg13679303	chr9:96623674	NA	-0.35	-4.58	-0.38	1.1e-5	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs1532993	0.518	rs3843445	chr4:98611576	C/T	cg05340658	chr4:99064831	C4orf37	-0.41	-4.96	-0.41	2.3e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs6598955	0.670	rs4659366	chr1:26542572	G/A	cg04990556	chr1:26633338	UBXN11	-0.89	-11.3	-0.71	8.55e-21	Obesity-related traits;
TGCT	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg12311346	chr5:56204834	C5orf35	-0.67	-6.77	-0.52	4.59e-10	Initial pursuit acceleration;
TGCT	cis	rs72781680	0.821	rs1022346	chr2:24127849	T/C	cg08917208	chr2:24149416	ATAD2B	0.74	4.66	0.39	7.9e-6	Lymphocyte counts;
TGCT	cis	rs789859	1.000	rs789862	chr3:194404522	C/T	cg21106136	chr3:194405973	FAM43A	0.38	5.42	0.44	3e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
TGCT	cis	rs7302981	0.900	rs836179	chr12:50503082	A/G	cg23855989	chr12:50355821	AQP5	0.3	4.44	0.37	2e-5	Systolic blood pressure;
TGCT	cis	rs62244186	0.748	rs13319803	chr3:44635461	G/A	cg02073558	chr3:44770973	ZNF501	0.62	6.04	0.48	1.66e-8	Depressive symptoms;
TGCT	cis	rs2982552	0.901	rs2982561	chr6:152052652	C/T	cg22157087	chr6:152012887	ESR1	0.19	4.67	0.39	7.62e-6	Bone properties (heel);
TGCT	cis	rs8103278	0.507	rs4802276	chr19:46260748	T/C	cg11657440	chr19:46296263	DMWD	0.73	7.76	0.57	2.78e-12	Coronary artery disease;
TGCT	cis	rs4689388	0.853	rs13114527	chr4:6294655	T/G	cg00701064	chr4:6280414	WFS1	0.37	4.72	0.39	6.3e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs8051431	0.876	rs7205914	chr16:72018901	A/G	cg06353428	chr16:71660113	MARVELD3	0.57	4.54	0.38	1.31e-5	LDL cholesterol levels;
TGCT	cis	rs3749237	0.595	rs4855877	chr3:49448527	T/C	cg03060546	chr3:49711283	APEH	0.77	9.0	0.63	3.2e-15	Resting heart rate;
TGCT	cis	rs4722166	0.597	rs1554606	chr7:22768707	T/G	cg05265849	chr7:22767390	IL6	0.23	4.57	0.38	1.18e-5	Lung cancer;
TGCT	cis	rs9611565	0.546	rs2092274	chr22:42123737	A/G	cg06634786	chr22:41940651	POLR3H	0.89	9.09	0.63	1.96e-15	Vitiligo;
TGCT	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg23708337	chr7:1209742	NA	0.6	5.57	0.45	1.53e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg04772025	chr11:68637568	NA	0.59	6.69	0.52	6.73e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	trans	rs12145833	0.920	rs12354170	chr1:243457776	G/T	cg15780870	chr12:130953802	RIMBP2	0.48	6.73	0.52	5.57e-10	Obesity (early onset extreme);
TGCT	cis	rs13256369	0.851	rs13267036	chr8:8566685	G/A	cg18904891	chr8:8559673	CLDN23	0.58	5.3	0.43	5.11e-7	Obesity-related traits;
TGCT	cis	rs4517514	0.509	rs10830411	chr11:89865532	A/G	cg05041596	chr11:89867385	NAALAD2	0.52	4.56	0.38	1.22e-5	Trans fatty acid levels;
TGCT	cis	rs9303401	0.659	rs17822837	chr17:56737838	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.64	6.0	0.47	2.05e-8	Cognitive test performance;
TGCT	cis	rs7000551	0.751	rs1116084	chr8:22395309	C/T	cg12081754	chr8:22256438	SLC39A14	0.28	4.54	0.38	1.34e-5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs78487399	0.808	rs17030889	chr2:43702829	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-5.45	-0.44	2.63e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs4689388	0.853	rs13108780	chr4:6294630	A/G	cg14416269	chr4:6271139	WFS1	0.37	4.9	0.4	2.95e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs10256972	0.721	rs10435145	chr7:1065988	C/T	cg23708337	chr7:1209742	NA	0.33	4.47	0.37	1.77e-5	Longevity;Endometriosis;
TGCT	cis	rs2742417	1.000	rs2742431	chr3:45737121	C/G	cg04837898	chr3:45731254	SACM1L	0.55	5.68	0.45	9.14e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs10206020	0.885	rs11886082	chr2:1576683	T/C	cg01028140	chr2:1542097	TPO	-0.29	-4.56	-0.38	1.22e-5	IgG glycosylation;
TGCT	trans	rs8073060	0.586	rs11080356	chr17:33895309	T/C	cg19694781	chr19:47549865	TMEM160	0.61	13.83	0.78	6.76e-27	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs7975161	0.832	rs11111955	chr12:104650735	T/C	cg25273343	chr12:104657179	TXNRD1	-0.36	-5.29	-0.43	5.32e-7	Toenail selenium levels;
TGCT	cis	rs244731	0.959	rs9313752	chr5:176645435	G/T	cg17509989	chr5:176798049	RGS14	-0.63	-7.44	-0.56	1.44e-11	Urate levels in lean individuals;
TGCT	cis	rs7726839	0.561	rs72703058	chr5:584519	G/A	cg09021430	chr5:549028	NA	-0.37	-5.23	-0.42	7.12e-7	Obesity-related traits;
TGCT	cis	rs74233809	1.000	rs732998	chr10:104897901	C/T	cg05855489	chr10:104503620	C10orf26	-0.82	-4.44	-0.37	1.97e-5	Birth weight;
TGCT	cis	rs981844	0.775	rs10517580	chr4:154744128	T/G	cg14289246	chr4:154710475	SFRP2	1.01	8.8	0.62	9.72e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg08045932	chr20:61659980	NA	0.49	9.18	0.64	1.24e-15	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2952156	0.684	rs931992	chr17:37821435	G/T	cg00129232	chr17:37814104	STARD3	-0.22	-4.48	-0.37	1.68e-5	Asthma;
TGCT	cis	rs1371867	0.846	rs1660324	chr8:101281271	C/T	cg00191853	chr8:101177733	SPAG1	-0.22	-4.5	-0.37	1.53e-5	Atrioventricular conduction;
TGCT	cis	rs2153535	0.542	rs9393012	chr6:8439809	G/A	cg07606381	chr6:8435919	SLC35B3	0.57	5.25	0.43	6.46e-7	Motion sickness;
TGCT	cis	rs7611238	0.560	rs7618499	chr3:195059315	A/G	cg27323046	chr3:195102265	ACAP2	0.35	4.75	0.39	5.5e-6	Body mass index;
TGCT	trans	rs931812	0.895	rs13251731	chr8:101902528	C/G	cg20993868	chr7:22813445	NA	0.4	8.85	0.62	7.57e-15	Attention deficit hyperactivity disorder and conduct disorder;
TGCT	cis	rs3091242	0.933	rs61775167	chr1:25780893	A/G	cg09222892	chr1:25734099	RHCE	0.42	7.15	0.54	6.72e-11	Erythrocyte sedimentation rate;
TGCT	cis	rs4704846	1.000	rs919745	chr5:156531279	A/G	cg12943317	chr5:156479607	HAVCR1	0.32	4.56	0.38	1.23e-5	Blood protein levels;
TGCT	cis	rs73198271	0.722	rs11785741	chr8:8605512	A/G	cg06671706	chr8:8559999	CLDN23	-0.36	-4.52	-0.38	1.43e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg16680214	chr1:154839983	KCNN3	-0.42	-9.27	-0.64	7.16e-16	Prostate cancer;
TGCT	cis	rs4711336	1.000	rs2229642	chr6:33659472	C/G	cg14003231	chr6:33640908	ITPR3	0.28	4.52	0.38	1.41e-5	Height;
TGCT	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg18230493	chr5:56204884	C5orf35	-0.68	-5.85	-0.46	4.13e-8	Initial pursuit acceleration;
TGCT	cis	rs7586879	0.639	rs3903070	chr2:25123463	C/G	cg01884057	chr2:25150051	NA	0.35	6.9	0.53	2.39e-10	Body mass index;
TGCT	cis	rs459571	1.000	rs467387	chr9:136907005	G/A	cg13789015	chr9:136890014	NCRNA00094	0.41	7.62	0.56	5.63e-12	Platelet distribution width;
TGCT	cis	rs10782582	0.569	rs4549990	chr1:76125075	A/G	cg10523679	chr1:76189770	ACADM	-0.7	-7.51	-0.56	9.94e-12	Daytime sleep phenotypes;
TGCT	cis	rs35934224	0.783	rs7290770	chr22:19861161	C/T	cg11182965	chr22:19864308	TXNRD2	-0.38	-5.06	-0.41	1.47e-6	Glaucoma (primary open-angle);
TGCT	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg18876405	chr7:65276391	NA	0.35	5.2	0.42	7.81e-7	Aortic root size;
TGCT	cis	rs55883249	1.000	rs17453752	chr2:9766171	C/T	cg23886495	chr2:9695866	ADAM17	-0.76	-4.8	-0.4	4.56e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs2228479	1.000	rs12596492	chr16:89957169	T/G	cg06558623	chr16:89946397	TCF25	0.57	6.52	0.51	1.62e-9	Skin colour saturation;
TGCT	cis	rs1062177	1.000	rs1062177	chr5:151184701	C/T	cg00977110	chr5:151150581	G3BP1	0.4	4.48	0.37	1.64e-5	Preschool internalizing problems;
TGCT	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9325144	0.560	rs1843910	chr12:38677408	T/C	cg26384229	chr12:38710491	ALG10B	-0.69	-6.57	-0.51	1.26e-9	Morning vs. evening chronotype;
TGCT	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.41	0.55	1.68e-11	Prudent dietary pattern;
TGCT	cis	rs9611565	0.571	rs7364123	chr22:42216326	A/G	cg17554472	chr22:41940697	POLR3H	-0.45	-4.67	-0.39	7.66e-6	Vitiligo;
TGCT	cis	rs7085104	0.513	rs619824	chr10:104581288	G/T	cg04362960	chr10:104952993	NT5C2	0.52	4.61	0.38	9.85e-6	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg06238570	chr21:40685208	BRWD1	0.59	5.25	0.43	6.37e-7	Cognitive function;
TGCT	cis	rs6570726	0.791	rs7765675	chr6:145915077	A/C	cg13319975	chr6:146136371	FBXO30	-0.54	-4.77	-0.39	5.1e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9653442	0.564	rs7590378	chr2:100789877	A/G	cg22139774	chr2:100720529	AFF3	-0.35	-5.55	-0.45	1.63e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs10089	1.000	rs7703634	chr5:127509223	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	7.4	0.55	1.83e-11	Ileal carcinoids;
TGCT	cis	rs763121	0.853	rs2235230	chr22:39124467	A/G	cg06022373	chr22:39101656	GTPBP1	-0.78	-6.86	-0.52	2.91e-10	Menopause (age at onset);
TGCT	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg24060327	chr5:131705240	SLC22A5	-0.66	-6.87	-0.53	2.75e-10	Acylcarnitine levels;
TGCT	cis	rs36022378	0.504	rs4688688	chr3:50042690	C/G	cg12257692	chr3:49977190	RBM6	-0.33	-5.32	-0.43	4.72e-7	Diastolic blood pressure;
TGCT	cis	rs17253792	0.822	rs79747476	chr14:56160485	C/A	cg01858014	chr14:56050164	KTN1	-0.35	-4.47	-0.37	1.73e-5	Putamen volume;
TGCT	cis	rs6740322	0.748	rs6544634	chr2:43471528	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.4	-6.2	-0.49	7.78e-9	Coronary artery disease;
TGCT	cis	rs9300255	0.602	rs2695478	chr12:123689521	C/T	cg00376283	chr12:123451042	ABCB9	0.72	4.99	0.41	2e-6	Neutrophil percentage of white cells;
TGCT	cis	rs6835098	1.000	rs28477433	chr4:174085820	T/C	cg08422745	chr4:174089978	GALNT7	-0.94	-11.2	-0.71	1.48e-20	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs12477438	0.765	rs7340412	chr2:99661148	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-4.88	-0.4	3.17e-6	Chronic sinus infection;
TGCT	trans	rs8076431	0.515	rs7213467	chr17:11254004	T/A	cg16283179	chr19:3624140	C19orf29	-0.76	-7.33	-0.55	2.58e-11	IgG glycosylation;
TGCT	cis	rs1005224	0.926	rs7143743	chr14:76127805	G/C	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.66	-6.06	-0.48	1.55e-8	Large artery stroke;
TGCT	cis	rs10927875	0.632	rs10927863	chr1:16165247	C/A	cg14742211	chr1:16348397	CLCNKA	-0.19	-4.69	-0.39	7.1e-6	Dilated cardiomyopathy;
TGCT	cis	rs13343954	0.778	rs10425324	chr19:33541302	C/T	cg07624008	chr19:33672378	NA	-0.28	-4.71	-0.39	6.43e-6	Colorectal cancer;
TGCT	cis	rs2594989	0.887	rs2437684	chr3:11593261	C/T	cg00170343	chr3:11313890	ATG7	-0.66	-5.0	-0.41	1.88e-6	Circulating chemerin levels;
TGCT	cis	rs1525293	0.965	rs6963281	chr7:70490070	C/G	cg21135135	chr7:70597687	WBSCR17	0.46	4.61	0.38	9.89e-6	Colonoscopy-negative controls vs population controls;Major depressive disorder;
TGCT	cis	rs10927875	0.541	rs1763607	chr1:16337509	G/A	cg21385522	chr1:16154831	NA	0.46	4.76	0.39	5.35e-6	Dilated cardiomyopathy;
TGCT	cis	rs6088580	0.634	rs6059856	chr20:33057954	G/C	cg06115741	chr20:33292138	TP53INP2	0.51	4.51	0.38	1.46e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs11030122	0.547	rs4910865	chr11:3950546	T/C	cg18678763	chr11:4115507	RRM1	-0.39	-4.76	-0.39	5.24e-6	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs7267979	0.903	rs6132819	chr20:25218618	C/G	cg03522245	chr20:25566470	NINL	0.6	6.58	0.51	1.21e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs174449	0.603	rs174460	chr11:61657110	C/T	cg19610905	chr11:61596333	FADS2	0.67	6.01	0.47	1.96e-8	Trans fatty acid levels;
TGCT	cis	rs7089973	0.872	rs3180654	chr10:116615045	T/C	cg03647239	chr10:116582469	FAM160B1	0.52	4.64	0.38	8.75e-6	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs7223966	1.000	rs752621	chr17:61901880	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	4.62	0.38	9.63e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs317689	0.718	rs315122	chr12:69771073	G/T	cg11871910	chr12:69753446	YEATS4	0.54	4.6	0.38	1.02e-5	Response to diuretic therapy;
TGCT	cis	rs12497850	0.829	rs8926	chr3:49052785	T/A	cg18654377	chr3:49208889	KLHDC8B	-0.41	-5.4	-0.44	3.33e-7	Parkinson's disease;
TGCT	cis	rs950776	0.714	rs3743074	chr15:78909480	G/A	cg06917634	chr15:78832804	PSMA4	-0.62	-4.95	-0.41	2.39e-6	Sudden cardiac arrest;
TGCT	trans	rs4332037	0.664	rs73046334	chr7:1887037	T/C	cg25206134	chr2:45395956	NA	0.93	7.88	0.58	1.43e-12	Bipolar disorder;
TGCT	cis	rs4665809	0.617	rs930263	chr2:26402594	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.82	-5.77	-0.46	5.83e-8	Gut microbiome composition (summer);
TGCT	cis	rs17221829	0.932	rs7924841	chr11:89460284	C/A	cg02982614	chr11:89391479	FOLH1B	-0.28	-4.87	-0.4	3.32e-6	Anxiety in major depressive disorder;
TGCT	cis	rs765787	0.530	rs4544188	chr15:45535393	C/A	cg24006582	chr15:45444508	DUOX1	-0.25	-5.54	-0.45	1.76e-7	Uric acid levels;
TGCT	trans	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg27523141	chr10:43048294	ZNF37B	0.7	8.15	0.59	3.36e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs3806843	0.576	rs246036	chr5:140331886	T/G	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs644799	0.635	rs10831428	chr11:95508404	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.81	9.02	0.63	2.92e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs2404602	0.735	rs2048856	chr15:76800083	C/T	cg06069100	chr15:77574588	SGK269	0.27	4.74	0.39	5.68e-6	Blood metabolite levels;
TGCT	cis	rs11030122	0.702	rs11030276	chr11:3946134	A/G	cg18678763	chr11:4115507	RRM1	-0.49	-6.14	-0.48	1.01e-8	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs208515	0.525	rs10944869	chr6:66687576	G/T	cg07460842	chr6:66804631	NA	0.88	9.35	0.64	4.63e-16	Exhaled nitric oxide levels;
TGCT	cis	rs497273	0.512	rs1177585	chr12:121325321	C/T	cg02419362	chr12:121203948	SPPL3	-0.19	-4.51	-0.38	1.5e-5	Systemic lupus erythematosus;
TGCT	cis	rs9393692	0.905	rs7761298	chr6:26278436	C/T	cg13736514	chr6:26305472	NA	-0.37	-5.42	-0.44	3.01e-7	Educational attainment;
TGCT	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9858542	0.953	rs35169793	chr3:49423274	A/G	cg03060546	chr3:49711283	APEH	-0.64	-5.61	-0.45	1.27e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs2463822	1.000	rs2513749	chr11:62105391	C/T	cg23876832	chr11:62092739	NA	0.67	4.91	0.4	2.82e-6	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs2404602	0.692	rs35077207	chr15:76935306	A/G	cg22467129	chr15:76604101	ETFA	-0.45	-5.11	-0.42	1.18e-6	Blood metabolite levels;
TGCT	cis	rs8062405	1.000	rs7205323	chr16:28865892	C/T	cg09754948	chr16:28834200	ATXN2L	0.59	4.45	0.37	1.91e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs6964587	1.000	rs10234071	chr7:91645152	C/G	cg22709100	chr7:91322751	NA	-0.28	-4.6	-0.38	1.02e-5	Breast cancer;
TGCT	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg13395646	chr4:1353034	KIAA1530	-0.54	-6.85	-0.52	3.1e-10	Obesity-related traits;
TGCT	trans	rs208520	1.000	rs12193164	chr6:66978962	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.83	7.46	0.56	1.31e-11	Exhaled nitric oxide output;
TGCT	cis	rs4783244	0.862	rs9939683	chr16:82653535	G/T	cg09415485	chr16:82663111	CDH13	-0.24	-4.51	-0.38	1.47e-5	Adiponectin levels;
TGCT	cis	rs7666738	0.830	rs1124253	chr4:98949682	C/T	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.7	-5.93	-0.47	2.75e-8	Tonsillectomy;
TGCT	cis	rs459571	0.916	rs467303	chr9:136904835	C/T	cg13789015	chr9:136890014	NCRNA00094	0.41	7.58	0.56	7.09e-12	Platelet distribution width;
TGCT	trans	rs1814175	0.904	rs1846289	chr11:49620253	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.34	-6.67	-0.51	7.47e-10	Height;
TGCT	cis	rs2204008	0.546	rs11519978	chr12:37998170	C/T	cg13010199	chr12:38710504	ALG10B	0.65	5.22	0.42	7.4e-7	Bladder cancer;
TGCT	cis	rs3796352	1.000	rs35576914	chr3:53092270	G/A	cg07884673	chr3:53033167	SFMBT1	0.61	6.25	0.49	6e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs9467773	0.935	rs1884947	chr6:26553273	G/T	cg05738196	chr6:26577821	NA	0.88	11.96	0.73	2.18e-22	Intelligence (multi-trait analysis);
TGCT	cis	rs1371867	0.846	rs1660323	chr8:101278724	T/A	cg06636551	chr8:101224915	SPAG1	-0.49	-6.83	-0.52	3.32e-10	Atrioventricular conduction;
TGCT	cis	rs9581857	0.556	rs9581861	chr13:28039991	C/T	cg22138327	chr13:27999177	GTF3A	0.73	5.63	0.45	1.13e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs2980439	0.807	rs2980438	chr8:8094825	T/C	cg15556689	chr8:8085844	FLJ10661	0.7	6.51	0.5	1.64e-9	Neuroticism;
TGCT	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.0	7.42	0.55	1.64e-11	Gut microbiome composition (summer);
TGCT	cis	rs1887596	0.629	rs1625599	chr13:27257688	C/T	cg01312412	chr13:27282625	NA	-0.31	-5.56	-0.45	1.56e-7	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg06873352	chr17:61820015	STRADA	0.56	6.22	0.49	6.93e-9	Prudent dietary pattern;
TGCT	cis	rs4803468	0.967	rs4803461	chr19:41908871	G/A	cg09537434	chr19:41945824	ATP5SL	-0.93	-11.02	-0.7	4.1e-20	Height;
TGCT	cis	rs10791323	0.569	rs1119851	chr11:133742842	T/C	cg15485101	chr11:133734466	NA	0.37	5.42	0.44	3e-7	Childhood ear infection;
TGCT	cis	rs4285028	0.747	rs1574133	chr3:121468794	G/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.96	-7.66	-0.57	4.71e-12	Multiple sclerosis;
TGCT	cis	rs244731	0.959	rs3105419	chr5:176551396	G/C	cg17509989	chr5:176798049	RGS14	0.58	6.71	0.52	6.17e-10	Urate levels in lean individuals;
TGCT	cis	rs422249	0.512	rs174554	chr11:61579463	A/G	cg01500311	chr11:61656094	FADS3	-0.3	-5.25	-0.43	6.42e-7	Trans fatty acid levels;
TGCT	cis	rs10832169	0.967	rs10832171	chr11:14071734	A/G	cg04547675	chr11:13986162	SPON1	0.53	4.73	0.39	6.04e-6	Blood protein levels;
TGCT	cis	rs2721195	0.845	rs3757966	chr8:145744618	G/A	cg11211951	chr8:145729740	GPT	0.27	6.59	0.51	1.1e-9	Age at first birth;
TGCT	cis	rs10927875	0.662	rs698893	chr1:16302982	C/T	cg21385522	chr1:16154831	NA	0.43	4.56	0.38	1.21e-5	Dilated cardiomyopathy;
TGCT	cis	rs826838	0.967	rs1486345	chr12:39131677	G/A	cg13010199	chr12:38710504	ALG10B	-0.63	-5.06	-0.41	1.46e-6	Heart rate;
TGCT	cis	rs1552244	1.000	rs13433680	chr3:10136390	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	6.33	0.49	4.08e-9	Alzheimer's disease;
TGCT	cis	rs2535633	0.631	rs9823697	chr3:53002150	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-5.18	-0.42	8.63e-7	Body mass index;
TGCT	cis	rs346785	0.666	rs9902690	chr17:74295140	A/G	cg09812376	chr17:74270190	QRICH2	-0.35	-5.2	-0.42	8.14e-7	White matter hyperintensities in ischemic stroke;
TGCT	cis	rs10782582	0.593	rs11576534	chr1:76112751	C/T	cg03433033	chr1:76189801	ACADM	-0.61	-7.17	-0.54	5.91e-11	Daytime sleep phenotypes;
TGCT	cis	rs6909430	0.539	rs34109912	chr6:98795355	C/T	cg20000812	chr6:99276697	NA	-0.52	-4.6	-0.38	1.03e-5	Quantitative traits;
TGCT	cis	rs4494114	0.967	rs9439083	chr1:39344766	C/T	cg25970120	chr1:39325951	RRAGC	-0.6	-6.23	-0.49	6.58e-9	Blood protein levels;
TGCT	cis	rs4664308	0.691	rs1877196	chr2:160915150	G/T	cg03641300	chr2:160917029	PLA2R1	-0.26	-6.55	-0.51	1.36e-9	Idiopathic membranous nephropathy;
TGCT	cis	rs11190604	0.767	rs11190533	chr10:102190792	T/C	cg16005271	chr10:102321736	NA	0.45	4.7	0.39	6.81e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2224391	0.911	rs9504368	chr6:5261460	A/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.79	-6.05	-0.48	1.61e-8	Height;
TGCT	cis	rs10057188	1.000	rs10077632	chr5:77874940	C/T	cg06873401	chr5:77792105	LHFPL2	-0.22	-4.49	-0.37	1.61e-5	Pulse pressure;
TGCT	cis	rs12580194	0.593	rs7314118	chr12:55737403	A/C	cg10672482	chr12:55725839	OR6C3	-0.53	-4.68	-0.39	7.28e-6	Cancer;
TGCT	cis	rs10876993	0.890	rs7963927	chr12:58046272	T/G	cg15848620	chr12:58087721	OS9	-0.72	-5.82	-0.46	4.71e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs4780355	0.918	rs1646019	chr16:11359680	C/T	cg00044050	chr16:11439710	C16orf75	0.54	4.77	0.39	5.01e-6	Crohn's disease and psoriasis;
TGCT	cis	rs694739	0.734	rs663743	chr11:64107735	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.7	6.55	0.51	1.36e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs3812831	0.669	rs7327370	chr13:114946858	A/G	cg15513719	chr13:114904418	NA	0.37	4.59	0.38	1.05e-5	Schizophrenia;
TGCT	cis	rs6840360	0.593	rs6847844	chr4:152693246	C/T	cg17479576	chr4:152424074	FAM160A1	-0.53	-5.26	-0.43	5.99e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1800469	1.000	rs2241714	chr19:41869392	C/T	cg09537434	chr19:41945824	ATP5SL	0.59	5.32	0.43	4.72e-7	Colorectal cancer;
TGCT	cis	rs2677744	0.626	rs867468	chr15:91498127	G/A	cg22570213	chr15:91497863	RCCD1	0.38	4.61	0.38	9.98e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs933688	1.000	rs10073657	chr5:90689749	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.06	9.9	0.66	2.21e-17	Smoking behavior;
TGCT	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg21016266	chr12:122356598	WDR66	0.53	6.62	0.51	9.84e-10	Mean corpuscular volume;
TGCT	cis	rs2594989	0.943	rs2454508	chr3:11493232	T/C	cg00170343	chr3:11313890	ATG7	0.69	5.1	0.42	1.26e-6	Circulating chemerin levels;
TGCT	cis	rs8014204	0.743	rs35809608	chr14:75254762	A/G	cg06637938	chr14:75390232	RPS6KL1	0.7	6.77	0.52	4.47e-10	Caffeine consumption;
TGCT	cis	rs727505	0.789	rs66756015	chr7:124740641	C/A	cg23710748	chr7:124431027	NA	-0.26	-4.54	-0.38	1.33e-5	Lewy body disease;
TGCT	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg17554472	chr22:41940697	POLR3H	-0.49	-5.27	-0.43	5.9e-7	Vitiligo;
TGCT	cis	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg18252515	chr7:66147081	NA	-1.13	-6.81	-0.52	3.7e-10	Diabetic kidney disease;
TGCT	cis	rs7975161	0.515	rs7299866	chr12:104576197	C/T	cg25273343	chr12:104657179	TXNRD1	-0.32	-6.03	-0.48	1.76e-8	Toenail selenium levels;
TGCT	cis	rs4689388	0.890	rs4481292	chr4:6298375	C/T	cg14416269	chr4:6271139	WFS1	0.4	5.32	0.43	4.78e-7	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs12220238	1.000	rs10824128	chr10:76007903	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.92	7.91	0.58	1.21e-12	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs9640161	0.750	rs3800780	chr7:150027284	C/A	cg17279839	chr7:150038598	RARRES2	0.43	4.54	0.38	1.29e-5	Blood protein levels;Circulating chemerin levels;
TGCT	trans	rs3780486	0.505	rs10117038	chr9:33122626	T/C	cg20290983	chr6:43655470	MRPS18A	0.8	8.58	0.61	3.34e-14	IgG glycosylation;
TGCT	cis	rs4478858	0.684	rs7549343	chr1:31752260	A/G	cg00250761	chr1:31883323	NA	-0.26	-4.55	-0.38	1.28e-5	Alcohol dependence;
TGCT	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg25036284	chr2:26402008	FAM59B	-0.57	-4.97	-0.41	2.15e-6	Gut microbiome composition (summer);
TGCT	cis	rs11190604	0.767	rs7916904	chr10:102186778	C/G	cg16005271	chr10:102321736	NA	0.45	4.7	0.39	6.81e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs61931739	0.500	rs10772160	chr12:34456848	G/A	cg06521331	chr12:34319734	NA	-0.28	-4.52	-0.38	1.4e-5	Morning vs. evening chronotype;
TGCT	cis	rs651907	0.557	rs11925001	chr3:101373966	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.03	0.41	1.65e-6	Colorectal cancer;
TGCT	cis	rs950169	0.840	rs12905223	chr15:85114268	T/C	cg17173187	chr15:85201210	NMB	0.47	4.93	0.4	2.62e-6	Schizophrenia;
TGCT	cis	rs2075371	1.000	rs2544211	chr7:133973230	A/G	cg11752832	chr7:134001865	SLC35B4	0.7	6.52	0.51	1.56e-9	Mean platelet volume;
TGCT	cis	rs7666738	0.546	rs9993299	chr4:98815976	G/A	cg18180107	chr4:99064573	C4orf37	0.54	4.72	0.39	6.21e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs881375	0.678	rs3761846	chr9:123689597	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	5.3	0.43	5.07e-7	Rheumatoid arthritis;
TGCT	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.58	-5.5	-0.44	2.08e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs9308731	0.505	rs10169613	chr2:111934977	C/T	cg04202892	chr2:111875749	ACOXL	0.43	4.73	0.39	5.88e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs67311347	1.000	rs2276868	chr3:40498845	C/T	cg17264618	chr3:40429014	ENTPD3	-0.35	-5.1	-0.42	1.21e-6	Renal cell carcinoma;
TGCT	trans	rs1974653	0.672	rs9606235	chr22:20069172	A/G	cg08822737	chr17:71088851	SLC39A11	-0.93	-7.61	-0.56	5.97e-12	Schizophrenia;
TGCT	cis	rs9818758	0.607	rs11706189	chr3:49210833	C/A	cg07636037	chr3:49044803	WDR6	-1.02	-5.13	-0.42	1.09e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs12682352	0.715	rs332039	chr8:8723651	C/G	cg08975724	chr8:8085496	FLJ10661	0.54	5.05	0.41	1.53e-6	Neuroticism;
TGCT	cis	rs259282	0.562	rs2021772	chr19:33107651	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.53	4.81	0.4	4.24e-6	Schizophrenia;
TGCT	cis	rs7731657	0.537	rs4705995	chr5:130350688	G/A	cg08523029	chr5:130500466	HINT1	-0.61	-5.08	-0.42	1.34e-6	Fasting plasma glucose;
TGCT	cis	rs1801251	1.000	rs7587309	chr2:233705702	G/T	cg08000102	chr2:233561755	GIGYF2	-0.64	-6.48	-0.5	1.95e-9	Coronary artery disease;
TGCT	cis	rs9354352	0.818	rs9453548	chr6:66691885	T/C	cg07460842	chr6:66804631	NA	-0.58	-5.84	-0.46	4.29e-8	Initial pursuit acceleration in psychotic disorders;
TGCT	cis	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg20637647	chr7:64974828	NA	1.0	5.59	0.45	1.4e-7	Diabetic kidney disease;
TGCT	cis	rs8062405	0.929	rs11864750	chr16:28875204	A/T	cg09754948	chr16:28834200	ATXN2L	0.59	4.45	0.37	1.91e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs12681288	0.676	rs2701923	chr8:994605	A/G	cg04851639	chr8:1020857	NA	-0.31	-5.21	-0.42	7.57e-7	Schizophrenia;
TGCT	cis	rs986417	0.748	rs9989223	chr14:60942525	C/A	cg27398547	chr14:60952738	C14orf39	1.39	10.61	0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs28595532	0.920	rs115464801	chr4:119730673	T/C	cg21605333	chr4:119757512	SEC24D	1.66	8.33	0.6	1.28e-13	Cannabis dependence symptom count;
TGCT	cis	rs6074578	0.679	rs1858594	chr20:138555	A/G	cg16931068	chr20:139680	DEFB127	0.28	4.98	0.41	2.11e-6	Hirschsprung disease;
TGCT	cis	rs394563	0.726	rs6906384	chr6:149664540	G/A	cg16235748	chr6:149772707	ZC3H12D	0.5	5.95	0.47	2.55e-8	Dupuytren's disease;
TGCT	cis	rs6430585	0.528	rs309113	chr2:136737460	C/A	cg07169764	chr2:136633963	MCM6	1.18	11.33	0.71	7.22e-21	Corneal structure;
TGCT	cis	rs9300255	0.602	rs1716172	chr12:123712712	G/T	cg00376283	chr12:123451042	ABCB9	0.67	5.3	0.43	5.07e-7	Neutrophil percentage of white cells;
TGCT	cis	rs1215050	0.791	rs503863	chr4:98707663	T/C	cg05340658	chr4:99064831	C4orf37	0.44	5.52	0.44	1.85e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs10875746	0.669	rs61941003	chr12:48619625	G/A	cg20731937	chr12:48336164	NA	0.59	4.49	0.37	1.61e-5	Longevity (90 years and older);
TGCT	cis	rs9372498	0.536	rs724868	chr6:118795152	C/T	cg07617317	chr6:118971624	C6orf204	0.5	5.39	0.44	3.36e-7	Diastolic blood pressure;
TGCT	cis	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg02503808	chr4:7069936	GRPEL1	0.98	9.23	0.64	9.22e-16	Monocyte percentage of white cells;
TGCT	cis	rs17030434	0.953	rs11099906	chr4:154691690	A/T	cg14289246	chr4:154710475	SFRP2	-0.96	-7.72	-0.57	3.43e-12	Electrocardiographic conduction measures;
TGCT	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.71	0.39	6.53e-6	Prudent dietary pattern;
TGCT	cis	rs734999	0.545	rs28568531	chr1:2555640	T/A	cg18854424	chr1:2615690	NA	0.45	5.15	0.42	1e-6	Ulcerative colitis;
TGCT	cis	rs7312933	0.618	rs6582394	chr12:42686189	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.58	5.42	0.44	3.03e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs2982552	1.000	rs2982575	chr6:152069791	A/G	cg22157087	chr6:152012887	ESR1	0.18	4.54	0.38	1.31e-5	Bone properties (heel);
TGCT	cis	rs7267979	0.932	rs446649	chr20:25467359	A/G	cg03522245	chr20:25566470	NINL	0.58	6.37	0.5	3.42e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7100689	0.646	rs1538819	chr10:82122523	A/G	cg01528321	chr10:82214614	TSPAN14	0.8	7.76	0.57	2.7e-12	Post bronchodilator FEV1;
TGCT	cis	rs240764	0.658	rs6925823	chr6:101179273	C/A	cg09795085	chr6:101329169	ASCC3	-0.51	-4.51	-0.38	1.48e-5	Neuroticism;
TGCT	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg24675658	chr1:53192096	ZYG11B	-0.7	-7.91	-0.58	1.22e-12	Monocyte count;
TGCT	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg26119090	chr2:26468346	HADHA;HADHB	0.99	7.28	0.55	3.39e-11	Gut microbiome composition (summer);
TGCT	cis	rs9814567	0.964	rs9847788	chr3:134186496	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.96	-9.76	-0.66	4.96e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	trans	rs11512640	0.826	rs11220091	chr11:125361138	C/T	cg09813145	chr16:48012664	NA	-0.57	-6.65	-0.51	8.31e-10	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs3008870	1.000	rs2815370	chr1:67503727	A/G	cg03991309	chr1:68237761	GNG12	-0.27	-4.72	-0.39	6.32e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs11605924	1.000	rs1401419	chr11:45879739	T/C	ch.11.939596F	chr11:45881766	CRY2	-0.38	-4.67	-0.39	7.8e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
TGCT	cis	rs9674544	0.757	rs9896443	chr17:47125982	A/G	cg22947322	chr17:47091978	IGF2BP1	-0.25	-4.47	-0.37	1.75e-5	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
TGCT	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg21724239	chr8:58056113	NA	0.46	4.98	0.41	2.04e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs62103177	0.525	rs10438902	chr18:77745640	A/G	cg07235805	chr18:78004237	PARD6G	-0.46	-4.54	-0.38	1.32e-5	Opioid sensitivity;
TGCT	cis	rs6693567	0.545	rs1260403	chr1:150303666	A/G	cg09579323	chr1:150459698	TARS2	0.54	4.79	0.4	4.59e-6	Migraine;
TGCT	cis	rs9400467	0.537	rs12214550	chr6:111505499	C/T	cg15721981	chr6:111408429	SLC16A10	0.71	4.6	0.38	1.04e-5	Blood metabolite levels;Amino acid levels;
TGCT	cis	rs11105298	0.891	rs3741899	chr12:89933931	G/A	cg00757033	chr12:89920650	WDR51B	0.29	4.6	0.38	1.01e-5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg07061783	chr6:25882402	NA	-0.68	-6.83	-0.52	3.35e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs4268898	0.722	rs35520052	chr2:24415277	C/T	cg02683114	chr2:24398427	C2orf84	0.19	4.7	0.39	6.78e-6	Asthma;
TGCT	cis	rs9913156	0.841	rs56239958	chr17:4600280	G/C	cg19197139	chr17:4613644	ARRB2	0.83	7.74	0.57	3.03e-12	Lymphocyte counts;
TGCT	cis	rs9883204	1.000	rs56371916	chr3:123095543	T/C	cg04890266	chr3:123102914	ADCY5	0.36	5.11	0.42	1.17e-6	Birth weight;
TGCT	cis	rs9814567	0.752	rs4955544	chr3:134332776	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-6.45	-0.5	2.3e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs4455778	0.580	rs6951015	chr7:49115139	T/A	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs644799	0.930	rs3802764	chr11:95514599	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	8.53	0.61	4.41e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs12753569	0.934	rs10430051	chr1:76491628	T/G	cg01259156	chr1:75594592	LHX8	0.26	4.69	0.39	7.19e-6	Personality dimensions;
TGCT	cis	rs6121246	0.567	rs7361893	chr20:30200751	C/T	cg10886678	chr20:30946050	ASXL1	-0.71	-4.8	-0.4	4.39e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg12564285	chr5:131593104	PDLIM4	0.4	4.78	0.39	4.79e-6	Acylcarnitine levels;
TGCT	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.73	-0.39	5.93e-6	Prudent dietary pattern;
TGCT	cis	rs79349575	0.715	rs999474	chr17:46987665	G/A	cg26022315	chr17:47021804	SNF8	-0.54	-5.37	-0.43	3.73e-7	Type 2 diabetes;
TGCT	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg27286337	chr10:134555280	INPP5A	0.4	4.91	0.4	2.76e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs11696501	0.739	rs2235600	chr20:44238299	T/G	cg11783356	chr20:44313418	WFDC10B	-0.32	-4.63	-0.38	9.25e-6	Brain structure;
TGCT	cis	rs7226408	0.894	rs55797519	chr18:34386020	A/G	cg06757138	chr18:34340585	FHOD3	0.26	4.79	0.4	4.62e-6	Obesity-related traits;
TGCT	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg07507251	chr3:52567010	NT5DC2	0.47	6.7	0.52	6.49e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs11690935	0.595	rs788166	chr2:172915489	G/C	cg13550731	chr2:172543902	DYNC1I2	0.68	6.32	0.49	4.31e-9	Schizophrenia;
TGCT	cis	rs17433780	0.964	rs12146148	chr1:89471892	C/T	cg09516651	chr1:89888402	LOC400759	0.32	5.89	0.47	3.35e-8	Carotid intima media thickness;
TGCT	cis	rs4851254	0.626	rs71413861	chr2:100673501	A/G	cg07810366	chr2:100720526	AFF3	-0.49	-5.22	-0.42	7.36e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2235642	0.893	rs2076439	chr16:1587277	C/T	cg11375102	chr16:1583810	IFT140;TMEM204	-0.31	-5.51	-0.44	2e-7	Coronary artery disease;
TGCT	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	8.55	0.61	3.84e-14	Platelet count;
TGCT	cis	rs2288884	1.000	rs2043298	chr19:52573067	A/C	cg15405931	chr19:52693188	PPP2R1A	0.69	4.52	0.38	1.41e-5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg07061783	chr6:25882402	NA	0.58	5.59	0.45	1.39e-7	Intelligence (multi-trait analysis);
TGCT	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg18110333	chr6:292329	DUSP22	-0.74	-7.88	-0.58	1.46e-12	Menopause (age at onset);
TGCT	cis	rs17221829	0.590	rs10830300	chr11:89363066	A/G	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.65	-0.39	8.43e-6	Anxiety in major depressive disorder;
TGCT	cis	rs3806843	0.548	rs246058	chr5:140325134	G/A	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs8016982	0.674	rs6574631	chr14:81675772	C/T	cg01989461	chr14:81687754	GTF2A1	0.84	9.08	0.63	2.14e-15	Schizophrenia;
TGCT	cis	rs4988958	0.527	rs11465641	chr2:103000868	T/G	cg03938978	chr2:103052716	IL18RAP	0.26	5.22	0.42	7.15e-7	Asthma (childhood onset);
TGCT	cis	rs9818758	0.607	rs55873331	chr3:49597055	C/T	cg08550065	chr3:50336684	HYAL3;NAT6	1.04	5.13	0.42	1.08e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs7173743	0.525	rs7173955	chr15:79143857	A/G	cg00540400	chr15:79124168	NA	0.18	4.52	0.38	1.4e-5	Coronary artery disease;
TGCT	cis	rs2354432	0.556	rs2353975	chr1:146837703	C/A	cg25205988	chr1:146714368	CHD1L	1.33	5.9	0.47	3.26e-8	Mitochondrial DNA levels;
TGCT	cis	rs9814567	1.000	rs4334685	chr3:134304335	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.91	-8.83	-0.62	8.17e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs3784262	0.740	rs1441829	chr15:58289739	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.42	-5.95	-0.47	2.58e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs3772130	0.962	rs9848027	chr3:121551227	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.72	0.39	6.25e-6	Cognitive performance;
TGCT	cis	rs4252435	0.522	rs10279865	chr7:142598708	C/T	cg09833174	chr7:143059591	FAM131B	-0.96	-4.52	-0.38	1.41e-5	Cancer;
TGCT	cis	rs9952991	0.941	rs888270	chr18:12774894	G/A	cg09945482	chr18:12777974	NA	-0.52	-4.73	-0.39	6.08e-6	Inflammatory skin disease;
TGCT	cis	rs1997103	1.000	rs6945937	chr7:55407140	C/T	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs7208859	0.623	rs73263788	chr17:29216490	T/C	cg18442181	chr17:29233375	C17orf42	-0.76	-4.55	-0.38	1.27e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs3749237	0.595	rs4855839	chr3:49507847	G/A	cg02487422	chr3:49467188	NICN1	0.58	5.92	0.47	3e-8	Resting heart rate;
TGCT	cis	rs1218582	0.596	rs906595	chr1:154822907	C/T	cg09359103	chr1:154839909	KCNN3	-0.52	-8.22	-0.59	2.36e-13	Prostate cancer;
TGCT	cis	rs6752107	0.870	rs13003866	chr2:234143373	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.2	4.92	0.4	2.73e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs2235642	0.750	rs1894649	chr16:1657284	C/G	cg08296037	chr16:1584118	IFT140;TMEM204	-0.29	-4.98	-0.41	2.06e-6	Coronary artery disease;
TGCT	cis	rs11098499	0.954	rs1546505	chr4:120241224	A/G	cg09307838	chr4:120376055	NA	0.65	6.01	0.48	1.9e-8	Corneal astigmatism;
TGCT	cis	rs3771570	1.000	rs56052835	chr2:242243251	T/G	cg21155796	chr2:242212141	HDLBP	0.98	6.68	0.51	7.29e-10	Prostate cancer;
TGCT	cis	rs981844	0.826	rs1545604	chr4:154682733	C/T	cg14289246	chr4:154710475	SFRP2	1.06	9.98	0.67	1.4e-17	Response to statins (LDL cholesterol change);
TGCT	cis	rs644799	0.648	rs1255182	chr11:95472391	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.53	5.13	0.42	1.11e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs4727027	1.000	rs4727027	chr7:148869277	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	4.59	0.38	1.07e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs4455778	0.580	rs4285433	chr7:49114185	A/G	cg26309511	chr7:48887640	NA	0.51	6.64	0.51	8.83e-10	Lung cancer in never smokers;
TGCT	cis	rs7666738	0.830	rs7678250	chr4:98922109	G/A	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs478304	0.651	rs4930319	chr11:65555458	G/C	cg10518572	chr11:65560635	OVOL1	-0.25	-4.76	-0.39	5.32e-6	Acne (severe);
TGCT	cis	rs11098499	0.909	rs7681978	chr4:120383775	T/C	cg09307838	chr4:120376055	NA	0.68	6.53	0.51	1.54e-9	Corneal astigmatism;
TGCT	cis	rs3784262	0.669	rs12905608	chr15:58314139	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.43	-6.27	-0.49	5.58e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs751728	0.965	rs4713683	chr6:33757550	C/G	cg13859433	chr6:33739653	LEMD2	-0.43	-7.94	-0.58	1.04e-12	Crohn's disease;
TGCT	cis	rs79057730	0.639	rs6463933	chr7:793954	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.78	6.05	0.48	1.62e-8	Initial pursuit acceleration;
TGCT	cis	rs6460942	0.908	rs7781919	chr7:12235351	T/C	cg06484146	chr7:12443880	VWDE	-0.54	-4.76	-0.39	5.21e-6	Coronary artery disease;
TGCT	cis	rs9814567	1.000	rs6766818	chr3:134226159	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.96	-9.19	-0.64	1.16e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs644799	0.965	rs565771	chr11:95644179	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	10.28	0.68	2.67e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs2594989	0.887	rs6442253	chr3:11474238	T/C	cg00170343	chr3:11313890	ATG7	0.73	5.41	0.44	3.16e-7	Circulating chemerin levels;
TGCT	cis	rs1541995	0.789	rs35974115	chr15:96231079	T/C	cg00882281	chr15:96346592	NA	0.3	4.76	0.39	5.28e-6	Photic sneeze reflex;
TGCT	cis	rs4925386	0.840	rs6143034	chr20:60920545	T/C	cg06026331	chr20:60912101	LAMA5	0.36	5.99	0.47	2.09e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs2224391	0.628	rs9405260	chr6:5249612	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.96	-5.44	-0.44	2.67e-7	Height;
TGCT	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.55	-5.32	-0.43	4.68e-7	Bipolar disorder;
TGCT	cis	rs2730260	0.537	rs73169233	chr7:158882201	C/T	cg02078164	chr7:157982224	PTPRN2	0.41	4.58	0.38	1.11e-5	Myopia (pathological);
TGCT	cis	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg18188782	chr20:61659543	NA	0.44	5.38	0.43	3.6e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2046867	0.862	rs2322611	chr3:72830087	T/G	cg25664220	chr3:72788482	NA	-0.57	-7.07	-0.54	9.9e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	trans	rs9859260	0.710	rs41298097	chr3:195779155	C/T	cg17074656	chr11:63784126	MACROD1	0.52	6.67	0.51	7.49e-10	Mean corpuscular volume;
TGCT	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg20007245	chr22:24372913	LOC391322	-0.74	-7.49	-0.56	1.11e-11	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.6	-5.38	-0.43	3.65e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs709400	0.628	rs1951392	chr14:103853367	T/G	cg26031613	chr14:104095156	KLC1	0.85	8.95	0.63	4.36e-15	Body mass index;
TGCT	cis	rs61990749	0.686	rs11159288	chr14:78216972	G/A	cg23188588	chr14:78226832	SNW1;C14orf178	0.67	4.73	0.39	6.09e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg23172400	chr8:95962367	TP53INP1	-0.38	-6.26	-0.49	5.71e-9	Type 2 diabetes;
TGCT	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg06028808	chr11:68637592	NA	0.51	6.88	0.53	2.57e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	5.8	0.46	5.19e-8	Alzheimer's disease;
TGCT	cis	rs17221829	0.645	rs10830325	chr11:89389068	G/C	cg02982614	chr11:89391479	FOLH1B	-0.25	-4.46	-0.37	1.8e-5	Anxiety in major depressive disorder;
TGCT	cis	rs7394190	0.748	rs78790589	chr10:75539598	G/A	cg07699608	chr10:75541558	CHCHD1	0.79	5.45	0.44	2.63e-7	Incident atrial fibrillation;
TGCT	cis	rs2239547	0.657	rs12488303	chr3:52862003	G/A	cg10802521	chr3:52805072	NEK4	-0.62	-5.85	-0.47	4.1e-8	Schizophrenia;
TGCT	cis	rs1712790	0.613	rs2213072	chr11:114640554	G/C	cg19978728	chr11:115335092	CADM1	0.3	4.76	0.39	5.23e-6	Urinary albumin excretion;
TGCT	cis	rs295140	0.605	rs34693942	chr2:201184348	T/C	cg23649088	chr2:200775458	C2orf69	-0.28	-4.52	-0.38	1.41e-5	QT interval;
TGCT	cis	rs1555895	0.576	rs12413228	chr10:849230	G/T	cg02193355	chr10:851439	NA	0.23	5.38	0.43	3.6e-7	Survival in rectal cancer;
TGCT	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg23172400	chr8:95962367	TP53INP1	-0.39	-6.52	-0.51	1.59e-9	Type 2 diabetes;
TGCT	cis	rs2235642	0.653	rs7197288	chr16:1654753	C/A	cg07639376	chr16:1584516	IFT140;TMEM204	-0.29	-4.97	-0.41	2.22e-6	Coronary artery disease;
TGCT	cis	rs7264396	0.676	rs58372200	chr20:34555445	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.04	-0.41	1.58e-6	Total cholesterol levels;
TGCT	cis	rs4971059	0.507	rs11264321	chr1:155085898	C/A	cg23973274	chr1:155060172	NA	-0.25	-4.51	-0.38	1.48e-5	Breast cancer;
TGCT	cis	rs514406	0.505	rs269286	chr1:53169018	C/T	cg08859206	chr1:53392774	SCP2	0.36	5.21	0.42	7.7e-7	Monocyte count;
TGCT	cis	rs523522	0.673	rs643372	chr12:121022640	C/G	cg12219531	chr12:120966889	COQ5	0.82	7.38	0.55	2.05e-11	High light scatter reticulocyte count;
TGCT	cis	rs9788682	0.894	rs4461039	chr15:78817447	A/T	cg06917634	chr15:78832804	PSMA4	0.69	5.09	0.42	1.29e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs354033	0.959	rs354041	chr7:149297035	A/C	cg24335155	chr7:149193227	ZNF746	0.34	4.82	0.4	4.06e-6	Multiple sclerosis;
TGCT	cis	rs2797780	0.964	rs75330988	chr6:37504507	C/T	cg00985040	chr6:37553208	NA	0.25	4.8	0.4	4.48e-6	Systemic lupus erythematosus;
TGCT	cis	rs4713118	0.868	rs742047	chr6:27739380	A/G	cg20933634	chr6:27740509	NA	0.34	4.81	0.4	4.25e-6	Parkinson's disease;
TGCT	cis	rs9640161	0.789	rs10952250	chr7:150025966	T/C	cg10018233	chr7:150070692	REPIN1	0.32	4.66	0.39	8e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs2880765	0.566	rs55899824	chr15:86004091	C/T	cg13263323	chr15:86062960	AKAP13	-0.2	-4.48	-0.37	1.68e-5	Coronary artery disease;
TGCT	cis	rs910187	0.605	rs6124961	chr20:45804467	G/C	cg27589058	chr20:45804311	EYA2	-0.38	-8.37	-0.6	1.02e-13	Migraine;
TGCT	cis	rs11098499	0.754	rs7672778	chr4:120248585	A/G	cg09307838	chr4:120376055	NA	0.61	5.91	0.47	3.14e-8	Corneal astigmatism;
TGCT	cis	rs644799	1.000	rs693364	chr11:95621926	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	9.44	0.65	2.8e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs2439831	1.000	rs2256764	chr15:43735763	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	5.49	0.44	2.14e-7	Lung cancer in ever smokers;
TGCT	cis	rs73110464	0.562	rs2363634	chr12:53354683	A/G	cg25025879	chr12:53359317	NA	-0.52	-5.56	-0.45	1.57e-7	Cancer (pleiotropy);
TGCT	cis	rs79057730	0.684	rs6955004	chr7:790792	A/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.79	6.14	0.48	1.03e-8	Initial pursuit acceleration;
TGCT	cis	rs7264396	0.790	rs6060539	chr20:34239382	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.25	-0.43	6.33e-7	Total cholesterol levels;
TGCT	cis	rs9388451	0.869	rs7764016	chr6:126070789	T/G	cg05901451	chr6:126070800	HEY2	-1.03	-15.09	-0.8	7.37e-30	Brugada syndrome;
TGCT	cis	rs7937682	0.921	rs34584980	chr11:111441537	G/A	cg09085632	chr11:111637200	PPP2R1B	0.84	6.68	0.51	7.09e-10	Primary sclerosing cholangitis;
TGCT	cis	rs7210837	0.527	rs35353236	chr17:16788996	G/T	cg00849854	chr17:17780937	TOM1L2	0.35	4.45	0.37	1.85e-5	Response to platinum-based chemotherapy (cisplatin);
TGCT	cis	rs4285028	0.948	rs12493408	chr3:121692119	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.77	-6.5	-0.5	1.78e-9	Multiple sclerosis;
TGCT	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.91	-9.53	-0.65	1.78e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs6752107	0.782	rs12692254	chr2:234161211	A/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.2	4.86	0.4	3.46e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs6964587	1.000	rs12536529	chr7:91684086	C/T	cg17063962	chr7:91808500	NA	-0.86	-9.31	-0.64	6.01e-16	Breast cancer;
TGCT	cis	rs7119	0.604	rs2271398	chr15:77907784	G/A	cg27398640	chr15:77910606	LINGO1	0.32	6.88	0.53	2.63e-10	Type 2 diabetes;
TGCT	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg02725872	chr8:58115012	NA	-0.4	-4.83	-0.4	3.92e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6088590	1.000	rs6087625	chr20:33342477	A/G	cg24642439	chr20:33292090	TP53INP2	-0.7	-6.26	-0.49	5.87e-9	Coronary artery disease;
TGCT	cis	rs35146811	0.735	rs858512	chr7:99824453	A/G	cg22906224	chr7:99728672	NA	-0.5	-4.51	-0.38	1.48e-5	Coronary artery disease;
TGCT	cis	rs231513	0.911	rs231521	chr17:41955158	A/G	cg26893861	chr17:41843967	DUSP3	-0.76	-5.45	-0.44	2.62e-7	Cognitive function;
TGCT	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg23708337	chr7:1209742	NA	0.44	4.87	0.4	3.27e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs896854	0.608	rs7004862	chr8:95876963	T/G	cg16049864	chr8:95962084	TP53INP1	-0.6	-7.21	-0.54	4.92e-11	Type 2 diabetes;
TGCT	cis	rs514406	0.607	rs6696940	chr1:53203427	C/T	cg25767906	chr1:53392781	SCP2	0.46	5.1	0.42	1.24e-6	Monocyte count;
TGCT	cis	rs4851266	1.000	rs11684761	chr2:100826871	C/A	cg22139774	chr2:100720529	AFF3	-0.35	-5.19	-0.42	8.51e-7	Educational attainment;
TGCT	cis	rs7172809	0.599	rs11856084	chr15:77750410	T/G	cg22256960	chr15:77711686	NA	-0.51	-4.86	-0.4	3.47e-6	Glucose homeostasis traits;
TGCT	cis	rs7511006	1.000	rs17836662	chr22:50672154	A/G	cg08875078	chr22:50639485	SELO	-0.52	-4.93	-0.4	2.62e-6	Obesity-related traits;
TGCT	cis	rs4321325	0.733	rs79995601	chr2:127947452	T/C	cg09760422	chr2:128146352	NA	0.42	4.5	0.37	1.57e-5	Protein C levels;
TGCT	cis	rs66573146	1.000	rs67067921	chr4:6984341	A/T	cg01220768	chr4:7056774	TADA2B	0.39	4.91	0.4	2.77e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs4478858	0.735	rs10914344	chr1:31769025	T/C	cg00250761	chr1:31883323	NA	-0.27	-4.96	-0.41	2.28e-6	Alcohol dependence;
TGCT	cis	rs9921222	1.000	rs10794639	chr16:377367	A/G	cg12437481	chr16:420112	MRPL28	-0.49	-5.21	-0.42	7.8e-7	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs10464366	0.746	rs6945402	chr7:39145385	A/T	cg18850127	chr7:39170497	POU6F2	0.3	6.61	0.51	1e-9	IgG glycosylation;
TGCT	cis	rs11696845	0.776	rs6073538	chr20:43379264	A/C	cg25301532	chr20:43378953	KCNK15	0.47	5.24	0.43	6.8e-7	Obesity-related traits;
TGCT	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg11494091	chr17:61959527	GH2	0.42	7.39	0.55	1.86e-11	Height;
TGCT	cis	rs6815814	0.731	rs66735315	chr4:38774180	G/T	cg02016764	chr4:38805732	TLR1	-0.28	-4.79	-0.4	4.63e-6	Breast cancer;
TGCT	cis	rs7267979	0.727	rs2474765	chr20:25245950	G/T	cg14121845	chr20:25566513	NINL	0.45	4.8	0.4	4.44e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	5.14	0.42	1.03e-6	Height;
TGCT	cis	rs11190604	1.000	rs2489051	chr10:102351785	C/T	cg16342193	chr10:102329863	NA	0.39	5.41	0.44	3.13e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs12643440	0.538	rs1357233	chr4:17143376	A/C	cg22650099	chr4:17144496	NA	-0.46	-4.7	-0.39	6.79e-6	Metabolite levels (Pyroglutamine);
TGCT	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg03351412	chr1:154909251	PMVK	0.54	4.98	0.41	2.06e-6	Prostate cancer;
TGCT	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg06028605	chr16:24865363	SLC5A11	-0.42	-4.69	-0.39	7.14e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9393692	0.905	rs9379843	chr6:26289435	A/G	cg00631329	chr6:26305371	NA	-0.45	-6.58	-0.51	1.16e-9	Educational attainment;
TGCT	cis	rs2013441	1.000	rs17686839	chr17:20039171	A/G	cg18979559	chr17:20280153	CCDC144C	0.44	4.61	0.38	9.78e-6	Obesity-related traits;
TGCT	cis	rs1348850	0.914	rs6761593	chr2:178451600	A/G	cg22681709	chr2:178499509	PDE11A	0.4	5.11	0.42	1.16e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs12497850	1.000	rs10865952	chr3:48744484	A/G	cg07636037	chr3:49044803	WDR6	0.92	10.34	0.68	1.91e-18	Parkinson's disease;
TGCT	cis	rs7666738	0.830	rs13144564	chr4:98939276	A/G	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg07157834	chr1:205819609	PM20D1	0.32	4.53	0.38	1.37e-5	Menarche (age at onset);
TGCT	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg18867708	chr6:26865862	GUSBL1	-0.38	-5.03	-0.41	1.65e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7666738	0.888	rs13110683	chr4:98983368	G/C	cg18180107	chr4:99064573	C4orf37	0.56	4.54	0.38	1.3e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3784262	0.669	rs2414530	chr15:58356362	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.42	-6.24	-0.49	6.32e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs9926296	0.632	rs7206546	chr16:89799079	C/T	cg04287289	chr16:89883240	FANCA	-0.64	-6.39	-0.5	3.08e-9	Vitiligo;
TGCT	cis	rs11599315	0.507	rs12220554	chr10:1341852	C/T	cg27336068	chr10:1336103	ADARB2	-0.34	-5.47	-0.44	2.41e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	cis	rs2997447	0.846	rs2997445	chr1:26390154	C/T	cg19633962	chr1:26362018	EXTL1	-0.68	-4.62	-0.38	9.47e-6	QRS complex (12-leadsum);
TGCT	cis	rs1048238	0.506	rs7525608	chr1:16141901	A/G	cg21385522	chr1:16154831	NA	0.58	6.38	0.5	3.21e-9	Systolic blood pressure;
TGCT	cis	rs6500602	0.673	rs4786513	chr16:4576423	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	7.85	0.58	1.7e-12	Schizophrenia;
TGCT	cis	rs79149102	0.579	rs76900720	chr15:75348895	A/T	cg09165964	chr15:75287851	SCAMP5	-1.14	-6.16	-0.48	9.2e-9	Lung cancer;
TGCT	cis	rs72945132	0.714	rs117232799	chr11:70157182	G/A	cg00319359	chr11:70116639	PPFIA1	0.97	7.07	0.54	1.01e-10	Coronary artery disease;
TGCT	cis	rs17376456	0.569	rs2924374	chr5:93151141	T/C	cg21475434	chr5:93447410	FAM172A	-0.63	-4.96	-0.41	2.23e-6	Diabetic retinopathy;
TGCT	cis	rs1568889	1.000	rs12808162	chr11:28067027	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	8.87	0.62	6.72e-15	Bipolar disorder;
TGCT	cis	rs5167	0.781	rs909134	chr19:45493061	T/C	cg09555818	chr19:45449301	APOC2	0.24	5.11	0.42	1.2e-6	Blood protein levels;
TGCT	cis	rs9807989	0.773	rs5010059	chr2:102968826	C/G	cg09003973	chr2:102972529	NA	0.64	5.7	0.46	8.28e-8	Asthma;
TGCT	cis	rs6426558	0.537	rs6682642	chr1:227244600	G/T	cg10327440	chr1:227177885	CDC42BPA	0.57	7.03	0.53	1.22e-10	Neutrophil percentage of white cells;
TGCT	cis	rs67311347	1.000	rs9860162	chr3:40403875	C/T	cg13409248	chr3:40428643	ENTPD3	0.54	4.52	0.38	1.41e-5	Renal cell carcinoma;
TGCT	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-5.1	-0.42	1.23e-6	Bipolar disorder;
TGCT	cis	rs13242816	1.000	rs73208106	chr7:116173263	G/A	cg02799643	chr7:116139180	CAV2	-0.43	-5.29	-0.43	5.24e-7	P wave duration;
TGCT	cis	rs2832191	0.791	rs2832197	chr21:30497790	T/C	cg24692254	chr21:30365293	RNF160	-0.86	-9.11	-0.63	1.83e-15	Dental caries;
TGCT	cis	rs7017914	0.935	rs6981435	chr8:71637148	T/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.03	-0.41	1.69e-6	Bone mineral density;
TGCT	cis	rs10875746	0.951	rs61918826	chr12:48543978	T/C	cg20731937	chr12:48336164	NA	0.62	4.94	0.41	2.46e-6	Longevity (90 years and older);
TGCT	cis	rs17345786	0.906	rs11708616	chr3:101231731	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.86	8.92	0.63	5.18e-15	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs73058052	0.597	rs16981329	chr19:50097932	G/C	cg09250473	chr19:50168907	IRF3;BCL2L12	0.68	5.59	0.45	1.4e-7	Fibrinogen levels;
TGCT	cis	rs9486719	0.947	rs11755945	chr6:96908038	G/C	cg06623918	chr6:96969491	KIAA0776	-0.98	-8.77	-0.62	1.15e-14	Migraine;Coronary artery disease;
TGCT	cis	rs514406	0.763	rs7535088	chr1:53215042	A/G	cg24675658	chr1:53192096	ZYG11B	0.71	7.96	0.58	9.48e-13	Monocyte count;
TGCT	cis	rs11239930	0.538	rs4950359	chr1:146558743	C/A	cg00044796	chr1:146552390	NA	-0.35	-4.5	-0.37	1.54e-5	AIDS progression;
TGCT	cis	rs7681440	0.904	rs7672979	chr4:90767873	A/G	cg14346243	chr4:90757452	SNCA	-0.57	-5.6	-0.45	1.31e-7	Dementia with Lewy bodies;
TGCT	cis	rs1577917	1.000	rs1911553	chr6:86630892	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.22	-0.42	7.27e-7	Response to antipsychotic treatment;
TGCT	cis	rs11809207	0.951	rs111772533	chr1:26523404	C/G	cg03844060	chr1:26490628	NA	0.25	4.62	0.38	9.44e-6	Height;
TGCT	cis	rs2456568	0.802	rs11020585	chr11:93638493	A/C	cg14065697	chr11:93583672	C11orf90	0.36	4.53	0.38	1.35e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs9993613	0.875	rs7670141	chr4:73510707	G/A	cg15102770	chr4:73434591	ADAMTS3	-0.52	-4.87	-0.4	3.28e-6	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs11731606	0.508	rs12108275	chr4:95298847	T/G	cg00507259	chr4:95128692	SMARCAD1	0.63	4.72	0.39	6.14e-6	Mean platelet volume;
TGCT	cis	rs4642101	0.793	rs6763619	chr3:12822147	T/G	cg05775895	chr3:12838266	CAND2	0.79	8.91	0.62	5.38e-15	QRS complex (12-leadsum);
TGCT	trans	rs561341	1.000	rs501312	chr17:30329066	A/G	cg20587970	chr11:113659929	NA	-1.04	-12.57	-0.75	6.97e-24	Hip circumference adjusted for BMI;
TGCT	cis	rs4253772	0.744	rs4253760	chr22:46622384	T/G	cg09491104	chr22:46646882	C22orf40	-0.47	-4.62	-0.38	9.58e-6	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs13191362	1.000	rs34228197	chr6:163008232	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.68	5.79	0.46	5.33e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs9611519	0.542	rs8139770	chr22:41416181	C/T	cg03806693	chr22:41940476	POLR3H	-0.64	-6.08	-0.48	1.38e-8	Neuroticism;
TGCT	cis	rs3008870	1.000	rs2755256	chr1:67471692	A/T	cg11518657	chr1:67396239	MIER1	0.54	4.61	0.38	9.72e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs478304	0.934	rs498354	chr11:65528213	A/G	cg27068330	chr11:65405492	SIPA1	0.75	7.57	0.56	7.2e-12	Acne (severe);
TGCT	cis	rs9916302	0.800	rs11869259	chr17:37518141	C/A	cg15445000	chr17:37608096	MED1	-0.33	-4.74	-0.39	5.87e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs4654899	0.785	rs10916911	chr1:21290061	C/T	cg01072550	chr1:21505969	NA	-0.54	-8.87	-0.62	6.79e-15	Superior frontal gyrus grey matter volume;
TGCT	cis	rs1635	0.655	rs73742535	chr6:28302925	G/A	cg15743358	chr6:28303923	ZNF323	-1.28	-6.27	-0.49	5.57e-9	Schizophrenia;
TGCT	cis	rs12893668	0.703	rs7148456	chr14:104028270	C/T	cg26031613	chr14:104095156	KLC1	0.54	4.55	0.38	1.28e-5	Reticulocyte count;
TGCT	cis	rs7726839	0.507	rs56282020	chr5:596701	T/C	cg09021430	chr5:549028	NA	-0.43	-5.74	-0.46	6.95e-8	Obesity-related traits;
TGCT	cis	rs7917772	0.503	rs7893155	chr10:104294228	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs10984561	0.786	rs77747958	chr9:122196767	T/A	cg14242995	chr9:122249943	NA	0.62	5.19	0.42	8.25e-7	Pulmonary function decline;
TGCT	cis	rs9467711	0.659	rs36014129	chr6:25884519	G/A	cg16898833	chr6:26189333	HIST1H4D	1.32	5.63	0.45	1.16e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12765878	0.580	rs11191839	chr10:105634895	G/A	cg11005552	chr10:105648138	OBFC1	-0.4	-6.28	-0.49	5.19e-9	Coronary artery disease;
TGCT	cis	rs9611565	0.592	rs4822044	chr22:41979668	G/C	cg17554472	chr22:41940697	POLR3H	-0.5	-5.14	-0.42	1.04e-6	Vitiligo;
TGCT	cis	rs8014204	0.762	rs12891131	chr14:75240090	A/G	cg06637938	chr14:75390232	RPS6KL1	0.58	5.13	0.42	1.11e-6	Caffeine consumption;
TGCT	cis	rs9330316	0.632	rs7596172	chr2:110339623	G/A	cg25199208	chr2:109402912	CCDC138	-0.41	-4.44	-0.37	1.99e-5	Schizophrenia;
TGCT	cis	rs76935404	0.811	rs28417358	chr19:41428105	G/A	cg19493303	chr19:41414353	NA	0.41	5.07	0.41	1.43e-6	nicotine metabolite ratio in current smokers;
TGCT	cis	rs9467773	0.620	rs9461276	chr6:26595168	T/C	cg15659132	chr6:26577336	NA	0.87	11.0	0.7	4.77e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs7681440	0.904	rs2870029	chr4:90772057	G/T	cg20003494	chr4:90757398	SNCA	-0.59	-5.52	-0.44	1.9e-7	Dementia with Lewy bodies;
TGCT	cis	rs7100689	0.524	rs7902460	chr10:82199263	T/A	cg00277334	chr10:82204260	NA	-0.4	-5.0	-0.41	1.94e-6	Post bronchodilator FEV1;
TGCT	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg08219700	chr8:58056026	NA	0.38	4.56	0.38	1.22e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.12	0.42	1.15e-6	Prudent dietary pattern;
TGCT	cis	rs78456975	0.527	rs7590743	chr2:1575048	A/G	cg01028140	chr2:1542097	TPO	-0.28	-4.51	-0.38	1.47e-5	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs9926296	0.607	rs2079672	chr16:89884917	A/G	cg04287289	chr16:89883240	FANCA	-0.69	-7.08	-0.54	9.59e-11	Vitiligo;
TGCT	cis	rs2880765	0.835	rs2170736	chr15:86043398	A/G	cg13263323	chr15:86062960	AKAP13	-0.23	-4.82	-0.4	4.1e-6	Coronary artery disease;
TGCT	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	8.16	0.59	3.1400000000000003e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg24846343	chr22:24311635	DDTL	0.22	5.65	0.45	1.05e-7	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7236492	0.748	rs8092987	chr18:77208141	C/T	cg15644404	chr18:77186268	NFATC1	-0.35	-4.57	-0.38	1.15e-5	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs6840360	1.000	rs3749563	chr4:152596508	T/C	cg17479576	chr4:152424074	FAM160A1	-0.5	-5.26	-0.43	6.16e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs4689388	0.890	rs4689398	chr4:6302199	C/T	cg00701064	chr4:6280414	WFS1	0.44	5.85	0.47	4.08e-8	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs7786808	0.649	rs1377374	chr7:158215647	G/T	cg01191920	chr7:158217561	PTPRN2	0.38	5.74	0.46	6.98e-8	Obesity-related traits;
TGCT	cis	rs6964587	0.773	rs12536421	chr7:92008220	A/G	cg17063962	chr7:91808500	NA	0.83	8.04	0.59	6.09e-13	Breast cancer;
TGCT	cis	rs7095607	0.630	rs7069569	chr10:69955140	T/A	cg18986048	chr10:69913749	MYPN	0.56	6.0	0.47	2e-8	Lung function (FVC);
TGCT	cis	rs12681287	0.547	rs6998303	chr8:87510185	T/C	cg27223183	chr8:87520930	FAM82B	-0.95	-6.95	-0.53	1.81e-10	Caudate activity during reward;
TGCT	cis	rs6977660	0.714	rs10486365	chr7:19801364	A/G	cg07541023	chr7:19748670	TWISTNB	0.77	4.58	0.38	1.12e-5	Thyroid stimulating hormone;
TGCT	cis	rs155076	1.000	rs261431	chr13:21865738	A/G	cg11317459	chr13:21872234	NA	1.42	12.92	0.76	1.05e-24	White matter hyperintensity burden;
TGCT	cis	rs12421382	0.507	rs2186673	chr11:109285519	G/A	cg27471124	chr11:109292789	C11orf87	0.54	6.3	0.49	4.62e-9	Schizophrenia;
TGCT	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.18	0.49	8.32e-9	Bipolar disorder;
TGCT	cis	rs12701220	0.894	rs10263252	chr7:1049949	G/A	cg27454412	chr7:1067447	C7orf50	-0.5	-4.75	-0.39	5.51e-6	Bronchopulmonary dysplasia;
TGCT	cis	rs61935443	0.720	rs10859785	chr12:95295081	A/T	cg21533806	chr12:95267307	NA	0.54	4.67	0.39	7.66e-6	Schizophrenia;
TGCT	cis	rs6815814	0.950	rs11725779	chr4:38811668	G/A	cg02016764	chr4:38805732	TLR1	-0.36	-5.71	-0.46	7.91e-8	Breast cancer;
TGCT	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg06221963	chr1:154839813	KCNN3	-0.82	-15.79	-0.82	1.86e-31	Prostate cancer;
TGCT	cis	rs2228479	1.000	rs62052186	chr16:89969567	A/T	cg06558623	chr16:89946397	TCF25	0.57	6.58	0.51	1.18e-9	Skin colour saturation;
TGCT	cis	rs7635838	0.750	rs7625680	chr3:11378069	G/A	cg00170343	chr3:11313890	ATG7	0.62	6.09	0.48	1.28e-8	HDL cholesterol;
TGCT	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg11764359	chr7:65958608	NA	-0.57	-5.25	-0.43	6.43e-7	Aortic root size;
TGCT	trans	rs288326	0.704	rs2118588	chr2:183704681	C/G	cg06580014	chr4:25931115	C4orf52	0.68	6.8	0.52	3.96e-10	Blood protein levels;
TGCT	cis	rs250677	0.687	rs185155	chr5:148455893	T/C	cg18129178	chr5:148520854	ABLIM3	-0.43	-6.29	-0.49	5.05e-9	Breast cancer;
TGCT	cis	rs380904	0.963	rs410836	chr8:144576849	A/G	cg12686110	chr8:144635478	GSDMD	0.56	4.56	0.38	1.21e-5	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs7772486	0.686	rs7744014	chr6:146123818	G/A	cg05347473	chr6:146136440	FBXO30	0.47	4.48	0.37	1.7e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9916302	0.861	rs9903363	chr17:37499604	C/G	cg15445000	chr17:37608096	MED1	-0.33	-4.71	-0.39	6.46e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs1862618	0.525	rs2662019	chr5:56263104	A/G	cg24549020	chr5:56110836	MAP3K1	-0.63	-4.81	-0.4	4.37e-6	Initial pursuit acceleration;
TGCT	cis	rs7954584	0.813	rs1523261	chr12:122462877	C/A	cg13699009	chr12:122356056	WDR66	0.26	5.4	0.44	3.31e-7	Mean corpuscular volume;
TGCT	cis	rs11627546	0.615	rs61980576	chr14:70364769	G/A	cg10496350	chr14:71275911	MAP3K9	-0.91	-4.53	-0.38	1.38e-5	Red blood cell traits;
TGCT	cis	rs9807989	0.507	rs6749014	chr2:103006448	C/T	cg03938978	chr2:103052716	IL18RAP	0.26	5.22	0.42	7.15e-7	Asthma;
TGCT	cis	rs2456568	0.803	rs10765642	chr11:93640355	C/T	cg14065697	chr11:93583672	C11orf90	0.36	4.55	0.38	1.25e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs2404602	0.692	rs34181263	chr15:77065388	C/T	cg22467129	chr15:76604101	ETFA	-0.44	-4.96	-0.41	2.27e-6	Blood metabolite levels;
TGCT	cis	rs7781977	0.782	rs1993444	chr7:50338499	G/A	cg01139861	chr7:50343298	IKZF1	0.49	5.15	0.42	9.88e-7	IgG glycosylation;
TGCT	cis	rs589249	1.000	rs589249	chr1:37162352	A/G	cg04012535	chr1:37176647	NA	-0.33	-5.21	-0.42	7.59e-7	Neuroticism (multi-trait analysis);Schizophrenia;
TGCT	cis	rs4319547	1.000	rs6489071	chr12:123025576	C/G	cg23029597	chr12:123009494	RSRC2	-0.3	-4.96	-0.41	2.26e-6	Body mass index;
TGCT	cis	rs610932	0.517	rs604085	chr11:59977401	G/A	cg18570331	chr11:60101691	MS4A6E	0.52	4.75	0.39	5.44e-6	Alzheimer's disease;
TGCT	cis	rs7119038	0.774	rs11217020	chr11:118639353	G/A	cg19308663	chr11:118741387	NA	0.3	5.59	0.45	1.37e-7	Sjögren's syndrome;
TGCT	cis	rs739496	0.579	rs10849985	chr12:112347754	C/T	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs7208859	0.623	rs6505207	chr17:29076571	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs9534288	0.797	rs2404727	chr13:46581697	T/C	cg15192986	chr13:46630673	CPB2	-0.53	-7.62	-0.56	5.82e-12	Blood protein levels;
TGCT	trans	rs459571	0.920	rs2520094	chr9:136919985	A/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.74	-7.83	-0.58	1.87e-12	Platelet distribution width;
TGCT	cis	rs4443100	0.535	rs13055979	chr22:23474085	C/T	cg14186256	chr22:23484241	RTDR1	0.62	5.29	0.43	5.32e-7	Serum parathyroid hormone levels;
TGCT	cis	rs910316	0.763	rs13712	chr14:75483812	T/C	cg11812906	chr14:75593930	NEK9	0.58	5.55	0.45	1.68e-7	Height;
TGCT	trans	rs1075232	0.677	rs72714666	chr15:31492226	T/C	cg05369791	chr7:130131146	MESTIT1;MEST	0.91	6.71	0.52	6.19e-10	Survival in colorectal cancer (non-distant metastatic);
TGCT	cis	rs1475911	0.708	rs56109792	chr21:43520060	A/G	cg19766460	chr21:43528205	UMODL1;C21orf128	0.64	9.39	0.64	3.87e-16	IgG glycosylation;
TGCT	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg20607798	chr8:58055168	NA	0.61	5.16	0.42	9.38e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs10744422	1.000	rs7139055	chr12:123364198	A/G	cg25930673	chr12:123319894	HIP1R	0.86	5.02	0.41	1.73e-6	Schizophrenia;
TGCT	cis	rs11190604	1.000	rs10883507	chr10:102291275	C/T	cg23241863	chr10:102295624	HIF1AN	0.68	5.17	0.42	9.14e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.52	-6.03	-0.48	1.75e-8	Longevity;Endometriosis;
TGCT	cis	rs6545883	0.894	rs12622458	chr2:61523554	A/C	cg15711740	chr2:61764176	XPO1	0.56	4.81	0.4	4.21e-6	Tuberculosis;
TGCT	cis	rs9653442	0.527	rs11123812	chr2:100761548	T/C	cg07810366	chr2:100720526	AFF3	-0.36	-5.31	-0.43	4.89e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg20637647	chr7:64974828	NA	-0.95	-5.3	-0.43	5.09e-7	Diabetic kidney disease;
TGCT	cis	rs1949733	0.636	rs16842498	chr4:8539529	C/T	cg13073564	chr4:8508604	NA	0.49	4.8	0.4	4.48e-6	Response to antineoplastic agents;
TGCT	cis	rs8026198	0.929	rs12441642	chr15:42515276	C/G	cg13682096	chr15:43513306	EPB42	0.3	4.49	0.37	1.59e-5	Fibrinogen levels;
TGCT	cis	rs11650494	0.908	rs9891264	chr17:47407342	T/A	cg08112188	chr17:47440006	ZNF652	1.04	5.34	0.43	4.3e-7	Prostate cancer;
TGCT	cis	rs12682352	0.579	rs7006589	chr8:8668486	A/G	cg15556689	chr8:8085844	FLJ10661	0.57	5.0	0.41	1.95e-6	Neuroticism;
TGCT	cis	rs6598955	0.671	rs11247896	chr1:26600483	A/G	cg04990556	chr1:26633338	UBXN11	0.66	5.0	0.41	1.88e-6	Obesity-related traits;
TGCT	cis	rs6089584	0.927	rs11697597	chr20:60584748	C/T	cg13665807	chr20:60559372	TAF4	-0.42	-4.5	-0.37	1.52e-5	Body mass index;
TGCT	cis	rs877426	0.591	rs56188498	chr13:114827804	A/G	cg16820615	chr13:114884918	RASA3	0.33	5.35	0.43	4.05e-7	Facial morphology (factor 14, intercanthal width);
TGCT	cis	rs13326165	0.760	rs2016575	chr3:52477080	T/C	cg27565382	chr3:53032988	SFMBT1	-0.37	-4.9	-0.4	2.97e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs35146811	0.735	rs2528900	chr7:99805319	A/G	cg00553149	chr7:99775558	STAG3;GPC2	-0.31	-4.61	-0.38	9.75e-6	Coronary artery disease;
TGCT	cis	rs12541335	0.615	rs4872464	chr8:22153381	G/A	cg02788857	chr8:22132959	PIWIL2	0.26	4.57	0.38	1.15e-5	Hypertriglyceridemia;
TGCT	cis	rs6089584	0.927	rs11697597	chr20:60584748	C/T	cg06108461	chr20:60628389	TAF4	-0.6	-8.6	-0.61	2.88e-14	Body mass index;
TGCT	cis	rs10791323	0.660	rs10791332	chr11:133732150	A/G	cg03690763	chr11:133734501	NA	-0.28	-4.48	-0.37	1.66e-5	Childhood ear infection;
TGCT	cis	rs59197085	0.515	rs17165191	chr7:128451004	T/C	cg00260937	chr7:128520193	KCP	0.46	5.06	0.41	1.49e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
TGCT	cis	rs6121246	0.909	rs6060793	chr20:30288830	T/G	cg13852791	chr20:30311386	BCL2L1	0.78	5.8	0.46	5.15e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs17473412	0.609	rs7705070	chr5:122862876	C/T	cg15125798	chr5:122621645	NA	-0.53	-4.9	-0.4	2.93e-6	Total body bone mineral density;
TGCT	cis	rs68170813	0.641	rs79328953	chr7:106901557	C/T	cg02696742	chr7:106810147	HBP1	-0.69	-5.61	-0.45	1.26e-7	Coronary artery disease;
TGCT	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg17345569	chr6:42928274	GNMT	-0.48	-5.01	-0.41	1.81e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg10802521	chr3:52805072	NEK4	-0.78	-10.0	-0.67	1.26e-17	Electroencephalogram traits;
TGCT	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.01	0.48	1.87e-8	Cognitive function;
TGCT	cis	rs3125734	0.653	rs1007976	chr10:63970144	C/T	cg09941381	chr10:64027924	RTKN2	0.36	5.42	0.44	3.04e-7	Rheumatoid arthritis;
TGCT	cis	rs988712	0.705	rs4244531	chr11:27657250	A/G	cg10635145	chr11:27742435	BDNF	-0.38	-5.23	-0.43	7e-7	Obesity;
TGCT	cis	rs1538970	0.816	rs34673142	chr1:45985561	G/A	cg05343316	chr1:45956843	TESK2	0.78	6.07	0.48	1.47e-8	Platelet count;
TGCT	cis	rs7246657	0.882	rs6508719	chr19:37877419	A/G	cg03233940	chr19:37894644	NA	-0.35	-4.54	-0.38	1.3e-5	Coronary artery calcification;
TGCT	cis	rs17030434	0.784	rs6835640	chr4:154650494	C/T	cg14289246	chr4:154710475	SFRP2	-0.87	-7.36	-0.55	2.23e-11	Electrocardiographic conduction measures;
TGCT	cis	rs1205863	0.607	rs864244	chr6:11929602	C/A	cg07106625	chr6:11870215	NA	0.47	4.73	0.39	6.09e-6	Disc degeneration (lumbar);
TGCT	cis	rs2980439	0.557	rs2921056	chr8:8319182	T/C	cg06636001	chr8:8085503	FLJ10661	0.79	7.34	0.55	2.4e-11	Neuroticism;
TGCT	cis	rs617219	0.726	rs1962002	chr5:78430689	T/C	cg05890484	chr5:78407552	BHMT	0.39	5.34	0.43	4.35e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs9811920	0.609	rs793447	chr3:99598278	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.58	-6.55	-0.51	1.35e-9	Axial length;
TGCT	cis	rs1008375	1.000	rs7671752	chr4:17661398	C/T	cg10189774	chr4:17578691	LAP3	0.56	5.04	0.41	1.57e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2075371	1.000	rs2075371	chr7:133984127	A/G	cg11752832	chr7:134001865	SLC35B4	0.69	6.32	0.49	4.19e-9	Mean platelet volume;
TGCT	cis	rs7572733	0.555	rs13395030	chr2:198750806	A/G	cg00792783	chr2:198669748	PLCL1	0.56	5.08	0.42	1.35e-6	Dermatomyositis;
TGCT	cis	rs3091242	0.836	rs34997029	chr1:25783823	A/G	cg00786635	chr1:25594202	NA	-0.53	-5.58	-0.45	1.41e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs11864453	0.647	rs10492813	chr16:72122463	A/G	cg14768367	chr16:72042858	DHODH	-0.51	-5.05	-0.41	1.56e-6	Fibrinogen levels;
TGCT	cis	rs9357506	1.000	rs6934171	chr6:46316742	G/C	cg21115430	chr6:46460003	NA	-0.26	-5.05	-0.41	1.53e-6	Body mass index;
TGCT	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg04025307	chr7:1156635	C7orf50	0.24	5.76	0.46	6.22e-8	Longevity;Endometriosis;
TGCT	cis	rs6815814	0.851	rs11736207	chr4:38766285	G/A	cg02016764	chr4:38805732	TLR1	-0.33	-5.13	-0.42	1.08e-6	Breast cancer;
TGCT	cis	rs7584330	0.868	rs58057291	chr2:238395479	T/A	cg14458575	chr2:238380390	NA	0.57	8.58	0.61	3.25e-14	Prostate cancer;
TGCT	cis	rs8051431	0.840	rs6499556	chr16:72017298	A/G	cg06353428	chr16:71660113	MARVELD3	0.58	4.62	0.38	9.32e-6	LDL cholesterol levels;
TGCT	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg22508957	chr16:3507546	NAT15	0.49	5.58	0.45	1.41e-7	Tuberculosis;
TGCT	cis	rs8033133	0.647	rs1124767	chr15:25326173	T/C	cg14481604	chr15:25334117	SNORD116-22	-0.24	-5.32	-0.43	4.77e-7	Blood osmolality (transformed sodium);
TGCT	cis	rs1992660	0.528	rs6883302	chr5:40411414	C/T	cg01087697	chr5:40835557	RPL37	0.55	4.96	0.41	2.22e-6	Crohn's disease;
TGCT	cis	rs2180341	0.920	rs1073931	chr6:127681762	A/T	cg24812749	chr6:127587940	RNF146	0.93	7.4	0.55	1.83e-11	Breast cancer;
TGCT	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg04944784	chr2:26401820	FAM59B	-0.75	-6.36	-0.5	3.5e-9	Gut microbiome composition (summer);
TGCT	cis	rs910187	0.597	rs2073172	chr20:45809176	A/G	cg27589058	chr20:45804311	EYA2	-0.37	-8.26	-0.6	1.9e-13	Migraine;
TGCT	cis	rs7095607	0.742	rs10997965	chr10:69923835	A/G	cg18986048	chr10:69913749	MYPN	0.49	5.79	0.46	5.36e-8	Lung function (FVC);
TGCT	cis	rs2013441	1.000	rs2703799	chr17:20085768	G/T	cg18979559	chr17:20280153	CCDC144C	-0.44	-4.61	-0.38	9.78e-6	Obesity-related traits;
TGCT	cis	rs17030434	0.834	rs6843172	chr4:154760600	T/C	cg14289246	chr4:154710475	SFRP2	-0.91	-7.82	-0.57	1.98e-12	Electrocardiographic conduction measures;
TGCT	cis	rs7647973	0.626	rs2131108	chr3:49665390	C/T	cg03060546	chr3:49711283	APEH	0.62	5.43	0.44	2.86e-7	Menarche (age at onset);
TGCT	cis	rs3617	0.625	rs6445541	chr3:52880128	G/T	cg11645453	chr3:52864694	ITIH4	0.27	5.11	0.42	1.21e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2013441	1.000	rs2107566	chr17:20103252	C/T	cg18979559	chr17:20280153	CCDC144C	-0.46	-4.84	-0.4	3.81e-6	Obesity-related traits;
TGCT	cis	rs35306767	0.668	rs35657988	chr10:1103590	A/G	cg20503657	chr10:835505	NA	0.44	4.83	0.4	3.9e-6	Eosinophil percentage of granulocytes;
TGCT	cis	rs6912958	0.781	rs2207146	chr6:88180641	A/G	cg06598631	chr6:88300029	RARS2;ORC3L	-0.53	-4.85	-0.4	3.69e-6	Monocyte percentage of white cells;
TGCT	cis	rs8017423	0.967	rs7142513	chr14:90705182	T/C	cg04374321	chr14:90722782	PSMC1	0.78	7.88	0.58	1.45e-12	Mortality in heart failure;
TGCT	cis	rs2439831	0.681	rs28594657	chr15:43588888	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.12	7.16	0.54	6.1e-11	Lung cancer in ever smokers;
TGCT	cis	rs6570726	0.791	rs11155432	chr6:145898761	T/C	cg13319975	chr6:146136371	FBXO30	-0.5	-4.51	-0.38	1.48e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.51	5.4	0.44	3.28e-7	Lymphocyte counts;
TGCT	cis	rs9467773	1.000	rs6940053	chr6:26562122	C/T	cg15659132	chr6:26577336	NA	0.9	13.19	0.76	2.26e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs6504663	0.586	rs60117965	chr17:48569755	G/A	cg03168497	chr17:48586147	MYCBPAP	0.56	5.88	0.47	3.5e-8	Visceral fat;
TGCT	cis	rs7552404	0.727	rs61770533	chr1:76306490	C/G	cg10523679	chr1:76189770	ACADM	0.74	7.08	0.54	9.41e-11	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2688608	0.620	rs11000767	chr10:75516626	G/T	cg15838173	chr10:75533400	FUT11	-0.3	-5.02	-0.41	1.76e-6	Inflammatory bowel disease;
TGCT	cis	rs2439831	0.681	rs2278858	chr15:43632755	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.06	7.72	0.57	3.41e-12	Lung cancer in ever smokers;
TGCT	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg11494091	chr17:61959527	GH2	0.61	14.8	0.8	3.65e-29	Prudent dietary pattern;
TGCT	cis	rs9443189	0.570	rs276684	chr6:76427065	A/G	cg01950844	chr6:76311363	SENP6	-0.99	-6.07	-0.48	1.47e-8	Prostate cancer;
TGCT	cis	rs595982	0.527	rs55670257	chr19:49382654	G/A	cg17863274	chr19:49399704	TULP2	-0.53	-7.73	-0.57	3.1e-12	Red cell distribution width;
TGCT	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg20607798	chr8:58055168	NA	0.45	4.68	0.39	7.52e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9911578	0.967	rs6416932	chr17:57148991	G/A	cg12560992	chr17:57184187	TRIM37	0.79	9.71	0.66	6.56e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs7647973	0.626	rs4855833	chr3:49657441	A/G	cg03060546	chr3:49711283	APEH	0.63	5.63	0.45	1.12e-7	Menarche (age at onset);
TGCT	cis	rs4803468	0.967	rs4605279	chr19:41888131	C/G	cg09537434	chr19:41945824	ATP5SL	-0.88	-9.94	-0.67	1.73e-17	Height;
TGCT	cis	rs2013441	1.000	rs9905493	chr17:20188581	C/G	cg18979559	chr17:20280153	CCDC144C	-0.45	-4.67	-0.39	7.61e-6	Obesity-related traits;
TGCT	cis	rs7599312	0.534	rs7355673	chr2:213404389	T/C	cg20637307	chr2:213403960	ERBB4	0.91	11.8	0.73	5.21e-22	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs13326165	0.715	rs11716017	chr3:52380991	C/T	cg27565382	chr3:53032988	SFMBT1	0.36	4.8	0.4	4.54e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs7666738	0.791	rs10856934	chr4:99010844	A/G	cg17366294	chr4:99064904	C4orf37	-0.61	-5.59	-0.45	1.4e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1903068	0.853	rs9997685	chr4:56022903	A/T	cg01777861	chr4:56023843	NA	0.54	5.95	0.47	2.57e-8	Endometriosis;
TGCT	cis	rs1372520	0.684	rs356188	chr4:90691537	T/C	cg15133208	chr4:90757351	SNCA	0.47	5.58	0.45	1.43e-7	Neuroticism;
TGCT	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg03060546	chr3:49711283	APEH	0.53	5.14	0.42	1.05e-6	Menarche (age at onset);
TGCT	trans	rs7698623	0.850	rs1477604	chr4:88771060	C/T	cg12051260	chr11:78380599	ODZ4	-0.63	-6.62	-0.51	9.95e-10	Cardiovascular disease risk factors;
TGCT	trans	rs1814175	0.754	rs10219245	chr11:49645052	C/T	cg03929089	chr4:120376271	NA	-0.74	-8.94	-0.63	4.49e-15	Height;
TGCT	cis	rs57221529	0.664	rs72704802	chr5:554211	C/T	cg09021430	chr5:549028	NA	-0.4	-5.34	-0.43	4.25e-7	Lung disease severity in cystic fibrosis;
TGCT	cis	rs17376456	0.569	rs11948511	chr5:93286601	A/C	cg21475434	chr5:93447410	FAM172A	-0.64	-6.0	-0.47	1.99e-8	Diabetic retinopathy;
TGCT	cis	rs9916302	0.851	rs9909064	chr17:37500434	G/T	cg15445000	chr17:37608096	MED1	-0.33	-4.71	-0.39	6.46e-6	Glomerular filtration rate (creatinine);
TGCT	trans	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg27523141	chr10:43048294	ZNF37B	0.73	8.65	0.61	2.22e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs9985766	1.000	rs28413051	chr4:151001278	G/A	cg05926478	chr4:151174724	DCLK2	-0.31	-5.79	-0.46	5.39e-8	Coronary artery disease;Myocardial infarction;
TGCT	cis	rs9914988	0.725	rs66531973	chr17:27125993	G/T	cg20469991	chr17:27169893	C17orf63	-0.72	-5.09	-0.42	1.29e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs9291683	0.588	rs12507330	chr4:10002195	G/A	cg00071950	chr4:10020882	SLC2A9	0.73	9.56	0.65	1.46e-16	Bone mineral density;
TGCT	cis	rs8177179	0.565	rs4355280	chr3:133468425	A/G	cg08048268	chr3:133502702	NA	-0.38	-4.61	-0.38	9.86e-6	Iron status biomarkers (transferrin levels);
TGCT	cis	rs10791323	0.604	rs2853115	chr11:133707908	C/T	cg03690763	chr11:133734501	NA	0.3	4.71	0.39	6.48e-6	Childhood ear infection;
TGCT	cis	rs62380364	0.565	rs40504	chr5:88011139	G/C	cg22951263	chr5:87985283	NA	-0.58	-6.19	-0.49	7.88e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs4746818	1.000	rs10823313	chr10:70952115	G/A	cg04149295	chr10:70884716	VPS26A	0.78	5.32	0.43	4.7e-7	Left atrial antero-posterior diameter;
TGCT	cis	rs1990950	0.692	rs4704862	chr5:156857630	T/C	cg25387487	chr5:157003181	ADAM19	0.31	4.65	0.39	8.2e-6	Lung function (FEV1/FVC);
TGCT	cis	rs7590720	1.000	rs4674058	chr2:216909368	A/G	cg12620499	chr2:216877984	MREG	0.87	8.73	0.62	1.48e-14	Alcohol dependence;
TGCT	cis	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg07424592	chr7:64974309	NA	1.36	8.15	0.59	3.36e-13	Diabetic kidney disease;
TGCT	cis	rs2299587	0.527	rs10112643	chr8:17726019	A/G	cg01800426	chr8:17659068	MTUS1	-0.55	-4.96	-0.41	2.25e-6	Economic and political preferences;
TGCT	cis	rs9650657	0.515	rs6601560	chr8:10950866	T/C	cg27411982	chr8:10470053	RP1L1	-0.21	-4.51	-0.38	1.47e-5	Neuroticism;
TGCT	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg18876405	chr7:65276391	NA	-0.37	-5.58	-0.45	1.47e-7	Aortic root size;
TGCT	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg18402987	chr7:1209562	NA	0.81	6.94	0.53	1.9e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs711245	0.637	rs6729495	chr2:36834192	T/A	cg09467607	chr2:36825704	FEZ2	0.38	5.79	0.46	5.38e-8	Height;
TGCT	cis	rs2120019	1.000	rs2415253	chr15:75375699	A/G	cg09165964	chr15:75287851	SCAMP5	-1.07	-8.58	-0.61	3.34e-14	Blood trace element (Zn levels);
TGCT	cis	rs155076	1.000	rs9509638	chr13:21860193	G/A	cg11317459	chr13:21872234	NA	-1.32	-10.89	-0.7	8.4e-20	White matter hyperintensity burden;
TGCT	cis	rs765787	0.530	rs11070445	chr15:45513163	T/A	cg24006582	chr15:45444508	DUOX1	0.25	5.35	0.43	4.11e-7	Uric acid levels;
TGCT	cis	rs55794721	0.509	rs6699896	chr1:25762902	A/T	cg23205692	chr1:25664452	TMEM50A	0.48	5.0	0.41	1.92e-6	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs9650657	0.645	rs4841409	chr8:10516374	C/T	cg27411982	chr8:10470053	RP1L1	0.22	4.97	0.41	2.15e-6	Neuroticism;
TGCT	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg16497277	chr3:49208875	KLHDC8B	-0.54	-5.17	-0.42	9.07e-7	Menarche (age at onset);
TGCT	trans	rs3780486	0.718	rs3818593	chr9:33120706	A/G	cg20290983	chr6:43655470	MRPS18A	0.98	7.4	0.55	1.85e-11	IgG glycosylation;
TGCT	cis	rs7659604	0.702	rs58649165	chr4:122693752	C/A	cg19748678	chr4:122722346	EXOSC9	0.84	9.03	0.63	2.75e-15	Type 2 diabetes;
TGCT	cis	rs12210905	1.000	rs72843641	chr6:27203335	C/G	cg08851530	chr6:28072375	NA	1.05	5.07	0.41	1.42e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs2730245	0.528	rs1188954	chr7:158691417	G/A	cg11984989	chr7:158649758	WDR60	1.09	10.52	0.69	6.69e-19	Height;
TGCT	cis	rs17001868	0.527	rs11913132	chr22:40778778	A/G	cg07138101	chr22:40742427	ADSL	0.74	5.68	0.45	9.15e-8	Mammographic density (dense area);
TGCT	cis	rs9905704	0.647	rs11650809	chr17:56972741	A/G	cg12560992	chr17:57184187	TRIM37	0.58	4.93	0.4	2.57e-6	Testicular germ cell tumor;
TGCT	cis	rs7412746	0.611	rs10888394	chr1:150749913	C/T	cg09365446	chr1:150670422	GOLPH3L	0.36	5.19	0.42	8.25e-7	Melanoma;
TGCT	cis	rs10510102	0.872	rs12246693	chr10:123716888	T/G	cg23691251	chr10:123688108	ATE1	-0.59	-4.7	-0.39	6.75e-6	Breast cancer;
TGCT	cis	rs1153858	1.000	rs10519022	chr15:45663684	C/T	cg26924012	chr15:45694286	SPATA5L1	-1.13	-13.32	-0.77	1.12e-25	Homoarginine levels;
TGCT	cis	rs72781680	1.000	rs72788280	chr2:24095907	A/G	cg08917208	chr2:24149416	ATAD2B	0.73	4.51	0.38	1.48e-5	Lymphocyte counts;
TGCT	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg07061783	chr6:25882402	NA	0.72	7.44	0.56	1.44e-11	Blood metabolite levels;
TGCT	cis	rs3749237	0.576	rs4241406	chr3:49600426	C/T	cg07636037	chr3:49044803	WDR6	0.62	5.75	0.46	6.61e-8	Resting heart rate;
TGCT	cis	rs7666738	0.830	rs11097582	chr4:98772201	G/A	cg05340658	chr4:99064831	C4orf37	0.49	5.75	0.46	6.46e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6582630	0.500	rs35251810	chr12:38577666	T/C	cg26384229	chr12:38710491	ALG10B	-0.54	-4.79	-0.4	4.57e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs2153535	0.542	rs1120393	chr6:8486890	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg18402987	chr7:1209562	NA	0.7	5.67	0.45	9.66e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg08509172	chr19:19383838	TM6SF2	0.35	4.65	0.39	8.26e-6	Tonsillectomy;
TGCT	cis	rs1008375	0.931	rs6449310	chr4:17575530	T/C	cg16339924	chr4:17578868	LAP3	0.82	7.11	0.54	8.13e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9916302	0.851	rs11657899	chr17:37626963	G/A	cg07936489	chr17:37558343	FBXL20	-0.62	-4.91	-0.4	2.85e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7119	0.651	rs34829483	chr15:77835986	C/T	cg27398640	chr15:77910606	LINGO1	-0.28	-5.13	-0.42	1.09e-6	Type 2 diabetes;
TGCT	cis	rs7267979	0.966	rs3002698	chr20:25303379	C/G	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6570726	0.935	rs388394	chr6:145852689	C/T	cg23711669	chr6:146136114	FBXO30	0.69	6.62	0.51	9.73e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6598955	0.543	rs6690461	chr1:26543097	T/A	cg04990556	chr1:26633338	UBXN11	0.81	7.35	0.55	2.29e-11	Obesity-related traits;
TGCT	cis	rs57545798	0.500	rs36094016	chr15:100643420	T/C	cg05884870	chr15:100654807	ADAMTS17	0.25	4.48	0.37	1.67e-5	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs250677	0.687	rs42364	chr5:148438858	T/A	cg23229984	chr5:148520753	ABLIM3	0.21	4.89	0.4	3.11e-6	Breast cancer;
TGCT	cis	rs11098499	0.865	rs1112817	chr4:120297800	T/C	cg09307838	chr4:120376055	NA	0.65	6.39	0.5	3.02e-9	Corneal astigmatism;
TGCT	cis	rs2072499	0.966	rs1137703	chr1:156184458	T/C	cg24450063	chr1:156163899	SLC25A44	1.14	16.5	0.83	4.43e-33	Testicular germ cell tumor;
TGCT	cis	rs926938	0.560	rs360610	chr1:115393915	T/C	cg12756093	chr1:115239321	AMPD1	0.41	5.84	0.46	4.25e-8	Autism;
TGCT	cis	rs9611565	0.592	rs5996039	chr22:41981957	A/G	cg17554472	chr22:41940697	POLR3H	-0.49	-5.15	-0.42	9.88e-7	Vitiligo;
TGCT	cis	rs36093844	0.848	rs2084079	chr11:85590436	C/A	cg25872744	chr11:85566296	CCDC83	-0.52	-4.73	-0.39	6.09e-6	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
TGCT	cis	rs11122272	0.735	rs2491404	chr1:231512127	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.14	-0.54	6.86e-11	Hemoglobin concentration;
TGCT	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg22963979	chr7:1858916	MAD1L1	-0.36	-5.53	-0.45	1.78e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.54	4.88	0.4	3.18e-6	Prudent dietary pattern;
TGCT	cis	rs9467603	0.920	rs68006638	chr6:25710571	G/A	cg16898833	chr6:26189333	HIST1H4D	1.37	6.13	0.48	1.1e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9383153	0.793	rs6937740	chr6:16348080	C/T	cg06493612	chr6:15502050	JARID2	0.62	4.91	0.4	2.79e-6	Gambling;
TGCT	cis	rs7681440	0.967	rs920624	chr4:90748195	T/A	cg26578617	chr4:90757533	SNCA	-0.47	-4.83	-0.4	3.9e-6	Dementia with Lewy bodies;
TGCT	cis	rs2066819	1.000	rs77447765	chr12:56690662	G/A	cg26714650	chr12:56694279	CS	-1.36	-6.06	-0.48	1.54e-8	Psoriasis vulgaris;
TGCT	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.94	-11.62	-0.72	1.43e-21	Prudent dietary pattern;
TGCT	cis	rs1669338	0.507	rs4685607	chr3:3179400	C/T	cg16797762	chr3:3221439	CRBN	0.82	5.38	0.44	3.51e-7	White matter integrity;
TGCT	cis	rs9534288	0.699	rs1409433	chr13:46655501	T/C	cg15192986	chr13:46630673	CPB2	-0.53	-6.39	-0.5	3.01e-9	Blood protein levels;
TGCT	cis	rs2760061	0.717	rs708117	chr1:228199902	G/A	cg18477163	chr1:228402036	OBSCN	0.34	7.22	0.54	4.65e-11	Diastolic blood pressure;
TGCT	cis	rs6722750	1.000	rs4671552	chr2:64393955	A/G	cg22352474	chr2:64371530	PELI1	0.62	5.53	0.44	1.81e-7	Neuroticism;
TGCT	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg09359103	chr1:154839909	KCNN3	-0.71	-15.31	-0.81	2.37e-30	Prostate cancer;
TGCT	cis	rs7017914	0.905	rs2732112	chr8:71927841	A/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.56	-5.11	-0.42	1.21e-6	Bone mineral density;
TGCT	cis	rs9527	0.590	rs10883839	chr10:104920341	A/G	cg15744005	chr10:104629667	AS3MT	-0.41	-4.71	-0.39	6.45e-6	Arsenic metabolism;
TGCT	cis	rs7666738	0.830	rs7659593	chr4:98934823	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7666738	0.830	rs28417716	chr4:98864859	C/T	cg18180107	chr4:99064573	C4orf37	0.55	5.14	0.42	1.03e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg13683864	chr3:40499215	RPL14	1.16	12.09	0.74	1.04e-22	Renal cell carcinoma;
TGCT	cis	rs7267979	0.899	rs2179459	chr20:25456141	C/A	cg03522245	chr20:25566470	NINL	0.58	6.26	0.49	5.69e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs17152411	0.947	rs55674450	chr10:126592153	G/T	cg07906193	chr10:126599966	NA	0.42	5.28	0.43	5.6e-7	Height;
TGCT	cis	rs2012796	1.000	rs8009171	chr14:81820060	G/A	cg02996355	chr14:81879375	NA	0.47	4.61	0.38	9.68e-6	Night sleep phenotypes;
TGCT	cis	rs9522267	0.535	rs9522305	chr13:112237550	A/G	cg10483660	chr13:112241077	NA	-0.27	-4.61	-0.38	9.78e-6	Hepatitis;
TGCT	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg06238570	chr21:40685208	BRWD1	0.7	6.45	0.5	2.3e-9	Cognitive function;
TGCT	cis	rs7937682	0.564	rs9633937	chr11:111372799	C/T	cg09085632	chr11:111637200	PPP2R1B	0.54	4.87	0.4	3.35e-6	Primary sclerosing cholangitis;
TGCT	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg23283495	chr1:209979779	IRF6	0.68	5.79	0.46	5.34e-8	Cleft lip with or without cleft palate;
TGCT	cis	rs3752962	0.569	rs12451788	chr17:1941048	C/T	cg24156229	chr17:1948635	NA	0.37	7.07	0.54	1.02e-10	Itch intensity from mosquito bite;
TGCT	cis	rs34014631	1.000	rs17697908	chr10:103562936	T/G	cg22630918	chr10:102748988	C10orf2	0.43	4.8	0.4	4.57e-6	Coronary artery calcification;
TGCT	cis	rs9527	0.569	rs10883801	chr10:104677887	A/C	cg15744005	chr10:104629667	AS3MT	-0.45	-5.31	-0.43	4.9e-7	Arsenic metabolism;
TGCT	cis	rs3796352	1.000	rs13072818	chr3:53074263	C/T	cg07884673	chr3:53033167	SFMBT1	0.6	6.24	0.49	6.25e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs4747241	1.000	rs10509767	chr10:74045917	G/T	cg09661010	chr10:73848153	SPOCK2	-0.4	-4.51	-0.38	1.48e-5	Heschl's gyrus morphology;
TGCT	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg08859206	chr1:53392774	SCP2	0.35	5.04	0.41	1.62e-6	Monocyte count;
TGCT	cis	rs2439831	1.000	rs561863	chr15:43761352	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.01	8.37	0.6	1.02e-13	Lung cancer in ever smokers;
TGCT	trans	rs10506458	1.000	rs73127086	chr12:63415626	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.47	-7.59	-0.56	6.63e-12	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs950169	0.580	rs1061737	chr15:85183790	G/C	cg17173187	chr15:85201210	NMB	0.62	7.09	0.54	8.99e-11	Schizophrenia;
TGCT	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg00149659	chr3:10157352	C3orf10	1.19	7.74	0.57	3.08e-12	Alzheimer's disease;
TGCT	cis	rs8177179	0.967	rs4078166	chr3:133435979	C/A	cg24879335	chr3:133465180	TF	0.37	5.03	0.41	1.7e-6	Iron status biomarkers (transferrin levels);
TGCT	cis	rs11167764	1.000	rs10057309	chr5:141479870	T/C	cg08523384	chr5:141488047	NDFIP1	-0.25	-5.06	-0.41	1.5e-6	Crohn's disease;
TGCT	cis	rs782590	0.967	rs1975487	chr2:55809054	A/G	cg18811423	chr2:55921094	PNPT1	0.64	6.66	0.51	7.97e-10	Metabolic syndrome;
TGCT	cis	rs4285028	0.948	rs35415993	chr3:121669236	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.77	-6.55	-0.51	1.35e-9	Multiple sclerosis;
TGCT	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg26513180	chr16:89883248	FANCA	1.05	14.87	0.8	2.47e-29	Vitiligo;
TGCT	cis	rs1043515	0.642	rs8592	chr17:36958065	A/G	cg20826740	chr17:37024042	NA	0.42	4.45	0.37	1.92e-5	Height;
TGCT	cis	rs7044106	0.791	rs10985009	chr9:123493039	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.71	-8.1	-0.59	4.39e-13	Hip circumference adjusted for BMI;
TGCT	cis	rs950776	0.518	rs2869055	chr15:78822388	G/C	cg06917634	chr15:78832804	PSMA4	-0.89	-8.89	-0.62	6.13e-15	Sudden cardiac arrest;
TGCT	cis	rs7666738	0.830	rs34135615	chr4:99001325	C/T	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs13022357	1.000	rs3821301	chr2:160087535	T/G	cg00168785	chr2:160142643	WDSUB1	0.46	4.6	0.38	1.04e-5	Sudden cardiac arrest;
TGCT	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg11941060	chr3:133502564	NA	-0.3	-6.41	-0.5	2.69e-9	Iron status biomarkers;
TGCT	cis	rs6688613	0.685	rs10918599	chr1:166918786	T/C	cg07049167	chr1:166818506	POGK	0.25	5.15	0.42	9.89e-7	Refractive astigmatism;
TGCT	cis	rs7611238	0.560	rs57124286	chr3:194992911	A/G	cg27323046	chr3:195102265	ACAP2	0.36	4.77	0.39	5.12e-6	Body mass index;
TGCT	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg11965913	chr1:205819406	PM20D1	0.53	7.51	0.56	1.01e-11	Menarche (age at onset);
TGCT	cis	rs9297145	0.724	rs62473013	chr7:98762418	G/T	cg05967295	chr7:98741636	SMURF1	0.99	12.81	0.75	1.84e-24	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs4689388	0.926	rs12508672	chr4:6287965	G/A	cg25554036	chr4:6271136	WFS1	0.54	7.56	0.56	7.85e-12	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs921968	0.541	rs523305	chr2:219402691	T/C	cg02176678	chr2:219576539	TTLL4	0.48	6.78	0.52	4.32e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs7246657	0.722	rs2909093	chr19:38199462	T/C	cg18154014	chr19:37997991	ZNF793	-0.72	-5.06	-0.41	1.48e-6	Coronary artery calcification;
TGCT	cis	rs9913156	0.517	rs7215300	chr17:4608622	T/C	cg00122941	chr17:4613640	ARRB2	-0.73	-6.79	-0.52	4.14e-10	Lymphocyte counts;
TGCT	cis	rs13191362	1.000	rs67840803	chr6:163049048	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.92	7.24	0.55	4.11e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs2730245	0.527	rs1188971	chr7:158664463	G/T	cg11984989	chr7:158649758	WDR60	1.01	7.85	0.58	1.65e-12	Height;
TGCT	cis	rs3008870	1.000	rs2755250	chr1:67495283	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.01	0.7	4.47e-20	Lymphocyte percentage of white cells;
TGCT	cis	rs12497850	0.931	rs7647813	chr3:48833348	G/T	cg18654377	chr3:49208889	KLHDC8B	-0.41	-5.49	-0.44	2.15e-7	Parkinson's disease;
TGCT	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg12310025	chr6:25882481	NA	-0.66	-5.95	-0.47	2.57e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs826838	1.000	rs11168218	chr12:38884466	A/G	cg13010199	chr12:38710504	ALG10B	0.78	6.59	0.51	1.14e-9	Heart rate;
TGCT	cis	rs6087990	0.814	rs2424895	chr20:31335978	C/T	cg13636640	chr20:31349939	DNMT3B	-0.97	-14.25	-0.79	7.1e-28	Ulcerative colitis;
TGCT	cis	rs7772486	0.790	rs2253307	chr6:146196181	T/G	cg05347473	chr6:146136440	FBXO30	0.54	4.98	0.41	2.05e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg04608855	chr19:58913158	NA	0.58	5.76	0.46	6.2e-8	Uric acid clearance;
TGCT	cis	rs7824557	0.510	rs2736297	chr8:11234885	C/G	cg21775007	chr8:11205619	TDH	-0.65	-6.4	-0.5	2.97e-9	Retinal vascular caliber;
TGCT	cis	rs2075371	1.000	rs1421485	chr7:133985181	C/T	cg11752832	chr7:134001865	SLC35B4	0.69	6.32	0.49	4.19e-9	Mean platelet volume;
TGCT	cis	rs2777491	0.574	rs1757468	chr15:41743574	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.94	-17.35	-0.84	5.64e-35	Ulcerative colitis;
TGCT	cis	rs595982	0.517	rs4801779	chr19:49406651	T/G	cg11637076	chr19:49575188	KCNA7	-0.44	-5.42	-0.44	3.01e-7	Red cell distribution width;
TGCT	cis	rs6866344	0.697	rs11743893	chr5:178125194	C/T	cg10224037	chr5:178157518	ZNF354A	0.99	8.29	0.6	1.55e-13	Neutrophil percentage of white cells;
TGCT	cis	rs9611565	0.592	rs80477	chr22:42001183	C/T	cg17554472	chr22:41940697	POLR3H	0.5	5.23	0.43	6.93e-7	Vitiligo;
TGCT	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.55	-6.86	-0.52	2.91e-10	Longevity;Endometriosis;
TGCT	cis	rs1580019	0.961	rs1868776	chr7:32494435	G/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.78	-7.29	-0.55	3.16e-11	Cognitive ability;
TGCT	cis	rs9527	0.518	rs10883802	chr10:104680362	C/T	cg15744005	chr10:104629667	AS3MT	0.6	4.84	0.4	3.71e-6	Arsenic metabolism;
TGCT	cis	rs826838	1.000	rs826851	chr12:39112639	A/G	cg13010199	chr12:38710504	ALG10B	-0.68	-5.47	-0.44	2.34e-7	Heart rate;
TGCT	cis	rs736408	0.581	rs3617	chr3:52833805	C/A	cg10802521	chr3:52805072	NEK4	-0.66	-7.59	-0.56	6.49e-12	Bipolar disorder;
TGCT	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg01516881	chr6:292596	DUSP22	-0.79	-8.23	-0.59	2.24e-13	Menopause (age at onset);
TGCT	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg26338869	chr17:61819248	STRADA	-0.55	-5.08	-0.41	1.37e-6	Prudent dietary pattern;
TGCT	cis	rs1865760	0.786	rs1436308	chr6:25939567	T/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.66	6.2	0.49	7.8e-9	Height;
TGCT	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg25036284	chr2:26402008	FAM59B	0.65	5.18	0.42	8.59e-7	Gut microbiome composition (summer);
TGCT	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg11301795	chr4:187892539	NA	-0.33	-4.82	-0.4	4.14e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7267979	0.932	rs433352	chr20:25467992	C/T	cg14121845	chr20:25566513	NINL	-0.5	-5.37	-0.43	3.69e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11098499	0.775	rs10029303	chr4:120286755	T/A	cg09307838	chr4:120376055	NA	0.58	5.76	0.46	6.16e-8	Corneal astigmatism;
TGCT	cis	rs9486719	1.000	rs35487471	chr6:96879715	C/T	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.86	-0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs4851254	0.618	rs35300735	chr2:100667829	G/A	cg22139774	chr2:100720529	AFF3	-0.44	-4.69	-0.39	7.04e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs992157	0.732	rs10932771	chr2:219170236	A/T	cg00012203	chr2:219082015	ARPC2	0.76	7.6	0.56	6.44e-12	Colorectal cancer;
TGCT	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	7.58	0.56	6.84e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.0	7.42	0.55	1.64e-11	Gut microbiome composition (summer);
TGCT	cis	rs16866061	0.926	rs17479770	chr2:225335814	A/G	cg12698349	chr2:225449008	CUL3	0.94	8.82	0.62	8.6e-15	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	cis	rs7547997	0.685	rs12734093	chr1:158358660	G/A	cg07950803	chr1:158223934	CD1A	0.32	4.78	0.39	4.95e-6	QRS duration;
TGCT	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg04772025	chr11:68637568	NA	0.62	6.89	0.53	2.53e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs854765	0.624	rs9902941	chr17:17733760	C/T	cg09796270	chr17:17721594	SREBF1	-0.24	-4.52	-0.38	1.42e-5	Total body bone mineral density;
TGCT	cis	rs1865760	0.865	rs1115920	chr6:25954027	A/G	cg16482183	chr6:26056742	HIST1H1C	0.52	4.84	0.4	3.78e-6	Height;
TGCT	cis	rs56036086	0.938	rs6712	chr22:50637922	C/G	cg01548456	chr22:50352384	NA	0.37	4.84	0.4	3.71e-6	Platelet count;Plateletcrit;
TGCT	trans	rs1814175	0.712	rs9665784	chr11:50030617	C/T	cg15704280	chr7:45808275	SEPT13	-0.72	-8.47	-0.61	6.02e-14	Height;
TGCT	cis	rs2050392	0.517	rs2771242	chr10:30762973	C/T	cg18806716	chr10:30721971	MAP3K8	-0.6	-7.39	-0.55	1.92e-11	Inflammatory bowel disease;
TGCT	cis	rs9910055	0.593	rs58392387	chr17:42297889	A/G	cg13607699	chr17:42295918	UBTF	1.14	12.78	0.75	2.21e-24	Total body bone mineral density;
TGCT	cis	rs9394169	0.613	rs4713685	chr6:33774525	C/T	cg18005901	chr6:33739558	LEMD2	0.48	5.87	0.47	3.78e-8	Essential tremor;
TGCT	cis	rs1461503	0.966	rs11218910	chr11:122842861	G/A	cg27398637	chr11:122830231	C11orf63	-0.42	-5.25	-0.43	6.42e-7	Menarche (age at onset);
TGCT	trans	rs2469997	0.843	rs2470013	chr8:120360758	G/C	cg01792902	chr3:178864926	PIK3CA	0.83	6.77	0.52	4.49e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg20637647	chr7:64974828	NA	0.94	5.16	0.42	9.35e-7	Diabetic kidney disease;
TGCT	cis	rs675209	0.634	rs1413700	chr6:7216484	G/C	cg27097018	chr6:6320614	F13A1	0.36	5.1	0.42	1.24e-6	Urate levels;
TGCT	cis	rs9300255	0.679	rs58809476	chr12:123724880	C/T	cg00376283	chr12:123451042	ABCB9	-0.73	-4.95	-0.41	2.41e-6	Neutrophil percentage of white cells;
TGCT	cis	rs3820928	0.839	rs4675123	chr2:227800205	T/C	cg11843606	chr2:227700838	RHBDD1	-0.53	-4.73	-0.39	5.9e-6	Pulmonary function;
TGCT	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg19774624	chr17:42201019	HDAC5	-0.84	-8.45	-0.6	6.55e-14	Total body bone mineral density;
TGCT	cis	rs10791323	0.593	rs2156676	chr11:133715791	G/C	cg15485101	chr11:133734466	NA	0.4	5.04	0.41	1.59e-6	Childhood ear infection;
TGCT	cis	rs9486715	0.838	rs9386473	chr6:96873341	C/A	cg06623918	chr6:96969491	KIAA0776	1.09	15.47	0.81	1.02e-30	Headache;
TGCT	cis	rs9303542	0.559	rs55859232	chr17:46612645	A/G	cg25032089	chr17:46643351	HOXB3	0.58	5.48	0.44	2.23e-7	Ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs9400467	0.537	rs12197886	chr6:111491405	C/G	cg15721981	chr6:111408429	SLC16A10	0.69	4.5	0.37	1.56e-5	Blood metabolite levels;Amino acid levels;
TGCT	cis	rs1887596	0.624	rs1331008	chr13:27154435	G/A	cg01312412	chr13:27282625	NA	0.29	5.3	0.43	5.16e-7	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg24060327	chr5:131705240	SLC22A5	-0.74	-7.98	-0.58	8.3e-13	Breast cancer;
TGCT	cis	rs68170813	0.562	rs11770061	chr7:107071310	A/G	cg02696742	chr7:106810147	HBP1	-0.68	-5.44	-0.44	2.69e-7	Coronary artery disease;
TGCT	cis	rs4499344	0.633	rs259282	chr19:33163043	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.87	9.25	0.64	8.19e-16	Mean platelet volume;
TGCT	cis	rs6088590	1.000	rs2236270	chr20:33523155	G/T	cg06115741	chr20:33292138	TP53INP2	0.68	5.26	0.43	6.2e-7	Coronary artery disease;
TGCT	cis	rs1372520	0.627	rs2583964	chr4:90727218	A/G	cg20003494	chr4:90757398	SNCA	-0.66	-5.21	-0.42	7.59e-7	Neuroticism;
TGCT	trans	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-1.03	-13.16	-0.76	2.65e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs2658782	0.547	rs4753453	chr11:93041174	T/G	cg15737290	chr11:93063684	CCDC67	1.02	10.75	0.69	1.88e-19	Pulmonary function decline;
TGCT	cis	rs5769765	1.000	rs910800	chr22:50278642	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	1.11	11.81	0.73	5.03e-22	Schizophrenia;
TGCT	cis	rs6912958	0.500	rs3828759	chr6:87806640	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.69	-6.56	-0.51	1.31e-9	Monocyte percentage of white cells;
TGCT	cis	rs2268241	0.938	rs17879003	chr21:34778527	C/T	cg14850771	chr21:34775459	IFNGR2	0.61	5.23	0.43	6.88e-7	Obesity-related traits;
TGCT	cis	rs5417	1.000	rs5417	chr17:7185062	C/A	cg25256661	chr17:7137939	DVL2	-0.53	-4.97	-0.41	2.13e-6	Diastolic blood pressure;
TGCT	cis	rs2180341	0.889	rs9321074	chr6:127618019	G/A	cg27446573	chr6:127587934	RNF146	1.13	10.12	0.67	6.64e-18	Breast cancer;
TGCT	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs61677309	1.000	rs12576941	chr11:118158002	A/G	cg16594165	chr11:118135105	MPZL2	-0.36	-4.45	-0.37	1.85e-5	Lung cancer in ever smokers;
TGCT	cis	rs2276314	1.000	rs62101367	chr18:33550884	C/T	cg19628046	chr18:33552617	C18orf21	0.54	4.62	0.38	9.52e-6	Endometriosis;Drug-induced torsades de pointes;
TGCT	cis	rs7647973	1.000	rs9862534	chr3:49598064	A/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.56	-4.82	-0.4	4.16e-6	Menarche (age at onset);
TGCT	cis	rs9611565	0.559	rs5758428	chr22:42106216	G/A	cg06634786	chr22:41940651	POLR3H	0.89	8.81	0.62	9.46e-15	Vitiligo;
TGCT	cis	rs2980439	0.557	rs2976876	chr8:8318850	T/C	cg08975724	chr8:8085496	FLJ10661	0.6	5.45	0.44	2.59e-7	Neuroticism;
TGCT	cis	rs9355610	0.892	rs2247314	chr6:167370230	T/C	cg23791538	chr6:167370224	RNASET2	0.64	6.13	0.48	1.07e-8	Graves' disease;
TGCT	cis	rs698813	0.674	rs11680456	chr2:44497544	C/G	cg00619915	chr2:44497795	NA	-0.24	-5.41	-0.44	3.11e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
TGCT	cis	rs9291683	0.935	rs1860910	chr4:10275470	T/G	cg11266682	chr4:10021025	SLC2A9	0.45	5.41	0.44	3.11e-7	Bone mineral density;
TGCT	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.43	4.84	0.4	3.75e-6	Lymphocyte counts;
TGCT	cis	rs2404602	0.536	rs17364330	chr15:76765385	A/T	cg22467129	chr15:76604101	ETFA	-0.47	-5.87	-0.47	3.82e-8	Blood metabolite levels;
TGCT	cis	rs9611519	0.929	rs11090039	chr22:41496800	G/A	cg03806693	chr22:41940476	POLR3H	-0.67	-6.2	-0.49	7.86e-9	Neuroticism;
TGCT	cis	rs41271951	0.512	rs34761930	chr1:151089523	T/C	cg00666978	chr1:150947442	LASS2	0.89	4.64	0.38	8.54e-6	Blood protein levels;
TGCT	cis	rs295140	0.803	rs12469091	chr2:201124735	A/T	cg04283868	chr2:201171347	SPATS2L	0.53	5.32	0.43	4.73e-7	QT interval;
TGCT	cis	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg08045932	chr20:61659980	NA	0.48	9.16	0.64	1.36e-15	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs539096	0.500	rs2367804	chr1:44314266	C/T	cg12908607	chr1:44402522	ARTN	-0.67	-8.11	-0.59	4.16e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs9467773	0.844	rs2393669	chr6:26503873	C/T	cg09904177	chr6:26538194	HMGN4	0.65	6.53	0.51	1.5e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs3733585	0.673	rs4312757	chr4:9956145	T/A	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.73	-0.57	3.25e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs2066819	1.000	rs1274493	chr12:56682371	C/T	cg26714650	chr12:56694279	CS	1.53	8.28	0.6	1.67e-13	Psoriasis vulgaris;
TGCT	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.54	4.95	0.41	2.35e-6	Prudent dietary pattern;
TGCT	cis	rs2637266	1.000	rs2395387	chr10:78357029	T/C	cg18941641	chr10:78392320	NA	0.4	5.01	0.41	1.81e-6	Pulmonary function;
TGCT	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg08975724	chr8:8085496	FLJ10661	-0.57	-5.14	-0.42	1.04e-6	Mood instability;
TGCT	cis	rs4790312	0.513	rs2232486	chr17:1968983	T/C	cg24156229	chr17:1948635	NA	-0.36	-5.69	-0.45	8.83e-8	Left atrial antero-posterior diameter;
TGCT	cis	rs899997	0.814	rs28661610	chr15:78985317	G/A	cg04896959	chr15:78267971	NA	-0.35	-4.82	-0.4	4.14e-6	Coronary artery disease or large artery stroke;
TGCT	cis	rs881375	0.967	rs10733648	chr9:123700779	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.39	4.54	0.38	1.34e-5	Rheumatoid arthritis;
TGCT	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg20607798	chr8:58055168	NA	0.5	4.66	0.39	8.04e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs861020	0.527	rs614662	chr1:209962419	C/T	cg22029157	chr1:209979665	IRF6	-0.48	-4.89	-0.4	3.05e-6	Orofacial clefts;
TGCT	cis	rs832540	0.898	rs2662024	chr5:56257515	T/C	cg24531977	chr5:56204891	C5orf35	0.47	4.77	0.39	5.09e-6	Coronary artery disease;
TGCT	cis	rs4843185	0.667	rs4143865	chr16:85716612	T/A	cg02644593	chr16:85391138	NA	0.22	4.94	0.41	2.43e-6	Platelet distribution width;
TGCT	cis	rs7809950	0.817	rs2807	chr7:107260778	G/A	cg23024343	chr7:107201750	COG5	0.43	6.22	0.49	6.92e-9	Coronary artery disease;
TGCT	cis	rs7267979	1.000	rs6050590	chr20:25384994	G/A	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs28374715	0.662	rs16971558	chr15:41458619	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.77	-10.94	-0.7	6.44e-20	Ulcerative colitis;
TGCT	cis	rs1997103	1.000	rs2331068	chr7:55408220	G/A	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs9325144	0.581	rs6582564	chr12:38671282	G/A	cg26384229	chr12:38710491	ALG10B	-0.63	-5.92	-0.47	2.9e-8	Morning vs. evening chronotype;
TGCT	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.55	5.21	0.42	7.75e-7	Menarche (age at onset);
TGCT	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg22963979	chr7:1858916	MAD1L1	-0.4	-6.51	-0.5	1.7e-9	Bipolar disorder and schizophrenia;
TGCT	cis	rs3772130	1.000	rs3772130	chr3:121344140	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.55	4.95	0.41	2.35e-6	Cognitive performance;
TGCT	cis	rs6430585	0.528	rs309167	chr2:136669264	C/T	cg07169764	chr2:136633963	MCM6	1.25	12.39	0.74	1.91e-23	Corneal structure;
TGCT	cis	rs2730245	0.527	rs842700	chr7:158697565	G/A	cg11984989	chr7:158649758	WDR60	1.01	7.85	0.58	1.65e-12	Height;
TGCT	cis	rs651907	0.557	rs11712748	chr3:101383562	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.91	11.43	0.72	4.08e-21	Colorectal cancer;
TGCT	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg08859206	chr1:53392774	SCP2	-0.42	-6.8	-0.52	3.92e-10	Monocyte count;
TGCT	cis	rs9549367	0.789	rs9549716	chr13:113908478	G/A	cg18105134	chr13:113819100	PROZ	-0.35	-5.94	-0.47	2.68e-8	Platelet distribution width;
TGCT	cis	rs514406	0.698	rs1775540	chr1:53407893	C/A	cg08859206	chr1:53392774	SCP2	-0.45	-7.37	-0.55	2.16e-11	Monocyte count;
TGCT	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.05	12.3	0.74	3.15e-23	Height;
TGCT	cis	rs2235642	0.928	rs9932984	chr16:1605051	A/G	cg10465839	chr16:1584050	IFT140;TMEM204	-0.29	-4.83	-0.4	3.88e-6	Coronary artery disease;
TGCT	cis	rs1969363	0.509	rs8189633	chr12:38065155	C/G	cg26384229	chr12:38710491	ALG10B	0.86	7.77	0.57	2.55e-12	Morning vs. evening chronotype;
TGCT	cis	rs61774743	0.557	rs4660192	chr1:41842350	C/T	cg01193554	chr1:41846683	NA	-0.41	-5.01	-0.41	1.86e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1784581	0.588	rs9458428	chr6:162424579	A/G	cg17173639	chr6:162384350	PARK2	-0.39	-6.43	-0.5	2.49e-9	Itch intensity from mosquito bite;
TGCT	cis	rs508618	0.638	rs479200	chr1:231543780	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.6	-4.92	-0.4	2.64e-6	Red blood cell count;
TGCT	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg07157834	chr1:205819609	PM20D1	0.43	7.03	0.53	1.25e-10	Menarche (age at onset);
TGCT	cis	rs7208859	0.623	rs9899268	chr17:29150255	T/C	cg14008862	chr17:28927542	LRRC37B2	0.8	4.73	0.39	6.11e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg05872129	chr22:39784769	NA	-0.97	-10.46	-0.68	9.44e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg02487422	chr3:49467188	NICN1	-0.54	-5.2	-0.42	8.11e-7	Menarche (age at onset);
TGCT	cis	rs644799	0.710	rs3748253	chr11:95519506	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.28	0.6	1.63e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7659604	0.521	rs4833235	chr4:122695136	C/A	cg19748678	chr4:122722346	EXOSC9	-0.57	-5.69	-0.45	8.7e-8	Type 2 diabetes;
TGCT	cis	rs9341808	0.667	rs2505929	chr6:80834208	A/G	cg08355045	chr6:80787529	NA	0.31	5.31	0.43	4.96e-7	Sitting height ratio;
TGCT	cis	rs12762955	0.561	rs4880744	chr10:1012026	A/G	cg20503657	chr10:835505	NA	-0.39	-5.09	-0.42	1.29e-6	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg09436375	chr6:42928200	GNMT	-0.4	-5.16	-0.42	9.43e-7	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs28595532	0.920	rs116146507	chr4:119749556	A/G	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs910316	1.000	rs175425	chr14:75626131	T/C	cg23033748	chr14:75592666	NEK9	-0.28	-4.84	-0.4	3.84e-6	Height;
TGCT	cis	rs8180040	0.593	rs10433549	chr3:47031433	C/T	cg27129171	chr3:47204927	SETD2	-0.7	-8.27	-0.6	1.75e-13	Colorectal cancer;
TGCT	cis	rs2997447	0.688	rs3008431	chr1:26371281	A/G	cg19633962	chr1:26362018	EXTL1	-0.69	-5.01	-0.41	1.81e-6	QRS complex (12-leadsum);
TGCT	cis	rs56104184	0.775	rs117016425	chr19:49400216	C/T	cg21252483	chr19:49399788	TULP2	-0.42	-5.89	-0.47	3.47e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	trans	rs6560039	1	rs6560039	chr9:90474946	C/T	cg24436365	chr6:63940138	NA	0.49	7.46	0.56	1.35e-11	Gait variability;
TGCT	cis	rs7914558	1.000	rs4917996	chr10:104925829	A/C	cg05855489	chr10:104503620	C10orf26	0.5	4.47	0.37	1.71e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg11211951	chr8:145729740	GPT	-0.22	-5.28	-0.43	5.56e-7	Age at first birth;
TGCT	cis	rs7209700	0.889	rs16941801	chr17:45354543	G/C	cg21624342	chr17:45890973	OSBPL7	0.18	5.1	0.42	1.25e-6	IgG glycosylation;
TGCT	cis	rs9368481	0.761	rs4713062	chr6:26948195	A/G	cg02458000	chr6:26745757	NA	-0.49	-4.48	-0.37	1.66e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs921968	0.613	rs2912737	chr2:219545789	A/G	cg02176678	chr2:219576539	TTLL4	-0.33	-4.45	-0.37	1.91e-5	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs2276314	1.000	rs2298716	chr18:33552598	C/T	cg05985134	chr18:33552581	C18orf21	0.56	4.94	0.41	2.52e-6	Endometriosis;Drug-induced torsades de pointes;
TGCT	cis	rs6582630	0.502	rs11522899	chr12:38270637	T/C	cg26384229	chr12:38710491	ALG10B	0.86	7.48	0.56	1.17e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg23758822	chr17:41437982	NA	0.72	6.96	0.53	1.79e-10	Menopause (age at onset);
TGCT	cis	rs7954584	0.813	rs12827200	chr12:122451278	G/A	cg22618164	chr12:122356400	WDR66	0.53	4.86	0.4	3.55e-6	Mean corpuscular volume;
TGCT	cis	rs1018836	0.608	rs2205150	chr8:91483232	G/A	cg16814680	chr8:91681699	NA	-0.7	-7.06	-0.54	1.07e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6993813	0.620	rs6984675	chr8:120045227	T/G	cg17171407	chr8:119960777	TNFRSF11B	0.26	4.66	0.39	8.02e-6	Bone mineral density (hip);
TGCT	cis	rs753778	0.667	rs10092439	chr8:142210881	C/T	cg18755752	chr8:142205143	DENND3	-0.28	-5.11	-0.42	1.19e-6	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs12681288	0.862	rs2004701	chr8:1022287	A/G	cg04851639	chr8:1020857	NA	-0.37	-6.84	-0.52	3.27e-10	Schizophrenia;
TGCT	cis	rs910316	0.874	rs61980828	chr14:75630378	G/A	cg08847533	chr14:75593920	NEK9	-0.94	-10.45	-0.68	1.01e-18	Height;
TGCT	cis	rs938554	0.657	rs9994216	chr4:9984541	G/T	cg11266682	chr4:10021025	SLC2A9	0.48	4.91	0.4	2.82e-6	Blood metabolite levels;
TGCT	cis	rs1008375	0.835	rs13122181	chr4:17708815	C/A	cg10189774	chr4:17578691	LAP3	-0.54	-4.76	-0.39	5.33e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1670533	1.000	rs641987	chr4:1077542	C/T	cg20887711	chr4:1340912	KIAA1530	0.7	5.55	0.45	1.64e-7	Recombination rate (females);
TGCT	cis	rs854765	0.505	rs4506969	chr17:17899839	A/G	cg09796270	chr17:17721594	SREBF1	0.23	4.49	0.37	1.59e-5	Total body bone mineral density;
TGCT	cis	rs2013441	1.000	rs9897328	chr17:20174852	G/A	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.63	-0.38	9.19e-6	Obesity-related traits;
TGCT	cis	rs12931792	0.712	rs56399904	chr16:30166183	C/T	cg17640201	chr16:30407289	ZNF48	0.62	5.59	0.45	1.39e-7	Tonsillectomy;
TGCT	cis	rs4499344	0.576	rs259280	chr19:33161452	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.85	9.14	0.63	1.5e-15	Mean platelet volume;
TGCT	trans	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg23505145	chr19:12996616	KLF1	0.79	8.07	0.59	5.16e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1215050	0.782	rs6853916	chr4:98653387	C/T	cg05340658	chr4:99064831	C4orf37	-0.43	-5.4	-0.44	3.2e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs3096299	0.967	rs11648663	chr16:89466307	C/T	cg06640241	chr16:89574553	SPG7	0.66	6.3	0.49	4.82e-9	Multiple myeloma (IgH translocation);
TGCT	cis	rs1395	0.571	rs114507490	chr2:27527246	T/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.59	7.61	0.56	6.1e-12	Blood metabolite levels;
TGCT	cis	rs10114408	0.959	rs10761292	chr9:96645017	T/G	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs6665290	0.870	rs17600725	chr1:227204231	A/G	cg11404489	chr1:228071452	NA	-0.19	-4.44	-0.37	1.96e-5	Myeloid white cell count;
TGCT	cis	rs12908161	1.000	rs12911736	chr15:85240008	A/G	cg17173187	chr15:85201210	NMB	0.59	6.74	0.52	5.44e-10	Schizophrenia;
TGCT	cis	rs9611565	0.729	rs505533	chr22:41864216	A/C	cg03806693	chr22:41940476	POLR3H	1.03	11.32	0.71	7.58e-21	Vitiligo;
TGCT	cis	rs7617773	0.817	rs936426	chr3:48215253	C/T	cg11946769	chr3:48343235	NME6	0.72	6.17	0.48	8.8e-9	Coronary artery disease;
TGCT	cis	rs41307935	0.915	rs34696599	chr1:27203728	A/T	cg23921621	chr1:27994728	IFI6	-0.42	-4.59	-0.38	1.06e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs11690462	0.963	rs7588538	chr2:26613329	A/G	cg04726446	chr2:26624865	C2orf39	0.42	4.63	0.38	9.27e-6	Coronary artery disease;
TGCT	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg19318889	chr4:1322082	MAEA	0.19	4.53	0.38	1.39e-5	Longevity;
TGCT	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg22920501	chr2:26401640	FAM59B	-0.81	-6.54	-0.51	1.43e-9	Gut microbiome composition (summer);
TGCT	cis	rs12950390	0.853	rs59513807	chr17:45867925	G/A	cg24803719	chr17:45855879	NA	-0.49	-5.03	-0.41	1.64e-6	IgG glycosylation;
TGCT	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg06481639	chr22:41940642	POLR3H	-0.74	-6.74	-0.52	5.38e-10	Vitiligo;
TGCT	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg23758822	chr17:41437982	NA	0.72	6.77	0.52	4.51e-10	Menopause (age at onset);
TGCT	cis	rs10501293	0.667	rs993904	chr11:42992769	G/T	cg03447554	chr11:43094025	NA	0.44	6.4	0.5	2.93e-9	Cognitive performance;
TGCT	cis	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg07424592	chr7:64974309	NA	1.36	8.08	0.59	4.97e-13	Diabetic kidney disease;
TGCT	cis	rs1018836	0.847	rs35409073	chr8:91648036	G/T	cg16814680	chr8:91681699	NA	-0.89	-9.56	-0.65	1.46e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7975161	0.572	rs4614534	chr12:104597917	C/T	cg25273343	chr12:104657179	TXNRD1	0.33	4.95	0.41	2.34e-6	Toenail selenium levels;
TGCT	cis	rs2204008	0.616	rs1607852	chr12:38398125	G/A	cg13010199	chr12:38710504	ALG10B	0.61	4.82	0.4	4.12e-6	Bladder cancer;
TGCT	cis	rs7666738	0.830	rs13101766	chr4:98957696	C/A	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg16325326	chr1:53192061	ZYG11B	0.62	6.85	0.52	3.05e-10	Monocyte count;
TGCT	cis	rs7659604	0.539	rs11098645	chr4:122729251	G/A	cg23574427	chr4:122746245	BBS7;CCNA2	-0.34	-5.31	-0.43	4.82e-7	Type 2 diabetes;
TGCT	cis	rs7940866	0.804	rs10894289	chr11:130808685	C/T	cg12179176	chr11:130786555	SNX19	0.59	5.81	0.46	4.88e-8	Schizophrenia;
TGCT	cis	rs634534	0.622	rs624273	chr11:65712413	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.52	5.3	0.43	5.03e-7	Sum eosinophil basophil counts;Eosinophil counts;
TGCT	cis	rs4851266	1.000	rs11691409	chr2:100826165	T/A	cg22139774	chr2:100720529	AFF3	-0.35	-5.19	-0.42	8.51e-7	Educational attainment;
TGCT	cis	rs968451	1.000	rs968451	chr22:39670851	G/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.78	6.76	0.52	4.73e-10	Primary biliary cholangitis;
TGCT	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg24675658	chr1:53192096	ZYG11B	-0.7	-7.91	-0.58	1.22e-12	Monocyte count;
TGCT	cis	rs7829975	0.511	rs2980426	chr8:8145609	T/C	cg15462221	chr8:8086144	FLJ10661	-0.55	-4.74	-0.39	5.87e-6	Mood instability;
TGCT	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg21171335	chr12:122356390	WDR66	0.69	6.98	0.53	1.56e-10	Mean corpuscular volume;
TGCT	cis	rs6770219	0.516	rs11916718	chr3:186141651	A/G	cg20306810	chr3:186501757	SNORD2;EIF4A2	0.73	4.46	0.37	1.81e-5	Cerebrospinal T-tau levels;
TGCT	cis	rs2073300	1.000	rs78000067	chr20:23439507	A/G	cg09953122	chr20:23471693	CST8	-0.66	-4.64	-0.38	8.6e-6	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	trans	rs1814175	0.791	rs9787917	chr11:49937281	C/T	cg03929089	chr4:120376271	NA	-0.71	-8.09	-0.59	4.74e-13	Height;
TGCT	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg03188948	chr7:1209495	NA	0.54	4.48	0.37	1.67e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs11190604	1.000	rs11190558	chr10:102209397	C/A	cg23241863	chr10:102295624	HIF1AN	0.62	4.87	0.4	3.27e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs6087990	0.806	rs910085	chr20:31383353	T/G	cg13636640	chr20:31349939	DNMT3B	1.08	15.49	0.81	8.74e-31	Ulcerative colitis;
TGCT	trans	rs459571	0.804	rs448918	chr9:136885979	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.73	-7.83	-0.58	1.84e-12	Platelet distribution width;
TGCT	cis	rs9916302	0.904	rs612194	chr17:37442707	T/A	cg15445000	chr17:37608096	MED1	-0.31	-4.59	-0.38	1.06e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs4824093	0.610	rs60036544	chr22:50264019	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.11	-6.79	-0.52	4.13e-10	Amyotrophic lateral sclerosis (sporadic);
TGCT	trans	rs28735056	1.000	rs59183289	chr18:77631198	A/G	cg05926928	chr17:57297772	GDPD1	-0.67	-6.96	-0.53	1.76e-10	Schizophrenia;
TGCT	cis	rs644799	0.965	rs534488	chr11:95562327	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.82	8.63	0.61	2.52e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs477895	0.878	rs7478730	chr11:64018827	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.83	6.93	0.53	2.04e-10	Mean platelet volume;
TGCT	cis	rs6500602	0.893	rs934888	chr16:4462832	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	6.34	0.49	3.84e-9	Schizophrenia;
TGCT	cis	rs7336332	0.598	rs10220056	chr13:28003781	T/G	cg22138327	chr13:27999177	GTF3A	0.83	6.51	0.5	1.67e-9	Weight;
TGCT	cis	rs9914544	0.966	rs1737943	chr17:18841590	A/G	cg26378065	chr17:18585709	ZNF286B	-0.52	-4.71	-0.39	6.57e-6	Educational attainment (years of education);
TGCT	cis	rs3096299	0.738	rs9929606	chr16:89527537	C/T	cg02187348	chr16:89574699	SPG7	0.6	6.01	0.47	1.92e-8	Multiple myeloma (IgH translocation);
TGCT	cis	rs3096299	0.606	rs4785674	chr16:89536613	A/G	cg06640241	chr16:89574553	SPG7	0.5	4.51	0.38	1.5e-5	Multiple myeloma (IgH translocation);
TGCT	cis	rs1577917	1.000	rs6933377	chr6:86705255	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.61	5.39	0.44	3.42e-7	Response to antipsychotic treatment;
TGCT	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg20203395	chr5:56204925	C5orf35	-0.59	-5.12	-0.42	1.12e-6	Initial pursuit acceleration;
TGCT	cis	rs3827735	0.599	rs6537835	chr1:115108914	G/A	cg12756093	chr1:115239321	AMPD1	0.54	4.62	0.38	9.47e-6	Autism;
TGCT	cis	rs3806843	0.735	rs801180	chr5:140092903	G/T	cg19875535	chr5:140030758	IK	-0.36	-6.1	-0.48	1.25e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.98	10.67	0.69	2.97e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs17539620	0.624	rs62432746	chr6:154838986	A/G	cg20019720	chr6:154832845	CNKSR3	0.57	4.99	0.41	2.02e-6	Lipoprotein (a) levels;
TGCT	cis	rs78456975	0.941	rs11886649	chr2:1567757	A/G	cg01028140	chr2:1542097	TPO	-0.33	-4.54	-0.38	1.29e-5	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs34467563	0.934	rs1356458	chr8:97404033	C/A	cg15747595	chr8:98289880	TSPYL5	-0.41	-4.43	-0.37	2.01e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg11890956	chr21:40555474	PSMG1	1.1	12.22	0.74	5.02e-23	Cognitive function;
TGCT	cis	rs2404602	0.716	rs1588961	chr15:76752698	A/G	cg22467129	chr15:76604101	ETFA	-0.57	-6.83	-0.52	3.31e-10	Blood metabolite levels;
TGCT	cis	rs79387448	0.701	rs11465586	chr2:102982709	C/G	cg09003973	chr2:102972529	NA	1.39	11.37	0.71	5.75e-21	Gut microbiota (bacterial taxa);
TGCT	cis	rs6952808	0.578	rs6949478	chr7:1841342	A/G	cg22963979	chr7:1858916	MAD1L1	0.37	5.99	0.47	2.11e-8	Bipolar disorder and schizophrenia;
TGCT	cis	rs2224391	1.000	rs2753246	chr6:5261845	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.79	-6.04	-0.48	1.66e-8	Height;
TGCT	cis	rs11997175	0.756	rs4739435	chr8:33818818	A/G	ch.8.33884649F	chr8:33765107	NA	0.34	5.28	0.43	5.56e-7	Body mass index;
TGCT	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg03303774	chr4:1407052	NA	0.32	4.9	0.4	2.96e-6	Obesity-related traits;
TGCT	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg06896619	chr17:61851486	DDX42;CCDC47	-0.52	-5.06	-0.41	1.45e-6	Prudent dietary pattern;
TGCT	cis	rs7772486	0.641	rs9390370	chr6:146357569	C/T	cg05347473	chr6:146136440	FBXO30	0.57	5.38	0.44	3.56e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7336332	0.598	rs76790205	chr13:28002885	C/T	cg22138327	chr13:27999177	GTF3A	0.83	6.51	0.5	1.67e-9	Weight;
TGCT	cis	rs10186029	0.680	rs4673726	chr2:213981115	T/C	cg08319019	chr2:214017104	IKZF2	0.65	5.95	0.47	2.49e-8	Systemic sclerosis;
TGCT	cis	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg07424592	chr7:64974309	NA	1.26	7.79	0.57	2.25e-12	Diabetic kidney disease;
TGCT	cis	rs1775715	0.644	rs2799022	chr10:32137198	C/T	cg14930904	chr10:32216787	ARHGAP12	0.51	4.91	0.4	2.79e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs1401999	0.714	rs13066518	chr3:183635498	T/A	cg01324343	chr3:183735012	ABCC5	0.68	7.95	0.58	1.01e-12	Anterior chamber depth;
TGCT	cis	rs9581857	0.547	rs9581881	chr13:28106637	A/G	cg22138327	chr13:27999177	GTF3A	0.77	4.89	0.4	3.05e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs55882075	0.690	rs12374485	chr5:179131395	G/C	cg14593053	chr5:179126677	CANX	0.47	5.27	0.43	5.73e-7	Monocyte percentage of white cells;
TGCT	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg00149659	chr3:10157352	C3orf10	1.19	7.35	0.55	2.38e-11	Alzheimer's disease;
TGCT	cis	rs6500602	0.627	rs1641866	chr16:4593040	A/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.4	6.96	0.53	1.77e-10	Schizophrenia;
TGCT	cis	rs9300255	0.596	rs10732573	chr12:123743883	G/C	cg00376283	chr12:123451042	ABCB9	0.79	6.68	0.51	7.08e-10	Neutrophil percentage of white cells;
TGCT	cis	rs734999	0.588	rs6689711	chr1:2531467	T/C	cg18854424	chr1:2615690	NA	-0.46	-5.36	-0.43	3.84e-7	Ulcerative colitis;
TGCT	cis	rs4638749	0.953	rs12475415	chr2:108860477	G/A	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.69	-0.39	6.95e-6	Blood pressure;
TGCT	cis	rs12549902	0.966	rs10504042	chr8:41515993	G/A	cg21772509	chr8:41503840	NKX6-3	0.85	9.62	0.65	1.04e-16	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
TGCT	cis	rs9549367	0.789	rs34568744	chr13:113894564	G/T	cg00898013	chr13:113819073	PROZ	-0.4	-4.98	-0.41	2.13e-6	Platelet distribution width;
TGCT	trans	rs731174	0.559	rs66536721	chr1:38195582	A/G	cg19725343	chr19:51830960	IGLON5	-0.62	-6.99	-0.53	1.48e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs12210905	0.688	rs12193557	chr6:27435944	T/C	cg08851530	chr6:28072375	NA	1.34	6.29	0.49	5.02e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg04944784	chr2:26401820	FAM59B	0.77	5.18	0.42	8.59e-7	Gut microbiome composition (summer);
TGCT	cis	rs9926296	0.744	rs164749	chr16:89708224	A/C	cg03388025	chr16:89894329	SPIRE2	-0.31	-4.93	-0.41	2.55e-6	Vitiligo;
TGCT	cis	rs7589728	0.858	rs79992736	chr2:88530575	A/C	cg04511125	chr2:88470314	THNSL2	0.63	5.13	0.42	1.08e-6	Plasma clusterin levels;
TGCT	cis	rs2710642	0.777	rs2539987	chr2:63142864	A/G	cg17519650	chr2:63277830	OTX1	0.58	5.29	0.43	5.47e-7	LDL cholesterol levels;LDL cholesterol;
TGCT	cis	rs7647973	0.559	rs9586	chr3:49213637	C/T	cg07690219	chr3:49449608	TCTA;RHOA	-0.57	-4.51	-0.38	1.48e-5	Menarche (age at onset);
TGCT	cis	rs12579753	0.917	rs11115032	chr12:82205073	T/C	cg07988820	chr12:82153109	PPFIA2	-0.59	-6.19	-0.49	7.93e-9	Resting heart rate;
TGCT	cis	rs7647973	0.516	rs4499638	chr3:49202782	C/G	cg03060546	chr3:49711283	APEH	0.5	4.7	0.39	6.82e-6	Menarche (age at onset);
TGCT	cis	rs72945132	0.882	rs7937984	chr11:70144254	C/T	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs7267979	1.000	rs2387884	chr20:25379069	C/T	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs941408	0.963	rs1640268	chr19:2791469	T/C	cg19676328	chr12:49525230	TUBA1B	-0.77	-7.92	-0.58	1.16e-12	Total cholesterol levels;
TGCT	cis	rs12681287	0.547	rs13267858	chr8:87510871	G/A	cg27223183	chr8:87520930	FAM82B	-0.95	-6.95	-0.53	1.81e-10	Caudate activity during reward;
TGCT	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9467773	0.595	rs2451736	chr6:26620544	G/A	cg05738196	chr6:26577821	NA	0.87	11.3	0.71	8.47e-21	Intelligence (multi-trait analysis);
TGCT	trans	rs10506458	0.915	rs2013050	chr12:63394310	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.47	-7.58	-0.56	6.97e-12	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs10927875	0.662	rs848309	chr1:16308447	T/C	cg22431228	chr1:16359049	CLCNKA	-0.26	-5.43	-0.44	2.79e-7	Dilated cardiomyopathy;
TGCT	trans	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg25482853	chr8:67687455	SGK3	1.21	10.93	0.7	6.89e-20	Obesity-related traits;
TGCT	cis	rs1801251	1.000	rs6746294	chr2:233583050	C/G	cg25237894	chr2:233734115	C2orf82	-0.3	-5.36	-0.43	3.83e-7	Coronary artery disease;
TGCT	cis	rs9393777	0.920	rs35869525	chr6:26946687	C/T	cg12315302	chr6:26189340	HIST1H4D	0.93	4.48	0.37	1.71e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7086627	0.515	rs11202957	chr10:82209592	A/G	cg00277334	chr10:82204260	NA	-0.54	-8.46	-0.61	6.23e-14	Post bronchodilator FEV1;
TGCT	cis	rs4654899	0.758	rs10218584	chr1:21474480	C/G	cg01072550	chr1:21505969	NA	0.57	9.41	0.65	3.42e-16	Superior frontal gyrus grey matter volume;
TGCT	cis	rs3784262	1.000	rs12903474	chr15:58276747	A/C	cg12031962	chr15:58353849	ALDH1A2	0.49	7.56	0.56	7.97e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs1975974	0.872	rs66502681	chr17:21722119	T/A	cg18423549	chr17:21743878	NA	-0.54	-5.15	-0.42	1.01e-6	Psoriasis;
TGCT	cis	rs6582630	0.519	rs1851130	chr12:38507819	C/T	cg26384229	chr12:38710491	ALG10B	0.85	7.87	0.58	1.53e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs6570726	0.935	rs392014	chr6:145843691	A/C	cg23711669	chr6:146136114	FBXO30	0.67	6.26	0.49	5.65e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9467773	0.649	rs2145318	chr6:26496603	T/A	cg09904177	chr6:26538194	HMGN4	0.59	5.56	0.45	1.56e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7447593	0.518	rs4074995	chr5:176797343	C/T	cg16006841	chr5:176797999	RGS14	0.71	12.13	0.74	8.0700000000000006e-23	Urinary electrolytes (magnesium/calcium ratio);
TGCT	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg21280719	chr6:42927975	GNMT	-0.37	-4.56	-0.38	1.22e-5	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs244731	0.959	rs7721671	chr5:176630984	A/G	cg16006841	chr5:176797999	RGS14	-0.53	-6.95	-0.53	1.88e-10	Urate levels in lean individuals;
TGCT	cis	rs2996428	0.667	rs7538067	chr1:3761772	C/T	cg13057898	chr1:3703894	LRRC47	0.21	4.62	0.38	9.46e-6	Red cell distribution width;
TGCT	cis	rs9653442	0.564	rs11687586	chr2:100789346	A/G	cg22139774	chr2:100720529	AFF3	-0.35	-5.55	-0.45	1.63e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs12497850	0.829	rs8926	chr3:49052785	T/A	cg07636037	chr3:49044803	WDR6	0.96	10.9	0.7	8.39e-20	Parkinson's disease;
TGCT	cis	rs9467773	1.000	rs9357010	chr6:26527945	C/G	cg09904177	chr6:26538194	HMGN4	0.66	6.83	0.52	3.37e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs10927875	0.596	rs1806990	chr1:16129377	G/A	cg21385522	chr1:16154831	NA	-0.96	-15.71	-0.82	2.84e-31	Dilated cardiomyopathy;
TGCT	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg20203395	chr5:56204925	C5orf35	0.64	4.73	0.39	6.02e-6	Initial pursuit acceleration;
TGCT	cis	rs9611519	0.558	rs8137906	chr22:41442566	A/G	cg13695892	chr22:41940480	POLR3H	-0.56	-5.29	-0.43	5.29e-7	Neuroticism;
TGCT	cis	rs12971120	0.947	rs3764509	chr18:72167124	C/G	cg26446133	chr18:72167187	CNDP2	-0.4	-7.7	-0.57	3.64e-12	Refractive error;
TGCT	cis	rs4689388	0.926	rs3889821	chr4:6282596	C/T	cg14416269	chr4:6271139	WFS1	0.38	5.23	0.42	7.12e-7	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg17328964	chr8:145687451	CYHR1	0.45	6.66	0.51	7.93e-10	Age at first birth;
TGCT	cis	rs2980439	0.783	rs2955587	chr8:8098079	A/G	cg15556689	chr8:8085844	FLJ10661	0.88	9.13	0.63	1.6e-15	Neuroticism;
TGCT	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	trans	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg17830980	chr10:43048298	ZNF37B	-0.85	-10.98	-0.7	5.08e-20	Extrinsic epigenetic age acceleration;
TGCT	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg16049864	chr8:95962084	TP53INP1	-0.73	-10.16	-0.67	5.23e-18	Type 2 diabetes;
TGCT	cis	rs2120019	0.938	rs1867150	chr15:75321139	T/C	cg17294928	chr15:75287854	SCAMP5	-0.79	-6.27	-0.49	5.46e-9	Blood trace element (Zn levels);
TGCT	cis	rs11172134	0.508	rs1800175	chr12:57561379	G/T	cg19258868	chr12:57585184	LRP1	-0.32	-6.22	-0.49	6.94e-9	Urate levels in overweight individuals;
TGCT	cis	rs986417	1.000	rs1313249	chr14:60881997	C/G	cg27398547	chr14:60952738	C14orf39	-1.49	-10.81	-0.7	1.38e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs3008870	0.958	rs12131222	chr1:67438535	A/T	cg03991309	chr1:68237761	GNG12	-0.27	-4.53	-0.38	1.36e-5	Lymphocyte percentage of white cells;
TGCT	trans	rs7615952	0.866	rs11922276	chr3:125631326	G/T	cg07211511	chr3:129823064	LOC729375	-0.45	-7.36	-0.55	2.2e-11	Blood pressure (smoking interaction);
TGCT	cis	rs1997103	1.000	rs6957984	chr7:55397331	G/A	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs709400	0.598	rs11627529	chr14:104004557	C/T	cg12935359	chr14:103987150	CKB	-0.37	-5.54	-0.45	1.73e-7	Body mass index;
TGCT	cis	rs7829975	0.560	rs4841013	chr8:8552013	A/G	cg06636001	chr8:8085503	FLJ10661	-0.61	-5.31	-0.43	4.81e-7	Mood instability;
TGCT	cis	rs9467711	0.606	rs9379875	chr6:26444732	C/T	cg16898833	chr6:26189333	HIST1H4D	1.12	5.36	0.43	3.91e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs11785400	0.793	rs9297972	chr8:143723660	C/T	cg10596483	chr8:143751796	JRK	0.53	5.3	0.43	5.12e-7	Schizophrenia;
TGCT	cis	rs1008375	1.000	rs12648232	chr4:17612537	C/T	cg16339924	chr4:17578868	LAP3	-0.66	-5.6	-0.45	1.34e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10984561	0.748	rs12236090	chr9:122250920	A/G	cg14242995	chr9:122249943	NA	0.73	5.96	0.47	2.46e-8	Pulmonary function decline;
TGCT	cis	rs2439831	0.702	rs2467402	chr15:44024490	A/C	cg11515196	chr15:44829065	EIF3J	0.73	4.47	0.37	1.74e-5	Lung cancer in ever smokers;
TGCT	cis	rs921968	0.643	rs600057	chr2:219456737	A/G	cg02176678	chr2:219576539	TTLL4	0.44	6.33	0.49	4.17e-9	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs4845570	1.000	rs7542898	chr1:151753622	T/G	cg07092448	chr1:151763213	TDRKH	-1.12	-8.18	-0.59	2.84e-13	Coronary artery disease;
TGCT	trans	rs8073060	0.592	rs225306	chr17:33920036	A/C	cg19694781	chr19:47549865	TMEM160	0.38	7.43	0.56	1.53e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.81	7.61	0.56	5.98e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg04025307	chr7:1156635	C7orf50	0.2	4.67	0.39	7.62e-6	Longevity;Endometriosis;
TGCT	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.49	-4.63	-0.38	9.09e-6	Bipolar disorder;
TGCT	cis	rs651907	0.535	rs36060163	chr3:101360963	C/T	cg12386194	chr3:101231763	SENP7	0.52	5.01	0.41	1.81e-6	Colorectal cancer;
TGCT	cis	rs6500596	0.570	rs8055628	chr16:4447477	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.36	5.31	0.43	4.92e-7	Schizophrenia;
TGCT	cis	rs9303401	0.659	rs1864754	chr17:56688789	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.62	-6.32	-0.49	4.18e-9	Cognitive test performance;
TGCT	trans	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg13615516	chr5:77269221	NA	0.67	8.36	0.6	1.09e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs12908161	0.920	rs12904605	chr15:85201419	T/C	cg17173187	chr15:85201210	NMB	0.6	6.74	0.52	5.37e-10	Schizophrenia;
TGCT	cis	rs6121246	0.567	rs6060344	chr20:30207316	A/G	cg18721089	chr20:30220636	NA	-0.64	-6.86	-0.52	2.84e-10	Mean corpuscular hemoglobin;
TGCT	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg25036284	chr2:26402008	FAM59B	-0.54	-4.71	-0.39	6.53e-6	Gut microbiome composition (summer);
TGCT	cis	rs910316	0.673	rs2012627	chr14:75443103	C/T	cg08847533	chr14:75593920	NEK9	0.83	8.56	0.61	3.57e-14	Height;
TGCT	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg22920501	chr2:26401640	FAM59B	-0.73	-6.44	-0.5	2.35e-9	Gut microbiome composition (summer);
TGCT	cis	rs4478858	0.684	rs7549343	chr1:31752260	A/G	cg07478791	chr1:31886160	SERINC2	-0.52	-5.02	-0.41	1.73e-6	Alcohol dependence;
TGCT	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg09365446	chr1:150670422	GOLPH3L	0.31	4.64	0.38	8.7e-6	Tonsillectomy;
TGCT	cis	rs7781977	0.960	rs17732497	chr7:50336073	C/A	cg14216940	chr7:50343131	IKZF1	0.4	4.51	0.38	1.49e-5	IgG glycosylation;
TGCT	cis	rs2404602	0.967	rs12148805	chr15:76800659	G/A	cg22467129	chr15:76604101	ETFA	-0.51	-5.89	-0.47	3.45e-8	Blood metabolite levels;
TGCT	cis	rs425277	0.585	rs3128294	chr1:2065343	G/C	cg03732007	chr1:2071316	PRKCZ	-0.28	-6.32	-0.49	4.33e-9	Height;
TGCT	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.72	5.19	0.42	8.33e-7	Platelet count;
TGCT	cis	rs254779	0.538	rs254776	chr5:88006893	G/C	cg22951263	chr5:87985283	NA	-0.55	-4.93	-0.4	2.63e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs6141769	0.542	rs4425162	chr20:31312916	A/G	cg13636640	chr20:31349939	DNMT3B	-0.52	-4.54	-0.38	1.34e-5	Subjective well-being;
TGCT	cis	rs2404602	0.647	rs907594	chr15:77197745	C/A	cg22467129	chr15:76604101	ETFA	0.48	4.86	0.4	3.42e-6	Blood metabolite levels;
TGCT	cis	rs7833790	0.724	rs72603871	chr8:82754460	C/G	cg23324259	chr8:82754387	SNX16	0.62	4.71	0.39	6.47e-6	Diastolic blood pressure;
TGCT	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg08736216	chr1:53307985	ZYG11A	0.26	5.07	0.41	1.43e-6	Monocyte count;
TGCT	cis	rs1371867	0.846	rs1660328	chr8:101303450	A/G	cg00191853	chr8:101177733	SPAG1	-0.23	-4.76	-0.39	5.2e-6	Atrioventricular conduction;
TGCT	cis	rs7106204	0.748	rs28552633	chr11:24207518	A/C	ch.11.24196551F	chr11:24239977	NA	0.47	4.45	0.37	1.91e-5	Response to Homoharringtonine (cytotoxicity);
TGCT	cis	rs11577318	0.853	rs7541333	chr1:26622889	C/T	cg04990556	chr1:26633338	UBXN11	-0.58	-5.37	-0.43	3.68e-7	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs10782582	0.609	rs111914775	chr1:76319036	C/T	cg03433033	chr1:76189801	ACADM	-0.5	-4.98	-0.41	2.11e-6	Daytime sleep phenotypes;
TGCT	cis	rs7296418	0.518	rs28825193	chr12:123878262	T/C	cg00376283	chr12:123451042	ABCB9	0.63	5.46	0.44	2.47e-7	Platelet count;
TGCT	cis	rs2013441	1.000	rs17759959	chr17:20024095	A/G	cg18979559	chr17:20280153	CCDC144C	0.48	5.06	0.41	1.48e-6	Obesity-related traits;
TGCT	cis	rs6684514	1.000	rs10752615	chr1:156248609	T/C	cg16558208	chr1:156270281	VHLL	0.46	9.38	0.64	3.92e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.25	-0.43	6.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9467773	0.526	rs9688946	chr6:26367445	C/A	cg15659132	chr6:26577336	NA	-0.5	-5.05	-0.41	1.53e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7584330	0.910	rs12465081	chr2:238401784	A/G	cg14458575	chr2:238380390	NA	0.38	5.61	0.45	1.25e-7	Prostate cancer;
TGCT	cis	rs7208859	0.573	rs73267829	chr17:29003939	G/A	cg14008862	chr17:28927542	LRRC37B2	0.85	5.11	0.42	1.2e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7428	0.527	rs1554110	chr2:85547963	C/T	cg24342717	chr2:85555507	TGOLN2	-0.49	-7.81	-0.57	2.04e-12	Ear protrusion;
TGCT	trans	rs34421088	0.560	rs11780851	chr8:11401116	G/A	cg15556689	chr8:8085844	FLJ10661	-0.74	-7.04	-0.53	1.14e-10	Neuroticism;
TGCT	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg13607699	chr17:42295918	UBTF	-0.59	-5.38	-0.43	3.65e-7	Total body bone mineral density;
TGCT	cis	rs904251	0.766	rs1757175	chr6:37486694	T/C	cg25019722	chr6:37503610	NA	-0.51	-7.0	-0.53	1.43e-10	Cognitive performance;
TGCT	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.87	0.47	3.73e-8	Alzheimer's disease;
TGCT	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.55	-5.1	-0.42	1.21e-6	Bipolar disorder;
TGCT	cis	rs28735056	0.933	rs72980085	chr18:77631679	A/C	cg20368463	chr18:77673604	PQLC1	-0.45	-5.55	-0.45	1.65e-7	Schizophrenia;
TGCT	cis	rs909002	0.800	rs3753613	chr1:32082000	C/T	cg11573219	chr1:32083031	HCRTR1	0.43	5.59	0.45	1.41e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.59	-5.71	-0.46	7.79e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.12	14.83	0.8	3.07e-29	Height;
TGCT	cis	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg18252515	chr7:66147081	NA	1.25	7.62	0.56	5.7e-12	Diabetic kidney disease;
TGCT	cis	rs10875595	0.836	rs56756237	chr5:140678342	T/C	cg20560182	chr5:140700478	TAF7	-0.64	-4.78	-0.39	4.77e-6	Pulmonary function decline;
TGCT	cis	rs9303401	0.659	rs35928756	chr17:56702652	C/T	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs7584330	0.704	rs7598954	chr2:238364776	C/T	cg14458575	chr2:238380390	NA	0.59	8.88	0.62	6.18e-15	Prostate cancer;
TGCT	cis	rs7666738	0.753	rs35146453	chr4:98902278	A/G	cg05340658	chr4:99064831	C4orf37	0.51	5.93	0.47	2.84e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9942416	0.630	rs253388	chr5:74975912	A/G	cg19683494	chr5:74908142	NA	-0.6	-6.34	-0.49	3.83e-9	Age-related disease endophenotypes;
TGCT	cis	rs7666738	0.830	rs13125537	chr4:98978428	A/G	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7100689	0.577	rs4934038	chr10:82057334	C/A	cg01528321	chr10:82214614	TSPAN14	0.7	6.78	0.52	4.43e-10	Post bronchodilator FEV1;
TGCT	cis	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg07424592	chr7:64974309	NA	1.4	8.42	0.6	7.87e-14	Diabetic kidney disease;
TGCT	cis	rs11112613	0.713	rs55646142	chr12:105949557	G/A	cg03607813	chr12:105948248	NA	0.52	6.0	0.47	2.03e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	cis	rs7412746	0.658	rs6660845	chr1:150841066	G/A	cg04414720	chr1:150670196	GOLPH3L	0.39	4.75	0.39	5.55e-6	Melanoma;
TGCT	cis	rs7120118	0.517	rs56177220	chr11:47328377	C/T	cg13308137	chr11:47528955	CUGBP1	0.33	5.19	0.42	8.26e-7	HDL cholesterol;
TGCT	cis	rs899997	0.953	rs11633519	chr15:78999552	A/G	cg00061860	chr15:78953028	NA	-0.29	-4.87	-0.4	3.33e-6	Coronary artery disease or large artery stroke;
TGCT	cis	rs12142240	0.698	rs72677600	chr1:46834449	G/A	cg00530320	chr1:46809349	NSUN4	0.28	5.78	0.46	5.69e-8	Menopause (age at onset);
TGCT	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg25036284	chr2:26402008	FAM59B	0.65	5.18	0.42	8.59e-7	Gut microbiome composition (summer);
TGCT	cis	rs10927875	0.597	rs61782184	chr1:16150976	G/A	cg14742211	chr1:16348397	CLCNKA	-0.19	-4.65	-0.38	8.54e-6	Dilated cardiomyopathy;
TGCT	cis	rs10782582	0.609	rs78748984	chr1:76340467	G/A	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.52	4.53	0.38	1.37e-5	Daytime sleep phenotypes;
TGCT	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg09359103	chr1:154839909	KCNN3	-0.66	-12.15	-0.74	7.27e-23	Prostate cancer;
TGCT	cis	rs7927592	0.513	rs7950129	chr11:68202903	A/G	cg16797656	chr11:68205561	LRP5	0.28	5.13	0.42	1.08e-6	Total body bone mineral density;
TGCT	cis	rs938554	0.571	rs7696092	chr4:10025320	C/A	cg00071950	chr4:10020882	SLC2A9	0.53	4.79	0.4	4.69e-6	Blood metabolite levels;
TGCT	cis	rs17253792	0.822	rs79262019	chr14:56092704	A/G	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs933688	1.000	rs2839728	chr5:90727412	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.06	10.58	0.69	4.88e-19	Smoking behavior;
TGCT	cis	rs12220898	0.679	rs7082585	chr10:50486747	G/T	cg06072769	chr10:50146962	WDFY4	0.39	5.18	0.42	8.72e-7	Inflammatory biomarkers;
TGCT	cis	rs2562456	0.833	rs62110429	chr19:21613786	C/T	cg25650185	chr19:21324782	ZNF431	-0.58	-4.55	-0.38	1.25e-5	Pain;
TGCT	trans	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg27523141	chr10:43048294	ZNF37B	0.73	8.51	0.61	4.68e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs4253772	0.591	rs6007795	chr22:46686792	C/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.7	5.27	0.43	5.83e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs6992820	0.902	rs6999008	chr8:56768236	G/A	cg06880721	chr8:56792545	LYN	-0.72	-5.98	-0.47	2.25e-8	Mean platelet volume;
TGCT	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg13393036	chr8:95962371	TP53INP1	-0.63	-8.52	-0.61	4.43e-14	Type 2 diabetes;
TGCT	cis	rs67311347	1.000	rs4128740	chr3:40519532	C/A	cg13683864	chr3:40499215	RPL14	-1.2	-13.3	-0.77	1.27e-25	Renal cell carcinoma;
TGCT	cis	rs9393692	0.552	rs806789	chr6:26229161	C/A	cg05868516	chr6:26286170	HIST1H4H	0.52	5.02	0.41	1.79e-6	Educational attainment;
TGCT	cis	rs3829109	0.534	rs563	chr9:139296485	C/T	cg13741927	chr9:139327495	INPP5E	0.26	5.51	0.44	2.03e-7	Peak insulin response;Acute insulin response;
TGCT	cis	rs10883723	0.775	rs2296579	chr10:104241375	A/G	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.12	0.42	1.15e-6	Prudent dietary pattern;
TGCT	cis	rs9473924	0.505	rs7756058	chr6:50904438	G/A	cg14470998	chr6:50812995	TFAP2B	1.35	8.39	0.6	9.05e-14	Body mass index;
TGCT	cis	rs4746818	0.892	rs10823298	chr10:70867083	T/C	cg11621586	chr10:70884670	VPS26A	1.15	9.19	0.64	1.14e-15	Left atrial antero-posterior diameter;
TGCT	cis	rs2486288	0.656	rs9921035	chr15:45546660	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.74	-7.8	-0.57	2.23e-12	Glomerular filtration rate;
TGCT	cis	rs35306767	0.714	rs67696450	chr10:1090684	C/T	cg20503657	chr10:835505	NA	0.6	6.93	0.53	2e-10	Eosinophil percentage of granulocytes;
TGCT	cis	rs554111	0.593	rs7540023	chr1:21310092	T/C	cg01072550	chr1:21505969	NA	0.36	5.43	0.44	2.9e-7	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs5769765	0.778	rs4574208	chr22:50256738	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	1.11	11.32	0.71	7.61e-21	Schizophrenia;
TGCT	cis	rs259282	0.532	rs259283	chr19:33163103	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	1.06	12.87	0.76	1.38e-24	Schizophrenia;
TGCT	cis	rs317689	0.513	rs317678	chr12:69692166	C/G	cg20891283	chr12:69753455	YEATS4	0.56	5.13	0.42	1.1e-6	Response to diuretic therapy;
TGCT	cis	rs9300255	0.596	rs10734900	chr12:123743445	G/A	cg00376283	chr12:123451042	ABCB9	0.79	6.68	0.51	7.08e-10	Neutrophil percentage of white cells;
TGCT	cis	rs910316	0.967	rs175498	chr14:75536369	G/A	cg08847533	chr14:75593920	NEK9	-0.95	-10.3	-0.68	2.36e-18	Height;
TGCT	cis	rs1862618	0.641	rs170733	chr5:56249251	A/G	cg20203395	chr5:56204925	C5orf35	0.52	4.77	0.39	5e-6	Initial pursuit acceleration;
TGCT	cis	rs208520	0.954	rs72884027	chr6:66995044	T/G	cg07460842	chr6:66804631	NA	0.8	6.98	0.53	1.61e-10	Exhaled nitric oxide output;
TGCT	trans	rs1814175	0.817	rs1621090	chr11:49895868	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.34	-0.55	2.4e-11	Height;
TGCT	cis	rs12497850	0.931	rs9311433	chr3:48863835	T/C	cg18654377	chr3:49208889	KLHDC8B	-0.41	-5.49	-0.44	2.15e-7	Parkinson's disease;
TGCT	cis	rs3008870	1.000	rs12117131	chr1:67451922	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.1	-11.8	-0.73	5.15e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs9611565	0.512	rs5751145	chr22:42133552	C/T	cg13695892	chr22:41940480	POLR3H	0.89	8.43	0.6	7.37e-14	Vitiligo;
TGCT	cis	rs9326248	1.000	rs7107152	chr11:117056080	C/T	cg11861562	chr11:117069780	TAGLN	-0.26	-4.62	-0.38	9.44e-6	Blood protein levels;
TGCT	cis	rs1691799	0.899	rs1168299	chr12:66736074	C/G	cg16791601	chr12:66731901	HELB	-0.28	-6.17	-0.48	8.87e-9	White blood cell count (basophil);
TGCT	cis	rs35146811	0.961	rs11771139	chr7:99736059	C/T	cg22906224	chr7:99728672	NA	0.5	4.68	0.39	7.42e-6	Coronary artery disease;
TGCT	cis	rs3091242	0.933	rs1534954	chr1:25761924	A/T	cg23205692	chr1:25664452	TMEM50A	0.47	4.88	0.4	3.15e-6	Erythrocyte sedimentation rate;
TGCT	cis	rs7666738	0.830	rs10034330	chr4:99064849	G/A	cg18180107	chr4:99064573	C4orf37	0.58	5.31	0.43	4.87e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1153858	1.000	rs2453541	chr15:45645378	G/A	cg14582100	chr15:45693742	SPATA5L1	0.48	5.69	0.46	8.56e-8	Homoarginine levels;
TGCT	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg06481639	chr22:41940642	POLR3H	-0.74	-6.51	-0.5	1.71e-9	Vitiligo;
TGCT	cis	rs7937682	0.924	rs875257	chr11:111530453	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.12	-11.81	-0.73	4.86e-22	Primary sclerosing cholangitis;
TGCT	cis	rs9611565	0.568	rs5751159	chr22:42175365	G/A	cg06481639	chr22:41940642	POLR3H	0.53	4.54	0.38	1.29e-5	Vitiligo;
TGCT	cis	rs2013441	0.931	rs4925089	chr17:20064784	A/T	cg18979559	chr17:20280153	CCDC144C	0.44	4.61	0.38	9.78e-6	Obesity-related traits;
TGCT	cis	rs3091242	0.933	rs1534954	chr1:25761924	A/T	cg09222892	chr1:25734099	RHCE	-0.42	-6.88	-0.53	2.6200000000000003e-10	Erythrocyte sedimentation rate;
TGCT	cis	rs1801251	1.000	rs283480	chr2:233648742	G/A	cg25237894	chr2:233734115	C2orf82	0.28	4.82	0.4	4.05e-6	Coronary artery disease;
TGCT	cis	rs7552404	0.731	rs17650138	chr1:76398887	C/T	cg22875332	chr1:76189707	ACADM	-0.75	-7.0	-0.53	1.42e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg14784868	chr12:69753453	YEATS4	0.89	10.48	0.69	8.4e-19	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs7666738	0.791	rs10022061	chr4:98926821	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10858047	0.883	rs6695699	chr1:115209951	C/A	cg12756093	chr1:115239321	AMPD1	-0.47	-4.96	-0.41	2.27e-6	Autism;
TGCT	cis	rs40363	1.000	rs1690443	chr16:3517787	C/G	cg22508957	chr16:3507546	NAT15	0.56	5.25	0.43	6.33e-7	Tuberculosis;
TGCT	cis	rs854765	0.547	rs4584886	chr17:17896205	C/T	cg04398451	chr17:18023971	MYO15A	-0.33	-5.18	-0.42	8.63e-7	Total body bone mineral density;
TGCT	cis	rs12477438	0.798	rs1453561	chr2:99613924	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.69	-5.87	-0.47	3.64e-8	Chronic sinus infection;
TGCT	cis	rs6714788	0.565	rs7558817	chr2:100654482	C/A	cg07810366	chr2:100720526	AFF3	-0.36	-5.07	-0.41	1.43e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs12188164	0.610	rs6555242	chr5:416546	A/C	cg13013644	chr5:502571	SLC9A3	-0.27	-4.45	-0.37	1.91e-5	Cystic fibrosis severity;
TGCT	cis	rs7714584	1.000	rs76872831	chr5:150171559	A/G	cg22134413	chr5:150180641	NA	1.11	7.3	0.55	3.05e-11	Crohn's disease;
TGCT	cis	rs7666738	0.570	rs1921415	chr4:99093804	C/T	cg05340658	chr4:99064831	C4orf37	0.44	4.72	0.39	6.23e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7646881	0.504	rs4264773	chr3:158463225	G/T	cg18349298	chr3:158450550	RARRES1	0.42	4.44	0.37	1.97e-5	Tetralogy of Fallot;
TGCT	cis	rs4629710	0.645	rs34601891	chr6:131551238	C/T	cg12606694	chr6:131520996	AKAP7	0.39	4.63	0.38	9.14e-6	Multiple myeloma (IgH translocation);
TGCT	cis	rs67478160	0.654	rs1997913	chr14:104213960	C/T	cg26031613	chr14:104095156	KLC1	-0.63	-6.37	-0.5	3.33e-9	Schizophrenia;
TGCT	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg13395646	chr4:1353034	KIAA1530	-0.57	-7.74	-0.57	2.98e-12	Obesity-related traits;
TGCT	cis	rs986417	1.000	rs9989167	chr14:60942374	T/C	cg27398547	chr14:60952738	C14orf39	1.39	10.61	0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs3845702	0.736	rs6433818	chr2:180810264	A/T	cg01881094	chr2:180872142	CWC22	-1.03	-6.51	-0.5	1.72e-9	Schizophrenia;
TGCT	cis	rs1008375	0.900	rs1003413	chr4:17582442	C/T	cg16339924	chr4:17578868	LAP3	-0.84	-7.17	-0.54	5.96e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1075232	1.000	rs72722847	chr15:31682346	C/T	cg01030201	chr15:31746330	NA	-1.1	-5.4	-0.44	3.27e-7	Survival in colorectal cancer (non-distant metastatic);
TGCT	cis	rs7267979	1.000	rs2424704	chr20:25273929	A/G	cg03522245	chr20:25566470	NINL	0.62	6.56	0.51	1.34e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9948	0.655	rs62156210	chr2:97393736	A/T	cg01990225	chr2:97406019	LMAN2L	-1.02	-5.19	-0.42	8.43e-7	Erectile dysfunction and prostate cancer treatment;
TGCT	trans	rs4919669	0.668	rs7086898	chr10:104386152	A/G	cg24066601	chr6:26271455	HIST1H3G	0.66	6.81	0.52	3.7e-10	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs6088580	0.634	rs4911421	chr20:32998948	T/C	cg24642439	chr20:33292090	TP53INP2	-0.49	-4.49	-0.37	1.59e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs7698623	0.850	rs3886171	chr4:88800053	A/G	cg27387453	chr4:88533842	DSPP	-0.6	-4.53	-0.38	1.35e-5	Cardiovascular disease risk factors;
TGCT	cis	rs9818758	0.607	rs35673421	chr3:49139406	G/A	cg07636037	chr3:49044803	WDR6	-1.04	-5.16	-0.42	9.65e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs4478858	0.684	rs12121165	chr1:31725542	G/A	cg00250761	chr1:31883323	NA	-0.28	-5.01	-0.41	1.86e-6	Alcohol dependence;
TGCT	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg26338869	chr17:61819248	STRADA	0.53	4.92	0.4	2.71e-6	Prudent dietary pattern;
TGCT	cis	rs9291683	0.645	rs11557743	chr4:10118377	C/G	cg11266682	chr4:10021025	SLC2A9	-0.44	-5.17	-0.42	9.18e-7	Bone mineral density;
TGCT	cis	rs7714584	1.000	rs73282255	chr5:150223647	A/T	cg22134413	chr5:150180641	NA	0.89	6.96	0.53	1.73e-10	Crohn's disease;
TGCT	cis	rs7208859	0.524	rs77498725	chr17:29063986	C/T	cg14008862	chr17:28927542	LRRC37B2	0.76	4.52	0.38	1.42e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg25767906	chr1:53392781	SCP2	-0.59	-7.49	-0.56	1.12e-11	Monocyte count;
TGCT	cis	rs2224391	1.000	rs9504370	chr6:5261601	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.8	-6.12	-0.48	1.13e-8	Height;
TGCT	cis	rs7635838	0.587	rs347591	chr3:11290122	G/T	cg00170343	chr3:11313890	ATG7	0.65	6.52	0.51	1.63e-9	HDL cholesterol;
TGCT	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs10751667	0.666	rs10902235	chr11:938892	T/C	cg06064525	chr11:970664	AP2A2	-0.35	-8.28	-0.6	1.65e-13	Alzheimer's disease (late onset);
TGCT	cis	rs9527	0.590	rs7088200	chr10:104793235	G/A	cg04362960	chr10:104952993	NT5C2	0.66	5.57	0.45	1.48e-7	Arsenic metabolism;
TGCT	cis	rs6684514	1.000	rs12121805	chr1:156257876	A/G	cg20302342	chr1:156215951	PAQR6	0.34	4.6	0.38	1.01e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs10088262	0.629	rs12549683	chr8:124798276	G/C	cg20713898	chr8:124780851	FAM91A1	-0.84	-7.19	-0.54	5.3e-11	Pancreatic cancer;
TGCT	cis	rs11250098	0.583	rs7000276	chr8:10804843	G/A	cg21775007	chr8:11205619	TDH	-0.57	-5.36	-0.43	3.87e-7	Morning vs. evening chronotype;
TGCT	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg20203395	chr5:56204925	C5orf35	0.75	5.74	0.46	6.81e-8	Initial pursuit acceleration;
TGCT	trans	rs2688608	0.967	rs2675663	chr10:75660270	T/G	cg13918328	chr10:52500089	ASAH2B	0.64	6.65	0.51	8.42e-10	Inflammatory bowel disease;
TGCT	cis	rs3784262	0.669	rs4646595	chr15:58302341	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.42	-6.17	-0.48	8.83e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.64	0.38	8.63e-6	Prudent dietary pattern;
TGCT	cis	rs11731606	0.508	rs7677981	chr4:95299736	C/T	cg00507259	chr4:95128692	SMARCAD1	0.63	4.72	0.39	6.14e-6	Mean platelet volume;
TGCT	cis	rs7267979	1.000	rs6050573	chr20:25366065	C/G	cg03522245	chr20:25566470	NINL	0.61	6.52	0.51	1.62e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs911263	0.603	rs61985136	chr14:68769199	C/T	cg18825221	chr14:68749962	RAD51L1	0.22	4.44	0.37	1.97e-5	Primary biliary cholangitis;
TGCT	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg27286337	chr10:134555280	INPP5A	0.4	4.91	0.4	2.76e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs3087591	1.000	rs2854331	chr17:29711728	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.46	-6.97	-0.53	1.65e-10	Hip circumference;
TGCT	cis	rs6912958	0.559	rs1201409	chr6:88055264	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.69	7.07	0.54	1.02e-10	Monocyte percentage of white cells;
TGCT	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg11764359	chr7:65958608	NA	-0.57	-5.12	-0.42	1.12e-6	Aortic root size;
TGCT	cis	rs245880	0.740	rs245886	chr7:29189336	G/T	cg17163760	chr7:29186267	CPVL	-0.44	-5.54	-0.45	1.73e-7	Warfarin maintenance dose;
TGCT	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg24829409	chr8:58192753	C8orf71	-0.59	-5.18	-0.42	8.54e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg10862848	chr6:42927986	GNMT	-0.39	-4.72	-0.39	6.22e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs681343	0.746	rs633372	chr19:49209226	G/A	cg00822241	chr19:49201468	FUT2	0.28	4.53	0.38	1.36e-5	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
TGCT	cis	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg20637647	chr7:64974828	NA	0.92	5.09	0.42	1.26e-6	Diabetic kidney disease;
TGCT	cis	rs13102973	0.611	rs4298187	chr4:135886186	G/A	cg14419869	chr4:135874104	NA	0.26	4.6	0.38	1.03e-5	Subjective well-being;
TGCT	cis	rs4654899	0.865	rs7541923	chr1:21403582	G/C	cg01072550	chr1:21505969	NA	-0.46	-6.77	-0.52	4.55e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs4786125	0.555	rs7196838	chr16:6920457	A/G	cg03623568	chr16:6915990	A2BP1	-0.45	-6.68	-0.51	7.28e-10	Heart rate variability traits (SDNN);
TGCT	cis	rs6570726	0.935	rs391820	chr6:145821284	C/T	cg23711669	chr6:146136114	FBXO30	0.69	6.22	0.49	6.89e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs5769707	0.839	rs73176988	chr22:49989649	G/T	cg10356904	chr22:49881777	NA	-0.23	-4.68	-0.39	7.54e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs877282	1.000	rs71494928	chr10:769134	A/G	cg17470449	chr10:769945	NA	0.35	5.21	0.42	7.51e-7	Uric acid levels;
TGCT	cis	rs858239	0.899	rs5850	chr7:23314547	C/T	cg05602783	chr7:23145260	KLHL7	-0.7	-5.55	-0.45	1.63e-7	Cerebrospinal fluid biomarker levels;
TGCT	trans	rs11722228	0.508	rs9732	chr4:10076658	T/C	cg26043149	chr18:55253948	FECH	1.13	11.36	0.71	6.22e-21	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs35306767	0.903	rs4522091	chr10:874116	G/T	cg26597838	chr10:835615	NA	0.71	10.12	0.67	6.47e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs56036086	1.000	rs73187245	chr22:50625449	C/T	cg01548456	chr22:50352384	NA	0.36	5.17	0.42	9.29e-7	Platelet count;Plateletcrit;
TGCT	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg13699009	chr12:122356056	WDR66	0.32	7.33	0.55	2.6e-11	Mean corpuscular volume;
TGCT	cis	rs6546537	0.571	rs4852274	chr2:69780637	G/A	cg10773587	chr2:69614142	GFPT1	-0.76	-6.86	-0.52	2.87e-10	Serum thyroid-stimulating hormone levels;
TGCT	cis	rs459571	0.916	rs109536	chr9:136889987	G/C	cg14405625	chr9:136855902	VAV2	-0.3	-4.48	-0.37	1.67e-5	Platelet distribution width;
TGCT	cis	rs12989701	1.000	rs6710467	chr2:127889932	C/T	cg02161262	chr2:127865248	BIN1	0.68	4.51	0.38	1.5e-5	Alzheimer's disease (late onset);
TGCT	cis	rs12048904	1.000	rs12048904	chr1:101331536	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.47	-4.45	-0.37	1.91e-5	Multiple sclerosis;
TGCT	cis	rs12477438	0.508	rs2516832	chr2:99771268	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	17.43	0.84	3.73e-35	Chronic sinus infection;
TGCT	cis	rs12142240	0.698	rs67200518	chr1:46835777	T/C	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs3947	0.951	rs1736086	chr8:11704897	C/T	cg02840367	chr8:11660030	FDFT1	0.91	6.83	0.52	3.37e-10	Blood protein levels;
TGCT	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.59	5.97	0.47	2.31e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7208859	0.623	rs11651858	chr17:29170718	A/G	cg14008862	chr17:28927542	LRRC37B2	0.72	4.66	0.39	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs11711311	0.955	rs34048496	chr3:113414121	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.77	-6.83	-0.52	3.42e-10	IgG glycosylation;
TGCT	cis	rs12188164	0.930	rs11743825	chr5:475463	C/T	cg22025206	chr5:502436	SLC9A3	-0.25	-4.44	-0.37	1.97e-5	Cystic fibrosis severity;
TGCT	cis	rs11690935	0.851	rs10201430	chr2:172813241	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.81	-7.08	-0.54	9.26e-11	Schizophrenia;
TGCT	cis	rs1887596	0.705	rs533287	chr13:27197419	G/A	cg01312412	chr13:27282625	NA	0.3	5.38	0.44	3.56e-7	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.69	-6.94	-0.53	1.94e-10	Prostate cancer;
TGCT	cis	rs6815814	0.678	rs9715841	chr4:38774503	T/C	cg02016764	chr4:38805732	TLR1	-0.28	-4.79	-0.4	4.63e-6	Breast cancer;
TGCT	cis	rs17539620	0.534	rs76931320	chr6:154833508	G/A	cg20019720	chr6:154832845	CNKSR3	0.57	4.77	0.39	5.03e-6	Lipoprotein (a) levels;
TGCT	cis	rs73198271	0.960	rs73198287	chr8:8612786	C/T	ch.8.214553F	chr8:8189620	PRAGMIN	-0.27	-4.65	-0.39	8.24e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs9913156	0.639	rs72824971	chr17:4604270	A/G	cg23387401	chr17:4582204	PELP1	0.31	4.61	0.38	9.84e-6	Lymphocyte counts;
TGCT	cis	rs9486715	0.867	rs9384602	chr6:96919561	G/A	cg06623918	chr6:96969491	KIAA0776	1.1	15.31	0.81	2.34e-30	Headache;
TGCT	trans	rs1814175	0.754	rs28593359	chr11:50042357	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.26	-0.55	3.77e-11	Height;
TGCT	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg08280861	chr8:58055591	NA	0.36	4.91	0.4	2.77e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2439831	0.850	rs12442297	chr15:44168470	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.74	4.66	0.39	7.89e-6	Lung cancer in ever smokers;
TGCT	cis	rs9467773	0.620	rs2504565	chr6:26656890	G/A	cg11502198	chr6:26597334	ABT1	0.55	4.88	0.4	3.2e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg16325326	chr1:53192061	ZYG11B	0.59	7.1	0.54	8.48e-11	Monocyte count;
TGCT	trans	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.83	-8.69	-0.62	1.76e-14	Body mass index;
TGCT	cis	rs2486288	0.656	rs10519018	chr15:45549265	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.46	-5.59	-0.45	1.39e-7	Glomerular filtration rate;
TGCT	cis	rs1903068	0.657	rs2239702	chr4:55992139	C/T	cg01777861	chr4:56023843	NA	0.51	5.49	0.44	2.13e-7	Endometriosis;
TGCT	cis	rs12421382	0.881	rs1808843	chr11:109389471	A/G	cg16359550	chr11:109292809	C11orf87	0.53	5.87	0.47	3.69e-8	Schizophrenia;
TGCT	cis	rs763014	0.865	rs2018789	chr16:632051	T/C	cg09263875	chr16:632152	PIGQ	0.3	6.4	0.5	2.88e-9	Height;
TGCT	cis	rs67311347	1.000	rs9848083	chr3:40466979	A/G	cg13683864	chr3:40499215	RPL14	1.04	10.79	0.7	1.54e-19	Renal cell carcinoma;
TGCT	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9894429	0.690	rs11869779	chr17:79570067	C/T	cg21984481	chr17:79567631	NPLOC4	0.26	4.9	0.4	2.91e-6	Eye color traits;
TGCT	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg01802117	chr1:53393560	SCP2	-0.41	-4.8	-0.4	4.39e-6	Monocyte count;
TGCT	cis	rs1371867	0.875	rs1371868	chr8:101330267	C/T	cg06002616	chr8:101225028	SPAG1	-0.56	-6.58	-0.51	1.2e-9	Atrioventricular conduction;
TGCT	cis	rs2458413	0.935	rs2514667	chr8:105358590	C/T	cg23108931	chr8:105342351	NA	0.4	7.02	0.53	1.27e-10	Paget's disease;
TGCT	cis	rs8077889	1.000	rs17742905	chr17:41891143	C/A	cg26893861	chr17:41843967	DUSP3	1.07	12.6	0.75	5.99e-24	Triglycerides;
TGCT	cis	rs707040	1.000	rs6726767	chr2:155237339	A/T	cg18104148	chr2:154337490	NA	0.19	4.56	0.38	1.2e-5	Sudden cardiac arrest;
TGCT	cis	rs7666738	0.753	rs11097594	chr4:98944486	A/G	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7584330	0.737	rs7584314	chr2:238361089	C/T	cg14458575	chr2:238380390	NA	0.51	8.09	0.59	4.69e-13	Prostate cancer;
TGCT	cis	rs6570726	0.791	rs12208019	chr6:145935572	T/C	cg13319975	chr6:146136371	FBXO30	-0.53	-4.75	-0.39	5.62e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg11644478	chr21:40555479	PSMG1	-0.55	-5.17	-0.42	9.24e-7	Menarche (age at onset);
TGCT	cis	rs367943	1.000	rs348957	chr5:112821178	C/T	cg12552261	chr5:112820674	MCC	0.24	4.91	0.4	2.81e-6	Type 2 diabetes;
TGCT	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg04608855	chr19:58913158	NA	0.57	5.7	0.46	8.44e-8	Uric acid clearance;
TGCT	cis	rs2235642	0.893	rs8051295	chr16:1588087	A/G	cg07639376	chr16:1584516	IFT140;TMEM204	-0.32	-5.56	-0.45	1.61e-7	Coronary artery disease;
TGCT	cis	rs12762955	0.561	rs7918118	chr10:1042823	C/A	cg26597838	chr10:835615	NA	-0.46	-6.1	-0.48	1.23e-8	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs17266357	0.625	rs75088535	chr4:102725320	A/C	cg14855874	chr4:102712397	BANK1	0.41	4.86	0.4	3.47e-6	Blood protein levels;
TGCT	cis	rs6671200	1.000	rs35143903	chr1:95622527	C/T	cg03123541	chr1:95699097	RWDD3	0.85	5.93	0.47	2.86e-8	Stearic acid (18:0) levels;
TGCT	cis	rs2153535	0.601	rs4140584	chr6:8540614	C/G	cg23788917	chr6:8435910	SLC35B3	-0.62	-5.57	-0.45	1.49e-7	Motion sickness;
TGCT	cis	rs17270561	0.541	rs12192932	chr6:25911502	A/G	cg16482183	chr6:26056742	HIST1H1C	0.94	7.33	0.55	2.58e-11	Iron status biomarkers;
TGCT	cis	rs950169	0.509	rs71395455	chr15:85153804	A/G	cg12863693	chr15:85201151	NMB	0.41	4.88	0.4	3.26e-6	Schizophrenia;
TGCT	cis	rs904251	0.772	rs10692	chr6:37450914	T/C	cg08126542	chr6:37504118	NA	-0.39	-4.58	-0.38	1.1e-5	Cognitive performance;
TGCT	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg27121462	chr16:89883253	FANCA	0.81	9.17	0.64	1.26e-15	Vitiligo;
TGCT	cis	rs6714710	0.603	rs35505530	chr2:98506910	T/C	cg26665480	chr2:98280029	ACTR1B	0.64	6.03	0.48	1.71e-8	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs2956278	0.717	rs7136513	chr12:84674445	T/C	cg25678815	chr12:85673915	ALX1	-0.54	-4.83	-0.4	3.96e-6	Depressive symptoms;Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg03517284	chr6:25882590	NA	0.78	8.11	0.59	4.26e-13	Blood metabolite levels;
TGCT	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg05665937	chr4:1216051	CTBP1	0.23	4.48	0.37	1.69e-5	Obesity-related traits;
TGCT	cis	rs9916302	0.706	rs9908131	chr17:37520449	T/C	cg07936489	chr17:37558343	FBXL20	0.87	6.27	0.49	5.47e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs6933660	0.745	rs6557138	chr6:151732017	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.65	6.34	0.49	3.82e-9	Menarche (age at onset);
TGCT	cis	rs7572733	0.534	rs11890137	chr2:198816662	G/A	cg00792783	chr2:198669748	PLCL1	0.57	5.23	0.43	6.99e-7	Dermatomyositis;
TGCT	cis	rs7727544	0.716	rs7701414	chr5:131585958	A/G	cg24060327	chr5:131705240	SLC22A5	-0.56	-5.45	-0.44	2.58e-7	Blood metabolite levels;
TGCT	cis	rs5769765	0.955	rs1321	chr22:50297435	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.11	-12.1	-0.74	9.56e-23	Schizophrenia;
TGCT	cis	rs7975161	0.506	rs7953434	chr12:104622101	T/G	cg25273343	chr12:104657179	TXNRD1	-0.42	-5.8	-0.46	5.29e-8	Toenail selenium levels;
TGCT	cis	rs447921	0.736	rs28715905	chr17:74448063	A/C	cg09812376	chr17:74270190	QRICH2	0.45	4.76	0.39	5.3e-6	Mitochondrial DNA levels;
TGCT	cis	rs9341808	0.754	rs10806185	chr6:80954511	G/A	cg08355045	chr6:80787529	NA	0.29	5.1	0.42	1.23e-6	Sitting height ratio;
TGCT	cis	rs36051895	0.664	rs12340866	chr9:5094185	G/A	cg02405213	chr9:5042618	JAK2	-0.72	-9.52	-0.65	1.85e-16	Pediatric autoimmune diseases;
TGCT	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg08280861	chr8:58055591	NA	0.39	4.86	0.4	3.45e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4746818	1.000	rs7893492	chr10:70960448	C/T	cg11621586	chr10:70884670	VPS26A	-1.1	-7.75	-0.57	2.8e-12	Left atrial antero-posterior diameter;
TGCT	cis	rs7208859	0.673	rs73263785	chr17:29214808	C/T	cg14008862	chr17:28927542	LRRC37B2	0.72	4.66	0.39	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs3796352	1.000	rs71299622	chr3:52917038	G/A	cg15956490	chr3:53032818	SFMBT1	0.56	4.94	0.41	2.52e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs739496	0.843	rs625093	chr12:111988432	A/G	cg10833066	chr12:111807467	FAM109A	0.37	4.96	0.41	2.31e-6	Platelet count;
TGCT	cis	rs896322	0.843	rs1172155	chr1:205220241	T/C	cg03975844	chr1:205318888	KLHDC8A	-0.24	-4.5	-0.37	1.52e-5	Mean platelet volume;
TGCT	cis	rs6582630	0.555	rs1906260	chr12:38601013	T/G	cg13010199	chr12:38710504	ALG10B	0.65	5.15	0.42	9.92e-7	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs12220238	0.722	rs10509350	chr10:76383071	A/C	cg19889307	chr10:75911429	ADK;AP3M1	-0.64	-5.11	-0.42	1.17e-6	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs7043114	0.525	rs1133908	chr9:95068046	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-5.57	-0.45	1.53e-7	Height;
TGCT	cis	rs7178572	1.000	rs7178572	chr15:77747190	A/G	cg22256960	chr15:77711686	NA	-0.95	-10.89	-0.7	8.57e-20	Type 2 diabetes;
TGCT	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg06221963	chr1:154839813	KCNN3	-0.76	-13.06	-0.76	4.81e-25	Prostate cancer;
TGCT	cis	rs9985766	0.958	rs10031412	chr4:151005755	G/A	cg05926478	chr4:151174724	DCLK2	-0.24	-4.72	-0.39	6.32e-6	Coronary artery disease;Myocardial infarction;
TGCT	cis	rs7100689	0.577	rs10749550	chr10:82031197	A/G	cg01528321	chr10:82214614	TSPAN14	0.69	6.61	0.51	1.02e-9	Post bronchodilator FEV1;
TGCT	cis	rs9549367	0.737	rs11619691	chr13:113904636	T/C	cg00898013	chr13:113819073	PROZ	-0.4	-5.03	-0.41	1.64e-6	Platelet distribution width;
TGCT	cis	rs7605378	1.000	rs2346662	chr2:200679158	C/T	cg23649088	chr2:200775458	C2orf69	0.32	5.6	0.45	1.31e-7	Osteoporosis;
TGCT	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg06481639	chr22:41940642	POLR3H	-0.71	-6.02	-0.48	1.79e-8	Vitiligo;
TGCT	cis	rs6088580	0.634	rs6119497	chr20:33012529	T/A	cg24642439	chr20:33292090	TP53INP2	0.49	4.5	0.37	1.55e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs950169	0.922	rs4842939	chr15:84827966	C/T	cg17173187	chr15:85201210	NMB	-0.51	-5.34	-0.43	4.26e-7	Schizophrenia;
TGCT	cis	rs76419734	0.614	rs17035951	chr4:106527613	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.81	4.63	0.38	9.19e-6	Post bronchodilator FEV1;
TGCT	cis	rs62064224	0.553	rs9896320	chr17:30689814	G/A	cg18200150	chr17:30822561	MYO1D	0.41	4.91	0.4	2.81e-6	Schizophrenia;
TGCT	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg06221963	chr1:154839813	KCNN3	-0.76	-12.68	-0.75	3.85e-24	Prostate cancer;
TGCT	cis	rs1997103	1.000	rs2140915	chr7:55410699	G/C	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs4319547	0.661	rs10846830	chr12:122897220	C/G	cg08088222	chr12:122070432	ORAI1	0.25	4.43	0.37	2.01e-5	Body mass index;
TGCT	cis	rs9534288	0.913	rs9534299	chr13:46625586	A/T	cg15192986	chr13:46630673	CPB2	-0.49	-6.18	-0.49	8.64e-9	Blood protein levels;
TGCT	cis	rs6460942	1.000	rs73053531	chr7:12317474	T/C	cg06484146	chr7:12443880	VWDE	-0.55	-4.56	-0.38	1.22e-5	Coronary artery disease;
TGCT	cis	rs807669	0.777	rs9605972	chr22:19253274	C/T	cg02655711	chr22:19163373	SLC25A1	0.34	7.65	0.57	4.96e-12	Metabolite levels;
TGCT	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg08859206	chr1:53392774	SCP2	0.35	5.04	0.41	1.62e-6	Monocyte count;
TGCT	cis	rs6840360	1.000	rs1366909	chr4:152588421	A/C	cg17479576	chr4:152424074	FAM160A1	-0.46	-4.9	-0.4	2.95e-6	Intelligence (multi-trait analysis);
TGCT	trans	rs2727020	0.513	rs10839307	chr11:49609843	A/C	cg03929089	chr4:120376271	NA	-0.74	-9.0	-0.63	3.22e-15	Coronary artery disease;
TGCT	cis	rs1799949	0.929	rs4792988	chr17:41437547	T/C	cg23758822	chr17:41437982	NA	0.68	6.37	0.5	3.42e-9	Menopause (age at onset);
TGCT	cis	rs9814567	0.963	rs36006513	chr3:134291913	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.95	8.76	0.62	1.21e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs3087591	1.000	rs7406983	chr17:29703374	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.48	-7.52	-0.56	9.58e-12	Hip circumference;
TGCT	cis	rs854765	0.647	rs7212447	chr17:17987067	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.68	7.01	0.53	1.33e-10	Total body bone mineral density;
TGCT	trans	rs1973993	0.544	rs2800427	chr1:97002766	A/C	cg10631902	chr5:14652156	NA	0.37	9.46	0.65	2.54e-16	Weight;
TGCT	cis	rs3733585	0.638	rs28715627	chr4:9958140	T/A	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.7	-0.57	3.71e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.2	0.42	8.14e-7	Menopause (age at onset);
TGCT	cis	rs1334894	1.000	rs72913423	chr6:35575707	A/G	cg24281267	chr6:35479648	TULP1	-0.43	-4.5	-0.37	1.56e-5	Coronary artery disease;
TGCT	cis	rs6088580	0.634	rs6059867	chr20:33078103	C/T	cg08999081	chr20:33150536	PIGU	0.29	5.95	0.47	2.56e-8	Glomerular filtration rate (creatinine);
TGCT	cis	rs10464366	0.544	rs9639812	chr7:39192058	C/T	cg18850127	chr7:39170497	POU6F2	0.32	6.96	0.53	1.78e-10	IgG glycosylation;
TGCT	cis	rs9467773	1.000	rs6933176	chr6:26540178	G/A	cg26531700	chr6:26746687	NA	0.47	4.57	0.38	1.14e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs9653442	0.593	rs2309811	chr2:100862359	A/G	cg07810366	chr2:100720526	AFF3	-0.4	-6.33	-0.49	4.07e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	trans	rs877282	1.000	rs11253361	chr10:770387	T/C	cg22713356	chr15:30763199	NA	1.26	10.48	0.69	8.73e-19	Uric acid levels;
TGCT	cis	rs10927875	0.722	rs1763605	chr1:16338925	T/G	cg21385522	chr1:16154831	NA	0.6	6.38	0.5	3.14e-9	Dilated cardiomyopathy;
TGCT	cis	rs344364	0.511	rs1742473	chr16:1953095	T/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.46	-5.31	-0.43	4.97e-7	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs9517313	0.592	rs11069311	chr13:99202101	G/T	cg07423050	chr13:99094983	FARP1	-0.27	-5.42	-0.44	2.92e-7	Neuroticism;
TGCT	trans	rs12339966	0.653	rs4237128	chr9:11289842	C/T	cg07173112	chr1:1114698	TTLL10	-0.34	-6.88	-0.53	2.65e-10	Systolic blood pressure;
TGCT	cis	rs3733585	0.638	rs28715627	chr4:9958140	T/A	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.68	-0.51	7.16e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs9467711	0.932	rs11966360	chr6:26316982	A/G	cg02458000	chr6:26745757	NA	-0.92	-5.21	-0.42	7.52e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2535633	0.631	rs2465101	chr3:52991307	A/T	cg05573699	chr3:52720067	GNL3;PBRM1	0.57	5.41	0.44	3.06e-7	Body mass index;
TGCT	cis	rs7565124	0.909	rs6747472	chr2:20252007	C/T	cg00462460	chr2:20212509	MATN3	-0.44	-4.66	-0.39	8.07e-6	Major depressive disorder;
TGCT	cis	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg08564027	chr20:61660810	NA	0.38	7.08	0.54	9.36e-11	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg18867708	chr6:26865862	GUSBL1	-0.38	-5.03	-0.41	1.65e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1729951	0.546	rs835634	chr3:136676303	C/T	cg21827317	chr3:136751795	NA	0.4	5.61	0.45	1.28e-7	Neuroticism;
TGCT	cis	rs7980687	0.657	rs2851447	chr12:123665113	G/C	cg00376283	chr12:123451042	ABCB9	0.78	6.64	0.51	8.94e-10	Height;Educational attainment;Head circumference (infant);
TGCT	cis	rs2832191	0.720	rs7277028	chr21:30494604	T/C	cg08807101	chr21:30365312	RNF160	-0.62	-5.74	-0.46	6.74e-8	Dental caries;
TGCT	cis	rs6088590	0.931	rs12625149	chr20:33425812	A/C	cg06115741	chr20:33292138	TP53INP2	-0.64	-5.17	-0.42	9.29e-7	Coronary artery disease;
TGCT	cis	rs1008375	0.932	rs4235390	chr4:17696378	G/T	cg18681998	chr4:17616180	MED28	0.78	7.35	0.55	2.35e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.49	-6.64	-0.51	8.8e-10	Alzheimer's disease;
TGCT	cis	rs7659604	0.521	rs4833234	chr4:122694799	T/C	cg19748678	chr4:122722346	EXOSC9	-0.57	-5.67	-0.45	9.35e-8	Type 2 diabetes;
TGCT	cis	rs6831352	0.918	rs17218108	chr4:100055755	T/C	cg12011299	chr4:100065546	ADH4	-0.4	-4.88	-0.4	3.26e-6	Alcohol dependence;
TGCT	cis	rs11690935	0.571	rs1008151	chr2:172912098	G/A	cg13550731	chr2:172543902	DYNC1I2	0.64	5.83	0.46	4.45e-8	Schizophrenia;
TGCT	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.43	6.25	0.49	6.02e-9	Schizophrenia;
TGCT	cis	rs7267979	1.000	rs6076339	chr20:25348712	T/C	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg23302884	chr18:44338147	ST8SIA5	0.4	4.79	0.4	4.67e-6	Personality dimensions;
TGCT	cis	rs1577917	0.687	rs1470531	chr6:86507369	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-5.53	-0.44	1.82e-7	Response to antipsychotic treatment;
TGCT	cis	rs8062405	0.824	rs62034326	chr16:28539293	A/G	cg09754948	chr16:28834200	ATXN2L	0.58	4.57	0.38	1.14e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs11098499	0.954	rs3733519	chr4:120423448	A/G	cg09307838	chr4:120376055	NA	0.67	6.3	0.49	4.63e-9	Corneal astigmatism;
TGCT	cis	rs2204008	0.702	rs8175764	chr12:38363690	T/C	cg26384229	chr12:38710491	ALG10B	0.83	7.23	0.54	4.44e-11	Bladder cancer;
TGCT	cis	rs6967414	0.605	rs7786706	chr7:6747267	C/T	cg09896999	chr7:6746977	ZNF12	-0.43	-5.28	-0.43	5.51e-7	Hematocrit;Hemoglobin concentration;
TGCT	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	8.0	0.58	7.67e-13	Platelet count;
TGCT	cis	rs290268	0.838	rs290989	chr9:93561836	T/C	cg02608019	chr9:93564028	SYK	0.44	4.44	0.37	1.94e-5	Platelet count;
TGCT	cis	rs885389	0.920	rs1880842	chr12:131621997	A/G	cg07124762	chr12:131619285	GPR133	-0.29	-5.21	-0.42	7.65e-7	RR interval (heart rate);
TGCT	cis	rs7267979	0.714	rs6115107	chr20:25237390	A/G	cg03522245	chr20:25566470	NINL	0.48	4.59	0.38	1.06e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3617	0.539	rs9825369	chr3:52953311	T/C	cg11645453	chr3:52864694	ITIH4	-0.27	-5.39	-0.44	3.38e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7772486	0.754	rs4896838	chr6:146015451	T/C	cg23711669	chr6:146136114	FBXO30	-0.93	-10.83	-0.7	1.24e-19	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg03806693	chr22:41940476	POLR3H	-1.13	-13.26	-0.77	1.59e-25	Vitiligo;
TGCT	cis	rs7223966	1.000	rs17549954	chr17:61707032	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	4.76	0.39	5.39e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg22442454	chr1:209979470	IRF6	0.62	4.53	0.38	1.35e-5	Cleft lip with or without cleft palate;
TGCT	cis	rs4285028	0.948	rs2332033	chr3:121699548	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.77	-6.5	-0.5	1.78e-9	Multiple sclerosis;
TGCT	cis	rs9517320	0.515	rs9556972	chr13:99209815	C/T	cg07423050	chr13:99094983	FARP1	-0.22	-4.46	-0.37	1.79e-5	Longevity;
TGCT	cis	rs7940866	0.838	rs1991898	chr11:130801786	C/G	cg12179176	chr11:130786555	SNX19	-0.64	-6.42	-0.5	2.66e-9	Schizophrenia;
TGCT	cis	rs7226408	0.857	rs72887024	chr18:34468482	G/T	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs926938	0.527	rs360666	chr1:115481290	C/T	cg12756093	chr1:115239321	AMPD1	0.34	4.97	0.41	2.19e-6	Autism;
TGCT	cis	rs1497406	0.590	rs3818162	chr1:16528600	G/A	cg20430773	chr1:16534157	ARHGEF19	0.49	5.61	0.45	1.25e-7	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg11494091	chr17:61959527	GH2	-0.58	-14.95	-0.8	1.58e-29	Prudent dietary pattern;
TGCT	cis	rs3796352	1.000	rs71301809	chr3:53090312	C/T	cg07884673	chr3:53033167	SFMBT1	0.61	6.25	0.49	6e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs12142240	0.667	rs55887761	chr1:46826587	C/A	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs8083786	1	rs8083786	chr18:12881361	A/G	cg23598886	chr18:12777645	NA	-0.55	-4.86	-0.4	3.43e-6	Rheumatoid arthritis;
TGCT	cis	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg07424592	chr7:64974309	NA	1.4	8.42	0.6	7.87e-14	Diabetic kidney disease;
TGCT	cis	rs2276314	0.947	rs4799831	chr18:33554775	A/G	cg05985134	chr18:33552581	C18orf21	0.54	4.82	0.4	4.12e-6	Endometriosis;Drug-induced torsades de pointes;
TGCT	cis	rs10875746	0.859	rs12305511	chr12:48582716	C/T	cg20731937	chr12:48336164	NA	-0.59	-4.72	-0.39	6.13e-6	Longevity (90 years and older);
TGCT	cis	rs11105298	0.891	rs10858902	chr12:89927789	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.7	-5.12	-0.42	1.12e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg03709012	chr19:19516395	GATAD2A	0.67	5.75	0.46	6.45e-8	Tonsillectomy;
TGCT	cis	rs2721195	0.626	rs59464125	chr8:145857786	G/A	cg12270520	chr8:146023939	ZNF517	-0.6	-5.25	-0.43	6.29e-7	Age at first birth;
TGCT	cis	rs854765	0.562	rs2955381	chr17:17945500	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.79	-8.27	-0.6	1.76e-13	Total body bone mineral density;
TGCT	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg12310025	chr6:25882481	NA	0.54	5.46	0.44	2.44e-7	Blood metabolite levels;
TGCT	cis	rs4919044	0.674	rs11187260	chr10:94809187	A/G	cg05127821	chr10:94822908	CYP26C1	-0.74	-4.83	-0.4	3.95e-6	Coronary artery disease;
TGCT	cis	rs13188771	0.690	rs10040426	chr5:100896781	T/C	cg18665594	chr5:101119420	NA	0.44	4.47	0.37	1.74e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs42648	0.935	rs7803012	chr7:90026166	A/T	cg25739043	chr7:89950458	NA	0.65	6.24	0.49	6.29e-9	Homocysteine levels;
TGCT	cis	rs7267979	0.789	rs6083810	chr20:25329759	T/A	cg21995068	chr20:25989032	LOC100134868	0.43	5.19	0.42	8.41e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4805272	0.626	rs6509072	chr19:29331703	C/G	cg04546413	chr19:29218101	NA	0.56	4.47	0.37	1.73e-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
TGCT	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg05025164	chr4:1340916	KIAA1530	-0.65	-5.45	-0.44	2.63e-7	Longevity;
TGCT	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	5.23	0.43	6.92e-7	Menopause (age at onset);
TGCT	cis	rs4961252	0.505	rs4961327	chr8:142102053	C/T	cg09914555	chr8:142094789	NA	-0.4	-6.0	-0.47	1.99e-8	Isovolumetric relaxation time;Response to interferon beta therapy;
TGCT	cis	rs807669	0.548	rs5748028	chr22:19172281	G/A	cg02655711	chr22:19163373	SLC25A1	0.33	6.89	0.53	2.54e-10	Metabolite levels;
TGCT	cis	rs7267979	0.789	rs1983974	chr20:25530619	A/C	cg14121845	chr20:25566513	NINL	-0.45	-4.69	-0.39	7.14e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4237845	0.804	rs10877034	chr12:58286444	T/C	cg02175503	chr12:58329896	NA	0.49	5.01	0.41	1.85e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6121246	0.512	rs6060941	chr20:30367383	C/T	cg13852791	chr20:30311386	BCL2L1	0.82	8.0	0.58	7.65e-13	Mean corpuscular hemoglobin;
TGCT	cis	rs6429082	0.818	rs704714	chr1:235632094	T/C	cg26050004	chr1:235667680	B3GALNT2	0.59	5.26	0.43	6.02e-7	Adiposity;
TGCT	cis	rs7726839	0.540	rs3749615	chr5:601485	C/T	cg09021430	chr5:549028	NA	-0.39	-5.32	-0.43	4.78e-7	Obesity-related traits;
TGCT	cis	rs6087771	0.642	rs6060403	chr20:30221104	C/A	cg10886678	chr20:30946050	ASXL1	-0.57	-4.5	-0.37	1.55e-5	Subcortical brain region volumes;Putamen volume;
TGCT	cis	rs3947	0.789	rs8005	chr8:11701096	A/C	cg02840367	chr8:11660030	FDFT1	-1.03	-8.54	-0.61	3.97e-14	Blood protein levels;
TGCT	cis	rs7772486	0.875	rs9390371	chr6:146363180	A/G	cg23711669	chr6:146136114	FBXO30	0.85	9.44	0.65	2.92e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2479724	0.905	rs2274578	chr6:41888827	C/G	cg08135965	chr6:41755394	TOMM6	0.48	4.65	0.39	8.44e-6	Menarche (age at onset);
TGCT	cis	rs28595532	0.920	rs10018977	chr4:119785229	C/T	cg14228332	chr4:119757509	SEC24D	1.19	6.66	0.51	8.07e-10	Cannabis dependence symptom count;
TGCT	cis	rs782590	0.818	rs2627765	chr2:55883317	G/T	cg18811423	chr2:55921094	PNPT1	0.61	5.83	0.46	4.58e-8	Metabolic syndrome;
TGCT	cis	rs9902453	0.817	rs17226179	chr17:28168573	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	6.89	0.53	2.51e-10	Coffee consumption (cups per day);
TGCT	cis	rs4803468	1.000	rs10422783	chr19:41906436	T/C	cg09537434	chr19:41945824	ATP5SL	-0.89	-10.02	-0.67	1.14e-17	Height;
TGCT	cis	rs9467711	0.659	rs36162392	chr6:26569135	T/C	cg16898833	chr6:26189333	HIST1H4D	1.26	5.87	0.47	3.76e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1577917	0.958	rs12215232	chr6:86785430	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-5.0	-0.41	1.95e-6	Response to antipsychotic treatment;
TGCT	cis	rs9677476	0.516	rs10199752	chr2:231969554	A/C	cg07929768	chr2:232055508	NA	0.33	5.24	0.43	6.78e-7	Food antigen IgG levels;
TGCT	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg21724239	chr8:58056113	NA	0.39	4.91	0.4	2.81e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2067615	0.524	rs4964483	chr12:107099057	T/C	cg15890332	chr12:107067104	RFX4	0.29	5.77	0.46	5.9e-8	Heart rate;
TGCT	cis	rs9443645	0.869	rs1507154	chr6:79503700	C/T	cg09184832	chr6:79620586	NA	-0.45	-4.78	-0.39	4.96e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7833790	0.660	rs7839178	chr8:82763479	A/G	cg17211192	chr8:82754475	SNX16	0.97	9.09	0.63	2.04e-15	Diastolic blood pressure;
TGCT	cis	rs2013441	1.000	rs2526472	chr17:20137888	G/A	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.63	-0.38	9.19e-6	Obesity-related traits;
TGCT	cis	rs595982	0.527	rs56021835	chr19:49369989	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.69	-9.25	-0.64	8.09e-16	Red cell distribution width;
TGCT	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.6	-4.99	-0.41	1.97e-6	Lung function (FEV1/FVC);
TGCT	cis	rs2070433	0.556	rs8129460	chr21:47822544	C/T	cg12379764	chr21:47803548	PCNT	0.55	4.77	0.39	5.07e-6	Lymphocyte counts;
TGCT	cis	rs854765	0.647	rs854818	chr17:18022039	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	7.51	0.56	1.01e-11	Total body bone mineral density;
TGCT	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg03188948	chr7:1209495	NA	0.68	5.8	0.46	5.09e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs427394	0.802	rs274720	chr5:6719933	A/G	cg10857441	chr5:6722123	POLS	-0.32	-7.8	-0.57	2.17e-12	Menopause (age at onset);
TGCT	cis	rs7089973	0.604	rs11196952	chr10:116607592	G/A	cg03647239	chr10:116582469	FAM160B1	0.59	5.74	0.46	6.72e-8	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs9899728	0.539	rs56267297	chr17:73046996	T/C	cg27626185	chr17:73056755	KCTD2	-0.91	-8.01	-0.58	7.02e-13	Alzheimer's disease or small vessel stroke;
TGCT	cis	rs2997447	0.846	rs72886619	chr1:26452604	G/A	cg03844060	chr1:26490628	NA	0.27	4.44	0.37	1.99e-5	QRS complex (12-leadsum);
TGCT	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg02725872	chr8:58115012	NA	-0.38	-5.16	-0.42	9.32e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs4820539	0.933	rs2267004	chr22:23459863	G/A	cg14186256	chr22:23484241	RTDR1	0.99	11.73	0.73	7.92e-22	Bone mineral density;
TGCT	trans	rs6089829	0.888	rs4809268	chr20:61675249	C/G	cg23505145	chr19:12996616	KLF1	0.96	9.99	0.67	1.36e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9611565	0.512	rs5751145	chr22:42133552	C/T	cg06634786	chr22:41940651	POLR3H	0.87	8.12	0.59	3.86e-13	Vitiligo;
TGCT	cis	rs950169	0.922	rs6603022	chr15:84830170	T/C	cg17173187	chr15:85201210	NMB	-0.54	-5.52	-0.44	1.94e-7	Schizophrenia;
TGCT	cis	rs9549367	0.789	rs9549699	chr13:113878263	T/A	cg00898013	chr13:113819073	PROZ	-0.39	-4.78	-0.39	4.78e-6	Platelet distribution width;
TGCT	cis	rs950880	0.560	rs10191914	chr2:102930657	T/C	cg09003973	chr2:102972529	NA	-0.51	-4.49	-0.37	1.59e-5	Serum protein levels (sST2);
TGCT	cis	rs7822232	0.908	rs7821112	chr8:145147169	G/A	cg06495924	chr8:145149574	CYC1	1.04	4.49	0.37	1.6e-5	Blood metabolite levels;
TGCT	cis	rs2842992	0.915	rs2842980	chr6:160100116	A/T	cg11366901	chr6:160182831	ACAT2	0.83	5.33	0.43	4.48e-7	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs4332037	0.539	rs34809719	chr7:2028968	G/T	cg25834613	chr7:1915315	MAD1L1	-0.47	-4.51	-0.38	1.48e-5	Bipolar disorder;
TGCT	cis	rs8072100	0.581	rs4267364	chr17:45781264	A/G	cg08085267	chr17:45401833	C17orf57	-0.43	-4.85	-0.4	3.6e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs8014204	0.816	rs4903262	chr14:75340818	A/G	cg06637938	chr14:75390232	RPS6KL1	0.54	4.68	0.39	7.5e-6	Caffeine consumption;
TGCT	cis	rs1215050	0.818	rs165238	chr4:98712138	G/T	cg05340658	chr4:99064831	C4orf37	0.44	5.63	0.45	1.15e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg00684032	chr4:1343700	KIAA1530	0.23	4.68	0.39	7.3e-6	Obesity-related traits;
TGCT	cis	rs151997	0.508	rs9292165	chr5:50272619	T/C	cg06027927	chr5:50259733	NA	0.54	5.44	0.44	2.76e-7	Callous-unemotional behaviour;
TGCT	cis	rs950776	0.518	rs12916483	chr15:78832397	G/A	cg06917634	chr15:78832804	PSMA4	0.95	9.52	0.65	1.81e-16	Sudden cardiac arrest;
TGCT	cis	rs2404602	1.000	rs6495206	chr15:76870963	C/T	cg22467129	chr15:76604101	ETFA	-0.44	-4.94	-0.41	2.5e-6	Blood metabolite levels;
TGCT	cis	rs2228479	0.717	rs34027607	chr16:89808939	T/C	cg26513180	chr16:89883248	FANCA	0.78	4.54	0.38	1.32e-5	Skin colour saturation;
TGCT	cis	rs877282	0.842	rs35872126	chr10:764545	G/A	cg17470449	chr10:769945	NA	0.37	5.59	0.45	1.37e-7	Uric acid levels;
TGCT	cis	rs79057730	0.599	rs79272827	chr7:807015	C/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.65	5.29	0.43	5.3e-7	Initial pursuit acceleration;
TGCT	cis	rs35264875	1.000	rs72928652	chr11:68851547	G/A	cg02660097	chr11:68866761	NA	0.32	4.96	0.41	2.3e-6	Blond vs. brown hair color;
TGCT	cis	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg20637647	chr7:64974828	NA	1.0	5.59	0.45	1.4e-7	Diabetic kidney disease;
TGCT	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.75	5.41	0.44	3.09e-7	Platelet count;
TGCT	cis	rs4803468	1.000	rs284648	chr19:41926790	T/C	cg09537434	chr19:41945824	ATP5SL	-0.92	-10.57	-0.69	5.19e-19	Height;
TGCT	cis	rs9372498	0.536	rs62422224	chr6:118941116	G/A	cg21191810	chr6:118973309	C6orf204	-0.38	-4.98	-0.41	2.04e-6	Diastolic blood pressure;
TGCT	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	5.53	0.44	1.8e-7	Alzheimer's disease;
TGCT	cis	rs7043114	0.525	rs6479417	chr9:95064562	G/C	cg14631576	chr9:95140430	CENPP	-0.28	-4.65	-0.39	8.23e-6	Height;
TGCT	cis	rs7249142	0.549	rs12609573	chr19:19297567	C/T	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	-0.54	-5.36	-0.43	3.9e-7	IgG glycosylation;
TGCT	cis	rs858239	0.601	rs929508	chr7:23166709	C/A	cg05602783	chr7:23145260	KLHL7	-0.65	-5.48	-0.44	2.32e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs950169	0.840	rs72748702	chr15:84915246	A/G	cg11189052	chr15:85197271	WDR73	0.83	6.67	0.51	7.71e-10	Schizophrenia;
TGCT	cis	rs2549003	0.966	rs2706386	chr5:131832687	C/T	cg02551604	chr5:131831745	NA	0.93	12.59	0.75	6.56e-24	Asthma (sex interaction);
TGCT	cis	rs453301	0.686	rs28665409	chr8:8869277	G/A	cg00184457	chr8:8946301	NA	-0.26	-4.71	-0.39	6.41e-6	Joint mobility (Beighton score);
TGCT	cis	rs16957091	0.647	rs4924705	chr15:43380260	C/T	cg17935677	chr15:44119062	WDR76	0.55	4.78	0.39	4.95e-6	MGMT methylation in smokers;
TGCT	cis	rs308447	0.516	rs6815982	chr4:123677472	C/T	cg10495464	chr4:123653540	BBS12;LOC729338	-0.65	-6.46	-0.5	2.12e-9	Perceived unattractiveness to mosquitoes;
TGCT	cis	rs3099143	1.000	rs2011635	chr15:77134891	T/A	cg21673338	chr15:77095150	SCAPER	-0.52	-5.0	-0.41	1.94e-6	Recalcitrant atopic dermatitis;
TGCT	cis	rs6088590	0.542	rs6059956	chr20:33220070	A/G	cg06115741	chr20:33292138	TP53INP2	0.56	5.04	0.41	1.59e-6	Coronary artery disease;
TGCT	cis	rs78366141	0.649	rs112818517	chr4:89653103	G/A	cg01026744	chr4:89619053	NAP1L5;HERC3	1.16	5.16	0.42	9.33e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
TGCT	cis	rs2692947	0.599	rs7561198	chr2:96774981	C/G	cg22654517	chr2:96458247	NA	-0.21	-4.58	-0.38	1.11e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs7752195	0.558	rs74548903	chr6:25245898	C/T	cg16898833	chr6:26189333	HIST1H4D	1.17	5.47	0.44	2.34e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12477438	0.520	rs11123763	chr2:99750673	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.82	0.62	8.67e-15	Chronic sinus infection;
TGCT	cis	rs250677	0.522	rs10040798	chr5:148367324	A/G	cg18129178	chr5:148520854	ABLIM3	0.36	4.73	0.39	5.97e-6	Breast cancer;
TGCT	cis	rs72720396	1.000	rs72720396	chr1:91191582	A/G	cg13456504	chr1:91191583	NA	0.74	5.83	0.46	4.57e-8	Morning vs. evening chronotype;Chronotype;
TGCT	cis	rs6901004	0.596	rs411604	chr6:111565847	A/G	cg15721981	chr6:111408429	SLC16A10	-0.61	-5.02	-0.41	1.78e-6	Blood metabolite levels;
TGCT	cis	rs765787	0.530	rs1706764	chr15:45524256	T/A	cg24006582	chr15:45444508	DUOX1	-0.25	-5.53	-0.44	1.82e-7	Uric acid levels;
TGCT	cis	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg07424592	chr7:64974309	NA	-1.27	-7.84	-0.58	1.8e-12	Diabetic kidney disease;
TGCT	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg13695892	chr22:41940480	POLR3H	-0.87	-8.08	-0.59	4.83e-13	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs66573146	1.000	rs6838250	chr4:6973184	C/G	cg05069807	chr4:6945702	TBC1D14	0.35	4.94	0.41	2.51e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs7937612	0.965	rs7932037	chr11:120259430	T/A	cg24566217	chr11:120254723	ARHGEF12	-0.28	-4.5	-0.37	1.53e-5	Intraocular pressure;
TGCT	cis	rs7666738	0.606	rs4637413	chr4:99088151	A/G	cg05340658	chr4:99064831	C4orf37	0.44	4.8	0.4	4.5e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg26818010	chr10:134567672	INPP5A	-0.38	-5.37	-0.43	3.66e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs11792861	0.816	rs3818932	chr9:111664178	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.53	5.01	0.41	1.85e-6	Menarche (age at onset);
TGCT	cis	rs826838	0.967	rs11183514	chr12:38760744	A/T	cg26384229	chr12:38710491	ALG10B	1.08	10.86	0.7	1.01e-19	Heart rate;
TGCT	cis	rs2658782	0.724	rs2248655	chr11:93254612	T/C	cg15737290	chr11:93063684	CCDC67	0.6	4.6	0.38	1.01e-5	Pulmonary function decline;
TGCT	cis	rs6688613	0.694	rs12062326	chr1:166820186	G/A	cg07049167	chr1:166818506	POGK	0.24	5.15	0.42	9.86e-7	Refractive astigmatism;
TGCT	cis	rs9430161	0.579	rs7542158	chr1:11040193	G/A	cg02454025	chr1:11042201	C1orf127	0.97	12.71	0.75	3.27e-24	Ewing sarcoma;
TGCT	cis	rs12519773	0.550	rs4242242	chr5:92519387	G/A	cg04854328	chr5:92914828	FLJ42709	-0.3	-4.54	-0.38	1.29e-5	Migraine;
TGCT	cis	rs144345632	1	rs144345632	chr6:96886894	T/TA	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.86	-0.62	7.18e-15	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs265548	0.510	rs28415068	chr19:17910582	T/A	cg04517722	chr19:17905589	B3GNT3	0.4	5.22	0.42	7.22e-7	Tumor biomarkers;
TGCT	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	5.03	0.41	1.69e-6	Prudent dietary pattern;
TGCT	cis	rs4466137	0.951	rs336958	chr5:82973396	A/G	cg16102102	chr5:83017553	HAPLN1	-0.91	-9.61	-0.65	1.12e-16	Prostate cancer;
TGCT	cis	rs12220238	1.000	rs2395077	chr10:75932001	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.28	0.55	3.4e-11	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs3091242	0.933	rs9438904	chr1:25756860	T/C	cg09222892	chr1:25734099	RHCE	-0.43	-7.1	-0.54	8.62e-11	Erythrocyte sedimentation rate;
TGCT	cis	rs1008375	0.868	rs6816286	chr4:17698088	A/G	cg18681998	chr4:17616180	MED28	0.8	7.36	0.55	2.24e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs12510870	0.599	rs1247668	chr4:74446796	A/G	cg05868023	chr4:75230803	EREG	0.53	4.67	0.39	7.77e-6	Iris color (b* coordinate);
TGCT	cis	rs3784262	0.709	rs4080	chr15:58201341	C/G	cg12031962	chr15:58353849	ALDH1A2	0.51	7.26	0.55	3.66e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs2463822	0.688	rs7121684	chr11:62162389	T/C	cg06239285	chr11:62104954	ASRGL1	-0.85	-5.54	-0.45	1.76e-7	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg08219700	chr8:58056026	NA	0.3	4.57	0.38	1.14e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg11644478	chr21:40555479	PSMG1	-0.56	-5.01	-0.41	1.8e-6	Cognitive function;
TGCT	cis	rs2832191	0.791	rs2065270	chr21:30485420	T/C	cg08807101	chr21:30365312	RNF160	-0.66	-6.19	-0.49	8.15e-9	Dental caries;
TGCT	cis	rs9393777	0.546	rs35589403	chr6:27219491	C/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.53	-4.44	-0.37	1.97e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs6969780	0.841	rs10246712	chr7:27198860	C/T	cg04317399	chr7:27170313	HOXA4	0.45	4.56	0.38	1.2e-5	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs12791968	1.000	rs1005935	chr11:45002498	A/C	cg11846598	chr11:44996168	LOC221122	-0.36	-6.79	-0.52	4.04e-10	Inhibitory control;
TGCT	cis	rs6490294	0.539	rs2238151	chr12:112211833	T/C	cg10833066	chr12:111807467	FAM109A	0.32	5.24	0.43	6.57e-7	Mean platelet volume;
TGCT	cis	rs7267979	0.932	rs6115200	chr20:25487377	G/T	cg16686733	chr20:25566563	NINL	0.56	5.69	0.46	8.49e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs12339966	0.581	rs73642443	chr9:11335388	A/G	cg03488587	chr11:64876988	C11orf2	0.31	6.88	0.53	2.67e-10	Systolic blood pressure;
TGCT	cis	rs12479064	0.694	rs4341989	chr2:100046783	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.59	-4.74	-0.39	5.67e-6	Chronic sinus infection;
TGCT	cis	rs3780378	1.000	rs10117591	chr9:5094539	G/A	cg03508284	chr9:4985524	JAK2	-0.49	-4.61	-0.38	9.8200000000000008e-06	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs62244186	0.748	rs13319803	chr3:44635461	G/A	cg04389838	chr3:44770851	ZNF501	-0.4	-5.27	-0.43	5.85e-7	Depressive symptoms;
TGCT	cis	rs7772486	0.875	rs9403764	chr6:146360582	G/A	cg05347473	chr6:146136440	FBXO30	0.57	5.51	0.44	2.02e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2832191	0.791	rs2832199	chr21:30498501	G/A	cg08807101	chr21:30365312	RNF160	-0.65	-6.08	-0.48	1.35e-8	Dental caries;
TGCT	cis	rs11122272	0.735	rs2739518	chr1:231537633	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-6.5	-0.5	1.77e-9	Hemoglobin concentration;
TGCT	cis	rs11249608	0.548	rs6601007	chr5:178455796	G/C	cg21905437	chr5:178450457	ZNF879	0.44	4.57	0.38	1.16e-5	Pubertal anthropometrics;
TGCT	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg13342137	chr4:2252803	MXD4	0.17	4.56	0.38	1.23e-5	Obesity-related traits;
TGCT	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg11890956	chr21:40555474	PSMG1	1.04	10.78	0.7	1.56e-19	Cognitive function;
TGCT	cis	rs2361710	0.611	rs3816257	chr17:78074446	G/T	cg22161269	chr17:78836513	RPTOR	0.23	4.54	0.38	1.29e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
TGCT	cis	rs12908161	1.000	rs12908549	chr15:85322351	C/G	cg17173187	chr15:85201210	NMB	0.57	6.4	0.5	2.89e-9	Schizophrenia;
TGCT	cis	rs10782582	0.569	rs74090722	chr1:76197262	A/G	cg22875332	chr1:76189707	ACADM	-0.49	-5.33	-0.43	4.44e-7	Daytime sleep phenotypes;
TGCT	cis	rs6964587	1.000	rs6951972	chr7:91689446	T/G	cg17063962	chr7:91808500	NA	0.88	9.65	0.66	8.73e-17	Breast cancer;
TGCT	cis	rs1008375	0.932	rs9283698	chr4:17662471	T/C	cg16339924	chr4:17578868	LAP3	0.63	5.22	0.42	7.29e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs11674184	0.632	rs17529680	chr2:11727087	A/C	cg07314298	chr2:11723111	GREB1	0.38	6.76	0.52	4.79e-10	Endometriosis;
TGCT	cis	rs12780845	0.505	rs11254419	chr10:17209192	A/C	cg01003015	chr10:17271136	VIM	-0.63	-5.39	-0.44	3.42e-7	Homocysteine levels;
TGCT	cis	rs2243480	0.522	rs12698511	chr7:65474919	G/T	cg18252515	chr7:66147081	NA	-1.13	-6.09	-0.48	1.29e-8	Diabetic kidney disease;
TGCT	cis	rs6988636	1.000	rs16898095	chr8:124193523	T/C	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs734999	0.545	rs28532547	chr1:2561286	T/G	cg18854424	chr1:2615690	NA	-0.45	-5.15	-0.42	1e-6	Ulcerative colitis;
TGCT	cis	rs9987353	0.522	rs2929466	chr8:9063899	G/T	cg15556689	chr8:8085844	FLJ10661	-0.55	-5.36	-0.43	3.97e-7	Recombination measurement;
TGCT	cis	rs7107174	1.000	rs10899456	chr11:78000155	C/G	cg12700464	chr11:78128424	GAB2	-0.64	-4.51	-0.38	1.46e-5	Testicular germ cell tumor;
TGCT	cis	rs1670533	1.000	rs6857085	chr4:1095920	C/A	cg27284194	chr4:1044797	NA	-0.7	-6.06	-0.48	1.53e-8	Recombination rate (females);
TGCT	cis	rs651907	0.535	rs36060163	chr3:101360963	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.91	10.82	0.7	1.27e-19	Colorectal cancer;
TGCT	cis	rs6690583	0.623	rs61770879	chr1:85504938	A/C	cg20280350	chr1:85513789	MCOLN3	-0.71	-4.53	-0.38	1.38e-5	Serum sulfate level;
TGCT	cis	rs939658	0.805	rs8036435	chr15:79420031	T/C	cg17916960	chr15:79447300	NA	-0.5	-7.7	-0.57	3.74e-12	Refractive error;
TGCT	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.47	4.6	0.38	1.04e-5	Prudent dietary pattern;
TGCT	cis	rs7666738	0.962	rs2865950	chr4:99040061	T/C	cg17366294	chr4:99064904	C4orf37	0.71	6.53	0.51	1.55e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1580019	0.547	rs56981934	chr7:32535202	C/G	cg07520158	chr7:32535189	LSM5;AVL9	0.59	5.02	0.41	1.72e-6	Cognitive ability;
TGCT	cis	rs7267979	0.844	rs4815413	chr20:25359229	G/T	cg16686733	chr20:25566563	NINL	-0.52	-4.93	-0.4	2.61e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7617773	1.000	rs6442106	chr3:48190815	G/A	cg11946769	chr3:48343235	NME6	-0.62	-5.59	-0.45	1.37e-7	Coronary artery disease;
TGCT	cis	rs2050392	1.000	rs2183176	chr10:30698544	C/T	cg18806716	chr10:30721971	MAP3K8	0.52	6.47	0.5	2.04e-9	Inflammatory bowel disease;
TGCT	cis	rs9611565	0.921	rs6002333	chr22:41719469	C/T	cg13695892	chr22:41940480	POLR3H	-0.81	-8.08	-0.59	4.88e-13	Vitiligo;
TGCT	cis	rs4478037	1.000	rs75576169	chr3:33167801	G/A	cg19404215	chr3:33155277	CRTAP	1.26	7.88	0.58	1.43e-12	Major depressive disorder;
TGCT	cis	rs6582630	0.537	rs8189533	chr12:38391068	A/G	cg26384229	chr12:38710491	ALG10B	0.86	7.56	0.56	7.83e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs2544527	0.635	rs2693008	chr2:15913019	C/G	cg26669897	chr2:15909070	NA	-0.44	-5.17	-0.42	8.97e-7	Pulmonary function (smoking interaction);Pulmonary function;
TGCT	cis	rs763121	0.853	rs5757231	chr22:39071658	C/T	cg06022373	chr22:39101656	GTPBP1	-0.77	-7.46	-0.56	1.35e-11	Menopause (age at onset);
TGCT	cis	rs2180341	0.782	rs4487601	chr6:127723521	A/G	cg24812749	chr6:127587940	RNF146	0.65	5.19	0.42	8.37e-7	Breast cancer;
TGCT	cis	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg07424592	chr7:64974309	NA	1.38	8.17	0.59	3.04e-13	Diabetic kidney disease;
TGCT	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg11644478	chr21:40555479	PSMG1	1.02	11.05	0.7	3.46e-20	Cognitive function;
TGCT	cis	rs11779988	0.545	rs431961	chr8:17786204	T/G	cg01800426	chr8:17659068	MTUS1	-0.7	-5.46	-0.44	2.5e-7	Breast cancer;
TGCT	cis	rs2742234	1.000	rs1864395	chr10:43655697	G/A	cg02780029	chr10:43622663	RET	-0.26	-5.03	-0.41	1.7e-6	Hirschsprung disease;
TGCT	cis	rs11626933	1.000	rs61986782	chr14:90751344	C/T	cg14092571	chr14:90743983	NA	-0.3	-6.13	-0.48	1.06e-8	Gut microbiota (bacterial taxa);
TGCT	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg15691649	chr6:25882328	NA	0.38	5.06	0.41	1.5e-6	Blood metabolite levels;
TGCT	cis	rs9810089	0.835	rs6791611	chr3:136160590	C/G	cg12473912	chr3:136751656	NA	-0.35	-5.12	-0.42	1.12e-6	Gestational age at birth (child effect);
TGCT	cis	rs3935685	0.874	rs4886521	chr15:78000321	A/G	cg25212270	chr15:78015279	NA	0.26	5.64	0.45	1.08e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs16866061	0.890	rs72972401	chr2:225404668	T/C	cg12698349	chr2:225449008	CUL3	1.0	9.83	0.66	3.23e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg04267008	chr7:1944627	MAD1L1	-0.4	-5.57	-0.45	1.52e-7	Schizophrenia;
TGCT	cis	rs2075371	0.764	rs1643034	chr7:134006176	A/G	cg11752832	chr7:134001865	SLC35B4	0.78	7.42	0.55	1.59e-11	Mean platelet volume;
TGCT	trans	rs3780486	1.000	rs3780486	chr9:33139453	C/T	cg04842962	chr6:43655489	MRPS18A	1.15	11.21	0.71	1.47e-20	IgG glycosylation;
TGCT	cis	rs10751667	0.666	rs6597966	chr11:950750	T/C	cg06064525	chr11:970664	AP2A2	-0.35	-8.22	-0.59	2.29e-13	Alzheimer's disease (late onset);
TGCT	cis	rs950169	0.686	rs12906474	chr15:85109237	A/G	cg11189052	chr15:85197271	WDR73	0.79	6.37	0.5	3.37e-9	Schizophrenia;
TGCT	cis	rs2295359	0.824	rs12060309	chr1:67604219	T/C	cg08029281	chr1:67600428	NA	0.4	4.54	0.38	1.31e-5	Psoriasis;
TGCT	cis	rs11118844	0.744	rs10863655	chr1:221952515	A/G	cg04222084	chr1:221915650	DUSP10	-0.78	-4.66	-0.39	8.03e-6	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
TGCT	cis	rs7586879	0.593	rs10198356	chr2:25130592	A/G	cg15423357	chr2:25149977	NA	0.52	5.03	0.41	1.65e-6	Body mass index;
TGCT	cis	rs910316	0.967	rs175432	chr14:75615246	C/G	cg23033748	chr14:75592666	NEK9	-0.29	-4.78	-0.39	4.86e-6	Height;
TGCT	cis	rs7599312	0.517	rs10192988	chr2:213407782	T/G	cg16329650	chr2:213403929	ERBB4	1.07	16.03	0.82	5.29e-32	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs9948	0.786	rs62152783	chr2:97457389	T/A	cg01990225	chr2:97406019	LMAN2L	-0.88	-4.81	-0.4	4.37e-6	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs2658782	0.789	rs2658775	chr11:93126799	C/T	cg18152523	chr11:93063302	CCDC67	-0.58	-4.6	-0.38	1.03e-5	Pulmonary function decline;
TGCT	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg02187348	chr16:89574699	SPG7	0.61	6.53	0.51	1.53e-9	Multiple myeloma (IgH translocation);
TGCT	cis	rs782590	0.869	rs782599	chr2:55847423	C/T	cg03859395	chr2:55845619	SMEK2	0.9	11.04	0.7	3.81e-20	Metabolic syndrome;
TGCT	cis	rs35306767	0.903	rs35957139	chr10:884889	C/T	cg20503657	chr10:835505	NA	0.77	11.34	0.71	6.95e-21	Eosinophil percentage of granulocytes;
TGCT	cis	rs9896933	0.778	rs80243549	chr17:80821485	G/T	cg20578329	chr17:80767326	TBCD	-0.35	-4.99	-0.41	1.99e-6	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
TGCT	cis	rs7267979	1.000	rs910997	chr20:25267301	G/A	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs17384381	1.000	rs17388521	chr1:85897904	A/G	cg16011679	chr1:85725395	C1orf52	-0.77	-6.34	-0.49	3.87e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7666738	0.576	rs7660951	chr4:98651581	T/A	cg18180107	chr4:99064573	C4orf37	0.52	4.57	0.38	1.15e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg01585852	chr22:24235823	MIF	-0.22	-4.67	-0.39	7.81e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9534288	0.797	rs2104516	chr13:46602123	T/C	cg15192986	chr13:46630673	CPB2	-0.52	-7.53	-0.56	9.22e-12	Blood protein levels;
TGCT	cis	rs9814567	1.000	rs9835204	chr3:134261342	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.95	-9.55	-0.65	1.56e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs7698623	0.850	rs7676119	chr4:88780778	G/A	cg02735620	chr4:88950514	PKD2	-0.44	-4.81	-0.4	4.22e-6	Cardiovascular disease risk factors;
TGCT	cis	rs56399783	0.708	rs55868372	chr7:2758563	G/C	cg19731401	chr7:2775893	GNA12	0.36	5.22	0.42	7.45e-7	Childhood ear infection;
TGCT	cis	rs74181299	0.964	rs2723065	chr2:65279414	A/G	cg05010058	chr2:65284262	CEP68	0.43	4.87	0.4	3.38e-6	Pulse pressure;
TGCT	cis	rs7926906	1.000	rs4298862	chr11:90523629	C/G	cg26138821	chr11:89956704	CHORDC1	-0.53	-5.69	-0.46	8.52e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9303401	0.659	rs35082010	chr17:56936867	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs9916302	0.595	rs4795371	chr17:37636695	T/G	cg15445000	chr17:37608096	MED1	0.31	4.57	0.38	1.17e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg11494091	chr17:61959527	GH2	0.61	14.49	0.79	1.92e-28	Prudent dietary pattern;
TGCT	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg18230493	chr5:56204884	C5orf35	-0.67	-5.76	-0.46	6.2e-8	Initial pursuit acceleration;
TGCT	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg15691649	chr6:25882328	NA	-0.35	-4.55	-0.38	1.25e-5	Blood metabolite levels;
TGCT	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg25036284	chr2:26402008	FAM59B	-0.61	-4.89	-0.4	3.1e-6	Gut microbiome composition (summer);
TGCT	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg23758822	chr17:41437982	NA	0.7	6.6	0.51	1.1e-9	Menopause (age at onset);
TGCT	cis	rs9486719	1.000	rs11152968	chr6:96908653	A/G	cg18709589	chr6:96969512	KIAA0776	0.68	5.05	0.41	1.55e-6	Migraine;Coronary artery disease;
TGCT	cis	rs7017914	0.934	rs6987313	chr8:71570989	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.53	-4.9	-0.4	2.87e-6	Bone mineral density;
TGCT	cis	rs78456975	0.739	rs72776248	chr2:1521314	A/G	cg01028140	chr2:1542097	TPO	-0.36	-4.86	-0.4	3.55e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs13242816	1.000	rs987790	chr7:116134633	T/A	cg02799643	chr7:116139180	CAV2	-0.46	-5.52	-0.44	1.87e-7	P wave duration;
TGCT	cis	rs990171	1.000	rs4851584	chr2:103060313	A/G	cg04239558	chr2:103089729	SLC9A4	0.34	4.67	0.39	7.64e-6	Lymphocyte counts;
TGCT	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg08280861	chr8:58055591	NA	0.4	4.56	0.38	1.22e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9393692	0.645	rs766407	chr6:26319534	T/C	cg00631329	chr6:26305371	NA	-0.46	-6.91	-0.53	2.23e-10	Educational attainment;
TGCT	trans	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	1.03	13.16	0.76	2.65e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs250677	0.522	rs6580589	chr5:148360335	C/G	cg18129178	chr5:148520854	ABLIM3	0.36	4.69	0.39	7.23e-6	Breast cancer;
TGCT	cis	rs1468333	0.724	rs12514307	chr5:137612143	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.46	4.46	0.37	1.79e-5	Resting heart rate;
TGCT	cis	rs9906944	0.933	rs4794018	chr17:47093398	T/C	cg20966754	chr17:47091339	IGF2BP1	-0.44	-4.99	-0.41	2.04e-6	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs9894429	0.604	rs9912071	chr17:79609654	G/A	cg21028142	chr17:79581711	NPLOC4	0.28	6.12	0.48	1.13e-8	Eye color traits;
TGCT	cis	rs35306767	0.903	rs11253475	chr10:907262	C/A	cg20503657	chr10:835505	NA	0.75	10.41	0.68	1.3e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs7312933	0.524	rs11181465	chr12:42765098	T/G	cg19980929	chr12:42632907	YAF2	0.43	6.03	0.48	1.79e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs3772130	0.583	rs58088236	chr3:121561765	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.59	5.43	0.44	2.8e-7	Cognitive performance;
TGCT	cis	rs42648	0.869	rs1015402	chr7:89913269	C/T	cg25739043	chr7:89950458	NA	-0.73	-7.31	-0.55	2.87e-11	Homocysteine levels;
TGCT	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	0.53	4.96	0.41	2.25e-6	Bipolar disorder;
TGCT	cis	rs854765	0.964	rs854762	chr17:18009102	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.65	-6.31	-0.49	4.57e-9	Total body bone mineral density;
TGCT	cis	rs4273100	0.688	rs4143829	chr17:19241505	G/A	cg03910582	chr17:19030146	GRAPL	-0.51	-6.21	-0.49	7.47e-9	Schizophrenia;
TGCT	cis	rs57590327	0.528	rs13086292	chr3:81705368	G/A	cg07356753	chr3:81810745	GBE1	-0.77	-6.97	-0.53	1.63e-10	Extraversion;
TGCT	cis	rs72843506	0.722	rs74255387	chr17:20101383	G/A	cg23224458	chr17:20280056	CCDC144C	-0.56	-4.59	-0.38	1.09e-5	Schizophrenia;
TGCT	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.72	5.19	0.42	8.33e-7	Platelet count;
TGCT	cis	rs16854884	0.837	rs989665	chr3:143792854	C/T	cg06585982	chr3:143692056	C3orf58	0.62	4.81	0.4	4.32e-6	Economic and political preferences (feminism/equality);
TGCT	cis	rs10744422	1.000	rs2061101	chr12:123348925	C/A	cg25930673	chr12:123319894	HIP1R	-0.87	-4.79	-0.4	4.66e-6	Schizophrenia;
TGCT	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg13342137	chr4:2252803	MXD4	0.17	4.59	0.38	1.07e-5	Obesity-related traits;
TGCT	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg22029157	chr1:209979665	IRF6	0.78	8.98	0.63	3.67e-15	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
TGCT	cis	rs1127311	1.000	rs10908419	chr1:154567699	G/A	cg17218026	chr1:154582156	ADAR	0.31	7.75	0.57	2.93e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	trans	rs1496653	0.602	rs35055753	chr3:23454366	T/C	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs1801251	1.000	rs283486	chr2:233644223	A/G	cg08000102	chr2:233561755	GIGYF2	0.64	6.56	0.51	1.34e-9	Coronary artery disease;
TGCT	cis	rs1997103	1.000	rs12718956	chr7:55407763	A/G	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs9858542	1.000	rs11130213	chr3:49712297	C/T	cg03060546	chr3:49711283	APEH	-0.67	-6.09	-0.48	1.28e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs1005277	0.505	rs7917943	chr10:38195811	T/A	cg13531842	chr10:38383804	ZNF37A	0.38	4.55	0.38	1.24e-5	Extrinsic epigenetic age acceleration;
TGCT	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg11494091	chr17:61959527	GH2	0.43	7.3	0.55	3.05e-11	Height;
TGCT	cis	rs9296092	0.521	rs6929165	chr6:33515958	T/G	cg13560919	chr6:33536144	NA	-0.2	-4.91	-0.4	2.75e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs4319547	1.000	rs4319547	chr12:123079035	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.68	-5.41	-0.44	3.16e-7	Body mass index;
TGCT	cis	rs11098499	0.908	rs71614449	chr4:120387055	C/T	cg09307838	chr4:120376055	NA	0.68	6.53	0.51	1.54e-9	Corneal astigmatism;
TGCT	cis	rs62244186	0.566	rs2135531	chr3:44881158	C/G	cg11003573	chr3:44754125	ZNF502	-0.46	-5.34	-0.43	4.34e-7	Depressive symptoms;
TGCT	cis	rs7824557	0.564	rs35009431	chr8:11232788	G/A	cg21775007	chr8:11205619	TDH	-0.58	-5.42	-0.44	3.02e-7	Retinal vascular caliber;
TGCT	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg06108461	chr20:60628389	TAF4	-0.69	-10.65	-0.69	3.24e-19	Body mass index;
TGCT	cis	rs7017914	1.000	rs7007450	chr8:71640269	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.03	-0.41	1.69e-6	Bone mineral density;
TGCT	cis	rs4722166	0.695	rs56061963	chr7:22800397	T/C	cg26061582	chr7:22766209	IL6	0.48	6.25	0.49	6.15e-9	Lung cancer;
TGCT	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg10047753	chr17:41438598	NA	0.94	9.23	0.64	9.06e-16	Menopause (age at onset);
TGCT	cis	rs6722750	1.000	rs35573827	chr2:64394433	C/G	cg22352474	chr2:64371530	PELI1	0.62	5.51	0.44	1.97e-7	Neuroticism;
TGCT	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg24578937	chr1:2090814	PRKCZ	0.26	6.95	0.53	1.8e-10	Height;
TGCT	trans	rs4332037	0.522	rs4721098	chr7:1881527	G/C	cg25206134	chr2:45395956	NA	-0.92	-7.78	-0.57	2.44e-12	Bipolar disorder;
TGCT	cis	rs7666738	0.830	rs13108705	chr4:99044438	T/C	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2602836	0.830	rs2602874	chr4:100039396	A/T	cg12011299	chr4:100065546	ADH4	0.4	5.72	0.46	7.52e-8	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs739496	0.894	rs11065898	chr12:111862575	C/T	cg10833066	chr12:111807467	FAM109A	0.33	4.54	0.38	1.31e-5	Platelet count;
TGCT	trans	rs7824557	0.547	rs6601570	chr8:11079367	G/A	cg06636001	chr8:8085503	FLJ10661	-0.82	-7.42	-0.55	1.63e-11	Retinal vascular caliber;
TGCT	cis	rs13191362	1.000	rs13212608	chr6:163032128	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.62	4.55	0.38	1.26e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7086627	0.515	rs7078254	chr10:82212193	C/T	cg01528321	chr10:82214614	TSPAN14	0.67	6.37	0.5	3.39e-9	Post bronchodilator FEV1;
TGCT	cis	rs9807989	0.507	rs6758936	chr2:102991369	A/G	cg03938978	chr2:103052716	IL18RAP	-0.26	-5.22	-0.42	7.3e-7	Asthma;
TGCT	cis	rs12478296	0.581	rs56142391	chr2:242992248	C/T	cg06360820	chr2:242988706	NA	-0.61	-4.72	-0.39	6.25e-6	Obesity-related traits;
TGCT	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg12310025	chr6:25882481	NA	-0.54	-5.47	-0.44	2.39e-7	Blood metabolite levels;
TGCT	cis	rs7255045	0.743	rs10426080	chr19:12957850	A/G	cg23899408	chr19:12877188	HOOK2	-0.6	-5.03	-0.41	1.67e-6	Mean corpuscular volume;
TGCT	cis	rs2688608	0.901	rs2633312	chr10:75631755	T/A	cg19442545	chr10:75533431	FUT11	-0.31	-5.04	-0.41	1.61e-6	Inflammatory bowel disease;
TGCT	cis	rs9311474	0.713	rs352168	chr3:52237970	C/T	cg07507251	chr3:52567010	NT5DC2	0.39	5.15	0.42	1e-6	Electroencephalogram traits;
TGCT	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	6.05	0.48	1.59e-8	Alzheimer's disease;
TGCT	cis	rs12477438	0.520	rs6542866	chr2:99764592	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.75	7.25	0.55	3.92e-11	Chronic sinus infection;
TGCT	cis	rs9357506	1.000	rs60277913	chr6:46302757	A/G	cg21115430	chr6:46460003	NA	-0.27	-5.47	-0.44	2.43e-7	Body mass index;
TGCT	cis	rs17376456	1.000	rs12187701	chr5:93522290	A/G	cg25358565	chr5:93447407	FAM172A	0.94	7.86	0.58	1.55e-12	Diabetic retinopathy;
TGCT	cis	rs11650494	0.808	rs61286260	chr17:47433222	T/C	cg08112188	chr17:47440006	ZNF652	1.04	5.34	0.43	4.3e-7	Prostate cancer;
TGCT	cis	rs595982	0.559	rs73061643	chr19:49368151	A/G	cg21252483	chr19:49399788	TULP2	-0.42	-6.39	-0.5	3.02e-9	Red cell distribution width;
TGCT	cis	rs4240897	1.000	rs4240897	chr1:12042755	A/G	cg13216073	chr1:12042593	MFN2	-0.16	-4.53	-0.38	1.38e-5	Tuberculosis;
TGCT	cis	rs4870684	1.000	rs4870684	chr7:57699151	C/T	cg01314568	chr7:57830625	NA	-0.36	-4.63	-0.38	9.03e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg21724239	chr8:58056113	NA	0.38	5.09	0.42	1.31e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9443645	0.901	rs9443632	chr6:79664440	T/C	cg09184832	chr6:79620586	NA	-0.49	-5.29	-0.43	5.29e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs12142240	0.698	rs66911505	chr1:46823298	A/G	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs7513165	0.935	rs2510	chr1:204161591	T/C	cg12731349	chr1:204159619	KISS1	0.5	5.69	0.46	8.55e-8	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
TGCT	cis	rs877282	0.853	rs7092652	chr10:756109	G/A	cg17470449	chr10:769945	NA	0.32	4.91	0.4	2.76e-6	Uric acid levels;
TGCT	cis	rs10114408	0.959	rs10739962	chr9:96649758	A/G	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs80262450	1	rs80262450	chr18:12818922	G/A	cg23544223	chr18:12777786	NA	-0.62	-4.6	-0.38	1.04e-5	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs8062405	1.000	rs4788099	chr16:28855727	A/G	cg09754948	chr16:28834200	ATXN2L	0.59	4.45	0.37	1.91e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg21862992	chr11:68658383	NA	0.46	6.52	0.51	1.6e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs4689388	0.926	rs4689391	chr4:6280449	G/A	cg25554036	chr4:6271136	WFS1	0.55	8.09	0.59	4.65e-13	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg13206674	chr6:150067644	NUP43	0.51	4.47	0.37	1.75e-5	Lung cancer;
TGCT	cis	rs1215050	0.740	rs700740	chr4:98976003	A/C	cg17366294	chr4:99064904	C4orf37	-0.55	-5.8	-0.46	5.23e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2251381	0.741	rs2735966	chr21:30538174	G/A	cg24692254	chr21:30365293	RNF160	0.74	7.47	0.56	1.28e-11	Selective IgA deficiency;
TGCT	cis	rs62244186	0.535	rs59726036	chr3:44850074	G/T	cg10108389	chr3:44770937	ZNF501	-0.46	-4.45	-0.37	1.88e-5	Depressive symptoms;
TGCT	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg24503407	chr1:205819492	PM20D1	0.57	7.6	0.56	6.42e-12	Menarche (age at onset);
TGCT	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg02725872	chr8:58115012	NA	-0.38	-4.99	-0.41	1.98e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9486719	1.000	rs12208011	chr6:96991105	G/A	cg06623918	chr6:96969491	KIAA0776	-0.99	-7.99	-0.58	7.78e-13	Migraine;Coronary artery disease;
TGCT	cis	rs8038465	0.615	rs6495075	chr15:73981005	A/G	cg15420318	chr15:73925796	NPTN	0.68	7.53	0.56	9.28e-12	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7937612	0.965	rs9633919	chr11:120249493	G/A	cg24566217	chr11:120254723	ARHGEF12	-0.28	-4.53	-0.38	1.37e-5	Intraocular pressure;
TGCT	cis	rs614226	0.935	rs2235222	chr12:120892193	G/C	cg01236616	chr12:121019343	POP5	-1.24	-12.17	-0.74	6.5e-23	Type 1 diabetes nephropathy;
TGCT	cis	rs7267979	0.789	rs9927	chr20:25277244	A/G	cg03522245	chr20:25566470	NINL	0.57	5.72	0.46	7.63e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7312933	0.703	rs10880268	chr12:42599122	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	5.06	0.41	1.45e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs7584330	0.554	rs80151891	chr2:238398826	G/T	cg14458575	chr2:238380390	NA	0.59	5.08	0.42	1.34e-6	Prostate cancer;
TGCT	cis	rs12477438	1.000	rs11897712	chr2:99735697	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.97	-8.46	-0.61	6.14e-14	Chronic sinus infection;
TGCT	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg22963979	chr7:1858916	MAD1L1	-0.45	-7.37	-0.55	2.15e-11	Bipolar disorder and schizophrenia;
TGCT	cis	rs111803315	1.000	rs112476368	chr14:59991452	A/G	cg22995959	chr14:59931024	GPR135	0.66	4.8	0.4	4.39e-6	Schizophrenia;
TGCT	cis	rs12643440	0.538	rs6852278	chr4:17138490	A/C	cg22650099	chr4:17144496	NA	0.47	4.79	0.4	4.7e-6	Metabolite levels (Pyroglutamine);
TGCT	cis	rs6484504	0.576	rs2150213	chr11:31244634	A/G	cg26647111	chr11:31128758	NA	-0.34	-4.7	-0.39	6.78e-6	Red blood cell count;
TGCT	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg19626725	chr5:178986131	RUFY1	0.45	5.7	0.46	8.11e-8	Lung cancer;
TGCT	cis	rs7552404	1.000	rs12127402	chr1:76205643	C/A	cg22875332	chr1:76189707	ACADM	0.77	9.42	0.65	3.17e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs713587	0.563	rs1529897	chr2:25086827	T/G	cg01884057	chr2:25150051	NA	0.3	5.65	0.45	1.03e-7	Body mass index in non-asthmatics;
TGCT	cis	rs7674212	0.541	rs2720458	chr4:104052963	C/G	cg16532752	chr4:104119610	CENPE	-0.61	-5.58	-0.45	1.44e-7	Type 2 diabetes;
TGCT	cis	rs1215050	0.605	rs1817221	chr4:98615180	G/A	cg05340658	chr4:99064831	C4orf37	-0.41	-4.96	-0.41	2.3e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9902453	0.904	rs12936302	chr17:28349476	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.8	-7.56	-0.56	7.78e-12	Coffee consumption (cups per day);
TGCT	cis	rs11096990	0.613	rs7690414	chr4:39212289	G/C	cg20847110	chr4:39482781	LOC401127	0.16	4.58	0.38	1.13e-5	Cognitive function;
TGCT	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg17971929	chr21:40555470	PSMG1	-0.71	-6.63	-0.51	9.09e-10	Cognitive function;
TGCT	cis	rs12200560	0.505	rs211166	chr6:97068598	T/C	cg06623918	chr6:96969491	KIAA0776	0.57	4.83	0.4	3.93e-6	Coronary heart disease;
TGCT	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg16414030	chr3:133502952	NA	0.62	9.75	0.66	5.13e-17	Iron status biomarkers;
TGCT	cis	rs7937682	0.921	rs1944119	chr11:111436387	A/G	cg09085632	chr11:111637200	PPP2R1B	0.86	7.2	0.54	5.06e-11	Primary sclerosing cholangitis;
TGCT	cis	rs617219	0.726	rs72764969	chr5:78451409	A/G	cg05890484	chr5:78407552	BHMT	0.39	5.29	0.43	5.44e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs7727544	0.816	rs274555	chr5:131722951	C/T	cg21138405	chr5:131827807	IRF1	0.18	4.7	0.39	6.78e-6	Blood metabolite levels;
TGCT	cis	rs853679	0.607	rs201002	chr6:27808192	A/G	cg08798685	chr6:27730294	NA	-0.32	-4.58	-0.38	1.1e-5	Depression;
TGCT	cis	rs4148883	0.651	rs2851301	chr4:100010127	C/T	cg12011299	chr4:100065546	ADH4	0.38	5.72	0.46	7.41e-8	Alcohol dependence;
TGCT	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg18876405	chr7:65276391	NA	0.31	4.79	0.4	4.58e-6	Aortic root size;
TGCT	cis	rs12497850	0.931	rs7628719	chr3:48995487	C/T	cg06212747	chr3:49208901	KLHDC8B	0.6	5.43	0.44	2.82e-7	Parkinson's disease;
TGCT	cis	rs76878669	0.561	rs7107191	chr11:66140397	G/A	cg18002602	chr11:66138449	SLC29A2	0.53	6.49	0.5	1.89e-9	Educational attainment (years of education);
TGCT	cis	rs6912958	0.559	rs369674	chr6:88043402	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.73	-7.68	-0.57	4.16e-12	Monocyte percentage of white cells;
TGCT	cis	rs9611565	0.546	rs34077262	chr22:42061639	A/G	cg03806693	chr22:41940476	POLR3H	0.96	9.65	0.65	8.84e-17	Vitiligo;
TGCT	cis	rs3091242	0.804	rs631133	chr1:25724146	T/C	cg09222892	chr1:25734099	RHCE	-0.45	-7.34	-0.55	2.52e-11	Erythrocyte sedimentation rate;
TGCT	cis	rs751728	0.965	rs2296743	chr6:33740025	C/T	cg00334056	chr6:33755658	LEMD2	-0.25	-4.55	-0.38	1.25e-5	Crohn's disease;
TGCT	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg20607798	chr8:58055168	NA	0.62	5.19	0.42	8.32e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9534288	0.742	rs1022953	chr13:46649126	G/T	cg15192986	chr13:46630673	CPB2	-0.53	-6.61	-0.51	1.03e-9	Blood protein levels;
TGCT	cis	rs7666738	0.830	rs2865980	chr4:99027422	T/G	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7572733	0.515	rs1356542	chr2:198835702	G/T	cg00792783	chr2:198669748	PLCL1	0.57	5.23	0.43	6.99e-7	Dermatomyositis;
TGCT	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg13695892	chr22:41940480	POLR3H	-0.91	-8.8	-0.62	9.77e-15	Vitiligo;
TGCT	cis	rs10465746	0.967	rs7531537	chr1:84414924	C/T	cg10977910	chr1:84465055	TTLL7	0.63	6.25	0.49	5.95e-9	Obesity-related traits;
TGCT	cis	rs2153535	0.547	rs9502720	chr6:8541362	C/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.61	0.45	1.23e-7	Motion sickness;
TGCT	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg17554472	chr22:41940697	POLR3H	0.42	4.56	0.38	1.19e-5	Vitiligo;
TGCT	cis	rs17030434	0.954	rs11724154	chr4:154753108	G/T	cg14289246	chr4:154710475	SFRP2	-0.9	-7.05	-0.54	1.09e-10	Electrocardiographic conduction measures;
TGCT	cis	rs7551345	0.653	rs6425719	chr1:31700777	T/C	cg18936040	chr1:31673095	NA	0.27	4.44	0.37	1.98e-5	Schizophrenia;
TGCT	cis	rs7826238	0.564	rs2921053	chr8:8319963	G/C	cg08975724	chr8:8085496	FLJ10661	0.54	4.9	0.4	2.87e-6	Systolic blood pressure;
TGCT	cis	rs8031584	1.000	rs35811129	chr15:31241346	G/A	cg08704250	chr15:31115839	NA	-0.36	-4.52	-0.38	1.43e-5	Huntington's disease progression;
TGCT	cis	rs3935685	0.874	rs4886521	chr15:78000321	A/G	cg03457338	chr15:78040120	NA	-0.23	-5.88	-0.47	3.6e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs12497850	0.931	rs6442130	chr3:48778027	A/G	cg06212747	chr3:49208901	KLHDC8B	0.58	5.32	0.43	4.69e-7	Parkinson's disease;
TGCT	cis	rs17376456	0.877	rs10073039	chr5:93467709	A/G	cg25358565	chr5:93447407	FAM172A	0.92	8.38	0.6	9.58e-14	Diabetic retinopathy;
TGCT	cis	rs4953076	0.573	rs13008237	chr2:44404902	A/G	cg04920474	chr2:44395004	PPM1B	0.56	5.58	0.45	1.47e-7	Height;
TGCT	cis	rs7809950	0.598	rs2283038	chr7:106835410	C/T	cg23024343	chr7:107201750	COG5	-0.44	-6.03	-0.48	1.74e-8	Coronary artery disease;
TGCT	cis	rs7119	0.717	rs12915548	chr15:77818042	A/G	cg27398640	chr15:77910606	LINGO1	-0.25	-4.6	-0.38	1.05e-5	Type 2 diabetes;
TGCT	cis	rs6770219	0.516	rs57136001	chr3:186140693	A/T	cg20306810	chr3:186501757	SNORD2;EIF4A2	0.73	4.46	0.37	1.81e-5	Cerebrospinal T-tau levels;
TGCT	cis	rs4700695	0.668	rs253212	chr5:65497553	C/T	cg21114390	chr5:65439923	SFRS12	-0.81	-7.72	-0.57	3.34e-12	Facial morphology (factor 19);
TGCT	cis	rs17253792	0.822	rs17253744	chr14:56161950	C/G	cg01858014	chr14:56050164	KTN1	-0.36	-4.55	-0.38	1.24e-5	Putamen volume;
TGCT	cis	rs12549902	1.000	rs12550613	chr8:41510260	G/C	cg21772509	chr8:41503840	NKX6-3	0.87	10.06	0.67	9.27e-18	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
TGCT	cis	rs7107174	0.688	rs2063725	chr11:78133452	T/G	cg12700464	chr11:78128424	GAB2	-0.68	-4.54	-0.38	1.33e-5	Testicular germ cell tumor;
TGCT	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.49	-6.5	-0.5	1.76e-9	Alzheimer's disease;
TGCT	cis	rs6543140	0.964	rs13393175	chr2:103078849	T/G	cg09003973	chr2:102972529	NA	0.55	4.56	0.38	1.2e-5	Blood protein levels;
TGCT	cis	rs3008870	1.000	rs3008873	chr1:67425770	G/A	cg08660285	chr1:67390436	MIER1;WDR78	1.1	11.8	0.73	5.15e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs5760092	0.755	rs11090298	chr22:24262061	G/A	cg11905131	chr22:24372483	LOC391322	0.69	5.52	0.44	1.87e-7	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs4889855	0.511	rs9908700	chr17:78466594	A/G	cg16591659	chr17:78472290	NA	-0.35	-5.51	-0.44	1.99e-7	Fractional excretion of uric acid;
TGCT	trans	rs3780486	0.846	rs10813960	chr9:33180362	C/T	cg04842962	chr6:43655489	MRPS18A	1.12	12.06	0.73	1.25e-22	IgG glycosylation;
TGCT	cis	rs8017423	0.935	rs11624890	chr14:90738165	T/A	cg04374321	chr14:90722782	PSMC1	-0.75	-7.32	-0.55	2.75e-11	Mortality in heart failure;
TGCT	cis	rs7192750	0.583	rs8046916	chr16:72047751	C/G	cg14768367	chr16:72042858	DHODH	-0.92	-4.89	-0.4	3.12e-6	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.74	0.52	5.28e-10	Electroencephalogram traits;
TGCT	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/C	cg18654377	chr3:49208889	KLHDC8B	-0.44	-6.06	-0.48	1.52e-8	Parkinson's disease;
TGCT	cis	rs3733585	0.773	rs13107466	chr4:10019390	G/A	cg02734326	chr4:10020555	SLC2A9	0.38	4.54	0.38	1.34e-5	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg12516959	chr21:47718080	NA	-0.35	-4.9	-0.4	2.88e-6	Testicular germ cell tumor;
TGCT	cis	rs7611238	0.560	rs62287109	chr3:195053916	C/T	cg27323046	chr3:195102265	ACAP2	0.35	4.75	0.39	5.5e-6	Body mass index;
TGCT	cis	rs3862030	0.503	rs6584505	chr10:104254412	C/A	cg05855489	chr10:104503620	C10orf26	-0.58	-5.06	-0.41	1.47e-6	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
TGCT	cis	rs554111	0.656	rs10799680	chr1:21361181	C/T	cg01072550	chr1:21505969	NA	0.36	5.44	0.44	2.77e-7	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs10206020	0.885	rs11885392	chr2:1578182	C/A	cg12573674	chr2:1569213	NA	-0.46	-5.2	-0.42	7.88e-7	IgG glycosylation;
TGCT	cis	rs7786808	0.608	rs7784758	chr7:158214386	A/G	cg01191920	chr7:158217561	PTPRN2	-0.38	-5.74	-0.46	6.98e-8	Obesity-related traits;
TGCT	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg25767906	chr1:53392781	SCP2	0.45	4.91	0.4	2.83e-6	Monocyte count;
TGCT	cis	rs7772486	0.875	rs6914813	chr6:146397798	A/G	cg13319975	chr6:146136371	FBXO30	-0.54	-4.72	-0.39	6.27e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs12220238	1.000	rs7081350	chr10:75990328	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.78	0.57	2.42e-12	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs9467711	0.539	rs34436535	chr6:26370365	G/C	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1215050	0.755	rs7696354	chr4:98820330	T/C	cg05340658	chr4:99064831	C4orf37	0.44	5.57	0.45	1.54e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg11494091	chr17:61959527	GH2	-0.6	-16.42	-0.83	6.81e-33	Prudent dietary pattern;
TGCT	cis	rs4730250	0.707	rs6977868	chr7:106790555	T/G	cg02696742	chr7:106810147	HBP1	0.71	5.89	0.47	3.42e-8	Osteoarthritis;
TGCT	cis	rs3733585	0.699	rs7694997	chr4:9947811	A/G	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.42	-0.55	1.62e-11	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7666738	0.830	rs9307218	chr4:99024885	T/C	cg17366294	chr4:99064904	C4orf37	0.72	7.54	0.56	8.52e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7666738	0.546	rs10440329	chr4:98903735	C/T	cg17366294	chr4:99064904	C4orf37	0.63	5.54	0.45	1.72e-7	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs2832077	0.527	rs59730679	chr21:30226244	T/C	cg14791747	chr16:20752902	THUMPD1	1.09	12.67	0.75	4.09e-24	Cognitive test performance;
TGCT	cis	rs66887589	0.616	rs11731675	chr4:120212514	T/C	cg24670566	chr4:120433619	PDE5A	0.21	4.57	0.38	1.15e-5	Diastolic blood pressure;
TGCT	cis	rs7666738	0.830	rs2865951	chr4:99040191	C/T	cg17366294	chr4:99064904	C4orf37	0.72	7.36	0.55	2.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs782590	0.902	rs7582278	chr2:55742924	C/G	cg03859395	chr2:55845619	SMEK2	0.93	11.51	0.72	2.7e-21	Metabolic syndrome;
TGCT	cis	rs11249608	0.636	rs13359549	chr5:178449178	T/A	cg21905437	chr5:178450457	ZNF879	0.45	4.48	0.37	1.67e-5	Pubertal anthropometrics;
TGCT	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg23758822	chr17:41437982	NA	0.71	6.94	0.53	1.89e-10	Menopause (age at onset);
TGCT	cis	rs17125944	0.505	rs75661138	chr14:53259262	G/A	cg00686598	chr14:53173677	PSMC6	1.08	6.32	0.49	4.37e-9	Alzheimer's disease (late onset);
TGCT	cis	rs11997175	0.574	rs9642707	chr8:33645789	C/G	ch.8.33884649F	chr8:33765107	NA	0.28	4.53	0.38	1.35e-5	Body mass index;
TGCT	cis	rs62012628	0.527	rs12438008	chr15:79084680	C/T	cg04896959	chr15:78267971	NA	-0.34	-5.85	-0.47	4.02e-8	Diastolic blood pressure;
TGCT	cis	rs7666738	0.830	rs4345191	chr4:98945408	A/G	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs13256369	0.851	rs12541477	chr8:8563895	G/A	cg17143192	chr8:8559678	CLDN23	0.57	5.35	0.43	4.09e-7	Obesity-related traits;
TGCT	cis	rs9921338	1.000	rs8055427	chr16:11436883	T/A	cg00044050	chr16:11439710	C16orf75	-0.87	-6.68	-0.51	7.32e-10	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs9733	0.569	rs11588404	chr1:150688529	C/A	cg09365446	chr1:150670422	GOLPH3L	0.3	4.52	0.38	1.4e-5	Tonsillectomy;
TGCT	cis	rs7312933	0.703	rs10459290	chr12:42613290	T/G	cg19980929	chr12:42632907	YAF2	0.43	5.72	0.46	7.48e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs7666738	0.830	rs35560671	chr4:99069095	G/A	cg05340658	chr4:99064831	C4orf37	0.52	5.79	0.46	5.32e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11690935	0.851	rs10174055	chr2:172858214	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.89	-7.88	-0.58	1.41e-12	Schizophrenia;
TGCT	cis	rs3617	0.573	rs9825230	chr3:52901974	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	5.09	0.42	1.29e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs11748023	0.605	rs185123	chr5:139517197	T/C	cg01081189	chr5:139537190	NA	0.26	4.6	0.38	1.05e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs4839421	0.966	rs6677767	chr1:111022475	C/T	cg06880108	chr1:111021908	CYMP	-0.16	-4.96	-0.41	2.29e-6	Response to bupropion in depression;
TGCT	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg09359103	chr1:154839909	KCNN3	-0.66	-12.15	-0.74	7.27e-23	Prostate cancer;
TGCT	cis	rs8077889	1.000	rs17674998	chr17:41879544	A/G	cg26893861	chr17:41843967	DUSP3	1.12	13.18	0.76	2.48e-25	Triglycerides;
TGCT	cis	rs7172809	0.573	rs28437977	chr15:77681453	C/T	cg22256960	chr15:77711686	NA	-0.5	-4.74	-0.39	5.82e-6	Glucose homeostasis traits;
TGCT	cis	rs3806843	0.521	rs192231	chr5:140248539	C/T	cg07102913	chr5:140593443	PCDHB13	0.47	4.54	0.38	1.29e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs1005277	0.522	rs200943	chr10:38148730	A/G	cg13531842	chr10:38383804	ZNF37A	-0.38	-4.55	-0.38	1.24e-5	Extrinsic epigenetic age acceleration;
TGCT	cis	rs921968	0.510	rs591573	chr2:219478193	C/T	cg02176678	chr2:219576539	TTLL4	0.48	6.79	0.52	4.05e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs1949733	1.000	rs2688233	chr4:8491885	T/C	cg13073564	chr4:8508604	NA	-0.5	-5.53	-0.44	1.84e-7	Response to antineoplastic agents;
TGCT	cis	rs2075371	0.933	rs2544191	chr7:133954248	A/G	cg11752832	chr7:134001865	SLC35B4	0.68	5.89	0.47	3.32e-8	Mean platelet volume;
TGCT	cis	rs12142240	0.698	rs56344958	chr1:46814518	G/A	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg18305652	chr10:134549665	INPP5A	0.34	5.84	0.46	4.32e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs12615966	0.858	rs17030286	chr2:105381220	T/G	cg16465502	chr2:105461796	NA	0.81	4.47	0.37	1.76e-5	Pancreatic cancer;
TGCT	cis	rs36051895	0.593	rs12682970	chr9:5168137	C/T	cg02405213	chr9:5042618	JAK2	-0.69	-8.7	-0.62	1.67e-14	Pediatric autoimmune diseases;
TGCT	cis	rs2692947	0.630	rs1168966	chr2:96798510	G/A	cg23100626	chr2:96804247	ASTL	0.41	5.03	0.41	1.65e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs3902035	0.964	rs17349301	chr6:119002581	A/T	cg07617317	chr6:118971624	C6orf204	-0.49	-5.7	-0.46	8.29e-8	QT interval;
TGCT	cis	rs11025559	0.617	rs11025592	chr11:20534286	T/C	cg19653624	chr11:20408972	PRMT3	-0.76	-6.64	-0.51	8.98e-10	Pursuit maintenance gain;
TGCT	cis	rs6003958	1	rs6003958	chr22:24264089	T/G	cg10150615	chr22:24372951	LOC391322	0.86	7.67	0.57	4.36e-12	S-phenylmercapturic acid levels in smokers;
TGCT	cis	rs2535633	0.631	rs11915851	chr3:53096047	C/T	cg10802521	chr3:52805072	NEK4	-0.5	-5.38	-0.43	3.6e-7	Body mass index;
TGCT	cis	rs9393692	0.875	rs9393690	chr6:26271713	A/T	cg13736514	chr6:26305472	NA	-0.39	-5.6	-0.45	1.31e-7	Educational attainment;
TGCT	cis	rs5750830	0.594	rs6001568	chr22:39775786	G/A	cg24399712	chr22:39784796	NA	-0.95	-11.19	-0.71	1.59e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg26116260	chr4:7069785	GRPEL1	1.13	11.1	0.71	2.59e-20	Monocyte percentage of white cells;
TGCT	cis	rs6484504	0.576	rs286653	chr11:31227824	C/T	cg26647111	chr11:31128758	NA	-0.34	-4.68	-0.39	7.25e-6	Red blood cell count;
TGCT	cis	rs7666738	0.830	rs13102652	chr4:99006737	T/G	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7000551	0.725	rs2469756	chr8:22360423	G/A	cg12081754	chr8:22256438	SLC39A14	0.28	4.6	0.38	1.04e-5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs9633740	0.773	rs1870148	chr10:82271341	G/A	cg01528321	chr10:82214614	TSPAN14	0.93	6.74	0.52	5.44e-10	Post bronchodilator FEV1;
TGCT	cis	rs922182	1.000	rs922182	chr15:64277642	C/T	cg02919090	chr15:64263738	DAPK2	0.29	5.44	0.44	2.72e-7	Blood protein levels;
TGCT	cis	rs34526934	0.608	rs13017511	chr2:177035395	A/G	cg16982199	chr2:177418664	NA	-0.48	-4.49	-0.37	1.58e-5	Obstructive sleep apnea trait (apnea hypopnea index);
TGCT	cis	rs1801251	1.000	rs2675974	chr2:233727071	A/G	cg08000102	chr2:233561755	GIGYF2	0.63	6.48	0.5	1.92e-9	Coronary artery disease;
TGCT	cis	rs2730245	0.527	rs712199	chr7:158662250	A/G	cg11984989	chr7:158649758	WDR60	0.98	7.84	0.58	1.81e-12	Height;
TGCT	cis	rs9393692	0.645	rs11756673	chr6:26323505	A/G	cg13736514	chr6:26305472	NA	-0.45	-6.67	-0.51	7.52e-10	Educational attainment;
TGCT	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg06238570	chr21:40685208	BRWD1	-0.79	-8.46	-0.6	6.28e-14	Cognitive function;
TGCT	trans	rs11082438	1.000	rs11082438	chr18:42865210	G/T	cg20111269	chr12:107972364	BTBD11	-0.88	-7.09	-0.54	8.76e-11	Follicular lymphoma;
TGCT	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg17054783	chr10:134559939	INPP5A	0.27	5.15	0.42	1e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	trans	rs1814175	0.727	rs2140597	chr11:49873946	G/A	cg03929089	chr4:120376271	NA	-0.72	-8.26	-0.6	1.84e-13	Height;
TGCT	cis	rs2233152	0.572	rs10403040	chr19:41296046	A/T	cg11601297	chr19:41224147	ITPKC;ADCK4	-0.49	-4.73	-0.39	5.94e-6	Kawasaki disease;
TGCT	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg24250549	chr1:154909240	PMVK	-0.66	-6.53	-0.51	1.51e-9	Prostate cancer;
TGCT	cis	rs77741769	0.571	rs11065300	chr12:121298512	G/C	cg02419362	chr12:121203948	SPPL3	0.19	4.49	0.37	1.63e-5	Mean corpuscular volume;
TGCT	cis	rs12681287	0.752	rs10104138	chr8:87247659	G/A	cg27223183	chr8:87520930	FAM82B	-0.81	-5.77	-0.46	5.91e-8	Caudate activity during reward;
TGCT	cis	rs2180341	0.597	rs11154397	chr6:127646649	G/C	cg27446573	chr6:127587934	RNF146	0.65	5.79	0.46	5.52e-8	Breast cancer;
TGCT	cis	rs17767294	0.708	rs72848769	chr6:27918379	G/A	cg08851530	chr6:28072375	NA	1.56	7.22	0.54	4.47e-11	Parkinson's disease;
TGCT	cis	rs10992471	0.603	rs11788523	chr9:95256593	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.6	-5.47	-0.44	2.4e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs72781680	0.846	rs72782114	chr2:24025740	G/A	cg08917208	chr2:24149416	ATAD2B	0.81	5.01	0.41	1.8e-6	Lymphocyte counts;
TGCT	cis	rs1153858	1.000	rs56850226	chr15:45633118	T/C	cg14582100	chr15:45693742	SPATA5L1	0.48	5.7	0.46	8.17e-8	Homoarginine levels;
TGCT	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg16423285	chr20:60520624	NA	0.61	6.55	0.51	1.39e-9	Body mass index;
TGCT	cis	rs9549367	0.789	rs34448227	chr13:113884754	A/C	cg18105134	chr13:113819100	PROZ	-0.34	-5.44	-0.44	2.75e-7	Platelet distribution width;
TGCT	cis	rs6570726	0.935	rs434298	chr6:145846873	G/A	cg23711669	chr6:146136114	FBXO30	0.67	6.41	0.5	2.7e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1008375	0.966	rs2098152	chr4:17684392	G/T	cg10189774	chr4:17578691	LAP3	0.52	4.71	0.39	6.54e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2075165	0.901	rs7542045	chr1:156246473	G/C	cg16558208	chr1:156270281	VHLL	0.27	4.83	0.4	3.87e-6	Tonsillectomy;
TGCT	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg17971929	chr21:40555470	PSMG1	0.95	9.18	0.64	1.22e-15	Cognitive function;
TGCT	cis	rs10193935	1.000	rs72796507	chr2:42409840	A/G	cg27598129	chr2:42591480	NA	-0.4	-5.15	-0.42	9.93e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7192750	0.617	rs9929256	chr16:72040032	A/C	cg14768367	chr16:72042858	DHODH	0.89	5.06	0.41	1.48e-6	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs6665290	0.835	rs11578479	chr1:227210888	A/T	cg10327440	chr1:227177885	CDC42BPA	-0.91	-16.3	-0.83	1.24e-32	Myeloid white cell count;
TGCT	cis	rs1577917	0.771	rs4351223	chr6:86237797	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.61	5.32	0.43	4.64e-7	Response to antipsychotic treatment;
TGCT	cis	rs8032315	0.965	rs1894400	chr15:91428955	C/T	cg05180856	chr15:91428056	FES	0.25	4.62	0.38	9.41e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg03161606	chr19:29218774	NA	0.6	5.84	0.46	4.28e-8	Methadone dose in opioid dependence;
TGCT	cis	rs763121	0.853	rs5750668	chr22:39079964	T/C	cg06022373	chr22:39101656	GTPBP1	0.74	7.28	0.55	3.38e-11	Menopause (age at onset);
TGCT	trans	rs3808502	0.563	rs12549150	chr8:11422936	C/T	cg15556689	chr8:8085844	FLJ10661	0.79	7.18	0.54	5.71e-11	Neuroticism;
TGCT	cis	rs208520	0.690	rs207081	chr6:66773742	A/G	cg07460842	chr6:66804631	NA	-0.96	-10.25	-0.68	3.18e-18	Exhaled nitric oxide output;
TGCT	cis	rs7635838	0.586	rs379241	chr3:11291565	G/A	cg00170343	chr3:11313890	ATG7	0.64	6.43	0.5	2.5e-9	HDL cholesterol;
TGCT	cis	rs1799949	0.794	rs116409325	chr17:41445460	C/A	cg10047753	chr17:41438598	NA	0.92	8.97	0.63	3.79e-15	Menopause (age at onset);
TGCT	cis	rs734999	0.572	rs3748816	chr1:2526746	A/G	cg18854424	chr1:2615690	NA	0.5	5.78	0.46	5.64e-8	Ulcerative colitis;
TGCT	cis	rs8072100	0.790	rs34200664	chr17:45744652	C/T	cg10024583	chr17:45772800	TBKBP1	-0.43	-4.47	-0.37	1.72e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs7772486	0.875	rs10457796	chr6:146416087	T/G	cg23711669	chr6:146136114	FBXO30	0.89	9.4	0.65	3.51e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7666738	0.830	rs9992391	chr4:98916052	G/A	cg18180107	chr4:99064573	C4orf37	0.53	4.99	0.41	1.98e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs78487399	0.808	rs114563746	chr2:43760880	T/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-4.81	-0.4	4.35e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-5.1	-0.42	1.23e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.4	-4.76	-0.39	5.24e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg10819733	chr22:24237672	NA	-0.28	-4.59	-0.38	1.09e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7666738	0.830	rs1967979	chr4:98966201	G/T	cg05340658	chr4:99064831	C4orf37	0.53	5.93	0.47	2.84e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs208520	1.000	rs12192261	chr6:66985268	A/G	cg07460842	chr6:66804631	NA	0.78	6.82	0.52	3.61e-10	Exhaled nitric oxide output;
TGCT	cis	rs2180341	0.782	rs6924274	chr6:127721556	T/A	cg27446573	chr6:127587934	RNF146	0.8	7.08	0.54	9.53e-11	Breast cancer;
TGCT	cis	rs9393777	0.513	rs7740197	chr6:26663478	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.62	5.71	0.46	7.95e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg21016266	chr12:122356598	WDR66	0.51	6.46	0.5	2.15e-9	Mean corpuscular volume;
TGCT	cis	rs651907	0.557	rs13066768	chr3:101486920	A/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.86	-10.23	-0.68	3.5e-18	Colorectal cancer;
TGCT	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg13342137	chr4:2252803	MXD4	0.17	4.59	0.38	1.07e-5	Obesity-related traits;
TGCT	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg06481639	chr22:41940642	POLR3H	0.75	6.64	0.51	8.81e-10	Vitiligo;
TGCT	cis	rs6570726	0.875	rs416243	chr6:145868081	A/T	cg23711669	chr6:146136114	FBXO30	0.71	7.03	0.53	1.25e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6424115	1.000	rs4649115	chr1:24155731	A/G	cg15997130	chr1:24165203	NA	-0.92	-10.57	-0.69	5.26e-19	Immature fraction of reticulocytes;
TGCT	cis	rs2677744	0.626	rs12905855	chr15:91498429	G/C	cg23684204	chr15:91497937	RCCD1	0.39	5.92	0.47	2.91e-8	Attention deficit hyperactivity disorder;
TGCT	cis	rs9611565	0.802	rs9611571	chr22:41784867	G/A	cg03806693	chr22:41940476	POLR3H	-1.01	-11.18	-0.71	1.71e-20	Vitiligo;
TGCT	cis	rs1023500	1.000	rs10154646	chr22:42331409	G/C	cg04692870	chr22:42525206	CYP2D6	-0.35	-5.27	-0.43	5.73e-7	Schizophrenia;
TGCT	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg06028808	chr11:68637592	NA	0.52	6.63	0.51	9.23e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg00149659	chr3:10157352	C3orf10	0.91	5.89	0.47	3.32e-8	Alzheimer's disease;
TGCT	cis	rs910316	0.967	rs4899549	chr14:75647494	G/A	cg08847533	chr14:75593920	NEK9	-0.91	-9.96	-0.67	1.56e-17	Height;
TGCT	cis	rs853679	0.546	rs483143	chr6:27846744	G/C	cg08798685	chr6:27730294	NA	-0.36	-5.06	-0.41	1.45e-6	Depression;
TGCT	cis	rs9814567	0.679	rs1880379	chr3:134330612	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-6.41	-0.5	2.8e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg01802117	chr1:53393560	SCP2	0.43	5.12	0.42	1.14e-6	Monocyte count;
TGCT	cis	rs9653442	0.712	rs7582731	chr2:100686486	T/C	cg22139774	chr2:100720529	AFF3	-0.43	-7.77	-0.57	2.58e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs4654899	0.833	rs12135548	chr1:21084367	G/A	cg01072550	chr1:21505969	NA	-0.49	-8.03	-0.59	6.29e-13	Superior frontal gyrus grey matter volume;
TGCT	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg03517284	chr6:25882590	NA	-0.68	-6.01	-0.47	1.94e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9467773	0.620	rs2504592	chr6:26640951	C/G	cg11502198	chr6:26597334	ABT1	0.54	4.87	0.4	3.4e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4891159	0.790	rs10514217	chr18:74144939	A/G	cg24786174	chr18:74118243	ZNF516	-0.46	-4.86	-0.4	3.49e-6	Longevity;
TGCT	cis	rs763014	0.898	rs4984897	chr16:632180	G/C	cg09263875	chr16:632152	PIGQ	0.3	6.4	0.5	2.88e-9	Height;
TGCT	cis	rs6496667	0.600	rs28674812	chr15:91077809	G/T	cg22089800	chr15:90895588	ZNF774	0.66	4.76	0.39	5.28e-6	Rheumatoid arthritis;
TGCT	cis	rs7772486	0.754	rs9497434	chr6:146260753	C/T	cg23711669	chr6:146136114	FBXO30	-0.89	-10.38	-0.68	1.54e-18	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs208520	0.507	rs7755710	chr6:66783355	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.09	-16.9	-0.84	5.6e-34	Exhaled nitric oxide output;
TGCT	trans	rs1974653	0.672	rs9606244	chr22:20082881	C/T	cg08822737	chr17:71088851	SLC39A11	-0.93	-7.61	-0.56	5.97e-12	Schizophrenia;
TGCT	cis	rs62244186	0.748	rs4682987	chr3:44674996	C/T	cg25151919	chr3:44754333	ZNF502	-0.4	-4.62	-0.38	9.54e-6	Depressive symptoms;
TGCT	cis	rs765787	0.530	rs2413776	chr15:45544170	A/G	cg24006582	chr15:45444508	DUOX1	-0.26	-5.61	-0.45	1.24e-7	Uric acid levels;
TGCT	cis	rs1008375	1.000	rs10027755	chr4:17615954	G/C	cg18681998	chr4:17616180	MED28	1.01	11.57	0.72	1.95e-21	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4664308	0.935	rs6731260	chr2:160977769	A/G	cg03641300	chr2:160917029	PLA2R1	-0.28	-6.94	-0.53	1.96e-10	Idiopathic membranous nephropathy;
TGCT	cis	rs7552404	1.000	rs11161510	chr1:76210289	A/G	cg22875332	chr1:76189707	ACADM	-0.78	-9.44	-0.65	2.8e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg23574427	chr4:122746245	BBS7;CCNA2	-0.34	-5.26	-0.43	6.07e-7	Type 2 diabetes;
TGCT	cis	rs2180341	0.814	rs6919082	chr6:127737888	T/G	cg27446573	chr6:127587934	RNF146	0.87	7.93	0.58	1.08e-12	Breast cancer;
TGCT	cis	rs950776	0.518	rs12591557	chr15:78811732	A/G	cg06917634	chr15:78832804	PSMA4	0.97	9.62	0.65	1.05e-16	Sudden cardiac arrest;
TGCT	cis	rs12602901	0.528	rs12601694	chr17:4980381	C/T	cg07834574	chr17:4802847	CHRNE;C17orf107	-0.46	-4.53	-0.38	1.36e-5	Blood metabolite levels;
TGCT	cis	rs76419734	0.558	rs4326019	chr4:106527381	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.82	4.66	0.39	7.91e-6	Post bronchodilator FEV1;
TGCT	cis	rs4631830	0.900	rs10763588	chr10:51539762	G/T	cg10326726	chr10:51549505	MSMB	-0.26	-5.3	-0.43	5.07e-7	Prostate-specific antigen levels;
TGCT	cis	rs7829975	0.902	rs777707	chr8:8584344	A/G	cg08975724	chr8:8085496	FLJ10661	0.51	4.53	0.38	1.38e-5	Mood instability;
TGCT	cis	rs17376456	0.542	rs1982439	chr5:93160560	C/G	cg25358565	chr5:93447407	FAM172A	-0.75	-6.28	-0.49	5.26e-9	Diabetic retinopathy;
TGCT	cis	rs7772486	0.806	rs4243478	chr6:146284560	A/G	cg05347473	chr6:146136440	FBXO30	-0.55	-5.41	-0.44	3.16e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.01	0.41	1.86e-6	Prudent dietary pattern;
TGCT	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg00684032	chr4:1343700	KIAA1530	0.21	4.53	0.38	1.39e-5	Obesity-related traits;
TGCT	cis	rs9902453	1.000	rs9896062	chr17:28357047	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-6.56	-0.51	1.3e-9	Coffee consumption (cups per day);
TGCT	cis	rs74233809	0.636	rs284861	chr10:104572276	A/G	cg05855489	chr10:104503620	C10orf26	-0.73	-4.99	-0.41	1.96e-6	Birth weight;
TGCT	cis	rs3820068	0.677	rs72643691	chr1:15856251	T/C	cg05660106	chr1:15850417	CASP9	1.16	14.82	0.8	3.11e-29	Systolic blood pressure;
TGCT	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg04944784	chr2:26401820	FAM59B	0.76	6.24	0.49	6.46e-9	Gut microbiome composition (summer);
TGCT	cis	rs644799	0.610	rs1255179	chr11:95472097	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.51	5.05	0.41	1.55e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7772486	0.790	rs3924499	chr6:146232978	A/T	cg23711669	chr6:146136114	FBXO30	-0.87	-10.04	-0.67	1.01e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs208520	0.754	rs7753158	chr6:66875633	A/C	cg07460842	chr6:66804631	NA	-0.88	-8.65	-0.61	2.21e-14	Exhaled nitric oxide output;
TGCT	cis	rs3780378	0.935	rs6476939	chr9:5084837	T/A	cg03508284	chr9:4985524	JAK2	-0.49	-4.6	-0.38	1.03e-5	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg08045932	chr20:61659980	NA	0.49	9.25	0.64	8.42e-16	Prostate cancer (SNP x SNP interaction);
TGCT	trans	rs7618501	0.933	rs1128535	chr3:49866392	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	1.03	13.16	0.76	2.65e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs6545883	0.929	rs1186711	chr2:61688505	T/C	cg15711740	chr2:61764176	XPO1	-0.6	-5.5	-0.44	2.03e-7	Tuberculosis;
TGCT	cis	rs4699052	0.635	rs6821137	chr4:104246093	G/C	cg16532752	chr4:104119610	CENPE	-0.55	-5.43	-0.44	2.87e-7	Testicular germ cell tumor;
TGCT	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg04154034	chr17:28927549	LRRC37B2	0.74	4.56	0.38	1.22e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs2073300	1.000	rs6137983	chr20:23469465	C/A	cg09953122	chr20:23471693	CST8	-0.7	-4.76	-0.39	5.31e-6	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs7647973	0.731	rs7617480	chr3:49210732	G/T	cg05785598	chr3:49045655	WDR6	-0.45	-4.98	-0.41	2.1e-6	Menarche (age at onset);
TGCT	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	6.14	0.48	1.03e-8	Bipolar disorder;
TGCT	cis	rs554111	0.656	rs12567861	chr1:21395133	C/T	cg01072550	chr1:21505969	NA	0.36	5.46	0.44	2.51e-7	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs7666738	0.830	rs13118945	chr4:98968586	T/G	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.93	7.44	0.56	1.44e-11	Platelet count;
TGCT	cis	rs1150668	0.764	rs9368565	chr6:28345210	C/T	cg19488431	chr6:28601329	NA	-0.2	-4.51	-0.38	1.49e-5	Pubertal anthropometrics;
TGCT	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg04267008	chr7:1944627	MAD1L1	-0.38	-5.0	-0.41	1.94e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs2290402	0.536	rs4690204	chr4:881195	C/T	cg23332689	chr4:987652	IDUA;SLC26A1	0.33	5.0	0.41	1.94e-6	Type 2 diabetes;
TGCT	cis	rs4849845	0.653	rs3933618	chr2:121035552	T/G	cg24070213	chr2:121070622	NA	0.35	4.64	0.38	8.58e-6	Mean platelet volume;
TGCT	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg06618935	chr21:46677482	NA	-0.35	-5.44	-0.44	2.72e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs12477438	0.798	rs4622780	chr2:99631760	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-5.75	-0.46	6.58e-8	Chronic sinus infection;
TGCT	cis	rs9467773	1.000	rs1321480	chr6:26532742	A/G	cg15659132	chr6:26577336	NA	0.86	12.18	0.74	6.18e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg17971929	chr21:40555470	PSMG1	0.98	9.65	0.65	9.11e-17	Cognitive function;
TGCT	cis	rs13242816	1.000	rs2188243	chr7:116109293	G/A	cg16553024	chr7:116138462	CAV2	-0.44	-4.53	-0.38	1.34e-5	P wave duration;
TGCT	cis	rs6671200	1.000	rs60929805	chr1:95646386	C/T	cg20701556	chr1:95698924	RWDD3	0.65	5.58	0.45	1.43e-7	Stearic acid (18:0) levels;
TGCT	cis	rs9911578	0.967	rs4076229	chr17:56937256	C/T	cg12560992	chr17:57184187	TRIM37	0.76	9.21	0.64	1.03e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs908922	0.676	rs11205018	chr1:152496249	T/G	cg20991723	chr1:152506922	NA	0.46	6.26	0.49	5.7e-9	Hair morphology;
TGCT	cis	rs2204008	0.774	rs11616004	chr12:38278822	G/A	cg26384229	chr12:38710491	ALG10B	0.86	7.48	0.56	1.17e-11	Bladder cancer;
TGCT	cis	rs3741404	0.620	rs11231722	chr11:63967770	C/G	cg00022866	chr11:64108440	CCDC88B	0.24	4.54	0.38	1.29e-5	Platelet count;
TGCT	cis	rs2439831	0.571	rs689883	chr15:43812596	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	5.3	0.43	5.23e-7	Lung cancer in ever smokers;
TGCT	trans	rs12191082	0.591	rs12664748	chr6:46913149	T/G	cg15621338	chr7:128577916	IRF5	-1.27	-7.2	-0.54	5.04e-11	Mean platelet volume;
TGCT	cis	rs7213347	0.611	rs1231207	chr17:2125450	A/C	cg13315690	chr17:1944831	OVCA2;DPH1	-0.38	-4.83	-0.4	3.98e-6	Total body bone mineral density;
TGCT	cis	rs7772486	0.558	rs9376965	chr6:146130055	G/A	cg23711669	chr6:146136114	FBXO30	0.73	6.75	0.52	5.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6460942	0.730	rs7780477	chr7:12233750	G/C	cg06484146	chr7:12443880	VWDE	-0.54	-4.76	-0.39	5.21e-6	Coronary artery disease;
TGCT	cis	rs11249608	0.548	rs7733072	chr5:178456007	A/G	cg01312482	chr5:178451176	ZNF879	-0.48	-4.77	-0.39	5.15e-6	Pubertal anthropometrics;
TGCT	trans	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg13615516	chr5:77269221	NA	0.68	8.54	0.61	3.97e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7681440	0.904	rs6817001	chr4:90766019	C/T	cg20003494	chr4:90757398	SNCA	-0.62	-5.93	-0.47	2.74e-8	Dementia with Lewy bodies;
TGCT	cis	rs2019216	0.542	rs8073228	chr17:21909838	C/G	cg22648282	chr17:21454238	C17orf51	-0.59	-5.89	-0.47	3.46e-8	Pelvic organ prolapse;
TGCT	cis	rs59698941	0.527	rs7719428	chr5:132180919	C/G	cg27099455	chr5:132201840	GDF9;UQCRQ	-0.29	-4.93	-0.4	2.59e-6	Apolipoprotein A-IV levels;
TGCT	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg11494091	chr17:61959527	GH2	0.42	7.46	0.56	1.29e-11	Height;
TGCT	cis	rs9325144	0.624	rs7979541	chr12:39129679	T/C	cg26384229	chr12:38710491	ALG10B	-0.62	-5.85	-0.47	4.06e-8	Morning vs. evening chronotype;
TGCT	cis	rs2816062	0.786	rs735946	chr1:18901323	T/C	cg18795169	chr1:18902165	NA	-0.6	-13.84	-0.78	6.55e-27	Urate levels in lean individuals;
TGCT	cis	rs6570726	0.791	rs408443	chr6:145874643	T/C	cg05347473	chr6:146136440	FBXO30	0.54	5.15	0.42	1.01e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10789207	0.672	rs17472890	chr1:66991492	A/T	cg22855438	chr1:67395917	MIER1	0.64	4.53	0.38	1.38e-5	Resting heart rate;
TGCT	cis	rs17767294	0.708	rs72848760	chr6:27886877	T/A	cg08851530	chr6:28072375	NA	1.56	7.22	0.54	4.47e-11	Parkinson's disease;
TGCT	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.96	7.8	0.57	2.16e-12	Platelet count;
TGCT	cis	rs35883536	0.528	rs10783138	chr1:101031061	C/T	cg10298815	chr1:101004474	GPR88	0.25	4.68	0.39	7.46e-6	Monocyte count;
TGCT	cis	rs7267979	1.000	rs4815411	chr20:25350223	A/G	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg06634786	chr22:41940651	POLR3H	0.89	8.55	0.61	3.83e-14	Vitiligo;
TGCT	cis	rs6964587	1.000	rs2075881	chr7:91734552	T/C	cg17063962	chr7:91808500	NA	0.88	9.58	0.65	1.33e-16	Breast cancer;
TGCT	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg10047753	chr17:41438598	NA	0.96	9.49	0.65	2.15e-16	Menopause (age at onset);
TGCT	trans	rs1496653	0.602	rs35587590	chr3:23344579	T/C	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs2013441	0.965	rs9896221	chr17:20180337	G/A	cg18979559	chr17:20280153	CCDC144C	-0.45	-4.67	-0.39	7.61e-6	Obesity-related traits;
TGCT	cis	rs10875746	0.903	rs10875738	chr12:48473739	T/A	cg20731937	chr12:48336164	NA	0.62	4.95	0.41	2.36e-6	Longevity (90 years and older);
TGCT	cis	rs9486715	0.867	rs4598081	chr6:96975227	A/G	cg06623918	chr6:96969491	KIAA0776	1.09	15.75	0.82	2.31e-31	Headache;
TGCT	cis	rs2718812	0.766	rs11924101	chr3:133394478	T/G	cg08048268	chr3:133502702	NA	-0.38	-4.7	-0.39	6.68e-6	Iron status biomarkers;
TGCT	cis	rs11098499	0.754	rs938056	chr4:120237453	C/T	cg09307838	chr4:120376055	NA	0.57	5.25	0.43	6.47e-7	Corneal astigmatism;
TGCT	cis	rs950169	0.887	rs71395453	chr15:85113490	G/C	cg12863693	chr15:85201151	NMB	0.39	4.44	0.37	1.99e-5	Schizophrenia;
TGCT	cis	rs473651	0.935	rs10170056	chr2:239339291	G/C	cg18131467	chr2:239335373	ASB1	0.95	9.87	0.66	2.62e-17	Multiple system atrophy;
TGCT	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.0	-7.42	-0.55	1.64e-11	Gut microbiome composition (summer);
TGCT	cis	rs72634258	0.554	rs12745962	chr1:7919825	C/T	cg26816564	chr1:7831052	VAMP3	0.64	4.94	0.41	2.46e-6	Inflammatory bowel disease;
TGCT	cis	rs28927680	0.655	rs11820589	chr11:116633862	G/A	cg01124546	chr11:117515332	DSCAML1	-0.45	-4.81	-0.4	4.27e-6	Lipid traits;Triglycerides;
TGCT	cis	rs7666738	0.830	rs13138051	chr4:99050367	C/T	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg11764359	chr7:65958608	NA	-0.57	-5.12	-0.42	1.12e-6	Aortic root size;
TGCT	cis	rs4455778	0.659	rs7795168	chr7:49057274	T/C	cg26309511	chr7:48887640	NA	0.44	5.12	0.42	1.13e-6	Lung cancer in never smokers;
TGCT	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs12681287	0.547	rs4961197	chr8:87512436	T/C	cg27223183	chr8:87520930	FAM82B	-0.95	-6.95	-0.53	1.81e-10	Caudate activity during reward;
TGCT	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg23302884	chr18:44338147	ST8SIA5	-0.4	-4.61	-0.38	9.88e-6	Personality dimensions;
TGCT	cis	rs7173389	0.867	rs74022964	chr15:73677264	C/T	cg02916102	chr15:74658244	CYP11A1	-0.81	-4.56	-0.38	1.19e-5	Resting heart rate;
TGCT	cis	rs9457247	1.000	rs409356	chr6:167405226	T/A	cg23791538	chr6:167370224	RNASET2	-0.49	-4.96	-0.41	2.26e-6	Crohn's disease;
TGCT	cis	rs7267979	1.000	rs422424	chr20:25445446	G/C	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs61990749	0.597	rs8016447	chr14:78222068	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	0.67	4.73	0.39	6.09e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs911555	0.655	rs10149470	chr14:104017953	A/G	cg12935359	chr14:103987150	CKB	-0.31	-4.59	-0.38	1.06e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs2933343	1.000	rs876756	chr3:128627623	G/A	cg11901034	chr3:128598214	ACAD9	-0.63	-5.13	-0.42	1.08e-6	IgG glycosylation;
TGCT	cis	rs7845219	0.539	rs13271644	chr8:95853948	A/G	cg16049864	chr8:95962084	TP53INP1	-0.55	-6.3	-0.49	4.83e-9	Type 2 diabetes;
TGCT	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg03388025	chr16:89894329	SPIRE2	0.48	8.33	0.6	1.26e-13	Vitiligo;
TGCT	cis	rs2594989	0.887	rs7624357	chr3:11412882	C/G	cg00170343	chr3:11313890	ATG7	0.63	4.72	0.39	6.17e-6	Circulating chemerin levels;
TGCT	cis	rs2235649	0.585	rs7201108	chr16:1940283	G/C	cg02432467	chr16:1963432	HS3ST6	-0.33	-5.11	-0.42	1.18e-6	Blood metabolite levels;
TGCT	trans	rs8073060	0.533	rs178736	chr17:33928158	G/T	cg19694781	chr19:47549865	TMEM160	-0.6	-13.04	-0.76	5.29e-25	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs9914544	0.545	rs3826380	chr17:18793225	A/G	cg26378065	chr17:18585709	ZNF286B	0.53	4.63	0.38	9.01e-6	Educational attainment (years of education);
TGCT	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg10560079	chr2:191398806	TMEM194B	0.38	5.53	0.45	1.77e-7	Pulse pressure;
TGCT	cis	rs73001065	0.892	rs58542926	chr19:19379549	C/T	cg03709012	chr19:19516395	GATAD2A	1.05	4.86	0.4	3.45e-6	LDL cholesterol;
TGCT	cis	rs35306767	1.000	rs35306767	chr10:989437	A/T	cg26597838	chr10:835615	NA	0.61	8.05	0.59	5.89e-13	Eosinophil percentage of granulocytes;
TGCT	cis	rs9467603	0.800	rs1892252	chr6:25772639	C/G	cg27579711	chr6:26172931	NA	0.65	4.9	0.4	2.97e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4713118	0.699	rs200969	chr6:27859453	T/C	cg18675097	chr6:28227127	NKAPL	-0.35	-4.61	-0.38	9.67e-6	Parkinson's disease;
TGCT	cis	rs10883723	0.810	rs11191304	chr10:104255284	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs2456568	0.802	rs7101791	chr11:93638998	A/G	cg26875233	chr11:93583750	C11orf90	-0.48	-6.47	-0.5	2.09e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	6.18	0.49	8.58e-9	Bipolar disorder;
TGCT	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.04	11.55	0.72	2.13e-21	Height;
TGCT	cis	rs2239547	0.522	rs2581780	chr3:53058960	C/T	cg10802521	chr3:52805072	NEK4	0.62	5.53	0.44	1.85e-7	Schizophrenia;
TGCT	trans	rs2727020	0.894	rs1880438	chr11:49370698	A/G	cg03929089	chr4:120376271	NA	-0.67	-6.99	-0.53	1.52e-10	Coronary artery disease;
TGCT	cis	rs9549367	0.713	rs3024744	chr13:113821477	A/C	cg09473364	chr13:112927190	NA	-0.3	-4.47	-0.37	1.71e-5	Platelet distribution width;
TGCT	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg03351412	chr1:154909251	PMVK	0.53	4.93	0.4	2.6e-6	Prostate cancer;
TGCT	cis	rs2235642	0.685	rs2667681	chr16:1653206	C/T	cg07639376	chr16:1584516	IFT140;TMEM204	-0.29	-4.97	-0.41	2.22e-6	Coronary artery disease;
TGCT	cis	rs2307449	0.964	rs758130	chr15:89873797	A/G	cg01877814	chr15:89879097	POLG	0.32	4.55	0.38	1.26e-5	Menopause (age at onset);
TGCT	cis	rs7959452	0.868	rs12812860	chr12:69746671	T/C	cg14784868	chr12:69753453	YEATS4	0.7	7.22	0.54	4.55e-11	Blood protein levels;
TGCT	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg06873352	chr17:61820015	STRADA	0.58	6.36	0.5	3.51e-9	Prudent dietary pattern;
TGCT	cis	rs7221109	0.560	rs758630	chr17:38869305	T/A	cg07480653	chr17:39868082	GAST	-0.24	-5.09	-0.42	1.3e-6	Type 1 diabetes;
TGCT	cis	rs6582630	0.519	rs11514078	chr12:38408817	G/C	cg13010199	chr12:38710504	ALG10B	0.67	5.35	0.43	4.04e-7	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs7208859	0.673	rs61348930	chr17:29221763	C/T	cg18442181	chr17:29233375	C17orf42	-0.78	-4.61	-0.38	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg12756686	chr19:29218302	NA	0.77	6.61	0.51	1.01e-9	Methadone dose in opioid dependence;
TGCT	cis	rs7308116	0.967	rs10778578	chr12:108190020	T/C	cg19508191	chr12:109124361	CORO1C	-0.46	-4.6	-0.38	1.04e-5	Pelvic organ prolapse (moderate/severe);
TGCT	cis	rs68170813	0.559	rs12537011	chr7:107027833	G/A	cg02696742	chr7:106810147	HBP1	-0.68	-5.44	-0.44	2.69e-7	Coronary artery disease;
TGCT	cis	rs1801251	1.000	rs12990821	chr2:233617585	C/G	cg25237894	chr2:233734115	C2orf82	0.33	5.95	0.47	2.53e-8	Coronary artery disease;
TGCT	cis	rs13242816	1.000	rs62471189	chr7:116101588	G/A	cg02799643	chr7:116139180	CAV2	-0.44	-5.12	-0.42	1.11e-6	P wave duration;
TGCT	cis	rs910316	1.000	rs12889472	chr14:75543979	A/G	cg23033748	chr14:75592666	NEK9	0.28	4.76	0.39	5.28e-6	Height;
TGCT	cis	rs11785400	1.000	rs4736342	chr8:143735190	A/G	cg10596483	chr8:143751796	JRK	0.55	5.94	0.47	2.68e-8	Schizophrenia;
TGCT	cis	rs12765878	1.000	rs35223321	chr10:105646395	C/T	cg11005552	chr10:105648138	OBFC1	0.44	7.69	0.57	4.01e-12	Coronary artery disease;
TGCT	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs6089829	0.925	rs4809270	chr20:61676709	C/A	cg03213289	chr20:61660250	NA	0.73	9.58	0.65	1.31e-16	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7208859	0.623	rs383436	chr17:28959179	A/G	cg14008862	chr17:28927542	LRRC37B2	0.88	5.32	0.43	4.75e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs796364	0.616	rs2103094	chr2:200687954	T/C	cg17644776	chr2:200775616	C2orf69	0.35	4.96	0.41	2.29e-6	Schizophrenia;
TGCT	cis	rs7017914	0.905	rs2639898	chr8:71920310	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.55	-5.05	-0.41	1.52e-6	Bone mineral density;
TGCT	cis	rs1475911	1.000	rs12482477	chr21:43517233	T/A	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.24	-4.79	-0.4	4.7e-6	IgG glycosylation;
TGCT	cis	rs6088580	0.634	rs4258875	chr20:32924895	C/A	cg06115741	chr20:33292138	TP53INP2	-0.55	-4.84	-0.4	3.85e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs1971762	0.545	rs9788134	chr12:54046067	A/T	cg16917193	chr12:54089295	NA	1.07	11.43	0.72	4.28e-21	Height;
TGCT	cis	rs7095607	0.606	rs7100561	chr10:69958472	G/A	cg18986048	chr10:69913749	MYPN	0.57	5.92	0.47	2.89e-8	Lung function (FVC);
TGCT	cis	rs6430585	0.528	rs3112496	chr2:136711064	C/T	cg07169764	chr2:136633963	MCM6	1.21	11.87	0.73	3.62e-22	Corneal structure;
TGCT	cis	rs2730245	0.527	rs2527187	chr7:158716912	T/C	cg11984989	chr7:158649758	WDR60	-1.01	-7.88	-0.58	1.4e-12	Height;
TGCT	cis	rs709400	0.663	rs55723020	chr14:103991401	G/A	cg12935359	chr14:103987150	CKB	-0.39	-5.77	-0.46	5.87e-8	Body mass index;
TGCT	cis	rs617219	0.710	rs10474578	chr5:78542290	T/C	cg09550809	chr5:78407562	BHMT	0.37	5.24	0.43	6.65e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs10927875	0.722	rs6696912	chr1:16338474	T/C	cg14742211	chr1:16348397	CLCNKA	0.19	4.53	0.38	1.37e-5	Dilated cardiomyopathy;
TGCT	cis	rs4906332	0.966	rs35799018	chr14:103893475	G/A	cg26031613	chr14:104095156	KLC1	-0.54	-4.82	-0.4	4.04e-6	Coronary artery disease;
TGCT	cis	rs752092	1.000	rs8033360	chr15:101778710	C/A	cg25114630	chr15:101792522	CHSY1	0.57	5.54	0.45	1.71e-7	Corneal structure;
TGCT	cis	rs208520	0.690	rs9345764	chr6:66820597	C/T	cg07460842	chr6:66804631	NA	-0.96	-9.89	-0.66	2.33e-17	Exhaled nitric oxide output;
TGCT	cis	rs1018836	0.923	rs4735230	chr8:91574184	G/C	cg16814680	chr8:91681699	NA	-0.9	-9.91	-0.66	2.06e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs66569888	0.507	rs17032699	chr2:106886471	A/G	cg16099169	chr2:106886729	NA	-0.48	-6.16	-0.48	9.37e-9	Facial morphology (factor 23);
TGCT	cis	rs2115630	1.000	rs10220733	chr15:85280864	G/A	cg12501888	chr15:85177176	SCAND2	-0.48	-4.49	-0.37	1.6e-5	P wave terminal force;
TGCT	cis	rs1371867	0.726	rs1660333	chr8:101309989	A/G	cg00191853	chr8:101177733	SPAG1	-0.23	-4.72	-0.39	6.15e-6	Atrioventricular conduction;
TGCT	cis	rs12477438	0.765	rs12468807	chr2:99691994	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-5.87	-0.47	3.74e-8	Chronic sinus infection;
TGCT	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg17054783	chr10:134559939	INPP5A	0.27	5.24	0.43	6.75e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs9300255	0.602	rs1727313	chr12:123640853	C/G	cg00376283	chr12:123451042	ABCB9	0.72	4.96	0.41	2.31e-6	Neutrophil percentage of white cells;
TGCT	cis	rs7772486	0.558	rs702322	chr6:146007166	G/A	cg05347473	chr6:146136440	FBXO30	-0.65	-6.11	-0.48	1.17e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg23248424	chr5:179741104	GFPT2	0.37	7.04	0.53	1.16e-10	Height;
TGCT	trans	rs66573146	1.000	rs73088528	chr4:6967747	G/C	cg07817883	chr1:32538562	TMEM39B	1.56	8.31	0.6	1.45e-13	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg10047753	chr17:41438598	NA	-0.74	-7.09	-0.54	8.78e-11	Menopause (age at onset);
TGCT	cis	rs1865760	0.566	rs7772312	chr6:26049616	G/C	cg16482183	chr6:26056742	HIST1H1C	0.58	4.98	0.41	2.12e-6	Height;
TGCT	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-1.06	-14.78	-0.8	3.86e-29	Menarche (age at onset);
TGCT	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg26338869	chr17:61819248	STRADA	-0.55	-5.08	-0.41	1.37e-6	Prudent dietary pattern;
TGCT	cis	rs7917772	0.503	rs7068535	chr10:104349127	C/T	cg05855489	chr10:104503620	C10orf26	-0.61	-5.41	-0.44	3.16e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9372498	0.505	rs9320655	chr6:118830981	T/C	cg21191810	chr6:118973309	C6orf204	-0.37	-4.79	-0.39	4.73e-6	Diastolic blood pressure;
TGCT	trans	rs57221529	0.766	rs4527146	chr5:555236	A/G	cg25482853	chr8:67687455	SGK3	1.2	10.19	0.68	4.33e-18	Lung disease severity in cystic fibrosis;
TGCT	cis	rs12701220	0.690	rs10243973	chr7:1064983	T/C	cg07217954	chr7:1067459	C7orf50	-0.47	-4.57	-0.38	1.14e-5	Bronchopulmonary dysplasia;
TGCT	cis	rs6500602	0.627	rs934929	chr16:4587789	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	-0.26	-4.76	-0.39	5.38e-6	Schizophrenia;
TGCT	cis	rs526231	0.926	rs35805	chr5:102673133	G/C	cg05225461	chr5:102596755	C5orf30	0.24	4.5	0.37	1.52e-5	Primary biliary cholangitis;
TGCT	cis	rs2046867	0.862	rs11922794	chr3:72813582	G/C	cg25664220	chr3:72788482	NA	-0.54	-6.81	-0.52	3.77e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs208520	1.000	rs72884033	chr6:66995747	T/C	cg07460842	chr6:66804631	NA	0.8	6.98	0.53	1.61e-10	Exhaled nitric oxide output;
TGCT	cis	rs7937682	0.961	rs11601674	chr11:111634354	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.2	-11.44	-0.72	3.93e-21	Primary sclerosing cholangitis;
TGCT	cis	rs939658	0.805	rs2177056	chr15:79441489	T/C	cg17916960	chr15:79447300	NA	-0.49	-7.41	-0.55	1.73e-11	Refractive error;
TGCT	cis	rs3796352	1.000	rs11713859	chr3:53042080	C/A	cg07884673	chr3:53033167	SFMBT1	0.64	6.39	0.5	3.03e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs8013055	0.796	rs11628497	chr14:105970789	C/T	cg23356831	chr14:105996513	TMEM121	0.4	6.29	0.49	5.05e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs2455799	0.613	rs13080145	chr3:15880060	C/G	cg16303742	chr3:15540471	COLQ	-0.25	-4.74	-0.39	5.76e-6	Mean platelet volume;
TGCT	cis	rs2842992	0.750	rs2758354	chr6:160125854	A/G	cg11366901	chr6:160182831	ACAT2	1.01	6.75	0.52	5.02e-10	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs7267979	1.000	rs1888999	chr20:25291848	C/T	cg03522245	chr20:25566470	NINL	0.6	6.49	0.5	1.87e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9914988	1.000	rs6803	chr17:27187789	C/T	cg20469991	chr17:27169893	C17orf63	0.69	5.05	0.41	1.51e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs2404602	0.735	rs56246286	chr15:76690731	C/T	cg22467129	chr15:76604101	ETFA	0.49	5.06	0.41	1.5e-6	Blood metabolite levels;
TGCT	cis	rs3617	0.591	rs2276823	chr3:52869263	C/A	cg05573699	chr3:52720067	GNL3;PBRM1	0.49	4.7	0.39	6.91e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2692947	0.550	rs4613327	chr2:96583823	G/A	cg13655245	chr2:97463316	CNNM4	0.15	4.51	0.38	1.48e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs7949030	0.591	rs35156678	chr11:62369881	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.64	9.48	0.65	2.35e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9500256	0.903	rs726783	chr6:58332861	A/C	cg16251399	chr6:58287822	GUSBL2	0.66	6.02	0.48	1.82e-8	Eosinophilic esophagitis (pediatric);
TGCT	cis	rs7944584	0.632	rs749067	chr11:47318157	T/C	cg20307385	chr11:47447363	PSMC3	0.79	7.89	0.58	1.37e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
TGCT	cis	rs6459788	0.720	rs11974772	chr7:157250645	G/A	cg06271696	chr7:157225062	NA	-0.28	-4.95	-0.41	2.37e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs6964587	0.904	rs6465339	chr7:91570790	T/A	cg17063962	chr7:91808500	NA	-0.91	-9.71	-0.66	6.35e-17	Breast cancer;
TGCT	cis	rs3784262	1.000	rs7495968	chr15:58244103	C/G	cg12031962	chr15:58353849	ALDH1A2	0.49	7.5	0.56	1.08e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs2439831	0.867	rs7170489	chr15:43636651	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	8.65	0.61	2.26e-14	Lung cancer in ever smokers;
TGCT	cis	rs10992471	0.603	rs1980848	chr9:95248571	A/G	cg14631576	chr9:95140430	CENPP	0.3	4.49	0.37	1.63e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg10802521	chr3:52805072	NEK4	-0.78	-10.0	-0.67	1.26e-17	Electroencephalogram traits;
TGCT	cis	rs7914558	1.000	rs7920251	chr10:104950197	C/T	cg05855489	chr10:104503620	C10orf26	0.52	4.59	0.38	1.06e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs9611565	0.694	rs5758411	chr22:42079734	G/A	cg03806693	chr22:41940476	POLR3H	0.97	9.76	0.66	4.74e-17	Vitiligo;
TGCT	cis	rs17331151	0.573	rs2240916	chr3:52859212	T/A	cg07884673	chr3:53033167	SFMBT1	0.5	5.97	0.47	2.3e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs1801251	1.000	rs6747645	chr2:233571033	C/T	cg08000102	chr2:233561755	GIGYF2	-0.64	-6.67	-0.51	7.63e-10	Coronary artery disease;
TGCT	cis	rs7226408	0.948	rs72883588	chr18:34390473	T/C	cg06757138	chr18:34340585	FHOD3	0.26	4.79	0.4	4.62e-6	Obesity-related traits;
TGCT	cis	rs12220238	1.000	rs7905536	chr10:75997209	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.24	0.55	4.07e-11	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs9359856	0.510	rs2748298	chr6:90436877	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.45	-4.66	-0.39	7.9e-6	Bipolar disorder;
TGCT	cis	rs34546498	1	rs34546498	chr6:26961280	C/T	cg16898833	chr6:26189333	HIST1H4D	1.37	6.2	0.49	7.83e-9	Breast cancer;
TGCT	cis	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg20637647	chr7:64974828	NA	0.89	4.95	0.41	2.37e-6	Diabetic kidney disease;
TGCT	cis	rs1799949	0.965	rs4792989	chr17:41437552	T/C	cg23758822	chr17:41437982	NA	0.68	6.37	0.5	3.42e-9	Menopause (age at onset);
TGCT	cis	rs9611565	0.592	rs4822044	chr22:41979668	G/C	cg06481639	chr22:41940642	POLR3H	-0.77	-6.69	-0.51	6.88e-10	Vitiligo;
TGCT	cis	rs208520	0.690	rs12198297	chr6:66714665	G/A	cg07460842	chr6:66804631	NA	0.95	10.11	0.67	6.77e-18	Exhaled nitric oxide output;
TGCT	cis	rs9611519	0.566	rs4821981	chr22:41415644	A/C	cg13695892	chr22:41940480	POLR3H	0.54	5.1	0.42	1.21e-6	Neuroticism;
TGCT	cis	rs7044106	0.537	rs10739573	chr9:123489818	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	5.55	0.45	1.62e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs10791097	0.694	rs4936123	chr11:130740967	G/A	cg12179176	chr11:130786555	SNX19	0.82	9.86	0.66	2.82e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs6952808	0.898	rs7799782	chr7:1868039	A/G	cg22963979	chr7:1858916	MAD1L1	0.32	5.0	0.41	1.88e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs614226	0.938	rs12857	chr12:120933946	T/G	cg01236616	chr12:121019343	POP5	1.25	13.58	0.77	2.71e-26	Type 1 diabetes nephropathy;
TGCT	cis	rs2292864	0.764	rs3892085	chr17:45340480	A/G	cg17233517	chr17:45285328	MYL4	0.37	4.79	0.39	4.76e-6	Left atrial antero-posterior diameter;
TGCT	trans	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg13615516	chr5:77269221	NA	0.68	8.54	0.61	3.97e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7804356	1.000	rs10486478	chr7:26819465	C/T	cg03456212	chr7:26904342	SKAP2	-0.59	-4.44	-0.37	1.93e-5	Type 1 diabetes;
TGCT	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg27170947	chr2:26402098	FAM59B	-0.4	-4.48	-0.37	1.7e-5	Gut microbiome composition (summer);
TGCT	trans	rs4650994	0.789	rs2761471	chr1:178599348	A/C	cg05059571	chr16:84539110	KIAA1609	0.4	7.44	0.56	1.49e-11	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs9650657	0.513	rs7005884	chr8:10796472	A/G	cg27411982	chr8:10470053	RP1L1	-0.22	-4.55	-0.38	1.26e-5	Neuroticism;
TGCT	trans	rs3780486	0.522	rs1328898	chr9:33163271	A/G	cg04842962	chr6:43655489	MRPS18A	0.8	8.67	0.61	2.02e-14	IgG glycosylation;
TGCT	cis	rs11018874	0.808	rs71471032	chr11:89888921	A/T	cg05041596	chr11:89867385	NAALAD2	0.54	4.9	0.4	2.97e-6	White blood cell types;
TGCT	cis	rs3008870	1.000	rs2815348	chr1:67472165	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.1	11.8	0.73	5.15e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs7020830	0.830	rs17487601	chr9:37213641	G/A	cg14294708	chr9:37120828	ZCCHC7	1.22	14.18	0.79	1.03e-27	Schizophrenia;
TGCT	trans	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg21659725	chr3:3221576	CRBN	0.69	7.72	0.57	3.29e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg10047753	chr17:41438598	NA	0.96	9.6	0.65	1.16e-16	Menopause (age at onset);
TGCT	cis	rs7511006	1.000	rs17836662	chr22:50672154	A/G	cg16473166	chr22:50639996	SELO	-0.62	-6.09	-0.48	1.29e-8	Obesity-related traits;
TGCT	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg04317338	chr11:64019027	PLCB3	0.77	6.33	0.49	4e-9	Mean platelet volume;
TGCT	cis	rs7542091	0.669	rs7540534	chr1:210044824	A/T	cg00989853	chr1:209979345	IRF6	0.43	4.58	0.38	1.12e-5	Monobrow;
TGCT	cis	rs72781680	0.898	rs72786278	chr2:24063243	C/T	cg08917208	chr2:24149416	ATAD2B	0.78	4.79	0.4	4.69e-6	Lymphocyte counts;
TGCT	cis	rs9393777	0.720	rs34864993	chr6:26970895	C/A	cg16898833	chr6:26189333	HIST1H4D	0.97	5.95	0.47	2.6e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs1729951	0.575	rs16844326	chr3:136678385	G/C	cg12473912	chr3:136751656	NA	0.39	6.18	0.49	8.36e-9	Neuroticism;
TGCT	cis	rs902774	0.530	rs12819597	chr12:53353956	T/C	cg05393297	chr12:53359155	NA	-0.85	-5.44	-0.44	2.73e-7	Prostate cancer;
TGCT	cis	rs2239547	0.603	rs71301807	chr3:53085475	C/G	cg10802521	chr3:52805072	NEK4	-0.54	-4.9	-0.4	2.99e-6	Schizophrenia;
TGCT	cis	rs826838	0.935	rs11169511	chr12:39175802	T/C	cg26384229	chr12:38710491	ALG10B	1.0	8.98	0.63	3.56e-15	Heart rate;
TGCT	cis	rs3947	0.687	rs1736065	chr8:11685453	A/G	cg02840367	chr8:11660030	FDFT1	0.87	6.14	0.48	1e-8	Blood protein levels;
TGCT	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg13683864	chr3:40499215	RPL14	-1.18	-13.68	-0.78	1.54e-26	Renal cell carcinoma;
TGCT	cis	rs7772486	0.875	rs2814866	chr6:146339414	C/A	cg05347473	chr6:146136440	FBXO30	0.5	4.73	0.39	6.03e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9486715	0.867	rs3849199	chr6:97049191	T/C	cg18709589	chr6:96969512	KIAA0776	-0.84	-8.23	-0.59	2.19e-13	Headache;
TGCT	cis	rs28595532	0.920	rs116047800	chr4:119773569	G/T	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs6964587	1.000	rs13231238	chr7:91653851	T/G	cg17063962	chr7:91808500	NA	0.91	9.99	0.67	1.32e-17	Breast cancer;
TGCT	cis	rs9906944	0.707	rs4794020	chr17:47111399	C/T	cg07075026	chr17:47091521	IGF2BP1	-0.43	-4.6	-0.38	1.03e-5	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs2688608	0.587	rs2894040	chr10:75478159	A/C	cg15838173	chr10:75533400	FUT11	-0.31	-5.02	-0.41	1.73e-6	Inflammatory bowel disease;
TGCT	cis	rs7226408	0.857	rs17567674	chr18:34480016	C/T	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs478304	0.651	rs4930312	chr11:65499719	G/A	cg27068330	chr11:65405492	SIPA1	-0.94	-9.4	-0.65	3.49e-16	Acne (severe);
TGCT	cis	rs4919694	1.000	rs75219158	chr10:104747594	C/T	cg04362960	chr10:104952993	NT5C2	1.07	7.11	0.54	7.9e-11	Arsenic metabolism;
TGCT	cis	rs13082711	0.522	rs4973760	chr3:27349047	G/A	cg02860705	chr3:27208620	NA	0.34	5.58	0.45	1.43e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs7829975	0.536	rs2980439	chr8:8094870	G/A	cg06636001	chr8:8085503	FLJ10661	0.89	9.08	0.63	2.07e-15	Mood instability;
TGCT	cis	rs929354	1.000	rs8101	chr7:157061474	A/G	cg05182265	chr7:156933206	UBE3C	0.3	6.34	0.5	3.81e-9	Body mass index;
TGCT	cis	rs16854884	0.837	rs13062793	chr3:143808387	A/G	cg06585982	chr3:143692056	C3orf58	0.66	5.04	0.41	1.59e-6	Economic and political preferences (feminism/equality);
TGCT	cis	rs6728642	0.572	rs2872686	chr2:97601024	A/G	cg26665480	chr2:98280029	ACTR1B	-0.9	-6.56	-0.51	1.34e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	trans	rs941408	1.000	rs1640272	chr19:2800192	A/T	cg22153745	chr1:153894579	GATAD2B	-0.64	-7.07	-0.54	9.84e-11	Total cholesterol levels;
TGCT	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.44	-6.37	-0.5	3.32e-9	Lymphocyte counts;
TGCT	cis	rs4975616	0.869	rs31484	chr5:1337906	A/T	cg07493874	chr5:1342172	CLPTM1L	-0.28	-6.82	-0.52	3.59e-10	Lung cancer;
TGCT	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	14.26	0.79	6.49e-28	Height;
TGCT	cis	rs2692947	0.683	rs62153700	chr2:96581338	C/T	cg22654517	chr2:96458247	NA	0.22	4.57	0.38	1.16e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs524023	0.957	rs12365089	chr11:64364735	A/T	cg07733098	chr11:64478343	NRXN2	0.32	4.87	0.4	3.4e-6	Urate levels in obese individuals;
TGCT	cis	rs2721195	0.845	rs1063739	chr8:145729727	C/A	cg17328964	chr8:145687451	CYHR1	-0.4	-5.41	-0.44	3.08e-7	Age at first birth;
TGCT	cis	rs7769051	0.522	rs7761207	chr6:133110430	G/A	cg07930552	chr6:133119739	C6orf192	1.28	5.03	0.41	1.69e-6	Type 2 diabetes nephropathy;
TGCT	cis	rs6430585	0.527	rs62168836	chr2:136463117	G/A	cg07169764	chr2:136633963	MCM6	1.01	9.4	0.64	3.64e-16	Corneal structure;
TGCT	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg13699009	chr12:122356056	WDR66	0.29	5.95	0.47	2.6e-8	Mean corpuscular volume;
TGCT	trans	rs9354352	1.000	rs9354352	chr6:66696272	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	7.89	0.58	1.33e-12	Initial pursuit acceleration in psychotic disorders;
TGCT	cis	rs7539409	0.831	rs6576940	chr1:84220236	C/T	cg10977910	chr1:84465055	TTLL7	-0.83	-4.62	-0.38	9.6e-6	Alzheimer's disease;
TGCT	cis	rs1371867	0.846	rs1660348	chr8:101315248	A/G	cg06636551	chr8:101224915	SPAG1	-0.42	-5.65	-0.45	1.06e-7	Atrioventricular conduction;
TGCT	cis	rs7666738	0.791	rs13146909	chr4:98934198	C/T	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs709400	0.633	rs10143247	chr14:103920927	G/A	cg12935359	chr14:103987150	CKB	-0.35	-5.33	-0.43	4.54e-7	Body mass index;
TGCT	cis	rs80282103	0.764	rs12268949	chr10:1104257	A/G	cg08668510	chr10:1095578	IDI1	1.01	4.51	0.38	1.48e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs7666738	0.830	rs13118892	chr4:98968497	T/C	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs13191362	1.000	rs1333963	chr6:163192571	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.94	6.77	0.52	4.6e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.07	-9.63	-0.65	1.01e-16	Platelet count;
TGCT	cis	rs1476679	1.000	rs34919929	chr7:100012334	G/A	cg00553149	chr7:99775558	STAG3;GPC2	-0.31	-4.5	-0.37	1.52e-5	Alzheimer's disease (late onset);
TGCT	cis	rs12477438	0.798	rs9808541	chr2:99642179	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-5.87	-0.47	3.74e-8	Chronic sinus infection;
TGCT	trans	rs525455	1.000	rs1761794	chr10:13102815	T/C	cg21721093	chr17:8906386	NA	0.63	6.62	0.51	9.7e-10	Platelet aggregation;
TGCT	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg05552183	chr6:42928497	GNMT	0.52	4.55	0.38	1.25e-5	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs7772486	0.806	rs4243478	chr6:146284560	A/G	cg23711669	chr6:146136114	FBXO30	-0.8	-8.72	-0.62	1.51e-14	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.55	4.92	0.4	2.74e-6	Prudent dietary pattern;
TGCT	cis	rs981844	1.000	rs72731669	chr4:154662464	G/A	cg14289246	chr4:154710475	SFRP2	1.01	8.46	0.6	6.31e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs79057730	0.599	rs6951032	chr7:794092	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.8	6.13	0.48	1.06e-8	Initial pursuit acceleration;
TGCT	cis	rs7617480	0.648	rs9859473	chr3:48837182	A/G	cg07636037	chr3:49044803	WDR6	0.78	6.47	0.5	2.07e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs6938	0.596	rs11630918	chr15:75155896	C/T	cg09165964	chr15:75287851	SCAMP5	0.56	5.1	0.42	1.22e-6	Breast cancer;
TGCT	cis	rs938554	0.513	rs3775947	chr4:9995240	C/T	cg00071950	chr4:10020882	SLC2A9	0.57	4.77	0.39	5.07e-6	Blood metabolite levels;
TGCT	cis	rs9393777	0.582	rs6936561	chr6:26640895	C/T	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.51	-4.68	-0.39	7.36e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7267979	1.000	rs2482931	chr20:25334445	G/A	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs208520	0.690	rs207108	chr6:66794096	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-10.77	-0.7	1.66e-19	Exhaled nitric oxide output;
TGCT	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg22968622	chr17:43663579	NA	1.3	11.58	0.72	1.83e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs9811920	0.599	rs61148087	chr3:99539891	C/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.6	7.0	0.53	1.44e-10	Axial length;
TGCT	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.56	-7.1	-0.54	8.54e-11	Longevity;Endometriosis;
TGCT	cis	rs9309473	0.687	rs11126399	chr2:73613341	G/A	cg20560298	chr2:73613845	ALMS1	-0.48	-5.38	-0.44	3.58e-7	Metabolite levels;
TGCT	cis	rs5769707	0.521	rs5769719	chr22:50062101	G/A	cg05373962	chr22:49881684	NA	-0.32	-5.47	-0.44	2.43e-7	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs6570726	0.935	rs422540	chr6:145837815	G/T	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg05890377	chr2:74357713	NA	0.5	6.75	0.52	5.16e-10	Gestational age at birth (maternal effect);
TGCT	cis	rs506338	0.517	rs12269736	chr11:64471986	T/C	cg19395706	chr11:64412079	NRXN2	0.54	6.47	0.5	2.06e-9	Body mass index;Urate levels;
TGCT	cis	rs2180341	0.781	rs877102	chr6:127587086	T/C	cg24812749	chr6:127587940	RNF146	0.79	6.6	0.51	1.09e-9	Breast cancer;
TGCT	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg04944784	chr2:26401820	FAM59B	-0.7	-6.49	-0.5	1.89e-9	Gut microbiome composition (summer);
TGCT	cis	rs7178572	0.849	rs12901503	chr15:77819056	A/G	cg22256960	chr15:77711686	NA	-0.97	-11.03	-0.7	3.83e-20	Type 2 diabetes;
TGCT	cis	rs9467773	1.000	rs9986382	chr6:26550619	T/C	cg09904177	chr6:26538194	HMGN4	0.65	6.55	0.51	1.36e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs9818758	0.607	rs12715434	chr3:49295025	G/C	cg00383909	chr3:49044727	WDR6	1.28	6.57	0.51	1.23e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs35306767	0.668	rs12784928	chr10:1083617	A/C	cg26597838	chr10:835615	NA	0.47	5.38	0.43	3.58e-7	Eosinophil percentage of granulocytes;
TGCT	cis	rs9397585	0.588	rs9371676	chr6:153445965	C/A	cg24028809	chr6:153414101	RGS17	0.22	4.66	0.39	8.15e-6	Body mass index;
TGCT	trans	rs74910095	0.786	rs73117196	chr5:62943718	G/A	cg02938449	chr2:220419364	OBSL1	0.8	6.75	0.52	4.95e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7524258	0.868	rs6693725	chr1:7307810	G/T	cg07173049	chr1:7289937	CAMTA1	0.28	4.54	0.38	1.32e-5	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs68170813	0.559	rs75154004	chr7:106903326	C/T	cg02696742	chr7:106810147	HBP1	-0.69	-5.61	-0.45	1.27e-7	Coronary artery disease;
TGCT	cis	rs6840360	0.642	rs10454251	chr4:152383962	A/G	cg17479576	chr4:152424074	FAM160A1	-0.59	-6.12	-0.48	1.13e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9303401	0.659	rs35928756	chr17:56702652	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs2404602	0.583	rs4381566	chr15:76589262	A/G	cg22467129	chr15:76604101	ETFA	-0.61	-7.93	-0.58	1.07e-12	Blood metabolite levels;
TGCT	cis	rs2230307	0.536	rs526128	chr1:100473427	T/A	cg24955406	chr1:100503596	HIAT1	0.75	4.88	0.4	3.2e-6	Carotid intima media thickness;
TGCT	cis	rs62244186	0.520	rs9311361	chr3:44796132	T/G	cg18722847	chr3:44754129	ZNF502	-0.4	-4.47	-0.37	1.75e-5	Depressive symptoms;
TGCT	cis	rs8038465	0.874	rs2291013	chr15:74000506	T/G	cg15420318	chr15:73925796	NPTN	0.57	5.15	0.42	1.02e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1371867	0.846	rs1660351	chr8:101275034	C/T	cg06002616	chr8:101225028	SPAG1	-0.57	-6.77	-0.52	4.48e-10	Atrioventricular conduction;
TGCT	cis	rs9650657	0.801	rs7018334	chr8:10612075	G/A	cg16664915	chr8:10907788	XKR6	-0.3	-4.76	-0.39	5.38e-6	Neuroticism;
TGCT	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg08859206	chr1:53392774	SCP2	-0.41	-6.12	-0.48	1.11e-8	Monocyte count;
TGCT	cis	rs11031096	0.655	rs10835695	chr11:4178962	G/T	cg18678763	chr11:4115507	RRM1	-0.44	-5.75	-0.46	6.48e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs7193541	0.550	rs28607667	chr16:74476015	C/T	cg05800356	chr16:74706258	MLKL	-0.23	-4.5	-0.37	1.53e-5	Multiple myeloma;
TGCT	cis	rs1488864	0.614	rs1552516	chr11:6351787	A/T	cg12755421	chr11:6342214	PRKCDBP	-0.6	-4.51	-0.38	1.47e-5	Smooth-surface caries;
TGCT	cis	rs10875746	0.855	rs17122620	chr12:48464475	A/G	cg20731937	chr12:48336164	NA	0.62	4.95	0.41	2.36e-6	Longevity (90 years and older);
TGCT	cis	rs12134245	0.742	rs17501381	chr1:92003919	A/G	cg07090678	chr1:91966139	CDC7	0.35	4.75	0.39	5.58e-6	Breast cancer;
TGCT	cis	rs62380364	0.565	rs13158247	chr5:88030670	C/T	cg24804195	chr5:87968844	LOC645323	-0.61	-6.27	-0.49	5.52e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs908922	0.651	rs4240885	chr1:152529850	G/C	cg20991723	chr1:152506922	NA	0.44	5.98	0.47	2.2e-8	Hair morphology;
TGCT	cis	rs12620999	1.000	rs10803655	chr2:238075551	C/T	cg23555395	chr2:238036564	NA	-0.28	-4.8	-0.4	4.49e-6	Systemic lupus erythematosus;
TGCT	cis	rs394563	0.726	rs6942381	chr6:149662991	G/C	cg16235748	chr6:149772707	ZC3H12D	0.47	5.53	0.44	1.84e-7	Dupuytren's disease;
TGCT	cis	rs60154123	0.730	rs10779528	chr1:210457378	C/T	cg22029157	chr1:209979665	IRF6	0.6	4.46	0.37	1.81e-5	Coronary artery disease;
TGCT	cis	rs7208859	0.623	rs55961983	chr17:29119286	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs9394169	0.875	rs1547670	chr6:33775868	G/A	cg13859433	chr6:33739653	LEMD2	-0.33	-5.85	-0.47	4.02e-8	Essential tremor;
TGCT	cis	rs9467773	1.000	rs9467791	chr6:26562486	A/G	cg26531700	chr6:26746687	NA	-0.46	-4.5	-0.37	1.55e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7000551	0.527	rs12677619	chr8:22243326	G/A	cg12081754	chr8:22256438	SLC39A14	0.32	4.58	0.38	1.09e-5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs28595532	0.920	rs116550416	chr4:119753467	A/C	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs2688608	0.592	rs10762560	chr10:75495405	T/G	cg23231163	chr10:75533350	FUT11	-0.28	-4.68	-0.39	7.4e-6	Inflammatory bowel disease;
TGCT	cis	rs12477438	0.798	rs6740267	chr2:99561867	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.83	-8.07	-0.59	5.19e-13	Chronic sinus infection;
TGCT	cis	rs7572733	0.555	rs10202569	chr2:198934726	C/G	cg00792783	chr2:198669748	PLCL1	0.58	5.16	0.42	9.47e-7	Dermatomyositis;
TGCT	cis	rs4733781	0.787	rs6470812	chr8:131340265	G/A	cg16277922	chr8:131349729	ASAP1	-0.36	-4.63	-0.38	9.06e-6	Tuberculosis;
TGCT	cis	rs9883204	0.817	rs35606005	chr3:123129170	C/T	cg04890266	chr3:123102914	ADCY5	0.36	5.08	0.42	1.34e-6	Birth weight;
TGCT	cis	rs80282103	0.618	rs11816485	chr10:1147974	T/C	cg08668510	chr10:1095578	IDI1	1.05	5.31	0.43	4.8e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs12220898	0.749	rs4497321	chr10:50475018	C/T	cg09603381	chr10:49954066	WDFY4	0.38	4.45	0.37	1.85e-5	Inflammatory biomarkers;
TGCT	trans	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg27523141	chr10:43048294	ZNF37B	0.73	8.58	0.61	3.32e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs11711311	0.955	rs12636240	chr3:113391282	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.8	-6.99	-0.53	1.48e-10	IgG glycosylation;
TGCT	cis	rs7100689	0.784	rs3802637	chr10:82179699	G/C	cg01528321	chr10:82214614	TSPAN14	0.9	9.37	0.64	4.33e-16	Post bronchodilator FEV1;
TGCT	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg06873352	chr17:61820015	STRADA	0.56	6.23	0.49	6.49e-9	Prudent dietary pattern;
TGCT	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg18538332	chr22:24372958	LOC391322	-1.01	-12.84	-0.76	1.6e-24	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs62244186	0.566	rs3762636	chr3:44854563	A/G	cg02073558	chr3:44770973	ZNF501	0.67	6.68	0.51	7.31e-10	Depressive symptoms;
TGCT	cis	rs644799	0.542	rs10831418	chr11:95468828	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.67	6.5	0.5	1.76e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	trans	rs1415174	0.916	rs746191	chr1:87849215	A/G	cg23065576	chr20:25207247	ENTPD6	-0.26	-6.91	-0.53	2.29e-10	Breast cancer;
TGCT	cis	rs739401	0.611	rs7109088	chr11:3027485	G/T	cg05729581	chr11:3078854	CARS	-0.53	-4.81	-0.4	4.3e-6	Longevity;
TGCT	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-6.74	-0.52	5.26e-10	Alzheimer's disease;
TGCT	cis	rs477895	0.838	rs12798333	chr11:64012784	G/A	cg04317338	chr11:64019027	PLCB3	0.81	6.9	0.53	2.35e-10	Mean platelet volume;
TGCT	trans	rs9650657	0.572	rs11250098	chr8:10818607	A/G	cg15556689	chr8:8085844	FLJ10661	-0.95	-10.05	-0.67	9.79e-18	Neuroticism;
TGCT	cis	rs10791097	0.694	rs4937581	chr11:130740335	T/C	cg14779329	chr11:130786720	SNX19	0.28	4.82	0.4	4.09e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs1903068	0.785	rs28584303	chr4:55997622	C/T	cg01777861	chr4:56023843	NA	0.55	6.37	0.5	3.34e-9	Endometriosis;
TGCT	cis	rs11098499	0.954	rs2892848	chr4:120381341	C/T	cg09307838	chr4:120376055	NA	0.68	6.53	0.51	1.54e-9	Corneal astigmatism;
TGCT	cis	rs4889855	0.530	rs75398920	chr17:78544540	C/T	cg16591659	chr17:78472290	NA	0.29	4.47	0.37	1.76e-5	Fractional excretion of uric acid;
TGCT	cis	rs13202913	0.518	rs13205543	chr6:151813779	C/T	cg03627880	chr6:151815985	C6orf97	-0.66	-6.01	-0.47	1.95e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs4888262	0.545	rs7342732	chr16:74698716	A/C	cg01733217	chr16:74700730	RFWD3	0.75	7.65	0.57	4.96e-12	Testicular germ cell tumor;
TGCT	trans	rs7615952	0.932	rs6438948	chr3:125650045	A/T	cg07211511	chr3:129823064	LOC729375	0.43	7.48	0.56	1.18e-11	Blood pressure (smoking interaction);
TGCT	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg20203395	chr5:56204925	C5orf35	-0.59	-5.12	-0.42	1.12e-6	Initial pursuit acceleration;
TGCT	cis	rs7944584	0.837	rs11039149	chr11:47276675	A/G	cg20307385	chr11:47447363	PSMC3	0.77	7.16	0.54	6.19e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
TGCT	cis	rs55971108	0.653	rs12284518	chr11:134876086	C/T	cg21104351	chr11:134152202	GLB1L3	0.48	4.46	0.37	1.82e-5	Alcoholic chronic pancreatitis;
TGCT	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg04317338	chr11:64019027	PLCB3	0.78	6.46	0.5	2.17e-9	Mean platelet volume;
TGCT	cis	rs813218	0.647	rs6788750	chr3:99774720	G/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-5.7	-0.46	8.42e-8	Orofacial clefts;
TGCT	cis	rs11098499	0.909	rs10026736	chr4:120384322	G/C	cg09307838	chr4:120376055	NA	0.67	6.38	0.5	3.14e-9	Corneal astigmatism;
TGCT	cis	rs2204008	0.775	rs12099736	chr12:38344111	C/G	cg13010199	chr12:38710504	ALG10B	0.59	4.63	0.38	9.17e-6	Bladder cancer;
TGCT	cis	rs9972944	0.756	rs9901885	chr17:63769559	T/C	cg07283582	chr17:63770753	CCDC46	-0.26	-5.27	-0.43	5.91e-7	Total body bone mineral density;
TGCT	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg07507251	chr3:52567010	NT5DC2	0.48	6.95	0.53	1.82e-10	Bipolar disorder;
TGCT	cis	rs3862260	0.509	rs10802124	chr1:120164252	G/A	cg16322792	chr1:120165303	ZNF697	0.35	8.4	0.6	8.92e-14	Systemic lupus erythematosus;
TGCT	cis	rs57994353	0.861	rs3812591	chr9:139341612	C/T	cg13741927	chr9:139327495	INPP5E	0.25	5.76	0.46	6.12e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs9372498	0.536	rs9489450	chr6:118904385	G/A	cg07617317	chr6:118971624	C6orf204	0.5	5.32	0.43	4.71e-7	Diastolic blood pressure;
TGCT	cis	rs2535633	0.820	rs7626551	chr3:52938092	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	-0.5	-4.65	-0.39	8.52e-6	Body mass index;
TGCT	cis	rs2288278	0.580	rs10853099	chr17:46602379	T/C	cg25032089	chr17:46643351	HOXB3	-0.42	-5.0	-0.41	1.89e-6	Hand grip strength;
TGCT	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6460942	0.915	rs62447640	chr7:12488282	A/T	cg06484146	chr7:12443880	VWDE	-0.61	-5.43	-0.44	2.87e-7	Coronary artery disease;
TGCT	cis	rs9394841	0.667	rs9367112	chr6:41769920	T/C	cg08135965	chr6:41755394	TOMM6	0.55	5.15	0.42	9.77e-7	Mean corpuscular hemoglobin;Red cell distribution width;
TGCT	cis	rs7681440	0.804	rs1442135	chr4:90819093	C/T	cg20003494	chr4:90757398	SNCA	0.59	5.97	0.47	2.29e-8	Dementia with Lewy bodies;
TGCT	cis	rs4555082	0.834	rs2816631	chr14:105739477	G/A	cg01266790	chr14:105781312	PACS2	0.56	4.6	0.38	1.04e-5	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs6121246	0.529	rs6058196	chr20:30194714	A/T	cg13852791	chr20:30311386	BCL2L1	0.69	4.54	0.38	1.33e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs8072100	0.905	rs9901869	chr17:45575206	G/A	cg08085267	chr17:45401833	C17orf57	-0.44	-4.72	-0.39	6.17e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs1997103	0.871	rs1997100	chr7:55399656	C/G	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs694739	0.536	rs671976	chr11:64046029	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.55	5.33	0.43	4.5e-7	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg10047753	chr17:41438598	NA	0.96	9.6	0.65	1.16e-16	Menopause (age at onset);
TGCT	cis	rs9346649	1.000	rs9346649	chr6:168490232	A/G	cg02770688	chr6:168491649	NA	-0.27	-5.23	-0.42	7.09e-7	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
TGCT	cis	rs72949976	0.646	rs1441171	chr2:214033637	G/T	cg08319019	chr2:214017104	IKZF2	0.85	8.35	0.6	1.17e-13	Lung cancer;Squamous cell lung carcinoma;
TGCT	trans	rs11764590	0.671	rs56226325	chr7:2078981	C/T	cg25206134	chr2:45395956	NA	0.97	6.73	0.52	5.68e-10	Neuroticism;
TGCT	cis	rs4654899	0.897	rs7515308	chr1:21085653	G/C	cg01072550	chr1:21505969	NA	-0.49	-7.89	-0.58	1.37e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs4389656	0.784	rs274723	chr5:6718563	A/G	cg10857441	chr5:6722123	POLS	-0.22	-4.86	-0.4	3.44e-6	Coronary artery disease;
TGCT	cis	rs9486719	1.000	rs13207333	chr6:96882254	T/C	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.86	-0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs796364	1.000	rs281763	chr2:200794870	C/T	cg17644776	chr2:200775616	C2orf69	0.31	4.85	0.4	3.58e-6	Schizophrenia;
TGCT	cis	rs2228479	0.717	rs1800358	chr16:89809319	T/C	cg04287289	chr16:89883240	FANCA	0.74	4.44	0.37	1.99e-5	Skin colour saturation;
TGCT	cis	rs11105298	0.891	rs10858879	chr12:89886578	A/T	cg00757033	chr12:89920650	WDR51B	-0.34	-5.37	-0.43	3.75e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs425277	0.520	rs10910030	chr1:2035684	C/T	cg03732007	chr1:2071316	PRKCZ	-0.28	-6.06	-0.48	1.51e-8	Height;
TGCT	cis	rs4737010	0.501	rs2032736	chr8:41639266	C/A	cg07235638	chr8:41625417	ANK1	-0.49	-4.66	-0.39	7.96e-6	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
TGCT	cis	rs13191362	0.507	rs2846519	chr6:163045463	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.61	-5.78	-0.46	5.77e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs12681287	0.752	rs10086569	chr8:87247209	C/T	cg27223183	chr8:87520930	FAM82B	-0.81	-5.7	-0.46	8.13e-8	Caudate activity during reward;
TGCT	cis	rs8103278	0.507	rs7246377	chr19:46292259	G/A	cg11657440	chr19:46296263	DMWD	0.76	8.25	0.6	1.93e-13	Coronary artery disease;
TGCT	cis	rs9583531	0.600	rs6492303	chr13:111356800	G/A	cg24331049	chr13:111365604	ING1	0.77	7.44	0.56	1.45e-11	Coronary artery disease;
TGCT	cis	rs1865760	0.713	rs9461229	chr6:25992279	G/T	cg17042849	chr6:26104293	HIST1H4C	-0.55	-4.8	-0.4	4.4e-6	Height;
TGCT	cis	rs7833790	1.000	rs7834808	chr8:82704996	A/G	cg17211192	chr8:82754475	SNX16	-1.11	-8.7	-0.62	1.72e-14	Diastolic blood pressure;
TGCT	cis	rs9942416	0.660	rs2047059	chr5:75008193	T/C	cg19683494	chr5:74908142	NA	0.6	6.16	0.48	9.25e-9	Age-related disease endophenotypes;
TGCT	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	-1.04	-12.35	-0.74	2.39e-23	Height;
TGCT	cis	rs4888262	0.526	rs8062959	chr16:74627628	T/C	cg01733217	chr16:74700730	RFWD3	0.74	7.42	0.55	1.6e-11	Testicular germ cell tumor;
TGCT	cis	rs10791323	0.598	rs10750550	chr11:133736083	A/G	cg03690763	chr11:133734501	NA	-0.29	-4.86	-0.4	3.54e-6	Childhood ear infection;
TGCT	cis	rs1519814	0.654	rs6469888	chr8:121018175	A/G	cg22335954	chr8:121166405	COL14A1	-0.38	-4.76	-0.39	5.35e-6	Breast cancer;
TGCT	cis	rs6430585	0.591	rs12466487	chr2:136407078	C/T	cg07169764	chr2:136633963	MCM6	-1.06	-8.97	-0.63	3.94e-15	Corneal structure;
TGCT	cis	rs155076	1.000	rs261432	chr13:21865915	G/C	cg14456004	chr13:21872349	NA	-1.18	-10.17	-0.67	5e-18	White matter hyperintensity burden;
TGCT	cis	rs732765	0.734	rs3784021	chr14:75200653	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.55	-4.48	-0.37	1.71e-5	Non-small cell lung cancer;
TGCT	cis	rs4332037	0.539	rs1533827	chr7:2074290	A/G	cg24505167	chr7:1915268	MAD1L1	0.3	4.5	0.37	1.52e-5	Bipolar disorder;
TGCT	cis	rs137699	1.000	rs2049986	chr22:39756854	C/G	cg24399712	chr22:39784796	NA	0.67	6.35	0.5	3.72e-9	IgG glycosylation;
TGCT	cis	rs62244186	0.659	rs56231820	chr3:44530329	C/T	cg25151919	chr3:44754333	ZNF502	-0.39	-4.6	-0.38	1.02e-5	Depressive symptoms;
TGCT	cis	rs12477438	0.798	rs4851179	chr2:99568774	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.9	-9.1	-0.63	1.84e-15	Chronic sinus infection;
TGCT	cis	rs2235642	0.750	rs2755185	chr16:1645827	A/G	cg10465839	chr16:1584050	IFT140;TMEM204	-0.28	-4.57	-0.38	1.17e-5	Coronary artery disease;
TGCT	cis	rs3749237	0.929	rs62260715	chr3:49829326	G/A	cg03060546	chr3:49711283	APEH	0.73	7.58	0.56	7.07e-12	Resting heart rate;
TGCT	cis	rs9486719	1.000	rs2472889	chr6:96866803	T/G	cg06623918	chr6:96969491	KIAA0776	1.01	8.86	0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs7586879	0.639	rs2384058	chr2:25100328	A/G	cg15423357	chr2:25149977	NA	0.49	4.76	0.39	5.32e-6	Body mass index;
TGCT	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg00343986	chr7:65444356	GUSB	0.26	6.07	0.48	1.42e-8	Aortic root size;
TGCT	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg21963583	chr11:68658836	MRPL21	0.36	6.08	0.48	1.35e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs10186029	0.648	rs13022006	chr2:213940309	A/C	cg08319019	chr2:214017104	IKZF2	0.63	5.94	0.47	2.67e-8	Systemic sclerosis;
TGCT	cis	rs28595532	0.920	rs17325129	chr4:119778284	T/C	cg11846333	chr4:119757529	SEC24D	0.92	4.64	0.38	8.74e-6	Cannabis dependence symptom count;
TGCT	cis	rs7193541	0.646	rs4888267	chr16:74687906	A/G	cg01733217	chr16:74700730	RFWD3	1.0	13.51	0.77	3.95e-26	Multiple myeloma;
TGCT	cis	rs9467711	0.591	rs13216785	chr6:26079185	C/T	cg16898833	chr6:26189333	HIST1H4D	0.78	4.45	0.37	1.87e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg17264618	chr3:40429014	ENTPD3	-0.33	-4.78	-0.39	4.92e-6	Renal cell carcinoma;
TGCT	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2243480	1.000	rs313832	chr7:65550891	G/T	cg07424592	chr7:64974309	NA	1.25	8.03	0.58	6.38e-13	Diabetic kidney disease;
TGCT	cis	rs2243480	1.000	rs958550	chr7:65635679	C/T	cg07424592	chr7:64974309	NA	-1.29	-7.96	-0.58	9.33e-13	Diabetic kidney disease;
TGCT	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg13342137	chr4:2252803	MXD4	0.17	4.58	0.38	1.09e-5	Obesity-related traits;
TGCT	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.91	7.28	0.55	3.32e-11	Platelet count;
TGCT	cis	rs7937682	0.924	rs10891288	chr11:111552053	G/T	cg09085632	chr11:111637200	PPP2R1B	1.08	11.72	0.73	8.02e-22	Primary sclerosing cholangitis;
TGCT	trans	rs11764590	0.715	rs56289396	chr7:2091415	G/A	cg25206134	chr2:45395956	NA	0.97	6.72	0.52	5.86e-10	Neuroticism;
TGCT	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg23758822	chr17:41437982	NA	0.71	6.64	0.51	8.91e-10	Menopause (age at onset);
TGCT	cis	rs67311347	1.000	rs66841330	chr3:40531123	G/A	cg13409248	chr3:40428643	ENTPD3	0.65	5.29	0.43	5.25e-7	Renal cell carcinoma;
TGCT	cis	rs12908161	0.920	rs12904605	chr15:85201419	T/C	cg11189052	chr15:85197271	WDR73	0.74	6.09	0.48	1.3e-8	Schizophrenia;
TGCT	cis	rs2439831	1.000	rs2444032	chr15:43755346	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	7.96	0.58	9.41e-13	Lung cancer in ever smokers;
TGCT	cis	rs1348850	0.914	rs7565022	chr2:178320222	A/T	cg22681709	chr2:178499509	PDE11A	-0.34	-4.47	-0.37	1.72e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs4389656	0.857	rs274709	chr5:6726464	T/C	cg10857441	chr5:6722123	POLS	-0.22	-4.74	-0.39	5.75e-6	Coronary artery disease;
TGCT	cis	rs7412746	0.658	rs2089082	chr1:150800090	T/G	cg09365446	chr1:150670422	GOLPH3L	0.35	5.13	0.42	1.1e-6	Melanoma;
TGCT	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg22433210	chr17:43662623	NA	1.05	7.46	0.56	1.3e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs514406	0.893	rs6588445	chr1:53424928	T/C	cg24675658	chr1:53192096	ZYG11B	0.69	8.05	0.59	5.8e-13	Monocyte count;
TGCT	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg04944784	chr2:26401820	FAM59B	-0.76	-6.45	-0.5	2.29e-9	Gut microbiome composition (summer);
TGCT	cis	rs2282802	0.685	rs1529693	chr5:139678213	A/G	cg01081189	chr5:139537190	NA	0.29	5.31	0.43	5e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg22535103	chr8:58192502	C8orf71	-0.37	-4.73	-0.39	6.08e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7172809	0.574	rs74026913	chr15:77733083	A/G	cg22256960	chr15:77711686	NA	-0.51	-4.87	-0.4	3.32e-6	Glucose homeostasis traits;
TGCT	cis	rs7208859	0.673	rs9899943	chr17:29223925	G/A	cg14008862	chr17:28927542	LRRC37B2	0.72	4.66	0.39	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.6	0.51	1.05e-9	Bipolar disorder;
TGCT	cis	rs74233809	1.000	rs11191551	chr10:104850835	A/G	cg05855489	chr10:104503620	C10orf26	0.79	4.56	0.38	1.19e-5	Birth weight;
TGCT	cis	rs11577318	0.853	rs11803933	chr1:26629465	G/C	cg12733254	chr1:26682999	NA	-0.2	-4.45	-0.37	1.89e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs11122272	0.735	rs2749723	chr1:231493302	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.73	-7.08	-0.54	9.65e-11	Hemoglobin concentration;
TGCT	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg11644478	chr21:40555479	PSMG1	-0.87	-7.93	-0.58	1.09e-12	Cognitive function;
TGCT	cis	rs10782582	0.593	rs11579752	chr1:76178694	C/T	cg22875332	chr1:76189707	ACADM	-0.52	-6.04	-0.48	1.69e-8	Daytime sleep phenotypes;
TGCT	cis	rs67478160	0.634	rs1955660	chr14:104229985	C/T	cg26031613	chr14:104095156	KLC1	-0.63	-6.38	-0.5	3.18e-9	Schizophrenia;
TGCT	cis	rs6087990	0.701	rs1997797	chr20:31387954	C/G	cg13636640	chr20:31349939	DNMT3B	0.97	12.84	0.76	1.63e-24	Ulcerative colitis;
TGCT	cis	rs1865760	0.566	rs9348706	chr6:26065481	G/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.79	7.55	0.56	8.02e-12	Height;
TGCT	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg26338869	chr17:61819248	STRADA	-0.53	-4.94	-0.41	2.48e-6	Prudent dietary pattern;
TGCT	trans	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-1.04	-13.29	-0.77	1.33e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs9581857	0.579	rs9581846	chr13:27987953	A/G	cg22138327	chr13:27999177	GTF3A	0.73	5.34	0.43	4.23e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs6604026	0.630	rs35807969	chr1:93459069	T/A	cg17283838	chr1:93427260	FAM69A	0.57	4.64	0.38	8.79e-6	Multiple sclerosis;
TGCT	cis	rs854765	0.547	rs9894138	chr17:17964345	G/A	cg04398451	chr17:18023971	MYO15A	0.31	4.97	0.41	2.18e-6	Total body bone mineral density;
TGCT	cis	rs1023500	0.505	rs134885	chr22:42673811	C/G	cg15557168	chr22:42548783	NA	-0.21	-4.99	-0.41	2.03e-6	Schizophrenia;
TGCT	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg22963979	chr7:1858916	MAD1L1	-0.37	-5.8	-0.46	5.31e-8	Bipolar disorder and schizophrenia;
TGCT	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg26513180	chr16:89883248	FANCA	-0.99	-13.33	-0.77	1.03e-25	Vitiligo;
TGCT	cis	rs10484885	0.878	rs72921934	chr6:90579464	T/A	cg13799429	chr6:90582589	CASP8AP2	-0.47	-4.58	-0.38	1.11e-5	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs9611565	0.559	rs13056262	chr22:42081921	A/G	cg17554472	chr22:41940697	POLR3H	0.49	5.22	0.42	7.4e-7	Vitiligo;
TGCT	cis	rs10193935	0.901	rs1390609	chr2:42666230	G/T	cg27598129	chr2:42591480	NA	0.33	4.81	0.4	4.32e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs68170813	0.641	rs75254991	chr7:106938903	C/T	cg02696742	chr7:106810147	HBP1	-0.71	-5.93	-0.47	2.88e-8	Coronary artery disease;
TGCT	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg00684032	chr4:1343700	KIAA1530	0.24	5.01	0.41	1.83e-6	Obesity-related traits;
TGCT	cis	rs7666738	0.716	rs6817529	chr4:99023213	T/C	cg18180107	chr4:99064573	C4orf37	0.54	5.03	0.41	1.7e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7666738	0.791	rs62318907	chr4:99037120	C/T	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2239547	0.563	rs9876403	chr3:52916916	C/T	cg11645453	chr3:52864694	ITIH4	0.33	5.7	0.46	8.39e-8	Schizophrenia;
TGCT	cis	rs7698623	0.850	rs4693883	chr4:88770174	A/G	cg27387453	chr4:88533842	DSPP	-0.61	-4.6	-0.38	1.03e-5	Cardiovascular disease risk factors;
TGCT	cis	rs17473412	0.963	rs7731697	chr5:122735452	A/T	cg15125798	chr5:122621645	NA	-0.55	-4.86	-0.4	3.5e-6	Total body bone mineral density;
TGCT	cis	rs12497850	0.627	rs4974078	chr3:49009386	C/T	cg02487422	chr3:49467188	NICN1	0.52	5.75	0.46	6.52e-8	Parkinson's disease;
TGCT	trans	rs7698623	0.850	rs7684659	chr4:88769571	G/A	cg01186725	chr1:53905612	FLJ40434	-0.48	-6.63	-0.51	9.21e-10	Cardiovascular disease risk factors;
TGCT	cis	rs7772486	0.806	rs4075696	chr6:146250947	T/C	cg23711669	chr6:146136114	FBXO30	-0.8	-8.9	-0.62	5.72e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs151997	0.962	rs27268	chr5:50184778	T/C	cg06027927	chr5:50259733	NA	0.47	4.83	0.4	4e-6	Callous-unemotional behaviour;
TGCT	cis	rs17387100	0.901	rs73230225	chr4:15983944	C/T	cg14577840	chr4:16257979	FLJ39653	0.48	4.7	0.39	6.69e-6	Suicide attempts in depression or bipolar disorder;
TGCT	cis	rs9910055	0.529	rs228766	chr17:42186813	A/G	cg13607699	chr17:42295918	UBTF	-0.62	-5.01	-0.41	1.85e-6	Total body bone mineral density;
TGCT	cis	rs8068544	0.818	rs8079958	chr17:40155467	C/T	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.09	-5.37	-0.43	3.82e-7	Reticulocyte fraction of red cells;Reticulocyte count;
TGCT	cis	rs3733585	0.673	rs4495037	chr4:9954050	C/G	cg00071950	chr4:10020882	SLC2A9	-0.55	-6.58	-0.51	1.21e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs9916302	0.904	rs11078897	chr17:37415870	C/T	cg07936489	chr17:37558343	FBXL20	-0.63	-4.99	-0.41	2.03e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs4372836	0.893	rs745645	chr2:28931571	G/T	cg09522027	chr2:28974177	PPP1CB	0.57	4.76	0.39	5.24e-6	Body mass index;
TGCT	cis	rs10262624	0.528	rs5029444	chr7:23737795	T/C	cg09690326	chr7:23720549	C7orf46	0.43	4.65	0.39	8.21e-6	Schizophrenia;
TGCT	cis	rs3749237	1.000	rs2291542	chr3:49751585	C/T	cg03060546	chr3:49711283	APEH	0.75	7.46	0.56	1.33e-11	Resting heart rate;
TGCT	cis	rs7647973	0.731	rs7617480	chr3:49210732	G/T	cg07636037	chr3:49044803	WDR6	-0.66	-4.81	-0.4	4.26e-6	Menarche (age at onset);
TGCT	cis	rs589249	0.963	rs761718	chr1:37161263	A/G	cg04012535	chr1:37176647	NA	-0.31	-5.1	-0.42	1.25e-6	Neuroticism (multi-trait analysis);Schizophrenia;
TGCT	cis	rs6032067	0.673	rs4522674	chr20:43893276	T/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.45	-6.37	-0.5	3.36e-9	Blood protein levels;
TGCT	cis	rs2688608	0.592	rs7908825	chr10:75554541	C/G	cg23231163	chr10:75533350	FUT11	0.28	4.68	0.39	7.32e-6	Inflammatory bowel disease;
TGCT	cis	rs617219	0.726	rs7717669	chr5:78452983	A/C	cg23987322	chr5:78407566	BHMT	0.36	4.82	0.4	4.19e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs2204008	0.805	rs11180825	chr12:38242916	G/T	cg26384229	chr12:38710491	ALG10B	0.86	7.42	0.55	1.6e-11	Bladder cancer;
TGCT	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.32	-4.75	-0.39	5.59e-6	Personality dimensions;
TGCT	cis	rs362272	0.545	rs2748447	chr4:3337831	G/A	cg18352616	chr4:3374830	RGS12	0.22	4.44	0.37	1.93e-5	Serum sulfate level;
TGCT	cis	rs17030434	0.813	rs11732480	chr4:154665733	C/A	cg14289246	chr4:154710475	SFRP2	-0.89	-7.26	-0.55	3.75e-11	Electrocardiographic conduction measures;
TGCT	cis	rs2692947	0.795	rs2252697	chr2:96778190	G/C	cg22654517	chr2:96458247	NA	-0.22	-4.86	-0.4	3.44e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs6088580	0.567	rs6088520	chr20:33132364	A/G	cg06115741	chr20:33292138	TP53INP2	-0.51	-4.49	-0.37	1.58e-5	Glomerular filtration rate (creatinine);
TGCT	trans	rs1864729	0.748	rs973756	chr8:98297422	G/T	cg08679828	chr8:102218111	ZNF706	-1.03	-6.8	-0.52	3.9e-10	Estradiol plasma levels (breast cancer);
TGCT	cis	rs931127	0.719	rs2170082	chr11:65454795	A/G	cg27068330	chr11:65405492	SIPA1	-0.63	-6.28	-0.49	5.15e-9	Systemic lupus erythematosus;
TGCT	cis	rs2594989	0.790	rs2443712	chr3:11538063	A/G	cg00170343	chr3:11313890	ATG7	0.68	5.2	0.42	8.04e-7	Circulating chemerin levels;
TGCT	cis	rs367943	1.000	rs348930	chr5:112814763	T/C	cg12552261	chr5:112820674	MCC	-0.24	-4.91	-0.4	2.81e-6	Type 2 diabetes;
TGCT	cis	rs3770081	1.000	rs12622009	chr2:86248325	T/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.18	-4.81	-0.4	4.33e-6	Facial emotion recognition (sad faces);
TGCT	cis	rs7119	0.634	rs11635634	chr15:77863412	T/C	cg27398640	chr15:77910606	LINGO1	0.26	4.73	0.39	6.12e-6	Type 2 diabetes;
TGCT	cis	rs6570726	0.577	rs406868	chr6:145809983	C/T	cg23711669	chr6:146136114	FBXO30	0.71	6.52	0.51	1.62e-9	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs1864729	1.000	rs2053481	chr8:98278923	C/T	cg08679828	chr8:102218111	ZNF706	-1.1	-7.71	-0.57	3.56e-12	Estradiol plasma levels (breast cancer);
TGCT	cis	rs17376456	0.825	rs10064368	chr5:93266396	C/A	cg21475434	chr5:93447410	FAM172A	0.65	4.47	0.37	1.72e-5	Diabetic retinopathy;
TGCT	cis	rs7829975	0.533	rs7820146	chr8:8699757	T/A	cg15556689	chr8:8085844	FLJ10661	0.66	5.8	0.46	5.2e-8	Mood instability;
TGCT	cis	rs7246657	0.943	rs1382357	chr19:37977609	G/A	cg18154014	chr19:37997991	ZNF793	0.7	4.78	0.39	4.87e-6	Coronary artery calcification;
TGCT	cis	rs6912958	0.559	rs242287	chr6:88071825	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.66	6.41	0.5	2.7e-9	Monocyte percentage of white cells;
TGCT	cis	rs2251381	0.808	rs7364112	chr21:30548968	C/A	cg24692254	chr21:30365293	RNF160	0.74	7.33	0.55	2.63e-11	Selective IgA deficiency;
TGCT	cis	rs4654899	1.000	rs12126133	chr1:21456537	T/C	cg01072550	chr1:21505969	NA	-0.5	-8.07	-0.59	5.13e-13	Superior frontal gyrus grey matter volume;
TGCT	cis	rs7091068	0.567	rs1572773	chr10:95432968	T/C	cg20715218	chr10:95462985	C10orf4	0.52	5.56	0.45	1.59e-7	Urinary tract infection frequency;
TGCT	cis	rs7772486	0.754	rs1415746	chr6:146077107	A/G	cg13319975	chr6:146136371	FBXO30	0.54	4.88	0.4	3.19e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg25036284	chr2:26402008	FAM59B	0.65	5.19	0.42	8.36e-7	Gut microbiome composition (summer);
TGCT	cis	rs56399783	0.901	rs17132741	chr7:2868997	C/T	cg19731401	chr7:2775893	GNA12	-0.32	-4.73	-0.39	5.93e-6	Childhood ear infection;
TGCT	cis	rs11971779	0.793	rs11543827	chr7:139032693	G/A	cg07862535	chr7:139043722	LUC7L2	0.76	6.17	0.48	8.86e-9	Diisocyanate-induced asthma;
TGCT	cis	rs12220898	0.749	rs7905866	chr10:50483552	T/C	cg09603381	chr10:49954066	WDFY4	0.39	4.5	0.37	1.54e-5	Inflammatory biomarkers;
TGCT	cis	rs2637266	1.000	rs2579746	chr10:78327674	C/T	cg18941641	chr10:78392320	NA	0.41	5.02	0.41	1.74e-6	Pulmonary function;
TGCT	cis	rs28785552	0.589	rs7257371	chr19:53243910	A/G	cg10871876	chr19:53194124	ZNF83	0.46	5.91	0.47	3.08e-8	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs7937612	1.000	rs6589811	chr11:120235703	C/T	cg24566217	chr11:120254723	ARHGEF12	-0.3	-4.81	-0.4	4.21e-6	Intraocular pressure;
TGCT	cis	rs9435341	0.728	rs1762486	chr1:107627697	G/A	cg09367891	chr1:107599246	PRMT6	-0.58	-4.74	-0.39	5.74e-6	Facial morphology (factor 21, depth of nasal alae);
TGCT	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg18110333	chr6:292329	DUSP22	-0.61	-6.63	-0.51	9.1e-10	Menopause (age at onset);
TGCT	cis	rs514406	0.893	rs1242317	chr1:53414766	T/C	cg25767906	chr1:53392781	SCP2	-0.5	-6.0	-0.47	2e-8	Monocyte count;
TGCT	cis	rs986417	1.000	rs4901985	chr14:60948318	A/C	cg27398547	chr14:60952738	C14orf39	1.35	10.21	0.68	3.99e-18	Gut microbiota (bacterial taxa);
TGCT	cis	rs12142240	0.698	rs72677587	chr1:46813982	G/A	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs561341	0.739	rs6505267	chr17:30225950	A/C	cg13647721	chr17:30228624	UTP6	0.62	4.93	0.4	2.6e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs7043114	0.525	rs7047089	chr9:95117980	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-5.56	-0.45	1.61e-7	Height;
TGCT	cis	rs921968	0.541	rs6717433	chr2:219375711	G/C	cg02176678	chr2:219576539	TTLL4	-0.48	-6.84	-0.52	3.21e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs12049351	0.665	rs10449251	chr1:229640911	A/G	cg12130225	chr1:229698885	NA	-0.39	-4.59	-0.38	1.06e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs6429082	0.783	rs390539	chr1:235679690	A/C	cg26050004	chr1:235667680	B3GALNT2	0.6	5.38	0.43	3.65e-7	Adiposity;
TGCT	cis	rs4246949	0.681	rs10902810	chr10:125521877	G/C	cg12769705	chr10:125521557	CPXM2	-0.43	-4.82	-0.4	4.09e-6	Ulcerative colitis;
TGCT	cis	rs2239547	0.563	rs9839035	chr3:52909877	C/T	cg10802521	chr3:52805072	NEK4	-0.58	-5.46	-0.44	2.53e-7	Schizophrenia;
TGCT	cis	rs7091068	0.522	rs11187621	chr10:95483074	T/C	cg20715218	chr10:95462985	C10orf4	0.5	4.86	0.4	3.49e-6	Urinary tract infection frequency;
TGCT	cis	rs11190604	1.000	rs7477246	chr10:102261538	C/T	cg23241863	chr10:102295624	HIF1AN	0.67	5.13	0.42	1.1e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9467773	0.583	rs2498380	chr6:26643996	C/G	cg15659132	chr6:26577336	NA	-0.84	-10.66	-0.69	3.09e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs3809566	0.654	rs4775606	chr15:63327605	A/G	cg00520135	chr15:63333846	TPM1	-0.43	-5.35	-0.43	4.07e-7	Platelet count;
TGCT	cis	rs1012621	0.715	rs214809	chr20:2295066	C/G	cg20323491	chr20:3218393	SLC4A11	0.33	4.47	0.37	1.73e-5	Inflammatory skin disease;
TGCT	cis	rs184907858	1	rs184907858	chr11:47211786	A/G	cg13308137	chr11:47528955	CUGBP1	0.38	4.48	0.37	1.65e-5	Total body bone mineral density;
TGCT	cis	rs7178572	1.000	rs965480	chr15:77781926	A/G	cg15453836	chr15:77711506	NA	-0.4	-4.59	-0.38	1.07e-5	Type 2 diabetes;
TGCT	cis	rs9303401	0.614	rs56284918	chr17:57178838	A/G	cg25039879	chr17:56429692	SUPT4H1	0.55	4.9	0.4	2.93e-6	Cognitive test performance;
TGCT	cis	rs61867294	0.553	rs1404787	chr10:106727681	A/G	cg08000847	chr10:105880925	C10orf78	0.48	4.46	0.37	1.81e-5	Schizophrenia;
TGCT	cis	rs4720575	1.000	rs1074575	chr7:47090545	A/C	cg00036614	chr7:47093842	NA	-0.22	-5.48	-0.44	2.23e-7	Angiotensin-converting enzyme inhibitor intolerance;
TGCT	cis	rs6430585	0.528	rs115553816	chr2:136692893	G/A	cg07169764	chr2:136633963	MCM6	1.25	12.67	0.75	4.02e-24	Corneal structure;
TGCT	cis	rs7666738	0.791	rs10017624	chr4:98984009	G/T	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7666738	0.791	rs11097601	chr4:98960103	C/T	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg26338869	chr17:61819248	STRADA	-0.53	-4.87	-0.4	3.29e-6	Prudent dietary pattern;
TGCT	cis	rs6969780	0.722	rs983185	chr7:27188607	G/A	cg11410718	chr7:27170412	HOXA4	-0.47	-4.52	-0.38	1.42e-5	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg21280719	chr6:42927975	GNMT	-0.37	-4.54	-0.38	1.32e-5	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs1008375	0.900	rs10019460	chr4:17686337	T/C	cg18681998	chr4:17616180	MED28	-0.87	-8.73	-0.62	1.45e-14	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs709400	0.633	rs7160208	chr14:103965528	G/A	cg12935359	chr14:103987150	CKB	-0.36	-5.64	-0.45	1.11e-7	Body mass index;
TGCT	cis	rs11671005	0.735	rs11670871	chr19:58940514	C/T	cg13877915	chr19:58951672	ZNF132	-0.63	-4.97	-0.41	2.14e-6	Mean platelet volume;
TGCT	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg19626725	chr5:178986131	RUFY1	0.55	7.64	0.57	5.16e-12	Lung cancer;
TGCT	cis	rs2013441	1.000	rs4924809	chr17:20044673	C/T	cg23224458	chr17:20280056	CCDC144C	0.38	4.61	0.38	9.96e-6	Obesity-related traits;
TGCT	cis	rs3748682	0.821	rs12751325	chr1:38289383	T/C	cg04496824	chr1:38276835	MTF1	0.21	4.55	0.38	1.26e-5	Hypothyroidism;
TGCT	cis	rs6921919	0.583	rs6922374	chr6:28381272	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.54	-5.25	-0.43	6.29e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs11190604	1.000	rs3750626	chr10:102266316	C/T	cg23241863	chr10:102295624	HIF1AN	0.67	5.13	0.42	1.1e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs886427	0.517	rs12918697	chr16:3002851	G/C	cg27042294	chr16:2982532	FLYWCH1	0.21	4.56	0.38	1.2e-5	Metabolic syndrome;
TGCT	cis	rs807669	0.903	rs807666	chr22:19160549	C/T	cg02655711	chr22:19163373	SLC25A1	0.42	10.06	0.67	8.99e-18	Metabolite levels;
TGCT	cis	rs826838	0.967	rs826856	chr12:39115434	G/A	cg26384229	chr12:38710491	ALG10B	-0.86	-7.76	-0.57	2.68e-12	Heart rate;
TGCT	cis	rs1949733	1.000	rs1357481	chr4:8496221	A/T	cg11789530	chr4:8429930	ACOX3	0.56	5.21	0.42	7.55e-7	Response to antineoplastic agents;
TGCT	cis	rs6750047	0.549	rs151096	chr2:38316571	A/C	cg07380506	chr2:38303506	CYP1B1	-0.59	-5.47	-0.44	2.39e-7	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs7666738	0.830	rs4401456	chr4:98959902	C/T	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7904368	0.659	rs3740169	chr10:16873547	C/T	cg14835575	chr10:16859367	RSU1	0.52	5.58	0.45	1.43e-7	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
TGCT	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg10802521	chr3:52805072	NEK4	-0.71	-8.81	-0.62	9.29e-15	Bipolar disorder;
TGCT	cis	rs9796	0.553	rs1869908	chr15:41257224	C/A	cg18705301	chr15:41695430	NDUFAF1	0.57	7.44	0.56	1.47e-11	Menopause (age at onset);
TGCT	cis	rs6087771	0.682	rs2038397	chr20:30217759	A/G	cg18721089	chr20:30220636	NA	-0.43	-5.37	-0.43	3.7e-7	Subcortical brain region volumes;Putamen volume;
TGCT	cis	rs79387448	0.745	rs72993722	chr2:103124916	A/G	cg09003973	chr2:102972529	NA	0.87	5.8	0.46	5.22e-8	Gut microbiota (bacterial taxa);
TGCT	cis	rs11677370	0.561	rs10084170	chr2:3820204	G/C	cg17052675	chr2:3827356	NA	-0.46	-8.18	-0.59	2.9e-13	Type 2 diabetes;
TGCT	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7226408	0.857	rs72887031	chr18:34472083	C/A	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs478222	0.930	rs510107	chr2:25319471	G/A	cg01884057	chr2:25150051	NA	-0.26	-4.82	-0.4	4.04e-6	Type 1 diabetes;
TGCT	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg22166914	chr1:53195759	ZYG11B	0.37	6.17	0.48	8.84e-9	Monocyte count;
TGCT	cis	rs7666738	0.830	rs28867388	chr4:98962794	A/T	cg05340658	chr4:99064831	C4orf37	0.53	5.93	0.47	2.85e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2404602	0.669	rs8036703	chr15:76951040	A/G	cg22467129	chr15:76604101	ETFA	-0.44	-4.87	-0.4	3.36e-6	Blood metabolite levels;
TGCT	cis	rs28374715	0.681	rs28728213	chr15:41653602	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.88	-14.18	-0.79	1e-27	Ulcerative colitis;
TGCT	cis	rs34638657	0.732	rs62045964	chr16:82200920	T/C	cg09439754	chr16:82129088	HSD17B2	-0.24	-4.53	-0.38	1.37e-5	Lung adenocarcinoma;
TGCT	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7584330	0.704	rs7602387	chr2:238356795	A/G	cg14458575	chr2:238380390	NA	0.49	7.56	0.56	7.65e-12	Prostate cancer;
TGCT	cis	rs8078723	1.000	rs8078723	chr17:38166879	A/G	cg17467752	chr17:38218738	THRA	0.54	5.22	0.42	7.25e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs950776	0.642	rs7178007	chr15:78965254	G/A	cg03762349	chr15:79060523	ADAMTS7	0.27	5.35	0.43	4.08e-7	Sudden cardiac arrest;
TGCT	cis	rs4332037	0.539	rs11764590	chr7:2032803	C/T	cg25834613	chr7:1915315	MAD1L1	-0.47	-4.51	-0.38	1.48e-5	Bipolar disorder;
TGCT	cis	rs427394	0.632	rs377137	chr5:6740468	T/G	cg10857441	chr5:6722123	POLS	-0.28	-6.08	-0.48	1.38e-8	Menopause (age at onset);
TGCT	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.51	-4.82	-0.4	4.16e-6	Bipolar disorder;
TGCT	cis	rs7666738	0.830	rs17483521	chr4:98974058	A/T	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg11494091	chr17:61959527	GH2	0.6	14.54	0.79	1.46e-28	Prudent dietary pattern;
TGCT	trans	rs2243480	1.000	rs2533288	chr7:66056711	C/G	cg07424592	chr7:64974309	NA	1.3	8.23	0.59	2.19e-13	Diabetic kidney disease;
TGCT	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg22920501	chr2:26401640	FAM59B	-0.78	-6.26	-0.49	5.88e-9	Gut microbiome composition (summer);
TGCT	cis	rs986417	0.818	rs2092722	chr14:61062890	T/A	cg27398547	chr14:60952738	C14orf39	1.33	9.93	0.67	1.82e-17	Gut microbiota (bacterial taxa);
TGCT	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	-0.95	-7.88	-0.58	1.45e-12	Platelet count;
TGCT	cis	rs9467773	0.595	rs7767847	chr6:26597893	A/T	cg15659132	chr6:26577336	NA	0.86	10.93	0.7	6.8e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs12142240	0.698	rs17361805	chr1:46813967	C/T	cg00765921	chr1:46154277	TMEM69	0.57	5.03	0.41	1.7e-6	Menopause (age at onset);
TGCT	cis	rs8054556	0.740	rs11649612	chr16:29946670	T/C	cg26859862	chr16:30389551	SEPT1	-0.53	-4.54	-0.38	1.31e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2832191	0.671	rs2832212	chr21:30511417	G/A	cg24692254	chr21:30365293	RNF160	-0.61	-5.41	-0.44	3.08e-7	Dental caries;
TGCT	cis	rs13191362	0.938	rs13213746	chr6:163167777	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.68	5.79	0.46	5.5e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs8180040	0.966	rs6792488	chr3:47503349	C/T	cg27129171	chr3:47204927	SETD2	-0.65	-7.68	-0.57	4.2e-12	Colorectal cancer;
TGCT	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg11494091	chr17:61959527	GH2	0.6	14.76	0.8	4.43e-29	Prudent dietary pattern;
TGCT	cis	rs9549367	0.601	rs558869	chr13:113849932	G/T	cg00898013	chr13:113819073	PROZ	0.53	7.2	0.54	5.17e-11	Platelet distribution width;
TGCT	cis	rs208520	0.526	rs2881644	chr6:66803535	A/C	cg07460842	chr6:66804631	NA	1.07	16.07	0.82	4.2e-32	Exhaled nitric oxide output;
TGCT	cis	rs1541995	0.824	rs12903641	chr15:96239445	A/T	cg00882281	chr15:96346592	NA	0.3	4.82	0.4	4.07e-6	Photic sneeze reflex;
TGCT	cis	rs1062177	0.756	rs2915826	chr5:151119963	G/A	cg00977110	chr5:151150581	G3BP1	-0.4	-4.67	-0.39	7.7e-6	Preschool internalizing problems;
TGCT	cis	rs7546668	0.640	rs6675825	chr1:15811346	C/T	cg17657618	chr1:15427654	KIAA1026	-0.25	-4.56	-0.38	1.19e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs7523273	0.565	rs2796232	chr1:207900368	T/A	cg22525895	chr1:207977042	MIR29B2	-0.32	-5.05	-0.41	1.53e-6	Schizophrenia;
TGCT	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg08859206	chr1:53392774	SCP2	0.4	5.97	0.47	2.38e-8	Monocyte count;
TGCT	cis	rs12693043	0.727	rs35923732	chr2:175413376	G/A	cg11778734	chr2:175439522	WIPF1	-0.4	-5.15	-0.42	9.9e-7	Urate levels (BMI interaction);
TGCT	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg07507251	chr3:52567010	NT5DC2	0.48	6.95	0.53	1.82e-10	Bipolar disorder;
TGCT	cis	rs709400	0.628	rs2273700	chr14:103923414	A/G	cg26031613	chr14:104095156	KLC1	0.86	9.43	0.65	2.96e-16	Body mass index;
TGCT	trans	rs324780	0.544	rs1873342	chr12:83915004	G/C	cg27144766	chr5:150604977	CCDC69	0.24	6.63	0.51	9.29e-10	Vertical cup-disc ratio;
TGCT	cis	rs3772130	1.000	rs62268732	chr3:121370455	T/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.55	5.02	0.41	1.77e-6	Cognitive performance;
TGCT	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	9.52	0.65	1.86e-16	Platelet count;
TGCT	cis	rs12908161	0.959	rs1051168	chr15:85200520	G/T	cg12863693	chr15:85201151	NMB	0.46	5.45	0.44	2.66e-7	Schizophrenia;
TGCT	cis	rs6546537	1.000	rs6546535	chr2:69833382	G/T	cg10773587	chr2:69614142	GFPT1	-0.65	-5.64	-0.45	1.09e-7	Serum thyroid-stimulating hormone levels;
TGCT	trans	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.84	9.34	0.64	4.98e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs6977660	0.660	rs61670426	chr7:19790460	A/G	cg05791153	chr7:19748676	TWISTNB	0.88	5.05	0.41	1.52e-6	Thyroid stimulating hormone;
TGCT	cis	rs7267979	0.789	rs6050472	chr20:25219852	A/G	cg21995068	chr20:25989032	LOC100134868	-0.39	-4.54	-0.38	1.3e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1023500	0.596	rs5758562	chr22:42448238	C/G	cg15557168	chr22:42548783	NA	-0.19	-4.84	-0.4	3.73e-6	Schizophrenia;
TGCT	cis	rs9653442	0.564	rs7601892	chr2:100789490	G/A	cg07810366	chr2:100720526	AFF3	-0.35	-5.26	-0.43	6e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs1055129	0.537	rs2467100	chr17:73949038	C/G	cg08125733	chr17:73851984	WBP2	0.55	5.32	0.43	4.7e-7	White matter hyperintensity burden;
TGCT	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg08439880	chr3:133502540	NA	-0.35	-6.91	-0.53	2.29e-10	Iron status biomarkers;
TGCT	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	16.07	0.82	4.16e-32	Prudent dietary pattern;
TGCT	cis	rs3806843	0.966	rs2563261	chr5:140137713	G/T	cg19875535	chr5:140030758	IK	-0.37	-6.23	-0.49	6.53e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs10832169	0.967	rs10832172	chr11:14072410	T/C	cg04547675	chr11:13986162	SPON1	0.51	4.51	0.38	1.49e-5	Blood protein levels;
TGCT	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg23708337	chr7:1209742	NA	0.64	5.94	0.47	2.63e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	trans	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg17470723	chr8:74884337	TCEB1	0.72	6.94	0.53	1.91e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1448094	0.717	rs7298614	chr12:86296513	C/T	cg00310523	chr12:86230176	RASSF9	0.34	4.77	0.39	5e-6	Major depressive disorder;
TGCT	cis	rs2112347	0.502	rs34342	chr5:74934213	A/C	cg19683494	chr5:74908142	NA	-0.65	-6.07	-0.48	1.42e-8	Body mass index (joint analysis main effects and smoking interaction);Waist circumference;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Hip circumference;Body mass index;Body mass index in physically active individuals;Obesity;
TGCT	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg05985448	chr10:134359359	INPP5A	0.21	4.67	0.39	7.69e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	trans	rs1496653	0.602	rs35245309	chr3:23419624	A/G	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs7772486	0.566	rs735536	chr6:146036832	A/C	cg23711669	chr6:146136114	FBXO30	-0.89	-10.12	-0.67	6.37e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs908922	0.676	rs6587681	chr1:152512135	C/T	cg20991723	chr1:152506922	NA	0.46	6.18	0.48	8.66e-9	Hair morphology;
TGCT	cis	rs1800469	1.000	rs2317130	chr19:41861674	C/T	cg09537434	chr19:41945824	ATP5SL	-0.52	-4.77	-0.39	5.08e-6	Colorectal cancer;
TGCT	cis	rs2439831	0.850	rs2439832	chr15:43779686	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.98	7.72	0.57	3.37e-12	Lung cancer in ever smokers;
TGCT	cis	rs3734905	1.000	rs12526225	chr6:169861325	T/C	cg05229362	chr6:169789120	NA	-0.48	-4.44	-0.37	1.94e-5	HIV-1 control;
TGCT	cis	rs1949733	0.701	rs1880024	chr4:8454639	A/G	cg13073564	chr4:8508604	NA	-0.42	-4.65	-0.39	8.41e-6	Response to antineoplastic agents;
TGCT	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg11764359	chr7:65958608	NA	-0.55	-5.08	-0.42	1.34e-6	Aortic root size;
TGCT	cis	rs4077515	0.874	rs3812575	chr9:139293259	T/C	cg13741927	chr9:139327495	INPP5E	-0.19	-4.59	-0.38	1.05e-5	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
TGCT	trans	rs4332037	0.539	rs56016347	chr7:2060126	C/T	cg25206134	chr2:45395956	NA	0.96	7.31	0.55	2.89e-11	Bipolar disorder;
TGCT	cis	rs9388451	0.626	rs2875881	chr6:126072853	C/G	cg10911889	chr6:126070802	HEY2	0.5	4.69	0.39	7.17e-6	Brugada syndrome;
TGCT	cis	rs939658	0.805	rs6495374	chr15:79434031	C/T	cg17916960	chr15:79447300	NA	-0.49	-7.41	-0.55	1.73e-11	Refractive error;
TGCT	cis	rs2688608	0.934	rs2675679	chr10:75658581	C/T	cg04320760	chr10:75533139	FUT11	-0.29	-4.44	-0.37	1.96e-5	Inflammatory bowel disease;
TGCT	cis	rs7044106	0.762	rs4142158	chr9:123410819	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.62	6.6	0.51	1.08e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs9810089	0.934	rs1279949	chr3:135996870	T/A	cg12473912	chr3:136751656	NA	0.35	4.9	0.4	2.9e-6	Gestational age at birth (child effect);
TGCT	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.66	0.39	8.18e-6	Prudent dietary pattern;
TGCT	cis	rs7246657	0.943	rs10409204	chr19:37917692	G/A	cg18154014	chr19:37997991	ZNF793	0.94	6.42	0.5	2.6e-9	Coronary artery calcification;
TGCT	cis	rs7666738	0.830	rs7664340	chr4:99037820	C/T	cg17366294	chr4:99064904	C4orf37	0.72	7.54	0.56	8.52e-12	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.88	9.92	0.67	1.99e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg24829409	chr8:58192753	C8orf71	-0.59	-5.18	-0.42	8.54e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg11062466	chr8:58055876	NA	0.42	4.48	0.37	1.71e-5	Developmental language disorder (linguistic errors);
TGCT	trans	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg21659725	chr3:3221576	CRBN	0.73	8.48	0.61	5.64e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs12477438	1.000	rs57846982	chr2:99921574	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-6.02	-0.48	1.87e-8	Chronic sinus infection;
TGCT	cis	rs910316	0.967	rs10246	chr14:75544470	T/A	cg23033748	chr14:75592666	NEK9	0.28	4.76	0.39	5.27e-6	Height;
TGCT	cis	rs12908161	0.920	rs35738019	chr15:85280210	T/C	cg12863693	chr15:85201151	NMB	0.44	5.21	0.42	7.63e-7	Schizophrenia;
TGCT	cis	rs3862435	0.518	rs2601169	chr15:90913890	T/C	cg14166756	chr15:90894880	ZNF774	-0.31	-4.88	-0.4	3.17e-6	Response to exercise (triglyceride level interaction);
TGCT	trans	rs7824557	0.507	rs7010590	chr8:11062882	C/T	cg15556689	chr8:8085844	FLJ10661	0.72	7.01	0.53	1.34e-10	Retinal vascular caliber;
TGCT	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg04546413	chr19:29218101	NA	0.84	6.82	0.52	3.52e-10	Methadone dose in opioid dependence;
TGCT	cis	rs9291683	0.609	rs12507050	chr4:10007305	G/T	cg00071950	chr4:10020882	SLC2A9	0.7	9.44	0.65	2.86e-16	Bone mineral density;
TGCT	cis	rs7044106	0.762	rs10760107	chr9:123383630	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	4.57	0.38	1.14e-5	Hip circumference adjusted for BMI;
TGCT	cis	rs11098499	0.954	rs12502423	chr4:120424172	A/C	cg09307838	chr4:120376055	NA	0.68	6.37	0.5	3.41e-9	Corneal astigmatism;
TGCT	cis	rs4631830	0.863	rs10826125	chr10:51530505	G/A	cg10326726	chr10:51549505	MSMB	-0.26	-5.3	-0.43	5.17e-7	Prostate-specific antigen levels;
TGCT	trans	rs6089829	0.925	rs4809270	chr20:61676709	C/A	cg17470723	chr8:74884337	TCEB1	0.78	6.87	0.53	2.7e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs4409675	0.576	rs1474908	chr1:28213213	C/T	cg23691781	chr1:28212827	C1orf38	-0.27	-5.28	-0.43	5.57e-7	Corneal astigmatism;
TGCT	cis	rs9818758	0.607	rs66991555	chr3:49228643	A/G	cg07636037	chr3:49044803	WDR6	-1.04	-5.13	-0.42	1.09e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs939574	1.000	rs7574937	chr2:220099331	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.04	5.78	0.46	5.83e-8	Platelet distribution width;
TGCT	cis	rs12142240	0.698	rs67200518	chr1:46835777	T/C	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs1153858	0.945	rs1974981	chr15:45729123	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.99	-12.56	-0.75	7.42e-24	Homoarginine levels;
TGCT	cis	rs4253772	0.550	rs738444	chr22:46721088	C/T	cg24881330	chr22:46731750	TRMU	0.94	6.36	0.5	3.54e-9	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs13242816	0.881	rs12706091	chr7:116130783	G/C	cg16553024	chr7:116138462	CAV2	-0.45	-5.04	-0.41	1.57e-6	P wave duration;
TGCT	cis	rs12477438	0.501	rs12613624	chr2:99732741	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.3	-0.68	2.42e-18	Chronic sinus infection;
TGCT	cis	rs17376456	0.877	rs56373208	chr5:93491276	C/A	cg21475434	chr5:93447410	FAM172A	0.63	4.63	0.38	8.98e-6	Diabetic retinopathy;
TGCT	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg03709012	chr19:19516395	GATAD2A	-0.67	-5.79	-0.46	5.55e-8	Tonsillectomy;
TGCT	trans	rs7615952	0.733	rs13314847	chr3:125644788	C/T	cg07211511	chr3:129823064	LOC729375	-0.48	-8.02	-0.58	6.91e-13	Blood pressure (smoking interaction);
TGCT	cis	rs2963155	0.518	rs853176	chr5:142636456	A/G	cg17617527	chr5:142782415	NR3C1	-0.83	-6.97	-0.53	1.63e-10	Breast cancer;
TGCT	cis	rs9527	0.544	rs3781280	chr10:104863843	T/G	cg15744005	chr10:104629667	AS3MT	-0.42	-4.84	-0.4	3.84e-6	Arsenic metabolism;
TGCT	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg03517284	chr6:25882590	NA	-0.69	-7.5	-0.56	1.07e-11	Blood metabolite levels;
TGCT	cis	rs651907	0.535	rs11714444	chr3:101513682	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.86	10.4	0.68	1.35e-18	Colorectal cancer;
TGCT	cis	rs2289577	0.698	rs17513180	chr6:90634912	A/G	cg19995471	chr6:90052148	UBE2J1	-0.31	-4.59	-0.38	1.08e-5	Cognitive performance;
TGCT	cis	rs12497850	0.864	rs4521268	chr3:49137904	G/T	cg18654377	chr3:49208889	KLHDC8B	-0.37	-4.69	-0.39	7.12e-6	Parkinson's disease;
TGCT	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg03264133	chr6:25882463	NA	-0.61	-6.51	-0.5	1.69e-9	Blood metabolite levels;
TGCT	cis	rs75229567	0.717	rs74527680	chr12:70235392	A/G	cg10114359	chr12:70132523	RAB3IP	1.55	7.66	0.57	4.5e-12	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
TGCT	cis	rs7727544	0.547	rs56083751	chr5:131664638	T/A	cg14196790	chr5:131705035	SLC22A5	0.34	4.79	0.4	4.62e-6	Blood metabolite levels;
TGCT	cis	rs11971779	0.941	rs7802779	chr7:139122579	G/T	cg07862535	chr7:139043722	LUC7L2	0.72	5.52	0.44	1.88e-7	Diisocyanate-induced asthma;
TGCT	cis	rs7611238	0.560	rs62288360	chr3:195089307	T/C	cg27323046	chr3:195102265	ACAP2	0.37	5.01	0.41	1.86e-6	Body mass index;
TGCT	cis	rs2760061	0.603	rs697762	chr1:228192410	G/A	cg18477163	chr1:228402036	OBSCN	0.34	6.91	0.53	2.25e-10	Diastolic blood pressure;
TGCT	cis	rs11874712	0.527	rs12709735	chr18:43687087	T/C	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.49	4.86	0.4	3.47e-6	Migraine - clinic-based;
TGCT	trans	rs10953454	1.000	rs35146170	chr7:104472431	T/C	cg04208666	chr6:19734707	NA	-0.57	-6.89	-0.53	2.54e-10	Obesity;
TGCT	cis	rs7017914	0.967	rs6998786	chr8:71694630	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.53	-4.98	-0.41	2.09e-6	Bone mineral density;
TGCT	trans	rs17471911	0.708	rs80045285	chr10:100776216	G/A	cg03484267	chr2:207988651	KLF7	-0.52	-6.7	-0.52	6.49e-10	Neuroticism;
TGCT	cis	rs17331151	0.573	rs79664140	chr3:52866936	A/G	cg07884673	chr3:53033167	SFMBT1	0.49	5.66	0.45	1.01e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs6977660	0.714	rs10276518	chr7:19781325	C/A	cg05791153	chr7:19748676	TWISTNB	0.89	5.08	0.41	1.37e-6	Thyroid stimulating hormone;
TGCT	cis	rs5769765	0.908	rs138867	chr22:50207703	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	1.05	10.64	0.69	3.55e-19	Schizophrenia;
TGCT	cis	rs9393777	0.720	rs13217285	chr6:26999845	C/T	cg16898833	chr6:26189333	HIST1H4D	1.01	5.9	0.47	3.18e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs1865760	0.566	rs9348706	chr6:26065481	G/C	cg16482183	chr6:26056742	HIST1H1C	0.58	4.97	0.41	2.19e-6	Height;
TGCT	cis	rs9549260	0.755	rs7986407	chr13:41179798	A/G	cg21288729	chr13:41239152	FOXO1	1.0	9.93	0.67	1.88e-17	Red blood cell count;
TGCT	cis	rs9473924	1.000	rs9463656	chr6:50859655	A/G	cg14470998	chr6:50812995	TFAP2B	0.61	4.48	0.37	1.7e-5	Body mass index;
TGCT	cis	rs826838	0.967	rs1719853	chr12:39128515	A/G	cg26384229	chr12:38710491	ALG10B	-0.83	-7.31	-0.55	2.88e-11	Heart rate;
TGCT	cis	rs4253772	0.591	rs6007726	chr22:46650858	A/C	cg09491104	chr22:46646882	C22orf40	-0.62	-6.49	-0.5	1.87e-9	LDL cholesterol;Cholesterol, total;
TGCT	trans	rs1814175	0.654	rs7482446	chr11:49779020	A/G	cg03929089	chr4:120376271	NA	-0.69	-8.17	-0.59	3.03e-13	Height;
TGCT	cis	rs2463822	0.858	rs2463836	chr11:62126494	A/G	cg23876832	chr11:62092739	NA	0.64	4.72	0.39	6.28e-6	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs7027203	0.521	rs9299412	chr9:96523268	G/T	cg13679303	chr9:96623674	NA	-0.53	-7.48	-0.56	1.18e-11	DNA methylation (variation);
TGCT	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg23708337	chr7:1209742	NA	0.44	4.97	0.41	2.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7089973	0.604	rs2420067	chr10:116590348	A/G	cg03647239	chr10:116582469	FAM160B1	0.59	5.75	0.46	6.46e-8	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs7572733	0.555	rs35563720	chr2:198923075	A/G	cg00792783	chr2:198669748	PLCL1	0.59	5.15	0.42	1.01e-6	Dermatomyositis;
TGCT	cis	rs8179	0.645	rs6960181	chr7:92277477	C/T	cg15732164	chr7:92237376	CDK6	-0.29	-5.06	-0.41	1.46e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
TGCT	cis	rs889512	0.642	rs72802352	chr16:75240883	G/A	cg08092318	chr16:75625571	NA	0.74	4.63	0.38	9.14e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs916888	0.821	rs70600	chr17:44860021	C/T	cg15921436	chr17:44337874	NA	0.51	6.96	0.53	1.77e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg06481639	chr22:41940642	POLR3H	0.69	5.92	0.47	2.95e-8	Vitiligo;
TGCT	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg02038168	chr22:39784481	NA	0.67	5.78	0.46	5.82e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7824557	0.806	rs7007394	chr8:11094566	G/A	cg21775007	chr8:11205619	TDH	-0.5	-4.55	-0.38	1.27e-5	Retinal vascular caliber;
TGCT	cis	rs2159324	1.000	rs2159324	chr19:45695738	A/G	cg24080119	chr19:45644694	NA	0.3	4.79	0.4	4.61e-6	Quantitative traits;
TGCT	cis	rs9914544	0.545	rs2386404	chr17:18769349	T/C	cg26378065	chr17:18585709	ZNF286B	0.52	4.5	0.37	1.56e-5	Educational attainment (years of education);
TGCT	cis	rs6032067	0.516	rs6032087	chr20:43902305	A/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.38	-5.96	-0.47	2.38e-8	Blood protein levels;
TGCT	cis	rs6570726	0.764	rs448258	chr6:145869145	C/A	cg23711669	chr6:146136114	FBXO30	0.89	9.93	0.67	1.82e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9682041	0.696	rs11709437	chr3:170085568	T/G	cg11886554	chr3:170076028	SKIL	0.6	4.76	0.39	5.35e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg09359103	chr1:154839909	KCNN3	-0.7	-13.89	-0.78	4.86e-27	Prostate cancer;
TGCT	cis	rs2688608	0.592	rs10824031	chr10:75509273	C/T	cg19442545	chr10:75533431	FUT11	-0.36	-5.74	-0.46	6.99e-8	Inflammatory bowel disease;
TGCT	cis	rs4285028	0.747	rs12634032	chr3:121524575	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-1.03	-8.75	-0.62	1.26e-14	Multiple sclerosis;
TGCT	cis	rs6912958	0.559	rs107689	chr6:88069333	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.69	7.0	0.53	1.43e-10	Monocyte percentage of white cells;
TGCT	cis	rs7666738	0.830	rs13122054	chr4:98972974	G/A	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs208520	0.690	rs207091	chr6:66799847	G/T	cg07460842	chr6:66804631	NA	-0.94	-9.91	-0.66	2.15e-17	Exhaled nitric oxide output;
TGCT	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg13944838	chr5:179740914	GFPT2	-0.4	-6.42	-0.5	2.66e-9	Height;
TGCT	cis	rs11690935	0.632	rs1607254	chr2:172626552	A/G	cg13550731	chr2:172543902	DYNC1I2	0.68	6.0	0.47	2.02e-8	Schizophrenia;
TGCT	cis	rs2228479	0.867	rs73276534	chr16:89950557	A/G	cg06558623	chr16:89946397	TCF25	0.4	4.73	0.39	5.89e-6	Skin colour saturation;
TGCT	cis	rs11098499	0.863	rs3822190	chr4:120428098	G/A	cg09307838	chr4:120376055	NA	0.68	6.37	0.5	3.36e-9	Corneal astigmatism;
TGCT	cis	rs2439831	1.000	rs689754	chr15:43775895	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	7.5	0.56	1.08e-11	Lung cancer in ever smokers;
TGCT	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg07507251	chr3:52567010	NT5DC2	0.47	6.64	0.51	8.85e-10	Electroencephalogram traits;
TGCT	cis	rs7666738	0.830	rs11942114	chr4:99066261	C/G	cg17366294	chr4:99064904	C4orf37	0.72	7.39	0.55	1.9e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7010267	0.773	rs4355801	chr8:119923873	A/G	cg17171407	chr8:119960777	TNFRSF11B	-0.28	-4.94	-0.41	2.46e-6	Total body bone mineral density (age 45-60);
TGCT	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg14582100	chr15:45693742	SPATA5L1	-0.49	-5.75	-0.46	6.62e-8	Homoarginine levels;
TGCT	cis	rs17152411	0.895	rs17151676	chr10:126583640	T/C	cg07906193	chr10:126599966	NA	0.41	5.06	0.41	1.48e-6	Height;
TGCT	cis	rs11785400	0.701	rs9297967	chr8:143723002	A/C	cg10596483	chr8:143751796	JRK	0.53	5.23	0.43	7.02e-7	Schizophrenia;
TGCT	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.0	8.22	0.59	2.32e-13	Platelet count;
TGCT	cis	rs7666738	0.830	rs34461023	chr4:99023751	C/T	cg18180107	chr4:99064573	C4orf37	0.57	5.24	0.43	6.72e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7647973	0.626	rs4855882	chr3:49715354	G/T	cg03034192	chr3:50606346	HEMK1;C3orf18	0.37	4.8	0.4	4.56e-6	Menarche (age at onset);
TGCT	cis	rs7727544	0.716	rs4594848	chr5:131586598	C/A	cg22598563	chr5:131563921	P4HA2	-0.28	-4.55	-0.38	1.27e-5	Blood metabolite levels;
TGCT	cis	rs514406	0.505	rs447581	chr1:53177098	T/C	cg08859206	chr1:53392774	SCP2	-0.36	-5.13	-0.42	1.1e-6	Monocyte count;
TGCT	cis	rs854765	0.663	rs12941550	chr17:17753828	C/A	cg04398451	chr17:18023971	MYO15A	0.3	4.6	0.38	1.02e-5	Total body bone mineral density;
TGCT	cis	rs72945132	0.882	rs7116191	chr11:70159781	G/A	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs7191700	0.644	rs918738	chr16:11439679	C/G	cg00044050	chr16:11439710	C16orf75	-0.97	-12.5	-0.75	1.05e-23	Multiple sclerosis;
TGCT	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg18876405	chr7:65276391	NA	0.31	4.8	0.4	4.53e-6	Aortic root size;
TGCT	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg11890956	chr21:40555474	PSMG1	1.1	12.36	0.74	2.27e-23	Cognitive function;
TGCT	cis	rs111803315	0.661	rs112716995	chr14:59978004	T/C	cg22995959	chr14:59931024	GPR135	0.66	4.8	0.4	4.39e-6	Schizophrenia;
TGCT	cis	rs7119	0.651	rs12902072	chr15:77848732	T/C	cg27398640	chr15:77910606	LINGO1	-0.28	-5.2	-0.42	7.98e-7	Type 2 diabetes;
TGCT	cis	rs751728	0.689	rs3763257	chr6:33773696	T/A	cg00334056	chr6:33755658	LEMD2	-0.26	-4.75	-0.39	5.41e-6	Crohn's disease;
TGCT	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg03188948	chr7:1209495	NA	0.44	5.38	0.43	3.64e-7	Longevity;Endometriosis;
TGCT	cis	rs986417	0.818	rs761557	chr14:61077484	C/T	cg13065475	chr14:61176368	SIX4	-0.32	-4.53	-0.38	1.34e-5	Gut microbiota (bacterial taxa);
TGCT	cis	rs524281	0.861	rs10896077	chr11:65851733	C/G	cg00563793	chr11:65837595	PACS1	0.56	4.68	0.39	7.32e-6	Electroencephalogram traits;
TGCT	cis	rs7772486	0.846	rs2892453	chr6:146377717	C/A	cg05347473	chr6:146136440	FBXO30	0.51	4.82	0.4	4.07e-6	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs2688608	0.672	rs2688622	chr10:75688981	C/A	cg13918328	chr10:52500089	ASAH2B	0.67	6.78	0.52	4.42e-10	Inflammatory bowel disease;
TGCT	cis	rs7017914	0.905	rs3110255	chr8:71938050	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-4.93	-0.4	2.63e-6	Bone mineral density;
TGCT	cis	rs62244186	0.748	rs4682987	chr3:44674996	C/T	cg02073558	chr3:44770973	ZNF501	0.64	6.22	0.49	7.06e-9	Depressive symptoms;
TGCT	cis	rs6901250	0.610	rs9400964	chr6:117144808	G/T	cg12892004	chr6:117198278	RFX6	0.42	5.07	0.41	1.4e-6	C-reactive protein levels;
TGCT	cis	rs2204008	0.774	rs7305085	chr12:38263511	C/T	cg13010199	chr12:38710504	ALG10B	0.64	4.97	0.41	2.15e-6	Bladder cancer;
TGCT	cis	rs2594989	0.943	rs2454500	chr3:11500103	C/T	cg26283222	chr3:11613257	VGLL4	-0.21	-4.49	-0.37	1.58e-5	Circulating chemerin levels;
TGCT	trans	rs9929218	0.529	rs35854485	chr16:68730855	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.53	6.71	0.52	6.1e-10	Colorectal cancer;
TGCT	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg13732083	chr21:47605072	C21orf56	-0.35	-4.51	-0.38	1.5e-5	Testicular germ cell tumor;
TGCT	cis	rs1865760	0.516	rs9379818	chr6:26023206	G/T	cg16482183	chr6:26056742	HIST1H1C	0.59	5.2	0.42	7.96e-7	Height;
TGCT	cis	rs9914544	0.966	rs9915346	chr17:18787931	G/A	cg26306683	chr17:18585705	ZNF286B	0.57	5.08	0.41	1.36e-6	Educational attainment (years of education);
TGCT	cis	rs7582180	0.663	rs4850930	chr2:100990955	T/C	cg08017756	chr2:100939284	LONRF2	-0.31	-5.14	-0.42	1.06e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg14773178	chr5:1868261	NA	0.34	5.62	0.45	1.21e-7	Cardiovascular disease risk factors;
TGCT	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg04234412	chr22:24373322	LOC391322	0.92	8.49	0.61	5.4e-14	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs16939607	1.000	rs16939605	chr8:79005815	C/G	cg21244580	chr8:79934476	NA	0.48	4.77	0.39	5e-6	White blood cell count;
TGCT	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg20607798	chr8:58055168	NA	0.44	4.54	0.38	1.32e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7582180	0.627	rs4851312	chr2:101011241	G/A	cg14675211	chr2:100938903	LONRF2	0.47	4.56	0.38	1.19e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg20887711	chr4:1340912	KIAA1530	-0.58	-4.97	-0.41	2.17e-6	Obesity-related traits;
TGCT	cis	rs7715806	0.500	rs17563589	chr5:74980019	A/G	cg19683494	chr5:74908142	NA	0.57	4.95	0.41	2.35e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs2180341	0.694	rs2875972	chr6:127585522	T/C	cg24812749	chr6:127587940	RNF146	0.83	6.69	0.51	6.91e-10	Breast cancer;
TGCT	cis	rs1018836	0.632	rs6988302	chr8:91477660	C/T	cg16814680	chr8:91681699	NA	-0.79	-8.28	-0.6	1.65e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7666738	0.791	rs10010438	chr4:99022177	C/T	cg17366294	chr4:99064904	C4orf37	0.68	7.04	0.53	1.17e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs36051895	0.623	rs28872016	chr9:5253558	T/G	cg02405213	chr9:5042618	JAK2	-0.71	-8.34	-0.6	1.18e-13	Pediatric autoimmune diseases;
TGCT	cis	rs12497850	0.864	rs12493001	chr3:49181885	A/G	cg06212747	chr3:49208901	KLHDC8B	0.61	5.4	0.44	3.31e-7	Parkinson's disease;
TGCT	cis	rs1371867	0.846	rs1788194	chr8:101277916	T/C	cg06636551	chr8:101224915	SPAG1	-0.49	-6.83	-0.52	3.32e-10	Atrioventricular conduction;
TGCT	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg10047753	chr17:41438598	NA	0.9	8.32	0.6	1.37e-13	Menopause (age at onset);
TGCT	trans	rs7819412	0.775	rs4841490	chr8:10936891	T/C	cg15556689	chr8:8085844	FLJ10661	-0.84	-8.16	-0.59	3.26e-13	Triglycerides;
TGCT	cis	rs6964587	1.000	rs7806184	chr7:91601978	A/G	cg22709100	chr7:91322751	NA	0.27	4.48	0.37	1.68e-5	Breast cancer;
TGCT	cis	rs13064447	0.935	rs7624347	chr3:12756045	T/A	cg20675869	chr3:12750130	NA	0.19	4.94	0.41	2.5e-6	Major depression and alcohol dependence;
TGCT	cis	rs9486719	1.000	rs2499816	chr6:96878206	C/T	cg06623918	chr6:96969491	KIAA0776	1.01	8.86	0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs7631605	0.819	rs1392748	chr3:37265313	T/C	cg17445812	chr3:36986805	TRANK1	0.22	4.78	0.39	4.77e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs12049351	0.719	rs34804247	chr1:229620685	C/T	cg12130225	chr1:229698885	NA	0.39	4.59	0.38	1.06e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs314370	0.570	rs314314	chr7:100423841	C/T	cg10426581	chr7:100472382	SRRT	0.72	7.45	0.56	1.37e-11	Resting heart rate;
TGCT	cis	rs2242116	0.896	rs724449	chr3:46935681	C/T	cg23352942	chr3:46931381	PTH1R	-0.37	-5.91	-0.47	3.05e-8	Birth weight;
TGCT	cis	rs2153535	0.580	rs9406143	chr6:8444583	C/T	cg07606381	chr6:8435919	SLC35B3	0.57	5.25	0.43	6.46e-7	Motion sickness;
TGCT	cis	rs2070488	1.000	rs4147025	chr3:38456531	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	9.65	0.65	9.06e-17	Electrocardiographic conduction measures;
TGCT	cis	rs12762955	0.561	rs7075141	chr10:1091195	C/T	cg20503657	chr10:835505	NA	-0.37	-4.86	-0.4	3.47e-6	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs7666738	0.606	rs6839946	chr4:99076132	A/C	cg18180107	chr4:99064573	C4orf37	0.53	4.67	0.39	7.59e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9372498	0.536	rs62422224	chr6:118941116	G/A	cg07617317	chr6:118971624	C6orf204	0.47	4.95	0.41	2.33e-6	Diastolic blood pressure;
TGCT	cis	rs62209	0.752	rs72772071	chr10:11011821	A/G	cg26901096	chr10:10994189	LOC254312	0.43	6.99	0.53	1.46e-10	Alzheimer's disease (late onset);
TGCT	cis	rs7552404	1.000	rs2133134	chr1:76179587	G/A	cg22875332	chr1:76189707	ACADM	0.79	9.77	0.66	4.68e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7226408	0.857	rs17652450	chr18:34473583	T/C	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	5.03	0.41	1.69e-6	Prudent dietary pattern;
TGCT	cis	rs3806933	0.522	rs17553936	chr5:110454681	A/G	cg04022379	chr5:110408740	TSLP	0.59	6.25	0.49	5.92e-9	Eosinophilic esophagitis;
TGCT	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg06238570	chr21:40685208	BRWD1	0.72	6.84	0.52	3.16e-10	Cognitive function;
TGCT	cis	rs1008375	0.933	rs4698637	chr4:17632843	A/T	cg10189774	chr4:17578691	LAP3	0.65	5.78	0.46	5.69e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs17102423	0.531	rs2763888	chr14:65571493	T/C	cg11161011	chr14:65562177	MAX	-0.47	-6.42	-0.5	2.67e-9	Obesity-related traits;
TGCT	cis	rs4819852	0.958	rs9606203	chr22:19972118	C/A	cg07821417	chr22:19972146	ARVCF	0.2	4.94	0.41	2.45e-6	Pulse pressure;
TGCT	cis	rs67311347	0.911	rs6776044	chr3:40377503	T/G	cg13683864	chr3:40499215	RPL14	-1.09	-11.46	-0.72	3.52e-21	Renal cell carcinoma;
TGCT	cis	rs2657888	1.000	rs7309685	chr12:56935413	A/G	cg23002907	chr12:56915593	RBMS2	-0.48	-6.6	-0.51	1.08e-9	Adiponectin levels;
TGCT	trans	rs7819412	0.807	rs9657519	chr8:10945439	A/G	cg06636001	chr8:8085503	FLJ10661	-0.8	-7.43	-0.56	1.52e-11	Triglycerides;
TGCT	cis	rs9325144	0.647	rs7316392	chr12:39064381	T/G	cg26384229	chr12:38710491	ALG10B	-0.55	-5.1	-0.42	1.22e-6	Morning vs. evening chronotype;
TGCT	cis	rs910316	0.789	rs4899552	chr14:75667921	C/A	cg11812906	chr14:75593930	NEK9	-0.61	-5.51	-0.44	2.01e-7	Height;
TGCT	cis	rs9807989	0.507	rs1833174	chr2:103034843	T/A	cg03938978	chr2:103052716	IL18RAP	0.27	5.41	0.44	3.17e-7	Asthma;
TGCT	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg11644478	chr21:40555479	PSMG1	1.03	11.12	0.71	2.32e-20	Cognitive function;
TGCT	cis	rs6940638	0.662	rs6915678	chr6:27235866	T/G	cg26531700	chr6:26746687	NA	-0.58	-4.98	-0.41	2.05e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	5.7	0.46	8.33e-8	Height;
TGCT	cis	rs7635838	0.718	rs2594973	chr3:11395821	C/G	cg00170343	chr3:11313890	ATG7	0.65	6.48	0.5	1.97e-9	HDL cholesterol;
TGCT	cis	rs7666738	0.830	rs11727235	chr4:98946331	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs523522	0.962	rs12309824	chr12:120990582	A/C	cg27279351	chr12:120934652	DYNLL1	0.74	6.43	0.5	2.45e-9	High light scatter reticulocyte count;
TGCT	cis	rs644799	0.511	rs10831420	chr11:95478209	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.59	5.76	0.46	6.12e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg12570787	chr5:219185	SDHA;CCDC127	0.65	4.46	0.37	1.83e-5	Breast cancer;
TGCT	cis	rs7772486	0.748	rs2748484	chr6:146333653	C/T	cg05347473	chr6:146136440	FBXO30	0.52	4.9	0.4	2.93e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg25036284	chr2:26402008	FAM59B	0.65	5.18	0.42	8.8e-7	Gut microbiome composition (summer);
TGCT	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg17554472	chr22:41940697	POLR3H	0.49	5.16	0.42	9.72e-7	Vitiligo;
TGCT	cis	rs10791097	0.694	rs1893018	chr11:130756632	T/C	cg14779329	chr11:130786720	SNX19	0.29	4.94	0.41	2.45e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs7568458	0.870	rs1058588	chr2:85808871	A/G	cg02493740	chr2:85810744	VAMP5	0.27	4.77	0.39	4.99e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs4836694	0.517	rs1017112	chr9:132936804	A/G	cg05251000	chr9:132935664	FREQ	0.53	6.02	0.48	1.8e-8	Alzheimer's disease (cognitive decline);
TGCT	cis	rs2147959	0.714	rs6670856	chr1:228723355	G/T	cg22700015	chr1:228743131	NA	-0.53	-4.45	-0.37	1.87e-5	Adult asthma;
TGCT	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg23719950	chr11:63933701	MACROD1	-0.71	-5.91	-0.47	3.06e-8	Mean platelet volume;
TGCT	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg04234412	chr22:24373322	LOC391322	-0.9	-10.44	-0.68	1.07e-18	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6433857	0.534	rs1157535	chr2:181361736	T/A	cg23363182	chr2:181467187	NA	-0.3	-4.57	-0.38	1.17e-5	Body mass index;
TGCT	cis	rs4499344	0.504	rs259248	chr19:33148041	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.76	7.52	0.56	9.49e-12	Mean platelet volume;
TGCT	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.4	-4.76	-0.39	5.31e-6	Longevity;Endometriosis;
TGCT	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg10047753	chr17:41438598	NA	0.96	9.86	0.66	2.71e-17	Menopause (age at onset);
TGCT	cis	rs72781680	0.800	rs56398785	chr2:24091515	T/A	cg08917208	chr2:24149416	ATAD2B	0.85	5.28	0.43	5.53e-7	Lymphocyte counts;
TGCT	cis	rs713587	0.967	rs6749422	chr2:25150011	C/G	cg15423357	chr2:25149977	NA	0.63	6.47	0.5	2.01e-9	Body mass index in non-asthmatics;
TGCT	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs11711311	1.000	rs9288984	chr3:113525956	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.7	-6.64	-0.51	8.96e-10	IgG glycosylation;
TGCT	cis	rs10875746	0.807	rs12297004	chr12:48453820	A/G	cg20731937	chr12:48336164	NA	0.62	4.95	0.41	2.36e-6	Longevity (90 years and older);
TGCT	cis	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg06558623	chr16:89946397	TCF25	0.53	6.84	0.52	3.24e-10	Skin colour saturation;
TGCT	cis	rs10206020	0.842	rs7590900	chr2:1574902	A/G	cg01028140	chr2:1542097	TPO	-0.28	-4.51	-0.38	1.47e-5	IgG glycosylation;
TGCT	cis	rs9325144	0.513	rs12313652	chr12:38665412	G/A	cg26384229	chr12:38710491	ALG10B	-0.66	-6.0	-0.47	2.06e-8	Morning vs. evening chronotype;
TGCT	cis	rs7786877	0.587	rs56328569	chr7:100202219	C/G	cg19543017	chr7:100164136	AGFG2	-0.32	-4.64	-0.38	8.85e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs908922	0.676	rs568661	chr1:152519787	C/A	cg20991723	chr1:152506922	NA	0.45	6.09	0.48	1.33e-8	Hair morphology;
TGCT	cis	rs459571	0.959	rs465535	chr9:136910905	C/T	cg13789015	chr9:136890014	NCRNA00094	0.39	6.81	0.52	3.72e-10	Platelet distribution width;
TGCT	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg20607798	chr8:58055168	NA	-0.5	-4.66	-0.39	8.04e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs208520	0.690	rs7764570	chr6:66827600	G/C	cg07460842	chr6:66804631	NA	-0.87	-8.37	-0.6	1.05e-13	Exhaled nitric oxide output;
TGCT	cis	rs62103177	0.608	rs34383580	chr18:77833263	A/G	cg07235805	chr18:78004237	PARD6G	-0.51	-4.98	-0.41	2.11e-6	Opioid sensitivity;
TGCT	trans	rs7726839	0.540	rs11738281	chr5:662547	T/C	cg25482853	chr8:67687455	SGK3	1.23	10.87	0.7	9.57e-20	Obesity-related traits;
TGCT	cis	rs11577318	0.853	rs2276712	chr1:26627478	T/C	cg04990556	chr1:26633338	UBXN11	-0.63	-5.83	-0.46	4.58e-8	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg03396347	chr1:1875803	NA	-0.36	-6.58	-0.51	1.19e-9	Body mass index;
TGCT	cis	rs3816788	0.620	rs11783414	chr8:21773384	A/G	cg17168535	chr8:21777572	XPO7	-0.78	-7.81	-0.57	2.09e-12	Lung cancer in ever smokers;
TGCT	cis	rs7914558	0.966	rs746293	chr10:104897254	G/T	cg15744005	chr10:104629667	AS3MT	-0.42	-5.24	-0.43	6.69e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs17270561	0.887	rs717551	chr6:25855624	T/C	cg17691542	chr6:26056736	HIST1H1C	0.82	4.88	0.4	3.15e-6	Iron status biomarkers;
TGCT	cis	rs62244186	0.748	rs4682987	chr3:44674996	C/T	cg21672276	chr3:44754072	ZNF502	-0.45	-5.0	-0.41	1.94e-6	Depressive symptoms;
TGCT	trans	rs7618501	0.501	rs35275715	chr3:49959148	A/G	cg21659725	chr3:3221576	CRBN	0.72	8.08	0.59	4.98e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.56	-5.46	-0.44	2.48e-7	Longevity;Endometriosis;
TGCT	cis	rs6933660	0.745	rs9397405	chr6:151736084	G/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.51	-4.62	-0.38	9.46e-6	Menarche (age at onset);
TGCT	cis	rs7178424	0.875	rs7179506	chr15:62187955	T/G	cg00456672	chr15:62358751	C2CD4A	-0.31	-4.69	-0.39	7.14e-6	Height;
TGCT	cis	rs10927875	0.631	rs945418	chr1:16344730	T/C	cg22431228	chr1:16359049	CLCNKA	-0.25	-4.64	-0.38	8.84e-6	Dilated cardiomyopathy;
TGCT	cis	rs2230307	0.536	rs834278	chr1:100510882	T/C	cg24955406	chr1:100503596	HIAT1	0.74	4.86	0.4	3.41e-6	Carotid intima media thickness;
TGCT	cis	rs6671200	0.607	rs10874908	chr1:95704151	C/G	cg26537280	chr1:95699037	RWDD3	-0.51	-4.9	-0.4	2.94e-6	Stearic acid (18:0) levels;
TGCT	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg05890377	chr2:74357713	NA	0.5	6.75	0.52	5.16e-10	Gestational age at birth (maternal effect);
TGCT	cis	rs3892630	0.619	rs61062732	chr19:33304717	T/C	cg22980127	chr19:33182716	NUDT19	0.74	6.02	0.48	1.84e-8	Red blood cell traits;
TGCT	cis	rs711245	1.000	rs848602	chr2:36778372	G/A	cg15105969	chr2:36825350	FEZ2	0.55	4.84	0.4	3.73e-6	Height;
TGCT	cis	rs1878931	0.501	rs42329	chr16:3425524	G/A	cg22508957	chr16:3507546	NAT15	0.39	5.15	0.42	9.92e-7	Body mass index (adult);
TGCT	cis	rs12477438	0.520	rs7604557	chr2:99747829	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.89	9.05	0.63	2.42e-15	Chronic sinus infection;
TGCT	cis	rs7824557	0.602	rs11784458	chr8:11204184	G/A	cg21775007	chr8:11205619	TDH	0.69	6.8	0.52	3.88e-10	Retinal vascular caliber;
TGCT	cis	rs78461346	0.706	rs76797925	chr17:80476993	G/C	cg15014069	chr17:80540666	FOXK2	0.38	5.0	0.41	1.91e-6	3-hydroxypropylmercapturic acid levels in smokers;
TGCT	cis	rs8078723	1.000	rs6503530	chr17:38161823	T/C	cg17467752	chr17:38218738	THRA	0.54	5.22	0.42	7.25e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs733175	0.855	rs9291641	chr4:10007259	C/T	cg11266682	chr4:10021025	SLC2A9	0.48	4.56	0.38	1.21e-5	Psychosis and Alzheimer's disease;
TGCT	cis	rs7681440	0.835	rs6532198	chr4:90798870	C/T	cg20003494	chr4:90757398	SNCA	-0.62	-5.94	-0.47	2.7e-8	Dementia with Lewy bodies;
TGCT	cis	rs7937682	0.855	rs11213985	chr11:111581521	C/A	cg09085632	chr11:111637200	PPP2R1B	-1.12	-12.34	-0.74	2.58e-23	Primary sclerosing cholangitis;
TGCT	cis	rs7119038	0.686	rs55894437	chr11:118607417	C/T	cg19308663	chr11:118741387	NA	0.23	4.54	0.38	1.29e-5	Sjögren's syndrome;
TGCT	cis	rs9527	0.545	rs11191602	chr10:104954219	C/T	cg15744005	chr10:104629667	AS3MT	-0.41	-4.78	-0.39	4.88e-6	Arsenic metabolism;
TGCT	cis	rs709400	0.550	rs942865	chr14:104015250	G/A	cg12935359	chr14:103987150	CKB	-0.46	-6.02	-0.48	1.87e-8	Body mass index;
TGCT	cis	rs7772486	0.720	rs7752286	chr6:146072662	C/T	cg23711669	chr6:146136114	FBXO30	-0.97	-11.03	-0.7	4.03e-20	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg17971929	chr21:40555470	PSMG1	0.95	8.7	0.62	1.67e-14	Cognitive function;
TGCT	cis	rs7267979	0.565	rs6076364	chr20:25556801	T/C	cg03522245	chr20:25566470	NINL	-0.44	-4.59	-0.38	1.06e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg00343986	chr7:65444356	GUSB	-0.25	-6.04	-0.48	1.67e-8	Corneal structure;
TGCT	cis	rs6570726	1.000	rs436066	chr6:145847127	C/T	cg05347473	chr6:146136440	FBXO30	0.49	4.44	0.37	1.96e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg16680214	chr1:154839983	KCNN3	-0.35	-7.11	-0.54	8.04e-11	Prostate cancer;
TGCT	cis	rs2153535	0.580	rs7741403	chr6:8530578	C/T	cg07606381	chr6:8435919	SLC35B3	-0.52	-4.85	-0.4	3.57e-6	Motion sickness;
TGCT	cis	rs826838	0.904	rs10880981	chr12:38763911	G/A	cg26384229	chr12:38710491	ALG10B	1.08	10.86	0.7	1.01e-19	Heart rate;
TGCT	cis	rs6570726	0.846	rs6570698	chr6:145918635	C/G	cg05347473	chr6:146136440	FBXO30	0.5	4.59	0.38	1.07e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2742417	0.603	rs2673055	chr3:45772772	G/A	cg04837898	chr3:45731254	SACM1L	-0.67	-7.3	-0.55	3.06e-11	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs12477438	0.520	rs13012481	chr2:99754290	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.85	8.37	0.6	1.02e-13	Chronic sinus infection;
TGCT	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg08280861	chr8:58055591	NA	0.56	6.34	0.49	3.88e-9	Developmental language disorder (linguistic errors);
TGCT	cis	rs7172809	0.796	rs4886870	chr15:77827471	A/C	cg22256960	chr15:77711686	NA	-0.44	-4.48	-0.37	1.67e-5	Glucose homeostasis traits;
TGCT	cis	rs6964587	0.869	rs10278155	chr7:91532456	T/G	cg17063962	chr7:91808500	NA	-0.86	-9.28	-0.64	6.82e-16	Breast cancer;
TGCT	cis	rs9902453	0.845	rs2617875	chr17:28090024	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	7.28	0.55	3.4e-11	Coffee consumption (cups per day);
TGCT	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg11247378	chr22:39784982	NA	-0.7	-9.59	-0.65	1.25e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs3096299	0.586	rs4572400	chr16:89533516	T/A	cg02187348	chr16:89574699	SPG7	0.58	5.83	0.46	4.47e-8	Multiple myeloma (IgH translocation);
TGCT	cis	rs12533831	0.654	rs2487151	chr7:150890241	C/T	cg04712895	chr7:150801789	AGAP3	-0.22	-4.66	-0.39	7.93e-6	Childhood ear infection;
TGCT	cis	rs7635838	0.927	rs13082150	chr3:11437813	T/C	cg00170343	chr3:11313890	ATG7	0.65	6.23	0.49	6.56e-9	HDL cholesterol;
TGCT	cis	rs2072438	0.503	rs1323474	chr9:123852859	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.44	4.47	0.37	1.77e-5	Rheumatoid arthritis;
TGCT	cis	rs5769707	0.933	rs2157444	chr22:49994292	A/G	cg10356904	chr22:49881777	NA	-0.24	-4.89	-0.4	3.11e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs1865760	0.602	rs9467662	chr6:26021327	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.8	7.57	0.56	7.45e-12	Height;
TGCT	cis	rs12891047	1.000	rs11158693	chr14:68241261	A/G	cg26938013	chr14:69015199	RAD51L1	-0.43	-4.54	-0.38	1.32e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs12701220	0.895	rs12534778	chr7:1065861	C/T	cg07217954	chr7:1067459	C7orf50	0.46	4.54	0.38	1.34e-5	Bronchopulmonary dysplasia;
TGCT	cis	rs4824093	0.544	rs73443957	chr22:50305515	T/C	cg20569369	chr22:51173646	NA	0.28	4.47	0.37	1.73e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs2153535	0.580	rs6597325	chr6:8461053	A/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg21724239	chr8:58056113	NA	0.34	4.64	0.38	8.88e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2230307	0.536	rs700533	chr1:100483822	A/G	cg24955406	chr1:100503596	HIAT1	0.74	4.83	0.4	4e-6	Carotid intima media thickness;
TGCT	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg11890956	chr21:40555474	PSMG1	0.8	7.66	0.57	4.53e-12	Cognitive function;
TGCT	cis	rs9473924	0.542	rs55648125	chr6:50816718	A/G	cg14470998	chr6:50812995	TFAP2B	1.32	6.51	0.5	1.65e-9	Body mass index;
TGCT	cis	rs9811920	0.809	rs4577503	chr3:99657922	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.46	5.2	0.42	7.88e-7	Axial length;
TGCT	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.05	-0.48	1.57e-8	Gut microbiome composition (summer);
TGCT	cis	rs42648	0.935	rs2188233	chr7:89958315	G/A	cg25739043	chr7:89950458	NA	-0.77	-7.39	-0.55	1.93e-11	Homocysteine levels;
TGCT	cis	rs16957091	0.647	rs28871732	chr15:43188848	C/T	cg17935677	chr15:44119062	WDR76	0.52	4.71	0.39	6.44e-6	MGMT methylation in smokers;
TGCT	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg02487422	chr3:49467188	NICN1	0.54	5.2	0.42	8.11e-7	Menarche (age at onset);
TGCT	cis	rs7216064	1.000	rs62085993	chr17:65923152	T/C	cg12091567	chr17:66097778	LOC651250	-0.81	-6.15	-0.48	9.71e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs9534288	0.797	rs2806922	chr13:46518059	A/G	cg15192986	chr13:46630673	CPB2	-0.51	-6.91	-0.53	2.28e-10	Blood protein levels;
TGCT	cis	rs11122272	0.766	rs2808614	chr1:231550168	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.71	6.89	0.53	2.5e-10	Hemoglobin concentration;
TGCT	cis	rs9814567	1.000	rs2370578	chr3:134199612	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.97	-9.24	-0.64	8.89e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs2299587	0.775	rs10113677	chr8:17767684	T/A	cg04898035	chr8:17640624	MTUS1	-0.21	-4.5	-0.37	1.56e-5	Economic and political preferences;
TGCT	cis	rs6121246	0.909	rs6060870	chr20:30303299	C/T	cg18721089	chr20:30220636	NA	-0.42	-4.65	-0.39	8.2e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg11764359	chr7:65958608	NA	-0.6	-5.32	-0.43	4.63e-7	Aortic root size;
TGCT	cis	rs12908161	1.000	rs11632465	chr15:85282045	A/T	cg11189052	chr15:85197271	WDR73	0.7	5.76	0.46	6.18e-8	Schizophrenia;
TGCT	cis	rs1153858	0.621	rs1719237	chr15:45579822	G/A	cg14582100	chr15:45693742	SPATA5L1	0.47	5.2	0.42	8.07e-7	Homoarginine levels;
TGCT	cis	rs208515	0.525	rs10944868	chr6:66687508	A/G	cg07460842	chr6:66804631	NA	0.87	9.16	0.64	1.32e-15	Exhaled nitric oxide levels;
TGCT	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg06618935	chr21:46677482	NA	-0.37	-5.51	-0.44	1.98e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs4455778	0.600	rs4478520	chr7:49079788	A/G	cg26309511	chr7:48887640	NA	0.5	6.47	0.5	2.03e-9	Lung cancer in never smokers;
TGCT	cis	rs2019872	0.810	rs9892559	chr17:2067737	C/A	cg24156229	chr17:1948635	NA	-0.36	-4.57	-0.38	1.15e-5	Schizophrenia;
TGCT	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg16414030	chr3:133502952	NA	-0.61	-9.66	-0.66	8.36e-17	Iron status biomarkers;
TGCT	cis	rs12908161	0.960	rs11633450	chr15:85307287	C/T	cg12863693	chr15:85201151	NMB	0.44	4.68	0.39	7.54e-6	Schizophrenia;
TGCT	cis	rs694739	0.595	rs11606015	chr11:64136877	C/G	cg23796481	chr11:64053134	BAD;GPR137	0.64	6.62	0.51	9.49e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs9814567	0.896	rs10935123	chr3:134345327	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-7.29	-0.55	3.14e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs7246657	0.943	rs7259968	chr19:37811854	T/C	cg18154014	chr19:37997991	ZNF793	0.74	5.08	0.42	1.34e-6	Coronary artery calcification;
TGCT	cis	rs7681440	1.000	rs7681440	chr4:90756550	C/G	cg14346243	chr4:90757452	SNCA	0.53	5.16	0.42	9.54e-7	Dementia with Lewy bodies;
TGCT	cis	rs838147	0.534	rs2638280	chr19:49209318	G/A	cg05248581	chr19:49925731	PTH2	0.43	4.7	0.39	6.89e-6	Dietary macronutrient intake;
TGCT	cis	rs7769051	1.000	rs3813347	chr6:133119778	G/A	cg07930552	chr6:133119739	C6orf192	0.94	5.04	0.41	1.6e-6	Type 2 diabetes nephropathy;
TGCT	cis	rs7926906	0.664	rs10765389	chr11:90519401	C/A	cg26138821	chr11:89956704	CHORDC1	-0.43	-4.53	-0.38	1.37e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.61	-6.11	-0.48	1.17e-8	Bipolar disorder;
TGCT	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg02487422	chr3:49467188	NICN1	0.5	4.55	0.38	1.24e-5	Parkinson's disease;
TGCT	cis	rs2072438	0.503	rs4837810	chr9:123881199	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.44	4.48	0.37	1.65e-5	Rheumatoid arthritis;
TGCT	cis	rs7432375	0.901	rs7616204	chr3:136444589	C/T	cg12473912	chr3:136751656	NA	-0.36	-5.06	-0.41	1.5e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9638182	0.778	rs3812316	chr7:73020337	C/G	cg14087351	chr7:73037990	MLXIPL	-0.71	-5.51	-0.44	1.95e-7	Triglycerides;
TGCT	cis	rs7599312	0.534	rs7607363	chr2:213402705	A/G	cg16329650	chr2:213403929	ERBB4	1.06	16.47	0.83	5.13e-33	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs6545883	0.791	rs2600665	chr2:61405795	G/T	cg15711740	chr2:61764176	XPO1	-0.54	-4.68	-0.39	7.34e-6	Tuberculosis;
TGCT	cis	rs9926296	0.656	rs2376882	chr16:89827002	T/C	cg03388025	chr16:89894329	SPIRE2	0.31	4.62	0.38	9.35e-6	Vitiligo;
TGCT	cis	rs3008870	1.000	rs1925412	chr1:67405057	G/A	cg11518657	chr1:67396239	MIER1	0.54	4.68	0.39	7.24e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs1461503	0.780	rs75981430	chr11:122842469	A/C	cg27398637	chr11:122830231	C11orf63	-0.42	-5.24	-0.43	6.58e-7	Menarche (age at onset);
TGCT	cis	rs1865760	0.713	rs1130000	chr6:25985396	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.72	6.94	0.53	1.97e-10	Height;
TGCT	cis	rs8032315	1.000	rs6227	chr15:91425232	C/T	cg03209642	chr15:91427605	FES	0.5	4.64	0.38	8.73e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6750047	0.585	rs336033	chr2:38263808	A/G	cg07380506	chr2:38303506	CYP1B1	-0.55	-5.03	-0.41	1.69e-6	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs11578119	0.933	rs12135326	chr1:170490570	G/A	cg09767346	chr1:170501363	GORAB	0.66	5.31	0.43	4.99e-7	Male-pattern baldness;
TGCT	cis	rs903263	0.965	rs12094426	chr1:84597131	T/A	cg09664975	chr1:84543551	PRKACB	0.5	4.74	0.39	5.69e-6	Breast cancer (male);
TGCT	cis	rs9811920	0.609	rs10936005	chr3:99674093	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.62	7.25	0.55	3.85e-11	Axial length;
TGCT	trans	rs2727020	0.894	rs1917328	chr11:49359606	G/A	cg03929089	chr4:120376271	NA	-0.65	-6.9	-0.53	2.32e-10	Coronary artery disease;
TGCT	trans	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	1.03	13.16	0.76	2.65e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs116095464	0.558	rs55838121	chr5:266890	G/A	cg22857025	chr5:266934	NA	-0.33	-6.69	-0.51	6.9e-10	Breast cancer;
TGCT	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg10295955	chr4:187884368	NA	0.96	14.59	0.79	1.08e-28	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7412746	0.611	rs4970984	chr1:150887377	T/C	cg04414720	chr1:150670196	GOLPH3L	0.37	4.46	0.37	1.81e-5	Melanoma;
TGCT	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg04944784	chr2:26401820	FAM59B	-0.68	-6.13	-0.48	1.1e-8	Gut microbiome composition (summer);
TGCT	cis	rs9611565	0.729	rs203320	chr22:41913477	T/C	cg03806693	chr22:41940476	POLR3H	-0.96	-10.58	-0.69	4.92e-19	Vitiligo;
TGCT	cis	rs2692947	0.832	rs2438978	chr2:96679740	G/C	cg13655245	chr2:97463316	CNNM4	0.16	4.71	0.39	6.63e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs79349575	0.783	rs58591767	chr17:47026076	G/A	cg26022315	chr17:47021804	SNF8	0.49	4.9	0.4	2.94e-6	Type 2 diabetes;
TGCT	cis	rs7017914	0.870	rs3098880	chr8:71938921	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-4.97	-0.41	2.16e-6	Bone mineral density;
TGCT	cis	rs9788682	0.948	rs59683676	chr15:78833453	T/C	cg24631222	chr15:78858424	CHRNA5	0.92	7.57	0.56	7.51e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg18252515	chr7:66147081	NA	-1.2	-7.83	-0.58	1.89e-12	Diabetic kidney disease;
TGCT	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg11764359	chr7:65958608	NA	0.59	5.09	0.42	1.31e-6	Aortic root size;
TGCT	cis	rs7666738	0.753	rs17027308	chr4:99091088	T/A	cg17366294	chr4:99064904	C4orf37	0.69	6.76	0.52	4.88e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10465746	0.725	rs1359331	chr1:84360301	C/A	cg10977910	chr1:84465055	TTLL7	0.68	6.7	0.52	6.46e-10	Obesity-related traits;
TGCT	cis	rs11578119	0.866	rs10919378	chr1:170354387	G/A	cg09767346	chr1:170501363	GORAB	0.61	4.61	0.38	9.8e-6	Male-pattern baldness;
TGCT	cis	rs72781680	0.752	rs55806536	chr2:23912697	A/G	cg08917208	chr2:24149416	ATAD2B	1.0	5.79	0.46	5.41e-8	Lymphocyte counts;
TGCT	cis	rs9560113	0.597	rs1163644	chr13:112241223	C/T	cg10483660	chr13:112241077	NA	-0.36	-5.58	-0.45	1.42e-7	Menarche (age at onset);
TGCT	cis	rs727563	0.555	rs5751136	chr22:42075581	T/A	cg13695892	chr22:41940480	POLR3H	0.9	8.67	0.61	1.99e-14	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs3858526	0.642	rs10838783	chr11:5900282	T/G	cg13902645	chr11:5959945	NA	-0.43	-4.61	-0.38	9.96e-6	DNA methylation (variation);
TGCT	trans	rs8073060	0.544	rs9912939	chr17:34005264	T/G	cg19694781	chr19:47549865	TMEM160	-0.6	-13.37	-0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs9916302	0.851	rs6503502	chr17:37501855	A/G	cg07936489	chr17:37558343	FBXL20	0.65	5.08	0.41	1.36e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg13395646	chr4:1353034	KIAA1530	-0.38	-4.65	-0.39	8.41e-6	Longevity;
TGCT	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6450176	0.909	rs3776721	chr5:53292522	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.49	-4.59	-0.38	1.08e-5	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs11650494	0.908	rs118099826	chr17:47447836	G/T	cg08112188	chr17:47440006	ZNF652	0.97	5.04	0.41	1.62e-6	Prostate cancer;
TGCT	cis	rs3749237	0.595	rs1050088	chr3:49570882	C/T	cg03060546	chr3:49711283	APEH	-0.74	-8.38	-0.6	9.96e-14	Resting heart rate;
TGCT	cis	rs1008375	0.863	rs10003291	chr4:17600728	A/C	cg16339924	chr4:17578868	LAP3	0.85	6.84	0.52	3.29e-10	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4803468	1.000	rs3810175	chr19:41904396	C/T	cg09537434	chr19:41945824	ATP5SL	0.89	10.04	0.67	9.93e-18	Height;
TGCT	cis	rs425277	0.606	rs3128295	chr1:2068480	C/T	cg24578937	chr1:2090814	PRKCZ	-0.26	-6.05	-0.48	1.57e-8	Height;
TGCT	cis	rs11676348	0.818	rs7423433	chr2:218985084	G/A	cg00012203	chr2:219082015	ARPC2	-0.52	-4.99	-0.41	2e-6	Ulcerative colitis;
TGCT	cis	rs9948	0.521	rs59648446	chr2:97351561	A/G	cg01990225	chr2:97406019	LMAN2L	-0.82	-4.74	-0.39	5.66e-6	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs6495367	1.000	rs1007365	chr15:79379492	T/G	cg17916960	chr15:79447300	NA	0.36	5.22	0.42	7.42e-7	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg06618935	chr21:46677482	NA	-0.37	-5.56	-0.45	1.58e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9811920	0.609	rs793463	chr3:99620252	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.6	-6.75	-0.52	5.15e-10	Axial length;
TGCT	cis	rs13256369	0.802	rs1060107	chr8:8561399	G/T	cg18904891	chr8:8559673	CLDN23	0.58	5.32	0.43	4.68e-7	Obesity-related traits;
TGCT	cis	rs7707921	0.602	rs10514231	chr5:81307412	C/T	cg15871215	chr5:81402204	ATG10	0.28	4.87	0.4	3.26e-6	Breast cancer;
TGCT	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.78	8.3	0.6	1.5e-13	Age at first birth;
TGCT	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.6	-5.9	-0.47	3.28e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg13732083	chr21:47605072	C21orf56	-0.35	-4.54	-0.38	1.31e-5	Testicular germ cell tumor;
TGCT	cis	rs2299587	0.554	rs2073567	chr8:17754034	G/A	cg04898035	chr8:17640624	MTUS1	-0.21	-4.7	-0.39	6.74e-6	Economic and political preferences;
TGCT	cis	rs2562456	0.761	rs35008138	chr19:21731624	A/T	cg01304269	chr19:21688519	ZNF429	0.57	4.74	0.39	5.86e-6	Pain;
TGCT	cis	rs727563	0.565	rs132774	chr22:42031953	C/G	cg03806693	chr22:41940476	POLR3H	-0.91	-8.88	-0.62	6.25e-15	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs7727544	0.631	rs13357280	chr5:131600187	A/G	cg24060327	chr5:131705240	SLC22A5	-0.54	-5.29	-0.43	5.45e-7	Blood metabolite levels;
TGCT	cis	rs17345786	0.520	rs12638134	chr3:101334609	G/T	cg12386194	chr3:101231763	SENP7	0.51	5.5	0.44	2.03e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6540559	0.546	rs74991018	chr1:210033790	T/G	cg22029157	chr1:209979665	IRF6	0.79	5.78	0.46	5.6e-8	Cleft lip with or without cleft palate;
TGCT	cis	rs11148252	0.538	rs9535879	chr13:52704624	T/A	cg00495681	chr13:53174319	NA	0.57	5.87	0.47	3.78e-8	Lewy body disease;
TGCT	cis	rs394563	0.591	rs11964335	chr6:149658101	A/T	cg16235748	chr6:149772707	ZC3H12D	0.44	5.06	0.41	1.47e-6	Dupuytren's disease;
TGCT	cis	rs2458413	0.903	rs2669448	chr8:105372324	T/G	cg04554929	chr8:105342491	NA	0.5	6.4	0.5	2.95e-9	Paget's disease;
TGCT	cis	rs10892173	0.716	rs12792357	chr11:117666595	C/T	cg07621104	chr11:117668040	DSCAML1	0.51	5.4	0.44	3.27e-7	Myopia;
TGCT	cis	rs4988958	0.584	rs12712149	chr2:103045193	A/G	cg03938978	chr2:103052716	IL18RAP	0.27	5.41	0.44	3.17e-7	Asthma (childhood onset);
TGCT	cis	rs11252926	0.563	rs10795103	chr10:451849	C/A	cg13477178	chr10:375248	DIP2C	-0.24	-4.44	-0.37	1.95e-5	Psychosis in Alzheimer's disease;
TGCT	cis	rs7772486	0.790	rs1062068	chr6:146207465	A/G	cg05347473	chr6:146136440	FBXO30	0.53	5.08	0.42	1.33e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9467711	0.606	rs9393707	chr6:26362486	T/C	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	trans	rs1908814	0.516	rs13281315	chr8:11794855	C/G	cg15556689	chr8:8085844	FLJ10661	0.75	7.26	0.55	3.66e-11	Neuroticism;
TGCT	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg26818010	chr10:134567672	INPP5A	-0.37	-5.02	-0.41	1.74e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs11239930	0.538	rs4950355	chr1:146554249	C/T	cg00044796	chr1:146552390	NA	-0.34	-4.46	-0.37	1.84e-5	AIDS progression;
TGCT	cis	rs7666738	0.830	rs28802909	chr4:99039410	G/A	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9916302	0.904	rs602282	chr17:37433021	C/T	cg07936489	chr17:37558343	FBXL20	-0.64	-5.03	-0.41	1.68e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs11098499	0.779	rs7356491	chr4:120381974	C/T	cg09307838	chr4:120376055	NA	0.71	6.98	0.53	1.57e-10	Corneal astigmatism;
TGCT	cis	rs9457247	0.935	rs401260	chr6:167405888	T/C	cg23791538	chr6:167370224	RNASET2	-0.49	-4.96	-0.41	2.26e-6	Crohn's disease;
TGCT	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs1448094	0.556	rs2061686	chr12:86170951	C/T	cg02569458	chr12:86230093	RASSF9	-0.39	-4.58	-0.38	1.14e-5	Major depressive disorder;
TGCT	cis	rs5769707	0.837	rs1573726	chr22:50032872	G/A	cg20744362	chr22:50050164	C22orf34	0.29	4.64	0.38	8.88e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs4499344	0.622	rs7246407	chr19:33061209	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.62	-5.31	-0.43	4.93e-7	Mean platelet volume;
TGCT	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg07157834	chr1:205819609	PM20D1	0.49	8.61	0.61	2.77e-14	Menarche (age at onset);
TGCT	cis	rs751728	0.717	rs3763258	chr6:33773744	A/G	cg13859433	chr6:33739653	LEMD2	-0.38	-6.73	-0.52	5.64e-10	Crohn's disease;
TGCT	cis	rs62209	0.800	rs201082	chr10:11005704	G/A	cg26901096	chr10:10994189	LOC254312	0.3	4.95	0.41	2.41e-6	Alzheimer's disease (late onset);
TGCT	cis	rs9399137	0.507	rs12663447	chr6:135317026	A/C	cg24558204	chr6:135376177	HBS1L	0.47	4.78	0.39	4.95e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
TGCT	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.75	0.52	5.11e-10	Bipolar disorder;
TGCT	trans	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg21659725	chr3:3221576	CRBN	0.67	7.53	0.56	9.05e-12	Body mass index;
TGCT	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg26338869	chr17:61819248	STRADA	0.52	4.83	0.4	3.94e-6	Prudent dietary pattern;
TGCT	cis	rs9926296	0.656	rs2376881	chr16:89827011	C/G	cg04287289	chr16:89883240	FANCA	0.68	6.85	0.52	3.13e-10	Vitiligo;
TGCT	cis	rs4499344	0.696	rs10402929	chr19:33100245	C/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	8.81	0.62	9.52e-15	Mean platelet volume;
TGCT	cis	rs1008375	1.000	rs1121091	chr4:17676386	A/C	cg18681998	chr4:17616180	MED28	0.89	10.2	0.68	4.06e-18	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6121246	0.609	rs4453755	chr20:30331047	G/A	cg13852791	chr20:30311386	BCL2L1	0.84	8.15	0.59	3.38e-13	Mean corpuscular hemoglobin;
TGCT	cis	rs13191362	1.000	rs13214516	chr6:163121583	A/T	cg21926612	chr6:163149169	PACRG;PARK2	1.16	9.92	0.67	1.96e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs2506889	0.553	rs11580264	chr1:10605796	C/A	cg17425144	chr1:10567563	PEX14	0.53	7.34	0.55	2.4e-11	Breast cancer;
TGCT	cis	rs9646954	0.542	rs4149512	chr2:101022886	C/T	cg14675211	chr2:100938903	LONRF2	0.5	4.76	0.39	5.2e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2180341	1.000	rs2144743	chr6:127633810	A/T	cg27446573	chr6:127587934	RNF146	1.12	10.11	0.67	6.87e-18	Breast cancer;
TGCT	cis	rs7572733	0.534	rs11899188	chr2:198740121	C/T	cg00792783	chr2:198669748	PLCL1	0.56	5.08	0.42	1.35e-6	Dermatomyositis;
TGCT	cis	rs1629083	0.875	rs4938490	chr11:118080977	G/A	cg16594165	chr11:118135105	MPZL2	-0.33	-4.59	-0.38	1.09e-5	Lung cancer;
TGCT	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg04267008	chr7:1944627	MAD1L1	-0.34	-4.6	-0.38	1.01e-5	Bipolar disorder and schizophrenia;
TGCT	cis	rs1362404	0.648	rs1861321	chr16:51992170	A/C	cg03955530	chr16:52681474	NA	0.31	4.55	0.38	1.24e-5	Gut microbiota (bacterial taxa);
TGCT	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.36	-4.45	-0.37	1.9e-5	Total body bone mineral density;
TGCT	cis	rs8103278	1.000	rs7252126	chr19:46302374	T/A	cg14061069	chr19:46274453	DMPK	-0.42	-5.81	-0.46	4.92e-8	Coronary artery disease;
TGCT	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg21862992	chr11:68658383	NA	0.48	6.84	0.52	3.19e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs57590327	0.508	rs4622918	chr3:81965382	A/G	cg07356753	chr3:81810745	GBE1	-0.74	-6.9	-0.53	2.41e-10	Extraversion;
TGCT	cis	rs7829975	0.623	rs10092965	chr8:8373485	A/G	cg15556689	chr8:8085844	FLJ10661	0.76	7.39	0.55	1.93e-11	Mood instability;
TGCT	cis	rs7666738	0.830	rs34313689	chr4:99013689	T/C	cg18180107	chr4:99064573	C4orf37	0.54	5.03	0.41	1.7e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs548987	0.507	rs35875210	chr6:25827484	A/G	cg12310025	chr6:25882481	NA	-0.57	-4.61	-0.38	9.67e-6	Homocysteine levels;
TGCT	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg08736216	chr1:53307985	ZYG11A	0.24	4.59	0.38	1.09e-5	Monocyte count;
TGCT	cis	rs1215050	0.791	rs1605259	chr4:98799732	T/C	cg05340658	chr4:99064831	C4orf37	0.44	5.51	0.44	2.01e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2739330	0.964	rs2739338	chr22:24297130	T/C	cg23131131	chr22:24373011	LOC391322	-0.81	-9.08	-0.63	2.09e-15	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs28595532	0.920	rs56322132	chr4:119742496	T/A	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs4654899	0.733	rs10799678	chr1:21322785	C/T	cg01072550	chr1:21505969	NA	-0.55	-8.91	-0.62	5.34e-15	Superior frontal gyrus grey matter volume;
TGCT	cis	rs6967414	0.786	rs3757482	chr7:6748927	A/G	cg09896999	chr7:6746977	ZNF12	-0.57	-6.37	-0.5	3.36e-9	Hematocrit;Hemoglobin concentration;
TGCT	cis	rs7412746	0.524	rs58304714	chr1:150831561	T/A	cg09365446	chr1:150670422	GOLPH3L	0.35	4.98	0.41	2.11e-6	Melanoma;
TGCT	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg10862848	chr6:42927986	GNMT	-0.38	-4.72	-0.39	6.35e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs7113874	0.569	rs10840077	chr11:8601210	A/T	cg14521421	chr11:8862019	ST5	-0.28	-4.44	-0.37	1.96e-5	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs1182436	1	rs1182436	chr7:157027753	T/C	cg05182265	chr7:156933206	UBE3C	0.27	4.49	0.37	1.59e-5	Type 2 diabetes;
TGCT	cis	rs12134133	1.000	rs1583090	chr1:207435783	T/C	cg02152968	chr1:207494213	CD55	0.63	4.88	0.4	3.22e-6	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs10254284	1.000	rs10254284	chr7:28167391	A/T	cg23620719	chr7:28220237	JAZF1	-0.56	-4.97	-0.41	2.21e-6	Lymphocyte percentage of white cells;Systemic lupus erythematosus;
TGCT	cis	rs1799949	0.965	rs4793237	chr17:41436595	A/T	cg10047753	chr17:41438598	NA	0.74	6.98	0.53	1.61e-10	Menopause (age at onset);
TGCT	cis	rs7772486	0.875	rs2748502	chr6:146298239	A/G	cg23711669	chr6:146136114	FBXO30	0.84	8.85	0.62	7.33e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs79349575	0.783	rs17708633	chr17:47011620	C/G	cg26022315	chr17:47021804	SNF8	0.49	4.9	0.4	2.94e-6	Type 2 diabetes;
TGCT	cis	rs6952808	0.609	rs6970033	chr7:1948087	G/A	cg04267008	chr7:1944627	MAD1L1	-0.37	-4.83	-0.4	3.94e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs4906332	0.966	rs34372508	chr14:103977515	G/A	cg26031613	chr14:104095156	KLC1	-0.54	-4.66	-0.39	8.15e-6	Coronary artery disease;
TGCT	cis	rs7246657	0.722	rs2927742	chr19:38133618	T/C	cg18154014	chr19:37997991	ZNF793	-0.68	-4.59	-0.38	1.09e-5	Coronary artery calcification;
TGCT	cis	rs9952991	0.566	rs34846641	chr18:12875975	A/G	cg23598886	chr18:12777645	NA	-0.55	-4.86	-0.4	3.43e-6	Inflammatory skin disease;
TGCT	cis	rs7104764	0.879	rs6598070	chr11:225466	T/C	cg18336825	chr11:236787	PSMD13;SIRT3	1.07	10.53	0.69	6.69e-19	Menarche (age at onset);
TGCT	cis	rs2933343	0.649	rs789219	chr3:128592520	G/A	cg11901034	chr3:128598214	ACAD9	-0.65	-6.02	-0.48	1.83e-8	IgG glycosylation;
TGCT	cis	rs6582630	0.537	rs3942440	chr12:38459672	A/G	cg13010199	chr12:38710504	ALG10B	0.58	4.72	0.39	6.16e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs9650657	0.645	rs4841408	chr8:10516336	A/G	cg27411982	chr8:10470053	RP1L1	-0.23	-4.98	-0.41	2.07e-6	Neuroticism;
TGCT	cis	rs7647973	0.626	rs62262722	chr3:49769419	G/C	cg05785598	chr3:49045655	WDR6	-0.44	-5.19	-0.42	8.17e-7	Menarche (age at onset);
TGCT	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg13206674	chr6:150067644	NUP43	0.52	4.46	0.37	1.78e-5	Lung cancer;
TGCT	cis	rs858239	0.600	rs28646184	chr7:23139595	T/C	cg05602783	chr7:23145260	KLHL7	-0.68	-5.76	-0.46	6.17e-8	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs924607	0.900	rs1697950	chr5:616890	G/A	cg04476341	chr5:669733	TPPP	-0.26	-4.57	-0.38	1.14e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs4851254	0.618	rs13001130	chr2:100668699	G/A	cg07810366	chr2:100720526	AFF3	-0.49	-5.04	-0.41	1.61e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg11494091	chr17:61959527	GH2	0.42	7.28	0.55	3.36e-11	Height;
TGCT	cis	rs6589563	0.737	rs61905086	chr11:116614863	T/C	cg26530557	chr11:116448269	NA	-0.27	-4.47	-0.37	1.73e-5	Eosinophil counts;
TGCT	cis	rs17345786	1.000	rs7641261	chr3:101279006	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.42	-8.66	-0.61	2.07e-14	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1483890	0.723	rs13075664	chr3:69411365	G/A	cg22125112	chr3:69402811	FRMD4B	0.29	4.74	0.39	5.85e-6	Resting heart rate;
TGCT	cis	rs7666738	0.830	rs62318906	chr4:99037110	C/T	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11085466	0.948	rs76881507	chr19:21762189	A/T	cg02997983	chr19:21646781	NA	-0.63	-4.53	-0.38	1.35e-5	Colorectal or endometrial cancer;
TGCT	cis	rs12911832	1.000	rs12911961	chr15:58985867	C/T	cg05156742	chr15:59063176	FAM63B	0.54	5.11	0.42	1.19e-6	Schizophrenia;
TGCT	cis	rs9457247	0.756	rs1811123	chr6:167403443	T/C	cg23791538	chr6:167370224	RNASET2	-0.46	-4.45	-0.37	1.87e-5	Crohn's disease;
TGCT	cis	rs1371867	0.846	rs2439460	chr8:101312665	C/T	cg00191853	chr8:101177733	SPAG1	-0.23	-4.76	-0.39	5.2e-6	Atrioventricular conduction;
TGCT	trans	rs11992162	0.597	rs7011924	chr8:11780593	G/A	cg15556689	chr8:8085844	FLJ10661	-0.79	-6.77	-0.52	4.69e-10	Monocyte count;
TGCT	cis	rs7772486	0.875	rs2180192	chr6:146322284	T/C	cg05347473	chr6:146136440	FBXO30	0.53	5.01	0.41	1.81e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2153535	0.541	rs6923558	chr6:8461467	T/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs10782582	0.609	rs5745325	chr1:76269460	G/A	cg10523679	chr1:76189770	ACADM	-0.58	-5.38	-0.43	3.6e-7	Daytime sleep phenotypes;
TGCT	cis	rs9296092	0.517	rs7743178	chr6:33470462	G/A	cg13560919	chr6:33536144	NA	-0.22	-4.49	-0.37	1.6e-5	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs17221829	0.703	rs10830347	chr11:89415165	C/T	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.44	-0.37	2e-5	Anxiety in major depressive disorder;
TGCT	cis	rs9611565	0.729	rs202654	chr22:41841034	G/A	cg06634786	chr22:41940651	POLR3H	0.81	7.71	0.57	3.43e-12	Vitiligo;
TGCT	cis	rs4746818	1.000	rs7909631	chr10:70918676	C/T	cg11621586	chr10:70884670	VPS26A	1.23	10.93	0.7	6.87e-20	Left atrial antero-posterior diameter;
TGCT	cis	rs9905704	0.647	rs6503892	chr17:57067086	G/A	cg05425664	chr17:57184151	TRIM37	-0.56	-4.44	-0.37	2e-5	Testicular germ cell tumor;
TGCT	cis	rs7666738	0.830	rs13328042	chr4:99055406	A/G	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.44e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7914558	0.933	rs2066323	chr10:104871361	A/G	cg04362960	chr10:104952993	NT5C2	0.63	5.64	0.45	1.07e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs45430	1.000	rs45430	chr21:42746081	C/T	cg22778903	chr21:42741698	MX2	0.31	5.23	0.43	6.92e-7	Melanoma;
TGCT	cis	rs6570726	0.791	rs13202312	chr6:145913093	T/G	cg13319975	chr6:146136371	FBXO30	-0.54	-4.77	-0.39	5.1e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs910316	0.967	rs12147532	chr14:75651858	T/G	cg23033748	chr14:75592666	NEK9	-0.27	-4.47	-0.37	1.73e-5	Height;
TGCT	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.51	-4.9	-0.4	2.98e-6	Longevity;Endometriosis;
TGCT	cis	rs7621025	0.664	rs6439657	chr3:136494639	C/T	cg15507776	chr3:136538369	TMEM22	-0.5	-4.55	-0.38	1.24e-5	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
TGCT	cis	rs4803468	1.000	rs11880539	chr19:41918949	A/C	cg09537434	chr19:41945824	ATP5SL	0.88	10.4	0.68	1.32e-18	Height;
TGCT	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg02503808	chr4:7069936	GRPEL1	1.01	9.65	0.66	8.71e-17	Monocyte percentage of white cells;
TGCT	cis	rs1401999	0.966	rs2139560	chr3:183653869	A/G	cg01324343	chr3:183735012	ABCC5	0.85	11.38	0.71	5.52e-21	Anterior chamber depth;
TGCT	cis	rs3820068	0.554	rs60233444	chr1:15921330	A/C	cg05660106	chr1:15850417	CASP9	0.84	8.27	0.6	1.8e-13	Systolic blood pressure;
TGCT	cis	rs7666738	0.783	rs10028584	chr4:98962404	C/T	cg18180107	chr4:99064573	C4orf37	0.57	5.18	0.42	8.63e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9467773	0.620	rs2101582	chr6:26622734	C/T	cg11502198	chr6:26597334	ABT1	0.51	4.78	0.39	4.82e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1372520	0.684	rs2583968	chr4:90745395	C/G	cg15133208	chr4:90757351	SNCA	-0.49	-5.69	-0.45	8.67e-8	Neuroticism;
TGCT	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs9910055	0.529	rs850851	chr17:42177674	C/T	cg19774624	chr17:42201019	HDAC5	0.69	6.36	0.5	3.46e-9	Total body bone mineral density;
TGCT	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg06481639	chr22:41940642	POLR3H	-0.74	-6.55	-0.51	1.41e-9	Vitiligo;
TGCT	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg27286337	chr10:134555280	INPP5A	0.45	5.32	0.43	4.64e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs861020	0.883	rs680331	chr1:209959872	G/A	cg05527609	chr1:210001259	C1orf107	0.91	7.99	0.58	7.87e-13	Orofacial clefts;
TGCT	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg08280861	chr8:58055591	NA	0.38	4.51	0.38	1.48e-5	Developmental language disorder (linguistic errors);
TGCT	trans	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg21659725	chr3:3221576	CRBN	0.65	7.16	0.54	6.39e-11	Body mass index;
TGCT	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg11890956	chr21:40555474	PSMG1	1.12	11.44	0.72	3.95e-21	Cognitive function;
TGCT	cis	rs7769051	0.711	rs9493437	chr6:133088405	A/T	cg07930552	chr6:133119739	C6orf192	0.87	4.55	0.38	1.27e-5	Type 2 diabetes nephropathy;
TGCT	cis	rs61990749	0.544	rs8003979	chr14:78211290	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.6	4.45	0.37	1.88e-5	Fibroblast growth factor basic levels;
TGCT	trans	rs525455	1.000	rs525535	chr10:13103316	G/A	cg21721093	chr17:8906386	NA	0.64	6.7	0.52	6.38e-10	Platelet aggregation;
TGCT	cis	rs6910741	0.592	rs9379800	chr6:25889099	C/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.78	5.3	0.43	5.02e-7	Blood pressure;
TGCT	cis	rs1062177	0.855	rs62395861	chr5:151269270	A/G	cg12924095	chr5:151150029	G3BP1	0.37	5.04	0.41	1.59e-6	Preschool internalizing problems;
TGCT	cis	rs4851266	0.898	rs12615145	chr2:100853116	C/T	cg07810366	chr2:100720526	AFF3	-0.36	-5.21	-0.42	7.59e-7	Educational attainment;
TGCT	cis	rs17401966	0.558	rs6541090	chr1:10402842	A/G	cg19773385	chr1:10388646	KIF1B	-0.22	-5.27	-0.43	5.96e-7	Hepatocellular carcinoma;
TGCT	cis	rs7582180	0.764	rs12999779	chr2:100924321	T/G	cg14675211	chr2:100938903	LONRF2	0.51	4.93	0.4	2.61e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7267979	0.586	rs1007708	chr20:25190959	C/T	cg16686733	chr20:25566563	NINL	0.55	5.49	0.44	2.17e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1476679	0.927	rs2405442	chr7:99971313	T/C	cg13334819	chr7:99746414	C7orf59	0.74	6.38	0.5	3.23e-9	Alzheimer's disease (late onset);
TGCT	cis	rs7193541	0.694	rs3896277	chr16:74480694	A/T	cg01733217	chr16:74700730	RFWD3	0.63	5.8	0.46	5.25e-8	Multiple myeloma;
TGCT	cis	rs6669072	0.647	rs814543	chr1:91241709	C/T	cg08895590	chr1:91227319	NA	0.34	4.51	0.38	1.5e-5	Cognitive function;
TGCT	cis	rs748404	0.660	rs690446	chr15:43761264	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	4.77	0.39	5.05e-6	Lung cancer;
TGCT	cis	rs13064411	0.660	rs1872747	chr3:113175785	T/A	cg18753928	chr3:113234510	CCDC52	-0.68	-4.74	-0.39	5.8e-6	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs11779988	0.571	rs208053	chr8:17825327	G/A	cg01800426	chr8:17659068	MTUS1	-0.66	-4.94	-0.41	2.42e-6	Breast cancer;
TGCT	cis	rs477895	0.838	rs11607007	chr11:64007976	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.84	7.07	0.54	1.02e-10	Mean platelet volume;
TGCT	cis	rs7027203	0.964	rs6479512	chr9:96556985	G/A	cg14396892	chr9:96623032	NA	0.25	4.78	0.39	4.79e-6	DNA methylation (variation);
TGCT	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg15691649	chr6:25882328	NA	-0.38	-5.03	-0.41	1.65e-6	Blood metabolite levels;
TGCT	cis	rs6471915	0.502	rs12548415	chr8:61968256	G/A	cg05142030	chr8:62551054	ASPH	0.24	4.51	0.38	1.48e-5	Prudent dietary pattern;
TGCT	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg25036284	chr2:26402008	FAM59B	-0.65	-5.19	-0.42	8.36e-7	Gut microbiome composition (summer);
TGCT	cis	rs2806561	0.765	rs623988	chr1:23519477	C/T	cg12483005	chr1:23474871	LUZP1	0.38	4.73	0.39	5.93e-6	Height;
TGCT	cis	rs6460942	0.915	rs62448621	chr7:12459941	G/A	cg06484146	chr7:12443880	VWDE	-0.57	-5.54	-0.45	1.71e-7	Coronary artery disease;
TGCT	cis	rs5769707	0.967	rs5770585	chr22:50007874	G/A	cg20744362	chr22:50050164	C22orf34	0.28	4.61	0.38	1e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs7681440	0.874	rs1372524	chr4:90776045	A/G	cg20003494	chr4:90757398	SNCA	-0.56	-5.35	-0.43	4.11e-7	Dementia with Lewy bodies;
TGCT	cis	rs2046867	0.818	rs62249860	chr3:72866073	T/G	cg25664220	chr3:72788482	NA	-0.56	-7.04	-0.53	1.16e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7772486	0.688	rs1884364	chr6:146337817	C/G	cg05347473	chr6:146136440	FBXO30	0.56	5.31	0.43	4.9e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1475911	0.708	rs56185023	chr21:43521538	T/C	cg19766460	chr21:43528205	UMODL1;C21orf128	0.64	9.26	0.64	7.72e-16	IgG glycosylation;
TGCT	cis	rs2180341	0.782	rs6912750	chr6:127723081	A/T	cg24812749	chr6:127587940	RNF146	0.65	5.19	0.42	8.37e-7	Breast cancer;
TGCT	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg08859206	chr1:53392774	SCP2	0.39	6.07	0.48	1.41e-8	Monocyte count;
TGCT	cis	rs736408	1.000	rs736408	chr3:52835354	C/T	cg18404041	chr3:52824283	ITIH1	-0.21	-4.45	-0.37	1.93e-5	Bipolar disorder;
TGCT	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg13342137	chr4:2252803	MXD4	0.17	4.46	0.37	1.84e-5	Obesity-related traits;
TGCT	cis	rs17221829	0.733	rs35757457	chr11:89358250	T/A	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.65	-0.39	8.43e-6	Anxiety in major depressive disorder;
TGCT	cis	rs6740322	0.895	rs6744746	chr2:43555805	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.39	6.65	0.51	8.25e-10	Coronary artery disease;
TGCT	cis	rs1055129	0.537	rs1135640	chr17:73949540	C/G	cg10935138	chr17:73851978	WBP2	-0.51	-4.58	-0.38	1.1e-5	White matter hyperintensity burden;
TGCT	cis	rs263156	0.903	rs263115	chr6:142885777	T/C	cg18419694	chr6:143832440	FUCA2	-0.38	-4.53	-0.38	1.36e-5	Ear morphology;Lobe size;Lobe attachment;
TGCT	cis	rs7666738	0.830	rs7679961	chr4:99000202	C/T	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9486715	0.867	rs4839687	chr6:96951732	C/A	cg18709589	chr6:96969512	KIAA0776	0.82	8.01	0.58	7.14e-13	Headache;
TGCT	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg22963979	chr7:1858916	MAD1L1	-0.36	-5.62	-0.45	1.21e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg09417038	chr21:47716443	C21orf57	-0.32	-4.83	-0.4	3.95e-6	Testicular germ cell tumor;
TGCT	cis	rs6546537	0.550	rs6546531	chr2:69779963	C/A	cg10773587	chr2:69614142	GFPT1	-0.65	-5.94	-0.47	2.7e-8	Serum thyroid-stimulating hormone levels;
TGCT	cis	rs60843830	1.000	rs62114505	chr2:242426	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.76	7.7	0.57	3.78e-12	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg11890956	chr21:40555474	PSMG1	-0.73	-7.15	-0.54	6.65e-11	Menarche (age at onset);
TGCT	cis	rs4499344	0.535	rs7260509	chr19:33121595	G/A	cg26639809	chr19:33781782	NA	0.24	5.11	0.42	1.18e-6	Mean platelet volume;
TGCT	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg04352962	chr1:209979756	IRF6	0.61	4.67	0.39	7.72e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg09033563	chr22:24373618	LOC391322	-0.46	-4.49	-0.37	1.61e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7027203	1.000	rs7027203	chr9:96562563	A/C	cg13679303	chr9:96623674	NA	0.65	9.81	0.66	3.61e-17	DNA methylation (variation);
TGCT	cis	rs9807989	0.839	rs6749114	chr2:102967587	A/C	cg09003973	chr2:102972529	NA	0.64	5.7	0.46	8.28e-8	Asthma;
TGCT	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg00149659	chr3:10157352	C3orf10	0.78	4.99	0.41	2.04e-6	Alzheimer's disease;
TGCT	cis	rs7336332	0.569	rs7988412	chr13:28000282	C/T	cg22138327	chr13:27999177	GTF3A	0.9	7.49	0.56	1.12e-11	Weight;
TGCT	cis	rs903263	0.932	rs1521518	chr1:84601048	T/C	cg09664975	chr1:84543551	PRKACB	0.5	4.74	0.39	5.73e-6	Breast cancer (male);
TGCT	cis	rs1532993	0.518	rs4330355	chr4:98638317	C/T	cg05340658	chr4:99064831	C4orf37	0.42	4.82	0.4	4.03e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs6912958	0.703	rs9359748	chr6:88095500	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.61	6.04	0.48	1.66e-8	Monocyte percentage of white cells;
TGCT	cis	rs7267979	1.000	rs6107046	chr20:25442049	G/A	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs478304	0.651	rs11604462	chr11:65551648	G/A	cg27068330	chr11:65405492	SIPA1	-0.95	-9.42	-0.65	3.19e-16	Acne (severe);
TGCT	cis	rs713587	0.520	rs522806	chr2:25316584	C/A	cg01884057	chr2:25150051	NA	-0.26	-4.82	-0.4	4.04e-6	Body mass index in non-asthmatics;
TGCT	cis	rs765787	0.530	rs2413786	chr15:45525394	C/A	cg24006582	chr15:45444508	DUOX1	-0.25	-5.54	-0.45	1.75e-7	Uric acid levels;
TGCT	cis	rs2075165	0.901	rs10908492	chr1:156224795	C/T	cg20302342	chr1:156215951	PAQR6	0.39	5.67	0.45	9.49e-8	Tonsillectomy;
TGCT	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg04267008	chr7:1944627	MAD1L1	-0.36	-4.82	-0.4	4.05e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs1568889	1.000	rs1568889	chr11:28009463	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.97	8.72	0.62	1.51e-14	Bipolar disorder;
TGCT	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg20607798	chr8:58055168	NA	0.67	5.62	0.45	1.22e-7	Developmental language disorder (linguistic errors);
TGCT	trans	rs1974653	0.631	rs41281423	chr22:20097730	C/T	cg08822737	chr17:71088851	SLC39A11	-0.93	-7.65	-0.57	4.76e-12	Schizophrenia;
TGCT	cis	rs35146811	0.695	rs858509	chr7:99821470	A/G	cg00553149	chr7:99775558	STAG3;GPC2	-0.32	-4.81	-0.4	4.28e-6	Coronary artery disease;
TGCT	cis	rs2033711	0.936	rs3794968	chr19:58986799	G/C	cg13877915	chr19:58951672	ZNF132	0.81	8.73	0.62	1.43e-14	Uric acid clearance;
TGCT	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	5.24	0.43	6.73e-7	Menopause (age at onset);
TGCT	cis	rs4727027	0.704	rs12535154	chr7:148895304	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	4.45	0.37	1.9e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs6988636	1.000	rs13261100	chr8:124190312	G/A	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs8033133	0.560	rs1549478	chr15:25332200	T/C	cg14481604	chr15:25334117	SNORD116-22	-0.23	-4.84	-0.4	3.82e-6	Blood osmolality (transformed sodium);
TGCT	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg09033563	chr22:24373618	LOC391322	-0.47	-4.64	-0.38	8.83e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs13256369	0.851	rs11249890	chr8:8565245	G/T	cg18904891	chr8:8559673	CLDN23	0.59	5.46	0.44	2.54e-7	Obesity-related traits;
TGCT	cis	rs7674212	0.541	rs4699051	chr4:104114394	T/C	cg16532752	chr4:104119610	CENPE	-0.61	-5.67	-0.45	9.45e-8	Type 2 diabetes;
TGCT	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg06873352	chr17:61820015	STRADA	0.56	6.22	0.49	6.93e-9	Prudent dietary pattern;
TGCT	cis	rs7973719	1.000	rs12828421	chr12:7335217	C/T	cg07052231	chr12:7363540	PEX5	-0.33	-4.93	-0.4	2.61e-6	IgG glycosylation;
TGCT	cis	rs3733606	0.503	rs11734132	chr4:6891519	C/G	cg18375902	chr4:7764949	AFAP1;LOC84740	-0.23	-4.62	-0.38	9.37e-6	Platelet count;
TGCT	cis	rs1008375	1.000	rs7694020	chr4:17682597	C/T	cg18681998	chr4:17616180	MED28	0.95	11.38	0.71	5.45e-21	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs16986825	0.607	rs5762852	chr22:29242473	T/C	cg02153584	chr22:29168773	CCDC117	0.67	4.57	0.38	1.17e-5	Pancreatic cancer;
TGCT	cis	rs7914558	0.933	rs12763665	chr10:104653717	G/A	cg15744005	chr10:104629667	AS3MT	-0.41	-5.09	-0.42	1.29e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg18188782	chr20:61659543	NA	0.46	5.5	0.44	2.03e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9638182	0.667	rs33951980	chr7:73029437	C/T	cg14087351	chr7:73037990	MLXIPL	-0.74	-5.15	-0.42	9.73e-7	Triglycerides;
TGCT	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg06238570	chr21:40685208	BRWD1	0.68	6.32	0.49	4.3e-9	Cognitive function;
TGCT	cis	rs3820068	0.532	rs1547034	chr1:15919049	T/A	cg05660106	chr1:15850417	CASP9	0.86	8.84	0.62	8.07e-15	Systolic blood pressure;
TGCT	cis	rs2456568	0.548	rs10466334	chr11:93663512	A/G	cg26875233	chr11:93583750	C11orf90	-0.41	-4.97	-0.41	2.14e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs3087591	0.960	rs1013947	chr17:29530362	C/T	cg24425628	chr17:29625626	OMG;NF1	0.47	7.35	0.55	2.32e-11	Hip circumference;
TGCT	cis	rs79057730	0.599	rs112891948	chr7:816059	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.65	5.3	0.43	5.08e-7	Initial pursuit acceleration;
TGCT	cis	rs2012796	0.956	rs56161464	chr14:81814749	A/T	cg02996355	chr14:81879375	NA	0.5	4.82	0.4	4.2e-6	Night sleep phenotypes;
TGCT	cis	rs6988636	1.000	rs28513831	chr8:124189208	T/C	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs13064411	0.735	rs6438157	chr3:113207316	G/T	cg18753928	chr3:113234510	CCDC52	-0.7	-5.75	-0.46	6.6e-8	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs17712049	1.000	rs62447152	chr7:48200018	A/G	cg16849860	chr7:48352531	ABCA13	0.32	5.26	0.43	6.19e-7	Refractive astigmatism;
TGCT	cis	rs908922	0.676	rs11205031	chr1:152527662	C/T	cg20991723	chr1:152506922	NA	0.44	5.96	0.47	2.38e-8	Hair morphology;
TGCT	cis	rs5760092	0.755	rs6003959	chr22:24264395	C/T	cg18538332	chr22:24372958	LOC391322	0.89	7.91	0.58	1.21e-12	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs4629710	0.534	rs6916881	chr6:131565153	C/T	cg12606694	chr6:131520996	AKAP7	0.4	4.64	0.38	8.58e-6	Multiple myeloma (IgH translocation);
TGCT	cis	rs2370759	0.891	rs77706860	chr10:32628537	C/T	cg01819863	chr10:32635814	EPC1	1.05	6.73	0.52	5.68e-10	Sexual dysfunction (female);
TGCT	cis	rs12368653	0.701	rs238517	chr12:58117737	T/G	cg12615879	chr12:58013172	SLC26A10	0.51	6.39	0.5	3.05e-9	Multiple sclerosis;
TGCT	cis	rs478304	0.651	rs11532071	chr11:65500198	C/A	cg17480646	chr11:65405466	SIPA1	-0.57	-6.95	-0.53	1.84e-10	Acne (severe);
TGCT	cis	rs17401966	0.867	rs12403443	chr1:10423988	A/G	cg19773385	chr1:10388646	KIF1B	-0.21	-4.61	-0.38	9.77e-6	Hepatocellular carcinoma;
TGCT	trans	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg13615516	chr5:77269221	NA	0.68	8.54	0.61	3.97e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.91	-6.62	-0.51	9.5e-10	Gut microbiome composition (summer);
TGCT	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg24675658	chr1:53192096	ZYG11B	-0.75	-8.61	-0.61	2.72e-14	Monocyte count;
TGCT	cis	rs17268829	0.775	rs11770656	chr7:94077554	T/G	cg06439941	chr7:93550756	GNG11	-0.24	-4.47	-0.37	1.74e-5	Breast cancer;
TGCT	cis	rs2115630	0.691	rs8040066	chr15:85176465	G/C	cg11189052	chr15:85197271	WDR73	-0.72	-7.12	-0.54	7.59e-11	P wave terminal force;
TGCT	trans	rs9388451	0.874	rs7739566	chr6:126094757	A/T	cg05039488	chr6:79577232	IRAK1BP1	-0.74	-8.38	-0.6	9.89e-14	Brugada syndrome;
TGCT	cis	rs7267979	0.764	rs2474767	chr20:25246733	T/C	cg03522245	chr20:25566470	NINL	0.52	5.4	0.44	3.22e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg05368731	chr17:41323189	NBR1	1.16	13.24	0.77	1.79e-25	Menopause (age at onset);
TGCT	cis	rs3862030	0.503	rs6584506	chr10:104254428	T/C	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
TGCT	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.63	0.38	9.2e-6	Prudent dietary pattern;
TGCT	cis	rs4389656	0.806	rs71600298	chr5:6763290	T/A	cg12187999	chr5:6845652	NA	-0.33	-4.49	-0.37	1.59e-5	Coronary artery disease;
TGCT	cis	rs881375	0.715	rs10818482	chr9:123648085	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.5	-5.42	-0.44	3.05e-7	Rheumatoid arthritis;
TGCT	cis	rs11648796	0.757	rs3809665	chr16:764520	G/C	cg07343612	chr16:622815	PIGQ	-0.34	-4.93	-0.41	2.54e-6	Height;
TGCT	cis	rs6998277	1.000	rs34217554	chr8:103646352	T/C	cg10187029	chr8:103597600	NA	0.48	6.26	0.49	5.81e-9	Migraine;
TGCT	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	5.24	0.43	6.73e-7	Menopause (age at onset);
TGCT	trans	rs2469997	1.000	rs2470012	chr8:120360488	T/G	cg01792902	chr3:178864926	PIK3CA	0.83	6.77	0.52	4.49e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs9467773	1.000	rs9393732	chr6:26530898	G/A	cg26531700	chr6:26746687	NA	0.47	4.57	0.38	1.14e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7772486	0.790	rs9376971	chr6:146259505	C/T	cg23711669	chr6:146136114	FBXO30	-0.87	-9.9	-0.66	2.24e-17	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs1814175	0.817	rs7932683	chr11:49983640	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.36	-7.14	-0.54	6.88e-11	Height;
TGCT	cis	rs6121246	0.909	rs2376992	chr20:30263418	T/C	cg18721089	chr20:30220636	NA	-0.42	-4.65	-0.39	8.2e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs2235642	0.750	rs1894649	chr16:1657284	C/G	cg07639376	chr16:1584516	IFT140;TMEM204	-0.29	-4.93	-0.4	2.6e-6	Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs28522896	chr4:99008243	C/T	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1023500	0.551	rs2859438	chr22:42466980	A/T	cg05082376	chr22:42548792	NA	-0.23	-5.43	-0.44	2.83e-7	Schizophrenia;
TGCT	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg03188948	chr7:1209495	NA	0.63	5.71	0.46	7.71e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg06481639	chr22:41940642	POLR3H	-0.76	-7.05	-0.54	1.08e-10	Vitiligo;
TGCT	cis	rs12477438	0.798	rs13393860	chr2:99590397	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-6.25	-0.49	5.98e-9	Chronic sinus infection;
TGCT	cis	rs2905347	0.895	rs2961281	chr7:22640292	T/G	cg26061582	chr7:22766209	IL6	-0.4	-4.49	-0.37	1.63e-5	Major depression and alcohol dependence;
TGCT	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg19626725	chr5:178986131	RUFY1	0.46	6.02	0.48	1.87e-8	Lung cancer;
TGCT	cis	rs9650657	0.615	rs4840519	chr8:10693113	T/C	cg16664915	chr8:10907788	XKR6	-0.29	-4.59	-0.38	1.09e-5	Neuroticism;
TGCT	cis	rs9814567	1.000	rs13081688	chr3:134259954	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.96	9.11	0.63	1.79e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs9534288	0.699	rs9534321	chr13:46669032	A/G	cg15192986	chr13:46630673	CPB2	-0.5	-5.94	-0.47	2.7e-8	Blood protein levels;
TGCT	cis	rs775227	0.574	rs66866534	chr3:113147315	T/C	cg18753928	chr3:113234510	CCDC52	-0.7	-5.12	-0.42	1.12e-6	Dental caries;
TGCT	cis	rs67311347	0.524	rs7649168	chr3:40356158	T/C	cg13683864	chr3:40499215	RPL14	-0.84	-7.85	-0.58	1.71e-12	Renal cell carcinoma;
TGCT	cis	rs910316	0.967	rs175479	chr14:75561871	A/C	cg23033748	chr14:75592666	NEK9	-0.28	-4.76	-0.39	5.27e-6	Height;
TGCT	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg08736216	chr1:53307985	ZYG11A	-0.29	-5.7	-0.46	8.08e-8	Monocyte count;
TGCT	cis	rs2153535	0.580	rs4960413	chr6:8438466	C/T	cg07606381	chr6:8435919	SLC35B3	0.57	5.25	0.43	6.46e-7	Motion sickness;
TGCT	cis	rs6912958	0.781	rs9444519	chr6:88290398	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-5.06	-0.41	1.45e-6	Monocyte percentage of white cells;
TGCT	cis	rs1577917	0.958	rs10944136	chr6:86448499	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.4	-0.44	3.28e-7	Response to antipsychotic treatment;
TGCT	cis	rs17741873	0.779	rs3812634	chr10:75594486	C/T	cg07699608	chr10:75541558	CHCHD1	0.72	5.15	0.42	1.02e-6	Paclitaxel disposition in epithelial ovarian cancer;
TGCT	cis	rs910316	0.967	rs10142770	chr14:75525449	G/A	cg08847533	chr14:75593920	NEK9	0.95	10.36	0.68	1.73e-18	Height;
TGCT	trans	rs17780086	0.527	rs72827712	chr17:30538600	A/G	cg20587970	chr11:113659929	NA	-0.89	-7.15	-0.54	6.46e-11	Height;
TGCT	cis	rs9486719	1.000	rs34209750	chr6:96882215	G/T	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.86	-0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs1878931	0.501	rs9635563	chr16:3416940	A/G	cg05754148	chr16:3507555	NAT15	-0.33	-4.46	-0.37	1.82e-5	Body mass index (adult);
TGCT	cis	rs1552244	0.554	rs2272121	chr3:10047680	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.33	-4.95	-0.41	2.39e-6	Alzheimer's disease;
TGCT	cis	rs4722585	0.764	rs4259314	chr7:26182214	A/G	cg07876897	chr7:26191696	NFE2L3	-0.39	-5.73	-0.46	7.32e-8	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
TGCT	cis	rs2204008	0.775	rs2387809	chr12:38363338	T/A	cg13010199	chr12:38710504	ALG10B	0.59	4.58	0.38	1.14e-5	Bladder cancer;
TGCT	trans	rs561341	0.883	rs4795661	chr17:30201774	T/A	cg20587970	chr11:113659929	NA	0.8	9.45	0.65	2.65e-16	Hip circumference adjusted for BMI;
TGCT	trans	rs12599106	0.629	rs1391904	chr16:34548934	C/T	cg01516881	chr6:292596	DUSP22	-0.72	-7.58	-0.56	6.97e-12	Menopause (age at onset);
TGCT	cis	rs3733585	0.648	rs7378305	chr4:9954893	C/T	cg11266682	chr4:10021025	SLC2A9	-0.59	-7.76	-0.57	2.73e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg04025307	chr7:1156635	C7orf50	0.24	5.59	0.45	1.39e-7	Longevity;Endometriosis;
TGCT	cis	rs7949030	0.620	rs2428551	chr11:62329758	T/A	cg22862634	chr11:62369728	EML3;MTA2	0.69	9.06	0.63	2.33e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs644799	0.932	rs572015	chr11:95637416	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	7.9	0.58	1.28e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs6754311	0.551	rs9287442	chr2:136522710	A/G	cg07169764	chr2:136633963	MCM6	-0.7	-6.26	-0.49	5.75e-9	Mosquito bite size;
TGCT	cis	rs7772486	0.875	rs9403770	chr6:146423334	C/T	cg05347473	chr6:146136440	FBXO30	0.56	5.22	0.42	7.31e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs12134245	0.874	rs17501937	chr1:92021705	C/T	cg25838465	chr1:92012736	NA	0.31	5.16	0.42	9.72e-7	Breast cancer;
TGCT	trans	rs1814175	0.527	rs7128827	chr11:49665644	C/T	cg11707556	chr5:10655725	ANKRD33B	0.42	8.44	0.6	7.13e-14	Height;
TGCT	cis	rs1580019	0.587	rs7804457	chr7:32557981	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.11	14.04	0.78	2.14e-27	Cognitive ability;
TGCT	cis	rs2115630	1.000	rs11073730	chr15:85354596	C/T	cg11189052	chr15:85197271	WDR73	-0.63	-6.04	-0.48	1.67e-8	P wave terminal force;
TGCT	cis	rs7412746	0.658	rs4537557	chr1:150734436	A/G	cg09365446	chr1:150670422	GOLPH3L	0.35	5.08	0.42	1.33e-6	Melanoma;
TGCT	cis	rs4478858	0.698	rs10914370	chr1:31854955	T/C	cg07478791	chr1:31886160	SERINC2	-0.49	-4.71	-0.39	6.45e-6	Alcohol dependence;
TGCT	cis	rs12460587	0.587	rs10415150	chr19:52604625	C/G	cg13540795	chr19:52551618	ZNF432	-0.45	-4.8	-0.4	4.49e-6	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg08509172	chr19:19383838	TM6SF2	-0.34	-4.48	-0.37	1.71e-5	Tonsillectomy;
TGCT	cis	rs514406	0.584	rs7524702	chr1:53197830	G/A	cg25767906	chr1:53392781	SCP2	0.44	4.79	0.39	4.72e-6	Monocyte count;
TGCT	cis	rs8020441	0.632	rs6572688	chr14:51165441	A/G	cg04730355	chr14:51134070	SAV1	0.74	6.11	0.48	1.18e-8	Cognitive performance;
TGCT	cis	rs6754311	0.731	rs12988076	chr2:136569848	C/A	cg07169764	chr2:136633963	MCM6	-0.61	-5.61	-0.45	1.25e-7	Mosquito bite size;
TGCT	cis	rs2637266	1.000	rs12251568	chr10:78345667	C/T	cg18941641	chr10:78392320	NA	0.4	5.02	0.41	1.77e-6	Pulmonary function;
TGCT	cis	rs9549367	0.789	rs8001506	chr13:113867153	A/C	cg18105134	chr13:113819100	PROZ	-0.37	-6.34	-0.49	3.95e-9	Platelet distribution width;
TGCT	cis	rs1577917	0.917	rs35283633	chr6:86690787	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.54	-0.45	1.73e-7	Response to antipsychotic treatment;
TGCT	cis	rs9831754	0.906	rs2089934	chr3:78382448	T/C	cg06138941	chr3:78371609	NA	-0.5	-5.16	-0.42	9.33e-7	Calcium levels;
TGCT	cis	rs7208859	0.673	rs9909497	chr17:29173228	C/A	cg18442181	chr17:29233375	C17orf42	-0.78	-4.61	-0.38	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg04267008	chr7:1944627	MAD1L1	-0.34	-4.43	-0.37	2.01e-5	Schizophrenia, schizoaffective disorder or bipolar disorder;
TGCT	cis	rs17030434	0.749	rs1125228	chr4:154769052	C/T	cg14289246	chr4:154710475	SFRP2	-0.91	-7.45	-0.56	1.4e-11	Electrocardiographic conduction measures;
TGCT	cis	rs6570726	1.000	rs404229	chr6:145868200	G/A	cg23711669	chr6:146136114	FBXO30	0.71	6.66	0.51	7.78e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3740393	0.562	rs4147155	chr10:104536771	G/A	cg05855489	chr10:104503620	C10orf26	0.78	6.57	0.51	1.25e-9	Microalbuminuria;
TGCT	cis	rs6674176	0.628	rs2301993	chr1:44426025	G/A	cg13606994	chr1:44402422	ARTN	-0.46	-4.95	-0.41	2.36e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs3772130	0.923	rs7649092	chr3:121561950	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.62	0.38	9.48e-6	Cognitive performance;
TGCT	cis	rs2463822	0.858	rs2513077	chr11:62105925	A/G	cg06239285	chr11:62104954	ASRGL1	-0.9	-6.54	-0.51	1.42e-9	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs6684514	1.000	rs12134983	chr1:156290409	T/C	cg16558208	chr1:156270281	VHLL	0.48	9.6	0.65	1.19e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs2980439	0.525	rs2945238	chr8:8170136	A/C	cg15556689	chr8:8085844	FLJ10661	0.77	7.07	0.54	1e-10	Neuroticism;
TGCT	cis	rs7666738	0.830	rs28444709	chr4:99028496	A/T	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1395	0.925	rs1659701	chr2:27414877	T/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.49	-6.52	-0.51	1.61e-9	Blood metabolite levels;
TGCT	cis	rs4822044	0.680	rs8138780	chr22:42097462	A/T	cg03806693	chr22:41940476	POLR3H	1.08	11.79	0.73	5.53e-22	Cannabis dependence symptom count;
TGCT	cis	rs36051895	0.559	rs7858422	chr9:5209797	G/T	cg02405213	chr9:5042618	JAK2	-0.66	-8.17	-0.59	2.96e-13	Pediatric autoimmune diseases;
TGCT	cis	rs12575480	0.709	rs7107076	chr11:2094303	C/T	cg15541987	chr11:2077307	NA	-0.37	-4.47	-0.37	1.71e-5	Pursuit maintenance gain;
TGCT	cis	rs2204008	0.537	rs11170128	chr12:38006632	G/A	cg13010199	chr12:38710504	ALG10B	0.64	5.08	0.42	1.33e-6	Bladder cancer;
TGCT	cis	rs1857353	1.000	rs74089237	chr1:75888085	G/T	cg11838876	chr1:75668600	SLC44A5	-0.51	-4.81	-0.4	4.23e-6	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg03609598	chr5:56110824	MAP3K1	-0.56	-4.57	-0.38	1.14e-5	Initial pursuit acceleration;
TGCT	cis	rs113084984	0.718	rs4669744	chr2:11681568	T/C	cg25804072	chr2:10829725	NOL10	0.54	4.51	0.38	1.47e-5	Breast cancer;
TGCT	cis	rs6912958	0.678	rs9450744	chr6:88280529	T/C	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.91	-0.4	2.78e-6	Monocyte percentage of white cells;
TGCT	cis	rs9653442	0.527	rs10185059	chr2:100790172	C/T	cg22139774	chr2:100720529	AFF3	-0.35	-5.4	-0.44	3.2e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs8072100	0.935	rs12943464	chr17:45690351	A/T	cg08085267	chr17:45401833	C17orf57	0.43	4.64	0.38	8.8e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs2120019	0.938	rs8036573	chr15:75308690	C/T	cg17294928	chr15:75287854	SCAMP5	-0.86	-6.7	-0.52	6.39e-10	Blood trace element (Zn levels);
TGCT	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg17264618	chr3:40429014	ENTPD3	0.32	4.57	0.38	1.18e-5	Renal cell carcinoma;
TGCT	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg12311346	chr5:56204834	C5orf35	0.53	5.53	0.44	1.79e-7	Initial pursuit acceleration;
TGCT	cis	rs10465746	0.780	rs7529293	chr1:84331981	A/G	cg10977910	chr1:84465055	TTLL7	0.66	6.65	0.51	8.38e-10	Obesity-related traits;
TGCT	cis	rs916888	0.821	rs199513	chr17:44856932	A/G	cg17911788	chr17:44343683	NA	0.53	5.79	0.46	5.5e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs6547741	0.775	rs11692692	chr2:27861707	G/A	cg27432699	chr2:27873401	GPN1	-0.24	-6.05	-0.48	1.57e-8	Oral cavity cancer;
TGCT	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg03709012	chr19:19516395	GATAD2A	-0.75	-6.2	-0.49	7.59e-9	Tonsillectomy;
TGCT	cis	rs12220238	1.000	rs10824105	chr10:75952881	C/A	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.06	0.54	1.05e-10	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs2739330	0.964	rs2739338	chr22:24297130	T/C	cg24846343	chr22:24311635	DDTL	0.22	5.68	0.45	9.16e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs986417	0.901	rs713449	chr14:61029084	C/G	cg27398547	chr14:60952738	C14orf39	1.42	8.85	0.62	7.44e-15	Gut microbiota (bacterial taxa);
TGCT	cis	rs2832191	0.716	rs2692625	chr21:30446360	C/G	cg24692254	chr21:30365293	RNF160	0.98	11.36	0.71	6.16e-21	Dental caries;
TGCT	cis	rs9644630	0.930	rs6586840	chr8:19365832	C/T	cg01280390	chr8:19363452	CSGALNACT1	-0.27	-4.68	-0.39	7.47e-6	Oropharynx cancer;
TGCT	cis	rs3820068	0.626	rs61103742	chr1:15909153	A/C	cg05660106	chr1:15850417	CASP9	1.05	12.15	0.74	7.58e-23	Systolic blood pressure;
TGCT	cis	rs12908161	1.000	rs60957376	chr15:85280792	T/G	cg11189052	chr15:85197271	WDR73	0.7	5.76	0.46	6.18e-8	Schizophrenia;
TGCT	cis	rs3824867	0.920	rs7107853	chr11:47453518	T/C	cg20307385	chr11:47447363	PSMC3	-0.69	-5.86	-0.47	3.99e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs9951602	0.920	rs3859334	chr18:76684193	G/A	cg00806245	chr18:76673096	NA	-0.31	-4.43	-0.37	2.01e-5	Obesity-related traits;
TGCT	cis	rs9611519	0.929	rs926914	chr22:41418154	C/T	cg13695892	chr22:41940480	POLR3H	-0.53	-4.66	-0.39	7.97e-6	Neuroticism;
TGCT	cis	rs644799	0.710	rs522536	chr11:95528714	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.79	8.65	0.61	2.18e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9611565	0.506	rs1883825	chr22:41703408	A/G	cg13695892	chr22:41940480	POLR3H	-0.64	-6.03	-0.48	1.78e-8	Vitiligo;
TGCT	cis	rs7044106	0.762	rs966396	chr9:123453281	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	4.7	0.39	6.66e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs7923609	0.934	rs2893919	chr10:65134778	G/A	cg08743896	chr10:65200160	JMJD1C	-0.34	-4.57	-0.38	1.15e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.51	-4.82	-0.4	4.16e-6	Bipolar disorder;
TGCT	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg09263875	chr16:632152	PIGQ	0.31	6.88	0.53	2.65e-10	Height;
TGCT	cis	rs7786808	0.505	rs67537656	chr7:158192646	C/T	cg01191920	chr7:158217561	PTPRN2	0.35	5.13	0.42	1.1e-6	Obesity-related traits;
TGCT	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg25767906	chr1:53392781	SCP2	0.48	5.57	0.45	1.49e-7	Monocyte count;
TGCT	trans	rs4332037	0.707	rs62435132	chr7:1891315	C/T	cg10840412	chr1:235813424	GNG4	0.86	6.67	0.51	7.59e-10	Bipolar disorder;
TGCT	cis	rs9372253	0.934	rs9320327	chr6:110715194	T/A	cg01119278	chr6:110721349	DDO	-0.35	-5.68	-0.45	9.11e-8	Platelet distribution width;
TGCT	cis	rs9473924	0.580	rs58105163	chr6:50832730	C/T	cg14470998	chr6:50812995	TFAP2B	1.35	8.39	0.6	9.05e-14	Body mass index;
TGCT	cis	rs11098499	0.954	rs34858317	chr4:120387110	A/C	cg09307838	chr4:120376055	NA	0.68	6.53	0.51	1.54e-9	Corneal astigmatism;
TGCT	cis	rs16866061	1.000	rs72974219	chr2:225423784	G/C	cg12698349	chr2:225449008	CUL3	1.0	9.83	0.66	3.23e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	cis	rs1552244	1.000	rs7626117	chr3:10140671	G/A	cg00149659	chr3:10157352	C3orf10	0.76	5.73	0.46	7.13e-8	Alzheimer's disease;
TGCT	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg09323728	chr8:95962352	TP53INP1	-0.52	-6.6	-0.51	1.07e-9	Type 2 diabetes;
TGCT	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	8.39	0.6	9.03e-14	Platelet count;
TGCT	cis	rs7769051	0.522	rs60133731	chr6:133095818	T/C	cg07930552	chr6:133119739	C6orf192	1.21	4.81	0.4	4.24e-6	Type 2 diabetes nephropathy;
TGCT	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.0	0.41	1.89e-6	Menopause (age at onset);
TGCT	cis	rs394563	0.622	rs237024	chr6:149721965	T/C	cg16235748	chr6:149772707	ZC3H12D	-0.44	-5.06	-0.41	1.46e-6	Dupuytren's disease;
TGCT	cis	rs739496	0.947	rs7134740	chr12:111927739	G/A	cg10833066	chr12:111807467	FAM109A	0.37	5.16	0.42	9.31e-7	Platelet count;
TGCT	cis	rs889312	0.500	rs33323	chr5:56175566	C/G	cg24531977	chr5:56204891	C5orf35	-0.5	-5.24	-0.43	6.6e-7	Breast cancer;Breast cancer (early onset);
TGCT	cis	rs10206020	0.879	rs72778007	chr2:1573178	C/T	cg12573674	chr2:1569213	NA	-0.49	-5.3	-0.43	5.1e-7	IgG glycosylation;
TGCT	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg01802117	chr1:53393560	SCP2	-0.39	-4.81	-0.4	4.37e-6	Monocyte count;
TGCT	cis	rs346785	0.518	rs11077811	chr17:74285242	G/A	cg09812376	chr17:74270190	QRICH2	-0.42	-6.4	-0.5	2.83e-9	White matter hyperintensities in ischemic stroke;
TGCT	cis	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg04267008	chr7:1944627	MAD1L1	-0.35	-4.44	-0.37	1.95e-5	Bipolar disorder and schizophrenia;
TGCT	cis	rs9611565	0.592	rs9611612	chr22:41961189	T/C	cg06634786	chr22:41940651	POLR3H	-0.89	-8.45	-0.6	6.75e-14	Vitiligo;
TGCT	cis	rs78545713	1.000	rs77281308	chr6:26250029	C/T	cg12260798	chr6:26240519	HIST1H4F	-0.54	-4.57	-0.38	1.16e-5	Iron status biomarkers (total iron binding capacity);
TGCT	cis	rs763121	0.853	rs3761454	chr22:39066820	C/T	cg06022373	chr22:39101656	GTPBP1	0.77	7.57	0.56	7.47e-12	Menopause (age at onset);
TGCT	cis	rs1568889	0.838	rs6484347	chr11:28040969	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.89	-11.05	-0.7	3.48e-20	Bipolar disorder;
TGCT	cis	rs9303401	0.659	rs12948133	chr17:56673602	T/C	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs9549260	0.564	rs9315785	chr13:41322732	T/C	cg21288729	chr13:41239152	FOXO1	0.88	8.53	0.61	4.38e-14	Red blood cell count;
TGCT	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.2	0.49	7.71e-9	Bipolar disorder;
TGCT	cis	rs2836974	0.545	rs2776311	chr21:40716885	A/G	cg11644478	chr21:40555479	PSMG1	0.64	6.06	0.48	1.52e-8	Cognitive function;
TGCT	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg11301795	chr4:187892539	NA	-0.34	-5.2	-0.42	7.94e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2120019	1.000	rs7175720	chr15:75348962	C/G	cg09165964	chr15:75287851	SCAMP5	1.17	10.07	0.67	8.48e-18	Blood trace element (Zn levels);
TGCT	cis	rs7666738	0.830	rs6830124	chr4:99054872	C/T	cg18180107	chr4:99064573	C4orf37	-0.57	-5.06	-0.41	1.44e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.55	-5.42	-0.44	2.98e-7	Electroencephalogram traits;
TGCT	cis	rs7772486	0.790	rs9485024	chr6:146142487	A/G	cg23711669	chr6:146136114	FBXO30	-0.85	-9.89	-0.66	2.39e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6674176	0.561	rs4660263	chr1:44421433	A/C	cg12908607	chr1:44402522	ARTN	-0.68	-8.19	-0.59	2.7e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs56104184	0.830	rs17272645	chr19:49342366	C/G	cg17863274	chr19:49399704	TULP2	0.41	5.26	0.43	6.03e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg14773178	chr5:1868261	NA	0.35	6.05	0.48	1.58e-8	Cardiovascular disease risk factors;
TGCT	cis	rs10744422	0.528	rs6489245	chr12:123360151	G/A	cg25930673	chr12:123319894	HIP1R	-0.86	-5.13	-0.42	1.11e-6	Schizophrenia;
TGCT	cis	rs12477438	0.798	rs972768	chr2:99682397	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-8.52	-0.61	4.5e-14	Chronic sinus infection;
TGCT	cis	rs6952808	0.898	rs7799807	chr7:1868092	A/G	cg22963979	chr7:1858916	MAD1L1	0.31	4.91	0.4	2.78e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs10871290	0.801	rs3851726	chr16:74471644	G/C	cg01733217	chr16:74700730	RFWD3	-0.59	-5.7	-0.46	8.27e-8	Breast cancer;
TGCT	cis	rs4957048	0.577	rs56294732	chr5:568144	T/C	cg09021430	chr5:549028	NA	-0.42	-5.68	-0.45	9.25e-8	Ulcerative colitis;
TGCT	cis	rs1153858	1.000	rs4774578	chr15:45646051	G/A	cg26924012	chr15:45694286	SPATA5L1	1.09	15.16	0.81	5.15e-30	Homoarginine levels;
TGCT	cis	rs854765	0.724	rs2955371	chr17:17967397	G/A	cg04398451	chr17:18023971	MYO15A	0.31	4.82	0.4	4.06e-6	Total body bone mineral density;
TGCT	cis	rs9914544	0.583	rs11078422	chr17:18804413	C/T	cg26378065	chr17:18585709	ZNF286B	0.54	4.71	0.39	6.58e-6	Educational attainment (years of education);
TGCT	cis	rs13631	0.928	rs9411308	chr9:140000115	C/T	cg14289826	chr9:140003911	NA	0.27	6.31	0.49	4.53e-9	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs3806843	0.676	rs2563304	chr5:140072057	C/T	cg19875535	chr5:140030758	IK	-0.37	-6.23	-0.49	6.51e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs1453308	0.938	rs6431445	chr2:237181343	G/C	cg19324714	chr2:237145437	ASB18	0.59	5.22	0.42	7.18e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs35306767	0.761	rs12771539	chr10:1050653	A/G	cg18964960	chr10:1102726	WDR37	0.78	5.46	0.44	2.45e-7	Eosinophil percentage of granulocytes;
TGCT	cis	rs7681440	0.647	rs6814221	chr4:90805501	C/T	cg20003494	chr4:90757398	SNCA	-0.53	-4.71	-0.39	6.56e-6	Dementia with Lewy bodies;
TGCT	cis	rs524281	0.861	rs7929909	chr11:65951698	C/T	cg00563793	chr11:65837595	PACS1	0.57	4.91	0.4	2.8e-6	Electroencephalogram traits;
TGCT	cis	rs62380364	0.542	rs601499	chr5:88052687	A/C	cg24804195	chr5:87968844	LOC645323	-0.57	-5.58	-0.45	1.47e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs3820068	0.705	rs72643683	chr1:15824905	C/A	cg05660106	chr1:15850417	CASP9	1.18	13.63	0.77	2.04e-26	Systolic blood pressure;
TGCT	cis	rs10883723	0.810	rs11191304	chr10:104255284	C/T	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs7666738	0.830	rs13137808	chr4:99047095	T/C	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	8.0	0.58	7.67e-13	Platelet count;
TGCT	trans	rs1814175	0.817	rs10839397	chr11:49857074	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.35	-0.55	2.38e-11	Height;
TGCT	cis	rs41271473	0.500	rs4440831	chr1:228887522	C/T	cg16512390	chr1:228756714	NA	-0.52	-4.45	-0.37	1.91e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs4824093	0.544	rs73443951	chr22:50301251	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.99	-5.49	-0.44	2.19e-7	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg05896524	chr21:47604654	C21orf56	-0.42	-4.45	-0.37	1.91e-5	Testicular germ cell tumor;
TGCT	cis	rs7937682	0.562	rs519850	chr11:111376888	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.68	-6.36	-0.5	3.55e-9	Primary sclerosing cholangitis;
TGCT	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg06238570	chr21:40685208	BRWD1	0.69	6.38	0.5	3.25e-9	Cognitive function;
TGCT	cis	rs16866061	1.000	rs11686590	chr2:225334070	A/G	cg12698349	chr2:225449008	CUL3	0.96	9.57	0.65	1.4e-16	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	cis	rs7635838	0.859	rs9826803	chr3:11461863	G/A	cg00170343	chr3:11313890	ATG7	0.64	6.11	0.48	1.2e-8	HDL cholesterol;
TGCT	cis	rs9837602	0.507	rs1059905	chr3:99516879	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.44	4.98	0.41	2.08e-6	Breast cancer;
TGCT	cis	rs459571	0.839	rs2519831	chr9:136886257	T/A	cg13789015	chr9:136890014	NCRNA00094	0.39	6.95	0.53	1.84e-10	Platelet distribution width;
TGCT	cis	rs916888	0.647	rs199524	chr17:44848438	G/T	cg15921436	chr17:44337874	NA	-0.43	-6.49	-0.5	1.89e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2242116	0.932	rs7646906	chr3:46949379	G/A	cg23352942	chr3:46931381	PTH1R	-0.35	-5.29	-0.43	5.44e-7	Birth weight;
TGCT	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg24060327	chr5:131705240	SLC22A5	-0.58	-5.89	-0.47	3.46e-8	Breast cancer;
TGCT	cis	rs6598955	0.671	rs6681452	chr1:26621101	G/A	cg04990556	chr1:26633338	UBXN11	0.64	4.91	0.4	2.78e-6	Obesity-related traits;
TGCT	cis	rs765787	0.505	rs1648302	chr15:45494238	A/G	cg24006582	chr15:45444508	DUOX1	-0.25	-5.37	-0.43	3.77e-7	Uric acid levels;
TGCT	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.08	0.48	1.37e-8	Bipolar disorder;
TGCT	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg18876405	chr7:65276391	NA	0.32	4.87	0.4	3.29e-6	Aortic root size;
TGCT	cis	rs1891275	0.515	rs1592051	chr10:93542186	A/G	cg07889827	chr10:93443413	NA	0.31	6.51	0.5	1.65e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs79976124	0.879	rs10944856	chr6:66636960	G/C	cg07460842	chr6:66804631	NA	0.56	5.03	0.41	1.71e-6	Type 2 diabetes;
TGCT	cis	rs250677	0.687	rs41181	chr5:148444257	C/G	cg18129178	chr5:148520854	ABLIM3	0.45	6.65	0.51	8.56e-10	Breast cancer;
TGCT	cis	rs9611565	0.559	rs132761	chr22:42004371	C/T	cg13695892	chr22:41940480	POLR3H	0.88	8.46	0.6	6.38e-14	Vitiligo;
TGCT	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg04414720	chr1:150670196	GOLPH3L	0.37	4.81	0.4	4.38e-6	Tonsillectomy;
TGCT	cis	rs986417	0.551	rs4901991	chr14:61065025	T/C	cg27398547	chr14:60952738	C14orf39	1.41	8.43	0.6	7.41e-14	Gut microbiota (bacterial taxa);
TGCT	cis	rs9611565	0.559	rs7290990	chr22:41964357	C/A	cg06634786	chr22:41940651	POLR3H	-0.88	-8.25	-0.6	1.98e-13	Vitiligo;
TGCT	cis	rs7647973	0.626	rs62260723	chr3:49872124	T/C	cg03060546	chr3:49711283	APEH	-0.66	-5.91	-0.47	3.08e-8	Menarche (age at onset);
TGCT	cis	rs73001065	0.551	rs79954596	chr19:19548643	T/G	cg03709012	chr19:19516395	GATAD2A	0.9	4.9	0.4	2.99e-6	LDL cholesterol;
TGCT	cis	rs72615157	0.716	rs75779608	chr7:99768957	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.63	-5.03	-0.41	1.7e-6	Lung function (FEV1/FVC);
TGCT	cis	rs11024102	1.000	rs10766368	chr11:17014882	G/C	cg15378786	chr11:17036137	PLEKHA7	0.49	4.57	0.38	1.18e-5	Glaucoma (primary angle closure);
TGCT	cis	rs2070488	0.931	rs6599212	chr3:38558906	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.83	-8.45	-0.6	6.78e-14	Electrocardiographic conduction measures;
TGCT	trans	rs2688608	0.623	rs2633317	chr10:75690268	A/G	cg13918328	chr10:52500089	ASAH2B	0.7	7.0	0.53	1.4e-10	Inflammatory bowel disease;
TGCT	cis	rs6879260	1.000	rs1035411	chr5:179729519	A/G	cg02891314	chr5:179741120	GFPT2	-0.42	-7.36	-0.55	2.24e-11	Height;
TGCT	cis	rs2180341	0.521	rs12189967	chr6:127718058	G/A	cg27446573	chr6:127587934	RNF146	0.64	5.83	0.46	4.45e-8	Breast cancer;
TGCT	cis	rs12653946	0.846	rs4975758	chr5:1891174	C/G	cg22472608	chr5:1891194	NA	-0.67	-8.64	-0.61	2.34e-14	Prostate cancer;
TGCT	cis	rs939658	1.000	rs4778935	chr15:79453282	T/C	cg17916960	chr15:79447300	NA	0.52	8.17	0.59	2.94e-13	Refractive error;
TGCT	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.18	0.49	8.32e-9	Bipolar disorder;
TGCT	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg11890956	chr21:40555474	PSMG1	-0.67	-6.43	-0.5	2.49e-9	Menarche (age at onset);
TGCT	cis	rs6918586	0.658	rs198828	chr6:26119459	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.68	-6.46	-0.5	2.15e-9	Schizophrenia;
TGCT	cis	rs4595586	0.525	rs7977228	chr12:39395060	A/G	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs7647973	1.000	rs11130190	chr3:49402137	T/C	cg06212747	chr3:49208901	KLHDC8B	0.59	4.7	0.39	6.94e-6	Menarche (age at onset);
TGCT	cis	rs7267979	1.000	rs4815409	chr20:25346697	C/A	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs28785552	0.931	rs8112235	chr19:53239010	C/G	cg04754360	chr19:53238445	ZNF611	-0.63	-4.93	-0.41	2.54e-6	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs6964587	1.000	rs6979085	chr7:91673623	C/T	cg22709100	chr7:91322751	NA	0.28	4.56	0.38	1.19e-5	Breast cancer;
TGCT	cis	rs8179	0.645	rs17766836	chr7:92258961	C/T	cg15732164	chr7:92237376	CDK6	-0.29	-5.06	-0.41	1.46e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
TGCT	cis	rs7394190	0.748	rs4746139	chr10:75407649	A/C	cg07699608	chr10:75541558	CHCHD1	0.63	4.7	0.39	6.67e-6	Incident atrial fibrillation;
TGCT	cis	rs17376456	0.877	rs10063045	chr5:93457584	A/T	cg21475434	chr5:93447410	FAM172A	0.61	4.49	0.37	1.6e-5	Diabetic retinopathy;
TGCT	cis	rs9473924	0.542	rs9473952	chr6:50921779	T/C	cg14470998	chr6:50812995	TFAP2B	1.26	7.3	0.55	3.1e-11	Body mass index;
TGCT	cis	rs240764	0.853	rs4461738	chr6:100977940	T/C	cg21058520	chr6:100914733	NA	0.35	4.63	0.38	9.07e-6	Neuroticism;
TGCT	cis	rs11098499	0.697	rs6832410	chr4:120296800	A/G	cg09307838	chr4:120376055	NA	0.66	6.48	0.5	1.98e-9	Corneal astigmatism;
TGCT	cis	rs3733631	1.000	rs10007754	chr4:104627442	T/G	cg24090629	chr4:104641072	TACR3	-0.73	-5.81	-0.46	4.96e-8	Menarche (age at onset);
TGCT	cis	rs9611519	0.964	rs2179744	chr22:41621714	G/A	cg13695892	chr22:41940480	POLR3H	-0.51	-4.68	-0.39	7.46e-6	Neuroticism;
TGCT	cis	rs17376456	1.000	rs66978370	chr5:93553633	G/A	cg21475434	chr5:93447410	FAM172A	0.65	4.66	0.39	7.92e-6	Diabetic retinopathy;
TGCT	cis	rs9527	0.615	rs7089065	chr10:104723022	C/T	cg04362960	chr10:104952993	NT5C2	0.66	5.55	0.45	1.66e-7	Arsenic metabolism;
TGCT	cis	rs3099143	1.000	rs3106380	chr15:77104377	G/A	cg21673338	chr15:77095150	SCAPER	-0.52	-4.97	-0.41	2.15e-6	Recalcitrant atopic dermatitis;
TGCT	cis	rs5167	0.781	rs909134	chr19:45493061	T/C	cg13119609	chr19:45449297	APOC2	0.23	4.81	0.4	4.29e-6	Blood protein levels;
TGCT	cis	rs7949030	0.626	rs11231141	chr11:62326265	T/C	cg11742103	chr11:62369870	EML3;MTA2	0.61	8.72	0.62	1.56e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs8032315	0.965	rs7497304	chr15:91429176	G/T	cg05211768	chr15:91427848	FES	0.48	4.86	0.4	3.52e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4975616	0.804	rs31489	chr5:1342714	C/A	cg07493874	chr5:1342172	CLPTM1L	-0.26	-6.3	-0.49	4.77e-9	Lung cancer;
TGCT	cis	rs6969780	0.722	rs3823764	chr7:27187753	C/T	cg04321618	chr7:27170880	HOXA4	-0.52	-5.33	-0.43	4.47e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs2075371	0.863	rs1646635	chr7:134006728	T/C	cg11752832	chr7:134001865	SLC35B4	0.78	7.42	0.55	1.59e-11	Mean platelet volume;
TGCT	trans	rs17685	0.753	rs11764129	chr7:75761890	T/C	cg19862616	chr7:65841803	NCRNA00174	0.52	9.01	0.63	3.02e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs12497850	0.931	rs28642807	chr3:48926816	A/G	cg07636037	chr3:49044803	WDR6	0.94	10.39	0.68	1.46e-18	Parkinson's disease;
TGCT	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs3015497	0.789	rs3015498	chr14:51112824	T/C	cg04730355	chr14:51134070	SAV1	-0.68	-6.57	-0.51	1.26e-9	Mean platelet volume;
TGCT	cis	rs4919694	1.000	rs12246689	chr10:104817031	C/T	cg04362960	chr10:104952993	NT5C2	1.07	7.09	0.54	8.9e-11	Arsenic metabolism;
TGCT	cis	rs7267979	1.000	rs4815418	chr20:25382211	T/G	cg16686733	chr20:25566563	NINL	-0.59	-6.05	-0.48	1.57e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs734999	1.000	rs734999	chr1:2513216	C/T	cg18854424	chr1:2615690	NA	0.44	5.33	0.43	4.46e-7	Ulcerative colitis;
TGCT	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg13699009	chr12:122356056	WDR66	-0.28	-5.48	-0.44	2.27e-7	Mean corpuscular volume;
TGCT	cis	rs7666738	0.830	rs11727235	chr4:98946331	T/C	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6545883	0.965	rs7421663	chr2:61753786	C/T	cg15711740	chr2:61764176	XPO1	-0.57	-5.25	-0.43	6.39e-7	Tuberculosis;
TGCT	cis	rs9296092	0.538	rs62405943	chr6:33517359	A/G	cg13560919	chr6:33536144	NA	-0.21	-4.74	-0.39	5.87e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs2235642	0.928	rs9932984	chr16:1605051	A/G	cg07639376	chr16:1584516	IFT140;TMEM204	-0.32	-5.75	-0.46	6.52e-8	Coronary artery disease;
TGCT	cis	rs6840360	0.642	rs2709838	chr4:152371364	G/A	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.83e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs302668	0.609	rs12270038	chr11:87870354	A/G	cg01568784	chr11:87908783	RAB38	0.34	4.52	0.38	1.4e-5	Frontotemporal dementia;
TGCT	cis	rs7681440	0.904	rs6816736	chr4:90765746	G/A	cg01966878	chr4:90757139	SNCA	-0.25	-4.56	-0.38	1.2e-5	Dementia with Lewy bodies;
TGCT	cis	rs3820928	0.605	rs10186145	chr2:227781150	A/G	cg11843606	chr2:227700838	RHBDD1	-0.51	-4.84	-0.4	3.86e-6	Pulmonary function;
TGCT	cis	rs11209002	0.567	rs2755268	chr1:67539881	T/C	cg02640540	chr1:67518911	SLC35D1	0.53	4.45	0.37	1.86e-5	Crohn's disease;
TGCT	cis	rs6845621	0.901	rs9991568	chr4:18922645	A/G	cg12196642	chr4:18937545	NA	0.26	4.56	0.38	1.2e-5	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
TGCT	cis	rs6880778	0.505	rs6891041	chr5:40406238	G/A	cg01087697	chr5:40835557	RPL37	0.55	4.96	0.41	2.22e-6	Inflammatory bowel disease;
TGCT	cis	rs9913156	0.793	rs72835644	chr17:4573667	G/A	cg19197139	chr17:4613644	ARRB2	0.88	8.13	0.59	3.75e-13	Lymphocyte counts;
TGCT	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg13699009	chr12:122356056	WDR66	0.29	5.69	0.46	8.63e-8	Mean corpuscular volume;
TGCT	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg07092213	chr7:1199455	ZFAND2A	-0.42	-4.46	-0.37	1.84e-5	Longevity;Endometriosis;
TGCT	cis	rs1375194	0.582	rs13388224	chr2:33802902	T/C	cg04131969	chr2:33951647	MYADML	-0.57	-5.03	-0.41	1.66e-6	Response to antidepressants in depression;
TGCT	cis	rs6088580	0.609	rs6058029	chr20:32969643	T/C	cg08999081	chr20:33150536	PIGU	-0.29	-5.65	-0.45	1.02e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg00149659	chr3:10157352	C3orf10	0.96	6.1	0.48	1.26e-8	Alzheimer's disease;
TGCT	cis	rs910316	0.763	rs175016	chr14:75459633	C/T	cg08847533	chr14:75593920	NEK9	-0.84	-9.15	-0.64	1.4e-15	Height;
TGCT	cis	rs74233809	1.000	rs2297787	chr10:104680137	T/A	cg19559179	chr10:103815996	C10orf76	0.82	4.5	0.37	1.52e-5	Birth weight;
TGCT	cis	rs751728	1.000	rs9394166	chr6:33751122	G/C	cg13859433	chr6:33739653	LEMD2	-0.4	-7.27	-0.55	3.51e-11	Crohn's disease;
TGCT	cis	rs950169	1.000	rs35658069	chr15:84780146	C/T	cg11189052	chr15:85197271	WDR73	0.69	5.91	0.47	3.07e-8	Schizophrenia;
TGCT	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg24250549	chr1:154909240	PMVK	0.62	6.21	0.49	7.36e-9	Prostate cancer;
TGCT	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg06481639	chr22:41940642	POLR3H	0.62	5.59	0.45	1.4e-7	Vitiligo;
TGCT	cis	rs9362426	0.608	rs56329400	chr6:88158712	A/G	cg10919329	chr6:88182879	SLC35A1	-0.58	-4.48	-0.37	1.7e-5	Depressive episodes in bipolar disorder;
TGCT	cis	rs2288884	1.000	rs78543982	chr19:52550867	T/C	cg15405931	chr19:52693188	PPP2R1A	-0.69	-4.5	-0.37	1.56e-5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs4803468	1.000	rs10417997	chr19:41902361	G/A	cg09537434	chr19:41945824	ATP5SL	-0.9	-10.43	-0.68	1.11e-18	Height;
TGCT	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg17178900	chr1:205818956	PM20D1	0.66	9.32	0.64	5.66e-16	Menarche (age at onset);
TGCT	cis	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg20637647	chr7:64974828	NA	1.0	5.59	0.45	1.4e-7	Diabetic kidney disease;
TGCT	cis	rs12579753	1.000	rs2401004	chr12:82214822	T/C	cg07988820	chr12:82153109	PPFIA2	-0.64	-6.68	-0.51	7.15e-10	Resting heart rate;
TGCT	cis	rs7666738	0.830	rs6830124	chr4:99054872	C/T	cg05340658	chr4:99064831	C4orf37	-0.53	-5.87	-0.47	3.75e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6121246	0.567	rs6060399	chr20:30220823	C/T	cg18721089	chr20:30220636	NA	-0.65	-6.84	-0.52	3.17e-10	Mean corpuscular hemoglobin;
TGCT	trans	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg17830980	chr10:43048298	ZNF37B	-0.81	-10.13	-0.67	6.19e-18	Extrinsic epigenetic age acceleration;
TGCT	trans	rs7618501	0.933	rs1128535	chr3:49866392	C/T	cg21659725	chr3:3221576	CRBN	0.98	15.33	0.81	2.1000000000000002e-30	Intelligence (multi-trait analysis);
TGCT	cis	rs138880	0.580	rs28562884	chr22:50312869	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.22	-7.53	-0.56	9.3e-12	Schizophrenia;
TGCT	cis	rs9916302	0.904	rs7210488	chr17:37539819	T/G	cg15445000	chr17:37608096	MED1	-0.33	-4.71	-0.39	6.46e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs739496	0.579	rs3177647	chr12:112277576	C/T	cg10833066	chr12:111807467	FAM109A	0.39	5.36	0.43	3.91e-7	Platelet count;
TGCT	cis	rs7267979	1.000	rs6050559	chr20:25329915	A/G	cg14121845	chr20:25566513	NINL	0.51	5.5	0.44	2.05e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9389248	0.737	rs56358308	chr6:135306980	A/T	cg24558204	chr6:135376177	HBS1L	0.46	4.65	0.39	8.46e-6	High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs1784581	0.588	rs9295180	chr6:162420579	T/C	cg17173639	chr6:162384350	PARK2	0.4	6.6	0.51	1.08e-9	Itch intensity from mosquito bite;
TGCT	cis	rs6589563	0.737	rs73588403	chr11:116628271	C/T	cg20660624	chr11:117307972	DSCAML1	-0.37	-4.92	-0.4	2.71e-6	Eosinophil counts;
TGCT	cis	rs4372836	0.729	rs6547882	chr2:29037001	T/C	cg09522027	chr2:28974177	PPP1CB	-0.7	-7.26	-0.55	3.68e-11	Body mass index;
TGCT	cis	rs4654899	0.758	rs6697284	chr1:21295599	G/A	cg01072550	chr1:21505969	NA	-0.55	-8.89	-0.62	6.13e-15	Superior frontal gyrus grey matter volume;
TGCT	cis	rs9972944	0.756	rs6504350	chr17:63764336	G/A	cg07283582	chr17:63770753	CCDC46	-0.26	-5.3	-0.43	5.02e-7	Total body bone mineral density;
TGCT	cis	rs6598541	0.505	rs12904731	chr15:99310956	A/G	cg18742785	chr15:100270048	LYSMD4	-0.26	-4.51	-0.38	1.49e-5	Urate levels;
TGCT	cis	rs2296887	0.673	rs3802680	chr10:104114886	A/G	cg26089160	chr10:104170217	PSD	0.55	5.54	0.45	1.75e-7	Parkinson's disease;
TGCT	cis	rs1018836	0.923	rs4735268	chr8:91629715	C/T	cg16814680	chr8:91681699	NA	-0.85	-8.83	-0.62	8.15e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs858239	0.509	rs57611130	chr7:23184552	C/A	cg05602783	chr7:23145260	KLHL7	-0.62	-4.99	-0.41	1.97e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs28595532	0.764	rs55704595	chr4:119780607	G/A	cg14228332	chr4:119757509	SEC24D	1.26	7.08	0.54	9.26e-11	Cannabis dependence symptom count;
TGCT	cis	rs9611565	0.605	rs202638	chr22:41855458	A/G	cg06481639	chr22:41940642	POLR3H	0.68	5.99	0.47	2.14e-8	Vitiligo;
TGCT	cis	rs6912958	0.525	rs586771	chr6:88064971	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.44	5.71	0.46	7.78e-8	Monocyte percentage of white cells;
TGCT	cis	rs3096299	1.000	rs3096299	chr16:89448663	G/A	cg02187348	chr16:89574699	SPG7	0.49	4.67	0.39	7.77e-6	Multiple myeloma (IgH translocation);
TGCT	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.99	8.17	0.59	3.09e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg08355456	chr11:67383691	NA	0.32	5.09	0.42	1.31e-6	Mean corpuscular volume;
TGCT	cis	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg08045932	chr20:61659980	NA	0.48	9.28	0.64	7.07e-16	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs13326165	0.760	rs11707931	chr3:52358417	C/G	cg27565382	chr3:53032988	SFMBT1	0.37	4.9	0.4	2.97e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs1670533	1.000	rs6836350	chr4:1069973	C/T	cg20887711	chr4:1340912	KIAA1530	0.63	4.95	0.41	2.32e-6	Recombination rate (females);
TGCT	cis	rs524281	0.861	rs10791855	chr11:65963737	A/G	cg00563793	chr11:65837595	PACS1	0.52	4.63	0.38	9.13e-6	Electroencephalogram traits;
TGCT	trans	rs9329221	0.741	rs55975067	chr8:9806824	C/G	cg06636001	chr8:8085503	FLJ10661	-0.77	-6.81	-0.52	3.74e-10	Neuroticism;
TGCT	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg09359103	chr1:154839909	KCNN3	-0.62	-11.25	-0.71	1.15e-20	Prostate cancer;
TGCT	cis	rs910316	1.000	rs10136948	chr14:75511075	C/T	cg11812906	chr14:75593930	NEK9	0.74	7.38	0.55	1.99e-11	Height;
TGCT	cis	rs7617773	0.817	rs11928691	chr3:48286765	C/T	cg11946769	chr3:48343235	NME6	0.76	6.66	0.51	7.89e-10	Coronary artery disease;
TGCT	cis	rs9811920	0.569	rs793445	chr3:99576644	T/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.6	6.82	0.52	3.63e-10	Axial length;
TGCT	cis	rs4629710	0.592	rs66533103	chr6:131531016	C/T	cg12606694	chr6:131520996	AKAP7	0.39	4.58	0.38	1.11e-5	Multiple myeloma (IgH translocation);
TGCT	cis	rs7824557	0.767	rs1897950	chr8:11169551	C/A	cg21775007	chr8:11205619	TDH	0.58	5.46	0.44	2.46e-7	Retinal vascular caliber;
TGCT	cis	rs7027203	0.595	rs7846827	chr9:96546525	C/T	cg13679303	chr9:96623674	NA	0.53	7.59	0.56	6.5e-12	DNA methylation (variation);
TGCT	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.69	-6.97	-0.53	1.64e-10	Prostate cancer;
TGCT	cis	rs10197940	0.662	rs6735771	chr2:152273503	G/A	cg19508488	chr2:152266495	RIF1	-0.74	-6.66	-0.51	7.77e-10	Lung cancer;
TGCT	cis	rs1018836	0.545	rs7840203	chr8:91701223	A/G	cg16814680	chr8:91681699	NA	-1.05	-14.7	-0.8	6.21e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1008375	1.000	rs12648232	chr4:17612537	C/T	cg10189774	chr4:17578691	LAP3	-0.57	-5.07	-0.41	1.42e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs28785552	0.769	rs11669363	chr19:53232321	C/A	cg22067481	chr19:53234126	ZNF611	-0.46	-6.67	-0.51	7.47e-10	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs17270561	0.514	rs10946805	chr6:26077891	C/T	cg17691542	chr6:26056736	HIST1H1C	1.03	7.31	0.55	2.9e-11	Iron status biomarkers;
TGCT	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	8.39	0.6	9.03e-14	Platelet count;
TGCT	cis	rs7172809	0.573	rs74025074	chr15:77439363	T/C	cg22256960	chr15:77711686	NA	-0.48	-4.52	-0.38	1.41e-5	Glucose homeostasis traits;
TGCT	cis	rs3125734	0.660	rs4979780	chr10:63992740	A/C	cg19640130	chr10:64028056	RTKN2	-0.39	-5.04	-0.41	1.64e-6	Rheumatoid arthritis;
TGCT	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	15.94	0.82	8.5e-32	Prudent dietary pattern;
TGCT	cis	rs2204008	0.837	rs1589395	chr12:38420405	C/T	cg26384229	chr12:38710491	ALG10B	0.84	7.7	0.57	3.77e-12	Bladder cancer;
TGCT	cis	rs7267979	1.000	rs6050626	chr20:25428261	T/C	cg14121845	chr20:25566513	NINL	0.51	5.46	0.44	2.44e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg21963583	chr11:68658836	MRPL21	0.39	6.32	0.49	4.21e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9611565	0.525	rs9611548	chr22:41704143	G/T	cg06634786	chr22:41940651	POLR3H	-0.59	-5.54	-0.45	1.74e-7	Vitiligo;
TGCT	cis	rs2153535	0.580	rs1414340	chr6:8491139	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs10927875	0.541	rs1739840	chr1:16342237	A/G	cg21385522	chr1:16154831	NA	0.46	4.85	0.4	3.64e-6	Dilated cardiomyopathy;
TGCT	cis	rs2797160	1.000	rs2797158	chr6:126009398	G/A	cg05901451	chr6:126070800	HEY2	0.72	6.11	0.48	1.18e-8	Endometrial cancer;
TGCT	cis	rs901683	0.702	rs73292848	chr10:46169752	T/C	cg18240400	chr10:46168597	ANUBL1	0.56	4.63	0.38	8.93e-6	Red blood cell traits;Mean corpuscular volume;
TGCT	cis	rs7666738	0.753	rs7657644	chr4:99057734	T/A	cg05340658	chr4:99064831	C4orf37	0.52	5.79	0.46	5.32e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs17122693	0.748	rs72681630	chr14:51141250	A/G	cg04730355	chr14:51134070	SAV1	1.33	11.77	0.73	6.15e-22	Cognitive performance;
TGCT	cis	rs7607369	0.714	rs4674338	chr2:219647487	A/G	cg02176678	chr2:219576539	TTLL4	0.38	4.87	0.4	3.36e-6	Red blood cell count;Amyotrophic lateral sclerosis;
TGCT	cis	rs10875746	0.855	rs2269936	chr12:48425235	G/A	cg20731937	chr12:48336164	NA	0.68	5.29	0.43	5.3e-7	Longevity (90 years and older);
TGCT	cis	rs2075371	0.966	rs1646646	chr7:133996905	G/T	cg11752832	chr7:134001865	SLC35B4	0.7	6.44	0.5	2.41e-9	Mean platelet volume;
TGCT	cis	rs1205863	0.915	rs1205857	chr6:11942760	C/T	cg07106625	chr6:11870215	NA	0.51	5.05	0.41	1.51e-6	Disc degeneration (lumbar);
TGCT	cis	rs9915657	0.743	rs7502198	chr17:70110507	C/T	cg06234051	chr17:70120541	SOX9	-0.24	-4.91	-0.4	2.76e-6	Thyroid hormone levels;
TGCT	cis	rs3862030	0.503	rs6584505	chr10:104254412	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	8.36	0.6	1.1e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
TGCT	cis	rs4663969	0.545	rs4663334	chr2:234674924	C/T	cg25479499	chr2:234183424	ATG16L1;SCARNA5	0.32	4.56	0.38	1.19e-5	Total bilirubin levels in HIV-1 infection;
TGCT	cis	rs7614311	0.731	rs3774719	chr3:63950338	C/A	cg22134162	chr3:63841271	THOC7	-0.45	-5.86	-0.47	4e-8	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs7267979	1.000	rs2184000	chr20:25395878	G/A	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.9	7.25	0.55	3.93e-11	Platelet count;
TGCT	cis	rs17331151	0.505	rs13066389	chr3:52565317	C/T	cg15956490	chr3:53032818	SFMBT1	0.7	5.14	0.42	1.02e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs8083786	1	rs8083786	chr18:12881361	A/G	cg23544223	chr18:12777786	NA	-0.54	-4.81	-0.4	4.31e-6	Rheumatoid arthritis;
TGCT	cis	rs9913156	0.793	rs11655166	chr17:4559302	T/A	cg19197139	chr17:4613644	ARRB2	-0.86	-7.97	-0.58	8.75e-13	Lymphocyte counts;
TGCT	cis	rs7246967	0.673	rs34126042	chr19:22909218	G/A	cg05241461	chr19:22816980	ZNF492	0.66	4.5	0.37	1.57e-5	Bronchopulmonary dysplasia;
TGCT	cis	rs9457247	1.000	rs364451	chr6:167384756	G/A	cg23791538	chr6:167370224	RNASET2	-0.53	-5.18	-0.42	8.72e-7	Crohn's disease;
TGCT	cis	rs42648	0.566	rs13247629	chr7:89889585	A/G	cg25739043	chr7:89950458	NA	-0.48	-4.75	-0.39	5.64e-6	Homocysteine levels;
TGCT	trans	rs1908814	0.516	rs35391955	chr8:11796728	A/C	cg15556689	chr8:8085844	FLJ10661	0.75	7.07	0.54	9.74e-11	Neuroticism;
TGCT	trans	rs1814175	0.791	rs10839468	chr11:49986288	A/G	cg15704280	chr7:45808275	SEPT13	-0.73	-8.48	-0.61	5.58e-14	Height;
TGCT	cis	rs78487399	0.908	rs76450091	chr2:43767189	T/C	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.64	4.51	0.38	1.49e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs2239547	0.522	rs6768844	chr3:53004620	A/G	cg11645453	chr3:52864694	ITIH4	-0.34	-5.45	-0.44	2.6e-7	Schizophrenia;
TGCT	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg06873352	chr17:61820015	STRADA	0.58	6.37	0.5	3.32e-9	Prudent dietary pattern;
TGCT	cis	rs10992471	0.598	rs230222	chr9:95265558	C/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.52	-4.93	-0.4	2.59e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs7666738	0.791	rs4440223	chr4:99044796	G/A	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7666738	0.830	rs28818218	chr4:98880575	A/C	cg17366294	chr4:99064904	C4orf37	0.74	7.62	0.56	5.55e-12	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs1814175	0.645	rs7119101	chr11:49955665	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.67	-0.69	2.92e-19	Height;
TGCT	cis	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg07424592	chr7:64974309	NA	-1.27	-7.84	-0.58	1.8e-12	Diabetic kidney disease;
TGCT	cis	rs8013055	0.796	rs8021330	chr14:106002352	C/A	cg19700328	chr14:106028568	NA	-0.49	-5.75	-0.46	6.66e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	trans	rs1814175	0.817	rs1390676	chr11:50056778	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.26	-0.55	3.77e-11	Height;
TGCT	cis	rs172166	0.694	rs536704	chr6:28092603	T/G	cg10876282	chr6:28092338	ZSCAN16	0.51	4.69	0.39	6.99e-6	Cardiac Troponin-T levels;
TGCT	cis	rs1949733	0.701	rs2631735	chr4:8476118	A/G	cg11789530	chr4:8429930	ACOX3	0.57	4.97	0.41	2.15e-6	Response to antineoplastic agents;
TGCT	cis	rs9467773	1.000	rs6940188	chr6:26562029	G/C	cg09904177	chr6:26538194	HMGN4	0.66	6.6	0.51	1.05e-9	Intelligence (multi-trait analysis);
TGCT	trans	rs10506458	0.915	rs2013042	chr12:63394211	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.46	-7.33	-0.55	2.6e-11	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs62380364	0.602	rs448809	chr5:88005828	G/T	cg24804195	chr5:87968844	LOC645323	-0.61	-6.15	-0.48	9.97e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs13217239	0.608	rs6930508	chr6:27053142	T/C	cg06035815	chr6:26189597	HIST1H4D	0.44	4.53	0.38	1.39e-5	Schizophrenia;
TGCT	cis	rs62064224	0.720	rs8078837	chr17:30763537	A/G	cg18200150	chr17:30822561	MYO1D	0.56	7.72	0.57	3.4e-12	Schizophrenia;
TGCT	cis	rs896854	0.684	rs10099059	chr8:95986972	G/C	cg09323728	chr8:95962352	TP53INP1	-0.48	-6.22	-0.49	7.08e-9	Type 2 diabetes;
TGCT	trans	rs9383153	1.000	rs9370888	chr6:16335544	A/G	cg16722931	chr17:75312494	SEPT9	1.09	6.82	0.52	3.52e-10	Gambling;
TGCT	cis	rs2455799	0.613	rs12485852	chr3:15914511	G/C	cg16303742	chr3:15540471	COLQ	-0.24	-4.64	-0.38	8.68e-6	Mean platelet volume;
TGCT	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg23302884	chr18:44338147	ST8SIA5	-0.4	-4.61	-0.38	9.88e-6	Personality dimensions;
TGCT	cis	rs9640161	0.783	rs1132261	chr7:150059987	G/A	cg10018233	chr7:150070692	REPIN1	0.33	4.86	0.4	3.41e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs9467711	0.520	rs13211947	chr6:25864818	C/T	cg16898833	chr6:26189333	HIST1H4D	1.36	6.0	0.47	2.05e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs3091242	0.933	rs11249250	chr1:25767609	G/A	cg00786635	chr1:25594202	NA	0.54	5.69	0.45	8.79e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs7945705	0.869	rs7925728	chr11:9013002	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.52	-5.87	-0.47	3.68e-8	Hemoglobin concentration;
TGCT	cis	rs72945132	0.882	rs4567496	chr11:70193208	A/T	cg00319359	chr11:70116639	PPFIA1	0.97	7.07	0.54	1.01e-10	Coronary artery disease;
TGCT	cis	rs7586879	0.593	rs10198275	chr2:25130542	A/C	cg15423357	chr2:25149977	NA	0.52	5.11	0.42	1.17e-6	Body mass index;
TGCT	cis	rs3848445	1.000	rs3912263	chr17:14292908	A/C	cg01636575	chr17:13447853	HS3ST3A1	0.74	4.56	0.38	1.22e-5	Protein quantitative trait loci;
TGCT	cis	rs6570726	0.935	rs401888	chr6:145831535	A/G	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg03213289	chr20:61660250	NA	0.68	9.9	0.66	2.25e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs4780355	0.843	rs243325	chr16:11354497	A/G	cg00044050	chr16:11439710	C16orf75	0.6	5.35	0.43	4.05e-7	Crohn's disease and psoriasis;
TGCT	cis	rs11969893	0.649	rs9390699	chr6:101306502	C/G	cg12253828	chr6:101329408	ASCC3	1.22	5.92	0.47	3e-8	Economic and political preferences (immigration/crime);
TGCT	cis	rs986417	1.000	rs1024223	chr14:60926119	C/T	cg27398547	chr14:60952738	C14orf39	1.39	10.61	0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs2153535	0.580	rs4639392	chr6:8446547	A/G	cg07606381	chr6:8435919	SLC35B3	0.53	5.02	0.41	1.79e-6	Motion sickness;
TGCT	cis	rs4972806	0.814	rs6710370	chr2:177045969	T/C	cg14324370	chr2:177042789	NA	0.71	6.81	0.52	3.67e-10	IgG glycosylation;
TGCT	cis	rs10782582	0.609	rs5745545	chr1:76377356	A/G	cg03433033	chr1:76189801	ACADM	-0.5	-4.82	-0.4	4.13e-6	Daytime sleep phenotypes;
TGCT	cis	rs7666738	0.830	rs969048	chr4:98988921	T/C	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs798554	0.655	rs798492	chr7:2799184	C/T	cg25467336	chr7:2757616	NA	0.24	4.72	0.39	6.33e-6	Height;
TGCT	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.36	-4.58	-0.38	1.11e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9814567	1.000	rs9883753	chr3:134247231	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.92	-9.2	-0.64	1.11e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs7017914	0.967	rs1477944	chr8:71615600	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.55	-5.13	-0.42	1.11e-6	Bone mineral density;
TGCT	trans	rs3780486	0.757	rs10758189	chr9:33125804	A/G	cg04842962	chr6:43655489	MRPS18A	1.21	15.78	0.82	1.96e-31	IgG glycosylation;
TGCT	cis	rs858239	0.704	rs199656	chr7:23337615	G/T	cg05602783	chr7:23145260	KLHL7	0.72	5.72	0.46	7.3900000000000007e-08	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.49	5.29	0.43	5.37e-7	Lymphocyte counts;
TGCT	cis	rs727563	0.638	rs4820443	chr22:42193913	A/G	cg06634786	chr22:41940651	POLR3H	-0.82	-7.77	-0.57	2.62e-12	Crohn's disease;Inflammatory bowel disease;
TGCT	trans	rs7726839	0.561	rs6555357	chr5:560923	A/G	cg25482853	chr8:67687455	SGK3	1.09	9.17	0.64	1.25e-15	Obesity-related traits;
TGCT	cis	rs7208859	0.573	rs216443	chr17:28931871	A/G	cg13385521	chr17:29058706	SUZ12P	0.79	4.75	0.39	5.45e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7267979	0.873	rs6083853	chr20:25404541	T/C	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7552404	0.727	rs6683437	chr1:76316619	G/A	cg22875332	chr1:76189707	ACADM	0.59	6.19	0.49	8.22e-9	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs1153858	1.000	rs10519021	chr15:45631795	G/A	cg26924012	chr15:45694286	SPATA5L1	1.07	14.56	0.79	1.32e-28	Homoarginine levels;
TGCT	cis	rs13064411	0.696	rs6438161	chr3:113227637	G/A	cg10517650	chr3:113235015	CCDC52	-0.32	-4.45	-0.37	1.85e-5	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs7824557	0.628	rs11991153	chr8:11203107	A/T	cg21775007	chr8:11205619	TDH	0.67	6.53	0.51	1.49e-9	Retinal vascular caliber;
TGCT	trans	rs3780486	0.846	rs12554995	chr9:33132044	A/G	cg04842962	chr6:43655489	MRPS18A	1.24	15.83	0.82	1.46e-31	IgG glycosylation;
TGCT	cis	rs2996428	0.667	rs61768932	chr1:3765671	G/C	cg13057898	chr1:3703894	LRRC47	0.22	4.68	0.39	7.24e-6	Red cell distribution width;
TGCT	cis	rs10510102	0.872	rs79865971	chr10:123700723	C/A	cg23691251	chr10:123688108	ATE1	-0.58	-4.58	-0.38	1.11e-5	Breast cancer;
TGCT	cis	rs9858542	0.953	rs9811982	chr3:49624377	A/C	cg03060546	chr3:49711283	APEH	-0.63	-5.48	-0.44	2.28e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs9814567	0.806	rs11927539	chr3:134319448	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.76	-7.11	-0.54	8.15e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs877282	0.898	rs12357995	chr10:765739	T/C	cg17470449	chr10:769945	NA	0.37	5.59	0.45	1.37e-7	Uric acid levels;
TGCT	cis	rs9787249	0.957	rs1046988	chr1:40219065	A/G	cg19912559	chr1:40204330	PPIE	-0.46	-5.54	-0.45	1.73e-7	Blood protein levels;
TGCT	cis	rs12477438	0.520	rs2516835	chr2:99779131	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	10.3	0.68	2.42e-18	Chronic sinus infection;
TGCT	cis	rs4700695	0.614	rs37232	chr5:65219869	A/C	cg21114390	chr5:65439923	SFRS12	0.65	4.54	0.38	1.3e-5	Facial morphology (factor 19);
TGCT	cis	rs7698623	0.850	rs1982623	chr4:88790777	C/G	cg02735620	chr4:88950514	PKD2	-0.44	-4.81	-0.4	4.22e-6	Cardiovascular disease risk factors;
TGCT	cis	rs7246657	0.653	rs10425441	chr19:37670648	T/C	cg24025825	chr19:37761650	NA	-0.32	-5.02	-0.41	1.79e-6	Coronary artery calcification;
TGCT	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.56	-7.42	-0.55	1.65e-11	Longevity;Endometriosis;
TGCT	cis	rs7180079	0.620	rs477966	chr15:64783725	A/G	cg03791955	chr15:65024147	NA	0.28	4.49	0.37	1.59e-5	Monocyte count;
TGCT	cis	rs9611565	0.512	rs2899349	chr22:42164660	T/C	cg06634786	chr22:41940651	POLR3H	0.85	8.15	0.59	3.41e-13	Vitiligo;
TGCT	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg05368731	chr17:41323189	NBR1	1.04	12.44	0.75	1.48e-23	Menopause (age at onset);
TGCT	cis	rs6933660	0.800	rs9383900	chr6:151782816	A/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.52	-4.65	-0.39	8.27e-6	Menarche (age at onset);
TGCT	cis	rs4975616	0.836	rs13178866	chr5:1323212	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.29	-7.01	-0.53	1.34e-10	Lung cancer;
TGCT	cis	rs2361718	0.500	rs4889970	chr17:78096086	C/T	cg17882374	chr17:78041429	CCDC40	-0.29	-4.46	-0.37	1.83e-5	Yeast infection;
TGCT	cis	rs13256369	0.951	rs13270852	chr8:8566853	A/G	cg18904891	chr8:8559673	CLDN23	0.59	5.52	0.44	1.93e-7	Obesity-related traits;
TGCT	cis	rs3947	0.950	rs2740592	chr8:11701253	A/G	cg02840367	chr8:11660030	FDFT1	0.91	6.7	0.52	6.58e-10	Blood protein levels;
TGCT	cis	rs617219	0.737	rs2166343	chr5:78484060	A/G	cg23987322	chr5:78407566	BHMT	0.37	4.97	0.41	2.19e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs10197940	0.662	rs1047957	chr2:152333773	C/T	cg06191203	chr2:152266755	RIF1	-0.71	-6.28	-0.49	5.14e-9	Lung cancer;
TGCT	cis	rs1163251	0.837	rs595283	chr1:120247887	C/G	cg19096424	chr1:120255104	PHGDH	-0.61	-5.93	-0.47	2.8e-8	Blood metabolite levels;
TGCT	cis	rs9468199	0.505	rs72848793	chr6:27999578	A/G	cg08851530	chr6:28072375	NA	1.56	7.22	0.54	4.47e-11	Parkinson's disease;
TGCT	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg23708337	chr7:1209742	NA	0.61	5.68	0.45	9.08e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs17376456	0.542	rs10070350	chr5:93103753	C/G	cg25358565	chr5:93447407	FAM172A	0.76	6.68	0.51	7.23e-10	Diabetic retinopathy;
TGCT	cis	rs12048904	0.541	rs1571046	chr1:101299216	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.71	5.7	0.46	8.15e-8	Multiple sclerosis;
TGCT	cis	rs514406	0.505	rs416968	chr1:53183513	A/G	cg16325326	chr1:53192061	ZYG11B	0.85	12.44	0.75	1.44e-23	Monocyte count;
TGCT	cis	rs4664308	1.000	rs17831251	chr2:160914156	C/T	cg03641300	chr2:160917029	PLA2R1	-0.26	-6.53	-0.51	1.49e-9	Idiopathic membranous nephropathy;
TGCT	cis	rs7547997	0.615	rs35752748	chr1:158321565	A/C	cg03528325	chr1:158223921	CD1A	0.33	4.55	0.38	1.25e-5	QRS duration;
TGCT	cis	rs10489202	0.632	rs275143	chr1:168056724	A/G	cg24449463	chr1:168025552	DCAF6	-0.58	-6.45	-0.5	2.26e-9	Schizophrenia;
TGCT	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs694739	0.964	rs2510066	chr11:64052447	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.66	6.88	0.53	2.67e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	trans	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg17830980	chr10:43048298	ZNF37B	-0.85	-10.98	-0.7	5.08e-20	Extrinsic epigenetic age acceleration;
TGCT	cis	rs9814567	0.752	rs1534029	chr3:134330213	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-6.41	-0.5	2.8e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs7666738	0.570	rs11097612	chr4:99079772	T/C	cg18180107	chr4:99064573	C4orf37	0.53	4.67	0.39	7.61e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9790314	0.812	rs2004862	chr3:161135638	C/T	cg03342759	chr3:160939853	NMD3	-0.46	-4.51	-0.38	1.48e-5	Morning vs. evening chronotype;
TGCT	cis	rs301043	0.667	rs301004	chr12:95915680	T/C	cg07805603	chr12:95869602	METAP2	0.34	4.58	0.38	1.13e-5	Immature fraction of reticulocytes;
TGCT	cis	rs7674212	0.772	rs13113099	chr4:103974122	A/G	cg16532752	chr4:104119610	CENPE	-0.52	-4.8	-0.4	4.48e-6	Type 2 diabetes;
TGCT	cis	rs4689388	0.890	rs4688989	chr4:6290594	T/C	cg25554036	chr4:6271136	WFS1	0.54	7.61	0.56	5.93e-12	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	trans	rs4650994	0.544	rs2761469	chr1:178590638	A/C	cg05059571	chr16:84539110	KIAA1609	0.52	10.37	0.68	1.56e-18	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs1865760	0.566	rs9366634	chr6:26072396	C/G	cg16482183	chr6:26056742	HIST1H1C	0.57	4.89	0.4	3.05e-6	Height;
TGCT	cis	rs6089829	0.925	rs4809270	chr20:61676709	C/A	cg02380750	chr20:61661411	NA	0.35	5.76	0.46	6.25e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9926296	0.682	rs258328	chr16:89730314	C/T	cg04287289	chr16:89883240	FANCA	-0.54	-5.01	-0.41	1.86e-6	Vitiligo;
TGCT	cis	rs7829975	0.606	rs7833171	chr8:8699761	C/T	cg15556689	chr8:8085844	FLJ10661	0.66	5.8	0.46	5.2e-8	Mood instability;
TGCT	cis	rs789852	0.764	rs1705999	chr3:194316333	C/T	cg18000598	chr3:194342907	TMEM44	-0.76	-5.09	-0.42	1.31e-6	QT interval;
TGCT	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.93	7.44	0.56	1.44e-11	Platelet count;
TGCT	cis	rs9467773	1.000	rs9461271	chr6:26554968	G/A	cg05738196	chr6:26577821	NA	0.91	13.19	0.76	2.28e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs12477438	0.501	rs1133977	chr2:99741984	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.05	-14.93	-0.8	1.8e-29	Chronic sinus infection;
TGCT	cis	rs4862750	0.832	rs4862744	chr4:187877074	T/A	cg03452623	chr4:187889614	NA	-0.34	-4.88	-0.4	3.21e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg03934478	chr11:495069	RNH1	0.36	5.84	0.46	4.26e-8	Body mass index;
TGCT	trans	rs1814175	0.740	rs10839439	chr11:49918240	C/T	cg15704280	chr7:45808275	SEPT13	-0.71	-8.0	-0.58	7.45e-13	Height;
TGCT	cis	rs12765878	0.967	rs10883948	chr10:105667552	G/T	cg11005552	chr10:105648138	OBFC1	0.44	7.7	0.57	3.69e-12	Coronary artery disease;
TGCT	cis	rs7621025	0.630	rs1681816	chr3:136474762	C/G	cg15507776	chr3:136538369	TMEM22	-0.5	-4.56	-0.38	1.22e-5	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
TGCT	cis	rs250677	0.522	rs62378210	chr5:148384885	G/A	cg18129178	chr5:148520854	ABLIM3	-0.36	-4.69	-0.39	7.23e-6	Breast cancer;
TGCT	cis	rs5769765	0.955	rs61136468	chr22:50312679	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.13	-11.29	-0.71	9.05e-21	Schizophrenia;
TGCT	cis	rs7213347	0.707	rs216215	chr17:2140668	C/T	cg13315690	chr17:1944831	OVCA2;DPH1	-0.37	-4.7	-0.39	6.77e-6	Total body bone mineral density;
TGCT	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg11764359	chr7:65958608	NA	0.61	5.54	0.45	1.76e-7	Aortic root size;
TGCT	cis	rs478304	0.637	rs11227255	chr11:65454044	C/T	cg27068330	chr11:65405492	SIPA1	-1.0	-11.14	-0.71	2.07e-20	Acne (severe);
TGCT	cis	rs9972944	0.756	rs8077164	chr17:63764645	C/T	cg07283582	chr17:63770753	CCDC46	-0.25	-5.11	-0.42	1.2e-6	Total body bone mineral density;
TGCT	cis	rs734999	0.505	rs4073286	chr1:2539901	A/C	cg18854424	chr1:2615690	NA	0.46	5.36	0.43	4e-7	Ulcerative colitis;
TGCT	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs904251	0.828	rs1757178	chr6:37486310	C/T	cg08126542	chr6:37504118	NA	0.42	5.55	0.45	1.66e-7	Cognitive performance;
TGCT	trans	rs3780486	0.881	rs10738906	chr9:33135634	T/C	cg04842962	chr6:43655489	MRPS18A	1.24	15.76	0.82	2.18e-31	IgG glycosylation;
TGCT	cis	rs7681440	0.904	rs6532192	chr4:90764131	G/A	cg14346243	chr4:90757452	SNCA	-0.59	-5.74	-0.46	6.82e-8	Dementia with Lewy bodies;
TGCT	cis	rs6430585	0.583	rs3087343	chr2:136622543	T/G	cg07169764	chr2:136633963	MCM6	1.22	12.03	0.73	1.46e-22	Corneal structure;
TGCT	cis	rs4689388	0.926	rs4308429	chr4:6294001	A/G	cg25554036	chr4:6271136	WFS1	0.54	7.37	0.55	2.11e-11	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg21280719	chr6:42927975	GNMT	-0.37	-4.54	-0.38	1.32e-5	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs7772486	0.840	rs2814867	chr6:146334030	C/A	cg05347473	chr6:146136440	FBXO30	0.55	5.12	0.42	1.15e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6540559	0.673	rs17015224	chr1:209968918	G/A	cg23283495	chr1:209979779	IRF6	0.65	5.04	0.41	1.63e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs7666738	0.830	rs3846444	chr4:99032888	T/C	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2663905	0.611	rs1509558	chr15:81391244	C/T	cg27045999	chr15:81426544	C15orf26	-0.52	-5.09	-0.42	1.32e-6	QT interval (drug interaction);
TGCT	cis	rs2688608	0.592	rs13013	chr10:75562161	C/A	cg23231163	chr10:75533350	FUT11	-0.28	-4.69	-0.39	7.19e-6	Inflammatory bowel disease;
TGCT	cis	rs9818758	0.607	rs9880088	chr3:49178990	G/A	cg07636037	chr3:49044803	WDR6	-1.04	-5.13	-0.42	1.09e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs7246657	0.943	rs7258692	chr19:37818829	C/A	cg18154014	chr19:37997991	ZNF793	0.91	6.09	0.48	1.29e-8	Coronary artery calcification;
TGCT	cis	rs7267979	1.000	rs8125868	chr20:25324410	A/G	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs7819412	0.594	rs60921132	chr8:10964969	T/A	cg15556689	chr8:8085844	FLJ10661	-0.73	-7.13	-0.54	7.33e-11	Triglycerides;
TGCT	cis	rs910316	1.000	rs175443	chr14:75601963	C/T	cg11812906	chr14:75593930	NEK9	-0.73	-7.13	-0.54	7.35e-11	Height;
TGCT	cis	rs7674212	0.541	rs2720448	chr4:104030589	C/T	cg16532752	chr4:104119610	CENPE	-0.62	-5.36	-0.43	3.83e-7	Type 2 diabetes;
TGCT	cis	rs4927850	0.666	rs4927853	chr3:195752053	G/C	cg22891161	chr3:195456627	MUC20	-0.23	-4.55	-0.38	1.24e-5	Pancreatic cancer;
TGCT	cis	rs11971779	0.941	rs6954453	chr7:139031794	C/T	cg07862535	chr7:139043722	LUC7L2	0.79	5.97	0.47	2.38e-8	Diisocyanate-induced asthma;
TGCT	cis	rs6570726	0.599	rs9376951	chr6:145898911	C/T	cg13319975	chr6:146136371	FBXO30	-0.68	-6.23	-0.49	6.81e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7267979	0.966	rs2257705	chr20:25264664	T/C	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10751667	0.666	rs7394958	chr11:965944	C/G	cg06064525	chr11:970664	AP2A2	-0.36	-8.28	-0.6	1.66e-13	Alzheimer's disease (late onset);
TGCT	cis	rs1801251	1.000	rs35212961	chr2:233582762	C/T	cg25237894	chr2:233734115	C2orf82	0.32	5.81	0.46	5.01e-8	Coronary artery disease;
TGCT	cis	rs950169	0.922	rs4842940	chr15:84831225	C/T	cg17173187	chr15:85201210	NMB	-0.52	-5.23	-0.42	7.11e-7	Schizophrenia;
TGCT	cis	rs981844	0.712	rs1037650	chr4:154737657	G/A	cg14289246	chr4:154710475	SFRP2	-1.0	-9.32	-0.64	5.46e-16	Response to statins (LDL cholesterol change);
TGCT	cis	rs10779751	1.000	rs10779751	chr1:11284336	A/G	cg08854313	chr1:11322531	MTOR	0.96	8.74	0.62	1.37e-14	Body mass index;
TGCT	trans	rs2727020	0.702	rs609054	chr11:49219725	C/G	cg03929089	chr4:120376271	NA	0.71	7.91	0.58	1.2e-12	Coronary artery disease;
TGCT	cis	rs2251381	0.750	rs2776250	chr21:30528094	T/G	cg08807101	chr21:30365312	RNF160	0.53	4.65	0.39	8.51e-6	Selective IgA deficiency;
TGCT	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg23708337	chr7:1209742	NA	0.53	5.6	0.45	1.29e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7192750	0.586	rs2335712	chr16:71906597	A/G	cg06353428	chr16:71660113	MARVELD3	-0.8	-6.09	-0.48	1.34e-8	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs80282103	0.717	rs41299206	chr10:1120236	T/C	cg08668510	chr10:1095578	IDI1	1.06	5.26	0.43	6.17e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg02953382	chr22:24373134	LOC391322	-0.83	-9.46	-0.65	2.54e-16	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7100689	0.524	rs7902460	chr10:82199263	T/A	cg01528321	chr10:82214614	TSPAN14	0.71	6.15	0.48	9.9e-9	Post bronchodilator FEV1;
TGCT	cis	rs6964587	1.000	rs13239875	chr7:91716104	G/A	cg22709100	chr7:91322751	NA	0.29	4.8	0.4	4.45e-6	Breast cancer;
TGCT	cis	rs2180341	0.960	rs7756884	chr6:127684018	A/G	cg27446573	chr6:127587934	RNF146	1.21	10.87	0.7	9.57e-20	Breast cancer;
TGCT	cis	rs709400	0.663	rs1803283	chr14:103986255	C/T	cg12935359	chr14:103987150	CKB	0.4	5.92	0.47	2.88e-8	Body mass index;
TGCT	cis	rs6690583	0.623	rs893620	chr1:85425821	T/C	cg20280350	chr1:85513789	MCOLN3	-0.68	-4.49	-0.37	1.6e-5	Serum sulfate level;
TGCT	cis	rs1461503	0.868	rs7126785	chr11:122839564	C/A	cg27398637	chr11:122830231	C11orf63	-0.43	-5.31	-0.43	5e-7	Menarche (age at onset);
TGCT	cis	rs3096299	0.754	rs2965942	chr16:89510327	G/A	cg06640241	chr16:89574553	SPG7	0.74	7.97	0.58	8.88e-13	Multiple myeloma (IgH translocation);
TGCT	cis	rs9372498	0.536	rs62422229	chr6:118959288	T/C	cg21191810	chr6:118973309	C6orf204	-0.38	-4.97	-0.41	2.14e-6	Diastolic blood pressure;
TGCT	trans	rs1814175	0.645	rs11040535	chr11:49808669	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.45	-11.09	-0.71	2.8e-20	Height;
TGCT	cis	rs3096299	0.967	rs28575874	chr16:89469890	C/T	cg06640241	chr16:89574553	SPG7	0.65	6.24	0.49	6.32e-9	Multiple myeloma (IgH translocation);
TGCT	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg22166914	chr1:53195759	ZYG11B	0.38	6.19	0.49	8.03e-9	Monocyte count;
TGCT	cis	rs1395	0.744	rs11126935	chr2:27476740	G/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.62	7.72	0.57	3.38e-12	Blood metabolite levels;
TGCT	cis	rs68170813	0.652	rs6947674	chr7:107193504	T/C	cg02696742	chr7:106810147	HBP1	-0.62	-4.93	-0.4	2.59e-6	Coronary artery disease;
TGCT	cis	rs9972944	0.729	rs6504351	chr17:63765275	C/T	cg07283582	chr17:63770753	CCDC46	-0.26	-5.31	-0.43	4.9e-7	Total body bone mineral density;
TGCT	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.64	0.51	8.93e-10	Bipolar disorder;
TGCT	cis	rs10992471	0.580	rs7030920	chr9:95122952	A/G	cg14631576	chr9:95140430	CENPP	-0.32	-4.84	-0.4	3.72e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg02380750	chr20:61661411	NA	0.33	5.96	0.47	2.4e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs78487399	0.808	rs10200815	chr2:43673273	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.41	-5.31	-0.43	4.82e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs2012796	1.000	rs7153469	chr14:81820979	T/G	cg02996355	chr14:81879375	NA	0.47	4.61	0.38	9.68e-6	Night sleep phenotypes;
TGCT	cis	rs910316	0.763	rs175490	chr14:75545685	A/G	cg11812906	chr14:75593930	NEK9	0.62	5.62	0.45	1.17e-7	Height;
TGCT	cis	rs35306767	0.714	rs28512382	chr10:1092195	G/C	cg20503657	chr10:835505	NA	0.6	6.85	0.52	3.05e-10	Eosinophil percentage of granulocytes;
TGCT	cis	rs7809950	0.817	rs10224503	chr7:107075569	A/C	cg23024343	chr7:107201750	COG5	-0.5	-6.99	-0.53	1.48e-10	Coronary artery disease;
TGCT	cis	rs6570726	0.791	rs447992	chr6:145817184	C/T	cg23711669	chr6:146136114	FBXO30	0.89	9.72	0.66	6.02e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6121246	0.529	rs6120862	chr20:30199459	T/C	cg21427119	chr20:30132790	HM13	-0.43	-6.17	-0.48	8.86e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs8042680	0.554	rs8035844	chr15:91519642	C/T	cg23684204	chr15:91497937	RCCD1	0.36	4.63	0.38	9e-6	Type 2 diabetes;
TGCT	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg10802521	chr3:52805072	NEK4	-0.78	-10.0	-0.67	1.26e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs3771570	1.000	rs62193175	chr2:242284405	G/A	cg21155796	chr2:242212141	HDLBP	0.94	6.69	0.51	6.9e-10	Prostate cancer;
TGCT	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg18402987	chr7:1209562	NA	0.75	6.35	0.5	3.67e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs17221829	0.644	rs7943100	chr11:89382037	C/A	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.63	-0.38	8.95e-6	Anxiety in major depressive disorder;
TGCT	cis	rs2201841	0.960	rs10889677	chr1:67725120	C/A	cg25131922	chr1:68698529	GPR177	0.44	4.66	0.39	8.11e-6	Ulcerative colitis;Psoriasis;Crohn's disease;
TGCT	cis	rs1878931	0.501	rs17136359	chr16:3420814	C/T	cg22508957	chr16:3507546	NAT15	0.38	4.8	0.4	4.54e-6	Body mass index (adult);
TGCT	cis	rs3015497	0.789	rs2934688	chr14:51112360	G/A	cg04730355	chr14:51134070	SAV1	-0.68	-6.57	-0.51	1.26e-9	Mean platelet volume;
TGCT	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.95	-10.7	-0.69	2.52e-19	Age at first birth;
TGCT	cis	rs78456975	0.689	rs10194040	chr2:1543293	T/G	cg12573674	chr2:1569213	NA	-0.49	-4.8	-0.4	4.43e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg26338869	chr17:61819248	STRADA	-0.53	-4.83	-0.4	3.91e-6	Prudent dietary pattern;
TGCT	cis	rs4654899	0.758	rs7530739	chr1:21447480	C/A	cg01072550	chr1:21505969	NA	-0.57	-9.35	-0.64	4.68e-16	Superior frontal gyrus grey matter volume;
TGCT	cis	rs11098499	0.648	rs2002047	chr4:120257228	A/G	cg09307838	chr4:120376055	NA	0.63	6.07	0.48	1.44e-8	Corneal astigmatism;
TGCT	cis	rs10789285	0.650	rs4265389	chr1:69693244	G/A	ch.1.69469992R	chr1:69697404	NA	0.31	4.54	0.38	1.32e-5	Psoriasis;
TGCT	cis	rs11105298	0.891	rs11105316	chr12:89925200	T/G	cg00757033	chr12:89920650	WDR51B	0.3	4.78	0.39	4.9100000000000004e-06	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs950027	0.620	rs1617634	chr15:45615578	A/G	cg26924012	chr15:45694286	SPATA5L1	0.82	9.1	0.63	1.85e-15	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs10802346	0.636	rs12047380	chr1:246394817	C/T	cg12448285	chr1:245534821	KIF26B	-0.36	-4.89	-0.4	3.11e-6	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs16957091	0.647	rs7166705	chr15:43265126	C/A	cg17935677	chr15:44119062	WDR76	0.52	4.67	0.39	7.6e-6	MGMT methylation in smokers;
TGCT	cis	rs4253772	0.591	rs6520010	chr22:46721223	G/A	cg24881330	chr22:46731750	TRMU	0.94	6.36	0.5	3.54e-9	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.34	0.55	2.43e-11	Prudent dietary pattern;
TGCT	cis	rs1997103	1.000	rs10270618	chr7:55396712	T/A	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs1372520	0.577	rs1811443	chr4:90747883	G/C	cg14346243	chr4:90757452	SNCA	-0.67	-5.64	-0.45	1.09e-7	Neuroticism;
TGCT	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs2224391	0.628	rs2753232	chr6:5250765	G/T	cg09085698	chr6:5261316	LYRM4;FARS2	-1.04	-6.69	-0.51	6.87e-10	Height;
TGCT	cis	rs12477438	0.798	rs6716913	chr2:99580641	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-8.65	-0.61	2.22e-14	Chronic sinus infection;
TGCT	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg24549020	chr5:56110836	MAP3K1	0.67	5.78	0.46	5.74e-8	Initial pursuit acceleration;
TGCT	cis	rs7246657	0.943	rs4803229	chr19:37864682	T/G	cg18154014	chr19:37997991	ZNF793	0.74	5.33	0.43	4.48e-7	Coronary artery calcification;
TGCT	cis	rs4919694	1.000	rs4917382	chr10:104838510	G/A	cg04362960	chr10:104952993	NT5C2	1.07	7.2	0.54	5.11e-11	Arsenic metabolism;
TGCT	cis	rs1797081	0.561	rs2603795	chr10:16860256	A/G	cg23933602	chr10:16859644	RSU1	0.7	7.05	0.53	1.1e-10	Platelet distribution width;
TGCT	trans	rs1814175	0.715	rs11040586	chr11:49858432	T/A	cg15704280	chr7:45808275	SEPT13	-0.72	-8.14	-0.59	3.61e-13	Height;
TGCT	cis	rs36051895	0.632	rs11791350	chr9:5172907	G/T	cg02405213	chr9:5042618	JAK2	-0.7	-9.12	-0.63	1.65e-15	Pediatric autoimmune diseases;
TGCT	cis	rs3784262	0.528	rs1994926	chr15:58334587	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.41	-6.22	-0.49	6.9e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs9291683	0.609	rs12507050	chr4:10007305	G/T	cg11266682	chr4:10021025	SLC2A9	0.68	9.86	0.66	2.76e-17	Bone mineral density;
TGCT	cis	rs9650657	0.645	rs9969657	chr8:10515278	A/G	cg27411982	chr8:10470053	RP1L1	0.22	4.92	0.4	2.73e-6	Neuroticism;
TGCT	cis	rs2739330	0.576	rs2858912	chr22:24297197	A/G	cg23131131	chr22:24373011	LOC391322	-0.81	-9.08	-0.63	2.09e-15	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1372520	0.873	rs2737026	chr4:90779823	A/G	cg20003494	chr4:90757398	SNCA	-0.65	-5.22	-0.42	7.45e-7	Neuroticism;
TGCT	cis	rs7100689	0.577	rs9420359	chr10:82054873	C/T	cg01528321	chr10:82214614	TSPAN14	0.7	6.78	0.52	4.43e-10	Post bronchodilator FEV1;
TGCT	cis	rs7666738	0.861	rs28821920	chr4:98962743	T/C	cg18180107	chr4:99064573	C4orf37	0.57	5.18	0.42	8.63e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg19318889	chr4:1322082	MAEA	0.26	6.49	0.5	1.82e-9	Longevity;
TGCT	cis	rs1757171	0.542	rs3818985	chr6:37484214	G/T	cg25019722	chr6:37503610	NA	-0.5	-7.68	-0.57	4.04e-12	Cognitive performance;
TGCT	cis	rs1008375	1.000	rs1558378	chr4:17650351	T/C	cg10189774	chr4:17578691	LAP3	0.6	5.29	0.43	5.23e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs700590	0.723	rs160042	chr5:88143526	C/T	cg22951263	chr5:87985283	NA	0.54	5.06	0.41	1.48e-6	Educational attainment (years of education);
TGCT	cis	rs17376456	0.877	rs66696214	chr5:93424533	G/A	cg25358565	chr5:93447407	FAM172A	0.93	8.37	0.6	1.04e-13	Diabetic retinopathy;
TGCT	cis	rs3960554	0.709	rs56163935	chr7:75788744	T/C	cg17325771	chr7:75508891	RHBDD2	-0.54	-4.51	-0.38	1.46e-5	Eotaxin levels;
TGCT	cis	rs2439831	0.850	rs2228368	chr15:44102010	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	6.25	0.49	6.04e-9	Lung cancer in ever smokers;
TGCT	cis	rs910316	0.839	rs35977276	chr14:75637359	A/C	cg23033748	chr14:75592666	NEK9	-0.29	-4.88	-0.4	3.17e-6	Height;
TGCT	cis	rs74233809	0.534	rs176185	chr10:104556054	G/C	cg05855489	chr10:104503620	C10orf26	-0.75	-5.01	-0.41	1.8e-6	Birth weight;
TGCT	cis	rs6940638	0.662	rs7759694	chr6:27240956	C/T	cg05738196	chr6:26577821	NA	-0.5	-4.5	-0.37	1.56e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7822232	0.908	rs6558297	chr8:145143934	C/T	cg26272248	chr8:145163034	KIAA1875	-0.49	-4.81	-0.4	4.24e-6	Blood metabolite levels;
TGCT	cis	rs739496	0.579	rs7294623	chr12:112317096	G/A	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs5769765	0.908	rs9616370	chr22:50306316	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.48	-7.05	-0.53	1.11e-10	Schizophrenia;
TGCT	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.64	-0.51	8.67e-10	Alzheimer's disease;
TGCT	cis	rs2797160	0.651	rs6569437	chr6:126034540	T/G	cg05901451	chr6:126070800	HEY2	0.73	6.81	0.52	3.66e-10	Endometrial cancer;
TGCT	cis	rs826838	0.900	rs9739128	chr12:38948960	A/T	cg26384229	chr12:38710491	ALG10B	1.05	10.5	0.69	7.87e-19	Heart rate;
TGCT	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg12756686	chr19:29218302	NA	0.62	4.67	0.39	7.69e-6	Methadone dose in opioid dependence;
TGCT	cis	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg02380750	chr20:61661411	NA	0.33	5.96	0.47	2.4e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs904251	1.000	rs12212090	chr6:37431808	A/G	cg08126542	chr6:37504118	NA	-0.4	-5.27	-0.43	5.92e-7	Cognitive performance;
TGCT	cis	rs6555855	0.830	rs1592817	chr5:168744302	A/G	cg26492514	chr5:168728236	SLIT3	0.28	4.45	0.37	1.91e-5	Menarche (age at onset);
TGCT	cis	rs9911578	1.000	rs10401050	chr17:56953786	A/C	cg12560992	chr17:57184187	TRIM37	0.76	9.21	0.64	1.03e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs57994353	1.000	rs57994353	chr9:139356987	T/C	cg13741927	chr9:139327495	INPP5E	-0.25	-5.81	-0.46	4.88e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs7662987	0.517	rs1311618	chr4:100012612	A/G	cg12011299	chr4:100065546	ADH4	0.4	4.76	0.39	5.33e-6	Smoking initiation;
TGCT	cis	rs11578119	0.933	rs10919416	chr1:170441709	T/C	cg09767346	chr1:170501363	GORAB	0.71	5.68	0.45	9.07e-8	Male-pattern baldness;
TGCT	cis	rs12701220	0.803	rs12701432	chr7:1052453	C/T	cg07217954	chr7:1067459	C7orf50	-0.49	-4.9	-0.4	2.95e-6	Bronchopulmonary dysplasia;
TGCT	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9467711	0.606	rs12176317	chr6:26372786	A/G	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs669446	0.558	rs6429631	chr1:44113441	T/C	cg12908607	chr1:44402522	ARTN	-0.55	-5.9	-0.47	3.25e-8	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs12220898	0.749	rs4483512	chr10:50480390	G/A	cg06072769	chr10:50146962	WDFY4	0.38	4.98	0.41	2.07e-6	Inflammatory biomarkers;
TGCT	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2456568	0.803	rs10831140	chr11:93640689	G/A	cg17595323	chr11:93583763	C11orf90	-0.47	-6.24	-0.49	6.39e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg06634786	chr22:41940651	POLR3H	0.89	8.55	0.61	3.83e-14	Vitiligo;
TGCT	cis	rs6964587	0.869	rs11769726	chr7:91485231	A/G	cg17063962	chr7:91808500	NA	-0.85	-8.94	-0.63	4.52e-15	Breast cancer;
TGCT	cis	rs4253772	0.701	rs9627280	chr22:46643964	T/C	cg09491104	chr22:46646882	C22orf40	-0.5	-5.35	-0.43	4.04e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs9467773	0.583	rs1021373	chr6:26632457	G/A	cg09904177	chr6:26538194	HMGN4	0.67	6.48	0.5	1.94e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs9435341	0.965	rs1730864	chr1:107607810	C/T	cg09367891	chr1:107599246	PRMT6	-0.62	-5.17	-0.42	8.93e-7	Facial morphology (factor 21, depth of nasal alae);
TGCT	cis	rs7923452	1.000	rs7923452	chr10:30751171	T/C	cg18806716	chr10:30721971	MAP3K8	0.7	6.19	0.49	7.95e-9	Itch intensity from mosquito bite;
TGCT	cis	rs807669	0.525	rs2282684	chr22:19184244	C/T	cg02655711	chr22:19163373	SLC25A1	0.24	4.58	0.38	1.13e-5	Metabolite levels;
TGCT	cis	rs259282	0.583	rs12981373	chr19:33108189	C/T	cg26639809	chr19:33781782	NA	0.24	4.78	0.39	4.77e-6	Schizophrenia;
TGCT	cis	rs644799	0.542	rs10831415	chr11:95466159	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.59	5.77	0.46	6.06e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7000551	0.715	rs7839577	chr8:22307325	T/A	cg12081754	chr8:22256438	SLC39A14	0.33	5.47	0.44	2.43e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs9902453	0.808	rs12452288	chr17:28235220	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.81	7.28	0.55	3.32e-11	Coffee consumption (cups per day);
TGCT	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg25036284	chr2:26402008	FAM59B	0.65	5.19	0.42	8.36e-7	Gut microbiome composition (summer);
TGCT	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg22764044	chr5:178986830	RUFY1	-0.47	-5.27	-0.43	5.84e-7	Lung cancer;
TGCT	cis	rs9467773	0.869	rs742090	chr6:26415637	A/C	cg26531700	chr6:26746687	NA	-0.51	-4.97	-0.41	2.2e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs5769765	0.825	rs9616780	chr22:50292763	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.39	5.91	0.47	3.12e-8	Schizophrenia;
TGCT	cis	rs35160687	0.901	rs34048420	chr2:86529748	A/G	cg03171300	chr2:86307199	POLR1A	0.32	5.57	0.45	1.48e-7	Night sleep phenotypes;
TGCT	cis	rs200810	0.694	rs112311189	chr6:98030472	T/C	cg16511841	chr6:97730490	C6orf167;MIR548H3	-0.65	-4.44	-0.37	1.94e-5	Body mass index;
TGCT	cis	rs74181299	0.571	rs6728523	chr2:65282708	G/C	cg05010058	chr2:65284262	CEP68	0.49	5.01	0.41	1.79e-6	Pulse pressure;
TGCT	cis	rs9910055	0.529	rs850851	chr17:42177674	C/T	cg13607699	chr17:42295918	UBTF	-0.6	-4.93	-0.4	2.59e-6	Total body bone mineral density;
TGCT	cis	rs1865760	0.516	rs9393683	chr6:26066198	A/G	cg16482183	chr6:26056742	HIST1H1C	0.57	4.99	0.41	1.99e-6	Height;
TGCT	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg08280861	chr8:58055591	NA	0.48	5.85	0.46	4.17e-8	Developmental language disorder (linguistic errors);
TGCT	cis	rs6714788	0.546	rs12712062	chr2:100654307	A/T	cg07810366	chr2:100720526	AFF3	-0.36	-5.07	-0.41	1.43e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg25767906	chr1:53392781	SCP2	0.49	5.52	0.44	1.87e-7	Monocyte count;
TGCT	cis	rs1371867	0.764	rs1020171	chr8:101288610	T/C	cg06002616	chr8:101225028	SPAG1	-0.57	-6.77	-0.52	4.48e-10	Atrioventricular conduction;
TGCT	cis	rs4722585	0.605	rs10268883	chr7:26200417	C/T	cg03781084	chr7:26191726	NFE2L3	-0.5	-5.04	-0.41	1.61e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
TGCT	cis	rs4072705	0.967	rs4838200	chr9:127451057	A/G	cg13476313	chr9:127244764	NR5A1	-0.28	-4.45	-0.37	1.93e-5	Menarche (age at onset);
TGCT	cis	rs7925523	0.838	rs60507107	chr11:61463769	C/T	cg18476690	chr11:61125255	CYBASC3	0.27	4.53	0.38	1.36e-5	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
TGCT	cis	rs804280	0.662	rs11250164	chr8:11610686	C/T	cg26752888	chr8:11627280	NEIL2	0.58	4.49	0.37	1.58e-5	Myopia (pathological);
TGCT	cis	rs7772486	0.686	rs4896827	chr6:145953338	T/A	cg05347473	chr6:146136440	FBXO30	0.48	4.56	0.38	1.19e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7412746	0.611	rs72704679	chr1:150897477	C/T	cg04414720	chr1:150670196	GOLPH3L	0.37	4.46	0.37	1.81e-5	Melanoma;
TGCT	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg18402987	chr7:1209562	NA	0.75	6.29	0.49	4.9e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg07424592	chr7:64974309	NA	1.36	8.15	0.59	3.36e-13	Diabetic kidney disease;
TGCT	cis	rs3806843	0.521	rs246061	chr5:140324656	C/A	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs57024841	0.517	rs28578007	chr9:139838690	T/C	cg00693599	chr9:139836323	FBXW5	0.21	4.68	0.39	7.33e-6	Beta-trace protein levels;
TGCT	cis	rs4851266	1.000	rs12990462	chr2:100827216	G/A	cg07810366	chr2:100720526	AFF3	-0.38	-5.44	-0.44	2.7e-7	Educational attainment;
TGCT	cis	rs78545713	0.892	rs113432940	chr6:26256324	T/A	cg12260798	chr6:26240519	HIST1H4F	-0.49	-4.52	-0.38	1.4e-5	Iron status biomarkers (total iron binding capacity);
TGCT	cis	rs2455799	0.517	rs1579901	chr3:15938463	C/G	cg12172478	chr3:16357591	RFTN1	-0.33	-4.81	-0.4	4.31e-6	Mean platelet volume;
TGCT	cis	rs909685	1.000	rs909685	chr22:39747671	T/A	cg17798944	chr22:39715225	SNORD43;RPL3	0.66	6.42	0.5	2.65e-9	Rheumatoid arthritis;
TGCT	cis	rs6121246	0.529	rs6060144	chr20:30178624	A/G	cg21427119	chr20:30132790	HM13	-0.44	-6.39	-0.5	3.11e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs1670533	1.000	rs7669399	chr4:1058478	T/G	cg20887711	chr4:1340912	KIAA1530	0.69	5.48	0.44	2.32e-7	Recombination rate (females);
TGCT	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg22920501	chr2:26401640	FAM59B	0.72	5.73	0.46	7.24e-8	Gut microbiome composition (summer);
TGCT	cis	rs2871473	1.000	rs1030024	chr2:103105769	A/T	cg09003973	chr2:102972529	NA	-0.64	-4.52	-0.38	1.4e-5	Blood protein levels;
TGCT	cis	rs7678296	0.649	rs4585313	chr4:37240236	C/T	cg06805348	chr4:37245195	KIAA1239	-0.58	-4.92	-0.4	2.68e-6	3-hydroxypropylmercapturic acid levels in smokers;
TGCT	cis	rs4319547	0.956	rs10773302	chr12:123043145	G/T	cg23029597	chr12:123009494	RSRC2	-0.3	-4.83	-0.4	3.98e-6	Body mass index;
TGCT	cis	rs8070128	0.534	rs2955350	chr17:17953548	G/A	cg09796270	chr17:17721594	SREBF1	-0.24	-4.7	-0.39	6.8e-6	Total body bone mineral density;
TGCT	cis	rs7659604	1.000	rs35224452	chr4:122664677	C/T	cg19748678	chr4:122722346	EXOSC9	0.57	5.5	0.44	2.07e-7	Type 2 diabetes;
TGCT	cis	rs9467773	1.000	rs6925703	chr6:26521589	G/A	cg09904177	chr6:26538194	HMGN4	0.65	6.53	0.51	1.53e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.46	-4.92	-0.4	2.73e-6	Longevity;Endometriosis;
TGCT	cis	rs826838	0.967	rs1352122	chr12:39130885	G/A	cg13010199	chr12:38710504	ALG10B	-0.63	-5.06	-0.41	1.46e-6	Heart rate;
TGCT	cis	rs9916302	0.851	rs6503502	chr17:37501855	A/G	cg15445000	chr17:37608096	MED1	-0.33	-4.71	-0.39	6.46e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs10193935	0.901	rs13384323	chr2:42631346	C/T	cg27598129	chr2:42591480	NA	-0.36	-5.17	-0.42	9.2e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12493885	0.697	rs73153977	chr3:153659196	G/T	cg17054900	chr3:154042577	DHX36	-0.52	-4.68	-0.39	7.33e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs910316	0.967	rs2010678	chr14:75567178	C/T	cg11812906	chr14:75593930	NEK9	0.74	7.38	0.55	1.97e-11	Height;
TGCT	cis	rs1568889	0.774	rs11030235	chr11:28212375	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.92	10.5	0.69	7.72e-19	Bipolar disorder;
TGCT	cis	rs7647973	0.626	rs9870858	chr3:49769071	C/T	cg03034192	chr3:50606346	HEMK1;C3orf18	0.36	4.75	0.39	5.61e-6	Menarche (age at onset);
TGCT	cis	rs3749237	0.595	rs3870338	chr3:49557051	A/G	cg02487422	chr3:49467188	NICN1	0.57	5.88	0.47	3.54e-8	Resting heart rate;
TGCT	cis	rs6693567	0.565	rs834237	chr1:150363930	A/G	cg09579323	chr1:150459698	TARS2	0.52	4.64	0.38	8.63e-6	Migraine;
TGCT	cis	rs4851266	1.000	rs11686372	chr2:100827907	C/A	cg07810366	chr2:100720526	AFF3	-0.38	-5.44	-0.44	2.7e-7	Educational attainment;
TGCT	cis	rs2050392	1.000	rs2050392	chr10:30691503	G/A	cg18806716	chr10:30721971	MAP3K8	-0.44	-5.17	-0.42	9.28e-7	Inflammatory bowel disease;
TGCT	cis	rs1475911	1.000	rs12482477	chr21:43517233	T/A	cg08663969	chr21:43620345	ABCG1	0.19	4.48	0.37	1.7e-5	IgG glycosylation;
TGCT	cis	rs11030122	0.702	rs7102215	chr11:3943970	C/T	cg18678763	chr11:4115507	RRM1	-0.49	-6.14	-0.48	1.01e-8	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs3617	0.539	rs9985365	chr3:52953844	A/G	cg10802521	chr3:52805072	NEK4	0.54	6.27	0.49	5.52e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs3796352	0.527	rs11715498	chr3:52943551	G/C	cg07884673	chr3:53033167	SFMBT1	0.46	4.7	0.39	6.89e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs4077515	0.967	rs11145874	chr9:139290011	G/A	cg13741927	chr9:139327495	INPP5E	-0.2	-4.67	-0.39	7.55e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs12142240	0.698	rs45449893	chr1:46859024	A/G	cg14993813	chr1:46806288	NSUN4	-0.59	-4.86	-0.4	3.45e-6	Menopause (age at onset);
TGCT	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg00024416	chr22:24240387	NA	0.35	5.93	0.47	2.79e-8	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs936229	0.690	rs2445618	chr15:75035256	T/C	cg10253484	chr15:75165896	SCAMP2	-0.59	-5.0	-0.41	1.89e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
TGCT	cis	rs2050392	0.517	rs160018	chr10:30772703	T/C	cg18806716	chr10:30721971	MAP3K8	-0.5	-5.67	-0.45	9.52e-8	Inflammatory bowel disease;
TGCT	cis	rs9948	0.655	rs62152771	chr2:97447121	C/G	cg01990225	chr2:97406019	LMAN2L	-1.01	-5.13	-0.42	1.08e-6	Erectile dysfunction and prostate cancer treatment;
TGCT	trans	rs10506458	1.000	rs10506458	chr12:63445092	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.47	-7.62	-0.56	5.8e-12	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs6912958	0.559	rs242270	chr6:88062190	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.63	-6.25	-0.49	6.08e-9	Monocyte percentage of white cells;
TGCT	cis	rs2970818	0.831	rs2970810	chr12:4608103	A/G	cg09670175	chr12:4923468	KCNA6	0.2	4.45	0.37	1.91e-5	Phosphorus levels;
TGCT	cis	rs6089584	0.816	rs4134440	chr20:60624296	A/G	cg16423285	chr20:60520624	NA	-0.69	-7.11	-0.54	8.23e-11	Body mass index;
TGCT	cis	rs4951018	0.821	rs11240547	chr1:205632932	A/G	cg14159672	chr1:205819179	PM20D1	0.4	4.53	0.38	1.36e-5	Prostate-specific antigen levels;
TGCT	cis	rs360798	0.512	rs4461246	chr2:63027671	C/T	cg17519650	chr2:63277830	OTX1	-0.57	-4.98	-0.41	2.1e-6	Coronary artery disease;
TGCT	cis	rs9303401	0.527	rs12946522	chr17:56768103	A/C	cg25039879	chr17:56429692	SUPT4H1	0.52	4.52	0.38	1.41e-5	Cognitive test performance;
TGCT	cis	rs79349575	0.811	rs1057897	chr17:47005509	T/G	cg07967210	chr17:47022446	SNF8	0.44	6.13	0.48	1.1e-8	Type 2 diabetes;
TGCT	cis	rs7666738	0.546	rs10440329	chr4:98903735	C/T	cg05340658	chr4:99064831	C4orf37	0.56	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9611565	0.729	rs137831	chr22:41903813	A/C	cg17554472	chr22:41940697	POLR3H	-0.47	-5.07	-0.41	1.43e-6	Vitiligo;
TGCT	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg06873352	chr17:61820015	STRADA	0.56	6.22	0.49	6.93e-9	Prudent dietary pattern;
TGCT	cis	rs9534288	0.619	rs6561292	chr13:46683560	G/T	cg15192986	chr13:46630673	CPB2	0.51	6.19	0.49	7.96e-9	Blood protein levels;
TGCT	cis	rs9916302	0.861	rs33933929	chr17:37426441	A/C	cg15445000	chr17:37608096	MED1	0.32	4.69	0.39	7.11e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs4517514	0.509	rs2156434	chr11:89896417	A/G	cg05041596	chr11:89867385	NAALAD2	0.53	5.08	0.42	1.33e-6	Trans fatty acid levels;
TGCT	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg00814883	chr7:100076585	TSC22D4	-0.92	-9.76	-0.66	4.73e-17	Platelet count;
TGCT	cis	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg20362242	chr5:692897	TPPP	-0.5	-4.57	-0.38	1.17e-5	Obesity-related traits;
TGCT	cis	rs2486012	1.000	rs61770287	chr1:44359205	C/T	cg12908607	chr1:44402522	ARTN	0.71	5.86	0.47	3.87e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs60843830	1.000	rs62114505	chr2:242426	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.72	6.81	0.52	3.81e-10	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs981844	1.000	rs2405431	chr4:154656396	A/G	cg14289246	chr4:154710475	SFRP2	1.04	8.19	0.59	2.74e-13	Response to statins (LDL cholesterol change);
TGCT	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg14820908	chr5:178986412	RUFY1	-0.44	-4.52	-0.38	1.44e-5	Lung cancer;
TGCT	cis	rs1008375	0.966	rs6449330	chr4:17703949	C/T	cg18681998	chr4:17616180	MED28	-0.77	-7.84	-0.58	1.77e-12	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs3772130	0.962	rs7629369	chr3:121566282	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.62	0.38	9.48e-6	Cognitive performance;
TGCT	cis	rs7666738	0.800	rs12163918	chr4:98835794	T/C	cg18180107	chr4:99064573	C4orf37	0.56	5.18	0.42	8.78e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs17221829	0.626	rs10830340	chr11:89413850	C/T	cg02982614	chr11:89391479	FOLH1B	-0.28	-4.66	-0.39	7.94e-6	Anxiety in major depressive disorder;
TGCT	cis	rs4820539	0.966	rs5751587	chr22:23470090	G/A	cg14186256	chr22:23484241	RTDR1	0.99	12.58	0.75	6.81e-24	Bone mineral density;
TGCT	cis	rs7364180	0.515	rs6002503	chr22:42208672	A/G	cg13695892	chr22:41940480	POLR3H	-0.56	-5.54	-0.45	1.75e-7	Alzheimer's disease biomarkers;
TGCT	cis	rs2361718	0.603	rs12951255	chr17:78085597	A/G	cg08005872	chr17:78999347	NA	0.27	4.57	0.38	1.18e-5	Yeast infection;
TGCT	cis	rs7219021	0.739	rs4793993	chr17:47008546	C/T	cg26022315	chr17:47021804	SNF8	-0.54	-4.65	-0.39	8.2e-6	Schizophrenia or bipolar disorder;
TGCT	cis	rs11718455	0.960	rs4682712	chr3:43997971	T/C	cg08738300	chr3:44038990	NA	0.83	6.19	0.49	8.13e-9	Coronary artery disease;
TGCT	cis	rs4400599	0.786	rs11265123	chr1:154087255	G/T	cg08031413	chr1:154528842	UBE2Q1	0.27	4.62	0.38	9.41e-6	Platelet distribution width;
TGCT	cis	rs2842992	1.000	rs2842992	chr6:160071159	G/A	cg11366901	chr6:160182831	ACAT2	0.92	6.27	0.49	5.5e-9	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs7607369	0.648	rs7559629	chr2:219657013	A/T	cg02176678	chr2:219576539	TTLL4	-0.47	-6.0	-0.47	1.98e-8	Red blood cell count;Amyotrophic lateral sclerosis;
TGCT	cis	rs55794721	0.509	rs909834	chr1:25757996	A/G	cg23205692	chr1:25664452	TMEM50A	0.49	5.16	0.42	9.32e-7	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs4664308	0.905	rs62177860	chr2:160960571	C/T	cg03641300	chr2:160917029	PLA2R1	-0.28	-6.89	-0.53	2.44e-10	Idiopathic membranous nephropathy;
TGCT	cis	rs67460515	0.892	rs13073147	chr3:161045237	T/C	cg03342759	chr3:160939853	NMD3	-0.49	-5.29	-0.43	5.28e-7	Parkinson's disease;
TGCT	cis	rs16866061	0.515	rs13020268	chr2:225437923	C/T	cg12698349	chr2:225449008	CUL3	1.12	15.51	0.81	8.08e-31	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	cis	rs314253	1.000	rs314253	chr17:7091650	A/G	cg17016524	chr17:7405958	POLR2A	0.18	5.08	0.42	1.35e-6	LDL cholesterol levels;Cholesterol, total;LDL cholesterol;Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs35306767	0.715	rs12777801	chr10:1036285	T/A	cg26597838	chr10:835615	NA	0.63	7.0	0.53	1.45e-10	Eosinophil percentage of granulocytes;
TGCT	cis	rs7772486	0.754	rs702323	chr6:146008274	A/G	cg23711669	chr6:146136114	FBXO30	-0.85	-9.45	-0.65	2.66e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg11890956	chr21:40555474	PSMG1	1.12	12.59	0.75	6.25e-24	Cognitive function;
TGCT	cis	rs72781680	0.898	rs56315094	chr2:23941952	T/C	cg08917208	chr2:24149416	ATAD2B	0.77	4.71	0.39	6.52e-6	Lymphocyte counts;
TGCT	cis	rs1997103	1.000	rs1997103	chr7:55395390	C/G	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs7681440	0.874	rs10028246	chr4:90766704	G/A	cg01966878	chr4:90757139	SNCA	-0.25	-4.56	-0.38	1.2e-5	Dementia with Lewy bodies;
TGCT	cis	rs9969804	0.818	rs6479429	chr9:95501785	A/T	cg13940029	chr9:95239186	CENPP;ASPN	-0.17	-4.51	-0.38	1.47e-5	Height;
TGCT	cis	rs9660992	0.512	rs12123773	chr1:205122420	C/G	cg00857998	chr1:205179979	DSTYK	0.48	4.48	0.37	1.68e-5	Mean corpuscular volume;Mean platelet volume;
TGCT	cis	rs7943203	0.568	rs597788	chr11:108256859	C/T	cg04873221	chr11:107992290	ACAT1	-0.59	-5.0	-0.41	1.87e-6	Red blood cell count;Mean corpuscular volume;
TGCT	cis	rs67478160	0.643	rs11847468	chr14:104220295	G/A	cg26031613	chr14:104095156	KLC1	-0.63	-6.53	-0.51	1.56e-9	Schizophrenia;
TGCT	cis	rs1887596	0.624	rs9319306	chr13:27151170	A/G	cg01312412	chr13:27282625	NA	0.29	5.32	0.43	4.77e-7	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs2549003	1.000	rs2548997	chr5:131835395	C/T	cg21138405	chr5:131827807	IRF1	-0.19	-5.03	-0.41	1.65e-6	Asthma (sex interaction);
TGCT	cis	rs12580194	1.000	rs58332180	chr12:55711353	C/A	cg20672549	chr12:56432144	IKZF4	0.26	4.67	0.39	7.82e-6	Cancer;
TGCT	cis	rs595982	0.702	rs638050	chr19:49375676	A/G	cg21252483	chr19:49399788	TULP2	-0.27	-4.81	-0.4	4.37e-6	Red cell distribution width;
TGCT	cis	rs2070433	1.000	rs2839306	chr21:47954219	G/T	cg12379764	chr21:47803548	PCNT	-0.54	-4.65	-0.39	8.47e-6	Lymphocyte counts;
TGCT	cis	rs12893668	0.572	rs1606	chr14:104161281	G/A	cg26031613	chr14:104095156	KLC1	-0.59	-5.05	-0.41	1.53e-6	Reticulocyte count;
TGCT	cis	rs9911578	0.967	rs4076229	chr17:56937256	C/T	cg05425664	chr17:57184151	TRIM37	-0.62	-6.18	-0.49	8.33e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs11601602	0.576	rs4075635	chr11:28511643	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.69	5.67	0.45	9.35e-8	Obesity-related traits;
TGCT	cis	rs7666738	0.753	rs1527520	chr4:98929164	A/G	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3806843	0.576	rs246011	chr5:140336405	G/C	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs10779751	0.770	rs11121691	chr1:11181327	C/T	cg08854313	chr1:11322531	MTOR	-0.82	-6.58	-0.51	1.17e-9	Body mass index;
TGCT	cis	rs9512730	0.553	rs6491211	chr13:28049533	A/G	cg04070771	chr13:27998621	GTF3A	0.51	4.58	0.38	1.13e-5	Schizophrenia;
TGCT	cis	rs72781680	0.848	rs56218741	chr2:23977377	A/C	cg08917208	chr2:24149416	ATAD2B	0.83	5.24	0.43	6.62e-7	Lymphocyte counts;
TGCT	cis	rs1552244	0.554	rs9878047	chr3:9985457	T/C	cg00149659	chr3:10157352	C3orf10	0.61	4.44	0.37	1.97e-5	Alzheimer's disease;
TGCT	cis	rs9611565	0.802	rs4822028	chr22:41789408	A/G	cg06634786	chr22:41940651	POLR3H	-0.72	-6.68	-0.51	7.15e-10	Vitiligo;
TGCT	cis	rs11031096	0.782	rs4910888	chr11:4152915	G/A	cg18678763	chr11:4115507	RRM1	-0.46	-5.87	-0.47	3.74e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs9911578	1.000	rs302840	chr17:56673079	C/G	cg12560992	chr17:57184187	TRIM37	0.78	9.62	0.65	1.03e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg11211951	chr8:145729740	GPT	-0.25	-5.8	-0.46	5.1e-8	Age at first birth;
TGCT	cis	rs7584330	0.554	rs7582964	chr2:238385766	C/T	cg14458575	chr2:238380390	NA	-0.44	-4.44	-0.37	1.99e-5	Prostate cancer;
TGCT	cis	rs453301	0.598	rs2921383	chr8:8892221	C/T	cg06636001	chr8:8085503	FLJ10661	0.77	6.89	0.53	2.53e-10	Joint mobility (Beighton score);
TGCT	cis	rs9660180	0.967	rs61422524	chr1:1767565	C/A	cg13866156	chr1:1669148	SLC35E2	-0.23	-5.51	-0.44	1.97e-7	Body mass index;
TGCT	cis	rs12615966	0.872	rs72830464	chr2:105395283	G/A	cg16465502	chr2:105461796	NA	0.79	5.07	0.41	1.39e-6	Pancreatic cancer;
TGCT	cis	rs11098499	0.754	rs11724409	chr4:120252361	A/G	cg09307838	chr4:120376055	NA	0.61	5.91	0.47	3.14e-8	Corneal astigmatism;
TGCT	cis	rs9325144	0.647	rs61930266	chr12:38922048	A/G	cg26384229	chr12:38710491	ALG10B	-0.56	-5.07	-0.41	1.4e-6	Morning vs. evening chronotype;
TGCT	cis	rs2334880	0.638	rs17343777	chr16:71439172	T/A	cg06353428	chr16:71660113	MARVELD3	-1.28	-7.41	-0.55	1.67e-11	Malaria;
TGCT	cis	rs17376456	0.825	rs74825443	chr5:93254973	T/C	cg25358565	chr5:93447407	FAM172A	0.98	7.85	0.58	1.68e-12	Diabetic retinopathy;
TGCT	cis	rs7017914	0.905	rs3110253	chr8:71937553	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-4.97	-0.41	2.16e-6	Bone mineral density;
TGCT	cis	rs910316	0.967	rs8007539	chr14:75664953	T/C	cg08847533	chr14:75593920	NEK9	-0.93	-9.92	-0.67	1.93e-17	Height;
TGCT	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg18654377	chr3:49208889	KLHDC8B	0.37	4.85	0.4	3.65e-6	Menarche (age at onset);
TGCT	cis	rs8180040	0.620	rs7373821	chr3:47080127	A/C	cg27129171	chr3:47204927	SETD2	0.71	8.51	0.61	4.8e-14	Colorectal cancer;
TGCT	cis	rs10876993	0.928	rs1628552	chr12:58082142	C/T	cg15848620	chr12:58087721	OS9	-0.73	-6.05	-0.48	1.6e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs116095464	0.558	rs62346508	chr5:203668	T/C	cg22857025	chr5:266934	NA	-0.35	-6.52	-0.51	1.63e-9	Breast cancer;
TGCT	cis	rs62244186	0.659	rs9835270	chr3:44553722	G/A	cg15687855	chr3:44754131	ZNF502	-0.45	-5.38	-0.43	3.62e-7	Depressive symptoms;
TGCT	cis	rs6088590	0.965	rs6120730	chr20:33385102	G/C	cg24642439	chr20:33292090	TP53INP2	0.68	6.06	0.48	1.48e-8	Coronary artery disease;
TGCT	trans	rs4576506	1.000	rs10116483	chr9:31539221	G/A	cg05645557	chr17:16290151	NA	1.19	6.62	0.51	9.86e-10	Psychosis and Alzheimer's disease;
TGCT	cis	rs916888	0.610	rs199529	chr17:44837217	A/C	cg15921436	chr17:44337874	NA	0.51	7.12	0.54	7.74e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2982552	0.873	rs977532	chr6:152068883	C/T	cg22157087	chr6:152012887	ESR1	0.2	4.77	0.39	5e-6	Bone properties (heel);
TGCT	cis	rs11864453	0.612	rs11862813	chr16:72132356	C/T	cg14768367	chr16:72042858	DHODH	0.52	5.21	0.42	7.61e-7	Fibrinogen levels;
TGCT	cis	rs752590	0.832	rs6542124	chr2:113951924	C/A	cg27425262	chr2:113953981	PSD4;LOC440839	0.43	4.83	0.4	3.93e-6	Mucinous ovarian carcinoma;
TGCT	cis	rs6500602	0.702	rs11645519	chr16:4538989	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.3	5.57	0.45	1.51e-7	Schizophrenia;
TGCT	cis	rs12220238	1.000	rs11000888	chr10:75901929	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.91	7.77	0.57	2.63e-12	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs4975616	0.869	rs465498	chr5:1325803	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.29	-6.9	-0.53	2.32e-10	Lung cancer;
TGCT	cis	rs4808199	0.948	rs12982276	chr19:19459800	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.71	5.73	0.46	7.17e-8	Nonalcoholic fatty liver disease;
TGCT	cis	rs6785206	0.527	rs35970262	chr3:128642936	C/T	cg25356066	chr3:128598488	ACAD9	-0.74	-4.65	-0.39	8.51e-6	Lymphocyte percentage of white cells;
TGCT	trans	rs9929218	0.529	rs8060790	chr16:68729112	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.55	6.87	0.53	2.77e-10	Colorectal cancer;
TGCT	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.71	7.58	0.56	6.92e-12	Blood metabolite levels;
TGCT	cis	rs2948294	0.588	rs4840913	chr8:8116906	A/C	cg15462221	chr8:8086144	FLJ10661	-0.54	-4.74	-0.39	5.73e-6	Red cell distribution width;
TGCT	cis	rs9653442	0.712	rs6714788	chr2:100686173	A/G	cg22139774	chr2:100720529	AFF3	0.43	7.8	0.57	2.15e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs208520	1.000	rs208535	chr6:66962286	G/A	cg07460842	chr6:66804631	NA	-0.83	-7.52	-0.56	9.8e-12	Exhaled nitric oxide output;
TGCT	cis	rs4713118	0.513	rs149962	chr6:28015918	G/A	cg10876282	chr6:28092338	ZSCAN16	0.5	4.6	0.38	1.01e-5	Parkinson's disease;
TGCT	cis	rs700651	0.821	rs700663	chr2:198670478	T/A	cg00792783	chr2:198669748	PLCL1	0.56	5.08	0.42	1.35e-6	Intracranial aneurysm;
TGCT	cis	rs11651000	0.817	rs11657479	chr17:45822901	T/C	cg06532163	chr17:45867833	NA	0.33	4.82	0.4	4.14e-6	IgG glycosylation;
TGCT	cis	rs10876993	0.672	rs2640611	chr12:58037757	T/A	cg15848620	chr12:58087721	OS9	-0.72	-5.78	-0.46	5.57e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs6500602	0.598	rs3859155	chr16:4593741	A/C	cg08645402	chr16:4508243	NA	-0.17	-4.76	-0.39	5.39e-6	Schizophrenia;
TGCT	cis	rs6424115	1.000	rs2179395	chr1:24148365	T/C	cg15997130	chr1:24165203	NA	0.9	10.23	0.68	3.51e-18	Immature fraction of reticulocytes;
TGCT	cis	rs67311347	0.956	rs6771527	chr3:40506548	T/C	cg17264618	chr3:40429014	ENTPD3	-0.32	-4.64	-0.38	8.57e-6	Renal cell carcinoma;
TGCT	cis	rs877282	0.945	rs34367686	chr10:791868	G/C	cg17470449	chr10:769945	NA	0.3	4.82	0.4	4.14e-6	Uric acid levels;
TGCT	cis	rs8070740	1.000	rs8076900	chr17:5327927	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	4.55	0.38	1.27e-5	Menopause (age at onset);
TGCT	cis	rs611744	0.967	rs702805	chr8:109235929	G/A	cg21045802	chr8:109455806	TTC35	0.52	4.72	0.39	6.21e-6	Dupuytren's disease;
TGCT	cis	rs12908161	1.000	rs17601029	chr15:85347709	A/G	cg11189052	chr15:85197271	WDR73	0.69	5.69	0.46	8.57e-8	Schizophrenia;
TGCT	cis	rs8072100	0.967	rs4289035	chr17:45707211	C/T	cg08085267	chr17:45401833	C17orf57	-0.43	-4.63	-0.38	9.04e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs936229	0.813	rs1378938	chr15:75096443	T/C	cg10253484	chr15:75165896	SCAMP2	-0.65	-5.23	-0.42	7.07e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
TGCT	cis	rs11190604	1.000	rs6584383	chr10:102303065	C/G	cg23241863	chr10:102295624	HIF1AN	0.73	5.23	0.43	6.9e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg17054783	chr10:134559939	INPP5A	0.25	4.79	0.4	4.66e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs12477438	0.798	rs1349779	chr2:99645055	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.67	-5.89	-0.47	3.39e-8	Chronic sinus infection;
TGCT	cis	rs4727027	0.704	rs12537763	chr7:148903984	G/A	cg23583168	chr7:148888333	NA	-0.79	-10.49	-0.69	8.14e-19	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs208520	0.770	rs2224422	chr6:66883993	G/A	cg07460842	chr6:66804631	NA	-0.9	-9.33	-0.64	5.29e-16	Exhaled nitric oxide output;
TGCT	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.31	-4.82	-0.4	4.12e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs4845570	1.000	rs4845570	chr1:151759104	C/T	cg07092448	chr1:151763213	TDRKH	1.16	9.27	0.64	7.5e-16	Coronary artery disease;
TGCT	cis	rs6752107	1.000	rs2241880	chr2:234183368	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.2	4.81	0.4	4.36e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	trans	rs2727020	0.595	rs10466496	chr11:49501514	C/T	cg03929089	chr4:120376271	NA	-0.76	-9.15	-0.63	1.43e-15	Coronary artery disease;
TGCT	cis	rs1843834	0.539	rs6749402	chr2:225443901	T/G	cg22455342	chr2:225449267	CUL3	1.04	10.75	0.69	1.87e-19	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs17376456	1.000	rs34756085	chr5:93556294	A/G	cg21475434	chr5:93447410	FAM172A	0.65	4.66	0.39	7.92e-6	Diabetic retinopathy;
TGCT	cis	rs76878669	0.561	rs10896111	chr11:66115690	T/C	cg18002602	chr11:66138449	SLC29A2	-0.53	-6.58	-0.51	1.16e-9	Educational attainment (years of education);
TGCT	cis	rs11190604	0.767	rs10736150	chr10:102195341	G/A	cg23241863	chr10:102295624	HIF1AN	-0.66	-4.9	-0.4	2.98e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs62244186	0.541	rs62244226	chr3:44831831	G/A	cg02073558	chr3:44770973	ZNF501	0.71	7.07	0.54	9.87e-11	Depressive symptoms;
TGCT	cis	rs6684514	1.000	rs12038217	chr1:156248297	C/T	cg16558208	chr1:156270281	VHLL	0.46	9.38	0.64	3.92e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs1215050	0.818	rs6532703	chr4:98777486	A/T	cg05340658	chr4:99064831	C4orf37	0.46	5.51	0.44	1.94e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg06238570	chr21:40685208	BRWD1	-0.61	-6.34	-0.49	3.83e-9	Menarche (age at onset);
TGCT	cis	rs3771570	0.901	rs9052	chr2:242434809	G/T	cg21155796	chr2:242212141	HDLBP	0.93	6.79	0.52	4.12e-10	Prostate cancer;
TGCT	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg11644478	chr21:40555479	PSMG1	-0.63	-5.92	-0.47	2.93e-8	Cognitive function;
TGCT	cis	rs75229567	0.618	rs11177819	chr12:70134836	T/G	cg10114359	chr12:70132523	RAB3IP	1.36	6.73	0.52	5.51e-10	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
TGCT	cis	rs13177918	0.559	rs10447225	chr5:149834454	C/T	cg14059543	chr5:149831962	NA	-0.62	-7.86	-0.58	1.63e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs651907	0.588	rs1707608	chr3:101644769	C/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.55	5.45	0.44	2.66e-7	Colorectal cancer;
TGCT	cis	rs9581857	0.547	rs76971629	chr13:28051031	C/T	cg22138327	chr13:27999177	GTF3A	0.74	4.82	0.4	4.15e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs13256369	1.000	rs9329165	chr8:8576642	C/T	cg18904891	chr8:8559673	CLDN23	-0.58	-5.34	-0.43	4.31e-7	Obesity-related traits;
TGCT	cis	rs10875746	0.669	rs10875779	chr12:48629869	G/A	cg20731937	chr12:48336164	NA	0.59	4.49	0.37	1.61e-5	Longevity (90 years and older);
TGCT	cis	rs6810498	0.804	rs907495	chr4:26081011	T/C	cg04611865	chr4:25162039	SEPSECS	-0.5	-4.49	-0.37	1.63e-5	Alcohol dependence;
TGCT	cis	rs7772486	0.846	rs2748496	chr6:146321829	T/A	cg23711669	chr6:146136114	FBXO30	0.82	8.92	0.63	5.14e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs56176327	0.532	rs9849038	chr3:49771990	A/G	cg03060546	chr3:49711283	APEH	0.63	5.63	0.45	1.12e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9486719	0.947	rs12194971	chr6:96911073	T/C	cg18709589	chr6:96969512	KIAA0776	-0.72	-5.24	-0.43	6.58e-7	Migraine;Coronary artery disease;
TGCT	cis	rs2204008	0.521	rs7311188	chr12:38542813	C/G	cg26384229	chr12:38710491	ALG10B	-0.53	-4.7	-0.39	6.9e-6	Bladder cancer;
TGCT	cis	rs35306767	0.953	rs35693858	chr10:979813	C/T	cg26597838	chr10:835615	NA	0.56	7.67	0.57	4.27e-12	Eosinophil percentage of granulocytes;
TGCT	cis	rs250677	0.687	rs250678	chr5:148434830	C/T	cg23229984	chr5:148520753	ABLIM3	0.21	4.89	0.4	3.11e-6	Breast cancer;
TGCT	cis	rs3806843	0.735	rs2563306	chr5:140070017	C/T	cg19875535	chr5:140030758	IK	-0.37	-6.23	-0.49	6.51e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs986417	1.000	rs1951115	chr14:60922006	G/C	cg27398547	chr14:60952738	C14orf39	-1.39	-10.61	-0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs77633900	0.614	rs280013	chr15:76978139	C/T	cg21673338	chr15:77095150	SCAPER	0.54	5.15	0.42	1.01e-6	Non-glioblastoma glioma;Glioma;
TGCT	cis	rs2242116	0.796	rs7623898	chr3:46974172	C/T	cg02527881	chr3:46936655	PTH1R	0.32	6.0	0.47	1.99e-8	Birth weight;
TGCT	cis	rs301043	0.500	rs188523	chr12:95916843	A/G	cg07805603	chr12:95869602	METAP2	0.44	5.42	0.44	2.92e-7	Immature fraction of reticulocytes;
TGCT	cis	rs11098499	0.863	rs10034450	chr4:120455649	A/G	cg09307838	chr4:120376055	NA	0.69	6.53	0.51	1.49e-9	Corneal astigmatism;
TGCT	cis	rs7666738	0.830	rs6532720	chr4:99043781	C/T	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg26338869	chr17:61819248	STRADA	-0.58	-5.23	-0.43	6.97e-7	Prudent dietary pattern;
TGCT	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg24829409	chr8:58192753	C8orf71	-0.59	-4.97	-0.41	2.17e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1635	0.655	rs2159275	chr6:28308446	G/A	cg15743358	chr6:28303923	ZNF323	-1.29	-6.5	-0.5	1.73e-9	Schizophrenia;
TGCT	cis	rs2309757	1	rs2309757	chr2:100807725	T/C	cg22139774	chr2:100720529	AFF3	-0.35	-5.29	-0.43	5.24e-7	Educational attainment (college completion);
TGCT	cis	rs9916302	0.904	rs12452880	chr17:37591149	G/C	cg15445000	chr17:37608096	MED1	0.32	4.68	0.39	7.47e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg04287289	chr16:89883240	FANCA	0.91	11.7	0.72	9.35e-22	Vitiligo;
TGCT	cis	rs9457247	1.000	rs408080	chr6:167392522	T/C	cg25258033	chr6:167368657	RNASET2	0.2	4.82	0.4	4.03e-6	Crohn's disease;
TGCT	cis	rs2692947	0.644	rs2969491	chr2:96794982	C/T	cg05933789	chr2:97190408	NA	0.16	4.64	0.38	8.81e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs7666738	0.791	rs4699324	chr4:98967496	G/A	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1215050	0.791	rs1506438	chr4:98789542	C/T	cg17366294	chr4:99064904	C4orf37	0.52	5.47	0.44	2.37e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs12497850	0.931	rs7430198	chr3:48988760	T/C	cg05785598	chr3:49045655	WDR6	0.37	4.83	0.4	3.94e-6	Parkinson's disease;
TGCT	cis	rs9807989	0.507	rs4851572	chr2:103019031	G/A	cg03938978	chr2:103052716	IL18RAP	0.27	5.41	0.44	3.17e-7	Asthma;
TGCT	cis	rs13217239	0.646	rs62401067	chr6:27018101	T/A	cg06035815	chr6:26189597	HIST1H4D	-0.44	-4.58	-0.38	1.12e-5	Schizophrenia;
TGCT	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.08	0.48	1.37e-8	Bipolar disorder;
TGCT	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg11494091	chr17:61959527	GH2	0.61	14.43	0.79	2.59e-28	Prudent dietary pattern;
TGCT	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg25703541	chr22:24373054	LOC391322	-0.91	-10.75	-0.69	1.94e-19	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9303401	0.659	rs35082010	chr17:56936867	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs710216	0.843	rs3768043	chr1:43419354	C/A	cg03128534	chr1:43423976	SLC2A1	-0.61	-5.02	-0.41	1.79e-6	Red cell distribution width;
TGCT	cis	rs447921	1.000	rs372126	chr17:74413216	A/G	cg09812376	chr17:74270190	QRICH2	0.44	4.5	0.37	1.57e-5	Mitochondrial DNA levels;
TGCT	cis	rs9926296	0.562	rs4785725	chr16:89893243	A/G	cg05177932	chr16:89631655	NA	0.29	4.93	0.41	2.53e-6	Vitiligo;
TGCT	cis	rs2637266	0.875	rs12783253	chr10:78378108	A/G	cg18941641	chr10:78392320	NA	0.4	4.75	0.39	5.48e-6	Pulmonary function;
TGCT	cis	rs4319547	0.695	rs10846699	chr12:122853073	A/G	cg08088222	chr12:122070432	ORAI1	-0.25	-4.56	-0.38	1.22e-5	Body mass index;
TGCT	cis	rs9560113	0.580	rs9560116	chr13:112193731	G/A	cg10483660	chr13:112241077	NA	0.32	4.64	0.38	8.8e-6	Menarche (age at onset);
TGCT	cis	rs3020736	0.500	rs7292241	chr22:42492063	G/A	cg15557168	chr22:42548783	NA	0.22	5.47	0.44	2.34e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg23221052	chr5:179740743	GFPT2	0.36	5.73	0.46	7.23e-8	Height;
TGCT	cis	rs9926296	0.712	rs459920	chr16:89730827	T/C	cg04287289	chr16:89883240	FANCA	-0.54	-5.01	-0.41	1.86e-6	Vitiligo;
TGCT	cis	rs7662987	0.517	rs2851268	chr4:100027878	A/G	cg12011299	chr4:100065546	ADH4	0.4	4.82	0.4	4.07e-6	Smoking initiation;
TGCT	cis	rs2235642	0.821	rs8051895	chr16:1602811	A/G	cg00463982	chr16:1583984	IFT140;TMEM204	-0.29	-5.06	-0.41	1.46e-6	Coronary artery disease;
TGCT	cis	rs17122693	1.000	rs2934682	chr14:51061207	A/T	cg04730355	chr14:51134070	SAV1	1.1	8.05	0.59	5.75e-13	Cognitive performance;
TGCT	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-6.74	-0.52	5.26e-10	Alzheimer's disease;
TGCT	cis	rs950776	0.518	rs62008174	chr15:78808947	C/T	cg06917634	chr15:78832804	PSMA4	0.97	9.62	0.65	1.05e-16	Sudden cardiac arrest;
TGCT	cis	rs7666738	0.830	rs36047842	chr4:99004902	C/A	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs896854	0.625	rs13281709	chr8:95972819	T/A	cg09323728	chr8:95962352	TP53INP1	-0.52	-6.6	-0.51	1.07e-9	Type 2 diabetes;
TGCT	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg18876405	chr7:65276391	NA	-0.31	-4.57	-0.38	1.16e-5	Aortic root size;
TGCT	cis	rs72627509	0.857	rs55762216	chr4:57765731	G/C	cg26694713	chr4:57773883	REST	0.73	6.57	0.51	1.27e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs6088590	1.000	rs10048849	chr20:33419680	C/T	cg06115741	chr20:33292138	TP53INP2	0.65	5.3	0.43	5.12e-7	Coronary artery disease;
TGCT	cis	rs9733	0.650	rs2048558	chr1:150571730	A/G	cg13175981	chr1:150552382	MCL1	0.54	6.21	0.49	7.46e-9	Tonsillectomy;
TGCT	cis	rs4975709	0.544	rs4975748	chr5:1866025	G/A	cg15595755	chr5:1867978	NA	0.47	5.56	0.45	1.57e-7	Cardiovascular disease risk factors;
TGCT	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.26	4.86	0.4	3.44e-6	Schizophrenia;
TGCT	cis	rs11874712	1.000	rs28757346	chr18:43696540	C/T	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	5.09	0.42	1.29e-6	Migraine - clinic-based;
TGCT	cis	rs6714710	0.557	rs17490429	chr2:98449024	G/A	cg26665480	chr2:98280029	ACTR1B	0.66	6.27	0.49	5.45e-9	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs11792861	0.926	rs12686736	chr9:111888739	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.48	4.51	0.38	1.48e-5	Menarche (age at onset);
TGCT	cis	rs514406	0.525	rs269291	chr1:53189297	C/T	cg16325326	chr1:53192061	ZYG11B	0.89	12.69	0.75	3.63e-24	Monocyte count;
TGCT	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg00343986	chr7:65444356	GUSB	-0.23	-5.16	-0.42	9.66e-7	Aortic root size;
TGCT	cis	rs240764	0.658	rs10457077	chr6:101196767	C/T	cg09795085	chr6:101329169	ASCC3	-0.51	-4.51	-0.38	1.45e-5	Neuroticism;
TGCT	cis	rs4325129	0.651	rs2028933	chr1:159501125	G/A	cg07417683	chr1:159440267	NA	0.37	4.64	0.38	8.54e-6	Obesity-related traits;
TGCT	cis	rs10823500	0.777	rs10999196	chr10:71982305	T/C	cg04118878	chr10:71993077	PPA1	0.57	5.25	0.43	6.25e-7	Blood protein levels;
TGCT	cis	rs1371867	0.875	rs1788168	chr8:101324960	G/T	cg06002616	chr8:101225028	SPAG1	-0.53	-6.21	-0.49	7.16e-9	Atrioventricular conduction;
TGCT	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg12310025	chr6:25882481	NA	-1.1	-14.2	-0.79	9.06e-28	Urate levels;
TGCT	cis	rs2235642	0.685	rs2667681	chr16:1653206	C/T	cg10465839	chr16:1584050	IFT140;TMEM204	-0.28	-4.52	-0.38	1.44e-5	Coronary artery disease;
TGCT	cis	rs6921919	0.515	rs1339898	chr6:28395506	C/T	cg09682330	chr6:28411287	ZSCAN23	-0.48	-4.5	-0.37	1.54e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs8062405	1.000	rs62036617	chr16:28827498	T/C	cg09754948	chr16:28834200	ATXN2L	0.62	4.68	0.39	7.4e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg12756686	chr19:29218302	NA	0.77	6.61	0.51	1.01e-9	Methadone dose in opioid dependence;
TGCT	trans	rs2688608	0.672	rs2688621	chr10:75687849	C/T	cg13918328	chr10:52500089	ASAH2B	0.66	6.86	0.52	2.86e-10	Inflammatory bowel disease;
TGCT	cis	rs7020830	0.830	rs308499	chr9:37348059	C/G	cg14294708	chr9:37120828	ZCCHC7	1.02	12.67	0.75	4.19e-24	Schizophrenia;
TGCT	cis	rs1008375	1.000	rs13149474	chr4:17688582	G/A	cg10189774	chr4:17578691	LAP3	-0.61	-5.25	-0.43	6.52e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs911555	0.755	rs11627446	chr14:103946450	G/C	cg12935359	chr14:103987150	CKB	-0.33	-4.59	-0.38	1.07e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs9911578	0.835	rs10853006	chr17:56489076	G/A	cg12560992	chr17:57184187	TRIM37	-0.76	-8.7	-0.62	1.68e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs763121	0.853	rs1013338	chr22:38974154	C/A	cg06022373	chr22:39101656	GTPBP1	0.84	8.71	0.62	1.64e-14	Menopause (age at onset);
TGCT	cis	rs826838	0.935	rs1486357	chr12:39073675	A/G	cg13010199	chr12:38710504	ALG10B	0.83	6.9	0.53	2.4e-10	Heart rate;
TGCT	cis	rs6933660	0.745	rs9322320	chr6:151751908	C/G	cg17179660	chr6:151773299	C6orf211;RMND1	-0.53	-4.81	-0.4	4.28e-6	Menarche (age at onset);
TGCT	cis	rs6964587	1.000	rs6960867	chr7:91712698	A/G	cg22709100	chr7:91322751	NA	0.29	4.67	0.39	7.85e-6	Breast cancer;
TGCT	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg21017887	chr14:105400489	NA	0.33	4.77	0.39	5.12e-6	Rheumatoid arthritis;
TGCT	cis	rs1075232	1.000	rs1075232	chr15:31741216	C/A	cg01030201	chr15:31746330	NA	-1.03	-5.61	-0.45	1.27e-7	Survival in colorectal cancer (non-distant metastatic);
TGCT	cis	rs13191362	1.000	rs55822577	chr6:163069710	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.03	7.35	0.55	2.37e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	trans	rs2727020	0.595	rs10839281	chr11:49483373	A/C	cg15704280	chr7:45808275	SEPT13	-0.77	-9.09	-0.63	2e-15	Coronary artery disease;
TGCT	cis	rs9372253	0.818	rs2207360	chr6:110706337	G/C	cg01119278	chr6:110721349	DDO	-0.3	-4.79	-0.4	4.71e-6	Platelet distribution width;
TGCT	cis	rs5760092	0.842	rs5760103	chr22:24248781	A/G	cg04234412	chr22:24373322	LOC391322	-0.91	-8.04	-0.59	5.92e-13	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs477895	1.000	rs2276014	chr11:64081445	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	5.19	0.42	8.41e-7	Mean platelet volume;
TGCT	cis	rs36051895	0.632	rs57698263	chr9:5143262	G/A	cg02405213	chr9:5042618	JAK2	-0.72	-10.05	-0.67	9.59e-18	Pediatric autoimmune diseases;
TGCT	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg25036284	chr2:26402008	FAM59B	-0.65	-5.19	-0.42	8.36e-7	Gut microbiome composition (summer);
TGCT	cis	rs9611519	0.929	rs73174657	chr22:41434158	G/A	cg03806693	chr22:41940476	POLR3H	-0.7	-6.22	-0.49	6.88e-9	Neuroticism;
TGCT	cis	rs9341808	0.667	rs742833	chr6:80921446	C/T	cg08355045	chr6:80787529	NA	0.29	4.88	0.4	3.2e-6	Sitting height ratio;
TGCT	cis	rs523522	0.962	rs10849759	chr12:120994488	T/A	cg12219531	chr12:120966889	COQ5	0.82	7.38	0.55	2.05e-11	High light scatter reticulocyte count;
TGCT	cis	rs4822044	0.568	rs1883370	chr22:42143740	C/A	cg13695892	chr22:41940480	POLR3H	0.83	7.85	0.58	1.63e-12	Cannabis dependence symptom count;
TGCT	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg10150615	chr22:24372951	LOC391322	0.84	7.28	0.55	3.42e-11	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	trans	rs17685	0.672	rs6465011	chr7:75811297	T/C	cg19862616	chr7:65841803	NCRNA00174	0.51	8.78	0.62	1.12e-14	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs17401966	0.838	rs4846197	chr1:10282166	G/A	cg19773385	chr1:10388646	KIF1B	-0.22	-4.78	-0.39	4.79e-6	Hepatocellular carcinoma;
TGCT	cis	rs1577917	1.000	rs12215903	chr6:86675028	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.48	-0.44	2.27e-7	Response to antipsychotic treatment;
TGCT	cis	rs981844	0.712	rs4302444	chr4:154745663	A/G	cg14289246	chr4:154710475	SFRP2	-0.99	-9.12	-0.63	1.65e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs17376456	0.825	rs66564678	chr5:93165894	C/T	cg25358565	chr5:93447407	FAM172A	0.91	7.39	0.55	1.88e-11	Diabetic retinopathy;
TGCT	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg26338869	chr17:61819248	STRADA	-0.53	-4.85	-0.4	3.68e-6	Prudent dietary pattern;
TGCT	cis	rs709400	0.633	rs10135868	chr14:104004147	T/C	cg26031613	chr14:104095156	KLC1	0.87	9.64	0.65	9.63e-17	Body mass index;
TGCT	trans	rs3780486	0.881	rs10738906	chr9:33135634	T/C	cg20290983	chr6:43655470	MRPS18A	1.2	14.83	0.8	3.07e-29	IgG glycosylation;
TGCT	cis	rs62402013	1	rs62402013	chr6:26915000	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.47	5.04	0.41	1.62e-6	Schizophrenia;
TGCT	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	5.71	0.46	7.78e-8	Bipolar disorder;
TGCT	cis	rs72615157	0.595	rs112241539	chr7:99847237	C/T	cg00814883	chr7:100076585	TSC22D4	-0.59	-5.7	-0.46	8.45e-8	Lung function (FEV1/FVC);
TGCT	cis	rs6496667	0.586	rs7162687	chr15:90889323	C/T	cg22089800	chr15:90895588	ZNF774	-0.63	-5.6	-0.45	1.32e-7	Rheumatoid arthritis;
TGCT	cis	rs1903068	1.000	rs73236109	chr4:56007425	C/T	cg09978860	chr4:56023921	NA	0.59	6.74	0.52	5.22e-10	Endometriosis;
TGCT	cis	rs911555	0.755	rs34411783	chr14:103900639	G/A	cg23461800	chr14:103021989	NA	-0.37	-4.73	-0.39	5.89e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2456568	0.695	rs7942055	chr11:93691063	A/C	cg17595323	chr11:93583763	C11orf90	0.39	4.83	0.4	3.95e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs9326248	0.953	rs488962	chr11:117072525	C/T	cg16524733	chr11:117070046	TAGLN	-0.32	-4.48	-0.37	1.64e-5	Blood protein levels;
TGCT	cis	rs3087591	0.708	rs3785956	chr17:29647707	C/A	cg24425628	chr17:29625626	OMG;NF1	0.39	5.74	0.46	6.74e-8	Hip circumference;
TGCT	cis	rs7208859	0.673	rs216435	chr17:28922737	G/T	cg04154034	chr17:28927549	LRRC37B2	0.79	4.8	0.4	4.54e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs17253792	0.822	rs77741349	chr14:56097462	C/T	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs9894429	0.646	rs7406825	chr17:79619188	C/T	cg21028142	chr17:79581711	NPLOC4	0.29	5.91	0.47	3.09e-8	Eye color traits;
TGCT	cis	rs4808199	0.895	rs8105094	chr19:19374061	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.68	5.14	0.42	1.03e-6	Nonalcoholic fatty liver disease;
TGCT	cis	rs9860250	0.644	rs4928106	chr3:100763611	C/T	cg05801080	chr3:100119813	LNP1;TOMM70A	-0.63	-4.69	-0.39	7.18e-6	Optic disc area;
TGCT	cis	rs711245	0.573	rs11899523	chr2:36800918	T/C	cg01206211	chr2:36825736	FEZ2	0.31	4.8	0.4	4.51e-6	Height;
TGCT	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg20203395	chr5:56204925	C5orf35	0.67	4.91	0.4	2.8e-6	Initial pursuit acceleration;
TGCT	cis	rs2012796	0.785	rs61986593	chr14:81840659	G/A	cg02996355	chr14:81879375	NA	0.54	5.35	0.43	4.05e-7	Night sleep phenotypes;
TGCT	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg10802521	chr3:52805072	NEK4	-0.72	-9.11	-0.63	1.82e-15	Bipolar disorder;
TGCT	cis	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg18252515	chr7:66147081	NA	-1.31	-8.18	-0.59	2.87e-13	Diabetic kidney disease;
TGCT	cis	rs3027009	0.881	rs3026955	chr1:159144034	C/A	cg11719576	chr1:158153771	CD1D	-0.39	-4.52	-0.38	1.41e-5	Lean body mass and age at menarche (combined);
TGCT	cis	rs763014	0.898	rs916414	chr16:632073	C/T	cg07343612	chr16:622815	PIGQ	-0.41	-7.87	-0.58	1.52e-12	Height;
TGCT	cis	rs1008375	1.000	rs1558377	chr4:17650758	A/G	cg18681998	chr4:17616180	MED28	1.06	12.43	0.74	1.57e-23	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9611565	0.918	rs4820438	chr22:41767135	C/T	cg06481639	chr22:41940642	POLR3H	-0.61	-5.11	-0.42	1.17e-6	Vitiligo;
TGCT	cis	rs1205863	1.000	rs1205890	chr6:11948579	G/T	cg07106625	chr6:11870215	NA	0.51	5.05	0.41	1.51e-6	Disc degeneration (lumbar);
TGCT	cis	rs7714584	1.000	rs7736554	chr5:150258308	T/C	cg22134413	chr5:150180641	NA	0.78	6.12	0.48	1.16e-8	Crohn's disease;
TGCT	cis	rs4919044	0.808	rs860669	chr10:94796031	T/C	cg05127821	chr10:94822908	CYP26C1	-0.74	-4.83	-0.4	3.95e-6	Coronary artery disease;
TGCT	cis	rs576982	1	rs576982	chr15:78870803	C/T	cg24631222	chr15:78858424	CHRNA5	0.86	6.45	0.5	2.3e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg23574427	chr4:122746245	BBS7;CCNA2	-0.35	-5.32	-0.43	4.66e-7	Type 2 diabetes;
TGCT	cis	rs514406	0.505	rs12726160	chr1:53175099	A/G	cg22166914	chr1:53195759	ZYG11B	0.45	7.93	0.58	1.11e-12	Monocyte count;
TGCT	cis	rs7216064	1.000	rs7214758	chr17:65880538	T/C	cg12091567	chr17:66097778	LOC651250	-0.82	-6.39	-0.5	3.03e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs6547741	0.904	rs2384659	chr2:27856793	G/A	cg27432699	chr2:27873401	GPN1	0.18	4.49	0.37	1.59e-5	Oral cavity cancer;
TGCT	cis	rs111803315	0.661	rs111908790	chr14:59999137	A/G	cg22995959	chr14:59931024	GPR135	0.66	4.8	0.4	4.39e-6	Schizophrenia;
TGCT	cis	rs2777491	1.000	rs2730055	chr15:41735708	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.75	-11.01	-0.7	4.47e-20	Ulcerative colitis;
TGCT	cis	rs4014195	0.521	rs12576996	chr11:65580638	G/T	cg27068330	chr11:65405492	SIPA1	0.61	4.86	0.4	3.55e-6	Glomerular filtration rate (creatinine);Chronic kidney disease;
TGCT	trans	rs8073060	0.586	rs225288	chr17:33929291	G/A	cg19694781	chr19:47549865	TMEM160	-0.6	-13.04	-0.76	5.29e-25	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs4808199	0.649	rs12983940	chr19:19516431	G/A	cg03709012	chr19:19516395	GATAD2A	1.01	7.94	0.58	1.02e-12	Nonalcoholic fatty liver disease;
TGCT	cis	rs9611565	0.921	rs3927	chr22:41722864	A/G	cg06634786	chr22:41940651	POLR3H	-0.74	-7.19	-0.54	5.26e-11	Vitiligo;
TGCT	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg11890956	chr21:40555474	PSMG1	1.12	12.26	0.74	4.02e-23	Cognitive function;
TGCT	cis	rs477895	0.838	rs2070765	chr11:64010085	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.8	6.59	0.51	1.11e-9	Mean platelet volume;
TGCT	cis	rs6534347	0.573	rs4833837	chr4:123536963	G/A	cg10583651	chr4:123538969	IL21	-0.31	-4.51	-0.38	1.49e-5	Type 1 diabetes;
TGCT	cis	rs7246657	0.525	rs10405238	chr19:37488055	T/G	cg18154014	chr19:37997991	ZNF793	0.73	4.6	0.38	1.04e-5	Coronary artery calcification;
TGCT	cis	rs1949733	0.701	rs2631735	chr4:8476118	A/G	cg13073564	chr4:8508604	NA	-0.46	-4.73	-0.39	6.07e-6	Response to antineoplastic agents;
TGCT	cis	rs890835	0.571	rs114640249	chr5:175932010	C/T	cg07482766	chr5:176901844	DBN1	0.21	4.54	0.38	1.29e-5	Menopause (age at onset);
TGCT	cis	rs826838	0.967	rs1719858	chr12:39124505	C/T	cg26384229	chr12:38710491	ALG10B	-0.86	-7.76	-0.57	2.68e-12	Heart rate;
TGCT	cis	rs12762955	0.528	rs10903358	chr10:1102386	G/A	cg26597838	chr10:835615	NA	0.56	6.38	0.5	3.23e-9	Response to angiotensin II receptor blocker therapy;
TGCT	trans	rs13064411	0.591	rs7628945	chr3:113201754	A/T	cg00307254	chr3:126706825	PLXNA1	0.34	6.72	0.52	5.79e-10	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	trans	rs1814175	0.615	rs10839378	chr11:49806943	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.45	-11.22	-0.71	1.34e-20	Height;
TGCT	cis	rs4460629	0.742	rs11264312	chr1:155075888	T/C	cg23973274	chr1:155060172	NA	-0.26	-4.66	-0.39	8.1e-6	Serum magnesium levels;
TGCT	cis	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg22121687	chr7:65037720	NA	-0.78	-4.69	-0.39	7.07e-6	Diabetic kidney disease;
TGCT	cis	rs797680	0.856	rs797681	chr1:93717746	T/C	cg17826107	chr1:92977322	EVI5	0.24	5.29	0.43	5.47e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs2067615	0.560	rs10861671	chr12:107220927	T/C	cg15890332	chr12:107067104	RFX4	0.29	5.83	0.46	4.51e-8	Heart rate;
TGCT	cis	rs854765	0.534	rs7207461	chr17:17949789	T/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.79	-8.27	-0.6	1.76e-13	Total body bone mineral density;
TGCT	cis	rs10501293	0.746	rs4755691	chr11:43054865	C/T	cg03447554	chr11:43094025	NA	0.45	6.58	0.51	1.2e-9	Cognitive performance;
TGCT	cis	rs8064299	0.565	rs12453550	chr17:72786086	G/T	cg25054828	chr17:72772726	NAT9;TMEM104	0.93	10.47	0.69	9.02e-19	Monocyte count;
TGCT	cis	rs910316	1.000	rs7303	chr14:75520065	T/C	cg11812906	chr14:75593930	NEK9	0.74	7.25	0.55	3.9e-11	Height;
TGCT	cis	rs79349575	0.715	rs55724082	chr17:47017879	G/A	cg07967210	chr17:47022446	SNF8	0.44	6.14	0.48	1.01e-8	Type 2 diabetes;
TGCT	cis	rs9633740	1.000	rs1870138	chr10:82269611	A/G	cg01528321	chr10:82214614	TSPAN14	0.98	8.15	0.59	3.34e-13	Post bronchodilator FEV1;
TGCT	cis	rs2115630	1.000	rs56074163	chr15:85351332	C/T	cg17173187	chr15:85201210	NMB	-0.39	-4.78	-0.39	4.83e-6	P wave terminal force;
TGCT	cis	rs2836974	0.563	rs6517522	chr21:40553845	T/C	cg17971929	chr21:40555470	PSMG1	0.65	5.98	0.47	2.18e-8	Cognitive function;
TGCT	cis	rs9291683	0.575	rs3756223	chr4:10105797	C/T	cg11266682	chr4:10021025	SLC2A9	0.49	5.38	0.44	3.56e-7	Bone mineral density;
TGCT	cis	rs1867631	1.000	rs10789212	chr1:67128155	G/A	cg13052034	chr1:66999238	SGIP1	0.57	4.87	0.4	3.32e-6	Menopause (age at onset);
TGCT	cis	rs13242816	0.881	rs17138706	chr7:116109019	A/G	cg16553024	chr7:116138462	CAV2	-0.44	-4.53	-0.38	1.34e-5	P wave duration;
TGCT	cis	rs6500602	0.727	rs2058811	chr16:4575162	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.32	6.12	0.48	1.15e-8	Schizophrenia;
TGCT	cis	rs710216	0.912	rs11537640	chr1:43424519	T/G	cg03128534	chr1:43423976	SLC2A1	0.59	4.54	0.38	1.33e-5	Red cell distribution width;
TGCT	cis	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg18252515	chr7:66147081	NA	-1.31	-8.18	-0.59	2.87e-13	Diabetic kidney disease;
TGCT	cis	rs9916302	0.660	rs4795367	chr17:37608843	G/C	cg07936489	chr17:37558343	FBXL20	-0.87	-6.27	-0.49	5.47e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs17401966	0.558	rs12128374	chr1:10426417	G/A	cg19773385	chr1:10388646	KIF1B	-0.22	-5.27	-0.43	5.96e-7	Hepatocellular carcinoma;
TGCT	cis	rs62244186	0.516	rs11922470	chr3:44777795	C/T	cg09333631	chr3:44802604	KIF15;KIAA1143	-0.46	-4.86	-0.4	3.49e-6	Depressive symptoms;
TGCT	cis	rs595982	0.546	rs12461075	chr19:49399821	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.41	-5.3	-0.43	5.08e-7	Red cell distribution width;
TGCT	trans	rs9329221	0.741	rs9650622	chr8:9804292	G/T	cg15556689	chr8:8085844	FLJ10661	-0.82	-7.75	-0.57	2.83e-12	Neuroticism;
TGCT	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.0	7.42	0.55	1.64e-11	Gut microbiome composition (summer);
TGCT	cis	rs10782582	0.609	rs80059220	chr1:76279112	G/T	cg03433033	chr1:76189801	ACADM	-0.5	-4.95	-0.41	2.39e-6	Daytime sleep phenotypes;
TGCT	cis	rs72781680	0.898	rs17509001	chr2:24021231	T/C	cg08917208	chr2:24149416	ATAD2B	0.81	5.01	0.41	1.8e-6	Lymphocyte counts;
TGCT	cis	rs3733585	0.781	rs57250714	chr4:9984529	C/T	cg00071950	chr4:10020882	SLC2A9	0.57	6.82	0.52	3.56e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg11494091	chr17:61959527	GH2	0.42	7.33	0.55	2.54e-11	Height;
TGCT	cis	rs7156960	0.898	rs12884039	chr14:76717953	A/G	cg13981132	chr14:76734493	NA	0.29	4.48	0.37	1.7e-5	Acute lymphoblastic leukemia (childhood);
TGCT	cis	rs36051895	0.623	rs62541543	chr9:5042082	G/A	cg02405213	chr9:5042618	JAK2	-0.76	-10.28	-0.68	2.59e-18	Pediatric autoimmune diseases;
TGCT	cis	rs6570726	0.791	rs435671	chr6:145881215	A/G	cg05347473	chr6:146136440	FBXO30	0.54	5.15	0.42	1.01e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs514406	0.505	rs269287	chr1:53168842	T/C	cg08859206	chr1:53392774	SCP2	-0.34	-4.77	-0.39	5.09e-6	Monocyte count;
TGCT	cis	rs9894429	0.816	rs7406040	chr17:79597583	A/C	cg21984481	chr17:79567631	NPLOC4	-0.26	-4.9	-0.4	2.91e-6	Eye color traits;
TGCT	cis	rs2742417	1.000	rs2742454	chr3:45766222	T/A	cg04837898	chr3:45731254	SACM1L	-0.51	-5.27	-0.43	5.85e-7	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs651907	0.557	rs13099674	chr3:101489629	G/A	cg12386194	chr3:101231763	SENP7	0.48	4.7	0.39	6.71e-6	Colorectal cancer;
TGCT	cis	rs12477438	0.798	rs12473029	chr2:99637961	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-8.66	-0.61	2.13e-14	Chronic sinus infection;
TGCT	cis	rs709400	0.633	rs3783395	chr14:103895020	T/C	cg26031613	chr14:104095156	KLC1	0.84	9.31	0.64	5.77e-16	Body mass index;
TGCT	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg22920501	chr2:26401640	FAM59B	0.74	5.78	0.46	5.68e-8	Gut microbiome composition (summer);
TGCT	cis	rs2456568	0.548	rs6483280	chr11:93661592	T/C	cg26875233	chr11:93583750	C11orf90	-0.44	-5.41	-0.44	3.08e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs9486715	0.867	rs4839834	chr6:96882109	C/A	cg06623918	chr6:96969491	KIAA0776	1.11	16.62	0.83	2.35e-33	Headache;
TGCT	cis	rs28374715	0.532	rs1899	chr15:41689232	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.94	-16.61	-0.83	2.59e-33	Ulcerative colitis;
TGCT	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg05785598	chr3:49045655	WDR6	0.36	4.8	0.4	4.57e-6	Parkinson's disease;
TGCT	cis	rs7095607	0.560	rs2634709	chr10:69925789	C/T	cg18986048	chr10:69913749	MYPN	0.54	5.83	0.46	4.48e-8	Lung function (FVC);
TGCT	cis	rs56114371	0.530	rs2056923	chr6:27689939	T/C	cg10876282	chr6:28092338	ZSCAN16	0.66	5.0	0.41	1.93e-6	Breast cancer;
TGCT	cis	rs3771570	1.000	rs62193207	chr2:242318501	G/C	cg21155796	chr2:242212141	HDLBP	0.94	6.69	0.51	6.9e-10	Prostate cancer;
TGCT	cis	rs3845702	0.736	rs6727890	chr2:180832675	T/C	cg01881094	chr2:180872142	CWC22	-1.07	-6.88	-0.53	2.6e-10	Schizophrenia;
TGCT	cis	rs910316	1.000	rs10149880	chr14:75633008	A/G	cg23033748	chr14:75592666	NEK9	-0.28	-4.77	-0.39	4.98e-6	Height;
TGCT	cis	rs727563	0.638	rs5996058	chr22:42141452	A/G	cg13695892	chr22:41940480	POLR3H	0.86	8.23	0.59	2.23e-13	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs727505	0.954	rs1009450	chr7:124628723	C/G	cg23710748	chr7:124431027	NA	-0.27	-4.58	-0.38	1.11e-5	Lewy body disease;
TGCT	cis	rs78487399	0.808	rs7561287	chr2:43689071	A/G	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.74	4.59	0.38	1.09e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs6840360	1.000	rs6834095	chr4:152603278	C/T	cg17479576	chr4:152424074	FAM160A1	-0.45	-4.87	-0.4	3.29e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs933688	1.000	rs1964292	chr5:90743608	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.0	8.47	0.61	6.09e-14	Smoking behavior;
TGCT	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.61	5.06	0.41	1.5e-6	Tonsillectomy;
TGCT	cis	rs896854	0.846	rs2340584	chr8:95916811	A/G	cg09323728	chr8:95962352	TP53INP1	-0.49	-6.32	-0.49	4.31e-9	Type 2 diabetes;
TGCT	trans	rs4650994	0.789	rs2811300	chr1:178590394	T/C	cg05059571	chr16:84539110	KIAA1609	0.41	7.51	0.56	1e-11	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs78707713	0.560	rs61848436	chr10:71247714	C/T	cg14388049	chr10:71211838	TSPAN15	-0.4	-4.76	-0.39	5.31e-6	Venous thromboembolism;
TGCT	trans	rs2624839	0.679	rs2624835	chr3:50209049	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.78	6.93	0.53	2.05e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs33794	1.000	rs33794	chr3:45300605	C/T	cg18645101	chr3:44551900	NA	-0.51	-4.46	-0.37	1.8e-5	Lung function (forced expiratory volume in 1 second);
TGCT	trans	rs10953454	1.000	rs10243336	chr7:104494560	C/A	cg04208666	chr6:19734707	NA	-0.57	-6.89	-0.53	2.52e-10	Obesity;
TGCT	cis	rs9611519	0.639	rs7289989	chr22:41476799	A/C	cg03806693	chr22:41940476	POLR3H	-0.5	-4.47	-0.37	1.72e-5	Neuroticism;
TGCT	cis	rs10751667	0.666	rs7934963	chr11:957220	C/T	cg06064525	chr11:970664	AP2A2	-0.35	-8.06	-0.59	5.6e-13	Alzheimer's disease (late onset);
TGCT	cis	rs2549003	1.000	rs7734334	chr5:131815004	C/A	cg00255919	chr5:131827918	IRF1	0.22	5.15	0.42	1.01e-6	Asthma (sex interaction);
TGCT	cis	rs4851266	1.000	rs999052	chr2:100836106	C/T	cg22139774	chr2:100720529	AFF3	-0.35	-5.41	-0.44	3.1e-7	Educational attainment;
TGCT	cis	rs11105298	0.891	rs10858872	chr12:89872932	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.7	-5.02	-0.41	1.79e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs62103177	0.535	rs62101568	chr18:77934671	G/A	cg07235805	chr18:78004237	PARD6G	0.54	5.03	0.41	1.67e-6	Opioid sensitivity;
TGCT	cis	rs10782582	0.609	rs1770882	chr1:76411549	G/A	cg10523679	chr1:76189770	ACADM	-0.57	-5.14	-0.42	1.04e-6	Daytime sleep phenotypes;
TGCT	cis	rs7647973	0.961	rs4955443	chr3:49286618	T/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.55	-4.48	-0.37	1.68e-5	Menarche (age at onset);
TGCT	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg11141652	chr22:24348549	GSTTP1	0.33	4.54	0.38	1.29e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs12477438	0.765	rs6542846	chr2:99563654	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.74	-7.21	-0.54	4.82e-11	Chronic sinus infection;
TGCT	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg04608855	chr19:58913158	NA	0.58	5.76	0.46	6.2e-8	Uric acid clearance;
TGCT	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg11301795	chr4:187892539	NA	-0.3	-4.48	-0.37	1.69e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7582180	0.676	rs10048665	chr2:100933085	A/G	cg14675211	chr2:100938903	LONRF2	0.53	5.24	0.43	6.82e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7113874	0.569	rs10160430	chr11:8599876	G/T	cg14521421	chr11:8862019	ST5	-0.28	-4.44	-0.37	1.96e-5	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs9788682	0.706	rs924840	chr15:78731808	A/T	cg24631222	chr15:78858424	CHRNA5	0.63	4.67	0.39	7.67e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs9419702	0.568	rs9419635	chr10:133546164	C/T	cg23460707	chr10:133558971	NA	0.44	4.94	0.41	2.52e-6	Survival in rectal cancer;
TGCT	cis	rs7208859	0.623	rs73269974	chr17:29112384	C/T	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs3733585	0.783	rs13148371	chr4:10032561	C/T	cg00071950	chr4:10020882	SLC2A9	0.68	8.84	0.62	7.71e-15	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs12220238	1.000	rs10824106	chr10:75958408	C/T	cg19889307	chr10:75911429	ADK;AP3M1	-1.03	-6.03	-0.48	1.78e-8	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg06634786	chr22:41940651	POLR3H	-0.72	-6.68	-0.51	7.15e-10	Vitiligo;
TGCT	cis	rs9393692	0.905	rs6940237	chr6:26282322	T/C	cg05868516	chr6:26286170	HIST1H4H	0.63	5.91	0.47	3.02e-8	Educational attainment;
TGCT	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg13395646	chr4:1353034	KIAA1530	-0.47	-5.77	-0.46	5.99e-8	Obesity-related traits;
TGCT	cis	rs9916302	0.904	rs11867312	chr17:37597748	C/T	cg15445000	chr17:37608096	MED1	0.33	4.78	0.39	4.93e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs2228479	0.541	rs12918575	chr16:89811151	A/G	cg26513180	chr16:89883248	FANCA	0.78	4.54	0.38	1.32e-5	Skin colour saturation;
TGCT	trans	rs629535	0.814	rs545720	chr8:70063370	T/C	cg21567404	chr3:27674614	NA	0.54	8.61	0.61	2.81e-14	Dupuytren's disease;
TGCT	cis	rs2762353	0.574	rs9467574	chr6:25705718	C/G	cg03264133	chr6:25882463	NA	0.86	8.5	0.61	5.01e-14	Blood metabolite levels;
TGCT	cis	rs56309584	0.715	rs3027246	chr17:8131223	C/T	cg08322244	chr17:8066669	VAMP2	-0.57	-5.26	-0.43	6.01e-7	Initial pursuit acceleration;
TGCT	cis	rs3087591	1.000	rs4795579	chr17:29458682	T/C	cg24425628	chr17:29625626	OMG;NF1	0.46	7.25	0.55	3.92e-11	Hip circumference;
TGCT	trans	rs797680	0.856	rs12118262	chr1:93651547	C/T	cg27528825	chr2:159282178	CCDC148	0.34	6.65	0.51	8.53e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs1372520	0.684	rs2572318	chr4:90718719	C/T	cg20003494	chr4:90757398	SNCA	-0.65	-4.54	-0.38	1.34e-5	Neuroticism;
TGCT	cis	rs8077577	0.895	rs62072464	chr17:18108314	T/C	cg09161412	chr17:18057145	MYO15A	-0.64	-5.22	-0.42	7.2e-7	Obesity-related traits;
TGCT	cis	rs12210905	0.688	rs114157955	chr6:27329878	C/T	cg08851530	chr6:28072375	NA	1.25	5.39	0.44	3.38e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs4478037	0.822	rs9863331	chr3:33123235	G/T	cg19404215	chr3:33155277	CRTAP	0.98	5.13	0.42	1.1e-6	Major depressive disorder;
TGCT	cis	rs7044106	0.708	rs2416760	chr9:123374639	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.55	5.99	0.47	2.07e-8	Hip circumference adjusted for BMI;
TGCT	cis	rs713587	0.520	rs1530016	chr2:25305756	C/T	cg01884057	chr2:25150051	NA	-0.26	-4.89	-0.4	3.12e-6	Body mass index in non-asthmatics;
TGCT	cis	rs2153535	0.580	rs1855769	chr6:8473095	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg10295955	chr4:187884368	NA	-0.99	-15.24	-0.81	3.38e-30	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs78456975	1.000	rs13422995	chr2:1553554	C/A	cg01028140	chr2:1542097	TPO	-0.35	-4.57	-0.38	1.17e-5	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs7772486	0.875	rs2814866	chr6:146339414	C/A	cg23711669	chr6:146136114	FBXO30	0.84	9.13	0.63	1.59e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9807989	0.801	rs4851566	chr2:102972799	G/C	cg09003973	chr2:102972529	NA	0.64	5.7	0.46	8.28e-8	Asthma;
TGCT	cis	rs12378800	0.520	rs734769	chr9:100844198	C/T	cg00089695	chr9:101746445	COL15A1	-0.32	-4.45	-0.37	1.89e-5	Alzheimer disease and age of onset;
TGCT	cis	rs17221829	0.733	rs117029483	chr11:89365918	C/T	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.65	-0.39	8.43e-6	Anxiety in major depressive disorder;
TGCT	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg03517284	chr6:25882590	NA	-0.62	-6.45	-0.5	2.23e-9	Blood metabolite levels;
TGCT	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg22920501	chr2:26401640	FAM59B	-0.72	-6.38	-0.5	3.19e-9	Gut microbiome composition (summer);
TGCT	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg18876405	chr7:65276391	NA	0.35	5.2	0.42	7.81e-7	Aortic root size;
TGCT	cis	rs67311347	0.956	rs13066971	chr3:40462510	A/T	cg17264618	chr3:40429014	ENTPD3	-0.31	-4.59	-0.38	1.08e-5	Renal cell carcinoma;
TGCT	cis	rs7940866	0.774	rs10894292	chr11:130820757	C/T	cg12179176	chr11:130786555	SNX19	0.56	5.46	0.44	2.54e-7	Schizophrenia;
TGCT	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg00080972	chr5:178986291	RUFY1	0.59	7.71	0.57	3.57e-12	Lung cancer;
TGCT	cis	rs7267979	0.934	rs2257464	chr20:25265872	C/T	cg16686733	chr20:25566563	NINL	0.58	5.83	0.46	4.44e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7769051	1.000	rs73554431	chr6:133129922	T/G	cg22852734	chr6:133119734	C6orf192	1.23	7.09	0.54	9.13e-11	Type 2 diabetes nephropathy;
TGCT	cis	rs12368653	0.584	rs7295422	chr12:58099736	G/A	cg12615879	chr12:58013172	SLC26A10	0.49	5.9	0.47	3.27e-8	Multiple sclerosis;
TGCT	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg12310025	chr6:25882481	NA	0.49	5.12	0.42	1.15e-6	Blood metabolite levels;
TGCT	cis	rs1348850	0.914	rs1374437	chr2:178363423	T/C	cg22681709	chr2:178499509	PDE11A	-0.35	-4.57	-0.38	1.18e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs7267979	1.000	rs11087521	chr20:25440648	G/A	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.03	-14.96	-0.8	1.51e-29	Prudent dietary pattern;
TGCT	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	6.23	0.49	6.6e-9	Bipolar disorder;
TGCT	trans	rs10506458	1.000	rs12425932	chr12:63410497	C/A	cg22491629	chr6:157744540	C6orf35	-0.99	-8.58	-0.61	3.18e-14	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs10836699	0.635	rs999242	chr11:37201401	C/G	cg18520238	chr11:36422557	PRR5L	-0.18	-4.48	-0.37	1.66e-5	Low high density lipoprotein cholesterol levels;
TGCT	cis	rs1971762	0.509	rs1247955	chr12:53964133	G/T	cg16917193	chr12:54089295	NA	-1.04	-11.02	-0.7	4.2e-20	Height;
TGCT	cis	rs1577917	0.958	rs34765423	chr6:86484448	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.46	-0.44	2.47e-7	Response to antipsychotic treatment;
TGCT	cis	rs4654899	0.865	rs6665549	chr1:21475884	G/C	cg01072550	chr1:21505969	NA	-0.47	-6.96	-0.53	1.74e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs10782582	0.545	rs111927462	chr1:76195422	A/G	cg10523679	chr1:76189770	ACADM	-0.66	-6.69	-0.52	6.7e-10	Daytime sleep phenotypes;
TGCT	cis	rs4819052	0.840	rs914217	chr21:46698299	A/G	cg06618935	chr21:46677482	NA	-0.38	-4.96	-0.41	2.28e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg07507251	chr3:52567010	NT5DC2	0.47	6.71	0.52	6.11e-10	Bipolar disorder;
TGCT	cis	rs6921919	0.609	rs9468357	chr6:28342053	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.56	-5.37	-0.43	3.8e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs72949976	0.584	rs12467619	chr2:214022933	T/C	cg08319019	chr2:214017104	IKZF2	0.84	8.41	0.6	8.42e-14	Lung cancer;Squamous cell lung carcinoma;
TGCT	cis	rs35306767	0.953	rs11253517	chr10:970524	A/G	cg18964960	chr10:1102726	WDR37	-0.57	-4.46	-0.37	1.82e-5	Eosinophil percentage of granulocytes;
TGCT	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg00149659	chr3:10157352	C3orf10	0.73	4.72	0.39	6.17e-6	Alzheimer's disease;
TGCT	cis	rs4285214	0.715	rs12515071	chr5:124031011	C/T	cg15082166	chr5:124005151	ZNF608	0.36	4.85	0.4	3.63e-6	Survival in pancreatic cancer;
TGCT	cis	rs6964587	1.000	rs4727266	chr7:91570129	C/T	cg17063962	chr7:91808500	NA	-0.9	-9.67	-0.66	7.91e-17	Breast cancer;
TGCT	cis	rs3784262	0.669	rs12909979	chr15:58241022	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.42	-6.01	-0.47	1.94e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs57221529	0.766	rs12521988	chr5:556421	C/T	cg09021430	chr5:549028	NA	-0.4	-5.46	-0.44	2.44e-7	Lung disease severity in cystic fibrosis;
TGCT	cis	rs9467773	1.000	rs9393729	chr6:26514166	C/T	cg15659132	chr6:26577336	NA	0.86	12.21	0.74	5.3e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg05872129	chr22:39784769	NA	-1.01	-11.68	-0.72	1.05e-21	Intelligence (multi-trait analysis);
TGCT	cis	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg22857025	chr5:266934	NA	-0.34	-6.7	-0.52	6.65e-10	Breast cancer;
TGCT	cis	rs926938	0.520	rs2007231	chr1:115266306	C/T	cg12756093	chr1:115239321	AMPD1	-0.42	-5.2	-0.42	7.84e-7	Autism;
TGCT	cis	rs1865760	1.000	rs9348698	chr6:25929689	T/A	cg16482183	chr6:26056742	HIST1H1C	0.51	4.57	0.38	1.17e-5	Height;
TGCT	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg13395646	chr4:1353034	KIAA1530	-0.36	-4.62	-0.38	9.52e-6	Obesity-related traits;
TGCT	trans	rs629535	0.814	rs654452	chr8:70074344	C/G	cg21567404	chr3:27674614	NA	0.57	9.09	0.63	1.94e-15	Dupuytren's disease;
TGCT	cis	rs4851254	0.961	rs11692215	chr2:100746573	C/T	cg04109781	chr2:100722022	AFF3	0.42	4.49	0.37	1.6e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs16866061	1.000	rs16866061	chr2:225439844	A/G	cg12698349	chr2:225449008	CUL3	0.97	10.26	0.68	2.88e-18	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	cis	rs7605378	0.658	rs4673507	chr2:200710167	G/C	cg19045956	chr2:200819837	C2orf60;C2orf47	0.51	4.89	0.4	3.11e-6	Osteoporosis;
TGCT	cis	rs478304	0.817	rs524475	chr11:65518065	T/A	cg17480646	chr11:65405466	SIPA1	0.43	5.35	0.43	4.01e-7	Acne (severe);
TGCT	cis	rs2361710	0.704	rs12937349	chr17:78120320	G/C	cg09238746	chr17:78121135	EIF4A3	-0.78	-7.37	-0.55	2.1e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
TGCT	cis	rs2010099	0.759	rs78365741	chr3:124294281	A/C	cg04915618	chr3:124304960	KALRN	0.53	4.77	0.39	5.16e-6	Thyroid peroxidase antibody levels;
TGCT	cis	rs290268	0.874	rs290994	chr9:93559515	T/A	cg02608019	chr9:93564028	SYK	0.46	4.74	0.39	5.69e-6	Platelet count;
TGCT	cis	rs66561647	0.661	rs7835090	chr8:128940177	A/C	cg11792826	chr8:129160931	MIR1208	0.22	4.96	0.41	2.25e-6	Hemoglobin concentration;
TGCT	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg00814883	chr7:100076585	TSC22D4	-0.86	-8.1	-0.59	4.49e-13	Platelet count;
TGCT	cis	rs1933488	0.898	rs11155895	chr6:153421545	C/A	cg24028809	chr6:153414101	RGS17	0.2	4.55	0.38	1.25e-5	Prostate cancer;
TGCT	cis	rs4820539	1.000	rs916584	chr22:23469433	A/G	cg14186256	chr22:23484241	RTDR1	0.98	12.28	0.74	3.5e-23	Bone mineral density;
TGCT	cis	rs2050392	0.767	rs10763787	chr10:30700753	G/A	cg18806716	chr10:30721971	MAP3K8	0.69	9.36	0.64	4.5e-16	Inflammatory bowel disease;
TGCT	cis	rs7178424	0.616	rs9920945	chr15:62136913	G/A	cg00456672	chr15:62358751	C2CD4A	-0.31	-4.71	-0.39	6.66e-6	Height;
TGCT	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg22618164	chr12:122356400	WDR66	0.66	6.17	0.48	9.08e-9	Mean corpuscular volume;
TGCT	cis	rs3820068	0.705	rs4646110	chr1:15817318	A/T	cg05660106	chr1:15850417	CASP9	1.15	14.12	0.79	1.41e-27	Systolic blood pressure;
TGCT	cis	rs7552404	0.889	rs1250874	chr1:76190978	A/G	cg03433033	chr1:76189801	ACADM	0.77	9.35	0.64	4.77e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7666738	0.830	rs6811940	chr4:98777898	G/A	cg18180107	chr4:99064573	C4orf37	0.53	5.05	0.41	1.51e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg02487422	chr3:49467188	NICN1	0.54	5.2	0.42	8.11e-7	Menarche (age at onset);
TGCT	cis	rs3749237	0.964	rs10865959	chr3:49891002	G/C	cg03060546	chr3:49711283	APEH	0.7	6.71	0.52	6.05e-10	Resting heart rate;
TGCT	cis	rs28595532	0.920	rs116305850	chr4:119779892	A/G	cg14228332	chr4:119757509	SEC24D	1.26	7.08	0.54	9.26e-11	Cannabis dependence symptom count;
TGCT	cis	rs12911832	0.727	rs682619	chr15:59098773	T/C	cg05156742	chr15:59063176	FAM63B	0.55	5.33	0.43	4.49e-7	Schizophrenia;
TGCT	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.43	-4.62	-0.38	9.36e-6	Longevity;Endometriosis;
TGCT	cis	rs137603	0.562	rs137644	chr22:39728139	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	-0.64	-6.77	-0.52	4.55e-10	Primary biliary cholangitis;
TGCT	cis	rs9527	0.637	rs11191424	chr10:104625886	G/A	cg15744005	chr10:104629667	AS3MT	-0.49	-6.35	-0.5	3.65e-9	Arsenic metabolism;
TGCT	cis	rs2120019	1.000	rs8036197	chr15:75370232	T/C	cg17294928	chr15:75287854	SCAMP5	-0.86	-6.62	-0.51	9.55e-10	Blood trace element (Zn levels);
TGCT	cis	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg18188782	chr20:61659543	NA	0.44	5.38	0.43	3.6e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs514406	0.505	rs12726160	chr1:53175099	A/G	cg24675658	chr1:53192096	ZYG11B	-0.79	-9.45	-0.65	2.78e-16	Monocyte count;
TGCT	cis	rs9913156	0.793	rs72835643	chr17:4573612	G/A	cg19197139	chr17:4613644	ARRB2	0.88	8.13	0.59	3.75e-13	Lymphocyte counts;
TGCT	cis	rs7267979	0.966	rs6037083	chr20:25290543	T/C	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7666738	0.830	rs1876192	chr4:98727555	T/C	cg17366294	chr4:99064904	C4orf37	0.65	6.78	0.52	4.31e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8180040	0.726	rs6785790	chr3:47146932	C/T	cg27129171	chr3:47204927	SETD2	0.74	9.88	0.66	2.48e-17	Colorectal cancer;
TGCT	cis	rs9921222	0.509	rs3743883	chr16:404750	T/C	cg12437481	chr16:420112	MRPL28	-0.48	-4.6	-0.38	1.04e-5	Bone mineral density (spine);Bone mineral density;
TGCT	trans	rs3780486	0.505	rs10813959	chr9:33166234	C/T	cg20290983	chr6:43655470	MRPS18A	-0.79	-8.48	-0.61	5.57e-14	IgG glycosylation;
TGCT	cis	rs7552404	0.731	rs12090849	chr1:76400261	A/G	cg03433033	chr1:76189801	ACADM	0.71	6.77	0.52	4.62e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.5	5.64	0.45	1.08e-7	Lymphocyte counts;
TGCT	cis	rs13088281	1.000	rs13088281	chr3:53147576	A/C	cg15956490	chr3:53032818	SFMBT1	-0.58	-7.12	-0.54	7.59e-11	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs10791097	0.694	rs10894273	chr11:130742155	G/T	cg05962950	chr11:130786565	SNX19	0.92	11.55	0.72	2.13e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs1692580	0.777	rs12136830	chr1:2189196	A/T	cg21194808	chr1:2205498	SKI	0.29	5.78	0.46	5.71e-8	Coronary artery disease;
TGCT	cis	rs11676348	0.846	rs11677534	chr2:219007060	T/C	cg00012203	chr2:219082015	ARPC2	-0.52	-4.84	-0.4	3.78e-6	Ulcerative colitis;
TGCT	cis	rs1371867	0.846	rs1660328	chr8:101303450	A/G	cg06002616	chr8:101225028	SPAG1	-0.53	-6.21	-0.49	7.16e-9	Atrioventricular conduction;
TGCT	cis	rs4285028	0.747	rs4048699	chr3:121404483	A/G	cg17324707	chr3:122103153	FAM162A;CCDC58	0.62	4.55	0.38	1.28e-5	Multiple sclerosis;
TGCT	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6693567	0.565	rs1313569	chr1:150344171	G/A	cg09579323	chr1:150459698	TARS2	0.54	4.79	0.4	4.59e-6	Migraine;
TGCT	cis	rs9611565	0.559	rs132771	chr22:42025350	A/G	cg17554472	chr22:41940697	POLR3H	0.5	5.26	0.43	6.02e-7	Vitiligo;
TGCT	cis	rs17221829	0.702	rs72969198	chr11:89357607	T/A	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.65	-0.39	8.43e-6	Anxiety in major depressive disorder;
TGCT	cis	rs1903068	0.853	rs73236111	chr4:56019068	A/C	cg01777861	chr4:56023843	NA	0.54	6.05	0.48	1.6e-8	Endometriosis;
TGCT	cis	rs17331151	0.573	rs2240916	chr3:52859212	T/A	cg27565382	chr3:53032988	SFMBT1	0.4	5.05	0.41	1.57e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs7582180	0.764	rs12622318	chr2:100927375	T/C	cg08017756	chr2:100939284	LONRF2	-0.3	-4.91	-0.4	2.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs11785400	0.612	rs10110864	chr8:143750072	A/G	cg10596483	chr8:143751796	JRK	0.58	6.04	0.48	1.64e-8	Schizophrenia;
TGCT	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg17911788	chr17:44343683	NA	-0.65	-6.61	-0.51	1.04e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2288884	0.690	rs11666341	chr19:52601399	G/A	cg13540795	chr19:52551618	ZNF432	-0.7	-6.03	-0.48	1.78e-8	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs919433	0.617	rs34632716	chr2:198542619	C/T	cg00792783	chr2:198669748	PLCL1	-0.55	-5.04	-0.41	1.62e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs6460942	1.000	rs118083671	chr7:12466036	C/T	cg06484146	chr7:12443880	VWDE	-0.58	-5.62	-0.45	1.21e-7	Coronary artery disease;
TGCT	cis	rs887829	0.588	rs4663971	chr2:234674252	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.26	-4.49	-0.37	1.63e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
TGCT	cis	rs7845219	0.597	rs7002058	chr8:95873993	G/C	cg13393036	chr8:95962371	TP53INP1	-0.49	-5.86	-0.47	3.92e-8	Type 2 diabetes;
TGCT	cis	rs1008375	1.000	rs4698200	chr4:17657051	G/A	cg10189774	chr4:17578691	LAP3	0.58	5.26	0.43	6.24e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs3771570	1.000	rs62193208	chr2:242322430	G/A	cg21155796	chr2:242212141	HDLBP	0.94	6.69	0.51	6.9e-10	Prostate cancer;
TGCT	trans	rs210152	0.588	rs1755040	chr6:33495175	A/C	cg22108809	chr5:56777663	ACTBL2	-0.54	-6.67	-0.51	7.44e-10	Schizophrenia;
TGCT	cis	rs12421382	0.543	rs10890996	chr11:109328421	A/G	cg16359550	chr11:109292809	C11orf87	-0.69	-7.9	-0.58	1.29e-12	Schizophrenia;
TGCT	cis	rs7208859	0.673	rs11080138	chr17:29224542	A/G	cg18442181	chr17:29233375	C17orf42	-0.78	-4.61	-0.38	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs35264875	0.898	rs55648928	chr11:68861591	G/T	cg02660097	chr11:68866761	NA	0.32	4.61	0.38	9.94e-6	Blond vs. brown hair color;
TGCT	cis	rs10823500	0.636	rs7082396	chr10:71945511	C/A	cg02100629	chr10:71892760	AIFM2	-0.45	-4.85	-0.4	3.62e-6	Blood protein levels;
TGCT	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg05368731	chr17:41323189	NBR1	1.16	13.44	0.77	5.72e-26	Menopause (age at onset);
TGCT	cis	rs9611565	0.546	rs132793	chr22:42063681	A/G	cg17554472	chr22:41940697	POLR3H	0.49	5.2	0.42	8.09e-7	Vitiligo;
TGCT	cis	rs2404602	0.536	rs1587381	chr15:76769620	G/A	cg22467129	chr15:76604101	ETFA	-0.48	-5.9	-0.47	3.27e-8	Blood metabolite levels;
TGCT	cis	rs6460942	1.000	rs73053527	chr7:12313008	C/A	cg06484146	chr7:12443880	VWDE	-0.57	-4.87	-0.4	3.35e-6	Coronary artery disease;
TGCT	cis	rs9549260	0.755	rs3892360	chr13:41184078	C/G	cg21288729	chr13:41239152	FOXO1	1.01	10.14	0.67	5.8e-18	Red blood cell count;
TGCT	cis	rs9859260	0.710	rs41298097	chr3:195779155	C/T	cg22891161	chr3:195456627	MUC20	0.23	4.6	0.38	1.04e-5	Mean corpuscular volume;
TGCT	cis	rs13242816	1.000	rs56275709	chr7:116108489	A/G	cg02799643	chr7:116139180	CAV2	-0.45	-5.38	-0.44	3.5e-7	P wave duration;
TGCT	cis	rs854765	0.647	rs2974999	chr17:17997547	T/G	cg04398451	chr17:18023971	MYO15A	-0.38	-6.61	-0.51	1.04e-9	Total body bone mineral density;
TGCT	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg09323728	chr8:95962352	TP53INP1	-0.52	-6.71	-0.52	6.14e-10	Type 2 diabetes;
TGCT	cis	rs6831352	0.734	rs1453872	chr4:100022482	G/A	cg12011299	chr4:100065546	ADH4	0.39	5.2	0.42	7.81e-7	Alcohol dependence;
TGCT	cis	rs8100891	0.734	rs741445	chr19:32836592	G/T	cg16662424	chr19:32837316	ZNF507	-0.45	-5.43	-0.44	2.85e-7	Neuroticism;
TGCT	cis	rs67385638	1.000	rs67385638	chr11:5290370	C/G	cg12559170	chr11:5275217	HBG2	0.46	8.17	0.59	3.04e-13	Hemoglobin levels;
TGCT	cis	rs78456975	0.607	rs72776258	chr2:1530732	C/G	cg01028140	chr2:1542097	TPO	-0.35	-4.48	-0.37	1.69e-5	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs7586879	0.616	rs6722587	chr2:25132192	C/A	cg15423357	chr2:25149977	NA	0.52	5.03	0.41	1.65e-6	Body mass index;
TGCT	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg27588902	chr6:42928151	GNMT	0.44	5.54	0.45	1.76e-7	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg03517284	chr6:25882590	NA	0.69	7.52	0.56	9.42e-12	Blood metabolite levels;
TGCT	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg05872129	chr22:39784769	NA	-0.87	-9.82	-0.66	3.49e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs10788264	0.621	rs9633734	chr10:124057667	T/C	cg09507567	chr10:124027408	NA	0.39	5.6	0.45	1.3e-7	Total body bone mineral density;
TGCT	cis	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg20637647	chr7:64974828	NA	0.94	5.17	0.42	9.06e-7	Diabetic kidney disease;
TGCT	cis	rs797680	0.856	rs797672	chr1:93702119	A/T	cg17826107	chr1:92977322	EVI5	0.24	5.29	0.43	5.47e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs8177253	0.665	rs8177178	chr3:133463272	G/A	cg16414030	chr3:133502952	NA	-0.5	-6.85	-0.52	3.05e-10	Iron status biomarkers;
TGCT	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg06481639	chr22:41940642	POLR3H	0.74	6.59	0.51	1.11e-9	Vitiligo;
TGCT	cis	rs7818688	0.697	rs11784212	chr8:95976995	G/A	cg16049864	chr8:95962084	TP53INP1	0.54	4.64	0.38	8.87e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg08439880	chr3:133502540	NA	-0.31	-5.9	-0.47	3.22e-8	Iron status biomarkers;
TGCT	cis	rs13191362	0.872	rs13196631	chr6:163001588	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg02463440	chr8:22132932	PIWIL2	0.26	5.2	0.42	7.85e-7	Hypertriglyceridemia;
TGCT	cis	rs6460942	0.908	rs75704904	chr7:12233583	G/A	cg06484146	chr7:12443880	VWDE	-0.54	-4.76	-0.39	5.21e-6	Coronary artery disease;
TGCT	cis	rs11785693	0.862	rs62491171	chr8:4987177	G/A	cg26367366	chr8:4980734	NA	0.58	4.51	0.38	1.48e-5	Neuroticism (multi-trait analysis);Neuroticism;
TGCT	cis	rs3847687	1.000	rs11061292	chr12:131518981	T/A	cg25772418	chr12:131519998	GPR133	-0.32	-5.66	-0.45	1.01e-7	Longevity;
TGCT	cis	rs28595532	0.841	rs116093021	chr4:119763872	C/G	cg14228332	chr4:119757509	SEC24D	1.3	6.62	0.51	9.62e-10	Cannabis dependence symptom count;
TGCT	cis	rs13191362	0.935	rs35378894	chr6:163123933	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.99	8.17	0.59	3.08e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg06028605	chr16:24865363	SLC5A11	-0.42	-4.69	-0.39	7.14e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	7.12	0.54	7.55e-11	Platelet count;
TGCT	cis	rs4824093	0.610	rs73443906	chr22:50274293	A/G	cg14114931	chr22:50943910	LMF2	0.37	4.58	0.38	1.11e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs2354432	0.556	rs1932979	chr1:146708912	A/G	cg25205988	chr1:146714368	CHD1L	-1.15	-4.8	-0.4	4.49e-6	Mitochondrial DNA levels;
TGCT	cis	rs9399135	0.660	rs9389248	chr6:135282656	T/C	cg24558204	chr6:135376177	HBS1L	0.46	4.8	0.4	4.45e-6	Red blood cell count;
TGCT	cis	rs35306767	0.761	rs12771539	chr10:1050653	A/G	cg26597838	chr10:835615	NA	0.6	6.63	0.51	9.45e-10	Eosinophil percentage of granulocytes;
TGCT	cis	rs9868809	0.881	rs34368826	chr3:48670827	G/T	cg00383909	chr3:49044727	WDR6	0.97	5.08	0.42	1.34e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs9303401	0.625	rs10515159	chr17:56802693	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.67	6.3	0.49	4.7e-9	Cognitive test performance;
TGCT	cis	rs2880765	0.835	rs11074276	chr15:86030363	C/A	cg13263323	chr15:86062960	AKAP13	-0.22	-4.8	-0.4	4.44e-6	Coronary artery disease;
TGCT	cis	rs8072100	0.790	rs3760371	chr17:45695914	T/C	cg08085267	chr17:45401833	C17orf57	0.46	5.01	0.41	1.82e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs644799	0.710	rs519511	chr11:95538270	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.79	8.65	0.61	2.18e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs10276381	0.579	rs73072539	chr7:28146255	C/G	cg23620719	chr7:28220237	JAZF1	0.74	4.5	0.37	1.56e-5	Crohn's disease;
TGCT	cis	rs9383153	0.590	rs2072736	chr6:16328068	T/C	cg23850913	chr6:15505452	JARID2	0.92	4.86	0.4	3.42e-6	Gambling;
TGCT	cis	rs11098499	0.754	rs1980027	chr4:120251577	C/T	cg09307838	chr4:120376055	NA	0.61	5.91	0.47	3.14e-8	Corneal astigmatism;
TGCT	cis	rs9522267	0.737	rs9515448	chr13:112229526	A/T	cg10483660	chr13:112241077	NA	-0.29	-4.76	-0.39	5.19e-6	Hepatitis;
TGCT	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg12311346	chr5:56204834	C5orf35	-0.67	-6.77	-0.52	4.59e-10	Initial pursuit acceleration;
TGCT	cis	rs6570726	0.846	rs9399559	chr6:145945778	C/T	cg23711669	chr6:146136114	FBXO30	0.84	9.16	0.64	1.36e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6087990	0.735	rs6058883	chr20:31365719	C/T	cg13636640	chr20:31349939	DNMT3B	-0.95	-12.3	-0.74	3.17e-23	Ulcerative colitis;
TGCT	cis	rs11190604	1.000	rs2495743	chr10:102329739	G/C	cg23241863	chr10:102295624	HIF1AN	0.67	4.9	0.4	2.99e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2832191	0.716	rs7284006	chr21:30475186	T/A	cg24692254	chr21:30365293	RNF160	1.01	11.59	0.72	1.73e-21	Dental caries;
TGCT	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs916888	0.610	rs199529	chr17:44837217	A/C	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.75	5.23	0.43	6.99e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg23149560	chr2:74406255	MOBKL1B	0.6	4.56	0.38	1.19e-5	Gestational age at birth (maternal effect);
TGCT	cis	rs7000551	0.689	rs2449339	chr8:22387981	G/A	cg12081754	chr8:22256438	SLC39A14	0.27	4.53	0.38	1.38e-5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg15921436	chr17:44337874	NA	0.53	7.54	0.56	8.43e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg04156016	chr5:1868137	NA	0.32	4.44	0.37	1.99e-5	Cardiovascular disease risk factors;
TGCT	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg04267008	chr7:1944627	MAD1L1	-0.38	-5.19	-0.42	8.33e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg23758822	chr17:41437982	NA	0.73	6.94	0.53	1.93e-10	Menopause (age at onset);
TGCT	cis	rs31872	0.521	rs246050	chr5:140326860	T/G	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Visceral adipose tissue adjusted for BMI;
TGCT	cis	rs11096990	0.613	rs12505690	chr4:39169045	G/A	cg20847110	chr4:39482781	LOC401127	0.17	4.96	0.41	2.3e-6	Cognitive function;
TGCT	cis	rs6088580	0.602	rs6059834	chr20:33019299	A/G	cg08999081	chr20:33150536	PIGU	0.29	5.66	0.45	9.92e-8	Glomerular filtration rate (creatinine);
TGCT	cis	rs10114408	0.959	rs7863704	chr9:96638610	C/T	cg13679303	chr9:96623674	NA	-0.36	-4.69	-0.39	6.98e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg27425262	chr2:113953981	PSD4;LOC440839	-0.52	-8.2	-0.59	2.52e-13	Lymphocyte counts;
TGCT	cis	rs17076896	0.618	rs80110795	chr13:19929059	T/C	cg00777926	chr13:20807375	GJB6	-0.37	-4.51	-0.38	1.5e-5	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs710216	0.879	rs710218	chr1:43427218	A/T	cg03128534	chr1:43423976	SLC2A1	0.6	4.96	0.41	2.27e-6	Red cell distribution width;
TGCT	cis	rs9462846	0.658	rs9471970	chr6:42913646	G/A	cg02353165	chr6:42928485	GNMT	0.73	5.66	0.45	1e-7	Blood protein levels;
TGCT	cis	rs734999	0.870	rs3748825	chr1:2483270	T/C	cg18854424	chr1:2615690	NA	0.46	5.36	0.43	3.98e-7	Ulcerative colitis;
TGCT	cis	rs4689388	0.853	rs4293850	chr4:6292020	A/C	cg14416269	chr4:6271139	WFS1	0.4	5.21	0.42	7.57e-7	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs1949733	1.000	rs2688223	chr4:8471398	T/C	cg13073564	chr4:8508604	NA	-0.48	-5.18	-0.42	8.61e-7	Response to antineoplastic agents;
TGCT	cis	rs10504229	0.679	rs4737454	chr8:58033965	A/T	cg08280861	chr8:58055591	NA	0.35	5.07	0.41	1.43e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7647973	1.000	rs974495	chr3:49400482	T/C	cg05785598	chr3:49045655	WDR6	0.39	4.65	0.39	8.28e-6	Menarche (age at onset);
TGCT	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	12.04	0.73	1.36e-22	Height;
TGCT	cis	rs778371	0.723	rs13001052	chr2:233683984	C/T	cg08000102	chr2:233561755	GIGYF2	-0.67	-7.64	-0.57	5.21e-12	Schizophrenia;
TGCT	trans	rs10506458	0.834	rs55966529	chr12:63384114	A/C	cg22491629	chr6:157744540	C6orf35	-0.96	-8.25	-0.6	2.01e-13	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs8042680	0.554	rs59278520	chr15:91514707	G/A	cg22570213	chr15:91497863	RCCD1	0.44	4.69	0.39	7.23e-6	Type 2 diabetes;
TGCT	cis	rs5769765	0.955	rs9616368	chr22:50303533	C/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.41	5.84	0.46	4.39e-8	Schizophrenia;
TGCT	cis	rs9905704	0.647	rs12940492	chr17:56954655	C/G	cg05425664	chr17:57184151	TRIM37	-0.59	-4.69	-0.39	7.16e-6	Testicular germ cell tumor;
TGCT	cis	rs17376456	0.825	rs12188163	chr5:93250608	A/G	cg21475434	chr5:93447410	FAM172A	-0.63	-4.86	-0.4	3.44e-6	Diabetic retinopathy;
TGCT	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg19318889	chr4:1322082	MAEA	0.19	4.8	0.4	4.43e-6	Longevity;
TGCT	cis	rs4494114	1.000	rs2147914	chr1:39352271	G/T	cg25970120	chr1:39325951	RRAGC	-0.6	-6.23	-0.49	6.58e-9	Blood protein levels;
TGCT	cis	rs9291683	0.588	rs35099040	chr4:10018839	T/C	cg00071950	chr4:10020882	SLC2A9	0.75	10.2	0.68	4.17e-18	Bone mineral density;
TGCT	cis	rs453301	0.598	rs10104303	chr8:8834528	A/T	cg06636001	chr8:8085503	FLJ10661	0.77	6.99	0.53	1.5e-10	Joint mobility (Beighton score);
TGCT	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg11764359	chr7:65958608	NA	-0.55	-4.87	-0.4	3.3e-6	Aortic root size;
TGCT	cis	rs2120019	0.935	rs8043181	chr15:75380424	T/C	cg11632617	chr15:75315747	PPCDC	-0.34	-4.88	-0.4	3.2e-6	Blood trace element (Zn levels);
TGCT	cis	rs9325144	0.647	rs12830095	chr12:38864199	C/T	cg26384229	chr12:38710491	ALG10B	-0.59	-5.42	-0.44	2.98e-7	Morning vs. evening chronotype;
TGCT	cis	rs9467773	0.620	rs9467810	chr6:26608261	A/C	cg09904177	chr6:26538194	HMGN4	0.67	6.26	0.49	5.61e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs17376456	0.825	rs10051878	chr5:93064164	T/G	cg25358565	chr5:93447407	FAM172A	0.9	7.65	0.57	4.86e-12	Diabetic retinopathy;
TGCT	cis	rs6977660	0.607	rs10243965	chr7:19797893	G/A	cg05791153	chr7:19748676	TWISTNB	0.96	5.53	0.44	1.83e-7	Thyroid stimulating hormone;
TGCT	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg13393036	chr8:95962371	TP53INP1	-0.61	-8.39	-0.6	9.13e-14	Type 2 diabetes;
TGCT	trans	rs1814175	0.717	rs11040450	chr11:49650638	G/A	cg03929089	chr4:120376271	NA	-0.65	-7.44	-0.56	1.46e-11	Height;
TGCT	cis	rs6964587	1.000	rs756647	chr7:91586389	A/G	cg17063962	chr7:91808500	NA	0.91	9.99	0.67	1.32e-17	Breast cancer;
TGCT	cis	rs12478296	1.000	rs56136197	chr2:243043877	T/C	cg06360820	chr2:242988706	NA	-0.61	-4.66	-0.39	8.13e-6	Obesity-related traits;
TGCT	cis	rs10032931	0.962	rs1385671	chr4:96455967	C/T	cg17031751	chr4:96469067	UNC5C	-0.38	-4.92	-0.4	2.73e-6	Optic nerve measurement (cup-to-disc ratio);
TGCT	cis	rs9814567	0.762	rs13070654	chr3:134219348	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.83	6.53	0.51	1.51e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs10089	1.000	rs11957052	chr5:127524055	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	7.4	0.55	1.83e-11	Ileal carcinoids;
TGCT	cis	rs2637266	1.000	rs7897015	chr10:78366566	G/C	cg18941641	chr10:78392320	NA	0.4	4.73	0.39	6.03e-6	Pulmonary function;
TGCT	cis	rs9916302	0.904	rs7216086	chr17:37709422	G/A	cg15445000	chr17:37608096	MED1	0.31	4.5	0.37	1.53e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.68	-7.03	-0.53	1.19e-10	Prostate cancer;
TGCT	cis	rs72781680	1.000	rs75046532	chr2:24167267	A/G	cg08917208	chr2:24149416	ATAD2B	0.73	4.51	0.38	1.48e-5	Lymphocyte counts;
TGCT	cis	rs2050392	0.590	rs694346	chr10:30711929	C/T	cg12408189	chr10:30722286	MAP3K8	-0.45	-4.49	-0.37	1.6e-5	Inflammatory bowel disease;
TGCT	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg06873352	chr17:61820015	STRADA	0.58	6.39	0.5	3.01e-9	Prudent dietary pattern;
TGCT	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.51	-4.79	-0.4	4.68e-6	Bipolar disorder;
TGCT	cis	rs17253792	0.822	rs74940664	chr14:56135065	A/G	cg01858014	chr14:56050164	KTN1	-0.35	-4.65	-0.39	8.23e-6	Putamen volume;
TGCT	cis	rs6088580	0.561	rs3761147	chr20:32996689	G/T	cg08999081	chr20:33150536	PIGU	-0.29	-5.65	-0.45	1.02e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs2811893	0.967	rs232776	chr1:59124803	C/T	cg26196860	chr1:59745563	NA	0.25	4.68	0.39	7.49e-6	Diabetic retinopathy;
TGCT	cis	rs6558530	0.579	rs6558528	chr8:1703063	C/T	cg09410841	chr8:1729607	CLN8	0.7	6.09	0.48	1.28e-8	Systolic blood pressure;
TGCT	cis	rs881375	0.967	rs7039505	chr9:123705945	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.44	4.72	0.39	6.28e-6	Rheumatoid arthritis;
TGCT	cis	rs9611519	0.894	rs4821990	chr22:41438710	A/C	cg13695892	chr22:41940480	POLR3H	-0.55	-4.97	-0.41	2.15e-6	Neuroticism;
TGCT	cis	rs1691799	0.867	rs1168339	chr12:66759236	T/G	cg16791601	chr12:66731901	HELB	-0.29	-6.18	-0.49	8.39e-9	White blood cell count (basophil);
TGCT	cis	rs7267979	0.966	rs6083817	chr20:25343998	G/C	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg18252515	chr7:66147081	NA	-1.32	-8.25	-0.6	1.93e-13	Diabetic kidney disease;
TGCT	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg10473311	chr7:158046358	PTPRN2	0.28	4.65	0.39	8.48e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2439831	0.717	rs2470132	chr15:43835481	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.97	7.38	0.55	2.03e-11	Lung cancer in ever smokers;
TGCT	cis	rs2997447	0.655	rs2275950	chr1:26385003	T/C	cg19759804	chr1:25889155	LDLRAP1	0.33	4.56	0.38	1.23e-5	QRS complex (12-leadsum);
TGCT	cis	rs3796352	0.571	rs71301816	chr3:53142071	G/A	cg27565382	chr3:53032988	SFMBT1	0.42	4.76	0.39	5.31e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs36051895	0.626	rs10283563	chr9:5075603	C/T	cg02405213	chr9:5042618	JAK2	-0.86	-12.6	-0.75	5.97e-24	Pediatric autoimmune diseases;
TGCT	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg25319279	chr11:5960081	NA	0.38	4.5	0.37	1.54e-5	DNA methylation (variation);
TGCT	cis	rs765787	0.530	rs4442750	chr15:45535328	G/T	cg24006582	chr15:45444508	DUOX1	-0.25	-5.54	-0.45	1.76e-7	Uric acid levels;
TGCT	cis	rs28595532	0.920	rs114667001	chr4:119786974	T/C	cg14228332	chr4:119757509	SEC24D	1.3	6.62	0.51	9.62e-10	Cannabis dependence symptom count;
TGCT	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg06108461	chr20:60628389	TAF4	0.39	4.73	0.39	5.98e-6	Obesity-related traits;
TGCT	cis	rs473651	0.935	rs578510	chr2:239343140	C/T	cg08773314	chr2:239334832	ASB1	0.45	7.5	0.56	1.07e-11	Multiple system atrophy;
TGCT	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg12311346	chr5:56204834	C5orf35	-0.67	-6.82	-0.52	3.63e-10	Initial pursuit acceleration;
TGCT	cis	rs2243480	1.000	rs160642	chr7:65558373	C/T	cg20637647	chr7:64974828	NA	0.88	5.34	0.43	4.19e-7	Diabetic kidney disease;
TGCT	cis	rs6684514	0.922	rs12022657	chr1:156314147	A/G	cg16558208	chr1:156270281	VHLL	0.48	9.48	0.65	2.27e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs9527	0.614	rs4919691	chr10:104624475	A/C	cg15744005	chr10:104629667	AS3MT	-0.49	-6.24	-0.49	6.21e-9	Arsenic metabolism;
TGCT	cis	rs1538970	1.000	rs4660852	chr1:45848931	A/C	cg05343316	chr1:45956843	TESK2	-0.64	-5.06	-0.41	1.47e-6	Platelet count;
TGCT	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.75	5.41	0.44	3.09e-7	Platelet count;
TGCT	cis	rs1008375	1.000	rs28552744	chr4:17620165	A/G	cg16339924	chr4:17578868	LAP3	0.63	5.13	0.42	1.07e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs651907	0.557	rs13081846	chr3:101383321	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.03	0.41	1.65e-6	Colorectal cancer;
TGCT	cis	rs9921338	0.961	rs66555362	chr16:11388833	G/T	cg00044050	chr16:11439710	C16orf75	-1.0	-7.37	-0.55	2.06e-11	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs9393777	0.513	rs9379895	chr6:26592707	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.49	-4.61	-0.38	9.77e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6495122	0.532	rs2472304	chr15:75044238	G/A	cg10253484	chr15:75165896	SCAMP2	-0.69	-6.0	-0.47	2.05e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
TGCT	cis	rs7246657	0.722	rs10406379	chr19:38036725	G/A	cg18154014	chr19:37997991	ZNF793	0.69	4.63	0.38	9.25e-6	Coronary artery calcification;
TGCT	cis	rs11621121	0.521	rs2127868	chr14:65794327	G/A	cg04536575	chr14:65016802	C14orf50	-0.64	-4.57	-0.38	1.17e-5	N-glycan levels;
TGCT	cis	rs56235845	0.694	rs6875461	chr5:176754665	C/T	cg16006841	chr5:176797999	RGS14	-0.49	-7.2	-0.54	5.08e-11	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs1348850	0.750	rs55792594	chr2:178496468	C/T	cg22681709	chr2:178499509	PDE11A	-0.47	-5.62	-0.45	1.18e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs1576263	0.565	rs9392214	chr6:8374696	T/G	cg01815076	chr6:8435968	SLC35B3	-0.46	-4.49	-0.37	1.63e-5	Photic sneeze reflex;
TGCT	cis	rs6840360	0.615	rs1877188	chr4:152607931	T/C	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.15	-0.48	9.82e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg03388025	chr16:89894329	SPIRE2	0.48	8.44	0.6	6.98e-14	Vitiligo;
TGCT	cis	rs826838	0.967	rs980572	chr12:39127673	A/C	cg26384229	chr12:38710491	ALG10B	0.89	8.38	0.6	9.61e-14	Heart rate;
TGCT	cis	rs453301	0.522	rs1964356	chr8:8853270	G/T	cg06636001	chr8:8085503	FLJ10661	0.71	6.32	0.49	4.32e-9	Joint mobility (Beighton score);
TGCT	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg17971929	chr21:40555470	PSMG1	0.98	9.47	0.65	2.42e-16	Cognitive function;
TGCT	cis	rs2204008	0.806	rs35534445	chr12:38279093	C/T	cg13010199	chr12:38710504	ALG10B	0.64	4.97	0.41	2.15e-6	Bladder cancer;
TGCT	cis	rs10858047	0.883	rs3789624	chr1:115116434	A/G	cg12756093	chr1:115239321	AMPD1	0.47	4.96	0.41	2.27e-6	Autism;
TGCT	cis	rs1008375	0.966	rs3775924	chr4:17585984	T/C	cg18681998	chr4:17616180	MED28	0.94	9.56	0.65	1.44e-16	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7119	0.651	rs34607443	chr15:77847892	C/T	cg27398640	chr15:77910606	LINGO1	-0.28	-5.11	-0.42	1.21e-6	Type 2 diabetes;
TGCT	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	5.71	0.46	8.05e-8	Alzheimer's disease;
TGCT	cis	rs7312933	0.703	rs12370778	chr12:42599696	T/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	5.06	0.41	1.45e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs9486719	0.947	rs72932805	chr6:96902933	T/G	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.77	-0.62	1.18e-14	Migraine;Coronary artery disease;
TGCT	cis	rs3996993	0.752	rs2749026	chr6:52630635	A/G	cg20803780	chr6:52668592	GSTA1	-0.36	-4.59	-0.38	1.06e-5	Hemoglobin concentration;
TGCT	cis	rs360798	0.512	rs2710642	chr2:63149557	G/A	cg17519650	chr2:63277830	OTX1	0.57	4.87	0.4	3.3e-6	Coronary artery disease;
TGCT	cis	rs57590327	0.503	rs11711024	chr3:81910207	T/C	cg07356753	chr3:81810745	GBE1	-0.67	-6.19	-0.49	7.97e-9	Extraversion;
TGCT	cis	rs12579753	1.000	rs10862371	chr12:82249298	C/T	cg07988820	chr12:82153109	PPFIA2	-0.6	-6.61	-0.51	1.02e-9	Resting heart rate;
TGCT	cis	rs3845702	0.736	rs259810	chr2:180787821	T/C	cg01881094	chr2:180872142	CWC22	-1.02	-6.47	-0.5	2.09e-9	Schizophrenia;
TGCT	cis	rs3617	0.539	rs9880619	chr3:52953055	G/A	cg11645453	chr3:52864694	ITIH4	-0.27	-5.37	-0.43	3.76e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg10047753	chr17:41438598	NA	0.94	9.23	0.64	9.06e-16	Menopause (age at onset);
TGCT	cis	rs9611565	0.512	rs768414	chr22:42135751	T/C	cg06481639	chr22:41940642	POLR3H	0.7	6.1	0.48	1.24e-8	Vitiligo;
TGCT	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg11890956	chr21:40555474	PSMG1	-1.09	-12.05	-0.73	1.28e-22	Cognitive function;
TGCT	cis	rs548987	0.507	rs1408268	chr6:25826986	T/A	cg12310025	chr6:25882481	NA	-0.57	-4.61	-0.38	9.67e-6	Homocysteine levels;
TGCT	cis	rs35146811	0.700	rs2950520	chr7:99827148	T/C	cg22906224	chr7:99728672	NA	-0.49	-4.49	-0.37	1.62e-5	Coronary artery disease;
TGCT	cis	rs72627509	0.904	rs7687767	chr4:57824932	C/T	cg26694713	chr4:57773883	REST	-0.75	-6.8	-0.52	3.94e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs13217239	0.646	rs4583981	chr6:26992023	G/T	cg02458000	chr6:26745757	NA	0.51	4.72	0.39	6.22e-6	Schizophrenia;
TGCT	cis	rs478304	0.651	rs10896037	chr11:65503424	A/G	cg27068330	chr11:65405492	SIPA1	-0.94	-9.4	-0.65	3.49e-16	Acne (severe);
TGCT	cis	rs2455799	0.613	rs13080234	chr3:15852492	C/T	cg16303742	chr3:15540471	COLQ	-0.25	-4.88	-0.4	3.19e-6	Mean platelet volume;
TGCT	cis	rs13323323	0.691	rs9814256	chr3:44668037	A/T	cg04389838	chr3:44770851	ZNF501	-0.44	-4.68	-0.39	7.43e-6	IgG glycosylation;
TGCT	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg24675658	chr1:53192096	ZYG11B	-0.71	-7.73	-0.57	3.2e-12	Monocyte count;
TGCT	cis	rs11190604	1.000	rs11190555	chr10:102209160	A/G	cg16342193	chr10:102329863	NA	-0.4	-5.31	-0.43	4.85e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs4455778	0.633	rs2098127	chr7:49007109	A/G	cg26309511	chr7:48887640	NA	-0.5	-5.95	-0.47	2.57e-8	Lung cancer in never smokers;
TGCT	trans	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	1.03	13.16	0.76	2.65e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs7552404	0.696	rs12140121	chr1:76455001	A/G	cg10523679	chr1:76189770	ACADM	0.83	6.78	0.52	4.35e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7677751	0.767	rs11133315	chr4:55082158	G/A	cg17187183	chr4:55093834	PDGFRA	0.54	7.02	0.53	1.26e-10	Corneal astigmatism;
TGCT	cis	rs2115630	0.691	rs61322921	chr15:85163638	T/C	cg11189052	chr15:85197271	WDR73	-0.74	-7.35	-0.55	2.34e-11	P wave terminal force;
TGCT	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg01802117	chr1:53393560	SCP2	0.48	5.82	0.46	4.82e-8	Monocyte count;
TGCT	cis	rs9467773	0.935	rs1056668	chr6:26510605	C/T	cg05738196	chr6:26577821	NA	0.85	11.07	0.71	3.1e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs4372836	0.543	rs3768665	chr2:29005602	G/A	cg09522027	chr2:28974177	PPP1CB	-0.72	-6.88	-0.53	2.59e-10	Body mass index;
TGCT	cis	rs6969780	0.722	rs983185	chr7:27188607	G/A	cg04321618	chr7:27170880	HOXA4	-0.56	-5.49	-0.44	2.19e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs7826238	0.509	rs2948288	chr8:8115304	A/G	cg06636001	chr8:8085503	FLJ10661	0.84	8.38	0.6	9.46e-14	Systolic blood pressure;
TGCT	cis	rs6671200	1.000	rs6671200	chr1:95697529	A/C	cg03123541	chr1:95699097	RWDD3	-0.91	-6.4	-0.5	2.93e-9	Stearic acid (18:0) levels;
TGCT	cis	rs2288278	0.601	rs72829818	chr17:46589885	C/A	cg25032089	chr17:46643351	HOXB3	-0.41	-4.8	-0.4	4.55e-6	Hand grip strength;
TGCT	cis	rs4664308	1.000	rs4665147	chr2:160917062	A/G	cg03641300	chr2:160917029	PLA2R1	-0.26	-6.44	-0.5	2.33e-9	Idiopathic membranous nephropathy;
TGCT	cis	rs758129	0.501	rs12899409	chr15:89868256	A/C	cg24365117	chr15:89879190	POLG	0.34	4.84	0.4	3.8e-6	Schizophrenia;
TGCT	cis	rs539096	0.872	rs2842186	chr1:44035093	A/G	cg12908607	chr1:44402522	ARTN	0.51	5.32	0.43	4.65e-7	Intelligence (multi-trait analysis);
TGCT	trans	rs1864729	1.000	rs2635162	chr8:98283629	C/T	cg08679828	chr8:102218111	ZNF706	-1.1	-7.71	-0.57	3.56e-12	Estradiol plasma levels (breast cancer);
TGCT	cis	rs6964587	0.967	rs6465341	chr7:91596121	G/C	cg22709100	chr7:91322751	NA	0.27	4.48	0.37	1.68e-5	Breast cancer;
TGCT	cis	rs6582630	0.537	rs3942440	chr12:38459672	A/G	cg26384229	chr12:38710491	ALG10B	0.83	7.6	0.56	6.18e-12	Drug-induced liver injury (flucloxacillin);
TGCT	trans	rs877282	0.945	rs11599043	chr10:777972	C/T	cg22713356	chr15:30763199	NA	1.14	10.34	0.68	1.93e-18	Uric acid levels;
TGCT	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg11764359	chr7:65958608	NA	0.61	5.53	0.44	1.84e-7	Aortic root size;
TGCT	cis	rs9916302	0.904	rs801426	chr17:37441109	C/T	cg15445000	chr17:37608096	MED1	-0.33	-4.7	-0.39	6.89e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs17122693	0.551	rs1812181	chr14:51052669	C/T	cg04730355	chr14:51134070	SAV1	1.19	11.83	0.73	4.33e-22	Cognitive performance;
TGCT	cis	rs208520	0.754	rs851593	chr6:66875783	C/T	cg07460842	chr6:66804631	NA	0.91	9.43	0.65	2.99e-16	Exhaled nitric oxide output;
TGCT	cis	rs7772486	0.875	rs854146	chr6:146341033	A/G	cg05347473	chr6:146136440	FBXO30	0.53	5.02	0.41	1.73e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3008870	1.000	rs2009319	chr1:67481070	G/T	cg11518657	chr1:67396239	MIER1	0.54	4.65	0.39	8.44e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs35146811	0.806	rs1534310	chr7:99699169	A/T	cg22906224	chr7:99728672	NA	0.5	4.46	0.37	1.82e-5	Coronary artery disease;
TGCT	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg21171335	chr12:122356390	WDR66	0.7	7.03	0.53	1.24e-10	Mean corpuscular volume;
TGCT	trans	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg27523141	chr10:43048294	ZNF37B	0.71	8.26	0.6	1.84e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs67460515	0.892	rs16832082	chr3:161043571	A/G	cg03342759	chr3:160939853	NMD3	-0.49	-5.29	-0.43	5.28e-7	Parkinson's disease;
TGCT	trans	rs9388451	0.626	rs3799712	chr6:126075103	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.87	-9.72	-0.66	6.01e-17	Brugada syndrome;
TGCT	trans	rs629535	1.000	rs629535	chr8:70007938	C/T	cg21567404	chr3:27674614	NA	-0.55	-8.31	-0.6	1.43e-13	Dupuytren's disease;
TGCT	cis	rs35306767	0.714	rs66797613	chr10:1090469	C/T	cg18964960	chr10:1102726	WDR37	0.68	4.77	0.39	5.02e-6	Eosinophil percentage of granulocytes;
TGCT	cis	rs7917772	0.636	rs7069489	chr10:104525371	A/G	cg05855489	chr10:104503620	C10orf26	-0.65	-5.38	-0.43	3.64e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7267979	1.000	rs2027004	chr20:25350618	C/T	cg03522245	chr20:25566470	NINL	-0.61	-6.63	-0.51	9.11e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs5417	0.662	rs8067500	chr17:7172631	A/G	cg25256661	chr17:7137939	DVL2	0.71	7.26	0.55	3.73e-11	Diastolic blood pressure;
TGCT	cis	rs7131987	0.903	rs918873	chr12:29390501	G/T	cg09582351	chr12:29534625	ERGIC2	-0.23	-4.52	-0.38	1.43e-5	QT interval;
TGCT	cis	rs7091068	0.507	rs913046	chr10:95408484	A/C	cg20715218	chr10:95462985	C10orf4	0.48	6.0	0.47	2.01e-8	Urinary tract infection frequency;
TGCT	cis	rs28493229	0.881	rs10404911	chr19:41174903	A/T	cg11601297	chr19:41224147	ITPKC;ADCK4	0.59	5.61	0.45	1.27e-7	Kawasaki disease;
TGCT	cis	rs595982	0.702	rs623520	chr19:49369943	A/G	cg21252483	chr19:49399788	TULP2	-0.26	-4.57	-0.38	1.18e-5	Red cell distribution width;
TGCT	cis	rs57920188	0.535	rs10915658	chr1:4092921	T/C	cg20703997	chr1:4087676	NA	0.48	5.74	0.46	6.87e-8	Interleukin-17 levels;
TGCT	cis	rs12220898	0.749	rs2377978	chr10:50476193	C/A	cg09603381	chr10:49954066	WDFY4	0.38	4.45	0.37	1.85e-5	Inflammatory biomarkers;
TGCT	cis	rs9467773	0.595	rs13207371	chr6:26591074	G/A	cg02458000	chr6:26745757	NA	0.63	6.04	0.48	1.68e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg07424592	chr7:64974309	NA	-1.27	-7.28	-0.55	3.29e-11	Diabetic kidney disease;
TGCT	cis	rs28595532	0.920	rs116612909	chr4:119749823	C/T	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs10174077	0.687	rs4664491	chr2:152479986	C/T	cg06191203	chr2:152266755	RIF1	-0.62	-5.8	-0.46	5.06e-8	Squamous cell lung carcinoma;
TGCT	cis	rs9581857	0.579	rs76578450	chr13:27982656	C/A	cg22138327	chr13:27999177	GTF3A	0.71	5.23	0.43	6.91e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs6570726	0.935	rs436212	chr6:145849400	G/A	cg23711669	chr6:146136114	FBXO30	0.68	6.67	0.51	7.58e-10	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs208520	0.690	rs12213928	chr6:66762978	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	11.29	0.71	9.4e-21	Exhaled nitric oxide output;
TGCT	cis	rs12682352	0.715	rs332039	chr8:8723651	C/G	cg17143192	chr8:8559678	CLDN23	0.45	4.64	0.38	8.65e-6	Neuroticism;
TGCT	cis	rs950169	0.922	rs12912934	chr15:85114447	C/T	cg17173187	chr15:85201210	NMB	0.47	4.93	0.4	2.62e-6	Schizophrenia;
TGCT	cis	rs370915	0.542	rs1895844	chr4:187833759	C/T	cg19519643	chr4:187840862	NA	-0.22	-4.49	-0.37	1.6e-5	Gout;
TGCT	cis	rs7786808	0.564	rs10267128	chr7:158198490	G/A	cg01191920	chr7:158217561	PTPRN2	0.37	5.4	0.44	3.23e-7	Obesity-related traits;
TGCT	cis	rs933688	1.000	rs11959525	chr5:90703840	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.91	7.87	0.58	1.49e-12	Smoking behavior;
TGCT	cis	rs6969780	0.545	rs983184	chr7:27188379	C/T	cg04321618	chr7:27170880	HOXA4	-0.52	-5.33	-0.43	4.47e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs2235642	0.691	rs2281235	chr16:1603535	T/C	cg08296037	chr16:1584118	IFT140;TMEM204	-0.31	-5.64	-0.45	1.08e-7	Coronary artery disease;
TGCT	cis	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg22857025	chr5:266934	NA	-0.31	-6.32	-0.49	4.33e-9	Breast cancer;
TGCT	cis	rs11874712	0.931	rs8095031	chr18:43666861	T/C	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	5.23	0.42	7.11e-7	Migraine - clinic-based;
TGCT	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg03303774	chr4:1407052	NA	-0.32	-4.88	-0.4	3.21e-6	Obesity-related traits;
TGCT	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg06634786	chr22:41940651	POLR3H	0.69	6.54	0.51	1.45e-9	Vitiligo;
TGCT	cis	rs77140172	0.655	rs79387006	chr4:89672775	A/T	cg01026744	chr4:89619053	NAP1L5;HERC3	1.15	5.23	0.43	6.86e-7	Post bronchodilator FEV1;
TGCT	cis	rs6882076	1.000	rs13167071	chr5:156373637	G/C	cg12943317	chr5:156479607	HAVCR1	-0.3	-5.24	-0.43	6.73e-7	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
TGCT	cis	rs4566357	0.787	rs6748048	chr2:227822440	T/C	cg11843606	chr2:227700838	RHBDD1	-0.61	-5.26	-0.43	6.15e-7	Coronary artery disease;
TGCT	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-5.79	-0.46	5.39e-8	Alzheimer's disease;
TGCT	cis	rs12497850	0.897	rs9884022	chr3:48956862	G/C	cg06212747	chr3:49208901	KLHDC8B	0.61	5.62	0.45	1.19e-7	Parkinson's disease;
TGCT	cis	rs28595532	0.920	rs55758547	chr4:119769475	T/C	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs3806843	0.576	rs265316	chr5:140290843	T/C	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.44	-5.32	-0.43	4.6e-7	Depressive symptoms (multi-trait analysis);
TGCT	trans	rs2727020	0.619	rs11040300	chr11:49269984	C/A	cg15704280	chr7:45808275	SEPT13	0.68	7.13	0.54	7.39e-11	Coronary artery disease;
TGCT	trans	rs17685	0.753	rs1637044	chr7:75703744	T/C	cg19862616	chr7:65841803	NCRNA00174	0.52	9.01	0.63	3.02e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs4242434	0.819	rs7843128	chr8:22473465	T/C	cg03733263	chr8:22462867	KIAA1967	1.08	17.06	0.84	2.57e-34	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs1215050	0.791	rs2123099	chr4:98803456	A/G	cg17366294	chr4:99064904	C4orf37	0.52	5.59	0.45	1.4e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg20818283	chr2:191399100	TMEM194B	0.49	4.44	0.37	1.94e-5	Pulse pressure;
TGCT	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg02788857	chr8:22132959	PIWIL2	0.27	5.06	0.41	1.45e-6	Hypertriglyceridemia;
TGCT	cis	rs950027	0.620	rs1145093	chr15:45649813	C/A	cg26924012	chr15:45694286	SPATA5L1	0.79	8.86	0.62	6.92e-15	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg25036284	chr2:26402008	FAM59B	-0.57	-4.97	-0.41	2.15e-6	Gut microbiome composition (summer);
TGCT	cis	rs2013441	1.000	rs2120282	chr17:20209474	C/T	cg23224458	chr17:20280056	CCDC144C	-0.41	-4.88	-0.4	3.25e-6	Obesity-related traits;
TGCT	cis	rs60843830	1.000	rs36216559	chr2:262335	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.72	6.93	0.53	2.07e-10	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs17122693	1.000	rs72679549	chr14:51050822	G/A	cg04730355	chr14:51134070	SAV1	1.25	8.82	0.62	8.76e-15	Cognitive performance;
TGCT	cis	rs3734905	1.000	rs77336201	chr6:169942337	T/G	cg20469989	chr6:170102314	C6orf120;WDR27	-0.88	-4.67	-0.39	7.59e-6	HIV-1 control;
TGCT	cis	rs11587400	0.532	rs2268700	chr1:115228879	T/G	cg12756093	chr1:115239321	AMPD1	-0.33	-4.87	-0.4	3.31e-6	Autism;
TGCT	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg18402987	chr7:1209562	NA	0.7	5.67	0.45	9.66e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9659323	1.000	rs10923714	chr1:119512913	C/T	cg07961512	chr1:119535619	NA	0.44	5.07	0.41	1.4e-6	Body mass index;
TGCT	cis	rs10089	1.000	rs10478803	chr5:127488855	T/C	cg19767477	chr5:127420684	SLC12A2	-0.43	-4.52	-0.38	1.43e-5	Ileal carcinoids;
TGCT	cis	rs1215050	0.791	rs165237	chr4:98712029	T/C	cg05340658	chr4:99064831	C4orf37	0.44	5.52	0.44	1.85e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg16680214	chr1:154839983	KCNN3	-0.42	-9.22	-0.64	9.71e-16	Prostate cancer;
TGCT	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg05368731	chr17:41323189	NBR1	1.18	13.93	0.78	3.99e-27	Menopause (age at onset);
TGCT	cis	rs4319547	0.956	rs10847179	chr12:123040985	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.69	-5.49	-0.44	2.22e-7	Body mass index;
TGCT	cis	rs9467773	0.596	rs2451751	chr6:26646714	T/C	cg26531700	chr6:26746687	NA	0.51	4.61	0.38	9.86e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs12579753	0.719	rs4418884	chr12:82277006	C/T	cg07988820	chr12:82153109	PPFIA2	-0.42	-4.44	-0.37	1.93e-5	Resting heart rate;
TGCT	cis	rs4746818	0.892	rs12437	chr10:70864065	T/C	cg11621586	chr10:70884670	VPS26A	1.15	9.19	0.64	1.14e-15	Left atrial antero-posterior diameter;
TGCT	cis	rs10751667	0.643	rs10794352	chr11:946294	T/C	cg06064525	chr11:970664	AP2A2	-0.35	-8.29	-0.6	1.6e-13	Alzheimer's disease (late onset);
TGCT	cis	rs59948050	1	rs59948050	chr1:15915157	T/G	cg05660106	chr1:15850417	CASP9	0.88	6.35	0.5	3.65e-9	Morning vs. evening chronotype;
TGCT	cis	rs9522267	0.737	rs9522285	chr13:112230701	C/T	cg10483660	chr13:112241077	NA	-0.28	-4.6	-0.38	1.01e-5	Hepatitis;
TGCT	cis	rs10791097	0.667	rs2155358	chr11:130740357	T/C	cg14779329	chr11:130786720	SNX19	0.28	4.82	0.4	4.09e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9952991	0.941	rs7237497	chr18:12777325	T/C	cg23544223	chr18:12777786	NA	0.64	6.12	0.48	1.15e-8	Inflammatory skin disease;
TGCT	cis	rs71435601	0.628	rs532300	chr2:21381608	C/A	cg25035485	chr2:21266500	APOB	0.51	4.48	0.37	1.66e-5	Cholesterol, total;
TGCT	cis	rs611744	0.967	rs702802	chr8:109218238	G/A	cg21045802	chr8:109455806	TTC35	0.52	4.72	0.39	6.21e-6	Dupuytren's disease;
TGCT	cis	rs7726839	0.540	rs3749618	chr5:602650	A/G	cg20362242	chr5:692897	TPPP	0.5	4.49	0.37	1.64e-5	Obesity-related traits;
TGCT	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.29	-4.49	-0.37	1.64e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs12286929	0.651	rs12274772	chr11:115098768	C/T	cg04017736	chr11:115827165	NA	-0.2	-4.95	-0.41	2.42e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs986417	0.748	rs1956552	chr14:60942685	A/G	cg27398547	chr14:60952738	C14orf39	1.49	10.81	0.7	1.38e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs2230307	0.536	rs506044	chr1:100611931	A/G	cg24955406	chr1:100503596	HIAT1	-0.73	-4.96	-0.41	2.27e-6	Carotid intima media thickness;
TGCT	cis	rs9916302	0.706	rs28482878	chr17:37497100	A/G	cg07936489	chr17:37558343	FBXL20	0.87	6.27	0.49	5.47e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg03213289	chr20:61660250	NA	0.68	9.99	0.67	1.36e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9914988	0.943	rs2046759	chr17:27138817	T/C	cg20469991	chr17:27169893	C17orf63	-0.72	-5.09	-0.42	1.28e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs9790314	0.846	rs4856738	chr3:160986637	C/G	cg03342759	chr3:160939853	NMD3	-0.48	-5.23	-0.43	6.93e-7	Morning vs. evening chronotype;
TGCT	cis	rs67478160	0.619	rs11160759	chr14:104231542	C/T	cg26031613	chr14:104095156	KLC1	-0.63	-6.57	-0.51	1.25e-9	Schizophrenia;
TGCT	cis	rs5167	0.566	rs934427	chr19:45478816	T/G	cg13119609	chr19:45449297	APOC2	0.23	4.62	0.38	9.31e-6	Blood protein levels;
TGCT	trans	rs4824093	0.610	rs73441787	chr22:50269646	A/G	cg09872104	chr7:134855509	C7orf49	-0.94	-7.68	-0.57	4.2e-12	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs35883536	0.626	rs10783140	chr1:101042083	A/G	cg10298815	chr1:101004474	GPR88	-0.25	-4.73	-0.39	6.03e-6	Monocyte count;
TGCT	cis	rs9534288	0.797	rs7328081	chr13:46611695	T/C	cg15192986	chr13:46630673	CPB2	-0.53	-7.75	-0.57	2.87e-12	Blood protein levels;
TGCT	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg08219700	chr8:58056026	NA	0.38	4.71	0.39	6.56e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9457247	1.000	rs364283	chr6:167383750	C/T	cg23791538	chr6:167370224	RNASET2	-0.5	-4.98	-0.41	2.08e-6	Crohn's disease;
TGCT	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg26513180	chr16:89883248	FANCA	-1.08	-15.47	-0.81	1e-30	Vitiligo;
TGCT	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg05665937	chr4:1216051	CTBP1	0.26	4.89	0.4	3.02e-6	Obesity-related traits;
TGCT	cis	rs651907	0.557	rs7651406	chr3:101393296	C/T	cg12386194	chr3:101231763	SENP7	0.51	5.04	0.41	1.61e-6	Colorectal cancer;
TGCT	cis	rs1538970	0.851	rs61788285	chr1:45919234	A/C	cg05343316	chr1:45956843	TESK2	0.86	6.87	0.53	2.7e-10	Platelet count;
TGCT	cis	rs9611565	0.592	rs9611612	chr22:41961189	T/C	cg13695892	chr22:41940480	POLR3H	-0.87	-8.29	-0.6	1.6e-13	Vitiligo;
TGCT	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg00343986	chr7:65444356	GUSB	0.26	6.07	0.48	1.42e-8	Aortic root size;
TGCT	cis	rs4822044	0.561	rs132781	chr22:42046122	T/G	cg03806693	chr22:41940476	POLR3H	1.1	11.41	0.72	4.6e-21	Cannabis dependence symptom count;
TGCT	cis	rs2204008	0.557	rs11520191	chr12:38197057	T/A	cg13010199	chr12:38710504	ALG10B	0.62	4.87	0.4	3.35e-6	Bladder cancer;
TGCT	cis	rs7474896	0.515	rs624359	chr10:38299132	T/C	cg13720705	chr10:37990370	NA	-0.35	-4.73	-0.39	5.99e-6	Obesity (extreme);
TGCT	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg20203395	chr5:56204925	C5orf35	-0.59	-5.12	-0.42	1.12e-6	Initial pursuit acceleration;
TGCT	cis	rs587847	0.558	rs681830	chr15:37676786	T/A	cg16890051	chr15:37175029	LOC145845	-0.37	-4.44	-0.37	1.95e-5	Intraocular pressure;
TGCT	trans	rs1814175	0.817	rs4881623	chr11:49804991	C/T	cg15704280	chr7:45808275	SEPT13	-0.7	-8.08	-0.59	4.89e-13	Height;
TGCT	cis	rs35146811	0.735	rs1727138	chr7:99815247	A/G	cg22906224	chr7:99728672	NA	-0.49	-4.45	-0.37	1.88e-5	Coronary artery disease;
TGCT	cis	rs9868809	0.772	rs2302295	chr3:48690110	T/C	cg00383909	chr3:49044727	WDR6	0.99	5.68	0.45	8.95e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs1538970	0.924	rs1007858	chr1:45912005	C/T	cg05343316	chr1:45956843	TESK2	0.76	6.19	0.49	7.93e-9	Platelet count;
TGCT	cis	rs60871478	0.947	rs62432239	chr7:794576	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.44	4.44	0.37	1.96e-5	Cerebrospinal P-tau181p levels;
TGCT	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	7.4	0.55	1.78e-11	Schizophrenia;
TGCT	cis	rs950169	0.887	rs62029593	chr15:84955180	A/G	cg11189052	chr15:85197271	WDR73	0.81	6.22	0.49	6.89e-9	Schizophrenia;
TGCT	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg21285383	chr16:89894308	SPIRE2	-0.45	-7.18	-0.54	5.5e-11	Vitiligo;
TGCT	cis	rs2439831	0.850	rs8032649	chr15:44134922	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.68	-4.47	-0.37	1.74e-5	Lung cancer in ever smokers;
TGCT	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.07	-9.63	-0.65	1.01e-16	Platelet count;
TGCT	cis	rs2932538	0.961	rs6537747	chr1:113179597	C/T	cg22162597	chr1:113214053	CAPZA1	-0.26	-5.82	-0.46	4.83e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs4664308	0.967	rs17241792	chr2:160915205	C/T	cg03641300	chr2:160917029	PLA2R1	-0.26	-6.38	-0.5	3.26e-9	Idiopathic membranous nephropathy;
TGCT	cis	rs3749237	0.595	rs1568661	chr3:49520958	A/G	cg03060546	chr3:49711283	APEH	0.75	8.45	0.6	6.48e-14	Resting heart rate;
TGCT	cis	rs10832169	0.967	rs12797530	chr11:14063439	C/T	cg04547675	chr11:13986162	SPON1	0.51	4.51	0.38	1.49e-5	Blood protein levels;
TGCT	cis	rs1555895	0.611	rs2892159	chr10:855061	G/A	cg02193355	chr10:851439	NA	0.21	4.78	0.39	4.82e-6	Survival in rectal cancer;
TGCT	cis	rs1372520	0.577	rs2737021	chr4:90739992	T/A	cg20003494	chr4:90757398	SNCA	-0.66	-5.2	-0.42	7.87e-7	Neuroticism;
TGCT	cis	rs9611519	0.780	rs5751071	chr22:41656332	G/A	cg03806693	chr22:41940476	POLR3H	-0.75	-7.3	-0.55	3e-11	Neuroticism;
TGCT	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.2	0.42	8.14e-7	Menopause (age at onset);
TGCT	trans	rs7819412	0.654	rs4840550	chr8:11029029	T/G	cg06636001	chr8:8085503	FLJ10661	-0.81	-7.4	-0.55	1.82e-11	Triglycerides;
TGCT	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg02353165	chr6:42928485	GNMT	0.99	10.14	0.67	5.89e-18	Plasma homocysteine levels (post-methionine load test);
TGCT	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg11890956	chr21:40555474	PSMG1	-0.72	-6.47	-0.5	2.07e-9	Cognitive function;
TGCT	cis	rs3849570	1.000	rs9842330	chr3:81814688	G/A	cg07356753	chr3:81810745	GBE1	-0.82	-7.62	-0.56	5.6e-12	Waist circumference;Body mass index;
TGCT	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg19318889	chr4:1322082	MAEA	0.28	6.7	0.52	6.39e-10	Longevity;
TGCT	trans	rs2727020	0.658	rs7120136	chr11:49384358	A/C	cg03929089	chr4:120376271	NA	-0.75	-8.63	-0.61	2.53e-14	Coronary artery disease;
TGCT	cis	rs2153535	0.562	rs6901765	chr6:8455436	A/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs4285028	0.948	rs34158925	chr3:121678465	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.77	-6.55	-0.51	1.35e-9	Multiple sclerosis;
TGCT	cis	rs3806843	0.576	rs246074	chr5:140307969	C/G	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.43	-5.33	-0.43	4.42e-7	Depressive symptoms (multi-trait analysis);
TGCT	trans	rs2760061	0.819	rs964941	chr1:228193857	G/A	cg16006296	chr10:38738647	LOC399744	-0.31	-7.24	-0.55	4.17e-11	Diastolic blood pressure;
TGCT	cis	rs3806843	0.521	rs192231	chr5:140248539	C/T	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	0.42	5.06	0.41	1.48e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs6893807	0.778	rs1501672	chr5:87963761	A/G	cg24804195	chr5:87968844	LOC645323	0.81	4.9	0.4	2.87e-6	Body mass index;
TGCT	cis	rs9905704	0.647	rs3809723	chr17:57061978	T/G	cg12560992	chr17:57184187	TRIM37	0.58	5.17	0.42	9.08e-7	Testicular germ cell tumor;
TGCT	cis	rs35306767	0.855	rs2050944	chr10:918910	T/C	cg20503657	chr10:835505	NA	0.74	10.27	0.68	2.77e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs9807989	0.507	rs1420097	chr2:103009354	C/G	cg03938978	chr2:103052716	IL18RAP	-0.26	-5.19	-0.42	8.29e-7	Asthma;
TGCT	cis	rs6725041	0.819	rs1521645	chr2:213091216	A/G	cg16329650	chr2:213403929	ERBB4	-0.53	-4.58	-0.38	1.12e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs4689592	0.503	rs4689064	chr4:7055603	A/G	cg25660036	chr4:7070649	GRPEL1	0.56	4.46	0.37	1.79e-5	Monocyte percentage of white cells;
TGCT	cis	rs7312933	0.703	rs12370778	chr12:42599696	T/A	cg19980929	chr12:42632907	YAF2	0.47	6.46	0.5	2.13e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg10802521	chr3:52805072	NEK4	-0.71	-8.64	-0.61	2.37e-14	Electroencephalogram traits;
TGCT	cis	rs713587	0.713	rs62143001	chr2:25288675	G/A	cg01884057	chr2:25150051	NA	-0.39	-8.01	-0.58	7.24e-13	Body mass index in non-asthmatics;
TGCT	cis	rs76419734	0.558	rs10516520	chr4:106534110	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.81	4.68	0.39	7.31e-6	Post bronchodilator FEV1;
TGCT	cis	rs7572733	0.534	rs1983359	chr2:198805098	C/T	cg00792783	chr2:198669748	PLCL1	0.57	5.23	0.43	6.99e-7	Dermatomyositis;
TGCT	cis	rs2932538	0.922	rs12143068	chr1:113138110	A/G	cg22162597	chr1:113214053	CAPZA1	0.27	5.98	0.47	2.24e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs9560113	0.573	rs9560134	chr13:112244011	C/T	cg10483660	chr13:112241077	NA	0.36	5.51	0.44	1.97e-7	Menarche (age at onset);
TGCT	cis	rs6089829	0.851	rs10854168	chr20:61669550	A/G	cg08045932	chr20:61659980	NA	0.5	8.69	0.62	1.75e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs72717009	0.756	rs10494359	chr1:161463876	G/C	cg23840854	chr1:161414152	NA	-1.02	-6.37	-0.5	3.42e-9	Rheumatoid arthritis;
TGCT	cis	rs1903068	0.962	rs17773813	chr4:56008969	G/A	cg01777861	chr4:56023843	NA	0.55	6.49	0.5	1.86e-9	Endometriosis;
TGCT	cis	rs7584330	0.518	rs74003108	chr2:238448000	T/C	cg14458575	chr2:238380390	NA	0.43	4.55	0.38	1.25e-5	Prostate cancer;
TGCT	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs1857353	1.000	rs12408226	chr1:75889444	G/A	cg11838876	chr1:75668600	SLC44A5	-0.51	-4.81	-0.4	4.23e-6	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs903263	0.965	rs11163907	chr1:84597396	T/C	cg09664975	chr1:84543551	PRKACB	0.5	4.67	0.39	7.62e-6	Breast cancer (male);
TGCT	trans	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg11887960	chr12:57824829	NA	1.2	9.65	0.65	8.99e-17	Obesity-related traits;
TGCT	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg06238570	chr21:40685208	BRWD1	0.58	5.16	0.42	9.63e-7	Cognitive function;
TGCT	cis	rs3820928	0.967	rs4675113	chr2:227766339	G/A	cg11843606	chr2:227700838	RHBDD1	-0.51	-4.49	-0.37	1.6e-5	Pulmonary function;
TGCT	cis	rs9467773	1.000	rs9467782	chr6:26542773	G/A	cg05738196	chr6:26577821	NA	0.88	12.5	0.75	1.03e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs2692947	0.644	rs772175	chr2:96944553	G/A	cg22654517	chr2:96458247	NA	0.22	4.85	0.4	3.67e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs17376456	0.877	rs10061080	chr5:93420559	A/G	cg25358565	chr5:93447407	FAM172A	0.94	8.34	0.6	1.2e-13	Diabetic retinopathy;
TGCT	cis	rs2066819	0.901	rs1274490	chr12:56649601	A/G	cg26714650	chr12:56694279	CS	1.51	8.32	0.6	1.33e-13	Psoriasis vulgaris;
TGCT	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg12963246	chr6:28129442	ZNF389	0.45	4.48	0.37	1.64e-5	Parkinson's disease;
TGCT	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.62	4.95	0.41	2.34e-6	Lung function (FEV1/FVC);
TGCT	cis	rs10779751	0.690	rs743577	chr1:11119135	G/A	cg08854313	chr1:11322531	MTOR	0.84	8.17	0.59	2.98e-13	Body mass index;
TGCT	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg08280861	chr8:58055591	NA	0.36	4.98	0.41	2.08e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2440129	0.591	rs312466	chr17:6899221	G/A	cg02493798	chr17:6899577	ALOX12	-0.43	-5.06	-0.41	1.47e-6	Tonsillectomy;
TGCT	cis	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg12570787	chr5:219185	SDHA;CCDC127	0.66	4.49	0.37	1.62e-5	Breast cancer;
TGCT	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg03060546	chr3:49711283	APEH	0.53	5.14	0.42	1.05e-6	Menarche (age at onset);
TGCT	cis	rs8016982	0.633	rs4363794	chr14:81674327	C/A	cg01989461	chr14:81687754	GTF2A1	0.75	7.13	0.54	7.17e-11	Schizophrenia;
TGCT	cis	rs7914558	0.966	rs2065977	chr10:104729415	C/T	cg15744005	chr10:104629667	AS3MT	-0.4	-4.97	-0.41	2.21e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs3796352	1.000	rs35720014	chr3:52982110	A/C	cg07884673	chr3:53033167	SFMBT1	0.63	5.74	0.46	6.83e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg20637647	chr7:64974828	NA	0.88	5.12	0.42	1.13e-6	Diabetic kidney disease;
TGCT	cis	rs7552404	0.731	rs5745458	chr1:76345429	G/A	cg22875332	chr1:76189707	ACADM	-0.68	-7.11	-0.54	7.96e-11	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7017914	0.905	rs1908036	chr8:71922324	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.55	-5.1	-0.42	1.24e-6	Bone mineral density;
TGCT	cis	rs7655841	0.704	rs3113490	chr4:129965671	T/C	cg26347359	chr4:129759716	PHF17	-0.43	-4.98	-0.41	2.07e-6	Chronic obstructive pulmonary disease (moderate to severe);
TGCT	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg16680214	chr1:154839983	KCNN3	-0.36	-7.26	-0.55	3.81e-11	Prostate cancer;
TGCT	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg05896524	chr21:47604654	C21orf56	0.42	4.45	0.37	1.91e-5	Testicular germ cell tumor;
TGCT	cis	rs9921222	0.509	rs3743883	chr16:404750	T/C	cg10349874	chr16:420996	TMEM8A;MRPL28	-0.34	-6.24	-0.49	6.35e-9	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs12477438	0.798	rs13393860	chr2:99590397	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-8.65	-0.61	2.22e-14	Chronic sinus infection;
TGCT	cis	rs6867032	0.958	rs4975795	chr5:2015390	G/A	cg26168224	chr5:2018326	NA	0.43	7.81	0.57	2.03e-12	Gut microbiome composition (winter);
TGCT	cis	rs11792861	0.888	rs11794648	chr9:111829792	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.5	4.9	0.4	2.89e-6	Menarche (age at onset);
TGCT	cis	rs12200560	0.505	rs2015196	chr6:97075331	G/C	cg06623918	chr6:96969491	KIAA0776	0.59	5.03	0.41	1.71e-6	Coronary heart disease;
TGCT	cis	rs9818758	0.607	rs9850917	chr3:49286983	A/G	cg07636037	chr3:49044803	WDR6	-1.04	-5.13	-0.42	1.09e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs7666738	0.822	rs9992360	chr4:98937123	T/C	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6912958	0.781	rs3934838	chr6:88284699	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-5.06	-0.41	1.45e-6	Monocyte percentage of white cells;
TGCT	cis	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg20637647	chr7:64974828	NA	0.95	5.3	0.43	5.09e-7	Diabetic kidney disease;
TGCT	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg05368731	chr17:41323189	NBR1	1.07	12.07	0.73	1.17e-22	Menopause (age at onset);
TGCT	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs3008870	0.755	rs3736905	chr1:67392614	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.8	8.47	0.61	5.86e-14	Lymphocyte percentage of white cells;
TGCT	cis	rs7412746	0.658	rs2230061	chr1:150727539	G/A	cg04414720	chr1:150670196	GOLPH3L	0.37	4.57	0.38	1.15e-5	Melanoma;
TGCT	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg17178900	chr1:205818956	PM20D1	0.67	9.42	0.65	3.15e-16	Menarche (age at onset);
TGCT	cis	rs9399135	0.967	rs17638970	chr6:135320063	A/G	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.36e-6	Red blood cell count;
TGCT	cis	rs10779751	1.000	rs4845854	chr1:11261929	T/C	cg08854313	chr1:11322531	MTOR	0.93	8.83	0.62	8.25e-15	Body mass index;
TGCT	cis	rs137699	0.652	rs137707	chr22:39751401	T/C	cg24399712	chr22:39784796	NA	-0.81	-6.51	-0.5	1.66e-9	IgG glycosylation;
TGCT	cis	rs6545883	1.000	rs778763	chr2:61785639	C/G	cg15711740	chr2:61764176	XPO1	-0.57	-5.23	-0.43	6.89e-7	Tuberculosis;
TGCT	cis	rs709400	0.663	rs72708893	chr14:103929535	G/A	cg26031613	chr14:104095156	KLC1	0.86	9.53	0.65	1.71e-16	Body mass index;
TGCT	cis	rs3096299	0.685	rs4785676	chr16:89553624	T/C	cg06640241	chr16:89574553	SPG7	0.8	9.08	0.63	2.12e-15	Multiple myeloma (IgH translocation);
TGCT	cis	rs7586879	0.796	rs916486	chr2:25082629	C/A	cg01884057	chr2:25150051	NA	0.26	4.59	0.38	1.08e-5	Body mass index;
TGCT	cis	rs926938	0.552	rs360613	chr1:115394864	C/G	cg12756093	chr1:115239321	AMPD1	0.4	5.79	0.46	5.56e-8	Autism;
TGCT	cis	rs2469997	0.925	rs2470004	chr8:120358445	C/T	cg00681363	chr8:120844660	TAF2	0.69	4.48	0.37	1.64e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs4242434	0.927	rs2291234	chr8:22464390	T/C	cg21658235	chr8:22456391	C8orf58	0.43	4.53	0.38	1.37e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs2239547	0.618	rs3733047	chr3:52871929	A/G	cg11645453	chr3:52864694	ITIH4	-0.32	-5.59	-0.45	1.38e-7	Schizophrenia;
TGCT	cis	rs11748684	1.000	rs59463904	chr5:42559473	T/C	cg01169772	chr5:41904236	C5orf51	-0.92	-4.5	-0.37	1.54e-5	Response to taxane treatment (docetaxel);
TGCT	trans	rs2688608	0.592	rs12253482	chr10:75496130	G/A	cg13918328	chr10:52500089	ASAH2B	0.68	6.77	0.52	4.51e-10	Inflammatory bowel disease;
TGCT	cis	rs1541995	1.000	rs4984607	chr15:96314174	G/A	cg00882281	chr15:96346592	NA	0.29	4.68	0.39	7.26e-6	Photic sneeze reflex;
TGCT	cis	rs7666738	0.830	rs35213297	chr4:98984049	T/C	cg17366294	chr4:99064904	C4orf37	0.68	6.94	0.53	1.95e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs13242816	0.881	rs35210394	chr7:116104911	C/G	cg02799643	chr7:116139180	CAV2	-0.45	-5.38	-0.44	3.5e-7	P wave duration;
TGCT	cis	rs4455778	0.580	rs3924858	chr7:49121340	G/A	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs4727027	0.840	rs12670633	chr7:148796707	G/A	cg23583168	chr7:148888333	NA	-0.72	-9.11	-0.63	1.8e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs7412746	0.621	rs7518156	chr1:150945794	A/C	cg04414720	chr1:150670196	GOLPH3L	0.39	4.6	0.38	1.04e-5	Melanoma;
TGCT	cis	rs751728	0.689	rs3763257	chr6:33773696	T/A	cg13859433	chr6:33739653	LEMD2	-0.38	-6.72	-0.52	5.77e-10	Crohn's disease;
TGCT	cis	rs2334880	0.678	rs57821244	chr16:71553791	G/C	cg06353428	chr16:71660113	MARVELD3	-1.32	-7.58	-0.56	6.9e-12	Malaria;
TGCT	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg04154034	chr17:28927549	LRRC37B2	0.74	4.56	0.38	1.22e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs11122272	0.735	rs2486730	chr1:231534987	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-6.64	-0.51	8.59e-10	Hemoglobin concentration;
TGCT	cis	rs9467773	0.620	rs2451731	chr6:26624822	A/C	cg11502198	chr6:26597334	ABT1	0.54	4.97	0.41	2.14e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs910316	0.737	rs175048	chr14:75479894	A/T	cg08847533	chr14:75593920	NEK9	-0.83	-8.92	-0.63	5.18e-15	Height;
TGCT	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.12	0.54	7.8e-11	Prudent dietary pattern;
TGCT	cis	rs2841233	0.558	rs10145270	chr14:105349891	G/A	cg03469805	chr14:105330648	KIAA0284	-0.47	-5.52	-0.44	1.87e-7	IgG glycosylation;
TGCT	cis	rs9549367	0.789	rs9577220	chr13:113908294	T/A	cg00898013	chr13:113819073	PROZ	-0.43	-5.55	-0.45	1.68e-7	Platelet distribution width;
TGCT	cis	rs2227564	0.620	rs12783161	chr10:75572201	G/C	cg19442545	chr10:75533431	FUT11	-0.31	-4.48	-0.37	1.65e-5	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs9296661	0.522	rs2182505	chr6:51653864	T/C	cg20180370	chr6:50691003	TFAP2D	-0.49	-4.7	-0.39	6.71e-6	Weight loss (gastric bypass surgery);
TGCT	cis	rs7412746	0.658	rs8444	chr1:150938571	G/A	cg04414720	chr1:150670196	GOLPH3L	0.4	4.62	0.38	9.58e-6	Melanoma;
TGCT	trans	rs62103177	0.759	rs7227794	chr18:77610925	C/T	cg05926928	chr17:57297772	GDPD1	1.22	11.62	0.72	1.41e-21	Opioid sensitivity;
TGCT	cis	rs2797160	1.000	rs1739371	chr6:126011291	G/A	cg05901451	chr6:126070800	HEY2	0.75	6.33	0.49	4.14e-9	Endometrial cancer;
TGCT	cis	rs6582630	0.555	rs11182202	chr12:38476451	C/G	cg13010199	chr12:38710504	ALG10B	0.58	4.72	0.39	6.16e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs56235845	0.694	rs6876677	chr5:176755342	T/C	cg16006841	chr5:176797999	RGS14	0.49	7.24	0.55	4.06e-11	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs1514658	0.903	rs7661210	chr4:119280167	G/T	cg21605333	chr4:119757512	SEC24D	-0.51	-4.52	-0.38	1.43e-5	Congenital heart disease (maternal effect);
TGCT	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg11764359	chr7:65958608	NA	0.58	5.34	0.43	4.22e-7	Aortic root size;
TGCT	cis	rs3096299	0.632	rs8051537	chr16:89544384	T/A	cg08392591	chr16:89556376	ANKRD11	0.55	5.21	0.42	7.49e-7	Multiple myeloma (IgH translocation);
TGCT	cis	rs4319547	0.698	rs10744217	chr12:122942070	A/G	cg23029597	chr12:123009494	RSRC2	-0.27	-4.53	-0.38	1.38e-5	Body mass index;
TGCT	cis	rs6809651	0.524	rs6444106	chr3:185811495	C/T	cg00760338	chr3:185826511	ETV5	-0.78	-6.3	-0.49	4.82e-9	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
TGCT	cis	rs3818285	0.679	rs552419	chr10:111630883	G/T	cg00817464	chr10:111662876	XPNPEP1	0.32	5.69	0.46	8.6e-8	Superior crus of antihelix expression;
TGCT	cis	rs2832191	0.646	rs2832210	chr21:30508723	T/G	cg24692254	chr21:30365293	RNF160	-0.61	-5.41	-0.44	3.08e-7	Dental caries;
TGCT	cis	rs4795419	1	rs4795419	chr17:38166003	G/A	cg17467752	chr17:38218738	THRA	0.55	5.32	0.43	4.76e-7	Monocyte percentage of white cells;
TGCT	cis	rs793571	0.503	rs1427281	chr15:58959273	T/C	cg05156742	chr15:59063176	FAM63B	0.51	4.89	0.4	3.1e-6	Schizophrenia;
TGCT	cis	rs9926296	0.609	rs4785709	chr16:89796665	G/A	cg27121462	chr16:89883253	FANCA	-0.56	-5.28	-0.43	5.47e-7	Vitiligo;
TGCT	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg05665937	chr4:1216051	CTBP1	0.25	4.7	0.39	6.84e-6	Obesity-related traits;
TGCT	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.47	-4.88	-0.4	3.15e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7929679	0.840	rs1396890	chr11:34780715	T/C	cg18414381	chr11:34642885	EHF	-0.23	-4.6	-0.38	1.03e-5	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
TGCT	cis	rs4319547	0.656	rs10773088	chr12:122828069	A/T	cg08088222	chr12:122070432	ORAI1	0.26	4.66	0.39	8.01e-6	Body mass index;
TGCT	cis	rs10858047	0.883	rs9308267	chr1:115174843	C/T	cg12756093	chr1:115239321	AMPD1	-0.45	-4.73	-0.39	6.09e-6	Autism;
TGCT	cis	rs7914558	0.966	rs3977751	chr10:104920232	A/G	cg15744005	chr10:104629667	AS3MT	-0.39	-4.74	-0.39	5.81e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs12620999	0.941	rs10929213	chr2:238020637	A/G	cg23555395	chr2:238036564	NA	-0.29	-4.89	-0.4	3e-6	Systemic lupus erythematosus;
TGCT	cis	rs7428	0.545	rs1053561	chr2:85546052	A/G	cg03728395	chr2:85555865	TGOLN2	-0.29	-5.21	-0.42	7.53e-7	Ear protrusion;
TGCT	cis	rs7605378	0.528	rs281791	chr2:200850402	A/G	cg17644776	chr2:200775616	C2orf69	-0.32	-7.18	-0.54	5.5e-11	Osteoporosis;
TGCT	cis	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg07424592	chr7:64974309	NA	1.4	8.42	0.6	7.87e-14	Diabetic kidney disease;
TGCT	cis	rs5771225	0.505	rs2341111	chr22:50690322	G/C	cg16473166	chr22:50639996	SELO	0.72	5.96	0.47	2.39e-8	Late-onset Alzheimer's disease;
TGCT	cis	rs2069837	0.515	rs62449526	chr7:22797667	T/C	cg00365470	chr7:22893924	NA	-0.61	-4.5	-0.37	1.55e-5	Longevity;
TGCT	cis	rs2832191	0.692	rs2245734	chr21:30359965	C/T	cg24692254	chr21:30365293	RNF160	0.96	11.17	0.71	1.77e-20	Dental caries;
TGCT	cis	rs7568458	0.527	rs35416445	chr2:85773659	A/G	cg02493740	chr2:85810744	VAMP5	-0.28	-5.26	-0.43	6.1e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs7267979	0.903	rs6115101	chr20:25229564	C/A	cg03522245	chr20:25566470	NINL	0.6	6.58	0.51	1.21e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3008870	0.920	rs1925413	chr1:67417101	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.1	11.91	0.73	2.83e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg12310025	chr6:25882481	NA	-0.65	-6.72	-0.52	6.03e-10	Blood metabolite levels;
TGCT	cis	rs4319547	0.695	rs10744211	chr12:122931820	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.71	-5.49	-0.44	2.16e-7	Body mass index;
TGCT	cis	rs6088580	0.634	rs6088502	chr20:33037644	A/T	cg06115741	chr20:33292138	TP53INP2	0.53	4.67	0.39	7.67e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs9952991	0.941	rs34920518	chr18:12783086	A/G	cg23598886	chr18:12777645	NA	-0.61	-5.58	-0.45	1.42e-7	Inflammatory skin disease;
TGCT	cis	rs56399783	0.614	rs73047355	chr7:2758145	G/A	cg19731401	chr7:2775893	GNA12	0.39	5.36	0.43	3.88e-7	Childhood ear infection;
TGCT	cis	rs17473412	0.677	rs11745493	chr5:122847622	A/G	cg15125798	chr5:122621645	NA	-0.57	-5.2	-0.42	8.05e-7	Total body bone mineral density;
TGCT	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg08280861	chr8:58055591	NA	0.53	5.96	0.47	2.44e-8	Developmental language disorder (linguistic errors);
TGCT	cis	rs651907	0.535	rs34161138	chr3:101510388	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	4.85	0.4	3.68e-6	Colorectal cancer;
TGCT	cis	rs2239547	0.522	rs9846976	chr3:53007995	T/C	cg11645453	chr3:52864694	ITIH4	0.34	5.54	0.45	1.76e-7	Schizophrenia;
TGCT	cis	rs17221829	0.733	rs10830326	chr11:89389110	T/C	cg02982614	chr11:89391479	FOLH1B	-0.25	-4.46	-0.37	1.8e-5	Anxiety in major depressive disorder;
TGCT	cis	rs17376456	0.825	rs17374166	chr5:93238655	T/C	cg25358565	chr5:93447407	FAM172A	1.01	8.13	0.59	3.77e-13	Diabetic retinopathy;
TGCT	cis	rs7666738	0.753	rs10029372	chr4:98859002	T/C	cg18180107	chr4:99064573	C4orf37	0.55	5.14	0.42	1.03e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs16867321	0.671	rs17455235	chr2:181476447	G/A	cg23363182	chr2:181467187	NA	-0.47	-4.93	-0.4	2.56e-6	Obesity;
TGCT	cis	rs1552244	0.554	rs2272122	chr3:10047975	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.33	-4.95	-0.41	2.39e-6	Alzheimer's disease;
TGCT	cis	rs2067615	0.579	rs1811458	chr12:107203683	G/A	cg15890332	chr12:107067104	RFX4	0.28	5.57	0.45	1.52e-7	Heart rate;
TGCT	cis	rs3772130	0.962	rs9878086	chr3:121488353	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.54	4.89	0.4	3.07e-6	Cognitive performance;
TGCT	cis	rs854765	0.624	rs11652144	chr17:17733934	C/T	cg09796270	chr17:17721594	SREBF1	-0.27	-5.16	-0.42	9.57e-7	Total body bone mineral density;
TGCT	cis	rs6138458	0.816	rs2151463	chr20:24911819	A/C	cg26195577	chr20:24973756	C20orf3	1.2	12.04	0.73	1.35e-22	Blood protein levels;
TGCT	cis	rs5769765	0.773	rs6520065	chr22:50294470	A/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.11	-12.1	-0.74	9.56e-23	Schizophrenia;
TGCT	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg07061783	chr6:25882402	NA	-0.59	-5.5	-0.44	2.03e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg10150615	chr22:24372951	LOC391322	-1.01	-13.1	-0.76	3.84e-25	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs8014204	0.762	rs8016389	chr14:75287554	T/C	cg06637938	chr14:75390232	RPS6KL1	0.58	5.12	0.42	1.15e-6	Caffeine consumption;
TGCT	cis	rs2075165	0.901	rs759329	chr1:156230936	A/G	cg20302342	chr1:156215951	PAQR6	0.39	5.67	0.45	9.49e-8	Tonsillectomy;
TGCT	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg12310025	chr6:25882481	NA	-0.59	-5.31	-0.43	4.96e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs10875746	0.951	rs4760690	chr12:48563653	G/A	cg20731937	chr12:48336164	NA	0.62	4.94	0.41	2.46e-6	Longevity (90 years and older);
TGCT	cis	rs7584330	0.738	rs13398506	chr2:238374824	A/G	cg14458575	chr2:238380390	NA	0.48	7.62	0.56	5.63e-12	Prostate cancer;
TGCT	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.82	-11.05	-0.7	3.56e-20	Birth weight;
TGCT	cis	rs5769765	0.908	rs9616217	chr22:50318946	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.45	5.05	0.41	1.56e-6	Schizophrenia;
TGCT	cis	rs2404618	0.624	rs4338133	chr8:1477507	T/C	cg13402656	chr8:1511478	DLGAP2	-0.37	-6.16	-0.48	9.52e-9	Lung cancer;
TGCT	cis	rs12908161	1.000	rs58416181	chr15:85264461	G/A	cg11189052	chr15:85197271	WDR73	0.75	6.29	0.49	5.02e-9	Schizophrenia;
TGCT	cis	rs478304	0.651	rs7110576	chr11:65512057	T/G	cg10518572	chr11:65560635	OVOL1	-0.23	-4.52	-0.38	1.42e-5	Acne (severe);
TGCT	cis	rs1472147	1.000	rs3736609	chr7:128509319	G/A	cg00260937	chr7:128520193	KCP	0.47	6.74	0.52	5.36e-10	Calcium levels;
TGCT	trans	rs9650657	0.572	rs4841465	chr8:10819854	C/T	cg15556689	chr8:8085844	FLJ10661	-0.95	-10.16	-0.67	5.18e-18	Neuroticism;
TGCT	cis	rs4689388	0.782	rs4262051	chr4:6281775	G/A	cg25554036	chr4:6271136	WFS1	0.57	7.77	0.57	2.63e-12	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs734999	0.549	rs867436	chr1:2523723	C/T	cg18854424	chr1:2615690	NA	0.48	5.7	0.46	8.11e-8	Ulcerative colitis;
TGCT	cis	rs6728642	0.908	rs11901495	chr2:98017804	A/G	cg26665480	chr2:98280029	ACTR1B	0.95	5.34	0.43	4.21e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	cis	rs75686122	0.892	rs79475473	chr8:104610018	A/T	cg04852977	chr8:104510831	NA	0.59	4.45	0.37	1.92e-5	Cocaine dependence;
TGCT	cis	rs950169	0.922	rs11633534	chr15:85124642	C/T	cg17173187	chr15:85201210	NMB	0.47	4.87	0.4	3.39e-6	Schizophrenia;
TGCT	cis	rs137699	0.604	rs137702	chr22:39750158	T/C	cg01416388	chr22:39784598	NA	-0.61	-4.84	-0.4	3.85e-6	IgG glycosylation;
TGCT	cis	rs425277	0.583	rs925905	chr1:2044037	T/C	cg03732007	chr1:2071316	PRKCZ	-0.26	-5.86	-0.47	3.95e-8	Height;
TGCT	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg22535103	chr8:58192502	C8orf71	-0.42	-4.79	-0.4	4.7e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7681440	0.904	rs28507349	chr4:90767063	G/A	cg20003494	chr4:90757398	SNCA	-0.62	-5.93	-0.47	2.74e-8	Dementia with Lewy bodies;
TGCT	cis	rs2549003	0.966	rs2706386	chr5:131832687	C/T	cg21138405	chr5:131827807	IRF1	-0.2	-4.99	-0.41	2.03e-6	Asthma (sex interaction);
TGCT	cis	rs17401966	0.838	rs946503	chr1:10308631	C/G	cg19773385	chr1:10388646	KIF1B	0.22	4.78	0.39	4.92e-6	Hepatocellular carcinoma;
TGCT	cis	rs2963155	0.518	rs72801029	chr5:142625806	T/C	cg17617527	chr5:142782415	NR3C1	0.88	6.29	0.49	5e-9	Breast cancer;
TGCT	cis	rs4654899	0.758	rs6694455	chr1:21352185	C/T	cg01072550	chr1:21505969	NA	-0.56	-9.17	-0.64	1.28e-15	Superior frontal gyrus grey matter volume;
TGCT	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg06481639	chr22:41940642	POLR3H	0.73	6.72	0.52	5.93e-10	Vitiligo;
TGCT	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg07507251	chr3:52567010	NT5DC2	0.49	6.96	0.53	1.74e-10	Bipolar disorder;
TGCT	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.29	-4.49	-0.37	1.64e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg06238570	chr21:40685208	BRWD1	0.79	8.63	0.61	2.42e-14	Cognitive function;
TGCT	cis	rs17712049	0.908	rs62447147	chr7:48198596	A/G	cg16849860	chr7:48352531	ABCA13	0.32	5.26	0.43	6.19e-7	Refractive astigmatism;
TGCT	cis	rs6835098	0.923	rs7671278	chr4:174095769	A/G	cg08422745	chr4:174089978	GALNT7	-0.9	-10.08	-0.67	7.91e-18	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs6089829	0.888	rs4809268	chr20:61675249	C/G	cg18188782	chr20:61659543	NA	0.44	4.88	0.4	3.17e-6	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2013441	0.931	rs12937827	chr17:20033202	G/C	cg18979559	chr17:20280153	CCDC144C	0.44	4.61	0.38	9.78e-6	Obesity-related traits;
TGCT	cis	rs7666738	0.830	rs6846739	chr4:99016647	G/A	cg05340658	chr4:99064831	C4orf37	0.48	5.43	0.44	2.92e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4237845	0.788	rs6581157	chr12:58288793	C/T	cg02175503	chr12:58329896	NA	0.5	4.69	0.39	7.13e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg06028808	chr11:68637592	NA	0.55	7.12	0.54	7.56e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.96	7.8	0.57	2.16e-12	Platelet count;
TGCT	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg11890956	chr21:40555474	PSMG1	-0.7	-6.88	-0.53	2.68e-10	Menarche (age at onset);
TGCT	cis	rs1395	0.744	rs9653564	chr2:27472618	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.62	7.72	0.57	3.38e-12	Blood metabolite levels;
TGCT	cis	rs2180341	1.000	rs13218061	chr6:127653758	G/A	cg27446573	chr6:127587934	RNF146	1.12	10.11	0.67	6.87e-18	Breast cancer;
TGCT	cis	rs12142240	0.698	rs41534051	chr1:46828734	A/G	cg00530320	chr1:46809349	NSUN4	0.29	5.88	0.47	3.51e-8	Menopause (age at onset);
TGCT	cis	rs6782228	1.000	rs35604103	chr3:128334852	C/T	cg15113803	chr3:129247119	RHO	0.18	4.56	0.38	1.2e-5	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
TGCT	cis	rs1348850	0.874	rs2166558	chr2:178373652	G/T	cg22681709	chr2:178499509	PDE11A	-0.35	-4.55	-0.38	1.27e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs11122272	0.701	rs2790887	chr1:231523724	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-6.94	-0.53	1.98e-10	Hemoglobin concentration;
TGCT	cis	rs644799	0.542	rs10831417	chr11:95467262	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	-0.58	-5.67	-0.45	9.29e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg25036284	chr2:26402008	FAM59B	-0.61	-4.9	-0.4	2.92e-6	Gut microbiome composition (summer);
TGCT	cis	rs2204008	0.744	rs2222344	chr12:38406832	T/G	cg13010199	chr12:38710504	ALG10B	0.55	4.46	0.37	1.84e-5	Bladder cancer;
TGCT	cis	rs478304	0.934	rs1193496	chr11:65537556	C/T	cg17480646	chr11:65405466	SIPA1	-0.45	-5.41	-0.44	3.11e-7	Acne (severe);
TGCT	cis	rs595982	0.546	rs12461075	chr19:49399821	G/A	cg21252483	chr19:49399788	TULP2	-0.3	-5.05	-0.41	1.54e-6	Red cell distribution width;
TGCT	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.31	-4.82	-0.4	4.12e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	trans	rs10504390	0.656	rs74776773	chr8:66544150	G/A	cg26037026	chr7:1641922	NA	-0.64	-6.84	-0.52	3.29e-10	IgG glycosylation;
TGCT	cis	rs35883536	0.647	rs2783703	chr1:101040794	T/C	cg10298815	chr1:101004474	GPR88	0.24	4.51	0.38	1.47e-5	Monocyte count;
TGCT	cis	rs6754311	0.731	rs748841	chr2:136558157	C/T	cg07169764	chr2:136633963	MCM6	-0.61	-5.61	-0.45	1.25e-7	Mosquito bite size;
TGCT	cis	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg09021430	chr5:549028	NA	-0.37	-5.16	-0.42	9.7e-7	Lung disease severity in cystic fibrosis;
TGCT	cis	rs62244186	0.535	rs59726036	chr3:44850074	G/T	cg15687855	chr3:44754131	ZNF502	-0.55	-6.65	-0.51	8.38e-10	Depressive symptoms;
TGCT	cis	rs2153535	0.526	rs1796689	chr6:8536433	A/C	cg23788917	chr6:8435910	SLC35B3	0.67	5.94	0.47	2.69e-8	Motion sickness;
TGCT	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg00343986	chr7:65444356	GUSB	-0.2	-4.51	-0.38	1.51e-5	Aortic root size;
TGCT	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg04267008	chr7:1944627	MAD1L1	-0.35	-4.72	-0.39	6.16e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs12220898	0.749	rs10776553	chr10:50482929	C/T	cg25968469	chr10:49687287	ARHGAP22	0.25	4.57	0.38	1.14e-5	Inflammatory biomarkers;
TGCT	cis	rs6728302	0.557	rs111524519	chr2:233271763	C/A	cg06555452	chr2:233241558	NA	0.35	4.69	0.39	7.05e-6	Height;
TGCT	cis	rs2885056	0.830	rs7259124	chr19:10671664	T/C	cg04833646	chr19:10679720	CDKN2D	0.99	9.8	0.66	3.83e-17	Red cell distribution width;
TGCT	cis	rs36051895	0.664	rs10815153	chr9:5092864	G/C	cg02405213	chr9:5042618	JAK2	-0.79	-11.01	-0.7	4.39e-20	Pediatric autoimmune diseases;
TGCT	cis	rs751728	0.965	rs2013381	chr6:33763837	C/T	cg13859433	chr6:33739653	LEMD2	-0.39	-7.08	-0.54	9.45e-11	Crohn's disease;
TGCT	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg06028605	chr16:24865363	SLC5A11	0.4	4.44	0.37	1.98e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg09365446	chr1:150670422	GOLPH3L	0.31	4.64	0.38	8.7e-6	Tonsillectomy;
TGCT	cis	rs9902453	0.904	rs4547389	chr17:28364768	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.81	-7.67	-0.57	4.37e-12	Coffee consumption (cups per day);
TGCT	cis	rs7017914	1.000	rs7017914	chr8:71591203	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.03	-0.41	1.69e-6	Bone mineral density;
TGCT	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg22920501	chr2:26401640	FAM59B	0.81	6.36	0.5	3.52e-9	Gut microbiome composition (summer);
TGCT	cis	rs12497850	0.897	rs7373778	chr3:48836392	C/G	cg05785598	chr3:49045655	WDR6	0.36	4.75	0.39	5.46e-6	Parkinson's disease;
TGCT	cis	rs57590327	0.503	rs13080520	chr3:81850742	T/C	cg07356753	chr3:81810745	GBE1	-0.54	-4.68	-0.39	7.39e-6	Extraversion;
TGCT	cis	rs7100689	0.516	rs10788546	chr10:82034854	T/C	cg01528321	chr10:82214614	TSPAN14	0.64	6.22	0.49	6.87e-9	Post bronchodilator FEV1;
TGCT	trans	rs66573146	1.000	rs66519732	chr4:6990569	C/G	cg07817883	chr1:32538562	TMEM39B	1.67	8.39	0.6	9.16e-14	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs2243480	1.000	rs6964530	chr7:65718851	G/C	cg20637647	chr7:64974828	NA	-0.91	-5.06	-0.41	1.44e-6	Diabetic kidney disease;
TGCT	cis	rs10851411	0.779	rs61071861	chr15:42710219	G/C	cg23803468	chr15:43513504	EPB42	0.27	5.29	0.43	5.45e-7	Glucose homeostasis traits;
TGCT	trans	rs7726839	0.540	rs28364691	chr5:664084	G/A	cg11887960	chr12:57824829	NA	1.15	9.91	0.66	2.07e-17	Obesity-related traits;
TGCT	cis	rs2228479	0.850	rs45567439	chr16:89814604	G/A	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs9611565	0.512	rs5751148	chr22:42139078	A/G	cg03806693	chr22:41940476	POLR3H	1.06	10.94	0.7	6.7e-20	Vitiligo;
TGCT	cis	rs1008375	0.835	rs9760627	chr4:17651508	C/T	cg10189774	chr4:17578691	LAP3	0.6	5.19	0.42	8.2e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs709400	0.633	rs45441198	chr14:104002611	T/C	cg12935359	chr14:103987150	CKB	-0.35	-5.24	-0.43	6.73e-7	Body mass index;
TGCT	cis	rs10875746	0.904	rs10875750	chr12:48545630	C/T	cg20731937	chr12:48336164	NA	0.62	4.94	0.41	2.46e-6	Longevity (90 years and older);
TGCT	cis	rs7819412	0.549	rs28887839	chr8:11000413	C/T	cg21775007	chr8:11205619	TDH	-0.58	-5.5	-0.44	2.07e-7	Triglycerides;
TGCT	cis	rs12042938	0.935	rs1094657	chr1:231773407	G/C	cg04892437	chr1:231737901	TSNAX-DISC1	0.45	4.69	0.39	7.15e-6	Neuranatomic and neurocognitive phenotypes;
TGCT	trans	rs57221529	0.709	rs72707024	chr5:667915	G/A	cg11887960	chr12:57824829	NA	1.14	9.34	0.64	4.86e-16	Lung disease severity in cystic fibrosis;
TGCT	cis	rs6988636	0.901	rs2602001	chr8:124195974	T/C	cg22384356	chr8:124195192	FAM83A	0.38	5.04	0.41	1.59e-6	Urinary uromodulin levels;
TGCT	cis	rs9325144	0.600	rs10785621	chr12:38744912	C/T	cg26384229	chr12:38710491	ALG10B	0.61	5.61	0.45	1.26e-7	Morning vs. evening chronotype;
TGCT	cis	rs6121246	0.567	rs6120879	chr20:30202961	T/C	cg18721089	chr20:30220636	NA	-0.64	-6.86	-0.52	2.84e-10	Mean corpuscular hemoglobin;
TGCT	cis	rs56104184	0.775	rs17272700	chr19:49391770	G/A	cg21252483	chr19:49399788	TULP2	-0.42	-5.89	-0.47	3.47e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs11105298	0.891	rs10858864	chr12:89846230	C/T	cg00757033	chr12:89920650	WDR51B	0.34	5.36	0.43	4e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs9486719	0.749	rs1009596	chr6:96843688	A/G	cg18709589	chr6:96969512	KIAA0776	0.75	5.13	0.42	1.1e-6	Migraine;Coronary artery disease;
TGCT	cis	rs1865760	0.566	rs9467672	chr6:26083904	C/T	cg16482183	chr6:26056742	HIST1H1C	0.58	4.97	0.41	2.13e-6	Height;
TGCT	cis	rs17221829	0.733	rs11018689	chr11:89367791	G/A	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.63	-0.38	9.04e-6	Anxiety in major depressive disorder;
TGCT	cis	rs2282802	0.651	rs6863474	chr5:139630862	C/T	cg01081189	chr5:139537190	NA	0.29	5.24	0.43	6.57e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs614226	0.935	rs7956998	chr12:120994932	G/A	cg10072921	chr12:121022843	NA	-0.44	-4.74	-0.39	5.78e-6	Type 1 diabetes nephropathy;
TGCT	cis	rs6547741	1.000	rs2384654	chr2:27847364	C/T	cg27432699	chr2:27873401	GPN1	0.18	4.56	0.38	1.19e-5	Oral cavity cancer;
TGCT	cis	rs473651	0.904	rs508274	chr2:239337723	G/A	cg21699342	chr2:239360505	ASB1	0.18	4.89	0.4	3.05e-6	Multiple system atrophy;
TGCT	cis	rs9372498	0.536	rs72952793	chr6:118892979	T/A	cg07617317	chr6:118971624	C6orf204	0.49	5.19	0.42	8.37e-7	Diastolic blood pressure;
TGCT	cis	rs9788721	0.592	rs28564957	chr15:78906107	C/A	cg06917634	chr15:78832804	PSMA4	-0.68	-5.56	-0.45	1.59e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
TGCT	trans	rs7824557	0.564	rs2736301	chr8:11236413	C/T	cg15556689	chr8:8085844	FLJ10661	-0.74	-6.68	-0.51	7.12e-10	Retinal vascular caliber;
TGCT	cis	rs8020441	0.541	rs2131837	chr14:51154779	A/G	cg04730355	chr14:51134070	SAV1	1.28	10.23	0.68	3.46e-18	Cognitive performance;
TGCT	cis	rs4563143	0.675	rs17498203	chr19:29279734	G/T	cg03161606	chr19:29218774	NA	0.62	6.0	0.47	2e-8	Methadone dose in opioid dependence;
TGCT	cis	rs7267979	0.903	rs2474766	chr20:25246153	A/G	cg16686733	chr20:25566563	NINL	0.59	6.06	0.48	1.53e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs28374715	0.733	rs9568	chr15:41573612	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.83	-13.31	-0.77	1.22e-25	Ulcerative colitis;
TGCT	cis	rs17253792	0.822	rs2147114	chr14:56077118	C/T	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs910316	0.783	rs11850751	chr14:75590113	A/T	cg08847533	chr14:75593920	NEK9	0.95	10.55	0.69	5.83e-19	Height;
TGCT	cis	rs11209185	0.509	rs9436357	chr1:68452488	C/T	cg22082780	chr1:68452167	NA	0.32	5.05	0.41	1.56e-6	Itch intensity from mosquito bite adjusted by bite size;
TGCT	trans	rs1814175	0.616	rs1851848	chr11:49992254	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.67	-0.69	2.92e-19	Height;
TGCT	cis	rs28595532	0.702	rs72670252	chr4:119337546	A/C	cg21605333	chr4:119757512	SEC24D	0.87	5.49	0.44	2.14e-7	Cannabis dependence symptom count;
TGCT	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	4.87	0.4	3.32e-6	Menopause (age at onset);
TGCT	cis	rs7267979	0.657	rs6107073	chr20:25716363	T/C	cg16686733	chr20:25566563	NINL	0.47	4.59	0.38	1.06e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2412208	0.585	rs11120824	chr1:7113591	G/A	cg20434152	chr1:7120926	CAMTA1	-0.31	-5.04	-0.41	1.6e-6	Survival in sporadic amyotrophic lateral sclerosis;
TGCT	cis	rs789859	0.833	rs9834693	chr3:194383487	G/A	cg21106136	chr3:194405973	FAM43A	-0.39	-5.15	-0.42	9.92e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
TGCT	cis	rs2016266	0.819	rs6580942	chr12:53662624	C/A	cg16917193	chr12:54089295	NA	0.69	5.04	0.41	1.62e-6	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs7666738	0.612	rs6830172	chr4:99093947	G/A	cg17366294	chr4:99064904	C4orf37	0.71	6.93	0.53	2.04e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2191566	0.639	rs7260075	chr19:44566766	T/C	cg03039196	chr19:44506973	ZNF230	0.52	4.45	0.37	1.88e-5	Acute lymphoblastic leukemia (childhood);
TGCT	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg25036284	chr2:26402008	FAM59B	-0.56	-4.85	-0.4	3.62e-6	Gut microbiome composition (summer);
TGCT	cis	rs1153858	1.000	rs2461701	chr15:45703391	G/A	cg14582100	chr15:45693742	SPATA5L1	0.47	5.62	0.45	1.22e-7	Homoarginine levels;
TGCT	cis	rs453301	0.686	rs7814328	chr8:8876229	T/C	cg06636001	chr8:8085503	FLJ10661	-0.66	-5.46	-0.44	2.51e-7	Joint mobility (Beighton score);
TGCT	cis	rs7552404	0.924	rs12136754	chr1:76230232	C/A	cg10523679	chr1:76189770	ACADM	0.88	9.35	0.64	4.67e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7267979	0.903	rs6115118	chr20:25246734	G/A	cg16686733	chr20:25566563	NINL	0.59	6.06	0.48	1.53e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7412746	0.658	rs12090215	chr1:150893660	C/A	cg04414720	chr1:150670196	GOLPH3L	0.37	4.46	0.37	1.81e-5	Melanoma;
TGCT	cis	rs899997	0.862	rs12912524	chr15:78952756	G/A	cg00061860	chr15:78953028	NA	-0.33	-5.94	-0.47	2.65e-8	Coronary artery disease or large artery stroke;
TGCT	cis	rs9814567	1.000	rs9864439	chr3:134298671	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.91	-8.83	-0.62	8.17e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs9527	0.521	rs12259163	chr10:104961477	A/G	cg15744005	chr10:104629667	AS3MT	-0.41	-4.76	-0.39	5.36e-6	Arsenic metabolism;
TGCT	cis	rs9303401	1.000	rs6503877	chr17:56841948	C/T	cg12560992	chr17:57184187	TRIM37	0.53	5.44	0.44	2.71e-7	Cognitive test performance;
TGCT	trans	rs13064411	0.542	rs2087130	chr3:113226983	T/A	cg00307254	chr3:126706825	PLXNA1	0.34	6.78	0.52	4.36e-10	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs3796352	1.000	rs13091844	chr3:53010271	C/T	cg07884673	chr3:53033167	SFMBT1	0.62	6.19	0.49	8.26e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs2439831	0.681	rs540388	chr15:43606494	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	6.75	0.52	4.98e-10	Lung cancer in ever smokers;
TGCT	cis	rs9486719	0.948	rs11152953	chr6:96894305	C/T	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.86	-0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs7523050	0.730	rs77425121	chr1:109417677	C/A	cg08274380	chr1:109419600	GPSM2	1.35	6.86	0.52	2.89e-10	Fat distribution (HIV);
TGCT	cis	rs6138458	1.000	rs11905625	chr20:24977065	A/C	cg26195577	chr20:24973756	C20orf3	1.22	12.1	0.74	9.98e-23	Blood protein levels;
TGCT	cis	rs9372498	0.536	rs9320660	chr6:118956827	A/T	cg21191810	chr6:118973309	C6orf204	-0.38	-4.97	-0.41	2.14e-6	Diastolic blood pressure;
TGCT	cis	rs7772486	0.875	rs2777479	chr6:146309178	C/A	cg05347473	chr6:146136440	FBXO30	0.51	4.76	0.39	5.34e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9457247	1.000	rs436707	chr6:167388843	T/C	cg23791538	chr6:167370224	RNASET2	-0.5	-4.98	-0.41	2.08e-6	Crohn's disease;
TGCT	cis	rs72945132	0.714	rs72947077	chr11:70197431	A/G	cg00319359	chr11:70116639	PPFIA1	0.97	7.02	0.53	1.3e-10	Coronary artery disease;
TGCT	cis	rs6740322	0.895	rs6544643	chr2:43560072	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.37	-6.02	-0.48	1.86e-8	Coronary artery disease;
TGCT	cis	rs4595586	0.545	rs7970850	chr12:39397878	T/C	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs7772486	0.790	rs2247206	chr6:146216184	C/T	cg05347473	chr6:146136440	FBXO30	0.5	4.9	0.4	2.94e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs713587	0.646	rs2384061	chr2:25135620	C/T	cg01884057	chr2:25150051	NA	0.32	6.29	0.49	4.99e-9	Body mass index in non-asthmatics;
TGCT	cis	rs4925386	0.765	rs6142737	chr20:60919800	C/G	cg06026331	chr20:60912101	LAMA5	0.4	6.81	0.52	3.82e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs244731	0.959	rs10037110	chr5:176658066	A/T	cg17509989	chr5:176798049	RGS14	-0.62	-7.54	-0.56	8.56e-12	Urate levels in lean individuals;
TGCT	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg11890956	chr21:40555474	PSMG1	1.13	12.73	0.75	2.92e-24	Cognitive function;
TGCT	cis	rs6074578	0.679	rs12624951	chr20:139409	G/A	cg16931068	chr20:139680	DEFB127	0.27	4.52	0.38	1.4e-5	Hirschsprung disease;
TGCT	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg03264133	chr6:25882463	NA	-0.57	-6.07	-0.48	1.45e-8	Blood metabolite levels;
TGCT	cis	rs13191362	1.000	rs35754151	chr6:163074867	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.02	7.3	0.55	2.97e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs6901004	0.803	rs354531	chr6:111548933	C/T	cg15721981	chr6:111408429	SLC16A10	-0.54	-4.65	-0.39	8.38e-6	Blood metabolite levels;
TGCT	cis	rs9325144	0.624	rs10783333	chr12:39118931	A/T	cg26384229	chr12:38710491	ALG10B	0.62	5.86	0.47	3.95e-8	Morning vs. evening chronotype;
TGCT	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg18876405	chr7:65276391	NA	-0.37	-5.85	-0.46	4.19e-8	Aortic root size;
TGCT	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg11890956	chr21:40555474	PSMG1	-1.12	-11.72	-0.73	8.04e-22	Cognitive function;
TGCT	cis	rs9303401	0.659	rs36109237	chr17:56653834	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs8070740	0.898	rs9303192	chr17:5324836	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.49	4.88	0.4	3.15e-6	Menopause (age at onset);
TGCT	cis	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg06636001	chr8:8085503	FLJ10661	0.59	5.03	0.41	1.71e-6	Mood instability;
TGCT	cis	rs10927875	0.691	rs1048261	chr1:16340951	A/T	cg21385522	chr1:16154831	NA	0.6	6.34	0.49	3.95e-9	Dilated cardiomyopathy;
TGCT	cis	rs11696845	1.000	rs11696845	chr20:43371320	C/T	cg25301532	chr20:43378953	KCNK15	0.4	4.53	0.38	1.37e-5	Obesity-related traits;
TGCT	cis	rs9467773	0.620	rs2494700	chr6:26631306	C/T	cg11502198	chr6:26597334	ABT1	0.54	4.97	0.41	2.14e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs832540	0.931	rs2662040	chr5:56246610	A/G	cg12311346	chr5:56204834	C5orf35	0.44	4.71	0.39	6.6e-6	Coronary artery disease;
TGCT	cis	rs7647973	1.000	rs11719762	chr3:49409002	G/C	cg07636037	chr3:49044803	WDR6	0.66	5.33	0.43	4.45e-7	Menarche (age at onset);
TGCT	cis	rs7666738	0.800	rs13107147	chr4:99028753	C/T	cg05340658	chr4:99064831	C4orf37	0.51	5.82	0.46	4.75e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1801251	0.896	rs2305141	chr2:233684402	A/G	cg25237894	chr2:233734115	C2orf82	-0.29	-5.37	-0.43	3.72e-7	Coronary artery disease;
TGCT	cis	rs3849570	0.961	rs10154945	chr3:81833766	A/C	cg07356753	chr3:81810745	GBE1	-0.82	-7.62	-0.56	5.6e-12	Waist circumference;Body mass index;
TGCT	cis	rs6570726	0.837	rs419991	chr6:145864212	C/T	cg05347473	chr6:146136440	FBXO30	0.49	4.54	0.38	1.29e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11711311	1.000	rs9288983	chr3:113488699	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.79	-7.32	-0.55	2.75e-11	IgG glycosylation;
TGCT	cis	rs4765905	0.737	rs2370414	chr12:2368396	A/G	cg08884539	chr12:3361725	TSPAN9	-0.26	-4.45	-0.37	1.85e-5	Schizophrenia;
TGCT	cis	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg18252515	chr7:66147081	NA	-1.26	-7.88	-0.58	1.41e-12	Diabetic kidney disease;
TGCT	cis	rs11688237	0.936	rs4662351	chr2:144559694	G/T	cg07409629	chr2:144282743	ARHGAP15	-0.36	-4.59	-0.38	1.05e-5	Chin dimples;
TGCT	cis	rs13191362	1.000	rs13199223	chr6:163001083	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs6988636	0.901	rs62521825	chr8:124185786	C/A	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg24675658	chr1:53192096	ZYG11B	-0.75	-9.11	-0.63	1.78e-15	Monocyte count;
TGCT	cis	rs7666738	0.830	rs34313689	chr4:99013689	T/C	cg05340658	chr4:99064831	C4orf37	0.48	5.43	0.44	2.92e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3731896	0.706	rs7589023	chr2:220138586	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.74	-4.44	-0.37	1.96e-5	Educational attainment;
TGCT	cis	rs10791323	0.569	rs2156680	chr11:133742292	T/G	cg15485101	chr11:133734466	NA	0.37	5.42	0.44	3e-7	Childhood ear infection;
TGCT	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg08280861	chr8:58055591	NA	0.36	4.91	0.4	2.81e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6545883	0.929	rs2256615	chr2:61679894	C/G	cg15711740	chr2:61764176	XPO1	-0.56	-5.1	-0.42	1.23e-6	Tuberculosis;
TGCT	cis	rs9926296	0.712	rs447735	chr16:89734349	T/C	cg03388025	chr16:89894329	SPIRE2	-0.34	-4.92	-0.4	2.73e-6	Vitiligo;
TGCT	cis	rs7959452	0.640	rs1598543	chr12:69688757	G/T	cg11871910	chr12:69753446	YEATS4	0.63	6.37	0.5	3.34e-9	Blood protein levels;
TGCT	cis	rs1113500	0.748	rs1781048	chr1:108555050	A/T	cg22161131	chr1:109420278	GPSM2	0.51	4.58	0.38	1.1e-5	Growth-regulated protein alpha levels;
TGCT	cis	rs2404602	0.647	rs12910081	chr15:77022959	G/C	cg23625390	chr15:77176239	SCAPER	-0.36	-4.56	-0.38	1.21e-5	Blood metabolite levels;
TGCT	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg23708337	chr7:1209742	NA	0.6	5.57	0.45	1.53e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg02725872	chr8:58115012	NA	-0.38	-4.79	-0.39	4.73e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9486719	1.000	rs11153064	chr6:97021959	A/G	cg06623918	chr6:96969491	KIAA0776	-0.99	-8.05	-0.59	5.65e-13	Migraine;Coronary artery disease;
TGCT	cis	rs9787249	0.957	rs11206754	chr1:40216234	A/G	cg20968010	chr1:40505947	CAP1	-0.52	-4.94	-0.41	2.46e-6	Blood protein levels;
TGCT	trans	rs1814175	0.817	rs1851860	chr11:49861310	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.35	-0.55	2.37e-11	Height;
TGCT	cis	rs7666738	0.515	rs13434650	chr4:98889886	A/G	cg17366294	chr4:99064904	C4orf37	0.63	5.59	0.45	1.38e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs61774743	0.754	rs61774744	chr1:41834444	G/A	cg01193554	chr1:41846683	NA	0.41	4.91	0.4	2.84e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6570726	0.905	rs452770	chr6:145847162	T/C	cg23711669	chr6:146136114	FBXO30	0.68	6.67	0.51	7.58e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4919694	0.908	rs11191523	chr10:104792400	A/G	cg04362960	chr10:104952993	NT5C2	1.06	7.05	0.53	1.09e-10	Arsenic metabolism;
TGCT	cis	rs7542091	0.648	rs688464	chr1:209992539	C/T	cg22029157	chr1:209979665	IRF6	-0.6	-6.17	-0.48	8.87e-9	Monobrow;
TGCT	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.64	-6.48	-0.5	2e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs6964587	1.000	rs10245095	chr7:91710845	A/G	cg17063962	chr7:91808500	NA	0.88	9.63	0.65	9.8e-17	Breast cancer;
TGCT	trans	rs7726839	0.540	rs3792720	chr5:643028	T/G	cg11887960	chr12:57824829	NA	1.12	9.19	0.64	1.16e-15	Obesity-related traits;
TGCT	cis	rs7246657	0.943	rs1382357	chr19:37977609	G/A	cg03233940	chr19:37894644	NA	-0.36	-4.49	-0.37	1.61e-5	Coronary artery calcification;
TGCT	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg04772025	chr11:68637568	NA	-0.55	-5.96	-0.47	2.48e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg01802117	chr1:53393560	SCP2	0.48	5.82	0.46	4.82e-8	Monocyte count;
TGCT	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg11494091	chr17:61959527	GH2	0.56	12.2	0.74	5.55e-23	Prudent dietary pattern;
TGCT	cis	rs10833905	0.680	rs2470327	chr11:23033872	A/C	cg06387204	chr11:22647648	FANCF	0.53	4.83	0.4	3.92e-6	Sudden cardiac arrest;
TGCT	cis	rs7726839	0.540	rs72703083	chr5:595365	C/T	cg16624210	chr5:671434	TPPP	0.44	4.85	0.4	3.68e-6	Obesity-related traits;
TGCT	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg13695892	chr22:41940480	POLR3H	0.89	8.48	0.61	5.62e-14	Cannabis dependence symptom count;
TGCT	cis	rs7666738	0.791	rs2865958	chr4:99040732	G/T	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg12963246	chr6:28129442	ZNF389	0.5	4.94	0.41	2.48e-6	Depression;
TGCT	cis	rs6570726	0.818	rs412350	chr6:145852409	T/C	cg13319975	chr6:146136371	FBXO30	-0.52	-4.68	-0.39	7.27e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4294134	0.608	rs11532803	chr7:135245734	T/A	cg08396481	chr7:135194601	CNOT4	-0.62	-4.81	-0.4	4.25e-6	Paget's disease;
TGCT	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg04025307	chr7:1156635	C7orf50	0.24	5.51	0.44	1.98e-7	Longevity;Endometriosis;
TGCT	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.61	-6.3	-0.49	4.74e-9	Longevity;Endometriosis;
TGCT	cis	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg08564027	chr20:61660810	NA	0.38	7.08	0.54	9.36e-11	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg06634786	chr22:41940651	POLR3H	-0.88	-8.54	-0.61	3.98e-14	Vitiligo;
TGCT	cis	rs1975974	1.000	rs72842072	chr17:21730703	G/A	cg18423549	chr17:21743878	NA	-0.55	-5.07	-0.41	1.42e-6	Psoriasis;
TGCT	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg22535103	chr8:58192502	C8orf71	0.38	4.55	0.38	1.25e-5	Developmental language disorder (linguistic errors);
TGCT	trans	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.88	-9.92	-0.67	1.95e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs910316	0.503	rs4903273	chr14:75441795	G/A	cg08847533	chr14:75593920	NEK9	-0.63	-6.34	-0.49	3.84e-9	Height;
TGCT	trans	rs9329221	0.741	rs13271489	chr8:9803712	T/C	cg15556689	chr8:8085844	FLJ10661	-0.77	-7.11	-0.54	8.03e-11	Neuroticism;
TGCT	cis	rs950169	1.000	rs1818950	chr15:84722521	A/G	cg17173187	chr15:85201210	NMB	0.5	5.58	0.45	1.46e-7	Schizophrenia;
TGCT	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg04287289	chr16:89883240	FANCA	0.93	11.73	0.73	7.97e-22	Vitiligo;
TGCT	cis	rs11690935	0.632	rs12998411	chr2:172530707	G/C	cg13550731	chr2:172543902	DYNC1I2	0.71	6.19	0.49	8.01e-9	Schizophrenia;
TGCT	cis	rs35146811	0.700	rs866500	chr7:99840461	A/G	cg13334819	chr7:99746414	C7orf59	0.81	7.06	0.54	1.04e-10	Coronary artery disease;
TGCT	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg19318889	chr4:1322082	MAEA	-0.27	-6.59	-0.51	1.12e-9	Longevity;
TGCT	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs8072100	0.817	rs9905581	chr17:45547185	C/T	cg08085267	chr17:45401833	C17orf57	-0.47	-5.14	-0.42	1.05e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs9916302	0.851	rs11870631	chr17:37645129	C/T	cg15445000	chr17:37608096	MED1	0.31	4.59	0.38	1.06e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs7220401	0.789	rs3760456	chr17:27948844	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.91	-8.83	-0.62	8.43e-15	Coronary artery disease;
TGCT	cis	rs11098499	0.954	rs9998585	chr4:120396802	T/A	cg09307838	chr4:120376055	NA	0.69	6.64	0.51	8.97e-10	Corneal astigmatism;
TGCT	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.36	4.68	0.39	7.24e-6	Total body bone mineral density;
TGCT	cis	rs7772486	0.840	rs2474355	chr6:146312540	C/G	cg13319975	chr6:146136371	FBXO30	-0.51	-4.55	-0.38	1.27e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2688608	0.592	rs11814282	chr10:75490217	T/C	cg23231163	chr10:75533350	FUT11	-0.28	-4.68	-0.39	7.4e-6	Inflammatory bowel disease;
TGCT	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg12310025	chr6:25882481	NA	-0.55	-5.58	-0.45	1.41e-7	Blood metabolite levels;
TGCT	cis	rs7103648	0.695	rs12223593	chr11:47789082	T/G	cg20307385	chr11:47447363	PSMC3	0.77	7.25	0.55	3.99e-11	Diastolic blood pressure;Systolic blood pressure;
TGCT	cis	rs362272	0.524	rs3129334	chr4:3368526	T/C	cg18352616	chr4:3374830	RGS12	0.23	4.66	0.39	8.19e-6	Serum sulfate level;
TGCT	cis	rs4727027	0.933	rs6464940	chr7:148826309	G/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	4.58	0.38	1.13e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs459571	0.839	rs10993895	chr9:136887726	C/T	cg13789015	chr9:136890014	NCRNA00094	-0.39	-7.09	-0.54	8.9e-11	Platelet distribution width;
TGCT	cis	rs2820315	0.867	rs2644135	chr1:201856256	C/G	cg12730843	chr1:201915899	LMOD1	0.28	4.97	0.41	2.15e-6	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
TGCT	cis	rs2404602	1.000	rs2404602	chr15:77030792	A/G	cg22467129	chr15:76604101	ETFA	-0.49	-5.53	-0.44	1.82e-7	Blood metabolite levels;
TGCT	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg23758822	chr17:41437982	NA	0.69	6.37	0.5	3.34e-9	Menopause (age at onset);
TGCT	cis	rs56309584	0.596	rs11649742	chr17:8176415	C/T	cg08322244	chr17:8066669	VAMP2	-0.57	-5.31	-0.43	4.89e-7	Initial pursuit acceleration;
TGCT	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg24549020	chr5:56110836	MAP3K1	0.67	5.78	0.46	5.74e-8	Initial pursuit acceleration;
TGCT	cis	rs11711311	0.824	rs35341324	chr3:113351719	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.75	-6.27	-0.49	5.45e-9	IgG glycosylation;
TGCT	cis	rs35146811	0.555	rs2527896	chr7:99537653	A/G	cg13334819	chr7:99746414	C7orf59	-0.6	-5.1	-0.42	1.26e-6	Coronary artery disease;
TGCT	cis	rs9899728	0.539	rs35928207	chr17:73033629	T/G	cg27626185	chr17:73056755	KCTD2	-0.97	-7.74	-0.57	3.08e-12	Alzheimer's disease or small vessel stroke;
TGCT	cis	rs12220898	0.749	rs7913851	chr10:50482996	C/G	cg06072769	chr10:50146962	WDFY4	0.38	5.07	0.41	1.38e-6	Inflammatory biomarkers;
TGCT	cis	rs60843830	0.661	rs62116682	chr2:104618	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.54	4.51	0.38	1.45e-5	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs2692947	0.673	rs2229169	chr2:96780716	T/G	cg22654517	chr2:96458247	NA	-0.22	-4.72	-0.39	6.17e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs68170813	0.652	rs116894096	chr7:107178477	G/A	cg02696742	chr7:106810147	HBP1	-0.58	-4.47	-0.37	1.74e-5	Coronary artery disease;
TGCT	cis	rs523522	0.962	rs11065145	chr12:120947419	A/G	cg27279351	chr12:120934652	DYNLL1	0.76	6.59	0.51	1.15e-9	High light scatter reticulocyte count;
TGCT	cis	rs826838	0.834	rs2387842	chr12:38736442	T/C	cg13010199	chr12:38710504	ALG10B	0.83	6.86	0.52	2.92e-10	Heart rate;
TGCT	cis	rs6088590	1.000	rs6120747	chr20:33449769	T/C	cg06115741	chr20:33292138	TP53INP2	0.64	5.1	0.42	1.26e-6	Coronary artery disease;
TGCT	cis	rs6088590	0.561	rs6087600	chr20:33157217	T/C	cg08999081	chr20:33150536	PIGU	0.25	4.99	0.41	1.97e-6	Coronary artery disease;
TGCT	cis	rs6060987	1	rs6060987	chr20:30427077	T/A	cg13852791	chr20:30311386	BCL2L1	0.76	5.67	0.45	9.7e-8	Mean corpuscular volume;
TGCT	cis	rs7914558	0.933	rs2066323	chr10:104871361	A/G	cg15744005	chr10:104629667	AS3MT	-0.42	-5.21	-0.42	7.57e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg01802117	chr1:53393560	SCP2	0.47	5.68	0.45	8.92e-8	Monocyte count;
TGCT	cis	rs10089	1.000	rs3805612	chr5:127505316	G/A	cg19767477	chr5:127420684	SLC12A2	-0.44	-4.56	-0.38	1.2e-5	Ileal carcinoids;
TGCT	cis	rs1691799	0.867	rs1183274	chr12:66732057	C/G	cg16791601	chr12:66731901	HELB	-0.29	-6.31	-0.49	4.41e-9	White blood cell count (basophil);
TGCT	cis	rs1372520	0.748	rs2737002	chr4:90753180	A/G	cg14346243	chr4:90757452	SNCA	-0.67	-5.64	-0.45	1.09e-7	Neuroticism;
TGCT	cis	rs7208859	0.673	rs75142521	chr17:29240537	G/A	cg18442181	chr17:29233375	C17orf42	-0.8	-4.81	-0.4	4.38e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs13191362	1.000	rs34066731	chr6:163011047	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7726839	0.507	rs111707179	chr5:593308	T/A	cg09021430	chr5:549028	NA	-0.43	-5.83	-0.46	4.57e-8	Obesity-related traits;
TGCT	cis	rs10488031	0.557	rs34429167	chr7:37081417	G/A	cg06458904	chr7:36312573	EEPD1	0.56	4.7	0.39	6.79e-6	QT interval;
TGCT	cis	rs7786808	0.615	rs4909209	chr7:158194329	C/T	cg01191920	chr7:158217561	PTPRN2	-0.42	-6.25	-0.49	5.89e-9	Obesity-related traits;
TGCT	cis	rs7085104	0.632	rs3781287	chr10:104595420	A/C	cg15744005	chr10:104629667	AS3MT	-0.42	-5.39	-0.44	3.43e-7	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs7267979	0.966	rs2261747	chr20:25261784	G/A	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg07636037	chr3:49044803	WDR6	0.95	10.21	0.68	3.98e-18	Parkinson's disease;
TGCT	cis	rs425277	1.000	rs196128	chr1:2078444	T/G	cg24578937	chr1:2090814	PRKCZ	0.32	8.03	0.58	6.41e-13	Height;
TGCT	cis	rs4901869	0.966	rs12148052	chr14:59338970	C/T	cg02291164	chr14:59296302	NA	0.24	4.7	0.39	6.86e-6	Panic disorder;
TGCT	cis	rs7584330	0.617	rs10202195	chr2:238352128	A/G	cg14458575	chr2:238380390	NA	0.51	7.51	0.56	1e-11	Prostate cancer;
TGCT	cis	rs1865760	0.566	rs9379825	chr6:26083871	C/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.78	7.49	0.56	1.15e-11	Height;
TGCT	cis	rs6088580	0.601	rs6059827	chr20:33016358	C/T	cg06115741	chr20:33292138	TP53INP2	0.53	4.68	0.39	7.4e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs6570726	0.764	rs4263604	chr6:145916697	A/G	cg05347473	chr6:146136440	FBXO30	0.53	4.91	0.4	2.87e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs12497850	1.000	rs12493578	chr3:48730116	C/T	cg07636037	chr3:49044803	WDR6	-0.91	-9.89	-0.66	2.37e-17	Parkinson's disease;
TGCT	trans	rs3780486	0.846	rs10758192	chr9:33131651	G/A	cg04842962	chr6:43655489	MRPS18A	1.24	15.83	0.82	1.46e-31	IgG glycosylation;
TGCT	cis	rs9291683	0.588	rs3796842	chr4:9995851	A/T	cg11266682	chr4:10021025	SLC2A9	0.69	9.03	0.63	2.78e-15	Bone mineral density;
TGCT	cis	rs7208859	0.673	rs73265624	chr17:29232066	G/A	cg18442181	chr17:29233375	C17orf42	-0.78	-4.61	-0.38	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs6840360	0.615	rs1962910	chr4:152479392	T/A	cg17479576	chr4:152424074	FAM160A1	-0.72	-7.98	-0.58	8.25e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs79387448	0.810	rs75218113	chr2:103239356	C/G	cg09003973	chr2:102972529	NA	0.94	5.3	0.43	5.15e-7	Gut microbiota (bacterial taxa);
TGCT	cis	rs910316	0.737	rs91144	chr14:75449517	G/A	cg08847533	chr14:75593920	NEK9	-0.82	-8.88	-0.62	6.17e-15	Height;
TGCT	cis	rs9486719	0.948	rs2092095	chr6:96870864	T/G	cg18709589	chr6:96969512	KIAA0776	0.71	5.21	0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs854765	0.587	rs12936927	chr17:17726965	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.68	-6.51	-0.5	1.66e-9	Total body bone mineral density;
TGCT	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.07	-9.63	-0.65	1.01e-16	Platelet count;
TGCT	trans	rs17685	0.633	rs3801471	chr7:75696188	T/G	cg19862616	chr7:65841803	NCRNA00174	0.51	8.63	0.61	2.45e-14	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs7119038	0.731	rs28409215	chr11:118679304	G/A	cg19308663	chr11:118741387	NA	0.31	6.42	0.5	2.65e-9	Sjögren's syndrome;
TGCT	cis	rs1205863	1.000	rs1205876	chr6:11945675	G/A	cg07106625	chr6:11870215	NA	0.51	5.05	0.41	1.51e-6	Disc degeneration (lumbar);
TGCT	cis	rs2153535	0.540	rs9378557	chr6:8517381	T/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.01	0.41	1.86e-6	Motion sickness;
TGCT	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg13206674	chr6:150067644	NUP43	0.52	4.51	0.38	1.5e-5	Lung cancer;
TGCT	cis	rs2072499	0.833	rs2842873	chr1:156204653	C/T	cg25208724	chr1:156163844	SLC25A44	0.96	12.29	0.74	3.48e-23	Testicular germ cell tumor;
TGCT	cis	rs6089829	0.962	rs6089825	chr20:61668447	C/T	cg08564027	chr20:61660810	NA	0.37	6.57	0.51	1.22e-9	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg11644478	chr21:40555479	PSMG1	0.98	10.34	0.68	1.91e-18	Cognitive function;
TGCT	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg22963979	chr7:1858916	MAD1L1	-0.31	-4.6	-0.38	1.01e-5	Bipolar disorder and schizophrenia;
TGCT	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg17554472	chr22:41940697	POLR3H	-0.48	-5.15	-0.42	9.89e-7	Vitiligo;
TGCT	cis	rs453301	0.538	rs7830804	chr8:8970762	G/T	cg15556689	chr8:8085844	FLJ10661	-0.58	-4.56	-0.38	1.22e-5	Joint mobility (Beighton score);
TGCT	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg22618164	chr12:122356400	WDR66	0.6	6.19	0.49	8.01e-9	Mean corpuscular volume;
TGCT	cis	rs763121	0.853	rs5757226	chr22:39070550	T/C	cg06022373	chr22:39101656	GTPBP1	0.77	7.46	0.56	1.35e-11	Menopause (age at onset);
TGCT	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg10150615	chr22:24372951	LOC391322	0.99	10.76	0.69	1.8e-19	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs929354	0.772	rs2023975	chr7:157012096	G/A	cg05182265	chr7:156933206	UBE3C	-0.41	-9.31	-0.64	5.91e-16	Body mass index;
TGCT	cis	rs2404602	0.655	rs4886824	chr15:76969256	A/G	cg22467129	chr15:76604101	ETFA	-0.45	-5.11	-0.42	1.2e-6	Blood metabolite levels;
TGCT	cis	rs858239	0.600	rs7789237	chr7:23124713	T/G	cg05602783	chr7:23145260	KLHL7	-0.6	-5.02	-0.41	1.76e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs2153535	0.580	rs1932279	chr6:8473653	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs1018836	0.632	rs7017295	chr8:91482356	C/T	cg16814680	chr8:91681699	NA	0.75	8.2	0.59	2.58e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg16325326	chr1:53192061	ZYG11B	0.7	8.24	0.59	2.04e-13	Monocyte count;
TGCT	cis	rs2236918	0.643	rs3121389	chr1:242020264	C/T	cg04158730	chr1:242011433	EXO1	0.49	4.6	0.38	1.02e-5	Menopause (age at onset);
TGCT	cis	rs9393777	0.546	rs9366673	chr6:26893329	C/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.65	-6.01	-0.48	1.91e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg21171335	chr12:122356390	WDR66	-0.65	-6.8	-0.52	3.97e-10	Mean corpuscular volume;
TGCT	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg25036284	chr2:26402008	FAM59B	-0.61	-4.9	-0.4	2.92e-6	Gut microbiome composition (summer);
TGCT	cis	rs7246657	0.943	rs4801759	chr19:37954985	G/A	cg18154014	chr19:37997991	ZNF793	0.95	6.63	0.51	9.39e-10	Coronary artery calcification;
TGCT	cis	rs6121246	0.609	rs2377317	chr20:30402502	A/G	cg13852791	chr20:30311386	BCL2L1	-0.82	-7.69	-0.57	3.88e-12	Mean corpuscular hemoglobin;
TGCT	cis	rs9534288	0.740	rs7989892	chr13:46630641	C/T	cg15192986	chr13:46630673	CPB2	-0.48	-5.6	-0.45	1.29e-7	Blood protein levels;
TGCT	cis	rs17384381	1.000	rs35193119	chr1:85859265	T/C	cg16011679	chr1:85725395	C1orf52	0.8	6.51	0.5	1.69e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg05872129	chr22:39784769	NA	0.91	9.47	0.65	2.42e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs67311347	1.000	rs1119179	chr3:40424929	A/C	cg13683864	chr3:40499215	RPL14	1.12	12.14	0.74	8.04e-23	Renal cell carcinoma;
TGCT	cis	rs950776	0.616	rs495090	chr15:78870003	A/G	cg06917634	chr15:78832804	PSMA4	-0.66	-5.29	-0.43	5.47e-7	Sudden cardiac arrest;
TGCT	cis	rs1348850	0.872	rs13004955	chr2:178398923	A/T	cg22681709	chr2:178499509	PDE11A	0.38	4.73	0.39	6.12e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs7119038	0.818	rs10892289	chr11:118646003	C/T	cg19308663	chr11:118741387	NA	0.31	6.12	0.48	1.14e-8	Sjögren's syndrome;
TGCT	cis	rs56235845	0.694	rs6860069	chr5:176755841	C/T	cg06060754	chr5:176797920	RGS14	0.41	6.26	0.49	5.83e-9	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg10802521	chr3:52805072	NEK4	-0.64	-7.63	-0.57	5.3e-12	Electroencephalogram traits;
TGCT	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg12310025	chr6:25882481	NA	-0.63	-5.41	-0.44	3.17e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs12579753	0.871	rs10862364	chr12:82201280	C/T	cg07988820	chr12:82153109	PPFIA2	-0.59	-6.19	-0.49	7.93e-9	Resting heart rate;
TGCT	cis	rs2762353	0.806	rs6909187	chr6:25785925	C/T	cg12310025	chr6:25882481	NA	0.5	5.09	0.42	1.29e-6	Blood metabolite levels;
TGCT	cis	rs6752107	0.967	rs56049444	chr2:234157688	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.2	4.89	0.4	3.07e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg08736216	chr1:53307985	ZYG11A	0.25	4.93	0.4	2.59e-6	Monocyte count;
TGCT	cis	rs6490294	0.659	rs7294578	chr12:112197837	A/C	cg10833066	chr12:111807467	FAM109A	0.32	4.96	0.41	2.25e-6	Mean platelet volume;
TGCT	cis	rs8179	0.700	rs42043	chr7:92247333	A/G	cg15732164	chr7:92237376	CDK6	-0.29	-5.02	-0.41	1.77e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
TGCT	cis	rs1941023	0.584	rs10897057	chr11:60172273	A/T	cg08716584	chr11:60157161	MS4A7	-0.31	-4.69	-0.39	7.18e-6	Congenital heart disease (maternal effect);
TGCT	cis	rs7804356	1.000	rs10272303	chr7:26827815	T/C	cg03456212	chr7:26904342	SKAP2	-0.64	-4.88	-0.4	3.16e-6	Type 1 diabetes;
TGCT	cis	rs9394841	0.585	rs9381096	chr6:41821137	C/T	cg08135965	chr6:41755394	TOMM6	0.59	4.89	0.4	3.04e-6	Mean corpuscular hemoglobin;Red cell distribution width;
TGCT	cis	rs2288073	1.000	rs6708328	chr2:24412413	A/G	cg05570707	chr2:24270316	C2orf44	-0.51	-4.61	-0.38	1e-5	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs617219	0.551	rs2131978	chr5:78613986	G/A	cg09550809	chr5:78407562	BHMT	-0.37	-5.2	-0.42	7.81e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg09365446	chr1:150670422	GOLPH3L	0.3	4.49	0.37	1.63e-5	Tonsillectomy;
TGCT	cis	rs1475911	1.000	rs1475911	chr21:43513480	A/C	cg19766460	chr21:43528205	UMODL1;C21orf128	0.53	7.12	0.54	7.61e-11	IgG glycosylation;
TGCT	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg10295955	chr4:187884368	NA	-0.95	-14.86	-0.8	2.58e-29	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9952991	0.582	rs658158	chr18:12823402	T/G	cg23598886	chr18:12777645	NA	0.54	4.74	0.39	5.88e-6	Inflammatory skin disease;
TGCT	cis	rs6424115	0.708	rs2076343	chr1:24129126	A/G	cg15997130	chr1:24165203	NA	-0.67	-6.97	-0.53	1.7e-10	Immature fraction of reticulocytes;
TGCT	cis	rs17122693	1.000	rs17122683	chr14:51080422	G/A	cg04730355	chr14:51134070	SAV1	1.18	8.2	0.59	2.52e-13	Cognitive performance;
TGCT	cis	rs806795	0.605	rs809871	chr6:26256526	C/G	cg13736514	chr6:26305472	NA	0.32	4.85	0.4	3.64e-6	Mosquito bite size;
TGCT	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg23708337	chr7:1209742	NA	0.62	5.93	0.47	2.76e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs6964587	1.000	rs17164263	chr7:91581566	T/A	cg22709100	chr7:91322751	NA	-0.27	-4.48	-0.37	1.68e-5	Breast cancer;
TGCT	cis	rs10875746	0.903	rs58952582	chr12:48458448	T/G	cg20731937	chr12:48336164	NA	0.62	4.95	0.41	2.36e-6	Longevity (90 years and older);
TGCT	cis	rs9302065	1.000	rs2389236	chr13:95971477	G/A	cg26751094	chr13:95954534	ABCC4	-0.32	-5.34	-0.43	4.22e-7	Blood metabolite levels;
TGCT	cis	rs7412746	0.587	rs3849279	chr1:150944707	T/C	cg09365446	chr1:150670422	GOLPH3L	0.34	4.7	0.39	6.76e-6	Melanoma;
TGCT	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg10253484	chr15:75165896	SCAMP2	-0.63	-5.78	-0.46	5.71e-8	Breast cancer;
TGCT	cis	rs6912958	0.525	rs242262	chr6:88018057	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.38	4.46	0.37	1.83e-5	Monocyte percentage of white cells;
TGCT	cis	rs616402	0.527	rs10779737	chr1:10580275	C/G	cg17425144	chr1:10567563	PEX14	0.53	7.75	0.57	2.87e-12	Breast size;
TGCT	cis	rs899997	0.906	rs1809415	chr15:79028201	C/T	cg04896959	chr15:78267971	NA	-0.36	-4.86	-0.4	3.43e-6	Coronary artery disease or large artery stroke;
TGCT	cis	rs13326165	0.663	rs634382	chr3:52482851	A/G	cg07884673	chr3:53033167	SFMBT1	-0.39	-4.71	-0.39	6.47e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs6831352	0.734	rs1154400	chr4:100010010	C/T	cg12011299	chr4:100065546	ADH4	0.38	4.96	0.41	2.29e-6	Alcohol dependence;
TGCT	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg06028808	chr11:68637592	NA	0.51	6.66	0.51	7.87e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs10191773	0.535	rs72833432	chr2:113102746	T/C	cg07905836	chr2:113190072	RGPD8;RGPD5	0.44	4.62	0.38	9.4e-6	Yeast infection;
TGCT	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg03452623	chr4:187889614	NA	0.34	5.24	0.43	6.57e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs17345786	0.520	rs13062677	chr3:101305078	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.54	5.51	0.44	1.99e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs854765	0.929	rs2955360	chr17:17974887	G/A	cg09796270	chr17:17721594	SREBF1	-0.27	-5.16	-0.42	9.67e-7	Total body bone mineral density;
TGCT	cis	rs8072100	0.902	rs12051716	chr17:45582395	G/A	cg08085267	chr17:45401833	C17orf57	0.44	4.64	0.38	8.86e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs1429606	1.000	rs3910021	chr5:87278744	A/G	cg09451457	chr5:87440246	NA	0.72	4.72	0.39	6.19e-6	Number of children (6+ vs. 0 or 1);
TGCT	cis	rs7666738	0.830	rs10005120	chr4:99038200	A/G	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9549367	0.789	rs7317558	chr13:113893625	G/A	cg18105134	chr13:113819100	PROZ	-0.35	-5.89	-0.47	3.46e-8	Platelet distribution width;
TGCT	cis	rs453301	0.574	rs10081437	chr8:8948979	T/C	cg15556689	chr8:8085844	FLJ10661	-0.68	-5.53	-0.45	1.78e-7	Joint mobility (Beighton score);
TGCT	cis	rs9814567	1.000	rs3846056	chr3:134227292	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.95	-9.62	-0.65	1.04e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs2072499	0.833	rs2842873	chr1:156204653	C/T	cg24450063	chr1:156163899	SLC25A44	1.02	13.07	0.76	4.58e-25	Testicular germ cell tumor;
TGCT	cis	rs698813	0.604	rs768007	chr2:44487486	G/A	cg00619915	chr2:44497795	NA	-0.25	-5.7	-0.46	8.4e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
TGCT	cis	rs11203032	0.831	rs9651424	chr10:90932935	A/G	cg16672925	chr10:90967113	CH25H	0.73	4.5	0.37	1.55e-5	Heart failure;
TGCT	cis	rs2458413	1.000	rs2458414	chr8:105355840	A/G	cg13045555	chr8:105342365	NA	0.38	5.93	0.47	2.78e-8	Paget's disease;
TGCT	cis	rs950173	1.000	rs13000153	chr2:172586067	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.98	-6.05	-0.48	1.57e-8	Hippocampal volume;
TGCT	cis	rs9911578	1.000	rs172565	chr17:56808996	A/T	cg12560992	chr17:57184187	TRIM37	0.76	9.34	0.64	4.88e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs4631830	0.863	rs3101227	chr10:51520203	C/A	cg10326726	chr10:51549505	MSMB	-0.24	-4.87	-0.4	3.32e-6	Prostate-specific antigen levels;
TGCT	cis	rs1997103	0.911	rs10238738	chr7:55412359	T/C	cg17469321	chr7:55412551	NA	0.65	6.75	0.52	5.08e-10	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs1865760	0.508	rs9379820	chr6:26049924	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.78	7.49	0.56	1.1e-11	Height;
TGCT	cis	rs2637266	1.000	rs4979784	chr10:78355476	T/A	cg18941641	chr10:78392320	NA	0.4	5.01	0.41	1.81e-6	Pulmonary function;
TGCT	cis	rs7772486	0.875	rs9322044	chr6:146369608	T/C	cg23711669	chr6:146136114	FBXO30	0.91	10.09	0.67	7.53e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs35883536	0.669	rs1932352	chr1:101161251	G/A	cg06223162	chr1:101003688	GPR88	-0.38	-6.28	-0.49	5.1e-9	Monocyte count;
TGCT	cis	rs11172134	0.508	rs10876967	chr12:57570593	G/A	cg19258868	chr12:57585184	LRP1	-0.31	-5.76	-0.46	6.18e-8	Urate levels in overweight individuals;
TGCT	cis	rs10940138	0.774	rs57209938	chr5:67234233	A/G	ch.5.1281357F	chr5:67228439	NA	0.39	4.66	0.39	8.11e-6	Menarche (age at onset);
TGCT	cis	rs13256369	1.000	rs10098234	chr8:8576692	G/A	cg18904891	chr8:8559673	CLDN23	0.63	5.82	0.46	4.83e-8	Obesity-related traits;
TGCT	cis	rs8031584	0.736	rs11635775	chr15:31160640	A/G	cg14829155	chr15:31115871	NA	-0.37	-4.86	-0.4	3.46e-6	Huntington's disease progression;
TGCT	cis	rs1371867	0.875	rs1788176	chr8:101332112	A/G	cg06002616	chr8:101225028	SPAG1	-0.56	-6.58	-0.51	1.2e-9	Atrioventricular conduction;
TGCT	cis	rs6674176	0.628	rs3791116	chr1:44414156	T/A	cg12908607	chr1:44402522	ARTN	-0.67	-8.15	-0.59	3.4e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs908922	0.676	rs545418	chr1:152497338	C/T	cg20991723	chr1:152506922	NA	0.46	6.26	0.49	5.7e-9	Hair morphology;
TGCT	cis	rs711245	0.574	rs1179494	chr2:36809496	C/G	cg10546459	chr2:36825355	FEZ2	-0.53	-4.6	-0.38	1.02e-5	Height;
TGCT	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg19318889	chr4:1322082	MAEA	-0.2	-4.91	-0.4	2.8e-6	Obesity-related traits;
TGCT	cis	rs2708977	0.966	rs2708978	chr2:97202243	A/C	cg01950434	chr2:97203154	ARID5A	-0.69	-6.36	-0.5	3.5e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	trans	rs7819412	0.783	rs28722721	chr8:10948968	G/A	cg15556689	chr8:8085844	FLJ10661	-0.79	-7.44	-0.56	1.43e-11	Triglycerides;
TGCT	cis	rs10489202	0.608	rs10918827	chr1:168077044	A/G	cg24449463	chr1:168025552	DCAF6	0.49	5.06	0.41	1.49e-6	Schizophrenia;
TGCT	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg24531977	chr5:56204891	C5orf35	-0.77	-7.61	-0.56	5.83e-12	Initial pursuit acceleration;
TGCT	cis	rs10193935	0.901	rs2374405	chr2:42479874	A/C	cg27598129	chr2:42591480	NA	-0.39	-5.41	-0.44	3.06e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9733	0.596	rs11582840	chr1:150688487	A/G	cg04414720	chr1:150670196	GOLPH3L	0.37	4.91	0.4	2.76e-6	Tonsillectomy;
TGCT	cis	rs1056107	0.898	rs7021564	chr9:115002314	C/A	cg02332936	chr9:115140584	NA	-0.25	-4.44	-0.37	1.96e-5	Colorectal cancer;
TGCT	cis	rs42648	0.935	rs42668	chr7:89986525	A/C	cg25739043	chr7:89950458	NA	-0.65	-6.22	-0.49	6.96e-9	Homocysteine levels;
TGCT	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg08280861	chr8:58055591	NA	0.53	6.52	0.51	1.63e-9	Developmental language disorder (linguistic errors);
TGCT	cis	rs514406	0.505	rs7543239	chr1:53162416	A/G	cg08859206	chr1:53392774	SCP2	-0.34	-4.74	-0.39	5.77e-6	Monocyte count;
TGCT	cis	rs1971762	0.509	rs10783592	chr12:54037430	G/A	cg16917193	chr12:54089295	NA	1.02	11.48	0.72	3.1e-21	Height;
TGCT	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg00343986	chr7:65444356	GUSB	0.22	4.87	0.4	3.28e-6	Aortic root size;
TGCT	cis	rs9457247	1.000	rs394522	chr6:167398071	A/C	cg23791538	chr6:167370224	RNASET2	-0.49	-4.96	-0.41	2.28e-6	Crohn's disease;
TGCT	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg22683308	chr4:1340831	KIAA1530	-0.68	-6.42	-0.5	2.62e-9	Longevity;
TGCT	cis	rs651907	0.557	rs35850993	chr3:101437433	A/G	cg12386194	chr3:101231763	SENP7	0.49	4.69	0.39	7.17e-6	Colorectal cancer;
TGCT	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg12963246	chr6:28129442	ZNF389	0.52	5.1	0.42	1.23e-6	Depression;
TGCT	cis	rs7043114	0.525	rs7853859	chr9:95151377	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-4.82	-0.4	4.1e-6	Height;
TGCT	cis	rs7809950	1.000	rs2520260	chr7:107172794	A/G	cg23024343	chr7:107201750	COG5	-0.35	-5.55	-0.45	1.67e-7	Coronary artery disease;
TGCT	cis	rs7552404	0.960	rs12134854	chr1:76137606	A/G	cg10523679	chr1:76189770	ACADM	0.92	10.26	0.68	3.03e-18	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs34526934	0.566	rs35563571	chr2:177044459	T/G	cg26754761	chr2:177040938	NA	-0.29	-5.43	-0.44	2.88e-7	Obstructive sleep apnea trait (apnea hypopnea index);
TGCT	cis	rs904251	0.523	rs10947675	chr6:37479972	G/A	cg01843034	chr6:37503916	NA	-0.54	-7.03	-0.53	1.2e-10	Cognitive performance;
TGCT	cis	rs2777491	0.507	rs34040639	chr15:41760807	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.93	-17.19	-0.84	1.29e-34	Ulcerative colitis;
TGCT	cis	rs7666738	0.830	rs1456208	chr4:98678563	C/T	cg18180107	chr4:99064573	C4orf37	0.53	5.07	0.41	1.41e-6	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs1973993	0.691	rs1980683	chr1:96890379	A/G	cg10631902	chr5:14652156	NA	0.4	10.92	0.7	7.4e-20	Weight;
TGCT	cis	rs938554	0.513	rs3775946	chr4:9995256	A/G	cg00071950	chr4:10020882	SLC2A9	0.56	4.67	0.39	7.85e-6	Blood metabolite levels;
TGCT	cis	rs6866344	0.697	rs11748495	chr5:178130000	A/G	cg03877680	chr5:178157825	ZNF354A	-0.76	-6.1	-0.48	1.23e-8	Neutrophil percentage of white cells;
TGCT	cis	rs8030485	0.728	rs4778886	chr15:79389019	T/C	cg17916960	chr15:79447300	NA	0.34	4.64	0.38	8.89e-6	Left ventricle wall thickness;
TGCT	cis	rs2288884	1.000	rs11669540	chr19:52549739	C/A	cg13540795	chr19:52551618	ZNF432	-0.59	-5.02	-0.41	1.79e-6	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs11711311	1.000	rs1043132	chr3:113528689	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.72	-6.83	-0.52	3.44e-10	IgG glycosylation;
TGCT	cis	rs11030122	0.702	rs2898947	chr11:3977572	G/A	cg18678763	chr11:4115507	RRM1	-0.49	-6.13	-0.48	1.08e-8	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs4478858	0.647	rs11577679	chr1:31726185	T/C	cg00250761	chr1:31883323	NA	-0.28	-5.01	-0.41	1.86e-6	Alcohol dependence;
TGCT	cis	rs7027203	0.576	rs7874836	chr9:96559370	C/T	cg13679303	chr9:96623674	NA	-0.55	-7.82	-0.57	2e-12	DNA methylation (variation);
TGCT	cis	rs950169	0.922	rs4842940	chr15:84831225	C/T	cg11189052	chr15:85197271	WDR73	-0.8	-6.36	-0.5	3.52e-9	Schizophrenia;
TGCT	trans	rs9593057	0.892	rs116976730	chr13:35746621	A/G	cg01625621	chr15:34260433	AVEN;CHRM5	0.5	7.01	0.53	1.35e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs71636778	0.509	rs17162339	chr1:27252823	A/C	cg23921621	chr1:27994728	IFI6	0.43	4.61	0.38	9.92e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
TGCT	cis	rs9303401	0.659	rs7225896	chr17:56637337	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs2455799	0.559	rs1947147	chr3:15903002	G/A	cg12172478	chr3:16357591	RFTN1	-0.36	-5.3	-0.43	5.07e-7	Mean platelet volume;
TGCT	cis	rs4786125	0.587	rs12709158	chr16:6925056	A/G	cg03623568	chr16:6915990	A2BP1	-0.41	-6.41	-0.5	2.69e-9	Heart rate variability traits (SDNN);
TGCT	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.5	5.64	0.45	1.08e-7	Lymphocyte counts;
TGCT	cis	rs10791097	0.694	rs1050071	chr11:130747231	C/G	cg12179176	chr11:130786555	SNX19	0.88	10.19	0.67	4.45e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs3770081	1.000	rs59947468	chr2:86289436	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.17	-4.56	-0.38	1.21e-5	Facial emotion recognition (sad faces);
TGCT	cis	rs9486715	0.809	rs9486467	chr6:96971803	C/T	cg18709589	chr6:96969512	KIAA0776	0.83	8.13	0.59	3.67e-13	Headache;
TGCT	cis	rs6940638	0.662	rs6915678	chr6:27235866	T/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.44	-4.51	-0.38	1.47e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs6671200	1.000	rs259346	chr1:95728746	G/T	cg26537280	chr1:95699037	RWDD3	0.7	5.55	0.45	1.62e-7	Stearic acid (18:0) levels;
TGCT	cis	rs9914544	0.591	rs9900052	chr17:18699398	G/A	cg26306683	chr17:18585705	ZNF286B	0.53	4.83	0.4	3.97e-6	Educational attainment (years of education);
TGCT	cis	rs903263	0.932	rs10782824	chr1:84670584	T/A	cg09664975	chr1:84543551	PRKACB	0.48	4.56	0.38	1.2e-5	Breast cancer (male);
TGCT	cis	rs514406	0.893	rs6588445	chr1:53424928	T/C	cg16325326	chr1:53192061	ZYG11B	-0.59	-6.94	-0.53	1.89e-10	Monocyte count;
TGCT	cis	rs6690583	0.524	rs12045710	chr1:85451765	T/C	cg20280350	chr1:85513789	MCOLN3	-0.74	-5.11	-0.42	1.2e-6	Serum sulfate level;
TGCT	cis	rs2777491	0.574	rs72739644	chr15:41719706	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.93	-17.17	-0.84	1.44e-34	Ulcerative colitis;
TGCT	cis	rs9368481	0.645	rs10456350	chr6:26975581	A/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.52	5.88	0.47	3.64e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs644799	0.965	rs11021310	chr11:95502106	A/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	8.46	0.6	6.27e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs737008	0.960	rs11640295	chr16:11390728	C/G	cg00044050	chr16:11439710	C16orf75	0.79	8.15	0.59	3.4e-13	Obesity-related traits;
TGCT	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg24531977	chr5:56204891	C5orf35	-0.68	-7.22	-0.54	4.69e-11	Initial pursuit acceleration;
TGCT	cis	rs4808199	0.847	rs34647936	chr19:19548239	T/G	cg03709012	chr19:19516395	GATAD2A	0.98	7.76	0.57	2.68e-12	Nonalcoholic fatty liver disease;
TGCT	cis	rs12142240	0.698	rs17357711	chr1:46829013	A/G	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs7666738	1.000	rs13106934	chr4:99028685	C/T	cg17366294	chr4:99064904	C4orf37	0.76	7.12	0.54	7.6e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9926296	0.643	rs12596429	chr16:89841374	T/C	cg03388025	chr16:89894329	SPIRE2	0.35	5.15	0.42	1e-6	Vitiligo;
TGCT	cis	rs4149178	0.656	rs11753396	chr6:43290742	A/C	cg12269535	chr6:43142014	SRF	0.61	5.14	0.42	1.02e-6	Urate levels;
TGCT	trans	rs7088591	0.702	rs10491208	chr10:59703352	C/G	cg11531339	chr2:20069134	NA	0.76	7.09	0.54	9.03e-11	Blood pressure;
TGCT	cis	rs9436747	0.641	rs1938487	chr1:66047267	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.56	5.03	0.41	1.69e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs1008375	0.966	rs2872957	chr4:17651757	C/A	cg18681998	chr4:17616180	MED28	1.06	12.43	0.74	1.57e-23	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg19761014	chr17:28927070	LRRC37B2	0.53	4.64	0.38	8.86e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7666738	0.712	rs34043080	chr4:99008748	G/C	cg18180107	chr4:99064573	C4orf37	0.51	4.69	0.39	7.09e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8077577	0.895	rs11655588	chr17:18107451	C/T	cg09161412	chr17:18057145	MYO15A	0.67	5.44	0.44	2.79e-7	Obesity-related traits;
TGCT	cis	rs832540	0.931	rs832535	chr5:56213334	C/T	cg24531977	chr5:56204891	C5orf35	-0.52	-5.18	-0.42	8.65e-7	Coronary artery disease;
TGCT	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg17911788	chr17:44343683	NA	-0.6	-6.35	-0.5	3.68e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2276314	1.000	rs56050783	chr18:33553791	A/G	cg05985134	chr18:33552581	C18orf21	0.54	4.82	0.4	4.12e-6	Endometriosis;Drug-induced torsades de pointes;
TGCT	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg10150615	chr22:24372951	LOC391322	0.78	8.65	0.61	2.21e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs4727027	0.901	rs1534197	chr7:148771970	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	4.99	0.41	2.02e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs6964587	1.000	rs2282974	chr7:91761617	G/A	cg17063962	chr7:91808500	NA	0.89	9.51	0.65	1.9e-16	Breast cancer;
TGCT	cis	rs763014	0.898	rs916414	chr16:632073	C/T	cg09263875	chr16:632152	PIGQ	0.3	6.4	0.5	2.88e-9	Height;
TGCT	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg06634786	chr22:41940651	POLR3H	0.87	8.16	0.59	3.1400000000000003e-13	Vitiligo;
TGCT	trans	rs7613875	0.543	rs34034116	chr3:49959156	C/A	cg21659725	chr3:3221576	CRBN	0.68	7.62	0.56	5.76e-12	Body mass index;
TGCT	trans	rs11722228	0.522	rs881641	chr4:10133747	G/A	cg26043149	chr18:55253948	FECH	1.24	14.21	0.79	8.82e-28	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs1322512	0.796	rs1744391	chr6:152936761	A/G	cg03415253	chr6:152958462	SYNE1	-0.54	-5.01	-0.41	1.83e-6	Tonometry;
TGCT	cis	rs2637266	1.000	rs7475686	chr10:78358761	T/C	cg18941641	chr10:78392320	NA	0.39	4.87	0.4	3.29e-6	Pulmonary function;
TGCT	cis	rs250677	0.522	rs6580590	chr5:148360374	C/T	cg18129178	chr5:148520854	ABLIM3	0.36	4.69	0.39	7.23e-6	Breast cancer;
TGCT	cis	rs7020830	0.867	rs1339553	chr9:37266123	C/G	cg14294708	chr9:37120828	ZCCHC7	1.23	15.94	0.82	8.25e-32	Schizophrenia;
TGCT	cis	rs12802200	0.561	rs746707	chr11:571984	C/T	cg27205902	chr11:1006985	AP2A2	0.27	4.47	0.37	1.76e-5	Systemic lupus erythematosus;
TGCT	cis	rs9388451	0.839	rs3757217	chr6:126069636	G/C	cg05901451	chr6:126070800	HEY2	-1.04	-15.8	-0.82	1.76e-31	Brugada syndrome;
TGCT	cis	rs6500602	0.627	rs3848372	chr16:4587875	C/A	cg08645402	chr16:4508243	NA	0.21	5.5	0.44	2.09e-7	Schizophrenia;
TGCT	cis	rs7552404	0.924	rs1313071	chr1:76195542	C/G	cg22875332	chr1:76189707	ACADM	0.72	9.02	0.63	2.88e-15	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs13190036	1.000	rs3733875	chr5:176637240	G/T	cg18465082	chr5:176734745	MXD3	0.32	4.46	0.37	1.78e-5	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
TGCT	cis	rs9611519	0.929	rs12484971	chr22:41439304	A/T	cg13695892	chr22:41940480	POLR3H	-0.55	-4.9	-0.4	2.99e-6	Neuroticism;
TGCT	cis	rs17221829	0.733	rs10830329	chr11:89390612	A/G	cg02982614	chr11:89391479	FOLH1B	-0.25	-4.46	-0.37	1.8e-5	Anxiety in major depressive disorder;
TGCT	cis	rs7267979	0.789	rs6076347	chr20:25398790	C/T	cg03522245	chr20:25566470	NINL	-0.52	-5.26	-0.43	6.07e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6121246	0.529	rs6060195	chr20:30185638	C/T	cg18721089	chr20:30220636	NA	-0.63	-6.88	-0.53	2.67e-10	Mean corpuscular hemoglobin;
TGCT	cis	rs6684514	1.000	rs12122180	chr1:156244559	G/A	cg20302342	chr1:156215951	PAQR6	0.34	4.6	0.38	1.01e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	trans	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg17830980	chr10:43048298	ZNF37B	-0.86	-11.18	-0.71	1.68e-20	Extrinsic epigenetic age acceleration;
TGCT	cis	rs4072705	0.586	rs7869042	chr9:127246751	C/T	cg13476313	chr9:127244764	NR5A1	-0.3	-5.17	-0.42	8.97e-7	Menarche (age at onset);
TGCT	cis	rs7208859	0.623	rs28433704	chr17:29084285	G/C	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs11105298	0.891	rs11105325	chr12:89938590	G/A	cg00757033	chr12:89920650	WDR51B	0.29	4.49	0.37	1.58e-5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	6.18	0.49	8.58e-9	Bipolar disorder;
TGCT	cis	rs4819052	0.959	rs9976074	chr21:46655638	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	5.28	0.43	5.61e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg04267008	chr7:1944627	MAD1L1	-0.38	-5.12	-0.42	1.12e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs36051895	0.659	rs7036476	chr9:5063664	T/C	cg02405213	chr9:5042618	JAK2	-0.8	-11.47	-0.72	3.33e-21	Pediatric autoimmune diseases;
TGCT	cis	rs6460942	0.915	rs62448619	chr7:12457743	C/T	cg06484146	chr7:12443880	VWDE	-0.57	-5.52	-0.44	1.92e-7	Coronary artery disease;
TGCT	cis	rs3733585	0.783	rs13148371	chr4:10032561	C/T	cg11266682	chr4:10021025	SLC2A9	0.64	8.92	0.63	5e-15	Cleft plate (environmental tobacco smoke interaction);
TGCT	trans	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg25482853	chr8:67687455	SGK3	1.27	10.56	0.69	5.48e-19	Obesity-related traits;
TGCT	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg27121462	chr16:89883253	FANCA	-0.78	-8.32	-0.6	1.37e-13	Vitiligo;
TGCT	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg22963979	chr7:1858916	MAD1L1	-0.34	-5.2	-0.42	8e-7	Schizophrenia;
TGCT	cis	rs1878931	0.624	rs1149492	chr16:3445239	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.76	-6.45	-0.5	2.3e-9	Body mass index (adult);
TGCT	trans	rs10953454	1.000	rs10247246	chr7:104501165	G/A	cg04208666	chr6:19734707	NA	-0.57	-6.89	-0.53	2.52e-10	Obesity;
TGCT	cis	rs3091242	0.933	rs34006994	chr1:25780668	C/T	cg23205692	chr1:25664452	TMEM50A	-0.47	-4.97	-0.41	2.22e-6	Erythrocyte sedimentation rate;
TGCT	cis	rs2921073	0.510	rs2976945	chr8:8270871	G/T	cg08975724	chr8:8085496	FLJ10661	0.57	4.92	0.4	2.71e-6	Parkinson's disease;
TGCT	cis	rs986417	1.000	rs1262174	chr14:60887194	C/T	cg27398547	chr14:60952738	C14orf39	1.42	9.05	0.63	2.48e-15	Gut microbiota (bacterial taxa);
TGCT	cis	rs114540395	0.925	rs80151341	chr10:103139960	G/A	cg18276125	chr10:102749041	C10orf2	0.38	4.6	0.38	1.05e-5	Schizophrenia;
TGCT	cis	rs17376456	0.569	rs1026279	chr5:93209581	C/A	cg25358565	chr5:93447407	FAM172A	-0.81	-6.54	-0.51	1.47e-9	Diabetic retinopathy;
TGCT	cis	rs11209002	0.522	rs2224502	chr1:67539439	A/G	cg02640540	chr1:67518911	SLC35D1	0.53	4.45	0.37	1.86e-5	Crohn's disease;
TGCT	cis	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg18252515	chr7:66147081	NA	-1.1	-6.4	-0.5	2.85e-9	Diabetic kidney disease;
TGCT	cis	rs2204008	0.774	rs7304438	chr12:38361146	T/G	cg13010199	chr12:38710504	ALG10B	0.59	4.58	0.38	1.14e-5	Bladder cancer;
TGCT	cis	rs1045714	0.895	rs1107690	chr7:2640595	G/T	cg17215154	chr7:2644645	IQCE	0.28	4.97	0.41	2.2e-6	Urate levels in lean individuals;
TGCT	cis	rs4891159	0.660	rs4891160	chr18:74102135	C/T	cg24786174	chr18:74118243	ZNF516	0.56	8.19	0.59	2.75e-13	Longevity;
TGCT	cis	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg20637647	chr7:64974828	NA	0.9	5.31	0.43	4.87e-7	Diabetic kidney disease;
TGCT	cis	rs854765	0.647	rs2974999	chr17:17997547	T/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.68	7.1	0.54	8.35e-11	Total body bone mineral density;
TGCT	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	5.53	0.44	1.8e-7	Alzheimer's disease;
TGCT	cis	rs9902453	1.000	rs4575590	chr17:28361969	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-6.56	-0.51	1.3e-9	Coffee consumption (cups per day);
TGCT	cis	rs7224685	0.569	rs35586982	chr17:4001993	G/A	cg09580393	chr17:4869866	SPAG7	-0.38	-4.48	-0.37	1.64e-5	Type 2 diabetes;
TGCT	cis	rs2153535	0.580	rs6913100	chr6:8456855	A/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.1	0.42	1.21e-6	Motion sickness;
TGCT	cis	rs35306767	0.903	rs11253458	chr10:882843	T/C	cg20503657	chr10:835505	NA	0.7	9.83	0.66	3.22e-17	Eosinophil percentage of granulocytes;
TGCT	cis	rs12134133	0.962	rs6668560	chr1:207416807	G/C	cg02152968	chr1:207494213	CD55	0.61	4.74	0.39	5.83e-6	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs2692947	0.673	rs2229169	chr2:96780716	T/G	cg05933789	chr2:97190408	NA	-0.17	-4.87	-0.4	3.39e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs858239	0.600	rs10488077	chr7:23144182	A/T	cg05602783	chr7:23145260	KLHL7	-0.73	-6.3	-0.49	4.74e-9	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs367943	1.000	rs348928	chr5:112815295	C/T	cg12552261	chr5:112820674	MCC	-0.24	-4.91	-0.4	2.81e-6	Type 2 diabetes;
TGCT	cis	rs55794721	0.509	rs12027135	chr1:25775733	A/T	cg00786635	chr1:25594202	NA	0.53	5.58	0.45	1.41e-7	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs6076065	0.707	rs2024746	chr20:23356862	G/A	cg11657817	chr20:23433608	CST11	0.31	5.42	0.44	3.02e-7	Facial morphology (factor 15, philtrum width);
TGCT	trans	rs17685	0.523	rs10246583	chr7:75746667	C/A	cg19862616	chr7:65841803	NCRNA00174	0.52	9.01	0.63	3.02e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg11062466	chr8:58055876	NA	0.44	4.62	0.38	9.53e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs317689	0.718	rs315130	chr12:69761444	T/C	cg11871910	chr12:69753446	YEATS4	0.55	4.64	0.38	8.6e-6	Response to diuretic therapy;
TGCT	cis	rs3008870	1.000	rs2985817	chr1:67398607	G/C	cg03991309	chr1:68237761	GNG12	0.27	4.55	0.38	1.26e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs2228479	0.717	rs12917681	chr16:89810941	C/A	cg04287289	chr16:89883240	FANCA	0.74	4.44	0.37	1.99e-5	Skin colour saturation;
TGCT	cis	rs7772486	0.774	rs2247571	chr6:146219533	T/A	cg23711669	chr6:146136114	FBXO30	0.77	7.63	0.57	5.28e-12	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10466239	0.730	rs12221341	chr10:43857330	C/G	cg14116799	chr10:43800154	NA	-0.55	-4.72	-0.39	6.21e-6	Telomere length;
TGCT	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg17971929	chr21:40555470	PSMG1	0.98	9.67	0.66	8.18e-17	Cognitive function;
TGCT	cis	rs7659604	0.540	rs28672860	chr4:122705051	G/A	cg05802129	chr4:122689817	NA	0.3	4.46	0.37	1.84e-5	Type 2 diabetes;
TGCT	cis	rs797680	0.856	rs6680107	chr1:93770880	G/A	cg17826107	chr1:92977322	EVI5	-0.23	-5.1	-0.42	1.24e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs1057239	0.510	rs3766694	chr1:175143207	T/C	cg00321850	chr1:175162397	KIAA0040	-0.47	-6.88	-0.53	2.66e-10	Diastolic blood pressure;
TGCT	cis	rs17376456	0.877	rs13169675	chr5:93331284	A/G	cg25358565	chr5:93447407	FAM172A	0.98	8.48	0.61	5.62e-14	Diabetic retinopathy;
TGCT	cis	rs3820068	0.626	rs11580170	chr1:15909744	C/T	cg05660106	chr1:15850417	CASP9	1.04	11.74	0.73	7.33e-22	Systolic blood pressure;
TGCT	cis	rs6840360	0.615	rs12641433	chr4:152607548	A/C	cg17479576	chr4:152424074	FAM160A1	-0.63	-6.4	-0.5	2.89e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs2456568	0.867	rs2462750	chr11:93668590	C/T	cg26875233	chr11:93583750	C11orf90	-0.46	-5.59	-0.45	1.4e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg19748678	chr4:122722346	EXOSC9	0.9	9.1	0.63	1.85e-15	Type 2 diabetes;
TGCT	cis	rs6969780	0.630	rs3735530	chr7:27189982	C/T	cg22997113	chr7:27170241	HOXA4	-0.44	-4.46	-0.37	1.79e-5	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs9914988	0.619	rs35477460	chr17:27320276	C/T	cg16968985	chr17:27313254	SEZ6	-0.35	-4.47	-0.37	1.75e-5	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs4285028	0.948	rs73855481	chr3:121676951	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.77	-6.55	-0.51	1.35e-9	Multiple sclerosis;
TGCT	cis	rs7647973	0.560	rs7638154	chr3:49299375	C/A	cg16497277	chr3:49208875	KLHDC8B	-0.54	-5.17	-0.42	9.07e-7	Menarche (age at onset);
TGCT	cis	rs36051895	0.593	rs2094619	chr9:5167712	G/C	cg02405213	chr9:5042618	JAK2	-0.74	-9.77	-0.66	4.49e-17	Pediatric autoimmune diseases;
TGCT	cis	rs3796352	1.000	rs11718834	chr3:52963668	A/C	cg07884673	chr3:53033167	SFMBT1	0.64	6.02	0.48	1.83e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs1775715	0.737	rs2808090	chr10:32143208	A/C	cg14930904	chr10:32216787	ARHGAP12	0.55	5.45	0.44	2.63e-7	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs6570726	0.577	rs441982	chr6:145842848	A/G	cg05347473	chr6:146136440	FBXO30	0.61	5.5	0.44	2.08e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs904251	0.965	rs62406516	chr6:37439364	C/T	cg01843034	chr6:37503916	NA	-0.46	-5.44	-0.44	2.72e-7	Cognitive performance;
TGCT	cis	rs2688608	0.617	rs6480709	chr10:75479125	T/C	cg19442545	chr10:75533431	FUT11	-0.37	-5.87	-0.47	3.81e-8	Inflammatory bowel disease;
TGCT	cis	rs11080107	0.542	rs894606	chr17:27909352	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	4.85	0.4	3.67e-6	Coronary artery disease;
TGCT	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg01585852	chr22:24235823	MIF	-0.22	-4.85	-0.4	3.67e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1670533	1.000	rs676561	chr4:1083112	C/T	cg27284194	chr4:1044797	NA	0.69	5.93	0.47	2.78e-8	Recombination rate (females);
TGCT	cis	rs7726839	0.574	rs72705017	chr5:623733	G/A	cg09021430	chr5:549028	NA	-0.46	-6.07	-0.48	1.42e-8	Obesity-related traits;
TGCT	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg18876405	chr7:65276391	NA	-0.36	-5.41	-0.44	3.12e-7	Aortic root size;
TGCT	cis	rs7552404	0.628	rs4949686	chr1:76473299	G/C	cg22875332	chr1:76189707	ACADM	0.66	5.93	0.47	2.83e-8	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs988712	0.705	rs1829469	chr11:27730556	A/G	cg10635145	chr11:27742435	BDNF	-0.44	-6.2	-0.49	7.51e-9	Obesity;
TGCT	cis	rs2072499	1.000	rs2241108	chr1:156181007	C/G	cg06970220	chr1:156163860	SLC25A44	0.67	5.84	0.46	4.32e-8	Testicular germ cell tumor;
TGCT	cis	rs2153535	0.580	rs1034273	chr6:8468145	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs308403	0.600	rs309361	chr4:123657978	A/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.73	6.85	0.52	3e-10	Blood protein levels;
TGCT	cis	rs11098499	0.863	rs1552092	chr4:120488496	C/T	cg09307838	chr4:120376055	NA	0.72	6.9	0.53	2.41e-10	Corneal astigmatism;
TGCT	cis	rs3892630	0.824	rs34425841	chr19:33231619	C/T	cg22980127	chr19:33182716	NUDT19	0.7	4.96	0.41	2.25e-6	Red blood cell traits;
TGCT	cis	rs3091242	0.933	rs7541095	chr1:25761291	T/C	cg09222892	chr1:25734099	RHCE	-0.43	-7.05	-0.53	1.11e-10	Erythrocyte sedimentation rate;
TGCT	cis	rs903263	0.965	rs6661492	chr1:84592444	T/C	cg09664975	chr1:84543551	PRKACB	0.49	4.55	0.38	1.26e-5	Breast cancer (male);
TGCT	cis	rs17253792	0.822	rs118027213	chr14:56039076	T/C	cg01858014	chr14:56050164	KTN1	-0.36	-4.57	-0.38	1.15e-5	Putamen volume;
TGCT	cis	rs1403694	0.695	rs10937266	chr3:186433075	G/A	cg12454167	chr3:186435060	KNG1	0.5	8.55	0.61	3.86e-14	Blood protein levels;
TGCT	cis	rs611744	0.839	rs672552	chr8:109164223	A/G	cg21045802	chr8:109455806	TTC35	0.69	6.06	0.48	1.51e-8	Dupuytren's disease;
TGCT	cis	rs4242434	0.854	rs4872007	chr8:22538879	G/A	cg03733263	chr8:22462867	KIAA1967	-1.14	-17.33	-0.84	6.37e-35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs7582180	0.652	rs12997725	chr2:100935136	A/G	cg14675211	chr2:100938903	LONRF2	0.51	4.98	0.41	2.11e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2404602	0.632	rs34338978	chr15:77226805	T/C	cg22467129	chr15:76604101	ETFA	-0.5	-5.65	-0.45	1.06e-7	Blood metabolite levels;
TGCT	cis	rs114540395	0.687	rs75269434	chr10:103473111	G/C	cg18276125	chr10:102749041	C10orf2	0.42	5.21	0.42	7.67e-7	Schizophrenia;
TGCT	cis	rs9807989	0.811	rs11689730	chr2:102969984	C/A	cg09003973	chr2:102972529	NA	0.64	5.7	0.46	8.28e-8	Asthma;
TGCT	cis	rs8077889	0.719	rs2079006	chr17:41865745	C/G	cg26893861	chr17:41843967	DUSP3	1.1	20.06	0.87	9.8e-41	Triglycerides;
TGCT	trans	rs9393366	1.000	rs9393366	chr6:23077311	A/G	cg09418321	chr12:4699618	DYRK4	0.28	6.82	0.52	3.59e-10	Tourette syndrome;
TGCT	cis	rs36051895	0.623	rs12720	chr9:5231712	T/A	cg02405213	chr9:5042618	JAK2	-0.69	-8.63	-0.61	2.52e-14	Pediatric autoimmune diseases;
TGCT	cis	rs933688	0.536	rs332537	chr5:90794973	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.93	-6.12	-0.48	1.14e-8	Smoking behavior;
TGCT	cis	rs12478296	0.685	rs6705935	chr2:242995110	C/T	cg06360820	chr2:242988706	NA	-0.62	-5.29	-0.43	5.25e-7	Obesity-related traits;
TGCT	cis	rs57994353	0.793	rs12552167	chr9:139322927	C/T	cg13741927	chr9:139327495	INPP5E	-0.27	-6.14	-0.48	1.01e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs35306767	0.714	rs67205460	chr10:1090366	C/T	cg20503657	chr10:835505	NA	0.6	6.93	0.53	2e-10	Eosinophil percentage of granulocytes;
TGCT	cis	rs13191362	1.000	rs13192894	chr6:163052444	T/A	cg21926612	chr6:163149169	PACRG;PARK2	1.07	8.5	0.61	5.17e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs4972806	0.776	rs2072589	chr2:177042871	C/T	cg14324370	chr2:177042789	NA	0.77	7.09	0.54	9.09e-11	IgG glycosylation;
TGCT	cis	rs910316	0.503	rs12894709	chr14:75441734	G/A	cg08847533	chr14:75593920	NEK9	0.67	6.56	0.51	1.31e-9	Height;
TGCT	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.68	5.73	0.46	7.3e-8	Tonsillectomy;
TGCT	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg13395646	chr4:1353034	KIAA1530	-0.36	-4.61	-0.38	9.75e-6	Obesity-related traits;
TGCT	cis	rs4372836	0.504	rs6547881	chr2:29032746	C/T	cg09522027	chr2:28974177	PPP1CB	0.57	5.74	0.46	6.84e-8	Body mass index;
TGCT	cis	rs11731606	0.508	rs56943028	chr4:95285813	T/C	cg00507259	chr4:95128692	SMARCAD1	0.63	4.72	0.39	6.18e-6	Mean platelet volume;
TGCT	cis	rs6500602	0.893	rs4786490	chr16:4491190	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.29	-5.09	-0.42	1.27e-6	Schizophrenia;
TGCT	cis	rs6988636	1.000	rs6988636	chr8:124185970	A/G	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2708977	0.637	rs585781	chr2:97088623	C/A	cg01950434	chr2:97203154	ARID5A	-0.61	-5.26	-0.43	6.08e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg16325326	chr1:53192061	ZYG11B	0.59	6.92	0.53	2.17e-10	Monocyte count;
TGCT	cis	rs473651	0.935	rs482775	chr2:239335403	G/C	cg08773314	chr2:239334832	ASB1	0.45	7.58	0.56	7.07e-12	Multiple system atrophy;
TGCT	cis	rs1997103	1.000	rs4947499	chr7:55407196	T/C	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs2997447	0.761	rs17184884	chr1:26446565	G/A	cg03844060	chr1:26490628	NA	0.28	4.55	0.38	1.27e-5	QRS complex (12-leadsum);
TGCT	cis	rs854765	0.583	rs12452254	chr17:17829434	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	7.77	0.57	2.58e-12	Total body bone mineral density;
TGCT	cis	rs2486012	0.737	rs641356	chr1:44287186	C/T	cg12908607	chr1:44402522	ARTN	-0.69	-5.35	-0.43	4.16e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7208859	0.673	rs9907197	chr17:29018263	C/T	cg13385521	chr17:29058706	SUZ12P	0.74	4.65	0.39	8.3e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs2404602	0.647	rs11072636	chr15:77185786	A/G	cg22467129	chr15:76604101	ETFA	0.45	4.53	0.38	1.35e-5	Blood metabolite levels;
TGCT	cis	rs7412746	0.658	rs12067685	chr1:150952917	T/C	cg04414720	chr1:150670196	GOLPH3L	0.39	4.68	0.39	7.48e-6	Melanoma;
TGCT	trans	rs11082438	0.786	rs11660485	chr18:42866471	A/C	cg13513804	chr10:50121894	LRRC18;WDFY4	-0.73	-6.64	-0.51	9e-10	Follicular lymphoma;
TGCT	trans	rs1814175	0.817	rs12287396	chr11:49819798	G/C	cg03929089	chr4:120376271	NA	-0.72	-8.26	-0.6	1.84e-13	Height;
TGCT	cis	rs858239	0.537	rs6942981	chr7:23231548	C/T	cg05602783	chr7:23145260	KLHL7	-0.73	-5.76	-0.46	6.13e-8	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs4654899	0.865	rs10916927	chr1:21385795	T/C	cg01072550	chr1:21505969	NA	-0.47	-7.08	-0.54	9.59e-11	Superior frontal gyrus grey matter volume;
TGCT	cis	rs4499344	0.526	rs11084655	chr19:33034698	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.69	5.89	0.47	3.34e-8	Mean platelet volume;
TGCT	cis	rs28595532	0.920	rs116548907	chr4:119735285	G/A	cg21605333	chr4:119757512	SEC24D	1.67	8.38	0.6	9.82e-14	Cannabis dependence symptom count;
TGCT	cis	rs151997	0.777	rs3846500	chr5:50254488	A/T	cg06027927	chr5:50259733	NA	-0.6	-6.47	-0.5	2.04e-9	Callous-unemotional behaviour;
TGCT	cis	rs1971762	0.527	rs7300936	chr12:54030586	C/T	cg16917193	chr12:54089295	NA	1.06	11.82	0.73	4.57e-22	Height;
TGCT	cis	rs9583531	0.600	rs2119479	chr13:111371181	A/C	cg24331049	chr13:111365604	ING1	0.77	7.38	0.55	1.97e-11	Coronary artery disease;
TGCT	cis	rs2180341	0.842	rs7739679	chr6:127545428	G/A	cg27446573	chr6:127587934	RNF146	1.05	8.19	0.59	2.67e-13	Breast cancer;
TGCT	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg13393036	chr8:95962371	TP53INP1	-0.63	-8.52	-0.61	4.43e-14	Type 2 diabetes;
TGCT	cis	rs36051895	0.632	rs62541959	chr9:5175687	G/C	cg02405213	chr9:5042618	JAK2	-0.72	-9.73	-0.66	5.69e-17	Pediatric autoimmune diseases;
TGCT	cis	rs6138458	0.847	rs56312312	chr20:24959386	C/A	cg26195577	chr20:24973756	C20orf3	1.21	10.66	0.69	3.07e-19	Blood protein levels;
TGCT	trans	rs324780	0.544	rs3112089	chr12:83907973	T/C	cg27144766	chr5:150604977	CCDC69	0.24	6.63	0.51	9.42e-10	Vertical cup-disc ratio;
TGCT	cis	rs854765	0.594	rs8066560	chr17:17728043	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.66	-6.06	-0.48	1.52e-8	Total body bone mineral density;
TGCT	cis	rs1215050	0.791	rs2123100	chr4:98803747	T/C	cg05340658	chr4:99064831	C4orf37	0.44	5.51	0.44	2.01e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs13242816	1.000	rs3807987	chr7:116179834	G/A	cg16553024	chr7:116138462	CAV2	-0.44	-5.26	-0.43	6.11e-7	P wave duration;
TGCT	cis	rs7249142	0.597	rs759999	chr19:19281207	A/C	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.45	-4.5	-0.37	1.53e-5	IgG glycosylation;
TGCT	cis	rs936229	0.861	rs7162232	chr15:75115895	G/A	cg10253484	chr15:75165896	SCAMP2	-0.66	-5.34	-0.43	4.28e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
TGCT	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg14827481	chr10:134361889	INPP5A	0.31	4.99	0.41	1.99e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs7178572	0.568	rs62008452	chr15:77591007	A/G	cg22256960	chr15:77711686	NA	-0.85	-8.73	-0.62	1.4e-14	Type 2 diabetes;
TGCT	cis	rs1950500	0.545	rs1950501	chr14:24806800	C/G	cg22990158	chr14:24802150	ADCY4	-0.52	-4.63	-0.38	9.25e-6	Height;
TGCT	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg02725872	chr8:58115012	NA	-0.36	-4.62	-0.38	9.53e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1371867	0.846	rs1660345	chr8:101322762	C/A	cg06002616	chr8:101225028	SPAG1	-0.56	-6.58	-0.51	1.2e-9	Atrioventricular conduction;
TGCT	cis	rs208515	0.556	rs12201658	chr6:66678457	T/C	cg07460842	chr6:66804631	NA	0.87	9.16	0.64	1.32e-15	Exhaled nitric oxide levels;
TGCT	cis	rs2486288	0.656	rs12911861	chr15:45566718	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.78	-7.46	-0.56	1.3e-11	Glomerular filtration rate;
TGCT	cis	rs17221829	0.769	rs11018674	chr11:89357113	G/A	cg02982614	chr11:89391479	FOLH1B	-0.28	-4.87	-0.4	3.35e-6	Anxiety in major depressive disorder;
TGCT	cis	rs79057730	0.528	rs6965219	chr7:821807	C/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.74	5.61	0.45	1.25e-7	Initial pursuit acceleration;
TGCT	cis	rs453301	0.719	rs34004903	chr8:8892604	C/T	cg15556689	chr8:8085844	FLJ10661	-0.62	-5.24	-0.43	6.69e-7	Joint mobility (Beighton score);
TGCT	cis	rs2836974	0.583	rs9981884	chr21:40585633	G/A	cg11890956	chr21:40555474	PSMG1	0.81	8.43	0.6	7.55e-14	Cognitive function;
TGCT	cis	rs1568889	1.000	rs12797712	chr11:28290890	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.81	7.99	0.58	7.84e-13	Bipolar disorder;
TGCT	cis	rs644799	0.710	rs523153	chr11:95570961	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.82	7.93	0.58	1.07e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7617773	0.851	rs7647817	chr3:48236507	G/A	cg11946769	chr3:48343235	NME6	0.76	6.67	0.51	7.6e-10	Coronary artery disease;
TGCT	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg10047753	chr17:41438598	NA	0.81	7.41	0.55	1.73e-11	Menopause (age at onset);
TGCT	cis	rs6992820	0.967	rs7816303	chr8:56723278	A/G	cg06880721	chr8:56792545	LYN	-0.53	-4.44	-0.37	1.97e-5	Mean platelet volume;
TGCT	cis	rs7267979	1.000	rs6076345	chr20:25381895	T/G	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg05368731	chr17:41323189	NBR1	1.21	14.63	0.8	8.89e-29	Menopause (age at onset);
TGCT	cis	rs12477438	0.798	rs1349778	chr2:99645011	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.69	-5.87	-0.47	3.64e-8	Chronic sinus infection;
TGCT	cis	rs4631830	0.863	rs2843550	chr10:51521452	C/T	cg10326726	chr10:51549505	MSMB	-0.25	-4.86	-0.4	3.46e-6	Prostate-specific antigen levels;
TGCT	cis	rs2742417	0.967	rs2742426	chr3:45735901	A/G	cg04837898	chr3:45731254	SACM1L	-0.55	-5.68	-0.45	9.14e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	trans	rs1814175	0.791	rs11040513	chr11:49778153	G/C	cg03929089	chr4:120376271	NA	-0.69	-8.17	-0.59	3.03e-13	Height;
TGCT	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg18876405	chr7:65276391	NA	0.32	4.89	0.4	3.12e-6	Aortic root size;
TGCT	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg25036284	chr2:26402008	FAM59B	0.67	4.46	0.37	1.79e-5	Gut microbiome composition (summer);
TGCT	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg00149659	chr3:10157352	C3orf10	-0.74	-4.7	-0.39	6.84e-6	Alzheimer's disease;
TGCT	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg03303774	chr4:1407052	NA	0.38	6.03	0.48	1.78e-8	Obesity-related traits;
TGCT	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg12311346	chr5:56204834	C5orf35	-0.59	-6.11	-0.48	1.21e-8	Coronary artery disease;
TGCT	cis	rs9486715	0.867	rs9372106	chr6:96875058	T/C	cg18709589	chr6:96969512	KIAA0776	0.77	7.5	0.56	1.09e-11	Headache;
TGCT	cis	rs2295359	1.000	rs11209007	chr1:67619345	C/G	cg12940439	chr1:67600707	NA	0.56	6.04	0.48	1.63e-8	Psoriasis;
TGCT	cis	rs7586879	0.828	rs9631061	chr2:25109804	C/T	cg01884057	chr2:25150051	NA	0.27	4.8	0.4	4.57e-6	Body mass index;
TGCT	trans	rs10109025	0.701	rs10101292	chr8:10856474	T/C	cg06636001	chr8:8085503	FLJ10661	-0.78	-7.02	-0.53	1.26e-10	Joint mobility (Beighton score);
TGCT	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7072216	0.763	rs7091709	chr10:100167605	G/A	cg26618903	chr10:100175079	PYROXD2	-0.41	-4.5	-0.38	1.51e-5	Metabolite levels;
TGCT	cis	rs916888	0.531	rs183211	chr17:44788310	G/A	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.46	-4.43	-0.37	2.01e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs854765	0.927	rs4925138	chr17:17992793	T/G	cg04398451	chr17:18023971	MYO15A	0.3	4.68	0.39	7.36e-6	Total body bone mineral density;
TGCT	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg26338869	chr17:61819248	STRADA	-0.53	-4.9	-0.4	2.95e-6	Prudent dietary pattern;
TGCT	cis	rs6860806	0.631	rs6863548	chr5:131575920	G/A	cg24060327	chr5:131705240	SLC22A5	-0.59	-5.99	-0.47	2.15e-8	Breast cancer;
TGCT	cis	rs2836950	0.545	rs2836956	chr21:40623018	C/G	cg17971929	chr21:40555470	PSMG1	0.55	5.05	0.41	1.55e-6	Menarche (age at onset);
TGCT	cis	rs10927875	0.894	rs10927878	chr1:16319957	C/T	cg14742211	chr1:16348397	CLCNKA	-0.19	-4.48	-0.37	1.66e-5	Dilated cardiomyopathy;
TGCT	cis	rs1865760	0.820	rs9348697	chr6:25890834	C/T	cg16482183	chr6:26056742	HIST1H1C	0.52	4.59	0.38	1.08e-5	Height;
TGCT	cis	rs13202913	0.652	rs9371528	chr6:151832668	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.72	-4.93	-0.4	2.61e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs9583531	0.657	rs9521915	chr13:111384528	C/T	cg24331049	chr13:111365604	ING1	0.83	8.23	0.59	2.16e-13	Coronary artery disease;
TGCT	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg11890956	chr21:40555474	PSMG1	-0.76	-7.45	-0.56	1.36e-11	Cognitive function;
TGCT	cis	rs3782455	1.000	rs16943542	chr12:114406301	C/T	cg10631684	chr12:113795897	PLBD2	-0.8	-5.22	-0.42	7.25e-7	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs7809950	0.731	rs4730238	chr7:107054787	G/A	cg23024343	chr7:107201750	COG5	-0.48	-6.44	-0.5	2.43e-9	Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs1834645	chr4:98979593	T/A	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs950169	0.922	rs4586394	chr15:84822385	G/A	cg12863693	chr15:85201151	NMB	-0.43	-4.81	-0.4	4.36e-6	Schizophrenia;
TGCT	cis	rs9457247	1.000	rs2013815	chr6:167373812	T/A	cg23791538	chr6:167370224	RNASET2	0.5	4.98	0.41	2.05e-6	Crohn's disease;
TGCT	cis	rs10875746	0.517	rs12721420	chr12:48358794	C/T	cg20731937	chr12:48336164	NA	0.9	6.62	0.51	9.82e-10	Longevity (90 years and older);
TGCT	cis	rs9303401	0.614	rs34941454	chr17:57102742	T/G	cg25039879	chr17:56429692	SUPT4H1	0.54	4.8	0.4	4.57e-6	Cognitive test performance;
TGCT	cis	rs10791097	0.694	rs7940027	chr11:130745591	A/G	cg14779329	chr11:130786720	SNX19	0.28	4.82	0.4	4.1e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	6.95	0.53	1.86e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6598955	0.671	rs10902727	chr1:26597781	C/T	cg04990556	chr1:26633338	UBXN11	0.66	5.0	0.41	1.88e-6	Obesity-related traits;
TGCT	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg03303774	chr4:1407052	NA	0.3	4.78	0.39	4.8e-6	Obesity-related traits;
TGCT	cis	rs422249	0.819	rs174605	chr11:61626921	G/T	cg19610905	chr11:61596333	FADS2	-0.56	-4.52	-0.38	1.42e-5	Trans fatty acid levels;
TGCT	cis	rs7552404	0.924	rs1694419	chr1:76219801	C/T	cg10523679	chr1:76189770	ACADM	0.7	6.35	0.5	3.77e-9	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2439831	0.681	rs498837	chr15:43608024	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	6.75	0.52	4.98e-10	Lung cancer in ever smokers;
TGCT	cis	rs1371867	0.846	rs1692006	chr8:101252462	C/T	cg06002616	chr8:101225028	SPAG1	0.54	6.4	0.5	2.87e-9	Atrioventricular conduction;
TGCT	cis	rs763014	0.865	rs2018789	chr16:632051	T/C	cg27436995	chr16:743998	FBXL16	-0.45	-4.82	-0.4	4.17e-6	Height;
TGCT	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.51	-4.97	-0.41	2.18e-6	Prudent dietary pattern;
TGCT	cis	rs9399137	0.507	rs10484496	chr6:135299682	T/C	cg24558204	chr6:135376177	HBS1L	0.47	4.76	0.39	5.27e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
TGCT	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg08509172	chr19:19383838	TM6SF2	-0.35	-4.54	-0.38	1.32e-5	Tonsillectomy;
TGCT	cis	rs2580764	0.624	rs12713284	chr2:55228861	G/A	cg09592903	chr2:55203963	RTN4	-0.25	-5.45	-0.44	2.58e-7	Mean platelet volume;
TGCT	cis	rs896854	0.517	rs2013597	chr8:95951807	G/A	cg13393036	chr8:95962371	TP53INP1	-0.49	-5.61	-0.45	1.26e-7	Type 2 diabetes;
TGCT	cis	rs12580194	0.593	rs61957941	chr12:55748058	G/A	cg10672482	chr12:55725839	OR6C3	-0.51	-4.43	-0.37	2.01e-5	Cancer;
TGCT	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg23302884	chr18:44338147	ST8SIA5	-0.41	-4.7	-0.39	6.77e-6	Personality dimensions;
TGCT	cis	rs7043114	0.525	rs4744136	chr9:95275024	A/G	cg13798575	chr9:95087839	CENPP;NOL8	0.54	5.41	0.44	3.18e-7	Height;
TGCT	cis	rs8072100	0.713	rs11079776	chr17:45546893	C/T	cg08085267	chr17:45401833	C17orf57	-0.47	-5.16	-0.42	9.45e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs709400	0.663	rs1028613	chr14:103888324	G/A	cg12935359	chr14:103987150	CKB	-0.36	-5.47	-0.44	2.42e-7	Body mass index;
TGCT	cis	rs2013441	1.000	rs2526480	chr17:20130074	A/G	cg23224458	chr17:20280056	CCDC144C	0.4	4.7	0.39	6.74e-6	Obesity-related traits;
TGCT	cis	rs6570726	0.791	rs1280276	chr6:145892350	A/C	cg23711669	chr6:146136114	FBXO30	0.89	9.87	0.66	2.56e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs933688	1.000	rs1895448	chr5:90743854	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.1	10.42	0.68	1.18e-18	Smoking behavior;
TGCT	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg23758822	chr17:41437982	NA	0.73	6.74	0.52	5.43e-10	Menopause (age at onset);
TGCT	cis	rs11605924	0.692	rs877412	chr11:45897651	A/C	ch.11.939596F	chr11:45881766	CRY2	0.44	5.51	0.44	2.02e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);
TGCT	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg23758822	chr17:41437982	NA	0.72	6.77	0.52	4.51e-10	Menopause (age at onset);
TGCT	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg05025164	chr4:1340916	KIAA1530	0.54	4.79	0.4	4.64e-6	Longevity;
TGCT	cis	rs2463822	1.000	rs2513052	chr11:62108248	C/G	cg06239285	chr11:62104954	ASRGL1	0.93	6.71	0.52	6.27e-10	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs11098499	0.644	rs3806808	chr4:120551085	A/C	cg09307838	chr4:120376055	NA	0.62	5.82	0.46	4.83e-8	Corneal astigmatism;
TGCT	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg16325326	chr1:53192061	ZYG11B	0.56	6.29	0.49	4.85e-9	Monocyte count;
TGCT	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg09323728	chr8:95962352	TP53INP1	-0.52	-6.6	-0.51	1.05e-9	Type 2 diabetes;
TGCT	cis	rs858239	0.636	rs7808488	chr7:23221870	T/C	cg05602783	chr7:23145260	KLHL7	-0.64	-5.31	-0.43	4.98e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs6545883	0.929	rs55806663	chr2:61740487	G/T	cg15711740	chr2:61764176	XPO1	-0.56	-5.11	-0.42	1.17e-6	Tuberculosis;
TGCT	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg10802521	chr3:52805072	NEK4	-0.78	-10.01	-0.67	1.22e-17	Bipolar disorder;
TGCT	cis	rs7829975	0.510	rs332037	chr8:8722675	C/T	cg08975724	chr8:8085496	FLJ10661	0.57	5.23	0.43	7.02e-7	Mood instability;
TGCT	trans	rs3780486	1.000	rs3780480	chr9:33163486	G/T	cg20290983	chr6:43655470	MRPS18A	1.1	10.66	0.69	3.1400000000000002e-19	IgG glycosylation;
TGCT	cis	rs2562456	0.793	rs7259708	chr19:21750648	T/C	cg01304269	chr19:21688519	ZNF429	0.58	4.73	0.39	5.93e-6	Pain;
TGCT	cis	rs77861329	1.000	rs164639	chr3:52210872	A/G	cg08692210	chr3:52188851	WDR51A	-0.83	-5.04	-0.41	1.58e-6	Macrophage inflammatory protein 1b levels;
TGCT	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg01802117	chr1:53393560	SCP2	-0.46	-5.57	-0.45	1.49e-7	Monocyte count;
TGCT	cis	rs1532993	0.518	rs9990450	chr4:98568821	C/A	cg05340658	chr4:99064831	C4orf37	-0.38	-4.53	-0.38	1.36e-5	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg03188948	chr7:1209495	NA	0.5	5.23	0.42	7.12e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs77633900	0.614	rs2170998	chr15:77007159	C/T	cg21673338	chr15:77095150	SCAPER	0.51	5.12	0.42	1.11e-6	Non-glioblastoma glioma;Glioma;
TGCT	cis	rs9467773	1.000	rs6456734	chr6:26566965	G/T	cg15659132	chr6:26577336	NA	0.88	12.27	0.74	3.83e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs7582180	0.629	rs4851295	chr2:100945605	T/C	cg14675211	chr2:100938903	LONRF2	0.5	4.78	0.39	4.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7119	0.635	rs2667767	chr15:77876031	T/C	cg27398640	chr15:77910606	LINGO1	0.31	6.19	0.49	8.16e-9	Type 2 diabetes;
TGCT	cis	rs7945705	0.935	rs2568061	chr11:8886260	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-5.5	-0.44	2.03e-7	Hemoglobin concentration;
TGCT	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg18876405	chr7:65276391	NA	0.31	4.78	0.39	4.81e-6	Aortic root size;
TGCT	cis	rs1371867	0.764	rs1020171	chr8:101288610	T/C	cg06636551	chr8:101224915	SPAG1	-0.49	-6.83	-0.52	3.32e-10	Atrioventricular conduction;
TGCT	trans	rs877282	0.891	rs11599917	chr10:762288	G/A	cg22713356	chr15:30763199	NA	1.15	8.97	0.63	3.86e-15	Uric acid levels;
TGCT	cis	rs727563	0.638	rs5996058	chr22:42141452	A/G	cg06481639	chr22:41940642	POLR3H	0.7	6.16	0.48	9.5e-9	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs68170813	0.562	rs78181351	chr7:106999301	A/G	cg02696742	chr7:106810147	HBP1	-0.73	-5.95	-0.47	2.6e-8	Coronary artery disease;
TGCT	trans	rs629535	0.814	rs56301437	chr8:70108518	C/T	cg21567404	chr3:27674614	NA	-0.57	-8.81	-0.62	9.34e-15	Dupuytren's disease;
TGCT	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg13699009	chr12:122356056	WDR66	-0.28	-5.7	-0.46	8.42e-8	Mean corpuscular volume;
TGCT	cis	rs67311347	0.955	rs73080163	chr3:40533061	G/T	cg02782426	chr3:40428986	ENTPD3	0.44	4.74	0.39	5.88e-6	Renal cell carcinoma;
TGCT	cis	rs11167764	1.000	rs11167764	chr5:141479065	A/C	cg23435118	chr5:141488016	NDFIP1	-0.28	-4.49	-0.37	1.58e-5	Crohn's disease;
TGCT	cis	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg19635926	chr16:89946313	TCF25	0.28	4.82	0.4	4.06e-6	Skin colour saturation;
TGCT	cis	rs7192750	0.586	rs8044342	chr16:71869532	A/G	cg06353428	chr16:71660113	MARVELD3	0.76	6.74	0.52	5.2400000000000005e-10	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs12950390	0.853	rs17700008	chr17:45863591	A/C	cg24803719	chr17:45855879	NA	0.49	5.03	0.41	1.64e-6	IgG glycosylation;
TGCT	cis	rs36051895	0.632	rs2149552	chr9:5132838	A/G	cg02405213	chr9:5042618	JAK2	-0.73	-10.16	-0.67	5.11e-18	Pediatric autoimmune diseases;
TGCT	cis	rs1580019	0.961	rs1868777	chr7:32494076	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.77	6.09	0.48	1.33e-8	Cognitive ability;
TGCT	cis	rs9303401	0.614	rs35057477	chr17:57097064	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.58	5.83	0.46	4.4e-8	Cognitive test performance;
TGCT	cis	rs1044826	0.642	rs9826544	chr3:139162831	A/G	cg00490450	chr3:139108681	COPB2	0.53	4.59	0.38	1.06e-5	Obesity-related traits;
TGCT	cis	rs904251	0.828	rs2797803	chr6:37487340	T/C	cg01843034	chr6:37503916	NA	-0.52	-6.28	-0.49	5.17e-9	Cognitive performance;
TGCT	cis	rs4820539	1.000	rs2267003	chr22:23457098	A/G	cg14186256	chr22:23484241	RTDR1	1.0	12.29	0.74	3.48e-23	Bone mineral density;
TGCT	cis	rs1018836	0.663	rs2205151	chr8:91483468	A/C	cg16814680	chr8:91681699	NA	-0.81	-8.41	-0.6	8.09e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs561341	0.739	rs9906455	chr17:30215669	G/A	cg13647721	chr17:30228624	UTP6	-0.61	-4.8	-0.4	4.39e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23598886	chr18:12777645	NA	-0.36	-4.6	-0.38	1.05e-5	C-reactive protein levels;Esophageal cancer (squamous cell);
TGCT	cis	rs2290416	0.584	rs3816477	chr8:144685271	T/C	cg17524265	chr8:144659883	NAPRT1	-0.65	-5.23	-0.43	7.03e-7	Attention deficit hyperactivity disorder;
TGCT	cis	rs6740322	0.948	rs6715072	chr2:43562230	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.38	-6.32	-0.49	4.21e-9	Coronary artery disease;
TGCT	trans	rs1814175	0.817	rs1818890	chr11:49856882	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.35	-0.55	2.38e-11	Height;
TGCT	cis	rs6430585	0.583	rs3769013	chr2:136556182	C/T	cg07169764	chr2:136633963	MCM6	1.22	11.84	0.73	4.08e-22	Corneal structure;
TGCT	cis	rs2228479	0.557	rs62056064	chr16:89903843	G/A	cg06558623	chr16:89946397	TCF25	0.55	4.86	0.4	3.55e-6	Skin colour saturation;
TGCT	cis	rs62244186	0.659	rs9873072	chr3:44516496	G/A	cg21672276	chr3:44754072	ZNF502	-0.41	-4.68	-0.39	7.51e-6	Depressive symptoms;
TGCT	cis	rs3820928	1.000	rs10193316	chr2:227777650	A/G	cg11843606	chr2:227700838	RHBDD1	-0.53	-4.73	-0.39	5.89e-6	Pulmonary function;
TGCT	cis	rs4077468	1.000	rs4077468	chr1:205914757	A/G	cg24503407	chr1:205819492	PM20D1	-0.39	-4.59	-0.38	1.07e-5	Cystic fibrosis-related diabetes;
TGCT	cis	rs3733585	0.699	rs6449172	chr4:9966036	A/T	cg00071950	chr4:10020882	SLC2A9	-0.57	-6.85	-0.52	3.12e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7312933	0.558	rs55702525	chr12:42814309	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.58	-5.69	-0.46	8.61e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs797680	0.897	rs3767962	chr1:93814411	A/G	cg17826107	chr1:92977322	EVI5	-0.24	-5.74	-0.46	6.97e-8	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs2760061	0.846	rs3094912	chr1:228209815	T/A	cg18477163	chr1:228402036	OBSCN	0.35	7.47	0.56	1.22e-11	Diastolic blood pressure;
TGCT	cis	rs2067615	0.524	rs10778505	chr12:107143126	G/C	cg15890332	chr12:107067104	RFX4	0.29	5.88	0.47	3.53e-8	Heart rate;
TGCT	cis	rs10875746	1.000	rs10875746	chr12:48518264	A/C	cg20731937	chr12:48336164	NA	0.61	4.83	0.4	4.02e-6	Longevity (90 years and older);
TGCT	cis	rs9341808	0.935	rs2298307	chr6:80816296	A/G	cg08355045	chr6:80787529	NA	0.29	5.18	0.42	8.61e-7	Sitting height ratio;
TGCT	cis	rs4076764	0.881	rs10917758	chr1:163430652	G/A	cg24596788	chr1:163392923	NA	-0.17	-4.85	-0.4	3.64e-6	Motion sickness;
TGCT	cis	rs709400	0.628	rs11621510	chr14:103869620	T/C	cg12935359	chr14:103987150	CKB	-0.36	-5.37	-0.43	3.67e-7	Body mass index;
TGCT	cis	rs7772486	0.701	rs2244308	chr6:146213706	C/T	cg23711669	chr6:146136114	FBXO30	0.87	9.99	0.67	1.3e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2034088	0.632	rs8067311	chr17:405603	T/G	cg04370829	chr17:406249	NA	-0.36	-5.26	-0.43	6.01e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs9467773	0.935	rs1056668	chr6:26510605	C/T	cg15659132	chr6:26577336	NA	0.81	10.38	0.68	1.52e-18	Intelligence (multi-trait analysis);
TGCT	cis	rs7834745	0.501	rs12679857	chr8:119977337	A/G	cg17171407	chr8:119960777	TNFRSF11B	0.31	5.2	0.42	7.98e-7	Eosinophil counts;Sum eosinophil basophil counts;
TGCT	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg03395511	chr6:291903	DUSP22	-0.7	-7.09	-0.54	9.19e-11	Menopause (age at onset);
TGCT	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	5.08	0.42	1.35e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg04944784	chr2:26401820	FAM59B	-0.76	-6.24	-0.49	6.46e-9	Gut microbiome composition (summer);
TGCT	cis	rs12681287	0.752	rs13256500	chr8:87247063	G/A	cg27223183	chr8:87520930	FAM82B	-0.83	-5.76	-0.46	6.33e-8	Caudate activity during reward;
TGCT	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg21963583	chr11:68658836	MRPL21	0.36	6.08	0.48	1.35e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7809950	0.954	rs2520245	chr7:107137428	G/C	cg23024343	chr7:107201750	COG5	-0.35	-5.48	-0.44	2.24e-7	Coronary artery disease;
TGCT	cis	rs17401966	0.838	rs1013953	chr1:10319459	T/A	cg19773385	chr1:10388646	KIF1B	-0.2	-4.5	-0.37	1.54e-5	Hepatocellular carcinoma;
TGCT	cis	rs5769707	0.681	rs2071902	chr22:50034538	G/C	cg06623630	chr22:50017776	C22orf34	-0.27	-4.67	-0.39	7.81e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs3812831	0.643	rs7322339	chr13:114929726	C/A	cg08824895	chr13:115047677	UPF3A	0.51	4.85	0.4	3.58e-6	Schizophrenia;
TGCT	cis	rs7208859	0.623	rs58089675	chr17:29196764	C/G	cg14008862	chr17:28927542	LRRC37B2	0.72	4.66	0.39	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7104764	0.957	rs3817629	chr11:237312	T/C	cg18336825	chr11:236787	PSMD13;SIRT3	1.07	11.15	0.71	2.05e-20	Menarche (age at onset);
TGCT	cis	rs9611565	0.879	rs5758311	chr22:41759375	G/T	cg03806693	chr22:41940476	POLR3H	-1.02	-11.06	-0.7	3.31e-20	Vitiligo;
TGCT	cis	rs9905704	0.624	rs4932691	chr17:57094617	T/C	cg12560992	chr17:57184187	TRIM37	-0.58	-5.15	-0.42	9.78e-7	Testicular germ cell tumor;
TGCT	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg12310025	chr6:25882481	NA	-0.94	-8.97	-0.63	3.8e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs1018836	0.828	rs12548806	chr8:91564256	C/T	cg16814680	chr8:91681699	NA	-0.75	-7.85	-0.58	1.71e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9611565	0.592	rs80477	chr22:42001183	C/T	cg13695892	chr22:41940480	POLR3H	0.85	7.97	0.58	8.64e-13	Vitiligo;
TGCT	cis	rs79349575	0.783	rs61576918	chr17:46985593	A/C	cg26022315	chr17:47021804	SNF8	0.48	4.82	0.4	4.06e-6	Type 2 diabetes;
TGCT	cis	rs1044826	0.619	rs57357132	chr3:139118358	A/T	cg00490450	chr3:139108681	COPB2	-0.53	-4.56	-0.38	1.2e-5	Obesity-related traits;
TGCT	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.07	-9.63	-0.65	1.01e-16	Platelet count;
TGCT	cis	rs514406	0.679	rs11206006	chr1:53218380	A/G	cg08859206	chr1:53392774	SCP2	0.44	6.63	0.51	9.33e-10	Monocyte count;
TGCT	cis	rs910316	0.967	rs4903285	chr14:75609268	A/T	cg08847533	chr14:75593920	NEK9	0.96	10.86	0.7	1.05e-19	Height;
TGCT	cis	rs1372520	0.684	rs356191	chr4:90688120	G/A	cg01966878	chr4:90757139	SNCA	0.3	4.82	0.4	4.11e-6	Neuroticism;
TGCT	cis	rs1997103	0.798	rs12154964	chr7:55414041	G/A	cg17469321	chr7:55412551	NA	0.65	6.75	0.52	5.08e-10	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg06221963	chr1:154839813	KCNN3	-0.75	-12.65	-0.75	4.66e-24	Prostate cancer;
TGCT	trans	rs28595532	0.623	rs11932674	chr4:119306807	A/C	cg26518628	chr1:97050305	NA	-0.51	-7.54	-0.56	8.58e-12	Cannabis dependence symptom count;
TGCT	cis	rs42648	0.567	rs12669304	chr7:89891040	T/C	cg25739043	chr7:89950458	NA	-0.63	-6.12	-0.48	1.16e-8	Homocysteine levels;
TGCT	cis	rs1371867	0.846	rs1660348	chr8:101315248	A/G	cg06002616	chr8:101225028	SPAG1	-0.53	-6.21	-0.49	7.16e-9	Atrioventricular conduction;
TGCT	cis	rs61867294	0.553	rs10884072	chr10:106732440	A/T	cg08000847	chr10:105880925	C10orf78	0.48	4.46	0.37	1.81e-5	Schizophrenia;
TGCT	cis	rs2224391	0.534	rs2753229	chr6:5246633	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-1.04	-6.69	-0.51	6.87e-10	Height;
TGCT	cis	rs7567389	0.740	rs1604817	chr2:127999921	C/T	cg09760422	chr2:128146352	NA	-0.35	-4.49	-0.37	1.58e-5	Self-rated health;
TGCT	cis	rs12762955	0.561	rs7075141	chr10:1091195	C/T	cg26597838	chr10:835615	NA	-0.41	-5.45	-0.44	2.63e-7	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs7572733	0.555	rs6745726	chr2:198934080	A/G	cg00792783	chr2:198669748	PLCL1	0.58	5.16	0.42	9.47e-7	Dermatomyositis;
TGCT	cis	rs17376456	0.825	rs13182631	chr5:93115701	A/G	cg21475434	chr5:93447410	FAM172A	0.63	4.92	0.4	2.72e-6	Diabetic retinopathy;
TGCT	cis	rs2120019	1.000	rs2083731	chr15:75368538	A/C	cg11632617	chr15:75315747	PPCDC	-0.34	-4.82	-0.4	4.18e-6	Blood trace element (Zn levels);
TGCT	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg10047753	chr17:41438598	NA	0.94	9.23	0.64	9.06e-16	Menopause (age at onset);
TGCT	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg24675658	chr1:53192096	ZYG11B	0.86	11.3	0.71	8.54e-21	Monocyte count;
TGCT	cis	rs1949733	0.701	rs1880024	chr4:8454639	A/G	cg11789530	chr4:8429930	ACOX3	0.54	5.09	0.42	1.28e-6	Response to antineoplastic agents;
TGCT	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg00149659	chr3:10157352	C3orf10	0.78	4.99	0.41	2.04e-6	Alzheimer's disease;
TGCT	cis	rs1696756	0.638	rs1290396	chr17:77830767	C/T	cg00646381	chr17:77835854	NA	0.44	6.6	0.51	1.06e-9	Glucocorticoid-induced osteonecrosis (age 10 years and older);
TGCT	trans	rs66573146	1.000	rs28729690	chr4:6962061	C/T	cg07817883	chr1:32538562	TMEM39B	1.56	8.31	0.6	1.45e-13	Granulocyte percentage of myeloid white cells;
TGCT	trans	rs208520	1.000	rs208535	chr6:66962286	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.88	-8.21	-0.59	2.37e-13	Exhaled nitric oxide output;
TGCT	cis	rs13102973	0.932	rs13149380	chr4:135866539	A/C	cg14419869	chr4:135874104	NA	0.24	4.46	0.37	1.83e-5	Subjective well-being;
TGCT	cis	rs62244186	0.545	rs7640654	chr3:44763037	A/C	cg10263370	chr3:44754102	ZNF502	-0.45	-5.35	-0.43	4.08e-7	Depressive symptoms;
TGCT	cis	rs6748734	0.948	rs9973334	chr2:241838142	A/G	cg04034577	chr2:241836375	C2orf54	-0.42	-6.33	-0.49	4.04e-9	Urinary metabolites;
TGCT	cis	rs7226408	0.857	rs72885256	chr18:34430466	A/T	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs9549260	0.755	rs12585277	chr13:41224813	C/T	cg21288729	chr13:41239152	FOXO1	0.99	10.42	0.68	1.22e-18	Red blood cell count;
TGCT	cis	rs36051895	0.623	rs1830610	chr9:5260079	C/T	cg02405213	chr9:5042618	JAK2	-0.71	-9.72	-0.66	6.17e-17	Pediatric autoimmune diseases;
TGCT	cis	rs45509595	0.841	rs200485	chr6:27775697	G/C	cg10876282	chr6:28092338	ZSCAN16	0.76	4.53	0.38	1.38e-5	Breast cancer;
TGCT	cis	rs4689388	0.926	rs4688986	chr4:6285797	C/A	cg00701064	chr4:6280414	WFS1	0.46	6.31	0.49	4.55e-9	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg04632378	chr13:21900426	NA	0.43	5.04	0.41	1.6e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	cis	rs4727027	0.704	rs13221837	chr7:148903597	C/T	cg23583168	chr7:148888333	NA	-0.78	-10.61	-0.69	4.12e-19	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs11098499	0.954	rs4309825	chr4:120314881	C/T	cg09307838	chr4:120376055	NA	-0.66	-6.46	-0.5	2.11e-9	Corneal astigmatism;
TGCT	cis	rs2760061	0.505	rs708109	chr1:228190657	C/T	cg18477163	chr1:228402036	OBSCN	0.35	7.09	0.54	8.81e-11	Diastolic blood pressure;
TGCT	cis	rs11779988	0.629	rs7465361	chr8:17854155	T/C	cg01800426	chr8:17659068	MTUS1	-0.57	-4.97	-0.41	2.14e-6	Breast cancer;
TGCT	cis	rs986417	0.901	rs1955694	chr14:61020617	G/T	cg27398547	chr14:60952738	C14orf39	1.29	10.37	0.68	1.57e-18	Gut microbiota (bacterial taxa);
TGCT	cis	rs11577318	0.853	rs11247913	chr1:26648551	G/C	cg04990556	chr1:26633338	UBXN11	-0.64	-5.56	-0.45	1.56e-7	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs7614311	0.636	rs6802053	chr3:63999823	A/C	cg22134162	chr3:63841271	THOC7	-0.37	-4.73	-0.39	5.91e-6	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs2816062	0.813	rs2816044	chr1:18892826	A/G	cg18795169	chr1:18902165	NA	-0.58	-13.28	-0.77	1.36e-25	Urate levels in lean individuals;
TGCT	cis	rs600231	0.708	rs1784100	chr11:65249227	T/C	cg17120908	chr11:65337727	SSSCA1	-0.56	-5.23	-0.42	7.04e-7	Bone mineral density;
TGCT	cis	rs2153535	0.601	rs969420	chr6:8451966	T/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.76	0.46	6.39e-8	Motion sickness;
TGCT	cis	rs56104184	0.723	rs1058483	chr19:49407660	G/A	cg21252483	chr19:49399788	TULP2	-0.42	-5.89	-0.47	3.47e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs67311347	1.000	rs73080126	chr3:40509153	A/G	cg13409248	chr3:40428643	ENTPD3	0.56	4.45	0.37	1.91e-5	Renal cell carcinoma;
TGCT	cis	rs7017914	0.870	rs1353057	chr8:71922097	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.55	-5.1	-0.42	1.24e-6	Bone mineral density;
TGCT	cis	rs478304	0.654	rs10896034	chr11:65460783	T/A	cg17480646	chr11:65405466	SIPA1	-0.61	-8.27	-0.6	1.8e-13	Acne (severe);
TGCT	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg06418219	chr1:154948305	SHC1;CKS1B	-0.64	-6.32	-0.49	4.33e-9	Prostate cancer;
TGCT	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	5.24	0.43	6.6e-7	Height;
TGCT	cis	rs4765905	0.522	rs2283291	chr12:2337460	G/A	cg07807026	chr12:2041581	NA	-0.25	-4.57	-0.38	1.17e-5	Schizophrenia;
TGCT	cis	rs7843479	0.601	rs6557712	chr8:21826421	C/T	cg17168535	chr8:21777572	XPO7	0.82	8.4	0.6	8.71e-14	Mean corpuscular volume;
TGCT	cis	rs9486719	1.000	rs11153064	chr6:97021959	A/G	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.0	-0.41	1.9e-6	Migraine;Coronary artery disease;
TGCT	cis	rs11690935	0.959	rs12692970	chr2:172594197	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.18	-12.51	-0.75	9.78e-24	Schizophrenia;
TGCT	cis	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg26116260	chr4:7069785	GRPEL1	1.07	9.82	0.66	3.49e-17	Monocyte percentage of white cells;
TGCT	cis	rs7731657	0.537	rs72801772	chr5:130341294	G/T	cg08523029	chr5:130500466	HINT1	-0.61	-5.08	-0.42	1.34e-6	Fasting plasma glucose;
TGCT	cis	rs78456975	1.000	rs11891809	chr2:1566001	A/G	cg01028140	chr2:1542097	TPO	-0.33	-4.54	-0.38	1.29e-5	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs346785	0.692	rs8072944	chr17:74291733	T/G	cg09812376	chr17:74270190	QRICH2	-0.36	-5.33	-0.43	4.43e-7	White matter hyperintensities in ischemic stroke;
TGCT	cis	rs2349775	0.513	rs984505	chr7:8622589	C/A	cg10443049	chr7:8481537	NXPH1	0.45	4.45	0.37	1.9e-5	Neuroticism;
TGCT	cis	rs10464366	0.746	rs12674262	chr7:39141728	G/T	cg15212455	chr7:39170539	POU6F2	0.27	5.9	0.47	3.28e-8	IgG glycosylation;
TGCT	cis	rs9611565	0.559	rs9611619	chr22:41986714	C/T	cg03806693	chr22:41940476	POLR3H	-1.11	-11.64	-0.72	1.26e-21	Vitiligo;
TGCT	cis	rs60843830	1.000	rs17713396	chr2:227201	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.72	6.89	0.53	2.52e-10	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs17125944	0.505	rs2295827	chr14:53174981	C/T	cg00686598	chr14:53173677	PSMC6	1.2	6.42	0.5	2.59e-9	Alzheimer's disease (late onset);
TGCT	cis	rs1372520	0.532	rs2583972	chr4:90747411	T/G	cg20003494	chr4:90757398	SNCA	-0.6	-4.66	-0.39	7.93e-6	Neuroticism;
TGCT	cis	rs854765	0.583	rs11656840	chr17:17837354	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.74	7.73	0.57	3.18e-12	Total body bone mineral density;
TGCT	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg00343986	chr7:65444356	GUSB	-0.23	-5.16	-0.42	9.66e-7	Aortic root size;
TGCT	trans	rs7342694	0.965	rs7189462	chr16:81907867	T/G	cg04928372	chr6:27720905	NA	0.7	6.7	0.52	6.54e-10	Coronary artery disease;
TGCT	cis	rs4780401	0.609	rs55934118	chr16:11820003	G/C	cg01061890	chr16:11836724	TXNDC11	-0.6	-5.82	-0.46	4.74e-8	Rheumatoid arthritis;
TGCT	cis	rs9435341	0.965	rs61798468	chr1:107569316	T/G	cg09367891	chr1:107599246	PRMT6	0.62	5.28	0.43	5.67e-7	Facial morphology (factor 21, depth of nasal alae);
TGCT	cis	rs2243480	1.000	rs10807702	chr7:65767843	C/T	cg20637647	chr7:64974828	NA	0.98	5.18	0.42	8.86e-7	Diabetic kidney disease;
TGCT	cis	rs17376456	0.825	rs6874766	chr5:93213807	C/G	cg25358565	chr5:93447407	FAM172A	-0.99	-8.12	-0.59	4.01e-13	Diabetic retinopathy;
TGCT	cis	rs2120019	0.938	rs8030089	chr15:75290377	C/T	cg17294928	chr15:75287854	SCAMP5	-0.78	-6.08	-0.48	1.4e-8	Blood trace element (Zn levels);
TGCT	cis	rs2243480	1.000	rs160642	chr7:65558373	C/T	cg07424592	chr7:64974309	NA	1.26	8.11	0.59	4.17e-13	Diabetic kidney disease;
TGCT	cis	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg25427524	chr10:38739819	LOC399744	-0.39	-8.05	-0.59	5.9e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs295140	0.546	rs842830	chr2:201131124	C/T	cg23649088	chr2:200775458	C2orf69	-0.29	-4.91	-0.4	2.75e-6	QT interval;
TGCT	cis	rs4455778	0.659	rs10262746	chr7:49031298	G/T	cg26309511	chr7:48887640	NA	0.44	5.22	0.42	7.26e-7	Lung cancer in never smokers;
TGCT	cis	rs6088580	0.634	rs6059851	chr20:33047945	G/A	cg06115741	chr20:33292138	TP53INP2	0.55	4.68	0.39	7.39e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs8017423	0.647	rs10132599	chr14:90815342	C/T	cg04374321	chr14:90722782	PSMC1	-0.54	-5.57	-0.45	1.51e-7	Mortality in heart failure;
TGCT	cis	rs933688	1.000	rs1035476	chr5:90745976	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.97	8.15	0.59	3.38e-13	Smoking behavior;
TGCT	cis	rs2439831	0.681	rs484846	chr15:43600803	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	6.63	0.51	9.35e-10	Lung cancer in ever smokers;
TGCT	trans	rs208520	0.526	rs1385219	chr6:66754476	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.06	14.9	0.8	2.08e-29	Exhaled nitric oxide output;
TGCT	cis	rs3733585	0.699	rs10001964	chr4:9959275	C/T	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.54	-0.56	8.83e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs17152411	1.000	rs10901843	chr10:126638020	A/G	cg07906193	chr10:126599966	NA	0.42	5.29	0.43	5.32e-7	Height;
TGCT	cis	rs1538970	0.847	rs1771550	chr1:45883565	C/T	cg05343316	chr1:45956843	TESK2	-0.75	-6.08	-0.48	1.39e-8	Platelet count;
TGCT	cis	rs6435161	0.959	rs72926966	chr2:203493293	C/A	cg18429434	chr2:203499731	FAM117B	-0.48	-4.52	-0.38	1.45e-5	Total cholesterol levels;
TGCT	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg10053473	chr17:62856997	LRRC37A3	0.4	6.77	0.52	4.68e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs1971136	1	rs1971136	chr2:25291539	C/T	cg01884057	chr2:25150051	NA	-0.39	-8.01	-0.58	7.24e-13	Breast cancer;
TGCT	cis	rs9733	0.596	rs6692960	chr1:150695965	G/A	cg04414720	chr1:150670196	GOLPH3L	0.37	4.91	0.4	2.76e-6	Tonsillectomy;
TGCT	cis	rs2677744	0.814	rs4932379	chr15:91488676	T/C	cg23684204	chr15:91497937	RCCD1	0.34	5.25	0.43	6.37e-7	Attention deficit hyperactivity disorder;
TGCT	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg20999797	chr1:1681921	NA	0.18	4.61	0.38	9.67e-6	Body mass index;
TGCT	cis	rs3796352	0.881	rs35385050	chr3:52997945	C/A	cg07884673	chr3:53033167	SFMBT1	0.63	5.74	0.46	6.83e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg06618935	chr21:46677482	NA	-0.37	-5.04	-0.41	1.64e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg21016266	chr12:122356598	WDR66	0.5	7.11	0.54	7.97e-11	Mean corpuscular volume;
TGCT	cis	rs9513593	1.000	rs2296044	chr13:100038825	T/C	cg21788972	chr13:99853209	UBAC2	0.56	4.68	0.39	7.51e-6	Psoriasis;
TGCT	cis	rs1857353	1.000	rs12410333	chr1:75895626	T/C	cg11838876	chr1:75668600	SLC44A5	-0.47	-4.56	-0.38	1.2e-5	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs2013441	1.000	rs2189710	chr17:20078964	C/A	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.61	-0.38	9.96e-6	Obesity-related traits;
TGCT	cis	rs11792861	0.816	rs113624314	chr9:111689953	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.54	5.13	0.42	1.07e-6	Menarche (age at onset);
TGCT	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg04944784	chr2:26401820	FAM59B	0.76	6.21	0.49	7.25e-9	Gut microbiome composition (summer);
TGCT	cis	rs611744	0.608	rs667742	chr8:109254003	T/C	cg21045802	chr8:109455806	TTC35	0.72	7.28	0.55	3.32e-11	Dupuytren's disease;
TGCT	cis	rs7647973	0.925	rs4955423	chr3:49220448	G/A	cg05785598	chr3:49045655	WDR6	0.38	4.68	0.39	7.48e-6	Menarche (age at onset);
TGCT	cis	rs8180040	0.653	rs6808742	chr3:47051512	G/A	cg27129171	chr3:47204927	SETD2	0.74	9.79	0.66	4.15e-17	Colorectal cancer;
TGCT	cis	rs17030434	0.953	rs12639885	chr4:154700374	G/A	cg14289246	chr4:154710475	SFRP2	-0.95	-7.52	-0.56	9.48e-12	Electrocardiographic conduction measures;
TGCT	cis	rs593982	0.843	rs552312	chr11:65477349	C/T	cg08755490	chr11:65554678	OVOL1	1.31	7.71	0.57	3.5e-12	Atopic dermatitis;
TGCT	cis	rs896854	0.517	rs1011795	chr8:95951073	G/A	cg13393036	chr8:95962371	TP53INP1	-0.49	-5.61	-0.45	1.26e-7	Type 2 diabetes;
TGCT	cis	rs1577917	1.000	rs12205548	chr6:86759770	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.43	-0.44	2.86e-7	Response to antipsychotic treatment;
TGCT	cis	rs4699052	0.928	rs2866642	chr4:104213866	T/G	cg16532752	chr4:104119610	CENPE	-0.53	-4.8	-0.4	4.42e-6	Testicular germ cell tumor;
TGCT	cis	rs6671200	0.607	rs6671408	chr1:95697091	T/C	cg26537280	chr1:95699037	RWDD3	-0.51	-4.73	-0.39	6.03e-6	Stearic acid (18:0) levels;
TGCT	trans	rs877282	1.000	rs112522746	chr10:772288	T/C	cg22713356	chr15:30763199	NA	1.16	10.02	0.67	1.16e-17	Uric acid levels;
TGCT	cis	rs57590327	0.503	rs17019299	chr3:81851643	A/G	cg07356753	chr3:81810745	GBE1	-0.67	-6.15	-0.48	9.91e-9	Extraversion;
TGCT	cis	rs7267979	0.773	rs6132821	chr20:25226192	A/G	cg16686733	chr20:25566563	NINL	0.52	4.9	0.4	2.98e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2239547	0.618	rs2071041	chr3:52864693	T/G	cg11645453	chr3:52864694	ITIH4	0.37	6.32	0.49	4.19e-9	Schizophrenia;
TGCT	cis	rs968451	0.865	rs2007418	chr22:39712394	T/C	cg17798944	chr22:39715225	SNORD43;RPL3	0.84	8.45	0.6	6.74e-14	Primary biliary cholangitis;
TGCT	cis	rs10514758	0.744	rs74657184	chr3:114821549	G/A	cg05943254	chr3:114009756	NA	-0.85	-5.06	-0.41	1.48e-6	Urate levels in obese individuals;
TGCT	cis	rs763121	0.853	rs138709	chr22:39139216	C/G	cg06022373	chr22:39101656	GTPBP1	0.73	7.11	0.54	8.14e-11	Menopause (age at onset);
TGCT	cis	rs2721195	0.874	rs2721197	chr8:145727705	A/G	cg15857475	chr8:145742913	RECQL4;LRRC14	0.89	9.55	0.65	1.6e-16	Age at first birth;
TGCT	cis	rs42648	0.837	rs13239439	chr7:89924400	C/A	cg25739043	chr7:89950458	NA	-0.73	-7.32	-0.55	2.79e-11	Homocysteine levels;
TGCT	cis	rs854765	0.505	rs4924832	chr17:17897739	A/G	cg04398451	chr17:18023971	MYO15A	-0.31	-4.84	-0.4	3.84e-6	Total body bone mineral density;
TGCT	cis	rs854765	0.547	rs2955384	chr17:17939573	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.76	8.14	0.59	3.6e-13	Total body bone mineral density;
TGCT	trans	rs1496653	0.602	rs34322396	chr3:23488499	T/C	cg02770683	chr12:57597238	LRP1	0.38	6.89	0.53	2.53e-10	Type 2 diabetes;
TGCT	cis	rs2153535	0.580	rs1360054	chr6:8520377	C/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.55e-8	Motion sickness;
TGCT	cis	rs875971	0.830	rs427973	chr7:65526648	C/A	cg11764359	chr7:65958608	NA	0.53	4.65	0.38	8.53e-6	Aortic root size;
TGCT	cis	rs7208859	0.673	rs2269916	chr17:29233763	A/G	cg18442181	chr17:29233375	C17orf42	-0.78	-4.61	-0.38	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6964587	1.000	rs6956431	chr7:91750016	T/C	cg22709100	chr7:91322751	NA	0.28	4.49	0.37	1.62e-5	Breast cancer;
TGCT	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg10802521	chr3:52805072	NEK4	-0.78	-10.01	-0.67	1.22e-17	Bipolar disorder;
TGCT	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg14983838	chr19:29218262	NA	0.84	6.9	0.53	2.42e-10	Methadone dose in opioid dependence;
TGCT	cis	rs838147	0.537	rs603985	chr19:49207257	T/C	cg13540341	chr19:49222985	MAMSTR	-0.37	-4.91	-0.4	2.84e-6	Dietary macronutrient intake;
TGCT	cis	rs617219	0.698	rs10055956	chr5:78479678	G/A	cg05890484	chr5:78407552	BHMT	0.38	5.23	0.42	7.13e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs9916302	0.731	rs11868030	chr17:37650332	A/G	cg07936489	chr17:37558343	FBXL20	-0.62	-4.91	-0.4	2.85e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7614311	0.555	rs58676857	chr3:63903883	G/A	cg22134162	chr3:63841271	THOC7	-0.37	-4.89	-0.4	3.01e-6	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs1941023	0.584	rs2241921	chr11:60164302	C/T	cg08716584	chr11:60157161	MS4A7	-0.34	-5.03	-0.41	1.66e-6	Congenital heart disease (maternal effect);
TGCT	cis	rs61867294	0.578	rs7095209	chr10:106781929	A/G	cg10601616	chr10:106400702	SORCS3	-0.61	-4.58	-0.38	1.12e-5	Schizophrenia;
TGCT	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg27588902	chr6:42928151	GNMT	-0.49	-5.93	-0.47	2.85e-8	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs7267979	0.933	rs6138571	chr20:25435388	A/G	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7662987	0.517	rs2602876	chr4:100039535	A/T	cg12011299	chr4:100065546	ADH4	0.4	4.76	0.39	5.26e-6	Smoking initiation;
TGCT	cis	rs208520	0.690	rs866452	chr6:66849936	A/T	cg07460842	chr6:66804631	NA	-0.92	-9.58	-0.65	1.33e-16	Exhaled nitric oxide output;
TGCT	cis	rs17331151	0.505	rs35225119	chr3:52623465	A/T	cg15956490	chr3:53032818	SFMBT1	0.75	5.94	0.47	2.74e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs7216064	1.000	rs35243555	chr17:65876477	G/C	cg12091567	chr17:66097778	LOC651250	-0.83	-6.49	-0.5	1.9e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg03806693	chr22:41940476	POLR3H	-1.01	-11.18	-0.71	1.71e-20	Vitiligo;
TGCT	cis	rs9914988	0.943	rs7211502	chr17:27163295	C/A	cg20469991	chr17:27169893	C17orf63	-0.72	-5.09	-0.42	1.28e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs7103648	0.838	rs11039244	chr11:47466442	G/A	cg20307385	chr11:47447363	PSMC3	0.98	10.95	0.7	6.2e-20	Diastolic blood pressure;Systolic blood pressure;
TGCT	cis	rs2832191	0.967	rs2898160	chr21:30487496	A/G	cg08807101	chr21:30365312	RNF160	-0.49	-4.48	-0.37	1.65e-5	Dental caries;
TGCT	cis	rs6570726	0.537	rs1280279	chr6:145884048	G/T	cg05347473	chr6:146136440	FBXO30	0.64	5.1	0.42	1.21e-6	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs2018683	1.000	rs4719963	chr7:29011064	A/G	cg19402173	chr7:128379420	CALU	0.72	7.02	0.53	1.25e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
TGCT	cis	rs114540395	0.858	rs17767748	chr10:103285900	A/G	cg18276125	chr10:102749041	C10orf2	-0.42	-4.89	-0.4	3.04e-6	Schizophrenia;
TGCT	cis	rs9486715	0.838	rs6928442	chr6:96870118	A/G	cg18709589	chr6:96969512	KIAA0776	0.79	7.77	0.57	2.5e-12	Headache;
TGCT	cis	rs12413816	0.784	rs11258560	chr10:13770137	A/G	cg16485048	chr10:13749193	FRMD4A	0.26	5.32	0.43	4.71e-7	Red cell distribution width;
TGCT	cis	rs7917772	0.503	rs2031601	chr10:104308064	T/G	cg05855489	chr10:104503620	C10orf26	-0.6	-5.25	-0.43	6.32e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7666738	0.830	rs28416660	chr4:98899525	C/G	cg17366294	chr4:99064904	C4orf37	0.67	6.83	0.52	3.3e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs910316	0.967	rs175432	chr14:75615246	C/G	cg08847533	chr14:75593920	NEK9	-0.93	-9.75	-0.66	5.19e-17	Height;
TGCT	cis	rs28735056	0.875	rs62103181	chr18:77625652	A/G	cg20368463	chr18:77673604	PQLC1	0.4	4.89	0.4	3.09e-6	Schizophrenia;
TGCT	cis	rs3784262	0.771	rs4775005	chr15:58208165	C/T	cg12031962	chr15:58353849	ALDH1A2	0.56	7.98	0.58	8.5e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs6693567	0.526	rs3818978	chr1:150266338	T/A	cg09579323	chr1:150459698	TARS2	-0.52	-4.7	-0.39	6.77e-6	Migraine;
TGCT	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg05368731	chr17:41323189	NBR1	1.1	11.12	0.71	2.38e-20	Menopause (age at onset);
TGCT	cis	rs12908161	0.853	rs12912342	chr15:85248216	T/C	cg17173187	chr15:85201210	NMB	0.42	5.0	0.41	1.92e-6	Schizophrenia;
TGCT	cis	rs12497850	0.931	rs1134591	chr3:48972892	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.46	-5.77	-0.46	6.1e-8	Parkinson's disease;
TGCT	cis	rs6681544	0.544	rs2182601	chr1:82396801	C/T	cg04226724	chr1:82268649	LPHN2	0.47	4.99	0.41	2.02e-6	Metabolite levels  (X-11787);
TGCT	cis	rs2832191	0.716	rs1543652	chr21:30448000	G/C	cg24692254	chr21:30365293	RNF160	0.98	11.33	0.71	7.51e-21	Dental caries;
TGCT	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg03735888	chr19:58951602	ZNF132	0.79	6.69	0.52	6.81e-10	Mean platelet volume;
TGCT	cis	rs35146811	0.735	rs858505	chr7:99819577	G/A	cg13334819	chr7:99746414	C7orf59	0.74	6.41	0.5	2.82e-9	Coronary artery disease;
TGCT	cis	rs4654899	0.680	rs11805006	chr1:21249603	C/T	cg01072550	chr1:21505969	NA	-0.53	-8.74	-0.62	1.39e-14	Superior frontal gyrus grey matter volume;
TGCT	cis	rs7833790	1.000	rs7833384	chr8:82730915	T/C	cg17211192	chr8:82754475	SNX16	-1.05	-8.95	-0.63	4.23e-15	Diastolic blood pressure;
TGCT	cis	rs644799	0.965	rs10831425	chr11:95500628	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	8.85	0.62	7.27e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs694739	0.628	rs645078	chr11:64135298	A/C	cg23796481	chr11:64053134	BAD;GPR137	0.65	6.82	0.52	3.49e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs1903068	0.719	rs1380068	chr4:56003707	C/G	cg01777861	chr4:56023843	NA	0.52	5.79	0.46	5.56e-8	Endometriosis;
TGCT	trans	rs17685	0.753	rs11982200	chr7:75714883	T/C	cg19862616	chr7:65841803	NCRNA00174	0.51	8.59	0.61	3.07e-14	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs977747	0.872	rs12145836	chr1:47672289	A/T	cg03885399	chr1:47691550	TAL1	-0.43	-5.42	-0.44	2.97e-7	Body mass index;
TGCT	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg10150615	chr22:24372951	LOC391322	0.77	6.51	0.5	1.7e-9	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs2456568	0.775	rs1607404	chr11:93660449	C/G	cg26875233	chr11:93583750	C11orf90	-0.47	-5.86	-0.47	3.87e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs3806843	0.547	rs183679	chr5:140271017	C/T	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	0.42	5.05	0.41	1.52e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9419702	0.538	rs9419628	chr10:133539299	A/C	cg04492858	chr10:133558786	NA	0.57	6.03	0.48	1.71e-8	Survival in rectal cancer;
TGCT	cis	rs7568458	0.811	rs1446668	chr2:85764960	G/T	cg02493740	chr2:85810744	VAMP5	-0.29	-5.33	-0.43	4.51e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs8072100	0.817	rs9912101	chr17:45547078	A/G	cg08085267	chr17:45401833	C17orf57	-0.45	-5.09	-0.42	1.31e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs889312	0.500	rs33328	chr5:56143419	T/C	cg24531977	chr5:56204891	C5orf35	-0.52	-5.39	-0.44	3.44e-7	Breast cancer;Breast cancer (early onset);
TGCT	cis	rs6733011	0.531	rs13004923	chr2:99497561	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.5	-4.9	-0.4	2.99e-6	Bipolar disorder;
TGCT	cis	rs7833790	0.750	rs10108955	chr8:82690644	C/T	cg06027949	chr8:82754900	SNX16	-0.67	-4.47	-0.37	1.75e-5	Diastolic blood pressure;
TGCT	cis	rs9796	0.870	rs11854472	chr15:41357687	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.43	-5.62	-0.45	1.22e-7	Menopause (age at onset);
TGCT	cis	rs2692947	0.740	rs11695514	chr2:96548068	C/T	cg13655245	chr2:97463316	CNNM4	0.16	4.6	0.38	1.02e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs4951018	0.853	rs1573104	chr1:205636907	A/C	cg26354017	chr1:205819088	PM20D1	-0.39	-4.59	-0.38	1.08e-5	Prostate-specific antigen levels;
TGCT	cis	rs11711311	1.000	rs12497716	chr3:113453258	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.73	-6.83	-0.52	3.45e-10	IgG glycosylation;
TGCT	cis	rs7412746	0.587	rs11204722	chr1:150730184	A/C	cg04414720	chr1:150670196	GOLPH3L	-0.4	-5.16	-0.42	9.42e-7	Melanoma;
TGCT	cis	rs1865760	0.566	rs9295688	chr6:26084217	G/A	cg16482183	chr6:26056742	HIST1H1C	0.58	4.97	0.41	2.13e-6	Height;
TGCT	cis	rs8051149	0.688	rs3815559	chr16:87871366	G/C	cg01412419	chr16:87856264	NA	0.49	5.79	0.46	5.38e-8	Blood metabolite levels;
TGCT	cis	rs7666738	0.830	rs34412187	chr4:99010454	A/G	cg05340658	chr4:99064831	C4orf37	0.48	5.43	0.44	2.92e-7	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg21659725	chr3:3221576	CRBN	0.76	9.03	0.63	2.74e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.63	-0.51	9.04e-10	Alzheimer's disease;
TGCT	cis	rs478304	0.619	rs10896028	chr11:65432187	A/T	cg27068330	chr11:65405492	SIPA1	-1.0	-10.85	-0.7	1.09e-19	Acne (severe);
TGCT	cis	rs1008375	0.931	rs10939733	chr4:17570658	T/C	cg10189774	chr4:17578691	LAP3	0.67	5.87	0.47	3.77e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg00149659	chr3:10157352	C3orf10	0.91	5.89	0.47	3.32e-8	Alzheimer's disease;
TGCT	cis	rs711245	0.545	rs848617	chr2:36811298	G/C	cg10546459	chr2:36825355	FEZ2	0.55	4.71	0.39	6.61e-6	Height;
TGCT	cis	rs6088580	0.609	rs945674	chr20:32964247	G/C	cg08999081	chr20:33150536	PIGU	-0.29	-5.65	-0.45	1.02e-7	Glomerular filtration rate (creatinine);
TGCT	trans	rs877282	0.685	rs56234340	chr10:781339	A/G	cg22713356	chr15:30763199	NA	1.0	8.75	0.62	1.27e-14	Uric acid levels;
TGCT	cis	rs7588654	1.000	rs72613757	chr2:219968869	G/A	cg06736663	chr2:219754761	WNT10A	-0.48	-4.79	-0.39	4.72e-6	Height;
TGCT	cis	rs3849570	0.695	rs6792696	chr3:81874009	G/A	cg07356753	chr3:81810745	GBE1	-0.6	-5.31	-0.43	4.92e-7	Waist circumference;Body mass index;
TGCT	cis	rs2820315	0.867	rs2819351	chr1:201885157	C/T	cg12730843	chr1:201915899	LMOD1	-0.27	-4.86	-0.4	3.46e-6	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
TGCT	cis	rs7819412	0.669	rs7823349	chr8:10998630	G/T	cg03192020	chr8:11204681	TDH	-0.52	-4.5	-0.37	1.53e-5	Triglycerides;
TGCT	cis	rs7267979	0.966	rs2261794	chr20:25263062	T/G	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs910316	0.789	rs4899552	chr14:75667921	C/A	cg08847533	chr14:75593920	NEK9	-0.84	-8.25	-0.6	1.92e-13	Height;
TGCT	cis	rs765787	0.530	rs2899378	chr15:45537584	C/T	cg24006582	chr15:45444508	DUOX1	0.24	5.28	0.43	5.64e-7	Uric acid levels;
TGCT	cis	rs4595586	0.967	rs11169807	chr12:39244161	A/G	cg10518543	chr12:38710700	ALG10B	0.48	4.81	0.4	4.25e-6	Morning vs. evening chronotype;
TGCT	cis	rs7572733	0.534	rs734037	chr2:198749269	G/A	cg00792783	chr2:198669748	PLCL1	0.56	5.08	0.42	1.35e-6	Dermatomyositis;
TGCT	cis	rs7192750	0.562	rs152838	chr16:72105702	C/T	cg14768367	chr16:72042858	DHODH	0.89	4.65	0.39	8.32e-6	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs2120019	1.000	rs2083731	chr15:75368538	A/C	cg09165964	chr15:75287851	SCAMP5	-1.09	-8.86	-0.62	7.08e-15	Blood trace element (Zn levels);
TGCT	cis	rs7666738	0.830	rs6852015	chr4:99054373	C/A	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs904251	0.523	rs1776455	chr6:37482923	A/T	cg01843034	chr6:37503916	NA	-0.51	-6.91	-0.53	2.24e-10	Cognitive performance;
TGCT	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg23758822	chr17:41437982	NA	0.75	7.03	0.53	1.22e-10	Menopause (age at onset);
TGCT	cis	rs727563	0.635	rs5751149	chr22:42139501	A/G	cg06634786	chr22:41940651	POLR3H	0.87	8.12	0.59	3.86e-13	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs6831352	0.918	rs29001199	chr4:100053891	A/G	cg12011299	chr4:100065546	ADH4	-0.4	-4.88	-0.4	3.26e-6	Alcohol dependence;
TGCT	cis	rs7568458	0.684	rs60012532	chr2:85752474	A/C	cg17127132	chr2:85788382	GGCX	0.51	4.72	0.39	6.29e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs72634258	0.520	rs12078018	chr1:7857309	G/A	cg26816564	chr1:7831052	VAMP3	0.87	6.44	0.5	2.34e-9	Inflammatory bowel disease;
TGCT	cis	rs78707713	0.560	rs35060419	chr10:71229539	A/G	cg12610070	chr10:71211762	TSPAN15	-0.62	-7.31	-0.55	2.83e-11	Venous thromboembolism;
TGCT	cis	rs6061231	0.837	rs6061235	chr20:60978524	C/G	cg24112000	chr20:60950667	NA	-0.39	-5.06	-0.41	1.48e-6	Colorectal cancer;
TGCT	cis	rs4727027	0.870	rs11524138	chr7:148799125	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	4.68	0.39	7.53e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs7267979	1.000	rs2482930	chr20:25334115	G/C	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs926938	0.527	rs6680112	chr1:115548915	G/C	cg12756093	chr1:115239321	AMPD1	0.35	5.11	0.42	1.18e-6	Autism;
TGCT	cis	rs13191362	1.000	rs34177053	chr6:163007772	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.57	4.94	0.41	2.45e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs473651	0.904	rs501333	chr2:239336045	G/A	cg08773314	chr2:239334832	ASB1	0.45	7.5	0.56	1.07e-11	Multiple system atrophy;
TGCT	cis	rs2067615	0.579	rs9651957	chr12:107170128	A/G	cg15890332	chr12:107067104	RFX4	0.28	5.83	0.46	4.48e-8	Heart rate;
TGCT	trans	rs1005277	0.522	rs289650	chr10:37975505	G/T	cg17830980	chr10:43048298	ZNF37B	-0.66	-7.51	-0.56	1.03e-11	Extrinsic epigenetic age acceleration;
TGCT	cis	rs12048904	0.595	rs10493937	chr1:101342650	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.65	-7.03	-0.53	1.21e-10	Multiple sclerosis;
TGCT	cis	rs11971779	0.651	rs74368518	chr7:139004327	A/G	cg07862535	chr7:139043722	LUC7L2	0.71	5.82	0.46	4.83e-8	Diisocyanate-induced asthma;
TGCT	cis	rs1018836	0.886	rs12545351	chr8:91636668	C/T	cg16814680	chr8:91681699	NA	-0.8	-8.6	-0.61	2.89e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6901004	0.803	rs11153272	chr6:111479539	C/T	cg15721981	chr6:111408429	SLC16A10	-0.51	-4.57	-0.38	1.16e-5	Blood metabolite levels;
TGCT	cis	rs2880765	0.835	rs7164106	chr15:86032590	T/C	cg13263323	chr15:86062960	AKAP13	-0.22	-4.79	-0.4	4.68e-6	Coronary artery disease;
TGCT	cis	rs7772486	0.875	rs2224120	chr6:146343280	A/C	cg13319975	chr6:146136371	FBXO30	-0.51	-4.56	-0.38	1.23e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs739496	0.793	rs73199895	chr12:111866087	G/A	cg10833066	chr12:111807467	FAM109A	0.37	5.2	0.42	8.01e-7	Platelet count;
TGCT	trans	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg27523141	chr10:43048294	ZNF37B	0.7	8.15	0.59	3.36e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs748404	0.660	rs690012	chr15:43719755	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	4.75	0.39	5.51e-6	Lung cancer;
TGCT	cis	rs9549367	0.569	rs3024719	chr13:113814225	G/A	cg00898013	chr13:113819073	PROZ	-0.55	-6.53	-0.51	1.52e-9	Platelet distribution width;
TGCT	cis	rs28595532	0.920	rs55869953	chr4:119751893	T/C	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs7614311	0.639	rs73119035	chr3:63993966	A/G	cg22134162	chr3:63841271	THOC7	-0.49	-6.44	-0.5	2.41e-9	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg12310025	chr6:25882481	NA	0.9	9.22	0.64	9.6e-16	Blood metabolite levels;
TGCT	cis	rs704	0.628	rs8081240	chr17:26722728	C/T	cg10342447	chr17:26645325	TMEM97	-0.47	-4.69	-0.39	7.22e-6	Osteoprotegerin levels;
TGCT	cis	rs858239	0.932	rs1624451	chr7:23262435	A/T	cg05602783	chr7:23145260	KLHL7	0.61	4.9	0.4	2.98e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs3008870	0.755	rs1925410	chr1:67365230	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.75	-7.86	-0.58	1.63e-12	Lymphocyte percentage of white cells;
TGCT	cis	rs9905704	0.624	rs11652761	chr17:56986095	C/T	cg12560992	chr17:57184187	TRIM37	0.58	4.93	0.4	2.57e-6	Testicular germ cell tumor;
TGCT	cis	rs798766	1.000	rs4865463	chr4:1742400	T/C	cg05874882	chr4:1763078	NA	-0.33	-4.56	-0.38	1.2e-5	Bladder cancer;Urinary bladder cancer;
TGCT	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg21285383	chr16:89894308	SPIRE2	0.45	7.16	0.54	6.39e-11	Vitiligo;
TGCT	cis	rs7940866	0.834	rs10894298	chr11:130840571	C/A	cg12179176	chr11:130786555	SNX19	0.62	5.95	0.47	2.57e-8	Schizophrenia;
TGCT	cis	rs7103648	1.000	rs7103648	chr11:47461783	A/G	cg20307385	chr11:47447363	PSMC3	1.07	13.03	0.76	5.56e-25	Diastolic blood pressure;Systolic blood pressure;
TGCT	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.61	5.06	0.41	1.5e-6	Tonsillectomy;
TGCT	cis	rs9611565	0.729	rs202654	chr22:41841034	G/A	cg06481639	chr22:41940642	POLR3H	0.59	5.12	0.42	1.12e-6	Vitiligo;
TGCT	cis	rs13064411	0.696	rs35860985	chr3:113209828	C/T	cg18753928	chr3:113234510	CCDC52	-0.7	-5.75	-0.46	6.6e-8	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs7465272	0.530	rs10103161	chr8:143738571	A/G	cg10596483	chr8:143751796	JRK	0.56	5.58	0.45	1.46e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs10114408	0.959	rs2095779	chr9:96648831	T/C	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs6570726	0.935	rs419850	chr6:145827281	A/G	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1580019	0.563	rs34319173	chr7:32585904	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.2	15.19	0.81	4.33e-30	Cognitive ability;
TGCT	cis	rs2296887	0.585	rs10786663	chr10:104064548	A/G	cg26089160	chr10:104170217	PSD	-0.56	-5.66	-0.45	9.94e-8	Parkinson's disease;
TGCT	cis	rs2463822	1.000	rs2513074	chr11:62100880	A/C	cg06239285	chr11:62104954	ASRGL1	0.93	6.71	0.52	6.27e-10	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	trans	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg13565492	chr6:43139072	SRF	-0.77	-7.34	-0.55	2.43e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9972944	0.622	rs1895033	chr17:63777493	A/C	cg07283582	chr17:63770753	CCDC46	0.26	5.05	0.41	1.53e-6	Total body bone mineral density;
TGCT	cis	rs12042938	0.507	rs2570408	chr1:231732934	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.55	-5.4	-0.44	3.2e-7	Neuranatomic and neurocognitive phenotypes;
TGCT	cis	rs3008870	1.000	rs2009319	chr1:67481070	G/T	cg08660285	chr1:67390436	MIER1;WDR78	1.1	11.91	0.73	2.83e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs1163251	0.902	rs839605	chr1:120217524	C/A	cg19096424	chr1:120255104	PHGDH	0.56	5.29	0.43	5.46e-7	Blood metabolite levels;
TGCT	cis	rs7666738	0.830	rs7661264	chr4:98961574	G/A	cg05340658	chr4:99064831	C4orf37	0.53	5.93	0.47	2.85e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs477895	0.713	rs3802933	chr11:63988102	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	6.82	0.52	3.53e-10	Mean platelet volume;
TGCT	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg00149659	chr3:10157352	C3orf10	0.97	5.09	0.42	1.28e-6	Alzheimer's disease;
TGCT	cis	rs2882667	0.931	rs10044736	chr5:138320809	A/G	cg04439458	chr5:138467593	SIL1	0.29	4.62	0.38	9.64e-6	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs2469997	1.000	rs2957356	chr8:120373995	T/G	cg00681363	chr8:120844660	TAF2	0.69	4.48	0.37	1.64e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs911555	0.713	rs10162425	chr14:103931621	C/T	cg12935359	chr14:103987150	CKB	-0.32	-4.47	-0.37	1.73e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs2652822	0.686	rs4774476	chr15:63407390	A/G	cg12855773	chr15:63363890	TPM1	0.16	4.66	0.39	7.92e-6	Metabolic traits;
TGCT	cis	rs2235642	0.750	rs2755185	chr16:1645827	A/G	cg07639376	chr16:1584516	IFT140;TMEM204	-0.28	-4.88	-0.4	3.24e-6	Coronary artery disease;
TGCT	cis	rs6570726	0.764	rs4896821	chr6:145896181	G/A	cg05347473	chr6:146136440	FBXO30	0.51	4.78	0.39	4.8e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs12971120	0.947	rs34676212	chr18:72170006	A/G	cg25817165	chr18:72167213	CNDP2	-0.3	-5.6	-0.45	1.33e-7	Refractive error;
TGCT	cis	rs896854	0.654	rs10104909	chr8:95977973	C/T	cg09323728	chr8:95962352	TP53INP1	-0.49	-6.32	-0.49	4.32e-9	Type 2 diabetes;
TGCT	cis	rs4742903	0.967	rs6479215	chr9:106885243	A/G	cg21169611	chr9:106856078	SMC2	-0.56	-5.37	-0.43	3.73e-7	High-grade serous ovarian cancer;Breast cancer;
TGCT	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg10802521	chr3:52805072	NEK4	-0.71	-8.79	-0.62	1.04e-14	Bipolar disorder;
TGCT	cis	rs4888262	0.716	rs6564157	chr16:74710254	T/C	cg01733217	chr16:74700730	RFWD3	0.92	10.74	0.69	1.97e-19	Testicular germ cell tumor;
TGCT	cis	rs2228479	0.764	rs11641201	chr16:89983276	T/C	cg06558623	chr16:89946397	TCF25	0.47	6.27	0.49	5.52e-9	Skin colour saturation;
TGCT	cis	rs9733	0.519	rs7511673	chr1:150707636	A/T	cg09365446	chr1:150670422	GOLPH3L	0.3	4.52	0.38	1.4e-5	Tonsillectomy;
TGCT	cis	rs1541995	0.824	rs17506333	chr15:96253243	C/T	cg00882281	chr15:96346592	NA	-0.29	-4.77	-0.39	5.12e-6	Photic sneeze reflex;
TGCT	cis	rs7208859	0.673	rs9896095	chr17:29187497	A/G	cg18442181	chr17:29233375	C17orf42	-0.79	-4.78	-0.39	4.95e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	trans	rs7618501	0.966	rs2246832	chr3:49881134	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	1.03	13.16	0.76	2.7e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs7113874	0.589	rs9705253	chr11:8596483	A/T	cg14521421	chr11:8862019	ST5	0.28	4.44	0.37	1.96e-5	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs7208859	0.623	rs9895785	chr17:29107708	C/T	cg13385521	chr17:29058706	SUZ12P	-0.86	-5.16	-0.42	9.48e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7267979	0.586	rs6050429	chr20:25183058	G/A	cg03522245	chr20:25566470	NINL	0.5	5.27	0.43	5.88e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs922182	0.783	rs12438519	chr15:64311345	C/T	cg02919090	chr15:64263738	DAPK2	0.25	4.54	0.38	1.29e-5	Blood protein levels;
TGCT	cis	rs617219	0.671	rs12189188	chr5:78552312	C/T	cg23987322	chr5:78407566	BHMT	0.36	4.66	0.39	8.06e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs28595532	0.920	rs114210107	chr4:119734491	G/A	cg14228332	chr4:119757509	SEC24D	1.32	6.38	0.5	3.2e-9	Cannabis dependence symptom count;
TGCT	cis	rs6089584	0.546	rs6061978	chr20:60615604	C/T	cg06108461	chr20:60628389	TAF4	-0.43	-5.5	-0.44	2.06e-7	Body mass index;
TGCT	trans	rs7618501	1.000	rs57648519	chr3:49813169	C/A	cg21659725	chr3:3221576	CRBN	0.98	15.33	0.81	2.1000000000000002e-30	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs4699591	chr4:98974171	A/G	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1552244	0.554	rs7638846	chr3:10048601	A/G	cg00149659	chr3:10157352	C3orf10	0.73	5.21	0.42	7.77e-7	Alzheimer's disease;
TGCT	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.7	-0.39	6.79e-6	Prudent dietary pattern;
TGCT	cis	rs9611565	1.000	rs1109151	chr22:41752944	A/G	cg03806693	chr22:41940476	POLR3H	-0.98	-10.5	-0.69	7.62e-19	Vitiligo;
TGCT	trans	rs7618501	0.521	rs7615206	chr3:49937505	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.8	8.36	0.6	1.06e-13	Intelligence (multi-trait analysis);
TGCT	trans	rs877282	0.898	rs11253348	chr10:765852	C/T	cg22713356	chr15:30763199	NA	1.2	9.39	0.64	3.76e-16	Uric acid levels;
TGCT	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.44	0.56	1.46e-11	Prudent dietary pattern;
TGCT	cis	rs67311347	0.955	rs11711994	chr3:40391086	T/C	cg13683864	chr3:40499215	RPL14	-1.13	-12.23	-0.74	4.85e-23	Renal cell carcinoma;
TGCT	cis	rs7666738	0.830	rs34916200	chr4:98851593	C/T	cg05340658	chr4:99064831	C4orf37	0.52	6.0	0.47	1.98e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2836974	0.897	rs2776308	chr21:40715175	A/G	cg11890956	chr21:40555474	PSMG1	0.99	9.11	0.63	1.78e-15	Cognitive function;
TGCT	cis	rs909674	0.865	rs5757683	chr22:39850174	G/A	cg05872129	chr22:39784769	NA	-0.97	-9.64	-0.65	9.53e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg10150615	chr22:24372951	LOC391322	-0.98	-11.96	-0.73	2.1e-22	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9868809	0.505	rs35064573	chr3:48740280	C/A	cg00383909	chr3:49044727	WDR6	1.06	6.28	0.49	5.26e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg02725872	chr8:58115012	NA	-0.38	-4.99	-0.41	1.98e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1372520	0.873	rs2736989	chr4:90776257	T/C	cg15133208	chr4:90757351	SNCA	-0.5	-5.9	-0.47	3.18e-8	Neuroticism;
TGCT	cis	rs7017914	0.869	rs11987511	chr8:71645871	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.03	-0.41	1.69e-6	Bone mineral density;
TGCT	cis	rs4851254	0.660	rs13430705	chr2:100690616	G/A	cg22139774	chr2:100720529	AFF3	-0.45	-4.91	-0.4	2.75e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg25737836	chr21:47705150	C21orf57;MCM3AP	-0.18	-4.45	-0.37	1.92e-5	Testicular germ cell tumor;
TGCT	cis	rs3096299	0.606	rs4785573	chr16:89565403	A/G	cg06640241	chr16:89574553	SPG7	0.52	4.67	0.39	7.7e-6	Multiple myeloma (IgH translocation);
TGCT	cis	rs7524258	0.835	rs7543228	chr1:7306538	G/C	cg04342483	chr1:7259290	CAMTA1	-0.31	-4.43	-0.37	2.01e-5	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs9611565	0.512	rs964899	chr22:42142386	G/A	cg17554472	chr22:41940697	POLR3H	0.43	4.47	0.37	1.73e-5	Vitiligo;
TGCT	cis	rs7267979	0.789	rs6083841	chr20:25384564	C/T	cg21995068	chr20:25989032	LOC100134868	0.43	5.17	0.42	9.2e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs79839061	0.520	rs2279187	chr4:875529	C/T	cg07828340	chr4:882639	GAK	0.36	4.71	0.39	6.4e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.31	-4.76	-0.39	5.36e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	trans	rs1814175	0.645	rs11040671	chr11:49958776	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.67	-0.69	2.92e-19	Height;
TGCT	cis	rs10883723	0.810	rs3818470	chr10:104263675	T/C	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs4689388	0.610	rs4328980	chr4:6281756	A/G	cg14416269	chr4:6271139	WFS1	0.39	4.97	0.41	2.18e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs7192750	0.586	rs1834035	chr16:71972271	C/G	cg06353428	chr16:71660113	MARVELD3	0.77	6.82	0.52	3.61e-10	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg12437481	chr16:420112	MRPL28	-0.5	-5.03	-0.41	1.65e-6	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.71	-7.06	-0.54	1.07e-10	Prudent dietary pattern;
TGCT	cis	rs7586879	0.681	rs6756609	chr2:25121125	C/A	cg01884057	chr2:25150051	NA	0.35	6.9	0.53	2.39e-10	Body mass index;
TGCT	cis	rs9527	0.590	rs4917992	chr10:104786313	G/A	cg04362960	chr10:104952993	NT5C2	0.58	4.65	0.39	8.5e-6	Arsenic metabolism;
TGCT	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs67311347	1.000	rs9865348	chr3:40397658	A/C	cg13683864	chr3:40499215	RPL14	-1.1	-11.83	-0.73	4.49e-22	Renal cell carcinoma;
TGCT	cis	rs11167764	1.000	rs7730511	chr5:141480418	T/C	cg23435118	chr5:141488016	NDFIP1	-0.29	-4.89	-0.4	3.06e-6	Crohn's disease;
TGCT	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg18402987	chr7:1209562	NA	0.37	4.73	0.39	6.09e-6	Longevity;Endometriosis;
TGCT	trans	rs210152	0.588	rs449978	chr6:33496060	G/A	cg08795360	chr21:41033440	B3GALT5	-0.44	-6.68	-0.51	7.12e-10	Schizophrenia;
TGCT	cis	rs10972341	1.000	rs7046814	chr9:35142258	A/G	cg00812861	chr9:35114699	KIAA1539	0.33	4.92	0.4	2.73e-6	Weight;
TGCT	cis	rs10464366	0.510	rs62442212	chr7:39146896	A/C	cg15212455	chr7:39170539	POU6F2	0.25	5.85	0.46	4.18e-8	IgG glycosylation;
TGCT	cis	rs5760092	0.842	rs5760103	chr22:24248781	A/G	cg12419862	chr22:24373484	LOC391322	-0.79	-6.49	-0.5	1.89e-9	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs3751972	0.748	rs1034895	chr17:26225558	C/G	cg02948944	chr17:26242737	NA	-0.48	-6.82	-0.52	3.52e-10	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs72615157	0.595	rs112241539	chr7:99847237	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.65	-5.2	-0.42	8.01e-7	Lung function (FEV1/FVC);
TGCT	cis	rs4919669	0.777	rs11191375	chr10:104464657	T/C	cg05855489	chr10:104503620	C10orf26	0.73	4.45	0.37	1.91e-5	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs3087591	1.000	rs7216033	chr17:29574642	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.48	-7.42	-0.55	1.64e-11	Hip circumference;
TGCT	cis	rs7666738	0.791	rs62318641	chr4:98816964	T/C	cg18180107	chr4:99064573	C4orf37	0.55	5.25	0.43	6.31e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs56104184	0.775	rs73061697	chr19:49400000	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.73	-9.15	-0.63	1.47e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	trans	rs4576506	0.536	rs13292862	chr9:31506598	T/C	cg11445191	chr5:140227765	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA5;PCDHA9;PCDHA3;PCDHA4;PCDHA8	0.98	6.69	0.51	6.76e-10	Psychosis and Alzheimer's disease;
TGCT	cis	rs2204008	0.744	rs11182316	chr12:38499552	G/A	cg13010199	chr12:38710504	ALG10B	0.64	5.15	0.42	9.97e-7	Bladder cancer;
TGCT	cis	rs10782582	0.609	rs78748984	chr1:76340467	G/A	cg10523679	chr1:76189770	ACADM	-0.59	-5.42	-0.44	2.94e-7	Daytime sleep phenotypes;
TGCT	cis	rs7819412	0.594	rs7460507	chr8:10969075	C/T	cg03192020	chr8:11204681	TDH	-0.56	-5.41	-0.44	3.06e-7	Triglycerides;
TGCT	cis	rs2204008	0.599	rs2320526	chr12:38220405	T/A	cg26384229	chr12:38710491	ALG10B	0.83	7.45	0.56	1.35e-11	Bladder cancer;
TGCT	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg20203395	chr5:56204925	C5orf35	-0.58	-4.87	-0.4	3.34e-6	Initial pursuit acceleration;
TGCT	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg07870213	chr5:140052090	DND1	0.64	7.57	0.56	7.47e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg09323728	chr8:95962352	TP53INP1	-0.54	-6.92	-0.53	2.17e-10	Type 2 diabetes;
TGCT	cis	rs3540	0.597	rs1978151	chr15:91037300	C/T	cg22089800	chr15:90895588	ZNF774	0.76	7.77	0.57	2.62e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs11190604	1.000	rs11190556	chr10:102209223	G/A	cg16342193	chr10:102329863	NA	-0.4	-5.31	-0.43	4.85e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9926296	0.535	rs36022917	chr16:89893238	A/G	cg03388025	chr16:89894329	SPIRE2	0.35	5.28	0.43	5.66e-7	Vitiligo;
TGCT	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg22433210	chr17:43662623	NA	-0.95	-8.12	-0.59	3.95e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs68170813	0.652	rs6957186	chr7:107200592	T/C	cg02696742	chr7:106810147	HBP1	-0.59	-4.71	-0.39	6.61e-6	Coronary artery disease;
TGCT	cis	rs478304	0.903	rs61895677	chr11:65549415	T/C	cg17480646	chr11:65405466	SIPA1	0.41	5.03	0.41	1.7e-6	Acne (severe);
TGCT	cis	rs11931598	0.783	rs28661210	chr4:7050956	C/A	cg02503808	chr4:7069936	GRPEL1	0.58	5.35	0.43	4.14e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.61	0.38	9.85e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg03709012	chr19:19516395	GATAD2A	0.75	6.16	0.48	9.21e-9	Tonsillectomy;
TGCT	cis	rs9653442	1.000	rs7580200	chr2:100811903	G/T	cg22139774	chr2:100720529	AFF3	0.43	7.46	0.56	1.31e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs11167764	1.000	rs7722567	chr5:141483178	C/T	cg08523384	chr5:141488047	NDFIP1	-0.26	-5.21	-0.42	7.52e-7	Crohn's disease;
TGCT	cis	rs60843830	1.000	rs7595075	chr2:264019	C/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.72	6.93	0.53	2.07e-10	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs8070740	0.898	rs4239056	chr17:5324406	A/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	4.77	0.39	5.1e-6	Menopause (age at onset);
TGCT	cis	rs10186029	0.680	rs10179508	chr2:213978526	C/T	cg08319019	chr2:214017104	IKZF2	-0.64	-5.82	-0.46	4.64e-8	Systemic sclerosis;
TGCT	cis	rs6750795	0.502	rs11685196	chr2:232381298	A/G	cg07301105	chr2:232379665	C2orf52	0.4	5.48	0.44	2.29e-7	Height;
TGCT	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs2153535	0.580	rs1928184	chr6:8532108	T/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.01	0.41	1.86e-6	Motion sickness;
TGCT	cis	rs1552244	0.554	rs2272118	chr3:10049287	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.33	-4.95	-0.41	2.39e-6	Alzheimer's disease;
TGCT	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg18876405	chr7:65276391	NA	-0.35	-5.49	-0.44	2.13e-7	Aortic root size;
TGCT	cis	rs68170813	0.599	rs12532849	chr7:106959226	A/C	cg02696742	chr7:106810147	HBP1	-0.69	-5.81	-0.46	4.85e-8	Coronary artery disease;
TGCT	cis	rs2456568	0.503	rs11020603	chr11:93667439	A/G	cg26875233	chr11:93583750	C11orf90	0.44	5.27	0.43	5.78e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs78366141	0.649	rs78959409	chr4:89659712	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	1.16	5.16	0.42	9.33e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
TGCT	cis	rs2288073	0.965	rs10192600	chr2:24396680	A/G	cg02683114	chr2:24398427	C2orf84	-0.25	-5.61	-0.45	1.26e-7	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs981844	1.000	rs72731674	chr4:154667447	C/A	cg14289246	chr4:154710475	SFRP2	1.01	8.67	0.61	2.02e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg10253484	chr15:75165896	SCAMP2	-0.6	-5.5	-0.44	2.06e-7	Breast cancer;
TGCT	cis	rs8020441	1.000	rs72681672	chr14:51169600	C/T	cg04730355	chr14:51134070	SAV1	0.73	5.86	0.47	3.91e-8	Cognitive performance;
TGCT	cis	rs2354432	0.607	rs6703847	chr1:146669444	G/A	cg25205988	chr1:146714368	CHD1L	1.34	6.29	0.49	4.92e-9	Mitochondrial DNA levels;
TGCT	cis	rs137699	1.000	rs5757632	chr22:39756097	A/C	cg11247378	chr22:39784982	NA	-0.47	-5.2	-0.42	8.13e-7	IgG glycosylation;
TGCT	cis	rs8051431	0.840	rs3929023	chr16:72011040	A/G	cg06353428	chr16:71660113	MARVELD3	0.59	5.02	0.41	1.73e-6	LDL cholesterol levels;
TGCT	cis	rs1843834	0.898	rs11887386	chr2:225526975	T/G	cg22455342	chr2:225449267	CUL3	0.74	7.25	0.55	3.9e-11	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs425277	0.606	rs3128295	chr1:2068480	C/T	cg03732007	chr1:2071316	PRKCZ	-0.28	-5.99	-0.47	2.12e-8	Height;
TGCT	cis	rs262150	0.579	rs73167299	chr7:158784367	C/T	cg01219135	chr7:158766336	NA	-0.47	-4.92	-0.4	2.72e-6	Facial morphology (factor 20);
TGCT	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg03806693	chr22:41940476	POLR3H	-1.15	-13.16	-0.76	2.69e-25	Vitiligo;
TGCT	cis	rs67311347	0.956	rs11714871	chr3:40428938	T/G	cg13683864	chr3:40499215	RPL14	-1.05	-11.13	-0.71	2.2e-20	Renal cell carcinoma;
TGCT	cis	rs6540559	0.546	rs75308488	chr1:210030639	T/C	cg12034118	chr1:209979487	IRF6	0.64	4.48	0.37	1.7e-5	Cleft lip with or without cleft palate;
TGCT	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	trans	rs6089829	0.925	rs4809270	chr20:61676709	C/A	cg13615516	chr5:77269221	NA	0.73	8.42	0.6	7.74e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9457247	1.000	rs448060	chr6:167382622	A/G	cg25258033	chr6:167368657	RNASET2	0.18	4.49	0.37	1.63e-5	Crohn's disease;
TGCT	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg23758822	chr17:41437982	NA	0.72	6.81	0.52	3.77e-10	Menopause (age at onset);
TGCT	cis	rs4409675	0.548	rs1000432	chr1:28225119	T/C	cg23691781	chr1:28212827	C1orf38	0.25	5.26	0.43	6.19e-7	Corneal astigmatism;
TGCT	cis	rs10779751	1.000	rs7525957	chr1:11318236	C/T	cg08854313	chr1:11322531	MTOR	0.99	10.58	0.69	4.78e-19	Body mass index;
TGCT	cis	rs992157	0.796	rs55680399	chr2:219160621	T/C	cg00012203	chr2:219082015	ARPC2	0.78	7.72	0.57	3.38e-12	Colorectal cancer;
TGCT	cis	rs9788721	0.836	rs17405217	chr15:78731149	C/T	cg18825076	chr15:78729989	IREB2	-0.35	-5.23	-0.43	7.03e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
TGCT	cis	rs7772486	0.754	rs6570718	chr6:146088443	T/G	cg05347473	chr6:146136440	FBXO30	-0.53	-5.01	-0.41	1.84e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2180341	0.960	rs7766802	chr6:127709871	T/G	cg27446573	chr6:127587934	RNF146	1.16	10.47	0.68	9.13e-19	Breast cancer;
TGCT	cis	rs6088580	0.634	rs6059880	chr20:33088669	G/A	cg06115741	chr20:33292138	TP53INP2	0.53	4.66	0.39	7.96e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs9972944	0.756	rs4594282	chr17:63762930	G/A	cg07283582	chr17:63770753	CCDC46	-0.26	-5.24	-0.43	6.6e-7	Total body bone mineral density;
TGCT	cis	rs8180040	0.900	rs10865946	chr3:47425060	T/G	cg27129171	chr3:47204927	SETD2	0.65	7.74	0.57	2.99e-12	Colorectal cancer;
TGCT	cis	rs9325144	0.723	rs11169482	chr12:39164327	A/T	cg26384229	chr12:38710491	ALG10B	0.61	5.89	0.47	3.44e-8	Morning vs. evening chronotype;
TGCT	cis	rs2070433	0.539	rs1008548	chr21:47959692	G/A	cg12379764	chr21:47803548	PCNT	0.53	5.29	0.43	5.36e-7	Lymphocyte counts;
TGCT	cis	rs1008375	0.966	rs28441502	chr4:17598384	G/A	cg18681998	chr4:17616180	MED28	0.94	9.66	0.66	8.59e-17	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6088580	0.634	rs6059779	chr20:32950325	C/T	cg08999081	chr20:33150536	PIGU	-0.27	-5.33	-0.43	4.46e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg18402987	chr7:1209562	NA	0.74	6.19	0.49	7.92e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs4969178	0.622	rs4129767	chr17:76403984	G/A	cg05887092	chr17:76393375	PGS1	0.22	4.64	0.38	8.75e-6	HDL cholesterol levels;
TGCT	cis	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg18252515	chr7:66147081	NA	-1.1	-6.4	-0.5	2.85e-9	Diabetic kidney disease;
TGCT	cis	rs3091242	0.933	rs9645452	chr1:25668326	C/T	cg10117171	chr1:25599238	RHD	0.35	5.57	0.45	1.5e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg13395646	chr4:1353034	KIAA1530	-0.4	-5.25	-0.43	6.39e-7	Obesity-related traits;
TGCT	trans	rs1908814	0.541	rs7824267	chr8:11794279	G/T	cg15556689	chr8:8085844	FLJ10661	0.76	7.3	0.55	3.04e-11	Neuroticism;
TGCT	cis	rs295140	0.732	rs1367858	chr2:201160771	C/T	cg04283868	chr2:201171347	SPATS2L	0.53	4.89	0.4	3.05e-6	QT interval;
TGCT	cis	rs546131	0.890	rs485845	chr11:34830389	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.59	-5.16	-0.42	9.4e-7	Lung disease severity in cystic fibrosis;
TGCT	cis	rs9467773	1.000	rs1321481	chr6:26538210	A/T	cg09904177	chr6:26538194	HMGN4	0.65	6.53	0.51	1.53e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg06753367	chr22:24256600	NA	-0.24	-4.53	-0.38	1.36e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs4555082	1.000	rs7146683	chr14:105759385	A/G	cg10792982	chr14:105748885	BRF1	0.22	4.58	0.38	1.13e-5	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs9467773	1.000	rs1321479	chr6:26501897	C/T	cg26531700	chr6:26746687	NA	-0.48	-4.82	-0.4	4.07e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7010267	0.544	rs6984287	chr8:120054122	C/G	cg17171407	chr8:119960777	TNFRSF11B	0.26	4.62	0.38	9.52e-6	Total body bone mineral density (age 45-60);
TGCT	cis	rs4862750	0.872	rs10027252	chr4:187873462	T/G	cg03452623	chr4:187889614	NA	-0.35	-5.17	-0.42	9.06e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4788570	0.667	rs8053186	chr16:71790166	G/A	cg06353428	chr16:71660113	MARVELD3	1.53	12.17	0.74	6.57e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs7226408	0.857	rs117376812	chr18:34549886	C/G	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs1670533	0.872	rs6854793	chr4:1055768	T/C	cg20887711	chr4:1340912	KIAA1530	0.69	5.48	0.44	2.32e-7	Recombination rate (females);
TGCT	cis	rs10744422	1.000	rs1587856	chr12:123342229	A/G	cg25930673	chr12:123319894	HIP1R	-0.86	-5.02	-0.41	1.72e-6	Schizophrenia;
TGCT	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg01802117	chr1:53393560	SCP2	-0.45	-5.73	-0.46	7.03e-8	Monocyte count;
TGCT	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg22963979	chr7:1858916	MAD1L1	-0.4	-6.25	-0.49	6.04e-9	Bipolar disorder and schizophrenia;
TGCT	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg12419862	chr22:24373484	LOC391322	-0.78	-8.06	-0.59	5.58e-13	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6558530	0.730	rs7014327	chr8:1724052	C/T	cg09410841	chr8:1729607	CLN8	0.86	10.13	0.67	6e-18	Systolic blood pressure;
TGCT	cis	rs9303401	0.614	rs34678056	chr17:57177549	G/A	cg25039879	chr17:56429692	SUPT4H1	0.55	4.9	0.4	2.93e-6	Cognitive test performance;
TGCT	cis	rs7412746	0.658	rs12090215	chr1:150893660	C/A	cg09365446	chr1:150670422	GOLPH3L	0.34	4.71	0.39	6.58e-6	Melanoma;
TGCT	cis	rs6430585	0.528	rs6750549	chr2:136707480	A/G	cg07169764	chr2:136633963	MCM6	1.26	12.74	0.75	2.79e-24	Corneal structure;
TGCT	cis	rs7666738	0.546	rs10461174	chr4:98698293	G/A	cg05340658	chr4:99064831	C4orf37	0.52	5.76	0.46	6.27e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3741404	0.672	rs4980524	chr11:63959259	A/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.79	8.19	0.59	2.68e-13	Platelet count;
TGCT	cis	rs12908161	1.000	rs35316992	chr15:85248133	A/G	cg12863693	chr15:85201151	NMB	0.46	5.51	0.44	1.95e-7	Schizophrenia;
TGCT	cis	rs10751667	1.000	rs12798036	chr11:947585	T/C	cg06064525	chr11:970664	AP2A2	-0.33	-6.59	-0.51	1.12e-9	Alzheimer's disease (late onset);
TGCT	cis	rs7659604	0.605	rs2071486	chr4:122740162	C/T	cg19748678	chr4:122722346	EXOSC9	0.81	8.3	0.6	1.46e-13	Type 2 diabetes;
TGCT	cis	rs877529	0.625	rs139390	chr22:39532853	A/G	cg18708252	chr22:39545030	CBX7	-0.38	-5.61	-0.45	1.28e-7	Multiple myeloma;
TGCT	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg21171335	chr12:122356390	WDR66	0.7	6.84	0.52	3.28e-10	Mean corpuscular volume;
TGCT	cis	rs8077889	0.672	rs4793028	chr17:41857212	T/C	cg26893861	chr17:41843967	DUSP3	1.14	20.46	0.88	1.46e-41	Triglycerides;
TGCT	cis	rs11252926	0.537	rs6560836	chr10:444997	C/T	cg18196295	chr10:418757	DIP2C	0.3	4.92	0.4	2.69e-6	Psychosis in Alzheimer's disease;
TGCT	cis	rs1008375	0.618	rs13129002	chr4:17567513	A/G	cg10189774	chr4:17578691	LAP3	0.57	4.9	0.4	2.9e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs899997	1.000	rs7182993	chr15:79045014	G/A	cg04896959	chr15:78267971	NA	0.35	5.07	0.41	1.4e-6	Coronary artery disease or large artery stroke;
TGCT	cis	rs17331151	0.505	rs71299613	chr3:52698805	G/A	cg24616795	chr3:53032891	SFMBT1	0.58	4.85	0.4	3.59e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg17971929	chr21:40555470	PSMG1	0.98	9.65	0.65	9.11e-17	Cognitive function;
TGCT	cis	rs2859741	0.967	rs535876	chr1:37484052	C/G	cg09363841	chr1:37513479	NA	-0.19	-4.46	-0.37	1.84e-5	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
TGCT	cis	rs17826219	0.636	rs12946563	chr17:29103166	C/G	cg13385521	chr17:29058706	SUZ12P	0.8	4.71	0.39	6.51e-6	Body mass index;
TGCT	cis	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg25427524	chr10:38739819	LOC399744	-0.39	-8.04	-0.59	5.95e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs6424115	0.830	rs2501425	chr1:24199339	A/C	cg15997130	chr1:24165203	NA	0.86	9.44	0.65	2.86e-16	Immature fraction of reticulocytes;
TGCT	cis	rs4631830	0.863	rs3123078	chr10:51524971	A/G	cg10326726	chr10:51549505	MSMB	0.24	4.85	0.4	3.68e-6	Prostate-specific antigen levels;
TGCT	cis	rs3771570	1.000	rs73002111	chr2:242277833	C/T	cg21155796	chr2:242212141	HDLBP	0.98	6.68	0.51	7.29e-10	Prostate cancer;
TGCT	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg08439880	chr3:133502540	NA	-0.28	-4.98	-0.41	2.09e-6	Iron status biomarkers;
TGCT	cis	rs9733	0.596	rs72702580	chr1:150691285	A/T	cg09365446	chr1:150670422	GOLPH3L	0.3	4.52	0.38	1.4e-5	Tonsillectomy;
TGCT	cis	rs12579753	0.719	rs12369450	chr12:82266940	A/G	cg07988820	chr12:82153109	PPFIA2	-0.42	-4.44	-0.37	1.97e-5	Resting heart rate;
TGCT	cis	rs6752107	0.967	rs12162308	chr2:234172188	C/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.19	4.65	0.39	8.35e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs1797081	0.811	rs1797076	chr10:16853076	A/G	cg14835575	chr10:16859367	RSU1	0.4	5.02	0.41	1.72e-6	Platelet distribution width;
TGCT	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.7	0.52	6.47e-10	Bipolar disorder;
TGCT	cis	rs9985766	1.000	rs10003178	chr4:150998544	A/G	cg05926478	chr4:151174724	DCLK2	-0.24	-4.64	-0.38	8.63e-6	Coronary artery disease;Myocardial infarction;
TGCT	cis	rs2288073	0.965	rs13387930	chr2:24414400	A/G	cg05570707	chr2:24270316	C2orf44	-0.5	-4.47	-0.37	1.72e-5	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs17068510	0.630	rs17068551	chr8:3873763	T/C	cg25338036	chr8:3047536	CSMD1	-0.46	-4.88	-0.4	3.19e-6	Cerebrospinal fluid clusterin levels;
TGCT	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9486719	0.895	rs12190520	chr6:96928620	A/C	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.77	-0.62	1.18e-14	Migraine;Coronary artery disease;
TGCT	cis	rs2115630	0.967	rs7171167	chr15:85239123	A/T	cg12501888	chr15:85177176	SCAND2	-0.51	-4.84	-0.4	3.85e-6	P wave terminal force;
TGCT	cis	rs737008	0.922	rs11074957	chr16:11378151	G/A	cg00044050	chr16:11439710	C16orf75	-0.71	-7.27	-0.55	3.49e-11	Obesity-related traits;
TGCT	cis	rs6076065	0.748	rs6048781	chr20:23380027	T/C	cg11657817	chr20:23433608	CST11	0.31	5.42	0.44	3.02e-7	Facial morphology (factor 15, philtrum width);
TGCT	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.25	4.54	0.38	1.32e-5	Schizophrenia;
TGCT	cis	rs11031096	0.711	rs17283923	chr11:4173841	C/T	cg18678763	chr11:4115507	RRM1	-0.44	-5.75	-0.46	6.48e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs2204008	0.522	rs12370263	chr12:38113311	A/G	cg13010199	chr12:38710504	ALG10B	0.6	4.79	0.4	4.7e-6	Bladder cancer;
TGCT	cis	rs9467773	0.511	rs11755443	chr6:26891603	T/C	cg02458000	chr6:26745757	NA	0.66	5.88	0.47	3.59e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs10986311	0.775	rs3758206	chr9:127151871	C/T	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.21	-4.94	-0.41	2.47e-6	Vitiligo;
TGCT	cis	rs7647973	0.961	rs4955430	chr3:49378088	G/A	cg06212747	chr3:49208901	KLHDC8B	0.59	4.72	0.39	6.22e-6	Menarche (age at onset);
TGCT	cis	rs1008375	1.000	rs2315556	chr4:17670861	T/C	cg10189774	chr4:17578691	LAP3	0.53	4.99	0.41	2e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1050631	0.960	rs1789512	chr18:33694542	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	-0.54	-5.29	-0.43	5.4e-7	Esophageal squamous cell cancer (length of survival);
TGCT	cis	rs936229	1.000	rs4886615	chr15:75131661	A/G	cg10253484	chr15:75165896	SCAMP2	-0.78	-6.44	-0.5	2.4e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
TGCT	cis	rs908922	0.887	rs1538084	chr1:152496012	A/C	cg20991723	chr1:152506922	NA	0.42	5.32	0.43	4.6e-7	Hair morphology;
TGCT	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg00343986	chr7:65444356	GUSB	0.23	5.14	0.42	1.06e-6	Aortic root size;
TGCT	cis	rs317865	0.867	rs73234625	chr4:16166206	G/A	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.8	5.08	0.42	1.34e-6	Kidney disease (early stage) in type 1 diabetes;
TGCT	cis	rs1488864	0.655	rs1844188	chr11:6346572	A/G	cg12755421	chr11:6342214	PRKCDBP	-0.56	-4.45	-0.37	1.89e-5	Smooth-surface caries;
TGCT	trans	rs17685	0.725	rs7807647	chr7:75628669	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.5	-8.68	-0.61	1.94e-14	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.7	-5.93	-0.47	2.75e-8	Tonsillectomy;
TGCT	cis	rs3749237	0.595	rs11130199	chr3:49538799	T/C	cg03060546	chr3:49711283	APEH	0.77	8.86	0.62	6.92e-15	Resting heart rate;
TGCT	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-6.74	-0.52	5.26e-10	Alzheimer's disease;
TGCT	cis	rs782590	0.967	rs58003472	chr2:55797507	T/C	cg18811423	chr2:55921094	PNPT1	0.65	6.88	0.53	2.6e-10	Metabolic syndrome;
TGCT	cis	rs1865760	0.532	rs9295687	chr6:26082710	T/C	cg16482183	chr6:26056742	HIST1H1C	0.58	4.97	0.41	2.13e-6	Height;
TGCT	cis	rs433598	0.765	rs234288	chr16:20660327	A/G	cg08248577	chr16:19727447	IQCK;C16orf88	0.22	5.03	0.41	1.64e-6	Schizophrenia;
TGCT	cis	rs11711311	0.955	rs12630791	chr3:113387717	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.74	6.52	0.51	1.58e-9	IgG glycosylation;
TGCT	cis	rs4819052	0.765	rs2838868	chr21:46714641	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.61	-4.76	-0.39	5.35e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6495122	0.532	rs2470890	chr15:75047426	C/T	cg13906792	chr15:75199810	C15orf17	-0.22	-4.71	-0.39	6.64e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
TGCT	cis	rs11722228	1.000	rs6823877	chr4:9921931	T/C	cg11266682	chr4:10021025	SLC2A9	-0.52	-5.86	-0.47	3.98e-8	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs2404602	0.655	rs3829489	chr15:77223256	A/C	cg26408565	chr15:76604113	ETFA	-0.37	-4.63	-0.38	9.04e-6	Blood metabolite levels;
TGCT	cis	rs2842992	0.789	rs2295901	chr6:160201295	C/A	cg11366901	chr6:160182831	ACAT2	1.03	6.92	0.53	2.14e-10	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs950169	1.000	rs79318564	chr15:84786150	G/A	cg11189052	chr15:85197271	WDR73	0.72	6.09	0.48	1.32e-8	Schizophrenia;
TGCT	cis	rs9527	0.590	rs12355120	chr10:104852166	T/G	cg04362960	chr10:104952993	NT5C2	0.68	5.78	0.46	5.57e-8	Arsenic metabolism;
TGCT	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.5	-6.94	-0.53	1.89e-10	Alzheimer's disease;
TGCT	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg08859206	chr1:53392774	SCP2	-0.41	-6.12	-0.48	1.11e-8	Monocyte count;
TGCT	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7246657	0.722	rs13744	chr19:38077912	C/T	cg03611452	chr19:38183253	ZNF781	0.58	4.64	0.38	8.62e-6	Coronary artery calcification;
TGCT	cis	rs17473412	0.677	rs11749673	chr5:122834239	C/G	cg15125798	chr5:122621645	NA	0.61	5.31	0.43	4.92e-7	Total body bone mineral density;
TGCT	cis	rs2235642	0.750	rs1894649	chr16:1657284	C/G	cg00463982	chr16:1583984	IFT140;TMEM204	-0.27	-4.53	-0.38	1.37e-5	Coronary artery disease;
TGCT	cis	rs3733585	0.699	rs60045583	chr4:9971950	G/A	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.7	-0.52	6.51e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs11105298	0.891	rs10777162	chr12:89830523	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.65	-4.61	-0.38	9.91e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs3733585	0.563	rs881971	chr4:9930962	A/G	cg00071950	chr4:10020882	SLC2A9	-0.51	-5.76	-0.46	6.2e-8	Cleft plate (environmental tobacco smoke interaction);
TGCT	trans	rs1864729	1.000	rs1835743	chr8:98282643	T/C	cg08679828	chr8:102218111	ZNF706	-0.98	-6.67	-0.51	7.76e-10	Estradiol plasma levels (breast cancer);
TGCT	cis	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg07424592	chr7:64974309	NA	1.27	7.08	0.54	9.24e-11	Diabetic kidney disease;
TGCT	trans	rs2970818	0.831	rs2970810	chr12:4608103	A/G	cg03310518	chr7:30954522	AQP1	0.31	6.88	0.53	2.56e-10	Phosphorus levels;
TGCT	cis	rs2034088	0.619	rs4968170	chr17:404712	T/C	cg04370829	chr17:406249	NA	-0.36	-5.26	-0.43	6.01e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg03351412	chr1:154909251	PMVK	0.53	4.93	0.4	2.6e-6	Prostate cancer;
TGCT	cis	rs10465746	0.967	rs6703382	chr1:84435700	G/A	cg10977910	chr1:84465055	TTLL7	0.63	6.23	0.49	6.49e-9	Obesity-related traits;
TGCT	cis	rs8067545	0.750	rs3862152	chr17:19959693	C/T	cg13482628	chr17:19912719	NA	0.53	4.59	0.38	1.07e-5	Schizophrenia;
TGCT	cis	rs10986311	0.779	rs10818942	chr9:127077395	G/A	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.21	-5.04	-0.41	1.58e-6	Vitiligo;
TGCT	cis	rs9341808	0.667	rs7746917	chr6:80931503	T/C	cg08355045	chr6:80787529	NA	0.3	4.99	0.41	1.99e-6	Sitting height ratio;
TGCT	cis	rs7772486	0.875	rs854145	chr6:146349650	C/T	cg05347473	chr6:146136440	FBXO30	0.57	5.42	0.44	2.92e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2859741	1.000	rs1773575	chr1:37505129	T/C	cg09363841	chr1:37513479	NA	-0.19	-4.49	-0.37	1.63e-5	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
TGCT	cis	rs4727027	0.865	rs13236754	chr7:148845773	G/A	cg23583168	chr7:148888333	NA	-0.76	-9.69	-0.66	7.27e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs8084125	1.000	rs72978665	chr18:74953641	A/G	cg15443732	chr18:74961078	GALR1	0.49	4.82	0.4	4.18e-6	Obesity-related traits;
TGCT	cis	rs9457247	0.565	rs2239823	chr6:167512131	T/C	cg07741184	chr6:167504864	NA	0.28	5.6	0.45	1.33e-7	Crohn's disease;
TGCT	cis	rs1971762	0.730	rs7963016	chr12:54072819	T/A	cg22546318	chr12:54070378	ATP5G2	-0.31	-4.48	-0.37	1.68e-5	Height;
TGCT	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs912057	1.000	rs912056	chr6:6736197	A/T	cg06612196	chr6:6737390	NA	0.38	4.77	0.39	5.06e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs6912958	0.781	rs4707376	chr6:88270947	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-5.06	-0.41	1.45e-6	Monocyte percentage of white cells;
TGCT	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg14820908	chr5:178986412	RUFY1	0.59	6.22	0.49	6.87e-9	Lung cancer;
TGCT	cis	rs425277	0.916	rs414777	chr1:2101687	G/A	cg24578937	chr1:2090814	PRKCZ	0.31	7.58	0.56	6.92e-12	Height;
TGCT	cis	rs7824557	0.564	rs2736304	chr8:11236964	C/T	cg21775007	chr8:11205619	TDH	-0.65	-6.4	-0.5	2.92e-9	Retinal vascular caliber;
TGCT	cis	rs28735056	0.846	rs12958903	chr18:77628996	A/G	cg20368463	chr18:77673604	PQLC1	0.4	4.89	0.4	3.09e-6	Schizophrenia;
TGCT	cis	rs7772486	0.686	rs9497396	chr6:146014963	C/A	cg23711669	chr6:146136114	FBXO30	-0.85	-9.45	-0.65	2.66e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs8064299	0.597	rs4789098	chr17:72781292	C/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.88	10.27	0.68	2.76e-18	Monocyte count;
TGCT	cis	rs13102973	0.931	rs6822196	chr4:135855582	T/A	cg14419869	chr4:135874104	NA	0.23	4.58	0.38	1.12e-5	Subjective well-being;
TGCT	cis	rs6545883	0.862	rs778141	chr2:61682178	A/G	cg15711740	chr2:61764176	XPO1	-0.53	-4.79	-0.4	4.59e-6	Tuberculosis;
TGCT	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg23758822	chr17:41437982	NA	0.71	6.77	0.52	4.56e-10	Menopause (age at onset);
TGCT	cis	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg06636001	chr8:8085503	FLJ10661	0.78	7.57	0.56	7.46e-12	Mood instability;
TGCT	cis	rs2657888	1.000	rs17540509	chr12:56943840	T/C	cg23002907	chr12:56915593	RBMS2	-0.44	-5.82	-0.46	4.69e-8	Adiponectin levels;
TGCT	cis	rs1163251	0.902	rs514491	chr1:120216743	C/T	cg19096424	chr1:120255104	PHGDH	0.56	5.29	0.43	5.46e-7	Blood metabolite levels;
TGCT	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg06873352	chr17:61820015	STRADA	0.56	6.22	0.49	6.93e-9	Prudent dietary pattern;
TGCT	cis	rs7572733	0.555	rs11889006	chr2:198928647	A/G	cg00792783	chr2:198669748	PLCL1	0.57	4.98	0.41	2.1e-6	Dermatomyositis;
TGCT	cis	rs28595532	0.920	rs114916728	chr4:119776886	G/A	cg21605333	chr4:119757512	SEC24D	1.53	8.87	0.62	6.71e-15	Cannabis dependence symptom count;
TGCT	cis	rs7208859	0.673	rs9895815	chr17:29138033	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs1568889	1.000	rs12802830	chr11:28321196	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.84	8.47	0.61	5.84e-14	Bipolar disorder;
TGCT	cis	rs6912958	1.000	rs6912958	chr6:88133315	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.31	-0.43	4.88e-7	Monocyte percentage of white cells;
TGCT	cis	rs554111	0.634	rs10799673	chr1:21274671	T/G	cg01072550	chr1:21505969	NA	0.35	5.36	0.43	3.88e-7	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs4372836	0.504	rs13030945	chr2:29087799	C/A	cg09522027	chr2:28974177	PPP1CB	-0.57	-5.63	-0.45	1.14e-7	Body mass index;
TGCT	cis	rs2242116	0.727	rs4683298	chr3:46966387	C/G	cg23352942	chr3:46931381	PTH1R	-0.32	-4.8	-0.4	4.49e-6	Birth weight;
TGCT	trans	rs1864729	0.748	rs2567770	chr8:98296720	C/T	cg08679828	chr8:102218111	ZNF706	-1.03	-6.8	-0.52	3.9e-10	Estradiol plasma levels (breast cancer);
TGCT	cis	rs72717009	0.825	rs7515174	chr1:161476949	C/G	cg23840854	chr1:161414152	NA	-0.98	-5.86	-0.47	3.95e-8	Rheumatoid arthritis;
TGCT	cis	rs6988636	1.000	rs57902736	chr8:124189893	G/A	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs11671005	0.735	rs11666716	chr19:58920952	A/G	cg13877915	chr19:58951672	ZNF132	0.63	4.99	0.41	1.99e-6	Mean platelet volume;
TGCT	cis	rs3733585	0.673	rs4311316	chr4:9955971	A/C	cg11266682	chr4:10021025	SLC2A9	0.58	7.7	0.57	3.72e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	trans	rs1814175	0.715	rs10839409	chr11:49884647	G/T	cg15704280	chr7:45808275	SEPT13	-0.72	-8.14	-0.59	3.61e-13	Height;
TGCT	cis	rs9913156	0.517	rs12452404	chr17:4587355	C/T	cg00122941	chr17:4613640	ARRB2	-0.73	-6.88	-0.53	2.68e-10	Lymphocyte counts;
TGCT	cis	rs1215050	0.755	rs6843393	chr4:98822619	C/G	cg05340658	chr4:99064831	C4orf37	0.45	5.78	0.46	5.8e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs36051895	0.659	rs11999076	chr9:5037694	C/T	cg02405213	chr9:5042618	JAK2	-0.83	-11.98	-0.73	1.89e-22	Pediatric autoimmune diseases;
TGCT	cis	rs9611519	0.603	rs4821999	chr22:41470001	A/G	cg03806693	chr22:41940476	POLR3H	-0.51	-4.57	-0.38	1.14e-5	Neuroticism;
TGCT	cis	rs7267979	1.000	rs6050629	chr20:25430680	G/A	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2742417	1.000	rs2673033	chr3:45756350	C/G	cg04837898	chr3:45731254	SACM1L	-0.56	-5.98	-0.47	2.24e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs6684514	1.000	rs12027103	chr1:156244856	G/A	cg16558208	chr1:156270281	VHLL	0.46	9.38	0.64	3.92e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.07	0.82	4.17e-32	Prudent dietary pattern;
TGCT	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg22963979	chr7:1858916	MAD1L1	-0.39	-6.18	-0.49	8.65e-9	Bipolar disorder and schizophrenia;
TGCT	cis	rs62283056	0.512	rs10028875	chr4:6283460	C/T	cg14416269	chr4:6271139	WFS1	0.39	4.91	0.4	2.85e-6	Cisplatin-induced ototoxicity;
TGCT	cis	rs1568889	1.000	rs66702115	chr11:28181703	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	8.75	0.62	1.26e-14	Bipolar disorder;
TGCT	cis	rs2842992	0.915	rs2842985	chr6:160085434	C/T	cg11366901	chr6:160182831	ACAT2	0.96	6.28	0.49	5.21e-9	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs6866344	0.697	rs6873150	chr5:178125704	G/A	cg10224037	chr5:178157518	ZNF354A	0.94	8.06	0.59	5.44e-13	Neutrophil percentage of white cells;
TGCT	cis	rs7584330	0.554	rs113271883	chr2:238425594	A/G	cg08992911	chr2:238395768	MLPH	0.7	4.72	0.39	6.32e-6	Prostate cancer;
TGCT	cis	rs6690583	0.623	rs12042845	chr1:85429801	A/G	cg20280350	chr1:85513789	MCOLN3	-0.68	-4.49	-0.37	1.6e-5	Serum sulfate level;
TGCT	cis	rs1941023	0.584	rs4938941	chr11:60173360	C/T	cg08716584	chr11:60157161	MS4A7	0.31	4.77	0.39	5.13e-6	Congenital heart disease (maternal effect);
TGCT	cis	rs9467773	1.000	rs1884946	chr6:26545308	C/G	cg09904177	chr6:26538194	HMGN4	0.65	6.48	0.5	1.95e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs6893300	0.524	rs12374446	chr5:179131143	A/G	cg14593053	chr5:179126677	CANX	0.47	5.24	0.43	6.56e-7	Resting heart rate;
TGCT	cis	rs7681440	0.835	rs6532198	chr4:90798870	C/T	cg14346243	chr4:90757452	SNCA	-0.5	-4.75	-0.39	5.46e-6	Dementia with Lewy bodies;
TGCT	cis	rs611744	0.967	rs686630	chr8:109233239	G/C	cg21045802	chr8:109455806	TTC35	0.52	4.71	0.39	6.5e-6	Dupuytren's disease;
TGCT	cis	rs7772486	0.712	rs6570726	chr6:146159460	T/C	cg23711669	chr6:146136114	FBXO30	0.78	7.51	0.56	1.02e-11	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs10435719	0.902	rs12681142	chr8:11802601	T/C	cg15556689	chr8:8085844	FLJ10661	0.76	7.24	0.55	4.06e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs1008375	1.000	rs1860596	chr4:17660082	C/T	cg18681998	chr4:17616180	MED28	1.01	11.83	0.73	4.51e-22	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6940638	0.688	rs7744759	chr6:27119826	G/A	cg26531700	chr6:26746687	NA	-0.52	-4.51	-0.38	1.5e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs4689592	0.503	rs56099074	chr4:7071259	A/G	cg26116260	chr4:7069785	GRPEL1	-0.97	-7.78	-0.57	2.39e-12	Monocyte percentage of white cells;
TGCT	cis	rs10464366	0.519	rs6974609	chr7:39219149	C/T	cg18850127	chr7:39170497	POU6F2	0.31	6.2	0.49	7.75e-9	IgG glycosylation;
TGCT	cis	rs17221829	0.627	rs7130892	chr11:89386606	T/C	cg02982614	chr11:89391479	FOLH1B	-0.25	-4.46	-0.37	1.8e-5	Anxiety in major depressive disorder;
TGCT	cis	rs478304	0.651	rs12225620	chr11:65505448	T/C	cg17480646	chr11:65405466	SIPA1	-0.57	-6.95	-0.53	1.84e-10	Acne (severe);
TGCT	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	5.24	0.43	6.79e-7	Menopause (age at onset);
TGCT	cis	rs595982	0.559	rs17206714	chr19:49362001	T/A	cg21252483	chr19:49399788	TULP2	-0.42	-6.43	-0.5	2.44e-9	Red cell distribution width;
TGCT	cis	rs992157	0.710	rs56364928	chr2:219059058	G/A	cg00012203	chr2:219082015	ARPC2	0.83	10.59	0.69	4.61e-19	Colorectal cancer;
TGCT	cis	rs7296418	0.885	rs1716184	chr12:123637509	G/C	cg00376283	chr12:123451042	ABCB9	0.84	7.66	0.57	4.68e-12	Platelet count;
TGCT	cis	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg06558623	chr16:89946397	TCF25	0.53	6.48	0.5	1.99e-9	Skin colour saturation;
TGCT	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg06238570	chr21:40685208	BRWD1	-0.8	-9.1	-0.63	1.91e-15	Cognitive function;
TGCT	cis	rs9467711	0.606	rs34273322	chr6:26415409	T/A	cg16898833	chr6:26189333	HIST1H4D	1.12	5.36	0.43	3.91e-7	Autism spectrum disorder or schizophrenia;
TGCT	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg05064044	chr6:292385	DUSP22	-0.69	-7.17	-0.54	5.94e-11	Menopause (age at onset);
TGCT	cis	rs950169	0.579	rs62027818	chr15:84661145	T/C	cg11189052	chr15:85197271	WDR73	0.65	5.06	0.41	1.45e-6	Schizophrenia;
TGCT	cis	rs12477438	0.798	rs9308816	chr2:99637230	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-5.79	-0.46	5.44e-8	Chronic sinus infection;
TGCT	cis	rs644799	1.000	rs487609	chr11:95588102	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	8.63	0.61	2.51e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs2239815	0.515	rs5762849	chr22:29238086	G/A	cg02153584	chr22:29168773	CCDC117	0.67	4.57	0.38	1.17e-5	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
TGCT	cis	rs901683	0.702	rs78034568	chr10:46149580	G/C	cg09623279	chr10:45395734	NA	-0.49	-5.33	-0.43	4.55e-7	Red blood cell traits;Mean corpuscular volume;
TGCT	cis	rs2180341	0.960	rs7766802	chr6:127709871	T/G	cg24812749	chr6:127587940	RNF146	0.98	7.53	0.56	9.29e-12	Breast cancer;
TGCT	cis	rs4720575	1.000	rs4724535	chr7:47100396	G/A	cg00036614	chr7:47093842	NA	-0.21	-5.28	-0.43	5.69e-7	Angiotensin-converting enzyme inhibitor intolerance;
TGCT	cis	rs6988636	0.710	rs73339621	chr8:124138936	C/T	cg27053337	chr8:124217698	FAM83A	0.77	5.55	0.45	1.65e-7	Urinary uromodulin levels;
TGCT	cis	rs17221829	0.699	rs78403327	chr11:89384225	C/T	cg02982614	chr11:89391479	FOLH1B	-0.27	-4.66	-0.39	7.89e-6	Anxiety in major depressive disorder;
TGCT	cis	rs62185668	0.693	rs6077966	chr20:10919740	A/G	cg17778165	chr20:10414372	MKKS	-0.58	-4.53	-0.38	1.35e-5	Urinary bladder cancer;
TGCT	cis	rs6430585	0.591	rs309118	chr2:136746224	G/C	cg07169764	chr2:136633963	MCM6	1.21	11.71	0.72	8.7e-22	Corneal structure;
TGCT	cis	rs1887596	0.705	rs1590954	chr13:27200239	A/G	cg01312412	chr13:27282625	NA	0.3	5.31	0.43	4.89e-7	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs763121	0.853	rs138712	chr22:39141600	C/T	cg06022373	chr22:39101656	GTPBP1	0.69	6.49	0.5	1.88e-9	Menopause (age at onset);
TGCT	cis	rs1372520	0.684	rs2583968	chr4:90745395	C/G	cg01966878	chr4:90757139	SNCA	-0.3	-4.69	-0.39	7.05e-6	Neuroticism;
TGCT	cis	rs10782582	0.609	rs79835994	chr1:76287508	G/T	cg03433033	chr1:76189801	ACADM	-0.5	-4.98	-0.41	2.11e-6	Daytime sleep phenotypes;
TGCT	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.71	-0.39	6.54e-6	Prudent dietary pattern;
TGCT	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg18876405	chr7:65276391	NA	-0.37	-5.66	-0.45	1e-7	Aortic root size;
TGCT	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.94	7.39	0.55	1.89e-11	Platelet count;
TGCT	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg11764359	chr7:65958608	NA	-0.54	-4.86	-0.4	3.45e-6	Aortic root size;
TGCT	cis	rs1008375	0.902	rs7654332	chr4:17691778	A/T	cg18681998	chr4:17616180	MED28	0.76	7.28	0.55	3.42e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs3733585	0.673	rs4292333	chr4:9953871	G/A	cg00071950	chr4:10020882	SLC2A9	-0.55	-6.58	-0.51	1.21e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs1971762	0.561	rs4759288	chr12:54084006	T/A	cg16917193	chr12:54089295	NA	1.39	17.84	0.85	4.9e-36	Height;
TGCT	cis	rs453301	0.686	rs11785819	chr8:8870378	T/G	cg06636001	chr8:8085503	FLJ10661	-0.68	-5.63	-0.45	1.13e-7	Joint mobility (Beighton score);
TGCT	trans	rs8073060	0.544	rs8071584	chr17:33999435	G/A	cg19694781	chr19:47549865	TMEM160	-0.6	-13.37	-0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs7677751	0.806	rs17084051	chr4:55087581	C/A	cg17187183	chr4:55093834	PDGFRA	0.54	7.13	0.54	7.45e-11	Corneal astigmatism;
TGCT	trans	rs931812	1.000	rs931812	chr8:101919321	A/G	cg20993868	chr7:22813445	NA	-0.35	-7.72	-0.57	3.35e-12	Attention deficit hyperactivity disorder and conduct disorder;
TGCT	cis	rs2730245	0.527	rs2527194	chr7:158732959	G/A	cg11984989	chr7:158649758	WDR60	-1.01	-7.85	-0.58	1.65e-12	Height;
TGCT	cis	rs6089584	1.000	rs3787424	chr20:60559219	G/A	cg16423285	chr20:60520624	NA	-0.52	-5.45	-0.44	2.6e-7	Body mass index;
TGCT	cis	rs8180040	0.966	rs11130137	chr3:47578838	C/T	cg27129171	chr3:47204927	SETD2	0.62	7.22	0.54	4.69e-11	Colorectal cancer;
TGCT	cis	rs929596	0.785	rs6747843	chr2:234664354	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.34	-5.49	-0.44	2.13e-7	Total bilirubin levels in HIV-1 infection;
TGCT	cis	rs881375	0.967	rs1014529	chr9:123684943	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.42	4.63	0.38	9.27e-6	Rheumatoid arthritis;
TGCT	cis	rs910316	1.000	rs2300601	chr14:75639571	A/G	cg08847533	chr14:75593920	NEK9	0.91	10.09	0.67	7.72e-18	Height;
TGCT	cis	rs501916	0.833	rs3809486	chr15:48051549	G/T	cg16110827	chr15:48056943	SEMA6D	-0.17	-4.68	-0.39	7.32e-6	Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg09165964	chr15:75287851	SCAMP5	0.51	4.65	0.39	8.33e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
TGCT	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.61	5.06	0.41	1.5e-6	Tonsillectomy;
TGCT	cis	rs4372836	1.000	rs2169751	chr2:28966758	G/C	cg09522027	chr2:28974177	PPP1CB	-0.59	-5.15	-0.42	1e-6	Body mass index;
TGCT	trans	rs1973993	0.691	rs4000303	chr1:96913765	A/G	cg10631902	chr5:14652156	NA	0.39	10.65	0.69	3.3e-19	Weight;
TGCT	cis	rs10193935	0.901	rs222486	chr2:42649664	C/T	cg27598129	chr2:42591480	NA	-0.32	-4.65	-0.39	8.33e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2228479	0.541	rs12918575	chr16:89811151	A/G	cg27121462	chr16:89883253	FANCA	0.77	4.61	0.38	9.93e-6	Skin colour saturation;
TGCT	cis	rs1971762	0.527	rs6580958	chr12:54073483	A/G	cg16917193	chr12:54089295	NA	1.31	16.3	0.83	1.29e-32	Height;
TGCT	cis	rs1635	0.655	rs16893975	chr6:28302278	C/T	cg15743358	chr6:28303923	ZNF323	1.24	6.25	0.49	5.93e-9	Schizophrenia;
TGCT	cis	rs5769707	0.521	rs74351010	chr22:50036820	G/A	cg03598726	chr22:50246859	ZBED4	-0.45	-4.49	-0.37	1.63e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs644799	0.544	rs1150360	chr11:95512060	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.57	6.21	0.49	7.25e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9814567	0.727	rs4437193	chr3:134352344	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-5.92	-0.47	2.97e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs938554	0.513	rs1014290	chr4:10001861	G/A	cg00071950	chr4:10020882	SLC2A9	0.58	5.44	0.44	2.67e-7	Blood metabolite levels;
TGCT	cis	rs2769264	0.505	rs4246526	chr1:151403916	G/T	cg18801370	chr1:151430492	POGZ	0.62	5.62	0.45	1.19e-7	Blood trace element (Cu levels);
TGCT	cis	rs4478858	0.735	rs34960310	chr1:31816197	A/G	cg07478791	chr1:31886160	SERINC2	-0.51	-4.95	-0.41	2.33e-6	Alcohol dependence;
TGCT	trans	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg20587970	chr11:113659929	NA	-1.03	-10.98	-0.7	5.21e-20	Hip circumference adjusted for BMI;
TGCT	cis	rs8180040	0.603	rs9854790	chr3:47101306	T/G	cg27129171	chr3:47204927	SETD2	0.71	8.55	0.61	3.9e-14	Colorectal cancer;
TGCT	cis	rs7191439	0.522	rs745326	chr16:88755245	C/G	cg27087555	chr16:88793112	FAM38A	-0.44	-4.57	-0.38	1.17e-5	Plateletcrit;
TGCT	cis	rs6987853	0.966	rs2974359	chr8:42434194	T/C	cg20539142	chr8:42623718	CHRNA6	-0.2	-4.84	-0.4	3.76e-6	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs1008375	1.000	rs6449323	chr4:17683916	A/T	cg18681998	chr4:17616180	MED28	0.86	8.97	0.63	3.76e-15	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7267979	0.932	rs6138588	chr20:25487523	C/T	cg14121845	chr20:25566513	NINL	0.49	5.36	0.43	3.83e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs68170813	0.559	rs7809508	chr7:107004119	T/C	cg02696742	chr7:106810147	HBP1	-0.68	-5.73	-0.46	7.19e-8	Coronary artery disease;
TGCT	cis	rs526231	0.578	rs17154825	chr5:102246069	T/C	cg23492399	chr5:102201601	PAM	-0.51	-4.49	-0.37	1.62e-5	Primary biliary cholangitis;
TGCT	cis	rs2404602	0.692	rs2117369	chr15:76748861	A/T	cg26408565	chr15:76604113	ETFA	-0.4	-5.26	-0.43	6.23e-7	Blood metabolite levels;
TGCT	cis	rs9611565	0.512	rs1534932	chr22:42150146	C/T	cg13695892	chr22:41940480	POLR3H	0.85	8.06	0.59	5.4e-13	Vitiligo;
TGCT	cis	rs6598955	0.671	rs55791848	chr1:26582711	G/A	cg04990556	chr1:26633338	UBXN11	0.62	4.73	0.39	6.12e-6	Obesity-related traits;
TGCT	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.69	-0.39	7e-6	Prudent dietary pattern;
TGCT	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg24829409	chr8:58192753	C8orf71	-0.59	-4.97	-0.41	2.17e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6598955	0.670	rs10794525	chr1:26537193	C/A	cg04990556	chr1:26633338	UBXN11	-0.89	-11.24	-0.71	1.2e-20	Obesity-related traits;
TGCT	cis	rs523522	0.962	rs55848094	chr12:120966659	G/A	cg27279351	chr12:120934652	DYNLL1	0.76	6.59	0.51	1.15e-9	High light scatter reticulocyte count;
TGCT	cis	rs73058052	0.597	rs10404887	chr19:50096421	C/G	cg09250473	chr19:50168907	IRF3;BCL2L12	0.65	5.22	0.42	7.33e-7	Fibrinogen levels;
TGCT	cis	rs6490294	0.799	rs11066082	chr12:112351348	T/C	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Mean platelet volume;
TGCT	cis	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg25427524	chr10:38739819	LOC399744	-0.39	-7.9	-0.58	1.31e-12	Extrinsic epigenetic age acceleration;
TGCT	cis	rs1008375	0.932	rs6857678	chr4:17696964	A/T	cg18681998	chr4:17616180	MED28	0.78	7.33	0.55	2.6e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7020830	0.867	rs56098516	chr9:37362220	A/G	cg14294708	chr9:37120828	ZCCHC7	1.15	15.73	0.82	2.55e-31	Schizophrenia;
TGCT	cis	rs10465746	0.780	rs1952065	chr1:84464205	T/C	cg10977910	chr1:84465055	TTLL7	0.67	6.54	0.51	1.47e-9	Obesity-related traits;
TGCT	cis	rs35146811	0.695	rs1727132	chr7:99812297	T/C	cg04778012	chr7:99775508	STAG3;GPC2	-0.35	-4.93	-0.41	2.55e-6	Coronary artery disease;
TGCT	cis	rs6964587	1.000	rs3753109	chr7:91630001	G/C	cg22709100	chr7:91322751	NA	0.27	4.48	0.37	1.68e-5	Breast cancer;
TGCT	cis	rs4253772	0.530	rs6008662	chr22:46713917	G/A	cg24881330	chr22:46731750	TRMU	0.96	6.17	0.48	8.81e-9	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs3806843	0.900	rs3756334	chr5:140213796	G/A	cg19875535	chr5:140030758	IK	0.37	5.94	0.47	2.67e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2880765	0.835	rs4536419	chr15:86039471	C/T	cg13263323	chr15:86062960	AKAP13	-0.21	-4.5	-0.37	1.53e-5	Coronary artery disease;
TGCT	cis	rs9811920	0.609	rs793466	chr3:99609837	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.6	-6.82	-0.52	3.63e-10	Axial length;
TGCT	cis	rs2594989	1.000	rs2594978	chr3:11383347	C/A	cg00170343	chr3:11313890	ATG7	0.68	5.19	0.42	8.47e-7	Circulating chemerin levels;
TGCT	cis	rs259282	0.692	rs17693106	chr19:33125055	C/T	cg26639809	chr19:33781782	NA	-0.25	-5.19	-0.42	8.26e-7	Schizophrenia;
TGCT	cis	rs929354	0.742	rs7784442	chr7:156934475	G/C	cg05182265	chr7:156933206	UBE3C	-0.39	-8.98	-0.63	3.72e-15	Body mass index;
TGCT	cis	rs11874712	0.712	rs2578183	chr18:43676720	A/G	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.49	4.9	0.4	2.91e-6	Migraine - clinic-based;
TGCT	trans	rs79643899	1	rs79643899	chr5:35429449	A/C	cg16965576	chr1:245238552	EFCAB2	0.72	6.71	0.52	6.05e-10	Post bronchodilator FEV1 in COPD;
TGCT	cis	rs9303401	0.659	rs34275691	chr17:56736640	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs28595532	0.841	rs114107504	chr4:119771080	T/C	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs3796352	1.000	rs11718834	chr3:52963668	A/C	cg15956490	chr3:53032818	SFMBT1	0.63	6.53	0.51	1.55e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs9560113	0.622	rs4773388	chr13:112195250	A/C	cg10483660	chr13:112241077	NA	0.3	4.51	0.38	1.47e-5	Menarche (age at onset);
TGCT	cis	rs9788682	1.000	rs34138960	chr15:78831668	A/G	cg24631222	chr15:78858424	CHRNA5	0.92	7.57	0.56	7.51e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs1538970	0.962	rs9429158	chr1:45821393	A/G	cg05343316	chr1:45956843	TESK2	0.64	5.13	0.42	1.08e-6	Platelet count;
TGCT	cis	rs74233809	0.901	rs4409766	chr10:104616663	A/G	cg05855489	chr10:104503620	C10orf26	0.78	4.47	0.37	1.73e-5	Birth weight;
TGCT	trans	rs1814175	0.817	rs11040700	chr11:50023832	C/T	cg15704280	chr7:45808275	SEPT13	-0.72	-8.47	-0.61	6.02e-14	Height;
TGCT	cis	rs36051895	0.664	rs10815154	chr9:5095538	G/A	cg02405213	chr9:5042618	JAK2	-0.77	-10.81	-0.7	1.32e-19	Pediatric autoimmune diseases;
TGCT	cis	rs6733011	0.500	rs11123754	chr2:99433782	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-4.73	-0.39	6.12e-6	Bipolar disorder;
TGCT	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg11764359	chr7:65958608	NA	0.54	5.02	0.41	1.73e-6	Aortic root size;
TGCT	cis	rs17376456	0.825	rs10061377	chr5:93174513	T/C	cg21475434	chr5:93447410	FAM172A	0.69	4.97	0.41	2.15e-6	Diabetic retinopathy;
TGCT	cis	rs66573146	0.803	rs59809420	chr4:6969928	G/T	cg05069807	chr4:6945702	TBC1D14	0.33	4.72	0.39	6.27e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs4851254	0.660	rs4851250	chr2:100729293	T/C	cg07810366	chr2:100720526	AFF3	-0.45	-4.66	-0.39	8.15e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs861020	0.582	rs630065	chr1:209998662	C/T	cg05527609	chr1:210001259	C1orf107	0.86	7.45	0.56	1.39e-11	Orofacial clefts;
TGCT	cis	rs7772486	0.875	rs9322043	chr6:146352690	A/G	cg23711669	chr6:146136114	FBXO30	0.9	10.19	0.68	4.4e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9486715	0.830	rs1475748	chr6:97034143	T/C	cg18709589	chr6:96969512	KIAA0776	-0.84	-8.23	-0.59	2.19e-13	Headache;
TGCT	cis	rs6460942	0.915	rs62448620	chr7:12458170	C/T	cg06484146	chr7:12443880	VWDE	-0.57	-5.52	-0.44	1.92e-7	Coronary artery disease;
TGCT	cis	rs6714710	0.603	rs34373359	chr2:98442202	G/A	cg26665480	chr2:98280029	ACTR1B	0.66	6.27	0.49	5.45e-9	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs2777491	0.915	rs7180418	chr15:41629502	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.75	-10.44	-0.68	1.07e-18	Ulcerative colitis;
TGCT	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg20887711	chr4:1340912	KIAA1530	0.91	8.31	0.6	1.41e-13	Longevity;
TGCT	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg15691649	chr6:25882328	NA	-0.35	-4.55	-0.38	1.25e-5	Blood metabolite levels;
TGCT	cis	rs13191362	0.507	rs2849527	chr6:163117932	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.54	5.25	0.43	6.38e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs2657888	1.000	rs28697089	chr12:56938703	A/G	cg23932658	chr12:57637574	STAC3	-0.51	-4.73	-0.39	5.9e-6	Adiponectin levels;
TGCT	cis	rs1153858	1.000	rs56850226	chr15:45633118	T/C	cg26924012	chr15:45694286	SPATA5L1	1.07	14.56	0.79	1.32e-28	Homoarginine levels;
TGCT	cis	rs9611565	0.512	rs5758439	chr22:42131762	C/T	cg03806693	chr22:41940476	POLR3H	1.06	10.94	0.7	6.7e-20	Vitiligo;
TGCT	cis	rs7582180	0.652	rs4851307	chr2:100971778	C/T	cg14675211	chr2:100938903	LONRF2	0.5	4.79	0.4	4.66e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2204008	0.548	rs8189475	chr12:38037115	C/T	cg26384229	chr12:38710491	ALG10B	0.71	6.3	0.49	4.78e-9	Bladder cancer;
TGCT	cis	rs6089584	0.861	rs2180302	chr20:60576369	A/G	cg06108461	chr20:60628389	TAF4	-0.65	-9.34	-0.64	5.08e-16	Body mass index;
TGCT	cis	rs7914558	0.899	rs7913682	chr10:104684392	T/A	cg15744005	chr10:104629667	AS3MT	-0.43	-5.27	-0.43	5.86e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs7659604	0.702	rs6826506	chr4:122710865	T/G	cg23574427	chr4:122746245	BBS7;CCNA2	-0.35	-5.51	-0.44	1.95e-7	Type 2 diabetes;
TGCT	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg07205460	chr22:24236375	MIF	0.59	4.65	0.39	8.26e-6	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs9916302	0.706	rs9890198	chr17:37457480	A/C	cg07936489	chr17:37558343	FBXL20	0.85	6.28	0.49	5.22e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg18230493	chr5:56204884	C5orf35	-0.68	-5.92	-0.47	2.92e-8	Initial pursuit acceleration;
TGCT	cis	rs1532993	0.518	rs11097575	chr4:98642418	G/T	cg05340658	chr4:99064831	C4orf37	-0.41	-4.92	-0.4	2.72e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg06028808	chr11:68637592	NA	0.54	6.94	0.53	1.93e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs13256369	0.826	rs12678414	chr8:8586016	G/T	cg18904891	chr8:8559673	CLDN23	0.54	4.63	0.38	9.19e-6	Obesity-related traits;
TGCT	cis	rs112591243	0.685	rs4819263	chr21:47950866	G/A	cg10657630	chr21:48055338	PRMT2	1.06	5.21	0.42	7.69e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs9916302	0.706	rs8182252	chr17:37727950	T/C	cg15445000	chr17:37608096	MED1	-0.34	-4.73	-0.39	6.02e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7226408	0.901	rs56209075	chr18:34386033	C/G	cg06757138	chr18:34340585	FHOD3	0.26	4.79	0.4	4.62e-6	Obesity-related traits;
TGCT	trans	rs2243480	1.000	rs1796228	chr7:66033084	G/A	cg07424592	chr7:64974309	NA	1.3	8.23	0.59	2.19e-13	Diabetic kidney disease;
TGCT	cis	rs6835098	0.924	rs2332669	chr4:174163398	G/A	cg08422745	chr4:174089978	GALNT7	-0.85	-9.14	-0.63	1.49e-15	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs11249608	0.548	rs6875622	chr5:178451397	C/T	cg01312482	chr5:178451176	ZNF879	-0.56	-5.5	-0.44	2.09e-7	Pubertal anthropometrics;
TGCT	cis	rs2544527	0.819	rs2693019	chr2:15922288	T/C	cg26669897	chr2:15909070	NA	0.42	4.98	0.41	2.09e-6	Pulmonary function (smoking interaction);Pulmonary function;
TGCT	cis	rs77633900	0.614	rs2439992	chr15:76863023	T/G	cg21673338	chr15:77095150	SCAPER	-0.49	-4.59	-0.38	1.08e-5	Non-glioblastoma glioma;Glioma;
TGCT	cis	rs9291683	0.509	rs10939671	chr4:10050815	T/C	cg00071950	chr4:10020882	SLC2A9	0.57	6.43	0.5	2.5e-9	Bone mineral density;
TGCT	cis	rs28785552	0.769	rs28796114	chr19:53234319	T/C	cg04754360	chr19:53238445	ZNF611	-0.59	-4.55	-0.38	1.26e-5	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs9467773	1.000	rs1078679	chr6:26568741	C/T	cg26531700	chr6:26746687	NA	0.5	4.85	0.4	3.64e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg06238570	chr21:40685208	BRWD1	0.69	6.39	0.5	3.07e-9	Cognitive function;
TGCT	cis	rs7043114	0.525	rs10761161	chr9:95262342	C/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-5.39	-0.44	3.43e-7	Height;
TGCT	cis	rs1018836	0.608	rs11997663	chr8:91474484	A/C	cg16814680	chr8:91681699	NA	-0.71	-7.18	-0.54	5.67e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7043114	0.525	rs7026361	chr9:95138564	A/C	cg14631576	chr9:95140430	CENPP	0.29	4.82	0.4	4.05e-6	Height;
TGCT	cis	rs2799081	1	rs2799081	chr6:28270584	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.47	-4.65	-0.39	8.23e-6	Myopia;
TGCT	cis	rs17076896	0.655	rs61956063	chr13:19928471	T/C	cg00777926	chr13:20807375	GJB6	-0.37	-4.51	-0.38	1.5e-5	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs2228479	0.850	rs17226666	chr16:89835401	G/A	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs1577917	0.572	rs911927	chr6:86327860	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-4.76	-0.39	5.23e-6	Response to antipsychotic treatment;
TGCT	cis	rs9457247	0.967	rs447042	chr6:167405435	C/T	cg23791538	chr6:167370224	RNASET2	-0.49	-4.96	-0.41	2.26e-6	Crohn's disease;
TGCT	cis	rs11910985	1.000	rs11910985	chr21:48042766	C/T	cg23283320	chr21:48055893	PRMT2	1.35	6.43	0.5	2.51e-9	Cerebrospinal fluid t-tau:AB1-42 ratio;
TGCT	cis	rs308403	0.509	rs13117125	chr4:123670824	T/C	cg10495464	chr4:123653540	BBS12;LOC729338	0.82	11.84	0.73	4.22e-22	Blood protein levels;
TGCT	cis	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg18188782	chr20:61659543	NA	0.46	5.55	0.45	1.61e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg04234412	chr22:24373322	LOC391322	-0.78	-8.55	-0.61	3.78e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs5769707	0.604	rs1018814	chr22:50036900	T/C	cg06623630	chr22:50017776	C22orf34	-0.27	-4.67	-0.39	7.81e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs3960554	0.529	rs7793844	chr7:75883147	C/T	cg19105122	chr7:75896889	SRRM3	0.58	4.91	0.4	2.85e-6	Eotaxin levels;
TGCT	cis	rs11731606	0.508	rs28501313	chr4:95281023	G/A	cg00507259	chr4:95128692	SMARCAD1	0.65	4.89	0.4	3.02e-6	Mean platelet volume;
TGCT	trans	rs1974653	0.672	rs8139374	chr22:20093522	C/T	cg08822737	chr17:71088851	SLC39A11	-0.93	-7.61	-0.56	5.97e-12	Schizophrenia;
TGCT	cis	rs2204008	0.774	rs8189620	chr12:38241621	A/G	cg26384229	chr12:38710491	ALG10B	0.86	7.42	0.55	1.6e-11	Bladder cancer;
TGCT	trans	rs11722228	1.000	rs6825187	chr4:9915325	T/C	cg26043149	chr18:55253948	FECH	-0.74	-7.62	-0.56	5.78e-12	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs4372836	1.000	rs7579277	chr2:28996295	G/A	cg09522027	chr2:28974177	PPP1CB	-0.65	-5.74	-0.46	7.01e-8	Body mass index;
TGCT	cis	rs3820068	0.705	rs72643701	chr1:15866219	G/A	cg05660106	chr1:15850417	CASP9	1.16	14.82	0.8	3.11e-29	Systolic blood pressure;
TGCT	cis	rs2463822	0.920	rs28678254	chr11:62151875	G/C	cg06239285	chr11:62104954	ASRGL1	-0.94	-6.61	-0.51	1.03e-9	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.67	-0.39	7.73e-6	Prudent dietary pattern;
TGCT	cis	rs752092	0.894	rs8036083	chr15:101767822	T/G	cg25114630	chr15:101792522	CHSY1	0.51	4.8	0.4	4.54e-6	Corneal structure;
TGCT	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg21862992	chr11:68658383	NA	0.47	6.54	0.51	1.42e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6546537	0.869	rs13035491	chr2:69827456	G/A	cg10773587	chr2:69614142	GFPT1	-0.72	-6.73	-0.52	5.54e-10	Serum thyroid-stimulating hormone levels;
TGCT	cis	rs9952991	0.941	rs9952749	chr18:12780456	A/G	cg24737193	chr18:12778029	NA	0.53	5.93	0.47	2.8e-8	Inflammatory skin disease;
TGCT	cis	rs7618915	1.000	rs7618915	chr3:52279594	G/A	cg07507251	chr3:52567010	NT5DC2	0.43	5.83	0.46	4.46e-8	Bipolar disorder;
TGCT	cis	rs62103177	0.564	rs11874805	chr18:77697110	T/C	cg12964065	chr18:77638022	KCNG2	0.33	4.7	0.39	6.68e-6	Opioid sensitivity;
TGCT	cis	rs3782455	1.000	rs75409372	chr12:114405283	C/T	cg23502203	chr12:113549970	RASAL1	-0.57	-4.95	-0.41	2.34e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs9611519	0.780	rs9611546	chr22:41698542	C/G	cg13695892	chr22:41940480	POLR3H	-0.71	-6.86	-0.52	2.89e-10	Neuroticism;
TGCT	cis	rs1801251	0.752	rs709938	chr2:233746457	C/T	cg25237894	chr2:233734115	C2orf82	-0.31	-5.98	-0.47	2.2e-8	Coronary artery disease;
TGCT	cis	rs7246657	0.722	rs2927739	chr19:38149330	C/A	cg18154014	chr19:37997991	ZNF793	-0.67	-4.69	-0.39	6.96e-6	Coronary artery calcification;
TGCT	trans	rs901683	0.702	rs73292848	chr10:46169752	T/C	cg03236627	chr11:44786104	TSPAN18	-0.58	-6.72	-0.52	5.96e-10	Red blood cell traits;Mean corpuscular volume;
TGCT	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.72	5.19	0.42	8.33e-7	Platelet count;
TGCT	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.52	-4.87	-0.4	3.3e-6	Prudent dietary pattern;
TGCT	cis	rs8103278	0.864	rs2070737	chr19:46282890	A/T	cg14061069	chr19:46274453	DMPK	-0.43	-6.29	-0.49	5e-9	Coronary artery disease;
TGCT	cis	rs2836950	0.565	rs2836934	chr21:40564885	A/C	cg17971929	chr21:40555470	PSMG1	-0.51	-4.7	-0.39	6.68e-6	Menarche (age at onset);
TGCT	cis	rs1555895	0.576	rs2274376	chr10:850157	A/G	cg02193355	chr10:851439	NA	0.21	4.71	0.39	6.42e-6	Survival in rectal cancer;
TGCT	cis	rs1997103	1.000	rs2331064	chr7:55408610	C/G	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs295140	1.000	rs1431766	chr2:201191034	A/G	cg04283868	chr2:201171347	SPATS2L	0.64	6.63	0.51	9.15e-10	QT interval;
TGCT	cis	rs72781680	1.000	rs56068891	chr2:24230633	A/G	cg08917208	chr2:24149416	ATAD2B	0.84	5.12	0.42	1.12e-6	Lymphocyte counts;
TGCT	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg11247378	chr22:39784982	NA	-0.73	-9.57	-0.65	1.37e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs7095607	0.606	rs10998011	chr10:69958623	A/G	cg18986048	chr10:69913749	MYPN	0.57	5.92	0.47	2.89e-8	Lung function (FVC);
TGCT	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg01448562	chr3:133502909	NA	-0.33	-6.78	-0.52	4.41e-10	Iron status biomarkers;
TGCT	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg13012494	chr21:47604986	C21orf56	0.38	4.56	0.38	1.21e-5	Testicular germ cell tumor;
TGCT	cis	rs2663905	0.706	rs2683260	chr15:81385552	A/C	cg25029264	chr15:81426347	C15orf26	-0.69	-5.23	-0.42	7.14e-7	QT interval (drug interaction);
TGCT	cis	rs13256369	0.802	rs13280101	chr8:8562773	G/A	cg17143192	chr8:8559678	CLDN23	0.56	5.31	0.43	4.9e-7	Obesity-related traits;
TGCT	trans	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg11887960	chr12:57824829	NA	1.1	9.51	0.65	1.98e-16	Lung disease severity in cystic fibrosis;
TGCT	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg24549020	chr5:56110836	MAP3K1	0.66	5.79	0.46	5.56e-8	Initial pursuit acceleration;
TGCT	cis	rs7772486	0.875	rs2814875	chr6:146305810	G/A	cg23711669	chr6:146136114	FBXO30	0.88	9.48	0.65	2.31e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4851266	1.000	rs11123817	chr2:100835032	C/T	cg22139774	chr2:100720529	AFF3	-0.35	-5.41	-0.44	3.1e-7	Educational attainment;
TGCT	cis	rs2721195	0.683	rs6989368	chr8:145813457	A/G	cg15857475	chr8:145742913	RECQL4;LRRC14	0.97	10.18	0.67	4.71e-18	Age at first birth;
TGCT	cis	rs6542838	0.582	rs6542845	chr2:99537600	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.59	-5.57	-0.45	1.49e-7	Fear of minor pain;
TGCT	cis	rs2836950	0.565	rs2836945	chr21:40596757	C/T	cg11890956	chr21:40555474	PSMG1	-0.7	-6.87	-0.52	2.79e-10	Menarche (age at onset);
TGCT	cis	rs6901250	0.655	rs1398404	chr6:117126345	A/C	cg12892004	chr6:117198278	RFX6	0.45	5.65	0.45	1.05e-7	C-reactive protein levels;
TGCT	cis	rs9926296	0.656	rs4522419	chr16:89853307	T/C	cg08627397	chr16:89984028	MC1R	-0.31	-4.83	-0.4	3.92e-6	Vitiligo;
TGCT	cis	rs1472147	0.744	rs34692078	chr7:128488456	T/C	cg00260937	chr7:128520193	KCP	0.41	5.68	0.45	9.1e-8	Calcium levels;
TGCT	cis	rs4780401	0.610	rs933574	chr16:11792700	A/C	cg01061890	chr16:11836724	TXNDC11	-0.47	-4.71	-0.39	6.59e-6	Rheumatoid arthritis;
TGCT	cis	rs8017423	0.935	rs3742668	chr14:90767759	G/A	cg04374321	chr14:90722782	PSMC1	-0.75	-7.14	-0.54	6.96e-11	Mortality in heart failure;
TGCT	cis	rs3008870	0.792	rs72673729	chr1:67441673	T/TG	cg11518657	chr1:67396239	MIER1	-0.53	-4.59	-0.38	1.08e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs13202913	0.837	rs9383901	chr6:151788059	T/A	cg03627880	chr6:151815985	C6orf97	-0.76	-5.88	-0.47	3.48e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs7772486	0.558	rs9376965	chr6:146130055	G/A	cg05347473	chr6:146136440	FBXO30	0.66	6.2	0.49	7.78e-9	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg10053473	chr17:62856997	LRRC37A3	0.4	6.77	0.52	4.68e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs6964587	0.967	rs41371748	chr7:91708219	A/G	cg17063962	chr7:91808500	NA	0.84	8.41	0.6	8.2e-14	Breast cancer;
TGCT	cis	rs7246657	0.943	rs8106839	chr19:37958475	C/G	cg18154014	chr19:37997991	ZNF793	0.81	5.85	0.46	4.18e-8	Coronary artery calcification;
TGCT	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg08280861	chr8:58055591	NA	0.32	4.46	0.37	1.83e-5	Developmental language disorder (linguistic errors);
TGCT	trans	rs1814175	0.817	rs7947526	chr11:49983654	T/C	cg03929089	chr4:120376271	NA	-0.72	-8.53	-0.61	4.24e-14	Height;
TGCT	cis	rs319204	1.000	rs319241	chr5:146236889	G/A	cg25021259	chr5:146258546	PPP2R2B	0.36	4.53	0.38	1.37e-5	Schizophrenia;
TGCT	cis	rs4746818	1.000	rs1506769	chr10:70959710	T/C	cg04149295	chr10:70884716	VPS26A	0.8	5.41	0.44	3.1e-7	Left atrial antero-posterior diameter;
TGCT	cis	rs4808199	0.895	rs2163805	chr19:19575945	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.73	5.16	0.42	9.65e-7	Nonalcoholic fatty liver disease;
TGCT	cis	rs1577917	1.000	rs12204015	chr6:86598334	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.32	-0.43	4.59e-7	Response to antipsychotic treatment;
TGCT	cis	rs2153535	0.541	rs1414347	chr6:8471831	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.73	0.46	7.1e-8	Motion sickness;
TGCT	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg07507251	chr3:52567010	NT5DC2	0.49	6.82	0.52	3.48e-10	Bipolar disorder;
TGCT	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg11494091	chr17:61959527	GH2	-0.43	-7.2	-0.54	5.18e-11	Height;
TGCT	cis	rs763121	0.819	rs5757161	chr22:38990662	G/A	cg06022373	chr22:39101656	GTPBP1	0.79	7.98	0.58	8.44e-13	Menopause (age at onset);
TGCT	cis	rs72615157	0.645	rs11771660	chr7:99851269	T/A	cg00814883	chr7:100076585	TSC22D4	-0.58	-5.56	-0.45	1.57e-7	Lung function (FEV1/FVC);
TGCT	cis	rs7666738	0.830	rs1896154	chr4:99021161	T/C	cg05340658	chr4:99064831	C4orf37	0.48	5.43	0.44	2.92e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1865760	0.613	rs7749342	chr6:25920265	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.6	6.38	0.5	3.26e-9	Height;
TGCT	cis	rs9549367	0.713	rs4907593	chr13:113830459	C/T	cg18105134	chr13:113819100	PROZ	0.47	8.52	0.61	4.58e-14	Platelet distribution width;
TGCT	cis	rs1395	0.925	rs1659696	chr2:27407831	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.5	-6.75	-0.52	5.06e-10	Blood metabolite levels;
TGCT	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg03264133	chr6:25882463	NA	0.65	6.05	0.48	1.58e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs12497850	0.931	rs9311432	chr3:48850443	T/A	cg07636037	chr3:49044803	WDR6	0.95	10.74	0.69	2e-19	Parkinson's disease;
TGCT	cis	rs3099143	1.000	rs3099142	chr15:77104909	C/T	cg21673338	chr15:77095150	SCAPER	-0.52	-4.97	-0.41	2.15e-6	Recalcitrant atopic dermatitis;
TGCT	cis	rs763121	0.925	rs1043312	chr22:39131727	T/G	cg06022373	chr22:39101656	GTPBP1	0.7	6.71	0.52	6.11e-10	Menopause (age at onset);
TGCT	cis	rs1362404	0.614	rs9928406	chr16:51995705	A/T	cg00216305	chr16:51625890	NA	0.25	4.44	0.37	1.95e-5	Gut microbiota (bacterial taxa);
TGCT	cis	rs546131	0.928	rs547504	chr11:34847225	G/T	cg06937548	chr11:34938143	PDHX;APIP	0.63	5.59	0.45	1.41e-7	Lung disease severity in cystic fibrosis;
TGCT	cis	rs778371	0.676	rs2293780	chr2:233635213	T/C	cg08000102	chr2:233561755	GIGYF2	0.72	8.68	0.61	1.91e-14	Schizophrenia;
TGCT	cis	rs6969780	0.673	rs2301721	chr7:27196113	C/T	cg22997113	chr7:27170241	HOXA4	-0.44	-4.46	-0.37	1.79e-5	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs6754311	0.684	rs11681248	chr2:136820076	C/T	cg07169764	chr2:136633963	MCM6	-0.54	-5.31	-0.43	4.8e-7	Mosquito bite size;
TGCT	cis	rs2932538	0.961	rs4240534	chr1:113175429	T/A	cg22162597	chr1:113214053	CAPZA1	-0.27	-5.98	-0.47	2.24e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs6570726	0.791	rs9373466	chr6:145912016	T/C	cg23711669	chr6:146136114	FBXO30	0.86	9.28	0.64	7.13e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs12477438	0.520	rs7605843	chr2:99811894	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.05	13.04	0.76	5.31e-25	Chronic sinus infection;
TGCT	cis	rs12580194	0.593	rs55659159	chr12:55747754	C/T	cg10672482	chr12:55725839	OR6C3	-0.52	-4.66	-0.39	8.13e-6	Cancer;
TGCT	cis	rs1891498	0.602	rs10793707	chr1:147244022	G/A	cg17941330	chr1:147245494	GJA5	0.36	4.79	0.4	4.62e-6	Cognitive performance;
TGCT	cis	rs526231	0.578	rs1898672	chr5:102293853	A/T	cg23492399	chr5:102201601	PAM	0.51	4.48	0.37	1.64e-5	Primary biliary cholangitis;
TGCT	cis	rs3772130	0.962	rs11706783	chr3:121534322	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.72	0.39	6.25e-6	Cognitive performance;
TGCT	cis	rs9611565	0.649	rs2064189	chr22:42127999	A/G	cg17554472	chr22:41940697	POLR3H	0.46	4.83	0.4	3.93e-6	Vitiligo;
TGCT	cis	rs896854	0.573	rs13271375	chr8:95853907	A/G	cg09323728	chr8:95962352	TP53INP1	-0.41	-4.79	-0.39	4.72e-6	Type 2 diabetes;
TGCT	cis	rs73198271	0.740	rs10112989	chr8:8647334	A/C	cg06671706	chr8:8559999	CLDN23	-0.35	-4.5	-0.37	1.52e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs11614062	1.000	rs11614062	chr12:93956672	A/T	cg18151635	chr12:93972918	NA	-0.21	-4.74	-0.39	5.83e-6	Height;
TGCT	cis	rs9653442	0.527	rs12712064	chr2:100756548	C/T	cg07810366	chr2:100720526	AFF3	-0.35	-5.0	-0.41	1.88e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg22618164	chr12:122356400	WDR66	0.69	6.48	0.5	1.93e-9	Mean corpuscular volume;
TGCT	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg22029157	chr1:209979665	IRF6	-0.74	-6.21	-0.49	7.49e-9	Cleft lip with or without cleft palate;
TGCT	cis	rs68170813	0.559	rs7807648	chr7:106965091	C/T	cg02696742	chr7:106810147	HBP1	-0.67	-5.75	-0.46	6.63e-8	Coronary artery disease;
TGCT	cis	rs7565124	0.955	rs11096638	chr2:20266386	G/T	cg00462460	chr2:20212509	MATN3	-0.43	-4.66	-0.39	8.1e-6	Major depressive disorder;
TGCT	cis	rs7100689	0.646	rs9804236	chr10:82135100	T/C	cg01528321	chr10:82214614	TSPAN14	0.8	7.72	0.57	3.42e-12	Post bronchodilator FEV1;
TGCT	cis	rs873917	0.620	rs784595	chr1:40135017	C/T	cg18438793	chr1:40149837	HPCAL4	0.52	4.74	0.39	5.77e-6	Amyotrophic lateral sclerosis;
TGCT	cis	rs7412746	0.658	rs3768015	chr1:150812954	C/T	cg09365446	chr1:150670422	GOLPH3L	0.37	5.34	0.43	4.18e-7	Melanoma;
TGCT	cis	rs806215	0.526	rs11768841	chr7:127551403	T/C	cg11539674	chr7:127291444	SND1	-0.36	-4.67	-0.39	7.76e-6	Type 2 diabetes;
TGCT	cis	rs614226	1.000	rs591992	chr12:121019323	T/C	cg01236616	chr12:121019343	POP5	1.31	14.0	0.78	2.71e-27	Type 1 diabetes nephropathy;
TGCT	cis	rs892961	0.899	rs35217221	chr17:75412385	G/A	cg05865280	chr17:75406074	SEPT9	0.29	6.93	0.53	1.99e-10	Airflow obstruction;
TGCT	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.31	-4.82	-0.4	4.12e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs6586163	0.872	rs1926197	chr10:90748626	A/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.38	-4.78	-0.39	4.79e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs860295	0.580	rs2016251	chr1:155914988	C/T	cg13795986	chr1:155880507	RIT1	0.36	4.45	0.37	1.87e-5	Body mass index;
TGCT	cis	rs35306767	0.714	rs12767171	chr10:1084491	A/G	cg20503657	chr10:835505	NA	0.45	5.05	0.41	1.51e-6	Eosinophil percentage of granulocytes;
TGCT	cis	rs2404602	0.692	rs4641709	chr15:77047736	C/T	cg22467129	chr15:76604101	ETFA	0.45	5.11	0.42	1.2e-6	Blood metabolite levels;
TGCT	cis	rs2013441	1.000	rs2526462	chr17:20079460	A/T	cg18979559	chr17:20280153	CCDC144C	-0.43	-4.46	-0.37	1.82e-5	Obesity-related traits;
TGCT	cis	rs28595532	0.920	rs114382134	chr4:119733215	T/C	cg14228332	chr4:119757509	SEC24D	1.32	6.38	0.5	3.2e-9	Cannabis dependence symptom count;
TGCT	cis	rs10986311	0.775	rs1984001	chr9:127137801	T/C	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.19	4.8	0.4	4.5e-6	Vitiligo;
TGCT	cis	rs6121246	0.909	rs6058450	chr20:30343911	G/A	cg13852791	chr20:30311386	BCL2L1	0.8	6.12	0.48	1.15e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs1577917	0.958	rs10944168	chr6:86680156	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.08	-0.41	1.37e-6	Response to antipsychotic treatment;
TGCT	cis	rs11122272	0.705	rs2808599	chr1:231533482	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-6.53	-0.51	1.55e-9	Hemoglobin concentration;
TGCT	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.07	-9.63	-0.65	1.01e-16	Platelet count;
TGCT	cis	rs9920506	0.518	rs11072774	chr15:78952697	C/T	cg24631222	chr15:78858424	CHRNA5	0.73	5.0	0.41	1.91e-6	Post bronchodilator FEV1;
TGCT	cis	rs9400467	0.537	rs12195305	chr6:111449228	G/A	cg15721981	chr6:111408429	SLC16A10	0.75	4.74	0.39	5.66e-6	Blood metabolite levels;Amino acid levels;
TGCT	cis	rs4820539	1.000	rs4822362	chr22:23482744	C/A	cg21100191	chr22:23484243	RTDR1	0.89	10.78	0.7	1.61e-19	Bone mineral density;
TGCT	cis	rs4699052	0.625	rs28498687	chr4:104333731	T/C	cg16532752	chr4:104119610	CENPE	-0.54	-5.27	-0.43	5.78e-7	Testicular germ cell tumor;
TGCT	cis	rs11098499	0.954	rs17006190	chr4:120418838	C/G	cg09307838	chr4:120376055	NA	0.68	6.56	0.51	1.28e-9	Corneal astigmatism;
TGCT	cis	rs35306767	0.714	rs17293608	chr10:1056252	C/T	cg18964960	chr10:1102726	WDR37	0.74	5.46	0.44	2.52e-7	Eosinophil percentage of granulocytes;
TGCT	cis	rs981844	0.712	rs55656103	chr4:154757478	T/C	cg14289246	chr4:154710475	SFRP2	1.02	9.48	0.65	2.3e-16	Response to statins (LDL cholesterol change);
TGCT	cis	rs9549260	0.755	rs9566553	chr13:41174231	A/G	cg21288729	chr13:41239152	FOXO1	1.01	10.53	0.69	6.43e-19	Red blood cell count;
TGCT	cis	rs9527	0.590	rs11191572	chr10:104893137	A/G	cg15744005	chr10:104629667	AS3MT	-0.43	-4.94	-0.41	2.45e-6	Arsenic metabolism;
TGCT	cis	rs3741404	0.609	rs669913	chr11:63869879	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.72	7.32	0.55	2.78e-11	Platelet count;
TGCT	cis	rs6964587	0.839	rs6950538	chr7:91417816	T/C	cg22709100	chr7:91322751	NA	0.29	4.57	0.38	1.16e-5	Breast cancer;
TGCT	cis	rs9814567	1.000	rs17694011	chr3:134213981	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.95	-9.62	-0.65	1.04e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs36051895	0.632	rs10116823	chr9:5171944	T/A	cg02405213	chr9:5042618	JAK2	-0.72	-9.67	-0.66	7.86e-17	Pediatric autoimmune diseases;
TGCT	cis	rs7312933	0.558	rs4768399	chr12:42742696	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.59	-5.72	-0.46	7.52e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs7918232	0.800	rs7907981	chr10:27444329	T/C	cg14442939	chr10:27389572	ANKRD26	0.78	5.48	0.44	2.26e-7	Breast cancer;
TGCT	cis	rs3845702	1.000	rs10497555	chr2:180864967	A/G	cg01881094	chr2:180872142	CWC22	0.68	5.98	0.47	2.24e-8	Schizophrenia;
TGCT	cis	rs854765	0.647	rs854767	chr17:18018263	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.71	-7.38	-0.55	1.95e-11	Total body bone mineral density;
TGCT	cis	rs6684514	0.961	rs11264469	chr1:156276746	A/G	cg16558208	chr1:156270281	VHLL	0.47	9.22	0.64	9.78e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs9443645	0.901	rs4706077	chr6:79548845	G/A	cg09184832	chr6:79620586	NA	-0.48	-5.3	-0.43	5.16e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs17253792	0.822	rs75663029	chr14:56092385	T/C	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg22920501	chr2:26401640	FAM59B	0.77	5.98	0.47	2.26e-8	Gut microbiome composition (summer);
TGCT	trans	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg23505145	chr19:12996616	KLF1	0.78	8.12	0.59	4.03e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg00149659	chr3:10157352	C3orf10	0.85	5.83	0.46	4.48e-8	Alzheimer's disease;
TGCT	cis	rs7772486	0.713	rs79248977	chr6:146319388	C/A	cg05347473	chr6:146136440	FBXO30	0.55	5.06	0.41	1.5e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3784262	0.616	rs2704197	chr15:58323236	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.38	-5.58	-0.45	1.45e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	trans	rs1814175	0.754	rs7103235	chr11:49699191	A/G	cg03929089	chr4:120376271	NA	-0.71	-8.31	-0.6	1.43e-13	Height;
TGCT	cis	rs7666738	0.830	rs7663661	chr4:99014761	A/G	cg18180107	chr4:99064573	C4orf37	0.54	5.03	0.41	1.7e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg10295955	chr4:187884368	NA	0.99	15.42	0.81	1.32e-30	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg20887711	chr4:1340912	KIAA1530	-0.99	-9.19	-0.64	1.17e-15	Longevity;
TGCT	cis	rs881375	1.000	rs10818480	chr9:123643170	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.39	4.5	0.37	1.52e-5	Rheumatoid arthritis;
TGCT	cis	rs7552167	0.925	rs78312791	chr1:24513613	C/A	cg01960748	chr1:24522592	NA	0.46	5.14	0.42	1.02e-6	Psoriasis vulgaris;
TGCT	cis	rs7681440	0.746	rs10001067	chr4:90818216	C/G	cg20003494	chr4:90757398	SNCA	-0.54	-5.07	-0.41	1.41e-6	Dementia with Lewy bodies;
TGCT	cis	rs7666738	0.830	rs4699600	chr4:99019429	C/G	cg17366294	chr4:99064904	C4orf37	0.68	7.04	0.53	1.17e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7666738	0.716	rs7656233	chr4:99079237	G/A	cg18180107	chr4:99064573	C4orf37	0.57	5.01	0.41	1.83e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4319547	0.695	rs4758666	chr12:122902840	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.64	-4.99	-0.41	1.98e-6	Body mass index;
TGCT	cis	rs11098499	0.954	rs28429722	chr4:120300093	G/A	cg09307838	chr4:120376055	NA	0.65	6.39	0.5	3.02e-9	Corneal astigmatism;
TGCT	cis	rs79149102	0.579	rs78434425	chr15:75304754	C/T	cg09165964	chr15:75287851	SCAMP5	-1.04	-5.46	-0.44	2.48e-7	Lung cancer;
TGCT	cis	rs933688	1.000	rs7720132	chr5:90745105	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.96	8.25	0.6	1.91e-13	Smoking behavior;
TGCT	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg18876405	chr7:65276391	NA	-0.34	-5.19	-0.42	8.37e-7	Aortic root size;
TGCT	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.55	0.45	1.62e-7	Alzheimer's disease;
TGCT	cis	rs10751667	0.666	rs10902249	chr11:958566	C/T	cg06064525	chr11:970664	AP2A2	0.35	8.12	0.59	4.04e-13	Alzheimer's disease (late onset);
TGCT	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg06112835	chr11:68658793	MRPL21	0.47	8.09	0.59	4.66e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg21017887	chr14:105400489	NA	0.38	5.42	0.44	3.03e-7	Rheumatoid arthritis;
TGCT	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg27535305	chr1:53392650	SCP2	0.26	5.15	0.42	1e-6	Monocyte count;
TGCT	cis	rs7666738	0.830	rs10022331	chr4:98960392	C/A	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7267979	1.000	rs6083828	chr20:25369918	T/C	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7917772	0.503	rs7087665	chr10:104282418	T/C	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs1153858	1.000	rs1145081	chr15:45679667	C/G	cg26924012	chr15:45694286	SPATA5L1	0.99	12.23	0.74	4.74e-23	Homoarginine levels;
TGCT	cis	rs6121246	0.909	rs57726761	chr20:30314046	A/G	cg13852791	chr20:30311386	BCL2L1	0.78	5.8	0.46	5.15e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.43	-4.73	-0.39	5.94e-6	Blood metabolite levels;
TGCT	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg25036284	chr2:26402008	FAM59B	-0.61	-4.89	-0.4	3.1e-6	Gut microbiome composition (summer);
TGCT	cis	rs9811920	0.609	rs809415	chr3:99582242	G/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.58	6.55	0.51	1.35e-9	Axial length;
TGCT	cis	rs57994353	0.865	rs35857370	chr9:139354097	G/A	cg13741927	chr9:139327495	INPP5E	-0.26	-6.0	-0.47	2.05e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs9388451	0.839	rs3966775	chr6:126067655	C/A	cg10911889	chr6:126070802	HEY2	0.57	6.05	0.48	1.56e-8	Brugada syndrome;
TGCT	cis	rs7654585	0.962	rs2309289	chr4:25947094	T/A	cg10409131	chr4:25915609	C4orf52	0.75	7.81	0.57	2.06e-12	Obesity-related traits;
TGCT	cis	rs79976124	0.797	rs77895756	chr6:66626782	C/T	cg07460842	chr6:66804631	NA	0.58	5.32	0.43	4.77e-7	Type 2 diabetes;
TGCT	cis	rs7772486	0.654	rs702321	chr6:146006695	A/G	cg23711669	chr6:146136114	FBXO30	-0.85	-9.45	-0.65	2.66e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs72843506	0.722	rs9895177	chr17:20207594	T/A	cg18979559	chr17:20280153	CCDC144C	-0.65	-4.86	-0.4	3.54e-6	Schizophrenia;
TGCT	cis	rs8111998	0.826	rs4932777	chr19:22766764	C/T	cg19914732	chr19:22715077	NA	-0.56	-4.51	-0.38	1.46e-5	Corneal structure;
TGCT	cis	rs734999	0.545	rs7368105	chr1:2556548	C/T	cg18854424	chr1:2615690	NA	0.45	5.15	0.42	1e-6	Ulcerative colitis;
TGCT	cis	rs2439831	1.000	rs2467736	chr15:43784917	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.01	8.19	0.59	2.67e-13	Lung cancer in ever smokers;
TGCT	cis	rs8177253	0.665	rs6774822	chr3:133442012	G/T	cg11941060	chr3:133502564	NA	-0.26	-5.43	-0.44	2.88e-7	Iron status biomarkers;
TGCT	cis	rs739496	0.579	rs3742000	chr12:112338539	A/G	cg10833066	chr12:111807467	FAM109A	0.35	5.41	0.44	3.12e-7	Platelet count;
TGCT	cis	rs4700695	0.719	rs27084	chr5:65435286	G/A	cg21114390	chr5:65439923	SFRS12	-0.85	-7.61	-0.56	5.94e-12	Facial morphology (factor 19);
TGCT	cis	rs71435601	0.600	rs557197	chr2:21381781	T/G	cg25035485	chr2:21266500	APOB	0.51	4.48	0.37	1.66e-5	Cholesterol, total;
TGCT	cis	rs17473412	0.892	rs77910830	chr5:122649995	T/C	cg15125798	chr5:122621645	NA	-0.61	-5.52	-0.44	1.9e-7	Total body bone mineral density;
TGCT	cis	rs9393777	0.513	rs9295702	chr6:26634040	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.59	-5.33	-0.43	4.44e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9467773	0.620	rs2494696	chr6:26620894	A/G	cg05738196	chr6:26577821	NA	0.87	11.3	0.71	8.47e-21	Intelligence (multi-trait analysis);
TGCT	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg24531977	chr5:56204891	C5orf35	-0.9	-8.25	-0.6	1.95e-13	Type 2 diabetes;
TGCT	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.07	0.82	4.17e-32	Prudent dietary pattern;
TGCT	cis	rs9814567	0.806	rs55835132	chr3:134325256	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-7.21	-0.54	4.87e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs3008870	0.755	rs1024230	chr1:67512920	A/C	cg02640540	chr1:67518911	SLC35D1	0.65	5.79	0.46	5.46e-8	Lymphocyte percentage of white cells;
TGCT	cis	rs36051895	0.632	rs10758674	chr9:5163645	G/A	cg02405213	chr9:5042618	JAK2	-0.78	-10.38	-0.68	1.54e-18	Pediatric autoimmune diseases;
TGCT	cis	rs6969780	1.000	rs73071548	chr7:27147430	A/G	cg04321618	chr7:27170880	HOXA4	0.58	4.7	0.39	6.81e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs74006954	0.571	rs71465229	chr15:27674961	A/G	cg21575005	chr15:28358302	HERC2	0.32	4.78	0.39	4.79e-6	Alzheimer's disease (cognitive decline);
TGCT	cis	rs7208859	0.623	rs56018041	chr17:29059985	G/A	cg14008862	chr17:28927542	LRRC37B2	0.77	4.59	0.38	1.08e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs4563143	0.514	rs112651366	chr19:29299704	A/T	cg12756686	chr19:29218302	NA	0.67	5.15	0.42	9.79e-7	Methadone dose in opioid dependence;
TGCT	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg08280861	chr8:58055591	NA	0.39	4.64	0.38	8.72e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs28595532	0.920	rs115576008	chr4:119736967	T/C	cg11846333	chr4:119757529	SEC24D	0.93	4.44	0.37	2e-5	Cannabis dependence symptom count;
TGCT	cis	rs9926296	0.744	rs164747	chr16:89708680	T/G	cg01097406	chr16:89675127	NA	0.35	6.3	0.49	4.68e-9	Vitiligo;
TGCT	cis	rs4455778	0.561	rs6977535	chr7:49001350	C/T	cg26309511	chr7:48887640	NA	0.55	7.04	0.53	1.14e-10	Lung cancer in never smokers;
TGCT	cis	rs7666738	0.830	rs13141752	chr4:98893128	G/A	cg05340658	chr4:99064831	C4orf37	0.52	6.02	0.48	1.81e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs881375	1.000	rs881375	chr9:123652898	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.39	4.53	0.38	1.35e-5	Rheumatoid arthritis;
TGCT	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg24531977	chr5:56204891	C5orf35	-0.76	-7.43	-0.56	1.54e-11	Initial pursuit acceleration;
TGCT	cis	rs17253792	0.822	rs74653073	chr14:56079528	T/C	cg01858014	chr14:56050164	KTN1	-0.35	-4.53	-0.38	1.37e-5	Putamen volume;
TGCT	cis	rs3784262	0.528	rs4646588	chr15:58304313	A/G	cg12031962	chr15:58353849	ALDH1A2	0.38	5.52	0.44	1.89e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs6424115	1.000	rs974698	chr1:24132785	C/T	cg15997130	chr1:24165203	NA	0.88	9.6	0.65	1.19e-16	Immature fraction of reticulocytes;
TGCT	cis	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg22121687	chr7:65037720	NA	-0.78	-4.7	-0.39	6.74e-6	Diabetic kidney disease;
TGCT	cis	rs921968	0.541	rs523937	chr2:219437596	G/C	cg02176678	chr2:219576539	TTLL4	0.48	6.78	0.52	4.32e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg13877915	chr19:58951672	ZNF132	-0.92	-11.95	-0.73	2.3e-22	Uric acid clearance;
TGCT	trans	rs2288327	0.643	rs1559908	chr2:179336347	C/T	cg18634211	chr1:26737262	LIN28	-0.91	-7.49	-0.56	1.11e-11	Atrial fibrillation;
TGCT	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg22166914	chr1:53195759	ZYG11B	-0.36	-5.93	-0.47	2.8e-8	Monocyte count;
TGCT	cis	rs6912958	0.781	rs9450752	chr6:88300013	A/G	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.91	-0.4	2.78e-6	Monocyte percentage of white cells;
TGCT	cis	rs13082711	0.522	rs533175	chr3:27361432	A/G	cg02860705	chr3:27208620	NA	-0.29	-4.79	-0.39	4.72e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs9534288	0.797	rs2148414	chr13:46582368	G/T	cg15192986	chr13:46630673	CPB2	-0.53	-7.62	-0.56	5.82e-12	Blood protein levels;
TGCT	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg08859206	chr1:53392774	SCP2	0.39	5.78	0.46	5.77e-8	Monocyte count;
TGCT	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg18305652	chr10:134549665	INPP5A	0.33	5.54	0.45	1.74e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs72781680	0.898	rs72780111	chr2:23991146	G/A	cg08917208	chr2:24149416	ATAD2B	0.83	5.24	0.43	6.62e-7	Lymphocyte counts;
TGCT	cis	rs7582180	0.629	rs6716636	chr2:100940067	C/G	cg14675211	chr2:100938903	LONRF2	0.51	4.95	0.41	2.32e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2549003	1.000	rs7735073	chr5:131815357	G/A	cg21138405	chr5:131827807	IRF1	0.2	5.08	0.41	1.36e-6	Asthma (sex interaction);
TGCT	cis	rs11239930	0.560	rs632334	chr1:146551521	C/T	cg00044796	chr1:146552390	NA	-0.34	-4.46	-0.37	1.84e-5	AIDS progression;
TGCT	cis	rs35306767	0.903	rs7074642	chr10:878359	A/G	cg20503657	chr10:835505	NA	0.7	9.83	0.66	3.22e-17	Eosinophil percentage of granulocytes;
TGCT	cis	rs6076065	0.748	rs4142246	chr20:23388975	A/G	cg11657817	chr20:23433608	CST11	0.32	5.62	0.45	1.22e-7	Facial morphology (factor 15, philtrum width);
TGCT	cis	rs899997	1.000	rs11072793	chr15:79006442	C/T	cg00061860	chr15:78953028	NA	-0.26	-4.85	-0.4	3.63e-6	Coronary artery disease or large artery stroke;
TGCT	cis	rs7172971	0.655	rs72727735	chr15:42342226	T/C	cg05886115	chr15:42349113	NA	0.32	5.1	0.42	1.25e-6	3-hydroxypropylmercapturic acid levels in smokers;
TGCT	cis	rs2996428	0.667	rs7538067	chr1:3761772	C/T	cg17848003	chr1:3704513	LRRC47	0.19	5.14	0.42	1.04e-6	Red cell distribution width;
TGCT	cis	rs9913156	0.793	rs55884013	chr17:4579301	G/A	cg00122941	chr17:4613640	ARRB2	0.87	6.89	0.53	2.44e-10	Lymphocyte counts;
TGCT	cis	rs17767294	0.708	rs72851156	chr6:28060086	T/C	cg08851530	chr6:28072375	NA	1.56	7.21	0.54	4.9e-11	Parkinson's disease;
TGCT	cis	rs12479064	0.694	rs4341989	chr2:100046783	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.77	-6.72	-0.52	6.03e-10	Chronic sinus infection;
TGCT	cis	rs4851254	0.618	rs4851243	chr2:100639482	G/A	cg22139774	chr2:100720529	AFF3	-0.45	-4.9	-0.4	2.94e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs617219	0.671	rs1316753	chr5:78531337	G/C	cg23987322	chr5:78407566	BHMT	0.35	4.7	0.39	6.68e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs6840360	0.571	rs12650655	chr4:152556075	G/A	cg17479576	chr4:152424074	FAM160A1	-0.73	-7.94	-0.58	1.03e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs12142240	0.698	rs6659228	chr1:46811027	C/G	cg14993813	chr1:46806288	NSUN4	-0.58	-4.67	-0.39	7.69e-6	Menopause (age at onset);
TGCT	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg18230493	chr5:56204884	C5orf35	-0.68	-5.92	-0.47	2.92e-8	Initial pursuit acceleration;
TGCT	cis	rs9611565	0.722	rs202635	chr22:41809637	C/T	cg13695892	chr22:41940480	POLR3H	0.8	8.01	0.58	7.2e-13	Vitiligo;
TGCT	cis	rs3796619	0.924	rs11940546	chr4:1072485	C/T	cg27284194	chr4:1044797	NA	0.46	4.45	0.37	1.85e-5	Recombination rate (males);
TGCT	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg15691649	chr6:25882328	NA	-0.41	-4.75	-0.39	5.64e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2404602	0.647	rs12439141	chr15:77095423	T/C	cg22467129	chr15:76604101	ETFA	0.48	4.7	0.39	6.7e-6	Blood metabolite levels;
TGCT	cis	rs4936894	0.500	rs6590056	chr11:124170064	A/G	cg27160556	chr11:124181099	OR8D1	0.33	4.5	0.37	1.54e-5	Aging (time to death);
TGCT	cis	rs9638182	0.725	rs12056034	chr7:72878645	A/G	cg14087351	chr7:73037990	MLXIPL	-0.61	-4.81	-0.4	4.34e-6	Triglycerides;
TGCT	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg15595755	chr5:1867978	NA	0.46	5.29	0.43	5.29e-7	Cardiovascular disease risk factors;
TGCT	cis	rs6088580	0.634	rs6059866	chr20:33075810	A/C	cg08999081	chr20:33150536	PIGU	0.29	5.83	0.46	4.46e-8	Glomerular filtration rate (creatinine);
TGCT	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.63	-0.51	9.04e-10	Alzheimer's disease;
TGCT	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg13395646	chr4:1353034	KIAA1530	-0.48	-5.8	-0.46	5.13e-8	Obesity-related traits;
TGCT	cis	rs4689388	0.816	rs13147655	chr4:6293474	A/G	cg14416269	chr4:6271139	WFS1	0.37	4.77	0.39	4.99e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs7246657	0.882	rs4803539	chr19:37897522	A/C	cg18154014	chr19:37997991	ZNF793	0.73	5.38	0.44	3.53e-7	Coronary artery calcification;
TGCT	cis	rs6424115	0.708	rs12748109	chr1:24181177	C/T	cg15997130	chr1:24165203	NA	-0.7	-7.02	-0.53	1.26e-10	Immature fraction of reticulocytes;
TGCT	cis	rs2033711	0.503	rs6510141	chr19:58885786	C/G	cg13877915	chr19:58951672	ZNF132	-0.52	-5.02	-0.41	1.76e-6	Uric acid clearance;
TGCT	cis	rs1215050	0.791	rs260890	chr4:98741698	A/G	cg17366294	chr4:99064904	C4orf37	0.51	5.4	0.44	3.29e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9427116	0.967	rs7547072	chr1:154639255	A/G	cg17218026	chr1:154582156	ADAR	-0.2	-4.95	-0.41	2.32e-6	Blood protein levels;
TGCT	cis	rs7666738	0.830	rs9884501	chr4:98893721	A/C	cg17366294	chr4:99064904	C4orf37	0.68	6.87	0.53	2.72e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg02038168	chr22:39784481	NA	-0.76	-6.36	-0.5	3.47e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs1577917	0.727	rs2758840	chr6:86304625	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.58	-0.45	1.43e-7	Response to antipsychotic treatment;
TGCT	cis	rs40363	1.000	rs1690441	chr16:3517635	C/G	cg05754148	chr16:3507555	NAT15	0.48	4.69	0.39	7.24e-6	Tuberculosis;
TGCT	cis	rs1005224	0.927	rs8007792	chr14:76175666	C/A	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.71	-5.88	-0.47	3.58e-8	Large artery stroke;
TGCT	cis	rs853679	0.538	rs13199081	chr6:28331834	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.53	-4.71	-0.39	6.63e-6	Depression;
TGCT	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.68	5.62	0.45	1.18e-7	Tonsillectomy;
TGCT	cis	rs6964587	0.869	rs6946764	chr7:91539003	A/G	cg17063962	chr7:91808500	NA	-0.86	-9.28	-0.64	6.82e-16	Breast cancer;
TGCT	cis	rs7568458	0.660	rs2289972	chr2:85766545	C/T	cg02493740	chr2:85810744	VAMP5	-0.29	-5.31	-0.43	4.91e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs2468186	0.710	rs2450075	chr8:120093547	A/G	cg02248809	chr8:120845432	TAF2	-0.42	-4.47	-0.37	1.72e-5	Osteoprotegerin levels;
TGCT	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7267979	0.844	rs6076343	chr20:25376663	C/T	cg14121845	chr20:25566513	NINL	-0.45	-4.6	-0.38	1.02e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2204008	0.806	rs1589382	chr12:38408565	T/A	cg13010199	chr12:38710504	ALG10B	0.61	4.86	0.4	3.44e-6	Bladder cancer;
TGCT	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg24846343	chr22:24311635	DDTL	0.22	5.62	0.45	1.19e-7	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs28735056	0.875	rs4239346	chr18:77641226	A/G	cg20368463	chr18:77673604	PQLC1	0.4	4.82	0.4	4.16e-6	Schizophrenia;
TGCT	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg13732083	chr21:47605072	C21orf56	0.35	4.69	0.39	7.17e-6	Testicular germ cell tumor;
TGCT	cis	rs9858542	0.953	rs11706370	chr3:49441091	G/A	cg03060546	chr3:49711283	APEH	-0.63	-5.49	-0.44	2.18e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs42648	0.693	rs3747800	chr7:89899488	G/T	cg25739043	chr7:89950458	NA	-0.55	-5.12	-0.42	1.13e-6	Homocysteine levels;
TGCT	cis	rs9560113	0.959	rs9560108	chr13:112180303	A/C	cg14154082	chr13:112174009	NA	0.37	5.07	0.41	1.42e-6	Menarche (age at onset);
TGCT	cis	rs4566357	0.615	rs3769645	chr2:227913717	A/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-4.99	-0.41	1.97e-6	Coronary artery disease;
TGCT	cis	rs7267979	0.816	rs422148	chr20:25512604	G/C	cg03522245	chr20:25566470	NINL	0.56	5.79	0.46	5.51e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9291683	0.632	rs12508991	chr4:10041104	C/T	cg11266682	chr4:10021025	SLC2A9	0.64	8.75	0.62	1.31e-14	Bone mineral density;
TGCT	trans	rs7726839	0.540	rs72703080	chr5:595238	A/G	cg25482853	chr8:67687455	SGK3	1.26	10.61	0.69	4.22e-19	Obesity-related traits;
TGCT	cis	rs892864	0.554	rs17608692	chr5:127682131	T/C	cg01939274	chr5:127874478	FBN2	0.95	4.56	0.38	1.21e-5	Multiple system atrophy;
TGCT	cis	rs2204008	0.542	rs34770471	chr12:38009613	C/T	cg13010199	chr12:38710504	ALG10B	0.65	5.29	0.43	5.47e-7	Bladder cancer;
TGCT	cis	rs634534	0.622	rs501353	chr11:65739549	T/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.56	5.35	0.43	4.04e-7	Sum eosinophil basophil counts;Eosinophil counts;
TGCT	cis	rs319204	1.000	rs2082405	chr5:146258596	C/T	cg25021259	chr5:146258546	PPP2R2B	0.38	4.64	0.38	8.81e-6	Schizophrenia;
TGCT	cis	rs2073300	1.000	rs6114142	chr20:23461082	A/G	cg09953122	chr20:23471693	CST8	-0.56	-4.45	-0.37	1.86e-5	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	trans	rs1814175	0.817	rs10128730	chr11:50023369	G/T	cg15704280	chr7:45808275	SEPT13	-0.72	-8.47	-0.61	6.02e-14	Height;
TGCT	cis	rs514406	0.800	rs4926930	chr1:53217335	A/G	cg22166914	chr1:53195759	ZYG11B	-0.41	-7.06	-0.54	1.05e-10	Monocyte count;
TGCT	cis	rs7267979	1.000	rs2482941	chr20:25361216	T/C	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6918586	0.658	rs198825	chr6:26122502	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.68	-6.53	-0.51	1.52e-9	Schizophrenia;
TGCT	cis	rs61990749	0.597	rs176952	chr14:78180736	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	0.63	4.62	0.38	9.34e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs7666738	0.830	rs7696686	chr4:98938445	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs782590	0.967	rs782588	chr2:55841640	T/C	cg03859395	chr2:55845619	SMEK2	0.92	11.37	0.71	5.88e-21	Metabolic syndrome;
TGCT	cis	rs9913156	0.841	rs72824957	chr17:4590496	C/T	cg19197139	chr17:4613644	ARRB2	0.83	7.74	0.57	3.03e-12	Lymphocyte counts;
TGCT	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg11644478	chr21:40555479	PSMG1	-0.61	-5.74	-0.46	6.75e-8	Cognitive function;
TGCT	cis	rs12681288	0.754	rs4735975	chr8:1000470	T/C	cg04851639	chr8:1020857	NA	-0.36	-6.43	-0.5	2.55e-9	Schizophrenia;
TGCT	cis	rs7635838	0.590	rs2256773	chr3:11386329	C/G	cg00170343	chr3:11313890	ATG7	0.62	6.09	0.48	1.28e-8	HDL cholesterol;
TGCT	cis	rs78487399	0.710	rs7572923	chr2:43685109	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-5.19	-0.42	8.37e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs4906332	1.000	rs8012127	chr14:103942762	G/A	cg26031613	chr14:104095156	KLC1	-0.52	-4.72	-0.39	6.31e-6	Coronary artery disease;
TGCT	cis	rs1891275	0.515	rs7911755	chr10:93489817	G/A	cg07889827	chr10:93443413	NA	-0.32	-6.71	-0.52	6.35e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs13256369	0.851	rs13271698	chr8:8567539	C/A	cg18904891	chr8:8559673	CLDN23	0.59	5.52	0.44	1.93e-7	Obesity-related traits;
TGCT	cis	rs751728	0.544	rs2281820	chr6:33768897	A/G	cg13859433	chr6:33739653	LEMD2	-0.32	-5.39	-0.44	3.43e-7	Crohn's disease;
TGCT	cis	rs73001065	0.818	rs10500212	chr19:19723215	C/T	cg03709012	chr19:19516395	GATAD2A	1.04	5.1	0.42	1.26e-6	LDL cholesterol;
TGCT	cis	rs6089584	0.927	rs1886007	chr20:60581049	G/A	cg06108461	chr20:60628389	TAF4	-0.58	-8.35	-0.6	1.14e-13	Body mass index;
TGCT	cis	rs8180040	0.654	rs62246451	chr3:47211632	C/T	cg27129171	chr3:47204927	SETD2	-0.7	-8.33	-0.6	1.26e-13	Colorectal cancer;
TGCT	cis	rs2458413	0.521	rs2458427	chr8:105339594	G/T	cg04554929	chr8:105342491	NA	-0.63	-10.35	-0.68	1.77e-18	Paget's disease;
TGCT	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg27121462	chr16:89883253	FANCA	0.81	8.95	0.63	4.42e-15	Vitiligo;
TGCT	cis	rs40363	0.645	rs1690449	chr16:3520893	C/G	cg22508957	chr16:3507546	NAT15	0.54	6.18	0.49	8.58e-9	Tuberculosis;
TGCT	cis	rs2228479	0.850	rs62054599	chr16:89808850	C/G	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs7681440	0.904	rs6532193	chr4:90764188	G/A	cg14346243	chr4:90757452	SNCA	-0.59	-5.74	-0.46	6.82e-8	Dementia with Lewy bodies;
TGCT	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg26354017	chr1:205819088	PM20D1	0.53	6.2	0.49	7.86e-9	Menarche (age at onset);
TGCT	cis	rs6754311	0.593	rs10202489	chr2:136494186	G/A	cg07169764	chr2:136633963	MCM6	-0.66	-6.12	-0.48	1.13e-8	Mosquito bite size;
TGCT	cis	rs727563	0.635	rs5751149	chr22:42139501	A/G	cg03806693	chr22:41940476	POLR3H	1.06	10.94	0.7	6.7e-20	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs826838	1.000	rs851934	chr12:39104453	G/T	cg26384229	chr12:38710491	ALG10B	-0.85	-8.16	-0.59	3.22e-13	Heart rate;
TGCT	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg08736216	chr1:53307985	ZYG11A	-0.24	-4.74	-0.39	5.75e-6	Monocyte count;
TGCT	cis	rs5769765	0.862	rs138897	chr22:50231067	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.09	-11.75	-0.73	7.01e-22	Schizophrenia;
TGCT	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg18876405	chr7:65276391	NA	-0.35	-5.31	-0.43	4.85e-7	Aortic root size;
TGCT	cis	rs743757	0.608	rs175634	chr3:50644134	A/G	cg08173110	chr3:50359005	HYAL2	0.69	4.59	0.38	1.09e-5	Diastolic blood pressure;
TGCT	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.1	0.54	8.35e-11	Prudent dietary pattern;
TGCT	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg06238570	chr21:40685208	BRWD1	-0.8	-9.02	-0.63	2.92e-15	Cognitive function;
TGCT	cis	rs595982	0.527	rs17206707	chr19:49361441	A/C	cg15549821	chr19:49342101	PLEKHA4	-0.74	-9.74	-0.66	5.46e-17	Red cell distribution width;
TGCT	cis	rs9611565	0.512	rs6519289	chr22:42170432	A/C	cg17554472	chr22:41940697	POLR3H	0.46	4.8	0.4	4.46e-6	Vitiligo;
TGCT	cis	rs727505	1.000	rs28702851	chr7:124442991	G/A	cg23710748	chr7:124431027	NA	-0.28	-4.9	-0.4	2.92e-6	Lewy body disease;
TGCT	cis	rs12765878	1.000	rs11191865	chr10:105672842	G/A	cg11005552	chr10:105648138	OBFC1	0.44	7.61	0.56	5.93e-12	Coronary artery disease;
TGCT	cis	rs7119	0.635	rs2667764	chr15:77881239	C/T	cg27398640	chr15:77910606	LINGO1	0.31	6.31	0.49	4.49e-9	Type 2 diabetes;
TGCT	cis	rs11096990	0.634	rs2839765	chr4:39295553	T/C	cg20847110	chr4:39482781	LOC401127	-0.16	-4.51	-0.38	1.48e-5	Cognitive function;
TGCT	cis	rs2066819	1.000	rs2643623	chr12:56689725	G/C	cg26714650	chr12:56694279	CS	1.53	8.28	0.6	1.67e-13	Psoriasis vulgaris;
TGCT	trans	rs804280	0.543	rs13261205	chr8:11791216	A/G	cg15556689	chr8:8085844	FLJ10661	0.75	7.26	0.55	3.66e-11	Myopia (pathological);
TGCT	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg16414030	chr3:133502952	NA	-0.65	-10.78	-0.7	1.59e-19	Iron status biomarkers;
TGCT	cis	rs6988636	1.000	rs28513831	chr8:124189208	T/C	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs7552404	1.000	rs11161511	chr1:76210477	A/G	cg03433033	chr1:76189801	ACADM	-0.79	-9.38	-0.64	4.11e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2658782	1.000	rs2658778	chr11:93148948	C/G	cg18152523	chr11:93063302	CCDC67	-0.7	-5.35	-0.43	4.12e-7	Pulmonary function decline;
TGCT	cis	rs617219	0.698	rs12189248	chr5:78517143	A/G	cg05890484	chr5:78407552	BHMT	-0.4	-5.47	-0.44	2.33e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs6964587	0.900	rs7783674	chr7:91784212	T/A	cg22709100	chr7:91322751	NA	0.29	4.68	0.39	7.32e-6	Breast cancer;
TGCT	cis	rs9303401	0.659	rs11079357	chr17:56902778	A/G	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg22857025	chr5:266934	NA	-0.31	-6.32	-0.49	4.33e-9	Breast cancer;
TGCT	cis	rs6484504	0.553	rs413067	chr11:31223497	T/C	cg26647111	chr11:31128758	NA	-0.34	-4.61	-0.38	9.92e-6	Red blood cell count;
TGCT	cis	rs2455799	0.517	rs1466072	chr3:15939311	G/T	cg12172478	chr3:16357591	RFTN1	-0.33	-4.81	-0.4	4.31e-6	Mean platelet volume;
TGCT	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg08392591	chr16:89556376	ANKRD11	0.57	5.26	0.43	6.05e-7	Multiple myeloma (IgH translocation);
TGCT	cis	rs1997103	1.000	rs11238364	chr7:55407632	G/T	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs7267979	0.966	rs2227890	chr20:25260931	A/G	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2932538	0.922	rs11102508	chr1:113141175	T/C	cg22162597	chr1:113214053	CAPZA1	0.25	5.6	0.45	1.34e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs7769051	1.000	rs5006218	chr6:133126220	T/G	cg07930552	chr6:133119739	C6orf192	0.94	5.09	0.42	1.28e-6	Type 2 diabetes nephropathy;
TGCT	cis	rs6752107	1.000	rs12994997	chr2:234173503	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.19	4.65	0.39	8.35e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg07298985	chr8:22133076	PIWIL2	0.34	5.42	0.44	3e-7	Hypertriglyceridemia;
TGCT	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg10862848	chr6:42927986	GNMT	-0.4	-4.98	-0.41	2.11e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs11190604	0.767	rs77838250	chr10:102180090	T/G	cg16342193	chr10:102329863	NA	-0.4	-5.02	-0.41	1.74e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs11264213	0.901	rs630364	chr1:36449304	C/T	cg07093915	chr1:36184400	C1orf216	0.65	4.47	0.37	1.77e-5	Schizophrenia;
TGCT	cis	rs12477438	0.765	rs6737257	chr2:99683330	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-4.88	-0.4	3.17e-6	Chronic sinus infection;
TGCT	cis	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg02503808	chr4:7069936	GRPEL1	0.98	9.23	0.64	9.22e-16	Monocyte percentage of white cells;
TGCT	cis	rs2617583	0.509	rs4738	chr5:1461568	C/T	cg13982541	chr5:1466431	LPCAT1	0.2	4.57	0.38	1.15e-5	Breast cancer;
TGCT	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.6	-6.02	-0.48	1.84e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs60843830	1.000	rs59937473	chr2:271797	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.71	6.79	0.52	4.18e-10	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs9291683	0.561	rs3733584	chr4:10036506	T/C	cg11266682	chr4:10021025	SLC2A9	0.64	8.92	0.63	5e-15	Bone mineral density;
TGCT	cis	rs7959452	0.719	rs57954211	chr12:69748397	C/A	cg11871910	chr12:69753446	YEATS4	0.85	9.48	0.65	2.25e-16	Blood protein levels;
TGCT	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg26354017	chr1:205819088	PM20D1	-0.52	-6.45	-0.5	2.29e-9	Menarche (age at onset);
TGCT	cis	rs6964587	0.869	rs7793946	chr7:91520628	T/C	cg17063962	chr7:91808500	NA	-0.86	-9.19	-0.64	1.16e-15	Breast cancer;
TGCT	cis	rs11785400	0.762	rs7460801	chr8:143730972	C/A	cg10596483	chr8:143751796	JRK	0.53	5.21	0.42	7.5e-7	Schizophrenia;
TGCT	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg00684032	chr4:1343700	KIAA1530	0.23	4.9	0.4	2.95e-6	Obesity-related traits;
TGCT	cis	rs933688	0.532	rs4916851	chr5:90536300	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.54	-4.68	-0.39	7.32e-6	Smoking behavior;
TGCT	cis	rs2233152	0.572	rs10411008	chr19:41297241	T/C	cg23743927	chr19:41304969	EGLN2	-0.65	-4.51	-0.38	1.47e-5	Kawasaki disease;
TGCT	cis	rs7666738	0.830	rs7664340	chr4:99037820	C/T	cg05340658	chr4:99064831	C4orf37	0.51	5.82	0.46	4.75e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10423674	0.526	rs757317	chr19:18819984	C/T	cg20185461	chr19:18899082	COMP	-0.53	-5.03	-0.41	1.68e-6	Menarche (age at onset);
TGCT	cis	rs17767294	0.708	rs72851168	chr6:28080008	C/T	cg08851530	chr6:28072375	NA	1.56	7.22	0.54	4.47e-11	Parkinson's disease;
TGCT	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg25036284	chr2:26402008	FAM59B	0.65	5.19	0.42	8.36e-7	Gut microbiome composition (summer);
TGCT	cis	rs9500256	0.966	rs1322446	chr6:58311950	C/T	cg16251399	chr6:58287822	GUSBL2	0.67	5.96	0.47	2.44e-8	Eosinophilic esophagitis (pediatric);
TGCT	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs12510870	0.566	rs13115877	chr4:74460288	C/T	cg05868023	chr4:75230803	EREG	0.56	5.01	0.41	1.83e-6	Iris color (b* coordinate);
TGCT	cis	rs6684514	0.961	rs10908503	chr1:156300683	C/T	cg16558208	chr1:156270281	VHLL	0.48	9.6	0.65	1.19e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs7119	0.604	rs2682924	chr15:77863720	C/T	cg27398640	chr15:77910606	LINGO1	-0.26	-4.75	-0.39	5.61e-6	Type 2 diabetes;
TGCT	cis	rs1670533	1.000	rs6850784	chr4:1059809	G/A	cg27284194	chr4:1044797	NA	0.69	5.96	0.47	2.44e-8	Recombination rate (females);
TGCT	cis	rs1451375	0.698	rs1813214	chr7:50637525	A/G	cg18232548	chr7:50535776	DDC	0.44	6.72	0.52	5.81e-10	Malaria;
TGCT	cis	rs10751667	0.666	rs7395267	chr11:962326	C/A	cg06064525	chr11:970664	AP2A2	-0.35	-8.23	-0.59	2.17e-13	Alzheimer's disease (late onset);
TGCT	cis	rs4664308	0.840	rs1870102	chr2:161070582	A/G	cg03641300	chr2:160917029	PLA2R1	-0.25	-5.94	-0.47	2.7e-8	Idiopathic membranous nephropathy;
TGCT	cis	rs3015497	0.648	rs10144512	chr14:51082271	A/C	cg04730355	chr14:51134070	SAV1	-0.64	-6.17	-0.48	8.98e-9	Mean platelet volume;
TGCT	cis	rs13217239	0.646	rs7768407	chr6:27016795	G/A	cg26531700	chr6:26746687	NA	0.66	6.45	0.5	2.31e-9	Schizophrenia;
TGCT	cis	rs6840360	0.571	rs4696100	chr4:152514242	C/T	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.0	-0.58	7.69e-13	Intelligence (multi-trait analysis);
TGCT	trans	rs804280	0.509	rs13268030	chr8:11783073	C/T	cg15556689	chr8:8085844	FLJ10661	0.8	7.54	0.56	8.53e-12	Myopia (pathological);
TGCT	cis	rs317689	0.581	rs315132	chr12:69761996	G/C	cg19645103	chr12:69753606	YEATS4	-0.57	-4.8	-0.4	4.5e-6	Response to diuretic therapy;
TGCT	cis	rs1577917	0.958	rs11756615	chr6:86679835	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.08	-0.41	1.37e-6	Response to antipsychotic treatment;
TGCT	cis	rs11098499	0.863	rs6835635	chr4:120458867	A/G	cg09307838	chr4:120376055	NA	0.7	6.7	0.52	6.41e-10	Corneal astigmatism;
TGCT	cis	rs1062177	0.756	rs2964589	chr5:151118189	G/T	cg00977110	chr5:151150581	G3BP1	-0.43	-4.82	-0.4	4.14e-6	Preschool internalizing problems;
TGCT	cis	rs11096990	0.572	rs35040563	chr4:39155882	G/A	cg20847110	chr4:39482781	LOC401127	0.17	4.96	0.41	2.28e-6	Cognitive function;
TGCT	cis	rs2456568	0.741	rs10831137	chr11:93636912	C/T	cg26875233	chr11:93583750	C11orf90	-0.48	-6.46	-0.5	2.1e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg04025307	chr7:1156635	C7orf50	0.22	5.32	0.43	4.6e-7	Longevity;Endometriosis;
TGCT	cis	rs916888	0.779	rs199498	chr17:44865603	A/G	cg01570182	chr17:44337453	NA	0.77	6.58	0.51	1.17e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs3087591	0.922	rs9892839	chr17:29618990	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.49	-7.6	-0.56	6.42e-12	Hip circumference;
TGCT	cis	rs4713118	0.513	rs156739	chr6:28013410	C/A	cg10876282	chr6:28092338	ZSCAN16	0.52	4.88	0.4	3.15e-6	Parkinson's disease;
TGCT	cis	rs5769765	0.955	rs9616204	chr22:50303530	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.41	5.84	0.46	4.39e-8	Schizophrenia;
TGCT	cis	rs295140	0.903	rs56326533	chr2:201168758	T/C	cg04283868	chr2:201171347	SPATS2L	0.6	5.95	0.47	2.55e-8	QT interval;
TGCT	cis	rs6500602	0.789	rs2404546	chr16:4479734	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.3	5.16	0.42	9.6e-7	Schizophrenia;
TGCT	cis	rs1461503	0.966	rs11218905	chr11:122840303	A/G	cg27398637	chr11:122830231	C11orf63	0.41	5.2	0.42	8.05e-7	Menarche (age at onset);
TGCT	cis	rs17767294	0.612	rs12332927	chr6:27955115	T/C	cg08851530	chr6:28072375	NA	0.81	4.9	0.4	2.9e-6	Parkinson's disease;
TGCT	cis	rs587847	0.505	rs599218	chr15:37685780	A/T	cg16890051	chr15:37175029	LOC145845	-0.39	-4.57	-0.38	1.16e-5	Intraocular pressure;
TGCT	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.1	0.42	1.24e-6	Menopause (age at onset);
TGCT	cis	rs1008375	0.863	rs4698632	chr4:17614894	T/C	cg18681998	chr4:17616180	MED28	1.0	10.56	0.69	5.37e-19	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs17376456	0.825	rs10079708	chr5:93261796	G/C	cg25358565	chr5:93447407	FAM172A	1.02	8.11	0.59	4.23e-13	Diabetic retinopathy;
TGCT	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg17054783	chr10:134559939	INPP5A	0.24	4.72	0.39	6.38e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg03303774	chr4:1407052	NA	0.28	4.5	0.37	1.54e-5	Obesity-related traits;
TGCT	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg10047753	chr17:41438598	NA	0.96	9.64	0.65	9.37e-17	Menopause (age at onset);
TGCT	cis	rs8072100	0.871	rs7206971	chr17:45425115	A/G	cg08085267	chr17:45401833	C17orf57	0.45	5.06	0.41	1.46e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg03303774	chr4:1407052	NA	0.31	4.87	0.4	3.31e-6	Obesity-related traits;
TGCT	cis	rs7975161	0.630	rs4246264	chr12:104637743	C/G	cg25273343	chr12:104657179	TXNRD1	-0.35	-4.83	-0.4	3.87e-6	Toenail selenium levels;
TGCT	cis	rs9926296	0.609	rs4785710	chr16:89796756	C/T	cg04287289	chr16:89883240	FANCA	-0.64	-6.46	-0.5	2.16e-9	Vitiligo;
TGCT	cis	rs10992471	0.729	rs7042335	chr9:95122547	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.61	-6.26	-0.49	5.87e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs7246657	0.654	rs10407568	chr19:38123009	A/T	cg18154014	chr19:37997991	ZNF793	0.69	4.67	0.39	7.7e-6	Coronary artery calcification;
TGCT	cis	rs6882046	0.513	rs254779	chr5:88019629	T/C	cg24804195	chr5:87968844	LOC645323	-0.57	-5.57	-0.45	1.5e-7	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs6964587	1.000	rs10280927	chr7:91582205	G/A	cg22709100	chr7:91322751	NA	-0.27	-4.48	-0.37	1.68e-5	Breast cancer;
TGCT	cis	rs72945132	0.882	rs3900797	chr11:70186614	C/T	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs9325144	0.647	rs61937754	chr12:39060543	T/C	cg10518543	chr12:38710700	ALG10B	-0.48	-4.47	-0.37	1.77e-5	Morning vs. evening chronotype;
TGCT	cis	rs12679857	0.686	rs1032129	chr8:119951900	A/C	cg17171407	chr8:119960777	TNFRSF11B	0.33	5.95	0.47	2.51e-8	Type 1 diabetes;
TGCT	trans	rs1814175	0.647	rs10769646	chr11:49992204	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.67	-0.69	2.92e-19	Height;
TGCT	cis	rs4776059	1.000	rs12915981	chr15:52901433	C/T	cg25063058	chr15:52860530	ARPP19	0.53	4.76	0.39	5.22e-6	Schizophrenia;
TGCT	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg10047753	chr17:41438598	NA	0.96	9.54	0.65	1.61e-16	Menopause (age at onset);
TGCT	cis	rs7914558	1.000	rs4917380	chr10:104775335	C/G	cg04362960	chr10:104952993	NT5C2	0.6	5.34	0.43	4.34e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs7312933	0.558	rs1796388	chr12:42785987	G/C	cg19980929	chr12:42632907	YAF2	-0.4	-5.7	-0.46	8.24e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs896854	0.517	rs9643353	chr8:95957063	A/G	cg13393036	chr8:95962371	TP53INP1	0.49	5.83	0.46	4.61e-8	Type 2 diabetes;
TGCT	cis	rs1401999	0.714	rs7646621	chr3:183640865	A/C	cg01324343	chr3:183735012	ABCC5	-0.72	-8.93	-0.63	4.7e-15	Anterior chamber depth;
TGCT	cis	rs12935418	0.616	rs11859567	chr16:80969848	A/G	cg07676361	chr16:80966860	NA	-0.35	-4.69	-0.39	6.99e-6	Mean corpuscular volume;
TGCT	cis	rs7584330	0.518	rs113812061	chr2:238447934	T/C	cg14458575	chr2:238380390	NA	0.43	4.56	0.38	1.23e-5	Prostate cancer;
TGCT	cis	rs734999	0.967	rs6667605	chr1:2502780	C/T	cg18854424	chr1:2615690	NA	0.47	5.92	0.47	3.01e-8	Ulcerative colitis;
TGCT	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg05985448	chr10:134359359	INPP5A	-0.22	-4.97	-0.41	2.15e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	trans	rs7824557	0.564	rs7821459	chr8:11236681	T/G	cg15556689	chr8:8085844	FLJ10661	-0.74	-6.68	-0.51	7.12e-10	Retinal vascular caliber;
TGCT	cis	rs7216064	0.628	rs62084702	chr17:66043157	C/T	cg12091567	chr17:66097778	LOC651250	1.08	8.86	0.62	7.21e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs9926296	0.572	rs2376878	chr16:89885161	G/A	cg03388025	chr16:89894329	SPIRE2	0.34	5.01	0.41	1.81e-6	Vitiligo;
TGCT	cis	rs61895110	1	rs61895110	chr11:47557160	G/A	cg13308137	chr11:47528955	CUGBP1	0.48	5.21	0.42	7.78e-7	Total body bone mineral density;
TGCT	cis	rs2295359	1.000	rs9729046	chr1:67607082	C/G	cg03340356	chr1:67600835	NA	0.37	4.48	0.37	1.66e-5	Psoriasis;
TGCT	cis	rs12477438	0.798	rs2309524	chr2:99659510	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-8.52	-0.61	4.5e-14	Chronic sinus infection;
TGCT	cis	rs12681287	0.547	rs10956873	chr8:87547028	T/C	cg27223183	chr8:87520930	FAM82B	0.94	6.91	0.53	2.24e-10	Caudate activity during reward;
TGCT	cis	rs9486719	0.901	rs760619	chr6:96857431	A/G	cg18709589	chr6:96969512	KIAA0776	0.68	4.93	0.4	2.63e-6	Migraine;Coronary artery disease;
TGCT	cis	rs6964587	1.000	rs2075881	chr7:91734552	T/C	cg22709100	chr7:91322751	NA	0.28	4.56	0.38	1.21e-5	Breast cancer;
TGCT	cis	rs1008375	1.000	rs6819132	chr4:17689752	G/T	cg10189774	chr4:17578691	LAP3	-0.61	-5.25	-0.43	6.52e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4499344	0.730	rs35098593	chr19:33103939	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.83	8.63	0.61	2.53e-14	Mean platelet volume;
TGCT	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg11644478	chr21:40555479	PSMG1	-0.53	-4.57	-0.38	1.17e-5	Cognitive function;
TGCT	cis	rs6484504	0.576	rs208103	chr11:31167400	A/G	cg26647111	chr11:31128758	NA	-0.34	-4.6	-0.38	1.02e-5	Red blood cell count;
TGCT	cis	rs10193935	1.000	rs10190326	chr2:42388262	A/C	cg27598129	chr2:42591480	NA	0.39	5.07	0.41	1.39e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2404602	0.647	rs116505114	chr15:77074794	T/C	cg23625390	chr15:77176239	SCAPER	-0.37	-4.69	-0.39	7.04e-6	Blood metabolite levels;
TGCT	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg13877915	chr19:58951672	ZNF132	0.88	11.12	0.71	2.43e-20	Uric acid clearance;
TGCT	cis	rs447921	0.861	rs423130	chr17:74416189	A/G	cg09812376	chr17:74270190	QRICH2	0.46	4.6	0.38	1.01e-5	Mitochondrial DNA levels;
TGCT	cis	rs1949733	0.917	rs10461079	chr4:8392724	G/A	cg11789530	chr4:8429930	ACOX3	-0.55	-4.94	-0.41	2.51e-6	Response to antineoplastic agents;
TGCT	cis	rs3793683	0.928	rs10781585	chr10:134553369	C/A	cg27286337	chr10:134555280	INPP5A	-0.47	-7.34	-0.55	2.52e-11	Migraine;
TGCT	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg20849893	chr7:64541193	NA	0.5	5.21	0.42	7.7e-7	Calcium levels;
TGCT	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg02038168	chr22:39784481	NA	-0.77	-6.65	-0.51	8.24e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs2241685	0.850	rs58404476	chr2:1936998	C/T	cg21862353	chr2:1801628	MYT1L	-0.53	-4.86	-0.4	3.47e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs3812831	0.599	rs428636	chr13:114927133	T/C	cg08824895	chr13:115047677	UPF3A	0.48	4.66	0.39	8.08e-6	Schizophrenia;
TGCT	cis	rs4595586	0.525	rs12812749	chr12:39363254	C/T	cg10518543	chr12:38710700	ALG10B	0.54	4.45	0.37	1.92e-5	Morning vs. evening chronotype;
TGCT	cis	rs62064224	0.589	rs8069673	chr17:30661250	C/T	cg18200150	chr17:30822561	MYO1D	-0.39	-4.58	-0.38	1.13e-5	Schizophrenia;
TGCT	cis	rs981844	1.000	rs10517579	chr4:154666321	T/C	cg14289246	chr4:154710475	SFRP2	1.01	8.67	0.61	2.02e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs4746818	0.793	rs2805913	chr10:70858062	A/G	cg11621586	chr10:70884670	VPS26A	1.04	8.35	0.6	1.13e-13	Left atrial antero-posterior diameter;
TGCT	cis	rs9913156	0.793	rs56020376	chr17:4560909	A/G	cg19197139	chr17:4613644	ARRB2	0.86	7.9	0.58	1.32e-12	Lymphocyte counts;
TGCT	cis	rs6909279	0.678	rs11753987	chr6:151851428	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	0.62	5.66	0.45	9.77e-8	Bone mineral density;
TGCT	cis	rs4478858	0.746	rs60073066	chr1:31689589	G/A	cg00250761	chr1:31883323	NA	0.29	4.88	0.4	3.25e-6	Alcohol dependence;
TGCT	cis	rs68170813	0.522	rs12154818	chr7:107074515	G/C	cg02696742	chr7:106810147	HBP1	-0.67	-5.69	-0.46	8.58e-8	Coronary artery disease;
TGCT	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.51	-4.84	-0.4	3.76e-6	Longevity;Endometriosis;
TGCT	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg15595755	chr5:1867978	NA	0.46	5.45	0.44	2.62e-7	Cardiovascular disease risk factors;
TGCT	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg23302884	chr18:44338147	ST8SIA5	-0.41	-4.68	-0.39	7.26e-6	Personality dimensions;
TGCT	cis	rs6681544	0.510	rs3790910	chr1:82378937	A/G	cg04226724	chr1:82268649	LPHN2	0.47	4.95	0.41	2.33e-6	Metabolite levels  (X-11787);
TGCT	cis	rs6547741	0.563	rs10196039	chr2:27971195	C/T	cg27432699	chr2:27873401	GPN1	-0.22	-5.4	-0.44	3.34e-7	Oral cavity cancer;
TGCT	cis	rs6565180	1.000	rs12930787	chr16:30381303	C/G	cg17640201	chr16:30407289	ZNF48	-0.91	-8.83	-0.62	8.55e-15	Tonsillectomy;
TGCT	cis	rs1023500	1.000	rs1047997	chr22:42334953	C/G	cg04692870	chr22:42525206	CYP2D6	-0.35	-5.26	-0.43	6.16e-7	Schizophrenia;
TGCT	cis	rs11098499	0.779	rs10016060	chr4:120298412	A/G	cg09307838	chr4:120376055	NA	0.65	6.39	0.5	3.02e-9	Corneal astigmatism;
TGCT	cis	rs2228479	0.702	rs62056092	chr16:89930426	A/G	cg06558623	chr16:89946397	TCF25	0.52	4.6	0.38	1.05e-5	Skin colour saturation;
TGCT	cis	rs7582180	0.790	rs4851288	chr2:100920451	T/C	cg08017756	chr2:100939284	LONRF2	-0.32	-5.4	-0.44	3.2e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs344364	0.511	rs12596510	chr16:1949480	G/A	cg26617929	chr16:1858877	NA	-0.27	-4.9	-0.4	2.99e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs1056107	0.541	rs10739349	chr9:115178029	C/A	cg02332936	chr9:115140584	NA	-0.27	-4.6	-0.38	1.02e-5	Colorectal cancer;
TGCT	cis	rs11673344	0.523	rs6510585	chr19:37553983	C/T	cg08039142	chr19:36980659	ZNF566	0.49	4.5	0.37	1.57e-5	Obesity-related traits;
TGCT	cis	rs2235642	0.717	rs2236269	chr16:1652614	T/A	cg10465839	chr16:1584050	IFT140;TMEM204	-0.28	-4.63	-0.38	9.16e-6	Coronary artery disease;
TGCT	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.42	6.05	0.48	1.57e-8	Lymphocyte counts;
TGCT	cis	rs11249608	0.548	rs10479519	chr5:178450693	T/C	cg01312482	chr5:178451176	ZNF879	-0.56	-5.5	-0.44	2.09e-7	Pubertal anthropometrics;
TGCT	cis	rs860554	1.000	rs860554	chr1:201262432	A/G	cg01022117	chr1:201258280	PKP1	-0.31	-4.85	-0.4	3.6e-6	Panic disorder;
TGCT	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.78	6.27	0.49	5.58e-9	Mean platelet volume;
TGCT	cis	rs6089829	0.962	rs57684920	chr20:61662639	G/A	cg08045932	chr20:61659980	NA	-0.45	-8.05	-0.59	5.73e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg22166914	chr1:53195759	ZYG11B	0.34	5.42	0.44	2.95e-7	Monocyte count;
TGCT	cis	rs9902453	0.845	rs2321493	chr17:28230359	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.81	7.26	0.55	3.67e-11	Coffee consumption (cups per day);
TGCT	cis	rs3008870	0.701	rs2815358	chr1:67493778	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.78	8.17	0.59	3.04e-13	Lymphocyte percentage of white cells;
TGCT	cis	rs7833790	0.724	rs12676336	chr8:82771008	C/T	cg06027949	chr8:82754900	SNX16	0.67	5.14	0.42	1.06e-6	Diastolic blood pressure;
TGCT	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg13206674	chr6:150067644	NUP43	0.52	4.46	0.37	1.78e-5	Lung cancer;
TGCT	cis	rs17376456	0.825	rs28645862	chr5:93233128	G/C	cg25358565	chr5:93447407	FAM172A	1.01	8.13	0.59	3.77e-13	Diabetic retinopathy;
TGCT	cis	rs922182	0.692	rs7162147	chr15:64291500	G/A	cg02919090	chr15:64263738	DAPK2	0.27	4.71	0.39	6.62e-6	Blood protein levels;
TGCT	cis	rs6988636	1.000	rs28537152	chr8:124189071	T/C	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs7647973	0.588	rs9883000	chr3:49667691	A/G	cg03034192	chr3:50606346	HEMK1;C3orf18	0.36	4.65	0.39	8.24e-6	Menarche (age at onset);
TGCT	cis	rs2307449	0.892	rs2238301	chr15:89851438	C/T	cg24365117	chr15:89879190	POLG	-0.32	-4.51	-0.38	1.51e-5	Menopause (age at onset);
TGCT	cis	rs7582180	0.607	rs1530029	chr2:100968205	C/T	cg08017756	chr2:100939284	LONRF2	-0.3	-4.82	-0.4	4.16e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg06481639	chr22:41940642	POLR3H	-0.72	-6.52	-0.51	1.61e-9	Vitiligo;
TGCT	cis	rs11623869	0.711	rs2403173	chr14:103909289	T/C	cg12935359	chr14:103987150	CKB	-0.33	-4.84	-0.4	3.86e-6	Bone mineral density;
TGCT	cis	rs12681288	0.676	rs935819	chr8:1021814	T/C	cg04851639	chr8:1020857	NA	-0.36	-6.56	-0.51	1.31e-9	Schizophrenia;
TGCT	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg11644478	chr21:40555479	PSMG1	1.0	10.69	0.69	2.7e-19	Cognitive function;
TGCT	cis	rs10832963	1.000	rs2084220	chr11:18656932	C/T	cg09201001	chr11:18656081	SPTY2D1	1.04	11.74	0.73	7.48e-22	Breast cancer;
TGCT	cis	rs7917772	0.503	rs2031601	chr10:104308064	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	8.6	0.61	2.97e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs796364	1.000	rs35220450	chr2:200780737	T/C	cg17644776	chr2:200775616	C2orf69	-0.31	-4.83	-0.4	3.99e-6	Schizophrenia;
TGCT	cis	rs11690462	0.929	rs11678646	chr2:26602262	C/T	cg04726446	chr2:26624865	C2orf39	0.43	4.66	0.39	8.15e-6	Coronary artery disease;
TGCT	cis	rs9486719	0.656	rs4839826	chr6:96853616	A/G	cg06623918	chr6:96969491	KIAA0776	-0.91	-7.71	-0.57	3.55e-12	Migraine;Coronary artery disease;
TGCT	cis	rs9394841	0.656	rs9349209	chr6:41940546	G/A	cg08135965	chr6:41755394	TOMM6	0.51	4.62	0.38	9.47e-6	Mean corpuscular hemoglobin;Red cell distribution width;
TGCT	cis	rs13242816	1.000	rs13247987	chr7:116113344	A/C	cg02799643	chr7:116139180	CAV2	-0.48	-5.52	-0.44	1.87e-7	P wave duration;
TGCT	cis	rs17253792	0.822	rs8007065	chr14:56081272	A/G	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs7666738	0.791	rs10017624	chr4:98984009	G/T	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	16.1	0.82	3.69e-32	Prudent dietary pattern;
TGCT	trans	rs72809171	0.661	rs72809197	chr17:12493710	C/G	cg03074370	chr19:50352995	PTOV1	0.51	6.93	0.53	1.99e-10	Male-pattern baldness;
TGCT	cis	rs7208859	0.673	rs12103588	chr17:29197460	C/T	cg18442181	chr17:29233375	C17orf42	-0.79	-4.78	-0.39	4.95e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg06640241	chr16:89574553	SPG7	0.81	9.15	0.64	1.39e-15	Multiple myeloma (IgH translocation);
TGCT	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg26338869	chr17:61819248	STRADA	-0.58	-5.23	-0.43	6.97e-7	Prudent dietary pattern;
TGCT	cis	rs7786808	0.552	rs4909207	chr7:158187136	G/A	cg01191920	chr7:158217561	PTPRN2	-0.37	-5.44	-0.44	2.67e-7	Obesity-related traits;
TGCT	cis	rs8077577	0.945	rs62073604	chr17:18065888	T/C	cg09161412	chr17:18057145	MYO15A	-0.67	-5.44	-0.44	2.69e-7	Obesity-related traits;
TGCT	cis	rs12579753	0.879	rs1987116	chr12:82156478	G/A	cg07988820	chr12:82153109	PPFIA2	-0.67	-7.45	-0.56	1.4e-11	Resting heart rate;
TGCT	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.9	-5.8	-0.46	5.19e-8	Alzheimer's disease;
TGCT	cis	rs13188771	0.651	rs68082730	chr5:100903250	C/T	cg10455971	chr5:101119566	NA	0.44	4.45	0.37	1.87e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs2882877	0.610	rs1123109	chr2:190444392	C/T	cg10752008	chr2:190445175	SLC40A1	-0.79	-6.23	-0.49	6.62e-9	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs10875746	0.903	rs886588	chr12:48477422	A/G	cg20731937	chr12:48336164	NA	0.62	4.95	0.41	2.36e-6	Longevity (90 years and older);
TGCT	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg07157834	chr1:205819609	PM20D1	0.43	6.9	0.53	2.38e-10	Menarche (age at onset);
TGCT	trans	rs9951602	0.512	rs12454617	chr18:76656007	C/T	cg02800362	chr5:177631904	HNRNPAB	1.13	12.71	0.75	3.32e-24	Obesity-related traits;
TGCT	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg10047753	chr17:41438598	NA	0.96	9.64	0.65	9.37e-17	Menopause (age at onset);
TGCT	cis	rs4918072	0.874	rs3850670	chr10:105659369	C/T	cg11005552	chr10:105648138	OBFC1	0.41	5.4	0.44	3.29e-7	Coronary artery disease;
TGCT	cis	rs12971120	0.947	rs8084410	chr18:72168486	T/C	cg25817165	chr18:72167213	CNDP2	-0.29	-5.51	-0.44	1.98e-7	Refractive error;
TGCT	cis	rs11711311	0.955	rs3796254	chr3:113380332	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.8	-7.13	-0.54	7.24e-11	IgG glycosylation;
TGCT	cis	rs10242455	0.571	rs28365067	chr7:99272310	G/A	cg25640893	chr7:99214727	ZNF498	0.96	4.44	0.37	2e-5	Blood metabolite levels;
TGCT	cis	rs9902453	1.000	rs55971458	chr17:28427016	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.74	6.52	0.51	1.63e-9	Coffee consumption (cups per day);
TGCT	cis	rs12893668	0.703	rs34186780	chr14:104027595	T/G	cg26031613	chr14:104095156	KLC1	-0.54	-4.55	-0.38	1.28e-5	Reticulocyte count;
TGCT	cis	rs72781680	0.848	rs56021814	chr2:24073437	T/A	cg08917208	chr2:24149416	ATAD2B	0.72	4.44	0.37	1.96e-5	Lymphocyte counts;
TGCT	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg22508957	chr16:3507546	NAT15	0.48	5.48	0.44	2.31e-7	Tuberculosis;
TGCT	trans	rs2727020	0.521	rs4980445	chr11:49570183	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.42	-8.32	-0.6	1.34e-13	Coronary artery disease;
TGCT	cis	rs35883536	0.647	rs55728953	chr1:101046863	T/C	cg06223162	chr1:101003688	GPR88	-0.41	-7.64	-0.57	5.04e-12	Monocyte count;
TGCT	cis	rs116095464	0.558	rs10065584	chr5:253997	G/A	cg22857025	chr5:266934	NA	-0.35	-6.87	-0.53	2.7e-10	Breast cancer;
TGCT	cis	rs79149102	0.579	rs74023908	chr15:75310710	T/C	cg09165964	chr15:75287851	SCAMP5	-1.05	-5.73	-0.46	7.26e-8	Lung cancer;
TGCT	cis	rs10089	1.000	rs9968597	chr5:127455383	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	8.17	0.59	2.99e-13	Ileal carcinoids;
TGCT	cis	rs9638182	1.000	rs34594435	chr7:72977249	C/T	cg14087351	chr7:73037990	MLXIPL	-0.58	-4.91	-0.4	2.83e-6	Triglycerides;
TGCT	cis	rs950169	0.840	rs4842854	chr15:84942339	T/G	cg11189052	chr15:85197271	WDR73	0.81	6.22	0.49	6.89e-9	Schizophrenia;
TGCT	cis	rs7614311	0.681	rs2241822	chr3:63965304	A/G	cg22134162	chr3:63841271	THOC7	-0.45	-5.73	-0.46	7.3e-8	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs6540559	0.808	rs11119358	chr1:210042456	T/C	cg04352962	chr1:209979756	IRF6	0.66	4.87	0.4	3.28e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs2404602	0.716	rs12917430	chr15:76674360	T/C	cg26408565	chr15:76604113	ETFA	-0.4	-5.09	-0.42	1.28e-6	Blood metabolite levels;
TGCT	cis	rs78487399	0.808	rs74600494	chr2:43743491	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.02	-0.41	1.75e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs6956675	0.830	rs4585626	chr7:62671592	C/G	cg27518014	chr7:62859535	LOC100287834	-0.49	-4.65	-0.38	8.54e-6	Obesity-related traits;
TGCT	cis	rs5769765	0.954	rs5770739	chr22:50268014	C/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.41	-6.13	-0.48	1.08e-8	Schizophrenia;
TGCT	cis	rs6598955	0.670	rs3795688	chr1:26560481	C/A	cg04990556	chr1:26633338	UBXN11	-0.91	-11.87	-0.73	3.59e-22	Obesity-related traits;
TGCT	cis	rs2820315	0.867	rs2819348	chr1:201884952	T/C	cg12730843	chr1:201915899	LMOD1	-0.27	-4.82	-0.4	4.17e-6	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
TGCT	cis	rs2204008	0.692	rs11613378	chr12:38213138	T/A	cg13010199	chr12:38710504	ALG10B	0.62	4.96	0.41	2.32e-6	Bladder cancer;
TGCT	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg12310025	chr6:25882481	NA	-0.54	-5.7	-0.46	8.31e-8	Height;
TGCT	cis	rs6545883	0.868	rs2427885	chr2:61816777	A/G	cg15711740	chr2:61764176	XPO1	-0.59	-5.51	-0.44	1.97e-7	Tuberculosis;
TGCT	cis	rs6500602	0.702	rs56895104	chr16:4548132	G/A	cg08645402	chr16:4508243	NA	0.18	5.15	0.42	1.01e-6	Schizophrenia;
TGCT	cis	rs514406	0.525	rs269291	chr1:53189297	C/T	cg08859206	chr1:53392774	SCP2	-0.35	-4.91	-0.4	2.76e-6	Monocyte count;
TGCT	cis	rs17376456	0.825	rs28412976	chr5:93248377	T/C	cg25358565	chr5:93447407	FAM172A	1.01	7.59	0.56	6.78e-12	Diabetic retinopathy;
TGCT	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg08439880	chr3:133502540	NA	-0.28	-5.15	-0.42	9.73e-7	Iron status biomarkers;
TGCT	cis	rs155076	1.000	rs9509638	chr13:21860193	G/A	cg14456004	chr13:21872349	NA	-1.23	-9.97	-0.67	1.49e-17	White matter hyperintensity burden;
TGCT	cis	rs2832191	0.716	rs7284006	chr21:30475186	T/A	cg08807101	chr21:30365312	RNF160	0.67	6.13	0.48	1.08e-8	Dental caries;
TGCT	cis	rs7727544	0.514	rs3846728	chr5:131436217	G/A	cg24060327	chr5:131705240	SLC22A5	-0.45	-4.48	-0.37	1.64e-5	Blood metabolite levels;
TGCT	cis	rs6540559	0.673	rs17317411	chr1:209961314	C/T	cg21951975	chr1:209979733	IRF6	-0.67	-4.99	-0.41	2.03e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs769267	1.000	rs2285627	chr19:19467937	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	-0.68	-5.66	-0.45	9.97e-8	Tonsillectomy;
TGCT	cis	rs7647973	0.626	rs4855846	chr3:49683526	G/A	cg03034192	chr3:50606346	HEMK1;C3orf18	0.36	4.75	0.39	5.61e-6	Menarche (age at onset);
TGCT	cis	rs35785195	0.593	rs35304519	chr12:114236677	C/T	cg11070030	chr12:114232702	NA	0.26	4.45	0.37	1.9e-5	Daytime sleep phenotypes;
TGCT	cis	rs3782455	1.000	rs16943542	chr12:114406301	C/T	cg23502203	chr12:113549970	RASAL1	-0.57	-4.92	-0.4	2.64e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs10782582	0.593	rs12132750	chr1:76136222	A/G	cg03433033	chr1:76189801	ACADM	-0.63	-7.25	-0.55	3.83e-11	Daytime sleep phenotypes;
TGCT	cis	rs918629	0.761	rs3777173	chr5:95281353	C/T	cg16656078	chr5:95278638	ELL2	-0.28	-4.52	-0.38	1.42e-5	IgG glycosylation;
TGCT	cis	rs4494114	0.902	rs12751382	chr1:39307275	G/A	cg25970120	chr1:39325951	RRAGC	-0.6	-6.43	-0.5	2.52e-9	Blood protein levels;
TGCT	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.14	0.42	1.06e-6	Prudent dietary pattern;
TGCT	cis	rs9814567	0.712	rs4306900	chr3:134334327	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.73	6.66	0.51	7.8e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs1865760	1.000	rs7757666	chr6:25902626	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.65	6.24	0.49	6.27e-9	Height;
TGCT	cis	rs259282	0.605	rs17692992	chr19:33099430	T/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.61	5.43	0.44	2.85e-7	Schizophrenia;
TGCT	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg17971929	chr21:40555470	PSMG1	0.97	9.52	0.65	1.86e-16	Cognitive function;
TGCT	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.73	-7.36	-0.55	2.27e-11	Prudent dietary pattern;
TGCT	cis	rs422249	0.547	rs102275	chr11:61557803	T/C	cg01500311	chr11:61656094	FADS3	-0.36	-6.37	-0.5	3.28e-9	Trans fatty acid levels;
TGCT	cis	rs2180341	0.920	rs9401951	chr6:127671632	A/C	cg27446573	chr6:127587934	RNF146	1.22	10.94	0.7	6.36e-20	Breast cancer;
TGCT	cis	rs709400	0.663	rs10133035	chr14:103979127	C/T	cg26031613	chr14:104095156	KLC1	0.86	9.54	0.65	1.61e-16	Body mass index;
TGCT	cis	rs858239	0.601	rs10278700	chr7:23160529	T/C	cg05602783	chr7:23145260	KLHL7	-0.65	-5.52	-0.44	1.93e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs2016266	0.929	rs11170495	chr12:53665202	G/A	cg16917193	chr12:54089295	NA	0.65	5.36	0.43	3.98e-7	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs9653442	0.564	rs10197987	chr2:100790783	A/T	cg22139774	chr2:100720529	AFF3	-0.34	-5.27	-0.43	5.98e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs6831352	0.734	rs12502237	chr4:100015675	G/A	cg12011299	chr4:100065546	ADH4	0.38	5.02	0.41	1.78e-6	Alcohol dependence;
TGCT	cis	rs7267979	1.000	rs4815424	chr20:25390284	T/C	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg07424592	chr7:64974309	NA	1.39	8.24	0.59	2.08e-13	Diabetic kidney disease;
TGCT	cis	rs61931739	0.500	rs11053140	chr12:34316122	T/C	cg06521331	chr12:34319734	NA	-0.3	-4.45	-0.37	1.87e-5	Morning vs. evening chronotype;
TGCT	cis	rs4563143	0.502	rs73029061	chr19:29283980	T/A	cg12756686	chr19:29218302	NA	0.78	6.69	0.51	6.93e-10	Methadone dose in opioid dependence;
TGCT	cis	rs1670533	1.000	rs2290411	chr4:1051077	T/C	cg20887711	chr4:1340912	KIAA1530	0.7	5.66	0.45	9.77e-8	Recombination rate (females);
TGCT	cis	rs6121246	0.567	rs6120890	chr20:30207659	T/G	cg13852791	chr20:30311386	BCL2L1	0.7	4.68	0.39	7.29e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs2404602	0.692	rs66866130	chr15:77128574	T/C	cg22467129	chr15:76604101	ETFA	-0.45	-5.11	-0.42	1.21e-6	Blood metabolite levels;
TGCT	cis	rs7666738	0.716	rs13108535	chr4:99046324	A/G	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg19723775	chr5:179050963	HNRNPH1	-0.48	-4.73	-0.39	6.1e-6	Lung cancer;
TGCT	cis	rs2197308	0.605	rs2387437	chr12:37919367	T/C	cg13010199	chr12:38710504	ALG10B	0.61	4.93	0.4	2.57e-6	Morning vs. evening chronotype;
TGCT	cis	rs6570726	0.526	rs72994723	chr6:145722948	G/A	cg23711669	chr6:146136114	FBXO30	-0.56	-4.99	-0.41	1.96e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9467773	0.583	rs2498380	chr6:26643996	C/G	cg05738196	chr6:26577821	NA	-0.85	-10.7	-0.69	2.5e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs7914558	0.966	rs7096269	chr10:104736721	A/G	cg04362960	chr10:104952993	NT5C2	0.6	5.34	0.43	4.34e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs8141529	0.748	rs9620841	chr22:29290981	C/T	cg02153584	chr22:29168773	CCDC117	0.63	4.87	0.4	3.3e-6	Lymphocyte counts;
TGCT	cis	rs3772130	0.961	rs1573819	chr3:121469646	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.53	4.7	0.39	6.84e-6	Cognitive performance;
TGCT	cis	rs10479542	0.929	rs7718673	chr5:178980009	C/T	cg19626725	chr5:178986131	RUFY1	-0.44	-5.46	-0.44	2.52e-7	Lung cancer;
TGCT	cis	rs6920965	0.527	rs584032	chr6:126165003	G/A	cg05901451	chr6:126070800	HEY2	0.56	5.11	0.42	1.18e-6	High light scatter reticulocyte count;
TGCT	cis	rs4566357	0.595	rs6707159	chr2:227909339	T/A	cg11843606	chr2:227700838	RHBDD1	-0.52	-4.92	-0.4	2.71e-6	Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs11727653	chr4:99001774	T/C	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7666738	0.680	rs11097613	chr4:99079991	G/T	cg17366294	chr4:99064904	C4orf37	0.68	6.58	0.51	1.19e-9	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs877282	0.945	rs12776447	chr10:790625	A/G	cg22713356	chr15:30763199	NA	1.18	10.55	0.69	5.81e-19	Uric acid levels;
TGCT	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg03709012	chr19:19516395	GATAD2A	-0.66	-5.7	-0.46	8.46e-8	Tonsillectomy;
TGCT	cis	rs11105298	0.891	rs8181784	chr12:89828591	A/G	cg00757033	chr12:89920650	WDR51B	0.31	4.92	0.4	2.72e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	trans	rs1496653	0.602	rs71322187	chr3:23473926	T/C	cg02770683	chr12:57597238	LRP1	0.38	6.89	0.53	2.53e-10	Type 2 diabetes;
TGCT	cis	rs3771570	1.000	rs12619369	chr2:242282957	A/T	cg21155796	chr2:242212141	HDLBP	0.91	6.86	0.52	2.85e-10	Prostate cancer;
TGCT	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.62	-5.11	-0.42	1.17e-6	Tonsillectomy;
TGCT	cis	rs861020	1.000	rs674433	chr1:209964875	A/C	cg05527609	chr1:210001259	C1orf107	-0.92	-8.19	-0.59	2.71e-13	Orofacial clefts;
TGCT	cis	rs12580194	0.593	rs7311751	chr12:55748847	A/G	cg10672482	chr12:55725839	OR6C3	-0.51	-4.58	-0.38	1.13e-5	Cancer;
TGCT	cis	rs6964587	0.967	rs2188153	chr7:91595117	G/T	cg22709100	chr7:91322751	NA	0.27	4.48	0.37	1.68e-5	Breast cancer;
TGCT	cis	rs11671005	0.735	rs11666303	chr19:58922502	T/G	cg13877915	chr19:58951672	ZNF132	0.63	4.99	0.41	1.99e-6	Mean platelet volume;
TGCT	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.93	-6.86	-0.52	2.86e-10	Gut microbiome composition (summer);
TGCT	cis	rs67311347	0.822	rs9826847	chr3:40345312	A/T	cg13683864	chr3:40499215	RPL14	-0.9	-8.68	-0.61	1.87e-14	Renal cell carcinoma;
TGCT	cis	rs9653442	0.564	rs12992234	chr2:100767886	G/A	cg22139774	chr2:100720529	AFF3	-0.35	-5.55	-0.45	1.63e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs7258465	0.965	rs1560118	chr19:18570035	G/A	cg06462663	chr19:18546047	ISYNA1	0.2	4.51	0.38	1.5e-5	Breast cancer;
TGCT	cis	rs877282	0.945	rs877280	chr10:771599	C/T	cg17470449	chr10:769945	NA	0.31	4.77	0.39	5.04e-6	Uric acid levels;
TGCT	cis	rs2692947	0.637	rs1168967	chr2:96826016	A/G	cg22654517	chr2:96458247	NA	0.23	5.1	0.42	1.22e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs968451	0.865	rs12627970	chr22:39721745	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.84	8.54	0.61	4.02e-14	Primary biliary cholangitis;
TGCT	cis	rs908922	0.676	rs7547628	chr1:152527738	T/C	cg20991723	chr1:152506922	NA	0.45	6.06	0.48	1.55e-8	Hair morphology;
TGCT	cis	rs35306767	0.714	rs17293608	chr10:1056252	C/T	cg26597838	chr10:835615	NA	0.57	6.57	0.51	1.23e-9	Eosinophil percentage of granulocytes;
TGCT	cis	rs12911832	1.000	rs12911832	chr15:58985904	A/T	cg05156742	chr15:59063176	FAM63B	0.5	4.78	0.39	4.94e-6	Schizophrenia;
TGCT	cis	rs1997103	1.000	rs6976824	chr7:55396115	A/C	cg17469321	chr7:55412551	NA	0.62	6.55	0.51	1.35e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs644799	1.000	rs693597	chr11:95589629	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	10.76	0.7	1.74e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs11190604	1.000	rs7079756	chr10:102302105	G/A	cg16342193	chr10:102329863	NA	-0.41	-4.98	-0.41	2.1e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs10507380	0.824	rs77417706	chr13:27919510	G/A	cg25543773	chr13:27185723	WASF3	0.34	4.83	0.4	3.97e-6	Electrocardiographic traits;
TGCT	cis	rs2204008	0.540	rs3908193	chr12:38410907	G/T	cg26384229	chr12:38710491	ALG10B	-0.54	-4.81	-0.4	4.32e-6	Bladder cancer;
TGCT	cis	rs55794721	0.509	rs12027110	chr1:25775682	A/T	cg10117171	chr1:25599238	RHD	-0.32	-5.22	-0.42	7.21e-7	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg10117171	chr1:25599238	RHD	-0.35	-5.7	-0.46	8.2e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs9677476	0.516	rs2303351	chr2:232030510	C/A	cg07929768	chr2:232055508	NA	0.33	5.24	0.43	6.78e-7	Food antigen IgG levels;
TGCT	cis	rs12510870	0.599	rs16849675	chr4:74452122	C/T	cg05868023	chr4:75230803	EREG	-0.55	-4.74	-0.39	5.71e-6	Iris color (b* coordinate);
TGCT	cis	rs6088590	0.813	rs1884668	chr20:33285514	A/G	cg08999081	chr20:33150536	PIGU	0.27	5.01	0.41	1.81e-6	Coronary artery disease;
TGCT	cis	rs7017914	0.967	rs17689955	chr8:71848864	C/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.55	-5.29	-0.43	5.39e-7	Bone mineral density;
TGCT	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	8.0	0.58	7.67e-13	Platelet count;
TGCT	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg23982607	chr1:1823379	GNB1	-0.56	-8.56	-0.61	3.65e-14	Body mass index;
TGCT	trans	rs8073060	0.586	rs6505485	chr17:33996102	C/T	cg19694781	chr19:47549865	TMEM160	-0.59	-10.9	-0.7	8.12e-20	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs7666738	0.519	rs28539191	chr4:98821552	C/T	cg17366294	chr4:99064904	C4orf37	0.65	5.96	0.47	2.39e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs34891900	0.507	rs1008378	chr22:18207251	T/C	cg19898043	chr22:18121309	BCL2L13	0.55	4.7	0.39	6.8e-6	Sum neutrophil eosinophil counts;
TGCT	trans	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.87	9.39	0.64	3.82e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs7772486	0.875	rs9373485	chr6:146401429	A/T	cg05347473	chr6:146136440	FBXO30	0.56	5.22	0.42	7.31e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2404602	0.692	rs2137307	chr15:77149020	T/A	cg26408565	chr15:76604113	ETFA	-0.36	-4.53	-0.38	1.36e-5	Blood metabolite levels;
TGCT	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg20276088	chr3:133502917	NA	-0.24	-5.02	-0.41	1.74e-6	Iron status biomarkers;
TGCT	cis	rs1018836	0.818	rs715057	chr8:91624340	T/C	cg16814680	chr8:91681699	NA	-0.78	-8.2	-0.59	2.54e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs778371	0.522	rs6704768	chr2:233592501	C/T	cg08000102	chr2:233561755	GIGYF2	0.63	7.17	0.54	5.87e-11	Schizophrenia;
TGCT	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg08859206	chr1:53392774	SCP2	0.4	5.96	0.47	2.46e-8	Monocyte count;
TGCT	cis	rs17376456	0.877	rs55832164	chr5:93436579	C/T	cg21475434	chr5:93447410	FAM172A	0.59	4.66	0.39	8.09e-6	Diabetic retinopathy;
TGCT	cis	rs35160687	0.901	rs12622200	chr2:86498595	A/G	cg03171300	chr2:86307199	POLR1A	-0.32	-5.49	-0.44	2.18e-7	Night sleep phenotypes;
TGCT	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg02788857	chr8:22132959	PIWIL2	0.28	5.09	0.42	1.29e-6	Hypertriglyceridemia;
TGCT	cis	rs10771431	0.817	rs10843149	chr12:9362067	G/A	cg08997352	chr12:9597637	DDX12	-0.26	-5.24	-0.43	6.71e-7	Breast size;
TGCT	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs1797081	1.000	rs812426	chr10:16857133	C/G	cg14835575	chr10:16859367	RSU1	0.42	4.94	0.41	2.51e-6	Platelet distribution width;
TGCT	cis	rs17030434	0.654	rs10021447	chr4:154646459	A/C	cg14289246	chr4:154710475	SFRP2	-0.78	-5.9	-0.47	3.28e-8	Electrocardiographic conduction measures;
TGCT	cis	rs7772486	0.754	rs10872580	chr6:146140281	C/T	cg05347473	chr6:146136440	FBXO30	-0.55	-5.21	-0.42	7.69e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs854765	0.547	rs8075189	chr17:17901946	C/G	cg04398451	chr17:18023971	MYO15A	-0.31	-5.05	-0.41	1.56e-6	Total body bone mineral density;
TGCT	trans	rs1814175	0.817	rs7950856	chr11:49976394	C/T	cg03929089	chr4:120376271	NA	-0.72	-8.53	-0.61	4.24e-14	Height;
TGCT	cis	rs12530845	0.943	rs55889179	chr7:135331631	C/T	cg23117316	chr7:135346802	PL-5283	-0.5	-4.74	-0.39	5.83e-6	Red blood cell traits;
TGCT	cis	rs1348850	0.914	rs7604673	chr2:178392346	A/G	cg22681709	chr2:178499509	PDE11A	-0.35	-4.58	-0.38	1.1e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	trans	rs2243480	1.000	rs1267820	chr7:66050295	C/G	cg07424592	chr7:64974309	NA	1.3	8.23	0.59	2.19e-13	Diabetic kidney disease;
TGCT	cis	rs9419702	0.614	rs9419567	chr10:133535149	C/G	cg23460707	chr10:133558971	NA	0.42	4.84	0.4	3.8e-6	Survival in rectal cancer;
TGCT	cis	rs4722166	0.630	rs6969258	chr7:22782528	C/T	cg26061582	chr7:22766209	IL6	0.57	7.31	0.55	2.85e-11	Lung cancer;
TGCT	cis	rs763121	0.853	rs5750677	chr22:39147715	C/T	cg06022373	chr22:39101656	GTPBP1	0.77	7.17	0.54	6e-11	Menopause (age at onset);
TGCT	cis	rs2274273	0.682	rs8008134	chr14:55507520	T/C	cg01923255	chr14:55878535	KIAA0831	0.56	4.94	0.41	2.51e-6	Protein biomarker;
TGCT	cis	rs2180341	1.000	rs9398838	chr6:127635285	C/T	cg24812749	chr6:127587940	RNF146	0.98	7.64	0.57	5.06e-12	Breast cancer;
TGCT	trans	rs1814175	0.817	rs28679516	chr11:50055998	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.26	-0.55	3.77e-11	Height;
TGCT	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.71	0.39	6.5e-6	Prudent dietary pattern;
TGCT	trans	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg13615516	chr5:77269221	NA	0.67	8.36	0.6	1.09e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2933343	0.649	rs2638845	chr3:128587369	A/G	cg11901034	chr3:128598214	ACAD9	-0.64	-6.16	-0.48	9.37e-9	IgG glycosylation;
TGCT	cis	rs7772486	0.875	rs863820	chr6:146347402	C/T	cg23711669	chr6:146136114	FBXO30	-0.89	-10.0	-0.67	1.25e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs617219	0.591	rs1840805	chr5:78565563	T/A	cg23987322	chr5:78407566	BHMT	-0.35	-4.57	-0.38	1.15e-5	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	5.11	0.42	1.18e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs11085466	0.948	rs11668453	chr19:21759357	C/A	cg23026602	chr19:21646605	NA	-0.57	-4.59	-0.38	1.07e-5	Colorectal or endometrial cancer;
TGCT	cis	rs2486288	0.656	rs2413768	chr15:45561984	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.44	-5.15	-0.42	1.01e-6	Glomerular filtration rate;
TGCT	cis	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg20637647	chr7:64974828	NA	0.93	5.2	0.42	8.11e-7	Diabetic kidney disease;
TGCT	cis	rs56104184	0.779	rs4802513	chr19:49357656	T/A	cg17863274	chr19:49399704	TULP2	-0.43	-5.04	-0.41	1.6e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg16414030	chr3:133502952	NA	-0.5	-7.01	-0.53	1.39e-10	Iron status biomarkers;
TGCT	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg03709012	chr19:19516395	GATAD2A	-0.66	-5.7	-0.46	8.46e-8	Tonsillectomy;
TGCT	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg10047753	chr17:41438598	NA	0.64	5.77	0.46	6.06e-8	Menopause (age at onset);
TGCT	cis	rs28595532	1.000	rs75497896	chr4:119636703	T/C	cg14228332	chr4:119757509	SEC24D	1.04	5.37	0.43	3.66e-7	Cannabis dependence symptom count;
TGCT	cis	rs28595532	0.920	rs115706007	chr4:119733638	C/T	cg21605333	chr4:119757512	SEC24D	1.66	8.33	0.6	1.28e-13	Cannabis dependence symptom count;
TGCT	cis	rs6940638	0.615	rs9393801	chr6:27242681	A/G	cg11262757	chr6:27280423	POM121L2	0.53	4.56	0.38	1.19e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs66573146	0.901	rs55659111	chr4:7012338	G/T	cg01220768	chr4:7056774	TADA2B	0.44	5.07	0.41	1.38e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs6912958	0.754	rs7762864	chr6:88236213	A/G	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.91	-0.4	2.78e-6	Monocyte percentage of white cells;
TGCT	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg05872129	chr22:39784769	NA	0.93	10.21	0.68	3.83e-18	Intelligence (multi-trait analysis);
TGCT	cis	rs4555082	0.874	rs2142190	chr14:105719306	G/A	cg01266790	chr14:105781312	PACS2	0.55	4.51	0.38	1.49e-5	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs7584330	0.910	rs6713555	chr2:238398182	A/G	cg14458575	chr2:238380390	NA	-0.44	-5.74	-0.46	6.93e-8	Prostate cancer;
TGCT	cis	rs12142240	0.667	rs45524035	chr1:46862780	C/T	cg00530320	chr1:46809349	NSUN4	0.29	5.79	0.46	5.34e-8	Menopause (age at onset);
TGCT	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg18876405	chr7:65276391	NA	-0.36	-5.69	-0.45	8.79e-8	Aortic root size;
TGCT	cis	rs2688608	0.905	rs2633300	chr10:75656647	A/C	cg19442545	chr10:75533431	FUT11	-0.29	-4.71	-0.39	6.5e-6	Inflammatory bowel disease;
TGCT	cis	rs6988636	1.000	rs28537152	chr8:124189071	T/C	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs9611565	0.918	rs12484074	chr22:41752747	G/A	cg03806693	chr22:41940476	POLR3H	-1.18	-12.3	-0.74	3.18e-23	Vitiligo;
TGCT	cis	rs79149102	0.579	rs3812946	chr15:75288610	G/C	cg09165964	chr15:75287851	SCAMP5	-1.06	-5.63	-0.45	1.17e-7	Lung cancer;
TGCT	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg25036284	chr2:26402008	FAM59B	0.65	5.19	0.42	8.36e-7	Gut microbiome composition (summer);
TGCT	cis	rs6752107	0.936	rs10195395	chr2:234206504	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.21	4.71	0.39	6.47e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg25660036	chr4:7070649	GRPEL1	-0.67	-5.91	-0.47	3.15e-8	Monocyte percentage of white cells;
TGCT	cis	rs9902453	0.904	rs12952179	chr17:28412687	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-7.31	-0.55	2.88e-11	Coffee consumption (cups per day);
TGCT	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg03396347	chr1:1875803	NA	-0.35	-6.4	-0.5	2.95e-9	Body mass index;
TGCT	cis	rs4849845	0.653	rs34874174	chr2:121011980	A/C	cg24070213	chr2:121070622	NA	0.35	4.64	0.38	8.58e-6	Mean platelet volume;
TGCT	cis	rs12549025	0.530	rs11135740	chr8:23367757	A/G	cg00472375	chr8:23315376	ENTPD4	-0.62	-5.37	-0.43	3.72e-7	Reticulocyte fraction of red cells;
TGCT	cis	rs2836633	0.929	rs2836610	chr21:40044502	C/T	cg12884169	chr21:40033163	ERG	0.43	4.69	0.39	6.99e-6	Coronary artery disease;
TGCT	cis	rs6669072	0.590	rs10922922	chr1:91237055	G/A	cg08895590	chr1:91227319	NA	0.32	4.44	0.37	1.98e-5	Cognitive function;
TGCT	cis	rs7192750	0.586	rs4788447	chr16:71874860	C/T	cg06353428	chr16:71660113	MARVELD3	0.83	7.37	0.55	2.07e-11	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs9733	0.570	rs951281	chr1:150691122	A/C	cg04414720	chr1:150670196	GOLPH3L	0.37	4.91	0.4	2.76e-6	Tonsillectomy;
TGCT	cis	rs2288884	0.943	rs11671792	chr19:52581683	A/T	cg13540795	chr19:52551618	ZNF432	-0.6	-5.1	-0.42	1.25e-6	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs1018836	0.851	rs2023624	chr8:91618874	T/C	cg16814680	chr8:91681699	NA	-0.83	-8.73	-0.62	1.46e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10992471	0.630	rs10992322	chr9:95159196	A/G	cg14631576	chr9:95140430	CENPP	-0.27	-4.56	-0.38	1.22e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs77972916	0.609	rs72790907	chr2:43575195	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.39	-4.48	-0.37	1.65e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs910316	0.935	rs175448	chr14:75591071	G/A	cg11812906	chr14:75593930	NEK9	-0.73	-7.13	-0.54	7.35e-11	Height;
TGCT	cis	rs523522	0.885	rs524735	chr12:121022099	T/C	cg12219531	chr12:120966889	COQ5	0.82	7.38	0.55	2.05e-11	High light scatter reticulocyte count;
TGCT	cis	rs4252435	0.614	rs10270914	chr7:142596224	C/T	cg09833174	chr7:143059591	FAM131B	-0.96	-4.52	-0.38	1.41e-5	Cancer;
TGCT	cis	rs9486719	1.000	rs12210146	chr6:96903962	A/G	cg18709589	chr6:96969512	KIAA0776	0.68	5.05	0.41	1.55e-6	Migraine;Coronary artery disease;
TGCT	cis	rs8141529	0.748	rs132533	chr22:29299571	A/G	cg02153584	chr22:29168773	CCDC117	-0.64	-4.91	-0.4	2.87e-6	Lymphocyte counts;
TGCT	cis	rs10089	1.000	rs6887847	chr5:127473807	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	8.19	0.59	2.7e-13	Ileal carcinoids;
TGCT	cis	rs909002	0.800	rs3753612	chr1:32082410	C/G	cg11573219	chr1:32083031	HCRTR1	-0.43	-5.59	-0.45	1.41e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs763121	0.853	rs3788545	chr22:39065172	A/G	cg06022373	chr22:39101656	GTPBP1	0.76	7.52	0.56	9.49e-12	Menopause (age at onset);
TGCT	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.93	7.44	0.56	1.44e-11	Platelet count;
TGCT	cis	rs1322512	0.677	rs2695255	chr6:152926004	G/A	cg03415253	chr6:152958462	SYNE1	-0.55	-5.22	-0.42	7.33e-7	Tonometry;
TGCT	cis	rs8077889	0.826	rs60085355	chr17:41847415	T/C	cg26893861	chr17:41843967	DUSP3	1.09	13.68	0.78	1.57e-26	Triglycerides;
TGCT	trans	rs2727020	0.615	rs10128582	chr11:49447424	C/T	cg03929089	chr4:120376271	NA	-0.77	-9.03	-0.63	2.74e-15	Coronary artery disease;
TGCT	cis	rs7547997	0.858	rs9793907	chr1:158358405	A/G	cg07950803	chr1:158223934	CD1A	0.32	4.63	0.38	9.01e-6	QRS duration;
TGCT	cis	rs17433780	0.860	rs61798916	chr1:89493957	G/A	cg09516651	chr1:89888402	LOC400759	0.26	4.48	0.37	1.67e-5	Carotid intima media thickness;
TGCT	cis	rs9427116	0.502	rs9427100	chr1:154583762	G/A	cg17218026	chr1:154582156	ADAR	0.3	7.54	0.56	8.85e-12	Blood protein levels;
TGCT	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9549367	0.713	rs4907599	chr13:113861441	C/T	cg18105134	chr13:113819100	PROZ	0.46	8.57	0.61	3.49e-14	Platelet distribution width;
TGCT	cis	rs17433780	0.897	rs17434151	chr1:89500526	G/T	cg09516651	chr1:89888402	LOC400759	0.26	4.48	0.37	1.67e-5	Carotid intima media thickness;
TGCT	cis	rs7582180	0.764	rs1530028	chr2:100927910	A/C	cg08017756	chr2:100939284	LONRF2	-0.3	-4.91	-0.4	2.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs17108533	0.588	rs12886420	chr14:71301332	A/G	cg23900759	chr14:71108106	TTC9	-1.14	-4.61	-0.38	9.92e-6	Response to antipsychotic treatment in schizophrenia (reasoning);
TGCT	cis	rs2034088	0.833	rs9748016	chr17:410451	G/T	cg06217071	chr17:408420	NA	0.35	5.28	0.43	5.59e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs4900538	0.927	rs1190544	chr14:102903398	G/A	cg18135206	chr14:102964638	TECPR2	-0.22	-5.31	-0.43	4.81e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs2276314	1.000	rs4573997	chr18:33552568	C/T	cg05985134	chr18:33552581	C18orf21	0.56	4.93	0.4	2.57e-6	Endometriosis;Drug-induced torsades de pointes;
TGCT	cis	rs6967414	0.579	rs11980762	chr7:6756878	G/A	cg09896999	chr7:6746977	ZNF12	-0.59	-6.54	-0.51	1.45e-9	Hematocrit;Hemoglobin concentration;
TGCT	cis	rs7193541	0.673	rs12716769	chr16:74652537	T/C	cg01733217	chr16:74700730	RFWD3	0.99	13.69	0.78	1.46e-26	Multiple myeloma;
TGCT	cis	rs826838	1.000	rs826892	chr12:39100790	T/C	cg13010199	chr12:38710504	ALG10B	-0.59	-4.88	-0.4	3.25e-6	Heart rate;
TGCT	cis	rs13217239	0.646	rs12209886	chr6:26984757	G/A	cg15659132	chr6:26577336	NA	0.55	5.55	0.45	1.62e-7	Schizophrenia;
TGCT	cis	rs1532993	0.518	rs7669638	chr4:98640359	T/C	cg05340658	chr4:99064831	C4orf37	-0.41	-4.92	-0.4	2.72e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs7528684	0.816	rs1970265	chr1:157693714	G/C	cg17134153	chr1:157670328	FCRL3	-0.26	-4.68	-0.39	7.53e-6	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;
TGCT	cis	rs372883	0.563	rs1153293	chr21:30691325	C/T	cg24692254	chr21:30365293	RNF160	0.51	4.53	0.38	1.39e-5	Pancreatic cancer;
TGCT	cis	rs2637266	1.000	rs7896831	chr10:78366649	A/T	cg18941641	chr10:78392320	NA	0.39	4.88	0.4	3.24e-6	Pulmonary function;
TGCT	cis	rs9527	0.590	rs11191553	chr10:104851396	G/T	cg04362960	chr10:104952993	NT5C2	0.67	5.76	0.46	6.28e-8	Arsenic metabolism;
TGCT	cis	rs950169	0.922	rs17531523	chr15:85132449	C/G	cg17173187	chr15:85201210	NMB	0.47	4.99	0.41	1.97e-6	Schizophrenia;
TGCT	cis	rs11711311	1.000	rs2566963	chr3:113531849	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.7	6.72	0.52	5.98e-10	IgG glycosylation;
TGCT	cis	rs13242816	1.000	rs2052105	chr7:116187979	T/C	cg02799643	chr7:116139180	CAV2	-0.45	-5.55	-0.45	1.66e-7	P wave duration;
TGCT	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg20607798	chr8:58055168	NA	0.45	4.62	0.38	9.54e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9916302	0.904	rs8070695	chr17:37478062	C/T	cg07936489	chr17:37558343	FBXL20	0.62	4.97	0.41	2.16e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7246657	0.943	rs7252325	chr19:37930645	A/G	cg18154014	chr19:37997991	ZNF793	0.73	5.38	0.44	3.53e-7	Coronary artery calcification;
TGCT	cis	rs12900413	0.523	rs11636525	chr15:90300478	A/G	cg24249390	chr15:90295951	MESP1	-0.3	-5.2	-0.42	8.04e-7	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs2274273	0.653	rs1209087	chr14:55493220	C/T	cg01923255	chr14:55878535	KIAA0831	-0.57	-5.01	-0.41	1.82e-6	Protein biomarker;
TGCT	cis	rs78487399	0.808	rs77791126	chr2:43744050	G/A	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.78	4.84	0.4	3.8e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs7666738	0.791	rs7678564	chr4:99057341	A/G	cg17366294	chr4:99064904	C4orf37	0.73	7.45	0.56	1.4e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2354432	0.556	rs66501488	chr1:146853992	T/C	cg25205988	chr1:146714368	CHD1L	-1.34	-5.79	-0.46	5.52e-8	Mitochondrial DNA levels;
TGCT	cis	rs56104184	0.775	rs73061697	chr19:49400000	C/T	cg17863274	chr19:49399704	TULP2	-0.54	-7.43	-0.55	1.58e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs2933343	1.000	rs1680784	chr3:128644458	A/G	cg11901034	chr3:128598214	ACAD9	-0.63	-5.13	-0.42	1.08e-6	IgG glycosylation;
TGCT	cis	rs3806843	0.966	rs4141841	chr5:140203432	C/T	cg19875535	chr5:140030758	IK	0.37	6.16	0.48	9.55e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg05368731	chr17:41323189	NBR1	1.1	11.24	0.71	1.23e-20	Menopause (age at onset);
TGCT	cis	rs9915657	0.840	rs10512582	chr17:70139393	A/C	cg06234051	chr17:70120541	SOX9	-0.25	-5.09	-0.42	1.3e-6	Thyroid hormone levels;
TGCT	cis	rs7267979	1.000	rs761025	chr20:25426968	G/A	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1903068	0.853	rs12505096	chr4:56006102	C/A	cg16572876	chr4:56024045	NA	0.46	5.01	0.41	1.83e-6	Endometriosis;
TGCT	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs739496	0.579	rs2285695	chr12:112375308	T/G	cg10833066	chr12:111807467	FAM109A	0.38	5.61	0.45	1.24e-7	Platelet count;
TGCT	cis	rs9911578	0.967	rs686425	chr17:56776730	A/G	cg05425664	chr17:57184151	TRIM37	-0.63	-6.26	-0.49	5.86e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs4972806	0.668	rs2072588	chr2:177042930	G/C	cg03152288	chr2:177042942	NA	0.65	5.69	0.46	8.63e-8	IgG glycosylation;
TGCT	cis	rs11864453	0.713	rs7190995	chr16:72124157	A/G	cg14768367	chr16:72042858	DHODH	0.5	4.8	0.4	4.5e-6	Fibrinogen levels;
TGCT	cis	rs548181	0.611	rs609200	chr11:125383808	G/A	cg03464685	chr11:125439445	EI24	-1.63	-11.43	-0.72	4.29e-21	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs3733585	0.648	rs35954357	chr4:9978758	G/C	cg00071950	chr4:10020882	SLC2A9	0.57	6.68	0.51	7.18e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg20999797	chr1:1681921	NA	0.18	4.61	0.38	9.72e-6	Body mass index;
TGCT	cis	rs3617	0.573	rs3821873	chr3:52913006	C/T	cg10802521	chr3:52805072	NEK4	0.56	6.33	0.49	4.09e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.01	8.32	0.6	1.34e-13	Platelet count;
TGCT	cis	rs11711311	1.000	rs13070720	chr3:113473754	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.72	-6.74	-0.52	5.36e-10	IgG glycosylation;
TGCT	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg19901468	chr14:105411992	AHNAK2	-0.28	-6.09	-0.48	1.31e-8	Rheumatoid arthritis;
TGCT	cis	rs8177253	0.633	rs10935073	chr3:133439184	T/C	cg01448562	chr3:133502909	NA	-0.26	-4.94	-0.41	2.46e-6	Iron status biomarkers;
TGCT	cis	rs9660992	0.573	rs1172147	chr1:205225457	G/A	cg00857998	chr1:205179979	DSTYK	0.51	4.56	0.38	1.21e-5	Mean corpuscular volume;Mean platelet volume;
TGCT	trans	rs1814175	0.702	rs4881644	chr11:49786367	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.38	-7.76	-0.57	2.75e-12	Height;
TGCT	cis	rs1949733	0.877	rs940133	chr4:8473614	T/C	cg11789530	chr4:8429930	ACOX3	0.65	5.61	0.45	1.24e-7	Response to antineoplastic agents;
TGCT	cis	rs3099143	1.000	rs2063542	chr15:77149498	A/G	cg21673338	chr15:77095150	SCAPER	-0.52	-5.05	-0.41	1.54e-6	Recalcitrant atopic dermatitis;
TGCT	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg11764359	chr7:65958608	NA	0.61	5.54	0.45	1.76e-7	Aortic root size;
TGCT	cis	rs9902453	0.765	rs2250320	chr17:28128657	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.83	-7.95	-0.58	9.99e-13	Coffee consumption (cups per day);
TGCT	cis	rs4727027	0.933	rs757738	chr7:148872351	T/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	4.69	0.39	7.23e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs17764205	0.777	rs4807434	chr19:3259054	G/T	cg18738857	chr19:3606974	TBXA2R	-0.74	-4.54	-0.38	1.31e-5	Bipolar disorder and schizophrenia;
TGCT	cis	rs9467773	0.620	rs2494701	chr6:26634432	C/T	cg11502198	chr6:26597334	ABT1	0.54	4.97	0.41	2.14e-6	Intelligence (multi-trait analysis);
TGCT	trans	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg21659725	chr3:3221576	CRBN	0.98	15.33	0.81	2.1000000000000002e-30	Intelligence (multi-trait analysis);
TGCT	cis	rs13188771	0.690	rs72660735	chr5:100886099	A/T	cg18665594	chr5:101119420	NA	0.45	4.5	0.37	1.54e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs36051895	0.632	rs117896567	chr9:5141281	C/G	cg02405213	chr9:5042618	JAK2	-0.7	-9.44	-0.65	2.91e-16	Pediatric autoimmune diseases;
TGCT	cis	rs12477438	0.520	rs10865029	chr2:99718298	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	17.43	0.84	3.73e-35	Chronic sinus infection;
TGCT	cis	rs2178146	0.535	rs4843944	chr16:86443965	C/G	cg11165158	chr16:86613094	FOXL1	0.36	4.71	0.39	6.63e-6	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Esophageal adenocarcinoma;
TGCT	cis	rs8014204	0.575	rs1045430	chr14:75130235	T/G	cg06637938	chr14:75390232	RPS6KL1	0.64	5.88	0.47	3.57e-8	Caffeine consumption;
TGCT	trans	rs7726839	0.561	rs56410216	chr5:583216	C/A	cg25482853	chr8:67687455	SGK3	1.07	8.9	0.62	5.55e-15	Obesity-related traits;
TGCT	cis	rs1401999	0.690	rs6773408	chr3:183716609	G/T	cg01324343	chr3:183735012	ABCC5	0.74	9.11	0.63	1.82e-15	Anterior chamber depth;
TGCT	cis	rs57590327	0.555	rs3821551	chr3:81710179	A/T	cg07356753	chr3:81810745	GBE1	-0.77	-7.03	-0.53	1.22e-10	Extraversion;
TGCT	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg22963979	chr7:1858916	MAD1L1	-0.41	-6.6	-0.51	1.06e-9	Bipolar disorder and schizophrenia;
TGCT	cis	rs9467773	0.596	rs2494693	chr6:26619226	T/C	cg26531700	chr6:26746687	NA	0.52	5.01	0.41	1.8e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9915657	0.933	rs4793272	chr17:70139257	A/T	cg06234051	chr17:70120541	SOX9	-0.25	-4.88	-0.4	3.22e-6	Thyroid hormone levels;
TGCT	cis	rs67311347	1.000	rs11716675	chr3:40485280	G/T	cg13683864	chr3:40499215	RPL14	-1.04	-10.79	-0.7	1.54e-19	Renal cell carcinoma;
TGCT	cis	rs17767294	0.708	rs72848785	chr6:27977603	T/G	cg08851530	chr6:28072375	NA	1.56	7.22	0.54	4.47e-11	Parkinson's disease;
TGCT	cis	rs13256369	1.000	rs12550458	chr8:8567832	G/A	cg18904891	chr8:8559673	CLDN23	0.59	5.52	0.44	1.93e-7	Obesity-related traits;
TGCT	cis	rs7513165	0.551	rs11571077	chr1:204134822	G/A	cg12731349	chr1:204159619	KISS1	0.48	4.79	0.4	4.68e-6	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
TGCT	cis	rs2380220	0.541	rs9285413	chr6:96023439	G/A	cg04719120	chr6:96025338	MANEA	0.73	5.48	0.44	2.31e-7	Behavioural disinhibition (generation interaction);
TGCT	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg11644478	chr21:40555479	PSMG1	1.03	11.02	0.7	4.14e-20	Cognitive function;
TGCT	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg17971929	chr21:40555470	PSMG1	-0.54	-4.88	-0.4	3.26e-6	Menarche (age at onset);
TGCT	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg05985448	chr10:134359359	INPP5A	0.22	4.73	0.39	6e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs7226408	0.842	rs62083176	chr18:34324695	G/A	cg06757138	chr18:34340585	FHOD3	0.27	4.79	0.4	4.59e-6	Obesity-related traits;
TGCT	cis	rs67478160	0.643	rs3818085	chr14:104215985	C/T	cg26031613	chr14:104095156	KLC1	-0.63	-6.53	-0.51	1.56e-9	Schizophrenia;
TGCT	cis	rs6964587	1.000	rs12540055	chr7:91707921	A/G	cg17063962	chr7:91808500	NA	0.9	9.96	0.67	1.57e-17	Breast cancer;
TGCT	cis	rs9911578	0.967	rs2567892	chr17:56668929	T/C	cg12560992	chr17:57184187	TRIM37	0.76	9.34	0.64	4.88e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9372498	0.572	rs62422190	chr6:118909235	A/G	cg21191810	chr6:118973309	C6orf204	-0.39	-5.14	-0.42	1.02e-6	Diastolic blood pressure;
TGCT	cis	rs10504229	1.000	rs59843034	chr8:58195756	T/G	cg21724239	chr8:58056113	NA	0.38	4.76	0.39	5.41e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg22920501	chr2:26401640	FAM59B	-0.81	-6.36	-0.5	3.52e-9	Gut microbiome composition (summer);
TGCT	cis	rs4727027	0.769	rs10952797	chr7:148816722	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	4.64	0.38	8.88e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs17665859	0.844	rs6980614	chr8:447844	G/A	cg17960703	chr8:356704	FBXO25	1.35	5.22	0.42	7.35e-7	Bilirubin levels;
TGCT	cis	rs67311347	0.668	rs73071710	chr3:40288587	A/G	cg13683864	chr3:40499215	RPL14	-0.84	-7.91	-0.58	1.2e-12	Renal cell carcinoma;
TGCT	cis	rs7666738	0.830	rs7687315	chr4:98900613	A/G	cg17366294	chr4:99064904	C4orf37	0.67	6.83	0.52	3.3e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg06221963	chr1:154839813	KCNN3	-0.7	-11.66	-0.72	1.16e-21	Prostate cancer;
TGCT	cis	rs2486012	1.000	rs61770289	chr1:44363710	T/C	cg12908607	chr1:44402522	ARTN	0.71	5.86	0.47	3.87e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs6121246	0.697	rs6060912	chr20:30325755	C/A	cg13852791	chr20:30311386	BCL2L1	0.8	6.12	0.48	1.15e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs56235845	0.694	rs11748912	chr5:176765395	G/A	cg06060754	chr5:176797920	RGS14	0.4	6.33	0.49	3.99e-9	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs2832191	0.933	rs2832236	chr21:30547602	C/T	cg24692254	chr21:30365293	RNF160	-0.7	-6.95	-0.53	1.85e-10	Dental caries;
TGCT	cis	rs6087771	0.650	rs6060395	chr20:30219823	G/C	cg21427119	chr20:30132790	HM13	-0.3	-5.15	-0.42	9.81e-7	Subcortical brain region volumes;Putamen volume;
TGCT	cis	rs9858542	0.953	rs3811697	chr3:49590770	C/T	cg03060546	chr3:49711283	APEH	-0.61	-5.37	-0.43	3.78e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg21963583	chr11:68658836	MRPL21	0.36	6.03	0.48	1.74e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9788682	1.000	rs7163730	chr15:78814681	A/G	cg24631222	chr15:78858424	CHRNA5	0.89	7.68	0.57	4.22e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg21724239	chr8:58056113	NA	0.42	4.63	0.38	8.93e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2541522	0.600	rs62025788	chr16:10746045	C/T	cg21839338	chr16:10912331	FAM18A	0.41	4.67	0.39	7.71e-6	Gut microbiome composition (summer);
TGCT	cis	rs7394190	0.748	rs11000777	chr10:75545063	G/C	cg07699608	chr10:75541558	CHCHD1	0.79	5.44	0.44	2.72e-7	Incident atrial fibrillation;
TGCT	cis	rs7312933	0.558	rs11181467	chr12:42765250	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.54	5.14	0.42	1.03e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs4389656	0.857	rs274719	chr5:6720916	A/G	cg10857441	chr5:6722123	POLS	-0.22	-4.85	-0.4	3.68e-6	Coronary artery disease;
TGCT	cis	rs1577917	1.000	rs35761942	chr6:86629504	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-5.36	-0.43	3.86e-7	Response to antipsychotic treatment;
TGCT	trans	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg23505145	chr19:12996616	KLF1	0.84	9.12	0.63	1.68e-15	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2735413	0.564	rs73580826	chr16:78110889	G/T	cg09132178	chr16:78079569	NA	0.37	4.8	0.4	4.4e-6	Systolic blood pressure (alcohol consumption interaction);
TGCT	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs1483890	0.642	rs1843049	chr3:69404078	T/C	cg22125112	chr3:69402811	FRMD4B	0.28	4.66	0.39	7.99e-6	Resting heart rate;
TGCT	cis	rs796364	0.806	rs6435041	chr2:200867144	A/G	cg17644776	chr2:200775616	C2orf69	0.33	5.0	0.41	1.91e-6	Schizophrenia;
TGCT	trans	rs561341	1.000	rs530715	chr17:30320544	T/G	cg20587970	chr11:113659929	NA	-1.05	-12.74	-0.75	2.84e-24	Hip circumference adjusted for BMI;
TGCT	cis	rs6570726	0.693	rs450921	chr6:145864260	C/T	cg05347473	chr6:146136440	FBXO30	0.54	5.15	0.42	1.01e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg18188782	chr20:61659543	NA	0.44	5.38	0.43	3.6e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7223966	1.000	rs9908044	chr17:61747032	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	5.05	0.41	1.51e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs3125734	0.633	rs4979773	chr10:63967731	G/C	cg19640130	chr10:64028056	RTKN2	-0.4	-5.21	-0.42	7.77e-7	Rheumatoid arthritis;
TGCT	cis	rs12477438	0.765	rs6740054	chr2:99576631	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.56	-4.9	-0.4	2.95e-6	Chronic sinus infection;
TGCT	cis	rs9325144	0.560	rs11183046	chr12:38655270	A/T	cg26384229	chr12:38710491	ALG10B	-0.66	-6.0	-0.47	2.06e-8	Morning vs. evening chronotype;
TGCT	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg25036284	chr2:26402008	FAM59B	-0.63	-5.09	-0.42	1.29e-6	Gut microbiome composition (summer);
TGCT	cis	rs806215	1.000	rs712698	chr7:127249098	C/T	cg25922125	chr7:127225783	GCC1	0.59	5.98	0.47	2.21e-8	Type 2 diabetes;
TGCT	cis	rs986417	1.000	rs6573312	chr14:60952536	G/T	cg27398547	chr14:60952738	C14orf39	1.39	10.61	0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	trans	rs208520	0.837	rs208498	chr6:66931560	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-9.93	-0.67	1.84e-17	Exhaled nitric oxide output;
TGCT	cis	rs881375	0.715	rs11794516	chr9:123640230	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	5.34	0.43	4.23e-7	Rheumatoid arthritis;
TGCT	cis	rs9341808	0.718	rs9448898	chr6:80845341	T/A	cg08355045	chr6:80787529	NA	0.32	5.83	0.46	4.48e-8	Sitting height ratio;
TGCT	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9549367	0.713	rs4907593	chr13:113830459	C/T	cg00898013	chr13:113819073	PROZ	0.55	7.3	0.55	3.03e-11	Platelet distribution width;
TGCT	cis	rs514406	0.683	rs10157120	chr1:53210888	A/G	cg16325326	chr1:53192061	ZYG11B	0.89	13.41	0.77	6.6900000000000006e-26	Monocyte count;
TGCT	cis	rs6061231	0.631	rs2427318	chr20:60975727	G/T	cg15674680	chr20:60982522	CABLES2	0.57	5.01	0.41	1.86e-6	Colorectal cancer;
TGCT	cis	rs2404602	0.692	rs12910734	chr15:77149931	A/G	cg22467129	chr15:76604101	ETFA	-0.47	-5.4	-0.44	3.26e-7	Blood metabolite levels;
TGCT	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg22535103	chr8:58192502	C8orf71	-0.42	-4.72	-0.39	6.36e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg13699009	chr12:122356056	WDR66	0.29	5.73	0.46	7.13e-8	Mean corpuscular volume;
TGCT	cis	rs67478160	0.583	rs12879612	chr14:104233618	T/A	cg26031613	chr14:104095156	KLC1	-0.63	-6.42	-0.5	2.66e-9	Schizophrenia;
TGCT	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.69	-5.47	-0.44	2.41e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2235642	0.750	rs2974845	chr16:1648162	T/C	cg08296037	chr16:1584118	IFT140;TMEM204	-0.28	-4.77	-0.39	5.1e-6	Coronary artery disease;
TGCT	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg13607699	chr17:42295918	UBTF	-0.59	-5.38	-0.43	3.65e-7	Total body bone mineral density;
TGCT	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg25036284	chr2:26402008	FAM59B	-0.57	-4.97	-0.41	2.15e-6	Gut microbiome composition (summer);
TGCT	cis	rs1497406	0.744	rs7538966	chr1:16504549	T/C	cg20430773	chr1:16534157	ARHGEF19	0.52	5.77	0.46	6.06e-8	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs78456975	0.527	rs7590742	chr2:1575049	A/T	cg12573674	chr2:1569213	NA	-0.46	-5.2	-0.42	7.88e-7	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs1008375	0.868	rs6816286	chr4:17698088	A/G	cg10189774	chr4:17578691	LAP3	0.53	4.48	0.37	1.68e-5	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs751728	0.664	rs6929696	chr6:33759290	C/T	cg13859433	chr6:33739653	LEMD2	0.34	6.03	0.48	1.76e-8	Crohn's disease;
TGCT	cis	rs35883536	1.000	rs12566507	chr1:101089679	T/A	cg06223162	chr1:101003688	GPR88	0.29	4.56	0.38	1.19e-5	Monocyte count;
TGCT	cis	rs7809950	1.000	rs2237676	chr7:107198079	C/A	cg23024343	chr7:107201750	COG5	-0.34	-5.26	-0.43	6.08e-7	Coronary artery disease;
TGCT	cis	rs6121246	0.609	rs2377317	chr20:30402502	A/G	cg10886678	chr20:30946050	ASXL1	0.56	4.66	0.39	8.07e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg07061783	chr6:25882402	NA	0.72	7.4	0.55	1.8e-11	Blood metabolite levels;
TGCT	cis	rs362272	0.524	rs3129334	chr4:3368526	T/C	cg06533319	chr4:3265114	C4orf44	-0.25	-5.22	-0.42	7.43e-7	Serum sulfate level;
TGCT	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg04234412	chr22:24373322	LOC391322	-0.91	-10.69	-0.69	2.69e-19	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9611565	0.532	rs4401299	chr22:42156517	A/G	cg13695892	chr22:41940480	POLR3H	0.81	7.62	0.56	5.82e-12	Vitiligo;
TGCT	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.94	7.92	0.58	1.17e-12	Platelet count;
TGCT	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg06028605	chr16:24865363	SLC5A11	0.41	4.58	0.38	1.13e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs903263	1.000	rs2134647	chr1:84678418	C/T	cg09664975	chr1:84543551	PRKACB	0.49	4.69	0.39	7.05e-6	Breast cancer (male);
TGCT	cis	rs7260538	0.773	rs2200238	chr19:41527265	G/A	cg20630647	chr19:41531805	NA	0.32	5.02	0.41	1.74e-6	DDT metabolite (p,p'-DDE levels);
TGCT	cis	rs2535633	0.631	rs2336670	chr3:52998504	T/G	cg05573699	chr3:52720067	GNL3;PBRM1	0.55	5.16	0.42	9.33e-7	Body mass index;
TGCT	cis	rs713587	0.624	rs1550110	chr2:25124563	T/C	cg01884057	chr2:25150051	NA	0.35	6.9	0.53	2.39e-10	Body mass index in non-asthmatics;
TGCT	cis	rs9467773	0.620	rs2494696	chr6:26620894	A/G	cg09904177	chr6:26538194	HMGN4	0.66	6.33	0.49	3.99e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs74233809	0.534	rs284841	chr10:104550079	G/A	cg05855489	chr10:104503620	C10orf26	-0.76	-5.24	-0.43	6.78e-7	Birth weight;
TGCT	cis	rs67311347	0.955	rs11711994	chr3:40391086	T/C	cg17264618	chr3:40429014	ENTPD3	0.32	4.59	0.38	1.05e-5	Renal cell carcinoma;
TGCT	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg08280861	chr8:58055591	NA	0.36	4.91	0.4	2.77e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs73099903	0.611	rs10876400	chr12:53436855	T/C	cg24505307	chr12:53448429	TENC1	0.36	4.71	0.39	6.56e-6	Systolic blood pressure;
TGCT	cis	rs10256972	0.630	rs10282584	chr7:1081442	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.44	-5.04	-0.41	1.61e-6	Longevity;Endometriosis;
TGCT	cis	rs6893807	1.000	rs1422191	chr5:87949158	G/A	cg24804195	chr5:87968844	LOC645323	0.76	5.64	0.45	1.09e-7	Body mass index;
TGCT	trans	rs2469997	1.000	rs2470016	chr8:120361220	T/G	cg01792902	chr3:178864926	PIK3CA	0.83	6.77	0.52	4.49e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs2072499	0.750	rs7534339	chr1:156156219	A/G	cg24450063	chr1:156163899	SLC25A44	1.09	10.01	0.67	1.19e-17	Testicular germ cell tumor;
TGCT	cis	rs9611565	0.506	rs7364221	chr22:41650190	C/A	cg13695892	chr22:41940480	POLR3H	-0.63	-5.84	-0.46	4.28e-8	Vitiligo;
TGCT	trans	rs3824451	1.000	rs10985825	chr9:101072843	C/T	cg11574975	chr1:112058304	ADORA3	-0.42	-6.66	-0.51	7.91e-10	Schizophrenia;
TGCT	cis	rs4722166	0.630	rs2091115	chr7:22810166	G/T	cg23864514	chr7:22882512	NA	0.21	4.57	0.38	1.16e-5	Lung cancer;
TGCT	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg17554472	chr22:41940697	POLR3H	-0.46	-4.74	-0.39	5.83e-6	Vitiligo;
TGCT	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg11494091	chr17:61959527	GH2	0.6	13.99	0.78	2.88e-27	Prudent dietary pattern;
TGCT	cis	rs2242194	0.844	rs11264295	chr1:154987526	C/T	cg06221963	chr1:154839813	KCNN3	-0.51	-6.38	-0.5	3.13e-9	Schizophrenia;
TGCT	cis	rs6840360	0.593	rs6847844	chr4:152693246	C/T	cg22705602	chr4:152727874	NA	-0.34	-5.9	-0.47	3.24e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs11190604	1.000	rs11816840	chr10:102309220	G/C	cg23241863	chr10:102295624	HIF1AN	0.68	5.13	0.42	1.08e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs6987853	0.830	rs9643888	chr8:42352007	T/C	cg20539142	chr8:42623718	CHRNA6	0.19	4.52	0.38	1.44e-5	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs7044106	0.791	rs10760116	chr9:123494681	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	7.29	0.55	3.24e-11	Hip circumference adjusted for BMI;
TGCT	cis	rs34421088	0.548	rs2618443	chr8:11384556	A/G	cg21775007	chr8:11205619	TDH	-0.49	-4.59	-0.38	1.09e-5	Neuroticism;
TGCT	cis	rs13256369	0.760	rs7816171	chr8:8575835	T/C	cg06671706	chr8:8559999	CLDN23	0.35	4.62	0.38	9.35e-6	Obesity-related traits;
TGCT	cis	rs8056742	0.642	rs34776984	chr16:85037574	C/G	cg00229868	chr16:85520891	NA	0.37	4.76	0.39	5.33e-6	Amyotrophic lateral sclerosis;
TGCT	cis	rs7666738	0.830	rs1593573	chr4:98925293	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1865760	0.532	rs1061482	chr6:26086699	G/T	cg16482183	chr6:26056742	HIST1H1C	0.57	4.95	0.41	2.39e-6	Height;
TGCT	cis	rs36405	1.000	rs36410	chr14:72356580	C/A	cg10066683	chr14:71515513	PCNX	0.24	4.45	0.37	1.87e-5	Yang-deficiency constitution;
TGCT	cis	rs7666738	0.791	rs10022061	chr4:98926821	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs76878669	0.538	rs73489638	chr11:66127639	C/T	cg18002602	chr11:66138449	SLC29A2	-0.54	-6.62	-0.51	9.76e-10	Educational attainment (years of education);
TGCT	cis	rs7246657	0.722	rs6508736	chr19:38061757	A/G	cg18154014	chr19:37997991	ZNF793	0.69	4.63	0.38	9.25e-6	Coronary artery calcification;
TGCT	cis	rs4919044	0.808	rs2486687	chr10:94778283	T/C	cg05127821	chr10:94822908	CYP26C1	-0.77	-5.03	-0.41	1.71e-6	Coronary artery disease;
TGCT	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.47	-0.5	2.01e-9	Alzheimer's disease;
TGCT	cis	rs2153535	0.580	rs2327050	chr6:8440630	A/G	cg07606381	chr6:8435919	SLC35B3	0.57	5.25	0.43	6.46e-7	Motion sickness;
TGCT	cis	rs62380364	0.602	rs650702	chr5:88055313	G/A	cg22951263	chr5:87985283	NA	-0.59	-6.32	-0.49	4.3e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs60843830	1.000	rs62114501	chr2:231741	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.77	7.78	0.57	2.49e-12	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	trans	rs8073060	0.544	rs225274	chr17:33971221	C/T	cg19694781	chr19:47549865	TMEM160	0.6	13.37	0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs425277	0.561	rs925906	chr1:2044054	A/C	cg24578937	chr1:2090814	PRKCZ	-0.24	-5.78	-0.46	5.78e-8	Height;
TGCT	cis	rs9733	0.628	rs7540874	chr1:150702663	A/C	cg04414720	chr1:150670196	GOLPH3L	0.37	4.91	0.4	2.76e-6	Tonsillectomy;
TGCT	cis	rs40363	0.857	rs55989968	chr16:3530658	C/G	cg00484396	chr16:3507460	NAT15	0.42	5.03	0.41	1.64e-6	Tuberculosis;
TGCT	cis	rs1008375	1.000	rs6819132	chr4:17689752	G/T	cg16339924	chr4:17578868	LAP3	-0.61	-4.81	-0.4	4.33e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs8017423	0.967	rs4904657	chr14:90721600	A/G	cg04374321	chr14:90722782	PSMC1	0.76	7.71	0.57	3.59e-12	Mortality in heart failure;
TGCT	cis	rs319204	1.000	rs223100	chr5:146229816	C/G	cg25021259	chr5:146258546	PPP2R2B	-0.36	-4.57	-0.38	1.17e-5	Schizophrenia;
TGCT	trans	rs13270892	0.556	rs57487396	chr8:20469493	C/T	cg26117265	chr10:49674348	ARHGAP22	-0.62	-6.64	-0.51	8.74e-10	Daytime sleep phenotypes;
TGCT	cis	rs9611565	0.592	rs5996038	chr22:41965300	T/C	cg06634786	chr22:41940651	POLR3H	-0.88	-8.25	-0.6	1.98e-13	Vitiligo;
TGCT	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.75	5.41	0.44	3.09e-7	Platelet count;
TGCT	cis	rs8180040	0.620	rs2278963	chr3:47054869	G/T	cg27129171	chr3:47204927	SETD2	-0.71	-8.32	-0.6	1.32e-13	Colorectal cancer;
TGCT	cis	rs6424115	0.830	rs2502999	chr1:24198321	A/G	cg15997130	chr1:24165203	NA	0.86	9.53	0.65	1.76e-16	Immature fraction of reticulocytes;
TGCT	cis	rs6121246	0.908	rs6089094	chr20:30431771	C/T	cg13852791	chr20:30311386	BCL2L1	0.76	5.67	0.45	9.7e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	6.75	0.52	5.02e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs763014	0.898	rs8050792	chr16:656033	T/C	cg27436995	chr16:743998	FBXL16	-0.45	-4.92	-0.4	2.64e-6	Height;
TGCT	cis	rs6671200	1.000	rs71654417	chr1:95661200	G/A	cg03123541	chr1:95699097	RWDD3	0.87	6.17	0.48	8.81e-9	Stearic acid (18:0) levels;
TGCT	cis	rs7267979	0.866	rs6138609	chr20:25570985	T/A	cg14121845	chr20:25566513	NINL	0.49	5.31	0.43	4.97e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7647973	0.922	rs7620024	chr3:49451691	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.57	-4.59	-0.38	1.07e-5	Menarche (age at onset);
TGCT	cis	rs3733585	0.579	rs4235356	chr4:10123106	G/C	cg00071950	chr4:10020882	SLC2A9	-0.51	-5.29	-0.43	5.31e-7	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs13256369	0.708	rs11249886	chr8:8562021	T/A	cg18904891	chr8:8559673	CLDN23	0.58	5.34	0.43	4.27e-7	Obesity-related traits;
TGCT	cis	rs2439831	0.867	rs12324572	chr15:43636200	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	8.65	0.61	2.26e-14	Lung cancer in ever smokers;
TGCT	cis	rs3125734	0.633	rs12217669	chr10:63988456	A/G	cg19640130	chr10:64028056	RTKN2	0.4	5.08	0.42	1.33e-6	Rheumatoid arthritis;
TGCT	cis	rs3749237	0.964	rs11714957	chr3:49776178	C/T	cg10152585	chr3:50297680	NA	0.5	4.65	0.39	8.38e-6	Resting heart rate;
TGCT	cis	rs1056107	0.931	rs7847972	chr9:114976870	C/T	cg02332936	chr9:115140584	NA	0.28	4.81	0.4	4.35e-6	Colorectal cancer;
TGCT	cis	rs12286929	0.651	rs12274772	chr11:115098768	C/T	cg16269184	chr11:114127960	NA	-0.19	-4.45	-0.37	1.91e-5	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs11252926	0.563	rs10904173	chr10:462885	G/A	cg20256804	chr10:444983	DIP2C	0.23	4.91	0.4	2.83e-6	Psychosis in Alzheimer's disease;
TGCT	cis	rs9457247	1.000	rs2757047	chr6:167374489	C/T	cg25258033	chr6:167368657	RNASET2	-0.18	-4.48	-0.37	1.65e-5	Crohn's disease;
TGCT	trans	rs7618501	0.521	rs6774354	chr3:49961780	G/A	cg21659725	chr3:3221576	CRBN	0.72	8.08	0.59	4.98e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs3771570	1.000	rs57196672	chr2:242235193	G/A	cg21155796	chr2:242212141	HDLBP	0.98	6.68	0.51	7.29e-10	Prostate cancer;
TGCT	cis	rs2404602	0.692	rs8037005	chr15:76951109	C/T	cg22467129	chr15:76604101	ETFA	-0.45	-5.11	-0.42	1.18e-6	Blood metabolite levels;
TGCT	cis	rs10791323	0.660	rs2156681	chr11:133731644	G/T	cg15485101	chr11:133734466	NA	0.37	4.97	0.41	2.19e-6	Childhood ear infection;
TGCT	cis	rs7584330	0.740	rs11891348	chr2:238440449	T/G	cg14458575	chr2:238380390	NA	0.34	4.76	0.39	5.32e-6	Prostate cancer;
TGCT	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	7.37	0.55	2.11e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7246657	0.722	rs1291	chr19:38229378	G/A	cg18154014	chr19:37997991	ZNF793	-0.7	-4.94	-0.41	2.47e-6	Coronary artery calcification;
TGCT	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg23248424	chr5:179741104	GFPT2	-0.38	-7.0	-0.53	1.41e-10	Height;
TGCT	cis	rs933688	0.938	rs6869048	chr5:90664322	G/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	9.32	0.64	5.44e-16	Smoking behavior;
TGCT	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg21963583	chr11:68658836	MRPL21	0.38	6.24	0.49	6.45e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7255045	0.582	rs4804209	chr19:12985955	G/C	cg23899408	chr19:12877188	HOOK2	-0.61	-4.94	-0.41	2.52e-6	Mean corpuscular volume;
TGCT	cis	rs2115630	0.905	rs6496401	chr15:85297793	A/T	cg11189052	chr15:85197271	WDR73	-0.63	-6.04	-0.48	1.67e-8	P wave terminal force;
TGCT	cis	rs2404602	0.583	rs4381566	chr15:76589262	A/G	cg26408565	chr15:76604113	ETFA	-0.45	-6.35	-0.5	3.66e-9	Blood metabolite levels;
TGCT	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg17971929	chr21:40555470	PSMG1	0.96	8.86	0.62	6.96e-15	Cognitive function;
TGCT	cis	rs739496	0.694	rs7296651	chr12:112246954	C/G	cg10833066	chr12:111807467	FAM109A	-0.38	-5.67	-0.45	9.69e-8	Platelet count;
TGCT	cis	rs7226408	0.857	rs11662124	chr18:34728434	T/C	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs2050392	0.590	rs17547917	chr10:30718303	G/A	cg13289132	chr10:30722225	MAP3K8	-0.46	-5.57	-0.45	1.47e-7	Inflammatory bowel disease;
TGCT	trans	rs66573146	0.831	rs1048009	chr4:6988677	G/A	cg07817883	chr1:32538562	TMEM39B	1.29	6.94	0.53	1.97e-10	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs9926296	0.656	rs11861084	chr16:89875710	G/T	cg21285383	chr16:89894308	SPIRE2	-0.35	-4.78	-0.39	4.79e-6	Vitiligo;
TGCT	cis	rs6964587	0.869	rs2013334	chr7:91549657	G/A	cg17063962	chr7:91808500	NA	-0.86	-9.28	-0.64	6.82e-16	Breast cancer;
TGCT	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg18876405	chr7:65276391	NA	0.31	4.78	0.39	4.81e-6	Aortic root size;
TGCT	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg06634786	chr22:41940651	POLR3H	-0.91	-8.79	-0.62	1.02e-14	Vitiligo;
TGCT	cis	rs2204008	0.837	rs11611861	chr12:38357459	A/G	cg26384229	chr12:38710491	ALG10B	0.83	7.27	0.55	3.51e-11	Bladder cancer;
TGCT	cis	rs6835098	1.000	rs9990666	chr4:174083150	G/T	cg08422745	chr4:174089978	GALNT7	-0.93	-10.95	-0.7	6.1e-20	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs7267979	0.816	rs374701	chr20:25483616	A/G	cg03522245	chr20:25566470	NINL	0.56	5.79	0.46	5.51e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6121246	0.909	rs6119651	chr20:30259246	G/T	cg18721089	chr20:30220636	NA	-0.44	-4.79	-0.39	4.75e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs1538970	0.924	rs11211111	chr1:45908782	C/T	cg05343316	chr1:45956843	TESK2	0.76	6.19	0.49	7.93e-9	Platelet count;
TGCT	cis	rs3862260	0.509	rs3795662	chr1:120165135	G/T	cg16322792	chr1:120165303	ZNF697	0.35	8.4	0.6	8.92e-14	Systemic lupus erythematosus;
TGCT	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg27121462	chr16:89883253	FANCA	0.79	8.57	0.61	3.44e-14	Vitiligo;
TGCT	cis	rs68170813	0.559	rs3823959	chr7:107009379	T/G	cg02696742	chr7:106810147	HBP1	-0.7	-5.7	-0.46	8.16e-8	Coronary artery disease;
TGCT	cis	rs7208859	0.623	rs9912283	chr17:29110373	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg03609598	chr5:56110824	MAP3K1	-0.59	-4.78	-0.39	4.81e-6	Initial pursuit acceleration;
TGCT	cis	rs9677476	0.516	rs11893395	chr2:232022981	G/A	cg07929768	chr2:232055508	NA	0.33	5.21	0.42	7.7300000000000005e-07	Food antigen IgG levels;
TGCT	cis	rs9611565	0.918	rs9538	chr22:41755857	G/T	cg03806693	chr22:41940476	POLR3H	-1.15	-13.26	-0.77	1.52e-25	Vitiligo;
TGCT	cis	rs734999	0.588	rs3748818	chr1:2525660	G/A	cg18854424	chr1:2615690	NA	0.46	5.23	0.43	6.92e-7	Ulcerative colitis;
TGCT	cis	rs10779751	1.000	rs12730522	chr1:11284091	G/A	cg08854313	chr1:11322531	MTOR	0.92	10.07	0.67	8.5e-18	Body mass index;
TGCT	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.26	4.7	0.39	6.74e-6	Schizophrenia;
TGCT	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg13695892	chr22:41940480	POLR3H	0.93	9.17	0.64	1.31e-15	Vitiligo;
TGCT	cis	rs727505	0.908	rs56155943	chr7:124606346	T/G	cg23710748	chr7:124431027	NA	-0.26	-4.52	-0.38	1.41e-5	Lewy body disease;
TGCT	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7666738	0.830	rs10049985	chr4:99023517	C/T	cg05340658	chr4:99064831	C4orf37	0.48	5.43	0.44	2.92e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs151997	0.925	rs28077	chr5:50191946	T/A	cg06027927	chr5:50259733	NA	0.47	4.83	0.4	4e-6	Callous-unemotional behaviour;
TGCT	cis	rs1670533	0.697	rs658846	chr4:1084723	G/C	cg18657303	chr4:1051139	NA	0.3	4.56	0.38	1.21e-5	Recombination rate (females);
TGCT	cis	rs2243480	1.000	rs186378	chr7:65582058	A/C	cg20637647	chr7:64974828	NA	0.84	4.85	0.4	3.63e-6	Diabetic kidney disease;
TGCT	cis	rs10927875	0.864	rs6674071	chr1:16144855	G/C	cg14742211	chr1:16348397	CLCNKA	-0.2	-4.5	-0.37	1.55e-5	Dilated cardiomyopathy;
TGCT	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.03	5.55	0.45	1.62e-7	Alzheimer's disease;
TGCT	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.54	4.95	0.41	2.35e-6	Prudent dietary pattern;
TGCT	trans	rs17471911	0.708	rs4132968	chr10:100802473	G/A	cg03484267	chr2:207988651	KLF7	-0.52	-6.76	-0.52	4.84e-10	Neuroticism;
TGCT	cis	rs4975616	0.869	rs467095	chr5:1336221	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.28	-6.88	-0.53	2.69e-10	Lung cancer;
TGCT	cis	rs1008375	0.897	rs3733577	chr4:17649233	T/G	cg10189774	chr4:17578691	LAP3	0.58	4.99	0.41	1.96e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7308116	1.000	rs7297404	chr12:108236164	T/A	cg19508191	chr12:109124361	CORO1C	-0.45	-4.46	-0.37	1.84e-5	Pelvic organ prolapse (moderate/severe);
TGCT	cis	rs12681287	0.640	rs7460342	chr8:87475137	C/T	cg27223183	chr8:87520930	FAM82B	-0.89	-6.41	-0.5	2.8e-9	Caudate activity during reward;
TGCT	cis	rs7647973	0.961	rs10154992	chr3:49276077	C/T	cg07690219	chr3:49449608	TCTA;RHOA	-0.55	-4.48	-0.37	1.68e-5	Menarche (age at onset);
TGCT	trans	rs57221529	0.709	rs4957056	chr5:570105	T/C	cg11887960	chr12:57824829	NA	1.11	8.99	0.63	3.47e-15	Lung disease severity in cystic fibrosis;
TGCT	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs13191362	1.000	rs55847707	chr6:163003414	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7617773	0.780	rs35190747	chr3:48343290	C/T	cg11946769	chr3:48343235	NME6	0.82	7.09	0.54	9.1e-11	Coronary artery disease;
TGCT	cis	rs860554	0.705	rs832144	chr1:201262477	G/A	cg01022117	chr1:201258280	PKP1	0.34	5.01	0.41	1.87e-6	Panic disorder;
TGCT	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg01448562	chr3:133502909	NA	-0.28	-5.27	-0.43	5.8e-7	Iron status biomarkers;
TGCT	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg11301795	chr4:187892539	NA	-0.34	-4.9	-0.4	2.97e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs68170813	0.641	rs4730248	chr7:107125939	A/G	cg02696742	chr7:106810147	HBP1	-0.66	-5.21	-0.42	7.7e-7	Coronary artery disease;
TGCT	cis	rs6988636	1.000	rs13261021	chr8:124190239	G/A	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs7236492	0.627	rs76032846	chr18:77198322	G/A	cg15644404	chr18:77186268	NFATC1	-0.36	-4.69	-0.39	7.07e-6	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs7914558	1.000	rs10883826	chr10:104830819	A/G	cg04362960	chr10:104952993	NT5C2	0.61	5.36	0.43	3.86e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs6448317	0.539	rs11931422	chr4:24936925	T/C	cg21108841	chr4:24914750	CCDC149	-0.78	-7.24	-0.55	4.15e-11	Heschl's gyrus morphology;
TGCT	trans	rs2727020	0.729	rs10742932	chr11:49173234	T/C	cg15704280	chr7:45808275	SEPT13	-0.7	-7.75	-0.57	2.92e-12	Coronary artery disease;
TGCT	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg17971929	chr21:40555470	PSMG1	0.98	9.13	0.63	1.6e-15	Cognitive function;
TGCT	cis	rs950776	0.714	rs514743	chr15:78884227	A/T	cg06917634	chr15:78832804	PSMA4	-0.65	-5.26	-0.43	6.03e-7	Sudden cardiac arrest;
TGCT	cis	rs1519814	0.654	rs2139438	chr8:121007717	T/C	cg22335954	chr8:121166405	COL14A1	-0.37	-4.61	-0.38	9.72e-6	Breast cancer;
TGCT	cis	rs2594989	0.733	rs2616538	chr3:11581076	G/T	cg00170343	chr3:11313890	ATG7	0.67	5.24	0.43	6.68e-7	Circulating chemerin levels;
TGCT	cis	rs12540874	0.663	rs1451371	chr7:50553051	T/C	cg18232548	chr7:50535776	DDC	-0.37	-6.65	-0.51	8.5e-10	Systemic sclerosis;
TGCT	cis	rs763121	0.853	rs5757166	chr22:38995385	G/T	cg06022373	chr22:39101656	GTPBP1	0.81	8.26	0.6	1.84e-13	Menopause (age at onset);
TGCT	cis	rs7666738	0.924	rs62318940	chr4:99064768	C/T	cg17366294	chr4:99064904	C4orf37	0.77	6.93	0.53	2e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs910187	0.605	rs6018320	chr20:45804412	A/G	cg27589058	chr20:45804311	EYA2	-0.4	-8.9	-0.62	5.58e-15	Migraine;
TGCT	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.54	-6.95	-0.53	1.86e-10	Longevity;Endometriosis;
TGCT	cis	rs1008375	1.000	rs17507481	chr4:17620066	A/G	cg16339924	chr4:17578868	LAP3	0.71	5.79	0.46	5.36e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg07343612	chr16:622815	PIGQ	-0.42	-8.39	-0.6	9.08e-14	Height;
TGCT	cis	rs11077998	0.901	rs3794723	chr17:80529495	G/A	cg10255544	chr17:80519551	FOXK2	0.23	4.44	0.37	1.97e-5	Reticulocyte fraction of red cells;
TGCT	cis	rs13242816	1.000	rs35505552	chr7:116104867	T/A	cg16553024	chr7:116138462	CAV2	-0.43	-4.8	-0.4	4.41e-6	P wave duration;
TGCT	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg08509172	chr19:19383838	TM6SF2	-0.34	-4.52	-0.38	1.4e-5	Tonsillectomy;
TGCT	cis	rs9303401	0.538	rs35454383	chr17:56475599	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.73	6.69	0.51	7.01e-10	Cognitive test performance;
TGCT	cis	rs5769765	0.778	rs4574208	chr22:50256738	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	-0.38	-5.55	-0.45	1.62e-7	Schizophrenia;
TGCT	cis	rs9915657	0.870	rs11077595	chr17:70130030	C/T	cg06234051	chr17:70120541	SOX9	-0.25	-4.99	-0.41	2.04e-6	Thyroid hormone levels;
TGCT	cis	rs587847	0.558	rs621096	chr15:37680339	A/T	cg16890051	chr15:37175029	LOC145845	-0.37	-4.44	-0.37	1.95e-5	Intraocular pressure;
TGCT	cis	rs1008375	1.000	rs2058339	chr4:17678456	C/T	cg16339924	chr4:17578868	LAP3	0.53	4.63	0.38	9.27e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9300255	0.602	rs2851450	chr12:123703501	C/T	cg00376283	chr12:123451042	ABCB9	0.73	5.67	0.45	9.46e-8	Neutrophil percentage of white cells;
TGCT	cis	rs908922	0.584	rs10888500	chr1:152532749	G/A	cg20991723	chr1:152506922	NA	0.44	5.99	0.47	2.14e-8	Hair morphology;
TGCT	cis	rs453301	0.686	rs4840389	chr8:8884503	G/C	cg00184457	chr8:8946301	NA	-0.27	-4.85	-0.4	3.69e-6	Joint mobility (Beighton score);
TGCT	cis	rs7829975	0.684	rs488904	chr8:8587571	T/G	cg15556689	chr8:8085844	FLJ10661	-0.63	-5.46	-0.44	2.44e-7	Mood instability;
TGCT	cis	rs644799	0.648	rs1016031	chr11:95473365	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.6	-5.7	-0.46	8.3e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs10501293	0.746	rs7943869	chr11:43006238	T/C	cg03447554	chr11:43094025	NA	0.44	6.28	0.49	5.2e-9	Cognitive performance;
TGCT	cis	rs6594499	0.903	rs1438672	chr5:110467753	G/A	cg04022379	chr5:110408740	TSLP	0.45	4.76	0.39	5.33e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	trans	rs4942242	1.000	rs4942242	chr13:44217064	A/G	cg19169023	chr15:41853346	TYRO3	0.33	6.68	0.51	7.18e-10	Response to tocilizumab in rheumatoid arthritis;
TGCT	cis	rs60154123	0.505	rs7540237	chr1:210053325	C/T	cg23283495	chr1:209979779	IRF6	0.63	4.69	0.39	7.02e-6	Coronary artery disease;
TGCT	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg27535305	chr1:53392650	SCP2	-0.24	-4.69	-0.39	6.96e-6	Monocyte count;
TGCT	cis	rs909674	0.865	rs5757684	chr22:39851584	G/A	cg02038168	chr22:39784481	NA	-0.68	-5.2	-0.42	8.03e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.85	-8.89	-0.62	6.06e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs9913156	0.696	rs72835620	chr17:4558128	G/A	cg19197139	chr17:4613644	ARRB2	0.86	7.9	0.58	1.32e-12	Lymphocyte counts;
TGCT	cis	rs6450176	1.000	rs7707547	chr5:53295737	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.53	-5.1	-0.42	1.23e-6	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs7611238	0.583	rs9848473	chr3:195122930	T/G	cg27323046	chr3:195102265	ACAP2	0.39	5.18	0.42	8.86e-7	Body mass index;
TGCT	cis	rs950027	0.787	rs2433616	chr15:45728599	A/G	cg14582100	chr15:45693742	SPATA5L1	0.39	4.93	0.4	2.61e-6	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs4499344	0.531	rs259247	chr19:33147657	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.77	7.61	0.56	6.04e-12	Mean platelet volume;
TGCT	cis	rs7120173	0.693	rs12799198	chr11:116801422	C/T	cg20847018	chr11:116580245	NA	0.24	4.6	0.38	1.01e-5	Visceral adipose tissue adjusted for BMI;
TGCT	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg08048268	chr3:133502702	NA	-0.65	-9.84	-0.66	3.1e-17	Iron status biomarkers;
TGCT	cis	rs12477438	0.520	rs6542865	chr2:99764521	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	17.43	0.84	3.73e-35	Chronic sinus infection;
TGCT	cis	rs614226	1.000	rs1167726	chr12:120967364	A/C	cg10072921	chr12:121022843	NA	0.44	4.66	0.39	8.13e-6	Type 1 diabetes nephropathy;
TGCT	cis	rs7937890	0.967	rs963212	chr11:14324732	A/G	cg19336497	chr11:14380999	RRAS2	0.31	4.93	0.4	2.59e-6	Mitochondrial DNA levels;
TGCT	cis	rs11785693	0.862	rs17435605	chr8:4987302	A/G	cg26367366	chr8:4980734	NA	0.58	4.51	0.38	1.48e-5	Neuroticism (multi-trait analysis);Neuroticism;
TGCT	cis	rs4629710	0.592	rs11759926	chr6:131571269	G/T	cg12606694	chr6:131520996	AKAP7	0.41	4.86	0.4	3.55e-6	Multiple myeloma (IgH translocation);
TGCT	cis	rs8014204	0.566	rs752857	chr14:75130944	C/T	cg06637938	chr14:75390232	RPS6KL1	0.57	5.17	0.42	9.18e-7	Caffeine consumption;
TGCT	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg01802117	chr1:53393560	SCP2	-0.41	-4.8	-0.4	4.39e-6	Monocyte count;
TGCT	cis	rs3091242	1.000	rs646867	chr1:25709258	A/C	cg00786635	chr1:25594202	NA	0.52	5.33	0.43	4.43e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs713587	0.571	rs2918630	chr2:25314186	A/G	cg01884057	chr2:25150051	NA	-0.25	-4.8	-0.4	4.42e-6	Body mass index in non-asthmatics;
TGCT	cis	rs7044106	0.791	rs10739572	chr9:123489815	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.2	4.77	0.39	5.13e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs17152411	0.895	rs7906592	chr10:126627861	C/G	cg07906193	chr10:126599966	NA	0.41	5.14	0.42	1.05e-6	Height;
TGCT	cis	rs3924048	0.574	rs11588028	chr1:12612385	T/C	cg00291366	chr1:12616550	NA	0.32	4.87	0.4	3.34e-6	Optic cup area;
TGCT	cis	rs13217239	0.646	rs2142685	chr6:27054497	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.42	-4.61	-0.38	1.01e-5	Schizophrenia;
TGCT	cis	rs3820928	0.874	rs10210997	chr2:227859108	C/T	cg11843606	chr2:227700838	RHBDD1	-0.5	-4.47	-0.37	1.77e-5	Pulmonary function;
TGCT	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.51	-4.96	-0.41	2.24e-6	Prudent dietary pattern;
TGCT	cis	rs17376456	1.000	rs67150649	chr5:93292377	A/G	cg21475434	chr5:93447410	FAM172A	0.65	4.47	0.37	1.72e-5	Diabetic retinopathy;
TGCT	cis	rs7552404	0.731	rs1770887	chr1:76401812	A/G	cg03433033	chr1:76189801	ACADM	-0.78	-7.85	-0.58	1.69e-12	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2046867	0.818	rs7637138	chr3:72910886	A/G	cg25664220	chr3:72788482	NA	-0.55	-7.37	-0.55	2.12e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7586879	0.789	rs7560156	chr2:25124794	T/C	cg01884057	chr2:25150051	NA	0.27	4.81	0.4	4.36e-6	Body mass index;
TGCT	cis	rs12220238	0.915	rs11001021	chr10:76139657	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.88	5.39	0.44	3.41e-7	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg00149659	chr3:10157352	C3orf10	0.73	4.72	0.39	6.17e-6	Alzheimer's disease;
TGCT	cis	rs7914558	0.966	rs10748837	chr10:104880236	T/C	cg04362960	chr10:104952993	NT5C2	0.63	5.64	0.45	1.07e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs427394	0.659	rs175594	chr5:6729885	T/G	cg10857441	chr5:6722123	POLS	-0.28	-6.08	-0.48	1.38e-8	Menopause (age at onset);
TGCT	cis	rs1075232	1.000	rs16956838	chr15:31819695	C/G	cg01030201	chr15:31746330	NA	-0.88	-5.07	-0.41	1.44e-6	Survival in colorectal cancer (non-distant metastatic);
TGCT	cis	rs7267979	0.738	rs2892409	chr20:25638138	C/T	cg13486641	chr20:25479848	NINL	-0.15	-4.54	-0.38	1.32e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7945705	0.747	rs1980428	chr11:9010497	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.43	4.6	0.38	1.04e-5	Hemoglobin concentration;
TGCT	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.61	-6.12	-0.48	1.16e-8	Bipolar disorder;
TGCT	cis	rs9814567	1.000	rs6782563	chr3:134295959	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.91	8.83	0.62	8.17e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg07424592	chr7:64974309	NA	1.27	7.28	0.55	3.29e-11	Diabetic kidney disease;
TGCT	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg11764359	chr7:65958608	NA	0.61	5.53	0.44	1.84e-7	Aortic root size;
TGCT	cis	rs3096299	0.933	rs28608022	chr16:89454292	C/T	cg06640241	chr16:89574553	SPG7	0.64	6.3	0.49	4.76e-9	Multiple myeloma (IgH translocation);
TGCT	cis	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg20637647	chr7:64974828	NA	0.97	5.37	0.43	3.82e-7	Diabetic kidney disease;
TGCT	cis	rs9942416	0.592	rs10462521	chr5:74985867	T/C	cg19683494	chr5:74908142	NA	0.59	6.26	0.49	5.62e-9	Age-related disease endophenotypes;
TGCT	cis	rs394563	0.559	rs13219868	chr6:149686518	T/G	cg16235748	chr6:149772707	ZC3H12D	0.44	5.03	0.41	1.66e-6	Dupuytren's disease;
TGCT	cis	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg25427524	chr10:38739819	LOC399744	-0.39	-8.05	-0.59	5.9e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7582180	0.625	rs12612755	chr2:100906061	T/C	cg14675211	chr2:100938903	LONRF2	0.45	4.52	0.38	1.4e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7258465	1.000	rs2007981	chr19:18567555	C/A	cg06462663	chr19:18546047	ISYNA1	0.2	4.51	0.38	1.5e-5	Breast cancer;
TGCT	cis	rs9581857	0.579	rs7332104	chr13:27957831	C/G	cg22138327	chr13:27999177	GTF3A	-0.65	-4.45	-0.37	1.9e-5	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs6938	0.662	rs12487	chr15:75136694	A/G	cg09165964	chr15:75287851	SCAMP5	0.51	4.65	0.39	8.52e-6	Breast cancer;
TGCT	cis	rs4595586	0.546	rs11169801	chr12:39241429	G/A	cg13010199	chr12:38710504	ALG10B	0.6	4.72	0.39	6.26e-6	Morning vs. evening chronotype;
TGCT	cis	rs9527	0.615	rs2152915	chr10:104691732	A/T	cg15744005	chr10:104629667	AS3MT	-0.45	-5.31	-0.43	4.9e-7	Arsenic metabolism;
TGCT	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg01238044	chr22:24384105	GSTT1	-0.49	-4.49	-0.37	1.63e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.0	0.41	1.89e-6	Menopause (age at onset);
TGCT	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.69	-7.19	-0.54	5.48e-11	Prostate cancer;
TGCT	cis	rs2404602	0.583	rs2469542	chr15:76557476	A/G	cg26408565	chr15:76604113	ETFA	0.47	6.51	0.5	1.65e-9	Blood metabolite levels;
TGCT	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg08280861	chr8:58055591	NA	0.4	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2688608	0.653	rs12775558	chr10:75570868	G/A	cg15838173	chr10:75533400	FUT11	-0.3	-4.83	-0.4	4.02e-6	Inflammatory bowel disease;
TGCT	cis	rs6424115	1.000	rs4237	chr1:24114129	C/T	cg15997130	chr1:24165203	NA	0.89	10.32	0.68	2.11e-18	Immature fraction of reticulocytes;
TGCT	cis	rs6912958	0.781	rs4707379	chr6:88310623	A/G	cg06598631	chr6:88300029	RARS2;ORC3L	-0.57	-5.2	-0.42	7.9e-7	Monocyte percentage of white cells;
TGCT	cis	rs2013441	1.000	rs8079701	chr17:20216565	G/A	cg18979559	chr17:20280153	CCDC144C	-0.45	-4.67	-0.39	7.61e-6	Obesity-related traits;
TGCT	cis	rs3771570	0.901	rs6757876	chr2:242245570	T/C	cg21155796	chr2:242212141	HDLBP	0.88	6.39	0.5	3.1e-9	Prostate cancer;
TGCT	cis	rs11098499	0.691	rs10010355	chr4:120261043	A/G	cg09307838	chr4:120376055	NA	0.55	5.36	0.43	3.98e-7	Corneal astigmatism;
TGCT	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	12.81	0.75	1.93e-24	Height;
TGCT	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg23758822	chr17:41437982	NA	0.73	6.99	0.53	1.52e-10	Menopause (age at onset);
TGCT	cis	rs7552404	0.727	rs12122939	chr1:76276353	T/C	cg03433033	chr1:76189801	ACADM	0.66	6.88	0.53	2.57e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg05368731	chr17:41323189	NBR1	1.16	13.52	0.77	3.79e-26	Menopause (age at onset);
TGCT	cis	rs669446	0.591	rs574736	chr1:44106266	C/T	cg12908607	chr1:44402522	ARTN	-0.55	-5.9	-0.47	3.25e-8	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs2404602	1.000	rs12443137	chr15:76840832	G/T	cg22467129	chr15:76604101	ETFA	-0.49	-5.48	-0.44	2.24e-7	Blood metabolite levels;
TGCT	cis	rs56104184	0.775	rs73061692	chr19:49399676	T/C	cg17863274	chr19:49399704	TULP2	-0.54	-7.43	-0.55	1.58e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs6831352	0.918	rs2851253	chr4:100043505	G/T	cg12011299	chr4:100065546	ADH4	-0.41	-4.92	-0.4	2.64e-6	Alcohol dependence;
TGCT	cis	rs524281	0.692	rs2302884	chr11:65824084	C/T	cg00563793	chr11:65837595	PACS1	0.53	4.66	0.39	8e-6	Electroencephalogram traits;
TGCT	cis	rs3771570	1.000	rs6752050	chr2:242228780	T/C	cg21155796	chr2:242212141	HDLBP	0.98	6.68	0.51	7.29e-10	Prostate cancer;
TGCT	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg16049864	chr8:95962084	TP53INP1	-0.75	-10.48	-0.69	8.55e-19	Type 2 diabetes;
TGCT	cis	rs60843830	1.000	rs3828165	chr2:220889	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.77	7.44	0.56	1.47e-11	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs12220238	0.915	rs11000988	chr10:76073723	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.9	6.28	0.49	5.18e-9	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs66573146	0.831	rs6851488	chr4:6987412	C/T	cg05069807	chr4:6945702	TBC1D14	0.3	4.83	0.4	3.98e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs7726839	0.540	rs72703080	chr5:595238	A/G	cg20362242	chr5:692897	TPPP	0.53	4.62	0.38	9.42e-6	Obesity-related traits;
TGCT	cis	rs4730250	0.707	rs257385	chr7:106807448	T/C	cg02696742	chr7:106810147	HBP1	-0.71	-5.83	-0.46	4.6e-8	Osteoarthritis;
TGCT	cis	rs66573146	1.000	rs55688389	chr4:7030689	C/G	cg05069807	chr4:6945702	TBC1D14	0.4	5.33	0.43	4.49e-7	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg18135555	chr8:22132992	PIWIL2	0.3	6.2	0.49	7.71e-9	Hypertriglyceridemia;
TGCT	cis	rs6545883	0.929	rs9679557	chr2:61709349	C/A	cg15711740	chr2:61764176	XPO1	-0.56	-4.97	-0.41	2.13e-6	Tuberculosis;
TGCT	cis	rs853679	0.527	rs853693	chr6:28282648	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.46	-4.95	-0.41	2.41e-6	Depression;
TGCT	cis	rs931127	0.658	rs7926512	chr11:65464487	T/A	cg27068330	chr11:65405492	SIPA1	-0.66	-6.59	-0.51	1.13e-9	Systemic lupus erythematosus;
TGCT	cis	rs4891159	0.536	rs690392	chr18:74152618	G/A	cg24786174	chr18:74118243	ZNF516	0.66	11.85	0.73	3.89e-22	Longevity;
TGCT	cis	rs1568889	0.592	rs11828877	chr11:28384030	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.7	5.27	0.43	5.86e-7	Bipolar disorder;
TGCT	cis	rs6906287	0.625	rs7757892	chr6:118844221	G/A	cg21191810	chr6:118973309	C6orf204	0.26	4.49	0.37	1.58e-5	Electrocardiographic conduction measures;
TGCT	trans	rs7698623	0.850	rs4147244	chr4:88779168	C/T	cg01186725	chr1:53905612	FLJ40434	-0.48	-6.63	-0.51	9.21e-10	Cardiovascular disease risk factors;
TGCT	cis	rs2050392	0.931	rs2265189	chr10:30689316	C/T	cg13289132	chr10:30722225	MAP3K8	0.36	4.45	0.37	1.92e-5	Inflammatory bowel disease;
TGCT	cis	rs9911578	1.000	rs2009948	chr17:56611920	A/C	cg05425664	chr17:57184151	TRIM37	0.63	6.26	0.49	5.86e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs2235642	0.859	rs12599207	chr16:1606445	A/G	cg00463982	chr16:1583984	IFT140;TMEM204	-0.28	-4.8	-0.4	4.41e-6	Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs880472	chr4:98922595	C/A	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11107903	1.000	rs11107900	chr12:95505052	C/T	cg10621809	chr12:95840313	NA	0.7	4.61	0.38	9.89e-6	Coronary artery disease;
TGCT	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg26338869	chr17:61819248	STRADA	-0.53	-4.94	-0.41	2.48e-6	Prudent dietary pattern;
TGCT	trans	rs9383153	1.000	rs2237223	chr6:16329741	G/A	cg22767166	chr8:49833685	SNAI2	0.92	6.66	0.51	7.98e-10	Gambling;
TGCT	cis	rs7829975	0.682	rs7013471	chr8:8687325	A/G	cg15556689	chr8:8085844	FLJ10661	-0.66	-5.86	-0.47	3.91e-8	Mood instability;
TGCT	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.64	-5.6	-0.45	1.32e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg20637647	chr7:64974828	NA	0.99	5.38	0.44	3.53e-7	Diabetic kidney disease;
TGCT	cis	rs12765878	0.513	rs10883922	chr10:105595430	C/G	cg11005552	chr10:105648138	OBFC1	-0.39	-6.06	-0.48	1.49e-8	Coronary artery disease;
TGCT	cis	rs17376456	0.877	rs12374463	chr5:93483569	C/G	cg21475434	chr5:93447410	FAM172A	0.63	4.67	0.39	7.67e-6	Diabetic retinopathy;
TGCT	cis	rs12971120	0.891	rs2278159	chr18:72178161	T/C	cg26446133	chr18:72167187	CNDP2	-0.35	-5.89	-0.47	3.42e-8	Refractive error;
TGCT	cis	rs9302065	0.681	rs59108692	chr13:95962424	C/A	cg24476569	chr13:95954382	ABCC4	-0.44	-6.35	-0.5	3.64e-9	Blood metabolite levels;
TGCT	cis	rs7691216	0.514	rs7694080	chr4:86134264	C/T	cg05688618	chr4:86699962	ARHGAP24	-0.35	-4.51	-0.38	1.5e-5	IgG glycosylation;
TGCT	cis	rs12134245	0.776	rs13447526	chr1:91983174	A/G	cg25838465	chr1:92012736	NA	0.44	7.01	0.53	1.34e-10	Breast cancer;
TGCT	cis	rs2562456	0.793	rs2562428	chr19:21625454	G/C	cg01304269	chr19:21688519	ZNF429	-0.58	-4.66	-0.39	8e-6	Pain;
TGCT	cis	rs3617	0.625	rs2071042	chr3:52864584	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	4.53	0.38	1.35e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7246657	0.550	rs9941475	chr19:38064517	C/T	cg03611452	chr19:38183253	ZNF781	0.58	4.64	0.38	8.62e-6	Coronary artery calcification;
TGCT	cis	rs7914558	0.966	rs10748835	chr10:104660256	C/T	cg15744005	chr10:104629667	AS3MT	-0.39	-5.04	-0.41	1.6e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs6138458	0.887	rs227622	chr20:24910597	T/C	cg26195577	chr20:24973756	C20orf3	1.2	12.04	0.73	1.35e-22	Blood protein levels;
TGCT	cis	rs4805272	0.962	rs1363327	chr19:29325571	A/C	cg15000279	chr19:29285009	NA	-0.52	-5.64	-0.45	1.07e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
TGCT	cis	rs10986311	0.683	rs2150237	chr9:127082375	G/A	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.2	-4.83	-0.4	3.87e-6	Vitiligo;
TGCT	cis	rs7119038	0.509	rs11216960	chr11:118577873	G/A	cg19308663	chr11:118741387	NA	0.24	4.5	0.37	1.54e-5	Sjögren's syndrome;
TGCT	cis	rs12477438	0.520	rs11678456	chr2:99708237	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	16.87	0.83	6.81e-34	Chronic sinus infection;
TGCT	cis	rs9383153	0.793	rs2016498	chr6:16344914	C/T	cg20052079	chr6:15504923	JARID2	0.85	5.13	0.42	1.09e-6	Gambling;
TGCT	cis	rs6546537	1.000	rs4852892	chr2:69866769	T/A	cg10773587	chr2:69614142	GFPT1	-0.71	-6.21	-0.49	7.48e-9	Serum thyroid-stimulating hormone levels;
TGCT	cis	rs694419	0.602	rs12150719	chr18:60180026	A/C	cg13506219	chr18:60193840	ZCCHC2	-0.55	-4.93	-0.4	2.58e-6	Serum albumin level;
TGCT	cis	rs3008870	0.755	rs2815355	chr1:67485034	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.8	8.37	0.6	1.04e-13	Lymphocyte percentage of white cells;
TGCT	cis	rs10131894	0.635	rs174997	chr14:75434806	G/A	cg08847533	chr14:75593920	NEK9	-0.66	-6.31	-0.49	4.51e-9	Coronary artery disease;
TGCT	cis	rs2440129	1.000	rs2920420	chr17:6906944	A/G	cg05215272	chr17:6899095	ALOX12	0.43	4.45	0.37	1.86e-5	Tonsillectomy;
TGCT	cis	rs2120019	1.000	rs2120019	chr15:75334184	T/C	cg09165964	chr15:75287851	SCAMP5	-1.14	-10.22	-0.68	3.76e-18	Blood trace element (Zn levels);
TGCT	cis	rs7786808	0.579	rs55701656	chr7:158188812	G/A	cg01191920	chr7:158217561	PTPRN2	-0.36	-5.38	-0.43	3.65e-7	Obesity-related traits;
TGCT	cis	rs1008375	0.932	rs7697329	chr4:17657853	C/A	cg16339924	chr4:17578868	LAP3	0.66	5.52	0.44	1.89e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs62244186	0.566	rs6766221	chr3:44882784	C/T	cg18722847	chr3:44754129	ZNF502	-0.4	-4.49	-0.37	1.58e-5	Depressive symptoms;
TGCT	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg10802521	chr3:52805072	NEK4	-0.74	-9.02	-0.63	2.87e-15	Bipolar disorder;
TGCT	cis	rs74181299	0.806	rs1009360	chr2:65276049	T/C	cg05010058	chr2:65284262	CEP68	0.39	4.48	0.37	1.67e-5	Pulse pressure;
TGCT	cis	rs1552244	0.688	rs9875667	chr3:10180041	T/C	cg00149659	chr3:10157352	C3orf10	0.77	5.61	0.45	1.25e-7	Alzheimer's disease;
TGCT	cis	rs1982963	0.950	rs2645750	chr14:52502792	C/A	cg10843707	chr14:52510701	NID2	-0.42	-6.47	-0.5	2.07e-9	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9810089	0.708	rs711977	chr3:136227387	G/A	cg12473912	chr3:136751656	NA	0.34	4.81	0.4	4.29e-6	Gestational age at birth (child effect);
TGCT	cis	rs10032931	1.000	rs10032931	chr4:96458433	T/C	cg03008707	chr4:96468962	UNC5C	-0.4	-5.39	-0.44	3.44e-7	Optic nerve measurement (cup-to-disc ratio);
TGCT	cis	rs3820068	0.603	rs59558854	chr1:15971399	T/G	cg05660106	chr1:15850417	CASP9	0.83	8.16	0.59	3.25e-13	Systolic blood pressure;
TGCT	trans	rs4332037	0.624	rs73046339	chr7:1889300	G/A	cg25206134	chr2:45395956	NA	0.95	8.08	0.59	4.81e-13	Bipolar disorder;
TGCT	cis	rs7264396	0.635	rs6058382	chr20:34553948	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.04	-0.41	1.58e-6	Total cholesterol levels;
TGCT	cis	rs12148488	0.763	rs12898551	chr15:75297907	C/G	cg10253484	chr15:75165896	SCAMP2	-0.61	-5.24	-0.43	6.6e-7	Caffeine consumption;
TGCT	cis	rs938554	0.513	rs11943372	chr4:9999346	T/A	cg00071950	chr4:10020882	SLC2A9	0.56	5.13	0.42	1.09e-6	Blood metabolite levels;
TGCT	cis	rs9443189	0.617	rs2842570	chr6:76415274	A/T	cg01950844	chr6:76311363	SENP6	0.74	4.85	0.4	3.62e-6	Prostate cancer;
TGCT	cis	rs9399135	0.967	rs6910530	chr6:135332770	C/T	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.36e-6	Red blood cell count;
TGCT	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg06238570	chr21:40685208	BRWD1	-0.82	-8.86	-0.62	7.17e-15	Cognitive function;
TGCT	cis	rs554111	0.656	rs17450586	chr1:21254593	T/G	cg01072550	chr1:21505969	NA	0.35	5.33	0.43	4.44e-7	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs9816226	0.590	rs872602	chr3:185826028	A/G	cg00760338	chr3:185826511	ETV5	0.71	6.24	0.49	6.28e-9	Obesity;Body mass index;
TGCT	cis	rs16854884	1.000	rs34730687	chr3:143813193	A/G	cg06585982	chr3:143692056	C3orf58	0.67	4.44	0.37	1.95e-5	Economic and political preferences (feminism/equality);
TGCT	cis	rs7296418	0.961	rs1790122	chr12:123606739	G/A	cg13010344	chr12:123464640	ARL6IP4	-0.31	-4.44	-0.37	2e-5	Platelet count;
TGCT	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg02725872	chr8:58115012	NA	-0.37	-4.57	-0.38	1.19e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg00149659	chr3:10157352	C3orf10	0.78	4.99	0.41	2.04e-6	Alzheimer's disease;
TGCT	cis	rs9368481	0.761	rs3931464	chr6:26939856	C/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.46	5.0	0.41	1.88e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12903563	0.505	rs12898861	chr15:77983802	A/G	cg25212270	chr15:78015279	NA	0.23	4.48	0.37	1.67e-5	Neuroticism (multi-trait analysis);Neuroticism;
TGCT	cis	rs17601876	0.843	rs28518777	chr15:51553507	G/A	cg19946085	chr15:51559439	CYP19A1	-0.31	-4.75	-0.39	5.44e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs80282103	0.618	rs11816485	chr10:1147974	T/C	cg18964960	chr10:1102726	WDR37	0.98	4.57	0.38	1.15e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs7017914	0.967	rs34042354	chr8:71730961	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.55	-5.1	-0.42	1.24e-6	Bone mineral density;
TGCT	cis	rs1865760	0.534	rs72834629	chr6:26023032	C/T	cg17691542	chr6:26056736	HIST1H1C	0.7	5.34	0.43	4.28e-7	Height;
TGCT	cis	rs208520	0.690	rs1304672	chr6:66847973	A/G	cg07460842	chr6:66804631	NA	0.89	8.59	0.61	3.06e-14	Exhaled nitric oxide output;
TGCT	cis	rs9859260	0.710	rs419068	chr3:195782176	C/T	cg02975922	chr3:195473998	MUC4	0.25	5.1	0.42	1.24e-6	Mean corpuscular volume;
TGCT	cis	rs1538970	0.962	rs9429075	chr1:45818421	G/A	cg05343316	chr1:45956843	TESK2	0.64	5.06	0.41	1.47e-6	Platelet count;
TGCT	cis	rs7255045	0.752	rs2242514	chr19:12982798	C/T	cg23899408	chr19:12877188	HOOK2	0.59	4.86	0.4	3.45e-6	Mean corpuscular volume;
TGCT	cis	rs9583531	0.574	rs7319459	chr13:111352408	T/C	cg24331049	chr13:111365604	ING1	-0.82	-7.94	-0.58	1.04e-12	Coronary artery disease;
TGCT	cis	rs9611565	0.592	rs4481089	chr22:41980892	T/C	cg13695892	chr22:41940480	POLR3H	-0.83	-7.82	-0.57	1.94e-12	Vitiligo;
TGCT	cis	rs12579753	0.917	rs7132732	chr12:82206053	C/G	cg07988820	chr12:82153109	PPFIA2	-0.59	-6.19	-0.49	7.93e-9	Resting heart rate;
TGCT	cis	rs9303401	0.612	rs2526370	chr17:56487636	G/C	cg12560992	chr17:57184187	TRIM37	0.62	6.56	0.51	1.32e-9	Cognitive test performance;
TGCT	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg11764359	chr7:65958608	NA	-0.61	-5.52	-0.44	1.93e-7	Aortic root size;
TGCT	cis	rs28595532	0.541	rs114463740	chr4:119763329	C/T	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs11971779	0.711	rs6961204	chr7:139047399	T/G	cg07862535	chr7:139043722	LUC7L2	0.75	5.43	0.44	2.86e-7	Diisocyanate-induced asthma;
TGCT	cis	rs67311347	0.713	rs4974018	chr3:40307419	G/A	cg13683864	chr3:40499215	RPL14	-0.87	-8.51	-0.61	4.77e-14	Renal cell carcinoma;
TGCT	cis	rs9611565	0.559	rs12483860	chr22:41961916	C/T	cg06481639	chr22:41940642	POLR3H	-0.67	-5.71	-0.46	7.87e-8	Vitiligo;
TGCT	cis	rs9443645	0.901	rs1984195	chr6:79657391	G/A	cg09184832	chr6:79620586	NA	-0.49	-5.29	-0.43	5.29e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg12963246	chr6:28129442	ZNF389	0.51	5.02	0.41	1.73e-6	Depression;
TGCT	cis	rs2046867	0.628	rs7356055	chr3:72912878	A/C	cg25664220	chr3:72788482	NA	-0.44	-5.71	-0.46	7.76e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs35000415	0.938	rs34725944	chr7:128641653	T/C	cg06242719	chr7:129414860	MIR183;MIR96	-0.31	-4.52	-0.38	1.4e-5	Systemic lupus erythematosus;
TGCT	cis	rs2996428	0.667	rs17412654	chr1:3758493	T/C	cg13057898	chr1:3703894	LRRC47	0.21	4.62	0.38	9.46e-6	Red cell distribution width;
TGCT	cis	rs854765	0.583	rs4244602	chr17:17841456	A/G	cg09796270	chr17:17721594	SREBF1	0.28	5.66	0.45	9.89e-8	Total body bone mineral density;
TGCT	trans	rs61931739	0.500	rs11053193	chr12:34438838	G/T	cg26384229	chr12:38710491	ALG10B	0.73	6.93	0.53	2e-10	Morning vs. evening chronotype;
TGCT	cis	rs1887596	0.554	rs1888547	chr13:27103257	T/C	cg01312412	chr13:27282625	NA	-0.26	-4.44	-0.37	1.96e-5	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs3008870	1.000	rs2755240	chr1:67477339	T/G	cg08660285	chr1:67390436	MIER1;WDR78	1.07	11.37	0.71	5.7e-21	Lymphocyte percentage of white cells;
TGCT	cis	rs7666738	0.830	rs9998682	chr4:98939009	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12780845	0.540	rs3780961	chr10:17195132	G/A	cg01003015	chr10:17271136	VIM	-0.52	-4.78	-0.39	4.89e-6	Homocysteine levels;
TGCT	cis	rs137603	0.644	rs137621	chr22:39710244	G/A	cg17798944	chr22:39715225	SNORD43;RPL3	-0.68	-7.19	-0.54	5.24e-11	Primary biliary cholangitis;
TGCT	cis	rs35306767	0.951	rs11253530	chr10:993729	T/C	cg20503657	chr10:835505	NA	0.63	8.32	0.6	1.37e-13	Eosinophil percentage of granulocytes;
TGCT	cis	rs2836950	0.509	rs4816618	chr21:40599529	G/A	cg17971929	chr21:40555470	PSMG1	-0.51	-4.64	-0.38	8.88e-6	Menarche (age at onset);
TGCT	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg19626725	chr5:178986131	RUFY1	0.51	6.7	0.52	6.43e-10	Lung cancer;
TGCT	cis	rs2354432	0.607	rs10900350	chr1:146828017	T/G	cg25205988	chr1:146714368	CHD1L	1.36	6.23	0.49	6.77e-9	Mitochondrial DNA levels;
TGCT	cis	rs7833790	0.636	rs12544174	chr8:82731477	G/A	cg17211192	chr8:82754475	SNX16	-0.95	-8.83	-0.62	8.45e-15	Diastolic blood pressure;
TGCT	cis	rs11662586	0.517	rs7230837	chr18:77695384	A/T	cg20368463	chr18:77673604	PQLC1	0.56	6.81	0.52	3.71e-10	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
TGCT	cis	rs4499344	0.531	rs863905	chr19:33146403	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.76	7.52	0.56	9.49e-12	Mean platelet volume;
TGCT	cis	rs250677	0.652	rs250675	chr5:148438565	A/C	cg23229984	chr5:148520753	ABLIM3	-0.26	-5.79	-0.46	5.31e-8	Breast cancer;
TGCT	cis	rs7666738	0.830	rs113999196	chr4:99041961	C/T	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7568458	0.811	rs3755015	chr2:85764041	G/A	cg02493740	chr2:85810744	VAMP5	-0.29	-5.47	-0.44	2.35e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs28595532	0.920	rs114667001	chr4:119786974	T/C	cg21605333	chr4:119757512	SEC24D	1.55	8.04	0.59	6.15e-13	Cannabis dependence symptom count;
TGCT	cis	rs11030122	0.702	rs10835312	chr11:3950253	G/A	cg18678763	chr11:4115507	RRM1	-0.49	-6.14	-0.48	1.01e-8	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg12310025	chr6:25882481	NA	0.51	4.59	0.38	1.06e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs644799	1.000	rs596277	chr11:95566886	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	7.92	0.58	1.12e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs877529	0.605	rs79505	chr22:39551567	A/G	cg18708252	chr22:39545030	CBX7	-0.39	-5.82	-0.46	4.66e-8	Multiple myeloma;
TGCT	cis	rs950027	0.620	rs1719245	chr15:45623782	T/C	cg14582100	chr15:45693742	SPATA5L1	0.49	6.17	0.48	8.68e-9	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs2180341	0.960	rs6913424	chr6:127707010	A/C	cg24812749	chr6:127587940	RNF146	0.93	7.25	0.55	3.85e-11	Breast cancer;
TGCT	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg08859206	chr1:53392774	SCP2	-0.41	-6.57	-0.51	1.24e-9	Monocyte count;
TGCT	trans	rs877282	0.891	rs12767062	chr10:797961	C/T	cg22713356	chr15:30763199	NA	1.16	10.18	0.67	4.53e-18	Uric acid levels;
TGCT	cis	rs10754283	0.967	rs10737708	chr1:90119804	A/G	cg03145924	chr1:90228473	NA	-0.4	-4.52	-0.38	1.4e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs7681440	0.904	rs7698219	chr4:90771351	C/A	cg26578617	chr4:90757533	SNCA	-0.46	-4.73	-0.39	6.01e-6	Dementia with Lewy bodies;
TGCT	cis	rs7666738	0.830	rs11721726	chr4:98996314	T/C	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9911578	1.000	rs2079703	chr17:56603978	G/A	cg12560992	chr17:57184187	TRIM37	-0.76	-9.34	-0.64	4.88e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs896854	0.548	rs574183	chr8:95973816	A/G	cg16049864	chr8:95962084	TP53INP1	0.65	7.91	0.58	1.23e-12	Type 2 diabetes;
TGCT	cis	rs3733585	0.673	rs4292332	chr4:9953830	C/A	cg11266682	chr4:10021025	SLC2A9	-0.57	-7.6	-0.56	6.21e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs4268898	0.760	rs7597919	chr2:24563646	A/G	cg02683114	chr2:24398427	C2orf84	0.2	4.92	0.4	2.65e-6	Asthma;
TGCT	cis	rs11098499	0.863	rs7699064	chr4:120428309	A/G	cg09307838	chr4:120376055	NA	-0.71	-6.91	-0.53	2.24e-10	Corneal astigmatism;
TGCT	trans	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.83	8.71	0.62	1.65e-14	Body mass index;
TGCT	cis	rs4321325	0.733	rs79208542	chr2:127935686	G/C	cg09760422	chr2:128146352	NA	0.44	4.55	0.38	1.26e-5	Protein C levels;
TGCT	trans	rs2727020	0.619	rs11040300	chr11:49269984	C/A	cg03929089	chr4:120376271	NA	0.68	7.2	0.54	5.2e-11	Coronary artery disease;
TGCT	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.73	-0.39	5.93e-6	Prudent dietary pattern;
TGCT	cis	rs10875746	0.855	rs11168369	chr12:48431168	G/A	cg20731937	chr12:48336164	NA	0.68	5.29	0.43	5.3e-7	Longevity (90 years and older);
TGCT	cis	rs11148252	0.967	rs4286007	chr13:53022518	A/G	cg00495681	chr13:53174319	NA	0.5	5.08	0.42	1.34e-6	Lewy body disease;
TGCT	cis	rs2970818	0.831	rs7304949	chr12:4609625	A/G	cg20471076	chr12:4920472	KCNA6	0.2	4.85	0.4	3.59e-6	Phosphorus levels;
TGCT	cis	rs1008375	0.966	rs3733576	chr4:17586703	T/C	cg10189774	chr4:17578691	LAP3	0.61	5.28	0.43	5.6e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2233152	0.520	rs56101381	chr19:41272902	T/C	cg11601297	chr19:41224147	ITPKC;ADCK4	0.53	4.86	0.4	3.46e-6	Kawasaki disease;
TGCT	cis	rs4788570	0.615	rs8053745	chr16:71689693	A/G	cg06353428	chr16:71660113	MARVELD3	1.56	12.36	0.74	2.34e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs9303401	0.538	rs12603174	chr17:56489279	T/C	cg25039879	chr17:56429692	SUPT4H1	0.58	4.81	0.4	4.31e-6	Cognitive test performance;
TGCT	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg27535305	chr1:53392650	SCP2	-0.25	-5.06	-0.41	1.47e-6	Monocyte count;
TGCT	cis	rs950169	0.960	rs35159785	chr15:84804014	G/A	cg17173187	chr15:85201210	NMB	0.49	5.13	0.42	1.1e-6	Schizophrenia;
TGCT	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg06238570	chr21:40685208	BRWD1	0.79	9.41	0.65	3.36e-16	Cognitive function;
TGCT	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg22105103	chr4:187893119	NA	0.33	4.53	0.38	1.35e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2404602	0.692	rs8043474	chr15:76974723	T/C	cg22467129	chr15:76604101	ETFA	-0.45	-5.11	-0.42	1.2e-6	Blood metabolite levels;
TGCT	cis	rs9549367	0.789	rs7317558	chr13:113893625	G/A	cg00898013	chr13:113819073	PROZ	-0.43	-5.5	-0.44	2.11e-7	Platelet distribution width;
TGCT	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg06238570	chr21:40685208	BRWD1	-0.62	-6.17	-0.48	8.82e-9	Menarche (age at onset);
TGCT	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.06	-9.57	-0.65	1.41e-16	Platelet count;
TGCT	cis	rs12220777	0.786	rs2342607	chr10:81821489	C/T	cg03267442	chr10:82210566	NA	0.39	4.57	0.38	1.16e-5	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs9916302	0.718	rs10445306	chr17:37591422	A/G	cg15445000	chr17:37608096	MED1	0.32	4.68	0.39	7.47e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs11096990	0.593	rs4580660	chr4:39153836	G/A	cg20847110	chr4:39482781	LOC401127	0.17	4.96	0.41	2.28e-6	Cognitive function;
TGCT	cis	rs1008375	1.000	rs1121089	chr4:17676476	C/A	cg16339924	chr4:17578868	LAP3	0.53	4.62	0.38	9.58e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs62244186	0.541	rs9859879	chr3:44840166	G/A	cg18722847	chr3:44754129	ZNF502	-0.39	-4.44	-0.37	1.94e-5	Depressive symptoms;
TGCT	trans	rs1814175	0.817	rs28594987	chr11:50045181	C/T	cg15704280	chr7:45808275	SEPT13	-0.72	-8.47	-0.61	6.02e-14	Height;
TGCT	cis	rs8072100	0.782	rs62074054	chr17:45771816	T/C	cg08085267	chr17:45401833	C17orf57	-0.43	-4.82	-0.4	4.04e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs9291683	0.552	rs11736410	chr4:10017241	G/A	cg00071950	chr4:10020882	SLC2A9	0.75	10.33	0.68	2.04e-18	Bone mineral density;
TGCT	cis	rs11249608	0.590	rs36051170	chr5:178447971	T/C	cg01312482	chr5:178451176	ZNF879	-0.58	-5.74	-0.46	7.02e-8	Pubertal anthropometrics;
TGCT	cis	rs2732480	0.500	rs7966829	chr12:48615603	G/T	cg04545296	chr12:48745243	ZNF641	0.33	4.64	0.38	8.74e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
TGCT	cis	rs9807841	0.544	rs10417412	chr19:10766798	A/C	cg17848348	chr19:10766748	ILF3	-0.4	-4.5	-0.37	1.55e-5	Inflammatory skin disease;
TGCT	cis	rs2066819	1.000	rs118130855	chr12:56677979	T/A	cg26714650	chr12:56694279	CS	-1.36	-6.06	-0.48	1.54e-8	Psoriasis vulgaris;
TGCT	cis	rs7772486	0.790	rs9386141	chr6:146268623	T/A	cg05347473	chr6:146136440	FBXO30	-0.5	-4.85	-0.4	3.68e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6674176	0.561	rs12127226	chr1:44395309	C/T	cg12908607	chr1:44402522	ARTN	-0.74	-9.15	-0.63	1.43e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs7959452	0.562	rs11177630	chr12:69767963	G/C	cg20891283	chr12:69753455	YEATS4	0.83	8.61	0.61	2.8e-14	Blood protein levels;
TGCT	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg11644478	chr21:40555479	PSMG1	-0.52	-4.83	-0.4	3.98e-6	Menarche (age at onset);
TGCT	cis	rs17331151	0.573	rs2240916	chr3:52859212	T/A	cg15956490	chr3:53032818	SFMBT1	0.47	6.14	0.48	1.03e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs6912958	0.781	rs9444524	chr6:88311260	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-4.46	-0.37	1.83e-5	Monocyte percentage of white cells;
TGCT	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg26338869	chr17:61819248	STRADA	-0.53	-4.85	-0.4	3.68e-6	Prudent dietary pattern;
TGCT	cis	rs896854	0.517	rs10112447	chr8:95955701	C/T	cg09323728	chr8:95962352	TP53INP1	-0.43	-4.92	-0.4	2.72e-6	Type 2 diabetes;
TGCT	cis	rs524281	0.861	rs11227403	chr11:65858428	T/C	cg00563793	chr11:65837595	PACS1	0.55	4.62	0.38	9.44e-6	Electroencephalogram traits;
TGCT	cis	rs7829975	0.560	rs6994131	chr8:8550958	G/A	cg15556689	chr8:8085844	FLJ10661	-0.54	-4.61	-0.38	1e-5	Mood instability;
TGCT	trans	rs28595532	0.557	rs28657902	chr4:119305491	C/T	cg26518628	chr1:97050305	NA	-0.52	-7.71	-0.57	3.51e-12	Cannabis dependence symptom count;
TGCT	cis	rs1525293	0.709	rs11984380	chr7:70481029	G/A	cg21135135	chr7:70597687	WBSCR17	-0.49	-4.98	-0.41	2.08e-6	Colonoscopy-negative controls vs population controls;Major depressive disorder;
TGCT	cis	rs826838	0.967	rs7299170	chr12:38789536	G/A	cg13010199	chr12:38710504	ALG10B	0.82	6.85	0.52	3e-10	Heart rate;
TGCT	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg18876405	chr7:65276391	NA	-0.33	-5.05	-0.41	1.55e-6	Aortic root size;
TGCT	cis	rs6831352	0.918	rs29001232	chr4:100046654	G/C	cg12011299	chr4:100065546	ADH4	-0.41	-4.92	-0.4	2.72e-6	Alcohol dependence;
TGCT	cis	rs4654899	0.931	rs6661116	chr1:21337155	C/G	cg01072550	chr1:21505969	NA	-0.5	-7.94	-0.58	1.04e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs908922	0.676	rs11205033	chr1:152527966	C/A	cg20991723	chr1:152506922	NA	0.44	5.99	0.47	2.14e-8	Hair morphology;
TGCT	cis	rs7103648	0.864	rs10742802	chr11:47432725	T/G	cg20307385	chr11:47447363	PSMC3	1.02	12.61	0.75	5.75e-24	Diastolic blood pressure;Systolic blood pressure;
TGCT	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg11494091	chr17:61959527	GH2	0.43	7.49	0.56	1.13e-11	Height;
TGCT	cis	rs6867032	0.839	rs4314451	chr5:2001859	T/C	cg26168224	chr5:2018326	NA	-0.37	-5.67	-0.45	9.66e-8	Gut microbiome composition (winter);
TGCT	cis	rs13040088	1.000	rs6090155	chr20:61527378	G/A	cg23096297	chr20:61557774	DIDO1	1.13	9.5	0.65	2e-16	Menopause (age at onset);
TGCT	cis	rs7267979	1.000	rs1888997	chr20:25298988	G/A	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs644799	1.000	rs632388	chr11:95563775	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	10.52	0.69	6.94e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7258465	1.000	rs7252848	chr19:18612351	C/G	cg06462663	chr19:18546047	ISYNA1	0.2	4.58	0.38	1.1e-5	Breast cancer;
TGCT	cis	rs9814567	1.000	rs4367113	chr3:134287975	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.91	-8.45	-0.6	6.55e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs950776	0.616	rs12901300	chr15:78892952	G/A	cg06917634	chr15:78832804	PSMA4	0.65	5.3	0.43	5.01e-7	Sudden cardiac arrest;
TGCT	trans	rs2727020	0.658	rs10839269	chr11:49385596	A/G	cg03929089	chr4:120376271	NA	-0.75	-8.6	-0.61	2.96e-14	Coronary artery disease;
TGCT	trans	rs1814175	0.817	rs10839397	chr11:49857074	C/T	cg03929089	chr4:120376271	NA	-0.72	-8.26	-0.6	1.84e-13	Height;
TGCT	cis	rs9905704	0.671	rs28709536	chr17:57008912	C/A	cg12560992	chr17:57184187	TRIM37	0.58	4.93	0.4	2.57e-6	Testicular germ cell tumor;
TGCT	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg18876405	chr7:65276391	NA	0.32	4.93	0.4	2.61e-6	Aortic root size;
TGCT	cis	rs782590	0.935	rs2586954	chr2:55892261	A/C	cg18811423	chr2:55921094	PNPT1	0.63	6.36	0.5	3.48e-9	Metabolic syndrome;
TGCT	cis	rs12477438	0.798	rs6705821	chr2:99602832	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-5.87	-0.47	3.74e-8	Chronic sinus infection;
TGCT	cis	rs860554	0.705	rs832175	chr1:201259645	G/A	cg01022117	chr1:201258280	PKP1	0.34	5.01	0.41	1.87e-6	Panic disorder;
TGCT	cis	rs3858526	0.833	rs4758184	chr11:5926719	A/G	cg13902645	chr11:5959945	NA	-0.43	-4.62	-0.38	9.28e-6	DNA methylation (variation);
TGCT	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs28735056	0.904	rs12962619	chr18:77628832	T/C	cg20368463	chr18:77673604	PQLC1	0.4	4.89	0.4	3.09e-6	Schizophrenia;
TGCT	cis	rs55882075	0.936	rs34646062	chr5:179186318	A/G	cg14593053	chr5:179126677	CANX	-0.48	-5.25	-0.43	6.37e-7	Monocyte percentage of white cells;
TGCT	cis	rs4252435	0.614	rs4252430	chr7:142623217	T/A	cg09833174	chr7:143059591	FAM131B	-0.93	-4.5	-0.37	1.56e-5	Cancer;
TGCT	cis	rs854765	0.583	rs6502619	chr17:17779704	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.74	-7.98	-0.58	8.43e-13	Total body bone mineral density;
TGCT	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.39	5.24	0.43	6.78e-7	Lymphocyte counts;
TGCT	cis	rs8077889	0.719	rs57227660	chr17:41858984	T/C	cg26893861	chr17:41843967	DUSP3	1.11	20.15	0.88	6.31e-41	Triglycerides;
TGCT	cis	rs1865760	0.593	rs2097273	chr6:25941310	A/C	cg12310025	chr6:25882481	NA	-0.53	-5.34	-0.43	4.2e-7	Height;
TGCT	cis	rs4711350	0.678	rs658087	chr6:33665020	A/T	cg00334056	chr6:33755658	LEMD2	0.34	4.53	0.38	1.35e-5	Schizophrenia;
TGCT	cis	rs73815153	0.744	rs28415335	chr5:180459592	T/C	cg00299286	chr5:180478185	BTNL9	0.87	4.98	0.41	2.08e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
TGCT	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg08439880	chr3:133502540	NA	-0.35	-6.71	-0.52	6.07e-10	Iron status biomarkers;
TGCT	cis	rs9443645	0.869	rs2095724	chr6:79742101	C/T	cg09184832	chr6:79620586	NA	-0.48	-5.34	-0.43	4.21e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs12048904	0.505	rs10493936	chr1:101213335	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.56	-4.91	-0.4	2.79e-6	Multiple sclerosis;
TGCT	cis	rs12413816	0.818	rs35567671	chr10:13769722	C/A	cg16485048	chr10:13749193	FRMD4A	0.26	5.32	0.43	4.71e-7	Red cell distribution width;
TGCT	cis	rs926938	0.618	rs360587	chr1:115467553	A/G	cg12756093	chr1:115239321	AMPD1	0.4	5.93	0.47	2.85e-8	Autism;
TGCT	cis	rs6570726	0.935	rs386344	chr6:145855622	A/G	cg05347473	chr6:146136440	FBXO30	0.49	4.66	0.39	8.1e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs12220898	0.679	rs7082585	chr10:50486747	G/T	cg09603381	chr10:49954066	WDFY4	0.39	4.62	0.38	9.57e-6	Inflammatory biomarkers;
TGCT	cis	rs473651	0.935	rs35080527	chr2:239351387	T/C	cg21699342	chr2:239360505	ASB1	0.17	4.78	0.39	4.78e-6	Multiple system atrophy;
TGCT	cis	rs7666738	0.830	rs11940273	chr4:98979965	T/A	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10858047	0.883	rs6691804	chr1:115193549	T/C	cg12756093	chr1:115239321	AMPD1	-0.47	-4.96	-0.41	2.27e-6	Autism;
TGCT	cis	rs10186029	0.680	rs12694293	chr2:213937221	T/C	cg08319019	chr2:214017104	IKZF2	0.63	5.81	0.46	5.05e-8	Systemic sclerosis;
TGCT	cis	rs2153535	0.580	rs1335633	chr6:8448800	C/T	cg07606381	chr6:8435919	SLC35B3	0.53	5.02	0.41	1.79e-6	Motion sickness;
TGCT	cis	rs11096990	0.634	rs12648793	chr4:39286093	T/C	cg20847110	chr4:39482781	LOC401127	-0.16	-4.51	-0.38	1.46e-5	Cognitive function;
TGCT	cis	rs17221829	0.733	rs10830299	chr11:89362670	C/T	cg02982614	chr11:89391479	FOLH1B	-0.28	-4.87	-0.4	3.35e-6	Anxiety in major depressive disorder;
TGCT	cis	rs1215050	0.791	rs649866	chr4:98738826	T/C	cg17366294	chr4:99064904	C4orf37	0.52	5.57	0.45	1.53e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.36	0.55	2.25e-11	Prudent dietary pattern;
TGCT	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg13409248	chr3:40428643	ENTPD3	0.57	4.53	0.38	1.37e-5	Renal cell carcinoma;
TGCT	cis	rs10174077	0.874	rs4664490	chr2:152471923	C/G	cg06191203	chr2:152266755	RIF1	0.7	6.68	0.51	7.28e-10	Squamous cell lung carcinoma;
TGCT	cis	rs2228479	0.717	rs2286392	chr16:89809549	A/G	cg27121462	chr16:89883253	FANCA	0.77	4.61	0.38	9.93e-6	Skin colour saturation;
TGCT	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg08280861	chr8:58055591	NA	0.34	4.67	0.39	7.83e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1185460	0.967	rs11217137	chr11:118931030	A/G	cg01677386	chr11:118938358	VPS11	-0.56	-4.71	-0.39	6.62e-6	Coronary artery disease;
TGCT	trans	rs71007656	1	rs71007656	chr10:37970845	CGGCTG/C	cg17830980	chr10:43048298	ZNF37B	-0.66	-7.47	-0.56	1.22e-11	Extrinsic epigenetic age acceleration;
TGCT	cis	rs3540	0.554	rs34650360	chr15:91059017	T/C	cg22089800	chr15:90895588	ZNF774	-0.76	-7.96	-0.58	9.33e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg11494091	chr17:61959527	GH2	0.43	7.3	0.55	3.05e-11	Height;
TGCT	cis	rs7017914	0.902	rs7831792	chr8:71565356	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.5	-4.68	-0.39	7.37e-6	Bone mineral density;
TGCT	cis	rs6854137	1.000	rs6854137	chr4:169728236	T/G	cg20607169	chr4:169750834	PALLD	0.23	4.97	0.41	2.13e-6	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs2197308	0.655	rs1971964	chr12:37870474	C/T	cg13010199	chr12:38710504	ALG10B	0.67	5.31	0.43	4.84e-7	Morning vs. evening chronotype;
TGCT	cis	rs6714710	0.603	rs116309486	chr2:98493359	A/G	cg26665480	chr2:98280029	ACTR1B	0.64	6.06	0.48	1.48e-8	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs17376456	0.569	rs7736892	chr5:93205597	G/A	cg25358565	chr5:93447407	FAM172A	-0.8	-6.09	-0.48	1.31e-8	Diabetic retinopathy;
TGCT	cis	rs9388451	0.839	rs9321054	chr6:126079968	A/G	cg10911889	chr6:126070802	HEY2	-0.53	-5.52	-0.44	1.88e-7	Brugada syndrome;
TGCT	cis	rs16975963	0.793	rs1807157	chr19:38465523	G/T	cg14550563	chr19:38990264	RYR1	0.28	4.58	0.38	1.09e-5	Longevity;
TGCT	cis	rs1784581	0.588	rs9295178	chr6:162419226	T/A	cg17173639	chr6:162384350	PARK2	0.4	6.6	0.51	1.08e-9	Itch intensity from mosquito bite;
TGCT	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg23719950	chr11:63933701	MACROD1	-0.72	-5.92	-0.47	2.99e-8	Mean platelet volume;
TGCT	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg24675658	chr1:53192096	ZYG11B	0.74	8.68	0.61	1.87e-14	Monocyte count;
TGCT	cis	rs3806843	0.576	rs246062	chr5:140324580	T/A	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs428668	0.523	rs3926389	chr5:150677806	C/T	cg11125805	chr5:150678162	SLC36A3	0.31	7.89	0.58	1.37e-12	Skin aging (microtopography measurement);
TGCT	cis	rs6540559	0.673	rs1073150	chr1:210017083	G/A	cg21951975	chr1:209979733	IRF6	0.63	4.76	0.39	5.36e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs36051895	0.626	rs9695934	chr9:5153108	C/G	cg02405213	chr9:5042618	JAK2	-0.73	-9.46	-0.65	2.54e-16	Pediatric autoimmune diseases;
TGCT	cis	rs7582180	0.591	rs11674569	chr2:101010860	G/A	cg08017756	chr2:100939284	LONRF2	-0.31	-4.87	-0.4	3.32e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9486719	1.000	rs2205755	chr6:96864704	A/G	cg06623918	chr6:96969491	KIAA0776	1.01	8.86	0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs5417	0.751	rs1634381	chr17:7180007	C/T	cg25256661	chr17:7137939	DVL2	-0.62	-6.13	-0.48	1.07e-8	Diastolic blood pressure;
TGCT	cis	rs9911578	0.967	rs7502208	chr17:57165097	G/A	cg12560992	chr17:57184187	TRIM37	0.78	9.66	0.66	8.55e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs6424115	0.867	rs10917431	chr1:24174093	T/G	cg15997130	chr1:24165203	NA	-0.89	-10.18	-0.67	4.6e-18	Immature fraction of reticulocytes;
TGCT	cis	rs10466239	0.730	rs12221341	chr10:43857330	C/G	cg20669305	chr10:44070200	ZNF239	-0.66	-4.45	-0.37	1.86e-5	Telomere length;
TGCT	trans	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg17470723	chr8:74884337	TCEB1	0.74	6.92	0.53	2.19e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg25767906	chr1:53392781	SCP2	0.48	5.55	0.45	1.62e-7	Monocyte count;
TGCT	cis	rs9303401	0.659	rs35564417	chr17:56718286	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs12421382	0.778	rs12804063	chr11:109495509	C/T	cg16359550	chr11:109292809	C11orf87	-0.49	-4.88	-0.4	3.23e-6	Schizophrenia;
TGCT	cis	rs7394190	0.748	rs11000728	chr10:75404300	C/G	cg07699608	chr10:75541558	CHCHD1	0.62	4.64	0.38	8.58e-6	Incident atrial fibrillation;
TGCT	cis	rs7769051	1.000	rs9493445	chr6:133125409	C/T	cg22852734	chr6:133119734	C6orf192	1.22	7.01	0.53	1.38e-10	Type 2 diabetes nephropathy;
TGCT	cis	rs8072100	0.544	rs7214993	chr17:45386797	C/G	cg08085267	chr17:45401833	C17orf57	-0.49	-5.58	-0.45	1.47e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.68	4.84	0.4	3.86e-6	Platelet count;
TGCT	cis	rs7523050	0.643	rs35526993	chr1:109405107	A/T	cg08274380	chr1:109419600	GPSM2	1.3	6.39	0.5	2.99e-9	Fat distribution (HIV);
TGCT	cis	rs6933660	0.665	rs6921042	chr6:151732385	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.65	6.34	0.49	3.82e-9	Menarche (age at onset);
TGCT	cis	rs67311347	1.000	rs56291770	chr3:40515370	T/C	cg17264618	chr3:40429014	ENTPD3	0.32	4.45	0.37	1.88e-5	Renal cell carcinoma;
TGCT	cis	rs4523957	0.614	rs7212964	chr17:2059319	C/T	cg16513277	chr17:2031491	SMG6	-0.2	-4.64	-0.38	8.83e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg26513180	chr16:89883248	FANCA	1.05	14.37	0.79	3.52e-28	Vitiligo;
TGCT	cis	rs3935685	0.874	rs4076998	chr15:78025420	T/G	cg25212270	chr15:78015279	NA	0.27	5.84	0.46	4.38e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs911186	0.786	rs72842197	chr6:27067083	C/T	cg16898833	chr6:26189333	HIST1H4D	0.8	4.85	0.4	3.57e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9457247	0.534	rs4710149	chr6:167386346	T/C	cg23791538	chr6:167370224	RNASET2	0.63	6.27	0.49	5.55e-9	Crohn's disease;
TGCT	cis	rs6690583	0.623	rs1371142	chr1:85455373	A/T	cg20280350	chr1:85513789	MCOLN3	-0.74	-5.11	-0.42	1.2e-6	Serum sulfate level;
TGCT	cis	rs9467773	1.000	rs9461259	chr6:26504835	C/A	cg05738196	chr6:26577821	NA	0.88	12.49	0.75	1.09e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg21951975	chr1:209979733	IRF6	0.7	6.01	0.47	1.92e-8	Cleft lip with or without cleft palate;
TGCT	cis	rs7568458	0.684	rs1048739	chr2:85764968	T/G	cg02493740	chr2:85810744	VAMP5	-0.28	-5.26	-0.43	6.1e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs1018836	0.632	rs9642910	chr8:91475724	G/T	cg16814680	chr8:91681699	NA	-0.8	-8.32	-0.6	1.33e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs611744	0.967	rs641721	chr8:109230140	G/A	cg21045802	chr8:109455806	TTC35	0.52	4.72	0.39	6.21e-6	Dupuytren's disease;
TGCT	cis	rs3812831	0.695	rs423237	chr13:114930955	C/T	cg06611532	chr13:114900021	NA	0.35	6.42	0.5	2.57e-9	Schizophrenia;
TGCT	trans	rs61931739	0.500	rs11053203	chr12:34456593	C/T	cg26384229	chr12:38710491	ALG10B	0.73	6.92	0.53	2.09e-10	Morning vs. evening chronotype;
TGCT	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.51	4.49	0.37	1.58e-5	Height;
TGCT	cis	rs877282	0.947	rs4133015	chr10:774131	T/C	cg17470449	chr10:769945	NA	0.3	4.77	0.39	5.05e-6	Uric acid levels;
TGCT	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg11644478	chr21:40555479	PSMG1	1.01	10.73	0.69	2.08e-19	Cognitive function;
TGCT	cis	rs12500482	0.935	rs2239736	chr4:2438929	T/C	cg01601518	chr4:2404284	ZFYVE28	-0.28	-4.62	-0.38	9.36e-6	Cognitive function;
TGCT	cis	rs514406	0.698	rs1672913	chr1:53408326	A/T	cg16325326	chr1:53192061	ZYG11B	0.5	5.59	0.45	1.38e-7	Monocyte count;
TGCT	cis	rs9326248	0.520	rs2735183	chr11:117015195	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.59	5.32	0.43	4.69e-7	Blood protein levels;
TGCT	cis	rs707040	1.000	rs1154759	chr2:155236334	G/A	cg18104148	chr2:154337490	NA	0.19	4.56	0.38	1.2e-5	Sudden cardiac arrest;
TGCT	cis	rs1865760	0.516	rs9379819	chr6:26049819	A/C	cg17042849	chr6:26104293	HIST1H4C	-0.65	-5.76	-0.46	6.19e-8	Height;
TGCT	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg05025164	chr4:1340916	KIAA1530	0.76	6.51	0.5	1.65e-9	Longevity;
TGCT	cis	rs826838	0.967	rs11168299	chr12:38902028	G/T	cg13010199	chr12:38710504	ALG10B	0.78	6.42	0.5	2.61e-9	Heart rate;
TGCT	cis	rs4819052	0.851	rs1056100	chr21:46678711	A/C	cg06618935	chr21:46677482	NA	-0.36	-5.37	-0.43	3.67e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2243480	1.000	rs462853	chr7:65558167	G/C	cg07424592	chr7:64974309	NA	1.26	8.11	0.59	4.17e-13	Diabetic kidney disease;
TGCT	trans	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg21659725	chr3:3221576	CRBN	-0.98	-15.33	-0.81	2.1000000000000002e-30	Intelligence (multi-trait analysis);
TGCT	cis	rs425277	1.000	rs262657	chr1:2088577	G/A	cg03732007	chr1:2071316	PRKCZ	0.26	5.33	0.43	4.49e-7	Height;
TGCT	cis	rs910316	1.000	rs7142235	chr14:75559963	T/C	cg08847533	chr14:75593920	NEK9	0.96	10.9	0.7	8.37e-20	Height;
TGCT	cis	rs5167	0.601	rs892131	chr19:45496996	C/T	cg13119609	chr19:45449297	APOC2	0.23	4.65	0.39	8.26e-6	Blood protein levels;
TGCT	cis	rs2832191	0.935	rs11910316	chr21:30519729	G/A	cg24692254	chr21:30365293	RNF160	-0.79	-8.35	-0.6	1.12e-13	Dental caries;
TGCT	cis	rs9611565	0.512	rs5758465	chr22:42175314	T/C	cg06481639	chr22:41940642	POLR3H	0.69	6.05	0.48	1.59e-8	Vitiligo;
TGCT	cis	rs10949834	0.824	rs2285025	chr7:73529976	T/C	cg07137043	chr7:73588983	EIF4H	-0.74	-4.53	-0.38	1.38e-5	Verbal memory performance (residualized delayed recall change);
TGCT	cis	rs11098499	0.909	rs10020034	chr4:120294331	A/G	cg09307838	chr4:120376055	NA	0.65	6.4	0.5	2.84e-9	Corneal astigmatism;
TGCT	cis	rs12950390	0.820	rs58391889	chr17:45865959	A/G	cg24803719	chr17:45855879	NA	-0.47	-4.75	-0.39	5.63e-6	IgG glycosylation;
TGCT	cis	rs262150	0.579	rs4481540	chr7:158785846	A/G	cg01219135	chr7:158766336	NA	-0.47	-4.86	-0.4	3.46e-6	Facial morphology (factor 20);
TGCT	cis	rs61884328	0.852	rs17790390	chr11:47151897	A/G	cg13308137	chr11:47528955	CUGBP1	-0.38	-4.59	-0.38	1.09e-5	Total body bone mineral density (age over 60);
TGCT	cis	rs1729951	0.575	rs168635	chr3:136699078	A/G	cg21827317	chr3:136751795	NA	0.4	5.61	0.45	1.28e-7	Neuroticism;
TGCT	cis	rs367615	0.918	rs4270746	chr5:108876839	T/C	cg17395555	chr5:108820864	NA	0.31	5.01	0.41	1.85e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs10992471	0.597	rs11789163	chr9:95234973	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-5.39	-0.44	3.43e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs7572733	0.515	rs13408411	chr2:198825462	G/A	cg00792783	chr2:198669748	PLCL1	0.57	5.23	0.43	6.99e-7	Dermatomyositis;
TGCT	cis	rs9467773	1.000	rs10946835	chr6:26533757	C/T	cg26531700	chr6:26746687	NA	0.47	4.57	0.38	1.14e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs6558530	0.692	rs6558522	chr8:1702370	C/G	cg09410841	chr8:1729607	CLN8	-0.69	-6.1	-0.48	1.22e-8	Systolic blood pressure;
TGCT	cis	rs453301	0.686	rs7017868	chr8:8873293	G/A	cg15556689	chr8:8085844	FLJ10661	-0.64	-5.29	-0.43	5.37e-7	Joint mobility (Beighton score);
TGCT	cis	rs36051895	0.695	rs60221565	chr9:5029077	T/G	cg02405213	chr9:5042618	JAK2	-0.77	-10.43	-0.68	1.16e-18	Pediatric autoimmune diseases;
TGCT	cis	rs2675662	0.525	rs12264025	chr10:75494450	A/G	cg19442545	chr10:75533431	FUT11	-0.37	-5.77	-0.46	5.89e-8	Psoriasis vulgaris;Psoriasis;
TGCT	cis	rs11249608	0.600	rs6859767	chr5:178451107	T/C	cg01312482	chr5:178451176	ZNF879	-0.56	-5.5	-0.44	2.09e-7	Pubertal anthropometrics;
TGCT	cis	rs7772486	0.875	rs9322046	chr6:146393625	A/G	cg23711669	chr6:146136114	FBXO30	0.89	9.59	0.65	1.22e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs916888	0.610	rs199436	chr17:44789285	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.59	-4.73	-0.39	6.05e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg17971929	chr21:40555470	PSMG1	0.95	9.06	0.63	2.31e-15	Cognitive function;
TGCT	cis	rs6964587	0.900	rs6972027	chr7:91781380	T/C	cg22709100	chr7:91322751	NA	0.29	4.62	0.38	9.33e-6	Breast cancer;
TGCT	cis	rs2153535	0.526	rs9406179	chr6:8538224	G/A	cg07606381	chr6:8435919	SLC35B3	0.55	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs514406	0.621	rs928452	chr1:53195926	G/C	cg25767906	chr1:53392781	SCP2	0.44	4.79	0.4	4.68e-6	Monocyte count;
TGCT	cis	rs9465539	0.544	rs6910773	chr6:19820658	T/C	cg23687194	chr6:19839375	ID4	0.56	4.53	0.38	1.35e-5	Neuroticism;
TGCT	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.01	0.41	1.86e-6	Prudent dietary pattern;
TGCT	cis	rs17376456	0.877	rs7702521	chr5:93484579	G/T	cg21475434	chr5:93447410	FAM172A	0.63	4.67	0.39	7.67e-6	Diabetic retinopathy;
TGCT	cis	rs2562456	0.876	rs7252585	chr19:21657943	C/T	cg25650185	chr19:21324782	ZNF431	0.56	4.79	0.4	4.63e-6	Pain;
TGCT	cis	rs514406	0.505	rs447581	chr1:53177098	T/C	cg25767906	chr1:53392781	SCP2	-0.47	-5.22	-0.42	7.39e-7	Monocyte count;
TGCT	cis	rs35883536	1.000	rs2297715	chr1:101092594	A/G	cg06223162	chr1:101003688	GPR88	0.29	4.56	0.38	1.19e-5	Monocyte count;
TGCT	cis	rs3008870	0.920	rs12132532	chr1:67457015	G/T	cg11518657	chr1:67396239	MIER1	-0.54	-4.61	-0.38	9.72e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs1865760	0.516	rs9379819	chr6:26049819	A/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.77	7.39	0.55	1.92e-11	Height;
TGCT	cis	rs903263	0.901	rs3768258	chr1:84670457	A/G	cg09664975	chr1:84543551	PRKACB	0.49	4.69	0.39	7.19e-6	Breast cancer (male);
TGCT	cis	rs904251	0.600	rs1874736	chr6:37447994	C/G	cg01843034	chr6:37503916	NA	-0.47	-6.02	-0.48	1.83e-8	Cognitive performance;
TGCT	cis	rs10904908	0.763	rs10795469	chr10:17334935	A/G	cg01003015	chr10:17271136	VIM	0.58	4.68	0.39	7.45e-6	Total cholesterol levels;Cholesterol, total;
TGCT	cis	rs5750830	0.645	rs756640	chr22:39779300	G/A	cg05872129	chr22:39784769	NA	-0.96	-11.07	-0.7	3.18e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs11690935	0.879	rs908671	chr2:172690265	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.17	-12.01	-0.73	1.6400000000000001e-22	Schizophrenia;
TGCT	cis	rs9987353	0.522	rs2929466	chr8:9063899	G/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-5.01	-0.41	1.8e-6	Recombination measurement;
TGCT	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg00814883	chr7:100076585	TSC22D4	-0.85	-8.62	-0.61	2.62e-14	Platelet count;
TGCT	cis	rs6088580	0.609	rs6058029	chr20:32969643	T/C	cg24642439	chr20:33292090	TP53INP2	-0.49	-4.49	-0.37	1.59e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs3829109	0.564	rs11145910	chr9:139300494	A/G	cg13741927	chr9:139327495	INPP5E	-0.24	-5.32	-0.43	4.78e-7	Peak insulin response;Acute insulin response;
TGCT	trans	rs17684571	0.938	rs17684511	chr6:56566015	G/C	cg14229071	chr15:89282588	NA	0.52	6.82	0.52	3.54e-10	Schizophrenia;
TGCT	cis	rs7014346	0.767	rs2060776	chr8:128420117	G/T	cg04263511	chr8:128962092	PVT1	-0.31	-4.55	-0.38	1.25e-5	Colorectal cancer;
TGCT	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.13	0.82	3.12e-32	Prudent dietary pattern;
TGCT	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg22764044	chr5:178986830	RUFY1	0.42	4.73	0.39	5.98e-6	Lung cancer;
TGCT	cis	rs11098499	0.954	rs10518328	chr4:120401779	G/A	cg09307838	chr4:120376055	NA	0.69	6.64	0.51	8.97e-10	Corneal astigmatism;
TGCT	cis	rs35771425	0.500	rs3738199	chr1:211545344	A/G	cg25617285	chr1:211431773	RCOR3	-0.51	-6.16	-0.48	9.51e-9	Educational attainment (years of education);
TGCT	cis	rs2046867	0.908	rs28822756	chr3:72825011	C/T	cg25664220	chr3:72788482	NA	-0.53	-6.73	-0.52	5.56e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7223966	1.000	rs7220892	chr17:61908316	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	4.68	0.39	7.5e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg25767906	chr1:53392781	SCP2	0.48	5.55	0.45	1.62e-7	Monocyte count;
TGCT	cis	rs12908161	0.959	rs11637728	chr15:85203392	A/T	cg17173187	chr15:85201210	NMB	0.57	6.33	0.49	4.18e-9	Schizophrenia;
TGCT	cis	rs17253792	0.822	rs2296181	chr14:56107051	G/A	cg01858014	chr14:56050164	KTN1	-0.35	-4.5	-0.37	1.53e-5	Putamen volume;
TGCT	cis	rs7091068	0.532	rs637959	chr10:95399031	T/C	cg20715218	chr10:95462985	C10orf4	-0.49	-5.9	-0.47	3.27e-8	Urinary tract infection frequency;
TGCT	cis	rs67311347	0.911	rs9849224	chr3:40392562	T/C	cg13683864	chr3:40499215	RPL14	-1.02	-10.8	-0.7	1.43e-19	Renal cell carcinoma;
TGCT	cis	rs67311347	1.000	rs28434528	chr3:40484893	A/G	cg17264618	chr3:40429014	ENTPD3	0.32	4.76	0.39	5.36e-6	Renal cell carcinoma;
TGCT	cis	rs2688608	1.000	rs2688608	chr10:75658349	G/T	cg19442545	chr10:75533431	FUT11	-0.3	-4.75	-0.39	5.44e-6	Inflammatory bowel disease;
TGCT	cis	rs295140	0.565	rs295139	chr2:201159988	T/A	cg23649088	chr2:200775458	C2orf69	0.27	4.5	0.37	1.54e-5	QT interval;
TGCT	cis	rs2235649	0.588	rs11863172	chr16:1909083	C/G	cg02432467	chr16:1963432	HS3ST6	-0.32	-4.6	-0.38	1.02e-5	Blood metabolite levels;
TGCT	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	5.8	0.46	5.19e-8	Alzheimer's disease;
TGCT	cis	rs11676348	0.846	rs6723449	chr2:218997580	C/T	cg00012203	chr2:219082015	ARPC2	0.51	4.85	0.4	3.59e-6	Ulcerative colitis;
TGCT	cis	rs3008870	1.000	rs1118393	chr1:67366668	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.07	11.84	0.73	4.25e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg08219700	chr8:58056026	NA	0.3	4.55	0.38	1.25e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs155076	1.000	rs58519241	chr13:21845006	C/A	cg11317459	chr13:21872234	NA	-1.42	-12.02	-0.73	1.53e-22	White matter hyperintensity burden;
TGCT	cis	rs9926296	0.744	rs164746	chr16:89709019	C/T	cg26513180	chr16:89883248	FANCA	-0.57	-5.42	-0.44	3.04e-7	Vitiligo;
TGCT	cis	rs7647973	0.925	rs6446257	chr3:49253492	A/G	cg07636037	chr3:49044803	WDR6	-0.69	-5.82	-0.46	4.72e-8	Menarche (age at onset);
TGCT	cis	rs12579753	0.709	rs34503239	chr12:82124199	G/T	cg21231944	chr12:82153410	PPFIA2	-0.36	-4.75	-0.39	5.5e-6	Resting heart rate;
TGCT	cis	rs2228479	0.681	rs8044906	chr16:89969603	T/C	cg27121462	chr16:89883253	FANCA	0.62	4.51	0.38	1.51e-5	Skin colour saturation;
TGCT	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg01802117	chr1:53393560	SCP2	0.47	5.77	0.46	5.88e-8	Monocyte count;
TGCT	cis	rs7617773	0.817	rs9837228	chr3:48324466	A/T	cg11946769	chr3:48343235	NME6	-0.72	-6.16	-0.48	9.39e-9	Coronary artery disease;
TGCT	cis	rs12479064	0.604	rs11893359	chr2:99954608	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.77	-6.7	-0.52	6.68e-10	Chronic sinus infection;
TGCT	trans	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg11887960	chr12:57824829	NA	1.14	9.3	0.64	6.29e-16	Lung disease severity in cystic fibrosis;
TGCT	cis	rs3751972	0.911	rs8078361	chr17:26230480	C/T	cg02948944	chr17:26242737	NA	0.5	7.28	0.55	3.35e-11	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs56104184	0.779	rs17206693	chr19:49360252	C/G	cg21252483	chr19:49399788	TULP2	-0.4	-5.09	-0.42	1.27e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs67311347	0.544	rs6804545	chr3:40354040	G/C	cg13683864	chr3:40499215	RPL14	-0.8	-7.5	-0.56	1.09e-11	Renal cell carcinoma;
TGCT	cis	rs7312933	0.558	rs2178753	chr12:42732804	T/C	cg19980929	chr12:42632907	YAF2	-0.41	-5.76	-0.46	6.18e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg08280861	chr8:58055591	NA	0.46	5.19	0.42	8.5e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs13191362	1.000	rs13218900	chr6:163081638	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.07	8.36	0.6	1.07e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs8180040	0.726	rs1869869	chr3:47027833	G/A	cg27129171	chr3:47204927	SETD2	0.72	9.15	0.63	1.47e-15	Colorectal cancer;
TGCT	cis	rs2439831	0.867	rs2412780	chr15:43655794	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	8.65	0.61	2.26e-14	Lung cancer in ever smokers;
TGCT	cis	rs3862030	0.500	rs11191327	chr10:104303883	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.72	0.62	1.54e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
TGCT	cis	rs1524927	1.000	rs11765843	chr7:96341168	T/A	cg03808172	chr7:96339361	SHFM1	0.49	5.06	0.41	1.45e-6	Total body bone mineral density;
TGCT	cis	rs56235845	0.964	rs11741640	chr5:176792743	G/A	cg16006841	chr5:176797999	RGS14	0.72	12.49	0.75	1.09e-23	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs17384381	1.000	rs12133722	chr1:85873237	C/T	cg16011679	chr1:85725395	C1orf52	0.8	6.44	0.5	2.39e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2439831	0.717	rs7165471	chr15:43644788	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	8.65	0.61	2.26e-14	Lung cancer in ever smokers;
TGCT	cis	rs7302981	0.967	rs6580729	chr12:50547038	G/A	cg23855989	chr12:50355821	AQP5	0.3	4.5	0.38	1.52e-5	Systolic blood pressure;
TGCT	cis	rs67385638	0.925	rs12417960	chr11:5265106	C/A	cg12559170	chr11:5275217	HBG2	0.49	8.65	0.61	2.2e-14	Hemoglobin levels;
TGCT	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg13628971	chr7:2884303	GNA12	0.54	4.64	0.38	8.74e-6	Height;
TGCT	trans	rs2688482	0.512	rs1106502	chr3:195517258	G/A	cg17952111	chr19:54960355	LENG8	0.83	6.82	0.52	3.57e-10	Lung disease severity in cystic fibrosis;
TGCT	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg03709012	chr19:19516395	GATAD2A	0.75	6.18	0.49	8.32e-9	Tonsillectomy;
TGCT	cis	rs9611565	0.918	rs2281333	chr22:41749630	T/C	cg06634786	chr22:41940651	POLR3H	-0.79	-7.66	-0.57	4.71e-12	Vitiligo;
TGCT	cis	rs3091242	0.809	rs660129	chr1:25727438	C/T	cg10117171	chr1:25599238	RHD	-0.36	-5.73	-0.46	7.35e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs1371867	0.839	rs1660313	chr8:101332712	G/A	cg06002616	chr8:101225028	SPAG1	-0.56	-6.58	-0.51	1.2e-9	Atrioventricular conduction;
TGCT	cis	rs1981331	0.609	rs57896262	chr21:48028188	C/T	cg23283320	chr21:48055893	PRMT2	1.33	7.14	0.54	7.05e-11	Cerebrospinal fluid t-tau:AB1-42 ratio;
TGCT	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg17775962	chr7:1200435	ZFAND2A	0.3	4.98	0.41	2.05e-6	Longevity;Endometriosis;
TGCT	trans	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.88	9.5	0.65	2.02e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs4699052	0.963	rs4699057	chr4:104171123	A/G	cg16532752	chr4:104119610	CENPE	0.54	4.56	0.38	1.22e-5	Testicular germ cell tumor;
TGCT	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg23302884	chr18:44338147	ST8SIA5	-0.4	-4.58	-0.38	1.11e-5	Personality dimensions;
TGCT	cis	rs2739330	0.576	rs2858912	chr22:24297197	A/G	cg20007245	chr22:24372913	LOC391322	-0.65	-6.44	-0.5	2.34e-9	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs524023	0.957	rs528211	chr11:64351721	C/T	cg07733098	chr11:64478343	NRXN2	-0.31	-4.63	-0.38	9.14e-6	Urate levels in obese individuals;
TGCT	cis	rs7110373	1	rs7110373	chr11:122813224	C/T	cg14473756	chr11:122847823	NA	-0.47	-4.63	-0.38	8.99e-6	Age at voice drop;
TGCT	cis	rs2982552	0.873	rs3020305	chr6:152064487	T/C	cg22157087	chr6:152012887	ESR1	0.21	4.93	0.4	2.61e-6	Bone properties (heel);
TGCT	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg17054783	chr10:134559939	INPP5A	0.27	5.15	0.42	1e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs3849570	1.000	rs9826270	chr3:81841869	C/T	cg07356753	chr3:81810745	GBE1	-0.82	-7.62	-0.56	5.6e-12	Waist circumference;Body mass index;
TGCT	cis	rs9926296	0.569	rs4785708	chr16:89796569	C/T	cg26513180	chr16:89883248	FANCA	-0.65	-6.28	-0.49	5.24e-9	Vitiligo;
TGCT	cis	rs7119	0.717	rs12910975	chr15:77817487	C/T	cg27398640	chr15:77910606	LINGO1	-0.25	-4.6	-0.38	1.05e-5	Type 2 diabetes;
TGCT	cis	rs11711311	1.000	rs13061150	chr3:113506734	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.7	-6.64	-0.51	8.96e-10	IgG glycosylation;
TGCT	cis	rs28595532	0.920	rs56027489	chr4:119780882	A/G	cg11846333	chr4:119757529	SEC24D	0.92	4.64	0.38	8.74e-6	Cannabis dependence symptom count;
TGCT	trans	rs7824557	0.510	rs2736297	chr8:11234885	C/G	cg15556689	chr8:8085844	FLJ10661	-0.74	-6.7	-0.52	6.42e-10	Retinal vascular caliber;
TGCT	cis	rs7726839	0.561	rs3915384	chr5:573395	G/T	cg09021430	chr5:549028	NA	-0.38	-5.56	-0.45	1.6e-7	Obesity-related traits;
TGCT	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.56	-5.49	-0.44	2.13e-7	Hemoglobin concentration;
TGCT	cis	rs9457247	0.565	rs55873403	chr6:167511800	C/T	cg07741184	chr6:167504864	NA	0.28	5.6	0.45	1.33e-7	Crohn's disease;
TGCT	cis	rs4886920	0.563	rs4509984	chr15:78079267	C/G	cg25212270	chr15:78015279	NA	-0.23	-4.87	-0.4	3.37e-6	Neuroticism;
TGCT	cis	rs7432375	0.578	rs17366234	chr3:136577085	C/T	cg12473912	chr3:136751656	NA	0.34	4.67	0.39	7.67e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs13191362	0.507	rs2849540	chr6:163094522	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.6	-5.55	-0.45	1.67e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs3806843	0.868	rs2531345	chr5:140126781	T/G	cg19875535	chr5:140030758	IK	-0.35	-5.97	-0.47	2.27e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg21724239	chr8:58056113	NA	0.38	5.09	0.42	1.31e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs3733585	0.648	rs7376155	chr4:9952588	C/T	cg00071950	chr4:10020882	SLC2A9	-0.55	-6.63	-0.51	9.3e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs12220898	0.584	rs10857455	chr10:50474712	A/T	cg09603381	chr10:49954066	WDFY4	0.38	4.45	0.37	1.85e-5	Inflammatory biomarkers;
TGCT	cis	rs11018874	0.709	rs10830428	chr11:89894294	C/G	cg05041596	chr11:89867385	NAALAD2	-0.52	-5.2	-0.42	8.14e-7	White blood cell types;
TGCT	cis	rs8032315	0.965	rs8027450	chr15:91418394	C/T	cg03209642	chr15:91427605	FES	0.55	5.41	0.44	3.11e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9486719	0.895	rs3734238	chr6:96996228	A/T	cg06623918	chr6:96969491	KIAA0776	-0.99	-7.99	-0.58	7.78e-13	Migraine;Coronary artery disease;
TGCT	trans	rs1814175	0.791	rs10219223	chr11:49791468	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.46	-0.56	1.33e-11	Height;
TGCT	cis	rs9902453	0.817	rs59420007	chr17:28196114	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	7.18	0.54	5.62e-11	Coffee consumption (cups per day);
TGCT	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg26668828	chr6:292823	DUSP22	-0.76	-7.85	-0.58	1.66e-12	Menopause (age at onset);
TGCT	cis	rs9486719	0.947	rs11153071	chr6:97039741	G/A	cg18709589	chr6:96969512	KIAA0776	-0.74	-5.21	-0.42	7.5e-7	Migraine;Coronary artery disease;
TGCT	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7508	0.612	rs17636098	chr8:17918726	G/A	cg01800426	chr8:17659068	MTUS1	0.52	4.51	0.38	1.49e-5	Atrial fibrillation;
TGCT	cis	rs1538970	0.924	rs7531253	chr1:45890183	T/C	cg05343316	chr1:45956843	TESK2	0.76	6.19	0.49	7.93e-9	Platelet count;
TGCT	cis	rs9814567	0.762	rs13071253	chr3:134316653	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	6.63	0.51	9.15e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs28374715	0.662	rs72737786	chr15:41500361	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.78	-11.07	-0.7	3.18e-20	Ulcerative colitis;
TGCT	cis	rs7772486	0.686	rs857882	chr6:145969716	T/G	cg13319975	chr6:146136371	FBXO30	0.54	4.98	0.41	2.09e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg06221963	chr1:154839813	KCNN3	-0.71	-11.67	-0.72	1.1e-21	Prostate cancer;
TGCT	cis	rs736408	0.812	rs2071507	chr3:52826707	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.48	-4.53	-0.38	1.39e-5	Bipolar disorder;
TGCT	cis	rs826838	1.000	rs11168367	chr12:38913397	T/G	cg13010199	chr12:38710504	ALG10B	0.77	6.38	0.5	3.21e-9	Heart rate;
TGCT	cis	rs7681440	0.605	rs1372509	chr4:90817311	A/G	cg20003494	chr4:90757398	SNCA	-0.54	-4.88	-0.4	3.21e-6	Dementia with Lewy bodies;
TGCT	cis	rs854765	0.533	rs2955354	chr17:17948716	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.79	-8.27	-0.6	1.76e-13	Total body bone mineral density;
TGCT	cis	rs6545883	0.965	rs2305156	chr2:61729268	T/C	cg15711740	chr2:61764176	XPO1	-0.54	-4.95	-0.41	2.39e-6	Tuberculosis;
TGCT	cis	rs12477438	0.798	rs7570657	chr2:99654281	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-4.62	-0.38	9.47e-6	Chronic sinus infection;
TGCT	cis	rs9926296	0.632	rs9935559	chr16:89800529	C/T	cg03388025	chr16:89894329	SPIRE2	-0.33	-4.9	-0.4	2.89e-6	Vitiligo;
TGCT	cis	rs634534	0.622	rs552130	chr11:65732800	T/C	cg04055107	chr11:65626734	MUS81;CFL1	0.45	4.47	0.37	1.73e-5	Sum eosinophil basophil counts;Eosinophil counts;
TGCT	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg06697600	chr4:7070879	GRPEL1	-0.45	-4.69	-0.39	7e-6	Monocyte percentage of white cells;
TGCT	cis	rs7267979	1.000	rs2258066	chr20:25271326	C/T	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg03709012	chr19:19516395	GATAD2A	0.67	5.74	0.46	6.83e-8	Tonsillectomy;
TGCT	cis	rs911263	0.603	rs12889949	chr14:68774854	T/G	cg18825221	chr14:68749962	RAD51L1	0.22	4.48	0.37	1.64e-5	Primary biliary cholangitis;
TGCT	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg09359103	chr1:154839909	KCNN3	-0.66	-12.15	-0.74	7.27e-23	Prostate cancer;
TGCT	cis	rs5167	0.566	rs35080293	chr19:45496624	T/G	cg13119609	chr19:45449297	APOC2	0.24	4.7	0.39	6.88e-6	Blood protein levels;
TGCT	cis	rs651907	0.557	rs62284198	chr3:101474699	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.9	10.87	0.7	9.43e-20	Colorectal cancer;
TGCT	cis	rs2836950	0.565	rs2836945	chr21:40596757	C/T	cg06238570	chr21:40685208	BRWD1	-0.6	-6.21	-0.49	7.27e-9	Menarche (age at onset);
TGCT	cis	rs76419734	0.850	rs115962916	chr4:106801715	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	1.01	4.61	0.38	9.71e-6	Post bronchodilator FEV1;
TGCT	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg15691649	chr6:25882328	NA	-0.35	-4.75	-0.39	5.41e-6	Blood metabolite levels;
TGCT	cis	rs9427116	0.502	rs9426830	chr1:154594690	A/G	cg17218026	chr1:154582156	ADAR	0.31	7.97	0.58	8.71e-13	Blood protein levels;
TGCT	cis	rs7975161	0.630	rs4964260	chr12:104634270	A/G	cg25273343	chr12:104657179	TXNRD1	-0.35	-4.83	-0.4	3.87e-6	Toenail selenium levels;
TGCT	cis	rs910316	0.967	rs175479	chr14:75561871	A/C	cg11812906	chr14:75593930	NEK9	-0.76	-7.41	-0.55	1.69e-11	Height;
TGCT	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg14983838	chr19:29218262	NA	0.83	6.81	0.52	3.8e-10	Methadone dose in opioid dependence;
TGCT	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg27170947	chr2:26402098	FAM59B	-0.39	-4.46	-0.37	1.8e-5	Gut microbiome composition (summer);
TGCT	cis	rs12188164	0.762	rs11745923	chr5:475408	T/G	cg21144161	chr5:423903	AHRR	0.26	4.81	0.4	4.22e-6	Cystic fibrosis severity;
TGCT	cis	rs3931020	0.530	rs6668736	chr1:75234550	C/T	cg17719053	chr1:75198211	TYW3;CRYZ	0.49	5.05	0.41	1.53e-6	Resistin levels;
TGCT	cis	rs2832191	0.692	rs8134627	chr21:30349069	C/T	cg24692254	chr21:30365293	RNF160	-0.99	-11.38	-0.71	5.44e-21	Dental caries;
TGCT	cis	rs9400467	0.537	rs73530977	chr6:111504819	C/T	cg15721981	chr6:111408429	SLC16A10	0.71	4.6	0.38	1.04e-5	Blood metabolite levels;Amino acid levels;
TGCT	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg18230493	chr5:56204884	C5orf35	-0.68	-5.92	-0.47	2.92e-8	Initial pursuit acceleration;
TGCT	cis	rs1215050	0.791	rs260889	chr4:98742340	A/G	cg17366294	chr4:99064904	C4orf37	0.52	5.61	0.45	1.27e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7914558	0.902	rs7092200	chr10:104844872	T/C	cg04362960	chr10:104952993	NT5C2	0.54	4.65	0.39	8.38e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs2458413	0.522	rs2669449	chr8:105372173	A/C	cg04554929	chr8:105342491	NA	0.48	5.77	0.46	5.95e-8	Paget's disease;
TGCT	cis	rs2236918	1.000	rs1627006	chr1:242038004	C/T	cg04158730	chr1:242011433	EXO1	0.53	4.64	0.38	8.79e-6	Menopause (age at onset);
TGCT	cis	rs6540559	0.673	rs41305104	chr1:209950848	G/A	cg22029157	chr1:209979665	IRF6	0.73	5.21	0.42	7.62e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs10782582	0.609	rs76260657	chr1:76338017	C/T	cg10523679	chr1:76189770	ACADM	-0.59	-5.42	-0.44	2.94e-7	Daytime sleep phenotypes;
TGCT	cis	rs3125734	0.671	rs3852406	chr10:64015162	T/C	cg09941381	chr10:64027924	RTKN2	-0.36	-5.52	-0.44	1.85e-7	Rheumatoid arthritis;
TGCT	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg03709012	chr19:19516395	GATAD2A	0.67	5.77	0.46	5.88e-8	Tonsillectomy;
TGCT	cis	rs7681440	0.626	rs2289515	chr4:90816790	T/A	cg10208370	chr4:90758469	SNCA	-0.57	-5.41	-0.44	3.05e-7	Dementia with Lewy bodies;
TGCT	cis	rs2742417	1.000	rs2742418	chr3:45731920	C/T	cg04837898	chr3:45731254	SACM1L	-0.55	-5.67	-0.45	9.39e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs13188386	0.585	rs7716495	chr5:42428091	G/A	cg14919554	chr5:43018629	NA	0.59	4.55	0.38	1.25e-5	Iron status biomarkers;
TGCT	cis	rs10114408	0.959	rs11791409	chr9:96642124	T/C	cg13679303	chr9:96623674	NA	-0.36	-4.69	-0.39	6.98e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs17345786	1.000	rs58907984	chr3:101305170	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	4.69	0.39	7.21e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs72634258	0.554	rs35307738	chr1:7919839	C/G	cg26816564	chr1:7831052	VAMP3	0.64	4.94	0.41	2.46e-6	Inflammatory bowel disease;
TGCT	cis	rs2072499	0.966	rs2842865	chr1:156159532	G/A	cg24450063	chr1:156163899	SLC25A44	1.19	17.21	0.84	1.15e-34	Testicular germ cell tumor;
TGCT	cis	rs7714584	1.000	rs79780973	chr5:150174810	T/C	cg22134413	chr5:150180641	NA	1.13	8.18	0.59	2.91e-13	Crohn's disease;
TGCT	cis	rs2180341	1.000	rs9388561	chr6:127634921	C/T	cg24812749	chr6:127587940	RNF146	0.98	7.64	0.57	5.06e-12	Breast cancer;
TGCT	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg21963583	chr11:68658836	MRPL21	0.39	6.34	0.49	3.91e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.94	-6.76	-0.52	4.89e-10	Gut microbiome composition (summer);
TGCT	cis	rs1568889	1.000	rs12804198	chr11:28143114	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	9.0	0.63	3.18e-15	Bipolar disorder;
TGCT	cis	rs11190604	1.000	rs11190557	chr10:102209369	G/A	cg16342193	chr10:102329863	NA	-0.4	-5.31	-0.43	4.85e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs6835098	0.962	rs3733477	chr4:174090004	G/A	cg08422745	chr4:174089978	GALNT7	-0.95	-11.46	-0.72	3.51e-21	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9473924	0.505	rs7768747	chr6:50931762	G/A	cg14470998	chr6:50812995	TFAP2B	1.37	7.34	0.55	2.4e-11	Body mass index;
TGCT	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs6545883	0.965	rs11887205	chr2:61774473	T/G	cg15711740	chr2:61764176	XPO1	-0.55	-5.06	-0.41	1.5e-6	Tuberculosis;
TGCT	cis	rs7927484	0.891	rs2000796	chr11:123136552	A/G	cg19096475	chr11:123066529	ASAM	-0.48	-4.79	-0.4	4.59e-6	Colorectal cancer;Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4319547	1.000	rs6489157	chr12:123101673	C/G	cg05707623	chr12:122985044	ZCCHC8	0.69	5.44	0.44	2.68e-7	Body mass index;
TGCT	cis	rs4808199	0.895	rs2285628	chr19:19467996	T/A	cg03709012	chr19:19516395	GATAD2A	0.84	6.72	0.52	5.97e-10	Nonalcoholic fatty liver disease;
TGCT	cis	rs6570726	0.755	rs2092296	chr6:145893684	A/C	cg13319975	chr6:146136371	FBXO30	-0.5	-4.51	-0.38	1.48e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6570726	0.818	rs437147	chr6:145875423	A/T	cg05347473	chr6:146136440	FBXO30	0.54	5.15	0.42	1.01e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs916888	0.610	rs142167	chr17:44795234	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.59	-4.64	-0.38	8.84e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs28493229	0.522	rs2233152	chr19:41281016	C/T	cg00475131	chr19:41117096	LTBP4	0.29	4.49	0.37	1.61e-5	Kawasaki disease;
TGCT	cis	rs35146811	0.700	rs866500	chr7:99840461	A/G	cg04778012	chr7:99775508	STAG3;GPC2	-0.34	-4.61	-0.38	9.7e-6	Coronary artery disease;
TGCT	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg08859206	chr1:53392774	SCP2	0.41	6.06	0.48	1.54e-8	Monocyte count;
TGCT	cis	rs75229567	0.618	rs11177848	chr12:70180892	A/G	cg10114359	chr12:70132523	RAB3IP	1.35	6.71	0.52	6.17e-10	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
TGCT	cis	rs9303401	0.659	rs17822735	chr17:56620167	C/T	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs892961	0.899	rs8071024	chr17:75414067	T/C	cg05865280	chr17:75406074	SEPT9	0.28	6.71	0.52	6.16e-10	Airflow obstruction;
TGCT	cis	rs9467773	0.967	rs6932865	chr6:26540166	C/A	cg05738196	chr6:26577821	NA	0.88	12.5	0.75	1.03e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs9972944	0.756	rs4791133	chr17:63769118	T/C	cg07283582	chr17:63770753	CCDC46	-0.26	-5.27	-0.43	5.91e-7	Total body bone mineral density;
TGCT	cis	rs9457247	0.967	rs2015864	chr6:167381476	T/C	cg23791538	chr6:167370224	RNASET2	0.5	4.98	0.41	2.08e-6	Crohn's disease;
TGCT	trans	rs1814175	0.647	rs28456013	chr11:50047629	T/C	cg03929089	chr4:120376271	NA	-0.59	-6.66	-0.51	7.82e-10	Height;
TGCT	cis	rs6893807	0.778	rs10514301	chr5:87939654	C/T	cg24804195	chr5:87968844	LOC645323	0.8	4.66	0.39	7.91e-6	Body mass index;
TGCT	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg11890956	chr21:40555474	PSMG1	1.12	12.59	0.75	6.25e-24	Cognitive function;
TGCT	cis	rs981844	1.000	rs55702511	chr4:154665978	A/C	cg14289246	chr4:154710475	SFRP2	1.01	8.67	0.61	2.02e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs40363	1.000	rs1635393	chr16:3520493	C/T	cg22508957	chr16:3507546	NAT15	0.56	5.25	0.43	6.33e-7	Tuberculosis;
TGCT	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.52	-5.85	-0.47	4.02e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs17767294	0.708	rs72848773	chr6:27926520	C/T	cg08851530	chr6:28072375	NA	1.56	7.22	0.54	4.47e-11	Parkinson's disease;
TGCT	cis	rs854765	0.964	rs12950562	chr17:17995166	C/T	cg09796270	chr17:17721594	SREBF1	-0.26	-5.08	-0.41	1.37e-6	Total body bone mineral density;
TGCT	trans	rs4650994	1.000	rs4650993	chr1:178515187	A/G	cg05059571	chr16:84539110	KIAA1609	-0.41	-7.68	-0.57	4.07e-12	HDL cholesterol levels;HDL cholesterol;
TGCT	trans	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg21659725	chr3:3221576	CRBN	-0.76	-9.35	-0.64	4.6e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs6138458	1.000	rs227624	chr20:24911562	T/C	cg26195577	chr20:24973756	C20orf3	1.2	12.04	0.73	1.35e-22	Blood protein levels;
TGCT	cis	rs9810089	0.903	rs711975	chr3:136235908	T/C	cg12473912	chr3:136751656	NA	0.34	4.83	0.4	3.9e-6	Gestational age at birth (child effect);
TGCT	cis	rs2777491	0.915	rs7165675	chr15:41614704	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.75	-10.44	-0.68	1.07e-18	Ulcerative colitis;
TGCT	cis	rs7954584	0.583	rs6486782	chr12:122359172	T/C	cg22618164	chr12:122356400	WDR66	0.53	5.18	0.42	8.83e-7	Mean corpuscular volume;
TGCT	cis	rs7191700	0.509	rs415595	chr16:11363692	A/G	cg00044050	chr16:11439710	C16orf75	0.65	6.36	0.5	3.54e-9	Multiple sclerosis;
TGCT	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs12615966	0.651	rs72830476	chr2:105414655	A/C	cg16465502	chr2:105461796	NA	0.85	5.6	0.45	1.34e-7	Pancreatic cancer;
TGCT	cis	rs6121246	0.909	rs6089071	chr20:30378384	C/G	cg18721089	chr20:30220636	NA	-0.43	-4.75	-0.39	5.54e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs4455778	0.659	rs2041340	chr7:49023478	A/C	cg26309511	chr7:48887640	NA	-0.43	-5.13	-0.42	1.09e-6	Lung cancer in never smokers;
TGCT	cis	rs4808199	0.947	rs1465695	chr19:19588546	A/C	cg03709012	chr19:19516395	GATAD2A	0.97	7.53	0.56	9.28e-12	Nonalcoholic fatty liver disease;
TGCT	cis	rs12477438	0.501	rs6542868	chr2:99782848	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	10.3	0.68	2.42e-18	Chronic sinus infection;
TGCT	cis	rs8180040	0.966	rs6790763	chr3:47572585	C/A	cg27129171	chr3:47204927	SETD2	0.62	7.29	0.55	3.27e-11	Colorectal cancer;
TGCT	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg11890956	chr21:40555474	PSMG1	-0.7	-6.76	-0.52	4.9e-10	Menarche (age at onset);
TGCT	cis	rs4478858	0.684	rs2271074	chr1:31734841	C/T	cg00250761	chr1:31883323	NA	-0.26	-4.55	-0.38	1.28e-5	Alcohol dependence;
TGCT	trans	rs2727020	0.681	rs2866362	chr11:49379316	A/G	cg03929089	chr4:120376271	NA	-0.74	-8.61	-0.61	2.73e-14	Coronary artery disease;
TGCT	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg24399712	chr22:39784796	NA	-1.05	-12.52	-0.75	9.61e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs60871478	1.000	rs34086011	chr7:805430	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.46	4.6	0.38	1.04e-5	Cerebrospinal P-tau181p levels;
TGCT	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg08509172	chr19:19383838	TM6SF2	-0.34	-4.48	-0.37	1.71e-5	Tonsillectomy;
TGCT	cis	rs9467773	0.869	rs9295689	chr6:26455811	T/C	cg26531700	chr6:26746687	NA	0.55	5.56	0.45	1.6e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs8051431	0.876	rs1559400	chr16:72011193	A/C	cg06353428	chr16:71660113	MARVELD3	0.59	5.02	0.41	1.73e-6	LDL cholesterol levels;
TGCT	trans	rs1496653	0.602	rs13100605	chr3:23325020	C/T	cg02770683	chr12:57597238	LRP1	0.36	6.66	0.51	8.06e-10	Type 2 diabetes;
TGCT	cis	rs765787	0.530	rs2554457	chr15:45520926	G/A	cg24006582	chr15:45444508	DUOX1	-0.25	-5.45	-0.44	2.66e-7	Uric acid levels;
TGCT	cis	rs9611565	0.592	rs5996039	chr22:41981957	A/G	cg13695892	chr22:41940480	POLR3H	-0.83	-7.82	-0.57	1.94e-12	Vitiligo;
TGCT	cis	rs72945132	0.882	rs6592554	chr11:70226040	G/A	cg00319359	chr11:70116639	PPFIA1	1.03	7.86	0.58	1.59e-12	Coronary artery disease;
TGCT	cis	rs2544527	0.586	rs1477253	chr2:15910457	T/C	cg26669897	chr2:15909070	NA	0.44	5.49	0.44	2.19e-7	Pulmonary function (smoking interaction);Pulmonary function;
TGCT	trans	rs7613875	0.620	rs11721204	chr3:49982765	C/T	cg21659725	chr3:3221576	CRBN	0.66	7.37	0.55	2.1e-11	Body mass index;
TGCT	trans	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg11887960	chr12:57824829	NA	1.14	9.88	0.66	2.52e-17	Obesity-related traits;
TGCT	cis	rs7172971	0.576	rs8042219	chr15:42352153	A/G	cg05886115	chr15:42349113	NA	-0.32	-5.2	-0.42	8.03e-7	3-hydroxypropylmercapturic acid levels in smokers;
TGCT	cis	rs2303745	0.589	rs1965717	chr19:17398559	C/T	cg02221750	chr19:17393354	ANKLE1	-0.46	-5.86	-0.47	3.98e-8	Systemic lupus erythematosus;
TGCT	cis	rs7412746	0.658	rs12410394	chr1:150860186	G/A	cg09365446	chr1:150670422	GOLPH3L	0.35	5.0	0.41	1.87e-6	Melanoma;
TGCT	cis	rs5167	0.566	rs2075618	chr19:45495668	G/C	cg09555818	chr19:45449301	APOC2	0.23	4.62	0.38	9.53e-6	Blood protein levels;
TGCT	cis	rs9611565	0.500	rs2011053	chr22:42121278	G/A	cg13695892	chr22:41940480	POLR3H	0.83	8.18	0.59	2.79e-13	Vitiligo;
TGCT	cis	rs12681288	0.862	rs935821	chr8:1022455	G/A	cg04851639	chr8:1020857	NA	-0.39	-7.5	-0.56	1.08e-11	Schizophrenia;
TGCT	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg17971929	chr21:40555470	PSMG1	0.91	8.16	0.59	3.18e-13	Cognitive function;
TGCT	cis	rs7572733	0.514	rs700686	chr2:198721054	G/A	cg00792783	chr2:198669748	PLCL1	0.56	5.08	0.42	1.35e-6	Dermatomyositis;
TGCT	cis	rs1801251	1.000	rs2592102	chr2:233726772	G/T	cg08000102	chr2:233561755	GIGYF2	-0.64	-6.45	-0.5	2.24e-9	Coronary artery disease;
TGCT	cis	rs9993613	0.875	rs4694124	chr4:73479251	A/G	cg15102770	chr4:73434591	ADAMTS3	0.5	4.66	0.39	8.03e-6	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs3099143	1.000	rs3099138	chr15:77115524	G/A	cg21673338	chr15:77095150	SCAPER	-0.52	-4.97	-0.41	2.15e-6	Recalcitrant atopic dermatitis;
TGCT	cis	rs56104184	0.775	rs56149557	chr19:49401384	C/A	cg17863274	chr19:49399704	TULP2	-0.54	-7.43	-0.55	1.58e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs2188554	0.785	rs11772396	chr7:117132919	C/T	cg08576598	chr7:116962626	WNT2	0.38	4.88	0.4	3.13e-6	Esophageal adenocarcinoma;
TGCT	cis	rs7568458	0.684	rs7608074	chr2:85809703	T/G	cg17127132	chr2:85788382	GGCX	0.51	4.5	0.37	1.56e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs3784262	1.000	rs11071356	chr15:58240518	T/G	cg12031962	chr15:58353849	ALDH1A2	-0.47	-7.12	-0.54	7.85e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs2997447	0.761	rs17257120	chr1:26450101	A/G	cg03844060	chr1:26490628	NA	0.28	4.57	0.38	1.17e-5	QRS complex (12-leadsum);
TGCT	trans	rs877282	0.838	rs34778553	chr10:796865	T/C	cg22713356	chr15:30763199	NA	1.18	10.55	0.69	5.81e-19	Uric acid levels;
TGCT	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg03609598	chr5:56110824	MAP3K1	-0.58	-4.66	-0.39	7.94e-6	Initial pursuit acceleration;
TGCT	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg06238570	chr21:40685208	BRWD1	0.72	6.58	0.51	1.16e-9	Cognitive function;
TGCT	cis	rs6598955	0.671	rs17257176	chr1:26578233	G/A	cg04990556	chr1:26633338	UBXN11	0.62	4.73	0.39	6.12e-6	Obesity-related traits;
TGCT	cis	rs904251	0.523	rs2776920	chr6:37480605	G/A	cg01843034	chr6:37503916	NA	-0.55	-7.33	-0.55	2.54e-11	Cognitive performance;
TGCT	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg11644478	chr21:40555479	PSMG1	0.99	10.5	0.69	7.73e-19	Cognitive function;
TGCT	cis	rs2637266	1.000	rs7897348	chr10:78359620	G/A	cg18941641	chr10:78392320	NA	0.39	4.88	0.4	3.24e-6	Pulmonary function;
TGCT	cis	rs2224391	0.518	rs116670419	chr6:5261263	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-1.03	-6.43	-0.5	2.47e-9	Height;
TGCT	cis	rs9303401	0.614	rs35057477	chr17:57097064	G/A	cg25039879	chr17:56429692	SUPT4H1	0.54	4.8	0.4	4.57e-6	Cognitive test performance;
TGCT	cis	rs9993613	0.875	rs34975463	chr4:73490011	T/A	cg15102770	chr4:73434591	ADAMTS3	0.5	4.59	0.38	1.05e-5	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs1941023	0.503	rs7944025	chr11:60142538	C/A	cg08716584	chr11:60157161	MS4A7	-0.34	-4.84	-0.4	3.81e-6	Congenital heart disease (maternal effect);
TGCT	cis	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg22121687	chr7:65037720	NA	-0.78	-4.7	-0.39	6.74e-6	Diabetic kidney disease;
TGCT	cis	rs2120019	1.000	rs2120019	chr15:75334184	T/C	cg17294928	chr15:75287854	SCAMP5	-0.78	-6.12	-0.48	1.14e-8	Blood trace element (Zn levels);
TGCT	cis	rs2067615	0.542	rs4346064	chr12:107081599	C/A	cg15890332	chr12:107067104	RFX4	0.29	5.73	0.46	7.31e-8	Heart rate;
TGCT	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg22618164	chr12:122356400	WDR66	0.51	4.93	0.4	2.63e-6	Mean corpuscular volume;
TGCT	cis	rs12540874	0.542	rs4947582	chr7:50566090	C/T	cg18232548	chr7:50535776	DDC	-0.35	-6.01	-0.48	1.89e-8	Systemic sclerosis;
TGCT	cis	rs114540395	0.777	rs117550974	chr10:103166645	A/G	cg18276125	chr10:102749041	C10orf2	0.38	4.6	0.38	1.05e-5	Schizophrenia;
TGCT	cis	rs2404602	0.655	rs4886507	chr15:77209694	T/C	cg26408565	chr15:76604113	ETFA	-0.37	-4.62	-0.38	9.38e-6	Blood metabolite levels;
TGCT	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg06713675	chr4:122721982	EXOSC9	-0.69	-9.7	-0.66	6.92e-17	Type 2 diabetes;
TGCT	cis	rs6723226	0.638	rs6543657	chr2:32705085	T/C	cg02381751	chr2:32503542	YIPF4	0.48	4.68	0.39	7.29e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.65	-5.18	-0.42	8.67e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	trans	rs208515	0.525	rs9453538	chr6:66668508	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.9	9.56	0.65	1.46e-16	Exhaled nitric oxide levels;
TGCT	cis	rs7044106	0.762	rs10818471	chr9:123394045	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	6.92	0.53	2.11e-10	Hip circumference adjusted for BMI;
TGCT	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	6.54	0.51	1.43e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6684514	0.885	rs12036837	chr1:156283895	A/C	cg20302342	chr1:156215951	PAQR6	0.35	4.74	0.39	5.77e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs2075371	0.933	rs2544181	chr7:133944934	C/T	cg11752832	chr7:134001865	SLC35B4	0.7	6.0	0.47	2.04e-8	Mean platelet volume;
TGCT	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg02725872	chr8:58115012	NA	-0.4	-4.87	-0.4	3.34e-6	Developmental language disorder (linguistic errors);
TGCT	trans	rs28735056	0.904	rs35201860	chr18:77628719	T/C	cg05926928	chr17:57297772	GDPD1	0.65	6.74	0.52	5.44e-10	Schizophrenia;
TGCT	cis	rs28595532	0.920	rs114659035	chr4:119740028	C/T	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg22963979	chr7:1858916	MAD1L1	-0.35	-5.4	-0.44	3.3e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs3771570	1.000	rs55645375	chr2:242269024	A/G	cg21155796	chr2:242212141	HDLBP	0.98	6.68	0.51	7.29e-10	Prostate cancer;
TGCT	cis	rs11122272	0.735	rs2244986	chr1:231537452	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-6.5	-0.5	1.77e-9	Hemoglobin concentration;
TGCT	cis	rs7914558	1.000	rs1890184	chr10:104748459	A/C	cg15744005	chr10:104629667	AS3MT	-0.4	-4.91	-0.4	2.83e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs36051895	0.632	rs62541945	chr9:5161571	T/C	cg02405213	chr9:5042618	JAK2	-0.71	-9.01	-0.63	3.02e-15	Pediatric autoimmune diseases;
TGCT	cis	rs4642101	0.680	rs7626609	chr3:12806080	A/G	cg05775895	chr3:12838266	CAND2	-0.68	-7.05	-0.53	1.11e-10	QRS complex (12-leadsum);
TGCT	cis	rs4237845	0.715	rs4760340	chr12:58275176	A/T	cg26785896	chr12:58013354	SLC26A10	-0.38	-4.66	-0.39	7.88e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9952991	0.566	rs657555	chr18:12847136	C/T	cg23544223	chr18:12777786	NA	0.57	5.0	0.41	1.87e-6	Inflammatory skin disease;
TGCT	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg21963583	chr11:68658836	MRPL21	0.35	5.89	0.47	3.33e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs3617	0.503	rs9866243	chr3:52915219	C/T	cg10802521	chr3:52805072	NEK4	0.58	6.69	0.51	6.96e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1580019	0.522	rs10951340	chr7:32562408	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.14	14.68	0.8	6.88e-29	Cognitive ability;
TGCT	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg24549020	chr5:56110836	MAP3K1	0.71	6.08	0.48	1.35e-8	Initial pursuit acceleration;
TGCT	cis	rs42648	1.000	rs42648	chr7:89977760	A/G	cg25739043	chr7:89950458	NA	-0.67	-6.69	-0.51	6.97e-10	Homocysteine levels;
TGCT	cis	rs68170813	0.559	rs75932578	chr7:106844694	C/T	cg02696742	chr7:106810147	HBP1	-0.67	-5.3	-0.43	5.21e-7	Coronary artery disease;
TGCT	cis	rs10986311	0.802	rs6478659	chr9:127128274	A/G	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.19	-4.74	-0.39	5.86e-6	Vitiligo;
TGCT	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg07205460	chr22:24236375	MIF	0.58	4.49	0.37	1.62e-5	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs2841277	0.708	rs2582533	chr14:105398787	G/C	cg19901468	chr14:105411992	AHNAK2	-0.27	-5.52	-0.44	1.89e-7	Rheumatoid arthritis;
TGCT	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg07747251	chr5:1868357	NA	0.38	5.28	0.43	5.55e-7	Cardiovascular disease risk factors;
TGCT	cis	rs17331151	0.541	rs4687676	chr3:52890418	C/T	cg07884673	chr3:53033167	SFMBT1	-0.5	-5.82	-0.46	4.7e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg25427524	chr10:38739819	LOC399744	-0.39	-7.87	-0.58	1.5e-12	Extrinsic epigenetic age acceleration;
TGCT	cis	rs6504950	0.566	rs7226272	chr17:53046447	G/A	cg19360675	chr17:53046073	COX11;STXBP4	0.56	5.41	0.44	3.06e-7	Breast cancer;
TGCT	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg16049864	chr8:95962084	TP53INP1	-0.75	-10.48	-0.69	8.55e-19	Type 2 diabetes;
TGCT	cis	rs929354	0.772	rs933344	chr7:157011265	A/T	cg05182265	chr7:156933206	UBE3C	-0.41	-9.31	-0.64	5.91e-16	Body mass index;
TGCT	trans	rs608114	1.000	rs591522	chr6:96378048	T/C	cg04008557	chr11:2826328	KCNQ1	-0.65	-6.82	-0.52	3.51e-10	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
TGCT	cis	rs8180040	0.726	rs7625070	chr3:47095518	A/G	cg27129171	chr3:47204927	SETD2	0.76	9.8	0.66	3.91e-17	Colorectal cancer;
TGCT	cis	rs67385638	0.862	rs11036641	chr11:5310578	A/G	cg12559170	chr11:5275217	HBG2	0.44	7.97	0.58	9.03e-13	Hemoglobin levels;
TGCT	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg00343986	chr7:65444356	GUSB	0.23	5.13	0.42	1.08e-6	Aortic root size;
TGCT	trans	rs114540395	0.858	rs75204036	chr10:103248050	T/C	cg10198749	chr1:39920707	MACF1	0.55	7.12	0.54	7.73e-11	Schizophrenia;
TGCT	cis	rs4631830	0.720	rs2012677	chr10:51504797	T/A	cg10326726	chr10:51549505	MSMB	-0.23	-4.62	-0.38	9.64e-6	Prostate-specific antigen levels;
TGCT	cis	rs7666738	0.830	rs13112037	chr4:98976986	A/T	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7772486	0.654	rs4896829	chr6:145953675	T/A	cg05347473	chr6:146136440	FBXO30	0.51	5.0	0.41	1.88e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11249608	0.548	rs11958355	chr5:178451640	T/C	cg01312482	chr5:178451176	ZNF879	-0.56	-5.5	-0.44	2.09e-7	Pubertal anthropometrics;
TGCT	cis	rs3091242	0.933	rs35148262	chr1:25766623	A/G	cg09222892	chr1:25734099	RHCE	-0.41	-6.72	-0.52	5.98e-10	Erythrocyte sedimentation rate;
TGCT	cis	rs7666738	0.830	rs13110410	chr4:98920018	T/C	cg18180107	chr4:99064573	C4orf37	0.57	5.23	0.43	6.88e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg03609598	chr5:56110824	MAP3K1	-0.57	-4.5	-0.37	1.57e-5	Initial pursuit acceleration;
TGCT	cis	rs6740322	0.895	rs6711966	chr2:43561989	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.38	-6.32	-0.49	4.21e-9	Coronary artery disease;
TGCT	cis	rs6565180	1.000	rs11862806	chr16:30364071	A/G	cg17640201	chr16:30407289	ZNF48	-0.9	-8.94	-0.63	4.48e-15	Tonsillectomy;
TGCT	cis	rs11252926	0.527	rs10904093	chr10:436848	A/G	cg20256804	chr10:444983	DIP2C	0.2	4.46	0.37	1.83e-5	Psychosis in Alzheimer's disease;
TGCT	cis	rs10114408	0.959	rs10761293	chr9:96645086	T/C	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs4901869	0.966	rs1820557	chr14:59334863	C/G	cg02291164	chr14:59296302	NA	0.24	4.69	0.39	7.18e-6	Panic disorder;
TGCT	cis	rs7027203	0.688	rs4075733	chr9:96624645	C/T	cg13679303	chr9:96623674	NA	-0.69	-11.4	-0.72	4.94e-21	DNA methylation (variation);
TGCT	cis	rs1018836	0.923	rs2023626	chr8:91619264	G/T	cg16814680	chr8:91681699	NA	0.84	8.65	0.61	2.28e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs796364	0.950	rs188146	chr2:200750444	C/T	cg17644776	chr2:200775616	C2orf69	0.31	4.83	0.4	3.99e-6	Schizophrenia;
TGCT	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg17971929	chr21:40555470	PSMG1	-0.51	-4.6	-0.38	1.02e-5	Menarche (age at onset);
TGCT	cis	rs2197308	0.765	rs11182434	chr12:37923968	C/A	cg26384229	chr12:38710491	ALG10B	0.89	7.98	0.58	8.43e-13	Morning vs. evening chronotype;
TGCT	cis	rs2932538	0.922	rs6681371	chr1:113101168	A/C	cg22162597	chr1:113214053	CAPZA1	0.26	5.51	0.44	1.98e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs6089584	0.566	rs6061963	chr20:60607480	C/G	cg13770153	chr20:60521292	NA	-0.39	-4.67	-0.39	7.61e-6	Body mass index;
TGCT	cis	rs4595586	0.545	rs7967295	chr12:39376866	G/A	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs904251	0.704	rs2776873	chr6:37483142	A/G	cg01843034	chr6:37503916	NA	-0.47	-5.12	-0.42	1.15e-6	Cognitive performance;
TGCT	cis	rs7666738	0.830	rs7672720	chr4:98938760	A/T	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9303401	0.659	rs12150536	chr17:56640834	C/T	cg25039879	chr17:56429692	SUPT4H1	0.52	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs11031096	0.711	rs12270809	chr11:4206537	G/A	cg18678763	chr11:4115507	RRM1	-0.45	-5.84	-0.46	4.31e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs9486719	1.000	rs12190397	chr6:97036465	G/A	cg18709589	chr6:96969512	KIAA0776	-0.74	-5.21	-0.42	7.5e-7	Migraine;Coronary artery disease;
TGCT	cis	rs9467711	1.000	rs6903015	chr6:26322526	A/G	cg26531700	chr6:26746687	NA	-0.94	-5.09	-0.42	1.28e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2832191	0.740	rs2853830	chr21:30416824	A/G	cg24692254	chr21:30365293	RNF160	0.99	11.67	0.72	1.1e-21	Dental caries;
TGCT	cis	rs13424612	1.000	rs4149547	chr2:240933308	C/T	cg26363272	chr2:240904871	NDUFA10	0.28	4.74	0.39	5.84e-6	Odorant perception (isobutyraldehyde);
TGCT	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg02953382	chr22:24373134	LOC391322	-0.77	-8.01	-0.58	7.12e-13	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1008375	1.000	rs11724495	chr4:17621310	G/A	cg10189774	chr4:17578691	LAP3	0.59	5.28	0.43	5.68e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2832191	0.716	rs2249028	chr21:30365322	G/A	cg08807101	chr21:30365312	RNF160	0.64	6.09	0.48	1.33e-8	Dental caries;
TGCT	cis	rs642803	0.933	rs644740	chr11:65561468	C/T	cg27068330	chr11:65405492	SIPA1	0.56	4.6	0.38	1.04e-5	Urate levels;
TGCT	cis	rs11190604	1.000	rs4917901	chr10:102201773	A/C	cg23241863	chr10:102295624	HIF1AN	0.62	4.87	0.4	3.27e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs10791323	0.569	rs329664	chr11:133754975	G/T	cg15485101	chr11:133734466	NA	0.38	5.49	0.44	2.13e-7	Childhood ear infection;
TGCT	cis	rs7584330	0.554	rs3751105	chr2:238428459	G/A	cg08992911	chr2:238395768	MLPH	0.67	4.52	0.38	1.41e-5	Prostate cancer;
TGCT	cis	rs8077577	0.945	rs11654146	chr17:18076141	A/C	cg09161412	chr17:18057145	MYO15A	-0.67	-5.44	-0.44	2.69e-7	Obesity-related traits;
TGCT	cis	rs7582180	0.652	rs4851307	chr2:100971778	C/T	cg08017756	chr2:100939284	LONRF2	-0.3	-4.87	-0.4	3.38e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs76935404	0.736	rs57274441	chr19:41431422	T/G	cg19493303	chr19:41414353	NA	0.41	5.04	0.41	1.63e-6	nicotine metabolite ratio in current smokers;
TGCT	cis	rs9916302	0.851	rs2338795	chr17:37399364	T/G	cg07936489	chr17:37558343	FBXL20	-0.64	-5.18	-0.42	8.65e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs3784262	1.000	rs4646640	chr15:58247563	C/G	cg12031962	chr15:58353849	ALDH1A2	0.51	7.81	0.57	2.04e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs981844	1.000	rs17298985	chr4:154664261	C/T	cg14289246	chr4:154710475	SFRP2	0.97	7.78	0.57	2.42e-12	Response to statins (LDL cholesterol change);
TGCT	cis	rs10904908	1.000	rs10795465	chr10:17260525	C/T	cg01003015	chr10:17271136	VIM	-0.51	-4.44	-0.37	2.01e-5	Total cholesterol levels;Cholesterol, total;
TGCT	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg03709012	chr19:19516395	GATAD2A	0.76	6.42	0.5	2.64e-9	Tonsillectomy;
TGCT	cis	rs1005224	1.000	rs1981898	chr14:76175565	C/A	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.69	-6.06	-0.48	1.54e-8	Large artery stroke;
TGCT	cis	rs1018836	0.828	rs10091275	chr8:91559751	A/G	cg16814680	chr8:91681699	NA	-0.75	-7.83	-0.58	1.82e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg21724239	chr8:58056113	NA	0.48	5.17	0.42	9.18e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg11494091	chr17:61959527	GH2	0.59	12.62	0.75	5.45e-24	Prudent dietary pattern;
TGCT	cis	rs7666738	0.830	rs7669407	chr4:98750251	G/A	cg05340658	chr4:99064831	C4orf37	0.49	5.77	0.46	6.02e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1018836	0.770	rs12543806	chr8:91664011	C/T	cg16814680	chr8:91681699	NA	-0.96	-12.12	-0.74	8.65e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6088580	0.634	rs4911418	chr20:32994257	G/A	cg06115741	chr20:33292138	TP53INP2	-0.55	-4.81	-0.4	4.28e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs8077889	0.763	rs4792913	chr17:41854497	T/C	cg26893861	chr17:41843967	DUSP3	1.14	20.46	0.88	1.46e-41	Triglycerides;
TGCT	cis	rs3818285	0.655	rs623980	chr10:111646147	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.32	-5.77	-0.46	5.9e-8	Superior crus of antihelix expression;
TGCT	cis	rs8014204	0.967	rs1319171	chr14:75334096	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.77	-7.49	-0.56	1.14e-11	Caffeine consumption;
TGCT	trans	rs17685	0.753	rs10476	chr7:75696420	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.49	-8.22	-0.59	2.25e-13	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg07424592	chr7:64974309	NA	-1.27	-7.84	-0.58	1.8e-12	Diabetic kidney disease;
TGCT	cis	rs1153858	1.000	rs7169587	chr15:45640379	A/G	cg14582100	chr15:45693742	SPATA5L1	0.48	5.7	0.46	8.17e-8	Homoarginine levels;
TGCT	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg13395646	chr4:1353034	KIAA1530	-0.38	-4.72	-0.39	6.28e-6	Obesity-related traits;
TGCT	cis	rs6831352	0.734	rs1311620	chr4:100013091	C/T	cg12011299	chr4:100065546	ADH4	0.38	5.02	0.41	1.78e-6	Alcohol dependence;
TGCT	cis	rs6903823	0.508	rs1233660	chr6:28260249	T/A	cg18815343	chr6:28367644	ZSCAN12	-0.44	-4.65	-0.39	8.28e-6	Pulmonary function;
TGCT	cis	rs7267979	1.000	rs7019	chr20:25278278	C/T	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6426558	0.502	rs10916080	chr1:227232040	A/G	cg10327440	chr1:227177885	CDC42BPA	0.62	7.52	0.56	9.35e-12	Neutrophil percentage of white cells;
TGCT	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.29	-4.49	-0.37	1.64e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs8180040	0.620	rs6414435	chr3:47121140	A/G	cg27129171	chr3:47204927	SETD2	0.71	8.55	0.61	3.9e-14	Colorectal cancer;
TGCT	cis	rs367615	0.918	rs10070104	chr5:108866438	C/T	cg17395555	chr5:108820864	NA	-0.31	-5.01	-0.41	1.85e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	7.12	0.54	7.55e-11	Platelet count;
TGCT	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.11	13.91	0.78	4.47e-27	Height;
TGCT	cis	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg09021430	chr5:549028	NA	-0.38	-5.06	-0.41	1.45e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs17376456	0.825	rs13357713	chr5:93145423	T/C	cg21475434	chr5:93447410	FAM172A	0.62	4.67	0.39	7.58e-6	Diabetic retinopathy;
TGCT	cis	rs2594989	0.943	rs4684070	chr3:11437551	A/G	cg00170343	chr3:11313890	ATG7	0.69	5.09	0.42	1.27e-6	Circulating chemerin levels;
TGCT	cis	rs9549367	0.789	rs9549708	chr13:113891887	A/G	cg00898013	chr13:113819073	PROZ	-0.4	-4.98	-0.41	2.13e-6	Platelet distribution width;
TGCT	cis	rs3749237	0.964	rs2352975	chr3:49891885	T/C	cg07636037	chr3:49044803	WDR6	0.56	4.68	0.39	7.52e-6	Resting heart rate;
TGCT	cis	rs112591243	0.685	rs117450955	chr21:47990916	T/A	cg10657630	chr21:48055338	PRMT2	0.97	4.93	0.4	2.63e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	trans	rs4332037	0.624	rs56256289	chr7:1892529	C/T	cg10840412	chr1:235813424	GNG4	0.85	6.86	0.52	2.96e-10	Bipolar disorder;
TGCT	cis	rs397020	0.904	rs203547	chr20:1195245	T/A	cg16922058	chr20:1206700	RAD21L1	0.83	10.49	0.69	8.36e-19	Multiple sclerosis;
TGCT	cis	rs3806843	0.706	rs2563302	chr5:140079051	T/C	cg19875535	chr5:140030758	IK	-0.37	-6.23	-0.49	6.51e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs4722585	0.533	rs3753097	chr7:26198207	A/G	cg07876897	chr7:26191696	NFE2L3	0.38	5.13	0.42	1.07e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
TGCT	cis	rs12134245	0.747	rs17501512	chr1:92012481	C/G	cg25838465	chr1:92012736	NA	0.44	6.91	0.53	2.27e-10	Breast cancer;
TGCT	cis	rs9796	0.621	rs691702	chr15:41474399	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.52	-7.17	-0.54	5.94e-11	Menopause (age at onset);
TGCT	cis	rs2456568	0.802	rs10765640	chr11:93636462	C/T	cg14065697	chr11:93583672	C11orf90	-0.37	-4.63	-0.38	9.11e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs11098499	0.954	rs4345162	chr4:120312959	G/A	cg09307838	chr4:120376055	NA	0.65	6.39	0.5	3.02e-9	Corneal astigmatism;
TGCT	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg11644478	chr21:40555479	PSMG1	1.04	10.72	0.69	2.25e-19	Cognitive function;
TGCT	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg24060327	chr5:131705240	SLC22A5	-0.58	-5.88	-0.47	3.48e-8	Breast cancer;
TGCT	cis	rs9902453	0.619	rs2255489	chr17:28084974	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-6.86	-0.52	2.93e-10	Coffee consumption (cups per day);
TGCT	cis	rs10875746	0.669	rs10431526	chr12:48690143	A/G	cg20731937	chr12:48336164	NA	0.61	4.65	0.39	8.23e-6	Longevity (90 years and older);
TGCT	cis	rs67478160	0.634	rs2144080	chr14:104258761	A/C	cg26031613	chr14:104095156	KLC1	-0.62	-6.19	-0.49	8.13e-9	Schizophrenia;
TGCT	cis	rs317865	0.737	rs55949632	chr4:16207072	T/C	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.77	5.08	0.42	1.32e-6	Kidney disease (early stage) in type 1 diabetes;
TGCT	cis	rs911263	0.961	rs1885013	chr14:68754695	G/A	cg18825221	chr14:68749962	RAD51L1	0.28	5.57	0.45	1.52e-7	Primary biliary cholangitis;
TGCT	cis	rs2729354	0.768	rs2584856	chr11:57267312	C/A	cg24343310	chr11:57249947	NA	0.28	4.62	0.38	9.65e-6	Blood protein levels;
TGCT	cis	rs9611565	0.512	rs6002474	chr22:42168181	A/G	cg13695892	chr22:41940480	POLR3H	0.85	8.06	0.59	5.4e-13	Vitiligo;
TGCT	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg14893161	chr1:205819251	PM20D1	0.66	10.84	0.7	1.13e-19	Menarche (age at onset);
TGCT	cis	rs2469997	1.000	rs2447167	chr8:120366068	T/C	cg00681363	chr8:120844660	TAF2	0.69	4.48	0.37	1.64e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs17539620	0.534	rs6557363	chr6:154827813	A/G	cg17771515	chr6:154831774	CNKSR3	0.68	4.63	0.38	9.07e-6	Lipoprotein (a) levels;
TGCT	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg17971929	chr21:40555470	PSMG1	0.68	6.04	0.48	1.64e-8	Cognitive function;
TGCT	cis	rs1372520	0.684	rs2583979	chr4:90750588	A/T	cg01966878	chr4:90757139	SNCA	-0.3	-4.76	-0.39	5.2e-6	Neuroticism;
TGCT	cis	rs11031096	0.711	rs10767881	chr11:4205122	C/G	cg18678763	chr11:4115507	RRM1	-0.47	-6.04	-0.48	1.64e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs7772486	0.790	rs2253764	chr6:146199881	T/A	cg23711669	chr6:146136114	FBXO30	0.93	10.56	0.69	5.35e-19	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11122272	0.735	rs2486743	chr1:231506928	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.14	-0.54	6.86e-11	Hemoglobin concentration;
TGCT	cis	rs8062405	0.824	rs240702	chr16:28531353	C/T	cg09754948	chr16:28834200	ATXN2L	0.57	4.48	0.37	1.67e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs7829975	0.871	rs7829826	chr8:8578120	T/A	cg06636001	chr8:8085503	FLJ10661	-0.6	-4.92	-0.4	2.73e-6	Mood instability;
TGCT	cis	rs6500602	0.928	rs3747581	chr16:4462619	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.3	5.17	0.42	9.2e-7	Schizophrenia;
TGCT	cis	rs4803468	1.000	rs878082	chr19:41897674	G/A	cg09537434	chr19:41945824	ATP5SL	-0.9	-10.15	-0.67	5.45e-18	Height;
TGCT	cis	rs4509693	0.941	rs7914169	chr10:102495725	A/G	cg24127310	chr10:102502104	NA	0.66	5.85	0.47	4.03e-8	Alzheimer's disease;
TGCT	cis	rs12497850	0.931	rs4974082	chr3:48999323	G/A	cg06212747	chr3:49208901	KLHDC8B	0.6	5.45	0.44	2.62e-7	Parkinson's disease;
TGCT	cis	rs4319547	0.915	rs7966094	chr12:123115771	A/G	cg23029597	chr12:123009494	RSRC2	-0.31	-5.16	-0.42	9.31e-7	Body mass index;
TGCT	cis	rs57590327	0.503	rs2049415	chr3:81901887	A/T	cg07356753	chr3:81810745	GBE1	-0.7	-6.42	-0.5	2.68e-9	Extraversion;
TGCT	cis	rs904251	0.523	rs9369005	chr6:37483109	A/G	cg08126542	chr6:37504118	NA	-0.43	-6.22	-0.49	6.82e-9	Cognitive performance;
TGCT	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg12923728	chr3:195709715	SDHAP1	-0.33	-7.26	-0.55	3.8e-11	Pancreatic cancer;
TGCT	cis	rs478304	0.627	rs11227254	chr11:65454000	A/G	cg27068330	chr11:65405492	SIPA1	-1.0	-11.14	-0.71	2.07e-20	Acne (severe);
TGCT	cis	rs4478858	0.684	rs16834336	chr1:31751512	G/A	cg00250761	chr1:31883323	NA	-0.26	-4.55	-0.38	1.28e-5	Alcohol dependence;
TGCT	cis	rs2288884	1.000	rs12609219	chr19:52580996	T/C	cg13540795	chr19:52551618	ZNF432	-0.59	-5.02	-0.41	1.79e-6	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	trans	rs1814175	0.867	rs7926002	chr11:49616018	A/G	cg03929089	chr4:120376271	NA	-0.65	-7.45	-0.56	1.35e-11	Height;
TGCT	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg18402987	chr7:1209562	NA	0.65	5.32	0.43	4.65e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1538970	0.924	rs12037201	chr1:45941349	G/T	cg05343316	chr1:45956843	TESK2	0.75	6.2	0.49	7.66e-9	Platelet count;
TGCT	trans	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg25482853	chr8:67687455	SGK3	1.26	10.61	0.69	4.22e-19	Obesity-related traits;
TGCT	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg06713675	chr4:122721982	EXOSC9	-0.69	-9.69	-0.66	7.11e-17	Type 2 diabetes;
TGCT	cis	rs6062302	0.540	rs2281926	chr20:62384309	G/C	cg14758556	chr20:62440591	NA	0.36	4.8	0.4	4.57e-6	Glioblastoma;
TGCT	cis	rs2153535	0.580	rs2184583	chr6:8447808	A/G	cg07606381	chr6:8435919	SLC35B3	0.53	5.02	0.41	1.79e-6	Motion sickness;
TGCT	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg06238570	chr21:40685208	BRWD1	0.69	6.47	0.5	2.08e-9	Cognitive function;
TGCT	cis	rs4803468	1.000	rs284656	chr19:41929251	T/C	cg09537434	chr19:41945824	ATP5SL	-0.92	-10.57	-0.69	5.19e-19	Height;
TGCT	cis	rs1008375	0.902	rs12503164	chr4:17656107	C/T	cg16339924	chr4:17578868	LAP3	0.63	5.33	0.43	4.49e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7826238	0.601	rs2976907	chr8:8345168	C/T	cg08975724	chr8:8085496	FLJ10661	0.61	5.93	0.47	2.78e-8	Systolic blood pressure;
TGCT	cis	rs7914558	1.000	rs4917994	chr10:104811699	C/T	cg05855489	chr10:104503620	C10orf26	0.51	4.48	0.37	1.67e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs2594989	0.779	rs2443701	chr3:11588773	C/T	cg00170343	chr3:11313890	ATG7	-0.72	-5.29	-0.43	5.29e-7	Circulating chemerin levels;
TGCT	trans	rs10506458	0.915	rs2013050	chr12:63394310	C/T	cg22491629	chr6:157744540	C6orf35	-0.99	-8.55	-0.61	3.94e-14	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs2404602	0.598	rs11634019	chr15:76634680	A/G	cg17529965	chr15:77327887	PSTPIP1	0.3	4.43	0.37	2.01e-5	Blood metabolite levels;
TGCT	cis	rs9911578	0.967	rs2567892	chr17:56668929	T/C	cg05425664	chr17:57184151	TRIM37	-0.63	-6.26	-0.49	5.86e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs7662948	chr4:99020132	G/C	cg17366294	chr4:99064904	C4orf37	0.66	6.55	0.51	1.35e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9611565	0.512	rs2050031	chr22:42152266	A/G	cg03806693	chr22:41940476	POLR3H	1.04	10.57	0.69	5.2e-19	Vitiligo;
TGCT	cis	rs826838	0.754	rs2387920	chr12:38626351	A/G	cg13010199	chr12:38710504	ALG10B	0.65	5.15	0.42	9.92e-7	Heart rate;
TGCT	cis	rs10791097	0.694	rs4436551	chr11:130755739	A/G	cg12179176	chr11:130786555	SNX19	-0.81	-9.85	-0.66	2.99e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs79349575	0.783	rs17635252	chr17:47006950	T/C	cg26022315	chr17:47021804	SNF8	0.49	4.9	0.4	2.94e-6	Type 2 diabetes;
TGCT	cis	rs62380364	0.602	rs448809	chr5:88005828	G/T	cg22951263	chr5:87985283	NA	-0.58	-6.22	-0.49	6.92e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs10501293	0.543	rs4272772	chr11:42989183	T/C	cg03447554	chr11:43094025	NA	0.44	6.45	0.5	2.25e-9	Cognitive performance;
TGCT	cis	rs1062177	0.756	rs2915827	chr5:151119705	T/A	cg00977110	chr5:151150581	G3BP1	-0.4	-4.67	-0.39	7.7e-6	Preschool internalizing problems;
TGCT	cis	rs9467773	1.000	rs2393670	chr6:26535541	A/G	cg15659132	chr6:26577336	NA	0.86	12.21	0.74	5.3e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs4788570	0.566	rs8056735	chr16:71502483	A/G	cg06353428	chr16:71660113	MARVELD3	-1.19	-7.74	-0.57	3.06e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs12477438	0.501	rs6727749	chr2:99793590	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	10.3	0.68	2.42e-18	Chronic sinus infection;
TGCT	cis	rs6540559	0.673	rs6540560	chr1:209982073	A/G	cg23283495	chr1:209979779	IRF6	-0.57	-5.03	-0.41	1.65e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg11644478	chr21:40555479	PSMG1	-0.5	-4.7	-0.39	6.78e-6	Menarche (age at onset);
TGCT	cis	rs908922	0.676	rs539393	chr1:152518896	C/T	cg20991723	chr1:152506922	NA	0.45	6.09	0.48	1.33e-8	Hair morphology;
TGCT	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg18876405	chr7:65276391	NA	-0.36	-5.41	-0.44	3.12e-7	Aortic root size;
TGCT	cis	rs10905099	0.505	rs35832749	chr10:7079152	C/T	cg20312131	chr10:7139482	NA	0.28	4.45	0.37	1.86e-5	Orofacial clefts;
TGCT	cis	rs9467773	0.595	rs13207371	chr6:26591074	G/A	cg05738196	chr6:26577821	NA	0.86	10.29	0.68	2.46e-18	Intelligence (multi-trait analysis);
TGCT	cis	rs854765	0.624	rs12946746	chr17:17741669	T/C	cg09796270	chr17:17721594	SREBF1	-0.27	-5.19	-0.42	8.39e-7	Total body bone mineral density;
TGCT	cis	rs4523957	0.583	rs923864	chr17:2031507	C/T	cg16513277	chr17:2031491	SMG6	-0.2	-4.58	-0.38	1.13e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg24675658	chr1:53192096	ZYG11B	-0.76	-8.67	-0.61	1.98e-14	Monocyte count;
TGCT	cis	rs9486715	0.758	rs2971610	chr6:97027380	C/T	cg06623918	chr6:96969491	KIAA0776	-1.1	-14.44	-0.79	2.5e-28	Headache;
TGCT	cis	rs12134245	0.776	rs13447526	chr1:91983174	A/G	cg02896835	chr1:92012615	NA	0.29	4.89	0.4	3.03e-6	Breast cancer;
TGCT	cis	rs250677	0.522	rs4705302	chr5:148354962	G/C	cg18129178	chr5:148520854	ABLIM3	0.36	4.62	0.38	9.43e-6	Breast cancer;
TGCT	cis	rs17376456	0.877	rs10057814	chr5:93399092	C/G	cg25358565	chr5:93447407	FAM172A	0.93	8.65	0.61	2.26e-14	Diabetic retinopathy;
TGCT	cis	rs7584330	0.554	rs62186170	chr2:238425883	C/T	cg08992911	chr2:238395768	MLPH	0.7	4.72	0.39	6.32e-6	Prostate cancer;
TGCT	cis	rs3135071	1.000	rs3135071	chr4:2406321	C/T	cg08330972	chr4:2403930	ZFYVE28	0.58	4.92	0.4	2.72e-6	Influenza A (H1N1) severity;
TGCT	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg03709012	chr19:19516395	GATAD2A	-0.78	-6.68	-0.51	7.12e-10	Tonsillectomy;
TGCT	cis	rs11671005	0.735	rs3826683	chr19:58918733	T/C	cg13877915	chr19:58951672	ZNF132	0.63	4.92	0.4	2.74e-6	Mean platelet volume;
TGCT	cis	rs7172809	0.643	rs61483316	chr15:77834147	C/T	cg22256960	chr15:77711686	NA	-0.48	-4.63	-0.38	9.21e-6	Glucose homeostasis traits;
TGCT	cis	rs11785400	1.000	rs4297023	chr8:143733307	C/A	cg10596483	chr8:143751796	JRK	0.55	6.01	0.47	1.93e-8	Schizophrenia;
TGCT	cis	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg06697600	chr4:7070879	GRPEL1	-0.44	-4.55	-0.38	1.26e-5	Monocyte percentage of white cells;
TGCT	cis	rs11190604	1.000	rs3793772	chr10:102222825	A/G	cg16342193	chr10:102329863	NA	-0.41	-5.44	-0.44	2.76e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9914544	0.545	rs4510081	chr17:18798846	A/C	cg26378065	chr17:18585709	ZNF286B	0.51	4.6	0.38	1.03e-5	Educational attainment (years of education);
TGCT	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg07343612	chr16:622815	PIGQ	-0.35	-6.32	-0.49	4.23e-9	Height;
TGCT	cis	rs11428934	1	rs11428934	chr19:49144245	T/TG	cg07996880	chr19:49339085	HSD17B14	0.29	4.97	0.41	2.19e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Granulocyte count;
TGCT	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-5.1	-0.42	1.23e-6	Electroencephalogram traits;
TGCT	cis	rs7824557	0.527	rs2409756	chr8:11242025	A/C	cg21775007	chr8:11205619	TDH	-0.59	-5.62	-0.45	1.21e-7	Retinal vascular caliber;
TGCT	cis	rs35306767	0.668	rs72760914	chr10:1070952	A/G	cg26597838	chr10:835615	NA	0.51	5.94	0.47	2.71e-8	Eosinophil percentage of granulocytes;
TGCT	cis	rs7474896	0.583	rs11011347	chr10:38019264	G/A	cg25427524	chr10:38739819	LOC399744	-0.34	-5.47	-0.44	2.43e-7	Obesity (extreme);
TGCT	cis	rs12615966	1.000	rs882424	chr2:105370336	C/A	cg16465502	chr2:105461796	NA	0.76	4.5	0.37	1.57e-5	Pancreatic cancer;
TGCT	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg03609598	chr5:56110824	MAP3K1	-0.58	-4.7	-0.39	6.72e-6	Initial pursuit acceleration;
TGCT	cis	rs7705042	0.865	rs7723666	chr5:141513966	C/T	cg07392085	chr5:141489673	NDFIP1	0.32	4.69	0.39	7.12e-6	Asthma;
TGCT	cis	rs7246967	0.673	rs6511383	chr19:22956900	C/T	cg05241461	chr19:22816980	ZNF492	0.62	4.47	0.37	1.71e-5	Bronchopulmonary dysplasia;
TGCT	cis	rs1670533	1.000	rs7669622	chr4:1058659	A/G	cg20887711	chr4:1340912	KIAA1530	0.7	5.62	0.45	1.18e-7	Recombination rate (females);
TGCT	cis	rs10875595	0.836	rs4912747	chr5:140676027	T/A	cg20560182	chr5:140700478	TAF7	-0.64	-4.92	-0.4	2.7e-6	Pulmonary function decline;
TGCT	cis	rs12477438	0.822	rs6727170	chr2:99588042	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.79	-6.91	-0.53	2.22e-10	Chronic sinus infection;
TGCT	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg03188948	chr7:1209495	NA	0.68	5.8	0.46	5.09e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9611565	0.500	rs10775759	chr22:42088158	T/C	cg06481639	chr22:41940642	POLR3H	0.73	6.62	0.51	9.76e-10	Vitiligo;
TGCT	cis	rs6840360	0.615	rs72728173	chr4:152469373	C/T	cg17479576	chr4:152424074	FAM160A1	-0.71	-7.74	-0.57	2.95e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs12510870	0.599	rs28450939	chr4:74450577	G/A	cg05868023	chr4:75230803	EREG	-0.54	-4.76	-0.39	5.33e-6	Iris color (b* coordinate);
TGCT	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg02725872	chr8:58115012	NA	-0.39	-4.83	-0.4	3.9e-6	Developmental language disorder (linguistic errors);
TGCT	trans	rs1814175	0.935	rs1827017	chr11:49632592	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.34	-6.67	-0.51	7.47e-10	Height;
TGCT	cis	rs11642862	1.000	rs11645175	chr16:30803299	C/T	cg02466173	chr16:30829666	NA	-0.38	-4.57	-0.38	1.16e-5	Tonsillectomy;
TGCT	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg04414720	chr1:150670196	GOLPH3L	0.37	4.81	0.4	4.38e-6	Tonsillectomy;
TGCT	cis	rs12891047	1.000	rs7160196	chr14:68265744	C/T	cg26938013	chr14:69015199	RAD51L1	0.45	4.54	0.38	1.32e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs2836950	0.520	rs59916147	chr21:40634702	T/G	cg17971929	chr21:40555470	PSMG1	-0.54	-4.87	-0.4	3.28e-6	Menarche (age at onset);
TGCT	cis	rs28595532	0.920	rs114262028	chr4:119734877	C/T	cg21605333	chr4:119757512	SEC24D	1.66	8.33	0.6	1.28e-13	Cannabis dependence symptom count;
TGCT	cis	rs208520	0.661	rs7766144	chr6:66827795	C/T	cg07460842	chr6:66804631	NA	-0.95	-9.74	-0.66	5.26e-17	Exhaled nitric oxide output;
TGCT	cis	rs6121246	0.529	rs6120862	chr20:30199459	T/C	cg18721089	chr20:30220636	NA	-0.64	-6.86	-0.52	2.84e-10	Mean corpuscular hemoglobin;
TGCT	cis	rs748404	0.690	rs2244981	chr15:43752751	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	4.71	0.39	6.65e-6	Lung cancer;
TGCT	cis	rs6892003	0.857	rs58897526	chr5:174179812	C/T	cg06056415	chr5:174162510	NA	0.44	4.62	0.38	9.46e-6	Clopidogrel active metabolite levels;
TGCT	cis	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg09021430	chr5:549028	NA	-0.44	-5.71	-0.46	7.94e-8	Lung disease severity in cystic fibrosis;
TGCT	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg18402987	chr7:1209562	NA	0.67	5.94	0.47	2.72e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7044106	0.791	rs10985000	chr9:123484115	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	6.46	0.5	2.12e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs11098499	0.954	rs11098525	chr4:120390152	G/A	cg09307838	chr4:120376055	NA	0.68	6.53	0.51	1.54e-9	Corneal astigmatism;
TGCT	cis	rs11676348	0.846	rs13009946	chr2:219007752	A/C	cg00012203	chr2:219082015	ARPC2	-0.49	-4.62	-0.38	9.62e-6	Ulcerative colitis;
TGCT	cis	rs1153858	1.000	rs8032904	chr15:45651309	C/T	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.62e-8	Homoarginine levels;
TGCT	cis	rs12579753	0.869	rs12366920	chr12:82223015	G/A	cg07988820	chr12:82153109	PPFIA2	-0.6	-6.48	-0.5	1.91e-9	Resting heart rate;
TGCT	cis	rs6921919	0.583	rs2027361	chr6:28388308	A/G	cg18815343	chr6:28367644	ZSCAN12	-0.54	-5.25	-0.43	6.29e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs921968	0.678	rs2230115	chr2:219509618	C/A	cg02176678	chr2:219576539	TTLL4	0.37	5.2	0.42	7.81e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs11030122	0.702	rs10767713	chr11:3950157	T/C	cg18678763	chr11:4115507	RRM1	-0.48	-5.99	-0.47	2.15e-8	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs7010267	0.668	rs4563920	chr8:119993689	A/G	cg17171407	chr8:119960777	TNFRSF11B	0.32	6.05	0.48	1.62e-8	Total body bone mineral density (age 45-60);
TGCT	cis	rs1008375	0.800	rs10008598	chr4:17607323	T/C	cg18681998	chr4:17616180	MED28	1.05	11.09	0.71	2.85e-20	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs12643440	0.538	rs2314602	chr4:17144535	A/G	cg22650099	chr4:17144496	NA	-0.46	-4.7	-0.39	6.79e-6	Metabolite levels (Pyroglutamine);
TGCT	cis	rs12210905	1.000	rs12196889	chr6:27156095	G/C	cg08851530	chr6:28072375	NA	1.12	5.43	0.44	2.82e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs1008375	1.000	rs2215450	chr4:17675394	T/G	cg16339924	chr4:17578868	LAP3	0.6	5.14	0.42	1.05e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7681440	0.904	rs28415623	chr4:90767110	C/T	cg26578617	chr4:90757533	SNCA	-0.47	-4.87	-0.4	3.34e-6	Dementia with Lewy bodies;
TGCT	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg07870213	chr5:140052090	DND1	0.67	7.88	0.58	1.42e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg07138768	chr7:917805	C7orf20	0.45	5.63	0.45	1.14e-7	Perceived unattractiveness to mosquitoes;
TGCT	cis	rs36051895	0.632	rs7469563	chr9:5139489	C/T	cg02405213	chr9:5042618	JAK2	-0.73	-10.37	-0.68	1.59e-18	Pediatric autoimmune diseases;
TGCT	cis	rs1801251	1.000	rs4973053	chr2:233670099	G/A	cg08000102	chr2:233561755	GIGYF2	-0.64	-6.56	-0.51	1.28e-9	Coronary artery disease;
TGCT	trans	rs804280	0.509	rs7461273	chr8:11777977	C/G	cg15556689	chr8:8085844	FLJ10661	0.82	7.71	0.57	3.46e-12	Myopia (pathological);
TGCT	cis	rs11098499	0.754	rs12510269	chr4:120241646	A/G	cg09307838	chr4:120376055	NA	0.6	5.77	0.46	5.95e-8	Corneal astigmatism;
TGCT	cis	rs7552404	0.924	rs12136754	chr1:76230232	C/A	cg22875332	chr1:76189707	ACADM	0.74	8.9	0.62	5.76e-15	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7772486	0.846	rs1854901	chr6:146325685	T/C	cg05347473	chr6:146136440	FBXO30	0.52	4.9	0.4	2.93e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs655029	0.837	rs3769631	chr2:31462373	C/A	cg14018959	chr2:31480232	EHD3	-0.36	-4.88	-0.4	3.18e-6	Mean platelet volume;Platelet distribution width;Platelet count;Plateletcrit;
TGCT	cis	rs8180040	0.620	rs17784127	chr3:47061700	T/C	cg27129171	chr3:47204927	SETD2	-0.71	-8.51	-0.61	4.8e-14	Colorectal cancer;
TGCT	cis	rs1218582	0.741	rs11264291	chr1:154914797	C/T	cg09359103	chr1:154839909	KCNN3	-0.64	-11.86	-0.73	3.66e-22	Prostate cancer;
TGCT	cis	rs17376456	0.597	rs10064158	chr5:93095186	C/T	cg25358565	chr5:93447407	FAM172A	0.74	6.42	0.5	2.66e-9	Diabetic retinopathy;
TGCT	cis	rs2439831	1.000	rs689596	chr15:43761717	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.01	8.37	0.6	1.02e-13	Lung cancer in ever smokers;
TGCT	cis	rs7819412	0.806	rs10113808	chr8:10926892	C/A	cg21775007	chr8:11205619	TDH	-0.49	-4.68	-0.39	7.45e-6	Triglycerides;
TGCT	cis	rs4253772	0.744	rs9627278	chr22:46643432	C/G	cg09491104	chr22:46646882	C22orf40	-0.49	-5.36	-0.43	3.95e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg00343986	chr7:65444356	GUSB	-0.23	-5.12	-0.42	1.13e-6	Aortic root size;
TGCT	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg03709012	chr19:19516395	GATAD2A	0.67	5.74	0.46	6.83e-8	Tonsillectomy;
TGCT	cis	rs8180040	0.966	rs17784882	chr3:47544003	C/A	cg27129171	chr3:47204927	SETD2	-0.63	-7.18	-0.54	5.57e-11	Colorectal cancer;
TGCT	trans	rs1496653	0.602	rs13073761	chr3:23390594	A/G	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs1801251	1.000	rs283479	chr2:233648754	A/G	cg08000102	chr2:233561755	GIGYF2	0.63	6.35	0.5	3.67e-9	Coronary artery disease;
TGCT	cis	rs611744	0.647	rs11785776	chr8:109264933	C/T	cg21045802	chr8:109455806	TTC35	0.7	7.23	0.54	4.3e-11	Dupuytren's disease;
TGCT	cis	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg18188782	chr20:61659543	NA	0.44	5.37	0.43	3.73e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs6901250	0.851	rs339307	chr6:117177340	A/G	cg12892004	chr6:117198278	RFX6	-0.54	-6.63	-0.51	9.17e-10	C-reactive protein levels;
TGCT	cis	rs12477438	0.520	rs7572660	chr2:99788582	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.54	0.61	4.06e-14	Chronic sinus infection;
TGCT	cis	rs10927875	0.631	rs28579893	chr1:16347534	A/G	cg22431228	chr1:16359049	CLCNKA	-0.24	-4.51	-0.38	1.46e-5	Dilated cardiomyopathy;
TGCT	cis	rs6088580	0.634	rs6088478	chr20:32971719	T/C	cg24642439	chr20:33292090	TP53INP2	-0.49	-4.49	-0.37	1.59e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs2153535	0.580	rs1577471	chr6:8485905	T/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.71	0.39	6.53e-6	Prudent dietary pattern;
TGCT	cis	rs11122272	0.735	rs2790876	chr1:231536033	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-6.5	-0.5	1.77e-9	Hemoglobin concentration;
TGCT	trans	rs7819412	0.745	rs28591576	chr8:11080675	C/T	cg06636001	chr8:8085503	FLJ10661	-0.77	-6.86	-0.52	2.93e-10	Triglycerides;
TGCT	cis	rs921968	0.541	rs3755042	chr2:219317248	T/C	cg02176678	chr2:219576539	TTLL4	-0.47	-6.78	-0.52	4.34e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs12477438	0.765	rs7605218	chr2:99593080	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-7.6	-0.56	6.47e-12	Chronic sinus infection;
TGCT	cis	rs7681440	0.904	rs35424815	chr4:90767877	C/T	cg20003494	chr4:90757398	SNCA	-0.62	-5.93	-0.47	2.74e-8	Dementia with Lewy bodies;
TGCT	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg03806693	chr22:41940476	POLR3H	-1.13	-13.26	-0.77	1.59e-25	Vitiligo;
TGCT	cis	rs7772486	0.754	rs10872580	chr6:146140281	C/T	cg13319975	chr6:146136371	FBXO30	0.55	5.01	0.41	1.87e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1577917	1.000	rs4706254	chr6:86602813	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.1	-0.42	1.26e-6	Response to antipsychotic treatment;
TGCT	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg01238044	chr22:24384105	GSTT1	0.53	4.99	0.41	1.98e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9430161	0.645	rs6675082	chr1:11033797	T/C	cg27631724	chr1:11040367	C1orf127	0.53	6.05	0.48	1.58e-8	Ewing sarcoma;
TGCT	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg17264618	chr3:40429014	ENTPD3	0.32	4.57	0.38	1.18e-5	Renal cell carcinoma;
TGCT	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg06238570	chr21:40685208	BRWD1	0.69	6.38	0.5	3.27e-9	Cognitive function;
TGCT	cis	rs892864	0.685	rs10041869	chr5:127739700	A/C	cg01939274	chr5:127874478	FBN2	0.91	4.52	0.38	1.44e-5	Multiple system atrophy;
TGCT	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg18654377	chr3:49208889	KLHDC8B	0.39	5.0	0.41	1.87e-6	Menarche (age at onset);
TGCT	cis	rs921968	0.508	rs72965103	chr2:219312469	T/C	cg02176678	chr2:219576539	TTLL4	-0.47	-6.78	-0.52	4.34e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs3806843	1.000	rs10477033	chr5:140169603	G/C	cg19875535	chr5:140030758	IK	0.37	6.22	0.49	7.08e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs11098499	0.722	rs1814814	chr4:120258124	C/G	cg09307838	chr4:120376055	NA	0.57	5.64	0.45	1.07e-7	Corneal astigmatism;
TGCT	cis	rs7949030	0.596	rs11231137	chr11:62315699	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.6	7.14	0.54	6.96e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7523654	1.000	rs4565713	chr1:115869499	G/A	cg07790079	chr1:116021925	NA	-0.37	-4.71	-0.39	6.52e-6	Schizophrenia;
TGCT	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg03517284	chr6:25882590	NA	-0.5	-5.08	-0.41	1.37e-6	Height;
TGCT	cis	rs12497850	0.931	rs9835307	chr3:48857805	T/C	cg05785598	chr3:49045655	WDR6	0.36	4.75	0.39	5.46e-6	Parkinson's disease;
TGCT	cis	rs7267979	0.933	rs2261109	chr20:25259200	T/C	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg03303774	chr4:1407052	NA	0.31	4.89	0.4	3.09e-6	Obesity-related traits;
TGCT	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg23982607	chr1:1823379	GNB1	0.41	5.39	0.44	3.49e-7	Body mass index;
TGCT	cis	rs7647973	0.626	rs1996663	chr3:49878264	C/G	cg05785598	chr3:49045655	WDR6	-0.38	-4.44	-0.37	1.94e-5	Menarche (age at onset);
TGCT	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg24399712	chr22:39784796	NA	1.04	12.5	0.75	1.06e-23	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg06873352	chr17:61820015	STRADA	0.56	6.22	0.49	6.93e-9	Prudent dietary pattern;
TGCT	cis	rs67073037	0.955	rs4666133	chr2:29136623	T/C	cg09522027	chr2:28974177	PPP1CB	0.57	4.49	0.37	1.59e-5	Breast cancer;Breast cancer (estrogen-receptor negative);
TGCT	trans	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg13565492	chr6:43139072	SRF	-0.82	-7.87	-0.58	1.51e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2120019	1.000	rs12185102	chr15:75352201	G/A	cg11632617	chr15:75315747	PPCDC	-0.32	-4.67	-0.39	7.58e-6	Blood trace element (Zn levels);
TGCT	cis	rs7666738	0.830	rs7684646	chr4:99071062	C/T	cg17366294	chr4:99064904	C4orf37	0.7	7.11	0.54	8.05e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg27170947	chr2:26402098	FAM59B	-0.4	-4.63	-0.38	8.93e-6	Gut microbiome composition (summer);
TGCT	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg08219700	chr8:58056026	NA	0.29	4.5	0.37	1.54e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2204008	0.774	rs12810027	chr12:38212165	A/G	cg26384229	chr12:38710491	ALG10B	0.84	7.43	0.56	1.51e-11	Bladder cancer;
TGCT	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg08219700	chr8:58056026	NA	0.3	4.48	0.37	1.66e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9790314	0.846	rs1478568	chr3:161014276	C/T	cg03342759	chr3:160939853	NMD3	-0.48	-5.23	-0.43	6.93e-7	Morning vs. evening chronotype;
TGCT	cis	rs950776	0.593	rs555018	chr15:78879242	G/A	cg06917634	chr15:78832804	PSMA4	-0.67	-5.5	-0.44	2.07e-7	Sudden cardiac arrest;
TGCT	cis	rs35306767	0.903	rs34847097	chr10:902252	A/T	cg20503657	chr10:835505	NA	0.75	10.41	0.68	1.3e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs308403	0.568	rs67050821	chr4:123674383	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.7	6.48	0.5	1.9e-9	Blood protein levels;
TGCT	cis	rs7582180	0.764	rs7425797	chr2:100928337	T/C	cg14675211	chr2:100938903	LONRF2	0.52	4.98	0.41	2.1e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs225245	0.817	rs2301730	chr17:33998683	A/G	cg05299278	chr17:33885742	SLFN14	0.21	4.5	0.37	1.54e-5	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs2982552	0.844	rs2982559	chr6:152055905	G/A	cg22157087	chr6:152012887	ESR1	0.21	5.16	0.42	9.59e-7	Bone properties (heel);
TGCT	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg13732083	chr21:47605072	C21orf56	0.34	4.51	0.38	1.51e-5	Testicular germ cell tumor;
TGCT	cis	rs11696501	0.739	rs6073815	chr20:44234615	A/T	cg11783356	chr20:44313418	WFDC10B	-0.32	-4.63	-0.38	9.25e-6	Brain structure;
TGCT	cis	rs28374715	0.578	rs10518717	chr15:41623368	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.9	-14.83	-0.8	2.99e-29	Ulcerative colitis;
TGCT	cis	rs6495367	1.000	rs745030	chr15:79381705	G/A	cg17916960	chr15:79447300	NA	0.37	5.21	0.42	7.75e-7	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs28595532	0.920	rs114575045	chr4:119739794	A/G	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs2153535	0.580	rs763376	chr6:8492776	G/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs2288884	0.806	rs59667666	chr19:52586194	A/G	cg13540795	chr19:52551618	ZNF432	-0.61	-5.28	-0.43	5.48e-7	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs6570726	0.791	rs6570694	chr6:145911204	C/G	cg23711669	chr6:146136114	FBXO30	0.86	9.28	0.64	7.13e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10193935	0.901	rs871045	chr2:42609431	G/C	cg27598129	chr2:42591480	NA	-0.41	-5.66	-0.45	1e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9372498	0.536	rs62424195	chr6:118812108	T/A	cg07617317	chr6:118971624	C6orf204	0.46	5.08	0.41	1.36e-6	Diastolic blood pressure;
TGCT	cis	rs12530134	0.590	rs760492	chr6:170743989	A/G	cg18217622	chr6:170732253	NA	0.72	4.68	0.39	7.37e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs68190844	1	rs68190844	chr17:4568953	CTA/C	cg19197139	chr17:4613644	ARRB2	-0.87	-8.05	-0.59	5.79e-13	Eosinophil percentage of white cells;
TGCT	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg18230493	chr5:56204884	C5orf35	-0.68	-5.92	-0.47	2.92e-8	Initial pursuit acceleration;
TGCT	cis	rs62244186	1.000	rs62244186	chr3:44739783	G/A	cg21672276	chr3:44754072	ZNF502	-0.48	-5.43	-0.44	2.88e-7	Depressive symptoms;
TGCT	cis	rs11190604	1.000	rs2298075	chr10:102247408	C/A	cg16342193	chr10:102329863	NA	-0.4	-5.34	-0.43	4.36e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs968451	0.901	rs5757584	chr22:39662550	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.8	6.83	0.52	3.41e-10	Primary biliary cholangitis;
TGCT	cis	rs4704846	0.950	rs919746	chr5:156531316	C/T	cg12943317	chr5:156479607	HAVCR1	-0.34	-4.75	-0.39	5.43e-6	Blood protein levels;
TGCT	cis	rs2730260	0.537	rs55662704	chr7:158864184	T/C	cg09066883	chr7:157932951	PTPRN2	0.41	4.52	0.38	1.41e-5	Myopia (pathological);
TGCT	trans	rs28735056	1.000	rs28735056	chr18:77622879	A/G	cg05926928	chr17:57297772	GDPD1	-0.67	-7.05	-0.53	1.08e-10	Schizophrenia;
TGCT	cis	rs9318086	0.648	rs4067969	chr13:24469120	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.83	9.04	0.63	2.62e-15	Myopia (pathological);
TGCT	cis	rs6912958	1.000	rs2207144	chr6:88150816	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.63	-6.22	-0.49	7.06e-9	Monocyte percentage of white cells;
TGCT	cis	rs3617	0.573	rs62253582	chr3:52928333	G/A	cg10802521	chr3:52805072	NEK4	0.58	6.62	0.51	9.63e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9381040	0.599	rs2057001	chr6:41022947	A/G	cg03526776	chr6:41159608	TREML2	0.27	5.29	0.43	5.37e-7	Alzheimer's disease (late onset);
TGCT	cis	rs514406	0.893	rs1242317	chr1:53414766	T/C	cg22166914	chr1:53195759	ZYG11B	0.37	6.37	0.5	3.34e-9	Monocyte count;
TGCT	cis	rs7726839	0.526	rs11960158	chr5:568665	C/T	cg09021430	chr5:549028	NA	-0.42	-5.68	-0.45	9.25e-8	Obesity-related traits;
TGCT	cis	rs9467773	0.869	rs742090	chr6:26415637	A/C	cg05738196	chr6:26577821	NA	-0.62	-6.65	-0.51	8.17e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs1008375	1.000	rs6818639	chr4:17633049	A/G	cg18681998	chr4:17616180	MED28	1.01	11.55	0.72	2.15e-21	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2933343	0.729	rs813945	chr3:128660937	A/G	cg11901034	chr3:128598214	ACAD9	-0.64	-6.26	-0.49	5.66e-9	IgG glycosylation;
TGCT	cis	rs6088580	0.634	rs4911151	chr20:32932273	T/C	cg08999081	chr20:33150536	PIGU	-0.26	-4.98	-0.41	2.06e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs2456568	0.867	rs72962810	chr11:93663619	A/G	cg17595323	chr11:93583763	C11orf90	-0.46	-5.93	-0.47	2.77e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7267979	0.966	rs2424714	chr20:25418681	T/G	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg13732083	chr21:47605072	C21orf56	0.35	4.69	0.39	7.17e-6	Testicular germ cell tumor;
TGCT	cis	rs950169	1.000	rs12916348	chr15:84765527	C/T	cg17173187	chr15:85201210	NMB	0.47	5.23	0.43	7.01e-7	Schizophrenia;
TGCT	cis	rs10411936	0.962	rs10404046	chr19:16477255	G/C	cg14704714	chr19:15740395	CYP4F8	0.25	4.46	0.37	1.85e-5	White blood cell count;Multiple sclerosis;
TGCT	cis	rs1150668	0.768	rs1150716	chr6:28262698	T/G	cg11262757	chr6:27280423	POM121L2	0.46	4.62	0.38	9.52e-6	Pubertal anthropometrics;
TGCT	cis	rs6570726	0.791	rs9403729	chr6:145907007	C/T	cg23711669	chr6:146136114	FBXO30	0.89	9.85	0.66	2.95e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg17179660	chr6:151773299	C6orf211;RMND1	-0.54	-4.88	-0.4	3.17e-6	Menarche (age at onset);
TGCT	cis	rs10934753	0.632	rs4350878	chr3:125914214	C/G	cg01346077	chr3:125931526	NA	0.44	7.17	0.54	6.06e-11	Plasma homocysteine levels (post-methionine load test);
TGCT	cis	rs1669338	0.588	rs73005226	chr3:3195369	A/G	cg16797762	chr3:3221439	CRBN	-0.89	-5.74	-0.46	6.95e-8	White matter integrity;
TGCT	cis	rs10504229	0.679	rs11783557	chr8:58030644	A/G	cg08280861	chr8:58055591	NA	0.35	5.07	0.41	1.43e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6901004	0.803	rs193282	chr6:111543067	G/A	cg15721981	chr6:111408429	SLC16A10	-0.52	-4.55	-0.38	1.27e-5	Blood metabolite levels;
TGCT	cis	rs459571	0.920	rs460154	chr9:136909309	C/T	cg14405625	chr9:136855902	VAV2	-0.3	-4.46	-0.37	1.79e-5	Platelet distribution width;
TGCT	cis	rs12579753	1.000	rs11613196	chr12:82173251	A/T	cg07988820	chr12:82153109	PPFIA2	0.65	6.79	0.52	4.09e-10	Resting heart rate;
TGCT	cis	rs1348850	0.539	rs1453371	chr2:178227862	T/G	cg22681709	chr2:178499509	PDE11A	-0.36	-4.51	-0.38	1.49e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs17665859	0.925	rs62484458	chr8:482717	T/C	cg17960703	chr8:356704	FBXO25	1.2	4.7	0.39	6.74e-6	Bilirubin levels;
TGCT	cis	rs78456975	0.546	rs72776254	chr2:1527881	C/T	cg01028140	chr2:1542097	TPO	-0.36	-4.61	-0.38	9.93e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs4242434	0.819	rs751680	chr8:22475627	G/A	cg03733263	chr8:22462867	KIAA1967	1.06	16.43	0.83	6.43e-33	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs3858526	0.959	rs11039540	chr11:5928334	C/T	cg13902645	chr11:5959945	NA	-0.44	-4.8	-0.4	4.54e-6	DNA methylation (variation);
TGCT	cis	rs6582630	0.519	rs1607868	chr12:38385512	G/T	cg13010199	chr12:38710504	ALG10B	0.62	4.94	0.41	2.47e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs4919694	1.000	rs76892505	chr10:104719290	G/A	cg04362960	chr10:104952993	NT5C2	1.07	7.15	0.54	6.49e-11	Arsenic metabolism;
TGCT	cis	rs6570726	0.738	rs6925594	chr6:145898454	T/C	cg13319975	chr6:146136371	FBXO30	-0.5	-4.51	-0.38	1.48e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs904251	0.523	rs9366935	chr6:37480404	C/T	cg25019722	chr6:37503610	NA	-0.54	-7.82	-0.57	1.92e-12	Cognitive performance;
TGCT	cis	rs2735413	0.564	rs73578735	chr16:78104936	C/G	cg09132178	chr16:78079569	NA	0.35	4.72	0.39	6.29e-6	Systolic blood pressure (alcohol consumption interaction);
TGCT	cis	rs6089829	0.888	rs4809465	chr20:61671156	G/C	cg03213289	chr20:61660250	NA	0.72	9.45	0.65	2.69e-16	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs67311347	1.000	rs4973997	chr3:40460145	G/A	cg13683864	chr3:40499215	RPL14	-1.04	-10.79	-0.7	1.54e-19	Renal cell carcinoma;
TGCT	cis	rs3935685	0.874	rs4334265	chr15:78007432	T/C	cg03457338	chr15:78040120	NA	-0.23	-6.08	-0.48	1.36e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2663905	0.706	rs7162859	chr15:81360038	C/T	cg18837035	chr15:81426597	C15orf26	0.8	6.82	0.52	3.59e-10	QT interval (drug interaction);
TGCT	cis	rs11585357	0.895	rs72633808	chr1:17618665	A/G	cg08277548	chr1:17600880	PADI3	-0.95	-9.6	-0.65	1.15e-16	Hair shape;
TGCT	cis	rs6582630	0.555	rs10880612	chr12:38509427	A/G	cg26384229	chr12:38710491	ALG10B	0.85	7.86	0.58	1.55e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs9788333	0.788	rs35007728	chr13:21893221	G/C	cg10411590	chr13:21900810	NA	0.35	4.44	0.37	1.98e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	cis	rs10791323	0.604	rs2250025	chr11:133710914	G/A	cg03690763	chr11:133734501	NA	-0.31	-4.79	-0.39	4.72e-6	Childhood ear infection;
TGCT	cis	rs6565180	0.888	rs12921440	chr16:30408765	C/T	cg17640201	chr16:30407289	ZNF48	1.03	9.96	0.67	1.61e-17	Tonsillectomy;
TGCT	trans	rs7618501	0.522	rs73077175	chr3:49774658	G/A	cg21659725	chr3:3221576	CRBN	-0.68	-6.74	-0.52	5.33e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs4319547	0.656	rs1553179	chr12:122831073	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.6	-4.68	-0.39	7.27e-6	Body mass index;
TGCT	cis	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg02503808	chr4:7069936	GRPEL1	0.89	7.17	0.54	5.92e-11	Monocyte percentage of white cells;
TGCT	cis	rs425277	0.565	rs3128293	chr1:2065339	A/G	cg03732007	chr1:2071316	PRKCZ	-0.29	-6.49	-0.5	1.89e-9	Height;
TGCT	cis	rs7772486	0.805	rs4896831	chr6:145959481	T/C	cg05347473	chr6:146136440	FBXO30	0.51	4.84	0.4	3.82e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs904251	0.861	rs1757173	chr6:37486952	A/C	cg25019722	chr6:37503610	NA	-0.5	-6.92	-0.53	2.17e-10	Cognitive performance;
TGCT	cis	rs4595586	0.546	rs10876163	chr12:39244915	G/A	cg13010199	chr12:38710504	ALG10B	0.6	4.72	0.39	6.26e-6	Morning vs. evening chronotype;
TGCT	cis	rs7192750	0.586	rs9937936	chr16:71934419	A/T	cg06353428	chr16:71660113	MARVELD3	0.83	7.32	0.55	2.74e-11	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.11	13.91	0.78	4.47e-27	Height;
TGCT	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg13397359	chr6:42928475	GNMT	0.72	6.47	0.5	2.07e-9	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs6912958	0.781	rs9450732	chr6:88249826	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-5.06	-0.41	1.45e-6	Monocyte percentage of white cells;
TGCT	cis	rs35146811	0.589	rs1727142	chr7:99816179	T/C	cg22906224	chr7:99728672	NA	-0.51	-4.49	-0.37	1.62e-5	Coronary artery disease;
TGCT	cis	rs1538970	0.884	rs781226	chr1:45872662	T/C	cg05343316	chr1:45956843	TESK2	-0.7	-5.46	-0.44	2.47e-7	Platelet count;
TGCT	cis	rs4660261	0.526	rs2485996	chr1:44354661	C/T	cg12908607	chr1:44402522	ARTN	-0.66	-8.26	-0.6	1.85e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.593	rs80174614	chr8:58024631	G/A	cg08280861	chr8:58055591	NA	0.36	5.16	0.42	9.31e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6831352	0.879	rs29001196	chr4:100054116	C/T	cg12011299	chr4:100065546	ADH4	-0.4	-4.88	-0.4	3.26e-6	Alcohol dependence;
TGCT	cis	rs1215050	0.791	rs1506438	chr4:98789542	C/T	cg05340658	chr4:99064831	C4orf37	0.46	5.64	0.45	1.07e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg12667521	chr19:29218732	NA	0.55	5.84	0.46	4.36e-8	Methadone dose in opioid dependence;
TGCT	cis	rs7666738	0.791	rs13120773	chr4:98972589	C/T	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12497850	0.931	rs9682444	chr3:48852639	A/G	cg07636037	chr3:49044803	WDR6	0.94	10.39	0.68	1.46e-18	Parkinson's disease;
TGCT	cis	rs10875746	0.855	rs10875731	chr12:48432743	G/A	cg20731937	chr12:48336164	NA	0.68	5.29	0.43	5.3e-7	Longevity (90 years and older);
TGCT	cis	rs2580764	0.565	rs6545466	chr2:55228392	C/T	cg09592903	chr2:55203963	RTN4	-0.25	-5.45	-0.44	2.58e-7	Mean platelet volume;
TGCT	cis	rs9650657	0.740	rs12676417	chr8:10668634	C/T	cg27411982	chr8:10470053	RP1L1	0.22	5.0	0.41	1.9e-6	Neuroticism;
TGCT	cis	rs7914558	0.932	rs4307650	chr10:104959852	C/A	cg15744005	chr10:104629667	AS3MT	-0.39	-4.84	-0.4	3.83e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs2469997	1.000	rs2470021	chr8:120362644	T/C	cg00681363	chr8:120844660	TAF2	0.69	4.48	0.37	1.64e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs3027234	0.734	rs11650309	chr17:8129538	C/G	cg08322244	chr17:8066669	VAMP2	-0.57	-5.53	-0.45	1.77e-7	Telomere length;
TGCT	cis	rs346785	0.965	rs17509527	chr17:74286173	A/G	cg09812376	chr17:74270190	QRICH2	-0.4	-6.14	-0.48	1.01e-8	White matter hyperintensities in ischemic stroke;
TGCT	cis	rs3806843	0.900	rs2337984	chr5:140136811	G/A	cg19875535	chr5:140030758	IK	-0.36	-6.0	-0.47	2.05e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg23131131	chr22:24373011	LOC391322	-0.71	-7.38	-0.55	1.97e-11	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs4253772	0.550	rs6008762	chr22:46736228	T/C	cg24881330	chr22:46731750	TRMU	0.99	5.31	0.43	4.99e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs3733585	0.673	rs4235347	chr4:9951956	C/T	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.65	-0.57	4.78e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs250677	1.000	rs250676	chr5:148425518	A/T	cg18129178	chr5:148520854	ABLIM3	-0.42	-6.21	-0.49	7.23e-9	Breast cancer;
TGCT	cis	rs7312933	0.501	rs3810793	chr12:42729407	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	5.16	0.42	9.38e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs2997447	0.846	rs61775430	chr1:26411109	G/A	cg03844060	chr1:26490628	NA	0.28	4.57	0.38	1.17e-5	QRS complex (12-leadsum);
TGCT	cis	rs912057	0.632	rs1294429	chr6:6744652	G/A	cg06612196	chr6:6737390	NA	0.47	6.77	0.52	4.57e-10	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.49	5.08	0.41	1.38e-6	Lymphocyte counts;
TGCT	cis	rs6684514	0.845	rs12138564	chr1:156291600	G/T	cg16558208	chr1:156270281	VHLL	0.48	9.6	0.65	1.19e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs1008375	0.932	rs6449315	chr4:17590219	A/G	cg16339924	chr4:17578868	LAP3	0.83	7.21	0.54	4.92e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6459788	0.692	rs10807645	chr7:157258979	T/C	cg03453431	chr7:157225567	NA	0.38	5.86	0.47	3.86e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs6430585	0.583	rs58509842	chr2:136586027	G/A	cg07169764	chr2:136633963	MCM6	1.18	11.26	0.71	1.09e-20	Corneal structure;
TGCT	cis	rs881375	1.000	rs10818480	chr9:123643170	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	5.47	0.44	2.33e-7	Rheumatoid arthritis;
TGCT	cis	rs514406	0.698	rs11206043	chr1:53402552	C/T	cg24675658	chr1:53192096	ZYG11B	-0.75	-9.12	-0.63	1.71e-15	Monocyte count;
TGCT	cis	rs2836950	0.501	rs2070865	chr21:40715519	C/T	cg11890956	chr21:40555474	PSMG1	-0.6	-5.53	-0.45	1.78e-7	Menarche (age at onset);
TGCT	cis	rs3091242	1.000	rs3091242	chr1:25674785	C/T	cg00786635	chr1:25594202	NA	0.6	6.25	0.49	6.14e-9	Erythrocyte sedimentation rate;
TGCT	cis	rs11971779	0.938	rs28477480	chr7:139036058	C/T	cg07862535	chr7:139043722	LUC7L2	-0.67	-4.83	-0.4	3.88e-6	Diisocyanate-induced asthma;
TGCT	cis	rs9419702	0.568	rs7920966	chr10:133555185	G/T	cg23460707	chr10:133558971	NA	0.41	4.68	0.39	7.46e-6	Survival in rectal cancer;
TGCT	cis	rs929354	0.742	rs7807556	chr7:156934329	T/C	cg05182265	chr7:156933206	UBE3C	-0.38	-8.4	-0.6	8.9e-14	Body mass index;
TGCT	cis	rs9911578	1.000	rs10401050	chr17:56953786	A/C	cg05425664	chr17:57184151	TRIM37	-0.62	-6.18	-0.49	8.33e-9	Intelligence (multi-trait analysis);
TGCT	trans	rs7726839	0.794	rs10474792	chr5:600058	G/A	cg11887960	chr12:57824829	NA	0.97	7.56	0.56	7.58e-12	Obesity-related traits;
TGCT	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg06238570	chr21:40685208	BRWD1	-0.69	-6.47	-0.5	2.03e-9	Cognitive function;
TGCT	cis	rs636291	0.517	rs673254	chr1:10550352	C/T	cg17425144	chr1:10567563	PEX14	0.54	7.52	0.56	9.62e-12	Prostate cancer;
TGCT	cis	rs651907	0.535	rs61396602	chr3:101509046	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.86	10.4	0.68	1.35e-18	Colorectal cancer;
TGCT	cis	rs25645	0.800	rs11078935	chr17:38192137	T/G	cg17467752	chr17:38218738	THRA	-0.59	-5.45	-0.44	2.55e-7	Myeloid white cell count;
TGCT	cis	rs7523050	0.730	rs35100394	chr1:109433989	C/G	cg08274380	chr1:109419600	GPSM2	1.35	6.86	0.52	2.89e-10	Fat distribution (HIV);
TGCT	cis	rs12681287	0.547	rs9942792	chr8:87509046	C/T	cg19078186	chr8:87526527	CPNE3	-0.37	-4.57	-0.38	1.15e-5	Caudate activity during reward;
TGCT	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg07507251	chr3:52567010	NT5DC2	0.49	6.88	0.53	2.67e-10	Bipolar disorder;
TGCT	cis	rs910187	0.678	rs3818014	chr20:45816649	C/T	cg27589058	chr20:45804311	EYA2	-0.35	-7.6	-0.56	6.23e-12	Migraine;
TGCT	cis	rs2228479	0.681	rs7199685	chr16:89959805	G/C	cg06558623	chr16:89946397	TCF25	0.39	4.85	0.4	3.56e-6	Skin colour saturation;
TGCT	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg20203395	chr5:56204925	C5orf35	-0.59	-5.12	-0.42	1.12e-6	Initial pursuit acceleration;
TGCT	cis	rs290268	0.874	rs290991	chr9:93561450	A/C	cg02608019	chr9:93564028	SYK	-0.46	-4.71	-0.39	6.64e-6	Platelet count;
TGCT	cis	rs1887596	0.663	rs2476713	chr13:27251602	A/G	cg01312412	chr13:27282625	NA	0.27	4.76	0.39	5.31e-6	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs3806843	0.576	rs246066	chr5:140323147	T/G	cg09824255	chr5:140014002	CD14	0.25	4.48	0.37	1.68e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs13185784	0.667	rs6882940	chr5:179648989	A/G	cg04734276	chr5:178882605	NA	0.29	4.52	0.38	1.42e-5	TRAIL levels;
TGCT	cis	rs6940638	0.615	rs9393801	chr6:27242681	A/G	cg26531700	chr6:26746687	NA	-0.59	-5.16	-0.42	9.53e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2412208	0.545	rs6685979	chr1:7067911	A/G	cg09549827	chr1:6484616	ESPN	0.27	4.72	0.39	6.38e-6	Survival in sporadic amyotrophic lateral sclerosis;
TGCT	cis	rs7666738	0.819	rs62318904	chr4:99036101	A/T	cg17366294	chr4:99064904	C4orf37	0.74	7.59	0.56	6.7e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6088590	0.610	rs6120663	chr20:33081906	A/C	cg08999081	chr20:33150536	PIGU	-0.27	-5.02	-0.41	1.75e-6	Coronary artery disease;
TGCT	cis	rs881375	1.000	rs10117059	chr9:123653477	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.39	4.44	0.37	1.98e-5	Rheumatoid arthritis;
TGCT	cis	rs1577917	0.771	rs9362233	chr6:86358247	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.58	-0.45	1.43e-7	Response to antipsychotic treatment;
TGCT	cis	rs9611519	1.000	rs9611505	chr22:41540279	T/C	cg13695892	chr22:41940480	POLR3H	-0.51	-4.57	-0.38	1.16e-5	Neuroticism;
TGCT	cis	rs7666738	0.830	rs6833822	chr4:98951354	G/A	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1865760	0.566	rs3752419	chr6:26027433	C/T	cg16482183	chr6:26056742	HIST1H1C	0.6	5.33	0.43	4.53e-7	Height;
TGCT	cis	rs1129187	0.805	rs1053539	chr6:42903766	T/G	cg09436375	chr6:42928200	GNMT	-0.39	-5.13	-0.42	1.08e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs7552404	1.000	rs7534754	chr1:76185308	G/A	cg03433033	chr1:76189801	ACADM	0.83	9.83	0.66	3.18e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.57	-5.22	-0.42	7.14e-7	Prudent dietary pattern;
TGCT	cis	rs9368481	0.729	rs10946881	chr6:26914611	C/T	cg26531700	chr6:26746687	NA	0.7	6.44	0.5	2.43e-9	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg12963246	chr6:28129442	ZNF389	0.52	5.01	0.41	1.85e-6	Depression;
TGCT	trans	rs2688608	0.592	rs11000760	chr10:75493734	G/A	cg13918328	chr10:52500089	ASAH2B	0.68	6.7	0.52	6.48e-10	Inflammatory bowel disease;
TGCT	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.45	-5.37	-0.43	3.72e-7	Alzheimer's disease;
TGCT	cis	rs4383453	0.539	rs60870039	chr3:123101990	A/G	cg04890266	chr3:123102914	ADCY5	-0.49	-7.91	-0.58	1.23e-12	Gestational age at birth (maternal effect);
TGCT	cis	rs7044106	0.537	rs10739573	chr9:123489818	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	7.0	0.53	1.45e-10	Hip circumference adjusted for BMI;
TGCT	cis	rs17401966	0.931	rs10864448	chr1:10277497	A/T	cg19773385	chr1:10388646	KIF1B	-0.22	-4.78	-0.39	4.96e-6	Hepatocellular carcinoma;
TGCT	cis	rs909002	0.849	rs6663012	chr1:32091779	T/G	cg11573219	chr1:32083031	HCRTR1	-0.46	-6.0	-0.47	2.01e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs939658	0.805	rs35291410	chr15:79438660	C/T	cg17916960	chr15:79447300	NA	-0.49	-7.59	-0.56	6.76e-12	Refractive error;
TGCT	cis	rs6840360	0.530	rs12645029	chr4:152650032	T/C	cg17479576	chr4:152424074	FAM160A1	-0.66	-6.47	-0.5	2.02e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs6674176	0.628	rs7556565	chr1:44416090	C/T	cg12908607	chr1:44402522	ARTN	-0.68	-8.19	-0.59	2.7e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs9467773	1.000	rs1884948	chr6:26567988	G/A	cg05738196	chr6:26577821	NA	0.9	12.48	0.75	1.16e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs7552404	0.924	rs1303169	chr1:76195041	T/C	cg10523679	chr1:76189770	ACADM	0.85	9.41	0.65	3.37e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2404602	0.710	rs2469541	chr15:76562118	C/T	cg26408565	chr15:76604113	ETFA	0.52	6.98	0.53	1.59e-10	Blood metabolite levels;
TGCT	cis	rs3733631	1.000	rs6533106	chr4:104596455	A/G	cg24090629	chr4:104641072	TACR3	-0.73	-5.72	-0.46	7.65e-8	Menarche (age at onset);
TGCT	trans	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg23505145	chr19:12996616	KLF1	0.78	8.12	0.59	4.03e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg20637647	chr7:64974828	NA	0.89	4.95	0.41	2.37e-6	Diabetic kidney disease;
TGCT	cis	rs832540	0.931	rs832535	chr5:56213334	C/T	cg12311346	chr5:56204834	C5orf35	-0.47	-4.97	-0.41	2.15e-6	Coronary artery disease;
TGCT	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7772486	0.754	rs9386132	chr6:146140751	T/C	cg23711669	chr6:146136114	FBXO30	0.94	10.7	0.69	2.56e-19	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs929354	1.000	rs929354	chr7:157045557	C/T	cg05182265	chr7:156933206	UBE3C	0.28	5.99	0.47	2.1e-8	Body mass index;
TGCT	cis	rs4783244	0.897	rs4783242	chr16:82651428	C/A	cg09415485	chr16:82663111	CDH13	-0.24	-4.52	-0.38	1.4e-5	Adiponectin levels;
TGCT	trans	rs2727020	0.729	rs10839268	chr11:49380328	G/A	cg15704280	chr7:45808275	SEPT13	-0.74	-8.5	-0.61	5.01e-14	Coronary artery disease;
TGCT	cis	rs7655841	0.704	rs11934740	chr4:129882748	C/T	cg26347359	chr4:129759716	PHF17	0.4	4.55	0.38	1.25e-5	Chronic obstructive pulmonary disease (moderate to severe);
TGCT	cis	rs66561647	0.517	rs7819924	chr8:128914008	A/T	cg11792826	chr8:129160931	MIR1208	0.2	4.48	0.37	1.67e-5	Hemoglobin concentration;
TGCT	cis	rs6840360	1.000	rs4696284	chr4:152595836	C/G	cg17479576	chr4:152424074	FAM160A1	-0.5	-5.4	-0.44	3.26e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs6088580	0.634	rs6059868	chr20:33079460	A/G	cg08999081	chr20:33150536	PIGU	0.29	5.57	0.45	1.54e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs1018836	0.923	rs6986001	chr8:91650205	T/C	cg16814680	chr8:91681699	NA	-0.83	-8.71	-0.62	1.62e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9916302	0.851	rs9904919	chr17:37556431	G/C	cg07936489	chr17:37558343	FBXL20	0.65	4.98	0.41	2.11e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	16.04	0.82	5e-32	Prudent dietary pattern;
TGCT	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg03806693	chr22:41940476	POLR3H	-1.15	-13.26	-0.77	1.52e-25	Vitiligo;
TGCT	cis	rs1461503	0.966	rs1461502	chr11:122844927	C/G	cg27398637	chr11:122830231	C11orf63	-0.42	-5.25	-0.43	6.42e-7	Menarche (age at onset);
TGCT	cis	rs116095464	0.614	rs4371799	chr5:268192	C/A	cg22857025	chr5:266934	NA	-0.34	-6.64	-0.51	8.6e-10	Breast cancer;
TGCT	cis	rs295140	1.000	rs1367856	chr2:201160739	T/A	cg04283868	chr2:201171347	SPATS2L	0.63	6.36	0.5	3.56e-9	QT interval;
TGCT	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg23172400	chr8:95962367	TP53INP1	-0.39	-6.52	-0.51	1.59e-9	Type 2 diabetes;
TGCT	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg17554472	chr22:41940697	POLR3H	-0.48	-5.15	-0.42	9.89e-7	Vitiligo;
TGCT	cis	rs10751667	0.666	rs7124480	chr11:971601	G/A	cg06064525	chr11:970664	AP2A2	-0.35	-8.11	-0.59	4.14e-13	Alzheimer's disease (late onset);
TGCT	cis	rs11098499	0.691	rs12510133	chr4:120271344	A/C	cg09307838	chr4:120376055	NA	0.56	5.5	0.44	2.05e-7	Corneal astigmatism;
TGCT	trans	rs17684571	0.938	rs35408048	chr6:56559544	G/T	cg14229071	chr15:89282588	NA	0.52	6.74	0.52	5.33e-10	Schizophrenia;
TGCT	cis	rs9549260	0.755	rs8001443	chr13:41216646	C/T	cg21288729	chr13:41239152	FOXO1	-0.96	-10.19	-0.68	4.34e-18	Red blood cell count;
TGCT	cis	rs6750047	0.567	rs336039	chr2:38258827	C/T	cg07380506	chr2:38303506	CYP1B1	-0.57	-5.39	-0.44	3.49e-7	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs61931739	0.500	rs7955933	chr12:34473608	A/G	cg06521331	chr12:34319734	NA	-0.27	-4.53	-0.38	1.37e-5	Morning vs. evening chronotype;
TGCT	cis	rs611744	0.967	rs602384	chr8:109188185	G/C	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	trans	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg21659725	chr3:3221576	CRBN	-0.67	-7.53	-0.56	9.05e-12	Body mass index;
TGCT	cis	rs4711350	1.000	rs2182659	chr6:33751767	A/G	cg00334056	chr6:33755658	LEMD2	-0.29	-4.61	-0.38	9.83e-6	Schizophrenia;
TGCT	cis	rs2239547	0.522	rs2336162	chr3:52951519	C/T	cg10802521	chr3:52805072	NEK4	0.6	5.85	0.47	4.1e-8	Schizophrenia;
TGCT	cis	rs911555	0.755	rs975892	chr14:103883349	A/T	cg23461800	chr14:103021989	NA	0.35	4.67	0.39	7.67e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs13326165	0.760	rs13075370	chr3:52399278	G/A	cg07884673	chr3:53033167	SFMBT1	0.38	4.65	0.39	8.36e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs950776	0.518	rs11632604	chr15:78821914	T/C	cg06917634	chr15:78832804	PSMA4	0.95	9.52	0.65	1.81e-16	Sudden cardiac arrest;
TGCT	cis	rs60154123	0.505	rs7540237	chr1:210053325	C/T	cg21951975	chr1:209979733	IRF6	0.64	4.77	0.39	5.12e-6	Coronary artery disease;
TGCT	cis	rs748404	0.631	rs12905772	chr15:43648444	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	4.72	0.39	6.3e-6	Lung cancer;
TGCT	cis	rs28595532	0.841	rs56388366	chr4:119769242	A/G	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs3935685	0.874	rs4334265	chr15:78007432	T/C	cg25212270	chr15:78015279	NA	0.26	5.49	0.44	2.14e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs250677	0.687	rs36046	chr5:148441257	A/C	cg18129178	chr5:148520854	ABLIM3	-0.43	-6.29	-0.49	5.05e-9	Breast cancer;
TGCT	cis	rs13256369	0.756	rs13282580	chr8:8562903	C/T	cg06671706	chr8:8559999	CLDN23	0.34	4.52	0.38	1.4e-5	Obesity-related traits;
TGCT	cis	rs6545883	0.718	rs3771260	chr2:61762384	G/T	cg15711740	chr2:61764176	XPO1	-0.57	-5.29	-0.43	5.32e-7	Tuberculosis;
TGCT	cis	rs3784262	1.000	rs4646638	chr15:58248783	C/T	cg12031962	chr15:58353849	ALDH1A2	0.52	7.91	0.58	1.22e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs1245541	0.595	rs11818980	chr10:73872574	C/T	cg10983208	chr10:73848320	SPOCK2	-0.26	-4.48	-0.37	1.7e-5	Insulin-like growth factors;
TGCT	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.78	6.27	0.49	5.58e-9	Mean platelet volume;
TGCT	cis	rs7249142	0.549	rs2238667	chr19:19282523	G/A	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.56	5.55	0.45	1.63e-7	IgG glycosylation;
TGCT	cis	rs12142240	0.621	rs13374968	chr1:46843908	T/G	cg14993813	chr1:46806288	NSUN4	-0.58	-4.79	-0.4	4.69e-6	Menopause (age at onset);
TGCT	cis	rs6725041	0.547	rs1505353	chr2:213203057	C/A	cg20637307	chr2:213403960	ERBB4	-0.54	-4.51	-0.38	1.51e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs9341808	0.754	rs3805925	chr6:80883833	T/C	cg08355045	chr6:80787529	NA	0.32	5.6	0.45	1.29e-7	Sitting height ratio;
TGCT	cis	rs9368481	0.678	rs62402024	chr6:26923976	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.47	5.04	0.41	1.62e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs5760092	0.755	rs11090298	chr22:24262061	G/A	cg00024416	chr22:24240387	NA	0.36	6.11	0.48	1.19e-8	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs11264213	0.901	rs72661640	chr1:36447232	T/G	cg27506609	chr1:36549197	TEKT2	0.41	4.61	0.38	9.88e-6	Schizophrenia;
TGCT	cis	rs950169	0.922	rs4842946	chr15:84942331	G/A	cg17173187	chr15:85201210	NMB	0.58	5.93	0.47	2.77e-8	Schizophrenia;
TGCT	cis	rs3733585	0.699	rs6834893	chr4:9959123	C/T	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.7	-0.57	3.69e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg14500267	chr11:67383377	NA	-0.31	-4.83	-0.4	3.97e-6	Mean corpuscular volume;
TGCT	cis	rs6912958	0.712	rs6908386	chr6:88354746	T/C	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.98	-0.41	2.06e-6	Monocyte percentage of white cells;
TGCT	cis	rs7312933	0.533	rs3747557	chr12:42717961	G/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.59	-5.7	-0.46	8.16e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.82	7.52	0.56	9.42e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs35306767	0.951	rs61833265	chr10:990143	C/T	cg26597838	chr10:835615	NA	0.62	8.25	0.6	1.94e-13	Eosinophil percentage of granulocytes;
TGCT	cis	rs9303401	0.614	rs62084384	chr17:57126842	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.63	5.8	0.46	5.11e-8	Cognitive test performance;
TGCT	cis	rs751728	0.626	rs4711348	chr6:33736295	G/A	cg13859433	chr6:33739653	LEMD2	-0.33	-6.03	-0.48	1.72e-8	Crohn's disease;
TGCT	cis	rs478304	0.593	rs7120713	chr11:65483374	G/C	cg27068330	chr11:65405492	SIPA1	-0.96	-9.18	-0.64	1.19e-15	Acne (severe);
TGCT	cis	rs7103648	0.897	rs3758675	chr11:47400602	G/A	cg20307385	chr11:47447363	PSMC3	1.05	12.13	0.74	8.16e-23	Diastolic blood pressure;Systolic blood pressure;
TGCT	cis	rs7944584	0.563	rs61895112	chr11:47560433	T/C	cg20307385	chr11:47447363	PSMC3	0.9	8.49	0.61	5.41e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
TGCT	cis	rs9291683	0.655	rs35750364	chr4:10049049	T/C	cg00071950	chr4:10020882	SLC2A9	0.68	8.66	0.61	2.13e-14	Bone mineral density;
TGCT	cis	rs11578119	0.689	rs6665215	chr1:170392281	A/G	cg09767346	chr1:170501363	GORAB	-0.57	-4.7	-0.39	6.94e-6	Male-pattern baldness;
TGCT	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg00484396	chr16:3507460	NAT15	0.43	6.62	0.51	9.89e-10	Tuberculosis;
TGCT	cis	rs1127311	0.846	rs61811388	chr1:154581231	G/C	cg17218026	chr1:154582156	ADAR	0.31	7.76	0.57	2.66e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs9300255	0.739	rs4759415	chr12:123743674	C/T	cg00376283	chr12:123451042	ABCB9	-0.72	-5.54	-0.45	1.76e-7	Neutrophil percentage of white cells;
TGCT	cis	rs1552244	0.554	rs17050704	chr3:10045734	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.33	-4.95	-0.41	2.39e-6	Alzheimer's disease;
TGCT	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg00814883	chr7:100076585	TSC22D4	-0.85	-8.62	-0.61	2.62e-14	Platelet count;
TGCT	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.66	-6.6	-0.51	1.09e-9	Prostate cancer;
TGCT	cis	rs7659604	0.643	rs6838881	chr4:122663616	A/T	cg19748678	chr4:122722346	EXOSC9	0.56	4.86	0.4	3.43e-6	Type 2 diabetes;
TGCT	cis	rs992157	1.000	rs10932766	chr2:219122090	G/A	cg00012203	chr2:219082015	ARPC2	0.77	8.2	0.59	2.56e-13	Colorectal cancer;
TGCT	cis	rs2594989	0.733	rs6779007	chr3:11583254	C/T	cg00170343	chr3:11313890	ATG7	-0.66	-5.1	-0.42	1.23e-6	Circulating chemerin levels;
TGCT	cis	rs1008375	0.932	rs10009933	chr4:17670107	A/C	cg18681998	chr4:17616180	MED28	0.87	9.09	0.63	1.95e-15	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10789285	0.681	rs2249229	chr1:69701433	T/C	ch.1.69469992R	chr1:69697404	NA	0.3	4.46	0.37	1.82e-5	Psoriasis;
TGCT	cis	rs12134133	1.000	rs2661357	chr1:207483938	A/T	cg02152968	chr1:207494213	CD55	0.57	4.52	0.38	1.43e-5	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs7208859	0.673	rs999797	chr17:29159329	G/A	cg18442181	chr17:29233375	C17orf42	-0.78	-4.65	-0.39	8.38e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg21862992	chr11:68658383	NA	0.46	6.54	0.51	1.45e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs28595532	0.764	rs115011450	chr4:119778171	C/T	cg11846333	chr4:119757529	SEC24D	0.92	4.64	0.38	8.74e-6	Cannabis dependence symptom count;
TGCT	cis	rs6912958	0.535	rs448580	chr6:88040399	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.45	5.95	0.47	2.59e-8	Monocyte percentage of white cells;
TGCT	cis	rs11122272	0.525	rs2739517	chr1:231537914	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-6.28	-0.49	5.32e-9	Hemoglobin concentration;
TGCT	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.97	-12.73	-0.75	2.98e-24	Prudent dietary pattern;
TGCT	cis	rs986417	1.000	rs1956549	chr14:60928201	G/A	cg27398547	chr14:60952738	C14orf39	1.39	10.61	0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs9611565	0.694	rs202641	chr22:41833116	C/T	cg06634786	chr22:41940651	POLR3H	0.87	8.08	0.59	4.79e-13	Vitiligo;
TGCT	cis	rs611744	0.901	rs655320	chr8:109197482	T/A	cg21045802	chr8:109455806	TTC35	0.5	4.5	0.37	1.53e-5	Dupuytren's disease;
TGCT	cis	rs7582180	0.629	rs11694642	chr2:100957813	A/G	cg14675211	chr2:100938903	LONRF2	0.5	4.78	0.39	4.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7582180	0.629	rs11684516	chr2:100949883	C/A	cg08017756	chr2:100939284	LONRF2	-0.3	-4.87	-0.4	3.27e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9921338	0.961	rs9936093	chr16:11437316	C/G	cg00044050	chr16:11439710	C16orf75	-0.87	-6.68	-0.51	7.32e-10	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs10934753	0.632	rs1447661	chr3:125924981	A/G	cg01346077	chr3:125931526	NA	0.37	6.11	0.48	1.21e-8	Plasma homocysteine levels (post-methionine load test);
TGCT	cis	rs1865760	0.963	rs3846838	chr6:25911775	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.65	6.24	0.49	6.27e-9	Height;
TGCT	cis	rs9368481	0.594	rs2636425	chr6:26799460	A/G	cg26531700	chr6:26746687	NA	0.7	6.48	0.5	2e-9	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs78456975	0.941	rs28913033	chr2:1523194	T/C	cg01028140	chr2:1542097	TPO	-0.35	-4.67	-0.39	7.82e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs11731606	0.508	rs6828270	chr4:95309212	G/A	cg00507259	chr4:95128692	SMARCAD1	0.6	4.45	0.37	1.88e-5	Mean platelet volume;
TGCT	cis	rs9807989	0.524	rs2110662	chr2:103020139	A/T	cg03938978	chr2:103052716	IL18RAP	0.27	5.41	0.44	3.17e-7	Asthma;
TGCT	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.37	4.74	0.39	5.7e-6	Lymphocyte counts;
TGCT	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg24675658	chr1:53192096	ZYG11B	-0.81	-9.94	-0.67	1.76e-17	Monocyte count;
TGCT	cis	rs9788682	1.000	rs12438181	chr15:78812098	G/A	cg24631222	chr15:78858424	CHRNA5	0.91	7.98	0.58	8.29e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs2070488	0.745	rs7649153	chr3:38467753	T/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.66	5.14	0.42	1.02e-6	Electrocardiographic conduction measures;
TGCT	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg18538332	chr22:24372958	LOC391322	-1.01	-12.94	-0.76	9.13e-25	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg05368731	chr17:41323189	NBR1	1.2	14.2	0.79	8.98e-28	Menopause (age at onset);
TGCT	cis	rs35306767	0.903	rs12769873	chr10:936526	G/T	cg20503657	chr10:835505	NA	0.74	10.3	0.68	2.41e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs56104184	0.723	rs73063524	chr19:49409004	T/C	cg21252483	chr19:49399788	TULP2	-0.42	-5.89	-0.47	3.47e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs3862435	0.610	rs2589942	chr15:90935181	T/C	cg00487526	chr15:90818384	NA	-0.39	-4.65	-0.39	8.28e-6	Response to exercise (triglyceride level interaction);
TGCT	cis	rs4455778	0.580	rs7455537	chr7:49076576	G/A	cg26309511	chr7:48887640	NA	0.5	6.47	0.5	2.07e-9	Lung cancer in never smokers;
TGCT	cis	rs9302065	0.866	rs75006318	chr13:95968259	T/G	cg24476569	chr13:95954382	ABCC4	-0.44	-6.57	-0.51	1.26e-9	Blood metabolite levels;
TGCT	cis	rs9916302	0.851	rs4794810	chr17:37603774	T/C	cg15445000	chr17:37608096	MED1	0.32	4.69	0.39	7.11e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs1933488	0.804	rs9397586	chr6:153414287	C/A	cg24028809	chr6:153414101	RGS17	0.2	4.55	0.38	1.25e-5	Prostate cancer;
TGCT	cis	rs6901250	1.000	rs993394	chr6:117117143	G/A	cg12892004	chr6:117198278	RFX6	0.46	5.13	0.42	1.07e-6	C-reactive protein levels;
TGCT	cis	rs67072384	1.000	rs7120605	chr11:72444615	A/G	cg03713592	chr11:72463424	ARAP1	-0.9	-4.63	-0.38	9.26e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs7552404	0.855	rs385897	chr1:76106962	T/C	cg22875332	chr1:76189707	ACADM	-0.79	-9.72	-0.66	6.2e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg03517284	chr6:25882590	NA	-1.13	-14.86	-0.8	2.55e-29	Urate levels;
TGCT	cis	rs367615	0.840	rs113540823	chr5:108879084	C/T	cg17395555	chr5:108820864	NA	0.31	5.01	0.41	1.85e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs6897795	0.680	rs9329133	chr5:177609540	C/T	cg13600420	chr5:177614205	GMCL1L	0.5	4.66	0.39	7.92e-6	Plateletcrit;
TGCT	cis	rs3096299	0.967	rs28689480	chr16:89460093	T/C	cg06640241	chr16:89574553	SPG7	0.62	5.89	0.47	3.38e-8	Multiple myeloma (IgH translocation);
TGCT	cis	rs9467773	1.000	rs1535277	chr6:26567802	G/T	cg15659132	chr6:26577336	NA	0.88	12.27	0.74	3.83e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.753	rs35194639	chr4:99053819	G/C	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10746514	1.000	rs10746514	chr1:232246027	G/A	cg09506761	chr1:232265262	NA	0.5	5.11	0.42	1.17e-6	Response to statin therapy;
TGCT	trans	rs1814175	0.935	rs28586931	chr11:49693872	G/A	cg03929089	chr4:120376271	NA	-0.63	-7.0	-0.53	1.41e-10	Height;
TGCT	cis	rs6569992	0.636	rs62429819	chr6:135490468	A/T	cg22676075	chr6:135203613	NA	0.74	5.03	0.41	1.69e-6	Red blood cell traits;
TGCT	cis	rs17401966	0.838	rs2182326	chr1:10385664	G/A	cg19773385	chr1:10388646	KIF1B	-0.23	-5.45	-0.44	2.63e-7	Hepatocellular carcinoma;
TGCT	cis	rs6540559	0.546	rs735694	chr1:210034029	T/C	cg04352962	chr1:209979756	IRF6	0.69	4.73	0.39	6.04e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs7777484	0.517	rs2644306	chr7:2831602	A/G	cg25467336	chr7:2757616	NA	-0.26	-4.78	-0.39	4.92e-6	Height;
TGCT	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg14893161	chr1:205819251	PM20D1	0.53	7.38	0.55	1.98e-11	Monocyte percentage of white cells;
TGCT	cis	rs3015497	0.554	rs8011039	chr14:51091267	C/T	cg04730355	chr14:51134070	SAV1	-0.67	-6.35	-0.5	3.64e-9	Mean platelet volume;
TGCT	cis	rs11112613	0.713	rs11112591	chr12:105951620	C/T	cg03607813	chr12:105948248	NA	0.49	5.88	0.47	3.53e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	cis	rs6582630	0.519	rs4436613	chr12:38293653	T/C	cg13010199	chr12:38710504	ALG10B	0.57	4.49	0.37	1.62e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg00343986	chr7:65444356	GUSB	-0.24	-5.29	-0.43	5.43e-7	Aortic root size;
TGCT	cis	rs3784262	0.669	rs17820990	chr15:58349568	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.42	-6.24	-0.49	6.32e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs854765	0.624	rs1889018	chr17:17734740	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.69	-6.67	-0.51	7.5e-10	Total body bone mineral density;
TGCT	cis	rs59197085	0.591	rs73238120	chr7:128432108	C/T	cg00260937	chr7:128520193	KCP	0.44	4.73	0.39	6.07e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
TGCT	cis	rs654950	0.934	rs641974	chr1:42002137	G/A	cg06885757	chr1:42089581	HIVEP3	-0.26	-4.6	-0.38	1.01e-5	Airway imaging phenotypes;
TGCT	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.11	13.91	0.78	4.47e-27	Height;
TGCT	cis	rs9818758	0.607	rs113186424	chr3:49272726	T/C	cg00383909	chr3:49044727	WDR6	1.28	6.57	0.51	1.23e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs3741151	1.000	rs3741149	chr11:73021084	A/G	cg17517138	chr11:73019481	ARHGEF17	-1.04	-5.36	-0.43	3.97e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
TGCT	cis	rs17331151	0.573	rs79664140	chr3:52866936	A/G	cg27565382	chr3:53032988	SFMBT1	0.47	5.96	0.47	2.42e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs60843830	0.661	rs7588043	chr2:104979	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.62	5.52	0.44	1.92e-7	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs1552244	0.748	rs9862221	chr3:10059658	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	5.53	0.45	1.78e-7	Alzheimer's disease;
TGCT	cis	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.21	4.49	0.37	1.61e-5	Eosinophil percentage of white cells;
TGCT	cis	rs17376456	0.825	rs13171131	chr5:93223028	C/T	cg25358565	chr5:93447407	FAM172A	1.02	8.11	0.59	4.17e-13	Diabetic retinopathy;
TGCT	cis	rs2072499	0.750	rs57056972	chr1:156159064	C/A	cg24450063	chr1:156163899	SLC25A44	1.11	10.16	0.67	5.03e-18	Testicular germ cell tumor;
TGCT	trans	rs7726839	0.526	rs55647623	chr5:567747	T/C	cg25482853	chr8:67687455	SGK3	1.1	8.74	0.62	1.34e-14	Obesity-related traits;
TGCT	cis	rs3820928	0.845	rs4234065	chr2:227882006	C/T	cg11843606	chr2:227700838	RHBDD1	-0.54	-4.94	-0.41	2.51e-6	Pulmonary function;
TGCT	cis	rs12291225	0.546	rs11023199	chr11:14394258	A/G	cg19336497	chr11:14380999	RRAS2	-0.46	-7.39	-0.55	1.87e-11	Sense of smell;
TGCT	cis	rs9677476	0.516	rs2303350	chr2:232030555	G/A	cg07929768	chr2:232055508	NA	0.33	5.24	0.43	6.78e-7	Food antigen IgG levels;
TGCT	cis	rs61990749	0.597	rs3783980	chr14:78219807	T/C	cg23188588	chr14:78226832	SNW1;C14orf178	0.67	4.73	0.39	6.09e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs1532993	0.518	rs10003706	chr4:98573238	G/C	cg05340658	chr4:99064831	C4orf37	-0.38	-4.53	-0.38	1.36e-5	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs9325144	0.600	rs11183505	chr12:38759110	G/T	cg26384229	chr12:38710491	ALG10B	-0.62	-5.77	-0.46	5.9e-8	Morning vs. evening chronotype;
TGCT	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg25767906	chr1:53392781	SCP2	-0.53	-6.21	-0.49	7.34e-9	Monocyte count;
TGCT	cis	rs11190604	1.000	rs2295776	chr10:102295629	G/T	cg16342193	chr10:102329863	NA	-0.41	-5.37	-0.43	3.78e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs6500602	0.627	rs934929	chr16:4587789	A/G	cg08645402	chr16:4508243	NA	-0.21	-5.51	-0.44	2e-7	Schizophrenia;
TGCT	cis	rs7223966	1.000	rs56383601	chr17:61929968	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	4.62	0.38	9.63e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs3772130	1.000	rs11719458	chr3:121382005	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.55	5.06	0.41	1.45e-6	Cognitive performance;
TGCT	cis	rs2242116	0.896	rs724448	chr3:46935734	A/C	cg02527881	chr3:46936655	PTH1R	-0.3	-5.77	-0.46	5.91e-8	Birth weight;
TGCT	cis	rs709400	0.663	rs62007687	chr14:103903763	G/T	cg26031613	chr14:104095156	KLC1	0.86	9.43	0.65	2.96e-16	Body mass index;
TGCT	cis	rs7043114	0.525	rs7869742	chr9:95256174	A/G	cg14631576	chr9:95140430	CENPP	-0.28	-4.61	-0.38	9.88e-6	Height;
TGCT	cis	rs9814567	0.896	rs4245907	chr3:134347876	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-7.29	-0.55	3.14e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs13191362	1.000	rs13204439	chr6:163015358	A/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.57	-4.94	-0.41	2.45e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7659604	0.521	rs4833234	chr4:122694799	T/C	cg06713675	chr4:122721982	EXOSC9	0.35	4.48	0.37	1.7e-5	Type 2 diabetes;
TGCT	cis	rs7552404	0.731	rs10873788	chr1:76367857	A/C	cg10523679	chr1:76189770	ACADM	0.79	6.8	0.52	4.01e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg12419862	chr22:24373484	LOC391322	-0.79	-8.23	-0.59	2.19e-13	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs17152411	0.709	rs1896530	chr10:126581925	A/T	cg07906193	chr10:126599966	NA	-0.32	-4.52	-0.38	1.42e-5	Height;
TGCT	cis	rs7617773	0.539	rs11706939	chr3:48383992	G/T	cg11946769	chr3:48343235	NME6	0.57	4.83	0.4	4.01e-6	Coronary artery disease;
TGCT	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg03188948	chr7:1209495	NA	0.5	5.27	0.43	5.87e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1903068	0.752	rs28517654	chr4:55993468	T/C	cg09978860	chr4:56023921	NA	0.55	6.09	0.48	1.31e-8	Endometriosis;
TGCT	cis	rs13256369	0.851	rs11249890	chr8:8565245	G/T	cg06671706	chr8:8559999	CLDN23	0.34	4.53	0.38	1.38e-5	Obesity-related traits;
TGCT	cis	rs807669	0.934	rs1780643	chr22:19191725	T/C	cg02655711	chr22:19163373	SLC25A1	0.4	9.27	0.64	7.35e-16	Metabolite levels;
TGCT	cis	rs78487399	0.908	rs74854268	chr2:43844079	C/G	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.65	4.58	0.38	1.12e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs1801251	0.963	rs7562712	chr2:233606580	A/G	cg08000102	chr2:233561755	GIGYF2	0.64	6.56	0.51	1.34e-9	Coronary artery disease;
TGCT	cis	rs611744	0.967	rs685690	chr8:109192145	A/G	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs6688613	1.000	rs7554962	chr1:166956297	C/T	cg07049167	chr1:166818506	POGK	0.21	4.52	0.38	1.43e-5	Refractive astigmatism;
TGCT	cis	rs12136530	0.636	rs4244001	chr1:19734368	C/T	cg24875000	chr1:19041556	PAX7	-0.26	-4.62	-0.38	9.56e-6	Lead levels in blood;
TGCT	cis	rs2303745	0.640	rs10403581	chr19:17384192	A/C	cg02221750	chr19:17393354	ANKLE1	-0.49	-6.34	-0.5	3.81e-9	Systemic lupus erythematosus;
TGCT	cis	rs2153535	0.580	rs1414348	chr6:8471940	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg06636001	chr8:8085503	FLJ10661	0.73	7.08	0.54	9.63e-11	Mood instability;
TGCT	cis	rs2933343	0.951	rs789217	chr3:128593201	C/T	cg11901034	chr3:128598214	ACAD9	-0.64	-4.95	-0.41	2.39e-6	IgG glycosylation;
TGCT	cis	rs9467773	0.804	rs2073526	chr6:26374658	C/T	cg14124522	chr6:26610872	NA	0.17	4.48	0.37	1.7e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg22920501	chr2:26401640	FAM59B	-0.72	-6.38	-0.5	3.19e-9	Gut microbiome composition (summer);
TGCT	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg15242686	chr22:24348715	GSTTP1	-0.49	-7.1	-0.54	8.64e-11	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs3771570	0.901	rs73008106	chr2:242422446	C/T	cg21155796	chr2:242212141	HDLBP	0.87	6.47	0.5	2e-9	Prostate cancer;
TGCT	trans	rs57221529	0.766	rs72703064	chr5:587825	T/C	cg25482853	chr8:67687455	SGK3	1.2	10.12	0.67	6.42e-18	Lung disease severity in cystic fibrosis;
TGCT	cis	rs8056742	0.730	rs34771435	chr16:85092201	T/A	cg00229868	chr16:85520891	NA	0.36	4.83	0.4	3.96e-6	Amyotrophic lateral sclerosis;
TGCT	cis	rs6695640	0.854	rs2762889	chr1:17733147	A/C	cg25979543	chr1:17888104	ARHGEF10L	-0.25	-4.48	-0.37	1.7e-5	Mean platelet volume;
TGCT	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg19010396	chr19:19431384	KIAA0892;SF4	-0.54	-4.54	-0.38	1.3e-5	Tonsillectomy;
TGCT	cis	rs1059312	0.808	rs12816551	chr12:129295616	T/C	cg09035930	chr12:129282057	SLC15A4	0.55	10.73	0.69	2.06e-19	Systemic lupus erythematosus;
TGCT	cis	rs9814567	0.712	rs9838621	chr3:134332319	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-6.41	-0.5	2.8e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs9916302	0.904	rs57399933	chr17:37551189	A/G	cg15445000	chr17:37608096	MED1	-0.34	-4.79	-0.39	4.71e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs67311347	1.000	rs28491638	chr3:40496263	T/C	cg13683864	chr3:40499215	RPL14	-1.2	-13.25	-0.77	1.68e-25	Renal cell carcinoma;
TGCT	cis	rs346785	0.640	rs9905488	chr17:74283535	A/G	cg09812376	chr17:74270190	QRICH2	0.36	5.37	0.43	3.68e-7	White matter hyperintensities in ischemic stroke;
TGCT	cis	rs1800469	1.000	rs2241715	chr19:41856886	A/C	cg09537434	chr19:41945824	ATP5SL	-0.5	-4.66	-0.39	8.16e-6	Colorectal cancer;
TGCT	cis	rs2456568	0.867	rs2462744	chr11:93682913	G/A	cg17595323	chr11:93583763	C11orf90	-0.46	-6.01	-0.47	1.92e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs6669384	0.774	rs61821315	chr1:208027696	C/T	cg22525895	chr1:207977042	MIR29B2	-0.4	-5.69	-0.45	8.83e-8	Immune response to measles vaccine (measles-specific neutralising antibody titre);
TGCT	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg06481639	chr22:41940642	POLR3H	-0.73	-6.47	-0.5	2.07e-9	Vitiligo;
TGCT	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	5.93	0.47	2.76e-8	Alzheimer's disease;
TGCT	cis	rs1153858	1.000	rs4774579	chr15:45651803	G/A	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.62e-8	Homoarginine levels;
TGCT	cis	rs523522	0.962	rs7471	chr12:120941215	T/C	cg27279351	chr12:120934652	DYNLL1	0.76	6.59	0.51	1.15e-9	High light scatter reticulocyte count;
TGCT	cis	rs8013055	0.796	rs28733392	chr14:105993258	G/A	cg19700328	chr14:106028568	NA	-0.48	-4.93	-0.4	2.62e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	trans	rs941408	0.890	rs1640269	chr19:2793194	A/C	cg19676328	chr12:49525230	TUBA1B	-0.73	-6.74	-0.52	5.45e-10	Total cholesterol levels;
TGCT	cis	rs644799	1.000	rs623191	chr11:95548359	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	8.74	0.62	1.39e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7208859	0.623	rs9915566	chr17:29132158	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs6964587	1.000	rs2961020	chr7:91573308	G/A	cg17063962	chr7:91808500	NA	-0.91	-9.88	-0.66	2.45e-17	Breast cancer;
TGCT	cis	rs4253772	0.550	rs55926596	chr22:46682955	C/T	cg24881330	chr22:46731750	TRMU	1.01	4.95	0.41	2.35e-6	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs9527	0.590	rs10883820	chr10:104764661	A/C	cg04362960	chr10:104952993	NT5C2	-0.65	-5.54	-0.45	1.73e-7	Arsenic metabolism;
TGCT	cis	rs9929218	0.679	rs9924886	chr16:68743939	A/C	cg01251360	chr16:68772225	CDH1	0.29	4.64	0.38	8.58e-6	Colorectal cancer;
TGCT	trans	rs7726839	0.540	rs72703095	chr5:601789	T/C	cg11887960	chr12:57824829	NA	1.2	9.56	0.65	1.47e-16	Obesity-related traits;
TGCT	cis	rs2463822	1.000	rs72921498	chr11:62113090	C/T	cg23876832	chr11:62092739	NA	-0.64	-4.72	-0.39	6.28e-6	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs372883	0.638	rs117213	chr21:30720536	G/A	cg24692254	chr21:30365293	RNF160	-0.54	-4.84	-0.4	3.83e-6	Pancreatic cancer;
TGCT	cis	rs2153535	0.580	rs6921036	chr6:8455400	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	trans	rs877282	1.000	rs10904552	chr10:774326	A/G	cg22713356	chr15:30763199	NA	1.13	10.07	0.67	8.48e-18	Uric acid levels;
TGCT	cis	rs3749237	1.000	rs11717256	chr3:49868520	C/T	cg10152585	chr3:50297680	NA	0.51	4.84	0.4	3.79e-6	Resting heart rate;
TGCT	cis	rs7043114	0.525	rs1053446	chr9:95146761	T/A	cg14631576	chr9:95140430	CENPP	-0.27	-4.56	-0.38	1.22e-5	Height;
TGCT	cis	rs4862307	0.688	rs6552743	chr4:184990516	C/G	cg06737308	chr4:185021514	ENPP6	0.37	5.41	0.44	3.19e-7	Serum dimethylarginine levels (asymmetric/symetric ratio);
TGCT	cis	rs6460942	0.915	rs80345607	chr7:12442249	T/C	cg06484146	chr7:12443880	VWDE	-0.57	-5.52	-0.44	1.92e-7	Coronary artery disease;
TGCT	trans	rs2622849	1.000	rs1676488	chr1:103390327	C/G	cg25934198	chr9:139920781	C9orf139;ABCA2	0.49	6.91	0.53	2.27e-10	Bone mineral density change response to combined chemotherapy in acute lymphoblastic leukemia;
TGCT	cis	rs7829975	0.510	rs332037	chr8:8722675	C/T	cg17143192	chr8:8559678	CLDN23	0.46	4.7	0.39	6.77e-6	Mood instability;
TGCT	cis	rs10751667	0.666	rs10794354	chr11:954615	A/T	cg06064525	chr11:970664	AP2A2	-0.35	-8.22	-0.59	2.29e-13	Alzheimer's disease (late onset);
TGCT	cis	rs66573146	0.901	rs55882710	chr4:7030704	G/A	cg05069807	chr4:6945702	TBC1D14	0.34	4.84	0.4	3.83e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs9633740	1.000	rs10748526	chr10:82273079	T/C	cg01528321	chr10:82214614	TSPAN14	1.0	7.95	0.58	1.01e-12	Post bronchodilator FEV1;
TGCT	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs986417	0.748	rs10142401	chr14:61039403	A/G	cg18240143	chr14:60952599	C14orf39	0.82	4.51	0.38	1.46e-5	Gut microbiota (bacterial taxa);
TGCT	cis	rs9393692	0.905	rs9366649	chr6:26329103	A/T	cg00631329	chr6:26305371	NA	0.41	6.12	0.48	1.12e-8	Educational attainment;
TGCT	cis	rs6540559	0.673	rs58637469	chr1:209971480	T/A	cg04352962	chr1:209979756	IRF6	0.65	4.6	0.38	1.05e-5	Cleft lip with or without cleft palate;
TGCT	cis	rs3848445	1.000	rs7214411	chr17:14288990	C/T	cg01636575	chr17:13447853	HS3ST3A1	-0.97	-5.56	-0.45	1.59e-7	Protein quantitative trait loci;
TGCT	cis	rs7659604	0.643	rs6838881	chr4:122663616	A/T	cg06713675	chr4:122721982	EXOSC9	-0.45	-5.24	-0.43	6.75e-7	Type 2 diabetes;
TGCT	cis	rs4742903	0.967	rs10820605	chr9:106881402	C/T	cg21169611	chr9:106856078	SMC2	0.52	4.89	0.4	3.08e-6	High-grade serous ovarian cancer;Breast cancer;
TGCT	cis	rs7089973	0.872	rs34683721	chr10:116619849	G/A	cg03647239	chr10:116582469	FAM160B1	0.52	4.64	0.38	8.75e-6	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg05368731	chr17:41323189	NBR1	1.1	11.12	0.71	2.38e-20	Menopause (age at onset);
TGCT	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.43	-4.56	-0.38	1.22e-5	Blood metabolite levels;
TGCT	cis	rs9303401	1.000	rs9904677	chr17:56873025	A/G	cg12560992	chr17:57184187	TRIM37	0.53	5.44	0.44	2.71e-7	Cognitive test performance;
TGCT	cis	rs2404602	0.536	rs7165025	chr15:76766434	G/A	cg22467129	chr15:76604101	ETFA	-0.48	-5.9	-0.47	3.27e-8	Blood metabolite levels;
TGCT	cis	rs2455799	0.559	rs7614145	chr3:15917898	A/G	cg12172478	chr3:16357591	RFTN1	-0.36	-5.3	-0.43	5.07e-7	Mean platelet volume;
TGCT	cis	rs9611519	0.929	rs12484971	chr22:41439304	A/T	cg03806693	chr22:41940476	POLR3H	-0.68	-6.1	-0.48	1.25e-8	Neuroticism;
TGCT	cis	rs950776	0.518	rs1504545	chr15:78818471	C/G	cg06917634	chr15:78832804	PSMA4	-0.94	-9.29	-0.64	6.76e-16	Sudden cardiac arrest;
TGCT	cis	rs11098499	0.863	rs1480939	chr4:120456927	T/C	cg09307838	chr4:120376055	NA	0.69	6.53	0.51	1.49e-9	Corneal astigmatism;
TGCT	cis	rs447921	0.861	rs56154175	chr17:74419086	C/T	cg09812376	chr17:74270190	QRICH2	-0.45	-4.48	-0.37	1.69e-5	Mitochondrial DNA levels;
TGCT	cis	rs2153535	0.580	rs4960412	chr6:8438261	G/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.58	0.45	1.42e-7	Motion sickness;
TGCT	cis	rs4824093	0.610	rs3761496	chr22:50246466	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.11	-6.76	-0.52	4.86e-10	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs17152411	1.000	rs733401	chr10:126594158	A/T	cg07906193	chr10:126599966	NA	0.42	5.28	0.43	5.6e-7	Height;
TGCT	cis	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg22857025	chr5:266934	NA	-0.32	-6.58	-0.51	1.18e-9	Breast cancer;
TGCT	cis	rs1577917	0.917	rs2084293	chr6:86566002	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.29	-0.43	5.34e-7	Response to antipsychotic treatment;
TGCT	cis	rs1997103	1.000	rs4947501	chr7:55407342	C/T	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs71597109	0.639	rs4699262	chr4:102726005	A/G	cg14855874	chr4:102712397	BANK1	-0.42	-4.82	-0.4	4.12e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs9916302	0.851	rs12936646	chr17:37647450	A/T	cg07936489	chr17:37558343	FBXL20	-0.62	-4.91	-0.4	2.85e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs73110464	0.609	rs727266	chr12:53356411	C/T	cg14581129	chr12:53358946	NA	-0.63	-6.78	-0.52	4.39e-10	Cancer (pleiotropy);
TGCT	cis	rs3540	0.597	rs4932346	chr15:91048991	T/C	cg22089800	chr15:90895588	ZNF774	-0.76	-7.77	-0.57	2.55e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs7666738	0.830	rs13125537	chr4:98978428	A/G	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4566357	1.000	rs7567796	chr2:227922109	T/A	cg11843606	chr2:227700838	RHBDD1	-0.57	-5.17	-0.42	8.99e-7	Coronary artery disease;
TGCT	cis	rs4638749	1.000	rs1466212	chr2:108856532	G/A	cg06795125	chr2:108905320	SULT1C2	-0.39	-4.81	-0.4	4.26e-6	Blood pressure;
TGCT	cis	rs9296661	0.522	rs4510663	chr6:51661714	G/A	cg20180370	chr6:50691003	TFAP2D	-0.48	-4.67	-0.39	7.68e-6	Weight loss (gastric bypass surgery);
TGCT	cis	rs7666738	0.830	rs4699603	chr4:99056172	T/C	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.44e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs929354	0.709	rs1182363	chr7:157019151	A/G	cg05182265	chr7:156933206	UBE3C	0.4	9.08	0.63	2.11e-15	Body mass index;
TGCT	cis	rs3020736	0.500	rs6002614	chr22:42501802	G/A	cg05082376	chr22:42548792	NA	0.23	5.43	0.44	2.83e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg02725872	chr8:58115012	NA	-0.39	-5.15	-0.42	1.01e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg18876405	chr7:65276391	NA	0.37	5.89	0.47	3.33e-8	Calcium levels;
TGCT	cis	rs7819412	0.806	rs10113808	chr8:10926892	C/A	cg27411982	chr8:10470053	RP1L1	-0.21	-4.61	-0.38	9.95e-6	Triglycerides;
TGCT	cis	rs2970818	0.831	rs2909381	chr12:4606527	T/C	cg02722637	chr12:4922070	KCNA6	0.3	4.49	0.37	1.59e-5	Phosphorus levels;
TGCT	cis	rs4478858	0.684	rs16865957	chr1:31753353	G/A	cg00250761	chr1:31883323	NA	-0.26	-4.55	-0.38	1.28e-5	Alcohol dependence;
TGCT	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.27	4.78	0.39	4.88e-6	Schizophrenia;
TGCT	cis	rs4803468	1.000	rs4674	chr19:41930396	A/G	cg09537434	chr19:41945824	ATP5SL	-0.91	-10.63	-0.69	3.74e-19	Height;
TGCT	cis	rs9467773	1.000	rs9461271	chr6:26554968	G/A	cg09904177	chr6:26538194	HMGN4	0.66	6.6	0.51	1.05e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs6500602	0.727	rs11644481	chr16:4581002	T/G	cg08645402	chr16:4508243	NA	0.19	5.32	0.43	4.65e-7	Schizophrenia;
TGCT	cis	rs7945705	0.818	rs2653613	chr11:8879105	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.42	-4.64	-0.38	8.82e-6	Hemoglobin concentration;
TGCT	cis	rs9906944	0.933	rs12945020	chr17:47082775	G/A	cg07075026	chr17:47091521	IGF2BP1	-0.43	-4.8	-0.4	4.47e-6	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs4631830	0.863	rs4554834	chr10:51530146	A/C	cg10326726	chr10:51549505	MSMB	-0.26	-5.3	-0.43	5.17e-7	Prostate-specific antigen levels;
TGCT	cis	rs7639513	0.767	rs7617041	chr3:12709167	A/G	cg23032965	chr3:12705835	RAF1	0.77	8.55	0.61	3.81e-14	Itch intensity from mosquito bite;
TGCT	cis	rs427394	0.659	rs274725	chr5:6717408	C/G	cg10857441	chr5:6722123	POLS	-0.28	-6.08	-0.48	1.38e-8	Menopause (age at onset);
TGCT	cis	rs6570726	0.764	rs1912023	chr6:145824278	C/A	cg05347473	chr6:146136440	FBXO30	0.53	4.95	0.41	2.4e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg17054783	chr10:134559939	INPP5A	0.23	4.64	0.38	8.89e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs2303745	0.640	rs10403581	chr19:17384192	A/C	cg04248312	chr19:17393744	ANKLE1	-0.34	-5.71	-0.46	7.88e-8	Systemic lupus erythematosus;
TGCT	cis	rs9788682	1.000	rs12441426	chr15:78812329	T/C	cg24631222	chr15:78858424	CHRNA5	0.89	7.75	0.57	2.91e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs5771242	0.518	rs67881086	chr22:50673439	G/A	cg16473166	chr22:50639996	SELO	0.58	4.77	0.39	5.03e-6	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
TGCT	cis	rs6121246	0.529	rs6060359	chr20:30209740	A/G	cg18721089	chr20:30220636	NA	-0.64	-6.86	-0.52	2.84e-10	Mean corpuscular hemoglobin;
TGCT	cis	rs7940866	0.834	rs10894302	chr11:130861994	C/T	cg12179176	chr11:130786555	SNX19	0.62	5.77	0.46	5.87e-8	Schizophrenia;
TGCT	cis	rs4601821	0.823	rs4938013	chr11:113264470	A/C	cg14159747	chr11:113255604	NA	0.38	4.49	0.37	1.61e-5	Alcoholic chronic pancreatitis;
TGCT	cis	rs12220238	0.722	rs6480744	chr10:76398989	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.59	4.54	0.38	1.29e-5	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs9430161	0.579	rs79323519	chr1:11036050	T/C	cg27631724	chr1:11040367	C1orf127	0.55	6.05	0.48	1.55e-8	Ewing sarcoma;
TGCT	cis	rs11690462	0.926	rs12467721	chr2:26558489	T/G	cg04726446	chr2:26624865	C2orf39	0.44	4.68	0.39	7.29e-6	Coronary artery disease;
TGCT	cis	rs918629	0.679	rs56002885	chr5:95269602	A/G	cg16656078	chr5:95278638	ELL2	-0.28	-4.55	-0.38	1.25e-5	IgG glycosylation;
TGCT	cis	rs17345786	0.861	rs17402964	chr3:101067945	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.85	8.98	0.63	3.67e-15	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7100689	0.784	rs2153455	chr10:82139732	T/C	cg01528321	chr10:82214614	TSPAN14	0.89	8.97	0.63	3.94e-15	Post bronchodilator FEV1;
TGCT	cis	rs2180341	0.920	rs6906717	chr6:127596782	C/A	cg24812749	chr6:127587940	RNF146	0.99	7.72	0.57	3.33e-12	Breast cancer;
TGCT	cis	rs66573146	1.000	rs55913461	chr4:7017509	C/T	cg01220768	chr4:7056774	TADA2B	0.41	5.11	0.42	1.2e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs10986311	0.775	rs6478658	chr9:127127810	A/G	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.19	-4.78	-0.39	4.84e-6	Vitiligo;
TGCT	cis	rs6500602	0.673	rs4786513	chr16:4576423	T/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.28	5.16	0.42	9.66e-7	Schizophrenia;
TGCT	cis	rs6424115	0.830	rs2501431	chr1:24201643	G/A	cg15997130	chr1:24165203	NA	0.85	9.25	0.64	8.02e-16	Immature fraction of reticulocytes;
TGCT	cis	rs7226408	0.857	rs72887066	chr18:34496371	C/T	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg18402987	chr7:1209562	NA	0.7	5.67	0.45	9.66e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg06221963	chr1:154839813	KCNN3	-0.69	-11.52	-0.72	2.49e-21	Prostate cancer;
TGCT	cis	rs7399018	0.739	rs10747608	chr12:51616582	A/G	cg25754956	chr12:51612065	POU6F1	0.74	6.95	0.53	1.84e-10	Cisplatin-induced ototoxicity;
TGCT	cis	rs28595532	0.920	rs17325017	chr4:119774607	A/G	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs7760949	0.852	rs9349847	chr6:13927711	T/C	cg27413430	chr6:13925136	RNF182	0.73	6.83	0.52	3.37e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs7826238	0.601	rs2976907	chr8:8345168	C/T	cg15556689	chr8:8085844	FLJ10661	0.6	5.55	0.45	1.62e-7	Systolic blood pressure;
TGCT	cis	rs12368653	0.840	rs10877020	chr12:58188014	G/A	cg12615879	chr12:58013172	SLC26A10	0.5	5.99	0.47	2.16e-8	Multiple sclerosis;
TGCT	cis	rs4906332	1.000	rs28711288	chr14:103906126	T/C	cg26031613	chr14:104095156	KLC1	-0.55	-4.9	-0.4	2.88e-6	Coronary artery disease;
TGCT	cis	rs7940866	0.834	rs10791105	chr11:130839161	A/G	cg05962950	chr11:130786565	SNX19	0.73	7.14	0.54	6.88e-11	Schizophrenia;
TGCT	cis	rs36051895	0.659	rs10974938	chr9:5056037	A/G	cg02405213	chr9:5042618	JAK2	-0.75	-9.15	-0.63	1.42e-15	Pediatric autoimmune diseases;
TGCT	cis	rs3096299	0.967	rs2965935	chr16:89481274	C/T	cg06640241	chr16:89574553	SPG7	-0.62	-6.05	-0.48	1.56e-8	Multiple myeloma (IgH translocation);
TGCT	cis	rs909674	0.734	rs5757675	chr22:39838892	G/T	cg11247378	chr22:39784982	NA	-0.73	-8.98	-0.63	3.69e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs3845702	1.000	rs3845697	chr2:180798553	C/T	cg01881094	chr2:180872142	CWC22	0.66	5.81	0.46	4.86e-8	Schizophrenia;
TGCT	cis	rs858239	0.508	rs2390754	chr7:23190494	A/G	cg05602783	chr7:23145260	KLHL7	-0.69	-5.57	-0.45	1.54e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs8067545	0.750	rs4925077	chr17:19982276	C/T	cg13482628	chr17:19912719	NA	0.51	4.59	0.38	1.09e-5	Schizophrenia;
TGCT	cis	rs611744	0.647	rs1457211	chr8:109261318	C/T	cg21045802	chr8:109455806	TTC35	-0.72	-7.28	-0.55	3.42e-11	Dupuytren's disease;
TGCT	cis	rs4319547	0.774	rs7295105	chr12:123124225	G/A	cg23029597	chr12:123009494	RSRC2	-0.27	-4.73	-0.39	6.11e-6	Body mass index;
TGCT	cis	rs9682041	0.696	rs13101192	chr3:170080752	C/G	cg11886554	chr3:170076028	SKIL	0.6	4.74	0.39	5.77e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg10802521	chr3:52805072	NEK4	-0.65	-7.6	-0.56	6.21e-12	Bipolar disorder;
TGCT	cis	rs6121246	0.559	rs6060962	chr20:30397847	A/G	cg13852791	chr20:30311386	BCL2L1	0.8	7.42	0.55	1.61e-11	Mean corpuscular hemoglobin;
TGCT	cis	rs1580019	0.520	rs6945238	chr7:32646096	C/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.94	-8.9	-0.62	5.7e-15	Cognitive ability;
TGCT	cis	rs2288884	1.000	rs12609219	chr19:52580996	T/C	cg15405931	chr19:52693188	PPP2R1A	-0.69	-4.5	-0.37	1.56e-5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg08280861	chr8:58055591	NA	0.4	5.57	0.45	1.49e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs78487399	0.808	rs17031005	chr2:43761299	A/G	cg03762820	chr2:43823654	THADA	-0.54	-4.95	-0.41	2.37e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs7822232	0.908	rs6558295	chr8:145139522	C/G	cg06239191	chr8:145163136	KIAA1875	-0.88	-6.45	-0.5	2.26e-9	Blood metabolite levels;
TGCT	cis	rs2832191	0.716	rs9983051	chr21:30371890	C/T	cg24692254	chr21:30365293	RNF160	0.97	11.35	0.71	6.68e-21	Dental caries;
TGCT	cis	rs35306767	0.904	rs35667562	chr10:950630	G/A	cg20503657	chr10:835505	NA	0.81	12.21	0.74	5.29e-23	Eosinophil percentage of granulocytes;
TGCT	cis	rs7020830	0.861	rs13289001	chr9:37311592	A/G	cg14235030	chr9:37121269	ZCCHC7	0.41	4.49	0.37	1.58e-5	Schizophrenia;
TGCT	cis	rs6964587	1.000	rs13231238	chr7:91653851	T/G	cg22709100	chr7:91322751	NA	0.27	4.48	0.37	1.68e-5	Breast cancer;
TGCT	cis	rs3809566	1.000	rs4775612	chr15:63332157	T/C	cg05507819	chr15:63340323	TPM1	0.48	4.52	0.38	1.4e-5	Platelet count;
TGCT	cis	rs4851254	0.618	rs7596359	chr2:100665274	T/G	cg07810366	chr2:100720526	AFF3	-0.49	-5.09	-0.42	1.28e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2797160	1.000	rs2797160	chr6:126010116	A/G	cg05901451	chr6:126070800	HEY2	0.72	6.11	0.48	1.18e-8	Endometrial cancer;
TGCT	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	5.38	0.44	3.58e-7	Alzheimer's disease;
TGCT	cis	rs2963155	0.518	rs853178	chr5:142634799	C/T	cg17617527	chr5:142782415	NR3C1	0.85	6.28	0.49	5.22e-9	Breast cancer;
TGCT	cis	rs4906332	0.966	rs7159665	chr14:103984616	C/T	cg26031613	chr14:104095156	KLC1	-0.56	-5.04	-0.41	1.64e-6	Coronary artery disease;
TGCT	cis	rs2153535	0.601	rs9379224	chr6:8538413	A/G	cg07606381	chr6:8435919	SLC35B3	0.55	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs2153535	0.580	rs9406167	chr6:8502852	T/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs2227564	0.533	rs3870402	chr10:75473787	A/C	cg04320760	chr10:75533139	FUT11	-0.32	-4.5	-0.37	1.56e-5	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs6500602	0.701	rs1362626	chr16:4549226	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.4	7.21	0.54	4.84e-11	Schizophrenia;
TGCT	cis	rs7264396	0.635	rs6058375	chr20:34531997	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.04	-0.41	1.58e-6	Total cholesterol levels;
TGCT	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-8.64	-0.61	2.39e-14	Platelet count;
TGCT	cis	rs8013055	0.846	rs12717698	chr14:105979015	G/A	cg23356831	chr14:105996513	TMEM121	0.37	5.32	0.43	4.61e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs3784262	1.000	rs1372368	chr15:58297363	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.5	-7.82	-0.57	1.98e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs992157	0.798	rs10193383	chr2:219157692	C/T	cg00012203	chr2:219082015	ARPC2	0.81	8.08	0.59	4.97e-13	Colorectal cancer;
TGCT	cis	rs9611565	0.649	rs5758442	chr22:42133060	T/C	cg06634786	chr22:41940651	POLR3H	0.79	7.29	0.55	3.13e-11	Vitiligo;
TGCT	cis	rs899997	1.000	rs4887078	chr15:79011073	C/T	cg04896959	chr15:78267971	NA	0.35	5.55	0.45	1.65e-7	Coronary artery disease or large artery stroke;
TGCT	cis	rs155076	1.000	rs2783107	chr13:21837532	C/A	cg14456004	chr13:21872349	NA	-1.32	-10.82	-0.7	1.25e-19	White matter hyperintensity burden;
TGCT	cis	rs6088590	0.561	rs11167239	chr20:33140472	G/A	cg08999081	chr20:33150536	PIGU	0.28	5.41	0.44	3.11e-7	Coronary artery disease;
TGCT	cis	rs71597109	0.607	rs35446399	chr4:102729766	G/A	cg14855874	chr4:102712397	BANK1	0.42	4.59	0.38	1.09e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs227163	0.905	rs227162	chr1:7960565	G/T	cg23631229	chr1:7962850	NA	-0.33	-4.55	-0.38	1.28e-5	Rheumatoid arthritis;
TGCT	cis	rs360798	0.512	rs11893131	chr2:63079528	C/A	cg17519650	chr2:63277830	OTX1	0.65	6.0	0.47	2.03e-8	Coronary artery disease;
TGCT	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg22535103	chr8:58192502	C8orf71	-0.42	-5.39	-0.44	3.49e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg21237687	chr17:6899380	ALOX12	0.52	5.6	0.45	1.33e-7	Tonsillectomy;
TGCT	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg12288994	chr5:1860383	NA	0.25	4.99	0.41	2.02e-6	Cardiovascular disease risk factors;
TGCT	cis	rs7703051	0.585	rs918623	chr5:74596682	A/C	cg19683494	chr5:74908142	NA	0.68	6.65	0.51	8.36e-10	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
TGCT	cis	rs651907	0.557	rs11914318	chr3:101453858	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.87	10.21	0.68	3.89e-18	Colorectal cancer;
TGCT	cis	rs7044106	0.791	rs3904196	chr9:123480369	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	6.99	0.53	1.48e-10	Hip circumference adjusted for BMI;
TGCT	cis	rs763121	0.853	rs5750626	chr22:38977890	G/C	cg06022373	chr22:39101656	GTPBP1	0.8	7.88	0.58	1.42e-12	Menopause (age at onset);
TGCT	cis	rs7949030	0.523	rs12223627	chr11:62368557	G/C	cg11742103	chr11:62369870	EML3;MTA2	0.55	6.35	0.5	3.71e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs10197940	0.578	rs2045025	chr2:152317531	T/C	cg06191203	chr2:152266755	RIF1	-0.58	-4.88	-0.4	3.22e-6	Lung cancer;
TGCT	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg18765753	chr7:1198926	ZFAND2A	-0.51	-6.04	-0.48	1.7e-8	Longevity;Endometriosis;
TGCT	cis	rs910316	1.000	rs12589815	chr14:75544101	C/T	cg11812906	chr14:75593930	NEK9	0.74	7.18	0.54	5.58e-11	Height;
TGCT	trans	rs1864729	1.000	rs2853320	chr8:98283523	C/G	cg08679828	chr8:102218111	ZNF706	-1.08	-7.52	-0.56	9.47e-12	Estradiol plasma levels (breast cancer);
TGCT	cis	rs3820068	0.705	rs72645804	chr1:15868387	A/C	cg05660106	chr1:15850417	CASP9	1.15	13.74	0.78	1.14e-26	Systolic blood pressure;
TGCT	cis	rs61990749	0.544	rs3759728	chr14:78230159	A/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.62	4.58	0.38	1.13e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs5769707	0.521	rs5769720	chr22:50062133	G/C	cg05373962	chr22:49881684	NA	-0.32	-5.47	-0.44	2.43e-7	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs9467773	1.000	rs767471	chr6:26557854	C/T	cg15659132	chr6:26577336	NA	0.9	13.19	0.76	2.26e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs3820928	0.775	rs10179756	chr2:227897076	A/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-4.96	-0.41	2.29e-6	Pulmonary function;
TGCT	trans	rs11722228	0.508	rs73212864	chr4:10104191	G/A	cg26043149	chr18:55253948	FECH	1.18	11.39	0.72	5.19e-21	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg22920501	chr2:26401640	FAM59B	-0.72	-6.22	-0.49	7.14e-9	Gut microbiome composition (summer);
TGCT	cis	rs9467711	1.000	rs9467704	chr6:26319486	A/G	cg26531700	chr6:26746687	NA	1.04	5.71	0.46	7.81e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg06634786	chr22:41940651	POLR3H	-0.9	-8.93	-0.63	4.7e-15	Vitiligo;
TGCT	cis	rs9527	0.590	rs6584537	chr10:104778267	C/G	cg15744005	chr10:104629667	AS3MT	-0.42	-4.92	-0.4	2.74e-6	Arsenic metabolism;
TGCT	cis	rs7666738	0.785	rs11944120	chr4:99079932	A/C	cg17366294	chr4:99064904	C4orf37	0.71	5.48	0.44	2.27e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11098499	0.863	rs28718422	chr4:120466304	C/A	cg09307838	chr4:120376055	NA	0.72	6.87	0.52	2.81e-10	Corneal astigmatism;
TGCT	cis	rs6906287	0.561	rs2078079	chr6:118705213	G/A	cg21191810	chr6:118973309	C6orf204	0.27	4.55	0.38	1.28e-5	Electrocardiographic conduction measures;
TGCT	cis	rs9818758	0.607	rs34823813	chr3:49749976	G/A	cg00383909	chr3:49044727	WDR6	1.31	6.62	0.51	9.53e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs13256369	1.000	rs13256369	chr8:8577379	T/C	cg18904891	chr8:8559673	CLDN23	0.64	5.87	0.47	3.71e-8	Obesity-related traits;
TGCT	cis	rs7666738	0.830	rs62318503	chr4:98935479	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11190604	0.767	rs11190519	chr10:102175133	C/T	cg23241863	chr10:102295624	HIF1AN	0.6	4.57	0.38	1.17e-5	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs10992471	0.575	rs1152759	chr9:95129359	T/C	cg13798575	chr9:95087839	CENPP;NOL8	0.62	5.98	0.47	2.2e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs916888	0.821	rs199513	chr17:44856932	A/G	cg16520312	chr17:43971471	MAPT;LOC100128977	0.52	4.72	0.39	6.16e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg06618935	chr21:46677482	NA	-0.36	-5.43	-0.44	2.87e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9818758	0.607	rs35673421	chr3:49139406	G/A	cg00383909	chr3:49044727	WDR6	1.3	6.73	0.52	5.74e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs2820315	1.000	rs1400875	chr1:201821443	T/C	cg12730843	chr1:201915899	LMOD1	-0.27	-4.76	-0.39	5.2e-6	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
TGCT	cis	rs9611565	0.649	rs79005	chr22:41835544	G/A	cg03806693	chr22:41940476	POLR3H	1.11	12.05	0.73	1.3e-22	Vitiligo;
TGCT	cis	rs8070740	0.898	rs8074617	chr17:5323989	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	4.77	0.39	5.1e-6	Menopause (age at onset);
TGCT	cis	rs7246657	0.654	rs10407568	chr19:38123009	A/T	cg03611452	chr19:38183253	ZNF781	0.59	4.76	0.39	5.34e-6	Coronary artery calcification;
TGCT	cis	rs698813	0.604	rs1596010	chr2:44491804	A/C	cg00619915	chr2:44497795	NA	-0.24	-5.5	-0.44	2.05e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
TGCT	cis	rs858239	0.600	rs6961406	chr7:23134891	C/T	cg05602783	chr7:23145260	KLHL7	-0.6	-4.99	-0.41	2.02e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs10788264	0.621	rs7907952	chr10:124056774	C/T	cg05723130	chr10:124248994	HTRA1	-0.2	-4.58	-0.38	1.12e-5	Total body bone mineral density;
TGCT	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg00343986	chr7:65444356	GUSB	-0.24	-5.29	-0.43	5.4e-7	Cotinine glucuronidation;
TGCT	cis	rs7586879	0.681	rs6545800	chr2:25118885	A/G	cg15423357	chr2:25149977	NA	-0.5	-4.89	-0.4	3.06e-6	Body mass index;
TGCT	trans	rs4824093	0.545	rs58876234	chr22:50258868	G/A	cg09872104	chr7:134855509	C7orf49	-0.94	-7.68	-0.57	4.2e-12	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs2479724	0.840	rs10498752	chr6:41768510	T/C	cg08135965	chr6:41755394	TOMM6	-0.45	-4.53	-0.38	1.38e-5	Menarche (age at onset);
TGCT	cis	rs240764	0.853	rs2398132	chr6:100981200	A/C	cg21058520	chr6:100914733	NA	0.37	4.86	0.4	3.54e-6	Neuroticism;
TGCT	cis	rs1385374	0.858	rs12298615	chr12:129286756	G/A	cg09035930	chr12:129282057	SLC15A4	-0.55	-4.69	-0.39	6.99e-6	Systemic lupus erythematosus;
TGCT	cis	rs1163251	0.902	rs639216	chr1:120217414	C/T	cg19096424	chr1:120255104	PHGDH	0.56	5.29	0.43	5.46e-7	Blood metabolite levels;
TGCT	cis	rs6598955	0.543	rs3795689	chr1:26560366	C/G	cg24519413	chr1:26490540	NA	-0.26	-4.73	-0.39	6.1e-6	Obesity-related traits;
TGCT	trans	rs66573146	0.831	rs67702333	chr4:6983040	C/G	cg07817883	chr1:32538562	TMEM39B	1.42	7.53	0.56	8.92e-12	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs4911259	0.552	rs13038017	chr20:31467551	T/C	cg13636640	chr20:31349939	DNMT3B	-0.89	-9.83	-0.66	3.33e-17	Inflammatory bowel disease;
TGCT	cis	rs6558530	0.666	rs6558526	chr8:1702572	A/G	cg09410841	chr8:1729607	CLN8	0.72	6.49	0.5	1.87e-9	Systolic blood pressure;
TGCT	cis	rs7647973	0.626	rs9830730	chr3:49675875	G/C	cg03034192	chr3:50606346	HEMK1;C3orf18	0.36	4.75	0.39	5.61e-6	Menarche (age at onset);
TGCT	cis	rs514406	0.763	rs9988539	chr1:53213884	T/C	cg08859206	chr1:53392774	SCP2	0.4	5.88	0.47	3.56e-8	Monocyte count;
TGCT	cis	rs7829975	0.511	rs2976902	chr8:8341105	T/G	cg08975724	chr8:8085496	FLJ10661	0.55	5.37	0.43	3.82e-7	Mood instability;
TGCT	cis	rs2806561	0.577	rs488438	chr1:23498999	T/A	cg12483005	chr1:23474871	LUZP1	0.39	4.88	0.4	3.24e-6	Height;
TGCT	cis	rs2729354	0.953	rs1846567	chr11:57357593	T/C	cg24343310	chr11:57249947	NA	0.29	4.71	0.39	6.6e-6	Blood protein levels;
TGCT	cis	rs13256369	0.851	rs13249700	chr8:8563637	C/T	cg06671706	chr8:8559999	CLDN23	0.34	4.53	0.38	1.38e-5	Obesity-related traits;
TGCT	cis	rs2075165	1.000	rs2075165	chr1:156215899	G/A	cg20302342	chr1:156215951	PAQR6	0.36	5.24	0.43	6.62e-7	Tonsillectomy;
TGCT	cis	rs12477438	0.520	rs11695379	chr2:99742161	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.85	8.48	0.61	5.52e-14	Chronic sinus infection;
TGCT	trans	rs629535	0.699	rs539956	chr8:70033647	G/A	cg21567404	chr3:27674614	NA	0.57	9.15	0.63	1.45e-15	Dupuytren's disease;
TGCT	cis	rs10782582	0.593	rs12130832	chr1:76234294	T/C	cg10523679	chr1:76189770	ACADM	-0.61	-6.17	-0.48	8.87e-9	Daytime sleep phenotypes;
TGCT	cis	rs981844	1.000	rs2118862	chr4:154657782	A/T	cg14289246	chr4:154710475	SFRP2	1.01	8.46	0.6	6.31e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs1865760	0.566	rs2858993	chr6:26087856	T/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.8	7.46	0.56	1.3e-11	Height;
TGCT	cis	rs1466788	1.000	rs7533623	chr1:110616475	T/C	cg11787288	chr1:111506544	C1orf103	0.49	4.44	0.37	1.93e-5	Blood metabolite levels;
TGCT	cis	rs10114408	0.959	rs10992957	chr9:96651655	G/T	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs28595532	0.920	rs56283736	chr4:119747268	A/G	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs394563	0.619	rs4895787	chr6:149646500	G/A	cg03678062	chr6:149772716	ZC3H12D	0.37	4.75	0.39	5.59e-6	Dupuytren's disease;
TGCT	cis	rs2730260	0.537	rs55683317	chr7:158878599	C/T	cg27122614	chr7:157913741	PTPRN2	0.42	4.48	0.37	1.68e-5	Myopia (pathological);
TGCT	cis	rs3935685	0.874	rs4578613	chr15:78002360	A/T	cg25212270	chr15:78015279	NA	0.27	5.66	0.45	9.87e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs4253772	0.530	rs11090865	chr22:46731689	G/T	cg24881330	chr22:46731750	TRMU	0.97	4.75	0.39	5.52e-6	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg22663859	chr13:21900854	NA	0.34	4.93	0.4	2.59e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	cis	rs9527	0.590	rs943039	chr10:104825132	C/T	cg04362960	chr10:104952993	NT5C2	0.66	5.55	0.45	1.62e-7	Arsenic metabolism;
TGCT	cis	rs2204008	0.837	rs34381557	chr12:38181983	T/C	cg26384229	chr12:38710491	ALG10B	0.86	7.65	0.57	4.87e-12	Bladder cancer;
TGCT	cis	rs2228479	0.619	rs77847775	chr16:89896243	C/T	cg06558623	chr16:89946397	TCF25	0.55	4.77	0.39	5.13e-6	Skin colour saturation;
TGCT	cis	rs11690935	0.921	rs908670	chr2:172690180	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.17	-12.01	-0.73	1.6400000000000001e-22	Schizophrenia;
TGCT	cis	rs2980439	0.557	rs2921056	chr8:8319182	T/C	cg15556689	chr8:8085844	FLJ10661	0.7	6.4	0.5	2.85e-9	Neuroticism;
TGCT	cis	rs1971762	0.545	rs10747675	chr12:54000031	A/G	cg16917193	chr12:54089295	NA	-0.92	-9.72	-0.66	5.94e-17	Height;
TGCT	cis	rs1008375	0.932	rs7677212	chr4:17675932	A/G	cg10189774	chr4:17578691	LAP3	-0.55	-4.75	-0.39	5.62e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9467773	1.000	rs1884948	chr6:26567988	G/A	cg26531700	chr6:26746687	NA	0.5	4.85	0.4	3.64e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4665630	0.522	rs114880940	chr2:23930352	G/A	cg08063864	chr2:24346004	PFN4;LOC375190	1.13	4.97	0.41	2.21e-6	Hypertension;
TGCT	trans	rs1814175	0.817	rs7946556	chr11:49944874	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.36	-7.05	-0.53	1.13e-10	Height;
TGCT	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg23758822	chr17:41437982	NA	0.72	6.81	0.52	3.77e-10	Menopause (age at onset);
TGCT	trans	rs4957048	0.577	rs56294732	chr5:568144	T/C	cg11887960	chr12:57824829	NA	1.02	7.74	0.57	3.07e-12	Ulcerative colitis;
TGCT	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg11062466	chr8:58055876	NA	0.42	4.51	0.38	1.48e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs11170631	0.507	rs12307701	chr12:54090724	A/C	cg16917193	chr12:54089295	NA	1.34	17.35	0.84	5.83e-35	Height;
TGCT	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg03351412	chr1:154909251	PMVK	0.53	4.93	0.4	2.6e-6	Prostate cancer;
TGCT	cis	rs4788570	0.566	rs2052873	chr16:71505303	C/T	cg06353428	chr16:71660113	MARVELD3	-1.1	-6.61	-0.51	1.02e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs6964587	1.000	rs9785013	chr7:91674302	G/A	cg17063962	chr7:91808500	NA	0.88	9.63	0.65	9.8e-17	Breast cancer;
TGCT	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg09436375	chr6:42928200	GNMT	-0.42	-5.44	-0.44	2.78e-7	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs6582630	0.555	rs7969922	chr12:38529491	C/T	cg13010199	chr12:38710504	ALG10B	0.61	4.9	0.4	2.91e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs2180341	0.538	rs4392733	chr6:127712603	T/C	cg27446573	chr6:127587934	RNF146	0.64	6.01	0.47	1.95e-8	Breast cancer;
TGCT	cis	rs910316	0.967	rs11159116	chr14:75550584	G/T	cg23033748	chr14:75592666	NEK9	0.27	4.57	0.38	1.16e-5	Height;
TGCT	cis	rs782590	0.935	rs2627776	chr2:55873301	T/A	cg18811423	chr2:55921094	PNPT1	0.66	6.83	0.52	3.46e-10	Metabolic syndrome;
TGCT	cis	rs34783982	0.529	rs12917490	chr15:89473805	A/C	cg26213453	chr15:89455860	MFGE8	-0.34	-4.77	-0.39	5e-6	Squamous cell lung carcinoma;
TGCT	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg03388025	chr16:89894329	SPIRE2	0.5	8.55	0.61	3.83e-14	Vitiligo;
TGCT	cis	rs4629710	0.592	rs9492877	chr6:131562577	C/G	cg12606694	chr6:131520996	AKAP7	0.4	4.76	0.39	5.26e-6	Multiple myeloma (IgH translocation);
TGCT	cis	rs5769765	0.818	rs8140681	chr22:50292081	C/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.39	5.91	0.47	3.12e-8	Schizophrenia;
TGCT	cis	rs4936894	0.500	rs7107539	chr11:124180282	G/T	cg27160556	chr11:124181099	OR8D1	0.39	4.81	0.4	4.32e-6	Aging (time to death);
TGCT	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg06873352	chr17:61820015	STRADA	0.58	6.35	0.5	3.76e-9	Prudent dietary pattern;
TGCT	cis	rs7615952	0.932	rs11922218	chr3:125631289	C/T	cg05084668	chr3:125655381	ALG1L	-0.74	-6.05	-0.48	1.6e-8	Blood pressure (smoking interaction);
TGCT	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg03188948	chr7:1209495	NA	0.72	6.43	0.5	2.44e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7208859	0.673	rs9891413	chr17:29208209	G/C	cg14008862	chr17:28927542	LRRC37B2	0.72	4.66	0.39	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs614226	1.000	rs12310837	chr12:120880572	C/T	cg01236616	chr12:121019343	POP5	1.2	12.21	0.74	5.39e-23	Type 1 diabetes nephropathy;
TGCT	cis	rs10883723	0.810	rs10786671	chr10:104271303	G/A	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs7666738	0.716	rs1426660	chr4:98876792	T/A	cg05340658	chr4:99064831	C4orf37	0.52	6.0	0.47	1.98e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12510870	0.599	rs7676850	chr4:74449693	C/T	cg05868023	chr4:75230803	EREG	-0.54	-4.76	-0.39	5.33e-6	Iris color (b* coordinate);
TGCT	cis	rs7172809	0.615	rs74026926	chr15:77802961	T/C	cg22256960	chr15:77711686	NA	-0.52	-4.9	-0.4	2.91e-6	Glucose homeostasis traits;
TGCT	cis	rs826838	1.000	rs860400	chr12:39081279	A/G	cg26384229	chr12:38710491	ALG10B	-0.85	-8.09	-0.59	4.68e-13	Heart rate;
TGCT	cis	rs13064447	0.845	rs58411770	chr3:12773868	C/T	cg20675869	chr3:12750130	NA	-0.2	-5.14	-0.42	1.06e-6	Major depression and alcohol dependence;
TGCT	cis	rs2404602	0.583	rs12907668	chr15:76589767	A/T	cg26408565	chr15:76604113	ETFA	-0.45	-6.36	-0.5	3.61e-9	Blood metabolite levels;
TGCT	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg11764359	chr7:65958608	NA	0.57	5.13	0.42	1.07e-6	Aortic root size;
TGCT	cis	rs7267979	0.966	rs2261790	chr20:25262789	T/C	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg11890956	chr21:40555474	PSMG1	-0.76	-7.32	-0.55	2.7e-11	Cognitive function;
TGCT	cis	rs748404	0.660	rs694725	chr15:43756210	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	4.71	0.39	6.65e-6	Lung cancer;
TGCT	cis	rs7927592	0.513	rs608343	chr11:68196830	T/C	cg16797656	chr11:68205561	LRP5	0.28	5.13	0.42	1.1e-6	Total body bone mineral density;
TGCT	cis	rs972578	0.532	rs4822251	chr22:43415060	A/G	cg03373887	chr22:44389424	SAMM50	0.2	4.51	0.38	1.48e-5	Mean platelet volume;
TGCT	cis	rs2075165	0.838	rs12072638	chr1:156267480	T/G	cg16558208	chr1:156270281	VHLL	0.27	4.83	0.4	3.87e-6	Tonsillectomy;
TGCT	cis	rs4237845	0.735	rs11172375	chr12:58291574	G/C	cg23860436	chr12:58378763	NA	0.35	4.92	0.4	2.7e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7582180	0.629	rs12991172	chr2:100941671	A/G	cg14675211	chr2:100938903	LONRF2	0.51	4.95	0.41	2.32e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs17767294	0.708	rs72847365	chr6:27837227	G/A	cg08851530	chr6:28072375	NA	1.58	7.16	0.54	6.15e-11	Parkinson's disease;
TGCT	cis	rs497273	0.511	rs1151862	chr12:121331285	G/A	cg02419362	chr12:121203948	SPPL3	-0.19	-4.51	-0.38	1.48e-5	Systemic lupus erythematosus;
TGCT	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg11494091	chr17:61959527	GH2	0.61	14.81	0.8	3.37e-29	Prudent dietary pattern;
TGCT	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg10802521	chr3:52805072	NEK4	-0.71	-8.79	-0.62	1.04e-14	Bipolar disorder;
TGCT	cis	rs10096908	0.892	rs10086218	chr8:41641757	A/G	cg13603914	chr8:41518004	ANK1;MIR486	0.39	4.53	0.38	1.38e-5	Hypertension;Blood pressure traits (multi-trait analysis);Systolic blood pressure;
TGCT	cis	rs79349575	0.749	rs12601672	chr17:47006493	T/C	cg26022315	chr17:47021804	SNF8	0.49	4.9	0.4	2.94e-6	Type 2 diabetes;
TGCT	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg17971929	chr21:40555470	PSMG1	0.98	9.41	0.65	3.31e-16	Cognitive function;
TGCT	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg25319279	chr11:5960081	NA	0.4	4.77	0.39	5.07e-6	DNA methylation (variation);
TGCT	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg13866156	chr1:1669148	SLC35E2	-0.24	-5.87	-0.47	3.74e-8	Body mass index;
TGCT	cis	rs314370	0.855	rs76181418	chr7:100494960	G/T	cg10426581	chr7:100472382	SRRT	1.0	10.93	0.7	6.98e-20	Resting heart rate;
TGCT	cis	rs6901250	0.807	rs1606366	chr6:117132438	C/G	cg12892004	chr6:117198278	RFX6	0.54	6.6	0.51	1.05e-9	C-reactive protein levels;
TGCT	cis	rs2073300	1.000	rs6114139	chr20:23458390	T/G	cg09953122	chr20:23471693	CST8	-0.59	-4.75	-0.39	5.62e-6	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs2274273	0.682	rs7151224	chr14:55517262	G/A	cg01923255	chr14:55878535	KIAA0831	0.58	4.91	0.4	2.78e-6	Protein biomarker;
TGCT	cis	rs1577917	1.000	rs12204365	chr6:86700532	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.54	-0.45	1.73e-7	Response to antipsychotic treatment;
TGCT	cis	rs7547997	0.649	rs7543890	chr1:158342937	A/G	cg03528325	chr1:158223921	CD1A	0.33	4.56	0.38	1.22e-5	QRS duration;
TGCT	cis	rs9972944	0.902	rs59009755	chr17:63772263	C/T	cg07283582	chr17:63770753	CCDC46	0.27	5.27	0.43	5.91e-7	Total body bone mineral density;
TGCT	cis	rs832540	0.512	rs33320	chr5:56206529	C/T	cg12311346	chr5:56204834	C5orf35	-0.49	-4.91	-0.4	2.78e-6	Coronary artery disease;
TGCT	cis	rs7249142	0.549	rs72997174	chr19:19294389	T/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.51	4.9	0.4	2.98e-6	IgG glycosylation;
TGCT	cis	rs9549367	0.713	rs2476328	chr13:113829350	C/T	cg18105134	chr13:113819100	PROZ	0.46	8.12	0.59	3.94e-13	Platelet distribution width;
TGCT	trans	rs459571	0.959	rs408307	chr9:136892523	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	0.7	7.46	0.56	1.29e-11	Platelet distribution width;
TGCT	cis	rs12950390	0.893	rs11079789	chr17:45849715	A/G	cg06532163	chr17:45867833	NA	0.34	5.31	0.43	4.82e-7	IgG glycosylation;
TGCT	cis	rs2486288	0.656	rs1706768	chr15:45569443	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.82	-8.18	-0.59	2.85e-13	Glomerular filtration rate;
TGCT	cis	rs10510102	0.810	rs12267347	chr10:123698625	A/T	cg23691251	chr10:123688108	ATE1	-0.58	-4.58	-0.38	1.11e-5	Breast cancer;
TGCT	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg01802117	chr1:53393560	SCP2	0.43	5.13	0.42	1.1e-6	Monocyte count;
TGCT	cis	rs9858542	0.537	rs56038006	chr3:49362369	C/T	cg08550065	chr3:50336684	HYAL3;NAT6	0.65	4.53	0.38	1.37e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	trans	rs877282	0.891	rs11253393	chr10:788824	G/T	cg22713356	chr15:30763199	NA	1.16	10.26	0.68	3.01e-18	Uric acid levels;
TGCT	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg11494091	chr17:61959527	GH2	0.61	14.8	0.8	3.65e-29	Prudent dietary pattern;
TGCT	cis	rs8017423	0.608	rs12589866	chr14:90820977	T/C	cg04374321	chr14:90722782	PSMC1	-0.56	-5.62	-0.45	1.19e-7	Mortality in heart failure;
TGCT	cis	rs704	0.628	rs1128161	chr17:26721895	G/A	cg10342447	chr17:26645325	TMEM97	-0.47	-4.69	-0.39	7.21e-6	Osteoprotegerin levels;
TGCT	cis	rs9894429	0.646	rs58398000	chr17:79576923	G/A	cg18240062	chr17:79603768	NPLOC4	-0.56	-4.92	-0.4	2.67e-6	Eye color traits;
TGCT	cis	rs10514758	0.744	rs1521566	chr3:114808210	C/T	cg05943254	chr3:114009756	NA	0.76	4.53	0.38	1.39e-5	Urate levels in obese individuals;
TGCT	cis	rs12413816	0.963	rs10796116	chr10:13762786	C/T	cg16485048	chr10:13749193	FRMD4A	-0.26	-5.35	-0.43	4.08e-7	Red cell distribution width;
TGCT	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg03452623	chr4:187889614	NA	-0.36	-5.3	-0.43	5.01e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4786125	0.587	rs9938245	chr16:6926744	T/G	cg03623568	chr16:6915990	A2BP1	-0.42	-6.23	-0.49	6.77e-9	Heart rate variability traits (SDNN);
TGCT	cis	rs9329221	0.935	rs3750311	chr8:10283602	C/A	cg12940923	chr8:10282607	MSRA	-0.2	-4.79	-0.39	4.75e-6	Neuroticism;
TGCT	cis	rs3806843	0.576	rs246005	chr5:140339884	A/C	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7615952	1.000	rs9289275	chr3:125648659	A/T	cg05084668	chr3:125655381	ALG1L	-0.76	-6.36	-0.5	3.5e-9	Blood pressure (smoking interaction);
TGCT	cis	rs6952808	0.578	rs6949478	chr7:1841342	A/G	cg21782813	chr7:2030301	MAD1L1	-0.32	-4.7	-0.39	6.75e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs6582630	0.574	rs12146797	chr12:38436499	T/C	cg26384229	chr12:38710491	ALG10B	0.84	7.7	0.57	3.77e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs2888674	1.000	rs2888674	chr7:150510915	G/A	cg10409299	chr7:150498843	TMEM176B;TMEM176A	0.28	4.8	0.4	4.47e-6	Forced expiratory volume in 1 second (occupational environmental exposures interaction);
TGCT	cis	rs727505	1.000	rs7790856	chr7:124459852	C/T	cg23710748	chr7:124431027	NA	-0.27	-4.54	-0.38	1.33e-5	Lewy body disease;
TGCT	cis	rs2243480	1.000	rs465359	chr7:65558164	C/T	cg20637647	chr7:64974828	NA	0.88	5.34	0.43	4.19e-7	Diabetic kidney disease;
TGCT	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.75	5.41	0.44	3.09e-7	Platelet count;
TGCT	cis	rs7264396	0.635	rs6060710	chr20:34536055	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.13	-0.42	1.1e-6	Total cholesterol levels;
TGCT	cis	rs3743266	0.507	rs62003261	chr15:60761489	T/C	cg18480781	chr15:60294291	NA	0.63	4.95	0.41	2.4e-6	Menarche (age at onset);
TGCT	cis	rs12681288	0.676	rs6559208	chr8:1018833	A/G	cg04851639	chr8:1020857	NA	-0.34	-6.2	-0.49	7.82e-9	Schizophrenia;
TGCT	cis	rs13191362	0.507	rs1079020	chr6:163066596	C/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.59	-5.45	-0.44	2.58e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs2549003	1.000	rs2549007	chr5:131826875	T/C	cg02551604	chr5:131831745	NA	0.9	11.87	0.73	3.59e-22	Asthma (sex interaction);
TGCT	cis	rs7659604	0.540	rs67150579	chr4:122704331	T/A	cg05802129	chr4:122689817	NA	0.3	4.51	0.38	1.45e-5	Type 2 diabetes;
TGCT	cis	rs397020	0.904	rs203547	chr20:1195245	T/A	cg03932398	chr20:1206703	RAD21L1	0.81	9.63	0.65	9.89e-17	Multiple sclerosis;
TGCT	cis	rs2404602	0.647	rs2404604	chr15:76991105	A/G	cg22467129	chr15:76604101	ETFA	0.48	4.73	0.39	5.9e-6	Blood metabolite levels;
TGCT	cis	rs7213347	0.707	rs2038677	chr17:2178092	C/G	cg20777128	chr17:1945076	DPH1;OVCA2	-0.5	-4.57	-0.38	1.17e-5	Total body bone mineral density;
TGCT	cis	rs858239	0.509	rs6975524	chr7:23186452	T/C	cg05602783	chr7:23145260	KLHL7	-0.62	-5.03	-0.41	1.67e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs3733585	0.699	rs4276278	chr4:9948870	T/C	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.43	-0.55	1.56e-11	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs17376456	0.825	rs17314825	chr5:93234937	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.79	5.05	0.41	1.54e-6	Diabetic retinopathy;
TGCT	cis	rs7824557	0.701	rs4568582	chr8:11160495	A/T	cg21775007	chr8:11205619	TDH	0.58	5.45	0.44	2.55e-7	Retinal vascular caliber;
TGCT	cis	rs737008	0.821	rs28671554	chr16:11403753	A/G	cg00044050	chr16:11439710	C16orf75	0.69	6.89	0.53	2.5e-10	Obesity-related traits;
TGCT	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg26924012	chr15:45694286	SPATA5L1	-1.09	-15.16	-0.81	5.15e-30	Homoarginine levels;
TGCT	cis	rs5167	0.601	rs892131	chr19:45496996	C/T	cg09555818	chr19:45449301	APOC2	0.23	4.62	0.38	9.53e-6	Blood protein levels;
TGCT	cis	rs554111	0.679	rs906254	chr1:21324760	G/A	cg01072550	chr1:21505969	NA	0.35	5.35	0.43	4.11e-7	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	trans	rs7618501	0.519	rs3774749	chr3:50207227	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.79	-8.22	-0.59	2.36e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs394563	0.622	rs237024	chr6:149721965	T/C	cg11245181	chr6:149772854	ZC3H12D	-0.28	-4.52	-0.38	1.43e-5	Dupuytren's disease;
TGCT	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg00343986	chr7:65444356	GUSB	0.24	5.41	0.44	3.13e-7	Aortic root size;
TGCT	cis	rs1878931	0.507	rs1218762	chr16:3405986	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.66	-5.19	-0.42	8.27e-7	Body mass index (adult);
TGCT	cis	rs1215050	0.791	rs783969	chr4:98906504	C/T	cg05340658	chr4:99064831	C4orf37	0.46	5.75	0.46	6.49e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs595982	0.559	rs4802516	chr19:49366170	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.69	-9.25	-0.64	8.09e-16	Red cell distribution width;
TGCT	trans	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg06636001	chr8:8085503	FLJ10661	-0.7	-6.78	-0.52	4.34e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	trans	rs2469997	1.000	rs2447163	chr8:120373249	G/A	cg01792902	chr3:178864926	PIK3CA	0.83	6.77	0.52	4.49e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs7917772	0.508	rs2252147	chr10:104467774	G/A	cg05855489	chr10:104503620	C10orf26	-0.69	-5.67	-0.45	9.46e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9549367	0.713	rs553316	chr13:113838015	A/G	cg18105134	chr13:113819100	PROZ	0.46	8.58	0.61	3.25e-14	Platelet distribution width;
TGCT	cis	rs28785552	0.589	rs7257371	chr19:53243910	A/G	cg22067481	chr19:53234126	ZNF611	-0.45	-6.39	-0.5	3.09e-9	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs7772486	0.754	rs2064185	chr6:146066814	G/A	cg05347473	chr6:146136440	FBXO30	-0.54	-4.95	-0.41	2.33e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2882877	0.610	rs13008848	chr2:190445284	C/G	cg10752008	chr2:190445175	SLC40A1	0.78	6.16	0.48	9.3e-9	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.73	-7.39	-0.55	1.92e-11	Prudent dietary pattern;
TGCT	cis	rs9807989	0.839	rs7603730	chr2:102974371	A/C	cg09003973	chr2:102972529	NA	0.66	5.89	0.47	3.46e-8	Asthma;
TGCT	cis	rs10833905	0.680	rs11026907	chr11:23038698	T/C	cg06387204	chr11:22647648	FANCF	0.52	4.77	0.39	5.01e-6	Sudden cardiac arrest;
TGCT	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg03517284	chr6:25882590	NA	-0.49	-4.51	-0.38	1.48e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs2549003	0.966	rs2706385	chr5:131831766	T/G	cg21138405	chr5:131827807	IRF1	-0.18	-4.69	-0.39	7.11e-6	Asthma (sex interaction);
TGCT	cis	rs4294134	0.608	rs11764262	chr7:135243932	T/G	cg08396481	chr7:135194601	CNOT4	-0.62	-4.81	-0.4	4.25e-6	Paget's disease;
TGCT	cis	rs4906332	0.966	rs12894275	chr14:103901424	A/G	cg26031613	chr14:104095156	KLC1	0.53	4.72	0.39	6.2e-6	Coronary artery disease;
TGCT	cis	rs7552404	0.924	rs1146588	chr1:76229787	C/G	cg22875332	chr1:76189707	ACADM	0.69	8.32	0.6	1.32e-13	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs711245	0.545	rs848617	chr2:36811298	G/C	cg15105969	chr2:36825350	FEZ2	0.52	4.52	0.38	1.44e-5	Height;
TGCT	cis	rs10851411	0.862	rs2255995	chr15:42816868	A/C	cg23803468	chr15:43513504	EPB42	-0.24	-4.56	-0.38	1.2e-5	Glucose homeostasis traits;
TGCT	cis	rs1857353	1.000	rs2040080	chr1:75906724	C/T	cg11838876	chr1:75668600	SLC44A5	-0.51	-4.81	-0.4	4.23e-6	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs9972944	0.729	rs1421033	chr17:63766714	A/C	cg07283582	chr17:63770753	CCDC46	-0.26	-5.3	-0.43	5.02e-7	Total body bone mineral density;
TGCT	cis	rs8078723	1.000	rs4794823	chr17:38166265	A/T	cg17467752	chr17:38218738	THRA	0.54	5.22	0.42	7.25e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg18305652	chr10:134549665	INPP5A	0.35	5.94	0.47	2.73e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	trans	rs1814175	0.559	rs1818892	chr11:49863084	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.45	-11.09	-0.71	2.8e-20	Height;
TGCT	cis	rs9527	0.545	rs7100369	chr10:104956218	C/A	cg04362960	chr10:104952993	NT5C2	0.68	5.73	0.46	7.14e-8	Arsenic metabolism;
TGCT	trans	rs7088591	0.702	rs10491208	chr10:59703352	C/G	cg00178119	chr8:105235184	RIMS2	0.59	6.85	0.52	3.01e-10	Blood pressure;
TGCT	cis	rs28595532	0.920	rs114213539	chr4:119758794	G/C	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs734999	1.000	rs10797432	chr1:2501338	C/T	cg18854424	chr1:2615690	NA	0.45	5.5	0.44	2.05e-7	Ulcerative colitis;
TGCT	cis	rs11030122	0.660	rs10835232	chr11:3900133	T/C	cg18678763	chr11:4115507	RRM1	-0.35	-4.47	-0.37	1.71e-5	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg04267008	chr7:1944627	MAD1L1	-0.35	-4.91	-0.4	2.76e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs7267979	0.932	rs6037125	chr20:25463382	G/A	cg16686733	chr20:25566563	NINL	0.56	5.69	0.46	8.49e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1801251	0.644	rs283473	chr2:233654847	A/G	cg25237894	chr2:233734115	C2orf82	0.26	4.83	0.4	3.9e-6	Coronary artery disease;
TGCT	cis	rs813218	0.523	rs1708167	chr3:99459236	T/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.42	5.03	0.41	1.68e-6	Orofacial clefts;
TGCT	cis	rs4851266	1.000	rs4303732	chr2:100830040	T/C	cg07810366	chr2:100720526	AFF3	-0.38	-5.44	-0.44	2.7e-7	Educational attainment;
TGCT	cis	rs698813	0.674	rs4953080	chr2:44500849	C/A	cg00619915	chr2:44497795	NA	-0.22	-4.91	-0.4	2.79e-6	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
TGCT	cis	rs7213347	0.707	rs4790323	chr17:2181658	A/G	cg13315690	chr17:1944831	OVCA2;DPH1	-0.39	-4.95	-0.41	2.36e-6	Total body bone mineral density;
TGCT	cis	rs17345786	0.511	rs13061565	chr3:101392270	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.35	-7.28	-0.55	3.4e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2235642	0.893	rs2076440	chr16:1587322	G/A	cg07639376	chr16:1584516	IFT140;TMEM204	-0.33	-5.76	-0.46	6.11e-8	Coronary artery disease;
TGCT	cis	rs478304	0.934	rs517115	chr11:65526988	C/T	cg27068330	chr11:65405492	SIPA1	0.75	7.57	0.56	7.2e-12	Acne (severe);
TGCT	cis	rs1395	1.000	rs3769143	chr2:27450724	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.5	-6.73	-0.52	5.69e-10	Blood metabolite levels;
TGCT	cis	rs367615	0.704	rs4286723	chr5:108835959	G/A	cg17395555	chr5:108820864	NA	0.31	5.86	0.47	3.94e-8	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs11209002	0.567	rs983111	chr1:67539356	T/C	cg02640540	chr1:67518911	SLC35D1	0.53	4.45	0.37	1.86e-5	Crohn's disease;
TGCT	cis	rs9611565	0.649	rs2413659	chr22:42164862	A/G	cg13695892	chr22:41940480	POLR3H	0.79	7.5	0.56	1.08e-11	Vitiligo;
TGCT	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg06481639	chr22:41940642	POLR3H	0.69	5.92	0.47	2.95e-8	Vitiligo;
TGCT	cis	rs7027203	0.576	rs7874836	chr9:96559370	C/T	cg14396892	chr9:96623032	NA	-0.25	-5.0	-0.41	1.94e-6	DNA methylation (variation);
TGCT	cis	rs10992471	0.580	rs13284106	chr9:95433845	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.6	-4.89	-0.4	3.04e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs9902453	1.000	rs9890205	chr17:28382704	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-6.56	-0.51	1.3e-9	Coffee consumption (cups per day);
TGCT	cis	rs3087591	0.708	rs35109242	chr17:29649223	A/G	cg24425628	chr17:29625626	OMG;NF1	0.4	5.63	0.45	1.14e-7	Hip circumference;
TGCT	cis	rs7666738	0.830	rs1559859	chr4:99024325	C/T	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.74	5.28	0.43	5.62e-7	Platelet count;
TGCT	cis	rs9303401	0.659	rs72828726	chr17:56951217	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs7611238	0.560	rs7632534	chr3:194998493	G/T	cg27323046	chr3:195102265	ACAP2	0.36	4.73	0.39	5.89e-6	Body mass index;
TGCT	cis	rs208520	0.837	rs208467	chr6:66914837	T/C	cg07460842	chr6:66804631	NA	-0.9	-9.16	-0.64	1.34e-15	Exhaled nitric oxide output;
TGCT	cis	rs11785400	1.000	rs7002932	chr8:143738816	C/A	cg10596483	chr8:143751796	JRK	0.56	6.05	0.48	1.61e-8	Schizophrenia;
TGCT	cis	rs939574	1.000	rs3817424	chr2:220096903	A/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.06	6.52	0.51	1.6e-9	Platelet distribution width;
TGCT	cis	rs2820315	0.867	rs2820319	chr1:201878650	G/A	cg12730843	chr1:201915899	LMOD1	-0.28	-5.12	-0.42	1.14e-6	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
TGCT	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg22963979	chr7:1858916	MAD1L1	-0.36	-5.62	-0.45	1.2e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs77633900	0.614	rs2629025	chr15:76943363	G/C	cg21673338	chr15:77095150	SCAPER	-0.52	-4.92	-0.4	2.72e-6	Non-glioblastoma glioma;Glioma;
TGCT	cis	rs7824557	0.592	rs920044	chr8:11224313	C/T	cg21775007	chr8:11205619	TDH	0.64	5.95	0.47	2.59e-8	Retinal vascular caliber;
TGCT	cis	rs9952991	0.941	rs45450798	chr18:12792940	C/G	cg23598886	chr18:12777645	NA	-0.61	-5.45	-0.44	2.62e-7	Inflammatory skin disease;
TGCT	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs208520	1.000	rs208527	chr6:66957209	A/C	cg07460842	chr6:66804631	NA	-0.83	-7.52	-0.56	9.8e-12	Exhaled nitric oxide output;
TGCT	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7904368	0.806	rs1130684	chr10:16859335	C/G	cg23933602	chr10:16859644	RSU1	0.61	4.52	0.38	1.43e-5	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
TGCT	cis	rs950027	0.549	rs11636114	chr15:45601412	C/G	cg14582100	chr15:45693742	SPATA5L1	0.5	6.1	0.48	1.25e-8	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs2028201	0.900	rs4674068	chr2:201306139	A/G	cg04781494	chr2:202047246	CASP10	0.24	4.44	0.37	1.97e-5	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
TGCT	cis	rs1062177	1.000	rs17804178	chr5:151197729	T/G	cg00977110	chr5:151150581	G3BP1	0.4	4.5	0.38	1.51e-5	Preschool internalizing problems;
TGCT	cis	rs2880765	0.835	rs7168860	chr15:86037030	G/A	cg13263323	chr15:86062960	AKAP13	-0.22	-4.84	-0.4	3.84e-6	Coronary artery disease;
TGCT	cis	rs7819412	0.744	rs6601562	chr8:10962929	G/C	cg21775007	chr8:11205619	TDH	-0.5	-4.79	-0.4	4.64e-6	Triglycerides;
TGCT	cis	rs12200560	0.505	rs211182	chr6:97074513	G/A	cg06623918	chr6:96969491	KIAA0776	0.59	5.03	0.41	1.71e-6	Coronary heart disease;
TGCT	cis	rs548181	0.545	rs76179820	chr11:125616379	A/G	cg03464685	chr11:125439445	EI24	-1.3	-7.93	-0.58	1.12e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs7937682	0.889	rs10749984	chr11:111492861	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.05	-11.36	-0.71	6.21e-21	Primary sclerosing cholangitis;
TGCT	cis	rs4820792	0.623	rs743185	chr22:29103217	G/A	cg03733026	chr22:29445468	ZNRF3	0.26	4.9	0.4	2.94e-6	Breast size;
TGCT	cis	rs17253792	0.822	rs75232282	chr14:56067290	G/C	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg11890956	chr21:40555474	PSMG1	0.68	6.67	0.51	7.51e-10	Menarche (age at onset);
TGCT	cis	rs6496667	0.565	rs7162107	chr15:90889046	A/G	cg22089800	chr15:90895588	ZNF774	0.63	5.53	0.44	1.81e-7	Rheumatoid arthritis;
TGCT	cis	rs12935418	0.616	rs62054213	chr16:80968203	G/C	cg07676361	chr16:80966860	NA	-0.35	-4.6	-0.38	1.02e-5	Mean corpuscular volume;
TGCT	cis	rs1903068	0.819	rs10517343	chr4:56002267	T/A	cg01777861	chr4:56023843	NA	0.54	6.38	0.5	3.2e-9	Endometriosis;
TGCT	cis	rs2486012	0.737	rs37468	chr1:44280381	A/T	cg12908607	chr1:44402522	ARTN	0.72	5.68	0.45	8.89e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7267979	1.000	rs11100	chr20:25281184	G/C	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7674212	0.539	rs6815783	chr4:104122146	A/C	cg16532752	chr4:104119610	CENPE	-0.6	-5.46	-0.44	2.51e-7	Type 2 diabetes;
TGCT	cis	rs4566357	0.595	rs1320406	chr2:227920474	C/T	cg11843606	chr2:227700838	RHBDD1	-0.51	-4.78	-0.39	4.97e-6	Coronary artery disease;
TGCT	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.63	-0.51	9.04e-10	Alzheimer's disease;
TGCT	cis	rs3820068	0.608	rs7519899	chr1:16045579	A/G	cg17385448	chr1:15911702	AGMAT	0.35	4.63	0.38	8.97e-6	Systolic blood pressure;
TGCT	cis	rs57994353	0.632	rs68142670	chr9:139324573	T/C	cg13741927	chr9:139327495	INPP5E	-0.27	-6.14	-0.48	1.01e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs9583531	0.600	rs9521909	chr13:111362170	A/G	cg24331049	chr13:111365604	ING1	0.76	7.31	0.55	2.95e-11	Coronary artery disease;
TGCT	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	6.18	0.49	8.58e-9	Bipolar disorder;
TGCT	cis	rs1670533	0.818	rs643484	chr4:1085826	A/G	cg20887711	chr4:1340912	KIAA1530	0.66	5.33	0.43	4.49e-7	Recombination rate (females);
TGCT	cis	rs2282802	0.685	rs11748023	chr5:139558584	C/T	cg01081189	chr5:139537190	NA	-0.3	-5.37	-0.43	3.82e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs75686122	0.892	rs79054943	chr8:104601404	A/G	cg04852977	chr8:104510831	NA	0.59	4.45	0.37	1.92e-5	Cocaine dependence;
TGCT	cis	rs1667284	1.000	rs1612691	chr18:29220918	A/G	cg15259973	chr18:29078565	DSG2	0.53	5.19	0.42	8.27e-7	Problematic alcohol use in trauma-exposed individuals;
TGCT	cis	rs35306767	0.903	rs12240651	chr10:943656	A/G	cg20503657	chr10:835505	NA	0.75	10.55	0.69	5.67e-19	Eosinophil percentage of granulocytes;
TGCT	cis	rs8014204	0.901	rs4899536	chr14:75316614	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.72	-6.83	-0.52	3.32e-10	Caffeine consumption;
TGCT	cis	rs9581857	0.685	rs9319370	chr13:28042493	G/T	cg22138327	chr13:27999177	GTF3A	0.72	4.6	0.38	1.03e-5	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs6969780	0.722	rs985652	chr7:27198083	A/C	cg04321618	chr7:27170880	HOXA4	-0.52	-5.15	-0.42	9.77e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6835098	0.692	rs28701033	chr4:174079376	T/A	cg08422745	chr4:174089978	GALNT7	-0.77	-8.6	-0.61	2.87e-14	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg10802521	chr3:52805072	NEK4	-0.74	-8.94	-0.63	4.47e-15	Bipolar disorder;
TGCT	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg21951975	chr1:209979733	IRF6	0.7	6.01	0.47	1.92e-8	Cleft lip with or without cleft palate;
TGCT	cis	rs6671200	0.607	rs3767313	chr1:95712797	G/A	cg06440946	chr1:95699313	RWDD3	-0.62	-5.3	-0.43	5.09e-7	Stearic acid (18:0) levels;
TGCT	cis	rs968567	0.539	rs174555	chr11:61579760	T/C	cg01500311	chr11:61656094	FADS3	-0.29	-4.98	-0.41	2.1e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
TGCT	cis	rs7937682	1.000	rs11608149	chr11:111535102	G/A	cg09085632	chr11:111637200	PPP2R1B	1.03	9.46	0.65	2.53e-16	Primary sclerosing cholangitis;
TGCT	cis	rs6495367	0.898	rs2049176	chr15:79392548	A/C	cg17916960	chr15:79447300	NA	0.37	5.44	0.44	2.71e-7	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs7586879	0.616	rs11900505	chr2:25131986	A/C	cg01884057	chr2:25150051	NA	0.36	7.1	0.54	8.43e-11	Body mass index;
TGCT	cis	rs7169223	0.653	rs1976007	chr15:79085023	T/C	cg03762349	chr15:79060523	ADAMTS7	-0.24	-5.0	-0.41	1.92e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
TGCT	cis	rs3796352	1.000	rs11713206	chr3:52999243	A/G	cg15956490	chr3:53032818	SFMBT1	0.61	6.11	0.48	1.17e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg21724239	chr8:58056113	NA	0.49	5.15	0.42	9.92e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg03303774	chr4:1407052	NA	0.3	4.78	0.39	4.8e-6	Obesity-related traits;
TGCT	cis	rs7524258	0.868	rs4908451	chr1:7299618	C/G	cg04342483	chr1:7259290	CAMTA1	0.31	4.57	0.38	1.17e-5	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs6542838	0.609	rs12712043	chr2:99541494	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.55	-5.25	-0.43	6.43e-7	Fear of minor pain;
TGCT	cis	rs9486719	0.843	rs1009597	chr6:96843540	A/T	cg06623918	chr6:96969491	KIAA0776	0.93	7.08	0.54	9.59e-11	Migraine;Coronary artery disease;
TGCT	cis	rs68170813	0.559	rs76534758	chr7:106963262	T/C	cg02696742	chr7:106810147	HBP1	-0.69	-5.61	-0.45	1.27e-7	Coronary artery disease;
TGCT	cis	rs734999	0.967	rs10910089	chr1:2498618	G/T	cg18854424	chr1:2615690	NA	0.45	5.57	0.45	1.5e-7	Ulcerative colitis;
TGCT	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg06112835	chr11:68658793	MRPL21	0.47	8.03	0.59	6.25e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	trans	rs6089829	0.962	rs6089825	chr20:61668447	C/T	cg23505145	chr19:12996616	KLF1	0.87	9.61	0.65	1.09e-16	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs11122272	0.735	rs2486740	chr1:231517552	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.13	-0.54	7.33e-11	Hemoglobin concentration;
TGCT	cis	rs7193541	0.564	rs4888274	chr16:74706298	A/T	cg01733217	chr16:74700730	RFWD3	1.0	13.58	0.77	2.66e-26	Multiple myeloma;
TGCT	cis	rs5769707	1.000	rs5769707	chr22:50013402	G/T	cg10356904	chr22:49881777	NA	-0.23	-4.67	-0.39	7.64e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs114540395	0.925	rs7090062	chr10:103408014	A/G	cg03300883	chr10:102748874	C10orf2	0.43	4.5	0.37	1.52e-5	Schizophrenia;
TGCT	cis	rs621559	0.681	rs11210796	chr1:43627976	C/T	cg01614716	chr1:43834120	ELOVL1	-0.91	-4.46	-0.37	1.82e-5	Telomere length;
TGCT	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg13607699	chr17:42295918	UBTF	0.6	5.47	0.44	2.35e-7	Total body bone mineral density;
TGCT	cis	rs7208859	0.573	rs11654035	chr17:29136426	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.66e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7119	0.651	rs17394732	chr15:77835657	A/G	cg27398640	chr15:77910606	LINGO1	0.27	5.12	0.42	1.15e-6	Type 2 diabetes;
TGCT	trans	rs853356	0.843	rs4441955	chr6:14182725	G/A	cg14262035	chr17:42019790	PPY	0.51	6.79	0.52	4.21e-10	Height;
TGCT	cis	rs9858542	0.953	rs6766581	chr3:49539401	T/C	cg03060546	chr3:49711283	APEH	-0.61	-5.37	-0.43	3.78e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs7523050	0.730	rs12729728	chr1:109431110	C/A	cg08274380	chr1:109419600	GPSM2	1.3	6.39	0.5	2.99e-9	Fat distribution (HIV);
TGCT	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.12	0.42	1.15e-6	Prudent dietary pattern;
TGCT	cis	rs10992471	0.580	rs10992366	chr9:95317214	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.6	-5.67	-0.45	9.37e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs6663390	0.510	rs2267897	chr1:208075378	C/T	cg03990033	chr1:208084030	CD34	0.73	6.41	0.5	2.77e-9	Facial morphology (factor 18);
TGCT	cis	rs9300255	0.602	rs1790116	chr12:123618544	G/T	cg00376283	chr12:123451042	ABCB9	0.67	5.27	0.43	5.78e-7	Neutrophil percentage of white cells;
TGCT	cis	rs8016982	0.674	rs61980899	chr14:81676844	T/C	cg01989461	chr14:81687754	GTF2A1	0.8	8.26	0.6	1.89e-13	Schizophrenia;
TGCT	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg04944784	chr2:26401820	FAM59B	0.72	5.92	0.47	2.93e-8	Gut microbiome composition (summer);
TGCT	cis	rs5760092	0.755	rs5760096	chr22:24247310	A/G	cg11905131	chr22:24372483	LOC391322	-0.69	-6.1	-0.48	1.25e-8	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs1670533	0.818	rs585735	chr4:1080391	G/C	cg20887711	chr4:1340912	KIAA1530	0.7	5.55	0.45	1.64e-7	Recombination rate (females);
TGCT	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg16680214	chr1:154839983	KCNN3	-0.36	-7.31	-0.55	2.89e-11	Prostate cancer;
TGCT	trans	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.86	-9.4	-0.65	3.49e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs34779708	0.931	rs11592404	chr10:35273476	G/A	cg04310649	chr10:35416472	CREM	-0.51	-4.54	-0.38	1.31e-5	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs651907	0.514	rs12636046	chr3:101434448	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	4.73	0.39	5.91e-6	Colorectal cancer;
TGCT	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg06238570	chr21:40685208	BRWD1	0.69	6.47	0.5	2.08e-9	Cognitive function;
TGCT	cis	rs11696501	0.688	rs8123346	chr20:44309987	A/T	cg11783356	chr20:44313418	WFDC10B	-0.33	-4.49	-0.37	1.6e-5	Brain structure;
TGCT	cis	rs1023500	0.552	rs5758566	chr22:42454354	G/A	cg05082376	chr22:42548792	NA	-0.21	-4.93	-0.4	2.63e-6	Schizophrenia;
TGCT	cis	rs17376456	0.825	rs17314825	chr5:93234937	A/G	cg25358565	chr5:93447407	FAM172A	1.08	8.3	0.6	1.48e-13	Diabetic retinopathy;
TGCT	cis	rs921968	0.643	rs864990	chr2:219494037	G/A	cg02176678	chr2:219576539	TTLL4	0.38	5.48	0.44	2.31e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs7223966	1.000	rs8075521	chr17:61804954	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	4.68	0.39	7.5e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs6912958	0.703	rs6903219	chr6:88096498	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.4	5.22	0.42	7.22e-7	Monocyte percentage of white cells;
TGCT	cis	rs2456568	0.741	rs9633811	chr11:93628327	A/G	cg26875233	chr11:93583750	C11orf90	0.47	6.36	0.5	3.48e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs12142240	0.659	rs1984491	chr1:46858607	T/G	cg14993813	chr1:46806288	NSUN4	-0.59	-4.86	-0.4	3.45e-6	Menopause (age at onset);
TGCT	cis	rs7119	0.651	rs12905044	chr15:77846215	G/A	cg27398640	chr15:77910606	LINGO1	-0.28	-5.11	-0.42	1.21e-6	Type 2 diabetes;
TGCT	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg17971929	chr21:40555470	PSMG1	0.97	9.54	0.65	1.67e-16	Cognitive function;
TGCT	cis	rs7772486	0.754	rs9390356	chr6:146118983	A/T	cg23711669	chr6:146136114	FBXO30	-0.93	-10.49	-0.69	8.22e-19	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6840360	0.593	rs3805356	chr4:152680701	C/T	cg22705602	chr4:152727874	NA	0.34	5.88	0.47	3.57e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2017387	0.572	rs157547	chr19:50495082	C/T	cg19230443	chr19:49950584	PIH1D1	-0.28	-4.62	-0.38	9.5e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
TGCT	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9858542	0.537	rs9873994	chr3:49359943	T/C	cg00383909	chr3:49044727	WDR6	0.67	4.56	0.38	1.19e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs12477438	0.765	rs1453564	chr2:99564428	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-7.6	-0.56	6.47e-12	Chronic sinus infection;
TGCT	cis	rs35306767	0.903	rs11253462	chr10:889323	T/G	cg26597838	chr10:835615	NA	0.71	10.12	0.67	6.47e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs7772486	0.754	rs2328709	chr6:146106819	A/G	cg13319975	chr6:146136371	FBXO30	0.6	5.42	0.44	2.97e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	5.08	0.42	1.35e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg18876405	chr7:65276391	NA	-0.39	-5.92	-0.47	3e-8	Aortic root size;
TGCT	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg22166914	chr1:53195759	ZYG11B	0.33	5.33	0.43	4.4e-7	Monocyte count;
TGCT	cis	rs7223966	1.000	rs28463311	chr17:61919643	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	4.62	0.38	9.63e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs473651	0.935	rs474478	chr2:239335473	C/T	cg21699342	chr2:239360505	ASB1	0.18	5.01	0.41	1.8e-6	Multiple system atrophy;
TGCT	cis	rs9467773	0.620	rs2494694	chr6:26619328	A/T	cg26531700	chr6:26746687	NA	0.52	5.01	0.41	1.8e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg23302884	chr18:44338147	ST8SIA5	-0.4	-4.61	-0.38	9.88e-6	Personality dimensions;
TGCT	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg24531977	chr5:56204891	C5orf35	-0.77	-7.61	-0.56	5.83e-12	Initial pursuit acceleration;
TGCT	cis	rs7666738	0.830	rs12233741	chr4:98950296	C/T	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6570726	0.791	rs9376945	chr6:145828080	T/A	cg05347473	chr6:146136440	FBXO30	0.53	4.95	0.41	2.4e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7567389	0.600	rs3732209	chr2:128079806	A/G	cg09760422	chr2:128146352	NA	0.39	5.18	0.42	8.76e-7	Self-rated health;
TGCT	cis	rs854765	0.505	rs4506969	chr17:17899839	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.78	8.08	0.59	4.9e-13	Total body bone mineral density;
TGCT	cis	rs79349575	0.783	rs4794003	chr17:47029904	C/T	cg26022315	chr17:47021804	SNF8	0.49	4.9	0.4	2.94e-6	Type 2 diabetes;
TGCT	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.06	-9.57	-0.65	1.41e-16	Platelet count;
TGCT	trans	rs4650994	0.525	rs4457535	chr1:178497186	C/T	cg05059571	chr16:84539110	KIAA1609	0.54	11.23	0.71	1.27e-20	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg26338869	chr17:61819248	STRADA	-0.53	-4.94	-0.41	2.48e-6	Prudent dietary pattern;
TGCT	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg22920501	chr2:26401640	FAM59B	-0.81	-6.36	-0.5	3.52e-9	Gut microbiome composition (summer);
TGCT	cis	rs9911578	1.000	rs391370	chr17:56675050	A/C	cg05425664	chr17:57184151	TRIM37	-0.63	-6.3	-0.49	4.84e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs3011225	0.691	rs3791102	chr1:44366617	C/T	cg13606994	chr1:44402422	ARTN	-0.42	-4.56	-0.38	1.22e-5	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg05368731	chr17:41323189	NBR1	1.16	13.7	0.78	1.41e-26	Menopause (age at onset);
TGCT	cis	rs2404602	1.000	rs1117367	chr15:76872330	A/C	cg26408565	chr15:76604113	ETFA	-0.38	-4.88	-0.4	3.24e-6	Blood metabolite levels;
TGCT	cis	rs13177918	0.677	rs13164105	chr5:149826066	T/A	cg14059543	chr5:149831962	NA	-0.71	-9.45	-0.65	2.77e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs7937682	0.883	rs631490	chr11:111452040	G/C	cg09085632	chr11:111637200	PPP2R1B	-0.99	-10.36	-0.68	1.64e-18	Primary sclerosing cholangitis;
TGCT	cis	rs2276314	0.857	rs72883058	chr18:33612917	G/A	cg19628046	chr18:33552617	C18orf21	0.51	4.46	0.37	1.79e-5	Endometriosis;Drug-induced torsades de pointes;
TGCT	cis	rs782590	0.764	rs2586969	chr2:55829392	G/C	cg03859395	chr2:55845619	SMEK2	0.84	10.09	0.67	7.69e-18	Metabolic syndrome;
TGCT	cis	rs7698623	0.850	rs6532020	chr4:88768928	C/T	cg02735620	chr4:88950514	PKD2	-0.44	-4.81	-0.4	4.22e-6	Cardiovascular disease risk factors;
TGCT	cis	rs6912958	0.874	rs9294381	chr6:88152681	A/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.36	-4.55	-0.38	1.28e-5	Monocyte percentage of white cells;
TGCT	cis	rs12682352	0.579	rs7006589	chr8:8668486	A/G	cg06636001	chr8:8085503	FLJ10661	0.57	4.89	0.4	3.04e-6	Neuroticism;
TGCT	cis	rs9393777	0.513	rs7759969	chr6:26663096	T/A	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.53	-4.88	-0.4	3.19e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs34065801	0.526	rs8001225	chr13:36514506	C/A	cg03563146	chr13:37393157	RFXAP	0.5	4.84	0.4	3.78e-6	Breast size;
TGCT	cis	rs950169	0.922	rs17531523	chr15:85132449	C/G	cg11189052	chr15:85197271	WDR73	0.78	6.49	0.5	1.88e-9	Schizophrenia;
TGCT	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg11764359	chr7:65958608	NA	-0.6	-5.32	-0.43	4.68e-7	Aortic root size;
TGCT	cis	rs367615	0.704	rs6889301	chr5:108835181	C/T	cg17395555	chr5:108820864	NA	0.31	5.86	0.47	3.94e-8	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs2271316	0.587	rs11078659	chr17:6903944	G/A	cg03407747	chr17:6899364	ALOX12	0.43	4.74	0.39	5.86e-6	Blood metabolite levels;
TGCT	cis	rs9611565	0.729	rs505533	chr22:41864216	A/C	cg13695892	chr22:41940480	POLR3H	0.86	8.55	0.61	3.95e-14	Vitiligo;
TGCT	cis	rs56399783	0.614	rs55776032	chr7:2762255	T/C	cg19731401	chr7:2775893	GNA12	0.38	5.34	0.43	4.22e-7	Childhood ear infection;
TGCT	cis	rs1048238	0.846	rs945419	chr1:16344858	C/T	cg22431228	chr1:16359049	CLCNKA	-0.29	-6.2	-0.49	7.76e-9	Systolic blood pressure;
TGCT	cis	rs10791097	0.720	rs7119425	chr11:130733185	C/T	cg12179176	chr11:130786555	SNX19	0.81	9.98	0.67	1.43e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs6582630	0.502	rs11182760	chr12:38606273	A/T	cg13010199	chr12:38710504	ALG10B	0.66	5.18	0.42	8.76e-7	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs2120019	0.938	rs35911108	chr15:75322179	G/A	cg09165964	chr15:75287851	SCAMP5	-1.14	-10.33	-0.68	2.05e-18	Blood trace element (Zn levels);
TGCT	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.78	-7.34	-0.55	2.45e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	trans	rs17450420	1.000	rs10508146	chr13:105056807	C/T	cg14737571	chr13:113436568	ATP11A	0.61	6.64	0.51	8.8e-10	Esophageal cancer  (alcohol interaction);
TGCT	cis	rs72949976	0.646	rs4673731	chr2:214028544	C/T	cg08319019	chr2:214017104	IKZF2	0.87	8.64	0.61	2.34e-14	Lung cancer;Squamous cell lung carcinoma;
TGCT	cis	rs514406	0.763	rs9988539	chr1:53213884	T/C	cg16325326	chr1:53192061	ZYG11B	-0.74	-9.11	-0.63	1.79e-15	Monocyte count;
TGCT	cis	rs11648796	0.765	rs2003832	chr16:769538	G/A	cg07343612	chr16:622815	PIGQ	-0.38	-5.29	-0.43	5.39e-7	Height;
TGCT	cis	rs80033912	0.713	rs7629936	chr3:49836707	G/A	cg07636037	chr3:49044803	WDR6	0.6	4.91	0.4	2.79e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9467773	0.620	rs2504540	chr6:26641626	A/G	cg05738196	chr6:26577821	NA	0.87	10.75	0.69	1.87e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs7226408	0.857	rs72885245	chr18:34425458	A/G	cg06757138	chr18:34340585	FHOD3	0.25	4.83	0.4	4.02e-6	Obesity-related traits;
TGCT	cis	rs425277	0.958	rs262652	chr1:2090816	T/C	cg03732007	chr1:2071316	PRKCZ	0.26	5.44	0.44	2.77e-7	Height;
TGCT	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg04025307	chr7:1156635	C7orf50	0.23	5.43	0.44	2.85e-7	Longevity;Endometriosis;
TGCT	cis	rs751728	1.000	rs4342423	chr6:33732679	C/T	cg13859433	chr6:33739653	LEMD2	-0.39	-7.43	-0.56	1.5e-11	Crohn's disease;
TGCT	cis	rs4689388	0.889	rs13101355	chr4:6293446	T/C	cg14416269	chr4:6271139	WFS1	0.37	4.9	0.4	2.95e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs9527	0.590	rs11191544	chr10:104827198	C/G	cg15744005	chr10:104629667	AS3MT	-0.42	-4.87	-0.4	3.29e-6	Arsenic metabolism;
TGCT	cis	rs2147959	0.766	rs35362491	chr1:228782552	C/A	cg22700015	chr1:228743131	NA	0.58	5.02	0.41	1.71e-6	Adult asthma;
TGCT	cis	rs7953249	0.542	rs1169284	chr12:121419926	T/C	cg02403541	chr12:121454288	C12orf43	0.65	5.63	0.45	1.15e-7	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs478607	1.000	rs551890	chr11:64477999	C/T	cg19395706	chr11:64412079	NRXN2	-0.47	-5.02	-0.41	1.72e-6	Urate levels;
TGCT	cis	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg07424592	chr7:64974309	NA	1.3	8.23	0.59	2.19e-13	Diabetic kidney disease;
TGCT	cis	rs10892173	0.566	rs2298649	chr11:117672225	A/G	cg07621104	chr11:117668040	DSCAML1	0.73	7.95	0.58	9.58e-13	Myopia;
TGCT	cis	rs459571	1.000	rs2810489	chr9:136922700	C/T	cg13789015	chr9:136890014	NCRNA00094	0.39	6.65	0.51	8.54e-10	Platelet distribution width;
TGCT	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg06634786	chr22:41940651	POLR3H	-0.9	-8.93	-0.63	4.7e-15	Vitiligo;
TGCT	cis	rs9303401	0.538	rs8078280	chr17:56473132	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.54	5.28	0.43	5.53e-7	Cognitive test performance;
TGCT	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg18230493	chr5:56204884	C5orf35	0.86	6.85	0.52	3.08e-10	Initial pursuit acceleration;
TGCT	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg14159672	chr1:205819179	PM20D1	0.63	7.92	0.58	1.16e-12	Menarche (age at onset);
TGCT	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg23302884	chr18:44338147	ST8SIA5	-0.41	-4.78	-0.39	4.94e-6	Personality dimensions;
TGCT	cis	rs12039431	0.788	rs58284750	chr1:38042926	C/A	cg17933807	chr1:38061675	GNL2	-0.81	-8.0	-0.58	7.58e-13	Epithelial ovarian cancer;
TGCT	cis	rs2832191	1.000	rs2832191	chr21:30489300	A/C	cg24692254	chr21:30365293	RNF160	-0.82	-8.73	-0.62	1.43e-14	Dental caries;
TGCT	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg03609598	chr5:56110824	MAP3K1	-0.66	-4.64	-0.38	8.89e-6	Initial pursuit acceleration;
TGCT	cis	rs7666738	0.830	rs34212748	chr4:99068708	G/A	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.44e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1008375	0.806	rs13139898	chr4:17706928	T/G	cg18681998	chr4:17616180	MED28	-0.83	-8.36	-0.6	1.09e-13	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg11764359	chr7:65958608	NA	-0.55	-4.98	-0.41	2.1e-6	Aortic root size;
TGCT	cis	rs57244997	0.860	rs9458425	chr6:162376946	C/T	cg17173639	chr6:162384350	PARK2	-0.48	-5.27	-0.43	5.87e-7	Mosquito bite size;
TGCT	cis	rs236907	0.859	rs35631282	chr1:171760682	C/T	cg20598894	chr1:171756153	METTL13	-0.2	-4.54	-0.38	1.31e-5	Mean platelet volume;
TGCT	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg18402987	chr7:1209562	NA	0.78	6.64	0.51	8.96e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2932538	0.922	rs12125361	chr1:113144779	C/T	cg22162597	chr1:113214053	CAPZA1	0.27	5.9	0.47	3.31e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs7208859	0.673	rs9911989	chr17:29237702	A/C	cg14008862	chr17:28927542	LRRC37B2	-0.76	-4.95	-0.41	2.35e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs968451	1.000	rs1569495	chr22:39665142	G/C	cg17798944	chr22:39715225	SNORD43;RPL3	0.78	6.76	0.52	4.85e-10	Primary biliary cholangitis;
TGCT	cis	rs651907	0.557	rs2288272	chr3:101378476	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.6	5.5	0.44	2.04e-7	Colorectal cancer;
TGCT	cis	rs1008375	0.863	rs10003291	chr4:17600728	A/C	cg18681998	chr4:17616180	MED28	0.94	8.59	0.61	3.17e-14	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10779751	0.770	rs2258621	chr1:11141187	C/G	cg08854313	chr1:11322531	MTOR	0.85	6.96	0.53	1.74e-10	Body mass index;
TGCT	cis	rs2153535	0.601	rs4140585	chr6:8503298	T/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs763121	0.853	rs2281019	chr22:39064378	T/A	cg06022373	chr22:39101656	GTPBP1	0.77	7.57	0.56	7.47e-12	Menopause (age at onset);
TGCT	cis	rs9467773	1.000	rs2224380	chr6:26553943	G/A	cg09904177	chr6:26538194	HMGN4	0.66	6.6	0.51	1.05e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7312933	0.558	rs7305397	chr12:42850058	T/C	cg19980929	chr12:42632907	YAF2	0.43	6.1	0.48	1.23e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs4654899	0.802	rs7519685	chr1:21192623	G/A	cg01072550	chr1:21505969	NA	-0.47	-7.09	-0.54	8.84e-11	Superior frontal gyrus grey matter volume;
TGCT	cis	rs7567389	0.600	rs11679414	chr2:128151003	G/A	cg02161262	chr2:127865248	BIN1	0.52	4.64	0.38	8.54e-6	Self-rated health;
TGCT	cis	rs9911578	0.874	rs302874	chr17:56767996	A/G	cg05425664	chr17:57184151	TRIM37	-0.66	-6.58	-0.51	1.18e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg03709012	chr19:19516395	GATAD2A	-0.77	-6.49	-0.5	1.86e-9	Tonsillectomy;
TGCT	cis	rs13102973	0.720	rs13137075	chr4:135889366	G/A	cg14419869	chr4:135874104	NA	0.26	4.6	0.38	1.03e-5	Subjective well-being;
TGCT	cis	rs1278769	0.786	rs3742238	chr13:113540425	C/T	cg17842918	chr13:113540400	ATP11A	-0.32	-4.48	-0.37	1.67e-5	Interstitial lung disease;
TGCT	cis	rs71636778	0.509	rs34514856	chr1:27287560	G/T	cg23921621	chr1:27994728	IFI6	-0.43	-4.61	-0.38	9.92e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
TGCT	cis	rs9916302	0.861	rs12150493	chr17:37586154	T/C	cg07936489	chr17:37558343	FBXL20	-0.61	-4.81	-0.4	4.27e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg18876405	chr7:65276391	NA	0.31	4.8	0.4	4.53e-6	Aortic root size;
TGCT	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg03351412	chr1:154909251	PMVK	0.51	4.82	0.4	4.18e-6	Prostate cancer;
TGCT	cis	rs6912958	0.781	rs2284908	chr6:88194500	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-5.08	-0.41	1.36e-6	Monocyte percentage of white cells;
TGCT	cis	rs17376456	0.877	rs10514380	chr5:93409370	C/T	cg25358565	chr5:93447407	FAM172A	0.92	8.38	0.6	9.58e-14	Diabetic retinopathy;
TGCT	cis	rs986417	0.818	rs10133871	chr14:61063771	A/C	cg27398547	chr14:60952738	C14orf39	1.33	9.93	0.67	1.82e-17	Gut microbiota (bacterial taxa);
TGCT	cis	rs2120019	0.938	rs8028632	chr15:75321262	T/C	cg11632617	chr15:75315747	PPCDC	-0.3	-4.44	-0.37	1.95e-5	Blood trace element (Zn levels);
TGCT	cis	rs7772486	0.790	rs9497427	chr6:146238302	T/A	cg23711669	chr6:146136114	FBXO30	-0.85	-9.7	-0.66	6.73e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7178572	0.568	rs12914345	chr15:77670401	A/C	cg15453836	chr15:77711506	NA	-0.41	-4.68	-0.39	7.43e-6	Type 2 diabetes;
TGCT	cis	rs28595532	1.000	rs28600971	chr4:119712728	G/T	cg14228332	chr4:119757509	SEC24D	0.9	4.91	0.4	2.82e-6	Cannabis dependence symptom count;
TGCT	cis	rs3764400	0.567	rs16951519	chr17:46152291	G/A	cg02340556	chr17:46797764	NA	0.41	4.47	0.37	1.72e-5	Body mass index;
TGCT	cis	rs11190604	1.000	rs11292	chr10:102313607	A/G	cg16342193	chr10:102329863	NA	-0.41	-5.21	-0.42	7.68e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs950027	0.620	rs2461700	chr15:45640627	T/C	cg26924012	chr15:45694286	SPATA5L1	0.79	8.86	0.62	6.92e-15	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs6725041	0.819	rs10175497	chr2:213082649	A/G	cg16329650	chr2:213403929	ERBB4	-0.54	-4.61	-0.38	9.88e-6	QT interval (ambient particulate matter interaction);
TGCT	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg11644478	chr21:40555479	PSMG1	-0.52	-4.84	-0.4	3.83e-6	Menarche (age at onset);
TGCT	cis	rs7666738	0.830	rs7698771	chr4:98986479	T/G	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	6.18	0.49	8.58e-9	Bipolar disorder;
TGCT	cis	rs2832191	0.791	rs2832182	chr21:30481612	G/A	cg08807101	chr21:30365312	RNF160	-0.66	-6.19	-0.49	8.16e-9	Dental caries;
TGCT	cis	rs13217239	0.646	rs9379956	chr6:27033735	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.42	-4.6	-0.38	1.01e-5	Schizophrenia;
TGCT	cis	rs9311474	0.713	rs352166	chr3:52238677	C/T	cg07507251	chr3:52567010	NT5DC2	0.42	5.7	0.46	8.37e-8	Electroencephalogram traits;
TGCT	cis	rs2723064	0.543	rs2080385	chr2:65292762	G/T	cg05010058	chr2:65284262	CEP68	0.56	5.76	0.46	6.34e-8	Atrial fibrillation;
TGCT	cis	rs9814567	0.929	rs1863912	chr3:134205227	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.99	-9.97	-0.67	1.5e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs4664308	1.000	rs62175515	chr2:160909524	A/T	cg03641300	chr2:160917029	PLA2R1	-0.26	-6.53	-0.51	1.49e-9	Idiopathic membranous nephropathy;
TGCT	cis	rs2730260	0.537	rs56023468	chr7:158875329	T/C	cg27122614	chr7:157913741	PTPRN2	0.42	4.47	0.37	1.74e-5	Myopia (pathological);
TGCT	cis	rs9399135	0.933	rs4559100	chr6:135324085	T/C	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.36e-6	Red blood cell count;
TGCT	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg13695892	chr22:41940480	POLR3H	0.93	9.1	0.63	1.88e-15	Vitiligo;
TGCT	cis	rs1847202	0.859	rs11923247	chr3:72923306	A/G	cg25664220	chr3:72788482	NA	-0.38	-4.88	-0.4	3.13e-6	Motion sickness;
TGCT	cis	rs7586879	0.593	rs6733224	chr2:25130907	C/T	cg15423357	chr2:25149977	NA	-0.48	-4.65	-0.39	8.28e-6	Body mass index;
TGCT	cis	rs4499344	0.769	rs114289041	chr19:33083746	A/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.71	-6.33	-0.49	4.12e-9	Mean platelet volume;
TGCT	cis	rs8077889	0.957	rs17742929	chr17:41891437	C/T	cg25876840	chr17:41920477	NA	0.24	4.59	0.38	1.09e-5	Triglycerides;
TGCT	cis	rs17601876	0.814	rs2414101	chr15:51562434	A/G	cg19946085	chr15:51559439	CYP19A1	-0.33	-5.06	-0.41	1.45e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs6964587	1.000	rs17164275	chr7:91590408	A/G	cg17063962	chr7:91808500	NA	0.91	9.99	0.67	1.32e-17	Breast cancer;
TGCT	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg11941060	chr3:133502564	NA	-0.29	-6.17	-0.48	8.85e-9	Iron status biomarkers;
TGCT	trans	rs9388451	0.626	rs7748729	chr6:126077381	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.85	-9.81	-0.66	3.6e-17	Brugada syndrome;
TGCT	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg21862992	chr11:68658383	NA	0.46	6.52	0.51	1.6e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs2455799	0.559	rs2121737	chr3:15907946	C/G	cg12172478	chr3:16357591	RFTN1	0.36	5.08	0.41	1.37e-6	Mean platelet volume;
TGCT	cis	rs2013441	1.000	rs1992562	chr17:20218793	A/C	cg23224458	chr17:20280056	CCDC144C	-0.37	-4.46	-0.37	1.78e-5	Obesity-related traits;
TGCT	cis	rs3027009	0.881	rs61828174	chr1:159134846	T/A	cg18972751	chr1:158261555	CD1C	-0.42	-4.52	-0.38	1.4e-5	Lean body mass and age at menarche (combined);
TGCT	cis	rs6831352	0.918	rs13113166	chr4:100050528	A/G	cg12011299	chr4:100065546	ADH4	-0.41	-4.92	-0.4	2.72e-6	Alcohol dependence;
TGCT	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg24829409	chr8:58192753	C8orf71	-0.59	-5.18	-0.42	8.54e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9388451	0.626	rs1935983	chr6:126068914	C/T	cg05901451	chr6:126070800	HEY2	-1.04	-13.0	-0.76	6.65e-25	Brugada syndrome;
TGCT	trans	rs877282	0.853	rs7079450	chr10:755932	T/A	cg22713356	chr15:30763199	NA	1.07	8.27	0.6	1.75e-13	Uric acid levels;
TGCT	cis	rs1488864	1.000	rs10742972	chr11:6347128	G/T	cg12755421	chr11:6342214	PRKCDBP	-0.56	-4.48	-0.37	1.7e-5	Smooth-surface caries;
TGCT	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg05368731	chr17:41323189	NBR1	1.05	10.39	0.68	1.45e-18	Menopause (age at onset);
TGCT	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg11890956	chr21:40555474	PSMG1	-0.77	-7.6	-0.56	6.17e-12	Cognitive function;
TGCT	cis	rs7010267	0.596	rs6999476	chr8:120032259	C/G	cg17171407	chr8:119960777	TNFRSF11B	0.25	4.49	0.37	1.59e-5	Total body bone mineral density (age 45-60);
TGCT	cis	rs739496	0.615	rs3742001	chr12:112103148	C/T	cg10833066	chr12:111807467	FAM109A	0.35	5.18	0.42	8.83e-7	Platelet count;
TGCT	cis	rs17376456	0.877	rs10064520	chr5:93427358	T/C	cg25358565	chr5:93447407	FAM172A	0.93	8.37	0.6	1.04e-13	Diabetic retinopathy;
TGCT	cis	rs28595532	0.920	rs56302600	chr4:119770162	T/C	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs7949030	0.626	rs11231141	chr11:62326265	T/C	cg22862634	chr11:62369728	EML3;MTA2	0.71	9.06	0.63	2.4e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg03303774	chr4:1407052	NA	-0.32	-4.92	-0.4	2.7e-6	Obesity-related traits;
TGCT	cis	rs1023500	0.573	rs133382	chr22:42471774	C/T	cg15557168	chr22:42548783	NA	-0.22	-5.58	-0.45	1.47e-7	Schizophrenia;
TGCT	cis	rs2034088	0.619	rs4968170	chr17:404712	T/C	cg01214346	chr17:406501	NA	-0.36	-5.48	-0.44	2.25e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs9309473	0.718	rs10175529	chr2:73606093	A/G	cg20560298	chr2:73613845	ALMS1	-0.44	-4.86	-0.4	3.52e-6	Metabolite levels;
TGCT	cis	rs7267979	1.000	rs2258769	chr20:25276680	G/C	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs13217239	0.646	rs10456351	chr6:26986792	C/T	cg15659132	chr6:26577336	NA	0.55	5.55	0.45	1.62e-7	Schizophrenia;
TGCT	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.0	0.41	1.89e-6	Menopause (age at onset);
TGCT	cis	rs1371867	0.846	rs1788199	chr8:101292854	A/G	cg06636551	chr8:101224915	SPAG1	-0.48	-6.52	-0.51	1.62e-9	Atrioventricular conduction;
TGCT	cis	rs3847687	1.000	rs10848269	chr12:131518622	A/G	cg13586425	chr12:131519906	GPR133	-0.33	-5.0	-0.41	1.87e-6	Longevity;
TGCT	cis	rs1153858	1.000	rs4775907	chr15:45638647	G/A	cg14582100	chr15:45693742	SPATA5L1	0.48	5.7	0.46	8.17e-8	Homoarginine levels;
TGCT	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg08280861	chr8:58055591	NA	0.42	4.82	0.4	4.15e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7191700	0.644	rs12149160	chr16:11439303	G/T	cg00044050	chr16:11439710	C16orf75	-0.88	-10.43	-0.68	1.16e-18	Multiple sclerosis;
TGCT	cis	rs12134133	0.962	rs2564970	chr1:207464041	C/A	cg02152968	chr1:207494213	CD55	0.57	4.47	0.37	1.74e-5	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs4925386	0.759	rs2427293	chr20:60925859	A/G	cg06026331	chr20:60912101	LAMA5	-0.37	-5.98	-0.47	2.25e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg05368731	chr17:41323189	NBR1	1.08	11.0	0.7	4.76e-20	Menopause (age at onset);
TGCT	cis	rs11098499	0.754	rs7672594	chr4:120248543	A/C	cg09307838	chr4:120376055	NA	0.61	5.91	0.47	3.14e-8	Corneal astigmatism;
TGCT	cis	rs9858542	0.953	rs6809216	chr3:49412559	G/A	cg03060546	chr3:49711283	APEH	-0.64	-5.61	-0.45	1.27e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs7666738	0.791	rs7657399	chr4:98851861	T/C	cg17366294	chr4:99064904	C4orf37	0.7	7.27	0.55	3.62e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg18402987	chr7:1209562	NA	0.67	5.43	0.44	2.86e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs3820068	0.529	rs79570154	chr1:15990912	T/C	cg05660106	chr1:15850417	CASP9	0.79	7.22	0.54	4.55e-11	Systolic blood pressure;
TGCT	cis	rs17376456	0.778	rs10476604	chr5:93461838	C/T	cg25358565	chr5:93447407	FAM172A	0.64	6.04	0.48	1.63e-8	Diabetic retinopathy;
TGCT	cis	rs797680	0.822	rs1572343	chr1:93616202	T/C	cg17826107	chr1:92977322	EVI5	-0.24	-5.21	-0.42	7.63e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs9393777	0.778	rs74689501	chr6:26887821	G/A	cg16898833	chr6:26189333	HIST1H4D	1.13	5.55	0.45	1.65e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg23758822	chr17:41437982	NA	0.71	6.99	0.53	1.49e-10	Menopause (age at onset);
TGCT	cis	rs11122272	0.735	rs2572253	chr1:231512768	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.14	-0.54	6.86e-11	Hemoglobin concentration;
TGCT	cis	rs6570726	0.846	rs446031	chr6:145885592	C/T	cg05347473	chr6:146136440	FBXO30	0.48	4.5	0.37	1.57e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg12963246	chr6:28129442	ZNF389	0.52	5.01	0.41	1.85e-6	Depression;
TGCT	cis	rs7666738	0.830	rs991169	chr4:98928567	C/A	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs4332037	0.539	rs55790766	chr7:2021248	C/T	cg25834613	chr7:1915315	MAD1L1	-0.47	-4.51	-0.38	1.48e-5	Bipolar disorder;
TGCT	cis	rs4851254	0.618	rs13001130	chr2:100668699	G/A	cg22139774	chr2:100720529	AFF3	-0.43	-4.63	-0.38	9.26e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs13082711	0.596	rs479404	chr3:27363064	T/C	cg02860705	chr3:27208620	NA	0.3	4.9	0.4	2.95e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs6570726	0.791	rs440477	chr6:145854188	C/T	cg23711669	chr6:146136114	FBXO30	0.89	9.93	0.67	1.82e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7120118	0.517	rs56168519	chr11:47317987	T/C	cg13308137	chr11:47528955	CUGBP1	0.33	5.19	0.42	8.26e-7	HDL cholesterol;
TGCT	cis	rs78456975	0.550	rs111467480	chr2:1569154	A/G	cg12573674	chr2:1569213	NA	-0.49	-5.35	-0.43	4.16e-7	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs7824557	0.606	rs2736264	chr8:11186639	G/C	cg21775007	chr8:11205619	TDH	0.69	6.62	0.51	9.87e-10	Retinal vascular caliber;
TGCT	cis	rs1976403	0.633	rs1780322	chr1:21823076	T/C	cg17800788	chr1:21766015	NBPF3	0.25	4.61	0.38	1e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs4950928	0.774	rs4950931	chr1:203164075	G/A	cg17014757	chr1:203156097	CHI3L1	-0.38	-4.75	-0.39	5.55e-6	YKL-40 levels;
TGCT	cis	rs2842992	0.789	rs4709370	chr6:160210061	A/G	cg11366901	chr6:160182831	ACAT2	1.07	7.3	0.55	2.97e-11	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs139371	0.516	rs139342	chr22:39507654	C/A	cg18708252	chr22:39545030	CBX7	-0.31	-4.65	-0.39	8.52e-6	Multiple myeloma (IgH translocation);Multiple myeloma (hyperdiploidy);
TGCT	cis	rs2464469	0.648	rs7173078	chr15:58203953	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.33	-4.61	-0.38	9.94e-6	Barrett's esophagus  or Esophageal adenocarcinoma;
TGCT	cis	rs68170813	0.605	rs10464620	chr7:107135653	A/G	cg02696742	chr7:106810147	HBP1	0.66	5.24	0.43	6.72e-7	Coronary artery disease;
TGCT	cis	rs2721195	0.743	rs2306386	chr8:145742879	T/C	cg11211951	chr8:145729740	GPT	0.23	5.22	0.42	7.25e-7	Age at first birth;
TGCT	cis	rs9486715	1.000	rs7752277	chr6:97065131	C/T	cg18709589	chr6:96969512	KIAA0776	-0.78	-7.13	-0.54	7.19e-11	Headache;
TGCT	cis	rs4924935	0.770	rs4924946	chr17:18846525	A/T	cg26378065	chr17:18585709	ZNF286B	-0.54	-5.23	-0.42	7.08e-7	Pancreatic cancer;
TGCT	cis	rs593982	0.920	rs1151501	chr11:65484883	A/G	cg08755490	chr11:65554678	OVOL1	1.33	7.99	0.58	7.81e-13	Atopic dermatitis;
TGCT	cis	rs28595532	0.765	rs114082534	chr4:119734184	G/A	cg21605333	chr4:119757512	SEC24D	1.62	7.49	0.56	1.1e-11	Cannabis dependence symptom count;
TGCT	cis	rs7666738	0.830	rs35752787	chr4:98935202	G/A	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9814567	0.964	rs9841180	chr3:134191880	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.97	-9.32	-0.64	5.68e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	16.07	0.82	4.16e-32	Prudent dietary pattern;
TGCT	cis	rs9467711	0.606	rs9379899	chr6:26603015	T/A	cg16898833	chr6:26189333	HIST1H4D	1.02	5.25	0.43	6.32e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs904251	0.523	rs914348	chr6:37484729	G/A	cg08126542	chr6:37504118	NA	-0.42	-6.16	-0.48	9.53e-9	Cognitive performance;
TGCT	cis	rs2816958	0.803	rs2737687	chr1:200094805	T/A	cg07971716	chr1:199773294	NA	0.46	4.52	0.38	1.45e-5	Ulcerative colitis;Inflammatory bowel disease;
TGCT	cis	rs7666738	0.830	rs35433756	chr4:99070555	C/T	cg17366294	chr4:99064904	C4orf37	0.73	7.45	0.56	1.4e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9527	0.615	rs7073295	chr10:104672233	A/G	cg04362960	chr10:104952993	NT5C2	0.64	5.4	0.44	3.33e-7	Arsenic metabolism;
TGCT	cis	rs9368481	0.761	rs4358615	chr6:26998567	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.46	5.31	0.43	4.82e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7666738	0.687	rs6830176	chr4:99093955	G/C	cg05340658	chr4:99064831	C4orf37	0.44	4.73	0.39	5.98e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1670533	0.872	rs6854793	chr4:1055768	T/C	cg27284194	chr4:1044797	NA	0.68	5.88	0.47	3.56e-8	Recombination rate (females);
TGCT	cis	rs13191362	1.000	rs34398656	chr6:162999612	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.68	5.79	0.46	5.33e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7666738	0.925	rs2865952	chr4:99040305	C/T	cg17366294	chr4:99064904	C4orf37	0.78	7.1	0.54	8.71e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7611238	0.560	rs6806850	chr3:195079711	A/G	cg27323046	chr3:195102265	ACAP2	0.37	4.93	0.4	2.56e-6	Body mass index;
TGCT	cis	rs79349575	0.729	rs62075824	chr17:46986679	A/G	cg26022315	chr17:47021804	SNF8	0.48	4.82	0.4	4.06e-6	Type 2 diabetes;
TGCT	cis	rs11648796	0.757	rs763206	chr16:770103	C/G	cg00908189	chr16:619842	PIGQ	0.7	5.72	0.46	7.69e-8	Height;
TGCT	cis	rs208520	0.955	rs28684412	chr6:66979430	A/C	cg07460842	chr6:66804631	NA	0.78	6.82	0.52	3.61e-10	Exhaled nitric oxide output;
TGCT	cis	rs2066819	1.000	rs79750959	chr12:56702012	C/A	cg26714650	chr12:56694279	CS	-1.36	-6.06	-0.48	1.54e-8	Psoriasis vulgaris;
TGCT	cis	rs67478160	0.634	rs2368558	chr14:104230518	A/G	cg26031613	chr14:104095156	KLC1	-0.63	-6.38	-0.5	3.18e-9	Schizophrenia;
TGCT	cis	rs4689388	0.926	rs11732178	chr4:6292643	G/C	cg25554036	chr4:6271136	WFS1	0.56	7.96	0.58	9.12e-13	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs12541335	0.639	rs3923439	chr8:22170079	G/A	cg09517075	chr8:22133004	PIWIL2	0.25	4.91	0.4	2.8e-6	Hypertriglyceridemia;
TGCT	cis	rs2832191	0.755	rs55671430	chr21:30492421	G/C	cg24692254	chr21:30365293	RNF160	-0.92	-9.97	-0.67	1.45e-17	Dental caries;
TGCT	cis	rs7666738	0.791	rs2081622	chr4:98927369	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2439831	1.000	rs689647	chr15:43762196	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.01	8.37	0.6	1.02e-13	Lung cancer in ever smokers;
TGCT	trans	rs12599106	0.679	rs34584967	chr16:34475725	T/G	cg18110333	chr6:292329	DUSP22	-0.67	-7.4	-0.55	1.84e-11	Menopause (age at onset);
TGCT	cis	rs7095607	0.538	rs2634706	chr10:69917590	A/C	cg18986048	chr10:69913749	MYPN	0.61	5.85	0.46	4.16e-8	Lung function (FVC);
TGCT	cis	rs7666738	0.791	rs6828752	chr4:99063382	C/T	cg05340658	chr4:99064831	C4orf37	0.52	5.79	0.46	5.32e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg06873352	chr17:61820015	STRADA	0.56	6.22	0.49	6.93e-9	Prudent dietary pattern;
TGCT	cis	rs6893807	1.000	rs1422192	chr5:87959023	G/A	cg24804195	chr5:87968844	LOC645323	0.76	5.64	0.45	1.09e-7	Body mass index;
TGCT	cis	rs7043114	0.525	rs6479416	chr9:95053871	G/T	cg14631576	chr9:95140430	CENPP	-0.28	-4.65	-0.39	8.23e-6	Height;
TGCT	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg11644478	chr21:40555479	PSMG1	1.0	10.32	0.68	2.15e-18	Cognitive function;
TGCT	cis	rs1334894	1.000	rs1334894	chr6:35615130	C/T	cg24281267	chr6:35479648	TULP1	-0.43	-4.51	-0.38	1.46e-5	Coronary artery disease;
TGCT	cis	rs8032315	1.000	rs6227	chr15:91425232	C/T	cg06330618	chr15:91428456	FES	0.19	4.57	0.38	1.17e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1372520	0.577	rs1811443	chr4:90747883	G/C	cg01966878	chr4:90757139	SNCA	-0.3	-4.76	-0.39	5.2e-6	Neuroticism;
TGCT	cis	rs7833790	0.724	rs4739627	chr8:82734657	A/G	cg23324259	chr8:82754387	SNX16	-0.61	-4.71	-0.39	6.42e-6	Diastolic blood pressure;
TGCT	cis	rs4242434	0.927	rs10099846	chr8:22534178	C/T	cg21658235	chr8:22456391	C8orf58	-0.43	-4.47	-0.37	1.77e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs709400	1.000	rs861536	chr14:104167564	A/G	cg26031613	chr14:104095156	KLC1	1.13	17.13	0.84	1.75e-34	Body mass index;
TGCT	cis	rs9611565	0.921	rs5751081	chr22:41742788	A/T	cg06634786	chr22:41940651	POLR3H	-0.63	-6.01	-0.47	1.93e-8	Vitiligo;
TGCT	cis	rs4689388	0.856	rs1046314	chr4:6303955	A/G	cg14416269	chr4:6271139	WFS1	-0.4	-5.4	-0.44	3.25e-7	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs995000	0.965	rs1570694	chr1:63103217	A/G	cg15066888	chr1:62901829	USP1	-0.52	-4.52	-0.38	1.41e-5	Triglyceride levels;
TGCT	cis	rs1008375	1.000	rs12507142	chr4:17656103	A/G	cg10189774	chr4:17578691	LAP3	0.55	4.9	0.4	2.96e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2486288	0.656	rs2461705	chr15:45570241	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.42	-4.64	-0.38	8.63e-6	Glomerular filtration rate;
TGCT	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg27454412	chr7:1067447	C7orf50	0.6	4.72	0.39	6.32e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs4713118	0.513	rs149878	chr6:27878738	T/G	cg10876282	chr6:28092338	ZSCAN16	0.48	4.52	0.38	1.45e-5	Parkinson's disease;
TGCT	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg27454412	chr7:1067447	C7orf50	0.6	4.72	0.39	6.32e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs921968	0.678	rs500422	chr2:219432995	C/A	cg02176678	chr2:219576539	TTLL4	0.36	5.11	0.42	1.2e-6	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs76878669	0.561	rs12420203	chr11:66163794	T/C	cg18002602	chr11:66138449	SLC29A2	0.53	6.57	0.51	1.22e-9	Educational attainment (years of education);
TGCT	cis	rs7829975	0.606	rs10112585	chr8:8795030	A/T	cg15556689	chr8:8085844	FLJ10661	-0.69	-6.25	-0.49	5.93e-9	Mood instability;
TGCT	cis	rs1113500	0.575	rs1781070	chr1:108569698	A/G	cg22161131	chr1:109420278	GPSM2	-0.58	-5.57	-0.45	1.54e-7	Growth-regulated protein alpha levels;
TGCT	cis	rs7552404	0.961	rs448710	chr1:76116554	T/C	cg03433033	chr1:76189801	ACADM	-0.84	-10.12	-0.67	6.47e-18	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs1008375	1.000	rs10939738	chr4:17604295	G/C	cg10189774	chr4:17578691	LAP3	0.57	4.9	0.4	2.93e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	trans	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.82	-8.52	-0.61	4.53e-14	Body mass index;
TGCT	cis	rs7824557	0.583	rs2263511	chr8:11233318	A/C	cg21775007	chr8:11205619	TDH	-0.66	-6.81	-0.52	3.79e-10	Retinal vascular caliber;
TGCT	cis	rs1395	0.744	rs3739092	chr2:27462076	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.7	9.4	0.65	3.52e-16	Blood metabolite levels;
TGCT	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg11494091	chr17:61959527	GH2	0.61	14.43	0.79	2.59e-28	Prudent dietary pattern;
TGCT	cis	rs425277	1.000	rs425277	chr1:2069172	C/T	cg24578937	chr1:2090814	PRKCZ	0.31	7.13	0.54	7.33e-11	Height;
TGCT	cis	rs4919669	0.668	rs10883735	chr10:104308446	C/T	cg05855489	chr10:104503620	C10orf26	0.71	4.57	0.38	1.18e-5	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs10883723	0.810	rs7090276	chr10:104281239	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs1461503	0.966	rs4936764	chr11:122844492	G/A	cg27398637	chr11:122830231	C11orf63	-0.42	-5.25	-0.43	6.42e-7	Menarche (age at onset);
TGCT	cis	rs877282	1.000	rs2004479	chr10:770854	G/A	cg17470449	chr10:769945	NA	0.32	4.93	0.4	2.56e-6	Uric acid levels;
TGCT	cis	rs924607	0.931	rs1709556	chr5:637058	A/G	cg18765565	chr5:669397	TPPP	0.58	6.07	0.48	1.45e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs10464366	0.560	rs12672089	chr7:39132816	G/A	cg15212455	chr7:39170539	POU6F2	0.24	5.54	0.45	1.72e-7	IgG glycosylation;
TGCT	cis	rs13242816	1.000	rs35184471	chr7:116133246	G/A	cg16553024	chr7:116138462	CAV2	-0.45	-5.04	-0.41	1.57e-6	P wave duration;
TGCT	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg07870213	chr5:140052090	DND1	-0.62	-7.4	-0.55	1.84e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs782590	0.559	rs12617719	chr2:55915826	G/C	cg03859395	chr2:55845619	SMEK2	-0.72	-7.85	-0.58	1.67e-12	Metabolic syndrome;
TGCT	cis	rs2013441	1.000	rs12451216	chr17:20025840	C/A	cg18979559	chr17:20280153	CCDC144C	0.46	4.8	0.4	4.42e-6	Obesity-related traits;
TGCT	cis	rs10992471	0.603	rs10761163	chr9:95313287	A/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.6	-5.68	-0.45	9.01e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs4906332	1.000	rs35862113	chr14:103857229	G/T	cg26031613	chr14:104095156	KLC1	-0.52	-4.77	-0.39	5.12e-6	Coronary artery disease;
TGCT	cis	rs11754661	1.000	rs11755145	chr6:151207249	G/A	cg11579907	chr6:151412213	MTHFD1L	0.54	4.91	0.4	2.83e-6	Alzheimer's disease (late onset);
TGCT	cis	rs2239547	0.657	rs7638524	chr3:52874861	G/A	cg11645453	chr3:52864694	ITIH4	0.35	5.88	0.47	3.57e-8	Schizophrenia;
TGCT	cis	rs9549260	0.522	rs4245401	chr13:41277736	G/T	cg21288729	chr13:41239152	FOXO1	0.93	9.23	0.64	8.96e-16	Red blood cell count;
TGCT	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	-0.64	-5.43	-0.44	2.84e-7	Initial pursuit acceleration;
TGCT	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg19318889	chr4:1322082	MAEA	0.28	6.72	0.52	6.01e-10	Longevity;
TGCT	cis	rs1775715	0.966	rs1755066	chr10:32309160	C/G	cg14930904	chr10:32216787	ARHGAP12	-0.5	-4.63	-0.38	8.96e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs16866061	0.962	rs72972361	chr2:225341550	G/A	cg12698349	chr2:225449008	CUL3	0.96	9.45	0.65	2.69e-16	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	cis	rs9372498	0.505	rs9489462	chr6:118927855	C/T	cg07617317	chr6:118971624	C6orf204	0.48	5.08	0.42	1.32e-6	Diastolic blood pressure;
TGCT	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.95	-7.12	-0.54	7.49e-11	Gut microbiome composition (summer);
TGCT	cis	rs1903068	0.597	rs10013070	chr4:55997201	A/G	cg16572876	chr4:56024045	NA	0.43	4.6	0.38	1.04e-5	Endometriosis;
TGCT	cis	rs6570726	0.791	rs6915094	chr6:145883540	C/G	cg13319975	chr6:146136371	FBXO30	-0.51	-4.6	-0.38	1.01e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7659604	1.000	rs28618203	chr4:122663935	T/C	cg19748678	chr4:122722346	EXOSC9	0.57	5.43	0.44	2.83e-7	Type 2 diabetes;
TGCT	cis	rs9467773	0.933	rs2024970	chr6:26497520	T/A	cg15659132	chr6:26577336	NA	0.63	6.72	0.52	5.88e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs7829975	0.577	rs7816329	chr8:8543843	G/A	cg06636001	chr8:8085503	FLJ10661	-0.61	-5.17	-0.42	9.06e-7	Mood instability;
TGCT	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg24675658	chr1:53192096	ZYG11B	0.7	7.98	0.58	8.42e-13	Monocyte count;
TGCT	cis	rs4919044	0.808	rs9420608	chr10:94800903	C/G	cg05127821	chr10:94822908	CYP26C1	0.74	4.83	0.4	3.95e-6	Coronary artery disease;
TGCT	cis	rs1532993	0.518	rs11097569	chr4:98602671	C/A	cg05340658	chr4:99064831	C4orf37	-0.38	-4.49	-0.37	1.58e-5	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs9419702	0.568	rs11156445	chr10:133542301	T/C	cg23460707	chr10:133558971	NA	0.42	4.83	0.4	4e-6	Survival in rectal cancer;
TGCT	cis	rs10804591	0.832	rs1075469	chr3:129340295	C/T	cg07730360	chr3:128845626	NA	0.23	4.63	0.38	9.25e-6	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Hip circumference adjusted for BMI;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7647973	0.771	rs9865051	chr3:49166069	C/T	cg07636037	chr3:49044803	WDR6	0.81	6.32	0.49	4.31e-9	Menarche (age at onset);
TGCT	cis	rs10992471	0.627	rs10820980	chr9:95253342	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.6	-5.47	-0.44	2.4e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs4523957	0.651	rs9898819	chr17:2076352	G/A	cg16513277	chr17:2031491	SMG6	-0.2	-4.64	-0.38	8.83e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs2276314	1.000	rs2298716	chr18:33552598	C/T	cg19628046	chr18:33552617	C18orf21	0.53	4.5	0.37	1.57e-5	Endometriosis;Drug-induced torsades de pointes;
TGCT	cis	rs2832191	0.755	rs55671430	chr21:30492421	G/C	cg08807101	chr21:30365312	RNF160	-0.62	-5.74	-0.46	6.74e-8	Dental caries;
TGCT	cis	rs9811920	0.809	rs793476	chr3:99541747	G/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.45	5.03	0.41	1.7e-6	Axial length;
TGCT	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg10876282	chr6:28092338	ZSCAN16	0.49	4.54	0.38	1.3e-5	Parkinson's disease;
TGCT	cis	rs12210905	1.000	rs72843611	chr6:27131382	C/T	cg08851530	chr6:28072375	NA	1.12	5.43	0.44	2.82e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs12900413	0.603	rs11629982	chr15:90300272	G/A	cg24249390	chr15:90295951	MESP1	-0.3	-5.2	-0.42	8.04e-7	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs10510102	0.872	rs74318512	chr10:123700980	G/T	cg23691251	chr10:123688108	ATE1	-0.58	-4.58	-0.38	1.11e-5	Breast cancer;
TGCT	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg08048268	chr3:133502702	NA	-0.53	-7.17	-0.54	5.89e-11	Iron status biomarkers;
TGCT	cis	rs881375	0.967	rs2416805	chr9:123676482	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.44	4.78	0.39	4.84e-6	Rheumatoid arthritis;
TGCT	cis	rs2354432	0.556	rs2353977	chr1:146839637	G/T	cg25205988	chr1:146714368	CHD1L	1.33	5.89	0.47	3.34e-8	Mitochondrial DNA levels;
TGCT	cis	rs617219	0.726	rs955897	chr5:78431486	A/C	cg23514016	chr5:78407564	BHMT	0.33	4.93	0.4	2.58e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs67311347	0.824	rs59922539	chr3:40337110	G/A	cg13683864	chr3:40499215	RPL14	-0.9	-8.68	-0.61	1.87e-14	Renal cell carcinoma;
TGCT	trans	rs1814175	0.817	rs11493756	chr11:50017885	T/C	cg15704280	chr7:45808275	SEPT13	-0.72	-8.47	-0.61	6.02e-14	Height;
TGCT	cis	rs7044106	0.762	rs13291660	chr9:123392748	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.62	6.58	0.51	1.19e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg04944784	chr2:26401820	FAM59B	-0.78	-6.56	-0.51	1.34e-9	Gut microbiome composition (summer);
TGCT	cis	rs12765878	1.000	rs2902639	chr10:105658588	G/C	cg11005552	chr10:105648138	OBFC1	0.44	7.7	0.57	3.69e-12	Coronary artery disease;
TGCT	cis	rs17594362	0.573	rs79859984	chr13:42147427	G/A	cg09909069	chr13:41860793	NA	-0.36	-4.45	-0.37	1.86e-5	Multiple sclerosis;
TGCT	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg13206674	chr6:150067644	NUP43	0.52	4.51	0.38	1.5e-5	Lung cancer;
TGCT	cis	rs7226408	0.948	rs11665642	chr18:34387438	A/C	cg06757138	chr18:34340585	FHOD3	-0.25	-4.57	-0.38	1.17e-5	Obesity-related traits;
TGCT	cis	rs6545883	0.929	rs3732171	chr2:61749690	C/T	cg15711740	chr2:61764176	XPO1	-0.59	-5.44	-0.44	2.76e-7	Tuberculosis;
TGCT	trans	rs9951602	0.512	rs77157626	chr18:76644771	C/T	cg02800362	chr5:177631904	HNRNPAB	1.13	12.94	0.76	9.39e-25	Obesity-related traits;
TGCT	cis	rs896854	0.548	rs574183	chr8:95973816	A/G	cg23172400	chr8:95962367	TP53INP1	0.37	5.94	0.47	2.74e-8	Type 2 diabetes;
TGCT	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	9.52	0.65	1.86e-16	Platelet count;
TGCT	cis	rs727563	0.635	rs713988	chr22:42159072	A/G	cg06481639	chr22:41940642	POLR3H	0.69	6.02	0.48	1.83e-8	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs9952991	0.528	rs612058	chr18:12850211	T/C	cg23544223	chr18:12777786	NA	0.55	4.88	0.4	3.22e-6	Inflammatory skin disease;
TGCT	cis	rs9902453	0.874	rs7220004	chr17:28369548	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.81	-7.67	-0.57	4.37e-12	Coffee consumption (cups per day);
TGCT	cis	rs9640161	0.789	rs3735172	chr7:150028958	C/T	cg10018233	chr7:150070692	REPIN1	-0.31	-4.62	-0.38	9.33e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs10465746	1.000	rs10465746	chr1:84387632	T/G	cg10977910	chr1:84465055	TTLL7	0.67	6.63	0.51	9.19e-10	Obesity-related traits;
TGCT	cis	rs7937682	0.889	rs578022	chr11:111490552	G/T	cg09085632	chr11:111637200	PPP2R1B	-1.05	-11.36	-0.71	6.21e-21	Primary sclerosing cholangitis;
TGCT	cis	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg03213289	chr20:61660250	NA	0.68	9.99	0.67	1.36e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs12477438	0.953	rs3851334	chr2:99794704	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.97	-8.46	-0.61	6.14e-14	Chronic sinus infection;
TGCT	cis	rs2074038	1.000	rs2074038	chr11:44087989	G/T	cg20240860	chr11:44087423	ACCS	-0.49	-4.85	-0.4	3.63e-6	IgA nephropathy;
TGCT	cis	rs9368481	0.761	rs3931464	chr6:26939856	C/A	cg18867708	chr6:26865862	GUSBL1	0.36	4.67	0.39	7.78e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs61884328	0.777	rs61897784	chr11:47154514	A/G	cg13308137	chr11:47528955	CUGBP1	0.38	4.47	0.37	1.76e-5	Total body bone mineral density (age over 60);
TGCT	cis	rs13401104	0.587	rs7569760	chr2:237145713	A/C	cg26422059	chr2:237146110	ASB18	0.57	4.56	0.38	1.19e-5	Educational attainment;
TGCT	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg06481639	chr22:41940642	POLR3H	-0.74	-6.74	-0.52	5.38e-10	Vitiligo;
TGCT	cis	rs9291683	0.551	rs2240720	chr4:10020480	C/T	cg11266682	chr4:10021025	SLC2A9	0.69	10.28	0.68	2.66e-18	Bone mineral density;
TGCT	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.46	-6.7	-0.52	6.44e-10	Alzheimer's disease;
TGCT	cis	rs16939607	0.908	rs16939604	chr8:79005681	T/A	cg21244580	chr8:79934476	NA	0.48	4.77	0.39	5e-6	White blood cell count;
TGCT	cis	rs227917	1.000	rs7803526	chr7:23686084	G/A	cg12601843	chr7:23510954	IGF2BP3	0.63	4.87	0.4	3.28e-6	Common carotid intima-media thickness in HIV negative individuals;
TGCT	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg11890956	chr21:40555474	PSMG1	-0.8	-7.51	-0.56	9.89e-12	Cognitive function;
TGCT	cis	rs10510102	0.810	rs34738294	chr10:123710872	A/G	cg23691251	chr10:123688108	ATE1	-0.59	-4.7	-0.39	6.75e-6	Breast cancer;
TGCT	cis	rs5769765	0.862	rs9616384	chr22:50313082	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.43	6.08	0.48	1.35e-8	Schizophrenia;
TGCT	cis	rs644148	0.867	rs2571060	chr19:44971647	C/G	cg15540054	chr19:45004280	ZNF180	-0.59	-5.21	-0.42	7.8e-7	Personality dimensions;
TGCT	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg12000995	chr2:27665139	KRTCAP3	-0.36	-4.45	-0.37	1.9e-5	Total body bone mineral density;
TGCT	cis	rs67311347	1.000	rs7636719	chr3:40432084	C/T	cg13683864	chr3:40499215	RPL14	-1.05	-11.13	-0.71	2.2e-20	Renal cell carcinoma;
TGCT	cis	rs9527	0.544	rs3781280	chr10:104863843	T/G	cg04362960	chr10:104952993	NT5C2	0.68	5.83	0.46	4.43e-8	Arsenic metabolism;
TGCT	cis	rs9581857	0.547	rs9581882	chr13:28110682	C/G	cg22138327	chr13:27999177	GTF3A	0.7	4.53	0.38	1.36e-5	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs4906332	0.811	rs2756138	chr14:103996733	C/G	cg26031613	chr14:104095156	KLC1	0.58	4.69	0.39	7.07e-6	Coronary artery disease;
TGCT	cis	rs763121	0.962	rs5757130	chr22:38937794	G/A	cg06022373	chr22:39101656	GTPBP1	0.74	7.38	0.55	2.04e-11	Menopause (age at onset);
TGCT	cis	rs7824557	0.564	rs7834572	chr8:11236685	C/T	cg21775007	chr8:11205619	TDH	-0.65	-6.39	-0.5	3.07e-9	Retinal vascular caliber;
TGCT	trans	rs12655019	0.920	rs75167082	chr5:56211404	T/C	cg25190722	chr1:3801660	DFFB	0.62	7.17	0.54	5.87e-11	Breast cancer (early onset);
TGCT	cis	rs6754311	0.509	rs12616520	chr2:136516748	A/T	cg07169764	chr2:136633963	MCM6	-0.71	-6.37	-0.5	3.33e-9	Mosquito bite size;
TGCT	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.91	7.44	0.56	1.45e-11	Platelet count;
TGCT	cis	rs600231	0.665	rs1616810	chr11:65220105	A/G	cg11802864	chr11:65308245	LTBP3	0.46	4.56	0.38	1.22e-5	Bone mineral density;
TGCT	cis	rs7119	0.717	rs12901100	chr15:77815558	T/A	cg27398640	chr15:77910606	LINGO1	-0.25	-4.6	-0.38	1.05e-5	Type 2 diabetes;
TGCT	cis	rs12360000	0.864	rs12767731	chr10:1907712	T/C	cg26364871	chr10:1889757	NA	0.41	4.63	0.38	9.26e-6	Metabolite levels (Dihydroxy docosatrienoic acid);
TGCT	cis	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg22857025	chr5:266934	NA	-0.31	-6.32	-0.49	4.33e-9	Breast cancer;
TGCT	cis	rs910187	0.641	rs3818011	chr20:45816566	A/G	cg27589058	chr20:45804311	EYA2	-0.35	-7.6	-0.56	6.23e-12	Migraine;
TGCT	cis	rs2688608	0.592	rs2306328	chr10:75579510	C/T	cg04320760	chr10:75533139	FUT11	-0.37	-5.72	-0.46	7.3900000000000007e-08	Inflammatory bowel disease;
TGCT	trans	rs1814175	0.626	rs1722008	chr11:49897676	A/T	cg15704280	chr7:45808275	SEPT13	-0.7	-7.79	-0.57	2.32e-12	Height;
TGCT	cis	rs7666738	0.753	rs13137152	chr4:98938044	A/T	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4149178	0.722	rs10948072	chr6:43307861	G/A	cg07522644	chr6:43142093	SRF	0.63	4.5	0.37	1.52e-5	Urate levels;
TGCT	cis	rs2862064	1.000	rs6896499	chr5:156431325	A/G	cg12943317	chr5:156479607	HAVCR1	-0.45	-5.92	-0.47	2.96e-8	Platelet count;
TGCT	cis	rs778371	0.723	rs6739794	chr2:233576165	G/A	cg08000102	chr2:233561755	GIGYF2	0.75	8.97	0.63	3.75e-15	Schizophrenia;
TGCT	cis	rs9910055	0.550	rs113844752	chr17:42297631	C/A	cg13607699	chr17:42295918	UBTF	1.14	12.78	0.75	2.21e-24	Total body bone mineral density;
TGCT	cis	rs17376456	0.569	rs2045019	chr5:93201971	C/T	cg21475434	chr5:93447410	FAM172A	-0.68	-5.22	-0.42	7.16e-7	Diabetic retinopathy;
TGCT	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-5.1	-0.42	1.23e-6	Bipolar disorder;
TGCT	cis	rs7829975	0.606	rs891570	chr8:8794454	G/A	cg15556689	chr8:8085844	FLJ10661	-0.7	-6.26	-0.49	5.66e-9	Mood instability;
TGCT	cis	rs2439831	0.850	rs8032649	chr15:44134922	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.85	-6.18	-0.48	8.67e-9	Lung cancer in ever smokers;
TGCT	cis	rs7572733	0.515	rs1401096	chr2:198823828	A/G	cg00792783	chr2:198669748	PLCL1	0.57	5.23	0.43	6.99e-7	Dermatomyositis;
TGCT	cis	rs17221829	0.965	rs72952901	chr11:89457303	A/G	cg02982614	chr11:89391479	FOLH1B	-0.27	-4.88	-0.4	3.23e-6	Anxiety in major depressive disorder;
TGCT	cis	rs4727027	0.840	rs12670633	chr7:148796707	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	4.68	0.39	7.53e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	trans	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg25206134	chr2:45395956	NA	1.1	9.34	0.64	5.11e-16	Bipolar disorder;
TGCT	cis	rs860554	0.705	rs832165	chr1:201255517	G/C	cg01022117	chr1:201258280	PKP1	0.34	5.05	0.41	1.52e-6	Panic disorder;
TGCT	trans	rs10022799	0.725	rs7683098	chr4:168137979	A/G	cg08507725	chr4:8239220	SH3TC1	0.42	7.37	0.55	2.15e-11	Cognitive function;
TGCT	cis	rs2197308	0.765	rs11182481	chr12:37926019	T/C	cg26384229	chr12:38710491	ALG10B	0.85	7.79	0.57	2.32e-12	Morning vs. evening chronotype;
TGCT	cis	rs2072499	0.932	rs3001790	chr1:156165290	T/G	cg24450063	chr1:156163899	SLC25A44	1.17	16.76	0.83	1.19e-33	Testicular germ cell tumor;
TGCT	cis	rs9638182	0.725	rs35173225	chr7:73001021	C/T	cg14087351	chr7:73037990	MLXIPL	-0.69	-5.34	-0.43	4.19e-7	Triglycerides;
TGCT	cis	rs62244186	0.520	rs2372828	chr3:44784949	A/G	cg25151919	chr3:44754333	ZNF502	0.47	5.45	0.44	2.56e-7	Depressive symptoms;
TGCT	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg23131131	chr22:24373011	LOC391322	-0.82	-8.88	-0.62	6.37e-15	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6570726	0.764	rs451108	chr6:145844309	T/C	cg05347473	chr6:146136440	FBXO30	0.52	4.84	0.4	3.75e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs950169	0.800	rs4842847	chr15:84931199	G/A	cg17173187	chr15:85201210	NMB	0.58	5.93	0.47	2.77e-8	Schizophrenia;
TGCT	cis	rs2370759	1.000	rs7910776	chr10:32639093	C/T	cg01819863	chr10:32635814	EPC1	0.93	5.54	0.45	1.75e-7	Sexual dysfunction (female);
TGCT	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg06713675	chr4:122721982	EXOSC9	-0.67	-8.88	-0.62	6.44e-15	Type 2 diabetes;
TGCT	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.62	-6.91	-0.53	2.28e-10	Blood metabolite levels;
TGCT	cis	rs8103278	1.000	rs8108590	chr19:46301620	A/G	cg14061069	chr19:46274453	DMPK	-0.41	-5.78	-0.46	5.56e-8	Coronary artery disease;
TGCT	cis	rs4925386	1.000	rs4925386	chr20:60921044	C/T	cg06026331	chr20:60912101	LAMA5	0.29	5.47	0.44	2.33e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs4566357	0.615	rs10184991	chr2:227916533	G/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-5.24	-0.43	6.55e-7	Coronary artery disease;
TGCT	cis	rs36051895	0.664	rs10121077	chr9:5098411	G/A	cg02405213	chr9:5042618	JAK2	-0.77	-10.92	-0.7	7.16e-20	Pediatric autoimmune diseases;
TGCT	cis	rs28595532	0.920	rs114653217	chr4:119769216	G/A	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs7412746	0.646	rs1972060	chr1:150937594	T/C	cg09365446	chr1:150670422	GOLPH3L	0.34	4.7	0.39	6.76e-6	Melanoma;
TGCT	cis	rs1943345	0.731	rs498292	chr11:82903283	C/T	cg07047830	chr11:82868014	PCF11	0.52	5.27	0.43	5.97e-7	Obesity-related traits;
TGCT	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg22963979	chr7:1858916	MAD1L1	-0.41	-6.66	-0.51	7.83e-10	Schizophrenia;
TGCT	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg08219700	chr8:58056026	NA	0.3	4.6	0.38	1.02e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg12570787	chr5:219185	SDHA;CCDC127	0.65	4.46	0.37	1.83e-5	Breast cancer;
TGCT	cis	rs6500602	0.727	rs7193136	chr16:4580034	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.32	5.97	0.47	2.35e-8	Schizophrenia;
TGCT	cis	rs9325144	0.560	rs10876005	chr12:39126149	C/G	cg26384229	chr12:38710491	ALG10B	-0.63	-5.87	-0.47	3.66e-8	Morning vs. evening chronotype;
TGCT	cis	rs1129187	0.782	rs9462860	chr6:42947013	G/C	cg02353165	chr6:42928485	GNMT	0.95	9.59	0.65	1.26e-16	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs7336332	0.598	rs12018313	chr13:28012266	C/A	cg22138327	chr13:27999177	GTF3A	0.81	6.35	0.5	3.66e-9	Weight;
TGCT	cis	rs8179	0.553	rs42038	chr7:92243719	A/G	cg15732164	chr7:92237376	CDK6	0.24	4.46	0.37	1.78e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
TGCT	cis	rs79349575	0.783	rs4793992	chr17:47008207	A/G	cg07967210	chr17:47022446	SNF8	0.42	5.86	0.47	3.94e-8	Type 2 diabetes;
TGCT	cis	rs11148252	0.508	rs11148260	chr13:53162643	A/C	cg00495681	chr13:53174319	NA	0.6	5.83	0.46	4.59e-8	Lewy body disease;
TGCT	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg05665937	chr4:1216051	CTBP1	0.24	4.63	0.38	8.9e-6	Obesity-related traits;
TGCT	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg20203395	chr5:56204925	C5orf35	-0.59	-4.94	-0.41	2.52e-6	Initial pursuit acceleration;
TGCT	cis	rs6835098	0.961	rs11737748	chr4:174130503	T/C	cg08422745	chr4:174089978	GALNT7	0.9	10.24	0.68	3.33e-18	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs1056107	0.931	rs10817295	chr9:114997590	T/A	cg02332936	chr9:115140584	NA	-0.25	-4.44	-0.37	1.96e-5	Colorectal cancer;
TGCT	cis	rs17270561	1.000	rs79867288	chr6:25828416	A/G	cg15022984	chr6:26056706	HIST1H1C	-0.73	-4.6	-0.38	1.02e-5	Iron status biomarkers;
TGCT	cis	rs9902453	0.899	rs1979572	chr17:28511978	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	5.41	0.44	3.13e-7	Coffee consumption (cups per day);
TGCT	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg05573699	chr3:52720067	GNL3;PBRM1	0.51	4.82	0.4	4.07e-6	Bipolar disorder;
TGCT	cis	rs916888	0.821	rs199514	chr17:44856881	G/A	cg01570182	chr17:44337453	NA	-1.02	-9.18	-0.64	1.24e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs9467711	0.606	rs9366653	chr6:26354247	G/A	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7258465	1.000	rs271624	chr19:18627953	A/G	cg06462663	chr19:18546047	ISYNA1	0.21	4.98	0.41	2.12e-6	Breast cancer;
TGCT	cis	rs6663390	0.831	rs3754172	chr1:208086878	G/T	cg03990033	chr1:208084030	CD34	0.55	5.55	0.45	1.67e-7	Facial morphology (factor 18);
TGCT	cis	rs5769707	0.749	rs8137251	chr22:50036669	G/A	cg05373962	chr22:49881684	NA	-0.33	-6.28	-0.49	5.24e-9	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs1670533	1.000	rs4690212	chr4:1054898	T/C	cg27284194	chr4:1044797	NA	0.67	5.79	0.46	5.37e-8	Recombination rate (females);
TGCT	cis	rs17433780	0.504	rs7525985	chr1:89460948	C/T	cg09516651	chr1:89888402	LOC400759	0.26	5.39	0.44	3.35e-7	Carotid intima media thickness;
TGCT	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg22968622	chr17:43663579	NA	-1.23	-10.98	-0.7	5.31e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7192750	0.586	rs8054111	chr16:71990651	A/G	cg06353428	chr16:71660113	MARVELD3	0.71	6.25	0.49	5.94e-9	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs3008870	1.000	rs2985811	chr1:67377722	G/T	cg08660285	chr1:67390436	MIER1;WDR78	1.1	12.08	0.74	1.11e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs9560113	1.000	rs9555805	chr13:112179765	C/T	cg14154082	chr13:112174009	NA	0.37	5.07	0.41	1.42e-6	Menarche (age at onset);
TGCT	cis	rs796364	0.806	rs12619136	chr2:200910347	C/A	cg17644776	chr2:200775616	C2orf69	-0.33	-5.0	-0.41	1.91e-6	Schizophrenia;
TGCT	cis	rs2046867	0.862	rs2322612	chr3:72830058	A/G	cg25664220	chr3:72788482	NA	-0.57	-7.14	-0.54	7.09e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.84	0.46	4.39e-8	Height;
TGCT	cis	rs6922617	0.786	rs11961196	chr6:41344962	A/C	cg07798131	chr6:41471673	NA	0.97	4.79	0.4	4.65e-6	Alzheimer's disease biomarkers;
TGCT	cis	rs7829975	0.511	rs2921028	chr8:8340477	T/C	cg06636001	chr8:8085503	FLJ10661	0.63	5.86	0.47	3.86e-8	Mood instability;
TGCT	cis	rs9788682	1.000	rs7181447	chr15:78814567	A/G	cg24631222	chr15:78858424	CHRNA5	0.89	7.68	0.57	4.22e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs4689388	0.856	rs3200	chr4:6304878	C/T	cg25554036	chr4:6271136	WFS1	0.56	7.87	0.58	1.51e-12	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs9926296	0.712	rs258330	chr16:89729574	T/G	cg01097406	chr16:89675127	NA	0.34	5.88	0.47	3.54e-8	Vitiligo;
TGCT	cis	rs2371030	1.000	rs12473296	chr2:211583281	A/C	cg18417063	chr2:211583084	NA	-0.31	-4.45	-0.37	1.91e-5	Non-small cell lung cancer;
TGCT	cis	rs7552404	1.000	rs4949674	chr1:76213715	C/A	cg22875332	chr1:76189707	ACADM	0.76	9.2	0.64	1.1e-15	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs10464366	0.544	rs12668821	chr7:39167846	T/A	cg18850127	chr7:39170497	POU6F2	0.33	7.16	0.54	6.13e-11	IgG glycosylation;
TGCT	cis	rs7818688	0.697	rs76215523	chr8:95987015	T/C	cg16049864	chr8:95962084	TP53INP1	0.54	4.64	0.38	8.87e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs797680	0.927	rs797675	chr1:93674226	A/T	cg17826107	chr1:92977322	EVI5	-0.24	-5.3	-0.43	5.16e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs57590327	0.555	rs3755713	chr3:81811224	A/G	cg07356753	chr3:81810745	GBE1	-0.73	-6.73	-0.52	5.57e-10	Extraversion;
TGCT	cis	rs7615952	0.932	rs6438948	chr3:125650045	A/T	cg05084668	chr3:125655381	ALG1L	0.73	6.26	0.49	5.78e-9	Blood pressure (smoking interaction);
TGCT	cis	rs2439831	0.867	rs28461955	chr15:43661459	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	6.61	0.51	1e-9	Lung cancer in ever smokers;
TGCT	cis	rs7267979	0.844	rs35735333	chr20:25337205	T/G	cg14121845	chr20:25566513	NINL	-0.45	-4.6	-0.38	1.02e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg26513180	chr16:89883248	FANCA	1.04	14.31	0.79	4.97e-28	Vitiligo;
TGCT	cis	rs2354432	0.607	rs6593751	chr1:146726023	A/G	cg25205988	chr1:146714368	CHD1L	-1.34	-6.07	-0.48	1.44e-8	Mitochondrial DNA levels;
TGCT	cis	rs734999	0.588	rs6668149	chr1:2558308	A/C	cg18854424	chr1:2615690	NA	-0.45	-5.15	-0.42	1e-6	Ulcerative colitis;
TGCT	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg27588902	chr6:42928151	GNMT	0.44	5.23	0.43	7e-7	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs7267979	1.000	rs7018	chr20:25278261	A/G	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs854765	0.505	rs4506969	chr17:17899839	A/G	cg04398451	chr17:18023971	MYO15A	-0.31	-4.87	-0.4	3.26e-6	Total body bone mineral density;
TGCT	cis	rs62283056	0.512	rs10028875	chr4:6283460	C/T	cg25554036	chr4:6271136	WFS1	0.53	6.86	0.52	2.94e-10	Cisplatin-induced ototoxicity;
TGCT	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg16680214	chr1:154839983	KCNN3	-0.36	-7.26	-0.55	3.81e-11	Prostate cancer;
TGCT	cis	rs854765	0.547	rs9897761	chr17:17912011	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.79	8.4	0.6	8.61e-14	Total body bone mineral density;
TGCT	cis	rs611744	0.507	rs1579924	chr8:109324884	G/T	cg21045802	chr8:109455806	TTC35	0.75	7.56	0.56	7.59e-12	Dupuytren's disease;
TGCT	cis	rs9921338	0.961	rs7191093	chr16:11442279	A/G	cg00044050	chr16:11439710	C16orf75	-0.87	-6.68	-0.51	7.37e-10	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs12765878	1.000	rs11191847	chr10:105650626	G/C	cg11005552	chr10:105648138	OBFC1	0.44	7.7	0.57	3.69e-12	Coronary artery disease;
TGCT	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.29	-4.49	-0.37	1.64e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9858542	0.537	rs2304442	chr3:49322027	A/T	cg00383909	chr3:49044727	WDR6	-0.65	-4.49	-0.37	1.6e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs7727544	0.513	rs10065787	chr5:131436486	G/T	cg24060327	chr5:131705240	SLC22A5	-0.48	-4.8	-0.4	4.57e-6	Blood metabolite levels;
TGCT	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs11098499	0.908	rs7695996	chr4:120322033	C/T	cg09307838	chr4:120376055	NA	0.68	6.45	0.5	2.25e-9	Corneal astigmatism;
TGCT	cis	rs3796352	0.881	rs13100714	chr3:53074824	T/G	cg27565382	chr3:53032988	SFMBT1	0.43	4.62	0.38	9.64e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	trans	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg17830980	chr10:43048298	ZNF37B	0.87	11.26	0.71	1.1e-20	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7917772	0.546	rs10883743	chr10:104338389	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	5.36	0.43	3.84e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9952991	0.883	rs2847293	chr18:12782448	A/T	cg23544223	chr18:12777786	NA	0.63	6.02	0.48	1.85e-8	Inflammatory skin disease;
TGCT	cis	rs4891159	0.790	rs72975930	chr18:74144645	G/A	cg24786174	chr18:74118243	ZNF516	-0.53	-6.98	-0.53	1.6e-10	Longevity;
TGCT	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg17971929	chr21:40555470	PSMG1	-0.51	-4.47	-0.37	1.74e-5	Menarche (age at onset);
TGCT	cis	rs9467773	1.000	rs6456733	chr6:26566804	C/T	cg26531700	chr6:26746687	NA	0.5	4.85	0.4	3.64e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.753	rs11097607	chr4:99011640	C/T	cg17366294	chr4:99064904	C4orf37	0.68	7.04	0.53	1.17e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9660992	0.686	rs1668870	chr1:205239031	C/G	cg00857998	chr1:205179979	DSTYK	0.52	4.56	0.38	1.19e-5	Mean corpuscular volume;Mean platelet volume;
TGCT	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.97	-7.19	-0.54	5.48e-11	Gut microbiome composition (summer);
TGCT	cis	rs3027009	0.881	rs12042284	chr1:159132649	A/C	cg24432768	chr1:158149974	CD1D	-0.48	-4.76	-0.39	5.25e-6	Lean body mass and age at menarche (combined);
TGCT	cis	rs523522	0.962	rs3759394	chr12:120933173	C/A	cg27279351	chr12:120934652	DYNLL1	0.76	6.59	0.51	1.15e-9	High light scatter reticulocyte count;
TGCT	cis	rs2549003	1.000	rs2548999	chr5:131831058	G/T	cg02551604	chr5:131831745	NA	0.9	12.24	0.74	4.6e-23	Asthma (sex interaction);
TGCT	cis	rs9467773	0.620	rs2504565	chr6:26656890	G/A	cg05738196	chr6:26577821	NA	0.88	10.62	0.69	3.92e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs2188554	0.771	rs213951	chr7:117202434	A/G	cg08576598	chr7:116962626	WNT2	-0.36	-4.56	-0.38	1.23e-5	Esophageal adenocarcinoma;
TGCT	cis	rs10832963	1.000	rs7943121	chr11:18656062	G/C	cg20219074	chr11:18656078	SPTY2D1	0.98	9.9	0.66	2.19e-17	Breast cancer;
TGCT	cis	rs61884328	0.733	rs57012996	chr11:47194924	T/G	cg13308137	chr11:47528955	CUGBP1	0.38	4.48	0.37	1.65e-5	Total body bone mineral density (age over 60);
TGCT	cis	rs2404602	1.000	rs2404741	chr15:76851735	C/T	cg22467129	chr15:76604101	ETFA	-0.58	-6.68	-0.51	7.09e-10	Blood metabolite levels;
TGCT	trans	rs62103177	0.810	rs62103189	chr18:77627815	G/A	cg05926928	chr17:57297772	GDPD1	1.22	11.16	0.71	1.85e-20	Opioid sensitivity;
TGCT	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg07332563	chr6:291687	DUSP22	-0.76	-7.73	-0.57	3.11e-12	Menopause (age at onset);
TGCT	cis	rs10484885	0.824	rs72919954	chr6:90515665	T/A	cg13799429	chr6:90582589	CASP8AP2	-0.47	-4.51	-0.38	1.46e-5	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs6988636	1.000	rs28670850	chr8:124189125	A/G	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs8033133	0.602	rs3803326	chr15:25328715	A/G	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	-0.25	-4.89	-0.4	3.04e-6	Blood osmolality (transformed sodium);
TGCT	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg24250549	chr1:154909240	PMVK	0.65	6.41	0.5	2.78e-9	Prostate cancer;
TGCT	cis	rs7394190	0.748	rs11000764	chr10:75506864	A/G	cg07699608	chr10:75541558	CHCHD1	0.77	4.86	0.4	3.48e-6	Incident atrial fibrillation;
TGCT	cis	rs9534288	0.830	rs2404963	chr13:46632836	C/T	cg15192986	chr13:46630673	CPB2	-0.5	-6.23	-0.49	6.66e-9	Blood protein levels;
TGCT	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.18	0.49	8.32e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs514406	0.505	rs431459	chr1:53183230	T/G	cg08859206	chr1:53392774	SCP2	-0.35	-5.18	-0.42	8.58e-7	Monocyte count;
TGCT	cis	rs10057188	0.903	rs10064912	chr5:77909527	C/G	cg21097283	chr5:76934461	OTP	0.47	4.49	0.37	1.62e-5	Pulse pressure;
TGCT	cis	rs4517514	0.509	rs10765252	chr11:89875664	C/T	cg14505434	chr11:89522851	NA	0.45	4.45	0.37	1.87e-5	Trans fatty acid levels;
TGCT	cis	rs7432375	0.901	rs6802702	chr3:136489563	G/A	cg12473912	chr3:136751656	NA	-0.36	-5.11	-0.42	1.17e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9926296	0.656	rs2376882	chr16:89827002	T/C	cg04287289	chr16:89883240	FANCA	0.64	6.51	0.5	1.69e-9	Vitiligo;
TGCT	cis	rs74233809	1.000	rs12221193	chr10:104665267	A/C	cg05855489	chr10:104503620	C10orf26	0.74	4.45	0.37	1.87e-5	Birth weight;
TGCT	cis	rs6754311	0.544	rs11693502	chr2:136808949	C/T	cg07169764	chr2:136633963	MCM6	-0.57	-5.55	-0.45	1.65e-7	Mosquito bite size;
TGCT	cis	rs2404602	0.684	rs10851888	chr15:76902506	C/T	cg22467129	chr15:76604101	ETFA	0.47	4.61	0.38	9.77e-6	Blood metabolite levels;
TGCT	cis	rs2997447	0.637	rs2000403	chr1:26410161	A/G	cg03844060	chr1:26490628	NA	0.28	4.57	0.38	1.17e-5	QRS complex (12-leadsum);
TGCT	cis	rs651907	0.737	rs9844218	chr3:101584983	C/T	cg11279151	chr3:101281821	RG9MTD1	0.25	5.18	0.42	8.81e-7	Colorectal cancer;
TGCT	cis	rs5750830	0.594	rs9611166	chr22:39775268	T/C	cg05872129	chr22:39784769	NA	-0.84	-8.83	-0.62	8.39e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs854765	0.583	rs11078406	chr17:17840823	G/T	cg09796270	chr17:17721594	SREBF1	0.24	4.78	0.39	4.92e-6	Total body bone mineral density;
TGCT	cis	rs7402982	0.934	rs8027457	chr15:99204101	A/G	cg03437748	chr15:99193247	IGF1R	0.55	6.05	0.48	1.57e-8	Birth weight;
TGCT	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.51	-5.02	-0.41	1.78e-6	Prudent dietary pattern;
TGCT	cis	rs6714710	0.603	rs11679828	chr2:98517626	G/A	cg26665480	chr2:98280029	ACTR1B	0.64	6.06	0.48	1.48e-8	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs2204008	0.777	rs8189597	chr12:38307739	G/C	cg13010199	chr12:38710504	ALG10B	-0.6	-4.7	-0.39	6.73e-6	Bladder cancer;
TGCT	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg11764359	chr7:65958608	NA	0.58	5.31	0.43	4.91e-7	Aortic root size;
TGCT	cis	rs854765	0.647	rs854818	chr17:18022039	A/C	cg04398451	chr17:18023971	MYO15A	-0.39	-6.81	-0.52	3.78e-10	Total body bone mineral density;
TGCT	cis	rs7772486	0.790	rs9403749	chr6:146162239	A/G	cg13319975	chr6:146136371	FBXO30	-0.53	-4.77	-0.39	5.05e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4713118	0.868	rs760587	chr6:27740300	C/A	cg20933634	chr6:27740509	NA	0.35	4.72	0.39	6.38e-6	Parkinson's disease;
TGCT	cis	rs9325144	0.647	rs12229104	chr12:39110811	T/A	cg26384229	chr12:38710491	ALG10B	-0.57	-5.3	-0.43	5.16e-7	Morning vs. evening chronotype;
TGCT	cis	rs2404602	0.692	rs3110382	chr15:77148688	G/A	cg22467129	chr15:76604101	ETFA	0.47	5.4	0.44	3.26e-7	Blood metabolite levels;
TGCT	cis	rs7666738	0.830	rs9998803	chr4:99002519	C/T	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7552404	0.556	rs12124417	chr1:76353294	T/C	cg10523679	chr1:76189770	ACADM	0.74	6.8	0.52	4.01e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7020830	0.898	rs12000309	chr9:37230844	G/A	cg14294708	chr9:37120828	ZCCHC7	1.26	18.08	0.85	1.49e-36	Schizophrenia;
TGCT	cis	rs6840360	0.806	rs11932383	chr4:152716136	T/C	cg22705602	chr4:152727874	NA	0.25	4.61	0.38	9.95e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs10028505	chr4:98962310	C/A	cg18180107	chr4:99064573	C4orf37	0.57	5.18	0.42	8.63e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4746818	1.000	rs906217	chr10:70954661	T/C	cg11621586	chr10:70884670	VPS26A	1.1	7.75	0.57	2.8e-12	Left atrial antero-posterior diameter;
TGCT	cis	rs11105298	0.891	rs10858900	chr12:89925081	C/A	cg00757033	chr12:89920650	WDR51B	0.31	4.92	0.4	2.7e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs478304	0.654	rs10896034	chr11:65460783	T/A	cg27068330	chr11:65405492	SIPA1	-0.99	-11.32	-0.71	7.67e-21	Acne (severe);
TGCT	cis	rs9362426	1.000	rs414013	chr6:88085866	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.46	5.19	0.42	8.5e-7	Depressive episodes in bipolar disorder;
TGCT	cis	rs4443100	0.670	rs9612225	chr22:23406619	G/A	cg14186256	chr22:23484241	RTDR1	0.57	4.47	0.37	1.76e-5	Serum parathyroid hormone levels;
TGCT	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg16325326	chr1:53192061	ZYG11B	-0.71	-8.81	-0.62	9.22e-15	Monocyte count;
TGCT	cis	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg12570787	chr5:219185	SDHA;CCDC127	0.68	4.49	0.37	1.59e-5	Breast cancer;
TGCT	cis	rs938554	0.513	rs3733588	chr4:9997303	A/G	cg11266682	chr4:10021025	SLC2A9	-0.57	-5.99	-0.47	2.07e-8	Blood metabolite levels;
TGCT	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg06238570	chr21:40685208	BRWD1	0.67	5.95	0.47	2.5e-8	Cognitive function;
TGCT	cis	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg18252515	chr7:66147081	NA	-1.06	-6.34	-0.49	3.94e-9	Diabetic kidney disease;
TGCT	cis	rs4889855	0.530	rs4890052	chr17:78564245	G/T	cg16591659	chr17:78472290	NA	0.28	4.46	0.37	1.84e-5	Fractional excretion of uric acid;
TGCT	cis	rs7412746	0.611	rs4509581	chr1:150774465	A/G	cg04414720	chr1:150670196	GOLPH3L	0.38	4.73	0.39	6.04e-6	Melanoma;
TGCT	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg21724239	chr8:58056113	NA	0.4	5.01	0.41	1.8e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg05665937	chr4:1216051	CTBP1	0.25	4.75	0.39	5.64e-6	Obesity-related traits;
TGCT	cis	rs7085104	0.632	rs4290163	chr10:104610926	G/T	cg15744005	chr10:104629667	AS3MT	-0.46	-5.87	-0.47	3.68e-8	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs7914558	1.000	rs4917996	chr10:104925829	A/C	cg15744005	chr10:104629667	AS3MT	-0.39	-4.75	-0.39	5.53e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs4808199	0.948	rs2301668	chr19:19452249	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.69	5.33	0.43	4.49e-7	Nonalcoholic fatty liver disease;
TGCT	cis	rs9372498	0.505	rs72956993	chr6:118949708	A/T	cg07617317	chr6:118971624	C6orf204	0.48	5.08	0.42	1.32e-6	Diastolic blood pressure;
TGCT	cis	rs7246657	0.882	rs28623164	chr19:37913453	G/A	cg18154014	chr19:37997991	ZNF793	0.73	5.38	0.44	3.53e-7	Coronary artery calcification;
TGCT	cis	rs709400	0.633	rs10141433	chr14:103962559	A/G	cg26031613	chr14:104095156	KLC1	0.84	9.5	0.65	2.08e-16	Body mass index;
TGCT	cis	rs17030434	0.728	rs2124641	chr4:154645810	T/C	cg14289246	chr4:154710475	SFRP2	0.8	5.87	0.47	3.66e-8	Electrocardiographic conduction measures;
TGCT	cis	rs6964587	0.967	rs10280620	chr7:91582183	C/G	cg17063962	chr7:91808500	NA	-0.91	-9.99	-0.67	1.32e-17	Breast cancer;
TGCT	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg27588902	chr6:42928151	GNMT	-0.56	-6.8	-0.52	4.02e-10	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs2439831	0.702	rs28699233	chr15:44122866	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	5.79	0.46	5.46e-8	Lung cancer in ever smokers;
TGCT	cis	rs11971779	0.680	rs7801613	chr7:139039927	A/G	cg07862535	chr7:139043722	LUC7L2	-0.57	-4.52	-0.38	1.42e-5	Diisocyanate-induced asthma;
TGCT	cis	rs7647973	0.925	rs7429661	chr3:49228800	G/A	cg07636037	chr3:49044803	WDR6	0.65	5.26	0.43	6.25e-7	Menarche (age at onset);
TGCT	cis	rs9905704	0.647	rs3809723	chr17:57061978	T/G	cg05425664	chr17:57184151	TRIM37	-0.58	-4.71	-0.39	6.56e-6	Testicular germ cell tumor;
TGCT	cis	rs2856321	1.000	rs11054423	chr12:11859731	A/G	cg11375112	chr12:11883006	ETV6	0.3	4.48	0.37	1.67e-5	Height;
TGCT	cis	rs651907	0.535	rs12631513	chr3:101517476	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	4.85	0.4	3.68e-6	Colorectal cancer;
TGCT	cis	rs9467711	0.659	rs66757203	chr6:26454956	C/T	cg16898833	chr6:26189333	HIST1H4D	1.24	5.8	0.46	5.12e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs10504229	1.000	rs59708460	chr8:58196526	G/A	cg22535103	chr8:58192502	C8orf71	-0.39	-4.55	-0.38	1.24e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs10986311	0.802	rs7049097	chr9:127110457	G/A	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.19	4.86	0.4	3.52e-6	Vitiligo;
TGCT	cis	rs2255336	0.616	rs6488285	chr12:10518706	G/A	cg16084090	chr12:10586130	KLRC2	0.3	4.62	0.38	9.55e-6	Blood protein levels;
TGCT	cis	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg21285383	chr16:89894308	SPIRE2	-0.34	-4.71	-0.39	6.54e-6	Vitiligo;
TGCT	cis	rs9527	0.525	rs12770034	chr10:104635595	A/G	cg15744005	chr10:104629667	AS3MT	-0.47	-5.86	-0.47	3.9e-8	Arsenic metabolism;
TGCT	cis	rs2980439	0.557	rs2976876	chr8:8318850	T/C	cg06636001	chr8:8085503	FLJ10661	0.79	7.34	0.55	2.4e-11	Neuroticism;
TGCT	cis	rs4595586	0.545	rs2197940	chr12:39401937	C/T	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs11792861	0.816	rs744980	chr9:111690388	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.53	4.92	0.4	2.68e-6	Menarche (age at onset);
TGCT	cis	rs2404602	0.716	rs66754747	chr15:76828568	G/A	cg26408565	chr15:76604113	ETFA	-0.37	-4.74	-0.39	5.83e-6	Blood metabolite levels;
TGCT	trans	rs66573146	0.634	rs56097119	chr4:7018692	C/G	cg07817883	chr1:32538562	TMEM39B	1.28	7.0	0.53	1.39e-10	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs8013055	0.796	rs4074937	chr14:106000977	A/G	cg25008857	chr14:105974488	NA	0.26	4.67	0.39	7.64e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs1577917	0.916	rs12203358	chr6:86603224	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-5.6	-0.45	1.34e-7	Response to antipsychotic treatment;
TGCT	cis	rs6484504	0.532	rs2150212	chr11:31255935	G/A	cg14844989	chr11:31128820	NA	-0.25	-4.84	-0.4	3.76e-6	Red blood cell count;
TGCT	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg06618935	chr21:46677482	NA	-0.37	-5.56	-0.45	1.58e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs981844	0.712	rs4292309	chr4:154745178	C/A	cg14289246	chr4:154710475	SFRP2	-0.99	-9.12	-0.63	1.65e-15	Response to statins (LDL cholesterol change);
TGCT	trans	rs28595532	0.557	rs4359977	chr4:119314055	T/C	cg26518628	chr1:97050305	NA	-0.5	-7.26	-0.55	3.79e-11	Cannabis dependence symptom count;
TGCT	cis	rs75686122	0.892	rs57252025	chr8:104547758	G/A	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs9787249	0.874	rs12094291	chr1:40226046	G/A	cg19912559	chr1:40204330	PPIE	0.47	5.5	0.44	2.05e-7	Blood protein levels;
TGCT	cis	rs10186029	0.509	rs6718004	chr2:213945280	A/T	cg08319019	chr2:214017104	IKZF2	0.61	4.57	0.38	1.14e-5	Systemic sclerosis;
TGCT	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg04267008	chr7:1944627	MAD1L1	-0.38	-4.85	-0.4	3.61e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs4803468	1.000	rs1043413	chr19:41939297	C/G	cg09537434	chr19:41945824	ATP5SL	0.91	10.21	0.68	3.82e-18	Height;
TGCT	cis	rs7542091	0.648	rs688464	chr1:209992539	C/T	cg21951975	chr1:209979733	IRF6	-0.57	-6.17	-0.48	8.98e-9	Monobrow;
TGCT	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg05872129	chr22:39784769	NA	0.94	10.97	0.7	5.66e-20	IgG glycosylation;
TGCT	cis	rs2456568	0.802	rs10765640	chr11:93636462	C/T	cg17595323	chr11:93583763	C11orf90	-0.47	-6.44	-0.5	2.38e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg06238570	chr21:40685208	BRWD1	-0.83	-9.08	-0.63	2.06e-15	Cognitive function;
TGCT	cis	rs12780845	0.540	rs6602180	chr10:17192362	T/C	cg01003015	chr10:17271136	VIM	0.58	5.25	0.43	6.37e-7	Homocysteine levels;
TGCT	cis	rs4704846	1.000	rs415392	chr5:156546990	C/T	cg12943317	chr5:156479607	HAVCR1	-0.31	-4.51	-0.38	1.51e-5	Blood protein levels;
TGCT	cis	rs554111	0.656	rs10799682	chr1:21424030	G/C	cg01072550	chr1:21505969	NA	0.36	5.46	0.44	2.51e-7	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs829883	0.639	rs829898	chr12:98857675	A/C	cg25150519	chr12:98850993	NA	0.64	7.54	0.56	8.56e-12	Colorectal adenoma (advanced);
TGCT	cis	rs909002	0.800	rs4949454	chr1:32099041	A/G	cg11573219	chr1:32083031	HCRTR1	0.43	5.6	0.45	1.33e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9894429	0.789	rs8074989	chr17:79598728	G/C	cg21028142	chr17:79581711	NPLOC4	0.3	7.03	0.53	1.2e-10	Eye color traits;
TGCT	cis	rs763121	0.925	rs9611008	chr22:39098787	T/C	cg06022373	chr22:39101656	GTPBP1	0.76	7.85	0.58	1.7e-12	Menopause (age at onset);
TGCT	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	trans	rs8073060	0.586	rs225307	chr17:33918311	A/G	cg19694781	chr19:47549865	TMEM160	0.6	13.04	0.76	5.29e-25	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs873946	0.689	rs2803993	chr10:134550606	T/C	cg26818010	chr10:134567672	INPP5A	-0.34	-4.51	-0.38	1.51e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg24675658	chr1:53192096	ZYG11B	-0.8	-9.75	-0.66	5.01e-17	Monocyte count;
TGCT	cis	rs6542838	0.702	rs4851177	chr2:99535188	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.57	-5.44	-0.44	2.74e-7	Fear of minor pain;
TGCT	trans	rs696279	0.967	rs697510	chr7:16700553	C/T	cg14841483	chr5:131310671	ACSL6	0.4	7.04	0.53	1.19e-10	Mean platelet volume;
TGCT	cis	rs57244997	0.790	rs73026528	chr6:162384271	T/C	cg17173639	chr6:162384350	PARK2	-0.5	-4.69	-0.39	7.19e-6	Mosquito bite size;
TGCT	cis	rs77106637	1.000	rs3862791	chr11:72501002	C/T	cg03713592	chr11:72463424	ARAP1	0.97	6.35	0.5	3.68e-9	Type 2 diabetes;
TGCT	cis	rs939574	0.818	rs6744146	chr2:220070597	T/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-1.06	-6.52	-0.51	1.6e-9	Platelet distribution width;
TGCT	cis	rs9814567	1.000	rs9968172	chr3:134231251	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.97	9.45	0.65	2.73e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs2072499	0.778	rs2842868	chr1:156196407	A/C	cg24450063	chr1:156163899	SLC25A44	1.03	9.7	0.66	6.78e-17	Testicular germ cell tumor;
TGCT	cis	rs12615966	1.000	rs6744707	chr2:105371087	G/A	cg16465502	chr2:105461796	NA	0.81	4.47	0.37	1.76e-5	Pancreatic cancer;
TGCT	cis	rs9814567	0.964	rs4539979	chr3:134287597	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.91	-8.83	-0.62	8.17e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs806215	0.526	rs62481419	chr7:127488007	A/G	cg11539674	chr7:127291444	SND1	-0.36	-4.67	-0.39	7.77e-6	Type 2 diabetes;
TGCT	trans	rs10802346	0.524	rs10802356	chr1:246385857	T/C	cg22732515	chr19:44031385	ETHE1	0.83	6.62	0.51	9.79e-10	Fractional exhaled nitric oxide (childhood);
TGCT	trans	rs4332037	0.901	rs11767040	chr7:1945468	C/T	cg10840412	chr1:235813424	GNG4	1.03	8.1	0.59	4.34e-13	Bipolar disorder;
TGCT	cis	rs6459804	0.566	rs113592117	chr7:157511889	C/A	cg14168080	chr7:157504135	PTPRN2	-0.42	-4.89	-0.4	3.08e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs9467773	0.901	rs1407045	chr6:26476155	A/G	cg09904177	chr6:26538194	HMGN4	0.59	5.55	0.45	1.66e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2729354	1.000	rs2729354	chr11:57355970	A/G	cg24343310	chr11:57249947	NA	0.28	4.8	0.4	4.5e-6	Blood protein levels;
TGCT	cis	rs1971136	1	rs1971136	chr2:25291539	C/T	cg15423357	chr2:25149977	NA	-0.6	-6.12	-0.48	1.15e-8	Breast cancer;
TGCT	cis	rs739496	0.947	rs2239195	chr12:111881309	G/T	cg10833066	chr12:111807467	FAM109A	0.37	5.2	0.42	8.01e-7	Platelet count;
TGCT	cis	rs3087591	0.708	rs67065748	chr17:29605631	T/A	cg24425628	chr17:29625626	OMG;NF1	0.47	7.21	0.54	4.8e-11	Hip circumference;
TGCT	cis	rs11239930	0.538	rs9663073	chr1:146554571	A/G	cg00044796	chr1:146552390	NA	-0.34	-4.46	-0.37	1.84e-5	AIDS progression;
TGCT	cis	rs78366141	0.649	rs77135481	chr4:89689680	T/C	cg01026744	chr4:89619053	NAP1L5;HERC3	1.26	5.58	0.45	1.43e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
TGCT	cis	rs4455778	0.538	rs6583513	chr7:49123526	G/A	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs1008375	0.966	rs3775925	chr4:17588437	A/G	cg16339924	chr4:17578868	LAP3	0.8	6.96	0.53	1.73e-10	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs67311347	1.000	rs1004655	chr3:40490009	G/A	cg13409248	chr3:40428643	ENTPD3	0.57	4.6	0.38	1.03e-5	Renal cell carcinoma;
TGCT	cis	rs11779988	0.629	rs11780813	chr8:17856014	T/C	cg01800426	chr8:17659068	MTUS1	-0.55	-4.77	-0.39	5e-6	Breast cancer;
TGCT	cis	rs9911578	1.000	rs172565	chr17:56808996	A/T	cg05425664	chr17:57184151	TRIM37	-0.63	-6.26	-0.49	5.86e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7647973	0.626	rs62262722	chr3:49769419	G/C	cg03034192	chr3:50606346	HEMK1;C3orf18	-0.36	-4.59	-0.38	1.08e-5	Menarche (age at onset);
TGCT	cis	rs67478160	0.619	rs3742365	chr14:104198251	A/G	cg26031613	chr14:104095156	KLC1	-0.72	-7.35	-0.55	2.38e-11	Schizophrenia;
TGCT	cis	rs2251381	0.778	rs2471947	chr21:30534219	G/T	cg24692254	chr21:30365293	RNF160	0.76	7.56	0.56	7.88e-12	Selective IgA deficiency;
TGCT	cis	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg25427524	chr10:38739819	LOC399744	-0.4	-8.5	-0.61	5.12e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg03709012	chr19:19516395	GATAD2A	-0.69	-5.76	-0.46	6.23e-8	Tonsillectomy;
TGCT	cis	rs9611565	0.592	rs80477	chr22:42001183	C/T	cg06634786	chr22:41940651	POLR3H	0.83	7.74	0.57	3.07e-12	Vitiligo;
TGCT	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.45	-5.37	-0.43	3.72e-7	Alzheimer's disease;
TGCT	cis	rs1577917	1.000	rs12154056	chr6:86634094	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.54	-0.45	1.73e-7	Response to antipsychotic treatment;
TGCT	cis	rs921968	0.643	rs13431399	chr2:219469498	G/C	cg02176678	chr2:219576539	TTLL4	-0.49	-6.85	-0.52	3.03e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs514406	0.683	rs10157120	chr1:53210888	A/G	cg25767906	chr1:53392781	SCP2	-0.44	-4.87	-0.4	3.27e-6	Monocyte count;
TGCT	cis	rs751728	0.965	rs9394168	chr6:33759701	T/A	cg13859433	chr6:33739653	LEMD2	-0.39	-7.23	-0.54	4.25e-11	Crohn's disease;
TGCT	cis	rs6430585	0.583	rs73957037	chr2:136588031	C/A	cg07169764	chr2:136633963	MCM6	1.05	9.48	0.65	2.35e-16	Corneal structure;
TGCT	cis	rs36051895	0.589	rs7874785	chr9:5196695	C/T	cg02405213	chr9:5042618	JAK2	0.69	8.29	0.6	1.62e-13	Pediatric autoimmune diseases;
TGCT	cis	rs929354	0.742	rs11980541	chr7:156988776	G/C	cg05182265	chr7:156933206	UBE3C	-0.39	-8.79	-0.62	1.03e-14	Body mass index;
TGCT	cis	rs9921338	0.924	rs7202024	chr16:11440758	A/G	cg00044050	chr16:11439710	C16orf75	-0.87	-6.68	-0.51	7.37e-10	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs7267979	0.844	rs869358	chr20:25374674	A/G	cg03522245	chr20:25566470	NINL	-0.55	-5.55	-0.45	1.68e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2066819	1.000	rs17118439	chr12:56667604	C/T	cg26714650	chr12:56694279	CS	1.36	6.06	0.48	1.54e-8	Psoriasis vulgaris;
TGCT	cis	rs6088590	1.000	rs6120747	chr20:33449769	T/C	cg24642439	chr20:33292090	TP53INP2	0.71	6.23	0.49	6.54e-9	Coronary artery disease;
TGCT	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	5.02	0.41	1.74e-6	Prudent dietary pattern;
TGCT	trans	rs797680	0.927	rs797675	chr1:93674226	A/T	cg27528825	chr2:159282178	CCDC148	-0.34	-6.7	-0.52	6.63e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg05985448	chr10:134359359	INPP5A	0.23	4.97	0.41	2.19e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs7666738	0.830	rs2903152	chr4:99067992	A/G	cg17366294	chr4:99064904	C4orf37	0.73	7.45	0.56	1.4e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs80282103	0.867	rs11250242	chr10:1100064	A/C	cg08668510	chr10:1095578	IDI1	-1.35	-5.47	-0.44	2.36e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs854765	0.547	rs7223696	chr17:17915791	G/T	cg04398451	chr17:18023971	MYO15A	-0.31	-5.05	-0.41	1.56e-6	Total body bone mineral density;
TGCT	cis	rs3760982	0.546	rs73048681	chr19:44289945	T/C	cg12072164	chr19:44306565	LYPD5	0.4	5.45	0.44	2.63e-7	Breast cancer (estrogen-receptor negative);Breast cancer;
TGCT	cis	rs3087591	0.708	rs4794887	chr17:29649696	G/A	cg24425628	chr17:29625626	OMG;NF1	0.4	5.63	0.45	1.14e-7	Hip circumference;
TGCT	cis	rs881375	1.000	rs4323544	chr9:123647377	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.39	4.47	0.37	1.74e-5	Rheumatoid arthritis;
TGCT	cis	rs7918232	1.000	rs6482595	chr10:27380261	A/G	cg14442939	chr10:27389572	ANKRD26	-0.75	-6.32	-0.49	4.22e-9	Breast cancer;
TGCT	cis	rs6988636	1.000	rs61422480	chr8:124188940	C/A	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg20637647	chr7:64974828	NA	-0.9	-5.31	-0.43	4.87e-7	Diabetic kidney disease;
TGCT	cis	rs4494114	0.967	rs9438977	chr1:39354958	A/G	cg25970120	chr1:39325951	RRAGC	-0.54	-5.5	-0.44	2.07e-7	Blood protein levels;
TGCT	cis	rs6964587	1.000	rs60147309	chr7:91736098	C/G	cg17063962	chr7:91808500	NA	0.87	9.34	0.64	4.87e-16	Breast cancer;
TGCT	cis	rs2836974	0.565	rs2836939	chr21:40578546	C/T	cg11644478	chr21:40555479	PSMG1	0.77	5.8	0.46	5.23e-8	Cognitive function;
TGCT	trans	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg25482853	chr8:67687455	SGK3	1.2	10.12	0.67	6.42e-18	Lung disease severity in cystic fibrosis;
TGCT	cis	rs1729951	0.575	rs361237	chr3:136702414	A/G	cg21827317	chr3:136751795	NA	0.37	5.2	0.42	8.02e-7	Neuroticism;
TGCT	cis	rs2197308	0.765	rs7295711	chr12:37903631	C/T	cg13010199	chr12:38710504	ALG10B	0.67	5.38	0.44	3.57e-7	Morning vs. evening chronotype;
TGCT	cis	rs2439831	0.867	rs2614811	chr15:43913487	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.91	6.47	0.5	2.09e-9	Lung cancer in ever smokers;
TGCT	cis	rs1153858	1.000	rs16942000	chr15:45633003	C/T	cg26924012	chr15:45694286	SPATA5L1	1.07	14.56	0.79	1.32e-28	Homoarginine levels;
TGCT	cis	rs826838	0.935	rs11169508	chr12:39173385	C/T	cg26384229	chr12:38710491	ALG10B	1.0	8.98	0.63	3.56e-15	Heart rate;
TGCT	cis	rs9926296	0.632	rs7184315	chr16:89799373	C/G	cg04287289	chr16:89883240	FANCA	-0.64	-6.49	-0.5	1.82e-9	Vitiligo;
TGCT	cis	rs3858526	0.883	rs10769326	chr11:5934358	C/T	cg05234568	chr11:5960015	NA	-0.45	-4.58	-0.38	1.13e-5	DNA methylation (variation);
TGCT	cis	rs67385638	0.962	rs2187608	chr11:5269931	G/C	cg12559170	chr11:5275217	HBG2	0.49	9.25	0.64	8.41e-16	Hemoglobin levels;
TGCT	cis	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg05590025	chr7:65112418	INTS4L2	-0.77	-4.5	-0.37	1.52e-5	Diabetic kidney disease;
TGCT	cis	rs986417	1.000	rs2093212	chr14:60843322	G/A	cg27398547	chr14:60952738	C14orf39	-1.37	-8.31	-0.6	1.44e-13	Gut microbiota (bacterial taxa);
TGCT	cis	rs7666738	0.822	rs979946	chr4:98921235	C/A	cg05340658	chr4:99064831	C4orf37	0.53	6.1	0.48	1.24e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg04944784	chr2:26401820	FAM59B	-0.76	-6.24	-0.49	6.46e-9	Gut microbiome composition (summer);
TGCT	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg06713675	chr4:122721982	EXOSC9	-0.62	-8.48	-0.61	5.69e-14	Type 2 diabetes;
TGCT	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg11941060	chr3:133502564	NA	-0.26	-5.32	-0.43	4.74e-7	Iron status biomarkers;
TGCT	cis	rs986417	0.579	rs1254281	chr14:60854300	T/C	cg27398547	chr14:60952738	C14orf39	-1.45	-10.38	-0.68	1.52e-18	Gut microbiota (bacterial taxa);
TGCT	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg03709012	chr19:19516395	GATAD2A	0.75	6.16	0.48	9.21e-9	Tonsillectomy;
TGCT	cis	rs1018836	0.774	rs35159732	chr8:91633094	A/G	cg16814680	chr8:91681699	NA	-0.92	-9.45	-0.65	2.72e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6426558	0.537	rs4653813	chr1:227461510	G/C	cg10327440	chr1:227177885	CDC42BPA	0.58	6.76	0.52	4.75e-10	Neutrophil percentage of white cells;
TGCT	cis	rs8014204	0.804	rs7154845	chr14:75247746	A/G	cg06637938	chr14:75390232	RPS6KL1	0.7	6.75	0.52	5.06e-10	Caffeine consumption;
TGCT	cis	rs7226408	0.948	rs11662292	chr18:34399694	T/G	cg06757138	chr18:34340585	FHOD3	0.26	4.79	0.4	4.62e-6	Obesity-related traits;
TGCT	cis	rs2153535	0.584	rs9502723	chr6:8541504	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.61	0.45	1.23e-7	Motion sickness;
TGCT	cis	rs3764563	1.000	rs4239617	chr19:15741537	C/T	cg20725493	chr19:15740067	CYP4F8	-0.43	-4.67	-0.39	7.75e-6	Inflammatory biomarkers;
TGCT	cis	rs611744	0.647	rs1448151	chr8:109276283	C/A	cg21045802	chr8:109455806	TTC35	0.72	7.39	0.55	1.94e-11	Dupuytren's disease;
TGCT	cis	rs7020830	0.898	rs12554874	chr9:37073902	C/T	cg14294708	chr9:37120828	ZCCHC7	1.28	19.85	0.87	2.54e-40	Schizophrenia;
TGCT	cis	rs10501293	0.746	rs1489200	chr11:43005220	G/A	cg03447554	chr11:43094025	NA	0.44	6.38	0.5	3.26e-9	Cognitive performance;
TGCT	cis	rs13191362	1.000	rs34192365	chr6:163012382	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs12477438	0.501	rs12992218	chr2:99753834	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	13.05	0.76	4.93e-25	Chronic sinus infection;
TGCT	cis	rs7940866	0.874	rs10791113	chr11:130873165	A/G	cg05962950	chr11:130786565	SNX19	0.67	6.61	0.51	1.02e-9	Schizophrenia;
TGCT	cis	rs10791097	0.967	rs10750450	chr11:130719061	G/T	cg05962950	chr11:130786565	SNX19	0.75	8.13	0.59	3.73e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs10037670	0.557	rs972596	chr5:153824197	A/G	cg21964928	chr5:153872958	NA	0.28	5.1	0.42	1.22e-6	Behavioural disinhibition (generation interaction);
TGCT	cis	rs1153858	1.000	rs3809472	chr15:45694318	G/T	cg26924012	chr15:45694286	SPATA5L1	1.09	15.16	0.81	5.15e-30	Homoarginine levels;
TGCT	cis	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg25427524	chr10:38739819	LOC399744	0.4	8.22	0.59	2.34e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2014572	0.875	rs10405008	chr19:57753643	C/G	cg24459738	chr19:57751996	ZNF805	0.59	5.77	0.46	5.84e-8	Hyperactive-impulsive symptoms;
TGCT	cis	rs2880765	0.631	rs55767890	chr15:86004142	C/G	cg13263323	chr15:86062960	AKAP13	-0.2	-4.48	-0.37	1.68e-5	Coronary artery disease;
TGCT	trans	rs2727020	0.553	rs61904166	chr11:49581461	T/C	cg03929089	chr4:120376271	NA	-0.64	-7.36	-0.55	2.21e-11	Coronary artery disease;
TGCT	cis	rs7617773	0.817	rs4131361	chr3:48328812	T/C	cg11946769	chr3:48343235	NME6	0.74	6.34	0.49	3.97e-9	Coronary artery disease;
TGCT	trans	rs459571	0.916	rs467303	chr9:136904835	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.72	-7.83	-0.58	1.87e-12	Platelet distribution width;
TGCT	cis	rs9660992	0.548	rs1172152	chr1:205220718	T/A	cg00857998	chr1:205179979	DSTYK	0.49	4.47	0.37	1.76e-5	Mean corpuscular volume;Mean platelet volume;
TGCT	cis	rs13177918	0.677	rs4541646	chr5:149822918	G/A	cg14059543	chr5:149831962	NA	-0.71	-9.45	-0.65	2.77e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs60843830	1.000	rs3791223	chr2:222336	T/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.74	6.76	0.52	4.93e-10	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs61990749	0.597	rs2267768	chr14:78216014	A/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.65	4.59	0.38	1.06e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs7647973	0.587	rs10452032	chr3:49680973	G/A	cg05785598	chr3:49045655	WDR6	0.42	5.24	0.43	6.67e-7	Menarche (age at onset);
TGCT	cis	rs131777	0.577	rs5770928	chr22:51029091	G/C	cg25309564	chr22:51001381	C22orf41	0.55	5.11	0.42	1.2e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs7572733	0.534	rs1401091	chr2:198790423	T/G	cg00792783	chr2:198669748	PLCL1	-0.57	-5.14	-0.42	1.03e-6	Dermatomyositis;
TGCT	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.2	0.42	8.14e-7	Menopause (age at onset);
TGCT	cis	rs7611238	0.560	rs13325966	chr3:195072841	T/G	cg27323046	chr3:195102265	ACAP2	0.36	4.88	0.4	3.23e-6	Body mass index;
TGCT	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.63	-6.45	-0.5	2.29e-9	Prostate cancer;
TGCT	cis	rs4654899	0.743	rs61781069	chr1:21130735	T/C	cg01072550	chr1:21505969	NA	-0.46	-6.79	-0.52	4.06e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs2629540	0.824	rs10901809	chr10:126410804	C/T	cg08799069	chr10:126477246	METTL10	0.28	4.63	0.38	9.24e-6	Cocaine dependence;
TGCT	cis	rs6671200	1.000	rs71654418	chr1:95662658	G/T	cg20701556	chr1:95698924	RWDD3	0.65	5.58	0.45	1.43e-7	Stearic acid (18:0) levels;
TGCT	cis	rs1784581	0.588	rs7451121	chr6:162412344	A/G	cg17173639	chr6:162384350	PARK2	0.4	6.6	0.51	1.07e-9	Itch intensity from mosquito bite;
TGCT	cis	rs7666738	0.830	rs13140676	chr4:98804978	C/T	cg18180107	chr4:99064573	C4orf37	0.53	5.05	0.41	1.51e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2370759	1.000	rs16933177	chr10:32565705	G/A	cg01819863	chr10:32635814	EPC1	1.03	9.87	0.66	2.63e-17	Sexual dysfunction (female);
TGCT	cis	rs1008375	1.000	rs917665	chr4:17668504	A/C	cg10189774	chr4:17578691	LAP3	-0.5	-4.51	-0.38	1.47e-5	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7192750	0.562	rs9302631	chr16:71943414	C/T	cg06353428	chr16:71660113	MARVELD3	0.83	7.32	0.55	2.74e-11	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg15556689	chr8:8085844	FLJ10661	-0.65	-6.23	-0.49	6.59e-9	Mood instability;
TGCT	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg10802521	chr3:52805072	NEK4	0.79	10.01	0.67	1.18e-17	Bipolar disorder;
TGCT	cis	rs9911578	0.835	rs9904993	chr17:56468569	G/T	cg05425664	chr17:57184151	TRIM37	0.61	5.71	0.46	8.06e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs705471	0.762	rs7919625	chr10:3669970	A/G	cg14308648	chr10:3568949	NA	0.25	4.44	0.37	1.95e-5	Capecitabine sensitivity;
TGCT	cis	rs12510870	0.599	rs4574378	chr4:74402790	G/T	cg05868023	chr4:75230803	EREG	0.56	5.14	0.42	1.06e-6	Iris color (b* coordinate);
TGCT	cis	rs2115630	1.000	rs8037423	chr15:85355494	C/T	cg17173187	chr15:85201210	NMB	-0.39	-4.82	-0.4	4.06e-6	P wave terminal force;
TGCT	cis	rs11809207	1.000	rs34587428	chr1:26522392	C/T	cg03844060	chr1:26490628	NA	0.25	4.62	0.38	9.44e-6	Height;
TGCT	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg12419862	chr22:24373484	LOC391322	0.88	7.71	0.57	3.51e-12	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs12893668	0.645	rs12889403	chr14:104034746	C/T	cg26031613	chr14:104095156	KLC1	-0.54	-4.45	-0.37	1.88e-5	Reticulocyte count;
TGCT	trans	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg17470723	chr8:74884337	TCEB1	0.71	6.77	0.52	4.48e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9486719	1.000	rs2145535	chr6:97034715	G/A	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.32	-0.6	1.32e-13	Migraine;Coronary artery disease;
TGCT	cis	rs2730245	0.661	rs842696	chr7:158662698	T/C	cg11984989	chr7:158649758	WDR60	1.07	9.87	0.66	2.58e-17	Height;
TGCT	cis	rs1109861	0.525	rs606139	chr10:11205719	A/G	cg20379239	chr10:11207015	CUGBP2	0.47	4.99	0.41	2e-6	Urinary albumin-to-creatinine ratio;
TGCT	cis	rs9818758	0.556	rs9880309	chr3:49304329	G/C	cg07636037	chr3:49044803	WDR6	-1.04	-5.13	-0.42	1.09e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs10791097	0.694	rs7926167	chr11:130745045	T/C	cg14779329	chr11:130786720	SNX19	0.28	4.82	0.4	4.09e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs7267979	1.000	rs1077889	chr20:25267893	A/G	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1865760	0.566	rs2032445	chr6:26044812	T/A	cg17042849	chr6:26104293	HIST1H4C	-0.6	-5.17	-0.42	8.99e-7	Height;
TGCT	cis	rs6840360	0.571	rs62329101	chr4:152512239	G/T	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.0	-0.58	7.69e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs4713118	0.662	rs9468278	chr6:28028482	C/T	cg12963246	chr6:28129442	ZNF389	0.45	4.55	0.38	1.27e-5	Parkinson's disease;
TGCT	cis	rs7666738	0.830	rs4699594	chr4:98980775	T/C	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs360798	0.512	rs6545973	chr2:63089434	C/T	cg17519650	chr2:63277830	OTX1	0.65	5.62	0.45	1.19e-7	Coronary artery disease;
TGCT	cis	rs11085466	0.948	rs11668453	chr19:21759357	C/A	cg02997983	chr19:21646781	NA	-0.64	-4.52	-0.38	1.43e-5	Colorectal or endometrial cancer;
TGCT	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.73	-0.39	5.93e-6	Prudent dietary pattern;
TGCT	cis	rs62244186	0.711	rs6778410	chr3:44743993	C/T	cg11003573	chr3:44754125	ZNF502	-0.43	-4.97	-0.41	2.18e-6	Depressive symptoms;
TGCT	cis	rs12900413	0.562	rs12898229	chr15:90295960	C/T	cg24249390	chr15:90295951	MESP1	-0.3	-5.13	-0.42	1.07e-6	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs2456568	0.548	rs6483281	chr11:93661840	G/C	cg26875233	chr11:93583750	C11orf90	-0.41	-4.94	-0.41	2.43e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs2832191	0.903	rs11700687	chr21:30486767	A/G	cg08807101	chr21:30365312	RNF160	-0.49	-4.48	-0.37	1.65e-5	Dental caries;
TGCT	cis	rs9467773	1.000	rs1321480	chr6:26532742	A/G	cg09904177	chr6:26538194	HMGN4	0.65	6.49	0.5	1.89e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs9948	0.655	rs56913233	chr2:97405896	A/G	cg01990225	chr2:97406019	LMAN2L	-1.02	-5.19	-0.42	8.43e-7	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs67311347	1.000	rs11706148	chr3:40407243	A/C	cg13683864	chr3:40499215	RPL14	-1.15	-12.35	-0.74	2.5e-23	Renal cell carcinoma;
TGCT	cis	rs7681440	0.869	rs894280	chr4:90760883	C/T	cg20003494	chr4:90757398	SNCA	-0.63	-6.03	-0.48	1.73e-8	Dementia with Lewy bodies;
TGCT	cis	rs6089584	1.000	rs6089587	chr20:60564829	C/T	cg16423285	chr20:60520624	NA	-0.52	-5.62	-0.45	1.18e-7	Body mass index;
TGCT	cis	rs10836699	0.741	rs1381158	chr11:37180913	A/C	cg18520238	chr11:36422557	PRR5L	0.17	4.44	0.37	1.94e-5	Low high density lipoprotein cholesterol levels;
TGCT	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg23719950	chr11:63933701	MACROD1	-0.71	-5.91	-0.47	3.06e-8	Mean platelet volume;
TGCT	cis	rs36051895	0.658	rs10974914	chr9:5014332	C/T	cg02405213	chr9:5042618	JAK2	-0.78	-10.93	-0.7	6.86e-20	Pediatric autoimmune diseases;
TGCT	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg26338869	chr17:61819248	STRADA	-0.53	-4.94	-0.41	2.48e-6	Prudent dietary pattern;
TGCT	cis	rs12421382	0.507	rs11600810	chr11:109356443	G/A	cg16359550	chr11:109292809	C11orf87	0.7	7.43	0.55	1.55e-11	Schizophrenia;
TGCT	cis	rs7829975	0.560	rs4841013	chr8:8552013	A/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-4.61	-0.38	1e-5	Mood instability;
TGCT	cis	rs13217239	0.646	rs12201393	chr6:26975690	C/A	cg05738196	chr6:26577821	NA	0.49	4.77	0.39	4.98e-6	Schizophrenia;
TGCT	cis	rs2204008	0.749	rs10880692	chr12:38592918	C/G	cg26384229	chr12:38710491	ALG10B	-0.92	-8.4	-0.6	8.58e-14	Bladder cancer;
TGCT	cis	rs4819052	0.851	rs2838866	chr21:46713014	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	6.71	0.52	6.33e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs782590	0.902	rs3762513	chr2:55762957	C/T	cg03859395	chr2:55845619	SMEK2	0.93	11.51	0.72	2.68e-21	Metabolic syndrome;
TGCT	cis	rs10114408	0.801	rs6479519	chr9:96663421	A/G	cg13679303	chr9:96623674	NA	-0.36	-4.61	-0.38	9.97e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs782590	0.774	rs782629	chr2:55900283	C/T	cg03859395	chr2:55845619	SMEK2	-0.84	-9.75	-0.66	4.99e-17	Metabolic syndrome;
TGCT	cis	rs17122693	0.748	rs72681608	chr14:51116090	C/T	cg04730355	chr14:51134070	SAV1	1.35	12.44	0.75	1.47e-23	Cognitive performance;
TGCT	cis	rs3617	0.539	rs4687689	chr3:52948674	A/C	cg10802521	chr3:52805072	NEK4	0.59	6.77	0.52	4.48e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs3733585	0.699	rs7663079	chr4:9966771	T/C	cg11266682	chr4:10021025	SLC2A9	-0.59	-7.87	-0.58	1.53e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs35306767	0.807	rs34885925	chr10:919032	G/C	cg26597838	chr10:835615	NA	0.8	12.11	0.74	9.26e-23	Eosinophil percentage of granulocytes;
TGCT	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg20007245	chr22:24372913	LOC391322	-0.64	-6.07	-0.48	1.44e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs11030122	0.632	rs11030599	chr11:4031677	A/G	cg18678763	chr11:4115507	RRM1	-0.49	-6.16	-0.48	9.44e-9	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg09436375	chr6:42928200	GNMT	-0.41	-5.38	-0.43	3.6e-7	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg11890956	chr21:40555474	PSMG1	1.02	9.9	0.66	2.16e-17	Cognitive function;
TGCT	cis	rs2469997	1.000	rs2470014	chr8:120360820	C/G	cg00681363	chr8:120844660	TAF2	0.69	4.48	0.37	1.64e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs9611565	0.921	rs761366	chr22:41744022	C/G	cg13695892	chr22:41940480	POLR3H	-0.76	-7.43	-0.56	1.54e-11	Vitiligo;
TGCT	cis	rs6450176	1.000	rs4334835	chr5:53300612	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.53	-5.1	-0.42	1.23e-6	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs2404602	0.503	rs284909	chr15:76736628	C/T	cg22467129	chr15:76604101	ETFA	-0.42	-4.71	-0.39	6.46e-6	Blood metabolite levels;
TGCT	cis	rs4819052	0.851	rs2255774	chr21:46683851	A/T	cg06618935	chr21:46677482	NA	-0.36	-5.7	-0.46	8.16e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs4478858	0.735	rs3806255	chr1:31791578	A/G	cg00250761	chr1:31883323	NA	-0.27	-4.84	-0.4	3.76e-6	Alcohol dependence;
TGCT	cis	rs3796352	0.881	rs11710394	chr3:53015839	A/G	cg07884673	chr3:53033167	SFMBT1	0.62	6.19	0.49	8.26e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	trans	rs1814175	0.817	rs1615305	chr11:49895222	T/A	cg15704280	chr7:45808275	SEPT13	-0.72	-8.14	-0.59	3.63e-13	Height;
TGCT	cis	rs12908161	0.959	rs34342559	chr15:85331271	A/G	cg11189052	chr15:85197271	WDR73	0.71	5.85	0.47	4.1e-8	Schizophrenia;
TGCT	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg27170947	chr2:26402098	FAM59B	-0.4	-4.63	-0.38	8.93e-6	Gut microbiome composition (summer);
TGCT	trans	rs877282	0.945	rs35342920	chr10:790484	T/C	cg22713356	chr15:30763199	NA	1.18	10.55	0.69	5.81e-19	Uric acid levels;
TGCT	cis	rs10901296	0.702	rs11244178	chr9:133766008	C/T	cg03924115	chr9:133768966	QRFP	-0.27	-4.43	-0.37	2.01e-5	Bilirubin levels;
TGCT	cis	rs2404602	0.716	rs2404736	chr15:76875943	T/C	cg22467129	chr15:76604101	ETFA	-0.44	-4.98	-0.41	2.08e-6	Blood metabolite levels;
TGCT	cis	rs9653442	0.545	rs2009095	chr2:100765081	C/T	cg07810366	chr2:100720526	AFF3	-0.37	-5.46	-0.44	2.46e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs2880765	0.835	rs12708553	chr15:86046833	C/G	cg13263323	chr15:86062960	AKAP13	0.23	4.75	0.39	5.62e-6	Coronary artery disease;
TGCT	cis	rs68170813	0.559	rs2395881	chr7:107074323	A/C	cg02696742	chr7:106810147	HBP1	-0.68	-5.44	-0.44	2.69e-7	Coronary artery disease;
TGCT	cis	rs7255045	0.788	rs2290688	chr19:12958697	T/C	cg04657146	chr19:12876947	HOOK2	-0.61	-4.53	-0.38	1.35e-5	Mean corpuscular volume;
TGCT	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg11890956	chr21:40555474	PSMG1	1.11	12.43	0.74	1.56e-23	Cognitive function;
TGCT	cis	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-6.01	-0.47	1.93e-8	Mood instability;
TGCT	cis	rs4786125	0.519	rs1388805	chr16:6929947	C/T	cg03623568	chr16:6915990	A2BP1	-0.4	-5.63	-0.45	1.13e-7	Heart rate variability traits (SDNN);
TGCT	cis	rs6460942	1.000	rs6460936	chr7:12404913	T/C	cg06484146	chr7:12443880	VWDE	-0.63	-5.65	-0.45	1.04e-7	Coronary artery disease;
TGCT	cis	rs60871478	1.000	rs62432250	chr7:801792	C/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.46	4.64	0.38	8.77e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs2702888	0.501	rs2738161	chr8:6748597	C/T	cg26795848	chr8:6756730	NA	-0.32	-6.39	-0.5	3e-9	Blood pressure;
TGCT	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg15242686	chr22:24348715	GSTTP1	0.44	5.98	0.47	2.23e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6061231	0.724	rs1570027	chr20:60968596	A/G	cg24112000	chr20:60950667	NA	-0.4	-5.06	-0.41	1.44e-6	Colorectal cancer;
TGCT	cis	rs7772486	0.625	rs9390355	chr6:146112942	C/T	cg13319975	chr6:146136371	FBXO30	0.5	4.62	0.38	9.6e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6882046	0.513	rs454214	chr5:88003403	A/G	cg22951263	chr5:87985283	NA	0.6	6.44	0.5	2.44e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs909341	0.830	rs1623866	chr20:62333022	G/A	cg14758556	chr20:62440591	NA	0.29	4.48	0.37	1.71e-5	Atopic dermatitis;
TGCT	cis	rs2115630	0.691	rs8040066	chr15:85176465	G/C	cg17173187	chr15:85201210	NMB	-0.47	-5.94	-0.47	2.67e-8	P wave terminal force;
TGCT	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg22535103	chr8:58192502	C8orf71	-0.41	-5.24	-0.43	6.56e-7	Developmental language disorder (linguistic errors);
TGCT	trans	rs1814175	0.817	rs4881658	chr11:49941123	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.12	-0.54	7.75e-11	Height;
TGCT	cis	rs6988636	1.000	rs13259806	chr8:124190103	A/T	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs9549260	0.567	rs7332730	chr13:41265979	C/A	cg21288729	chr13:41239152	FOXO1	0.98	9.67	0.66	8.01e-17	Red blood cell count;
TGCT	cis	rs72717009	0.825	rs61802846	chr1:161473873	A/C	cg23840854	chr1:161414152	NA	-0.98	-5.87	-0.47	3.79e-8	Rheumatoid arthritis;
TGCT	cis	rs11030122	0.702	rs10835403	chr11:3990941	A/C	cg18678763	chr11:4115507	RRM1	0.46	5.09	0.42	1.31e-6	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs9650657	0.801	rs2409663	chr8:10643233	G/T	cg27411982	chr8:10470053	RP1L1	-0.22	-4.62	-0.38	9.66e-6	Neuroticism;
TGCT	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg07507251	chr3:52567010	NT5DC2	0.45	6.49	0.5	1.85e-9	Bipolar disorder;
TGCT	cis	rs6938	0.534	rs11072512	chr15:75204026	C/T	cg10253484	chr15:75165896	SCAMP2	-0.57	-5.28	-0.43	5.69e-7	Breast cancer;
TGCT	cis	rs250677	0.524	rs40521	chr5:148439639	C/T	cg18129178	chr5:148520854	ABLIM3	0.35	5.01	0.41	1.85e-6	Breast cancer;
TGCT	cis	rs9796	0.576	rs13329511	chr15:41299121	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.5	-6.47	-0.5	2.05e-9	Menopause (age at onset);
TGCT	cis	rs919433	0.519	rs700656	chr2:198653667	T/C	cg00792783	chr2:198669748	PLCL1	0.56	5.08	0.42	1.35e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs1552244	0.554	rs7349576	chr3:10050893	T/C	cg00149659	chr3:10157352	C3orf10	0.69	4.99	0.41	2.03e-6	Alzheimer's disease;
TGCT	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg11764359	chr7:65958608	NA	-0.56	-5.06	-0.41	1.45e-6	Aortic root size;
TGCT	cis	rs644799	1.000	rs488246	chr11:95560473	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.82	8.63	0.61	2.52e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs10010223	chr4:99021758	G/A	cg05340658	chr4:99064831	C4orf37	0.48	5.43	0.44	2.92e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1371867	0.846	rs1788191	chr8:101260844	C/T	cg06636551	chr8:101224915	SPAG1	0.49	6.83	0.52	3.32e-10	Atrioventricular conduction;
TGCT	cis	rs6121246	0.909	rs7272062	chr20:30259145	A/G	cg18721089	chr20:30220636	NA	-0.42	-4.65	-0.39	8.2e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs644799	1.000	rs693364	chr11:95621926	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	7.25	0.55	3.86e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs6977955	1.000	rs10951192	chr7:28161033	C/G	cg23620719	chr7:28220237	JAZF1	-0.7	-5.33	-0.43	4.47e-7	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.95	-6.11	-0.48	1.17e-8	Alzheimer's disease;
TGCT	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.93	10.08	0.67	8.27e-18	Intelligence (multi-trait analysis);
TGCT	cis	rs10507380	0.825	rs9512639	chr13:27920666	C/A	cg25543773	chr13:27185723	WASF3	0.34	4.83	0.4	3.97e-6	Electrocardiographic traits;
TGCT	cis	rs67311347	0.544	rs12054197	chr3:40337562	C/T	cg13683864	chr3:40499215	RPL14	-0.78	-7.5	-0.56	1.06e-11	Renal cell carcinoma;
TGCT	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg13395646	chr4:1353034	KIAA1530	-0.36	-4.62	-0.38	9.52e-6	Obesity-related traits;
TGCT	cis	rs7113874	0.610	rs7947670	chr11:8525531	A/C	cg14521421	chr11:8862019	ST5	0.28	4.44	0.37	1.99e-5	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs7267979	1.000	rs6050617	chr20:25421648	C/T	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs1864729	0.748	rs2635165	chr8:98296209	T/C	cg08679828	chr8:102218111	ZNF706	-1.06	-6.94	-0.53	1.93e-10	Estradiol plasma levels (breast cancer);
TGCT	cis	rs2354432	0.556	rs11239965	chr1:146753907	C/A	cg25205988	chr1:146714368	CHD1L	-1.34	-6.07	-0.48	1.44e-8	Mitochondrial DNA levels;
TGCT	cis	rs317689	0.819	rs317664	chr12:69704747	C/A	cg14784868	chr12:69753453	YEATS4	0.57	4.9	0.4	2.96e-6	Response to diuretic therapy;
TGCT	trans	rs2727020	0.658	rs4980431	chr11:49350071	G/T	cg03929089	chr4:120376271	NA	-0.69	-7.95	-0.58	9.7e-13	Coronary artery disease;
TGCT	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs9467773	0.620	rs2504567	chr6:26662920	C/G	cg15659132	chr6:26577336	NA	0.87	10.79	0.7	1.52e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs6964587	0.869	rs6975243	chr7:91514672	G/A	cg17063962	chr7:91808500	NA	-0.86	-9.19	-0.64	1.16e-15	Breast cancer;
TGCT	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.33	0.55	2.59e-11	Prudent dietary pattern;
TGCT	cis	rs16866061	1.000	rs2047134	chr2:225347713	A/C	cg12698349	chr2:225449008	CUL3	1.01	9.93	0.67	1.87e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	cis	rs9972944	0.756	rs6416945	chr17:63763942	G/A	cg07283582	chr17:63770753	CCDC46	-0.26	-5.29	-0.43	5.45e-7	Total body bone mineral density;
TGCT	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg04944784	chr2:26401820	FAM59B	0.76	6.24	0.49	6.46e-9	Gut microbiome composition (summer);
TGCT	cis	rs1215050	0.791	rs260899	chr4:98707046	G/A	cg05340658	chr4:99064831	C4orf37	0.44	5.52	0.44	1.85e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9682041	0.932	rs9841852	chr3:170067049	C/G	cg11886554	chr3:170076028	SKIL	0.8	5.89	0.47	3.34e-8	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs7267979	0.934	rs2261753	chr20:25262291	G/A	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs208520	1.000	rs208523	chr6:66954195	G/C	cg07460842	chr6:66804631	NA	-0.83	-7.52	-0.56	9.8e-12	Exhaled nitric oxide output;
TGCT	cis	rs6570726	0.791	rs1935612	chr6:145906090	T/A	cg23711669	chr6:146136114	FBXO30	0.85	9.24	0.64	8.9e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9291683	0.609	rs13141233	chr4:10028729	T/C	cg00071950	chr4:10020882	SLC2A9	0.7	9.43	0.65	3.06e-16	Bone mineral density;
TGCT	cis	rs9303401	0.659	rs36093395	chr17:56957357	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs79057730	0.599	rs4721086	chr7:821123	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.62	5.12	0.42	1.14e-6	Initial pursuit acceleration;
TGCT	cis	rs600231	0.665	rs12790095	chr11:65326086	T/G	cg21890820	chr11:65308645	LTBP3	0.4	5.08	0.42	1.33e-6	Bone mineral density;
TGCT	cis	rs4237845	0.837	rs7954957	chr12:58299250	C/T	cg02175503	chr12:58329896	NA	0.52	5.5	0.44	2.09e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs765787	0.556	rs12915965	chr15:45512647	T/C	cg24006582	chr15:45444508	DUOX1	0.25	5.35	0.43	4.11e-7	Uric acid levels;
TGCT	cis	rs3812831	0.572	rs3118896	chr13:114931769	C/G	cg06611532	chr13:114900021	NA	0.31	5.62	0.45	1.19e-7	Schizophrenia;
TGCT	cis	rs7772486	0.720	rs702320	chr6:146006654	G/A	cg05347473	chr6:146136440	FBXO30	-0.51	-4.8	-0.4	4.44e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs80282103	0.618	rs74117849	chr10:1165425	A/G	cg18964960	chr10:1102726	WDR37	1.03	4.53	0.38	1.39e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs988913	1.000	rs960834	chr6:54823431	C/T	cg04690482	chr6:54711388	FAM83B	0.3	4.57	0.38	1.16e-5	Menarche (age at onset);
TGCT	cis	rs42648	0.869	rs10251227	chr7:89892286	T/G	cg25739043	chr7:89950458	NA	-0.64	-5.91	-0.47	3.16e-8	Homocysteine levels;
TGCT	cis	rs35883536	0.647	rs2783696	chr1:101044089	G/A	cg06223162	chr1:101003688	GPR88	0.41	7.55	0.56	7.99e-12	Monocyte count;
TGCT	cis	rs7635838	0.892	rs9823197	chr3:11503133	A/T	cg00170343	chr3:11313890	ATG7	0.6	5.29	0.43	5.3e-7	HDL cholesterol;
TGCT	cis	rs7172809	0.599	rs59362734	chr15:77755406	A/C	cg22256960	chr15:77711686	NA	-0.51	-4.86	-0.4	3.47e-6	Glucose homeostasis traits;
TGCT	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg09365446	chr1:150670422	GOLPH3L	0.31	4.64	0.38	8.7e-6	Tonsillectomy;
TGCT	cis	rs7043114	0.507	rs10992291	chr9:95033009	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.56	-5.5	-0.44	2.11e-7	Height;
TGCT	cis	rs9486715	1.000	rs9486715	chr6:97059769	A/C	cg06623918	chr6:96969491	KIAA0776	-1.11	-14.58	-0.79	1.16e-28	Headache;
TGCT	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg11644478	chr21:40555479	PSMG1	0.51	4.78	0.39	4.83e-6	Menarche (age at onset);
TGCT	cis	rs1826508	0.558	rs6505693	chr18:1206140	G/A	cg23365097	chr18:515465	NA	-0.46	-4.9	-0.4	2.87e-6	Metabolite levels (Dihydroxy docosatrienoic acid);
TGCT	cis	rs12887734	0.566	rs3742366	chr14:104198351	T/C	cg26031613	chr14:104095156	KLC1	-0.71	-6.03	-0.48	1.72e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs55794721	0.509	rs6699896	chr1:25762902	A/T	cg00786635	chr1:25594202	NA	0.56	5.95	0.47	2.54e-8	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs3849570	0.961	rs3849571	chr3:81777716	A/C	cg07356753	chr3:81810745	GBE1	-0.85	-8.17	-0.59	3.06e-13	Waist circumference;Body mass index;
TGCT	cis	rs7312933	0.618	rs6582394	chr12:42686189	A/G	cg19980929	chr12:42632907	YAF2	0.4	5.45	0.44	2.64e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs478304	0.651	rs4014192	chr11:65498915	C/T	cg10518572	chr11:65560635	OVOL1	-0.24	-4.68	-0.39	7.53e-6	Acne (severe);
TGCT	cis	rs9399137	0.507	rs56164974	chr6:135288716	C/T	cg24558204	chr6:135376177	HBS1L	0.47	4.78	0.39	4.95e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
TGCT	cis	rs2242116	0.727	rs7635480	chr3:46968227	T/C	cg23352942	chr3:46931381	PTH1R	-0.34	-5.13	-0.42	1.08e-6	Birth weight;
TGCT	cis	rs2204008	0.869	rs34438288	chr12:38211582	G/T	cg26384229	chr12:38710491	ALG10B	0.84	7.43	0.56	1.51e-11	Bladder cancer;
TGCT	cis	rs10876993	0.890	rs115106209	chr12:58059331	G/A	cg15848620	chr12:58087721	OS9	-0.72	-5.88	-0.47	3.56e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg20007245	chr22:24372913	LOC391322	-0.78	-8.28	-0.6	1.66e-13	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs854765	0.893	rs712265	chr17:18008447	G/A	cg09796270	chr17:17721594	SREBF1	-0.26	-5.22	-0.42	7.3e-7	Total body bone mineral density;
TGCT	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg10802521	chr3:52805072	NEK4	-0.71	-8.79	-0.62	1.04e-14	Bipolar disorder;
TGCT	cis	rs12477438	0.520	rs2964969	chr2:99782811	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.82	0.62	8.67e-15	Chronic sinus infection;
TGCT	cis	rs9443645	0.901	rs9352667	chr6:79572296	A/G	cg05283184	chr6:79620031	NA	0.21	4.71	0.39	6.64e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6840360	0.608	rs2724556	chr4:152341717	G/A	cg17479576	chr4:152424074	FAM160A1	-0.5	-5.07	-0.41	1.43e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6933660	0.720	rs6913515	chr6:151753470	G/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.61	5.97	0.47	2.29e-8	Menarche (age at onset);
TGCT	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg10047753	chr17:41438598	NA	0.77	7.29	0.55	3.18e-11	Menopause (age at onset);
TGCT	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg22920501	chr2:26401640	FAM59B	0.8	6.34	0.49	3.84e-9	Gut microbiome composition (summer);
TGCT	cis	rs2050392	0.517	rs602097	chr10:30747546	C/T	cg18806716	chr10:30721971	MAP3K8	-0.47	-5.45	-0.44	2.62e-7	Inflammatory bowel disease;
TGCT	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg02353165	chr6:42928485	GNMT	0.95	9.51	0.65	1.95e-16	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.18	0.49	8.33e-9	Electroencephalogram traits;
TGCT	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg21433313	chr16:3507492	NAT15	0.39	5.08	0.41	1.36e-6	Tuberculosis;
TGCT	cis	rs11718455	0.960	rs35869565	chr3:44002394	G/C	cg08738300	chr3:44038990	NA	0.85	6.41	0.5	2.72e-9	Coronary artery disease;
TGCT	cis	rs1670533	1.000	rs7679432	chr4:1050521	G/A	cg20887711	chr4:1340912	KIAA1530	0.7	5.66	0.45	9.77e-8	Recombination rate (females);
TGCT	cis	rs639012	0.636	rs7941541	chr11:85858538	A/G	cg07180834	chr11:85838833	NA	0.37	5.36	0.43	3.92e-7	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs1555895	0.576	rs4229	chr10:856918	A/T	cg02193355	chr10:851439	NA	0.24	5.41	0.44	3.1e-7	Survival in rectal cancer;
TGCT	cis	rs116095464	0.558	rs6879656	chr5:264428	T/C	cg22857025	chr5:266934	NA	-0.35	-6.87	-0.53	2.7e-10	Breast cancer;
TGCT	cis	rs17076896	0.655	rs74038131	chr13:19934867	C/T	cg00777926	chr13:20807375	GJB6	-0.37	-4.53	-0.38	1.36e-5	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs13256369	1.000	rs13266699	chr8:8570313	A/T	cg06671706	chr8:8559999	CLDN23	-0.34	-4.57	-0.38	1.18e-5	Obesity-related traits;
TGCT	cis	rs80282103	0.764	rs10047383	chr10:1103095	A/G	cg08668510	chr10:1095578	IDI1	1.01	4.51	0.38	1.48e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs780094	0.606	rs6729709	chr2:27583156	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.33	4.5	0.37	1.57e-5	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
TGCT	cis	rs10851411	0.789	rs1900920	chr15:42768198	C/T	cg12711755	chr15:41779622	NA	-0.19	-4.73	-0.39	5.95e-6	Glucose homeostasis traits;
TGCT	trans	rs561341	1.000	rs576985	chr17:30323323	C/T	cg20587970	chr11:113659929	NA	-1.04	-12.57	-0.75	6.97e-24	Hip circumference adjusted for BMI;
TGCT	trans	rs57221529	0.766	rs4527146	chr5:555236	A/G	cg11887960	chr12:57824829	NA	1.16	9.45	0.65	2.66e-16	Lung disease severity in cystic fibrosis;
TGCT	cis	rs2070488	0.965	rs1058945	chr3:38532511	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.88	-8.99	-0.63	3.5e-15	Electrocardiographic conduction measures;
TGCT	cis	rs12477438	0.501	rs13000731	chr2:99795231	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	14.89	0.8	2.21e-29	Chronic sinus infection;
TGCT	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg06212747	chr3:49208901	KLHDC8B	0.71	6.63	0.51	9.48e-10	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs9549367	0.826	rs2287249	chr13:113889355	A/G	cg18105134	chr13:113819100	PROZ	-0.34	-5.49	-0.44	2.18e-7	Platelet distribution width;
TGCT	cis	rs7666738	0.830	rs10034619	chr4:98970067	G/C	cg17366294	chr4:99064904	C4orf37	0.68	6.94	0.53	1.95e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg15691649	chr6:25882328	NA	-0.35	-4.55	-0.38	1.25e-5	Blood metabolite levels;
TGCT	trans	rs7819412	0.837	rs17724467	chr8:10975682	C/G	cg15556689	chr8:8085844	FLJ10661	-0.76	-7.24	-0.55	4.21e-11	Triglycerides;
TGCT	cis	rs1401999	0.934	rs1132776	chr3:183696402	A/G	cg01324343	chr3:183735012	ABCC5	0.82	10.97	0.7	5.41e-20	Anterior chamber depth;
TGCT	cis	rs4478037	0.822	rs9827863	chr3:33118951	C/T	cg19404215	chr3:33155277	CRTAP	-1.28	-6.37	-0.5	3.33e-9	Major depressive disorder;
TGCT	cis	rs9640161	0.789	rs1464751	chr7:150021282	C/T	cg10018233	chr7:150070692	REPIN1	0.32	4.62	0.38	9.64e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs17490626	0.512	rs12241097	chr10:71216678	T/G	cg14388049	chr10:71211838	TSPAN15	-0.39	-4.5	-0.37	1.55e-5	Thrombosis;
TGCT	cis	rs8014204	1.000	rs8014204	chr14:75322794	A/G	cg06637938	chr14:75390232	RPS6KL1	0.75	7.09	0.54	8.97e-11	Caffeine consumption;
TGCT	cis	rs9611565	0.921	rs5758297	chr22:41720697	A/G	cg17554472	chr22:41940697	POLR3H	-0.39	-4.49	-0.37	1.58e-5	Vitiligo;
TGCT	cis	rs9911578	0.967	rs8075786	chr17:56819216	T/C	cg12560992	chr17:57184187	TRIM37	0.76	9.34	0.64	4.88e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs35883536	0.647	rs2647325	chr1:101040195	T/C	cg06223162	chr1:101003688	GPR88	0.42	7.97	0.58	8.84e-13	Monocyte count;
TGCT	cis	rs1497406	0.744	rs6690317	chr1:16516585	T/C	cg20430773	chr1:16534157	ARHGEF19	0.52	6.25	0.49	6.18e-9	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.84	7.5	0.56	1.08e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs17331151	0.541	rs11709430	chr3:52862055	G/A	cg27565382	chr3:53032988	SFMBT1	0.4	5.05	0.41	1.57e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs9457247	0.565	rs2239824	chr6:167511799	T/A	cg07741184	chr6:167504864	NA	0.29	5.6	0.45	1.34e-7	Crohn's disease;
TGCT	cis	rs6061231	0.740	rs11698650	chr20:60958374	A/T	cg24112000	chr20:60950667	NA	-0.34	-5.07	-0.41	1.38e-6	Colorectal cancer;
TGCT	cis	rs28595532	0.920	rs114789346	chr4:119748652	G/A	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs9467773	1.000	rs6903973	chr6:26499942	C/A	cg15659132	chr6:26577336	NA	0.84	11.93	0.73	2.59e-22	Intelligence (multi-trait analysis);
TGCT	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg17747265	chr1:1875780	NA	-0.38	-7.18	-0.54	5.67e-11	Body mass index;
TGCT	cis	rs7666738	0.830	rs13133355	chr4:98919415	A/G	cg17366294	chr4:99064904	C4orf37	0.71	7.25	0.55	3.96e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6484504	0.532	rs2761589	chr11:31311429	C/G	cg26647111	chr11:31128758	NA	0.33	4.74	0.39	5.71e-6	Red blood cell count;
TGCT	cis	rs35883536	0.647	rs12043865	chr1:101042651	G/A	cg14855972	chr1:101004472	GPR88	-0.24	-4.49	-0.37	1.64e-5	Monocyte count;
TGCT	cis	rs7824557	0.583	rs2736292	chr8:11234500	A/T	cg21775007	chr8:11205619	TDH	0.71	7.57	0.56	7.28e-12	Retinal vascular caliber;
TGCT	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg15242686	chr22:24348715	GSTTP1	-0.5	-5.91	-0.47	3.07e-8	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs7666738	0.830	rs28497822	chr4:98906873	C/T	cg18180107	chr4:99064573	C4orf37	0.53	4.88	0.4	3.2e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2072499	0.966	rs2253677	chr1:156171296	C/G	cg25208724	chr1:156163844	SLC25A44	-1.14	-17.15	-0.84	1.56e-34	Testicular germ cell tumor;
TGCT	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg22166914	chr1:53195759	ZYG11B	0.4	6.61	0.51	1.04e-9	Monocyte count;
TGCT	cis	rs7615952	0.932	rs1976458	chr3:125647512	T/G	cg05084668	chr3:125655381	ALG1L	-0.76	-6.08	-0.48	1.39e-8	Blood pressure (smoking interaction);
TGCT	cis	rs2404602	0.679	rs12908421	chr15:76881794	T/G	cg22467129	chr15:76604101	ETFA	-0.44	-4.98	-0.41	2.07e-6	Blood metabolite levels;
TGCT	cis	rs66561647	0.661	rs7835090	chr8:128940177	A/C	cg05480350	chr8:128972681	MIR1205;PVT1	0.22	4.58	0.38	1.1e-5	Hemoglobin concentration;
TGCT	cis	rs10793273	1	rs10793273	chr11:77742595	T/C	cg09721595	chr11:77773924	THRSP	-0.4	-6.92	-0.53	2.19e-10	Pelvic organ prolapse;
TGCT	cis	rs7428	0.545	rs17026212	chr2:85551696	T/G	cg03728395	chr2:85555865	TGOLN2	-0.29	-5.09	-0.42	1.32e-6	Ear protrusion;
TGCT	trans	rs2727020	0.786	rs10839263	chr11:49354462	A/G	cg03929089	chr4:120376271	NA	-0.64	-6.74	-0.52	5.34e-10	Coronary artery disease;
TGCT	cis	rs4664308	0.935	rs877200	chr2:160903723	G/C	cg03641300	chr2:160917029	PLA2R1	-0.26	-6.52	-0.51	1.6e-9	Idiopathic membranous nephropathy;
TGCT	cis	rs9372498	0.536	rs62424172	chr6:118777533	C/A	cg21191810	chr6:118973309	C6orf204	-0.37	-4.77	-0.39	5.03e-6	Diastolic blood pressure;
TGCT	cis	rs13082711	0.554	rs66854845	chr3:27387008	C/T	cg02860705	chr3:27208620	NA	0.43	6.05	0.48	1.6e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs2486012	0.850	rs246774	chr1:44299695	C/T	cg12908607	chr1:44402522	ARTN	-0.76	-5.68	-0.45	9.1e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs11148252	0.574	rs2038826	chr13:53280013	G/A	cg00495681	chr13:53174319	NA	0.62	6.27	0.49	5.35e-9	Lewy body disease;
TGCT	cis	rs4478858	0.684	rs7519766	chr1:31735512	C/A	cg07478791	chr1:31886160	SERINC2	-0.49	-4.91	-0.4	2.82e-6	Alcohol dependence;
TGCT	cis	rs1865760	1.000	rs56118523	chr6:25908975	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.65	6.24	0.49	6.27e-9	Height;
TGCT	cis	rs2970818	0.831	rs2970810	chr12:4608103	A/G	cg20471076	chr12:4920472	KCNA6	0.2	4.5	0.37	1.52e-5	Phosphorus levels;
TGCT	cis	rs889312	0.500	rs702688	chr5:56190986	A/G	cg12311346	chr5:56204834	C5orf35	-0.48	-5.13	-0.42	1.08e-6	Breast cancer;Breast cancer (early onset);
TGCT	cis	rs3015497	0.789	rs3015500	chr14:51108877	C/T	cg04730355	chr14:51134070	SAV1	-0.68	-6.57	-0.51	1.26e-9	Mean platelet volume;
TGCT	cis	rs3125734	0.633	rs6479804	chr10:64048327	T/C	cg09941381	chr10:64027924	RTKN2	-0.33	-4.9	-0.4	2.94e-6	Rheumatoid arthritis;
TGCT	cis	rs12220238	1.000	rs1908331	chr10:75885817	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.91	7.77	0.57	2.63e-12	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs17789174	0.514	rs11548969	chr16:85126806	T/C	cg02687026	chr16:85133210	FAM92B	0.22	5.18	0.42	8.66e-7	Dysphagia;
TGCT	cis	rs11190604	0.767	rs12360395	chr10:102194074	A/T	cg16005271	chr10:102321736	NA	0.46	4.69	0.39	6.99e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs910316	1.000	rs4899544	chr14:75546556	C/T	cg23033748	chr14:75592666	NEK9	0.28	4.68	0.39	7.29e-6	Height;
TGCT	cis	rs514406	0.505	rs440871	chr1:53173052	C/T	cg16325326	chr1:53192061	ZYG11B	0.86	12.19	0.74	6.07e-23	Monocyte count;
TGCT	cis	rs4704846	1.000	rs4704850	chr5:156532952	A/G	cg12943317	chr5:156479607	HAVCR1	-0.34	-4.7	-0.39	6.82e-6	Blood protein levels;
TGCT	cis	rs1008375	0.966	rs2315553	chr4:17627332	T/C	cg10189774	chr4:17578691	LAP3	0.66	5.74	0.46	6.81e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg06873352	chr17:61820015	STRADA	-0.54	-5.61	-0.45	1.23e-7	Prudent dietary pattern;
TGCT	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.75	5.41	0.44	3.09e-7	Platelet count;
TGCT	cis	rs7959452	0.590	rs7968629	chr12:69782857	G/A	cg14784868	chr12:69753453	YEATS4	0.83	8.96	0.63	4.14e-15	Blood protein levels;
TGCT	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg02038168	chr22:39784481	NA	-0.76	-6.36	-0.5	3.47e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs4919694	1.000	rs12261040	chr10:104665397	T/C	cg04362960	chr10:104952993	NT5C2	1.02	6.9	0.53	2.41e-10	Arsenic metabolism;
TGCT	cis	rs4851266	0.966	rs13026283	chr2:100842638	C/T	cg07810366	chr2:100720526	AFF3	-0.36	-5.06	-0.41	1.48e-6	Educational attainment;
TGCT	cis	rs854765	0.547	rs6502632	chr17:17913057	A/G	cg09796270	chr17:17721594	SREBF1	0.25	5.04	0.41	1.61e-6	Total body bone mineral density;
TGCT	cis	rs11690935	1.000	rs2138348	chr2:172558172	A/C	cg13550731	chr2:172543902	DYNC1I2	1.23	12.97	0.76	7.83e-25	Schizophrenia;
TGCT	cis	rs1018836	0.923	rs6986088	chr8:91538474	A/C	cg16814680	chr8:91681699	NA	-0.86	-9.72	-0.66	6.1e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7091068	0.754	rs1326224	chr10:95459267	C/T	cg20715218	chr10:95462985	C10orf4	0.54	5.03	0.41	1.66e-6	Urinary tract infection frequency;
TGCT	cis	rs1153858	1.000	rs7494956	chr15:45668565	T/C	cg26924012	chr15:45694286	SPATA5L1	1.09	15.08	0.8	7.99e-30	Homoarginine levels;
TGCT	cis	rs6969780	0.673	rs2301721	chr7:27196113	C/T	cg04317399	chr7:27170313	HOXA4	-0.44	-4.9	-0.4	2.94e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs524023	0.914	rs2360872	chr11:64353405	T/C	cg07733098	chr11:64478343	NRXN2	0.31	4.62	0.38	9.53e-6	Urate levels in obese individuals;
TGCT	cis	rs6964587	0.773	rs13236026	chr7:91885873	A/G	cg17063962	chr7:91808500	NA	0.85	8.52	0.61	4.45e-14	Breast cancer;
TGCT	cis	rs17601876	0.651	rs12907866	chr15:51545454	A/G	cg19946085	chr15:51559439	CYP19A1	-0.34	-4.86	-0.4	3.5e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs3796619	0.924	rs4690209	chr4:1077575	G/A	cg27284194	chr4:1044797	NA	0.46	4.45	0.37	1.85e-5	Recombination rate (males);
TGCT	cis	rs7119038	0.818	rs11217040	chr11:118680648	C/A	cg19308663	chr11:118741387	NA	0.26	5.09	0.42	1.31e-6	Sjögren's syndrome;
TGCT	cis	rs733175	0.855	rs6853437	chr4:10005435	A/G	cg00071950	chr4:10020882	SLC2A9	-0.5	-4.58	-0.38	1.13e-5	Psychosis and Alzheimer's disease;
TGCT	cis	rs7914558	0.966	rs7921574	chr10:104840970	T/C	cg04362960	chr10:104952993	NT5C2	0.6	5.32	0.43	4.64e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs9467711	0.659	rs13195509	chr6:26463660	C/T	cg16898833	chr6:26189333	HIST1H4D	1.26	6.03	0.48	1.77e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg11812906	chr14:75593930	NEK9	0.5	4.49	0.37	1.62e-5	Height;
TGCT	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg09263875	chr16:632152	PIGQ	0.31	6.85	0.52	3.03e-10	Height;
TGCT	cis	rs12908161	1.000	rs62021219	chr15:85256159	C/T	cg11189052	chr15:85197271	WDR73	0.75	6.29	0.49	5.02e-9	Schizophrenia;
TGCT	cis	rs922182	0.557	rs6494452	chr15:64199208	G/A	cg02919090	chr15:64263738	DAPK2	0.38	7.01	0.53	1.37e-10	Blood protein levels;
TGCT	cis	rs12620999	0.589	rs6753960	chr2:238105270	C/G	cg23555395	chr2:238036564	NA	-0.26	-4.45	-0.37	1.88e-5	Systemic lupus erythematosus;
TGCT	cis	rs7584330	0.955	rs13432426	chr2:238388631	T/G	cg08992911	chr2:238395768	MLPH	0.67	5.44	0.44	2.69e-7	Prostate cancer;
TGCT	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg18230493	chr5:56204884	C5orf35	-0.68	-5.92	-0.47	2.92e-8	Initial pursuit acceleration;
TGCT	cis	rs2735413	0.564	rs73580821	chr16:78110304	A/G	cg09132178	chr16:78079569	NA	0.37	4.8	0.4	4.4e-6	Systolic blood pressure (alcohol consumption interaction);
TGCT	cis	rs35160687	0.901	rs17738096	chr2:86513893	C/G	cg03171300	chr2:86307199	POLR1A	0.32	5.54	0.45	1.73e-7	Night sleep phenotypes;
TGCT	cis	rs7666738	0.830	rs6854919	chr4:98947326	C/T	cg17366294	chr4:99064904	C4orf37	0.7	7.13	0.54	7.23e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2820315	1.000	rs2172935	chr1:201826340	A/G	cg12730843	chr1:201915899	LMOD1	0.27	4.8	0.4	4.44e-6	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
TGCT	cis	rs36051895	0.664	rs1034072	chr9:5088903	T/A	cg02405213	chr9:5042618	JAK2	-0.72	-9.52	-0.65	1.85e-16	Pediatric autoimmune diseases;
TGCT	cis	rs6570726	1.000	rs436066	chr6:145847127	C/T	cg23711669	chr6:146136114	FBXO30	0.69	6.5	0.5	1.78e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10875595	0.779	rs4912746	chr5:140673969	T/C	cg24830062	chr5:140700576	TAF7	-0.61	-5.14	-0.42	1.04e-6	Pulmonary function decline;
TGCT	cis	rs7659604	0.502	rs10013916	chr4:122702179	T/G	cg06713675	chr4:122721982	EXOSC9	0.36	4.51	0.38	1.48e-5	Type 2 diabetes;
TGCT	cis	rs3096299	0.900	rs4785663	chr16:89434888	G/A	cg02187348	chr16:89574699	SPG7	0.48	4.55	0.38	1.26e-5	Multiple myeloma (IgH translocation);
TGCT	trans	rs62103177	0.683	rs13838	chr18:77663409	C/G	cg05926928	chr17:57297772	GDPD1	1.22	10.76	0.69	1.81e-19	Opioid sensitivity;
TGCT	cis	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg18252515	chr7:66147081	NA	-1.13	-6.81	-0.52	3.7e-10	Diabetic kidney disease;
TGCT	cis	rs478304	0.619	rs10791822	chr11:65428706	T/C	cg17480646	chr11:65405466	SIPA1	-0.61	-7.88	-0.58	1.4e-12	Acne (severe);
TGCT	cis	rs56309584	0.560	rs79224651	chr17:8076667	T/G	cg08322244	chr17:8066669	VAMP2	-0.52	-4.89	-0.4	3.04e-6	Initial pursuit acceleration;
TGCT	cis	rs2414095	0.527	rs11632036	chr15:51542162	A/C	cg19946085	chr15:51559439	CYP19A1	-0.32	-4.55	-0.38	1.27e-5	Follicule stimulating hormone;Hormone measurements;Total body bone mineral density;
TGCT	cis	rs9660992	0.710	rs4951184	chr1:205240659	A/T	cg00857998	chr1:205179979	DSTYK	0.52	4.61	0.38	9.99e-6	Mean corpuscular volume;Mean platelet volume;
TGCT	cis	rs2404602	0.583	rs12592501	chr15:76554790	C/A	cg22467129	chr15:76604101	ETFA	-0.62	-8.06	-0.59	5.34e-13	Blood metabolite levels;
TGCT	cis	rs921968	0.541	rs634590	chr2:219372768	C/A	cg02176678	chr2:219576539	TTLL4	0.48	6.78	0.52	4.32e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs35306767	0.953	rs34405399	chr10:981015	G/A	cg20503657	chr10:835505	NA	0.58	8.09	0.59	4.54e-13	Eosinophil percentage of granulocytes;
TGCT	cis	rs6831352	1.000	rs10017466	chr4:100055800	C/T	cg12011299	chr4:100065546	ADH4	0.4	5.07	0.41	1.44e-6	Alcohol dependence;
TGCT	cis	rs854765	0.520	rs9899355	chr17:17898243	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.74	7.19	0.54	5.35e-11	Total body bone mineral density;
TGCT	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg12311346	chr5:56204834	C5orf35	-0.67	-6.82	-0.52	3.63e-10	Initial pursuit acceleration;
TGCT	cis	rs9660992	0.710	rs1172111	chr1:205232980	C/T	cg00857998	chr1:205179979	DSTYK	0.52	4.56	0.38	1.19e-5	Mean corpuscular volume;Mean platelet volume;
TGCT	cis	rs72700829	0.593	rs4418603	chr1:150989274	A/G	cg00666978	chr1:150947442	LASS2	0.9	4.62	0.38	9.37e-6	Schizophrenia;
TGCT	cis	rs9425766	0.640	rs9425756	chr1:173816586	C/T	cg07177756	chr1:173836307	SNORD75;SNORD78;ZBTB37;SNORD76;GAS5;SNORD77;SNORD44	0.49	4.51	0.38	1.49e-5	Life satisfaction;
TGCT	cis	rs9381040	0.610	rs2268196	chr6:41021950	C/G	cg03526776	chr6:41159608	TREML2	-0.27	-5.29	-0.43	5.37e-7	Alzheimer's disease (late onset);
TGCT	cis	rs7582180	0.764	rs11693424	chr2:100925439	G/A	cg08017756	chr2:100939284	LONRF2	-0.32	-5.31	-0.43	4.86e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs12681288	0.823	rs2701909	chr8:1003057	A/G	cg04851639	chr8:1020857	NA	-0.36	-6.47	-0.5	2.01e-9	Schizophrenia;
TGCT	cis	rs7296418	0.885	rs1727305	chr12:123633382	T/C	cg00376283	chr12:123451042	ABCB9	0.84	7.66	0.57	4.68e-12	Platelet count;
TGCT	cis	rs1568889	0.938	rs1464898	chr11:28034748	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.87	8.85	0.62	7.64e-15	Bipolar disorder;
TGCT	cis	rs2594989	0.895	rs439738	chr3:11322577	G/C	cg00170343	chr3:11313890	ATG7	0.68	5.18	0.42	8.63e-7	Circulating chemerin levels;
TGCT	cis	rs2153535	0.560	rs9379214	chr6:8480870	T/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.02	0.41	1.75e-6	Motion sickness;
TGCT	cis	rs11098499	0.866	rs12510451	chr4:120289143	C/T	cg09307838	chr4:120376055	NA	0.58	5.76	0.46	6.16e-8	Corneal astigmatism;
TGCT	cis	rs7582180	0.591	rs12991577	chr2:101010867	C/A	cg08017756	chr2:100939284	LONRF2	-0.31	-4.87	-0.4	3.32e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4919044	0.641	rs12357515	chr10:94725508	A/G	cg05127821	chr10:94822908	CYP26C1	-0.73	-4.47	-0.37	1.74e-5	Coronary artery disease;
TGCT	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg03352830	chr11:487213	PTDSS2	0.27	4.67	0.39	7.56e-6	Body mass index;
TGCT	cis	rs734999	0.505	rs10910108	chr1:2539532	A/G	cg18854424	chr1:2615690	NA	0.46	5.36	0.43	4e-7	Ulcerative colitis;
TGCT	cis	rs7647973	0.731	rs9831648	chr3:49214303	G/T	cg05785598	chr3:49045655	WDR6	0.43	5.01	0.41	1.83e-6	Menarche (age at onset);
TGCT	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg11764359	chr7:65958608	NA	-0.61	-5.51	-0.44	1.96e-7	Aortic root size;
TGCT	cis	rs1994135	0.669	rs10844629	chr12:33697096	T/A	cg06521331	chr12:34319734	NA	-0.3	-4.73	-0.39	6.09e-6	Resting heart rate;
TGCT	cis	rs2760061	0.583	rs3094911	chr1:228210179	A/G	cg02753203	chr1:228287806	NA	0.37	7.5	0.56	1.05e-11	Diastolic blood pressure;
TGCT	cis	rs514406	0.698	rs11206043	chr1:53402552	C/T	cg08859206	chr1:53392774	SCP2	-0.45	-7.34	-0.55	2.5e-11	Monocyte count;
TGCT	trans	rs208515	0.556	rs12201658	chr6:66678457	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.92	10.09	0.67	7.45e-18	Exhaled nitric oxide levels;
TGCT	cis	rs7255045	0.665	rs2014639	chr19:12975021	G/C	cg23899408	chr19:12877188	HOOK2	-0.62	-5.04	-0.41	1.58e-6	Mean corpuscular volume;
TGCT	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg22920501	chr2:26401640	FAM59B	-0.73	-6.32	-0.49	4.19e-9	Gut microbiome composition (summer);
TGCT	cis	rs9611565	0.649	rs5751144	chr22:42128097	A/G	cg06481639	chr22:41940642	POLR3H	-0.56	-4.87	-0.4	3.39e-6	Vitiligo;
TGCT	cis	rs7528684	0.725	rs10430455	chr1:157703238	T/A	cg17134153	chr1:157670328	FCRL3	0.27	4.75	0.39	5.61e-6	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;
TGCT	cis	rs2204008	0.540	rs1672425	chr12:38122842	G/A	cg26384229	chr12:38710491	ALG10B	-0.59	-5.23	-0.42	7.06e-7	Bladder cancer;
TGCT	cis	rs155076	0.938	rs261375	chr13:21871882	A/G	cg14456004	chr13:21872349	NA	1.3	9.95	0.67	1.7e-17	White matter hyperintensity burden;
TGCT	cis	rs12762955	0.561	rs10752022	chr10:1043798	C/T	cg26597838	chr10:835615	NA	-0.46	-6.1	-0.48	1.23e-8	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs151997	0.925	rs27570	chr5:50191974	G/A	cg06027927	chr5:50259733	NA	0.49	5.03	0.41	1.65e-6	Callous-unemotional behaviour;
TGCT	cis	rs4642101	0.765	rs3901665	chr3:12824610	C/A	cg05775895	chr3:12838266	CAND2	0.79	9.04	0.63	2.61e-15	QRS complex (12-leadsum);
TGCT	cis	rs76419734	0.558	rs4324546	chr4:106526987	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	-0.76	-4.79	-0.39	4.76e-6	Post bronchodilator FEV1;
TGCT	cis	rs4654899	0.758	rs12402486	chr1:21447935	A/G	cg01072550	chr1:21505969	NA	0.56	9.08	0.63	2.14e-15	Superior frontal gyrus grey matter volume;
TGCT	cis	rs2836950	0.509	rs4816618	chr21:40599529	G/A	cg11890956	chr21:40555474	PSMG1	-0.7	-6.87	-0.52	2.79e-10	Menarche (age at onset);
TGCT	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg16497277	chr3:49208875	KLHDC8B	-0.59	-5.59	-0.45	1.4e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	trans	rs877282	0.853	rs11253332	chr10:755262	G/C	cg22713356	chr15:30763199	NA	1.07	8.27	0.6	1.75e-13	Uric acid levels;
TGCT	cis	rs2404602	0.692	rs35395069	chr15:76986334	C/T	cg22467129	chr15:76604101	ETFA	-0.45	-5.11	-0.42	1.2e-6	Blood metabolite levels;
TGCT	cis	rs9811920	0.529	rs793442	chr3:99581062	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.61	6.99	0.53	1.47e-10	Axial length;
TGCT	cis	rs748404	0.631	rs6493086	chr15:43655394	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	4.72	0.39	6.3e-6	Lung cancer;
TGCT	trans	rs1814175	0.817	rs10839351	chr11:49758153	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.44	-0.56	1.47e-11	Height;
TGCT	cis	rs4851266	0.901	rs4851271	chr2:100833058	T/C	cg07810366	chr2:100720526	AFF3	-0.37	-5.33	-0.43	4.53e-7	Educational attainment;
TGCT	cis	rs12220238	1.000	rs7907801	chr10:75976638	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.91	7.77	0.57	2.63e-12	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs4566357	1.000	rs2141829	chr2:227922454	G/A	cg11843606	chr2:227700838	RHBDD1	-0.58	-5.31	-0.43	4.92e-7	Coronary artery disease;
TGCT	cis	rs9419702	0.568	rs7093241	chr10:133556596	G/A	cg04492858	chr10:133558786	NA	0.56	5.96	0.47	2.46e-8	Survival in rectal cancer;
TGCT	cis	rs10940138	0.720	rs2372188	chr5:67233704	T/C	ch.5.1281357F	chr5:67228439	NA	0.38	4.56	0.38	1.2e-5	Menarche (age at onset);
TGCT	cis	rs782590	0.902	rs782602	chr2:55849309	A/G	cg18811423	chr2:55921094	PNPT1	0.63	6.6	0.51	1.05e-9	Metabolic syndrome;
TGCT	cis	rs10883723	0.518	rs10786679	chr10:104315667	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.72	6.14	0.48	1.02e-8	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs4654899	0.601	rs6668094	chr1:21464387	C/T	cg01072550	chr1:21505969	NA	0.56	9.18	0.64	1.2e-15	Superior frontal gyrus grey matter volume;
TGCT	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg03188948	chr7:1209495	NA	0.59	4.8	0.4	4.51e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7647973	1.000	rs10865956	chr3:49581559	C/A	cg06212747	chr3:49208901	KLHDC8B	0.54	4.45	0.37	1.87e-5	Menarche (age at onset);
TGCT	cis	rs1215050	0.740	rs1084784	chr4:98961711	T/G	cg05340658	chr4:99064831	C4orf37	-0.44	-5.35	-0.43	4.13e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs4319547	0.656	rs7135419	chr12:122911861	T/A	cg05707623	chr12:122985044	ZCCHC8	-0.65	-5.07	-0.41	1.39e-6	Body mass index;
TGCT	cis	rs10875746	0.855	rs12296244	chr12:48441479	C/G	cg20731937	chr12:48336164	NA	0.62	4.95	0.41	2.36e-6	Longevity (90 years and older);
TGCT	cis	rs2739330	0.576	rs2858912	chr22:24297197	A/G	cg12419862	chr22:24373484	LOC391322	-0.8	-8.67	-0.61	1.97e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2074585	0.806	rs2657949	chr15:90950790	G/A	cg22089800	chr15:90895588	ZNF774	0.78	8.09	0.59	4.55e-13	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
TGCT	cis	rs3820068	0.544	rs7551750	chr1:16035008	T/C	cg17385448	chr1:15911702	AGMAT	0.35	4.99	0.41	1.96e-6	Systolic blood pressure;
TGCT	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg04944784	chr2:26401820	FAM59B	-0.76	-6.34	-0.49	3.94e-9	Gut microbiome composition (summer);
TGCT	cis	rs9788721	0.902	rs114205691	chr15:78901113	C/T	cg18825076	chr15:78729989	IREB2	-0.29	-4.45	-0.37	1.88e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
TGCT	cis	rs45509595	0.841	rs200501	chr6:27788942	C/T	cg10876282	chr6:28092338	ZSCAN16	0.78	4.57	0.38	1.17e-5	Breast cancer;
TGCT	cis	rs2204008	0.837	rs11168387	chr12:37962818	G/A	cg26384229	chr12:38710491	ALG10B	-0.7	-6.12	-0.48	1.11e-8	Bladder cancer;
TGCT	cis	rs5769765	0.862	rs138856	chr22:50199378	G/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.36	5.26	0.43	6.2e-7	Schizophrenia;
TGCT	cis	rs113507773	1	rs113507773	chr6:26255739	G/A	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.68	-4.45	-0.37	1.89e-5	Iron status biomarkers (transferrin saturation);Iron status biomarkers (iron levels);
TGCT	cis	rs10464366	0.560	rs12672089	chr7:39132816	G/A	cg18850127	chr7:39170497	POU6F2	0.28	6.39	0.5	3.1e-9	IgG glycosylation;
TGCT	cis	rs8017423	0.967	rs59006192	chr14:90706456	C/T	cg04374321	chr14:90722782	PSMC1	0.77	8.05	0.59	5.68e-13	Mortality in heart failure;
TGCT	cis	rs9916302	0.861	rs10491129	chr17:37461643	T/G	cg07936489	chr17:37558343	FBXL20	0.62	4.91	0.4	2.85e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs10858047	0.883	rs41274118	chr1:115119392	T/C	cg12756093	chr1:115239321	AMPD1	0.47	4.96	0.41	2.27e-6	Autism;
TGCT	cis	rs7945705	0.967	rs7123429	chr11:8866808	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.45	-5.2	-0.42	8.12e-7	Hemoglobin concentration;
TGCT	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.94	-6.05	-0.48	1.59e-8	Alzheimer's disease;
TGCT	cis	rs17331151	0.573	rs13080929	chr3:52885112	A/C	cg12962167	chr3:53033115	SFMBT1	0.42	4.62	0.38	9.36e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs3733585	0.657	rs62286568	chr4:10124889	C/T	cg00071950	chr4:10020882	SLC2A9	-0.48	-4.96	-0.41	2.25e-6	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg04267008	chr7:1944627	MAD1L1	-0.35	-4.66	-0.39	8.13e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs7666738	0.680	rs34267968	chr4:99002574	A/T	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs732765	1.000	rs3742785	chr14:75373034	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.62	-5.37	-0.43	3.7e-7	Non-small cell lung cancer;
TGCT	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg26338869	chr17:61819248	STRADA	-0.55	-5.08	-0.41	1.37e-6	Prudent dietary pattern;
TGCT	cis	rs7147624	1.000	rs1009465	chr14:65970370	G/C	cg03016385	chr14:66212404	NA	-0.49	-7.11	-0.54	8.13e-11	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs2580764	0.598	rs6726158	chr2:55239202	G/T	cg09592903	chr2:55203963	RTN4	-0.27	-6.12	-0.48	1.15e-8	Mean platelet volume;
TGCT	cis	rs9467711	0.606	rs9358936	chr6:26370657	A/G	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7043114	0.525	rs7047089	chr9:95117980	C/T	cg14631576	chr9:95140430	CENPP	-0.27	-4.45	-0.37	1.87e-5	Height;
TGCT	cis	rs7582180	0.563	rs4851304	chr2:100963871	C/T	cg08017756	chr2:100939284	LONRF2	-0.3	-4.87	-0.4	3.27e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9388451	0.626	rs1935983	chr6:126068914	C/T	cg10911889	chr6:126070802	HEY2	0.5	4.69	0.39	7.17e-6	Brugada syndrome;
TGCT	cis	rs10871290	1.000	rs11149710	chr16:74472546	G/T	cg01733217	chr16:74700730	RFWD3	-0.52	-4.78	-0.39	4.78e-6	Breast cancer;
TGCT	cis	rs9467773	0.595	rs7767847	chr6:26597893	A/T	cg02458000	chr6:26745757	NA	0.52	4.8	0.4	4.48e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg03351412	chr1:154909251	PMVK	0.53	4.93	0.4	2.6e-6	Prostate cancer;
TGCT	cis	rs7089973	0.624	rs11196940	chr10:116593791	T/G	cg03647239	chr10:116582469	FAM160B1	0.59	5.74	0.46	6.72e-8	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.48	-0.37	1.66e-5	Bipolar disorder;
TGCT	cis	rs3806843	0.576	rs155363	chr5:140301543	A/G	cg07102913	chr5:140593443	PCDHB13	-0.48	-4.77	-0.39	5.15e-6	Depressive symptoms (multi-trait analysis);
TGCT	trans	rs11088226	0.645	rs2409457	chr21:33929895	T/C	cg09050820	chr6:167586206	TCP10L2	0.76	6.79	0.52	4.22e-10	Gastritis;
TGCT	cis	rs9928842	0.823	rs2870472	chr16:75278841	C/G	cg09066997	chr16:75300724	BCAR1	0.26	4.67	0.39	7.84e-6	Alcoholic chronic pancreatitis;
TGCT	cis	rs7226408	0.842	rs9958203	chr18:34348958	A/G	cg06757138	chr18:34340585	FHOD3	0.29	5.15	0.42	1.01e-6	Obesity-related traits;
TGCT	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg23758822	chr17:41437982	NA	0.72	6.89	0.53	2.46e-10	Menopause (age at onset);
TGCT	cis	rs9993613	0.875	rs6841091	chr4:73459531	C/G	cg15102770	chr4:73434591	ADAMTS3	-0.51	-4.8	-0.4	4.47e-6	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs4788570	0.615	rs889568	chr16:71772399	T/C	cg06353428	chr16:71660113	MARVELD3	1.54	12.41	0.74	1.74e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs1670533	0.615	rs59985183	chr4:1087171	G/T	cg20887711	chr4:1340912	KIAA1530	0.62	4.93	0.41	2.53e-6	Recombination rate (females);
TGCT	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	8.22	0.59	2.35e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs71636778	0.509	rs11555809	chr1:27216669	G/A	cg23921621	chr1:27994728	IFI6	-0.42	-4.59	-0.38	1.06e-5	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
TGCT	cis	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg25427524	chr10:38739819	LOC399744	-0.41	-8.54	-0.61	4.04e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs12681287	0.752	rs4389908	chr8:87274852	A/G	cg27223183	chr8:87520930	FAM82B	-0.82	-5.86	-0.47	3.98e-8	Caudate activity during reward;
TGCT	cis	rs12210905	0.688	rs114843651	chr6:27449611	A/G	cg08851530	chr6:28072375	NA	1.34	6.29	0.49	5.02e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs155076	1.000	rs566364	chr13:21837583	T/C	cg14456004	chr13:21872349	NA	-1.32	-10.82	-0.7	1.25e-19	White matter hyperintensity burden;
TGCT	cis	rs1372520	0.684	rs2619356	chr4:90750844	C/T	cg15133208	chr4:90757351	SNCA	-0.5	-5.86	-0.47	4e-8	Neuroticism;
TGCT	cis	rs9308731	0.688	rs4302219	chr2:111880284	G/T	cg04202892	chr2:111875749	ACOXL	0.54	6.25	0.49	6.1e-9	Chronic lymphocytic leukemia;
TGCT	cis	rs9948	0.655	rs6751132	chr2:97405866	T/C	cg01990225	chr2:97406019	LMAN2L	-0.9	-5.35	-0.43	4.05e-7	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs12971120	0.838	rs3794950	chr18:72182965	G/A	cg25817165	chr18:72167213	CNDP2	-0.27	-4.65	-0.39	8.46e-6	Refractive error;
TGCT	cis	rs67478160	0.643	rs34813623	chr14:104263294	A/G	cg26031613	chr14:104095156	KLC1	-0.64	-6.58	-0.51	1.2e-9	Schizophrenia;
TGCT	cis	rs4727027	0.933	rs1058059	chr7:148879134	A/T	cg23583168	chr7:148888333	NA	-0.74	-9.81	-0.66	3.64e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs6674176	0.597	rs6671164	chr1:44403489	G/T	cg12908607	chr1:44402522	ARTN	-0.73	-8.91	-0.62	5.24e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	trans	rs9467711	1.000	rs6939978	chr6:26328462	G/C	cg20516262	chr7:155325649	CNPY1	0.54	6.63	0.51	9.34e-10	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7582180	0.629	rs11688285	chr2:100948054	A/C	cg14675211	chr2:100938903	LONRF2	0.5	4.73	0.39	5.96e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs79349575	0.783	rs1994970	chr17:47014127	C/T	cg00947319	chr17:47005597	UBE2Z	0.2	4.74	0.39	5.83e-6	Type 2 diabetes;
TGCT	cis	rs854765	0.663	rs16960744	chr17:17755259	A/G	cg09796270	chr17:17721594	SREBF1	-0.26	-4.93	-0.4	2.59e-6	Total body bone mineral density;
TGCT	cis	rs644799	0.710	rs523153	chr11:95570961	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.79	7.88	0.58	1.41e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs57221529	0.766	rs12522303	chr5:555564	A/C	cg09021430	chr5:549028	NA	-0.4	-5.46	-0.44	2.44e-7	Lung disease severity in cystic fibrosis;
TGCT	cis	rs763121	0.962	rs5757135	chr22:38952573	C/T	cg06022373	chr22:39101656	GTPBP1	0.74	7.2	0.54	5.19e-11	Menopause (age at onset);
TGCT	cis	rs1532993	0.500	rs2085324	chr4:98621066	T/C	cg05340658	chr4:99064831	C4orf37	-0.37	-4.44	-0.37	1.98e-5	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg11644478	chr21:40555479	PSMG1	-0.53	-4.97	-0.41	2.14e-6	Menarche (age at onset);
TGCT	cis	rs6545883	0.894	rs778143	chr2:61581890	A/C	cg15711740	chr2:61764176	XPO1	-0.54	-4.74	-0.39	5.82e-6	Tuberculosis;
TGCT	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg00908189	chr16:619842	PIGQ	0.86	10.48	0.69	8.48e-19	Height;
TGCT	cis	rs10779751	0.770	rs11585553	chr1:11233814	G/A	cg08854313	chr1:11322531	MTOR	-0.83	-6.46	-0.5	2.16e-9	Body mass index;
TGCT	cis	rs7772486	0.790	rs2265474	chr6:146182092	G/A	cg23711669	chr6:146136114	FBXO30	0.96	11.32	0.71	7.81e-21	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4713118	0.525	rs9357042	chr6:27582795	A/C	cg10876282	chr6:28092338	ZSCAN16	0.45	4.61	0.38	9.84e-6	Parkinson's disease;
TGCT	trans	rs66573146	1.000	rs55672215	chr4:6970529	T/C	cg07817883	chr1:32538562	TMEM39B	1.37	7.77	0.57	2.56e-12	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs6089584	0.606	rs7270469	chr20:60577258	G/A	cg13770153	chr20:60521292	NA	-0.41	-5.12	-0.42	1.16e-6	Body mass index;
TGCT	cis	rs317689	0.718	rs315130	chr12:69761444	T/C	cg20891283	chr12:69753455	YEATS4	0.55	4.5	0.37	1.53e-5	Response to diuretic therapy;
TGCT	cis	rs709400	1.000	rs2403205	chr14:104143385	C/T	cg26031613	chr14:104095156	KLC1	1.14	17.16	0.84	1.53e-34	Body mass index;
TGCT	cis	rs78487399	0.710	rs6743071	chr2:43586287	T/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.46	-5.22	-0.42	7.39e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.58	-5.86	-0.47	3.93e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs12049351	0.665	rs3738186	chr1:229657230	A/C	cg12130225	chr1:229698885	NA	0.35	4.46	0.37	1.85e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs13256369	0.802	rs11249883	chr8:8561537	G/A	cg17143192	chr8:8559678	CLDN23	0.54	5.03	0.41	1.64e-6	Obesity-related traits;
TGCT	cis	rs617219	0.726	rs1962002	chr5:78430689	T/C	cg23514016	chr5:78407564	BHMT	0.33	4.96	0.41	2.31e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs13242816	1.000	rs56010123	chr7:116173046	C/T	cg16553024	chr7:116138462	CAV2	-0.44	-5.26	-0.43	6.11e-7	P wave duration;
TGCT	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg12311346	chr5:56204834	C5orf35	-0.63	-6.53	-0.51	1.51e-9	Initial pursuit acceleration;
TGCT	cis	rs7904368	0.568	rs10752061	chr10:16853900	A/G	cg23933602	chr10:16859644	RSU1	0.6	5.31	0.43	4.83e-7	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
TGCT	cis	rs6484504	0.576	rs176373	chr11:31136026	G/T	cg26647111	chr11:31128758	NA	-0.33	-4.69	-0.39	6.96e-6	Red blood cell count;
TGCT	cis	rs7829975	0.777	rs486781	chr8:8639740	A/G	cg08975724	chr8:8085496	FLJ10661	-0.52	-4.51	-0.38	1.47e-5	Mood instability;
TGCT	cis	rs4654899	0.865	rs957163	chr1:21416181	G/T	cg01072550	chr1:21505969	NA	-0.47	-7.1	-0.54	8.54e-11	Superior frontal gyrus grey matter volume;
TGCT	cis	rs6570726	0.935	rs421690	chr6:145834594	A/C	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3733585	0.673	rs7378340	chr4:9955198	C/T	cg11266682	chr4:10021025	SLC2A9	-0.59	-7.81	-0.57	2.04e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs4253772	0.530	rs6008662	chr22:46713917	G/A	cg26492175	chr22:47022658	GRAMD4	0.2	4.47	0.37	1.72e-5	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs10479542	0.896	rs10078712	chr5:178978805	C/T	cg09060608	chr5:178986726	RUFY1	-0.48	-5.33	-0.43	4.42e-7	Lung cancer;
TGCT	cis	rs17376456	0.825	rs6898842	chr5:93213221	T/C	cg25358565	chr5:93447407	FAM172A	1.02	8.11	0.59	4.17e-13	Diabetic retinopathy;
TGCT	cis	rs864537	0.676	rs2056625	chr1:167420299	G/A	cg22356347	chr1:167427500	CD247	-0.21	-5.21	-0.42	7.58e-7	Celiac disease or Rheumatoid arthritis;Celiac disease;
TGCT	cis	rs7044106	0.791	rs735109	chr9:123488879	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	7.23	0.54	4.43e-11	Hip circumference adjusted for BMI;
TGCT	cis	rs12048904	0.505	rs11166511	chr1:101240686	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.81	-6.9	-0.53	2.4e-10	Multiple sclerosis;
TGCT	cis	rs270601	0.913	rs273899	chr5:131695178	G/A	cg24060327	chr5:131705240	SLC22A5	-0.77	-8.46	-0.6	6.27e-14	Acylcarnitine levels;
TGCT	cis	rs68170813	0.559	rs60255281	chr7:106963913	C/T	cg02696742	chr7:106810147	HBP1	-0.71	-5.83	-0.46	4.43e-8	Coronary artery disease;
TGCT	cis	rs4455778	0.626	rs1558307	chr7:49030540	A/C	cg26309511	chr7:48887640	NA	0.44	5.22	0.42	7.26e-7	Lung cancer in never smokers;
TGCT	cis	rs9393692	0.875	rs6939589	chr6:26289203	C/T	cg13736514	chr6:26305472	NA	0.4	5.64	0.45	1.1e-7	Educational attainment;
TGCT	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg15383120	chr6:291909	DUSP22	0.65	6.92	0.53	2.11e-10	Menopause (age at onset);
TGCT	cis	rs875971	0.564	rs313804	chr7:65514622	A/G	cg18876405	chr7:65276391	NA	0.33	4.95	0.41	2.39e-6	Aortic root size;
TGCT	cis	rs11190604	1.000	rs79831012	chr10:102237059	T/C	cg23241863	chr10:102295624	HIF1AN	0.62	4.87	0.4	3.27e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs35883536	0.647	rs2783696	chr1:101044089	G/A	cg10298815	chr1:101004474	GPR88	0.24	4.44	0.37	1.95e-5	Monocyte count;
TGCT	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg08736216	chr1:53307985	ZYG11A	0.25	4.93	0.41	2.55e-6	Monocyte count;
TGCT	cis	rs751728	0.687	rs943471	chr6:33738314	C/T	cg13859433	chr6:33739653	LEMD2	-0.32	-5.6	-0.45	1.29e-7	Crohn's disease;
TGCT	cis	rs2153535	0.580	rs9379215	chr6:8481225	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg09060608	chr5:178986726	RUFY1	0.63	8.01	0.58	7.23e-13	Lung cancer;
TGCT	cis	rs8020441	0.838	rs4901051	chr14:51164768	G/A	cg04730355	chr14:51134070	SAV1	0.71	5.84	0.46	4.39e-8	Cognitive performance;
TGCT	cis	rs2439831	0.867	rs3101443	chr15:43912372	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.93	6.64	0.51	8.7e-10	Lung cancer in ever smokers;
TGCT	cis	rs1371867	0.846	rs1660348	chr8:101315248	A/G	cg00191853	chr8:101177733	SPAG1	-0.23	-4.76	-0.39	5.2e-6	Atrioventricular conduction;
TGCT	cis	rs68170813	0.559	rs10953534	chr7:106913718	A/G	cg02696742	chr7:106810147	HBP1	0.73	6.11	0.48	1.18e-8	Coronary artery disease;
TGCT	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg23758822	chr17:41437982	NA	0.72	6.96	0.53	1.79e-10	Menopause (age at onset);
TGCT	cis	rs1865760	0.622	rs10946807	chr6:26079638	T/C	cg17691542	chr6:26056736	HIST1H1C	0.71	5.47	0.44	2.34e-7	Height;
TGCT	cis	rs7772486	0.738	rs2246334	chr6:146183635	G/A	cg23711669	chr6:146136114	FBXO30	0.95	10.95	0.7	6.09e-20	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg11235426	chr6:292522	DUSP22	-0.64	-6.71	-0.52	6.09e-10	Menopause (age at onset);
TGCT	cis	rs6684514	1.000	rs12040868	chr1:156284803	G/T	cg16558208	chr1:156270281	VHLL	0.48	9.6	0.65	1.19e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs4808199	0.947	rs2163804	chr19:19575965	G/A	cg03709012	chr19:19516395	GATAD2A	1.02	7.83	0.58	1.82e-12	Nonalcoholic fatty liver disease;
TGCT	cis	rs9611565	0.512	rs4820444	chr22:42202606	A/G	cg03806693	chr22:41940476	POLR3H	1.04	10.57	0.69	5.2e-19	Vitiligo;
TGCT	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg05315796	chr3:52349193	DNAH1	0.18	4.47	0.37	1.75e-5	Bipolar disorder;
TGCT	cis	rs56399783	0.901	rs56007918	chr7:2826205	A/G	cg19731401	chr7:2775893	GNA12	0.37	5.15	0.42	1e-6	Childhood ear infection;
TGCT	cis	rs16867321	0.627	rs73023570	chr2:181510582	C/A	cg23363182	chr2:181467187	NA	-0.45	-4.64	-0.38	8.67e-6	Obesity;
TGCT	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg12310025	chr6:25882481	NA	-0.66	-5.99	-0.47	2.11e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs17376456	0.542	rs6556833	chr5:93104707	T/C	cg21475434	chr5:93447410	FAM172A	0.64	6.04	0.48	1.69e-8	Diabetic retinopathy;
TGCT	trans	rs72772090	0.708	rs17082200	chr5:96048604	T/C	cg17670890	chr5:176011783	PCDH24	0.37	6.62	0.51	9.8e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs3806843	0.548	rs246056	chr5:140325600	G/A	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.42	-5.37	-0.43	3.69e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs1577917	0.771	rs4145082	chr6:86352016	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.58	-0.45	1.43e-7	Response to antipsychotic treatment;
TGCT	trans	rs3780486	0.846	rs73484568	chr9:33132492	G/A	cg04842962	chr6:43655489	MRPS18A	1.24	15.83	0.82	1.46e-31	IgG glycosylation;
TGCT	cis	rs35306767	0.671	rs11253473	chr10:906826	A/G	cg26597838	chr10:835615	NA	0.75	10.61	0.69	4.13e-19	Eosinophil percentage of granulocytes;
TGCT	cis	rs4285028	0.948	rs35737776	chr3:121677856	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.77	-6.55	-0.51	1.35e-9	Multiple sclerosis;
TGCT	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg08736216	chr1:53307985	ZYG11A	-0.26	-5.27	-0.43	5.72e-7	Monocyte count;
TGCT	cis	rs35306767	0.903	rs7914758	chr10:891702	T/C	cg20503657	chr10:835505	NA	0.77	11.34	0.71	6.95e-21	Eosinophil percentage of granulocytes;
TGCT	cis	rs7017914	0.905	rs3110248	chr8:71934935	A/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-4.97	-0.41	2.16e-6	Bone mineral density;
TGCT	cis	rs9611565	0.559	rs7290990	chr22:41964357	C/A	cg06481639	chr22:41940642	POLR3H	-0.67	-5.71	-0.46	7.87e-8	Vitiligo;
TGCT	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg07507251	chr3:52567010	NT5DC2	0.47	6.55	0.51	1.37e-9	Electroencephalogram traits;
TGCT	cis	rs1519814	0.654	rs1543201	chr8:121018888	A/T	cg22335954	chr8:121166405	COL14A1	0.39	4.81	0.4	4.22e-6	Breast cancer;
TGCT	cis	rs1843834	0.505	rs2140508	chr2:225355839	G/T	cg12698349	chr2:225449008	CUL3	0.77	6.28	0.49	5.2e-9	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.91	0.4	2.83e-6	Height;
TGCT	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	4.98	0.41	2.08e-6	Prudent dietary pattern;
TGCT	cis	rs7439150	1.000	rs4508864	chr4:155481289	C/T	cg22130008	chr4:155548532	NA	-0.4	-5.08	-0.42	1.32e-6	Fibrinogen levels;
TGCT	cis	rs6589563	0.737	rs61905086	chr11:116614863	T/C	cg20660624	chr11:117307972	DSCAML1	-0.34	-4.58	-0.38	1.13e-5	Eosinophil counts;
TGCT	cis	rs782590	0.807	rs782642	chr2:55928444	G/T	cg18811423	chr2:55921094	PNPT1	0.68	7.19	0.54	5.25e-11	Metabolic syndrome;
TGCT	cis	rs12039431	0.706	rs61776179	chr1:37986804	G/T	cg17933807	chr1:38061675	GNL2	-0.81	-7.8	-0.57	2.19e-12	Epithelial ovarian cancer;
TGCT	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg24675658	chr1:53192096	ZYG11B	0.84	10.45	0.68	1.03e-18	Monocyte count;
TGCT	cis	rs477895	0.713	rs11600867	chr11:63972052	T/A	cg04317338	chr11:64019027	PLCB3	0.8	6.61	0.51	1.01e-9	Mean platelet volume;
TGCT	cis	rs12142240	0.698	rs9661240	chr1:46827050	G/A	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs11122272	0.735	rs2572254	chr1:231512593	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.11	-0.54	8.07e-11	Hemoglobin concentration;
TGCT	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg24846343	chr22:24311635	DDTL	0.23	5.79	0.46	5.54e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs854765	0.547	rs12150369	chr17:17911014	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.79	8.4	0.6	8.61e-14	Total body bone mineral density;
TGCT	cis	rs6912958	1.000	rs9294380	chr6:88152667	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.6	-5.84	-0.46	4.27e-8	Monocyte percentage of white cells;
TGCT	cis	rs7072216	0.655	rs3830024	chr10:100176106	G/A	cg26618903	chr10:100175079	PYROXD2	-0.42	-4.44	-0.37	1.93e-5	Metabolite levels;
TGCT	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg01448562	chr3:133502909	NA	-0.33	-6.71	-0.52	6.3e-10	Iron status biomarkers;
TGCT	trans	rs10506458	0.834	rs17738403	chr12:63389200	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.47	-7.54	-0.56	8.62e-12	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs10032931	0.743	rs1385668	chr4:96459330	A/G	cg03008707	chr4:96468962	UNC5C	-0.38	-5.13	-0.42	1.08e-6	Optic nerve measurement (cup-to-disc ratio);
TGCT	cis	rs9811920	0.809	rs923472	chr3:99758029	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.45	5.02	0.41	1.79e-6	Axial length;
TGCT	cis	rs2777491	0.872	rs7176588	chr15:41588872	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.73	-10.55	-0.69	5.9e-19	Ulcerative colitis;
TGCT	cis	rs7523273	0.565	rs1998539	chr1:207886596	G/A	cg22525895	chr1:207977042	MIR29B2	0.35	5.62	0.45	1.19e-7	Schizophrenia;
TGCT	cis	rs7666738	0.571	rs7683769	chr4:99091742	T/C	cg17366294	chr4:99064904	C4orf37	0.58	5.38	0.43	3.6e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11690935	0.632	rs6723259	chr2:172622527	A/C	cg13550731	chr2:172543902	DYNC1I2	0.68	6.0	0.47	2.02e-8	Schizophrenia;
TGCT	cis	rs7639513	0.767	rs9861472	chr3:12707776	A/T	cg23032965	chr3:12705835	RAF1	-0.76	-8.34	-0.6	1.18e-13	Itch intensity from mosquito bite;
TGCT	cis	rs6964587	0.967	rs13233496	chr7:91813035	T/C	cg17063962	chr7:91808500	NA	0.92	9.92	0.67	2e-17	Breast cancer;
TGCT	cis	rs1801251	0.963	rs66549961	chr2:233602293	A/G	cg25237894	chr2:233734115	C2orf82	0.32	5.72	0.46	7.51e-8	Coronary artery disease;
TGCT	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg01448562	chr3:133502909	NA	-0.32	-6.31	-0.49	4.57e-9	Iron status biomarkers;
TGCT	cis	rs35306767	0.715	rs11253539	chr10:1011347	G/A	cg20503657	chr10:835505	NA	0.57	6.33	0.49	4.06e-9	Eosinophil percentage of granulocytes;
TGCT	cis	rs9911578	1.000	rs1057068	chr17:56598439	T/C	cg12560992	chr17:57184187	TRIM37	-0.76	-9.3	-0.64	6.22e-16	Intelligence (multi-trait analysis);
TGCT	trans	rs208520	0.690	rs12202401	chr6:66760544	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	11.22	0.71	1.34e-20	Exhaled nitric oxide output;
TGCT	cis	rs3806843	0.576	rs246008	chr5:140338485	C/T	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7267979	1.000	rs6050599	chr20:25400240	T/C	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs910316	0.967	rs7146523	chr14:75659880	T/C	cg08847533	chr14:75593920	NEK9	-0.94	-10.1	-0.67	7.14e-18	Height;
TGCT	cis	rs4645881	0.683	rs2387583	chr19:49461305	C/T	cg15040422	chr19:49955266	ALDH16A1;PIH1D1	-0.83	-4.54	-0.38	1.31e-5	Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil counts;
TGCT	cis	rs9399135	0.636	rs7749106	chr6:135268142	G/A	cg24558204	chr6:135376177	HBS1L	0.51	5.43	0.44	2.86e-7	Red blood cell count;
TGCT	cis	rs7267979	0.702	rs449801	chr20:25491847	C/T	cg03522245	chr20:25566470	NINL	0.53	5.42	0.44	3.01e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7605378	0.528	rs281767	chr2:200823281	C/A	cg17644776	chr2:200775616	C2orf69	0.32	7.16	0.54	6.12e-11	Osteoporosis;
TGCT	cis	rs7666738	0.791	rs7658177	chr4:99035192	T/C	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs67311347	1.000	rs7628796	chr3:40507332	G/A	cg17264618	chr3:40429014	ENTPD3	-0.32	-4.64	-0.38	8.57e-6	Renal cell carcinoma;
TGCT	cis	rs6867032	0.695	rs3902820	chr5:2000330	T/A	cg26168224	chr5:2018326	NA	-0.37	-5.73	-0.46	7.28e-8	Gut microbiome composition (winter);
TGCT	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg25036284	chr2:26402008	FAM59B	-0.55	-4.68	-0.39	7.51e-6	Gut microbiome composition (summer);
TGCT	cis	rs3935685	1.000	rs62007780	chr15:78025464	G/T	cg03457338	chr15:78040120	NA	-0.23	-5.38	-0.43	3.65e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs4950928	0.823	rs946262	chr1:203158229	C/T	cg17014757	chr1:203156097	CHI3L1	0.38	4.85	0.4	3.65e-6	YKL-40 levels;
TGCT	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg15383120	chr6:291909	DUSP22	-0.67	-7.01	-0.53	1.38e-10	Menopause (age at onset);
TGCT	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.08	0.48	1.37e-8	Bipolar disorder;
TGCT	cis	rs1048238	0.846	rs945422	chr1:16345619	T/C	cg22431228	chr1:16359049	CLCNKA	-0.29	-6.26	-0.49	5.66e-9	Systolic blood pressure;
TGCT	cis	rs13191362	1.000	rs34052221	chr6:163160803	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.96	7.62	0.56	5.6e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs6969780	0.915	rs3807597	chr7:27189195	C/T	cg04321618	chr7:27170880	HOXA4	-0.52	-4.5	-0.38	1.51e-5	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs10876993	0.890	rs1585781	chr12:58056701	T/G	cg15848620	chr12:58087721	OS9	-0.72	-5.86	-0.47	3.91e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs9341808	0.558	rs3805911	chr6:80933996	A/C	cg08355045	chr6:80787529	NA	0.3	4.83	0.4	3.92e-6	Sitting height ratio;
TGCT	cis	rs12780845	0.540	rs2273734	chr10:17216556	C/T	cg01003015	chr10:17271136	VIM	0.56	4.87	0.4	3.36e-6	Homocysteine levels;
TGCT	cis	rs8177179	0.565	rs4355280	chr3:133468425	A/G	cg24879335	chr3:133465180	TF	0.34	4.5	0.37	1.57e-5	Iron status biomarkers (transferrin levels);
TGCT	cis	rs225245	0.765	rs226428	chr17:34049950	C/T	cg05299278	chr17:33885742	SLFN14	-0.22	-4.68	-0.39	7.54e-6	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs9368481	0.678	rs62402024	chr6:26923976	T/C	cg02458000	chr6:26745757	NA	0.6	5.33	0.43	4.42e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg10295955	chr4:187884368	NA	1.03	15.89	0.82	1.07e-31	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs13394619	0.605	rs12476319	chr2:11748406	A/G	cg07314298	chr2:11723111	GREB1	0.28	4.59	0.38	1.07e-5	Endometriosis;
TGCT	cis	rs17376456	0.825	rs55947981	chr5:93278104	G/T	cg25358565	chr5:93447407	FAM172A	1.02	8.11	0.59	4.23e-13	Diabetic retinopathy;
TGCT	cis	rs9420907	0.579	rs35623220	chr10:105631657	C/T	cg26719024	chr10:105156444	PDCD11;USMG5	-0.85	-4.66	-0.39	8.08e-6	Telomere length;
TGCT	cis	rs9677476	0.516	rs2303351	chr2:232030510	C/A	cg27665808	chr2:232055229	NA	0.35	4.43	0.37	2.01e-5	Food antigen IgG levels;
TGCT	cis	rs9910055	0.664	rs433610	chr17:42197281	A/G	cg13607699	chr17:42295918	UBTF	-0.81	-7.58	-0.56	7.17e-12	Total body bone mineral density;
TGCT	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.5	-4.81	-0.4	4.26e-6	Bipolar disorder;
TGCT	cis	rs4851254	0.660	rs9784000	chr2:100697201	G/C	cg22139774	chr2:100720529	AFF3	-0.41	-4.47	-0.37	1.72e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg20637647	chr7:64974828	NA	0.89	4.95	0.41	2.37e-6	Diabetic kidney disease;
TGCT	cis	rs763014	0.865	rs8909	chr16:633851	T/C	cg07343612	chr16:622815	PIGQ	-0.41	-7.87	-0.58	1.52e-12	Height;
TGCT	cis	rs13082711	0.555	rs73149363	chr3:27265394	C/A	cg02860705	chr3:27208620	NA	0.48	7.64	0.57	5.02e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg13732083	chr21:47605072	C21orf56	-0.35	-4.51	-0.38	1.5e-5	Testicular germ cell tumor;
TGCT	cis	rs1903068	1.000	rs4516787	chr4:56010165	C/T	cg16572876	chr4:56024045	NA	-0.44	-5.15	-0.42	9.86e-7	Endometriosis;
TGCT	cis	rs6964587	0.839	rs62466809	chr7:91472801	A/G	cg17063962	chr7:91808500	NA	0.82	8.45	0.6	6.64e-14	Breast cancer;
TGCT	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg11890956	chr21:40555474	PSMG1	1.11	12.75	0.75	2.6e-24	Cognitive function;
TGCT	cis	rs2153535	0.580	rs1832100	chr6:8446956	G/A	cg07606381	chr6:8435919	SLC35B3	0.53	5.02	0.41	1.79e-6	Motion sickness;
TGCT	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg20573242	chr4:122745356	CCNA2	0.64	5.62	0.45	1.22e-7	Type 2 diabetes;
TGCT	cis	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg20637647	chr7:64974828	NA	0.9	5.31	0.43	4.87e-7	Diabetic kidney disease;
TGCT	cis	rs597480	0.892	rs550404	chr11:85435730	C/T	cg11817631	chr11:85522609	SYTL2	-0.47	-4.64	-0.38	8.67e-6	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);
TGCT	cis	rs12681287	0.640	rs13267782	chr8:87481887	G/T	cg27223183	chr8:87520930	FAM82B	-0.91	-6.52	-0.51	1.64e-9	Caudate activity during reward;
TGCT	cis	rs34734847	0.933	rs11065202	chr12:121112429	T/C	cg21892295	chr12:121157589	UNC119B	-0.22	-5.31	-0.43	4.79e-7	Mean corpuscular volume;
TGCT	cis	rs933688	1.000	rs7715402	chr5:90679504	T/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.07	10.05	0.67	9.51e-18	Smoking behavior;
TGCT	cis	rs295140	0.805	rs11890234	chr2:201206706	C/T	cg04283868	chr2:201171347	SPATS2L	0.58	5.84	0.46	4.27e-8	QT interval;
TGCT	cis	rs13242816	1.000	rs3801993	chr7:116190382	C/G	cg02799643	chr7:116139180	CAV2	-0.45	-5.55	-0.45	1.66e-7	P wave duration;
TGCT	cis	rs6121246	0.529	rs6060210	chr20:30187681	C/T	cg18721089	chr20:30220636	NA	-0.63	-6.88	-0.53	2.67e-10	Mean corpuscular hemoglobin;
TGCT	cis	rs2404602	0.692	rs7169663	chr15:77192843	A/C	cg26408565	chr15:76604113	ETFA	-0.36	-4.68	-0.39	7.39e-6	Blood metabolite levels;
TGCT	cis	rs2439831	0.867	rs2447208	chr15:43933895	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	6.61	0.51	1.03e-9	Lung cancer in ever smokers;
TGCT	cis	rs7666738	0.830	rs2019163	chr4:99022747	C/T	cg18180107	chr4:99064573	C4orf37	0.54	4.96	0.41	2.23e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4794202	0.534	rs9897598	chr17:45923496	G/A	cg02219949	chr17:45927392	SP6	0.37	4.44	0.37	1.97e-5	Alzheimer's disease (cognitive decline);
TGCT	cis	rs7666738	0.753	rs13111199	chr4:98953705	A/G	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs76878669	0.561	rs4930178	chr11:66129442	C/G	cg18002602	chr11:66138449	SLC29A2	0.54	6.62	0.51	9.76e-10	Educational attainment (years of education);
TGCT	cis	rs7568458	0.684	rs6731700	chr2:85760991	C/G	cg17127132	chr2:85788382	GGCX	0.51	4.58	0.38	1.12e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs57590327	0.508	rs7621968	chr3:81951460	A/G	cg07356753	chr3:81810745	GBE1	-0.71	-6.65	-0.51	8.31e-10	Extraversion;
TGCT	cis	rs1568889	1.000	rs7934085	chr11:28369660	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	7.92	0.58	1.13e-12	Bipolar disorder;
TGCT	cis	rs933688	0.938	rs7705465	chr5:90680949	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.02	8.42	0.6	7.91e-14	Smoking behavior;
TGCT	cis	rs1670533	1.000	rs7660779	chr4:1075940	A/G	cg27284194	chr4:1044797	NA	0.69	5.94	0.47	2.69e-8	Recombination rate (females);
TGCT	cis	rs10851411	1.000	rs10851411	chr15:42859235	T/G	cg23803468	chr15:43513504	EPB42	-0.23	-4.44	-0.37	1.93e-5	Glucose homeostasis traits;
TGCT	cis	rs2412819	0.599	rs2470120	chr15:43929070	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.45	4.5	0.37	1.54e-5	Lung cancer;
TGCT	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg03395511	chr6:291903	DUSP22	0.66	6.9	0.53	2.32e-10	Menopause (age at onset);
TGCT	cis	rs7552404	0.731	rs11161836	chr1:76354333	C/T	cg22875332	chr1:76189707	ACADM	0.67	6.71	0.52	6.12e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs11190604	1.000	rs74650218	chr10:102293830	C/T	cg23241863	chr10:102295624	HIF1AN	0.67	5.12	0.42	1.12e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs79387448	0.655	rs17639215	chr2:102953444	G/A	cg09003973	chr2:102972529	NA	1.38	9.42	0.65	3.27e-16	Gut microbiota (bacterial taxa);
TGCT	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg18402987	chr7:1209562	NA	0.81	6.94	0.53	1.9e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9611565	0.512	rs5758439	chr22:42131762	C/T	cg13695892	chr22:41940480	POLR3H	0.89	8.43	0.6	7.37e-14	Vitiligo;
TGCT	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg10802521	chr3:52805072	NEK4	-0.71	-8.79	-0.62	1.04e-14	Bipolar disorder;
TGCT	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	5.14	0.42	1.03e-6	Height;
TGCT	cis	rs12510870	0.599	rs16849656	chr4:74450420	T/C	cg05868023	chr4:75230803	EREG	-0.54	-4.76	-0.39	5.33e-6	Iris color (b* coordinate);
TGCT	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg24250549	chr1:154909240	PMVK	0.65	6.41	0.5	2.77e-9	Prostate cancer;
TGCT	cis	rs8177253	0.632	rs6782523	chr3:133438917	C/T	cg16414030	chr3:133502952	NA	-0.5	-6.8	-0.52	3.91e-10	Iron status biomarkers;
TGCT	cis	rs8177253	0.509	rs6762415	chr3:133478557	T/G	cg11941060	chr3:133502564	NA	-0.29	-5.35	-0.43	4.1e-7	Iron status biomarkers;
TGCT	cis	rs1577917	0.958	rs11758508	chr6:86506878	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.59	4.9	0.4	2.96e-6	Response to antipsychotic treatment;
TGCT	cis	rs912057	0.671	rs1294435	chr6:6745455	G/A	cg06612196	chr6:6737390	NA	0.47	6.63	0.51	9.47e-10	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs16867321	0.950	rs12477283	chr2:181501355	G/T	cg23363182	chr2:181467187	NA	-0.38	-5.55	-0.45	1.62e-7	Obesity;
TGCT	cis	rs2073300	1.000	rs74273799	chr20:23444492	T/C	cg09953122	chr20:23471693	CST8	-0.64	-4.56	-0.38	1.19e-5	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs62103177	0.810	rs3902996	chr18:77630571	A/G	cg12964065	chr18:77638022	KCNG2	0.37	4.76	0.39	5.4e-6	Opioid sensitivity;
TGCT	cis	rs157350	0.608	rs157334	chr5:156117431	T/A	cg19020398	chr5:156886415	NIPAL4	0.3	4.46	0.37	1.84e-5	Anthropometric traits;
TGCT	cis	rs9467711	0.606	rs9393718	chr6:26407482	G/A	cg10795676	chr6:26370623	BTN3A2	-0.45	-4.56	-0.38	1.23e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs908922	0.887	rs4845783	chr1:152492559	G/A	cg20991723	chr1:152506922	NA	0.42	5.38	0.43	3.62e-7	Hair morphology;
TGCT	cis	rs7674212	0.541	rs2251322	chr4:104079424	C/T	cg16532752	chr4:104119610	CENPE	-0.61	-5.67	-0.45	9.45e-8	Type 2 diabetes;
TGCT	cis	rs9611565	0.607	rs132792	chr22:42062822	C/T	cg06481639	chr22:41940642	POLR3H	0.59	5.02	0.41	1.77e-6	Vitiligo;
TGCT	cis	rs17376456	0.825	rs34592268	chr5:93232751	G/C	cg21475434	chr5:93447410	FAM172A	0.7	4.9	0.4	2.96e-6	Diabetic retinopathy;
TGCT	cis	rs7843479	1.000	rs11775444	chr8:21813018	A/G	cg17168535	chr8:21777572	XPO7	0.65	5.99	0.47	2.14e-8	Mean corpuscular volume;
TGCT	cis	rs2153535	0.601	rs9505451	chr6:8469950	C/T	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg08859206	chr1:53392774	SCP2	0.34	4.93	0.4	2.63e-6	Monocyte count;
TGCT	cis	rs1372520	0.935	rs1372519	chr4:90757309	A/G	cg15133208	chr4:90757351	SNCA	-0.47	-5.34	-0.43	4.3e-7	Neuroticism;
TGCT	cis	rs7044106	0.762	rs12003646	chr9:123470621	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	4.6	0.38	1.05e-5	Hip circumference adjusted for BMI;
TGCT	cis	rs7819412	0.805	rs2409710	chr8:10979821	A/G	cg27411982	chr8:10470053	RP1L1	-0.21	-4.76	-0.39	5.26e-6	Triglycerides;
TGCT	cis	rs10504229	0.636	rs77691549	chr8:58055126	G/T	cg21724239	chr8:58056113	NA	0.46	5.01	0.41	1.84e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs28595532	0.920	rs115506655	chr4:119757667	A/G	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs13217239	0.585	rs114919438	chr6:26963792	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.44	-4.88	-0.4	3.18e-6	Schizophrenia;
TGCT	cis	rs595982	0.527	rs17272673	chr19:49362992	C/A	cg15549821	chr19:49342101	PLEKHA4	-0.71	-9.62	-0.65	1.07e-16	Red cell distribution width;
TGCT	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg23758822	chr17:41437982	NA	0.68	6.78	0.52	4.4e-10	Menopause (age at onset);
TGCT	cis	rs4689388	0.926	rs12508672	chr4:6287965	G/A	cg00701064	chr4:6280414	WFS1	0.38	4.9	0.4	2.87e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs11608355	0.618	rs11066368	chr12:109790342	C/T	cg19025524	chr12:109796872	NA	-0.27	-4.55	-0.38	1.24e-5	Neuroticism;
TGCT	cis	rs2692947	0.644	rs1168976	chr2:96813480	G/A	cg23100626	chr2:96804247	ASTL	0.46	5.42	0.44	3.03e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs11190604	1.000	rs17113137	chr10:102241998	G/C	cg23241863	chr10:102295624	HIF1AN	0.64	5.0	0.41	1.92e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs992157	1.000	rs13429408	chr2:219142860	C/A	cg00012203	chr2:219082015	ARPC2	0.78	8.39	0.6	9.39e-14	Colorectal cancer;
TGCT	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg07061783	chr6:25882402	NA	-0.93	-11.08	-0.71	3.03e-20	Urate levels;
TGCT	cis	rs8017423	0.904	rs11621127	chr14:90802050	G/A	cg04374321	chr14:90722782	PSMC1	-0.74	-7.15	-0.54	6.48e-11	Mortality in heart failure;
TGCT	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg12140144	chr1:2984275	FLJ42875;PRDM16	0.32	4.44	0.37	1.98e-5	Height;
TGCT	cis	rs1534166	0.647	rs13321680	chr3:133507119	G/T	cg16414030	chr3:133502952	NA	0.45	5.85	0.47	4.11e-8	Alcohol consumption (transferrin glycosylation);
TGCT	cis	rs3858526	0.920	rs11039548	chr11:5930283	G/A	cg05234568	chr11:5960015	NA	-0.44	-4.6	-0.38	1.03e-5	DNA methylation (variation);
TGCT	cis	rs6500602	0.627	rs1641866	chr16:4593040	A/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.41	5.81	0.46	4.98e-8	Schizophrenia;
TGCT	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg22920501	chr2:26401640	FAM59B	-0.81	-6.36	-0.5	3.52e-9	Gut microbiome composition (summer);
TGCT	cis	rs10992471	0.598	rs2025389	chr9:95157674	A/G	cg13798575	chr9:95087839	CENPP;NOL8	0.63	6.12	0.48	1.13e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs1865760	0.713	rs2013063	chr6:25994098	C/T	cg16482183	chr6:26056742	HIST1H1C	0.54	4.77	0.39	5.15e-6	Height;
TGCT	cis	rs67385638	1.000	rs2855121	chr11:5277291	C/T	cg12559170	chr11:5275217	HBG2	0.48	8.71	0.62	1.63e-14	Hemoglobin levels;
TGCT	cis	rs6558530	0.666	rs6558520	chr8:1697573	T/C	cg09410841	chr8:1729607	CLN8	0.69	6.2	0.49	7.73e-9	Systolic blood pressure;
TGCT	cis	rs240764	0.853	rs11155496	chr6:100988939	T/C	cg21058520	chr6:100914733	NA	0.35	4.63	0.38	9.07e-6	Neuroticism;
TGCT	cis	rs6866344	0.570	rs1071882	chr5:178136040	C/T	cg03877680	chr5:178157825	ZNF354A	0.8	7.03	0.53	1.22e-10	Neutrophil percentage of white cells;
TGCT	cis	rs7666738	0.830	rs7673385	chr4:99024922	T/G	cg18180107	chr4:99064573	C4orf37	0.55	5.13	0.42	1.1e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10504229	0.813	rs6999878	chr8:58197243	C/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.32	-0.43	4.66e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs4824093	0.610	rs12168949	chr22:50317714	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.15	-4.45	-0.37	1.86e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg13012494	chr21:47604986	C21orf56	-0.38	-4.56	-0.38	1.21e-5	Testicular germ cell tumor;
TGCT	cis	rs910316	1.000	rs175425	chr14:75626131	T/C	cg11812906	chr14:75593930	NEK9	-0.73	-7.21	-0.54	4.87e-11	Height;
TGCT	cis	rs9658691	0.790	rs4345878	chr10:90756511	T/C	cg03111039	chr10:90751583	FAS;ACTA2	0.63	4.48	0.37	1.71e-5	Mosquito bite size;
TGCT	cis	rs763121	0.853	rs1062687	chr22:39134715	T/C	cg06022373	chr22:39101656	GTPBP1	0.73	7.11	0.54	8.14e-11	Menopause (age at onset);
TGCT	cis	rs6840360	0.615	rs10001603	chr4:152647577	T/A	cg17479576	chr4:152424074	FAM160A1	-0.53	-5.33	-0.43	4.47e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs72634258	0.503	rs707457	chr1:7831064	C/A	cg26816564	chr1:7831052	VAMP3	1.0	7.28	0.55	3.44e-11	Inflammatory bowel disease;
TGCT	cis	rs7809950	0.953	rs2237670	chr7:107131485	A/G	cg23024343	chr7:107201750	COG5	-0.34	-5.45	-0.44	2.58e-7	Coronary artery disease;
TGCT	cis	rs7246657	0.943	rs6508732	chr19:38000468	C/T	cg18154014	chr19:37997991	ZNF793	0.73	5.43	0.44	2.85e-7	Coronary artery calcification;
TGCT	cis	rs797680	0.856	rs11164880	chr1:93658096	A/C	cg17826107	chr1:92977322	EVI5	-0.23	-5.03	-0.41	1.67e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs9549260	0.709	rs2721072	chr13:41144919	G/A	cg21288729	chr13:41239152	FOXO1	0.98	10.08	0.67	8.21e-18	Red blood cell count;
TGCT	cis	rs7824557	0.628	rs58283816	chr8:11192551	G/C	cg21775007	chr8:11205619	TDH	0.7	6.86	0.52	2.93e-10	Retinal vascular caliber;
TGCT	cis	rs3008870	1.000	rs2985821	chr1:67403787	G/A	cg08660285	chr1:67390436	MIER1;WDR78	1.1	11.97	0.73	2.07e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs28595532	0.920	rs115860482	chr4:119759546	A/G	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs78487399	0.808	rs1388387	chr2:43736969	T/C	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.74	4.5	0.37	1.57e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs6815814	0.950	rs73236633	chr4:38839319	T/C	cg02016764	chr4:38805732	TLR1	-0.31	-4.7	-0.39	6.81e-6	Breast cancer;
TGCT	cis	rs2688608	0.901	rs2664280	chr10:75617344	A/T	cg04320760	chr10:75533139	FUT11	0.3	4.6	0.38	1.04e-5	Inflammatory bowel disease;
TGCT	cis	rs7119038	0.774	rs73005423	chr11:118681079	A/G	cg19308663	chr11:118741387	NA	0.28	5.48	0.44	2.32e-7	Sjögren's syndrome;
TGCT	cis	rs9814567	0.752	rs7623567	chr3:134330976	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-6.41	-0.5	2.8e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs12908161	1.000	rs12905057	chr15:85210765	A/G	cg12863693	chr15:85201151	NMB	0.49	5.85	0.47	4.08e-8	Schizophrenia;
TGCT	cis	rs11754661	1.000	rs73011386	chr6:151196854	C/T	cg11579907	chr6:151412213	MTHFD1L	0.54	4.9	0.4	2.99e-6	Alzheimer's disease (late onset);
TGCT	cis	rs66573146	0.831	rs68111914	chr4:6986677	C/T	cg05069807	chr4:6945702	TBC1D14	0.31	4.83	0.4	3.91e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.7	6.33	0.49	4.02e-9	Tonsillectomy;
TGCT	cis	rs6430585	0.528	rs78274583	chr2:136734569	C/T	cg07169764	chr2:136633963	MCM6	1.25	12.67	0.75	4.02e-24	Corneal structure;
TGCT	cis	rs10057188	1.000	rs17389148	chr5:77869903	G/T	cg06873401	chr5:77792105	LHFPL2	-0.23	-4.58	-0.38	1.14e-5	Pulse pressure;
TGCT	cis	rs79349575	0.783	rs62078370	chr17:47026836	G/C	cg07967210	chr17:47022446	SNF8	0.44	6.13	0.48	1.1e-8	Type 2 diabetes;
TGCT	cis	rs10927875	0.965	rs3961710	chr1:16313172	C/T	cg21385522	chr1:16154831	NA	-0.77	-8.44	-0.6	7.05e-14	Dilated cardiomyopathy;
TGCT	trans	rs797680	0.856	rs627779	chr1:93684089	T/C	cg27528825	chr2:159282178	CCDC148	0.35	6.88	0.53	2.65e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs922182	0.547	rs6494458	chr15:64271095	A/C	cg02919090	chr15:64263738	DAPK2	-0.28	-4.98	-0.41	2.1e-6	Blood protein levels;
TGCT	cis	rs6570726	0.791	rs6913727	chr6:145899826	A/G	cg23711669	chr6:146136114	FBXO30	0.86	9.54	0.65	1.64e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.65	-6.9	-0.53	2.4e-10	Longevity;Endometriosis;
TGCT	cis	rs2235642	0.691	rs2281235	chr16:1603535	T/C	cg07639376	chr16:1584516	IFT140;TMEM204	-0.33	-5.85	-0.46	4.15e-8	Coronary artery disease;
TGCT	cis	rs11785400	0.793	rs2280879	chr8:143722228	T/C	cg10596483	chr8:143751796	JRK	0.53	5.23	0.43	7.02e-7	Schizophrenia;
TGCT	cis	rs10782582	0.592	rs7513194	chr1:76382664	A/C	cg05598546	chr1:76251766	SNORD45C;RABGGTB	-0.55	-4.84	-0.4	3.72e-6	Daytime sleep phenotypes;
TGCT	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg26668828	chr6:292823	DUSP22	-0.7	-7.25	-0.55	3.83e-11	Menopause (age at onset);
TGCT	cis	rs8050907	0.744	rs7192051	chr16:4542117	A/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.54	4.74	0.39	5.78e-6	Obesity-related traits;
TGCT	cis	rs6912958	1.000	rs2223880	chr6:88167897	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.39	-5.0	-0.41	1.91e-6	Monocyte percentage of white cells;
TGCT	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg03188948	chr7:1209495	NA	0.65	5.5	0.44	2.07e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs56309584	0.673	rs11078735	chr17:8116861	C/A	cg08322244	chr17:8066669	VAMP2	-0.56	-5.37	-0.43	3.69e-7	Initial pursuit acceleration;
TGCT	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.4	0.44	3.25e-7	Tonsillectomy;
TGCT	cis	rs1215050	0.765	rs6852699	chr4:98767505	T/C	cg17366294	chr4:99064904	C4orf37	0.52	5.59	0.45	1.4e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs11096990	0.634	rs6829064	chr4:39291812	G/A	cg20847110	chr4:39482781	LOC401127	-0.16	-4.51	-0.38	1.48e-5	Cognitive function;
TGCT	cis	rs9357506	1.000	rs9349355	chr6:46308938	A/G	cg21115430	chr6:46460003	NA	-0.26	-5.17	-0.42	9.2e-7	Body mass index;
TGCT	cis	rs8051431	0.876	rs6499554	chr16:72009439	A/G	cg06353428	chr16:71660113	MARVELD3	0.58	4.98	0.41	2.07e-6	LDL cholesterol levels;
TGCT	cis	rs950169	0.922	rs11630507	chr15:85095725	A/G	cg17173187	chr15:85201210	NMB	0.51	5.29	0.43	5.25e-7	Schizophrenia;
TGCT	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg08280861	chr8:58055591	NA	0.4	4.73	0.39	5.97e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.61	-6.43	-0.5	2.55e-9	Longevity;Endometriosis;
TGCT	cis	rs644799	0.648	rs1255178	chr11:95471908	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.51	5.05	0.41	1.55e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	8.51	0.61	4.91e-14	Platelet count;
TGCT	cis	rs478304	0.654	rs10896035	chr11:65461160	G/A	cg17480646	chr11:65405466	SIPA1	-0.61	-8.27	-0.6	1.8e-13	Acne (severe);
TGCT	cis	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg20362242	chr5:692897	TPPP	0.52	4.65	0.39	8.29e-6	Obesity-related traits;
TGCT	cis	rs7296418	0.961	rs1790094	chr12:123586688	T/C	cg00376283	chr12:123451042	ABCB9	0.84	7.56	0.56	7.92e-12	Platelet count;
TGCT	cis	rs6460942	0.908	rs77799203	chr7:12264432	C/G	cg06484146	chr7:12443880	VWDE	-0.55	-4.63	-0.38	9.11e-6	Coronary artery disease;
TGCT	cis	rs1218582	0.596	rs4845676	chr1:154827861	C/G	cg06221963	chr1:154839813	KCNN3	-0.55	-7.56	-0.56	7.61e-12	Prostate cancer;
TGCT	cis	rs7829975	0.658	rs2409096	chr8:8692477	T/C	cg06636001	chr8:8085503	FLJ10661	0.7	6.2	0.49	7.53e-9	Mood instability;
TGCT	cis	rs7523273	0.606	rs859705	chr1:207959665	A/G	cg22525895	chr1:207977042	MIR29B2	0.53	9.01	0.63	3.16e-15	Schizophrenia;
TGCT	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg03709012	chr19:19516395	GATAD2A	0.74	6.36	0.5	3.48e-9	Tonsillectomy;
TGCT	cis	rs9527	0.615	rs9733635	chr10:104711940	G/A	cg04362960	chr10:104952993	NT5C2	0.65	5.5	0.44	2.08e-7	Arsenic metabolism;
TGCT	cis	rs9419702	0.568	rs7093241	chr10:133556596	G/A	cg20568497	chr10:133558893	NA	0.46	4.96	0.41	2.27e-6	Survival in rectal cancer;
TGCT	cis	rs6964587	0.610	rs6950682	chr7:91464218	G/T	cg17063962	chr7:91808500	NA	0.73	6.7	0.52	6.48e-10	Breast cancer;
TGCT	cis	rs1215050	0.755	rs6843393	chr4:98822619	C/G	cg17366294	chr4:99064904	C4orf37	0.56	6.05	0.48	1.57e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2153535	0.580	rs6597318	chr6:8437289	G/A	cg23788917	chr6:8435910	SLC35B3	0.61	5.36	0.43	4e-7	Motion sickness;
TGCT	cis	rs68170813	0.559	rs12538769	chr7:106984288	C/T	cg02696742	chr7:106810147	HBP1	-0.72	-6.15	-0.48	9.67e-9	Coronary artery disease;
TGCT	trans	rs561341	0.505	rs2344319	chr17:30406189	G/C	cg20587970	chr11:113659929	NA	-0.99	-8.12	-0.59	4.02e-13	Hip circumference adjusted for BMI;
TGCT	cis	rs12893668	0.703	rs12894729	chr14:104035292	G/A	cg26031613	chr14:104095156	KLC1	-0.54	-4.45	-0.37	1.88e-5	Reticulocyte count;
TGCT	cis	rs2050392	0.792	rs9338188	chr10:30721963	G/C	cg13289132	chr10:30722225	MAP3K8	-0.39	-4.67	-0.39	7.6e-6	Inflammatory bowel disease;
TGCT	trans	rs9383153	1.000	rs9370888	chr6:16335544	A/G	cg08154963	chr17:33426885	RAD51L3	0.64	7.14	0.54	6.91e-11	Gambling;
TGCT	cis	rs17345786	0.906	rs72940399	chr3:101122575	A/T	cg12386194	chr3:101231763	SENP7	0.65	6.39	0.5	3.06e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9902453	0.900	rs56195309	chr17:28453753	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	6.51	0.5	1.66e-9	Coffee consumption (cups per day);
TGCT	cis	rs832540	1.000	rs252913	chr5:56195846	C/T	cg24531977	chr5:56204891	C5orf35	0.5	5.04	0.41	1.58e-6	Coronary artery disease;
TGCT	cis	rs2361718	0.500	rs4889970	chr17:78096086	C/T	cg27614120	chr17:77386099	HRNBP3	-0.28	-4.8	-0.4	4.52e-6	Yeast infection;
TGCT	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg27286337	chr10:134555280	INPP5A	0.39	4.87	0.4	3.35e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs9467773	0.584	rs1021372	chr6:26632444	T/C	cg26531700	chr6:26746687	NA	0.5	4.68	0.39	7.52e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs8017423	0.967	rs61231898	chr14:90691696	G/A	cg04374321	chr14:90722782	PSMC1	0.77	8.04	0.59	5.98e-13	Mortality in heart failure;
TGCT	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg26338869	chr17:61819248	STRADA	-0.55	-5.08	-0.42	1.34e-6	Prudent dietary pattern;
TGCT	cis	rs7698623	0.850	rs6532021	chr4:88769661	C/G	cg27387453	chr4:88533842	DSPP	-0.61	-4.6	-0.38	1.03e-5	Cardiovascular disease risk factors;
TGCT	cis	rs6429082	0.764	rs2481095	chr1:235695756	T/C	cg26050004	chr1:235667680	B3GALNT2	-0.6	-5.25	-0.43	6.43e-7	Adiposity;
TGCT	cis	rs67311347	0.544	rs9814779	chr3:40340431	T/C	cg13683864	chr3:40499215	RPL14	-0.78	-7.5	-0.56	1.06e-11	Renal cell carcinoma;
TGCT	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg10047753	chr17:41438598	NA	0.97	10.04	0.67	1.04e-17	Menopause (age at onset);
TGCT	cis	rs7552404	0.731	rs61770556	chr1:76421902	T/C	cg22875332	chr1:76189707	ACADM	0.63	5.83	0.46	4.42e-8	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9788682	0.748	rs667282	chr15:78863472	T/C	cg24631222	chr15:78858424	CHRNA5	0.86	6.45	0.5	2.3e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs12497850	0.931	rs7627404	chr3:48819668	A/C	cg18654377	chr3:49208889	KLHDC8B	-0.42	-5.52	-0.44	1.93e-7	Parkinson's disease;
TGCT	cis	rs782590	0.738	rs4312532	chr2:55812061	A/G	cg03859395	chr2:55845619	SMEK2	-0.82	-8.88	-0.62	6.4e-15	Metabolic syndrome;
TGCT	cis	rs11785400	0.890	rs13279182	chr8:143720544	A/G	cg24634471	chr8:143751801	JRK	0.55	5.7	0.46	8.25e-8	Schizophrenia;
TGCT	cis	rs1775715	0.678	rs2105360	chr10:32210198	C/T	cg14930904	chr10:32216787	ARHGAP12	0.52	5.07	0.41	1.39e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg25036284	chr2:26402008	FAM59B	-0.57	-4.97	-0.41	2.15e-6	Gut microbiome composition (summer);
TGCT	cis	rs7216064	0.651	rs12947658	chr17:65903006	A/G	cg12091567	chr17:66097778	LOC651250	0.7	5.85	0.47	4.05e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs7809950	0.678	rs2237659	chr7:106847492	G/T	cg23024343	chr7:107201750	COG5	0.4	5.53	0.44	1.84e-7	Coronary artery disease;
TGCT	cis	rs1153858	0.723	rs11855527	chr15:45606685	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.87	-8.97	-0.63	3.81e-15	Homoarginine levels;
TGCT	cis	rs9611565	0.559	rs132771	chr22:42025350	A/G	cg13695892	chr22:41940480	POLR3H	0.86	8.2	0.59	2.63e-13	Vitiligo;
TGCT	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg14893161	chr1:205819251	PM20D1	0.55	7.75	0.57	2.78e-12	Menarche (age at onset);
TGCT	cis	rs40363	0.645	rs1690449	chr16:3520893	C/G	cg00484396	chr16:3507460	NAT15	0.46	6.9	0.53	2.42e-10	Tuberculosis;
TGCT	cis	rs7666738	0.791	rs11735105	chr4:98937357	C/T	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs111803315	1.000	rs113558975	chr14:59998385	G/A	cg22995959	chr14:59931024	GPR135	0.66	4.8	0.4	4.39e-6	Schizophrenia;
TGCT	cis	rs7100689	0.890	rs4934169	chr10:82203663	A/G	cg01528321	chr10:82214614	TSPAN14	1.11	11.61	0.72	1.52e-21	Post bronchodilator FEV1;
TGCT	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg21963583	chr11:68658836	MRPL21	0.36	6.08	0.48	1.35e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs3733585	0.648	rs13125029	chr4:9982029	A/G	cg11266682	chr4:10021025	SLC2A9	0.58	7.52	0.56	9.77e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs910316	1.000	rs175442	chr14:75603564	T/C	cg23033748	chr14:75592666	NEK9	-0.28	-4.84	-0.4	3.71e-6	Height;
TGCT	cis	rs13191362	0.935	rs73008456	chr6:163013697	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7674212	0.541	rs4699050	chr4:104114297	A/G	cg16532752	chr4:104119610	CENPE	-0.58	-5.37	-0.43	3.66e-7	Type 2 diabetes;
TGCT	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg10047753	chr17:41438598	NA	0.87	8.58	0.61	3.31e-14	Menopause (age at onset);
TGCT	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg12311346	chr5:56204834	C5orf35	-0.57	-5.84	-0.46	4.33e-8	Coronary artery disease;
TGCT	cis	rs62064224	0.553	rs9915115	chr17:30684858	A/G	cg18200150	chr17:30822561	MYO1D	0.39	4.7	0.39	6.66e-6	Schizophrenia;
TGCT	cis	rs7811142	0.945	rs6978739	chr7:100098680	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.72	5.02	0.41	1.76e-6	Platelet count;
TGCT	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg25767906	chr1:53392781	SCP2	-0.59	-7.49	-0.56	1.12e-11	Monocyte count;
TGCT	cis	rs4699052	0.662	rs6825489	chr4:104250184	T/C	cg16532752	chr4:104119610	CENPE	-0.5	-4.96	-0.41	2.28e-6	Testicular germ cell tumor;
TGCT	cis	rs13326165	0.760	rs6763882	chr3:52354772	A/G	cg27565382	chr3:53032988	SFMBT1	-0.34	-4.68	-0.39	7.5e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs6121246	0.908	rs17093657	chr20:30428894	G/A	cg18721089	chr20:30220636	NA	-0.45	-4.98	-0.41	2.12e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs524281	0.861	rs10896094	chr11:65959206	C/T	cg00563793	chr11:65837595	PACS1	0.52	4.5	0.37	1.55e-5	Electroencephalogram traits;
TGCT	cis	rs6088590	0.901	rs6087631	chr20:33403509	T/C	cg24642439	chr20:33292090	TP53INP2	0.68	6.06	0.48	1.48e-8	Coronary artery disease;
TGCT	cis	rs2760061	0.583	rs708110	chr1:228190805	T/A	cg02753203	chr1:228287806	NA	0.38	7.58	0.56	6.86e-12	Diastolic blood pressure;
TGCT	trans	rs629535	0.862	rs2472141	chr8:70054216	T/C	cg21567404	chr3:27674614	NA	0.57	8.67	0.61	2.01e-14	Dupuytren's disease;
TGCT	cis	rs11948739	0.573	rs736046	chr5:130278613	A/G	cg08523029	chr5:130500466	HINT1	0.58	4.84	0.4	3.8e-6	Pediatric bone mineral content (hip);
TGCT	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.47	-0.37	1.72e-5	Bipolar disorder;
TGCT	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg03806693	chr22:41940476	POLR3H	1.34	12.94	0.76	8.97e-25	Vitiligo;
TGCT	cis	rs11031096	0.727	rs12290828	chr11:4144867	C/G	cg18678763	chr11:4115507	RRM1	-0.46	-5.7	-0.46	8.24e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs2836974	0.800	rs73221174	chr21:40540939	T/C	cg11890956	chr21:40555474	PSMG1	1.09	11.53	0.72	2.41e-21	Cognitive function;
TGCT	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg19774624	chr17:42201019	HDAC5	-0.85	-10.09	-0.67	7.79e-18	Total body bone mineral density;
TGCT	cis	rs4891159	0.548	rs654754	chr18:74143695	T/C	cg24786174	chr18:74118243	ZNF516	0.65	11.92	0.73	2.63e-22	Longevity;
TGCT	trans	rs17685	0.712	rs56965035	chr7:75795670	G/A	cg19862616	chr7:65841803	NCRNA00174	0.51	8.88	0.62	6.28e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs2153535	0.580	rs7341201	chr6:8470270	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs4711350	1.000	rs10947436	chr6:33739960	A/G	cg18005901	chr6:33739558	LEMD2	-0.55	-5.91	-0.47	3.13e-8	Schizophrenia;
TGCT	cis	rs6570726	0.791	rs448939	chr6:145808320	T/C	cg13319975	chr6:146136371	FBXO30	-0.56	-4.79	-0.4	4.59e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11690462	0.963	rs13014464	chr2:26581018	C/T	cg04726446	chr2:26624865	C2orf39	0.42	4.63	0.38	9.08e-6	Coronary artery disease;
TGCT	cis	rs12478296	0.901	rs59191623	chr2:243028595	G/A	cg06360820	chr2:242988706	NA	-0.58	-4.74	-0.39	5.66e-6	Obesity-related traits;
TGCT	cis	rs12210905	1.000	rs5030955	chr6:27213867	C/T	cg08851530	chr6:28072375	NA	1.05	5.07	0.41	1.42e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs10751667	1.000	rs7395691	chr11:985006	T/C	cg06064525	chr11:970664	AP2A2	-0.32	-6.18	-0.49	8.28e-9	Alzheimer's disease (late onset);
TGCT	cis	rs3806843	0.576	rs251373	chr5:140252615	C/T	cg07102913	chr5:140593443	PCDHB13	0.49	4.71	0.39	6.4e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9677476	0.516	rs6707708	chr2:232020821	T/C	cg27665808	chr2:232055229	NA	0.36	4.51	0.38	1.48e-5	Food antigen IgG levels;
TGCT	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg03188948	chr7:1209495	NA	0.43	5.56	0.45	1.58e-7	Longevity;Endometriosis;
TGCT	cis	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg06636001	chr8:8085503	FLJ10661	-0.63	-5.54	-0.45	1.72e-7	Mood instability;
TGCT	trans	rs11082438	0.786	rs11660485	chr18:42866471	A/C	cg16697433	chr11:134398473	NA	-0.92	-6.77	-0.52	4.48e-10	Follicular lymphoma;
TGCT	cis	rs7917772	0.503	rs746552	chr10:104342501	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.8	8.21	0.59	2.44e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg27121462	chr16:89883253	FANCA	-0.55	-5.23	-0.43	6.92e-7	Vitiligo;
TGCT	cis	rs2228479	0.702	rs17233868	chr16:89803629	C/T	cg06558623	chr16:89946397	TCF25	0.45	4.51	0.38	1.47e-5	Skin colour saturation;
TGCT	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg12311346	chr5:56204834	C5orf35	-0.67	-6.82	-0.52	3.63e-10	Initial pursuit acceleration;
TGCT	cis	rs3809566	0.636	rs4775604	chr15:63323880	A/C	cg08198488	chr15:63333792	TPM1	-0.34	-4.97	-0.41	2.14e-6	Platelet count;
TGCT	cis	rs6121246	0.567	rs6058187	chr20:30190923	T/C	cg21427119	chr20:30132790	HM13	-0.42	-6.17	-0.48	8.75e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs2688608	0.905	rs2633300	chr10:75656647	A/C	cg02947784	chr10:75434997	AGAP5	0.16	4.56	0.38	1.21e-5	Inflammatory bowel disease;
TGCT	cis	rs76473307	1.000	rs6026563	chr20:57433342	A/G	cg06163629	chr20:57414884	GNASAS;GNAS	-0.67	-4.58	-0.38	1.11e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs8026198	0.517	rs8024113	chr15:42686838	G/C	cg02624051	chr15:42371635	PLA2G4D	0.36	4.47	0.37	1.73e-5	Fibrinogen levels;
TGCT	trans	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg20587970	chr11:113659929	NA	-1.04	-12.57	-0.75	6.97e-24	Hip circumference adjusted for BMI;
TGCT	cis	rs8028182	0.636	rs7163907	chr15:75845097	T/C	cg20655648	chr15:75932815	IMP3	0.62	4.77	0.39	5.07e-6	Sudden cardiac arrest;
TGCT	cis	rs9467711	0.606	rs2235251	chr6:26431982	C/T	cg16898833	chr6:26189333	HIST1H4D	1.12	5.36	0.43	3.91e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs28595532	0.841	rs114970257	chr4:119756937	G/A	cg14228332	chr4:119757509	SEC24D	1.29	6.0	0.47	1.98e-8	Cannabis dependence symptom count;
TGCT	cis	rs6540559	0.673	rs114467813	chr1:210017785	G/A	cg21951975	chr1:209979733	IRF6	0.65	4.79	0.39	4.73e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs1865760	0.573	rs7450342	chr6:25919480	T/C	cg12310025	chr6:25882481	NA	-0.48	-4.79	-0.4	4.63e-6	Height;
TGCT	cis	rs4805272	0.539	rs1075733	chr19:29324460	C/T	cg12756686	chr19:29218302	NA	0.63	4.53	0.38	1.34e-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
TGCT	cis	rs797680	0.897	rs2114273	chr1:93854517	T/C	cg17826107	chr1:92977322	EVI5	-0.24	-5.6	-0.45	1.29e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs1994135	0.692	rs7958788	chr12:33692179	T/C	cg06521331	chr12:34319734	NA	-0.31	-4.7	-0.39	6.83e-6	Resting heart rate;
TGCT	cis	rs8031584	0.679	rs34017474	chr15:31230611	T/C	cg19680485	chr15:31195859	MTMR15	-0.53	-5.13	-0.42	1.09e-6	Huntington's disease progression;
TGCT	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg17971929	chr21:40555470	PSMG1	0.95	9.59	0.65	1.22e-16	Cognitive function;
TGCT	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg22535103	chr8:58192502	C8orf71	-0.35	-4.65	-0.39	8.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs3849570	1.000	rs3849570	chr3:81792112	C/A	cg07356753	chr3:81810745	GBE1	-0.8	-7.5	-0.56	1.09e-11	Waist circumference;Body mass index;
TGCT	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg09359103	chr1:154839909	KCNN3	-0.66	-12.15	-0.74	7.27e-23	Prostate cancer;
TGCT	cis	rs477895	0.838	rs12794145	chr11:64006484	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.84	7.02	0.53	1.3e-10	Mean platelet volume;
TGCT	cis	rs1941023	0.584	rs10750937	chr11:60172087	C/T	cg08716584	chr11:60157161	MS4A7	-0.31	-4.69	-0.39	7.18e-6	Congenital heart disease (maternal effect);
TGCT	cis	rs78487399	0.908	rs61754256	chr2:43805739	C/T	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.66	4.67	0.39	7.66e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs2455799	0.613	rs4684259	chr3:15791279	G/A	cg16303742	chr3:15540471	COLQ	-0.25	-4.88	-0.4	3.18e-6	Mean platelet volume;
TGCT	cis	rs2455799	0.613	rs3924773	chr3:15796853	G/A	cg16303742	chr3:15540471	COLQ	-0.25	-4.88	-0.4	3.18e-6	Mean platelet volume;
TGCT	cis	rs9549260	0.620	rs4325427	chr13:41216534	C/T	cg21288729	chr13:41239152	FOXO1	0.84	7.92	0.58	1.16e-12	Red blood cell count;
TGCT	cis	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg20362242	chr5:692897	TPPP	0.53	4.62	0.38	9.42e-6	Obesity-related traits;
TGCT	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg03188948	chr7:1209495	NA	0.46	5.88	0.47	3.5e-8	Longevity;Endometriosis;
TGCT	cis	rs1008375	0.931	rs1860592	chr4:17577028	C/G	cg18681998	chr4:17616180	MED28	0.94	9.56	0.65	1.44e-16	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs933688	1.000	rs60513756	chr5:90727692	A/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.03	8.68	0.61	1.89e-14	Smoking behavior;
TGCT	cis	rs4927850	0.521	rs4927679	chr3:195658360	C/T	cg12923728	chr3:195709715	SDHAP1	0.26	4.76	0.39	5.2e-6	Pancreatic cancer;
TGCT	trans	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg17830980	chr10:43048298	ZNF37B	-0.86	-11.18	-0.71	1.68e-20	Extrinsic epigenetic age acceleration;
TGCT	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.73	-7.35	-0.55	2.29e-11	Prostate cancer;
TGCT	cis	rs10751667	0.643	rs7395592	chr11:934094	C/G	cg06064525	chr11:970664	AP2A2	-0.35	-8.09	-0.59	4.54e-13	Alzheimer's disease (late onset);
TGCT	cis	rs7635838	0.751	rs2437681	chr3:11594075	A/G	cg00170343	chr3:11313890	ATG7	-0.71	-6.46	-0.5	2.15e-9	HDL cholesterol;
TGCT	cis	rs778371	0.723	rs34707169	chr2:233699459	C/T	cg08000102	chr2:233561755	GIGYF2	-0.67	-7.64	-0.57	5.21e-12	Schizophrenia;
TGCT	cis	rs3540	0.512	rs7176518	chr15:91079637	C/T	cg22089800	chr15:90895588	ZNF774	-0.76	-7.92	-0.58	1.16e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs9549367	0.789	rs9549716	chr13:113908478	G/A	cg00898013	chr13:113819073	PROZ	-0.43	-5.55	-0.45	1.68e-7	Platelet distribution width;
TGCT	cis	rs17345786	1.000	rs17345528	chr3:101294830	A/C	cg12386194	chr3:101231763	SENP7	-0.59	-5.39	-0.44	3.43e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2197308	0.606	rs12314897	chr12:38392293	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-4.51	-0.38	1.5e-5	Morning vs. evening chronotype;
TGCT	trans	rs2970818	0.831	rs2909381	chr12:4606527	T/C	cg11728664	chr11:60285636	MS4A13	0.7	6.67	0.51	7.72e-10	Phosphorus levels;
TGCT	cis	rs2239547	0.522	rs2581823	chr3:53022076	C/G	cg11645453	chr3:52864694	ITIH4	-0.35	-5.71	-0.46	7.84e-8	Schizophrenia;
TGCT	cis	rs7829975	0.840	rs555617	chr8:8592845	C/G	cg15556689	chr8:8085844	FLJ10661	-0.66	-5.73	-0.46	7.27e-8	Mood instability;
TGCT	cis	rs2458413	0.586	rs2669453	chr8:105368930	C/A	cg23108931	chr8:105342351	NA	0.31	4.69	0.39	7.04e-6	Paget's disease;
TGCT	cis	rs5769707	0.632	rs135872	chr22:50009300	T/C	cg05373962	chr22:49881684	NA	-0.29	-4.93	-0.4	2.63e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs7772486	0.905	rs9373486	chr6:146446024	C/G	cg05347473	chr6:146136440	FBXO30	-0.51	-4.85	-0.4	3.56e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1215050	0.765	rs6852699	chr4:98767505	T/C	cg05340658	chr4:99064831	C4orf37	0.44	5.51	0.44	2.01e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg11644478	chr21:40555479	PSMG1	1.0	10.69	0.69	2.7e-19	Cognitive function;
TGCT	cis	rs36051895	0.589	rs6476950	chr9:5218416	A/T	cg02405213	chr9:5042618	JAK2	-0.72	-9.17	-0.64	1.29e-15	Pediatric autoimmune diseases;
TGCT	cis	rs1670533	1.000	rs3816474	chr4:1050653	G/A	cg20887711	chr4:1340912	KIAA1530	0.69	5.09	0.42	1.31e-6	Recombination rate (females);
TGCT	cis	rs4704846	1.000	rs2902306	chr5:156531561	C/T	cg12943317	chr5:156479607	HAVCR1	-0.34	-4.75	-0.39	5.43e-6	Blood protein levels;
TGCT	cis	rs4654899	0.865	rs6671056	chr1:21488610	G/A	cg01072550	chr1:21505969	NA	-0.48	-7.14	-0.54	7.03e-11	Superior frontal gyrus grey matter volume;
TGCT	cis	rs6598955	0.670	rs6598942	chr1:26531034	C/T	cg04990556	chr1:26633338	UBXN11	-0.88	-11.07	-0.7	3.2e-20	Obesity-related traits;
TGCT	cis	rs11190604	1.000	rs2489045	chr10:102344754	C/T	cg23241863	chr10:102295624	HIF1AN	0.66	4.87	0.4	3.37e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9393777	0.582	rs6936561	chr6:26640895	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.59	-5.33	-0.43	4.44e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9325144	0.678	rs7315271	chr12:39164731	A/G	cg26384229	chr12:38710491	ALG10B	-0.64	-5.99	-0.47	2.12e-8	Morning vs. evening chronotype;
TGCT	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg06481639	chr22:41940642	POLR3H	0.73	6.49	0.5	1.83e-9	Vitiligo;
TGCT	cis	rs9486719	0.857	rs4486027	chr6:96911886	T/C	cg18709589	chr6:96969512	KIAA0776	-0.83	-6.73	-0.52	5.74e-10	Migraine;Coronary artery disease;
TGCT	cis	rs7647973	0.961	rs4955443	chr3:49286618	T/G	cg07636037	chr3:49044803	WDR6	0.67	5.41	0.44	3.15e-7	Menarche (age at onset);
TGCT	cis	rs62244186	0.659	rs4682745	chr3:44508967	T/C	cg15687855	chr3:44754131	ZNF502	-0.43	-5.23	-0.42	7.08e-7	Depressive symptoms;
TGCT	cis	rs1577917	1.000	rs12196037	chr6:86694631	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-5.36	-0.43	3.86e-7	Response to antipsychotic treatment;
TGCT	cis	rs2153535	0.580	rs6920779	chr6:8437624	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.58	0.45	1.42e-7	Motion sickness;
TGCT	cis	rs1568079	0.516	rs2361382	chr10:125220299	C/G	cg02353154	chr10:124578028	NA	-0.37	-4.72	-0.39	6.34e-6	Body mass index;
TGCT	cis	rs2456568	0.802	rs10831139	chr11:93640537	G/A	cg16099599	chr11:93583650	C11orf90	-0.39	-4.78	-0.39	4.97e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs3824867	0.804	rs12419342	chr11:47468545	C/T	cg20307385	chr11:47447363	PSMC3	0.7	5.97	0.47	2.32e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs62244186	0.545	rs9284880	chr3:44759389	C/T	cg10263370	chr3:44754102	ZNF502	-0.45	-5.35	-0.43	4.08e-7	Depressive symptoms;
TGCT	cis	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg11266682	chr4:10021025	SLC2A9	0.44	4.94	0.41	2.45e-6	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs9915657	0.870	rs4140902	chr17:70133750	A/G	cg06234051	chr17:70120541	SOX9	-0.23	-4.61	-0.38	9.78e-6	Thyroid hormone levels;
TGCT	cis	rs9303401	0.614	rs34941454	chr17:57102742	T/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.58	5.83	0.46	4.4e-8	Cognitive test performance;
TGCT	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9388451	0.805	rs1028481	chr6:126106573	G/T	cg10911889	chr6:126070802	HEY2	0.51	5.33	0.43	4.47e-7	Brugada syndrome;
TGCT	cis	rs7552404	0.924	rs1251075	chr1:76190569	C/G	cg10523679	chr1:76189770	ACADM	0.85	9.49	0.65	2.17e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs11696501	0.588	rs6073831	chr20:44279550	A/T	cg11783356	chr20:44313418	WFDC10B	-0.32	-4.63	-0.38	9.25e-6	Brain structure;
TGCT	cis	rs2456568	0.802	rs11020585	chr11:93638493	A/C	cg26875233	chr11:93583750	C11orf90	0.47	6.27	0.49	5.51e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs2075371	0.932	rs34664116	chr7:133984878	G/A	cg11752832	chr7:134001865	SLC35B4	0.67	5.9	0.47	3.21e-8	Mean platelet volume;
TGCT	cis	rs801193	0.967	rs2420827	chr7:66147101	G/A	cg00343986	chr7:65444356	GUSB	-0.21	-4.59	-0.38	1.06e-5	Aortic root size;
TGCT	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg22508957	chr16:3507546	NAT15	0.51	5.92	0.47	2.89e-8	Tuberculosis;
TGCT	cis	rs6976053	0.875	rs7783543	chr7:100468398	T/C	cg03880458	chr7:100306854	NA	0.16	4.44	0.37	1.96e-5	Plasminogen activator inhibitor type 1 levels (PAI-1);
TGCT	cis	rs6460942	0.915	rs62448599	chr7:12453764	C/T	cg06484146	chr7:12443880	VWDE	-0.57	-5.52	-0.44	1.92e-7	Coronary artery disease;
TGCT	cis	rs858239	0.539	rs6461695	chr7:23197784	C/A	cg05602783	chr7:23145260	KLHL7	-0.7	-5.55	-0.45	1.67e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs12580194	0.593	rs59136392	chr12:55748204	C/T	cg10672482	chr12:55725839	OR6C3	-0.52	-4.66	-0.39	8.13e-6	Cancer;
TGCT	cis	rs17401966	0.838	rs55676616	chr1:10290126	T/C	cg19773385	chr1:10388646	KIF1B	-0.22	-4.61	-0.38	9.7e-6	Hepatocellular carcinoma;
TGCT	cis	rs3008870	1.000	rs1118393	chr1:67366668	A/G	cg11518657	chr1:67396239	MIER1	0.53	4.72	0.39	6.16e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs1949733	0.675	rs2688219	chr4:8444631	T/C	cg11789530	chr4:8429930	ACOX3	0.53	4.99	0.41	2e-6	Response to antineoplastic agents;
TGCT	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg11494091	chr17:61959527	GH2	0.39	6.73	0.52	5.49e-10	Height;
TGCT	cis	rs17767294	0.708	rs72848776	chr6:27954826	G/A	cg08851530	chr6:28072375	NA	1.56	7.22	0.54	4.47e-11	Parkinson's disease;
TGCT	cis	rs11190604	1.000	rs10883506	chr10:102289743	C/G	cg23241863	chr10:102295624	HIF1AN	0.68	5.17	0.42	9.14e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs3096299	0.503	rs9940093	chr16:89558705	G/A	cg06640241	chr16:89574553	SPG7	0.74	8.23	0.59	2.13e-13	Multiple myeloma (IgH translocation);
TGCT	cis	rs13326165	0.715	rs13091545	chr3:52377294	A/G	cg07884673	chr3:53033167	SFMBT1	0.39	4.8	0.4	4.54e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs7017914	0.905	rs3110250	chr8:71936384	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-4.97	-0.41	2.16e-6	Bone mineral density;
TGCT	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg06896619	chr17:61851486	DDX42;CCDC47	-0.5	-4.69	-0.39	7.05e-6	Prudent dietary pattern;
TGCT	cis	rs10791323	0.569	rs5019134	chr11:133713082	G/C	cg03690763	chr11:133734501	NA	-0.31	-4.92	-0.4	2.73e-6	Childhood ear infection;
TGCT	cis	rs2594989	0.778	rs6764721	chr3:11470639	A/T	cg00170343	chr3:11313890	ATG7	0.74	5.52	0.44	1.9e-7	Circulating chemerin levels;
TGCT	cis	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg26116260	chr4:7069785	GRPEL1	-0.97	-7.65	-0.57	4.97e-12	Monocyte percentage of white cells;
TGCT	cis	rs4663866	1.000	rs71426510	chr2:239178909	T/G	cg17283117	chr2:239148619	HES6	0.98	4.52	0.38	1.42e-5	Irritable bowel syndrome;
TGCT	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg22963979	chr7:1858916	MAD1L1	-0.45	-7.42	-0.55	1.59e-11	Bipolar disorder and schizophrenia;
TGCT	cis	rs12477438	0.520	rs4347885	chr2:99804007	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	10.3	0.68	2.42e-18	Chronic sinus infection;
TGCT	cis	rs4700695	1.000	rs153319	chr5:65419423	C/T	cg21114390	chr5:65439923	SFRS12	-0.62	-4.82	-0.4	4.13e-6	Facial morphology (factor 19);
TGCT	cis	rs1865760	1.000	rs56118523	chr6:25908975	A/G	cg17042849	chr6:26104293	HIST1H4C	-0.52	-4.68	-0.39	7.33e-6	Height;
TGCT	cis	rs1127311	0.875	rs9427102	chr1:154586957	A/G	cg17218026	chr1:154582156	ADAR	0.3	7.54	0.56	8.85e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs9814567	0.752	rs1534030	chr3:134330083	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-6.41	-0.5	2.8e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs3771570	0.901	rs62190415	chr2:242426692	A/G	cg21155796	chr2:242212141	HDLBP	0.93	6.69	0.52	6.74e-10	Prostate cancer;
TGCT	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg02725872	chr8:58115012	NA	-0.38	-4.96	-0.41	2.22e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10057188	1.000	rs34797797	chr5:77853085	G/A	cg06873401	chr5:77792105	LHFPL2	-0.23	-4.62	-0.38	9.39e-6	Pulse pressure;
TGCT	cis	rs13064411	0.627	rs28536176	chr3:113143625	T/C	cg18753928	chr3:113234510	CCDC52	-0.7	-5.12	-0.42	1.12e-6	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs10832963	1.000	rs11024739	chr11:18645843	A/C	cg20219074	chr11:18656078	SPTY2D1	-1.0	-10.15	-0.67	5.35e-18	Breast cancer;
TGCT	cis	rs7095607	0.813	rs1873111	chr10:69922446	T/C	cg18986048	chr10:69913749	MYPN	0.48	5.57	0.45	1.54e-7	Lung function (FVC);
TGCT	cis	rs57221529	0.766	rs72703026	chr5:572383	G/A	cg09021430	chr5:549028	NA	-0.41	-5.52	-0.44	1.9e-7	Lung disease severity in cystic fibrosis;
TGCT	cis	rs9650657	0.655	rs1991651	chr8:10706411	C/G	cg27411982	chr8:10470053	RP1L1	0.24	4.98	0.41	2.13e-6	Neuroticism;
TGCT	cis	rs10114408	0.959	rs10992958	chr9:96651789	C/T	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs1949733	0.959	rs2688242	chr4:8429943	T/G	cg11789530	chr4:8429930	ACOX3	0.59	5.33	0.43	4.41e-7	Response to antineoplastic agents;
TGCT	cis	rs13191362	0.872	rs13213421	chr6:163203805	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.19	0.59	2.72e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs6049375	1.000	rs62195318	chr20:24046713	T/C	cg14741141	chr20:24973699	C20orf3	0.86	4.92	0.4	2.74e-6	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs9814567	1.000	rs9985356	chr3:134232920	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.9	9.44	0.65	2.92e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs6690583	0.623	rs61768852	chr1:85454613	T/C	cg20280350	chr1:85513789	MCOLN3	-0.74	-5.11	-0.42	1.2e-6	Serum sulfate level;
TGCT	cis	rs790110	1.000	rs812047	chr3:122382074	C/G	cg07366462	chr3:123162899	ADCY5	0.4	4.53	0.38	1.38e-5	Acoustic startle blink response;
TGCT	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg04944784	chr2:26401820	FAM59B	-0.7	-6.49	-0.5	1.89e-9	Gut microbiome composition (summer);
TGCT	cis	rs1005224	0.889	rs9323617	chr14:76158638	A/G	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.66	-5.83	-0.46	4.56e-8	Large artery stroke;
TGCT	cis	rs1908814	0.541	rs7824267	chr8:11794279	G/T	cg02840367	chr8:11660030	FDFT1	-0.52	-4.47	-0.37	1.73e-5	Neuroticism;
TGCT	cis	rs28493229	0.748	rs10426415	chr19:41183590	A/G	cg11601297	chr19:41224147	ITPKC;ADCK4	0.59	5.69	0.46	8.61e-8	Kawasaki disease;
TGCT	cis	rs7666738	0.791	rs1405766	chr4:98965389	T/C	cg17366294	chr4:99064904	C4orf37	0.74	7.56	0.56	7.89e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7829975	0.582	rs6982832	chr8:8792217	A/C	cg06636001	chr8:8085503	FLJ10661	-0.72	-6.69	-0.52	6.68e-10	Mood instability;
TGCT	cis	rs12620999	0.774	rs13402764	chr2:237951984	C/T	cg23555395	chr2:238036564	NA	-0.25	-4.77	-0.39	5.07e-6	Systemic lupus erythematosus;
TGCT	cis	rs7224685	0.569	rs8070737	chr17:3981066	G/T	cg09580393	chr17:4869866	SPAG7	-0.39	-4.5	-0.37	1.53e-5	Type 2 diabetes;
TGCT	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg23574427	chr4:122746245	BBS7;CCNA2	-0.35	-5.32	-0.43	4.66e-7	Type 2 diabetes;
TGCT	cis	rs2282802	0.685	rs7715538	chr5:139665181	T/C	cg01081189	chr5:139537190	NA	0.28	5.06	0.41	1.46e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9633740	1.000	rs9633740	chr10:82265271	A/G	cg01528321	chr10:82214614	TSPAN14	1.03	8.28	0.6	1.66e-13	Post bronchodilator FEV1;
TGCT	cis	rs2820315	1.000	rs2820310	chr1:201838107	G/A	cg12730843	chr1:201915899	LMOD1	-0.27	-4.81	-0.4	4.31e-6	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
TGCT	cis	rs7267979	1.000	rs6115159	chr20:25350944	T/C	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7635838	0.687	rs9849485	chr3:11395741	G/A	cg00170343	chr3:11313890	ATG7	0.65	6.42	0.5	2.57e-9	HDL cholesterol;
TGCT	cis	rs208520	0.874	rs208517	chr6:66947040	G/T	cg07460842	chr6:66804631	NA	-0.9	-9.15	-0.63	1.45e-15	Exhaled nitric oxide output;
TGCT	cis	rs10744422	1.000	rs4759381	chr12:123348480	G/A	cg25930673	chr12:123319894	HIP1R	-0.9	-4.99	-0.41	1.96e-6	Schizophrenia;
TGCT	cis	rs9393692	0.905	rs6908328	chr6:26292855	C/A	cg05868516	chr6:26286170	HIST1H4H	0.61	5.78	0.46	5.65e-8	Educational attainment;
TGCT	cis	rs61774743	0.754	rs2364544	chr1:41833162	G/A	cg01193554	chr1:41846683	NA	0.41	4.91	0.4	2.84e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9303401	0.527	rs12946522	chr17:56768103	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.54	5.22	0.42	7.25e-7	Cognitive test performance;
TGCT	cis	rs6547741	0.935	rs6749426	chr2:27847606	T/C	cg27432699	chr2:27873401	GPN1	0.18	4.56	0.38	1.19e-5	Oral cavity cancer;
TGCT	cis	rs2204008	0.774	rs11180977	chr12:38263094	G/T	cg26384229	chr12:38710491	ALG10B	0.86	7.48	0.56	1.17e-11	Bladder cancer;
TGCT	cis	rs1200821	0.529	rs2475206	chr10:37802532	A/G	cg25427524	chr10:38739819	LOC399744	0.31	5.37	0.43	3.76e-7	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs8141529	0.753	rs5752813	chr22:29226570	T/G	cg02153584	chr22:29168773	CCDC117	0.68	5.9	0.47	3.26e-8	Lymphocyte counts;
TGCT	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg00814883	chr7:100076585	TSC22D4	-0.92	-9.76	-0.66	4.73e-17	Platelet count;
TGCT	trans	rs9383153	1.000	rs9370888	chr6:16335544	A/G	cg19776793	chr17:79225974	SLC38A10	0.8	6.93	0.53	2.07e-10	Gambling;
TGCT	cis	rs73110464	0.609	rs11170348	chr12:53355588	A/G	cg25025879	chr12:53359317	NA	-0.52	-5.7	-0.46	8.29e-8	Cancer (pleiotropy);
TGCT	cis	rs10875746	0.903	rs17122666	chr12:48502574	C/T	cg20731937	chr12:48336164	NA	0.62	4.94	0.41	2.46e-6	Longevity (90 years and older);
TGCT	cis	rs7937612	1.000	rs4938805	chr11:120274211	C/T	cg24566217	chr11:120254723	ARHGEF12	0.28	4.56	0.38	1.2e-5	Intraocular pressure;
TGCT	cis	rs644799	1.000	rs632388	chr11:95563775	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.82	8.63	0.61	2.52e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs4242434	0.889	rs11783129	chr8:22453426	G/A	cg03733263	chr8:22462867	KIAA1967	1.1	17.72	0.85	8.65e-36	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs4803468	0.967	rs3826713	chr19:41892269	C/T	cg09537434	chr19:41945824	ATP5SL	-0.9	-10.06	-0.67	9.09e-18	Height;
TGCT	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg26338869	chr17:61819248	STRADA	-0.54	-5.05	-0.41	1.54e-6	Prudent dietary pattern;
TGCT	cis	rs9393777	0.513	rs9368447	chr6:26646674	A/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.59	-4.66	-0.39	8.03e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9916302	0.904	rs35285898	chr17:37555872	A/C	cg07936489	chr17:37558343	FBXL20	0.65	4.98	0.41	2.11e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg13395646	chr4:1353034	KIAA1530	-0.36	-4.65	-0.39	8.47e-6	Obesity-related traits;
TGCT	cis	rs36051895	0.664	rs62541915	chr9:5151275	A/T	cg02405213	chr9:5042618	JAK2	-0.7	-8.84	-0.62	8.02e-15	Pediatric autoimmune diseases;
TGCT	trans	rs2469997	1.000	rs2447165	chr8:120371318	G/A	cg01792902	chr3:178864926	PIK3CA	0.83	6.77	0.52	4.49e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs2486012	0.850	rs42962	chr1:44298564	A/C	cg12908607	chr1:44402522	ARTN	-0.69	-5.57	-0.45	1.49e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2882877	0.648	rs35078179	chr2:190391921	A/C	cg10752008	chr2:190445175	SLC40A1	0.62	4.54	0.38	1.33e-5	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs76878669	0.519	rs10791869	chr11:66117113	C/T	cg18002602	chr11:66138449	SLC29A2	-0.54	-6.62	-0.51	9.76e-10	Educational attainment (years of education);
TGCT	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg04944784	chr2:26401820	FAM59B	-0.67	-5.92	-0.47	2.88e-8	Gut microbiome composition (summer);
TGCT	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg17054783	chr10:134559939	INPP5A	0.27	5.24	0.43	6.75e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs7226408	0.857	rs2007524	chr18:34450142	C/T	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs523522	0.962	rs4767912	chr12:120981202	A/G	cg27279351	chr12:120934652	DYNLL1	0.76	6.59	0.51	1.15e-9	High light scatter reticulocyte count;
TGCT	trans	rs10506458	1.000	rs12580997	chr12:63433420	G/A	cg22491629	chr6:157744540	C6orf35	-0.96	-8.34	-0.6	1.21e-13	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs7474896	0.583	rs12783272	chr10:38024885	T/G	cg25427524	chr10:38739819	LOC399744	-0.37	-5.71	-0.46	7.99e-8	Obesity (extreme);
TGCT	cis	rs11118844	0.843	rs11118848	chr1:221926826	A/G	cg04222084	chr1:221915650	DUSP10	0.83	5.6	0.45	1.34e-7	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
TGCT	cis	rs734999	0.588	rs4648652	chr1:2535758	A/G	cg18854424	chr1:2615690	NA	0.49	5.75	0.46	6.48e-8	Ulcerative colitis;
TGCT	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg11890956	chr21:40555474	PSMG1	1.11	12.17	0.74	6.69e-23	Cognitive function;
TGCT	cis	rs45509595	0.841	rs401754	chr6:27782538	T/A	cg08798685	chr6:27730294	NA	-0.35	-4.76	-0.39	5.24e-6	Breast cancer;
TGCT	cis	rs6121246	0.909	rs3203770	chr20:30382315	A/G	cg18721089	chr20:30220636	NA	-0.43	-4.75	-0.39	5.54e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg20607798	chr8:58055168	NA	0.45	4.62	0.38	9.54e-6	Developmental language disorder (linguistic errors);
TGCT	trans	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg15556689	chr8:8085844	FLJ10661	-0.8	-7.83	-0.58	1.87e-12	Neuroticism;
TGCT	cis	rs367943	0.966	rs348947	chr5:112822795	C/G	cg12552261	chr5:112820674	MCC	-0.24	-4.91	-0.4	2.81e-6	Type 2 diabetes;
TGCT	cis	rs7584330	0.518	rs74003103	chr2:238446699	G/A	cg14458575	chr2:238380390	NA	0.43	4.51	0.38	1.48e-5	Prostate cancer;
TGCT	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg08859206	chr1:53392774	SCP2	-0.42	-6.23	-0.49	6.54e-9	Monocyte count;
TGCT	cis	rs74054849	0.850	rs16851878	chr1:15955610	C/T	cg05660106	chr1:15850417	CASP9	0.86	4.48	0.37	1.68e-5	Alcoholic chronic pancreatitis;
TGCT	cis	rs2345546	1	rs2345546	chr16:25427472	C/T	cg08360281	chr16:25269390	ZKSCAN2	1.24	9.1	0.63	1.93e-15	Major depression and alcohol dependence;
TGCT	cis	rs7226408	0.842	rs8083264	chr18:34327499	G/A	cg06757138	chr18:34340585	FHOD3	0.3	5.14	0.42	1.04e-6	Obesity-related traits;
TGCT	cis	rs9660180	0.780	rs12038111	chr1:1703849	T/C	cg17747265	chr1:1875780	NA	-0.38	-7.18	-0.54	5.62e-11	Body mass index;
TGCT	cis	rs1461503	0.966	rs1461504	chr11:122845129	T/C	cg27398637	chr11:122830231	C11orf63	-0.42	-5.25	-0.43	6.42e-7	Menarche (age at onset);
TGCT	cis	rs12200560	0.505	rs9400167	chr6:97077192	G/T	cg06623918	chr6:96969491	KIAA0776	0.59	5.03	0.41	1.71e-6	Coronary heart disease;
TGCT	cis	rs2224391	0.554	rs928170	chr6:5255154	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-1.0	-6.14	-0.48	1.01e-8	Height;
TGCT	cis	rs56399783	0.614	rs11765492	chr7:2771642	G/A	cg19731401	chr7:2775893	GNA12	0.38	5.36	0.43	3.93e-7	Childhood ear infection;
TGCT	cis	rs2439831	0.681	rs478104	chr15:43594900	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	6.42	0.5	2.67e-9	Lung cancer in ever smokers;
TGCT	cis	rs11785400	0.701	rs9721143	chr8:143727511	A/T	cg10596483	chr8:143751796	JRK	0.53	5.3	0.43	5.12e-7	Schizophrenia;
TGCT	cis	rs9400467	0.537	rs12191266	chr6:111528041	T/C	cg15721981	chr6:111408429	SLC16A10	0.73	4.79	0.4	4.71e-6	Blood metabolite levels;Amino acid levels;
TGCT	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg12963246	chr6:28129442	ZNF389	0.52	5.01	0.41	1.85e-6	Depression;
TGCT	cis	rs9902453	0.904	rs7212292	chr17:28409264	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.82	-7.84	-0.58	1.77e-12	Coffee consumption (cups per day);
TGCT	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg12564285	chr5:131593104	PDLIM4	-0.41	-4.89	-0.4	3e-6	Acylcarnitine levels;
TGCT	cis	rs12908161	1.000	rs17600551	chr15:85319258	A/G	cg11189052	chr15:85197271	WDR73	0.71	5.85	0.47	4.04e-8	Schizophrenia;
TGCT	cis	rs11711311	0.747	rs7638449	chr3:113343646	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.68	-5.83	-0.46	4.6e-8	IgG glycosylation;
TGCT	cis	rs10782582	0.592	rs7513194	chr1:76382664	A/C	cg10523679	chr1:76189770	ACADM	0.53	4.88	0.4	3.2e-6	Daytime sleep phenotypes;
TGCT	cis	rs826838	1.000	rs1719830	chr12:39096992	T/G	cg13010199	chr12:38710504	ALG10B	-0.59	-4.88	-0.4	3.25e-6	Heart rate;
TGCT	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg10047753	chr17:41438598	NA	0.74	7.04	0.53	1.15e-10	Menopause (age at onset);
TGCT	cis	rs7833790	0.929	rs28464834	chr8:82797356	A/T	cg27398817	chr8:82754497	SNX16	0.74	5.19	0.42	8.37e-7	Diastolic blood pressure;
TGCT	trans	rs1496653	0.602	rs36063633	chr3:23384807	G/T	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg04944784	chr2:26401820	FAM59B	-0.7	-6.49	-0.5	1.89e-9	Gut microbiome composition (summer);
TGCT	cis	rs9303401	0.659	rs62083410	chr17:56964386	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg03351412	chr1:154909251	PMVK	0.52	4.78	0.39	4.93e-6	Prostate cancer;
TGCT	cis	rs617219	0.671	rs2220839	chr5:78603510	T/A	cg09550809	chr5:78407562	BHMT	-0.37	-5.25	-0.43	6.45e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs10256972	0.514	rs2140578	chr7:1214003	T/C	cg03188948	chr7:1209495	NA	0.46	6.02	0.48	1.83e-8	Longevity;Endometriosis;
TGCT	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg15595755	chr5:1867978	NA	0.46	5.38	0.43	3.59e-7	Cardiovascular disease risk factors;
TGCT	cis	rs9388451	0.626	rs3799712	chr6:126075103	A/G	cg10911889	chr6:126070802	HEY2	0.5	4.67	0.39	7.61e-6	Brugada syndrome;
TGCT	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg21285383	chr16:89894308	SPIRE2	0.44	6.87	0.53	2.77e-10	Vitiligo;
TGCT	cis	rs1215050	0.740	rs10025482	chr4:99053277	T/C	cg05340658	chr4:99064831	C4orf37	0.44	5.35	0.43	4.12e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs66573146	1.000	rs56178503	chr4:6961748	C/T	cg00086871	chr4:6988644	TBC1D14	0.98	4.57	0.38	1.16e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs853679	0.546	rs200981	chr6:27833174	A/G	cg10876282	chr6:28092338	ZSCAN16	0.75	4.45	0.37	1.88e-5	Depression;
TGCT	cis	rs4788570	0.537	rs56222754	chr16:71491806	G/A	cg06353428	chr16:71660113	MARVELD3	-1.33	-7.91	-0.58	1.24e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs9926296	0.682	rs467357	chr16:89717397	A/G	cg01097406	chr16:89675127	NA	0.36	6.22	0.49	6.91e-9	Vitiligo;
TGCT	cis	rs68170813	0.652	rs8180747	chr7:107106308	T/C	cg02696742	chr7:106810147	HBP1	-0.62	-4.63	-0.38	9.11e-6	Coronary artery disease;
TGCT	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg06873352	chr17:61820015	STRADA	0.54	5.95	0.47	2.51e-8	Prudent dietary pattern;
TGCT	cis	rs7918232	0.941	rs1775350	chr10:27441973	C/T	cg14442939	chr10:27389572	ANKRD26	-0.8	-5.32	-0.43	4.7e-7	Breast cancer;
TGCT	cis	rs3806843	1.000	rs7701755	chr5:140182101	G/T	cg19875535	chr5:140030758	IK	0.36	6.11	0.48	1.21e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs922182	1.000	rs1460546	chr15:64283108	C/A	cg02919090	chr15:64263738	DAPK2	0.31	5.77	0.46	6.05e-8	Blood protein levels;
TGCT	cis	rs6582630	0.537	rs1851124	chr12:38516404	G/A	cg13010199	chr12:38710504	ALG10B	0.59	4.77	0.39	5.14e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs4924935	0.509	rs28540773	chr17:18761754	T/C	cg26378065	chr17:18585709	ZNF286B	0.52	4.5	0.37	1.56e-5	Pancreatic cancer;
TGCT	cis	rs568617	0.626	rs10896050	chr11:65577516	G/T	cg04055107	chr11:65626734	MUS81;CFL1	0.57	4.73	0.39	5.97e-6	Crohn's disease;
TGCT	cis	rs5769765	0.624	rs2285187	chr22:50185432	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.34	4.72	0.39	6.23e-6	Schizophrenia;
TGCT	cis	rs1982963	1.000	rs2749876	chr14:52504397	T/G	cg10843707	chr14:52510701	NID2	-0.43	-6.6	-0.51	1.09e-9	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs909002	0.830	rs7542583	chr1:32110813	A/G	cg11573219	chr1:32083031	HCRTR1	-0.41	-5.19	-0.42	8.42e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9549260	0.753	rs10507486	chr13:41186501	A/G	cg21288729	chr13:41239152	FOXO1	-0.65	-4.72	-0.39	6.33e-6	Red blood cell count;
TGCT	trans	rs17685	0.712	rs11764119	chr7:75812358	T/G	cg19862616	chr7:65841803	NCRNA00174	0.5	8.69	0.62	1.77e-14	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs1008375	0.866	rs2109518	chr4:17572162	G/A	cg10189774	chr4:17578691	LAP3	0.65	5.65	0.45	1.06e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs11031096	0.769	rs12803541	chr11:4208906	G/A	cg22027985	chr11:4115532	RRM1	0.43	4.72	0.39	6.23e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs896854	0.530	rs10956934	chr8:95992473	C/A	cg23172400	chr8:95962367	TP53INP1	-0.36	-5.6	-0.45	1.3e-7	Type 2 diabetes;
TGCT	cis	rs11190604	1.000	rs2295779	chr10:102296061	A/G	cg23241863	chr10:102295624	HIF1AN	0.58	4.55	0.38	1.26e-5	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs6964587	1.000	rs57816416	chr7:91736078	A/C	cg17063962	chr7:91808500	NA	0.88	9.59	0.65	1.22e-16	Breast cancer;
TGCT	cis	rs9796	0.870	rs3900905	chr15:41260801	G/A	cg18705301	chr15:41695430	NDUFAF1	0.43	5.63	0.45	1.13e-7	Menopause (age at onset);
TGCT	cis	rs854765	0.547	rs12150369	chr17:17911014	G/A	cg09796270	chr17:17721594	SREBF1	0.25	5.03	0.41	1.65e-6	Total body bone mineral density;
TGCT	cis	rs13217239	0.646	rs9393789	chr6:27067028	G/T	cg02458000	chr6:26745757	NA	-0.51	-4.57	-0.38	1.18e-5	Schizophrenia;
TGCT	cis	rs36051895	0.658	rs11999928	chr9:5006743	T/G	cg02405213	chr9:5042618	JAK2	-0.8	-11.07	-0.7	3.18e-20	Pediatric autoimmune diseases;
TGCT	cis	rs11671005	0.735	rs3088284	chr19:58929427	G/A	cg13877915	chr19:58951672	ZNF132	0.63	4.99	0.41	1.95e-6	Mean platelet volume;
TGCT	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg18876405	chr7:65276391	NA	0.31	4.8	0.4	4.53e-6	Aortic root size;
TGCT	cis	rs6969780	1.000	rs6969780	chr7:27159136	G/C	cg04317399	chr7:27170313	HOXA4	0.45	4.47	0.37	1.77e-5	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs9300255	0.620	rs1716173	chr12:123660721	A/T	cg00376283	chr12:123451042	ABCB9	0.73	5.67	0.45	9.68e-8	Neutrophil percentage of white cells;
TGCT	cis	rs79349575	0.679	rs9894239	chr17:46997959	C/T	cg26022315	chr17:47021804	SNF8	-0.54	-5.37	-0.43	3.73e-7	Type 2 diabetes;
TGCT	cis	rs9611519	0.894	rs9623320	chr22:41478482	G/A	cg13695892	chr22:41940480	POLR3H	-0.51	-4.5	-0.37	1.54e-5	Neuroticism;
TGCT	cis	rs2677744	0.719	rs1266492	chr15:91456102	T/C	cg23684204	chr15:91497937	RCCD1	0.34	5.04	0.41	1.6e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs3780378	0.934	rs10815146	chr9:5015901	T/A	cg02405213	chr9:5042618	JAK2	-0.54	-7.05	-0.53	1.1e-10	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs7833790	0.700	rs7834483	chr8:82704828	A/G	cg06027949	chr8:82754900	SNX16	-0.64	-4.85	-0.4	3.56e-6	Diastolic blood pressure;
TGCT	cis	rs5769765	1.000	rs5769765	chr22:50271176	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.41	-6.13	-0.48	1.08e-8	Schizophrenia;
TGCT	cis	rs4727027	0.704	rs7784122	chr7:148904624	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	-0.52	-4.66	-0.39	8.02e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs7617773	0.784	rs11715799	chr3:48255220	A/G	cg11946769	chr3:48343235	NME6	0.76	6.67	0.51	7.6e-10	Coronary artery disease;
TGCT	cis	rs2463822	0.592	rs72919486	chr11:62043501	G/C	cg06239285	chr11:62104954	ASRGL1	-0.87	-5.04	-0.41	1.6e-6	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs2842992	0.789	rs9365093	chr6:160175819	C/G	cg11366901	chr6:160182831	ACAT2	1.03	6.92	0.53	2.14e-10	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs3091242	0.900	rs1811832	chr1:25753565	G/A	cg10117171	chr1:25599238	RHD	-0.35	-5.8	-0.46	5.14e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs12497850	0.644	rs11928552	chr3:48739883	T/C	cg07636037	chr3:49044803	WDR6	0.92	9.9	0.66	2.24e-17	Parkinson's disease;
TGCT	cis	rs2237234	0.542	rs7755997	chr6:26483048	G/A	cg26531700	chr6:26746687	NA	0.53	4.82	0.4	4.1e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs651907	0.557	rs11711079	chr3:101386918	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.91	10.9	0.7	8.24e-20	Colorectal cancer;
TGCT	cis	rs3540	0.533	rs2256110	chr15:90971036	T/C	cg22089800	chr15:90895588	ZNF774	0.76	8.15	0.59	3.29e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs651907	0.535	rs11707250	chr3:101509371	A/T	cg12386194	chr3:101231763	SENP7	-0.47	-4.7	-0.39	6.87e-6	Colorectal cancer;
TGCT	cis	rs4713118	0.629	rs149899	chr6:28019979	C/T	cg12963246	chr6:28129442	ZNF389	0.45	4.55	0.38	1.27e-5	Parkinson's disease;
TGCT	cis	rs910316	1.000	rs7156328	chr14:75532941	T/C	cg23033748	chr14:75592666	NEK9	0.28	4.68	0.39	7.29e-6	Height;
TGCT	cis	rs5167	0.781	rs2075619	chr19:45495682	A/G	cg09555818	chr19:45449301	APOC2	0.24	5.11	0.42	1.2e-6	Blood protein levels;
TGCT	cis	rs929354	0.742	rs6956046	chr7:156962874	G/A	cg05182265	chr7:156933206	UBE3C	-0.39	-8.79	-0.62	1.03e-14	Body mass index;
TGCT	cis	rs59197085	0.515	rs17165198	chr7:128451741	C/T	cg00260937	chr7:128520193	KCP	-0.46	-5.2	-0.42	8.01e-7	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
TGCT	cis	rs72627509	1.000	rs72627509	chr4:57839051	C/G	cg26694713	chr4:57773883	REST	0.76	6.61	0.51	1e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs2290402	0.536	rs56223707	chr4:881896	C/T	cg11315544	chr4:1222440	CTBP1	0.26	4.46	0.37	1.84e-5	Type 2 diabetes;
TGCT	cis	rs9914544	1.000	rs9916245	chr17:18766825	C/G	cg26378065	chr17:18585709	ZNF286B	0.52	4.73	0.39	5.94e-6	Educational attainment (years of education);
TGCT	cis	rs6912958	0.712	rs4706294	chr6:88317675	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-4.57	-0.38	1.16e-5	Monocyte percentage of white cells;
TGCT	trans	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg21659725	chr3:3221576	CRBN	0.98	15.33	0.81	2.1000000000000002e-30	Intelligence (multi-trait analysis);
TGCT	cis	rs17221829	0.733	rs11018688	chr11:89366824	G/T	cg02982614	chr11:89391479	FOLH1B	-0.28	-4.86	-0.4	3.4e-6	Anxiety in major depressive disorder;
TGCT	cis	rs2014572	0.967	rs8106734	chr19:57763546	C/T	cg24459738	chr19:57751996	ZNF805	-0.56	-5.59	-0.45	1.38e-7	Hyperactive-impulsive symptoms;
TGCT	cis	rs78461346	1.000	rs76206767	chr17:80496705	C/T	cg15014069	chr17:80540666	FOXK2	0.4	5.04	0.41	1.62e-6	3-hydroxypropylmercapturic acid levels in smokers;
TGCT	cis	rs7917772	0.599	rs2863717	chr10:104519829	A/G	cg05855489	chr10:104503620	C10orf26	0.66	5.25	0.43	6.47e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs79349575	0.811	rs12601072	chr17:46997998	T/C	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.51	-0.38	1.48e-5	Type 2 diabetes;
TGCT	cis	rs4900538	0.855	rs12586378	chr14:102853150	T/C	cg18135206	chr14:102964638	TECPR2	-0.2	-4.49	-0.37	1.62e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs9300255	0.602	rs949142	chr12:123634043	T/C	cg00376283	chr12:123451042	ABCB9	0.71	5.54	0.45	1.7e-7	Neutrophil percentage of white cells;
TGCT	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg13695892	chr22:41940480	POLR3H	-0.78	-7.52	-0.56	9.73e-12	Vitiligo;
TGCT	cis	rs72634258	0.519	rs744001	chr1:7934557	G/A	cg26816564	chr1:7831052	VAMP3	0.65	4.98	0.41	2.11e-6	Inflammatory bowel disease;
TGCT	cis	rs3820068	0.705	rs4646077	chr1:15827136	C/T	cg05660106	chr1:15850417	CASP9	1.16	14.82	0.8	3.11e-29	Systolic blood pressure;
TGCT	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.08	0.48	1.37e-8	Bipolar disorder;
TGCT	cis	rs1218582	0.510	rs2878411	chr1:154823545	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.49	-4.67	-0.39	7.72e-6	Prostate cancer;
TGCT	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg05665937	chr4:1216051	CTBP1	-0.24	-4.55	-0.38	1.26e-5	Obesity-related traits;
TGCT	cis	rs854765	0.964	rs854810	chr17:18006421	G/C	cg04398451	chr17:18023971	MYO15A	0.3	4.79	0.39	4.75e-6	Total body bone mineral density;
TGCT	cis	rs9911578	1.000	rs9807057	chr17:56889952	A/C	cg05425664	chr17:57184151	TRIM37	-0.63	-6.26	-0.49	5.86e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg19723775	chr5:179050963	HNRNPH1	0.49	4.96	0.41	2.27e-6	Lung cancer;
TGCT	cis	rs9486715	0.809	rs9486467	chr6:96971803	C/T	cg06623918	chr6:96969491	KIAA0776	1.11	15.54	0.81	6.95e-31	Headache;
TGCT	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg06028605	chr16:24865363	SLC5A11	0.41	4.57	0.38	1.17e-5	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9393692	0.676	rs806977	chr6:26189615	A/G	cg05868516	chr6:26286170	HIST1H4H	0.53	5.21	0.42	7.76e-7	Educational attainment;
TGCT	cis	rs4654899	0.897	rs59537090	chr1:21498737	C/T	cg01072550	chr1:21505969	NA	-0.5	-8.08	-0.59	4.94e-13	Superior frontal gyrus grey matter volume;
TGCT	cis	rs1949733	0.523	rs62287455	chr4:8544994	A/T	cg13073564	chr4:8508604	NA	0.5	4.89	0.4	3.06e-6	Response to antineoplastic agents;
TGCT	trans	rs4332037	0.539	rs11762636	chr7:2061111	C/A	cg25206134	chr2:45395956	NA	0.96	7.31	0.55	2.89e-11	Bipolar disorder;
TGCT	cis	rs9318086	0.687	rs9507182	chr13:24442365	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.77	8.28	0.6	1.66e-13	Myopia (pathological);
TGCT	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg08859206	chr1:53392774	SCP2	-0.45	-7.11	-0.54	8.09e-11	Monocyte count;
TGCT	cis	rs3733585	0.699	rs6449176	chr4:9967843	G/A	cg00071950	chr4:10020882	SLC2A9	-0.57	-6.83	-0.52	3.47e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs9911578	1.000	rs4793952	chr17:56608465	C/T	cg12560992	chr17:57184187	TRIM37	-0.76	-9.34	-0.64	4.88e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs7698623	0.850	rs4693895	chr4:88797839	C/T	cg27387453	chr4:88533842	DSPP	-0.61	-4.6	-0.38	1.03e-5	Cardiovascular disease risk factors;
TGCT	cis	rs11031096	0.655	rs35898891	chr11:4211112	G/C	cg18678763	chr11:4115507	RRM1	-0.45	-5.77	-0.46	6.11e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs6570726	0.791	rs374478	chr6:145840022	C/T	cg23711669	chr6:146136114	FBXO30	0.89	9.72	0.66	6.02e-17	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs9388451	0.626	rs3799708	chr6:126078530	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.85	-10.17	-0.67	4.96e-18	Brugada syndrome;
TGCT	cis	rs7552404	0.727	rs5745390	chr1:76306591	A/C	cg22875332	chr1:76189707	ACADM	0.63	6.74	0.52	5.33e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs908922	0.676	rs1337340	chr1:152508260	T/C	cg20991723	chr1:152506922	NA	0.46	6.18	0.48	8.66e-9	Hair morphology;
TGCT	cis	rs56104184	0.775	rs55756106	chr19:49403055	A/G	cg17863274	chr19:49399704	TULP2	-0.54	-7.43	-0.55	1.58e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs75686122	0.892	rs12676333	chr8:104542372	A/G	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs7178572	0.568	rs12907847	chr15:77493174	C/T	cg22256960	chr15:77711686	NA	-0.88	-8.99	-0.63	3.53e-15	Type 2 diabetes;
TGCT	cis	rs4851254	0.584	rs35774174	chr2:100655130	T/A	cg22139774	chr2:100720529	AFF3	-0.46	-4.97	-0.41	2.16e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1005277	0.505	rs200935	chr10:38132810	T/A	cg25427524	chr10:38739819	LOC399744	-0.37	-7.41	-0.55	1.74e-11	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2235642	0.891	rs2281231	chr16:1601879	A/G	cg08296037	chr16:1584118	IFT140;TMEM204	-0.3	-5.41	-0.44	3.18e-7	Coronary artery disease;
TGCT	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg00908189	chr16:619842	PIGQ	0.87	10.61	0.69	4.21e-19	Height;
TGCT	cis	rs8141529	0.748	rs132528	chr22:29295898	C/T	cg02153584	chr22:29168773	CCDC117	-0.67	-5.22	-0.42	7.25e-7	Lymphocyte counts;
TGCT	cis	rs2180341	0.782	rs6569490	chr6:127729615	C/T	cg27446573	chr6:127587934	RNF146	0.88	8.07	0.59	5.22e-13	Breast cancer;
TGCT	cis	rs1401999	0.659	rs4912518	chr3:183752027	C/T	cg01324343	chr3:183735012	ABCC5	-0.76	-9.03	-0.63	2.71e-15	Anterior chamber depth;
TGCT	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg06238570	chr21:40685208	BRWD1	0.7	6.45	0.5	2.3e-9	Cognitive function;
TGCT	cis	rs1023500	0.529	rs133375	chr22:42466509	C/G	cg15557168	chr22:42548783	NA	-0.22	-5.59	-0.45	1.41e-7	Schizophrenia;
TGCT	cis	rs11864453	0.647	rs2550035	chr16:72113416	C/G	cg14768367	chr16:72042858	DHODH	0.52	5.26	0.43	6.21e-7	Fibrinogen levels;
TGCT	cis	rs9467711	0.659	rs72845428	chr6:26550144	C/T	cg16898833	chr6:26189333	HIST1H4D	1.25	5.86	0.47	3.88e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs155076	0.702	rs482731	chr13:21846075	G/A	cg14456004	chr13:21872349	NA	-1.32	-10.82	-0.7	1.25e-19	White matter hyperintensity burden;
TGCT	cis	rs933688	1.000	rs35712350	chr5:90679519	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.03	9.42	0.65	3.21e-16	Smoking behavior;
TGCT	cis	rs8056742	0.643	rs71386888	chr16:85085937	A/G	cg00229868	chr16:85520891	NA	0.36	4.83	0.4	4.03e-6	Amyotrophic lateral sclerosis;
TGCT	cis	rs6866344	0.570	rs1071881	chr5:178135917	C/T	cg03877680	chr5:178157825	ZNF354A	0.75	6.45	0.5	2.25e-9	Neutrophil percentage of white cells;
TGCT	cis	rs77633900	0.614	rs2469244	chr15:76884127	G/A	cg21673338	chr15:77095150	SCAPER	-0.52	-4.83	-0.4	3.88e-6	Non-glioblastoma glioma;Glioma;
TGCT	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg23719950	chr11:63933701	MACROD1	-0.71	-5.91	-0.47	3.06e-8	Mean platelet volume;
TGCT	cis	rs10193935	1.000	rs10185742	chr2:42429666	A/G	cg27598129	chr2:42591480	NA	-0.39	-5.14	-0.42	1.05e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6540559	0.546	rs75308488	chr1:210030639	T/C	cg21951975	chr1:209979733	IRF6	0.68	5.11	0.42	1.19e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs2072499	0.966	rs2842865	chr1:156159532	G/A	cg06970220	chr1:156163860	SLC25A44	0.72	6.3	0.49	4.62e-9	Testicular germ cell tumor;
TGCT	cis	rs9677476	0.517	rs55970645	chr2:232052494	G/A	cg07929768	chr2:232055508	NA	0.31	4.97	0.41	2.14e-6	Food antigen IgG levels;
TGCT	cis	rs2188554	1.000	rs10237738	chr7:117007686	A/G	cg08576598	chr7:116962626	WNT2	-0.38	-4.57	-0.38	1.14e-5	Esophageal adenocarcinoma;
TGCT	cis	rs78487399	0.808	rs7567535	chr2:43668261	C/T	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.72	4.62	0.38	9.53e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs3771570	0.901	rs3815262	chr2:242352582	A/T	cg21155796	chr2:242212141	HDLBP	0.83	6.19	0.49	8.22e-9	Prostate cancer;
TGCT	cis	rs12908161	1.000	rs60957376	chr15:85280792	T/G	cg17173187	chr15:85201210	NMB	0.57	6.38	0.5	3.25e-9	Schizophrenia;
TGCT	cis	rs2242116	0.796	rs4587	chr3:46963502	T/C	cg23352942	chr3:46931381	PTH1R	-0.32	-4.53	-0.38	1.36e-5	Birth weight;
TGCT	cis	rs2594989	0.831	rs2443703	chr3:11564191	C/T	cg26283222	chr3:11613257	VGLL4	0.22	4.45	0.37	1.92e-5	Circulating chemerin levels;
TGCT	cis	rs3848445	1.000	rs3848445	chr17:14294021	C/T	cg05091736	chr17:14942129	NA	-0.58	-4.96	-0.41	2.29e-6	Protein quantitative trait loci;
TGCT	cis	rs11785400	0.793	rs750530	chr8:143744931	G/A	cg24634471	chr8:143751801	JRK	0.55	5.51	0.44	1.99e-7	Schizophrenia;
TGCT	trans	rs17685	0.753	rs6951943	chr7:75772452	A/G	cg19862616	chr7:65841803	NCRNA00174	0.52	9.01	0.63	3.02e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs76954792	0.826	rs28524657	chr17:30025992	A/C	cg18427091	chr17:30115417	NA	-0.36	-4.67	-0.39	7.61e-6	Coronary artery disease;
TGCT	trans	rs28595532	0.748	rs66615663	chr4:119336701	C/T	cg26518628	chr1:97050305	NA	-0.56	-6.79	-0.52	4.19e-10	Cannabis dependence symptom count;
TGCT	cis	rs2760061	0.583	rs697763	chr1:228192622	G/C	cg18477163	chr1:228402036	OBSCN	0.36	7.17	0.54	5.84e-11	Diastolic blood pressure;
TGCT	cis	rs1801251	1.000	rs13004406	chr2:233584557	A/T	cg08000102	chr2:233561755	GIGYF2	-0.62	-6.31	-0.49	4.46e-9	Coronary artery disease;
TGCT	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg18230493	chr5:56204884	C5orf35	-0.68	-5.92	-0.47	2.92e-8	Initial pursuit acceleration;
TGCT	cis	rs35771425	1.000	rs11577134	chr1:211602624	A/G	cg25617285	chr1:211431773	RCOR3	0.5	4.58	0.38	1.13e-5	Educational attainment (years of education);
TGCT	cis	rs350251	0.899	rs350274	chr16:12233259	G/C	cg01574788	chr16:12184133	SNX29	0.34	4.48	0.37	1.67e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg08564027	chr20:61660810	NA	0.37	6.85	0.52	3.1e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs13191362	1.000	rs36113695	chr6:163004733	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs832540	0.898	rs252888	chr5:56227326	T/A	cg24531977	chr5:56204891	C5orf35	-0.5	-5.32	-0.43	4.72e-7	Coronary artery disease;
TGCT	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.31	0.43	4.9e-7	Prudent dietary pattern;
TGCT	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg06028605	chr16:24865363	SLC5A11	0.41	4.59	0.38	1.05e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7312774	0.618	rs9651926	chr12:107356820	G/A	cg16260113	chr12:107380972	MTERFD3	1.02	5.27	0.43	5.92e-7	Severe influenza A (H1N1) infection;
TGCT	cis	rs9393692	0.905	rs7746807	chr6:26293338	C/A	cg05868516	chr6:26286170	HIST1H4H	0.61	5.78	0.46	5.65e-8	Educational attainment;
TGCT	cis	rs7666738	0.515	rs10015315	chr4:98700137	A/G	cg18180107	chr4:99064573	C4orf37	0.51	4.55	0.38	1.28e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2439831	0.541	rs12440854	chr15:43610672	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.92	5.4	0.44	3.26e-7	Lung cancer in ever smokers;
TGCT	cis	rs3935685	0.874	rs4886898	chr15:78004743	T/C	cg25212270	chr15:78015279	NA	0.26	5.57	0.45	1.48e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs11031096	0.678	rs10767872	chr11:4184239	T/G	cg18678763	chr11:4115507	RRM1	-0.46	-5.95	-0.47	2.5e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg00080972	chr5:178986291	RUFY1	0.46	5.38	0.44	3.5e-7	Lung cancer;
TGCT	cis	rs2806561	0.664	rs55764475	chr1:23318983	C/T	cg12483005	chr1:23474871	LUZP1	0.37	4.72	0.39	6.21e-6	Height;
TGCT	cis	rs3008870	0.959	rs2815359	chr1:67494374	T/C	cg11518657	chr1:67396239	MIER1	0.52	4.47	0.37	1.73e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs617219	0.698	rs7445125	chr5:78507417	A/G	cg23987322	chr5:78407566	BHMT	0.37	4.78	0.39	4.81e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs7104764	1.000	rs6598060	chr11:243987	C/T	cg18336825	chr11:236787	PSMD13;SIRT3	1.08	11.36	0.71	6.01e-21	Menarche (age at onset);
TGCT	cis	rs4780401	0.609	rs4781143	chr16:11809721	T/G	cg01061890	chr16:11836724	TXNDC11	-0.6	-5.82	-0.46	4.74e-8	Rheumatoid arthritis;
TGCT	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	6.07	0.48	1.45e-8	Alzheimer's disease;
TGCT	cis	rs7615952	1.000	rs7615952	chr3:125649403	A/C	cg05084668	chr3:125655381	ALG1L	0.83	7.03	0.53	1.23e-10	Blood pressure (smoking interaction);
TGCT	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg03264133	chr6:25882463	NA	0.54	4.78	0.39	4.9100000000000004e-06	Intelligence (multi-trait analysis);
TGCT	cis	rs7681440	0.904	rs6816305	chr4:90772902	C/G	cg26578617	chr4:90757533	SNCA	-0.46	-4.73	-0.39	6.01e-6	Dementia with Lewy bodies;
TGCT	cis	rs4595586	0.545	rs3911798	chr12:39389901	A/G	cg10518543	chr12:38710700	ALG10B	0.54	4.47	0.37	1.74e-5	Morning vs. evening chronotype;
TGCT	cis	rs9916302	0.706	rs4795358	chr17:37573065	A/C	cg07936489	chr17:37558343	FBXL20	-0.87	-6.27	-0.49	5.47e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs9430161	0.579	rs9659356	chr1:11034817	A/G	cg27631724	chr1:11040367	C1orf127	0.51	5.98	0.47	2.25e-8	Ewing sarcoma;
TGCT	cis	rs6964587	1.000	rs2157747	chr7:91750578	A/G	cg22709100	chr7:91322751	NA	0.28	4.52	0.38	1.45e-5	Breast cancer;
TGCT	cis	rs1371867	0.641	rs1788209	chr8:101337056	C/T	cg06002616	chr8:101225028	SPAG1	-0.54	-6.29	-0.49	4.88e-9	Atrioventricular conduction;
TGCT	cis	rs7147624	0.517	rs72716457	chr14:66258535	C/G	cg03016385	chr14:66212404	NA	0.52	6.0	0.47	2.03e-8	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs651907	0.535	rs11712309	chr3:101519097	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.86	10.4	0.68	1.35e-18	Colorectal cancer;
TGCT	cis	rs2721195	0.719	rs4925812	chr8:145808035	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.94	10.08	0.67	8.06e-18	Age at first birth;
TGCT	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg27425262	chr2:113953981	PSD4;LOC440839	-0.52	-7.84	-0.58	1.73e-12	Lymphocyte counts;
TGCT	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg16228356	chr17:43848958	NA	-0.26	-4.53	-0.38	1.37e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs1580019	0.537	rs7804609	chr7:32558094	A/C	cg06627557	chr7:32535165	LSM5;AVL9	1.09	13.35	0.77	9.67e-26	Cognitive ability;
TGCT	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg20203395	chr5:56204925	C5orf35	-0.59	-5.12	-0.42	1.12e-6	Initial pursuit acceleration;
TGCT	cis	rs6547741	1.000	rs1919126	chr2:27801418	C/A	cg27432699	chr2:27873401	GPN1	0.18	4.64	0.38	8.54e-6	Oral cavity cancer;
TGCT	cis	rs7523050	0.558	rs34880940	chr1:109487731	T/C	cg08274380	chr1:109419600	GPSM2	1.06	5.18	0.42	8.64e-7	Fat distribution (HIV);
TGCT	cis	rs6750047	0.609	rs2121259	chr2:38269475	T/C	cg07380506	chr2:38303506	CYP1B1	0.61	5.61	0.45	1.23e-7	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg01802117	chr1:53393560	SCP2	-0.45	-5.23	-0.43	7e-7	Monocyte count;
TGCT	cis	rs7772486	0.742	rs4896851	chr6:146278959	T/C	cg23711669	chr6:146136114	FBXO30	-0.74	-7.26	-0.55	3.78e-11	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9868809	0.772	rs2286651	chr3:48694147	G/A	cg07636037	chr3:49044803	WDR6	-0.89	-4.69	-0.39	7.23e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs7209700	0.708	rs2292699	chr17:45362295	A/G	cg21624342	chr17:45890973	OSBPL7	-0.17	-4.8	-0.4	4.51e-6	IgG glycosylation;
TGCT	cis	rs6684514	1.000	rs28372828	chr1:156253031	G/C	cg16558208	chr1:156270281	VHLL	0.46	9.38	0.64	3.92e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs35146811	0.735	rs2272345	chr7:99797031	C/G	cg00553149	chr7:99775558	STAG3;GPC2	0.31	4.61	0.38	9.75e-6	Coronary artery disease;
TGCT	cis	rs4786125	0.581	rs1473519	chr16:6921533	G/A	cg03623568	chr16:6915990	A2BP1	-0.45	-6.68	-0.51	7.28e-10	Heart rate variability traits (SDNN);
TGCT	cis	rs7226408	0.857	rs997661	chr18:34703727	G/A	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs6912958	0.684	rs2787893	chr6:88387359	C/G	cg06598631	chr6:88300029	RARS2;ORC3L	-0.53	-4.91	-0.4	2.79e-6	Monocyte percentage of white cells;
TGCT	cis	rs6845621	0.700	rs6449431	chr4:18894940	C/T	cg12196642	chr4:18937545	NA	-0.25	-4.57	-0.38	1.15e-5	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
TGCT	cis	rs2404602	0.716	rs67888330	chr15:76752483	A/G	cg22467129	chr15:76604101	ETFA	-0.57	-6.83	-0.52	3.31e-10	Blood metabolite levels;
TGCT	cis	rs2204008	0.811	rs12368410	chr12:38305705	C/T	cg26384229	chr12:38710491	ALG10B	0.83	7.22	0.54	4.62e-11	Bladder cancer;
TGCT	cis	rs7552404	1.000	rs437298	chr1:76113770	T/C	cg22875332	chr1:76189707	ACADM	-0.79	-9.64	-0.65	9.57e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs3820068	0.532	rs74057713	chr1:15944620	G/C	cg05660106	chr1:15850417	CASP9	0.83	8.16	0.59	3.26e-13	Systolic blood pressure;
TGCT	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg23758822	chr17:41437982	NA	0.71	6.75	0.52	5.16e-10	Menopause (age at onset);
TGCT	cis	rs7552404	1.000	rs28602663	chr1:76235355	C/T	cg10523679	chr1:76189770	ACADM	0.9	9.48	0.65	2.34e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9467711	0.606	rs9379863	chr6:26372427	A/G	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs651907	0.535	rs13094753	chr3:101525082	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.31	-6.52	-0.51	1.56e-9	Colorectal cancer;
TGCT	cis	rs12510870	0.634	rs11943798	chr4:74407716	C/G	cg05868023	chr4:75230803	EREG	0.56	5.05	0.41	1.55e-6	Iris color (b* coordinate);
TGCT	cis	rs10501293	0.675	rs720292	chr11:43036224	T/C	cg03447554	chr11:43094025	NA	0.44	6.29	0.49	5.05e-9	Cognitive performance;
TGCT	cis	rs2115630	0.653	rs61394864	chr15:85170174	T/C	cg12501888	chr15:85177176	SCAND2	-0.51	-4.7	-0.39	6.89e-6	P wave terminal force;
TGCT	cis	rs1580019	0.587	rs10951338	chr7:32560089	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.14	14.68	0.8	6.88e-29	Cognitive ability;
TGCT	cis	rs950169	1.000	rs35658069	chr15:84780146	C/T	cg17173187	chr15:85201210	NMB	0.47	5.23	0.43	7.01e-7	Schizophrenia;
TGCT	cis	rs854765	0.647	rs7211714	chr17:17986955	A/G	cg09796270	chr17:17721594	SREBF1	0.23	4.76	0.39	5.35e-6	Total body bone mineral density;
TGCT	cis	rs1018836	0.923	rs7837230	chr8:91574281	C/T	cg16814680	chr8:91681699	NA	-0.9	-9.91	-0.66	2.06e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10089	0.953	rs10223203	chr5:127527646	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.82	-7.4	-0.55	1.81e-11	Ileal carcinoids;
TGCT	cis	rs55883249	0.957	rs62119431	chr2:9750461	G/A	cg23886495	chr2:9695866	ADAM17	0.81	5.0	0.41	1.93e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs1018836	0.923	rs4735260	chr8:91617157	C/G	cg16814680	chr8:91681699	NA	0.84	9.32	0.64	5.66e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7666738	0.830	rs9884501	chr4:98893721	A/C	cg18180107	chr4:99064573	C4orf37	0.53	4.84	0.4	3.83e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8032315	0.965	rs35346340	chr15:91427872	G/C	cg05180856	chr15:91428056	FES	0.25	4.45	0.37	1.89e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1577917	0.740	rs2842614	chr6:86306069	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.54	-4.87	-0.4	3.28e-6	Response to antipsychotic treatment;
TGCT	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg17328964	chr8:145687451	CYHR1	-0.42	-5.99	-0.47	2.12e-8	Age at first birth;
TGCT	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.58	-5.78	-0.46	5.74e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs1670533	1.000	rs11247971	chr4:1053580	A/G	cg20887711	chr4:1340912	KIAA1530	0.69	5.54	0.45	1.69e-7	Recombination rate (females);
TGCT	cis	rs9911578	1.000	rs1472288	chr17:56910720	G/A	cg12560992	chr17:57184187	TRIM37	0.76	9.21	0.64	1.03e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs2739330	0.964	rs2739338	chr22:24297130	T/C	cg02953382	chr22:24373134	LOC391322	-0.75	-7.83	-0.58	1.82e-12	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2439831	0.850	rs28564774	chr15:44125475	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.44	0.37	1.99e-5	Lung cancer in ever smokers;
TGCT	cis	rs916888	0.821	rs199505	chr17:44859410	A/G	cg16520312	chr17:43971471	MAPT;LOC100128977	0.57	4.86	0.4	3.45e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs9653442	0.545	rs13032454	chr2:100756009	T/C	cg07810366	chr2:100720526	AFF3	-0.35	-5.0	-0.41	1.88e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg15556689	chr8:8085844	FLJ10661	0.66	6.09	0.48	1.31e-8	Mood instability;
TGCT	cis	rs11711311	0.955	rs9823423	chr3:113419741	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.75	-6.72	-0.52	5.86e-10	IgG glycosylation;
TGCT	cis	rs13223928	0.511	rs11773338	chr7:3144508	T/C	cg19214707	chr7:3157722	NA	-0.46	-6.45	-0.5	2.24e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
TGCT	cis	rs8141529	0.748	rs715531	chr22:29282679	A/G	cg02153584	chr22:29168773	CCDC117	0.66	5.19	0.42	8.5e-7	Lymphocyte counts;
TGCT	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg23172400	chr8:95962367	TP53INP1	-0.38	-6.4	-0.5	2.88e-9	Type 2 diabetes;
TGCT	cis	rs9291683	0.588	rs13113730	chr4:10017628	C/T	cg02734326	chr4:10020555	SLC2A9	0.38	4.54	0.38	1.34e-5	Bone mineral density;
TGCT	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg18230493	chr5:56204884	C5orf35	-0.68	-5.92	-0.47	2.92e-8	Initial pursuit acceleration;
TGCT	cis	rs911555	0.755	rs8018400	chr14:103901085	A/G	cg23461800	chr14:103021989	NA	-0.35	-4.57	-0.38	1.17e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs9534288	0.659	rs2146883	chr13:46660576	C/A	cg15192986	chr13:46630673	CPB2	-0.53	-6.41	-0.5	2.75e-9	Blood protein levels;
TGCT	cis	rs7208859	0.623	rs12103508	chr17:29086781	T/G	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs9549260	0.755	rs7988604	chr13:41215802	G/T	cg21288729	chr13:41239152	FOXO1	0.97	10.09	0.67	7.57e-18	Red blood cell count;
TGCT	cis	rs260461	0.920	rs79259289	chr19:58752257	T/C	cg08291996	chr19:58791159	ZNF8	-0.36	-4.72	-0.39	6.3e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs7666738	0.606	rs28625338	chr4:99076996	A/G	cg05340658	chr4:99064831	C4orf37	0.44	4.77	0.39	5.05e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7208859	0.623	rs73269945	chr17:29108759	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg21285383	chr16:89894308	SPIRE2	0.48	7.73	0.57	3.23e-12	Vitiligo;
TGCT	cis	rs6570726	0.791	rs9373463	chr6:145894762	C/T	cg13319975	chr6:146136371	FBXO30	-0.5	-4.51	-0.38	1.48e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg16325326	chr1:53192061	ZYG11B	-0.64	-7.45	-0.56	1.38e-11	Monocyte count;
TGCT	cis	rs13424612	0.965	rs2289407	chr2:240954110	A/G	cg26363272	chr2:240904871	NDUFA10	0.29	4.99	0.41	2.02e-6	Odorant perception (isobutyraldehyde);
TGCT	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg10295955	chr4:187884368	NA	-0.94	-14.39	-0.79	3.21e-28	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2806561	0.734	rs10799788	chr1:23356864	G/A	cg12483005	chr1:23474871	LUZP1	0.38	4.76	0.39	5.34e-6	Height;
TGCT	cis	rs763121	0.853	rs2072798	chr22:39148483	G/A	cg06022373	chr22:39101656	GTPBP1	0.77	7.17	0.54	6e-11	Menopause (age at onset);
TGCT	cis	rs9534288	0.742	rs7337140	chr13:46641481	C/T	cg15192986	chr13:46630673	CPB2	0.49	6.32	0.49	4.28e-9	Blood protein levels;
TGCT	cis	rs514406	0.683	rs10157120	chr1:53210888	A/G	cg22166914	chr1:53195759	ZYG11B	0.48	8.96	0.63	4.03e-15	Monocyte count;
TGCT	cis	rs2153535	0.580	rs9328479	chr6:8519646	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.55e-8	Motion sickness;
TGCT	cis	rs1215050	0.791	rs4699318	chr4:98664370	T/G	cg05340658	chr4:99064831	C4orf37	-0.43	-5.4	-0.44	3.2e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9522267	0.737	rs9522289	chr13:112232110	G/A	cg10483660	chr13:112241077	NA	-0.28	-4.51	-0.38	1.47e-5	Hepatitis;
TGCT	cis	rs854765	0.647	rs854814	chr17:18003648	G/A	cg04398451	chr17:18023971	MYO15A	-0.38	-6.53	-0.51	1.52e-9	Total body bone mineral density;
TGCT	cis	rs3125734	0.633	rs4561099	chr10:64041163	T/C	cg09941381	chr10:64027924	RTKN2	-0.32	-4.87	-0.4	3.36e-6	Rheumatoid arthritis;
TGCT	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg20007245	chr22:24372913	LOC391322	-0.74	-7.49	-0.56	1.11e-11	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs881375	0.678	rs10118357	chr9:123680068	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	4.85	0.4	3.66e-6	Rheumatoid arthritis;
TGCT	cis	rs13217239	0.646	rs9379956	chr6:27033735	T/C	cg26531700	chr6:26746687	NA	-0.68	-6.72	-0.52	5.75e-10	Schizophrenia;
TGCT	cis	rs4851254	0.579	rs78633727	chr2:100669457	T/C	cg22139774	chr2:100720529	AFF3	-0.43	-4.63	-0.38	9.26e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2702888	0.501	rs2738152	chr8:6752085	A/T	cg26795848	chr8:6756730	NA	0.32	6.6	0.51	1.05e-9	Blood pressure;
TGCT	cis	rs2996428	0.667	rs113120570	chr1:3770450	G/C	cg17848003	chr1:3704513	LRRC47	0.18	5.15	0.42	9.99e-7	Red cell distribution width;
TGCT	cis	rs6912958	0.559	rs173333	chr6:88047754	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.72	7.53	0.56	9.05e-12	Monocyte percentage of white cells;
TGCT	cis	rs13191362	1.000	rs34637087	chr6:163004064	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7674212	0.531	rs2866416	chr4:103880711	G/C	cg16532752	chr4:104119610	CENPE	-0.55	-4.72	-0.39	6.18e-6	Type 2 diabetes;
TGCT	cis	rs10504229	0.861	rs60346509	chr8:58196050	G/T	cg08280861	chr8:58055591	NA	0.36	4.61	0.38	9.98e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9303401	0.614	rs34683543	chr17:56520036	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.69	6.9	0.53	2.36e-10	Cognitive test performance;
TGCT	cis	rs7666738	0.830	rs10029849	chr4:99059362	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.79	0.46	5.32e-8	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs1974653	0.781	rs9606241	chr22:20075858	A/G	cg08822737	chr17:71088851	SLC39A11	-0.71	-6.62	-0.51	9.55e-10	Schizophrenia;
TGCT	cis	rs7824557	0.652	rs12677504	chr8:11133175	G/A	cg21775007	chr8:11205619	TDH	-0.6	-5.82	-0.46	4.81e-8	Retinal vascular caliber;
TGCT	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg16414030	chr3:133502952	NA	-0.66	-11.28	-0.71	9.62e-21	Iron status biomarkers;
TGCT	cis	rs2268241	0.938	rs17878783	chr21:34779185	G/A	cg14850771	chr21:34775459	IFNGR2	0.61	5.23	0.43	6.88e-7	Obesity-related traits;
TGCT	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.84	0.46	4.39e-8	Height;
TGCT	cis	rs3749237	0.595	rs12489092	chr3:49550914	G/C	cg02487422	chr3:49467188	NICN1	0.57	5.84	0.46	4.26e-8	Resting heart rate;
TGCT	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	8.99	0.63	3.48e-15	Platelet count;
TGCT	cis	rs3858526	0.584	rs10734559	chr11:5861788	A/C	cg13902645	chr11:5959945	NA	-0.37	-4.51	-0.38	1.47e-5	DNA methylation (variation);
TGCT	cis	rs1008375	0.931	rs3796814	chr4:17602033	G/C	cg16339924	chr4:17578868	LAP3	0.64	5.22	0.42	7.4e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9443645	0.901	rs6940637	chr6:79705845	C/T	cg09184832	chr6:79620586	NA	-0.48	-5.34	-0.43	4.21e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs896854	0.846	rs2340584	chr8:95916811	A/G	cg23172400	chr8:95962367	TP53INP1	-0.34	-5.49	-0.44	2.2e-7	Type 2 diabetes;
TGCT	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg08736216	chr1:53307985	ZYG11A	0.25	4.93	0.41	2.55e-6	Monocyte count;
TGCT	cis	rs265548	0.538	rs36688	chr19:17911212	A/C	cg03316864	chr19:17906309	B3GNT3	0.47	5.67	0.45	9.52e-8	Tumor biomarkers;
TGCT	cis	rs7246657	0.712	rs4803263	chr19:38066782	G/A	cg18154014	chr19:37997991	ZNF793	0.69	4.63	0.38	9.25e-6	Coronary artery calcification;
TGCT	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg06112835	chr11:68658793	MRPL21	0.47	8.28	0.6	1.65e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs17221829	0.965	rs11018753	chr11:89459064	T/C	cg02982614	chr11:89391479	FOLH1B	-0.27	-4.75	-0.39	5.63e-6	Anxiety in major depressive disorder;
TGCT	cis	rs9341808	0.754	rs9352817	chr6:81025879	T/G	cg08355045	chr6:80787529	NA	0.28	4.74	0.39	5.73e-6	Sitting height ratio;
TGCT	cis	rs813218	0.565	rs4244712	chr3:99679461	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.5	5.63	0.45	1.12e-7	Orofacial clefts;
TGCT	cis	rs78456975	0.527	rs10206020	chr2:1557927	A/G	cg01028140	chr2:1542097	TPO	-0.33	-5.12	-0.42	1.14e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs910187	1.000	rs910187	chr20:45841052	A/G	cg27589058	chr20:45804311	EYA2	0.31	5.76	0.46	6.24e-8	Migraine;
TGCT	cis	rs11098499	0.730	rs12505735	chr4:120532956	G/T	cg09307838	chr4:120376055	NA	0.68	6.33	0.49	4.11e-9	Corneal astigmatism;
TGCT	cis	rs7192750	0.586	rs11648353	chr16:71986764	G/A	cg06353428	chr16:71660113	MARVELD3	0.74	6.6	0.51	1.09e-9	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs7147624	0.573	rs10148699	chr14:66199662	G/A	cg03016385	chr14:66212404	NA	-0.5	-7.04	-0.53	1.13e-10	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg04267008	chr7:1944627	MAD1L1	-0.4	-5.27	-0.43	5.73e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs13191362	0.810	rs35509380	chr6:163053028	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.89	6.39	0.5	3.1e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs12762955	0.519	rs10795306	chr10:1019138	A/T	cg26597838	chr10:835615	NA	-0.46	-6.3	-0.49	4.79e-9	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs6840360	0.571	rs17360371	chr4:152565374	C/T	cg17479576	chr4:152424074	FAM160A1	-0.71	-7.72	-0.57	3.41e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs938554	0.779	rs7442295	chr4:9966380	A/G	cg11197905	chr4:10459435	ZNF518B	-0.29	-4.54	-0.38	1.32e-5	Blood metabolite levels;
TGCT	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg03188948	chr7:1209495	NA	0.59	4.8	0.4	4.57e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg06112835	chr11:68658793	MRPL21	0.5	8.25	0.6	1.92e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg12311346	chr5:56204834	C5orf35	-0.67	-6.82	-0.52	3.63e-10	Initial pursuit acceleration;
TGCT	cis	rs62283056	0.636	rs62283057	chr4:6276805	C/T	cg25554036	chr4:6271136	WFS1	-0.51	-4.75	-0.39	5.48e-6	Cisplatin-induced ototoxicity;
TGCT	cis	rs894734	0.535	rs2366142	chr12:54323148	T/C	cg17708016	chr12:54321992	NA	0.69	5.75	0.46	6.56e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
TGCT	cis	rs7769051	0.711	rs7770081	chr6:133089569	G/T	cg22852734	chr6:133119734	C6orf192	1.22	7.01	0.53	1.38e-10	Type 2 diabetes nephropathy;
TGCT	cis	rs7819412	0.775	rs2898257	chr8:10935368	A/C	cg21775007	chr8:11205619	TDH	-0.5	-4.61	-0.38	9.74e-6	Triglycerides;
TGCT	cis	rs6088580	0.601	rs6059827	chr20:33016358	C/T	cg08999081	chr20:33150536	PIGU	0.29	5.74	0.46	6.86e-8	Glomerular filtration rate (creatinine);
TGCT	cis	rs172166	0.516	rs2622322	chr6:28117443	C/G	cg13525197	chr6:28411240	ZSCAN23	-0.46	-4.5	-0.37	1.53e-5	Cardiac Troponin-T levels;
TGCT	cis	rs6882046	0.513	rs679232	chr5:88054763	A/C	cg24804195	chr5:87968844	LOC645323	0.57	5.58	0.45	1.42e-7	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs112591243	0.685	rs2839323	chr21:47978421	G/A	cg10657630	chr21:48055338	PRMT2	1.0	5.29	0.43	5.4e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs8050907	0.744	rs7195782	chr16:4539861	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.58	4.65	0.39	8.46e-6	Obesity-related traits;
TGCT	cis	rs42648	0.837	rs4728879	chr7:89924237	T/G	cg25739043	chr7:89950458	NA	-0.75	-7.35	-0.55	2.31e-11	Homocysteine levels;
TGCT	cis	rs10791097	0.694	rs4370948	chr11:130755700	A/C	cg14779329	chr11:130786720	SNX19	0.29	4.97	0.41	2.21e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs7089973	0.604	rs7915943	chr10:116618077	G/A	cg03647239	chr10:116582469	FAM160B1	0.56	5.41	0.44	3.06e-7	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs6089584	0.566	rs6061964	chr20:60607536	G/A	cg06108461	chr20:60628389	TAF4	-0.44	-5.58	-0.45	1.44e-7	Body mass index;
TGCT	cis	rs7267979	1.000	rs6050542	chr20:25318879	T/C	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs114540395	0.858	rs79692612	chr10:103322878	G/A	cg10198749	chr1:39920707	MACF1	0.55	7.05	0.53	1.11e-10	Schizophrenia;
TGCT	cis	rs2721195	0.816	rs4925826	chr8:145706276	G/A	cg11211951	chr8:145729740	GPT	0.27	6.36	0.5	3.48e-9	Age at first birth;
TGCT	cis	rs892961	0.932	rs7216116	chr17:75405078	C/T	cg05865280	chr17:75406074	SEPT9	0.29	6.76	0.52	4.91e-10	Airflow obstruction;
TGCT	cis	rs9914544	0.689	rs1634423	chr17:18844736	C/T	cg26378065	chr17:18585709	ZNF286B	0.55	5.21	0.42	7.59e-7	Educational attainment (years of education);
TGCT	cis	rs7666738	0.830	rs28444709	chr4:99028496	A/T	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3820928	1.000	rs7579961	chr2:227776976	T/A	cg11843606	chr2:227700838	RHBDD1	-0.53	-4.73	-0.39	5.89e-6	Pulmonary function;
TGCT	cis	rs9399137	0.529	rs7739722	chr6:135282225	T/C	cg24558204	chr6:135376177	HBS1L	0.47	4.78	0.39	4.95e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
TGCT	cis	rs1868673	0.679	rs6414375	chr3:150139360	A/G	cg24290546	chr3:150134309	TSC22D2	-0.25	-4.67	-0.39	7.66e-6	Waist circumference;
TGCT	cis	rs5760092	0.755	rs6003959	chr22:24264395	C/T	cg12419862	chr22:24373484	LOC391322	0.87	7.7	0.57	3.63e-12	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs7547997	0.615	rs34591069	chr1:158316990	G/C	cg07950803	chr1:158223934	CD1A	0.32	5.08	0.42	1.35e-6	QRS duration;
TGCT	cis	rs11792861	0.591	rs7027874	chr9:111717112	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.67	7.73	0.57	3.13e-12	Menarche (age at onset);
TGCT	cis	rs9467603	0.925	rs4712969	chr6:25764192	A/G	cg16898833	chr6:26189333	HIST1H4D	-0.99	-4.75	-0.39	5.62e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs259282	0.605	rs73028624	chr19:33111758	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.62	5.56	0.45	1.59e-7	Schizophrenia;
TGCT	cis	rs17376456	0.877	rs10035340	chr5:93490465	C/T	cg25358565	chr5:93447407	FAM172A	0.97	8.32	0.6	1.34e-13	Diabetic retinopathy;
TGCT	cis	rs12477438	0.784	rs13407840	chr2:99569928	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-4.62	-0.38	9.47e-6	Chronic sinus infection;
TGCT	cis	rs2025751	0.574	rs1326610	chr6:51590078	A/G	cg20180370	chr6:50691003	TFAP2D	0.47	4.54	0.38	1.31e-5	Intraocular pressure;
TGCT	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	5.07	0.41	1.42e-6	Electroencephalogram traits;
TGCT	trans	rs9467711	1.000	rs6908156	chr6:26322861	C/T	cg20516262	chr7:155325649	CNPY1	0.54	6.63	0.51	9.34e-10	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2172802	0.924	rs11131331	chr4:62446700	C/T	cg04118610	chr4:62707027	LPHN3	-0.39	-4.57	-0.38	1.15e-5	Partial epilepsies;
TGCT	cis	rs11190604	0.806	rs76835764	chr10:102193612	C/T	cg16342193	chr10:102329863	NA	-0.41	-5.2	-0.42	8.01e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs13191362	0.935	rs7769048	chr6:163010040	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs6554196	0.686	rs13106834	chr4:55501728	C/T	cg02821500	chr4:54931072	CHIC2	-0.47	-4.54	-0.38	1.31e-5	Monocyte count;
TGCT	cis	rs7666738	0.830	rs10022331	chr4:98960392	C/A	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs376008	0.526	rs447009	chr19:18185192	C/A	cg15085805	chr19:18433592	LSM4	0.54	4.53	0.38	1.37e-5	Blood protein levels;
TGCT	cis	rs7666738	0.830	rs13134216	chr4:98919765	C/T	cg17366294	chr4:99064904	C4orf37	0.73	7.51	0.56	1e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs288326	0.561	rs76304059	chr2:183779555	C/G	cg09997497	chr2:183902928	NCKAP1	1.11	4.95	0.41	2.38e-6	Blood protein levels;
TGCT	cis	rs2204008	0.774	rs10400552	chr12:38393577	C/G	cg13010199	chr12:38710504	ALG10B	0.59	4.68	0.39	7.35e-6	Bladder cancer;
TGCT	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg08219700	chr8:58056026	NA	0.3	4.48	0.37	1.66e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg11301795	chr4:187892539	NA	-0.34	-5.22	-0.42	7.29e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9611565	0.729	rs12165508	chr22:41819960	T/C	cg17554472	chr22:41940697	POLR3H	0.46	5.0	0.41	1.89e-6	Vitiligo;
TGCT	cis	rs3020736	0.500	rs4147641	chr22:42482502	C/G	cg05082376	chr22:42548792	NA	0.23	5.43	0.44	2.83e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs10484885	0.824	rs28372875	chr6:90529343	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.47	-4.58	-0.38	1.11e-5	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs36093844	0.898	rs11234457	chr11:85591041	C/T	cg25872744	chr11:85566296	CCDC83	-0.52	-4.73	-0.39	6.09e-6	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
TGCT	cis	rs12477438	0.501	rs2632260	chr2:99771590	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.15	18.47	0.86	2.08e-37	Chronic sinus infection;
TGCT	cis	rs12989701	0.825	rs873270	chr2:127859418	T/C	cg08168897	chr2:127865431	BIN1	0.52	5.56	0.45	1.55e-7	Alzheimer's disease (late onset);
TGCT	cis	rs79349575	0.783	rs2112617	chr17:46977125	G/A	cg27201301	chr17:47039149	GIP	0.26	4.68	0.39	7.38e-6	Type 2 diabetes;
TGCT	cis	rs2730245	0.550	rs2788478	chr7:158672619	A/G	cg24397884	chr7:158709396	WDR60	0.37	4.93	0.4	2.63e-6	Height;
TGCT	cis	rs546131	0.642	rs537873	chr11:34835121	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.58	4.94	0.41	2.45e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs9611519	0.894	rs4821990	chr22:41438710	A/C	cg03806693	chr22:41940476	POLR3H	-0.67	-6.09	-0.48	1.3e-8	Neuroticism;
TGCT	cis	rs9868809	0.649	rs3733086	chr3:48699519	C/T	cg07636037	chr3:49044803	WDR6	-0.89	-4.69	-0.39	7.23e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs250677	0.522	rs11954893	chr5:148392362	A/G	cg18129178	chr5:148520854	ABLIM3	-0.35	-4.58	-0.38	1.12e-5	Breast cancer;
TGCT	cis	rs6141600	0.627	rs2746102	chr20:34689247	G/A	cg09179691	chr20:35094251	DLGAP4	-0.19	-4.58	-0.38	1.1e-5	Height;Hip circumference;
TGCT	cis	rs8077889	0.917	rs9901676	chr17:41911818	T/C	cg26893861	chr17:41843967	DUSP3	1.09	13.08	0.76	4.26e-25	Triglycerides;
TGCT	cis	rs7611238	0.560	rs6801315	chr3:195072820	A/G	cg27323046	chr3:195102265	ACAP2	0.37	4.98	0.41	2.1e-6	Body mass index;
TGCT	cis	rs8014204	0.762	rs7144654	chr14:75298637	A/G	cg06637938	chr14:75390232	RPS6KL1	0.57	5.07	0.41	1.4e-6	Caffeine consumption;
TGCT	cis	rs67311347	1.000	rs56303661	chr3:40520778	C/G	cg13409248	chr3:40428643	ENTPD3	0.56	4.45	0.37	1.91e-5	Renal cell carcinoma;
TGCT	cis	rs13326165	0.760	rs390802	chr3:52431671	G/A	cg07884673	chr3:53033167	SFMBT1	0.39	4.69	0.39	7e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs7513165	0.660	rs12040249	chr1:204158228	C/T	cg04791601	chr1:204159016	NA	0.26	5.38	0.43	3.61e-7	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
TGCT	cis	rs7681440	0.835	rs6831847	chr4:90785341	A/G	cg26578617	chr4:90757533	SNCA	0.45	4.59	0.38	1.05e-5	Dementia with Lewy bodies;
TGCT	trans	rs9951602	0.512	rs9949512	chr18:76641845	T/C	cg02800362	chr5:177631904	HNRNPAB	1.13	12.94	0.76	9.39e-25	Obesity-related traits;
TGCT	cis	rs111803315	1.000	rs78177356	chr14:60008967	A/G	cg22995959	chr14:59931024	GPR135	0.66	4.8	0.4	4.39e-6	Schizophrenia;
TGCT	cis	rs11874712	1.000	rs7244921	chr18:43667528	T/C	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	5.23	0.42	7.11e-7	Migraine - clinic-based;
TGCT	cis	rs6964587	0.773	rs62467797	chr7:91889722	G/A	cg17063962	chr7:91808500	NA	0.83	7.96	0.58	9.29e-13	Breast cancer;
TGCT	cis	rs992157	0.560	rs6436048	chr2:219109033	C/T	cg00012203	chr2:219082015	ARPC2	0.78	8.94	0.63	4.67e-15	Colorectal cancer;
TGCT	cis	rs9522267	0.707	rs9522282	chr13:112222410	T/C	cg10483660	chr13:112241077	NA	-0.27	-4.46	-0.37	1.78e-5	Hepatitis;
TGCT	cis	rs9303401	0.659	rs34426768	chr17:56683385	C/T	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs7523273	0.565	rs1359147	chr1:207886150	C/T	cg22525895	chr1:207977042	MIR29B2	0.35	5.75	0.46	6.69e-8	Schizophrenia;
TGCT	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	7.32	0.55	2.74e-11	Platelet count;
TGCT	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg23708337	chr7:1209742	NA	0.44	4.99	0.41	2e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs6089829	0.962	rs1116450	chr20:61658210	T/C	cg03213289	chr20:61660250	NA	0.68	9.99	0.67	1.36e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.45	0.56	1.42e-11	Prudent dietary pattern;
TGCT	cis	rs7264396	0.790	rs3787164	chr20:34228866	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.28	-4.68	-0.39	7.38e-6	Total cholesterol levels;
TGCT	cis	rs12142240	0.698	rs72677593	chr1:46824363	T/C	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs2188554	0.667	rs213949	chr7:117197031	T/A	cg08576598	chr7:116962626	WNT2	-0.36	-4.56	-0.38	1.23e-5	Esophageal adenocarcinoma;
TGCT	cis	rs6969780	1.000	rs6461985	chr7:27150634	T/C	cg04321618	chr7:27170880	HOXA4	0.55	4.9	0.4	2.97e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg19774624	chr17:42201019	HDAC5	-0.87	-10.64	-0.69	3.48e-19	Total body bone mineral density;
TGCT	cis	rs6500602	1.000	rs7204827	chr16:4467533	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.3	5.11	0.42	1.17e-6	Schizophrenia;
TGCT	cis	rs1865760	0.622	rs9968910	chr6:26072095	A/C	cg16482183	chr6:26056742	HIST1H1C	0.68	5.61	0.45	1.28e-7	Height;
TGCT	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.68	-6.98	-0.53	1.62e-10	Prostate cancer;
TGCT	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs10089	1.000	rs1559263	chr5:127512873	A/C	cg19767477	chr5:127420684	SLC12A2	-0.43	-4.55	-0.38	1.25e-5	Ileal carcinoids;
TGCT	cis	rs2456568	0.548	rs10466334	chr11:93663512	A/G	cg17595323	chr11:93583763	C11orf90	-0.42	-5.26	-0.43	6.2e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs4273100	0.646	rs2296981	chr17:19213335	C/G	cg01534423	chr17:18965556	NA	-0.79	-6.76	-0.52	4.91e-10	Schizophrenia;
TGCT	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg12310025	chr6:25882481	NA	-0.64	-5.73	-0.46	7.07e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs12216125	0.554	rs6942196	chr6:26072804	A/G	cg17042849	chr6:26104293	HIST1H4C	-0.63	-5.5	-0.44	2.1e-7	Iron status biomarkers;
TGCT	cis	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg20637647	chr7:64974828	NA	0.96	5.18	0.42	8.81e-7	Diabetic kidney disease;
TGCT	cis	rs67478160	0.608	rs11628787	chr14:104323984	G/A	cg26031613	chr14:104095156	KLC1	0.67	6.73	0.52	5.51e-10	Schizophrenia;
TGCT	cis	rs6840360	0.550	rs6535806	chr4:152483906	G/A	cg17479576	chr4:152424074	FAM160A1	-0.73	-7.94	-0.58	1.03e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs877282	0.853	rs11596346	chr10:756673	A/T	cg17470449	chr10:769945	NA	0.32	4.91	0.4	2.76e-6	Uric acid levels;
TGCT	cis	rs3733631	1.000	rs17034046	chr4:104659604	C/T	cg24090629	chr4:104641072	TACR3	-0.73	-6.03	-0.48	1.76e-8	Menarche (age at onset);
TGCT	cis	rs5750830	0.594	rs5757647	chr22:39775047	C/A	cg05872129	chr22:39784769	NA	-0.84	-8.83	-0.62	8.39e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs12210905	0.920	rs9366690	chr6:27291079	T/C	cg08851530	chr6:28072375	NA	1.29	5.45	0.44	2.65e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs10262995	1.000	rs28619003	chr7:33548225	C/T	cg06206957	chr7:33080615	NT5C3	0.31	4.53	0.38	1.37e-5	Acute kidney injury in coronary artery bypass surgery (creatinine rise);
TGCT	cis	rs62244186	0.714	rs2293600	chr3:44599103	G/T	cg02073558	chr3:44770973	ZNF501	-0.61	-5.94	-0.47	2.69e-8	Depressive symptoms;
TGCT	cis	rs7647973	0.922	rs6809851	chr3:49309787	C/A	cg05785598	chr3:49045655	WDR6	0.38	4.5	0.37	1.57e-5	Menarche (age at onset);
TGCT	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg08280861	chr8:58055591	NA	0.49	5.38	0.43	3.64e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg23302884	chr18:44338147	ST8SIA5	0.41	4.81	0.4	4.25e-6	Personality dimensions;
TGCT	cis	rs6964587	1.000	rs416	chr7:91580571	A/G	cg22709100	chr7:91322751	NA	-0.27	-4.48	-0.37	1.68e-5	Breast cancer;
TGCT	cis	rs7824557	0.628	rs3174048	chr8:11184937	G/A	cg21775007	chr8:11205619	TDH	0.66	6.47	0.5	2.08e-9	Retinal vascular caliber;
TGCT	cis	rs36051895	0.658	rs7875265	chr9:5033882	C/A	cg02405213	chr9:5042618	JAK2	-0.83	-11.82	-0.73	4.65e-22	Pediatric autoimmune diseases;
TGCT	cis	rs1499614	1.000	rs1267818	chr7:66107024	C/T	cg18252515	chr7:66147081	NA	-1.23	-7.53	-0.56	9.12e-12	Gout;
TGCT	cis	rs1046896	0.553	rs1044661	chr17:80901020	G/A	cg03160526	chr17:80928410	B3GNTL1	0.33	4.53	0.38	1.38e-5	Glycated hemoglobin levels;
TGCT	cis	rs314370	0.951	rs12705095	chr7:100484381	T/G	cg10426581	chr7:100472382	SRRT	1.0	10.93	0.7	6.98e-20	Resting heart rate;
TGCT	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.51	4.72	0.39	6.14e-6	Menarche (age at onset);
TGCT	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg24578937	chr1:2090814	PRKCZ	-0.24	-5.9	-0.47	3.24e-8	Height;
TGCT	cis	rs11208691	0.513	rs1938484	chr1:66081282	C/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.59	4.56	0.38	1.22e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs9527	0.590	rs2066322	chr10:104909339	T/G	cg04362960	chr10:104952993	NT5C2	0.65	5.59	0.45	1.36e-7	Arsenic metabolism;
TGCT	cis	rs9341808	0.718	rs2322630	chr6:80841033	A/G	cg08355045	chr6:80787529	NA	0.33	6.02	0.48	1.82e-8	Sitting height ratio;
TGCT	cis	rs9914544	0.545	rs57035178	chr17:18797767	C/T	cg26378065	chr17:18585709	ZNF286B	0.51	4.59	0.38	1.09e-5	Educational attainment (years of education);
TGCT	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg00908189	chr16:619842	PIGQ	0.87	10.68	0.69	2.85e-19	Height;
TGCT	trans	rs4650994	1.000	rs4511075	chr1:178518636	G/A	cg05059571	chr16:84539110	KIAA1609	-0.41	-7.67	-0.57	4.37e-12	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs9733	0.596	rs12072339	chr1:150686099	A/G	cg04414720	chr1:150670196	GOLPH3L	0.37	4.91	0.4	2.76e-6	Tonsillectomy;
TGCT	cis	rs3617	0.625	rs7652667	chr3:52866535	C/A	cg11645453	chr3:52864694	ITIH4	-0.29	-5.71	-0.46	7.84e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7614311	0.681	rs73117036	chr3:63892725	G/C	cg22134162	chr3:63841271	THOC7	-0.4	-5.16	-0.42	9.41e-7	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs4919694	1.000	rs12253284	chr10:104665145	G/C	cg04362960	chr10:104952993	NT5C2	1.02	6.9	0.53	2.41e-10	Arsenic metabolism;
TGCT	cis	rs1801251	0.964	rs7589201	chr2:233724536	A/G	cg25237894	chr2:233734115	C2orf82	-0.31	-5.45	-0.44	2.57e-7	Coronary artery disease;
TGCT	cis	rs17345786	1.000	rs55641278	chr3:101290577	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	4.69	0.39	7.11e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3772130	0.962	rs6789736	chr3:121543084	T/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.72	0.39	6.25e-6	Cognitive performance;
TGCT	cis	rs611744	0.967	rs475865	chr8:109235858	G/C	cg21045802	chr8:109455806	TTC35	0.52	4.72	0.39	6.21e-6	Dupuytren's disease;
TGCT	cis	rs7208859	0.623	rs11652631	chr17:29060766	A/G	cg13385521	chr17:29058706	SUZ12P	0.79	4.77	0.39	5.16e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg20637647	chr7:64974828	NA	1.0	5.59	0.45	1.4e-7	Diabetic kidney disease;
TGCT	cis	rs4820539	1.000	rs916585	chr22:23469438	G/A	cg21100191	chr22:23484243	RTDR1	0.89	10.61	0.69	4.23e-19	Bone mineral density;
TGCT	cis	rs1348850	0.567	rs7605493	chr2:178534983	C/G	cg22681709	chr2:178499509	PDE11A	-0.46	-5.95	-0.47	2.58e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs2153535	0.580	rs7743995	chr6:8496212	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg26338869	chr17:61819248	STRADA	-0.53	-4.87	-0.4	3.29e-6	Prudent dietary pattern;
TGCT	cis	rs61990749	0.544	rs176962	chr14:78185510	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	0.6	4.45	0.37	1.88e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs732765	0.689	rs12411	chr14:75409043	T/A	cg06637938	chr14:75390232	RPS6KL1	0.65	5.36	0.43	3.85e-7	Non-small cell lung cancer;
TGCT	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg12963246	chr6:28129442	ZNF389	-0.47	-4.82	-0.4	4.2e-6	Depression;
TGCT	cis	rs7216064	1.000	rs56148300	chr17:65892752	T/C	cg12091567	chr17:66097778	LOC651250	-0.84	-6.17	-0.48	8.94e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs10788264	0.569	rs10749454	chr10:124029654	C/T	cg09507567	chr10:124027408	NA	0.43	6.72	0.52	6.02e-10	Total body bone mineral density;
TGCT	cis	rs208520	0.661	rs207079	chr6:66770462	C/T	cg07460842	chr6:66804631	NA	-0.92	-10.19	-0.68	4.36e-18	Exhaled nitric oxide output;
TGCT	cis	rs782590	0.902	rs2586947	chr2:55854009	C/G	cg03859395	chr2:55845619	SMEK2	0.91	11.16	0.71	1.92e-20	Metabolic syndrome;
TGCT	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg19626725	chr5:178986131	RUFY1	-0.54	-7.39	-0.55	1.94e-11	Lung cancer;
TGCT	cis	rs6484504	0.576	rs208093	chr11:31184400	C/T	cg14844989	chr11:31128820	NA	0.27	5.0	0.41	1.93e-6	Red blood cell count;
TGCT	cis	rs7552404	0.696	rs10782602	chr1:76464261	T/C	cg10523679	chr1:76189770	ACADM	0.84	7.2	0.54	4.99e-11	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7513165	0.736	rs4889	chr1:204159787	G/C	cg04791601	chr1:204159016	NA	0.26	5.21	0.42	7.68e-7	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
TGCT	cis	rs9677476	0.516	rs10206322	chr2:232050072	T/C	cg07929768	chr2:232055508	NA	0.32	5.05	0.41	1.53e-6	Food antigen IgG levels;
TGCT	cis	rs62229266	0.771	rs2835232	chr21:37393427	G/A	cg08632701	chr21:37451849	NA	-0.14	-4.44	-0.37	1.99e-5	Mitral valve prolapse;
TGCT	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg03806693	chr22:41940476	POLR3H	1.16	13.52	0.77	3.78e-26	Vitiligo;
TGCT	cis	rs2749592	0.611	rs176888	chr10:38406161	C/A	cg25427524	chr10:38739819	LOC399744	-0.41	-7.01	-0.53	1.36e-10	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs7666738	0.791	rs10022061	chr4:98926821	T/C	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs921968	0.541	rs7583449	chr2:219403022	A/C	cg02176678	chr2:219576539	TTLL4	-0.49	-6.94	-0.53	1.95e-10	Mean corpuscular hemoglobin concentration;
TGCT	trans	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg17470723	chr8:74884337	TCEB1	0.71	6.77	0.52	4.48e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs263156	0.967	rs263107	chr6:142878480	G/A	cg18419694	chr6:143832440	FUCA2	-0.38	-4.53	-0.38	1.36e-5	Ear morphology;Lobe size;Lobe attachment;
TGCT	cis	rs66573146	0.803	rs59742225	chr4:6969942	C/T	cg05069807	chr4:6945702	TBC1D14	0.31	4.6	0.38	1.03e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs2050392	0.965	rs2265370	chr10:30690581	C/T	cg18806716	chr10:30721971	MAP3K8	-0.44	-5.17	-0.42	9.28e-7	Inflammatory bowel disease;
TGCT	cis	rs9324022	0.580	rs10151519	chr14:101175798	G/A	cg18089426	chr14:101175970	NA	0.63	5.91	0.47	3.13e-8	Plateletcrit;
TGCT	cis	rs921968	0.613	rs1427445	chr2:219555573	C/A	cg02176678	chr2:219576539	TTLL4	-0.33	-4.46	-0.37	1.81e-5	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs28595532	0.920	rs56227053	chr4:119772460	C/T	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	trans	rs208520	0.507	rs3903670	chr6:66812183	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-16.45	-0.83	5.75e-33	Exhaled nitric oxide output;
TGCT	cis	rs80282103	0.867	rs12241632	chr10:1069070	A/T	cg15531433	chr10:1639090	ADARB2	0.4	4.58	0.38	1.12e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs9430161	0.579	rs7542158	chr1:11040193	G/A	cg27631724	chr1:11040367	C1orf127	0.55	6.58	0.51	1.2e-9	Ewing sarcoma;
TGCT	cis	rs1008375	1.000	rs1006722	chr4:17618713	A/G	cg18681998	chr4:17616180	MED28	-0.96	-10.39	-0.68	1.43e-18	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9357506	1.000	rs9296490	chr6:46315191	A/G	cg21115430	chr6:46460003	NA	-0.26	-5.16	-0.42	9.6e-7	Body mass index;
TGCT	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs60871478	1.000	rs62432861	chr7:807649	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.46	4.6	0.38	1.04e-5	Cerebrospinal P-tau181p levels;
TGCT	cis	rs4506170	0.887	rs72712339	chr8:128340554	C/T	cg07795030	chr8:128802207	NA	-0.21	-4.73	-0.39	5.95e-6	Prostate cancer;
TGCT	cis	rs748404	0.631	rs7167882	chr15:43678663	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	4.63	0.38	9.05e-6	Lung cancer;
TGCT	trans	rs77457752	0.567	rs12339494	chr9:13908934	T/C	cg23609682	chr1:3070786	PRDM16	0.51	6.82	0.52	3.5e-10	Breast cancer;
TGCT	cis	rs8180040	0.654	rs6766230	chr3:47196209	C/A	cg27129171	chr3:47204927	SETD2	0.7	8.33	0.6	1.26e-13	Colorectal cancer;
TGCT	cis	rs1532993	0.518	rs11097568	chr4:98597993	A/G	cg05340658	chr4:99064831	C4orf37	-0.38	-4.49	-0.37	1.59e-5	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs210152	0.588	rs1755040	chr6:33495175	A/C	cg16739976	chr6:34101401	GRM4	-0.64	-5.27	-0.43	5.8e-7	Schizophrenia;
TGCT	cis	rs939658	0.683	rs8024572	chr15:79465600	A/G	cg17916960	chr15:79447300	NA	0.42	6.67	0.51	7.59e-10	Refractive error;
TGCT	cis	rs8014204	0.604	rs11159109	chr14:75389074	G/A	cg06637938	chr14:75390232	RPS6KL1	0.92	9.95	0.67	1.66e-17	Caffeine consumption;
TGCT	cis	rs3008870	0.755	rs2755251	chr1:67496425	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.8	8.51	0.61	4.85e-14	Lymphocyte percentage of white cells;
TGCT	cis	rs9811920	0.609	rs4479633	chr3:99654510	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.59	6.77	0.52	4.51e-10	Axial length;
TGCT	cis	rs2072499	0.898	rs2736609	chr1:156202640	C/T	cg25208724	chr1:156163844	SLC25A44	0.97	10.22	0.68	3.76e-18	Testicular germ cell tumor;
TGCT	cis	rs11785400	0.793	rs3735993	chr8:143741170	G/A	cg24634471	chr8:143751801	JRK	0.55	5.52	0.44	1.89e-7	Schizophrenia;
TGCT	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg21171335	chr12:122356390	WDR66	0.6	6.57	0.51	1.22e-9	Mean corpuscular volume;
TGCT	trans	rs17685	0.712	rs10952842	chr7:75780413	G/A	cg19862616	chr7:65841803	NCRNA00174	0.53	9.19	0.64	1.13e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs7523273	0.606	rs2796271	chr1:207941927	A/G	cg22525895	chr1:207977042	MIR29B2	0.53	8.71	0.62	1.62e-14	Schizophrenia;
TGCT	cis	rs6598955	0.670	rs6676619	chr1:26539035	T/G	cg01614726	chr1:26633154	UBXN11	0.49	4.69	0.39	7.09e-6	Obesity-related traits;
TGCT	cis	rs2153535	0.580	rs9406162	chr6:8466196	C/T	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg19635926	chr16:89946313	TCF25	-0.28	-5.09	-0.42	1.28e-6	Skin colour saturation;
TGCT	cis	rs7666738	0.606	rs10006414	chr4:99101401	T/C	cg17366294	chr4:99064904	C4orf37	0.53	4.9	0.4	2.89e-6	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs9951602	0.512	rs61021837	chr18:76648210	A/C	cg02800362	chr5:177631904	HNRNPAB	1.15	12.91	0.76	1.08e-24	Obesity-related traits;
TGCT	cis	rs2235642	0.826	rs8053605	chr16:1594158	G/A	cg00463982	chr16:1583984	IFT140;TMEM204	-0.28	-4.79	-0.39	4.72e-6	Coronary artery disease;
TGCT	cis	rs11648796	0.757	rs66649828	chr16:766078	A/G	cg00908189	chr16:619842	PIGQ	0.66	5.39	0.44	3.41e-7	Height;
TGCT	cis	rs4478858	0.684	rs16834336	chr1:31751512	G/A	cg07478791	chr1:31886160	SERINC2	-0.52	-5.02	-0.41	1.73e-6	Alcohol dependence;
TGCT	cis	rs1158570	0.500	rs2554369	chr8:131314047	C/T	cg16277922	chr8:131349729	ASAP1	0.46	5.9	0.47	3.31e-8	Platelet count;
TGCT	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg22166914	chr1:53195759	ZYG11B	0.3	4.87	0.4	3.29e-6	Monocyte count;
TGCT	cis	rs9913156	0.841	rs72824957	chr17:4590496	C/T	cg00122941	chr17:4613640	ARRB2	0.88	7.63	0.57	5.46e-12	Lymphocyte counts;
TGCT	cis	rs1215050	0.740	rs9994227	chr4:98767094	T/G	cg17366294	chr4:99064904	C4orf37	0.52	5.59	0.45	1.4e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7178572	0.568	rs12914345	chr15:77670401	A/C	cg22256960	chr15:77711686	NA	-0.86	-8.87	-0.62	6.51e-15	Type 2 diabetes;
TGCT	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.01	8.32	0.6	1.34e-13	Platelet count;
TGCT	cis	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg07424592	chr7:64974309	NA	1.4	8.42	0.6	7.87e-14	Diabetic kidney disease;
TGCT	cis	rs11120822	0.814	rs6656691	chr1:7122453	C/G	cg20434152	chr1:7120926	CAMTA1	-0.29	-4.58	-0.38	1.11e-5	Stearic acid (18:0) levels;
TGCT	cis	rs853679	0.607	rs200489	chr6:27798257	T/C	cg10876282	chr6:28092338	ZSCAN16	0.76	4.47	0.37	1.73e-5	Depression;
TGCT	cis	rs68170813	0.559	rs74925723	chr7:106954536	G/C	cg02696742	chr7:106810147	HBP1	-0.69	-5.81	-0.46	4.85e-8	Coronary artery disease;
TGCT	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg24531977	chr5:56204891	C5orf35	-0.75	-5.9	-0.47	3.17e-8	Type 2 diabetes;
TGCT	cis	rs9372498	0.536	rs9320656	chr6:118894468	A/G	cg07617317	chr6:118971624	C6orf204	-0.5	-5.32	-0.43	4.71e-7	Diastolic blood pressure;
TGCT	cis	rs7666738	0.606	rs7663216	chr4:99088385	A/C	cg18180107	chr4:99064573	C4orf37	0.52	4.6	0.38	1.05e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11031096	0.782	rs4910904	chr11:4165529	C/T	cg18678763	chr11:4115507	RRM1	0.48	6.09	0.48	1.32e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs514406	0.584	rs12095247	chr1:53193796	A/C	cg25767906	chr1:53392781	SCP2	0.46	5.02	0.41	1.76e-6	Monocyte count;
TGCT	cis	rs7542091	0.669	rs11119357	chr1:210042382	C/T	cg23283495	chr1:209979779	IRF6	0.56	5.6	0.45	1.3e-7	Monobrow;
TGCT	cis	rs903263	0.901	rs11163913	chr1:84651183	G/T	cg09664975	chr1:84543551	PRKACB	0.49	4.57	0.38	1.17e-5	Breast cancer (male);
TGCT	cis	rs36051895	0.623	rs12351715	chr9:5262349	A/G	cg02405213	chr9:5042618	JAK2	-0.68	-8.37	-0.6	1.02e-13	Pediatric autoimmune diseases;
TGCT	cis	rs1347297	0.666	rs4404314	chr2:179250840	G/A	cg03991736	chr2:179345203	MIR548N;PLEKHA3	-0.49	-4.51	-0.38	1.46e-5	Alzheimer disease and age of onset;
TGCT	cis	rs75229567	0.618	rs78294090	chr12:70209959	G/T	cg10114359	chr12:70132523	RAB3IP	1.35	6.68	0.51	7.19e-10	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
TGCT	cis	rs2594989	0.943	rs2442780	chr3:11510568	A/G	cg26283222	chr3:11613257	VGLL4	-0.21	-4.54	-0.38	1.31e-5	Circulating chemerin levels;
TGCT	cis	rs6840360	0.667	rs2709832	chr4:152379394	C/G	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.82e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg06221963	chr1:154839813	KCNN3	-0.75	-12.79	-0.75	2.05e-24	Prostate cancer;
TGCT	cis	rs2594989	1.000	rs346082	chr3:11329216	C/G	cg00170343	chr3:11313890	ATG7	0.67	5.06	0.41	1.44e-6	Circulating chemerin levels;
TGCT	cis	rs362272	0.545	rs2748447	chr4:3337831	G/A	cg06533319	chr4:3265114	C4orf44	-0.28	-5.69	-0.46	8.63e-8	Serum sulfate level;
TGCT	cis	rs6978712	1.000	rs6961380	chr7:127148072	T/A	cg01017541	chr7:127776461	NA	0.76	4.6	0.38	1.01e-5	Medication adherence in chronic diseases;
TGCT	cis	rs362272	0.545	rs2236052	chr4:3318413	C/T	cg18352616	chr4:3374830	RGS12	-0.25	-5.09	-0.42	1.3e-6	Serum sulfate level;
TGCT	cis	rs13191362	0.507	rs2023036	chr6:163122736	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.6	5.77	0.46	6.04e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg12570787	chr5:219185	SDHA;CCDC127	0.65	4.46	0.37	1.83e-5	Breast cancer;
TGCT	cis	rs981844	1.000	rs116588966	chr4:154664794	T/C	cg14289246	chr4:154710475	SFRP2	1.0	8.25	0.6	1.96e-13	Response to statins (LDL cholesterol change);
TGCT	cis	rs7264396	0.790	rs6060519	chr20:34217383	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.28	-4.67	-0.39	7.62e-6	Total cholesterol levels;
TGCT	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs921968	0.643	rs585859	chr2:219383121	C/T	cg02176678	chr2:219576539	TTLL4	0.39	5.95	0.47	2.51e-8	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs7729723	0.533	rs6596435	chr5:137827361	C/G	cg19169342	chr5:137827400	NA	0.33	4.6	0.38	1.03e-5	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);
TGCT	cis	rs7267979	0.933	rs11699203	chr20:25435169	G/C	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6912958	0.712	rs9444525	chr6:88324142	T/C	cg06598631	chr6:88300029	RARS2;ORC3L	-0.57	-5.2	-0.42	7.9e-7	Monocyte percentage of white cells;
TGCT	cis	rs3749237	0.595	rs11130199	chr3:49538799	T/C	cg02487422	chr3:49467188	NICN1	0.58	5.92	0.47	3e-8	Resting heart rate;
TGCT	cis	rs3780378	0.967	rs7023146	chr9:5040163	G/A	cg02405213	chr9:5042618	JAK2	-0.59	-7.69	-0.57	3.87e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs60843830	1.000	rs7566279	chr2:281178	C/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.69	6.44	0.5	2.41e-9	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs7584330	0.868	rs67071074	chr2:238395429	T/C	cg14458575	chr2:238380390	NA	0.56	8.29	0.6	1.61e-13	Prostate cancer;
TGCT	cis	rs9611565	0.722	rs202635	chr22:41809637	C/T	cg06634786	chr22:41940651	POLR3H	0.7	6.65	0.51	8.51e-10	Vitiligo;
TGCT	cis	rs7605378	1.000	rs10194076	chr2:200677663	T/C	cg17644776	chr2:200775616	C2orf69	0.26	5.1	0.42	1.25e-6	Osteoporosis;
TGCT	cis	rs2688608	0.592	rs12253429	chr10:75496161	C/G	cg19442545	chr10:75533431	FUT11	-0.37	-5.77	-0.46	5.89e-8	Inflammatory bowel disease;
TGCT	cis	rs2535633	0.631	rs2581803	chr3:52994981	G/A	cg10802521	chr3:52805072	NEK4	0.53	5.7	0.46	8.42e-8	Body mass index;
TGCT	cis	rs9527	0.662	rs10786714	chr10:104598606	G/C	cg04362960	chr10:104952993	NT5C2	0.63	5.36	0.43	3.99e-7	Arsenic metabolism;
TGCT	cis	rs736408	0.812	rs4687654	chr3:52827566	G/A	cg07507251	chr3:52567010	NT5DC2	0.41	5.46	0.44	2.46e-7	Bipolar disorder;
TGCT	cis	rs10946940	0.965	rs62401383	chr6:27564547	C/T	cg10876282	chr6:28092338	ZSCAN16	-0.46	-4.73	-0.39	6.01e-6	Systemic lupus erythematosus;
TGCT	cis	rs6750047	0.756	rs336038	chr2:38260750	C/G	cg07380506	chr2:38303506	CYP1B1	0.55	4.98	0.41	2.08e-6	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs4478858	0.611	rs10914338	chr1:31733782	T/A	cg00250761	chr1:31883323	NA	-0.26	-4.55	-0.38	1.28e-5	Alcohol dependence;
TGCT	cis	rs7552404	0.889	rs380075	chr1:76106961	T/A	cg03433033	chr1:76189801	ACADM	-0.84	-10.07	-0.67	8.46e-18	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs295140	0.624	rs10445790	chr2:201078088	T/C	cg04283868	chr2:201171347	SPATS2L	0.54	5.36	0.43	3.85e-7	QT interval;
TGCT	cis	rs9325144	0.560	rs7980358	chr12:38640396	C/G	cg26384229	chr12:38710491	ALG10B	0.67	6.12	0.48	1.14e-8	Morning vs. evening chronotype;
TGCT	cis	rs9921338	0.961	rs4780357	chr16:11370971	G/A	cg00044050	chr16:11439710	C16orf75	-0.91	-6.23	-0.49	6.61e-9	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs4523957	0.651	rs9906705	chr17:2063714	T/G	cg16513277	chr17:2031491	SMG6	-0.2	-4.64	-0.38	8.83e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs1371867	0.875	rs1788174	chr8:101330957	C/G	cg06636551	chr8:101224915	SPAG1	0.48	6.51	0.5	1.7e-9	Atrioventricular conduction;
TGCT	cis	rs2742234	0.955	rs2435384	chr10:43673731	G/T	cg02780029	chr10:43622663	RET	-0.26	-4.94	-0.41	2.49e-6	Hirschsprung disease;
TGCT	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg21724239	chr8:58056113	NA	0.4	4.88	0.4	3.13e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7677751	0.806	rs4864862	chr4:55100489	G/A	cg17187183	chr4:55093834	PDGFRA	0.56	7.13	0.54	7.37e-11	Corneal astigmatism;
TGCT	cis	rs7208859	0.623	rs11658022	chr17:29085359	A/T	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.66e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs4851254	0.920	rs11123808	chr2:100750750	A/C	cg23118464	chr2:100721844	AFF3	0.74	5.52	0.44	1.86e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg22920501	chr2:26401640	FAM59B	-0.72	-6.22	-0.49	7.14e-9	Gut microbiome composition (summer);
TGCT	cis	rs8077889	1.000	rs8077889	chr17:41878166	G/T	cg26893861	chr17:41843967	DUSP3	-1.06	-12.33	-0.74	2.74e-23	Triglycerides;
TGCT	cis	rs7226408	0.901	rs11081986	chr18:34683307	T/A	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg11494091	chr17:61959527	GH2	-0.6	-16.09	-0.82	3.89e-32	Prudent dietary pattern;
TGCT	cis	rs7599312	0.534	rs10180824	chr2:213407975	G/A	cg20637307	chr2:213403960	ERBB4	0.92	11.46	0.72	3.54e-21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs35146811	0.696	rs1727124	chr7:99804104	T/G	cg04778012	chr7:99775508	STAG3;GPC2	-0.35	-4.93	-0.4	2.61e-6	Coronary artery disease;
TGCT	cis	rs763014	0.931	rs7192508	chr16:630367	C/T	cg07343612	chr16:622815	PIGQ	-0.41	-7.87	-0.58	1.52e-12	Height;
TGCT	cis	rs7095607	1.000	rs12780285	chr10:69958749	C/T	cg18986048	chr10:69913749	MYPN	0.46	5.0	0.41	1.91e-6	Lung function (FVC);
TGCT	cis	rs2013441	1.000	rs2526490	chr17:20097526	A/G	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.61	-0.38	9.96e-6	Obesity-related traits;
TGCT	cis	rs17001868	0.568	rs470113	chr22:40729614	A/G	cg07138101	chr22:40742427	ADSL	0.71	5.51	0.44	2.02e-7	Mammographic density (dense area);
TGCT	cis	rs9911578	1.000	rs7342903	chr17:56914588	C/G	cg12560992	chr17:57184187	TRIM37	0.76	9.21	0.64	1.03e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs3803170	0.513	rs10849944	chr12:111825389	C/T	cg10833066	chr12:111807467	FAM109A	-0.36	-5.41	-0.44	3.09e-7	Mean corpuscular hemoglobin;
TGCT	cis	rs858239	0.665	rs6964665	chr7:23211352	G/A	cg05602783	chr7:23145260	KLHL7	-0.68	-5.52	-0.44	1.91e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs1008375	1.000	rs2872959	chr4:17677163	G/A	cg16339924	chr4:17578868	LAP3	-0.62	-5.11	-0.42	1.19e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs60871478	1.000	rs62432251	chr7:801855	T/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.45	4.56	0.38	1.21e-5	Cerebrospinal P-tau181p levels;
TGCT	cis	rs6835098	0.961	rs2877748	chr4:174102397	G/A	cg08422745	chr4:174089978	GALNT7	-0.9	-10.08	-0.67	7.91e-18	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs10751667	0.643	rs10794343	chr11:925493	C/T	cg06064525	chr11:970664	AP2A2	-0.35	-8.09	-0.59	4.69e-13	Alzheimer's disease (late onset);
TGCT	cis	rs3091242	0.933	rs9438905	chr1:25764177	A/G	cg10117171	chr1:25599238	RHD	-0.32	-5.17	-0.42	9e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs1801251	1.000	rs13003675	chr2:233584109	C/T	cg08000102	chr2:233561755	GIGYF2	0.63	6.51	0.5	1.72e-9	Coronary artery disease;
TGCT	cis	rs2980439	0.818	rs2948300	chr8:8106508	C/T	cg15462221	chr8:8086144	FLJ10661	-0.55	-4.97	-0.41	2.17e-6	Neuroticism;
TGCT	cis	rs7959452	0.590	rs11177628	chr12:69765421	G/A	cg14784868	chr12:69753453	YEATS4	0.83	8.85	0.62	7.59e-15	Blood protein levels;
TGCT	cis	rs9807989	0.507	rs2310300	chr2:103049074	A/G	cg03938978	chr2:103052716	IL18RAP	0.27	5.41	0.44	3.17e-7	Asthma;
TGCT	cis	rs3774830	0.748	rs17367445	chr4:5464903	C/T	cg26943120	chr4:5472116	STK32B	0.22	4.82	0.4	4.15e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	trans	rs2727020	0.729	rs6485965	chr11:49166730	C/T	cg15704280	chr7:45808275	SEPT13	0.68	7.46	0.56	1.3e-11	Coronary artery disease;
TGCT	cis	rs3796352	1.000	rs116616340	chr3:53132371	C/G	cg15956490	chr3:53032818	SFMBT1	0.54	6.37	0.5	3.42e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg11764359	chr7:65958608	NA	-0.55	-5.08	-0.42	1.34e-6	Aortic root size;
TGCT	cis	rs3749237	0.964	rs2234385	chr3:49846041	G/A	cg07636037	chr3:49044803	WDR6	0.61	5.41	0.44	3.08e-7	Resting heart rate;
TGCT	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg08392591	chr16:89556376	ANKRD11	0.57	5.4	0.44	3.2e-7	Multiple myeloma (IgH translocation);
TGCT	cis	rs7809950	0.911	rs7778250	chr7:107224565	C/A	cg23024343	chr7:107201750	COG5	0.33	5.13	0.42	1.09e-6	Coronary artery disease;
TGCT	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg13409248	chr3:40428643	ENTPD3	0.57	4.53	0.38	1.37e-5	Renal cell carcinoma;
TGCT	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg24846343	chr22:24311635	DDTL	0.23	5.85	0.46	4.19e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2847281	0.614	rs2847261	chr18:12775296	A/T	cg23598886	chr18:12777645	NA	0.37	4.69	0.39	7.07e-6	C-reactive protein levels;Esophageal cancer (squamous cell);
TGCT	cis	rs17767294	0.708	rs34957169	chr6:27879397	T/C	cg08851530	chr6:28072375	NA	1.53	7.17	0.54	6.02e-11	Parkinson's disease;
TGCT	cis	rs9383153	0.793	rs2016498	chr6:16344914	C/T	cg10975897	chr6:15504844	JARID2	0.77	4.85	0.4	3.66e-6	Gambling;
TGCT	cis	rs9653442	0.866	rs12712065	chr2:100761105	C/G	cg07810366	chr2:100720526	AFF3	-0.47	-8.0	-0.58	7.36e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs11719291	0.504	rs34571182	chr3:49209057	T/A	cg07636037	chr3:49044803	WDR6	-1.02	-5.13	-0.42	1.09e-6	Cognitive function;
TGCT	cis	rs911555	0.504	rs8021368	chr14:104074810	G/A	cg26031613	chr14:104095156	KLC1	0.61	5.6	0.45	1.34e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2841277	0.509	rs11850949	chr14:105408827	A/C	cg21017887	chr14:105400489	NA	0.4	5.55	0.45	1.65e-7	Rheumatoid arthritis;
TGCT	cis	rs3733585	0.699	rs62294331	chr4:9959889	A/G	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.7	-0.57	3.69e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7264396	0.790	rs2425115	chr20:34322418	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.25	-0.43	6.33e-7	Total cholesterol levels;
TGCT	cis	rs6545883	0.929	rs7563678	chr2:61741811	C/T	cg15711740	chr2:61764176	XPO1	0.53	4.84	0.4	3.82e-6	Tuberculosis;
TGCT	cis	rs6546847	0.531	rs2567602	chr2:73985536	A/G	cg07208825	chr2:73871855	ALMS1P	0.29	5.27	0.43	5.73e-7	Urinary metabolites (H-NMR features);
TGCT	cis	rs4919044	0.799	rs56024810	chr10:94753313	G/A	cg05127821	chr10:94822908	CYP26C1	-0.73	-4.47	-0.37	1.74e-5	Coronary artery disease;
TGCT	cis	rs4144743	1.000	rs72823474	chr17:45321776	G/C	cg18085866	chr17:45331354	ITGB3	-0.7	-4.67	-0.39	7.81e-6	Body mass index;
TGCT	cis	rs2115630	0.805	rs8042926	chr15:85205454	T/A	cg11189052	chr15:85197271	WDR73	-0.71	-7.25	-0.55	3.98e-11	P wave terminal force;
TGCT	cis	rs7296418	0.922	rs1790134	chr12:123697898	T/C	cg00376283	chr12:123451042	ABCB9	0.84	7.67	0.57	4.4e-12	Platelet count;
TGCT	cis	rs8008758	0.517	rs1772024	chr14:101695220	A/C	cg26224664	chr14:101693935	NA	0.33	7.32	0.55	2.69e-11	Body mass index (alcohol intake interaction);
TGCT	cis	rs933688	0.639	rs332530	chr5:90789810	G/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.07	9.91	0.66	2.11e-17	Smoking behavior;
TGCT	cis	rs77880822	0.562	rs6078405	chr20:1247246	T/C	cg03932398	chr20:1206703	RAD21L1	0.81	5.23	0.42	7.11e-7	Angiotensin-converting enzyme inhibitor intolerance;
TGCT	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg22166914	chr1:53195759	ZYG11B	0.34	5.39	0.44	3.42e-7	Monocyte count;
TGCT	cis	rs7714584	1.000	rs57406211	chr5:150170966	C/T	cg22134413	chr5:150180641	NA	1.11	7.3	0.55	3.05e-11	Crohn's disease;
TGCT	cis	rs13040088	1.000	rs2273412	chr20:61553802	G/A	cg23096297	chr20:61557774	DIDO1	1.17	9.61	0.65	1.11e-16	Menopause (age at onset);
TGCT	cis	rs12142240	0.698	rs1984490	chr1:46858734	C/T	cg14993813	chr1:46806288	NSUN4	0.58	4.79	0.4	4.69e-6	Menopause (age at onset);
TGCT	cis	rs7666738	0.830	rs7657490	chr4:99043973	C/T	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs807669	0.557	rs712958	chr22:19167409	T/C	cg02655711	chr22:19163373	SLC25A1	0.32	6.55	0.51	1.38e-9	Metabolite levels;
TGCT	cis	rs910316	0.967	rs175451	chr14:75589729	C/T	cg23033748	chr14:75592666	NEK9	-0.28	-4.84	-0.4	3.71e-6	Height;
TGCT	cis	rs76788097	0.614	rs7151034	chr14:61820669	T/G	cg10081469	chr14:61748336	TMEM30B	-0.71	-4.96	-0.41	2.3e-6	Marginal zone lymphoma;
TGCT	cis	rs2299587	0.554	rs11778309	chr8:17747433	T/C	cg01800426	chr8:17659068	MTUS1	-0.58	-5.12	-0.42	1.16e-6	Economic and political preferences;
TGCT	cis	rs1062177	1.000	rs892006	chr5:151180890	G/T	cg12924095	chr5:151150029	G3BP1	0.36	5.12	0.42	1.11e-6	Preschool internalizing problems;
TGCT	cis	rs9788682	0.948	rs905739	chr15:78845110	A/G	cg24631222	chr15:78858424	CHRNA5	0.92	7.37	0.55	2.1e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs7914558	0.966	rs3758543	chr10:104944744	C/G	cg05855489	chr10:104503620	C10orf26	0.51	4.48	0.37	1.65e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs12510870	0.599	rs13353732	chr4:74397154	A/G	cg05868023	chr4:75230803	EREG	0.54	5.01	0.41	1.83e-6	Iris color (b* coordinate);
TGCT	cis	rs644799	0.687	rs11021318	chr11:95522996	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	8.5	0.61	5.03e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs288326	0.561	rs77541378	chr2:183886271	C/A	cg09997497	chr2:183902928	NCKAP1	1.11	4.95	0.41	2.38e-6	Blood protein levels;
TGCT	cis	rs9291683	0.546	rs13110307	chr4:10044364	T/C	cg00071950	chr4:10020882	SLC2A9	0.57	6.47	0.5	2.01e-9	Bone mineral density;
TGCT	cis	rs12142240	0.959	rs12137934	chr1:46728913	A/G	cg14993813	chr1:46806288	NSUN4	-0.61	-4.92	-0.4	2.75e-6	Menopause (age at onset);
TGCT	cis	rs453301	0.658	rs9329175	chr8:8866661	C/T	cg15556689	chr8:8085844	FLJ10661	-0.58	-4.87	-0.4	3.32e-6	Joint mobility (Beighton score);
TGCT	cis	rs526231	0.819	rs403214	chr5:102603701	A/G	cg05225461	chr5:102596755	C5orf30	0.23	4.62	0.38	9.51e-6	Primary biliary cholangitis;
TGCT	cis	rs9303401	0.614	rs8081058	chr17:57160513	G/C	cg25039879	chr17:56429692	SUPT4H1	0.55	4.9	0.4	2.93e-6	Cognitive test performance;
TGCT	cis	rs3733585	0.699	rs6449177	chr4:9968050	T/C	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.49	-0.5	1.85e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs6835098	0.608	rs2332668	chr4:174163360	A/G	cg08422745	chr4:174089978	GALNT7	-0.78	-8.44	-0.6	7.19e-14	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs236907	0.814	rs2232825	chr1:171763549	C/T	cg20598894	chr1:171756153	METTL13	-0.22	-5.05	-0.41	1.53e-6	Mean platelet volume;
TGCT	cis	rs4780401	0.588	rs1050069	chr16:11769963	C/T	cg01061890	chr16:11836724	TXNDC11	-0.46	-4.52	-0.38	1.45e-5	Rheumatoid arthritis;
TGCT	cis	rs1801251	1.000	rs2675971	chr2:233726154	A/G	cg08000102	chr2:233561755	GIGYF2	-0.64	-6.45	-0.5	2.24e-9	Coronary artery disease;
TGCT	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs7246657	0.943	rs6508711	chr19:37815134	G/T	cg18154014	chr19:37997991	ZNF793	0.74	5.08	0.42	1.34e-6	Coronary artery calcification;
TGCT	cis	rs9948	0.748	rs62156223	chr2:97412167	T/C	cg01990225	chr2:97406019	LMAN2L	-1.0	-5.09	-0.42	1.31e-6	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs3087591	0.960	rs9896041	chr17:29571326	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.47	-7.51	-0.56	1.01e-11	Hip circumference;
TGCT	cis	rs4081724	0.565	rs118046236	chr19:33807105	G/A	cg18823272	chr19:34111733	CHST8	0.42	4.7	0.39	6.85e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs79349575	0.681	rs56080003	chr17:47019049	A/T	cg07967210	chr17:47022446	SNF8	0.44	6.13	0.48	1.1e-8	Type 2 diabetes;
TGCT	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg08355456	chr11:67383691	NA	0.3	4.55	0.38	1.26e-5	Mean corpuscular volume;
TGCT	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg06713675	chr4:122721982	EXOSC9	-0.66	-8.76	-0.62	1.24e-14	Type 2 diabetes;
TGCT	cis	rs9653442	0.564	rs11902705	chr2:100795207	A/G	cg07810366	chr2:100720526	AFF3	0.34	5.03	0.41	1.69e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs10972341	0.874	rs7028146	chr9:35150228	G/A	cg00812861	chr9:35114699	KIAA1539	0.33	5.11	0.42	1.21e-6	Weight;
TGCT	cis	rs2243480	0.522	rs12698511	chr7:65474919	G/T	cg20637647	chr7:64974828	NA	0.99	5.12	0.42	1.14e-6	Diabetic kidney disease;
TGCT	cis	rs6430585	0.527	rs7592050	chr2:136459227	C/T	cg07169764	chr2:136633963	MCM6	-1.01	-9.4	-0.64	3.64e-16	Corneal structure;
TGCT	cis	rs228437	0.565	rs6569956	chr6:134939428	C/T	cg09872934	chr6:134495829	SGK1	-0.53	-4.6	-0.38	1.03e-5	Melanoma;
TGCT	cis	rs28595532	0.920	rs115242199	chr4:119728652	A/C	cg14228332	chr4:119757509	SEC24D	1.32	6.38	0.5	3.2e-9	Cannabis dependence symptom count;
TGCT	cis	rs9473924	0.542	rs2857501	chr6:50797286	A/G	cg14470998	chr6:50812995	TFAP2B	1.33	7.94	0.58	1.03e-12	Body mass index;
TGCT	cis	rs1667284	0.967	rs1791221	chr18:29219891	T/C	cg15259973	chr18:29078565	DSG2	0.53	5.19	0.42	8.27e-7	Problematic alcohol use in trauma-exposed individuals;
TGCT	cis	rs7954584	0.710	rs10840641	chr12:122465831	G/T	cg22618164	chr12:122356400	WDR66	0.52	4.79	0.4	4.67e-6	Mean corpuscular volume;
TGCT	cis	rs6687430	0.526	rs12120962	chr1:10609505	G/A	cg17425144	chr1:10567563	PEX14	0.5	5.71	0.46	7.93e-8	Hand grip strength;
TGCT	cis	rs7267979	1.000	rs910997	chr20:25267301	G/A	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6088590	1.000	rs2180276	chr20:33360785	T/A	cg06115741	chr20:33292138	TP53INP2	0.67	5.61	0.45	1.24e-7	Coronary artery disease;
TGCT	cis	rs2485376	0.842	rs1056890	chr10:104162770	G/A	cg26089160	chr10:104170217	PSD	0.52	5.09	0.42	1.3e-6	QT interval;
TGCT	cis	rs559928	0.606	rs55970968	chr11:63961433	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	4.57	0.38	1.18e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
TGCT	cis	rs8014204	0.839	rs6574197	chr14:75331487	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.77	-7.49	-0.56	1.14e-11	Caffeine consumption;
TGCT	cis	rs3820928	0.618	rs2141828	chr2:227922470	T/C	cg11843606	chr2:227700838	RHBDD1	-0.52	-4.69	-0.39	7.13e-6	Pulmonary function;
TGCT	cis	rs7666738	0.612	rs6830172	chr4:99093947	G/A	cg05340658	chr4:99064831	C4orf37	0.52	5.67	0.45	9.42e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs806215	0.951	rs327510	chr7:127257894	G/A	cg25922125	chr7:127225783	GCC1	0.48	4.98	0.41	2.06e-6	Type 2 diabetes;
TGCT	cis	rs7267979	0.903	rs6050481	chr20:25224580	C/T	cg16686733	chr20:25566563	NINL	0.59	6.06	0.48	1.53e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs344364	0.511	rs1657132	chr16:1949924	C/T	cg26617929	chr16:1858877	NA	-0.27	-4.9	-0.4	2.99e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs6582630	0.555	rs4601853	chr12:38435569	G/A	cg13010199	chr12:38710504	ALG10B	0.59	4.79	0.4	4.67e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg22963979	chr7:1858916	MAD1L1	-0.4	-6.44	-0.5	2.44e-9	Bipolar disorder and schizophrenia;
TGCT	cis	rs9926296	0.572	rs8047581	chr16:89884502	C/T	cg03388025	chr16:89894329	SPIRE2	0.35	5.3	0.43	5.05e-7	Vitiligo;
TGCT	cis	rs12950390	0.853	rs28589850	chr17:45855713	A/G	cg24803719	chr17:45855879	NA	-0.48	-4.93	-0.4	2.62e-6	IgG glycosylation;
TGCT	cis	rs9677476	1.000	rs6711312	chr2:232122348	T/C	cg07929768	chr2:232055508	NA	0.3	4.44	0.37	1.97e-5	Food antigen IgG levels;
TGCT	cis	rs11098499	0.909	rs10002083	chr4:120311152	C/T	cg09307838	chr4:120376055	NA	0.65	6.39	0.5	3.02e-9	Corneal astigmatism;
TGCT	cis	rs9916302	0.904	rs587343	chr17:37440603	C/T	cg15445000	chr17:37608096	MED1	-0.33	-4.93	-0.4	2.59e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7666738	0.830	rs732299	chr4:98995389	C/T	cg17366294	chr4:99064904	C4orf37	0.68	6.96	0.53	1.75e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs17401966	0.540	rs6674949	chr1:10458480	A/G	cg19773385	chr1:10388646	KIF1B	-0.22	-5.38	-0.44	3.55e-7	Hepatocellular carcinoma;
TGCT	cis	rs208515	0.525	rs10944871	chr6:66690306	A/G	cg07460842	chr6:66804631	NA	0.88	9.35	0.64	4.63e-16	Exhaled nitric oxide levels;
TGCT	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg04414720	chr1:150670196	GOLPH3L	0.39	4.95	0.41	2.39e-6	Tonsillectomy;
TGCT	cis	rs10423674	0.526	rs11668545	chr19:18829529	C/T	cg14292368	chr19:18793705	CRTC1	-0.52	-4.73	-0.39	6.06e-6	Menarche (age at onset);
TGCT	cis	rs9388451	0.587	rs1739385	chr6:126099939	G/A	cg05901451	chr6:126070800	HEY2	-0.92	-11.38	-0.71	5.49e-21	Brugada syndrome;
TGCT	cis	rs1670533	1.000	rs935970	chr4:1045323	C/G	cg20887711	chr4:1340912	KIAA1530	-0.71	-5.64	-0.45	1.07e-7	Recombination rate (females);
TGCT	cis	rs713587	0.934	rs6738433	chr2:25159501	G/C	cg01884057	chr2:25150051	NA	0.39	7.96	0.58	9.32e-13	Body mass index in non-asthmatics;
TGCT	cis	rs9443645	0.836	rs9352676	chr6:79629999	A/G	cg05283184	chr6:79620031	NA	-0.21	-4.71	-0.39	6.61e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7091068	0.522	rs866674	chr10:95487515	A/G	cg20715218	chr10:95462985	C10orf4	0.5	4.88	0.4	3.13e-6	Urinary tract infection frequency;
TGCT	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg06640241	chr16:89574553	SPG7	0.76	8.59	0.61	3.06e-14	Multiple myeloma (IgH translocation);
TGCT	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg05872129	chr22:39784769	NA	-1.01	-11.09	-0.71	2.82e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs35160687	0.901	rs6713456	chr2:86507653	T/A	cg27135286	chr2:85751921	NA	0.38	4.46	0.37	1.82e-5	Night sleep phenotypes;
TGCT	cis	rs739401	0.611	rs401707	chr11:3050965	T/C	cg05729581	chr11:3078854	CARS	-0.55	-5.15	-0.42	9.85e-7	Longevity;
TGCT	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg24549020	chr5:56110836	MAP3K1	0.67	5.78	0.46	5.74e-8	Initial pursuit acceleration;
TGCT	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg11890956	chr21:40555474	PSMG1	1.09	11.95	0.73	2.27e-22	Cognitive function;
TGCT	cis	rs2201728	0.967	rs3749551	chr4:100221551	C/T	cg07219303	chr4:100140905	ADH6	-0.35	-5.14	-0.42	1.04e-6	Cardiac Troponin-T levels;
TGCT	cis	rs9611565	0.512	rs139562	chr22:42196684	G/C	cg03806693	chr22:41940476	POLR3H	-0.99	-9.85	-0.66	2.9e-17	Vitiligo;
TGCT	cis	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg20637647	chr7:64974828	NA	1.0	5.59	0.45	1.4e-7	Diabetic kidney disease;
TGCT	cis	rs514406	0.683	rs6588440	chr1:53209587	C/T	cg25767906	chr1:53392781	SCP2	0.46	5.1	0.42	1.23e-6	Monocyte count;
TGCT	cis	rs1538970	1.000	rs1538970	chr1:45847562	G/A	cg05343316	chr1:45956843	TESK2	0.65	5.18	0.42	8.79e-7	Platelet count;
TGCT	cis	rs10510102	0.872	rs7906271	chr10:123707722	C/T	cg23691251	chr10:123688108	ATE1	0.61	4.71	0.39	6.49e-6	Breast cancer;
TGCT	cis	rs12477438	0.798	rs13414153	chr2:99624748	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.79	-7.94	-0.58	1.06e-12	Chronic sinus infection;
TGCT	cis	rs9362426	0.708	rs4707367	chr6:88101188	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.5	-5.81	-0.46	4.86e-8	Depressive episodes in bipolar disorder;
TGCT	cis	rs228437	0.565	rs7749820	chr6:134961923	C/T	cg09872934	chr6:134495829	SGK1	-0.56	-4.74	-0.39	5.69e-6	Melanoma;
TGCT	cis	rs7246657	0.943	rs4452075	chr19:37879589	A/G	cg03233940	chr19:37894644	NA	-0.35	-4.54	-0.38	1.3e-5	Coronary artery calcification;
TGCT	cis	rs67478160	0.643	rs1535098	chr14:104216513	T/A	cg26031613	chr14:104095156	KLC1	-0.63	-6.53	-0.51	1.56e-9	Schizophrenia;
TGCT	cis	rs9926296	0.712	rs258319	chr16:89732024	A/T	cg26513180	chr16:89883248	FANCA	-0.67	-6.23	-0.49	6.68e-9	Vitiligo;
TGCT	cis	rs3796352	1.000	rs11707780	chr3:53084326	A/G	cg27565382	chr3:53032988	SFMBT1	-0.4	-4.63	-0.38	9.09e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs17376456	0.569	rs17083377	chr5:93164870	C/G	cg21475434	chr5:93447410	FAM172A	0.66	5.2	0.42	8.03e-7	Diabetic retinopathy;
TGCT	cis	rs28595532	1.000	rs17323012	chr4:119605671	A/G	cg21605333	chr4:119757512	SEC24D	1.37	7.28	0.55	3.31e-11	Cannabis dependence symptom count;
TGCT	cis	rs7917772	0.560	rs3862030	chr10:104327584	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	5.36	0.43	3.84e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs12049351	0.774	rs12066463	chr1:229669287	C/T	cg12130225	chr1:229698885	NA	0.35	4.46	0.37	1.85e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	6.05	0.48	1.61e-8	Bipolar disorder;
TGCT	trans	rs551517	0.541	rs580721	chr9:113645310	A/G	cg18410444	chr5:89825535	LYSMD3	0.68	6.81	0.52	3.77e-10	Post bronchodilator FEV1 in COPD;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
TGCT	cis	rs1008375	0.932	rs6449315	chr4:17590219	A/G	cg10189774	chr4:17578691	LAP3	0.61	5.28	0.43	5.6e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	trans	rs1814175	0.588	rs1721994	chr11:49914050	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.51	-0.69	7.2e-19	Height;
TGCT	cis	rs7647973	0.925	rs6769821	chr3:49244657	G/A	cg06212747	chr3:49208901	KLHDC8B	0.59	4.71	0.39	6.39e-6	Menarche (age at onset);
TGCT	cis	rs6424115	0.546	rs35993651	chr1:24180613	C/G	cg15997130	chr1:24165203	NA	-0.91	-10.51	-0.69	7.36e-19	Immature fraction of reticulocytes;
TGCT	cis	rs2289583	0.503	rs113742359	chr15:75261643	A/G	cg10253484	chr15:75165896	SCAMP2	0.58	5.23	0.43	6.95e-7	Systemic lupus erythematosus;
TGCT	cis	rs4711350	0.734	rs7739273	chr6:33758065	G/A	cg18005901	chr6:33739558	LEMD2	-0.59	-6.61	-0.51	1.01e-9	Schizophrenia;
TGCT	cis	rs4654899	1.000	rs10916937	chr1:21439785	A/G	cg01072550	chr1:21505969	NA	-0.49	-7.88	-0.58	1.41e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs7917772	0.619	rs2251772	chr10:104470918	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	5.69	0.46	8.52e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	trans	rs877282	0.786	rs11253392	chr10:788768	G/A	cg22713356	chr15:30763199	NA	1.16	10.26	0.68	3.01e-18	Uric acid levels;
TGCT	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg22920501	chr2:26401640	FAM59B	-0.8	-6.34	-0.49	3.84e-9	Gut microbiome composition (summer);
TGCT	cis	rs2762353	0.603	rs4145221	chr6:25763192	A/G	cg03517284	chr6:25882590	NA	0.53	5.18	0.42	8.57e-7	Blood metabolite levels;
TGCT	cis	rs12765878	0.603	rs1570221	chr10:105656874	G/A	cg11005552	chr10:105648138	OBFC1	-0.39	-6.02	-0.48	1.85e-8	Coronary artery disease;
TGCT	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg09359103	chr1:154839909	KCNN3	-0.62	-11.25	-0.71	1.15e-20	Prostate cancer;
TGCT	cis	rs62229266	0.654	rs62230787	chr21:37376480	A/G	cg12218747	chr21:37451666	NA	-0.2	-4.48	-0.37	1.67e-5	Mitral valve prolapse;
TGCT	cis	rs10789491	0.953	rs1866770	chr1:47182468	G/T	cg15501359	chr1:47185051	KIAA0494	0.81	8.34	0.6	1.19e-13	Response to hepatitis C treatment;
TGCT	cis	rs76419734	0.850	rs10516529	chr4:106799316	G/T	cg24545054	chr4:106630052	GSTCD;INTS12	-0.96	-4.54	-0.38	1.29e-5	Post bronchodilator FEV1;
TGCT	cis	rs11605924	0.819	rs12805422	chr11:45839889	G/A	ch.11.939596F	chr11:45881766	CRY2	-0.36	-4.57	-0.38	1.18e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);
TGCT	cis	rs7914558	0.966	rs10786721	chr10:104654383	C/A	cg04362960	chr10:104952993	NT5C2	0.58	5.16	0.42	9.65e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs1797081	1.000	rs780634	chr10:16864327	T/G	cg14835575	chr10:16859367	RSU1	0.42	4.9	0.4	2.91e-6	Platelet distribution width;
TGCT	cis	rs2191566	1.000	rs2191566	chr19:44511389	A/C	cg03039196	chr19:44506973	ZNF230	-0.54	-4.7	-0.39	6.79e-6	Acute lymphoblastic leukemia (childhood);
TGCT	cis	rs6484504	0.512	rs2774402	chr11:31312897	G/C	cg26647111	chr11:31128758	NA	0.32	4.64	0.38	8.82e-6	Red blood cell count;
TGCT	cis	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg07424592	chr7:64974309	NA	1.4	8.42	0.6	7.87e-14	Diabetic kidney disease;
TGCT	cis	rs7091068	0.536	rs503758	chr10:95406935	C/A	cg20715218	chr10:95462985	C10orf4	-0.51	-5.65	-0.45	1.05e-7	Urinary tract infection frequency;
TGCT	cis	rs3796352	1.000	rs13072457	chr3:53102389	G/A	cg07884673	chr3:53033167	SFMBT1	0.59	6.05	0.48	1.6e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs453301	0.653	rs11784393	chr8:8903134	C/T	cg08975724	chr8:8085496	FLJ10661	0.58	4.89	0.4	3.02e-6	Joint mobility (Beighton score);
TGCT	cis	rs3125734	0.633	rs6479792	chr10:63983264	T/G	cg05499367	chr10:63213510	TMEM26	-0.33	-4.52	-0.38	1.4e-5	Rheumatoid arthritis;
TGCT	trans	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg17830980	chr10:43048298	ZNF37B	0.83	10.87	0.7	9.56e-20	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2268241	1.000	rs2268241	chr21:34781050	G/A	cg14850771	chr21:34775459	IFNGR2	0.61	5.19	0.42	8.21e-7	Obesity-related traits;
TGCT	cis	rs7633770	0.841	rs6442010	chr3:46669500	A/T	cg11219411	chr3:46661640	NA	0.33	4.69	0.39	6.99e-6	Coronary artery disease;
TGCT	cis	rs736408	0.581	rs3617	chr3:52833805	C/A	cg07507251	chr3:52567010	NT5DC2	0.49	6.84	0.52	3.28e-10	Bipolar disorder;
TGCT	cis	rs7223966	1.000	rs8075422	chr17:61804686	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	4.89	0.4	3.12e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs9467773	0.620	rs2451731	chr6:26624822	A/C	cg15659132	chr6:26577336	NA	0.86	11.04	0.7	3.71e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs9916302	0.706	rs9944459	chr17:37484185	T/C	cg07936489	chr17:37558343	FBXL20	0.84	6.23	0.49	6.68e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs7647973	1.000	rs11720542	chr3:49357427	A/G	cg06212747	chr3:49208901	KLHDC8B	0.59	4.72	0.39	6.22e-6	Menarche (age at onset);
TGCT	cis	rs6690583	0.623	rs75918067	chr1:85453413	T/C	cg20280350	chr1:85513789	MCOLN3	-0.74	-5.11	-0.42	1.2e-6	Serum sulfate level;
TGCT	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg27454412	chr7:1067447	C7orf50	0.59	4.72	0.39	6.34e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs736408	0.608	rs35004449	chr3:52852897	G/T	cg11645453	chr3:52864694	ITIH4	0.31	5.34	0.43	4.24e-7	Bipolar disorder;
TGCT	cis	rs11105298	0.891	rs10858851	chr12:89830870	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.7	-4.95	-0.41	2.36e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs4409675	0.576	rs6598912	chr1:28233289	C/T	cg23691781	chr1:28212827	C1orf38	0.25	5.31	0.43	4.87e-7	Corneal astigmatism;
TGCT	cis	rs2289583	0.503	rs12050494	chr15:75260896	G/A	cg10253484	chr15:75165896	SCAMP2	0.56	5.01	0.41	1.83e-6	Systemic lupus erythematosus;
TGCT	cis	rs763014	0.931	rs7192508	chr16:630367	C/T	cg00908189	chr16:619842	PIGQ	0.87	10.5	0.69	7.53e-19	Height;
TGCT	cis	rs694739	0.734	rs663743	chr11:64107735	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.64	6.42	0.5	2.6e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs3813359	0.614	rs11154581	chr6:130770833	A/T	cg25049486	chr6:130544510	SAMD3	0.43	5.58	0.45	1.46e-7	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs8033133	0.602	rs12439159	chr15:25323874	T/C	cg14481604	chr15:25334117	SNORD116-22	-0.23	-5.17	-0.42	9.25e-7	Blood osmolality (transformed sodium);
TGCT	cis	rs9325144	0.600	rs10880934	chr12:38730455	C/T	cg26384229	chr12:38710491	ALG10B	-0.6	-5.5	-0.44	2.12e-7	Morning vs. evening chronotype;
TGCT	cis	rs7681440	0.904	rs58864428	chr4:90766986	T/C	cg20003494	chr4:90757398	SNCA	-0.62	-5.93	-0.47	2.74e-8	Dementia with Lewy bodies;
TGCT	cis	rs1062177	0.951	rs2915876	chr5:151150745	C/A	cg12924095	chr5:151150029	G3BP1	0.36	5.06	0.41	1.49e-6	Preschool internalizing problems;
TGCT	cis	rs62244186	0.566	rs55852922	chr3:44826188	A/G	cg21672276	chr3:44754072	ZNF502	-0.55	-6.31	-0.49	4.58e-9	Depressive symptoms;
TGCT	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg23719950	chr11:63933701	MACROD1	-0.71	-5.87	-0.47	3.82e-8	Mean platelet volume;
TGCT	cis	rs1801251	0.778	rs778340	chr2:233734083	C/T	cg25237894	chr2:233734115	C2orf82	-0.31	-6.2	-0.49	7.85e-9	Coronary artery disease;
TGCT	cis	rs7769051	0.808	rs1467403	chr6:133089952	T/A	cg22852734	chr6:133119734	C6orf192	1.22	7.01	0.53	1.38e-10	Type 2 diabetes nephropathy;
TGCT	cis	rs11585357	0.947	rs3003441	chr1:17611869	C/T	cg08277548	chr1:17600880	PADI3	0.97	9.95	0.67	1.7e-17	Hair shape;
TGCT	cis	rs669446	0.528	rs4660743	chr1:44195404	C/T	cg12908607	chr1:44402522	ARTN	-0.62	-7.05	-0.53	1.11e-10	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs9611565	0.559	rs5758428	chr22:42106216	G/A	cg06481639	chr22:41940642	POLR3H	0.71	6.43	0.5	2.56e-9	Vitiligo;
TGCT	cis	rs7829975	0.623	rs10087493	chr8:8373557	A/G	cg08975724	chr8:8085496	FLJ10661	-0.6	-5.78	-0.46	5.68e-8	Mood instability;
TGCT	cis	rs2204008	0.659	rs4002655	chr12:38169881	T/G	cg26384229	chr12:38710491	ALG10B	0.86	7.68	0.57	4.17e-12	Bladder cancer;
TGCT	cis	rs854765	0.647	rs2974998	chr17:17995619	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.68	7.1	0.54	8.35e-11	Total body bone mineral density;
TGCT	cis	rs992157	0.560	rs6436047	chr2:219108913	A/C	cg00012203	chr2:219082015	ARPC2	0.81	9.25	0.64	8.28e-16	Colorectal cancer;
TGCT	cis	rs911555	0.723	rs12894652	chr14:103926024	A/G	cg23461800	chr14:103021989	NA	-0.35	-4.56	-0.38	1.23e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs9326248	0.906	rs171052	chr11:117081763	C/G	cg26566898	chr11:117069891	TAGLN	-0.37	-5.05	-0.41	1.51e-6	Blood protein levels;
TGCT	cis	rs142518269	1	rs142518269	chr2:24087095	G/A	cg08917208	chr2:24149416	ATAD2B	0.9	5.5	0.44	2.06e-7	Mean corpuscular hemoglobin;
TGCT	cis	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg22857025	chr5:266934	NA	-0.34	-6.72	-0.52	5.96e-10	Breast cancer;
TGCT	cis	rs9300255	0.679	rs4759409	chr12:123719585	G/C	cg00376283	chr12:123451042	ABCB9	0.67	5.26	0.43	6.13e-7	Neutrophil percentage of white cells;
TGCT	cis	rs7666738	0.830	rs6829567	chr4:99047340	T/C	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7681440	0.904	rs2870029	chr4:90772057	G/T	cg26578617	chr4:90757533	SNCA	-0.46	-4.73	-0.39	6.01e-6	Dementia with Lewy bodies;
TGCT	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg17971929	chr21:40555470	PSMG1	0.96	8.49	0.61	5.2e-14	Cognitive function;
TGCT	cis	rs9486719	1.000	rs12201449	chr6:96959382	C/T	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.86	-0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	trans	rs11764590	0.950	rs55683212	chr7:2078855	G/C	cg10840412	chr1:235813424	GNG4	0.95	6.94	0.53	1.97e-10	Neuroticism;
TGCT	cis	rs782590	0.537	rs7575170	chr2:55886780	C/T	cg03859395	chr2:55845619	SMEK2	-0.65	-5.3	-0.43	5.13e-7	Metabolic syndrome;
TGCT	cis	rs9486715	0.838	rs9386473	chr6:96873341	C/A	cg18709589	chr6:96969512	KIAA0776	0.77	7.5	0.56	1.09e-11	Headache;
TGCT	cis	rs1801251	1.000	rs11679079	chr2:233612656	C/T	cg25237894	chr2:233734115	C2orf82	0.33	5.95	0.47	2.53e-8	Coronary artery disease;
TGCT	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg24060327	chr5:131705240	SLC22A5	-0.73	-7.83	-0.58	1.83e-12	Breast cancer;
TGCT	cis	rs6683273	0.720	rs12566775	chr1:3226929	C/T	cg17435683	chr1:3230609	PRDM16	-0.4	-4.53	-0.38	1.35e-5	QRS duration;
TGCT	cis	rs200810	0.634	rs62422096	chr6:97991866	A/G	cg16511841	chr6:97730490	C6orf167;MIR548H3	-0.68	-4.65	-0.39	8.37e-6	Body mass index;
TGCT	cis	rs7666738	0.830	rs969049	chr4:98988857	C/T	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7027203	0.797	rs4744294	chr9:96612114	C/G	cg14598338	chr9:96623480	NA	-0.61	-9.56	-0.65	1.44e-16	DNA methylation (variation);
TGCT	cis	rs12039431	0.746	rs10908354	chr1:38014601	A/G	cg17933807	chr1:38061675	GNL2	-0.8	-7.69	-0.57	3.84e-12	Epithelial ovarian cancer;
TGCT	cis	rs4900538	0.855	rs72698597	chr14:102868633	C/T	cg18135206	chr14:102964638	TECPR2	-0.2	-4.55	-0.38	1.24e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs8056742	0.818	rs12926508	chr16:85092892	C/T	cg00229868	chr16:85520891	NA	-0.34	-4.8	-0.4	4.39e-6	Amyotrophic lateral sclerosis;
TGCT	cis	rs12134245	0.742	rs17501381	chr1:92003919	A/G	cg02896835	chr1:92012615	NA	-0.27	-4.59	-0.38	1.08e-5	Breast cancer;
TGCT	cis	rs12188164	0.931	rs115554641	chr5:443236	C/G	cg21144161	chr5:423903	AHRR	0.25	4.79	0.4	4.59e-6	Cystic fibrosis severity;
TGCT	cis	rs6570726	0.791	rs1509213	chr6:145783360	G/A	cg23711669	chr6:146136114	FBXO30	-0.89	-9.87	-0.66	2.55e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1008375	1.000	rs1121091	chr4:17676386	A/C	cg10189774	chr4:17578691	LAP3	0.53	5.0	0.41	1.91e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs708547	0.830	rs1713994	chr4:57868367	G/A	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.55	-5.02	-0.41	1.74e-6	Response to bleomycin (chromatid breaks);
TGCT	cis	rs7829975	0.502	rs11785183	chr8:8565957	G/A	cg17143192	chr8:8559678	CLDN23	-0.51	-5.11	-0.42	1.17e-6	Mood instability;
TGCT	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg12310025	chr6:25882481	NA	-0.92	-8.92	-0.63	5.07e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs7267979	1.000	rs447722	chr20:25443510	C/T	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg04944784	chr2:26401820	FAM59B	-0.76	-6.34	-0.49	3.94e-9	Gut microbiome composition (summer);
TGCT	cis	rs6860806	0.531	rs274556	chr5:131722075	A/G	cg24060327	chr5:131705240	SLC22A5	0.77	8.48	0.61	5.57e-14	Breast cancer;
TGCT	cis	rs10465746	0.935	rs4258241	chr1:84437929	G/A	cg10977910	chr1:84465055	TTLL7	0.63	6.23	0.49	6.49e-9	Obesity-related traits;
TGCT	cis	rs7647973	0.710	rs34890793	chr3:49619493	C/T	cg05785598	chr3:49045655	WDR6	0.4	4.62	0.38	9.42e-6	Menarche (age at onset);
TGCT	cis	rs9303401	0.659	rs35828828	chr17:56718205	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.61	6.26	0.49	5.86e-9	Cognitive test performance;
TGCT	cis	rs10779751	0.734	rs2791657	chr1:11128001	A/G	cg08854313	chr1:11322531	MTOR	0.82	7.04	0.53	1.19e-10	Body mass index;
TGCT	cis	rs1215050	0.740	rs185468	chr4:98756242	C/T	cg05340658	chr4:99064831	C4orf37	0.44	5.52	0.44	1.85e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg08736216	chr1:53307985	ZYG11A	-0.28	-5.73	-0.46	7.33e-8	Monocyte count;
TGCT	cis	rs3125734	0.719	rs10821972	chr10:64043735	G/A	cg09941381	chr10:64027924	RTKN2	-0.31	-4.52	-0.38	1.45e-5	Rheumatoid arthritis;
TGCT	cis	rs13191362	0.507	rs2803051	chr6:163034979	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.58	-5.72	-0.46	7.5e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs12220898	0.679	rs10745257	chr10:50473892	T/C	cg09603381	chr10:49954066	WDFY4	0.38	4.45	0.37	1.85e-5	Inflammatory biomarkers;
TGCT	cis	rs67133203	0.659	rs224589	chr12:51399050	A/C	cg01517968	chr12:52348879	ACVR1B	-0.35	-4.52	-0.38	1.44e-5	Urinary tract infection frequency;
TGCT	cis	rs7772486	0.686	rs9403739	chr6:146015357	A/G	cg13319975	chr6:146136371	FBXO30	0.48	4.43	0.37	2.01e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3020736	0.519	rs5996116	chr22:42517492	G/A	cg05082376	chr22:42548792	NA	0.23	5.43	0.44	2.83e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs76878669	0.561	rs4930363	chr11:66169676	C/T	cg18002602	chr11:66138449	SLC29A2	0.5	6.37	0.5	3.41e-9	Educational attainment (years of education);
TGCT	cis	rs6490294	0.904	rs12579298	chr12:112394022	G/T	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Mean platelet volume;
TGCT	cis	rs8177253	0.665	rs4525863	chr3:133436136	C/A	cg11941060	chr3:133502564	NA	-0.27	-5.38	-0.43	3.58e-7	Iron status biomarkers;
TGCT	cis	rs9467773	0.620	rs2451732	chr6:26622904	A/T	cg26531700	chr6:26746687	NA	-0.54	-4.89	-0.4	3.07e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10206020	0.879	rs72778007	chr2:1573178	C/T	cg01028140	chr2:1542097	TPO	-0.32	-4.99	-0.41	1.97e-6	IgG glycosylation;
TGCT	cis	rs7119	0.717	rs62009071	chr15:77817886	C/G	cg27398640	chr15:77910606	LINGO1	-0.25	-4.6	-0.38	1.05e-5	Type 2 diabetes;
TGCT	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg22105103	chr4:187893119	NA	0.34	4.62	0.38	9.32e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs933688	1.000	rs2052553	chr5:90729906	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.97	8.61	0.61	2.82e-14	Smoking behavior;
TGCT	cis	rs79349575	0.783	rs2112617	chr17:46977125	G/A	cg26022315	chr17:47021804	SNF8	0.53	5.31	0.43	4.82e-7	Type 2 diabetes;
TGCT	cis	rs6687430	0.526	rs6688558	chr1:10611403	A/G	cg17425144	chr1:10567563	PEX14	0.51	5.99	0.47	2.06e-8	Hand grip strength;
TGCT	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg12310025	chr6:25882481	NA	-1.1	-14.2	-0.79	9.06e-28	Urate levels;
TGCT	cis	rs13191362	0.507	rs2023038	chr6:163119280	C/G	cg06582575	chr6:163149167	PACRG;PARK2	-0.56	-5.39	-0.44	3.43e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs9393692	0.905	rs6931391	chr6:26279235	G/C	cg00631329	chr6:26305371	NA	-0.44	-6.59	-0.51	1.14e-9	Educational attainment;
TGCT	trans	rs1814175	0.754	rs10219245	chr11:49645052	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.38	-7.79	-0.57	2.3e-12	Height;
TGCT	cis	rs2639990	1.000	rs2639990	chr18:72915551	T/C	cg02750262	chr18:72916776	ZADH2	0.9	6.7	0.52	6.56e-10	Vascular endothelial growth factor levels;
TGCT	cis	rs7662987	0.517	rs1311615	chr4:100012261	G/A	cg12011299	chr4:100065546	ADH4	0.42	4.87	0.4	3.38e-6	Smoking initiation;
TGCT	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg11764359	chr7:65958608	NA	-0.55	-5.08	-0.42	1.34e-6	Aortic root size;
TGCT	cis	rs6121246	0.529	rs2889528	chr20:30210021	C/T	cg21427119	chr20:30132790	HM13	-0.43	-6.17	-0.48	8.86e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs5771225	0.544	rs13055135	chr22:50672479	A/G	cg16473166	chr22:50639996	SELO	0.57	4.71	0.39	6.57e-6	Late-onset Alzheimer's disease;
TGCT	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg26513180	chr16:89883248	FANCA	-1.06	-14.59	-0.79	1.13e-28	Vitiligo;
TGCT	cis	rs36051895	0.553	rs16922773	chr9:5197436	T/G	cg02405213	chr9:5042618	JAK2	-0.72	-8.66	-0.61	2.1e-14	Pediatric autoimmune diseases;
TGCT	cis	rs11627546	0.615	rs57951641	chr14:70365341	G/A	cg10496350	chr14:71275911	MAP3K9	-0.89	-4.5	-0.37	1.52e-5	Red blood cell traits;
TGCT	cis	rs10883723	0.962	rs10883726	chr10:104236276	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	7.52	0.56	9.74e-12	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs459571	0.959	rs416390	chr9:136908549	C/G	cg13789015	chr9:136890014	NCRNA00094	-0.42	-7.81	-0.57	2.03e-12	Platelet distribution width;
TGCT	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg06212747	chr3:49208901	KLHDC8B	0.67	6.36	0.5	3.57e-9	Menarche (age at onset);
TGCT	cis	rs651907	0.535	rs11717638	chr3:101505468	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	4.85	0.4	3.68e-6	Colorectal cancer;
TGCT	cis	rs2762353	0.935	rs1892249	chr6:25768992	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.41	4.6	0.38	1.03e-5	Blood metabolite levels;
TGCT	cis	rs17401966	1.000	rs11576866	chr1:10414432	A/G	cg19773385	chr1:10388646	KIF1B	-0.21	-4.5	-0.37	1.57e-5	Hepatocellular carcinoma;
TGCT	cis	rs6570726	0.818	rs9390338	chr6:145908265	A/G	cg05347473	chr6:146136440	FBXO30	0.51	4.75	0.39	5.42e-6	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs208515	0.556	rs10455193	chr6:66691456	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.93	10.3	0.68	2.34e-18	Exhaled nitric oxide levels;
TGCT	cis	rs28595532	0.920	rs115994240	chr4:119744622	C/T	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs9733	0.596	rs34600506	chr1:150687808	C/G	cg04414720	chr1:150670196	GOLPH3L	0.37	4.91	0.4	2.76e-6	Tonsillectomy;
TGCT	cis	rs7647973	0.925	rs7429661	chr3:49228800	G/A	cg06212747	chr3:49208901	KLHDC8B	0.56	4.54	0.38	1.32e-5	Menarche (age at onset);
TGCT	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg01341218	chr17:43662625	NA	1.11	9.15	0.63	1.43e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs427394	0.664	rs274701	chr5:6728707	C/A	cg10857441	chr5:6722123	POLS	-0.29	-7.24	-0.54	4.17e-11	Menopause (age at onset);
TGCT	cis	rs7666738	0.830	rs62321598	chr4:99014237	C/T	cg17366294	chr4:99064904	C4orf37	0.66	6.75	0.52	5.04e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2153535	0.580	rs7741403	chr6:8530578	C/T	cg23788917	chr6:8435910	SLC35B3	-0.6	-5.37	-0.43	3.79e-7	Motion sickness;
TGCT	cis	rs651907	0.535	rs34743741	chr3:101532448	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.31	-6.5	-0.5	1.8e-9	Colorectal cancer;
TGCT	cis	rs9926296	0.572	rs8046872	chr16:89841552	T/C	cg26513180	chr16:89883248	FANCA	0.72	7.02	0.53	1.3e-10	Vitiligo;
TGCT	cis	rs6998277	1.000	rs35155104	chr8:103646559	G/T	cg10187029	chr8:103597600	NA	0.48	6.26	0.49	5.81e-9	Migraine;
TGCT	cis	rs7737716	0.500	rs57503789	chr5:118228863	A/G	cg21035905	chr5:118964330	FAM170A	0.41	4.71	0.39	6.64e-6	Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;
TGCT	cis	rs4268898	0.662	rs2303291	chr2:24431184	C/T	cg02683114	chr2:24398427	C2orf84	-0.25	-4.73	-0.39	6.03e-6	Asthma;
TGCT	cis	rs13256369	0.851	rs13258283	chr8:8563630	T/C	cg18904891	chr8:8559673	CLDN23	0.59	5.46	0.44	2.54e-7	Obesity-related traits;
TGCT	cis	rs554111	0.656	rs4654893	chr1:21305596	G/C	cg01072550	chr1:21505969	NA	0.35	5.35	0.43	4.11e-7	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg08736216	chr1:53307985	ZYG11A	-0.24	-4.89	-0.4	3e-6	Monocyte count;
TGCT	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg07332563	chr6:291687	DUSP22	0.71	7.37	0.55	2.06e-11	Menopause (age at onset);
TGCT	cis	rs35146811	0.589	rs1727142	chr7:99816179	T/C	cg13334819	chr7:99746414	C7orf59	0.66	5.35	0.43	4.03e-7	Coronary artery disease;
TGCT	cis	rs62244186	0.632	rs1402751	chr3:44594030	C/A	cg10263370	chr3:44754102	ZNF502	-0.43	-5.14	-0.42	1.04e-6	Depressive symptoms;
TGCT	cis	rs9926296	0.581	rs12598477	chr16:89902482	T/C	cg21285383	chr16:89894308	SPIRE2	0.33	4.71	0.39	6.6e-6	Vitiligo;
TGCT	cis	rs7552404	0.924	rs1146574	chr1:76202671	A/G	cg10523679	chr1:76189770	ACADM	0.84	9.32	0.64	5.67e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.46	5.04	0.41	1.58e-6	Blood metabolite levels;
TGCT	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg06238570	chr21:40685208	BRWD1	0.75	7.06	0.54	1.07e-10	Cognitive function;
TGCT	cis	rs477895	0.838	rs12794145	chr11:64006484	C/T	cg04317338	chr11:64019027	PLCB3	0.82	7.06	0.54	1.06e-10	Mean platelet volume;
TGCT	cis	rs10504229	1.000	rs59843034	chr8:58195756	T/G	cg24829409	chr8:58192753	C8orf71	-0.55	-4.77	-0.39	5.18e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10501293	0.529	rs2902301	chr11:43093159	A/T	cg03447554	chr11:43094025	NA	-0.45	-7.65	-0.57	4.79e-12	Cognitive performance;
TGCT	trans	rs7726839	0.540	rs55929359	chr5:595956	C/G	cg11887960	chr12:57824829	NA	1.19	9.31	0.64	5.73e-16	Obesity-related traits;
TGCT	cis	rs9399135	0.967	rs13191501	chr6:135366880	T/C	cg24558204	chr6:135376177	HBS1L	0.46	4.55	0.38	1.24e-5	Red blood cell count;
TGCT	cis	rs1401999	0.659	rs7622660	chr3:183753337	C/T	cg01324343	chr3:183735012	ABCC5	0.75	8.92	0.63	5.1e-15	Anterior chamber depth;
TGCT	cis	rs9467773	0.620	rs2130657	chr6:26650826	C/T	cg26531700	chr6:26746687	NA	0.51	4.61	0.38	9.86e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9467711	0.790	rs55706012	chr6:26266311	A/C	cg10795676	chr6:26370623	BTN3A2	-0.49	-4.46	-0.37	1.79e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	4.93	0.4	2.63e-6	Menopause (age at onset);
TGCT	cis	rs2204008	0.744	rs11514071	chr12:38392076	C/T	cg13010199	chr12:38710504	ALG10B	0.58	4.59	0.38	1.05e-5	Bladder cancer;
TGCT	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg04267008	chr7:1944627	MAD1L1	-0.35	-4.72	-0.39	6.17e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg06873352	chr17:61820015	STRADA	-0.57	-6.38	-0.5	3.21e-9	Prudent dietary pattern;
TGCT	cis	rs12643440	0.538	rs970428	chr4:17136795	C/A	cg22650099	chr4:17144496	NA	-0.46	-4.66	-0.39	8.14e-6	Metabolite levels (Pyroglutamine);
TGCT	cis	rs7302981	0.934	rs7279	chr12:50523947	A/G	cg23855989	chr12:50355821	AQP5	-0.3	-4.44	-0.37	2e-5	Systolic blood pressure;
TGCT	cis	rs60843830	0.964	rs17713879	chr2:254215	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.65	6.13	0.48	1.06e-8	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg23708337	chr7:1209742	NA	0.51	4.46	0.37	1.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs422249	0.613	rs174465	chr11:61658800	C/T	cg01500311	chr11:61656094	FADS3	0.34	6.51	0.5	1.72e-9	Trans fatty acid levels;
TGCT	cis	rs2440129	1.000	rs2440129	chr17:6906571	C/G	cg05215272	chr17:6899095	ALOX12	0.43	4.45	0.37	1.86e-5	Tonsillectomy;
TGCT	cis	rs9906944	0.703	rs940088	chr17:47145848	T/C	cg20966754	chr17:47091339	IGF2BP1	-0.47	-5.33	-0.43	4.46e-7	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs9682041	0.627	rs11924474	chr3:170091333	T/G	cg07589077	chr3:170072950	NA	0.26	4.53	0.38	1.36e-5	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs3796352	1.000	rs34121720	chr3:53072167	C/T	cg07884673	chr3:53033167	SFMBT1	0.6	6.24	0.49	6.25e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs8031584	0.678	rs36047941	chr15:31159235	A/G	cg08704250	chr15:31115839	NA	-0.43	-6.31	-0.49	4.47e-9	Huntington's disease progression;
TGCT	trans	rs66573146	0.901	rs7668802	chr4:6986236	T/A	cg07817883	chr1:32538562	TMEM39B	1.76	8.28	0.6	1.7e-13	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs11096990	0.656	rs2123028	chr4:39303479	C/T	cg20847110	chr4:39482781	LOC401127	-0.16	-4.51	-0.38	1.46e-5	Cognitive function;
TGCT	cis	rs7824557	0.569	rs2409718	chr8:11012977	C/T	cg21775007	chr8:11205619	TDH	-0.53	-5.01	-0.41	1.84e-6	Retinal vascular caliber;
TGCT	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	5.56	0.45	1.58e-7	Height;
TGCT	cis	rs7567389	0.600	rs11679414	chr2:128151003	G/A	cg09760422	chr2:128146352	NA	0.38	4.94	0.41	2.43e-6	Self-rated health;
TGCT	cis	rs7513165	0.935	rs12097666	chr1:204162212	A/G	cg12731349	chr1:204159619	KISS1	0.48	5.41	0.44	3.1e-7	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
TGCT	cis	rs6977660	0.714	rs10231980	chr7:19789383	C/G	cg05791153	chr7:19748676	TWISTNB	0.88	5.05	0.41	1.52e-6	Thyroid stimulating hormone;
TGCT	cis	rs11148252	0.538	rs2408609	chr13:52714043	C/T	cg00495681	chr13:53174319	NA	0.57	5.86	0.47	3.84e-8	Lewy body disease;
TGCT	cis	rs9611565	0.559	rs8139993	chr22:41995335	T/C	cg17554472	chr22:41940697	POLR3H	-0.49	-5.15	-0.42	9.88e-7	Vitiligo;
TGCT	cis	rs9611565	0.559	rs4822048	chr22:41988225	C/T	cg06481639	chr22:41940642	POLR3H	-0.75	-6.47	-0.5	2.1e-9	Vitiligo;
TGCT	cis	rs60733400	0.644	rs28774982	chr1:2621352	C/G	cg18854424	chr1:2615690	NA	-0.44	-4.99	-0.41	2e-6	Multiple sclerosis;
TGCT	cis	rs3820928	1.000	rs978909	chr2:227771389	A/C	cg11843606	chr2:227700838	RHBDD1	-0.52	-4.63	-0.38	8.93e-6	Pulmonary function;
TGCT	cis	rs9811920	0.609	rs4244711	chr3:99657205	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.59	6.77	0.52	4.51e-10	Axial length;
TGCT	cis	rs3733585	0.631	rs3822236	chr4:10119961	T/G	cg00071950	chr4:10020882	SLC2A9	-0.51	-5.28	-0.43	5.7e-7	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7666738	0.830	rs17484890	chr4:99013778	T/C	cg05340658	chr4:99064831	C4orf37	0.48	5.53	0.44	1.79e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	5.3	0.43	5.06e-7	Height;
TGCT	cis	rs9300255	0.602	rs1790126	chr12:123683563	C/T	cg00376283	chr12:123451042	ABCB9	0.71	5.59	0.45	1.41e-7	Neutrophil percentage of white cells;
TGCT	cis	rs2836950	0.545	rs11700449	chr21:40522419	A/T	cg17971929	chr21:40555470	PSMG1	-0.55	-4.96	-0.41	2.25e-6	Menarche (age at onset);
TGCT	cis	rs60871478	0.541	rs56964970	chr7:910791	G/C	cg15782153	chr7:917662	C7orf20	0.57	5.12	0.42	1.14e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs6582630	0.555	rs7294313	chr12:38323603	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-4.49	-0.37	1.6e-5	Drug-induced liver injury (flucloxacillin);
TGCT	trans	rs9295123	0.898	rs9347388	chr6:160572557	T/A	cg22927510	chr22:50968328	TYMP	-0.51	-6.82	-0.52	3.63e-10	Blood protein levels;
TGCT	cis	rs2180341	1.000	rs9321073	chr6:127609691	C/T	cg24812749	chr6:127587940	RNF146	0.99	7.72	0.57	3.33e-12	Breast cancer;
TGCT	cis	rs2742417	0.603	rs13059502	chr3:45781380	A/G	cg04837898	chr3:45731254	SACM1L	-0.67	-7.3	-0.55	3.06e-11	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs57244997	0.932	rs73026582	chr6:162406460	C/T	cg17173639	chr6:162384350	PARK2	-0.43	-4.66	-0.39	7.92e-6	Mosquito bite size;
TGCT	cis	rs6977660	0.714	rs12386623	chr7:19791875	A/G	cg07541023	chr7:19748670	TWISTNB	-0.85	-4.84	-0.4	3.74e-6	Thyroid stimulating hormone;
TGCT	cis	rs2227564	0.620	rs3812637	chr10:75568846	C/T	cg23231163	chr10:75533350	FUT11	-0.28	-4.62	-0.38	9.65e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs854765	0.583	rs4414547	chr17:17859052	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	7.69	0.57	3.98e-12	Total body bone mineral density;
TGCT	cis	rs7095607	0.704	rs6480309	chr10:69953066	G/A	cg18986048	chr10:69913749	MYPN	0.58	6.79	0.52	4.14e-10	Lung function (FVC);
TGCT	cis	rs6570726	0.764	rs376257	chr6:145862949	G/A	cg13319975	chr6:146136371	FBXO30	-0.51	-4.6	-0.38	1.01e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs79057730	0.599	rs6944167	chr7:826274	G/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.64	5.98	0.47	2.17e-8	Initial pursuit acceleration;
TGCT	trans	rs1814175	0.935	rs7925863	chr11:49615802	C/A	cg03929089	chr4:120376271	NA	-0.65	-7.44	-0.56	1.46e-11	Height;
TGCT	cis	rs36051895	0.587	rs7848872	chr9:5197027	T/A	cg02405213	chr9:5042618	JAK2	-0.72	-8.79	-0.62	1.04e-14	Pediatric autoimmune diseases;
TGCT	cis	rs12681287	0.785	rs13263353	chr8:87244582	C/T	cg27223183	chr8:87520930	FAM82B	-0.8	-5.77	-0.46	5.94e-8	Caudate activity during reward;
TGCT	cis	rs3540	0.513	rs2589974	chr15:90891566	C/T	cg22089800	chr15:90895588	ZNF774	-0.82	-9.07	-0.63	2.21e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs6121246	0.865	rs6058421	chr20:30295013	G/C	cg18721089	chr20:30220636	NA	-0.42	-4.65	-0.39	8.2e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs17152411	0.652	rs10901842	chr10:126635262	C/T	cg07906193	chr10:126599966	NA	0.28	4.45	0.37	1.91e-5	Height;
TGCT	cis	rs1215050	0.765	rs588851	chr4:98678247	C/T	cg17366294	chr4:99064904	C4orf37	0.52	5.51	0.44	1.97e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs6933660	0.760	rs6904364	chr6:151754273	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.52	4.87	0.4	3.28e-6	Menarche (age at onset);
TGCT	trans	rs4332037	0.539	rs34809719	chr7:2028968	G/T	cg25206134	chr2:45395956	NA	0.97	7.33	0.55	2.6e-11	Bipolar disorder;
TGCT	cis	rs2816062	0.813	rs6698315	chr1:18895806	A/G	cg18795169	chr1:18902165	NA	-0.58	-13.28	-0.77	1.36e-25	Urate levels in lean individuals;
TGCT	cis	rs704	0.585	rs3093680	chr17:26664806	T/C	cg10342447	chr17:26645325	TMEM97	-0.59	-5.72	-0.46	7.56e-8	Osteoprotegerin levels;
TGCT	cis	rs9467711	0.790	rs35942569	chr6:26339131	A/G	cg16898833	chr6:26189333	HIST1H4D	1.29	5.8	0.46	5.25e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs933688	1.000	rs10045280	chr5:90717675	T/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.04	10.02	0.67	1.13e-17	Smoking behavior;
TGCT	cis	rs12477438	0.765	rs1115757	chr2:99660146	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-7.6	-0.56	6.47e-12	Chronic sinus infection;
TGCT	cis	rs3849570	0.555	rs4452351	chr3:82007977	C/T	cg07356753	chr3:81810745	GBE1	-0.62	-5.38	-0.44	3.5e-7	Waist circumference;Body mass index;
TGCT	cis	rs8028182	0.636	rs11634863	chr15:75766672	C/A	cg20655648	chr15:75932815	IMP3	0.58	4.51	0.38	1.48e-5	Sudden cardiac arrest;
TGCT	trans	rs10506458	0.688	rs60936040	chr12:63416461	G/A	cg22491629	chr6:157744540	C6orf35	-0.8	-6.96	-0.53	1.72e-10	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs11167764	1.000	rs3761757	chr5:141488219	A/C	cg08523384	chr5:141488047	NDFIP1	-0.25	-5.37	-0.43	3.72e-7	Crohn's disease;
TGCT	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	8.3	0.6	1.46e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs68170813	0.559	rs11773514	chr7:106958469	T/C	cg02696742	chr7:106810147	HBP1	-0.69	-5.81	-0.46	4.85e-8	Coronary artery disease;
TGCT	cis	rs7255045	0.788	rs8111370	chr19:12948864	G/T	cg06537894	chr19:12978706	MAST1	-0.49	-4.44	-0.37	1.98e-5	Mean corpuscular volume;
TGCT	cis	rs12477438	0.798	rs9808541	chr2:99642179	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-8.52	-0.61	4.5e-14	Chronic sinus infection;
TGCT	cis	rs6665290	0.935	rs6670924	chr1:227196048	A/C	cg10327440	chr1:227177885	CDC42BPA	-0.99	-20.13	-0.88	6.85e-41	Myeloid white cell count;
TGCT	cis	rs644799	1.000	rs472231	chr11:95532166	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	8.85	0.62	7.42e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg18188782	chr20:61659543	NA	0.44	5.38	0.43	3.6e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs67311347	1.000	rs7648952	chr3:40457038	C/T	cg13683864	chr3:40499215	RPL14	1.04	10.79	0.7	1.54e-19	Renal cell carcinoma;
TGCT	cis	rs9473924	0.505	rs7753025	chr6:50858352	A/C	cg14470998	chr6:50812995	TFAP2B	1.35	8.39	0.6	9.05e-14	Body mass index;
TGCT	cis	rs9880772	0.747	rs7621606	chr3:27819783	C/T	cg21473142	chr3:27762095	EOMES	-0.42	-4.53	-0.38	1.38e-5	Chronic lymphocytic leukemia;B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);
TGCT	cis	rs295140	1.000	rs10931899	chr2:201176901	A/G	cg04283868	chr2:201171347	SPATS2L	-0.65	-6.67	-0.51	7.73e-10	QT interval;
TGCT	cis	rs28595532	0.748	rs72670248	chr4:119335536	A/C	cg21605333	chr4:119757512	SEC24D	0.87	5.49	0.44	2.14e-7	Cannabis dependence symptom count;
TGCT	cis	rs981844	0.712	rs6855082	chr4:154754039	A/G	cg14289246	chr4:154710475	SFRP2	-0.98	-8.82	-0.62	8.67e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs3749237	0.964	rs2352975	chr3:49891885	T/C	cg10152585	chr3:50297680	NA	0.52	4.7	0.39	6.83e-6	Resting heart rate;
TGCT	cis	rs806215	0.547	rs17151377	chr7:127458009	G/T	cg11539674	chr7:127291444	SND1	-0.34	-4.45	-0.37	1.9e-5	Type 2 diabetes;
TGCT	cis	rs7264396	0.616	rs6142476	chr20:34581216	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.27	-4.9	-0.4	2.9e-6	Total cholesterol levels;
TGCT	cis	rs9399137	0.507	rs4289677	chr6:135275485	A/G	cg24558204	chr6:135376177	HBS1L	0.5	5.07	0.41	1.38e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
TGCT	trans	rs10435719	0.610	rs80269926	chr8:11790527	T/C	cg15556689	chr8:8085844	FLJ10661	0.75	6.87	0.53	2.77e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs4746818	1.000	rs4284308	chr10:70884861	C/T	cg04149295	chr10:70884716	VPS26A	0.75	5.31	0.43	4.84e-7	Left atrial antero-posterior diameter;
TGCT	cis	rs2153535	0.580	rs6421949	chr6:8531769	G/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.01	0.41	1.86e-6	Motion sickness;
TGCT	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg04414720	chr1:150670196	GOLPH3L	0.39	5.04	0.41	1.58e-6	Tonsillectomy;
TGCT	cis	rs9467773	0.967	rs1535276	chr6:26520941	T/C	cg09904177	chr6:26538194	HMGN4	0.65	6.53	0.51	1.53e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs12477438	0.520	rs6542863	chr2:99725138	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	17.43	0.84	3.73e-35	Chronic sinus infection;
TGCT	cis	rs112257498	1	rs112257498	chr2:190432985	C/T	cg10752008	chr2:190445175	SLC40A1	-0.49	-4.59	-0.38	1.05e-5	Red blood cell count;Mean corpuscular hemoglobin;
TGCT	cis	rs10875746	0.903	rs11168403	chr12:48484958	T/C	cg20731937	chr12:48336164	NA	0.62	4.95	0.41	2.36e-6	Longevity (90 years and older);
TGCT	trans	rs17685	0.672	rs55807301	chr7:75807401	C/A	cg19862616	chr7:65841803	NCRNA00174	0.51	8.83	0.62	8.1e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs2293052	0.697	rs551846	chr12:117754060	G/A	cg02962597	chr12:117799749	NOS1	0.26	4.62	0.38	9.57e-6	Schizophrenia;
TGCT	cis	rs2469997	1.000	rs2470028	chr8:120365878	A/G	cg00681363	chr8:120844660	TAF2	0.69	4.48	0.37	1.64e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs12620999	0.567	rs4663243	chr2:238102994	A/G	cg23555395	chr2:238036564	NA	-0.28	-4.97	-0.41	2.17e-6	Systemic lupus erythematosus;
TGCT	cis	rs7178572	0.889	rs59153558	chr15:77806770	A/G	cg22256960	chr15:77711686	NA	-0.95	-10.73	-0.69	2.16e-19	Type 2 diabetes;
TGCT	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg05025164	chr4:1340916	KIAA1530	0.8	6.69	0.51	7.02e-10	Longevity;
TGCT	cis	rs9303401	0.614	rs34683543	chr17:56520036	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.6	6.27	0.49	5.37e-9	Cognitive test performance;
TGCT	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg11890956	chr21:40555474	PSMG1	1.12	12.59	0.75	6.25e-24	Cognitive function;
TGCT	cis	rs7769051	0.711	rs7758703	chr6:133085417	T/C	cg07930552	chr6:133119739	C6orf192	0.9	4.67	0.39	7.86e-6	Type 2 diabetes nephropathy;
TGCT	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.63	-8.86	-0.62	7.11e-15	Longevity;Endometriosis;
TGCT	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg17971929	chr21:40555470	PSMG1	-0.7	-6.54	-0.51	1.44e-9	Cognitive function;
TGCT	cis	rs854765	0.547	rs9912096	chr17:17896673	A/C	cg09796270	chr17:17721594	SREBF1	0.25	5.04	0.41	1.61e-6	Total body bone mineral density;
TGCT	cis	rs2718812	0.792	rs1006098	chr3:133411605	G/T	cg08048268	chr3:133502702	NA	0.38	4.58	0.38	1.1e-5	Iron status biomarkers;
TGCT	cis	rs9467773	0.620	rs2451738	chr6:26618459	A/T	cg09904177	chr6:26538194	HMGN4	-0.61	-5.84	-0.46	4.38e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg02187348	chr16:89574699	SPG7	0.61	6.57	0.51	1.25e-9	Multiple myeloma (IgH translocation);
TGCT	cis	rs2302045	1.000	rs3796093	chr2:242039198	T/C	cg04553960	chr2:241721320	KIF1A	-0.7	-4.68	-0.39	7.4e-6	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio);
TGCT	cis	rs13256369	0.865	rs13282523	chr8:8577293	C/G	cg17143192	chr8:8559678	CLDN23	0.61	5.77	0.46	5.94e-8	Obesity-related traits;
TGCT	cis	rs739401	0.611	rs7394974	chr11:3038868	C/T	cg25174290	chr11:3078921	CARS	0.47	4.68	0.39	7.52e-6	Longevity;
TGCT	cis	rs11105298	0.891	rs10858900	chr12:89925081	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.67	-4.95	-0.41	2.41e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs7829975	0.514	rs2979151	chr8:8258019	A/G	cg15556689	chr8:8085844	FLJ10661	-0.69	-6.48	-0.5	1.99e-9	Mood instability;
TGCT	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg18654377	chr3:49208889	KLHDC8B	-0.37	-4.69	-0.39	7.12e-6	Parkinson's disease;
TGCT	cis	rs10949834	0.689	rs2269081	chr7:73519887	T/G	cg07137043	chr7:73588983	EIF4H	-0.83	-5.87	-0.47	3.69e-8	Verbal memory performance (residualized delayed recall change);
TGCT	cis	rs11190604	1.000	rs2495760	chr10:102318771	T/C	cg16342193	chr10:102329863	NA	-0.41	-5.17	-0.42	9.26e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg06112835	chr11:68658793	MRPL21	0.46	8.12	0.59	3.91e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs2120019	0.935	rs8042409	chr15:75350433	G/A	cg11632617	chr15:75315747	PPCDC	-0.32	-4.67	-0.39	7.58e-6	Blood trace element (Zn levels);
TGCT	cis	rs7937682	0.632	rs11214009	chr11:111683142	T/C	cg09085632	chr11:111637200	PPP2R1B	0.8	6.98	0.53	1.61e-10	Primary sclerosing cholangitis;
TGCT	cis	rs34638657	0.518	rs4889467	chr16:82169385	C/T	cg09439754	chr16:82129088	HSD17B2	-0.22	-4.54	-0.38	1.32e-5	Lung adenocarcinoma;
TGCT	cis	rs6460942	0.915	rs6945067	chr7:12444731	A/C	cg06484146	chr7:12443880	VWDE	-0.57	-5.52	-0.44	1.92e-7	Coronary artery disease;
TGCT	cis	rs3812831	0.695	rs10467349	chr13:114939441	A/G	cg08824895	chr13:115047677	UPF3A	0.48	4.6	0.38	1.04e-5	Schizophrenia;
TGCT	cis	rs7917772	0.582	rs10786685	chr10:104323103	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.57	5.63	0.45	1.13e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg13397359	chr6:42928475	GNMT	0.66	5.93	0.47	2.81e-8	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs308447	0.576	rs10005301	chr4:123715055	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	-0.74	-8.39	-0.6	9.37e-14	Perceived unattractiveness to mosquitoes;
TGCT	cis	rs854765	0.647	rs721669	chr17:18005073	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.7	7.22	0.54	4.53e-11	Total body bone mineral density;
TGCT	cis	rs3091242	0.933	rs10903129	chr1:25768937	A/G	cg00786635	chr1:25594202	NA	0.52	5.63	0.45	1.17e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs9916302	0.904	rs11078898	chr17:37536480	A/G	cg15445000	chr17:37608096	MED1	-0.33	-4.71	-0.39	6.51e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7572733	0.534	rs2574832	chr2:198704818	T/G	cg00792783	chr2:198669748	PLCL1	0.56	5.08	0.42	1.35e-6	Dermatomyositis;
TGCT	cis	rs6545883	0.929	rs2121660	chr2:61653058	T/C	cg15711740	chr2:61764176	XPO1	0.54	4.9	0.4	2.89e-6	Tuberculosis;
TGCT	cis	rs713587	0.691	rs754536	chr2:25176200	C/T	cg01884057	chr2:25150051	NA	-0.31	-5.93	-0.47	2.79e-8	Body mass index in non-asthmatics;
TGCT	cis	rs1371867	0.555	rs2861348	chr8:101285074	A/G	cg00191853	chr8:101177733	SPAG1	-0.23	-4.8	-0.4	4.44e-6	Atrioventricular conduction;
TGCT	cis	rs6975373	0.643	rs12540089	chr7:4446121	C/A	cg04153130	chr7:4456396	NA	0.44	4.54	0.38	1.32e-5	Borderline personality disorder;
TGCT	cis	rs4862750	0.881	rs6813866	chr4:187872161	T/G	cg03452623	chr4:187889614	NA	-0.36	-5.24	-0.43	6.6e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs35306767	0.903	rs7077278	chr10:911291	A/G	cg20503657	chr10:835505	NA	-0.73	-10.2	-0.68	4.09e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs9914988	0.887	rs11652710	chr17:27145075	C/T	cg20469991	chr17:27169893	C17orf63	-0.72	-5.09	-0.42	1.28e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs6430585	0.583	rs58116536	chr2:136585323	C/T	cg07169764	chr2:136633963	MCM6	1.23	11.99	0.73	1.85e-22	Corneal structure;
TGCT	cis	rs7772486	0.875	rs2180192	chr6:146322284	T/C	cg13319975	chr6:146136371	FBXO30	-0.52	-4.67	-0.39	7.83e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg05665937	chr4:1216051	CTBP1	0.24	4.47	0.37	1.72e-5	Obesity-related traits;
TGCT	cis	rs11858159	0.545	rs6576303	chr15:24641281	G/A	cg08449389	chr15:24672285	NA	0.43	4.53	0.38	1.36e-5	Platelet thrombus formation;
TGCT	cis	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg09021430	chr5:549028	NA	-0.37	-5.29	-0.43	5.46e-7	Lung disease severity in cystic fibrosis;
TGCT	cis	rs79349575	0.783	rs62075838	chr17:46996432	C/T	cg26022315	chr17:47021804	SNF8	0.49	4.89	0.4	3.03e-6	Type 2 diabetes;
TGCT	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg04287289	chr16:89883240	FANCA	-0.94	-11.74	-0.73	7.28e-22	Vitiligo;
TGCT	cis	rs9611565	0.918	rs9538	chr22:41755857	G/T	cg13695892	chr22:41940480	POLR3H	-0.92	-9.08	-0.63	2.06e-15	Vitiligo;
TGCT	cis	rs8064299	0.752	rs4789096	chr17:72772698	G/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.95	10.83	0.7	1.22e-19	Monocyte count;
TGCT	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg11247378	chr22:39784982	NA	0.73	9.83	0.66	3.27e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.06	13.37	0.77	8.58e-26	Height;
TGCT	cis	rs7824557	0.583	rs6601585	chr8:11233659	A/G	cg21775007	chr8:11205619	TDH	-0.66	-6.78	-0.52	4.4e-10	Retinal vascular caliber;
TGCT	cis	rs7000551	0.715	rs12544074	chr8:22338378	A/G	cg12081754	chr8:22256438	SLC39A14	0.31	5.06	0.41	1.48e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs4906332	1.000	rs2246490	chr14:103984294	G/T	cg26031613	chr14:104095156	KLC1	0.6	5.33	0.43	4.56e-7	Coronary artery disease;
TGCT	cis	rs9357506	0.967	rs1372568	chr6:46305454	T/C	cg21115430	chr6:46460003	NA	-0.26	-5.16	-0.42	9.37e-7	Body mass index;
TGCT	cis	rs2070433	0.706	rs2268524	chr21:47838700	C/T	cg12379764	chr21:47803548	PCNT	0.57	4.86	0.4	3.52e-6	Lymphocyte counts;
TGCT	cis	rs9911578	1.000	rs9915935	chr17:56843048	A/G	cg12560992	chr17:57184187	TRIM37	0.76	9.34	0.64	4.88e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs6570726	0.791	rs9390336	chr6:145896823	A/T	cg05347473	chr6:146136440	FBXO30	0.52	4.95	0.41	2.33e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg21862992	chr11:68658383	NA	0.46	6.39	0.5	3.1e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9921338	1.000	rs9921338	chr16:11416839	T/C	cg00044050	chr16:11439710	C16orf75	0.97	7.45	0.56	1.4e-11	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs9911578	0.935	rs2302189	chr17:56584205	A/C	cg05425664	chr17:57184151	TRIM37	0.63	6.4	0.5	2.84e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs72781680	0.665	rs2675356	chr2:24074734	C/T	cg08917208	chr2:24149416	ATAD2B	0.77	4.74	0.39	5.69e-6	Lymphocyte counts;
TGCT	cis	rs6684514	0.778	rs11264477	chr1:156321154	C/T	cg16558208	chr1:156270281	VHLL	0.4	8.41	0.6	8.11e-14	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs9796	0.558	rs6492993	chr15:41526104	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.53	-6.85	-0.52	3.01e-10	Menopause (age at onset);
TGCT	cis	rs13256369	0.951	rs10503394	chr8:8565775	A/G	cg18904891	chr8:8559673	CLDN23	0.6	5.58	0.45	1.47e-7	Obesity-related traits;
TGCT	cis	rs514406	0.893	rs1242317	chr1:53414766	T/C	cg08736216	chr1:53307985	ZYG11A	-0.29	-5.96	-0.47	2.43e-8	Monocyte count;
TGCT	cis	rs17376456	0.741	rs10036829	chr5:93309897	G/C	cg25358565	chr5:93447407	FAM172A	0.98	8.39	0.6	9.01e-14	Diabetic retinopathy;
TGCT	cis	rs734999	0.545	rs7364820	chr1:2556709	G/A	cg18854424	chr1:2615690	NA	0.45	5.15	0.42	1e-6	Ulcerative colitis;
TGCT	cis	rs2153535	0.580	rs6597322	chr6:8449952	T/G	cg07606381	chr6:8435919	SLC35B3	0.53	5.02	0.41	1.79e-6	Motion sickness;
TGCT	cis	rs921968	0.510	rs620887	chr2:219465594	C/A	cg02176678	chr2:219576539	TTLL4	0.48	6.78	0.52	4.32e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs7089973	0.584	rs6585300	chr10:116639889	A/C	cg03647239	chr10:116582469	FAM160B1	0.59	5.57	0.45	1.51e-7	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs748404	0.631	rs2467745	chr15:43722742	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	4.75	0.39	5.51e-6	Lung cancer;
TGCT	cis	rs6840360	0.571	rs4696270	chr4:152498289	G/A	cg17479576	chr4:152424074	FAM160A1	-0.73	-7.94	-0.58	1.03e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs7829975	0.774	rs11249893	chr8:8700851	C/T	cg15556689	chr8:8085844	FLJ10661	0.72	6.72	0.52	5.75e-10	Mood instability;
TGCT	cis	rs7714584	1.000	rs12054923	chr5:150249059	A/G	cg22134413	chr5:150180641	NA	0.87	6.8	0.52	3.87e-10	Crohn's disease;
TGCT	cis	rs910316	0.870	rs7147712	chr14:75670707	C/G	cg08847533	chr14:75593920	NEK9	-0.93	-10.86	-0.7	1.02e-19	Height;
TGCT	cis	rs79349575	0.721	rs2291725	chr17:47039132	T/C	cg26022315	chr17:47021804	SNF8	0.49	4.77	0.39	5.18e-6	Type 2 diabetes;
TGCT	cis	rs2880765	0.835	rs6497202	chr15:86021375	T/C	cg13263323	chr15:86062960	AKAP13	-0.23	-4.9	-0.4	2.91e-6	Coronary artery disease;
TGCT	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.56	4.97	0.41	2.19e-6	Height;
TGCT	cis	rs7208859	0.673	rs78799101	chr17:29215160	A/T	cg18442181	chr17:29233375	C17orf42	-0.78	-4.61	-0.38	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	trans	rs2233152	0.519	rs10423139	chr19:41320459	C/G	cg23963070	chr1:1162176	SDF4	0.32	6.9	0.53	2.33e-10	Kawasaki disease;
TGCT	cis	rs6539288	0.563	rs11113122	chr12:107211325	T/C	cg15890332	chr12:107067104	RFX4	0.23	4.75	0.39	5.45e-6	Total body bone mineral density;
TGCT	cis	rs9653442	0.564	rs7565895	chr2:100774773	G/A	cg22139774	chr2:100720529	AFF3	-0.34	-5.4	-0.44	3.21e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs6426558	0.537	rs6662583	chr1:227383889	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.61	-7.32	-0.55	2.72e-11	Neutrophil percentage of white cells;
TGCT	cis	rs7829975	0.560	rs6994131	chr8:8550958	G/A	cg17143192	chr8:8559678	CLDN23	-0.49	-4.94	-0.41	2.44e-6	Mood instability;
TGCT	cis	rs4727027	0.866	rs3927307	chr7:148774869	C/T	cg23583168	chr7:148888333	NA	-0.69	-8.67	-0.61	2.04e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg06634786	chr22:41940651	POLR3H	0.7	6.65	0.51	8.51e-10	Vitiligo;
TGCT	cis	rs3020736	0.500	rs6002603	chr22:42492362	C/G	cg05082376	chr22:42548792	NA	0.23	5.43	0.44	2.85e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg18876405	chr7:65276391	NA	0.32	4.9	0.4	2.99e-6	Aortic root size;
TGCT	cis	rs3087591	0.922	rs2905799	chr17:29536901	G/A	cg24425628	chr17:29625626	OMG;NF1	0.48	7.29	0.55	3.25e-11	Hip circumference;
TGCT	cis	rs7267979	1.000	rs3761117	chr20:25388070	G/A	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9677476	0.632	rs10198572	chr2:232096723	G/A	cg07929768	chr2:232055508	NA	0.33	5.16	0.42	9.37e-7	Food antigen IgG levels;
TGCT	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg10802521	chr3:52805072	NEK4	-0.72	-9.11	-0.63	1.82e-15	Bipolar disorder;
TGCT	cis	rs698813	0.543	rs12468824	chr2:44482448	G/T	cg00619915	chr2:44497795	NA	-0.24	-5.68	-0.45	9.26e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
TGCT	cis	rs9650657	0.737	rs2409669	chr8:10623969	A/G	cg27411982	chr8:10470053	RP1L1	-0.21	-4.44	-0.37	1.97e-5	Neuroticism;
TGCT	cis	rs72781680	0.752	rs72796130	chr2:23919740	T/C	cg08917208	chr2:24149416	ATAD2B	1.0	5.79	0.46	5.41e-8	Lymphocyte counts;
TGCT	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg17264618	chr3:40429014	ENTPD3	-0.32	-4.45	-0.37	1.9e-5	Renal cell carcinoma;
TGCT	cis	rs12291225	0.585	rs34171876	chr11:14353957	G/C	cg19336497	chr11:14380999	RRAS2	-0.44	-7.11	-0.54	8.3e-11	Sense of smell;
TGCT	cis	rs6121246	0.559	rs6119728	chr20:30413121	G/A	cg10886678	chr20:30946050	ASXL1	-0.57	-4.79	-0.4	4.68e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs7781977	0.695	rs6583437	chr7:50350267	C/T	cg14216940	chr7:50343131	IKZF1	0.36	4.55	0.38	1.25e-5	IgG glycosylation;
TGCT	cis	rs1692580	0.807	rs4648818	chr1:2178999	C/T	cg21194808	chr1:2205498	SKI	0.29	5.74	0.46	6.76e-8	Coronary artery disease;
TGCT	cis	rs2228479	0.702	rs17226841	chr16:89828484	C/T	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs35849525	1.000	rs35849525	chr3:50067350	T/C	cg14019146	chr3:50243930	SLC38A3	-0.21	-4.51	-0.38	1.47e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs950169	0.887	rs3860265	chr15:84945185	C/T	cg11189052	chr15:85197271	WDR73	0.81	6.22	0.49	6.89e-9	Schizophrenia;
TGCT	cis	rs12188164	0.965	rs41282625	chr5:475626	C/G	cg17553881	chr5:443987	EXOC3;C5orf55	-0.41	-4.76	-0.39	5.28e-6	Cystic fibrosis severity;
TGCT	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg01416388	chr22:39784598	NA	-0.72	-7.15	-0.54	6.43e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs73036520	0.646	rs11672894	chr19:45801951	A/G	cg20198684	chr19:45742032	NA	-0.24	-4.46	-0.37	1.78e-5	Monocyte percentage of white cells;
TGCT	cis	rs1372520	0.532	rs2583972	chr4:90747411	T/G	cg14346243	chr4:90757452	SNCA	-0.64	-5.26	-0.43	6.04e-7	Neuroticism;
TGCT	cis	rs950169	0.526	rs698620	chr15:85177208	G/A	cg12501888	chr15:85177176	SCAND2	-0.49	-4.61	-0.38	9.75e-6	Schizophrenia;
TGCT	cis	rs1018836	0.923	rs6989123	chr8:91551234	A/T	cg16814680	chr8:91681699	NA	-0.88	-9.81	-0.66	3.71e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs8038465	0.592	rs58443257	chr15:73930707	A/T	cg15420318	chr15:73925796	NPTN	0.67	6.99	0.53	1.52e-10	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1043515	0.642	rs8592	chr17:36958065	A/G	cg09592244	chr17:37024020	NA	0.49	4.86	0.4	3.55e-6	Height;
TGCT	cis	rs6657613	0.903	rs9435659	chr1:17313343	G/A	cg21692666	chr1:17199302	NA	-0.42	-4.52	-0.38	1.43e-5	Hip circumference adjusted for BMI;
TGCT	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg24829409	chr8:58192753	C8orf71	-0.59	-4.97	-0.41	2.17e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4972806	0.814	rs4246626	chr2:177046430	A/C	cg14324370	chr2:177042789	NA	0.72	6.82	0.52	3.54e-10	IgG glycosylation;
TGCT	cis	rs2153535	0.580	rs1335641	chr6:8487860	G/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs1035144	0.505	rs10145099	chr14:81456694	C/T	cg06600135	chr14:81408086	NA	-0.48	-4.49	-0.37	1.58e-5	Male sexual orientation;
TGCT	cis	rs7937682	0.889	rs558736	chr11:111500760	C/G	cg09085632	chr11:111637200	PPP2R1B	-1.1	-11.55	-0.72	2.12e-21	Primary sclerosing cholangitis;
TGCT	cis	rs7572733	0.534	rs700681	chr2:198711502	C/A	cg00792783	chr2:198669748	PLCL1	0.56	5.08	0.42	1.35e-6	Dermatomyositis;
TGCT	trans	rs4332037	0.624	rs73046339	chr7:1889300	G/A	cg10840412	chr1:235813424	GNG4	0.85	6.68	0.51	7.16e-10	Bipolar disorder;
TGCT	cis	rs2439831	0.850	rs12440573	chr15:44108997	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	6.27	0.49	5.48e-9	Lung cancer in ever smokers;
TGCT	cis	rs137699	1.000	rs760742	chr22:39755190	G/T	cg24399712	chr22:39784796	NA	-0.63	-5.63	-0.45	1.16e-7	IgG glycosylation;
TGCT	cis	rs36051895	0.632	rs12352022	chr9:5161836	T/G	cg02405213	chr9:5042618	JAK2	-0.71	-9.01	-0.63	3.02e-15	Pediatric autoimmune diseases;
TGCT	cis	rs9644630	0.504	rs62496181	chr8:19318989	A/T	cg06699216	chr8:19333253	CSGALNACT1	-0.25	-4.44	-0.37	1.95e-5	Oropharynx cancer;
TGCT	cis	rs1568889	0.877	rs57202579	chr11:28221677	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	7.68	0.57	4.16e-12	Bipolar disorder;
TGCT	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg11764359	chr7:65958608	NA	-0.55	-5.08	-0.42	1.34e-6	Aortic root size;
TGCT	cis	rs2836974	0.653	rs8130556	chr21:40516872	C/T	cg17971929	chr21:40555470	PSMG1	0.98	9.36	0.64	4.55e-16	Cognitive function;
TGCT	cis	rs7666738	0.830	rs1527517	chr4:98931907	C/T	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs5769765	1.000	rs5770742	chr22:50270309	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	1.11	11.76	0.73	6.5e-22	Schizophrenia;
TGCT	trans	rs2243480	1.000	rs2707831	chr7:66062511	G/A	cg07424592	chr7:64974309	NA	1.3	8.23	0.59	2.19e-13	Diabetic kidney disease;
TGCT	cis	rs17376456	0.877	rs12716460	chr5:93416733	A/G	cg25358565	chr5:93447407	FAM172A	0.93	8.45	0.6	6.7e-14	Diabetic retinopathy;
TGCT	cis	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg08564027	chr20:61660810	NA	0.37	6.85	0.52	3.1e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9468199	0.510	rs72845064	chr6:27654970	C/A	cg08851530	chr6:28072375	NA	1.56	7.38	0.55	1.95e-11	Parkinson's disease;
TGCT	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg05368731	chr17:41323189	NBR1	1.21	14.63	0.8	8.89e-29	Menopause (age at onset);
TGCT	cis	rs9291683	0.546	rs6829727	chr4:10051672	A/C	cg11266682	chr4:10021025	SLC2A9	0.61	7.77	0.57	2.57e-12	Bone mineral density;
TGCT	cis	rs9394841	0.692	rs35085306	chr6:41856002	A/G	cg08135965	chr6:41755394	TOMM6	0.56	4.99	0.41	1.98e-6	Mean corpuscular hemoglobin;Red cell distribution width;
TGCT	cis	rs8026198	0.705	rs4583208	chr15:42556757	A/C	cg23803468	chr15:43513504	EPB42	-0.36	-4.76	-0.39	5.38e-6	Fibrinogen levels;
TGCT	trans	rs4332037	0.906	rs6461009	chr7:1952139	T/C	cg10840412	chr1:235813424	GNG4	-1.06	-8.36	-0.6	1.05e-13	Bipolar disorder;
TGCT	cis	rs610932	0.517	rs620612	chr11:59991847	C/T	cg18570331	chr11:60101691	MS4A6E	0.5	4.55	0.38	1.28e-5	Alzheimer's disease;
TGCT	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg22168489	chr12:122356033	WDR66	0.22	4.78	0.39	4.94e-6	Mean corpuscular volume;
TGCT	cis	rs2013441	1.000	rs2526458	chr17:20092200	C/T	cg18979559	chr17:20280153	CCDC144C	-0.44	-4.61	-0.38	9.78e-6	Obesity-related traits;
TGCT	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg04944784	chr2:26401820	FAM59B	-0.68	-6.13	-0.48	1.1e-8	Gut microbiome composition (summer);
TGCT	cis	rs9399135	0.967	rs6908512	chr6:135367757	A/G	cg24558204	chr6:135376177	HBS1L	0.46	4.55	0.38	1.24e-5	Red blood cell count;
TGCT	cis	rs17718580	1.000	rs17718580	chr14:50973632	A/G	cg04730355	chr14:51134070	SAV1	-0.92	-5.17	-0.42	9e-7	Cognitive performance;
TGCT	cis	rs5769765	0.874	rs11703411	chr22:50258751	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	1.08	11.31	0.71	8.31e-21	Schizophrenia;
TGCT	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg05665937	chr4:1216051	CTBP1	0.24	4.63	0.38	8.9e-6	Obesity-related traits;
TGCT	cis	rs1867631	1.000	rs10889636	chr1:67089924	A/G	cg13052034	chr1:66999238	SGIP1	-0.55	-4.75	-0.39	5.5e-6	Menopause (age at onset);
TGCT	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.4	0.44	3.25e-7	Tonsillectomy;
TGCT	cis	rs7726839	0.718	rs6887972	chr5:597274	C/G	cg09021430	chr5:549028	NA	-0.41	-5.83	-0.46	4.48e-8	Obesity-related traits;
TGCT	cis	rs7208859	0.623	rs9899692	chr17:29156939	C/T	cg14008862	chr17:28927542	LRRC37B2	0.75	5.1	0.42	1.26e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs4819052	0.679	rs28623526	chr21:46712324	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	6.34	0.49	3.83e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.68	-5.73	-0.46	7.3e-8	Tonsillectomy;
TGCT	cis	rs2439831	1.000	rs690436	chr15:43761205	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.8	5.7	0.46	8.33e-8	Lung cancer in ever smokers;
TGCT	cis	rs950169	0.840	rs35522895	chr15:84928049	G/A	cg12863693	chr15:85201151	NMB	0.41	4.47	0.37	1.75e-5	Schizophrenia;
TGCT	cis	rs79839061	0.636	rs73207778	chr4:836762	C/T	cg07828340	chr4:882639	GAK	0.36	4.79	0.4	4.71e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7635838	0.892	rs9874535	chr3:11463730	A/G	cg00170343	chr3:11313890	ATG7	0.65	6.17	0.48	8.85e-9	HDL cholesterol;
TGCT	cis	rs12289510	0.539	rs3808995	chr11:124955977	A/G	cg03868193	chr11:124958746	SLC37A2	0.43	6.04	0.48	1.63e-8	Platelet-derived growth factor BB levels;
TGCT	cis	rs9653442	0.564	rs56054309	chr2:100794940	T/C	cg07810366	chr2:100720526	AFF3	-0.34	-5.15	-0.42	9.98e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs546131	0.928	rs535719	chr11:34853382	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.57	5.12	0.42	1.12e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs2692947	0.644	rs1168974	chr2:96814928	G/A	cg22654517	chr2:96458247	NA	0.23	4.86	0.4	3.42e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs4253772	0.530	rs9615958	chr22:46751122	A/G	cg24881330	chr22:46731750	TRMU	1.06	5.5	0.44	2.08e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs4319547	0.876	rs10846978	chr12:122964708	T/C	cg23029597	chr12:123009494	RSRC2	-0.29	-4.87	-0.4	3.34e-6	Body mass index;
TGCT	cis	rs950776	0.714	rs615470	chr15:78885988	T/C	cg06917634	chr15:78832804	PSMA4	-0.65	-5.29	-0.43	5.4e-7	Sudden cardiac arrest;
TGCT	cis	rs208520	0.955	rs12202599	chr6:67001573	A/G	cg07460842	chr6:66804631	NA	0.69	5.83	0.46	4.48e-8	Exhaled nitric oxide output;
TGCT	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.5	-6.94	-0.53	1.89e-10	Alzheimer's disease;
TGCT	cis	rs682748	0.870	rs4643956	chr5:17123497	C/G	cg23987134	chr5:17158319	LOC285696	-0.21	-4.98	-0.41	2.05e-6	Hippocampal atrophy;
TGCT	cis	rs2439831	1.000	rs2245790	chr15:43744457	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.01	8.37	0.6	1.02e-13	Lung cancer in ever smokers;
TGCT	cis	rs523522	0.962	rs4767914	chr12:120993817	C/T	cg27279351	chr12:120934652	DYNLL1	0.76	6.59	0.51	1.15e-9	High light scatter reticulocyte count;
TGCT	cis	rs17490626	0.568	rs12416520	chr10:71211945	A/G	cg12610070	chr10:71211762	TSPAN15	-0.62	-7.23	-0.54	4.32e-11	Thrombosis;
TGCT	cis	rs7017914	0.905	rs3110241	chr8:71932964	C/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-4.97	-0.41	2.16e-6	Bone mineral density;
TGCT	cis	rs2153535	0.541	rs6932434	chr6:8467679	G/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs3087591	0.810	rs2269856	chr17:29482701	C/T	cg24425628	chr17:29625626	OMG;NF1	0.43	6.31	0.49	4.5e-9	Hip circumference;
TGCT	cis	rs2688608	0.620	rs7076525	chr10:75512797	C/T	cg19442545	chr10:75533431	FUT11	-0.36	-5.74	-0.46	6.99e-8	Inflammatory bowel disease;
TGCT	cis	rs72781680	0.821	rs72796361	chr2:24160689	A/T	cg08917208	chr2:24149416	ATAD2B	0.74	4.66	0.39	7.9e-6	Lymphocyte counts;
TGCT	cis	rs1055129	0.560	rs3682	chr17:73942150	A/G	cg08125733	chr17:73851984	WBP2	0.57	5.37	0.43	3.73e-7	White matter hyperintensity burden;
TGCT	cis	rs72781680	0.898	rs72798041	chr2:23953076	T/C	cg08917208	chr2:24149416	ATAD2B	0.95	5.99	0.47	2.12e-8	Lymphocyte counts;
TGCT	cis	rs16866061	1.000	rs7588380	chr2:225341304	A/T	cg12698349	chr2:225449008	CUL3	-0.96	-9.45	-0.65	2.69e-16	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	cis	rs10782582	0.586	rs11161902	chr1:76392498	C/G	cg10523679	chr1:76189770	ACADM	-0.54	-4.89	-0.4	3.03e-6	Daytime sleep phenotypes;
TGCT	cis	rs17376456	0.569	rs2045020	chr5:93224466	T/C	cg25358565	chr5:93447407	FAM172A	-0.81	-6.5	-0.5	1.79e-9	Diabetic retinopathy;
TGCT	cis	rs9325144	0.510	rs7952795	chr12:38720686	C/T	cg26384229	chr12:38710491	ALG10B	0.64	6.0	0.47	2.03e-8	Morning vs. evening chronotype;
TGCT	cis	rs35146811	0.807	rs10228764	chr7:99608029	A/G	cg13334819	chr7:99746414	C7orf59	-0.82	-7.38	-0.55	2.05e-11	Coronary artery disease;
TGCT	cis	rs910187	0.532	rs6066209	chr20:45762795	G/T	cg27589058	chr20:45804311	EYA2	-0.33	-6.08	-0.48	1.35e-8	Migraine;
TGCT	cis	rs2455799	0.613	rs2246960	chr3:15717693	G/A	cg16303742	chr3:15540471	COLQ	-0.25	-4.74	-0.39	5.65e-6	Mean platelet volume;
TGCT	cis	rs523522	1.000	rs523522	chr12:121020250	A/T	cg27279351	chr12:120934652	DYNLL1	0.68	5.74	0.46	6.83e-8	High light scatter reticulocyte count;
TGCT	cis	rs34014631	0.681	rs115614611	chr10:103745041	G/A	cg22630918	chr10:102748988	C10orf2	0.4	4.44	0.37	1.93e-5	Coronary artery calcification;
TGCT	cis	rs763121	0.889	rs6001209	chr22:39121252	C/T	cg06022373	chr22:39101656	GTPBP1	-0.61	-5.09	-0.42	1.28e-6	Menopause (age at onset);
TGCT	cis	rs7590720	0.819	rs6435931	chr2:216892754	C/G	cg12620499	chr2:216877984	MREG	0.9	9.89	0.66	2.3e-17	Alcohol dependence;
TGCT	cis	rs939574	0.790	rs72955444	chr2:220094673	T/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.11	5.34	0.43	4.31e-7	Platelet distribution width;
TGCT	cis	rs7769051	1.000	rs6934161	chr6:133124077	C/T	cg22852734	chr6:133119734	C6orf192	-1.23	-7.35	-0.55	2.28e-11	Type 2 diabetes nephropathy;
TGCT	cis	rs514406	0.825	rs12089511	chr1:53436427	A/T	cg22166914	chr1:53195759	ZYG11B	-0.37	-6.35	-0.5	3.7e-9	Monocyte count;
TGCT	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg03609598	chr5:56110824	MAP3K1	-0.58	-4.7	-0.39	6.72e-6	Initial pursuit acceleration;
TGCT	trans	rs4820792	0.945	rs2017309	chr22:29131426	A/T	cg16744250	chr20:62209504	NA	0.29	6.9	0.53	2.41e-10	Breast size;
TGCT	cis	rs2070488	0.931	rs7630012	chr3:38552250	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.86	-8.57	-0.61	3.38e-14	Electrocardiographic conduction measures;
TGCT	cis	rs10197940	0.662	rs72860233	chr2:152289767	G/A	cg19508488	chr2:152266495	RIF1	0.72	6.56	0.51	1.31e-9	Lung cancer;
TGCT	cis	rs7552404	0.696	rs67487205	chr1:76373756	T/C	cg10523679	chr1:76189770	ACADM	0.84	7.32	0.55	2.77e-11	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg00024416	chr22:24240387	NA	0.25	4.85	0.4	3.64e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	5.03	0.41	1.69e-6	Prudent dietary pattern;
TGCT	cis	rs12986207	0.887	rs7251052	chr19:29897537	A/G	cg09614724	chr19:30719547	NA	-0.64	-4.5	-0.37	1.53e-5	Bulimia nervosa;
TGCT	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg04414720	chr1:150670196	GOLPH3L	0.38	4.85	0.4	3.65e-6	Tonsillectomy;
TGCT	cis	rs6598955	0.543	rs61608823	chr1:26555090	G/A	cg04990556	chr1:26633338	UBXN11	0.8	7.3	0.55	3.01e-11	Obesity-related traits;
TGCT	cis	rs9383153	1.000	rs2073518	chr6:16332730	T/C	cg23850913	chr6:15505452	JARID2	0.97	5.56	0.45	1.55e-7	Gambling;
TGCT	cis	rs174479	0.647	rs174457	chr11:61656975	T/C	cg01500311	chr11:61656094	FADS3	0.29	5.08	0.42	1.34e-6	Sphingolipid levels;
TGCT	cis	rs9653442	0.675	rs1115910	chr2:100647872	A/G	cg22139774	chr2:100720529	AFF3	-0.41	-7.3	-0.55	3e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs9926296	0.682	rs258328	chr16:89730314	C/T	cg03388025	chr16:89894329	SPIRE2	-0.36	-5.33	-0.43	4.49e-7	Vitiligo;
TGCT	cis	rs2180341	1.000	rs6903878	chr6:127638600	C/G	cg24812749	chr6:127587940	RNF146	0.98	7.64	0.57	5.06e-12	Breast cancer;
TGCT	cis	rs7086627	0.515	rs10887896	chr10:82210144	A/C	cg00277334	chr10:82204260	NA	-0.54	-8.46	-0.6	6.41e-14	Post bronchodilator FEV1;
TGCT	cis	rs17401966	0.540	rs11121566	chr1:10472848	C/G	cg19773385	chr1:10388646	KIF1B	-0.23	-5.46	-0.44	2.52e-7	Hepatocellular carcinoma;
TGCT	cis	rs17270561	0.723	rs12213243	chr6:25890108	C/T	cg17691542	chr6:26056736	HIST1H1C	0.88	6.05	0.48	1.56e-8	Iron status biomarkers;
TGCT	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg18765753	chr7:1198926	ZFAND2A	-0.56	-7.1	-0.54	8.67e-11	Longevity;Endometriosis;
TGCT	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg11764359	chr7:65958608	NA	0.59	5.28	0.43	5.64e-7	Aortic root size;
TGCT	cis	rs208520	0.802	rs208496	chr6:66930786	G/C	cg07460842	chr6:66804631	NA	-0.9	-9.16	-0.64	1.34e-15	Exhaled nitric oxide output;
TGCT	cis	rs2228479	0.850	rs62056091	chr16:89930414	G/A	cg06558623	chr16:89946397	TCF25	0.55	4.83	0.4	3.89e-6	Skin colour saturation;
TGCT	cis	rs6138458	1.000	rs6707	chr20:24944166	C/T	cg26195577	chr20:24973756	C20orf3	1.18	11.12	0.71	2.37e-20	Blood protein levels;
TGCT	cis	rs9467773	0.523	rs2498399	chr6:26706544	T/C	cg26531700	chr6:26746687	NA	0.68	6.28	0.49	5.15e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs6688613	1.000	rs6427049	chr1:166956593	C/T	cg07049167	chr1:166818506	POGK	0.21	4.52	0.38	1.43e-5	Refractive astigmatism;
TGCT	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg11062466	chr8:58055876	NA	0.43	4.64	0.38	8.85e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs910187	0.631	rs2228	chr20:45809941	G/A	cg27589058	chr20:45804311	EYA2	-0.38	-8.34	-0.6	1.18e-13	Migraine;
TGCT	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg26039829	chr8:22132926	PIWIL2	0.27	5.12	0.42	1.16e-6	Hypertriglyceridemia;
TGCT	cis	rs6424115	0.830	rs3003333	chr1:24194014	A/T	cg15997130	chr1:24165203	NA	-0.9	-10.58	-0.69	4.95e-19	Immature fraction of reticulocytes;
TGCT	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg08439880	chr3:133502540	NA	-0.31	-5.96	-0.47	2.43e-8	Iron status biomarkers;
TGCT	cis	rs1878931	0.582	rs9937267	chr16:3421073	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.76	6.35	0.5	3.66e-9	Body mass index (adult);
TGCT	cis	rs7565124	0.954	rs7568484	chr2:20255251	A/G	cg00462460	chr2:20212509	MATN3	-0.45	-4.84	-0.4	3.73e-6	Major depressive disorder;
TGCT	cis	rs11874712	0.965	rs11661945	chr18:43672194	T/A	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	5.23	0.42	7.04e-7	Migraine - clinic-based;
TGCT	cis	rs826838	0.934	rs10875647	chr12:38856995	G/A	cg26384229	chr12:38710491	ALG10B	1.06	10.68	0.69	2.84e-19	Heart rate;
TGCT	cis	rs7666738	0.830	rs6833312	chr4:98951356	A/T	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7098414	0.511	rs12262228	chr10:82160425	C/T	cg01528321	chr10:82214614	TSPAN14	0.56	4.98	0.41	2.07e-6	Post bronchodilator FEV1;
TGCT	cis	rs9341808	0.667	rs10943698	chr6:80934301	C/T	cg08355045	chr6:80787529	NA	0.3	4.94	0.41	2.47e-6	Sitting height ratio;
TGCT	cis	rs4680	0.737	rs3810595	chr22:19949644	G/C	cg23601416	chr22:19950040	COMT	-0.39	-5.07	-0.41	1.44e-6	Blood metabolite levels;
TGCT	cis	rs7666738	0.830	rs58367603	chr4:99015350	T/C	cg18180107	chr4:99064573	C4orf37	0.54	5.03	0.41	1.7e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6964587	1.000	rs6956596	chr7:91750107	T/G	cg17063962	chr7:91808500	NA	0.88	9.3	0.64	6.22e-16	Breast cancer;
TGCT	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg08736216	chr1:53307985	ZYG11A	-0.28	-5.53	-0.44	1.83e-7	Monocyte count;
TGCT	cis	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg25427524	chr10:38739819	LOC399744	-0.4	-8.5	-0.61	5.12e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs3902035	0.964	rs17349133	chr6:118998633	C/T	cg07617317	chr6:118971624	C6orf204	0.48	5.52	0.44	1.87e-7	QT interval;
TGCT	cis	rs7772486	0.686	rs1045820	chr6:145947080	C/T	cg23711669	chr6:146136114	FBXO30	0.84	9.16	0.64	1.36e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3772130	0.961	rs11716984	chr3:121362407	A/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.54	4.95	0.41	2.41e-6	Cognitive performance;
TGCT	cis	rs739496	0.579	rs2879603	chr12:112278025	A/G	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs6570726	0.818	rs412350	chr6:145852409	T/C	cg05347473	chr6:146136440	FBXO30	0.53	5.02	0.41	1.78e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs34779708	0.931	rs55724039	chr10:35465397	A/G	cg03585969	chr10:35415529	CREM	0.43	4.52	0.38	1.4e-5	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs11190604	1.000	rs7070776	chr10:102264672	A/G	cg16342193	chr10:102329863	NA	-0.39	-5.01	-0.41	1.83e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9902453	0.808	rs76039587	chr17:28233760	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.81	7.28	0.55	3.32e-11	Coffee consumption (cups per day);
TGCT	cis	rs1008375	0.931	rs6449309	chr4:17573208	C/T	cg18681998	chr4:17616180	MED28	0.84	8.03	0.58	6.49e-13	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4478858	0.684	rs3753374	chr1:31740668	C/T	cg07478791	chr1:31886160	SERINC2	-0.48	-4.6	-0.38	1.05e-5	Alcohol dependence;
TGCT	cis	rs909341	0.909	rs1741708	chr20:62372041	G/T	cg14758556	chr20:62440591	NA	0.3	4.53	0.38	1.38e-5	Atopic dermatitis;
TGCT	cis	rs9914544	1.000	rs28436199	chr17:18751730	C/T	cg26378065	chr17:18585709	ZNF286B	0.54	4.88	0.4	3.19e-6	Educational attainment (years of education);
TGCT	cis	rs7949030	0.695	rs11231161	chr11:62378221	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.69	8.84	0.62	7.84e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg10047753	chr17:41438598	NA	0.96	9.64	0.65	9.37e-17	Menopause (age at onset);
TGCT	trans	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.86	-9.4	-0.65	3.49e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs9837602	0.529	rs1087198	chr3:99524381	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.58	6.71	0.52	6.1e-10	Breast cancer;
TGCT	cis	rs2019216	0.542	rs1850564	chr17:21911794	T/C	cg22648282	chr17:21454238	C17orf51	-0.59	-5.8	-0.46	5.18e-8	Pelvic organ prolapse;
TGCT	cis	rs13217239	0.646	rs10946891	chr6:26973215	T/C	cg26531700	chr6:26746687	NA	0.68	6.79	0.52	4.1e-10	Schizophrenia;
TGCT	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg10047753	chr17:41438598	NA	0.72	7.0	0.53	1.39e-10	Menopause (age at onset);
TGCT	cis	rs4851266	0.966	rs2309838	chr2:100838455	T/C	cg22139774	chr2:100720529	AFF3	-0.34	-5.09	-0.42	1.28e-6	Educational attainment;
TGCT	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg11644478	chr21:40555479	PSMG1	1.03	10.99	0.7	4.96e-20	Cognitive function;
TGCT	cis	rs7100689	0.754	rs10736339	chr10:82059970	G/C	cg01528321	chr10:82214614	TSPAN14	0.8	7.9	0.58	1.29e-12	Post bronchodilator FEV1;
TGCT	cis	rs727563	0.593	rs132770	chr22:42017264	A/G	cg03806693	chr22:41940476	POLR3H	1.06	11.15	0.71	1.99e-20	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg19723775	chr5:179050963	HNRNPH1	-0.52	-5.25	-0.43	6.46e-7	Lung cancer;
TGCT	cis	rs6087990	0.735	rs2424914	chr20:31374520	A/G	cg13636640	chr20:31349939	DNMT3B	0.95	12.38	0.74	2.0500000000000001e-23	Ulcerative colitis;
TGCT	cis	rs1008375	0.932	rs2302391	chr4:17660237	T/C	cg18681998	chr4:17616180	MED28	1.03	11.57	0.72	1.95e-21	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.46	-6.43	-0.5	2.53e-9	Alzheimer's disease;
TGCT	cis	rs7582180	0.629	rs11686649	chr2:100946701	T/C	cg08017756	chr2:100939284	LONRF2	-0.3	-4.87	-0.4	3.27e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6912958	0.781	rs2207146	chr6:88180641	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.54	-5.23	-0.43	7.03e-7	Monocyte percentage of white cells;
TGCT	trans	rs1814175	0.817	rs1996982	chr11:49972619	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.36	-7.14	-0.54	6.88e-11	Height;
TGCT	cis	rs7666738	0.830	rs62321597	chr4:99014221	C/A	cg05340658	chr4:99064831	C4orf37	0.47	5.33	0.43	4.51e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7584330	0.704	rs11884395	chr2:238359366	C/T	cg14458575	chr2:238380390	NA	0.56	8.36	0.6	1.06e-13	Prostate cancer;
TGCT	cis	rs2730245	0.527	rs2527205	chr7:158706393	G/T	cg11984989	chr7:158649758	WDR60	-1.01	-7.85	-0.58	1.65e-12	Height;
TGCT	cis	rs10067451	0.711	rs116552258	chr5:87857702	C/T	cg24804195	chr5:87968844	LOC645323	0.91	4.77	0.39	5.04e-6	Photic sneeze reflex;
TGCT	cis	rs7542091	0.704	rs7537294	chr1:210043777	A/G	cg21951975	chr1:209979733	IRF6	0.6	6.1	0.48	1.24e-8	Monobrow;
TGCT	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg04772025	chr11:68637568	NA	0.61	6.53	0.51	1.51e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	trans	rs4650994	1.000	rs10913572	chr1:178526718	C/T	cg05059571	chr16:84539110	KIAA1609	-0.4	-7.43	-0.56	1.54e-11	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs6754311	0.509	rs3820794	chr2:136505546	C/T	cg07169764	chr2:136633963	MCM6	-0.71	-6.47	-0.5	2.09e-9	Mosquito bite size;
TGCT	cis	rs1691799	0.899	rs1185244	chr12:66725160	C/T	cg16791601	chr12:66731901	HELB	-0.28	-6.17	-0.48	8.77e-9	White blood cell count (basophil);
TGCT	cis	rs12620999	0.941	rs4663701	chr2:238036884	C/T	cg23555395	chr2:238036564	NA	-0.3	-5.21	-0.42	7.5e-7	Systemic lupus erythematosus;
TGCT	cis	rs425277	1.000	rs436045	chr1:2071556	A/G	cg24578937	chr1:2090814	PRKCZ	-0.31	-7.57	-0.56	7.52e-12	Height;
TGCT	cis	rs3808502	0.647	rs7821302	chr8:11236572	T/A	cg21775007	chr8:11205619	TDH	-0.65	-6.39	-0.5	3.07e-9	Neuroticism;
TGCT	cis	rs977747	0.872	rs4926524	chr1:47679258	C/T	cg03885399	chr1:47691550	TAL1	-0.4	-5.15	-0.42	1e-6	Body mass index;
TGCT	cis	rs4478858	0.735	rs34960310	chr1:31816197	A/G	cg00250761	chr1:31883323	NA	-0.28	-4.96	-0.41	2.32e-6	Alcohol dependence;
TGCT	cis	rs4911259	0.593	rs6058924	chr20:31464467	G/A	cg13636640	chr20:31349939	DNMT3B	-0.89	-9.83	-0.66	3.33e-17	Inflammatory bowel disease;
TGCT	cis	rs17030434	0.863	rs17030382	chr4:154650887	A/G	cg14289246	chr4:154710475	SFRP2	-0.88	-6.97	-0.53	1.62e-10	Electrocardiographic conduction measures;
TGCT	cis	rs739496	0.947	rs3803170	chr12:111847740	A/G	cg10833066	chr12:111807467	FAM109A	0.36	5.32	0.43	4.6e-7	Platelet count;
TGCT	cis	rs9300255	0.698	rs4759416	chr12:123746357	C/G	cg00376283	chr12:123451042	ABCB9	0.72	5.54	0.45	1.76e-7	Neutrophil percentage of white cells;
TGCT	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg08627397	chr16:89984028	MC1R	0.32	5.19	0.42	8.18e-7	Vitiligo;
TGCT	cis	rs6558174	0.965	rs4072394	chr8:22490800	C/T	cg03733263	chr8:22462867	KIAA1967	0.67	5.35	0.43	4.11e-7	Breast cancer;
TGCT	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg04944784	chr2:26401820	FAM59B	-0.76	-6.24	-0.49	6.46e-9	Gut microbiome composition (summer);
TGCT	cis	rs4499344	0.730	rs7247597	chr19:33102257	C/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.83	8.63	0.61	2.53e-14	Mean platelet volume;
TGCT	cis	rs6988636	1.000	rs28670850	chr8:124189125	A/G	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs66573146	1.000	rs66573146	chr4:6984464	C/G	cg05069807	chr4:6945702	TBC1D14	0.35	4.94	0.41	2.51e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs10089	0.953	rs4836358	chr5:127376869	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	6.93	0.53	2e-10	Ileal carcinoids;
TGCT	cis	rs6565180	0.962	rs6565182	chr16:30374381	C/T	cg17640201	chr16:30407289	ZNF48	-0.87	-8.21	-0.59	2.4e-13	Tonsillectomy;
TGCT	cis	rs7043114	0.525	rs7869742	chr9:95256174	A/G	cg14311495	chr9:95764742	FGD3	-0.22	-4.49	-0.37	1.6e-5	Height;
TGCT	cis	rs9902453	0.899	rs8067580	chr17:28471248	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	6.39	0.5	3.03e-9	Coffee consumption (cups per day);
TGCT	cis	rs1801251	1.000	rs12987513	chr2:233622066	A/G	cg08000102	chr2:233561755	GIGYF2	0.64	6.45	0.5	2.22e-9	Coronary artery disease;
TGCT	cis	rs526231	0.819	rs26232	chr5:102596720	C/T	cg05225461	chr5:102596755	C5orf30	0.22	4.49	0.37	1.64e-5	Primary biliary cholangitis;
TGCT	cis	rs9486719	1.000	rs2263192	chr6:96873037	C/G	cg18709589	chr6:96969512	KIAA0776	0.71	5.21	0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg16414030	chr3:133502952	NA	-0.61	-9.66	-0.66	8.36e-17	Iron status biomarkers;
TGCT	cis	rs4499344	0.633	rs259260	chr19:33153261	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.85	9.09	0.63	2.01e-15	Mean platelet volume;
TGCT	cis	rs250677	0.652	rs1422582	chr5:148436925	T/C	cg18129178	chr5:148520854	ABLIM3	-0.42	-5.74	-0.46	6.77e-8	Breast cancer;
TGCT	cis	rs12257961	0.549	rs1949435	chr10:15373670	G/T	cg10616319	chr10:15468812	NA	-0.25	-4.51	-0.38	1.46e-5	Selective IgA deficiency;
TGCT	cis	rs3806843	0.966	rs2563264	chr5:140137503	T/G	cg19875535	chr5:140030758	IK	-0.36	-6.17	-0.48	8.74e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs4689388	0.926	rs3889821	chr4:6282596	C/T	cg00701064	chr4:6280414	WFS1	0.45	6.19	0.49	8e-9	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs2239547	0.607	rs9836178	chr3:52925403	T/C	cg11645453	chr3:52864694	ITIH4	-0.36	-5.76	-0.46	6.15e-8	Schizophrenia;
TGCT	cis	rs6448317	0.911	rs10939013	chr4:24903015	G/A	cg21108841	chr4:24914750	CCDC149	0.68	5.58	0.45	1.43e-7	Heschl's gyrus morphology;
TGCT	cis	rs56804039	0.524	rs6982112	chr8:8372376	C/G	cg14215082	chr8:9055850	NA	-0.46	-4.47	-0.37	1.71e-5	Cervical cancer;
TGCT	cis	rs11148252	0.904	rs9526927	chr13:53051627	C/T	cg00495681	chr13:53174319	NA	0.61	6.42	0.5	2.61e-9	Lewy body disease;
TGCT	cis	rs1008375	1.000	rs2159583	chr4:17658838	T/C	cg10189774	chr4:17578691	LAP3	0.57	5.13	0.42	1.07e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg27286337	chr10:134555280	INPP5A	0.42	5.22	0.42	7.35e-7	Migraine;
TGCT	cis	rs62244186	0.566	rs2135531	chr3:44881158	C/G	cg10108389	chr3:44770937	ZNF501	-0.48	-4.82	-0.4	4.2e-6	Depressive symptoms;
TGCT	cis	rs10089	1.000	rs77086350	chr5:127494431	G/A	cg19767477	chr5:127420684	SLC12A2	-0.43	-4.61	-0.38	9.87e-6	Ileal carcinoids;
TGCT	cis	rs12368653	0.693	rs2640610	chr12:58037435	T/A	cg12615879	chr12:58013172	SLC26A10	0.44	5.06	0.41	1.48e-6	Multiple sclerosis;
TGCT	cis	rs9902453	1.000	rs11080114	chr17:28407287	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.76	-6.77	-0.52	4.55e-10	Coffee consumption (cups per day);
TGCT	cis	rs62244186	0.659	rs1806579	chr3:44509281	T/C	cg02073558	chr3:44770973	ZNF501	0.57	5.5	0.44	2.05e-7	Depressive symptoms;
TGCT	cis	rs9913156	0.517	rs2326118	chr17:4611851	C/T	cg00122941	chr17:4613640	ARRB2	0.79	7.1	0.54	8.67e-11	Lymphocyte counts;
TGCT	cis	rs9346649	0.630	rs4708643	chr6:168491681	A/G	cg02770688	chr6:168491649	NA	0.34	6.05	0.48	1.6e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
TGCT	cis	rs7959452	0.590	rs28778648	chr12:69771911	C/A	cg20891283	chr12:69753455	YEATS4	0.83	8.7	0.62	1.68e-14	Blood protein levels;
TGCT	cis	rs3780378	1.000	rs1328918	chr9:5107394	A/G	cg03508284	chr9:4985524	JAK2	-0.5	-4.57	-0.38	1.16e-5	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs9682041	0.622	rs7640791	chr3:170155726	G/C	cg11886554	chr3:170076028	SKIL	0.83	6.08	0.48	1.38e-8	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs7714584	1.000	rs11167521	chr5:150271785	A/G	cg22134413	chr5:150180641	NA	0.78	6.12	0.48	1.16e-8	Crohn's disease;
TGCT	cis	rs2180341	0.814	rs6914131	chr6:127737489	T/C	cg27446573	chr6:127587934	RNF146	0.88	8.07	0.59	5.22e-13	Breast cancer;
TGCT	cis	rs3751972	0.590	rs35106758	chr17:26263783	C/A	cg02948944	chr17:26242737	NA	-0.46	-5.71	-0.46	7.8e-8	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs240764	0.618	rs846778	chr6:101273147	T/C	cg21058520	chr6:100914733	NA	-0.36	-4.58	-0.38	1.12e-5	Neuroticism;
TGCT	cis	rs763121	0.853	rs1569492	chr22:38975511	A/G	cg06022373	chr22:39101656	GTPBP1	-0.72	-7.02	-0.53	1.28e-10	Menopause (age at onset);
TGCT	cis	rs2242116	0.727	rs7635480	chr3:46968227	T/C	cg27129171	chr3:47204927	SETD2	0.66	6.67	0.51	7.46e-10	Birth weight;
TGCT	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg20607798	chr8:58055168	NA	0.62	5.19	0.42	8.32e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6964587	0.677	rs62467839	chr7:91967371	A/G	cg17063962	chr7:91808500	NA	0.81	7.78	0.57	2.45e-12	Breast cancer;
TGCT	cis	rs3862435	0.572	rs2601164	chr15:90908402	A/G	cg14166756	chr15:90894880	ZNF774	0.31	4.99	0.41	2e-6	Response to exercise (triglyceride level interaction);
TGCT	cis	rs7927771	0.826	rs2293578	chr11:47437403	C/T	cg10139015	chr11:47448256	PSMC3	0.52	4.46	0.37	1.78e-5	Subjective well-being;
TGCT	cis	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg22857025	chr5:266934	NA	-0.33	-6.49	-0.5	1.84e-9	Breast cancer;
TGCT	cis	rs17102423	0.723	rs8181938	chr14:65555712	A/G	cg11161011	chr14:65562177	MAX	-0.55	-7.67	-0.57	4.42e-12	Obesity-related traits;
TGCT	cis	rs6940638	0.688	rs9379960	chr6:27121325	A/C	cg26531700	chr6:26746687	NA	-0.54	-4.84	-0.4	3.8e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs854765	0.682	rs13306736	chr17:17740281	C/T	cg09796270	chr17:17721594	SREBF1	-0.25	-4.93	-0.4	2.63e-6	Total body bone mineral density;
TGCT	cis	rs9894429	0.716	rs7405578	chr17:79588306	C/A	cg21028142	chr17:79581711	NPLOC4	0.3	7.03	0.53	1.22e-10	Eye color traits;
TGCT	cis	rs4253772	0.591	rs6008538	chr22:46685963	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.7	5.27	0.43	5.83e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs12681287	0.547	rs56752411	chr8:87515156	C/T	cg19078186	chr8:87526527	CPNE3	-0.36	-4.49	-0.37	1.59e-5	Caudate activity during reward;
TGCT	cis	rs3749237	0.595	rs1464567	chr3:49459252	C/G	cg02487422	chr3:49467188	NICN1	-0.63	-6.55	-0.51	1.37e-9	Resting heart rate;
TGCT	cis	rs1059312	0.932	rs11059916	chr12:129287609	C/A	cg09035930	chr12:129282057	SLC15A4	0.58	11.18	0.71	1.67e-20	Systemic lupus erythematosus;
TGCT	cis	rs6964587	1.000	rs6968870	chr7:91661111	G/C	cg22709100	chr7:91322751	NA	0.28	4.58	0.38	1.11e-5	Breast cancer;
TGCT	cis	rs617219	0.684	rs2896766	chr5:78586493	A/G	cg23514016	chr5:78407564	BHMT	-0.32	-4.86	-0.4	3.43e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs986417	0.901	rs10150982	chr14:60987006	T/G	cg27398547	chr14:60952738	C14orf39	1.42	8.85	0.62	7.44e-15	Gut microbiota (bacterial taxa);
TGCT	cis	rs6558530	0.730	rs10100341	chr8:1723749	A/G	cg09410841	chr8:1729607	CLN8	0.84	9.86	0.66	2.81e-17	Systolic blood pressure;
TGCT	cis	rs10832169	0.901	rs2697820	chr11:14077042	A/T	cg04547675	chr11:13986162	SPON1	0.52	4.72	0.39	6.15e-6	Blood protein levels;
TGCT	cis	rs3776081	0.600	rs56757464	chr5:149530423	G/T	cg18424208	chr5:149546337	CDX1	-0.25	-4.6	-0.38	1.01e-5	Blood protein levels;
TGCT	cis	rs1511802	0.666	rs4862662	chr4:187118662	A/C	cg19358738	chr4:186734530	SORBS2	-0.18	-4.57	-0.38	1.18e-5	Blood protein levels;
TGCT	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg11890956	chr21:40555474	PSMG1	1.11	12.17	0.74	6.69e-23	Cognitive function;
TGCT	cis	rs250677	1.000	rs28173	chr5:148423573	C/T	cg23229984	chr5:148520753	ABLIM3	0.21	5.08	0.41	1.37e-6	Breast cancer;
TGCT	trans	rs62103177	0.535	rs62101568	chr18:77934671	G/A	cg05926928	chr17:57297772	GDPD1	0.8	6.76	0.52	4.84e-10	Opioid sensitivity;
TGCT	cis	rs10876993	0.855	rs10877007	chr12:58100058	T/A	cg15848620	chr12:58087721	OS9	-0.72	-5.98	-0.47	2.25e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs7923609	0.783	rs7907451	chr10:65328740	T/A	cg08743896	chr10:65200160	JMJD1C	0.32	4.46	0.37	1.82e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs17376456	0.825	rs13357713	chr5:93145423	T/C	cg25358565	chr5:93447407	FAM172A	0.9	7.6	0.56	6.43e-12	Diabetic retinopathy;
TGCT	cis	rs6967414	0.681	rs11979878	chr7:6753803	A/G	cg00387323	chr7:6746715	ZNF12	0.77	4.73	0.39	6.05e-6	Hematocrit;Hemoglobin concentration;
TGCT	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg02353165	chr6:42928485	GNMT	-0.62	-5.75	-0.46	6.46e-8	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg06873352	chr17:61820015	STRADA	0.54	5.98	0.47	2.24e-8	Prudent dietary pattern;
TGCT	cis	rs9326248	1.000	rs10790175	chr11:117034729	A/G	cg26566898	chr11:117069891	TAGLN	0.35	4.93	0.41	2.55e-6	Blood protein levels;
TGCT	cis	rs7666738	0.830	rs7689495	chr4:98920152	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.51	0.56	1e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2153535	0.580	rs7767926	chr6:8453557	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.76	0.46	6.39e-8	Motion sickness;
TGCT	cis	rs1670533	0.932	rs13106586	chr4:1054182	G/A	cg27284194	chr4:1044797	NA	0.67	5.79	0.46	5.37e-8	Recombination rate (females);
TGCT	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg02018176	chr4:1364513	KIAA1530	0.29	4.81	0.4	4.22e-6	Longevity;
TGCT	cis	rs2230307	0.536	rs12733952	chr1:100611571	A/G	cg24955406	chr1:100503596	HIAT1	0.72	4.84	0.4	3.84e-6	Carotid intima media thickness;
TGCT	cis	rs7826238	0.517	rs35144760	chr8:8361723	A/G	cg06636001	chr8:8085503	FLJ10661	-0.62	-5.45	-0.44	2.62e-7	Systolic blood pressure;
TGCT	cis	rs9325144	0.555	rs4882359	chr12:38726679	T/C	cg13010199	chr12:38710504	ALG10B	0.52	4.54	0.38	1.32e-5	Morning vs. evening chronotype;
TGCT	cis	rs2295359	0.892	rs11209005	chr1:67618678	A/G	cg03340356	chr1:67600835	NA	0.39	4.67	0.39	7.71e-6	Psoriasis;
TGCT	cis	rs6840360	0.533	rs4696295	chr4:152717430	T/C	cg17479576	chr4:152424074	FAM160A1	0.49	4.84	0.4	3.8e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.55	-6.86	-0.52	2.84e-10	Longevity;Endometriosis;
TGCT	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg04944784	chr2:26401820	FAM59B	-0.67	-6.16	-0.48	9.54e-9	Gut microbiome composition (summer);
TGCT	cis	rs11249608	0.548	rs2047354	chr5:178455247	T/C	cg01312482	chr5:178451176	ZNF879	-0.49	-4.76	-0.39	5.2e-6	Pubertal anthropometrics;
TGCT	cis	rs589249	0.963	rs592799	chr1:37156547	A/G	cg04012535	chr1:37176647	NA	-0.3	-4.93	-0.4	2.58e-6	Neuroticism (multi-trait analysis);Schizophrenia;
TGCT	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg06873352	chr17:61820015	STRADA	0.55	6.13	0.48	1.09e-8	Prudent dietary pattern;
TGCT	cis	rs7674212	0.531	rs4698875	chr4:103933368	T/C	cg16532752	chr4:104119610	CENPE	-0.56	-5.0	-0.41	1.88e-6	Type 2 diabetes;
TGCT	cis	rs9341808	0.667	rs2505944	chr6:80888410	T/C	cg08355045	chr6:80787529	NA	0.3	5.09	0.42	1.27e-6	Sitting height ratio;
TGCT	cis	rs62244186	0.541	rs62244226	chr3:44831831	G/A	cg10108389	chr3:44770937	ZNF501	-0.49	-4.83	-0.4	3.86e-6	Depressive symptoms;
TGCT	cis	rs6912958	0.712	rs2754262	chr6:88405585	A/G	cg06598631	chr6:88300029	RARS2;ORC3L	-0.51	-4.83	-0.4	3.86e-6	Monocyte percentage of white cells;
TGCT	cis	rs13102973	0.720	rs7672296	chr4:135890056	C/G	cg14419869	chr4:135874104	NA	0.26	4.6	0.38	1.03e-5	Subjective well-being;
TGCT	cis	rs7674212	0.510	rs6856593	chr4:104177699	T/C	cg16532752	chr4:104119610	CENPE	-0.52	-4.76	-0.39	5.34e-6	Type 2 diabetes;
TGCT	cis	rs1395	0.922	rs11898114	chr2:27515527	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.47	6.13	0.48	1.09e-8	Blood metabolite levels;
TGCT	cis	rs1018836	0.923	rs10956720	chr8:91576222	C/T	cg16814680	chr8:91681699	NA	-0.91	-10.17	-0.67	5.03e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7714584	0.590	rs4352593	chr5:150269332	T/C	cg22134413	chr5:150180641	NA	0.78	6.12	0.48	1.16e-8	Crohn's disease;
TGCT	cis	rs17767294	0.708	rs72845062	chr6:27653578	C/T	cg08851530	chr6:28072375	NA	1.55	6.56	0.51	1.32e-9	Parkinson's disease;
TGCT	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg16325326	chr1:53192061	ZYG11B	0.61	6.62	0.51	9.84e-10	Monocyte count;
TGCT	cis	rs2658782	0.724	rs2605627	chr11:93259515	A/G	cg15737290	chr11:93063684	CCDC67	0.7	5.24	0.43	6.65e-7	Pulmonary function decline;
TGCT	cis	rs910187	0.678	rs6122564	chr20:45814745	A/C	cg27589058	chr20:45804311	EYA2	-0.35	-7.6	-0.56	6.23e-12	Migraine;
TGCT	cis	rs11785400	0.793	rs13248524	chr8:143739343	T/C	cg10596483	chr8:143751796	JRK	0.55	5.48	0.44	2.29e-7	Schizophrenia;
TGCT	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg06108461	chr20:60628389	TAF4	-0.71	-10.44	-0.68	1.08e-18	Body mass index;
TGCT	cis	rs55794721	0.509	rs12027110	chr1:25775682	A/T	cg23205692	chr1:25664452	TMEM50A	0.48	5.02	0.41	1.74e-6	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs7552404	0.655	rs1146646	chr1:76265500	G/A	cg10523679	chr1:76189770	ACADM	0.68	6.71	0.52	6.24e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.47	0.56	1.28e-11	Prudent dietary pattern;
TGCT	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg13628971	chr7:2884303	GNA12	0.56	4.48	0.37	1.69e-5	Height;
TGCT	cis	rs1580019	0.587	rs7804457	chr7:32557981	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.57	4.98	0.41	2.05e-6	Cognitive ability;
TGCT	cis	rs11249608	0.548	rs6859936	chr5:178451214	T/C	cg01312482	chr5:178451176	ZNF879	-0.56	-5.5	-0.44	2.09e-7	Pubertal anthropometrics;
TGCT	cis	rs67478160	0.584	rs2295147	chr14:104195664	A/G	cg26031613	chr14:104095156	KLC1	0.76	7.57	0.56	7.27e-12	Schizophrenia;
TGCT	trans	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg27523141	chr10:43048294	ZNF37B	0.73	8.5	0.61	5.09e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs1371867	0.875	rs1125706	chr8:101326739	T/A	cg00191853	chr8:101177733	SPAG1	-0.22	-4.47	-0.37	1.75e-5	Atrioventricular conduction;
TGCT	cis	rs7246657	0.943	rs2045908	chr19:37979768	C/G	cg18154014	chr19:37997991	ZNF793	0.69	4.74	0.39	5.76e-6	Coronary artery calcification;
TGCT	cis	rs1008375	0.931	rs979823	chr4:17700176	G/A	cg10189774	chr4:17578691	LAP3	0.53	4.6	0.38	1.04e-5	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs250677	0.522	rs6872172	chr5:148359529	G/C	cg18129178	chr5:148520854	ABLIM3	0.36	4.69	0.39	7.23e-6	Breast cancer;
TGCT	cis	rs11122272	0.735	rs2790873	chr1:231539685	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-6.28	-0.49	5.32e-9	Hemoglobin concentration;
TGCT	cis	rs9393692	0.905	rs989134	chr6:26336224	A/C	cg05868516	chr6:26286170	HIST1H4H	0.58	5.45	0.44	2.63e-7	Educational attainment;
TGCT	trans	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.86	9.38	0.64	3.95e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs2204008	0.685	rs4556621	chr12:38187236	C/A	cg13010199	chr12:38710504	ALG10B	0.62	4.9	0.4	2.87e-6	Bladder cancer;
TGCT	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg23302884	chr18:44338147	ST8SIA5	-0.4	-4.73	-0.39	5.92e-6	Personality dimensions;
TGCT	cis	rs911186	0.740	rs6938200	chr6:27231150	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.57	-4.97	-0.41	2.14e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4242434	0.892	rs34269854	chr8:22465160	G/C	cg21658235	chr8:22456391	C8orf58	0.43	4.47	0.37	1.72e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs9916302	0.706	rs8067511	chr17:37611352	C/T	cg07936489	chr17:37558343	FBXL20	-0.97	-7.39	-0.55	1.87e-11	Glomerular filtration rate (creatinine);
TGCT	cis	rs2562456	0.876	rs11085468	chr19:21751889	C/T	cg01304269	chr19:21688519	ZNF429	0.58	4.84	0.4	3.73e-6	Pain;
TGCT	trans	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg23505145	chr19:12996616	KLF1	0.78	8.12	0.59	4.03e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9383153	1.000	rs2073518	chr6:16332730	T/C	cg18081338	chr6:17212963	NA	0.52	4.95	0.41	2.39e-6	Gambling;
TGCT	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg06618935	chr21:46677482	NA	-0.37	-5.81	-0.46	5.06e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9467711	0.606	rs9358938	chr6:26387546	C/T	cg10795676	chr6:26370623	BTN3A2	-0.48	-4.81	-0.4	4.33e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs3803170	0.513	rs4766572	chr12:111830765	G/A	cg10833066	chr12:111807467	FAM109A	0.36	5.41	0.44	3.09e-7	Mean corpuscular hemoglobin;
TGCT	cis	rs2797160	0.935	rs926855	chr6:126021782	A/G	cg05901451	chr6:126070800	HEY2	0.74	6.21	0.49	7.18e-9	Endometrial cancer;
TGCT	cis	rs4713118	0.955	rs9393848	chr6:27688369	C/T	cg10876282	chr6:28092338	ZSCAN16	0.5	4.67	0.39	7.86e-6	Parkinson's disease;
TGCT	cis	rs9467773	0.620	rs2504599	chr6:26641060	C/T	cg02458000	chr6:26745757	NA	0.52	4.86	0.4	3.41e-6	Intelligence (multi-trait analysis);
TGCT	trans	rs7726839	0.561	rs4957050	chr5:579066	A/C	cg25482853	chr8:67687455	SGK3	1.05	9.29	0.64	6.67e-16	Obesity-related traits;
TGCT	trans	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg27523141	chr10:43048294	ZNF37B	0.7	8.15	0.59	3.36e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg24675658	chr1:53192096	ZYG11B	0.87	11.26	0.71	1.1e-20	Monocyte count;
TGCT	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.37	-4.44	-0.37	1.98e-5	Total body bone mineral density;
TGCT	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg20887711	chr4:1340912	KIAA1530	0.85	7.22	0.54	4.49e-11	Longevity;
TGCT	cis	rs2797160	1.000	rs4897152	chr6:126002400	A/G	cg05901451	chr6:126070800	HEY2	-0.74	-6.3	-0.49	4.62e-9	Endometrial cancer;
TGCT	cis	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg00343986	chr7:65444356	GUSB	-0.24	-5.36	-0.43	3.86e-7	Aortic root size;
TGCT	cis	rs8038465	1.000	rs67257650	chr15:73979507	C/T	cg15420318	chr15:73925796	NPTN	0.69	6.44	0.5	2.36e-9	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7267979	1.000	rs6050564	chr20:25344231	G/A	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6121246	0.559	rs6119652	chr20:30259445	C/G	cg13852791	chr20:30311386	BCL2L1	0.82	8.0	0.58	7.65e-13	Mean corpuscular hemoglobin;
TGCT	cis	rs12039431	0.589	rs61776186	chr1:38011993	G/C	cg17933807	chr1:38061675	GNL2	-0.8	-7.69	-0.57	3.84e-12	Epithelial ovarian cancer;
TGCT	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg08736216	chr1:53307985	ZYG11A	-0.26	-4.99	-0.41	2.02e-6	Monocyte count;
TGCT	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg04772025	chr11:68637568	NA	0.61	6.71	0.52	6.19e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9948	0.655	rs75763821	chr2:97392694	G/A	cg01990225	chr2:97406019	LMAN2L	-1.01	-5.01	-0.41	1.84e-6	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs35306767	0.714	rs67696450	chr10:1090684	C/T	cg26597838	chr10:835615	NA	0.61	7.09	0.54	8.8e-11	Eosinophil percentage of granulocytes;
TGCT	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg11764359	chr7:65958608	NA	0.61	5.53	0.44	1.79e-7	Aortic root size;
TGCT	cis	rs8067545	1.000	rs8071730	chr17:19932731	C/T	cg13482628	chr17:19912719	NA	0.53	4.48	0.37	1.66e-5	Schizophrenia;
TGCT	cis	rs6952808	0.609	rs10232234	chr7:1948110	G/T	cg22963979	chr7:1858916	MAD1L1	-0.36	-5.49	-0.44	2.18e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs7918232	0.941	rs1755399	chr10:27394958	A/G	cg14442939	chr10:27389572	ANKRD26	0.71	5.33	0.43	4.45e-7	Breast cancer;
TGCT	cis	rs9682041	1.000	rs15709	chr3:170110529	T/A	cg11886554	chr3:170076028	SKIL	0.83	6.37	0.5	3.41e-9	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs2439831	0.681	rs1549523	chr15:43624189	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.04	8.86	0.62	7.03e-15	Lung cancer in ever smokers;
TGCT	cis	rs2964802	0.505	rs13159419	chr5:10824302	C/A	cg14521931	chr5:10832172	NA	-0.28	-4.71	-0.39	6.44e-6	Major depressive disorder;Recurrent major depressive disorder;
TGCT	cis	rs13108904	0.604	rs13103860	chr4:1320120	G/A	cg13395646	chr4:1353034	KIAA1530	-0.52	-6.97	-0.53	1.64e-10	Obesity-related traits;
TGCT	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs981844	0.890	rs62325113	chr4:154692555	A/G	cg14289246	chr4:154710475	SFRP2	1.05	9.32	0.64	5.44e-16	Response to statins (LDL cholesterol change);
TGCT	cis	rs1158570	0.814	rs7460225	chr8:131339373	A/G	cg16277922	chr8:131349729	ASAP1	0.5	7.58	0.56	7.07e-12	Platelet count;
TGCT	cis	rs9902453	0.904	rs9905638	chr17:28261022	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.87	8.26	0.6	1.9e-13	Coffee consumption (cups per day);
TGCT	cis	rs3020736	0.500	rs4147640	chr22:42485292	T/C	cg15557168	chr22:42548783	NA	0.22	5.58	0.45	1.47e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7191439	0.790	rs2306046	chr16:88781419	A/G	cg27087555	chr16:88793112	FAM38A	-0.43	-4.87	-0.4	3.4e-6	Plateletcrit;
TGCT	cis	rs7226408	0.842	rs1863615	chr18:34348175	C/T	cg06757138	chr18:34340585	FHOD3	0.24	4.86	0.4	3.54e-6	Obesity-related traits;
TGCT	cis	rs2239547	0.603	rs6805298	chr3:53096552	A/G	cg10802521	chr3:52805072	NEK4	0.6	5.46	0.44	2.52e-7	Schizophrenia;
TGCT	cis	rs2050392	0.858	rs306583	chr10:30710057	C/T	cg18806716	chr10:30721971	MAP3K8	0.45	5.33	0.43	4.45e-7	Inflammatory bowel disease;
TGCT	cis	rs896854	0.517	rs9643353	chr8:95957063	A/G	cg09323728	chr8:95962352	TP53INP1	0.43	5.01	0.41	1.82e-6	Type 2 diabetes;
TGCT	cis	rs208520	1.000	rs72882086	chr6:66976671	G/A	cg07460842	chr6:66804631	NA	0.81	7.16	0.54	6.31e-11	Exhaled nitric oxide output;
TGCT	cis	rs709400	0.859	rs7693	chr14:104023704	C/T	cg26031613	chr14:104095156	KLC1	1.18	16.51	0.83	4.23e-33	Body mass index;
TGCT	cis	rs10865541	0.626	rs2324567	chr2:3386646	C/T	cg01472464	chr2:3383078	TTC15;TSSC1	0.26	4.85	0.4	3.65e-6	Obesity-related traits;
TGCT	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg22963979	chr7:1858916	MAD1L1	-0.36	-5.65	-0.45	1.05e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs9640161	0.783	rs1132261	chr7:150059987	G/A	cg21361702	chr7:150065534	REPIN1	0.51	4.62	0.38	9.46e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs6690583	0.623	rs111687161	chr1:85443533	A/G	cg20280350	chr1:85513789	MCOLN3	-0.67	-4.5	-0.37	1.52e-5	Serum sulfate level;
TGCT	cis	rs9291683	0.527	rs73212848	chr4:10093299	T/C	cg00071950	chr4:10020882	SLC2A9	-0.54	-5.74	-0.46	6.75e-8	Bone mineral density;
TGCT	cis	rs8028182	0.636	rs7184046	chr15:75866150	G/C	cg20655648	chr15:75932815	IMP3	0.57	4.45	0.37	1.9e-5	Sudden cardiac arrest;
TGCT	trans	rs1814175	0.745	rs7483456	chr11:49774613	C/T	cg03929089	chr4:120376271	NA	-0.69	-8.17	-0.59	3.03e-13	Height;
TGCT	trans	rs9859260	0.744	rs419059	chr3:195782184	C/T	cg17074656	chr11:63784126	MACROD1	0.52	6.67	0.51	7.49e-10	Mean corpuscular volume;
TGCT	cis	rs6121246	0.529	rs112367115	chr20:30178627	G/A	cg18721089	chr20:30220636	NA	-0.63	-6.68	-0.51	7.29e-10	Mean corpuscular hemoglobin;
TGCT	cis	rs10193935	0.901	rs222488	chr2:42648570	T/G	cg27598129	chr2:42591480	NA	-0.33	-4.83	-0.4	4.02e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8064299	0.655	rs895691	chr17:72766300	G/T	cg25054828	chr17:72772726	NAT9;TMEM104	0.63	5.8	0.46	5.28e-8	Monocyte count;
TGCT	cis	rs559406	0.623	rs3826557	chr18:12843263	A/T	cg23598886	chr18:12777645	NA	0.38	4.58	0.38	1.12e-5	Psoriasis;
TGCT	cis	rs9527	0.501	rs12244388	chr10:104640052	G/A	cg04362960	chr10:104952993	NT5C2	0.57	4.88	0.4	3.23e-6	Arsenic metabolism;
TGCT	cis	rs7772486	0.875	rs854148	chr6:146310979	G/C	cg23711669	chr6:146136114	FBXO30	0.89	9.5	0.65	2.02e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7552404	1.000	rs7518038	chr1:76154430	G/A	cg03433033	chr1:76189801	ACADM	0.82	9.81	0.66	3.67e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs6088580	0.634	rs6088478	chr20:32971719	T/C	cg08999081	chr20:33150536	PIGU	-0.29	-5.65	-0.45	1.02e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs28595532	0.920	rs115986613	chr4:119752156	G/A	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.52	-4.98	-0.41	2.04e-6	Longevity;Endometriosis;
TGCT	cis	rs2066819	1.000	rs11575232	chr12:56744422	G/A	cg26714650	chr12:56694279	CS	-1.36	-5.89	-0.47	3.4e-8	Psoriasis vulgaris;
TGCT	cis	rs7191439	0.858	rs4238685	chr16:88775220	T/C	cg27087555	chr16:88793112	FAM38A	-0.52	-5.99	-0.47	2.11e-8	Plateletcrit;
TGCT	cis	rs35306767	0.855	rs34251037	chr10:867884	C/T	cg20503657	chr10:835505	NA	0.77	11.28	0.71	9.73e-21	Eosinophil percentage of granulocytes;
TGCT	cis	rs7547997	0.548	rs11264962	chr1:158328294	C/T	cg03528325	chr1:158223921	CD1A	0.38	4.87	0.4	3.34e-6	QRS duration;
TGCT	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.07e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs4671400	0.516	rs1809028	chr2:61413723	A/G	cg15711740	chr2:61764176	XPO1	-0.62	-4.53	-0.38	1.38e-5	3-hydroxypropylmercapturic acid levels in smokers;
TGCT	cis	rs9911578	0.874	rs302874	chr17:56767996	A/G	cg12560992	chr17:57184187	TRIM37	0.74	8.69	0.62	1.77e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs9858542	0.953	rs3811699	chr3:49396360	T/C	cg03060546	chr3:49711283	APEH	-0.64	-5.61	-0.45	1.27e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs11690935	0.959	rs12692973	chr2:172642057	A/G	cg13550731	chr2:172543902	DYNC1I2	1.2	13.02	0.76	5.79e-25	Schizophrenia;
TGCT	cis	rs11105298	0.891	rs10858909	chr12:89935387	C/T	cg00757033	chr12:89920650	WDR51B	0.3	4.71	0.39	6.56e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs734999	0.588	rs6701238	chr1:2520500	G/A	cg18854424	chr1:2615690	NA	0.49	5.72	0.46	7.65e-8	Ulcerative colitis;
TGCT	trans	rs61931739	0.500	rs28624237	chr12:34457171	G/T	cg26384229	chr12:38710491	ALG10B	0.73	6.92	0.53	2.09e-10	Morning vs. evening chronotype;
TGCT	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg01570182	chr17:44337453	NA	1.07	9.81	0.66	3.57e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2120019	0.938	rs13056	chr15:75312187	A/G	cg17294928	chr15:75287854	SCAMP5	-0.79	-6.27	-0.49	5.46e-9	Blood trace element (Zn levels);
TGCT	cis	rs60871478	0.636	rs56393680	chr7:885696	A/G	cg22972055	chr7:872293	UNC84A	0.21	4.46	0.37	1.79e-5	Cerebrospinal P-tau181p levels;
TGCT	cis	rs34014631	0.688	rs36018485	chr10:103581114	T/C	cg22630918	chr10:102748988	C10orf2	0.34	4.56	0.38	1.21e-5	Coronary artery calcification;
TGCT	cis	rs4713118	0.513	rs149958	chr6:28013617	A/C	cg10876282	chr6:28092338	ZSCAN16	0.51	4.75	0.39	5.48e-6	Parkinson's disease;
TGCT	cis	rs6540559	0.546	rs735694	chr1:210034029	T/C	cg21951975	chr1:209979733	IRF6	0.69	5.18	0.42	8.74e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs67478160	0.643	rs12880167	chr14:104300829	C/T	cg26031613	chr14:104095156	KLC1	-0.63	-6.51	-0.5	1.67e-9	Schizophrenia;
TGCT	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg06636001	chr8:8085503	FLJ10661	-0.8	-8.39	-0.6	9.17e-14	Neuroticism;
TGCT	cis	rs9894429	0.646	rs9902264	chr17:79613828	G/A	cg21028142	chr17:79581711	NPLOC4	0.28	5.87	0.47	3.73e-8	Eye color traits;
TGCT	cis	rs12484776	0.729	rs8136149	chr22:40532484	C/T	cg07138101	chr22:40742427	ADSL	0.61	4.6	0.38	1.01e-5	Uterine fibroids;
TGCT	cis	rs651907	0.535	rs11716558	chr3:101528481	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.86	10.47	0.68	9.24e-19	Colorectal cancer;
TGCT	cis	rs7267979	0.739	rs6138555	chr20:25242910	G/A	cg14121845	chr20:25566513	NINL	0.49	4.96	0.41	2.24e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7651736	1.000	rs7651736	chr3:136760598	A/G	cg21827317	chr3:136751795	NA	0.35	4.92	0.4	2.67e-6	Neuroticism;
TGCT	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg25767906	chr1:53392781	SCP2	0.48	5.56	0.45	1.57e-7	Monocyte count;
TGCT	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg04944784	chr2:26401820	FAM59B	-0.67	-6.16	-0.48	9.54e-9	Gut microbiome composition (summer);
TGCT	cis	rs6840360	0.642	rs7676493	chr4:152426765	C/T	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.82e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7940866	0.834	rs2324315	chr11:130839772	C/G	cg05962950	chr11:130786565	SNX19	0.73	7.14	0.54	6.88e-11	Schizophrenia;
TGCT	cis	rs12220898	0.749	rs7905866	chr10:50483552	T/C	cg12697796	chr10:49954016	WDFY4	0.5	4.5	0.37	1.52e-5	Inflammatory biomarkers;
TGCT	cis	rs986417	0.681	rs17097373	chr14:60826810	T/C	cg27398547	chr14:60952738	C14orf39	-1.62	-7.58	-0.56	6.82e-12	Gut microbiota (bacterial taxa);
TGCT	cis	rs782590	0.764	rs2586970	chr2:55829967	A/G	cg18811423	chr2:55921094	PNPT1	0.55	5.72	0.46	7.65e-8	Metabolic syndrome;
TGCT	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.7	6.34	0.49	3.96e-9	Tonsillectomy;
TGCT	cis	rs9467773	1.000	rs1056667	chr6:26510564	T/C	cg15659132	chr6:26577336	NA	0.86	12.18	0.74	6.14e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs9399135	0.636	rs4646871	chr6:135265617	A/G	cg24558204	chr6:135376177	HBS1L	-0.48	-5.21	-0.42	7.59e-7	Red blood cell count;
TGCT	cis	rs17376456	0.825	rs28610997	chr5:93248374	T/C	cg21475434	chr5:93447410	FAM172A	0.69	4.67	0.39	7.58e-6	Diabetic retinopathy;
TGCT	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs12950390	0.530	rs11652510	chr17:45869644	C/G	cg06532163	chr17:45867833	NA	0.31	5.32	0.43	4.68e-7	IgG glycosylation;
TGCT	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.83	0.4	3.88e-6	Electroencephalogram traits;
TGCT	cis	rs6089584	0.821	rs4925332	chr20:60604639	C/T	cg13770153	chr20:60521292	NA	-0.54	-7.21	-0.54	4.83e-11	Body mass index;
TGCT	cis	rs921968	0.643	rs711191	chr2:219386084	T/A	cg02176678	chr2:219576539	TTLL4	0.44	6.33	0.49	4.17e-9	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs6426558	0.537	rs2492630	chr1:227286931	A/G	cg10327440	chr1:227177885	CDC42BPA	0.6	7.29	0.55	3.18e-11	Neutrophil percentage of white cells;
TGCT	cis	rs4727027	0.933	rs12704062	chr7:148827865	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	4.58	0.38	1.13e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs4950928	0.823	rs10920579	chr1:203158972	A/G	cg17014757	chr1:203156097	CHI3L1	-0.37	-4.73	-0.39	5.96e-6	YKL-40 levels;
TGCT	cis	rs3772130	1.000	rs7427165	chr3:121364624	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.54	4.95	0.41	2.41e-6	Cognitive performance;
TGCT	cis	rs13242816	1.000	rs62469031	chr7:116195841	A/G	cg02799643	chr7:116139180	CAV2	-0.41	-5.21	-0.42	7.65e-7	P wave duration;
TGCT	cis	rs514406	0.621	rs2003250	chr1:53196666	T/C	cg24675658	chr1:53192096	ZYG11B	0.84	10.45	0.68	1.03e-18	Monocyte count;
TGCT	cis	rs62244186	0.748	rs12635624	chr3:44678498	G/A	cg04389838	chr3:44770851	ZNF501	-0.39	-5.03	-0.41	1.66e-6	Depressive symptoms;
TGCT	cis	rs639012	0.599	rs472486	chr11:85831690	A/G	cg07180834	chr11:85838833	NA	-0.31	-4.47	-0.37	1.72e-5	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg12310025	chr6:25882481	NA	0.9	9.29	0.64	6.69e-16	Blood metabolite levels;
TGCT	trans	rs57221529	0.563	rs4957057	chr5:569230	C/G	cg11887960	chr12:57824829	NA	1.02	7.74	0.57	3.07e-12	Lung disease severity in cystic fibrosis;
TGCT	cis	rs9952991	0.883	rs2542148	chr18:12777573	C/G	cg23598886	chr18:12777645	NA	0.62	5.78	0.46	5.63e-8	Inflammatory skin disease;
TGCT	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg00149659	chr3:10157352	C3orf10	0.96	6.1	0.48	1.26e-8	Alzheimer's disease;
TGCT	cis	rs12682352	0.715	rs332039	chr8:8723651	C/G	cg15556689	chr8:8085844	FLJ10661	0.57	5.18	0.42	8.87e-7	Neuroticism;
TGCT	cis	rs73198271	0.694	rs73201840	chr8:8647067	G/T	cg06671706	chr8:8559999	CLDN23	-0.35	-4.5	-0.37	1.52e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs56702977	1	rs56702977	chr15:42671308	G/A	cg20699549	chr15:42567973	GANC	0.23	4.44	0.37	1.98e-5	Fibrinogen levels;
TGCT	cis	rs7103648	0.712	rs10838703	chr11:47422861	C/G	cg20307385	chr11:47447363	PSMC3	0.96	10.55	0.69	5.69e-19	Diastolic blood pressure;Systolic blood pressure;
TGCT	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg03264133	chr6:25882463	NA	-0.61	-6.51	-0.5	1.68e-9	Blood metabolite levels;
TGCT	cis	rs72781680	1.000	rs72796328	chr2:24141343	A/G	cg08917208	chr2:24149416	ATAD2B	0.85	5.28	0.43	5.53e-7	Lymphocyte counts;
TGCT	cis	rs7666738	0.800	rs10008654	chr4:98820498	C/A	cg17366294	chr4:99064904	C4orf37	0.7	7.45	0.56	1.42e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg00343986	chr7:65444356	GUSB	0.23	5.14	0.42	1.06e-6	Aortic root size;
TGCT	cis	rs9914988	0.943	rs7215000	chr17:27088436	C/T	cg20469991	chr17:27169893	C17orf63	-0.72	-5.04	-0.41	1.58e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs9894429	0.789	rs35887231	chr17:79587126	G/A	cg18240062	chr17:79603768	NPLOC4	0.84	9.67	0.66	8.03e-17	Eye color traits;
TGCT	cis	rs910316	1.000	rs175443	chr14:75601963	C/T	cg08847533	chr14:75593920	NEK9	-0.94	-10.33	-0.68	2.03e-18	Height;
TGCT	cis	rs1406084	0.636	rs4581850	chr2:154718003	A/C	cg25703346	chr2:154729189	GALNT13	0.77	4.6	0.38	1.03e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg19318889	chr4:1322082	MAEA	0.2	5.04	0.41	1.63e-6	Longevity;
TGCT	cis	rs909674	0.818	rs5757681	chr22:39845547	A/G	cg01416388	chr22:39784598	NA	-0.69	-6.29	-0.49	4.85e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs3749237	0.595	rs4955412	chr3:49418168	A/C	cg07636037	chr3:49044803	WDR6	0.64	6.04	0.48	1.63e-8	Resting heart rate;
TGCT	cis	rs2836974	0.565	rs34304022	chr21:40579619	G/A	cg11890956	chr21:40555474	PSMG1	0.93	6.97	0.53	1.66e-10	Cognitive function;
TGCT	cis	rs7192750	0.586	rs8054175	chr16:71990424	G/A	cg06353428	chr16:71660113	MARVELD3	0.73	6.21	0.49	7.34e-9	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs1008375	0.900	rs13144986	chr4:17675019	C/A	cg16339924	chr4:17578868	LAP3	-0.6	-5.02	-0.41	1.75e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs16867321	0.614	rs12693245	chr2:181445110	T/C	cg23363182	chr2:181467187	NA	0.41	6.04	0.48	1.69e-8	Obesity;
TGCT	trans	rs7618501	0.669	rs2230590	chr3:49936102	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.89	9.83	0.66	3.19e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs2439831	0.867	rs16957630	chr15:43642780	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	8.65	0.61	2.26e-14	Lung cancer in ever smokers;
TGCT	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg22105103	chr4:187893119	NA	0.32	4.51	0.38	1.5e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs56235845	0.964	rs11741640	chr5:176792743	G/A	cg17509989	chr5:176798049	RGS14	0.78	12.32	0.74	2.93e-23	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs12701220	0.847	rs10272002	chr7:1047615	A/G	cg27454412	chr7:1067447	C7orf50	-0.48	-4.44	-0.37	1.98e-5	Bronchopulmonary dysplasia;
TGCT	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg04944784	chr2:26401820	FAM59B	-0.7	-6.49	-0.5	1.89e-9	Gut microbiome composition (summer);
TGCT	cis	rs2120019	1.000	rs2415255	chr15:75332412	A/G	cg11632617	chr15:75315747	PPCDC	-0.3	-4.47	-0.37	1.71e-5	Blood trace element (Zn levels);
TGCT	cis	rs832540	0.801	rs7731700	chr5:56111927	C/T	cg12311346	chr5:56204834	C5orf35	-0.49	-5.13	-0.42	1.08e-6	Coronary artery disease;
TGCT	cis	rs921968	0.643	rs3770218	chr2:219525335	C/T	cg02176678	chr2:219576539	TTLL4	0.38	5.47	0.44	2.34e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs523522	0.962	rs655530	chr12:121022275	T/C	cg12219531	chr12:120966889	COQ5	0.82	7.38	0.55	2.05e-11	High light scatter reticulocyte count;
TGCT	cis	rs864537	0.676	rs1773561	chr1:167421951	C/T	cg22356347	chr1:167427500	CD247	-0.21	-5.34	-0.43	4.24e-7	Celiac disease or Rheumatoid arthritis;Celiac disease;
TGCT	cis	rs9467711	0.651	rs34888489	chr6:26073375	C/A	cg16898833	chr6:26189333	HIST1H4D	1.34	6.07	0.48	1.47e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2663905	0.611	rs2663924	chr15:81392903	T/G	cg09888468	chr15:81410853	NA	-0.61	-5.07	-0.41	1.43e-6	QT interval (drug interaction);
TGCT	cis	rs7586879	0.639	rs7567997	chr2:25096952	A/G	cg15423357	chr2:25149977	NA	0.47	4.56	0.38	1.2e-5	Body mass index;
TGCT	cis	rs9906944	0.864	rs9902512	chr17:47094274	C/G	cg20966754	chr17:47091339	IGF2BP1	-0.43	-4.88	-0.4	3.21e-6	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg08859206	chr1:53392774	SCP2	-0.41	-6.28	-0.49	5.12e-9	Monocyte count;
TGCT	cis	rs9393692	0.875	rs9358917	chr6:26284417	T/C	cg00631329	chr6:26305371	NA	-0.41	-6.09	-0.48	1.34e-8	Educational attainment;
TGCT	cis	rs1371867	0.817	rs1788185	chr8:101335529	T/C	cg06002616	chr8:101225028	SPAG1	-0.56	-6.58	-0.51	1.2e-9	Atrioventricular conduction;
TGCT	cis	rs2013441	1.000	rs4924810	chr17:20071819	T/C	cg18979559	chr17:20280153	CCDC144C	0.44	4.61	0.38	9.78e-6	Obesity-related traits;
TGCT	cis	rs60843830	1.000	rs62114501	chr2:231741	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.73	6.93	0.53	1.99e-10	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs478304	0.651	rs10896038	chr11:65505528	G/C	cg17480646	chr11:65405466	SIPA1	-0.57	-6.95	-0.53	1.84e-10	Acne (severe);
TGCT	trans	rs324780	0.504	rs3110191	chr12:83909897	A/G	cg27144766	chr5:150604977	CCDC69	0.24	6.63	0.51	9.42e-10	Vertical cup-disc ratio;
TGCT	cis	rs3027009	0.881	rs56184975	chr1:159149253	G/T	cg18972751	chr1:158261555	CD1C	-0.46	-4.81	-0.4	4.27e-6	Lean body mass and age at menarche (combined);
TGCT	cis	rs4149423	1.000	rs12620050	chr2:108919798	G/A	cg25838818	chr2:108905173	SULT1C2	-0.43	-7.22	-0.54	4.58e-11	Lobe size;
TGCT	cis	rs17376456	0.569	rs10067754	chr5:93093110	T/A	cg21475434	chr5:93447410	FAM172A	0.61	4.95	0.41	2.35e-6	Diabetic retinopathy;
TGCT	cis	rs7582180	0.614	rs4850931	chr2:101005145	C/T	cg14675211	chr2:100938903	LONRF2	0.51	4.85	0.4	3.6e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs644799	0.710	rs564480	chr11:95561741	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.78	8.58	0.61	3.3e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9911578	1.000	rs12936058	chr17:57017420	T/C	cg05425664	chr17:57184151	TRIM37	-0.62	-6.18	-0.49	8.33e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7267979	0.586	rs6050429	chr20:25183058	G/A	cg14121845	chr20:25566513	NINL	0.45	4.88	0.4	3.23e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs12497850	1.000	rs4858798	chr3:48727112	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.49	-4.67	-0.39	7.79e-6	Parkinson's disease;
TGCT	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.4	0.44	3.25e-7	Tonsillectomy;
TGCT	cis	rs11718455	0.767	rs6771202	chr3:43990087	A/T	cg08738300	chr3:44038990	NA	0.74	5.62	0.45	1.22e-7	Coronary artery disease;
TGCT	cis	rs7772486	0.727	rs4896843	chr6:146063451	T/C	cg05347473	chr6:146136440	FBXO30	-0.53	-4.91	-0.4	2.81e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1801251	1.000	rs778166	chr2:233664097	A/T	cg25237894	chr2:233734115	C2orf82	0.31	5.49	0.44	2.17e-7	Coronary artery disease;
TGCT	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg13683864	chr3:40499215	RPL14	-1.19	-13.2	-0.76	2.17e-25	Renal cell carcinoma;
TGCT	cis	rs8180040	0.620	rs2305635	chr3:47043622	G/A	cg27129171	chr3:47204927	SETD2	-0.7	-8.36	-0.6	1.09e-13	Colorectal cancer;
TGCT	cis	rs9527	0.590	rs10883820	chr10:104764661	A/C	cg15744005	chr10:104629667	AS3MT	0.42	4.92	0.4	2.74e-6	Arsenic metabolism;
TGCT	cis	rs66573146	0.831	rs56031152	chr4:6973832	C/A	cg05069807	chr4:6945702	TBC1D14	0.32	5.01	0.41	1.83e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs13424612	1.000	rs10189996	chr2:240908800	G/A	cg26363272	chr2:240904871	NDUFA10	0.29	4.85	0.4	3.58e-6	Odorant perception (isobutyraldehyde);
TGCT	cis	rs1865760	0.602	rs9467662	chr6:26021327	G/A	cg16482183	chr6:26056742	HIST1H1C	0.56	4.78	0.39	4.96e-6	Height;
TGCT	cis	rs9549260	0.620	rs12583418	chr13:41195411	G/A	cg21288729	chr13:41239152	FOXO1	1.0	10.25	0.68	3.06e-18	Red blood cell count;
TGCT	cis	rs4700695	0.719	rs27077	chr5:65445342	C/T	cg21114390	chr5:65439923	SFRS12	0.84	7.56	0.56	7.85e-12	Facial morphology (factor 19);
TGCT	cis	rs7819412	0.745	rs2898260	chr8:10939490	G/T	cg21775007	chr8:11205619	TDH	-0.51	-4.92	-0.4	2.64e-6	Triglycerides;
TGCT	cis	rs9902453	0.765	rs3102560	chr17:28029938	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.84	8.39	0.6	9.14e-14	Coffee consumption (cups per day);
TGCT	cis	rs899997	0.862	rs57260218	chr15:78973772	C/T	cg04896959	chr15:78267971	NA	-0.32	-4.57	-0.38	1.18e-5	Coronary artery disease or large artery stroke;
TGCT	cis	rs6840360	0.571	rs11931934	chr4:152552082	A/G	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.0	-0.58	7.69e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs2013441	1.000	rs2703778	chr17:20138900	T/C	cg18979559	chr17:20280153	CCDC144C	-0.45	-4.67	-0.39	7.61e-6	Obesity-related traits;
TGCT	cis	rs9814567	0.806	rs4074522	chr3:134325626	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.77	6.92	0.53	2.15e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs3820068	0.581	rs58425551	chr1:15922518	A/G	cg05660106	chr1:15850417	CASP9	0.83	8.29	0.6	1.58e-13	Systolic blood pressure;
TGCT	cis	rs7666738	0.830	rs13140676	chr4:98804978	C/T	cg05340658	chr4:99064831	C4orf37	0.49	5.75	0.46	6.46e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2239547	0.522	rs9831409	chr3:52985711	A/T	cg10802521	chr3:52805072	NEK4	0.64	6.06	0.48	1.48e-8	Schizophrenia;
TGCT	cis	rs12681288	0.676	rs2701901	chr8:1017816	G/C	cg04851639	chr8:1020857	NA	-0.36	-6.79	-0.52	4.13e-10	Schizophrenia;
TGCT	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg01341218	chr17:43662625	NA	1.11	9.34	0.64	5.11e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs10088262	0.591	rs13270541	chr8:124794849	G/A	cg20713898	chr8:124780851	FAM91A1	-0.84	-7.19	-0.54	5.3e-11	Pancreatic cancer;
TGCT	cis	rs950880	0.542	rs1558621	chr2:102930307	A/G	cg09003973	chr2:102972529	NA	-0.53	-4.69	-0.39	6.95e-6	Serum protein levels (sST2);
TGCT	cis	rs6964587	1.000	rs7784248	chr7:91758111	A/G	cg17063962	chr7:91808500	NA	0.87	9.26	0.64	7.86e-16	Breast cancer;
TGCT	cis	rs11648796	0.757	rs3809666	chr16:764753	C/G	cg07343612	chr16:622815	PIGQ	-0.35	-4.99	-0.41	2.01e-6	Height;
TGCT	cis	rs3096299	0.781	rs2965819	chr16:89501030	G/T	cg02187348	chr16:89574699	SPG7	-0.58	-6.18	-0.49	8.34e-9	Multiple myeloma (IgH translocation);
TGCT	cis	rs6500602	0.627	rs709632	chr16:4587811	C/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	-0.39	-5.7	-0.46	8.2e-8	Schizophrenia;
TGCT	cis	rs13191362	1.000	rs28360546	chr6:163210973	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.76	4.8	0.4	4.57e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	trans	rs1496653	0.557	rs34443476	chr3:23350466	G/C	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs28374715	0.578	rs17730888	chr15:41637547	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.94	-15.72	-0.82	2.7e-31	Ulcerative colitis;
TGCT	cis	rs1801251	0.711	rs2592117	chr2:233735693	C/T	cg25237894	chr2:233734115	C2orf82	-0.29	-5.63	-0.45	1.14e-7	Coronary artery disease;
TGCT	cis	rs6427419	0.934	rs6427420	chr1:158066834	A/G	cg07184316	chr1:157669111	FCRL3	0.26	4.86	0.4	3.52e-6	Obesity-related traits;
TGCT	cis	rs11098499	0.909	rs28571712	chr4:120375980	G/A	cg09307838	chr4:120376055	NA	0.68	6.53	0.51	1.54e-9	Corneal astigmatism;
TGCT	cis	rs727505	1.000	rs68091803	chr7:124526331	C/T	cg23710748	chr7:124431027	NA	-0.26	-4.49	-0.37	1.6e-5	Lewy body disease;
TGCT	cis	rs7772486	0.790	rs7753833	chr6:146161432	C/A	cg05347473	chr6:146136440	FBXO30	0.51	4.79	0.4	4.67e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs12900413	0.562	rs2118849	chr15:90302399	G/T	cg24249390	chr15:90295951	MESP1	-0.3	-5.2	-0.42	8.04e-7	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs2228479	0.681	rs3212346	chr16:89982358	G/A	cg06558623	chr16:89946397	TCF25	0.44	5.91	0.47	3.15e-8	Skin colour saturation;
TGCT	cis	rs3776081	0.537	rs58746386	chr5:149530269	T/C	cg18424208	chr5:149546337	CDX1	-0.25	-4.64	-0.38	8.8e-6	Blood protein levels;
TGCT	cis	rs912057	0.965	rs1294409	chr6:6738355	A/G	cg06612196	chr6:6737390	NA	-0.41	-5.11	-0.42	1.17e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs11195062	0.805	rs10884942	chr10:112016926	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.27	-4.69	-0.39	7.01e-6	Multiple myeloma;
TGCT	cis	rs4851254	0.920	rs11123816	chr2:100783653	G/A	cg23118464	chr2:100721844	AFF3	0.6	4.48	0.37	1.67e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.716	rs9994641	chr4:99101605	C/T	cg17366294	chr4:99064904	C4orf37	0.66	6.58	0.51	1.2e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs4824093	0.610	rs73443923	chr22:50285348	C/T	cg20569369	chr22:51173646	NA	0.32	5.29	0.43	5.29e-7	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs1577917	0.771	rs9294337	chr6:86248460	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.61	5.32	0.43	4.64e-7	Response to antipsychotic treatment;
TGCT	cis	rs12579753	0.879	rs12829053	chr12:82161926	T/A	cg21231944	chr12:82153410	PPFIA2	-0.34	-4.63	-0.38	8.95e-6	Resting heart rate;
TGCT	cis	rs12135062	0.687	rs6685614	chr1:3108517	C/T	cg21609526	chr1:3105151	PRDM16	0.34	5.4	0.44	3.32e-7	Migraine;
TGCT	cis	rs3796352	1.000	rs13092352	chr3:52969697	C/T	cg07884673	chr3:53033167	SFMBT1	0.6	5.53	0.44	1.82e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs1577917	0.740	rs9450302	chr6:86289673	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.54	4.91	0.4	2.86e-6	Response to antipsychotic treatment;
TGCT	cis	rs9818758	0.607	rs34580506	chr3:49113713	C/A	cg07636037	chr3:49044803	WDR6	-1.04	-5.16	-0.42	9.65e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs11098499	0.908	rs11098527	chr4:120399906	A/G	cg09307838	chr4:120376055	NA	0.69	6.64	0.51	8.97e-10	Corneal astigmatism;
TGCT	cis	rs2439831	0.850	rs28509275	chr15:44098105	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	5.03	0.41	1.69e-6	Lung cancer in ever smokers;
TGCT	cis	rs614226	1.000	rs541126	chr12:120972396	C/T	cg01236616	chr12:121019343	POP5	-1.26	-13.2	-0.76	2.23e-25	Type 1 diabetes nephropathy;
TGCT	cis	rs78456975	0.628	rs13426896	chr2:1554768	C/T	cg12573674	chr2:1569213	NA	-0.48	-4.76	-0.39	5.23e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs804280	0.565	rs1466785	chr8:11623456	C/T	cg26752888	chr8:11627280	NEIL2	-0.55	-4.99	-0.41	1.99e-6	Myopia (pathological);
TGCT	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg00684032	chr4:1343700	KIAA1530	0.23	4.95	0.41	2.36e-6	Obesity-related traits;
TGCT	cis	rs3820928	0.874	rs10166736	chr2:227900419	C/T	cg11843606	chr2:227700838	RHBDD1	-0.55	-4.96	-0.41	2.26e-6	Pulmonary function;
TGCT	cis	rs8141529	0.764	rs5752807	chr22:29223169	A/G	cg02153584	chr22:29168773	CCDC117	0.66	5.64	0.45	1.08e-7	Lymphocyte counts;
TGCT	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg01802117	chr1:53393560	SCP2	-0.48	-5.77	-0.46	6.09e-8	Monocyte count;
TGCT	cis	rs10197940	0.578	rs6718653	chr2:152346118	C/A	cg06191203	chr2:152266755	RIF1	-0.61	-5.14	-0.42	1.03e-6	Lung cancer;
TGCT	cis	rs55794721	0.509	rs12027135	chr1:25775733	A/T	cg09222892	chr1:25734099	RHCE	-0.42	-6.97	-0.53	1.68e-10	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs2637266	0.745	rs2579732	chr10:78442778	T/C	cg18941641	chr10:78392320	NA	0.37	4.47	0.37	1.73e-5	Pulmonary function;
TGCT	cis	rs7100689	0.646	rs11202751	chr10:82147802	G/A	cg01528321	chr10:82214614	TSPAN14	0.79	7.93	0.58	1.11e-12	Post bronchodilator FEV1;
TGCT	cis	rs9303401	0.614	rs34058624	chr17:57118121	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.65	6.06	0.48	1.54e-8	Cognitive test performance;
TGCT	cis	rs7113874	0.569	rs4929942	chr11:8625096	A/G	cg14521421	chr11:8862019	ST5	-0.31	-4.8	-0.4	4.44e-6	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs1348850	0.757	rs4893969	chr2:178478476	T/A	cg22681709	chr2:178499509	PDE11A	-0.47	-5.59	-0.45	1.35e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs71435601	0.600	rs572246	chr2:21385149	T/C	cg25035485	chr2:21266500	APOB	0.51	4.48	0.37	1.64e-5	Cholesterol, total;
TGCT	cis	rs12136530	0.593	rs4911990	chr1:19731873	A/C	cg24875000	chr1:19041556	PAX7	-0.25	-4.48	-0.37	1.66e-5	Lead levels in blood;
TGCT	cis	rs4478858	0.684	rs7521463	chr1:31761936	T/A	cg07478791	chr1:31886160	SERINC2	-0.49	-4.91	-0.4	2.82e-6	Alcohol dependence;
TGCT	cis	rs3806843	0.576	rs246045	chr5:140329884	C/T	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs10940138	0.779	rs62370675	chr5:67247975	G/A	ch.5.1281357F	chr5:67228439	NA	0.41	4.75	0.39	5.63e-6	Menarche (age at onset);
TGCT	cis	rs796364	0.756	rs2949006	chr2:200715388	T/G	cg17644776	chr2:200775616	C2orf69	0.29	4.49	0.37	1.58e-5	Schizophrenia;
TGCT	cis	rs6424115	0.679	rs2267961	chr1:24071048	A/G	cg15997130	chr1:24165203	NA	-0.67	-6.16	-0.48	9.48e-9	Immature fraction of reticulocytes;
TGCT	cis	rs7429990	0.932	rs12486714	chr3:48148700	C/G	cg11946769	chr3:48343235	NME6	-0.56	-4.63	-0.38	9.27e-6	Educational attainment (years of education);
TGCT	cis	rs78366141	0.649	rs7674009	chr4:89683324	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	-1.02	-5.28	-0.43	5.65e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
TGCT	cis	rs2228479	0.618	rs62052174	chr16:89950901	G/A	cg19635926	chr16:89946313	TCF25	0.28	4.8	0.4	4.47e-6	Skin colour saturation;
TGCT	cis	rs9443645	0.901	rs9343844	chr6:79586463	T/A	cg05283184	chr6:79620031	NA	-0.21	-4.71	-0.39	6.61e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2050392	0.624	rs303444	chr10:30729347	C/T	cg13289132	chr10:30722225	MAP3K8	-0.46	-5.61	-0.45	1.27e-7	Inflammatory bowel disease;
TGCT	trans	rs7726839	0.561	rs56410216	chr5:583216	C/A	cg11887960	chr12:57824829	NA	0.98	7.81	0.57	2.09e-12	Obesity-related traits;
TGCT	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg19748678	chr4:122722346	EXOSC9	0.9	9.35	0.64	4.81e-16	Type 2 diabetes;
TGCT	cis	rs7635838	0.617	rs346075	chr3:11294027	T/G	cg00170343	chr3:11313890	ATG7	0.64	6.43	0.5	2.5e-9	HDL cholesterol;
TGCT	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg17554472	chr22:41940697	POLR3H	-0.49	-5.27	-0.43	5.9e-7	Vitiligo;
TGCT	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg22029157	chr1:209979665	IRF6	0.81	6.42	0.5	2.67e-9	Cleft lip with or without cleft palate;
TGCT	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.95	7.54	0.56	8.47e-12	Platelet count;
TGCT	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.45	-5.37	-0.43	3.72e-7	Alzheimer's disease;
TGCT	cis	rs10197940	0.648	rs7587301	chr2:152347600	A/G	cg06191203	chr2:152266755	RIF1	-0.61	-5.16	-0.42	9.68e-7	Lung cancer;
TGCT	cis	rs79518236	1	rs79518236	chr7:98026554	ACT/A	cg09267113	chr7:98030324	BAIAP2L1	-0.95	-8.89	-0.62	5.83e-15	Breast cancer;
TGCT	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg03303774	chr4:1407052	NA	0.38	6.07	0.48	1.45e-8	Obesity-related traits;
TGCT	cis	rs739496	0.527	rs11066090	chr12:112365523	T/C	cg10833066	chr12:111807467	FAM109A	0.38	5.61	0.45	1.24e-7	Platelet count;
TGCT	cis	rs7172809	0.573	rs11854182	chr15:77448977	T/C	cg22256960	chr15:77711686	NA	-0.48	-4.63	-0.38	9.17e-6	Glucose homeostasis traits;
TGCT	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg03517284	chr6:25882590	NA	-0.65	-5.81	-0.46	4.87e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9902453	0.765	rs2447935	chr17:28057524	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.84	-8.39	-0.6	9.14e-14	Coffee consumption (cups per day);
TGCT	cis	rs6840360	1.000	rs12502055	chr4:152596668	G/A	cg17479576	chr4:152424074	FAM160A1	-0.5	-5.4	-0.44	3.26e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs992157	0.835	rs34353396	chr2:219153982	T/C	cg00012203	chr2:219082015	ARPC2	-0.8	-7.98	-0.58	8.26e-13	Colorectal cancer;
TGCT	cis	rs10791097	0.592	rs7116068	chr11:130732739	A/C	cg14779329	chr11:130786720	SNX19	-0.26	-4.59	-0.38	1.09e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs7772486	0.743	rs1292339	chr6:145967086	C/T	cg23711669	chr6:146136114	FBXO30	-0.8	-8.47	-0.61	5.92e-14	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3809566	0.597	rs9806545	chr15:63328490	C/T	cg00520135	chr15:63333846	TPM1	-0.42	-5.16	-0.42	9.55e-7	Platelet count;
TGCT	cis	rs854765	0.663	rs1108648	chr17:17750558	G/A	cg09796270	chr17:17721594	SREBF1	-0.3	-5.85	-0.46	4.18e-8	Total body bone mineral density;
TGCT	cis	rs9329289	0.510	rs28579610	chr10:2546080	C/A	cg07014206	chr10:2547000	NA	-0.28	-4.66	-0.39	8.13e-6	Age-related hearing impairment;
TGCT	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	6.23	0.49	6.56e-9	Bipolar disorder;
TGCT	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg07061783	chr6:25882402	NA	0.64	6.7	0.52	6.57e-10	Blood metabolite levels;
TGCT	cis	rs7666738	0.791	rs17549003	chr4:98969132	A/C	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2832191	0.967	rs2251377	chr21:30530599	T/C	cg24692254	chr21:30365293	RNF160	0.75	7.4	0.55	1.78e-11	Dental caries;
TGCT	cis	rs7523050	0.643	rs12741359	chr1:109400489	T/C	cg08274380	chr1:109419600	GPSM2	1.3	6.39	0.5	2.99e-9	Fat distribution (HIV);
TGCT	cis	rs231513	0.954	rs231497	chr17:41975947	A/G	cg26893861	chr17:41843967	DUSP3	-0.71	-5.29	-0.43	5.46e-7	Cognitive function;
TGCT	cis	rs6912958	0.516	rs242278	chr6:88047059	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.47	6.29	0.49	5.04e-9	Monocyte percentage of white cells;
TGCT	cis	rs7647973	0.961	rs4955430	chr3:49378088	G/A	cg07636037	chr3:49044803	WDR6	0.72	5.84	0.46	4.25e-8	Menarche (age at onset);
TGCT	cis	rs3733585	0.605	rs7656624	chr4:10121097	T/C	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.6	-0.51	1.08e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs28374715	0.578	rs7165914	chr15:41632451	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.9	-14.93	-0.8	1.76e-29	Ulcerative colitis;
TGCT	cis	rs492146	0.765	rs672281	chr6:52844045	G/A	cg06706454	chr6:52930286	FBXO9	-0.51	-4.66	-0.39	8.12e-6	Epilepsy (remission after treatment);
TGCT	cis	rs1371867	0.846	rs1660347	chr8:101314980	G/A	cg06002616	chr8:101225028	SPAG1	-0.56	-6.58	-0.51	1.2e-9	Atrioventricular conduction;
TGCT	cis	rs7666738	0.830	rs58696666	chr4:99006913	C/T	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7809950	0.784	rs7803102	chr7:107248929	T/G	cg23024343	chr7:107201750	COG5	0.33	5.23	0.42	7.11e-7	Coronary artery disease;
TGCT	cis	rs12477438	1.000	rs12466388	chr2:99916538	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.97	-8.78	-0.62	1.12e-14	Chronic sinus infection;
TGCT	cis	rs12049351	0.774	rs754022	chr1:229637645	C/A	cg12130225	chr1:229698885	NA	0.39	4.58	0.38	1.12e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs6433857	0.536	rs1542035	chr2:181351114	T/C	cg23363182	chr2:181467187	NA	-0.32	-4.85	-0.4	3.59e-6	Body mass index;
TGCT	cis	rs9325144	0.600	rs12424410	chr12:38758035	A/T	cg26384229	chr12:38710491	ALG10B	-0.62	-5.77	-0.46	5.9e-8	Morning vs. evening chronotype;
TGCT	cis	rs2637266	1.000	rs2894339	chr10:78354104	G/A	cg18941641	chr10:78392320	NA	0.4	5.01	0.41	1.81e-6	Pulmonary function;
TGCT	trans	rs208520	0.837	rs208488	chr6:66926902	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.97	-10.05	-0.67	9.41e-18	Exhaled nitric oxide output;
TGCT	cis	rs7918232	0.627	rs10829165	chr10:27319465	A/G	cg14442939	chr10:27389572	ANKRD26	0.56	4.67	0.39	7.8e-6	Breast cancer;
TGCT	cis	rs11731606	0.508	rs17376943	chr4:95277117	G/A	cg00507259	chr4:95128692	SMARCAD1	0.65	4.89	0.4	3.02e-6	Mean platelet volume;
TGCT	cis	rs9894429	1.000	rs9674872	chr17:79581931	T/A	cg21028142	chr17:79581711	NPLOC4	0.29	6.81	0.52	3.83e-10	Eye color traits;
TGCT	cis	rs950169	1.000	rs34751999	chr15:84758419	T/C	cg17173187	chr15:85201210	NMB	0.47	5.23	0.43	7.01e-7	Schizophrenia;
TGCT	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg11494091	chr17:61959527	GH2	0.6	14.54	0.79	1.46e-28	Prudent dietary pattern;
TGCT	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg21862992	chr11:68658383	NA	0.49	6.79	0.52	4.13e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9926296	0.581	rs1108064	chr16:89894150	G/C	cg04287289	chr16:89883240	FANCA	0.68	6.76	0.52	4.83e-10	Vitiligo;
TGCT	cis	rs5760092	0.755	rs5760096	chr22:24247310	A/G	cg00024416	chr22:24240387	NA	-0.29	-5.18	-0.42	8.65e-7	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs6061231	0.834	rs2427311	chr20:60970123	A/G	cg24112000	chr20:60950667	NA	-0.35	-4.79	-0.4	4.58e-6	Colorectal cancer;
TGCT	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg00343986	chr7:65444356	GUSB	-0.23	-5.16	-0.42	9.66e-7	Aortic root size;
TGCT	cis	rs7412746	0.658	rs11589458	chr1:150792616	A/G	cg04414720	chr1:150670196	GOLPH3L	0.42	5.35	0.43	4.06e-7	Melanoma;
TGCT	cis	rs694419	0.602	rs9951519	chr18:60166419	G/C	cg13506219	chr18:60193840	ZCCHC2	-0.54	-4.84	-0.4	3.86e-6	Serum albumin level;
TGCT	cis	rs1846974	1	rs1846974	chr5:87969927	G/A	cg24804195	chr5:87968844	LOC645323	0.77	4.58	0.38	1.11e-5	Body mass index;
TGCT	cis	rs9916302	0.706	rs9893735	chr17:37469858	A/C	cg07936489	chr17:37558343	FBXL20	0.84	6.23	0.49	6.68e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs367615	0.704	rs7726991	chr5:108847434	C/T	cg17395555	chr5:108820864	NA	0.31	5.86	0.47	3.94e-8	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs55720021	1	rs55720021	chr19:49144241	G/T	cg07996880	chr19:49339085	HSD17B14	0.27	4.58	0.38	1.09e-5	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;
TGCT	cis	rs4523957	0.583	rs2641444	chr17:2037402	T/C	cg16513277	chr17:2031491	SMG6	-0.2	-4.58	-0.38	1.13e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs556990	0.574	rs473598	chr13:113801189	C/T	cg00619561	chr13:112980676	NA	-0.29	-4.79	-0.4	4.67e-6	Blood protein levels;
TGCT	cis	rs9346649	0.933	rs9364398	chr6:168489433	G/T	cg02770688	chr6:168491649	NA	-0.27	-4.9	-0.4	2.92e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
TGCT	cis	rs9611519	0.964	rs2092563	chr22:41592677	G/A	cg13695892	chr22:41940480	POLR3H	-0.51	-4.56	-0.38	1.22e-5	Neuroticism;
TGCT	cis	rs80282103	0.618	rs17155886	chr10:1145182	A/G	cg18964960	chr10:1102726	WDR37	0.98	4.57	0.38	1.15e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs17068510	0.572	rs11779787	chr8:3883394	C/T	cg25338036	chr8:3047536	CSMD1	-0.44	-4.57	-0.38	1.18e-5	Cerebrospinal fluid clusterin levels;
TGCT	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg11494091	chr17:61959527	GH2	-0.61	-15.24	-0.81	3.34e-30	Prudent dietary pattern;
TGCT	cis	rs950169	0.840	rs62029595	chr15:84955301	C/T	cg12863693	chr15:85201151	NMB	0.45	4.96	0.41	2.28e-6	Schizophrenia;
TGCT	trans	rs8073060	0.855	rs12150450	chr17:33868896	A/T	cg19694781	chr19:47549865	TMEM160	0.42	7.72	0.57	3.37e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs2204008	0.905	rs7294297	chr12:38442573	T/C	cg26384229	chr12:38710491	ALG10B	0.83	7.46	0.56	1.32e-11	Bladder cancer;
TGCT	cis	rs12134133	0.752	rs57003024	chr1:207404344	T/C	cg02152968	chr1:207494213	CD55	0.69	4.75	0.39	5.46e-6	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg22166914	chr1:53195759	ZYG11B	0.42	7.25	0.55	3.97e-11	Monocyte count;
TGCT	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg13395646	chr4:1353034	KIAA1530	-0.48	-6.31	-0.49	4.59e-9	Obesity-related traits;
TGCT	cis	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg07424592	chr7:64974309	NA	-1.27	-7.84	-0.58	1.8e-12	Diabetic kidney disease;
TGCT	cis	rs1075232	0.826	rs60333545	chr15:31807319	G/C	cg01030201	chr15:31746330	NA	-1.07	-5.86	-0.47	3.84e-8	Survival in colorectal cancer (non-distant metastatic);
TGCT	cis	rs2204008	0.641	rs66876045	chr12:38205713	G/A	cg26384229	chr12:38710491	ALG10B	0.86	7.68	0.57	4.17e-12	Bladder cancer;
TGCT	cis	rs17221829	0.528	rs2860553	chr11:89355296	A/G	cg02982614	chr11:89391479	FOLH1B	-0.27	-4.65	-0.39	8.2e-6	Anxiety in major depressive disorder;
TGCT	trans	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg21659725	chr3:3221576	CRBN	0.75	9.02	0.63	2.97e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs17473412	1.000	rs79535450	chr5:122713989	C/T	cg15125798	chr5:122621645	NA	-0.57	-5.13	-0.42	1.08e-6	Total body bone mineral density;
TGCT	cis	rs10489202	0.583	rs201539	chr1:167995407	A/G	cg24449463	chr1:168025552	DCAF6	-0.6	-7.13	-0.54	7.21e-11	Schizophrenia;
TGCT	trans	rs561341	1.000	rs560132	chr17:30320019	C/T	cg20587970	chr11:113659929	NA	-1.03	-12.17	-0.74	6.53e-23	Hip circumference adjusted for BMI;
TGCT	cis	rs9926296	0.632	rs9935559	chr16:89800529	C/T	cg08627397	chr16:89984028	MC1R	0.3	4.75	0.39	5.52e-6	Vitiligo;
TGCT	cis	rs6424115	1.000	rs12031592	chr1:24127864	A/C	cg15997130	chr1:24165203	NA	0.89	10.03	0.67	1.08e-17	Immature fraction of reticulocytes;
TGCT	cis	rs447735	0.537	rs7190341	chr16:89917537	T/C	cg04287289	chr16:89883240	FANCA	0.68	6.18	0.49	8.39e-9	Hemoglobin concentration;
TGCT	cis	rs2440129	0.611	rs10852889	chr17:6900845	C/T	cg02493798	chr17:6899577	ALOX12	0.43	4.91	0.4	2.87e-6	Tonsillectomy;
TGCT	cis	rs6088580	0.634	rs4911153	chr20:32961547	C/T	cg06115741	chr20:33292138	TP53INP2	-0.53	-4.75	-0.39	5.59e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs698813	0.674	rs11678787	chr2:44496315	C/T	cg00619915	chr2:44497795	NA	-0.24	-5.52	-0.44	1.91e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
TGCT	cis	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg15556689	chr8:8085844	FLJ10661	0.66	6.12	0.48	1.15e-8	Mood instability;
TGCT	cis	rs611744	0.647	rs1584373	chr8:109263399	C/A	cg21045802	chr8:109455806	TTC35	0.7	7.05	0.54	1.07e-10	Dupuytren's disease;
TGCT	trans	rs17685	0.587	rs1623759	chr7:75724679	A/T	cg19862616	chr7:65841803	NCRNA00174	0.49	7.91	0.58	1.24e-12	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs7584330	0.910	rs6737914	chr2:238393434	A/G	cg08992911	chr2:238395768	MLPH	0.64	5.24	0.43	6.81e-7	Prostate cancer;
TGCT	cis	rs6969780	0.722	rs983185	chr7:27188607	G/A	cg03724423	chr7:27170755	HOXA4	-0.46	-4.74	-0.39	5.86e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs892961	0.932	rs11657725	chr17:75405501	G/C	cg05865280	chr17:75406074	SEPT9	0.29	6.76	0.52	4.91e-10	Airflow obstruction;
TGCT	cis	rs28493229	0.522	rs2287692	chr19:41289756	G/A	cg00475131	chr19:41117096	LTBP4	0.29	4.49	0.37	1.61e-5	Kawasaki disease;
TGCT	cis	rs6987853	0.966	rs1901282	chr8:42392942	C/G	cg20539142	chr8:42623718	CHRNA6	-0.21	-5.03	-0.41	1.69e-6	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg04944784	chr2:26401820	FAM59B	-0.76	-6.34	-0.49	3.94e-9	Gut microbiome composition (summer);
TGCT	cis	rs9916302	0.653	rs4239223	chr17:37717004	T/C	cg03321784	chr17:37729644	NA	0.44	4.58	0.38	1.1e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs2153535	0.580	rs9505446	chr6:8448691	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.76	0.46	6.39e-8	Motion sickness;
TGCT	cis	rs7666738	0.830	rs28615340	chr4:98896922	T/C	cg17366294	chr4:99064904	C4orf37	0.67	6.83	0.52	3.3e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs617219	0.710	rs16876598	chr5:78573970	T/C	cg23987322	chr5:78407566	BHMT	-0.35	-4.69	-0.39	7.07e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg16680214	chr1:154839983	KCNN3	-0.35	-7.11	-0.54	8.04e-11	Prostate cancer;
TGCT	cis	rs17607347	0.505	rs62051129	chr16:72453470	G/A	cg06220725	chr16:72042591	DHODH	-0.71	-4.71	-0.39	6.65e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg24829409	chr8:58192753	C8orf71	-0.55	-5.17	-0.42	9.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9926296	0.535	rs36022917	chr16:89893238	A/G	cg01719998	chr16:89642051	CPNE7	-0.44	-4.46	-0.37	1.81e-5	Vitiligo;
TGCT	trans	rs561341	0.883	rs7406056	chr17:30220224	C/T	cg20587970	chr11:113659929	NA	-0.8	-9.56	-0.65	1.44e-16	Hip circumference adjusted for BMI;
TGCT	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg00814883	chr7:100076585	TSC22D4	-0.52	-5.14	-0.42	1.06e-6	Lung function (FEV1/FVC);
TGCT	cis	rs9549367	0.789	rs12584981	chr13:113881185	T/C	cg18105134	chr13:113819100	PROZ	-0.34	-5.45	-0.44	2.63e-7	Platelet distribution width;
TGCT	cis	rs10791323	0.519	rs329663	chr11:133754543	A/G	cg03690763	chr11:133734501	NA	-0.31	-5.33	-0.43	4.52e-7	Childhood ear infection;
TGCT	cis	rs259282	0.813	rs259250	chr19:33149216	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.78	7.59	0.56	6.8e-12	Schizophrenia;
TGCT	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg08439880	chr3:133502540	NA	-0.31	-5.97	-0.47	2.29e-8	Iron status biomarkers;
TGCT	cis	rs2710642	0.962	rs2058567	chr2:63091426	T/C	cg17519650	chr2:63277830	OTX1	0.67	6.13	0.48	1.1e-8	LDL cholesterol levels;LDL cholesterol;
TGCT	cis	rs9467773	0.620	rs2451731	chr6:26624822	A/C	cg02458000	chr6:26745757	NA	0.53	5.02	0.41	1.76e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6988636	1.000	rs59834873	chr8:124188824	G/T	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs7681440	0.904	rs1822217	chr4:90765052	C/T	cg01966878	chr4:90757139	SNCA	-0.25	-4.56	-0.38	1.2e-5	Dementia with Lewy bodies;
TGCT	cis	rs13040088	0.872	rs13039291	chr20:61572760	C/T	cg23096297	chr20:61557774	DIDO1	1.18	9.71	0.66	6.5e-17	Menopause (age at onset);
TGCT	cis	rs4819052	0.851	rs2838866	chr21:46713014	G/C	cg06618935	chr21:46677482	NA	-0.35	-5.57	-0.45	1.49e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7246657	0.722	rs16958861	chr19:38124179	G/A	cg03611452	chr19:38183253	ZNF781	0.59	4.78	0.39	4.95e-6	Coronary artery calcification;
TGCT	cis	rs2486012	0.737	rs541487	chr1:44283909	G/A	cg12908607	chr1:44402522	ARTN	-0.69	-5.2	-0.42	7.81e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs12681287	0.605	rs2976181	chr8:87344470	C/T	cg27223183	chr8:87520930	FAM82B	-0.67	-4.99	-0.41	1.97e-6	Caudate activity during reward;
TGCT	cis	rs17784882	0.524	rs7433300	chr3:47120640	G/A	cg27129171	chr3:47204927	SETD2	0.67	7.72	0.57	3.33e-12	QT interval;
TGCT	cis	rs9527	0.590	rs7087459	chr10:104790999	T/C	cg15744005	chr10:104629667	AS3MT	-0.41	-4.8	-0.4	4.43e-6	Arsenic metabolism;
TGCT	cis	rs7917772	0.599	rs2863717	chr10:104519829	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.57	-4.62	-0.38	9.3e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	trans	rs62103177	0.525	rs9949598	chr18:77753037	G/A	cg05926928	chr17:57297772	GDPD1	-0.74	-6.66	-0.51	7.78e-10	Opioid sensitivity;
TGCT	cis	rs6032067	0.673	rs991048	chr20:43898227	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	0.45	6.77	0.52	4.51e-10	Blood protein levels;
TGCT	trans	rs13270892	0.556	rs76217929	chr8:20472368	C/A	cg14551562	chr9:130461838	NA	-0.91	-6.7	-0.52	6.41e-10	Daytime sleep phenotypes;
TGCT	cis	rs3806843	0.966	rs2563266	chr5:140136915	C/A	cg19875535	chr5:140030758	IK	-0.37	-6.32	-0.49	4.29e-9	Depressive symptoms (multi-trait analysis);
TGCT	trans	rs9329221	0.741	rs56243511	chr8:9805695	T/C	cg06636001	chr8:8085503	FLJ10661	-0.77	-6.93	-0.53	2.06e-10	Neuroticism;
TGCT	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg03452623	chr4:187889614	NA	-0.37	-5.56	-0.45	1.57e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg08045932	chr20:61659980	NA	0.48	9.28	0.64	7.07e-16	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs919433	0.713	rs2045245	chr2:198485341	A/C	cg00792783	chr2:198669748	PLCL1	0.53	5.03	0.41	1.64e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs9467773	1.000	rs4713008	chr6:26538268	T/C	cg09904177	chr6:26538194	HMGN4	0.65	6.53	0.51	1.53e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs9733	0.519	rs10788792	chr1:150638572	T/G	cg04414720	chr1:150670196	GOLPH3L	0.39	5.04	0.41	1.58e-6	Tonsillectomy;
TGCT	cis	rs10504229	1.000	rs59708460	chr8:58196526	G/A	cg21724239	chr8:58056113	NA	0.38	4.75	0.39	5.6e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10949834	0.529	rs7785826	chr7:73548785	C/A	cg07137043	chr7:73588983	EIF4H	-0.67	-4.61	-0.38	9.97e-6	Verbal memory performance (residualized delayed recall change);
TGCT	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg11644478	chr21:40555479	PSMG1	0.88	8.03	0.59	6.26e-13	Cognitive function;
TGCT	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg14773178	chr5:1868261	NA	0.34	5.87	0.47	3.78e-8	Cardiovascular disease risk factors;
TGCT	cis	rs67478160	0.619	rs2368560	chr14:104273311	C/T	cg26031613	chr14:104095156	KLC1	-0.63	-6.42	-0.5	2.64e-9	Schizophrenia;
TGCT	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.59	-5.94	-0.47	2.66e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs250677	0.687	rs250671	chr5:148446523	T/C	cg23229984	chr5:148520753	ABLIM3	0.21	4.89	0.4	3.11e-6	Breast cancer;
TGCT	cis	rs10927875	0.894	rs34957618	chr1:16320499	G/C	cg14742211	chr1:16348397	CLCNKA	-0.19	-4.48	-0.37	1.66e-5	Dilated cardiomyopathy;
TGCT	cis	rs28595532	0.841	rs116452272	chr4:119770802	T/C	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs10131894	0.575	rs6574203	chr14:75429846	T/C	cg06637938	chr14:75390232	RPS6KL1	0.56	4.81	0.4	4.26e-6	Coronary artery disease;
TGCT	cis	rs12497850	0.931	rs9311432	chr3:48850443	T/A	cg05785598	chr3:49045655	WDR6	0.35	4.72	0.39	6.35e-6	Parkinson's disease;
TGCT	cis	rs11190604	1.000	rs2273694	chr10:102256496	G/T	cg16342193	chr10:102329863	NA	-0.41	-5.3	-0.43	5.07e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9910055	0.550	rs113844752	chr17:42297631	C/A	cg19774624	chr17:42201019	HDAC5	-0.72	-6.64	-0.51	8.87e-10	Total body bone mineral density;
TGCT	cis	rs7937682	0.924	rs501089	chr11:111502479	G/T	cg09085632	chr11:111637200	PPP2R1B	1.0	9.51	0.65	1.98e-16	Primary sclerosing cholangitis;
TGCT	cis	rs7639513	0.591	rs9849171	chr3:12622623	G/C	cg23032965	chr3:12705835	RAF1	0.75	8.04	0.59	5.95e-13	Itch intensity from mosquito bite;
TGCT	cis	rs752010	0.523	rs10890159	chr1:42118282	A/G	cg06885757	chr1:42089581	HIVEP3	0.26	4.73	0.39	6.1e-6	Lupus nephritis in systemic lupus erythematosus;
TGCT	cis	rs933688	0.536	rs332537	chr5:90794973	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.97	-6.22	-0.49	6.96e-9	Smoking behavior;
TGCT	cis	rs3540	0.512	rs3930162	chr15:91075129	C/T	cg22089800	chr15:90895588	ZNF774	-0.74	-7.58	-0.56	7.14e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg25703541	chr22:24373054	LOC391322	0.81	8.47	0.61	5.88e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg08736216	chr1:53307985	ZYG11A	-0.28	-5.53	-0.44	1.83e-7	Monocyte count;
TGCT	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg05552183	chr6:42928497	GNMT	-0.53	-4.76	-0.39	5.35e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg03517284	chr6:25882590	NA	-0.61	-5.6	-0.45	1.31e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1371867	0.846	rs1660346	chr8:101312497	A/G	cg00191853	chr8:101177733	SPAG1	-0.22	-4.47	-0.37	1.75e-5	Atrioventricular conduction;
TGCT	cis	rs1670533	1.000	rs633556	chr4:1092405	A/G	cg27284194	chr4:1044797	NA	0.69	5.97	0.47	2.36e-8	Recombination rate (females);
TGCT	cis	rs700651	0.789	rs5007118	chr2:198909738	G/C	cg00792783	chr2:198669748	PLCL1	0.6	5.2	0.42	8.05e-7	Intracranial aneurysm;
TGCT	trans	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg17830980	chr10:43048298	ZNF37B	-0.81	-10.13	-0.67	6.19e-18	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7635838	0.964	rs7624086	chr3:11412620	C/G	cg00170343	chr3:11313890	ATG7	0.57	5.42	0.44	2.92e-7	HDL cholesterol;
TGCT	cis	rs9393692	0.905	rs9393693	chr6:26277408	C/A	cg05868516	chr6:26286170	HIST1H4H	0.56	5.35	0.43	4.01e-7	Educational attainment;
TGCT	cis	rs7249142	0.549	rs3787040	chr19:19297292	A/G	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.54	5.41	0.44	3.13e-7	IgG glycosylation;
TGCT	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg27436995	chr16:743998	FBXL16	-0.47	-5.12	-0.42	1.15e-6	Height;
TGCT	cis	rs11112613	0.713	rs11112587	chr12:105941285	G/A	cg03607813	chr12:105948248	NA	0.46	5.27	0.43	5.83e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	cis	rs11671005	0.735	rs11084544	chr19:58940127	C/G	cg13877915	chr19:58951672	ZNF132	0.65	5.13	0.42	1.09e-6	Mean platelet volume;
TGCT	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg25703541	chr22:24373054	LOC391322	-0.93	-10.82	-0.7	1.29e-19	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7845219	0.544	rs4735330	chr8:95917770	A/C	cg13393036	chr8:95962371	TP53INP1	-0.44	-5.14	-0.42	1.05e-6	Type 2 diabetes;
TGCT	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	7.26	0.55	3.73e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2439831	1.000	rs2251538	chr15:43767209	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.01	8.37	0.6	1.02e-13	Lung cancer in ever smokers;
TGCT	cis	rs2235642	0.821	rs2281236	chr16:1603576	G/A	cg07639376	chr16:1584516	IFT140;TMEM204	-0.33	-5.85	-0.46	4.15e-8	Coronary artery disease;
TGCT	cis	rs13202913	0.652	rs9383578	chr6:151838192	C/T	cg03627880	chr6:151815985	C6orf97	-0.55	-5.35	-0.43	4.1e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs7772486	0.875	rs2748490	chr6:146329681	G/T	cg05347473	chr6:146136440	FBXO30	0.49	4.7	0.39	6.88e-6	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs6089829	0.962	rs57684920	chr20:61662639	G/A	cg23505145	chr19:12996616	KLF1	-0.8	-8.25	-0.6	1.99e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7917772	0.502	rs2296584	chr10:104244323	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs4568518	0.530	rs4721672	chr7:17986098	T/C	cg03009463	chr7:17980271	SNX13	0.57	4.61	0.38	1e-5	Measles;
TGCT	cis	rs7945705	0.837	rs2742474	chr11:9002089	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.52	-6.01	-0.47	1.93e-8	Hemoglobin concentration;
TGCT	cis	rs7914558	0.966	rs11191518	chr10:104782853	C/G	cg05855489	chr10:104503620	C10orf26	0.51	4.48	0.37	1.67e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs4494114	0.967	rs9438976	chr1:39353386	C/T	cg25970120	chr1:39325951	RRAGC	-0.6	-6.19	-0.49	8.1e-9	Blood protein levels;
TGCT	cis	rs3008870	1.000	rs2985821	chr1:67403787	G/A	cg11518657	chr1:67396239	MIER1	0.54	4.68	0.39	7.24e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs11785400	1.000	rs4736342	chr8:143735190	A/G	cg24634471	chr8:143751801	JRK	0.55	6.04	0.48	1.68e-8	Schizophrenia;
TGCT	cis	rs4509693	0.782	rs7897782	chr10:102495856	C/A	cg24127310	chr10:102502104	NA	0.7	5.86	0.47	3.84e-8	Alzheimer's disease;
TGCT	cis	rs9394841	0.667	rs3827633	chr6:41759846	A/C	cg08135965	chr6:41755394	TOMM6	0.55	5.15	0.42	9.77e-7	Mean corpuscular hemoglobin;Red cell distribution width;
TGCT	cis	rs6582630	0.502	rs3902522	chr12:38271203	T/C	cg13010199	chr12:38710504	ALG10B	0.59	4.61	0.38	9.88e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs763121	0.853	rs2413546	chr22:39107001	G/A	cg06022373	chr22:39101656	GTPBP1	0.74	7.23	0.54	4.37e-11	Menopause (age at onset);
TGCT	cis	rs4975616	0.869	rs452932	chr5:1330253	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.28	-6.88	-0.53	2.69e-10	Lung cancer;
TGCT	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg17554472	chr22:41940697	POLR3H	0.49	5.16	0.42	9.72e-7	Vitiligo;
TGCT	cis	rs763121	0.819	rs5757133	chr22:38947835	A/G	cg06022373	chr22:39101656	GTPBP1	-0.77	-7.79	-0.57	2.27e-12	Menopause (age at onset);
TGCT	cis	rs9467773	1.000	rs6930120	chr6:26555484	A/G	cg26531700	chr6:26746687	NA	0.49	4.73	0.39	6.06e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg05985448	chr10:134359359	INPP5A	0.23	5.11	0.42	1.2e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs2304206	0.614	rs12104272	chr19:50148052	A/G	cg09250473	chr19:50168907	IRF3;BCL2L12	-0.77	-7.59	-0.56	6.52e-12	Vitiligo;
TGCT	cis	rs1005277	0.522	rs1208684	chr10:38093936	G/A	cg25427524	chr10:38739819	LOC399744	-0.32	-6.45	-0.5	2.22e-9	Extrinsic epigenetic age acceleration;
TGCT	cis	rs919433	0.679	rs7600862	chr2:198534514	C/T	cg00792783	chr2:198669748	PLCL1	0.55	4.93	0.4	2.56e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs713587	0.934	rs6738433	chr2:25159501	G/C	cg15423357	chr2:25149977	NA	0.58	5.85	0.46	4.18e-8	Body mass index in non-asthmatics;
TGCT	cis	rs7845219	0.539	rs13271644	chr8:95853948	A/G	cg13393036	chr8:95962371	TP53INP1	-0.49	-5.8	-0.46	5.25e-8	Type 2 diabetes;
TGCT	cis	rs9926296	0.656	rs11861084	chr16:89875710	G/T	cg04287289	chr16:89883240	FANCA	-0.71	-7.02	-0.53	1.3100000000000001e-10	Vitiligo;
TGCT	cis	rs7267979	0.816	rs1044573	chr20:25206654	A/G	cg03522245	chr20:25566470	NINL	0.47	4.53	0.38	1.35e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1008375	1.000	rs6848360	chr4:17634442	G/T	cg10189774	chr4:17578691	LAP3	0.65	5.64	0.45	1.08e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6701037	0.566	rs13373754	chr1:175139275	C/A	cg00321850	chr1:175162397	KIAA0040	0.38	5.04	0.41	1.61e-6	Alcohol dependence;
TGCT	cis	rs72781680	0.706	rs72796108	chr2:23904990	C/A	cg08917208	chr2:24149416	ATAD2B	1.0	5.56	0.45	1.59e-7	Lymphocyte counts;
TGCT	cis	rs2066819	1.000	rs59626664	chr12:56636975	C/G	cg26714650	chr12:56694279	CS	-1.32	-6.2	-0.49	7.69e-9	Psoriasis vulgaris;
TGCT	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	8.39	0.6	9.03e-14	Platelet count;
TGCT	cis	rs4727027	0.631	rs62507511	chr7:148796080	C/A	cg23583168	chr7:148888333	NA	-0.68	-8.44	-0.6	6.95e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg08736216	chr1:53307985	ZYG11A	-0.3	-6.06	-0.48	1.48e-8	Monocyte count;
TGCT	cis	rs12510870	0.566	rs9999939	chr4:74454004	C/T	cg05868023	chr4:75230803	EREG	-0.55	-4.74	-0.39	5.71e-6	Iris color (b* coordinate);
TGCT	cis	rs6835098	0.962	rs10014010	chr4:174083230	C/T	cg08422745	chr4:174089978	GALNT7	-0.93	-10.95	-0.7	6.1e-20	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs6565180	0.888	rs12447833	chr16:30390314	T/C	cg17640201	chr16:30407289	ZNF48	0.92	8.6	0.61	2.9e-14	Tonsillectomy;
TGCT	cis	rs7829975	0.577	rs79495969	chr8:8545250	G/A	cg06636001	chr8:8085503	FLJ10661	-0.61	-5.17	-0.42	9.06e-7	Mood instability;
TGCT	cis	rs2952156	1.000	rs1565923	chr17:37858678	A/G	cg19468946	chr17:37922297	IKZF3	-0.21	-4.76	-0.39	5.26e-6	Asthma;
TGCT	cis	rs9811920	0.809	rs6440967	chr3:99722396	G/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.46	-5.18	-0.42	8.59e-7	Axial length;
TGCT	cis	rs9682041	0.696	rs13067560	chr3:170094190	G/A	cg11886554	chr3:170076028	SKIL	0.61	4.78	0.39	4.77e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg02788857	chr8:22132959	PIWIL2	0.28	5.15	0.42	9.82e-7	Hypertriglyceridemia;
TGCT	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	trans	rs8073060	0.544	rs1080352	chr17:34002362	A/G	cg19694781	chr19:47549865	TMEM160	-0.6	-13.37	-0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs3784262	0.669	rs2414527	chr15:58256672	A/G	cg12031962	chr15:58353849	ALDH1A2	0.42	6.17	0.48	8.88e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs6964587	1.000	rs2282974	chr7:91761617	G/A	cg22709100	chr7:91322751	NA	0.29	4.7	0.39	6.9e-6	Breast cancer;
TGCT	cis	rs7474896	0.609	rs1830612	chr10:37999883	A/G	cg25427524	chr10:38739819	LOC399744	-0.31	-4.89	-0.4	3.01e-6	Obesity (extreme);
TGCT	cis	rs2836974	0.897	rs2776308	chr21:40715175	A/G	cg06238570	chr21:40685208	BRWD1	0.67	5.84	0.46	4.4e-8	Cognitive function;
TGCT	cis	rs28595532	0.920	rs114414928	chr4:119728188	T/C	cg21605333	chr4:119757512	SEC24D	1.66	8.33	0.6	1.28e-13	Cannabis dependence symptom count;
TGCT	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg22920501	chr2:26401640	FAM59B	0.81	6.36	0.5	3.52e-9	Mean corpuscular hemoglobin;
TGCT	trans	rs797680	0.964	rs797668	chr1:93694789	C/G	cg27528825	chr2:159282178	CCDC148	0.34	6.7	0.52	6.63e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs763121	0.853	rs6519120	chr22:38991393	A/C	cg06022373	chr22:39101656	GTPBP1	-0.78	-7.44	-0.56	1.48e-11	Menopause (age at onset);
TGCT	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg20007245	chr22:24372913	LOC391322	-0.74	-7.41	-0.55	1.71e-11	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs17221829	0.733	rs10765227	chr11:89385116	A/G	cg02982614	chr11:89391479	FOLH1B	-0.25	-4.46	-0.37	1.8e-5	Anxiety in major depressive disorder;
TGCT	cis	rs1044826	0.619	rs6439856	chr3:139134868	A/T	cg00490450	chr3:139108681	COPB2	-0.53	-4.56	-0.38	1.2e-5	Obesity-related traits;
TGCT	cis	rs2120019	0.786	rs12911421	chr15:75287822	C/A	cg09165964	chr15:75287851	SCAMP5	1.19	12.85	0.76	1.48e-24	Blood trace element (Zn levels);
TGCT	cis	rs1552244	0.554	rs2272118	chr3:10049287	T/C	cg00149659	chr3:10157352	C3orf10	0.69	4.99	0.41	2.03e-6	Alzheimer's disease;
TGCT	cis	rs8062405	0.824	rs4788084	chr16:28539848	C/T	cg09754948	chr16:28834200	ATXN2L	0.58	4.57	0.38	1.14e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs6087771	0.682	rs2038397	chr20:30217759	A/G	cg10886678	chr20:30946050	ASXL1	-0.58	-4.64	-0.38	8.56e-6	Subcortical brain region volumes;Putamen volume;
TGCT	cis	rs4087296	0.585	rs11865194	chr16:82381290	G/T	cg05453434	chr16:83371223	CDH13	0.33	4.49	0.37	1.61e-5	Bone mineral density;
TGCT	cis	rs55823223	0.503	rs9906971	chr17:73848477	A/G	cg08125733	chr17:73851984	WBP2	0.87	8.8	0.62	1e-14	Psoriasis;
TGCT	cis	rs2033711	0.870	rs6510152	chr19:58953319	C/T	cg04608855	chr19:58913158	NA	0.5	4.74	0.39	5.7e-6	Uric acid clearance;
TGCT	cis	rs9443645	0.901	rs12193319	chr6:79583437	C/A	cg05283184	chr6:79620031	NA	-0.21	-4.71	-0.39	6.61e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9467773	0.967	rs6456732	chr6:26514445	T/C	cg26531700	chr6:26746687	NA	0.47	4.57	0.38	1.14e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs637571	0.512	rs660118	chr11:65735174	G/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.21	4.49	0.37	1.61e-5	Eosinophil percentage of white cells;
TGCT	cis	rs9549367	0.713	rs9577211	chr13:113830718	G/C	cg18105134	chr13:113819100	PROZ	-0.47	-8.52	-0.61	4.48e-14	Platelet distribution width;
TGCT	cis	rs62244186	0.566	rs2135531	chr3:44881158	C/G	cg21672276	chr3:44754072	ZNF502	-0.53	-6.23	-0.49	6.64e-9	Depressive symptoms;
TGCT	cis	rs7926906	0.967	rs2213086	chr11:90528578	A/T	cg26138821	chr11:89956704	CHORDC1	-0.52	-5.61	-0.45	1.24e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.48	-0.37	1.66e-5	Bipolar disorder;
TGCT	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg20276088	chr3:133502917	NA	-0.27	-5.59	-0.45	1.38e-7	Iron status biomarkers;
TGCT	cis	rs514406	0.505	rs440871	chr1:53173052	C/T	cg08859206	chr1:53392774	SCP2	-0.34	-4.92	-0.4	2.69e-6	Monocyte count;
TGCT	cis	rs548181	0.736	rs556884	chr11:125550049	G/A	cg03464685	chr11:125439445	EI24	1.41	10.08	0.67	7.91e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs10089	1.000	rs4836366	chr5:127482494	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	8.19	0.59	2.64e-13	Ileal carcinoids;
TGCT	cis	rs988712	0.705	rs10767654	chr11:27640223	T/G	cg10635145	chr11:27742435	BDNF	0.36	4.88	0.4	3.18e-6	Obesity;
TGCT	cis	rs6940638	0.688	rs9393795	chr6:27217719	G/C	cg05738196	chr6:26577821	NA	-0.55	-5.01	-0.41	1.82e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs12908161	1.000	rs12899981	chr15:85302373	G/A	cg12863693	chr15:85201151	NMB	0.43	5.06	0.41	1.46e-6	Schizophrenia;
TGCT	cis	rs61990749	0.597	rs6574391	chr14:78208121	G/A	cg23188588	chr14:78226832	SNW1;C14orf178	0.67	4.73	0.39	6.09e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs10114408	0.959	rs10761303	chr9:96656918	T/G	cg13679303	chr9:96623674	NA	-0.36	-4.67	-0.39	7.67e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs6964587	1.000	rs58965837	chr7:91585258	T/A	cg17063962	chr7:91808500	NA	0.91	9.99	0.67	1.32e-17	Breast cancer;
TGCT	cis	rs6450176	0.625	rs11747281	chr5:53289047	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.69	-5.58	-0.45	1.45e-7	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg09021430	chr5:549028	NA	-0.41	-5.77	-0.46	6.04e-8	Obesity-related traits;
TGCT	cis	rs11190604	1.000	rs2295774	chr10:102265847	A/C	cg23241863	chr10:102295624	HIF1AN	0.66	4.86	0.4	3.55e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7666738	0.753	rs13111199	chr4:98953705	A/G	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs67311347	1.000	rs7617989	chr3:40512463	A/G	cg17264618	chr3:40429014	ENTPD3	-0.33	-4.8	-0.4	4.51e-6	Renal cell carcinoma;
TGCT	cis	rs595982	0.517	rs4801779	chr19:49406651	T/G	cg21252483	chr19:49399788	TULP2	-0.3	-5.24	-0.43	6.61e-7	Red cell distribution width;
TGCT	cis	rs2997447	0.739	rs72884784	chr1:26432246	G/A	cg03844060	chr1:26490628	NA	0.28	4.56	0.38	1.19e-5	QRS complex (12-leadsum);
TGCT	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg20276088	chr3:133502917	NA	-0.24	-5.06	-0.41	1.5e-6	Iron status biomarkers;
TGCT	cis	rs459571	0.883	rs2520096	chr9:136919416	A/G	cg14405625	chr9:136855902	VAV2	-0.31	-4.6	-0.38	1.04e-5	Platelet distribution width;
TGCT	cis	rs1568889	1.000	rs35343234	chr11:28034379	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.87	8.23	0.59	2.14e-13	Bipolar disorder;
TGCT	cis	rs6912958	1.000	rs9294379	chr6:88152535	C/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.63	-6.22	-0.49	7.06e-9	Monocyte percentage of white cells;
TGCT	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg01341218	chr17:43662625	NA	1.08	9.08	0.63	2.13e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs9467711	0.559	rs9393727	chr6:26500011	C/G	cg16898833	chr6:26189333	HIST1H4D	1.01	5.1	0.42	1.21e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs60843830	1.000	rs60149603	chr2:285421	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.7	6.48	0.5	1.97e-9	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg25767906	chr1:53392781	SCP2	0.48	5.56	0.45	1.57e-7	Monocyte count;
TGCT	cis	rs6570726	1.000	rs373778	chr6:145873252	C/T	cg23711669	chr6:146136114	FBXO30	0.71	6.66	0.51	7.78e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6121246	0.567	rs6058197	chr20:30194899	A/G	cg21427119	chr20:30132790	HM13	-0.42	-6.17	-0.48	8.75e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs12776158	0.901	rs59145567	chr10:71217065	G/T	cg12610070	chr10:71211762	TSPAN15	-0.59	-5.17	-0.42	9.16e-7	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs9653442	0.593	rs10865036	chr2:100860595	A/G	cg07810366	chr2:100720526	AFF3	-0.41	-6.26	-0.49	5.76e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs4321325	0.546	rs11886766	chr2:127948621	G/A	cg09760422	chr2:128146352	NA	0.42	4.52	0.38	1.43e-5	Protein C levels;
TGCT	cis	rs1568889	1.000	rs61889026	chr11:28274803	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	8.06	0.59	5.42e-13	Bipolar disorder;
TGCT	cis	rs68170813	0.559	rs17429118	chr7:106964052	C/T	cg02696742	chr7:106810147	HBP1	-0.71	-5.89	-0.47	3.42e-8	Coronary artery disease;
TGCT	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.71	-0.39	6.54e-6	Prudent dietary pattern;
TGCT	cis	rs9291683	0.585	rs12648479	chr4:10104571	G/A	cg11266682	chr4:10021025	SLC2A9	-0.48	-5.65	-0.45	1.03e-7	Bone mineral density;
TGCT	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg03709012	chr19:19516395	GATAD2A	-0.66	-5.7	-0.46	8.46e-8	Tonsillectomy;
TGCT	cis	rs9796	0.870	rs2925342	chr15:41305733	A/G	cg18705301	chr15:41695430	NDUFAF1	0.41	5.31	0.43	4.93e-7	Menopause (age at onset);
TGCT	cis	rs11098499	1.000	rs10029750	chr4:120172543	A/G	cg24670566	chr4:120433619	PDE5A	0.23	4.58	0.38	1.11e-5	Corneal astigmatism;
TGCT	cis	rs732765	0.734	rs10142036	chr14:75126992	T/A	cg06637938	chr14:75390232	RPS6KL1	-0.57	-4.95	-0.41	2.4e-6	Non-small cell lung cancer;
TGCT	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg11890956	chr21:40555474	PSMG1	-0.72	-6.49	-0.5	1.87e-9	Cognitive function;
TGCT	cis	rs4253772	0.550	rs6008600	chr22:46704676	A/G	cg24881330	chr22:46731750	TRMU	1.04	5.41	0.44	3.12e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs57920188	0.640	rs4478781	chr1:4086827	C/T	cg20703997	chr1:4087676	NA	0.45	4.71	0.39	6.56e-6	Interleukin-17 levels;
TGCT	cis	rs75229567	0.618	rs11177853	chr12:70184924	A/G	cg10114359	chr12:70132523	RAB3IP	1.35	6.68	0.51	7.19e-10	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
TGCT	trans	rs561341	0.602	rs114562703	chr17:30233899	G/T	cg20587970	chr11:113659929	NA	-0.68	-9.46	-0.65	2.55e-16	Hip circumference adjusted for BMI;
TGCT	cis	rs2580764	0.566	rs2920900	chr2:55280083	T/C	cg09592903	chr2:55203963	RTN4	0.25	5.92	0.47	2.96e-8	Mean platelet volume;
TGCT	cis	rs600550	0.926	rs633463	chr11:60005173	T/G	cg18570331	chr11:60101691	MS4A6E	0.5	4.49	0.37	1.63e-5	Lipoprotein-associated phospholipase A2 activity and mass;
TGCT	cis	rs514406	0.505	rs431427	chr1:53179094	C/A	cg08859206	chr1:53392774	SCP2	-0.36	-5.23	-0.42	7.05e-7	Monocyte count;
TGCT	cis	rs3743266	0.507	rs11637887	chr15:60765216	C/T	cg18480781	chr15:60294291	NA	0.63	4.94	0.41	2.46e-6	Menarche (age at onset);
TGCT	trans	rs9951602	0.512	rs4799248	chr18:76653459	G/A	cg02800362	chr5:177631904	HNRNPAB	1.13	12.84	0.76	1.57e-24	Obesity-related traits;
TGCT	cis	rs7264396	0.790	rs6058290	chr20:34247702	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.28	-4.68	-0.39	7.38e-6	Total cholesterol levels;
TGCT	cis	rs8077577	0.945	rs9916193	chr17:18057215	C/G	cg09161412	chr17:18057145	MYO15A	-0.64	-5.3	-0.43	5.21e-7	Obesity-related traits;
TGCT	cis	rs2439831	0.717	rs2470132	chr15:43835481	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.84	5.79	0.46	5.33e-8	Lung cancer in ever smokers;
TGCT	cis	rs765787	0.530	rs10467979	chr15:45521270	G/A	cg24006582	chr15:45444508	DUOX1	-0.25	-5.45	-0.44	2.66e-7	Uric acid levels;
TGCT	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg05064044	chr6:292385	DUSP22	-0.7	-7.14	-0.54	6.88e-11	Menopause (age at onset);
TGCT	cis	rs7666738	0.546	rs7679681	chr4:98882221	A/G	cg05340658	chr4:99064831	C4orf37	0.58	6.09	0.48	1.28e-8	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs17685	0.753	rs1806885	chr7:75785612	T/G	cg19862616	chr7:65841803	NCRNA00174	0.52	9.01	0.63	3.02e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs2204008	0.577	rs2623049	chr12:38018831	G/A	cg26384229	chr12:38710491	ALG10B	-0.7	-6.13	-0.48	1.1e-8	Bladder cancer;
TGCT	cis	rs1008375	0.931	rs2098151	chr4:17577490	T/C	cg16339924	chr4:17578868	LAP3	0.8	6.96	0.53	1.73e-10	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg11494091	chr17:61959527	GH2	0.6	14.54	0.79	1.46e-28	Prudent dietary pattern;
TGCT	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg03732007	chr1:2071316	PRKCZ	-0.27	-5.96	-0.47	2.39e-8	Height;
TGCT	trans	rs6089829	0.962	rs6089825	chr20:61668447	C/T	cg17470723	chr8:74884337	TCEB1	0.76	7.34	0.55	2.42e-11	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg07061783	chr6:25882402	NA	-0.45	-4.82	-0.4	4.14e-6	Blood metabolite levels;
TGCT	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.62	5.25	0.43	6.3e-7	Tonsillectomy;
TGCT	cis	rs7267979	1.000	rs4813562	chr20:25352588	G/A	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs61990749	0.597	rs2032781	chr14:78214875	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.6	4.45	0.37	1.88e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg06221963	chr1:154839813	KCNN3	-0.81	-15.28	-0.81	2.67e-30	Prostate cancer;
TGCT	cis	rs4780401	0.609	rs35902600	chr16:11800848	C/T	cg01061890	chr16:11836724	TXNDC11	-0.6	-5.82	-0.46	4.74e-8	Rheumatoid arthritis;
TGCT	cis	rs2458413	0.669	rs1812214	chr8:105344070	A/G	cg04554929	chr8:105342491	NA	-0.59	-9.16	-0.64	1.34e-15	Paget's disease;
TGCT	cis	rs78487399	0.808	rs6717636	chr2:43703684	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-5.45	-0.44	2.63e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs7412746	0.621	rs11204749	chr1:150929563	G/A	cg09365446	chr1:150670422	GOLPH3L	0.34	4.71	0.39	6.58e-6	Melanoma;
TGCT	cis	rs7666738	0.830	rs7674095	chr4:99048158	T/A	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs5769765	0.908	rs138889	chr22:50226673	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.37	5.59	0.45	1.36e-7	Schizophrenia;
TGCT	cis	rs4824093	0.610	rs60036544	chr22:50264019	C/T	cg14114931	chr22:50943910	LMF2	0.37	4.58	0.38	1.11e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs7043114	0.525	rs2274966	chr9:95155563	C/A	cg14631576	chr9:95140430	CENPP	-0.27	-4.56	-0.38	1.22e-5	Height;
TGCT	cis	rs1577917	0.958	rs4707223	chr6:86509802	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-5.77	-0.46	6.01e-8	Response to antipsychotic treatment;
TGCT	cis	rs1023500	0.551	rs2301521	chr22:42423110	G/C	cg05082376	chr22:42548792	NA	-0.22	-5.27	-0.43	5.83e-7	Schizophrenia;
TGCT	cis	rs71597109	0.594	rs13131198	chr4:102730555	A/G	cg14855874	chr4:102712397	BANK1	0.42	4.59	0.38	1.09e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs2439831	1.000	rs690263	chr15:43704465	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	8.12	0.59	3.99e-13	Lung cancer in ever smokers;
TGCT	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg21724239	chr8:58056113	NA	0.42	5.04	0.41	1.59e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg21963583	chr11:68658836	MRPL21	0.35	5.8	0.46	5.09e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg12570787	chr5:219185	SDHA;CCDC127	0.65	4.46	0.37	1.83e-5	Breast cancer;
TGCT	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg01448562	chr3:133502909	NA	-0.34	-6.76	-0.52	4.81e-10	Iron status biomarkers;
TGCT	cis	rs763014	1.000	rs8054842	chr16:672799	T/C	cg00908189	chr16:619842	PIGQ	0.88	10.66	0.69	3.21e-19	Height;
TGCT	cis	rs9906944	0.713	rs9899580	chr17:47106878	T/G	cg07075026	chr17:47091521	IGF2BP1	-0.43	-4.6	-0.38	1.03e-5	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	trans	rs17685	0.712	rs6976236	chr7:75741087	G/T	cg19862616	chr7:65841803	NCRNA00174	0.52	9.01	0.63	3.02e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg22618164	chr12:122356400	WDR66	-0.66	-6.18	-0.48	8.67e-9	Mean corpuscular volume;
TGCT	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg10876282	chr6:28092338	ZSCAN16	0.51	4.79	0.39	4.75e-6	Cardiac Troponin-T levels;
TGCT	cis	rs1461503	0.966	rs11218908	chr11:122841687	A/G	cg27398637	chr11:122830231	C11orf63	-0.42	-5.25	-0.43	6.42e-7	Menarche (age at onset);
TGCT	cis	rs6138458	1.000	rs11906373	chr20:24938832	A/G	cg26195577	chr20:24973756	C20orf3	1.18	11.12	0.71	2.37e-20	Blood protein levels;
TGCT	cis	rs929354	0.742	rs10251112	chr7:156963524	A/G	cg05182265	chr7:156933206	UBE3C	-0.39	-8.77	-0.62	1.19e-14	Body mass index;
TGCT	cis	rs7666738	0.716	rs6817529	chr4:99023213	T/C	cg17366294	chr4:99064904	C4orf37	0.68	7.04	0.53	1.17e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2836974	0.931	rs2989330	chr21:40716209	A/G	cg11890956	chr21:40555474	PSMG1	0.95	8.05	0.59	5.73e-13	Cognitive function;
TGCT	cis	rs3096299	0.719	rs2353581	chr16:89518908	T/C	cg08392591	chr16:89556376	ANKRD11	0.6	5.64	0.45	1.09e-7	Multiple myeloma (IgH translocation);
TGCT	cis	rs10193935	0.901	rs3088290	chr2:42578143	A/G	cg27598129	chr2:42591480	NA	-0.41	-5.66	-0.45	1e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg23758822	chr17:41437982	NA	0.72	6.81	0.52	3.83e-10	Menopause (age at onset);
TGCT	cis	rs9522267	0.535	rs914036	chr13:112235542	G/A	cg10483660	chr13:112241077	NA	-0.27	-4.61	-0.38	9.78e-6	Hepatitis;
TGCT	cis	rs9913156	0.589	rs7213481	chr17:4547906	C/T	cg19197139	chr17:4613644	ARRB2	0.85	7.84	0.58	1.76e-12	Lymphocyte counts;
TGCT	cis	rs17376456	1.000	rs35184505	chr5:93561535	A/G	cg25358565	chr5:93447407	FAM172A	0.95	7.18	0.54	5.63e-11	Diabetic retinopathy;
TGCT	cis	rs3008870	1.000	rs12117131	chr1:67451922	C/T	cg11518657	chr1:67396239	MIER1	-0.54	-4.61	-0.38	9.72e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs9611565	0.512	rs9607841	chr22:42186838	G/A	cg06634786	chr22:41940651	POLR3H	-0.84	-7.83	-0.57	1.91e-12	Vitiligo;
TGCT	cis	rs986417	1.000	rs1254287	chr14:60861774	C/T	cg27398547	chr14:60952738	C14orf39	-1.39	-10.61	-0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs9581857	0.512	rs9581866	chr13:28063176	G/A	cg22138327	chr13:27999177	GTF3A	0.73	4.55	0.38	1.25e-5	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs2486012	1.000	rs1859725	chr1:44379577	A/G	cg12908607	chr1:44402522	ARTN	0.71	5.86	0.47	3.87e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9653442	0.564	rs56054309	chr2:100794940	T/C	cg22139774	chr2:100720529	AFF3	-0.32	-4.98	-0.41	2.06e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg23719950	chr11:63933701	MACROD1	-0.72	-5.95	-0.47	2.61e-8	Mean platelet volume;
TGCT	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg17971929	chr21:40555470	PSMG1	0.98	9.57	0.65	1.43e-16	Cognitive function;
TGCT	cis	rs2594989	0.943	rs2454512	chr3:11487506	A/G	cg26283222	chr3:11613257	VGLL4	-0.21	-4.46	-0.37	1.84e-5	Circulating chemerin levels;
TGCT	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.53	-5.06	-0.41	1.47e-6	Longevity;Endometriosis;
TGCT	cis	rs6714710	0.603	rs717417	chr2:98416850	T/G	cg26665480	chr2:98280029	ACTR1B	0.7	6.61	0.51	1.05e-9	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs7552404	0.765	rs1251078	chr1:76189488	C/G	cg03433033	chr1:76189801	ACADM	-0.9	-13.97	-0.78	3.22e-27	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg03351412	chr1:154909251	PMVK	0.49	4.58	0.38	1.13e-5	Prostate cancer;
TGCT	trans	rs1814175	0.817	rs28679516	chr11:50055998	G/A	cg15704280	chr7:45808275	SEPT13	-0.72	-8.47	-0.61	6.02e-14	Height;
TGCT	cis	rs9733	0.818	rs4970926	chr1:150673684	T/C	cg13175981	chr1:150552382	MCL1	0.43	4.78	0.39	4.77e-6	Tonsillectomy;
TGCT	cis	rs2245008	0.671	rs907036	chr16:83989850	A/T	cg07978099	chr16:83986941	OSGIN1	0.4	5.03	0.41	1.68e-6	Pursuit maintenance gain;
TGCT	cis	rs2439831	0.867	rs12323999	chr15:43683115	T/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	8.14	0.59	3.58e-13	Lung cancer in ever smokers;
TGCT	cis	rs733175	0.855	rs10018666	chr4:10004805	C/T	cg11266682	chr4:10021025	SLC2A9	0.47	4.63	0.38	9.05e-6	Psychosis and Alzheimer's disease;
TGCT	cis	rs17125944	0.505	rs74642116	chr14:53213507	A/G	cg00686598	chr14:53173677	PSMC6	1.08	6.32	0.49	4.37e-9	Alzheimer's disease (late onset);
TGCT	cis	rs2933343	0.761	rs789225	chr3:128600229	G/A	cg11901034	chr3:128598214	ACAD9	-0.64	-6.11	-0.48	1.16e-8	IgG glycosylation;
TGCT	cis	rs12200560	0.505	rs211175	chr6:97073320	C/T	cg06623918	chr6:96969491	KIAA0776	0.62	5.37	0.43	3.66e-7	Coronary heart disease;
TGCT	cis	rs1723838	0.826	rs9651759	chr11:73602950	G/A	cg18195628	chr11:73498948	MRPL48	0.92	4.5	0.38	1.51e-5	Obesity-related traits;
TGCT	cis	rs12477438	0.798	rs6716913	chr2:99580641	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-5.97	-0.47	2.3e-8	Chronic sinus infection;
TGCT	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg10802521	chr3:52805072	NEK4	-0.72	-9.11	-0.63	1.82e-15	Bipolar disorder;
TGCT	cis	rs72781680	0.898	rs72788214	chr2:24087621	A/C	cg08917208	chr2:24149416	ATAD2B	0.77	4.69	0.39	7.06e-6	Lymphocyte counts;
TGCT	cis	rs9976767	0.637	rs2277799	chr21:43824123	G/C	cg23042151	chr21:43824109	UBASH3A	-0.22	-4.81	-0.4	4.32e-6	Type 1 diabetes;
TGCT	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg06634786	chr22:41940651	POLR3H	-0.85	-8.19	-0.59	2.72e-13	Vitiligo;
TGCT	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg09060608	chr5:178986726	RUFY1	0.48	5.46	0.44	2.49e-7	Lung cancer;
TGCT	cis	rs742614	0.935	rs6057929	chr20:32477633	A/G	cg18223379	chr20:31619647	BPIL3	-0.18	-4.48	-0.37	1.71e-5	Stearic acid (18:0) levels;
TGCT	cis	rs9611565	0.559	rs5758428	chr22:42106216	G/A	cg17554472	chr22:41940697	POLR3H	0.47	5.04	0.41	1.63e-6	Vitiligo;
TGCT	cis	rs11119608	0.960	rs11119609	chr1:210995866	A/G	cg24524366	chr1:211689016	NA	0.52	4.72	0.39	6.27e-6	Cancer;
TGCT	cis	rs13256369	0.901	rs12679831	chr8:8566411	T/G	cg18904891	chr8:8559673	CLDN23	0.59	5.52	0.44	1.93e-7	Obesity-related traits;
TGCT	cis	rs9926296	0.572	rs8046872	chr16:89841552	T/C	cg04287289	chr16:89883240	FANCA	0.66	6.54	0.51	1.42e-9	Vitiligo;
TGCT	cis	rs459571	0.883	rs2520096	chr9:136919416	A/G	cg13789015	chr9:136890014	NCRNA00094	0.37	6.37	0.5	3.34e-9	Platelet distribution width;
TGCT	cis	rs4499344	0.693	rs8106944	chr19:33097783	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.83	8.7	0.62	1.68e-14	Mean platelet volume;
TGCT	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg11764359	chr7:65958608	NA	-0.54	-4.9	-0.4	2.89e-6	Aortic root size;
TGCT	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs11031096	0.711	rs4910891	chr11:4153408	A/G	cg18678763	chr11:4115507	RRM1	-0.52	-6.66	-0.51	7.83e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs67311347	0.956	rs7640228	chr3:40516190	G/A	cg17264618	chr3:40429014	ENTPD3	-0.33	-4.69	-0.39	7.17e-6	Renal cell carcinoma;
TGCT	cis	rs7937682	0.924	rs489783	chr11:111520522	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.1	-11.55	-0.72	2.11e-21	Primary sclerosing cholangitis;
TGCT	cis	rs9913156	0.793	rs11568061	chr17:4546445	G/A	cg00122941	chr17:4613640	ARRB2	0.87	7.41	0.55	1.69e-11	Lymphocyte counts;
TGCT	cis	rs6938	0.563	rs12917376	chr15:75116167	C/T	cg10253484	chr15:75165896	SCAMP2	-0.55	-4.83	-0.4	3.91e-6	Breast cancer;
TGCT	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg15383120	chr6:291909	DUSP22	-0.7	-7.19	-0.54	5.32e-11	Menopause (age at onset);
TGCT	cis	rs10501293	0.917	rs9645617	chr11:43105620	G/A	cg03447554	chr11:43094025	NA	-0.47	-6.58	-0.51	1.2e-9	Cognitive performance;
TGCT	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg13395646	chr4:1353034	KIAA1530	-0.41	-5.02	-0.41	1.76e-6	Longevity;
TGCT	cis	rs7940866	1.000	rs7940866	chr11:130817579	A/T	cg05962950	chr11:130786565	SNX19	-0.74	-7.35	-0.55	2.33e-11	Schizophrenia;
TGCT	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg17747265	chr1:1875780	NA	-0.44	-8.44	-0.6	6.93e-14	Body mass index;
TGCT	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.08	0.48	1.37e-8	Bipolar disorder;
TGCT	cis	rs7714584	1.000	rs80075680	chr5:150223737	C/T	cg22134413	chr5:150180641	NA	0.89	6.96	0.53	1.73e-10	Crohn's disease;
TGCT	cis	rs9837602	0.507	rs793455	chr3:99526135	C/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.59	6.91	0.53	2.27e-10	Breast cancer;
TGCT	cis	rs928736	0.599	rs1000005	chr21:34433051	C/G	cg00274965	chr21:34405681	NA	0.55	6.36	0.5	3.58e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs6683273	0.830	rs3192920	chr1:3229385	T/G	cg17435683	chr1:3230609	PRDM16	-0.4	-4.53	-0.38	1.35e-5	QRS duration;
TGCT	cis	rs4455778	0.659	rs61486133	chr7:49027781	T/C	cg26309511	chr7:48887640	NA	-0.44	-5.22	-0.42	7.26e-7	Lung cancer in never smokers;
TGCT	cis	rs174479	0.647	rs174461	chr11:61657401	A/C	cg19610905	chr11:61596333	FADS2	0.58	5.05	0.41	1.56e-6	Sphingolipid levels;
TGCT	cis	rs7707921	0.752	rs12108681	chr5:81278375	T/C	cg17933386	chr5:81047246	SSBP2	0.57	4.45	0.37	1.88e-5	Breast cancer;
TGCT	cis	rs4319547	0.698	rs4039670	chr12:122822655	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.6	-4.68	-0.39	7.27e-6	Body mass index;
TGCT	cis	rs12497850	0.931	rs9755490	chr3:48871664	A/C	cg06212747	chr3:49208901	KLHDC8B	0.61	5.62	0.45	1.2e-7	Parkinson's disease;
TGCT	cis	rs708547	0.836	rs1718882	chr4:57859533	C/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.53	-4.92	-0.4	2.7e-6	Response to bleomycin (chromatid breaks);
TGCT	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg05665937	chr4:1216051	CTBP1	0.24	4.9	0.4	2.98e-6	Obesity-related traits;
TGCT	cis	rs9913156	0.793	rs4346260	chr17:4567215	A/G	cg00122941	chr17:4613640	ARRB2	-0.89	-7.56	-0.56	7.65e-12	Lymphocyte counts;
TGCT	cis	rs67311347	0.544	rs9864601	chr3:40345318	C/T	cg13683864	chr3:40499215	RPL14	-0.79	-7.57	-0.56	7.26e-12	Renal cell carcinoma;
TGCT	cis	rs7819412	0.775	rs6601564	chr8:10982051	A/G	cg21775007	chr8:11205619	TDH	-0.54	-5.21	-0.42	7.67e-7	Triglycerides;
TGCT	cis	rs2486288	0.656	rs11629807	chr15:45547037	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.72	-7.46	-0.56	1.34e-11	Glomerular filtration rate;
TGCT	cis	rs826838	1.000	rs4575342	chr12:38663831	G/A	cg13010199	chr12:38710504	ALG10B	0.77	6.31	0.49	4.59e-9	Heart rate;
TGCT	cis	rs6088590	1.000	rs6119530	chr20:33403930	A/G	cg06115741	chr20:33292138	TP53INP2	0.65	5.45	0.44	2.66e-7	Coronary artery disease;
TGCT	cis	rs7582180	0.629	rs13031906	chr2:100939524	T/C	cg14675211	chr2:100938903	LONRF2	0.51	4.95	0.41	2.32e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9381040	0.655	rs2268187	chr6:41042993	G/A	cg03526776	chr6:41159608	TREML2	0.27	5.34	0.43	4.21e-7	Alzheimer's disease (late onset);
TGCT	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg06238570	chr21:40685208	BRWD1	0.76	7.01	0.53	1.37e-10	Cognitive function;
TGCT	cis	rs6940638	0.688	rs6456766	chr6:27019575	G/A	cg26531700	chr6:26746687	NA	-0.56	-5.04	-0.41	1.61e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4822044	0.568	rs1883370	chr22:42143740	C/A	cg17554472	chr22:41940697	POLR3H	0.46	4.76	0.39	5.4e-6	Cannabis dependence symptom count;
TGCT	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg03609598	chr5:56110824	MAP3K1	-0.57	-4.5	-0.37	1.57e-5	Initial pursuit acceleration;
TGCT	cis	rs6815814	0.950	rs5743595	chr4:38802644	A/G	cg02016764	chr4:38805732	TLR1	-0.35	-5.82	-0.46	4.68e-8	Breast cancer;
TGCT	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg13866156	chr1:1669148	SLC35E2	0.23	5.66	0.45	9.78e-8	Body mass index;
TGCT	cis	rs477895	1.000	rs7947143	chr11:64090422	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	5.19	0.42	8.41e-7	Mean platelet volume;
TGCT	cis	rs7909074	0.865	rs10900123	chr10:45376574	C/T	cg04218760	chr10:45406644	TMEM72	-0.3	-5.92	-0.47	2.88e-8	Mean corpuscular volume;
TGCT	cis	rs1395	1.000	rs1275538	chr2:27441397	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.54	7.36	0.55	2.23e-11	Blood metabolite levels;
TGCT	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	6.87	0.52	2.82e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9611565	0.918	rs9538	chr22:41755857	G/T	cg17554472	chr22:41940697	POLR3H	-0.5	-5.2	-0.42	8.14e-7	Vitiligo;
TGCT	cis	rs950169	0.580	rs17532346	chr15:85171495	A/C	cg12863693	chr15:85201151	NMB	0.44	5.2	0.42	7.82e-7	Schizophrenia;
TGCT	cis	rs4888262	0.545	rs36097721	chr16:74648267	C/G	cg01733217	chr16:74700730	RFWD3	0.74	7.47	0.56	1.23e-11	Testicular germ cell tumor;
TGCT	cis	rs7223966	1.000	rs2854223	chr17:61939014	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	5.17	0.42	9.21e-7	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs9297145	0.565	rs12705030	chr7:98765041	A/G	cg05967295	chr7:98741636	SMURF1	-0.68	-8.69	-0.62	1.83e-14	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg11890956	chr21:40555474	PSMG1	1.02	9.9	0.66	2.16e-17	Cognitive function;
TGCT	cis	rs6714710	0.603	rs11678591	chr2:98541001	T/C	cg26665480	chr2:98280029	ACTR1B	0.63	5.98	0.47	2.19e-8	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs9303401	0.538	rs2240258	chr17:56458183	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.75	6.8	0.52	3.94e-10	Cognitive test performance;
TGCT	cis	rs7267979	1.000	rs2259837	chr20:25280205	T/C	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7666738	0.753	rs10004827	chr4:99037953	A/C	cg05340658	chr4:99064831	C4orf37	0.52	5.83	0.46	4.41e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10986311	0.832	rs7875898	chr9:127140523	G/A	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.21	-4.89	-0.4	3.02e-6	Vitiligo;
TGCT	cis	rs6912958	0.559	rs395358	chr6:88057924	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.68	6.88	0.53	2.68e-10	Monocyte percentage of white cells;
TGCT	cis	rs7666738	0.581	rs34205844	chr4:98887494	C/A	cg05340658	chr4:99064831	C4orf37	0.5	5.58	0.45	1.44e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2486288	0.656	rs2271438	chr15:45557468	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.75	-7.78	-0.57	2.39e-12	Glomerular filtration rate;
TGCT	cis	rs68170813	0.652	rs75136686	chr7:107180949	G/A	cg02696742	chr7:106810147	HBP1	-0.58	-4.47	-0.37	1.74e-5	Coronary artery disease;
TGCT	cis	rs13256369	1.000	rs883648	chr8:8569521	A/G	cg17143192	chr8:8559678	CLDN23	0.58	5.56	0.45	1.56e-7	Obesity-related traits;
TGCT	cis	rs72781680	0.706	rs72794290	chr2:23896106	A/T	cg08917208	chr2:24149416	ATAD2B	1.01	5.58	0.45	1.45e-7	Lymphocyte counts;
TGCT	cis	rs10876993	0.826	rs1678534	chr12:58057435	A/C	cg15848620	chr12:58087721	OS9	-0.73	-5.94	-0.47	2.74e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs10464366	0.560	rs12701692	chr7:39135551	A/G	cg18850127	chr7:39170497	POU6F2	0.25	5.76	0.46	6.29e-8	IgG glycosylation;
TGCT	cis	rs7819412	0.678	rs11991716	chr8:10948575	A/T	cg21775007	chr8:11205619	TDH	-0.51	-4.58	-0.38	1.1e-5	Triglycerides;
TGCT	cis	rs13102973	0.835	rs4280795	chr4:135857246	T/A	cg14419869	chr4:135874104	NA	0.23	4.58	0.38	1.12e-5	Subjective well-being;
TGCT	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg14827481	chr10:134361889	INPP5A	0.28	4.51	0.38	1.5e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs514406	0.861	rs11206026	chr1:53281708	G/A	cg16325326	chr1:53192061	ZYG11B	0.7	8.71	0.62	1.59e-14	Monocyte count;
TGCT	cis	rs9902453	0.967	rs56129908	chr17:28421382	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.74	6.52	0.51	1.63e-9	Coffee consumption (cups per day);
TGCT	cis	rs2932538	0.885	rs7516421	chr1:113089696	T/C	cg22162597	chr1:113214053	CAPZA1	0.25	5.5	0.44	2.06e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs4688759	0.719	rs73079018	chr3:49875327	T/C	cg00383909	chr3:49044727	WDR6	1.31	6.62	0.51	9.53e-10	Blood protein levels;
TGCT	cis	rs614226	1.000	rs580016	chr12:120933977	T/C	cg10072921	chr12:121022843	NA	0.45	4.85	0.4	3.68e-6	Type 1 diabetes nephropathy;
TGCT	cis	rs12478296	1.000	rs113129906	chr2:243004253	C/T	cg06360820	chr2:242988706	NA	-0.85	-5.6	-0.45	1.32e-7	Obesity-related traits;
TGCT	cis	rs9303401	0.659	rs17741087	chr17:56550300	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.77	0.52	4.6e-10	Cognitive test performance;
TGCT	cis	rs1843834	0.539	rs2047135	chr2:225427302	G/C	cg12698349	chr2:225449008	CUL3	0.78	6.41	0.5	2.77e-9	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs3784262	1.000	rs3204689	chr15:58246802	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.5	-7.6	-0.56	6.19e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs929596	0.755	rs6742078	chr2:234672639	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.34	5.62	0.45	1.22e-7	Total bilirubin levels in HIV-1 infection;
TGCT	cis	rs7267979	1.000	rs2259928	chr20:25281834	G/C	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4918072	0.667	rs4439443	chr10:105704814	G/T	cg11005552	chr10:105648138	OBFC1	0.34	4.8	0.4	4.53e-6	Coronary artery disease;
TGCT	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg02574844	chr11:5959923	NA	0.44	4.91	0.4	2.85e-6	DNA methylation (variation);
TGCT	cis	rs3772130	0.962	rs11721291	chr3:121563285	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.62	0.38	9.48e-6	Cognitive performance;
TGCT	cis	rs7674212	0.541	rs2615539	chr4:104081106	C/G	cg16532752	chr4:104119610	CENPE	-0.61	-5.67	-0.45	9.45e-8	Type 2 diabetes;
TGCT	cis	rs11105298	1.000	rs11105298	chr12:89876143	C/T	cg00757033	chr12:89920650	WDR51B	-0.32	-5.12	-0.42	1.16e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs208520	0.690	rs12208310	chr6:66730108	G/C	cg07460842	chr6:66804631	NA	0.95	10.11	0.67	6.77e-18	Exhaled nitric oxide output;
TGCT	cis	rs2242116	0.761	rs6780601	chr3:46965856	A/G	cg27129171	chr3:47204927	SETD2	0.66	6.34	0.49	3.88e-9	Birth weight;
TGCT	cis	rs12142240	0.698	rs67142569	chr1:46828460	C/T	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs4566357	1.000	rs2177598	chr2:227922900	T/C	cg11843606	chr2:227700838	RHBDD1	-0.58	-5.31	-0.43	4.92e-7	Coronary artery disease;
TGCT	cis	rs9486715	0.867	rs9386500	chr6:96889845	A/C	cg06623918	chr6:96969491	KIAA0776	1.11	16.62	0.83	2.35e-33	Headache;
TGCT	cis	rs9611565	0.649	rs9623450	chr22:42175231	G/A	cg17554472	chr22:41940697	POLR3H	0.43	4.61	0.38	9.67e-6	Vitiligo;
TGCT	cis	rs6969780	0.630	rs10238095	chr7:27196643	A/G	cg04321618	chr7:27170880	HOXA4	-0.54	-5.21	-0.42	7.8e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	trans	rs10022799	0.725	rs9996196	chr4:168136671	G/A	cg08507725	chr4:8239220	SH3TC1	0.42	7.37	0.55	2.15e-11	Cognitive function;
TGCT	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg08859206	chr1:53392774	SCP2	-0.41	-6.12	-0.48	1.11e-8	Monocyte count;
TGCT	cis	rs4727027	0.716	rs4727020	chr7:148837317	C/T	cg23583168	chr7:148888333	NA	-0.66	-7.38	-0.55	2e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs7100689	0.577	rs10749551	chr10:82054001	A/C	cg01528321	chr10:82214614	TSPAN14	0.7	6.78	0.52	4.43e-10	Post bronchodilator FEV1;
TGCT	cis	rs986417	0.901	rs1024224	chr14:60926942	C/G	cg27398547	chr14:60952738	C14orf39	1.39	10.61	0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs10782582	0.522	rs12125933	chr1:76130920	C/T	cg10523679	chr1:76189770	ACADM	-0.68	-7.1	-0.54	8.65e-11	Daytime sleep phenotypes;
TGCT	cis	rs854765	0.624	rs12946746	chr17:17741669	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.69	-6.67	-0.51	7.5e-10	Total body bone mineral density;
TGCT	cis	rs546131	0.642	rs2956073	chr11:34842883	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.54	4.67	0.39	7.64e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg21724239	chr8:58056113	NA	0.4	5.15	0.42	1.01e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10501293	0.746	rs7105687	chr11:43035922	C/T	cg03447554	chr11:43094025	NA	0.44	6.29	0.49	5.05e-9	Cognitive performance;
TGCT	cis	rs11792861	0.926	rs75472294	chr9:111804239	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.47	4.44	0.37	1.98e-5	Menarche (age at onset);
TGCT	cis	rs2404602	0.716	rs1125932	chr15:76820540	C/T	cg22467129	chr15:76604101	ETFA	-0.48	-5.53	-0.44	1.81e-7	Blood metabolite levels;
TGCT	cis	rs2204008	0.728	rs12369538	chr12:38443942	C/T	cg13010199	chr12:38710504	ALG10B	0.56	4.44	0.37	2e-5	Bladder cancer;
TGCT	cis	rs2797160	1.000	rs1739349	chr6:126014984	G/C	cg05901451	chr6:126070800	HEY2	0.73	6.29	0.49	5.01e-9	Endometrial cancer;
TGCT	cis	rs1348850	0.914	rs10497503	chr2:178371739	G/T	cg22681709	chr2:178499509	PDE11A	-0.34	-4.58	-0.38	1.11e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs977747	0.933	rs2008713	chr1:47702368	T/C	cg03885399	chr1:47691550	TAL1	-0.37	-4.46	-0.37	1.8e-5	Body mass index;
TGCT	cis	rs4972806	0.739	rs10834	chr2:177042087	A/G	cg14324370	chr2:177042789	NA	0.63	5.24	0.43	6.71e-7	IgG glycosylation;
TGCT	cis	rs1475911	0.671	rs12483409	chr21:43521902	G/A	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.31	-5.88	-0.47	3.64e-8	IgG glycosylation;
TGCT	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg12963246	chr6:28129442	ZNF389	0.48	4.65	0.39	8.28e-6	Parkinson's disease;
TGCT	cis	rs763121	1.000	rs138457	chr22:38898051	T/C	cg06022373	chr22:39101656	GTPBP1	-0.71	-7.06	-0.54	1.07e-10	Menopause (age at onset);
TGCT	cis	rs13242816	1.000	rs2191498	chr7:116138569	C/T	cg16553024	chr7:116138462	CAV2	-0.44	-5.34	-0.43	4.29e-7	P wave duration;
TGCT	trans	rs9951602	0.512	rs56009939	chr18:76644497	T/G	cg02800362	chr5:177631904	HNRNPAB	1.13	12.94	0.76	9.39e-25	Obesity-related traits;
TGCT	cis	rs10782582	0.593	rs4646960	chr1:76211103	C/A	cg10523679	chr1:76189770	ACADM	-0.67	-6.71	-0.52	6.18e-10	Daytime sleep phenotypes;
TGCT	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg20203395	chr5:56204925	C5orf35	-0.57	-4.82	-0.4	4.15e-6	Initial pursuit acceleration;
TGCT	cis	rs6138458	0.546	rs6050118	chr20:24891895	C/T	cg26195577	chr20:24973756	C20orf3	-0.87	-4.9	-0.4	2.99e-6	Blood protein levels;
TGCT	cis	rs6490294	0.950	rs7313892	chr12:112421352	G/T	cg10833066	chr12:111807467	FAM109A	0.35	5.13	0.42	1.09e-6	Mean platelet volume;
TGCT	cis	rs12765878	1.000	rs10883943	chr10:105651416	G/T	cg11005552	chr10:105648138	OBFC1	0.44	7.7	0.57	3.69e-12	Coronary artery disease;
TGCT	cis	rs13256369	0.802	rs4840350	chr8:8561442	A/G	cg17143192	chr8:8559678	CLDN23	0.54	5.03	0.41	1.64e-6	Obesity-related traits;
TGCT	cis	rs9372253	0.678	rs9372251	chr6:110700656	A/G	cg01119278	chr6:110721349	DDO	-0.31	-4.76	-0.39	5.25e-6	Platelet distribution width;
TGCT	cis	rs651907	0.535	rs13059470	chr3:101424800	A/G	cg11279151	chr3:101281821	RG9MTD1	0.34	7.13	0.54	7.37e-11	Colorectal cancer;
TGCT	cis	rs9611565	0.649	rs5758442	chr22:42133060	T/C	cg06481639	chr22:41940642	POLR3H	0.54	4.57	0.38	1.17e-5	Vitiligo;
TGCT	cis	rs4144743	1.000	rs72823473	chr17:45321775	A/T	cg18085866	chr17:45331354	ITGB3	-0.7	-4.67	-0.39	7.81e-6	Body mass index;
TGCT	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg06618935	chr21:46677482	NA	-0.36	-5.5	-0.44	2.06e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs826838	1.000	rs1843881	chr12:38733706	A/G	cg26384229	chr12:38710491	ALG10B	-1.07	-10.48	-0.69	8.51e-19	Heart rate;
TGCT	cis	rs9549367	0.713	rs576463	chr13:113846614	C/T	cg00898013	chr13:113819073	PROZ	0.53	7.2	0.54	5.17e-11	Platelet distribution width;
TGCT	cis	rs2921036	0.545	rs4840975	chr8:8363258	C/T	cg06636001	chr8:8085503	FLJ10661	-0.62	-5.48	-0.44	2.31e-7	Neuroticism;
TGCT	cis	rs2486288	0.656	rs1719236	chr15:45577783	G/T	cg14582100	chr15:45693742	SPATA5L1	-0.42	-4.85	-0.4	3.61e-6	Glomerular filtration rate;
TGCT	cis	rs67460515	0.926	rs13062740	chr3:161024208	G/A	cg03342759	chr3:160939853	NMD3	-0.51	-5.46	-0.44	2.47e-7	Parkinson's disease;
TGCT	cis	rs7095607	0.560	rs2087344	chr10:69922735	A/G	cg18986048	chr10:69913749	MYPN	-0.53	-5.62	-0.45	1.19e-7	Lung function (FVC);
TGCT	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg17054783	chr10:134559939	INPP5A	0.24	4.87	0.4	3.37e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs7236492	0.630	rs8086439	chr18:77173038	A/G	cg15644404	chr18:77186268	NFATC1	-0.43	-4.44	-0.37	1.96e-5	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs9894429	0.646	rs7405937	chr17:79597811	G/A	cg18240062	chr17:79603768	NPLOC4	0.58	5.12	0.42	1.15e-6	Eye color traits;
TGCT	cis	rs11997175	0.549	rs4349945	chr8:33654323	T/C	ch.8.33884649F	chr8:33765107	NA	0.28	4.54	0.38	1.33e-5	Body mass index;
TGCT	cis	rs7552404	0.924	rs1146579	chr1:76209792	C/T	cg03433033	chr1:76189801	ACADM	-0.76	-9.22	-0.64	9.89e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9457247	0.905	rs453184	chr6:167387404	A/C	cg23791538	chr6:167370224	RNASET2	-0.5	-4.98	-0.41	2.08e-6	Crohn's disease;
TGCT	cis	rs10936602	0.527	rs9878316	chr3:169533717	T/A	cg08193579	chr3:169529701	LRRC34	0.29	5.33	0.43	4.38e-7	Renal cell carcinoma;
TGCT	cis	rs2204008	0.837	rs7308714	chr12:38274307	T/C	cg13010199	chr12:38710504	ALG10B	0.61	4.67	0.39	7.69e-6	Bladder cancer;
TGCT	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg12963246	chr6:28129442	ZNF389	0.52	5.07	0.41	1.42e-6	Depression;
TGCT	cis	rs7582180	0.676	rs11691135	chr2:100934038	C/T	cg14675211	chr2:100938903	LONRF2	0.51	4.98	0.41	2.11e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs11648796	0.759	rs12597195	chr16:769026	G/C	cg00908189	chr16:619842	PIGQ	0.8	6.38	0.5	3.12e-9	Height;
TGCT	cis	rs7220711	0.967	rs4792909	chr17:41798824	G/T	cg26893861	chr17:41843967	DUSP3	0.51	4.72	0.39	6.38e-6	Bone mineral density (spine);Bone mineral density (hip);
TGCT	cis	rs2229238	0.868	rs41308419	chr1:154507197	T/C	cg13067139	chr1:155221277	FAM189B	0.2	4.51	0.38	1.47e-5	Coronary heart disease;
TGCT	cis	rs9972944	0.702	rs987929	chr17:63765856	A/G	cg07283582	chr17:63770753	CCDC46	-0.26	-5.3	-0.43	5.02e-7	Total body bone mineral density;
TGCT	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg08048268	chr3:133502702	NA	-0.64	-9.81	-0.66	3.68e-17	Iron status biomarkers;
TGCT	cis	rs35160687	0.871	rs2278105	chr2:86466516	A/G	cg04877910	chr2:85804641	VAMP8	0.34	4.47	0.37	1.72e-5	Night sleep phenotypes;
TGCT	cis	rs611744	0.967	rs628843	chr8:109196115	C/G	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	trans	rs17450420	1.000	rs75573069	chr13:105052442	T/C	cg14737571	chr13:113436568	ATP11A	0.61	6.63	0.51	9.35e-10	Esophageal cancer  (alcohol interaction);
TGCT	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg03303774	chr4:1407052	NA	0.34	5.43	0.44	2.91e-7	Obesity-related traits;
TGCT	cis	rs12477438	0.798	rs1349779	chr2:99645055	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-8.66	-0.61	2.13e-14	Chronic sinus infection;
TGCT	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg17554472	chr22:41940697	POLR3H	0.48	5.08	0.42	1.34e-6	Vitiligo;
TGCT	cis	rs2013441	1.000	rs9896709	chr17:20180550	G/A	cg18979559	chr17:20280153	CCDC144C	-0.45	-4.67	-0.39	7.61e-6	Obesity-related traits;
TGCT	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg06112835	chr11:68658793	MRPL21	0.46	8.07	0.59	5.25e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs3733585	0.699	rs6449178	chr4:9968684	A/G	cg11266682	chr4:10021025	SLC2A9	0.57	7.48	0.56	1.19e-11	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg07424592	chr7:64974309	NA	-1.33	-7.99	-0.58	7.81e-13	Diabetic kidney disease;
TGCT	cis	rs114540395	0.925	rs12244100	chr10:103379397	T/C	cg03300883	chr10:102748874	C10orf2	0.42	4.58	0.38	1.13e-5	Schizophrenia;
TGCT	cis	rs3008870	0.755	rs1121824	chr1:67475616	C/A	cg08660285	chr1:67390436	MIER1;WDR78	0.81	8.43	0.6	7.53e-14	Lymphocyte percentage of white cells;
TGCT	cis	rs4972806	0.776	rs2072589	chr2:177042871	C/T	cg13092806	chr2:177043255	NA	0.59	5.1	0.42	1.24e-6	IgG glycosylation;
TGCT	cis	rs4253772	0.614	rs11090859	chr22:46687460	T/G	cg26492175	chr22:47022658	GRAMD4	0.2	4.52	0.38	1.43e-5	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs2688608	0.592	rs11000759	chr10:75493726	G/A	cg19442545	chr10:75533431	FUT11	-0.37	-5.77	-0.46	5.89e-8	Inflammatory bowel disease;
TGCT	cis	rs4699052	0.625	rs10212959	chr4:104300935	C/G	cg16532752	chr4:104119610	CENPE	0.5	4.65	0.39	8.27e-6	Testicular germ cell tumor;
TGCT	trans	rs4332037	0.851	rs28728306	chr7:1961814	C/A	cg25206134	chr2:45395956	NA	1.1	9.53	0.65	1.75e-16	Bipolar disorder;
TGCT	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.55	4.92	0.4	2.74e-6	Prudent dietary pattern;
TGCT	cis	rs59197085	0.636	rs56377531	chr7:128460745	C/T	cg00260937	chr7:128520193	KCP	0.47	4.98	0.41	2.1e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
TGCT	cis	rs13326165	0.715	rs13091545	chr3:52377294	A/G	cg27565382	chr3:53032988	SFMBT1	0.37	4.93	0.41	2.55e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg00149659	chr3:10157352	C3orf10	0.93	5.98	0.47	2.25e-8	Alzheimer's disease;
TGCT	cis	rs7954584	0.616	rs10743186	chr12:122356436	C/T	cg22618164	chr12:122356400	WDR66	0.53	5.18	0.42	8.83e-7	Mean corpuscular volume;
TGCT	cis	rs2204008	0.599	rs2320526	chr12:38220405	T/A	cg13010199	chr12:38710504	ALG10B	0.58	4.59	0.38	1.08e-5	Bladder cancer;
TGCT	cis	rs4253772	0.637	rs9627295	chr22:46650100	C/T	cg09491104	chr22:46646882	C22orf40	-0.62	-6.49	-0.5	1.87e-9	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs9787249	0.957	rs56064244	chr1:40213890	C/T	cg19912559	chr1:40204330	PPIE	0.49	5.7	0.46	8.41e-8	Blood protein levels;
TGCT	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	4.89	0.4	3e-6	Menopause (age at onset);
TGCT	cis	rs2204008	0.688	rs12824232	chr12:38175901	G/A	cg26384229	chr12:38710491	ALG10B	0.86	7.65	0.57	4.87e-12	Bladder cancer;
TGCT	trans	rs7618501	0.501	rs7627864	chr3:49926613	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.8	8.36	0.6	1.06e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs933688	1.000	rs6867219	chr5:90718008	T/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.02	8.42	0.6	7.65e-14	Smoking behavior;
TGCT	cis	rs1865760	0.928	rs9295673	chr6:25912094	T/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.67	6.39	0.5	3.03e-9	Height;
TGCT	cis	rs74233809	0.901	rs3824755	chr10:104595849	G/C	cg05855489	chr10:104503620	C10orf26	0.83	4.75	0.39	5.63e-6	Birth weight;
TGCT	cis	rs4689388	0.890	rs4501291	chr4:6298582	C/T	cg14416269	chr4:6271139	WFS1	0.4	5.32	0.43	4.78e-7	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs75686122	0.892	rs1426288	chr8:104578464	C/G	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs7591446	0.517	rs13427985	chr2:45838840	C/A	cg15146906	chr2:45838581	SRBD1	0.73	4.94	0.41	2.45e-6	Squamous cell lung carcinoma;
TGCT	cis	rs909002	0.800	rs1056526	chr1:32084904	C/T	cg11573219	chr1:32083031	HCRTR1	-0.45	-5.86	-0.47	3.83e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2479724	0.901	rs33954419	chr6:41786136	A/G	cg08135965	chr6:41755394	TOMM6	0.51	4.91	0.4	2.81e-6	Menarche (age at onset);
TGCT	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg14983838	chr19:29218262	NA	0.76	6.86	0.52	2.94e-10	Methadone dose in opioid dependence;
TGCT	cis	rs9972944	0.756	rs7212901	chr17:63766499	T/C	cg07283582	chr17:63770753	CCDC46	-0.26	-5.16	-0.42	9.6e-7	Total body bone mineral density;
TGCT	cis	rs1971762	0.762	rs7312853	chr12:54073597	C/G	cg09709951	chr12:54017699	ATF7	-0.35	-5.36	-0.43	3.85e-7	Height;
TGCT	cis	rs67072384	0.818	rs2291290	chr11:72465877	T/C	cg03713592	chr11:72463424	ARAP1	-0.93	-4.68	-0.39	7.3e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs3858526	0.959	rs10838797	chr11:5920977	A/G	cg05234568	chr11:5960015	NA	-0.44	-4.61	-0.38	9.91e-6	DNA methylation (variation);
TGCT	cis	rs9486719	1.000	rs11756315	chr6:97008678	A/G	cg06623918	chr6:96969491	KIAA0776	0.94	7.9	0.58	1.31e-12	Migraine;Coronary artery disease;
TGCT	cis	rs1153858	1.000	rs8042786	chr15:45703539	T/C	cg26924012	chr15:45694286	SPATA5L1	1.1	15.34	0.81	2.01e-30	Homoarginine levels;
TGCT	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg21226059	chr5:178986404	RUFY1	0.63	7.74	0.57	2.98e-12	Lung cancer;
TGCT	cis	rs6671200	1.000	rs12755552	chr1:95685026	A/G	cg20701556	chr1:95698924	RWDD3	0.65	5.58	0.45	1.43e-7	Stearic acid (18:0) levels;
TGCT	cis	rs2239547	0.657	rs7620706	chr3:52891756	A/T	cg11645453	chr3:52864694	ITIH4	0.35	5.88	0.47	3.57e-8	Schizophrenia;
TGCT	cis	rs950169	0.526	rs698620	chr15:85177208	G/A	cg12863693	chr15:85201151	NMB	-0.41	-5.67	-0.45	9.49e-8	Schizophrenia;
TGCT	cis	rs1723838	0.510	rs2735572	chr11:73688492	C/T	cg26954736	chr11:73693896	UCP2	-1.29	-6.15	-0.48	9.74e-9	Obesity-related traits;
TGCT	cis	rs4234284	0.556	rs34147515	chr3:126965137	G/C	cg25436886	chr3:127056972	NA	-0.5	-4.87	-0.4	3.26e-6	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
TGCT	cis	rs826838	1.000	rs1719848	chr12:39085586	A/G	cg13010199	chr12:38710504	ALG10B	-0.59	-4.89	-0.4	3e-6	Heart rate;
TGCT	trans	rs17685	0.796	rs3757594	chr7:75678644	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.52	-8.84	-0.62	7.72e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	trans	rs17685	0.753	rs4398845	chr7:75716781	G/A	cg19862616	chr7:65841803	NCRNA00174	0.52	8.89	0.62	5.86e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs514406	0.644	rs928451	chr1:53195800	A/G	cg16325326	chr1:53192061	ZYG11B	-0.89	-13.12	-0.76	3.31e-25	Monocyte count;
TGCT	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.65	6.06	0.48	1.53e-8	Bipolar disorder;
TGCT	cis	rs6089829	0.962	rs6089826	chr20:61668595	G/A	cg03213289	chr20:61660250	NA	0.7	10.08	0.67	8.1e-18	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9457247	0.935	rs1187530	chr6:167376812	C/T	cg23791538	chr6:167370224	RNASET2	0.5	4.98	0.41	2.06e-6	Crohn's disease;
TGCT	cis	rs2075371	0.932	rs2241332	chr7:133969439	A/G	cg11752832	chr7:134001865	SLC35B4	0.6	5.11	0.42	1.21e-6	Mean platelet volume;
TGCT	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg13695892	chr22:41940480	POLR3H	-0.91	-8.86	-0.62	6.93e-15	Vitiligo;
TGCT	cis	rs7089973	0.604	rs7903663	chr10:116609904	G/A	cg03647239	chr10:116582469	FAM160B1	0.59	5.74	0.46	6.72e-8	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs1372520	0.684	rs3113355	chr4:90745345	A/T	cg15133208	chr4:90757351	SNCA	-0.49	-5.69	-0.45	8.67e-8	Neuroticism;
TGCT	cis	rs3784262	0.742	rs28379349	chr15:58202494	A/G	cg12031962	chr15:58353849	ALDH1A2	0.52	7.48	0.56	1.18e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs7246657	0.943	rs10420722	chr19:37973774	C/G	cg18154014	chr19:37997991	ZNF793	0.96	6.63	0.51	9.4e-10	Coronary artery calcification;
TGCT	cis	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg06636001	chr8:8085503	FLJ10661	0.68	5.82	0.46	4.67e-8	Mood instability;
TGCT	trans	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg17830980	chr10:43048298	ZNF37B	-0.87	-11.04	-0.7	3.63e-20	Extrinsic epigenetic age acceleration;
TGCT	cis	rs4674676	1	rs4674676	chr2:223529112	A/G	cg25565276	chr2:223520875	FARSB	1.05	8.28	0.6	1.67e-13	Chin dimples;
TGCT	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg03806693	chr22:41940476	POLR3H	1.16	13.52	0.77	3.78e-26	Vitiligo;
TGCT	cis	rs3808502	0.563	rs12549144	chr8:11422861	C/G	cg21775007	chr8:11205619	TDH	0.5	4.52	0.38	1.42e-5	Neuroticism;
TGCT	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg05368731	chr17:41323189	NBR1	1.2	14.2	0.79	8.98e-28	Menopause (age at onset);
TGCT	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg11905131	chr22:24372483	LOC391322	-0.95	-11.15	-0.71	2.06e-20	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9309473	0.607	rs7567017	chr2:73596270	C/T	cg20560298	chr2:73613845	ALMS1	-0.41	-4.54	-0.38	1.31e-5	Metabolite levels;
TGCT	cis	rs73198271	1.000	rs4840356	chr8:8607527	A/G	ch.8.214553F	chr8:8189620	PRAGMIN	-0.27	-4.56	-0.38	1.23e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs1018836	0.608	rs6982329	chr8:91467488	A/G	cg16814680	chr8:91681699	NA	-0.72	-7.54	-0.56	8.6e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2439831	0.702	rs16977724	chr15:44151299	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	5.92	0.47	3e-8	Lung cancer in ever smokers;
TGCT	cis	rs10791097	0.748	rs4937580	chr11:130734270	T/C	cg12179176	chr11:130786555	SNX19	0.8	9.62	0.65	1.07e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg02380750	chr20:61661411	NA	0.34	6.02	0.48	1.86e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg17971929	chr21:40555470	PSMG1	0.97	9.4	0.65	3.57e-16	Cognitive function;
TGCT	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg22920501	chr2:26401640	FAM59B	0.74	5.78	0.46	5.68e-8	Gut microbiome composition (summer);
TGCT	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg14159672	chr1:205819179	PM20D1	0.6	7.44	0.56	1.42e-11	Menarche (age at onset);
TGCT	cis	rs9640161	0.711	rs3800781	chr7:150027324	T/A	cg10018233	chr7:150070692	REPIN1	0.32	4.63	0.38	8.99e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs4819052	0.851	rs7279011	chr21:46655995	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	4.76	0.39	5.4e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7226408	0.857	rs72892509	chr18:34661797	C/T	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs11677370	0.963	rs6720814	chr2:3817590	A/C	cg17052675	chr2:3827356	NA	-0.3	-5.2	-0.42	7.86e-7	Type 2 diabetes;
TGCT	cis	rs514406	0.698	rs1672913	chr1:53408326	A/T	cg25767906	chr1:53392781	SCP2	-0.58	-7.3	-0.55	3.08e-11	Monocyte count;
TGCT	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg03264133	chr6:25882463	NA	-0.49	-5.14	-0.42	1.06e-6	Height;
TGCT	cis	rs7666738	0.570	rs10032272	chr4:99095601	T/C	cg05340658	chr4:99064831	C4orf37	0.43	4.62	0.38	9.29e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg18230493	chr5:56204884	C5orf35	-0.67	-5.88	-0.47	3.5e-8	Initial pursuit acceleration;
TGCT	cis	rs7119038	0.818	rs6421571	chr11:118743772	T/C	cg19308663	chr11:118741387	NA	-0.32	-6.29	-0.49	5.03e-9	Sjögren's syndrome;
TGCT	cis	rs61990749	0.597	rs8016447	chr14:78222068	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.6	4.45	0.37	1.88e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs7568458	0.709	rs11895401	chr2:85753847	C/T	cg02493740	chr2:85810744	VAMP5	-0.29	-5.7	-0.46	8.09e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs9393692	0.905	rs9379838	chr6:26277133	C/T	cg13736514	chr6:26305472	NA	-0.37	-5.42	-0.44	3.01e-7	Educational attainment;
TGCT	cis	rs71597109	0.639	rs35416717	chr4:102726657	C/A	cg14855874	chr4:102712397	BANK1	0.42	4.82	0.4	4.16e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg24829409	chr8:58192753	C8orf71	-0.57	-5.35	-0.43	4.14e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs763121	0.853	rs5757204	chr22:39046700	A/C	cg06022373	chr22:39101656	GTPBP1	0.77	7.46	0.56	1.35e-11	Menopause (age at onset);
TGCT	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg03188948	chr7:1209495	NA	0.45	5.97	0.47	2.34e-8	Longevity;Endometriosis;
TGCT	cis	rs9905704	0.624	rs8080071	chr17:57093825	C/T	cg05425664	chr17:57184151	TRIM37	0.68	5.61	0.45	1.25e-7	Testicular germ cell tumor;
TGCT	cis	rs9649213	0.559	rs56997921	chr7:98009224	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.93	-8.78	-0.62	1.09e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1018836	0.923	rs10956748	chr8:91621537	T/A	cg16814680	chr8:91681699	NA	-0.86	-9.19	-0.64	1.12e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg01448562	chr3:133502909	NA	-0.28	-5.27	-0.43	5.8e-7	Iron status biomarkers;
TGCT	cis	rs2115630	1.000	rs11854313	chr15:85304048	G/C	cg17173187	chr15:85201210	NMB	-0.39	-4.76	-0.39	5.4e-6	P wave terminal force;
TGCT	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.7	0.52	6.47e-10	Bipolar disorder;
TGCT	cis	rs643506	1.000	rs647080	chr11:111609174	A/G	cg09085632	chr11:111637200	PPP2R1B	0.55	4.56	0.38	1.19e-5	Breast cancer;
TGCT	cis	rs1903068	0.853	rs17773240	chr4:55999781	T/C	cg16572876	chr4:56024045	NA	0.43	4.94	0.41	2.43e-6	Endometriosis;
TGCT	cis	rs7666738	0.830	rs10017557	chr4:98983969	G/A	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4273100	0.512	rs1355128	chr17:19299144	G/A	cg01534423	chr17:18965556	NA	-0.76	-7.9	-0.58	1.31e-12	Schizophrenia;
TGCT	cis	rs9467711	0.591	rs76091509	chr6:26706602	T/A	cg16898833	chr6:26189333	HIST1H4D	1.53	5.95	0.47	2.55e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs3824867	0.920	rs7111873	chr11:47469439	A/G	cg20307385	chr11:47447363	PSMC3	0.7	6.03	0.48	1.71e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg13206674	chr6:150067644	NUP43	0.52	4.51	0.38	1.5e-5	Lung cancer;
TGCT	cis	rs2637266	0.714	rs7082421	chr10:78446313	G/A	cg18941641	chr10:78392320	NA	0.36	4.49	0.37	1.58e-5	Pulmonary function;
TGCT	cis	rs1757171	0.542	rs1757186	chr6:37484111	A/G	cg25019722	chr6:37503610	NA	-0.51	-7.96	-0.58	9.09e-13	Cognitive performance;
TGCT	cis	rs7666738	0.715	rs3857216	chr4:99032129	G/T	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6540559	0.611	rs11810817	chr1:210011747	C/G	cg22029157	chr1:209979665	IRF6	0.68	4.88	0.4	3.22e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs854624	0.792	rs1719197	chr17:34336876	T/C	cg02022384	chr17:34097390	MMP28	0.53	4.77	0.39	5.12e-6	Blood protein levels;
TGCT	cis	rs5769765	0.955	rs9616204	chr22:50303530	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.17	-11.76	-0.73	6.61e-22	Schizophrenia;
TGCT	cis	rs2153535	0.546	rs1335640	chr6:8485325	A/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs1372520	0.623	rs2583975	chr4:90748488	T/C	cg01966878	chr4:90757139	SNCA	-0.3	-4.64	-0.38	8.54e-6	Neuroticism;
TGCT	cis	rs17376456	0.825	rs13156202	chr5:93157721	C/T	cg21475434	chr5:93447410	FAM172A	-0.61	-4.75	-0.39	5.52e-6	Diabetic retinopathy;
TGCT	cis	rs56114371	0.777	rs200482	chr6:27773904	G/A	cg10876282	chr6:28092338	ZSCAN16	0.76	4.53	0.38	1.38e-5	Breast cancer;
TGCT	cis	rs9787249	0.874	rs7520588	chr1:40214525	T/A	cg20968010	chr1:40505947	CAP1	-0.53	-5.0	-0.41	1.91e-6	Blood protein levels;
TGCT	cis	rs9527	0.545	rs35756290	chr10:104585572	G/A	cg15744005	chr10:104629667	AS3MT	-0.47	-5.6	-0.45	1.33e-7	Arsenic metabolism;
TGCT	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg06634786	chr22:41940651	POLR3H	0.89	8.55	0.61	3.83e-14	Vitiligo;
TGCT	cis	rs72843506	0.656	rs9901357	chr17:20009042	A/C	cg18979559	chr17:20280153	CCDC144C	-0.63	-4.52	-0.38	1.45e-5	Schizophrenia;
TGCT	cis	rs2235642	0.891	rs2281231	chr16:1601879	A/G	cg10465839	chr16:1584050	IFT140;TMEM204	-0.28	-4.72	-0.39	6.19e-6	Coronary artery disease;
TGCT	cis	rs12776158	0.901	rs79980322	chr10:71201715	C/T	cg12610070	chr10:71211762	TSPAN15	-0.58	-5.04	-0.41	1.64e-6	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs10779751	0.686	rs1148478	chr1:11174067	A/T	cg08854313	chr1:11322531	MTOR	0.82	6.58	0.51	1.17e-9	Body mass index;
TGCT	cis	rs7267979	1.000	rs2259873	chr20:25280781	A/G	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.1	0.42	1.24e-6	Menopause (age at onset);
TGCT	cis	rs76419734	0.614	rs17036097	chr4:106597295	G/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.74	4.9	0.4	2.88e-6	Post bronchodilator FEV1;
TGCT	cis	rs9899728	0.764	rs9660	chr17:73038746	A/G	cg27626185	chr17:73056755	KCTD2	-0.61	-5.6	-0.45	1.32e-7	Alzheimer's disease or small vessel stroke;
TGCT	cis	rs2760061	0.819	rs3094914	chr1:228206934	C/T	cg02753203	chr1:228287806	NA	0.3	5.71	0.46	8.06e-8	Diastolic blood pressure;
TGCT	cis	rs3008870	0.755	rs2755243	chr1:67482783	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.81	8.4	0.6	8.51e-14	Lymphocyte percentage of white cells;
TGCT	cis	rs17076896	0.786	rs56682920	chr13:19937751	A/G	cg00777926	chr13:20807375	GJB6	-0.41	-4.82	-0.4	4.03e-6	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs2797160	1.000	rs1739374	chr6:126011825	C/T	cg05901451	chr6:126070800	HEY2	0.72	5.91	0.47	3.15e-8	Endometrial cancer;
TGCT	cis	rs55665837	0.559	rs9667144	chr11:14421101	C/T	cg19336497	chr11:14380999	RRAS2	0.33	4.97	0.41	2.2e-6	Vitamin D levels;
TGCT	cis	rs2354432	0.599	rs6693667	chr1:146817245	A/T	cg25205988	chr1:146714368	CHD1L	1.17	7.25	0.55	3.84e-11	Mitochondrial DNA levels;
TGCT	cis	rs9300255	0.510	rs1790133	chr12:123698518	T/G	cg00376283	chr12:123451042	ABCB9	0.71	5.52	0.44	1.88e-7	Neutrophil percentage of white cells;
TGCT	cis	rs2816062	0.813	rs742485	chr1:18900943	A/T	cg18795169	chr1:18902165	NA	-0.6	-13.84	-0.78	6.55e-27	Urate levels in lean individuals;
TGCT	cis	rs524281	0.692	rs2254388	chr11:65837599	C/T	cg00563793	chr11:65837595	PACS1	-0.57	-5.33	-0.43	4.54e-7	Electroencephalogram traits;
TGCT	cis	rs2072499	1.000	rs2540173	chr1:156188214	A/G	cg06970220	chr1:156163860	SLC25A44	0.67	5.98	0.47	2.22e-8	Testicular germ cell tumor;
TGCT	cis	rs7666738	0.791	rs4440223	chr4:99044796	G/A	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2073300	1.000	rs6137962	chr20:23443966	T/C	cg09953122	chr20:23471693	CST8	-0.64	-4.56	-0.38	1.19e-5	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs12484776	0.677	rs8136269	chr22:40532444	G/C	cg07138101	chr22:40742427	ADSL	0.61	4.6	0.38	1.01e-5	Uterine fibroids;
TGCT	cis	rs1008375	1.000	rs10939740	chr4:17617490	T/C	cg16339924	chr4:17578868	LAP3	0.63	5.23	0.43	6.91e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg20203395	chr5:56204925	C5orf35	-0.59	-5.12	-0.42	1.12e-6	Initial pursuit acceleration;
TGCT	cis	rs66573146	1.000	rs9942188	chr4:6984181	C/T	cg01220768	chr4:7056774	TADA2B	0.39	4.91	0.4	2.77e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs9611565	0.512	rs768414	chr22:42135751	T/C	cg17554472	chr22:41940697	POLR3H	0.46	4.72	0.39	6.36e-6	Vitiligo;
TGCT	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-6.74	-0.52	5.26e-10	Alzheimer's disease;
TGCT	cis	rs11190604	1.000	rs10786597	chr10:102291287	C/T	cg23241863	chr10:102295624	HIF1AN	0.68	5.17	0.42	9.14e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2663905	0.664	rs2460855	chr15:81361729	G/T	cg18028999	chr15:81426610	C15orf26	-0.55	-5.05	-0.41	1.57e-6	QT interval (drug interaction);
TGCT	cis	rs1568889	1.000	rs11604085	chr11:28141002	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	9.0	0.63	3.18e-15	Bipolar disorder;
TGCT	cis	rs3008870	1.000	rs3008858	chr1:67390416	G/C	cg11518657	chr1:67396239	MIER1	0.52	4.53	0.38	1.39e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs9467773	0.620	rs2451732	chr6:26622904	A/T	cg11502198	chr6:26597334	ABT1	-0.56	-4.88	-0.4	3.23e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs9549260	0.755	rs3900833	chr13:41188292	A/G	cg21288729	chr13:41239152	FOXO1	1.0	10.06	0.67	9.29e-18	Red blood cell count;
TGCT	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg27170947	chr2:26402098	FAM59B	-0.4	-4.63	-0.38	8.93e-6	Gut microbiome composition (summer);
TGCT	cis	rs9527	0.567	rs11191573	chr10:104896816	T/C	cg04362960	chr10:104952993	NT5C2	0.69	5.82	0.46	4.78e-8	Arsenic metabolism;
TGCT	cis	rs17331151	0.573	rs28552648	chr3:52865593	G/A	cg15956490	chr3:53032818	SFMBT1	0.46	5.75	0.46	6.57e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs11098499	0.754	rs28652763	chr4:120242312	C/T	cg09307838	chr4:120376055	NA	0.61	5.91	0.47	3.14e-8	Corneal astigmatism;
TGCT	cis	rs826838	0.967	rs2892410	chr12:38990282	A/G	cg26384229	chr12:38710491	ALG10B	-0.98	-9.59	-0.65	1.22e-16	Heart rate;
TGCT	cis	rs3027009	0.881	rs61828174	chr1:159134846	T/A	cg24432768	chr1:158149974	CD1D	-0.5	-4.54	-0.38	1.31e-5	Lean body mass and age at menarche (combined);
TGCT	cis	rs600231	0.708	rs2957268	chr11:65245816	A/G	cg17120908	chr11:65337727	SSSCA1	-0.55	-5.14	-0.42	1.03e-6	Bone mineral density;
TGCT	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg11764359	chr7:65958608	NA	-0.54	-4.9	-0.4	2.89e-6	Aortic root size;
TGCT	cis	rs713587	0.525	rs1541984	chr2:25082414	G/A	cg01884057	chr2:25150051	NA	0.3	5.87	0.47	3.8e-8	Body mass index in non-asthmatics;
TGCT	cis	rs7819412	0.669	rs7823349	chr8:10998630	G/T	cg21775007	chr8:11205619	TDH	-0.55	-5.05	-0.41	1.53e-6	Triglycerides;
TGCT	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	7.26	0.55	3.73e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs4727027	0.704	rs12704070	chr7:148902789	G/A	cg23583168	chr7:148888333	NA	-0.81	-10.9	-0.7	7.99e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs6684514	1.000	rs59468948	chr1:156288058	A/T	cg16558208	chr1:156270281	VHLL	0.48	9.6	0.65	1.19e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg04156016	chr5:1868137	NA	0.33	4.81	0.4	4.32e-6	Cardiovascular disease risk factors;
TGCT	cis	rs7216064	0.953	rs11868959	chr17:65840810	T/C	cg12091567	chr17:66097778	LOC651250	-0.83	-6.49	-0.5	1.9e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs1903068	0.657	rs10026340	chr4:55998136	G/A	cg01777861	chr4:56023843	NA	0.55	5.98	0.47	2.23e-8	Endometriosis;
TGCT	cis	rs3087591	0.708	rs7350943	chr17:29684553	C/T	cg24425628	chr17:29625626	OMG;NF1	0.39	5.56	0.45	1.57e-7	Hip circumference;
TGCT	cis	rs8008270	0.689	rs8012109	chr14:53399337	C/T	cg01926858	chr14:53619558	DDHD1	-0.74	-4.47	-0.37	1.76e-5	Prostate cancer;
TGCT	cis	rs7914558	0.966	rs943035	chr10:104839152	T/C	cg04362960	chr10:104952993	NT5C2	0.6	5.32	0.43	4.64e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs13188771	0.578	rs67960514	chr5:100905390	G/A	cg10455971	chr5:101119566	NA	0.44	4.45	0.37	1.87e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	trans	rs1814175	0.527	rs3974435	chr11:49619533	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.41	-8.24	-0.59	2.03e-13	Height;
TGCT	cis	rs2361718	0.500	rs8064429	chr17:78096187	A/C	cg09238746	chr17:78121135	EIF4A3	-0.9	-8.28	-0.6	1.69e-13	Yeast infection;
TGCT	cis	rs1008375	0.966	rs12509962	chr4:17680292	G/A	cg16339924	chr4:17578868	LAP3	0.52	4.57	0.38	1.16e-5	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg07507251	chr3:52567010	NT5DC2	0.47	6.63	0.51	9.08e-10	Electroencephalogram traits;
TGCT	cis	rs9549367	0.789	rs2287248	chr13:113889226	T/C	cg00898013	chr13:113819073	PROZ	-0.4	-4.92	-0.4	2.7e-6	Platelet distribution width;
TGCT	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg03188948	chr7:1209495	NA	0.64	5.38	0.43	3.61e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs6977660	0.507	rs4721822	chr7:19771693	T/C	cg05791153	chr7:19748676	TWISTNB	1.0	6.66	0.51	8e-10	Thyroid stimulating hormone;
TGCT	cis	rs10927875	0.722	rs1763605	chr1:16338925	T/G	cg14742211	chr1:16348397	CLCNKA	0.19	4.53	0.38	1.37e-5	Dilated cardiomyopathy;
TGCT	cis	rs9399137	0.507	rs13197750	chr6:135312380	G/A	cg24558204	chr6:135376177	HBS1L	0.47	4.78	0.39	4.95e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
TGCT	cis	rs2242116	0.896	rs724448	chr3:46935734	A/C	cg23352942	chr3:46931381	PTH1R	-0.37	-5.81	-0.46	5.02e-8	Birth weight;
TGCT	cis	rs7584330	0.955	rs7581882	chr2:238390745	T/C	cg08992911	chr2:238395768	MLPH	0.67	5.44	0.44	2.69e-7	Prostate cancer;
TGCT	cis	rs5760092	0.755	rs3884794	chr22:24251766	C/A	cg12419862	chr22:24373484	LOC391322	-0.83	-7.5	-0.56	1.09e-11	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs950169	0.881	rs62029596	chr15:84955434	A/G	cg17173187	chr15:85201210	NMB	0.58	5.93	0.47	2.77e-8	Schizophrenia;
TGCT	cis	rs7582180	0.764	rs13006224	chr2:100917109	C/T	cg14675211	chr2:100938903	LONRF2	0.51	4.96	0.41	2.31e-6	Intelligence (multi-trait analysis);
TGCT	trans	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg17830980	chr10:43048298	ZNF37B	-0.85	-11.06	-0.7	3.31e-20	Extrinsic epigenetic age acceleration;
TGCT	cis	rs9807989	0.839	rs9308857	chr2:102979624	G/A	cg09003973	chr2:102972529	NA	0.67	6.03	0.48	1.75e-8	Asthma;
TGCT	cis	rs8072100	0.790	rs7222225	chr17:45693497	A/G	cg08085267	chr17:45401833	C17orf57	0.46	5.01	0.41	1.82e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.05	8.69	0.62	1.83e-14	Platelet count;
TGCT	cis	rs6500602	0.647	rs1659497	chr16:4594635	G/A	cg08645402	chr16:4508243	NA	-0.18	-5.06	-0.41	1.47e-6	Schizophrenia;
TGCT	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg05234568	chr11:5960015	NA	0.52	5.61	0.45	1.26e-7	DNA methylation (variation);
TGCT	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg27286337	chr10:134555280	INPP5A	0.45	5.3	0.43	5.05e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs2440129	0.611	rs1042357	chr17:6905061	T/G	cg02493798	chr17:6899577	ALOX12	0.43	4.65	0.39	8.35e-6	Tonsillectomy;
TGCT	cis	rs4072705	0.835	rs7855360	chr9:127556704	C/T	cg13476313	chr9:127244764	NR5A1	0.29	4.73	0.39	5.9e-6	Menarche (age at onset);
TGCT	cis	rs360798	0.512	rs17027429	chr2:63079983	C/T	cg17519650	chr2:63277830	OTX1	0.65	5.98	0.47	2.23e-8	Coronary artery disease;
TGCT	cis	rs17376456	0.825	rs6874766	chr5:93213807	C/G	cg21475434	chr5:93447410	FAM172A	-0.66	-4.7	-0.39	6.94e-6	Diabetic retinopathy;
TGCT	cis	rs10782582	0.609	rs1001160	chr1:76358591	A/C	cg03433033	chr1:76189801	ACADM	-0.5	-4.95	-0.41	2.39e-6	Daytime sleep phenotypes;
TGCT	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg05457628	chr5:178986728	RUFY1	0.46	5.08	0.42	1.33e-6	Lung cancer;
TGCT	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	5.53	0.44	1.8e-7	Alzheimer's disease;
TGCT	cis	rs7267979	0.844	rs2474780	chr20:25285835	G/A	cg14121845	chr20:25566513	NINL	0.45	4.6	0.38	1.02e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6831352	0.918	rs29001202	chr4:100053782	T/A	cg12011299	chr4:100065546	ADH4	-0.41	-4.96	-0.41	2.29e-6	Alcohol dependence;
TGCT	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg22920501	chr2:26401640	FAM59B	-0.71	-6.1	-0.48	1.27e-8	Gut microbiome composition (summer);
TGCT	cis	rs2795502	1.000	rs2795508	chr10:43353555	G/T	cg20628663	chr10:43360327	NA	0.41	6.18	0.49	8.51e-9	Blood protein levels;
TGCT	cis	rs67311347	0.955	rs6782746	chr3:40510592	A/G	cg17264618	chr3:40429014	ENTPD3	-0.32	-4.64	-0.38	8.57e-6	Renal cell carcinoma;
TGCT	cis	rs3125734	0.633	rs3765002	chr10:64006124	G/T	cg19640130	chr10:64028056	RTKN2	-0.39	-5.04	-0.41	1.57e-6	Rheumatoid arthritis;
TGCT	cis	rs9902453	1.000	rs7221743	chr17:28407876	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.76	-6.77	-0.52	4.55e-10	Coffee consumption (cups per day);
TGCT	cis	rs7949030	0.626	rs11231145	chr11:62328854	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.61	8.71	0.62	1.65e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1903068	0.614	rs9998950	chr4:55996845	C/T	cg09978860	chr4:56023921	NA	0.54	5.58	0.45	1.43e-7	Endometriosis;
TGCT	cis	rs1541995	0.830	rs7171424	chr15:96266446	A/G	cg00882281	chr15:96346592	NA	0.29	4.45	0.37	1.92e-5	Photic sneeze reflex;
TGCT	cis	rs7681440	0.647	rs4522832	chr4:90819391	A/C	cg10208370	chr4:90758469	SNCA	-0.57	-5.39	-0.44	3.46e-7	Dementia with Lewy bodies;
TGCT	trans	rs7698623	0.850	rs4693895	chr4:88797839	C/T	cg01186725	chr1:53905612	FLJ40434	-0.48	-6.63	-0.51	9.21e-10	Cardiovascular disease risk factors;
TGCT	cis	rs916888	0.610	rs199454	chr17:44800110	G/A	cg15921436	chr17:44337874	NA	-0.4	-6.15	-0.48	9.83e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7829975	0.774	rs57312668	chr8:8680477	G/A	cg08975724	chr8:8085496	FLJ10661	0.53	4.74	0.39	5.88e-6	Mood instability;
TGCT	cis	rs1577917	0.771	rs9450290	chr6:86233397	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.6	5.27	0.43	5.84e-7	Response to antipsychotic treatment;
TGCT	cis	rs7666738	0.830	rs35560671	chr4:99069095	G/A	cg17366294	chr4:99064904	C4orf37	0.73	7.45	0.56	1.4e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg06618935	chr21:46677482	NA	-0.36	-5.61	-0.45	1.25e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	trans	rs2469997	1.000	rs2447164	chr8:120371887	G/T	cg01792902	chr3:178864926	PIK3CA	0.83	6.77	0.52	4.49e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	4.92	0.4	2.75e-6	Menopause (age at onset);
TGCT	cis	rs2019216	0.564	rs907707	chr17:21910083	G/C	cg22648282	chr17:21454238	C17orf51	-0.56	-5.45	-0.44	2.57e-7	Pelvic organ prolapse;
TGCT	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg11301795	chr4:187892539	NA	-0.32	-4.92	-0.4	2.7e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7666738	0.791	rs62318907	chr4:99037120	C/T	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs478304	0.619	rs10791822	chr11:65428706	T/C	cg27068330	chr11:65405492	SIPA1	-1.0	-10.96	-0.7	5.91e-20	Acne (severe);
TGCT	cis	rs208520	0.545	rs10944874	chr6:66752080	C/T	cg07460842	chr6:66804631	NA	-1.02	-13.72	-0.78	1.27e-26	Exhaled nitric oxide output;
TGCT	cis	rs7617773	0.539	rs13082217	chr3:48383264	T/C	cg11946769	chr3:48343235	NME6	0.57	4.83	0.4	4.01e-6	Coronary artery disease;
TGCT	cis	rs2249625	0.545	rs60835713	chr6:72880349	T/C	cg08500200	chr6:72892038	RIMS1	0.43	4.61	0.38	1e-5	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
TGCT	cis	rs7552404	0.924	rs1251075	chr1:76190569	C/G	cg03433033	chr1:76189801	ACADM	0.77	9.35	0.64	4.77e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs1577917	1.000	rs10944169	chr6:86683036	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-5.59	-0.45	1.36e-7	Response to antipsychotic treatment;
TGCT	cis	rs7208859	0.673	rs3816780	chr17:29161358	C/T	cg14008862	chr17:28927542	LRRC37B2	0.77	4.52	0.38	1.44e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs909674	0.775	rs4821896	chr22:39833437	T/C	cg05872129	chr22:39784769	NA	-1.0	-9.74	-0.66	5.52e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs17601876	0.814	rs3889391	chr15:51558422	G/A	cg19946085	chr15:51559439	CYP19A1	-0.31	-4.46	-0.37	1.78e-5	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg01802117	chr1:53393560	SCP2	0.43	5.12	0.42	1.14e-6	Monocyte count;
TGCT	cis	rs1524927	1.000	rs13310130	chr7:96346088	T/G	cg03808172	chr7:96339361	SHFM1	0.49	5.06	0.41	1.45e-6	Total body bone mineral density;
TGCT	cis	rs2180341	0.596	rs12215298	chr6:127676833	C/T	cg24812749	chr6:127587940	RNF146	0.67	5.53	0.44	1.84e-7	Breast cancer;
TGCT	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg21724239	chr8:58056113	NA	0.5	5.39	0.44	3.35e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs758129	0.501	rs2072266	chr15:89866954	A/G	cg24365117	chr15:89879190	POLG	0.35	4.76	0.39	5.4e-6	Schizophrenia;
TGCT	cis	rs5769707	0.706	rs2071903	chr22:50034517	G/A	cg05373962	chr22:49881684	NA	-0.31	-5.31	-0.43	4.88e-7	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs2486012	1.000	rs3120805	chr1:44406113	C/T	cg12908607	chr1:44402522	ARTN	0.78	6.04	0.48	1.68e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs13191362	1.000	rs13201023	chr6:162981381	C/G	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.73	0.46	7.24e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs3796352	1.000	rs11712653	chr3:53070875	A/C	cg15956490	chr3:53032818	SFMBT1	-0.61	-8.26	-0.6	1.91e-13	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs7918232	0.662	rs10741125	chr10:27288925	G/A	cg14442939	chr10:27389572	ANKRD26	0.58	4.57	0.38	1.17e-5	Breast cancer;
TGCT	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg23708337	chr7:1209742	NA	0.64	6.18	0.49	8.61e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs394563	0.726	rs6922130	chr6:149672375	C/G	cg16235748	chr6:149772707	ZC3H12D	0.48	5.53	0.44	1.8e-7	Dupuytren's disease;
TGCT	cis	rs9296092	0.517	rs11752179	chr6:33534713	G/T	cg13560919	chr6:33536144	NA	-0.23	-4.95	-0.41	2.4e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs6500602	0.627	rs841231	chr16:4583147	C/T	cg06139259	chr16:4526053	HMOX2;NMRAL1	-0.26	-4.76	-0.39	5.36e-6	Schizophrenia;
TGCT	cis	rs3784262	1.000	rs12915901	chr15:58279432	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.5	-7.82	-0.57	1.96e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs9325144	0.647	rs34963631	chr12:38912260	T/A	cg26384229	chr12:38710491	ALG10B	-0.6	-5.48	-0.44	2.31e-7	Morning vs. evening chronotype;
TGCT	cis	rs938554	0.571	rs12509955	chr4:10024303	C/T	cg11266682	chr4:10021025	SLC2A9	-0.57	-5.45	-0.44	2.59e-7	Blood metabolite levels;
TGCT	trans	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg17830980	chr10:43048298	ZNF37B	-0.83	-10.33	-0.68	2.02e-18	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2290402	0.536	rs4690336	chr4:867242	A/G	cg23332689	chr4:987652	IDUA;SLC26A1	-0.29	-4.44	-0.37	1.97e-5	Type 2 diabetes;
TGCT	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg11494091	chr17:61959527	GH2	0.6	13.05	0.76	5.09e-25	Prudent dietary pattern;
TGCT	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg06238570	chr21:40685208	BRWD1	-0.8	-9.11	-0.63	1.74e-15	Cognitive function;
TGCT	cis	rs3733585	0.648	rs13103497	chr4:9979262	A/G	cg11266682	chr4:10021025	SLC2A9	0.59	7.62	0.56	5.7e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs344364	0.511	rs1742463	chr16:1946110	A/G	cg26617929	chr16:1858877	NA	-0.27	-4.9	-0.4	2.99e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs4919669	0.668	rs10883761	chr10:104420018	A/G	cg05855489	chr10:104503620	C10orf26	0.8	4.59	0.38	1.05e-5	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs713587	0.713	rs12618252	chr2:25207950	G/A	cg15423357	chr2:25149977	NA	-0.58	-5.9	-0.47	3.16e-8	Body mass index in non-asthmatics;
TGCT	cis	rs12134245	0.776	rs13447464	chr1:91968278	G/A	cg02896835	chr1:92012615	NA	-0.29	-4.8	-0.4	4.47e-6	Breast cancer;
TGCT	trans	rs12599106	0.679	rs34584967	chr16:34475725	T/G	cg21548813	chr6:291882	DUSP22	-0.64	-6.85	-0.52	3.04e-10	Menopause (age at onset);
TGCT	cis	rs28830936	0.509	rs6493005	chr15:41859152	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.19	-4.77	-0.39	5.07e-6	Diastolic blood pressure;
TGCT	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.03	0.41	1.71e-6	Menopause (age at onset);
TGCT	cis	rs7226408	0.857	rs11659681	chr18:34458035	C/T	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg05368731	chr17:41323189	NBR1	1.1	11.24	0.71	1.23e-20	Menopause (age at onset);
TGCT	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg26338869	chr17:61819248	STRADA	-0.56	-5.11	-0.42	1.17e-6	Prudent dietary pattern;
TGCT	cis	rs1670533	0.685	rs56019586	chr4:1059842	C/G	cg20887711	chr4:1340912	KIAA1530	0.71	5.7	0.46	8.33e-8	Recombination rate (females);
TGCT	cis	rs7949030	0.591	rs12049914	chr11:62369436	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.7	8.89	0.62	5.98e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg22968622	chr17:43663579	NA	1.29	11.02	0.7	4.06e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs6988636	0.534	rs62521778	chr8:124122794	T/G	cg27053337	chr8:124217698	FAM83A	0.56	4.83	0.4	3.91e-6	Urinary uromodulin levels;
TGCT	cis	rs651907	0.557	rs7629753	chr3:101371922	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.53	-5.03	-0.41	1.69e-6	Colorectal cancer;
TGCT	trans	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg23505145	chr19:12996616	KLF1	0.78	8.12	0.59	4.03e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9302065	0.681	rs9524902	chr13:95963518	C/T	cg24476569	chr13:95954382	ABCC4	-0.45	-6.36	-0.5	3.61e-9	Blood metabolite levels;
TGCT	cis	rs4803468	1.000	rs3810174	chr19:41904165	C/T	cg09537434	chr19:41945824	ATP5SL	-0.89	-10.04	-0.67	9.93e-18	Height;
TGCT	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg04944784	chr2:26401820	FAM59B	0.76	6.24	0.49	6.46e-9	Gut microbiome composition (summer);
TGCT	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg24549020	chr5:56110836	MAP3K1	-0.69	-4.96	-0.41	2.29e-6	Initial pursuit acceleration;
TGCT	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg20573242	chr4:122745356	CCNA2	0.62	5.48	0.44	2.24e-7	Type 2 diabetes;
TGCT	cis	rs5769707	0.837	rs5769709	chr22:50021757	C/T	cg20744362	chr22:50050164	C22orf34	0.28	4.54	0.38	1.32e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs2933343	1.000	rs1683811	chr3:128612113	A/C	cg11901034	chr3:128598214	ACAD9	-0.64	-5.05	-0.41	1.56e-6	IgG glycosylation;
TGCT	trans	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-1.03	-13.16	-0.76	2.65e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	4.89	0.4	3e-6	Menopause (age at onset);
TGCT	cis	rs1371867	0.846	rs1660312	chr8:101330634	C/G	cg00191853	chr8:101177733	SPAG1	-0.23	-4.55	-0.38	1.24e-5	Atrioventricular conduction;
TGCT	cis	rs12477438	0.798	rs7570657	chr2:99654281	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-7.6	-0.56	6.47e-12	Chronic sinus infection;
TGCT	cis	rs7611238	0.560	rs62288365	chr3:195110720	T/C	cg27323046	chr3:195102265	ACAP2	0.37	5.01	0.41	1.81e-6	Body mass index;
TGCT	cis	rs7267979	1.000	rs6107033	chr20:25363591	A/G	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg05896524	chr21:47604654	C21orf56	0.42	4.45	0.37	1.91e-5	Testicular germ cell tumor;
TGCT	cis	rs6121246	0.529	rs6060210	chr20:30187681	C/T	cg21427119	chr20:30132790	HM13	-0.42	-6.17	-0.48	8.75e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs4253772	0.591	rs8143066	chr22:46656607	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.55	4.46	0.37	1.84e-5	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs910187	0.537	rs6122556	chr20:45763924	T/A	cg27589058	chr20:45804311	EYA2	-0.34	-6.29	-0.49	4.97e-9	Migraine;
TGCT	cis	rs7772486	0.875	rs2814877	chr6:146299763	C/G	cg23711669	chr6:146136114	FBXO30	0.87	9.35	0.64	4.65e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9303401	0.704	rs7359501	chr17:56641200	C/T	cg12560992	chr17:57184187	TRIM37	0.6	6.5	0.5	1.74e-9	Cognitive test performance;
TGCT	cis	rs7727544	0.582	rs3749756	chr5:131534499	C/T	cg24060327	chr5:131705240	SLC22A5	-0.44	-4.5	-0.37	1.56e-5	Blood metabolite levels;
TGCT	cis	rs7666738	0.830	rs4699592	chr4:98974202	A/C	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs908922	0.676	rs12132469	chr1:152491856	G/T	cg20991723	chr1:152506922	NA	0.46	6.28	0.49	5.16e-9	Hair morphology;
TGCT	cis	rs9399135	0.967	rs1023179	chr6:135343829	T/A	cg24558204	chr6:135376177	HBS1L	0.5	5.0	0.41	1.89e-6	Red blood cell count;
TGCT	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg13409248	chr3:40428643	ENTPD3	0.57	4.53	0.38	1.37e-5	Renal cell carcinoma;
TGCT	cis	rs2236918	0.710	rs2488470	chr1:242019580	A/G	cg04158730	chr1:242011433	EXO1	0.57	5.33	0.43	4.4e-7	Menopause (age at onset);
TGCT	cis	rs9807989	0.524	rs7594402	chr2:103021267	A/T	cg03938978	chr2:103052716	IL18RAP	0.27	5.41	0.44	3.17e-7	Asthma;
TGCT	trans	rs2727020	0.575	rs10769587	chr11:49549849	C/G	cg03929089	chr4:120376271	NA	-0.66	-7.6	-0.56	6.24e-12	Coronary artery disease;
TGCT	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.78	5.25	0.43	6.53e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2180341	0.883	rs6904630	chr6:127696869	A/G	cg24812749	chr6:127587940	RNF146	0.99	7.63	0.57	5.24e-12	Breast cancer;
TGCT	cis	rs9911578	0.967	rs4598970	chr17:57076893	T/A	cg05425664	chr17:57184151	TRIM37	0.68	6.89	0.53	2.55e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs4746818	1.000	rs6480384	chr10:70890757	C/T	cg11621586	chr10:70884670	VPS26A	1.21	10.66	0.69	3.17e-19	Left atrial antero-posterior diameter;
TGCT	cis	rs36051895	0.695	rs59384377	chr9:5005034	A/T	cg02405213	chr9:5042618	JAK2	-0.76	-10.25	-0.68	3.06e-18	Pediatric autoimmune diseases;
TGCT	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg09359103	chr1:154839909	KCNN3	-0.67	-12.42	-0.74	1.61e-23	Prostate cancer;
TGCT	cis	rs1023500	0.551	rs133379	chr22:42468535	A/G	cg15557168	chr22:42548783	NA	-0.21	-5.29	-0.43	5.31e-7	Schizophrenia;
TGCT	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	5.17	0.42	9.28e-7	Alzheimer's disease;
TGCT	cis	rs11122272	0.766	rs2790870	chr1:231543823	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-6.71	-0.52	6.09e-10	Hemoglobin concentration;
TGCT	cis	rs4824093	0.610	rs58671506	chr22:50288983	G/A	cg20569369	chr22:51173646	NA	0.28	4.58	0.38	1.13e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	trans	rs9650657	0.547	rs11250099	chr8:10818657	C/T	cg06636001	chr8:8085503	FLJ10661	0.84	8.29	0.6	1.58e-13	Neuroticism;
TGCT	cis	rs7843479	0.562	rs4872191	chr8:21824547	A/G	cg17168535	chr8:21777572	XPO7	0.81	8.33	0.6	1.25e-13	Mean corpuscular volume;
TGCT	cis	rs11621121	0.556	rs9635249	chr14:65797784	A/G	cg04536575	chr14:65016802	C14orf50	-0.64	-4.57	-0.38	1.17e-5	N-glycan levels;
TGCT	cis	rs6987853	0.933	rs6474401	chr8:42367068	T/C	cg20539142	chr8:42623718	CHRNA6	0.19	4.46	0.37	1.83e-5	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg03188948	chr7:1209495	NA	0.8	6.72	0.52	5.94e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg13695892	chr22:41940480	POLR3H	-0.92	-9.33	-0.64	5.22e-16	Vitiligo;
TGCT	cis	rs2013441	0.711	rs1682297	chr17:20384920	C/T	cg18979559	chr17:20280153	CCDC144C	0.52	5.78	0.46	5.65e-8	Obesity-related traits;
TGCT	cis	rs2070488	0.861	rs1858740	chr3:38438372	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.89	9.52	0.65	1.86e-16	Electrocardiographic conduction measures;
TGCT	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg13732083	chr21:47605072	C21orf56	0.38	4.89	0.4	3.11e-6	Testicular germ cell tumor;
TGCT	cis	rs12908161	1.000	rs58416181	chr15:85264461	G/A	cg12863693	chr15:85201151	NMB	0.46	5.51	0.44	1.95e-7	Schizophrenia;
TGCT	cis	rs6952808	0.858	rs12671113	chr7:1965255	G/A	cg04267008	chr7:1944627	MAD1L1	-0.34	-4.58	-0.38	1.13e-5	Bipolar disorder and schizophrenia;
TGCT	cis	rs4144743	0.941	rs7211563	chr17:45324061	T/C	cg18085866	chr17:45331354	ITGB3	-0.72	-4.8	-0.4	4.39e-6	Body mass index;
TGCT	trans	rs9295123	0.898	rs9347386	chr6:160571499	A/G	cg22927510	chr22:50968328	TYMP	-0.52	-6.96	-0.53	1.76e-10	Blood protein levels;
TGCT	cis	rs7809950	0.954	rs2712229	chr7:107295326	T/A	cg23024343	chr7:107201750	COG5	0.31	4.97	0.41	2.21e-6	Coronary artery disease;
TGCT	cis	rs3782455	1.000	rs77542721	chr12:114402518	C/T	cg23502203	chr12:113549970	RASAL1	-0.55	-4.92	-0.4	2.7e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs9527	0.590	rs11191553	chr10:104851396	G/T	cg15744005	chr10:104629667	AS3MT	-0.42	-4.84	-0.4	3.82e-6	Arsenic metabolism;
TGCT	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg24531977	chr5:56204891	C5orf35	-0.77	-7.61	-0.56	5.83e-12	Initial pursuit acceleration;
TGCT	cis	rs858239	0.600	rs28483572	chr7:23131785	A/G	cg05602783	chr7:23145260	KLHL7	-0.6	-4.99	-0.41	2.02e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs2637266	0.905	rs7076442	chr10:78360480	A/C	cg18941641	chr10:78392320	NA	-0.41	-5.18	-0.42	8.65e-7	Pulmonary function;
TGCT	cis	rs7829975	0.582	rs6982832	chr8:8792217	A/C	cg15556689	chr8:8085844	FLJ10661	-0.67	-6.1	-0.48	1.26e-8	Mood instability;
TGCT	cis	rs4237845	0.537	rs2002275	chr12:58283385	A/G	cg23860436	chr12:58378763	NA	0.32	4.46	0.37	1.79e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg04944784	chr2:26401820	FAM59B	-0.67	-6.16	-0.48	9.54e-9	Gut microbiome composition (summer);
TGCT	cis	rs17376456	0.877	rs9314100	chr5:93447394	T/C	cg25358565	chr5:93447407	FAM172A	0.93	8.37	0.6	1.04e-13	Diabetic retinopathy;
TGCT	cis	rs28595532	0.764	rs55704595	chr4:119780607	G/A	cg21605333	chr4:119757512	SEC24D	1.53	8.87	0.62	6.71e-15	Cannabis dependence symptom count;
TGCT	cis	rs427394	0.802	rs274698	chr5:6730957	T/G	cg10857441	chr5:6722123	POLS	-0.32	-7.93	-0.58	1.08e-12	Menopause (age at onset);
TGCT	cis	rs2235642	0.717	rs9937922	chr16:1658154	C/G	cg08296037	chr16:1584118	IFT140;TMEM204	-0.29	-5.01	-0.41	1.8e-6	Coronary artery disease;
TGCT	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg02353165	chr6:42928485	GNMT	0.94	9.63	0.65	1.01e-16	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs11190604	1.000	rs17746014	chr10:102315354	T/C	cg16342193	chr10:102329863	NA	-0.39	-4.95	-0.41	2.35e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs12497850	0.931	rs6442130	chr3:48778027	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.4	-5.19	-0.42	8.44e-7	Parkinson's disease;
TGCT	cis	rs1075232	1.000	rs72722829	chr15:31639114	G/A	cg01030201	chr15:31746330	NA	-1.01	-5.25	-0.43	6.38e-7	Survival in colorectal cancer (non-distant metastatic);
TGCT	cis	rs295140	0.526	rs295113	chr2:201197816	C/G	cg23649088	chr2:200775458	C2orf69	0.28	4.55	0.38	1.25e-5	QT interval;
TGCT	cis	rs11677370	0.963	rs6720903	chr2:3817635	A/G	cg17052675	chr2:3827356	NA	-0.3	-5.2	-0.42	7.86e-7	Type 2 diabetes;
TGCT	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.03	0.41	1.68e-6	Prudent dietary pattern;
TGCT	trans	rs2727020	0.575	rs10769587	chr11:49549849	C/G	cg15704280	chr7:45808275	SEPT13	-0.61	-6.78	-0.52	4.26e-10	Coronary artery disease;
TGCT	cis	rs7246657	0.722	rs8110865	chr19:38047387	G/A	cg03611452	chr19:38183253	ZNF781	0.58	4.64	0.38	8.62e-6	Coronary artery calcification;
TGCT	cis	rs6570726	0.846	rs439035	chr6:145887990	G/C	cg05347473	chr6:146136440	FBXO30	0.51	4.78	0.39	4.8e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3806843	0.548	rs246056	chr5:140325600	G/A	cg07102913	chr5:140593443	PCDHB13	-0.46	-4.65	-0.39	8.2e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg11301795	chr4:187892539	NA	-0.31	-4.79	-0.4	4.69e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg12751644	chr20:60527061	NA	-0.39	-4.55	-0.38	1.27e-5	Body mass index;
TGCT	cis	rs9329289	0.510	rs12359941	chr10:2547015	G/A	cg07014206	chr10:2547000	NA	-0.28	-4.66	-0.39	8.13e-6	Age-related hearing impairment;
TGCT	cis	rs12220238	0.730	rs4746177	chr10:75913033	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.91	7.94	0.58	1.02e-12	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs2153535	0.580	rs9406170	chr6:8514153	T/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.01	0.41	1.86e-6	Motion sickness;
TGCT	cis	rs4722166	0.564	rs1800797	chr7:22766221	A/G	cg26061582	chr7:22766209	IL6	0.48	6.26	0.49	5.87e-9	Lung cancer;
TGCT	cis	rs9436747	0.641	rs4655528	chr1:66049489	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.53	4.73	0.39	5.97e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs60154123	0.505	rs76426571	chr1:210041634	C/T	cg23283495	chr1:209979779	IRF6	0.67	4.99	0.41	1.96e-6	Coronary artery disease;
TGCT	trans	rs4942242	0.659	rs1105586	chr13:44232633	C/T	cg19169023	chr15:41853346	TYRO3	0.35	6.63	0.51	9.24e-10	Response to tocilizumab in rheumatoid arthritis;
TGCT	cis	rs11696501	0.688	rs6073862	chr20:44331705	T/C	cg16448223	chr20:44035136	DBNDD2;SYS1-DBNDD2	-0.62	-4.81	-0.4	4.31e-6	Brain structure;
TGCT	cis	rs3784262	1.000	rs9325	chr15:58245986	A/T	cg12031962	chr15:58353849	ALDH1A2	0.48	7.34	0.55	2.49e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs9397585	0.759	rs6920313	chr6:153402841	T/C	cg24028809	chr6:153414101	RGS17	0.22	4.58	0.38	1.11e-5	Body mass index;
TGCT	cis	rs2013441	1.000	rs2703802	chr17:20101039	T/C	cg18979559	chr17:20280153	CCDC144C	-0.44	-4.61	-0.38	9.78e-6	Obesity-related traits;
TGCT	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg18538332	chr22:24372958	LOC391322	-1.0	-12.7	-0.75	3.51e-24	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2302045	0.826	rs1444998	chr2:242053167	T/C	cg04553960	chr2:241721320	KIF1A	-0.7	-4.68	-0.39	7.4e-6	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio);
TGCT	cis	rs7752195	0.643	rs74983924	chr6:25248006	T/C	cg16898833	chr6:26189333	HIST1H4D	1.17	5.47	0.44	2.34e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12497850	0.627	rs4974078	chr3:49009386	C/T	cg03060546	chr3:49711283	APEH	0.52	5.7	0.46	8.28e-8	Parkinson's disease;
TGCT	cis	rs12142240	0.698	rs112089006	chr1:46812360	C/T	cg00530320	chr1:46809349	NSUN4	0.29	5.84	0.46	4.33e-8	Menopause (age at onset);
TGCT	cis	rs9814567	0.806	rs4245904	chr3:134321808	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.76	-7.11	-0.54	8.15e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs79057730	0.528	rs4719313	chr7:822501	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.65	5.31	0.43	4.93e-7	Initial pursuit acceleration;
TGCT	cis	rs644799	0.931	rs496305	chr11:95567035	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	7.92	0.58	1.12e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9653442	0.704	rs10211595	chr2:100726476	G/C	cg07810366	chr2:100720526	AFF3	-0.43	-7.11	-0.54	8.22e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs7246657	0.722	rs2972458	chr19:38135403	T/C	cg18154014	chr19:37997991	ZNF793	-0.67	-4.69	-0.39	6.96e-6	Coronary artery calcification;
TGCT	cis	rs1215050	0.547	rs6532690	chr4:98618571	C/A	cg05340658	chr4:99064831	C4orf37	-0.41	-4.96	-0.41	2.3e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs17270561	0.887	rs717551	chr6:25855624	T/C	cg17042849	chr6:26104293	HIST1H4C	-0.94	-6.13	-0.48	1.06e-8	Iron status biomarkers;
TGCT	cis	rs1499614	1.000	rs60326618	chr7:66166358	G/A	cg18252515	chr7:66147081	NA	-1.26	-7.95	-0.58	9.71e-13	Gout;
TGCT	cis	rs7666738	0.830	rs13328005	chr4:99055480	T/C	cg17366294	chr4:99064904	C4orf37	0.74	7.53	0.56	9.25e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10206020	0.885	rs6720797	chr2:1574340	T/C	cg12573674	chr2:1569213	NA	-0.46	-5.2	-0.42	7.88e-7	IgG glycosylation;
TGCT	cis	rs2440129	0.611	rs2292352	chr17:6902887	A/G	cg05215272	chr17:6899095	ALOX12	0.55	6.61	0.51	1.03e-9	Tonsillectomy;
TGCT	cis	rs3008870	1.000	rs3008873	chr1:67425770	G/A	cg03991309	chr1:68237761	GNG12	0.27	4.53	0.38	1.36e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs4455778	0.600	rs4461853	chr7:49090901	T/C	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs9388451	0.903	rs9388446	chr6:126064920	T/A	cg10911889	chr6:126070802	HEY2	0.51	5.16	0.42	9.49e-7	Brugada syndrome;
TGCT	cis	rs4494114	1.000	rs3790441	chr1:39352492	G/A	cg25970120	chr1:39325951	RRAGC	-0.6	-6.33	-0.49	4.16e-9	Blood protein levels;
TGCT	cis	rs6088590	0.930	rs6087618	chr20:33288407	C/T	cg08999081	chr20:33150536	PIGU	0.26	4.7	0.39	6.76e-6	Coronary artery disease;
TGCT	cis	rs3764563	0.877	rs4019751	chr19:15740716	T/G	cg20725493	chr19:15740067	CYP4F8	-0.43	-4.67	-0.39	7.75e-6	Inflammatory biomarkers;
TGCT	cis	rs9916302	0.904	rs35285898	chr17:37555872	A/C	cg15445000	chr17:37608096	MED1	-0.34	-4.8	-0.4	4.43e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7666738	0.830	rs6839277	chr4:99015563	C/T	cg18180107	chr4:99064573	C4orf37	0.54	5.03	0.41	1.7e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6740322	0.895	rs10210125	chr2:43556433	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.39	-6.58	-0.51	1.17e-9	Coronary artery disease;
TGCT	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg15383120	chr6:291909	DUSP22	-0.68	-7.03	-0.53	1.21e-10	Menopause (age at onset);
TGCT	cis	rs4937076	1.000	rs1065398	chr11:125828007	T/C	cg17967973	chr11:126139042	FOXRED1;SRPR	-0.41	-4.57	-0.38	1.15e-5	Primary tooth development (time to first tooth eruption);
TGCT	cis	rs9902453	0.967	rs12150261	chr17:28320473	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-6.77	-0.52	4.69e-10	Coffee consumption (cups per day);
TGCT	cis	rs9383153	1.000	rs9370888	chr6:16335544	A/G	cg20052079	chr6:15504923	JARID2	0.95	5.79	0.46	5.55e-8	Gambling;
TGCT	cis	rs72945132	0.882	rs17425511	chr11:70183737	C/G	cg00319359	chr11:70116639	PPFIA1	0.97	7.07	0.54	1.01e-10	Coronary artery disease;
TGCT	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg25811766	chr13:21894605	NA	0.28	5.38	0.44	3.53e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	cis	rs12580194	0.593	rs59676560	chr12:55745425	T/C	cg10672482	chr12:55725839	OR6C3	-0.52	-4.66	-0.39	8.13e-6	Cancer;
TGCT	cis	rs7043114	0.507	rs7037075	chr9:95216613	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-5.37	-0.43	3.72e-7	Height;
TGCT	cis	rs4654899	0.680	rs10916900	chr1:21239059	C/G	cg01072550	chr1:21505969	NA	-0.56	-9.17	-0.64	1.28e-15	Superior frontal gyrus grey matter volume;
TGCT	cis	rs10894604	0.579	rs12275225	chr11:132652897	A/G	cg16639665	chr11:133402497	OPCML	0.45	4.66	0.39	8.09e-6	Waist-hip ratio;
TGCT	cis	rs1005277	0.505	rs1208689	chr10:38097775	C/G	cg13531842	chr10:38383804	ZNF37A	-0.39	-4.58	-0.38	1.1e-5	Extrinsic epigenetic age acceleration;
TGCT	cis	rs1256061	0.528	rs10143616	chr14:64740175	G/A	cg07667295	chr14:64320118	SYNE2	-0.49	-4.49	-0.37	1.63e-5	Hemoglobin concentration;Red blood cell count;Hematocrit;
TGCT	cis	rs6430585	0.583	rs3754689	chr2:136590746	C/T	cg07169764	chr2:136633963	MCM6	1.09	9.89	0.66	2.28e-17	Corneal structure;
TGCT	cis	rs11718455	0.921	rs1404482	chr3:43997282	A/G	cg08738300	chr3:44038990	NA	0.81	6.02	0.48	1.8e-8	Coronary artery disease;
TGCT	cis	rs2239547	0.523	rs6803486	chr3:53098209	T/A	cg10802521	chr3:52805072	NEK4	-0.58	-5.31	-0.43	4.87e-7	Schizophrenia;
TGCT	cis	rs73099903	0.611	rs7485642	chr12:53391501	C/T	cg24505307	chr12:53448429	TENC1	0.35	4.58	0.38	1.11e-5	Systolic blood pressure;
TGCT	cis	rs910316	0.763	rs175047	chr14:75479039	C/G	cg08847533	chr14:75593920	NEK9	-0.84	-9.16	-0.64	1.34e-15	Height;
TGCT	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg04944784	chr2:26401820	FAM59B	-0.7	-6.49	-0.5	1.89e-9	Gut microbiome composition (summer);
TGCT	cis	rs7586879	0.828	rs9631062	chr2:25110084	C/T	cg01884057	chr2:25150051	NA	0.28	4.96	0.41	2.26e-6	Body mass index;
TGCT	cis	rs3820068	0.553	rs7545782	chr1:15955227	G/C	cg05660106	chr1:15850417	CASP9	0.84	8.28	0.6	1.64e-13	Systolic blood pressure;
TGCT	cis	rs853679	0.607	rs201002	chr6:27808192	A/G	cg10876282	chr6:28092338	ZSCAN16	0.72	4.48	0.37	1.65e-5	Depression;
TGCT	trans	rs11082438	1.000	rs11082438	chr18:42865210	G/T	cg16697433	chr11:134398473	NA	-0.92	-6.77	-0.52	4.48e-10	Follicular lymphoma;
TGCT	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg26119090	chr2:26468346	HADHA;HADHB	1.0	7.42	0.55	1.64e-11	Gut microbiome composition (summer);
TGCT	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg03709012	chr19:19516395	GATAD2A	0.73	6.26	0.49	5.86e-9	Tonsillectomy;
TGCT	cis	rs28595532	0.920	rs115103359	chr4:119739608	A/T	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs644799	0.544	rs1622515	chr11:95523433	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.56	6.01	0.48	1.91e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs6840360	0.550	rs7675818	chr4:152690777	C/G	cg17479576	chr4:152424074	FAM160A1	-0.53	-5.28	-0.43	5.53e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg08280861	chr8:58055591	NA	0.4	4.67	0.39	7.79e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6582630	0.638	rs12423236	chr12:38548162	G/A	cg26384229	chr12:38710491	ALG10B	-0.53	-4.77	-0.39	5.12e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg04267008	chr7:1944627	MAD1L1	0.34	4.57	0.38	1.17e-5	Bipolar disorder and schizophrenia;
TGCT	cis	rs2440129	0.632	rs15966	chr17:6905643	T/C	cg05215272	chr17:6899095	ALOX12	0.57	6.79	0.52	4.04e-10	Tonsillectomy;
TGCT	cis	rs12477438	0.765	rs6750876	chr2:99679673	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-4.88	-0.4	3.17e-6	Chronic sinus infection;
TGCT	cis	rs912057	0.671	rs1294420	chr6:6742752	C/T	cg06612196	chr6:6737390	NA	0.47	7.06	0.54	1.05e-10	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg13695892	chr22:41940480	POLR3H	-0.9	-8.66	-0.61	2.17e-14	Vitiligo;
TGCT	cis	rs778371	0.578	rs2675956	chr2:233753340	G/A	cg25237894	chr2:233734115	C2orf82	-0.25	-4.49	-0.37	1.63e-5	Schizophrenia;
TGCT	cis	rs910316	0.967	rs4899545	chr14:75568138	A/G	cg08847533	chr14:75593920	NEK9	0.96	10.9	0.7	8.37e-20	Height;
TGCT	trans	rs66573146	1.000	rs7675281	chr4:7002120	C/T	cg07817883	chr1:32538562	TMEM39B	1.77	8.38	0.6	9.8e-14	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs1018836	0.828	rs756568	chr8:91557038	G/C	cg16814680	chr8:91681699	NA	-0.75	-7.83	-0.58	1.82e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6835098	1.000	rs6835098	chr4:174089238	T/C	cg08422745	chr4:174089978	GALNT7	-0.95	-11.46	-0.72	3.51e-21	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg07507251	chr3:52567010	NT5DC2	0.47	6.6	0.51	1.05e-9	Bipolar disorder;
TGCT	cis	rs9457247	0.935	rs1044059	chr6:167369897	C/A	cg23791538	chr6:167370224	RNASET2	0.51	4.98	0.41	2.05e-6	Crohn's disease;
TGCT	cis	rs7312933	0.703	rs2406567	chr12:42551479	G/C	cg19980929	chr12:42632907	YAF2	0.46	6.3	0.49	4.75e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs2153535	0.580	rs7755284	chr6:8457479	T/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs9814567	0.752	rs13098546	chr3:134333161	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.73	6.6	0.51	1.08e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs17221829	0.739	rs72971036	chr11:89370552	G/C	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.63	-0.38	9.04e-6	Anxiety in major depressive disorder;
TGCT	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg14893161	chr1:205819251	PM20D1	0.57	8.2	0.59	2.52e-13	Menarche (age at onset);
TGCT	cis	rs854765	0.583	rs7214002	chr17:17852104	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.74	7.55	0.56	8.23e-12	Total body bone mineral density;
TGCT	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg00814883	chr7:100076585	TSC22D4	-0.89	-9.24	-0.64	8.75e-16	Platelet count;
TGCT	cis	rs9379774	0.623	rs6905021	chr6:25441831	C/G	cg13320114	chr6:26216906	HIST1H2AE;HIST1H2BG	0.75	4.72	0.39	6.15e-6	Coronary artery disease;
TGCT	cis	rs28830936	0.535	rs2289743	chr15:41860698	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.19	-4.57	-0.38	1.15e-5	Diastolic blood pressure;
TGCT	cis	rs6582630	0.555	rs11182193	chr12:38474090	C/G	cg13010199	chr12:38710504	ALG10B	0.58	4.72	0.39	6.16e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg22920501	chr2:26401640	FAM59B	-0.73	-6.44	-0.5	2.35e-9	Gut microbiome composition (summer);
TGCT	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg08439880	chr3:133502540	NA	-0.28	-5.15	-0.42	9.73e-7	Iron status biomarkers;
TGCT	cis	rs12541335	0.692	rs2290274	chr8:22214374	C/T	cg02788857	chr8:22132959	PIWIL2	0.3	5.44	0.44	2.7e-7	Hypertriglyceridemia;
TGCT	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg17971929	chr21:40555470	PSMG1	-0.91	-8.09	-0.59	4.63e-13	Cognitive function;
TGCT	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg22166914	chr1:53195759	ZYG11B	0.39	6.68	0.51	7.28e-10	Monocyte count;
TGCT	cis	rs78456975	1.000	rs13416881	chr2:1554808	G/A	cg01028140	chr2:1542097	TPO	-0.35	-4.57	-0.38	1.17e-5	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs6089584	1.000	rs6089585	chr20:60564395	G/A	cg06108461	chr20:60628389	TAF4	-0.53	-7.39	-0.55	1.9e-11	Body mass index;
TGCT	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg16680214	chr1:154839983	KCNN3	-0.37	-7.77	-0.57	2.54e-12	Prostate cancer;
TGCT	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-5.09	-0.42	1.27e-6	Bipolar disorder;
TGCT	cis	rs926938	0.608	rs360612	chr1:115394747	G/A	cg12756093	chr1:115239321	AMPD1	0.41	5.84	0.46	4.25e-8	Autism;
TGCT	cis	rs7302981	0.934	rs7301649	chr12:50540870	T/C	cg23855989	chr12:50355821	AQP5	-0.3	-4.5	-0.38	1.52e-5	Systolic blood pressure;
TGCT	cis	rs7547997	0.685	rs11264963	chr1:158335533	A/G	cg03528325	chr1:158223921	CD1A	0.33	4.69	0.39	7.06e-6	QRS duration;
TGCT	cis	rs8067545	0.750	rs4570919	chr17:20000815	C/T	cg13482628	chr17:19912719	NA	0.52	4.48	0.37	1.68e-5	Schizophrenia;
TGCT	trans	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg13615516	chr5:77269221	NA	0.67	8.36	0.6	1.09e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1555322	0.530	rs2425047	chr20:33871675	G/T	cg03689076	chr20:33865952	NA	-0.59	-4.46	-0.37	1.85e-5	Attention deficit hyperactivity disorder;
TGCT	cis	rs7926906	1.000	rs7952309	chr11:90526114	A/G	cg26138821	chr11:89956704	CHORDC1	-0.52	-5.46	-0.44	2.44e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs79349575	0.783	rs318090	chr17:46991752	G/A	cg07967210	chr17:47022446	SNF8	0.44	6.12	0.48	1.13e-8	Type 2 diabetes;
TGCT	cis	rs7772486	0.806	rs2247317	chr6:146217570	C/T	cg23711669	chr6:146136114	FBXO30	0.83	9.16	0.64	1.32e-15	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs1005277	0.522	rs1208767	chr10:38042295	G/T	cg17830980	chr10:43048298	ZNF37B	-0.64	-7.29	-0.55	3.24e-11	Extrinsic epigenetic age acceleration;
TGCT	trans	rs7819412	0.538	rs4523214	chr8:10970773	T/A	cg15556689	chr8:8085844	FLJ10661	-0.82	-8.13	-0.59	3.72e-13	Triglycerides;
TGCT	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg06873352	chr17:61820015	STRADA	0.55	6.13	0.48	1.09e-8	Prudent dietary pattern;
TGCT	cis	rs877529	0.605	rs139387	chr22:39531085	G/A	cg18708252	chr22:39545030	CBX7	-0.38	-5.6	-0.45	1.29e-7	Multiple myeloma;
TGCT	cis	rs10791097	0.765	rs10894269	chr11:130722789	C/T	cg14779329	chr11:130786720	SNX19	0.27	4.59	0.38	1.06e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs7904368	0.806	rs7899923	chr10:16857394	G/A	cg14835575	chr10:16859367	RSU1	0.7	7.5	0.56	1.04e-11	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
TGCT	cis	rs7223966	1.000	rs9903897	chr17:61716705	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	4.76	0.39	5.24e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	trans	rs829418	0.582	rs747662	chr1:21947218	C/G	cg12068366	chr19:4548354	SEMA6B	0.61	6.7	0.52	6.47e-10	Neurocognitive impairment in HIV-1 infection (continuous);
TGCT	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg23719950	chr11:63933701	MACROD1	-0.72	-5.95	-0.47	2.61e-8	Mean platelet volume;
TGCT	cis	rs2688608	0.592	rs7076585	chr10:75503692	T/C	cg15838173	chr10:75533400	FUT11	-0.31	-4.89	-0.4	3.12e-6	Inflammatory bowel disease;
TGCT	cis	rs2840044	1.000	rs10068	chr17:33901965	C/G	cg05299278	chr17:33885742	SLFN14	-0.24	-5.26	-0.43	6.14e-7	Response to radiotherapy in cancer (late toxicity);
TGCT	cis	rs3749237	0.964	rs11717463	chr3:49808981	C/T	cg07636037	chr3:49044803	WDR6	0.55	4.49	0.37	1.58e-5	Resting heart rate;
TGCT	cis	rs9818758	0.607	rs73082362	chr3:49113729	C/T	cg00383909	chr3:49044727	WDR6	1.54	5.91	0.47	3.14e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs2760061	0.626	rs592736	chr1:228116831	A/G	cg02753203	chr1:228287806	NA	-0.33	-6.25	-0.49	6e-9	Diastolic blood pressure;
TGCT	cis	rs6750047	0.566	rs1157185	chr2:38285735	C/T	cg07380506	chr2:38303506	CYP1B1	0.67	6.15	0.48	9.81e-9	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs3772130	0.564	rs28760466	chr3:121601510	A/G	cg20356878	chr3:121714668	ILDR1	0.38	4.85	0.4	3.59e-6	Cognitive performance;
TGCT	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs12367572	1.000	rs10880704	chr12:45318430	C/T	cg04608330	chr12:45269318	NELL2	-0.68	-7.2	-0.54	5e-11	Gut microbiome composition (summer);
TGCT	cis	rs263156	0.903	rs263130	chr6:142928295	A/G	cg18419694	chr6:143832440	FUCA2	0.43	4.97	0.41	2.16e-6	Ear morphology;Lobe size;Lobe attachment;
TGCT	cis	rs9807989	0.507	rs2160201	chr2:103033961	T/C	cg03938978	chr2:103052716	IL18RAP	0.27	5.41	0.44	3.17e-7	Asthma;
TGCT	cis	rs992157	0.737	rs3731860	chr2:219156979	G/A	cg00012203	chr2:219082015	ARPC2	-0.82	-8.15	-0.59	3.39e-13	Colorectal cancer;
TGCT	cis	rs9457247	0.967	rs443570	chr6:167389925	G/A	cg25258033	chr6:167368657	RNASET2	0.18	4.49	0.37	1.63e-5	Crohn's disease;
TGCT	cis	rs2243480	1.000	rs313820	chr7:65574466	A/C	cg07424592	chr7:64974309	NA	1.22	7.35	0.55	2.29e-11	Diabetic kidney disease;
TGCT	cis	rs7607369	0.679	rs6751527	chr2:219630965	C/G	cg02176678	chr2:219576539	TTLL4	0.48	6.36	0.5	3.6e-9	Red blood cell count;Amyotrophic lateral sclerosis;
TGCT	cis	rs9807989	0.801	rs11123925	chr2:102977511	G/A	cg09003973	chr2:102972529	NA	0.67	6.03	0.48	1.75e-8	Asthma;
TGCT	cis	rs9399401	0.667	rs6900233	chr6:142717283	C/G	cg03128060	chr6:142623767	GPR126	0.37	4.47	0.37	1.77e-5	Chronic obstructive pulmonary disease;
TGCT	cis	rs9926296	0.546	rs9935541	chr16:89905925	G/C	cg26513180	chr16:89883248	FANCA	0.78	7.68	0.57	4.06e-12	Vitiligo;
TGCT	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg24531977	chr5:56204891	C5orf35	-0.77	-7.61	-0.56	5.83e-12	Initial pursuit acceleration;
TGCT	cis	rs854765	0.547	rs2955380	chr17:17944349	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.79	-8.29	-0.6	1.59e-13	Total body bone mineral density;
TGCT	cis	rs6141769	0.518	rs2377665	chr20:31309054	T/C	cg13636640	chr20:31349939	DNMT3B	-0.51	-4.48	-0.37	1.68e-5	Subjective well-being;
TGCT	cis	rs11578119	0.933	rs12119012	chr1:170446678	C/T	cg09767346	chr1:170501363	GORAB	0.71	5.68	0.45	9.07e-8	Male-pattern baldness;
TGCT	cis	rs3749237	0.595	rs1464567	chr3:49459252	C/G	cg07636037	chr3:49044803	WDR6	-0.64	-6.02	-0.48	1.83e-8	Resting heart rate;
TGCT	cis	rs228437	0.507	rs228439	chr6:134898523	C/T	cg09872934	chr6:134495829	SGK1	0.49	4.44	0.37	1.99e-5	Melanoma;
TGCT	cis	rs752010	0.619	rs1123483	chr1:42114198	C/T	cg06885757	chr1:42089581	HIVEP3	-0.29	-5.1	-0.42	1.26e-6	Lupus nephritis in systemic lupus erythematosus;
TGCT	cis	rs9906944	0.898	rs9909861	chr17:47079416	C/A	cg20966754	chr17:47091339	IGF2BP1	-0.43	-4.95	-0.41	2.36e-6	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs12477438	0.765	rs2309454	chr2:99595418	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-4.62	-0.38	9.47e-6	Chronic sinus infection;
TGCT	cis	rs8051431	0.876	rs4788453	chr16:72020727	A/G	cg06353428	chr16:71660113	MARVELD3	0.6	4.65	0.39	8.53e-6	LDL cholesterol levels;
TGCT	cis	rs3091242	0.933	rs909833	chr1:25754140	C/G	cg10117171	chr1:25599238	RHD	-0.34	-5.48	-0.44	2.31e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs1156327	0.510	rs179223	chr16:19317148	G/T	cg27311092	chr16:19142612	NA	0.49	4.47	0.37	1.74e-5	Periodontal disease-related phenotypes;
TGCT	cis	rs1008375	0.932	rs12500912	chr4:17603318	C/T	cg10189774	chr4:17578691	LAP3	0.67	5.69	0.45	8.77e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9915657	0.870	rs4140903	chr17:70133771	C/T	cg06234051	chr17:70120541	SOX9	-0.23	-4.61	-0.38	9.78e-6	Thyroid hormone levels;
TGCT	cis	rs4689388	0.890	rs3821941	chr4:6286954	A/G	cg14416269	chr4:6271139	WFS1	0.39	5.19	0.42	8.22e-7	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs6435862	0.500	rs12477063	chr2:215673664	C/T	cg04004882	chr2:215674386	BARD1	-0.73	-6.51	-0.5	1.71e-9	Neuroblastoma (high-risk);
TGCT	cis	rs4713118	0.662	rs175954	chr6:28011585	A/G	cg18675097	chr6:28227127	NKAPL	-0.36	-4.54	-0.38	1.31e-5	Parkinson's disease;
TGCT	cis	rs682748	0.840	rs297177	chr5:17114476	C/T	cg23987134	chr5:17158319	LOC285696	-0.2	-4.76	-0.39	5.33e-6	Hippocampal atrophy;
TGCT	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg06634786	chr22:41940651	POLR3H	-0.86	-8.32	-0.6	1.34e-13	Vitiligo;
TGCT	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg06028808	chr11:68637592	NA	0.51	6.54	0.51	1.48e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs2013441	1.000	rs9904928	chr17:20180536	C/T	cg23224458	chr17:20280056	CCDC144C	0.39	4.65	0.39	8.34e-6	Obesity-related traits;
TGCT	cis	rs12908161	0.959	rs12908699	chr15:85240403	G/T	cg11189052	chr15:85197271	WDR73	0.75	6.3	0.49	4.8e-9	Schizophrenia;
TGCT	cis	rs56235845	0.694	rs4976643	chr5:176760227	A/C	cg16006841	chr5:176797999	RGS14	0.5	7.45	0.56	1.38e-11	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs1729951	0.575	rs16844362	chr3:136704008	T/C	cg12473912	chr3:136751656	NA	0.39	6.18	0.48	8.68e-9	Neuroticism;
TGCT	cis	rs9611565	0.568	rs5751159	chr22:42175365	G/A	cg06634786	chr22:41940651	POLR3H	0.78	7.31	0.55	2.85e-11	Vitiligo;
TGCT	cis	rs73198271	0.960	rs17154702	chr8:8609880	C/T	ch.8.214553F	chr8:8189620	PRAGMIN	-0.27	-4.91	-0.4	2.79e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg09359103	chr1:154839909	KCNN3	-0.64	-11.69	-0.72	9.69e-22	Prostate cancer;
TGCT	cis	rs9611565	0.765	rs132915	chr22:41805782	T/C	cg03806693	chr22:41940476	POLR3H	1.01	11.44	0.72	3.94e-21	Vitiligo;
TGCT	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	7.15	0.54	6.5500000000000006e-11	Platelet count;
TGCT	trans	rs4650994	0.544	rs10798613	chr1:178500022	C/T	cg05059571	chr16:84539110	KIAA1609	-0.54	-11.12	-0.71	2.39e-20	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs9640161	0.830	rs76741564	chr7:150059529	A/T	cg10018233	chr7:150070692	REPIN1	0.31	4.54	0.38	1.3e-5	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs829883	0.714	rs249847	chr12:98867716	C/T	cg25150519	chr12:98850993	NA	0.63	7.62	0.56	5.78e-12	Colorectal adenoma (advanced);
TGCT	trans	rs11722228	0.522	rs1109472	chr4:10134448	C/G	cg26043149	chr18:55253948	FECH	1.27	12.85	0.76	1.54e-24	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs9790314	1.000	rs4370045	chr3:160943865	A/G	cg03342759	chr3:160939853	NMD3	-0.42	-4.44	-0.37	1.94e-5	Morning vs. evening chronotype;
TGCT	cis	rs6964587	0.597	rs975707	chr7:91874527	C/G	cg17063962	chr7:91808500	NA	0.7	6.65	0.51	8.27e-10	Breast cancer;
TGCT	cis	rs514406	0.679	rs11206006	chr1:53218380	A/G	cg27535305	chr1:53392650	SCP2	0.26	5.04	0.41	1.57e-6	Monocyte count;
TGCT	cis	rs9325144	0.647	rs12227834	chr12:38849246	G/C	cg26384229	chr12:38710491	ALG10B	-0.6	-5.47	-0.44	2.33e-7	Morning vs. evening chronotype;
TGCT	cis	rs2070433	0.539	rs2839312	chr21:47958225	T/C	cg12379764	chr21:47803548	PCNT	0.53	5.38	0.43	3.6e-7	Lymphocyte counts;
TGCT	cis	rs7666738	0.791	rs1593571	chr4:98963763	T/C	cg18180107	chr4:99064573	C4orf37	0.57	5.18	0.42	8.63e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg16145915	chr7:1198662	ZFAND2A	-0.6	-8.51	-0.61	4.69e-14	Longevity;Endometriosis;
TGCT	cis	rs2797160	0.684	rs1832937	chr6:125985934	A/G	cg05901451	chr6:126070800	HEY2	0.79	7.35	0.55	2.34e-11	Endometrial cancer;
TGCT	cis	rs2797160	0.967	rs2747718	chr6:126009109	C/A	cg05901451	chr6:126070800	HEY2	0.72	6.11	0.48	1.18e-8	Endometrial cancer;
TGCT	cis	rs17270561	0.562	rs74293932	chr6:26014811	C/A	cg17042849	chr6:26104293	HIST1H4C	-0.81	-5.71	-0.46	7.76e-8	Iron status biomarkers;
TGCT	cis	rs72615157	0.645	rs76281814	chr7:99846414	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.65	-5.2	-0.42	8.01e-7	Lung function (FEV1/FVC);
TGCT	cis	rs2742417	0.624	rs2673030	chr3:45757900	T/G	cg04837898	chr3:45731254	SACM1L	-0.66	-7.02	-0.53	1.27e-10	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs17221829	0.626	rs2931188	chr11:89355428	A/T	cg02982614	chr11:89391479	FOLH1B	-0.28	-4.82	-0.4	4.1e-6	Anxiety in major depressive disorder;
TGCT	cis	rs7833790	0.927	rs61020899	chr8:82757090	C/T	cg17211192	chr8:82754475	SNX16	1.06	8.63	0.61	2.54e-14	Diastolic blood pressure;
TGCT	cis	rs9303401	0.659	rs34170300	chr17:56789905	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.59	5.99	0.47	2.08e-8	Cognitive test performance;
TGCT	cis	rs6964587	0.620	rs7808587	chr7:91620096	G/A	cg17063962	chr7:91808500	NA	0.75	7.1	0.54	8.68e-11	Breast cancer;
TGCT	cis	rs10197940	0.662	rs10173699	chr2:152281561	C/G	cg19508488	chr2:152266495	RIF1	-0.72	-6.45	-0.5	2.23e-9	Lung cancer;
TGCT	cis	rs7772486	0.875	rs9403765	chr6:146368041	C/T	cg23711669	chr6:146136114	FBXO30	-0.82	-8.87	-0.62	6.75e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1949733	0.958	rs2631731	chr4:8429817	A/G	cg13073564	chr4:8508604	NA	-0.47	-4.97	-0.41	2.15e-6	Response to antineoplastic agents;
TGCT	cis	rs12477438	0.501	rs6753063	chr2:99801469	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	17.43	0.84	3.73e-35	Chronic sinus infection;
TGCT	cis	rs17539620	0.624	rs62432737	chr6:154834772	G/A	cg20019720	chr6:154832845	CNKSR3	0.57	4.99	0.41	2.02e-6	Lipoprotein (a) levels;
TGCT	cis	rs4727027	0.866	rs10435245	chr7:148816081	C/G	cg23583168	chr7:148888333	NA	-0.72	-9.17	-0.64	1.3e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs11030122	0.632	rs10835556	chr11:4083013	A/G	cg18678763	chr11:4115507	RRM1	-0.48	-5.87	-0.47	3.66e-8	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs7589728	0.563	rs75606549	chr2:88466069	T/C	cg04511125	chr2:88470314	THNSL2	0.83	6.93	0.53	2e-10	Plasma clusterin levels;
TGCT	cis	rs9435341	0.965	rs1335053	chr1:107622823	C/T	cg09367891	chr1:107599246	PRMT6	-0.62	-5.24	-0.43	6.6e-7	Facial morphology (factor 21, depth of nasal alae);
TGCT	cis	rs76878669	0.561	rs4930177	chr11:66120784	T/C	cg18002602	chr11:66138449	SLC29A2	0.54	6.62	0.51	9.76e-10	Educational attainment (years of education);
TGCT	trans	rs10203711	1.000	rs907112	chr2:239566603	C/G	cg16021909	chr1:248021091	TRIM58	-0.67	-6.77	-0.52	4.51e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs514406	0.505	rs437954	chr1:53173321	C/G	cg16325326	chr1:53192061	ZYG11B	0.86	12.13	0.74	8.27e-23	Monocyte count;
TGCT	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg26338869	chr17:61819248	STRADA	-0.58	-5.24	-0.43	6.59e-7	Prudent dietary pattern;
TGCT	cis	rs62344088	0.590	rs73016639	chr5:172465	C/T	cg10601043	chr5:1076365	SLC12A7	0.58	4.74	0.39	5.71e-6	Asthma (childhood onset);
TGCT	cis	rs7781977	0.554	rs7789913	chr7:50352695	C/T	cg01139861	chr7:50343298	IKZF1	0.49	5.72	0.46	7.46e-8	IgG glycosylation;
TGCT	cis	rs9303401	0.659	rs35564417	chr17:56718286	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs74233809	0.636	rs284851	chr10:104578531	C/G	cg05855489	chr10:104503620	C10orf26	0.71	4.82	0.4	4.13e-6	Birth weight;
TGCT	cis	rs1629083	0.846	rs1806	chr11:118076004	C/T	cg16594165	chr11:118135105	MPZL2	-0.32	-4.45	-0.37	1.88e-5	Lung cancer;
TGCT	cis	rs7523273	0.606	rs2796263	chr1:207915978	T/C	cg22525895	chr1:207977042	MIR29B2	0.54	8.77	0.62	1.16e-14	Schizophrenia;
TGCT	cis	rs11792861	0.816	rs11788336	chr9:111688387	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.54	5.13	0.42	1.07e-6	Menarche (age at onset);
TGCT	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg05665937	chr4:1216051	CTBP1	0.24	4.61	0.38	1e-5	Obesity-related traits;
TGCT	cis	rs4595586	0.545	rs12820138	chr12:39357049	A/G	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs3782455	1.000	rs116855053	chr12:114403055	C/T	cg23502203	chr12:113549970	RASAL1	-0.55	-4.92	-0.4	2.7e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs921968	0.541	rs733925	chr2:219302466	G/A	cg02176678	chr2:219576539	TTLL4	-0.47	-6.71	-0.52	6.32e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs589448	0.535	rs12423794	chr12:69713018	G/A	cg20891283	chr12:69753455	YEATS4	0.72	7.48	0.56	1.17e-11	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs7584330	0.554	rs76980036	chr2:238426750	G/A	cg08992911	chr2:238395768	MLPH	0.7	4.72	0.39	6.32e-6	Prostate cancer;
TGCT	cis	rs1568889	1.000	rs12790932	chr11:28046189	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	7.88	0.58	1.45e-12	Bipolar disorder;
TGCT	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg06634786	chr22:41940651	POLR3H	0.69	6.54	0.51	1.45e-9	Vitiligo;
TGCT	cis	rs7662987	0.517	rs3018047	chr4:100014510	C/T	cg12011299	chr4:100065546	ADH4	-0.41	-4.96	-0.41	2.26e-6	Smoking initiation;
TGCT	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg06238570	chr21:40685208	BRWD1	0.68	6.36	0.5	3.5e-9	Cognitive function;
TGCT	cis	rs6597981	0.592	rs10902218	chr11:743813	C/T	cg01741372	chr11:783889	NA	-0.38	-4.81	-0.4	4.31e-6	Breast cancer;
TGCT	cis	rs6975373	0.730	rs1009528	chr7:4456304	G/T	cg10785373	chr7:4456119	NA	-0.55	-6.27	-0.49	5.5e-9	Borderline personality disorder;
TGCT	trans	rs9951602	0.512	rs12607561	chr18:76644284	G/A	cg02800362	chr5:177631904	HNRNPAB	1.13	12.94	0.76	9.39e-25	Obesity-related traits;
TGCT	cis	rs904251	1.000	rs12212090	chr6:37431808	A/G	cg25019722	chr6:37503610	NA	-0.47	-6.26	-0.49	5.69e-9	Cognitive performance;
TGCT	cis	rs9926296	0.681	rs12923946	chr16:89821080	C/T	cg27121462	chr16:89883253	FANCA	0.57	5.28	0.43	5.69e-7	Vitiligo;
TGCT	cis	rs2033711	0.905	rs1077420	chr19:58968875	A/C	cg03735888	chr19:58951602	ZNF132	0.53	4.71	0.39	6.41e-6	Uric acid clearance;
TGCT	cis	rs3847687	0.869	rs11061300	chr12:131523261	G/A	cg25772418	chr12:131519998	GPR133	-0.3	-4.77	-0.39	5e-6	Longevity;
TGCT	cis	rs1729951	0.575	rs1682357	chr3:136692009	G/A	cg12473912	chr3:136751656	NA	0.39	6.18	0.49	8.36e-9	Neuroticism;
TGCT	cis	rs17376456	0.877	rs9314095	chr5:93425495	T/C	cg25358565	chr5:93447407	FAM172A	0.92	8.38	0.6	9.58e-14	Diabetic retinopathy;
TGCT	cis	rs208520	1.000	rs12190773	chr6:66968194	T/C	cg07460842	chr6:66804631	NA	0.83	7.52	0.56	9.8e-12	Exhaled nitric oxide output;
TGCT	cis	rs3741151	1.000	rs74749711	chr11:73052839	A/T	cg17517138	chr11:73019481	ARHGEF17	1.03	5.19	0.42	8.31e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
TGCT	cis	rs1205863	0.607	rs1210621	chr6:11927921	A/G	cg07106625	chr6:11870215	NA	0.47	4.72	0.39	6.18e-6	Disc degeneration (lumbar);
TGCT	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg01341218	chr17:43662625	NA	1.09	8.66	0.61	2.15e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs1008375	0.898	rs7678654	chr4:17575376	T/G	cg10189774	chr4:17578691	LAP3	0.63	5.53	0.44	1.84e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs28595532	0.920	rs115226628	chr4:119639818	A/G	cg21605333	chr4:119757512	SEC24D	1.36	7.39	0.55	1.89e-11	Cannabis dependence symptom count;
TGCT	cis	rs1552244	0.700	rs9833566	chr3:9981671	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	5.89	0.47	3.37e-8	Alzheimer's disease;
TGCT	cis	rs67072384	0.818	rs1872128	chr11:72465526	C/T	cg03713592	chr11:72463424	ARAP1	-0.93	-4.68	-0.39	7.3e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs4972806	0.814	rs4246626	chr2:177046430	A/C	cg13092806	chr2:177043255	NA	0.56	5.03	0.41	1.66e-6	IgG glycosylation;
TGCT	cis	rs4273100	0.646	rs1472932	chr17:19220666	C/T	cg03910582	chr17:19030146	GRAPL	-0.49	-6.15	-0.48	9.9e-9	Schizophrenia;
TGCT	cis	rs6684514	0.961	rs10908501	chr1:156285513	G/T	cg20302342	chr1:156215951	PAQR6	0.35	4.74	0.39	5.77e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs9291683	0.632	rs11734375	chr4:10046298	A/G	cg00071950	chr4:10020882	SLC2A9	0.68	8.74	0.62	1.38e-14	Bone mineral density;
TGCT	cis	rs9858542	0.537	rs9818758	chr3:49382925	G/A	cg08550065	chr3:50336684	HYAL3;NAT6	0.66	4.59	0.38	1.08e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs17826219	0.706	rs61643715	chr17:29057762	A/G	cg13385521	chr17:29058706	SUZ12P	0.79	4.77	0.39	5.16e-6	Body mass index;
TGCT	cis	rs17376456	0.569	rs7713956	chr5:93133185	T/C	cg25358565	chr5:93447407	FAM172A	-0.76	-6.72	-0.52	5.94e-10	Diabetic retinopathy;
TGCT	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg25767906	chr1:53392781	SCP2	-0.63	-7.64	-0.57	5e-12	Monocyte count;
TGCT	cis	rs7918232	0.941	rs1753413	chr10:27397112	T/C	cg14442939	chr10:27389572	ANKRD26	0.71	5.33	0.43	4.45e-7	Breast cancer;
TGCT	cis	rs7429990	0.932	rs12493348	chr3:48143538	A/T	cg11946769	chr3:48343235	NME6	-0.57	-4.77	-0.39	5.14e-6	Educational attainment (years of education);
TGCT	cis	rs3784262	0.565	rs8041644	chr15:58266833	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.37	-5.23	-0.43	6.89e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs35000415	0.515	rs35518304	chr7:128732319	C/T	cg06242719	chr7:129414860	MIR183;MIR96	-0.31	-4.7	-0.39	6.77e-6	Systemic lupus erythematosus;
TGCT	cis	rs9611565	0.559	rs4822048	chr22:41988225	C/T	cg13695892	chr22:41940480	POLR3H	-0.87	-8.01	-0.58	6.94e-13	Vitiligo;
TGCT	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.02	0.53	1.3e-10	Prudent dietary pattern;
TGCT	cis	rs6570726	0.643	rs9403735	chr6:145936591	C/T	cg05347473	chr6:146136440	FBXO30	0.53	4.96	0.41	2.29e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs73198271	0.595	rs11780672	chr8:8584153	A/C	ch.8.214553F	chr8:8189620	PRAGMIN	-0.3	-4.85	-0.4	3.56e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs9902453	0.933	rs7216494	chr17:28502651	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	5.41	0.44	3.13e-7	Coffee consumption (cups per day);
TGCT	cis	rs61774743	0.754	rs11581271	chr1:41835061	C/G	cg01193554	chr1:41846683	NA	-0.42	-5.3	-0.43	5.12e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs12497850	0.864	rs7431857	chr3:48900347	G/A	cg05785598	chr3:49045655	WDR6	0.35	4.72	0.39	6.35e-6	Parkinson's disease;
TGCT	cis	rs62244186	0.715	rs13321717	chr3:44667455	C/A	cg11003573	chr3:44754125	ZNF502	-0.41	-4.69	-0.39	7.19e-6	Depressive symptoms;
TGCT	cis	rs4727027	0.901	rs4727019	chr7:148822266	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	4.58	0.38	1.13e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs6121246	0.821	rs6058448	chr20:30332396	C/T	cg13852791	chr20:30311386	BCL2L1	0.8	6.12	0.48	1.15e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs7302981	0.967	rs11831413	chr12:50550383	A/T	cg23855989	chr12:50355821	AQP5	0.3	4.5	0.38	1.52e-5	Systolic blood pressure;
TGCT	cis	rs60843830	1.000	rs58461606	chr2:267367	G/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.7	6.66	0.51	7.99e-10	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs7424096	0.793	rs17497197	chr2:37162975	T/C	cg14987922	chr2:37194071	STRN	0.58	4.75	0.39	5.53e-6	High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs4733781	1.000	rs12680942	chr8:131264033	A/G	cg16277922	chr8:131349729	ASAP1	0.43	5.48	0.44	2.31e-7	Tuberculosis;
TGCT	cis	rs6988636	1.000	rs13261066	chr8:124190276	G/A	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs7044106	0.762	rs7357638	chr9:123389204	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	4.93	0.4	2.59e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs4746818	1.000	rs906218	chr10:70960913	C/T	cg04149295	chr10:70884716	VPS26A	0.76	4.97	0.41	2.19e-6	Left atrial antero-posterior diameter;
TGCT	cis	rs17767294	0.803	rs59701161	chr6:27646117	T/C	cg08851530	chr6:28072375	NA	1.43	6.96	0.53	1.73e-10	Parkinson's disease;
TGCT	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.12	0.42	1.15e-6	Prudent dietary pattern;
TGCT	cis	rs13177918	0.677	rs13161099	chr5:149822362	G/A	cg14059543	chr5:149831962	NA	-0.72	-9.49	-0.65	2.17e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	8.39	0.6	9.03e-14	Platelet count;
TGCT	cis	rs12681288	0.823	rs2701903	chr8:1004029	A/G	cg04851639	chr8:1020857	NA	0.36	6.47	0.5	2.01e-9	Schizophrenia;
TGCT	cis	rs753778	0.667	rs10103731	chr8:142206068	C/T	cg18755752	chr8:142205143	DENND3	-0.25	-4.59	-0.38	1.06e-5	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs66573146	0.808	rs73202120	chr4:7005588	A/G	cg05069807	chr4:6945702	TBC1D14	0.3	4.87	0.4	3.26e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs12681287	0.752	rs10435564	chr8:87266239	T/C	cg27223183	chr8:87520930	FAM82B	-0.81	-5.66	-0.45	9.9e-8	Caudate activity during reward;
TGCT	cis	rs72781680	0.846	rs72780108	chr2:23986780	G/A	cg08917208	chr2:24149416	ATAD2B	0.83	5.24	0.43	6.62e-7	Lymphocyte counts;
TGCT	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	7.43	0.55	1.56e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs739496	0.947	rs2283358	chr12:111865565	C/T	cg10833066	chr12:111807467	FAM109A	0.37	5.2	0.42	8.01e-7	Platelet count;
TGCT	trans	rs9951602	0.573	rs78623099	chr18:76646228	G/T	cg02800362	chr5:177631904	HNRNPAB	1.14	13.02	0.76	6.04e-25	Obesity-related traits;
TGCT	cis	rs968451	1.000	rs17000962	chr22:39680187	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.89	7.9	0.58	1.28e-12	Primary biliary cholangitis;
TGCT	cis	rs7666738	0.830	rs1869897	chr4:98730997	C/T	cg18180107	chr4:99064573	C4orf37	0.53	5.07	0.41	1.38e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7949030	0.688	rs2849031	chr11:62365665	G/A	cg11742103	chr11:62369870	EML3;MTA2	-0.6	-8.74	-0.62	1.39e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs8072100	0.701	rs4794053	chr17:45769551	G/A	cg08085267	chr17:45401833	C17orf57	-0.43	-4.82	-0.4	4.04e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs7937682	0.575	rs7127010	chr11:111770782	C/T	cg09085632	chr11:111637200	PPP2R1B	0.91	8.56	0.61	3.6e-14	Primary sclerosing cholangitis;
TGCT	cis	rs2486288	0.656	rs11631021	chr15:45556829	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.42	-4.92	-0.4	2.7e-6	Glomerular filtration rate;
TGCT	cis	rs4253772	0.550	rs6007761	chr22:46670394	C/T	cg09491104	chr22:46646882	C22orf40	0.63	6.84	0.52	3.23e-10	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs5769707	0.681	rs9616329	chr22:50026314	G/A	cg05373962	chr22:49881684	NA	-0.31	-5.3	-0.43	5.1e-7	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg05985448	chr10:134359359	INPP5A	0.23	4.99	0.41	2.01e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs826838	0.967	rs73096706	chr12:38860563	G/A	cg13010199	chr12:38710504	ALG10B	0.82	6.85	0.52	3e-10	Heart rate;
TGCT	cis	rs7209700	0.778	rs3851807	chr17:45351519	C/G	cg21624342	chr17:45890973	OSBPL7	0.16	4.44	0.37	1.97e-5	IgG glycosylation;
TGCT	trans	rs7819412	0.807	rs9657519	chr8:10945439	A/G	cg15556689	chr8:8085844	FLJ10661	-0.88	-8.75	-0.62	1.29e-14	Triglycerides;
TGCT	cis	rs12049351	0.665	rs4148761	chr1:229662344	C/T	cg12130225	chr1:229698885	NA	0.38	4.63	0.38	8.95e-6	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs79349575	0.783	rs4793995	chr17:47019399	A/C	cg26022315	chr17:47021804	SNF8	0.49	4.9	0.4	2.94e-6	Type 2 diabetes;
TGCT	cis	rs422249	0.512	rs174574	chr11:61600342	A/C	cg19610905	chr11:61596333	FADS2	0.96	9.66	0.66	8.51e-17	Trans fatty acid levels;
TGCT	cis	rs96067	0.711	rs11263861	chr1:36628033	G/A	cg07093915	chr1:36184400	C1orf216	-0.46	-4.55	-0.38	1.24e-5	Corneal structure;
TGCT	cis	rs9894429	0.789	rs7219915	chr17:79591813	C/T	cg21984481	chr17:79567631	NPLOC4	-0.26	-4.9	-0.4	2.91e-6	Eye color traits;
TGCT	cis	rs35146811	0.625	rs858514	chr7:99825748	A/G	cg13334819	chr7:99746414	C7orf59	0.74	6.41	0.5	2.82e-9	Coronary artery disease;
TGCT	cis	rs9341808	0.500	rs2322629	chr6:80811540	C/T	cg08355045	chr6:80787529	NA	0.33	5.37	0.43	3.8e-7	Sitting height ratio;
TGCT	cis	rs3733606	0.775	rs66514314	chr4:6827238	C/T	cg25793812	chr4:6677191	LOC93622	0.39	4.85	0.4	3.68e-6	Platelet count;
TGCT	cis	rs546131	0.642	rs579926	chr11:34853155	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.52	4.55	0.38	1.24e-5	Lung disease severity in cystic fibrosis;
TGCT	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg23708337	chr7:1209742	NA	0.51	4.51	0.38	1.49e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs6570726	0.791	rs9373464	chr6:145907167	T/C	cg23711669	chr6:146136114	FBXO30	0.85	9.24	0.64	8.9e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1997103	1.000	rs1997102	chr7:55399322	A/C	cg17469321	chr7:55412551	NA	-0.59	-6.08	-0.48	1.39e-8	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs3858526	0.959	rs61876223	chr11:5943393	G/A	cg05234568	chr11:5960015	NA	-0.47	-4.66	-0.39	8.11e-6	DNA methylation (variation);
TGCT	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.61	0.38	9.85e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs10779751	0.922	rs2746637	chr1:11275588	A/G	cg08854313	chr1:11322531	MTOR	0.94	8.51	0.61	4.75e-14	Body mass index;
TGCT	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg03264133	chr6:25882463	NA	-1.07	-14.31	-0.79	5.01e-28	Urate levels;
TGCT	cis	rs7551222	0.716	rs6679311	chr1:204559676	T/C	cg09150239	chr1:204347429	NA	0.49	4.55	0.38	1.24e-5	Schizophrenia;
TGCT	cis	rs9357506	1.000	rs62402364	chr6:46313913	T/C	cg21115430	chr6:46460003	NA	-0.26	-5.16	-0.42	9.6e-7	Body mass index;
TGCT	cis	rs9362426	0.708	rs6907825	chr6:88102822	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.42	4.66	0.39	8.11e-6	Depressive episodes in bipolar disorder;
TGCT	cis	rs6964587	1.000	rs417	chr7:91581121	C/A	cg17063962	chr7:91808500	NA	-0.91	-10.02	-0.67	1.13e-17	Breast cancer;
TGCT	cis	rs1008375	1.000	rs6449319	chr4:17640283	T/A	cg16339924	chr4:17578868	LAP3	0.7	5.72	0.46	7.7e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6912958	0.630	rs4707377	chr6:88280332	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-5.06	-0.41	1.45e-6	Monocyte percentage of white cells;
TGCT	cis	rs28595532	0.920	rs114670456	chr4:119771202	A/G	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs2657888	0.593	rs2638319	chr12:56857057	A/G	cg23002907	chr12:56915593	RBMS2	-0.45	-6.08	-0.48	1.37e-8	Adiponectin levels;
TGCT	trans	rs8073060	0.586	rs225291	chr17:33927126	A/G	cg19694781	chr19:47549865	TMEM160	-0.51	-11.27	-0.71	9.98e-21	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs2075371	0.501	rs1646652	chr7:134024515	A/T	cg11752832	chr7:134001865	SLC35B4	0.59	5.1	0.42	1.25e-6	Mean platelet volume;
TGCT	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg25036284	chr2:26402008	FAM59B	0.65	5.19	0.42	8.36e-7	Gut microbiome composition (summer);
TGCT	cis	rs2980439	0.517	rs793753	chr8:8105359	T/G	cg06636001	chr8:8085503	FLJ10661	-0.61	-5.4	-0.44	3.24e-7	Neuroticism;
TGCT	cis	rs7659604	0.540	rs7676867	chr4:122671315	T/C	cg19748678	chr4:122722346	EXOSC9	-0.51	-4.93	-0.4	2.61e-6	Type 2 diabetes;
TGCT	cis	rs6088590	1.000	rs3787222	chr20:33333040	T/A	cg24642439	chr20:33292090	TP53INP2	0.69	6.19	0.49	8.14e-9	Coronary artery disease;
TGCT	cis	rs6424115	0.830	rs2502995	chr1:24199290	T/C	cg15997130	chr1:24165203	NA	0.86	9.44	0.65	2.86e-16	Immature fraction of reticulocytes;
TGCT	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg11905131	chr22:24372483	LOC391322	-0.98	-11.56	-0.72	2.04e-21	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7267979	0.966	rs2387882	chr20:25378802	C/T	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9527	0.590	rs7092029	chr10:104823909	A/T	cg04362960	chr10:104952993	NT5C2	0.66	5.55	0.45	1.62e-7	Arsenic metabolism;
TGCT	trans	rs1814175	0.715	rs10839409	chr11:49884647	G/T	cg03929089	chr4:120376271	NA	-0.72	-8.26	-0.6	1.84e-13	Height;
TGCT	cis	rs9894429	0.789	rs7213849	chr17:79567610	C/T	cg18240062	chr17:79603768	NPLOC4	-0.84	-9.67	-0.66	8.03e-17	Eye color traits;
TGCT	cis	rs6978712	1.000	rs75306531	chr7:127151869	A/T	cg01017541	chr7:127776461	NA	0.76	4.6	0.38	1.01e-5	Medication adherence in chronic diseases;
TGCT	cis	rs933688	1.000	rs1964292	chr5:90743608	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.04	8.8	0.62	9.68e-15	Smoking behavior;
TGCT	cis	rs79349575	0.783	rs12453394	chr17:46994970	G/A	cg07967210	chr17:47022446	SNF8	0.44	6.12	0.48	1.13e-8	Type 2 diabetes;
TGCT	cis	rs526231	0.547	rs72783895	chr5:102287496	C/A	cg23492399	chr5:102201601	PAM	-0.52	-4.52	-0.38	1.41e-5	Primary biliary cholangitis;
TGCT	cis	rs9296092	0.538	rs9461879	chr6:33516907	C/T	cg13560919	chr6:33536144	NA	-0.2	-4.63	-0.38	9.25e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg06873352	chr17:61820015	STRADA	0.57	6.21	0.49	7.34e-9	Prudent dietary pattern;
TGCT	cis	rs28595532	0.920	rs115484560	chr4:119756781	T/G	cg21605333	chr4:119757512	SEC24D	1.62	7.73	0.57	3.22e-12	Cannabis dependence symptom count;
TGCT	cis	rs71597109	0.639	rs17266552	chr4:102726519	G/A	cg14855874	chr4:102712397	BANK1	0.41	4.7	0.39	6.66e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs6598955	0.670	rs10794525	chr1:26537193	C/A	cg01614726	chr1:26633154	UBXN11	0.49	4.69	0.39	7.09e-6	Obesity-related traits;
TGCT	cis	rs9436747	0.630	rs12405556	chr1:66063117	G/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.52	4.52	0.38	1.42e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	trans	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg27523141	chr10:43048294	ZNF37B	0.7	8.15	0.59	3.36e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs3824867	0.920	rs3740684	chr11:47468820	C/T	cg20307385	chr11:47447363	PSMC3	0.7	6.03	0.48	1.71e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs12711979	0.509	rs10191674	chr2:3827891	C/T	cg17052675	chr2:3827356	NA	-0.56	-13.3	-0.77	1.28e-25	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs763121	0.853	rs5757200	chr22:39043491	T/G	cg06022373	chr22:39101656	GTPBP1	0.77	7.46	0.56	1.35e-11	Menopause (age at onset);
TGCT	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg25767906	chr1:53392781	SCP2	0.48	5.56	0.45	1.57e-7	Monocyte count;
TGCT	cis	rs79349575	0.783	rs9912829	chr17:46982749	G/C	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.44	-0.37	1.95e-5	Type 2 diabetes;
TGCT	cis	rs9398235	0.929	rs4945861	chr6:110728429	C/T	cg19196401	chr6:110721138	DDO	0.5	4.76	0.39	5.28e-6	Systemic lupus erythematosus;
TGCT	cis	rs1723838	0.510	rs2471904	chr11:73690599	G/A	cg26954736	chr11:73693896	UCP2	-1.41	-6.25	-0.49	5.93e-9	Obesity-related traits;
TGCT	cis	rs854765	0.618	rs8066982	chr17:17851377	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.76	7.85	0.58	1.65e-12	Total body bone mineral density;
TGCT	cis	rs11601602	0.576	rs12576396	chr11:28555952	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	5.74	0.46	6.71e-8	Obesity-related traits;
TGCT	cis	rs4237845	0.773	rs6650217	chr12:58289072	T/G	cg02175503	chr12:58329896	NA	0.52	5.49	0.44	2.17e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs111803315	0.661	rs113008598	chr14:60002312	C/T	cg22995959	chr14:59931024	GPR135	0.66	4.8	0.4	4.39e-6	Schizophrenia;
TGCT	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg24250549	chr1:154909240	PMVK	0.63	6.25	0.49	6.03e-9	Prostate cancer;
TGCT	cis	rs4911259	0.552	rs13042651	chr20:31467423	C/T	cg13636640	chr20:31349939	DNMT3B	-0.89	-9.83	-0.66	3.33e-17	Inflammatory bowel disease;
TGCT	cis	rs11112613	0.713	rs871220	chr12:105938558	G/A	cg03607813	chr12:105948248	NA	0.46	5.35	0.43	4.14e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg24578937	chr1:2090814	PRKCZ	0.24	6.16	0.48	9.35e-9	Height;
TGCT	cis	rs10751667	0.961	rs6421967	chr11:983966	T/C	cg06064525	chr11:970664	AP2A2	-0.31	-5.78	-0.46	5.58e-8	Alzheimer's disease (late onset);
TGCT	cis	rs2050392	0.799	rs303429	chr10:30708441	C/T	cg13289132	chr10:30722225	MAP3K8	-0.38	-4.58	-0.38	1.12e-5	Inflammatory bowel disease;
TGCT	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg17264618	chr3:40429014	ENTPD3	0.34	4.94	0.41	2.52e-6	Renal cell carcinoma;
TGCT	cis	rs2742417	1.000	rs2742417	chr3:45731451	C/T	cg04837898	chr3:45731254	SACM1L	-0.53	-5.44	-0.44	2.76e-7	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs4253311	0.520	rs10000459	chr4:187124459	A/C	cg19358738	chr4:186734530	SORBS2	0.17	4.49	0.37	1.6e-5	Plasma renin activity levels;Circulating chromogranin peptide levels;Blood metabolite levels;
TGCT	cis	rs12620999	1.000	rs11689249	chr2:238083542	T/A	cg23555395	chr2:238036564	NA	-0.29	-4.99	-0.41	1.95e-6	Systemic lupus erythematosus;
TGCT	cis	rs903263	0.601	rs6669045	chr1:84560735	A/T	cg09664975	chr1:84543551	PRKACB	0.5	4.87	0.4	3.36e-6	Breast cancer (male);
TGCT	cis	rs6893807	0.778	rs13162708	chr5:87943345	C/T	cg24804195	chr5:87968844	LOC645323	0.78	4.53	0.38	1.39e-5	Body mass index;
TGCT	cis	rs10256972	0.630	rs10282584	chr7:1081442	C/T	cg00431813	chr7:1051703	C7orf50	-0.3	-6.76	-0.52	4.92e-10	Longevity;Endometriosis;
TGCT	cis	rs12134245	0.776	rs12137878	chr1:91973210	G/T	cg25838465	chr1:92012736	NA	-0.44	-7.0	-0.53	1.41e-10	Breast cancer;
TGCT	cis	rs7772486	0.790	rs10223507	chr6:146285204	C/A	cg05347473	chr6:146136440	FBXO30	-0.53	-5.18	-0.42	8.75e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs17345786	0.911	rs10936707	chr3:101324063	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.88	9.32	0.64	5.46e-16	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg25767906	chr1:53392781	SCP2	0.47	5.26	0.43	6e-7	Monocyte count;
TGCT	cis	rs9383153	1.000	rs9370888	chr6:16335544	A/G	cg22235522	chr6:17169462	NA	0.64	4.63	0.38	9.07e-6	Gambling;
TGCT	cis	rs9914544	1.000	rs67411574	chr17:18797337	A/G	cg26306683	chr17:18585705	ZNF286B	0.57	5.08	0.41	1.36e-6	Educational attainment (years of education);
TGCT	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs739401	0.572	rs389128	chr11:3083873	G/T	cg25174290	chr11:3078921	CARS	0.53	5.18	0.42	8.8e-7	Longevity;
TGCT	cis	rs9467711	0.745	rs9467714	chr6:26340785	C/T	cg26531700	chr6:26746687	NA	-1.05	-5.26	-0.43	6.14e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs11671005	0.693	rs34230465	chr19:58943576	C/G	cg13877915	chr19:58951672	ZNF132	0.63	5.0	0.41	1.95e-6	Mean platelet volume;
TGCT	cis	rs4746818	0.901	rs4746816	chr10:70874866	G/T	cg04149295	chr10:70884716	VPS26A	0.76	4.48	0.37	1.69e-5	Left atrial antero-posterior diameter;
TGCT	cis	rs6671200	0.573	rs6666528	chr1:95697490	C/A	cg03123541	chr1:95699097	RWDD3	-0.81	-7.26	-0.55	3.81e-11	Stearic acid (18:0) levels;
TGCT	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg17554472	chr22:41940697	POLR3H	-0.49	-5.27	-0.43	5.9e-7	Vitiligo;
TGCT	cis	rs2439831	0.850	rs7169322	chr15:44131014	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.44	0.37	1.99e-5	Lung cancer in ever smokers;
TGCT	cis	rs614226	1.000	rs616157	chr12:120925795	T/C	cg01236616	chr12:121019343	POP5	-1.22	-12.32	-0.74	2.86e-23	Type 1 diabetes nephropathy;
TGCT	trans	rs8073060	0.586	rs225257	chr17:33956625	G/A	cg19694781	chr19:47549865	TMEM160	-0.6	-13.37	-0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg11890956	chr21:40555474	PSMG1	-0.75	-6.81	-0.52	3.82e-10	Cognitive function;
TGCT	cis	rs7120118	0.517	rs11530168	chr11:47322986	A/G	cg13308137	chr11:47528955	CUGBP1	0.33	5.19	0.42	8.26e-7	HDL cholesterol;
TGCT	cis	rs13256369	1.000	rs873063	chr8:8572447	A/G	cg18904891	chr8:8559673	CLDN23	0.62	5.7	0.46	8.41e-8	Obesity-related traits;
TGCT	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg25036284	chr2:26402008	FAM59B	-0.66	-5.34	-0.43	4.22e-7	Gut microbiome composition (summer);
TGCT	cis	rs7474896	0.515	rs2749582	chr10:38275284	A/G	cg13720705	chr10:37990370	NA	-0.35	-4.73	-0.39	5.99e-6	Obesity (extreme);
TGCT	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg24549020	chr5:56110836	MAP3K1	0.67	5.78	0.46	5.74e-8	Initial pursuit acceleration;
TGCT	cis	rs7635838	0.892	rs9310383	chr3:11491305	A/G	cg00170343	chr3:11313890	ATG7	-0.66	-6.15	-0.48	1e-8	HDL cholesterol;
TGCT	cis	rs12791968	1.000	rs11604565	chr11:45010336	A/G	cg11846598	chr11:44996168	LOC221122	-0.32	-5.92	-0.47	2.92e-8	Inhibitory control;
TGCT	cis	rs6429082	0.818	rs291381	chr1:235641924	A/G	cg26050004	chr1:235667680	B3GALNT2	0.62	5.58	0.45	1.43e-7	Adiposity;
TGCT	cis	rs6582630	0.519	rs9738104	chr12:38338459	A/C	cg26384229	chr12:38710491	ALG10B	0.83	7.29	0.55	3.15e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs12477438	0.765	rs2278895	chr2:99613484	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-7.6	-0.56	6.47e-12	Chronic sinus infection;
TGCT	cis	rs17345786	1.000	rs11715368	chr3:101336380	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.45	-9.88	-0.66	2.52e-17	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3892630	0.817	rs12609866	chr19:33184412	C/T	cg22980127	chr19:33182716	NUDT19	0.7	5.18	0.42	8.9e-7	Red blood cell traits;
TGCT	cis	rs2836950	0.501	rs1474490	chr21:40716136	C/A	cg06238570	chr21:40685208	BRWD1	-0.62	-6.23	-0.49	6.61e-9	Menarche (age at onset);
TGCT	cis	rs838147	0.508	rs507711	chr19:49208564	C/T	cg10667338	chr19:49617042	LIN7B	-0.34	-4.56	-0.38	1.19e-5	Dietary macronutrient intake;
TGCT	cis	rs8103278	1.000	rs11671524	chr19:46327166	G/A	cg14061069	chr19:46274453	DMPK	-0.44	-6.14	-0.48	1.04e-8	Coronary artery disease;
TGCT	cis	rs763121	0.962	rs138711	chr22:39139913	C/T	cg06022373	chr22:39101656	GTPBP1	0.84	5.41	0.44	3.18e-7	Menopause (age at onset);
TGCT	cis	rs922182	0.557	rs7161953	chr15:64202887	C/A	cg02919090	chr15:64263738	DAPK2	-0.38	-7.0	-0.53	1.4e-10	Blood protein levels;
TGCT	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/A	cg27121462	chr16:89883253	FANCA	0.54	4.59	0.38	1.05e-5	Vitiligo;
TGCT	cis	rs68170813	0.559	rs80341862	chr7:106934731	C/G	cg02696742	chr7:106810147	HBP1	-0.69	-5.81	-0.46	4.85e-8	Coronary artery disease;
TGCT	trans	rs10802346	0.545	rs10924545	chr1:246364592	C/T	cg13514129	chr1:39547527	MACF1	-0.85	-7.83	-0.58	1.89e-12	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs10927875	0.691	rs2017583	chr1:16350028	A/G	cg21385522	chr1:16154831	NA	0.62	6.38	0.5	3.17e-9	Dilated cardiomyopathy;
TGCT	cis	rs12477438	0.798	rs6759354	chr2:99632195	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-8.52	-0.61	4.5e-14	Chronic sinus infection;
TGCT	cis	rs1371867	0.839	rs1660313	chr8:101332712	G/A	cg00191853	chr8:101177733	SPAG1	-0.22	-4.47	-0.37	1.75e-5	Atrioventricular conduction;
TGCT	cis	rs12477438	0.798	rs1530996	chr2:99584079	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-5.99	-0.47	2.09e-8	Chronic sinus infection;
TGCT	cis	rs453301	0.606	rs6981060	chr8:8908235	C/A	cg06636001	chr8:8085503	FLJ10661	-0.71	-5.8	-0.46	5.19e-8	Joint mobility (Beighton score);
TGCT	cis	rs11864453	0.647	rs8043606	chr16:72135319	T/C	cg14768367	chr16:72042858	DHODH	0.52	5.27	0.43	5.78e-7	Fibrinogen levels;
TGCT	cis	rs6430585	1.000	rs6732236	chr2:136501509	T/G	cg07169764	chr2:136633963	MCM6	0.89	7.96	0.58	9.17e-13	Corneal structure;
TGCT	cis	rs6121246	0.954	rs6060989	chr20:30429763	C/T	cg18721089	chr20:30220636	NA	-0.45	-4.98	-0.41	2.12e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg03806693	chr22:41940476	POLR3H	-1.13	-13.26	-0.77	1.59e-25	Vitiligo;
TGCT	cis	rs752010	0.619	rs6703992	chr1:42115888	G/A	cg06885757	chr1:42089581	HIVEP3	0.28	4.84	0.4	3.74e-6	Lupus nephritis in systemic lupus erythematosus;
TGCT	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg07507251	chr3:52567010	NT5DC2	-0.46	-6.34	-0.49	3.89e-9	Bipolar disorder;
TGCT	cis	rs826838	0.709	rs4882355	chr12:38721462	A/T	cg26384229	chr12:38710491	ALG10B	0.64	6.0	0.47	2.03e-8	Heart rate;
TGCT	cis	rs7584330	0.868	rs6760842	chr2:238398165	C/T	cg11271282	chr2:238384023	NA	-0.58	-4.45	-0.37	1.89e-5	Prostate cancer;
TGCT	cis	rs4919044	0.674	rs9419766	chr10:94800788	G/A	cg05127821	chr10:94822908	CYP26C1	-0.74	-4.83	-0.4	3.95e-6	Coronary artery disease;
TGCT	cis	rs17681684	0.505	rs62064492	chr17:9803713	G/A	cg15743799	chr17:9805578	RCVRN	-0.28	-6.33	-0.49	4.01e-9	GIP levels in response to oral glucose tolerance test (fasting);
TGCT	cis	rs13256369	1.000	rs10103769	chr8:8573036	G/T	cg06671706	chr8:8559999	CLDN23	0.34	4.44	0.37	1.99e-5	Obesity-related traits;
TGCT	cis	rs9302065	0.565	rs2992910	chr13:95962216	T/A	cg24476569	chr13:95954382	ABCC4	-0.54	-8.26	-0.6	1.9e-13	Blood metabolite levels;
TGCT	cis	rs7611238	0.560	rs6763335	chr3:195076218	A/C	cg27323046	chr3:195102265	ACAP2	0.37	5.0	0.41	1.9e-6	Body mass index;
TGCT	cis	rs17767294	0.708	rs75543204	chr6:28108816	C/A	cg08851530	chr6:28072375	NA	1.56	7.22	0.54	4.47e-11	Parkinson's disease;
TGCT	cis	rs6728642	0.572	rs7574488	chr2:97599618	T/C	cg26665480	chr2:98280029	ACTR1B	-0.91	-6.78	-0.52	4.32e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	cis	rs17133449	0.718	rs2167695	chr10:4753980	G/C	cg04530666	chr10:3759553	NA	-0.28	-4.68	-0.39	7.48e-6	Major depressive disorder;
TGCT	cis	rs7552167	0.925	rs7546025	chr1:24510252	T/C	cg01960748	chr1:24522592	NA	-0.49	-5.51	-0.44	2.02e-7	Psoriasis vulgaris;
TGCT	cis	rs7568458	0.870	rs1010	chr2:85808982	C/T	cg17127132	chr2:85788382	GGCX	-0.68	-6.2	-0.49	7.7e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs12188164	1.000	rs34453673	chr5:434722	G/C	cg21144161	chr5:423903	AHRR	0.24	4.59	0.38	1.06e-5	Cystic fibrosis severity;
TGCT	cis	rs13082711	0.554	rs10514679	chr3:27412591	A/G	cg02860705	chr3:27208620	NA	0.41	5.87	0.47	3.64e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg08736216	chr1:53307985	ZYG11A	0.25	4.93	0.41	2.55e-6	Monocyte count;
TGCT	cis	rs1629083	0.935	rs1056562	chr11:118125625	T/C	cg16594165	chr11:118135105	MPZL2	-0.33	-4.62	-0.38	9.6e-6	Lung cancer;
TGCT	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg06418219	chr1:154948305	SHC1;CKS1B	-0.65	-6.51	-0.5	1.68e-9	Prostate cancer;
TGCT	cis	rs77972916	0.505	rs6753197	chr2:43527962	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.39	-5.68	-0.45	9.24e-8	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs986417	0.606	rs7156375	chr14:61110627	G/A	cg18240143	chr14:60952599	C14orf39	0.88	4.57	0.38	1.15e-5	Gut microbiota (bacterial taxa);
TGCT	cis	rs7914558	1.000	rs7077097	chr10:104945463	G/A	cg15744005	chr10:104629667	AS3MT	-0.39	-4.73	-0.39	5.91e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs11098499	0.954	rs6847248	chr4:120225955	A/G	cg09307838	chr4:120376055	NA	0.63	5.88	0.47	3.6e-8	Corneal astigmatism;
TGCT	cis	rs78545713	1.000	rs78545713	chr6:26248840	A/G	cg12260798	chr6:26240519	HIST1H4F	-0.59	-4.89	-0.4	3.09e-6	Iron status biomarkers (total iron binding capacity);
TGCT	cis	rs1362404	0.582	rs12149211	chr16:51961345	C/A	cg03955530	chr16:52681474	NA	0.3	4.72	0.39	6.36e-6	Gut microbiota (bacterial taxa);
TGCT	cis	rs76419734	0.850	rs11725523	chr4:106517866	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	1.08	4.44	0.37	1.93e-5	Post bronchodilator FEV1;
TGCT	cis	rs7914558	0.966	rs2297786	chr10:104679978	C/T	cg15744005	chr10:104629667	AS3MT	-0.41	-5.11	-0.42	1.16e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs6450176	1.000	rs58369491	chr5:53297295	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.53	-5.12	-0.42	1.15e-6	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	trans	rs2688608	0.592	rs11000757	chr10:75486815	T/C	cg13918328	chr10:52500089	ASAH2B	0.68	6.7	0.52	6.48e-10	Inflammatory bowel disease;
TGCT	cis	rs6424115	0.830	rs2229584	chr1:24200969	T/C	cg15997130	chr1:24165203	NA	0.85	9.25	0.64	8.02e-16	Immature fraction of reticulocytes;
TGCT	cis	rs2832191	0.791	rs2832187	chr21:30485543	T/C	cg08807101	chr21:30365312	RNF160	-0.64	-6.01	-0.48	1.9e-8	Dental caries;
TGCT	cis	rs924607	1.000	rs11746907	chr5:598224	G/A	cg18765565	chr5:669397	TPPP	-0.59	-6.34	-0.49	3.83e-9	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs950169	0.922	rs11633075	chr15:85113972	C/A	cg12863693	chr15:85201151	NMB	0.39	4.44	0.37	1.99e-5	Schizophrenia;
TGCT	cis	rs77633900	0.614	rs280028	chr15:77031466	A/G	cg21673338	chr15:77095150	SCAPER	-0.51	-5.12	-0.42	1.11e-6	Non-glioblastoma glioma;Glioma;
TGCT	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg21951975	chr1:209979733	IRF6	0.66	5.69	0.45	8.77e-8	Cleft lip with or without cleft palate;
TGCT	cis	rs36051895	0.632	rs62541916	chr9:5151904	C/A	cg02405213	chr9:5042618	JAK2	-0.75	-9.81	-0.66	3.66e-17	Pediatric autoimmune diseases;
TGCT	cis	rs367943	1.000	rs2248930	chr5:112811119	G/T	cg12552261	chr5:112820674	MCC	-0.24	-4.91	-0.4	2.81e-6	Type 2 diabetes;
TGCT	cis	rs6490294	0.752	rs608814	chr12:112126615	C/A	cg10833066	chr12:111807467	FAM109A	0.35	5.08	0.42	1.34e-6	Mean platelet volume;
TGCT	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg09365446	chr1:150670422	GOLPH3L	0.31	4.64	0.38	8.7e-6	Tonsillectomy;
TGCT	cis	rs72781680	1.000	rs72796337	chr2:24142957	G/A	cg08917208	chr2:24149416	ATAD2B	0.73	4.51	0.38	1.48e-5	Lymphocyte counts;
TGCT	cis	rs6546847	0.531	rs2567603	chr2:73986125	C/G	cg07208825	chr2:73871855	ALMS1P	0.29	5.27	0.43	5.73e-7	Urinary metabolites (H-NMR features);
TGCT	cis	rs10992471	0.603	rs10820968	chr9:95106443	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.6	-5.49	-0.44	2.14e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs55883249	1.000	rs60319753	chr2:9767944	A/G	cg23886495	chr2:9695866	ADAM17	0.75	4.7	0.39	6.76e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs11249608	0.636	rs6888539	chr5:178449010	T/A	cg21905437	chr5:178450457	ZNF879	0.45	4.48	0.37	1.67e-5	Pubertal anthropometrics;
TGCT	cis	rs5769707	0.681	rs135879	chr22:50018651	C/T	cg06623630	chr22:50017776	C22orf34	-0.27	-4.58	-0.38	1.11e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs9372498	0.536	rs10484286	chr6:118956447	T/C	cg07617317	chr6:118971624	C6orf204	0.47	4.95	0.41	2.33e-6	Diastolic blood pressure;
TGCT	cis	rs7727544	0.582	rs6896703	chr5:131521295	C/G	cg14196790	chr5:131705035	SLC22A5	-0.35	-4.56	-0.38	1.23e-5	Blood metabolite levels;
TGCT	cis	rs344364	0.511	rs2982446	chr16:1947153	C/T	cg26617929	chr16:1858877	NA	-0.27	-4.9	-0.4	2.99e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs6121246	0.697	rs6088864	chr20:30228157	G/A	cg18721089	chr20:30220636	NA	-0.53	-5.43	-0.44	2.86e-7	Mean corpuscular hemoglobin;
TGCT	cis	rs6540559	0.611	rs76766079	chr1:209997731	C/T	cg21951975	chr1:209979733	IRF6	0.65	4.84	0.4	3.78e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs7572733	0.515	rs35730302	chr2:198818626	A/T	cg00792783	chr2:198669748	PLCL1	-0.58	-5.31	-0.43	4.9e-7	Dermatomyositis;
TGCT	cis	rs7914558	1.000	rs67908413	chr10:104764989	T/C	cg15744005	chr10:104629667	AS3MT	-0.39	-4.77	-0.39	5.16e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs7267979	1.000	rs6076339	chr20:25348712	T/C	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs71597109	0.681	rs4699260	chr4:102725298	C/T	cg14855874	chr4:102712397	BANK1	0.41	4.86	0.4	3.43e-6	Chronic lymphocytic leukemia;
TGCT	trans	rs877282	0.945	rs11253388	chr10:787852	A/G	cg22713356	chr15:30763199	NA	1.16	10.26	0.68	3.01e-18	Uric acid levels;
TGCT	cis	rs2404602	0.583	rs2176623	chr15:76568579	C/T	cg22467129	chr15:76604101	ETFA	-0.61	-7.62	-0.56	5.66e-12	Blood metabolite levels;
TGCT	cis	rs9611565	0.694	rs79008	chr22:41850500	C/T	cg03806693	chr22:41940476	POLR3H	-1.11	-11.93	-0.73	2.47e-22	Vitiligo;
TGCT	cis	rs2836950	0.501	rs13047518	chr21:40707307	G/A	cg11890956	chr21:40555474	PSMG1	-0.64	-5.9	-0.47	3.27e-8	Menarche (age at onset);
TGCT	cis	rs7635838	0.523	rs9873503	chr3:11396100	T/C	cg00170343	chr3:11313890	ATG7	0.64	6.15	0.48	9.73e-9	HDL cholesterol;
TGCT	cis	rs539096	0.500	rs803678	chr1:44350898	G/T	cg12908607	chr1:44402522	ARTN	-0.7	-8.79	-0.62	1.01e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg19748678	chr4:122722346	EXOSC9	0.87	9.22	0.64	9.65e-16	Type 2 diabetes;
TGCT	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg27454412	chr7:1067447	C7orf50	0.6	4.72	0.39	6.32e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs35160687	0.901	rs67903513	chr2:86512099	A/C	cg03171300	chr2:86307199	POLR1A	0.32	5.57	0.45	1.51e-7	Night sleep phenotypes;
TGCT	cis	rs10779751	1.000	rs11121704	chr1:11293959	A/G	cg08854313	chr1:11322531	MTOR	-1.04	-8.94	-0.63	4.5e-15	Body mass index;
TGCT	cis	rs1577917	0.958	rs12660846	chr6:86573809	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.47	-0.44	2.33e-7	Response to antipsychotic treatment;
TGCT	cis	rs60154123	0.505	rs76426571	chr1:210041634	C/T	cg22029157	chr1:209979665	IRF6	0.79	5.78	0.46	5.6e-8	Coronary artery disease;
TGCT	cis	rs2281636	1.000	rs2804417	chr10:101516215	G/A	cg17885402	chr10:101492224	COX15;CUTC	-0.57	-4.49	-0.37	1.58e-5	Obesity-related traits;
TGCT	cis	rs2299587	0.573	rs6986123	chr8:17888073	G/A	cg01800426	chr8:17659068	MTUS1	-0.6	-5.1	-0.42	1.25e-6	Economic and political preferences;
TGCT	cis	rs651907	0.557	rs34457525	chr3:101435225	C/T	cg12386194	chr3:101231763	SENP7	0.51	4.9	0.4	2.89e-6	Colorectal cancer;
TGCT	cis	rs4654899	0.865	rs960564	chr1:21416435	G/T	cg01072550	chr1:21505969	NA	-0.46	-6.9	-0.53	2.33e-10	Superior frontal gyrus grey matter volume;
TGCT	trans	rs9295123	0.965	rs4709402	chr6:160574037	C/T	cg22927510	chr22:50968328	TYMP	-0.51	-6.96	-0.53	1.79e-10	Blood protein levels;
TGCT	cis	rs617219	0.710	rs2607142	chr5:78557948	T/C	cg05890484	chr5:78407552	BHMT	0.34	4.63	0.38	9.24e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs7524258	0.903	rs763197	chr1:7289959	A/G	cg07173049	chr1:7289937	CAMTA1	0.32	5.31	0.43	4.88e-7	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs497273	0.552	rs1179939	chr12:121326876	G/C	cg02419362	chr12:121203948	SPPL3	-0.19	-4.51	-0.38	1.48e-5	Systemic lupus erythematosus;
TGCT	cis	rs11690462	0.794	rs2384364	chr2:26541427	C/G	cg04726446	chr2:26624865	C2orf39	0.42	4.53	0.38	1.39e-5	Coronary artery disease;
TGCT	cis	rs9916302	0.800	rs11869259	chr17:37518141	C/A	cg07936489	chr17:37558343	FBXL20	0.65	5.09	0.42	1.3e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.45	6.41	0.5	2.77e-9	Alzheimer's disease;
TGCT	cis	rs6500602	0.702	rs2058812	chr16:4524443	C/G	cg08645402	chr16:4508243	NA	0.16	4.59	0.38	1.09e-5	Schizophrenia;
TGCT	cis	rs4363385	0.525	rs11205138	chr1:152890568	G/A	cg07796016	chr1:152779584	LCE1C	-0.49	-5.65	-0.45	1.02e-7	Inflammatory skin disease;
TGCT	cis	rs7714584	1.000	rs10463310	chr5:150260905	G/A	cg22134413	chr5:150180641	NA	0.78	6.12	0.48	1.16e-8	Crohn's disease;
TGCT	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg10802521	chr3:52805072	NEK4	-0.72	-9.1	-0.63	1.91e-15	Bipolar disorder;
TGCT	trans	rs621559	0.535	rs620455	chr1:43671144	G/A	cg19324027	chr2:74699582	MRPL53	0.87	6.75	0.52	5.12e-10	Telomere length;
TGCT	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg11871910	chr12:69753446	YEATS4	0.87	10.07	0.67	8.72e-18	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs6088580	0.634	rs6059835	chr20:33020141	A/G	cg24642439	chr20:33292090	TP53INP2	0.49	4.51	0.38	1.5e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs7586879	0.638	rs13035244	chr2:25134009	T/C	cg15423357	chr2:25149977	NA	0.52	5.04	0.41	1.63e-6	Body mass index;
TGCT	cis	rs514406	0.548	rs6670871	chr1:53212082	A/C	cg24675658	chr1:53192096	ZYG11B	0.83	10.11	0.67	6.99e-18	Monocyte count;
TGCT	cis	rs9549367	0.713	rs3024776	chr13:113827075	A/G	cg18105134	chr13:113819100	PROZ	0.48	8.44	0.6	7.06e-14	Platelet distribution width;
TGCT	cis	rs11030122	0.673	rs4910597	chr11:4094923	G/A	cg18678763	chr11:4115507	RRM1	-0.47	-5.62	-0.45	1.21e-7	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs9611565	0.592	rs5758427	chr22:42099688	A/G	cg17554472	chr22:41940697	POLR3H	0.48	5.17	0.42	9e-7	Vitiligo;
TGCT	cis	rs7017914	0.934	rs78923624	chr8:71677839	G/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.53	-4.9	-0.4	2.87e-6	Bone mineral density;
TGCT	cis	rs7432375	0.901	rs11919030	chr3:136348599	G/A	cg12473912	chr3:136751656	NA	0.34	4.82	0.4	4.1e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1878931	1.000	rs1878931	chr16:3450907	G/C	cg03543448	chr16:4384967	GLIS2	0.19	4.76	0.39	5.26e-6	Body mass index (adult);
TGCT	cis	rs9902453	0.933	rs9303628	chr17:28527228	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	6.9	0.53	2.31e-10	Coffee consumption (cups per day);
TGCT	cis	rs265548	0.646	rs36689	chr19:17910639	A/G	cg21960279	chr19:17905606	B3GNT3	0.49	5.73	0.46	7.21e-8	Tumor biomarkers;
TGCT	cis	rs77633900	0.614	rs280030	chr15:77026853	T/C	cg21673338	chr15:77095150	SCAPER	-0.51	-5.12	-0.42	1.11e-6	Non-glioblastoma glioma;Glioma;
TGCT	cis	rs422249	0.512	rs174568	chr11:61593816	C/T	cg19610905	chr11:61596333	FADS2	-1.07	-12.03	-0.73	1.43e-22	Trans fatty acid levels;
TGCT	cis	rs6725041	0.819	rs939225	chr2:213089002	T/C	cg16329650	chr2:213403929	ERBB4	-0.53	-4.52	-0.38	1.44e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs2204008	0.728	rs11495375	chr12:38282631	G/A	cg26384229	chr12:38710491	ALG10B	0.86	7.48	0.56	1.17e-11	Bladder cancer;
TGCT	cis	rs796364	0.616	rs2689765	chr2:200696352	T/C	cg17644776	chr2:200775616	C2orf69	0.35	4.99	0.41	1.97e-6	Schizophrenia;
TGCT	cis	rs1577917	0.876	rs1582126	chr6:86697205	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-5.33	-0.43	4.54e-7	Response to antipsychotic treatment;
TGCT	cis	rs902774	0.530	rs12819597	chr12:53353956	T/C	cg16329197	chr12:53359506	NA	-0.56	-4.71	-0.39	6.44e-6	Prostate cancer;
TGCT	cis	rs6540559	0.673	rs58637469	chr1:209971480	T/A	cg21951975	chr1:209979733	IRF6	0.69	5.42	0.44	2.99e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs317689	0.918	rs581911	chr12:69738293	C/T	cg14784868	chr12:69753453	YEATS4	0.53	4.45	0.37	1.9e-5	Response to diuretic therapy;
TGCT	cis	rs2228479	0.717	rs11644967	chr16:89806614	T/A	cg04287289	chr16:89883240	FANCA	0.74	4.47	0.37	1.75e-5	Skin colour saturation;
TGCT	cis	rs826838	1.000	rs34254519	chr12:39041235	G/A	cg26384229	chr12:38710491	ALG10B	1.01	9.61	0.65	1.09e-16	Heart rate;
TGCT	cis	rs9467773	0.620	rs3800303	chr6:26598188	A/G	cg26531700	chr6:26746687	NA	0.5	4.64	0.38	8.54e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs35146811	0.735	rs858512	chr7:99824453	A/G	cg00553149	chr7:99775558	STAG3;GPC2	-0.32	-4.81	-0.4	4.28e-6	Coronary artery disease;
TGCT	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg13393036	chr8:95962371	TP53INP1	-0.65	-9.03	-0.63	2.75e-15	Type 2 diabetes;
TGCT	cis	rs1887596	0.705	rs4771004	chr13:27214082	A/G	cg01312412	chr13:27282625	NA	0.31	5.47	0.44	2.43e-7	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs9467711	0.516	rs1165184	chr6:25836257	C/G	cg03517284	chr6:25882590	NA	-0.73	-5.02	-0.41	1.77e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs892961	0.899	rs3650	chr17:75415835	T/C	cg05865280	chr17:75406074	SEPT9	0.29	6.71	0.52	6.23e-10	Airflow obstruction;
TGCT	cis	rs17387100	0.551	rs16892805	chr4:16019505	C/G	cg13480465	chr4:16795757	LDB2	0.42	5.33	0.43	4.56e-7	Suicide attempts in depression or bipolar disorder;
TGCT	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg04352962	chr1:209979756	IRF6	0.76	8.41	0.6	8.36e-14	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
TGCT	cis	rs6582630	0.519	rs8189549	chr12:38245752	A/G	cg26384229	chr12:38710491	ALG10B	0.86	7.42	0.55	1.6e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs1483890	0.962	rs1483891	chr3:69410416	G/C	cg22125112	chr3:69402811	FRMD4B	0.27	4.52	0.38	1.45e-5	Resting heart rate;
TGCT	cis	rs13217239	0.646	rs10456351	chr6:26986792	C/T	cg26531700	chr6:26746687	NA	0.68	6.79	0.52	4.1e-10	Schizophrenia;
TGCT	cis	rs4494114	1.000	rs4494114	chr1:39339682	C/T	cg25970120	chr1:39325951	RRAGC	0.6	6.28	0.49	5.34e-9	Blood protein levels;
TGCT	cis	rs1372520	0.684	rs2583968	chr4:90745395	C/G	cg14346243	chr4:90757452	SNCA	-0.67	-5.64	-0.45	1.11e-7	Neuroticism;
TGCT	cis	rs2370759	0.898	rs113412621	chr10:32579306	C/T	cg01819863	chr10:32635814	EPC1	1.03	10.03	0.67	1.05e-17	Sexual dysfunction (female);
TGCT	cis	rs10255878	0.568	rs17168494	chr7:97041088	T/C	cg01534613	chr7:96337050	SHFM1	0.29	4.47	0.37	1.73e-5	Adverse response to radiation therapy;
TGCT	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg14893161	chr1:205819251	PM20D1	0.37	4.54	0.38	1.31e-5	Menarche (age at onset);
TGCT	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.51	-5.0	-0.41	1.92e-6	Bipolar disorder;
TGCT	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg03303774	chr4:1407052	NA	0.31	4.87	0.4	3.31e-6	Obesity-related traits;
TGCT	cis	rs7617773	0.817	rs34728236	chr3:48259108	A/G	cg11946769	chr3:48343235	NME6	0.76	6.67	0.51	7.6e-10	Coronary artery disease;
TGCT	cis	rs79149102	0.579	rs7172715	chr15:75287375	C/G	cg09165964	chr15:75287851	SCAMP5	-1.06	-5.63	-0.45	1.17e-7	Lung cancer;
TGCT	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg23758822	chr17:41437982	NA	0.72	6.91	0.53	2.23e-10	Menopause (age at onset);
TGCT	cis	rs2201728	0.905	rs7662955	chr4:100217128	G/A	cg07219303	chr4:100140905	ADH6	-0.36	-5.31	-0.43	4.8e-7	Cardiac Troponin-T levels;
TGCT	cis	rs9311474	0.713	rs352165	chr3:52242902	A/G	cg10802521	chr3:52805072	NEK4	-0.61	-6.58	-0.51	1.19e-9	Electroencephalogram traits;
TGCT	cis	rs2652822	0.507	rs7176597	chr15:63494482	G/A	cg12855773	chr15:63363890	TPM1	-0.17	-4.84	-0.4	3.79e-6	Metabolic traits;
TGCT	cis	rs877282	0.945	rs11253390	chr10:788678	A/G	cg17470449	chr10:769945	NA	0.3	4.71	0.39	6.53e-6	Uric acid levels;
TGCT	cis	rs6815814	0.950	rs5743795	chr4:38832495	C/T	cg02016764	chr4:38805732	TLR1	-0.32	-4.91	-0.4	2.75e-6	Breast cancer;
TGCT	cis	rs524281	0.861	rs11227426	chr11:65971951	T/C	cg00563793	chr11:65837595	PACS1	0.53	4.56	0.38	1.2e-5	Electroencephalogram traits;
TGCT	cis	rs6540559	0.611	rs76766079	chr1:209997731	C/T	cg23283495	chr1:209979779	IRF6	0.61	4.53	0.38	1.36e-5	Cleft lip with or without cleft palate;
TGCT	cis	rs9549367	0.713	rs3024746	chr13:113821777	G/A	cg09473364	chr13:112927190	NA	-0.3	-4.44	-0.37	1.95e-5	Platelet distribution width;
TGCT	cis	rs7829975	0.606	rs6601274	chr8:8799059	T/G	cg08975724	chr8:8085496	FLJ10661	-0.53	-4.51	-0.38	1.47e-5	Mood instability;
TGCT	cis	rs9646954	0.542	rs11674830	chr2:101024735	A/G	cg14675211	chr2:100938903	LONRF2	0.5	4.66	0.39	7.99e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs11122272	0.735	rs2066140	chr1:231504311	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-5.97	-0.47	2.33e-8	Hemoglobin concentration;
TGCT	cis	rs2404602	0.647	rs11072625	chr15:77084984	A/G	cg23625390	chr15:77176239	SCAPER	0.36	4.52	0.38	1.4e-5	Blood metabolite levels;
TGCT	cis	rs727479	0.543	rs4324076	chr15:51510868	A/C	cg19946085	chr15:51559439	CYP19A1	-0.3	-4.49	-0.37	1.62e-5	Estradiol levels;
TGCT	cis	rs854765	0.624	rs4925119	chr17:17742904	A/G	cg09796270	chr17:17721594	SREBF1	-0.24	-4.53	-0.38	1.39e-5	Total body bone mineral density;
TGCT	cis	rs587847	0.767	rs28668771	chr15:37688017	A/G	cg12309653	chr15:37170454	LOC145845	0.31	4.48	0.37	1.7e-5	Intraocular pressure;
TGCT	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg18876405	chr7:65276391	NA	-0.37	-5.58	-0.45	1.47e-7	Aortic root size;
TGCT	cis	rs12210905	0.688	rs72841399	chr6:27489832	T/G	cg08851530	chr6:28072375	NA	1.34	6.29	0.49	5.02e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs1981331	1.000	rs118078026	chr21:48012129	T/C	cg23283320	chr21:48055893	PRMT2	1.29	6.09	0.48	1.31e-8	Cerebrospinal fluid t-tau:AB1-42 ratio;
TGCT	cis	rs4808199	0.843	rs10402308	chr19:19657500	G/A	cg03709012	chr19:19516395	GATAD2A	0.93	7.21	0.54	4.93e-11	Nonalcoholic fatty liver disease;
TGCT	cis	rs6500602	0.563	rs917304	chr16:4440426	C/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.41	5.1	0.42	1.23e-6	Schizophrenia;
TGCT	cis	rs9430161	0.611	rs34032547	chr1:11034374	C/G	cg02454025	chr1:11042201	C1orf127	0.94	11.31	0.71	8.14e-21	Ewing sarcoma;
TGCT	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.64	7.0	0.53	1.43e-10	Blood metabolite levels;
TGCT	trans	rs7618501	1.000	rs2247036	chr3:49882349	C/T	cg21659725	chr3:3221576	CRBN	0.97	14.99	0.8	1.29e-29	Intelligence (multi-trait analysis);
TGCT	cis	rs1801251	0.778	rs2675967	chr2:233736133	C/G	cg25237894	chr2:233734115	C2orf82	-0.3	-5.85	-0.46	4.16e-8	Coronary artery disease;
TGCT	cis	rs7681440	0.904	rs28507349	chr4:90767063	G/A	cg14346243	chr4:90757452	SNCA	-0.57	-5.6	-0.45	1.31e-7	Dementia with Lewy bodies;
TGCT	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg12923728	chr3:195709715	SDHAP1	0.36	7.66	0.57	4.64e-12	Pancreatic cancer;
TGCT	cis	rs9393777	0.513	rs13215020	chr6:26656073	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.63	-5.75	-0.46	6.58e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs939658	0.805	rs35484723	chr15:79441032	A/G	cg17916960	chr15:79447300	NA	-0.49	-7.41	-0.55	1.73e-11	Refractive error;
TGCT	cis	rs12188164	0.610	rs57433159	chr5:418725	C/T	cg26850624	chr5:429559	AHRR	-0.19	-4.45	-0.37	1.89e-5	Cystic fibrosis severity;
TGCT	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg17554472	chr22:41940697	POLR3H	-0.49	-5.27	-0.43	5.9e-7	Vitiligo;
TGCT	cis	rs10927875	0.793	rs1763619	chr1:16326935	A/G	cg22431228	chr1:16359049	CLCNKA	-0.25	-4.8	-0.4	4.39e-6	Dilated cardiomyopathy;
TGCT	cis	rs4803468	0.967	rs13345590	chr19:41886455	T/G	cg09537434	chr19:41945824	ATP5SL	-0.88	-9.98	-0.67	1.4e-17	Height;
TGCT	cis	rs9611519	0.579	rs8136274	chr22:41415311	T/C	cg03806693	chr22:41940476	POLR3H	-0.64	-6.09	-0.48	1.29e-8	Neuroticism;
TGCT	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg03188948	chr7:1209495	NA	0.59	4.82	0.4	4.06e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs10114408	0.959	rs10821256	chr9:96657044	C/T	cg13679303	chr9:96623674	NA	-0.36	-4.65	-0.39	8.3e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs3796352	0.571	rs71301816	chr3:53142071	G/A	cg07884673	chr3:53033167	SFMBT1	0.57	6.13	0.48	1.09e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs7267979	0.966	rs6050532	chr20:25308793	A/T	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs8031584	0.678	rs8028173	chr15:31155749	A/G	cg08109568	chr15:31115862	NA	-0.38	-5.03	-0.41	1.67e-6	Huntington's disease progression;
TGCT	cis	rs1475911	0.708	rs8129075	chr21:43523430	G/T	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.28	-5.69	-0.45	8.8e-8	IgG glycosylation;
TGCT	cis	rs6426558	0.537	rs2102634	chr1:227324308	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.58	-6.91	-0.53	2.21e-10	Neutrophil percentage of white cells;
TGCT	cis	rs2115630	0.967	rs12595786	chr15:85336670	T/C	cg17173187	chr15:85201210	NMB	-0.4	-4.86	-0.4	3.51e-6	P wave terminal force;
TGCT	cis	rs8072100	0.537	rs9912450	chr17:45402208	C/T	cg08085267	chr17:45401833	C17orf57	-0.59	-6.48	-0.5	1.99e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs12615966	1.000	rs12618379	chr2:105386854	C/T	cg16465502	chr2:105461796	NA	0.78	4.98	0.41	2.11e-6	Pancreatic cancer;
TGCT	cis	rs79387448	0.638	rs11465698	chr2:103054577	T/C	cg09003973	chr2:102972529	NA	1.27	9.82	0.66	3.37e-17	Gut microbiota (bacterial taxa);
TGCT	cis	rs798554	0.704	rs798531	chr7:2770067	G/C	cg25467336	chr7:2757616	NA	-0.24	-4.61	-0.38	9.99e-6	Height;
TGCT	cis	rs6752107	1.000	rs12994971	chr2:234178453	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.2	4.8	0.4	4.54e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs929354	0.772	rs2301916	chr7:156974127	G/T	cg05182265	chr7:156933206	UBE3C	-0.38	-8.59	-0.61	3.18e-14	Body mass index;
TGCT	cis	rs7428	0.502	rs3184781	chr2:85549527	T/C	cg03728395	chr2:85555865	TGOLN2	-0.29	-5.09	-0.42	1.32e-6	Ear protrusion;
TGCT	cis	rs9372498	0.536	rs25422	chr6:118807847	A/G	cg21191810	chr6:118973309	C6orf204	0.39	4.95	0.41	2.32e-6	Diastolic blood pressure;
TGCT	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.01	0.41	1.86e-6	Prudent dietary pattern;
TGCT	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg03934478	chr11:495069	RNH1	0.35	5.81	0.46	4.96e-8	Body mass index;
TGCT	cis	rs6665290	0.901	rs11580229	chr1:227210820	G/A	cg10327440	chr1:227177885	CDC42BPA	-0.91	-16.3	-0.83	1.24e-32	Myeloid white cell count;
TGCT	cis	rs1577917	0.710	rs9342041	chr6:86280875	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.52	4.61	0.38	9.81e-6	Response to antipsychotic treatment;
TGCT	trans	rs1814175	0.817	rs7924619	chr11:49620632	G/A	cg03929089	chr4:120376271	NA	-0.74	-8.94	-0.63	4.47e-15	Height;
TGCT	cis	rs6598955	0.671	rs13374173	chr1:26602256	T/G	cg04990556	chr1:26633338	UBXN11	0.66	5.0	0.41	1.88e-6	Obesity-related traits;
TGCT	cis	rs1008375	1.000	rs12648232	chr4:17612537	C/T	cg18681998	chr4:17616180	MED28	-0.98	-11.03	-0.7	3.92e-20	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9467773	1.000	rs9467778	chr6:26534743	T/C	cg09904177	chr6:26538194	HMGN4	0.65	6.53	0.51	1.53e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-5.1	-0.42	1.23e-6	Bipolar disorder;
TGCT	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg00149659	chr3:10157352	C3orf10	0.91	5.89	0.47	3.32e-8	Alzheimer's disease;
TGCT	cis	rs9534288	0.699	rs2296642	chr13:46656669	A/G	cg15192986	chr13:46630673	CPB2	-0.53	-6.5	-0.5	1.8e-9	Blood protein levels;
TGCT	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg12034118	chr1:209979487	IRF6	0.68	5.13	0.42	1.07e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs9902453	0.757	rs12453308	chr17:28441604	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	6.5	0.5	1.77e-9	Coffee consumption (cups per day);
TGCT	cis	rs9929218	0.954	rs17715762	chr16:68828250	T/G	cg03880890	chr16:69439245	NA	-0.22	-4.48	-0.37	1.68e-5	Colorectal cancer;
TGCT	cis	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg18252515	chr7:66147081	NA	-1.09	-6.4	-0.5	2.88e-9	Diabetic kidney disease;
TGCT	cis	rs4919669	0.668	rs74558061	chr10:104384337	A/G	cg05855489	chr10:104503620	C10orf26	0.7	4.44	0.37	1.94e-5	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs1215050	0.791	rs1530904	chr4:98805436	A/G	cg17366294	chr4:99064904	C4orf37	0.52	5.59	0.45	1.4e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs28735056	0.967	rs4799092	chr18:77608203	C/G	cg20368463	chr18:77673604	PQLC1	-0.44	-5.46	-0.44	2.44e-7	Schizophrenia;
TGCT	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7267979	0.844	rs6132824	chr20:25238173	T/C	cg16686733	chr20:25566563	NINL	0.52	4.9	0.4	2.98e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6978712	1.000	rs17714284	chr7:127147205	G/A	cg01017541	chr7:127776461	NA	0.79	4.76	0.39	5.3e-6	Medication adherence in chronic diseases;
TGCT	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.25	4.75	0.39	5.51e-6	Total body bone mineral density;
TGCT	cis	rs12950390	0.893	rs4239166	chr17:45847329	A/G	cg24803719	chr17:45855879	NA	-0.47	-4.75	-0.39	5.6e-6	IgG glycosylation;
TGCT	cis	rs10465746	0.725	rs980417	chr1:84365331	C/A	cg10977910	chr1:84465055	TTLL7	0.68	6.7	0.52	6.46e-10	Obesity-related traits;
TGCT	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg15691649	chr6:25882328	NA	-0.35	-4.55	-0.38	1.25e-5	Blood metabolite levels;
TGCT	cis	rs7267979	0.740	rs2259961	chr20:25282626	T/G	cg14121845	chr20:25566513	NINL	0.45	4.6	0.38	1.02e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7772486	0.686	rs857877	chr6:145976230	A/C	cg05347473	chr6:146136440	FBXO30	-0.49	-4.59	-0.38	1.06e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11098499	0.754	rs17595608	chr4:120250506	C/T	cg09307838	chr4:120376055	NA	0.61	5.91	0.47	3.14e-8	Corneal astigmatism;
TGCT	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg24060327	chr5:131705240	SLC22A5	0.78	8.62	0.61	2.62e-14	Breast cancer;
TGCT	cis	rs7296418	0.754	rs1619283	chr12:123717362	A/G	cg05973401	chr12:123451056	ABCB9	0.54	4.51	0.38	1.48e-5	Platelet count;
TGCT	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg14159672	chr1:205819179	PM20D1	0.6	7.44	0.56	1.45e-11	Menarche (age at onset);
TGCT	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg08219700	chr8:58056026	NA	0.3	4.58	0.38	1.13e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs4074961	0.586	rs10908360	chr1:38058693	T/C	cg11397548	chr1:38022522	DNALI1	0.42	4.52	0.38	1.44e-5	Axial length;
TGCT	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg04352962	chr1:209979756	IRF6	0.64	4.89	0.4	3.12e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs7267979	0.934	rs6037085	chr20:25305202	C/T	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2735413	0.564	rs2344491	chr16:78096154	A/G	cg09132178	chr16:78079569	NA	0.33	4.44	0.37	1.98e-5	Systolic blood pressure (alcohol consumption interaction);
TGCT	cis	rs10791097	0.739	rs12279359	chr11:130730544	G/A	cg12179176	chr11:130786555	SNX19	0.73	8.6	0.61	2.98e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs4372836	0.518	rs1128416	chr2:29001691	A/G	cg09522027	chr2:28974177	PPP1CB	-0.77	-7.59	-0.56	6.62e-12	Body mass index;
TGCT	cis	rs138249	1.000	rs138252	chr22:50570873	G/T	cg24864161	chr22:50528282	MOV10L1	0.46	4.71	0.39	6.51e-6	Gestational age at birth in labor-initiated deliveries (child effect);
TGCT	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg06873352	chr17:61820015	STRADA	0.56	6.19	0.49	8.27e-9	Prudent dietary pattern;
TGCT	cis	rs3796352	1.000	rs11717619	chr3:53003179	A/C	cg15956490	chr3:53032818	SFMBT1	0.61	6.76	0.52	4.92e-10	Immune reponse to smallpox (secreted IL-2);
TGCT	trans	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg20587970	chr11:113659929	NA	-1.09	-13.5	-0.77	4.23e-26	Hip circumference adjusted for BMI;
TGCT	cis	rs651907	0.557	rs7645391	chr3:101361506	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.09	0.42	1.32e-6	Colorectal cancer;
TGCT	cis	rs2456568	0.835	rs7936182	chr11:93665532	T/A	cg16099599	chr11:93583650	C11orf90	-0.4	-4.72	-0.39	6.21e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7587476	0.601	rs1129804	chr2:215674323	C/G	cg04004882	chr2:215674386	BARD1	-0.65	-5.13	-0.42	1.09e-6	Neuroblastoma;
TGCT	cis	rs3812831	0.662	rs407531	chr13:114929218	G/A	cg08824895	chr13:115047677	UPF3A	0.51	4.84	0.4	3.82e-6	Schizophrenia;
TGCT	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.66	0.39	8.18e-6	Prudent dietary pattern;
TGCT	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs9972944	0.702	rs6416946	chr17:63763967	C/T	cg07283582	chr17:63770753	CCDC46	-0.26	-5.29	-0.43	5.45e-7	Total body bone mineral density;
TGCT	cis	rs10193935	1.000	rs13391906	chr2:42538617	C/G	cg27598129	chr2:42591480	NA	-0.41	-5.65	-0.45	1.04e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11690935	0.959	rs2674484	chr2:172574612	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.18	-12.58	-0.75	6.59e-24	Schizophrenia;
TGCT	cis	rs1371867	0.875	rs1660311	chr8:101330579	C/T	cg00191853	chr8:101177733	SPAG1	-0.22	-4.47	-0.37	1.75e-5	Atrioventricular conduction;
TGCT	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg20607798	chr8:58055168	NA	0.45	4.66	0.39	7.88e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg22920501	chr2:26401640	FAM59B	-0.74	-6.4	-0.5	2.86e-9	Gut microbiome composition (summer);
TGCT	cis	rs57221529	0.600	rs11750269	chr5:666270	G/A	cg20362242	chr5:692897	TPPP	0.52	4.76	0.39	5.4e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs7611238	0.560	rs9288746	chr3:195158031	T/C	cg27323046	chr3:195102265	ACAP2	0.33	4.44	0.37	1.96e-5	Body mass index;
TGCT	cis	rs7119	0.671	rs10152850	chr15:77904426	G/A	cg27398640	chr15:77910606	LINGO1	0.32	6.74	0.52	5.39e-10	Type 2 diabetes;
TGCT	cis	rs7937682	0.921	rs688354	chr11:111438762	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.85	-7.67	-0.57	4.42e-12	Primary sclerosing cholangitis;
TGCT	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg06481639	chr22:41940642	POLR3H	0.74	6.58	0.51	1.2e-9	Vitiligo;
TGCT	cis	rs11190604	1.000	rs2489050	chr10:102350898	T/A	cg23241863	chr10:102295624	HIF1AN	0.67	4.87	0.4	3.36e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs28408315	0.914	rs34577742	chr15:79215568	C/T	cg15822222	chr15:79164806	MORF4L1	0.49	5.18	0.42	8.55e-7	Lung cancer;Lung cancer in ever smokers;Lung adenocarcinoma;
TGCT	cis	rs9486719	1.000	rs12197411	chr6:97039621	G/A	cg18709589	chr6:96969512	KIAA0776	-0.74	-5.21	-0.42	7.5e-7	Migraine;Coronary artery disease;
TGCT	cis	rs9303280	0.901	rs869402	chr17:38068043	C/T	cg18711369	chr17:38081186	ORMDL3	0.23	4.85	0.4	3.6e-6	Self-reported allergy;
TGCT	cis	rs7666738	0.830	rs11938686	chr4:98964470	A/G	cg05340658	chr4:99064831	C4orf37	0.53	6.04	0.48	1.64e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7017914	0.967	rs7014012	chr8:71672743	G/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.53	-4.9	-0.4	2.87e-6	Bone mineral density;
TGCT	cis	rs6495122	0.630	rs12912343	chr15:75251041	C/G	cg10253484	chr15:75165896	SCAMP2	-0.6	-5.33	-0.43	4.52e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
TGCT	cis	rs910316	0.967	rs8007539	chr14:75664953	T/C	cg11812906	chr14:75593930	NEK9	-0.71	-6.8	-0.52	3.94e-10	Height;
TGCT	cis	rs903263	0.965	rs2037455	chr1:84645555	A/G	cg09664975	chr1:84543551	PRKACB	0.47	4.48	0.37	1.65e-5	Breast cancer (male);
TGCT	cis	rs12497850	0.931	rs7616815	chr3:48779715	C/T	cg06212747	chr3:49208901	KLHDC8B	0.61	5.74	0.46	6.86e-8	Parkinson's disease;
TGCT	cis	rs6831352	0.877	rs28987101	chr4:100049253	T/G	cg12011299	chr4:100065546	ADH4	-0.41	-4.92	-0.4	2.72e-6	Alcohol dependence;
TGCT	cis	rs7312933	0.618	rs6582390	chr12:42634586	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.53	5.05	0.41	1.54e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs9868809	0.772	rs28452701	chr3:48708575	C/T	cg00383909	chr3:49044727	WDR6	1.06	6.18	0.49	8.32e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs12579753	0.917	rs71466033	chr12:82242187	C/T	cg07988820	chr12:82153109	PPFIA2	-0.6	-6.48	-0.5	1.91e-9	Resting heart rate;
TGCT	cis	rs74233809	1.000	rs10509759	chr10:104689665	A/T	cg05855489	chr10:104503620	C10orf26	0.74	4.45	0.37	1.87e-5	Birth weight;
TGCT	cis	rs7829975	0.871	rs777709	chr8:8583872	T/C	cg15556689	chr8:8085844	FLJ10661	-0.66	-5.77	-0.46	6.03e-8	Mood instability;
TGCT	cis	rs7605378	0.528	rs281767	chr2:200823281	C/A	cg23649088	chr2:200775458	C2orf69	0.47	9.83	0.66	3.23e-17	Osteoporosis;
TGCT	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg23131131	chr22:24373011	LOC391322	-0.81	-8.72	-0.62	1.53e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9372253	1.000	rs9384740	chr6:110716207	G/A	cg00083206	chr6:110721305	DDO	-0.43	-6.46	-0.5	2.2e-9	Platelet distribution width;
TGCT	trans	rs1496653	0.602	rs13063451	chr3:23469372	T/C	cg02770683	chr12:57597238	LRP1	0.38	6.89	0.53	2.53e-10	Type 2 diabetes;
TGCT	cis	rs425277	1.000	rs74877653	chr1:2065949	C/T	cg03732007	chr1:2071316	PRKCZ	0.25	5.01	0.41	1.81e-6	Height;
TGCT	cis	rs11080466	1.000	rs11663246	chr18:10900614	C/T	cg02393756	chr18:9912783	VAPA	-0.25	-4.47	-0.37	1.72e-5	Non-small cell lung cancer;
TGCT	cis	rs12188164	0.965	rs72717415	chr5:430059	G/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.4	-4.76	-0.39	5.27e-6	Cystic fibrosis severity;
TGCT	cis	rs782590	0.620	rs4322879	chr2:55797033	G/T	cg03859395	chr2:55845619	SMEK2	-0.71	-6.85	-0.52	3.13e-10	Metabolic syndrome;
TGCT	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg03264133	chr6:25882463	NA	-0.58	-5.22	-0.42	7.29e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2242194	0.816	rs6671688	chr1:154994265	T/C	cg09359103	chr1:154839909	KCNN3	-0.45	-6.33	-0.49	4.13e-9	Schizophrenia;
TGCT	cis	rs1005277	0.505	rs200937	chr10:38135772	T/C	cg13531842	chr10:38383804	ZNF37A	-0.39	-4.58	-0.38	1.1e-5	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7552404	0.920	rs2788654	chr1:76219569	C/T	cg10523679	chr1:76189770	ACADM	0.82	8.79	0.62	1.05e-14	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg08219700	chr8:58056026	NA	0.38	4.61	0.38	1e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs6484504	0.576	rs58702363	chr11:31246397	C/A	cg14844989	chr11:31128820	NA	-0.23	-4.51	-0.38	1.47e-5	Red blood cell count;
TGCT	cis	rs9372498	0.536	rs9489394	chr6:118758234	T/C	cg07617317	chr6:118971624	C6orf204	0.5	5.39	0.44	3.37e-7	Diastolic blood pressure;
TGCT	cis	rs1801251	0.685	rs1515961	chr2:233623763	C/A	cg08000102	chr2:233561755	GIGYF2	0.61	6.89	0.53	2.54e-10	Coronary artery disease;
TGCT	cis	rs71435601	0.628	rs1712250	chr2:21386058	C/T	cg25035485	chr2:21266500	APOB	0.51	4.48	0.37	1.64e-5	Cholesterol, total;
TGCT	cis	rs10782582	0.609	rs78556436	chr1:76352875	G/A	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.52	4.54	0.38	1.31e-5	Daytime sleep phenotypes;
TGCT	cis	rs7220401	0.512	rs71371126	chr17:28002642	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-6.14	-0.48	1.01e-8	Coronary artery disease;
TGCT	cis	rs1401999	0.650	rs3749445	chr3:183638506	C/T	cg01324343	chr3:183735012	ABCC5	0.69	8.13	0.59	3.77e-13	Anterior chamber depth;
TGCT	cis	rs2832191	0.671	rs73346699	chr21:30515529	C/T	cg24692254	chr21:30365293	RNF160	-0.62	-5.46	-0.44	2.44e-7	Dental caries;
TGCT	cis	rs10804591	0.848	rs2811448	chr3:129314259	T/G	cg07730360	chr3:128845626	NA	0.21	4.64	0.38	8.88e-6	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Hip circumference adjusted for BMI;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs8103278	1.000	rs35302007	chr19:46219145	G/C	cg14061069	chr19:46274453	DMPK	-0.45	-6.49	-0.5	1.86e-9	Coronary artery disease;
TGCT	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg26119090	chr2:26468346	HADHA;HADHB	1.0	7.42	0.55	1.64e-11	Gut microbiome composition (summer);
TGCT	cis	rs2346177	0.875	rs12986585	chr2:46644121	T/A	cg26688816	chr2:46740690	ATP6V1E2	-0.43	-4.77	-0.39	5.07e-6	HDL cholesterol;
TGCT	cis	rs9926296	0.656	rs2376884	chr16:89826922	C/T	cg04287289	chr16:89883240	FANCA	0.66	6.63	0.51	9.24e-10	Vitiligo;
TGCT	cis	rs9926296	0.568	rs417323	chr16:89746277	T/G	cg26513180	chr16:89883248	FANCA	-0.66	-6.25	-0.49	6.16e-9	Vitiligo;
TGCT	cis	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg06636001	chr8:8085503	FLJ10661	0.71	6.29	0.49	4.94e-9	Mood instability;
TGCT	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg10053473	chr17:62856997	LRRC37A3	-0.45	-6.78	-0.52	4.41e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs12135062	0.901	rs2651928	chr1:3101722	C/T	cg00254258	chr1:3105189	PRDM16	-0.34	-5.57	-0.45	1.52e-7	Migraine;
TGCT	cis	rs11785400	0.793	rs13255558	chr8:143748080	C/T	cg10596483	chr8:143751796	JRK	0.55	5.34	0.43	4.27e-7	Schizophrenia;
TGCT	cis	rs12681288	0.578	rs10503154	chr8:969343	C/G	cg04851639	chr8:1020857	NA	-0.32	-5.5	-0.44	2.06e-7	Schizophrenia;
TGCT	cis	rs12477438	0.520	rs36071868	chr2:99737120	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.89	9.0	0.63	3.26e-15	Chronic sinus infection;
TGCT	cis	rs4746059	0.516	rs12777075	chr10:72471772	A/G	cg03087610	chr10:71892362	AIFM2	-0.5	-4.54	-0.38	1.29e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7940866	0.804	rs10894289	chr11:130808685	C/T	cg05962950	chr11:130786565	SNX19	0.67	6.64	0.51	8.71e-10	Schizophrenia;
TGCT	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg03264133	chr6:25882463	NA	-0.65	-5.81	-0.46	5.01e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs17601876	0.778	rs11632926	chr15:51564226	G/A	cg19946085	chr15:51559439	CYP19A1	-0.34	-5.04	-0.41	1.59e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg08439880	chr3:133502540	NA	-0.27	-4.82	-0.4	4.09e-6	Iron status biomarkers;
TGCT	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg03264133	chr6:25882463	NA	-0.53	-5.53	-0.44	1.81e-7	Blood metabolite levels;
TGCT	cis	rs12136530	0.625	rs12726614	chr1:19730957	G/C	cg24875000	chr1:19041556	PAX7	-0.26	-4.57	-0.38	1.15e-5	Lead levels in blood;
TGCT	cis	rs1532993	0.518	rs6532691	chr4:98632582	A/T	cg05340658	chr4:99064831	C4orf37	-0.4	-4.91	-0.4	2.77e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	trans	rs9985766	1.000	rs4339189	chr4:151024575	G/C	cg02993991	chr19:4064177	ZBTB7A	0.57	6.7	0.52	6.59e-10	Coronary artery disease;Myocardial infarction;
TGCT	cis	rs9911578	0.967	rs4132925	chr17:56938016	C/G	cg05425664	chr17:57184151	TRIM37	0.64	6.38	0.5	3.19e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs17102423	0.558	rs11628664	chr14:65615651	C/T	cg11161011	chr14:65562177	MAX	-0.41	-5.66	-0.45	9.83e-8	Obesity-related traits;
TGCT	cis	rs832540	0.931	rs702679	chr5:56221328	A/G	cg24531977	chr5:56204891	C5orf35	-0.52	-5.19	-0.42	8.26e-7	Coronary artery disease;
TGCT	cis	rs13191362	0.507	rs2023037	chr6:163120385	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.55	5.25	0.43	6.46e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs2440129	0.632	rs13396	chr17:6905624	T/C	cg03760483	chr17:6899297	ALOX12	0.48	5.5	0.44	2.11e-7	Tonsillectomy;
TGCT	cis	rs116095464	0.558	rs10055993	chr5:264296	A/C	cg22857025	chr5:266934	NA	-0.35	-6.91	-0.53	2.25e-10	Breast cancer;
TGCT	cis	rs17253792	0.822	rs8009608	chr14:56062590	C/T	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg08045932	chr20:61659980	NA	0.47	8.85	0.62	7.34e-15	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9549260	0.755	rs4943800	chr13:41216831	A/G	cg21288729	chr13:41239152	FOXO1	0.99	10.37	0.68	1.56e-18	Red blood cell count;
TGCT	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.84	7.5	0.56	1.08e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs13427251	0.868	rs1901284	chr2:100146040	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.54	4.98	0.41	2.04e-6	Chronic sinus infection;
TGCT	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg06238570	chr21:40685208	BRWD1	-0.62	-6.17	-0.48	8.82e-9	Menarche (age at onset);
TGCT	cis	rs7647973	0.580	rs12637576	chr3:49237334	C/T	cg07636037	chr3:49044803	WDR6	0.83	8.44	0.6	6.88e-14	Menarche (age at onset);
TGCT	cis	rs929354	0.935	rs1182392	chr7:157036200	C/T	cg05182265	chr7:156933206	UBE3C	0.31	6.4	0.5	2.93e-9	Body mass index;
TGCT	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg08509172	chr19:19383838	TM6SF2	-0.35	-4.51	-0.38	1.46e-5	Tonsillectomy;
TGCT	cis	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg03213289	chr20:61660250	NA	0.69	9.94	0.67	1.81e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2839186	0.504	rs4347941	chr21:47938239	T/C	cg10657630	chr21:48055338	PRMT2	0.49	4.73	0.39	5.91e-6	Testicular germ cell tumor;
TGCT	cis	rs35146811	0.735	rs858512	chr7:99824453	A/G	cg13334819	chr7:99746414	C7orf59	0.74	6.41	0.5	2.82e-9	Coronary artery disease;
TGCT	cis	rs7267979	0.966	rs2387885	chr20:25415224	G/A	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9467711	0.790	rs13198716	chr6:26582035	A/G	cg16898833	chr6:26189333	HIST1H4D	-1.37	-6.2	-0.49	7.83e-9	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2115630	0.967	rs8027779	chr15:85255385	T/C	cg11189052	chr15:85197271	WDR73	-0.67	-6.57	-0.51	1.25e-9	P wave terminal force;
TGCT	cis	rs2562456	0.917	rs10420016	chr19:21688602	C/G	cg25650185	chr19:21324782	ZNF431	0.61	5.38	0.43	3.6e-7	Pain;
TGCT	cis	rs6968419	0.674	rs1918911	chr7:115906748	G/T	cg25274503	chr7:116140128	CAV2	0.56	4.48	0.37	1.68e-5	Intraocular pressure;
TGCT	cis	rs797680	0.894	rs7418101	chr1:93756192	G/A	cg17826107	chr1:92977322	EVI5	0.23	5.12	0.42	1.15e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.43	6.28	0.49	5.19e-9	Schizophrenia;
TGCT	cis	rs9911578	1.000	rs9901181	chr17:56964271	C/T	cg05425664	chr17:57184151	TRIM37	-0.62	-6.18	-0.49	8.33e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs4494114	0.967	rs3814342	chr1:39325983	A/G	cg25970120	chr1:39325951	RRAGC	-0.6	-6.43	-0.5	2.52e-9	Blood protein levels;
TGCT	cis	rs8028182	0.636	rs7495610	chr15:75784441	T/C	cg20655648	chr15:75932815	IMP3	0.59	4.49	0.37	1.58e-5	Sudden cardiac arrest;
TGCT	cis	rs61897795	0.657	rs174587	chr11:61612830	C/T	cg19610905	chr11:61596333	FADS2	-0.8	-6.19	-0.49	8.16e-9	Neutrophil count;Sum basophil neutrophil counts;
TGCT	cis	rs853679	0.546	rs175597	chr6:27810626	T/C	cg10876282	chr6:28092338	ZSCAN16	0.74	4.44	0.37	1.98e-5	Depression;
TGCT	cis	rs7949030	0.653	rs2849030	chr11:62366986	G/A	cg13298116	chr11:62369859	EML3;MTA2	-0.62	-9.24	-0.64	8.81e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs3771570	0.901	rs3771585	chr2:242400723	G/A	cg21155796	chr2:242212141	HDLBP	0.89	6.82	0.52	3.55e-10	Prostate cancer;
TGCT	cis	rs10838634	0.803	rs7105217	chr11:46838838	T/A	cg18332754	chr11:46939436	LRP4	0.89	4.46	0.37	1.82e-5	Schizophrenia;
TGCT	cis	rs2239815	0.515	rs9625591	chr22:29232564	A/G	cg02153584	chr22:29168773	CCDC117	0.67	4.57	0.38	1.17e-5	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
TGCT	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg21724239	chr8:58056113	NA	0.38	5.18	0.42	8.82e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs4689388	0.926	rs1801214	chr4:6303022	C/T	cg14416269	chr4:6271139	WFS1	0.39	5.2	0.42	8.1e-7	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs6988636	0.710	rs59229243	chr8:124155673	G/A	cg27053337	chr8:124217698	FAM83A	0.72	5.08	0.42	1.34e-6	Urinary uromodulin levels;
TGCT	cis	rs59698941	0.550	rs11739194	chr5:132201230	T/C	cg27099455	chr5:132201840	GDF9;UQCRQ	0.3	5.02	0.41	1.75e-6	Apolipoprotein A-IV levels;
TGCT	cis	rs7927771	0.832	rs10838704	chr11:47424717	T/C	cg10139015	chr11:47448256	PSMC3	0.52	4.44	0.37	1.97e-5	Subjective well-being;
TGCT	cis	rs5769765	1.000	rs761879	chr22:50241210	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.38	-5.65	-0.45	1.03e-7	Schizophrenia;
TGCT	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg03806693	chr22:41940476	POLR3H	1.12	13.0	0.76	6.43e-25	Vitiligo;
TGCT	cis	rs2072499	0.966	rs1060604	chr1:156184268	T/C	cg25208724	chr1:156163844	SLC25A44	1.11	12.73	0.75	2.98e-24	Testicular germ cell tumor;
TGCT	cis	rs1008375	0.931	rs7435102	chr4:17571480	C/G	cg16339924	chr4:17578868	LAP3	0.82	7.13	0.54	7.32e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg06896619	chr17:61851486	DDX42;CCDC47	-0.51	-4.96	-0.41	2.24e-6	Prudent dietary pattern;
TGCT	cis	rs6088580	0.634	rs6059835	chr20:33020141	A/G	cg06115741	chr20:33292138	TP53INP2	0.55	4.81	0.4	4.24e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs1570884	0.516	rs2094108	chr13:50171550	G/A	cg03651054	chr13:50194643	NA	0.32	5.26	0.43	6.06e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
TGCT	cis	rs453301	0.686	rs6601280	chr8:8909236	A/T	cg06636001	chr8:8085503	FLJ10661	0.7	6.06	0.48	1.52e-8	Joint mobility (Beighton score);
TGCT	cis	rs1801251	1.000	rs12474040	chr2:233615345	T/G	cg25237894	chr2:233734115	C2orf82	0.32	5.68	0.45	8.93e-8	Coronary artery disease;
TGCT	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-6.74	-0.52	5.26e-10	Alzheimer's disease;
TGCT	cis	rs6469804	0.557	rs4295687	chr8:120058346	A/T	cg17171407	chr8:119960777	TNFRSF11B	0.27	4.72	0.39	6.29e-6	Bone mineral density (spine);
TGCT	cis	rs6430585	0.528	rs3099429	chr2:136655582	T/A	cg07169764	chr2:136633963	MCM6	1.17	10.98	0.7	5.11e-20	Corneal structure;
TGCT	cis	rs854765	0.547	rs6502633	chr17:17941037	G/C	cg09796270	chr17:17721594	SREBF1	0.24	4.7	0.39	6.94e-6	Total body bone mineral density;
TGCT	cis	rs2303745	0.589	rs7246262	chr19:17392483	C/G	cg02221750	chr19:17393354	ANKLE1	-0.48	-6.27	-0.49	5.46e-9	Systemic lupus erythematosus;
TGCT	cis	rs56036086	1.000	rs73187250	chr22:50634552	G/A	cg01548456	chr22:50352384	NA	0.37	4.82	0.4	4.17e-6	Platelet count;Plateletcrit;
TGCT	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg25036284	chr2:26402008	FAM59B	0.5	4.72	0.39	6.25e-6	Gut microbiome composition (summer);
TGCT	cis	rs6684514	1.000	rs12130361	chr1:156260301	C/T	cg16558208	chr1:156270281	VHLL	0.46	9.38	0.64	3.92e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs7940866	0.646	rs10894293	chr11:130824213	C/T	cg05962950	chr11:130786565	SNX19	-0.76	-7.5	-0.56	1.09e-11	Schizophrenia;
TGCT	cis	rs9467773	1.000	rs6926629	chr6:26499903	T/C	cg09904177	chr6:26538194	HMGN4	0.64	6.49	0.5	1.89e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs35146811	0.735	rs858506	chr7:99820050	T/C	cg04778012	chr7:99775508	STAG3;GPC2	-0.36	-5.1	-0.42	1.22e-6	Coronary artery disease;
TGCT	cis	rs7568458	0.905	rs59877521	chr2:85759494	C/T	cg17127132	chr2:85788382	GGCX	0.73	6.97	0.53	1.64e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs7552404	0.731	rs10873808	chr1:76406767	T/C	cg03433033	chr1:76189801	ACADM	0.78	7.49	0.56	1.12e-11	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2980439	0.818	rs2948300	chr8:8106508	C/T	cg08975724	chr8:8085496	FLJ10661	0.6	5.47	0.44	2.36e-7	Neuroticism;
TGCT	cis	rs7647973	0.593	rs28535523	chr3:49848414	C/T	cg03060546	chr3:49711283	APEH	-0.67	-5.93	-0.47	2.82e-8	Menarche (age at onset);
TGCT	cis	rs782590	0.902	rs782601	chr2:55848244	T/C	cg18811423	chr2:55921094	PNPT1	0.65	6.91	0.53	2.23e-10	Metabolic syndrome;
TGCT	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.51	-4.82	-0.4	4.16e-6	Bipolar disorder;
TGCT	cis	rs17826219	0.636	rs8080829	chr17:29058730	C/T	cg13385521	chr17:29058706	SUZ12P	0.79	4.77	0.39	5.16e-6	Body mass index;
TGCT	cis	rs7647973	0.560	rs77473999	chr3:49777660	T/C	cg03034192	chr3:50606346	HEMK1;C3orf18	-0.36	-4.59	-0.38	1.08e-5	Menarche (age at onset);
TGCT	cis	rs6570726	0.791	rs12208812	chr6:145900924	T/G	cg13319975	chr6:146136371	FBXO30	-0.51	-4.58	-0.38	1.13e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2688608	0.592	rs7080579	chr10:75504029	T/A	cg04320760	chr10:75533139	FUT11	-0.4	-6.06	-0.48	1.49e-8	Inflammatory bowel disease;
TGCT	cis	rs17376456	0.757	rs1031424	chr5:93139706	G/C	cg21475434	chr5:93447410	FAM172A	0.62	4.67	0.39	7.58e-6	Diabetic retinopathy;
TGCT	cis	rs912057	0.671	rs1294417	chr6:6741932	T/C	cg06612196	chr6:6737390	NA	0.48	7.07	0.54	1.01e-10	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs10883723	0.810	rs61873733	chr10:104251458	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs806215	0.526	rs882694	chr7:127496768	A/G	cg11539674	chr7:127291444	SND1	-0.36	-4.65	-0.39	8.46e-6	Type 2 diabetes;
TGCT	trans	rs8073060	0.586	rs6505484	chr17:33993152	G/A	cg19694781	chr19:47549865	TMEM160	-0.6	-13.37	-0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs3087591	0.960	rs12949230	chr17:29461899	G/A	cg24425628	chr17:29625626	OMG;NF1	0.47	7.3	0.55	3.03e-11	Hip circumference;
TGCT	cis	rs13088645	0.532	rs7623580	chr3:134164345	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.67	6.38	0.5	3.21e-9	Coronary artery disease;
TGCT	cis	rs208520	0.770	rs2153941	chr6:66885521	A/T	cg07460842	chr6:66804631	NA	-0.9	-9.36	-0.64	4.37e-16	Exhaled nitric oxide output;
TGCT	cis	rs10927875	0.722	rs1763606	chr1:16338282	A/G	cg14742211	chr1:16348397	CLCNKA	0.19	4.53	0.38	1.37e-5	Dilated cardiomyopathy;
TGCT	cis	rs6582630	0.555	rs11182422	chr12:38522833	A/G	cg13010199	chr12:38710504	ALG10B	0.6	4.99	0.41	2.02e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs295140	0.605	rs34693942	chr2:201184348	T/C	cg04283868	chr2:201171347	SPATS2L	0.49	4.69	0.39	7.21e-6	QT interval;
TGCT	cis	rs10501293	0.709	rs10742664	chr11:43034588	G/A	cg03447554	chr11:43094025	NA	0.44	6.29	0.49	5.05e-9	Cognitive performance;
TGCT	cis	rs2228479	0.717	rs2286392	chr16:89809549	A/G	cg04287289	chr16:89883240	FANCA	0.74	4.44	0.37	1.99e-5	Skin colour saturation;
TGCT	cis	rs478304	0.654	rs10896029	chr11:65452952	C/T	cg27068330	chr11:65405492	SIPA1	-1.0	-11.14	-0.71	2.07e-20	Acne (severe);
TGCT	trans	rs2727020	0.595	rs10769583	chr11:49483193	G/A	cg15704280	chr7:45808275	SEPT13	-0.74	-8.52	-0.61	4.54e-14	Coronary artery disease;
TGCT	cis	rs17206232	0.534	rs13165273	chr5:64693051	T/C	cg09571848	chr5:64330935	NA	-0.31	-4.59	-0.38	1.05e-5	Schizophrenia;
TGCT	cis	rs208515	0.525	rs12214310	chr6:66666308	A/G	cg07460842	chr6:66804631	NA	0.85	8.73	0.62	1.41e-14	Exhaled nitric oxide levels;
TGCT	cis	rs17345786	0.906	rs56171035	chr3:101111108	G/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.84	8.92	0.63	5.05e-15	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2637266	1.000	rs3923670	chr10:78375001	C/G	cg18941641	chr10:78392320	NA	0.4	4.73	0.39	6.03e-6	Pulmonary function;
TGCT	cis	rs12477438	0.677	rs12475034	chr2:99699464	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.82	-7.18	-0.54	5.51e-11	Chronic sinus infection;
TGCT	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.49	-6.62	-0.51	9.56e-10	Alzheimer's disease;
TGCT	cis	rs4478858	0.735	rs4949382	chr1:31776731	A/G	cg00250761	chr1:31883323	NA	-0.27	-4.94	-0.41	2.43e-6	Alcohol dependence;
TGCT	cis	rs2204008	0.580	rs11520047	chr12:38051778	T/A	cg13010199	chr12:38710504	ALG10B	0.65	5.29	0.43	5.47e-7	Bladder cancer;
TGCT	cis	rs4788570	0.566	rs9989376	chr16:71498983	C/T	cg06353428	chr16:71660113	MARVELD3	-1.19	-7.74	-0.57	3.06e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.11	14.12	0.79	1.4e-27	Height;
TGCT	cis	rs17376456	0.877	rs10476599	chr5:93383423	A/G	cg21475434	chr5:93447410	FAM172A	0.59	4.66	0.39	8.09e-6	Diabetic retinopathy;
TGCT	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg18538332	chr22:24372958	LOC391322	0.85	9.87	0.66	2.55e-17	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9921338	0.961	rs9302459	chr16:11420339	G/T	cg00044050	chr16:11439710	C16orf75	0.9	6.67	0.51	7.6e-10	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs1031925	0.640	rs6445959	chr3:51772347	C/T	cg10583097	chr3:51429234	RBM15B	0.52	4.96	0.41	2.26e-6	Melanoma;
TGCT	cis	rs6831352	0.693	rs2602875	chr4:100039495	C/G	cg12011299	chr4:100065546	ADH4	0.39	5.2	0.42	8.04e-7	Alcohol dependence;
TGCT	cis	rs72781680	0.583	rs6731333	chr2:24113354	C/T	cg08917208	chr2:24149416	ATAD2B	0.78	4.95	0.41	2.4e-6	Lymphocyte counts;
TGCT	cis	rs6964587	1.000	rs6953515	chr7:91658620	C/T	cg17063962	chr7:91808500	NA	0.91	9.88	0.66	2.45e-17	Breast cancer;
TGCT	cis	rs523522	0.962	rs1050187	chr12:120902111	A/G	cg12219531	chr12:120966889	COQ5	-0.83	-7.33	-0.55	2.6e-11	High light scatter reticulocyte count;
TGCT	cis	rs3806843	0.547	rs183679	chr5:140271017	C/T	cg07102913	chr5:140593443	PCDHB13	0.47	4.52	0.38	1.42e-5	Depressive symptoms (multi-trait analysis);
TGCT	trans	rs66573146	1.000	rs56074877	chr4:6990374	C/T	cg07817883	chr1:32538562	TMEM39B	1.3	6.83	0.52	3.41e-10	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs62064224	0.614	rs728718	chr17:30708960	T/G	cg18200150	chr17:30822561	MYO1D	0.39	4.7	0.39	6.77e-6	Schizophrenia;
TGCT	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg07157834	chr1:205819609	PM20D1	0.45	7.34	0.55	2.47e-11	Menarche (age at onset);
TGCT	cis	rs10089	0.953	rs1012851	chr5:127360241	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	6.91	0.53	2.29e-10	Ileal carcinoids;
TGCT	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg05754148	chr16:3507555	NAT15	0.41	4.94	0.41	2.46e-6	Tuberculosis;
TGCT	cis	rs1580019	0.922	rs1376289	chr7:32486980	C/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.9	-7.86	-0.58	1.55e-12	Cognitive ability;
TGCT	cis	rs72781680	0.898	rs116113042	chr2:23960194	G/T	cg08917208	chr2:24149416	ATAD2B	0.83	5.24	0.43	6.62e-7	Lymphocyte counts;
TGCT	cis	rs28595532	1.000	rs11931194	chr4:119631160	C/T	cg21605333	chr4:119757512	SEC24D	1.36	7.4	0.55	1.82e-11	Cannabis dependence symptom count;
TGCT	cis	rs4689388	0.853	rs13108780	chr4:6294630	A/G	cg25554036	chr4:6271136	WFS1	0.54	7.37	0.55	2.11e-11	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	trans	rs10435719	0.834	rs6985792	chr8:11795335	T/C	cg15556689	chr8:8085844	FLJ10661	0.75	7.18	0.54	5.55e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg08280861	chr8:58055591	NA	0.52	5.97	0.47	2.35e-8	Developmental language disorder (linguistic errors);
TGCT	cis	rs11718455	0.585	rs11719257	chr3:43914854	A/T	cg08738300	chr3:44038990	NA	0.66	4.52	0.38	1.44e-5	Coronary artery disease;
TGCT	cis	rs4499344	0.633	rs166310	chr19:33155187	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.85	9.09	0.63	2.01e-15	Mean platelet volume;
TGCT	cis	rs6003958	1	rs6003958	chr22:24264089	T/G	cg23131131	chr22:24373011	LOC391322	0.57	4.52	0.38	1.41e-5	S-phenylmercapturic acid levels in smokers;
TGCT	cis	rs11122272	0.735	rs2486733	chr1:231531465	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-6.35	-0.5	3.66e-9	Hemoglobin concentration;
TGCT	cis	rs3935685	0.874	rs35761651	chr15:78003069	G/T	cg03457338	chr15:78040120	NA	-0.23	-5.79	-0.46	5.55e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs6964587	0.773	rs38793	chr7:92027187	A/G	cg17063962	chr7:91808500	NA	-0.83	-8.02	-0.58	6.71e-13	Breast cancer;
TGCT	cis	rs1056053	0.514	rs1056051	chr6:166571579	T/G	cg17219086	chr6:166541254	NA	-0.2	-4.58	-0.38	1.1e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg06873352	chr17:61820015	STRADA	0.58	6.42	0.5	2.65e-9	Prudent dietary pattern;
TGCT	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg03709012	chr19:19516395	GATAD2A	0.74	6.09	0.48	1.28e-8	Tonsillectomy;
TGCT	cis	rs2066819	0.892	rs75274818	chr12:56627619	A/G	cg26714650	chr12:56694279	CS	-1.42	-5.7	-0.46	8.43e-8	Psoriasis vulgaris;
TGCT	trans	rs4332037	0.713	rs56093134	chr7:1973970	C/T	cg10840412	chr1:235813424	GNG4	0.98	7.54	0.56	8.81e-12	Bipolar disorder;
TGCT	cis	rs9467711	0.606	rs9379859	chr6:26369549	C/T	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6430585	0.583	rs1435577	chr2:136624947	C/G	cg07169764	chr2:136633963	MCM6	1.24	12.25	0.74	4.19e-23	Corneal structure;
TGCT	cis	rs1729951	0.575	rs361245	chr3:136695706	A/G	cg21827317	chr3:136751795	NA	0.39	5.52	0.44	1.86e-7	Neuroticism;
TGCT	cis	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg03213289	chr20:61660250	NA	0.68	9.99	0.67	1.36e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs4886920	0.666	rs11629621	chr15:78080737	C/G	cg03457338	chr15:78040120	NA	-0.18	-4.47	-0.37	1.74e-5	Neuroticism;
TGCT	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg27286337	chr10:134555280	INPP5A	0.41	5.16	0.42	9.57e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs11785400	0.762	rs1137522	chr8:143739020	A/C	cg10596483	chr8:143751796	JRK	0.55	5.48	0.44	2.29e-7	Schizophrenia;
TGCT	cis	rs4455778	0.580	rs7804423	chr7:49118270	A/G	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs6570726	0.791	rs414297	chr6:145887556	C/T	cg23711669	chr6:146136114	FBXO30	0.85	9.18	0.64	1.18e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7914558	0.966	rs3758543	chr10:104944744	C/G	cg15744005	chr10:104629667	AS3MT	-0.39	-4.73	-0.39	5.91e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs7772486	0.846	rs2748496	chr6:146321829	T/A	cg05347473	chr6:146136440	FBXO30	0.49	4.7	0.39	6.88e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10256972	0.514	rs2140578	chr7:1214003	T/C	cg04025307	chr7:1156635	C7orf50	0.22	4.91	0.4	2.86e-6	Longevity;Endometriosis;
TGCT	cis	rs6684514	1.000	rs67034206	chr1:156270260	C/T	cg16558208	chr1:156270281	VHLL	0.46	9.38	0.64	3.92e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs7172809	0.548	rs17385352	chr15:77651305	A/G	cg22256960	chr15:77711686	NA	-0.51	-4.81	-0.4	4.29e-6	Glucose homeostasis traits;
TGCT	cis	rs2228479	0.702	rs78331410	chr16:89917775	C/T	cg06558623	chr16:89946397	TCF25	0.55	4.86	0.4	3.55e-6	Skin colour saturation;
TGCT	cis	rs7474896	0.522	rs117157955	chr10:37984164	G/T	cg25427524	chr10:38739819	LOC399744	-0.31	-4.83	-0.4	3.98e-6	Obesity (extreme);
TGCT	cis	rs7731657	0.537	rs4705924	chr5:130210792	G/A	cg08523029	chr5:130500466	HINT1	-0.59	-4.9	-0.4	2.96e-6	Fasting plasma glucose;
TGCT	cis	rs3820068	0.580	rs12082523	chr1:16005792	A/G	cg17385448	chr1:15911702	AGMAT	-0.35	-4.96	-0.41	2.27e-6	Systolic blood pressure;
TGCT	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.67	0.39	7.57e-6	Prudent dietary pattern;
TGCT	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg17054783	chr10:134559939	INPP5A	0.26	5.0	0.41	1.89e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs4076764	0.958	rs10917748	chr1:163400377	T/C	cg24596788	chr1:163392923	NA	-0.17	-4.74	-0.39	5.85e-6	Motion sickness;
TGCT	cis	rs1005224	0.853	rs9323616	chr14:76151697	T/C	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.67	-5.96	-0.47	2.45e-8	Large artery stroke;
TGCT	cis	rs6582630	0.519	rs80226845	chr12:38528231	C/A	cg26384229	chr12:38710491	ALG10B	0.86	7.78	0.57	2.47e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs10489202	0.657	rs3767478	chr1:168069626	G/A	cg24449463	chr1:168025552	DCAF6	-0.52	-5.45	-0.44	2.58e-7	Schizophrenia;
TGCT	cis	rs826838	0.967	rs1684413	chr12:39128704	G/A	cg13010199	chr12:38710504	ALG10B	-0.63	-5.06	-0.41	1.46e-6	Heart rate;
TGCT	cis	rs7772486	0.754	rs697054	chr6:146003770	C/T	cg13319975	chr6:146136371	FBXO30	-0.54	-4.99	-0.41	1.96e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7149242	0.849	rs10146962	chr14:101170540	A/G	cg18089426	chr14:101175970	NA	0.4	4.84	0.4	3.79e-6	Platelet count;
TGCT	cis	rs2762353	0.574	rs4419666	chr6:25693274	C/T	cg07061783	chr6:25882402	NA	0.73	7.21	0.54	4.76e-11	Blood metabolite levels;
TGCT	cis	rs17767294	0.708	rs6908688	chr6:27886051	A/G	cg08851530	chr6:28072375	NA	1.33	6.57	0.51	1.25e-9	Parkinson's disease;
TGCT	cis	rs854765	0.547	rs4459604	chr17:17888549	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.79	8.22	0.59	2.35e-13	Total body bone mineral density;
TGCT	cis	rs3087591	0.614	rs3785955	chr17:29647802	C/T	cg24425628	chr17:29625626	OMG;NF1	0.4	5.63	0.45	1.14e-7	Hip circumference;
TGCT	cis	rs7572733	0.534	rs770662	chr2:198729283	T/C	cg00792783	chr2:198669748	PLCL1	0.56	5.08	0.42	1.35e-6	Dermatomyositis;
TGCT	cis	rs6815814	0.861	rs17616434	chr4:38812876	T/C	cg06935464	chr4:38784597	TLR10	0.29	4.55	0.38	1.26e-5	Breast cancer;
TGCT	cis	rs3806843	0.612	rs246075	chr5:140300557	T/C	cg07102913	chr5:140593443	PCDHB13	-0.46	-4.54	-0.38	1.3e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.75	5.41	0.44	3.09e-7	Platelet count;
TGCT	trans	rs28735056	1.000	rs56197868	chr18:77636077	C/T	cg05926928	chr17:57297772	GDPD1	-0.71	-7.64	-0.57	5e-12	Schizophrenia;
TGCT	cis	rs319204	1.000	rs2446369	chr5:146233790	A/T	cg25021259	chr5:146258546	PPP2R2B	0.36	4.53	0.38	1.37e-5	Schizophrenia;
TGCT	cis	rs36051895	0.626	rs3780368	chr9:5093188	G/C	cg02405213	chr9:5042618	JAK2	-0.72	-9.52	-0.65	1.85e-16	Pediatric autoimmune diseases;
TGCT	cis	rs4746818	1.000	rs7476357	chr10:70935660	G/A	cg04149295	chr10:70884716	VPS26A	0.78	5.32	0.43	4.7e-7	Left atrial antero-posterior diameter;
TGCT	cis	rs6831256	1.000	rs6831256	chr4:3473139	A/G	cg13455623	chr4:3480656	DOK7	0.25	4.51	0.38	1.5e-5	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
TGCT	cis	rs2274273	0.682	rs1201378	chr14:55493408	A/G	cg01923255	chr14:55878535	KIAA0831	-0.56	-4.88	-0.4	3.26e-6	Protein biomarker;
TGCT	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg16325326	chr1:53192061	ZYG11B	-0.71	-8.82	-0.62	8.9e-15	Monocyte count;
TGCT	cis	rs611744	0.967	rs677288	chr8:109177539	T/C	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs12615966	0.872	rs72830429	chr2:105367977	T/C	cg16465502	chr2:105461796	NA	0.75	4.65	0.39	8.22e-6	Pancreatic cancer;
TGCT	cis	rs694739	0.654	rs10897488	chr11:64140806	T/C	cg02228329	chr11:64053129	BAD;GPR137	0.7	6.8	0.52	4.02e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs796364	1.000	rs281762	chr2:200799201	C/G	cg17644776	chr2:200775616	C2orf69	0.31	4.85	0.4	3.58e-6	Schizophrenia;
TGCT	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.81	0.46	4.88e-8	Alzheimer's disease;
TGCT	cis	rs7267979	1.000	rs6107046	chr20:25442049	G/A	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11098499	0.909	rs10014719	chr4:120320715	G/A	cg09307838	chr4:120376055	NA	0.67	6.37	0.5	3.35e-9	Corneal astigmatism;
TGCT	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg10819733	chr22:24237672	NA	-0.29	-4.7	-0.39	6.71e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	trans	rs3780486	0.846	rs10971438	chr9:33180308	A/G	cg20290983	chr6:43655470	MRPS18A	1.08	11.4	0.72	5.03e-21	IgG glycosylation;
TGCT	cis	rs4478037	0.558	rs60462824	chr3:33085929	T/C	cg19404215	chr3:33155277	CRTAP	1.09	5.15	0.42	9.92e-7	Major depressive disorder;
TGCT	cis	rs7095607	1.000	rs7900891	chr10:69953042	G/A	cg18986048	chr10:69913749	MYPN	0.46	5.08	0.41	1.37e-6	Lung function (FVC);
TGCT	cis	rs2070488	0.804	rs2276541	chr3:38512779	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.78	7.9	0.58	1.26e-12	Electrocardiographic conduction measures;
TGCT	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg00343986	chr7:65444356	GUSB	0.22	5.32	0.43	4.62e-7	Calcium levels;
TGCT	cis	rs77372450	0.551	rs62387681	chr5:157107531	G/C	cg12606933	chr5:157078573	SOX30	-0.42	-4.75	-0.39	5.51e-6	Bipolar disorder (body mass index interaction);
TGCT	cis	rs2180341	1.000	rs9385419	chr6:127597591	A/G	cg24812749	chr6:127587940	RNF146	0.99	7.72	0.57	3.33e-12	Breast cancer;
TGCT	cis	rs11874712	0.563	rs2850646	chr18:43674646	C/A	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.49	4.9	0.4	2.91e-6	Migraine - clinic-based;
TGCT	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg11890956	chr21:40555474	PSMG1	1.11	12.48	0.75	1.21e-23	Cognitive function;
TGCT	cis	rs939574	0.790	rs2385397	chr2:220087796	G/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-1.14	-6.06	-0.48	1.49e-8	Platelet distribution width;
TGCT	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg27588902	chr6:42928151	GNMT	-0.56	-6.9	-0.53	2.41e-10	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.69	-6.96	-0.53	1.72e-10	Prostate cancer;
TGCT	cis	rs4689592	0.546	rs907523	chr4:7052777	A/G	cg02503808	chr4:7069936	GRPEL1	1.01	9.19	0.64	1.16e-15	Monocyte percentage of white cells;
TGCT	cis	rs7255045	0.788	rs2290689	chr19:12958360	T/C	cg23899408	chr19:12877188	HOOK2	-0.6	-5.03	-0.41	1.67e-6	Mean corpuscular volume;
TGCT	cis	rs1005277	0.638	rs1005278	chr10:38218748	G/A	cg25427524	chr10:38739819	LOC399744	0.31	4.79	0.4	4.68e-6	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7507204	0.767	rs12982509	chr19:3412057	C/T	cg08380311	chr19:3435252	NFIC	-0.94	-8.13	-0.59	3.71e-13	Height;
TGCT	trans	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg27523141	chr10:43048294	ZNF37B	0.72	8.36	0.6	1.09e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	trans	rs77457752	0.690	rs10123356	chr9:13912564	T/C	cg12973904	chr7:149457885	NA	0.46	7.39	0.55	1.88e-11	Breast cancer;
TGCT	trans	rs8073060	0.586	rs225286	chr17:33930458	G/A	cg19694781	chr19:47549865	TMEM160	-0.6	-13.04	-0.76	5.29e-25	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg21226059	chr5:178986404	RUFY1	0.47	5.2	0.42	7.83e-7	Lung cancer;
TGCT	cis	rs910316	0.737	rs175071	chr14:75498177	A/G	cg08847533	chr14:75593920	NEK9	-0.82	-8.58	-0.61	3.25e-14	Height;
TGCT	cis	rs5760092	0.755	rs3884794	chr22:24251766	C/A	cg18538332	chr22:24372958	LOC391322	-0.76	-6.61	-0.51	1.03e-9	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs7726839	0.561	rs6555357	chr5:560923	A/G	cg09021430	chr5:549028	NA	-0.41	-5.79	-0.46	5.55e-8	Obesity-related traits;
TGCT	cis	rs9660180	0.967	rs61422524	chr1:1767565	C/A	cg23982607	chr1:1823379	GNB1	-0.56	-8.38	-0.6	9.54e-14	Body mass index;
TGCT	cis	rs4325129	0.705	rs7514139	chr1:159498909	C/T	cg07417683	chr1:159440267	NA	0.37	4.64	0.38	8.54e-6	Obesity-related traits;
TGCT	cis	rs3862030	0.810	rs11593710	chr10:104328719	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-5.36	-0.43	3.84e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
TGCT	cis	rs17401966	0.838	rs1538557	chr1:10297230	T/C	cg19773385	chr1:10388646	KIF1B	-0.21	-4.57	-0.38	1.14e-5	Hepatocellular carcinoma;
TGCT	cis	rs11514810	1.000	rs4076699	chr7:1435521	C/T	cg24899294	chr7:1481343	MICALL2	-0.45	-5.49	-0.44	2.18e-7	Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder;
TGCT	cis	rs2239815	0.515	rs9625595	chr22:29238913	C/T	cg02153584	chr22:29168773	CCDC117	0.67	4.57	0.38	1.17e-5	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
TGCT	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.86	12.13	0.74	8.29e-23	Subjective well-being;
TGCT	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg24675658	chr1:53192096	ZYG11B	0.85	10.64	0.69	3.5e-19	Monocyte count;
TGCT	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg27454412	chr7:1067447	C7orf50	0.58	4.54	0.38	1.3e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg24549020	chr5:56110836	MAP3K1	0.7	5.97	0.47	2.34e-8	Initial pursuit acceleration;
TGCT	cis	rs1801251	1.000	rs283476	chr2:233650168	A/G	cg25237894	chr2:233734115	C2orf82	0.26	4.45	0.37	1.89e-5	Coronary artery disease;
TGCT	cis	rs6920965	0.507	rs9385389	chr6:126215486	G/C	cg05901451	chr6:126070800	HEY2	-0.67	-6.45	-0.5	2.26e-9	High light scatter reticulocyte count;
TGCT	cis	rs6964587	0.967	rs28594877	chr7:91644070	C/T	cg17063962	chr7:91808500	NA	0.91	9.97	0.67	1.53e-17	Breast cancer;
TGCT	cis	rs6921919	0.525	rs9468361	chr6:28346318	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.56	-5.33	-0.43	4.48e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs10501293	0.746	rs1544871	chr11:43054122	T/C	cg03447554	chr11:43094025	NA	0.45	6.58	0.51	1.2e-9	Cognitive performance;
TGCT	cis	rs3892630	0.824	rs2287884	chr19:33321447	A/G	cg22980127	chr19:33182716	NUDT19	0.72	5.22	0.42	7.45e-7	Red blood cell traits;
TGCT	cis	rs711245	0.670	rs7560321	chr2:36822318	C/G	cg01206211	chr2:36825736	FEZ2	-0.31	-5.18	-0.42	8.55e-7	Height;
TGCT	cis	rs1682361	1	rs1682361	chr3:136734014	G/C	cg21827317	chr3:136751795	NA	0.58	9.52	0.65	1.81e-16	Schizophrenia;
TGCT	cis	rs11098499	0.691	rs10028773	chr4:120265259	C/G	cg09307838	chr4:120376055	NA	-0.56	-5.52	-0.44	1.9e-7	Corneal astigmatism;
TGCT	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg13732083	chr21:47605072	C21orf56	0.34	4.51	0.38	1.51e-5	Testicular germ cell tumor;
TGCT	cis	rs7172809	0.561	rs28712147	chr15:77844661	C/G	cg22256960	chr15:77711686	NA	-0.47	-4.66	-0.39	7.96e-6	Glucose homeostasis traits;
TGCT	cis	rs8033133	0.560	rs11161166	chr15:25324677	A/T	cg14481604	chr15:25334117	SNORD116-22	0.21	4.61	0.38	9.73e-6	Blood osmolality (transformed sodium);
TGCT	cis	rs6977660	0.714	rs2390156	chr7:19786138	A/T	cg05791153	chr7:19748676	TWISTNB	0.84	4.71	0.39	6.52e-6	Thyroid stimulating hormone;
TGCT	cis	rs7826238	0.543	rs2976908	chr8:8345774	T/G	cg08975724	chr8:8085496	FLJ10661	0.53	4.76	0.39	5.32e-6	Systolic blood pressure;
TGCT	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg20607798	chr8:58055168	NA	0.45	4.59	0.38	1.06e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg13683864	chr3:40499215	RPL14	1.17	13.23	0.76	1.88e-25	Renal cell carcinoma;
TGCT	trans	rs7819412	0.505	rs34031674	chr8:10809490	G/C	cg15556689	chr8:8085844	FLJ10661	-0.84	-7.59	-0.56	6.55e-12	Triglycerides;
TGCT	cis	rs9611519	0.929	rs4820425	chr22:41431342	C/A	cg03806693	chr22:41940476	POLR3H	-0.67	-5.79	-0.46	5.32e-8	Neuroticism;
TGCT	cis	rs67385638	0.962	rs2071348	chr11:5264146	T/G	cg12559170	chr11:5275217	HBG2	0.49	8.71	0.62	1.6e-14	Hemoglobin levels;
TGCT	cis	rs858239	0.601	rs10255228	chr7:23158863	G/T	cg05602783	chr7:23145260	KLHL7	-0.65	-5.47	-0.44	2.4e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	trans	rs3780486	1.000	rs3780480	chr9:33163486	G/T	cg04842962	chr6:43655489	MRPS18A	1.12	10.81	0.7	1.32e-19	IgG glycosylation;
TGCT	cis	rs10779751	1.000	rs2300092	chr1:11266464	T/C	cg08854313	chr1:11322531	MTOR	0.92	10.31	0.68	2.23e-18	Body mass index;
TGCT	cis	rs7727544	0.709	rs441969	chr5:131702120	G/A	cg24060327	chr5:131705240	SLC22A5	-0.57	-6.38	-0.5	3.12e-9	Blood metabolite levels;
TGCT	cis	rs79349575	0.783	rs4399576	chr17:47009835	G/A	cg26022315	chr17:47021804	SNF8	0.49	4.9	0.4	2.94e-6	Type 2 diabetes;
TGCT	cis	rs11190604	1.000	rs12219789	chr10:102213778	A/G	cg16342193	chr10:102329863	NA	-0.4	-5.31	-0.43	4.85e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	trans	rs2727020	0.567	rs1164687	chr11:49290669	G/A	cg03929089	chr4:120376271	NA	0.71	7.73	0.57	3.16e-12	Coronary artery disease;
TGCT	cis	rs80282103	0.618	rs11818314	chr10:1148157	G/C	cg08668510	chr10:1095578	IDI1	1.05	5.31	0.43	4.8e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs7567389	0.677	rs11680949	chr2:128123562	C/G	cg09760422	chr2:128146352	NA	0.34	4.45	0.37	1.87e-5	Self-rated health;
TGCT	cis	rs11792861	0.591	rs11791855	chr9:111684139	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.69	8.23	0.59	2.2e-13	Menarche (age at onset);
TGCT	cis	rs7568458	0.811	rs1446668	chr2:85764960	G/T	cg17127132	chr2:85788382	GGCX	0.64	5.96	0.47	2.47e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs7647973	0.710	rs1491983	chr3:49639803	G/T	cg03060546	chr3:49711283	APEH	0.63	5.14	0.42	1.03e-6	Menarche (age at onset);
TGCT	cis	rs453301	0.686	rs3895823	chr8:8873646	T/C	cg11995313	chr8:8860691	ERI1	0.51	4.46	0.37	1.84e-5	Joint mobility (Beighton score);
TGCT	cis	rs7916852	0.618	rs3802520	chr10:28341783	C/T	cg15286905	chr10:27530250	ACBD5	-0.6	-5.01	-0.41	1.85e-6	Glaucoma (primary open-angle);
TGCT	cis	rs4836694	0.574	rs67899211	chr9:132935614	G/A	cg05251000	chr9:132935664	FREQ	0.55	6.1	0.48	1.25e-8	Alzheimer's disease (cognitive decline);
TGCT	cis	rs6840360	0.593	rs10222925	chr4:152690215	A/G	cg17479576	chr4:152424074	FAM160A1	-0.52	-5.2	-0.42	8.05e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg23172400	chr8:95962367	TP53INP1	-0.39	-6.52	-0.51	1.59e-9	Type 2 diabetes;
TGCT	cis	rs11785400	0.793	rs11543967	chr8:143739435	A/G	cg10596483	chr8:143751796	JRK	-0.55	-5.48	-0.44	2.29e-7	Schizophrenia;
TGCT	trans	rs9951602	0.512	rs9952372	chr18:76656295	A/G	cg02800362	chr5:177631904	HNRNPAB	1.13	12.71	0.75	3.32e-24	Obesity-related traits;
TGCT	cis	rs9611565	0.921	rs4822021	chr22:41726053	G/A	cg06481639	chr22:41940642	POLR3H	-0.54	-4.72	-0.39	6.29e-6	Vitiligo;
TGCT	cis	rs7552404	0.556	rs12124417	chr1:76353294	T/C	cg03433033	chr1:76189801	ACADM	0.66	6.55	0.51	1.35e-9	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs854765	0.647	rs9303144	chr17:17977355	T/C	cg09796270	chr17:17721594	SREBF1	0.25	4.91	0.4	2.77e-6	Total body bone mineral density;
TGCT	cis	rs112217694	1.000	rs17034020	chr4:104650673	G/A	cg24090629	chr4:104641072	TACR3	-1.0	-5.19	-0.42	8.44e-7	Menarche (age at onset);
TGCT	cis	rs7044106	0.791	rs10984994	chr9:123478769	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.63	-6.73	-0.52	5.54e-10	Hip circumference adjusted for BMI;
TGCT	cis	rs2637266	0.846	rs2579773	chr10:78402847	A/C	cg18941641	chr10:78392320	NA	0.43	5.58	0.45	1.46e-7	Pulmonary function;
TGCT	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	5.92	0.47	2.92e-8	Alzheimer's disease;
TGCT	cis	rs56235845	0.694	rs4532376	chr5:176774403	G/A	cg06060754	chr5:176797920	RGS14	0.42	6.57	0.51	1.23e-9	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs7666738	0.830	rs1534319	chr4:98964804	T/C	cg05340658	chr4:99064831	C4orf37	0.53	5.93	0.47	2.85e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs765787	0.530	rs7167389	chr15:45535683	A/G	cg24006582	chr15:45444508	DUOX1	-0.27	-5.85	-0.46	4.18e-8	Uric acid levels;
TGCT	cis	rs12134245	0.874	rs34842487	chr1:92021611	C/T	cg25838465	chr1:92012736	NA	-0.34	-5.64	-0.45	1.08e-7	Breast cancer;
TGCT	cis	rs28595532	0.920	rs116739193	chr4:119771024	G/A	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs931608	0.569	rs17461312	chr19:22554107	G/T	cg23859931	chr19:22123797	NA	-0.61	-4.83	-0.4	3.91e-6	Dental caries;Response to statins (LDL cholesterol change);
TGCT	cis	rs8180040	0.764	rs12629262	chr3:47196580	C/T	cg27129171	chr3:47204927	SETD2	0.75	9.86	0.66	2.82e-17	Colorectal cancer;
TGCT	cis	rs3812831	0.695	rs7995986	chr13:114938802	A/G	cg08824895	chr13:115047677	UPF3A	0.51	5.03	0.41	1.67e-6	Schizophrenia;
TGCT	cis	rs2997447	0.761	rs55815920	chr1:26457662	A/C	cg03844060	chr1:26490628	NA	0.27	4.44	0.37	2e-5	QRS complex (12-leadsum);
TGCT	cis	rs7666738	0.830	rs62318470	chr4:98925846	A/C	cg18180107	chr4:99064573	C4orf37	0.54	4.85	0.4	3.59e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs61867294	0.553	rs7907507	chr10:106711069	A/G	cg08000847	chr10:105880925	C10orf78	0.48	4.46	0.37	1.81e-5	Schizophrenia;
TGCT	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg16423285	chr20:60520624	NA	-0.55	-5.8	-0.46	5.24e-8	Body mass index;
TGCT	cis	rs12210905	0.920	rs9368500	chr6:27290981	A/C	cg08851530	chr6:28072375	NA	1.29	5.45	0.44	2.65e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs7714584	1.000	rs12656538	chr5:150251380	A/G	cg22134413	chr5:150180641	NA	1.17	8.71	0.62	1.61e-14	Crohn's disease;
TGCT	cis	rs6500602	0.701	rs6500614	chr16:4573938	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.44	6.5	0.5	1.8e-9	Schizophrenia;
TGCT	cis	rs3796352	0.892	rs35076015	chr3:53026366	C/T	cg27565382	chr3:53032988	SFMBT1	0.45	4.58	0.38	1.14e-5	Immune reponse to smallpox (secreted IL-2);
TGCT	trans	rs3857536	0.566	rs208463	chr6:66913962	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.74	-7.75	-0.57	2.85e-12	Blood trace element (Cu levels);
TGCT	cis	rs3091242	0.866	rs11249249	chr1:25758134	A/G	cg10117171	chr1:25599238	RHD	-0.35	-5.81	-0.46	5.05e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs7953249	0.656	rs2251468	chr12:121405126	A/C	cg02403541	chr12:121454288	C12orf43	0.61	5.47	0.44	2.42e-7	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg10802521	chr3:52805072	NEK4	0.63	7.18	0.54	5.56e-11	Bipolar disorder;
TGCT	cis	rs6728642	0.908	rs6576996	chr2:97623312	T/C	cg26665480	chr2:98280029	ACTR1B	-0.91	-5.86	-0.47	3.88e-8	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	cis	rs1153858	0.943	rs28605551	chr15:45641720	C/T	cg26924012	chr15:45694286	SPATA5L1	1.07	14.56	0.79	1.32e-28	Homoarginine levels;
TGCT	cis	rs478304	0.654	rs11227260	chr11:65461158	G/T	cg27068330	chr11:65405492	SIPA1	-1.0	-11.46	-0.72	3.57e-21	Acne (severe);
TGCT	cis	rs938554	0.513	rs1014290	chr4:10001861	G/A	cg11266682	chr4:10021025	SLC2A9	0.53	5.31	0.43	4.95e-7	Blood metabolite levels;
TGCT	cis	rs2070433	1.000	rs2839302	chr21:47952364	G/A	cg12379764	chr21:47803548	PCNT	0.51	4.47	0.37	1.71e-5	Lymphocyte counts;
TGCT	cis	rs4642101	0.793	rs12714880	chr3:12832101	G/A	cg05775895	chr3:12838266	CAND2	0.78	8.9	0.62	5.77e-15	QRS complex (12-leadsum);
TGCT	cis	rs10779751	0.762	rs6540965	chr1:11325521	C/G	cg08854313	chr1:11322531	MTOR	-0.79	-8.18	-0.59	2.91e-13	Body mass index;
TGCT	cis	rs4808199	0.895	rs7252888	chr19:19628037	C/T	cg03709012	chr19:19516395	GATAD2A	0.91	6.33	0.49	4.1e-9	Nonalcoholic fatty liver disease;
TGCT	cis	rs904251	0.766	rs1757175	chr6:37486694	T/C	cg08126542	chr6:37504118	NA	-0.45	-6.02	-0.48	1.79e-8	Cognitive performance;
TGCT	cis	rs9677476	0.516	rs6749	chr2:232035429	G/A	cg07929768	chr2:232055508	NA	0.33	5.24	0.43	6.78e-7	Food antigen IgG levels;
TGCT	cis	rs12477438	0.834	rs11903311	chr2:99701807	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-6.12	-0.48	1.13e-8	Chronic sinus infection;
TGCT	cis	rs7914558	0.966	rs1890185	chr10:104748718	A/G	cg05855489	chr10:104503620	C10orf26	0.51	4.53	0.38	1.39e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs2204008	0.652	rs11513964	chr12:37998214	C/G	cg26384229	chr12:38710491	ALG10B	0.87	7.79	0.57	2.32e-12	Bladder cancer;
TGCT	cis	rs17490626	0.533	rs5030925	chr10:71211150	A/C	cg12610070	chr10:71211762	TSPAN15	-0.6	-6.98	-0.53	1.62e-10	Thrombosis;
TGCT	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.96	-10.31	-0.68	2.22e-18	Intelligence (multi-trait analysis);
TGCT	cis	rs10193935	0.792	rs222472	chr2:42662911	C/T	cg27598129	chr2:42591480	NA	-0.38	-5.41	-0.44	3.09e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6754311	0.593	rs55825471	chr2:136526981	T/A	cg07169764	chr2:136633963	MCM6	-0.68	-6.18	-0.49	8.32e-9	Mosquito bite size;
TGCT	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg25767906	chr1:53392781	SCP2	-0.52	-6.19	-0.49	8.06e-9	Monocyte count;
TGCT	cis	rs4906332	0.966	rs12185021	chr14:103927805	A/G	cg26031613	chr14:104095156	KLC1	-0.53	-4.71	-0.39	6.62e-6	Coronary artery disease;
TGCT	cis	rs35417517	1	rs35417517	chr7:91772730	CG/C	cg22709100	chr7:91322751	NA	0.29	4.62	0.38	9.33e-6	Breast cancer;
TGCT	trans	rs7819412	0.635	rs4841501	chr8:11000976	T/C	cg15556689	chr8:8085844	FLJ10661	-0.74	-6.79	-0.52	4.2e-10	Triglycerides;
TGCT	cis	rs1887596	0.705	rs11619978	chr13:27167841	A/G	cg01312412	chr13:27282625	NA	0.32	5.75	0.46	6.65e-8	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs2204008	0.806	rs11520229	chr12:38246448	C/A	cg13010199	chr12:38710504	ALG10B	0.64	5.01	0.41	1.85e-6	Bladder cancer;
TGCT	cis	rs7119038	0.818	rs11217042	chr11:118682528	G/A	cg19308663	chr11:118741387	NA	0.28	5.69	0.45	8.68e-8	Sjögren's syndrome;
TGCT	cis	rs17376456	0.690	rs6892055	chr5:93113023	A/T	cg25358565	chr5:93447407	FAM172A	0.91	8.23	0.59	2.21e-13	Diabetic retinopathy;
TGCT	cis	rs2013441	1.000	rs2526462	chr17:20079460	A/T	cg23224458	chr17:20280056	CCDC144C	-0.37	-4.45	-0.37	1.93e-5	Obesity-related traits;
TGCT	cis	rs9443645	0.901	rs1354832	chr6:79613763	A/G	cg09184832	chr6:79620586	NA	0.47	5.15	0.42	9.96e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs72781680	0.898	rs12622290	chr2:23979894	C/G	cg08917208	chr2:24149416	ATAD2B	0.83	5.24	0.43	6.62e-7	Lymphocyte counts;
TGCT	cis	rs10788264	0.621	rs7907952	chr10:124056774	C/T	cg24635736	chr10:124739050	PSTK	-0.25	-4.55	-0.38	1.27e-5	Total body bone mineral density;
TGCT	cis	rs9303401	0.659	rs12946852	chr17:57013337	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.68	6.48	0.5	1.94e-9	Cognitive test performance;
TGCT	cis	rs72781680	0.848	rs72798057	chr2:23976731	T/C	cg08917208	chr2:24149416	ATAD2B	0.83	5.24	0.43	6.62e-7	Lymphocyte counts;
TGCT	cis	rs6893300	0.542	rs3797774	chr5:179193970	C/T	cg14593053	chr5:179126677	CANX	0.51	5.9	0.47	3.23e-8	Resting heart rate;
TGCT	cis	rs208520	1.000	rs208536	chr6:66963440	T/C	cg07460842	chr6:66804631	NA	-0.83	-7.52	-0.56	9.8e-12	Exhaled nitric oxide output;
TGCT	cis	rs3617	0.625	rs7612624	chr3:52893426	T/C	cg10802521	chr3:52805072	NEK4	0.62	7.17	0.54	6.08e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs10927875	0.619	rs7546589	chr1:16129530	A/G	cg21385522	chr1:16154831	NA	-0.73	-8.75	-0.62	1.27e-14	Dilated cardiomyopathy;
TGCT	cis	rs10751667	0.961	rs7479171	chr11:926809	G/A	cg06064525	chr11:970664	AP2A2	-0.31	-6.03	-0.48	1.79e-8	Alzheimer's disease (late onset);
TGCT	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg08219700	chr8:58056026	NA	0.4	4.92	0.4	2.67e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10089	1.000	rs4835943	chr5:127457569	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	7.41	0.55	1.72e-11	Ileal carcinoids;
TGCT	cis	rs228437	0.609	rs7749956	chr6:134961973	C/T	cg09872934	chr6:134495829	SGK1	-0.55	-4.45	-0.37	1.86e-5	Melanoma;
TGCT	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg11890956	chr21:40555474	PSMG1	1.12	12.23	0.74	4.65e-23	Cognitive function;
TGCT	cis	rs751728	0.717	rs2281816	chr6:33772335	A/G	cg13859433	chr6:33739653	LEMD2	-0.38	-6.54	-0.51	1.48e-9	Crohn's disease;
TGCT	cis	rs13102973	0.965	rs7693757	chr4:135856609	C/T	cg14419869	chr4:135874104	NA	0.23	4.57	0.38	1.15e-5	Subjective well-being;
TGCT	cis	rs3782455	0.793	rs77365057	chr12:114404294	G/A	cg10631684	chr12:113795897	PLBD2	-0.7	-4.61	-0.38	1e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs9911578	0.967	rs2643124	chr17:56741672	T/C	cg05425664	chr17:57184151	TRIM37	-0.63	-6.26	-0.49	5.86e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs259282	0.669	rs731673	chr19:33132295	A/C	cg26639809	chr19:33781782	NA	0.24	4.91	0.4	2.75e-6	Schizophrenia;
TGCT	cis	rs514406	0.505	rs6703127	chr1:53180565	C/T	cg22166914	chr1:53195759	ZYG11B	0.45	8.05	0.59	5.76e-13	Monocyte count;
TGCT	cis	rs66573146	1.000	rs6838042	chr4:6973049	G/T	cg05069807	chr4:6945702	TBC1D14	0.32	4.59	0.38	1.08e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs9905704	0.647	rs11652713	chr17:57079742	C/T	cg12560992	chr17:57184187	TRIM37	0.59	5.64	0.45	1.09e-7	Testicular germ cell tumor;
TGCT	cis	rs2299587	0.554	rs3853531	chr8:17748920	C/T	cg01800426	chr8:17659068	MTUS1	0.57	5.08	0.42	1.33e-6	Economic and political preferences;
TGCT	cis	rs8016982	0.674	rs11850714	chr14:81662993	C/G	cg01989461	chr14:81687754	GTF2A1	0.78	7.94	0.58	1.06e-12	Schizophrenia;
TGCT	cis	rs4788570	0.615	rs2052584	chr16:71688977	A/G	cg06353428	chr16:71660113	MARVELD3	-1.46	-12.33	-0.74	2.69e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs79349575	0.783	rs962272	chr17:46978283	A/G	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.44	-0.37	1.95e-5	Type 2 diabetes;
TGCT	cis	rs9296661	0.832	rs2209638	chr6:51668265	C/T	cg00593404	chr6:52377740	TRAM2	-0.27	-4.49	-0.37	1.62e-5	Weight loss (gastric bypass surgery);
TGCT	cis	rs1801251	1.000	rs4973055	chr2:233720283	G/T	cg25237894	chr2:233734115	C2orf82	-0.31	-5.45	-0.44	2.6e-7	Coronary artery disease;
TGCT	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg01585852	chr22:24235823	MIF	-0.21	-4.56	-0.38	1.23e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg13695892	chr22:41940480	POLR3H	-0.91	-9.07	-0.63	2.18e-15	Vitiligo;
TGCT	cis	rs2663905	1.000	rs2663905	chr15:81359137	G/A	cg18028999	chr15:81426610	C15orf26	-0.52	-4.97	-0.41	2.18e-6	QT interval (drug interaction);
TGCT	cis	rs11792861	0.926	rs72607163	chr9:111803128	G/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.48	4.49	0.37	1.6e-5	Menarche (age at onset);
TGCT	cis	rs2456568	0.867	rs2462750	chr11:93668590	C/T	cg16099599	chr11:93583650	C11orf90	-0.39	-4.63	-0.38	9.04e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs1992660	0.523	rs6897022	chr5:40336546	A/G	cg01087697	chr5:40835557	RPL37	-0.56	-4.94	-0.41	2.44e-6	Crohn's disease;
TGCT	cis	rs2404602	0.647	rs35940181	chr15:77180019	G/A	cg23625390	chr15:77176239	SCAPER	-0.39	-5.15	-0.42	9.85e-7	Blood metabolite levels;
TGCT	cis	rs1461503	0.966	rs10790545	chr11:122838350	G/C	cg27398637	chr11:122830231	C11orf63	-0.43	-5.31	-0.43	5e-7	Menarche (age at onset);
TGCT	cis	rs4689388	0.926	rs4688986	chr4:6285797	C/A	cg25554036	chr4:6271136	WFS1	0.56	8.15	0.59	3.3e-13	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs1008375	0.966	rs7675735	chr4:17587137	T/A	cg18681998	chr4:17616180	MED28	0.94	9.56	0.65	1.44e-16	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs394563	0.591	rs6570964	chr6:149691859	G/A	cg11245181	chr6:149772854	ZC3H12D	0.28	4.48	0.37	1.7e-5	Dupuytren's disease;
TGCT	trans	rs17685	0.753	rs10233282	chr7:75790081	C/T	cg19862616	chr7:65841803	NCRNA00174	0.51	8.88	0.62	6.28e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs17221829	0.899	rs10830367	chr11:89459400	T/C	cg02982614	chr11:89391479	FOLH1B	-0.27	-4.71	-0.39	6.47e-6	Anxiety in major depressive disorder;
TGCT	cis	rs5760092	0.755	rs6003959	chr22:24264395	C/T	cg00024416	chr22:24240387	NA	0.37	6.42	0.5	2.58e-9	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs9486715	0.867	rs6568428	chr6:96903604	A/G	cg18709589	chr6:96969512	KIAA0776	0.79	7.78	0.57	2.47e-12	Headache;
TGCT	cis	rs910316	0.763	rs175435	chr14:75612025	A/G	cg08847533	chr14:75593920	NEK9	0.86	8.79	0.62	1.04e-14	Height;
TGCT	cis	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg08564027	chr20:61660810	NA	0.38	7.08	0.54	9.36e-11	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7666738	0.830	rs35915560	chr4:98978649	C/T	cg17366294	chr4:99064904	C4orf37	0.7	7.25	0.55	3.88e-11	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs7507204	0.530	rs4807470	chr19:3443470	A/T	cg08382705	chr11:45687319	CHST1	-0.76	-7.35	-0.55	2.39e-11	Height;
TGCT	cis	rs8031584	0.723	rs711224	chr15:31127921	G/C	cg08704250	chr15:31115839	NA	0.44	6.44	0.5	2.33e-9	Huntington's disease progression;
TGCT	cis	rs7267979	1.000	rs1888999	chr20:25291848	C/T	cg16686733	chr20:25566563	NINL	0.58	5.95	0.47	2.6e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs12620999	0.941	rs2875690	chr2:237977737	G/A	cg23555395	chr2:238036564	NA	0.26	4.76	0.39	5.32e-6	Systemic lupus erythematosus;
TGCT	cis	rs9517313	0.565	rs9556978	chr13:99234648	G/A	cg07423050	chr13:99094983	FARP1	-0.23	-4.49	-0.37	1.58e-5	Neuroticism;
TGCT	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg01238044	chr22:24384105	GSTT1	-0.49	-4.57	-0.38	1.15e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7809950	0.678	rs4730235	chr7:107022506	T/C	cg23024343	chr7:107201750	COG5	-0.46	-6.18	-0.49	8.6e-9	Coronary artery disease;
TGCT	cis	rs9486719	0.741	rs2499799	chr6:96851676	T/C	cg18709589	chr6:96969512	KIAA0776	0.73	5.0	0.41	1.88e-6	Migraine;Coronary artery disease;
TGCT	cis	rs765787	0.530	rs1648289	chr15:45516494	A/G	cg24006582	chr15:45444508	DUOX1	-0.25	-5.37	-0.43	3.78e-7	Uric acid levels;
TGCT	cis	rs10037670	1.000	rs10043393	chr5:153812047	G/C	cg21964928	chr5:153872958	NA	0.26	5.03	0.41	1.71e-6	Behavioural disinhibition (generation interaction);
TGCT	cis	rs9348721	0.673	rs9358934	chr6:26363755	G/C	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs62244186	0.659	rs62251383	chr3:44552421	A/G	cg25151919	chr3:44754333	ZNF502	-0.41	-4.77	-0.39	5.13e-6	Depressive symptoms;
TGCT	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg20607798	chr8:58055168	NA	-0.64	-5.39	-0.44	3.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7226408	0.948	rs11660471	chr18:34406836	C/T	cg06757138	chr18:34340585	FHOD3	0.26	4.79	0.4	4.62e-6	Obesity-related traits;
TGCT	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg16325326	chr1:53192061	ZYG11B	-0.71	-8.81	-0.62	9.22e-15	Monocyte count;
TGCT	cis	rs9926296	0.607	rs11076629	chr16:89875259	T/C	cg21285383	chr16:89894308	SPIRE2	0.33	4.45	0.37	1.92e-5	Vitiligo;
TGCT	cis	rs7572733	0.515	rs13382697	chr2:198920560	A/C	cg00792783	chr2:198669748	PLCL1	0.59	5.15	0.42	1.01e-6	Dermatomyositis;
TGCT	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg10802521	chr3:52805072	NEK4	-0.64	-7.64	-0.57	4.98e-12	Electroencephalogram traits;
TGCT	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg19626725	chr5:178986131	RUFY1	-0.54	-7.34	-0.55	2.4e-11	Lung cancer;
TGCT	cis	rs9894429	0.550	rs6565617	chr17:79612333	G/A	cg21028142	chr17:79581711	NPLOC4	0.28	5.87	0.47	3.73e-8	Eye color traits;
TGCT	cis	rs7829975	0.511	rs2980426	chr8:8145609	T/C	cg08975724	chr8:8085496	FLJ10661	0.54	4.64	0.38	8.7e-6	Mood instability;
TGCT	cis	rs2832191	0.632	rs2246777	chr21:30309586	T/C	cg08807101	chr21:30365312	RNF160	-0.66	-6.25	-0.49	6.06e-9	Dental caries;
TGCT	cis	rs3091242	0.933	rs10903130	chr1:25769221	A/T	cg10117171	chr1:25599238	RHD	-0.3	-4.92	-0.4	2.69e-6	Erythrocyte sedimentation rate;
TGCT	cis	rs8031584	0.707	rs4556757	chr15:31188179	C/T	cg08704250	chr15:31115839	NA	-0.42	-6.28	-0.49	5.27e-9	Huntington's disease progression;
TGCT	cis	rs11098499	0.863	rs1010740	chr4:120463409	C/T	cg09307838	chr4:120376055	NA	-0.69	-6.84	-0.52	3.24e-10	Corneal astigmatism;
TGCT	cis	rs11785693	0.862	rs73183633	chr8:4994543	G/A	cg26367366	chr8:4980734	NA	0.58	4.45	0.37	1.91e-5	Neuroticism (multi-trait analysis);Neuroticism;
TGCT	cis	rs700651	0.821	rs771005	chr2:198675948	C/T	cg00792783	chr2:198669748	PLCL1	0.56	5.08	0.42	1.35e-6	Intracranial aneurysm;
TGCT	cis	rs8180040	0.764	rs2132173	chr3:47247060	C/T	cg27129171	chr3:47204927	SETD2	-0.72	-9.72	-0.66	6.21e-17	Colorectal cancer;
TGCT	cis	rs12579753	0.917	rs10778834	chr12:82199742	A/C	cg07988820	chr12:82153109	PPFIA2	-0.54	-5.55	-0.45	1.65e-7	Resting heart rate;
TGCT	trans	rs208520	0.779	rs208451	chr6:66906155	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.93	-9.78	-0.66	4.3e-17	Exhaled nitric oxide output;
TGCT	cis	rs6430585	0.536	rs3213892	chr2:136552517	G/A	cg07169764	chr2:136633963	MCM6	1.21	11.47	0.72	3.36e-21	Corneal structure;
TGCT	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.31	-4.88	-0.4	3.26e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg18252515	chr7:66147081	NA	-1.31	-8.18	-0.59	2.87e-13	Diabetic kidney disease;
TGCT	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg08219700	chr8:58056026	NA	-0.39	-4.78	-0.39	4.93e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs72717009	0.778	rs9427400	chr1:161477204	C/T	cg23840854	chr1:161414152	NA	-0.98	-5.86	-0.47	3.95e-8	Rheumatoid arthritis;
TGCT	trans	rs17684571	0.938	rs62412528	chr6:56558385	G/A	cg14229071	chr15:89282588	NA	0.52	6.74	0.52	5.33e-10	Schizophrenia;
TGCT	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg00149659	chr3:10157352	C3orf10	0.73	4.72	0.39	6.17e-6	Alzheimer's disease;
TGCT	cis	rs10791097	0.568	rs4411284	chr11:130738568	A/C	cg12179176	chr11:130786555	SNX19	0.84	10.16	0.67	5.21e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs433598	0.514	rs34894022	chr16:20678165	A/G	cg08248577	chr16:19727447	IQCK;C16orf88	-0.25	-4.82	-0.4	4.07e-6	Schizophrenia;
TGCT	cis	rs35160687	0.871	rs11127028	chr2:86537509	A/T	cg03171300	chr2:86307199	POLR1A	0.32	5.57	0.45	1.48e-7	Night sleep phenotypes;
TGCT	cis	rs4664308	0.967	rs34248629	chr2:160902497	C/T	cg03641300	chr2:160917029	PLA2R1	-0.27	-6.55	-0.51	1.39e-9	Idiopathic membranous nephropathy;
TGCT	cis	rs6671200	1.000	rs12749053	chr1:95660556	A/G	cg26537280	chr1:95699037	RWDD3	0.68	5.49	0.44	2.15e-7	Stearic acid (18:0) levels;
TGCT	cis	rs854765	0.583	rs28428991	chr17:17827649	C/T	cg09796270	chr17:17721594	SREBF1	0.24	4.77	0.39	5.16e-6	Total body bone mineral density;
TGCT	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg18876405	chr7:65276391	NA	-0.37	-5.88	-0.47	3.63e-8	Calcium levels;
TGCT	cis	rs12497850	1.000	rs4858831	chr3:48735558	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.44	-6.1	-0.48	1.24e-8	Parkinson's disease;
TGCT	cis	rs2688608	0.592	rs11000757	chr10:75486815	T/C	cg15838173	chr10:75533400	FUT11	-0.31	-5.02	-0.41	1.73e-6	Inflammatory bowel disease;
TGCT	cis	rs11585357	0.895	rs72646798	chr1:17614422	C/T	cg08277548	chr1:17600880	PADI3	-0.96	-9.72	-0.66	5.97e-17	Hair shape;
TGCT	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg21016266	chr12:122356598	WDR66	0.52	7.24	0.54	4.23e-11	Mean corpuscular volume;
TGCT	cis	rs12681287	0.752	rs9283958	chr8:87253048	T/C	cg27223183	chr8:87520930	FAM82B	-0.81	-5.66	-0.45	9.9e-8	Caudate activity during reward;
TGCT	cis	rs2153535	0.542	rs915353	chr6:8440370	A/G	cg07606381	chr6:8435919	SLC35B3	0.57	5.25	0.43	6.38e-7	Motion sickness;
TGCT	trans	rs11722228	0.549	rs73212853	chr4:10096230	C/T	cg26043149	chr18:55253948	FECH	1.15	10.93	0.7	6.83e-20	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs8180040	0.676	rs13098228	chr3:47138253	A/G	cg27129171	chr3:47204927	SETD2	0.75	9.48	0.65	2.35e-16	Colorectal cancer;
TGCT	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg26338869	chr17:61819248	STRADA	-0.51	-4.73	-0.39	6.02e-6	Prudent dietary pattern;
TGCT	cis	rs1577917	1.000	rs13196930	chr6:86652245	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-5.36	-0.43	3.86e-7	Response to antipsychotic treatment;
TGCT	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg24829409	chr8:58192753	C8orf71	-0.58	-5.2	-0.42	7.88e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs1008375	0.897	rs2315554	chr4:17660407	T/C	cg16339924	chr4:17578868	LAP3	0.64	5.32	0.43	4.78e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs228437	0.507	rs228446	chr6:134901441	C/T	cg09872934	chr6:134495829	SGK1	-0.51	-4.63	-0.38	9.17e-6	Melanoma;
TGCT	cis	rs7769051	1.000	rs9399041	chr6:133096233	T/G	cg07930552	chr6:133119739	C6orf192	0.93	5.0	0.41	1.87e-6	Type 2 diabetes nephropathy;
TGCT	cis	rs4478858	0.775	rs6701667	chr1:31707971	A/C	cg00250761	chr1:31883323	NA	-0.31	-5.98	-0.47	2.17e-8	Alcohol dependence;
TGCT	cis	rs62380364	0.870	rs57055575	chr5:88150992	T/A	cg22951263	chr5:87985283	NA	-0.47	-4.55	-0.38	1.26e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs6840360	0.615	rs56319216	chr4:152463716	C/T	cg17479576	chr4:152424074	FAM160A1	-0.71	-7.74	-0.57	2.95e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg25811766	chr13:21894605	NA	0.26	5.27	0.43	5.79e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	cis	rs2228479	0.717	rs11649210	chr16:89807233	C/G	cg27121462	chr16:89883253	FANCA	0.74	4.71	0.39	6.44e-6	Skin colour saturation;
TGCT	cis	rs76419734	0.558	rs28536076	chr4:106527896	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.82	4.67	0.39	7.63e-6	Post bronchodilator FEV1;
TGCT	cis	rs8177253	0.665	rs8177178	chr3:133463272	G/A	cg08439880	chr3:133502540	NA	-0.26	-4.73	-0.39	6.04e-6	Iron status biomarkers;
TGCT	cis	rs941408	1.000	rs1076447	chr19:2792128	C/G	cg06609049	chr19:2785107	THOP1	0.79	7.46	0.56	1.34e-11	Total cholesterol levels;
TGCT	cis	rs9733	0.596	rs12403255	chr1:150660412	C/T	cg09365446	chr1:150670422	GOLPH3L	0.31	4.66	0.39	8.17e-6	Tonsillectomy;
TGCT	cis	rs2742417	0.935	rs2673028	chr3:45759654	A/G	cg04837898	chr3:45731254	SACM1L	-0.51	-5.27	-0.43	5.85e-7	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs7666738	0.791	rs4699329	chr4:99056212	G/A	cg05340658	chr4:99064831	C4orf37	0.52	5.79	0.46	5.32e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg08280861	chr8:58055591	NA	0.39	4.86	0.4	3.45e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10927875	0.722	rs945425	chr1:16348412	T/C	cg22431228	chr1:16359049	CLCNKA	-0.25	-4.64	-0.38	8.84e-6	Dilated cardiomyopathy;
TGCT	cis	rs597539	0.521	rs2060982	chr11:68612927	A/G	cg21862992	chr11:68658383	NA	0.33	4.63	0.38	9.04e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg05665937	chr4:1216051	CTBP1	0.25	4.75	0.39	5.64e-6	Obesity-related traits;
TGCT	cis	rs2692947	0.832	rs2438978	chr2:96679740	G/C	cg23100626	chr2:96804247	ASTL	0.38	4.45	0.37	1.9e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs9894429	0.646	rs9904137	chr17:79613925	C/T	cg21028142	chr17:79581711	NPLOC4	0.28	5.87	0.47	3.73e-8	Eye color traits;
TGCT	cis	rs12134133	1.000	rs61822669	chr1:207421214	G/A	cg02152968	chr1:207494213	CD55	0.64	5.06	0.41	1.47e-6	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs769267	1.000	rs2285627	chr19:19467937	T/C	cg19010396	chr19:19431384	KIAA0892;SF4	-0.57	-4.69	-0.39	6.96e-6	Tonsillectomy;
TGCT	cis	rs1371867	0.846	rs959022	chr8:101295992	T/A	cg00191853	chr8:101177733	SPAG1	-0.22	-4.47	-0.37	1.75e-5	Atrioventricular conduction;
TGCT	cis	rs28595532	0.920	rs115841156	chr4:119740073	C/T	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs1692580	0.807	rs260508	chr1:2187085	T/G	cg21194808	chr1:2205498	SKI	0.3	5.87	0.47	3.68e-8	Coronary artery disease;
TGCT	cis	rs950027	0.620	rs1049518	chr15:45653367	G/A	cg14582100	chr15:45693742	SPATA5L1	0.47	6.02	0.48	1.8e-8	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs4689592	0.503	rs2292461	chr4:7058473	C/T	cg26116260	chr4:7069785	GRPEL1	0.69	5.17	0.42	9.12e-7	Monocyte percentage of white cells;
TGCT	cis	rs11098499	0.955	rs6815725	chr4:120158410	C/A	cg24670566	chr4:120433619	PDE5A	0.23	4.45	0.37	1.89e-5	Corneal astigmatism;
TGCT	cis	rs624899	0.522	rs645584	chr19:11612466	A/G	cg15237152	chr19:11649631	CNN1	0.44	5.66	0.45	1.01e-7	Presence of antiphospholipid antibodies;
TGCT	cis	rs7937682	0.847	rs500163	chr11:111462649	T/G	cg09085632	chr11:111637200	PPP2R1B	-0.99	-10.02	-0.67	1.16e-17	Primary sclerosing cholangitis;
TGCT	cis	rs3796352	1.000	rs2564926	chr3:53094730	G/A	cg07884673	chr3:53033167	SFMBT1	-0.6	-6.13	-0.48	1.09e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs2806561	0.765	rs641808	chr1:23514123	T/G	cg12483005	chr1:23474871	LUZP1	0.38	4.73	0.39	5.93e-6	Height;
TGCT	cis	rs858239	0.699	rs858260	chr7:23212934	G/T	cg05602783	chr7:23145260	KLHL7	-0.68	-5.52	-0.44	1.91e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs6835098	0.962	rs10027704	chr4:174083107	T/C	cg08422745	chr4:174089978	GALNT7	-0.93	-10.95	-0.7	6.1e-20	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	-0.74	-5.34	-0.43	4.36e-7	Platelet count;
TGCT	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg08859206	chr1:53392774	SCP2	-0.41	-6.06	-0.48	1.52e-8	Monocyte count;
TGCT	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg07507251	chr3:52567010	NT5DC2	-0.45	-6.45	-0.5	2.28e-9	Bipolar disorder;
TGCT	cis	rs9611565	0.512	rs5758464	chr22:42171300	A/G	cg03806693	chr22:41940476	POLR3H	1.27	9.96	0.67	1.62e-17	Vitiligo;
TGCT	cis	rs9674544	0.757	rs11871214	chr17:47124902	G/T	cg20966754	chr17:47091339	IGF2BP1	-0.42	-4.6	-0.38	1.03e-5	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
TGCT	cis	rs12477438	0.684	rs6756880	chr2:99676991	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-7.6	-0.56	6.47e-12	Chronic sinus infection;
TGCT	cis	rs7542091	0.666	rs7537070	chr1:210043565	A/G	cg22029157	chr1:209979665	IRF6	0.64	6.1	0.48	1.23e-8	Monobrow;
TGCT	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9381040	0.610	rs2057002	chr6:41022962	G/T	cg03526776	chr6:41159608	TREML2	0.26	4.95	0.41	2.38e-6	Alzheimer's disease (late onset);
TGCT	cis	rs9894429	0.690	rs11869779	chr17:79570067	C/T	cg18240062	chr17:79603768	NPLOC4	-0.84	-9.67	-0.66	8.03e-17	Eye color traits;
TGCT	cis	rs797680	0.856	rs10874759	chr1:93630172	G/A	cg17826107	chr1:92977322	EVI5	-0.24	-5.19	-0.42	8.19e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs12220898	0.749	rs74912367	chr10:50471012	T/A	cg25968469	chr10:49687287	ARHGAP22	-0.28	-4.51	-0.38	1.51e-5	Inflammatory biomarkers;
TGCT	cis	rs225245	0.817	rs1049379	chr17:33998802	G/C	cg05299278	chr17:33885742	SLFN14	0.21	4.5	0.37	1.54e-5	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs2243480	1.000	rs160637	chr7:65584318	C/T	cg07424592	chr7:64974309	NA	1.22	7.36	0.55	2.2e-11	Diabetic kidney disease;
TGCT	cis	rs2692947	0.673	rs1168965	chr2:96787899	C/G	cg22654517	chr2:96458247	NA	-0.22	-4.88	-0.4	3.15e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs7586673	0.930	rs2884364	chr2:161977647	G/A	cg22496339	chr2:162101262	NA	0.53	4.81	0.4	4.27e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.680	rs34267968	chr4:99002574	A/T	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs909674	0.690	rs5750825	chr22:39831278	A/G	cg02038168	chr22:39784481	NA	-0.74	-5.67	-0.45	9.63e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs9902453	0.868	rs9896012	chr17:28470091	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	6.9	0.53	2.37e-10	Coffee consumption (cups per day);
TGCT	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg10802521	chr3:52805072	NEK4	-0.7	-8.75	-0.62	1.28e-14	Bipolar disorder;
TGCT	cis	rs6565180	0.926	rs12446288	chr16:30388709	A/G	cg17640201	chr16:30407289	ZNF48	1.0	9.81	0.66	3.7e-17	Tonsillectomy;
TGCT	cis	rs2439831	0.867	rs2447211	chr15:43936351	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	6.61	0.51	1.03e-9	Lung cancer in ever smokers;
TGCT	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.8	5.52	0.44	1.89e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs1568079	0.516	rs2361382	chr10:125220299	C/G	cg04278168	chr10:124578263	NA	-0.42	-4.62	-0.38	9.35e-6	Body mass index;
TGCT	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.8	5.52	0.44	1.89e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs524023	0.958	rs11231825	chr11:64360274	T/C	cg07733098	chr11:64478343	NRXN2	0.31	4.66	0.39	8.01e-6	Urate levels in obese individuals;
TGCT	cis	rs11247915	0.583	rs34058882	chr1:26659794	C/T	cg23732845	chr1:26663426	AIM1L	-0.36	-4.55	-0.38	1.25e-5	Obesity-related traits;
TGCT	cis	rs1865760	1.000	rs2071301	chr6:25914263	G/T	cg17042849	chr6:26104293	HIST1H4C	-0.51	-4.55	-0.38	1.24e-5	Height;
TGCT	cis	rs4642101	0.737	rs9877165	chr3:12828497	C/T	cg05775895	chr3:12838266	CAND2	0.78	8.7	0.62	1.73e-14	QRS complex (12-leadsum);
TGCT	cis	rs12530845	1.000	rs78186690	chr7:135334991	G/C	cg23117316	chr7:135346802	PL-5283	-0.51	-4.83	-0.4	3.98e-6	Red blood cell traits;
TGCT	cis	rs999943	0.846	rs2274200	chr6:33625696	T/C	cg14003231	chr6:33640908	ITPR3	0.4	4.86	0.4	3.48e-6	Obesity (extreme);
TGCT	cis	rs6882076	0.883	rs1553318	chr5:156479323	G/C	cg12943317	chr5:156479607	HAVCR1	-0.32	-5.51	-0.44	1.94e-7	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
TGCT	cis	rs9916302	0.904	rs7216086	chr17:37709422	G/A	cg07936489	chr17:37558343	FBXL20	-0.61	-4.87	-0.4	3.29e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs1008375	0.646	rs13146455	chr4:17565617	T/G	cg10189774	chr4:17578691	LAP3	-0.65	-5.6	-0.45	1.32e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2302045	1.000	rs74000379	chr2:242034103	G/A	cg04553960	chr2:241721320	KIF1A	-0.7	-4.68	-0.39	7.4e-6	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio);
TGCT	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg15691649	chr6:25882328	NA	0.49	5.98	0.47	2.17e-8	Blood metabolite levels;
TGCT	cis	rs1903068	0.614	rs9998950	chr4:55996845	C/T	cg16572876	chr4:56024045	NA	0.43	4.6	0.38	1.04e-5	Endometriosis;
TGCT	cis	rs9362426	0.887	rs1209113	chr6:88079456	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.46	5.17	0.42	8.91e-7	Depressive episodes in bipolar disorder;
TGCT	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg22535103	chr8:58192502	C8orf71	-0.42	-5.39	-0.44	3.49e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs11585357	0.671	rs2501776	chr1:17619279	C/T	cg08277548	chr1:17600880	PADI3	0.85	8.9	0.62	5.75e-15	Hair shape;
TGCT	cis	rs2299587	0.637	rs7832527	chr8:17889343	C/A	cg01800426	chr8:17659068	MTUS1	-0.61	-5.17	-0.42	9.09e-7	Economic and political preferences;
TGCT	trans	rs4650994	1.000	rs10913571	chr1:178526648	A/T	cg05059571	chr16:84539110	KIAA1609	-0.4	-7.43	-0.56	1.54e-11	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs3812831	0.662	rs418027	chr13:114929344	A/C	cg08824895	chr13:115047677	UPF3A	0.49	4.68	0.39	7.38e-6	Schizophrenia;
TGCT	cis	rs208520	0.955	rs9345808	chr6:67008262	C/T	cg07460842	chr6:66804631	NA	0.55	4.75	0.39	5.48e-6	Exhaled nitric oxide output;
TGCT	cis	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg18252515	chr7:66147081	NA	1.2	7.83	0.58	1.89e-12	Diabetic kidney disease;
TGCT	cis	rs13082711	0.911	rs13100751	chr3:27454964	A/G	cg02860705	chr3:27208620	NA	0.35	4.83	0.4	3.9e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	trans	rs2727020	0.729	rs2299650	chr11:49174007	A/C	cg15704280	chr7:45808275	SEPT13	-0.69	-7.79	-0.57	2.36e-12	Coronary artery disease;
TGCT	cis	rs7267979	1.000	rs2482941	chr20:25361216	T/C	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2692947	0.644	rs1168975	chr2:96814075	G/A	cg23100626	chr2:96804247	ASTL	0.46	5.42	0.44	3.03e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs12142240	0.698	rs45517837	chr1:46859225	A/G	cg00530320	chr1:46809349	NSUN4	0.29	5.79	0.46	5.34e-8	Menopause (age at onset);
TGCT	cis	rs929596	1.000	rs929596	chr2:234674476	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.36	-5.58	-0.45	1.42e-7	Total bilirubin levels in HIV-1 infection;
TGCT	cis	rs2153535	0.580	rs2327062	chr6:8453858	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.76	0.46	6.39e-8	Motion sickness;
TGCT	cis	rs6671200	1.000	rs10747468	chr1:95686291	C/T	cg03123541	chr1:95699097	RWDD3	0.84	6.26	0.49	5.66e-9	Stearic acid (18:0) levels;
TGCT	cis	rs9309473	0.558	rs11679042	chr2:73907311	A/C	cg07208825	chr2:73871855	ALMS1P	0.28	5.07	0.41	1.44e-6	Metabolite levels;
TGCT	cis	rs459571	0.916	rs109536	chr9:136889987	G/C	cg13789015	chr9:136890014	NCRNA00094	0.4	7.14	0.54	6.95e-11	Platelet distribution width;
TGCT	cis	rs3892630	1.000	rs3892630	chr19:33181484	A/G	cg22980127	chr19:33182716	NUDT19	-0.72	-5.11	-0.42	1.16e-6	Red blood cell traits;
TGCT	cis	rs7666738	0.715	rs116787789	chr4:98718720	G/A	cg05340658	chr4:99064831	C4orf37	0.47	5.49	0.44	2.21e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg23758822	chr17:41437982	NA	0.69	6.41	0.5	2.75e-9	Menopause (age at onset);
TGCT	cis	rs11098499	0.820	rs28394116	chr4:120524283	T/G	cg09307838	chr4:120376055	NA	0.67	6.35	0.5	3.65e-9	Corneal astigmatism;
TGCT	cis	rs1129187	0.702	rs2296805	chr6:42928758	T/G	cg10862848	chr6:42927986	GNMT	-0.39	-4.67	-0.39	7.61e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs11203032	0.831	rs12217507	chr10:90922828	G/A	cg16672925	chr10:90967113	CH25H	0.73	4.5	0.37	1.55e-5	Heart failure;
TGCT	cis	rs2982552	0.873	rs2152750	chr6:152070145	C/T	cg22157087	chr6:152012887	ESR1	-0.21	-5.27	-0.43	5.79e-7	Bone properties (heel);
TGCT	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg21644426	chr2:191273491	MFSD6	0.66	6.24	0.49	6.46e-9	Pulse pressure;
TGCT	cis	rs11190604	1.000	rs10883510	chr10:102297018	C/T	cg23241863	chr10:102295624	HIF1AN	0.67	4.8	0.4	4.46e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs12497850	0.797	rs61583136	chr3:49189195	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.38	-4.79	-0.4	4.61e-6	Parkinson's disease;
TGCT	cis	rs9611565	0.513	rs739135	chr22:42090069	A/C	cg06634786	chr22:41940651	POLR3H	0.9	8.74	0.62	1.34e-14	Vitiligo;
TGCT	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg08736216	chr1:53307985	ZYG11A	-0.25	-4.68	-0.39	7.47e-6	Monocyte count;
TGCT	cis	rs910316	0.763	rs175036	chr14:75464295	C/T	cg08847533	chr14:75593920	NEK9	-0.84	-9.15	-0.64	1.4e-15	Height;
TGCT	cis	rs3784262	0.679	rs11071365	chr15:58334126	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.55	-8.46	-0.6	6.31e-14	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs9467711	0.790	rs1979	chr6:26377591	G/T	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.28	0.43	5.65e-7	Prudent dietary pattern;
TGCT	cis	rs7224685	0.774	rs8081417	chr17:3902650	T/A	cg25235380	chr17:4167449	ANKFY1	-0.54	-4.57	-0.38	1.17e-5	Type 2 diabetes;
TGCT	cis	rs2274459	0.545	rs35329444	chr6:33588985	C/A	cg11783815	chr6:33558433	C6orf227	0.32	4.56	0.38	1.21e-5	Obesity (extreme);
TGCT	cis	rs12142240	0.698	rs1053628	chr1:46827769	C/T	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs4383453	0.539	rs2877709	chr3:123100304	A/G	cg04890266	chr3:123102914	ADCY5	0.5	8.34	0.6	1.2e-13	Gestational age at birth (maternal effect);
TGCT	cis	rs73198271	0.595	rs56152067	chr8:8592992	G/A	ch.8.214553F	chr8:8189620	PRAGMIN	-0.32	-5.23	-0.42	7.04e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs2455799	0.559	rs9813577	chr3:15909323	C/T	cg13420985	chr3:16524424	RFTN1	0.35	4.6	0.38	1.05e-5	Mean platelet volume;
TGCT	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg15691649	chr6:25882328	NA	0.43	5.34	0.43	4.27e-7	Blood metabolite levels;
TGCT	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg08439880	chr3:133502540	NA	0.29	5.37	0.43	3.79e-7	Iron status biomarkers;
TGCT	cis	rs12620999	0.941	rs4408676	chr2:238085280	C/T	cg23555395	chr2:238036564	NA	-0.29	-4.99	-0.41	1.95e-6	Systemic lupus erythematosus;
TGCT	cis	rs7772486	0.846	rs2144478	chr6:146381445	A/G	cg05347473	chr6:146136440	FBXO30	0.52	4.86	0.4	3.48e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs617219	0.551	rs2131978	chr5:78613986	G/A	cg23987322	chr5:78407566	BHMT	-0.35	-4.73	-0.39	5.99e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg20637647	chr7:64974828	NA	0.89	4.99	0.41	2.01e-6	Diabetic kidney disease;
TGCT	cis	rs9549367	0.713	rs1755690	chr13:113824266	T/C	cg00898013	chr13:113819073	PROZ	0.55	7.02	0.53	1.27e-10	Platelet distribution width;
TGCT	cis	rs288326	0.561	rs77024950	chr2:183797227	T/C	cg09997497	chr2:183902928	NCKAP1	1.11	4.95	0.41	2.38e-6	Blood protein levels;
TGCT	cis	rs1568889	1.000	rs11826837	chr11:28322566	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.8	-8.39	-0.6	9.19e-14	Bipolar disorder;
TGCT	trans	rs1814175	0.740	rs10839439	chr11:49918240	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.36	-7.05	-0.53	1.13e-10	Height;
TGCT	cis	rs1483890	1.000	rs1483890	chr3:69410725	A/G	cg22125112	chr3:69402811	FRMD4B	0.27	4.52	0.38	1.45e-5	Resting heart rate;
TGCT	cis	rs11785400	0.793	rs2976400	chr8:143743611	G/A	cg10596483	chr8:143751796	JRK	0.55	5.48	0.44	2.29e-7	Schizophrenia;
TGCT	cis	rs2439831	0.571	rs2470121	chr15:43937618	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	4.95	0.41	2.38e-6	Lung cancer in ever smokers;
TGCT	cis	rs7267979	0.773	rs6132821	chr20:25226192	A/G	cg03522245	chr20:25566470	NINL	0.57	5.67	0.45	9.54e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs68170813	0.559	rs6971675	chr7:106833797	G/A	cg02696742	chr7:106810147	HBP1	-0.7	-5.81	-0.46	4.91e-8	Coronary artery disease;
TGCT	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg16414030	chr3:133502952	NA	-0.61	-9.47	-0.65	2.44e-16	Iron status biomarkers;
TGCT	cis	rs7666738	0.830	rs10050008	chr4:99025313	T/G	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs35883536	0.551	rs6666607	chr1:101032368	A/G	cg10298815	chr1:101004474	GPR88	-0.25	-4.61	-0.38	9.74e-6	Monocyte count;
TGCT	cis	rs4654899	0.733	rs6698440	chr1:21258712	C/T	cg01072550	chr1:21505969	NA	-0.53	-8.69	-0.62	1.83e-14	Superior frontal gyrus grey matter volume;
TGCT	cis	rs453301	0.624	rs2979256	chr8:8871710	C/T	cg06636001	chr8:8085503	FLJ10661	0.77	6.54	0.51	1.43e-9	Joint mobility (Beighton score);
TGCT	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.41	7.14	0.54	6.78e-11	Schizophrenia;
TGCT	cis	rs507506	0.712	rs1875673	chr17:7108506	T/G	cg25256661	chr17:7137939	DVL2	-0.57	-5.16	-0.42	9.6e-7	Adiponectin levels;
TGCT	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg01341218	chr17:43662625	NA	-0.83	-7.37	-0.55	2.14e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs992157	0.710	rs13026485	chr2:219057984	C/T	cg00012203	chr2:219082015	ARPC2	-0.82	-10.54	-0.69	6.02e-19	Colorectal cancer;
TGCT	cis	rs7428	0.527	rs3184780	chr2:85549547	C/T	cg24342717	chr2:85555507	TGOLN2	-0.48	-8.29	-0.6	1.6e-13	Ear protrusion;
TGCT	cis	rs116095464	0.614	rs62344292	chr5:244630	G/A	cg22857025	chr5:266934	NA	-0.34	-6.72	-0.52	5.96e-10	Breast cancer;
TGCT	cis	rs9467773	1.000	rs1884948	chr6:26567988	G/A	cg15659132	chr6:26577336	NA	0.88	12.27	0.74	3.83e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs28595532	0.920	rs55985953	chr4:119764971	T/A	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs617219	0.710	rs2166344	chr5:78534134	T/G	cg23514016	chr5:78407564	BHMT	0.32	4.87	0.4	3.38e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs2439831	1.000	rs2601014	chr15:43756013	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.77	4.61	0.38	9.74e-6	Lung cancer in ever smokers;
TGCT	cis	rs9911578	0.967	rs7502208	chr17:57165097	G/A	cg05425664	chr17:57184151	TRIM37	-0.68	-6.84	-0.52	3.19e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs9790314	0.586	rs16832246	chr3:161109916	A/G	cg03342759	chr3:160939853	NMD3	0.53	5.53	0.45	1.77e-7	Morning vs. evening chronotype;
TGCT	cis	rs9443189	0.615	rs602873	chr6:76323818	T/A	cg01950844	chr6:76311363	SENP6	0.99	6.27	0.49	5.49e-9	Prostate cancer;
TGCT	cis	rs11098499	0.779	rs7699346	chr4:120310542	C/T	cg09307838	chr4:120376055	NA	0.62	5.94	0.47	2.66e-8	Corneal astigmatism;
TGCT	cis	rs17001868	0.892	rs12483888	chr22:40801312	A/G	cg07138101	chr22:40742427	ADSL	0.71	4.72	0.39	6.31e-6	Mammographic density (dense area);
TGCT	cis	rs73198271	0.737	rs565203	chr8:8632957	T/C	cg06671706	chr8:8559999	CLDN23	-0.37	-4.84	-0.4	3.81e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs9467773	0.935	rs1884947	chr6:26553273	G/T	cg09904177	chr6:26538194	HMGN4	0.63	6.21	0.49	7.48e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7264396	0.635	rs6058365	chr20:34508092	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.04	-0.41	1.58e-6	Total cholesterol levels;
TGCT	cis	rs1215050	0.744	rs966380	chr4:98435389	C/T	cg05340658	chr4:99064831	C4orf37	0.4	4.55	0.38	1.26e-5	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg11494091	chr17:61959527	GH2	0.42	7.27	0.55	3.61e-11	Height;
TGCT	cis	rs28595532	0.920	rs115688334	chr4:119770805	C/T	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg24829409	chr8:58192753	C8orf71	-0.57	-5.35	-0.43	4.03e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7647973	0.626	rs4855846	chr3:49683526	G/A	cg05785598	chr3:49045655	WDR6	0.42	5.24	0.43	6.67e-7	Menarche (age at onset);
TGCT	cis	rs6570726	0.738	rs6917199	chr6:145918320	G/A	cg23711669	chr6:146136114	FBXO30	0.89	9.62	0.65	1.06e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs981844	0.740	rs10009844	chr4:154681576	C/T	cg14289246	chr4:154710475	SFRP2	-0.88	-7.71	-0.57	3.47e-12	Response to statins (LDL cholesterol change);
TGCT	cis	rs10782582	0.545	rs12138018	chr1:76186794	T/C	cg22875332	chr1:76189707	ACADM	-0.53	-5.78	-0.46	5.81e-8	Daytime sleep phenotypes;
TGCT	cis	rs5417	0.775	rs222852	chr17:7140606	A/G	cg25256661	chr17:7137939	DVL2	0.56	5.45	0.44	2.61e-7	Diastolic blood pressure;
TGCT	cis	rs1497406	0.591	rs12024558	chr1:16518748	T/A	cg20430773	chr1:16534157	ARHGEF19	0.47	5.33	0.43	4.44e-7	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9916302	0.706	rs8078599	chr17:37518660	C/T	cg03321784	chr17:37729644	NA	-0.49	-4.98	-0.41	2.04e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs9952991	0.941	rs888270	chr18:12774894	G/A	cg24737193	chr18:12778029	NA	-0.55	-5.89	-0.47	3.32e-8	Inflammatory skin disease;
TGCT	cis	rs2282802	0.685	rs6580473	chr5:139646962	C/T	cg01081189	chr5:139537190	NA	-0.28	-4.9	-0.4	2.91e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs950027	0.620	rs2453533	chr15:45641225	C/A	cg26924012	chr15:45694286	SPATA5L1	0.79	8.86	0.62	6.92e-15	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs2486012	1.000	rs3011226	chr1:44324060	G/A	cg12908607	chr1:44402522	ARTN	-0.72	-5.68	-0.45	8.89e-8	Intelligence (multi-trait analysis);
TGCT	trans	rs9951602	0.512	rs8098115	chr18:76653986	G/T	cg02800362	chr5:177631904	HNRNPAB	1.13	12.84	0.76	1.57e-24	Obesity-related traits;
TGCT	cis	rs4919694	1.000	rs11191490	chr10:104745174	T/A	cg04362960	chr10:104952993	NT5C2	1.07	7.09	0.54	8.9e-11	Arsenic metabolism;
TGCT	cis	rs4722404	0.835	rs28458463	chr7:3139506	G/A	cg17467898	chr7:2289054	NUDT1	-0.17	-4.46	-0.37	1.81e-5	Atopic dermatitis;
TGCT	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg11366901	chr6:160182831	ACAT2	-0.78	-5.8	-0.46	5.25e-8	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs11190604	1.000	rs6584383	chr10:102303065	C/G	cg16342193	chr10:102329863	NA	-0.41	-4.93	-0.4	2.57e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs763121	0.853	rs3747170	chr22:39067331	G/A	cg06022373	chr22:39101656	GTPBP1	0.77	7.57	0.56	7.47e-12	Menopause (age at onset);
TGCT	cis	rs2404602	0.692	rs35195096	chr15:76938447	C/T	cg22467129	chr15:76604101	ETFA	-0.45	-5.11	-0.42	1.18e-6	Blood metabolite levels;
TGCT	cis	rs478304	0.903	rs546202	chr11:65510024	C/T	cg17480646	chr11:65405466	SIPA1	-0.43	-5.42	-0.44	2.98e-7	Acne (severe);
TGCT	cis	rs4268898	0.760	rs55863105	chr2:24570695	C/T	cg02683114	chr2:24398427	C2orf84	0.2	4.92	0.4	2.65e-6	Asthma;
TGCT	cis	rs240110	0.539	rs6934256	chr6:101338728	G/A	cg09795085	chr6:101329169	ASCC3	0.56	4.45	0.37	1.85e-5	Neuroticism;
TGCT	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.06	-9.57	-0.65	1.41e-16	Platelet count;
TGCT	cis	rs7647973	1.000	rs7644148	chr3:49545241	G/A	cg07636037	chr3:49044803	WDR6	-0.7	-5.73	-0.46	7.08e-8	Menarche (age at onset);
TGCT	cis	rs7582180	0.629	rs6736576	chr2:100950854	C/T	cg08017756	chr2:100939284	LONRF2	-0.3	-4.95	-0.41	2.34e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs67311347	0.955	rs6782746	chr3:40510592	A/G	cg13683864	chr3:40499215	RPL14	1.17	13.19	0.76	2.34e-25	Renal cell carcinoma;
TGCT	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg21017887	chr14:105400489	NA	0.37	5.19	0.42	8.23e-7	Rheumatoid arthritis;
TGCT	cis	rs4332037	0.539	rs4719416	chr7:2106608	G/A	cg25834613	chr7:1915315	MAD1L1	-0.45	-4.92	-0.4	2.7e-6	Bipolar disorder;
TGCT	cis	rs7208859	0.573	rs55661352	chr17:29045628	A/G	cg14008862	chr17:28927542	LRRC37B2	0.78	4.68	0.39	7.38e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs10791097	0.694	rs2155751	chr11:130755240	G/A	cg14779329	chr11:130786720	SNX19	0.29	5.01	0.41	1.85e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs1008375	1.000	rs10012335	chr4:17628630	C/G	cg16339924	chr4:17578868	LAP3	0.62	5.11	0.42	1.17e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs208520	0.690	rs207096	chr6:66797287	T/C	cg07460842	chr6:66804631	NA	-0.94	-9.91	-0.66	2.15e-17	Exhaled nitric oxide output;
TGCT	cis	rs17767294	0.612	rs9461424	chr6:27919401	G/A	cg08851530	chr6:28072375	NA	0.78	4.81	0.4	4.34e-6	Parkinson's disease;
TGCT	cis	rs6087990	0.806	rs875041	chr20:31383530	C/T	cg13636640	chr20:31349939	DNMT3B	1.1	15.53	0.81	7.14e-31	Ulcerative colitis;
TGCT	cis	rs9291683	0.527	rs3822247	chr4:10094671	G/A	cg00071950	chr4:10020882	SLC2A9	-0.54	-5.63	-0.45	1.16e-7	Bone mineral density;
TGCT	cis	rs10875746	0.669	rs9634261	chr12:48686871	A/G	cg20731937	chr12:48336164	NA	0.61	4.59	0.38	1.07e-5	Longevity (90 years and older);
TGCT	cis	rs11718455	0.960	rs35666538	chr3:44004826	A/G	cg08738300	chr3:44038990	NA	0.85	6.34	0.49	3.94e-9	Coronary artery disease;
TGCT	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg08048268	chr3:133502702	NA	-0.54	-7.23	-0.54	4.34e-11	Iron status biomarkers;
TGCT	cis	rs2014572	0.933	rs8107516	chr19:57758445	A/G	cg24459738	chr19:57751996	ZNF805	-0.56	-5.6	-0.45	1.29e-7	Hyperactive-impulsive symptoms;
TGCT	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg22166914	chr1:53195759	ZYG11B	-0.42	-7.46	-0.56	1.33e-11	Monocyte count;
TGCT	cis	rs595982	0.546	rs10401443	chr19:49402059	C/A	cg11637076	chr19:49575188	KCNA7	-0.43	-5.31	-0.43	4.85e-7	Red cell distribution width;
TGCT	cis	rs11971779	1.000	rs11971779	chr7:139040258	A/G	cg07862535	chr7:139043722	LUC7L2	-0.81	-6.02	-0.48	1.83e-8	Diisocyanate-induced asthma;
TGCT	cis	rs4819052	0.851	rs7279011	chr21:46655995	G/A	cg06618935	chr21:46677482	NA	-0.36	-5.48	-0.44	2.23e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs13242816	1.000	rs35364754	chr7:116109716	T/G	cg02799643	chr7:116139180	CAV2	-0.48	-5.45	-0.44	2.56e-7	P wave duration;
TGCT	cis	rs6430585	0.527	rs57530667	chr2:136444338	A/G	cg07169764	chr2:136633963	MCM6	1.0	9.14	0.63	1.51e-15	Corneal structure;
TGCT	cis	rs1215050	0.791	rs260902	chr4:98764694	G/A	cg17366294	chr4:99064904	C4orf37	0.52	5.61	0.45	1.27e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs3096299	0.933	rs3096297	chr16:89453155	T/G	cg02187348	chr16:89574699	SPG7	0.48	4.71	0.39	6.63e-6	Multiple myeloma (IgH translocation);
TGCT	cis	rs72945132	0.882	rs7943547	chr11:70133282	C/A	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs9915657	0.870	rs759499	chr17:70133177	C/T	cg06234051	chr17:70120541	SOX9	-0.23	-4.64	-0.38	8.76e-6	Thyroid hormone levels;
TGCT	cis	rs12477438	0.798	rs10202452	chr2:99569409	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.7	-6.19	-0.49	8.1e-9	Chronic sinus infection;
TGCT	cis	rs7666738	0.830	rs28515641	chr4:98726419	G/A	cg18180107	chr4:99064573	C4orf37	0.53	5.07	0.41	1.38e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs62244186	0.659	rs56234157	chr3:44516221	G/A	cg25151919	chr3:44754333	ZNF502	-0.39	-4.54	-0.38	1.3e-5	Depressive symptoms;
TGCT	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg06896619	chr17:61851486	DDX42;CCDC47	0.51	5.18	0.42	8.6e-7	Prudent dietary pattern;
TGCT	cis	rs7666738	0.830	rs9999200	chr4:99030690	A/C	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4851266	0.966	rs1465800	chr2:100834777	T/C	cg07810366	chr2:100720526	AFF3	-0.39	-5.73	-0.46	7.19e-8	Educational attainment;
TGCT	cis	rs950169	0.800	rs4099846	chr15:84956894	C/G	cg11189052	chr15:85197271	WDR73	0.81	6.22	0.49	6.89e-9	Schizophrenia;
TGCT	cis	rs78456975	0.739	rs11891867	chr2:1517894	C/T	cg01028140	chr2:1542097	TPO	-0.36	-4.76	-0.39	5.3e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs79349575	0.783	rs2112617	chr17:46977125	G/A	cg07967210	chr17:47022446	SNF8	0.44	6.2	0.49	7.58e-9	Type 2 diabetes;
TGCT	cis	rs2549003	1.000	rs9282763	chr5:131822133	T/C	cg00255919	chr5:131827918	IRF1	0.2	4.65	0.39	8.22e-6	Asthma (sex interaction);
TGCT	cis	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg07424592	chr7:64974309	NA	1.36	8.15	0.59	3.36e-13	Diabetic kidney disease;
TGCT	cis	rs9883204	0.951	rs7613951	chr3:123070517	C/T	cg04890266	chr3:123102914	ADCY5	0.37	5.0	0.41	1.92e-6	Birth weight;
TGCT	cis	rs7809950	1.000	rs3801954	chr7:107117048	C/T	cg23024343	chr7:107201750	COG5	-0.34	-5.35	-0.43	4.11e-7	Coronary artery disease;
TGCT	cis	rs13217239	0.646	rs12527111	chr6:27006475	C/T	cg05738196	chr6:26577821	NA	0.49	4.75	0.39	5.45e-6	Schizophrenia;
TGCT	cis	rs2535633	0.661	rs4515041	chr3:52996032	T/A	cg05573699	chr3:52720067	GNL3;PBRM1	0.56	5.29	0.43	5.37e-7	Body mass index;
TGCT	cis	rs7246657	0.714	rs12972195	chr19:37752505	T/C	cg03233940	chr19:37894644	NA	-0.39	-4.93	-0.4	2.56e-6	Coronary artery calcification;
TGCT	trans	rs804280	0.509	rs10109241	chr8:11784985	A/T	cg15556689	chr8:8085844	FLJ10661	0.77	7.16	0.54	6.11e-11	Myopia (pathological);
TGCT	cis	rs709400	0.663	rs10141388	chr14:103939679	A/G	cg12935359	chr14:103987150	CKB	-0.36	-5.56	-0.45	1.59e-7	Body mass index;
TGCT	cis	rs12368653	0.666	rs799265	chr12:58112189	A/G	cg12615879	chr12:58013172	SLC26A10	0.47	5.67	0.45	9.53e-8	Multiple sclerosis;
TGCT	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg21724239	chr8:58056113	NA	0.34	4.54	0.38	1.31e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2856321	1.000	rs11054424	chr12:11860170	C/G	cg11375112	chr12:11883006	ETV6	0.3	4.48	0.37	1.67e-5	Height;
TGCT	cis	rs616402	0.564	rs7419116	chr1:10578606	G/A	cg17425144	chr1:10567563	PEX14	0.54	7.98	0.58	8.27e-13	Breast size;
TGCT	cis	rs6032067	0.636	rs6032095	chr20:43913255	A/T	cg16667508	chr20:43936853	MATN4;RBPJL	0.42	7.1	0.54	8.47e-11	Blood protein levels;
TGCT	cis	rs7586879	0.681	rs6752483	chr2:25120086	C/T	cg15423357	chr2:25149977	NA	0.48	4.62	0.38	9.27e-6	Body mass index;
TGCT	cis	rs9486719	0.895	rs3798294	chr6:97049587	G/A	cg18709589	chr6:96969512	KIAA0776	-0.74	-5.21	-0.42	7.5e-7	Migraine;Coronary artery disease;
TGCT	cis	rs9796	0.621	rs2928142	chr15:41470449	T/C	cg18705301	chr15:41695430	NDUFAF1	0.52	7.17	0.54	5.94e-11	Menopause (age at onset);
TGCT	trans	rs7615952	0.551	rs12695470	chr3:125635718	C/A	cg07211511	chr3:129823064	LOC729375	-0.45	-6.72	-0.52	5.83e-10	Blood pressure (smoking interaction);
TGCT	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg18538332	chr22:24372958	LOC391322	-1.01	-12.83	-0.76	1.7e-24	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9467711	1.000	rs6923139	chr6:26313348	C/T	cg03264133	chr6:25882463	NA	-0.82	-4.48	-0.37	1.65e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg00814883	chr7:100076585	TSC22D4	-0.82	-8.37	-0.6	1.03e-13	Platelet count;
TGCT	cis	rs1971762	0.545	rs10783585	chr12:53977317	T/G	cg16917193	chr12:54089295	NA	0.93	9.72	0.66	5.91e-17	Height;
TGCT	trans	rs7613875	0.620	rs11721204	chr3:49982765	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.8	8.29	0.6	1.6e-13	Body mass index;
TGCT	cis	rs7666738	0.830	rs10017201	chr4:98983561	G/A	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7226408	0.901	rs11081991	chr18:34743948	G/A	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs634534	0.622	rs531612	chr11:65705432	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.56	-5.51	-0.44	1.95e-7	Sum eosinophil basophil counts;Eosinophil counts;
TGCT	cis	rs6074578	0.535	rs6086289	chr20:138615	G/A	cg16931068	chr20:139680	DEFB127	0.27	4.47	0.37	1.75e-5	Hirschsprung disease;
TGCT	cis	rs362272	0.545	rs2239725	chr4:3305739	C/T	cg06533319	chr4:3265114	C4orf44	-0.28	-5.39	-0.44	3.35e-7	Serum sulfate level;
TGCT	cis	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg15556689	chr8:8085844	FLJ10661	0.67	6.2	0.49	7.84e-9	Mood instability;
TGCT	cis	rs453301	0.571	rs2929456	chr8:9083416	G/A	cg06636001	chr8:8085503	FLJ10661	-0.56	-4.97	-0.41	2.14e-6	Joint mobility (Beighton score);
TGCT	cis	rs924607	1.000	rs12523022	chr5:598643	C/T	cg18765565	chr5:669397	TPPP	-0.58	-6.32	-0.49	4.25e-9	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs6088580	0.634	rs6120642	chr20:33012531	A/G	cg24642439	chr20:33292090	TP53INP2	0.49	4.5	0.37	1.55e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs2777491	0.874	rs11633799	chr15:41576538	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.72	-9.31	-0.64	5.77e-16	Ulcerative colitis;
TGCT	cis	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg08564027	chr20:61660810	NA	0.37	6.85	0.52	3.1e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs765787	0.530	rs11855435	chr15:45522117	G/A	cg24006582	chr15:45444508	DUOX1	-0.26	-5.64	-0.45	1.12e-7	Uric acid levels;
TGCT	cis	rs16865717	0.513	rs6431838	chr2:7036838	G/C	cg20486407	chr2:7037101	RSAD2	-0.41	-5.42	-0.44	2.95e-7	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs62380364	0.602	rs11743441	chr5:88065637	G/T	cg24804195	chr5:87968844	LOC645323	-0.57	-5.45	-0.44	2.6e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1729951	0.546	rs12054219	chr3:136677472	G/A	cg21827317	chr3:136751795	NA	0.4	5.61	0.45	1.28e-7	Neuroticism;
TGCT	cis	rs2439831	1.000	rs2601014	chr15:43756013	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.0	6.7	0.52	6.45e-10	Lung cancer in ever smokers;
TGCT	cis	rs9788682	0.748	rs637137	chr15:78873976	T/A	cg24631222	chr15:78858424	CHRNA5	0.86	6.45	0.5	2.3e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs2204008	0.805	rs11179579	chr12:38213957	A/C	cg13010199	chr12:38710504	ALG10B	0.6	4.68	0.39	7.47e-6	Bladder cancer;
TGCT	cis	rs13256369	1.000	rs1109619	chr8:8571616	G/T	cg17143192	chr8:8559678	CLDN23	0.58	5.55	0.45	1.64e-7	Obesity-related traits;
TGCT	cis	rs447921	1.000	rs447921	chr17:74414559	T/C	cg09812376	chr17:74270190	QRICH2	0.44	4.5	0.37	1.57e-5	Mitochondrial DNA levels;
TGCT	cis	rs2820315	0.867	rs2644121	chr1:201881284	A/G	cg12730843	chr1:201915899	LMOD1	-0.26	-4.9	-0.4	2.91e-6	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
TGCT	cis	rs67072384	1.000	rs72964198	chr11:72446464	C/T	cg03713592	chr11:72463424	ARAP1	-0.94	-4.8	-0.4	4.41e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs4889855	0.530	rs78012645	chr17:78550939	C/T	cg16591659	chr17:78472290	NA	0.28	4.45	0.37	1.89e-5	Fractional excretion of uric acid;
TGCT	cis	rs6087771	0.747	rs6058261	chr20:30235470	C/A	cg13852791	chr20:30311386	BCL2L1	0.8	7.08	0.54	9.22e-11	Subcortical brain region volumes;Putamen volume;
TGCT	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg24549020	chr5:56110836	MAP3K1	0.7	5.97	0.47	2.34e-8	Initial pursuit acceleration;
TGCT	cis	rs2172802	0.570	rs10020698	chr4:62516024	T/C	cg04118610	chr4:62707027	LPHN3	0.41	4.89	0.4	3.07e-6	Partial epilepsies;
TGCT	cis	rs9297145	0.761	rs28545226	chr7:98732472	A/T	cg05967295	chr7:98741636	SMURF1	1.01	12.7	0.75	3.38e-24	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs17102423	0.623	rs4902368	chr14:65612048	A/G	cg11161011	chr14:65562177	MAX	0.4	5.51	0.44	1.98e-7	Obesity-related traits;
TGCT	cis	rs10883723	0.810	rs2296585	chr10:104245549	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	8.36	0.6	1.1e-13	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg26116260	chr4:7069785	GRPEL1	1.13	11.1	0.71	2.59e-20	Monocyte percentage of white cells;
TGCT	cis	rs3008870	0.755	rs2815365	chr1:67499628	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.8	8.48	0.61	5.61e-14	Lymphocyte percentage of white cells;
TGCT	cis	rs1865760	0.566	rs9295686	chr6:26081983	G/C	cg17042849	chr6:26104293	HIST1H4C	-0.63	-5.47	-0.44	2.43e-7	Height;
TGCT	cis	rs698813	0.572	rs13424464	chr2:44482263	A/C	cg00619915	chr2:44497795	NA	-0.24	-5.68	-0.45	9.26e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
TGCT	cis	rs12579753	0.917	rs7138651	chr12:82253615	A/G	cg07988820	chr12:82153109	PPFIA2	0.53	5.64	0.45	1.07e-7	Resting heart rate;
TGCT	trans	rs1496653	0.602	rs36124326	chr3:23435327	T/G	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs7659604	0.702	rs58649165	chr4:122693752	C/A	cg23574427	chr4:122746245	BBS7;CCNA2	-0.32	-5.2	-0.42	7.91e-7	Type 2 diabetes;
TGCT	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg09365446	chr1:150670422	GOLPH3L	0.31	4.64	0.38	8.74e-6	Tonsillectomy;
TGCT	cis	rs11249608	0.548	rs6875473	chr5:178451387	C/A	cg01312482	chr5:178451176	ZNF879	-0.56	-5.5	-0.44	2.09e-7	Pubertal anthropometrics;
TGCT	cis	rs36051895	0.659	rs12336577	chr9:5063690	T/A	cg02405213	chr9:5042618	JAK2	-0.71	-9.22	-0.64	9.86e-16	Pediatric autoimmune diseases;
TGCT	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.93	7.44	0.56	1.44e-11	Platelet count;
TGCT	cis	rs6840360	0.582	rs4696260	chr4:152318924	T/C	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.35	-0.5	3.67e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs10791097	0.547	rs12365680	chr11:130749059	C/T	cg14779329	chr11:130786720	SNX19	0.29	5.08	0.42	1.33e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs3780378	0.967	rs1328917	chr9:5049065	G/T	cg02405213	chr9:5042618	JAK2	-0.58	-7.5	-0.56	1.09e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs9527	0.830	rs12249194	chr10:104643698	T/C	cg04362960	chr10:104952993	NT5C2	0.62	5.06	0.41	1.46e-6	Arsenic metabolism;
TGCT	cis	rs950027	0.787	rs2433616	chr15:45728599	A/G	cg26924012	chr15:45694286	SPATA5L1	0.67	7.17	0.54	5.91e-11	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs13191362	1.000	rs13207239	chr6:163008772	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs11190604	1.000	rs2495760	chr10:102318771	T/C	cg23241863	chr10:102295624	HIF1AN	0.67	4.9	0.4	2.92e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs28374715	0.532	rs11854632	chr15:41682094	A/G	cg18705301	chr15:41695430	NDUFAF1	0.9	15.29	0.81	2.65e-30	Ulcerative colitis;
TGCT	cis	rs7625328	0.679	rs2049149	chr3:132776901	A/G	cg18115215	chr3:132757090	TMEM108	0.41	4.58	0.38	1.1e-5	Itch intensity from mosquito bite;
TGCT	cis	rs1153858	1.000	rs1049503	chr15:45653707	T/C	cg26924012	chr15:45694286	SPATA5L1	1.09	15.16	0.81	5.15e-30	Homoarginine levels;
TGCT	trans	rs57221529	0.825	rs72703051	chr5:582997	G/A	cg25482853	chr8:67687455	SGK3	1.22	9.53	0.65	1.7e-16	Lung disease severity in cystic fibrosis;
TGCT	cis	rs7681423	1.000	rs7659024	chr4:155520930	G/A	cg20735720	chr4:155535218	FGG	-0.46	-6.8	-0.52	4e-10	Fibrinogen;
TGCT	cis	rs7020830	0.505	rs12553878	chr9:37095705	C/T	cg14294708	chr9:37120828	ZCCHC7	0.8	8.65	0.61	2.19e-14	Schizophrenia;
TGCT	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg25703541	chr22:24373054	LOC391322	-0.61	-5.86	-0.47	3.88e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2288278	0.601	rs4793564	chr17:46599404	C/G	cg25032089	chr17:46643351	HOXB3	-0.42	-5.01	-0.41	1.86e-6	Hand grip strength;
TGCT	cis	rs727563	0.555	rs5751136	chr22:42075581	T/A	cg17554472	chr22:41940697	POLR3H	0.49	5.09	0.42	1.31e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg11764359	chr7:65958608	NA	0.61	5.53	0.44	1.79e-7	Aortic root size;
TGCT	cis	rs62244186	0.541	rs3804583	chr3:44884647	G/T	cg11003573	chr3:44754125	ZNF502	-0.45	-5.13	-0.42	1.1e-6	Depressive symptoms;
TGCT	cis	rs35306767	0.715	rs17221463	chr10:1038040	T/C	cg26597838	chr10:835615	NA	0.63	6.97	0.53	1.62e-10	Eosinophil percentage of granulocytes;
TGCT	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg06873352	chr17:61820015	STRADA	0.55	6.13	0.48	1.09e-8	Prudent dietary pattern;
TGCT	cis	rs4851266	1.000	rs4851267	chr2:100824104	G/A	cg07810366	chr2:100720526	AFF3	-0.41	-5.82	-0.46	4.72e-8	Educational attainment;
TGCT	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg09060608	chr5:178986726	RUFY1	0.61	7.14	0.54	6.87e-11	Lung cancer;
TGCT	cis	rs62244186	0.659	rs56231820	chr3:44530329	C/T	cg15687855	chr3:44754131	ZNF502	-0.43	-5.25	-0.43	6.25e-7	Depressive symptoms;
TGCT	cis	rs425277	0.958	rs626479	chr1:2110260	A/G	cg03732007	chr1:2071316	PRKCZ	-0.24	-5.15	-0.42	9.75e-7	Height;
TGCT	cis	rs904251	0.523	rs9369005	chr6:37483109	A/G	cg25019722	chr6:37503610	NA	-0.51	-7.81	-0.57	2.06e-12	Cognitive performance;
TGCT	cis	rs1857353	1.000	rs58890548	chr1:75887154	C/T	cg11838876	chr1:75668600	SLC44A5	-0.51	-4.81	-0.4	4.23e-6	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs2455799	0.613	rs11128760	chr3:15873407	A/G	cg16303742	chr3:15540471	COLQ	-0.25	-4.74	-0.39	5.76e-6	Mean platelet volume;
TGCT	cis	rs9807989	0.507	rs7581119	chr2:103049865	G/A	cg03938978	chr2:103052716	IL18RAP	0.27	5.41	0.44	3.17e-7	Asthma;
TGCT	cis	rs12497850	0.931	rs4974087	chr3:48919232	A/G	cg05785598	chr3:49045655	WDR6	0.36	4.75	0.39	5.46e-6	Parkinson's disease;
TGCT	cis	rs2688608	0.620	rs12253408	chr10:75495956	G/T	cg15838173	chr10:75533400	FUT11	-0.31	-5.02	-0.41	1.73e-6	Inflammatory bowel disease;
TGCT	trans	rs34421088	0.560	rs2618434	chr8:11398865	A/G	cg15556689	chr8:8085844	FLJ10661	-0.75	-7.08	-0.54	9.46e-11	Neuroticism;
TGCT	cis	rs4595586	0.545	rs2388176	chr12:39372357	G/A	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs6988636	1.000	rs11988157	chr8:124194740	A/G	cg23067535	chr8:124195133	FAM83A	0.35	5.45	0.44	2.6e-7	Urinary uromodulin levels;
TGCT	cis	rs319204	0.918	rs2963080	chr5:146261089	C/T	cg25021259	chr5:146258546	PPP2R2B	0.38	4.66	0.39	7.94e-6	Schizophrenia;
TGCT	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2153535	0.580	rs1932282	chr6:8477330	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs9467773	1.000	rs6930120	chr6:26555484	A/G	cg15659132	chr6:26577336	NA	0.9	13.19	0.76	2.26e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs68170813	0.559	rs12536485	chr7:106978005	T/C	cg02696742	chr7:106810147	HBP1	-0.68	-5.64	-0.45	1.09e-7	Coronary artery disease;
TGCT	cis	rs68170813	0.559	rs6947675	chr7:106817184	T/C	cg02696742	chr7:106810147	HBP1	-0.72	-6.28	-0.49	5.29e-9	Coronary artery disease;
TGCT	cis	rs422249	0.504	rs174538	chr11:61560081	G/A	cg01500311	chr11:61656094	FADS3	-0.32	-5.24	-0.43	6.64e-7	Trans fatty acid levels;
TGCT	cis	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg26116260	chr4:7069785	GRPEL1	1.08	10.43	0.68	1.12e-18	Monocyte percentage of white cells;
TGCT	cis	rs10504229	1.000	rs59843034	chr8:58195756	T/G	cg22535103	chr8:58192502	C8orf71	-0.39	-4.62	-0.38	9.61e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs861020	0.630	rs685248	chr1:210008367	C/G	cg05527609	chr1:210001259	C1orf107	0.85	7.37	0.55	2.05e-11	Orofacial clefts;
TGCT	cis	rs9911578	0.935	rs304261	chr17:56813782	A/G	cg12560992	chr17:57184187	TRIM37	0.76	9.34	0.64	4.88e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs317865	0.737	rs73234668	chr4:16240306	T/C	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.74	4.48	0.37	1.68e-5	Kidney disease (early stage) in type 1 diabetes;
TGCT	cis	rs7528419	0.591	rs4970837	chr1:109822008	G/T	cg00908766	chr1:109817496	CELSR2	0.45	4.59	0.38	1.06e-5	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
TGCT	cis	rs35883536	0.548	rs3176860	chr1:101187219	A/G	cg06223162	chr1:101003688	GPR88	0.34	5.49	0.44	2.2e-7	Monocyte count;
TGCT	cis	rs10823500	0.777	rs10762348	chr10:71952322	C/A	cg04118878	chr10:71993077	PPA1	0.59	5.41	0.44	3.15e-7	Blood protein levels;
TGCT	cis	rs10465746	0.967	rs1475263	chr1:84339497	A/T	cg10977910	chr1:84465055	TTLL7	0.63	6.19	0.49	8.08e-9	Obesity-related traits;
TGCT	cis	rs6460942	1.000	rs17274870	chr7:12406221	G/T	cg06484146	chr7:12443880	VWDE	-0.57	-5.34	-0.43	4.36e-7	Coronary artery disease;
TGCT	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg22166914	chr1:53195759	ZYG11B	0.39	6.32	0.49	4.39e-9	Monocyte count;
TGCT	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg09517075	chr8:22133004	PIWIL2	0.25	4.97	0.41	2.21e-6	Hypertriglyceridemia;
TGCT	cis	rs57590327	0.555	rs13062054	chr3:81833906	A/G	cg07356753	chr3:81810745	GBE1	-0.73	-6.73	-0.52	5.57e-10	Extraversion;
TGCT	trans	rs1814175	0.781	rs1851872	chr11:50009770	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.26	-0.55	3.77e-11	Height;
TGCT	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg09436375	chr6:42928200	GNMT	-0.42	-5.41	-0.44	3.16e-7	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs7010267	0.902	rs4242592	chr8:119968975	T/G	cg17171407	chr8:119960777	TNFRSF11B	0.33	6.26	0.49	5.67e-9	Total body bone mineral density (age 45-60);
TGCT	cis	rs76419734	0.718	rs11730660	chr4:106800379	A/C	cg24545054	chr4:106630052	GSTCD;INTS12	1.01	4.61	0.38	9.71e-6	Post bronchodilator FEV1;
TGCT	cis	rs3733585	0.699	rs6834893	chr4:9959123	C/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.67	-0.51	7.44e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg09359103	chr1:154839909	KCNN3	-0.63	-12.14	-0.74	7.75e-23	Prostate cancer;
TGCT	cis	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg18252515	chr7:66147081	NA	-1.09	-7.16	-0.54	6.39e-11	Diabetic kidney disease;
TGCT	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	5.09	0.42	1.26e-6	Height;
TGCT	cis	rs4332037	0.539	rs11763750	chr7:2080114	G/A	cg25834613	chr7:1915315	MAD1L1	-0.51	-4.98	-0.41	2.11e-6	Bipolar disorder;
TGCT	cis	rs11718455	0.960	rs1852036	chr3:44003862	C/T	cg08738300	chr3:44038990	NA	0.87	6.61	0.51	1.02e-9	Coronary artery disease;
TGCT	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg11764359	chr7:65958608	NA	-0.57	-5.25	-0.43	6.43e-7	Aortic root size;
TGCT	cis	rs478304	0.651	rs948493	chr11:65552154	C/T	cg10518572	chr11:65560635	OVOL1	-0.24	-4.44	-0.37	1.98e-5	Acne (severe);
TGCT	cis	rs7662987	0.517	rs2851263	chr4:100030354	A/G	cg12011299	chr4:100065546	ADH4	0.39	4.81	0.4	4.36e-6	Smoking initiation;
TGCT	cis	rs926938	0.584	rs2798663	chr1:115363582	G/A	cg12756093	chr1:115239321	AMPD1	0.42	6.0	0.47	2.04e-8	Autism;
TGCT	cis	rs2046867	0.908	rs11927166	chr3:72795149	C/G	cg25664220	chr3:72788482	NA	-0.56	-7.15	-0.54	6.59e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	trans	rs2469997	0.800	rs2447177	chr8:120356431	A/G	cg01792902	chr3:178864926	PIK3CA	0.84	6.81	0.52	3.74e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs9906944	0.898	rs9909861	chr17:47079416	C/A	cg07075026	chr17:47091521	IGF2BP1	-0.43	-4.8	-0.4	4.47e-6	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs1525293	0.714	rs13227328	chr7:70500643	C/T	cg21135135	chr7:70597687	WBSCR17	0.54	4.96	0.41	2.23e-6	Colonoscopy-negative controls vs population controls;Major depressive disorder;
TGCT	cis	rs950169	0.544	rs12913702	chr15:85153184	G/A	cg12863693	chr15:85201151	NMB	0.41	4.88	0.4	3.26e-6	Schizophrenia;
TGCT	cis	rs854765	0.893	rs712265	chr17:18008447	G/A	cg04398451	chr17:18023971	MYO15A	0.3	4.79	0.39	4.75e-6	Total body bone mineral density;
TGCT	cis	rs12765878	0.967	rs7920217	chr10:105668172	C/T	cg11005552	chr10:105648138	OBFC1	0.44	7.7	0.57	3.69e-12	Coronary artery disease;
TGCT	cis	rs2115630	0.755	rs7169629	chr15:85191274	C/G	cg12501888	chr15:85177176	SCAND2	0.45	4.45	0.37	1.86e-5	P wave terminal force;
TGCT	cis	rs835154	0.845	rs835158	chr5:14873254	C/G	cg14843632	chr5:14870594	ANKH	0.33	4.57	0.38	1.16e-5	Blood metabolite levels;
TGCT	cis	rs6490294	0.904	rs76300790	chr12:112402669	A/T	cg10833066	chr12:111807467	FAM109A	0.35	4.49	0.37	1.58e-5	Mean platelet volume;
TGCT	cis	rs586688	0.625	rs510576	chr1:201654962	G/T	cg14168733	chr1:201708718	NAV1	-0.55	-4.44	-0.37	1.93e-5	Obesity-related traits;
TGCT	cis	rs2239547	0.522	rs2581815	chr3:52982159	C/G	cg11645453	chr3:52864694	ITIH4	0.33	5.42	0.44	2.94e-7	Schizophrenia;
TGCT	cis	rs6547741	0.874	rs28381983	chr2:27804432	T/C	cg27432699	chr2:27873401	GPN1	0.18	4.58	0.38	1.13e-5	Oral cavity cancer;
TGCT	cis	rs9926296	0.581	rs2108838	chr16:89904426	A/G	cg04287289	chr16:89883240	FANCA	0.72	7.39	0.55	1.87e-11	Vitiligo;
TGCT	cis	rs62229266	0.682	rs2835224	chr21:37370030	A/T	cg08632701	chr21:37451849	NA	-0.15	-4.6	-0.38	1.03e-5	Mitral valve prolapse;
TGCT	cis	rs922182	0.617	rs12324438	chr15:64243436	A/C	cg02919090	chr15:64263738	DAPK2	-0.37	-6.84	-0.52	3.19e-10	Blood protein levels;
TGCT	cis	rs6088590	0.603	rs6579186	chr20:33282198	G/C	cg08999081	chr20:33150536	PIGU	0.26	4.88	0.4	3.17e-6	Coronary artery disease;
TGCT	cis	rs6569992	0.500	rs11965249	chr6:135497692	G/C	cg22676075	chr6:135203613	NA	0.75	4.64	0.38	8.82e-6	Red blood cell traits;
TGCT	cis	rs3617	0.625	rs56019197	chr3:52874753	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.48	-4.46	-0.37	1.83e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2963155	0.518	rs72801080	chr5:142751990	T/C	cg17617527	chr5:142782415	NR3C1	0.8	5.78	0.46	5.8e-8	Breast cancer;
TGCT	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg06896619	chr17:61851486	DDX42;CCDC47	-0.52	-4.91	-0.4	2.83e-6	Prudent dietary pattern;
TGCT	cis	rs9467711	0.606	rs12174602	chr6:26372827	C/T	cg16898833	chr6:26189333	HIST1H4D	1.13	5.38	0.43	3.63e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs3806843	0.966	rs2563265	chr5:140137005	C/T	cg19875535	chr5:140030758	IK	-0.35	-5.89	-0.47	3.46e-8	Depressive symptoms (multi-trait analysis);
TGCT	trans	rs1379326	1.000	rs1379326	chr8:4617810	C/T	cg01049870	chr14:95601239	DICER1	-0.22	-7.12	-0.54	7.72e-11	Interstitial lung disease;
TGCT	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg04414720	chr1:150670196	GOLPH3L	0.39	5.04	0.41	1.58e-6	Tonsillectomy;
TGCT	cis	rs9677476	0.863	rs60953838	chr2:232065864	G/C	cg07929768	chr2:232055508	NA	0.31	4.5	0.37	1.53e-5	Food antigen IgG levels;
TGCT	cis	rs13256369	1.000	rs12550762	chr8:8576535	T/A	cg06671706	chr8:8559999	CLDN23	0.35	4.7	0.39	6.89e-6	Obesity-related traits;
TGCT	cis	rs7647973	1.000	rs62259944	chr3:49430883	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.58	-4.58	-0.38	1.11e-5	Menarche (age at onset);
TGCT	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs12291225	0.535	rs16930126	chr11:14404983	C/T	cg19336497	chr11:14380999	RRAS2	0.32	4.73	0.39	5.99e-6	Sense of smell;
TGCT	cis	rs78456975	0.506	rs13402886	chr2:1575348	G/A	cg12573674	chr2:1569213	NA	-0.46	-5.2	-0.42	7.88e-7	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs9486719	0.857	rs1157316	chr6:96869710	G/A	cg18709589	chr6:96969512	KIAA0776	0.75	6.3	0.49	4.73e-9	Migraine;Coronary artery disease;
TGCT	cis	rs3118233	1	rs3118233	chr16:68733646	G/C	cg01251360	chr16:68772225	CDH1	0.27	4.54	0.38	1.31e-5	Red cell distribution width;
TGCT	cis	rs4975616	0.869	rs455433	chr5:1336243	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.28	-6.88	-0.53	2.69e-10	Lung cancer;
TGCT	cis	rs4711350	1.000	rs4711350	chr6:33741716	A/G	cg00334056	chr6:33755658	LEMD2	-0.29	-4.65	-0.39	8.32e-6	Schizophrenia;
TGCT	cis	rs231513	0.593	rs11654132	chr17:42149134	G/A	cg26893861	chr17:41843967	DUSP3	0.84	5.02	0.41	1.74e-6	Cognitive function;
TGCT	cis	rs4766566	0.694	rs3843673	chr12:111746499	A/G	cg10833066	chr12:111807467	FAM109A	0.4	7.5	0.56	1.07e-11	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
TGCT	cis	rs587847	0.767	rs4924152	chr15:37665396	T/C	cg00216138	chr15:37171175	LOC145845	0.31	4.45	0.37	1.91e-5	Intraocular pressure;
TGCT	cis	rs4984778	0.750	rs7198064	chr16:1272472	C/T	cg09075268	chr16:1270372	CACNA1H	0.32	4.78	0.39	4.96e-6	Blood protein levels;
TGCT	cis	rs11734570	0.581	rs55958238	chr4:38604331	A/G	cg18361445	chr4:38666374	KLF3;FLJ13197	0.63	5.25	0.43	6.25e-7	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs4595586	0.563	rs2388178	chr12:39364366	T/G	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs992157	0.710	rs12996912	chr2:219110555	A/G	cg00012203	chr2:219082015	ARPC2	0.81	9.98	0.67	1.41e-17	Colorectal cancer;
TGCT	cis	rs10992471	0.702	rs10820967	chr9:95101729	C/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.58	-5.61	-0.45	1.28e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs9393692	0.645	rs766407	chr6:26319534	T/C	cg13736514	chr6:26305472	NA	-0.45	-6.67	-0.51	7.52e-10	Educational attainment;
TGCT	cis	rs10504229	0.679	rs16921606	chr8:58034477	A/C	cg08280861	chr8:58055591	NA	0.34	4.98	0.41	2.12e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg13699009	chr12:122356056	WDR66	0.3	6.21	0.49	7.23e-9	Mean platelet volume;
TGCT	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg16680214	chr1:154839983	KCNN3	-0.36	-7.33	-0.55	2.59e-11	Prostate cancer;
TGCT	cis	rs10509586	0.826	rs58207706	chr10:91899453	C/T	cg25278353	chr10:91717815	NA	0.49	4.67	0.39	7.77e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
TGCT	cis	rs28595532	0.920	rs115334469	chr4:119596194	G/C	cg11846333	chr4:119757529	SEC24D	0.95	4.68	0.39	7.54e-6	Cannabis dependence symptom count;
TGCT	cis	rs709400	0.603	rs2296486	chr14:104003070	A/G	cg12935359	chr14:103987150	CKB	-0.37	-5.54	-0.45	1.73e-7	Body mass index;
TGCT	cis	rs17741873	0.779	rs4746153	chr10:75598282	G/C	cg07699608	chr10:75541558	CHCHD1	0.72	5.15	0.42	1.02e-6	Paclitaxel disposition in epithelial ovarian cancer;
TGCT	cis	rs838147	0.537	rs485186	chr19:49207206	A/G	cg04599840	chr19:48886497	KDELR1	0.22	4.58	0.38	1.14e-5	Dietary macronutrient intake;
TGCT	cis	rs3796352	0.667	rs34860124	chr3:52857778	T/A	cg07884673	chr3:53033167	SFMBT1	0.6	4.94	0.41	2.5e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs3020333	0.755	rs851996	chr6:152016803	C/T	cg22157087	chr6:152012887	ESR1	0.22	5.46	0.44	2.54e-7	Total body bone mineral density;
TGCT	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg11494091	chr17:61959527	GH2	0.61	14.78	0.8	4.02e-29	Prudent dietary pattern;
TGCT	cis	rs1801251	1.000	rs7606090	chr2:233606740	T/C	cg25237894	chr2:233734115	C2orf82	0.31	5.62	0.45	1.21e-7	Coronary artery disease;
TGCT	cis	rs67478160	0.643	rs11160762	chr14:104255083	A/G	cg26031613	chr14:104095156	KLC1	0.64	6.58	0.51	1.2e-9	Schizophrenia;
TGCT	cis	rs7662987	0.517	rs1133485	chr4:100023811	T/A	cg12011299	chr4:100065546	ADH4	0.4	4.82	0.4	4.07e-6	Smoking initiation;
TGCT	cis	rs12188164	0.931	rs115554641	chr5:443236	C/G	cg17553881	chr5:443987	EXOC3;C5orf55	-0.4	-4.71	-0.39	6.42e-6	Cystic fibrosis severity;
TGCT	cis	rs28595532	0.920	rs116795224	chr4:119734570	C/T	cg21605333	chr4:119757512	SEC24D	1.66	8.33	0.6	1.28e-13	Cannabis dependence symptom count;
TGCT	cis	rs7772486	0.738	rs75288066	chr6:146319386	C/A	cg23711669	chr6:146136114	FBXO30	0.84	8.53	0.61	4.35e-14	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg10047753	chr17:41438598	NA	0.69	5.71	0.46	7.78e-8	Menopause (age at onset);
TGCT	cis	rs4654899	1.000	rs2271115	chr1:21295864	C/T	cg01072550	chr1:21505969	NA	-0.5	-7.94	-0.58	1.04e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.63	-0.51	9.04e-10	Alzheimer's disease;
TGCT	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg13665807	chr20:60559372	TAF4	-0.46	-5.0	-0.41	1.92e-6	Body mass index;
TGCT	cis	rs80282103	0.867	rs17155821	chr10:1071701	A/G	cg08668510	chr10:1095578	IDI1	1.17	5.46	0.44	2.53e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs2072499	0.966	rs1060604	chr1:156184268	T/C	cg24450063	chr1:156163899	SLC25A44	1.18	13.56	0.77	2.93e-26	Testicular germ cell tumor;
TGCT	cis	rs7582180	0.568	rs10186134	chr2:100939501	T/A	cg08017756	chr2:100939284	LONRF2	-0.3	-5.0	-0.41	1.93e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2050392	0.767	rs1536833	chr10:30699265	C/T	cg13289132	chr10:30722225	MAP3K8	0.43	5.31	0.43	4.94e-7	Inflammatory bowel disease;
TGCT	cis	rs7528419	0.632	rs11102967	chr1:109817245	C/T	cg00908766	chr1:109817496	CELSR2	0.47	4.79	0.39	4.73e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
TGCT	cis	rs7010267	0.570	rs4305930	chr8:120058021	C/T	cg17171407	chr8:119960777	TNFRSF11B	0.26	4.62	0.38	9.29e-6	Total body bone mineral density (age 45-60);
TGCT	cis	rs734999	0.505	rs10797438	chr1:2540262	C/T	cg18854424	chr1:2615690	NA	0.46	5.36	0.43	4e-7	Ulcerative colitis;
TGCT	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg13342137	chr4:2252803	MXD4	0.17	4.44	0.37	1.94e-5	Obesity-related traits;
TGCT	cis	rs6121246	0.529	rs7261354	chr20:30202414	T/C	cg13852791	chr20:30311386	BCL2L1	0.7	4.68	0.39	7.29e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs7917772	0.503	rs7068535	chr10:104349127	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.8	8.21	0.59	2.44e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9467773	0.596	rs3001369	chr6:26670969	C/T	cg05738196	chr6:26577821	NA	0.89	10.01	0.67	1.22e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs9457247	0.846	rs2757052	chr6:167380174	T/C	cg25258033	chr6:167368657	RNASET2	-0.18	-4.49	-0.37	1.63e-5	Crohn's disease;
TGCT	cis	rs1008375	0.966	rs4698642	chr4:17679174	A/T	cg16339924	chr4:17578868	LAP3	0.52	4.57	0.38	1.16e-5	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg16325326	chr1:53192061	ZYG11B	0.6	6.77	0.52	4.62e-10	Monocyte count;
TGCT	cis	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg18252515	chr7:66147081	NA	1.24	7.65	0.57	4.78e-12	Diabetic kidney disease;
TGCT	cis	rs8084125	0.832	rs62105168	chr18:74944848	T/C	cg05528293	chr18:74961138	GALR1	0.49	4.84	0.4	3.74e-6	Obesity-related traits;
TGCT	cis	rs3782123	0.604	rs11245998	chr11:207462	A/G	cg18336825	chr11:236787	PSMD13;SIRT3	-0.51	-4.6	-0.38	1.01e-5	Glycated hemoglobin levels;Red cell distribution width;
TGCT	cis	rs981844	0.816	rs62325147	chr4:154727568	G/A	cg14289246	chr4:154710475	SFRP2	1.03	9.04	0.63	2.61e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs9303401	0.659	rs36093395	chr17:56957357	C/T	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg25427524	chr10:38739819	LOC399744	-0.4	-8.51	-0.61	4.69e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs826838	0.935	rs1684407	chr12:39127270	C/T	cg13010199	chr12:38710504	ALG10B	-0.63	-5.04	-0.41	1.6e-6	Heart rate;
TGCT	cis	rs12142240	0.659	rs67547686	chr1:46832229	G/C	cg00530320	chr1:46809349	NSUN4	0.29	6.03	0.48	1.71e-8	Menopause (age at onset);
TGCT	cis	rs8103278	0.894	rs74821481	chr19:46320041	G/T	cg14061069	chr19:46274453	DMPK	-0.44	-6.12	-0.48	1.11e-8	Coronary artery disease;
TGCT	cis	rs3096299	0.748	rs3102339	chr16:89442711	C/T	cg06640241	chr16:89574553	SPG7	0.62	5.74	0.46	6.96e-8	Multiple myeloma (IgH translocation);
TGCT	cis	rs7760949	0.925	rs9464420	chr6:13925892	C/T	cg27413430	chr6:13925136	RNF182	0.74	6.93	0.53	2.06e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs910316	1.000	rs7156105	chr14:75541954	C/A	cg23033748	chr14:75592666	NEK9	0.28	4.64	0.38	8.6e-6	Height;
TGCT	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.69	-0.39	7e-6	Prudent dietary pattern;
TGCT	cis	rs7027203	0.663	rs4428726	chr9:96623559	T/G	cg14598338	chr9:96623480	NA	-0.63	-10.08	-0.67	8.11e-18	DNA methylation (variation);
TGCT	cis	rs7582180	0.614	rs4340543	chr2:101005511	G/A	cg14675211	chr2:100938903	LONRF2	0.5	4.81	0.4	4.21e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs250677	1.000	rs36082	chr5:148428844	C/G	cg18129178	chr5:148520854	ABLIM3	-0.4	-5.54	-0.45	1.72e-7	Breast cancer;
TGCT	cis	rs35146811	0.844	rs4729576	chr7:99692594	G/A	cg22906224	chr7:99728672	NA	0.51	4.5	0.37	1.56e-5	Coronary artery disease;
TGCT	cis	rs1670533	1.000	rs6857085	chr4:1095920	C/A	cg20518497	chr4:1046821	NA	0.27	4.46	0.37	1.82e-5	Recombination rate (females);
TGCT	cis	rs7267979	1.000	rs4815409	chr20:25346697	C/A	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs8078723	1.000	rs7214085	chr17:38169095	T/C	cg17467752	chr17:38218738	THRA	0.52	4.93	0.41	2.54e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs7582180	0.577	rs6542942	chr2:100985378	G/T	cg08017756	chr2:100939284	LONRF2	-0.29	-4.62	-0.38	9.62e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7917772	0.503	rs11191320	chr10:104293394	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	8.36	0.6	1.1e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs8062405	0.720	rs9926245	chr16:28555706	T/A	cg09754948	chr16:28834200	ATXN2L	0.63	5.05	0.41	1.52e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs61990749	0.597	rs11623088	chr14:78137735	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	-0.63	-4.62	-0.38	9.31e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs2066819	1.000	rs1802236	chr12:56679751	A/G	cg26714650	chr12:56694279	CS	-1.36	-6.06	-0.48	1.54e-8	Psoriasis vulgaris;
TGCT	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg07507251	chr3:52567010	NT5DC2	0.47	6.6	0.51	1.05e-9	Bipolar disorder;
TGCT	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg03709012	chr19:19516395	GATAD2A	0.74	6.29	0.49	4.89e-9	Tonsillectomy;
TGCT	cis	rs3008870	0.583	rs2147838	chr1:67399466	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.97	8.18	0.59	2.82e-13	Lymphocyte percentage of white cells;
TGCT	cis	rs231513	0.954	rs11654245	chr17:41992650	T/C	cg26893861	chr17:41843967	DUSP3	0.77	5.46	0.44	2.5e-7	Cognitive function;
TGCT	cis	rs1857353	1.000	rs17584320	chr1:75879593	C/T	cg11838876	chr1:75668600	SLC44A5	-0.45	-4.49	-0.37	1.58e-5	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs28595532	0.920	rs115240535	chr4:119745395	G/C	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs3960554	0.808	rs59882870	chr7:75638421	G/A	cg17325771	chr7:75508891	RHBDD2	-0.55	-4.63	-0.38	9.19e-6	Eotaxin levels;
TGCT	cis	rs2594989	0.670	rs9845397	chr3:11470263	C/T	cg00170343	chr3:11313890	ATG7	0.79	5.8	0.46	5.18e-8	Circulating chemerin levels;
TGCT	trans	rs1814175	0.765	rs1794141	chr11:49914135	G/C	cg03929089	chr4:120376271	NA	-0.71	-8.09	-0.59	4.74e-13	Height;
TGCT	cis	rs12681288	0.862	rs2600493	chr8:1024970	A/G	cg06709756	chr8:1339049	NA	-0.23	-4.49	-0.37	1.62e-5	Schizophrenia;
TGCT	cis	rs1697139	0.604	rs874550	chr5:66530945	C/T	cg11553311	chr5:66541588	NA	-0.3	-6.07	-0.48	1.42e-8	Breast cancer;
TGCT	cis	rs7666738	0.830	rs9992391	chr4:98916052	G/A	cg17366294	chr4:99064904	C4orf37	0.69	7.2	0.54	5.03e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6866344	0.570	rs4266420	chr5:178137161	C/G	cg10224037	chr5:178157518	ZNF354A	0.95	9.38	0.64	3.96e-16	Neutrophil percentage of white cells;
TGCT	cis	rs929354	0.772	rs1182362	chr7:157019535	A/G	cg05182265	chr7:156933206	UBE3C	0.4	9.08	0.63	2.11e-15	Body mass index;
TGCT	cis	rs4595586	0.505	rs12827136	chr12:39412790	C/T	cg26384229	chr12:38710491	ALG10B	0.56	4.5	0.37	1.56e-5	Morning vs. evening chronotype;
TGCT	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg26818010	chr10:134567672	INPP5A	-0.38	-5.22	-0.42	7.33e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs2762353	0.904	rs13197601	chr6:25785935	G/A	cg12310025	chr6:25882481	NA	0.52	5.34	0.43	4.19e-7	Blood metabolite levels;
TGCT	cis	rs6430585	0.527	rs1900306	chr2:136416533	G/A	cg07169764	chr2:136633963	MCM6	1.04	9.13	0.63	1.63e-15	Corneal structure;
TGCT	cis	rs1483890	0.723	rs12629229	chr3:69411222	A/G	cg22125112	chr3:69402811	FRMD4B	0.29	4.92	0.4	2.66e-6	Resting heart rate;
TGCT	cis	rs986417	0.901	rs1989477	chr14:61024867	T/C	cg27398547	chr14:60952738	C14orf39	1.42	8.85	0.62	7.44e-15	Gut microbiota (bacterial taxa);
TGCT	cis	rs6988636	1.000	rs16898097	chr8:124195034	G/C	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs992157	0.764	rs2015863	chr2:219185161	C/T	cg00012203	chr2:219082015	ARPC2	-0.75	-6.84	-0.52	3.23e-10	Colorectal cancer;
TGCT	cis	rs1153858	0.621	rs2413769	chr15:45561868	A/C	cg26924012	chr15:45694286	SPATA5L1	1.0	10.41	0.68	1.28e-18	Homoarginine levels;
TGCT	cis	rs3796352	1.000	rs60942590	chr3:53016421	G/A	cg07884673	chr3:53033167	SFMBT1	0.62	6.19	0.49	8.26e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs2204008	0.743	rs2132212	chr12:38039405	G/A	cg26384229	chr12:38710491	ALG10B	0.7	6.14	0.48	1.04e-8	Bladder cancer;
TGCT	cis	rs2180341	0.961	rs7775493	chr6:127615000	C/A	cg24812749	chr6:127587940	RNF146	0.99	7.72	0.57	3.33e-12	Breast cancer;
TGCT	cis	rs12220238	0.915	rs11001027	chr10:76152655	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.9	6.17	0.48	9.08e-9	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs6121246	0.542	rs6059761	chr20:30110522	G/C	cg10886678	chr20:30946050	ASXL1	-0.7	-4.65	-0.39	8.46e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs7192750	0.586	rs4788581	chr16:71967695	T/A	cg06353428	chr16:71660113	MARVELD3	0.77	6.82	0.52	3.61e-10	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs7043114	0.525	rs10739927	chr9:95052081	G/T	cg14631576	chr9:95140430	CENPP	-0.28	-4.65	-0.39	8.23e-6	Height;
TGCT	cis	rs793571	0.536	rs7183336	chr15:58966236	C/T	cg05156742	chr15:59063176	FAM63B	0.54	5.22	0.42	7.16e-7	Schizophrenia;
TGCT	cis	rs8070128	0.600	rs8071238	chr17:17900990	T/C	cg04398451	chr17:18023971	MYO15A	-0.34	-5.39	-0.44	3.34e-7	Total body bone mineral density;
TGCT	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg04267008	chr7:1944627	MAD1L1	-0.35	-4.44	-0.37	2e-5	Bipolar disorder and schizophrenia;
TGCT	cis	rs9583531	0.891	rs7999536	chr13:111382199	G/A	cg24331049	chr13:111365604	ING1	0.76	5.3	0.43	5.03e-7	Coronary artery disease;
TGCT	cis	rs7208859	0.623	rs76633166	chr17:29113365	C/T	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs4689388	0.581	rs4688985	chr4:6285715	A/G	cg14416269	chr4:6271139	WFS1	0.47	5.65	0.45	1.07e-7	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs3617	0.573	rs9850563	chr3:52912214	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	0.5	4.88	0.4	3.15e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs826838	1.000	rs11183941	chr12:38851692	G/C	cg26384229	chr12:38710491	ALG10B	1.06	10.68	0.69	2.84e-19	Heart rate;
TGCT	cis	rs40363	0.671	rs4786425	chr16:3537650	A/G	cg22508957	chr16:3507546	NAT15	-0.51	-4.54	-0.38	1.29e-5	Tuberculosis;
TGCT	cis	rs7809950	0.954	rs3779494	chr7:107250355	G/A	cg23024343	chr7:107201750	COG5	0.33	5.29	0.43	5.36e-7	Coronary artery disease;
TGCT	cis	rs10875595	0.836	rs62378923	chr5:140656398	C/T	cg20560182	chr5:140700478	TAF7	-0.66	-5.06	-0.41	1.49e-6	Pulmonary function decline;
TGCT	cis	rs2120019	0.935	rs34835684	chr15:75331805	T/G	cg11632617	chr15:75315747	PPCDC	-0.3	-4.47	-0.37	1.71e-5	Blood trace element (Zn levels);
TGCT	cis	rs6570726	0.846	rs6899900	chr6:145883873	T/G	cg23711669	chr6:146136114	FBXO30	0.84	8.89	0.62	6.14e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg18252515	chr7:66147081	NA	-1.31	-8.18	-0.59	2.87e-13	Diabetic kidney disease;
TGCT	cis	rs1865760	0.713	rs1130000	chr6:25985396	A/G	cg17042849	chr6:26104293	HIST1H4C	-0.55	-4.8	-0.4	4.4e-6	Height;
TGCT	cis	rs10193935	0.901	rs13426988	chr2:42604081	G/A	cg27598129	chr2:42591480	NA	-0.4	-4.67	-0.39	7.83e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs854765	0.693	rs9915776	chr17:17749056	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.71	-6.75	-0.52	5.19e-10	Total body bone mineral density;
TGCT	cis	rs9952991	0.882	rs2847274	chr18:12777603	T/C	cg23598886	chr18:12777645	NA	0.62	5.9	0.47	3.25e-8	Inflammatory skin disease;
TGCT	cis	rs35306767	0.714	rs12767171	chr10:1084491	A/G	cg26597838	chr10:835615	NA	0.48	5.44	0.44	2.75e-7	Eosinophil percentage of granulocytes;
TGCT	cis	rs12510870	0.599	rs1528917	chr4:74452502	G/C	cg05868023	chr4:75230803	EREG	-0.55	-4.74	-0.39	5.71e-6	Iris color (b* coordinate);
TGCT	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	6.9	0.53	2.41e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs79349575	0.721	rs3744608	chr17:46993233	C/G	cg07967210	chr17:47022446	SNF8	0.44	6.12	0.48	1.13e-8	Type 2 diabetes;
TGCT	cis	rs7731657	0.569	rs12522693	chr5:130195731	G/A	cg08523029	chr5:130500466	HINT1	-0.79	-5.06	-0.41	1.5e-6	Fasting plasma glucose;
TGCT	cis	rs7246657	1.000	rs12709812	chr19:37794850	A/G	cg18154014	chr19:37997991	ZNF793	-0.85	-5.93	-0.47	2.85e-8	Coronary artery calcification;
TGCT	cis	rs2887571	1.000	rs4322451	chr12:1637963	C/T	cg01940102	chr12:1095972	NA	-0.26	-5.05	-0.41	1.52e-6	Bone mineral density;
TGCT	cis	rs6121246	0.559	rs6060950	chr20:30378031	T/C	cg13852791	chr20:30311386	BCL2L1	0.82	8.0	0.58	7.65e-13	Mean corpuscular hemoglobin;
TGCT	cis	rs2180341	0.782	rs6924274	chr6:127721556	T/A	cg24812749	chr6:127587940	RNF146	0.65	5.19	0.42	8.37e-7	Breast cancer;
TGCT	cis	rs1577917	0.771	rs2842613	chr6:86305702	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.63	5.58	0.45	1.43e-7	Response to antipsychotic treatment;
TGCT	cis	rs9473924	0.505	rs2817332	chr6:50848522	T/A	cg14470998	chr6:50812995	TFAP2B	-1.35	-8.53	-0.61	4.26e-14	Body mass index;
TGCT	trans	rs1814175	0.817	rs1988416	chr11:49932324	G/A	cg03929089	chr4:120376271	NA	-0.71	-8.09	-0.59	4.74e-13	Height;
TGCT	trans	rs1005277	0.522	rs9417256	chr10:37976990	A/G	cg17830980	chr10:43048298	ZNF37B	-0.66	-7.47	-0.56	1.22e-11	Extrinsic epigenetic age acceleration;
TGCT	cis	rs3780378	0.967	rs10815144	chr9:5010192	C/T	cg02405213	chr9:5042618	JAK2	-0.56	-7.61	-0.56	5.94e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs4808199	0.948	rs2074301	chr19:19381715	G/A	cg03709012	chr19:19516395	GATAD2A	0.8	6.14	0.48	1.03e-8	Nonalcoholic fatty liver disease;
TGCT	cis	rs9916302	0.851	rs11657899	chr17:37626963	G/A	cg15445000	chr17:37608096	MED1	0.31	4.59	0.38	1.06e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs921968	0.545	rs2433738	chr2:219551036	T/A	cg02176678	chr2:219576539	TTLL4	-0.33	-4.45	-0.37	1.92e-5	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs733175	0.855	rs10018666	chr4:10004805	C/T	cg00071950	chr4:10020882	SLC2A9	0.5	4.58	0.38	1.13e-5	Psychosis and Alzheimer's disease;
TGCT	cis	rs4820539	0.902	rs4822359	chr22:23474972	A/G	cg14186256	chr22:23484241	RTDR1	0.98	12.24	0.74	4.43e-23	Bone mineral density;
TGCT	cis	rs7267979	1.000	rs2482940	chr20:25349830	C/T	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg13206674	chr6:150067644	NUP43	0.52	4.51	0.38	1.5e-5	Lung cancer;
TGCT	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.38	5.06	0.41	1.47e-6	Lymphocyte counts;
TGCT	trans	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg27523141	chr10:43048294	ZNF37B	0.7	8.17	0.59	3.04e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs797680	0.891	rs9432453	chr1:93771629	G/A	cg17826107	chr1:92977322	EVI5	-0.23	-5.1	-0.42	1.24e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	trans	rs3780486	0.846	rs7036812	chr9:33143822	T/C	cg20290983	chr6:43655470	MRPS18A	1.19	14.23	0.79	7.61e-28	IgG glycosylation;
TGCT	cis	rs9611565	0.625	rs12483991	chr22:41935285	A/G	cg06634786	chr22:41940651	POLR3H	-0.81	-8.05	-0.59	5.62e-13	Vitiligo;
TGCT	cis	rs478304	0.580	rs11606947	chr11:65508237	A/C	cg17480646	chr11:65405466	SIPA1	-0.56	-6.87	-0.53	2.74e-10	Acne (severe);
TGCT	cis	rs7666738	0.830	rs2865990	chr4:99067399	C/A	cg17366294	chr4:99064904	C4orf37	0.73	7.45	0.56	1.4e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg08280861	chr8:58055591	NA	0.32	4.49	0.37	1.63e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs3780378	0.840	rs10119004	chr9:5071049	C/T	cg02405213	chr9:5042618	JAK2	-0.58	-8.18	-0.59	2.91e-13	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs7647973	1.000	rs6446262	chr3:49401153	T/C	cg07636037	chr3:49044803	WDR6	0.72	5.72	0.46	7.47e-8	Menarche (age at onset);
TGCT	cis	rs11785400	0.793	rs11785376	chr8:143730412	C/T	cg10596483	chr8:143751796	JRK	0.53	5.21	0.42	7.5e-7	Schizophrenia;
TGCT	cis	rs6540559	0.673	rs17015224	chr1:209968918	G/A	cg21951975	chr1:209979733	IRF6	0.69	5.42	0.44	2.99e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs11690935	0.851	rs6433319	chr2:172830953	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.81	-7.08	-0.54	9.26e-11	Schizophrenia;
TGCT	cis	rs6484504	0.553	rs7113880	chr11:31279557	A/G	cg14844989	chr11:31128820	NA	-0.25	-4.84	-0.4	3.76e-6	Red blood cell count;
TGCT	cis	rs908922	0.651	rs7529157	chr1:152531365	C/A	cg20991723	chr1:152506922	NA	0.45	6.05	0.48	1.6e-8	Hair morphology;
TGCT	cis	rs4711350	0.734	rs4713676	chr6:33722098	G/T	cg13859433	chr6:33739653	LEMD2	0.29	4.55	0.38	1.24e-5	Schizophrenia;
TGCT	cis	rs6714710	0.603	rs13023980	chr2:98502987	T/C	cg26665480	chr2:98280029	ACTR1B	0.64	6.03	0.48	1.71e-8	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs10510102	0.872	rs11498944	chr10:123698263	T/C	cg23691251	chr10:123688108	ATE1	-0.58	-4.58	-0.38	1.11e-5	Breast cancer;
TGCT	cis	rs10207060	0.778	rs6543581	chr2:240702308	C/T	cg24332364	chr2:240308692	HDAC4	-0.14	-4.61	-0.38	9.71e-6	Obesity-related traits;
TGCT	cis	rs698813	0.604	rs4953077	chr2:44481207	C/T	cg00619915	chr2:44497795	NA	-0.25	-5.7	-0.46	8.13e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
TGCT	cis	rs754133	0.891	rs12426399	chr12:54419910	G/T	cg16264616	chr12:54390824	NA	0.33	5.14	0.42	1.02e-6	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;
TGCT	cis	rs11190604	0.767	rs10883477	chr10:102161396	A/G	cg23241863	chr10:102295624	HIF1AN	0.6	4.6	0.38	1.02e-5	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs4824093	0.610	rs73443923	chr22:50285348	C/T	cg03660710	chr22:50631079	TRABD	0.34	4.51	0.38	1.46e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	trans	rs7726839	0.540	rs3749615	chr5:601485	C/T	cg11887960	chr12:57824829	NA	1.18	9.81	0.66	3.7e-17	Obesity-related traits;
TGCT	cis	rs9905704	0.647	rs11650809	chr17:56972741	A/G	cg05425664	chr17:57184151	TRIM37	-0.57	-4.44	-0.37	1.97e-5	Testicular germ cell tumor;
TGCT	cis	rs807669	0.749	rs361787	chr22:19263698	C/T	cg02655711	chr22:19163373	SLC25A1	0.32	6.98	0.53	1.57e-10	Metabolite levels;
TGCT	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg09174653	chr7:1063357	C7orf50;MIR339	-0.23	-4.48	-0.37	1.64e-5	Longevity;Endometriosis;
TGCT	cis	rs7209700	0.547	rs7219925	chr17:45341640	G/C	cg21624342	chr17:45890973	OSBPL7	0.19	4.77	0.39	5.02e-6	IgG glycosylation;
TGCT	cis	rs9467773	0.873	rs9295698	chr6:26566099	T/A	cg05738196	chr6:26577821	NA	0.91	13.19	0.76	2.28e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs2721195	1.000	rs2721195	chr8:145677011	T/C	cg15320075	chr8:145703422	NA	-0.68	-6.82	-0.52	3.52e-10	Age at first birth;
TGCT	cis	rs910316	0.737	rs175072	chr14:75502827	T/C	cg08847533	chr14:75593920	NEK9	-0.82	-8.66	-0.61	2.07e-14	Height;
TGCT	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg11301795	chr4:187892539	NA	-0.3	-4.48	-0.37	1.69e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6540559	0.673	rs17015218	chr1:209967915	A/G	cg22029157	chr1:209979665	IRF6	0.74	5.53	0.44	1.84e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs4494114	0.936	rs9439092	chr1:39375157	T/G	cg25970120	chr1:39325951	RRAGC	-0.6	-6.19	-0.49	8.18e-9	Blood protein levels;
TGCT	cis	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg18188782	chr20:61659543	NA	0.44	5.37	0.43	3.73e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7010267	0.596	rs6984572	chr8:120054168	G/A	cg17171407	chr8:119960777	TNFRSF11B	0.26	4.62	0.38	9.52e-6	Total body bone mineral density (age 45-60);
TGCT	cis	rs4566357	1.000	rs1317770	chr2:227911725	C/T	cg11843606	chr2:227700838	RHBDD1	-0.59	-5.59	-0.45	1.35e-7	Coronary artery disease;
TGCT	cis	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg18188782	chr20:61659543	NA	0.44	5.38	0.43	3.6e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs425277	0.539	rs3128338	chr1:2046786	G/A	cg24578937	chr1:2090814	PRKCZ	-0.24	-5.7	-0.46	8.26e-8	Height;
TGCT	cis	rs4886920	0.563	rs8039011	chr15:78078445	A/G	cg25212270	chr15:78015279	NA	-0.23	-4.87	-0.4	3.36e-6	Neuroticism;
TGCT	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg17554472	chr22:41940697	POLR3H	-0.47	-4.77	-0.39	5.13e-6	Vitiligo;
TGCT	cis	rs73001065	0.636	rs73002960	chr19:19582992	C/T	cg03709012	chr19:19516395	GATAD2A	0.9	4.77	0.39	5.17e-6	LDL cholesterol;
TGCT	cis	rs899997	0.906	rs1994018	chr15:79025584	G/A	cg04896959	chr15:78267971	NA	-0.36	-4.86	-0.4	3.43e-6	Coronary artery disease or large artery stroke;
TGCT	cis	rs16858210	0.647	rs12107414	chr3:183574548	G/C	cg25686905	chr3:183603175	PARL	-0.27	-4.58	-0.38	1.11e-5	Menopause (age at onset);
TGCT	cis	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg18252515	chr7:66147081	NA	-1.17	-7.49	-0.56	1.13e-11	Diabetic kidney disease;
TGCT	cis	rs9733	0.519	rs11800855	chr1:150800995	G/A	cg09365446	chr1:150670422	GOLPH3L	0.32	4.55	0.38	1.25e-5	Tonsillectomy;
TGCT	cis	rs2153535	0.580	rs7743995	chr6:8496212	A/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg12756686	chr19:29218302	NA	0.76	6.49	0.5	1.85e-9	Methadone dose in opioid dependence;
TGCT	cis	rs6500602	0.701	rs8129	chr16:4562351	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.4	5.91	0.47	3.1e-8	Schizophrenia;
TGCT	cis	rs7659604	0.537	rs6815973	chr4:122663430	A/T	cg20573242	chr4:122745356	CCNA2	-0.54	-4.45	-0.37	1.88e-5	Type 2 diabetes;
TGCT	cis	rs28374715	0.578	rs72739630	chr15:41631064	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.9	-14.83	-0.8	2.99e-29	Ulcerative colitis;
TGCT	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg16325326	chr1:53192061	ZYG11B	0.63	7.34	0.55	2.51e-11	Monocyte count;
TGCT	cis	rs908922	0.651	rs10888493	chr1:152503913	G/A	cg20991723	chr1:152506922	NA	0.46	6.28	0.49	5.26e-9	Hair morphology;
TGCT	cis	rs7208859	0.673	rs3764420	chr17:29164154	A/G	cg14008862	chr17:28927542	LRRC37B2	0.71	4.57	0.38	1.16e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs10876993	0.890	rs799575	chr12:58069107	A/G	cg15848620	chr12:58087721	OS9	-0.72	-5.91	-0.47	3.12e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs28374715	0.578	rs17730589	chr15:41600878	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.91	-14.59	-0.79	1.13e-28	Ulcerative colitis;
TGCT	cis	rs4389656	0.857	rs274679	chr5:6751426	A/C	cg10857441	chr5:6722123	POLS	-0.21	-4.55	-0.38	1.27e-5	Coronary artery disease;
TGCT	cis	rs9969804	0.744	rs10117377	chr9:95552437	C/T	cg13940029	chr9:95239186	CENPP;ASPN	-0.16	-4.51	-0.38	1.5e-5	Height;
TGCT	cis	rs447921	0.861	rs72860804	chr17:74413903	G/A	cg09812376	chr17:74270190	QRICH2	-0.46	-4.6	-0.38	1.01e-5	Mitochondrial DNA levels;
TGCT	cis	rs1018836	0.570	rs6471084	chr8:91463666	T/C	cg16814680	chr8:91681699	NA	-0.72	-7.15	-0.54	6.53e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs3743266	0.507	rs56261931	chr15:60731618	C/T	cg18480781	chr15:60294291	NA	0.62	4.88	0.4	3.2e-6	Menarche (age at onset);
TGCT	cis	rs7584330	0.910	rs7606177	chr2:238394913	G/C	cg14458575	chr2:238380390	NA	0.42	6.37	0.5	3.39e-9	Prostate cancer;
TGCT	cis	rs9902453	0.868	rs8066602	chr17:28523085	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	6.9	0.53	2.37e-10	Coffee consumption (cups per day);
TGCT	cis	rs2153535	0.601	rs2327059	chr6:8447071	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.76	0.46	6.39e-8	Motion sickness;
TGCT	cis	rs4888262	0.526	rs7191754	chr16:74610850	G/T	cg01733217	chr16:74700730	RFWD3	0.69	6.99	0.53	1.51e-10	Testicular germ cell tumor;
TGCT	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg10047753	chr17:41438598	NA	0.67	5.95	0.47	2.54e-8	Menopause (age at onset);
TGCT	cis	rs713477	1.000	rs713477	chr14:55904426	C/A	cg23573665	chr14:55907122	TBPL2	-0.28	-4.47	-0.37	1.76e-5	Pediatric bone mineral content (femoral neck);
TGCT	cis	rs7085104	0.700	rs10786712	chr10:104596396	A/G	cg15744005	chr10:104629667	AS3MT	0.43	5.48	0.44	2.26e-7	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs586688	0.625	rs602668	chr1:201657709	A/G	cg07139329	chr1:201708558	NAV1	0.5	5.37	0.43	3.76e-7	Obesity-related traits;
TGCT	cis	rs7666738	0.830	rs4392515	chr4:98957431	A/G	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7255045	0.788	rs7250751	chr19:12962648	A/G	cg06537894	chr19:12978706	MAST1	-0.49	-4.48	-0.37	1.69e-5	Mean corpuscular volume;
TGCT	cis	rs9611565	0.546	rs739134	chr22:42089623	T/C	cg06481639	chr22:41940642	POLR3H	0.73	6.62	0.51	9.76e-10	Vitiligo;
TGCT	cis	rs832540	0.629	rs10055224	chr5:56081201	C/T	cg24531977	chr5:56204891	C5orf35	0.5	5.08	0.42	1.34e-6	Coronary artery disease;
TGCT	cis	rs3125734	0.633	rs10740068	chr10:63982254	A/C	cg09941381	chr10:64027924	RTKN2	-0.36	-5.53	-0.44	1.83e-7	Rheumatoid arthritis;
TGCT	cis	rs11190604	0.767	rs872290	chr10:102198879	G/A	cg16342193	chr10:102329863	NA	-0.41	-5.22	-0.42	7.22e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7267979	0.966	rs6107031	chr20:25350677	C/T	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2997447	0.761	rs61776582	chr1:26437262	A/C	cg03844060	chr1:26490628	NA	0.28	4.55	0.38	1.27e-5	QRS complex (12-leadsum);
TGCT	cis	rs7572733	0.555	rs6434954	chr2:198929716	T/C	cg00792783	chr2:198669748	PLCL1	0.58	5.13	0.42	1.09e-6	Dermatomyositis;
TGCT	cis	rs7666738	0.830	rs4699593	chr4:98980628	A/G	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs617219	0.698	rs7706045	chr5:78507910	T/G	cg23514016	chr5:78407564	BHMT	0.35	5.44	0.44	2.78e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs4689388	0.609	rs4688988	chr4:6287456	C/T	cg25554036	chr4:6271136	WFS1	0.58	6.96	0.53	1.77e-10	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs9467773	0.967	rs9295694	chr6:26512994	A/T	cg26531700	chr6:26746687	NA	0.47	4.57	0.38	1.14e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg02725872	chr8:58115012	NA	-0.39	-5.15	-0.42	1.01e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs868036	0.681	rs28626095	chr15:68066729	T/C	cg05925327	chr15:68127851	NA	-0.5	-4.86	-0.4	3.43e-6	Restless legs syndrome;
TGCT	cis	rs35000415	0.688	rs17340542	chr7:128720045	C/T	cg06242719	chr7:129414860	MIR183;MIR96	0.3	4.58	0.38	1.1e-5	Systemic lupus erythematosus;
TGCT	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	5.59	0.45	1.39e-7	Mean platelet volume;
TGCT	cis	rs9796	0.621	rs557864	chr15:41471358	T/C	cg18705301	chr15:41695430	NDUFAF1	0.52	7.17	0.54	5.94e-11	Menopause (age at onset);
TGCT	cis	rs6674970	1.000	rs61819219	chr1:151084375	C/G	cg00003202	chr1:151319512	RFX5	-0.51	-4.46	-0.37	1.84e-5	Childhood ear infection;
TGCT	cis	rs2933343	1.000	rs1680795	chr3:128620388	T/C	cg11901034	chr3:128598214	ACAD9	-0.63	-5.13	-0.42	1.08e-6	IgG glycosylation;
TGCT	cis	rs9381040	0.748	rs9357348	chr6:41154232	A/G	cg03526776	chr6:41159608	TREML2	0.29	6.17	0.48	9.01e-9	Alzheimer's disease (late onset);
TGCT	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg07747251	chr5:1868357	NA	0.39	5.11	0.42	1.19e-6	Cardiovascular disease risk factors;
TGCT	cis	rs2075371	0.932	rs1862052	chr7:133981227	G/A	cg11752832	chr7:134001865	SLC35B4	0.67	5.95	0.47	2.54e-8	Mean platelet volume;
TGCT	cis	rs3749237	0.595	rs12489092	chr3:49550914	G/C	cg07636037	chr3:49044803	WDR6	0.62	5.83	0.46	4.59e-8	Resting heart rate;
TGCT	cis	rs9894429	0.789	rs35887231	chr17:79587126	G/A	cg21028142	chr17:79581711	NPLOC4	0.3	7.03	0.53	1.2e-10	Eye color traits;
TGCT	cis	rs2228479	1.000	rs62052180	chr16:89963289	C/G	cg06558623	chr16:89946397	TCF25	0.57	6.89	0.53	2.56e-10	Skin colour saturation;
TGCT	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg08509172	chr19:19383838	TM6SF2	0.35	4.69	0.39	7.2e-6	Tonsillectomy;
TGCT	cis	rs67311347	1.000	rs67311347	chr3:40533243	G/A	cg13683864	chr3:40499215	RPL14	-1.16	-10.84	-0.7	1.13e-19	Renal cell carcinoma;
TGCT	cis	rs912057	0.609	rs1294431	chr6:6745003	G/C	cg06612196	chr6:6737390	NA	0.47	6.65	0.51	8.22e-10	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.11	13.91	0.78	4.47e-27	Height;
TGCT	cis	rs6988636	1.000	rs62521841	chr8:124194625	G/A	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg11494091	chr17:61959527	GH2	0.61	14.49	0.79	1.92e-28	Prudent dietary pattern;
TGCT	cis	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg08564027	chr20:61660810	NA	0.38	7.08	0.54	9.36e-11	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg05872129	chr22:39784769	NA	-1.01	-11.09	-0.71	2.82e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs8017423	0.647	rs12883000	chr14:90820557	G/A	cg04374321	chr14:90722782	PSMC1	-0.56	-5.62	-0.45	1.19e-7	Mortality in heart failure;
TGCT	cis	rs7113874	0.569	rs10840095	chr11:8627975	G/T	cg14521421	chr11:8862019	ST5	-0.3	-4.61	-0.38	1e-5	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs2288073	0.965	rs6545338	chr2:24422156	C/T	cg05570707	chr2:24270316	C2orf44	-0.5	-4.47	-0.37	1.72e-5	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs9372498	0.908	rs4551203	chr6:118693502	G/A	cg18833306	chr6:118973337	C6orf204	-0.61	-4.81	-0.4	4.28e-6	Diastolic blood pressure;
TGCT	cis	rs4822044	0.680	rs8138780	chr22:42097462	A/T	cg06481639	chr22:41940642	POLR3H	0.73	6.57	0.51	1.27e-9	Cannabis dependence symptom count;
TGCT	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.42	4.57	0.38	1.15e-5	Lymphocyte counts;
TGCT	cis	rs12142240	0.698	rs41294456	chr1:46809782	T/C	cg00530320	chr1:46809349	NSUN4	0.29	5.88	0.47	3.63e-8	Menopause (age at onset);
TGCT	cis	rs7267979	0.586	rs6083776	chr20:25186116	G/A	cg03522245	chr20:25566470	NINL	0.5	5.24	0.43	6.66e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs561341	1.000	rs521919	chr17:30298039	G/T	cg20587970	chr11:113659929	NA	-1.02	-11.06	-0.7	3.39e-20	Hip circumference adjusted for BMI;
TGCT	cis	rs7666738	0.830	rs34164616	chr4:99015251	G/A	cg17366294	chr4:99064904	C4orf37	0.68	7.04	0.53	1.17e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7635838	0.617	rs346076	chr3:11292682	A/G	cg00170343	chr3:11313890	ATG7	-0.66	-6.69	-0.51	7.01e-10	HDL cholesterol;
TGCT	cis	rs644799	0.930	rs587123	chr11:95560539	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.82	8.63	0.61	2.52e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg27436995	chr16:743998	FBXL16	-0.47	-5.12	-0.42	1.12e-6	Height;
TGCT	cis	rs13191362	1.000	rs34697913	chr6:163000187	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs694419	0.602	rs9944724	chr18:60184611	T/G	cg13506219	chr18:60193840	ZCCHC2	-0.54	-4.9	-0.4	2.89e-6	Serum albumin level;
TGCT	cis	rs12580194	0.593	rs7485979	chr12:55789043	A/T	cg10672482	chr12:55725839	OR6C3	0.49	4.47	0.37	1.71e-5	Cancer;
TGCT	cis	rs61990749	0.597	rs2299930	chr14:78163722	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.6	-4.45	-0.37	1.88e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs28785552	0.897	rs10424736	chr19:53239176	G/A	cg22067481	chr19:53234126	ZNF611	-0.49	-7.05	-0.53	1.1e-10	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs72627509	0.904	rs3796529	chr4:57797414	C/T	cg26694713	chr4:57773883	REST	0.7	6.24	0.49	6.44e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs921943	0.554	rs163132	chr5:78285921	A/G	cg26802063	chr5:78281964	ARSB	0.65	6.23	0.49	6.66e-9	Blood and toenail selenium levels;Blood trace element (Se levels);
TGCT	cis	rs61867294	0.794	rs868009	chr10:106661592	G/A	cg08000847	chr10:105880925	C10orf78	0.56	4.46	0.37	1.82e-5	Schizophrenia;
TGCT	cis	rs1629083	0.901	rs1793150	chr11:118127314	G/A	cg16594165	chr11:118135105	MPZL2	-0.33	-4.59	-0.38	1.08e-5	Lung cancer;
TGCT	cis	rs62244186	0.683	rs6766334	chr3:44567065	T/C	cg21672276	chr3:44754072	ZNF502	-0.44	-4.85	-0.4	3.69e-6	Depressive symptoms;
TGCT	cis	rs2228479	0.850	rs17233567	chr16:89813821	G/A	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg08509172	chr19:19383838	TM6SF2	-0.34	-4.48	-0.37	1.71e-5	Tonsillectomy;
TGCT	cis	rs9916302	0.904	rs801419	chr17:37466327	A/G	cg15445000	chr17:37608096	MED1	-0.35	-5.05	-0.41	1.53e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs892961	0.932	rs7224442	chr17:75413439	A/G	cg05865280	chr17:75406074	SEPT9	0.28	6.86	0.52	2.9e-10	Airflow obstruction;
TGCT	cis	rs4786125	0.512	rs55818804	chr16:6930199	T/C	cg03623568	chr16:6915990	A2BP1	-0.4	-5.63	-0.45	1.13e-7	Heart rate variability traits (SDNN);
TGCT	cis	rs6429082	0.818	rs704722	chr1:235669988	G/A	cg26050004	chr1:235667680	B3GALNT2	0.58	5.16	0.42	9.46e-7	Adiposity;
TGCT	cis	rs10875746	0.859	rs3782910	chr12:48483507	T/C	cg20731937	chr12:48336164	NA	0.62	4.95	0.41	2.36e-6	Longevity (90 years and older);
TGCT	cis	rs1023500	0.551	rs2854837	chr22:42458481	G/A	cg15557168	chr22:42548783	NA	-0.2	-5.17	-0.42	9.05e-7	Schizophrenia;
TGCT	cis	rs1488864	1.000	rs1812173	chr11:6342018	T/G	cg12755421	chr11:6342214	PRKCDBP	-0.57	-4.6	-0.38	1.02e-5	Smooth-surface caries;
TGCT	cis	rs1937680	0.657	rs2339888	chr10:53634357	T/C	cg13719243	chr10:52750743	PRKG1	0.34	4.69	0.39	7.06e-6	Breast cancer;
TGCT	cis	rs2455799	0.559	rs6442552	chr3:15922740	T/C	cg12172478	chr3:16357591	RFTN1	-0.36	-5.3	-0.43	5.07e-7	Mean platelet volume;
TGCT	cis	rs736408	0.812	rs2240920	chr3:52831009	A/G	cg07507251	chr3:52567010	NT5DC2	-0.42	-5.48	-0.44	2.24e-7	Bipolar disorder;
TGCT	cis	rs1577917	0.682	rs6935918	chr6:86283575	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.52	4.65	0.39	8.31e-6	Response to antipsychotic treatment;
TGCT	cis	rs7216064	1.000	rs60432293	chr17:65860407	T/C	cg12091567	chr17:66097778	LOC651250	-0.87	-6.85	-0.52	3.1e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg13409248	chr3:40428643	ENTPD3	0.57	4.53	0.38	1.37e-5	Renal cell carcinoma;
TGCT	cis	rs10193935	0.786	rs10178087	chr2:42409631	C/A	cg27598129	chr2:42591480	NA	-0.39	-5.14	-0.42	1.05e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs56104184	0.775	rs73063505	chr19:49402765	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.73	-9.15	-0.63	1.47e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs9914544	0.545	rs8077775	chr17:18809543	A/G	cg26378065	chr17:18585709	ZNF286B	0.51	4.5	0.37	1.53e-5	Educational attainment (years of education);
TGCT	cis	rs3087591	0.683	rs4368212	chr17:29639263	C/T	cg24425628	chr17:29625626	OMG;NF1	0.4	6.04	0.48	1.69e-8	Hip circumference;
TGCT	cis	rs10465746	0.746	rs12749350	chr1:84456948	T/A	cg10977910	chr1:84465055	TTLL7	0.69	7.04	0.53	1.14e-10	Obesity-related traits;
TGCT	cis	rs3099143	1.000	rs3110379	chr15:77095175	A/G	cg21673338	chr15:77095150	SCAPER	-0.51	-4.91	-0.4	2.85e-6	Recalcitrant atopic dermatitis;
TGCT	cis	rs3776081	0.600	rs758588	chr5:149534730	G/A	cg18424208	chr5:149546337	CDX1	-0.25	-4.53	-0.38	1.37e-5	Blood protein levels;
TGCT	cis	rs3772130	0.961	rs34667636	chr3:121353291	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.55	4.95	0.41	2.35e-6	Cognitive performance;
TGCT	cis	rs6840360	0.904	rs73862064	chr4:152503100	T/A	cg17479576	chr4:152424074	FAM160A1	-0.55	-6.1	-0.48	1.22e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs12500482	0.935	rs2239736	chr4:2438929	T/C	cg08330972	chr4:2403930	ZFYVE28	-0.33	-4.45	-0.37	1.86e-5	Cognitive function;
TGCT	cis	rs1538970	0.962	rs2487442	chr1:45857176	C/G	cg05343316	chr1:45956843	TESK2	-0.71	-5.5	-0.44	2.04e-7	Platelet count;
TGCT	cis	rs9916302	0.904	rs8065963	chr17:37681332	C/T	cg07936489	chr17:37558343	FBXL20	-0.61	-4.92	-0.4	2.69e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7666738	0.724	rs28451676	chr4:98966990	C/T	cg17366294	chr4:99064904	C4orf37	0.74	7.56	0.56	7.81e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10791111	1	rs10791111	chr11:130856099	T/G	cg05962950	chr11:130786565	SNX19	0.71	6.87	0.52	2.8e-10	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg21963583	chr11:68658836	MRPL21	-0.3	-4.85	-0.4	3.64e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs11874712	1.000	rs1800639	chr18:43671240	G/T	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	5.23	0.42	7.11e-7	Migraine - clinic-based;
TGCT	cis	rs7829975	0.682	rs7013471	chr8:8687325	A/G	cg08975724	chr8:8085496	FLJ10661	-0.58	-5.18	-0.42	8.73e-7	Mood instability;
TGCT	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg01017244	chr2:74357527	NA	0.37	5.06	0.41	1.48e-6	Gestational age at birth (maternal effect);
TGCT	cis	rs9611565	0.571	rs7364123	chr22:42216326	A/G	cg13695892	chr22:41940480	POLR3H	-0.75	-6.79	-0.52	4.1e-10	Vitiligo;
TGCT	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg00343986	chr7:65444356	GUSB	-0.23	-5.13	-0.42	1.07e-6	Aortic root size;
TGCT	cis	rs1018836	0.770	rs13266461	chr8:91652817	T/C	cg16814680	chr8:91681699	NA	-0.94	-11.83	-0.73	4.43e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9291683	0.546	rs13139055	chr4:10038924	G/T	cg11266682	chr4:10021025	SLC2A9	0.61	7.73	0.57	3.25e-12	Bone mineral density;
TGCT	cis	rs227584	0.663	rs3180912	chr17:42259463	A/G	cg19774624	chr17:42201019	HDAC5	-0.63	-6.55	-0.51	1.35e-9	Bone mineral density (hip);Bone mineral density;
TGCT	cis	rs7267979	0.844	rs8184820	chr20:25250577	C/T	cg16686733	chr20:25566563	NINL	-0.52	-4.9	-0.4	2.98e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4870684	0.509	rs11763804	chr7:57702125	G/C	cg01314568	chr7:57830625	NA	-0.4	-5.01	-0.41	1.83e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs6121246	0.511	rs879982	chr20:30398510	A/G	cg13852791	chr20:30311386	BCL2L1	0.8	7.42	0.55	1.61e-11	Mean corpuscular hemoglobin;
TGCT	cis	rs66573146	0.808	rs56268690	chr4:6923887	C/T	cg05069807	chr4:6945702	TBC1D14	0.29	4.62	0.38	9.44e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs1784581	0.588	rs4131681	chr6:162422167	T/G	cg17173639	chr6:162384350	PARK2	0.4	6.6	0.51	1.08e-9	Itch intensity from mosquito bite;
TGCT	cis	rs1371867	0.875	rs1788187	chr8:101336099	A/G	cg06002616	chr8:101225028	SPAG1	-0.53	-6.21	-0.49	7.16e-9	Atrioventricular conduction;
TGCT	cis	rs78487399	0.710	rs6759383	chr2:43805228	C/T	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.66	4.67	0.39	7.66e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs9303401	0.659	rs1864754	chr17:56688789	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.7	-6.65	-0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs644799	0.931	rs496305	chr11:95567035	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.88	9.59	0.65	1.24e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9527	0.615	rs1556960	chr10:104726673	A/G	cg15744005	chr10:104629667	AS3MT	-0.45	-5.24	-0.43	6.54e-7	Arsenic metabolism;
TGCT	cis	rs1555895	0.543	rs749297	chr10:861837	A/G	cg02193355	chr10:851439	NA	0.24	5.4	0.44	3.29e-7	Survival in rectal cancer;
TGCT	cis	rs2224391	0.590	rs2773312	chr6:5251798	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-1.04	-6.69	-0.51	6.87e-10	Height;
TGCT	cis	rs2204008	0.654	rs1733410	chr12:38132172	G/A	cg26384229	chr12:38710491	ALG10B	-0.58	-5.09	-0.42	1.28e-6	Bladder cancer;
TGCT	cis	rs782590	0.935	rs2627776	chr2:55873301	T/A	cg03859395	chr2:55845619	SMEK2	0.93	11.2	0.71	1.53e-20	Metabolic syndrome;
TGCT	cis	rs11098499	0.820	rs13128602	chr4:120459366	C/T	cg09307838	chr4:120376055	NA	-0.67	-6.25	-0.49	6.01e-9	Corneal astigmatism;
TGCT	cis	rs2197308	0.643	rs1842597	chr12:37862142	C/G	cg26384229	chr12:38710491	ALG10B	-0.68	-6.18	-0.48	8.65e-9	Morning vs. evening chronotype;
TGCT	cis	rs11249608	0.636	rs6888539	chr5:178449010	T/A	cg01312482	chr5:178451176	ZNF879	-0.58	-5.77	-0.46	5.94e-8	Pubertal anthropometrics;
TGCT	cis	rs3806843	0.766	rs801399	chr5:140034844	C/T	cg19875535	chr5:140030758	IK	-0.35	-5.93	-0.47	2.81e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9430161	0.579	rs77578010	chr1:11035758	G/A	cg02454025	chr1:11042201	C1orf127	0.95	10.87	0.7	9.69e-20	Ewing sarcoma;
TGCT	cis	rs9811920	0.809	rs793437	chr3:99559854	C/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.46	5.2	0.42	7.91e-7	Axial length;
TGCT	cis	rs2652822	0.571	rs11858666	chr15:63526239	G/C	cg12855773	chr15:63363890	TPM1	-0.16	-4.62	-0.38	9.42e-6	Metabolic traits;
TGCT	cis	rs2486012	0.579	rs6680338	chr1:44246356	G/A	cg12908607	chr1:44402522	ARTN	-0.77	-4.96	-0.41	2.3e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10782582	0.609	rs12138898	chr1:76375183	G/T	cg03433033	chr1:76189801	ACADM	-0.5	-4.91	-0.4	2.85e-6	Daytime sleep phenotypes;
TGCT	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.56	-5.32	-0.43	4.76e-7	Prudent dietary pattern;
TGCT	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg21226059	chr5:178986404	RUFY1	-0.45	-4.91	-0.4	2.84e-6	Lung cancer;
TGCT	cis	rs4889855	0.614	rs9892081	chr17:78484484	A/C	cg16591659	chr17:78472290	NA	0.34	5.51	0.44	1.99e-7	Fractional excretion of uric acid;
TGCT	cis	rs9311474	0.652	rs352161	chr3:52221849	C/A	cg10802521	chr3:52805072	NEK4	-0.59	-6.41	-0.5	2.81e-9	Electroencephalogram traits;
TGCT	cis	rs1153858	1.000	rs12593230	chr15:45646968	A/T	cg26924012	chr15:45694286	SPATA5L1	1.09	15.16	0.81	5.15e-30	Homoarginine levels;
TGCT	cis	rs6967414	0.685	rs6944332	chr7:6758018	G/A	cg09896999	chr7:6746977	ZNF12	-0.59	-6.54	-0.51	1.45e-9	Hematocrit;Hemoglobin concentration;
TGCT	cis	rs2276314	1.000	rs2298715	chr18:33552425	T/C	cg05985134	chr18:33552581	C18orf21	0.56	4.93	0.4	2.57e-6	Endometriosis;Drug-induced torsades de pointes;
TGCT	cis	rs6964587	1.000	rs7802788	chr7:91736874	A/G	cg17063962	chr7:91808500	NA	0.88	9.58	0.65	1.33e-16	Breast cancer;
TGCT	cis	rs4273100	0.646	rs4924990	chr17:19294824	G/T	cg01534423	chr17:18965556	NA	-0.86	-6.37	-0.5	3.33e-9	Schizophrenia;
TGCT	cis	rs3806843	0.966	rs10036519	chr5:140151701	C/T	cg19875535	chr5:140030758	IK	-0.37	-6.43	-0.5	2.45e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs10838634	1.000	rs59197251	chr11:46844849	C/T	cg18332754	chr11:46939436	LRP4	0.94	4.84	0.4	3.83e-6	Schizophrenia;
TGCT	cis	rs55823223	0.564	rs12103594	chr17:73855279	C/T	cg08125733	chr17:73851984	WBP2	0.86	8.13	0.59	3.76e-13	Psoriasis;
TGCT	cis	rs4319547	0.656	rs10773088	chr12:122828069	A/T	cg05707623	chr12:122985044	ZCCHC8	-0.6	-4.68	-0.39	7.27e-6	Body mass index;
TGCT	cis	rs3820068	0.581	rs72645893	chr1:15930943	C/G	cg05660106	chr1:15850417	CASP9	0.82	8.02	0.58	6.63e-13	Systolic blood pressure;
TGCT	cis	rs864745	0.967	rs849134	chr7:28196222	A/G	cg23620719	chr7:28220237	JAZF1	-0.49	-4.56	-0.38	1.22e-5	Crohn's disease;Type 2 diabetes;
TGCT	cis	rs1403694	0.695	rs10439971	chr3:186434188	C/T	cg12454167	chr3:186435060	KNG1	0.51	8.67	0.61	1.95e-14	Blood protein levels;
TGCT	cis	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg07424592	chr7:64974309	NA	1.32	8.26	0.6	1.86e-13	Diabetic kidney disease;
TGCT	cis	rs4642101	0.618	rs7612317	chr3:12820558	C/T	cg05775895	chr3:12838266	CAND2	0.92	11.11	0.71	2.53e-20	QRS complex (12-leadsum);
TGCT	cis	rs12908161	1.000	rs36033486	chr15:85319692	A/G	cg17173187	chr15:85201210	NMB	0.57	6.4	0.5	2.89e-9	Schizophrenia;
TGCT	cis	rs12220238	1.000	rs11000912	chr10:75948477	A/C	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.06	0.54	1.05e-10	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs9868809	1.000	rs2310997	chr3:48678011	G/C	cg00383909	chr3:49044727	WDR6	0.96	4.76	0.39	5.32e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs9811920	0.638	rs796978	chr3:99564321	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.6	7.02	0.53	1.32e-10	Axial length;
TGCT	cis	rs9677476	0.516	rs3769989	chr2:232011440	C/A	cg27665808	chr2:232055229	NA	0.35	4.43	0.37	2.01e-5	Food antigen IgG levels;
TGCT	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg11494091	chr17:61959527	GH2	0.6	14.48	0.79	1.94e-28	Prudent dietary pattern;
TGCT	cis	rs10089	1.000	rs1559263	chr5:127512873	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	7.4	0.55	1.83e-11	Ileal carcinoids;
TGCT	cis	rs6088580	0.634	rs6087579	chr20:32985155	A/G	cg08999081	chr20:33150536	PIGU	-0.29	-5.65	-0.45	1.02e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs2730245	1.000	rs2730241	chr7:158723014	T/C	cg11984989	chr7:158649758	WDR60	-0.91	-8.06	-0.59	5.48e-13	Height;
TGCT	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg21724239	chr8:58056113	NA	0.4	5.01	0.41	1.8e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10782582	0.609	rs1770882	chr1:76411549	G/A	cg03433033	chr1:76189801	ACADM	-0.52	-5.06	-0.41	1.44e-6	Daytime sleep phenotypes;
TGCT	cis	rs137603	0.603	rs137581	chr22:39677838	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	-0.66	-6.79	-0.52	4.04e-10	Primary biliary cholangitis;
TGCT	cis	rs9549367	0.713	rs3024769	chr13:113825601	A/C	cg00898013	chr13:113819073	PROZ	0.54	7.1	0.54	8.57e-11	Platelet distribution width;
TGCT	trans	rs57221529	0.766	rs12521051	chr5:560440	A/G	cg11887960	chr12:57824829	NA	-1.11	-8.99	-0.63	3.47e-15	Lung disease severity in cystic fibrosis;
TGCT	cis	rs9921338	0.961	rs7187870	chr16:11431919	T/C	cg00044050	chr16:11439710	C16orf75	-0.88	-6.75	-0.52	5.08e-10	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs12681288	0.578	rs73176535	chr8:971916	C/T	cg04851639	chr8:1020857	NA	-0.31	-5.11	-0.42	1.17e-6	Schizophrenia;
TGCT	cis	rs7447593	0.626	rs3812036	chr5:176813404	C/T	cg17509989	chr5:176798049	RGS14	0.63	7.75	0.57	2.85e-12	Urinary electrolytes (magnesium/calcium ratio);
TGCT	cis	rs2204008	0.640	rs2320744	chr12:38162389	A/G	cg26384229	chr12:38710491	ALG10B	0.86	7.65	0.57	4.87e-12	Bladder cancer;
TGCT	cis	rs9653442	0.564	rs2164711	chr2:100775422	G/T	cg22139774	chr2:100720529	AFF3	-0.34	-5.4	-0.44	3.21e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	trans	rs9929218	0.551	rs2296406	chr16:68721340	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.63	8.27	0.6	1.74e-13	Colorectal cancer;
TGCT	cis	rs904251	0.797	rs2776878	chr6:37487273	G/A	cg01843034	chr6:37503916	NA	-0.52	-6.28	-0.49	5.17e-9	Cognitive performance;
TGCT	cis	rs2956278	0.610	rs2929743	chr12:84691484	C/T	cg25678815	chr12:85673915	ALX1	-0.53	-4.76	-0.39	5.4e-6	Depressive symptoms;Depressive symptoms (multi-trait analysis);
TGCT	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg11494091	chr17:61959527	GH2	0.61	14.43	0.79	2.59e-28	Prudent dietary pattern;
TGCT	cis	rs7267979	0.745	rs6132845	chr20:25547767	A/G	cg16686733	chr20:25566563	NINL	0.54	5.32	0.43	4.66e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1005277	0.577	rs4934906	chr10:38015028	C/T	cg25427524	chr10:38739819	LOC399744	-0.34	-6.73	-0.52	5.64e-10	Extrinsic epigenetic age acceleration;
TGCT	cis	rs4631830	0.733	rs4512771	chr10:51540906	C/A	cg10326726	chr10:51549505	MSMB	-0.26	-5.22	-0.42	7.19e-7	Prostate-specific antigen levels;
TGCT	cis	rs8044995	0.563	rs1110572	chr16:68396119	A/G	cg05110241	chr16:68378359	PRMT7	-0.36	-4.44	-0.37	1.93e-5	Schizophrenia;
TGCT	cis	rs9926296	0.586	rs1800359	chr16:89805261	A/G	cg04287289	chr16:89883240	FANCA	0.66	6.56	0.51	1.33e-9	Vitiligo;
TGCT	cis	rs12776158	0.901	rs57028689	chr10:71216345	G/A	cg12610070	chr10:71211762	TSPAN15	-0.55	-4.83	-0.4	3.87e-6	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg08045932	chr20:61659980	NA	-0.48	-8.73	-0.62	1.41e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7923609	1.000	rs4595427	chr10:65012944	A/C	cg08743896	chr10:65200160	JMJD1C	-0.34	-4.54	-0.38	1.32e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs288326	0.561	rs77535302	chr2:183870045	T/A	cg09997497	chr2:183902928	NCKAP1	1.11	4.95	0.41	2.38e-6	Blood protein levels;
TGCT	cis	rs17270561	0.779	rs12210620	chr6:25884785	T/C	cg17691542	chr6:26056736	HIST1H1C	0.87	6.0	0.47	2.02e-8	Iron status biomarkers;
TGCT	cis	rs2235642	0.859	rs9927529	chr16:1619488	C/T	cg11375102	chr16:1583810	IFT140;TMEM204	-0.31	-5.06	-0.41	1.44e-6	Coronary artery disease;
TGCT	cis	rs1971762	0.527	rs1683151	chr12:53946219	C/G	cg16917193	chr12:54089295	NA	-1.05	-10.82	-0.7	1.3e-19	Height;
TGCT	cis	rs40363	0.620	rs1137454	chr16:3533577	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.61	4.51	0.38	1.5e-5	Tuberculosis;
TGCT	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg03303774	chr4:1407052	NA	0.38	6.07	0.48	1.45e-8	Obesity-related traits;
TGCT	cis	rs2836633	1.000	rs11088437	chr21:40053372	A/G	cg05519781	chr21:40033154	ERG	0.69	6.61	0.51	1e-9	Coronary artery disease;
TGCT	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg01341218	chr17:43662625	NA	-1.11	-9.34	-0.64	5.11e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2404602	0.647	rs11072610	chr15:76930805	C/A	cg22467129	chr15:76604101	ETFA	0.47	4.61	0.38	9.77e-6	Blood metabolite levels;
TGCT	cis	rs12477438	0.871	rs13396584	chr2:99611768	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.6	4.61	0.38	1e-5	Chronic sinus infection;
TGCT	cis	rs7089973	0.604	rs10490909	chr10:116593532	C/T	cg03647239	chr10:116582469	FAM160B1	0.61	5.86	0.47	3.92e-8	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs6912958	0.535	rs1753153	chr6:88032834	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.72	7.32	0.55	2.77e-11	Monocyte percentage of white cells;
TGCT	cis	rs1903068	0.853	rs9312655	chr4:56002665	T/C	cg01777861	chr4:56023843	NA	0.53	6.21	0.49	7.2e-9	Endometriosis;
TGCT	cis	rs9902453	0.726	rs3115088	chr17:28031275	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.84	8.39	0.6	9.14e-14	Coffee consumption (cups per day);
TGCT	cis	rs265548	0.646	rs36692	chr19:17906839	C/T	cg04517722	chr19:17905589	B3GNT3	0.46	5.94	0.47	2.62e-8	Tumor biomarkers;
TGCT	cis	rs62244186	0.659	rs12489887	chr3:44547124	A/T	cg15687855	chr3:44754131	ZNF502	-0.43	-5.24	-0.43	6.74e-7	Depressive symptoms;
TGCT	cis	rs1577917	0.771	rs4441928	chr6:86241894	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.64	5.56	0.45	1.55e-7	Response to antipsychotic treatment;
TGCT	cis	rs9549367	0.713	rs2480949	chr13:113853149	T/C	cg18105134	chr13:113819100	PROZ	0.46	8.58	0.61	3.25e-14	Platelet distribution width;
TGCT	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs16854884	0.683	rs10935505	chr3:143777966	T/C	cg06585982	chr3:143692056	C3orf58	0.54	4.54	0.38	1.34e-5	Economic and political preferences (feminism/equality);
TGCT	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg16325326	chr1:53192061	ZYG11B	-0.85	-11.92	-0.73	2.72e-22	Monocyte count;
TGCT	cis	rs4383453	0.539	rs903572	chr3:123101144	A/G	cg04890266	chr3:123102914	ADCY5	-0.48	-7.9	-0.58	1.25e-12	Gestational age at birth (maternal effect);
TGCT	cis	rs896854	0.625	rs4735335	chr8:95973327	G/C	cg09323728	chr8:95962352	TP53INP1	-0.52	-6.6	-0.51	1.05e-9	Type 2 diabetes;
TGCT	cis	rs2188554	0.798	rs111495663	chr7:116984746	A/G	cg09181792	chr7:117119393	CFTR	0.57	4.54	0.38	1.34e-5	Esophageal adenocarcinoma;
TGCT	cis	rs10493773	0.862	rs12075929	chr1:86248138	A/C	cg17807903	chr1:86174739	ZNHIT6	0.39	5.16	0.42	9.7e-7	Urate levels in overweight individuals;
TGCT	cis	rs9300255	0.568	rs1790108	chr12:123636841	A/G	cg00376283	chr12:123451042	ABCB9	0.73	5.64	0.45	1.09e-7	Neutrophil percentage of white cells;
TGCT	cis	rs4888262	0.526	rs7191754	chr16:74610850	G/T	cg05423758	chr16:74752063	FA2H	0.16	4.47	0.37	1.74e-5	Testicular germ cell tumor;
TGCT	cis	rs4925386	0.840	rs6143024	chr20:60914229	A/G	cg06026331	chr20:60912101	LAMA5	0.39	6.51	0.5	1.69e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs11096990	0.892	rs1901404	chr4:39212610	A/C	ch.4.37949012R	chr4:38272617	NA	-0.38	-4.67	-0.39	7.77e-6	Cognitive function;
TGCT	cis	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg22857025	chr5:266934	NA	-0.34	-6.7	-0.52	6.65e-10	Breast cancer;
TGCT	cis	rs28595532	0.841	rs114155681	chr4:119736427	A/G	cg11846333	chr4:119757529	SEC24D	0.93	4.44	0.37	2e-5	Cannabis dependence symptom count;
TGCT	cis	rs7772486	0.846	rs6908063	chr6:146403618	T/C	cg05347473	chr6:146136440	FBXO30	0.55	5.14	0.42	1.05e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2980439	0.556	rs2921059	chr8:8317887	G/T	cg08975724	chr8:8085496	FLJ10661	0.57	5.19	0.42	8.42e-7	Neuroticism;
TGCT	cis	rs931127	0.719	rs7949980	chr11:65445950	T/C	cg27068330	chr11:65405492	SIPA1	-0.63	-6.18	-0.49	8.33e-9	Systemic lupus erythematosus;
TGCT	cis	rs3782455	1.000	rs75235459	chr12:114400776	C/T	cg23502203	chr12:113549970	RASAL1	-0.55	-4.92	-0.4	2.7e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs2067615	0.507	rs11113083	chr12:107073316	C/A	cg15890332	chr12:107067104	RFX4	0.29	5.77	0.46	5.9e-8	Heart rate;
TGCT	cis	rs6025261	0.788	rs6064468	chr20:55505301	A/C	cg04763273	chr20:55502381	NA	0.3	4.6	0.38	1.02e-5	Verbal memory performance (delayed recall level);
TGCT	cis	rs10489202	0.633	rs4657734	chr1:168086743	C/T	cg24449463	chr1:168025552	DCAF6	-0.45	-4.66	-0.39	7.92e-6	Schizophrenia;
TGCT	cis	rs1577917	1.000	rs2324843	chr6:86617501	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.46	-0.44	2.51e-7	Response to antipsychotic treatment;
TGCT	cis	rs6748734	0.948	rs9973366	chr2:241838151	T/C	cg04034577	chr2:241836375	C2orf54	-0.41	-6.31	-0.49	4.55e-9	Urinary metabolites;
TGCT	cis	rs4711350	1.000	rs751727	chr6:33764158	A/G	cg00334056	chr6:33755658	LEMD2	-0.29	-4.56	-0.38	1.22e-5	Schizophrenia;
TGCT	cis	rs28595532	0.920	rs115472708	chr4:119773407	C/T	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs9790314	1.000	rs7653233	chr3:160992033	G/A	cg03342759	chr3:160939853	NMD3	-0.43	-4.55	-0.38	1.25e-5	Morning vs. evening chronotype;
TGCT	cis	rs12579753	0.719	rs4418885	chr12:82275845	A/T	cg07988820	chr12:82153109	PPFIA2	-0.42	-4.44	-0.37	1.93e-5	Resting heart rate;
TGCT	cis	rs1044826	0.642	rs6784684	chr3:139177634	T/C	cg00490450	chr3:139108681	COPB2	0.52	4.53	0.38	1.39e-5	Obesity-related traits;
TGCT	cis	rs4273100	0.646	rs11652784	chr17:19217261	C/T	cg01534423	chr17:18965556	NA	-0.78	-7.04	-0.53	1.16e-10	Schizophrenia;
TGCT	cis	rs2549003	1.000	rs2070724	chr5:131822072	A/G	cg00255919	chr5:131827918	IRF1	0.2	4.65	0.39	8.22e-6	Asthma (sex interaction);
TGCT	cis	rs9297145	0.565	rs6952161	chr7:98733337	A/G	cg05967295	chr7:98741636	SMURF1	0.68	8.83	0.62	8.5e-15	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs453301	0.653	rs2956244	chr8:8885166	A/G	cg15556689	chr8:8085844	FLJ10661	0.82	7.24	0.55	4.15e-11	Joint mobility (Beighton score);
TGCT	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg23302884	chr18:44338147	ST8SIA5	-0.4	-4.57	-0.38	1.18e-5	Personality dimensions;
TGCT	cis	rs4689388	0.890	rs11732208	chr4:6292716	G/C	cg00701064	chr4:6280414	WFS1	0.37	4.72	0.39	6.3e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs3947	1.000	rs1736081	chr8:11702840	T/G	cg02840367	chr8:11660030	FDFT1	0.91	6.7	0.52	6.58e-10	Blood protein levels;
TGCT	cis	rs9399137	0.507	rs12663810	chr6:135289782	G/C	cg24558204	chr6:135376177	HBS1L	0.47	4.78	0.39	4.95e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
TGCT	cis	rs12477438	0.748	rs4851185	chr2:99666497	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-4.88	-0.4	3.17e-6	Chronic sinus infection;
TGCT	cis	rs3096299	0.967	rs2911256	chr16:89485096	G/C	cg02187348	chr16:89574699	SPG7	0.48	4.66	0.39	7.91e-6	Multiple myeloma (IgH translocation);
TGCT	cis	rs7681423	1.000	rs12644950	chr4:155537321	G/A	cg20735720	chr4:155535218	FGG	-0.46	-6.71	-0.52	6.24e-10	Fibrinogen;
TGCT	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg27121462	chr16:89883253	FANCA	0.82	9.11	0.63	1.78e-15	Vitiligo;
TGCT	cis	rs1784581	1.000	rs1784582	chr6:162400712	A/G	cg17173639	chr6:162384350	PARK2	-0.5	-9.17	-0.64	1.26e-15	Itch intensity from mosquito bite;
TGCT	cis	rs9902453	0.967	rs4294864	chr17:28440138	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.74	6.67	0.51	7.74e-10	Coffee consumption (cups per day);
TGCT	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg13770153	chr20:60521292	NA	-0.6	-7.83	-0.58	1.86e-12	Body mass index;
TGCT	cis	rs17331151	0.505	rs71299610	chr3:52641703	T/G	cg24616795	chr3:53032891	SFMBT1	0.58	4.85	0.4	3.59e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs3862260	0.509	rs7552885	chr1:120164966	C/T	cg16322792	chr1:120165303	ZNF697	0.35	8.4	0.6	8.92e-14	Systemic lupus erythematosus;
TGCT	cis	rs9733	0.570	rs951281	chr1:150691122	A/C	cg09365446	chr1:150670422	GOLPH3L	0.3	4.52	0.38	1.4e-5	Tonsillectomy;
TGCT	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg08280861	chr8:58055591	NA	0.36	4.77	0.39	5.18e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg25036284	chr2:26402008	FAM59B	-0.62	-5.06	-0.41	1.47e-6	Gut microbiome composition (summer);
TGCT	cis	rs3733585	0.699	rs6449172	chr4:9966036	A/T	cg11266682	chr4:10021025	SLC2A9	-0.59	-7.87	-0.58	1.53e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs6790105	1	rs6790105	chr3:49393409	C/T	cg07690219	chr3:49449608	TCTA;RHOA	-0.56	-4.6	-0.38	1.02e-5	Childhood ear infection;
TGCT	cis	rs11792861	0.926	rs12683988	chr9:111867290	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.48	4.48	0.37	1.66e-5	Menarche (age at onset);
TGCT	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	16.07	0.82	4.16e-32	Prudent dietary pattern;
TGCT	cis	rs3026101	0.624	rs1806219	chr17:5288073	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	4.63	0.38	9.15e-6	Body mass index;
TGCT	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg21016266	chr12:122356598	WDR66	0.53	6.58	0.51	1.19e-9	Mean corpuscular volume;
TGCT	cis	rs4234284	0.556	rs9968173	chr3:126965437	G/A	cg25436886	chr3:127056972	NA	-0.5	-4.9	-0.4	2.91e-6	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
TGCT	cis	rs77861329	1.000	rs6781635	chr3:52125343	A/G	cg08692210	chr3:52188851	WDR51A	0.86	4.46	0.37	1.79e-5	Macrophage inflammatory protein 1b levels;
TGCT	cis	rs7394190	0.748	rs60632610	chr10:75415677	C/T	cg07699608	chr10:75541558	CHCHD1	0.59	4.46	0.37	1.85e-5	Incident atrial fibrillation;
TGCT	cis	rs453301	0.686	rs7017868	chr8:8873293	G/A	cg06636001	chr8:8085503	FLJ10661	-0.68	-5.63	-0.45	1.13e-7	Joint mobility (Beighton score);
TGCT	cis	rs12497850	0.931	rs6791542	chr3:48787219	A/G	cg05785598	chr3:49045655	WDR6	0.34	4.59	0.38	1.08e-5	Parkinson's disease;
TGCT	cis	rs11031096	0.502	rs1442726	chr11:4094748	G/C	cg18678763	chr11:4115507	RRM1	-0.47	-5.64	-0.45	1.09e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs112790992	1	rs112790992	chr14:105758217	A/C	cg10792982	chr14:105748885	BRF1	0.22	4.53	0.38	1.39e-5	Platelet count;
TGCT	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg23172400	chr8:95962367	TP53INP1	-0.39	-6.52	-0.51	1.57e-9	Type 2 diabetes;
TGCT	cis	rs1150668	0.835	rs1233696	chr6:28143010	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.48	-4.69	-0.39	7.07e-6	Pubertal anthropometrics;
TGCT	cis	rs3820928	0.904	rs1835159	chr2:227764057	A/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-4.67	-0.39	7.79e-6	Pulmonary function;
TGCT	cis	rs3733585	0.699	rs4588456	chr4:9963895	A/T	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.7	-0.57	3.69e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs250677	0.916	rs17109279	chr5:148416581	A/G	cg23229984	chr5:148520753	ABLIM3	0.21	4.81	0.4	4.35e-6	Breast cancer;
TGCT	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg18876405	chr7:65276391	NA	-0.32	-4.93	-0.4	2.63e-6	Aortic root size;
TGCT	cis	rs10992471	0.528	rs4744135	chr9:95251874	A/C	cg13798575	chr9:95087839	CENPP;NOL8	0.52	4.84	0.4	3.81e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs9467773	1.000	rs1321479	chr6:26501897	C/T	cg05738196	chr6:26577821	NA	-0.87	-12.81	-0.75	1.87e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs2075165	0.901	rs1804999	chr1:156219450	A/G	cg16558208	chr1:156270281	VHLL	0.26	4.5	0.37	1.52e-5	Tonsillectomy;
TGCT	cis	rs524281	0.861	rs7941431	chr11:65960157	C/T	cg00563793	chr11:65837595	PACS1	0.6	4.92	0.4	2.72e-6	Electroencephalogram traits;
TGCT	cis	rs10791323	0.572	rs4412766	chr11:133742811	A/C	cg03690763	chr11:133734501	NA	-0.29	-4.89	-0.4	3.02e-6	Childhood ear infection;
TGCT	cis	rs903263	0.965	rs12057561	chr1:84584894	C/T	cg09664975	chr1:84543551	PRKACB	0.49	4.55	0.38	1.25e-5	Breast cancer (male);
TGCT	cis	rs4746818	0.892	rs12437	chr10:70864065	T/C	cg04149295	chr10:70884716	VPS26A	0.72	4.63	0.38	9.03e-6	Left atrial antero-posterior diameter;
TGCT	cis	rs908922	0.676	rs4845784	chr1:152494583	G/C	cg20991723	chr1:152506922	NA	0.46	6.28	0.49	5.25e-9	Hair morphology;
TGCT	cis	rs9467773	0.620	rs2504592	chr6:26640951	C/G	cg02458000	chr6:26745757	NA	0.52	4.86	0.4	3.41e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs11711311	0.955	rs9813630	chr3:113377361	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.8	-7.23	-0.54	4.28e-11	IgG glycosylation;
TGCT	cis	rs28595532	0.841	rs55823625	chr4:119780600	T/A	cg14228332	chr4:119757509	SEC24D	1.26	7.08	0.54	9.26e-11	Cannabis dependence symptom count;
TGCT	cis	rs12765878	0.692	rs10883926	chr10:105608838	G/A	cg11005552	chr10:105648138	OBFC1	0.44	7.07	0.54	9.91e-11	Coronary artery disease;
TGCT	cis	rs986417	0.818	rs1998189	chr14:60974987	A/T	cg27398547	chr14:60952738	C14orf39	1.41	9.11	0.63	1.75e-15	Gut microbiota (bacterial taxa);
TGCT	cis	rs9911578	1.000	rs654778	chr17:56736473	A/C	cg05425664	chr17:57184151	TRIM37	-0.64	-6.48	-0.5	1.99e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs950776	0.506	rs12915366	chr15:78831753	G/A	cg06917634	chr15:78832804	PSMA4	0.95	9.33	0.64	5.42e-16	Sudden cardiac arrest;
TGCT	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.6	-4.99	-0.41	1.97e-6	Lung function (FEV1/FVC);
TGCT	cis	rs7843479	0.828	rs4357289	chr8:21777476	G/A	cg17168535	chr8:21777572	XPO7	0.62	5.57	0.45	1.53e-7	Mean corpuscular volume;
TGCT	cis	rs12048904	0.647	rs7528268	chr1:101329295	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.68	5.67	0.45	9.44e-8	Multiple sclerosis;
TGCT	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg11062466	chr8:58055876	NA	0.38	4.62	0.38	9.5e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs13191362	0.507	rs2849520	chr6:163132038	T/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.61	-5.73	-0.46	7.28e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7296418	0.961	rs1790122	chr12:123606739	G/A	cg00376283	chr12:123451042	ABCB9	0.83	7.54	0.56	8.67e-12	Platelet count;
TGCT	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9427116	0.677	rs9426831	chr1:154609657	A/T	cg17218026	chr1:154582156	ADAR	-0.28	-7.02	-0.53	1.3e-10	Blood protein levels;
TGCT	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg22920501	chr2:26401640	FAM59B	-0.72	-6.38	-0.5	3.19e-9	Gut microbiome composition (summer);
TGCT	cis	rs1483890	0.723	rs6807930	chr3:69411662	C/T	cg22125112	chr3:69402811	FRMD4B	0.29	4.74	0.39	5.85e-6	Resting heart rate;
TGCT	cis	rs1395	0.778	rs2580761	chr2:27426362	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.66	9.16	0.64	1.39e-15	Blood metabolite levels;
TGCT	cis	rs3011225	0.683	rs4660753	chr1:44321044	G/A	cg12908607	chr1:44402522	ARTN	-0.64	-7.74	-0.57	3e-12	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs12188164	0.965	rs41282625	chr5:475626	C/G	cg22025206	chr5:502436	SLC9A3	-0.25	-4.47	-0.37	1.75e-5	Cystic fibrosis severity;
TGCT	cis	rs9473924	0.542	rs9473939	chr6:50877477	T/G	cg14470998	chr6:50812995	TFAP2B	1.35	8.21	0.59	2.48e-13	Body mass index;
TGCT	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg21862992	chr11:68658383	NA	0.44	6.07	0.48	1.42e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	trans	rs10203711	1.000	rs2334022	chr2:239565612	T/C	cg16021909	chr1:248021091	TRIM58	-0.66	-6.64	-0.51	8.76e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9549367	0.789	rs3861720	chr13:113906097	A/G	cg00898013	chr13:113819073	PROZ	-0.4	-5.03	-0.41	1.64e-6	Platelet distribution width;
TGCT	cis	rs7666738	0.830	rs1426667	chr4:98949772	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs4824093	0.544	rs73443957	chr22:50305515	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.96	-5.38	-0.44	3.5e-7	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs10540	1.000	rs61876342	chr11:496193	T/G	cg03934478	chr11:495069	RNH1	0.36	5.84	0.46	4.36e-8	Body mass index;
TGCT	cis	rs427394	0.582	rs274661	chr5:6704848	C/T	cg10857441	chr5:6722123	POLS	-0.29	-6.21	-0.49	7.15e-9	Menopause (age at onset);
TGCT	cis	rs7000551	0.689	rs6996872	chr8:22316753	T/C	cg12081754	chr8:22256438	SLC39A14	0.28	4.53	0.38	1.38e-5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs13424612	0.965	rs4149541	chr2:240957734	G/A	cg26363272	chr2:240904871	NDUFA10	0.28	4.83	0.4	4.01e-6	Odorant perception (isobutyraldehyde);
TGCT	cis	rs62244186	0.606	rs6798590	chr3:44556861	T/A	cg04389838	chr3:44770851	ZNF501	-0.39	-4.88	-0.4	3.23e-6	Depressive symptoms;
TGCT	cis	rs9291683	0.632	rs11734375	chr4:10046298	A/G	cg11266682	chr4:10021025	SLC2A9	0.64	8.75	0.62	1.29e-14	Bone mineral density;
TGCT	cis	rs1357245	0.534	rs6766181	chr3:27100290	A/G	cg03895047	chr3:27114861	NA	-0.3	-4.52	-0.38	1.41e-5	Breast cancer;
TGCT	cis	rs9457247	0.902	rs34560498	chr6:167395862	A/G	cg23791538	chr6:167370224	RNASET2	-0.5	-4.9	-0.4	2.88e-6	Crohn's disease;
TGCT	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7582180	0.627	rs4149517	chr2:101014247	C/A	cg08017756	chr2:100939284	LONRF2	-0.32	-5.19	-0.42	8.38e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs11792861	0.962	rs72607162	chr9:111793719	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.49	4.51	0.38	1.48e-5	Menarche (age at onset);
TGCT	cis	rs910316	0.726	rs61979167	chr14:75663610	C/T	cg08847533	chr14:75593920	NEK9	-0.84	-8.19	-0.59	2.75e-13	Height;
TGCT	cis	rs7584330	0.737	rs1497128	chr2:238369211	A/G	cg08992911	chr2:238395768	MLPH	0.56	4.6	0.38	1.04e-5	Prostate cancer;
TGCT	cis	rs9303401	0.614	rs68100606	chr17:56500898	G/A	cg25039879	chr17:56429692	SUPT4H1	0.5	4.55	0.38	1.27e-5	Cognitive test performance;
TGCT	cis	rs2050392	0.861	rs1042058	chr10:30728101	T/C	cg13289132	chr10:30722225	MAP3K8	-0.42	-5.05	-0.41	1.57e-6	Inflammatory bowel disease;
TGCT	cis	rs9644630	0.672	rs4486225	chr8:19313404	A/G	cg06699216	chr8:19333253	CSGALNACT1	-0.27	-4.79	-0.4	4.69e-6	Oropharynx cancer;
TGCT	cis	rs9419702	0.568	rs11156445	chr10:133542301	T/C	cg20568497	chr10:133558893	NA	0.44	4.84	0.4	3.84e-6	Survival in rectal cancer;
TGCT	cis	rs1670533	1.000	rs633556	chr4:1092405	A/G	cg20518497	chr4:1046821	NA	-0.28	-4.58	-0.38	1.13e-5	Recombination rate (females);
TGCT	cis	rs3780378	1.000	rs7847294	chr9:5097281	A/C	cg02405213	chr9:5042618	JAK2	-0.63	-7.67	-0.57	4.47e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs3820928	0.904	rs10188570	chr2:227792540	G/A	cg11843606	chr2:227700838	RHBDD1	-0.55	-5.0	-0.41	1.93e-6	Pulmonary function;
TGCT	cis	rs986417	1.000	rs6573320	chr14:61092022	A/G	cg27398547	chr14:60952738	C14orf39	1.36	7.38	0.55	1.96e-11	Gut microbiota (bacterial taxa);
TGCT	trans	rs1814175	0.817	rs1319547	chr11:49916705	C/T	cg15704280	chr7:45808275	SEPT13	-0.71	-8.0	-0.58	7.45e-13	Height;
TGCT	cis	rs9611565	0.559	rs13056262	chr22:42081921	A/G	cg06634786	chr22:41940651	POLR3H	0.9	8.74	0.62	1.34e-14	Vitiligo;
TGCT	cis	rs7829975	0.535	rs17683510	chr8:8500724	A/G	cg06636001	chr8:8085503	FLJ10661	0.48	4.45	0.37	1.9e-5	Mood instability;
TGCT	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg11062466	chr8:58055876	NA	0.34	4.67	0.39	7.79e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	16.07	0.82	4.16e-32	Prudent dietary pattern;
TGCT	cis	rs9902453	0.967	rs12449783	chr17:28527653	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	6.56	0.51	1.32e-9	Coffee consumption (cups per day);
TGCT	cis	rs2730245	0.550	rs2657364	chr7:158683825	T/C	cg24397884	chr7:158709396	WDR60	0.37	4.93	0.4	2.63e-6	Height;
TGCT	cis	rs4851254	0.961	rs7596385	chr2:100796598	A/T	cg23118464	chr2:100721844	AFF3	0.58	4.46	0.37	1.84e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs981844	0.712	rs1037649	chr4:154737796	G/A	cg14289246	chr4:154710475	SFRP2	-1.0	-9.32	-0.64	5.46e-16	Response to statins (LDL cholesterol change);
TGCT	cis	rs854765	0.604	rs12948749	chr17:17949802	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.77	-7.91	-0.58	1.24e-12	Total body bone mineral density;
TGCT	cis	rs4919694	1.000	rs12258551	chr10:104767892	C/G	cg04362960	chr10:104952993	NT5C2	1.06	7.05	0.53	1.09e-10	Arsenic metabolism;
TGCT	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg06634786	chr22:41940651	POLR3H	-0.86	-8.32	-0.6	1.34e-13	Vitiligo;
TGCT	cis	rs2710642	0.815	rs6545971	chr2:63074986	A/T	cg17519650	chr2:63277830	OTX1	0.62	5.54	0.45	1.72e-7	LDL cholesterol levels;LDL cholesterol;
TGCT	cis	rs4776059	1.000	rs4776058	chr15:52880263	A/G	cg25063058	chr15:52860530	ARPP19	0.53	4.72	0.39	6.28e-6	Schizophrenia;
TGCT	cis	rs9911578	1.000	rs1267545	chr17:56646909	A/G	cg05425664	chr17:57184151	TRIM37	-0.63	-6.26	-0.49	5.86e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs8141529	0.719	rs2097461	chr22:29191879	T/C	cg02153584	chr22:29168773	CCDC117	0.71	6.08	0.48	1.41e-8	Lymphocyte counts;
TGCT	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg11301795	chr4:187892539	NA	-0.3	-4.48	-0.37	1.69e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs8051431	0.840	rs8050981	chr16:72014470	T/C	cg06353428	chr16:71660113	MARVELD3	0.59	5.02	0.41	1.73e-6	LDL cholesterol levels;
TGCT	cis	rs2120019	0.938	rs2120020	chr15:75316845	T/C	cg17294928	chr15:75287854	SCAMP5	-0.79	-6.27	-0.49	5.46e-9	Blood trace element (Zn levels);
TGCT	cis	rs868036	0.718	rs28675295	chr15:68116400	C/A	cg05925327	chr15:68127851	NA	-0.51	-5.04	-0.41	1.63e-6	Restless legs syndrome;
TGCT	cis	rs7611238	0.583	rs6778652	chr3:195147883	G/A	cg27323046	chr3:195102265	ACAP2	0.39	5.14	0.42	1.05e-6	Body mass index;
TGCT	cis	rs9583531	0.657	rs7337126	chr13:111376788	A/G	cg24331049	chr13:111365604	ING1	0.9	8.96	0.63	4.09e-15	Coronary artery disease;
TGCT	cis	rs6430585	0.527	rs2289959	chr2:136423904	C/T	cg07169764	chr2:136633963	MCM6	0.93	8.19	0.59	2.71e-13	Corneal structure;
TGCT	cis	rs860554	0.529	rs861272	chr1:201269122	A/C	cg01022117	chr1:201258280	PKP1	0.3	4.44	0.37	1.96e-5	Panic disorder;
TGCT	cis	rs12136530	0.774	rs2014772	chr1:19781247	C/T	cg18923740	chr1:19971790	NBL1	0.39	4.78	0.39	4.86e-6	Lead levels in blood;
TGCT	cis	rs655029	0.883	rs662451	chr2:31464974	C/T	cg14018959	chr2:31480232	EHD3	-0.32	-4.45	-0.37	1.9e-5	Mean platelet volume;Platelet distribution width;Platelet count;Plateletcrit;
TGCT	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg03388025	chr16:89894329	SPIRE2	0.47	8.08	0.59	4.81e-13	Vitiligo;
TGCT	cis	rs16958440	0.867	rs75808931	chr18:44693042	C/T	cg17192377	chr18:44677553	HDHD2	0.63	4.7	0.39	6.74e-6	Sitting height ratio;
TGCT	cis	rs4654899	0.733	rs10799677	chr1:21318456	A/C	cg01072550	chr1:21505969	NA	-0.53	-8.46	-0.6	6.37e-14	Superior frontal gyrus grey matter volume;
TGCT	cis	rs9393692	0.902	rs6456711	chr6:26302572	A/C	cg13736514	chr6:26305472	NA	-0.43	-6.34	-0.49	3.98e-9	Educational attainment;
TGCT	cis	rs7698623	0.850	rs6532025	chr4:88777194	A/G	cg02735620	chr4:88950514	PKD2	-0.41	-4.56	-0.38	1.23e-5	Cardiovascular disease risk factors;
TGCT	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg08975724	chr8:8085496	FLJ10661	0.57	5.19	0.42	8.32e-7	Mood instability;
TGCT	cis	rs6484504	0.532	rs11031332	chr11:31278962	T/C	cg14844989	chr11:31128820	NA	-0.25	-4.89	-0.4	3e-6	Red blood cell count;
TGCT	cis	rs6542838	0.641	rs4850890	chr2:99535426	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.59	-5.57	-0.45	1.49e-7	Fear of minor pain;
TGCT	cis	rs1912483	0.505	rs11079772	chr17:45393739	A/C	cg25173405	chr17:45401733	C17orf57	0.41	4.62	0.38	9.35e-6	Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs13148324	chr4:98833616	G/A	cg18180107	chr4:99064573	C4orf37	0.56	5.18	0.42	8.78e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7772486	0.790	rs9399571	chr6:146282061	A/G	cg05347473	chr6:146136440	FBXO30	-0.54	-5.22	-0.42	7.38e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs61931739	0.500	rs7313094	chr12:34457508	T/C	cg06521331	chr12:34319734	NA	-0.28	-4.53	-0.38	1.38e-5	Morning vs. evening chronotype;
TGCT	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg15691649	chr6:25882328	NA	-0.35	-4.62	-0.38	9.55e-6	Blood metabolite levels;
TGCT	cis	rs3771570	0.901	rs35256094	chr2:242439938	A/C	cg21155796	chr2:242212141	HDLBP	0.92	6.63	0.51	9.25e-10	Prostate cancer;
TGCT	cis	rs6964587	0.934	rs4512319	chr7:91733829	G/A	cg17063962	chr7:91808500	NA	0.83	8.55	0.61	3.75e-14	Breast cancer;
TGCT	cis	rs3540	0.960	rs60825716	chr15:90958053	G/A	cg22089800	chr15:90895588	ZNF774	0.76	7.29	0.55	3.22e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg18252515	chr7:66147081	NA	-1.31	-8.18	-0.59	2.87e-13	Diabetic kidney disease;
TGCT	cis	rs1878931	0.582	rs10048083	chr16:3417465	A/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.76	6.34	0.49	3.87e-9	Body mass index (adult);
TGCT	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg09365446	chr1:150670422	GOLPH3L	0.31	4.64	0.38	8.74e-6	Tonsillectomy;
TGCT	cis	rs9814567	0.686	rs1404289	chr3:134358109	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.71	6.28	0.49	5.22e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs35146811	0.700	rs7788301	chr7:99782753	C/G	cg00553149	chr7:99775558	STAG3;GPC2	0.31	4.61	0.38	9.75e-6	Coronary artery disease;
TGCT	cis	rs12579753	0.917	rs7306043	chr12:82191282	G/A	cg07988820	chr12:82153109	PPFIA2	-0.59	-6.19	-0.49	7.93e-9	Resting heart rate;
TGCT	cis	rs4319547	0.695	rs6489002	chr12:122929822	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.71	-5.49	-0.44	2.16e-7	Body mass index;
TGCT	cis	rs1075232	1.000	rs66581165	chr15:31743767	A/G	cg01030201	chr15:31746330	NA	-1.03	-5.61	-0.45	1.27e-7	Survival in colorectal cancer (non-distant metastatic);
TGCT	cis	rs28735056	0.904	rs62103174	chr18:77621048	A/G	cg20368463	chr18:77673604	PQLC1	0.39	4.76	0.39	5.21e-6	Schizophrenia;
TGCT	trans	rs11662586	0.517	rs11662894	chr18:77713591	G/A	cg05926928	chr17:57297772	GDPD1	0.76	7.2	0.54	5.06e-11	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
TGCT	cis	rs77106637	0.789	rs76550717	chr11:72428172	A/G	cg03713592	chr11:72463424	ARAP1	1.1	8.29	0.6	1.56e-13	Type 2 diabetes;
TGCT	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg26338869	chr17:61819248	STRADA	-0.55	-5.08	-0.42	1.34e-6	Prudent dietary pattern;
TGCT	cis	rs3862435	0.518	rs2589960	chr15:90916387	A/G	cg14166756	chr15:90894880	ZNF774	-0.32	-5.07	-0.41	1.4e-6	Response to exercise (triglyceride level interaction);
TGCT	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg18876405	chr7:65276391	NA	-0.37	-5.57	-0.45	1.48e-7	Aortic root size;
TGCT	cis	rs9435341	0.930	rs12408634	chr1:107579540	G/A	cg09367891	chr1:107599246	PRMT6	0.64	5.71	0.46	7.78e-8	Facial morphology (factor 21, depth of nasal alae);
TGCT	cis	rs1552244	0.554	rs59465469	chr3:9990800	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.3	-4.56	-0.38	1.21e-5	Alzheimer's disease;
TGCT	cis	rs7666738	0.830	rs4443295	chr4:99044935	G/A	cg17366294	chr4:99064904	C4orf37	0.73	7.49	0.56	1.11e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10791097	0.629	rs11222361	chr11:130731424	T/G	cg14779329	chr11:130786720	SNX19	0.27	4.89	0.4	3.11e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs7918232	0.505	rs788221	chr10:27442247	G/C	cg14442939	chr10:27389572	ANKRD26	-0.87	-5.69	-0.45	8.7e-8	Breast cancer;
TGCT	cis	rs74417235	0.673	rs6873342	chr5:154051835	A/G	cg08754654	chr5:154026448	NA	-0.49	-4.65	-0.39	8.39e-6	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
TGCT	cis	rs4566357	0.615	rs10198214	chr2:227913314	A/C	cg11843606	chr2:227700838	RHBDD1	-0.54	-5.25	-0.43	6.53e-7	Coronary artery disease;
TGCT	cis	rs765787	0.530	rs3759893	chr15:45542950	G/T	cg24006582	chr15:45444508	DUOX1	-0.25	-5.54	-0.45	1.76e-7	Uric acid levels;
TGCT	cis	rs9611565	0.546	rs5758431	chr22:42109917	A/G	cg03806693	chr22:41940476	POLR3H	1.06	11.92	0.73	2.7e-22	Vitiligo;
TGCT	cis	rs6570726	0.846	rs973856	chr6:145781916	C/T	cg23711669	chr6:146136114	FBXO30	-0.72	-6.96	-0.53	1.78e-10	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs2970818	0.831	rs2970810	chr12:4608103	A/G	cg19263069	chr19:5846552	FUT3	0.33	6.78	0.52	4.26e-10	Phosphorus levels;
TGCT	cis	rs497273	0.534	rs13746	chr12:121201167	C/T	cg02419362	chr12:121203948	SPPL3	0.19	4.52	0.38	1.43e-5	Systemic lupus erythematosus;
TGCT	cis	rs6964587	0.967	rs10279210	chr7:91616891	G/A	cg17063962	chr7:91808500	NA	0.91	9.97	0.67	1.53e-17	Breast cancer;
TGCT	cis	rs3749237	0.555	rs7637665	chr3:49552295	T/C	cg07636037	chr3:49044803	WDR6	0.62	5.83	0.46	4.59e-8	Resting heart rate;
TGCT	cis	rs3733585	0.781	rs6449183	chr4:9970691	C/A	cg11266682	chr4:10021025	SLC2A9	-0.62	-8.54	-0.61	4.06e-14	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs6542838	0.673	rs1949424	chr2:99468341	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.51	4.97	0.41	2.19e-6	Fear of minor pain;
TGCT	cis	rs763121	0.719	rs138699	chr22:39129708	G/A	cg06022373	chr22:39101656	GTPBP1	0.7	5.95	0.47	2.61e-8	Menopause (age at onset);
TGCT	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg22433210	chr17:43662623	NA	-1.0	-7.13	-0.54	7.26e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs11030122	0.547	rs750525	chr11:3948894	G/A	cg18678763	chr11:4115507	RRM1	-0.39	-4.76	-0.39	5.24e-6	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs9303542	0.592	rs34378400	chr17:46589265	A/G	cg25032089	chr17:46643351	HOXB3	0.57	5.74	0.46	6.78e-8	Ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs3091242	0.933	rs9438905	chr1:25764177	A/G	cg00786635	chr1:25594202	NA	0.54	5.72	0.46	7.45e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg10802521	chr3:52805072	NEK4	-0.7	-8.58	-0.61	3.21e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs7208859	0.673	rs73263755	chr17:29198972	A/G	cg18442181	chr17:29233375	C17orf42	-0.78	-4.61	-0.38	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs10197940	0.624	rs6731486	chr2:152410732	C/T	cg19508488	chr2:152266495	RIF1	-0.69	-6.39	-0.5	3.01e-9	Lung cancer;
TGCT	cis	rs4713118	0.699	rs573179	chr6:27849676	C/A	cg18675097	chr6:28227127	NKAPL	-0.35	-4.47	-0.37	1.72e-5	Parkinson's disease;
TGCT	cis	rs78487399	0.908	rs17031079	chr2:43804933	A/C	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.66	4.67	0.39	7.66e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs72700829	0.518	rs72694990	chr1:150223780	G/A	cg03889479	chr1:149224237	NA	-0.74	-4.62	-0.38	9.63e-6	Schizophrenia;
TGCT	cis	rs7666738	0.546	rs10010088	chr4:98655945	C/T	cg05340658	chr4:99064831	C4orf37	0.49	5.29	0.43	5.45e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs986417	0.892	rs8016349	chr14:60798366	A/G	cg27398547	chr14:60952738	C14orf39	-1.55	-6.87	-0.53	2.7e-10	Gut microbiota (bacterial taxa);
TGCT	cis	rs7223966	1.000	rs72848797	chr17:61934664	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	4.62	0.38	9.63e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg23758822	chr17:41437982	NA	0.71	6.8	0.52	3.85e-10	Menopause (age at onset);
TGCT	cis	rs1129187	0.702	rs2395943	chr6:42940673	A/G	cg27588902	chr6:42928151	GNMT	-0.57	-6.87	-0.53	2.76e-10	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs12477438	0.798	rs7606635	chr2:99644782	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-4.62	-0.38	9.47e-6	Chronic sinus infection;
TGCT	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg01341218	chr17:43662625	NA	-1.11	-9.41	-0.65	3.31e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs17331151	0.573	rs3755801	chr3:52865798	G/A	cg15956490	chr3:53032818	SFMBT1	0.45	5.63	0.45	1.13e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs651907	0.514	rs12636047	chr3:101434449	T/C	cg12386194	chr3:101231763	SENP7	0.51	4.9	0.4	2.89e-6	Colorectal cancer;
TGCT	cis	rs8013055	0.846	rs35723046	chr14:105970548	C/T	cg25008857	chr14:105974488	NA	0.27	4.5	0.37	1.57e-5	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs9911578	1.000	rs1494977	chr17:56863064	C/T	cg12560992	chr17:57184187	TRIM37	0.76	9.34	0.64	4.88e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs617219	0.726	rs72764969	chr5:78451409	A/G	cg09550809	chr5:78407562	BHMT	0.41	5.67	0.45	9.4e-8	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg23574427	chr4:122746245	BBS7;CCNA2	-0.35	-5.3	-0.43	5.06e-7	Type 2 diabetes;
TGCT	cis	rs13256369	1.000	rs12550458	chr8:8567832	G/A	cg06671706	chr8:8559999	CLDN23	0.34	4.59	0.38	1.09e-5	Obesity-related traits;
TGCT	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg11247378	chr22:39784982	NA	-0.76	-10.44	-0.68	1.07e-18	Intelligence (multi-trait analysis);
TGCT	cis	rs6540559	0.546	rs7551944	chr1:210029430	G/C	cg21951975	chr1:209979733	IRF6	0.69	5.22	0.42	7.37e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs7010267	0.935	rs6469788	chr8:119952750	A/C	cg17171407	chr8:119960777	TNFRSF11B	0.33	6.2	0.49	7.72e-9	Total body bone mineral density (age 45-60);
TGCT	cis	rs7584330	0.518	rs7561919	chr2:238435241	A/G	cg14458575	chr2:238380390	NA	0.45	4.82	0.4	4.04e-6	Prostate cancer;
TGCT	cis	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg08045932	chr20:61659980	NA	0.48	9.16	0.64	1.36e-15	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs11969893	0.850	rs9485417	chr6:101300038	C/T	cg12253828	chr6:101329408	ASCC3	-1.36	-6.32	-0.49	4.33e-9	Economic and political preferences (immigration/crime);
TGCT	cis	rs11785400	0.793	rs9297969	chr8:143723237	A/G	cg24634471	chr8:143751801	JRK	0.53	5.33	0.43	4.41e-7	Schizophrenia;
TGCT	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg00343986	chr7:65444356	GUSB	0.26	5.96	0.47	2.4e-8	Calcium levels;
TGCT	cis	rs826838	1.000	rs6582619	chr12:38729904	A/G	cg26384229	chr12:38710491	ALG10B	1.08	10.88	0.7	9.18e-20	Heart rate;
TGCT	cis	rs1372520	0.873	rs2737026	chr4:90779823	A/G	cg14346243	chr4:90757452	SNCA	-0.63	-5.28	-0.43	5.7e-7	Neuroticism;
TGCT	cis	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg25427524	chr10:38739819	LOC399744	-0.39	-7.9	-0.58	1.31e-12	Extrinsic epigenetic age acceleration;
TGCT	cis	rs28595532	0.920	rs10018977	chr4:119785229	C/T	cg00700008	chr4:120138107	USP53	0.49	4.48	0.37	1.71e-5	Cannabis dependence symptom count;
TGCT	cis	rs2996428	0.667	rs11578070	chr1:3769871	G/C	cg13057898	chr1:3703894	LRRC47	0.21	4.64	0.38	8.81e-6	Red cell distribution width;
TGCT	cis	rs3820928	0.605	rs6748311	chr2:227792530	T/A	cg11843606	chr2:227700838	RHBDD1	-0.51	-4.84	-0.4	3.86e-6	Pulmonary function;
TGCT	cis	rs2204008	0.712	rs12371182	chr12:38321143	A/C	cg26384229	chr12:38710491	ALG10B	0.83	7.22	0.54	4.62e-11	Bladder cancer;
TGCT	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg23758822	chr17:41437982	NA	0.72	6.81	0.52	3.83e-10	Menopause (age at onset);
TGCT	cis	rs6693567	0.526	rs834239	chr1:150375458	C/A	cg09579323	chr1:150459698	TARS2	0.52	4.64	0.38	8.63e-6	Migraine;
TGCT	cis	rs7666738	0.830	rs1405767	chr4:98965295	T/C	cg17366294	chr4:99064904	C4orf37	0.74	7.56	0.56	7.89e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1348850	0.874	rs1348848	chr2:178358233	A/C	cg22681709	chr2:178499509	PDE11A	0.35	4.62	0.38	9.55e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs4654899	0.655	rs4654883	chr1:21213708	C/T	cg01072550	chr1:21505969	NA	0.55	8.92	0.63	5.11e-15	Superior frontal gyrus grey matter volume;
TGCT	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg02953382	chr22:24373134	LOC391322	0.77	8.01	0.58	7.12e-13	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6921919	0.551	rs13201753	chr6:28331128	A/C	cg18815343	chr6:28367644	ZSCAN12	-0.57	-5.36	-0.43	3.96e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2847281	0.622	rs2847258	chr18:12775963	C/T	cg23598886	chr18:12777645	NA	0.39	4.91	0.4	2.77e-6	C-reactive protein levels;Esophageal cancer (squamous cell);
TGCT	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg10047753	chr17:41438598	NA	0.97	10.04	0.67	1.04e-17	Menopause (age at onset);
TGCT	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg08280861	chr8:58055591	NA	0.39	4.64	0.38	8.72e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1863918	0.575	rs4701057	chr5:178571857	G/A	cg08616760	chr5:178157801	ZNF354A	0.52	4.53	0.38	1.34e-5	Depression in response to interferon-based therapy in chronic hepatitis C;
TGCT	cis	rs11264213	0.591	rs4653157	chr1:36543278	C/T	cg27506609	chr1:36549197	TEKT2	-0.33	-4.88	-0.4	3.15e-6	Schizophrenia;
TGCT	cis	rs7666738	0.830	rs10005173	chr4:98816062	T/C	cg05340658	chr4:99064831	C4orf37	0.51	6.03	0.48	1.76e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7726839	0.574	rs11739866	chr5:636299	C/T	cg16624210	chr5:671434	TPPP	0.42	4.68	0.39	7.38e-6	Obesity-related traits;
TGCT	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg23708337	chr7:1209742	NA	0.6	5.57	0.45	1.53e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs3734729	0.702	rs11155716	chr6:150575200	A/G	cg16439130	chr6:149658548	MAP3K7IP2	0.4	4.79	0.39	4.75e-6	Pulmonary function;Pulmonary function (smoking interaction);
TGCT	cis	rs17376456	0.825	rs10072232	chr5:93398890	G/A	cg25358565	chr5:93447407	FAM172A	0.92	8.38	0.6	9.58e-14	Diabetic retinopathy;
TGCT	cis	rs2404602	0.669	rs1875884	chr15:76638161	C/T	cg22467129	chr15:76604101	ETFA	-0.57	-6.86	-0.52	2.88e-10	Blood metabolite levels;
TGCT	cis	rs2933343	0.553	rs35076317	chr3:128715535	T/C	cg11901034	chr3:128598214	ACAD9	-0.56	-5.2	-0.42	7.83e-7	IgG glycosylation;
TGCT	cis	rs6570726	0.902	rs396681	chr6:145853603	T/C	cg05347473	chr6:146136440	FBXO30	0.48	4.53	0.38	1.34e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs137699	0.959	rs5757631	chr22:39755953	T/C	cg24399712	chr22:39784796	NA	-0.67	-5.99	-0.47	2.08e-8	IgG glycosylation;
TGCT	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg20007245	chr22:24372913	LOC391322	-0.7	-6.9	-0.53	2.38e-10	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9638182	0.614	rs79624003	chr7:73012785	A/G	cg14087351	chr7:73037990	MLXIPL	-0.65	-5.07	-0.41	1.43e-6	Triglycerides;
TGCT	cis	rs10262624	0.504	rs4722255	chr7:23746072	G/T	cg09690326	chr7:23720549	C7orf46	-0.44	-4.72	-0.39	6.27e-6	Schizophrenia;
TGCT	cis	rs6684514	1.000	rs67034206	chr1:156270260	C/T	cg20302342	chr1:156215951	PAQR6	0.34	4.6	0.38	1.01e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs6582630	0.555	rs61932279	chr12:38349096	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-4.51	-0.38	1.5e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg25767906	chr1:53392781	SCP2	0.5	5.85	0.46	4.15e-8	Monocyte count;
TGCT	cis	rs2486288	0.656	rs1706768	chr15:45569443	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.42	-4.65	-0.39	8.49e-6	Glomerular filtration rate;
TGCT	cis	rs11098499	0.954	rs12508504	chr4:120410607	A/C	cg09307838	chr4:120376055	NA	0.68	6.56	0.51	1.31e-9	Corneal astigmatism;
TGCT	trans	rs28735056	0.591	rs2277724	chr18:77694294	C/A	cg05926928	chr17:57297772	GDPD1	-0.68	-6.82	-0.52	3.55e-10	Schizophrenia;
TGCT	cis	rs6893807	1.000	rs2304608	chr5:87962298	C/A	cg24804195	chr5:87968844	LOC645323	0.76	5.64	0.45	1.09e-7	Body mass index;
TGCT	cis	rs11792861	0.591	rs2282206	chr9:111746267	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.65	7.43	0.56	1.54e-11	Menarche (age at onset);
TGCT	cis	rs10883723	0.810	rs17782574	chr10:104279394	G/A	cg05855489	chr10:104503620	C10orf26	-0.58	-5.06	-0.41	1.47e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg10295955	chr4:187884368	NA	0.93	13.76	0.78	9.85e-27	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3008870	0.755	rs3929738	chr1:67397865	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.78	8.29	0.6	1.59e-13	Lymphocyte percentage of white cells;
TGCT	cis	rs3008870	0.755	rs4655660	chr1:67402953	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.78	8.29	0.6	1.59e-13	Lymphocyte percentage of white cells;
TGCT	cis	rs13256369	1.000	rs12545771	chr8:8567977	C/G	cg06671706	chr8:8559999	CLDN23	0.34	4.59	0.38	1.09e-5	Obesity-related traits;
TGCT	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.07	-9.63	-0.65	1.01e-16	Platelet count;
TGCT	cis	rs4975709	0.569	rs4975742	chr5:1858612	T/C	cg14773178	chr5:1868261	NA	0.34	5.49	0.44	2.14e-7	Cardiovascular disease risk factors;
TGCT	cis	rs72781680	0.898	rs72788212	chr2:24087385	G/A	cg08917208	chr2:24149416	ATAD2B	0.77	4.69	0.39	7.06e-6	Lymphocyte counts;
TGCT	cis	rs6754311	0.773	rs309178	chr2:136611624	C/T	cg07169764	chr2:136633963	MCM6	-0.62	-5.74	-0.46	7e-8	Mosquito bite size;
TGCT	cis	rs66573146	0.831	rs6832482	chr4:7023433	A/T	cg01220768	chr4:7056774	TADA2B	0.32	4.43	0.37	2.01e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs752092	1.000	rs7182945	chr15:101784223	C/T	cg19997662	chr15:101784653	CHSY1	-0.31	-5.81	-0.46	4.9e-8	Corneal structure;
TGCT	cis	rs2172802	0.693	rs4860097	chr4:62482723	A/G	cg04118610	chr4:62707027	LPHN3	-0.44	-4.66	-0.39	8.18e-6	Partial epilepsies;
TGCT	cis	rs35264875	0.898	rs72928701	chr11:68861564	C/T	cg02660097	chr11:68866761	NA	0.32	4.61	0.38	9.94e-6	Blond vs. brown hair color;
TGCT	cis	rs7552404	0.924	rs2275378	chr1:76198436	T/C	cg10523679	chr1:76189770	ACADM	0.89	9.62	0.65	1.08e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg01017244	chr2:74357527	NA	0.5	8.09	0.59	4.6e-13	Gestational age at birth (maternal effect);
TGCT	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg16325326	chr1:53192061	ZYG11B	0.6	6.97	0.53	1.68e-10	Monocyte count;
TGCT	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.09	0.54	8.96e-11	Prudent dietary pattern;
TGCT	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg27535305	chr1:53392650	SCP2	-0.29	-5.59	-0.45	1.4e-7	Monocyte count;
TGCT	cis	rs1670533	1.000	rs10031302	chr4:1059664	G/A	cg20887711	chr4:1340912	KIAA1530	0.65	5.14	0.42	1.05e-6	Recombination rate (females);
TGCT	cis	rs6835174	0.730	rs28862337	chr4:5987097	C/T	cg13644262	chr4:6449564	PPP2R2C	-0.34	-4.74	-0.39	5.88e-6	Cannabis use (initiation);
TGCT	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	trans	rs4332037	0.539	rs11982455	chr7:1911458	A/C	cg25206134	chr2:45395956	NA	1.01	7.99	0.58	7.9e-13	Bipolar disorder;
TGCT	cis	rs9467773	0.620	rs2451732	chr6:26622904	A/T	cg09904177	chr6:26538194	HMGN4	-0.68	-6.12	-0.48	1.11e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7714584	1.000	rs7716903	chr5:150258574	C/A	cg22134413	chr5:150180641	NA	0.78	6.12	0.48	1.16e-8	Crohn's disease;
TGCT	cis	rs10791097	0.967	rs1944142	chr11:130717440	C/T	cg12179176	chr11:130786555	SNX19	0.65	6.88	0.53	2.6e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9394169	0.613	rs4713685	chr6:33774525	C/T	cg00334056	chr6:33755658	LEMD2	0.25	4.6	0.38	1.04e-5	Essential tremor;
TGCT	cis	rs1215050	0.740	rs783916	chr4:99026264	A/C	cg05340658	chr4:99064831	C4orf37	-0.43	-5.28	-0.43	5.7e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs950027	0.620	rs1719245	chr15:45623782	T/C	cg26924012	chr15:45694286	SPATA5L1	0.82	9.12	0.63	1.72e-15	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs8051149	0.688	rs12444670	chr16:87870312	C/T	cg01412419	chr16:87856264	NA	0.5	6.06	0.48	1.53e-8	Blood metabolite levels;
TGCT	cis	rs6121246	0.529	rs6060359	chr20:30209740	A/G	cg21427119	chr20:30132790	HM13	-0.43	-6.17	-0.48	8.86e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs6089584	0.546	rs6061980	chr20:60618877	G/A	cg06108461	chr20:60628389	TAF4	-0.42	-5.27	-0.43	5.89e-7	Body mass index;
TGCT	cis	rs11030122	0.673	rs10835508	chr11:4045360	A/T	cg18678763	chr11:4115507	RRM1	-0.47	-5.79	-0.46	5.47e-8	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs752010	0.631	rs4660549	chr1:42088102	A/G	cg06885757	chr1:42089581	HIVEP3	0.32	6.0	0.47	1.97e-8	Lupus nephritis in systemic lupus erythematosus;
TGCT	cis	rs6987853	0.933	rs2356610	chr8:42446238	T/G	cg20539142	chr8:42623718	CHRNA6	-0.2	-4.82	-0.4	4.2e-6	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs903263	1.000	rs2037454	chr1:84645266	G/A	cg09664975	chr1:84543551	PRKACB	0.48	4.6	0.38	1.01e-5	Breast cancer (male);
TGCT	cis	rs4699052	0.928	rs4456958	chr4:104215332	A/G	cg16532752	chr4:104119610	CENPE	-0.56	-5.05	-0.41	1.57e-6	Testicular germ cell tumor;
TGCT	cis	rs858239	0.614	rs10229956	chr7:23402936	C/G	cg05602783	chr7:23145260	KLHL7	0.61	5.43	0.44	2.89e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg19729930	chr2:74357872	NA	0.62	9.05	0.63	2.44e-15	Gestational age at birth (maternal effect);
TGCT	cis	rs4252435	0.520	rs7797908	chr7:142641207	T/C	cg09833174	chr7:143059591	FAM131B	-1.02	-4.65	-0.39	8.26e-6	Cancer;
TGCT	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg05368731	chr17:41323189	NBR1	1.16	13.76	0.78	1.03e-26	Menopause (age at onset);
TGCT	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7772486	0.754	rs9497401	chr6:146051271	T/C	cg13319975	chr6:146136371	FBXO30	0.56	5.0	0.41	1.9e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9644630	1.000	rs9644630	chr8:19370598	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.27	4.6	0.38	1.02e-5	Oropharynx cancer;
TGCT	trans	rs7726839	0.540	rs12520279	chr5:657291	T/C	cg11887960	chr12:57824829	NA	1.16	9.4	0.65	3.51e-16	Obesity-related traits;
TGCT	cis	rs1018836	0.923	rs10956749	chr8:91621573	G/A	cg16814680	chr8:91681699	NA	-0.86	-9.19	-0.64	1.12e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs797680	0.586	rs2281525	chr1:93595306	G/C	cg17826107	chr1:92977322	EVI5	-0.22	-4.61	-0.38	9.71e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs2115630	0.936	rs8033459	chr15:85253258	C/T	cg11189052	chr15:85197271	WDR73	-0.67	-6.57	-0.51	1.25e-9	P wave terminal force;
TGCT	cis	rs637571	0.528	rs566266	chr11:65573587	A/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.67	-6.01	-0.48	1.9e-8	Eosinophil percentage of white cells;
TGCT	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg08280861	chr8:58055591	NA	0.4	4.56	0.38	1.22e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs6665290	0.545	rs6426584	chr1:227374949	A/T	cg10327440	chr1:227177885	CDC42BPA	-0.57	-6.02	-0.48	1.83e-8	Myeloid white cell count;
TGCT	cis	rs1215050	0.791	rs13107606	chr4:98823187	C/A	cg17366294	chr4:99064904	C4orf37	0.56	6.05	0.48	1.57e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg13695892	chr22:41940480	POLR3H	0.92	9.08	0.63	2.08e-15	Vitiligo;
TGCT	cis	rs4730250	0.707	rs61014091	chr7:106810107	A/C	cg02696742	chr7:106810147	HBP1	-0.73	-5.98	-0.47	2.24e-8	Osteoarthritis;
TGCT	cis	rs12477438	0.798	rs7570657	chr2:99654281	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-4.88	-0.4	3.17e-6	Chronic sinus infection;
TGCT	cis	rs682748	0.810	rs6892968	chr5:17112350	A/T	cg23987134	chr5:17158319	LOC285696	-0.21	-4.91	-0.4	2.78e-6	Hippocampal atrophy;
TGCT	cis	rs617219	0.726	rs2364596	chr5:78434291	C/T	cg09550809	chr5:78407562	BHMT	0.41	5.65	0.45	1.04e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs7666738	0.830	rs7694889	chr4:98855596	T/C	cg05340658	chr4:99064831	C4orf37	0.52	6.0	0.47	1.98e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs765787	0.530	rs12910270	chr15:45512086	G/A	cg24006582	chr15:45444508	DUOX1	0.25	5.35	0.43	4.11e-7	Uric acid levels;
TGCT	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg13206674	chr6:150067644	NUP43	0.52	4.53	0.38	1.37e-5	Lung cancer;
TGCT	cis	rs2458413	0.933	rs2669450	chr8:105371752	C/T	cg23108931	chr8:105342351	NA	0.39	6.96	0.53	1.74e-10	Paget's disease;
TGCT	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.5	-6.8	-0.52	3.93e-10	Alzheimer's disease;
TGCT	cis	rs9914988	0.887	rs9895625	chr17:27108516	A/G	cg20469991	chr17:27169893	C17orf63	-0.72	-5.04	-0.41	1.58e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg26338869	chr17:61819248	STRADA	-0.53	-4.87	-0.4	3.29e-6	Prudent dietary pattern;
TGCT	cis	rs35883536	0.868	rs2484535	chr1:101107748	C/T	cg06223162	chr1:101003688	GPR88	-0.29	-4.86	-0.4	3.53e-6	Monocyte count;
TGCT	cis	rs7010267	0.712	rs4567065	chr8:120008274	C/A	cg17171407	chr8:119960777	TNFRSF11B	0.27	5.0	0.41	1.9e-6	Total body bone mineral density (age 45-60);
TGCT	cis	rs10791097	0.677	rs11222359	chr11:130730648	A/G	cg12179176	chr11:130786555	SNX19	0.75	8.81	0.62	9.16e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs1059312	0.966	rs2291349	chr12:129284248	T/C	cg09035930	chr12:129282057	SLC15A4	0.59	11.59	0.72	1.72e-21	Systemic lupus erythematosus;
TGCT	cis	rs6558530	0.965	rs4372027	chr8:1707958	T/C	cg09410841	chr8:1729607	CLN8	0.91	10.31	0.68	2.23e-18	Systolic blood pressure;
TGCT	cis	rs8084125	0.832	rs62105174	chr18:74948324	G/A	cg15443732	chr18:74961078	GALR1	0.48	4.7	0.39	6.75e-6	Obesity-related traits;
TGCT	cis	rs77741769	0.571	rs73415720	chr12:121344515	T/C	cg02419362	chr12:121203948	SPPL3	0.19	4.49	0.37	1.63e-5	Mean corpuscular volume;
TGCT	trans	rs4332037	0.539	rs868754	chr7:2033780	G/C	cg10840412	chr1:235813424	GNG4	0.96	6.63	0.51	9.15e-10	Bipolar disorder;
TGCT	cis	rs9682041	0.696	rs10936626	chr3:170095019	G/A	cg11886554	chr3:170076028	SKIL	0.61	4.78	0.39	4.77e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.87	-9.35	-0.64	4.66e-16	Menarche (age at onset);
TGCT	cis	rs78487399	0.808	rs114563746	chr2:43760880	T/G	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.78	4.78	0.39	4.9100000000000004e-06	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs12477438	0.765	rs2167930	chr2:99592551	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-5.97	-0.47	2.3e-8	Chronic sinus infection;
TGCT	cis	rs9300255	0.602	rs1716165	chr12:123648881	C/T	cg00376283	chr12:123451042	ABCB9	0.73	5.64	0.45	1.09e-7	Neutrophil percentage of white cells;
TGCT	cis	rs2239547	0.603	rs34230854	chr3:53078590	C/A	cg10802521	chr3:52805072	NEK4	-0.57	-5.32	-0.43	4.62e-7	Schizophrenia;
TGCT	cis	rs11969893	0.850	rs12664068	chr6:101362098	G/T	cg12253828	chr6:101329408	ASCC3	1.25	4.88	0.4	3.17e-6	Economic and political preferences (immigration/crime);
TGCT	cis	rs6840360	0.642	rs2724568	chr4:152352223	C/G	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.83e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7659604	0.791	rs57316471	chr4:122663939	A/G	cg23574427	chr4:122746245	BBS7;CCNA2	-0.32	-5.29	-0.43	5.32e-7	Type 2 diabetes;
TGCT	cis	rs2456568	0.867	rs2462744	chr11:93682913	G/A	cg26875233	chr11:93583750	C11orf90	-0.45	-5.65	-0.45	1.04e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs6088590	0.550	rs12624640	chr20:32952125	G/A	cg06115741	chr20:33292138	TP53INP2	0.59	4.75	0.39	5.57e-6	Coronary artery disease;
TGCT	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg23302884	chr18:44338147	ST8SIA5	0.41	4.7	0.39	6.81e-6	Personality dimensions;
TGCT	cis	rs4851266	0.966	rs2309838	chr2:100838455	T/C	cg07810366	chr2:100720526	AFF3	-0.37	-5.33	-0.43	4.53e-7	Educational attainment;
TGCT	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-5.1	-0.42	1.23e-6	Electroencephalogram traits;
TGCT	cis	rs9830388	0.604	rs11916411	chr3:23567980	G/T	cg25382821	chr3:23496403	UBE2E2	0.24	4.46	0.37	1.84e-5	RR interval (tricyclic/tetracyclic antidepressant use interaction);
TGCT	trans	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg11887960	chr12:57824829	NA	1.06	9.28	0.64	6.78e-16	Lung disease severity in cystic fibrosis;
TGCT	cis	rs939658	0.805	rs1915726	chr15:79420620	C/G	cg17916960	chr15:79447300	NA	-0.5	-7.7	-0.57	3.74e-12	Refractive error;
TGCT	cis	rs274567	0.599	rs11242110	chr5:131743777	A/C	cg24060327	chr5:131705240	SLC22A5	0.54	5.31	0.43	4.94e-7	Blood metabolite levels;
TGCT	trans	rs1814175	0.630	rs1722019	chr11:49904102	G/A	cg15704280	chr7:45808275	SEPT13	-0.59	-6.82	-0.52	3.49e-10	Height;
TGCT	trans	rs629535	0.665	rs2433331	chr8:70041943	T/C	cg21567404	chr3:27674614	NA	0.56	9.09	0.63	2.03e-15	Dupuytren's disease;
TGCT	cis	rs896854	0.654	rs13281625	chr8:95972738	T/C	cg23172400	chr8:95962367	TP53INP1	-0.39	-6.52	-0.51	1.57e-9	Type 2 diabetes;
TGCT	cis	rs12477438	0.765	rs28648058	chr2:99696417	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-5.23	-0.43	6.94e-7	Chronic sinus infection;
TGCT	cis	rs72945132	0.825	rs2298411	chr11:70206046	G/A	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs74417235	0.684	rs13179754	chr5:154059845	C/T	cg08754654	chr5:154026448	NA	0.58	5.53	0.44	1.84e-7	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
TGCT	cis	rs4851266	1.000	rs6750097	chr2:100836885	T/C	cg07810366	chr2:100720526	AFF3	-0.37	-5.33	-0.43	4.53e-7	Educational attainment;
TGCT	cis	rs9467773	0.596	rs2451751	chr6:26646714	T/C	cg11502198	chr6:26597334	ABT1	0.55	4.89	0.4	3.05e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7924176	0.643	rs1908339	chr10:75843100	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.55	5.09	0.42	1.28e-6	Primary tooth development (time to first tooth eruption);Permanent tooth development;Primary tooth development (number of teeth);
TGCT	cis	rs6728642	1.000	rs73959416	chr2:97604518	A/T	cg26665480	chr2:98280029	ACTR1B	-0.92	-5.56	-0.45	1.56e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	cis	rs732765	0.689	rs10139925	chr14:75123076	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.56	-4.67	-0.39	7.7e-6	Non-small cell lung cancer;
TGCT	cis	rs9611565	0.802	rs9611571	chr22:41784867	G/A	cg13695892	chr22:41940480	POLR3H	-0.77	-7.47	-0.56	1.24e-11	Vitiligo;
TGCT	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2180341	1.000	rs6569483	chr6:127658855	G/A	cg24812749	chr6:127587940	RNF146	0.98	7.64	0.57	5.06e-12	Breast cancer;
TGCT	cis	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg22963979	chr7:1858916	MAD1L1	-0.37	-5.58	-0.45	1.42e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs36051895	0.659	rs7046077	chr9:5045328	C/G	cg02405213	chr9:5042618	JAK2	-0.78	-10.85	-0.7	1.1e-19	Pediatric autoimmune diseases;
TGCT	cis	rs7226408	0.948	rs2217110	chr18:34400782	T/C	cg06757138	chr18:34340585	FHOD3	0.26	4.79	0.4	4.62e-6	Obesity-related traits;
TGCT	cis	rs35306767	0.714	rs12762955	chr10:1078782	A/C	cg20503657	chr10:835505	NA	0.5	5.69	0.45	8.72e-8	Eosinophil percentage of granulocytes;
TGCT	cis	rs6582630	0.555	rs1969362	chr12:38514843	C/T	cg26384229	chr12:38710491	ALG10B	0.86	7.74	0.57	3.09e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs9303401	0.614	rs35245220	chr17:56510305	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.59	6.15	0.48	9.66e-9	Cognitive test performance;
TGCT	cis	rs12497850	0.931	rs28642807	chr3:48926816	A/G	cg06212747	chr3:49208901	KLHDC8B	0.61	5.62	0.45	1.2e-7	Parkinson's disease;
TGCT	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg11965913	chr1:205819406	PM20D1	0.5	6.89	0.53	2.5e-10	Menarche (age at onset);
TGCT	cis	rs2204008	0.623	rs1663281	chr12:38120936	A/G	cg26384229	chr12:38710491	ALG10B	-0.58	-5.09	-0.42	1.28e-6	Bladder cancer;
TGCT	cis	rs6591182	0.504	rs7116712	chr11:65372518	A/G	cg12758867	chr11:65354231	EHBP1L1	0.24	4.8	0.4	4.56e-6	Non-alcoholic fatty liver disease histology (lobular);
TGCT	cis	rs9611565	0.644	rs2413652	chr22:42097238	C/T	cg06634786	chr22:41940651	POLR3H	0.82	7.82	0.57	1.92e-12	Vitiligo;
TGCT	cis	rs7552404	0.889	rs1250874	chr1:76190978	A/G	cg22875332	chr1:76189707	ACADM	0.73	9.16	0.64	1.34e-15	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs838147	0.537	rs632111	chr19:49208978	A/G	cg05248581	chr19:49925731	PTH2	0.41	4.5	0.37	1.54e-5	Dietary macronutrient intake;
TGCT	cis	rs35306767	0.903	rs61833260	chr10:975148	T/G	cg20503657	chr10:835505	NA	0.69	9.6	0.65	1.15e-16	Eosinophil percentage of granulocytes;
TGCT	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2242116	0.760	rs4682845	chr3:46955404	G/C	cg02527881	chr3:46936655	PTH1R	-0.3	-5.56	-0.45	1.58e-7	Birth weight;
TGCT	cis	rs2439831	1.000	rs2254321	chr15:43707542	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	8.12	0.59	3.99e-13	Lung cancer in ever smokers;
TGCT	trans	rs1814175	0.647	rs4881649	chr11:49845560	A/G	cg15704280	chr7:45808275	SEPT13	-0.59	-6.76	-0.52	4.71e-10	Height;
TGCT	cis	rs9814567	1.000	rs1357762	chr3:134264859	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.92	-9.16	-0.64	1.36e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs7681440	0.728	rs1812923	chr4:90739539	C/A	cg26578617	chr4:90757533	SNCA	-0.45	-4.58	-0.38	1.1e-5	Dementia with Lewy bodies;
TGCT	cis	rs6460942	0.731	rs7799372	chr7:12233784	T/A	cg06484146	chr7:12443880	VWDE	-0.54	-4.76	-0.39	5.21e-6	Coronary artery disease;
TGCT	cis	rs2130392	0.962	rs7660116	chr4:185626542	G/A	cg14471096	chr4:185570637	CCDC111;CASP3	0.52	4.82	0.4	4.06e-6	Kawasaki disease;
TGCT	cis	rs1163251	0.837	rs517533	chr1:120229170	T/G	cg19096424	chr1:120255104	PHGDH	0.61	5.99	0.47	2.09e-8	Blood metabolite levels;
TGCT	cis	rs2832191	0.755	rs2832192	chr21:30491173	G/T	cg24692254	chr21:30365293	RNF160	-0.87	-9.28	-0.64	7.12e-16	Dental caries;
TGCT	trans	rs12655019	0.920	rs79354983	chr5:56221537	A/G	cg25190722	chr1:3801660	DFFB	0.67	7.44	0.56	1.48e-11	Breast cancer (early onset);
TGCT	cis	rs7940866	0.903	rs11222421	chr11:130872351	A/T	cg05962950	chr11:130786565	SNX19	0.67	6.47	0.5	2.06e-9	Schizophrenia;
TGCT	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg25036284	chr2:26402008	FAM59B	-0.57	-4.97	-0.41	2.15e-6	Gut microbiome composition (summer);
TGCT	cis	rs1023500	0.551	rs133379	chr22:42468535	A/G	cg05082376	chr22:42548792	NA	-0.23	-5.49	-0.44	2.18e-7	Schizophrenia;
TGCT	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg12310025	chr6:25882481	NA	-0.68	-6.01	-0.47	1.96e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2404602	0.716	rs12594577	chr15:76828793	A/C	cg26408565	chr15:76604113	ETFA	-0.4	-5.24	-0.43	6.54e-7	Blood metabolite levels;
TGCT	cis	rs7917772	0.503	rs11191342	chr10:104344450	G/A	cg05855489	chr10:104503620	C10orf26	-0.61	-5.41	-0.44	3.16e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs911555	0.511	rs2296483	chr14:104029792	G/A	cg26031613	chr14:104095156	KLC1	0.52	4.82	0.4	4.14e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6866344	0.697	rs62392823	chr5:178126968	T/C	cg10224037	chr5:178157518	ZNF354A	0.94	7.97	0.58	8.92e-13	Neutrophil percentage of white cells;
TGCT	cis	rs61990749	0.544	rs3759728	chr14:78230159	A/T	cg23188588	chr14:78226832	SNW1;C14orf178	0.65	4.59	0.38	1.06e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs13191362	1.000	rs34344906	chr6:162993378	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.68	5.32	0.43	4.73e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs1483890	0.605	rs6549209	chr3:69413028	A/C	cg22125112	chr3:69402811	FRMD4B	0.28	4.68	0.39	7.47e-6	Resting heart rate;
TGCT	cis	rs17601876	0.814	rs34784350	chr15:51559552	C/T	cg19946085	chr15:51559439	CYP19A1	-0.33	-4.99	-0.41	2.01e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs13090388	1	rs13090388	chr3:49391082	C/T	cg03060546	chr3:49711283	APEH	-0.63	-5.47	-0.44	2.39e-7	Intelligence (multi-trait analysis);Educational attainment (years of education);
TGCT	cis	rs3760982	0.585	rs67773424	chr19:44293994	G/A	cg12072164	chr19:44306565	LYPD5	0.3	4.45	0.37	1.86e-5	Breast cancer (estrogen-receptor negative);Breast cancer;
TGCT	cis	rs9325144	0.555	rs7960411	chr12:38703019	A/G	cg26384229	chr12:38710491	ALG10B	-0.67	-6.17	-0.48	9.08e-9	Morning vs. evening chronotype;
TGCT	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.06	-9.57	-0.65	1.41e-16	Platelet count;
TGCT	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg17971929	chr21:40555470	PSMG1	-0.68	-6.21	-0.49	7.44e-9	Cognitive function;
TGCT	cis	rs2067615	0.579	rs7486905	chr12:107160169	G/A	cg15890332	chr12:107067104	RFX4	0.29	5.64	0.45	1.07e-7	Heart rate;
TGCT	cis	rs931127	0.692	rs7934517	chr11:65445673	C/T	cg17480646	chr11:65405466	SIPA1	-0.44	-5.8	-0.46	5.26e-8	Systemic lupus erythematosus;
TGCT	cis	rs12477438	0.520	rs6741772	chr2:99738961	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	12.85	0.76	1.49e-24	Chronic sinus infection;
TGCT	cis	rs1697139	0.583	rs11739727	chr5:66540940	G/A	cg11553311	chr5:66541588	NA	0.27	5.83	0.46	4.47e-8	Breast cancer;
TGCT	cis	rs6088590	0.582	rs6059909	chr20:33139691	C/A	cg08999081	chr20:33150536	PIGU	0.28	5.41	0.44	3.11e-7	Coronary artery disease;
TGCT	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg03160526	chr17:80928410	B3GNTL1	0.33	4.54	0.38	1.33e-5	Glycated hemoglobin levels;
TGCT	cis	rs61990749	0.597	rs1477262	chr14:78226653	G/A	cg23188588	chr14:78226832	SNW1;C14orf178	0.67	4.73	0.39	6.09e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs28595532	0.920	rs55901549	chr4:119770172	T/A	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs492146	0.756	rs374275	chr6:52840797	G/C	cg06706454	chr6:52930286	FBXO9	-0.51	-4.64	-0.38	8.63e-6	Epilepsy (remission after treatment);
TGCT	cis	rs7552404	0.924	rs1611823	chr1:76221706	T/G	cg10523679	chr1:76189770	ACADM	0.82	8.79	0.62	1.05e-14	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs10791097	0.608	rs12363140	chr11:130744268	A/C	cg05962950	chr11:130786565	SNX19	0.92	11.55	0.72	2.13e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs12220898	0.749	rs7905866	chr10:50483552	T/C	cg06072769	chr10:50146962	WDFY4	0.39	5.19	0.42	8.27e-7	Inflammatory biomarkers;
TGCT	cis	rs12477438	0.765	rs6735801	chr2:99657995	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-4.61	-0.38	9.83e-6	Chronic sinus infection;
TGCT	cis	rs10875746	0.951	rs2269935	chr12:48516464	G/T	cg20731937	chr12:48336164	NA	0.62	4.9	0.4	2.99e-6	Longevity (90 years and older);
TGCT	cis	rs9467603	1.000	rs6902211	chr6:25767437	G/A	cg16898833	chr6:26189333	HIST1H4D	-0.99	-4.75	-0.39	5.62e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs881375	0.692	rs2072438	chr9:123651301	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	5.4	0.44	3.34e-7	Rheumatoid arthritis;
TGCT	cis	rs6939532	0.522	rs9379870	chr6:26374410	A/G	cg05738196	chr6:26577821	NA	-0.52	-5.02	-0.41	1.76e-6	Autism spectrum disorder or schizophrenia;
TGCT	trans	rs11722228	0.522	rs7662229	chr4:10133014	A/T	cg26043149	chr18:55253948	FECH	1.23	14.06	0.78	1.97e-27	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs854765	0.583	rs7503334	chr17:17779458	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.74	-7.98	-0.58	8.43e-13	Total body bone mineral density;
TGCT	cis	rs7666738	0.830	rs7664305	chr4:99037691	G/A	cg05340658	chr4:99064831	C4orf37	0.51	5.76	0.46	6.23e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2153535	0.580	rs1119689	chr6:8460754	C/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs12477438	0.798	rs10196680	chr2:99628617	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-5.87	-0.47	3.74e-8	Chronic sinus infection;
TGCT	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg02725872	chr8:58115012	NA	-0.41	-5.38	-0.44	3.5e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg06238570	chr21:40685208	BRWD1	-0.81	-9.15	-0.64	1.4e-15	Cognitive function;
TGCT	cis	rs981844	0.689	rs6835372	chr4:154682056	T/C	cg14289246	chr4:154710475	SFRP2	-0.89	-8.12	-0.59	3.89e-13	Response to statins (LDL cholesterol change);
TGCT	cis	rs12142240	0.698	rs7515598	chr1:46818479	C/T	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs3749237	0.595	rs1050088	chr3:49570882	C/T	cg02487422	chr3:49467188	NICN1	-0.58	-5.92	-0.47	2.9e-8	Resting heart rate;
TGCT	cis	rs1008375	0.863	rs4698632	chr4:17614894	T/C	cg16339924	chr4:17578868	LAP3	0.64	5.17	0.42	9.1e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg15921436	chr17:44337874	NA	0.58	8.1	0.59	4.33e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7267979	0.816	rs409853	chr20:25506067	T/C	cg14121845	chr20:25566513	NINL	0.46	4.76	0.39	5.36e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs644799	1.000	rs586498	chr11:95537828	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	8.74	0.62	1.39e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs40363	0.729	rs6501176	chr16:3522197	A/G	cg00484396	chr16:3507460	NAT15	-0.33	-4.88	-0.4	3.18e-6	Tuberculosis;
TGCT	cis	rs40363	0.620	rs1137454	chr16:3533577	C/G	cg22508957	chr16:3507546	NAT15	-0.47	-5.33	-0.43	4.43e-7	Tuberculosis;
TGCT	cis	rs4654899	0.802	rs10737452	chr1:21199764	C/T	cg01072550	chr1:21505969	NA	0.46	7.19	0.54	5.32e-11	Superior frontal gyrus grey matter volume;
TGCT	cis	rs6543140	0.964	rs918000	chr2:103067862	C/T	cg09003973	chr2:102972529	NA	0.56	4.67	0.39	7.86e-6	Blood protein levels;
TGCT	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg00684032	chr4:1343700	KIAA1530	0.23	4.97	0.41	2.18e-6	Obesity-related traits;
TGCT	cis	rs12497850	0.931	rs3774628	chr3:48801840	C/T	cg07636037	chr3:49044803	WDR6	0.95	10.82	0.7	1.29e-19	Parkinson's disease;
TGCT	cis	rs35306767	0.903	rs35637113	chr10:874149	G/C	cg20503657	chr10:835505	NA	0.7	9.83	0.66	3.22e-17	Eosinophil percentage of granulocytes;
TGCT	cis	rs6089584	0.927	rs11697597	chr20:60584748	C/T	cg16423285	chr20:60520624	NA	-0.63	-7.07	-0.54	1.01e-10	Body mass index;
TGCT	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg19318889	chr4:1322082	MAEA	0.17	4.47	0.37	1.71e-5	Obesity-related traits;
TGCT	cis	rs11690935	0.959	rs75922913	chr2:172620152	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.2	-12.28	-0.74	3.49e-23	Schizophrenia;
TGCT	cis	rs4803468	0.934	rs2317131	chr19:41885151	C/T	cg09537434	chr19:41945824	ATP5SL	-0.85	-9.13	-0.63	1.57e-15	Height;
TGCT	cis	rs7666738	0.830	rs35951881	chr4:98999474	A/C	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12620999	1.000	rs4558538	chr2:238055975	C/T	cg23555395	chr2:238036564	NA	-0.28	-4.72	-0.39	6.18e-6	Systemic lupus erythematosus;
TGCT	cis	rs7786808	0.741	rs11765319	chr7:158226790	A/G	cg01191920	chr7:158217561	PTPRN2	-0.4	-6.21	-0.49	7.21e-9	Obesity-related traits;
TGCT	cis	rs950169	0.881	rs62029599	chr15:84956565	A/C	cg17173187	chr15:85201210	NMB	0.58	5.93	0.47	2.77e-8	Schizophrenia;
TGCT	cis	rs7959452	0.640	rs4274230	chr12:69700772	T/G	cg11871910	chr12:69753446	YEATS4	0.63	6.37	0.5	3.34e-9	Blood protein levels;
TGCT	cis	rs1153858	1.000	rs9788780	chr15:45685487	T/A	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.62e-8	Homoarginine levels;
TGCT	cis	rs362296	0.698	rs3135172	chr4:3258735	A/G	cg06533319	chr4:3265114	C4orf44	0.24	4.46	0.37	1.83e-5	Parental longevity (mother's age at death);
TGCT	cis	rs826838	0.967	rs12823908	chr12:38845686	T/C	cg13010199	chr12:38710504	ALG10B	0.82	6.85	0.52	3e-10	Heart rate;
TGCT	cis	rs7552404	0.883	rs77773255	chr1:76217193	G/A	cg10523679	chr1:76189770	ACADM	0.9	9.71	0.66	6.5e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7666738	0.927	rs6832373	chr4:99051967	A/G	cg05340658	chr4:99064831	C4orf37	0.52	5.81	0.46	5e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12615966	1.000	rs61424916	chr2:105390188	C/A	cg16465502	chr2:105461796	NA	0.78	5.03	0.41	1.66e-6	Pancreatic cancer;
TGCT	cis	rs6570726	0.791	rs400329	chr6:145879442	A/T	cg23711669	chr6:146136114	FBXO30	0.89	9.93	0.67	1.82e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg16325326	chr1:53192061	ZYG11B	0.55	5.9	0.47	3.23e-8	Monocyte count;
TGCT	cis	rs16957091	0.647	rs35838915	chr15:43357124	C/A	cg17935677	chr15:44119062	WDR76	0.54	4.83	0.4	3.88e-6	MGMT methylation in smokers;
TGCT	cis	rs3782455	1.000	rs79831570	chr12:114401608	T/C	cg10631684	chr12:113795897	PLBD2	-0.7	-4.61	-0.38	1e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs765787	0.530	rs2433228	chr15:45515371	A/C	cg24006582	chr15:45444508	DUOX1	-0.26	-5.62	-0.45	1.19e-7	Uric acid levels;
TGCT	cis	rs6969780	0.545	rs983184	chr7:27188379	C/T	cg11410718	chr7:27170412	HOXA4	-0.47	-4.68	-0.39	7.38e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs9611565	0.568	rs5758441	chr22:42132888	C/A	cg06481639	chr22:41940642	POLR3H	0.54	4.57	0.38	1.17e-5	Vitiligo;
TGCT	cis	rs4766566	0.651	rs933307	chr12:111735537	A/C	cg10833066	chr12:111807467	FAM109A	-0.39	-7.2	-0.54	5.07e-11	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
TGCT	cis	rs616402	0.527	rs11584327	chr1:10578791	T/C	cg17425144	chr1:10567563	PEX14	0.54	8.01	0.58	7.05e-13	Breast size;
TGCT	cis	rs704	0.790	rs9913833	chr17:26718592	C/T	cg10342447	chr17:26645325	TMEM97	-0.51	-4.91	-0.4	2.82e-6	Osteoprotegerin levels;
TGCT	cis	rs2836633	0.895	rs62217513	chr21:40024416	A/T	cg05519781	chr21:40033154	ERG	0.69	6.68	0.51	7.07e-10	Coronary artery disease;
TGCT	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg18110333	chr6:292329	DUSP22	0.68	7.38	0.55	2.02e-11	Menopause (age at onset);
TGCT	cis	rs68170813	0.559	rs7783181	chr7:106977613	A/G	cg02696742	chr7:106810147	HBP1	-0.68	-5.88	-0.47	3.53e-8	Coronary artery disease;
TGCT	cis	rs1451375	0.959	rs17133878	chr7:50620927	T/C	cg18232548	chr7:50535776	DDC	0.44	6.95	0.53	1.87e-10	Malaria;
TGCT	cis	rs7570971	0.517	rs10187402	chr2:135771974	C/G	cg07169764	chr2:136633963	MCM6	0.59	5.3	0.43	5.01e-7	Blood metabolite levels;Body mass index;Cholesterol, total;
TGCT	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	5.72	0.46	7.47e-8	Alzheimer's disease;
TGCT	cis	rs12653946	0.811	rs10866527	chr5:1891800	C/T	cg22472608	chr5:1891194	NA	-0.69	-8.93	-0.63	4.79e-15	Prostate cancer;
TGCT	cis	rs7772486	0.790	rs6926076	chr6:146232804	C/T	cg23711669	chr6:146136114	FBXO30	-0.87	-9.9	-0.66	2.24e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1568889	0.938	rs6484358	chr11:28260364	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.82	8.47	0.61	5.9e-14	Bipolar disorder;
TGCT	cis	rs8030485	0.716	rs12899109	chr15:79410970	T/C	cg17916960	chr15:79447300	NA	0.36	5.1	0.42	1.23e-6	Left ventricle wall thickness;
TGCT	cis	rs12477438	0.765	rs6735801	chr2:99657995	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-4.83	-0.4	4.01e-6	Chronic sinus infection;
TGCT	cis	rs7666738	0.716	rs35195511	chr4:98859660	G/A	cg18180107	chr4:99064573	C4orf37	0.55	5.14	0.42	1.03e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7267979	0.739	rs6138555	chr20:25242910	G/A	cg16686733	chr20:25566563	NINL	0.52	4.9	0.4	2.98e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs35160687	0.901	rs34069316	chr2:86529792	T/C	cg04877910	chr2:85804641	VAMP8	0.34	4.51	0.38	1.49e-5	Night sleep phenotypes;
TGCT	cis	rs7824557	0.614	rs2736277	chr8:11218893	C/T	cg21775007	chr8:11205619	TDH	-0.64	-6.24	-0.49	6.32e-9	Retinal vascular caliber;
TGCT	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg21963583	chr11:68658836	MRPL21	0.35	5.7	0.46	8.33e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7666738	0.830	rs2015828	chr4:98984594	A/G	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs601339	0.938	rs1696344	chr12:123183059	C/T	cg11919336	chr12:123188078	GPR109A	0.64	7.67	0.57	4.36e-12	Adiponectin levels;
TGCT	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	5.8	0.46	5.19e-8	Alzheimer's disease;
TGCT	cis	rs6500602	0.727	rs10451135	chr16:4580214	T/C	cg09549813	chr16:4587862	C16orf5	-0.28	-4.51	-0.38	1.5e-5	Schizophrenia;
TGCT	cis	rs7267979	0.816	rs6138593	chr20:25504492	A/G	cg16686733	chr20:25566563	NINL	0.52	5.05	0.41	1.52e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs514406	0.893	rs6588445	chr1:53424928	T/C	cg25767906	chr1:53392781	SCP2	0.5	6.0	0.47	2e-8	Monocyte count;
TGCT	cis	rs1525293	0.714	rs11773863	chr7:70511130	G/C	cg21135135	chr7:70597687	WBSCR17	0.49	4.62	0.38	9.38e-6	Colonoscopy-negative controls vs population controls;Major depressive disorder;
TGCT	cis	rs11148252	0.634	rs66849828	chr13:52714837	C/A	cg00495681	chr13:53174319	NA	0.5	4.53	0.38	1.37e-5	Lewy body disease;
TGCT	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.72	6.84	0.52	3.16e-10	Prudent dietary pattern;
TGCT	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg21724239	chr8:58056113	NA	0.45	7.02	0.53	1.27e-10	Developmental language disorder (linguistic errors);
TGCT	cis	rs4555082	0.874	rs2735828	chr14:105710486	C/A	cg01266790	chr14:105781312	PACS2	0.54	4.56	0.38	1.2e-5	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs7769051	0.803	rs12193474	chr6:133186168	T/C	cg07930552	chr6:133119739	C6orf192	1.06	5.77	0.46	5.88e-8	Type 2 diabetes nephropathy;
TGCT	cis	rs1395	0.634	rs62130713	chr2:27525661	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.59	7.3	0.55	3.08e-11	Blood metabolite levels;
TGCT	cis	rs6582630	0.555	rs12828034	chr12:38274249	C/T	cg26384229	chr12:38710491	ALG10B	-0.55	-4.71	-0.39	6.64e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs6540559	0.673	rs17317411	chr1:209961314	C/T	cg22029157	chr1:209979665	IRF6	-0.75	-5.34	-0.43	4.34e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs6088580	0.634	rs1205345	chr20:32914699	A/G	cg08999081	chr20:33150536	PIGU	-0.26	-5.06	-0.41	1.44e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs75718659	1.000	rs75718659	chr4:187743086	C/T	cg02756176	chr4:187491362	NA	0.76	5.05	0.41	1.51e-6	Alzheimer disease and age of onset;
TGCT	cis	rs7666738	0.830	rs10021709	chr4:99030587	G/A	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg01238044	chr22:24384105	GSTT1	-0.49	-4.56	-0.38	1.21e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7824557	0.564	rs2572394	chr8:11235393	A/G	cg21775007	chr8:11205619	TDH	-0.65	-6.4	-0.5	2.95e-9	Retinal vascular caliber;
TGCT	cis	rs8180040	0.764	rs4682852	chr3:47177772	C/T	cg27129171	chr3:47204927	SETD2	0.76	9.9	0.66	2.25e-17	Colorectal cancer;
TGCT	cis	rs9581857	0.547	rs77005033	chr13:28109793	A/G	cg22138327	chr13:27999177	GTF3A	0.7	4.53	0.38	1.36e-5	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg25427524	chr10:38739819	LOC399744	-0.39	-8.04	-0.59	5.95e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg11764359	chr7:65958608	NA	-0.55	-4.87	-0.4	3.3e-6	Aortic root size;
TGCT	cis	rs1729951	0.546	rs361246	chr3:136695667	G/A	cg21827317	chr3:136751795	NA	0.4	5.6	0.45	1.28e-7	Neuroticism;
TGCT	cis	rs477895	1.000	rs2286614	chr11:64068310	C/T	cg04317338	chr11:64019027	PLCB3	0.67	5.3	0.43	5.18e-7	Mean platelet volume;
TGCT	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg19536664	chr17:6899085	ALOX12	-0.37	-5.88	-0.47	3.64e-8	Tonsillectomy;
TGCT	cis	rs7020830	0.931	rs7027473	chr9:37132462	A/G	cg14294708	chr9:37120828	ZCCHC7	1.31	20.37	0.88	2.24e-41	Schizophrenia;
TGCT	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg07636037	chr3:49044803	WDR6	0.84	8.35	0.6	1.13e-13	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs739496	0.642	rs74849450	chr12:112208838	C/G	cg10833066	chr12:111807467	FAM109A	0.36	4.67	0.39	7.74e-6	Platelet count;
TGCT	cis	rs6912958	0.712	rs4707383	chr6:88330602	T/A	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.98	-0.41	2.06e-6	Monocyte percentage of white cells;
TGCT	cis	rs2414095	0.527	rs11636686	chr15:51542066	C/T	cg19946085	chr15:51559439	CYP19A1	-0.32	-4.6	-0.38	1.02e-5	Follicule stimulating hormone;Hormone measurements;Total body bone mineral density;
TGCT	cis	rs9399135	0.967	rs6909975	chr6:135315570	C/T	cg24558204	chr6:135376177	HBS1L	0.46	4.59	0.38	1.09e-5	Red blood cell count;
TGCT	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg05368731	chr17:41323189	NBR1	1.1	11.08	0.71	2.94e-20	Menopause (age at onset);
TGCT	cis	rs2463822	1.000	rs2463825	chr11:62094493	G/A	cg06239285	chr11:62104954	ASRGL1	0.93	6.71	0.52	6.27e-10	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs9467773	0.572	rs9467737	chr6:26381630	T/C	cg05738196	chr6:26577821	NA	-0.53	-5.5	-0.44	2.12e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7246657	0.722	rs12974225	chr19:38240098	G/T	cg18154014	chr19:37997991	ZNF793	-0.69	-4.92	-0.4	2.68e-6	Coronary artery calcification;
TGCT	cis	rs10489202	0.632	rs12401555	chr1:168069473	G/C	cg24449463	chr1:168025552	DCAF6	-0.52	-5.45	-0.44	2.58e-7	Schizophrenia;
TGCT	cis	rs6545883	0.929	rs1838978	chr2:61540923	T/C	cg15711740	chr2:61764176	XPO1	0.53	4.54	0.38	1.32e-5	Tuberculosis;
TGCT	cis	rs12893668	0.628	rs57072546	chr14:104063723	T/C	cg26031613	chr14:104095156	KLC1	-0.57	-4.75	-0.39	5.54e-6	Reticulocyte count;
TGCT	cis	rs797680	0.856	rs7541687	chr1:93656588	A/G	cg17826107	chr1:92977322	EVI5	-0.24	-5.23	-0.43	6.89e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs11785400	0.890	rs13279182	chr8:143720544	A/G	cg10596483	chr8:143751796	JRK	0.55	5.67	0.45	9.72e-8	Schizophrenia;
TGCT	cis	rs73416724	0.610	rs111981370	chr6:43255380	G/T	cg24109273	chr6:43484729	YIPF3;POLR1C	1.04	5.36	0.43	3.95e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs10791097	0.694	rs7106973	chr11:130758113	G/A	cg14779329	chr11:130786720	SNX19	0.31	5.25	0.43	6.26e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs916888	0.610	rs199529	chr17:44837217	A/C	cg16228356	chr17:43848958	NA	-0.26	-4.72	-0.39	6.14e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	trans	rs10504390	0.585	rs117486340	chr8:66542077	G/A	cg26037026	chr7:1641922	NA	-0.64	-6.84	-0.52	3.29e-10	IgG glycosylation;
TGCT	cis	rs950169	0.840	rs62019457	chr15:85102142	T/C	cg17173187	chr15:85201210	NMB	0.53	5.53	0.44	1.83e-7	Schizophrenia;
TGCT	cis	rs644799	0.562	rs1313288	chr11:95520695	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.55	5.67	0.45	9.5e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs1200821	0.529	rs2505707	chr10:37801254	T/C	cg25427524	chr10:38739819	LOC399744	-0.31	-5.4	-0.44	3.23e-7	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs9291683	0.552	rs11736410	chr4:10017241	G/A	cg02734326	chr4:10020555	SLC2A9	0.38	4.54	0.38	1.34e-5	Bone mineral density;
TGCT	trans	rs12655019	0.920	rs6882657	chr5:56222739	C/T	cg25190722	chr1:3801660	DFFB	0.67	7.44	0.56	1.48e-11	Breast cancer (early onset);
TGCT	cis	rs68170813	0.605	rs75659533	chr7:107134987	A/G	cg02696742	chr7:106810147	HBP1	-0.64	-5.08	-0.41	1.37e-6	Coronary artery disease;
TGCT	cis	rs13242816	0.881	rs56034786	chr7:116106360	T/C	cg02799643	chr7:116139180	CAV2	-0.45	-5.38	-0.44	3.5e-7	P wave duration;
TGCT	cis	rs916888	0.610	rs199444	chr17:44818276	T/C	cg15921436	chr17:44337874	NA	0.43	6.5	0.5	1.79e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs79387448	0.655	rs11891827	chr2:102951182	A/G	cg09003973	chr2:102972529	NA	1.4	9.44	0.65	2.87e-16	Gut microbiota (bacterial taxa);
TGCT	cis	rs9468199	0.510	rs72847349	chr6:27805303	T/C	cg08851530	chr6:28072375	NA	1.54	7.3	0.55	3.1e-11	Parkinson's disease;
TGCT	cis	rs17376456	1.000	rs12187701	chr5:93522290	A/G	cg21475434	chr5:93447410	FAM172A	0.61	4.48	0.37	1.68e-5	Diabetic retinopathy;
TGCT	cis	rs7412746	0.621	rs7518156	chr1:150945794	A/C	cg09365446	chr1:150670422	GOLPH3L	0.35	4.82	0.4	4.2e-6	Melanoma;
TGCT	cis	rs1348850	0.914	rs10194648	chr2:178337031	G/A	cg22681709	chr2:178499509	PDE11A	-0.36	-4.71	-0.39	6.46e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	trans	rs7819412	0.511	rs2409798	chr8:11435564	C/T	cg15556689	chr8:8085844	FLJ10661	-0.77	-7.17	-0.54	6.04e-11	Triglycerides;
TGCT	cis	rs6430585	0.528	rs16832205	chr2:136684632	G/A	cg07169764	chr2:136633963	MCM6	1.25	12.39	0.74	1.91e-23	Corneal structure;
TGCT	cis	rs6684514	1.000	rs2277870	chr1:156246792	C/T	cg16558208	chr1:156270281	VHLL	0.46	9.38	0.64	3.92e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs7615952	0.932	rs13086087	chr3:125646281	A/C	cg05084668	chr3:125655381	ALG1L	-0.75	-6.07	-0.48	1.41e-8	Blood pressure (smoking interaction);
TGCT	trans	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg20587970	chr11:113659929	NA	-1.09	-13.5	-0.77	4.23e-26	Hip circumference adjusted for BMI;
TGCT	cis	rs56104184	0.775	rs73061699	chr19:49400511	T/C	cg21252483	chr19:49399788	TULP2	-0.42	-5.89	-0.47	3.47e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs10484885	0.648	rs2777848	chr6:90535993	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.54	-6.32	-0.49	4.2e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs4378999	0.660	rs61108141	chr3:50966191	A/G	ch.3.1075622R	chr3:50010873	RBM6	0.36	4.56	0.38	1.23e-5	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
TGCT	cis	rs6121246	0.609	rs6088997	chr20:30289824	A/G	cg13852791	chr20:30311386	BCL2L1	-0.8	-7.2	-0.54	4.99e-11	Mean corpuscular hemoglobin;
TGCT	cis	rs6987853	0.933	rs2923401	chr8:42442208	T/C	cg20539142	chr8:42623718	CHRNA6	-0.2	-4.82	-0.4	4.2e-6	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs8180040	0.739	rs11719306	chr3:47184182	G/A	cg27129171	chr3:47204927	SETD2	0.76	9.89	0.66	2.32e-17	Colorectal cancer;
TGCT	cis	rs854765	0.583	rs4925129	chr17:17807186	A/G	cg09796270	chr17:17721594	SREBF1	0.26	5.44	0.44	2.75e-7	Total body bone mineral density;
TGCT	cis	rs3780378	0.935	rs1028912	chr9:5050369	G/C	cg02405213	chr9:5042618	JAK2	-0.58	-7.5	-0.56	1.09e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs734999	0.588	rs2764848	chr1:2530694	G/A	cg18854424	chr1:2615690	NA	-0.46	-5.36	-0.43	3.84e-7	Ulcerative colitis;
TGCT	cis	rs1215050	0.791	rs684210	chr4:98678740	G/C	cg05340658	chr4:99064831	C4orf37	0.43	5.4	0.44	3.2e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs992157	0.710	rs6719789	chr2:219057810	G/T	cg00012203	chr2:219082015	ARPC2	-0.85	-11.09	-0.71	2.86e-20	Colorectal cancer;
TGCT	trans	rs7618501	0.699	rs6446187	chr3:49907111	C/A	cg21659725	chr3:3221576	CRBN	0.78	9.37	0.64	4.19e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs7940866	0.838	rs10736592	chr11:130800572	C/T	cg05962950	chr11:130786565	SNX19	0.72	7.35	0.55	2.31e-11	Schizophrenia;
TGCT	cis	rs6121246	0.567	rs6120890	chr20:30207659	T/G	cg18721089	chr20:30220636	NA	-0.57	-6.19	-0.49	7.9e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg21862992	chr11:68658383	NA	0.48	6.6	0.51	1.06e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7914558	0.933	rs10883814	chr10:104737404	T/C	cg04362960	chr10:104952993	NT5C2	0.6	5.42	0.44	2.99e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs2072499	0.900	rs2248080	chr1:156195971	T/A	cg06970220	chr1:156163860	SLC25A44	0.74	5.98	0.47	2.22e-8	Testicular germ cell tumor;
TGCT	cis	rs2832191	1.000	rs9984793	chr21:30486471	T/C	cg08807101	chr21:30365312	RNF160	-0.49	-4.48	-0.37	1.65e-5	Dental caries;
TGCT	cis	rs1008375	0.966	rs12503540	chr4:17698781	C/G	cg18681998	chr4:17616180	MED28	-0.76	-7.28	-0.55	3.36e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9325144	0.555	rs11183215	chr12:38693127	G/A	cg26384229	chr12:38710491	ALG10B	-0.66	-6.15	-0.48	1e-8	Morning vs. evening chronotype;
TGCT	cis	rs2204008	0.701	rs3898237	chr12:38219714	A/G	cg26384229	chr12:38710491	ALG10B	0.84	7.43	0.56	1.51e-11	Bladder cancer;
TGCT	trans	rs1974653	0.672	rs9606247	chr22:20087473	T/A	cg08822737	chr17:71088851	SLC39A11	-0.93	-7.61	-0.56	5.97e-12	Schizophrenia;
TGCT	cis	rs727505	1.000	rs10246424	chr7:124494861	A/G	cg23710748	chr7:124431027	NA	-0.26	-4.49	-0.37	1.6e-5	Lewy body disease;
TGCT	cis	rs7095607	1.000	rs7079974	chr10:69959397	G/A	cg18986048	chr10:69913749	MYPN	0.45	4.86	0.4	3.52e-6	Lung function (FVC);
TGCT	cis	rs11578119	0.933	rs115701628	chr1:170421735	C/T	cg09767346	chr1:170501363	GORAB	0.71	5.65	0.45	1.04e-7	Male-pattern baldness;
TGCT	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg04025307	chr7:1156635	C7orf50	0.23	5.23	0.43	6.91e-7	Longevity;Endometriosis;
TGCT	cis	rs875971	0.660	rs10229345	chr7:65982168	G/C	cg18876405	chr7:65276391	NA	0.4	6.23	0.49	6.75e-9	Aortic root size;
TGCT	cis	rs6879260	1.000	rs10903252	chr5:179733934	T/C	cg23248424	chr5:179741104	GFPT2	-0.38	-7.07	-0.54	9.78e-11	Height;
TGCT	cis	rs4700695	0.925	rs4700090	chr5:65412434	C/T	cg21114390	chr5:65439923	SFRS12	-0.62	-4.72	-0.39	6.24e-6	Facial morphology (factor 19);
TGCT	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2762353	0.603	rs9393670	chr6:25789061	A/G	cg03264133	chr6:25882463	NA	0.52	5.26	0.43	6.21e-7	Blood metabolite levels;
TGCT	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg21285383	chr16:89894308	SPIRE2	0.45	7.12	0.54	7.61e-11	Vitiligo;
TGCT	cis	rs7833790	0.777	rs6473301	chr8:82691340	A/G	cg06027949	chr8:82754900	SNX16	-0.67	-4.47	-0.37	1.75e-5	Diastolic blood pressure;
TGCT	cis	rs11249608	0.548	rs7733072	chr5:178456007	A/G	cg21905437	chr5:178450457	ZNF879	0.44	4.57	0.38	1.16e-5	Pubertal anthropometrics;
TGCT	cis	rs17376456	0.825	rs17314762	chr5:93231200	C/T	cg25358565	chr5:93447407	FAM172A	1.02	8.11	0.59	4.17e-13	Diabetic retinopathy;
TGCT	cis	rs933688	1.000	rs6865495	chr5:90746424	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.11	10.58	0.69	4.97e-19	Smoking behavior;
TGCT	cis	rs17376456	0.825	rs13165400	chr5:93091427	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	4.43	0.37	2.01e-5	Diabetic retinopathy;
TGCT	cis	rs3008870	1.000	rs7511948	chr1:67430427	A/G	cg03991309	chr1:68237761	GNG12	0.27	4.53	0.38	1.36e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs4889855	0.530	rs72856551	chr17:78552267	G/T	cg16591659	chr17:78472290	NA	0.28	4.46	0.37	1.84e-5	Fractional excretion of uric acid;
TGCT	cis	rs9517320	0.534	rs9554478	chr13:99187792	G/A	cg07423050	chr13:99094983	FARP1	-0.28	-5.53	-0.44	1.83e-7	Longevity;
TGCT	cis	rs17767294	0.708	rs72847323	chr6:27744490	A/T	cg08851530	chr6:28072375	NA	1.54	7.3	0.55	3.1e-11	Parkinson's disease;
TGCT	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg02038168	chr22:39784481	NA	-0.73	-6.0	-0.47	2.05e-8	Intelligence (multi-trait analysis);
TGCT	trans	rs7613875	0.654	rs3774751	chr3:50209053	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.79	-8.22	-0.59	2.36e-13	Body mass index;
TGCT	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.03	0.41	1.68e-6	Prudent dietary pattern;
TGCT	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg07507251	chr3:52567010	NT5DC2	0.48	6.95	0.53	1.82e-10	Bipolar disorder;
TGCT	cis	rs9357506	1.000	rs9381442	chr6:46313545	C/T	cg21115430	chr6:46460003	NA	-0.26	-5.16	-0.42	9.6e-7	Body mass index;
TGCT	cis	rs832540	0.552	rs252924	chr5:56205643	A/G	cg12311346	chr5:56204834	C5orf35	-0.54	-5.44	-0.44	2.71e-7	Coronary artery disease;
TGCT	cis	rs782590	0.774	rs2627773	chr2:55900459	A/G	cg18811423	chr2:55921094	PNPT1	0.65	6.76	0.52	4.79e-10	Metabolic syndrome;
TGCT	cis	rs6754311	0.593	rs7355359	chr2:136462441	C/T	cg07169764	chr2:136633963	MCM6	-0.67	-6.11	-0.48	1.16e-8	Mosquito bite size;
TGCT	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg09365446	chr1:150670422	GOLPH3L	0.31	4.66	0.39	8.11e-6	Tonsillectomy;
TGCT	cis	rs250677	0.687	rs3095947	chr5:148436728	T/C	cg23229984	chr5:148520753	ABLIM3	0.21	4.89	0.4	3.11e-6	Breast cancer;
TGCT	cis	rs1348850	0.793	rs6736390	chr2:178480314	T/C	cg22681709	chr2:178499509	PDE11A	-0.47	-5.69	-0.45	8.85e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	trans	rs561341	1.000	rs550923	chr17:30327013	G/C	cg20587970	chr11:113659929	NA	-1.04	-12.57	-0.75	6.97e-24	Hip circumference adjusted for BMI;
TGCT	cis	rs7727544	0.716	rs4705928	chr5:131578637	A/G	cg24060327	chr5:131705240	SLC22A5	0.54	5.06	0.41	1.48e-6	Blood metabolite levels;
TGCT	cis	rs1577917	0.916	rs7759727	chr6:86518878	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-5.19	-0.42	8.31e-7	Response to antipsychotic treatment;
TGCT	cis	rs137603	0.602	rs9611146	chr22:39718120	G/T	cg17798944	chr22:39715225	SNORD43;RPL3	-0.68	-7.25	-0.55	3.85e-11	Primary biliary cholangitis;
TGCT	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg03806693	chr22:41940476	POLR3H	-1.12	-13.03	-0.76	5.66e-25	Vitiligo;
TGCT	cis	rs10791323	0.569	rs546381	chr11:133760651	T/G	cg15485101	chr11:133734466	NA	0.39	5.51	0.44	2.02e-7	Childhood ear infection;
TGCT	cis	rs826838	0.616	rs10880754	chr12:38628154	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-4.74	-0.39	5.87e-6	Heart rate;
TGCT	cis	rs9894429	1.000	rs7222241	chr17:79574714	C/G	cg18240062	chr17:79603768	NPLOC4	0.67	6.84	0.52	3.23e-10	Eye color traits;
TGCT	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg03303774	chr4:1407052	NA	0.29	4.67	0.39	7.71e-6	Obesity-related traits;
TGCT	cis	rs2594989	0.673	rs9854573	chr3:11602577	C/T	cg00170343	chr3:11313890	ATG7	-0.72	-5.16	-0.42	9.38e-7	Circulating chemerin levels;
TGCT	cis	rs524281	0.861	rs12049852	chr11:65884702	T/C	cg00563793	chr11:65837595	PACS1	0.55	4.63	0.38	9.13e-6	Electroencephalogram traits;
TGCT	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg11764359	chr7:65958608	NA	-0.55	-4.87	-0.4	3.3e-6	Aortic root size;
TGCT	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.76	5.03	0.41	1.68e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7017914	0.905	rs1493203	chr8:71926507	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.56	-5.11	-0.42	1.21e-6	Bone mineral density;
TGCT	cis	rs10791097	0.592	rs4936122	chr11:130734264	A/C	cg12179176	chr11:130786555	SNX19	0.81	9.76	0.66	4.74e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9952991	0.582	rs658158	chr18:12823402	T/G	cg23544223	chr18:12777786	NA	0.53	4.68	0.39	7.25e-6	Inflammatory skin disease;
TGCT	cis	rs2178146	0.535	rs1918826	chr16:86451996	C/T	cg11165158	chr16:86613094	FOXL1	-0.35	-4.78	-0.39	4.86e-6	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Esophageal adenocarcinoma;
TGCT	cis	rs2440129	0.611	rs1042357	chr17:6905061	T/G	cg09737314	chr17:6899359	ALOX12	0.51	5.31	0.43	4.82e-7	Tonsillectomy;
TGCT	cis	rs3617	0.539	rs11922975	chr3:52936763	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.5	-4.65	-0.39	8.52e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs78487399	1.000	rs79611878	chr2:43844803	A/G	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.65	4.58	0.38	1.12e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs909674	0.818	rs5750833	chr22:39843091	C/A	cg05872129	chr22:39784769	NA	-0.96	-9.51	-0.65	1.99e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs6598955	0.671	rs12142535	chr1:26589698	T/A	cg04990556	chr1:26633338	UBXN11	0.64	4.91	0.4	2.78e-6	Obesity-related traits;
TGCT	cis	rs11741688	0.557	rs6600994	chr5:178336005	T/A	cg08270223	chr5:178322770	ZFP2	-0.37	-5.49	-0.44	2.14e-7	Sleep duration;
TGCT	cis	rs968451	0.789	rs1569498	chr22:39714704	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.85	9.24	0.64	8.48e-16	Primary biliary cholangitis;
TGCT	cis	rs1865760	0.593	rs9393676	chr6:25936944	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.63	6.67	0.51	7.58e-10	Height;
TGCT	cis	rs79057730	0.639	rs6463933	chr7:793954	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.65	5.37	0.43	3.82e-7	Initial pursuit acceleration;
TGCT	cis	rs9814567	1.000	rs4417907	chr3:134291363	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.98	-9.53	-0.65	1.7e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	trans	rs8073060	0.586	rs72829922	chr17:34044809	G/A	cg19694781	chr19:47549865	TMEM160	0.6	13.37	0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg00533182	chr8:145726136	PPP1R16A	0.27	4.58	0.38	1.11e-5	Age at first birth;
TGCT	cis	rs4919694	0.901	rs113541728	chr10:104716771	A/T	cg04362960	chr10:104952993	NT5C2	1.07	7.15	0.54	6.49e-11	Arsenic metabolism;
TGCT	trans	rs2832077	0.689	rs2832055	chr21:30132382	C/G	cg14791747	chr16:20752902	THUMPD1	-0.81	-7.05	-0.53	1.13e-10	Cognitive test performance;
TGCT	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.0	8.11	0.59	4.07e-13	Platelet count;
TGCT	cis	rs1372520	0.684	rs1442148	chr4:90748846	T/A	cg20003494	chr4:90757398	SNCA	-0.63	-5.09	-0.42	1.3e-6	Neuroticism;
TGCT	cis	rs11690935	0.632	rs34242651	chr2:172553999	G/A	cg13550731	chr2:172543902	DYNC1I2	0.69	6.09	0.48	1.33e-8	Schizophrenia;
TGCT	cis	rs11098499	0.532	rs4833624	chr4:120585497	C/T	cg09307838	chr4:120376055	NA	0.59	5.6	0.45	1.31e-7	Corneal astigmatism;
TGCT	cis	rs854765	0.964	rs854764	chr17:18011750	A/G	cg04398451	chr17:18023971	MYO15A	0.31	5.06	0.41	1.47e-6	Total body bone mineral density;
TGCT	cis	rs7714584	1.000	rs11746807	chr5:150300419	G/A	cg22134413	chr5:150180641	NA	1.01	7.24	0.55	4.17e-11	Crohn's disease;
TGCT	cis	rs593982	0.858	rs663797	chr11:65552740	A/G	cg08755490	chr11:65554678	OVOL1	1.41	11.56	0.72	2e-21	Atopic dermatitis;
TGCT	cis	rs2637266	1.000	rs2130795	chr10:78333892	C/G	cg18941641	chr10:78392320	NA	0.41	4.98	0.41	2.05e-6	Pulmonary function;
TGCT	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg06221963	chr1:154839813	KCNN3	-0.71	-11.67	-0.72	1.1e-21	Prostate cancer;
TGCT	cis	rs3947	0.688	rs1293326	chr8:11694765	G/C	cg02840367	chr8:11660030	FDFT1	0.89	6.56	0.51	1.3e-9	Blood protein levels;
TGCT	cis	rs4972539	0.576	rs2358090	chr2:174098461	G/C	cg08748100	chr2:173100097	NA	0.45	4.93	0.4	2.59e-6	Parental longevity (mother's age at death);
TGCT	cis	rs17376456	0.825	rs13182631	chr5:93115701	A/G	cg25358565	chr5:93447407	FAM172A	0.91	8.22	0.59	2.27e-13	Diabetic retinopathy;
TGCT	cis	rs7213347	0.707	rs216215	chr17:2140668	C/T	cg20777128	chr17:1945076	DPH1;OVCA2	-0.5	-4.62	-0.38	9.49e-6	Total body bone mineral density;
TGCT	cis	rs3793683	0.928	rs2148666	chr10:134553785	A/G	cg27286337	chr10:134555280	INPP5A	0.48	7.35	0.55	2.3e-11	Migraine;
TGCT	cis	rs4722166	0.630	rs1829927	chr7:22779918	G/A	cg26061582	chr7:22766209	IL6	0.57	7.36	0.55	2.27e-11	Lung cancer;
TGCT	cis	rs892864	0.685	rs6886402	chr5:127738895	C/A	cg01939274	chr5:127874478	FBN2	0.91	4.52	0.38	1.44e-5	Multiple system atrophy;
TGCT	cis	rs10170846	0.861	rs12694582	chr2:223521955	G/C	cg25565276	chr2:223520875	FARSB	0.55	4.58	0.38	1.11e-5	Schizophrenia (inflammation and infection response interaction);
TGCT	cis	rs9430161	0.564	rs12081176	chr1:11034145	T/C	cg27631724	chr1:11040367	C1orf127	0.53	6.05	0.48	1.58e-8	Ewing sarcoma;
TGCT	cis	rs1577917	1.000	rs11758849	chr6:86708262	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.57	-0.45	1.53e-7	Response to antipsychotic treatment;
TGCT	cis	rs7674212	1.000	rs7691873	chr4:103987899	C/T	cg16532752	chr4:104119610	CENPE	0.49	4.67	0.39	7.71e-6	Type 2 diabetes;
TGCT	cis	rs6964587	0.967	rs10248102	chr7:91699779	G/A	cg22709100	chr7:91322751	NA	0.28	4.56	0.38	1.19e-5	Breast cancer;
TGCT	cis	rs55910451	0.723	rs3793707	chr10:5798730	G/T	cg09234995	chr10:5726438	C10orf18	0.48	4.43	0.37	2.01e-5	Breast cancer;
TGCT	cis	rs67311347	1.000	rs1454497	chr3:40496326	C/T	cg17264618	chr3:40429014	ENTPD3	-0.32	-4.45	-0.37	1.9e-5	Renal cell carcinoma;
TGCT	cis	rs9467773	0.596	rs3001369	chr6:26670969	C/T	cg26531700	chr6:26746687	NA	0.59	5.15	0.42	9.94e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7552404	1.000	rs441109	chr1:76120430	T/G	cg03433033	chr1:76189801	ACADM	-0.84	-10.12	-0.67	6.47e-18	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs904251	0.797	rs1757177	chr6:37486370	C/T	cg08126542	chr6:37504118	NA	-0.44	-5.58	-0.45	1.46e-7	Cognitive performance;
TGCT	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg00149659	chr3:10157352	C3orf10	1.18	7.44	0.56	1.44e-11	Alzheimer's disease;
TGCT	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg00343986	chr7:65444356	GUSB	-0.22	-5.01	-0.41	1.84e-6	Aortic root size;
TGCT	cis	rs1475911	1.000	rs34421316	chr21:43513989	C/T	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.27	-4.91	-0.4	2.77e-6	IgG glycosylation;
TGCT	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg17554472	chr22:41940697	POLR3H	0.43	4.79	0.39	4.73e-6	Vitiligo;
TGCT	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg11764359	chr7:65958608	NA	-0.57	-5.12	-0.42	1.12e-6	Aortic root size;
TGCT	cis	rs2458413	0.563	rs2458419	chr8:105337141	G/C	cg04554929	chr8:105342491	NA	-0.61	-9.81	-0.66	3.55e-17	Paget's disease;
TGCT	cis	rs12802200	0.561	rs7937217	chr11:571967	T/C	cg27205902	chr11:1006985	AP2A2	0.27	4.47	0.37	1.76e-5	Systemic lupus erythematosus;
TGCT	cis	rs4319547	0.956	rs7316149	chr12:123063912	G/A	cg23029597	chr12:123009494	RSRC2	-0.31	-5.09	-0.42	1.3e-6	Body mass index;
TGCT	trans	rs17685	0.753	rs1637051	chr7:75730659	G/A	cg19862616	chr7:65841803	NCRNA00174	0.49	7.91	0.58	1.24e-12	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs3027009	0.881	rs61828178	chr1:159159041	G/T	cg18972751	chr1:158261555	CD1C	-0.45	-4.74	-0.39	5.84e-6	Lean body mass and age at menarche (combined);
TGCT	cis	rs6088580	0.609	rs945674	chr20:32964247	G/C	cg06115741	chr20:33292138	TP53INP2	-0.55	-4.81	-0.4	4.28e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs1008375	1.000	rs6849704	chr4:17652031	G/C	cg18681998	chr4:17616180	MED28	1.01	11.89	0.73	3.17e-22	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10057188	1.000	rs12697888	chr5:77859646	C/T	cg06873401	chr5:77792105	LHFPL2	-0.24	-4.54	-0.38	1.32e-5	Pulse pressure;
TGCT	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg17971929	chr21:40555470	PSMG1	-0.68	-5.94	-0.47	2.67e-8	Cognitive function;
TGCT	cis	rs17068510	0.572	rs11780696	chr8:3875497	A/G	cg25338036	chr8:3047536	CSMD1	-0.46	-4.88	-0.4	3.19e-6	Cerebrospinal fluid clusterin levels;
TGCT	cis	rs3091242	0.933	rs35530120	chr1:25785451	A/G	cg00786635	chr1:25594202	NA	-0.53	-5.66	-0.45	9.94e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs9457247	1.000	rs385113	chr6:167403971	A/G	cg23791538	chr6:167370224	RNASET2	-0.49	-4.96	-0.41	2.26e-6	Crohn's disease;
TGCT	trans	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg17470723	chr8:74884337	TCEB1	0.71	6.77	0.52	4.48e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs896854	0.738	rs527234	chr8:95963798	C/G	cg13393036	chr8:95962371	TP53INP1	0.56	6.99	0.53	1.51e-10	Type 2 diabetes;
TGCT	cis	rs6121246	0.529	rs6058152	chr20:30178107	G/A	cg13852791	chr20:30311386	BCL2L1	0.69	4.53	0.38	1.36e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs3096299	0.632	rs8051537	chr16:89544384	T/A	cg06640241	chr16:89574553	SPG7	0.79	9.12	0.63	1.68e-15	Multiple myeloma (IgH translocation);
TGCT	cis	rs6450176	0.585	rs255761	chr5:53321956	G/T	ch.5.1024479R	chr5:53302184	ARL15	-0.52	-4.51	-0.38	1.47e-5	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs3743162	0.553	rs12915656	chr15:85415580	G/C	cg11189052	chr15:85197271	WDR73	0.65	4.78	0.39	4.97e-6	Alzheimer's disease (age of onset);
TGCT	cis	rs2235642	0.928	rs2076435	chr16:1607574	C/T	cg07639376	chr16:1584516	IFT140;TMEM204	-0.32	-5.75	-0.46	6.52e-8	Coronary artery disease;
TGCT	cis	rs988712	0.705	rs11030104	chr11:27684517	C/T	cg10635145	chr11:27742435	BDNF	0.44	6.19	0.49	8.21e-9	Obesity;
TGCT	cis	rs853679	0.567	rs1005126	chr6:28367623	C/G	cg18815343	chr6:28367644	ZSCAN12	-0.52	-4.67	-0.39	7.85e-6	Depression;
TGCT	cis	rs651907	0.967	rs641432	chr3:101587566	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.46	4.79	0.4	4.6e-6	Colorectal cancer;
TGCT	trans	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg25482853	chr8:67687455	SGK3	1.22	10.53	0.69	6.33e-19	Obesity-related traits;
TGCT	cis	rs10779751	0.959	rs2300091	chr1:11266711	C/T	cg08854313	chr1:11322531	MTOR	0.92	10.31	0.68	2.23e-18	Body mass index;
TGCT	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	8.39	0.6	9.03e-14	Platelet count;
TGCT	cis	rs7599312	1.000	rs7599312	chr2:213413231	C/T	cg16329650	chr2:213403929	ERBB4	0.75	6.37	0.5	3.31e-9	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7666738	0.830	rs10001701	chr4:98918871	G/C	cg18180107	chr4:99064573	C4orf37	0.55	5.02	0.41	1.78e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2862064	0.872	rs2902132	chr5:156445525	C/T	cg12943317	chr5:156479607	HAVCR1	-0.45	-5.71	-0.46	7.96e-8	Platelet count;
TGCT	cis	rs7267979	1.000	rs2387880	chr20:25377787	T/C	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs709400	0.628	rs11622320	chr14:103912194	A/T	cg12935359	chr14:103987150	CKB	-0.34	-4.95	-0.41	2.34e-6	Body mass index;
TGCT	cis	rs7731657	0.537	rs72801791	chr5:130374799	T/C	cg08523029	chr5:130500466	HINT1	-0.61	-5.08	-0.42	1.34e-6	Fasting plasma glucose;
TGCT	trans	rs7726839	0.540	rs56325086	chr5:640728	G/A	cg25482853	chr8:67687455	SGK3	1.21	10.75	0.69	1.86e-19	Obesity-related traits;
TGCT	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg24399712	chr22:39784796	NA	-1.06	-12.58	-0.75	6.72e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs11644362	0.966	rs4781348	chr16:12986742	A/C	cg06890432	chr16:12997467	SHISA9	-0.6	-6.4	-0.5	2.87e-9	Positive affect;Subjective well-being;
TGCT	cis	rs9329221	0.905	rs6601451	chr8:10243681	C/G	cg21775007	chr8:11205619	TDH	-0.52	-4.87	-0.4	3.33e-6	Neuroticism;
TGCT	cis	rs11190604	1.000	rs7099965	chr10:102301165	A/G	cg16342193	chr10:102329863	NA	-0.4	-4.97	-0.41	2.14e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9796	0.553	rs7171437	chr15:41315168	G/A	cg26219294	chr15:41245916	CHAC1	0.36	4.45	0.37	1.89e-5	Menopause (age at onset);
TGCT	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	5.8	0.46	5.19e-8	Alzheimer's disease;
TGCT	cis	rs76935404	0.811	rs12151139	chr19:41433543	A/G	cg19493303	chr19:41414353	NA	-0.43	-5.18	-0.42	8.63e-7	nicotine metabolite ratio in current smokers;
TGCT	cis	rs3820068	0.705	rs2145397	chr1:15896199	G/A	cg05660106	chr1:15850417	CASP9	1.17	14.8	0.8	3.47e-29	Systolic blood pressure;
TGCT	cis	rs137887	0.935	rs137885	chr22:50463231	T/C	cg17558497	chr22:50464837	TTLL8	0.2	4.45	0.37	1.92e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
TGCT	cis	rs9364220	0.662	rs2087570	chr6:168494037	C/T	cg02770688	chr6:168491649	NA	-0.29	-5.48	-0.44	2.29e-7	Attention deficit hyperactivity disorder (inattention symptoms);Attention deficit hyperactivity disorder (combined symptoms);
TGCT	cis	rs11715566	0.515	rs11713893	chr3:117606479	A/G	cg15509235	chr3:117715573	NA	0.56	5.14	0.42	1.04e-6	Menarche (age at onset);
TGCT	cis	rs611744	0.967	rs597992	chr8:109193808	A/T	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs8097348	0.817	rs8096095	chr18:1670019	A/C	cg07100532	chr18:713085	ENOSF1	-0.4	-4.45	-0.37	1.87e-5	Exercise (leisure time);
TGCT	cis	rs10782582	0.586	rs112368938	chr1:76336339	C/T	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.52	4.53	0.38	1.37e-5	Daytime sleep phenotypes;
TGCT	cis	rs2412459	0.611	rs4924402	chr15:40245754	C/T	cg22077389	chr15:40226273	EIF2AK4	-0.69	-4.44	-0.37	1.97e-5	Response to haloperidol in psychosis;
TGCT	cis	rs7568458	0.846	rs7605975	chr2:85772548	C/T	cg17127132	chr2:85788382	GGCX	0.68	6.59	0.51	1.12e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg06481639	chr22:41940642	POLR3H	0.75	6.66	0.51	8.03e-10	Vitiligo;
TGCT	cis	rs1385374	0.858	rs11059930	chr12:129297860	T/C	cg09035930	chr12:129282057	SLC15A4	-0.55	-4.76	-0.39	5.27e-6	Systemic lupus erythematosus;
TGCT	cis	rs6750047	0.625	rs336036	chr2:38261143	C/T	cg07380506	chr2:38303506	CYP1B1	-0.54	-4.73	-0.39	6.12e-6	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs2439831	0.850	rs3736180	chr15:44106624	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	6.27	0.49	5.48e-9	Lung cancer in ever smokers;
TGCT	cis	rs8013055	0.846	rs10139744	chr14:105974696	G/A	cg19700328	chr14:106028568	NA	-0.49	-5.23	-0.43	6.91e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs6545883	0.894	rs10496092	chr2:61524679	C/T	cg15711740	chr2:61764176	XPO1	0.55	4.72	0.39	6.17e-6	Tuberculosis;
TGCT	cis	rs4808199	0.948	rs757001	chr19:19448808	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.63	4.56	0.38	1.23e-5	Nonalcoholic fatty liver disease;
TGCT	cis	rs4494114	0.967	rs6679612	chr1:39313228	G/A	cg25970120	chr1:39325951	RRAGC	-0.6	-6.28	-0.49	5.09e-9	Blood protein levels;
TGCT	cis	rs114540395	0.858	rs17767748	chr10:103285900	A/G	cg09701700	chr10:104194843	MIR146B	0.46	4.76	0.39	5.28e-6	Schizophrenia;
TGCT	cis	rs1670533	0.818	rs6835141	chr4:1070140	G/T	cg20887711	chr4:1340912	KIAA1530	0.63	4.95	0.41	2.32e-6	Recombination rate (females);
TGCT	cis	rs7729723	0.568	rs11242430	chr5:137822866	C/A	cg19169342	chr5:137827400	NA	0.32	4.46	0.37	1.78e-5	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);
TGCT	cis	rs2688608	0.592	rs7923045	chr10:75487498	A/T	cg19442545	chr10:75533431	FUT11	-0.36	-5.68	-0.45	9.11e-8	Inflammatory bowel disease;
TGCT	cis	rs10465746	0.967	rs11576870	chr1:84333301	G/A	cg10977910	chr1:84465055	TTLL7	0.63	6.19	0.49	8.08e-9	Obesity-related traits;
TGCT	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg11644478	chr21:40555479	PSMG1	-0.58	-5.0	-0.41	1.94e-6	Cognitive function;
TGCT	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg20849893	chr7:64541193	NA	-0.48	-4.89	-0.4	3.1e-6	Calcium levels;
TGCT	cis	rs637571	0.522	rs491973	chr11:65727301	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.6	6.03	0.48	1.75e-8	Eosinophil percentage of white cells;
TGCT	cis	rs2230307	0.536	rs7530361	chr1:100462860	T/C	cg24955406	chr1:100503596	HIAT1	0.72	4.68	0.39	7.51e-6	Carotid intima media thickness;
TGCT	cis	rs1865760	1.000	rs1865760	chr6:25916979	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.65	6.18	0.49	8.59e-9	Height;
TGCT	cis	rs7617773	0.746	rs11713476	chr3:48375434	C/T	cg11946769	chr3:48343235	NME6	0.74	6.6	0.51	1.05e-9	Coronary artery disease;
TGCT	cis	rs7027203	0.797	rs7870672	chr9:96606693	A/C	cg13679303	chr9:96623674	NA	-0.66	-10.78	-0.7	1.64e-19	DNA methylation (variation);
TGCT	cis	rs78456975	1.000	rs6712176	chr2:1556393	C/T	cg01028140	chr2:1542097	TPO	-0.33	-4.53	-0.38	1.37e-5	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs523522	0.962	rs2393590	chr12:120913900	G/A	cg12219531	chr12:120966889	COQ5	0.83	7.33	0.55	2.6e-11	High light scatter reticulocyte count;
TGCT	cis	rs2239785	0.920	rs136178	chr22:36664339	A/G	cg15716373	chr22:36655542	APOL1	-0.48	-5.1	-0.42	1.26e-6	Glomerulosclerosis;
TGCT	cis	rs11167764	1.000	rs6580220	chr5:141480558	G/A	cg23435118	chr5:141488016	NDFIP1	-0.3	-4.96	-0.41	2.31e-6	Crohn's disease;
TGCT	cis	rs754133	0.535	rs7297416	chr12:54443090	A/C	cg16264616	chr12:54390824	NA	0.38	5.37	0.43	3.73e-7	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;
TGCT	cis	rs9611565	0.877	rs3817999	chr22:41747717	A/G	cg17554472	chr22:41940697	POLR3H	0.48	5.29	0.43	5.25e-7	Vitiligo;
TGCT	cis	rs6460942	0.915	rs6968695	chr7:12443878	G/C	cg06484146	chr7:12443880	VWDE	-0.57	-5.52	-0.44	1.92e-7	Coronary artery disease;
TGCT	cis	rs6964587	1.000	rs2282972	chr7:91666369	C/T	cg22709100	chr7:91322751	NA	0.28	4.56	0.38	1.19e-5	Breast cancer;
TGCT	cis	rs7659604	0.791	rs57316471	chr4:122663939	A/G	cg19748678	chr4:122722346	EXOSC9	0.73	7.37	0.55	2.08e-11	Type 2 diabetes;
TGCT	cis	rs78487399	0.808	rs13405076	chr2:43735353	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-4.84	-0.4	3.79e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg03161606	chr19:29218774	NA	0.6	5.84	0.46	4.28e-8	Methadone dose in opioid dependence;
TGCT	cis	rs56104184	0.830	rs17206679	chr19:49342237	C/G	cg17863274	chr19:49399704	TULP2	-0.48	-6.07	-0.48	1.44e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs9926296	0.744	rs164748	chr16:89708292	C/G	cg26513180	chr16:89883248	FANCA	-0.61	-5.73	-0.46	7.18e-8	Vitiligo;
TGCT	cis	rs12477438	0.798	rs9679602	chr2:99577827	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.68	5.97	0.47	2.3e-8	Chronic sinus infection;
TGCT	cis	rs7615952	0.673	rs115942855	chr3:125601960	G/A	cg05084668	chr3:125655381	ALG1L	-0.75	-4.68	-0.39	7.51e-6	Blood pressure (smoking interaction);
TGCT	cis	rs2197308	0.703	rs10880251	chr12:37903297	G/A	cg13010199	chr12:38710504	ALG10B	0.67	5.38	0.44	3.57e-7	Morning vs. evening chronotype;
TGCT	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg07507251	chr3:52567010	NT5DC2	0.46	6.66	0.51	7.92e-10	Bipolar disorder;
TGCT	cis	rs2404618	0.624	rs28439223	chr8:1476901	C/G	cg13402656	chr8:1511478	DLGAP2	-0.34	-5.55	-0.45	1.69e-7	Lung cancer;
TGCT	cis	rs7615952	0.800	rs12489350	chr3:125644116	T/C	cg05084668	chr3:125655381	ALG1L	-0.76	-6.22	-0.49	7.13e-9	Blood pressure (smoking interaction);
TGCT	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg13397359	chr6:42928475	GNMT	0.73	6.81	0.52	3.7e-10	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs4253772	0.551	rs9615936	chr22:46686328	C/G	cg24881330	chr22:46731750	TRMU	1.03	5.41	0.44	3.06e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7192750	0.586	rs8051038	chr16:71870700	G/A	cg06353428	chr16:71660113	MARVELD3	0.8	7.26	0.55	3.8e-11	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs7666738	0.830	rs13106434	chr4:98991651	T/A	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9443645	0.901	rs1567167	chr6:79553827	C/T	cg05283184	chr6:79620031	NA	-0.2	-4.67	-0.39	7.72e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs245880	0.740	rs245890	chr7:29190720	T/C	cg17163760	chr7:29186267	CPVL	-0.44	-5.54	-0.45	1.73e-7	Warfarin maintenance dose;
TGCT	cis	rs2288073	0.965	rs6545338	chr2:24422156	C/T	cg02683114	chr2:24398427	C2orf84	-0.25	-5.67	-0.45	9.72e-8	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg18402987	chr7:1209562	NA	0.76	6.39	0.5	3e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9325144	0.560	rs11183150	chr12:38674698	A/G	cg26384229	chr12:38710491	ALG10B	-0.64	-5.82	-0.46	4.63e-8	Morning vs. evening chronotype;
TGCT	cis	rs2354432	1.000	rs10900325	chr1:146692174	C/T	cg25205988	chr1:146714368	CHD1L	-1.33	-7.77	-0.57	2.56e-12	Mitochondrial DNA levels;
TGCT	cis	rs7666738	0.716	rs114187620	chr4:98819534	T/A	cg18180107	chr4:99064573	C4orf37	0.55	5.25	0.43	6.31e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs79057730	0.528	rs6965219	chr7:821807	C/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.65	6.04	0.48	1.67e-8	Initial pursuit acceleration;
TGCT	cis	rs7666738	0.830	rs28867087	chr4:98880349	T/A	cg18180107	chr4:99064573	C4orf37	0.57	5.19	0.42	8.47e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2046867	0.862	rs2174062	chr3:72826901	T/C	cg25664220	chr3:72788482	NA	-0.54	-6.72	-0.52	5.99e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.01	0.41	1.86e-6	Prudent dietary pattern;
TGCT	cis	rs7095607	0.813	rs7913516	chr10:69927932	G/A	cg18986048	chr10:69913749	MYPN	0.44	5.03	0.41	1.71e-6	Lung function (FVC);
TGCT	cis	rs7513165	0.935	rs4951319	chr1:204162230	A/G	cg12731349	chr1:204159619	KISS1	0.44	5.07	0.41	1.38e-6	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
TGCT	cis	rs2228479	0.541	rs13335395	chr16:89952843	T/A	cg06558623	chr16:89946397	TCF25	0.43	5.1	0.42	1.26e-6	Skin colour saturation;
TGCT	cis	rs4776059	0.761	rs12594964	chr15:52900208	G/A	cg25063058	chr15:52860530	ARPP19	-0.56	-4.44	-0.37	1.98e-5	Schizophrenia;
TGCT	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.85	-9.45	-0.65	2.76e-16	Age at first birth;
TGCT	cis	rs5769707	0.967	rs1018812	chr22:50010073	C/T	cg10356904	chr22:49881777	NA	-0.24	-4.81	-0.4	4.35e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs265548	0.608	rs265545	chr19:17903465	C/T	cg03316864	chr19:17906309	B3GNT3	0.43	4.95	0.41	2.36e-6	Tumor biomarkers;
TGCT	cis	rs1568889	0.838	rs11030229	chr11:28173634	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.92	10.74	0.69	1.97e-19	Bipolar disorder;
TGCT	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg18402987	chr7:1209562	NA	0.78	6.64	0.51	8.96e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7223966	1.000	rs7209758	chr17:61913621	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	4.68	0.39	7.5e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg14983838	chr19:29218262	NA	0.75	6.87	0.53	2.69e-10	Methadone dose in opioid dependence;
TGCT	cis	rs4478858	0.684	rs10798838	chr1:31719450	G/A	cg00250761	chr1:31883323	NA	-0.26	-4.74	-0.39	5.75e-6	Alcohol dependence;
TGCT	cis	rs208520	1.000	rs12195505	chr6:66986279	T/A	cg07460842	chr6:66804631	NA	0.78	6.82	0.52	3.61e-10	Exhaled nitric oxide output;
TGCT	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg13397359	chr6:42928475	GNMT	0.69	6.21	0.49	7.25e-9	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg10802521	chr3:52805072	NEK4	-0.7	-8.8	-0.62	9.89e-15	Bipolar disorder;
TGCT	cis	rs739496	0.527	rs61612992	chr12:112358064	T/C	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs11785400	0.762	rs7460801	chr8:143730972	C/A	cg24634471	chr8:143751801	JRK	0.53	5.24	0.43	6.79e-7	Schizophrenia;
TGCT	cis	rs11578119	0.933	rs4656776	chr1:170469838	C/T	cg09767346	chr1:170501363	GORAB	-0.67	-5.36	-0.43	3.85e-7	Male-pattern baldness;
TGCT	cis	rs11809207	0.859	rs61776644	chr1:26505548	T/C	cg03844060	chr1:26490628	NA	0.28	5.07	0.41	1.43e-6	Height;
TGCT	cis	rs7100689	0.646	rs2486302	chr10:82076600	G/A	cg01528321	chr10:82214614	TSPAN14	0.75	7.49	0.56	1.15e-11	Post bronchodilator FEV1;
TGCT	cis	rs9443645	0.869	rs10943609	chr6:79676328	A/T	cg05283184	chr6:79620031	NA	-0.21	-4.71	-0.39	6.56e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4631830	0.900	rs10763576	chr10:51538813	A/T	cg10326726	chr10:51549505	MSMB	-0.25	-5.05	-0.41	1.51e-6	Prostate-specific antigen levels;
TGCT	cis	rs56104184	1.000	rs56104184	chr19:49370310	C/T	cg21252483	chr19:49399788	TULP2	-0.33	-5.2	-0.42	7.94e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg16049864	chr8:95962084	TP53INP1	-0.75	-10.48	-0.69	8.55e-19	Type 2 diabetes;
TGCT	cis	rs7000551	0.532	rs4872486	chr8:22256359	G/T	cg12081754	chr8:22256438	SLC39A14	0.36	5.32	0.43	4.7e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs9486715	0.867	rs2475025	chr6:96988696	A/T	cg06623918	chr6:96969491	KIAA0776	-1.09	-15.75	-0.82	2.31e-31	Headache;
TGCT	cis	rs682748	0.904	rs297170	chr5:17151417	T/C	cg23987134	chr5:17158319	LOC285696	-0.23	-5.42	-0.44	2.93e-7	Hippocampal atrophy;
TGCT	cis	rs11578119	1.000	rs12120764	chr1:170514229	G/A	cg09767346	chr1:170501363	GORAB	0.65	5.17	0.42	9.21e-7	Male-pattern baldness;
TGCT	cis	rs72634258	0.519	rs4908708	chr1:7938113	G/C	cg26816564	chr1:7831052	VAMP3	0.57	4.51	0.38	1.46e-5	Inflammatory bowel disease;
TGCT	cis	rs394563	0.559	rs7753269	chr6:149671360	G/A	cg03678062	chr6:149772716	ZC3H12D	0.38	4.83	0.4	3.94e-6	Dupuytren's disease;
TGCT	cis	rs477895	0.713	rs11600867	chr11:63972052	T/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.79	6.38	0.5	3.12e-9	Mean platelet volume;
TGCT	cis	rs826838	1.000	rs9795768	chr12:39012479	T/C	cg26384229	chr12:38710491	ALG10B	1.02	9.78	0.66	4.37e-17	Heart rate;
TGCT	cis	rs7267979	1.000	rs11087520	chr20:25436827	C/T	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs10203711	0.933	rs4994752	chr2:239567309	C/A	cg16021909	chr1:248021091	TRIM58	-0.66	-6.66	-0.51	7.94e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9486719	1.000	rs6923212	chr6:97061940	A/G	cg06623918	chr6:96969491	KIAA0776	-0.95	-8.2	-0.59	2.62e-13	Migraine;Coronary artery disease;
TGCT	cis	rs6967414	1.000	rs6967414	chr7:6749758	G/A	cg09896999	chr7:6746977	ZNF12	-0.55	-6.34	-0.49	3.97e-9	Hematocrit;Hemoglobin concentration;
TGCT	trans	rs4919669	0.668	rs10883761	chr10:104420018	A/G	cg16267304	chr21:44985357	HSF2BP	0.65	6.69	0.51	6.85e-10	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs2580764	0.678	rs2588521	chr2:55203931	C/G	cg09592903	chr2:55203963	RTN4	0.24	5.4	0.44	3.29e-7	Mean platelet volume;
TGCT	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg16325326	chr1:53192061	ZYG11B	0.69	8.18	0.59	2.93e-13	Monocyte count;
TGCT	cis	rs3741404	0.895	rs1860368	chr11:63994692	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.9	-9.87	-0.66	2.64e-17	Platelet count;
TGCT	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.49	-4.76	-0.39	5.34e-6	Bipolar disorder;
TGCT	cis	rs4595586	0.545	rs7307303	chr12:39368976	A/G	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs7267979	1.000	rs2424710	chr20:25283886	C/G	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg06873352	chr17:61820015	STRADA	-0.47	-5.12	-0.42	1.14e-6	Prudent dietary pattern;
TGCT	cis	rs28595532	0.925	rs56200441	chr4:119497440	T/G	cg21605333	chr4:119757512	SEC24D	1.33	8.01	0.58	7.07e-13	Cannabis dependence symptom count;
TGCT	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg03709012	chr19:19516395	GATAD2A	-0.66	-5.7	-0.46	8.46e-8	Tonsillectomy;
TGCT	cis	rs514406	0.644	rs4926928	chr1:53210163	G/T	cg08736216	chr1:53307985	ZYG11A	-0.24	-4.55	-0.38	1.24e-5	Monocyte count;
TGCT	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.97	-8.37	-0.6	1.03e-13	Platelet count;
TGCT	cis	rs4919694	1.000	rs35159404	chr10:104805610	C/A	cg04362960	chr10:104952993	NT5C2	1.06	7.05	0.53	1.09e-10	Arsenic metabolism;
TGCT	cis	rs58722170	0.517	rs17559337	chr1:38039034	T/C	cg17933807	chr1:38061675	GNL2	-0.83	-7.46	-0.56	1.32e-11	High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs6430585	0.591	rs12477421	chr2:136433740	A/G	cg07169764	chr2:136633963	MCM6	1.07	9.6	0.65	1.19e-16	Corneal structure;
TGCT	cis	rs2236918	0.710	rs851781	chr1:242034868	C/T	cg04158730	chr1:242011433	EXO1	0.56	5.16	0.42	9.55e-7	Menopause (age at onset);
TGCT	cis	rs1670533	1.000	rs935972	chr4:1045171	A/G	cg20887711	chr4:1340912	KIAA1530	0.72	5.22	0.42	7.33e-7	Recombination rate (females);
TGCT	cis	rs2637266	1.000	rs10219021	chr10:78364516	C/T	cg18941641	chr10:78392320	NA	0.4	4.73	0.39	6.03e-6	Pulmonary function;
TGCT	cis	rs11098499	0.657	rs7664458	chr4:120371967	A/G	cg09307838	chr4:120376055	NA	0.68	6.53	0.51	1.54e-9	Corneal astigmatism;
TGCT	cis	rs9325144	0.647	rs35138700	chr12:38804474	C/T	cg26384229	chr12:38710491	ALG10B	-0.61	-5.72	-0.46	7.51e-8	Morning vs. evening chronotype;
TGCT	cis	rs2832191	0.716	rs1888440	chr21:30454484	C/T	cg24692254	chr21:30365293	RNF160	0.98	11.36	0.71	6.16e-21	Dental caries;
TGCT	trans	rs2727020	0.688	rs4929894	chr11:49196333	G/C	cg15704280	chr7:45808275	SEPT13	-0.72	-8.06	-0.59	5.53e-13	Coronary artery disease;
TGCT	cis	rs8050907	0.744	rs11862204	chr16:4519586	G/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.53	4.57	0.38	1.15e-5	Obesity-related traits;
TGCT	cis	rs7017914	0.905	rs2639955	chr8:71925342	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.56	-5.11	-0.42	1.21e-6	Bone mineral density;
TGCT	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg13342137	chr4:2252803	MXD4	-0.17	-4.6	-0.38	1.05e-5	Obesity-related traits;
TGCT	cis	rs2469997	0.800	rs2447177	chr8:120356431	A/G	cg00681363	chr8:120844660	TAF2	0.72	4.69	0.39	7.2e-6	Hypertension (SNP x SNP interaction);
TGCT	cis	rs12791968	0.765	rs2279359	chr11:44999605	A/G	cg11846598	chr11:44996168	LOC221122	0.31	5.02	0.41	1.73e-6	Inhibitory control;
TGCT	cis	rs7044106	0.791	rs10739572	chr9:123489815	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	5.16	0.42	9.67e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	9.52	0.65	1.86e-16	Platelet count;
TGCT	cis	rs7100689	0.622	rs10749595	chr10:82172975	C/T	cg01528321	chr10:82214614	TSPAN14	0.94	9.82	0.66	3.45e-17	Post bronchodilator FEV1;
TGCT	cis	rs2658782	1.000	rs2658782	chr11:93166731	T/G	cg15737290	chr11:93063684	CCDC67	0.79	5.61	0.45	1.24e-7	Pulmonary function decline;
TGCT	cis	rs12893668	0.542	rs12884809	chr14:104095320	G/A	cg26031613	chr14:104095156	KLC1	-0.58	-5.01	-0.41	1.8e-6	Reticulocyte count;
TGCT	cis	rs12477438	0.501	rs12619780	chr2:99707307	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	7.89	0.58	1.34e-12	Chronic sinus infection;
TGCT	cis	rs2354432	0.607	rs7516430	chr1:146767062	A/G	cg25205988	chr1:146714368	CHD1L	-1.18	-7.03	-0.53	1.24e-10	Mitochondrial DNA levels;
TGCT	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.46	4.87	0.4	3.39e-6	Menopause (age at onset);
TGCT	cis	rs12541335	0.639	rs3923433	chr8:22169798	A/T	cg02463440	chr8:22132932	PIWIL2	0.26	5.16	0.42	9.37e-7	Hypertriglyceridemia;
TGCT	cis	rs4689388	0.853	rs11729672	chr4:6293838	A/G	cg14416269	chr4:6271139	WFS1	0.37	4.9	0.4	2.95e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs459571	0.959	rs416390	chr9:136908549	C/G	cg14405625	chr9:136855902	VAV2	0.29	4.45	0.37	1.92e-5	Platelet distribution width;
TGCT	cis	rs35883536	0.647	rs7524322	chr1:101047730	C/G	cg06223162	chr1:101003688	GPR88	0.42	7.76	0.57	2.65e-12	Monocyte count;
TGCT	cis	rs5769765	1.000	rs5770728	chr22:50259984	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.4	-6.01	-0.47	1.96e-8	Schizophrenia;
TGCT	cis	rs2640806	0.506	rs13254991	chr8:97371686	T/C	cg04026948	chr8:97953330	PGCP	-0.25	-4.55	-0.38	1.27e-5	Obesity-related traits;
TGCT	cis	rs12477438	0.520	rs2516827	chr2:99772565	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.82	0.62	8.67e-15	Chronic sinus infection;
TGCT	cis	rs1008375	1.000	rs6854733	chr4:17640526	C/T	cg18681998	chr4:17616180	MED28	1.01	11.89	0.73	3.17e-22	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs12681287	0.752	rs10085920	chr8:87252666	C/T	cg27223183	chr8:87520930	FAM82B	-0.81	-5.64	-0.45	1.09e-7	Caudate activity during reward;
TGCT	cis	rs2070488	0.775	rs6599208	chr3:38558104	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.71	-6.89	-0.53	2.46e-10	Electrocardiographic conduction measures;
TGCT	cis	rs3820068	0.559	rs6675334	chr1:15923580	A/T	cg05660106	chr1:15850417	CASP9	0.8	8.18	0.59	2.86e-13	Systolic blood pressure;
TGCT	cis	rs2070488	0.965	rs1870915	chr3:38494228	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.95	10.55	0.69	5.82e-19	Electrocardiographic conduction measures;
TGCT	cis	rs3099143	1.000	rs3099134	chr15:77133168	T/G	cg21673338	chr15:77095150	SCAPER	-0.54	-5.15	-0.42	1.01e-6	Recalcitrant atopic dermatitis;
TGCT	cis	rs35883536	0.528	rs10783138	chr1:101031061	C/T	cg06223162	chr1:101003688	GPR88	0.43	8.41	0.6	8.23e-14	Monocyte count;
TGCT	cis	rs6831352	0.959	rs6532796	chr4:100042242	C/T	cg12011299	chr4:100065546	ADH4	-0.48	-5.72	-0.46	7.68e-8	Alcohol dependence;
TGCT	cis	rs4788439	0.901	rs72770501	chr16:24982324	G/C	cg07626409	chr16:25250191	ZKSCAN2	0.33	4.58	0.38	1.1e-5	Blood metabolite levels;
TGCT	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.01	0.41	1.86e-6	Prudent dietary pattern;
TGCT	cis	rs8013055	0.846	rs10147392	chr14:105978537	T/G	cg19700328	chr14:106028568	NA	-0.53	-5.85	-0.47	4.1e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs2204008	0.744	rs8189486	chr12:38244968	C/T	cg26384229	chr12:38710491	ALG10B	0.86	7.42	0.55	1.6e-11	Bladder cancer;
TGCT	cis	rs11098499	0.954	rs7437420	chr4:120312903	A/G	cg09307838	chr4:120376055	NA	0.66	6.35	0.5	3.66e-9	Corneal astigmatism;
TGCT	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg03806693	chr22:41940476	POLR3H	1.14	12.74	0.75	2.72e-24	Vitiligo;
TGCT	cis	rs3947	0.951	rs1692813	chr8:11704296	G/T	cg02840367	chr8:11660030	FDFT1	0.89	6.47	0.5	2e-9	Blood protein levels;
TGCT	cis	rs5760092	0.755	rs6003959	chr22:24264395	C/T	cg11905131	chr22:24372483	LOC391322	0.7	5.63	0.45	1.14e-7	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs11696501	0.688	rs6073855	chr20:44309670	C/T	cg11783356	chr20:44313418	WFDC10B	-0.33	-4.49	-0.37	1.6e-5	Brain structure;
TGCT	cis	rs1570884	0.516	rs7334387	chr13:50172133	T/A	cg08779649	chr13:50194554	NA	0.37	5.84	0.46	4.24e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
TGCT	trans	rs1496653	0.602	rs13087238	chr3:23380071	C/G	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs2832191	0.626	rs2254796	chr21:30341891	A/G	cg24692254	chr21:30365293	RNF160	-0.93	-10.77	-0.7	1.69e-19	Dental caries;
TGCT	cis	rs9291683	0.551	rs2240720	chr4:10020480	C/T	cg00071950	chr4:10020882	SLC2A9	0.72	9.86	0.66	2.78e-17	Bone mineral density;
TGCT	cis	rs3008870	1.000	rs2985824	chr1:67410171	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.04	-11.07	-0.71	3.1e-20	Lymphocyte percentage of white cells;
TGCT	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg06481639	chr22:41940642	POLR3H	0.72	6.4	0.5	2.96e-9	Vitiligo;
TGCT	cis	rs7552404	0.691	rs5745449	chr1:76344711	A/T	cg03433033	chr1:76189801	ACADM	-0.76	-7.76	-0.57	2.66e-12	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs1008375	1.000	rs2315561	chr4:17679695	C/T	cg10189774	chr4:17578691	LAP3	0.56	5.25	0.43	6.39e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9611565	0.512	rs8141103	chr22:42136930	T/C	cg06634786	chr22:41940651	POLR3H	0.87	8.12	0.59	3.86e-13	Vitiligo;
TGCT	cis	rs13326165	0.760	rs11707931	chr3:52358417	C/G	cg07884673	chr3:53033167	SFMBT1	0.39	4.69	0.39	7e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	trans	rs3780486	0.846	rs913214	chr9:33135085	G/A	cg04842962	chr6:43655489	MRPS18A	1.24	15.76	0.82	2.18e-31	IgG glycosylation;
TGCT	cis	rs6430585	0.527	rs62168792	chr2:136415217	A/G	cg07169764	chr2:136633963	MCM6	0.96	8.46	0.61	6.24e-14	Corneal structure;
TGCT	cis	rs780096	0.545	rs11695549	chr2:27586155	A/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.38	4.89	0.4	3.06e-6	Total body bone mineral density;
TGCT	cis	rs7666738	0.830	rs28516388	chr4:98987449	A/G	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs17125944	0.505	rs77137752	chr14:53230496	G/T	cg00686598	chr14:53173677	PSMC6	1.08	6.32	0.49	4.37e-9	Alzheimer's disease (late onset);
TGCT	cis	rs11105298	0.891	rs10858871	chr12:89871613	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.7	-5.02	-0.41	1.79e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg21724239	chr8:58056113	NA	0.52	5.47	0.44	2.37e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9640161	0.789	rs13223702	chr7:150058968	G/A	cg10018233	chr7:150070692	REPIN1	0.31	4.45	0.37	1.88e-5	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs4851254	0.550	rs13402289	chr2:100659389	C/T	cg07810366	chr2:100720526	AFF3	-0.46	-4.91	-0.4	2.76e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs28595532	0.920	rs115853212	chr4:119765354	C/T	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg22166914	chr1:53195759	ZYG11B	0.35	5.78	0.46	5.7e-8	Monocyte count;
TGCT	cis	rs523522	0.847	rs11065132	chr12:120908459	C/T	cg27279351	chr12:120934652	DYNLL1	0.76	6.58	0.51	1.19e-9	High light scatter reticulocyte count;
TGCT	cis	rs2688608	0.653	rs12775558	chr10:75570868	G/A	cg23231163	chr10:75533350	FUT11	-0.28	-4.79	-0.4	4.71e-6	Inflammatory bowel disease;
TGCT	cis	rs9916302	0.718	rs7219909	chr17:37706243	C/T	cg07936489	chr17:37558343	FBXL20	-0.61	-4.87	-0.4	3.29e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2456568	0.867	rs72962810	chr11:93663619	A/G	cg16099599	chr11:93583650	C11orf90	-0.38	-4.51	-0.38	1.47e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs716804	0.678	rs10770096	chr11:10178359	C/G	cg17061862	chr11:9590431	NA	-0.37	-4.89	-0.4	3.06e-6	Neuroticism;
TGCT	cis	rs9810089	0.802	rs73222302	chr3:136098085	A/G	cg12473912	chr3:136751656	NA	0.35	4.98	0.41	2.11e-6	Gestational age at birth (child effect);
TGCT	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg12379764	chr21:47803548	PCNT	0.53	5.87	0.47	3.75e-8	Testicular germ cell tumor;
TGCT	trans	rs8073060	0.586	rs225265	chr17:33961972	C/T	cg19694781	chr19:47549865	TMEM160	-0.6	-13.37	-0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	trans	rs2970818	0.831	rs10849086	chr12:4645400	G/A	cg16313944	chr11:67775857	ALDH3B1	0.34	6.76	0.52	4.8e-10	Phosphorus levels;
TGCT	cis	rs6663390	0.510	rs3754170	chr1:208087296	A/G	cg03990033	chr1:208084030	CD34	0.57	4.94	0.41	2.45e-6	Facial morphology (factor 18);
TGCT	cis	rs2840044	1.000	rs225295	chr17:33925755	A/G	cg05299278	chr17:33885742	SLFN14	0.23	5.05	0.41	1.53e-6	Response to radiotherapy in cancer (late toxicity);
TGCT	cis	rs35146811	0.735	rs6948729	chr7:99787372	A/G	cg22906224	chr7:99728672	NA	0.49	4.45	0.37	1.88e-5	Coronary artery disease;
TGCT	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg11890956	chr21:40555474	PSMG1	1.13	11.5	0.72	2.86e-21	Cognitive function;
TGCT	cis	rs13191362	0.935	rs34347104	chr6:163055716	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.91	6.86	0.52	2.88e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs35771425	1.000	rs12569232	chr1:211553064	G/C	cg25617285	chr1:211431773	RCOR3	-0.5	-4.49	-0.37	1.63e-5	Educational attainment (years of education);
TGCT	cis	rs3733346	0.553	rs2290403	chr4:942006	G/A	cg22718636	chr4:961658	DGKQ	0.46	4.55	0.38	1.24e-5	Sjögren's syndrome;
TGCT	cis	rs9467773	0.549	rs9467805	chr6:26583366	C/T	cg15659132	chr6:26577336	NA	0.86	11.1	0.71	2.67e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs709400	0.567	rs28496120	chr14:103897899	C/T	cg12935359	chr14:103987150	CKB	-0.33	-4.96	-0.41	2.27e-6	Body mass index;
TGCT	cis	rs17433780	0.504	rs6428494	chr1:89472196	C/T	cg09516651	chr1:89888402	LOC400759	0.24	5.13	0.42	1.1e-6	Carotid intima media thickness;
TGCT	cis	rs9733	0.544	rs72700902	chr1:150633347	C/T	cg04414720	chr1:150670196	GOLPH3L	0.39	5.04	0.41	1.58e-6	Tonsillectomy;
TGCT	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg10802521	chr3:52805072	NEK4	-0.78	-10.0	-0.67	1.28e-17	Electroencephalogram traits;
TGCT	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg24060327	chr5:131705240	SLC22A5	0.78	8.46	0.61	6.22e-14	Breast cancer;
TGCT	cis	rs11690935	0.959	rs11904009	chr2:172627343	T/G	cg13550731	chr2:172543902	DYNC1I2	-1.19	-12.78	-0.75	2.24e-24	Schizophrenia;
TGCT	cis	rs12549902	0.966	rs4737000	chr8:41509727	A/C	cg21772509	chr8:41503840	NKX6-3	0.87	10.06	0.67	9.27e-18	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
TGCT	cis	rs6545883	0.783	rs12713442	chr2:61848078	G/A	cg15711740	chr2:61764176	XPO1	-0.58	-5.31	-0.43	4.79e-7	Tuberculosis;
TGCT	cis	rs8062405	0.929	rs11150609	chr16:28870596	A/G	cg09754948	chr16:28834200	ATXN2L	0.59	4.45	0.37	1.91e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs295140	0.566	rs295141	chr2:201163556	C/T	cg23649088	chr2:200775458	C2orf69	-0.29	-4.65	-0.39	8.34e-6	QT interval;
TGCT	cis	rs11783469	0.522	rs4872125	chr8:23268270	G/A	cg00472375	chr8:23315376	ENTPD4	0.68	5.3	0.43	5.01e-7	Reticulocyte count;
TGCT	cis	rs644148	0.836	rs2686777	chr19:45000386	T/C	cg15540054	chr19:45004280	ZNF180	-0.66	-5.34	-0.43	4.23e-7	Personality dimensions;
TGCT	cis	rs2067615	0.579	rs4964489	chr12:107171808	A/G	cg15890332	chr12:107067104	RFX4	0.28	5.57	0.45	1.47e-7	Heart rate;
TGCT	cis	rs6901250	0.851	rs339360	chr6:117160872	G/T	cg12892004	chr6:117198278	RFX6	-0.54	-6.65	-0.51	8.24e-10	C-reactive protein levels;
TGCT	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg25036284	chr2:26402008	FAM59B	-0.57	-5.03	-0.41	1.65e-6	Gut microbiome composition (summer);
TGCT	cis	rs9677476	0.516	rs2303349	chr2:232030861	A/G	cg27665808	chr2:232055229	NA	0.36	4.51	0.38	1.48e-5	Food antigen IgG levels;
TGCT	cis	rs10992471	0.756	rs10123342	chr9:95087824	T/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.61	-6.25	-0.49	6.14e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg03303774	chr4:1407052	NA	0.3	4.78	0.39	4.82e-6	Obesity-related traits;
TGCT	cis	rs198813	0.611	rs198823	chr6:26122933	G/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.62	-5.27	-0.43	5.94e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs4455778	0.657	rs10233258	chr7:49003132	T/A	cg26309511	chr7:48887640	NA	-0.5	-6.02	-0.48	1.87e-8	Lung cancer in never smokers;
TGCT	cis	rs10927875	0.864	rs12135073	chr1:16167799	C/T	cg14742211	chr1:16348397	CLCNKA	0.18	4.55	0.38	1.26e-5	Dilated cardiomyopathy;
TGCT	cis	rs2562456	0.837	rs62110205	chr19:21760071	A/G	cg25650185	chr19:21324782	ZNF431	-0.64	-5.2	-0.42	8.11e-7	Pain;
TGCT	cis	rs208520	0.955	rs208532	chr6:66961280	T/A	cg07460842	chr6:66804631	NA	-0.83	-7.52	-0.56	9.8e-12	Exhaled nitric oxide output;
TGCT	cis	rs7412746	0.658	rs6658066	chr1:150918937	T/G	cg04414720	chr1:150670196	GOLPH3L	0.37	4.46	0.37	1.81e-5	Melanoma;
TGCT	cis	rs524023	1.000	rs10897518	chr11:64360705	A/G	cg07733098	chr11:64478343	NRXN2	-0.3	-4.51	-0.38	1.48e-5	Urate levels in obese individuals;
TGCT	cis	rs4654899	0.865	rs1472831	chr1:21435940	C/T	cg01072550	chr1:21505969	NA	-0.47	-7.09	-0.54	8.92e-11	Superior frontal gyrus grey matter volume;
TGCT	cis	rs9921338	0.961	rs56136462	chr16:11415595	A/G	cg00044050	chr16:11439710	C16orf75	-0.93	-6.96	-0.53	1.7e-10	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs9303401	0.659	rs62083436	chr17:57031742	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.59	5.99	0.47	2.08e-8	Cognitive test performance;
TGCT	cis	rs1129187	0.702	rs2296805	chr6:42928758	T/G	cg17345569	chr6:42928274	GNMT	-0.51	-5.15	-0.42	9.82e-7	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs10782582	0.593	rs12131344	chr1:76136437	C/T	cg10523679	chr1:76189770	ACADM	-0.72	-7.19	-0.54	5.48e-11	Daytime sleep phenotypes;
TGCT	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg16680214	chr1:154839983	KCNN3	-0.36	-7.26	-0.55	3.81e-11	Prostate cancer;
TGCT	cis	rs58722170	0.627	rs12046650	chr1:38082123	C/T	cg17933807	chr1:38061675	GNL2	-0.86	-8.69	-0.62	1.83e-14	High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs7666738	0.830	rs34890015	chr4:99023769	A/T	cg17366294	chr4:99064904	C4orf37	0.74	7.62	0.56	5.53e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7809950	0.678	rs17153981	chr7:106922106	A/G	cg23024343	chr7:107201750	COG5	-0.43	-5.88	-0.47	3.51e-8	Coronary artery disease;
TGCT	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg21285383	chr16:89894308	SPIRE2	0.43	6.85	0.52	3e-10	Vitiligo;
TGCT	cis	rs2012796	0.743	rs8020575	chr14:81859521	G/A	cg02996355	chr14:81879375	NA	0.56	5.45	0.44	2.66e-7	Night sleep phenotypes;
TGCT	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg11301795	chr4:187892539	NA	0.38	5.58	0.45	1.47e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6087990	0.735	rs4911260	chr20:31376490	T/C	cg13636640	chr20:31349939	DNMT3B	0.95	12.38	0.74	2.06e-23	Ulcerative colitis;
TGCT	cis	rs9467711	0.606	rs12174639	chr6:26373121	G/A	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7043114	0.507	rs10820971	chr9:95161740	G/C	cg14631576	chr9:95140430	CENPP	-0.29	-4.79	-0.39	4.76e-6	Height;
TGCT	cis	rs9303401	0.659	rs62081316	chr17:56781499	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.59	5.99	0.47	2.08e-8	Cognitive test performance;
TGCT	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs35306767	0.951	rs61833265	chr10:990143	C/T	cg20503657	chr10:835505	NA	0.63	8.32	0.6	1.37e-13	Eosinophil percentage of granulocytes;
TGCT	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg23302884	chr18:44338147	ST8SIA5	-0.4	-4.58	-0.38	1.11e-5	Personality dimensions;
TGCT	cis	rs3617	0.573	rs9825230	chr3:52901974	G/A	cg10802521	chr3:52805072	NEK4	-0.54	-6.05	-0.48	1.61e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9653442	0.564	rs10185510	chr2:100790581	C/T	cg22139774	chr2:100720529	AFF3	-0.35	-5.4	-0.44	3.2e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs11122272	0.735	rs2437149	chr1:231490105	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-6.65	-0.51	8.43e-10	Hemoglobin concentration;
TGCT	cis	rs9303401	0.614	rs62084387	chr17:57148027	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.63	5.81	0.46	4.99e-8	Cognitive test performance;
TGCT	cis	rs8072100	0.570	rs9905073	chr17:45468296	G/A	cg08085267	chr17:45401833	C17orf57	-0.52	-5.68	-0.45	8.95e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs6912958	0.967	rs9450688	chr6:88159276	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.37	-4.74	-0.39	5.79e-6	Monocyte percentage of white cells;
TGCT	cis	rs4273100	1.000	rs12602286	chr17:19236954	G/T	cg01534423	chr17:18965556	NA	-0.95	-5.98	-0.47	2.2e-8	Schizophrenia;
TGCT	cis	rs12541335	0.579	rs59283125	chr8:22212311	G/A	cg07298985	chr8:22133076	PIWIL2	0.34	5.18	0.42	8.75e-7	Hypertriglyceridemia;
TGCT	cis	rs17102423	0.602	rs1007914	chr14:65566261	C/A	cg11161011	chr14:65562177	MAX	-0.54	-7.71	-0.57	3.57e-12	Obesity-related traits;
TGCT	cis	rs6964587	0.967	rs10231350	chr7:91808499	G/T	cg17063962	chr7:91808500	NA	0.91	9.88	0.66	2.51e-17	Breast cancer;
TGCT	cis	rs9810089	0.934	rs570621	chr3:136000743	A/G	cg12473912	chr3:136751656	NA	0.35	4.91	0.4	2.77e-6	Gestational age at birth (child effect);
TGCT	cis	rs2742234	0.915	rs2742233	chr10:43610558	C/T	cg02780029	chr10:43622663	RET	-0.25	-4.84	-0.4	3.81e-6	Hirschsprung disease;
TGCT	cis	rs3935685	1.000	rs4886904	chr15:78027178	C/T	cg03457338	chr15:78040120	NA	-0.23	-5.38	-0.44	3.54e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9653442	0.545	rs1821826	chr2:100764711	C/T	cg22139774	chr2:100720529	AFF3	-0.37	-5.95	-0.47	2.54e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs734999	0.588	rs2843401	chr1:2528133	T/C	cg18854424	chr1:2615690	NA	-0.46	-5.23	-0.43	6.92e-7	Ulcerative colitis;
TGCT	cis	rs1857353	0.708	rs2040081	chr1:75906765	T/A	cg11838876	chr1:75668600	SLC44A5	-0.51	-4.81	-0.4	4.23e-6	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs1997103	0.954	rs9649854	chr7:55410213	G/A	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs17253792	0.822	rs77555779	chr14:56078430	A/G	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs36051895	0.632	rs62541958	chr9:5175621	T/C	cg02405213	chr9:5042618	JAK2	-0.72	-9.73	-0.66	5.69e-17	Pediatric autoimmune diseases;
TGCT	cis	rs2933343	0.621	rs789249	chr3:128578453	T/C	cg11901034	chr3:128598214	ACAD9	-0.64	-6.16	-0.48	9.37e-9	IgG glycosylation;
TGCT	cis	rs910316	0.726	rs12882664	chr14:75446778	C/T	cg08847533	chr14:75593920	NEK9	0.83	8.78	0.62	1.1e-14	Height;
TGCT	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg23131131	chr22:24373011	LOC391322	0.81	8.72	0.62	1.53e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs910316	1.000	rs9805979	chr14:75566209	G/A	cg08847533	chr14:75593920	NEK9	0.96	10.6	0.69	4.3e-19	Height;
TGCT	cis	rs7914558	1.000	rs7899084	chr10:104872547	A/T	cg15744005	chr10:104629667	AS3MT	-0.42	-5.21	-0.42	7.57e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs12765878	1.000	rs10883942	chr10:105651386	A/G	cg11005552	chr10:105648138	OBFC1	0.44	7.66	0.57	4.54e-12	Coronary artery disease;
TGCT	cis	rs733175	0.857	rs10018663	chr4:10004797	C/T	cg00071950	chr4:10020882	SLC2A9	0.55	4.45	0.37	1.85e-5	Psychosis and Alzheimer's disease;
TGCT	cis	rs4780401	0.573	rs8045673	chr16:11804385	C/A	cg01061890	chr16:11836724	TXNDC11	-0.6	-5.71	-0.46	7.74e-8	Rheumatoid arthritis;
TGCT	cis	rs9818758	0.607	rs13068038	chr3:49294250	C/A	cg07636037	chr3:49044803	WDR6	-1.04	-5.13	-0.42	1.09e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs6988636	0.901	rs2602001	chr8:124195974	T/C	cg27053337	chr8:124217698	FAM83A	-0.55	-4.55	-0.38	1.25e-5	Urinary uromodulin levels;
TGCT	cis	rs7523273	0.606	rs2724380	chr1:207949682	C/T	cg22525895	chr1:207977042	MIR29B2	0.53	8.71	0.62	1.62e-14	Schizophrenia;
TGCT	cis	rs734999	0.967	rs4486391	chr1:2513055	A/T	cg18854424	chr1:2615690	NA	0.46	5.84	0.46	4.32e-8	Ulcerative colitis;
TGCT	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.64	5.04	0.41	1.63e-6	Lung function (FEV1/FVC);
TGCT	cis	rs13394619	0.935	rs12468019	chr2:11725049	T/C	cg07314298	chr2:11723111	GREB1	-0.29	-5.14	-0.42	1.05e-6	Endometriosis;
TGCT	cis	rs6088580	0.634	rs6088475	chr20:32964987	T/C	cg08999081	chr20:33150536	PIGU	-0.28	-5.51	-0.44	1.96e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs10791323	0.569	rs2187450	chr11:133743792	A/G	cg03690763	chr11:133734501	NA	-0.3	-5.16	-0.42	9.36e-7	Childhood ear infection;
TGCT	cis	rs17076896	0.708	rs61956078	chr13:19932579	C/T	cg00777926	chr13:20807375	GJB6	-0.37	-4.53	-0.38	1.36e-5	Coronary artery aneurysm in Kawasaki disease;
TGCT	trans	rs10203711	1.000	rs12692239	chr2:239553947	T/C	cg16021909	chr1:248021091	TRIM58	-0.68	-6.93	-0.53	2.04e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6426558	0.514	rs3754418	chr1:227348473	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.6	-7.22	-0.54	4.62e-11	Neutrophil percentage of white cells;
TGCT	cis	rs3796352	1.000	rs59583591	chr3:53119581	T/C	cg07884673	chr3:53033167	SFMBT1	0.49	5.11	0.42	1.16e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs7223966	1.000	rs8068603	chr17:61755211	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	5.05	0.41	1.51e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs6500602	0.647	rs4786501	chr16:4536165	G/T	cg12031863	chr16:4587854	C16orf5	0.29	4.7	0.39	6.91e-6	Schizophrenia;
TGCT	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	5.03	0.41	1.69e-6	Prudent dietary pattern;
TGCT	cis	rs624899	0.522	rs645584	chr19:11612466	A/G	cg14128973	chr19:11649462	CNN1	0.45	6.22	0.49	7.14e-9	Presence of antiphospholipid antibodies;
TGCT	cis	rs9527	0.590	rs11191540	chr10:104822809	G/C	cg15744005	chr10:104629667	AS3MT	-0.42	-4.87	-0.4	3.29e-6	Arsenic metabolism;
TGCT	cis	rs12210905	1.000	rs9368498	chr6:27254006	G/A	cg08851530	chr6:28072375	NA	1.29	5.49	0.44	2.19e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs7103648	0.897	rs35032070	chr11:47408592	G/A	cg20307385	chr11:47447363	PSMC3	1.03	12.12	0.74	8.55e-23	Diastolic blood pressure;Systolic blood pressure;
TGCT	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.7	0.39	6.83e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg11764359	chr7:65958608	NA	0.54	4.66	0.39	7.88e-6	Aortic root size;
TGCT	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.07	-9.63	-0.65	1.01e-16	Platelet count;
TGCT	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg21963583	chr11:68658836	MRPL21	-0.34	-5.74	-0.46	6.87e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs344364	0.511	rs1657133	chr16:1950300	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.45	-5.08	-0.42	1.35e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs7552167	0.925	rs11249021	chr1:24512881	G/T	cg01960748	chr1:24522592	NA	-0.44	-5.01	-0.41	1.87e-6	Psoriasis vulgaris;
TGCT	cis	rs9291683	0.588	rs6844329	chr4:10018544	T/C	cg02734326	chr4:10020555	SLC2A9	0.38	4.54	0.38	1.34e-5	Bone mineral density;
TGCT	cis	rs3008870	0.755	rs4486425	chr1:67460791	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.82	-8.51	-0.61	4.75e-14	Lymphocyte percentage of white cells;
TGCT	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.38	4.88	0.4	3.18e-6	Total body bone mineral density;
TGCT	cis	rs10782582	0.593	rs11164042	chr1:76178440	G/A	cg22875332	chr1:76189707	ACADM	-0.56	-6.37	-0.5	3.39e-9	Daytime sleep phenotypes;
TGCT	cis	rs4970988	0.607	rs7548516	chr1:150980281	C/T	cg13201342	chr1:150782303	ARNT;CTSK	-0.27	-4.68	-0.39	7.39e-6	Urate levels;
TGCT	cis	rs9372253	0.934	rs9320327	chr6:110715194	T/A	cg13266496	chr6:110720918	DDO	-0.46	-5.68	-0.45	9.19e-8	Platelet distribution width;
TGCT	cis	rs7666738	0.515	rs13434650	chr4:98889886	A/G	cg05340658	chr4:99064831	C4orf37	0.57	6.06	0.48	1.48e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7666738	0.830	rs880470	chr4:98922522	A/T	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs778371	0.723	rs35491427	chr2:233688542	C/T	cg08000102	chr2:233561755	GIGYF2	-0.67	-7.64	-0.57	5.21e-12	Schizophrenia;
TGCT	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	7.43	0.55	1.56e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7267979	1.000	rs2500424	chr20:25391969	C/T	cg03522245	chr20:25566470	NINL	-0.63	-6.79	-0.52	4.05e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg18110333	chr6:292329	DUSP22	-0.72	-7.76	-0.57	2.71e-12	Menopause (age at onset);
TGCT	cis	rs2836950	0.545	rs2836952	chr21:40616651	G/C	cg11644478	chr21:40555479	PSMG1	-0.53	-4.91	-0.4	2.81e-6	Menarche (age at onset);
TGCT	cis	rs9341808	0.600	rs2505930	chr6:80837058	A/G	cg08355045	chr6:80787529	NA	0.34	5.42	0.44	2.95e-7	Sitting height ratio;
TGCT	cis	rs61931739	0.500	rs11053199	chr12:34450534	C/T	cg06521331	chr12:34319734	NA	0.27	4.56	0.38	1.19e-5	Morning vs. evening chronotype;
TGCT	cis	rs7223966	1.000	rs11658329	chr17:61763031	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.64	-5.29	-0.43	5.35e-7	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs2153535	0.560	rs9379214	chr6:8480870	T/C	cg23788917	chr6:8435910	SLC35B3	0.64	5.82	0.46	4.65e-8	Motion sickness;
TGCT	cis	rs17376456	0.569	rs11948511	chr5:93286601	A/C	cg25358565	chr5:93447407	FAM172A	-0.62	-5.85	-0.47	4.08e-8	Diabetic retinopathy;
TGCT	cis	rs12580194	1.000	rs12579030	chr12:55689194	T/C	cg20672549	chr12:56432144	IKZF4	0.27	4.75	0.39	5.55e-6	Cancer;
TGCT	cis	rs9640161	0.830	rs3757423	chr7:150067714	A/G	cg21361702	chr7:150065534	REPIN1	-0.48	-4.54	-0.38	1.29e-5	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg11890956	chr21:40555474	PSMG1	1.03	9.6	0.65	1.17e-16	Cognitive function;
TGCT	cis	rs4700695	0.841	rs152935	chr5:65358593	A/G	cg21114390	chr5:65439923	SFRS12	-0.6	-4.46	-0.37	1.79e-5	Facial morphology (factor 19);
TGCT	cis	rs1838472	0.607	rs9844005	chr3:123979763	G/A	cg19008133	chr3:123124015	ADCY5	-0.18	-4.58	-0.38	1.12e-5	Schizophrenia;
TGCT	cis	rs1059312	0.500	rs12303338	chr12:129276641	C/T	cg09035930	chr12:129282057	SLC15A4	-0.49	-7.24	-0.55	4.12e-11	Systemic lupus erythematosus;
TGCT	cis	rs477895	1.000	rs66968227	chr11:64070930	T/C	cg23719950	chr11:63933701	MACROD1	-0.59	-4.66	-0.39	8.19e-6	Mean platelet volume;
TGCT	cis	rs10510102	0.808	rs7920024	chr10:123703578	G/T	cg23691251	chr10:123688108	ATE1	-0.58	-4.58	-0.38	1.11e-5	Breast cancer;
TGCT	cis	rs1552244	0.554	rs3732965	chr3:10048760	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.33	-4.95	-0.41	2.39e-6	Alzheimer's disease;
TGCT	cis	rs2742417	0.603	rs1468542	chr3:45779136	A/T	cg04837898	chr3:45731254	SACM1L	0.67	7.3	0.55	3.06e-11	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs12220238	0.841	rs10824161	chr10:76133762	C/G	cg19889307	chr10:75911429	ADK;AP3M1	-0.9	-6.35	-0.5	3.66e-9	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg10802521	chr3:52805072	NEK4	-0.78	-10.01	-0.67	1.22e-17	Bipolar disorder;
TGCT	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	6.75	0.52	5.02e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs3617	0.573	rs62253582	chr3:52928333	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	-0.5	-4.67	-0.39	7.82e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs950776	0.620	rs7181405	chr15:78948152	A/G	cg03762349	chr15:79060523	ADAMTS7	0.24	4.91	0.4	2.82e-6	Sudden cardiac arrest;
TGCT	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg08048268	chr3:133502702	NA	0.53	7.22	0.54	4.55e-11	Iron status biomarkers;
TGCT	cis	rs1048238	0.548	rs848217	chr1:16272250	A/G	cg21385522	chr1:16154831	NA	-0.66	-8.24	-0.59	2.05e-13	Systolic blood pressure;
TGCT	cis	rs2742417	0.967	rs1534875	chr3:45741043	T/G	cg04837898	chr3:45731254	SACM1L	-0.55	-5.68	-0.45	9.14e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	trans	rs208520	0.507	rs9453585	chr6:66796668	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-16.96	-0.84	4.22e-34	Exhaled nitric oxide output;
TGCT	cis	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg04287289	chr16:89883240	FANCA	-0.67	-6.61	-0.51	1.01e-9	Vitiligo;
TGCT	cis	rs6500602	0.592	rs28789232	chr16:4447552	C/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.4	5.1	0.42	1.26e-6	Schizophrenia;
TGCT	cis	rs4819052	0.632	rs4819050	chr21:46692943	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.62	6.04	0.48	1.65e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs11122272	0.735	rs2491405	chr1:231513431	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.14	-0.54	6.86e-11	Hemoglobin concentration;
TGCT	cis	rs9926296	0.712	rs447735	chr16:89734349	T/C	cg26513180	chr16:89883248	FANCA	-0.68	-6.38	-0.5	3.15e-9	Vitiligo;
TGCT	cis	rs7091068	0.616	rs6583905	chr10:95504022	T/G	cg20715218	chr10:95462985	C10orf4	0.52	4.62	0.38	9.33e-6	Urinary tract infection frequency;
TGCT	cis	rs2115630	0.875	rs8039472	chr15:85361644	A/G	cg17173187	chr15:85201210	NMB	-0.49	-5.9	-0.47	3.2e-8	P wave terminal force;
TGCT	cis	rs6547741	0.752	rs7562863	chr2:27892694	T/A	cg27432699	chr2:27873401	GPN1	-0.24	-6.15	-0.48	9.74e-9	Oral cavity cancer;
TGCT	cis	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg02380750	chr20:61661411	NA	0.33	5.96	0.47	2.4e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg18305652	chr10:134549665	INPP5A	0.35	5.69	0.45	8.83e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs3741404	0.868	rs595880	chr11:64006466	T/G	cg19570321	chr11:63258214	HRASLS5	-0.45	-5.18	-0.42	8.76e-7	Platelet count;
TGCT	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg06238570	chr21:40685208	BRWD1	-0.61	-6.19	-0.49	7.89e-9	Menarche (age at onset);
TGCT	cis	rs9916302	0.904	rs6503507	chr17:37525274	C/T	cg15445000	chr17:37608096	MED1	-0.33	-4.71	-0.39	6.46e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7086627	0.515	rs10887895	chr10:82210011	A/G	cg01528321	chr10:82214614	TSPAN14	0.65	6.21	0.49	7.21e-9	Post bronchodilator FEV1;
TGCT	cis	rs4372836	0.504	rs13024443	chr2:29046185	C/T	cg09522027	chr2:28974177	PPP1CB	-0.56	-5.68	-0.45	9.2e-8	Body mass index;
TGCT	cis	rs7666738	0.830	rs7673880	chr4:99057262	A/G	cg05340658	chr4:99064831	C4orf37	0.51	5.66	0.45	9.76e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12908161	1.000	rs35808647	chr15:85377441	G/A	cg17173187	chr15:85201210	NMB	0.53	5.65	0.45	1.03e-7	Schizophrenia;
TGCT	trans	rs10022799	0.836	rs28444899	chr4:168128646	T/G	cg08507725	chr4:8239220	SH3TC1	0.34	7.03	0.53	1.23e-10	Cognitive function;
TGCT	cis	rs4689388	0.926	rs4343789	chr4:6285228	C/G	cg14416269	chr4:6271139	WFS1	0.39	5.25	0.43	6.47e-7	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	trans	rs629535	0.814	rs571682	chr8:70062793	A/G	cg21567404	chr3:27674614	NA	0.52	7.95	0.58	9.59e-13	Dupuytren's disease;
TGCT	cis	rs2276314	1.000	rs58054756	chr18:33554053	G/C	cg19628046	chr18:33552617	C18orf21	0.52	4.46	0.37	1.8e-5	Endometriosis;Drug-induced torsades de pointes;
TGCT	cis	rs6545883	0.772	rs1186709	chr2:61689380	G/A	cg15711740	chr2:61764176	XPO1	-0.59	-5.39	-0.44	3.36e-7	Tuberculosis;
TGCT	cis	rs9308731	1.000	rs7567444	chr2:111863438	T/C	cg04202892	chr2:111875749	ACOXL	0.44	4.58	0.38	1.12e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs1153858	0.887	rs28569043	chr15:45730926	A/T	cg26924012	chr15:45694286	SPATA5L1	0.99	12.56	0.75	7.42e-24	Homoarginine levels;
TGCT	cis	rs9549260	0.564	rs9549271	chr13:41295477	T/C	cg21288729	chr13:41239152	FOXO1	0.92	8.87	0.62	6.71e-15	Red blood cell count;
TGCT	cis	rs2242116	0.932	rs1531137	chr3:46943028	T/C	cg27129171	chr3:47204927	SETD2	0.61	6.15	0.48	9.79e-9	Birth weight;
TGCT	cis	rs617219	0.698	rs7379187	chr5:78521354	T/C	cg09550809	chr5:78407562	BHMT	0.39	5.63	0.45	1.12e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs922182	0.633	rs4776700	chr15:64270861	A/T	cg02919090	chr15:64263738	DAPK2	-0.29	-5.21	-0.42	7.69e-7	Blood protein levels;
TGCT	cis	rs12497850	0.931	rs9876848	chr3:48844059	G/A	cg18654377	chr3:49208889	KLHDC8B	-0.42	-5.52	-0.44	1.93e-7	Parkinson's disease;
TGCT	cis	rs72781680	0.846	rs55707417	chr2:24029928	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	5.84	0.46	4.22e-8	Lymphocyte counts;
TGCT	cis	rs4963124	0.886	rs10902216	chr11:739392	G/C	cg01741372	chr11:783889	NA	0.43	4.52	0.38	1.41e-5	Proteinuria and chronic kidney disease;
TGCT	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg13732083	chr21:47605072	C21orf56	0.35	4.69	0.39	7.17e-6	Testicular germ cell tumor;
TGCT	cis	rs6969780	0.722	rs983185	chr7:27188607	G/A	cg17457637	chr7:27170717	HOXA4	-0.47	-4.95	-0.41	2.32e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg07424592	chr7:64974309	NA	-1.27	-7.28	-0.55	3.29e-11	Diabetic kidney disease;
TGCT	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.38	-4.53	-0.38	1.35e-5	Longevity;Endometriosis;
TGCT	cis	rs6882046	0.513	rs34316	chr5:88015545	A/C	cg24804195	chr5:87968844	LOC645323	-0.6	-5.96	-0.47	2.4e-8	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	trans	rs13323436	1.000	rs13323436	chr3:85502845	A/T	cg11225405	chr1:117038246	NA	-0.65	-7.06	-0.54	1.05e-10	Visceral fat;
TGCT	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs4642101	0.680	rs6442330	chr3:12820501	A/G	cg05775895	chr3:12838266	CAND2	0.68	7.28	0.55	3.44e-11	QRS complex (12-leadsum);
TGCT	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg03609598	chr5:56110824	MAP3K1	-0.58	-4.7	-0.39	6.72e-6	Initial pursuit acceleration;
TGCT	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg17554472	chr22:41940697	POLR3H	0.49	5.16	0.42	9.72e-7	Vitiligo;
TGCT	cis	rs4240897	0.935	rs3766744	chr1:12043717	G/A	cg13216073	chr1:12042593	MFN2	0.2	5.89	0.47	3.32e-8	Tuberculosis;
TGCT	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.04	-9.22	-0.64	9.69e-16	Platelet count;
TGCT	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.68	4.89	0.4	3e-6	Platelet count;
TGCT	cis	rs62283056	0.512	rs752854	chr4:6281961	C/T	cg25554036	chr4:6271136	WFS1	0.53	6.84	0.52	3.27e-10	Cisplatin-induced ototoxicity;
TGCT	cis	rs7666738	0.830	rs2865989	chr4:99067532	G/A	cg17366294	chr4:99064904	C4orf37	0.73	7.45	0.56	1.4e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10782582	0.593	rs1412717	chr1:76125471	C/T	cg22875332	chr1:76189707	ACADM	-0.54	-6.21	-0.49	7.36e-9	Daytime sleep phenotypes;
TGCT	cis	rs3809566	0.637	rs8026047	chr15:63323347	C/G	cg00520135	chr15:63333846	TPM1	0.45	4.59	0.38	1.07e-5	Platelet count;
TGCT	cis	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg02380750	chr20:61661411	NA	0.34	6.13	0.48	1.08e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs12681287	0.640	rs12549332	chr8:87353392	G/A	cg27223183	chr8:87520930	FAM82B	-0.9	-6.64	-0.51	8.93e-10	Caudate activity during reward;
TGCT	cis	rs11190604	0.767	rs10883484	chr10:102174803	G/C	cg16005271	chr10:102321736	NA	0.45	4.74	0.39	5.87e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs1062177	1.000	rs2964584	chr5:151142878	T/C	cg12924095	chr5:151150029	G3BP1	0.36	5.26	0.43	6.22e-7	Preschool internalizing problems;
TGCT	cis	rs67478160	0.584	rs2295147	chr14:104195664	A/G	cg01849466	chr14:104193079	ZFYVE21	0.19	4.55	0.38	1.24e-5	Schizophrenia;
TGCT	cis	rs2070488	0.965	rs2154778	chr3:38553639	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.86	-8.57	-0.61	3.38e-14	Electrocardiographic conduction measures;
TGCT	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg04944784	chr2:26401820	FAM59B	-0.71	-6.24	-0.49	6.24e-9	Gut microbiome composition (summer);
TGCT	cis	rs12681287	0.640	rs7833049	chr8:87445898	T/C	cg27223183	chr8:87520930	FAM82B	0.89	6.43	0.5	2.54e-9	Caudate activity during reward;
TGCT	cis	rs71435601	0.628	rs538928	chr2:21389019	C/T	cg25035485	chr2:21266500	APOB	-0.51	-4.46	-0.37	1.82e-5	Cholesterol, total;
TGCT	cis	rs7267979	1.000	rs6107033	chr20:25363591	A/G	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs72945132	0.825	rs12287883	chr11:70122369	C/T	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs4919687	0.550	rs12259058	chr10:104484799	A/G	cg05855489	chr10:104503620	C10orf26	0.56	4.51	0.38	1.5e-5	Colorectal cancer;
TGCT	cis	rs7677751	0.806	rs4864863	chr4:55100831	A/G	cg17187183	chr4:55093834	PDGFRA	0.56	7.13	0.54	7.37e-11	Corneal astigmatism;
TGCT	cis	rs1801251	1.000	rs2305137	chr2:233712049	G/A	cg08000102	chr2:233561755	GIGYF2	-0.63	-6.36	-0.5	3.55e-9	Coronary artery disease;
TGCT	cis	rs12188164	0.965	rs41282625	chr5:475626	C/G	cg26850624	chr5:429559	AHRR	-0.21	-4.89	-0.4	3.01e-6	Cystic fibrosis severity;
TGCT	cis	rs2735413	0.564	rs74864339	chr16:78095071	C/T	cg09132178	chr16:78079569	NA	0.33	4.44	0.37	1.98e-5	Systolic blood pressure (alcohol consumption interaction);
TGCT	cis	rs6570726	0.846	rs411468	chr6:145832792	A/G	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs28595532	0.841	rs115918392	chr4:119610356	T/A	cg14228332	chr4:119757509	SEC24D	1.04	5.37	0.43	3.66e-7	Cannabis dependence symptom count;
TGCT	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg22535103	chr8:58192502	C8orf71	-0.4	-5.06	-0.41	1.44e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1153858	1.000	rs10519022	chr15:45663684	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.46	-4.9	-0.4	2.97e-6	Homoarginine levels;
TGCT	cis	rs12477438	0.520	rs13009147	chr2:99803998	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.82	0.62	8.67e-15	Chronic sinus infection;
TGCT	cis	rs6430585	0.583	rs12373779	chr2:136586840	A/C	cg07169764	chr2:136633963	MCM6	1.17	11.08	0.71	2.99e-20	Corneal structure;
TGCT	cis	rs7582180	0.715	rs7571306	chr2:100906084	G/C	cg14675211	chr2:100938903	LONRF2	0.45	4.52	0.38	1.4e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs3733585	0.699	rs7435196	chr4:9967556	A/C	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.62	-0.56	5.78e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	trans	rs3780486	0.957	rs10971434	chr9:33168891	C/A	cg04842962	chr6:43655489	MRPS18A	1.15	11.06	0.7	3.24e-20	IgG glycosylation;
TGCT	cis	rs6912958	0.559	rs499373	chr6:88042062	A/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.39	4.48	0.37	1.66e-5	Monocyte percentage of white cells;
TGCT	cis	rs5769765	0.505	rs4561759	chr22:50256686	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	1.0	6.16	0.48	9.32e-9	Schizophrenia;
TGCT	cis	rs6426558	0.537	rs6699828	chr1:227274591	T/C	cg10327440	chr1:227177885	CDC42BPA	0.61	7.41	0.55	1.72e-11	Neutrophil percentage of white cells;
TGCT	cis	rs902774	0.554	rs4503623	chr12:53353759	T/C	cg16329197	chr12:53359506	NA	-0.5	-7.02	-0.53	1.3e-10	Prostate cancer;
TGCT	cis	rs7666738	0.546	rs34159897	chr4:98787367	T/C	cg17366294	chr4:99064904	C4orf37	0.61	5.69	0.46	8.47e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1008375	0.897	rs3733577	chr4:17649233	T/G	cg18681998	chr4:17616180	MED28	1.05	12.0	0.73	1.69e-22	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg03934478	chr11:495069	RNH1	0.37	6.0	0.47	2.03e-8	Body mass index;
TGCT	trans	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg17470723	chr8:74884337	TCEB1	0.71	6.77	0.52	4.48e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs17173637	0.764	rs1044616	chr7:150502075	G/C	cg06746365	chr7:151468796	PRKAG2	0.3	4.62	0.38	9.65e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs433598	0.514	rs16970500	chr16:20680152	A/C	cg08248577	chr16:19727447	IQCK;C16orf88	-0.24	-4.71	-0.39	6.44e-6	Schizophrenia;
TGCT	cis	rs9910055	0.530	rs2269907	chr17:42294215	G/A	cg19774624	chr17:42201019	HDAC5	-0.71	-7.51	-0.56	9.96e-12	Total body bone mineral density;
TGCT	cis	rs950169	0.887	rs220333	chr15:85091133	C/T	cg11189052	chr15:85197271	WDR73	0.8	6.62	0.51	9.89e-10	Schizophrenia;
TGCT	cis	rs7586879	0.929	rs6545808	chr2:25124388	C/A	cg01884057	chr2:25150051	NA	0.28	5.03	0.41	1.69e-6	Body mass index;
TGCT	cis	rs4631830	0.896	rs7077830	chr10:51522276	C/G	cg10326726	chr10:51549505	MSMB	0.22	4.49	0.37	1.62e-5	Prostate-specific antigen levels;
TGCT	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg04267008	chr7:1944627	MAD1L1	-0.35	-4.53	-0.38	1.38e-5	Bipolar disorder and schizophrenia;
TGCT	cis	rs533581	0.866	rs475796	chr16:88970776	C/G	cg16701003	chr16:89028210	CBFA2T3	0.37	5.05	0.41	1.56e-6	Social autistic-like traits;
TGCT	cis	rs7666738	0.578	rs1989109	chr4:98881246	T/A	cg18180107	chr4:99064573	C4orf37	0.57	5.19	0.42	8.47e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7216064	1.000	rs12602912	chr17:65870073	C/T	cg12091567	chr17:66097778	LOC651250	-0.83	-6.49	-0.5	1.9e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs7772486	0.875	rs6570736	chr6:146388320	C/T	cg05347473	chr6:146136440	FBXO30	0.55	5.14	0.42	1.05e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6089829	0.747	rs57767914	chr20:61659108	C/G	cg08045932	chr20:61659980	NA	-0.31	-4.47	-0.37	1.76e-5	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg07747251	chr5:1868357	NA	0.38	5.52	0.44	1.92e-7	Cardiovascular disease risk factors;
TGCT	cis	rs12210905	1.000	rs7756481	chr6:27115069	G/C	cg08851530	chr6:28072375	NA	1.09	5.27	0.43	5.76e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs3020333	0.875	rs2982571	chr6:152012739	A/T	cg22157087	chr6:152012887	ESR1	-0.19	-4.83	-0.4	3.91e-6	Total body bone mineral density;
TGCT	cis	rs1018836	0.923	rs9643308	chr8:91625399	A/C	cg16814680	chr8:91681699	NA	-0.85	-9.22	-0.64	9.9e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9993613	1.000	rs4694504	chr4:73496691	A/G	cg15102770	chr4:73434591	ADAMTS3	0.52	4.8	0.4	4.5e-6	Hip circumference adjusted for BMI;Height;
TGCT	trans	rs561341	0.882	rs563539	chr17:30307958	A/G	cg20587970	chr11:113659929	NA	-1.03	-12.7	-0.75	3.52e-24	Hip circumference adjusted for BMI;
TGCT	cis	rs709400	0.628	rs72708854	chr14:103864885	T/C	cg12935359	chr14:103987150	CKB	-0.36	-5.37	-0.43	3.67e-7	Body mass index;
TGCT	cis	rs9468199	0.505	rs72847381	chr6:27873931	G/A	cg08851530	chr6:28072375	NA	1.53	7.14	0.54	6.96e-11	Parkinson's disease;
TGCT	cis	rs12451471	0.637	rs12950757	chr17:78096800	T/G	cg06718696	chr17:78121285	EIF4A3	0.74	6.09	0.48	1.29e-8	Plateletcrit;Mean corpuscular hemoglobin concentration;
TGCT	cis	rs10791323	0.569	rs2282602	chr11:133714522	G/A	cg15485101	chr11:133734466	NA	0.4	5.27	0.43	5.83e-7	Childhood ear infection;
TGCT	cis	rs1018836	0.637	rs7843684	chr8:91470035	G/C	cg16814680	chr8:91681699	NA	-0.71	-7.27	-0.55	3.49e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs35146811	0.883	rs4134903	chr7:99711040	G/A	cg22906224	chr7:99728672	NA	0.5	4.46	0.37	1.82e-5	Coronary artery disease;
TGCT	cis	rs10946940	0.930	rs12215012	chr6:27507494	C/G	cg10876282	chr6:28092338	ZSCAN16	-0.46	-4.6	-0.38	1.04e-5	Systemic lupus erythematosus;
TGCT	cis	rs67073037	0.915	rs12613887	chr2:29111099	T/C	cg09522027	chr2:28974177	PPP1CB	0.63	4.96	0.41	2.23e-6	Breast cancer;Breast cancer (estrogen-receptor negative);
TGCT	cis	rs763014	0.931	rs2071982	chr16:630405	T/G	cg09263875	chr16:632152	PIGQ	0.3	6.4	0.5	2.88e-9	Height;
TGCT	cis	rs1371867	0.875	rs1788178	chr8:101332518	A/C	cg00191853	chr8:101177733	SPAG1	-0.22	-4.47	-0.37	1.75e-5	Atrioventricular conduction;
TGCT	cis	rs7572733	0.555	rs2164071	chr2:198915467	T/C	cg00792783	chr2:198669748	PLCL1	0.59	5.15	0.42	1.01e-6	Dermatomyositis;
TGCT	cis	rs2742417	1.000	rs2673051	chr3:45732409	G/T	cg04837898	chr3:45731254	SACM1L	-0.55	-5.68	-0.45	9.14e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7666738	0.962	rs13147921	chr4:99069296	C/G	cg18180107	chr4:99064573	C4orf37	0.6	4.75	0.39	5.58e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7772486	0.603	rs2223411	chr6:146028767	T/C	cg13319975	chr6:146136371	FBXO30	0.68	6.18	0.49	8.39e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4253772	0.591	rs6007732	chr22:46652303	A/T	cg09491104	chr22:46646882	C22orf40	-0.63	-6.48	-0.5	1.94e-9	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs4820539	0.966	rs5751590	chr22:23486830	A/C	cg14186256	chr22:23484241	RTDR1	1.03	13.59	0.77	2.61e-26	Bone mineral density;
TGCT	cis	rs11874712	0.931	rs8095608	chr18:43678911	A/G	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	5.14	0.42	1.03e-6	Migraine - clinic-based;
TGCT	cis	rs4699052	0.625	rs6828829	chr4:104335667	A/G	cg16532752	chr4:104119610	CENPE	-0.53	-5.22	-0.42	7.32e-7	Testicular germ cell tumor;
TGCT	cis	rs7714584	1.000	rs1428552	chr5:150259831	T/C	cg22134413	chr5:150180641	NA	0.78	6.12	0.48	1.16e-8	Crohn's disease;
TGCT	cis	rs8056742	0.730	rs34776453	chr16:85098298	T/C	cg00229868	chr16:85520891	NA	0.38	4.77	0.39	5.03e-6	Amyotrophic lateral sclerosis;
TGCT	cis	rs9915657	1.000	rs9915657	chr17:70127536	T/C	cg06234051	chr17:70120541	SOX9	-0.29	-5.66	-0.45	9.85e-8	Thyroid hormone levels;
TGCT	cis	rs1670533	1.000	rs10084849	chr4:1053586	T/C	cg20887711	chr4:1340912	KIAA1530	0.69	5.54	0.45	1.69e-7	Recombination rate (females);
TGCT	cis	rs6570726	0.791	rs4335004	chr6:145904764	G/A	cg13319975	chr6:146136371	FBXO30	-0.51	-4.58	-0.38	1.13e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11623869	0.614	rs11627052	chr14:103863476	A/G	cg26031613	chr14:104095156	KLC1	-0.67	-5.37	-0.43	3.79e-7	Bone mineral density;
TGCT	cis	rs9399137	0.507	rs7745289	chr6:135380327	A/G	cg24558204	chr6:135376177	HBS1L	0.47	4.73	0.39	5.98e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
TGCT	cis	rs13191362	1.000	rs34931503	chr6:163003876	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs1903068	0.752	rs28517654	chr4:55993468	T/C	cg01777861	chr4:56023843	NA	0.53	6.16	0.48	9.28e-9	Endometriosis;
TGCT	cis	rs8044995	0.563	rs3785127	chr16:68399590	C/G	cg05110241	chr16:68378359	PRMT7	-0.36	-4.46	-0.37	1.84e-5	Schizophrenia;
TGCT	cis	rs9291683	0.588	rs17246745	chr4:9994583	T/C	cg02734326	chr4:10020555	SLC2A9	0.38	4.52	0.38	1.42e-5	Bone mineral density;
TGCT	cis	rs911555	0.755	rs1116095	chr14:103931879	A/G	cg23461800	chr14:103021989	NA	-0.35	-4.56	-0.38	1.23e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs2299587	0.623	rs7009476	chr8:17770376	T/C	cg01800426	chr8:17659068	MTUS1	-0.67	-5.71	-0.46	8.04e-8	Economic and political preferences;
TGCT	cis	rs12893668	0.603	rs12896171	chr14:104135966	A/G	cg26031613	chr14:104095156	KLC1	-0.59	-5.08	-0.42	1.34e-6	Reticulocyte count;
TGCT	cis	rs9611565	0.546	rs5758430	chr22:42109844	G/T	cg06481639	chr22:41940642	POLR3H	0.71	6.48	0.5	1.95e-9	Vitiligo;
TGCT	cis	rs7666738	0.830	rs7672127	chr4:98938477	A/G	cg05340658	chr4:99064831	C4orf37	0.54	6.09	0.48	1.28e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg03213289	chr20:61660250	NA	0.68	9.9	0.66	2.25e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg22166914	chr1:53195759	ZYG11B	0.34	5.57	0.45	1.52e-7	Monocyte count;
TGCT	cis	rs10791097	0.694	rs4937583	chr11:130741606	A/G	cg05962950	chr11:130786565	SNX19	0.92	11.55	0.72	2.13e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9677476	0.516	rs10202806	chr2:232050852	A/G	cg07929768	chr2:232055508	NA	0.33	5.26	0.43	6.24e-7	Food antigen IgG levels;
TGCT	cis	rs6666258	1.000	rs6691463	chr1:154814538	C/G	cg06418219	chr1:154948305	SHC1;CKS1B	0.65	5.26	0.43	6.14e-7	Atrial fibrillation;
TGCT	cis	rs11673344	0.523	rs17206540	chr19:37559911	A/G	cg08039142	chr19:36980659	ZNF566	0.49	4.5	0.37	1.57e-5	Obesity-related traits;
TGCT	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg13342137	chr4:2252803	MXD4	0.17	4.59	0.38	1.07e-5	Obesity-related traits;
TGCT	cis	rs61008539	0.821	rs10950789	chr7:897492	A/G	cg15782153	chr7:917662	C7orf20	0.52	6.5	0.5	1.76e-9	Perceived unattractiveness to mosquitoes;
TGCT	cis	rs28595532	0.920	rs115118317	chr4:119736613	C/T	cg21605333	chr4:119757512	SEC24D	1.61	8.95	0.63	4.36e-15	Cannabis dependence symptom count;
TGCT	cis	rs9326248	1.000	rs7946257	chr11:117053165	A/G	cg26566898	chr11:117069891	TAGLN	0.34	4.75	0.39	5.44e-6	Blood protein levels;
TGCT	cis	rs7772486	0.727	rs6941429	chr6:145952283	G/A	cg13319975	chr6:146136371	FBXO30	-0.56	-5.06	-0.41	1.46e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg15556689	chr8:8085844	FLJ10661	0.71	6.31	0.49	4.46e-9	Mood instability;
TGCT	cis	rs62244186	0.566	rs55852922	chr3:44826188	A/G	cg02073558	chr3:44770973	ZNF501	0.69	6.85	0.52	3.06e-10	Depressive symptoms;
TGCT	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.81	0.4	4.21e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs1723838	0.510	rs80217992	chr11:73694260	C/G	cg26954736	chr11:73693896	UCP2	-1.41	-6.38	-0.5	3.22e-9	Obesity-related traits;
TGCT	cis	rs9926296	0.632	rs4785716	chr16:89801127	T/C	cg08627397	chr16:89984028	MC1R	-0.32	-5.18	-0.42	8.68e-7	Vitiligo;
TGCT	cis	rs72945132	0.882	rs947812	chr11:70209169	C/T	cg00319359	chr11:70116639	PPFIA1	0.97	7.07	0.54	1.01e-10	Coronary artery disease;
TGCT	cis	rs9914544	0.545	rs8068683	chr17:18761827	T/G	cg26378065	chr17:18585709	ZNF286B	0.52	4.5	0.37	1.56e-5	Educational attainment (years of education);
TGCT	cis	rs3008870	1.000	rs3008853	chr1:67385488	C/T	cg03991309	chr1:68237761	GNG12	0.27	4.56	0.38	1.23e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs2243480	1.000	rs465359	chr7:65558164	C/T	cg18252515	chr7:66147081	NA	-1.1	-7.18	-0.54	5.77e-11	Diabetic kidney disease;
TGCT	cis	rs2204008	0.744	rs1115514	chr12:38280140	C/T	cg13010199	chr12:38710504	ALG10B	0.59	4.61	0.38	9.88e-6	Bladder cancer;
TGCT	cis	rs7923609	1.000	rs10822163	chr10:65124098	C/G	cg08743896	chr10:65200160	JMJD1C	-0.34	-4.57	-0.38	1.14e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs960450	0.826	rs9992841	chr4:98535757	T/C	cg05340658	chr4:99064831	C4orf37	-0.4	-4.61	-0.38	9.89e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg07424592	chr7:64974309	NA	1.4	8.42	0.6	7.87e-14	Diabetic kidney disease;
TGCT	cis	rs7917772	0.503	rs7893155	chr10:104294228	C/A	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs950776	0.642	rs34694149	chr15:78965917	C/T	cg03762349	chr15:79060523	ADAMTS7	0.28	5.42	0.44	2.98e-7	Sudden cardiac arrest;
TGCT	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg04234412	chr22:24373322	LOC391322	-0.72	-7.61	-0.56	6.11e-12	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg21862992	chr11:68658383	NA	0.42	5.81	0.46	5.06e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs11098499	0.865	rs9994730	chr4:120381564	A/C	cg09307838	chr4:120376055	NA	0.68	6.53	0.51	1.54e-9	Corneal astigmatism;
TGCT	cis	rs7666738	0.830	rs4619898	chr4:98959646	G/A	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4509693	1.000	rs4277047	chr10:102499416	T/A	cg24127310	chr10:102502104	NA	0.7	5.86	0.47	3.84e-8	Alzheimer's disease;
TGCT	cis	rs9972944	0.729	rs7209787	chr17:63769896	G/C	cg07283582	chr17:63770753	CCDC46	-0.26	-5.27	-0.43	5.91e-7	Total body bone mineral density;
TGCT	cis	rs6964587	0.692	rs4729018	chr7:91644613	C/T	cg17063962	chr7:91808500	NA	0.75	7.1	0.54	8.68e-11	Breast cancer;
TGCT	cis	rs7267979	0.604	rs242130	chr20:25594020	C/A	cg03522245	chr20:25566470	NINL	-0.54	-5.46	-0.44	2.46e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs12540874	0.759	rs12718572	chr7:50573325	C/T	cg18232548	chr7:50535776	DDC	-0.37	-6.38	-0.5	3.26e-9	Systemic sclerosis;
TGCT	cis	rs2239547	0.522	rs9865094	chr3:52985319	G/C	cg10802521	chr3:52805072	NEK4	0.64	6.1	0.48	1.26e-8	Schizophrenia;
TGCT	trans	rs62103177	0.525	rs4799116	chr18:77736735	A/G	cg05926928	chr17:57297772	GDPD1	-0.77	-6.89	-0.53	2.54e-10	Opioid sensitivity;
TGCT	cis	rs734999	0.505	rs4073285	chr1:2539796	C/T	cg18854424	chr1:2615690	NA	0.41	4.58	0.38	1.13e-5	Ulcerative colitis;
TGCT	cis	rs9300255	0.539	rs1969355	chr12:123742061	G/A	cg00376283	chr12:123451042	ABCB9	0.78	6.65	0.51	8.25e-10	Neutrophil percentage of white cells;
TGCT	cis	rs1941023	0.584	rs2241920	chr11:60164204	A/G	cg08716584	chr11:60157161	MS4A7	0.33	5.01	0.41	1.84e-6	Congenital heart disease (maternal effect);
TGCT	cis	rs35306767	0.761	rs11253538	chr10:1011166	C/T	cg26597838	chr10:835615	NA	0.57	6.42	0.5	2.6e-9	Eosinophil percentage of granulocytes;
TGCT	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.6	-5.05	-0.41	1.54e-6	Lung function (FEV1/FVC);
TGCT	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg23131131	chr22:24373011	LOC391322	-0.8	-8.69	-0.62	1.78e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs11190604	1.000	rs1080698	chr10:102295114	G/T	cg23241863	chr10:102295624	HIF1AN	0.66	4.85	0.4	3.62e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2153535	0.601	rs6906170	chr6:8543128	T/A	cg07606381	chr6:8435919	SLC35B3	0.56	5.16	0.42	9.56e-7	Motion sickness;
TGCT	cis	rs9926296	0.572	rs2376878	chr16:89885161	G/A	cg04287289	chr16:89883240	FANCA	0.69	7.08	0.54	9.59e-11	Vitiligo;
TGCT	cis	rs950169	0.887	rs220333	chr15:85091133	C/T	cg17173187	chr15:85201210	NMB	0.52	5.53	0.44	1.79e-7	Schizophrenia;
TGCT	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs6429082	0.689	rs4659923	chr1:235709519	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.51	-4.47	-0.37	1.77e-5	Adiposity;
TGCT	cis	rs7666738	0.830	rs58696666	chr4:99006913	C/T	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2730260	0.537	rs73169234	chr7:158882366	C/T	cg09066883	chr7:157932951	PTPRN2	0.42	4.66	0.39	8.09e-6	Myopia (pathological);
TGCT	cis	rs1865760	0.929	rs12195653	chr6:25958621	A/G	cg16482183	chr6:26056742	HIST1H1C	0.5	4.45	0.37	1.9e-5	Height;
TGCT	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	5.87	0.47	3.75e-8	Bipolar disorder;
TGCT	cis	rs2046867	0.862	rs62252362	chr3:72855218	A/G	cg25664220	chr3:72788482	NA	-0.56	-7.07	-0.54	1.02e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs17030434	0.906	rs11099901	chr4:154671468	T/A	cg14289246	chr4:154710475	SFRP2	-0.88	-7.18	-0.54	5.68e-11	Electrocardiographic conduction measures;
TGCT	cis	rs4074961	0.527	rs2294875	chr1:38052445	C/T	cg17933807	chr1:38061675	GNL2	1.06	15.42	0.81	1.27e-30	Axial length;
TGCT	cis	rs2692947	0.794	rs2140938	chr2:96751395	T/C	cg23100626	chr2:96804247	ASTL	0.39	4.59	0.38	1.09e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs9653442	0.545	rs4851257	chr2:100775297	C/T	cg07810366	chr2:100720526	AFF3	-0.36	-5.26	-0.43	6.14e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs6089829	0.926	rs73921625	chr20:61660891	C/T	cg03213289	chr20:61660250	NA	-0.51	-5.59	-0.45	1.38e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs709400	0.628	rs12879085	chr14:103874420	G/A	cg12935359	chr14:103987150	CKB	0.34	5.19	0.42	8.36e-7	Body mass index;
TGCT	cis	rs9534288	0.797	rs6561281	chr13:46596601	C/T	cg15192986	chr13:46630673	CPB2	-0.52	-7.53	-0.56	9.22e-12	Blood protein levels;
TGCT	cis	rs7918232	0.941	rs4749228	chr10:27433618	C/T	cg14442939	chr10:27389572	ANKRD26	-0.72	-5.35	-0.43	4.16e-7	Breast cancer;
TGCT	cis	rs7829975	0.559	rs4841025	chr8:8603160	A/G	cg15556689	chr8:8085844	FLJ10661	-0.65	-5.67	-0.45	9.37e-8	Mood instability;
TGCT	cis	rs7088591	0.614	rs16911518	chr10:59752987	C/T	cg07264682	chr10:60082823	NA	0.35	4.72	0.39	6.2e-6	Blood pressure;
TGCT	cis	rs9653442	0.932	rs893245	chr2:100814893	C/T	cg07810366	chr2:100720526	AFF3	-0.4	-6.07	-0.48	1.46e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs644799	0.562	rs1254989	chr11:95508121	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.59	6.03	0.48	1.77e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs6484504	0.532	rs11031342	chr11:31309818	G/A	cg26647111	chr11:31128758	NA	-0.32	-4.64	-0.38	8.82e-6	Red blood cell count;
TGCT	cis	rs1949733	0.675	rs2688235	chr4:8450546	T/C	cg11789530	chr4:8429930	ACOX3	0.55	5.22	0.42	7.42e-7	Response to antineoplastic agents;
TGCT	cis	rs2677744	0.597	rs16945091	chr15:91499081	A/T	cg01710897	chr15:91497902	RCCD1	0.33	4.67	0.39	7.75e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs2115630	0.967	rs8027779	chr15:85255385	T/C	cg12501888	chr15:85177176	SCAND2	-0.5	-4.83	-0.4	3.89e-6	P wave terminal force;
TGCT	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.61	5.06	0.41	1.5e-6	Tonsillectomy;
TGCT	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg05754148	chr16:3507555	NAT15	0.43	5.14	0.42	1.02e-6	Tuberculosis;
TGCT	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg04414720	chr1:150670196	GOLPH3L	0.39	5.04	0.41	1.58e-6	Tonsillectomy;
TGCT	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg02503808	chr4:7069936	GRPEL1	1.01	9.63	0.65	9.78e-17	Monocyte percentage of white cells;
TGCT	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg24531977	chr5:56204891	C5orf35	0.68	7.22	0.54	4.69e-11	Initial pursuit acceleration;
TGCT	cis	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg22857025	chr5:266934	NA	-0.34	-6.58	-0.51	1.19e-9	Breast cancer;
TGCT	cis	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg02002400	chr10:38691563	CDC10L	-0.38	-4.81	-0.4	4.22e-6	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs17221829	0.710	rs1844198	chr11:89388187	T/C	cg02982614	chr11:89391479	FOLH1B	-0.25	-4.46	-0.37	1.8e-5	Anxiety in major depressive disorder;
TGCT	cis	rs2046867	0.774	rs1393585	chr3:72886722	A/G	cg25664220	chr3:72788482	NA	-0.57	-6.33	-0.49	4.08e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	trans	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg17470723	chr8:74884337	TCEB1	0.72	6.94	0.53	1.91e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7772486	0.875	rs2814872	chr6:146310234	T/C	cg13319975	chr6:146136371	FBXO30	-0.53	-4.68	-0.39	7.44e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2242116	0.760	rs4682845	chr3:46955404	G/C	cg27129171	chr3:47204927	SETD2	0.62	6.06	0.48	1.54e-8	Birth weight;
TGCT	cis	rs7647973	1.000	rs6446262	chr3:49401153	T/C	cg06212747	chr3:49208901	KLHDC8B	0.59	4.68	0.39	7.32e-6	Menarche (age at onset);
TGCT	cis	rs3087591	0.960	rs2905880	chr17:29546175	A/G	cg24425628	chr17:29625626	OMG;NF1	0.44	6.67	0.51	7.64e-10	Hip circumference;
TGCT	cis	rs79149102	0.579	rs2304904	chr15:75315975	G/A	cg09165964	chr15:75287851	SCAMP5	-1.04	-5.48	-0.44	2.28e-7	Lung cancer;
TGCT	cis	rs7104764	0.719	rs3782116	chr11:223119	T/C	cg18336825	chr11:236787	PSMD13;SIRT3	0.91	8.99	0.63	3.42e-15	Menarche (age at onset);
TGCT	cis	rs79349575	0.783	rs9747646	chr17:47016882	C/T	cg26022315	chr17:47021804	SNF8	0.49	4.9	0.4	2.94e-6	Type 2 diabetes;
TGCT	cis	rs2486012	0.737	rs37466	chr1:44283071	T/C	cg12908607	chr1:44402522	ARTN	-0.69	-5.19	-0.42	8.38e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs231513	0.593	rs76204283	chr17:42111092	A/G	cg26893861	chr17:41843967	DUSP3	0.92	5.22	0.42	7.31e-7	Cognitive function;
TGCT	trans	rs797680	0.856	rs797681	chr1:93717746	T/C	cg27528825	chr2:159282178	CCDC148	0.35	6.88	0.53	2.65e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs3820068	0.603	rs6668726	chr1:15962614	G/A	cg05660106	chr1:15850417	CASP9	0.83	8.19	0.59	2.78e-13	Systolic blood pressure;
TGCT	cis	rs858239	0.863	rs466225	chr7:23332403	G/T	cg05602783	chr7:23145260	KLHL7	-0.58	-4.64	-0.38	8.55e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs11085466	1.000	rs75079001	chr19:21757375	A/G	cg23026602	chr19:21646605	NA	-0.57	-4.59	-0.38	1.07e-5	Colorectal or endometrial cancer;
TGCT	cis	rs9926296	0.712	rs258330	chr16:89729574	T/G	cg04287289	chr16:89883240	FANCA	-0.54	-5.01	-0.41	1.86e-6	Vitiligo;
TGCT	cis	rs7772486	0.875	rs2748498	chr6:146319166	C/G	cg13319975	chr6:146136371	FBXO30	-0.51	-4.54	-0.38	1.29e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg08048268	chr3:133502702	NA	0.65	9.75	0.66	5.07e-17	Iron status biomarkers;
TGCT	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg11905131	chr22:24372483	LOC391322	-0.85	-9.56	-0.65	1.43e-16	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg24829409	chr8:58192753	C8orf71	-0.59	-4.97	-0.41	2.17e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs3806843	0.551	rs246018	chr5:140335043	T/C	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg05025164	chr4:1340916	KIAA1530	0.78	6.86	0.52	2.86e-10	Longevity;
TGCT	cis	rs11098499	0.954	rs12499324	chr4:120393786	C/T	cg09307838	chr4:120376055	NA	0.68	6.37	0.5	3.41e-9	Corneal astigmatism;
TGCT	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg25767906	chr1:53392781	SCP2	-0.58	-5.2	-0.42	7.82e-7	Monocyte count;
TGCT	cis	rs7267979	1.000	rs2482937	chr20:25340786	A/G	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4803468	0.967	rs13344547	chr19:41945848	G/T	cg09537434	chr19:41945824	ATP5SL	0.92	10.36	0.68	1.69e-18	Height;
TGCT	cis	rs7582180	0.701	rs11693044	chr2:100922313	T/C	cg14675211	chr2:100938903	LONRF2	0.49	4.8	0.4	4.49e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9818758	0.556	rs9872660	chr3:49378832	G/T	cg08550065	chr3:50336684	HYAL3;NAT6	0.66	4.59	0.38	1.08e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs9926296	0.744	rs154657	chr16:89708096	A/G	cg26513180	chr16:89883248	FANCA	0.61	5.73	0.46	7.18e-8	Vitiligo;
TGCT	cis	rs4450131	0.618	rs7075794	chr10:126338093	A/G	cg20435097	chr10:126320824	FAM53B	0.18	4.44	0.37	1.95e-5	White blood cell count (basophil);
TGCT	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	7.12	0.54	7.55e-11	Platelet count;
TGCT	cis	rs1525293	1.000	rs10950235	chr7:70480631	C/T	cg21135135	chr7:70597687	WBSCR17	-0.44	-4.62	-0.38	9.46e-6	Colonoscopy-negative controls vs population controls;Major depressive disorder;
TGCT	cis	rs6484504	0.532	rs1929019	chr11:31267030	C/T	cg14844989	chr11:31128820	NA	-0.25	-4.72	-0.39	6.21e-6	Red blood cell count;
TGCT	cis	rs896854	0.715	rs12548874	chr8:95935164	A/C	cg16049864	chr8:95962084	TP53INP1	0.69	8.72	0.62	1.56e-14	Type 2 diabetes;
TGCT	cis	rs7027203	0.828	rs7037960	chr9:96584028	G/A	cg14598338	chr9:96623480	NA	-0.61	-9.56	-0.65	1.43e-16	DNA methylation (variation);
TGCT	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg22105103	chr4:187893119	NA	0.34	4.86	0.4	3.41e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2439831	0.681	rs2278859	chr15:43632960	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.05	9.14	0.63	1.54e-15	Lung cancer in ever smokers;
TGCT	cis	rs62380364	0.602	rs640177	chr5:88002084	T/A	cg24804195	chr5:87968844	LOC645323	-0.59	-5.71	-0.46	7.96e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7772486	0.875	rs9322043	chr6:146352690	A/G	cg13319975	chr6:146136371	FBXO30	-0.51	-4.65	-0.39	8.32e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9653442	0.564	rs10197987	chr2:100790783	A/T	cg07810366	chr2:100720526	AFF3	-0.35	-5.23	-0.43	6.98e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs12530845	0.943	rs58577912	chr7:135329269	T/G	cg23117316	chr7:135346802	PL-5283	-0.5	-4.74	-0.39	5.83e-6	Red blood cell traits;
TGCT	cis	rs10464366	0.544	rs12701697	chr7:39182165	C/T	cg18850127	chr7:39170497	POU6F2	0.33	7.18	0.54	5.5e-11	IgG glycosylation;
TGCT	cis	rs5750830	0.594	rs6001568	chr22:39775786	G/A	cg05872129	chr22:39784769	NA	-0.85	-8.99	-0.63	3.42e-15	Intelligence (multi-trait analysis);
TGCT	trans	rs561341	0.689	rs578635	chr17:30289897	A/C	cg20587970	chr11:113659929	NA	-0.63	-6.84	-0.52	3.25e-10	Hip circumference adjusted for BMI;
TGCT	cis	rs9916302	0.904	rs585961	chr17:37444036	G/A	cg15445000	chr17:37608096	MED1	-0.31	-4.59	-0.38	1.06e-5	Glomerular filtration rate (creatinine);
TGCT	trans	rs1814175	0.702	rs4881644	chr11:49786367	C/T	cg03929089	chr4:120376271	NA	-0.69	-8.17	-0.59	3.03e-13	Height;
TGCT	trans	rs7864133	1.000	rs11139253	chr9:84063913	T/C	cg23451063	chr7:1059876	C7orf50	0.55	6.93	0.53	2.02e-10	Post bronchodilator FEV1 in COPD;
TGCT	cis	rs3008870	0.628	rs2755257	chr1:67515309	C/T	cg02640540	chr1:67518911	SLC35D1	0.63	5.95	0.47	2.55e-8	Lymphocyte percentage of white cells;
TGCT	cis	rs2153535	0.580	rs2183112	chr6:8528212	G/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.01	0.41	1.86e-6	Motion sickness;
TGCT	cis	rs10992471	0.756	rs7043152	chr9:95138499	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.61	-6.31	-0.49	4.46e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs17030434	1.000	rs12645134	chr4:154713430	T/C	cg14289246	chr4:154710475	SFRP2	-0.91	-7.28	-0.55	3.3e-11	Electrocardiographic conduction measures;
TGCT	cis	rs10875746	0.669	rs1021313	chr12:48638041	T/A	cg20731937	chr12:48336164	NA	0.59	4.52	0.38	1.45e-5	Longevity (90 years and older);
TGCT	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg00684032	chr4:1343700	KIAA1530	0.22	4.83	0.4	3.99e-6	Obesity-related traits;
TGCT	cis	rs910316	0.737	rs175084	chr14:75519175	C/T	cg11812906	chr14:75593930	NEK9	-0.63	-5.74	-0.46	6.72e-8	Height;
TGCT	cis	rs1005277	0.522	rs289647	chr10:37968278	A/G	cg25427524	chr10:38739819	LOC399744	-0.32	-6.35	-0.5	3.63e-9	Extrinsic epigenetic age acceleration;
TGCT	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg21724239	chr8:58056113	NA	0.44	4.57	0.38	1.18e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs12136530	0.577	rs12120180	chr1:19791441	C/T	cg03884082	chr1:19971709	NBL1	0.43	4.51	0.38	1.5e-5	Lead levels in blood;
TGCT	cis	rs7178424	0.875	rs2414753	chr15:62200974	T/C	cg00456672	chr15:62358751	C2CD4A	-0.31	-4.69	-0.39	7.14e-6	Height;
TGCT	cis	rs73416724	0.544	rs111739263	chr6:43243151	G/T	cg24109273	chr6:43484729	YIPF3;POLR1C	0.9	4.48	0.37	1.69e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs28551159	1	rs28551159	chr6:26376368	A/G	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Urinary tract infection frequency;
TGCT	cis	rs9653442	0.564	rs13013594	chr2:100784190	A/G	cg22139774	chr2:100720529	AFF3	-0.36	-5.69	-0.46	8.67e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs9419702	0.538	rs9419628	chr10:133539299	A/C	cg23460707	chr10:133558971	NA	0.44	4.83	0.4	4.01e-6	Survival in rectal cancer;
TGCT	cis	rs950169	0.959	rs12902070	chr15:84793558	T/C	cg12863693	chr15:85201151	NMB	0.38	4.45	0.37	1.9e-5	Schizophrenia;
TGCT	trans	rs3780486	1.000	rs12342831	chr9:33124872	A/G	cg20290983	chr6:43655470	MRPS18A	1.08	10.71	0.69	2.34e-19	IgG glycosylation;
TGCT	cis	rs832540	0.556	rs4146565	chr5:56093825	T/C	cg12311346	chr5:56204834	C5orf35	-0.49	-5.13	-0.42	1.08e-6	Coronary artery disease;
TGCT	cis	rs3806843	0.547	rs246010	chr5:140336635	A/T	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs533581	0.844	rs564669	chr16:88968540	T/C	cg16701003	chr16:89028210	CBFA2T3	0.33	4.79	0.39	4.77e-6	Social autistic-like traits;
TGCT	cis	rs9790314	1.000	rs9872514	chr3:161042833	T/C	cg03342759	chr3:160939853	NMD3	-0.42	-4.53	-0.38	1.38e-5	Morning vs. evening chronotype;
TGCT	trans	rs2832077	0.527	rs2776210	chr21:30268558	A/G	cg14791747	chr16:20752902	THUMPD1	-1.07	-12.65	-0.75	4.54e-24	Cognitive test performance;
TGCT	cis	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg02503808	chr4:7069936	GRPEL1	1.04	10.28	0.68	2.58e-18	Monocyte percentage of white cells;
TGCT	cis	rs921968	0.541	rs488767	chr2:219466860	G/T	cg02176678	chr2:219576539	TTLL4	0.48	6.78	0.52	4.32e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs6964587	0.934	rs73226382	chr7:91692760	T/C	cg22709100	chr7:91322751	NA	0.28	4.56	0.38	1.19e-5	Breast cancer;
TGCT	cis	rs72700829	0.531	rs955955	chr1:151011543	G/A	cg00666978	chr1:150947442	LASS2	0.89	4.64	0.38	8.54e-6	Schizophrenia;
TGCT	cis	rs10782582	0.609	rs72979226	chr1:76302222	C/A	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.52	4.53	0.38	1.37e-5	Daytime sleep phenotypes;
TGCT	cis	rs2594989	0.616	rs6442254	chr3:11474491	T/C	cg00170343	chr3:11313890	ATG7	0.74	5.52	0.44	1.9e-7	Circulating chemerin levels;
TGCT	trans	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg13615516	chr5:77269221	NA	0.69	8.57	0.61	3.51e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs11785400	1.000	rs4736365	chr8:143742197	A/G	cg24634471	chr8:143751801	JRK	0.57	6.12	0.48	1.11e-8	Schizophrenia;
TGCT	cis	rs6604026	0.630	rs56193705	chr1:93455887	C/G	cg17283838	chr1:93427260	FAM69A	0.57	4.64	0.38	8.79e-6	Multiple sclerosis;
TGCT	cis	rs7246657	1.000	rs1529957	chr19:37739801	A/G	cg03233940	chr19:37894644	NA	-0.37	-4.79	-0.39	4.73e-6	Coronary artery calcification;
TGCT	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg10150615	chr22:24372951	LOC391322	-0.86	-10.22	-0.68	3.68e-18	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.69	-7.06	-0.54	1.07e-10	Prostate cancer;
TGCT	cis	rs9467711	1.000	rs1883215	chr6:26314233	G/C	cg16898833	chr6:26189333	HIST1H4D	0.99	4.9	0.4	2.95e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg27535305	chr1:53392650	SCP2	-0.28	-5.93	-0.47	2.85e-8	Monocyte count;
TGCT	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg20203395	chr5:56204925	C5orf35	-0.59	-5.12	-0.42	1.12e-6	Initial pursuit acceleration;
TGCT	cis	rs2463822	0.669	rs72919493	chr11:62049651	C/A	cg06239285	chr11:62104954	ASRGL1	-0.82	-4.63	-0.38	9.15e-6	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs4233949	1.000	rs4233949	chr2:54659707	C/G	cg14634210	chr2:54682758	SPTBN1	-0.54	-4.55	-0.38	1.26e-5	Bone mineral density;
TGCT	cis	rs10779751	1.000	rs12120734	chr1:11262020	A/G	cg08854313	chr1:11322531	MTOR	0.94	10.22	0.68	3.73e-18	Body mass index;
TGCT	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg22535103	chr8:58192502	C8orf71	-0.41	-5.24	-0.43	6.57e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7267979	1.000	rs6083856	chr20:25407585	C/T	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2594989	0.943	rs9836989	chr3:11463637	G/A	cg00170343	chr3:11313890	ATG7	0.67	5.12	0.42	1.13e-6	Circulating chemerin levels;
TGCT	cis	rs4242434	0.672	rs11785031	chr8:22486612	A/G	cg03733263	chr8:22462867	KIAA1967	0.98	13.14	0.76	2.97e-25	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs2239547	0.603	rs17304995	chr3:53070755	A/G	cg10802521	chr3:52805072	NEK4	-0.58	-5.26	-0.43	6.15e-7	Schizophrenia;
TGCT	cis	rs10751667	0.666	rs4072741	chr11:976565	T/C	cg06064525	chr11:970664	AP2A2	-0.36	-8.28	-0.6	1.67e-13	Alzheimer's disease (late onset);
TGCT	cis	rs8141529	0.778	rs5762795	chr22:29182500	C/A	cg02153584	chr22:29168773	CCDC117	0.75	6.44	0.5	2.33e-9	Lymphocyte counts;
TGCT	cis	rs7226408	0.857	rs12185461	chr18:34492036	A/G	cg06757138	chr18:34340585	FHOD3	-0.25	-4.88	-0.4	3.21e-6	Obesity-related traits;
TGCT	cis	rs1005224	0.853	rs6574251	chr14:76136883	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.66	-5.92	-0.47	2.97e-8	Large artery stroke;
TGCT	cis	rs782590	0.967	rs62165172	chr2:55736237	A/G	cg18811423	chr2:55921094	PNPT1	0.67	7.22	0.54	4.57e-11	Metabolic syndrome;
TGCT	cis	rs6903823	0.527	rs4713158	chr6:28277771	C/A	cg18815343	chr6:28367644	ZSCAN12	-0.46	-4.8	-0.4	4.46e-6	Pulmonary function;
TGCT	cis	rs7615952	0.932	rs7629977	chr3:125649573	T/G	cg05084668	chr3:125655381	ALG1L	-0.76	-6.21	-0.49	7.43e-9	Blood pressure (smoking interaction);
TGCT	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg08645402	chr16:4508243	NA	0.21	5.18	0.42	8.63e-7	Schizophrenia;
TGCT	cis	rs10782582	0.593	rs6664254	chr1:76235084	G/T	cg10523679	chr1:76189770	ACADM	-0.61	-6.13	-0.48	1.09e-8	Daytime sleep phenotypes;
TGCT	cis	rs12950390	0.893	rs72831644	chr17:45824391	T/C	cg24803719	chr17:45855879	NA	-0.48	-4.81	-0.4	4.3e-6	IgG glycosylation;
TGCT	cis	rs11190604	1.000	rs6584379	chr10:102224490	G/A	cg16342193	chr10:102329863	NA	-0.4	-5.31	-0.43	4.85e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg03609598	chr5:56110824	MAP3K1	-0.58	-4.7	-0.39	6.72e-6	Initial pursuit acceleration;
TGCT	cis	rs7552404	0.727	rs6683437	chr1:76316619	G/A	cg10523679	chr1:76189770	ACADM	0.68	6.36	0.5	3.5e-9	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.13	0.82	3.12e-32	Prudent dietary pattern;
TGCT	cis	rs4499344	0.623	rs259278	chr19:33161126	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.91	10.19	0.68	4.27e-18	Mean platelet volume;
TGCT	cis	rs10744422	0.858	rs12426809	chr12:123327143	C/T	cg25930673	chr12:123319894	HIP1R	-0.85	-5.01	-0.41	1.86e-6	Schizophrenia;
TGCT	cis	rs6977660	0.714	rs4721824	chr7:19785898	A/G	cg05791153	chr7:19748676	TWISTNB	0.84	4.71	0.39	6.52e-6	Thyroid stimulating hormone;
TGCT	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg18230493	chr5:56204884	C5orf35	-0.68	-5.92	-0.47	2.92e-8	Initial pursuit acceleration;
TGCT	cis	rs600231	0.706	rs10896016	chr11:65335705	C/T	cg17120908	chr11:65337727	SSSCA1	0.57	5.78	0.46	5.72e-8	Bone mineral density;
TGCT	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg25036284	chr2:26402008	FAM59B	0.65	5.19	0.42	8.36e-7	Gut microbiome composition (summer);
TGCT	cis	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg19635926	chr16:89946313	TCF25	0.26	4.56	0.38	1.2e-5	Skin colour saturation;
TGCT	cis	rs992157	0.730	rs2891078	chr2:219184432	C/T	cg00012203	chr2:219082015	ARPC2	0.7	6.59	0.51	1.11e-9	Colorectal cancer;
TGCT	cis	rs9473924	0.542	rs9473928	chr6:50842003	G/A	cg14470998	chr6:50812995	TFAP2B	1.35	8.39	0.6	9.05e-14	Body mass index;
TGCT	cis	rs9913156	0.553	rs1045280	chr17:4622638	C/T	cg19197139	chr17:4613644	ARRB2	-0.59	-5.36	-0.43	3.96e-7	Lymphocyte counts;
TGCT	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7119	0.745	rs11632602	chr15:77809764	C/G	cg27398640	chr15:77910606	LINGO1	-0.25	-4.6	-0.38	1.05e-5	Type 2 diabetes;
TGCT	cis	rs2710642	0.888	rs28447553	chr2:63224563	A/G	cg17519650	chr2:63277830	OTX1	0.58	5.05	0.41	1.53e-6	LDL cholesterol levels;LDL cholesterol;
TGCT	cis	rs2637266	0.935	rs1907300	chr10:78325091	A/G	cg18941641	chr10:78392320	NA	0.42	5.38	0.43	3.6e-7	Pulmonary function;
TGCT	cis	rs7772486	0.790	rs4075694	chr6:146251108	G/C	cg23711669	chr6:146136114	FBXO30	-0.89	-10.38	-0.68	1.54e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9650657	0.585	rs7830317	chr8:10700254	A/C	cg27411982	chr8:10470053	RP1L1	-0.23	-4.65	-0.39	8.22e-6	Neuroticism;
TGCT	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg06896619	chr17:61851486	DDX42;CCDC47	-0.53	-5.08	-0.41	1.37e-6	Prudent dietary pattern;
TGCT	cis	rs1075232	1.000	rs16956707	chr15:31641633	G/A	cg01030201	chr15:31746330	NA	-1.01	-5.25	-0.43	6.38e-7	Survival in colorectal cancer (non-distant metastatic);
TGCT	cis	rs1461503	0.966	rs1461501	chr11:122844416	A/G	cg27398637	chr11:122830231	C11orf63	-0.42	-5.25	-0.43	6.42e-7	Menarche (age at onset);
TGCT	trans	rs210152	0.588	rs210131	chr6:33535466	T/C	cg00293626	chr8:143463227	TSNARE1	-0.44	-6.78	-0.52	4.27e-10	Schizophrenia;
TGCT	cis	rs904251	0.828	rs1757174	chr6:37486695	G/A	cg25019722	chr6:37503610	NA	-0.51	-7.0	-0.53	1.43e-10	Cognitive performance;
TGCT	cis	rs1949733	1.000	rs2631740	chr4:8484106	C/A	cg11789530	chr4:8429930	ACOX3	-0.65	-6.0	-0.47	1.99e-8	Response to antineoplastic agents;
TGCT	cis	rs1042058	0.565	rs650110	chr10:30753132	A/G	cg18806716	chr10:30721971	MAP3K8	-0.57	-6.89	-0.53	2.46e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
TGCT	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg21951975	chr1:209979733	IRF6	0.73	5.94	0.47	2.72e-8	Cleft lip with or without cleft palate;
TGCT	cis	rs8017423	0.967	rs4904656	chr14:90721442	G/T	cg04374321	chr14:90722782	PSMC1	0.76	7.71	0.57	3.49e-12	Mortality in heart failure;
TGCT	cis	rs3733585	0.699	rs4473653	chr4:9971058	A/G	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.72	-0.52	5.74e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs4478037	1.000	rs56733391	chr3:33161434	G/A	cg19404215	chr3:33155277	CRTAP	1.39	9.26	0.64	7.94e-16	Major depressive disorder;
TGCT	cis	rs72843506	0.591	rs75334890	chr17:20221400	A/G	cg18979559	chr17:20280153	CCDC144C	-0.67	-4.89	-0.4	3.04e-6	Schizophrenia;
TGCT	cis	rs3540	0.513	rs2601182	chr15:90925430	A/T	cg22089800	chr15:90895588	ZNF774	0.82	9.2	0.64	1.09e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs9389248	0.690	rs2064101	chr6:135250530	G/A	cg24558204	chr6:135376177	HBS1L	-0.47	-4.81	-0.4	4.35e-6	High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs2288884	0.779	rs10411428	chr19:52607765	C/T	cg13540795	chr19:52551618	ZNF432	-0.6	-5.81	-0.46	5.06e-8	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs1372520	0.684	rs2572318	chr4:90718719	C/T	cg14346243	chr4:90757452	SNCA	-0.66	-4.74	-0.39	5.7e-6	Neuroticism;
TGCT	cis	rs4718428	0.705	rs4717331	chr7:66378886	C/T	cg18252515	chr7:66147081	NA	-0.59	-4.49	-0.37	1.6e-5	Corneal structure;
TGCT	cis	rs611744	0.816	rs626211	chr8:109189448	A/C	cg21045802	chr8:109455806	TTC35	0.68	6.03	0.48	1.72e-8	Dupuytren's disease;
TGCT	cis	rs941873	0.838	rs2233713	chr10:81107135	A/C	cg09469691	chr10:81107165	PPIF	0.65	6.69	0.51	6.97e-10	Height;
TGCT	cis	rs11514810	1.000	rs7812242	chr7:1431747	C/T	cg24899294	chr7:1481343	MICALL2	-0.45	-5.73	-0.46	7.11e-8	Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder;
TGCT	cis	rs3905510	0.903	rs10085115	chr5:123001137	C/T	cg15125798	chr5:122621645	NA	-0.59	-4.69	-0.39	7.12e-6	Total body bone mineral density;
TGCT	cis	rs12134133	0.752	rs61821050	chr1:207408598	C/A	cg02152968	chr1:207494213	CD55	0.69	4.75	0.39	5.46e-6	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs7909074	0.966	rs4245614	chr10:45397007	C/T	cg04218760	chr10:45406644	TMEM72	-0.27	-5.36	-0.43	3.95e-7	Mean corpuscular volume;
TGCT	cis	rs6500602	0.727	rs4786509	chr16:4568769	C/G	cg09549813	chr16:4587862	C16orf5	0.28	4.51	0.38	1.5e-5	Schizophrenia;
TGCT	cis	rs8017423	0.615	rs12586761	chr14:90820897	A/G	cg04374321	chr14:90722782	PSMC1	-0.56	-5.62	-0.45	1.19e-7	Mortality in heart failure;
TGCT	cis	rs11792861	0.851	rs17552292	chr9:111891954	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.48	4.47	0.37	1.73e-5	Menarche (age at onset);
TGCT	cis	rs2075371	0.611	rs12531769	chr7:134016899	C/G	cg11752832	chr7:134001865	SLC35B4	0.63	5.1	0.42	1.23e-6	Mean platelet volume;
TGCT	cis	rs2228479	0.850	rs17226966	chr16:89825338	A/G	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs7246657	0.722	rs10417576	chr19:38119212	A/C	cg03611452	chr19:38183253	ZNF781	0.59	4.76	0.39	5.34e-6	Coronary artery calcification;
TGCT	trans	rs1496653	0.544	rs35497505	chr3:23425798	G/T	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs858239	0.730	rs858289	chr7:23248158	C/T	cg05407003	chr7:23246146	NA	-0.28	-4.54	-0.38	1.29e-5	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs2227564	0.620	rs10740418	chr10:75519322	T/C	cg19442545	chr10:75533431	FUT11	-0.31	-4.55	-0.38	1.26e-5	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs1153858	1.000	rs3809472	chr15:45694318	G/T	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.62e-8	Homoarginine levels;
TGCT	cis	rs909002	0.800	rs1061770	chr1:32096265	A/G	cg11573219	chr1:32083031	HCRTR1	-0.43	-5.6	-0.45	1.33e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs11935103	0.673	rs1470753	chr4:187296119	A/G	cg16785698	chr4:186456103	PDLIM3	0.44	4.47	0.37	1.74e-5	Response to citalopram treatment;
TGCT	cis	rs9611565	0.729	rs202654	chr22:41841034	G/A	cg13695892	chr22:41940480	POLR3H	0.86	8.55	0.61	3.95e-14	Vitiligo;
TGCT	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	6.75	0.52	5.02e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs11098499	0.954	rs6846442	chr4:120326323	G/A	cg09307838	chr4:120376055	NA	0.68	6.53	0.51	1.54e-9	Corneal astigmatism;
TGCT	cis	rs11264213	0.591	rs4653158	chr1:36556187	G/A	cg27506609	chr1:36549197	TEKT2	-0.37	-6.07	-0.48	1.45e-8	Schizophrenia;
TGCT	cis	rs288326	0.561	rs74953433	chr2:183872665	T/C	cg09997497	chr2:183902928	NCKAP1	1.11	4.95	0.41	2.38e-6	Blood protein levels;
TGCT	cis	rs950169	1.000	rs1848093	chr15:84755527	G/C	cg11189052	chr15:85197271	WDR73	0.69	5.91	0.47	3.14e-8	Schizophrenia;
TGCT	cis	rs9527	0.662	rs10883783	chr10:104591152	T/A	cg04362960	chr10:104952993	NT5C2	0.63	5.37	0.43	3.77e-7	Arsenic metabolism;
TGCT	cis	rs526231	0.819	rs2569016	chr5:102603132	A/G	cg05225461	chr5:102596755	C5orf30	0.23	4.62	0.38	9.51e-6	Primary biliary cholangitis;
TGCT	cis	rs319204	1.000	rs319239	chr5:146238637	A/G	cg25021259	chr5:146258546	PPP2R2B	0.36	4.53	0.38	1.37e-5	Schizophrenia;
TGCT	cis	rs67073037	0.955	rs4666131	chr2:29136272	T/C	cg09522027	chr2:28974177	PPP1CB	0.57	4.49	0.37	1.59e-5	Breast cancer;Breast cancer (estrogen-receptor negative);
TGCT	cis	rs2673604	0.600	rs2673600	chr8:133414416	C/G	cg05740582	chr8:133573933	HPYR1	-0.31	-4.48	-0.37	1.65e-5	Interleukin-8 levels;
TGCT	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg04944784	chr2:26401820	FAM59B	-0.76	-6.24	-0.49	6.46e-9	Gut microbiome composition (summer);
TGCT	cis	rs3784262	0.565	rs9635346	chr15:58298118	C/G	cg12031962	chr15:58353849	ALDH1A2	0.38	5.53	0.44	1.82e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs6684514	1.000	rs12038203	chr1:156248265	C/T	cg16558208	chr1:156270281	VHLL	0.46	9.38	0.64	3.92e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs11098499	0.863	rs13136462	chr4:120543173	C/T	cg09307838	chr4:120376055	NA	0.67	6.29	0.49	5.06e-9	Corneal astigmatism;
TGCT	cis	rs2153535	0.580	rs7775909	chr6:8477778	A/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs7213347	0.611	rs1231207	chr17:2125450	A/C	cg20777128	chr17:1945076	DPH1;OVCA2	-0.51	-4.6	-0.38	1.01e-5	Total body bone mineral density;
TGCT	cis	rs9733	0.818	rs10888388	chr1:150687296	C/T	cg13175981	chr1:150552382	MCL1	0.43	4.78	0.39	4.88e-6	Tonsillectomy;
TGCT	cis	rs4986172	0.726	rs12946454	chr17:43208121	A/T	cg10701640	chr17:43249399	NA	0.52	6.28	0.49	5.25e-9	Height;
TGCT	cis	rs7267979	0.966	rs4815414	chr20:25361701	A/G	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9399135	0.967	rs11755229	chr6:135369913	A/G	cg24558204	chr6:135376177	HBS1L	0.46	4.55	0.38	1.24e-5	Red blood cell count;
TGCT	cis	rs68170813	0.562	rs7810216	chr7:107000353	G/A	cg02696742	chr7:106810147	HBP1	-0.7	-5.7	-0.46	8.16e-8	Coronary artery disease;
TGCT	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg21724239	chr8:58056113	NA	0.38	5.17	0.42	9.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6088580	0.608	rs8114616	chr20:32969092	G/T	cg08999081	chr20:33150536	PIGU	-0.26	-5.13	-0.42	1.09e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs763014	1.000	rs8054842	chr16:672799	T/C	cg09263875	chr16:632152	PIGQ	0.3	6.44	0.5	2.41e-9	Height;
TGCT	cis	rs9372253	0.678	rs9487392	chr6:110708626	C/T	cg01119278	chr6:110721349	DDO	0.31	4.73	0.39	6.05e-6	Platelet distribution width;
TGCT	cis	rs1420338	0.933	rs62451689	chr7:34178719	C/T	cg01275685	chr7:34179230	BMPER	-0.28	-5.0	-0.41	1.88e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs7666738	0.830	rs1426667	chr4:98949772	T/C	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.07	-9.63	-0.65	1.01e-16	Platelet count;
TGCT	cis	rs9640161	0.711	rs55881542	chr7:150025734	G/A	cg10018233	chr7:150070692	REPIN1	0.32	4.58	0.38	1.1e-5	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs198426	0.506	rs11230766	chr11:61426582	A/T	cg19838087	chr11:61442541	NA	-0.2	-4.62	-0.38	9.43e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);
TGCT	cis	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg07424592	chr7:64974309	NA	1.38	8.17	0.59	3.04e-13	Diabetic kidney disease;
TGCT	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg05985448	chr10:134359359	INPP5A	0.23	4.99	0.41	2.01e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg10802521	chr3:52805072	NEK4	-0.78	-10.01	-0.67	1.22e-17	Bipolar disorder;
TGCT	cis	rs12220238	1.000	rs3812638	chr10:75896072	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.85	5.91	0.47	3.14e-8	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs7666738	0.830	rs13148363	chr4:98847498	T/C	cg18180107	chr4:99064573	C4orf37	0.55	5.1	0.42	1.22e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs751728	0.571	rs4713691	chr6:33790415	A/G	cg13859433	chr6:33739653	LEMD2	0.34	5.66	0.45	1.01e-7	Crohn's disease;
TGCT	cis	rs4689388	0.853	rs1079214	chr4:6282157	T/C	cg00701064	chr4:6280414	WFS1	0.39	4.79	0.4	4.7e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs826838	1.000	rs11183160	chr12:38676702	T/C	cg26384229	chr12:38710491	ALG10B	1.11	10.88	0.7	9.29e-20	Heart rate;
TGCT	cis	rs4786125	0.665	rs1565634	chr16:6919370	T/C	cg03623568	chr16:6915990	A2BP1	-0.45	-6.77	-0.52	4.65e-10	Heart rate variability traits (SDNN);
TGCT	cis	rs57590327	0.679	rs13082940	chr3:81547264	C/T	cg07356753	chr3:81810745	GBE1	0.55	4.54	0.38	1.3e-5	Extraversion;
TGCT	cis	rs1372520	0.684	rs1811442	chr4:90747751	C/T	cg15133208	chr4:90757351	SNCA	-0.5	-5.86	-0.47	4e-8	Neuroticism;
TGCT	cis	rs950776	0.518	rs12900783	chr15:78815523	G/A	cg06917634	chr15:78832804	PSMA4	0.96	9.71	0.66	6.43e-17	Sudden cardiac arrest;
TGCT	trans	rs3780486	0.757	rs10121987	chr9:33119818	A/G	cg20290983	chr6:43655470	MRPS18A	1.2	14.8	0.8	3.47e-29	IgG glycosylation;
TGCT	cis	rs7635838	0.565	rs346067	chr3:11252095	T/C	cg00170343	chr3:11313890	ATG7	0.54	4.96	0.41	2.25e-6	HDL cholesterol;
TGCT	cis	rs9291683	0.588	rs2240721	chr4:10020564	G/A	cg00071950	chr4:10020882	SLC2A9	0.72	9.86	0.66	2.78e-17	Bone mineral density;
TGCT	cis	rs3796352	0.892	rs2581807	chr3:53088844	G/A	cg27565382	chr3:53032988	SFMBT1	-0.42	-4.79	-0.4	4.61e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs3772130	0.962	rs9826473	chr3:121556219	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.51	4.7	0.39	6.82e-6	Cognitive performance;
TGCT	cis	rs13188771	0.578	rs17137390	chr5:100918526	C/T	cg18665594	chr5:101119420	NA	0.48	4.78	0.39	4.83e-6	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs9911578	0.704	rs72628393	chr17:56585314	A/T	cg05425664	chr17:57184151	TRIM37	0.59	5.69	0.46	8.67e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2282802	0.685	rs11745502	chr5:139558808	G/A	cg01081189	chr5:139537190	NA	-0.3	-5.37	-0.43	3.82e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs826838	0.935	rs7301104	chr12:39182821	C/T	cg26384229	chr12:38710491	ALG10B	0.98	8.78	0.62	1.07e-14	Heart rate;
TGCT	cis	rs7666738	0.830	rs11941961	chr4:99065654	G/T	cg05340658	chr4:99064831	C4orf37	0.52	5.92	0.47	2.91e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9388451	0.626	rs1343116	chr6:126069702	C/A	cg10911889	chr6:126070802	HEY2	0.5	4.69	0.39	7.17e-6	Brugada syndrome;
TGCT	cis	rs2326825	0.585	rs1317391	chr6:6803971	C/T	cg06501113	chr6:6534839	LOC285780	-0.39	-5.1	-0.42	1.21e-6	Gastroesophageal reflux disease;
TGCT	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg11764359	chr7:65958608	NA	0.56	4.79	0.4	4.68e-6	Aortic root size;
TGCT	cis	rs7824557	0.767	rs7837036	chr8:11175489	A/G	cg21775007	chr8:11205619	TDH	0.54	5.18	0.42	8.68e-7	Retinal vascular caliber;
TGCT	cis	rs2338224	1.000	rs9293309	chr5:71746822	A/G	cg01187920	chr5:71015162	CARTPT	-0.53	-4.57	-0.38	1.15e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Granulocyte count;Myeloid white cell count;
TGCT	cis	rs7091068	0.566	rs7082701	chr10:95501042	G/T	cg20715218	chr10:95462985	C10orf4	0.52	4.62	0.38	9.33e-6	Urinary tract infection frequency;
TGCT	cis	rs2180341	0.960	rs3756996	chr6:127664258	G/C	cg24812749	chr6:127587940	RNF146	1.01	7.58	0.56	7.11e-12	Breast cancer;
TGCT	cis	rs7954584	0.616	rs10743185	chr12:122356435	G/A	cg21016266	chr12:122356598	WDR66	0.43	5.65	0.45	1.03e-7	Mean corpuscular volume;
TGCT	cis	rs250677	0.687	rs41181	chr5:148444257	C/G	cg23229984	chr5:148520753	ABLIM3	-0.2	-4.7	-0.39	6.82e-6	Breast cancer;
TGCT	cis	rs2033711	0.936	rs7257999	chr19:58964860	C/G	cg12042659	chr19:58951599	ZNF132	0.57	5.08	0.42	1.35e-6	Uric acid clearance;
TGCT	cis	rs887829	0.569	rs4663965	chr2:234650604	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.26	-4.76	-0.39	5.4e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
TGCT	cis	rs9985766	1.000	rs28392881	chr4:151007145	G/A	cg05926478	chr4:151174724	DCLK2	-0.26	-5.19	-0.42	8.26e-7	Coronary artery disease;Myocardial infarction;
TGCT	cis	rs9457247	0.508	rs2285147	chr6:167505548	G/A	cg07741184	chr6:167504864	NA	0.26	4.88	0.4	3.21e-6	Crohn's disease;
TGCT	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg02725872	chr8:58115012	NA	-0.38	-5.05	-0.41	1.55e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2239547	0.522	rs4519686	chr3:52997871	C/T	cg11645453	chr3:52864694	ITIH4	0.37	6.26	0.49	5.89e-9	Schizophrenia;
TGCT	cis	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg08564027	chr20:61660810	NA	0.38	7.08	0.54	9.36e-11	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7027203	1.000	rs7854820	chr9:96526027	A/G	cg14598338	chr9:96623480	NA	0.58	8.58	0.61	3.19e-14	DNA methylation (variation);
TGCT	cis	rs9902453	0.765	rs2127001	chr17:28098219	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.84	-8.18	-0.59	2.89e-13	Coffee consumption (cups per day);
TGCT	cis	rs60871478	0.636	rs55663559	chr7:884057	G/A	cg15782153	chr7:917662	C7orf20	0.52	4.78	0.39	4.84e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs7668190	0.924	rs6554162	chr4:55093955	G/A	cg17187183	chr4:55093834	PDGFRA	0.43	5.99	0.47	2.12e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg00080972	chr5:178986291	RUFY1	0.51	6.01	0.47	1.95e-8	Lung cancer;
TGCT	cis	rs295140	0.526	rs295113	chr2:201197816	C/G	cg04283868	chr2:201171347	SPATS2L	-0.47	-4.45	-0.37	1.87e-5	QT interval;
TGCT	cis	rs2032447	0.641	rs442601	chr6:25934524	G/A	cg12310025	chr6:25882481	NA	-0.63	-5.71	-0.46	7.79e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg04352962	chr1:209979756	IRF6	0.64	4.89	0.4	3.12e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs7769051	0.808	rs1467404	chr6:133090141	A/G	cg22852734	chr6:133119734	C6orf192	-1.22	-6.88	-0.53	2.57e-10	Type 2 diabetes nephropathy;
TGCT	cis	rs7267979	1.000	rs2474777	chr20:25272633	A/G	cg14121845	chr20:25566513	NINL	0.5	5.39	0.44	3.37e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7267979	1.000	rs6050617	chr20:25421648	C/T	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs12210905	0.688	rs12212632	chr6:27472416	T/C	cg08851530	chr6:28072375	NA	1.34	6.29	0.49	5.02e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs67311347	1.000	rs28871903	chr3:40511094	T/G	cg13409248	chr3:40428643	ENTPD3	0.56	4.45	0.37	1.91e-5	Renal cell carcinoma;
TGCT	cis	rs3087591	0.960	rs9807077	chr17:29634457	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.48	-7.57	-0.56	7.2e-12	Hip circumference;
TGCT	trans	rs2970818	0.831	rs7304949	chr12:4609625	A/G	cg23020582	chr12:54734966	COPZ1	0.45	7.02	0.53	1.27e-10	Phosphorus levels;
TGCT	cis	rs2797160	0.967	rs1343120	chr6:125992810	A/G	cg05901451	chr6:126070800	HEY2	-0.74	-6.49	-0.5	1.84e-9	Endometrial cancer;
TGCT	cis	rs13256369	0.851	rs13256611	chr8:8564341	G/A	cg17143192	chr8:8559678	CLDN23	0.57	5.35	0.43	4.09e-7	Obesity-related traits;
TGCT	cis	rs514406	0.644	rs4926928	chr1:53210163	G/T	cg25767906	chr1:53392781	SCP2	-0.44	-4.86	-0.4	3.44e-6	Monocyte count;
TGCT	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.71	6.36	0.5	3.53e-9	Tonsillectomy;
TGCT	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.46	-6.43	-0.5	2.53e-9	Alzheimer's disease;
TGCT	cis	rs11190604	1.000	rs2495758	chr10:102321900	C/G	cg16342193	chr10:102329863	NA	-0.42	-5.26	-0.43	5.99e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	16.1	0.82	3.69e-32	Prudent dietary pattern;
TGCT	cis	rs3091242	0.933	rs11249251	chr1:25770188	C/G	cg00786635	chr1:25594202	NA	0.52	5.56	0.45	1.59e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs4689388	0.853	rs1079214	chr4:6282157	T/C	cg14416269	chr4:6271139	WFS1	0.4	5.13	0.42	1.07e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs68170813	0.559	rs78404515	chr7:106909126	G/A	cg02696742	chr7:106810147	HBP1	-0.69	-5.61	-0.45	1.27e-7	Coronary artery disease;
TGCT	cis	rs34421088	0.506	rs2117616	chr8:11145911	A/G	cg03192020	chr8:11204681	TDH	-0.52	-4.58	-0.38	1.12e-5	Neuroticism;
TGCT	cis	rs9527	0.590	rs1541213	chr10:104885330	A/G	cg15744005	chr10:104629667	AS3MT	-0.43	-4.94	-0.41	2.45e-6	Arsenic metabolism;
TGCT	cis	rs67072384	1.000	rs67809272	chr11:72450941	T/A	cg03713592	chr11:72463424	ARAP1	-0.93	-4.66	-0.39	7.89e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg21862992	chr11:68658383	NA	0.47	6.67	0.51	7.49e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7666738	0.830	rs2865979	chr4:99027137	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg06238570	chr21:40685208	BRWD1	0.69	6.43	0.5	2.55e-9	Cognitive function;
TGCT	cis	rs7703051	0.520	rs13354746	chr5:74619132	C/T	cg00601450	chr5:74908170	NA	0.45	5.02	0.41	1.73e-6	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
TGCT	cis	rs1903068	0.853	rs10012589	chr4:56002689	A/T	cg09978860	chr4:56023921	NA	0.56	6.34	0.49	3.88e-9	Endometriosis;
TGCT	cis	rs6912958	0.781	rs7750207	chr6:88303967	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-4.57	-0.38	1.14e-5	Monocyte percentage of white cells;
TGCT	cis	rs3806843	0.576	rs251373	chr5:140252615	C/T	cg09824255	chr5:140014002	CD14	-0.26	-4.54	-0.38	1.3e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs8017423	0.935	rs12884698	chr14:90750566	G/A	cg04374321	chr14:90722782	PSMC1	-0.74	-6.98	-0.53	1.6e-10	Mortality in heart failure;
TGCT	cis	rs9467773	0.566	rs66972160	chr6:26359306	T/C	cg15659132	chr6:26577336	NA	-0.53	-5.47	-0.44	2.37e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7107174	0.688	rs869202	chr11:78127914	A/G	cg12700464	chr11:78128424	GAB2	-0.67	-4.46	-0.37	1.83e-5	Testicular germ cell tumor;
TGCT	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg06028808	chr11:68637592	NA	0.49	6.3	0.49	4.76e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.85	7.0	0.53	1.44e-10	Platelet count;
TGCT	cis	rs9381040	0.610	rs4140579	chr6:41041752	G/A	cg03526776	chr6:41159608	TREML2	0.27	5.34	0.43	4.21e-7	Alzheimer's disease (late onset);
TGCT	cis	rs6674176	0.542	rs803675	chr1:44353237	G/A	cg12908607	chr1:44402522	ARTN	-0.7	-7.96	-0.58	9.2e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs72634258	0.554	rs68024107	chr1:7914066	G/C	cg26816564	chr1:7831052	VAMP3	0.57	4.69	0.39	7.01e-6	Inflammatory bowel disease;
TGCT	cis	rs4372836	0.504	rs62131973	chr2:29044437	T/G	cg09522027	chr2:28974177	PPP1CB	-0.56	-5.68	-0.45	9.2e-8	Body mass index;
TGCT	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.68	-6.83	-0.52	3.38e-10	Prostate cancer;
TGCT	cis	rs797680	0.786	rs1559828	chr1:93825638	A/T	cg17826107	chr1:92977322	EVI5	-0.24	-5.65	-0.45	1.05e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs1865760	0.566	rs2032449	chr6:26026599	G/C	cg17042849	chr6:26104293	HIST1H4C	-0.61	-5.3	-0.43	5.08e-7	Height;
TGCT	cis	rs6450176	0.909	rs6898870	chr5:53293107	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.49	-4.59	-0.38	1.08e-5	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs8013055	0.796	rs4074453	chr14:105998544	T/C	cg23356831	chr14:105996513	TMEM121	0.38	5.69	0.46	8.5e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs11190604	0.767	rs10883479	chr10:102162860	A/G	cg16005271	chr10:102321736	NA	0.45	4.74	0.39	5.87e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2237234	0.580	rs7763910	chr6:26472655	C/T	cg26531700	chr6:26746687	NA	-0.5	-4.53	-0.38	1.37e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7659604	0.540	rs11734075	chr4:122695685	C/T	cg19748678	chr4:122722346	EXOSC9	-0.57	-5.69	-0.45	8.7e-8	Type 2 diabetes;
TGCT	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg13395646	chr4:1353034	KIAA1530	-0.36	-4.75	-0.39	5.64e-6	Obesity-related traits;
TGCT	cis	rs11190604	0.943	rs7085261	chr10:102209811	G/A	cg23241863	chr10:102295624	HIF1AN	0.62	4.87	0.4	3.27e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs73198271	0.694	rs115037021	chr8:8647080	A/C	cg15556689	chr8:8085844	FLJ10661	-0.6	-4.46	-0.37	1.8e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs9910055	0.530	rs7222349	chr17:42304644	C/T	cg13607699	chr17:42295918	UBTF	0.96	11.06	0.7	3.33e-20	Total body bone mineral density;
TGCT	cis	rs11748023	0.605	rs155943	chr5:139529987	A/T	cg01081189	chr5:139537190	NA	0.27	4.75	0.39	5.62e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7267979	0.789	rs2260197	chr20:25284343	T/C	cg21995068	chr20:25989032	LOC100134868	-0.43	-5.19	-0.42	8.41e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3540	0.960	rs4031435	chr15:91015566	G/C	cg22089800	chr15:90895588	ZNF774	0.74	6.9	0.53	2.33e-10	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.52	-4.98	-0.41	2.04e-6	Longevity;Endometriosis;
TGCT	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.94	7.92	0.58	1.17e-12	Platelet count;
TGCT	cis	rs916888	0.647	rs199524	chr17:44848438	G/T	cg17911788	chr17:44343683	NA	0.51	5.9	0.47	3.3e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs35160687	0.901	rs13020869	chr2:86523360	C/T	cg03171300	chr2:86307199	POLR1A	0.32	5.56	0.45	1.61e-7	Night sleep phenotypes;
TGCT	cis	rs7772486	0.754	rs702306	chr6:145991029	T/C	cg23711669	chr6:146136114	FBXO30	-0.93	-10.61	-0.69	4.16e-19	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs8062405	0.573	rs7140	chr16:28995757	C/A	cg01117621	chr16:28073818	GSG1L	-0.37	-4.73	-0.39	6.13e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs208520	0.690	rs1233103	chr6:66855943	T/G	cg07460842	chr6:66804631	NA	-0.92	-9.58	-0.65	1.29e-16	Exhaled nitric oxide output;
TGCT	cis	rs6460942	1.000	rs17191008	chr7:12417690	T/G	cg06484146	chr7:12443880	VWDE	-0.59	-5.6	-0.45	1.28e-7	Coronary artery disease;
TGCT	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg17328964	chr8:145687451	CYHR1	-0.53	-8.54	-0.61	4.17e-14	Age at first birth;
TGCT	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg05215272	chr17:6899095	ALOX12	-0.54	-6.45	-0.5	2.29e-9	Tonsillectomy;
TGCT	cis	rs6671200	1.000	rs35143903	chr1:95622527	C/T	cg20701556	chr1:95698924	RWDD3	0.63	5.22	0.42	7.28e-7	Stearic acid (18:0) levels;
TGCT	cis	rs57994353	0.568	rs10870171	chr9:139318530	C/T	cg13741927	chr9:139327495	INPP5E	-0.24	-5.36	-0.43	3.96e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs7539409	0.651	rs970457	chr1:84296540	C/T	cg10977910	chr1:84465055	TTLL7	0.9	5.47	0.44	2.39e-7	Alzheimer's disease;
TGCT	cis	rs6061231	0.518	rs639836	chr20:60926223	G/A	cg06026331	chr20:60912101	LAMA5	-0.26	-4.69	-0.39	7.23e-6	Colorectal cancer;
TGCT	cis	rs4253772	0.637	rs8135997	chr22:46651366	G/A	cg09491104	chr22:46646882	C22orf40	-0.62	-6.49	-0.5	1.87e-9	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg22718636	chr4:961658	DGKQ	0.45	4.45	0.37	1.86e-5	Sjögren's syndrome;
TGCT	cis	rs9926296	0.744	rs164748	chr16:89708292	C/G	cg27121462	chr16:89883253	FANCA	-0.49	-4.58	-0.38	1.11e-5	Vitiligo;
TGCT	cis	rs12681287	0.547	rs9297922	chr8:87542317	A/G	cg27223183	chr8:87520930	FAM82B	0.94	6.91	0.53	2.24e-10	Caudate activity during reward;
TGCT	cis	rs7213347	0.707	rs216182	chr17:2173063	A/G	cg13315690	chr17:1944831	OVCA2;DPH1	0.35	4.44	0.37	1.99e-5	Total body bone mineral density;
TGCT	cis	rs35160687	0.901	rs11127026	chr2:86531748	C/T	cg03171300	chr2:86307199	POLR1A	0.32	5.57	0.45	1.48e-7	Night sleep phenotypes;
TGCT	cis	rs7255374	0.566	rs11666982	chr19:41531368	T/G	cg27089200	chr19:41531976	NA	0.5	6.92	0.53	2.19e-10	DDT metabolite (p,p'-DDE levels);
TGCT	trans	rs1974653	0.711	rs9605066	chr22:20099654	C/T	cg08822737	chr17:71088851	SLC39A11	-0.93	-7.65	-0.57	4.76e-12	Schizophrenia;
TGCT	cis	rs2404602	0.618	rs12442266	chr15:76567142	T/C	cg22467129	chr15:76604101	ETFA	-0.62	-8.01	-0.58	7.08e-13	Blood metabolite levels;
TGCT	cis	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg19635926	chr16:89946313	TCF25	0.28	4.82	0.4	4.06e-6	Skin colour saturation;
TGCT	cis	rs797680	0.897	rs12752223	chr1:93837133	T/C	cg17826107	chr1:92977322	EVI5	-0.24	-5.72	-0.46	7.46e-8	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.51	4.48	0.37	1.68e-5	Prudent dietary pattern;
TGCT	cis	rs651907	0.557	rs3094295	chr3:101401995	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.03	0.41	1.65e-6	Colorectal cancer;
TGCT	cis	rs60871478	1.000	rs4374882	chr7:821798	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.47	4.71	0.39	6.58e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs9811920	0.638	rs793461	chr3:99615758	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.6	-6.82	-0.52	3.63e-10	Axial length;
TGCT	cis	rs35934224	0.740	rs35142928	chr22:19847751	T/C	cg11182965	chr22:19864308	TXNRD2	-0.36	-4.95	-0.41	2.33e-6	Glaucoma (primary open-angle);
TGCT	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.5	6.94	0.53	1.89e-10	Alzheimer's disease;
TGCT	cis	rs9814567	1.000	rs6804770	chr3:134230234	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.95	-9.62	-0.65	1.04e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs4972806	0.849	rs2071581	chr2:177026148	G/T	cg14324370	chr2:177042789	NA	0.73	6.61	0.51	1.04e-9	IgG glycosylation;
TGCT	cis	rs9303401	0.614	rs7215900	chr17:56654850	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.69	6.1	0.48	1.23e-8	Cognitive test performance;
TGCT	cis	rs131777	0.508	rs140518	chr22:50999182	C/T	cg25309564	chr22:51001381	C22orf41	0.77	6.97	0.53	1.68e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs7666738	0.830	rs4699574	chr4:98725544	C/T	cg18180107	chr4:99064573	C4orf37	0.53	5.07	0.41	1.38e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs185694	1.000	rs613291	chr13:30894404	T/C	cg07600127	chr13:30881527	KATNAL1	-0.82	-6.64	-0.51	8.92e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
TGCT	cis	rs9929218	1.000	rs12446575	chr16:68791644	C/G	cg01251360	chr16:68772225	CDH1	0.29	4.89	0.4	3.01e-6	Colorectal cancer;
TGCT	cis	rs2692947	0.770	rs12471925	chr2:96555522	C/A	cg13655245	chr2:97463316	CNNM4	0.15	4.46	0.37	1.84e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs80033912	0.640	rs6785832	chr3:49224316	C/T	cg02487422	chr3:49467188	NICN1	0.48	4.84	0.4	3.86e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs853679	0.567	rs13209596	chr6:28396190	C/A	cg18815343	chr6:28367644	ZSCAN12	-0.5	-4.61	-0.38	9.72e-6	Depression;
TGCT	cis	rs57590327	0.679	rs35395999	chr3:81613013	T/C	cg07356753	chr3:81810745	GBE1	-0.57	-4.72	-0.39	6.37e-6	Extraversion;
TGCT	cis	rs739496	0.501	rs441	chr12:112228849	T/C	cg10833066	chr12:111807467	FAM109A	0.37	4.72	0.39	6.22e-6	Platelet count;
TGCT	cis	rs67311347	1.000	rs7631893	chr3:40440869	C/T	cg13683864	chr3:40499215	RPL14	-1.03	-10.36	-0.68	1.68e-18	Renal cell carcinoma;
TGCT	cis	rs11621121	0.637	rs4902389	chr14:65793224	A/G	cg04536575	chr14:65016802	C14orf50	-0.64	-4.53	-0.38	1.36e-5	N-glycan levels;
TGCT	cis	rs4372836	0.964	rs11683296	chr2:28925404	A/G	cg09522027	chr2:28974177	PPP1CB	0.58	4.83	0.4	3.88e-6	Body mass index;
TGCT	cis	rs853679	0.567	rs7740429	chr6:28399246	G/A	cg18815343	chr6:28367644	ZSCAN12	-0.5	-4.56	-0.38	1.19e-5	Depression;
TGCT	trans	rs1814175	0.791	rs10769625	chr11:49869887	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.35	-0.55	2.38e-11	Height;
TGCT	cis	rs17490626	0.533	rs12771890	chr10:71189483	T/A	cg12610070	chr10:71211762	TSPAN15	-0.59	-6.86	-0.52	2.87e-10	Thrombosis;
TGCT	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs3845702	0.736	rs115569960	chr2:180848214	C/T	cg01881094	chr2:180872142	CWC22	1.04	6.62	0.51	9.91e-10	Schizophrenia;
TGCT	cis	rs8179	0.593	rs17164683	chr7:92286980	C/T	cg15732164	chr7:92237376	CDK6	-0.29	-4.98	-0.41	2.05e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
TGCT	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg03351412	chr1:154909251	PMVK	0.53	4.93	0.4	2.6e-6	Prostate cancer;
TGCT	cis	rs7267979	0.833	rs4619688	chr20:25244101	C/G	cg16686733	chr20:25566563	NINL	0.59	6.06	0.48	1.53e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9611565	0.649	rs139540	chr22:42178040	C/T	cg17554472	chr22:41940697	POLR3H	-0.44	-4.58	-0.38	1.13e-5	Vitiligo;
TGCT	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg05368731	chr17:41323189	NBR1	-1.06	-12.0	-0.73	1.76e-22	Menopause (age at onset);
TGCT	cis	rs17767294	0.541	rs72845044	chr6:27572479	G/A	cg08851530	chr6:28072375	NA	1.34	6.29	0.49	5.02e-9	Parkinson's disease;
TGCT	cis	rs559928	0.576	rs750832	chr11:64163302	C/T	cg12453748	chr11:64085041	PRDX5;TRMT112	-0.56	-4.82	-0.4	4.17e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
TGCT	cis	rs2730245	0.636	rs710421	chr7:158668575	T/C	cg24397884	chr7:158709396	WDR60	0.35	4.45	0.37	1.87e-5	Height;
TGCT	cis	rs1348850	0.567	rs7605609	chr2:178534942	C/G	cg22681709	chr2:178499509	PDE11A	-0.46	-5.95	-0.47	2.58e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs26868	0.816	rs26873	chr16:2247362	C/T	cg26873644	chr16:2260806	C16orf79	-0.24	-4.67	-0.39	7.57e-6	Height;
TGCT	cis	rs73198271	0.710	rs3827808	chr8:8679357	A/T	cg06671706	chr8:8559999	CLDN23	-0.36	-4.52	-0.38	1.45e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg08280861	chr8:58055591	NA	0.38	4.81	0.4	4.36e-6	Developmental language disorder (linguistic errors);
TGCT	trans	rs208520	0.955	rs28684412	chr6:66979430	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.83	7.46	0.56	1.31e-11	Exhaled nitric oxide output;
TGCT	cis	rs1801251	1.000	rs12478564	chr2:233598340	C/T	cg25237894	chr2:233734115	C2orf82	0.33	6.02	0.48	1.82e-8	Coronary artery disease;
TGCT	cis	rs3733585	0.699	rs6449178	chr4:9968684	A/G	cg00071950	chr4:10020882	SLC2A9	0.55	6.5	0.5	1.79e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7267979	0.509	rs6115218	chr20:25566485	A/G	cg16686733	chr20:25566563	NINL	0.84	8.95	0.63	4.19e-15	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg07507251	chr3:52567010	NT5DC2	0.47	6.7	0.52	6.47e-10	Bipolar disorder;
TGCT	cis	rs11096990	0.656	rs9993224	chr4:39300198	C/T	cg20847110	chr4:39482781	LOC401127	-0.16	-4.47	-0.37	1.75e-5	Cognitive function;
TGCT	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg04154034	chr17:28927549	LRRC37B2	0.82	5.01	0.41	1.85e-6	Body mass index;
TGCT	cis	rs838147	0.507	rs692854	chr19:49209464	C/A	cg13540341	chr19:49222985	MAMSTR	-0.37	-4.92	-0.4	2.69e-6	Dietary macronutrient intake;
TGCT	cis	rs1215050	0.765	rs471500	chr4:98714820	T/C	cg05340658	chr4:99064831	C4orf37	0.44	5.52	0.44	1.85e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1552244	0.832	rs17050674	chr3:10027258	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.44	-6.38	-0.5	3.16e-9	Alzheimer's disease;
TGCT	cis	rs4285028	0.948	rs12637351	chr3:121694412	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.77	6.5	0.5	1.78e-9	Multiple sclerosis;
TGCT	cis	rs910316	0.789	rs175457	chr14:75584507	C/T	cg08847533	chr14:75593920	NEK9	-0.85	-8.54	-0.61	4.13e-14	Height;
TGCT	cis	rs12477438	0.798	rs9679602	chr2:99577827	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.86	8.65	0.61	2.22e-14	Chronic sinus infection;
TGCT	cis	rs586688	0.582	rs662852	chr1:201672614	T/G	cg07139329	chr1:201708558	NAV1	-0.5	-5.19	-0.42	8.37e-7	Obesity-related traits;
TGCT	cis	rs79349575	0.749	rs46521	chr17:46988529	A/G	cg07967210	chr17:47022446	SNF8	0.43	6.06	0.48	1.54e-8	Type 2 diabetes;
TGCT	cis	rs2229238	0.826	rs111742980	chr1:154508764	T/A	cg13067139	chr1:155221277	FAM189B	0.2	4.51	0.38	1.47e-5	Coronary heart disease;
TGCT	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg13699009	chr12:122356056	WDR66	0.27	5.2	0.42	7.87e-7	Mean corpuscular volume;
TGCT	trans	rs66573146	1.000	rs7686168	chr4:6986057	C/A	cg07817883	chr1:32538562	TMEM39B	1.66	8.29	0.6	1.56e-13	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs7666738	0.830	rs10050008	chr4:99025313	T/G	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg06112835	chr11:68658793	MRPL21	0.43	7.25	0.55	3.9e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9659323	1.000	rs12073056	chr1:119508400	C/T	cg07961512	chr1:119535619	NA	0.44	5.07	0.41	1.41e-6	Body mass index;
TGCT	cis	rs6815814	0.948	rs73236649	chr4:38873332	C/T	cg02016764	chr4:38805732	TLR1	-0.39	-5.6	-0.45	1.3e-7	Breast cancer;
TGCT	cis	rs4969178	0.600	rs4969183	chr17:76393372	A/G	cg05887092	chr17:76393375	PGS1	0.22	4.66	0.39	8.19e-6	HDL cholesterol levels;
TGCT	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg04267008	chr7:1944627	MAD1L1	-0.38	-4.93	-0.4	2.55e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs1451375	0.959	rs1451373	chr7:50622606	A/G	cg18232548	chr7:50535776	DDC	0.43	6.8	0.52	3.98e-10	Malaria;
TGCT	cis	rs854765	0.647	rs712268	chr17:18025744	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	7.57	0.56	7.33e-12	Total body bone mineral density;
TGCT	cis	rs651907	0.557	rs34624546	chr3:101374226	T/G	cg12386194	chr3:101231763	SENP7	0.53	5.13	0.42	1.08e-6	Colorectal cancer;
TGCT	cis	rs7772486	0.727	rs10447449	chr6:146138707	A/G	cg05347473	chr6:146136440	FBXO30	0.52	4.88	0.4	3.23e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs16867321	0.950	rs1919155	chr2:181457053	T/C	cg23363182	chr2:181467187	NA	-0.39	-5.47	-0.44	2.38e-7	Obesity;
TGCT	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg07747251	chr5:1868357	NA	0.38	5.28	0.43	5.55e-7	Cardiovascular disease risk factors;
TGCT	cis	rs7937682	0.883	rs490492	chr11:111465150	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.99	-10.02	-0.67	1.16e-17	Primary sclerosing cholangitis;
TGCT	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg24250549	chr1:154909240	PMVK	-0.53	-4.92	-0.4	2.64e-6	Prostate cancer;
TGCT	cis	rs6121246	0.738	rs6121242	chr20:30410877	T/C	cg13852791	chr20:30311386	BCL2L1	0.8	6.12	0.48	1.15e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs2230307	0.536	rs490669	chr1:100484430	C/T	cg24955406	chr1:100503596	HIAT1	0.74	4.83	0.4	4e-6	Carotid intima media thickness;
TGCT	cis	rs10789491	1.000	rs2218191	chr1:47130628	C/T	cg15501359	chr1:47185051	KIAA0494	0.78	7.94	0.58	1.05e-12	Response to hepatitis C treatment;
TGCT	cis	rs12497850	0.627	rs4974078	chr3:49009386	C/T	cg07636037	chr3:49044803	WDR6	0.7	7.73	0.57	3.24e-12	Parkinson's disease;
TGCT	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg24675658	chr1:53192096	ZYG11B	-0.75	-9.11	-0.63	1.78e-15	Monocyte count;
TGCT	cis	rs25422	0.878	rs55894300	chr6:118982076	T/A	cg21191810	chr6:118973309	C6orf204	-0.37	-4.71	-0.39	6.4e-6	Renal cell carcinoma;
TGCT	cis	rs3733585	0.683	rs6449140	chr4:9936437	G/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.56	-0.56	7.61e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7226408	0.779	rs72896202	chr18:34766272	C/T	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs12477438	0.520	rs34252185	chr2:99737646	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.15	18.22	0.85	7.28e-37	Chronic sinus infection;
TGCT	cis	rs9814567	0.762	rs13075332	chr3:134329836	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	6.65	0.51	8.45e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs7524258	0.868	rs11120885	chr1:7306755	C/G	cg04342483	chr1:7259290	CAMTA1	-0.31	-4.52	-0.38	1.43e-5	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg25427524	chr10:38739819	LOC399744	-0.39	-8.05	-0.59	5.9e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2153535	0.580	rs1120392	chr6:8487053	C/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs3806843	0.576	rs246072	chr5:140320426	C/T	cg07102913	chr5:140593443	PCDHB13	-0.46	-4.65	-0.39	8.2e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg13531842	chr10:38383804	ZNF37A	-0.39	-4.64	-0.38	8.78e-6	Extrinsic epigenetic age acceleration;
TGCT	cis	rs12142240	0.698	rs66972124	chr1:46807445	A/G	cg14993813	chr1:46806288	NSUN4	-0.58	-4.81	-0.4	4.34e-6	Menopause (age at onset);
TGCT	cis	rs559406	0.501	rs2542160	chr18:12789246	C/G	cg23598886	chr18:12777645	NA	0.36	4.52	0.38	1.45e-5	Psoriasis;
TGCT	cis	rs634534	0.622	rs1308733	chr11:65720841	T/C	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.54	-5.2	-0.42	8.02e-7	Sum eosinophil basophil counts;Eosinophil counts;
TGCT	cis	rs7727544	0.904	rs7736102	chr5:131604257	G/A	cg24060327	chr5:131705240	SLC22A5	-0.6	-6.4	-0.5	2.87e-9	Blood metabolite levels;
TGCT	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg06896619	chr17:61851486	DDX42;CCDC47	0.49	4.47	0.37	1.71e-5	Prudent dietary pattern;
TGCT	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	5.71	0.46	8.05e-8	Alzheimer's disease;
TGCT	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg26818010	chr10:134567672	INPP5A	-0.38	-5.19	-0.42	8.5e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg18305652	chr10:134549665	INPP5A	0.34	5.75	0.46	6.52e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs6570726	0.967	rs9497316	chr6:145792387	G/T	cg23711669	chr6:146136114	FBXO30	-0.69	-6.34	-0.49	3.95e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7523273	0.568	rs1318653	chr1:208014922	C/T	cg22525895	chr1:207977042	MIR29B2	0.39	5.63	0.45	1.16e-7	Schizophrenia;
TGCT	cis	rs9341808	0.718	rs11962614	chr6:80823306	A/T	cg08355045	chr6:80787529	NA	0.32	5.83	0.46	4.48e-8	Sitting height ratio;
TGCT	cis	rs6835098	0.828	rs28612521	chr4:174085294	G/A	cg08422745	chr4:174089978	GALNT7	-0.94	-11.2	-0.71	1.48e-20	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	trans	rs1814175	0.645	rs28441045	chr11:50048971	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.84	-0.7	1.13e-19	Height;
TGCT	cis	rs3743266	0.507	rs9630426	chr15:60739053	C/T	cg18480781	chr15:60294291	NA	0.63	5.01	0.41	1.81e-6	Menarche (age at onset);
TGCT	cis	rs12360000	0.577	rs10430757	chr10:1906265	C/T	cg26364871	chr10:1889757	NA	0.38	4.54	0.38	1.3e-5	Metabolite levels (Dihydroxy docosatrienoic acid);
TGCT	cis	rs9457247	1.000	rs398278	chr6:167388169	A/G	cg23791538	chr6:167370224	RNASET2	-0.53	-5.18	-0.42	8.67e-7	Crohn's disease;
TGCT	cis	rs67072384	0.818	rs6592483	chr11:72463974	A/G	cg03713592	chr11:72463424	ARAP1	-0.9	-4.87	-0.4	3.33e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg08280861	chr8:58055591	NA	0.34	4.62	0.38	9.41e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs3771570	1.000	rs73004354	chr2:242356239	G/T	cg21155796	chr2:242212141	HDLBP	0.94	6.69	0.51	6.97e-10	Prostate cancer;
TGCT	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg20203395	chr5:56204925	C5orf35	-0.62	-4.92	-0.4	2.68e-6	Initial pursuit acceleration;
TGCT	cis	rs2013441	1.000	rs8074047	chr17:20176703	G/A	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.5	-0.37	1.55e-5	Obesity-related traits;
TGCT	trans	rs1496653	0.602	rs34916096	chr3:23443636	C/T	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg10047753	chr17:41438598	NA	0.95	9.61	0.65	1.12e-16	Menopause (age at onset);
TGCT	cis	rs17125944	0.505	rs17125746	chr14:53236079	C/T	cg00686598	chr14:53173677	PSMC6	1.08	6.32	0.49	4.37e-9	Alzheimer's disease (late onset);
TGCT	cis	rs12477438	0.520	rs2632276	chr2:99779655	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.06	12.88	0.76	1.27e-24	Chronic sinus infection;
TGCT	cis	rs9611565	0.512	rs139572	chr22:42214532	C/T	cg06634786	chr22:41940651	POLR3H	-0.86	-8.01	-0.58	7.16e-13	Vitiligo;
TGCT	cis	rs727505	1.000	rs988699	chr7:124409814	C/T	cg23710748	chr7:124431027	NA	-0.27	-4.71	-0.39	6.45e-6	Lewy body disease;
TGCT	cis	rs2663905	0.611	rs1509558	chr15:81391244	C/T	cg09888468	chr15:81410853	NA	-0.6	-4.9	-0.4	2.97e-6	QT interval (drug interaction);
TGCT	cis	rs7447593	0.518	rs4074995	chr5:176797343	C/T	cg06060754	chr5:176797920	RGS14	0.62	11.28	0.71	9.83e-21	Urinary electrolytes (magnesium/calcium ratio);
TGCT	cis	rs34526934	0.608	rs7606110	chr2:177028551	T/C	cg00278547	chr2:177037212	HOXD3	-0.4	-4.98	-0.41	2.09e-6	Obstructive sleep apnea trait (apnea hypopnea index);
TGCT	cis	rs9868809	0.505	rs28657585	chr3:48736216	A/T	cg00383909	chr3:49044727	WDR6	1.05	6.17	0.48	8.74e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs11785400	1.000	rs13265663	chr8:143732255	A/C	cg24634471	chr8:143751801	JRK	0.54	5.85	0.46	4.19e-8	Schizophrenia;
TGCT	cis	rs72945132	0.598	rs61887432	chr11:70239065	A/C	cg00319359	chr11:70116639	PPFIA1	1.0	7.12	0.54	7.76e-11	Coronary artery disease;
TGCT	cis	rs66573146	1.000	rs66712119	chr4:6965428	A/T	cg00086871	chr4:6988644	TBC1D14	0.98	4.57	0.38	1.16e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs11690935	0.632	rs62184165	chr2:172558328	A/G	cg13550731	chr2:172543902	DYNC1I2	0.69	6.09	0.48	1.33e-8	Schizophrenia;
TGCT	cis	rs12971120	0.947	rs8084109	chr18:72168312	T/A	cg26446133	chr18:72167187	CNDP2	-0.4	-7.7	-0.57	3.64e-12	Refractive error;
TGCT	cis	rs1205863	0.831	rs1205854	chr6:11942638	A/G	cg07106625	chr6:11870215	NA	0.51	5.05	0.41	1.51e-6	Disc degeneration (lumbar);
TGCT	cis	rs7666738	0.830	rs11097582	chr4:98772201	G/A	cg18180107	chr4:99064573	C4orf37	0.53	5.05	0.41	1.51e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1153858	1.000	rs7179743	chr15:45638331	G/C	cg14582100	chr15:45693742	SPATA5L1	0.48	5.7	0.46	8.17e-8	Homoarginine levels;
TGCT	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg10047753	chr17:41438598	NA	0.94	9.23	0.64	9.06e-16	Menopause (age at onset);
TGCT	cis	rs6121246	0.567	rs6087701	chr20:30217708	A/C	cg13852791	chr20:30311386	BCL2L1	0.7	4.58	0.38	1.1e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs7513165	0.542	rs4951317	chr1:204161507	C/T	cg04791601	chr1:204159016	NA	0.27	5.78	0.46	5.74e-8	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
TGCT	cis	rs4409675	0.576	rs3766396	chr1:28221554	C/T	cg23691781	chr1:28212827	C1orf38	-0.26	-5.32	-0.43	4.68e-7	Corneal astigmatism;
TGCT	cis	rs11190604	1.000	rs12355721	chr10:102244911	C/T	cg23241863	chr10:102295624	HIF1AN	0.63	4.95	0.41	2.41e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2708977	0.966	rs749027	chr2:97203137	A/C	cg01950434	chr2:97203154	ARID5A	-0.69	-6.36	-0.5	3.5e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs939658	0.776	rs35904425	chr15:79444567	G/A	cg17916960	chr15:79447300	NA	-0.49	-7.59	-0.56	6.76e-12	Refractive error;
TGCT	cis	rs4455778	0.580	rs10257863	chr7:49092400	C/A	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.05	8.52	0.61	4.51e-14	Platelet count;
TGCT	cis	rs7666738	0.830	rs1593569	chr4:99017485	C/G	cg17366294	chr4:99064904	C4orf37	0.7	7.34	0.55	2.41e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7833790	0.724	rs1054078	chr8:82712153	A/G	cg27398817	chr8:82754497	SNX16	-0.67	-5.34	-0.43	4.27e-7	Diastolic blood pressure;
TGCT	cis	rs6714710	0.603	rs7421146	chr2:98552271	G/C	cg26665480	chr2:98280029	ACTR1B	0.66	6.26	0.49	5.84e-9	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs78487399	0.808	rs6544668	chr2:43732488	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-4.84	-0.4	3.79e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs2243480	1.000	rs313824	chr7:65581207	C/T	cg20637647	chr7:64974828	NA	0.84	4.85	0.4	3.63e-6	Diabetic kidney disease;
TGCT	trans	rs10506458	1.000	rs12580997	chr12:63433420	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.47	-7.62	-0.56	5.8e-12	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs59107033	0.607	rs7635110	chr3:123124137	T/C	cg04890266	chr3:123102914	ADCY5	-0.38	-5.29	-0.43	5.31e-7	Lymphocyte counts;
TGCT	cis	rs7267979	0.868	rs6138546	chr20:25216534	G/A	cg14121845	chr20:25566513	NINL	0.5	5.51	0.44	1.98e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3772130	0.962	rs1318472	chr3:121556899	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.72	0.39	6.25e-6	Cognitive performance;
TGCT	cis	rs1801251	0.835	rs1446310	chr2:233683245	G/C	cg08000102	chr2:233561755	GIGYF2	-0.57	-5.89	-0.47	3.38e-8	Coronary artery disease;
TGCT	cis	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg08975724	chr8:8085496	FLJ10661	0.55	5.2	0.42	7.94e-7	Mood instability;
TGCT	cis	rs1865760	1.000	rs2071301	chr6:25914263	G/T	cg16482183	chr6:26056742	HIST1H1C	0.54	4.95	0.41	2.39e-6	Height;
TGCT	trans	rs3780486	0.846	rs913214	chr9:33135085	G/A	cg20290983	chr6:43655470	MRPS18A	1.2	14.83	0.8	3.07e-29	IgG glycosylation;
TGCT	cis	rs524281	0.861	rs485857	chr11:65959519	A/G	cg00563793	chr11:65837595	PACS1	0.52	4.57	0.38	1.18e-5	Electroencephalogram traits;
TGCT	cis	rs904251	0.772	rs2776906	chr6:37431757	A/G	cg08126542	chr6:37504118	NA	-0.4	-4.66	-0.39	7.87e-6	Cognitive performance;
TGCT	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	6.75	0.52	5.02e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9604529	0.557	rs61967979	chr13:114743190	C/T	cg13259177	chr13:114761607	RASA3	-0.28	-4.79	-0.4	4.66e-6	Response to tocilizumab in rheumatoid arthritis;
TGCT	cis	rs9858542	0.953	rs7622302	chr3:49547561	T/C	cg03060546	chr3:49711283	APEH	-0.61	-5.37	-0.43	3.78e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs67072384	0.892	rs11235578	chr11:72452970	G/T	cg03713592	chr11:72463424	ARAP1	-0.93	-4.66	-0.39	7.89e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs752010	0.668	rs10890147	chr1:42089725	A/T	cg06885757	chr1:42089581	HIVEP3	0.31	5.84	0.46	4.24e-8	Lupus nephritis in systemic lupus erythematosus;
TGCT	cis	rs36051895	0.626	rs10815149	chr9:5063701	T/C	cg02405213	chr9:5042618	JAK2	-0.8	-11.53	-0.72	2.44e-21	Pediatric autoimmune diseases;
TGCT	cis	rs13082711	0.516	rs1388785	chr3:27371843	T/C	cg02860705	chr3:27208620	NA	-0.31	-4.61	-0.38	9.69e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2153535	0.580	rs4451187	chr6:8473910	C/T	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.3e-6	Motion sickness;
TGCT	cis	rs734999	0.545	rs6666430	chr1:2698950	G/A	cg18854424	chr1:2615690	NA	0.45	5.01	0.41	1.82e-6	Ulcerative colitis;
TGCT	cis	rs7523273	0.606	rs1474742	chr1:207976666	A/C	cg22525895	chr1:207977042	MIR29B2	0.5	8.58	0.61	3.27e-14	Schizophrenia;
TGCT	cis	rs11690935	0.959	rs10497374	chr2:172640623	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.18	-12.58	-0.75	6.59e-24	Schizophrenia;
TGCT	cis	rs4808199	0.948	rs968525	chr19:19459215	C/T	cg03709012	chr19:19516395	GATAD2A	0.82	6.56	0.51	1.3e-9	Nonalcoholic fatty liver disease;
TGCT	cis	rs896854	0.654	rs896846	chr8:95972453	G/A	cg23172400	chr8:95962367	TP53INP1	-0.39	-6.52	-0.51	1.57e-9	Type 2 diabetes;
TGCT	trans	rs7819412	0.511	rs10108511	chr8:11435516	T/C	cg06636001	chr8:8085503	FLJ10661	-0.76	-6.97	-0.53	1.68e-10	Triglycerides;
TGCT	cis	rs1215050	0.791	rs7434393	chr4:98768576	T/C	cg05340658	chr4:99064831	C4orf37	0.44	5.51	0.44	2.01e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9916302	0.861	rs644173	chr17:37430519	T/C	cg15445000	chr17:37608096	MED1	0.31	4.48	0.37	1.66e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs919433	0.680	rs1961558	chr2:198487278	C/T	cg00792783	chr2:198669748	PLCL1	0.5	4.67	0.39	7.56e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs778371	0.834	rs778363	chr2:233778896	A/G	cg08000102	chr2:233561755	GIGYF2	-0.49	-4.58	-0.38	1.1e-5	Schizophrenia;
TGCT	cis	rs6964587	1.000	rs1859113	chr7:91679887	T/C	cg17063962	chr7:91808500	NA	0.88	9.65	0.66	8.73e-17	Breast cancer;
TGCT	trans	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg13615516	chr5:77269221	NA	0.68	8.54	0.61	3.97e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7666738	0.800	rs13106995	chr4:99028790	A/T	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12579753	0.879	rs35087297	chr12:82133398	C/T	cg21231944	chr12:82153410	PPFIA2	-0.36	-4.7	-0.39	6.72e-6	Resting heart rate;
TGCT	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg03303774	chr4:1407052	NA	0.3	4.74	0.39	5.79e-6	Obesity-related traits;
TGCT	cis	rs9443645	0.901	rs9448588	chr6:79590061	T/G	cg09184832	chr6:79620586	NA	-0.48	-5.17	-0.42	9.23e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs873917	0.577	rs784612	chr1:40122939	T/C	cg18438793	chr1:40149837	HPCAL4	0.53	4.72	0.39	6.17e-6	Amyotrophic lateral sclerosis;
TGCT	cis	rs7666738	0.819	rs13120307	chr4:99036100	A/C	cg17366294	chr4:99064904	C4orf37	0.74	7.59	0.56	6.7e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7178572	0.568	rs3743478	chr15:77400388	T/C	cg22256960	chr15:77711686	NA	-0.85	-8.66	-0.61	2.08e-14	Type 2 diabetes;
TGCT	cis	rs35306767	0.807	rs72778228	chr10:938435	A/G	cg20503657	chr10:835505	NA	0.8	11.88	0.73	3.41e-22	Eosinophil percentage of granulocytes;
TGCT	cis	rs1008375	0.966	rs28750296	chr4:17685826	A/T	cg18681998	chr4:17616180	MED28	0.92	10.51	0.69	7.15e-19	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs585510	1	rs585510	chr12:121000133	A/G	cg27279351	chr12:120934652	DYNLL1	0.74	6.46	0.5	2.19e-9	Reticulocyte fraction of red cells;
TGCT	cis	rs10057188	0.903	rs1441711	chr5:77910931	T/C	cg07379703	chr5:78279424	ARSB	-0.21	-4.79	-0.4	4.64e-6	Pulse pressure;
TGCT	cis	rs7772486	0.790	rs9403750	chr6:146167762	G/A	cg05347473	chr6:146136440	FBXO30	0.51	4.77	0.39	5.02e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.82	7.26	0.55	3.65e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs12220898	0.679	rs4838483	chr10:50481870	G/A	cg09603381	chr10:49954066	WDFY4	0.39	4.48	0.37	1.68e-5	Inflammatory biomarkers;
TGCT	cis	rs554111	0.656	rs10916930	chr1:21395357	C/T	cg01072550	chr1:21505969	NA	-0.37	-5.64	-0.45	1.1e-7	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs6912958	0.525	rs242262	chr6:88018057	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.69	7.11	0.54	7.98e-11	Monocyte percentage of white cells;
TGCT	cis	rs7267979	0.565	rs4815437	chr20:25584788	C/G	cg03522245	chr20:25566470	NINL	-0.44	-4.57	-0.38	1.18e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1903068	1.000	rs1903068	chr4:56008477	A/G	cg16572876	chr4:56024045	NA	0.44	5.1	0.42	1.23e-6	Endometriosis;
TGCT	cis	rs1153858	0.945	rs2467854	chr15:45701597	A/G	cg14582100	chr15:45693742	SPATA5L1	0.47	5.62	0.45	1.22e-7	Homoarginine levels;
TGCT	cis	rs2439831	0.867	rs12323999	chr15:43683115	T/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	6.11	0.48	1.19e-8	Lung cancer in ever smokers;
TGCT	cis	rs8141529	0.748	rs6005936	chr22:29289250	T/C	cg02153584	chr22:29168773	CCDC117	0.66	5.19	0.42	8.5e-7	Lymphocyte counts;
TGCT	cis	rs9291683	0.588	rs13113730	chr4:10017628	C/T	cg11266682	chr4:10021025	SLC2A9	0.73	10.98	0.7	5.33e-20	Bone mineral density;
TGCT	cis	rs3820068	0.581	rs16851855	chr1:15930869	G/A	cg05660106	chr1:15850417	CASP9	0.82	8.02	0.58	6.63e-13	Systolic blood pressure;
TGCT	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg22105103	chr4:187893119	NA	0.31	4.44	0.37	1.98e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg04944784	chr2:26401820	FAM59B	-0.73	-5.95	-0.47	2.61e-8	Gut microbiome composition (summer);
TGCT	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	5.98	0.47	2.23e-8	Alzheimer's disease;
TGCT	cis	rs12497850	0.931	rs7430198	chr3:48988760	T/C	cg18654377	chr3:49208889	KLHDC8B	-0.42	-5.42	-0.44	2.97e-7	Parkinson's disease;
TGCT	cis	rs12142240	0.698	rs17357759	chr1:46832534	A/G	cg00530320	chr1:46809349	NSUN4	0.33	7.21	0.54	4.73e-11	Menopause (age at onset);
TGCT	cis	rs7826238	0.502	rs10503377	chr8:8378422	C/T	cg15556689	chr8:8085844	FLJ10661	0.71	6.11	0.48	1.21e-8	Systolic blood pressure;
TGCT	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg07343612	chr16:622815	PIGQ	-0.42	-8.42	-0.6	7.67e-14	Height;
TGCT	cis	rs2075371	1.000	rs2505	chr7:133979552	C/T	cg11752832	chr7:134001865	SLC35B4	0.69	6.32	0.49	4.19e-9	Mean platelet volume;
TGCT	cis	rs651907	0.557	rs7651406	chr3:101393296	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.34	-7.08	-0.54	9.37e-11	Colorectal cancer;
TGCT	cis	rs6964587	1.000	rs10228800	chr7:91610111	T/G	cg17063962	chr7:91808500	NA	0.91	9.99	0.67	1.32e-17	Breast cancer;
TGCT	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg06238570	chr21:40685208	BRWD1	-0.82	-9.01	-0.63	3.07e-15	Cognitive function;
TGCT	cis	rs4851266	0.966	rs1160545	chr2:100832269	C/T	cg07810366	chr2:100720526	AFF3	-0.38	-5.44	-0.44	2.7e-7	Educational attainment;
TGCT	cis	rs12762955	0.561	rs7076107	chr10:1043647	T/C	cg26597838	chr10:835615	NA	-0.47	-6.22	-0.49	7.03e-9	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg05872129	chr22:39784769	NA	-1.02	-11.22	-0.71	1.32e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs1056107	0.898	rs10733586	chr9:114992183	A/G	cg02332936	chr9:115140584	NA	-0.25	-4.46	-0.37	1.79e-5	Colorectal cancer;
TGCT	cis	rs6665290	0.904	rs1045287	chr1:227178962	C/T	cg10327440	chr1:227177885	CDC42BPA	1.0	20.45	0.88	1.56e-41	Myeloid white cell count;
TGCT	cis	rs9611565	0.694	rs5758324	chr22:41787950	G/T	cg13695892	chr22:41940480	POLR3H	-0.85	-8.37	-0.6	1.01e-13	Vitiligo;
TGCT	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.67	0.39	7.57e-6	Prudent dietary pattern;
TGCT	cis	rs7647973	0.731	rs13084037	chr3:49214066	G/A	cg06212747	chr3:49208901	KLHDC8B	0.62	4.75	0.39	5.59e-6	Menarche (age at onset);
TGCT	cis	rs10191773	0.535	rs56048537	chr2:113078467	G/T	cg07905836	chr2:113190072	RGPD8;RGPD5	0.46	4.92	0.4	2.69e-6	Yeast infection;
TGCT	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg17971929	chr21:40555470	PSMG1	0.98	9.51	0.65	1.95e-16	Cognitive function;
TGCT	trans	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg13615516	chr5:77269221	NA	0.67	8.36	0.6	1.09e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg23758822	chr17:41437982	NA	0.72	6.81	0.52	3.83e-10	Menopause (age at onset);
TGCT	cis	rs4851266	1.000	rs1465801	chr2:100836060	C/T	cg22139774	chr2:100720529	AFF3	-0.34	-5.22	-0.42	7.28e-7	Educational attainment;
TGCT	cis	rs12210905	0.688	rs12374649	chr6:27343726	C/T	cg08851530	chr6:28072375	NA	1.25	5.39	0.44	3.38e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs6912958	0.781	rs985764	chr6:88215206	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-5.06	-0.41	1.45e-6	Monocyte percentage of white cells;
TGCT	cis	rs6582630	0.519	rs8189623	chr12:38351436	G/A	cg13010199	chr12:38710504	ALG10B	0.58	4.52	0.38	1.41e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg08048268	chr3:133502702	NA	-0.66	-10.0	-0.67	1.29e-17	Iron status biomarkers;
TGCT	cis	rs651907	0.557	rs3864012	chr3:101397623	T/C	cg12386194	chr3:101231763	SENP7	0.51	5.04	0.41	1.61e-6	Colorectal cancer;
TGCT	cis	rs931127	0.719	rs2127507	chr11:65454430	A/G	cg17480646	chr11:65405466	SIPA1	-0.43	-5.74	-0.46	6.76e-8	Systemic lupus erythematosus;
TGCT	cis	rs7474896	0.583	rs12776092	chr10:38015795	G/C	cg13720705	chr10:37990370	NA	0.33	4.81	0.4	4.21e-6	Obesity (extreme);
TGCT	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg22166914	chr1:53195759	ZYG11B	0.36	5.96	0.47	2.45e-8	Monocyte count;
TGCT	cis	rs28595532	0.920	rs116428408	chr4:119758514	G/C	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs7678296	0.649	rs4585313	chr4:37240236	C/T	cg18431856	chr4:37245254	KIAA1239	-0.71	-4.75	-0.39	5.62e-6	3-hydroxypropylmercapturic acid levels in smokers;
TGCT	cis	rs9818758	0.556	rs9872660	chr3:49378832	G/T	cg00383909	chr3:49044727	WDR6	0.7	4.75	0.39	5.48e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs7845219	0.544	rs4735331	chr8:95917958	C/T	cg16049864	chr8:95962084	TP53INP1	-0.48	-5.3	-0.43	5.23e-7	Type 2 diabetes;
TGCT	cis	rs9467773	1.000	rs6922824	chr6:26553815	C/G	cg09904177	chr6:26538194	HMGN4	-0.63	-6.33	-0.49	4.08e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs539096	0.692	rs7549094	chr1:44213178	C/A	cg12908607	chr1:44402522	ARTN	-0.63	-7.43	-0.56	1.52e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs6032067	0.636	rs17335251	chr20:43902946	T/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.47	-6.81	-0.52	3.84e-10	Blood protein levels;
TGCT	cis	rs453301	0.500	rs7015336	chr8:8830720	G/A	cg15556689	chr8:8085844	FLJ10661	0.66	5.33	0.43	4.56e-7	Joint mobility (Beighton score);
TGCT	cis	rs17102423	0.652	rs4902361	chr14:65548470	G/T	cg11161011	chr14:65562177	MAX	-0.47	-6.4	-0.5	2.89e-9	Obesity-related traits;
TGCT	cis	rs7762018	0.760	rs28660085	chr6:170101996	C/G	cg02388276	chr6:170744041	NA	-0.23	-4.45	-0.37	1.89e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	cis	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg18252515	chr7:66147081	NA	-1.2	-7.83	-0.58	1.89e-12	Diabetic kidney disease;
TGCT	cis	rs8078723	1.000	rs56922390	chr17:38157021	C/G	cg17467752	chr17:38218738	THRA	0.55	5.34	0.43	4.24e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	trans	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg27523141	chr10:43048294	ZNF37B	0.74	8.61	0.61	2.7e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs9640161	0.636	rs56190213	chr7:150025720	T/C	cg10018233	chr7:150070692	REPIN1	0.32	4.58	0.38	1.1e-5	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs9914544	0.583	rs35783872	chr17:18748820	A/C	cg26378065	chr17:18585709	ZNF286B	0.52	4.54	0.38	1.32e-5	Educational attainment (years of education);
TGCT	cis	rs12134245	0.747	rs11164912	chr1:92005191	A/T	cg25838465	chr1:92012736	NA	-0.43	-6.93	-0.53	2.04e-10	Breast cancer;
TGCT	cis	rs12477438	0.520	rs2309581	chr2:99784292	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-1.03	-12.73	-0.75	2.93e-24	Chronic sinus infection;
TGCT	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	4.99	0.41	2.04e-6	Tonsillectomy;
TGCT	cis	rs2075371	0.932	rs1035328	chr7:133978419	T/C	cg11752832	chr7:134001865	SLC35B4	0.72	6.62	0.51	9.63e-10	Mean platelet volume;
TGCT	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg17971929	chr21:40555470	PSMG1	0.98	9.61	0.65	1.14e-16	Cognitive function;
TGCT	cis	rs4819852	0.752	rs2238783	chr22:19972452	C/G	cg07821417	chr22:19972146	ARVCF	0.19	4.56	0.38	1.2e-5	Pulse pressure;
TGCT	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg03517284	chr6:25882590	NA	-0.64	-5.78	-0.46	5.8e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2836950	0.501	rs2836984	chr21:40700949	A/C	cg06238570	chr21:40685208	BRWD1	-0.64	-6.56	-0.51	1.34e-9	Menarche (age at onset);
TGCT	cis	rs9486719	0.857	rs2983897	chr6:97033780	C/T	cg06623918	chr6:96969491	KIAA0776	-0.98	-9.95	-0.67	1.64e-17	Migraine;Coronary artery disease;
TGCT	cis	rs1008375	0.931	rs7435102	chr4:17571480	C/G	cg10189774	chr4:17578691	LAP3	0.67	5.87	0.47	3.77e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs854765	0.663	rs9915248	chr17:17747514	C/T	cg04398451	chr17:18023971	MYO15A	0.3	4.6	0.38	1.04e-5	Total body bone mineral density;
TGCT	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9346649	0.583	rs4708642	chr6:168491500	G/A	cg02770688	chr6:168491649	NA	0.34	6.05	0.48	1.6e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
TGCT	cis	rs617219	0.671	rs12189188	chr5:78552312	C/T	cg23514016	chr5:78407564	BHMT	0.34	5.09	0.42	1.29e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs9393777	1.000	rs9393777	chr6:26942027	T/C	cg18364779	chr6:26104403	HIST1H4C	-0.65	-4.59	-0.38	1.06e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7917772	0.582	rs4919661	chr10:104358403	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	5.36	0.43	3.84e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	7.32	0.55	2.74e-11	Platelet count;
TGCT	cis	rs7772486	0.727	rs4896843	chr6:146063451	T/C	cg13319975	chr6:146136371	FBXO30	0.56	4.95	0.41	2.37e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs42648	0.596	rs194507	chr7:89843560	A/C	cg25739043	chr7:89950458	NA	0.47	4.51	0.38	1.47e-5	Homocysteine levels;
TGCT	cis	rs2153535	0.580	rs7341381	chr6:8470537	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg17554472	chr22:41940697	POLR3H	0.52	5.31	0.43	4.84e-7	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs74054849	0.850	rs55764623	chr1:15954383	G/A	cg05660106	chr1:15850417	CASP9	0.86	4.48	0.37	1.68e-5	Alcoholic chronic pancreatitis;
TGCT	cis	rs62380364	0.626	rs11749912	chr5:88065628	A/G	cg24804195	chr5:87968844	LOC645323	-0.57	-5.45	-0.44	2.6e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs911555	0.755	rs2756122	chr14:103983033	C/G	cg12935359	chr14:103987150	CKB	-0.37	-5.05	-0.41	1.55e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1008375	1.000	rs56974987	chr4:17627856	G/A	cg18681998	chr4:17616180	MED28	1.02	11.4	0.72	4.89e-21	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10206020	0.921	rs11884956	chr2:1566426	A/G	cg12573674	chr2:1569213	NA	-0.5	-5.49	-0.44	2.21e-7	IgG glycosylation;
TGCT	cis	rs6725041	0.532	rs12623803	chr2:213201642	G/C	cg20637307	chr2:213403960	ERBB4	-0.53	-4.49	-0.37	1.63e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg22029157	chr1:209979665	IRF6	0.76	6.24	0.49	6.3e-9	Cleft lip with or without cleft palate;
TGCT	cis	rs10791097	0.694	rs10791103	chr11:130757161	G/A	cg12179176	chr11:130786555	SNX19	0.84	10.46	0.68	9.82e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs908922	0.676	rs477621	chr1:152486252	T/C	cg20991723	chr1:152506922	NA	0.47	6.5	0.5	1.73e-9	Hair morphology;
TGCT	cis	rs7100689	0.542	rs10887869	chr10:82194689	A/G	cg00277334	chr10:82204260	NA	-0.41	-5.12	-0.42	1.15e-6	Post bronchodilator FEV1;
TGCT	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.82	9.44	0.65	2.93e-16	Menarche (age at onset);
TGCT	cis	rs6088580	0.609	rs6059845	chr20:33036500	G/A	cg06115741	chr20:33292138	TP53INP2	0.55	4.82	0.4	4.15e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs35306767	0.909	rs12264390	chr10:959111	T/C	cg26597838	chr10:835615	NA	0.66	9.01	0.63	3.04e-15	Eosinophil percentage of granulocytes;
TGCT	cis	rs4595586	0.545	rs12827197	chr12:39404362	C/T	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs56116382	0.604	rs9858428	chr3:49877585	G/T	cg07636037	chr3:49044803	WDR6	-0.96	-4.5	-0.37	1.52e-5	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
TGCT	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg09165964	chr15:75287851	SCAMP5	0.53	4.97	0.41	2.2e-6	Breast cancer;
TGCT	cis	rs4304924	0.500	rs7339081	chr13:79235501	A/G	cg01819759	chr13:79234251	RNF219	0.9	8.32	0.6	1.36e-13	Large artery stroke;
TGCT	cis	rs3087591	1.000	rs2051506	chr17:29699860	T/A	cg24425628	chr17:29625626	OMG;NF1	-0.48	-7.28	-0.55	3.31e-11	Hip circumference;
TGCT	cis	rs6987853	0.966	rs2923428	chr8:42388301	T/C	cg20539142	chr8:42623718	CHRNA6	-0.21	-5.03	-0.41	1.69e-6	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs7666738	0.830	rs11940273	chr4:98979965	T/A	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs35146811	0.735	rs1138417	chr7:99807146	C/G	cg00553149	chr7:99775558	STAG3;GPC2	-0.29	-4.43	-0.37	2.01e-5	Coronary artery disease;
TGCT	cis	rs6714710	0.580	rs57681139	chr2:98454473	C/T	cg26665480	chr2:98280029	ACTR1B	0.66	6.24	0.49	6.33e-9	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs13326165	0.760	rs13075370	chr3:52399278	G/A	cg27565382	chr3:53032988	SFMBT1	0.36	4.8	0.4	4.54e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs11098499	0.954	rs13107475	chr4:120393011	A/T	cg09307838	chr4:120376055	NA	0.71	6.95	0.53	1.85e-10	Corneal astigmatism;
TGCT	trans	rs1814175	0.541	rs12287397	chr11:49819799	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.35	-0.55	2.38e-11	Height;
TGCT	cis	rs7552404	1.000	rs4559448	chr1:76203456	A/G	cg03433033	chr1:76189801	ACADM	0.82	9.74	0.66	5.46e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2589561	0.872	rs2440781	chr10:9051328	A/G	cg08738443	chr10:8487762	NA	-0.37	-4.74	-0.39	5.74e-6	Asthma;
TGCT	cis	rs7552404	0.731	rs1689275	chr1:76409655	T/C	cg10523679	chr1:76189770	ACADM	-0.84	-7.83	-0.58	1.9e-12	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2440129	0.611	rs2292352	chr17:6902887	A/G	cg19536664	chr17:6899085	ALOX12	0.38	5.96	0.47	2.4e-8	Tonsillectomy;
TGCT	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.45	-5.49	-0.44	2.22e-7	Alzheimer's disease;
TGCT	cis	rs250677	0.522	rs17109208	chr5:148378475	G/A	cg18129178	chr5:148520854	ABLIM3	-0.36	-4.74	-0.39	5.82e-6	Breast cancer;
TGCT	cis	rs12477438	0.765	rs72957180	chr2:99694452	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-6.1	-0.48	1.22e-8	Chronic sinus infection;
TGCT	cis	rs7208859	0.623	rs56095789	chr17:29060170	A/G	cg13385521	chr17:29058706	SUZ12P	0.79	4.77	0.39	5.16e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg24250549	chr1:154909240	PMVK	0.47	4.5	0.37	1.55e-5	Prostate cancer;
TGCT	trans	rs2469997	0.925	rs2447170	chr8:120361421	C/T	cg01792902	chr3:178864926	PIK3CA	0.83	6.77	0.52	4.49e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg27170947	chr2:26402098	FAM59B	0.39	4.46	0.37	1.8e-5	Gut microbiome composition (summer);
TGCT	cis	rs7565124	1.000	rs7570953	chr2:20255015	T/C	cg00462460	chr2:20212509	MATN3	-0.45	-4.84	-0.4	3.73e-6	Major depressive disorder;
TGCT	cis	rs25422	0.938	rs9489443	chr6:118886163	T/A	cg07617317	chr6:118971624	C6orf204	0.51	5.46	0.44	2.44e-7	Renal cell carcinoma;
TGCT	cis	rs7617480	0.616	rs7429596	chr3:48808531	T/C	cg07636037	chr3:49044803	WDR6	0.79	6.43	0.5	2.54e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs832540	0.898	rs702680	chr5:56220382	T/C	cg12311346	chr5:56204834	C5orf35	-0.48	-5.02	-0.41	1.76e-6	Coronary artery disease;
TGCT	cis	rs62064224	0.791	rs2344977	chr17:30720573	C/G	cg09324608	chr17:30823087	MYO1D	0.26	5.3	0.43	5.19e-7	Schizophrenia;
TGCT	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg13206674	chr6:150067644	NUP43	0.53	4.56	0.38	1.23e-5	Lung cancer;
TGCT	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9467711	0.516	rs1324087	chr6:25841408	A/G	cg03264133	chr6:25882463	NA	0.67	4.47	0.37	1.76e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4148883	0.504	rs9307238	chr4:100136182	A/G	cg12011299	chr4:100065546	ADH4	-0.36	-5.17	-0.42	8.99e-7	Alcohol dependence;
TGCT	cis	rs11098499	0.863	rs10019674	chr4:120443489	C/T	cg09307838	chr4:120376055	NA	-0.68	-6.44	-0.5	2.39e-9	Corneal astigmatism;
TGCT	cis	rs67311347	1.000	rs6762997	chr3:40478151	C/T	cg13683864	chr3:40499215	RPL14	-1.04	-10.79	-0.7	1.54e-19	Renal cell carcinoma;
TGCT	cis	rs9611519	0.964	rs2179744	chr22:41621714	G/A	cg03806693	chr22:41940476	POLR3H	-0.67	-6.4	-0.5	2.9e-9	Neuroticism;
TGCT	cis	rs7975161	0.630	rs4964257	chr12:104633262	T/C	cg25273343	chr12:104657179	TXNRD1	-0.35	-4.83	-0.4	3.87e-6	Toenail selenium levels;
TGCT	cis	rs12200560	0.505	rs211164	chr6:97068140	G/T	cg06623918	chr6:96969491	KIAA0776	0.57	4.83	0.4	3.93e-6	Coronary heart disease;
TGCT	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg13732083	chr21:47605072	C21orf56	0.34	4.48	0.37	1.68e-5	Testicular germ cell tumor;
TGCT	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs5769707	0.706	rs2071903	chr22:50034517	G/A	cg06623630	chr22:50017776	C22orf34	-0.26	-4.53	-0.38	1.34e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs910316	0.967	rs10246	chr14:75544470	T/A	cg08847533	chr14:75593920	NEK9	0.96	10.53	0.69	6.43e-19	Height;
TGCT	cis	rs9399135	0.967	rs4142299	chr6:135377186	G/T	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.21e-6	Red blood cell count;
TGCT	cis	rs4780401	0.632	rs8055462	chr16:11834821	T/C	cg01061890	chr16:11836724	TXNDC11	-0.63	-6.09	-0.48	1.32e-8	Rheumatoid arthritis;
TGCT	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg03934478	chr11:495069	RNH1	0.33	5.08	0.42	1.33e-6	Body mass index;
TGCT	cis	rs8070740	0.947	rs3809842	chr17:5329199	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	4.55	0.38	1.27e-5	Menopause (age at onset);
TGCT	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg17178900	chr1:205818956	PM20D1	0.52	6.39	0.5	3.02e-9	Monocyte percentage of white cells;
TGCT	cis	rs7119038	0.818	rs56043232	chr11:118648373	C/T	cg19308663	chr11:118741387	NA	0.31	6.12	0.48	1.14e-8	Sjögren's syndrome;
TGCT	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg13770153	chr20:60521292	NA	0.62	8.77	0.62	1.15e-14	Obesity-related traits;
TGCT	trans	rs2970818	0.831	rs2970810	chr12:4608103	A/G	cg21748317	chr7:158073589	PTPRN2	0.47	7.27	0.55	3.63e-11	Phosphorus levels;
TGCT	cis	rs2486012	0.826	rs1008137	chr1:44420754	A/G	cg12908607	chr1:44402522	ARTN	-0.71	-5.84	-0.46	4.28e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs61990749	0.597	rs176955	chr14:78181220	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.6	4.45	0.37	1.88e-5	Fibroblast growth factor basic levels;
TGCT	trans	rs1814175	0.935	rs10839317	chr11:49657228	A/C	cg03929089	chr4:120376271	NA	-0.65	-7.44	-0.56	1.46e-11	Height;
TGCT	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg03161606	chr19:29218774	NA	0.62	5.97	0.47	2.36e-8	Methadone dose in opioid dependence;
TGCT	cis	rs12497850	0.897	rs6781790	chr3:49044767	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.41	-5.4	-0.44	3.33e-7	Parkinson's disease;
TGCT	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg11494091	chr17:61959527	GH2	0.61	14.8	0.8	3.65e-29	Prudent dietary pattern;
TGCT	trans	rs35851103	0.627	rs6601644	chr8:11847078	G/A	cg15556689	chr8:8085844	FLJ10661	0.85	8.65	0.61	2.22e-14	Neuroticism;
TGCT	cis	rs2440129	0.611	rs2292352	chr17:6902887	A/G	cg09737314	chr17:6899359	ALOX12	0.49	5.16	0.42	9.71e-7	Tonsillectomy;
TGCT	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg03806693	chr22:41940476	POLR3H	-1.15	-12.98	-0.76	7.24e-25	Vitiligo;
TGCT	cis	rs7528419	0.895	rs1277930	chr1:109822143	G/A	cg00908766	chr1:109817496	CELSR2	0.45	4.62	0.38	9.36e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
TGCT	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg04234412	chr22:24373322	LOC391322	-0.91	-10.67	-0.69	2.98e-19	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs3008870	0.917	rs12044492	chr1:67461667	T/C	cg11518657	chr1:67396239	MIER1	-0.54	-4.61	-0.38	9.72e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg17971929	chr21:40555470	PSMG1	-0.69	-6.01	-0.47	1.95e-8	Cognitive function;
TGCT	cis	rs17767294	0.614	rs116420641	chr6:28275458	G/A	cg08851530	chr6:28072375	NA	1.54	6.89	0.53	2.51e-10	Parkinson's disease;
TGCT	cis	rs8044995	0.501	rs7189887	chr16:68353915	C/T	cg05110241	chr16:68378359	PRMT7	-0.37	-4.5	-0.37	1.55e-5	Schizophrenia;
TGCT	cis	rs4925386	0.840	rs6143036	chr20:60921721	C/A	cg06026331	chr20:60912101	LAMA5	0.36	5.74	0.46	6.75e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs6684514	0.922	rs11264475	chr1:156306918	G/A	cg20302342	chr1:156215951	PAQR6	0.35	4.74	0.39	5.77e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs7267979	1.000	rs6083813	chr20:25337671	A/G	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9911578	0.842	rs12450766	chr17:56832965	G/C	cg05425664	chr17:57184151	TRIM37	0.61	5.45	0.44	2.62e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1050631	0.924	rs1785918	chr18:33693198	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	0.51	4.98	0.41	2.07e-6	Esophageal squamous cell cancer (length of survival);
TGCT	cis	rs11785400	0.762	rs7007349	chr8:143722673	T/C	cg24634471	chr8:143751801	JRK	0.53	5.23	0.42	7.05e-7	Schizophrenia;
TGCT	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg10047753	chr17:41438598	NA	0.96	9.64	0.65	9.37e-17	Menopause (age at onset);
TGCT	cis	rs12477438	0.677	rs12475034	chr2:99699464	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.64	-5.05	-0.41	1.53e-6	Chronic sinus infection;
TGCT	cis	rs6840360	0.571	rs4696110	chr4:152671325	G/A	cg17479576	chr4:152424074	FAM160A1	-0.53	-5.29	-0.43	5.31e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7528684	0.752	rs7546211	chr1:157741237	T/A	cg17134153	chr1:157670328	FCRL3	-0.27	-4.86	-0.4	3.48e-6	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;
TGCT	cis	rs6121246	0.523	rs6060286	chr20:30197663	C/A	cg21427119	chr20:30132790	HM13	-0.43	-6.17	-0.48	8.86e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs7829975	0.606	rs7837026	chr8:8801692	T/C	cg00184457	chr8:8946301	NA	-0.25	-4.53	-0.38	1.37e-5	Mood instability;
TGCT	cis	rs9916302	0.861	rs593480	chr17:37453780	A/C	cg15445000	chr17:37608096	MED1	-0.31	-4.59	-0.38	1.06e-5	Glomerular filtration rate (creatinine);
TGCT	trans	rs2727020	0.595	rs11040416	chr11:49566429	C/T	cg15704280	chr7:45808275	SEPT13	-0.75	-8.8	-0.62	9.9e-15	Coronary artery disease;
TGCT	cis	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg18188782	chr20:61659543	NA	0.44	5.38	0.43	3.6e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7208859	0.673	rs11080135	chr17:29176481	A/G	cg14008862	chr17:28927542	LRRC37B2	0.72	4.66	0.39	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs10504229	1.000	rs59708460	chr8:58196526	G/A	cg08280861	chr8:58055591	NA	0.36	4.6	0.38	1.05e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2204008	0.840	rs11181795	chr12:38401129	A/G	cg26384229	chr12:38710491	ALG10B	0.83	7.39	0.55	1.92e-11	Bladder cancer;
TGCT	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg19318889	chr4:1322082	MAEA	0.28	6.71	0.52	6.07e-10	Longevity;
TGCT	cis	rs8180040	0.764	rs4683324	chr3:47251284	T/C	cg27129171	chr3:47204927	SETD2	0.77	9.88	0.66	2.51e-17	Colorectal cancer;
TGCT	cis	rs8072100	0.967	rs4239163	chr17:45755954	C/T	cg08085267	chr17:45401833	C17orf57	-0.42	-4.6	-0.38	1.04e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs2688608	0.592	rs3849967	chr10:75483366	C/T	cg04320760	chr10:75533139	FUT11	-0.4	-6.25	-0.49	6.11e-9	Inflammatory bowel disease;
TGCT	cis	rs7954584	0.583	rs6486782	chr12:122359172	T/C	cg22168489	chr12:122356033	WDR66	0.23	5.55	0.45	1.63e-7	Mean corpuscular volume;
TGCT	cis	rs240764	0.853	rs2001102	chr6:100978351	C/T	cg21058520	chr6:100914733	NA	0.35	4.63	0.38	9.07e-6	Neuroticism;
TGCT	cis	rs1784581	0.588	rs7765624	chr6:162427462	C/A	cg17173639	chr6:162384350	PARK2	0.4	6.68	0.51	7.34e-10	Itch intensity from mosquito bite;
TGCT	cis	rs7584330	0.518	rs80282956	chr2:238447929	G/A	cg14458575	chr2:238380390	NA	0.43	4.55	0.38	1.25e-5	Prostate cancer;
TGCT	cis	rs6912958	0.712	rs2307379	chr6:88366771	A/G	cg06598631	chr6:88300029	RARS2;ORC3L	-0.55	-5.04	-0.41	1.58e-6	Monocyte percentage of white cells;
TGCT	cis	rs9972944	0.702	rs987931	chr17:63765911	T/G	cg07283582	chr17:63770753	CCDC46	-0.26	-5.3	-0.43	5.02e-7	Total body bone mineral density;
TGCT	cis	rs6570726	0.818	rs952405	chr6:145925952	T/C	cg05347473	chr6:146136440	FBXO30	0.5	4.59	0.38	1.07e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9649213	0.614	rs9641236	chr7:97998124	T/A	cg09267113	chr7:98030324	BAIAP2L1	-0.93	-8.73	-0.62	1.45e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs10992471	0.627	rs10820980	chr9:95253342	C/T	cg14631576	chr9:95140430	CENPP	-0.31	-4.61	-0.38	9.95e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs7666738	0.830	rs62321597	chr4:99014221	C/A	cg18180107	chr4:99064573	C4orf37	0.56	5.28	0.43	5.54e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1801251	0.727	rs283482	chr2:233646920	A/T	cg25237894	chr2:233734115	C2orf82	0.27	5.01	0.41	1.86e-6	Coronary artery disease;
TGCT	cis	rs78707713	0.560	rs12784882	chr10:71230334	C/G	cg14388049	chr10:71211838	TSPAN15	-0.39	-4.64	-0.38	8.84e-6	Venous thromboembolism;
TGCT	cis	rs2235642	0.826	rs8053605	chr16:1594158	G/A	cg07639376	chr16:1584516	IFT140;TMEM204	-0.32	-5.64	-0.45	1.08e-7	Coronary artery disease;
TGCT	cis	rs10782582	0.593	rs6704444	chr1:76205108	T/C	cg22875332	chr1:76189707	ACADM	-0.5	-5.46	-0.44	2.48e-7	Daytime sleep phenotypes;
TGCT	cis	rs9549260	0.564	rs9577107	chr13:41271676	A/T	cg21288729	chr13:41239152	FOXO1	0.94	9.32	0.64	5.56e-16	Red blood cell count;
TGCT	cis	rs751728	1.000	rs4711351	chr6:33754592	G/A	cg00334056	chr6:33755658	LEMD2	-0.25	-4.52	-0.38	1.44e-5	Crohn's disease;
TGCT	cis	rs73198271	0.595	rs117424193	chr8:8591377	T/C	ch.8.214553F	chr8:8189620	PRAGMIN	-0.32	-5.23	-0.42	7.04e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs13217239	0.646	rs12209886	chr6:26984757	G/A	cg05738196	chr6:26577821	NA	0.49	4.77	0.39	4.98e-6	Schizophrenia;
TGCT	cis	rs6138458	0.701	rs6138474	chr20:25012427	T/A	cg26195577	chr20:24973756	C20orf3	0.99	9.24	0.64	8.46e-16	Blood protein levels;
TGCT	cis	rs7044106	0.734	rs1981020	chr9:123388464	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.62	6.58	0.51	1.19e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs12477438	0.834	rs1563106	chr2:99701381	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.69	-6.1	-0.48	1.28e-8	Chronic sinus infection;
TGCT	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg03303774	chr4:1407052	NA	0.38	5.88	0.47	3.49e-8	Obesity-related traits;
TGCT	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg00814883	chr7:100076585	TSC22D4	-0.85	-8.62	-0.61	2.62e-14	Platelet count;
TGCT	cis	rs10510102	0.872	rs28586586	chr10:123709743	T/C	cg23691251	chr10:123688108	ATE1	-0.58	-4.67	-0.39	7.77e-6	Breast cancer;
TGCT	cis	rs7772486	0.875	rs854146	chr6:146341033	A/G	cg23711669	chr6:146136114	FBXO30	0.89	9.86	0.66	2.8e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg10047753	chr17:41438598	NA	0.96	9.64	0.65	9.37e-17	Menopause (age at onset);
TGCT	cis	rs7937612	1.000	rs11217841	chr11:120238721	C/A	cg24566217	chr11:120254723	ARHGEF12	-0.29	-4.7	-0.39	6.76e-6	Intraocular pressure;
TGCT	cis	rs9926296	0.581	rs12598477	chr16:89902482	T/C	cg04287289	chr16:89883240	FANCA	0.72	7.39	0.55	1.87e-11	Vitiligo;
TGCT	cis	rs739496	0.615	rs3809274	chr12:112044333	G/C	cg10833066	chr12:111807467	FAM109A	0.36	4.98	0.41	2.1e-6	Platelet count;
TGCT	cis	rs2439831	0.850	rs2957637	chr15:43951118	C/A	cg19166733	chr15:44192098	FRMD5	-0.25	-4.74	-0.39	5.85e-6	Lung cancer in ever smokers;
TGCT	cis	rs17767294	0.708	rs72848784	chr6:27970783	A/G	cg08851530	chr6:28072375	NA	1.56	7.22	0.54	4.47e-11	Parkinson's disease;
TGCT	cis	rs35306767	0.903	rs35370435	chr10:898205	T/C	cg20503657	chr10:835505	NA	0.77	11.34	0.71	6.95e-21	Eosinophil percentage of granulocytes;
TGCT	cis	rs7975161	0.572	rs10861163	chr12:104568613	C/A	cg25273343	chr12:104657179	TXNRD1	-0.32	-4.45	-0.37	1.88e-5	Toenail selenium levels;
TGCT	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg09436375	chr6:42928200	GNMT	-0.36	-4.46	-0.37	1.78e-5	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs10791097	0.694	rs1054869	chr11:130742630	G/A	cg12179176	chr11:130786555	SNX19	0.84	10.17	0.67	4.95e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs7909074	0.766	rs5000415	chr10:45383674	C/T	cg04218760	chr10:45406644	TMEM72	-0.29	-5.63	-0.45	1.15e-7	Mean corpuscular volume;
TGCT	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs3772130	1.000	rs11714406	chr3:121372513	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.55	5.02	0.41	1.77e-6	Cognitive performance;
TGCT	cis	rs3008870	0.755	rs2755242	chr1:67479598	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.81	8.4	0.6	8.51e-14	Lymphocyte percentage of white cells;
TGCT	trans	rs34421088	0.559	rs12386974	chr8:11400628	C/G	cg06636001	chr8:8085503	FLJ10661	0.72	6.87	0.53	2.81e-10	Neuroticism;
TGCT	cis	rs7617480	0.549	rs9879978	chr3:48846600	T/G	cg07636037	chr3:49044803	WDR6	0.78	6.5	0.5	1.73e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs7552404	1.000	rs1498316	chr1:76159198	G/A	cg03433033	chr1:76189801	ACADM	0.83	9.91	0.66	2.13e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7647973	1.000	rs73088137	chr3:49448423	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.59	-4.68	-0.39	7.32e-6	Menarche (age at onset);
TGCT	cis	rs2243480	1.000	rs2707831	chr7:66062511	G/A	cg18252515	chr7:66147081	NA	-1.22	-8.04	-0.59	6.02e-13	Diabetic kidney disease;
TGCT	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg23758822	chr17:41437982	NA	0.72	6.81	0.52	3.83e-10	Menopause (age at onset);
TGCT	cis	rs35146811	0.735	rs6465766	chr7:99785671	A/G	cg13334819	chr7:99746414	C7orf59	-0.74	-6.31	-0.49	4.4e-9	Coronary artery disease;
TGCT	cis	rs826838	0.651	rs1843892	chr12:38616965	A/G	cg26384229	chr12:38710491	ALG10B	0.65	6.07	0.48	1.44e-8	Heart rate;
TGCT	cis	rs12497850	0.805	rs11130176	chr3:48844077	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.41	-5.49	-0.44	2.15e-7	Parkinson's disease;
TGCT	cis	rs422249	0.547	rs174536	chr11:61551927	A/C	cg19610905	chr11:61596333	FADS2	-1.04	-10.72	-0.69	2.19e-19	Trans fatty acid levels;
TGCT	cis	rs614226	0.516	rs1794748	chr12:120953758	A/G	cg10072921	chr12:121022843	NA	-0.44	-4.74	-0.39	5.78e-6	Type 1 diabetes nephropathy;
TGCT	cis	rs60871478	0.579	rs56109762	chr7:925967	G/A	cg15782153	chr7:917662	C7orf20	0.58	5.19	0.42	8.5e-7	Cerebrospinal P-tau181p levels;
TGCT	cis	rs112591243	0.685	rs2839338	chr21:47987984	C/T	cg10657630	chr21:48055338	PRMT2	0.96	5.11	0.42	1.17e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs3784262	0.564	rs34958088	chr15:58328332	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.45	-6.67	-0.51	7.61e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs6088580	0.634	rs945673	chr20:32964265	C/A	cg06115741	chr20:33292138	TP53INP2	-0.54	-4.64	-0.38	8.77e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs6088580	0.634	rs2424992	chr20:33012060	C/T	cg08999081	chr20:33150536	PIGU	0.29	5.67	0.45	9.68e-8	Glomerular filtration rate (creatinine);
TGCT	cis	rs826838	0.967	rs1486345	chr12:39131677	G/A	cg26384229	chr12:38710491	ALG10B	-0.86	-7.7	-0.57	3.65e-12	Heart rate;
TGCT	cis	rs11252926	0.537	rs4881255	chr10:453638	T/C	cg13477178	chr10:375248	DIP2C	-0.25	-4.72	-0.39	6.33e-6	Psychosis in Alzheimer's disease;
TGCT	cis	rs57590327	0.612	rs820272	chr3:81554345	T/C	cg07356753	chr3:81810745	GBE1	0.54	4.44	0.37	1.98e-5	Extraversion;
TGCT	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg13695892	chr22:41940480	POLR3H	-0.91	-9.07	-0.63	2.18e-15	Vitiligo;
TGCT	cis	rs4803468	1.000	rs2241710	chr19:41912092	G/C	cg09537434	chr19:41945824	ATP5SL	-0.92	-10.69	-0.69	2.72e-19	Height;
TGCT	cis	rs79149102	0.579	rs9788648	chr15:75300284	A/G	cg09165964	chr15:75287851	SCAMP5	-1.04	-5.71	-0.46	7.93e-8	Lung cancer;
TGCT	cis	rs7666738	0.715	rs61114099	chr4:98931270	C/T	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7267979	0.586	rs6050432	chr20:25184028	T/C	cg16686733	chr20:25566563	NINL	0.53	5.43	0.44	2.9e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9818758	0.607	rs34784192	chr3:49274823	G/T	cg00383909	chr3:49044727	WDR6	1.28	6.57	0.51	1.23e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs28595532	0.841	rs114107504	chr4:119771080	T/C	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs7552404	0.731	rs1770885	chr1:76402212	C/T	cg22875332	chr1:76189707	ACADM	-0.67	-6.89	-0.53	2.5e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs4654899	1.000	rs7522722	chr1:21481840	G/A	cg01072550	chr1:21505969	NA	-0.5	-8.08	-0.59	4.94e-13	Superior frontal gyrus grey matter volume;
TGCT	cis	rs7829975	0.514	rs2979151	chr8:8258019	A/G	cg06636001	chr8:8085503	FLJ10661	-0.64	-5.78	-0.46	5.7e-8	Mood instability;
TGCT	cis	rs78487399	0.908	rs6712944	chr2:43834118	T/C	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.66	4.67	0.39	7.66e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs2227564	0.620	rs4746143	chr10:75477298	A/G	cg04320760	chr10:75533139	FUT11	-0.32	-4.5	-0.37	1.56e-5	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs6121246	0.567	rs6060261	chr20:30192948	C/G	cg18721089	chr20:30220636	NA	-0.63	-6.88	-0.53	2.67e-10	Mean corpuscular hemoglobin;
TGCT	cis	rs13242816	1.000	rs2191499	chr7:116138599	C/T	cg02799643	chr7:116139180	CAV2	-0.45	-5.85	-0.47	4.03e-8	P wave duration;
TGCT	cis	rs1008375	1.000	rs28480159	chr4:17685707	A/C	cg18681998	chr4:17616180	MED28	0.92	10.51	0.69	7.15e-19	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2239547	0.618	rs13083728	chr3:52868445	G/A	cg11645453	chr3:52864694	ITIH4	0.35	5.75	0.46	6.41e-8	Schizophrenia;
TGCT	cis	rs6430585	0.528	rs12474975	chr2:136702118	A/T	cg07169764	chr2:136633963	MCM6	1.25	12.67	0.75	4.02e-24	Corneal structure;
TGCT	cis	rs10992471	0.729	rs7042335	chr9:95122547	C/T	cg14631576	chr9:95140430	CENPP	-0.3	-4.85	-0.4	3.62e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs2456568	0.867	rs2511375	chr11:93671117	T/G	cg26875233	chr11:93583750	C11orf90	-0.45	-5.61	-0.45	1.28e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs9911578	0.935	rs7218105	chr17:57041119	A/G	cg05425664	chr17:57184151	TRIM37	-0.62	-6.18	-0.49	8.33e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs16867321	0.527	rs7571457	chr2:181590172	C/T	cg12875548	chr2:181044332	NA	-0.36	-4.7	-0.39	6.68e-6	Obesity;
TGCT	cis	rs6988636	1.000	rs6988636	chr8:124185970	A/G	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs687432	0.774	rs7945154	chr11:57912638	G/A	cg04811534	chr11:57115016	P2RX3	0.18	4.48	0.37	1.68e-5	Parkinson's disease;
TGCT	cis	rs3857536	0.566	rs208463	chr6:66913962	T/A	cg07460842	chr6:66804631	NA	-0.68	-6.73	-0.52	5.5e-10	Blood trace element (Cu levels);
TGCT	cis	rs7662987	0.517	rs4235436	chr4:100039620	G/A	cg12011299	chr4:100065546	ADH4	0.39	4.81	0.4	4.36e-6	Smoking initiation;
TGCT	cis	rs981844	0.645	rs72731677	chr4:154671475	C/G	cg14289246	chr4:154710475	SFRP2	1.01	8.67	0.61	2.02e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs9916302	0.904	rs35335692	chr17:37710006	A/G	cg15445000	chr17:37608096	MED1	0.31	4.5	0.37	1.53e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs6542838	0.609	rs13028500	chr2:99528296	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.56	-5.16	-0.42	9.49e-7	Fear of minor pain;
TGCT	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.68	4.84	0.4	3.86e-6	Platelet count;
TGCT	cis	rs9303401	0.614	rs17175663	chr17:57108437	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.63	5.8	0.46	5.11e-8	Cognitive test performance;
TGCT	cis	rs11874712	1.000	rs1800637	chr18:43670190	T/C	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	5.23	0.42	7.11e-7	Migraine - clinic-based;
TGCT	cis	rs854765	0.647	rs854770	chr17:18019048	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	7.37	0.55	2.15e-11	Total body bone mineral density;
TGCT	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg03264133	chr6:25882463	NA	0.52	5.51	0.44	2.01e-7	Blood metabolite levels;
TGCT	cis	rs9419702	0.568	rs7920966	chr10:133555185	G/T	cg04492858	chr10:133558786	NA	0.53	5.74	0.46	6.88e-8	Survival in rectal cancer;
TGCT	cis	rs7267979	1.000	rs6050598	chr20:25397257	C/G	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2013441	0.932	rs3850785	chr17:20185248	A/G	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.63	-0.38	9.19e-6	Obesity-related traits;
TGCT	cis	rs9581857	0.615	rs79553479	chr13:28007862	G/A	cg22138327	chr13:27999177	GTF3A	0.78	5.26	0.43	5.98e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs11098499	0.908	rs1002152	chr4:120273387	C/A	cg09307838	chr4:120376055	NA	0.63	6.17	0.48	8.9e-9	Corneal astigmatism;
TGCT	cis	rs7267979	1.000	rs7018	chr20:25278261	A/G	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6121246	0.567	rs6120937	chr20:30219721	C/T	cg18721089	chr20:30220636	NA	-0.64	-6.86	-0.52	2.84e-10	Mean corpuscular hemoglobin;
TGCT	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg08280861	chr8:58055591	NA	0.38	4.7	0.39	6.87e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4689592	0.503	rs66885632	chr4:7053738	T/C	cg25660036	chr4:7070649	GRPEL1	0.58	4.46	0.37	1.8e-5	Monocyte percentage of white cells;
TGCT	cis	rs6912958	0.582	rs242285	chr6:88070743	G/A	cg10393598	chr6:87862264	NA	-0.31	-4.45	-0.37	1.86e-5	Monocyte percentage of white cells;
TGCT	cis	rs73198271	0.740	rs1039912	chr8:8648229	C/T	cg06636001	chr8:8085503	FLJ10661	-0.6	-4.65	-0.39	8.23e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs919433	0.617	rs4850807	chr2:198575975	G/A	cg00792783	chr2:198669748	PLCL1	-0.55	-5.04	-0.41	1.62e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs67311347	0.876	rs13068097	chr3:40504424	T/A	cg13683864	chr3:40499215	RPL14	1.14	12.22	0.74	4.89e-23	Renal cell carcinoma;
TGCT	cis	rs8014252	0.803	rs73282126	chr14:70986041	T/C	cg11204974	chr14:71022665	NA	-0.53	-4.46	-0.37	1.79e-5	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
TGCT	cis	rs478304	0.654	rs6591185	chr11:65455742	A/G	cg27068330	chr11:65405492	SIPA1	-0.99	-11.36	-0.71	6.13e-21	Acne (severe);
TGCT	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg22920501	chr2:26401640	FAM59B	-0.72	-6.38	-0.5	3.19e-9	Gut microbiome composition (summer);
TGCT	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.49	6.64	0.51	8.8e-10	Alzheimer's disease;
TGCT	cis	rs6952808	0.730	rs55948146	chr7:1866953	G/C	cg22963979	chr7:1858916	MAD1L1	0.32	5.02	0.41	1.73e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs1401999	1.000	rs7620350	chr3:183710053	A/T	cg01324343	chr3:183735012	ABCC5	0.82	10.97	0.7	5.41e-20	Anterior chamber depth;
TGCT	cis	rs9486719	1.000	rs28623445	chr6:96899116	G/T	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.86	-0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs2334880	0.713	rs4788828	chr16:71724090	C/A	cg06353428	chr16:71660113	MARVELD3	1.56	12.9	0.76	1.15e-24	Malaria;
TGCT	cis	rs727563	0.594	rs5758408	chr22:42077737	A/C	cg03806693	chr22:41940476	POLR3H	1.08	11.79	0.73	5.53e-22	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs7119038	0.865	rs11217044	chr11:118696022	T/C	cg19308663	chr11:118741387	NA	0.27	5.62	0.45	1.22e-7	Sjögren's syndrome;
TGCT	cis	rs4654899	1.000	rs12133780	chr1:21270808	G/A	cg01072550	chr1:21505969	NA	-0.48	-7.63	-0.57	5.3e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg27535305	chr1:53392650	SCP2	-0.29	-5.59	-0.45	1.4e-7	Monocyte count;
TGCT	trans	rs2970818	0.831	rs7304949	chr12:4609625	A/G	cg22985033	chr20:36975012	LBP	0.24	7.21	0.54	4.77e-11	Phosphorus levels;
TGCT	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg10802521	chr3:52805072	NEK4	-0.71	-8.81	-0.62	9.29e-15	Bipolar disorder;
TGCT	cis	rs9522267	0.502	rs9522297	chr13:112234419	C/T	cg10483660	chr13:112241077	NA	-0.27	-4.61	-0.38	9.78e-6	Hepatitis;
TGCT	cis	rs72717009	0.825	rs12722986	chr1:161465420	A/G	cg23840854	chr1:161414152	NA	-1.05	-6.11	-0.48	1.18e-8	Rheumatoid arthritis;
TGCT	cis	rs6121246	0.583	rs28815498	chr20:30351560	T/C	cg13852791	chr20:30311386	BCL2L1	0.82	8.0	0.58	7.65e-13	Mean corpuscular hemoglobin;
TGCT	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg10053473	chr17:62856997	LRRC37A3	-0.41	-6.8	-0.52	3.85e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.31	-4.82	-0.4	4.12e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg10802521	chr3:52805072	NEK4	-0.7	-8.75	-0.62	1.28e-14	Bipolar disorder;
TGCT	cis	rs854765	0.647	rs9303144	chr17:17977355	T/C	cg00306284	chr17:18855313	SLC5A10	0.23	4.43	0.37	2.01e-5	Total body bone mineral density;
TGCT	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg12311346	chr5:56204834	C5orf35	0.57	6.09	0.48	1.28e-8	Initial pursuit acceleration;
TGCT	cis	rs4268898	0.735	rs34125395	chr2:24558242	C/T	cg02683114	chr2:24398427	C2orf84	0.2	4.92	0.4	2.65e-6	Asthma;
TGCT	cis	rs308403	0.608	rs309368	chr4:123662997	A/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.71	6.35	0.5	3.79e-9	Blood protein levels;
TGCT	cis	rs9640161	0.636	rs3735171	chr7:150033882	A/G	cg10018233	chr7:150070692	REPIN1	0.31	4.6	0.38	1.03e-5	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs9993613	0.808	rs1518492	chr4:73433875	G/A	cg15102770	chr4:73434591	ADAMTS3	-0.5	-4.59	-0.38	1.09e-5	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs7412746	0.611	rs2256355	chr1:150811794	A/G	cg09365446	chr1:150670422	GOLPH3L	0.32	4.61	0.38	9.85e-6	Melanoma;
TGCT	trans	rs3780486	0.522	rs1328898	chr9:33163271	A/G	cg20290983	chr6:43655470	MRPS18A	0.77	8.36	0.6	1.07e-13	IgG glycosylation;
TGCT	cis	rs7666738	0.830	rs13116691	chr4:98929771	A/C	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2639990	1.000	rs1702831	chr18:72897368	C/A	cg18449964	chr18:72917101	ZADH2	0.91	6.22	0.49	7e-9	Vascular endothelial growth factor levels;
TGCT	cis	rs904251	0.600	rs2270687	chr6:37418263	A/G	cg01843034	chr6:37503916	NA	-0.48	-6.05	-0.48	1.6e-8	Cognitive performance;
TGCT	cis	rs10876993	0.728	rs1082503	chr12:58036717	G/A	cg15848620	chr12:58087721	OS9	-0.72	-5.78	-0.46	5.57e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs6433895	1.000	rs55954384	chr2:182017630	A/G	cg16904960	chr2:182549928	NA	0.34	4.47	0.37	1.77e-5	Lymphocyte counts;
TGCT	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg27535305	chr1:53392650	SCP2	0.27	5.33	0.43	4.5e-7	Monocyte count;
TGCT	cis	rs6121246	0.909	rs6060812	chr20:30292803	C/T	cg13852791	chr20:30311386	BCL2L1	0.78	5.8	0.46	5.15e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs3020736	0.500	rs6002623	chr22:42513761	G/A	cg05082376	chr22:42548792	NA	0.23	5.43	0.44	2.83e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2469997	1.000	rs2470003	chr8:120357482	C/T	cg00681363	chr8:120844660	TAF2	0.69	4.48	0.37	1.64e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs514406	0.584	rs11205997	chr1:53195271	G/C	cg08859206	chr1:53392774	SCP2	0.34	4.82	0.4	4.1e-6	Monocyte count;
TGCT	cis	rs3812049	0.693	rs9327468	chr5:127441861	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	5.87	0.47	3.81e-8	Lymphocyte counts;Red cell distribution width;
TGCT	cis	rs709400	0.633	rs10135868	chr14:104004147	T/C	cg12935359	chr14:103987150	CKB	-0.38	-5.67	-0.45	9.37e-8	Body mass index;
TGCT	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg11366901	chr6:160182831	ACAT2	-1.02	-6.82	-0.52	3.57e-10	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs9611565	0.625	rs12483991	chr22:41935285	A/G	cg03806693	chr22:41940476	POLR3H	-1.01	-11.32	-0.71	7.68e-21	Vitiligo;
TGCT	cis	rs7267979	1.000	rs422844	chr20:25445591	T/C	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3784262	0.669	rs7180059	chr15:58288172	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.42	-5.96	-0.47	2.49e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg10047753	chr17:41438598	NA	0.99	10.22	0.68	3.71e-18	Menopause (age at onset);
TGCT	cis	rs514406	0.505	rs437954	chr1:53173321	C/G	cg01802117	chr1:53393560	SCP2	-0.4	-4.66	-0.39	8.05e-6	Monocyte count;
TGCT	cis	rs861020	0.630	rs592694	chr1:210009533	G/T	cg05527609	chr1:210001259	C1orf107	0.89	8.36	0.6	1.08e-13	Orofacial clefts;
TGCT	cis	rs11792861	0.781	rs2151426	chr9:111743797	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.5	4.53	0.38	1.37e-5	Menarche (age at onset);
TGCT	cis	rs2982552	0.708	rs1609624	chr6:152081009	T/C	cg22157087	chr6:152012887	ESR1	0.19	4.57	0.38	1.17e-5	Bone properties (heel);
TGCT	cis	rs1008375	0.863	rs7680984	chr4:17600884	A/G	cg18681998	chr4:17616180	MED28	1.05	10.51	0.69	7.43e-19	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs12210905	1.000	rs12189835	chr6:27198271	T/C	cg08851530	chr6:28072375	NA	1.05	5.07	0.41	1.42e-6	Hip circumference adjusted for BMI;
TGCT	trans	rs3780486	0.522	rs7029897	chr9:33124042	T/C	cg04842962	chr6:43655489	MRPS18A	0.83	9.02	0.63	2.9e-15	IgG glycosylation;
TGCT	cis	rs9682041	1.000	rs6444920	chr3:170090374	A/G	cg11886554	chr3:170076028	SKIL	0.83	6.42	0.5	2.66e-9	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg22920501	chr2:26401640	FAM59B	-0.73	-6.44	-0.5	2.35e-9	Gut microbiome composition (summer);
TGCT	trans	rs629535	0.862	rs654604	chr8:70048939	C/A	cg21567404	chr3:27674614	NA	0.58	9.18	0.64	1.22e-15	Dupuytren's disease;
TGCT	cis	rs40363	1.000	rs1635393	chr16:3520493	C/T	cg00484396	chr16:3507460	NAT15	0.42	5.05	0.41	1.51e-6	Tuberculosis;
TGCT	cis	rs11122272	0.735	rs2749706	chr1:231527170	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-6.32	-0.49	4.24e-9	Hemoglobin concentration;
TGCT	cis	rs6121246	0.865	rs77130187	chr20:30269060	G/A	cg13852791	chr20:30311386	BCL2L1	0.68	4.79	0.4	4.6e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs2115630	0.967	rs8027779	chr15:85255385	T/C	cg17173187	chr15:85201210	NMB	-0.4	-5.02	-0.41	1.78e-6	P wave terminal force;
TGCT	cis	rs57590327	0.504	rs4856349	chr3:81502928	C/T	cg07356753	chr3:81810745	GBE1	0.58	4.89	0.4	3.06e-6	Extraversion;
TGCT	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg00908189	chr16:619842	PIGQ	0.8	8.92	0.63	5.12e-15	Height;
TGCT	cis	rs2688608	0.836	rs2675668	chr10:75636148	G/A	cg19442545	chr10:75533431	FUT11	-0.31	-4.97	-0.41	2.13e-6	Inflammatory bowel disease;
TGCT	cis	rs752092	0.894	rs8042989	chr15:101770761	T/A	cg25114630	chr15:101792522	CHSY1	0.5	4.7	0.39	6.7e-6	Corneal structure;
TGCT	cis	rs17030434	0.654	rs10021631	chr4:154646675	A/G	cg14289246	chr4:154710475	SFRP2	-0.79	-5.87	-0.47	3.7e-8	Electrocardiographic conduction measures;
TGCT	cis	rs2456568	0.531	rs7105060	chr11:93661268	C/A	cg26875233	chr11:93583750	C11orf90	-0.41	-4.94	-0.41	2.43e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs1371867	0.764	rs1020171	chr8:101288610	T/C	cg00191853	chr8:101177733	SPAG1	-0.22	-4.5	-0.37	1.53e-5	Atrioventricular conduction;
TGCT	cis	rs67073037	0.955	rs11689719	chr2:29122001	G/T	cg09522027	chr2:28974177	PPP1CB	0.57	4.49	0.37	1.59e-5	Breast cancer;Breast cancer (estrogen-receptor negative);
TGCT	cis	rs6752107	1.000	rs6752107	chr2:234161448	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.19	4.65	0.39	8.38e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs2354432	0.607	rs1530335	chr1:146685288	T/C	cg25205988	chr1:146714368	CHD1L	1.34	6.23	0.49	6.59e-9	Mitochondrial DNA levels;
TGCT	cis	rs7944584	0.588	rs11988	chr11:47261260	G/A	cg20307385	chr11:47447363	PSMC3	0.79	7.75	0.57	2.86e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
TGCT	cis	rs79349575	0.745	rs170319	chr17:46991531	T/C	cg26022315	chr17:47021804	SNF8	0.49	4.89	0.4	3.03e-6	Type 2 diabetes;
TGCT	cis	rs12367572	1.000	rs12367572	chr12:45290466	C/T	cg04608330	chr12:45269318	NELL2	0.66	6.82	0.52	3.59e-10	Gut microbiome composition (summer);
TGCT	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg06238570	chr21:40685208	BRWD1	0.67	6.18	0.49	8.49e-9	Cognitive function;
TGCT	cis	rs9894429	0.683	rs112612275	chr17:79552604	C/A	cg18240062	chr17:79603768	NPLOC4	-0.85	-10.0	-0.67	1.28e-17	Eye color traits;
TGCT	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs6815814	0.904	rs67712706	chr4:38820616	A/G	cg02016764	chr4:38805732	TLR1	-0.34	-5.35	-0.43	4.05e-7	Breast cancer;
TGCT	cis	rs589448	0.538	rs622656	chr12:69753595	C/T	cg20891283	chr12:69753455	YEATS4	0.67	5.91	0.47	3.11e-8	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs9517313	0.551	rs2274051	chr13:99091634	A/G	cg07423050	chr13:99094983	FARP1	0.29	5.42	0.44	3.04e-7	Neuroticism;
TGCT	cis	rs9811920	0.609	rs17174947	chr3:99598884	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.58	-6.55	-0.51	1.35e-9	Axial length;
TGCT	cis	rs1670533	1.000	rs10084890	chr4:1053934	C/G	cg20887711	chr4:1340912	KIAA1530	-0.63	-4.93	-0.4	2.58e-6	Recombination rate (females);
TGCT	cis	rs344364	0.511	rs1657133	chr16:1950300	A/G	cg26617929	chr16:1858877	NA	-0.27	-4.9	-0.4	2.99e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs9486719	1.000	rs11153018	chr6:96956137	G/A	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.86	-0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs4595586	0.545	rs1400284	chr12:39400419	G/A	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs265548	0.646	rs36689	chr19:17910639	A/G	cg03316864	chr19:17906309	B3GNT3	0.47	5.67	0.45	9.52e-8	Tumor biomarkers;
TGCT	cis	rs2197308	0.765	rs11182964	chr12:37935052	C/T	cg26384229	chr12:38710491	ALG10B	0.87	7.83	0.58	1.85e-12	Morning vs. evening chronotype;
TGCT	cis	rs9916302	0.904	rs4795356	chr17:37535631	C/T	cg15445000	chr17:37608096	MED1	-0.33	-4.71	-0.39	6.46e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs2016266	0.750	rs10876432	chr12:53731891	G/A	cg16917193	chr12:54089295	NA	0.68	4.55	0.38	1.24e-5	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs7267979	0.933	rs1130694	chr20:25276297	G/A	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs317689	0.918	rs581911	chr12:69738293	C/T	cg11871910	chr12:69753446	YEATS4	0.57	4.88	0.4	3.13e-6	Response to diuretic therapy;
TGCT	trans	rs797680	0.856	rs7541687	chr1:93656588	A/G	cg27528825	chr2:159282178	CCDC148	-0.35	-6.82	-0.52	3.53e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs950169	0.580	rs11630887	chr15:85193015	A/T	cg12863693	chr15:85201151	NMB	0.45	5.38	0.44	3.55e-7	Schizophrenia;
TGCT	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.49	-6.61	-0.51	1e-9	Alzheimer's disease;
TGCT	trans	rs561341	0.883	rs2074102	chr17:30228884	G/A	cg20587970	chr11:113659929	NA	-0.82	-9.73	-0.66	5.87e-17	Hip circumference adjusted for BMI;
TGCT	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg12310025	chr6:25882481	NA	0.9	8.89	0.62	5.87e-15	Blood metabolite levels;
TGCT	cis	rs8014204	0.935	rs3742786	chr14:75373011	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.71	-6.87	-0.53	2.75e-10	Caffeine consumption;
TGCT	cis	rs1153858	1.000	rs12437840	chr15:45669055	C/A	cg14582100	chr15:45693742	SPATA5L1	0.49	5.73	0.46	7.14e-8	Homoarginine levels;
TGCT	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg23758822	chr17:41437982	NA	-0.7	-6.61	-0.51	1.05e-9	Menopause (age at onset);
TGCT	cis	rs7613051	0.945	rs7629880	chr3:33058811	C/T	cg19000631	chr3:33138515	GLB1;TMPPE	-0.64	-4.74	-0.39	5.79e-6	Atopic dermatitis;
TGCT	cis	rs4285028	0.948	rs34696871	chr3:121671880	T/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.79	-6.68	-0.51	7.11e-10	Multiple sclerosis;
TGCT	cis	rs832540	0.931	rs832536	chr5:56212595	C/T	cg12311346	chr5:56204834	C5orf35	-0.47	-4.97	-0.41	2.15e-6	Coronary artery disease;
TGCT	cis	rs10791323	0.572	rs10750551	chr11:133737462	G/A	cg03690763	chr11:133734501	NA	-0.28	-4.79	-0.39	4.75e-6	Childhood ear infection;
TGCT	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg08736216	chr1:53307985	ZYG11A	-0.27	-5.41	-0.44	3.12e-7	Monocyte count;
TGCT	cis	rs9796	0.558	rs7166205	chr15:41514733	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.52	-7.18	-0.54	5.56e-11	Menopause (age at onset);
TGCT	cis	rs3008870	0.883	rs2755249	chr1:67493662	A/G	cg11518657	chr1:67396239	MIER1	0.52	4.47	0.37	1.73e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs478304	0.654	rs7934036	chr11:65451020	G/T	cg27068330	chr11:65405492	SIPA1	-1.01	-11.16	-0.71	1.94e-20	Acne (severe);
TGCT	cis	rs8017423	1.000	rs10129210	chr14:90668379	G/T	cg04374321	chr14:90722782	PSMC1	0.77	7.95	0.58	9.78e-13	Mortality in heart failure;
TGCT	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg21226059	chr5:178986404	RUFY1	-0.62	-7.28	-0.55	3.37e-11	Lung cancer;
TGCT	cis	rs4273100	0.607	rs8072587	chr17:19211073	C/G	cg03910582	chr17:19030146	GRAPL	-0.51	-6.2	-0.49	7.86e-9	Schizophrenia;
TGCT	trans	rs1814175	0.935	rs6485999	chr11:49658986	G/C	cg03929089	chr4:120376271	NA	-0.65	-7.44	-0.56	1.46e-11	Height;
TGCT	cis	rs514406	0.584	rs11205997	chr1:53195271	G/C	cg24675658	chr1:53192096	ZYG11B	0.84	10.45	0.68	1.03e-18	Monocyte count;
TGCT	cis	rs12477438	0.871	rs62156364	chr2:99695097	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-4.71	-0.39	6.43e-6	Chronic sinus infection;
TGCT	cis	rs7267979	1.000	rs4815421	chr20:25386509	G/A	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7829975	0.572	rs28730413	chr8:8795447	A/C	cg15556689	chr8:8085844	FLJ10661	-0.67	-6.12	-0.48	1.14e-8	Mood instability;
TGCT	cis	rs28374715	0.635	rs8023530	chr15:41647775	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.85	-13.66	-0.78	1.71e-26	Ulcerative colitis;
TGCT	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg05368731	chr17:41323189	NBR1	1.16	13.48	0.77	4.59e-26	Menopause (age at onset);
TGCT	cis	rs7726839	0.507	rs60068988	chr5:597668	T/C	cg16624210	chr5:671434	TPPP	0.44	4.85	0.4	3.68e-6	Obesity-related traits;
TGCT	cis	rs35306767	0.761	rs11253538	chr10:1011166	C/T	cg18964960	chr10:1102726	WDR37	0.69	4.82	0.4	4.12e-6	Eosinophil percentage of granulocytes;
TGCT	cis	rs58688157	0.960	rs1131665	chr11:613208	T/C	cg16486109	chr11:613632	IRF7	0.36	5.26	0.43	6.02e-7	Systemic lupus erythematosus;
TGCT	cis	rs4805272	0.512	rs11879141	chr19:29320335	G/A	cg03161606	chr19:29218774	NA	0.54	4.48	0.37	1.68e-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
TGCT	cis	rs6665290	0.904	rs6690803	chr1:227189106	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.98	-20.01	-0.87	1.24e-40	Myeloid white cell count;
TGCT	cis	rs6671200	1.000	rs71654417	chr1:95661200	G/A	cg20701556	chr1:95698924	RWDD3	0.65	5.58	0.45	1.43e-7	Stearic acid (18:0) levels;
TGCT	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg12963246	chr6:28129442	ZNF389	0.52	5.01	0.41	1.85e-6	Depression;
TGCT	cis	rs8037137	0.915	rs12594752	chr15:91531995	C/T	cg22570213	chr15:91497863	RCCD1	0.5	4.65	0.39	8.27e-6	Platelet count;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
TGCT	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg09359103	chr1:154839909	KCNN3	-0.63	-11.36	-0.71	6.16e-21	Prostate cancer;
TGCT	cis	rs7829975	0.682	rs7013471	chr8:8687325	A/G	cg06636001	chr8:8085503	FLJ10661	-0.74	-6.68	-0.51	7.15e-10	Mood instability;
TGCT	cis	rs5769765	0.955	rs2319465	chr22:50265784	A/C	cg15316289	chr22:50310904	ALG12;CRELD2	-0.41	-6.13	-0.48	1.08e-8	Schizophrenia;
TGCT	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg08219700	chr8:58056026	NA	0.3	4.55	0.38	1.25e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs28595532	0.920	rs17323034	chr4:119606518	G/A	cg11846333	chr4:119757529	SEC24D	0.92	5.01	0.41	1.85e-6	Cannabis dependence symptom count;
TGCT	cis	rs6866344	0.697	rs17184302	chr5:178127676	C/T	cg10224037	chr5:178157518	ZNF354A	0.93	7.9	0.58	1.26e-12	Neutrophil percentage of white cells;
TGCT	cis	rs11679640	1.000	rs11679640	chr2:43141485	C/G	cg18281102	chr2:44065550	ABCG5;ABCG8	-0.27	-4.56	-0.38	1.22e-5	White matter hyperintensity burden;
TGCT	cis	rs2760061	0.583	rs708123	chr1:228220495	A/G	cg18477163	chr1:228402036	OBSCN	0.35	7.05	0.53	1.11e-10	Diastolic blood pressure;
TGCT	cis	rs881375	0.967	rs1930778	chr9:123641369	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.4	4.64	0.38	8.85e-6	Rheumatoid arthritis;
TGCT	cis	rs34467563	0.967	rs62516311	chr8:97400975	G/A	cg15747595	chr8:98289880	TSPYL5	-0.41	-4.44	-0.37	1.99e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9883204	0.817	rs17361324	chr3:123131254	C/T	cg04890266	chr3:123102914	ADCY5	0.33	4.79	0.4	4.68e-6	Birth weight;
TGCT	cis	rs1008375	0.686	rs34338142	chr4:17626174	T/A	cg16339924	chr4:17578868	LAP3	0.72	5.67	0.45	9.56e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs3820068	0.603	rs10492986	chr1:15988702	T/C	cg05660106	chr1:15850417	CASP9	0.81	7.67	0.57	4.28e-12	Systolic blood pressure;
TGCT	cis	rs6665290	0.901	rs61834005	chr1:227202789	C/T	cg11404489	chr1:228071452	NA	-0.19	-4.61	-0.38	9.97e-6	Myeloid white cell count;
TGCT	cis	rs7666738	0.830	rs1456208	chr4:98678563	C/T	cg05340658	chr4:99064831	C4orf37	0.46	5.42	0.44	3.01e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9814567	1.000	rs11708531	chr3:134224902	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.95	-9.62	-0.65	1.04e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs80282103	0.618	rs74117850	chr10:1165777	T/C	cg18964960	chr10:1102726	WDR37	1.03	4.53	0.38	1.39e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs60154123	0.505	rs1319435	chr1:210047618	C/T	cg23283495	chr1:209979779	IRF6	-0.63	-4.6	-0.38	1.04e-5	Coronary artery disease;
TGCT	cis	rs7786808	0.653	rs4909213	chr7:158202404	G/A	cg01191920	chr7:158217561	PTPRN2	-0.44	-6.59	-0.51	1.11e-9	Obesity-related traits;
TGCT	cis	rs34014631	1.000	rs75823291	chr10:103567057	A/C	cg22630918	chr10:102748988	C10orf2	0.43	4.8	0.4	4.57e-6	Coronary artery calcification;
TGCT	cis	rs6543140	0.964	rs7561351	chr2:103077780	A/G	cg09003973	chr2:102972529	NA	0.55	4.67	0.39	7.71e-6	Blood protein levels;
TGCT	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg02725872	chr8:58115012	NA	-0.37	-4.99	-0.41	1.99e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs12477438	0.520	rs4402818	chr2:99717608	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.05	12.68	0.75	3.78e-24	Chronic sinus infection;
TGCT	cis	rs6558530	0.625	rs7459507	chr8:1698192	A/G	cg09410841	chr8:1729607	CLN8	0.71	6.23	0.49	6.68e-9	Systolic blood pressure;
TGCT	cis	rs9611565	0.921	rs5758297	chr22:41720697	A/G	cg03806693	chr22:41940476	POLR3H	-0.86	-9.19	-0.64	1.16e-15	Vitiligo;
TGCT	cis	rs2354432	0.556	rs6593777	chr1:146884013	C/G	cg25205988	chr1:146714368	CHD1L	1.32	5.88	0.47	3.62e-8	Mitochondrial DNA levels;
TGCT	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.07	-9.63	-0.65	1.01e-16	Platelet count;
TGCT	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg04414720	chr1:150670196	GOLPH3L	0.39	5.04	0.41	1.58e-6	Tonsillectomy;
TGCT	cis	rs2153535	0.580	rs1414346	chr6:8471574	A/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs2932538	0.922	rs12401734	chr1:113071834	A/G	cg22162597	chr1:113214053	CAPZA1	0.26	5.65	0.45	1.06e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs4654899	0.680	rs6692553	chr1:21221497	C/T	cg01072550	chr1:21505969	NA	0.54	8.66	0.61	2.06e-14	Superior frontal gyrus grey matter volume;
TGCT	cis	rs854765	0.624	rs11652144	chr17:17733934	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.69	-6.66	-0.51	7.85e-10	Total body bone mineral density;
TGCT	cis	rs1982963	1.000	rs904061	chr14:52504624	T/C	cg10843707	chr14:52510701	NID2	-0.43	-6.6	-0.51	1.09e-9	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7666738	0.830	rs4699591	chr4:98974171	A/G	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3087591	0.683	rs17826544	chr17:29640225	A/G	cg24425628	chr17:29625626	OMG;NF1	0.39	5.74	0.46	6.74e-8	Hip circumference;
TGCT	cis	rs7267979	1.000	rs4815420	chr20:25383979	C/T	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6940638	0.956	rs36048693	chr6:27032711	T/G	cg26531700	chr6:26746687	NA	-0.62	-4.71	-0.39	6.59e-6	Intelligence (multi-trait analysis);
TGCT	trans	rs797680	0.964	rs547866	chr1:93725053	C/T	cg27528825	chr2:159282178	CCDC148	0.34	6.65	0.51	8.23e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs245880	0.740	rs245892	chr7:29191273	T/C	cg17163760	chr7:29186267	CPVL	-0.41	-5.21	-0.42	7.51e-7	Warfarin maintenance dose;
TGCT	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg22535103	chr8:58192502	C8orf71	-0.42	-4.79	-0.4	4.7e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7646881	0.504	rs67305172	chr3:158464274	A/G	cg18349298	chr3:158450550	RARRES1	0.42	4.44	0.37	1.97e-5	Tetralogy of Fallot;
TGCT	cis	rs826838	0.967	rs34496261	chr12:39023829	G/A	cg26384229	chr12:38710491	ALG10B	1.02	9.78	0.66	4.37e-17	Heart rate;
TGCT	cis	rs6582630	0.537	rs1949610	chr12:38387838	C/T	cg26384229	chr12:38710491	ALG10B	0.83	7.26	0.55	3.72e-11	Drug-induced liver injury (flucloxacillin);
TGCT	trans	rs804280	0.518	rs34266352	chr8:11791462	G/A	cg15556689	chr8:8085844	FLJ10661	0.75	7.26	0.55	3.66e-11	Myopia (pathological);
TGCT	cis	rs67311347	0.956	rs12633446	chr3:40505661	G/A	cg13683864	chr3:40499215	RPL14	1.04	10.6	0.69	4.48e-19	Renal cell carcinoma;
TGCT	cis	rs3824867	1.000	rs3824867	chr11:47468569	A/G	cg20307385	chr11:47447363	PSMC3	0.69	5.93	0.47	2.74e-8	Mean corpuscular hemoglobin;
TGCT	trans	rs7618501	0.521	rs3733134	chr3:49939503	C/T	cg21659725	chr3:3221576	CRBN	0.72	8.23	0.59	2.18e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs9393692	1.000	rs3999544	chr6:26285867	C/T	cg05868516	chr6:26286170	HIST1H4H	0.62	5.75	0.46	6.64e-8	Educational attainment;
TGCT	cis	rs7552404	1.000	rs11161515	chr1:76212559	C/T	cg10523679	chr1:76189770	ACADM	0.89	9.53	0.65	1.72e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9467773	0.595	rs2172007	chr6:26639777	A/C	cg09904177	chr6:26538194	HMGN4	0.64	5.95	0.47	2.56e-8	Intelligence (multi-trait analysis);
TGCT	trans	rs1814175	0.616	rs10839388	chr11:49842603	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.45	-11.09	-0.71	2.8e-20	Height;
TGCT	cis	rs7017914	0.967	rs2933853	chr8:71909222	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.59	-5.51	-0.44	1.97e-7	Bone mineral density;
TGCT	cis	rs593531	0.571	rs10793081	chr11:74092403	T/C	cg25592907	chr11:73676012	DNAJB13	0.31	4.52	0.38	1.45e-5	Neuroticism;
TGCT	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg00814883	chr7:100076585	TSC22D4	-0.9	-9.56	-0.65	1.5e-16	Platelet count;
TGCT	cis	rs7659604	0.846	rs35986491	chr4:122664528	A/T	cg19748678	chr4:122722346	EXOSC9	0.57	5.54	0.45	1.69e-7	Type 2 diabetes;
TGCT	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg26513180	chr16:89883248	FANCA	1.05	13.97	0.78	3.22e-27	Vitiligo;
TGCT	cis	rs60871478	0.786	rs55899111	chr7:827843	C/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	-0.48	-4.56	-0.38	1.22e-5	Cerebrospinal P-tau181p levels;
TGCT	cis	rs7940866	0.874	rs1433979	chr11:130871617	G/A	cg12179176	chr11:130786555	SNX19	0.47	4.56	0.38	1.22e-5	Schizophrenia;
TGCT	cis	rs60843830	1.000	rs3791220	chr2:227066	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.72	6.94	0.53	1.91e-10	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg10295955	chr4:187884368	NA	-1.0	-14.26	-0.79	6.69e-28	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7267979	0.966	rs3827014	chr20:25371559	C/T	cg03522245	chr20:25566470	NINL	-0.63	-6.71	-0.52	6.13e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2235642	0.821	rs2281234	chr16:1602938	A/G	cg00463982	chr16:1583984	IFT140;TMEM204	-0.29	-5.06	-0.41	1.46e-6	Coronary artery disease;
TGCT	cis	rs6032067	0.636	rs6104092	chr20:43906730	A/G	cg16667508	chr20:43936853	MATN4;RBPJL	0.44	6.99	0.53	1.48e-10	Blood protein levels;
TGCT	cis	rs12477438	0.520	rs720229	chr2:99704273	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	14.33	0.79	4.57e-28	Chronic sinus infection;
TGCT	cis	rs3812831	0.643	rs7322339	chr13:114929726	C/A	cg06611532	chr13:114900021	NA	0.37	6.85	0.52	3.08e-10	Schizophrenia;
TGCT	cis	rs3026101	0.599	rs1058381	chr17:5288018	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	4.63	0.38	9.15e-6	Body mass index;
TGCT	cis	rs9372498	0.536	rs72952761	chr6:118866758	A/C	cg07617317	chr6:118971624	C6orf204	0.52	5.55	0.45	1.69e-7	Diastolic blood pressure;
TGCT	cis	rs7044106	0.791	rs10818473	chr9:123484155	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	6.92	0.53	2.14e-10	Hip circumference adjusted for BMI;
TGCT	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	9.52	0.65	1.86e-16	Platelet count;
TGCT	cis	rs2204008	0.628	rs10876106	chr12:37990767	A/G	cg26384229	chr12:38710491	ALG10B	0.85	7.77	0.57	2.56e-12	Bladder cancer;
TGCT	cis	rs9394841	0.667	rs1891453	chr6:41765265	T/C	cg08135965	chr6:41755394	TOMM6	0.55	5.15	0.42	9.77e-7	Mean corpuscular hemoglobin;Red cell distribution width;
TGCT	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg24846343	chr22:24311635	DDTL	-0.21	-4.74	-0.39	5.69e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9467773	1.000	rs9467787	chr6:26556769	G/T	cg15659132	chr6:26577336	NA	0.9	13.19	0.76	2.26e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs35306767	0.716	rs34487581	chr10:897201	G/A	cg20503657	chr10:835505	NA	0.77	11.34	0.71	6.95e-21	Eosinophil percentage of granulocytes;
TGCT	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg03709012	chr19:19516395	GATAD2A	-0.66	-5.7	-0.46	8.46e-8	Tonsillectomy;
TGCT	cis	rs2742234	0.910	rs2505505	chr10:43648221	G/T	cg02780029	chr10:43622663	RET	-0.26	-5.05	-0.41	1.57e-6	Hirschsprung disease;
TGCT	cis	rs7829975	0.623	rs7010753	chr8:8373956	A/G	cg08975724	chr8:8085496	FLJ10661	0.58	5.42	0.44	2.99e-7	Mood instability;
TGCT	cis	rs1044826	0.692	rs295484	chr3:139231782	A/G	cg00490450	chr3:139108681	COPB2	-0.52	-4.6	-0.38	1.04e-5	Obesity-related traits;
TGCT	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg05985448	chr10:134359359	INPP5A	0.22	4.82	0.4	4.12e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs1878931	0.624	rs27235	chr16:3439138	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.77	-6.51	-0.5	1.66e-9	Body mass index (adult);
TGCT	cis	rs3733585	0.673	rs4697914	chr4:9952266	G/A	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.65	-0.57	4.78e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs4722166	0.603	rs7801406	chr7:22788274	A/G	cg26061582	chr7:22766209	IL6	0.58	7.34	0.55	2.49e-11	Lung cancer;
TGCT	cis	rs11098499	0.909	rs7659501	chr4:120371552	G/T	cg09307838	chr4:120376055	NA	0.68	6.53	0.51	1.54e-9	Corneal astigmatism;
TGCT	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg11644478	chr21:40555479	PSMG1	1.0	10.38	0.68	1.5e-18	Cognitive function;
TGCT	cis	rs9787249	0.915	rs6664570	chr1:40206298	G/A	cg20968010	chr1:40505947	CAP1	-0.53	-5.0	-0.41	1.91e-6	Blood protein levels;
TGCT	cis	rs6570726	0.791	rs11155435	chr6:145938545	T/C	cg13319975	chr6:146136371	FBXO30	-0.53	-4.75	-0.39	5.62e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg11062466	chr8:58055876	NA	0.44	4.62	0.38	9.46e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs3087591	0.887	rs7503395	chr17:29440554	C/T	cg24425628	chr17:29625626	OMG;NF1	0.46	7.17	0.54	6.01e-11	Hip circumference;
TGCT	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg09060608	chr5:178986726	RUFY1	-0.47	-5.4	-0.44	3.22e-7	Lung cancer;
TGCT	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.7	6.33	0.49	4.02e-9	Tonsillectomy;
TGCT	cis	rs950027	0.620	rs35861938	chr15:45637343	T/C	cg14582100	chr15:45693742	SPATA5L1	0.47	6.02	0.48	1.8e-8	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs13401104	0.587	rs6431443	chr2:237150311	T/C	cg19324714	chr2:237145437	ASB18	0.44	4.62	0.38	9.29e-6	Educational attainment;
TGCT	cis	rs2120019	0.938	rs3850093	chr15:75318482	A/G	cg17294928	chr15:75287854	SCAMP5	0.8	5.92	0.47	3e-8	Blood trace element (Zn levels);
TGCT	cis	rs7000551	0.505	rs73227818	chr8:22243325	T/C	cg12081754	chr8:22256438	SLC39A14	0.32	4.58	0.38	1.09e-5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs9807989	0.811	rs11688559	chr2:102969913	C/T	cg09003973	chr2:102972529	NA	0.64	5.7	0.46	8.28e-8	Asthma;
TGCT	cis	rs12286929	0.637	rs34138164	chr11:115050127	A/G	cg04017736	chr11:115827165	NA	-0.2	-4.6	-0.38	1.04e-5	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg12311346	chr5:56204834	C5orf35	-0.67	-6.82	-0.52	3.63e-10	Initial pursuit acceleration;
TGCT	cis	rs58950470	0.521	rs7950197	chr11:65446126	T/C	cg27068330	chr11:65405492	SIPA1	-0.51	-4.67	-0.39	7.86e-6	Schizophrenia;
TGCT	cis	rs797680	0.891	rs4847399	chr1:93584606	G/A	cg17826107	chr1:92977322	EVI5	-0.23	-5.12	-0.42	1.14e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs1580019	0.922	rs34545272	chr7:32460630	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.78	7.39	0.55	1.9e-11	Cognitive ability;
TGCT	cis	rs6088580	0.634	rs6059887	chr20:33101102	C/G	cg08999081	chr20:33150536	PIGU	0.29	5.57	0.45	1.54e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs7647973	0.560	rs7638154	chr3:49299375	C/A	cg03060546	chr3:49711283	APEH	0.53	5.14	0.42	1.05e-6	Menarche (age at onset);
TGCT	cis	rs11148252	0.904	rs9568734	chr13:53004222	G/A	cg00495681	chr13:53174319	NA	0.59	6.08	0.48	1.39e-8	Lewy body disease;
TGCT	cis	rs7267979	0.586	rs1473695	chr20:25186965	A/G	cg03522245	chr20:25566470	NINL	0.5	5.24	0.43	6.66e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11098499	0.909	rs6842762	chr4:120398236	A/T	cg09307838	chr4:120376055	NA	0.69	6.64	0.51	8.97e-10	Corneal astigmatism;
TGCT	cis	rs41271473	0.500	rs4440831	chr1:228887522	C/T	cg10167378	chr1:228756711	NA	-0.56	-4.83	-0.4	3.93e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs908922	0.676	rs1856120	chr1:152512441	G/A	cg20991723	chr1:152506922	NA	0.46	6.18	0.48	8.66e-9	Hair morphology;
TGCT	cis	rs9388451	0.807	rs1268070	chr6:126041164	A/G	cg10911889	chr6:126070802	HEY2	0.56	5.38	0.43	3.59e-7	Brugada syndrome;
TGCT	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.69	-7.06	-0.54	1.07e-10	Prostate cancer;
TGCT	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg11764359	chr7:65958608	NA	-0.54	-4.9	-0.4	2.99e-6	Aortic root size;
TGCT	cis	rs950027	0.620	rs1617634	chr15:45615578	A/G	cg14582100	chr15:45693742	SPATA5L1	0.48	6.08	0.48	1.35e-8	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.93	7.44	0.56	1.44e-11	Platelet count;
TGCT	cis	rs9303401	0.659	rs12940212	chr17:56674474	T/C	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs7647973	0.769	rs4974081	chr3:49070499	A/G	cg05785598	chr3:49045655	WDR6	-0.39	-4.52	-0.38	1.42e-5	Menarche (age at onset);
TGCT	cis	rs7582180	0.764	rs12615466	chr2:100924065	C/A	cg08017756	chr2:100939284	LONRF2	-0.32	-5.31	-0.43	4.86e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs68170813	0.523	rs7781947	chr7:106902219	A/G	cg02696742	chr7:106810147	HBP1	-0.69	-5.61	-0.45	1.27e-7	Coronary artery disease;
TGCT	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.64	-6.58	-0.51	1.21e-9	Prostate cancer;
TGCT	cis	rs921968	0.678	rs689116	chr2:219433888	C/A	cg02176678	chr2:219576539	TTLL4	0.38	5.48	0.44	2.31e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs41307935	0.730	rs12753968	chr1:27197363	C/T	cg23921621	chr1:27994728	IFI6	-0.42	-4.59	-0.38	1.06e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs637571	0.584	rs659824	chr11:65636509	A/G	cg26695010	chr11:65641043	EFEMP2	0.58	6.02	0.48	1.8e-8	Eosinophil percentage of white cells;
TGCT	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	6.18	0.49	8.58e-9	Bipolar disorder;
TGCT	cis	rs7474896	0.559	rs1024202	chr10:38278977	A/C	cg13720705	chr10:37990370	NA	-0.35	-4.73	-0.39	5.99e-6	Obesity (extreme);
TGCT	cis	rs11031096	0.782	rs10835684	chr11:4168308	G/T	cg18678763	chr11:4115507	RRM1	-0.46	-5.79	-0.46	5.36e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs62244186	0.683	rs6766334	chr3:44567065	T/C	cg25151919	chr3:44754333	ZNF502	-0.43	-4.96	-0.41	2.31e-6	Depressive symptoms;
TGCT	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.75	5.41	0.44	3.09e-7	Platelet count;
TGCT	cis	rs12549902	1.000	rs12550613	chr8:41510260	G/C	cg00088007	chr8:41504566	NKX6-3	0.34	5.38	0.43	3.59e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
TGCT	cis	rs6121246	0.567	rs6120937	chr20:30219721	C/T	cg21427119	chr20:30132790	HM13	-0.43	-6.17	-0.48	8.86e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg00024416	chr22:24240387	NA	0.35	5.93	0.47	2.79e-8	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs11577318	0.538	rs10902745	chr1:26687070	G/C	cg15090202	chr1:26687087	NA	0.58	4.49	0.37	1.64e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs2663905	0.664	rs2460855	chr15:81361729	G/T	cg09888468	chr15:81410853	NA	-0.62	-5.03	-0.41	1.68e-6	QT interval (drug interaction);
TGCT	cis	rs7666738	0.830	rs11097600	chr4:98959564	T/G	cg17366294	chr4:99064904	C4orf37	0.72	7.39	0.55	1.87e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs739496	0.527	rs4767074	chr12:112292962	G/C	cg10833066	chr12:111807467	FAM109A	0.38	5.61	0.45	1.24e-7	Platelet count;
TGCT	cis	rs7809950	1.000	rs10251808	chr7:107120453	G/A	cg23024343	chr7:107201750	COG5	-0.34	-5.33	-0.43	4.54e-7	Coronary artery disease;
TGCT	cis	rs1348850	0.914	rs1453370	chr2:178327727	C/T	cg22681709	chr2:178499509	PDE11A	-0.35	-4.6	-0.38	1.01e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs9457247	0.905	rs444210	chr6:167390242	A/G	cg23791538	chr6:167370224	RNASET2	-0.51	-4.93	-0.4	2.63e-6	Crohn's disease;
TGCT	cis	rs34526934	0.566	rs1374325	chr2:177043971	G/A	cg26754761	chr2:177040938	NA	-0.29	-5.39	-0.44	3.35e-7	Obstructive sleep apnea trait (apnea hypopnea index);
TGCT	cis	rs6770219	0.516	rs11922843	chr3:186135875	T/C	cg20306810	chr3:186501757	SNORD2;EIF4A2	0.73	4.45	0.37	1.89e-5	Cerebrospinal T-tau levels;
TGCT	cis	rs9611565	0.694	rs9611591	chr22:41830212	G/A	cg06634786	chr22:41940651	POLR3H	0.82	7.92	0.58	1.16e-12	Vitiligo;
TGCT	cis	rs1670533	0.929	rs6599280	chr4:1063818	A/G	cg20887711	chr4:1340912	KIAA1530	0.69	5.54	0.45	1.72e-7	Recombination rate (females);
TGCT	cis	rs1887596	0.554	rs4770995	chr13:27112522	C/T	cg01312412	chr13:27282625	NA	0.26	4.54	0.38	1.3e-5	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg26818010	chr10:134567672	INPP5A	-0.39	-5.51	-0.44	1.94e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs473651	0.935	rs541013	chr2:239336492	G/A	cg18131467	chr2:239335373	ASB1	1.03	15.25	0.81	3.21e-30	Multiple system atrophy;
TGCT	cis	rs231513	0.911	rs124719	chr17:41960343	T/C	cg26893861	chr17:41843967	DUSP3	-0.71	-5.33	-0.43	4.45e-7	Cognitive function;
TGCT	trans	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg17830980	chr10:43048298	ZNF37B	-0.86	-11.18	-0.71	1.68e-20	Extrinsic epigenetic age acceleration;
TGCT	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg03396347	chr1:1875803	NA	-0.4	-7.31	-0.55	2.86e-11	Body mass index;
TGCT	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg27211696	chr2:191398769	TMEM194B	-0.27	-5.07	-0.41	1.42e-6	Pulse pressure;
TGCT	cis	rs4824093	0.610	rs73443923	chr22:50285348	C/T	cg14114931	chr22:50943910	LMF2	0.41	4.98	0.41	2.09e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg21285383	chr16:89894308	SPIRE2	0.43	6.85	0.52	3e-10	Vitiligo;
TGCT	cis	rs4689388	0.926	rs4688987	chr4:6287329	C/T	cg00701064	chr4:6280414	WFS1	0.45	6.0	0.47	1.98e-8	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs514406	0.621	rs2003250	chr1:53196666	T/C	cg01802117	chr1:53393560	SCP2	0.42	4.92	0.4	2.69e-6	Monocyte count;
TGCT	cis	rs10114408	0.959	rs10821257	chr9:96657294	C/A	cg13679303	chr9:96623674	NA	-0.36	-4.73	-0.39	5.91e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	4.55	0.38	1.27e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9611565	0.545	rs5758432	chr22:42111693	T/C	cg06481639	chr22:41940642	POLR3H	0.71	6.35	0.5	3.62e-9	Vitiligo;
TGCT	cis	rs2952156	0.920	rs732083	chr17:37834367	G/A	cg20243544	chr17:37824526	PNMT	0.51	4.48	0.37	1.65e-5	Asthma;
TGCT	cis	rs9910055	0.920	rs2855818	chr17:42290015	G/A	cg13607699	chr17:42295918	UBTF	0.89	7.97	0.58	8.86e-13	Total body bone mineral density;
TGCT	cis	rs1541995	1.000	rs34567257	chr15:96304856	G/C	cg00882281	chr15:96346592	NA	0.29	4.68	0.39	7.26e-6	Photic sneeze reflex;
TGCT	cis	rs12291225	0.679	rs11023178	chr11:14310282	G/A	cg19336497	chr11:14380999	RRAS2	-0.38	-5.9	-0.47	3.23e-8	Sense of smell;
TGCT	cis	rs263156	0.967	rs263104	chr6:142875919	C/G	cg18419694	chr6:143832440	FUCA2	0.38	4.47	0.37	1.75e-5	Ear morphology;Lobe size;Lobe attachment;
TGCT	cis	rs9467711	0.606	rs35307327	chr6:26370474	C/T	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1532993	0.518	rs28408794	chr4:98625714	G/C	cg05340658	chr4:99064831	C4orf37	-0.37	-4.44	-0.37	1.98e-5	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs7043114	0.563	rs987554	chr9:95298738	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.53	-5.25	-0.43	6.26e-7	Height;
TGCT	cis	rs9902453	0.934	rs7213902	chr17:28322935	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.75	6.55	0.51	1.36e-9	Coffee consumption (cups per day);
TGCT	cis	rs7267979	0.789	rs2260197	chr20:25284343	T/C	cg03522245	chr20:25566470	NINL	0.52	5.23	0.43	6.85e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs67311347	0.955	rs73080163	chr3:40533061	G/T	cg13409248	chr3:40428643	ENTPD3	0.64	4.91	0.4	2.77e-6	Renal cell carcinoma;
TGCT	cis	rs916888	0.610	rs142167	chr17:44795234	C/T	cg15921436	chr17:44337874	NA	-0.4	-5.98	-0.47	2.23e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs35146811	0.695	rs858508	chr7:99821381	C/G	cg13334819	chr7:99746414	C7orf59	0.74	6.41	0.5	2.82e-9	Coronary artery disease;
TGCT	cis	rs7267979	0.932	rs417130	chr20:25458320	T/C	cg03522245	chr20:25566470	NINL	0.6	6.46	0.5	2.14e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg05985448	chr10:134359359	INPP5A	0.21	4.71	0.39	6.56e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs4891159	0.756	rs55763305	chr18:74161249	G/C	cg24786174	chr18:74118243	ZNF516	-0.48	-6.25	-0.49	5.97e-9	Longevity;
TGCT	cis	rs1552244	0.554	rs4488814	chr3:10002400	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	0.31	4.77	0.39	5.14e-6	Alzheimer's disease;
TGCT	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg14893161	chr1:205819251	PM20D1	0.56	7.96	0.58	9.21e-13	Menarche (age at onset);
TGCT	cis	rs7833790	0.724	rs6473309	chr8:82707880	A/G	cg23324259	chr8:82754387	SNX16	-0.66	-5.08	-0.41	1.36e-6	Diastolic blood pressure;
TGCT	cis	rs2153535	0.580	rs7741456	chr6:8452424	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.76	0.46	6.39e-8	Motion sickness;
TGCT	cis	rs6088580	0.634	rs6059829	chr20:33017074	G/A	cg24642439	chr20:33292090	TP53INP2	0.49	4.51	0.38	1.5e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs9527	0.545	rs12247514	chr10:104958066	C/A	cg15744005	chr10:104629667	AS3MT	-0.41	-4.78	-0.39	4.88e-6	Arsenic metabolism;
TGCT	cis	rs200810	0.694	rs13218275	chr6:97998314	C/T	cg16511841	chr6:97730490	C6orf167;MIR548H3	-0.65	-4.45	-0.37	1.91e-5	Body mass index;
TGCT	trans	rs17684571	0.938	rs13196211	chr6:56562495	C/T	cg14229071	chr15:89282588	NA	0.52	6.82	0.52	3.54e-10	Schizophrenia;
TGCT	cis	rs7246657	0.765	rs4803262	chr19:38066760	G/A	cg18154014	chr19:37997991	ZNF793	0.69	4.63	0.38	9.25e-6	Coronary artery calcification;
TGCT	cis	rs3764563	0.877	rs4646526	chr19:15729773	A/G	cg20725493	chr19:15740067	CYP4F8	-0.46	-5.06	-0.41	1.5e-6	Inflammatory biomarkers;
TGCT	cis	rs12893668	0.581	rs34843146	chr14:104079864	G/A	cg26031613	chr14:104095156	KLC1	-0.55	-4.64	-0.38	8.81e-6	Reticulocyte count;
TGCT	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg00814883	chr7:100076585	TSC22D4	-0.85	-8.62	-0.61	2.62e-14	Platelet count;
TGCT	cis	rs17152411	1.000	rs7097282	chr10:126593492	T/C	cg07906193	chr10:126599966	NA	0.42	5.28	0.43	5.6e-7	Height;
TGCT	cis	rs9796	0.804	rs28688742	chr15:41403638	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.52	-6.88	-0.53	2.64e-10	Menopause (age at onset);
TGCT	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg13342137	chr4:2252803	MXD4	0.17	4.59	0.38	1.07e-5	Obesity-related traits;
TGCT	cis	rs36051895	0.594	rs10115464	chr9:5144268	C/T	cg02405213	chr9:5042618	JAK2	-0.74	-10.39	-0.68	1.4e-18	Pediatric autoimmune diseases;
TGCT	trans	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg21659725	chr3:3221576	CRBN	0.98	15.33	0.81	2.1000000000000002e-30	Intelligence (multi-trait analysis);
TGCT	cis	rs7027203	0.790	rs10123836	chr9:96584109	G/T	cg13679303	chr9:96623674	NA	-0.66	-10.64	-0.69	3.54e-19	DNA methylation (variation);
TGCT	cis	rs7826238	0.543	rs2976908	chr8:8345774	T/G	cg15556689	chr8:8085844	FLJ10661	0.65	5.8	0.46	5.2100000000000003e-08	Systolic blood pressure;
TGCT	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg12963246	chr6:28129442	ZNF389	0.52	5.1	0.42	1.23e-6	Depression;
TGCT	cis	rs78487399	0.808	rs13419380	chr2:43739184	T/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.07	-0.41	1.41e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs9921222	1.000	rs9921222	chr16:375782	A/G	cg12437481	chr16:420112	MRPL28	0.48	5.09	0.42	1.29e-6	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs10789491	1.000	rs10749863	chr1:47174328	C/T	cg15501359	chr1:47185051	KIAA0494	0.81	8.37	0.6	9.97e-14	Response to hepatitis C treatment;
TGCT	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg14159672	chr1:205819179	PM20D1	0.6	7.44	0.56	1.45e-11	Menarche (age at onset);
TGCT	cis	rs707040	0.921	rs2037663	chr2:155231057	T/C	cg18104148	chr2:154337490	NA	0.19	4.63	0.38	9.05e-6	Sudden cardiac arrest;
TGCT	cis	rs9807989	0.507	rs4851579	chr2:103028984	G/A	cg03938978	chr2:103052716	IL18RAP	0.27	5.41	0.44	3.18e-7	Asthma;
TGCT	cis	rs4689388	0.926	rs4234730	chr4:6296343	A/G	cg14416269	chr4:6271139	WFS1	0.38	4.94	0.41	2.47e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs6582630	0.593	rs12816835	chr12:38533304	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-4.78	-0.39	4.9100000000000004e-06	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg20276088	chr3:133502917	NA	-0.24	-5.05	-0.41	1.53e-6	Iron status biomarkers;
TGCT	cis	rs2463822	0.925	rs74692811	chr11:62156572	G/A	cg23876832	chr11:62092739	NA	-0.63	-4.68	-0.39	7.29e-6	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs7312933	0.558	rs1796388	chr12:42785987	G/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.58	-5.69	-0.46	8.61e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.56	4.63	0.38	9.06e-6	Tonsillectomy;
TGCT	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg18402987	chr7:1209562	NA	0.74	6.19	0.49	7.92e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs3806843	0.551	rs246018	chr5:140335043	T/C	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	trans	rs2469997	0.925	rs2470005	chr8:120358483	T/G	cg01792902	chr3:178864926	PIK3CA	0.83	6.77	0.52	4.49e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg06108461	chr20:60628389	TAF4	-0.61	-8.83	-0.62	8.24e-15	Body mass index;
TGCT	cis	rs9427116	0.840	rs9427113	chr1:154626477	A/G	cg17218026	chr1:154582156	ADAR	0.26	6.24	0.49	6.39e-9	Blood protein levels;
TGCT	cis	rs1865760	0.593	rs9393676	chr6:25936944	G/A	cg03517284	chr6:25882590	NA	-0.47	-4.73	-0.39	5.95e-6	Height;
TGCT	cis	rs6981523	0.566	rs34162231	chr8:11003088	A/T	cg21775007	chr8:11205619	TDH	-0.58	-5.41	-0.44	3.09e-7	Neuroticism;
TGCT	cis	rs6089584	0.821	rs4925332	chr20:60604639	C/T	cg13665807	chr20:60559372	TAF4	-0.43	-4.66	-0.39	7.92e-6	Body mass index;
TGCT	cis	rs7208859	0.623	rs216445	chr17:28933576	A/G	cg14008862	chr17:28927542	LRRC37B2	0.88	5.32	0.43	4.75e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	trans	rs17685	0.753	rs10264760	chr7:75749694	A/G	cg19862616	chr7:65841803	NCRNA00174	0.52	9.01	0.63	3.02e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs7044106	0.708	rs1324472	chr9:123375110	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	4.61	0.38	9.68e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg11494091	chr17:61959527	GH2	-0.53	-11.98	-0.73	1.94e-22	Prudent dietary pattern;
TGCT	cis	rs4820539	0.902	rs737846	chr22:23460669	A/G	cg14186256	chr22:23484241	RTDR1	0.99	12.45	0.75	1.36e-23	Bone mineral density;
TGCT	cis	rs7575217	0.767	rs62152486	chr2:101745835	A/C	cg12737833	chr2:101500543	NPAS2	0.28	4.58	0.38	1.09e-5	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
TGCT	trans	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.85	8.89	0.62	6.01e-15	Body mass index;
TGCT	cis	rs854765	0.929	rs854766	chr17:18012775	A/G	cg09796270	chr17:17721594	SREBF1	0.27	5.31	0.43	4.87e-7	Total body bone mineral density;
TGCT	cis	rs7917772	0.636	rs4919676	chr10:104524352	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.56	-4.59	-0.38	1.07e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg20887711	chr4:1340912	KIAA1530	0.85	7.27	0.55	3.48e-11	Longevity;
TGCT	cis	rs12701220	0.894	rs10257744	chr7:1045612	C/T	cg07217954	chr7:1067459	C7orf50	-0.48	-4.75	-0.39	5.49e-6	Bronchopulmonary dysplasia;
TGCT	cis	rs7824557	0.767	rs718427	chr8:11139038	C/G	cg21775007	chr8:11205619	TDH	0.6	5.65	0.45	1.03e-7	Retinal vascular caliber;
TGCT	trans	rs1005277	0.691	rs2474558	chr10:38486141	A/C	cg17830980	chr10:43048298	ZNF37B	0.71	6.94	0.53	1.89e-10	Extrinsic epigenetic age acceleration;
TGCT	cis	rs6087990	0.735	rs1040554	chr20:31380073	C/T	cg13636640	chr20:31349939	DNMT3B	0.97	13.01	0.76	6.33e-25	Ulcerative colitis;
TGCT	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg13665807	chr20:60559372	TAF4	-0.53	-5.41	-0.44	3.06e-7	Body mass index;
TGCT	cis	rs10875746	0.859	rs11168371	chr12:48437686	C/T	cg20731937	chr12:48336164	NA	0.57	4.48	0.37	1.69e-5	Longevity (90 years and older);
TGCT	cis	rs7172809	0.599	rs2307141	chr15:77756418	A/G	cg22256960	chr15:77711686	NA	-0.51	-4.86	-0.4	3.47e-6	Glucose homeostasis traits;
TGCT	cis	rs4951018	0.821	rs7529037	chr1:205637501	C/G	cg26354017	chr1:205819088	PM20D1	-0.4	-4.72	-0.39	6.23e-6	Prostate-specific antigen levels;
TGCT	trans	rs629535	0.814	rs651985	chr8:70054966	G/A	cg21567404	chr3:27674614	NA	0.57	8.62	0.61	2.68e-14	Dupuytren's disease;
TGCT	cis	rs4273100	1.000	rs868698	chr17:19185211	G/T	cg01534423	chr17:18965556	NA	0.91	6.0	0.47	2.05e-8	Schizophrenia;
TGCT	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg15674680	chr20:60982522	CABLES2	-0.62	-5.21	-0.42	7.68e-7	Colorectal cancer;
TGCT	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg08859206	chr1:53392774	SCP2	-0.46	-6.97	-0.53	1.62e-10	Monocyte count;
TGCT	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg02038168	chr22:39784481	NA	-0.76	-6.36	-0.5	3.47e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs1580019	0.534	rs13237495	chr7:32560687	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.14	14.68	0.8	6.88e-29	Cognitive ability;
TGCT	cis	rs10493773	0.775	rs12739713	chr1:86150378	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.43	-6.07	-0.48	1.47e-8	Urate levels in overweight individuals;
TGCT	cis	rs7904368	0.901	rs7923189	chr10:16850214	C/T	cg14835575	chr10:16859367	RSU1	0.63	6.79	0.52	4.07e-10	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
TGCT	cis	rs1385374	1.000	rs1385374	chr12:129300694	C/T	cg09035930	chr12:129282057	SLC15A4	-0.55	-4.76	-0.39	5.27e-6	Systemic lupus erythematosus;
TGCT	cis	rs11874712	0.965	rs8085444	chr18:43652203	G/A	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	5.16	0.42	9.44e-7	Migraine - clinic-based;
TGCT	cis	rs601339	0.938	rs1696345	chr12:123183060	T/G	cg11919336	chr12:123188078	GPR109A	0.64	7.74	0.57	3.07e-12	Adiponectin levels;
TGCT	cis	rs10465746	0.935	rs12406984	chr1:84416215	C/G	cg10977910	chr1:84465055	TTLL7	0.63	6.25	0.49	5.95e-9	Obesity-related traits;
TGCT	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg14893161	chr1:205819251	PM20D1	0.57	8.17	0.59	2.97e-13	Menarche (age at onset);
TGCT	cis	rs317689	0.690	rs317630	chr12:69637847	T/C	cg14784868	chr12:69753453	YEATS4	0.54	4.46	0.37	1.84e-5	Response to diuretic therapy;
TGCT	cis	rs60843830	0.928	rs2306060	chr2:230912	A/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.75	7.17	0.54	5.87e-11	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	5.25	0.43	6.47e-7	Height;
TGCT	cis	rs7666738	0.800	rs7684523	chr4:98983175	G/T	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs344364	0.511	rs1742462	chr16:1946062	A/C	cg26617929	chr16:1858877	NA	-0.27	-4.9	-0.4	2.99e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs4788570	0.615	rs1058750	chr16:71679057	C/T	cg06353428	chr16:71660113	MARVELD3	1.54	12.33	0.74	2.73e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs72781680	0.821	rs72796369	chr2:24162663	G/T	cg08917208	chr2:24149416	ATAD2B	0.74	4.66	0.39	7.9e-6	Lymphocyte counts;
TGCT	cis	rs2180341	0.960	rs7751865	chr6:127683040	G/A	cg24812749	chr6:127587940	RNF146	0.93	7.4	0.55	1.83e-11	Breast cancer;
TGCT	cis	rs7940866	0.845	rs1991899	chr11:130801649	C/T	cg05962950	chr11:130786565	SNX19	-0.63	-6.38	-0.5	3.13e-9	Schizophrenia;
TGCT	cis	rs8078723	1.000	rs3213762	chr17:38178627	A/G	cg17467752	chr17:38218738	THRA	0.52	4.94	0.41	2.47e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs1903068	1.000	rs9312658	chr4:56005526	C/A	cg16572876	chr4:56024045	NA	0.46	5.23	0.42	7.13e-7	Endometriosis;
TGCT	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg16325326	chr1:53192061	ZYG11B	-0.71	-8.81	-0.62	9.22e-15	Monocyte count;
TGCT	cis	rs561341	0.739	rs7213369	chr17:30211878	G/A	cg13647721	chr17:30228624	UTP6	-0.61	-4.8	-0.4	4.39e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs763121	0.853	rs35565791	chr22:39063011	C/A	cg06022373	chr22:39101656	GTPBP1	0.77	7.57	0.56	7.47e-12	Menopause (age at onset);
TGCT	cis	rs6700896	0.500	rs4655564	chr1:66083537	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.59	4.56	0.38	1.22e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs453301	0.606	rs7462373	chr8:8899318	G/C	cg06636001	chr8:8085503	FLJ10661	-0.7	-5.86	-0.47	3.9e-8	Joint mobility (Beighton score);
TGCT	cis	rs6429082	0.715	rs2291687	chr1:235594182	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.54	-4.77	-0.39	5.07e-6	Adiposity;
TGCT	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg03264133	chr6:25882463	NA	-0.68	-7.58	-0.56	7e-12	Blood metabolite levels;
TGCT	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs3099143	0.901	rs78020233	chr15:77107050	T/G	cg21673338	chr15:77095150	SCAPER	-0.48	-4.47	-0.37	1.77e-5	Recalcitrant atopic dermatitis;
TGCT	cis	rs644799	0.562	rs1254989	chr11:95508121	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.58	6.24	0.49	6.43e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs514406	0.505	rs425520	chr1:53179805	C/G	cg01802117	chr1:53393560	SCP2	-0.4	-4.75	-0.39	5.55e-6	Monocyte count;
TGCT	cis	rs9913156	0.894	rs35741745	chr17:4620897	A/G	cg19197139	chr17:4613644	ARRB2	0.86	7.84	0.58	1.73e-12	Lymphocyte counts;
TGCT	cis	rs2932538	0.922	rs6663922	chr1:113095948	T/C	cg22162597	chr1:113214053	CAPZA1	0.25	5.5	0.44	2.06e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs7666738	0.791	rs60028147	chr4:99046618	G/A	cg05340658	chr4:99064831	C4orf37	0.52	5.94	0.47	2.68e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4689388	0.889	rs13128674	chr4:6294517	C/T	cg00701064	chr4:6280414	WFS1	0.37	4.72	0.39	6.3e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs2204008	0.837	rs73112346	chr12:38357606	C/T	cg26384229	chr12:38710491	ALG10B	0.83	7.25	0.55	4e-11	Bladder cancer;
TGCT	cis	rs7100689	0.577	rs1417219	chr10:82041409	C/T	cg01528321	chr10:82214614	TSPAN14	0.7	6.78	0.52	4.43e-10	Post bronchodilator FEV1;
TGCT	cis	rs6500602	0.727	rs8051389	chr16:4570570	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.32	5.95	0.47	2.54e-8	Schizophrenia;
TGCT	cis	rs2887571	1.000	rs4283041	chr12:1637913	C/T	cg01940102	chr12:1095972	NA	0.24	4.7	0.39	6.93e-6	Bone mineral density;
TGCT	cis	rs10465746	0.725	rs10127737	chr1:84368642	G/A	cg10977910	chr1:84465055	TTLL7	0.68	6.7	0.52	6.46e-10	Obesity-related traits;
TGCT	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg17328964	chr8:145687451	CYHR1	0.45	6.21	0.49	7.44e-9	Age at first birth;
TGCT	cis	rs7833790	0.660	rs10091077	chr8:82705464	A/G	cg27398817	chr8:82754497	SNX16	-0.6	-4.67	-0.39	7.62e-6	Diastolic blood pressure;
TGCT	cis	rs9611565	0.879	rs4820437	chr22:41761290	T/C	cg03806693	chr22:41940476	POLR3H	-1.02	-11.06	-0.7	3.31e-20	Vitiligo;
TGCT	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.51	4.48	0.37	1.68e-5	Prudent dietary pattern;
TGCT	cis	rs12142240	0.698	rs7515284	chr1:46809419	A/G	cg00530320	chr1:46809349	NSUN4	0.29	5.88	0.47	3.63e-8	Menopause (age at onset);
TGCT	cis	rs9467773	0.620	rs9461275	chr6:26590801	C/T	cg09904177	chr6:26538194	HMGN4	0.67	6.32	0.49	4.25e-9	Intelligence (multi-trait analysis);
TGCT	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg07870213	chr5:140052090	DND1	0.67	7.91	0.58	1.22e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7584330	0.910	rs6737914	chr2:238393434	A/G	cg16989719	chr2:238392110	NA	-0.26	-4.53	-0.38	1.35e-5	Prostate cancer;
TGCT	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg07167872	chr1:205819463	PM20D1	0.53	6.71	0.52	6.24e-10	Monocyte percentage of white cells;
TGCT	cis	rs2180341	1.000	rs6910763	chr6:127630925	T/C	cg24812749	chr6:127587940	RNF146	0.98	7.64	0.57	5.06e-12	Breast cancer;
TGCT	cis	rs6933660	0.646	rs9383899	chr6:151781022	G/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.73	7.65	0.57	4.75e-12	Menarche (age at onset);
TGCT	cis	rs78707713	0.512	rs35793747	chr10:71182165	A/G	cg12610070	chr10:71211762	TSPAN15	-0.59	-6.87	-0.52	2.82e-10	Venous thromboembolism;
TGCT	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg10802521	chr3:52805072	NEK4	-0.78	-10.0	-0.67	1.26e-17	Bipolar disorder;
TGCT	cis	rs7474896	0.522	rs117157955	chr10:37984164	G/T	cg13720705	chr10:37990370	NA	0.34	5.0	0.41	1.89e-6	Obesity (extreme);
TGCT	cis	rs1992660	0.523	rs12697408	chr5:40348573	T/A	cg01087697	chr5:40835557	RPL37	0.52	4.7	0.39	6.92e-6	Crohn's disease;
TGCT	cis	rs9902453	0.845	rs12602426	chr17:28158815	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	7.17	0.54	5.79e-11	Coffee consumption (cups per day);
TGCT	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs3947	0.813	rs1293316	chr8:11690915	A/G	cg02840367	chr8:11660030	FDFT1	0.92	6.56	0.51	1.3e-9	Blood protein levels;
TGCT	cis	rs675531	0.574	rs9482835	chr6:128054748	C/G	cg11613741	chr6:127780352	KIAA0408;C6orf174	0.25	4.48	0.37	1.66e-5	Recalcitrant atopic dermatitis;
TGCT	trans	rs1814175	0.935	rs7482690	chr11:49648814	C/T	cg15704280	chr7:45808275	SEPT13	-0.61	-6.75	-0.52	5e-10	Height;
TGCT	trans	rs2243480	0.901	rs13237344	chr7:66022256	T/A	cg07424592	chr7:64974309	NA	1.3	8.23	0.59	2.19e-13	Diabetic kidney disease;
TGCT	cis	rs1682825	0.858	rs76037015	chr3:10761118	G/A	cg23512531	chr3:10780469	NA	0.62	4.53	0.38	1.36e-5	Economic and political preferences (feminism/equality);
TGCT	cis	rs3733585	0.699	rs28610447	chr4:9971517	T/C	cg00071950	chr4:10020882	SLC2A9	-0.57	-6.83	-0.52	3.41e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs4253772	0.592	rs1807600	chr22:46644640	A/G	cg09491104	chr22:46646882	C22orf40	-0.51	-5.43	-0.44	2.86e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs9896933	0.832	rs77512810	chr17:80804589	C/T	cg20578329	chr17:80767326	TBCD	-0.35	-4.99	-0.41	1.99e-6	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
TGCT	cis	rs2180341	0.842	rs9375492	chr6:127545492	C/T	cg24812749	chr6:127587940	RNF146	-0.89	-6.27	-0.49	5.61e-9	Breast cancer;
TGCT	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg23708337	chr7:1209742	NA	0.64	5.94	0.47	2.63e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs12477438	1.000	rs6732980	chr2:99921613	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.8	-6.4	-0.5	2.91e-9	Chronic sinus infection;
TGCT	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg03303774	chr4:1407052	NA	0.3	4.74	0.39	5.73e-6	Obesity-related traits;
TGCT	cis	rs6582630	0.562	rs35080195	chr12:38310866	G/A	cg26384229	chr12:38710491	ALG10B	-0.54	-4.67	-0.39	7.55e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg11890956	chr21:40555474	PSMG1	-0.7	-6.8	-0.52	3.87e-10	Menarche (age at onset);
TGCT	cis	rs7666738	0.830	rs1426672	chr4:98923984	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6076065	0.748	rs1016628	chr20:23398738	C/G	cg11657817	chr20:23433608	CST11	-0.31	-5.47	-0.44	2.42e-7	Facial morphology (factor 15, philtrum width);
TGCT	cis	rs6121246	0.523	rs6060286	chr20:30197663	C/A	cg13852791	chr20:30311386	BCL2L1	0.7	4.58	0.38	1.1e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs12142240	0.698	rs3991877	chr1:46853749	C/A	cg14993813	chr1:46806288	NSUN4	-0.59	-4.86	-0.4	3.45e-6	Menopause (age at onset);
TGCT	cis	rs8179	0.700	rs42041	chr7:92246744	C/G	cg15732164	chr7:92237376	CDK6	-0.29	-5.01	-0.41	1.84e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
TGCT	cis	rs6460942	0.915	rs7803056	chr7:12306913	A/C	cg06484146	chr7:12443880	VWDE	-0.45	-4.68	-0.39	7.41e-6	Coronary artery disease;
TGCT	cis	rs2486288	0.656	rs12910009	chr15:45572408	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.79	-7.73	-0.57	3.24e-12	Glomerular filtration rate;
TGCT	cis	rs7705042	0.686	rs10068466	chr5:141524612	C/T	cg07392085	chr5:141489673	NDFIP1	-0.34	-4.57	-0.38	1.15e-5	Asthma;
TGCT	cis	rs933688	1.000	rs12651840	chr5:90729592	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.97	8.61	0.61	2.82e-14	Smoking behavior;
TGCT	cis	rs12477438	0.765	rs2309521	chr2:99592069	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-4.88	-0.4	3.17e-6	Chronic sinus infection;
TGCT	cis	rs4742903	0.868	rs4743684	chr9:106852385	A/C	cg21169611	chr9:106856078	SMC2	0.49	4.48	0.37	1.69e-5	High-grade serous ovarian cancer;Breast cancer;
TGCT	cis	rs4824093	0.535	rs73441802	chr22:50273916	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.5	5.14	0.42	1.05e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs9467773	1.000	rs9393728	chr6:26509330	C/G	cg26531700	chr6:26746687	NA	0.47	4.56	0.38	1.19e-5	Intelligence (multi-trait analysis);
TGCT	trans	rs62103177	0.673	rs55852342	chr18:77594109	G/C	cg05926928	chr17:57297772	GDPD1	1.04	9.91	0.66	2.12e-17	Opioid sensitivity;
TGCT	cis	rs7017914	0.934	rs13274062	chr8:71737087	G/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.55	-5.1	-0.42	1.24e-6	Bone mineral density;
TGCT	cis	rs9467711	0.659	rs3734542	chr6:26468326	G/A	cg16898833	chr6:26189333	HIST1H4D	1.13	5.05	0.41	1.56e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1371867	0.846	rs1788197	chr8:101290928	T/C	cg06636551	chr8:101224915	SPAG1	-0.43	-5.95	-0.47	2.58e-8	Atrioventricular conduction;
TGCT	trans	rs2469997	0.925	rs2447180	chr8:120355728	T/G	cg01792902	chr3:178864926	PIK3CA	0.78	6.66	0.51	7.93e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs1048238	0.506	rs598371	chr1:16212739	G/A	cg21385522	chr1:16154831	NA	-0.58	-6.36	-0.5	3.57e-9	Systolic blood pressure;
TGCT	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg07061783	chr6:25882402	NA	-0.41	-4.45	-0.37	1.89e-5	Height;
TGCT	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.7	6.33	0.49	4.02e-9	Tonsillectomy;
TGCT	cis	rs208520	0.690	rs176289	chr6:66766522	C/T	cg07460842	chr6:66804631	NA	-0.96	-10.32	-0.68	2.1e-18	Exhaled nitric oxide output;
TGCT	cis	rs3829109	0.564	rs11145889	chr9:139293843	A/G	cg13741927	chr9:139327495	INPP5E	-0.24	-5.18	-0.42	8.84e-7	Peak insulin response;Acute insulin response;
TGCT	cis	rs926938	0.563	rs360630	chr1:115415132	C/T	cg12756093	chr1:115239321	AMPD1	0.41	6.44	0.5	2.37e-9	Autism;
TGCT	trans	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg13615516	chr5:77269221	NA	0.72	9.16	0.64	1.36e-15	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg13607699	chr17:42295918	UBTF	-0.91	-8.08	-0.59	4.8e-13	Total body bone mineral density;
TGCT	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg22968622	chr17:43663579	NA	-0.99	-9.95	-0.67	1.71e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg10047753	chr17:41438598	NA	0.94	9.23	0.64	9.06e-16	Menopause (age at onset);
TGCT	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg22920501	chr2:26401640	FAM59B	0.81	6.36	0.5	3.52e-9	Gut microbiome composition (summer);
TGCT	cis	rs10875595	0.836	rs12187725	chr5:140662912	A/G	cg24830062	chr5:140700576	TAF7	-0.75	-6.28	-0.49	5.28e-9	Pulmonary function decline;
TGCT	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg22920501	chr2:26401640	FAM59B	0.81	6.36	0.5	3.52e-9	Gut microbiome composition (summer);
TGCT	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg04352962	chr1:209979756	IRF6	0.61	4.67	0.39	7.72e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs2836633	0.929	rs11702165	chr21:40035313	C/T	cg12884169	chr21:40033163	ERG	0.43	4.69	0.39	7.03e-6	Coronary artery disease;
TGCT	cis	rs7829975	0.577	rs940032	chr8:8546343	C/T	cg17143192	chr8:8559678	CLDN23	-0.52	-5.29	-0.43	5.45e-7	Mood instability;
TGCT	cis	rs2832191	0.967	rs2251377	chr21:30530599	T/C	cg08807101	chr21:30365312	RNF160	0.52	4.71	0.39	6.57e-6	Dental caries;
TGCT	trans	rs1814175	0.645	rs847639	chr11:49919603	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.51	-0.69	7.2e-19	Height;
TGCT	cis	rs73110464	0.609	rs11170348	chr12:53355588	A/G	cg16329197	chr12:53359506	NA	-0.56	-7.89	-0.58	1.32e-12	Cancer (pleiotropy);
TGCT	cis	rs7635838	0.684	rs346079	chr3:11328139	G/A	cg00170343	chr3:11313890	ATG7	0.62	6.09	0.48	1.28e-8	HDL cholesterol;
TGCT	cis	rs7666738	0.830	rs11947578	chr4:98930462	T/G	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7193541	0.684	rs4887783	chr16:74700743	G/C	cg01733217	chr16:74700730	RFWD3	1.02	14.66	0.8	7.69e-29	Multiple myeloma;
TGCT	cis	rs986417	1.000	rs1254332	chr14:60916587	T/C	cg27398547	chr14:60952738	C14orf39	-1.39	-10.61	-0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg25660036	chr4:7070649	GRPEL1	-0.67	-5.81	-0.46	4.85e-8	Monocyte percentage of white cells;
TGCT	cis	rs17221829	0.733	rs12421374	chr11:89381067	T/C	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.63	-0.38	9.04e-6	Anxiety in major depressive disorder;
TGCT	cis	rs7072216	0.763	rs10748729	chr10:100171371	G/C	cg26618903	chr10:100175079	PYROXD2	-0.4	-4.49	-0.37	1.64e-5	Metabolite levels;
TGCT	cis	rs13191362	1.000	rs13202339	chr6:163081812	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.91	6.97	0.53	1.69e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs6964587	1.000	rs17164275	chr7:91590408	A/G	cg22709100	chr7:91322751	NA	0.27	4.48	0.37	1.68e-5	Breast cancer;
TGCT	cis	rs11722228	1.000	rs4697695	chr4:9915850	C/T	cg00071950	chr4:10020882	SLC2A9	0.5	4.86	0.4	3.51e-6	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs2963155	0.518	rs2918419	chr5:142722353	T/C	cg17617527	chr5:142782415	NR3C1	0.84	6.18	0.49	8.6e-9	Breast cancer;
TGCT	cis	rs56114371	0.530	rs9357045	chr6:27688927	G/A	cg10876282	chr6:28092338	ZSCAN16	0.64	5.29	0.43	5.39e-7	Breast cancer;
TGCT	cis	rs7943191	0.810	rs7942154	chr11:62337163	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.59	5.99	0.47	2.11e-8	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg03188948	chr7:1209495	NA	0.45	5.85	0.47	4.04e-8	Longevity;Endometriosis;
TGCT	cis	rs950776	0.545	rs34275594	chr15:78981282	A/C	cg03762349	chr15:79060523	ADAMTS7	0.28	5.94	0.47	2.73e-8	Sudden cardiac arrest;
TGCT	cis	rs7552404	0.731	rs61770556	chr1:76421902	T/C	cg03433033	chr1:76189801	ACADM	0.73	6.67	0.51	7.74e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg11764359	chr7:65958608	NA	0.61	5.53	0.44	1.84e-7	Aortic root size;
TGCT	cis	rs666930	0.519	rs662602	chr1:120266903	C/G	cg19096424	chr1:120255104	PHGDH	0.62	5.63	0.45	1.17e-7	Breast cancer;
TGCT	cis	rs8077889	0.700	rs28571770	chr17:41904066	A/T	cg26893861	chr17:41843967	DUSP3	1.09	13.08	0.76	4.26e-25	Triglycerides;
TGCT	trans	rs116975820	0.698	rs11181503	chr12:42827697	A/G	cg26084949	chr14:75039090	LTBP2	-0.76	-6.74	-0.52	5.2400000000000005e-10	PR interval in Tripanosoma cruzi seropositivity;
TGCT	cis	rs651907	0.535	rs11712309	chr3:101519097	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	4.85	0.4	3.68e-6	Colorectal cancer;
TGCT	cis	rs60843830	0.633	rs1078763	chr2:113763	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	-0.53	-4.51	-0.38	1.47e-5	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	trans	rs1814175	0.817	rs10769618	chr11:49822336	A/G	cg15704280	chr7:45808275	SEPT13	-0.72	-8.14	-0.59	3.61e-13	Height;
TGCT	cis	rs644799	0.965	rs545342	chr11:95545369	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	10.57	0.69	5.17e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs2842992	0.830	rs1475123	chr6:160178007	A/G	cg11366901	chr6:160182831	ACAT2	1.01	6.79	0.52	4.21e-10	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs3845702	1.000	rs3738943	chr2:180846743	G/T	cg01881094	chr2:180872142	CWC22	-0.68	-6.01	-0.47	1.93e-8	Schizophrenia;
TGCT	cis	rs7714584	1.000	rs11749391	chr5:150229066	T/C	cg22134413	chr5:150180641	NA	0.83	6.53	0.51	1.54e-9	Crohn's disease;
TGCT	cis	rs3540	0.597	rs11639150	chr15:91042071	C/G	cg22089800	chr15:90895588	ZNF774	-0.75	-7.58	-0.56	6.96e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs2413583	0.591	rs75378967	chr22:39735210	T/G	cg24399712	chr22:39784796	NA	0.82	4.48	0.37	1.69e-5	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs67311347	1.000	rs2887995	chr3:40409029	C/G	cg17264618	chr3:40429014	ENTPD3	0.32	4.76	0.39	5.36e-6	Renal cell carcinoma;
TGCT	cis	rs4654899	0.865	rs6685831	chr1:21507888	G/A	cg01072550	chr1:21505969	NA	-0.48	-7.14	-0.54	7.03e-11	Superior frontal gyrus grey matter volume;
TGCT	cis	rs9443645	0.901	rs7742431	chr6:79679577	A/G	cg05283184	chr6:79620031	NA	-0.21	-4.74	-0.39	5.87e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1577917	0.958	rs1335442	chr6:86466692	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.43	-0.44	2.81e-7	Response to antipsychotic treatment;
TGCT	cis	rs12681288	0.862	rs2600493	chr8:1024970	A/G	cg04851639	chr8:1020857	NA	-0.4	-7.68	-0.57	4.17e-12	Schizophrenia;
TGCT	trans	rs3808502	0.563	rs12541800	chr8:11423072	A/G	cg15556689	chr8:8085844	FLJ10661	0.82	7.48	0.56	1.16e-11	Neuroticism;
TGCT	cis	rs8077577	0.895	rs3088233	chr17:18112675	C/T	cg09161412	chr17:18057145	MYO15A	-0.64	-5.22	-0.42	7.2e-7	Obesity-related traits;
TGCT	cis	rs727563	0.552	rs4822045	chr22:41985958	C/A	cg13695892	chr22:41940480	POLR3H	-0.87	-8.01	-0.58	6.94e-13	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs797680	0.964	rs12139009	chr1:93573493	A/G	cg17826107	chr1:92977322	EVI5	-0.22	-5.12	-0.42	1.12e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg11764359	chr7:65958608	NA	-0.57	-5.25	-0.43	6.43e-7	Aortic root size;
TGCT	cis	rs265548	0.538	rs36688	chr19:17911212	A/C	cg21960279	chr19:17905606	B3GNT3	0.49	5.73	0.46	7.21e-8	Tumor biomarkers;
TGCT	cis	rs4700695	0.534	rs152999	chr5:65213108	G/T	cg21114390	chr5:65439923	SFRS12	0.67	4.67	0.39	7.82e-6	Facial morphology (factor 19);
TGCT	cis	rs2742417	0.609	rs2673066	chr3:45771200	C/T	cg04837898	chr3:45731254	SACM1L	-0.67	-7.3	-0.55	3.06e-11	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs9818758	0.607	rs9850917	chr3:49286983	A/G	cg00383909	chr3:49044727	WDR6	1.28	6.57	0.51	1.23e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs9913156	0.793	rs72835643	chr17:4573612	G/A	cg00122941	chr17:4613640	ARRB2	0.89	7.52	0.56	9.78e-12	Lymphocyte counts;
TGCT	cis	rs2066819	1.000	rs59811639	chr12:56695954	C/T	cg26714650	chr12:56694279	CS	-1.36	-6.06	-0.48	1.54e-8	Psoriasis vulgaris;
TGCT	cis	rs854765	0.693	rs8079321	chr17:17760789	C/T	cg09796270	chr17:17721594	SREBF1	0.24	4.8	0.4	4.56e-6	Total body bone mineral density;
TGCT	cis	rs6121246	0.523	rs6060286	chr20:30197663	C/A	cg18721089	chr20:30220636	NA	-0.64	-6.86	-0.52	2.84e-10	Mean corpuscular hemoglobin;
TGCT	cis	rs8077889	0.956	rs4793025	chr17:41841621	T/C	cg26893861	chr17:41843967	DUSP3	1.08	13.44	0.77	5.71e-26	Triglycerides;
TGCT	cis	rs568617	0.953	rs1151519	chr11:65645831	G/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.57	-5.22	-0.42	7.39e-7	Crohn's disease;
TGCT	cis	rs9611565	0.559	rs132768	chr22:42013523	C/A	cg17554472	chr22:41940697	POLR3H	0.5	5.35	0.43	4.07e-7	Vitiligo;
TGCT	cis	rs7819412	0.505	rs67849263	chr8:11007544	G/T	cg21775007	chr8:11205619	TDH	-0.58	-5.4	-0.44	3.32e-7	Triglycerides;
TGCT	cis	rs8031584	0.706	rs2177670	chr15:31157751	G/T	cg14829155	chr15:31115871	NA	-0.36	-4.72	-0.39	6.14e-6	Huntington's disease progression;
TGCT	cis	rs6987853	0.933	rs1343875	chr8:42424749	C/T	cg20539142	chr8:42623718	CHRNA6	-0.21	-4.97	-0.41	2.13e-6	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs56104184	0.723	rs116909499	chr19:49407733	C/T	cg21252483	chr19:49399788	TULP2	-0.42	-5.89	-0.47	3.47e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg21724239	chr8:58056113	NA	0.52	5.47	0.44	2.37e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6683383	1.000	rs7555556	chr1:203090976	C/T	cg04395153	chr1:203052423	MYOG	-0.27	-4.58	-0.38	1.12e-5	Asthma;
TGCT	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg11494091	chr17:61959527	GH2	0.59	14.01	0.78	2.49e-27	Prudent dietary pattern;
TGCT	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg11247378	chr22:39784982	NA	-0.73	-9.59	-0.65	1.22e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs5417	0.788	rs2654185	chr17:7183362	G/T	cg25256661	chr17:7137939	DVL2	0.57	5.6	0.45	1.34e-7	Diastolic blood pressure;
TGCT	cis	rs2050392	0.544	rs598672	chr10:30742388	C/T	cg18806716	chr10:30721971	MAP3K8	-0.55	-6.73	-0.52	5.67e-10	Inflammatory bowel disease;
TGCT	cis	rs7666738	0.791	rs7665273	chr4:98997413	C/A	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.16e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs17001868	0.568	rs2280790	chr22:40745181	T/C	cg07138101	chr22:40742427	ADSL	0.74	5.52	0.44	1.92e-7	Mammographic density (dense area);
TGCT	cis	rs12681288	0.676	rs2701914	chr8:999935	C/T	cg04851639	chr8:1020857	NA	-0.32	-5.32	-0.43	4.74e-7	Schizophrenia;
TGCT	cis	rs6460942	1.000	rs111761262	chr7:12415916	T/C	cg06484146	chr7:12443880	VWDE	-0.59	-5.64	-0.45	1.1e-7	Coronary artery disease;
TGCT	cis	rs7223966	1.000	rs11871767	chr17:61698723	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	4.66	0.39	8.03e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg11301795	chr4:187892539	NA	-0.33	-5.11	-0.42	1.2e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7698623	0.850	rs6813016	chr4:88768808	T/C	cg02735620	chr4:88950514	PKD2	-0.44	-4.81	-0.4	4.28e-6	Cardiovascular disease risk factors;
TGCT	cis	rs1008375	1.000	rs4642241	chr4:17617111	T/C	cg16339924	chr4:17578868	LAP3	0.61	5.18	0.42	8.84e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2075371	1.000	rs447266	chr7:133989543	A/G	cg11752832	chr7:134001865	SLC35B4	0.7	6.44	0.5	2.39e-9	Mean platelet volume;
TGCT	cis	rs36051895	0.623	rs7023639	chr9:5244058	A/C	cg02405213	chr9:5042618	JAK2	-0.72	-8.76	-0.62	1.2e-14	Pediatric autoimmune diseases;
TGCT	cis	rs17345786	1.000	rs73863360	chr3:101316837	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.56	4.81	0.4	4.21e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6988636	0.710	rs62521799	chr8:124134987	G/A	cg27053337	chr8:124217698	FAM83A	0.79	4.85	0.4	3.65e-6	Urinary uromodulin levels;
TGCT	cis	rs2688608	0.618	rs28718766	chr10:75489844	C/A	cg19442545	chr10:75533431	FUT11	-0.37	-5.87	-0.47	3.81e-8	Inflammatory bowel disease;
TGCT	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	4.93	0.4	2.6e-6	Menopause (age at onset);
TGCT	cis	rs9534288	0.797	rs9534282	chr13:46588944	T/C	cg15192986	chr13:46630673	CPB2	-0.53	-7.62	-0.56	5.82e-12	Blood protein levels;
TGCT	cis	rs10744422	0.764	rs4038081	chr12:123292922	G/A	cg18912006	chr12:123335444	HIP1R	0.56	4.78	0.39	4.84e-6	Schizophrenia;
TGCT	cis	rs11676348	0.783	rs4674252	chr2:218984478	G/A	cg00012203	chr2:219082015	ARPC2	-0.52	-4.98	-0.41	2.08e-6	Ulcerative colitis;
TGCT	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg16414030	chr3:133502952	NA	-0.6	-8.73	-0.62	1.41e-14	Iron status biomarkers;
TGCT	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg18402987	chr7:1209562	NA	0.7	5.67	0.45	9.66e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1667284	1.000	rs1667283	chr18:29223621	C/T	cg15259973	chr18:29078565	DSG2	0.53	5.17	0.42	9.05e-7	Problematic alcohol use in trauma-exposed individuals;
TGCT	trans	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg25482853	chr8:67687455	SGK3	1.2	10.12	0.67	6.42e-18	Lung disease severity in cystic fibrosis;
TGCT	cis	rs838147	0.505	rs1688264	chr19:49209560	T/G	cg13540341	chr19:49222985	MAMSTR	-0.37	-4.98	-0.41	2.08e-6	Dietary macronutrient intake;
TGCT	cis	rs1421811	0.630	rs72740637	chr5:32710486	G/A	cg16267343	chr5:32710456	NPR3	0.83	7.14	0.54	7.02e-11	Blood pressure;
TGCT	cis	rs3026101	0.671	rs739768	chr17:5290703	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	4.57	0.38	1.16e-5	Body mass index;
TGCT	cis	rs7843479	0.930	rs4871903	chr8:21827833	C/T	cg17168535	chr8:21777572	XPO7	-0.62	-5.67	-0.45	9.37e-8	Mean corpuscular volume;
TGCT	cis	rs1215050	0.818	rs1214917	chr4:99080029	G/T	cg17366294	chr4:99064904	C4orf37	0.45	4.45	0.37	1.91e-5	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs4285028	0.699	rs1344279	chr3:121615679	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.75	-6.01	-0.48	1.89e-8	Multiple sclerosis;
TGCT	cis	rs2046867	0.661	rs9861834	chr3:72909272	C/T	cg25664220	chr3:72788482	NA	-0.44	-6.07	-0.48	1.47e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7513165	0.867	rs7524621	chr1:204160938	A/G	cg04791601	chr1:204159016	NA	-0.26	-5.05	-0.41	1.56e-6	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
TGCT	cis	rs2458413	0.542	rs2669451	chr8:105371096	C/A	cg04554929	chr8:105342491	NA	0.48	5.77	0.46	5.95e-8	Paget's disease;
TGCT	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg23131131	chr22:24373011	LOC391322	0.81	8.92	0.63	4.97e-15	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	trans	rs2832077	0.527	rs2738953	chr21:30238363	G/C	cg14791747	chr16:20752902	THUMPD1	-1.01	-10.54	-0.69	6.23e-19	Cognitive test performance;
TGCT	cis	rs2486012	0.649	rs37464	chr1:44284161	A/G	cg12908607	chr1:44402522	ARTN	-0.69	-5.2	-0.42	7.81e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs10193935	0.901	rs10174872	chr2:42459807	T/G	cg27598129	chr2:42591480	NA	-0.39	-5.15	-0.42	9.84e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9467711	0.591	rs34351439	chr6:25833010	T/C	cg16898833	chr6:26189333	HIST1H4D	1.21	5.94	0.47	2.64e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6598955	0.671	rs12116908	chr1:26587918	G/A	cg04990556	chr1:26633338	UBXN11	0.64	4.91	0.4	2.78e-6	Obesity-related traits;
TGCT	cis	rs10875746	0.951	rs4760689	chr12:48563644	G/A	cg20731937	chr12:48336164	NA	0.62	4.94	0.41	2.46e-6	Longevity (90 years and older);
TGCT	cis	rs59698941	0.943	rs17691584	chr5:132284251	A/C	cg27099455	chr5:132201840	GDF9;UQCRQ	0.37	4.47	0.37	1.74e-5	Apolipoprotein A-IV levels;
TGCT	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg03934478	chr11:495069	RNH1	0.35	5.89	0.47	3.34e-8	Body mass index;
TGCT	cis	rs9330316	0.506	rs56288075	chr2:110398506	A/G	cg03552103	chr2:110373002	SEPT10;ANKRD57	-0.4	-4.47	-0.37	1.76e-5	Schizophrenia;
TGCT	cis	rs904251	0.600	rs4714068	chr6:37455642	A/C	cg01843034	chr6:37503916	NA	-0.48	-6.23	-0.49	6.67e-9	Cognitive performance;
TGCT	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg11494091	chr17:61959527	GH2	-0.55	-12.26	-0.74	4.12e-23	Prudent dietary pattern;
TGCT	cis	rs35146811	0.735	rs2272344	chr7:99786819	C/T	cg04778012	chr7:99775508	STAG3;GPC2	0.35	4.93	0.41	2.55e-6	Coronary artery disease;
TGCT	cis	rs12681287	0.711	rs28420256	chr8:87255599	C/T	cg27223183	chr8:87520930	FAM82B	-0.8	-5.69	-0.46	8.66e-8	Caudate activity during reward;
TGCT	cis	rs12733856	0.906	rs4399167	chr1:221493176	A/G	cg16137147	chr1:221067896	NA	0.42	4.57	0.38	1.14e-5	Mortality in heart failure;
TGCT	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.61	5.06	0.41	1.5e-6	Tonsillectomy;
TGCT	cis	rs7552404	1.000	rs1498316	chr1:76159198	G/A	cg22875332	chr1:76189707	ACADM	0.79	9.77	0.66	4.68e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2050392	1.000	rs2265186	chr10:30691743	C/T	cg18806716	chr10:30721971	MAP3K8	0.41	4.84	0.4	3.77e-6	Inflammatory bowel disease;
TGCT	cis	rs10883723	0.810	rs6584504	chr10:104253507	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg03060546	chr3:49711283	APEH	0.54	5.13	0.42	1.11e-6	Menarche (age at onset);
TGCT	cis	rs453301	0.658	rs9650616	chr8:8869199	T/G	cg15556689	chr8:8085844	FLJ10661	-0.61	-4.98	-0.41	2.09e-6	Joint mobility (Beighton score);
TGCT	cis	rs12497850	1.000	rs12497850	chr3:48748989	G/T	cg18654377	chr3:49208889	KLHDC8B	-0.44	-6.06	-0.48	1.52e-8	Parkinson's disease;
TGCT	cis	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg25427524	chr10:38739819	LOC399744	-0.39	-8.05	-0.59	5.9e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs9911578	0.934	rs58092632	chr17:57111101	T/C	cg05425664	chr17:57184151	TRIM37	0.66	6.48	0.5	1.92e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7826238	0.623	rs2976893	chr8:8338219	G/T	cg06636001	chr8:8085503	FLJ10661	-0.6	-5.49	-0.44	2.13e-7	Systolic blood pressure;
TGCT	cis	rs1670533	0.932	rs13140571	chr4:1054358	T/C	cg20887711	chr4:1340912	KIAA1530	0.72	5.55	0.45	1.64e-7	Recombination rate (females);
TGCT	cis	rs13082711	0.522	rs586229	chr3:27354520	A/G	cg02860705	chr3:27208620	NA	0.33	5.37	0.43	3.67e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs709400	0.663	rs2273703	chr14:103918029	C/G	cg12935359	chr14:103987150	CKB	-0.35	-5.24	-0.43	6.66e-7	Body mass index;
TGCT	cis	rs2070488	0.699	rs13078966	chr3:38517914	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.77	7.53	0.56	9.03e-12	Electrocardiographic conduction measures;
TGCT	cis	rs910316	1.000	rs1043674	chr14:75549370	T/C	cg11812906	chr14:75593930	NEK9	0.74	7.38	0.55	1.97e-11	Height;
TGCT	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-5.1	-0.42	1.23e-6	Bipolar disorder;
TGCT	cis	rs12210905	0.920	rs72839469	chr6:27304539	G/A	cg08851530	chr6:28072375	NA	1.32	5.79	0.46	5.48e-8	Hip circumference adjusted for BMI;
TGCT	cis	rs9303401	0.659	rs2072316	chr17:56604813	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs7267979	0.586	rs6050431	chr20:25183908	C/T	cg16686733	chr20:25566563	NINL	0.53	5.43	0.44	2.9e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs72768842	0.808	rs72768807	chr5:78933644	G/A	cg24834873	chr5:79865402	ANKRD34B	-1.16	-4.61	-0.38	9.84e-6	Post bronchodilator FEV1/FVC ratio in COPD;
TGCT	cis	rs6570726	0.902	rs396681	chr6:145853603	T/C	cg23711669	chr6:146136114	FBXO30	0.7	6.88	0.53	2.56e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3096299	0.900	rs4785663	chr16:89434888	G/A	cg06640241	chr16:89574553	SPG7	0.66	6.51	0.5	1.71e-9	Multiple myeloma (IgH translocation);
TGCT	cis	rs11711311	1.000	rs11719303	chr3:113494524	A/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.79	-7.38	-0.55	2e-11	IgG glycosylation;
TGCT	cis	rs17345786	1.000	rs73863360	chr3:101316837	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.44	-9.59	-0.65	1.25e-16	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7824557	0.602	rs7816636	chr8:11205654	T/A	cg21775007	chr8:11205619	TDH	0.71	6.7	0.52	6.36e-10	Retinal vascular caliber;
TGCT	trans	rs17685	0.712	rs869805	chr7:75688596	C/T	cg19862616	chr7:65841803	NCRNA00174	0.52	8.84	0.62	7.72e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs12643440	0.538	rs6818238	chr4:17140193	C/T	cg22650099	chr4:17144496	NA	-0.46	-4.7	-0.39	6.79e-6	Metabolite levels (Pyroglutamine);
TGCT	cis	rs16975963	0.793	rs11666497	chr19:38464262	C/T	cg14550563	chr19:38990264	RYR1	0.28	4.58	0.38	1.09e-5	Longevity;
TGCT	cis	rs3617	0.573	rs9810807	chr3:52924227	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	0.51	4.97	0.41	2.21e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs137699	0.652	rs137706	chr22:39751400	T/G	cg01416388	chr22:39784598	NA	-0.59	-4.73	-0.39	6.08e-6	IgG glycosylation;
TGCT	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg07870213	chr5:140052090	DND1	0.68	8.26	0.6	1.83e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg05785598	chr3:49045655	WDR6	0.36	4.77	0.39	5.17e-6	Parkinson's disease;
TGCT	cis	rs317689	0.581	rs160829	chr12:69769538	G/C	cg20891283	chr12:69753455	YEATS4	0.65	5.74	0.46	6.91e-8	Response to diuretic therapy;
TGCT	cis	rs4862750	0.832	rs4862744	chr4:187877074	T/A	cg10295955	chr4:187884368	NA	-0.93	-12.48	-0.75	1.18e-23	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7027203	1.000	rs13288708	chr9:96509653	T/C	cg14598338	chr9:96623480	NA	0.57	7.82	0.57	1.97e-12	DNA methylation (variation);
TGCT	cis	rs992157	0.560	rs12992937	chr2:219087072	A/T	cg00012203	chr2:219082015	ARPC2	-0.81	-9.36	-0.64	4.37e-16	Colorectal cancer;
TGCT	cis	rs4722585	0.533	rs757371	chr7:26199207	A/G	cg07876897	chr7:26191696	NFE2L3	0.39	5.25	0.43	6.35e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
TGCT	cis	rs763014	0.931	rs2071981	chr16:630025	C/G	cg09263875	chr16:632152	PIGQ	0.3	6.4	0.5	2.88e-9	Height;
TGCT	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.55	4.92	0.4	2.74e-6	Prudent dietary pattern;
TGCT	cis	rs7226408	0.857	rs72888996	chr18:34580055	C/G	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs11578119	0.933	rs10919406	chr1:170419037	C/G	cg09767346	chr1:170501363	GORAB	0.71	5.69	0.46	8.66e-8	Male-pattern baldness;
TGCT	cis	rs2013441	1.000	rs2386429	chr17:20210809	G/A	cg23224458	chr17:20280056	CCDC144C	-0.41	-4.9	-0.4	2.98e-6	Obesity-related traits;
TGCT	cis	rs453301	0.686	rs6987107	chr8:8893581	A/G	cg15556689	chr8:8085844	FLJ10661	-0.62	-5.24	-0.43	6.69e-7	Joint mobility (Beighton score);
TGCT	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg07507251	chr3:52567010	NT5DC2	0.46	6.66	0.51	7.92e-10	Bipolar disorder;
TGCT	cis	rs2439831	1.000	rs2444029	chr15:43737484	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.01	8.37	0.6	1.02e-13	Lung cancer in ever smokers;
TGCT	trans	rs3790455	0.560	rs1171551	chr1:156472214	C/T	cg16443977	chr5:115884994	SEMA6A	-0.39	-6.86	-0.52	2.94e-10	Migraine;
TGCT	cis	rs7095607	1.000	rs7079481	chr10:69959242	C/A	cg18986048	chr10:69913749	MYPN	0.46	5.0	0.41	1.91e-6	Lung function (FVC);
TGCT	cis	rs6570726	0.791	rs6915094	chr6:145883540	C/G	cg23711669	chr6:146136114	FBXO30	0.89	9.93	0.67	1.82e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2760061	0.626	rs596675	chr1:228117892	G/A	cg18477163	chr1:228402036	OBSCN	-0.32	-6.37	-0.5	3.37e-9	Diastolic blood pressure;
TGCT	trans	rs561341	1.000	rs561341	chr17:30316385	T/G	cg20587970	chr11:113659929	NA	-1.04	-12.57	-0.75	6.97e-24	Hip circumference adjusted for BMI;
TGCT	cis	rs10779751	0.879	rs7543400	chr1:11283964	C/G	cg08854313	chr1:11322531	MTOR	0.92	10.06	0.67	9.08e-18	Body mass index;
TGCT	cis	rs922182	0.617	rs11852732	chr15:64239907	G/A	cg02919090	chr15:64263738	DAPK2	0.37	7.01	0.53	1.35e-10	Blood protein levels;
TGCT	cis	rs12602901	0.528	rs12601694	chr17:4980381	C/T	cg20814095	chr17:4802981	CHRNE;C17orf107	-0.51	-4.65	-0.39	8.39e-6	Blood metabolite levels;
TGCT	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg01341218	chr17:43662625	NA	0.84	7.62	0.56	5.79e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs4689388	0.926	rs3821940	chr4:6286711	C/A	cg25554036	chr4:6271136	WFS1	0.57	8.16	0.59	3.18e-13	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs3733585	0.699	rs6823361	chr4:9963127	A/G	cg11266682	chr4:10021025	SLC2A9	-0.57	-7.47	-0.56	1.23e-11	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs2932538	0.922	rs12402469	chr1:113076625	G/A	cg22162597	chr1:113214053	CAPZA1	0.28	5.98	0.47	2.26e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs3793917	0.948	rs3750847	chr10:124215421	C/T	cg09507567	chr10:124027408	NA	0.38	4.71	0.39	6.62e-6	Age-related macular degeneration;
TGCT	cis	rs9486719	0.948	rs2092095	chr6:96870864	T/G	cg06623918	chr6:96969491	KIAA0776	1.01	8.86	0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs801193	0.904	rs4718405	chr7:66254646	A/G	cg18876405	chr7:65276391	NA	0.39	5.8	0.46	5.07e-8	Aortic root size;
TGCT	cis	rs9916302	0.706	rs4794808	chr17:37531916	C/T	cg07936489	chr17:37558343	FBXL20	0.87	6.27	0.49	5.47e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs7681440	0.933	rs10005233	chr4:90743331	C/T	cg20003494	chr4:90757398	SNCA	-0.54	-5.04	-0.41	1.59e-6	Dementia with Lewy bodies;
TGCT	cis	rs3096299	0.719	rs2353581	chr16:89518908	T/C	cg06640241	chr16:89574553	SPG7	0.76	8.5	0.61	5.12e-14	Multiple myeloma (IgH translocation);
TGCT	cis	rs6669072	0.669	rs712031	chr1:91243395	A/G	cg08895590	chr1:91227319	NA	-0.35	-4.61	-0.38	1e-5	Cognitive function;
TGCT	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.31	-4.82	-0.4	4.12e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg04944784	chr2:26401820	FAM59B	-0.67	-6.16	-0.48	9.54e-9	Gut microbiome composition (summer);
TGCT	cis	rs617219	0.671	rs1316753	chr5:78531337	G/C	cg09550809	chr5:78407562	BHMT	0.37	5.25	0.43	6.49e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs7647973	1.000	rs1982861	chr3:49577665	A/G	cg06212747	chr3:49208901	KLHDC8B	0.54	4.45	0.37	1.87e-5	Menarche (age at onset);
TGCT	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg03161606	chr19:29218774	NA	0.55	5.86	0.47	3.91e-8	Methadone dose in opioid dependence;
TGCT	cis	rs1555895	0.656	rs4881532	chr10:845449	A/G	cg02193355	chr10:851439	NA	0.23	4.96	0.41	2.24e-6	Survival in rectal cancer;
TGCT	cis	rs4595586	0.525	rs4450203	chr12:39381493	T/G	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs317689	0.702	rs544696	chr12:69749939	T/C	cg11871910	chr12:69753446	YEATS4	0.62	5.48	0.44	2.3e-7	Response to diuretic therapy;
TGCT	cis	rs7095607	0.560	rs7095238	chr10:69913203	T/C	cg18986048	chr10:69913749	MYPN	0.52	5.78	0.46	5.75e-8	Lung function (FVC);
TGCT	cis	rs9911578	0.967	rs8082544	chr17:57185807	C/T	cg12560992	chr17:57184187	TRIM37	-0.79	-9.71	-0.66	6.56e-17	Intelligence (multi-trait analysis);
TGCT	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg10053473	chr17:62856997	LRRC37A3	0.4	6.71	0.52	6.33e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs10242455	0.702	rs76702117	chr7:98916779	A/G	cg13560068	chr7:99070416	ZNF789	1.1	4.68	0.39	7.38e-6	Blood metabolite levels;
TGCT	cis	rs7715806	0.500	rs4704233	chr5:75000792	G/A	cg19683494	chr5:74908142	NA	0.57	5.0	0.41	1.92e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs9914988	0.943	rs9898892	chr17:27150750	T/C	cg20469991	chr17:27169893	C17orf63	-0.72	-5.09	-0.42	1.28e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs78456975	0.628	rs13426896	chr2:1554768	C/T	cg01028140	chr2:1542097	TPO	-0.37	-5.32	-0.43	4.71e-7	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs2836974	0.965	rs8134733	chr21:40683459	C/T	cg17971929	chr21:40555470	PSMG1	0.98	8.77	0.62	1.16e-14	Cognitive function;
TGCT	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg26818010	chr10:134567672	INPP5A	-0.35	-4.56	-0.38	1.23e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs7826238	0.720	rs12546760	chr8:8374836	A/G	cg06636001	chr8:8085503	FLJ10661	-0.75	-6.99	-0.53	1.52e-10	Systolic blood pressure;
TGCT	cis	rs28595532	0.920	rs114210107	chr4:119734491	G/A	cg21605333	chr4:119757512	SEC24D	1.66	8.33	0.6	1.28e-13	Cannabis dependence symptom count;
TGCT	cis	rs854765	0.505	rs2955358	chr17:17946623	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.8	-8.44	-0.6	6.83e-14	Total body bone mineral density;
TGCT	cis	rs3820068	0.581	rs59991988	chr1:15950552	T/A	cg05660106	chr1:15850417	CASP9	0.86	8.48	0.61	5.53e-14	Systolic blood pressure;
TGCT	cis	rs1008375	1.000	rs2872959	chr4:17677163	G/A	cg18681998	chr4:17616180	MED28	-0.86	-8.6	-0.61	2.91e-14	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7769051	1.000	rs9399041	chr6:133096233	T/G	cg22852734	chr6:133119734	C6orf192	1.22	7.01	0.53	1.38e-10	Type 2 diabetes nephropathy;
TGCT	cis	rs1008375	0.931	rs3775926	chr4:17599837	G/A	cg18681998	chr4:17616180	MED28	0.96	9.77	0.66	4.67e-17	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg27535305	chr1:53392650	SCP2	-0.27	-5.1	-0.42	1.23e-6	Monocyte count;
TGCT	cis	rs2721195	0.577	rs4532636	chr8:145904423	A/C	cg17328964	chr8:145687451	CYHR1	0.44	5.64	0.45	1.1e-7	Age at first birth;
TGCT	cis	rs6003958	1	rs6003958	chr22:24264089	T/G	cg02953382	chr22:24373134	LOC391322	0.8	6.87	0.53	2.77e-10	S-phenylmercapturic acid levels in smokers;
TGCT	cis	rs61990749	0.597	rs12887282	chr14:78200585	C/A	cg02301378	chr14:78227641	SNW1;C14orf178	0.62	4.58	0.38	1.13e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg09165964	chr15:75287851	SCAMP5	0.51	4.65	0.39	8.33e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
TGCT	cis	rs157350	0.638	rs157333	chr5:156117200	G/C	cg19020398	chr5:156886415	NIPAL4	0.3	4.46	0.37	1.84e-5	Anthropometric traits;
TGCT	cis	rs62244186	1.000	rs62244186	chr3:44739783	G/A	cg25151919	chr3:44754333	ZNF502	-0.4	-4.62	-0.38	9.52e-6	Depressive symptoms;
TGCT	cis	rs9906944	0.864	rs9902512	chr17:47094274	C/G	cg07075026	chr17:47091521	IGF2BP1	-0.44	-4.81	-0.4	4.23e-6	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs35883536	0.647	rs12043865	chr1:101042651	G/A	cg10298815	chr1:101004474	GPR88	-0.25	-4.73	-0.39	6.03e-6	Monocyte count;
TGCT	cis	rs12477438	0.798	rs6740035	chr2:99576578	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-8.65	-0.61	2.22e-14	Chronic sinus infection;
TGCT	cis	rs7666738	0.546	rs34621463	chr4:98793357	G/C	cg18180107	chr4:99064573	C4orf37	0.52	4.58	0.38	1.13e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2153535	0.580	rs4960423	chr6:8477210	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs7914558	0.966	rs10883817	chr10:104755431	C/T	cg04362960	chr10:104952993	NT5C2	0.62	5.49	0.44	2.14e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs11935103	0.712	rs1470751	chr4:187296326	C/T	cg16785698	chr4:186456103	PDLIM3	0.44	4.47	0.37	1.74e-5	Response to citalopram treatment;
TGCT	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg06221963	chr1:154839813	KCNN3	-0.76	-13.06	-0.76	4.81e-25	Prostate cancer;
TGCT	cis	rs2948294	0.588	rs12544596	chr8:8116346	A/T	cg06636001	chr8:8085503	FLJ10661	0.8	6.86	0.52	2.97e-10	Red cell distribution width;
TGCT	cis	rs2180341	0.782	rs4897214	chr6:127723625	G/T	cg27446573	chr6:127587934	RNF146	0.8	7.08	0.54	9.53e-11	Breast cancer;
TGCT	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg09263875	chr16:632152	PIGQ	0.31	6.91	0.53	2.25e-10	Height;
TGCT	cis	rs7681440	0.904	rs2301134	chr4:90758945	A/G	cg20003494	chr4:90757398	SNCA	-0.61	-5.78	-0.46	5.59e-8	Dementia with Lewy bodies;
TGCT	cis	rs2836950	0.501	rs62223052	chr21:40708702	A/C	cg11890956	chr21:40555474	PSMG1	-0.63	-5.78	-0.46	5.67e-8	Menarche (age at onset);
TGCT	cis	rs9325144	0.647	rs12231313	chr12:39101929	C/T	cg26384229	chr12:38710491	ALG10B	-0.57	-5.29	-0.43	5.23e-7	Morning vs. evening chronotype;
TGCT	trans	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg27523141	chr10:43048294	ZNF37B	0.74	8.61	0.61	2.7e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	16.1	0.82	3.69e-32	Prudent dietary pattern;
TGCT	cis	rs2797160	1.000	rs2211419	chr6:125995533	C/T	cg05901451	chr6:126070800	HEY2	0.74	6.57	0.51	1.23e-9	Endometrial cancer;
TGCT	cis	rs1577917	0.958	rs72907388	chr6:86440207	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.43	-0.44	2.81e-7	Response to antipsychotic treatment;
TGCT	cis	rs2447097	1.000	rs2447097	chr17:2278064	A/C	cg27406664	chr17:2294951	MNT	0.27	5.57	0.45	1.5e-7	Autism spectrum disorder;
TGCT	cis	rs8180040	0.903	rs7636423	chr3:47309134	C/G	cg27129171	chr3:47204927	SETD2	0.71	8.58	0.61	3.22e-14	Colorectal cancer;
TGCT	cis	rs4808199	0.947	rs7250658	chr19:19571100	A/G	cg03709012	chr19:19516395	GATAD2A	1.0	7.8	0.57	2.23e-12	Nonalcoholic fatty liver disease;
TGCT	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.08	0.48	1.37e-8	Bipolar disorder;
TGCT	trans	rs9650657	0.538	rs11250093	chr8:10798828	C/T	cg15556689	chr8:8085844	FLJ10661	0.81	7.62	0.56	5.61e-12	Neuroticism;
TGCT	cis	rs4936891	0.645	rs896891	chr11:123910740	C/T	cg22125253	chr11:123886957	OR10G4	0.21	4.79	0.4	4.59e-6	Male fertility;
TGCT	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg22764044	chr5:178986830	RUFY1	0.53	6.15	0.48	9.81e-9	Lung cancer;
TGCT	cis	rs12681287	0.640	rs61106663	chr8:87477081	G/C	cg27223183	chr8:87520930	FAM82B	-0.89	-6.41	-0.5	2.8e-9	Caudate activity during reward;
TGCT	cis	rs453301	0.624	rs2979265	chr8:8858717	G/C	cg15556689	chr8:8085844	FLJ10661	0.79	7.07	0.54	1e-10	Joint mobility (Beighton score);
TGCT	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.65	-6.39	-0.5	3.02e-9	Prostate cancer;
TGCT	cis	rs7617773	0.780	rs11710257	chr3:48373214	T/G	cg11946769	chr3:48343235	NME6	0.81	6.96	0.53	1.71e-10	Coronary artery disease;
TGCT	cis	rs11792861	0.816	rs72607157	chr9:111748001	T/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.52	4.86	0.4	3.52e-6	Menarche (age at onset);
TGCT	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg00080972	chr5:178986291	RUFY1	0.46	5.57	0.45	1.54e-7	Lung cancer;
TGCT	cis	rs319204	0.837	rs319140	chr5:146306050	G/A	cg25021259	chr5:146258546	PPP2R2B	0.37	4.54	0.38	1.31e-5	Schizophrenia;
TGCT	cis	rs10131894	0.529	rs10162358	chr14:75429593	A/G	cg08847533	chr14:75593920	NEK9	0.64	5.9	0.47	3.23e-8	Coronary artery disease;
TGCT	cis	rs986417	0.901	rs1956558	chr14:60975956	T/C	cg27398547	chr14:60952738	C14orf39	1.44	8.82	0.62	8.61e-15	Gut microbiota (bacterial taxa);
TGCT	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg03188948	chr7:1209495	NA	0.45	5.77	0.46	6.08e-8	Longevity;Endometriosis;
TGCT	cis	rs6545883	0.811	rs2921718	chr2:61795267	C/A	cg15711740	chr2:61764176	XPO1	-0.6	-5.78	-0.46	5.66e-8	Tuberculosis;
TGCT	cis	rs1577917	0.958	rs3857480	chr6:86535149	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-5.53	-0.44	1.82e-7	Response to antipsychotic treatment;
TGCT	cis	rs11785400	0.793	rs9297969	chr8:143723237	A/G	cg10596483	chr8:143751796	JRK	0.53	5.3	0.43	5.12e-7	Schizophrenia;
TGCT	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.79	-7.29	-0.55	3.12e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs4654899	0.865	rs3856173	chr1:21114833	C/T	cg01072550	chr1:21505969	NA	-0.49	-7.97	-0.58	8.62e-13	Superior frontal gyrus grey matter volume;
TGCT	cis	rs11690935	0.959	rs7608403	chr2:172646765	A/C	cg13550731	chr2:172543902	DYNC1I2	-1.18	-12.58	-0.75	6.59e-24	Schizophrenia;
TGCT	cis	rs2204008	0.641	rs2387810	chr12:38368875	G/T	cg26384229	chr12:38710491	ALG10B	0.83	7.27	0.55	3.51e-11	Bladder cancer;
TGCT	cis	rs7044106	0.718	rs1981021	chr9:123388393	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	4.57	0.38	1.14e-5	Hip circumference adjusted for BMI;
TGCT	cis	rs4851254	0.660	rs34714421	chr2:100692175	T/C	cg22139774	chr2:100720529	AFF3	-0.45	-4.88	-0.4	3.13e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2197308	0.606	rs2218397	chr12:38278307	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-4.72	-0.39	6.19e-6	Morning vs. evening chronotype;
TGCT	cis	rs6121246	0.821	rs6119718	chr20:30331074	A/G	cg18721089	chr20:30220636	NA	-0.43	-4.75	-0.39	5.54e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs616402	0.527	rs11121581	chr1:10577740	A/G	cg17425144	chr1:10567563	PEX14	0.56	8.25	0.6	1.93e-13	Breast size;
TGCT	cis	rs2463822	1.000	rs118049526	chr11:62107508	C/T	cg06239285	chr11:62104954	ASRGL1	-0.95	-6.56	-0.51	1.33e-9	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs709400	0.663	rs8015918	chr14:103942991	A/G	cg12935359	chr14:103987150	CKB	-0.36	-5.55	-0.45	1.67e-7	Body mass index;
TGCT	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg10047753	chr17:41438598	NA	0.96	9.6	0.65	1.16e-16	Menopause (age at onset);
TGCT	cis	rs644799	0.965	rs602512	chr11:95561682	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	8.76	0.62	1.22e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs524281	0.861	rs7124165	chr11:65901218	C/T	cg00563793	chr11:65837595	PACS1	0.55	4.51	0.38	1.46e-5	Electroencephalogram traits;
TGCT	cis	rs11098499	0.754	rs878372	chr4:120238780	A/C	cg09307838	chr4:120376055	NA	0.61	5.91	0.47	3.14e-8	Corneal astigmatism;
TGCT	cis	rs13191362	0.935	rs34347104	chr6:163055716	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.06	8.12	0.59	3.96e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs9868809	0.881	rs3821876	chr3:48668394	G/T	cg00383909	chr3:49044727	WDR6	0.97	5.08	0.42	1.34e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs1008375	0.966	rs3796813	chr4:17591648	A/G	cg16339924	chr4:17578868	LAP3	0.8	6.9	0.53	2.43e-10	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10504229	0.512	rs77289815	chr8:57995242	A/G	cg20607798	chr8:58055168	NA	0.63	4.51	0.38	1.46e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs6978712	1.000	rs6978712	chr7:127147763	A/G	cg01017541	chr7:127776461	NA	-0.76	-4.6	-0.38	1.01e-5	Medication adherence in chronic diseases;
TGCT	cis	rs3820068	0.734	rs72645830	chr1:15889910	A/G	cg05660106	chr1:15850417	CASP9	1.17	14.8	0.8	3.47e-29	Systolic blood pressure;
TGCT	cis	rs514406	0.763	rs6685599	chr1:53213172	G/A	cg25767906	chr1:53392781	SCP2	0.48	5.36	0.43	3.95e-7	Monocyte count;
TGCT	cis	rs611744	0.647	rs585077	chr8:109245497	C/T	cg21045802	chr8:109455806	TTC35	0.72	7.28	0.55	3.32e-11	Dupuytren's disease;
TGCT	cis	rs7659604	0.540	rs4361412	chr4:122669403	C/T	cg19748678	chr4:122722346	EXOSC9	-0.5	-4.95	-0.41	2.37e-6	Type 2 diabetes;
TGCT	cis	rs7940866	0.838	rs12790299	chr11:130803634	A/G	cg12179176	chr11:130786555	SNX19	0.58	5.58	0.45	1.42e-7	Schizophrenia;
TGCT	cis	rs6430585	0.583	rs59243420	chr2:136584538	A/T	cg07169764	chr2:136633963	MCM6	1.23	11.99	0.73	1.85e-22	Corneal structure;
TGCT	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.91	7.47	0.56	1.26e-11	Platelet count;
TGCT	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.73	6.78	0.52	4.37e-10	Prudent dietary pattern;
TGCT	cis	rs9894429	0.646	rs8080391	chr17:79566319	A/T	cg21984481	chr17:79567631	NPLOC4	0.26	4.9	0.4	2.91e-6	Eye color traits;
TGCT	cis	rs6921919	0.583	rs6922429	chr6:28381345	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.54	-5.25	-0.43	6.29e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9467711	0.606	rs9379864	chr6:26372584	G/A	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs651907	0.535	rs61396602	chr3:101509046	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	4.85	0.4	3.68e-6	Colorectal cancer;
TGCT	cis	rs7552404	0.731	rs6699682	chr1:76340123	A/G	cg22875332	chr1:76189707	ACADM	-0.68	-7.04	-0.53	1.16e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.07	-9.63	-0.65	1.01e-16	Platelet count;
TGCT	cis	rs763121	0.815	rs9306328	chr22:39028913	C/T	cg06022373	chr22:39101656	GTPBP1	0.71	6.77	0.52	4.51e-10	Menopause (age at onset);
TGCT	cis	rs13242816	1.000	rs67652573	chr7:116109958	T/C	cg16553024	chr7:116138462	CAV2	-0.45	-4.75	-0.39	5.64e-6	P wave duration;
TGCT	cis	rs6840360	0.582	rs57585665	chr4:152327017	G/C	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.35	-0.5	3.68e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg10802521	chr3:52805072	NEK4	-0.72	-9.1	-0.63	1.91e-15	Bipolar disorder;
TGCT	cis	rs7666738	0.546	rs10026181	chr4:98814118	C/T	cg17366294	chr4:99064904	C4orf37	-0.67	-6.06	-0.48	1.52e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3125734	0.660	rs4979780	chr10:63992740	A/C	cg09941381	chr10:64027924	RTKN2	-0.37	-5.58	-0.45	1.45e-7	Rheumatoid arthritis;
TGCT	cis	rs62244186	0.541	rs62244226	chr3:44831831	G/A	cg11003573	chr3:44754125	ZNF502	-0.47	-5.39	-0.44	3.4e-7	Depressive symptoms;
TGCT	cis	rs17376456	0.877	rs67066109	chr5:93494101	G/C	cg25358565	chr5:93447407	FAM172A	0.97	8.32	0.6	1.34e-13	Diabetic retinopathy;
TGCT	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg06221963	chr1:154839813	KCNN3	-0.75	-12.65	-0.75	4.66e-24	Prostate cancer;
TGCT	cis	rs634534	0.622	rs593525	chr11:65727799	T/C	cg04055107	chr11:65626734	MUS81;CFL1	0.45	4.47	0.37	1.73e-5	Sum eosinophil basophil counts;Eosinophil counts;
TGCT	cis	rs7806994	1	rs7806994	chr7:56139505	A/T	cg20539350	chr7:56437009	NA	0.31	4.59	0.38	1.08e-5	PR interval in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6735179	0.565	rs733376	chr2:1751958	C/A	cg08534653	chr2:1747700	PXDN	0.54	4.45	0.37	1.92e-5	Response to antipsychotic treatment;
TGCT	cis	rs514406	0.570	rs1332776	chr1:53189816	C/T	cg25767906	chr1:53392781	SCP2	-0.42	-4.88	-0.4	3.16e-6	Monocyte count;
TGCT	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg01802117	chr1:53393560	SCP2	-0.47	-5.61	-0.45	1.23e-7	Monocyte count;
TGCT	cis	rs295140	0.681	rs6435048	chr2:201167854	C/T	cg04283868	chr2:201171347	SPATS2L	0.6	5.68	0.45	9.27e-8	QT interval;
TGCT	cis	rs8072100	0.935	rs78737171	chr17:45668760	A/T	cg08085267	chr17:45401833	C17orf57	0.43	4.63	0.38	9.02e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs6688613	0.840	rs6660048	chr1:166954186	C/T	cg07049167	chr1:166818506	POGK	-0.27	-5.5	-0.44	2.08e-7	Refractive astigmatism;
TGCT	cis	rs1878931	0.507	rs4429296	chr16:3408277	T/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.66	-5.19	-0.42	8.27e-7	Body mass index (adult);
TGCT	cis	rs2535633	0.631	rs2710314	chr3:52969128	T/C	cg10802521	chr3:52805072	NEK4	0.6	6.2	0.49	7.52e-9	Body mass index;
TGCT	cis	rs7208859	0.673	rs9907197	chr17:29018263	C/T	cg04154034	chr17:28927549	LRRC37B2	0.75	4.47	0.37	1.73e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs9905704	0.624	rs11652761	chr17:56986095	C/T	cg05425664	chr17:57184151	TRIM37	-0.57	-4.44	-0.37	1.97e-5	Testicular germ cell tumor;
TGCT	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg01802117	chr1:53393560	SCP2	-0.39	-4.63	-0.38	9.18e-6	Monocyte count;
TGCT	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-5.1	-0.42	1.23e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7772486	0.686	rs857879	chr6:145974043	C/A	cg13319975	chr6:146136371	FBXO30	0.5	4.6	0.38	1.01e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs73198271	0.765	rs534103	chr8:8634069	A/G	cg06671706	chr8:8559999	CLDN23	-0.36	-4.68	-0.39	7.27e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs7666738	0.830	rs13106434	chr4:98991651	T/A	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28595532	0.920	rs56302600	chr4:119770162	T/C	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs9443645	0.901	rs9361460	chr6:79589467	C/G	cg09184832	chr6:79620586	NA	-0.48	-5.17	-0.42	9.23e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1997103	0.954	rs10246216	chr7:55390479	C/T	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs9611565	0.512	rs139573	chr22:42214785	G/A	cg13695892	chr22:41940480	POLR3H	-0.87	-8.24	-0.59	2.06e-13	Vitiligo;
TGCT	cis	rs11578119	0.933	rs72709772	chr1:170470418	C/G	cg09767346	chr1:170501363	GORAB	0.66	5.29	0.43	5.27e-7	Male-pattern baldness;
TGCT	cis	rs4767364	0.645	rs7974383	chr12:112794714	T/G	cg10833066	chr12:111807467	FAM109A	0.38	5.67	0.45	9.61e-8	Oral cavity and pharyngeal cancer;
TGCT	cis	rs2692947	0.770	rs12471925	chr2:96555522	C/A	cg23100626	chr2:96804247	ASTL	0.37	4.47	0.37	1.74e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs7666738	0.830	rs4699589	chr4:98973889	A/G	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9611565	0.921	rs3927	chr22:41722864	A/G	cg06481639	chr22:41940642	POLR3H	-0.62	-5.74	-0.46	6.82e-8	Vitiligo;
TGCT	cis	rs2204008	0.837	rs12366727	chr12:38365748	A/C	cg13010199	chr12:38710504	ALG10B	0.61	4.77	0.39	5.11e-6	Bladder cancer;
TGCT	trans	rs1005277	0.540	rs4934907	chr10:38015230	A/C	cg17830980	chr10:43048298	ZNF37B	-0.65	-7.34	-0.55	2.4e-11	Extrinsic epigenetic age acceleration;
TGCT	cis	rs8072100	0.676	rs7221345	chr17:45405144	G/A	cg08085267	chr17:45401833	C17orf57	-0.52	-5.75	-0.46	6.62e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	trans	rs7819412	0.805	rs4333549	chr8:10979561	C/G	cg15556689	chr8:8085844	FLJ10661	-0.83	-8.24	-0.59	2.08e-13	Triglycerides;
TGCT	cis	rs4568518	0.530	rs10950690	chr7:17981310	C/G	cg03009463	chr7:17980271	SNX13	0.55	4.48	0.37	1.71e-5	Measles;
TGCT	cis	rs7707921	0.914	rs4081859	chr5:81466669	G/A	cg15871215	chr5:81402204	ATG10	0.28	4.47	0.37	1.75e-5	Breast cancer;
TGCT	cis	rs1050631	1.000	rs2236718	chr18:33705135	G/T	cg25426722	chr18:33708991	SLC39A6;ELP2	0.49	4.83	0.4	3.88e-6	Esophageal squamous cell cancer (length of survival);
TGCT	cis	rs7647973	0.710	rs7629322	chr3:49621994	C/T	cg03060546	chr3:49711283	APEH	0.62	5.21	0.42	7.77e-7	Menarche (age at onset);
TGCT	cis	rs2013441	1.000	rs34644796	chr17:20064128	C/G	cg23224458	chr17:20280056	CCDC144C	0.38	4.61	0.38	9.96e-6	Obesity-related traits;
TGCT	cis	rs7731657	0.509	rs6870590	chr5:130249954	A/G	cg08523029	chr5:130500466	HINT1	0.57	4.68	0.39	7.39e-6	Fasting plasma glucose;
TGCT	cis	rs933688	1.000	rs61612071	chr5:90741470	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.04	8.8	0.62	9.68e-15	Smoking behavior;
TGCT	cis	rs1784581	0.569	rs9365357	chr6:162414913	A/G	cg17173639	chr6:162384350	PARK2	0.39	6.51	0.5	1.7e-9	Itch intensity from mosquito bite;
TGCT	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg03351412	chr1:154909251	PMVK	0.53	4.93	0.4	2.6e-6	Prostate cancer;
TGCT	cis	rs2153535	0.580	rs9393022	chr6:8466588	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs8013055	0.846	rs8013827	chr14:105970176	C/T	cg19700328	chr14:106028568	NA	0.48	5.47	0.44	2.4e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs17376456	0.877	rs28633397	chr5:93447048	A/G	cg21475434	chr5:93447410	FAM172A	0.59	4.66	0.39	8.09e-6	Diabetic retinopathy;
TGCT	cis	rs7570971	0.583	rs1375132	chr2:135954405	A/G	cg07169764	chr2:136633963	MCM6	0.62	5.34	0.43	4.25e-7	Blood metabolite levels;Body mass index;Cholesterol, total;
TGCT	cis	rs739401	0.572	rs389128	chr11:3083873	G/T	cg05729581	chr11:3078854	CARS	-0.57	-5.21	-0.42	7.8e-7	Longevity;
TGCT	cis	rs742320	0.756	rs3765263	chr16:840378	A/G	cg03433313	chr16:819064	MIR662	-0.5	-6.78	-0.52	4.26e-10	Mean corpuscular volume;
TGCT	cis	rs7312933	0.618	rs7954523	chr12:42681508	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.57	5.4	0.44	3.2e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs78487399	0.808	rs12105399	chr2:43676939	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.24	-0.43	6.79e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs10894604	0.558	rs7944972	chr11:132651586	A/G	cg16639665	chr11:133402497	OPCML	0.45	4.69	0.39	6.99e-6	Waist-hip ratio;
TGCT	cis	rs981844	1.000	rs56232929	chr4:154665700	A/G	cg14289246	chr4:154710475	SFRP2	1.01	8.67	0.61	2.02e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs1865760	0.865	rs9467651	chr6:25958257	C/G	cg16482183	chr6:26056742	HIST1H1C	0.52	4.84	0.4	3.78e-6	Height;
TGCT	cis	rs3749237	0.595	rs885592	chr3:49497883	T/G	cg02487422	chr3:49467188	NICN1	0.61	6.29	0.49	5.08e-9	Resting heart rate;
TGCT	cis	rs9534288	0.797	rs9534283	chr13:46589256	C/A	cg15192986	chr13:46630673	CPB2	-0.53	-7.62	-0.56	5.82e-12	Blood protein levels;
TGCT	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg22963979	chr7:1858916	MAD1L1	0.34	5.34	0.43	4.35e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs7043114	0.525	rs10820964	chr9:95041636	G/A	cg14631576	chr9:95140430	CENPP	-0.28	-4.65	-0.39	8.23e-6	Height;
TGCT	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg14784868	chr12:69753453	YEATS4	0.9	10.6	0.69	4.47e-19	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs9788682	0.748	rs569207	chr15:78873119	A/G	cg24631222	chr15:78858424	CHRNA5	-0.88	-6.52	-0.51	1.61e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs9611565	0.512	rs5751145	chr22:42133552	C/T	cg03806693	chr22:41940476	POLR3H	1.06	10.94	0.7	6.7e-20	Vitiligo;
TGCT	cis	rs12477438	0.765	rs1453564	chr2:99564428	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-4.62	-0.38	9.47e-6	Chronic sinus infection;
TGCT	cis	rs11867934	0.577	rs9893676	chr17:17054951	C/G	cg26176665	chr17:16994978	MPRIP	0.23	4.45	0.37	1.87e-5	Diabetic retinopathy;
TGCT	cis	rs13242816	1.000	rs34936262	chr7:116160022	G/A	cg02799643	chr7:116139180	CAV2	-0.44	-5.54	-0.45	1.74e-7	P wave duration;
TGCT	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg08280861	chr8:58055591	NA	0.4	4.73	0.39	5.97e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9916302	0.707	rs11078903	chr17:37631924	G/A	cg15445000	chr17:37608096	MED1	0.31	4.6	0.38	1.01e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs35934224	0.783	rs7288170	chr22:19864252	C/G	cg11182965	chr22:19864308	TXNRD2	-0.38	-5.31	-0.43	4.86e-7	Glaucoma (primary open-angle);
TGCT	cis	rs2228479	1.000	rs62052180	chr16:89963289	C/G	cg04013166	chr16:89971882	TCF25	0.33	4.47	0.37	1.75e-5	Skin colour saturation;
TGCT	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg24675658	chr1:53192096	ZYG11B	-0.7	-8.15	-0.59	3.44e-13	Monocyte count;
TGCT	cis	rs7085104	0.727	rs12773892	chr10:104631177	G/T	cg04362960	chr10:104952993	NT5C2	0.89	6.19	0.49	8.04e-9	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs6433895	1.000	rs59395276	chr2:182020696	T/C	cg16904960	chr2:182549928	NA	0.34	4.45	0.37	1.87e-5	Lymphocyte counts;
TGCT	cis	rs864537	0.622	rs2949661	chr1:167424924	C/T	cg22356347	chr1:167427500	CD247	-0.19	-4.61	-0.38	9.81e-6	Celiac disease or Rheumatoid arthritis;Celiac disease;
TGCT	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	4.89	0.4	3e-6	Menopause (age at onset);
TGCT	cis	rs7552404	1.000	rs12123977	chr1:76209754	A/G	cg10523679	chr1:76189770	ACADM	-1.05	-7.93	-0.58	1.1e-12	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs79349575	0.783	rs55771415	chr17:46999937	C/T	cg26022315	chr17:47021804	SNF8	0.49	4.89	0.4	3.03e-6	Type 2 diabetes;
TGCT	cis	rs9611565	0.546	rs739132	chr22:42123099	A/T	cg06481639	chr22:41940642	POLR3H	0.71	6.43	0.5	2.56e-9	Vitiligo;
TGCT	cis	rs7666738	0.719	rs35184673	chr4:99050945	T/C	cg17366294	chr4:99064904	C4orf37	0.73	5.48	0.44	2.29e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2235642	0.750	rs1894649	chr16:1657284	C/G	cg10465839	chr16:1584050	IFT140;TMEM204	-0.28	-4.63	-0.38	9.27e-6	Coronary artery disease;
TGCT	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.51	5.37	0.43	3.71e-7	Menopause (age at onset);
TGCT	cis	rs2486288	0.656	rs8039153	chr15:45579813	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.46	-5.45	-0.44	2.57e-7	Glomerular filtration rate;
TGCT	cis	rs78545713	0.892	rs11751286	chr6:26241361	C/G	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.66	-4.71	-0.39	6.57e-6	Iron status biomarkers (total iron binding capacity);
TGCT	cis	rs10498514	1.000	rs76202452	chr14:65027352	C/G	cg25134081	chr14:64931936	AKAP5	1.13	4.63	0.38	9.22e-6	Cognitive performance;
TGCT	cis	rs6882076	0.961	rs58198139	chr5:156399039	C/T	cg12943317	chr5:156479607	HAVCR1	-0.3	-5.6	-0.45	1.34e-7	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
TGCT	cis	rs910316	1.000	rs4903275	chr14:75512509	C/T	cg11812906	chr14:75593930	NEK9	0.74	7.25	0.55	3.97e-11	Height;
TGCT	cis	rs3617	0.573	rs9825230	chr3:52901974	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.5	-4.86	-0.4	3.52e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs79349575	0.715	rs1058018	chr17:47000251	C/T	cg26022315	chr17:47021804	SNF8	0.49	4.95	0.41	2.37e-6	Type 2 diabetes;
TGCT	cis	rs7772486	0.875	rs2814872	chr6:146310234	T/C	cg23711669	chr6:146136114	FBXO30	0.89	9.5	0.65	2.02e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs8180040	0.966	rs11705957	chr3:47443262	T/G	cg27129171	chr3:47204927	SETD2	-0.64	-7.39	-0.55	1.89e-11	Colorectal cancer;
TGCT	cis	rs2346177	0.542	rs13024414	chr2:46687062	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.42	-4.51	-0.38	1.49e-5	HDL cholesterol;
TGCT	cis	rs9522267	0.624	rs2774433	chr13:112197418	A/C	cg10483660	chr13:112241077	NA	-0.28	-4.45	-0.37	1.92e-5	Hepatitis;
TGCT	cis	rs7513165	0.935	rs7538055	chr1:204161069	A/G	cg12731349	chr1:204159619	KISS1	0.49	5.62	0.45	1.19e-7	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
TGCT	cis	rs2137111	0.579	rs116951852	chr15:77721319	A/T	cg22256960	chr15:77711686	NA	-0.5	-4.75	-0.39	5.55e-6	Anticoagulant levels;
TGCT	cis	rs4268898	0.722	rs10445893	chr2:24407128	A/G	cg05570707	chr2:24270316	C2orf44	0.49	4.84	0.4	3.73e-6	Asthma;
TGCT	cis	rs6088590	1.000	rs28542147	chr20:33376323	G/A	cg06115741	chr20:33292138	TP53INP2	0.66	5.51	0.44	2.01e-7	Coronary artery disease;
TGCT	cis	rs1857353	1.000	rs12401896	chr1:75907626	C/T	cg11838876	chr1:75668600	SLC44A5	-0.51	-4.81	-0.4	4.23e-6	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs1577917	0.771	rs2842601	chr6:86330133	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.58	-0.45	1.43e-7	Response to antipsychotic treatment;
TGCT	cis	rs17345786	0.906	rs12638137	chr3:101150964	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.84	8.92	0.63	5.05e-15	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	5.53	0.44	1.8e-7	Alzheimer's disease;
TGCT	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-6.74	-0.52	5.26e-10	Alzheimer's disease;
TGCT	cis	rs9926296	0.712	rs447735	chr16:89734349	T/C	cg04287289	chr16:89883240	FANCA	-0.55	-5.16	-0.42	9.38e-7	Vitiligo;
TGCT	cis	rs2857078	0.720	rs9906669	chr17:42305706	A/G	cg13607699	chr17:42295918	UBTF	0.96	10.81	0.7	1.38e-19	Red cell distribution width;Reticulocyte count;
TGCT	cis	rs4788570	0.615	rs10852502	chr16:71652072	C/A	cg06353428	chr16:71660113	MARVELD3	1.54	12.75	0.75	2.57e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs57590327	0.645	rs62265395	chr3:81531932	C/T	cg07356753	chr3:81810745	GBE1	-0.58	-4.77	-0.39	5.11e-6	Extraversion;
TGCT	cis	rs4319547	1.000	rs7295397	chr12:123116209	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.68	-5.42	-0.44	3.02e-7	Body mass index;
TGCT	cis	rs981844	0.740	rs6841173	chr4:154682563	A/G	cg14289246	chr4:154710475	SFRP2	-0.95	-8.8	-0.62	9.96e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs909002	0.849	rs7546297	chr1:32106494	A/G	cg11573219	chr1:32083031	HCRTR1	-0.49	-6.44	-0.5	2.36e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	5.11	0.42	1.18e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs13082711	0.911	rs11709954	chr3:27421427	C/T	cg02860705	chr3:27208620	NA	0.35	4.82	0.4	4.03e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs2013441	0.965	rs2703820	chr17:20121479	G/A	cg18979559	chr17:20280153	CCDC144C	-0.44	-4.61	-0.38	9.78e-6	Obesity-related traits;
TGCT	cis	rs7582180	0.585	rs13031711	chr2:100939433	T/C	cg14675211	chr2:100938903	LONRF2	0.51	4.95	0.41	2.32e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs78456975	0.527	rs72776299	chr2:1570300	G/C	cg12573674	chr2:1569213	NA	-0.49	-5.3	-0.43	5.06e-7	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs9650657	0.584	rs28613656	chr8:10695419	G/A	cg16664915	chr8:10907788	XKR6	-0.29	-4.71	-0.39	6.47e-6	Neuroticism;
TGCT	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg24829409	chr8:58192753	C8orf71	-0.51	-4.93	-0.41	2.54e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs921968	0.643	rs2278529	chr2:219502132	C/T	cg02176678	chr2:219576539	TTLL4	0.43	6.04	0.48	1.69e-8	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs1670533	1.000	rs13134921	chr4:1054177	A/G	cg20887711	chr4:1340912	KIAA1530	0.71	5.7	0.46	8.33e-8	Recombination rate (females);
TGCT	cis	rs35146811	0.961	rs35991721	chr7:99728790	G/T	cg13334819	chr7:99746414	C7orf59	-0.82	-7.34	-0.55	2.49e-11	Coronary artery disease;
TGCT	cis	rs2303745	0.622	rs1864113	chr19:17393504	G/C	cg02221750	chr19:17393354	ANKLE1	-0.48	-6.28	-0.49	5.17e-9	Systemic lupus erythematosus;
TGCT	cis	rs4285028	0.699	rs1920298	chr3:121597888	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.78	-6.72	-0.52	5.95e-10	Multiple sclerosis;
TGCT	cis	rs8141529	0.509	rs5762863	chr22:29253335	A/C	cg02153584	chr22:29168773	CCDC117	0.59	4.65	0.39	8.49e-6	Lymphocyte counts;
TGCT	cis	rs1670533	0.932	rs13108207	chr4:1054218	C/T	cg20887711	chr4:1340912	KIAA1530	0.57	4.51	0.38	1.47e-5	Recombination rate (females);
TGCT	cis	rs62244186	0.659	rs9311358	chr3:44538748	C/G	cg10263370	chr3:44754102	ZNF502	-0.38	-4.44	-0.37	1.99e-5	Depressive symptoms;
TGCT	cis	rs12049351	0.774	rs6662732	chr1:229629245	A/C	cg12130225	chr1:229698885	NA	-0.39	-4.59	-0.38	1.06e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs3858526	0.920	rs11039698	chr11:5950907	C/T	cg13902645	chr11:5959945	NA	-0.48	-5.0	-0.41	1.95e-6	DNA methylation (variation);
TGCT	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg16325326	chr1:53192061	ZYG11B	0.7	8.19	0.59	2.73e-13	Monocyte count;
TGCT	trans	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg21659725	chr3:3221576	CRBN	-0.98	-15.33	-0.81	2.1000000000000002e-30	Intelligence (multi-trait analysis);
TGCT	cis	rs7552404	0.960	rs61797339	chr1:76189946	G/T	cg10523679	chr1:76189770	ACADM	0.91	9.92	0.67	2.01e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg21724239	chr8:58056113	NA	0.42	5.04	0.41	1.59e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9325144	0.647	rs7487395	chr12:38865660	C/A	cg26384229	chr12:38710491	ALG10B	-0.59	-5.47	-0.44	2.33e-7	Morning vs. evening chronotype;
TGCT	cis	rs8017423	0.967	rs11159956	chr14:90715890	C/T	cg04374321	chr14:90722782	PSMC1	-0.75	-8.2	-0.59	2.53e-13	Mortality in heart failure;
TGCT	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg20573242	chr4:122745356	CCNA2	0.54	4.88	0.4	3.2e-6	Type 2 diabetes;
TGCT	trans	rs12339966	0.653	rs10756228	chr9:11301783	T/C	cg07173112	chr1:1114698	TTLL10	-0.34	-6.91	-0.53	2.26e-10	Systolic blood pressure;
TGCT	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg18538332	chr22:24372958	LOC391322	1.02	13.19	0.76	2.24e-25	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg25767906	chr1:53392781	SCP2	0.5	5.71	0.46	7.92e-8	Monocyte count;
TGCT	cis	rs4460629	0.742	rs7366355	chr1:155076734	C/T	cg23973274	chr1:155060172	NA	-0.26	-4.66	-0.39	8.1e-6	Serum magnesium levels;
TGCT	cis	rs6845621	0.901	rs6834863	chr4:18919159	C/A	cg12196642	chr4:18937545	NA	-0.25	-4.47	-0.37	1.74e-5	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
TGCT	cis	rs1062177	0.756	rs2915815	chr5:151115883	G/C	cg12924095	chr5:151150029	G3BP1	-0.35	-4.95	-0.41	2.35e-6	Preschool internalizing problems;
TGCT	cis	rs3733585	0.648	rs28513781	chr4:9959334	G/C	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.67	-0.51	7.44e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg03188948	chr7:1209495	NA	0.65	5.39	0.44	3.36e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg00814883	chr7:100076585	TSC22D4	-0.92	-9.76	-0.66	4.73e-17	Platelet count;
TGCT	cis	rs11190604	1.000	rs10883505	chr10:102280772	C/T	cg23241863	chr10:102295624	HIF1AN	0.68	5.17	0.42	9.14e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9913156	0.670	rs9894225	chr17:4546559	A/G	cg23387401	chr17:4582204	PELP1	-0.3	-4.6	-0.38	1.01e-5	Lymphocyte counts;
TGCT	cis	rs2932538	0.845	rs6682678	chr1:113206920	A/G	cg22162597	chr1:113214053	CAPZA1	-0.28	-6.31	-0.49	4.46e-9	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs9467773	1.000	rs9295695	chr6:26528250	C/T	cg26531700	chr6:26746687	NA	-0.5	-4.9	-0.4	2.92e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.791	rs10013680	chr4:99023030	G/C	cg17366294	chr4:99064904	C4orf37	0.72	7.04	0.53	1.18e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs17376456	0.542	rs2043979	chr5:93120782	T/A	cg25358565	chr5:93447407	FAM172A	-0.62	-5.89	-0.47	3.43e-8	Diabetic retinopathy;
TGCT	cis	rs9318086	0.648	rs35449605	chr13:24472582	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.82	8.98	0.63	3.58e-15	Myopia (pathological);
TGCT	cis	rs2204008	0.805	rs2874289	chr12:38258420	G/A	cg26384229	chr12:38710491	ALG10B	0.85	7.47	0.56	1.27e-11	Bladder cancer;
TGCT	cis	rs9341808	0.754	rs9343973	chr6:80913216	A/G	cg08355045	chr6:80787529	NA	0.32	5.6	0.45	1.29e-7	Sitting height ratio;
TGCT	cis	rs3748682	0.731	rs9729719	chr1:38298207	G/A	cg04496824	chr1:38276835	MTF1	0.21	4.56	0.38	1.2e-5	Hypothyroidism;
TGCT	cis	rs36051895	0.622	rs13440043	chr9:5268264	A/G	cg02405213	chr9:5042618	JAK2	-0.61	-7.25	-0.55	3.96e-11	Pediatric autoimmune diseases;
TGCT	cis	rs265548	0.595	rs265543	chr19:17904260	T/G	cg16744531	chr19:17905626	B3GNT3	0.41	5.03	0.41	1.69e-6	Tumor biomarkers;
TGCT	cis	rs4285028	0.948	rs2091664	chr3:121684749	T/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.77	-6.5	-0.5	1.78e-9	Multiple sclerosis;
TGCT	cis	rs5760092	0.842	rs5751763	chr22:24247793	T/C	cg18538332	chr22:24372958	LOC391322	-0.76	-6.18	-0.49	8.62e-9	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg08564027	chr20:61660810	NA	0.37	6.53	0.51	1.49e-9	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.39	-4.9	-0.4	2.97e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7264396	0.580	rs7266028	chr20:34477169	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.04	-0.41	1.6e-6	Total cholesterol levels;
TGCT	trans	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg13615516	chr5:77269221	NA	0.67	8.36	0.6	1.09e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs6988636	0.710	rs62521797	chr8:124134321	A/T	cg27053337	chr8:124217698	FAM83A	0.79	4.87	0.4	3.3e-6	Urinary uromodulin levels;
TGCT	cis	rs2594989	0.895	rs2606741	chr3:11392426	G/A	cg00170343	chr3:11313890	ATG7	0.67	5.21	0.42	7.68e-7	Circulating chemerin levels;
TGCT	cis	rs6088580	0.634	rs6579165	chr20:32994715	A/G	cg06115741	chr20:33292138	TP53INP2	-0.55	-4.81	-0.4	4.28e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg08439880	chr3:133502540	NA	-0.28	-5.15	-0.42	9.73e-7	Iron status biomarkers;
TGCT	cis	rs9902453	0.765	rs3102555	chr17:28044101	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.84	8.39	0.6	9.14e-14	Coffee consumption (cups per day);
TGCT	cis	rs10744422	0.764	rs10847749	chr12:123291506	C/T	cg18912006	chr12:123335444	HIP1R	0.56	4.78	0.39	4.84e-6	Schizophrenia;
TGCT	cis	rs4449834	0.816	rs2875984	chr8:61674555	C/T	cg12485212	chr8:61565947	NA	0.59	4.61	0.38	9.88e-6	Sum eosinophil basophil counts;
TGCT	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg11644478	chr21:40555479	PSMG1	-0.52	-4.77	-0.39	4.98e-6	Menarche (age at onset);
TGCT	cis	rs2456568	0.802	rs10765639	chr11:93636194	G/A	cg16099599	chr11:93583650	C11orf90	-0.4	-4.98	-0.41	2.04e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs2180341	0.814	rs9385424	chr6:127726796	A/G	cg27446573	chr6:127587934	RNF146	0.88	8.07	0.59	5.22e-13	Breast cancer;
TGCT	cis	rs35883536	1.000	rs2491822	chr1:101115839	T/C	cg06223162	chr1:101003688	GPR88	-0.29	-4.79	-0.4	4.61e-6	Monocyte count;
TGCT	cis	rs28374715	0.635	rs112547435	chr15:41648737	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.91	-15.14	-0.81	5.81e-30	Ulcerative colitis;
TGCT	cis	rs7647973	1.000	rs1009051	chr3:49521549	G/A	cg07636037	chr3:49044803	WDR6	0.64	5.26	0.43	6.12e-7	Menarche (age at onset);
TGCT	cis	rs637571	0.544	rs55704213	chr11:65730002	C/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.63	6.33	0.49	4.02e-9	Eosinophil percentage of white cells;
TGCT	cis	rs804280	0.505	rs804271	chr8:11627214	C/A	cg12395012	chr8:11607386	GATA4	-0.18	-4.9	-0.4	2.96e-6	Myopia (pathological);
TGCT	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg15691649	chr6:25882328	NA	-0.38	-5.03	-0.41	1.65e-6	Blood metabolite levels;
TGCT	cis	rs904251	0.523	rs2797796	chr6:37480886	T/C	cg25019722	chr6:37503610	NA	-0.53	-8.19	-0.59	2.75e-13	Cognitive performance;
TGCT	cis	rs12580194	0.593	rs7959837	chr12:55734511	G/A	cg10672482	chr12:55725839	OR6C3	-0.52	-4.67	-0.39	7.84e-6	Cancer;
TGCT	cis	rs826838	0.935	rs11183940	chr12:38851642	A/G	cg13010199	chr12:38710504	ALG10B	0.82	6.85	0.52	3e-10	Heart rate;
TGCT	cis	rs11785693	0.862	rs11786595	chr8:5001621	T/G	cg26367366	chr8:4980734	NA	0.56	4.44	0.37	1.95e-5	Neuroticism (multi-trait analysis);Neuroticism;
TGCT	cis	rs12220238	0.558	rs76330316	chr10:76002291	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.93	0.58	1.11e-12	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs10489202	0.513	rs4657731	chr1:168081255	C/T	cg24449463	chr1:168025552	DCAF6	-0.51	-5.22	-0.42	7.23e-7	Schizophrenia;
TGCT	cis	rs2820315	1.000	rs2644107	chr1:201818629	T/C	cg12730843	chr1:201915899	LMOD1	-0.27	-4.77	-0.39	4.98e-6	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
TGCT	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg18876405	chr7:65276391	NA	-0.33	-5.02	-0.41	1.72e-6	Aortic root size;
TGCT	cis	rs11874712	1.000	rs9783888	chr18:43651370	G/T	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	5.16	0.42	9.44e-7	Migraine - clinic-based;
TGCT	cis	rs4788815	0.513	rs7204967	chr16:71804287	A/G	cg06353428	chr16:71660113	MARVELD3	1.53	12.59	0.75	6.48e-24	Metabolite levels;
TGCT	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg22535103	chr8:58192502	C8orf71	-0.38	-4.88	-0.4	3.25e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg12419862	chr22:24373484	LOC391322	-0.79	-8.14	-0.59	3.55e-13	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9859260	0.710	rs34906439	chr3:195779706	A/G	cg02975922	chr3:195473998	MUC4	0.25	5.1	0.42	1.24e-6	Mean corpuscular volume;
TGCT	cis	rs2067615	0.524	rs4964186	chr12:107080235	C/T	cg15890332	chr12:107067104	RFX4	0.29	5.77	0.46	5.9e-8	Heart rate;
TGCT	cis	rs12477438	0.520	rs11685759	chr2:99766217	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.06	13.28	0.77	1.43e-25	Chronic sinus infection;
TGCT	cis	rs2066819	1.000	rs11575231	chr12:56744445	T/C	cg26714650	chr12:56694279	CS	-1.36	-5.89	-0.47	3.4e-8	Psoriasis vulgaris;
TGCT	cis	rs288326	0.561	rs17265866	chr2:183822374	G/C	cg09997497	chr2:183902928	NCKAP1	1.11	4.95	0.41	2.38e-6	Blood protein levels;
TGCT	cis	rs6121246	0.567	rs2811	chr20:30194248	A/G	cg18721089	chr20:30220636	NA	-0.63	-6.88	-0.53	2.67e-10	Mean corpuscular hemoglobin;
TGCT	cis	rs986417	0.901	rs1015119	chr14:61027510	G/T	cg27398547	chr14:60952738	C14orf39	1.36	9.08	0.63	2.05e-15	Gut microbiota (bacterial taxa);
TGCT	cis	rs4478037	1.000	rs4478037	chr3:33160407	G/A	cg19404215	chr3:33155277	CRTAP	-1.21	-7.41	-0.55	1.7e-11	Major depressive disorder;
TGCT	cis	rs7091068	0.671	rs1223296	chr10:95404621	T/C	cg20715218	chr10:95462985	C10orf4	-0.54	-5.15	-0.42	9.95e-7	Urinary tract infection frequency;
TGCT	cis	rs11031096	0.542	rs11030404	chr11:3980638	T/C	cg18678763	chr11:4115507	RRM1	-0.41	-4.97	-0.41	2.16e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg23758822	chr17:41437982	NA	0.72	6.79	0.52	4.04e-10	Menopause (age at onset);
TGCT	cis	rs2439831	1.000	rs2584726	chr15:43715382	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.01	8.37	0.6	1.02e-13	Lung cancer in ever smokers;
TGCT	cis	rs2455799	0.559	rs7635539	chr3:15922908	A/G	cg13420985	chr3:16524424	RFTN1	-0.35	-4.58	-0.38	1.1e-5	Mean platelet volume;
TGCT	cis	rs7681440	0.845	rs6843084	chr4:90766230	T/C	cg26578617	chr4:90757533	SNCA	-0.47	-4.87	-0.4	3.34e-6	Dementia with Lewy bodies;
TGCT	cis	rs3796352	1.000	rs1346719	chr3:53077372	A/G	cg07884673	chr3:53033167	SFMBT1	0.57	5.55	0.45	1.68e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs4383453	0.539	rs12629585	chr3:123097706	T/A	cg04890266	chr3:123102914	ADCY5	-0.5	-8.32	-0.6	1.32e-13	Gestational age at birth (maternal effect);
TGCT	cis	rs8026198	0.929	rs57347762	chr15:42671558	G/A	cg02624051	chr15:42371635	PLA2G4D	0.35	4.46	0.37	1.8e-5	Fibrinogen levels;
TGCT	cis	rs1372520	0.873	rs983361	chr4:90761944	T/G	cg01966878	chr4:90757139	SNCA	-0.29	-4.78	-0.39	4.92e-6	Neuroticism;
TGCT	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg08736216	chr1:53307985	ZYG11A	-0.28	-5.83	-0.46	4.44e-8	Monocyte count;
TGCT	cis	rs9467773	1.000	rs1884949	chr6:26568067	G/A	cg05738196	chr6:26577821	NA	0.9	12.48	0.75	1.16e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs6684514	1.000	rs10908500	chr1:156280671	A/T	cg20302342	chr1:156215951	PAQR6	0.35	4.65	0.39	8.23e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	trans	rs2727020	0.796	rs7131672	chr11:49274421	A/C	cg03929089	chr4:120376271	NA	0.68	7.2	0.54	5.2e-11	Coronary artery disease;
TGCT	cis	rs854765	0.663	rs9915248	chr17:17747514	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.7	-6.65	-0.51	8.42e-10	Total body bone mineral density;
TGCT	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg10802521	chr3:52805072	NEK4	-0.71	-8.81	-0.62	9.29e-15	Bipolar disorder;
TGCT	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg18230493	chr5:56204884	C5orf35	-0.68	-5.92	-0.47	2.92e-8	Initial pursuit acceleration;
TGCT	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg04944784	chr2:26401820	FAM59B	0.76	6.24	0.49	6.46e-9	Gut microbiome composition (summer);
TGCT	cis	rs7940866	0.804	rs10894287	chr11:130808483	C/T	cg12179176	chr11:130786555	SNX19	0.59	5.97	0.47	2.31e-8	Schizophrenia;
TGCT	cis	rs752010	0.530	rs10789401	chr1:42081111	A/G	cg06885757	chr1:42089581	HIVEP3	0.3	5.31	0.43	4.86e-7	Lupus nephritis in systemic lupus erythematosus;
TGCT	cis	rs12049351	0.665	rs10799534	chr1:229657213	A/C	cg12130225	chr1:229698885	NA	0.35	4.46	0.37	1.85e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs1497406	0.744	rs4661718	chr1:16505908	C/T	cg20430773	chr1:16534157	ARHGEF19	0.51	5.68	0.45	9e-8	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7172809	0.573	rs2137977	chr15:77575505	T/C	cg22256960	chr15:77711686	NA	-0.47	-4.61	-0.38	9.99e-6	Glucose homeostasis traits;
TGCT	cis	rs9311474	0.607	rs2015971	chr3:52546820	C/T	cg07507251	chr3:52567010	NT5DC2	0.46	6.49	0.5	1.81e-9	Electroencephalogram traits;
TGCT	cis	rs7178572	0.598	rs907373	chr15:77844554	T/C	cg22256960	chr15:77711686	NA	-0.77	-8.79	-0.62	1.03e-14	Type 2 diabetes;
TGCT	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg06028605	chr16:24865363	SLC5A11	0.4	4.45	0.37	1.91e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs2439831	0.681	rs956391	chr15:43617493	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.92	-7.42	-0.55	1.63e-11	Lung cancer in ever smokers;
TGCT	cis	rs13256369	0.851	rs13255061	chr8:8563834	G/A	cg18904891	chr8:8559673	CLDN23	0.59	5.46	0.44	2.54e-7	Obesity-related traits;
TGCT	cis	rs7296418	0.883	rs1727312	chr12:123642220	G/T	cg05973401	chr12:123451056	ABCB9	0.54	4.47	0.37	1.71e-5	Platelet count;
TGCT	cis	rs476633	0.691	rs11858115	chr15:41542591	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.55	-7.43	-0.56	1.54e-11	Glomerular filtration rate (creatinine);
TGCT	cis	rs7582180	0.614	rs1530031	chr2:101009326	T/C	cg14675211	chr2:100938903	LONRF2	0.5	4.82	0.4	4.16e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs881375	0.967	rs1008382	chr9:123681255	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	5.31	0.43	4.83e-7	Rheumatoid arthritis;
TGCT	cis	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg08975724	chr8:8085496	FLJ10661	0.58	5.5	0.44	2.11e-7	Neuroticism;
TGCT	cis	rs13217239	0.646	rs12201393	chr6:26975690	C/A	cg15659132	chr6:26577336	NA	0.55	5.55	0.45	1.62e-7	Schizophrenia;
TGCT	cis	rs67311347	1.000	rs7628247	chr3:40512682	G/T	cg17264618	chr3:40429014	ENTPD3	-0.32	-4.64	-0.38	8.57e-6	Renal cell carcinoma;
TGCT	cis	rs7698623	0.717	rs1982624	chr4:88790847	A/G	cg02735620	chr4:88950514	PKD2	-0.44	-4.81	-0.4	4.22e-6	Cardiovascular disease risk factors;
TGCT	cis	rs3809566	1.000	rs3809566	chr15:63333724	A/G	cg05507819	chr15:63340323	TPM1	0.49	4.6	0.38	1.03e-5	Platelet count;
TGCT	cis	rs2836950	0.565	rs2836934	chr21:40564885	A/C	cg11644478	chr21:40555479	PSMG1	-0.52	-4.9	-0.4	2.88e-6	Menarche (age at onset);
TGCT	cis	rs7208859	0.623	rs216434	chr17:28922335	G/C	cg13385521	chr17:29058706	SUZ12P	0.86	5.14	0.42	1.05e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs72634258	0.554	rs13306061	chr1:7913445	C/T	cg26816564	chr1:7831052	VAMP3	0.64	4.94	0.41	2.46e-6	Inflammatory bowel disease;
TGCT	cis	rs10431058	0.708	rs11212292	chr11:107463936	T/G	cg18204760	chr11:107461044	ELMOD1;LOC643923	0.59	5.1	0.42	1.25e-6	Common traits (Other);
TGCT	cis	rs250677	0.958	rs36078	chr5:148430567	G/A	cg23229984	chr5:148520753	ABLIM3	0.22	5.03	0.41	1.66e-6	Breast cancer;
TGCT	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg06618935	chr21:46677482	NA	-0.37	-5.56	-0.45	1.58e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg13665807	chr20:60559372	TAF4	-0.54	-5.47	-0.44	2.39e-7	Body mass index;
TGCT	cis	rs11083475	0.714	rs1471432	chr19:39260282	G/A	cg22649124	chr19:39282077	LGALS7B	0.32	4.68	0.39	7.33e-6	Heart rate;
TGCT	cis	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg02380750	chr20:61661411	NA	0.33	5.96	0.47	2.4e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs6684514	1.000	rs12563631	chr1:156258953	T/C	cg16558208	chr1:156270281	VHLL	0.46	9.38	0.64	3.92e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs67311347	1.000	rs4974017	chr3:40473519	C/T	cg13683864	chr3:40499215	RPL14	-1.04	-10.79	-0.7	1.54e-19	Renal cell carcinoma;
TGCT	cis	rs6087990	0.899	rs6058893	chr20:31392777	C/T	cg13636640	chr20:31349939	DNMT3B	1.07	15.67	0.82	3.38e-31	Ulcerative colitis;
TGCT	cis	rs6693567	0.545	rs1694386	chr1:150377965	C/G	cg09579323	chr1:150459698	TARS2	0.52	4.64	0.38	8.63e-6	Migraine;
TGCT	cis	rs2404602	0.583	rs12908334	chr15:76581592	C/T	cg22467129	chr15:76604101	ETFA	-0.62	-8.06	-0.59	5.34e-13	Blood metabolite levels;
TGCT	cis	rs921968	0.643	rs10187066	chr2:219514759	A/G	cg02176678	chr2:219576539	TTLL4	0.38	5.47	0.44	2.34e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs617219	0.710	rs2607142	chr5:78557948	T/C	cg23987322	chr5:78407566	BHMT	0.35	4.69	0.39	7.07e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs904251	1.000	rs904251	chr6:37451696	G/T	cg01843034	chr6:37503916	NA	-0.46	-5.44	-0.44	2.72e-7	Cognitive performance;
TGCT	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg19774624	chr17:42201019	HDAC5	-0.84	-8.44	-0.6	7.03e-14	Total body bone mineral density;
TGCT	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg20007245	chr22:24372913	LOC391322	0.76	8.02	0.58	6.75e-13	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs3796352	0.527	rs11716506	chr3:52944328	C/T	cg15956490	chr3:53032818	SFMBT1	0.41	4.57	0.38	1.18e-5	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs7552404	0.889	rs2211080	chr1:76243438	G/A	cg22875332	chr1:76189707	ACADM	0.67	7.31	0.55	2.86e-11	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.84	0.52	3.14e-10	Electroencephalogram traits;
TGCT	cis	rs9303401	0.614	rs17175663	chr17:57108437	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.58	5.82	0.46	4.8e-8	Cognitive test performance;
TGCT	cis	rs67311347	0.544	rs2123998	chr3:40359005	C/G	cg17264618	chr3:40429014	ENTPD3	-0.29	-4.57	-0.38	1.15e-5	Renal cell carcinoma;
TGCT	cis	rs986417	1.000	rs4901995	chr14:61090629	C/G	cg27398547	chr14:60952738	C14orf39	1.41	8.46	0.6	6.27e-14	Gut microbiota (bacterial taxa);
TGCT	cis	rs7010267	0.570	rs7838083	chr8:120016805	A/G	cg17171407	chr8:119960777	TNFRSF11B	0.26	4.59	0.38	1.06e-5	Total body bone mineral density (age 45-60);
TGCT	trans	rs7618501	1.000	rs7431106	chr3:49808374	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	1.03	13.16	0.76	2.65e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs3796352	0.686	rs1560333	chr3:53138254	T/C	cg15956490	chr3:53032818	SFMBT1	-0.48	-5.98	-0.47	2.23e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs11690935	0.632	rs2292816	chr2:172586714	G/C	cg13550731	chr2:172543902	DYNC1I2	0.68	5.97	0.47	2.38e-8	Schizophrenia;
TGCT	cis	rs2274273	0.682	rs7141975	chr14:55542216	G/C	cg01923255	chr14:55878535	KIAA0831	0.56	4.57	0.38	1.15e-5	Protein biomarker;
TGCT	cis	rs1865760	1.000	rs6910138	chr6:25904352	C/G	cg16482183	chr6:26056742	HIST1H1C	0.55	4.97	0.41	2.19e-6	Height;
TGCT	cis	rs7208859	0.524	rs57670615	chr17:29069498	A/G	cg14008862	chr17:28927542	LRRC37B2	0.76	4.52	0.38	1.42e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs9443645	0.901	rs9352686	chr6:79758223	T/G	cg09184832	chr6:79620586	NA	-0.48	-5.34	-0.43	4.21e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs61884328	0.733	rs61897858	chr11:47235263	A/T	cg13308137	chr11:47528955	CUGBP1	0.38	4.56	0.38	1.23e-5	Total body bone mineral density (age over 60);
TGCT	trans	rs324780	0.544	rs10862688	chr12:83922912	C/T	cg27144766	chr5:150604977	CCDC69	0.24	6.91	0.53	2.27e-10	Vertical cup-disc ratio;
TGCT	cis	rs3008870	0.755	rs2815366	chr1:67499930	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.8	8.48	0.61	5.61e-14	Lymphocyte percentage of white cells;
TGCT	cis	rs2046867	0.908	rs62251654	chr3:72816488	C/T	cg25664220	chr3:72788482	NA	-0.56	-7.15	-0.54	6.59e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs17376456	0.542	rs2084916	chr5:93194961	A/T	cg25358565	chr5:93447407	FAM172A	-0.8	-6.09	-0.48	1.31e-8	Diabetic retinopathy;
TGCT	cis	rs1670533	1.000	rs2290408	chr4:1067267	A/C	cg20887711	chr4:1340912	KIAA1530	-0.67	-5.36	-0.43	3.93e-7	Recombination rate (females);
TGCT	cis	rs7914558	1.000	rs11191541	chr10:104824199	A/G	cg15744005	chr10:104629667	AS3MT	-0.39	-4.84	-0.4	3.81e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs9929218	0.551	rs2296408	chr16:68713823	A/C	cg01251360	chr16:68772225	CDH1	0.26	4.87	0.4	3.31e-6	Colorectal cancer;
TGCT	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg07138768	chr7:917805	C7orf20	0.42	5.07	0.41	1.42e-6	Perceived unattractiveness to mosquitoes;
TGCT	cis	rs11167764	0.945	rs4912619	chr5:141471847	G/A	cg23435118	chr5:141488016	NDFIP1	-0.28	-4.64	-0.38	8.69e-6	Crohn's disease;
TGCT	cis	rs55883249	1.000	rs62119423	chr2:9726601	C/T	cg23886495	chr2:9695866	ADAM17	0.77	4.69	0.39	7.19e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs40363	0.729	rs6501176	chr16:3522197	A/G	cg22508957	chr16:3507546	NAT15	-0.45	-5.3	-0.43	5.12e-7	Tuberculosis;
TGCT	cis	rs68170813	0.617	rs6964395	chr7:107080667	G/C	cg02696742	chr7:106810147	HBP1	-0.62	-4.63	-0.38	9.11e-6	Coronary artery disease;
TGCT	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg01341218	chr17:43662625	NA	1.1	8.86	0.62	6.94e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs9926296	0.656	rs7191144	chr16:89823393	C/T	cg03388025	chr16:89894329	SPIRE2	0.33	4.87	0.4	3.31e-6	Vitiligo;
TGCT	cis	rs35160687	0.901	rs12478575	chr2:86535314	C/G	cg03171300	chr2:86307199	POLR1A	0.32	5.57	0.45	1.48e-7	Night sleep phenotypes;
TGCT	cis	rs13191362	1.000	rs34697913	chr6:163000187	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs1008375	1.000	rs3933453	chr4:17636319	A/C	cg10189774	chr4:17578691	LAP3	0.6	5.2	0.42	7.82e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6429082	0.818	rs696248	chr1:235668511	C/A	cg26050004	chr1:235667680	B3GALNT2	0.61	5.45	0.44	2.62e-7	Adiposity;
TGCT	trans	rs877282	0.583	rs10904566	chr10:821662	C/G	cg22713356	chr15:30763199	NA	0.89	6.64	0.51	8.63e-10	Uric acid levels;
TGCT	cis	rs2239547	0.657	rs12496077	chr3:52886241	G/A	cg10802521	chr3:52805072	NEK4	-0.65	-6.14	-0.48	1.02e-8	Schizophrenia;
TGCT	cis	rs694739	0.628	rs617051	chr11:64133638	C/A	cg23796481	chr11:64053134	BAD;GPR137	0.63	6.54	0.51	1.44e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs7914558	1.000	rs10748838	chr10:104943986	T/A	cg15744005	chr10:104629667	AS3MT	-0.39	-4.73	-0.39	5.91e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs10197940	0.662	rs13555	chr2:152333304	C/A	cg19508488	chr2:152266495	RIF1	0.74	6.66	0.51	7.77e-10	Lung cancer;
TGCT	trans	rs10953454	1.000	rs35337480	chr7:104488467	A/G	cg04208666	chr6:19734707	NA	-0.57	-6.89	-0.53	2.52e-10	Obesity;
TGCT	cis	rs7267979	1.000	rs401166	chr20:25446308	C/G	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs763121	0.853	rs6001204	chr22:39100239	T/C	cg06022373	chr22:39101656	GTPBP1	0.78	8.1	0.59	4.34e-13	Menopause (age at onset);
TGCT	trans	rs615632	0.570	rs17734541	chr8:9708433	A/G	cg15556689	chr8:8085844	FLJ10661	0.74	7.31	0.55	2.85e-11	Neuroticism;
TGCT	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg17971929	chr21:40555470	PSMG1	-0.52	-4.72	-0.39	6.14e-6	Menarche (age at onset);
TGCT	cis	rs7937890	1.000	rs2970334	chr11:14329355	C/T	cg19336497	chr11:14380999	RRAS2	0.31	4.93	0.4	2.59e-6	Mitochondrial DNA levels;
TGCT	cis	rs9905704	0.647	rs6503888	chr17:57028126	T/C	cg05425664	chr17:57184151	TRIM37	-0.6	-4.75	-0.39	5.47e-6	Testicular germ cell tumor;
TGCT	cis	rs6570726	0.791	rs6900040	chr6:145893134	C/T	cg23711669	chr6:146136114	FBXO30	0.86	9.54	0.65	1.64e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs71435601	0.628	rs492255	chr2:21384272	C/T	cg25035485	chr2:21266500	APOB	0.51	4.48	0.37	1.64e-5	Cholesterol, total;
TGCT	cis	rs4820539	0.966	rs5996470	chr22:23483255	G/A	cg21100191	chr22:23484243	RTDR1	0.92	11.25	0.71	1.16e-20	Bone mineral density;
TGCT	cis	rs9394841	0.692	rs9381094	chr6:41800629	T/C	cg08135965	chr6:41755394	TOMM6	0.55	5.17	0.42	9.29e-7	Mean corpuscular hemoglobin;Red cell distribution width;
TGCT	cis	rs4285028	0.747	rs7648343	chr3:121426195	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.93	-7.31	-0.55	2.85e-11	Multiple sclerosis;
TGCT	cis	rs2290416	0.688	rs34892354	chr8:144690648	G/C	cg16316162	chr8:144660157	NAPRT1	0.68	4.48	0.37	1.71e-5	Attention deficit hyperactivity disorder;
TGCT	cis	rs200810	0.549	rs62422117	chr6:97996459	T/G	cg16511841	chr6:97730490	C6orf167;MIR548H3	-0.65	-4.45	-0.37	1.91e-5	Body mass index;
TGCT	cis	rs854765	0.551	rs12600546	chr17:17867614	A/G	cg09796270	chr17:17721594	SREBF1	0.23	4.55	0.38	1.27e-5	Total body bone mineral density;
TGCT	cis	rs6121246	0.567	rs6060297	chr20:30198560	A/G	cg13852791	chr20:30311386	BCL2L1	0.7	4.58	0.38	1.1e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs2153535	0.562	rs9379211	chr6:8463927	C/T	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg26818010	chr10:134567672	INPP5A	-0.39	-5.72	-0.46	7.66e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs7617773	0.851	rs6775179	chr3:48313418	T/C	cg11946769	chr3:48343235	NME6	0.72	6.2	0.49	7.83e-9	Coronary artery disease;
TGCT	cis	rs9926296	0.643	rs12596429	chr16:89841374	T/C	cg21285383	chr16:89894308	SPIRE2	0.32	4.55	0.38	1.27e-5	Vitiligo;
TGCT	cis	rs12142240	0.698	rs28578741	chr1:46825176	T/C	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg22105103	chr4:187893119	NA	0.34	4.73	0.39	5.91e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg10150615	chr22:24372951	LOC391322	-0.82	-8.88	-0.62	6.32e-15	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6866344	0.697	rs17184344	chr5:178129281	A/G	cg03877680	chr5:178157825	ZNF354A	0.72	5.84	0.46	4.2e-8	Neutrophil percentage of white cells;
TGCT	cis	rs1113500	0.580	rs1781058	chr1:108564059	C/G	cg22161131	chr1:109420278	GPSM2	0.49	4.45	0.37	1.9e-5	Growth-regulated protein alpha levels;
TGCT	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs3099143	1.000	rs3106378	chr15:77110524	A/C	cg21673338	chr15:77095150	SCAPER	-0.52	-4.97	-0.41	2.15e-6	Recalcitrant atopic dermatitis;
TGCT	cis	rs6977660	0.652	rs12673842	chr7:19747437	T/C	cg05791153	chr7:19748676	TWISTNB	1.21	7.93	0.58	1.07e-12	Thyroid stimulating hormone;
TGCT	cis	rs9486719	1.000	rs13207333	chr6:96882254	T/C	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.21	-0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg06028808	chr11:68637592	NA	0.54	6.94	0.53	1.93e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9325144	0.600	rs2171405	chr12:38741030	G/T	cg26384229	chr12:38710491	ALG10B	-0.61	-5.58	-0.45	1.43e-7	Morning vs. evening chronotype;
TGCT	cis	rs2677744	0.626	rs868547	chr15:91498760	G/A	cg01710897	chr15:91497902	RCCD1	0.34	4.84	0.4	3.83e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.87	-9.24	-0.64	8.59e-16	Menarche (age at onset);
TGCT	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg00343986	chr7:65444356	GUSB	0.21	5.14	0.42	1.03e-6	Calcium levels;
TGCT	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg04317338	chr11:64019027	PLCB3	0.78	6.46	0.5	2.17e-9	Mean platelet volume;
TGCT	cis	rs5769707	0.967	rs9616327	chr22:50010891	G/A	cg20744362	chr22:50050164	C22orf34	0.28	4.62	0.38	9.61e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs6663390	0.510	rs12566127	chr1:208070646	C/T	cg03990033	chr1:208084030	CD34	0.64	4.46	0.37	1.81e-5	Facial morphology (factor 18);
TGCT	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg00343986	chr7:65444356	GUSB	-0.25	-5.8	-0.46	5.09e-8	Aortic root size;
TGCT	cis	rs7617773	0.817	rs9853804	chr3:48327729	T/C	cg11946769	chr3:48343235	NME6	0.74	6.34	0.49	3.97e-9	Coronary artery disease;
TGCT	cis	rs1163251	0.869	rs629735	chr1:120206932	G/T	cg19096424	chr1:120255104	PHGDH	-0.58	-5.37	-0.43	3.79e-7	Blood metabolite levels;
TGCT	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg06896619	chr17:61851486	DDX42;CCDC47	0.48	4.53	0.38	1.37e-5	Prudent dietary pattern;
TGCT	trans	rs208520	1.000	rs208537	chr6:66963544	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.88	-8.21	-0.59	2.37e-13	Exhaled nitric oxide output;
TGCT	cis	rs2016266	0.859	rs11170506	chr12:53730759	G/T	cg16917193	chr12:54089295	NA	-0.71	-4.66	-0.39	8.11e-6	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs6087990	0.806	rs4911258	chr20:31369479	G/A	cg13636640	chr20:31349939	DNMT3B	1.06	12.99	0.76	6.85e-25	Ulcerative colitis;
TGCT	cis	rs9814567	0.929	rs9815297	chr3:134215052	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.93	-9.28	-0.64	7.11e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs11190604	0.767	rs77769532	chr10:102193646	T/C	cg23241863	chr10:102295624	HIF1AN	0.65	4.89	0.4	3e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs10746514	0.804	rs11122429	chr1:232261532	G/A	cg09506761	chr1:232265262	NA	-0.47	-4.74	-0.39	5.7e-6	Response to statin therapy;
TGCT	cis	rs3087591	0.960	rs9903754	chr17:29634468	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.48	-7.57	-0.56	7.2e-12	Hip circumference;
TGCT	cis	rs12134245	0.776	rs625525	chr1:91997593	C/T	cg02896835	chr1:92012615	NA	-0.26	-4.75	-0.39	5.59e-6	Breast cancer;
TGCT	cis	rs7772486	0.686	rs4896828	chr6:145953339	A/C	cg23711669	chr6:146136114	FBXO30	0.85	9.48	0.65	2.33e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2013441	0.965	rs2386485	chr17:20095246	G/A	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.61	-0.38	9.96e-6	Obesity-related traits;
TGCT	cis	rs709400	1.000	rs57218990	chr14:104128007	T/A	cg26031613	chr14:104095156	KLC1	1.14	17.16	0.84	1.53e-34	Body mass index;
TGCT	cis	rs13191362	1.000	rs4260737	chr6:163137746	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.0	7.73	0.57	3.24e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg11845111	chr2:191398756	TMEM194B	0.37	5.65	0.45	1.03e-7	Pulse pressure;
TGCT	cis	rs35146811	0.735	rs1636975	chr7:99812089	A/G	cg00553149	chr7:99775558	STAG3;GPC2	-0.31	-4.61	-0.38	9.75e-6	Coronary artery disease;
TGCT	cis	rs6121246	0.909	rs6089071	chr20:30378384	C/G	cg13852791	chr20:30311386	BCL2L1	0.8	6.12	0.48	1.15e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs7681440	0.904	rs3806789	chr4:90759556	C/T	cg26578617	chr4:90757533	SNCA	-0.48	-4.95	-0.41	2.35e-6	Dementia with Lewy bodies;
TGCT	cis	rs35160687	0.901	rs13017338	chr2:86501553	T/C	cg03171300	chr2:86307199	POLR1A	0.32	5.49	0.44	2.18e-7	Night sleep phenotypes;
TGCT	cis	rs6088580	0.634	rs9789792	chr20:32957709	G/A	cg06115741	chr20:33292138	TP53INP2	-0.55	-4.9	-0.4	2.97e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs3741151	1.000	rs79078097	chr11:73049771	G/A	cg17517138	chr11:73019481	ARHGEF17	1.18	6.18	0.49	8.29e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
TGCT	cis	rs981844	1.000	rs2606325	chr4:154652681	C/T	cg14289246	chr4:154710475	SFRP2	1.01	8.56	0.61	3.55e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs7429990	0.932	rs13085054	chr3:48134137	C/T	cg11946769	chr3:48343235	NME6	-0.57	-4.77	-0.39	5.14e-6	Educational attainment (years of education);
TGCT	cis	rs73058052	0.597	rs7249925	chr19:50093572	A/G	cg09250473	chr19:50168907	IRF3;BCL2L12	0.68	5.93	0.47	2.83e-8	Fibrinogen levels;
TGCT	cis	rs10089	1.000	rs77086350	chr5:127494431	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	7.4	0.55	1.77e-11	Ileal carcinoids;
TGCT	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.56	-5.35	-0.43	4.16e-7	Electroencephalogram traits;
TGCT	cis	rs7586879	0.639	rs6713978	chr2:25120851	T/C	cg15423357	chr2:25149977	NA	0.5	4.89	0.4	3.06e-6	Body mass index;
TGCT	cis	rs11098499	0.874	rs6832670	chr4:120118792	A/G	cg09307838	chr4:120376055	NA	0.5	4.64	0.38	8.86e-6	Corneal astigmatism;
TGCT	cis	rs8179	1.000	rs4272	chr7:92236829	C/T	cg15732164	chr7:92237376	CDK6	0.34	5.38	0.44	3.56e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
TGCT	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg08859206	chr1:53392774	SCP2	0.4	5.96	0.47	2.46e-8	Monocyte count;
TGCT	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg22963979	chr7:1858916	MAD1L1	-0.45	-7.41	-0.55	1.74e-11	Bipolar disorder and schizophrenia;
TGCT	cis	rs250677	0.617	rs166106	chr5:148447061	T/C	cg23229984	chr5:148520753	ABLIM3	0.22	4.98	0.41	2.05e-6	Breast cancer;
TGCT	cis	rs4478858	0.684	rs3766289	chr1:31760128	G/A	cg07478791	chr1:31886160	SERINC2	-0.49	-4.91	-0.4	2.82e-6	Alcohol dependence;
TGCT	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg22968622	chr17:43663579	NA	-1.23	-10.98	-0.7	5.31e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs1153858	1.000	rs67461176	chr15:45676819	C/T	cg26924012	chr15:45694286	SPATA5L1	1.09	15.08	0.8	7.99e-30	Homoarginine levels;
TGCT	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg11764359	chr7:65958608	NA	0.59	5.29	0.43	5.45e-7	Aortic root size;
TGCT	cis	rs904251	0.504	rs1757188	chr6:37483808	A/G	cg08126542	chr6:37504118	NA	-0.44	-6.47	-0.5	2.04e-9	Cognitive performance;
TGCT	cis	rs6921919	0.525	rs9468360	chr6:28344438	T/G	cg18815343	chr6:28367644	ZSCAN12	-0.56	-5.33	-0.43	4.48e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7772486	0.875	rs1331640	chr6:146427250	G/A	cg23711669	chr6:146136114	FBXO30	0.91	9.94	0.67	1.79e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6121246	0.609	rs6060843	chr20:30297047	G/C	cg18721089	chr20:30220636	NA	-0.36	-4.56	-0.38	1.2e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg22764044	chr5:178986830	RUFY1	0.52	6.1	0.48	1.22e-8	Lung cancer;
TGCT	cis	rs9733	0.519	rs11587444	chr1:150722844	A/G	cg09365446	chr1:150670422	GOLPH3L	0.32	4.73	0.39	6.05e-6	Tonsillectomy;
TGCT	cis	rs9487051	0.714	rs6903695	chr6:109631422	C/G	cg01475377	chr6:109611718	NA	0.31	4.9	0.4	2.88e-6	Reticulocyte fraction of red cells;
TGCT	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg18654377	chr3:49208889	KLHDC8B	-0.42	-5.43	-0.44	2.85e-7	Parkinson's disease;
TGCT	cis	rs9341808	0.727	rs10943697	chr6:80931506	A/C	cg08355045	chr6:80787529	NA	0.31	5.4	0.44	3.2e-7	Sitting height ratio;
TGCT	cis	rs2243480	0.615	rs34363376	chr7:65939536	T/C	cg20637647	chr7:64974828	NA	0.91	5.33	0.43	4.55e-7	Diabetic kidney disease;
TGCT	cis	rs1018836	0.923	rs6998150	chr8:91645969	A/C	cg16814680	chr8:91681699	NA	-0.88	-9.64	-0.65	9.18e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2228479	0.850	rs17233448	chr16:89816424	G/T	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg08859206	chr1:53392774	SCP2	0.4	5.97	0.47	2.38e-8	Monocyte count;
TGCT	cis	rs950169	0.580	rs4603535	chr15:85173872	C/T	cg12863693	chr15:85201151	NMB	0.46	5.56	0.45	1.6e-7	Schizophrenia;
TGCT	cis	rs2235642	0.653	rs7197288	chr16:1654753	C/A	cg11375102	chr16:1583810	IFT140;TMEM204	-0.27	-4.58	-0.38	1.12e-5	Coronary artery disease;
TGCT	trans	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg17830980	chr10:43048298	ZNF37B	-0.81	-10.01	-0.67	1.19e-17	Extrinsic epigenetic age acceleration;
TGCT	cis	rs1915146	0.967	rs7086481	chr10:126844523	A/T	cg23000734	chr10:126850823	CTBP2	-0.54	-6.18	-0.49	8.27e-9	Menarche (age at onset);
TGCT	cis	rs9611565	0.649	rs5758434	chr22:42116163	G/A	cg17554472	chr22:41940697	POLR3H	0.45	4.84	0.4	3.72e-6	Vitiligo;
TGCT	cis	rs10254284	0.851	rs740123	chr7:28166455	G/C	cg23620719	chr7:28220237	JAZF1	-0.54	-4.84	-0.4	3.71e-6	Lymphocyte percentage of white cells;Systemic lupus erythematosus;
TGCT	cis	rs7439150	0.954	rs72679194	chr4:155473212	G/T	cg22130008	chr4:155548532	NA	-0.43	-5.38	-0.44	3.5e-7	Fibrinogen levels;
TGCT	cis	rs10089	0.857	rs7718286	chr5:127459414	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	7.41	0.55	1.72e-11	Ileal carcinoids;
TGCT	cis	rs1008375	0.544	rs7685265	chr4:17568510	C/T	cg10189774	chr4:17578691	LAP3	0.59	4.89	0.4	3.03e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6582630	0.537	rs6582500	chr12:38534206	G/A	cg13010199	chr12:38710504	ALG10B	0.65	5.18	0.42	8.78e-7	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs67311347	1.000	rs6762251	chr3:40531136	A/G	cg17264618	chr3:40429014	ENTPD3	-0.35	-5.17	-0.42	9.04e-7	Renal cell carcinoma;
TGCT	cis	rs4919044	0.808	rs4917898	chr10:94808637	T/A	cg05127821	chr10:94822908	CYP26C1	-0.74	-4.83	-0.4	3.95e-6	Coronary artery disease;
TGCT	cis	rs56104184	0.779	rs17206693	chr19:49360252	C/G	cg17863274	chr19:49399704	TULP2	-0.46	-5.49	-0.44	2.13e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs8077889	0.672	rs1230400	chr17:41845451	G/A	cg26893861	chr17:41843967	DUSP3	-1.16	-21.87	-0.89	2.22e-44	Triglycerides;
TGCT	cis	rs6664467	1	rs6664467	chr1:151738403	G/A	cg07092448	chr1:151763213	TDRKH	-1.23	-8.17	-0.59	3.01e-13	Carotid plaque burden;
TGCT	cis	rs2243480	1.000	rs160642	chr7:65558373	C/T	cg18252515	chr7:66147081	NA	-1.1	-7.18	-0.54	5.77e-11	Diabetic kidney disease;
TGCT	cis	rs9560113	1.000	rs4773386	chr13:112180896	C/G	cg14154082	chr13:112174009	NA	0.37	5.07	0.41	1.42e-6	Menarche (age at onset);
TGCT	cis	rs2439831	0.867	rs2614811	chr15:43913487	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.8	5.15	0.42	9.77e-7	Lung cancer in ever smokers;
TGCT	cis	rs2153535	0.580	rs6912374	chr6:8456423	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs936229	0.690	rs2472300	chr15:75033909	A/G	cg10253484	chr15:75165896	SCAMP2	-0.57	-4.85	-0.4	3.63e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
TGCT	cis	rs12681287	0.640	rs7460650	chr8:87474085	A/G	cg27223183	chr8:87520930	FAM82B	-0.89	-6.43	-0.5	2.54e-9	Caudate activity during reward;
TGCT	cis	rs533581	0.866	rs871756	chr16:88969076	G/C	cg16701003	chr16:89028210	CBFA2T3	0.37	4.93	0.4	2.62e-6	Social autistic-like traits;
TGCT	cis	rs7216064	0.861	rs62084252	chr17:65879578	G/C	cg12091567	chr17:66097778	LOC651250	-0.87	-6.85	-0.52	3.1e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs9914544	0.545	rs7222893	chr17:18811702	A/G	cg26378065	chr17:18585709	ZNF286B	0.51	4.5	0.37	1.53e-5	Educational attainment (years of education);
TGCT	cis	rs11718455	0.883	rs4682926	chr3:44006170	C/T	cg08738300	chr3:44038990	NA	0.85	6.34	0.49	3.94e-9	Coronary artery disease;
TGCT	cis	rs7954584	0.560	rs745327	chr12:122456524	T/C	cg22168489	chr12:122356033	WDR66	-0.2	-4.71	-0.39	6.64e-6	Mean corpuscular volume;
TGCT	cis	rs28595532	0.844	rs80188901	chr4:119500014	C/T	cg11846333	chr4:119757529	SEC24D	0.96	4.75	0.39	5.58e-6	Cannabis dependence symptom count;
TGCT	cis	rs11792861	0.816	rs28361186	chr9:111704064	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.53	5.0	0.41	1.88e-6	Menarche (age at onset);
TGCT	cis	rs1372520	0.873	rs983361	chr4:90761944	T/G	cg15133208	chr4:90757351	SNCA	-0.46	-5.59	-0.45	1.39e-7	Neuroticism;
TGCT	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg02038168	chr22:39784481	NA	-0.67	-6.03	-0.48	1.78e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs3015497	0.616	rs1494181	chr14:51056600	C/T	cg04730355	chr14:51134070	SAV1	-0.64	-6.26	-0.49	5.77e-9	Mean platelet volume;
TGCT	cis	rs16866061	1.000	rs11681451	chr2:225334104	T/C	cg12698349	chr2:225449008	CUL3	0.96	9.4	0.65	3.52e-16	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg07507251	chr3:52567010	NT5DC2	0.47	6.64	0.51	8.85e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs13631	1.000	rs13631	chr9:140006202	G/A	cg14289826	chr9:140003911	NA	0.29	6.47	0.5	2.02e-9	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg04267008	chr7:1944627	MAD1L1	-0.35	-4.51	-0.38	1.5e-5	Bipolar disorder and schizophrenia;
TGCT	cis	rs6700896	0.522	rs17127905	chr1:66157125	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.54	4.44	0.37	1.98e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs2996428	0.667	rs72640928	chr1:3768568	T/C	cg17848003	chr1:3704513	LRRC47	0.18	5.15	0.42	9.99e-7	Red cell distribution width;
TGCT	cis	rs6750047	0.647	rs62136320	chr2:38275953	T/G	cg07380506	chr2:38303506	CYP1B1	0.62	5.7	0.46	8.25e-8	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs5771225	0.544	rs909688	chr22:50689030	A/G	cg16473166	chr22:50639996	SELO	0.7	5.73	0.46	7.2e-8	Late-onset Alzheimer's disease;
TGCT	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg11890956	chr21:40555474	PSMG1	1.1	12.28	0.74	3.66e-23	Cognitive function;
TGCT	cis	rs6095298	0.595	rs1885287	chr20:47435117	C/T	cg12307787	chr20:48099359	KCNB1	0.43	4.53	0.38	1.37e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs9611565	0.694	rs5758389	chr22:41941749	T/C	cg06634786	chr22:41940651	POLR3H	-0.81	-8.07	-0.59	5.26e-13	Vitiligo;
TGCT	trans	rs2970818	0.831	rs2970810	chr12:4608103	A/G	cg23273947	chr15:68267131	NA	0.27	7.22	0.54	4.67e-11	Phosphorus levels;
TGCT	cis	rs7100689	0.646	rs2039757	chr10:82078868	C/A	cg01528321	chr10:82214614	TSPAN14	0.75	7.49	0.56	1.15e-11	Post bronchodilator FEV1;
TGCT	cis	rs6992820	1.000	rs6992820	chr8:56764456	A/G	cg06880721	chr8:56792545	LYN	-0.66	-5.54	-0.45	1.69e-7	Mean platelet volume;
TGCT	cis	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg20637647	chr7:64974828	NA	0.92	5.36	0.43	3.87e-7	Diabetic kidney disease;
TGCT	cis	rs17345786	1.000	rs3804778	chr3:101294572	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.86	8.79	0.62	1.01e-14	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs250677	0.687	rs2963485	chr5:148452043	A/G	cg23229984	chr5:148520753	ABLIM3	-0.2	-4.68	-0.39	7.4e-6	Breast cancer;
TGCT	cis	rs9926296	0.744	rs154657	chr16:89708096	A/G	cg27121462	chr16:89883253	FANCA	0.49	4.58	0.38	1.11e-5	Vitiligo;
TGCT	cis	rs13223928	0.621	rs4722438	chr7:3155813	A/G	cg19214707	chr7:3157722	NA	0.47	7.21	0.54	4.73e-11	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
TGCT	cis	rs3008870	0.755	rs2815363	chr1:67497221	A/G	cg11518657	chr1:67396239	MIER1	-0.47	-4.61	-0.38	9.68e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs11992186	0.505	rs7845203	chr8:8145440	A/G	cg15556689	chr8:8085844	FLJ10661	0.67	5.9	0.47	3.27e-8	Neuroticism;
TGCT	cis	rs6918586	0.681	rs198831	chr6:26116996	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.71	-6.76	-0.52	4.93e-10	Schizophrenia;
TGCT	trans	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg13615516	chr5:77269221	NA	0.68	8.54	0.61	3.97e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2180341	0.781	rs6913350	chr6:127570560	C/T	cg24812749	chr6:127587940	RNF146	0.79	6.6	0.51	1.09e-9	Breast cancer;
TGCT	cis	rs6547741	0.844	rs9941696	chr2:27920064	C/T	cg27432699	chr2:27873401	GPN1	-0.24	-6.05	-0.48	1.57e-8	Oral cavity cancer;
TGCT	cis	rs6426558	0.537	rs4500279	chr1:227484482	G/A	cg10327440	chr1:227177885	CDC42BPA	0.58	6.88	0.53	2.6e-10	Neutrophil percentage of white cells;
TGCT	cis	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg06636001	chr8:8085503	FLJ10661	-0.7	-6.51	-0.5	1.69e-9	Mood instability;
TGCT	cis	rs6815814	0.768	rs6835514	chr4:38894380	C/T	cg02016764	chr4:38805732	TLR1	0.25	4.47	0.37	1.71e-5	Breast cancer;
TGCT	cis	rs8192284	0.965	rs4129267	chr1:154426264	C/T	cg00791854	chr1:154392070	IL6R	0.29	4.63	0.38	9.04e-6	Fibrinogen;C-reactive protein;Fibrinogen levels;
TGCT	cis	rs453301	0.686	rs1045527	chr8:8890041	A/G	cg00184457	chr8:8946301	NA	-0.26	-4.96	-0.41	2.22e-6	Joint mobility (Beighton score);
TGCT	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg06634786	chr22:41940651	POLR3H	0.87	8.2	0.59	2.56e-13	Vitiligo;
TGCT	cis	rs259282	0.583	rs3760938	chr19:33106907	C/T	cg26639809	chr19:33781782	NA	0.25	5.04	0.41	1.6e-6	Schizophrenia;
TGCT	cis	rs9814567	0.806	rs1880374	chr3:134322113	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.76	-7.11	-0.54	8.15e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs910316	1.000	rs13099	chr14:75599155	G/A	cg08847533	chr14:75593920	NEK9	-0.91	-9.69	-0.66	7.1e-17	Height;
TGCT	trans	rs941408	1.000	rs1736183	chr19:2809672	A/G	cg22153745	chr1:153894579	GATAD2B	-0.63	-7.23	-0.54	4.25e-11	Total cholesterol levels;
TGCT	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg01802117	chr1:53393560	SCP2	-0.39	-4.55	-0.38	1.27e-5	Monocyte count;
TGCT	trans	rs10802346	0.514	rs4443861	chr1:246372574	G/T	cg13514129	chr1:39547527	MACF1	0.83	7.37	0.55	2.06e-11	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs9467773	0.620	rs2504540	chr6:26641626	A/G	cg15659132	chr6:26577336	NA	0.86	10.81	0.7	1.36e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs9308731	0.966	rs3827536	chr2:111920741	G/T	cg04202892	chr2:111875749	ACOXL	0.43	4.6	0.38	1.04e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs2639990	1.000	rs632157	chr18:72911548	G/A	cg02750262	chr18:72916776	ZADH2	0.88	6.43	0.5	2.49e-9	Vascular endothelial growth factor levels;
TGCT	cis	rs739496	0.947	rs2285520	chr12:111867487	C/T	cg10833066	chr12:111807467	FAM109A	0.37	5.2	0.42	8.01e-7	Platelet count;
TGCT	cis	rs11614913	0.509	rs12300425	chr12:54395082	G/T	cg03037150	chr12:54402717	HOXC8	-0.59	-5.19	-0.42	8.4e-7	Waist circumference adjusted for body mass index;
TGCT	cis	rs9972944	0.657	rs9904302	chr17:63758238	A/G	cg07283582	chr17:63770753	CCDC46	-0.24	-4.84	-0.4	3.72e-6	Total body bone mineral density;
TGCT	cis	rs3772130	0.923	rs4298081	chr3:121526037	T/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.72	0.39	6.25e-6	Cognitive performance;
TGCT	cis	rs4975709	0.758	rs4975756	chr5:1882443	T/C	cg14773178	chr5:1868261	NA	0.35	4.73	0.39	6.08e-6	Cardiovascular disease risk factors;
TGCT	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg10802521	chr3:52805072	NEK4	-0.75	-9.32	-0.64	5.72e-16	Bipolar disorder;
TGCT	cis	rs478607	0.831	rs59739006	chr11:64415903	C/T	cg19395706	chr11:64412079	NRXN2	0.48	4.84	0.4	3.8e-6	Urate levels;
TGCT	cis	rs1975974	1.000	rs7224508	chr17:21722352	T/A	cg18423549	chr17:21743878	NA	-0.55	-5.25	-0.43	6.52e-7	Psoriasis;
TGCT	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg07061783	chr6:25882402	NA	-0.42	-4.51	-0.38	1.51e-5	Blood metabolite levels;
TGCT	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg22433210	chr17:43662623	NA	1.04	7.37	0.55	2.07e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg06753367	chr22:24256600	NA	-0.25	-4.73	-0.39	5.98e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6429082	0.818	rs291344	chr1:235663860	C/G	cg26050004	chr1:235667680	B3GALNT2	-0.56	-4.97	-0.41	2.19e-6	Adiposity;
TGCT	cis	rs6912958	0.559	rs373646	chr6:88056896	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.69	7.07	0.54	1.02e-10	Monocyte percentage of white cells;
TGCT	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg07870213	chr5:140052090	DND1	0.63	7.6	0.56	6.35e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs77972916	0.519	rs13411327	chr2:43515483	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-4.96	-0.41	2.23e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs10045504	0.502	rs17352751	chr5:38737836	G/A	cg15396434	chr5:38725168	NA	-0.35	-4.47	-0.37	1.78e-5	Night sleep phenotypes;
TGCT	cis	rs7681440	0.904	rs6817001	chr4:90766019	C/T	cg14346243	chr4:90757452	SNCA	-0.57	-5.6	-0.45	1.31e-7	Dementia with Lewy bodies;
TGCT	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg11764359	chr7:65958608	NA	-0.55	-4.87	-0.4	3.3e-6	Aortic root size;
TGCT	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg11062466	chr8:58055876	NA	0.34	4.67	0.39	7.79e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs3733585	0.624	rs58130873	chr4:9972081	T/C	cg11266682	chr4:10021025	SLC2A9	-0.59	-7.85	-0.58	1.63e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs6840360	0.571	rs4696102	chr4:152529658	C/T	cg17479576	chr4:152424074	FAM160A1	-0.71	-7.72	-0.57	3.41e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs2180341	1.000	rs2326567	chr6:127606160	G/A	cg24812749	chr6:127587940	RNF146	0.99	7.72	0.57	3.33e-12	Breast cancer;
TGCT	cis	rs7412746	0.658	rs57818453	chr1:150763139	G/A	cg09365446	chr1:150670422	GOLPH3L	0.36	5.19	0.42	8.25e-7	Melanoma;
TGCT	cis	rs7635838	0.892	rs4684773	chr3:11418508	C/T	cg00170343	chr3:11313890	ATG7	0.63	5.92	0.47	2.98e-8	HDL cholesterol;
TGCT	cis	rs28489187	0.505	rs7525786	chr1:85884076	C/T	cg16011679	chr1:85725395	C1orf52	-0.51	-4.66	-0.39	7.9e-6	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
TGCT	cis	rs6701037	0.566	rs13373754	chr1:175139275	C/A	cg08873628	chr1:175162347	KIAA0040	0.48	4.57	0.38	1.15e-5	Alcohol dependence;
TGCT	cis	rs9905704	0.647	rs9901655	chr17:56987142	G/A	cg05425664	chr17:57184151	TRIM37	-0.57	-4.44	-0.37	1.97e-5	Testicular germ cell tumor;
TGCT	cis	rs13191362	0.935	rs34709632	chr6:163048380	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.89	6.39	0.5	3.1e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs77861329	1.000	rs9843852	chr3:52132029	C/G	cg08692210	chr3:52188851	WDR51A	0.86	4.46	0.37	1.79e-5	Macrophage inflammatory protein 1b levels;
TGCT	cis	rs644799	0.965	rs502521	chr11:95533557	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	8.74	0.62	1.39e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs644799	1.000	rs7749	chr11:95565789	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.88	9.59	0.65	1.24e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs4689388	0.889	rs10026334	chr4:6294607	G/A	cg00701064	chr4:6280414	WFS1	0.37	4.72	0.39	6.3e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg08975724	chr8:8085496	FLJ10661	-0.57	-5.49	-0.44	2.14e-7	Mood instability;
TGCT	cis	rs1420338	0.933	rs6462533	chr7:34168028	G/A	cg01275685	chr7:34179230	BMPER	-0.25	-4.57	-0.38	1.16e-5	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs2197308	0.585	rs10878014	chr12:38114496	A/G	cg26384229	chr12:38710491	ALG10B	0.58	5.09	0.42	1.28e-6	Morning vs. evening chronotype;
TGCT	cis	rs35306767	0.855	rs55708963	chr10:925712	C/A	cg26597838	chr10:835615	NA	0.8	12.11	0.74	9.26e-23	Eosinophil percentage of granulocytes;
TGCT	cis	rs6748734	1.000	rs4675874	chr2:241819796	A/G	cg04034577	chr2:241836375	C2orf54	0.39	6.23	0.49	6.66e-9	Urinary metabolites;
TGCT	cis	rs11105298	1.000	rs11105298	chr12:89876143	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	0.71	5.25	0.43	6.38e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs9549367	0.789	rs3764125	chr13:113897648	A/G	cg18105134	chr13:113819100	PROZ	0.31	5.13	0.42	1.08e-6	Platelet distribution width;
TGCT	cis	rs1048238	0.506	rs848210	chr1:16259813	A/G	cg22431228	chr1:16359049	CLCNKA	0.23	4.51	0.38	1.46e-5	Systolic blood pressure;
TGCT	cis	rs9796	0.717	rs476633	chr15:41392134	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.52	-6.76	-0.52	4.79e-10	Menopause (age at onset);
TGCT	cis	rs7216169	1	rs7216169	chr17:5219511	C/T	cg21654974	chr17:5389607	DERL2;MIS12	1.08	6.01	0.47	1.95e-8	Red blood cell density in sickle cell anemia;
TGCT	cis	rs10131894	0.508	rs175006	chr14:75445499	C/G	cg08847533	chr14:75593920	NEK9	-0.74	-6.04	-0.48	1.66e-8	Coronary artery disease;
TGCT	cis	rs6831352	0.918	rs17218602	chr4:100061073	A/G	cg12011299	chr4:100065546	ADH4	-0.41	-4.97	-0.41	2.21e-6	Alcohol dependence;
TGCT	cis	rs7208859	0.673	rs36056619	chr17:29172284	T/C	cg18442181	chr17:29233375	C17orf42	-0.78	-4.61	-0.38	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs9467711	0.606	rs9379856	chr6:26366836	A/C	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg18188782	chr20:61659543	NA	0.44	5.37	0.43	3.73e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs478304	0.593	rs2236682	chr11:65480090	G/T	cg27068330	chr11:65405492	SIPA1	-0.96	-9.18	-0.64	1.19e-15	Acne (severe);
TGCT	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg12963246	chr6:28129442	ZNF389	0.52	5.1	0.42	1.23e-6	Depression;
TGCT	cis	rs7267979	0.744	rs6050464	chr20:25209299	C/A	cg14121845	chr20:25566513	NINL	0.48	4.96	0.41	2.31e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9487051	0.714	rs9386797	chr6:109632520	C/A	cg01475377	chr6:109611718	NA	-0.31	-4.73	-0.39	6.12e-6	Reticulocyte fraction of red cells;
TGCT	cis	rs6500602	0.647	rs3747600	chr16:4586222	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.29	5.49	0.44	2.18e-7	Schizophrenia;
TGCT	cis	rs9325144	0.600	rs10748442	chr12:38732939	A/T	cg26384229	chr12:38710491	ALG10B	0.61	5.65	0.45	1.05e-7	Morning vs. evening chronotype;
TGCT	cis	rs611744	0.870	rs640068	chr8:109158002	A/G	cg21045802	chr8:109455806	TTC35	0.55	4.8	0.4	4.57e-6	Dupuytren's disease;
TGCT	cis	rs7772486	0.790	rs9376968	chr6:146180364	T/C	cg13319975	chr6:146136371	FBXO30	-0.5	-4.47	-0.37	1.74e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9457247	1.000	rs365189	chr6:167384545	G/A	cg25258033	chr6:167368657	RNASET2	0.18	4.49	0.37	1.63e-5	Crohn's disease;
TGCT	cis	rs1023500	0.573	rs133380	chr22:42468910	C/T	cg15557168	chr22:42548783	NA	-0.23	-5.85	-0.46	4.16e-8	Schizophrenia;
TGCT	cis	rs2463822	1.000	rs951677	chr11:62107249	G/C	cg23876832	chr11:62092739	NA	0.65	4.56	0.38	1.19e-5	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs12477438	0.871	rs13396584	chr2:99611768	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.78	6.6	0.51	1.09e-9	Chronic sinus infection;
TGCT	cis	rs1577917	1.000	rs12203493	chr6:86758642	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.2	-0.42	8.12e-7	Response to antipsychotic treatment;
TGCT	cis	rs10488031	0.850	rs6955605	chr7:37109868	C/A	cg06458904	chr7:36312573	EEPD1	0.54	4.62	0.38	9.64e-6	QT interval;
TGCT	cis	rs9467773	1.000	rs2255070	chr6:26501777	C/G	cg09904177	chr6:26538194	HMGN4	0.62	6.14	0.48	1.01e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs13242816	1.000	rs67652573	chr7:116109958	T/C	cg02799643	chr7:116139180	CAV2	-0.48	-5.52	-0.44	1.87e-7	P wave duration;
TGCT	cis	rs2637266	0.703	rs2920792	chr10:78532842	A/T	cg18941641	chr10:78392320	NA	-0.4	-4.77	-0.39	5.1e-6	Pulmonary function;
TGCT	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg08509172	chr19:19383838	TM6SF2	-0.35	-4.6	-0.38	1.02e-5	Tonsillectomy;
TGCT	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.29	-4.49	-0.37	1.64e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7178572	0.568	rs1191196	chr15:77646504	C/T	cg22256960	chr15:77711686	NA	0.85	8.73	0.62	1.4e-14	Type 2 diabetes;
TGCT	cis	rs9916302	0.660	rs665413	chr17:37455678	T/A	cg07936489	chr17:37558343	FBXL20	0.87	6.27	0.49	5.47e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg10802521	chr3:52805072	NEK4	-0.78	-10.01	-0.67	1.22e-17	Bipolar disorder;
TGCT	cis	rs1903068	0.853	rs9312657	chr4:56003502	G/A	cg01777861	chr4:56023843	NA	0.53	6.21	0.49	7.2e-9	Endometriosis;
TGCT	cis	rs526231	0.784	rs28157	chr5:102595837	G/T	cg05225461	chr5:102596755	C5orf30	0.23	4.68	0.39	7.29e-6	Primary biliary cholangitis;
TGCT	cis	rs2067615	0.579	rs10861657	chr12:107131314	A/G	cg15890332	chr12:107067104	RFX4	0.3	5.93	0.47	2.85e-8	Heart rate;
TGCT	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg06634786	chr22:41940651	POLR3H	-0.86	-8.34	-0.6	1.18e-13	Vitiligo;
TGCT	cis	rs12579753	1.000	rs12366580	chr12:82222784	G/A	cg07988820	chr12:82153109	PPFIA2	-0.6	-6.48	-0.5	1.91e-9	Resting heart rate;
TGCT	cis	rs13424612	1.000	rs13424612	chr2:240900121	C/T	cg26363272	chr2:240904871	NDUFA10	0.3	5.13	0.42	1.07e-6	Odorant perception (isobutyraldehyde);
TGCT	cis	rs6543140	0.964	rs1523206	chr2:103070175	A/T	cg09003973	chr2:102972529	NA	0.55	4.67	0.39	7.71e-6	Blood protein levels;
TGCT	cis	rs72781680	0.898	rs72780121	chr2:23995918	T/C	cg08917208	chr2:24149416	ATAD2B	0.81	5.01	0.41	1.8e-6	Lymphocyte counts;
TGCT	cis	rs1801251	1.000	rs283480	chr2:233648742	G/A	cg08000102	chr2:233561755	GIGYF2	0.63	6.35	0.5	3.67e-9	Coronary artery disease;
TGCT	cis	rs9436747	0.641	rs12028951	chr1:66053081	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	-0.59	-5.12	-0.42	1.14e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs2439831	0.867	rs2245715	chr15:43818052	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.8	5.49	0.44	2.21e-7	Lung cancer in ever smokers;
TGCT	cis	rs317689	0.690	rs10878947	chr12:69642683	A/T	cg14784868	chr12:69753453	YEATS4	0.54	4.5	0.37	1.56e-5	Response to diuretic therapy;
TGCT	cis	rs950169	0.922	rs11635505	chr15:85097034	A/C	cg12863693	chr15:85201151	NMB	-0.4	-4.56	-0.38	1.21e-5	Schizophrenia;
TGCT	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg13607699	chr17:42295918	UBTF	0.84	7.55	0.56	8.34e-12	Total body bone mineral density;
TGCT	cis	rs832540	0.898	rs702680	chr5:56220382	T/C	cg24531977	chr5:56204891	C5orf35	-0.52	-5.19	-0.42	8.26e-7	Coronary artery disease;
TGCT	cis	rs6695640	0.819	rs2800697	chr1:17731751	C/T	cg25979543	chr1:17888104	ARHGEF10L	-0.25	-4.57	-0.38	1.14e-5	Mean platelet volume;
TGCT	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.49	-6.32	-0.49	4.28e-9	Alzheimer's disease;
TGCT	cis	rs13191362	0.938	rs35395472	chr6:163008493	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs6840360	0.642	rs2709817	chr4:152382050	A/G	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.82e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs9467773	0.595	rs6907924	chr6:26438817	T/G	cg15659132	chr6:26577336	NA	-0.43	-4.51	-0.38	1.47e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs4654899	0.865	rs4654891	chr1:21286391	T/C	cg01072550	chr1:21505969	NA	-0.47	-7.06	-0.54	1.03e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs11031096	0.621	rs12282967	chr11:4191477	A/T	cg18678763	chr11:4115507	RRM1	-0.46	-6.03	-0.48	1.78e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs6879260	0.963	rs11748619	chr5:179727399	C/G	cg13944838	chr5:179740914	GFPT2	-0.38	-5.87	-0.47	3.7e-8	Height;
TGCT	cis	rs7044106	0.791	rs4837793	chr9:123483621	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	5.04	0.41	1.59e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs4700695	1.000	rs111340	chr5:65420285	C/A	cg21114390	chr5:65439923	SFRS12	-0.65	-5.02	-0.41	1.76e-6	Facial morphology (factor 19);
TGCT	cis	rs11644362	0.966	rs1433746	chr16:12992204	T/C	cg06890432	chr16:12997467	SHISA9	-0.6	-6.35	-0.5	3.77e-9	Positive affect;Subjective well-being;
TGCT	cis	rs208520	0.690	rs7739253	chr6:66861052	A/G	cg07460842	chr6:66804631	NA	-0.92	-9.58	-0.65	1.29e-16	Exhaled nitric oxide output;
TGCT	cis	rs4722585	0.605	rs10268883	chr7:26200417	C/T	cg07876897	chr7:26191696	NFE2L3	0.41	5.52	0.44	1.93e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
TGCT	cis	rs2180341	1.000	rs7453272	chr6:127633959	C/T	cg27446573	chr6:127587934	RNF146	-1.17	-9.4	-0.65	3.58e-16	Breast cancer;
TGCT	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg11764359	chr7:65958608	NA	-0.54	-4.86	-0.4	3.45e-6	Aortic root size;
TGCT	cis	rs3820068	0.705	rs4646091	chr1:15822043	T/C	cg05660106	chr1:15850417	CASP9	1.16	14.82	0.8	3.11e-29	Systolic blood pressure;
TGCT	cis	rs611744	0.934	rs672591	chr8:109192453	T/A	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs8038465	0.516	rs8037836	chr15:73859855	G/A	cg15420318	chr15:73925796	NPTN	0.72	7.87	0.58	1.52e-12	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg16423285	chr20:60520624	NA	-0.61	-6.46	-0.5	2.12e-9	Body mass index;
TGCT	trans	rs4332037	0.707	rs56070303	chr7:1891015	C/T	cg10840412	chr1:235813424	GNG4	0.86	6.67	0.51	7.59e-10	Bipolar disorder;
TGCT	cis	rs9486719	0.948	rs2472904	chr6:96874962	T/G	cg06623918	chr6:96969491	KIAA0776	1.01	8.86	0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg08048268	chr3:133502702	NA	-0.52	-6.78	-0.52	4.26e-10	Iron status biomarkers;
TGCT	cis	rs7089973	0.872	rs7918253	chr10:116614501	T/C	cg03647239	chr10:116582469	FAM160B1	0.52	4.66	0.39	8.03e-6	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs1536827	0.541	rs11592589	chr10:135363657	G/A	cg12448312	chr10:135032219	KNDC1	-0.53	-5.09	-0.42	1.27e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs1577917	0.771	rs9362239	chr6:86429263	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.59	5.07	0.41	1.42e-6	Response to antipsychotic treatment;
TGCT	cis	rs35146811	0.700	rs858513	chr7:99825558	G/A	cg13334819	chr7:99746414	C7orf59	0.74	6.41	0.5	2.82e-9	Coronary artery disease;
TGCT	cis	rs10791097	0.568	rs4411284	chr11:130738568	A/C	cg14779329	chr11:130786720	SNX19	0.28	4.81	0.4	4.36e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs11105298	0.891	rs1008764	chr12:89887649	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.7	-5.02	-0.41	1.79e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs13242816	1.000	rs2402079	chr7:116128670	T/A	cg02799643	chr7:116139180	CAV2	-0.46	-5.53	-0.44	1.78e-7	P wave duration;
TGCT	cis	rs4253772	0.591	rs6007747	chr22:46657261	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.55	4.46	0.37	1.84e-5	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs4285028	0.747	rs11923248	chr3:121566498	G/T	cg01951420	chr3:121553821	IQCB1;EAF2	-1.02	-8.14	-0.59	3.63e-13	Multiple sclerosis;
TGCT	cis	rs4918072	0.716	rs2902638	chr10:105636989	T/C	cg11005552	chr10:105648138	OBFC1	0.4	5.13	0.42	1.07e-6	Coronary artery disease;
TGCT	cis	rs12580194	0.556	rs58780687	chr12:55736498	A/C	cg10672482	chr12:55725839	OR6C3	-0.51	-4.46	-0.37	1.79e-5	Cancer;
TGCT	cis	rs7552404	0.696	rs10782602	chr1:76464261	T/C	cg22875332	chr1:76189707	ACADM	0.66	6.2	0.49	7.69e-9	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg14827481	chr10:134361889	INPP5A	0.3	4.82	0.4	4.18e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg08736216	chr1:53307985	ZYG11A	-0.3	-6.07	-0.48	1.45e-8	Monocyte count;
TGCT	cis	rs62380364	0.727	rs216057	chr5:88170331	T/C	cg22951263	chr5:87985283	NA	0.5	5.02	0.41	1.79e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs12477438	1.000	rs995617	chr2:99857904	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.76	5.63	0.45	1.13e-7	Chronic sinus infection;
TGCT	cis	rs9291683	0.588	rs12507330	chr4:10002195	G/A	cg11266682	chr4:10021025	SLC2A9	0.68	9.45	0.65	2.76e-16	Bone mineral density;
TGCT	cis	rs17253792	0.822	rs112374071	chr14:56061919	C/T	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg23708337	chr7:1209742	NA	0.6	5.57	0.45	1.53e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1372520	0.873	rs2736989	chr4:90776257	T/C	cg20003494	chr4:90757398	SNCA	-0.61	-4.88	-0.4	3.15e-6	Neuroticism;
TGCT	cis	rs3812831	0.695	rs6560935	chr13:114945867	G/A	cg06611532	chr13:114900021	NA	0.35	6.4	0.5	2.93e-9	Schizophrenia;
TGCT	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	0.49	4.69	0.39	7.04e-6	Bipolar disorder;
TGCT	cis	rs7829975	0.711	rs1039916	chr8:8685854	A/G	cg15556689	chr8:8085844	FLJ10661	0.68	6.05	0.48	1.55e-8	Mood instability;
TGCT	cis	rs7106204	0.748	rs4360697	chr11:24217160	A/G	ch.11.24196551F	chr11:24239977	NA	0.46	4.69	0.39	7.23e-6	Response to Homoharringtonine (cytotoxicity);
TGCT	cis	rs6089584	0.924	rs6142906	chr20:60552554	G/C	cg16423285	chr20:60520624	NA	-0.53	-5.5	-0.44	2.11e-7	Body mass index;
TGCT	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg18876405	chr7:65276391	NA	0.31	4.79	0.4	4.64e-6	Aortic root size;
TGCT	cis	rs2862064	0.929	rs4704837	chr5:156464212	T/G	cg12943317	chr5:156479607	HAVCR1	-0.45	-5.29	-0.43	5.36e-7	Platelet count;
TGCT	cis	rs6977660	0.598	rs72591445	chr7:19773035	G/A	cg07541023	chr7:19748670	TWISTNB	1.13	7.17	0.54	6.05e-11	Thyroid stimulating hormone;
TGCT	cis	rs2115630	0.691	rs8040066	chr15:85176465	G/C	cg12863693	chr15:85201151	NMB	-0.41	-5.71	-0.46	7.79e-8	P wave terminal force;
TGCT	trans	rs2688608	0.901	rs2459446	chr10:75601596	C/T	cg13918328	chr10:52500089	ASAH2B	-0.67	-6.63	-0.51	9.32e-10	Inflammatory bowel disease;
TGCT	cis	rs4595586	0.545	rs6580910	chr12:39390052	C/A	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs9549367	0.789	rs34989271	chr13:113894766	G/A	cg00898013	chr13:113819073	PROZ	-0.4	-5.03	-0.41	1.64e-6	Platelet distribution width;
TGCT	cis	rs733175	0.855	rs10022499	chr4:10006537	C/A	cg00071950	chr4:10020882	SLC2A9	0.5	4.58	0.38	1.13e-5	Psychosis and Alzheimer's disease;
TGCT	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg03609598	chr5:56110824	MAP3K1	-0.58	-4.7	-0.39	6.72e-6	Initial pursuit acceleration;
TGCT	cis	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg15556689	chr8:8085844	FLJ10661	0.66	6.07	0.48	1.47e-8	Mood instability;
TGCT	cis	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg13531842	chr10:38383804	ZNF37A	-0.38	-4.51	-0.38	1.49e-5	Extrinsic epigenetic age acceleration;
TGCT	cis	rs12549902	0.966	rs716199	chr8:41515531	A/G	cg21772509	chr8:41503840	NKX6-3	0.85	9.62	0.65	1.04e-16	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
TGCT	cis	rs4803468	0.967	rs892044	chr19:41903671	A/G	cg09537434	chr19:41945824	ATP5SL	-0.89	-10.04	-0.67	9.93e-18	Height;
TGCT	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg17971929	chr21:40555470	PSMG1	0.95	9.22	0.64	9.9e-16	Cognitive function;
TGCT	cis	rs826838	1.000	rs826886	chr12:39095797	A/G	cg13010199	chr12:38710504	ALG10B	0.58	4.74	0.39	5.74e-6	Heart rate;
TGCT	cis	rs6547741	0.935	rs4666005	chr2:27855239	A/G	cg27432699	chr2:27873401	GPN1	0.18	4.63	0.38	9.2e-6	Oral cavity cancer;
TGCT	cis	rs9916302	0.904	rs10852933	chr17:37698194	G/T	cg07936489	chr17:37558343	FBXL20	-0.61	-4.87	-0.4	3.29e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs3099143	1.000	rs1398241	chr15:77153386	C/T	cg21673338	chr15:77095150	SCAPER	-0.51	-4.91	-0.4	2.85e-6	Recalcitrant atopic dermatitis;
TGCT	cis	rs7014346	0.683	rs10956368	chr8:128423650	C/T	cg04263511	chr8:128962092	PVT1	0.31	4.54	0.38	1.3e-5	Colorectal cancer;
TGCT	cis	rs7666738	0.830	rs10010698	chr4:98981594	C/T	cg17366294	chr4:99064904	C4orf37	0.68	6.94	0.53	1.95e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7666738	0.791	rs7657399	chr4:98851861	T/C	cg05340658	chr4:99064831	C4orf37	0.52	6.0	0.47	1.98e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7552404	0.655	rs1146646	chr1:76265500	G/A	cg22875332	chr1:76189707	ACADM	0.58	6.53	0.51	1.53e-9	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg20203395	chr5:56204925	C5orf35	-0.59	-5.12	-0.42	1.12e-6	Initial pursuit acceleration;
TGCT	cis	rs4886920	0.563	rs4542627	chr15:78070743	A/T	cg03457338	chr15:78040120	NA	-0.17	-4.46	-0.37	1.79e-5	Neuroticism;
TGCT	cis	rs11665748	0.538	rs266863	chr19:51355650	A/G	cg03104309	chr19:51052080	LRRC4B	0.24	4.46	0.37	1.82e-5	Prostate-specific antigen levels (conditioned on lead SNPs);Prostate-specific antigen levels;
TGCT	cis	rs6674176	0.561	rs7161	chr1:44438974	A/G	cg12908607	chr1:44402522	ARTN	0.69	8.47	0.61	6e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg17345569	chr6:42928274	GNMT	-0.47	-4.85	-0.4	3.69e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs7833790	0.963	rs28823280	chr8:82777716	G/A	cg23324259	chr8:82754387	SNX16	0.64	4.52	0.38	1.43e-5	Diastolic blood pressure;
TGCT	cis	rs9611565	0.649	rs139553	chr22:42187199	A/G	cg06634786	chr22:41940651	POLR3H	0.8	7.41	0.55	1.69e-11	Vitiligo;
TGCT	cis	rs4563143	0.675	rs55849754	chr19:29279665	G/A	cg12756686	chr19:29218302	NA	0.78	6.69	0.51	6.93e-10	Methadone dose in opioid dependence;
TGCT	cis	rs10089	1.000	rs6595806	chr5:127499764	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	7.4	0.55	1.77e-11	Ileal carcinoids;
TGCT	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg14624950	chr17:62577106	SMURF2	0.21	4.67	0.39	7.63e-6	Prudent dietary pattern;
TGCT	cis	rs262150	1.000	rs262149	chr7:158778256	A/G	cg19418458	chr7:158789849	NA	0.44	4.51	0.38	1.5e-5	Facial morphology (factor 20);
TGCT	cis	rs7089973	0.624	rs11196930	chr10:116583596	C/T	cg03647239	chr10:116582469	FAM160B1	0.58	5.63	0.45	1.16e-7	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs9926296	0.656	rs11861084	chr16:89875710	G/T	cg27121462	chr16:89883253	FANCA	-0.57	-5.17	-0.42	8.93e-7	Vitiligo;
TGCT	cis	rs7095607	0.813	rs960773	chr10:69931720	G/T	cg18986048	chr10:69913749	MYPN	0.44	5.02	0.41	1.72e-6	Lung function (FVC);
TGCT	cis	rs36051895	0.659	rs7046511	chr9:5045695	C/T	cg02405213	chr9:5042618	JAK2	-0.78	-10.85	-0.7	1.1e-19	Pediatric autoimmune diseases;
TGCT	cis	rs9894429	0.752	rs7502883	chr17:79588557	T/C	cg21984481	chr17:79567631	NPLOC4	-0.26	-4.9	-0.4	2.98e-6	Eye color traits;
TGCT	cis	rs72949976	1.000	rs62186568	chr2:214033955	G/A	cg08319019	chr2:214017104	IKZF2	-0.79	-7.3	-0.55	2.97e-11	Lung cancer;Squamous cell lung carcinoma;
TGCT	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg13393036	chr8:95962371	TP53INP1	-0.63	-8.66	-0.61	2.14e-14	Type 2 diabetes;
TGCT	cis	rs9948	0.521	rs62156207	chr2:97359236	C/A	cg01990225	chr2:97406019	LMAN2L	-0.9	-4.49	-0.37	1.59e-5	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs6964587	0.934	rs7798973	chr7:91588360	G/A	cg22709100	chr7:91322751	NA	0.27	4.48	0.37	1.68e-5	Breast cancer;
TGCT	cis	rs9549367	0.713	rs553316	chr13:113838015	A/G	cg09473364	chr13:112927190	NA	0.29	4.64	0.38	8.73e-6	Platelet distribution width;
TGCT	cis	rs2806561	0.514	rs11801120	chr1:23543307	C/T	cg19743168	chr1:23544995	NA	0.47	7.78	0.57	2.4e-12	Height;
TGCT	cis	rs453301	0.509	rs7000323	chr8:8792273	G/A	cg15556689	chr8:8085844	FLJ10661	-0.61	-4.97	-0.41	2.2e-6	Joint mobility (Beighton score);
TGCT	cis	rs13256369	0.865	rs13277708	chr8:8573936	T/C	cg17143192	chr8:8559678	CLDN23	0.63	6.01	0.47	1.96e-8	Obesity-related traits;
TGCT	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-5.11	-0.42	1.18e-6	Bipolar disorder;
TGCT	cis	rs9527	0.568	rs12772775	chr10:104702999	C/A	cg04362960	chr10:104952993	NT5C2	0.64	5.4	0.44	3.33e-7	Arsenic metabolism;
TGCT	cis	rs35883536	0.545	rs56674564	chr1:101097718	T/C	cg06223162	chr1:101003688	GPR88	0.33	5.45	0.44	2.66e-7	Monocyte count;
TGCT	cis	rs6089584	0.888	rs6142927	chr20:60605848	A/G	cg13770153	chr20:60521292	NA	-0.49	-6.21	-0.49	7.44e-9	Body mass index;
TGCT	cis	rs4478858	0.684	rs7519766	chr1:31735512	C/A	cg00250761	chr1:31883323	NA	-0.25	-4.52	-0.38	1.45e-5	Alcohol dependence;
TGCT	cis	rs2439831	0.867	rs2412779	chr15:43655927	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	6.61	0.51	1e-9	Lung cancer in ever smokers;
TGCT	cis	rs2228479	0.702	rs11076621	chr16:89837927	A/G	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs11971779	0.648	rs59791374	chr7:139116962	C/T	cg07862535	chr7:139043722	LUC7L2	0.66	5.07	0.41	1.42e-6	Diisocyanate-induced asthma;
TGCT	cis	rs1371867	0.846	rs1692006	chr8:101252462	C/T	cg00191853	chr8:101177733	SPAG1	0.23	4.67	0.39	7.55e-6	Atrioventricular conduction;
TGCT	cis	rs6121246	0.909	rs3203770	chr20:30382315	A/G	cg13852791	chr20:30311386	BCL2L1	0.8	6.12	0.48	1.15e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs7843479	1.000	rs66824050	chr8:21815425	T/G	cg17168535	chr8:21777572	XPO7	0.64	5.91	0.47	3.12e-8	Mean corpuscular volume;
TGCT	cis	rs11711311	0.824	rs9876528	chr3:113357196	G/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.72	-6.08	-0.48	1.35e-8	IgG glycosylation;
TGCT	cis	rs3772130	1.000	rs56314138	chr3:121356656	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.55	4.95	0.41	2.35e-6	Cognitive performance;
TGCT	cis	rs3026101	0.671	rs8081481	chr17:5282763	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.47	4.52	0.38	1.41e-5	Body mass index;
TGCT	cis	rs7937682	0.575	rs34558891	chr11:111737912	C/T	cg09085632	chr11:111637200	PPP2R1B	0.88	8.47	0.61	5.93e-14	Primary sclerosing cholangitis;
TGCT	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg24549020	chr5:56110836	MAP3K1	0.67	5.78	0.46	5.74e-8	Initial pursuit acceleration;
TGCT	cis	rs4820539	1.000	rs4820539	chr22:23477970	C/T	cg21100191	chr22:23484243	RTDR1	-0.91	-10.92	-0.7	7.27e-20	Bone mineral density;
TGCT	cis	rs6964587	0.839	rs6949700	chr7:91467435	A/G	cg17063962	chr7:91808500	NA	0.81	8.67	0.61	1.99e-14	Breast cancer;
TGCT	cis	rs11249608	0.548	rs2132671	chr5:178457434	A/G	cg21905437	chr5:178450457	ZNF879	-0.45	-4.6	-0.38	1.03e-5	Pubertal anthropometrics;
TGCT	cis	rs2153535	0.580	rs5001322	chr6:8451608	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.76	0.46	6.39e-8	Motion sickness;
TGCT	cis	rs77972916	0.505	rs3851318	chr2:43532808	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.41	-6.16	-0.48	9.38e-9	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs2997447	0.761	rs61776618	chr1:26456709	A/G	cg03844060	chr1:26490628	NA	0.27	4.44	0.37	2e-5	QRS complex (12-leadsum);
TGCT	cis	rs6565180	0.963	rs4787642	chr16:30359408	T/C	cg17640201	chr16:30407289	ZNF48	-0.88	-8.6	-0.61	2.91e-14	Tonsillectomy;
TGCT	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg24829409	chr8:58192753	C8orf71	0.51	4.51	0.38	1.47e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	6.75	0.52	5.02e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg08859206	chr1:53392774	SCP2	0.4	5.96	0.47	2.46e-8	Monocyte count;
TGCT	trans	rs66573146	1.000	rs6812391	chr4:6963893	G/A	cg07817883	chr1:32538562	TMEM39B	1.56	8.31	0.6	1.45e-13	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs1532993	0.518	rs6832426	chr4:98567966	G/A	cg05340658	chr4:99064831	C4orf37	-0.42	-5.05	-0.41	1.57e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs6582630	0.555	rs11182429	chr12:38526679	A/C	cg13010199	chr12:38710504	ALG10B	0.58	4.72	0.39	6.37e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs6866344	0.697	rs11742808	chr5:178131658	G/A	cg03877680	chr5:178157825	ZNF354A	0.75	6.1	0.48	1.25e-8	Neutrophil percentage of white cells;
TGCT	cis	rs797680	0.786	rs59417472	chr1:93848513	T/C	cg17826107	chr1:92977322	EVI5	-0.23	-5.51	-0.44	2.01e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs11673344	0.542	rs826328	chr19:37495381	A/C	cg08039142	chr19:36980659	ZNF566	0.57	5.44	0.44	2.74e-7	Obesity-related traits;
TGCT	cis	rs9787249	0.957	rs41267029	chr1:40214367	A/G	cg24920358	chr1:40204285	PPIE	0.57	10.56	0.69	5.57e-19	Blood protein levels;
TGCT	cis	rs752590	0.887	rs68090726	chr2:113962835	G/C	cg27425262	chr2:113953981	PSD4;LOC440839	0.42	4.73	0.39	5.92e-6	Mucinous ovarian carcinoma;
TGCT	cis	rs6089584	0.527	rs927589	chr20:60606363	A/G	cg06108461	chr20:60628389	TAF4	-0.44	-5.58	-0.45	1.44e-7	Body mass index;
TGCT	cis	rs1008375	0.932	rs11941874	chr4:17666416	C/T	cg18681998	chr4:17616180	MED28	-0.91	-9.5	-0.65	2.08e-16	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7980687	0.627	rs1727325	chr12:123698332	G/C	cg00376283	chr12:123451042	ABCB9	0.73	5.67	0.45	9.46e-8	Height;Educational attainment;Head circumference (infant);
TGCT	cis	rs7772486	0.846	rs9403767	chr6:146402386	G/T	cg05347473	chr6:146136440	FBXO30	0.52	4.82	0.4	4.11e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg04025307	chr7:1156635	C7orf50	0.23	5.42	0.44	2.94e-7	Longevity;Endometriosis;
TGCT	cis	rs9814567	0.752	rs13084192	chr3:134336095	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.75	6.75	0.52	4.98e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg09365446	chr1:150670422	GOLPH3L	0.31	4.64	0.38	8.7e-6	Tonsillectomy;
TGCT	cis	rs5167	0.566	rs7253458	chr19:45482570	C/T	cg09555818	chr19:45449301	APOC2	0.23	4.62	0.38	9.53e-6	Blood protein levels;
TGCT	cis	rs6840360	0.869	rs55668815	chr4:152473828	C/G	cg17479576	chr4:152424074	FAM160A1	-0.46	-4.88	-0.4	3.19e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs66716358	0.800	rs4755809	chr11:44323193	A/G	cg02785814	chr11:44338707	NA	-0.46	-4.66	-0.39	8.04e-6	Monobrow;
TGCT	cis	rs2456568	0.803	rs10831140	chr11:93640689	G/A	cg26875233	chr11:93583750	C11orf90	-0.48	-6.35	-0.5	3.67e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7089973	0.604	rs17663387	chr10:116588060	C/G	cg03647239	chr10:116582469	FAM160B1	0.6	5.86	0.47	4e-8	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs28595532	0.748	rs72670249	chr4:119336823	G/T	cg21605333	chr4:119757512	SEC24D	0.87	5.49	0.44	2.14e-7	Cannabis dependence symptom count;
TGCT	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg09365446	chr1:150670422	GOLPH3L	0.3	4.51	0.38	1.5e-5	Tonsillectomy;
TGCT	cis	rs9682041	0.740	rs6444929	chr3:170150076	C/T	cg11886554	chr3:170076028	SKIL	0.93	6.78	0.52	4.32e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs11690935	0.885	rs6725388	chr2:172730015	G/C	cg13550731	chr2:172543902	DYNC1I2	-0.9	-8.17	-0.59	3.02e-13	Schizophrenia;
TGCT	cis	rs6138458	0.620	rs2151462	chr20:24911823	T/C	cg26195577	chr20:24973756	C20orf3	1.2	12.04	0.73	1.35e-22	Blood protein levels;
TGCT	cis	rs3087591	1.000	rs2905795	chr17:29547601	A/G	cg24425628	chr17:29625626	OMG;NF1	0.48	7.42	0.55	1.65e-11	Hip circumference;
TGCT	cis	rs6450176	0.597	rs1541682	chr5:53304401	C/T	ch.5.1024479R	chr5:53302184	ARL15	-0.83	-6.16	-0.48	9.32e-9	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	trans	rs12145833	1.000	rs10926984	chr1:243462153	T/G	cg15780870	chr12:130953802	RIMBP2	0.48	6.73	0.52	5.57e-10	Obesity (early onset extreme);
TGCT	trans	rs8073060	0.559	rs17550632	chr17:33890883	G/C	cg19694781	chr19:47549865	TMEM160	0.6	13.13	0.76	3.12e-25	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs2806561	0.704	rs1757039	chr1:23508657	A/G	cg12483005	chr1:23474871	LUZP1	0.37	4.76	0.39	5.23e-6	Height;
TGCT	cis	rs2742417	0.624	rs2742394	chr3:45757591	C/T	cg04837898	chr3:45731254	SACM1L	-0.66	-7.02	-0.53	1.27e-10	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg13531842	chr10:38383804	ZNF37A	-0.38	-4.51	-0.38	1.49e-5	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.94	7.92	0.58	1.17e-12	Platelet count;
TGCT	cis	rs7226408	0.857	rs10502666	chr18:34423393	A/G	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg23302884	chr18:44338147	ST8SIA5	-0.4	-4.58	-0.38	1.11e-5	Personality dimensions;
TGCT	cis	rs2836950	0.501	rs11702505	chr21:40700614	G/T	cg06238570	chr21:40685208	BRWD1	-0.64	-6.56	-0.51	1.34e-9	Menarche (age at onset);
TGCT	cis	rs12693043	0.727	rs3205060	chr2:175425346	C/T	cg11778734	chr2:175439522	WIPF1	-0.38	-4.89	-0.4	3.05e-6	Urate levels (BMI interaction);
TGCT	cis	rs2469997	1.000	rs2470026	chr8:120365112	C/T	cg00681363	chr8:120844660	TAF2	-0.72	-4.63	-0.38	8.98e-6	Hypertension (SNP x SNP interaction);
TGCT	cis	rs6460942	1.000	rs75564554	chr7:12319362	A/C	cg06484146	chr7:12443880	VWDE	-0.54	-4.55	-0.38	1.26e-5	Coronary artery disease;
TGCT	cis	rs9399135	0.967	rs9376082	chr6:135346389	T/A	cg24558204	chr6:135376177	HBS1L	0.5	5.0	0.41	1.89e-6	Red blood cell count;
TGCT	cis	rs2361718	0.501	rs8065486	chr17:78138196	A/G	cg09238746	chr17:78121135	EIF4A3	1.01	11.13	0.71	2.2e-20	Yeast infection;
TGCT	cis	rs1949733	0.877	rs940133	chr4:8473614	T/C	cg13073564	chr4:8508604	NA	-0.5	-5.04	-0.41	1.63e-6	Response to antineoplastic agents;
TGCT	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg18402987	chr7:1209562	NA	0.47	4.78	0.39	4.93e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg02353165	chr6:42928485	GNMT	-0.9	-9.26	-0.64	7.66e-16	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs2766547	0.647	rs2766541	chr6:35707331	T/C	cg01618151	chr6:35707957	C6orf81	-0.27	-4.63	-0.38	9.02e-6	Eosinophil percentage of granulocytes;
TGCT	cis	rs6964587	0.839	rs13246743	chr7:91453945	G/T	cg17063962	chr7:91808500	NA	0.82	8.31	0.6	1.43e-13	Breast cancer;
TGCT	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg12963246	chr6:28129442	ZNF389	0.52	5.01	0.41	1.85e-6	Depression;
TGCT	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg05665937	chr4:1216051	CTBP1	0.25	4.75	0.39	5.64e-6	Obesity-related traits;
TGCT	cis	rs9486715	0.867	rs2499775	chr6:97007340	C/T	cg18709589	chr6:96969512	KIAA0776	-0.86	-8.45	-0.6	6.73e-14	Headache;
TGCT	cis	rs6424115	0.931	rs2473377	chr1:24148260	T/C	cg15997130	chr1:24165203	NA	0.9	10.23	0.68	3.51e-18	Immature fraction of reticulocytes;
TGCT	cis	rs2074977	0.550	rs11085020	chr19:3446107	C/T	cg08380311	chr19:3435252	NFIC	-0.72	-6.45	-0.5	2.32e-9	Height;
TGCT	cis	rs644799	1.000	rs3748256	chr11:95521953	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	8.53	0.61	4.41e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9910055	0.502	rs1684662	chr17:42180822	T/A	cg19774624	chr17:42201019	HDAC5	0.71	6.72	0.52	5.98e-10	Total body bone mineral density;
TGCT	cis	rs35160687	0.901	rs13020869	chr2:86523360	C/T	cg12542933	chr2:85804724	VAMP8	0.4	4.81	0.4	4.21e-6	Night sleep phenotypes;
TGCT	cis	rs1775715	0.870	rs7912121	chr10:32228995	T/G	cg14930904	chr10:32216787	ARHGAP12	0.49	4.6	0.38	1.03e-5	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs12693043	1.000	rs12693043	chr2:175377565	C/T	cg11778734	chr2:175439522	WIPF1	0.41	5.1	0.42	1.25e-6	Urate levels (BMI interaction);
TGCT	cis	rs4700695	0.698	rs416369	chr5:65231058	C/T	cg21114390	chr5:65439923	SFRS12	0.56	4.44	0.37	1.99e-5	Facial morphology (factor 19);
TGCT	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg20891283	chr12:69753455	YEATS4	0.9	10.36	0.68	1.69e-18	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg19748678	chr4:122722346	EXOSC9	0.9	9.34	0.64	4.9e-16	Type 2 diabetes;
TGCT	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg12311346	chr5:56204834	C5orf35	-0.57	-6.06	-0.48	1.51e-8	Initial pursuit acceleration;
TGCT	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg26513180	chr16:89883248	FANCA	1.04	14.77	0.8	4.11e-29	Vitiligo;
TGCT	cis	rs4073582	0.595	rs1151540	chr11:66041807	A/C	cg16950941	chr11:66035639	RAB1B	0.57	5.33	0.43	4.49e-7	Gout;
TGCT	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg21017887	chr14:105400489	NA	0.37	5.19	0.42	8.23e-7	Rheumatoid arthritis;
TGCT	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.39	-4.9	-0.4	2.97e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6460942	0.778	rs74993124	chr7:12462917	A/G	cg06484146	chr7:12443880	VWDE	-0.53	-5.59	-0.45	1.36e-7	Coronary artery disease;
TGCT	cis	rs7192750	0.586	rs9806882	chr16:71925511	G/T	cg06353428	chr16:71660113	MARVELD3	0.83	7.32	0.55	2.74e-11	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg01416388	chr22:39784598	NA	-0.73	-7.59	-0.56	6.65e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs1008375	0.966	rs7675735	chr4:17587137	T/A	cg16339924	chr4:17578868	LAP3	0.8	6.96	0.53	1.73e-10	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs8180040	0.701	rs34103310	chr3:47073266	C/T	cg27129171	chr3:47204927	SETD2	0.74	9.79	0.66	4.15e-17	Colorectal cancer;
TGCT	cis	rs16867321	0.694	rs721301	chr2:181387265	A/G	cg23363182	chr2:181467187	NA	0.39	6.02	0.48	1.86e-8	Obesity;
TGCT	cis	rs7429990	0.932	rs7630685	chr3:48131170	G/C	cg11946769	chr3:48343235	NME6	-0.55	-4.49	-0.37	1.62e-5	Educational attainment (years of education);
TGCT	cis	rs933688	1.000	rs10041402	chr5:90738948	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	9.69	0.66	7.22e-17	Smoking behavior;
TGCT	cis	rs13082711	0.595	rs4973761	chr3:27358620	T/C	cg02860705	chr3:27208620	NA	0.48	7.37	0.55	2.15e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg18252515	chr7:66147081	NA	-1.09	-6.4	-0.5	2.88e-9	Diabetic kidney disease;
TGCT	cis	rs7119038	0.629	rs11217000	chr11:118604984	A/G	cg19308663	chr11:118741387	NA	0.26	4.82	0.4	4.05e-6	Sjögren's syndrome;
TGCT	cis	rs7104764	0.833	rs12574034	chr11:212262	T/C	cg18336825	chr11:236787	PSMD13;SIRT3	-0.71	-6.75	-0.52	5.12e-10	Menarche (age at onset);
TGCT	cis	rs17376456	0.877	rs12716457	chr5:93397627	T/C	cg25358565	chr5:93447407	FAM172A	0.92	8.38	0.6	9.58e-14	Diabetic retinopathy;
TGCT	cis	rs9913156	0.696	rs72835620	chr17:4558128	G/A	cg00122941	chr17:4613640	ARRB2	0.87	7.38	0.55	1.95e-11	Lymphocyte counts;
TGCT	cis	rs7267979	1.000	rs2258719	chr20:25275843	C/T	cg14121845	chr20:25566513	NINL	0.51	5.5	0.44	2.05e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6840360	0.642	rs4263379	chr4:152399131	G/A	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.82e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs9467773	1.000	rs9357010	chr6:26527945	C/G	cg26531700	chr6:26746687	NA	0.51	5.15	0.42	9.84e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7647973	0.848	rs4955411	chr3:49145304	A/G	cg07636037	chr3:49044803	WDR6	0.77	6.08	0.48	1.34e-8	Menarche (age at onset);
TGCT	cis	rs459571	0.959	rs461462	chr9:136911272	C/T	cg14405625	chr9:136855902	VAV2	-0.3	-4.54	-0.38	1.3e-5	Platelet distribution width;
TGCT	cis	rs13191362	0.938	rs28360532	chr6:162997477	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7582180	0.638	rs9973536	chr2:100942243	C/T	cg14675211	chr2:100938903	LONRF2	0.51	5.02	0.41	1.72e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs11578119	0.933	rs12123065	chr1:170396098	C/T	cg09767346	chr1:170501363	GORAB	0.71	5.69	0.46	8.67e-8	Male-pattern baldness;
TGCT	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg24675658	chr1:53192096	ZYG11B	0.76	8.75	0.62	1.3e-14	Monocyte count;
TGCT	trans	rs877282	0.898	rs12356709	chr10:763365	A/G	cg22713356	chr15:30763199	NA	1.2	9.16	0.64	1.36e-15	Uric acid levels;
TGCT	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.9	-5.35	-0.43	4.1e-7	Alzheimer's disease;
TGCT	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg26818010	chr10:134567672	INPP5A	-0.35	-4.45	-0.37	1.86e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs7959452	0.590	rs6581889	chr12:69757429	T/C	cg11871910	chr12:69753446	YEATS4	0.82	8.82	0.62	8.61e-15	Blood protein levels;
TGCT	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg10411590	chr13:21900810	NA	0.38	5.06	0.41	1.48e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg03517284	chr6:25882590	NA	-0.62	-6.45	-0.5	2.24e-9	Blood metabolite levels;
TGCT	cis	rs2797160	1.000	rs13328298	chr6:126016580	G/A	cg05901451	chr6:126070800	HEY2	0.73	6.29	0.49	5.01e-9	Endometrial cancer;
TGCT	cis	rs7267979	0.668	rs2387977	chr20:25599776	C/T	cg03522245	chr20:25566470	NINL	-0.49	-5.32	-0.43	4.66e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs8054556	0.787	rs3814877	chr16:30042677	G/T	cg24235633	chr16:29875177	LOC440356;CDIPT	0.2	4.51	0.38	1.49e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12049351	0.774	rs12079612	chr1:229649372	T/C	cg12130225	chr1:229698885	NA	0.36	4.46	0.37	1.8e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs10791323	0.569	rs11533204	chr11:133743644	A/G	cg15485101	chr11:133734466	NA	0.37	5.42	0.44	3e-7	Childhood ear infection;
TGCT	cis	rs11711311	0.747	rs2895415	chr3:113345565	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.61	-5.03	-0.41	1.66e-6	IgG glycosylation;
TGCT	cis	rs12791968	0.765	rs12790121	chr11:45001089	G/A	cg11846598	chr11:44996168	LOC221122	-0.31	-5.02	-0.41	1.79e-6	Inhibitory control;
TGCT	trans	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg17830980	chr10:43048298	ZNF37B	-0.84	-10.46	-0.68	9.38e-19	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7666738	0.830	rs4699588	chr4:98973789	A/G	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs210152	0.588	rs449978	chr6:33496060	G/A	cg22108809	chr5:56777663	ACTBL2	-0.54	-6.67	-0.51	7.44e-10	Schizophrenia;
TGCT	cis	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg07424592	chr7:64974309	NA	1.36	8.15	0.59	3.36e-13	Diabetic kidney disease;
TGCT	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg10295955	chr4:187884368	NA	-0.96	-14.18	-0.79	9.89e-28	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	5.45	0.44	2.66e-7	Height;
TGCT	cis	rs79349575	0.687	rs12602179	chr17:47010034	G/T	cg07967210	chr17:47022446	SNF8	0.44	6.13	0.48	1.1e-8	Type 2 diabetes;
TGCT	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.75	5.41	0.44	3.09e-7	Platelet count;
TGCT	cis	rs10206020	0.921	rs9678719	chr2:1549628	A/G	cg12573674	chr2:1569213	NA	-0.49	-4.95	-0.41	2.41e-6	IgG glycosylation;
TGCT	cis	rs6500602	0.647	rs4786514	chr16:4576798	A/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.41	6.01	0.48	1.88e-8	Schizophrenia;
TGCT	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg06221963	chr1:154839813	KCNN3	-0.75	-12.65	-0.75	4.66e-24	Prostate cancer;
TGCT	cis	rs1797081	0.840	rs10904820	chr10:16848473	A/G	cg23933602	chr10:16859644	RSU1	0.97	11.98	0.73	1.93e-22	Platelet distribution width;
TGCT	cis	rs7926906	1.000	rs10741375	chr11:90521800	G/A	cg26138821	chr11:89956704	CHORDC1	-0.51	-5.52	-0.44	1.92e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs71435601	0.574	rs1652420	chr2:21383881	A/T	cg25035485	chr2:21266500	APOB	0.51	4.48	0.37	1.64e-5	Cholesterol, total;
TGCT	cis	rs2243480	1.000	rs160637	chr7:65584318	C/T	cg20637647	chr7:64974828	NA	0.84	4.85	0.4	3.63e-6	Diabetic kidney disease;
TGCT	cis	rs6831352	0.918	rs28987088	chr4:100059139	T/C	cg12011299	chr4:100065546	ADH4	-0.4	-4.88	-0.4	3.26e-6	Alcohol dependence;
TGCT	cis	rs4700695	0.764	rs10066817	chr5:65319853	A/G	cg21114390	chr5:65439923	SFRS12	0.6	4.47	0.37	1.74e-5	Facial morphology (factor 19);
TGCT	cis	rs2249625	0.545	rs10498880	chr6:72882183	G/T	cg08500200	chr6:72892038	RIMS1	0.43	4.61	0.38	1e-5	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
TGCT	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg00149659	chr3:10157352	C3orf10	1.18	7.44	0.56	1.44e-11	Alzheimer's disease;
TGCT	cis	rs1008375	1.000	rs1121091	chr4:17676386	A/C	cg16339924	chr4:17578868	LAP3	0.53	4.62	0.38	9.58e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs3782455	0.793	rs77046876	chr12:114404271	G/A	cg10631684	chr12:113795897	PLBD2	-0.7	-4.61	-0.38	1e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs6912958	0.702	rs2300909	chr6:88212100	G/A	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.91	-0.4	2.78e-6	Monocyte percentage of white cells;
TGCT	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg13206674	chr6:150067644	NUP43	0.52	4.46	0.37	1.78e-5	Lung cancer;
TGCT	cis	rs112158604	1	rs112158604	chr1:150696792	TCTTCTGCAG/T	cg13175981	chr1:150552382	MCL1	0.43	4.78	0.39	4.88e-6	Lymphocyte counts;
TGCT	cis	rs7586879	0.681	rs6545790	chr2:25109302	A/G	cg15423357	chr2:25149977	NA	0.51	4.84	0.4	3.79e-6	Body mass index;
TGCT	cis	rs9300255	0.602	rs1616181	chr12:123619856	T/A	cg00376283	chr12:123451042	ABCB9	0.71	5.54	0.45	1.7e-7	Neutrophil percentage of white cells;
TGCT	cis	rs2204008	0.811	rs11525004	chr12:38333807	T/A	cg26384229	chr12:38710491	ALG10B	0.83	7.19	0.54	5.37e-11	Bladder cancer;
TGCT	cis	rs514406	0.758	rs532242	chr1:53308665	C/G	cg24675658	chr1:53192096	ZYG11B	-0.7	-7.76	-0.57	2.67e-12	Monocyte count;
TGCT	cis	rs9430161	0.579	rs11576658	chr1:11037736	C/T	cg27631724	chr1:11040367	C1orf127	0.55	6.05	0.48	1.55e-8	Ewing sarcoma;
TGCT	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg11871910	chr12:69753446	YEATS4	-0.89	-10.53	-0.69	6.39e-19	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs7772486	0.738	rs2246334	chr6:146183635	G/A	cg05347473	chr6:146136440	FBXO30	0.55	5.22	0.42	7.17e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2120019	1.000	rs8033837	chr15:75353975	A/C	cg09165964	chr15:75287851	SCAMP5	-1.18	-10.44	-0.68	1.07e-18	Blood trace element (Zn levels);
TGCT	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg07061783	chr6:25882402	NA	-0.64	-6.25	-0.49	6.11e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs4295623	0.559	rs2409836	chr8:11689228	T/G	cg02840367	chr8:11660030	FDFT1	-0.66	-5.43	-0.44	2.79e-7	Morning vs. evening chronotype;
TGCT	cis	rs9467711	0.651	rs34555420	chr6:26090270	G/T	cg16898833	chr6:26189333	HIST1H4D	1.34	6.07	0.48	1.47e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs908922	0.676	rs10788842	chr1:152514588	A/T	cg20991723	chr1:152506922	NA	0.46	6.17	0.48	8.79e-9	Hair morphology;
TGCT	cis	rs10479542	0.630	rs6879664	chr5:178974576	T/G	cg14851468	chr5:179071604	C5orf60	0.25	4.86	0.4	3.46e-6	Lung cancer;
TGCT	cis	rs28595532	0.920	rs73842253	chr4:119721856	G/A	cg14228332	chr4:119757509	SEC24D	1.22	6.12	0.48	1.12e-8	Cannabis dependence symptom count;
TGCT	cis	rs62244186	0.566	rs55852922	chr3:44826188	A/G	cg15687855	chr3:44754131	ZNF502	-0.55	-6.8	-0.52	3.9e-10	Depressive symptoms;
TGCT	cis	rs9443645	0.869	rs7762022	chr6:79502859	C/A	cg09184832	chr6:79620586	NA	-0.45	-4.84	-0.4	3.76e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs317689	0.513	rs317659	chr12:69686132	T/A	cg14784868	chr12:69753453	YEATS4	0.66	6.45	0.5	2.31e-9	Response to diuretic therapy;
TGCT	cis	rs2456568	0.867	rs2456569	chr11:93691393	C/A	cg26875233	chr11:93583750	C11orf90	-0.45	-5.84	-0.46	4.35e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg10207240	chr12:122356781	WDR66	0.33	4.54	0.38	1.31e-5	Mean corpuscular volume;
TGCT	cis	rs7226408	0.802	rs1445529	chr18:34512757	G/A	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	trans	rs17471911	0.786	rs11189952	chr10:100808370	G/A	cg03484267	chr2:207988651	KLF7	-0.52	-6.67	-0.51	7.53e-10	Neuroticism;
TGCT	cis	rs2153535	0.580	rs6902001	chr6:8477055	T/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs13256369	0.802	rs13281933	chr8:8562665	C/A	cg06671706	chr8:8559999	CLDN23	0.34	4.52	0.38	1.4e-5	Obesity-related traits;
TGCT	cis	rs12579753	0.872	rs11519752	chr12:82207300	A/G	cg07988820	chr12:82153109	PPFIA2	-0.59	-6.19	-0.49	7.93e-9	Resting heart rate;
TGCT	cis	rs7937682	0.889	rs497111	chr11:111499512	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.11	-11.7	-0.72	9.24e-22	Primary sclerosing cholangitis;
TGCT	cis	rs12681288	0.723	rs35425201	chr8:971062	C/T	cg04851639	chr8:1020857	NA	-0.31	-5.13	-0.42	1.07e-6	Schizophrenia;
TGCT	cis	rs151997	0.962	rs27714	chr5:50180396	G/C	cg06027927	chr5:50259733	NA	0.46	4.61	0.38	9.69e-6	Callous-unemotional behaviour;
TGCT	cis	rs12950390	0.853	rs11658511	chr17:45856918	T/C	cg06532163	chr17:45867833	NA	0.37	5.89	0.47	3.46e-8	IgG glycosylation;
TGCT	cis	rs7959452	0.868	rs10878967	chr12:69740869	T/C	cg20891283	chr12:69753455	YEATS4	0.69	6.81	0.52	3.67e-10	Blood protein levels;
TGCT	cis	rs861020	0.630	rs599649	chr1:210003402	T/C	cg05527609	chr1:210001259	C1orf107	0.87	7.64	0.57	5.03e-12	Orofacial clefts;
TGCT	cis	rs10875746	0.903	rs61918774	chr12:48448134	C/G	cg20731937	chr12:48336164	NA	0.62	4.95	0.41	2.36e-6	Longevity (90 years and older);
TGCT	cis	rs921968	0.643	rs596076	chr2:219451015	T/G	cg02176678	chr2:219576539	TTLL4	0.38	5.48	0.44	2.31e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs854765	0.663	rs1052299	chr17:17750419	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.73	-7.04	-0.53	1.17e-10	Total body bone mineral density;
TGCT	cis	rs524023	1.000	rs12786214	chr11:64364203	G/A	cg07733098	chr11:64478343	NRXN2	0.32	4.87	0.4	3.4e-6	Urate levels in obese individuals;
TGCT	cis	rs12620999	0.627	rs12986628	chr2:238103439	C/T	cg23555395	chr2:238036564	NA	-0.28	-4.95	-0.41	2.4e-6	Systemic lupus erythematosus;
TGCT	cis	rs6500602	0.727	rs3761681	chr16:4566857	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.33	6.06	0.48	1.5e-8	Schizophrenia;
TGCT	cis	rs301043	0.697	rs2923014	chr12:95854146	G/T	cg07805603	chr12:95869602	METAP2	0.33	4.47	0.37	1.75e-5	Immature fraction of reticulocytes;
TGCT	cis	rs1903068	0.657	rs73236104	chr4:55990954	G/C	cg09978860	chr4:56023921	NA	0.54	5.48	0.44	2.26e-7	Endometriosis;
TGCT	cis	rs2188554	0.958	rs73480753	chr7:117027181	C/T	cg08576598	chr7:116962626	WNT2	-0.4	-4.72	-0.39	6.15e-6	Esophageal adenocarcinoma;
TGCT	cis	rs6831352	0.760	rs2602859	chr4:100030583	G/A	cg12011299	chr4:100065546	ADH4	0.39	4.81	0.4	4.36e-6	Alcohol dependence;
TGCT	cis	rs9649213	0.614	rs1006169	chr7:97938443	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.92	8.37	0.6	1.01e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs13064411	0.696	rs6808394	chr3:113122524	T/G	cg18753928	chr3:113234510	CCDC52	-0.7	-5.12	-0.42	1.12e-6	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs13082711	0.689	rs34946790	chr3:27345170	G/A	cg02860705	chr3:27208620	NA	0.56	8.75	0.62	1.3e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs4252435	0.522	rs4252443	chr7:142621201	C/G	cg09833174	chr7:143059591	FAM131B	-0.93	-4.5	-0.37	1.56e-5	Cancer;
TGCT	cis	rs28595532	0.920	rs115838006	chr4:119754356	T/C	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs13217239	0.574	rs9366680	chr6:27006123	A/T	cg15659132	chr6:26577336	NA	0.52	5.29	0.43	5.35e-7	Schizophrenia;
TGCT	cis	rs4851251	1.000	rs62150284	chr2:100784118	T/C	cg22139774	chr2:100720529	AFF3	0.4	5.68	0.45	8.94e-8	Educational attainment (years of education);
TGCT	cis	rs9309473	0.606	rs77962988	chr2:73886090	T/C	cg07208825	chr2:73871855	ALMS1P	0.28	5.35	0.43	4.16e-7	Metabolite levels;
TGCT	cis	rs12142240	0.698	rs55670684	chr1:46835139	C/T	cg14993813	chr1:46806288	NSUN4	-0.58	-4.83	-0.4	3.88e-6	Menopause (age at onset);
TGCT	cis	rs2797160	0.967	rs8180614	chr6:126000599	G/C	cg05901451	chr6:126070800	HEY2	-0.74	-6.48	-0.5	1.96e-9	Endometrial cancer;
TGCT	cis	rs151997	1.000	rs42415	chr5:50207442	T/A	cg06027927	chr5:50259733	NA	0.47	4.83	0.4	3.9e-6	Callous-unemotional behaviour;
TGCT	cis	rs10992471	0.603	rs1121978	chr9:95140351	T/G	cg14631576	chr9:95140430	CENPP	-0.33	-4.99	-0.41	2.02e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg12564285	chr5:131593104	PDLIM4	0.4	4.77	0.39	5.18e-6	Acylcarnitine levels;
TGCT	cis	rs7267979	1.000	rs4815417	chr20:25379526	C/T	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	5.98	0.47	2.23e-8	Alzheimer's disease;
TGCT	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg19010396	chr19:19431384	KIAA0892;SF4	-0.54	-4.54	-0.38	1.3e-5	Tonsillectomy;
TGCT	cis	rs7208859	0.673	rs9915139	chr17:29158515	A/G	cg14008862	chr17:28927542	LRRC37B2	0.75	5.1	0.42	1.26e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg05368731	chr17:41323189	NBR1	1.1	12.74	0.75	2.71e-24	Menopause (age at onset);
TGCT	cis	rs2303745	0.589	rs1864116	chr19:17393015	C/T	cg02221750	chr19:17393354	ANKLE1	-0.48	-6.27	-0.49	5.46e-9	Systemic lupus erythematosus;
TGCT	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg11764359	chr7:65958608	NA	-0.55	-5.0	-0.41	1.94e-6	Aortic root size;
TGCT	cis	rs7043114	0.525	rs12353096	chr9:95031144	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.56	-5.5	-0.44	2.11e-7	Height;
TGCT	cis	rs11148252	0.532	rs9536262	chr13:53303074	A/C	cg02158880	chr13:53174818	NA	-0.43	-5.07	-0.41	1.39e-6	Lewy body disease;
TGCT	trans	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg17830980	chr10:43048298	ZNF37B	-0.82	-10.26	-0.68	2.99e-18	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7733403	1	rs7733403	chr5:140154215	A/G	cg19875535	chr5:140030758	IK	0.37	6.23	0.49	6.56e-9	Schizophrenia;
TGCT	cis	rs700590	0.723	rs160044	chr5:88114476	T/C	cg22951263	chr5:87985283	NA	0.55	5.33	0.43	4.45e-7	Educational attainment (years of education);
TGCT	cis	rs28493229	0.708	rs80003555	chr19:41160612	C/G	cg11601297	chr19:41224147	ITPKC;ADCK4	0.57	5.16	0.42	9.45e-7	Kawasaki disease;
TGCT	cis	rs910316	0.967	rs175451	chr14:75589729	C/T	cg08847533	chr14:75593920	NEK9	-0.94	-10.33	-0.68	2.03e-18	Height;
TGCT	cis	rs6740731	0.518	rs13034360	chr2:145293154	C/T	cg07679370	chr2:145795797	NA	0.27	5.11	0.42	1.19e-6	Coronary artery disease;
TGCT	cis	rs614226	1.000	rs563920	chr12:121017439	A/G	cg10072921	chr12:121022843	NA	-0.44	-4.73	-0.39	6.09e-6	Type 1 diabetes nephropathy;
TGCT	cis	rs117785887	0.536	rs12216492	chr6:146376618	T/C	cg06708562	chr6:146285465	SHPRH	-0.85	-5.1	-0.42	1.25e-6	Interleukin-17 levels;
TGCT	cis	rs7681440	0.804	rs1442140	chr4:90816023	A/G	cg26578617	chr4:90757533	SNCA	-0.45	-4.77	-0.39	5.06e-6	Dementia with Lewy bodies;
TGCT	cis	rs7542091	0.704	rs12022221	chr1:210046178	A/C	cg21951975	chr1:209979733	IRF6	0.57	5.8	0.46	5.31e-8	Monobrow;
TGCT	cis	rs7772486	0.713	rs79248977	chr6:146319388	C/A	cg23711669	chr6:146136114	FBXO30	0.84	8.53	0.61	4.35e-14	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg20203395	chr5:56204925	C5orf35	-0.59	-5.12	-0.42	1.12e-6	Initial pursuit acceleration;
TGCT	cis	rs9911578	0.935	rs6503878	chr17:56884581	T/G	cg05425664	chr17:57184151	TRIM37	-0.63	-6.26	-0.49	5.86e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs910316	0.591	rs7157158	chr14:75457238	A/G	cg08847533	chr14:75593920	NEK9	0.83	8.89	0.62	5.99e-15	Height;
TGCT	cis	rs4919694	1.000	rs74749600	chr10:104732996	T/C	cg04362960	chr10:104952993	NT5C2	1.07	7.15	0.54	6.49e-11	Arsenic metabolism;
TGCT	cis	rs59964204	0.530	rs73342272	chr7:37026712	G/A	cg06458904	chr7:36312573	EEPD1	0.46	4.85	0.4	3.68e-6	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
TGCT	cis	rs6570726	0.537	rs1280279	chr6:145884048	G/T	cg23711669	chr6:146136114	FBXO30	0.74	5.81	0.46	4.96e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2243480	1.000	rs186378	chr7:65582058	A/C	cg07424592	chr7:64974309	NA	1.22	7.36	0.55	2.2e-11	Diabetic kidney disease;
TGCT	cis	rs2760061	0.583	rs708113	chr1:228192753	T/A	cg18477163	chr1:228402036	OBSCN	0.34	6.91	0.53	2.25e-10	Diastolic blood pressure;
TGCT	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg14827481	chr10:134361889	INPP5A	0.27	4.43	0.37	2.01e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs832540	0.618	rs41106	chr5:56145057	G/T	cg24531977	chr5:56204891	C5orf35	-0.54	-5.34	-0.43	4.33e-7	Coronary artery disease;
TGCT	cis	rs3741404	0.620	rs882147	chr11:63976689	T/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.79	8.19	0.59	2.67e-13	Platelet count;
TGCT	cis	rs10207060	0.500	rs7566489	chr2:240703985	C/T	cg15726768	chr2:241314588	NA	-0.32	-4.58	-0.38	1.1e-5	Obesity-related traits;
TGCT	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg21280719	chr6:42927975	GNMT	-0.37	-4.59	-0.38	1.07e-5	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs6674176	0.932	rs4660761	chr1:44440146	G/A	cg13606994	chr1:44402422	ARTN	-0.47	-4.7	-0.39	6.93e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs66573146	1.000	rs6838250	chr4:6973184	C/G	cg01220768	chr4:7056774	TADA2B	0.39	4.91	0.4	2.77e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs1256061	0.533	rs2357479	chr14:64792764	G/T	cg21174375	chr14:64681225	SYNE2	0.21	4.49	0.37	1.61e-5	Hemoglobin concentration;Red blood cell count;Hematocrit;
TGCT	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.79	6.08	0.48	1.35e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2404602	0.583	rs35707798	chr15:76565026	G/C	cg22467129	chr15:76604101	ETFA	-0.61	-7.93	-0.58	1.07e-12	Blood metabolite levels;
TGCT	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg07507251	chr3:52567010	NT5DC2	0.47	6.64	0.51	8.95e-10	Bipolar disorder;
TGCT	cis	rs7772486	0.875	rs9403768	chr6:146406458	A/C	cg05347473	chr6:146136440	FBXO30	0.54	5.09	0.42	1.31e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs916888	0.821	rs199507	chr17:44858855	A/G	cg16520312	chr17:43971471	MAPT;LOC100128977	0.57	4.86	0.4	3.45e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs3617	0.625	rs2240917	chr3:52851137	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.6	-0.38	1.02e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12762955	0.519	rs7094331	chr10:1022816	T/C	cg20503657	chr10:835505	NA	-0.37	-4.79	-0.4	4.61e-6	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs7772486	0.875	rs1330939	chr6:146308518	T/A	cg05347473	chr6:146136440	FBXO30	0.52	4.92	0.4	2.7e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11098499	0.722	rs10006192	chr4:120263022	T/C	cg09307838	chr4:120376055	NA	0.55	5.41	0.44	3.16e-7	Corneal astigmatism;
TGCT	cis	rs526231	0.543	rs34765	chr5:102506864	G/C	cg23492399	chr5:102201601	PAM	-0.51	-4.49	-0.37	1.6e-5	Primary biliary cholangitis;
TGCT	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg06112835	chr11:68658793	MRPL21	0.46	7.94	0.58	1.01e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg16325326	chr1:53192061	ZYG11B	-0.71	-8.81	-0.62	9.22e-15	Monocyte count;
TGCT	cis	rs8180040	0.726	rs4682844	chr3:46982737	T/C	cg27129171	chr3:47204927	SETD2	-0.71	-8.76	-0.62	1.25e-14	Colorectal cancer;
TGCT	cis	rs10501293	0.746	rs7936295	chr11:43004672	T/C	cg03447554	chr11:43094025	NA	0.44	6.39	0.5	3.03e-9	Cognitive performance;
TGCT	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg03732007	chr1:2071316	PRKCZ	0.28	6.63	0.51	9.05e-10	Height;
TGCT	cis	rs11249608	0.548	rs7732719	chr5:178463054	A/G	cg21905437	chr5:178450457	ZNF879	0.44	4.55	0.38	1.25e-5	Pubertal anthropometrics;
TGCT	cis	rs7918232	0.698	rs6482586	chr10:27297829	A/C	cg14442939	chr10:27389572	ANKRD26	0.58	4.63	0.38	9.13e-6	Breast cancer;
TGCT	cis	rs9467711	0.606	rs66827971	chr6:26365766	T/C	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7264396	0.747	rs2425112	chr20:34319775	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.25	-0.43	6.33e-7	Total cholesterol levels;
TGCT	cis	rs910316	0.967	rs175502	chr14:75533679	A/G	cg11812906	chr14:75593930	NEK9	-0.73	-7.08	-0.54	9.42e-11	Height;
TGCT	cis	rs12477438	0.700	rs10190421	chr2:99670711	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-6.1	-0.48	1.22e-8	Chronic sinus infection;
TGCT	cis	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg25427524	chr10:38739819	LOC399744	-0.4	-8.36	-0.6	1.05e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7677751	0.806	rs7682912	chr4:55085620	T/G	cg17187183	chr4:55093834	PDGFRA	0.55	7.13	0.54	7.35e-11	Corneal astigmatism;
TGCT	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg23172400	chr8:95962367	TP53INP1	-0.39	-6.44	-0.5	2.4e-9	Type 2 diabetes;
TGCT	cis	rs6087990	0.899	rs1883729	chr20:31363193	G/A	cg13636640	chr20:31349939	DNMT3B	1.08	14.21	0.79	8.84e-28	Ulcerative colitis;
TGCT	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg11764359	chr7:65958608	NA	0.54	4.85	0.4	3.67e-6	Aortic root size;
TGCT	trans	rs10802346	0.545	rs1770012	chr1:246426405	A/G	cg13514129	chr1:39547527	MACF1	0.98	8.97	0.63	3.85e-15	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs57221529	0.709	rs72707024	chr5:667915	G/A	cg09021430	chr5:549028	NA	-0.4	-5.52	-0.44	1.9e-7	Lung disease severity in cystic fibrosis;
TGCT	cis	rs12510870	0.599	rs10028276	chr4:74388956	T/C	cg05868023	chr4:75230803	EREG	0.55	4.7	0.39	6.84e-6	Iris color (b* coordinate);
TGCT	cis	rs889312	0.500	rs11960484	chr5:56109154	C/T	cg24531977	chr5:56204891	C5orf35	0.51	5.38	0.43	3.65e-7	Breast cancer;Breast cancer (early onset);
TGCT	cis	rs244731	1.000	rs244729	chr5:176539018	C/G	cg06060754	chr5:176797920	RGS14	0.41	5.61	0.45	1.23e-7	Urate levels in lean individuals;
TGCT	trans	rs7618501	1.000	rs7372725	chr3:49790544	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-1.03	-13.16	-0.76	2.65e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs2439831	0.867	rs2447196	chr15:43893818	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.82	-5.57	-0.45	1.5e-7	Lung cancer in ever smokers;
TGCT	cis	rs7904368	0.754	rs7091240	chr10:16855683	G/A	cg14835575	chr10:16859367	RSU1	0.69	7.36	0.55	2.17e-11	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
TGCT	cis	rs9929218	0.953	rs3118235	chr16:68732977	A/G	cg01251360	chr16:68772225	CDH1	-0.29	-4.65	-0.39	8.45e-6	Colorectal cancer;
TGCT	cis	rs4918072	0.667	rs7920793	chr10:105706446	T/C	cg11005552	chr10:105648138	OBFC1	0.34	4.78	0.39	4.93e-6	Coronary artery disease;
TGCT	cis	rs6121246	0.954	rs6089093	chr20:30421459	C/T	cg18721089	chr20:30220636	NA	-0.46	-4.87	-0.4	3.31e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs12681287	0.752	rs10111095	chr8:87250984	T/C	cg27223183	chr8:87520930	FAM82B	-0.8	-5.67	-0.45	9.58e-8	Caudate activity during reward;
TGCT	cis	rs7412746	0.611	rs7556661	chr1:150892009	C/T	cg09365446	chr1:150670422	GOLPH3L	0.34	4.71	0.39	6.58e-6	Melanoma;
TGCT	cis	rs6048205	0.764	rs1203907	chr20:22560971	C/T	cg10773670	chr20:23331356	NXT1	0.93	4.52	0.38	1.44e-5	Fasting blood glucose (BMI interaction);Fasting blood glucose;
TGCT	cis	rs9467773	1.000	rs4871	chr6:26545632	G/A	cg09904177	chr6:26538194	HMGN4	0.64	6.33	0.49	4.12e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs3087591	1.000	rs1800845	chr17:29703438	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.48	-7.52	-0.56	9.58e-12	Hip circumference;
TGCT	cis	rs981844	0.775	rs17371336	chr4:154749525	A/G	cg14289246	chr4:154710475	SFRP2	1.0	8.63	0.61	2.53e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg22920501	chr2:26401640	FAM59B	-0.72	-6.37	-0.5	3.3e-9	Gut microbiome composition (summer);
TGCT	cis	rs2486012	1.000	rs2485991	chr1:44391722	C/T	cg12908607	chr1:44402522	ARTN	-0.69	-5.84	-0.46	4.28e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs6684514	1.000	rs12563631	chr1:156258953	T/C	cg20302342	chr1:156215951	PAQR6	0.34	4.6	0.38	1.01e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs6547741	1.000	rs6737921	chr2:27839107	T/C	cg27432699	chr2:27873401	GPN1	0.18	4.56	0.38	1.19e-5	Oral cavity cancer;
TGCT	cis	rs11098499	0.863	rs9997631	chr4:120469995	C/G	cg09307838	chr4:120376055	NA	0.74	7.31	0.55	2.9e-11	Corneal astigmatism;
TGCT	cis	rs12950390	0.853	rs67441169	chr17:45854462	T/G	cg06532163	chr17:45867833	NA	0.37	5.87	0.47	3.74e-8	IgG glycosylation;
TGCT	cis	rs7917772	0.536	rs11191361	chr10:104411958	C/T	cg05855489	chr10:104503620	C10orf26	-0.59	-4.91	-0.4	2.76e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg01802117	chr1:53393560	SCP2	-0.46	-5.54	-0.45	1.77e-7	Monocyte count;
TGCT	cis	rs17253792	0.822	rs76201070	chr14:56063604	A/C	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs916888	0.821	rs199512	chr17:44857352	T/C	cg15921436	chr17:44337874	NA	-0.51	-6.96	-0.53	1.77e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs9303401	0.659	rs35103007	chr17:56900738	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs12477438	0.765	rs7605218	chr2:99593080	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-4.88	-0.4	3.17e-6	Chronic sinus infection;
TGCT	cis	rs453301	0.686	rs11785634	chr8:8892597	G/T	cg00184457	chr8:8946301	NA	-0.26	-4.94	-0.41	2.45e-6	Joint mobility (Beighton score);
TGCT	cis	rs6831352	0.918	rs17218162	chr4:100056060	G/A	cg12011299	chr4:100065546	ADH4	-0.4	-4.88	-0.4	3.26e-6	Alcohol dependence;
TGCT	trans	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg21659725	chr3:3221576	CRBN	0.76	9.02	0.63	2.92e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs6991838	0.593	rs953593	chr8:66631972	C/T	cg14353373	chr8:66472662	NA	-0.47	-4.66	-0.39	7.86e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9291683	0.530	rs11723591	chr4:9985398	T/A	cg00071950	chr4:10020882	SLC2A9	0.64	8.17	0.59	3.05e-13	Bone mineral density;
TGCT	cis	rs2404602	0.647	rs12440965	chr15:76958591	G/A	cg22467129	chr15:76604101	ETFA	0.47	4.67	0.39	7.62e-6	Blood metabolite levels;
TGCT	cis	rs7246657	0.663	rs10408619	chr19:38070474	C/T	cg18154014	chr19:37997991	ZNF793	0.69	4.63	0.38	9.25e-6	Coronary artery calcification;
TGCT	cis	rs10875746	0.807	rs12313300	chr12:48470717	G/A	cg20731937	chr12:48336164	NA	0.62	4.95	0.41	2.36e-6	Longevity (90 years and older);
TGCT	trans	rs12599106	0.629	rs1391904	chr16:34548934	C/T	cg21548813	chr6:291882	DUSP22	-0.65	-6.9	-0.53	2.41e-10	Menopause (age at onset);
TGCT	cis	rs7100689	0.622	rs1340379	chr10:82121455	G/A	cg01528321	chr10:82214614	TSPAN14	0.8	7.76	0.57	2.7e-12	Post bronchodilator FEV1;
TGCT	cis	rs6964587	1.000	rs34548928	chr7:91668365	G/A	cg22709100	chr7:91322751	NA	0.28	4.56	0.38	1.19e-5	Breast cancer;
TGCT	cis	rs7267979	1.000	rs4815404	chr20:25301845	T/G	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10791097	0.765	rs4622274	chr11:130729486	C/T	cg05962950	chr11:130786565	SNX19	0.8	9.6	0.65	1.15e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs2276314	1.000	rs2276314	chr18:33557466	C/T	cg19628046	chr18:33552617	C18orf21	-0.53	-4.5	-0.37	1.53e-5	Endometriosis;Drug-induced torsades de pointes;
TGCT	cis	rs7020830	0.571	rs7031314	chr9:37376122	A/T	cg14235030	chr9:37121269	ZCCHC7	-0.41	-4.57	-0.38	1.16e-5	Schizophrenia;
TGCT	cis	rs77861329	1.000	rs2304505	chr3:52184760	T/C	cg08692210	chr3:52188851	WDR51A	0.83	4.64	0.38	8.71e-6	Macrophage inflammatory protein 1b levels;
TGCT	cis	rs3806843	0.900	rs2262576	chr5:140135536	T/C	cg19875535	chr5:140030758	IK	-0.35	-5.98	-0.47	2.23e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs12908161	0.959	rs12906348	chr15:85329421	A/C	cg17173187	chr15:85201210	NMB	0.54	6.06	0.48	1.48e-8	Schizophrenia;
TGCT	cis	rs9910055	0.529	rs183462	chr17:42183376	G/C	cg13607699	chr17:42295918	UBTF	-0.61	-4.97	-0.41	2.19e-6	Total body bone mineral density;
TGCT	cis	rs910316	0.967	rs4903285	chr14:75609268	A/T	cg23033748	chr14:75592666	NEK9	0.28	4.79	0.39	4.73e-6	Height;
TGCT	cis	rs9972944	0.756	rs4791132	chr17:63769124	T/C	cg07283582	chr17:63770753	CCDC46	-0.26	-5.27	-0.43	5.91e-7	Total body bone mineral density;
TGCT	cis	rs17718580	0.536	rs56208926	chr14:51045042	C/T	cg04730355	chr14:51134070	SAV1	1.25	8.77	0.62	1.16e-14	Cognitive performance;
TGCT	cis	rs9560113	1.000	rs9555810	chr13:112181437	C/G	cg14154082	chr13:112174009	NA	0.38	5.01	0.41	1.83e-6	Menarche (age at onset);
TGCT	cis	rs9611565	0.512	rs5758439	chr22:42131762	C/T	cg17554472	chr22:41940697	POLR3H	0.46	4.72	0.39	6.36e-6	Vitiligo;
TGCT	cis	rs6138458	1.000	rs6114981	chr20:24974401	C/T	cg26195577	chr20:24973756	C20orf3	-1.22	-12.53	-0.75	9.05e-24	Blood protein levels;
TGCT	cis	rs7681440	0.904	rs28734152	chr4:90767359	C/T	cg01966878	chr4:90757139	SNCA	-0.25	-4.56	-0.38	1.2e-5	Dementia with Lewy bodies;
TGCT	cis	rs9436747	0.641	rs6691282	chr1:66046505	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.56	5.03	0.41	1.69e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs514406	0.763	rs9988539	chr1:53213884	T/C	cg22166914	chr1:53195759	ZYG11B	-0.41	-7.06	-0.54	1.05e-10	Monocyte count;
TGCT	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg03709012	chr19:19516395	GATAD2A	0.75	6.16	0.48	9.21e-9	Tonsillectomy;
TGCT	cis	rs9303401	0.614	rs34920953	chr17:56589406	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.71	6.81	0.52	3.77e-10	Cognitive test performance;
TGCT	cis	rs2067615	0.599	rs12369214	chr12:107198611	G/A	cg15890332	chr12:107067104	RFX4	0.28	5.53	0.44	1.8e-7	Heart rate;
TGCT	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg16680214	chr1:154839983	KCNN3	-0.4	-8.47	-0.61	5.8e-14	Prostate cancer;
TGCT	cis	rs909002	0.772	rs6681414	chr1:32070234	G/A	cg11573219	chr1:32083031	HCRTR1	-0.45	-5.94	-0.47	2.65e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs11785400	0.793	rs4736364	chr8:143742113	C/T	cg24634471	chr8:143751801	JRK	0.55	5.51	0.44	1.99e-7	Schizophrenia;
TGCT	cis	rs858239	0.730	rs10255155	chr7:23402147	A/T	cg05602783	chr7:23145260	KLHL7	0.68	5.74	0.46	6.94e-8	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs12477438	0.501	rs2632260	chr2:99771590	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.89	9.05	0.63	2.42e-15	Chronic sinus infection;
TGCT	cis	rs1667284	0.935	rs1791171	chr18:29216157	T/C	cg15259973	chr18:29078565	DSG2	0.52	5.04	0.41	1.58e-6	Problematic alcohol use in trauma-exposed individuals;
TGCT	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg04546413	chr19:29218101	NA	0.73	5.36	0.43	3.83e-7	Methadone dose in opioid dependence;
TGCT	cis	rs7666738	0.830	rs13110903	chr4:98946373	A/G	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7226408	0.948	rs72883590	chr18:34390793	G/A	cg06757138	chr18:34340585	FHOD3	0.26	4.78	0.39	4.78e-6	Obesity-related traits;
TGCT	cis	rs7043114	0.525	rs7847929	chr9:95154244	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-5.6	-0.45	1.32e-7	Height;
TGCT	cis	rs3741404	0.895	rs1860368	chr11:63994692	T/C	cg01727686	chr11:63997306	NUDT22;DNAJC4	-0.23	-4.83	-0.4	4e-6	Platelet count;
TGCT	cis	rs7158300	0.522	rs6575228	chr14:92561395	G/A	cg14974772	chr14:92414425	FBLN5	0.24	4.88	0.4	3.25e-6	Height;
TGCT	cis	rs11792861	0.890	rs3750465	chr9:111900677	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.48	4.47	0.37	1.73e-5	Menarche (age at onset);
TGCT	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg08509172	chr19:19383838	TM6SF2	-0.35	-4.6	-0.38	1.02e-5	Tonsillectomy;
TGCT	cis	rs9325144	0.600	rs6582634	chr12:38748041	G/A	cg26384229	chr12:38710491	ALG10B	0.65	6.17	0.48	8.94e-9	Morning vs. evening chronotype;
TGCT	cis	rs55823223	0.564	rs936391	chr17:73847799	A/G	cg08125733	chr17:73851984	WBP2	-0.88	-9.52	-0.65	1.87e-16	Psoriasis;
TGCT	cis	rs6835098	0.961	rs1574314	chr4:174106663	C/T	cg08422745	chr4:174089978	GALNT7	-0.9	-10.08	-0.67	7.91e-18	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs7945705	0.902	rs11042152	chr11:9020987	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.48	5.31	0.43	4.96e-7	Hemoglobin concentration;
TGCT	trans	rs1470506	0.507	rs62171962	chr2:77224930	C/T	cg15576869	chr7:50450374	IKZF1	-0.41	-6.76	-0.52	4.74e-10	IgG glycosylation;
TGCT	cis	rs9916302	0.706	rs11078894	chr17:37396805	C/G	cg07936489	chr17:37558343	FBXL20	-0.81	-6.1	-0.48	1.27e-8	Glomerular filtration rate (creatinine);
TGCT	cis	rs514406	0.505	rs448788	chr1:53161620	A/G	cg08859206	chr1:53392774	SCP2	0.35	4.81	0.4	4.25e-6	Monocyte count;
TGCT	cis	rs9649213	0.614	rs12539761	chr7:98013839	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.96	-9.08	-0.63	2.14e-15	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs78487399	0.808	rs77527404	chr2:43678387	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.24	-0.43	6.79e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs7843479	0.544	rs11135735	chr8:21791557	C/T	cg17168535	chr8:21777572	XPO7	0.91	9.55	0.65	1.52e-16	Mean corpuscular volume;
TGCT	cis	rs4746818	1.000	rs7918066	chr10:70913116	C/T	cg11621586	chr10:70884670	VPS26A	1.23	10.93	0.7	6.87e-20	Left atrial antero-posterior diameter;
TGCT	trans	rs114540395	0.858	rs77691531	chr10:103123526	G/A	cg10198749	chr1:39920707	MACF1	0.52	7.12	0.54	7.77e-11	Schizophrenia;
TGCT	cis	rs7428	0.924	rs12714140	chr2:85557591	A/T	cg24342717	chr2:85555507	TGOLN2	-0.4	-6.35	-0.5	3.76e-9	Ear protrusion;
TGCT	cis	rs425277	0.565	rs3128293	chr1:2065339	A/G	cg24578937	chr1:2090814	PRKCZ	-0.26	-6.45	-0.5	2.26e-9	Height;
TGCT	cis	rs910316	0.967	rs4903292	chr14:75656245	A/G	cg23033748	chr14:75592666	NEK9	0.27	4.54	0.38	1.31e-5	Height;
TGCT	cis	rs2153535	0.580	rs4960423	chr6:8477210	C/T	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs9611565	0.592	rs12484254	chr22:41962003	T/A	cg13695892	chr22:41940480	POLR3H	-0.87	-8.17	-0.59	2.95e-13	Vitiligo;
TGCT	cis	rs1348850	0.914	rs1975544	chr2:178465423	G/A	cg22681709	chr2:178499509	PDE11A	-0.45	-5.26	-0.43	6.13e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs3849570	0.555	rs4481177	chr3:81996817	A/T	cg07356753	chr3:81810745	GBE1	0.61	5.39	0.44	3.49e-7	Waist circumference;Body mass index;
TGCT	cis	rs67311347	1.000	rs6801185	chr3:40505060	C/T	cg13683864	chr3:40499215	RPL14	1.14	12.22	0.74	4.89e-23	Renal cell carcinoma;
TGCT	cis	rs28595532	0.841	rs115080469	chr4:119720501	C/T	cg21605333	chr4:119757512	SEC24D	1.56	8.07	0.59	5.21e-13	Cannabis dependence symptom count;
TGCT	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg27286337	chr10:134555280	INPP5A	0.39	4.73	0.39	6.02e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs644799	0.710	rs10831427	chr11:95508383	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.29	0.6	1.54e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs4845570	0.920	rs3811414	chr1:151763246	A/G	cg07092448	chr1:151763213	TDRKH	-1.07	-9.51	-0.65	1.94e-16	Coronary artery disease;
TGCT	cis	rs3091242	1.000	rs3091242	chr1:25674785	C/T	cg10117171	chr1:25599238	RHD	-0.36	-5.85	-0.46	4.18e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs9522267	0.737	rs12429582	chr13:112226657	A/G	cg10483660	chr13:112241077	NA	-0.31	-5.36	-0.43	4e-7	Hepatitis;
TGCT	cis	rs13064411	0.696	rs6438159	chr3:113217341	T/C	cg18753928	chr3:113234510	CCDC52	-0.7	-5.75	-0.46	6.6e-8	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs259282	0.605	rs73028624	chr19:33111758	C/T	cg26639809	chr19:33781782	NA	0.24	4.87	0.4	3.27e-6	Schizophrenia;
TGCT	cis	rs9807989	0.811	rs11688573	chr2:102969971	C/A	cg09003973	chr2:102972529	NA	0.64	5.7	0.46	8.28e-8	Asthma;
TGCT	cis	rs62193398	0.935	rs17384314	chr2:202531136	C/G	cg12618251	chr2:202899058	FZD7	0.53	4.46	0.37	1.83e-5	Breast cancer;
TGCT	cis	rs9303542	0.625	rs7207109	chr17:46607817	C/T	cg25032089	chr17:46643351	HOXB3	0.57	5.84	0.46	4.27e-8	Ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs669446	0.562	rs6429636	chr1:44183540	G/T	cg12908607	chr1:44402522	ARTN	-0.59	-6.47	-0.5	2.02e-9	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg03709012	chr19:19516395	GATAD2A	0.75	6.2	0.49	7.59e-9	Tonsillectomy;
TGCT	cis	rs9911578	0.967	rs1588322	chr17:56990099	T/C	cg05425664	chr17:57184151	TRIM37	-0.62	-6.18	-0.49	8.33e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg14773178	chr5:1868261	NA	0.34	5.34	0.43	4.3e-7	Cardiovascular disease risk factors;
TGCT	cis	rs7586879	0.789	rs13404163	chr2:25126616	A/G	cg01884057	chr2:25150051	NA	0.27	4.72	0.39	6.29e-6	Body mass index;
TGCT	cis	rs6665290	0.669	rs34267809	chr1:227176162	C/G	cg10327440	chr1:227177885	CDC42BPA	-0.91	-15.21	-0.81	4.04e-30	Myeloid white cell count;
TGCT	cis	rs1865760	0.566	rs9358904	chr6:26068566	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.79	7.43	0.55	1.56e-11	Height;
TGCT	cis	rs11785400	0.753	rs9773415	chr8:143731170	G/A	cg24634471	chr8:143751801	JRK	0.53	5.24	0.43	6.79e-7	Schizophrenia;
TGCT	cis	rs425277	0.585	rs364677	chr1:2071765	A/G	cg12140144	chr1:2984275	FLJ42875;PRDM16	0.35	4.93	0.41	2.55e-6	Height;
TGCT	cis	rs7822232	0.908	rs7821112	chr8:145147169	G/A	cg26272248	chr8:145163034	KIAA1875	0.49	4.81	0.4	4.24e-6	Blood metabolite levels;
TGCT	cis	rs35306767	0.903	rs7914758	chr10:891702	T/C	cg26597838	chr10:835615	NA	0.8	12.11	0.74	9.26e-23	Eosinophil percentage of granulocytes;
TGCT	cis	rs12533831	0.654	rs2435609	chr7:150890073	C/T	cg26284782	chr7:151513241	PRKAG2	-0.26	-4.46	-0.37	1.79e-5	Childhood ear infection;
TGCT	cis	rs2404602	0.532	rs12591100	chr15:76700801	C/A	cg22467129	chr15:76604101	ETFA	0.45	4.93	0.4	2.57e-6	Blood metabolite levels;
TGCT	cis	rs3771570	0.786	rs62186378	chr2:242211554	G/A	cg21155796	chr2:242212141	HDLBP	0.94	6.69	0.51	6.9e-10	Prostate cancer;
TGCT	cis	rs9467603	0.611	rs35789010	chr6:25514179	G/A	cg16898833	chr6:26189333	HIST1H4D	1.37	6.03	0.48	1.73e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7246657	0.722	rs8100646	chr19:38107943	T/C	cg03611452	chr19:38183253	ZNF781	0.58	4.64	0.38	8.62e-6	Coronary artery calcification;
TGCT	cis	rs7829975	0.502	rs11785183	chr8:8565957	G/A	cg06636001	chr8:8085503	FLJ10661	-0.6	-5.08	-0.42	1.33e-6	Mood instability;
TGCT	cis	rs11098499	0.954	rs71629403	chr4:120372567	C/T	cg09307838	chr4:120376055	NA	0.68	6.53	0.51	1.54e-9	Corneal astigmatism;
TGCT	cis	rs7666738	0.830	rs11725095	chr4:99009711	T/A	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7772486	0.875	rs10457793	chr6:146415403	A/G	cg23711669	chr6:146136114	FBXO30	0.91	9.95	0.67	1.67e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg18654377	chr3:49208889	KLHDC8B	-0.37	-4.9	-0.4	2.91e-6	Menarche (age at onset);
TGCT	cis	rs12422267	0.609	rs11246940	chr12:132623473	A/G	cg09764611	chr12:132620959	NA	-0.37	-5.68	-0.45	9e-8	Plasma amyloid beta peptide concentrations (ABx-40);
TGCT	cis	rs3784262	0.512	rs4646572	chr15:58343021	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.5	-7.57	-0.56	7.4e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs9902453	0.689	rs7216948	chr17:28203173	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.87	8.27	0.6	1.75e-13	Coffee consumption (cups per day);
TGCT	cis	rs7666738	0.546	rs13141117	chr4:98892798	G/A	cg17366294	chr4:99064904	C4orf37	0.64	5.73	0.46	7.05e-8	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs561341	1.000	rs546748	chr17:30324293	A/C	cg20587970	chr11:113659929	NA	-0.97	-12.38	-0.74	2.11e-23	Hip circumference adjusted for BMI;
TGCT	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg20203395	chr5:56204925	C5orf35	0.53	4.89	0.4	3.03e-6	Initial pursuit acceleration;
TGCT	cis	rs7614311	0.681	rs73119022	chr3:63979834	T/C	cg22134162	chr3:63841271	THOC7	-0.43	-5.68	-0.45	9.12e-8	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs11031096	0.655	rs10835734	chr11:4211832	A/C	cg18678763	chr11:4115507	RRM1	-0.45	-5.77	-0.46	6.11e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs1008375	1.000	rs7673500	chr4:17621383	C/T	cg18681998	chr4:17616180	MED28	1.03	11.4	0.72	4.96e-21	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs80282103	0.867	rs80254477	chr10:1077387	T/G	cg08668510	chr10:1095578	IDI1	1.18	5.51	0.44	2.02e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs28595532	0.764	rs116302502	chr4:119748848	T/A	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs17401966	1.000	rs1536263	chr1:10378914	T/C	cg19773385	chr1:10388646	KIF1B	-0.22	-4.56	-0.38	1.22e-5	Hepatocellular carcinoma;
TGCT	cis	rs13191362	0.507	rs2849520	chr6:163132038	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.62	-5.52	-0.44	1.88e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs17345786	0.906	rs72940399	chr3:101122575	A/T	cg11279151	chr3:101281821	RG9MTD1	-0.4	-8.36	-0.6	1.09e-13	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg07870213	chr5:140052090	DND1	-0.62	-7.4	-0.55	1.84e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs922182	0.589	rs11071778	chr15:64237608	A/G	cg02919090	chr15:64263738	DAPK2	-0.34	-6.39	-0.5	3e-9	Blood protein levels;
TGCT	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg03517284	chr6:25882590	NA	0.5	4.58	0.38	1.12e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg11890956	chr21:40555474	PSMG1	1.12	12.59	0.75	6.25e-24	Cognitive function;
TGCT	cis	rs624899	0.655	rs8109248	chr19:11641375	C/T	cg14128973	chr19:11649462	CNN1	0.54	6.44	0.5	2.34e-9	Presence of antiphospholipid antibodies;
TGCT	cis	rs12220238	1.000	rs115418388	chr10:75976296	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.92	7.79	0.57	2.29e-12	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.91	0.4	2.86e-6	Electroencephalogram traits;
TGCT	cis	rs896854	0.714	rs572547	chr8:95966286	A/G	cg09323728	chr8:95962352	TP53INP1	0.45	5.26	0.43	6.17e-7	Type 2 diabetes;
TGCT	cis	rs76878669	0.561	rs10896112	chr11:66116836	G/C	cg18002602	chr11:66138449	SLC29A2	-0.54	-6.62	-0.51	9.76e-10	Educational attainment (years of education);
TGCT	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.44	-6.41	-0.5	2.71e-9	Alzheimer's disease;
TGCT	cis	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg15556689	chr8:8085844	FLJ10661	0.65	6.06	0.48	1.51e-8	Mood instability;
TGCT	trans	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.89	-10.03	-0.67	1.1e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs2066819	0.786	rs111580405	chr12:56739557	A/G	cg26714650	chr12:56694279	CS	-1.36	-5.95	-0.47	2.56e-8	Psoriasis vulgaris;
TGCT	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg00684032	chr4:1343700	KIAA1530	0.23	4.95	0.41	2.36e-6	Obesity-related traits;
TGCT	cis	rs9394841	0.692	rs2395795	chr6:41802354	G/A	cg08135965	chr6:41755394	TOMM6	0.54	5.04	0.41	1.57e-6	Mean corpuscular hemoglobin;Red cell distribution width;
TGCT	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.88	8.57	0.61	3.38e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	1.000	rs59275611	chr8:58195191	G/A	cg21724239	chr8:58056113	NA	0.38	4.79	0.4	4.64e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs3771570	1.000	rs73002147	chr2:242302934	T/C	cg21155796	chr2:242212141	HDLBP	0.94	6.69	0.51	6.9e-10	Prostate cancer;
TGCT	cis	rs9303401	0.659	rs17822837	chr17:56737838	C/T	cg25039879	chr17:56429692	SUPT4H1	0.52	4.6	0.38	1.03e-5	Cognitive test performance;
TGCT	cis	rs12681287	0.640	rs72606633	chr8:87476236	T/C	cg27223183	chr8:87520930	FAM82B	-0.89	-6.41	-0.5	2.8e-9	Caudate activity during reward;
TGCT	cis	rs12682352	0.652	rs3789843	chr8:8724257	C/T	cg08975724	chr8:8085496	FLJ10661	0.56	5.13	0.42	1.07e-6	Neuroticism;
TGCT	cis	rs2956278	0.717	rs2956292	chr12:84680026	A/G	cg25678815	chr12:85673915	ALX1	-0.54	-4.83	-0.4	3.96e-6	Depressive symptoms;Depressive symptoms (multi-trait analysis);
TGCT	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg26338869	chr17:61819248	STRADA	-0.56	-5.11	-0.42	1.17e-6	Prudent dietary pattern;
TGCT	cis	rs9790314	0.846	rs6791213	chr3:161033721	A/G	cg03342759	chr3:160939853	NMD3	-0.51	-5.66	-0.45	9.9e-8	Morning vs. evening chronotype;
TGCT	cis	rs4766566	0.609	rs933305	chr12:111738287	G/A	cg07658449	chr12:111725167	CUX2	0.29	4.77	0.39	4.99e-6	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
TGCT	cis	rs11971779	0.838	rs4728468	chr7:139122978	G/A	cg07862535	chr7:139043722	LUC7L2	0.71	5.22	0.42	7.33e-7	Diisocyanate-induced asthma;
TGCT	cis	rs225245	0.817	rs1634684	chr17:33941051	A/G	cg05299278	chr17:33885742	SLFN14	0.21	4.44	0.37	1.98e-5	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs3617	0.539	rs4687689	chr3:52948674	A/C	cg11645453	chr3:52864694	ITIH4	-0.26	-5.03	-0.41	1.68e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs912057	0.560	rs1294416	chr6:6741327	A/G	cg06612196	chr6:6737390	NA	0.49	7.31	0.55	2.85e-11	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs2066819	1.000	rs2695782	chr12:56722830	C/T	cg26714650	chr12:56694279	CS	1.44	7.08	0.54	9.46e-11	Psoriasis vulgaris;
TGCT	cis	rs8014204	0.762	rs10148293	chr14:75296831	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.57	-5.07	-0.41	1.4e-6	Caffeine consumption;
TGCT	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg03188948	chr7:1209495	NA	0.79	6.66	0.51	8.12e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg16414030	chr3:133502952	NA	-0.48	-6.64	-0.51	8.96e-10	Iron status biomarkers;
TGCT	cis	rs9549260	0.709	rs12585870	chr13:41199487	A/C	cg21288729	chr13:41239152	FOXO1	0.99	10.49	0.69	8.15e-19	Red blood cell count;
TGCT	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg19774624	chr17:42201019	HDAC5	-0.81	-9.21	-0.64	1.02e-15	Total body bone mineral density;
TGCT	cis	rs644799	0.544	rs687559	chr11:95598629	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.5	-5.28	-0.43	5.49e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs6912958	0.702	rs6906769	chr6:88235949	T/C	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.91	-0.4	2.78e-6	Monocyte percentage of white cells;
TGCT	cis	rs62380364	0.613	rs254781	chr5:88000636	C/T	cg24804195	chr5:87968844	LOC645323	-0.58	-5.55	-0.45	1.64e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7072216	0.763	rs8181292	chr10:100175477	A/G	cg26618903	chr10:100175079	PYROXD2	-0.4	-4.49	-0.37	1.64e-5	Metabolite levels;
TGCT	cis	rs36051895	0.632	rs7040806	chr9:5174782	C/T	cg02405213	chr9:5042618	JAK2	-0.74	-10.54	-0.69	6.32e-19	Pediatric autoimmune diseases;
TGCT	cis	rs921968	0.540	rs646295	chr2:219408558	A/C	cg02176678	chr2:219576539	TTLL4	0.45	6.48	0.5	1.93e-9	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs877282	0.853	rs10904544	chr10:756966	A/G	cg17470449	chr10:769945	NA	0.35	5.06	0.41	1.44e-6	Uric acid levels;
TGCT	cis	rs61776719	0.738	rs7555461	chr1:38444749	T/C	cg12658694	chr1:38397304	INPP5B	-0.55	-5.69	-0.46	8.64e-8	Coronary artery disease;
TGCT	cis	rs11627546	0.615	rs61980618	chr14:70367202	C/G	cg10496350	chr14:71275911	MAP3K9	-0.94	-4.44	-0.37	1.96e-5	Red blood cell traits;
TGCT	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg11905131	chr22:24372483	LOC391322	-0.89	-9.98	-0.67	1.39e-17	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7666738	0.576	rs7660951	chr4:98651581	T/A	cg05340658	chr4:99064831	C4orf37	0.48	5.22	0.42	7.31e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8180040	0.652	rs13077398	chr3:47011120	G/C	cg27129171	chr3:47204927	SETD2	0.73	9.42	0.65	3.15e-16	Colorectal cancer;
TGCT	cis	rs11209185	0.509	rs9436791	chr1:68452857	A/C	cg22082780	chr1:68452167	NA	0.32	5.05	0.41	1.56e-6	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs7014346	0.767	rs7837644	chr8:128423398	A/T	cg04263511	chr8:128962092	PVT1	-0.31	-4.5	-0.37	1.54e-5	Colorectal cancer;
TGCT	cis	rs7829975	0.593	rs2979241	chr8:8303353	G/C	cg15556689	chr8:8085844	FLJ10661	0.67	6.21	0.49	7.41e-9	Mood instability;
TGCT	cis	rs3091242	0.728	rs706845	chr1:25730713	G/A	cg00786635	chr1:25594202	NA	0.59	6.09	0.48	1.34e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs1048238	0.846	rs945420	chr1:16345208	G/A	cg21385522	chr1:16154831	NA	0.43	4.52	0.38	1.43e-5	Systolic blood pressure;
TGCT	trans	rs208520	1.000	rs28773210	chr6:66993566	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.83	7.47	0.56	1.27e-11	Exhaled nitric oxide output;
TGCT	cis	rs2933343	0.700	rs1683787	chr3:128627021	C/T	cg11901034	chr3:128598214	ACAD9	0.63	6.0	0.47	2.01e-8	IgG glycosylation;
TGCT	cis	rs7666738	0.830	rs62321565	chr4:98976571	G/A	cg05340658	chr4:99064831	C4orf37	0.5	5.84	0.46	4.35e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3091242	0.933	rs1534954	chr1:25761924	A/T	cg00786635	chr1:25594202	NA	0.55	5.74	0.46	6.91e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs9818758	0.607	rs34823813	chr3:49749976	G/A	cg08550065	chr3:50336684	HYAL3;NAT6	1.04	5.12	0.42	1.13e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs17270561	0.779	rs17271767	chr6:25886921	C/T	cg17691542	chr6:26056736	HIST1H1C	0.87	6.0	0.47	2.02e-8	Iron status biomarkers;
TGCT	cis	rs1577917	0.958	rs12196175	chr6:86779370	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.43	-0.44	2.86e-7	Response to antipsychotic treatment;
TGCT	cis	rs7223966	1.000	rs7217982	chr17:61832150	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	4.68	0.39	7.5e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg08125733	chr17:73851984	WBP2	1.17	12.85	0.76	1.47e-24	Psoriasis;
TGCT	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg17971929	chr21:40555470	PSMG1	-0.71	-6.63	-0.51	9.09e-10	Cognitive function;
TGCT	cis	rs7666738	0.830	rs60391193	chr4:98933912	T/G	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs36051895	0.623	rs7859286	chr9:5260940	G/T	cg02405213	chr9:5042618	JAK2	-0.7	-9.4	-0.65	3.55e-16	Pediatric autoimmune diseases;
TGCT	cis	rs9300255	0.566	rs10744150	chr12:123721614	A/C	cg00376283	chr12:123451042	ABCB9	0.79	6.72	0.52	6e-10	Neutrophil percentage of white cells;
TGCT	cis	rs9467773	0.804	rs2073526	chr6:26374658	C/T	cg15659132	chr6:26577336	NA	-0.48	-4.79	-0.39	4.75e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs9992639	chr4:98940400	G/T	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9326248	0.911	rs474339	chr11:117059552	G/A	cg11861562	chr11:117069780	TAGLN	0.27	4.59	0.38	1.06e-5	Blood protein levels;
TGCT	cis	rs7552404	0.924	rs2173378	chr1:76201992	G/T	cg22875332	chr1:76189707	ACADM	0.72	8.9	0.62	5.76e-15	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg21724239	chr8:58056113	NA	0.39	5.14	0.42	1.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs68170813	0.559	rs4730223	chr7:106814234	A/T	cg02696742	chr7:106810147	HBP1	0.77	6.65	0.51	8.18e-10	Coronary artery disease;
TGCT	cis	rs11122272	0.735	rs2749708	chr1:231529610	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-6.34	-0.49	3.83e-9	Hemoglobin concentration;
TGCT	cis	rs7432375	0.901	rs7618518	chr3:136370092	C/T	cg12473912	chr3:136751656	NA	-0.36	-5.06	-0.41	1.5e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7811142	0.945	rs6978739	chr7:100098680	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.04	8.56	0.61	3.72e-14	Platelet count;
TGCT	cis	rs854765	0.547	rs2955385	chr17:17939247	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.77	8.07	0.59	5.16e-13	Total body bone mineral density;
TGCT	cis	rs2115630	0.902	rs8023276	chr15:85219638	C/T	cg11189052	chr15:85197271	WDR73	-0.67	-6.67	-0.51	7.74e-10	P wave terminal force;
TGCT	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg18305652	chr10:134549665	INPP5A	0.34	5.64	0.45	1.08e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg20891558	chr2:74357851	NA	0.62	9.22	0.64	9.54e-16	Gestational age at birth (maternal effect);
TGCT	cis	rs7665147	1	rs7665147	chr4:57767327	T/A	cg26694713	chr4:57773883	REST	0.72	6.38	0.5	3.19e-9	Platelet count;
TGCT	cis	rs4654899	0.802	rs12127519	chr1:21247365	C/T	cg01072550	chr1:21505969	NA	-0.46	-6.94	-0.53	1.96e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg22442454	chr1:209979470	IRF6	0.59	5.95	0.47	2.52e-8	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
TGCT	cis	rs933688	1.000	rs186717	chr5:90780467	T/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.88	8.22	0.59	2.36e-13	Smoking behavior;
TGCT	cis	rs2120019	1.000	rs12901243	chr15:75374233	C/T	cg17294928	chr15:75287854	SCAMP5	-0.86	-6.62	-0.51	9.55e-10	Blood trace element (Zn levels);
TGCT	cis	rs7660520	0.524	rs12643521	chr4:183728242	C/G	cg04181038	chr4:183730758	NA	0.68	5.79	0.46	5.38e-8	Pediatric autoimmune diseases;
TGCT	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	8.16	0.59	3.1400000000000003e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg20607798	chr8:58055168	NA	0.5	4.66	0.39	8.04e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs12681288	0.862	rs2701898	chr8:1020812	C/T	cg08872321	chr8:1308229	NA	-0.26	-4.75	-0.39	5.45e-6	Schizophrenia;
TGCT	cis	rs7666738	0.924	rs11097592	chr4:98927532	C/T	cg05340658	chr4:99064831	C4orf37	0.5	5.23	0.42	7.12e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9677476	0.909	rs6437010	chr2:232113263	G/C	cg07929768	chr2:232055508	NA	0.3	4.48	0.37	1.71e-5	Food antigen IgG levels;
TGCT	cis	rs3806843	0.900	rs2563280	chr5:140131530	G/C	cg19875535	chr5:140030758	IK	-0.35	-5.97	-0.47	2.27e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg01802117	chr1:53393560	SCP2	-0.41	-4.95	-0.41	2.39e-6	Monocyte count;
TGCT	cis	rs6912958	0.559	rs369674	chr6:88043402	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.47	-6.33	-0.49	4.08e-9	Monocyte percentage of white cells;
TGCT	cis	rs2688608	0.592	rs13013	chr10:75562161	C/A	cg19442545	chr10:75533431	FUT11	-0.36	-5.67	-0.45	9.71e-8	Inflammatory bowel disease;
TGCT	cis	rs28595532	0.920	rs114581578	chr4:119756404	C/T	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs7192750	0.586	rs62053803	chr16:71989413	G/A	cg06353428	chr16:71660113	MARVELD3	0.74	6.6	0.51	1.09e-9	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs514406	0.893	rs6588445	chr1:53424928	T/C	cg08736216	chr1:53307985	ZYG11A	0.29	5.96	0.47	2.43e-8	Monocyte count;
TGCT	cis	rs7677751	0.767	rs6846502	chr4:55062090	T/C	cg17187183	chr4:55093834	PDGFRA	0.48	6.38	0.5	3.27e-9	Corneal astigmatism;
TGCT	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg13395646	chr4:1353034	KIAA1530	-0.41	-4.69	-0.39	7.11e-6	Longevity;
TGCT	cis	rs2288884	1.000	rs11673286	chr19:52540318	C/T	cg13540795	chr19:52551618	ZNF432	-0.58	-5.03	-0.41	1.67e-6	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs12541335	0.615	rs4872464	chr8:22153381	G/A	cg02463440	chr8:22132932	PIWIL2	0.25	4.86	0.4	3.45e-6	Hypertriglyceridemia;
TGCT	cis	rs4713118	0.662	rs9468271	chr6:28024570	A/G	cg12963246	chr6:28129442	ZNF389	0.45	4.55	0.38	1.27e-5	Parkinson's disease;
TGCT	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg12667521	chr19:29218732	NA	0.53	5.63	0.45	1.16e-7	Methadone dose in opioid dependence;
TGCT	cis	rs9653442	0.545	rs4490209	chr2:100766711	C/G	cg07810366	chr2:100720526	AFF3	-0.35	-5.18	-0.42	8.67e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs10193935	0.901	rs10169971	chr2:42602189	G/A	cg27598129	chr2:42591480	NA	-0.4	-5.53	-0.44	1.83e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3780378	0.967	rs7852988	chr9:5010751	C/A	cg02405213	chr9:5042618	JAK2	-0.56	-7.5	-0.56	1.09e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs12220898	0.749	rs10735220	chr10:50473635	A/G	cg06072769	chr10:50146962	WDFY4	0.36	4.67	0.39	7.64e-6	Inflammatory biomarkers;
TGCT	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg09323728	chr8:95962352	TP53INP1	-0.54	-6.92	-0.53	2.17e-10	Type 2 diabetes;
TGCT	cis	rs2535633	0.631	rs2581827	chr3:52966558	C/T	cg10802521	chr3:52805072	NEK4	0.57	5.93	0.47	2.8e-8	Body mass index;
TGCT	cis	rs1865760	1.000	rs7757666	chr6:25902626	T/C	cg17042849	chr6:26104293	HIST1H4C	-0.52	-4.68	-0.39	7.33e-6	Height;
TGCT	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg11764359	chr7:65958608	NA	-0.54	-4.81	-0.4	4.32e-6	Aortic root size;
TGCT	cis	rs60843830	1.000	rs55936726	chr2:258210	T/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.76	7.78	0.57	2.42e-12	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs4663866	1.000	rs13033501	chr2:239181860	G/A	cg17283117	chr2:239148619	HES6	1.0	4.6	0.38	1.03e-5	Irritable bowel syndrome;
TGCT	cis	rs2439831	0.867	rs28415933	chr15:43635800	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	6.61	0.51	1e-9	Lung cancer in ever smokers;
TGCT	cis	rs4253772	0.550	rs9615913	chr22:46668515	A/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.57	-4.45	-0.37	1.86e-5	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs2549003	1.000	rs10068129	chr5:131821246	A/G	cg00255919	chr5:131827918	IRF1	-0.2	-4.56	-0.38	1.23e-5	Asthma (sex interaction);
TGCT	cis	rs7909074	1.000	rs12777258	chr10:45394961	A/G	cg05187965	chr10:45406764	TMEM72	0.25	5.43	0.44	2.8e-7	Mean corpuscular volume;
TGCT	cis	rs709400	0.593	rs12898029	chr14:103877884	T/C	cg12935359	chr14:103987150	CKB	0.34	5.17	0.42	9.21e-7	Body mass index;
TGCT	cis	rs28595532	0.920	rs114796605	chr4:119744472	C/A	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs11190604	0.767	rs10883479	chr10:102162860	A/G	cg16342193	chr10:102329863	NA	-0.39	-5.05	-0.41	1.54e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs6831352	0.918	rs29001203	chr4:100053091	A/G	cg12011299	chr4:100065546	ADH4	-0.42	-5.12	-0.42	1.14e-6	Alcohol dependence;
TGCT	cis	rs896854	0.714	rs572547	chr8:95966286	A/G	cg16049864	chr8:95962084	TP53INP1	0.64	7.66	0.57	4.51e-12	Type 2 diabetes;
TGCT	cis	rs644799	0.662	rs35793328	chr11:95490896	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.77	8.04	0.59	6.16e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs11585357	0.895	rs72633823	chr1:17630779	G/A	cg08277548	chr1:17600880	PADI3	-0.95	-9.6	-0.65	1.15e-16	Hair shape;
TGCT	cis	rs6547741	0.967	rs4665996	chr2:27814343	T/C	cg27432699	chr2:27873401	GPN1	0.18	4.65	0.38	8.53e-6	Oral cavity cancer;
TGCT	cis	rs5769765	0.908	rs138866	chr22:50205903	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.36	-5.69	-0.46	8.66e-8	Schizophrenia;
TGCT	cis	rs17345786	0.861	rs17402964	chr3:101067945	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.4	-8.21	-0.59	2.39e-13	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6674176	0.597	rs3762422	chr1:44400532	T/A	cg13606994	chr1:44402422	ARTN	-0.49	-5.4	-0.44	3.31e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg18230493	chr5:56204884	C5orf35	-0.63	-5.58	-0.45	1.47e-7	Initial pursuit acceleration;
TGCT	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.54	4.97	0.41	2.21e-6	Prudent dietary pattern;
TGCT	cis	rs7772486	0.720	rs6570713	chr6:146075085	G/A	cg23711669	chr6:146136114	FBXO30	-0.97	-11.03	-0.7	4.03e-20	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs941873	0.805	rs8837	chr10:81114813	C/G	cg09469691	chr10:81107165	PPIF	0.5	4.96	0.41	2.27e-6	Height;
TGCT	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg06221963	chr1:154839813	KCNN3	-0.75	-12.65	-0.75	4.66e-24	Prostate cancer;
TGCT	cis	rs6840360	0.615	rs6535822	chr4:152679722	A/G	cg17479576	chr4:152424074	FAM160A1	-0.52	-5.16	-0.42	9.49e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg10047753	chr17:41438598	NA	0.97	9.74	0.66	5.32e-17	Menopause (age at onset);
TGCT	cis	rs6463523	0.933	rs6974151	chr7:758269	T/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.86	11.91	0.73	2.85e-22	Subjective well-being;
TGCT	cis	rs28595532	0.920	rs55758547	chr4:119769475	T/C	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs13064411	0.696	rs9814395	chr3:113188885	C/T	cg18753928	chr3:113234510	CCDC52	-0.67	-5.46	-0.44	2.45e-7	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs6835098	0.692	rs6553679	chr4:174072292	C/T	cg08422745	chr4:174089978	GALNT7	-0.77	-8.6	-0.61	2.87e-14	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs7020830	0.861	rs13289001	chr9:37311592	A/G	cg14294708	chr9:37120828	ZCCHC7	1.28	18.22	0.85	7.33e-37	Schizophrenia;
TGCT	cis	rs453301	0.658	rs9650616	chr8:8869199	T/G	cg06636001	chr8:8085503	FLJ10661	-0.68	-5.62	-0.45	1.21e-7	Joint mobility (Beighton score);
TGCT	cis	rs10791097	0.667	rs4937585	chr11:130741940	A/G	cg12179176	chr11:130786555	SNX19	0.84	10.17	0.67	4.95e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg22166914	chr1:53195759	ZYG11B	0.37	5.95	0.47	2.57e-8	Monocyte count;
TGCT	cis	rs9733	0.566	rs11204675	chr1:150570985	A/C	cg13175981	chr1:150552382	MCL1	0.56	6.41	0.5	2.8e-9	Tonsillectomy;
TGCT	cis	rs9634489	0.502	rs77248334	chr13:97119162	T/G	cg11411106	chr13:97107445	HS6ST3	0.27	4.72	0.39	6.26e-6	Body mass index;
TGCT	cis	rs3733585	0.605	rs4697926	chr4:10124567	G/T	cg00071950	chr4:10020882	SLC2A9	0.49	5.1	0.42	1.23e-6	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs2153535	0.601	rs9505473	chr6:8538777	T/C	cg07606381	chr6:8435919	SLC35B3	0.55	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs10858047	0.700	rs7538880	chr1:115194374	G/A	cg12756093	chr1:115239321	AMPD1	-0.47	-4.96	-0.41	2.27e-6	Autism;
TGCT	cis	rs2777491	1.000	rs316605	chr15:41771591	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.76	-11.32	-0.71	7.77e-21	Ulcerative colitis;
TGCT	cis	rs8070740	0.898	rs4493114	chr17:5324207	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	4.77	0.39	5.14e-6	Menopause (age at onset);
TGCT	cis	rs9916302	0.731	rs11868030	chr17:37650332	A/G	cg15445000	chr17:37608096	MED1	0.31	4.59	0.38	1.06e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs9926296	0.643	rs2159114	chr16:89831841	A/G	cg27121462	chr16:89883253	FANCA	0.57	5.38	0.43	3.64e-7	Vitiligo;
TGCT	cis	rs2463822	1.000	rs72921498	chr11:62113090	C/T	cg06239285	chr11:62104954	ASRGL1	-0.92	-6.76	-0.52	4.71e-10	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	trans	rs7824557	0.564	rs2736295	chr8:11234780	C/G	cg15556689	chr8:8085844	FLJ10661	0.72	6.62	0.51	9.66e-10	Retinal vascular caliber;
TGCT	cis	rs7666738	0.791	rs6840669	chr4:99016020	G/T	cg17366294	chr4:99064904	C4orf37	0.68	7.04	0.53	1.17e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4595586	0.563	rs11169769	chr12:39233134	C/G	cg26384229	chr12:38710491	ALG10B	0.65	5.29	0.43	5.43e-7	Morning vs. evening chronotype;
TGCT	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg25767906	chr1:53392781	SCP2	0.44	4.84	0.4	3.8e-6	Monocyte count;
TGCT	cis	rs5769707	0.967	rs9616701	chr22:50025546	G/A	cg05373962	chr22:49881684	NA	-0.31	-6.42	-0.5	2.6e-9	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs644799	0.710	rs3017756	chr11:95537358	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	8.5	0.61	5.03e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9858542	0.543	rs2230929	chr3:49343175	G/A	cg00383909	chr3:49044727	WDR6	0.65	4.46	0.37	1.83e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs12464483	0.524	rs4952172	chr2:30888286	A/G	cg12454169	chr2:30669597	LCLAT1	-0.41	-4.47	-0.37	1.73e-5	Pre-treatment pain in head and neck squamous cell carcinoma;
TGCT	cis	rs12142240	0.698	rs72679807	chr1:46846490	G/A	cg14993813	chr1:46806288	NSUN4	-0.59	-4.86	-0.4	3.45e-6	Menopause (age at onset);
TGCT	cis	rs933688	1.000	rs1895448	chr5:90743854	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.93	8.3	0.6	1.46e-13	Smoking behavior;
TGCT	trans	rs1005277	0.540	rs1987431	chr10:37988887	T/C	cg17830980	chr10:43048298	ZNF37B	-0.65	-7.3	-0.55	2.95e-11	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7924176	0.521	rs11000959	chr10:76046811	C/G	cg19889307	chr10:75911429	ADK;AP3M1	-0.47	-4.46	-0.37	1.84e-5	Primary tooth development (time to first tooth eruption);Permanent tooth development;Primary tooth development (number of teeth);
TGCT	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg08280861	chr8:58055591	NA	0.39	4.86	0.4	3.45e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs765787	0.530	rs4775822	chr15:45527127	A/G	cg24006582	chr15:45444508	DUOX1	-0.25	-5.54	-0.45	1.75e-7	Uric acid levels;
TGCT	cis	rs2742417	0.603	rs2742458	chr3:45767602	C/T	cg04837898	chr3:45731254	SACM1L	-0.65	-6.95	-0.53	1.84e-10	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs35160687	0.842	rs1863052	chr2:86559358	A/G	cg03171300	chr2:86307199	POLR1A	0.27	4.69	0.39	6.99e-6	Night sleep phenotypes;
TGCT	cis	rs7811142	1.000	rs6972167	chr7:100080013	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.03	8.57	0.61	3.5e-14	Platelet count;
TGCT	cis	rs2070488	0.775	rs7647657	chr3:38573746	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.62	-5.32	-0.43	4.71e-7	Electrocardiographic conduction measures;
TGCT	cis	rs7260538	0.773	rs2200238	chr19:41527265	G/A	cg27089200	chr19:41531976	NA	0.43	5.32	0.43	4.75e-7	DDT metabolite (p,p'-DDE levels);
TGCT	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg16325326	chr1:53192061	ZYG11B	0.56	6.12	0.48	1.15e-8	Monocyte count;
TGCT	cis	rs6969780	0.630	rs3735530	chr7:27189982	C/T	cg04321618	chr7:27170880	HOXA4	-0.52	-5.18	-0.42	8.67e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs2153535	0.580	rs1414342	chr6:8462552	A/G	cg23788917	chr6:8435910	SLC35B3	0.62	5.58	0.45	1.44e-7	Motion sickness;
TGCT	trans	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg17830980	chr10:43048298	ZNF37B	-0.86	-11.18	-0.71	1.68e-20	Extrinsic epigenetic age acceleration;
TGCT	cis	rs9312648	1.000	rs9312648	chr4:55241581	C/T	cg22115196	chr4:54829461	NA	-0.26	-4.51	-0.38	1.46e-5	Response to amphetamines;
TGCT	cis	rs3784262	1.000	rs4646619	chr15:58258342	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.49	-7.7	-0.57	3.78e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs2486288	0.656	rs11637838	chr15:45550657	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.45	-5.34	-0.43	4.26e-7	Glomerular filtration rate;
TGCT	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg07507251	chr3:52567010	NT5DC2	0.47	6.64	0.51	8.85e-10	Bipolar disorder;
TGCT	cis	rs1941184	0.500	rs1460598	chr18:29028491	G/A	cg14871544	chr18:29027885	DSG3	0.43	4.51	0.38	1.47e-5	Parkinson's disease (age of onset);
TGCT	cis	rs17221829	0.699	rs7129641	chr11:89383706	C/T	cg02982614	chr11:89391479	FOLH1B	-0.25	-4.44	-0.37	1.96e-5	Anxiety in major depressive disorder;
TGCT	trans	rs17685	0.712	rs10235738	chr7:75773460	G/A	cg19862616	chr7:65841803	NCRNA00174	0.53	9.19	0.64	1.13e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs4372836	1.000	rs4640348	chr2:28965479	T/C	cg09522027	chr2:28974177	PPP1CB	-0.54	-4.68	-0.39	7.33e-6	Body mass index;
TGCT	cis	rs7833790	0.724	rs6473309	chr8:82707880	A/G	cg06027949	chr8:82754900	SNX16	-0.66	-5.09	-0.42	1.32e-6	Diastolic blood pressure;
TGCT	cis	rs2637266	0.967	rs12244619	chr10:78352502	C/T	cg18941641	chr10:78392320	NA	0.4	5.02	0.41	1.79e-6	Pulmonary function;
TGCT	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg26354017	chr1:205819088	PM20D1	0.57	7.08	0.54	9.44e-11	Menarche (age at onset);
TGCT	cis	rs10940138	0.779	rs991123	chr5:67246171	G/A	ch.5.1281357F	chr5:67228439	NA	0.41	4.76	0.39	5.34e-6	Menarche (age at onset);
TGCT	cis	rs55665837	0.583	rs78843135	chr11:14411254	T/G	cg19336497	chr11:14380999	RRAS2	-0.3	-4.61	-0.38	9.73e-6	Vitamin D levels;
TGCT	trans	rs1814175	0.527	rs10769595	chr11:49638212	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.19	-0.59	2.67e-13	Height;
TGCT	cis	rs10883723	0.810	rs17782574	chr10:104279394	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	8.36	0.6	1.1e-13	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs595982	0.702	rs638050	chr19:49375676	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.37	-5.07	-0.41	1.4e-6	Red cell distribution width;
TGCT	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg03806693	chr22:41940476	POLR3H	-1.14	-13.38	-0.77	8.05e-26	Vitiligo;
TGCT	cis	rs7542091	0.635	rs985431	chr1:210043948	A/T	cg00989853	chr1:209979345	IRF6	0.43	4.58	0.38	1.12e-5	Monobrow;
TGCT	cis	rs60843830	0.596	rs17041320	chr2:112051	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.53	4.69	0.39	7.12e-6	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg03161606	chr19:29218774	NA	0.58	6.44	0.5	2.4e-9	Methadone dose in opioid dependence;
TGCT	cis	rs28595532	0.748	rs72670246	chr4:119335061	G/A	cg21605333	chr4:119757512	SEC24D	0.83	5.05	0.41	1.55e-6	Cannabis dependence symptom count;
TGCT	cis	rs6598955	0.724	rs12096059	chr1:26596709	G/A	cg04990556	chr1:26633338	UBXN11	-0.91	-11.45	-0.72	3.65e-21	Obesity-related traits;
TGCT	cis	rs10782582	0.593	rs11802717	chr1:76124648	C/T	cg22875332	chr1:76189707	ACADM	-0.54	-6.36	-0.5	3.61e-9	Daytime sleep phenotypes;
TGCT	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg06873352	chr17:61820015	STRADA	0.56	6.22	0.49	7.1e-9	Prudent dietary pattern;
TGCT	cis	rs7223966	1.000	rs11654335	chr17:61797579	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	4.7	0.39	6.69e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs11030122	0.702	rs10767715	chr11:3951409	G/T	cg18678763	chr11:4115507	RRM1	-0.49	-6.14	-0.48	1.01e-8	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs11031096	0.503	rs67065286	chr11:4105273	A/C	cg18678763	chr11:4115507	RRM1	-0.47	-5.66	-0.45	9.94e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs9914544	0.564	rs1859083	chr17:18843306	C/T	cg26306683	chr17:18585705	ZNF286B	-0.52	-4.79	-0.4	4.66e-6	Educational attainment (years of education);
TGCT	cis	rs9527	0.590	rs1046411	chr10:104837816	G/A	cg04362960	chr10:104952993	NT5C2	0.63	5.44	0.44	2.74e-7	Arsenic metabolism;
TGCT	cis	rs1577917	1.000	rs34852683	chr6:86702330	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.22	-0.42	7.27e-7	Response to antipsychotic treatment;
TGCT	cis	rs2842992	0.872	rs2758328	chr6:160090731	T/A	cg11366901	chr6:160182831	ACAT2	0.96	6.28	0.49	5.21e-9	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs16958440	0.867	rs79078752	chr18:44667462	A/G	cg17192377	chr18:44677553	HDHD2	0.63	4.7	0.39	6.74e-6	Sitting height ratio;
TGCT	cis	rs11771526	0.901	rs34376799	chr7:32316932	T/C	cg27532318	chr7:32358331	NA	0.57	4.49	0.37	1.61e-5	Body mass index;
TGCT	cis	rs10791097	0.642	rs7107568	chr11:130779668	T/C	cg05962950	chr11:130786565	SNX19	0.89	10.79	0.7	1.51e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg17971929	chr21:40555470	PSMG1	0.92	7.86	0.58	1.58e-12	Cognitive function;
TGCT	cis	rs3087591	0.922	rs12950236	chr17:29431034	A/G	cg24425628	chr17:29625626	OMG;NF1	0.46	7.15	0.54	6.63e-11	Hip circumference;
TGCT	cis	rs539096	0.692	rs6669157	chr1:44216876	T/C	cg12908607	chr1:44402522	ARTN	-0.63	-7.47	-0.56	1.25e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs13318932	0.505	rs12108018	chr3:98650393	C/G	cg27410952	chr3:98620265	DCBLD2	-0.94	-4.71	-0.39	6.64e-6	Blood protein levels;
TGCT	cis	rs477895	0.713	rs1059440	chr11:63991801	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.86	-7.04	-0.53	1.17e-10	Mean platelet volume;
TGCT	cis	rs986417	1.000	rs1254324	chr14:60908551	C/T	cg27398547	chr14:60952738	C14orf39	-1.39	-10.61	-0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs7726839	0.540	rs11750321	chr5:599196	C/T	cg20362242	chr5:692897	TPPP	0.53	4.56	0.38	1.22e-5	Obesity-related traits;
TGCT	cis	rs2361718	0.521	rs2361724	chr17:78099114	G/A	cg27614120	chr17:77386099	HRNBP3	0.28	5.0	0.41	1.93e-6	Yeast infection;
TGCT	cis	rs35146811	0.735	rs1636975	chr7:99812089	A/G	cg04778012	chr7:99775508	STAG3;GPC2	-0.35	-4.93	-0.41	2.55e-6	Coronary artery disease;
TGCT	cis	rs10507380	0.654	rs74695290	chr13:27923224	T/C	cg25543773	chr13:27185723	WASF3	0.34	4.83	0.4	3.97e-6	Electrocardiographic traits;
TGCT	cis	rs514406	0.893	rs1242315	chr1:53417181	A/G	cg25767906	chr1:53392781	SCP2	-0.51	-6.01	-0.47	1.93e-8	Monocyte count;
TGCT	cis	rs9906944	0.703	rs940088	chr17:47145848	T/C	cg07075026	chr17:47091521	IGF2BP1	-0.45	-4.81	-0.4	4.38e-6	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs3749237	0.595	rs4955412	chr3:49418168	A/C	cg02487422	chr3:49467188	NICN1	0.59	6.01	0.47	1.92e-8	Resting heart rate;
TGCT	cis	rs6496667	0.600	rs62019401	chr15:91071855	C/T	cg22089800	chr15:90895588	ZNF774	0.63	4.5	0.37	1.53e-5	Rheumatoid arthritis;
TGCT	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg07507251	chr3:52567010	NT5DC2	0.5	7.29	0.55	3.14e-11	Electroencephalogram traits;
TGCT	cis	rs7646507	0.536	rs9857402	chr3:172559793	A/G	cg10532262	chr3:172428426	NCEH1	-0.82	-4.44	-0.37	1.99e-5	Obesity-related traits;
TGCT	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg22618164	chr12:122356400	WDR66	-0.55	-5.56	-0.45	1.57e-7	Mean corpuscular volume;
TGCT	cis	rs9328448	0.882	rs9502671	chr6:7981808	G/A	cg13863638	chr6:7199401	RREB1	0.19	4.49	0.37	1.64e-5	Coronary artery calcification;
TGCT	cis	rs4845570	0.850	rs11204892	chr1:151768048	A/G	cg07092448	chr1:151763213	TDRKH	1.07	9.04	0.63	2.62e-15	Coronary artery disease;
TGCT	cis	rs60843830	1.000	rs2290911	chr2:224919	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.74	6.83	0.52	3.3e-10	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.01	8.32	0.6	1.34e-13	Platelet count;
TGCT	cis	rs11112613	0.775	rs10507194	chr12:105959488	G/A	cg03607813	chr12:105948248	NA	0.47	5.74	0.46	6.71e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	cis	rs7954584	0.813	rs11043288	chr12:122451187	C/T	cg21171335	chr12:122356390	WDR66	-0.54	-5.43	-0.44	2.85e-7	Mean corpuscular volume;
TGCT	cis	rs2115630	0.754	rs12595321	chr15:85331269	G/A	cg11189052	chr15:85197271	WDR73	-0.56	-4.86	-0.4	3.41e-6	P wave terminal force;
TGCT	cis	rs7959452	0.640	rs11177599	chr12:69721970	G/A	cg11871910	chr12:69753446	YEATS4	0.63	6.4	0.5	2.88e-9	Blood protein levels;
TGCT	cis	rs7267979	1.000	rs2474777	chr20:25272633	A/G	cg03522245	chr20:25566470	NINL	0.62	6.67	0.51	7.51e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6429082	0.807	rs4659857	chr1:235581411	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.57	-5.03	-0.41	1.7e-6	Adiposity;
TGCT	cis	rs9467773	0.595	rs2172007	chr6:26639777	A/C	cg05738196	chr6:26577821	NA	0.86	10.49	0.69	8.31e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs4253772	0.550	rs12165597	chr22:46705584	A/G	cg24881330	chr22:46731750	TRMU	1.04	5.41	0.44	3.12e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs9894429	0.816	rs9747093	chr17:79584280	G/A	cg21028142	chr17:79581711	NPLOC4	0.29	6.81	0.52	3.83e-10	Eye color traits;
TGCT	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg13770153	chr20:60521292	NA	-0.54	-7.13	-0.54	7.45e-11	Body mass index;
TGCT	cis	rs7267979	1.000	rs6115159	chr20:25350944	T/C	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3749237	0.595	rs12489092	chr3:49550914	G/C	cg03060546	chr3:49711283	APEH	0.75	8.62	0.61	2.66e-14	Resting heart rate;
TGCT	cis	rs710216	0.917	rs2297977	chr1:43415288	G/T	cg03128534	chr1:43423976	SLC2A1	0.57	4.58	0.38	1.1e-5	Red cell distribution width;
TGCT	cis	rs9443645	0.810	rs9448607	chr6:79715620	G/A	cg09184832	chr6:79620586	NA	-0.43	-4.83	-0.4	3.93e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6674176	0.628	rs12145999	chr1:44428632	C/T	cg13606994	chr1:44402422	ARTN	-0.46	-4.98	-0.41	2.12e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs9486715	0.825	rs211158	chr6:97022938	C/G	cg18709589	chr6:96969512	KIAA0776	-0.85	-8.16	-0.59	3.2e-13	Headache;
TGCT	trans	rs1814175	0.791	rs10769593	chr11:49616217	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.38	-7.65	-0.57	4.76e-12	Height;
TGCT	cis	rs9868809	0.881	rs6773261	chr3:48675064	A/G	cg00383909	chr3:49044727	WDR6	0.95	5.29	0.43	5.34e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs6088590	0.561	rs6059934	chr20:33178324	G/T	cg08999081	chr20:33150536	PIGU	0.25	4.73	0.39	5.91e-6	Coronary artery disease;
TGCT	cis	rs8017423	0.967	rs4900033	chr14:90701963	C/A	cg04374321	chr14:90722782	PSMC1	0.77	8.05	0.59	5.68e-13	Mortality in heart failure;
TGCT	cis	rs12477438	0.501	rs9941561	chr2:99753829	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	8.52	0.61	4.42e-14	Chronic sinus infection;
TGCT	cis	rs4788570	0.566	rs16972808	chr16:71478717	A/G	cg06353428	chr16:71660113	MARVELD3	-1.32	-7.86	-0.58	1.6e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs12711979	0.509	rs10192699	chr2:3824297	A/G	cg17052675	chr2:3827356	NA	-0.55	-12.72	-0.75	3.04e-24	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs7937682	0.883	rs2212520	chr11:111462096	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.99	-10.02	-0.67	1.16e-17	Primary sclerosing cholangitis;
TGCT	cis	rs6570726	0.764	rs4263604	chr6:145916697	A/G	cg13319975	chr6:146136371	FBXO30	-0.51	-4.48	-0.37	1.71e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2074038	1.000	rs2074038	chr11:44087989	G/T	cg17479956	chr11:44115929	EXT2	0.35	5.09	0.42	1.27e-6	IgA nephropathy;
TGCT	cis	rs9534288	0.763	rs7989605	chr13:46534036	G/A	cg15192986	chr13:46630673	CPB2	-0.51	-7.28	-0.55	3.34e-11	Blood protein levels;
TGCT	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg13395646	chr4:1353034	KIAA1530	-0.55	-7.57	-0.56	7.56e-12	Obesity-related traits;
TGCT	cis	rs10984561	0.881	rs10984555	chr9:122247683	T/C	cg14242995	chr9:122249943	NA	0.75	6.41	0.5	2.7e-9	Pulmonary function decline;
TGCT	cis	rs10986311	0.928	rs4836973	chr9:127091587	G/A	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.2	4.59	0.38	1.05e-5	Vitiligo;
TGCT	cis	rs7208859	0.573	rs73277974	chr17:29189869	A/G	cg14008862	chr17:28927542	LRRC37B2	0.72	4.66	0.39	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs240764	0.853	rs12206945	chr6:101018032	C/T	cg21058520	chr6:100914733	NA	-0.35	-4.51	-0.38	1.49e-5	Neuroticism;
TGCT	cis	rs6964587	0.967	rs9656003	chr7:91766322	A/C	cg17063962	chr7:91808500	NA	0.91	9.8	0.66	3.89e-17	Breast cancer;
TGCT	cis	rs9393777	0.546	rs9366673	chr6:26893329	C/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.6	-4.79	-0.4	4.67e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs877282	0.891	rs11599917	chr10:762288	G/A	cg17470449	chr10:769945	NA	0.35	5.23	0.43	7e-7	Uric acid levels;
TGCT	cis	rs7100689	0.646	rs1953972	chr10:82145666	A/G	cg01528321	chr10:82214614	TSPAN14	0.78	7.86	0.58	1.56e-12	Post bronchodilator FEV1;
TGCT	cis	rs711830	1.000	rs1051929	chr2:177036754	T/C	cg13092806	chr2:177043255	NA	0.74	5.95	0.47	2.58e-8	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
TGCT	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg03609598	chr5:56110824	MAP3K1	-0.59	-4.74	-0.39	5.8e-6	Type 2 diabetes;
TGCT	cis	rs2180341	1.000	rs2057223	chr6:127637374	T/C	cg24812749	chr6:127587940	RNF146	0.98	7.64	0.57	5.06e-12	Breast cancer;
TGCT	cis	rs2688482	0.512	rs1104760	chr3:195517321	G/A	cg13752114	chr3:195489708	MUC4	0.32	4.72	0.39	6.34e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs1891498	0.560	rs35594137	chr1:147245497	C/T	cg17941330	chr1:147245494	GJA5	0.36	4.76	0.39	5.28e-6	Cognitive performance;
TGCT	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.61	0.38	9.85e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7727544	0.904	rs6897575	chr5:131604535	C/T	cg24060327	chr5:131705240	SLC22A5	-0.6	-6.4	-0.5	2.87e-9	Blood metabolite levels;
TGCT	cis	rs2404602	0.735	rs1607015	chr15:76702429	C/T	cg22467129	chr15:76604101	ETFA	0.52	5.5	0.44	2.05e-7	Blood metabolite levels;
TGCT	cis	rs2239547	0.563	rs6445547	chr3:52908577	T/C	cg11645453	chr3:52864694	ITIH4	0.34	5.72	0.46	7.68e-8	Schizophrenia;
TGCT	cis	rs7178572	0.568	rs11632966	chr15:77621805	A/C	cg15453836	chr15:77711506	NA	-0.42	-4.79	-0.4	4.68e-6	Type 2 diabetes;
TGCT	cis	rs559406	0.623	rs674222	chr18:12848349	G/C	cg23598886	chr18:12777645	NA	0.38	4.53	0.38	1.36e-5	Psoriasis;
TGCT	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6840360	0.582	rs2724553	chr4:152321881	T/C	cg17479576	chr4:152424074	FAM160A1	-0.53	-5.35	-0.43	4.05e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs34014631	1.000	rs17698831	chr10:103656466	T/A	cg22630918	chr10:102748988	C10orf2	0.42	4.82	0.4	4.15e-6	Coronary artery calcification;
TGCT	cis	rs11690935	0.959	rs10174525	chr2:172635697	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.18	-12.58	-0.75	6.59e-24	Schizophrenia;
TGCT	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg06238570	chr21:40685208	BRWD1	0.69	6.38	0.5	3.25e-9	Cognitive function;
TGCT	cis	rs7119038	0.818	rs10892293	chr11:118665575	A/T	cg19308663	chr11:118741387	NA	0.37	5.73	0.46	7.3e-8	Sjögren's syndrome;
TGCT	cis	rs9549367	0.865	rs9549366	chr13:113907644	G/A	cg00898013	chr13:113819073	PROZ	-0.43	-5.55	-0.45	1.68e-7	Platelet distribution width;
TGCT	cis	rs9467773	0.967	rs1056347	chr6:26527524	G/C	cg05738196	chr6:26577821	NA	0.88	12.5	0.75	1.03e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg09436375	chr6:42928200	GNMT	0.37	5.21	0.42	7.55e-7	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs950169	0.922	rs12912934	chr15:85114447	C/T	cg11189052	chr15:85197271	WDR73	0.77	6.44	0.5	2.34e-9	Schizophrenia;
TGCT	cis	rs3862030	0.533	rs715440	chr10:104258095	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.52	-4.99	-0.41	2.01e-6	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
TGCT	cis	rs57221529	0.709	rs72707023	chr5:667620	G/A	cg20362242	chr5:692897	TPPP	0.53	4.85	0.4	3.56e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs6121246	0.609	rs4453755	chr20:30331047	G/A	cg10886678	chr20:30946050	ASXL1	-0.52	-4.44	-0.37	1.97e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs11671005	0.735	rs34152946	chr19:58923263	C/T	cg13877915	chr19:58951672	ZNF132	0.63	4.99	0.41	1.99e-6	Mean platelet volume;
TGCT	trans	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg17470723	chr8:74884337	TCEB1	0.72	6.94	0.53	1.91e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs11585357	0.843	rs72646796	chr1:17612503	T/C	cg08277548	chr1:17600880	PADI3	-0.96	-9.72	-0.66	5.97e-17	Hair shape;
TGCT	cis	rs35146811	0.735	rs11764176	chr7:99786964	G/T	cg22906224	chr7:99728672	NA	0.49	4.45	0.37	1.88e-5	Coronary artery disease;
TGCT	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg11644478	chr21:40555479	PSMG1	-0.62	-5.76	-0.46	6.13e-8	Cognitive function;
TGCT	cis	rs4727027	0.933	rs28767030	chr7:148825918	T/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	4.58	0.38	1.13e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs9790314	0.765	rs4856768	chr3:161004392	G/A	cg03342759	chr3:160939853	NMD3	-0.47	-5.09	-0.42	1.29e-6	Morning vs. evening chronotype;
TGCT	cis	rs10193935	0.792	rs10204778	chr2:42498121	G/T	cg27598129	chr2:42591480	NA	-0.42	-5.7	-0.46	8.35e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7552404	0.924	rs1146580	chr1:76209935	T/C	cg22875332	chr1:76189707	ACADM	0.72	8.9	0.62	5.76e-15	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.51	-4.82	-0.4	4.16e-6	Bipolar disorder;
TGCT	cis	rs2235642	0.928	rs2076435	chr16:1607574	C/T	cg11375102	chr16:1583810	IFT140;TMEM204	-0.3	-5.26	-0.43	6.24e-7	Coronary artery disease;
TGCT	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg02187348	chr16:89574699	SPG7	0.6	6.51	0.5	1.71e-9	Multiple myeloma (IgH translocation);
TGCT	cis	rs2692947	0.673	rs3111873	chr2:96781986	G/C	cg23100626	chr2:96804247	ASTL	-0.42	-4.97	-0.41	2.18e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs35306767	0.951	rs55742421	chr10:961037	A/C	cg20503657	chr10:835505	NA	0.74	10.28	0.68	2.58e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs801193	0.569	rs35070132	chr7:66238083	C/T	cg11764359	chr7:65958608	NA	0.53	4.64	0.38	8.62e-6	Aortic root size;
TGCT	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg18876405	chr7:65276391	NA	0.31	4.79	0.4	4.58e-6	Aortic root size;
TGCT	cis	rs6448317	0.954	rs13116026	chr4:24922242	T/A	cg21108841	chr4:24914750	CCDC149	-0.62	-4.72	-0.39	6.25e-6	Heschl's gyrus morphology;
TGCT	cis	rs1524927	1.000	rs12704873	chr7:96336279	G/C	cg03808172	chr7:96339361	SHFM1	0.49	5.06	0.41	1.45e-6	Total body bone mineral density;
TGCT	cis	rs9549367	0.664	rs3794419	chr13:113851874	T/C	cg09473364	chr13:112927190	NA	-0.32	-5.08	-0.41	1.38e-6	Platelet distribution width;
TGCT	cis	rs7937682	0.575	rs1940391	chr11:111776891	G/A	cg09085632	chr11:111637200	PPP2R1B	0.97	10.03	0.67	1.06e-17	Primary sclerosing cholangitis;
TGCT	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.56	-0.51	1.31e-9	Alzheimer's disease;
TGCT	cis	rs9534288	0.716	rs2573304	chr13:46514642	C/T	cg15192986	chr13:46630673	CPB2	0.52	6.95	0.53	1.87e-10	Blood protein levels;
TGCT	cis	rs1062177	1.000	rs2964612	chr5:151198750	G/A	cg12924095	chr5:151150029	G3BP1	0.35	5.05	0.41	1.53e-6	Preschool internalizing problems;
TGCT	cis	rs1971762	0.527	rs784562	chr12:53919700	A/C	cg16917193	chr12:54089295	NA	-1.0	-10.24	-0.68	3.39e-18	Height;
TGCT	trans	rs8073060	0.586	rs9649	chr17:34050934	C/T	cg19694781	chr19:47549865	TMEM160	0.6	13.37	0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg17554472	chr22:41940697	POLR3H	-0.47	-4.79	-0.4	4.68e-6	Vitiligo;
TGCT	cis	rs933688	1.000	rs6869717	chr5:90694797	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.02	8.42	0.6	7.91e-14	Smoking behavior;
TGCT	cis	rs9611565	0.765	rs132905	chr22:41799106	C/A	cg06634786	chr22:41940651	POLR3H	0.7	6.65	0.51	8.51e-10	Vitiligo;
TGCT	cis	rs9611565	0.506	rs1984839	chr22:41685937	G/C	cg13695892	chr22:41940480	POLR3H	-0.67	-6.23	-0.49	6.73e-9	Vitiligo;
TGCT	cis	rs1451375	0.785	rs6593010	chr7:50629888	A/G	cg18232548	chr7:50535776	DDC	0.45	7.11	0.54	8.09e-11	Malaria;
TGCT	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	6.39	0.5	3.12e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6733011	0.542	rs6542860	chr2:99679376	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-4.52	-0.38	1.4e-5	Bipolar disorder;
TGCT	cis	rs7010267	1.000	rs7010267	chr8:119946656	A/C	cg17171407	chr8:119960777	TNFRSF11B	0.32	6.24	0.49	6.25e-9	Total body bone mineral density (age 45-60);
TGCT	cis	rs473651	0.716	rs548179	chr2:239320505	G/A	cg21699342	chr2:239360505	ASB1	0.19	5.19	0.42	8.4e-7	Multiple system atrophy;
TGCT	cis	rs7940866	0.903	rs10791112	chr11:130870215	A/C	cg05962950	chr11:130786565	SNX19	-0.67	-7.04	-0.53	1.19e-10	Schizophrenia;
TGCT	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg22166914	chr1:53195759	ZYG11B	0.37	6.41	0.5	2.77e-9	Monocyte count;
TGCT	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.45	-5.37	-0.43	3.72e-7	Alzheimer's disease;
TGCT	cis	rs3796352	1.000	rs17052727	chr3:53070914	T/C	cg07884673	chr3:53033167	SFMBT1	0.57	5.98	0.47	2.16e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs6912958	0.754	rs6918909	chr6:88247251	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-5.07	-0.41	1.41e-6	Monocyte percentage of white cells;
TGCT	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg03188948	chr7:1209495	NA	0.44	5.79	0.46	5.49e-8	Longevity;Endometriosis;
TGCT	cis	rs9916302	0.904	rs10221223	chr17:37489100	T/G	cg15445000	chr17:37608096	MED1	-0.35	-5.05	-0.41	1.53e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs17376456	0.877	rs7734897	chr5:93305402	G/A	cg21475434	chr5:93447410	FAM172A	0.65	4.85	0.4	3.58e-6	Diabetic retinopathy;
TGCT	cis	rs78456975	0.527	rs11901028	chr2:1557972	A/G	cg01028140	chr2:1542097	TPO	-0.33	-5.12	-0.42	1.14e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg13866156	chr1:1669148	SLC35E2	-0.22	-5.23	-0.42	7.06e-7	Body mass index;
TGCT	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg12310025	chr6:25882481	NA	0.62	6.5	0.5	1.78e-9	Blood metabolite levels;
TGCT	cis	rs9916302	0.904	rs4794814	chr17:37696852	G/A	cg15445000	chr17:37608096	MED1	0.31	4.5	0.37	1.53e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs6430585	0.591	rs77096272	chr2:136663605	C/A	cg07169764	chr2:136633963	MCM6	1.25	12.39	0.74	1.91e-23	Corneal structure;
TGCT	cis	rs789859	0.611	rs1077729	chr3:194418126	A/G	cg21106136	chr3:194405973	FAM43A	0.37	4.79	0.39	4.75e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
TGCT	cis	rs10493773	0.609	rs12097932	chr1:86182216	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.52	-8.15	-0.59	3.45e-13	Urate levels in overweight individuals;
TGCT	cis	rs6831352	0.918	rs2851249	chr4:100044822	T/C	cg12011299	chr4:100065546	ADH4	0.44	5.08	0.42	1.34e-6	Alcohol dependence;
TGCT	cis	rs9527	0.590	rs10786738	chr10:104869451	C/T	cg15744005	chr10:104629667	AS3MT	-0.43	-4.9	-0.4	2.89e-6	Arsenic metabolism;
TGCT	cis	rs9814567	0.731	rs34797591	chr3:134192516	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.85	6.71	0.52	6.04e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs208520	0.837	rs208489	chr6:66927584	G/A	cg07460842	chr6:66804631	NA	-0.94	-9.3	-0.64	6.32e-16	Exhaled nitric oxide output;
TGCT	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg10150615	chr22:24372951	LOC391322	1.01	13.29	0.77	1.32e-25	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs36051895	0.623	rs11506293	chr9:5257430	A/G	cg02405213	chr9:5042618	JAK2	-0.69	-8.19	-0.59	2.68e-13	Pediatric autoimmune diseases;
TGCT	cis	rs797680	0.856	rs6682670	chr1:93649732	A/G	cg17826107	chr1:92977322	EVI5	-0.24	-5.23	-0.43	6.89e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs7819412	0.811	rs2409691	chr8:10943276	C/T	cg21775007	chr8:11205619	TDH	-0.51	-4.94	-0.41	2.46e-6	Triglycerides;
TGCT	cis	rs11969893	0.850	rs9390697	chr6:101294431	G/A	cg12253828	chr6:101329408	ASCC3	1.37	6.33	0.49	4.13e-9	Economic and political preferences (immigration/crime);
TGCT	cis	rs8017423	0.874	rs4900029	chr14:90686257	T/A	cg04374321	chr14:90722782	PSMC1	0.77	7.93	0.58	1.12e-12	Mortality in heart failure;
TGCT	cis	rs9467711	0.517	rs16901784	chr6:26555433	C/A	cg16898833	chr6:26189333	HIST1H4D	1.1	5.65	0.45	1.05e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9291683	0.530	rs35908990	chr4:9976105	G/A	cg00071950	chr4:10020882	SLC2A9	0.65	8.23	0.59	2.21e-13	Bone mineral density;
TGCT	cis	rs72615157	0.539	rs4729575	chr7:99686873	G/T	cg13334819	chr7:99746414	C7orf59	0.58	4.49	0.37	1.61e-5	Lung function (FEV1/FVC);
TGCT	cis	rs7617773	0.743	rs11715876	chr3:48377922	G/A	cg11946769	chr3:48343235	NME6	0.82	6.99	0.53	1.49e-10	Coronary artery disease;
TGCT	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.54	4.95	0.41	2.35e-6	Prudent dietary pattern;
TGCT	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg16228356	chr17:43848958	NA	-0.27	-4.68	-0.39	7.42e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2710247	1	rs2710247	chr2:219467508	A/G	cg02176678	chr2:219576539	TTLL4	0.38	5.48	0.44	2.31e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10465746	0.809	rs2389617	chr1:84437652	A/T	cg10977910	chr1:84465055	TTLL7	0.69	7.1	0.54	8.59e-11	Obesity-related traits;
TGCT	trans	rs7221878	1.000	rs7210540	chr17:36188882	T/C	cg03614664	chr22:41346948	RBX1	1.39	6.64	0.51	8.97e-10	Macrophage inflammatory protein 1b levels;
TGCT	cis	rs1483890	0.605	rs1843045	chr3:69413121	C/T	cg22125112	chr3:69402811	FRMD4B	0.28	4.68	0.39	7.47e-6	Resting heart rate;
TGCT	cis	rs7772486	0.875	rs2777481	chr6:146310036	G/T	cg23711669	chr6:146136114	FBXO30	0.86	9.13	0.63	1.59e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs28595532	0.920	rs116634064	chr4:119736514	C/T	cg21605333	chr4:119757512	SEC24D	1.61	8.95	0.63	4.36e-15	Cannabis dependence symptom count;
TGCT	cis	rs10876993	0.893	rs3825078	chr12:58089413	A/T	cg15848620	chr12:58087721	OS9	-0.73	-5.95	-0.47	2.56e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs7845219	0.525	rs6471501	chr8:95922491	A/G	cg09323728	chr8:95962352	TP53INP1	-0.41	-4.57	-0.38	1.17e-5	Type 2 diabetes;
TGCT	cis	rs4595586	0.545	rs6580892	chr12:39370237	G/C	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs9902453	0.845	rs12452201	chr17:28214173	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.8	7.07	0.54	9.76e-11	Coffee consumption (cups per day);
TGCT	cis	rs453301	0.606	rs6601279	chr8:8908231	G/A	cg08975724	chr8:8085496	FLJ10661	-0.58	-4.75	-0.39	5.63e-6	Joint mobility (Beighton score);
TGCT	cis	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg13531842	chr10:38383804	ZNF37A	-0.38	-4.51	-0.38	1.49e-5	Extrinsic epigenetic age acceleration;
TGCT	cis	rs17221829	0.965	rs10830368	chr11:89459706	C/T	cg02982614	chr11:89391479	FOLH1B	-0.27	-4.76	-0.39	5.25e-6	Anxiety in major depressive disorder;
TGCT	cis	rs7584330	0.518	rs11884238	chr2:238424671	T/G	cg08992911	chr2:238395768	MLPH	0.73	5.01	0.41	1.85e-6	Prostate cancer;
TGCT	cis	rs2288884	0.767	rs17835716	chr19:52551042	A/G	cg15405931	chr19:52693188	PPP2R1A	-0.64	-4.5	-0.38	1.51e-5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs926938	0.584	rs360607	chr1:115392401	C/A	cg12756093	chr1:115239321	AMPD1	0.4	5.77	0.46	5.88e-8	Autism;
TGCT	cis	rs2637266	1.000	rs6480827	chr10:78356333	T/G	cg18941641	chr10:78392320	NA	0.4	5.01	0.41	1.81e-6	Pulmonary function;
TGCT	trans	rs4332037	0.539	rs4470910	chr7:2071723	C/T	cg10840412	chr1:235813424	GNG4	0.96	6.97	0.53	1.66e-10	Bipolar disorder;
TGCT	cis	rs8028182	0.636	rs11636031	chr15:75815758	T/C	cg20655648	chr15:75932815	IMP3	0.59	4.62	0.38	9.55e-6	Sudden cardiac arrest;
TGCT	cis	rs9640161	0.750	rs3735173	chr7:150020526	C/T	cg10018233	chr7:150070692	REPIN1	0.32	4.65	0.39	8.41e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs6582630	0.555	rs11503799	chr12:38294578	G/A	cg26384229	chr12:38710491	ALG10B	-0.54	-4.7	-0.39	6.68e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs7567389	0.740	rs4536600	chr2:128002572	A/G	cg09760422	chr2:128146352	NA	0.35	4.82	0.4	4.09e-6	Self-rated health;
TGCT	cis	rs11105298	0.891	rs11105319	chr12:89927177	G/A	cg00757033	chr12:89920650	WDR51B	0.29	4.56	0.38	1.22e-5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs6460942	0.915	rs1595800	chr7:12439816	G/A	cg06484146	chr7:12443880	VWDE	-0.57	-5.46	-0.44	2.47e-7	Coronary artery disease;
TGCT	cis	rs9807989	0.839	rs6543123	chr2:102977196	C/T	cg09003973	chr2:102972529	NA	0.67	6.03	0.48	1.75e-8	Asthma;
TGCT	cis	rs7824557	0.767	rs2164272	chr8:11162496	A/C	cg21775007	chr8:11205619	TDH	0.58	5.46	0.44	2.46e-7	Retinal vascular caliber;
TGCT	cis	rs10791323	0.581	rs2723608	chr11:133710149	A/G	cg15485101	chr11:133734466	NA	0.39	5.03	0.41	1.71e-6	Childhood ear infection;
TGCT	trans	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg17470723	chr8:74884337	TCEB1	0.71	6.77	0.52	4.48e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs17376456	0.877	rs10078194	chr5:93364310	A/C	cg25358565	chr5:93447407	FAM172A	0.92	8.4	0.6	8.88e-14	Diabetic retinopathy;
TGCT	cis	rs7044106	0.537	rs4434680	chr9:123489688	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	7.0	0.53	1.45e-10	Hip circumference adjusted for BMI;
TGCT	cis	rs3812831	0.654	rs9314900	chr13:114937618	A/C	cg08824895	chr13:115047677	UPF3A	0.47	4.88	0.4	3.18e-6	Schizophrenia;
TGCT	cis	rs72781680	0.898	rs72786276	chr2:24062566	G/A	cg08917208	chr2:24149416	ATAD2B	0.9	5.6	0.45	1.29e-7	Lymphocyte counts;
TGCT	cis	rs7727544	0.735	rs2631370	chr5:131703776	T/C	cg24060327	chr5:131705240	SLC22A5	0.59	6.61	0.51	1.01e-9	Blood metabolite levels;
TGCT	cis	rs9303542	0.559	rs62066693	chr17:46617530	G/C	cg25032089	chr17:46643351	HOXB3	0.56	5.33	0.43	4.44e-7	Ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs1949733	1.000	rs3103072	chr4:8508431	C/T	cg13073564	chr4:8508604	NA	0.47	4.94	0.41	2.49e-6	Response to antineoplastic agents;
TGCT	cis	rs9911578	1.000	rs302854	chr17:56683612	G/A	cg12560992	chr17:57184187	TRIM37	0.75	9.13	0.63	1.64e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs9611565	0.571	rs2050032	chr22:42152429	C/T	cg03806693	chr22:41940476	POLR3H	0.93	8.76	0.62	1.21e-14	Vitiligo;
TGCT	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg00684032	chr4:1343700	KIAA1530	-0.22	-4.72	-0.39	6.18e-6	Obesity-related traits;
TGCT	cis	rs1008375	0.966	rs11733730	chr4:17625209	G/C	cg10189774	chr4:17578691	LAP3	0.66	5.74	0.46	6.81e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg03188948	chr7:1209495	NA	0.71	6.3	0.49	4.79e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs751984	0.852	rs10897164	chr11:61277775	A/G	cg17652291	chr11:60500967	NA	-0.41	-4.58	-0.38	1.1e-5	Diastolic blood pressure;Systolic blood pressure;Mean arterial pressure;
TGCT	cis	rs57994353	0.897	rs11999609	chr9:139363539	C/T	cg13741927	chr9:139327495	INPP5E	-0.26	-6.13	-0.48	1.06e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg06238570	chr21:40685208	BRWD1	-0.83	-9.11	-0.63	1.81e-15	Cognitive function;
TGCT	cis	rs17253792	0.822	rs75115817	chr14:56069537	G/A	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs7223966	1.000	rs8073373	chr17:61703320	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	5.17	0.42	9.12e-7	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs7698623	0.850	rs6813016	chr4:88768808	T/C	cg27387453	chr4:88533842	DSPP	-0.61	-4.64	-0.38	8.7e-6	Cardiovascular disease risk factors;
TGCT	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg12963246	chr6:28129442	ZNF389	0.52	5.01	0.41	1.85e-6	Parkinson's disease;
TGCT	cis	rs5769765	0.862	rs9616380	chr22:50312225	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.43	6.08	0.48	1.35e-8	Schizophrenia;
TGCT	trans	rs3780486	1.000	rs10813951	chr9:33128021	C/T	cg20290983	chr6:43655470	MRPS18A	-1.1	-10.76	-0.69	1.75e-19	IgG glycosylation;
TGCT	cis	rs72945132	0.882	rs12282678	chr11:70152457	G/A	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs7089973	0.604	rs10885618	chr10:116617718	A/G	cg03647239	chr10:116582469	FAM160B1	0.59	5.61	0.45	1.26e-7	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs9911578	1.000	rs9897326	chr17:56902297	A/G	cg05425664	chr17:57184151	TRIM37	-0.62	-6.18	-0.49	8.33e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs2440129	0.632	rs13396	chr17:6905624	T/C	cg09737314	chr17:6899359	ALOX12	0.51	5.31	0.43	4.82e-7	Tonsillectomy;
TGCT	cis	rs7552404	1.000	rs12127402	chr1:76205643	C/A	cg10523679	chr1:76189770	ACADM	0.9	9.71	0.66	6.5e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	trans	rs17471911	0.708	rs78287224	chr10:100778265	C/T	cg03484267	chr2:207988651	KLF7	-0.52	-6.7	-0.52	6.49e-10	Neuroticism;
TGCT	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.62	5.22	0.42	7.25e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg05665937	chr4:1216051	CTBP1	0.24	4.65	0.39	8.32e-6	Obesity-related traits;
TGCT	cis	rs78456975	0.941	rs13412229	chr2:1520381	C/T	cg01028140	chr2:1542097	TPO	-0.35	-4.73	-0.39	6.04e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs7267979	0.966	rs2261795	chr20:25263136	T/C	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4891159	0.730	rs11874719	chr18:74101053	A/G	cg24786174	chr18:74118243	ZNF516	-0.58	-9.07	-0.63	2.19e-15	Longevity;
TGCT	trans	rs3780486	0.629	rs10971439	chr9:33180813	C/T	cg20290983	chr6:43655470	MRPS18A	-0.99	-7.03	-0.53	1.24e-10	IgG glycosylation;
TGCT	cis	rs34638657	0.673	rs11645286	chr16:82201898	C/A	cg09439754	chr16:82129088	HSD17B2	-0.25	-4.66	-0.39	7.87e-6	Lung adenocarcinoma;
TGCT	cis	rs1729951	0.546	rs12054218	chr3:136677496	C/G	cg21827317	chr3:136751795	NA	0.4	5.61	0.45	1.28e-7	Neuroticism;
TGCT	cis	rs7089973	0.604	rs7897937	chr10:116591318	A/G	cg03647239	chr10:116582469	FAM160B1	0.59	5.75	0.46	6.46e-8	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg06028808	chr11:68637592	NA	0.52	6.73	0.52	5.58e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs10992471	0.575	rs2147060	chr9:95160477	T/C	cg13798575	chr9:95087839	CENPP;NOL8	0.52	4.79	0.39	4.74e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg03806693	chr22:41940476	POLR3H	-1.14	-13.03	-0.76	5.42e-25	Vitiligo;
TGCT	cis	rs9443645	0.869	rs7756858	chr6:79619968	A/G	cg09184832	chr6:79620586	NA	-0.5	-5.43	-0.44	2.87e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1348850	0.567	rs3821006	chr2:178537694	G/A	cg22681709	chr2:178499509	PDE11A	-0.49	-6.15	-0.48	9.86e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs2276314	0.857	rs16967327	chr18:33587036	C/T	cg19628046	chr18:33552617	C18orf21	0.51	4.46	0.37	1.79e-5	Endometriosis;Drug-induced torsades de pointes;
TGCT	cis	rs453301	0.522	rs2929455	chr8:9083433	A/T	cg15556689	chr8:8085844	FLJ10661	-0.59	-5.36	-0.43	3.91e-7	Joint mobility (Beighton score);
TGCT	cis	rs11679640	0.836	rs17682575	chr2:43152304	C/T	cg17485141	chr2:42566556	NA	-0.27	-4.49	-0.37	1.58e-5	White matter hyperintensity burden;
TGCT	cis	rs2307449	0.729	rs1006659	chr15:89883672	T/G	cg01877814	chr15:89879097	POLG	0.29	4.53	0.38	1.36e-5	Menopause (age at onset);
TGCT	cis	rs10089	1.000	rs4836361	chr5:127459991	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	7.41	0.55	1.72e-11	Ileal carcinoids;
TGCT	cis	rs763121	0.752	rs5757222	chr22:39060473	C/T	cg06022373	chr22:39101656	GTPBP1	0.77	7.51	0.56	9.9e-12	Menopause (age at onset);
TGCT	cis	rs9611519	0.780	rs1535048	chr22:41684093	C/T	cg13695892	chr22:41940480	POLR3H	-0.66	-6.02	-0.48	1.82e-8	Neuroticism;
TGCT	cis	rs3812831	0.695	rs7983872	chr13:114944781	T/G	cg08824895	chr13:115047677	UPF3A	0.51	5.02	0.41	1.76e-6	Schizophrenia;
TGCT	cis	rs11969893	0.737	rs4098482	chr6:101377808	C/T	cg12253828	chr6:101329408	ASCC3	1.21	6.03	0.48	1.74e-8	Economic and political preferences (immigration/crime);
TGCT	cis	rs61867294	0.553	rs6584645	chr10:106703759	C/T	cg08000847	chr10:105880925	C10orf78	0.48	4.44	0.37	2e-5	Schizophrenia;
TGCT	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg20849893	chr7:64541193	NA	-0.51	-5.26	-0.43	6.15e-7	Calcium levels;
TGCT	cis	rs422249	0.512	rs174562	chr11:61585144	A/G	cg19610905	chr11:61596333	FADS2	-1.07	-12.03	-0.73	1.43e-22	Trans fatty acid levels;
TGCT	cis	rs6681544	0.544	rs3790909	chr1:82379971	T/A	cg04226724	chr1:82268649	LPHN2	0.47	4.95	0.41	2.33e-6	Metabolite levels  (X-11787);
TGCT	cis	rs6840360	1.000	rs4696285	chr4:152605449	A/G	cg17479576	chr4:152424074	FAM160A1	-0.45	-4.69	-0.39	7e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7312933	0.558	rs1796382	chr12:42840955	C/G	cg19980929	chr12:42632907	YAF2	-0.41	-5.8	-0.46	5.14e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs11098499	0.863	rs1480940	chr4:120457682	T/C	cg09307838	chr4:120376055	NA	0.69	6.53	0.51	1.49e-9	Corneal astigmatism;
TGCT	cis	rs13191362	1.000	rs34138336	chr6:163144929	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.17	9.35	0.64	4.74e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs8062405	0.964	rs11864107	chr16:28885931	T/C	cg09754948	chr16:28834200	ATXN2L	0.6	4.46	0.37	1.79e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs9517320	0.534	rs4772090	chr13:99150674	T/C	cg07423050	chr13:99094983	FARP1	-0.29	-5.88	-0.47	3.58e-8	Longevity;
TGCT	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg05368731	chr17:41323189	NBR1	1.17	13.8	0.78	7.84e-27	Menopause (age at onset);
TGCT	cis	rs2013441	1.000	rs972966	chr17:20030992	G/C	cg23224458	chr17:20280056	CCDC144C	0.39	4.73	0.39	5.88e-6	Obesity-related traits;
TGCT	cis	rs6598955	0.671	rs7544	chr1:26607726	T/G	cg04990556	chr1:26633338	UBXN11	0.66	5.0	0.41	1.88e-6	Obesity-related traits;
TGCT	cis	rs6750047	0.516	rs458704	chr2:38318134	G/A	cg07380506	chr2:38303506	CYP1B1	0.57	5.33	0.43	4.47e-7	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg22963979	chr7:1858916	MAD1L1	-0.37	-5.8	-0.46	5.08e-8	Bipolar disorder and schizophrenia;
TGCT	cis	rs2836974	0.897	rs2836923	chr21:40524236	T/C	cg11890956	chr21:40555474	PSMG1	1.13	12.02	0.73	1.54e-22	Cognitive function;
TGCT	cis	rs28595532	0.920	rs56291421	chr4:119732294	G/A	cg14228332	chr4:119757509	SEC24D	1.32	6.38	0.5	3.2e-9	Cannabis dependence symptom count;
TGCT	cis	rs7089973	0.668	rs10885622	chr10:116643844	C/T	cg03647239	chr10:116582469	FAM160B1	0.55	5.19	0.42	8.49e-7	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs4654899	0.932	rs10916943	chr1:21472429	T/C	cg01072550	chr1:21505969	NA	0.51	8.3	0.6	1.5e-13	Superior frontal gyrus grey matter volume;
TGCT	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg03396347	chr1:1875803	NA	-0.37	-6.7	-0.52	6.64e-10	Body mass index;
TGCT	cis	rs9914544	0.545	rs2386403	chr17:18769600	A/G	cg26378065	chr17:18585709	ZNF286B	0.52	4.5	0.37	1.56e-5	Educational attainment (years of education);
TGCT	cis	rs12893668	0.572	rs11846404	chr14:104156108	C/G	cg26031613	chr14:104095156	KLC1	-0.59	-5.05	-0.41	1.53e-6	Reticulocyte count;
TGCT	cis	rs12210905	1.000	rs72843608	chr6:27122750	G/A	cg08851530	chr6:28072375	NA	1.12	5.43	0.44	2.82e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs12971120	0.891	rs12608037	chr18:72169395	A/G	cg26446133	chr18:72167187	CNDP2	-0.37	-6.33	-0.49	4.13e-9	Refractive error;
TGCT	cis	rs7605378	1.000	rs769954	chr2:200692159	C/G	cg17644776	chr2:200775616	C2orf69	-0.28	-5.33	-0.43	4.51e-7	Osteoporosis;
TGCT	cis	rs4253772	0.591	rs11703245	chr22:46684890	A/G	cg24881330	chr22:46731750	TRMU	1.04	5.38	0.44	3.54e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs74417235	0.684	rs13179358	chr5:154059746	C/A	cg08754654	chr5:154026448	NA	0.58	5.53	0.44	1.84e-7	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
TGCT	cis	rs9916302	0.752	rs12150047	chr17:37601755	A/G	cg07936489	chr17:37558343	FBXL20	-0.87	-6.27	-0.49	5.47e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs3020736	0.500	rs4147638	chr22:42487900	G/A	cg05082376	chr22:42548792	NA	0.23	5.43	0.44	2.83e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs67311347	1.000	rs28871903	chr3:40511094	T/G	cg17264618	chr3:40429014	ENTPD3	0.32	4.45	0.37	1.88e-5	Renal cell carcinoma;
TGCT	trans	rs2469997	0.925	rs2447173	chr8:120359513	C/T	cg01792902	chr3:178864926	PIK3CA	0.83	6.77	0.52	4.49e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs4862307	0.808	rs7666346	chr4:185000657	G/A	cg06737308	chr4:185021514	ENPP6	-0.35	-5.13	-0.42	1.08e-6	Serum dimethylarginine levels (asymmetric/symetric ratio);
TGCT	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg18876405	chr7:65276391	NA	0.32	4.83	0.4	3.98e-6	Aortic root size;
TGCT	cis	rs6032067	0.673	rs6017532	chr20:43904095	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.46	-6.61	-0.51	1.03e-9	Blood protein levels;
TGCT	cis	rs6540559	0.673	rs17015183	chr1:209948711	A/C	cg04352962	chr1:209979756	IRF6	0.65	4.54	0.38	1.33e-5	Cleft lip with or without cleft palate;
TGCT	cis	rs854765	0.583	rs8070722	chr17:17813562	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.74	7.7	0.57	3.68e-12	Total body bone mineral density;
TGCT	cis	rs2811893	1.000	rs232851	chr1:59122871	A/G	cg26196860	chr1:59745563	NA	-0.24	-4.65	-0.39	8.26e-6	Diabetic retinopathy;
TGCT	trans	rs208520	0.690	rs851467	chr6:66802721	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-10.83	-0.7	1.19e-19	Exhaled nitric oxide output;
TGCT	cis	rs6545883	0.965	rs12713439	chr2:61752154	G/A	cg15711740	chr2:61764176	XPO1	-0.57	-5.25	-0.43	6.39e-7	Tuberculosis;
TGCT	cis	rs11098499	0.866	rs6847778	chr4:120293582	A/G	cg09307838	chr4:120376055	NA	0.57	5.56	0.45	1.6e-7	Corneal astigmatism;
TGCT	cis	rs7726839	0.540	rs55929359	chr5:595956	C/G	cg09021430	chr5:549028	NA	-0.43	-5.59	-0.45	1.34e-7	Obesity-related traits;
TGCT	cis	rs9926296	0.712	rs258330	chr16:89729574	T/G	cg03388025	chr16:89894329	SPIRE2	-0.36	-5.33	-0.43	4.49e-7	Vitiligo;
TGCT	cis	rs7772486	0.875	rs6934467	chr6:146410529	G/T	cg23711669	chr6:146136114	FBXO30	0.89	9.8	0.66	3.86e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1546060	0.668	rs9876122	chr3:56465762	A/G	cg24436196	chr3:56448270	ERC2	0.18	4.48	0.37	1.67e-5	Night sleep phenotypes;
TGCT	cis	rs11031096	0.678	rs12223062	chr11:4180178	G/T	cg18678763	chr11:4115507	RRM1	-0.44	-5.75	-0.46	6.48e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs1048238	0.506	rs56352596	chr1:16297592	G/A	cg21385522	chr1:16154831	NA	0.61	6.94	0.53	1.95e-10	Systolic blood pressure;
TGCT	cis	rs56873913	0.904	rs7251295	chr19:50096859	G/C	cg09250473	chr19:50168907	IRF3;BCL2L12	0.68	5.62	0.45	1.19e-7	Schizophrenia;
TGCT	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg04414720	chr1:150670196	GOLPH3L	0.37	4.81	0.4	4.38e-6	Tonsillectomy;
TGCT	cis	rs548181	0.604	rs11608103	chr11:125627917	G/A	cg03464685	chr11:125439445	EI24	-0.84	-5.52	-0.44	1.93e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs743757	1.000	rs734767	chr3:50431410	C/G	cg16953475	chr3:49711973	APEH	0.73	4.81	0.4	4.22e-6	Diastolic blood pressure;
TGCT	cis	rs72627509	0.904	rs12645070	chr4:57770106	G/A	cg26694713	chr4:57773883	REST	0.74	6.67	0.51	7.45e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs9911578	1.000	rs9807057	chr17:56889952	A/C	cg12560992	chr17:57184187	TRIM37	0.76	9.34	0.64	4.88e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs3892630	0.824	rs12976069	chr19:33280084	G/A	cg22980127	chr19:33182716	NUDT19	0.7	5.07	0.41	1.44e-6	Red blood cell traits;
TGCT	cis	rs887829	0.569	rs3806597	chr2:234637569	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.26	4.46	0.37	1.84e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
TGCT	cis	rs9467711	1.000	rs9467713	chr6:26338128	T/C	cg02458000	chr6:26745757	NA	-1.07	-6.66	-0.51	7.97e-10	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs8077889	0.871	rs72836549	chr17:41904360	G/T	cg26893861	chr17:41843967	DUSP3	1.08	12.97	0.76	7.86e-25	Triglycerides;
TGCT	cis	rs939574	1.000	rs939574	chr2:220118531	G/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-1.05	-6.46	-0.5	2.12e-9	Platelet distribution width;
TGCT	cis	rs12477438	1.000	rs6542873	chr2:99824965	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-8.3	-0.6	1.52e-13	Chronic sinus infection;
TGCT	cis	rs79349575	0.783	rs62075820	chr17:46983171	G/C	cg07967210	chr17:47022446	SNF8	0.43	6.06	0.48	1.54e-8	Type 2 diabetes;
TGCT	cis	rs16867321	0.901	rs768116	chr2:181511012	A/G	cg23363182	chr2:181467187	NA	-0.41	-5.54	-0.45	1.73e-7	Obesity;
TGCT	cis	rs2762353	0.904	rs13197601	chr6:25785935	G/A	cg03264133	chr6:25882463	NA	0.5	5.29	0.43	5.3e-7	Blood metabolite levels;
TGCT	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg03060546	chr3:49711283	APEH	-0.51	-4.91	-0.4	2.84e-6	Menarche (age at onset);
TGCT	cis	rs7843479	0.965	rs11784535	chr8:21857787	G/A	cg17168535	chr8:21777572	XPO7	0.64	5.82	0.46	4.81e-8	Mean corpuscular volume;
TGCT	cis	rs236907	0.812	rs2232807	chr1:171750095	T/C	cg20598894	chr1:171756153	METTL13	-0.19	-4.47	-0.37	1.72e-5	Mean platelet volume;
TGCT	trans	rs561341	0.882	rs504887	chr17:30322881	T/A	cg20587970	chr11:113659929	NA	-1.02	-12.58	-0.75	6.75e-24	Hip circumference adjusted for BMI;
TGCT	cis	rs6089584	1.000	rs6142910	chr20:60562181	C/A	cg16423285	chr20:60520624	NA	-0.52	-5.45	-0.44	2.6e-7	Body mass index;
TGCT	cis	rs2228479	0.681	rs11641790	chr16:89961957	A/G	cg06558623	chr16:89946397	TCF25	-0.43	-4.99	-0.41	1.96e-6	Skin colour saturation;
TGCT	cis	rs17102423	0.755	rs884683	chr14:65574482	C/T	cg11161011	chr14:65562177	MAX	-0.54	-7.49	-0.56	1.15e-11	Obesity-related traits;
TGCT	cis	rs1075232	0.510	rs78884938	chr15:31510885	C/T	cg01030201	chr15:31746330	NA	-0.87	-4.47	-0.37	1.76e-5	Survival in colorectal cancer (non-distant metastatic);
TGCT	cis	rs1153858	1.000	rs10519021	chr15:45631795	G/A	cg14582100	chr15:45693742	SPATA5L1	0.48	5.7	0.46	8.17e-8	Homoarginine levels;
TGCT	cis	rs7980687	0.638	rs7299943	chr12:123593485	A/T	cg00376283	chr12:123451042	ABCB9	0.67	4.81	0.4	4.34e-6	Height;Educational attainment;Head circumference (infant);
TGCT	cis	rs28595532	0.920	rs115259971	chr4:119762654	T/C	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs13256369	0.802	rs11249883	chr8:8561537	G/A	cg18904891	chr8:8559673	CLDN23	0.57	5.27	0.43	5.87e-7	Obesity-related traits;
TGCT	cis	rs7552404	1.000	rs7534754	chr1:76185308	G/A	cg10523679	chr1:76189770	ACADM	0.91	9.87	0.66	2.66e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs11718455	0.921	rs35872933	chr3:44028515	T/G	cg08738300	chr3:44038990	NA	0.85	6.31	0.49	4.55e-9	Coronary artery disease;
TGCT	cis	rs12887734	0.546	rs4900597	chr14:104266664	A/G	cg26031613	chr14:104095156	KLC1	0.76	6.81	0.52	3.71e-10	Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7614311	0.731	rs73130544	chr3:63868596	G/A	cg22134162	chr3:63841271	THOC7	-0.4	-5.27	-0.43	5.98e-7	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs3806843	0.900	rs116210441	chr5:140128649	T/A	cg19875535	chr5:140030758	IK	-0.35	-5.75	-0.46	6.59e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9467711	0.651	rs13198474	chr6:25874423	G/A	cg16898833	chr6:26189333	HIST1H4D	1.36	6.0	0.47	2.05e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg08280861	chr8:58055591	NA	0.42	4.82	0.4	4.15e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9611565	0.512	rs5758465	chr22:42175314	T/C	cg03806693	chr22:41940476	POLR3H	1.02	10.49	0.69	7.92e-19	Vitiligo;
TGCT	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg07061783	chr6:25882402	NA	0.64	6.7	0.52	6.57e-10	Blood metabolite levels;
TGCT	cis	rs12360000	0.770	rs12251959	chr10:1902277	C/T	cg26364871	chr10:1889757	NA	0.41	4.63	0.38	9.26e-6	Metabolite levels (Dihydroxy docosatrienoic acid);
TGCT	cis	rs12477438	0.765	rs6740054	chr2:99576631	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.79	-7.82	-0.57	1.99e-12	Chronic sinus infection;
TGCT	trans	rs12599106	0.679	rs34584967	chr16:34475725	T/G	cg03395511	chr6:291903	DUSP22	-0.64	-6.8	-0.52	3.97e-10	Menopause (age at onset);
TGCT	cis	rs713587	0.563	rs7605335	chr2:25109317	G/A	cg01884057	chr2:25150051	NA	0.31	5.82	0.46	4.71e-8	Body mass index in non-asthmatics;
TGCT	cis	rs4803468	1.000	rs2241709	chr19:41912250	C/T	cg09537434	chr19:41945824	ATP5SL	-0.93	-11.06	-0.7	3.31e-20	Height;
TGCT	cis	rs6460942	0.915	rs62448600	chr7:12454944	T/G	cg06484146	chr7:12443880	VWDE	-0.57	-5.52	-0.44	1.92e-7	Coronary artery disease;
TGCT	cis	rs2295359	0.724	rs10489630	chr1:67662622	G/T	cg12940439	chr1:67600707	NA	-0.44	-4.9	-0.4	2.89e-6	Psoriasis;
TGCT	cis	rs7017914	0.905	rs3110243	chr8:71933069	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-4.97	-0.41	2.16e-6	Bone mineral density;
TGCT	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.46	0.56	1.3e-11	Prudent dietary pattern;
TGCT	cis	rs7582180	0.652	rs4851311	chr2:100980398	C/T	cg08017756	chr2:100939284	LONRF2	-0.3	-4.86	-0.4	3.45e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs634534	0.562	rs1151505	chr11:65734539	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.46	4.48	0.37	1.65e-5	Sum eosinophil basophil counts;Eosinophil counts;
TGCT	cis	rs17401966	0.597	rs11121555	chr1:10442856	C/T	cg19773385	chr1:10388646	KIF1B	-0.22	-5.1	-0.42	1.23e-6	Hepatocellular carcinoma;
TGCT	cis	rs6964587	1.000	rs10235941	chr7:91587050	T/G	cg17063962	chr7:91808500	NA	0.91	9.99	0.67	1.32e-17	Breast cancer;
TGCT	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg11764359	chr7:65958608	NA	-0.59	-5.17	-0.42	9.13e-7	Aortic root size;
TGCT	cis	rs17102884	0.506	rs4899540	chr14:75403408	G/A	cg08847533	chr14:75593920	NEK9	-0.62	-5.5	-0.44	2.09e-7	Neuroticism;
TGCT	cis	rs7552404	1.000	rs7516226	chr1:76234257	G/A	cg22875332	chr1:76189707	ACADM	0.77	8.99	0.63	3.37e-15	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs250677	0.687	rs36043	chr5:148440983	G/A	cg23229984	chr5:148520753	ABLIM3	0.21	4.99	0.41	1.98e-6	Breast cancer;
TGCT	cis	rs11252926	0.574	rs4881254	chr10:453567	C/T	cg13477178	chr10:375248	DIP2C	-0.25	-4.72	-0.39	6.33e-6	Psychosis in Alzheimer's disease;
TGCT	cis	rs7772486	0.754	rs9386133	chr6:146141213	A/G	cg13319975	chr6:146136371	FBXO30	-0.5	-4.66	-0.39	8.04e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg02725872	chr8:58115012	NA	-0.41	-5.38	-0.44	3.5e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs3784262	0.904	rs17820823	chr15:58239358	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.49	-7.29	-0.55	3.16e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs4780401	0.609	rs9923954	chr16:11816855	G/T	cg01061890	chr16:11836724	TXNDC11	-0.6	-5.82	-0.46	4.74e-8	Rheumatoid arthritis;
TGCT	cis	rs1878931	0.624	rs37810	chr16:3451881	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.76	-6.26	-0.49	5.69e-9	Body mass index (adult);
TGCT	cis	rs116095464	0.558	rs10462754	chr5:246669	T/C	cg22857025	chr5:266934	NA	-0.34	-6.72	-0.52	5.96e-10	Breast cancer;
TGCT	cis	rs1008375	1.000	rs10805358	chr4:17652450	A/C	cg16339924	chr4:17578868	LAP3	0.6	5.08	0.42	1.34e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9926296	1.000	rs9926296	chr16:89818089	A/G	cg21285383	chr16:89894308	SPIRE2	0.38	5.73	0.46	7.35e-8	Vitiligo;
TGCT	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.36	0.55	2.25e-11	Prudent dietary pattern;
TGCT	trans	rs208515	0.525	rs4145045	chr6:66678949	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.92	10.09	0.67	7.45e-18	Exhaled nitric oxide levels;
TGCT	cis	rs1577917	0.837	rs10944157	chr6:86577199	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.04	-0.41	1.64e-6	Response to antipsychotic treatment;
TGCT	trans	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg17470723	chr8:74884337	TCEB1	0.71	6.77	0.52	4.48e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs587847	0.737	rs8040571	chr15:37626493	C/A	cg00216138	chr15:37171175	LOC145845	0.3	4.52	0.38	1.43e-5	Intraocular pressure;
TGCT	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg26119090	chr2:26468346	HADHA;HADHB	1.0	7.42	0.55	1.64e-11	Gut microbiome composition (summer);
TGCT	cis	rs10507380	0.824	rs76246060	chr13:27909484	G/A	cg25543773	chr13:27185723	WASF3	0.32	4.58	0.38	1.09e-5	Electrocardiographic traits;
TGCT	cis	rs7647973	1.000	rs3866330	chr3:49582994	T/C	cg05785598	chr3:49045655	WDR6	0.37	4.59	0.38	1.05e-5	Menarche (age at onset);
TGCT	cis	rs7000551	0.556	rs6998780	chr8:22254639	C/T	cg12081754	chr8:22256438	SLC39A14	0.33	4.82	0.4	4.13e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs79349575	0.783	rs4793991	chr17:47001801	A/G	cg07967210	chr17:47022446	SNF8	0.44	6.12	0.48	1.13e-8	Type 2 diabetes;
TGCT	cis	rs7666738	0.830	rs13111977	chr4:98953813	G/A	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg20637647	chr7:64974828	NA	1.0	5.59	0.45	1.4e-7	Diabetic kidney disease;
TGCT	cis	rs713587	0.571	rs2438679	chr2:25317653	C/T	cg01884057	chr2:25150051	NA	-0.26	-4.88	-0.4	3.16e-6	Body mass index in non-asthmatics;
TGCT	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg23758822	chr17:41437982	NA	0.69	6.94	0.53	1.94e-10	Menopause (age at onset);
TGCT	cis	rs7523273	0.564	rs1977268	chr1:207881036	A/C	cg22525895	chr1:207977042	MIR29B2	0.29	4.6	0.38	1.02e-5	Schizophrenia;
TGCT	cis	rs6912958	0.500	rs4707352	chr6:87929705	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-5.82	-0.46	4.71e-8	Monocyte percentage of white cells;
TGCT	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg23708337	chr7:1209742	NA	0.44	4.99	0.41	2e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9357506	1.000	rs9367243	chr6:46316112	A/C	cg21115430	chr6:46460003	NA	0.24	4.95	0.41	2.36e-6	Body mass index;
TGCT	cis	rs7819412	0.765	rs7000132	chr8:11030935	T/C	cg21775007	chr8:11205619	TDH	-0.56	-5.12	-0.42	1.11e-6	Triglycerides;
TGCT	cis	rs9858542	0.953	rs9824092	chr3:49674147	C/G	cg03060546	chr3:49711283	APEH	-0.64	-5.7	-0.46	8.18e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs514406	0.560	rs1889033	chr1:53211887	A/G	cg01802117	chr1:53393560	SCP2	0.44	5.14	0.42	1.05e-6	Monocyte count;
TGCT	cis	rs7178572	0.568	rs11636554	chr15:77608747	C/T	cg15453836	chr15:77711506	NA	-0.43	-4.87	-0.4	3.4e-6	Type 2 diabetes;
TGCT	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg03188948	chr7:1209495	NA	0.42	5.61	0.45	1.24e-7	Longevity;Endometriosis;
TGCT	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg21171335	chr12:122356390	WDR66	-0.71	-7.5	-0.56	1.06e-11	Mean corpuscular volume;
TGCT	cis	rs3008870	0.958	rs12131222	chr1:67438535	A/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.1	-11.8	-0.73	5.15e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs3784262	0.565	rs2642630	chr15:58316960	C/G	cg12031962	chr15:58353849	ALDH1A2	-0.39	-5.54	-0.45	1.72e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs3812049	1.000	rs3812049	chr5:127418850	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.65	5.96	0.47	2.46e-8	Lymphocyte counts;Red cell distribution width;
TGCT	cis	rs476633	0.691	rs6492997	chr15:41541171	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.57	-7.44	-0.56	1.44e-11	Glomerular filtration rate (creatinine);
TGCT	cis	rs7953249	0.791	rs1920792	chr12:121404584	T/C	cg00044289	chr12:121019603	POP5	-0.41	-4.57	-0.38	1.14e-5	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs478304	0.934	rs537786	chr11:65494987	C/T	cg27068330	chr11:65405492	SIPA1	0.76	7.47	0.56	1.25e-11	Acne (severe);
TGCT	cis	rs644799	0.930	rs3802764	chr11:95514599	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	11.08	0.71	2.9e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9394841	0.692	rs9349202	chr6:41805581	A/C	cg08135965	chr6:41755394	TOMM6	0.54	4.94	0.41	2.46e-6	Mean corpuscular hemoglobin;Red cell distribution width;
TGCT	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs936229	0.813	rs7085	chr15:75095483	T/C	cg10253484	chr15:75165896	SCAMP2	-0.65	-5.19	-0.42	8.24e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
TGCT	cis	rs12579753	0.917	rs7132465	chr12:82205840	C/T	cg07988820	chr12:82153109	PPFIA2	-0.59	-6.19	-0.49	7.93e-9	Resting heart rate;
TGCT	cis	rs2688608	0.592	rs7080579	chr10:75504029	T/A	cg19442545	chr10:75533431	FUT11	-0.36	-5.66	-0.45	9.76e-8	Inflammatory bowel disease;
TGCT	cis	rs76878669	0.561	rs2236679	chr11:66108894	G/C	cg18002602	chr11:66138449	SLC29A2	-0.53	-6.44	-0.5	2.32e-9	Educational attainment (years of education);
TGCT	cis	rs10875746	0.859	rs11558768	chr12:48577789	C/T	cg20731937	chr12:48336164	NA	0.61	4.88	0.4	3.17e-6	Longevity (90 years and older);
TGCT	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg12963246	chr6:28129442	ZNF389	0.53	5.09	0.42	1.27e-6	Depression;
TGCT	trans	rs1496653	0.602	rs35028631	chr3:23443819	G/A	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs12612619	0.627	rs13391244	chr2:27287609	T/C	cg03606774	chr2:27432830	SLC5A6	-0.28	-4.63	-0.38	8.97e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
TGCT	cis	rs7267979	1.000	rs11087520	chr20:25436827	C/T	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2730260	0.578	rs56375711	chr7:158854935	G/A	cg09066883	chr7:157932951	PTPRN2	0.43	4.65	0.39	8.22e-6	Myopia (pathological);
TGCT	cis	rs12477438	0.520	rs6712704	chr2:99719687	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	13.05	0.76	4.93e-25	Chronic sinus infection;
TGCT	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg10047753	chr17:41438598	NA	0.95	9.61	0.65	1.12e-16	Menopause (age at onset);
TGCT	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg21285383	chr16:89894308	SPIRE2	0.43	6.47	0.5	2.03e-9	Vitiligo;
TGCT	cis	rs4891159	0.790	rs8085133	chr18:74144083	A/C	cg24786174	chr18:74118243	ZNF516	-0.55	-7.86	-0.58	1.61e-12	Longevity;
TGCT	cis	rs60843830	1.000	rs62114497	chr2:214837	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.7	6.44	0.5	2.37e-9	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs6088590	0.582	rs6059909	chr20:33139691	C/A	cg06115741	chr20:33292138	TP53INP2	0.54	4.72	0.39	6.29e-6	Coronary artery disease;
TGCT	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg12564285	chr5:131593104	PDLIM4	0.4	4.78	0.39	4.79e-6	Acylcarnitine levels;
TGCT	cis	rs2235642	0.826	rs8053605	chr16:1594158	G/A	cg08296037	chr16:1584118	IFT140;TMEM204	-0.3	-5.3	-0.43	5.02e-7	Coronary artery disease;
TGCT	cis	rs4790312	0.513	rs12939002	chr17:1965096	C/T	cg24156229	chr17:1948635	NA	-0.37	-5.95	-0.47	2.51e-8	Left atrial antero-posterior diameter;
TGCT	cis	rs9814567	0.727	rs4245908	chr3:134349205	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-6.27	-0.49	5.37e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs9611565	0.592	rs1811113	chr22:42073134	C/T	cg06481639	chr22:41940642	POLR3H	0.73	6.57	0.51	1.27e-9	Vitiligo;
TGCT	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg13607699	chr17:42295918	UBTF	0.67	6.26	0.49	5.86e-9	Total body bone mineral density;
TGCT	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6460942	0.555	rs7803268	chr7:12306793	G/A	cg06484146	chr7:12443880	VWDE	-0.54	-4.77	-0.39	5.06e-6	Coronary artery disease;
TGCT	cis	rs10936602	0.527	rs9838444	chr3:169547573	A/G	cg08193579	chr3:169529701	LRRC34	0.28	5.16	0.42	9.66e-7	Renal cell carcinoma;
TGCT	cis	rs3782455	1.000	rs78363483	chr12:114401643	T/C	cg23502203	chr12:113549970	RASAL1	-0.55	-4.92	-0.4	2.7e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs10465746	0.846	rs12146038	chr1:84405065	A/T	cg10977910	chr1:84465055	TTLL7	0.65	6.56	0.51	1.31e-9	Obesity-related traits;
TGCT	cis	rs2180341	1.000	rs2180341	chr6:127600630	C/T	cg24812749	chr6:127587940	RNF146	0.99	7.73	0.57	3.25e-12	Breast cancer;
TGCT	cis	rs42648	1.000	rs42658	chr7:89981915	T/A	cg25739043	chr7:89950458	NA	-0.57	-5.49	-0.44	2.13e-7	Homocysteine levels;
TGCT	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg08280861	chr8:58055591	NA	0.49	5.51	0.44	1.98e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7727544	0.716	rs4705926	chr5:131561758	C/T	cg24060327	chr5:131705240	SLC22A5	-0.54	-5.1	-0.42	1.22e-6	Blood metabolite levels;
TGCT	cis	rs73198271	1.000	rs11775476	chr8:8607869	T/C	ch.8.214553F	chr8:8189620	PRAGMIN	-0.27	-4.57	-0.38	1.17e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs259282	0.628	rs2287669	chr19:33110204	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.54	4.91	0.4	2.76e-6	Schizophrenia;
TGCT	cis	rs7267979	1.000	rs12428	chr20:25433821	G/T	cg14121845	chr20:25566513	NINL	-0.44	-4.8	-0.4	4.48e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6450176	0.909	rs1541681	chr5:53304620	G/T	ch.5.1024479R	chr5:53302184	ARL15	-0.49	-4.6	-0.38	1.03e-5	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs9883204	0.807	rs11708067	chr3:123065778	A/G	cg04890266	chr3:123102914	ADCY5	0.35	4.85	0.4	3.59e-6	Birth weight;
TGCT	cis	rs9291683	0.517	rs11736479	chr4:10017387	G/C	cg00071950	chr4:10020882	SLC2A9	0.75	10.33	0.68	2.04e-18	Bone mineral density;
TGCT	cis	rs3733585	0.673	rs4235348	chr4:9951968	T/C	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.65	-0.57	4.78e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs2303745	0.841	rs10409801	chr19:17407415	A/G	cg02221750	chr19:17393354	ANKLE1	-0.44	-4.67	-0.39	7.63e-6	Systemic lupus erythematosus;
TGCT	cis	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg15556689	chr8:8085844	FLJ10661	-0.67	-6.34	-0.49	3.84e-9	Mood instability;
TGCT	cis	rs67311347	0.911	rs6773917	chr3:40469254	G/T	cg13683864	chr3:40499215	RPL14	-1.04	-10.79	-0.7	1.54e-19	Renal cell carcinoma;
TGCT	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg11494091	chr17:61959527	GH2	0.61	14.43	0.79	2.59e-28	Prudent dietary pattern;
TGCT	cis	rs79349575	0.756	rs937301	chr17:47046276	A/G	cg07967210	chr17:47022446	SNF8	-0.44	-5.94	-0.47	2.68e-8	Type 2 diabetes;
TGCT	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg12311346	chr5:56204834	C5orf35	-0.63	-6.36	-0.5	3.5e-9	Initial pursuit acceleration;
TGCT	cis	rs2120019	0.938	rs1867150	chr15:75321139	T/C	cg09165964	chr15:75287851	SCAMP5	-1.14	-10.33	-0.68	2.05e-18	Blood trace element (Zn levels);
TGCT	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg07167872	chr1:205819463	PM20D1	0.59	7.68	0.57	4.23e-12	Menarche (age at onset);
TGCT	trans	rs2675662	0.525	rs12264025	chr10:75494450	A/G	cg13918328	chr10:52500089	ASAH2B	0.68	6.7	0.52	6.48e-10	Psoriasis vulgaris;Psoriasis;
TGCT	cis	rs2204008	0.683	rs12370288	chr12:38127740	G/A	cg26384229	chr12:38710491	ALG10B	0.89	7.92	0.58	1.14e-12	Bladder cancer;
TGCT	cis	rs9916302	0.851	rs11868029	chr17:37650304	A/G	cg07936489	chr17:37558343	FBXL20	-0.6	-4.75	-0.39	5.45e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs317689	0.513	rs317659	chr12:69686132	T/A	cg20891283	chr12:69753455	YEATS4	0.56	5.13	0.42	1.1e-6	Response to diuretic therapy;
TGCT	cis	rs7264396	0.635	rs6060685	chr20:34512023	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.04	-0.41	1.58e-6	Total cholesterol levels;
TGCT	cis	rs2932538	0.744	rs6537742	chr1:113085197	G/T	cg22162597	chr1:113214053	CAPZA1	0.29	5.4	0.44	3.19e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs1568889	1.000	rs6484346	chr11:28040767	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	8.94	0.63	4.66e-15	Bipolar disorder;
TGCT	cis	rs13191362	1.000	rs13215491	chr6:163010325	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs2996428	0.667	rs61768933	chr1:3766587	G/A	cg13057898	chr1:3703894	LRRC47	0.21	4.64	0.38	8.81e-6	Red cell distribution width;
TGCT	cis	rs28595532	0.800	rs114321375	chr4:119341663	G/A	cg11846333	chr4:119757529	SEC24D	0.72	4.51	0.38	1.48e-5	Cannabis dependence symptom count;
TGCT	cis	rs868036	0.645	rs28539889	chr15:68121428	T/A	cg05925327	chr15:68127851	NA	-0.48	-4.6	-0.38	1.05e-5	Restless legs syndrome;
TGCT	cis	rs9467773	1.000	rs9467791	chr6:26562486	A/G	cg09904177	chr6:26538194	HMGN4	-0.67	-6.77	-0.52	4.63e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs4919694	1.000	rs77318450	chr10:104733098	A/G	cg04362960	chr10:104952993	NT5C2	1.07	7.15	0.54	6.49e-11	Arsenic metabolism;
TGCT	cis	rs3741404	0.609	rs666497	chr11:63869821	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.72	7.32	0.55	2.78e-11	Platelet count;
TGCT	cis	rs12200560	0.505	rs211171	chr6:97070579	T/G	cg06623918	chr6:96969491	KIAA0776	0.59	5.02	0.41	1.76e-6	Coronary heart disease;
TGCT	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg06713675	chr4:122721982	EXOSC9	-0.67	-8.73	-0.62	1.41e-14	Type 2 diabetes;
TGCT	cis	rs2847281	0.561	rs888271	chr18:12774981	A/G	cg23598886	chr18:12777645	NA	0.37	4.69	0.39	7.07e-6	C-reactive protein levels;Esophageal cancer (squamous cell);
TGCT	cis	rs6754311	0.689	rs192822	chr2:136682274	A/T	cg07169764	chr2:136633963	MCM6	0.63	5.87	0.47	3.81e-8	Mosquito bite size;
TGCT	cis	rs8002180	0.959	rs7996898	chr13:95922453	A/G	cg24476569	chr13:95954382	ABCC4	0.41	5.07	0.41	1.42e-6	Blood metabolite levels;
TGCT	cis	rs7830933	0.911	rs13251678	chr8:23594229	C/T	cg04349084	chr8:23602677	NA	0.23	4.59	0.38	1.08e-5	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
TGCT	cis	rs8051431	0.876	rs8061657	chr16:72016695	A/G	cg06353428	chr16:71660113	MARVELD3	0.57	4.61	0.38	9.79e-6	LDL cholesterol levels;
TGCT	cis	rs9948	0.786	rs111237064	chr2:97456578	T/C	cg01990225	chr2:97406019	LMAN2L	-0.88	-4.81	-0.4	4.37e-6	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs35306767	0.807	rs11253513	chr10:968450	C/T	cg26597838	chr10:835615	NA	0.63	9.0	0.63	3.31e-15	Eosinophil percentage of granulocytes;
TGCT	cis	rs13242816	1.000	rs34082946	chr7:116154313	G/A	cg16553024	chr7:116138462	CAV2	-0.45	-5.27	-0.43	5.81e-7	P wave duration;
TGCT	cis	rs2637266	1.000	rs7101318	chr10:78379780	T/C	cg18941641	chr10:78392320	NA	0.4	4.73	0.39	6.03e-6	Pulmonary function;
TGCT	cis	rs3770081	1.000	rs111295372	chr2:86283357	T/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.17	-4.56	-0.38	1.21e-5	Facial emotion recognition (sad faces);
TGCT	cis	rs1153858	1.000	rs66714503	chr15:45648038	G/C	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.62e-8	Homoarginine levels;
TGCT	cis	rs12497850	0.931	rs11924597	chr3:48937790	T/C	cg05785598	chr3:49045655	WDR6	0.36	4.75	0.39	5.46e-6	Parkinson's disease;
TGCT	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.01	0.41	1.86e-6	Prudent dietary pattern;
TGCT	trans	rs17685	0.784	rs1613890	chr7:75735037	T/C	cg19862616	chr7:65841803	NCRNA00174	0.51	8.3	0.6	1.51e-13	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs9790314	0.586	rs35713426	chr3:161131271	A/G	cg03342759	chr3:160939853	NMD3	-0.5	-5.1	-0.42	1.25e-6	Morning vs. evening chronotype;
TGCT	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	5.02	0.41	1.78e-6	Prudent dietary pattern;
TGCT	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg07157834	chr1:205819609	PM20D1	0.34	5.01	0.41	1.81e-6	Menarche (age at onset);
TGCT	cis	rs7772486	0.686	rs2179323	chr6:145982786	T/G	cg23711669	chr6:146136114	FBXO30	-0.84	-9.16	-0.64	1.35e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3820068	0.608	rs12091644	chr1:16044945	G/A	cg17385448	chr1:15911702	AGMAT	0.35	4.65	0.39	8.37e-6	Systolic blood pressure;
TGCT	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg11644478	chr21:40555479	PSMG1	-1.01	-10.78	-0.7	1.56e-19	Cognitive function;
TGCT	cis	rs4799461	0.778	rs62081464	chr18:35142133	C/T	cg27332583	chr18:35150602	NA	0.3	4.61	0.38	9.9e-6	Neuroticism;
TGCT	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg18305652	chr10:134549665	INPP5A	0.35	5.94	0.47	2.73e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs4654899	0.643	rs651538	chr1:21097866	A/G	cg01072550	chr1:21505969	NA	-0.54	-8.85	-0.62	7.62e-15	Superior frontal gyrus grey matter volume;
TGCT	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.33	-5.17	-0.42	9.08e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs910316	1.000	rs12589876	chr14:75544189	G/A	cg08847533	chr14:75593920	NEK9	0.96	10.53	0.69	6.43e-19	Height;
TGCT	cis	rs763121	0.853	rs8138996	chr22:39047435	G/T	cg06022373	chr22:39101656	GTPBP1	0.77	7.46	0.56	1.35e-11	Menopause (age at onset);
TGCT	cis	rs12477438	0.520	rs6743355	chr2:99732360	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	17.43	0.84	3.73e-35	Chronic sinus infection;
TGCT	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg06634786	chr22:41940651	POLR3H	0.73	6.81	0.52	3.75e-10	Vitiligo;
TGCT	cis	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg03213289	chr20:61660250	NA	0.68	9.9	0.66	2.25e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7172809	0.897	rs1317320	chr15:77830090	G/A	cg22256960	chr15:77711686	NA	-0.44	-4.47	-0.37	1.76e-5	Glucose homeostasis traits;
TGCT	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg23719950	chr11:63933701	MACROD1	-0.71	-5.87	-0.47	3.72e-8	Mean platelet volume;
TGCT	cis	rs6815814	0.731	rs4513579	chr4:38773816	T/C	cg02016764	chr4:38805732	TLR1	-0.28	-4.79	-0.4	4.63e-6	Breast cancer;
TGCT	cis	rs28595532	0.920	rs115334469	chr4:119596194	G/C	cg21605333	chr4:119757512	SEC24D	1.36	7.24	0.55	4.12e-11	Cannabis dependence symptom count;
TGCT	cis	rs11230394	0.916	rs17627710	chr11:60379083	G/A	cg24026212	chr11:59952134	MS4A6A	0.32	5.05	0.41	1.57e-6	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
TGCT	cis	rs7267979	0.657	rs6107073	chr20:25716363	T/C	cg03522245	chr20:25566470	NINL	0.51	5.28	0.43	5.62e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg02380750	chr20:61661411	NA	0.34	6.02	0.48	1.86e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg00149659	chr3:10157352	C3orf10	-1.16	-7.48	-0.56	1.21e-11	Alzheimer's disease;
TGCT	cis	rs172166	0.516	rs2021826	chr6:28132756	G/A	cg13525197	chr6:28411240	ZSCAN23	-0.48	-4.71	-0.39	6.43e-6	Cardiac Troponin-T levels;
TGCT	cis	rs9372498	0.536	rs62424175	chr6:118797381	T/A	cg07617317	chr6:118971624	C6orf204	0.5	5.39	0.44	3.36e-7	Diastolic blood pressure;
TGCT	cis	rs9291683	0.517	rs11736479	chr4:10017387	G/C	cg11266682	chr4:10021025	SLC2A9	0.73	10.98	0.7	5.33e-20	Bone mineral density;
TGCT	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg11941060	chr3:133502564	NA	-0.32	-6.61	-0.51	1.01e-9	Iron status biomarkers;
TGCT	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg17971929	chr21:40555470	PSMG1	0.96	8.86	0.62	6.96e-15	Cognitive function;
TGCT	cis	rs4845570	1.000	rs17568246	chr1:151736456	A/G	cg07092448	chr1:151763213	TDRKH	-1.05	-7.56	-0.56	7.85e-12	Coronary artery disease;
TGCT	cis	rs7107174	1.000	rs4944198	chr11:78032605	T/A	cg12700464	chr11:78128424	GAB2	-0.67	-4.78	-0.39	4.82e-6	Testicular germ cell tumor;
TGCT	cis	rs9527	0.615	rs7089065	chr10:104723022	C/T	cg15744005	chr10:104629667	AS3MT	-0.44	-5.19	-0.42	8.3e-7	Arsenic metabolism;
TGCT	cis	rs13191362	1.000	rs13215491	chr6:163010325	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs9443645	0.901	rs2174739	chr6:79659170	C/T	cg05283184	chr6:79620031	NA	0.22	4.99	0.41	2.01e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs17030434	0.784	rs11099900	chr4:154669471	C/T	cg14289246	chr4:154710475	SFRP2	-0.86	-7.36	-0.55	2.24e-11	Electrocardiographic conduction measures;
TGCT	cis	rs7666738	0.830	rs1967980	chr4:98966426	C/G	cg18180107	chr4:99064573	C4orf37	0.57	5.19	0.42	8.47e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10949834	0.652	rs2269082	chr7:73519875	A/G	cg07137043	chr7:73588983	EIF4H	-0.67	-5.12	-0.42	1.14e-6	Verbal memory performance (residualized delayed recall change);
TGCT	cis	rs61774743	0.557	rs4359027	chr1:41848296	G/A	cg01193554	chr1:41846683	NA	-0.41	-5.01	-0.41	1.86e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6750047	0.638	rs336031	chr2:38265130	C/A	cg07380506	chr2:38303506	CYP1B1	-0.56	-4.98	-0.41	2.04e-6	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs7208859	0.673	rs9909497	chr17:29173228	C/A	cg14008862	chr17:28927542	LRRC37B2	0.72	4.66	0.39	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs4713118	0.662	rs9357060	chr6:28024486	C/G	cg12963246	chr6:28129442	ZNF389	0.45	4.55	0.38	1.27e-5	Parkinson's disease;
TGCT	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg03352830	chr11:487213	PTDSS2	0.26	4.58	0.38	1.12e-5	Body mass index;
TGCT	cis	rs9733	0.596	rs17606613	chr1:150683015	C/T	cg04414720	chr1:150670196	GOLPH3L	0.37	4.91	0.4	2.76e-6	Tonsillectomy;
TGCT	cis	rs2204008	0.775	rs11514369	chr12:38305411	C/T	cg13010199	chr12:38710504	ALG10B	0.58	4.54	0.38	1.3e-5	Bladder cancer;
TGCT	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.71	-0.39	6.54e-6	Prudent dietary pattern;
TGCT	cis	rs4660261	0.526	rs3094954	chr1:44320919	C/T	cg12908607	chr1:44402522	ARTN	-0.64	-7.74	-0.57	3e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs6831352	0.918	rs13127582	chr4:100058194	G/A	cg12011299	chr4:100065546	ADH4	-0.41	-4.97	-0.41	2.18e-6	Alcohol dependence;
TGCT	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg11764359	chr7:65958608	NA	0.54	5.02	0.41	1.73e-6	Aortic root size;
TGCT	cis	rs9329289	0.851	rs61835719	chr10:2543390	A/G	cg15501526	chr10:2543763	NA	0.39	4.87	0.4	3.32e-6	Age-related hearing impairment;
TGCT	cis	rs1371867	0.846	rs1660329	chr8:101304048	G/T	cg06636551	chr8:101224915	SPAG1	-0.48	-6.52	-0.51	1.62e-9	Atrioventricular conduction;
TGCT	cis	rs2455799	0.613	rs2470536	chr3:15715156	G/C	cg16303742	chr3:15540471	COLQ	-0.25	-4.74	-0.39	5.65e-6	Mean platelet volume;
TGCT	cis	rs12762955	0.507	rs7095853	chr10:1040798	T/C	cg20503657	chr10:835505	NA	-0.42	-5.31	-0.43	4.8e-7	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg12311346	chr5:56204834	C5orf35	-0.78	-6.56	-0.51	1.32e-9	Initial pursuit acceleration;
TGCT	cis	rs3008870	0.628	rs2755257	chr1:67515309	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.73	7.1	0.54	8.47e-11	Lymphocyte percentage of white cells;
TGCT	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg22963979	chr7:1858916	MAD1L1	-0.37	-5.9	-0.47	3.17e-8	Bipolar disorder and schizophrenia;
TGCT	cis	rs28595532	0.920	rs115744897	chr4:119749064	A/G	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs3784262	0.669	rs4646642	chr15:58246916	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.44	-6.27	-0.49	5.41e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs8064299	0.574	rs12452204	chr17:72774128	T/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.92	10.38	0.68	1.49e-18	Monocyte count;
TGCT	cis	rs9952991	0.941	rs2542151	chr18:12779947	G/T	cg23544223	chr18:12777786	NA	0.63	6.1	0.48	1.24e-8	Inflammatory skin disease;
TGCT	cis	rs9295536	0.676	rs7743854	chr6:22122389	A/G	cg25792714	chr6:21666554	FLJ22536	-0.52	-4.63	-0.38	9.17e-6	Neuroblastoma;
TGCT	cis	rs832540	1.000	rs192249	chr5:56197514	C/G	cg12311346	chr5:56204834	C5orf35	-0.51	-5.38	-0.44	3.54e-7	Coronary artery disease;
TGCT	cis	rs4746818	1.000	rs9299502	chr10:70876934	C/T	cg11621586	chr10:70884670	VPS26A	1.22	11.35	0.71	6.63e-21	Left atrial antero-posterior diameter;
TGCT	cis	rs763014	0.931	rs710925	chr16:633354	G/A	cg00908189	chr16:619842	PIGQ	0.87	10.5	0.69	7.53e-19	Height;
TGCT	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg04267008	chr7:1944627	MAD1L1	-0.42	-5.58	-0.45	1.46e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs3796352	1.000	rs7622420	chr3:53111069	A/G	cg27565382	chr3:53032988	SFMBT1	0.44	5.31	0.43	4.91e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs7552404	1.000	rs211718	chr1:76106675	C/T	cg22875332	chr1:76189707	ACADM	0.77	9.38	0.64	4.01e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2730260	0.537	rs55864635	chr7:158859744	C/T	cg27122614	chr7:157913741	PTPRN2	0.43	4.45	0.37	1.87e-5	Myopia (pathological);
TGCT	cis	rs739496	0.843	rs10774629	chr12:112020214	G/C	cg10833066	chr12:111807467	FAM109A	-0.37	-5.2	-0.42	8.01e-7	Platelet count;
TGCT	cis	rs523522	0.962	rs4766969	chr12:120988238	A/G	cg27279351	chr12:120934652	DYNLL1	0.76	6.59	0.51	1.15e-9	High light scatter reticulocyte count;
TGCT	cis	rs6598955	0.670	rs11247892	chr1:26592727	A/G	cg04990556	chr1:26633338	UBXN11	-0.91	-11.45	-0.72	3.65e-21	Obesity-related traits;
TGCT	cis	rs2739330	1.000	rs2739330	chr22:24295286	T/C	cg11905131	chr22:24372483	LOC391322	-0.98	-12.39	-0.74	1.97e-23	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7246657	0.722	rs1564206	chr19:38040076	C/T	cg03611452	chr19:38183253	ZNF781	0.58	4.64	0.38	8.62e-6	Coronary artery calcification;
TGCT	cis	rs12579753	0.827	rs7958100	chr12:82200782	G/A	cg07988820	chr12:82153109	PPFIA2	-0.59	-6.19	-0.49	7.93e-9	Resting heart rate;
TGCT	cis	rs12510870	0.599	rs12506675	chr4:74449853	T/C	cg05868023	chr4:75230803	EREG	-0.54	-4.76	-0.39	5.33e-6	Iris color (b* coordinate);
TGCT	cis	rs887829	0.569	rs4124874	chr2:234665659	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.26	-4.51	-0.38	1.46e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
TGCT	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg06634786	chr22:41940651	POLR3H	-0.85	-7.8	-0.57	2.16e-12	Vitiligo;
TGCT	cis	rs10927875	0.541	rs1739840	chr1:16342237	A/G	cg22431228	chr1:16359049	CLCNKA	-0.29	-6.07	-0.48	1.42e-8	Dilated cardiomyopathy;
TGCT	cis	rs11650494	0.908	rs11650087	chr17:47362923	T/A	cg08112188	chr17:47440006	ZNF652	1.05	5.4	0.44	3.32e-7	Prostate cancer;
TGCT	cis	rs1355223	0.583	rs2956074	chr11:34864880	T/C	cg24088639	chr11:34937564	PDHX;APIP	-0.51	-4.64	-0.38	8.76e-6	Systemic lupus erythematosus and Systemic sclerosis;
TGCT	cis	rs1018836	0.923	rs7840846	chr8:91565501	T/A	cg16814680	chr8:91681699	NA	-0.9	-9.91	-0.66	2.06e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs739496	0.579	rs6489817	chr12:112291242	A/C	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs6459680	0.723	rs7793415	chr7:156258646	C/T	cg02321112	chr7:156810523	NA	-0.34	-4.81	-0.4	4.34e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs12983728	1.000	rs12983728	chr19:58671267	G/A	cg07378217	chr19:58662286	ZNF329	-0.83	-4.69	-0.39	6.97e-6	Cholesterol, total;
TGCT	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg10411590	chr13:21900810	NA	0.38	5.06	0.41	1.48e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg10047753	chr17:41438598	NA	0.96	9.49	0.65	2.15e-16	Menopause (age at onset);
TGCT	cis	rs6570726	0.689	rs411785	chr6:145888398	G/A	cg13319975	chr6:146136371	FBXO30	-0.51	-4.6	-0.38	1.01e-5	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs9388451	0.839	rs9321054	chr6:126079968	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.74	8.58	0.61	3.3e-14	Brugada syndrome;
TGCT	cis	rs9896933	0.778	rs80112422	chr17:80827719	G/T	cg20578329	chr17:80767326	TBCD	-0.33	-4.67	-0.39	7.66e-6	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
TGCT	cis	rs6938	0.618	rs12912839	chr15:75221245	C/T	cg09165964	chr15:75287851	SCAMP5	0.55	5.03	0.41	1.67e-6	Breast cancer;
TGCT	cis	rs7937682	0.924	rs7924683	chr11:111555796	C/A	cg09085632	chr11:111637200	PPP2R1B	-1.11	-11.61	-0.72	1.55e-21	Primary sclerosing cholangitis;
TGCT	cis	rs9611565	0.649	rs139540	chr22:42178040	C/T	cg03806693	chr22:41940476	POLR3H	-0.95	-9.22	-0.64	9.83e-16	Vitiligo;
TGCT	cis	rs6016142	0.759	rs292858	chr20:38333579	A/G	cg22128431	chr20:37434409	PPP1R16B	0.6	4.62	0.38	9.48e-6	Estradiol levels;Dupuytren's disease;
TGCT	cis	rs1005277	0.505	rs1208689	chr10:38097775	C/G	cg25427524	chr10:38739819	LOC399744	-0.37	-7.41	-0.55	1.75e-11	Extrinsic epigenetic age acceleration;
TGCT	cis	rs1153858	1.000	rs1288775	chr15:45661678	T/A	cg14582100	chr15:45693742	SPATA5L1	0.48	5.69	0.46	8.56e-8	Homoarginine levels;
TGCT	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg24829409	chr8:58192753	C8orf71	-0.52	-5.02	-0.41	1.73e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2288884	1.000	rs58817690	chr19:52536692	C/T	cg13540795	chr19:52551618	ZNF432	-0.57	-4.9	-0.4	2.97e-6	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs11785400	0.793	rs4301430	chr8:143737416	A/G	cg10596483	chr8:143751796	JRK	0.55	5.43	0.44	2.91e-7	Schizophrenia;
TGCT	cis	rs478304	0.514	rs75601653	chr11:65483370	C/G	cg17480646	chr11:65405466	SIPA1	-0.58	-6.56	-0.51	1.34e-9	Acne (severe);
TGCT	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg03732007	chr1:2071316	PRKCZ	-0.28	-6.39	-0.5	3.11e-9	Height;
TGCT	cis	rs57590327	0.503	rs9874184	chr3:81505439	C/T	cg07356753	chr3:81810745	GBE1	0.58	4.89	0.4	3.06e-6	Extraversion;
TGCT	cis	rs6754311	0.517	rs1469996	chr2:136542560	A/G	cg07169764	chr2:136633963	MCM6	0.89	7.81	0.57	2.05e-12	Mosquito bite size;
TGCT	cis	rs644799	1.000	rs472231	chr11:95532166	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	10.58	0.69	4.97e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs6570726	0.791	rs441290	chr6:145883183	A/G	cg05347473	chr6:146136440	FBXO30	0.52	4.86	0.4	3.43e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7954584	0.531	rs6486781	chr12:122318985	A/C	cg21171335	chr12:122356390	WDR66	0.57	6.07	0.48	1.43e-8	Mean corpuscular volume;
TGCT	cis	rs9916302	0.904	rs6503503	chr17:37514373	G/A	cg15445000	chr17:37608096	MED1	-0.35	-5.05	-0.41	1.53e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.71	-0.39	6.54e-6	Prudent dietary pattern;
TGCT	cis	rs7260538	0.808	rs707265	chr19:41524087	A/G	cg20630647	chr19:41531805	NA	0.32	5.07	0.41	1.41e-6	DDT metabolite (p,p'-DDE levels);
TGCT	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.18	0.49	8.32e-9	Electroencephalogram traits;
TGCT	cis	rs9549367	0.789	rs7994324	chr13:113906497	T/C	cg00898013	chr13:113819073	PROZ	-0.4	-5.03	-0.41	1.64e-6	Platelet distribution width;
TGCT	cis	rs7095607	0.813	rs7903493	chr10:69931156	C/A	cg18986048	chr10:69913749	MYPN	0.46	5.24	0.43	6.63e-7	Lung function (FVC);
TGCT	cis	rs7552404	0.924	rs7550974	chr1:76204185	A/G	cg22875332	chr1:76189707	ACADM	0.77	9.49	0.65	2.13e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs3947	1.000	rs1736082	chr8:11703420	C/T	cg02840367	chr8:11660030	FDFT1	0.91	6.66	0.51	7.98e-10	Blood protein levels;
TGCT	cis	rs7267979	0.586	rs11087505	chr20:25196520	T/A	cg03522245	chr20:25566470	NINL	0.49	5.17	0.42	9.26e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9811920	0.732	rs793446	chr3:99578114	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.46	5.2	0.42	7.93e-7	Axial length;
TGCT	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg11494091	chr17:61959527	GH2	0.43	7.3	0.55	3.05e-11	Height;
TGCT	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg24060327	chr5:131705240	SLC22A5	-0.59	-5.9	-0.47	3.16e-8	Breast cancer;
TGCT	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg04267008	chr7:1944627	MAD1L1	0.41	5.36	0.43	3.96e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs6964587	0.900	rs11984136	chr7:91766953	T/C	cg22709100	chr7:91322751	NA	0.28	4.44	0.37	1.96e-5	Breast cancer;
TGCT	cis	rs7100689	0.577	rs10788545	chr10:82034675	A/G	cg01528321	chr10:82214614	TSPAN14	0.7	6.78	0.52	4.43e-10	Post bronchodilator FEV1;
TGCT	cis	rs861020	0.563	rs35898529	chr1:210053096	G/A	cg05527609	chr1:210001259	C1orf107	-0.96	-7.33	-0.55	2.65e-11	Orofacial clefts;
TGCT	cis	rs11673344	0.523	rs1667379	chr19:37492094	A/T	cg08039142	chr19:36980659	ZNF566	0.59	5.58	0.45	1.41e-7	Obesity-related traits;
TGCT	cis	rs807669	0.903	rs756651	chr22:19179367	T/C	cg02655711	chr22:19163373	SLC25A1	0.42	9.92	0.67	1.94e-17	Metabolite levels;
TGCT	cis	rs10493773	1.000	rs7523292	chr1:86134992	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.37	-4.69	-0.39	7.01e-6	Urate levels in overweight individuals;
TGCT	cis	rs35146811	0.700	rs858513	chr7:99825558	G/A	cg04778012	chr7:99775508	STAG3;GPC2	-0.36	-5.1	-0.42	1.22e-6	Coronary artery disease;
TGCT	cis	rs9326248	1.000	rs664082	chr11:117071070	C/G	cg26566898	chr11:117069891	TAGLN	0.35	5.09	0.42	1.27e-6	Blood protein levels;
TGCT	cis	rs3540	0.513	rs1072879	chr15:90922038	C/T	cg22089800	chr15:90895588	ZNF774	0.82	9.09	0.63	2.03e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs2404602	0.647	rs11629727	chr15:77009038	G/C	cg22467129	chr15:76604101	ETFA	0.47	4.7	0.39	6.84e-6	Blood metabolite levels;
TGCT	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg09323728	chr8:95962352	TP53INP1	-0.52	-6.6	-0.51	1.05e-9	Type 2 diabetes;
TGCT	trans	rs1814175	0.817	rs2866863	chr11:49953242	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.36	-7.14	-0.54	6.88e-11	Height;
TGCT	cis	rs12477438	0.748	rs4851185	chr2:99666497	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-7.6	-0.56	6.47e-12	Chronic sinus infection;
TGCT	cis	rs6121246	0.529	rs6060195	chr20:30185638	C/T	cg21427119	chr20:30132790	HM13	-0.42	-6.17	-0.48	8.75e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs3087591	0.708	rs2525568	chr17:29675878	T/G	cg24425628	chr17:29625626	OMG;NF1	0.38	5.5	0.44	2.09e-7	Hip circumference;
TGCT	cis	rs2204008	0.571	rs7970136	chr12:38531951	G/C	cg26384229	chr12:38710491	ALG10B	-0.53	-4.78	-0.39	4.9100000000000004e-06	Bladder cancer;
TGCT	cis	rs11874712	1.000	rs7235373	chr18:43653763	C/A	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.54	5.28	0.43	5.47e-7	Migraine - clinic-based;
TGCT	cis	rs12360000	0.864	rs34695673	chr10:1907540	G/T	cg26364871	chr10:1889757	NA	0.41	4.63	0.38	9.26e-6	Metabolite levels (Dihydroxy docosatrienoic acid);
TGCT	cis	rs1552244	0.706	rs279545	chr3:9972493	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.33	-5.8	-0.46	5.09e-8	Alzheimer's disease;
TGCT	cis	rs7267979	0.903	rs6050481	chr20:25224580	C/T	cg03522245	chr20:25566470	NINL	0.6	6.58	0.51	1.21e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs8084125	0.832	rs62105175	chr18:74948498	T/C	cg05528293	chr18:74961138	GALR1	0.52	5.2	0.42	8.04e-7	Obesity-related traits;
TGCT	cis	rs2594989	0.943	rs2454492	chr3:11507793	G/A	cg26283222	chr3:11613257	VGLL4	-0.22	-4.53	-0.38	1.36e-5	Circulating chemerin levels;
TGCT	cis	rs3791556	0.898	rs3791549	chr2:240109024	A/G	cg03281426	chr2:240109471	HDAC4	-0.28	-4.59	-0.38	1.08e-5	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs9368481	0.678	rs62402024	chr6:26923976	T/C	cg26531700	chr6:26746687	NA	0.69	6.41	0.5	2.71e-9	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs34779708	0.931	rs79749947	chr10:35277081	A/T	cg04310649	chr10:35416472	CREM	-0.51	-4.55	-0.38	1.24e-5	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs7267979	1.000	rs4815420	chr20:25383979	C/T	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs12220898	0.749	rs7098191	chr10:50481213	A/G	cg09603381	chr10:49954066	WDFY4	0.39	4.48	0.37	1.68e-5	Inflammatory biomarkers;
TGCT	cis	rs17270561	0.943	rs4478398	chr6:25694684	T/C	cg17042849	chr6:26104293	HIST1H4C	-0.69	-4.48	-0.37	1.64e-5	Iron status biomarkers;
TGCT	cis	rs7914558	1.000	rs8139	chr10:104848123	G/A	cg04362960	chr10:104952993	NT5C2	0.62	5.5	0.44	2.09e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg05785598	chr3:49045655	WDR6	0.36	4.86	0.4	3.41e-6	Menarche (age at onset);
TGCT	cis	rs13242816	1.000	rs34228114	chr7:116106986	C/T	cg02799643	chr7:116139180	CAV2	-0.45	-5.38	-0.44	3.5e-7	P wave duration;
TGCT	cis	rs986417	0.892	rs8010656	chr14:60797112	G/A	cg27398547	chr14:60952738	C14orf39	-1.56	-6.75	-0.52	5.13e-10	Gut microbiota (bacterial taxa);
TGCT	cis	rs11105298	0.891	rs10777184	chr12:89919568	C/T	cg00757033	chr12:89920650	WDR51B	0.32	5.13	0.42	1.11e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg13695892	chr22:41940480	POLR3H	0.92	9.08	0.63	2.08e-15	Vitiligo;
TGCT	trans	rs7819412	0.775	rs6601564	chr8:10982051	A/G	cg06636001	chr8:8085503	FLJ10661	-0.74	-6.85	-0.52	3.12e-10	Triglycerides;
TGCT	cis	rs921968	0.643	rs552882	chr2:219401726	G/A	cg02176678	chr2:219576539	TTLL4	0.44	6.34	0.49	3.92e-9	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg06634786	chr22:41940651	POLR3H	-0.88	-8.54	-0.61	3.98e-14	Vitiligo;
TGCT	cis	rs7582180	0.790	rs13020451	chr2:100927131	T/G	cg14675211	chr2:100938903	LONRF2	0.51	4.93	0.4	2.61e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2282802	0.685	rs4913079	chr5:139683029	A/G	cg01081189	chr5:139537190	NA	0.29	5.31	0.43	5e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7264396	0.676	rs6060729	chr20:34557004	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.04	-0.41	1.58e-6	Total cholesterol levels;
TGCT	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg01802117	chr1:53393560	SCP2	-0.39	-4.61	-0.38	1e-5	Monocyte count;
TGCT	cis	rs4073582	0.555	rs521109	chr11:66030948	G/A	cg16950941	chr11:66035639	RAB1B	0.58	5.44	0.44	2.67e-7	Gout;
TGCT	cis	rs4711350	0.749	rs7752348	chr6:33718252	C/G	cg18005901	chr6:33739558	LEMD2	-0.58	-6.4	-0.5	2.89e-9	Schizophrenia;
TGCT	cis	rs73001065	0.901	rs17217098	chr19:19702384	G/A	cg03709012	chr19:19516395	GATAD2A	1.25	5.58	0.45	1.43e-7	LDL cholesterol;
TGCT	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg04944784	chr2:26401820	FAM59B	-0.69	-6.23	-0.49	6.54e-9	Gut microbiome composition (summer);
TGCT	cis	rs9952991	0.566	rs484020	chr18:12855440	G/A	cg23598886	chr18:12777645	NA	0.55	4.77	0.39	5.06e-6	Inflammatory skin disease;
TGCT	cis	rs6582630	0.537	rs2204006	chr12:38407098	A/G	cg13010199	chr12:38710504	ALG10B	0.55	4.46	0.37	1.84e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs782590	0.967	rs62165172	chr2:55736237	A/G	cg03859395	chr2:55845619	SMEK2	0.92	11.31	0.71	8e-21	Metabolic syndrome;
TGCT	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	5.05	0.41	1.51e-6	Menopause (age at onset);
TGCT	cis	rs17376456	1.000	rs17323433	chr5:93551028	G/A	cg25358565	chr5:93447407	FAM172A	0.94	7.65	0.57	4.96e-12	Diabetic retinopathy;
TGCT	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg19723775	chr5:179050963	HNRNPH1	-0.54	-5.47	-0.44	2.43e-7	Lung cancer;
TGCT	cis	rs7772486	0.754	rs1415746	chr6:146077107	A/G	cg05347473	chr6:146136440	FBXO30	-0.54	-5.03	-0.41	1.65e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4820539	1.000	rs3827316	chr22:23468538	T/C	cg14186256	chr22:23484241	RTDR1	0.98	11.82	0.73	4.6e-22	Bone mineral density;
TGCT	cis	rs7937682	0.632	rs4936800	chr11:111734097	T/A	cg09085632	chr11:111637200	PPP2R1B	0.88	8.47	0.61	5.93e-14	Primary sclerosing cholangitis;
TGCT	cis	rs17221829	0.644	rs72971008	chr11:89358706	G/A	cg02982614	chr11:89391479	FOLH1B	-0.28	-4.87	-0.4	3.35e-6	Anxiety in major depressive disorder;
TGCT	cis	rs9972944	0.729	rs1541610	chr17:63773836	C/T	cg07283582	chr17:63770753	CCDC46	0.26	5.05	0.41	1.53e-6	Total body bone mineral density;
TGCT	cis	rs13191362	1.000	rs34228197	chr6:163008232	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.57	4.94	0.41	2.45e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs2832191	0.716	rs1984012	chr21:30392472	T/C	cg24692254	chr21:30365293	RNF160	0.97	11.38	0.71	5.5e-21	Dental caries;
TGCT	cis	rs3617	0.573	rs62253583	chr3:52928334	G/A	cg10802521	chr3:52805072	NEK4	0.58	6.62	0.51	9.63e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12510870	0.599	rs3756073	chr4:74413589	A/G	cg05868023	chr4:75230803	EREG	-0.53	-4.63	-0.38	9.08e-6	Iris color (b* coordinate);
TGCT	cis	rs3733585	0.806	rs7375599	chr4:9954918	C/T	cg00071950	chr4:10020882	SLC2A9	0.65	8.21	0.59	2.4e-13	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7666738	0.830	rs10049985	chr4:99023517	C/T	cg18180107	chr4:99064573	C4orf37	0.54	5.03	0.41	1.7e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7666738	0.791	rs1967978	chr4:98966152	T/C	cg17366294	chr4:99064904	C4orf37	0.74	7.54	0.56	8.74e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs941873	0.836	rs6480931	chr10:81108482	T/C	cg09469691	chr10:81107165	PPIF	0.54	5.37	0.43	3.75e-7	Height;
TGCT	cis	rs8056742	0.730	rs13335706	chr16:85091957	T/A	cg00229868	chr16:85520891	NA	0.33	4.97	0.41	2.18e-6	Amyotrophic lateral sclerosis;
TGCT	cis	rs7917772	0.503	rs11191320	chr10:104293394	T/C	cg05855489	chr10:104503620	C10orf26	-0.58	-5.06	-0.41	1.47e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	trans	rs941408	1.000	rs2741990	chr19:2796644	C/T	cg22153745	chr1:153894579	GATAD2B	-0.64	-7.15	-0.54	6.54e-11	Total cholesterol levels;
TGCT	cis	rs7619833	0.607	rs7634878	chr3:27241219	C/T	cg02860705	chr3:27208620	NA	0.26	4.44	0.37	1.94e-5	Breast cancer;
TGCT	cis	rs732765	0.734	rs1057500	chr14:75205116	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.57	-5.03	-0.41	1.69e-6	Non-small cell lung cancer;
TGCT	cis	rs2013441	1.000	rs2703782	chr17:20144799	A/G	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.63	-0.38	9.19e-6	Obesity-related traits;
TGCT	cis	rs6940638	0.688	rs9461335	chr6:27138529	C/A	cg26531700	chr6:26746687	NA	-0.53	-4.6	-0.38	1.04e-5	Intelligence (multi-trait analysis);
TGCT	trans	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg21659725	chr3:3221576	CRBN	0.98	15.33	0.81	2.1000000000000002e-30	Intelligence (multi-trait analysis);
TGCT	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg12963246	chr6:28129442	ZNF389	0.5	4.93	0.4	2.63e-6	Depression;
TGCT	cis	rs6701037	0.748	rs11583687	chr1:175132049	A/C	cg00321850	chr1:175162397	KIAA0040	0.39	5.47	0.44	2.38e-7	Alcohol dependence;
TGCT	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg24829409	chr8:58192753	C8orf71	-0.51	-5.08	-0.42	1.32e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs367943	1.000	rs348931	chr5:112812864	G/C	cg12552261	chr5:112820674	MCC	-0.24	-4.91	-0.4	2.81e-6	Type 2 diabetes;
TGCT	cis	rs3733585	0.699	rs62294332	chr4:9959989	T/C	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.67	-0.51	7.44e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs6669919	0.647	rs10863900	chr1:211675597	A/G	cg26515805	chr1:211431828	RCOR3	-0.5	-5.12	-0.42	1.14e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg06112835	chr11:68658793	MRPL21	0.46	7.86	0.58	1.56e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs8031584	0.678	rs3122	chr15:31170290	A/T	cg08109568	chr15:31115862	NA	0.4	5.04	0.41	1.62e-6	Huntington's disease progression;
TGCT	cis	rs10114408	0.959	rs7863529	chr9:96639160	T/G	cg13679303	chr9:96623674	NA	-0.36	-4.69	-0.39	6.98e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.71	5.14	0.42	1.02e-6	Platelet count;
TGCT	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg27588902	chr6:42928151	GNMT	-0.56	-6.87	-0.53	2.77e-10	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg02380750	chr20:61661411	NA	0.33	5.96	0.47	2.4e-8	Prostate cancer (SNP x SNP interaction);
TGCT	trans	rs57221529	0.709	rs72707024	chr5:667915	G/A	cg25482853	chr8:67687455	SGK3	1.22	10.55	0.69	5.87e-19	Lung disease severity in cystic fibrosis;
TGCT	cis	rs2658782	0.724	rs2248020	chr11:93259965	A/C	cg15737290	chr11:93063684	CCDC67	0.71	5.32	0.43	4.73e-7	Pulmonary function decline;
TGCT	cis	rs9611565	0.592	rs4822046	chr22:41987543	G/A	cg03806693	chr22:41940476	POLR3H	-1.11	-11.64	-0.72	1.26e-21	Vitiligo;
TGCT	cis	rs13191362	1.000	rs66789102	chr6:163104432	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.96	7.87	0.58	1.5e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs62380364	0.507	rs34321	chr5:88020319	C/G	cg24804195	chr5:87968844	LOC645323	-0.59	-5.92	-0.47	2.9e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs78456975	1.000	rs6708604	chr2:1556887	C/T	cg01028140	chr2:1542097	TPO	-0.33	-4.53	-0.38	1.37e-5	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg02725872	chr8:58115012	NA	-0.38	-5.16	-0.42	9.32e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs151227923	1	rs151227923	chr7:155106564	C/T	cg04811098	chr7:155088454	INSIG1	0.32	4.96	0.41	2.23e-6	Stem cell growth factor beta levels;
TGCT	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg07167872	chr1:205819463	PM20D1	0.57	7.37	0.55	2.12e-11	Menarche (age at onset);
TGCT	cis	rs6424115	0.729	rs586173	chr1:24055718	A/G	cg15997130	chr1:24165203	NA	-0.69	-6.59	-0.51	1.12e-9	Immature fraction of reticulocytes;
TGCT	cis	rs4474742	1	rs4474742	chr17:28065578	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.8	-7.97	-0.58	8.91e-13	Monocyte count;
TGCT	cis	rs9467773	1.000	rs9393728	chr6:26509330	C/G	cg09904177	chr6:26538194	HMGN4	0.65	6.53	0.51	1.5e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs2268241	0.877	rs17885509	chr21:34779630	C/T	cg14850771	chr21:34775459	IFNGR2	0.61	5.23	0.43	6.88e-7	Obesity-related traits;
TGCT	cis	rs617219	0.710	rs6874525	chr5:78574237	C/T	cg09550809	chr5:78407562	BHMT	-0.37	-5.24	-0.43	6.65e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs922182	0.542	rs7179912	chr15:64263854	C/T	cg02919090	chr15:64263738	DAPK2	0.36	6.87	0.53	2.76e-10	Blood protein levels;
TGCT	cis	rs734999	0.566	rs4648563	chr1:2536002	C/G	cg18854424	chr1:2615690	NA	0.43	4.96	0.41	2.31e-6	Ulcerative colitis;
TGCT	cis	rs13022357	0.826	rs6720840	chr2:160087815	T/C	cg00168785	chr2:160142643	WDSUB1	0.46	4.6	0.38	1.04e-5	Sudden cardiac arrest;
TGCT	cis	rs2729354	1.000	rs2729355	chr11:57353983	T/G	cg24343310	chr11:57249947	NA	0.28	4.8	0.4	4.5e-6	Blood protein levels;
TGCT	cis	rs17221829	0.965	rs10830366	chr11:89459254	C/T	cg02982614	chr11:89391479	FOLH1B	-0.27	-4.71	-0.39	6.47e-6	Anxiety in major depressive disorder;
TGCT	cis	rs12477438	0.520	rs1453563	chr2:99720267	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	14.89	0.8	2.21e-29	Chronic sinus infection;
TGCT	cis	rs7666738	0.570	rs1869351	chr4:99077286	T/C	cg05340658	chr4:99064831	C4orf37	0.44	4.77	0.39	5.05e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs709400	0.633	rs10143247	chr14:103920927	G/A	cg26031613	chr14:104095156	KLC1	0.84	9.43	0.65	2.98e-16	Body mass index;
TGCT	cis	rs9394169	1.000	rs9394169	chr6:33778964	A/G	cg13859433	chr6:33739653	LEMD2	-0.27	-4.72	-0.39	6.19e-6	Essential tremor;
TGCT	cis	rs2439831	0.702	rs3759791	chr15:44090798	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	6.01	0.47	1.91e-8	Lung cancer in ever smokers;
TGCT	cis	rs7089973	0.604	rs11196924	chr10:116571796	A/C	cg03647239	chr10:116582469	FAM160B1	-0.56	-5.15	-0.42	9.97e-7	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs6546847	0.531	rs2567601	chr2:73985167	T/G	cg07208825	chr2:73871855	ALMS1P	0.29	5.27	0.43	5.73e-7	Urinary metabolites (H-NMR features);
TGCT	cis	rs763121	0.853	rs1056610	chr22:39080078	C/T	cg06022373	chr22:39101656	GTPBP1	-0.75	-7.78	-0.57	2.41e-12	Menopause (age at onset);
TGCT	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg15242686	chr22:24348715	GSTTP1	0.42	5.66	0.45	1.01e-7	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2637266	1.000	rs7905033	chr10:78368212	A/C	cg18941641	chr10:78392320	NA	0.4	4.69	0.39	6.99e-6	Pulmonary function;
TGCT	cis	rs9911578	1.000	rs6503870	chr17:56659018	C/T	cg05425664	chr17:57184151	TRIM37	-0.63	-6.26	-0.49	5.86e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs4273100	0.512	rs7502682	chr17:19295450	G/T	cg03910582	chr17:19030146	GRAPL	-0.45	-6.22	-0.49	6.97e-9	Schizophrenia;
TGCT	cis	rs950776	0.616	rs6495307	chr15:78890321	C/T	cg06917634	chr15:78832804	PSMA4	0.65	5.3	0.43	5.01e-7	Sudden cardiac arrest;
TGCT	cis	rs6598955	0.694	rs4659416	chr1:26580937	T/G	cg04990556	chr1:26633338	UBXN11	-0.91	-11.45	-0.72	3.65e-21	Obesity-related traits;
TGCT	cis	rs797680	0.856	rs12030549	chr1:93669218	T/C	cg17826107	chr1:92977322	EVI5	-0.24	-5.23	-0.42	7.05e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs17253792	0.822	rs74412558	chr14:56054311	C/T	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs7542091	0.748	rs2357231	chr1:210028454	A/C	cg21951975	chr1:209979733	IRF6	-0.44	-4.62	-0.38	9.39e-6	Monobrow;
TGCT	cis	rs4689592	0.503	rs56099074	chr4:7071259	A/G	cg25660036	chr4:7070649	GRPEL1	0.59	4.73	0.39	5.9e-6	Monocyte percentage of white cells;
TGCT	trans	rs877282	0.945	rs11253398	chr10:790012	T/C	cg22713356	chr15:30763199	NA	1.18	10.55	0.69	5.81e-19	Uric acid levels;
TGCT	cis	rs9534288	0.659	rs1581846	chr13:46650686	G/A	cg15192986	chr13:46630673	CPB2	-0.53	-6.66	-0.51	8.13e-10	Blood protein levels;
TGCT	cis	rs2229238	0.866	rs59741504	chr1:154504601	T/C	cg13067139	chr1:155221277	FAM189B	0.2	4.51	0.38	1.47e-5	Coronary heart disease;
TGCT	cis	rs4132509	0.739	rs10927033	chr1:243695539	C/A	cg21452805	chr1:244014465	NA	0.75	4.55	0.38	1.28e-5	RR interval (heart rate);
TGCT	cis	rs11264213	0.901	rs72661608	chr1:36333850	C/G	cg27506609	chr1:36549197	TEKT2	0.42	4.48	0.37	1.69e-5	Schizophrenia;
TGCT	cis	rs4767364	0.796	rs4767293	chr12:112463296	A/G	cg10833066	chr12:111807467	FAM109A	0.34	5.53	0.44	1.78e-7	Oral cavity and pharyngeal cancer;
TGCT	cis	rs7104764	1.000	rs7482591	chr11:245861	G/C	cg18336825	chr11:236787	PSMD13;SIRT3	1.07	11.19	0.71	1.61e-20	Menarche (age at onset);
TGCT	cis	rs9291683	0.551	rs2276961	chr4:10022981	C/T	cg11266682	chr4:10021025	SLC2A9	0.68	9.96	0.67	1.58e-17	Bone mineral density;
TGCT	cis	rs9916302	0.821	rs1966915	chr17:37425262	A/C	cg07936489	chr17:37558343	FBXL20	-0.62	-4.91	-0.4	2.77e-6	Glomerular filtration rate (creatinine);
TGCT	trans	rs877282	0.842	rs35872126	chr10:764545	G/A	cg22713356	chr15:30763199	NA	1.2	9.39	0.64	3.76e-16	Uric acid levels;
TGCT	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg06713675	chr4:122721982	EXOSC9	-0.68	-9.18	-0.64	1.23e-15	Type 2 diabetes;
TGCT	cis	rs7552404	0.924	rs3818855	chr1:76198785	C/T	cg10523679	chr1:76189770	ACADM	0.89	9.85	0.66	2.9e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9911578	0.967	rs7503190	chr17:57184162	A/C	cg05425664	chr17:57184151	TRIM37	-0.68	-6.9	-0.53	2.4e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs12579753	0.871	rs12822050	chr12:82183041	C/T	cg07988820	chr12:82153109	PPFIA2	-0.59	-6.19	-0.49	7.93e-9	Resting heart rate;
TGCT	cis	rs9527	0.615	rs3897401	chr10:104696379	T/C	cg15744005	chr10:104629667	AS3MT	-0.45	-5.31	-0.43	4.9e-7	Arsenic metabolism;
TGCT	cis	rs9894429	0.700	rs113915083	chr17:79552696	G/C	cg21028142	chr17:79581711	NPLOC4	-0.3	-6.96	-0.53	1.79e-10	Eye color traits;
TGCT	cis	rs7095607	0.967	rs3956959	chr10:69964861	T/C	cg18986048	chr10:69913749	MYPN	0.43	4.45	0.37	1.92e-5	Lung function (FVC);
TGCT	cis	rs2840044	1.000	rs1671656	chr17:33939661	C/T	cg05299278	chr17:33885742	SLFN14	0.23	5.07	0.41	1.38e-6	Response to radiotherapy in cancer (late toxicity);
TGCT	cis	rs11247915	0.600	rs3795686	chr1:26582091	G/A	cg23732845	chr1:26663426	AIM1L	-0.34	-4.5	-0.37	1.53e-5	Obesity-related traits;
TGCT	cis	rs11696501	0.688	rs4810465	chr20:44311354	A/G	cg11783356	chr20:44313418	WFDC10B	0.33	4.49	0.37	1.6e-5	Brain structure;
TGCT	cis	rs7819412	0.807	rs10105315	chr8:10932203	G/C	cg27411982	chr8:10470053	RP1L1	-0.21	-4.55	-0.38	1.24e-5	Triglycerides;
TGCT	cis	rs17076896	0.786	rs61956075	chr13:19931905	G/C	cg00777926	chr13:20807375	GJB6	-0.37	-4.51	-0.38	1.5e-5	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg04772025	chr11:68637568	NA	0.63	7.15	0.54	6.66e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg25427524	chr10:38739819	LOC399744	-0.39	-8.25	-0.6	2e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7772486	0.875	rs11155452	chr6:146424631	C/T	cg23711669	chr6:146136114	FBXO30	0.91	9.95	0.67	1.67e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2153535	0.525	rs1335644	chr6:8488041	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs9399137	0.507	rs7748708	chr6:135275142	G/A	cg24558204	chr6:135376177	HBS1L	0.49	4.96	0.41	2.24e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
TGCT	cis	rs6876348	0.598	rs2577539	chr5:128301211	A/G	cg25555059	chr5:128301488	SLC27A6	-0.29	-4.72	-0.39	6.18e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9902453	0.845	rs58575982	chr17:28221776	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	7.06	0.54	1.04e-10	Coffee consumption (cups per day);
TGCT	cis	rs4851254	0.517	rs13020141	chr2:100653842	G/A	cg22139774	chr2:100720529	AFF3	-0.45	-4.9	-0.4	2.94e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9911578	1.000	rs2531734	chr17:56550804	T/C	cg05425664	chr17:57184151	TRIM37	0.63	6.21	0.49	7.48e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs1538970	0.962	rs3219472	chr1:45804050	A/G	cg05343316	chr1:45956843	TESK2	-0.63	-5.06	-0.41	1.45e-6	Platelet count;
TGCT	cis	rs7666738	0.830	rs10001479	chr4:98918764	A/G	cg18180107	chr4:99064573	C4orf37	-0.53	-4.81	-0.4	4.28e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2153535	0.580	rs9393025	chr6:8490618	G/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs7178572	0.633	rs11854328	chr15:77840129	A/G	cg22256960	chr15:77711686	NA	-0.81	-7.65	-0.57	4.82e-12	Type 2 diabetes;
TGCT	cis	rs35146811	0.625	rs2906645	chr7:99817859	A/G	cg22906224	chr7:99728672	NA	-0.5	-4.51	-0.38	1.48e-5	Coronary artery disease;
TGCT	cis	rs7208859	0.524	rs60114476	chr17:29097667	A/T	cg13385521	chr17:29058706	SUZ12P	0.81	4.84	0.4	3.77e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7917772	0.619	rs2801050	chr10:104509393	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.66	5.42	0.44	2.94e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2439831	0.681	rs526450	chr15:43599325	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.94	6.62	0.51	9.66e-10	Lung cancer in ever smokers;
TGCT	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg07507251	chr3:52567010	NT5DC2	0.5	7.16	0.54	6.19e-11	Bipolar disorder;
TGCT	trans	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg27523141	chr10:43048294	ZNF37B	0.73	8.4	0.6	8.55e-14	Extrinsic epigenetic age acceleration;
TGCT	trans	rs208520	0.565	rs1385222	chr6:66753013	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.06	14.91	0.8	1.98e-29	Exhaled nitric oxide output;
TGCT	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg25036284	chr2:26402008	FAM59B	0.58	4.58	0.38	1.12e-5	Gut microbiome composition (summer);
TGCT	cis	rs2658782	0.950	rs2446061	chr11:93149277	C/T	cg15737290	chr11:93063684	CCDC67	0.82	5.67	0.45	9.52e-8	Pulmonary function decline;
TGCT	cis	rs3617	0.625	rs2336558	chr3:52886240	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	0.49	4.73	0.39	6.09e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg05368731	chr17:41323189	NBR1	1.17	13.8	0.78	7.84e-27	Menopause (age at onset);
TGCT	cis	rs2180341	0.960	rs9401952	chr6:127677027	A/C	cg24812749	chr6:127587940	RNF146	0.93	7.4	0.55	1.83e-11	Breast cancer;
TGCT	cis	rs1355223	0.583	rs2956074	chr11:34864880	T/C	cg11058730	chr11:34937778	PDHX;APIP	0.75	8.24	0.59	2.05e-13	Systemic lupus erythematosus and Systemic sclerosis;
TGCT	cis	rs6570726	0.791	rs418701	chr6:145889992	C/T	cg13319975	chr6:146136371	FBXO30	-0.5	-4.51	-0.38	1.48e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9640161	0.750	rs3735167	chr7:150039555	C/T	cg10018233	chr7:150070692	REPIN1	0.32	4.59	0.38	1.09e-5	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs8031584	0.697	rs798080	chr15:31122169	T/C	cg08109568	chr15:31115862	NA	0.39	5.22	0.42	7.26e-7	Huntington's disease progression;
TGCT	cis	rs7246657	0.722	rs2287229	chr19:38188652	G/A	cg18154014	chr19:37997991	ZNF793	-0.72	-5.06	-0.41	1.48e-6	Coronary artery calcification;
TGCT	cis	rs17270561	0.887	rs9358870	chr6:25719210	T/C	cg16482183	chr6:26056742	HIST1H1C	0.71	4.82	0.4	4.1e-6	Iron status biomarkers;
TGCT	cis	rs17376456	0.757	rs1031424	chr5:93139706	G/C	cg25358565	chr5:93447407	FAM172A	0.9	7.6	0.56	6.43e-12	Diabetic retinopathy;
TGCT	cis	rs2836950	0.501	rs11088470	chr21:40689162	A/G	cg11890956	chr21:40555474	PSMG1	-0.66	-6.24	-0.49	6.47e-9	Menarche (age at onset);
TGCT	trans	rs10504390	0.585	rs117486340	chr8:66542077	G/A	cg18118147	chr19:51128640	SYT3	-0.77	-6.85	-0.52	2.99e-10	IgG glycosylation;
TGCT	cis	rs6840360	0.967	rs10776524	chr4:152602585	G/A	cg17479576	chr4:152424074	FAM160A1	-0.52	-5.66	-0.45	9.86e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs6964587	1.000	rs12540565	chr7:91633213	T/G	cg17063962	chr7:91808500	NA	0.91	9.99	0.67	1.32e-17	Breast cancer;
TGCT	cis	rs7095607	0.693	rs7896727	chr10:69952376	C/T	cg18986048	chr10:69913749	MYPN	0.58	6.79	0.52	4.14e-10	Lung function (FVC);
TGCT	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg04025307	chr7:1156635	C7orf50	0.21	4.97	0.41	2.18e-6	Longevity;Endometriosis;
TGCT	cis	rs910316	1.000	rs12879542	chr14:75507525	C/T	cg11812906	chr14:75593930	NEK9	0.74	7.25	0.55	3.97e-11	Height;
TGCT	cis	rs34816374	1	rs34816374	chr6:26949672	A/G	cg16898833	chr6:26189333	HIST1H4D	1.28	6.15	0.48	9.89e-9	Lung cancer in ever smokers;
TGCT	cis	rs6060717	0.654	rs6060686	chr20:34512606	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.28	-4.69	-0.39	6.98e-6	Hip circumference adjusted for BMI;
TGCT	trans	rs8073060	0.586	rs226090	chr17:34034059	C/T	cg19694781	chr19:47549865	TMEM160	-0.61	-13.57	-0.77	2.84e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs9640161	0.789	rs1047207	chr7:150037660	A/G	cg10018233	chr7:150070692	REPIN1	0.33	4.95	0.41	2.4e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs3849570	0.961	rs11915042	chr3:81834060	G/A	cg07356753	chr3:81810745	GBE1	-0.82	-7.62	-0.56	5.6e-12	Waist circumference;Body mass index;
TGCT	cis	rs9633740	1.000	rs7900536	chr10:82253701	G/T	cg01528321	chr10:82214614	TSPAN14	1.03	8.56	0.61	3.66e-14	Post bronchodilator FEV1;
TGCT	cis	rs72781680	0.898	rs72780191	chr2:24007122	T/C	cg08917208	chr2:24149416	ATAD2B	0.93	5.84	0.46	4.22e-8	Lymphocyte counts;
TGCT	cis	rs1775715	0.966	rs1755067	chr10:32296195	C/T	cg14930904	chr10:32216787	ARHGAP12	-0.52	-4.87	-0.4	3.27e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs9303401	0.614	rs3803752	chr17:56540267	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.22	0.49	6.83e-9	Cognitive test performance;
TGCT	cis	rs13064411	0.696	rs3732803	chr3:113211957	T/C	cg18753928	chr3:113234510	CCDC52	-0.7	-5.64	-0.45	1.08e-7	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	trans	rs1814175	0.669	rs11040455	chr11:49669829	G/C	cg15704280	chr7:45808275	SEPT13	-0.61	-7.03	-0.53	1.23e-10	Height;
TGCT	cis	rs1670533	1.000	rs688785	chr4:1082707	G/C	cg27284194	chr4:1044797	NA	0.69	5.93	0.47	2.78e-8	Recombination rate (females);
TGCT	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg22535103	chr8:58192502	C8orf71	-0.35	-4.61	-0.38	1e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs56104184	0.830	rs73061617	chr19:49350984	G/A	cg21252483	chr19:49399788	TULP2	-0.43	-5.49	-0.44	2.2e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs9972944	0.756	rs11870607	chr17:63773122	A/G	cg07283582	chr17:63770753	CCDC46	0.26	5.05	0.41	1.53e-6	Total body bone mineral density;
TGCT	cis	rs12643440	0.538	rs981886	chr4:17136883	T/C	cg22650099	chr4:17144496	NA	-0.46	-4.66	-0.39	8.14e-6	Metabolite levels (Pyroglutamine);
TGCT	cis	rs526231	0.819	rs366437	chr5:102605601	T/C	cg05225461	chr5:102596755	C5orf30	0.23	4.62	0.38	9.51e-6	Primary biliary cholangitis;
TGCT	cis	rs7975161	0.786	rs10861181	chr12:104651110	T/C	cg25273343	chr12:104657179	TXNRD1	-0.34	-5.21	-0.42	7.61e-7	Toenail selenium levels;
TGCT	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs8031584	0.678	rs4779790	chr15:31164595	T/C	cg08704250	chr15:31115839	NA	-0.43	-6.31	-0.49	4.47e-9	Huntington's disease progression;
TGCT	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg13395646	chr4:1353034	KIAA1530	-0.48	-6.33	-0.49	4.16e-9	Obesity-related traits;
TGCT	cis	rs2439831	0.867	rs2245176	chr15:43750762	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.01	8.18	0.59	2.83e-13	Lung cancer in ever smokers;
TGCT	cis	rs4689388	0.791	rs1046317	chr4:6304242	T/C	cg14416269	chr4:6271139	WFS1	0.48	5.94	0.47	2.72e-8	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs473651	0.935	rs558924	chr2:239339511	A/G	cg18131467	chr2:239335373	ASB1	0.95	9.87	0.66	2.62e-17	Multiple system atrophy;
TGCT	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg23708337	chr7:1209742	NA	0.64	5.94	0.47	2.63e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs138229	0.506	rs9628282	chr22:50534952	G/T	cg16473166	chr22:50639996	SELO	0.58	4.81	0.4	4.38e-6	Behavioural disinhibition (generation interaction);
TGCT	cis	rs13217239	0.646	rs7451149	chr6:27057518	A/G	cg15659132	chr6:26577336	NA	-0.53	-5.31	-0.43	4.88e-7	Schizophrenia;
TGCT	cis	rs1401999	0.966	rs4148585	chr3:183670642	A/G	cg01324343	chr3:183735012	ABCC5	0.83	11.02	0.7	4.13e-20	Anterior chamber depth;
TGCT	cis	rs3772130	0.564	rs28620947	chr3:121585631	G/A	cg20356878	chr3:121714668	ILDR1	0.38	4.84	0.4	3.71e-6	Cognitive performance;
TGCT	cis	rs2739330	0.964	rs2739338	chr22:24297130	T/C	cg10819733	chr22:24237672	NA	-0.3	-5.01	-0.41	1.87e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs3806843	0.548	rs246052	chr5:140326413	G/A	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs526231	0.543	rs62362521	chr5:102306061	G/A	cg23492399	chr5:102201601	PAM	-0.53	-4.56	-0.38	1.23e-5	Primary biliary cholangitis;
TGCT	cis	rs11671005	0.735	rs12977592	chr19:58961056	C/G	cg13877915	chr19:58951672	ZNF132	0.59	5.04	0.41	1.58e-6	Mean platelet volume;
TGCT	cis	rs6815814	0.950	rs73236615	chr4:38786869	G/T	cg02016764	chr4:38805732	TLR1	-0.36	-5.46	-0.44	2.53e-7	Breast cancer;
TGCT	cis	rs7043114	0.544	rs12335553	chr9:95297871	A/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.53	-5.25	-0.43	6.26e-7	Height;
TGCT	cis	rs1215050	0.755	rs1238462	chr4:98850603	A/G	cg05340658	chr4:99064831	C4orf37	-0.47	-5.9	-0.47	3.18e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7267979	0.932	rs6037125	chr20:25463382	G/A	cg03522245	chr20:25566470	NINL	0.6	6.46	0.5	2.14e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6671200	1.000	rs62625008	chr1:95702582	A/G	cg03123541	chr1:95699097	RWDD3	0.91	6.4	0.5	2.93e-9	Stearic acid (18:0) levels;
TGCT	cis	rs2663905	1.000	rs2663905	chr15:81359137	G/A	cg09888468	chr15:81410853	NA	-0.66	-5.71	-0.46	8.06e-8	QT interval (drug interaction);
TGCT	cis	rs62244186	0.520	rs9311361	chr3:44796132	T/G	cg25151919	chr3:44754333	ZNF502	-0.48	-5.59	-0.45	1.38e-7	Depressive symptoms;
TGCT	cis	rs7552404	0.961	rs17587071	chr1:76225083	A/C	cg10523679	chr1:76189770	ACADM	0.92	9.51	0.65	1.94e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs669446	0.562	rs10890273	chr1:44186444	T/A	cg12908607	chr1:44402522	ARTN	-0.59	-6.47	-0.5	2.02e-9	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg01802117	chr1:53393560	SCP2	0.46	5.52	0.44	1.86e-7	Monocyte count;
TGCT	cis	rs72781680	0.898	rs55761273	chr2:23957849	A/G	cg08917208	chr2:24149416	ATAD2B	0.83	5.24	0.43	6.62e-7	Lymphocyte counts;
TGCT	cis	rs7412746	0.611	rs10888395	chr1:150762171	C/T	cg04414720	chr1:150670196	GOLPH3L	0.38	4.73	0.39	6.04e-6	Melanoma;
TGCT	cis	rs9814567	0.727	rs4543053	chr3:134351724	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-5.92	-0.47	2.97e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs2361718	0.501	rs11869566	chr17:78143248	T/C	cg09238746	chr17:78121135	EIF4A3	-1.06	-11.03	-0.7	3.89e-20	Yeast infection;
TGCT	cis	rs2224391	0.910	rs2875979	chr6:5275243	A/T	cg09085698	chr6:5261316	LYRM4;FARS2	0.74	4.79	0.4	4.58e-6	Height;
TGCT	cis	rs4822044	0.561	rs132781	chr22:42046122	T/G	cg06634786	chr22:41940651	POLR3H	0.86	7.82	0.57	1.92e-12	Cannabis dependence symptom count;
TGCT	cis	rs732765	1.000	rs59159639	chr14:75351106	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.65	-5.54	-0.45	1.7e-7	Non-small cell lung cancer;
TGCT	cis	rs651907	0.557	rs7651404	chr3:101393294	C/A	cg12386194	chr3:101231763	SENP7	0.53	5.13	0.42	1.08e-6	Colorectal cancer;
TGCT	cis	rs1532993	0.518	rs11097565	chr4:98569259	A/G	cg05340658	chr4:99064831	C4orf37	-0.42	-5.05	-0.41	1.57e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs1868673	0.737	rs10154963	chr3:150169559	C/T	cg24290546	chr3:150134309	TSC22D2	-0.23	-4.67	-0.39	7.69e-6	Waist circumference;
TGCT	cis	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg06697600	chr4:7070879	GRPEL1	-0.47	-4.94	-0.41	2.42e-6	Monocyte percentage of white cells;
TGCT	cis	rs3087591	0.960	rs2905869	chr17:29519016	C/A	cg24425628	chr17:29625626	OMG;NF1	0.48	7.29	0.55	3.25e-11	Hip circumference;
TGCT	cis	rs11105298	0.891	rs10777163	chr12:89830720	T/C	cg00757033	chr12:89920650	WDR51B	0.31	4.92	0.4	2.72e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	6.75	0.52	5.02e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6671200	1.000	rs60929805	chr1:95646386	C/T	cg03123541	chr1:95699097	RWDD3	0.87	6.17	0.48	8.81e-9	Stearic acid (18:0) levels;
TGCT	cis	rs6495367	1.000	rs4778634	chr15:79380822	C/T	cg17916960	chr15:79447300	NA	0.38	5.29	0.43	5.46e-7	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs7727544	0.684	rs274560	chr5:131719450	T/C	cg24060327	chr5:131705240	SLC22A5	0.61	6.85	0.52	3.12e-10	Blood metabolite levels;
TGCT	cis	rs2274273	0.682	rs1187876	chr14:55495199	A/T	cg01923255	chr14:55878535	KIAA0831	-0.55	-4.72	-0.39	6.29e-6	Protein biomarker;
TGCT	cis	rs4478858	0.735	rs6679393	chr1:31770944	T/C	cg07478791	chr1:31886160	SERINC2	-0.52	-5.03	-0.41	1.67e-6	Alcohol dependence;
TGCT	cis	rs881375	0.933	rs2239657	chr9:123671520	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.39	-4.54	-0.38	1.29e-5	Rheumatoid arthritis;
TGCT	cis	rs35146811	0.735	rs1727130	chr7:99811464	C/G	cg13334819	chr7:99746414	C7orf59	0.74	6.31	0.49	4.4e-9	Coronary artery disease;
TGCT	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg23248424	chr5:179741104	GFPT2	-0.38	-7.0	-0.53	1.43e-10	Height;
TGCT	cis	rs919433	0.679	rs55656916	chr2:198519628	T/C	cg00792783	chr2:198669748	PLCL1	0.55	4.88	0.4	3.24e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs11098499	0.789	rs1980024	chr4:120253047	C/T	cg09307838	chr4:120376055	NA	0.61	5.91	0.47	3.14e-8	Corneal astigmatism;
TGCT	cis	rs854765	0.583	rs4341796	chr17:17839024	C/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	7.91	0.58	1.2e-12	Total body bone mineral density;
TGCT	cis	rs5757676	1.000	rs5757676	chr22:39841700	T/C	cg05872129	chr22:39784769	NA	-0.92	-7.35	-0.55	2.38e-11	IgG glycosylation;
TGCT	cis	rs727563	0.594	rs5758408	chr22:42077737	A/C	cg17554472	chr22:41940697	POLR3H	0.49	5.22	0.42	7.4e-7	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs4689592	0.583	rs12501362	chr4:7083563	C/T	cg26116260	chr4:7069785	GRPEL1	-0.84	-7.8	-0.57	2.24e-12	Monocyte percentage of white cells;
TGCT	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.89	10.08	0.67	7.89e-18	Age at first birth;
TGCT	cis	rs2249625	0.564	rs2496496	chr6:72884053	A/G	cg08500200	chr6:72892038	RIMS1	-0.42	-4.54	-0.38	1.33e-5	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
TGCT	cis	rs208520	0.507	rs3903670	chr6:66812183	T/C	cg07460842	chr6:66804631	NA	-1.07	-15.45	-0.81	1.12e-30	Exhaled nitric oxide output;
TGCT	cis	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg02380750	chr20:61661411	NA	0.35	6.1	0.48	1.25e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1129187	0.702	rs2296805	chr6:42928758	T/G	cg02353165	chr6:42928485	GNMT	0.8	7.05	0.54	1.09e-10	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs9308731	0.644	rs3789061	chr2:111918230	T/C	cg04202892	chr2:111875749	ACOXL	0.55	6.46	0.5	2.1e-9	Chronic lymphocytic leukemia;
TGCT	cis	rs17665859	0.844	rs76478160	chr8:446900	G/C	cg17960703	chr8:356704	FBXO25	1.4	5.27	0.43	5.9e-7	Bilirubin levels;
TGCT	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg06675538	chr2:114033490	PAX8;LOC440839	-0.43	-4.75	-0.39	5.44e-6	Lymphocyte counts;
TGCT	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg10047753	chr17:41438598	NA	0.96	9.64	0.65	9.37e-17	Menopause (age at onset);
TGCT	cis	rs2439831	0.867	rs2920781	chr15:43924682	G/A	cg19166733	chr15:44192098	FRMD5	-0.24	-4.89	-0.4	3.08e-6	Lung cancer in ever smokers;
TGCT	cis	rs858239	0.600	rs6961131	chr7:23134790	A/G	cg05602783	chr7:23145260	KLHL7	-0.64	-5.37	-0.43	3.69e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs3862030	0.500	rs11191327	chr10:104303883	T/C	cg05855489	chr10:104503620	C10orf26	-0.58	-5.02	-0.41	1.73e-6	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
TGCT	cis	rs7208859	0.623	rs73269913	chr17:29092183	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs9354352	0.791	rs4710306	chr6:66700271	A/G	cg07460842	chr6:66804631	NA	-0.54	-5.39	-0.44	3.38e-7	Initial pursuit acceleration in psychotic disorders;
TGCT	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg20887711	chr4:1340912	KIAA1530	0.91	8.34	0.6	1.22e-13	Longevity;
TGCT	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg06221963	chr1:154839813	KCNN3	-0.73	-11.82	-0.73	4.65e-22	Prostate cancer;
TGCT	cis	rs7959452	0.536	rs4761237	chr12:69776461	C/G	cg20891283	chr12:69753455	YEATS4	0.83	8.7	0.62	1.68e-14	Blood protein levels;
TGCT	cis	rs904251	0.861	rs1757180	chr6:37486145	T/C	cg25019722	chr6:37503610	NA	-0.5	-6.94	-0.53	1.94e-10	Cognitive performance;
TGCT	cis	rs7771547	0.508	rs3798471	chr6:36499571	C/T	cg07856975	chr6:36356162	ETV7	0.21	4.66	0.39	7.92e-6	Platelet distribution width;
TGCT	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg10047753	chr17:41438598	NA	0.79	6.59	0.51	1.13e-9	Menopause (age at onset);
TGCT	cis	rs6546537	0.562	rs7565783	chr2:69750113	C/T	cg10773587	chr2:69614142	GFPT1	-0.85	-8.68	-0.61	1.93e-14	Serum thyroid-stimulating hormone levels;
TGCT	cis	rs10489202	0.632	rs3767476	chr1:168066940	C/T	cg24449463	chr1:168025552	DCAF6	-0.55	-5.73	-0.46	7.31e-8	Schizophrenia;
TGCT	cis	rs36229146	1	rs36229146	chr7:22784486	TTATATATAAATATATATATATATATA/T	cg26061582	chr7:22766209	IL6	0.57	7.24	0.54	4.22e-11	Eosinophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
TGCT	cis	rs7267979	0.932	rs13040655	chr20:25582197	C/T	cg14121845	chr20:25566513	NINL	0.5	5.21	0.42	7.6e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg08280861	chr8:58055591	NA	0.55	6.12	0.48	1.13e-8	Developmental language disorder (linguistic errors);
TGCT	cis	rs9796	0.553	rs1869908	chr15:41257224	C/A	cg26219294	chr15:41245916	CHAC1	-0.38	-4.53	-0.38	1.35e-5	Menopause (age at onset);
TGCT	cis	rs11190604	1.000	rs3750630	chr10:102275780	A/G	cg23241863	chr10:102295624	HIF1AN	0.7	5.39	0.44	3.36e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs72781680	1.000	rs55982282	chr2:24188128	G/A	cg08917208	chr2:24149416	ATAD2B	0.79	4.78	0.39	4.83e-6	Lymphocyte counts;
TGCT	cis	rs7523050	0.643	rs35885176	chr1:109401868	G/A	cg08274380	chr1:109419600	GPSM2	1.3	6.39	0.5	2.99e-9	Fat distribution (HIV);
TGCT	cis	rs7918232	0.941	rs788220	chr10:27447205	T/C	cg14442939	chr10:27389572	ANKRD26	-0.82	-5.76	-0.46	6.15e-8	Breast cancer;
TGCT	cis	rs9309473	0.519	rs13027816	chr2:73897691	C/T	cg20560298	chr2:73613845	ALMS1	0.41	4.51	0.38	1.46e-5	Metabolite levels;
TGCT	cis	rs7508	0.511	rs2237853	chr8:17877880	G/A	cg01800426	chr8:17659068	MTUS1	-0.68	-5.63	-0.45	1.14e-7	Atrial fibrillation;
TGCT	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg23302884	chr18:44338147	ST8SIA5	-0.41	-4.78	-0.39	4.89e-6	Personality dimensions;
TGCT	cis	rs11190604	0.697	rs4559619	chr10:102199884	C/T	cg16342193	chr10:102329863	NA	0.4	5.05	0.41	1.56e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs514406	0.525	rs269291	chr1:53189297	C/T	cg01802117	chr1:53393560	SCP2	-0.39	-4.44	-0.37	1.94e-5	Monocyte count;
TGCT	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg23283495	chr1:209979779	IRF6	-0.64	-5.55	-0.45	1.67e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs7917772	0.604	rs11191358	chr10:104399250	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-5.26	-0.43	6.16e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs6558530	0.692	rs6981804	chr8:1700284	C/A	cg09410841	chr8:1729607	CLN8	0.72	6.55	0.51	1.35e-9	Systolic blood pressure;
TGCT	cis	rs9467773	0.838	rs3734540	chr6:26463321	A/C	cg05738196	chr6:26577821	NA	0.68	7.66	0.57	4.58e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg03517284	chr6:25882590	NA	0.52	4.73	0.39	6.01e-6	Intelligence (multi-trait analysis);
TGCT	trans	rs10504390	0.656	rs74675840	chr8:66485845	G/A	cg18118147	chr19:51128640	SYT3	-0.77	-6.81	-0.52	3.71e-10	IgG glycosylation;
TGCT	cis	rs10197940	0.510	rs7557092	chr2:152423459	T/A	cg06191203	chr2:152266755	RIF1	-0.69	-6.36	-0.5	3.52e-9	Lung cancer;
TGCT	trans	rs4332037	0.624	rs58169303	chr7:1883274	T/C	cg25206134	chr2:45395956	NA	0.92	7.78	0.57	2.44e-12	Bipolar disorder;
TGCT	cis	rs9303542	0.559	rs2326012	chr17:46618581	C/T	cg25032089	chr17:46643351	HOXB3	0.56	5.34	0.43	4.33e-7	Ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs72781680	0.898	rs6545127	chr2:24060670	C/T	cg08917208	chr2:24149416	ATAD2B	0.76	4.83	0.4	3.97e-6	Lymphocyte counts;
TGCT	cis	rs509477	1.000	rs509477	chr18:32559295	C/G	cg23791764	chr18:32556832	MAPRE2	0.59	4.83	0.4	3.9e-6	Cerebrospinal fluid AB1-42 levels;
TGCT	cis	rs4820539	0.966	rs2267001	chr22:23456696	T/C	cg14186256	chr22:23484241	RTDR1	1.0	12.28	0.74	3.58e-23	Bone mineral density;
TGCT	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg01171360	chr6:293285	DUSP22	-0.78	-7.98	-0.58	8.31e-13	Menopause (age at onset);
TGCT	cis	rs10779751	0.770	rs6701524	chr1:11198502	A/G	cg08854313	chr1:11322531	MTOR	-0.82	-6.66	-0.51	7.99e-10	Body mass index;
TGCT	cis	rs2816062	0.965	rs2816061	chr1:18903819	A/G	cg18795169	chr1:18902165	NA	0.57	12.57	0.75	7.15e-24	Urate levels in lean individuals;
TGCT	cis	rs1056107	0.931	rs10759538	chr9:114996327	A/C	cg02332936	chr9:115140584	NA	-0.25	-4.44	-0.37	1.96e-5	Colorectal cancer;
TGCT	cis	rs587847	0.597	rs17542178	chr15:37711776	G/T	cg00216138	chr15:37171175	LOC145845	0.31	4.71	0.39	6.53e-6	Intraocular pressure;
TGCT	cis	rs2228479	0.541	rs9922515	chr16:89954138	G/C	cg06558623	chr16:89946397	TCF25	0.39	4.85	0.4	3.56e-6	Skin colour saturation;
TGCT	cis	rs36051895	0.632	rs10974982	chr9:5149382	G/C	cg02405213	chr9:5042618	JAK2	-0.75	-9.81	-0.66	3.74e-17	Pediatric autoimmune diseases;
TGCT	cis	rs7666738	0.618	rs10856932	chr4:98819992	C/T	cg17366294	chr4:99064904	C4orf37	0.7	7.45	0.56	1.42e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1729951	0.575	rs1654923	chr3:136692620	A/T	cg12473912	chr3:136751656	NA	0.39	6.18	0.49	8.36e-9	Neuroticism;
TGCT	trans	rs1814175	0.817	rs2866863	chr11:49953242	C/T	cg03929089	chr4:120376271	NA	-0.72	-8.53	-0.61	4.24e-14	Height;
TGCT	cis	rs748404	0.660	rs518288	chr15:43763999	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	4.77	0.39	5.05e-6	Lung cancer;
TGCT	cis	rs6489882	0.548	rs15895	chr12:113448288	A/G	cg04001726	chr12:112547043	NAA25	-0.44	-4.45	-0.37	1.91e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs12477438	0.520	rs6542869	chr2:99783403	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	16.87	0.83	6.81e-34	Chronic sinus infection;
TGCT	cis	rs28735056	0.935	rs72980082	chr18:77630170	G/T	cg20368463	chr18:77673604	PQLC1	-0.45	-5.55	-0.45	1.65e-7	Schizophrenia;
TGCT	cis	rs3753275	0.568	rs7533113	chr1:8813243	C/T	cg17029193	chr1:8510607	RERE	-0.29	-4.48	-0.37	1.66e-5	Educational attainment;
TGCT	cis	rs7666738	0.830	rs1534319	chr4:98964804	T/C	cg17366294	chr4:99064904	C4orf37	0.74	7.56	0.56	7.89e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6690583	0.943	rs1837329	chr1:85469614	G/A	cg22153463	chr1:85462885	MCOLN2	-0.65	-4.47	-0.37	1.71e-5	Serum sulfate level;
TGCT	cis	rs796364	0.951	rs281769	chr2:200809709	T/C	cg17644776	chr2:200775616	C2orf69	0.31	4.85	0.4	3.58e-6	Schizophrenia;
TGCT	cis	rs1865760	0.963	rs9356991	chr6:25901758	C/A	cg16482183	chr6:26056742	HIST1H1C	0.55	4.97	0.41	2.19e-6	Height;
TGCT	trans	rs561341	0.663	rs72821936	chr17:30224068	C/G	cg20587970	chr11:113659929	NA	-0.58	-8.79	-0.62	1.04e-14	Hip circumference adjusted for BMI;
TGCT	trans	rs62103177	0.525	rs4283293	chr18:77759582	A/G	cg05926928	chr17:57297772	GDPD1	-0.76	-6.89	-0.53	2.48e-10	Opioid sensitivity;
TGCT	cis	rs7169223	0.653	rs2904228	chr15:79086099	G/A	cg03762349	chr15:79060523	ADAMTS7	0.25	4.92	0.4	2.68e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
TGCT	cis	rs877282	0.898	rs12359731	chr10:759497	A/G	cg17470449	chr10:769945	NA	0.31	4.87	0.4	3.28e-6	Uric acid levels;
TGCT	cis	rs7582180	0.629	rs12989897	chr2:100940998	A/G	cg08017756	chr2:100939284	LONRF2	-0.3	-4.87	-0.4	3.27e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg07747251	chr5:1868357	NA	0.36	5.12	0.42	1.12e-6	Cardiovascular disease risk factors;
TGCT	cis	rs941873	0.900	rs7092536	chr10:81131332	A/C	cg09469691	chr10:81107165	PPIF	0.56	5.42	0.44	3.05e-7	Height;
TGCT	cis	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg18252515	chr7:66147081	NA	-1.27	-7.73	-0.57	3.17e-12	Diabetic kidney disease;
TGCT	cis	rs12220898	0.568	rs4838376	chr10:50482048	T/C	cg25968469	chr10:49687287	ARHGAP22	0.25	4.47	0.37	1.78e-5	Inflammatory biomarkers;
TGCT	cis	rs6840360	0.615	rs58977077	chr4:152470239	T/G	cg17479576	chr4:152424074	FAM160A1	-0.72	-7.98	-0.58	8.25e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs13256369	0.774	rs13260303	chr8:8587342	A/C	cg17143192	chr8:8559678	CLDN23	0.57	4.87	0.4	3.39e-6	Obesity-related traits;
TGCT	cis	rs7618915	1.000	rs7618915	chr3:52279594	G/A	cg10802521	chr3:52805072	NEK4	-0.5	-5.3	-0.43	5.1e-7	Bipolar disorder;
TGCT	cis	rs11112613	0.762	rs73184077	chr12:105949999	G/A	cg03607813	chr12:105948248	NA	0.52	6.0	0.47	2.03e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	cis	rs1997103	1.000	rs10263552	chr7:55404747	C/T	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs58950470	0.521	rs7950197	chr11:65446126	T/C	cg17480646	chr11:65405466	SIPA1	-0.41	-5.12	-0.42	1.14e-6	Schizophrenia;
TGCT	cis	rs60843830	1.000	rs56321614	chr2:268191	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.72	7.27	0.55	3.56e-11	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs78487399	0.808	rs79955955	chr2:43686985	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-5.06	-0.41	1.48e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg26818010	chr10:134567672	INPP5A	-0.39	-5.36	-0.43	3.97e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs2153535	0.505	rs1737583	chr6:8536812	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.67	0.45	9.45e-8	Motion sickness;
TGCT	cis	rs6570726	0.577	rs399502	chr6:145805874	A/G	cg05347473	chr6:146136440	FBXO30	0.62	5.75	0.46	6.64e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6728642	1.000	rs7593754	chr2:97607544	C/T	cg26665480	chr2:98280029	ACTR1B	-0.9	-5.45	-0.44	2.65e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	cis	rs2178146	0.535	rs17266666	chr16:86448832	T/G	cg11165158	chr16:86613094	FOXL1	0.35	4.67	0.39	7.79e-6	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Esophageal adenocarcinoma;
TGCT	cis	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg07424592	chr7:64974309	NA	1.4	8.42	0.6	7.87e-14	Diabetic kidney disease;
TGCT	cis	rs7226408	0.857	rs2162389	chr18:34437033	C/A	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs7729723	0.556	rs13167336	chr5:137816101	G/C	cg19169342	chr5:137827400	NA	0.32	4.67	0.39	7.63e-6	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);
TGCT	cis	rs1008375	0.863	rs2058336	chr4:17608299	T/C	cg16339924	chr4:17578868	LAP3	0.64	5.22	0.42	7.4e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	trans	rs11722228	1.000	rs6823877	chr4:9921931	T/C	cg26043149	chr18:55253948	FECH	-0.74	-7.51	-0.56	9.93e-12	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs736408	0.562	rs1014969	chr3:52808341	G/A	cg07507251	chr3:52567010	NT5DC2	0.52	6.94	0.53	1.98e-10	Bipolar disorder;
TGCT	cis	rs12908161	0.959	rs17534709	chr15:85314397	G/C	cg11189052	chr15:85197271	WDR73	0.7	5.66	0.45	9.77e-8	Schizophrenia;
TGCT	cis	rs17401966	0.838	rs4333852	chr1:10387704	A/T	cg19773385	chr1:10388646	KIF1B	0.24	5.52	0.44	1.92e-7	Hepatocellular carcinoma;
TGCT	cis	rs4862307	0.836	rs4862304	chr4:184996607	C/T	cg06737308	chr4:185021514	ENPP6	0.32	4.58	0.38	1.1e-5	Serum dimethylarginine levels (asymmetric/symetric ratio);
TGCT	cis	rs308403	0.509	rs309357	chr4:123653576	G/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.81	11.07	0.71	3.09e-20	Blood protein levels;
TGCT	cis	rs7698623	0.850	rs4693895	chr4:88797839	C/T	cg02735620	chr4:88950514	PKD2	-0.44	-4.81	-0.4	4.22e-6	Cardiovascular disease risk factors;
TGCT	cis	rs9916302	0.610	rs11078902	chr17:37631883	C/G	cg07936489	chr17:37558343	FBXL20	-0.61	-4.79	-0.39	4.73e-6	Glomerular filtration rate (creatinine);
TGCT	trans	rs561341	1.000	rs554078	chr17:30330109	A/C	cg20587970	chr11:113659929	NA	-1.04	-12.57	-0.75	6.97e-24	Hip circumference adjusted for BMI;
TGCT	cis	rs6671200	1.000	rs34396223	chr1:95697828	C/T	cg03123541	chr1:95699097	RWDD3	0.91	6.4	0.5	2.93e-9	Stearic acid (18:0) levels;
TGCT	cis	rs73001065	0.786	rs72999033	chr19:19366632	C/T	cg03709012	chr19:19516395	GATAD2A	1.25	5.53	0.44	1.82e-7	LDL cholesterol;
TGCT	cis	rs9674544	0.740	rs11870560	chr17:47114033	T/C	cg07075026	chr17:47091521	IGF2BP1	-0.45	-4.64	-0.38	8.84e-6	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
TGCT	cis	rs7100689	0.577	rs2185427	chr10:82056667	G/T	cg01528321	chr10:82214614	TSPAN14	-0.68	-6.63	-0.51	9.17e-10	Post bronchodilator FEV1;
TGCT	cis	rs138880	0.542	rs9616215	chr22:50318834	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.18	-5.98	-0.47	2.2e-8	Schizophrenia;
TGCT	cis	rs7666738	0.830	rs28785514	chr4:98959135	G/A	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2594989	0.733	rs2616539	chr3:11580371	C/A	cg00170343	chr3:11313890	ATG7	0.66	5.15	0.42	9.89e-7	Circulating chemerin levels;
TGCT	cis	rs3008870	1.000	rs12039172	chr1:67447450	A/G	cg03991309	chr1:68237761	GNG12	-0.27	-4.53	-0.38	1.36e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs3793917	0.901	rs36212733	chr10:124215211	T/C	cg09507567	chr10:124027408	NA	0.4	4.85	0.4	3.6e-6	Age-related macular degeneration;
TGCT	trans	rs7726839	0.794	rs10053310	chr5:595661	C/G	cg11887960	chr12:57824829	NA	0.95	7.37	0.55	2.12e-11	Obesity-related traits;
TGCT	cis	rs7267979	0.789	rs6083810	chr20:25329759	T/A	cg03522245	chr20:25566470	NINL	-0.52	-5.23	-0.43	6.85e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6840360	0.642	rs7677131	chr4:152353015	T/C	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.83e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7178572	1.000	rs12904938	chr15:77721225	A/G	cg15453836	chr15:77711506	NA	-0.39	-4.49	-0.37	1.62e-5	Type 2 diabetes;
TGCT	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg07167872	chr1:205819463	PM20D1	0.67	9.75	0.66	5.09e-17	Menarche (age at onset);
TGCT	cis	rs4654899	0.680	rs10799670	chr1:21179445	T/C	cg01072550	chr1:21505969	NA	0.54	8.72	0.62	1.54e-14	Superior frontal gyrus grey matter volume;
TGCT	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg07157834	chr1:205819609	PM20D1	0.52	9.21	0.64	1.02e-15	Menarche (age at onset);
TGCT	cis	rs2204008	0.744	rs8189486	chr12:38244968	C/T	cg13010199	chr12:38710504	ALG10B	0.64	5.01	0.41	1.85e-6	Bladder cancer;
TGCT	cis	rs3125734	0.633	rs4979754	chr10:64048959	G/A	cg09941381	chr10:64027924	RTKN2	-0.33	-4.94	-0.41	2.51e-6	Rheumatoid arthritis;
TGCT	cis	rs7786808	0.741	rs35059736	chr7:158224692	C/T	cg01191920	chr7:158217561	PTPRN2	-0.39	-5.89	-0.47	3.32e-8	Obesity-related traits;
TGCT	cis	rs790110	1.000	rs60226894	chr3:122384152	C/T	cg07366462	chr3:123162899	ADCY5	0.42	4.71	0.39	6.54e-6	Acoustic startle blink response;
TGCT	cis	rs765787	0.530	rs55771002	chr15:45541566	T/C	cg24006582	chr15:45444508	DUOX1	-0.25	-5.54	-0.45	1.76e-7	Uric acid levels;
TGCT	cis	rs4523957	0.620	rs9894215	chr17:2070698	G/A	cg16513277	chr17:2031491	SMG6	-0.2	-4.46	-0.37	1.8e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs10206020	0.921	rs4072986	chr2:1547734	C/G	cg01028140	chr2:1542097	TPO	-0.32	-4.65	-0.39	8.2e-6	IgG glycosylation;
TGCT	cis	rs9916302	0.904	rs10491128	chr17:37551988	G/A	cg07936489	chr17:37558343	FBXL20	0.62	4.78	0.39	4.9e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7647973	0.626	rs4855849	chr3:49653378	A/G	cg05785598	chr3:49045655	WDR6	0.42	5.24	0.43	6.67e-7	Menarche (age at onset);
TGCT	cis	rs7681440	0.626	rs6812593	chr4:90817991	C/T	cg10208370	chr4:90758469	SNCA	-0.57	-5.41	-0.44	3.05e-7	Dementia with Lewy bodies;
TGCT	cis	rs28595532	0.841	rs56388366	chr4:119769242	A/G	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs6424115	0.830	rs6663474	chr1:24199642	G/A	cg15997130	chr1:24165203	NA	0.85	9.25	0.64	8.02e-16	Immature fraction of reticulocytes;
TGCT	cis	rs4727027	0.933	rs4725800	chr7:148862516	C/G	cg23583168	chr7:148888333	NA	-0.76	-10.09	-0.67	7.46e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs6598955	0.543	rs57564009	chr1:26557618	A/T	cg04990556	chr1:26633338	UBXN11	0.81	7.43	0.55	1.56e-11	Obesity-related traits;
TGCT	cis	rs13191362	0.935	rs66507030	chr6:162953825	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.67	5.16	0.42	9.64e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs10479542	0.806	rs4700835	chr5:178976313	A/G	cg09060608	chr5:178986726	RUFY1	0.47	5.25	0.43	6.34e-7	Lung cancer;
TGCT	cis	rs826838	0.868	rs864324	chr12:39122853	A/G	cg13010199	chr12:38710504	ALG10B	0.56	4.51	0.38	1.51e-5	Heart rate;
TGCT	cis	rs8033133	0.957	rs7162559	chr15:25352341	C/T	cg14481604	chr15:25334117	SNORD116-22	0.3	6.27	0.49	5.57e-9	Blood osmolality (transformed sodium);
TGCT	cis	rs12142240	0.698	rs56130131	chr1:46861306	A/C	cg14993813	chr1:46806288	NSUN4	-0.59	-4.86	-0.4	3.45e-6	Menopause (age at onset);
TGCT	cis	rs57590327	0.555	rs2053805	chr3:81738414	T/C	cg07356753	chr3:81810745	GBE1	-0.78	-7.36	-0.55	2.18e-11	Extraversion;
TGCT	cis	rs6669919	1.000	rs6669919	chr1:211674383	T/C	cg26515805	chr1:211431828	RCOR3	-0.4	-4.72	-0.39	6.33e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7727544	0.716	rs4594848	chr5:131586598	C/A	cg24060327	chr5:131705240	SLC22A5	-0.56	-5.45	-0.44	2.58e-7	Blood metabolite levels;
TGCT	cis	rs9814567	1.000	rs7648990	chr3:134244390	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.95	-9.55	-0.65	1.56e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs63406760	1	rs63406760	chr12:123742692	TG/T	cg00376283	chr12:123451042	ABCB9	0.72	5.54	0.45	1.76e-7	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs11690462	0.895	rs11686204	chr2:26600226	G/A	cg04726446	chr2:26624865	C2orf39	0.43	4.66	0.39	8.15e-6	Coronary artery disease;
TGCT	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg05872129	chr22:39784769	NA	-1.01	-11.68	-0.72	1.05e-21	Intelligence (multi-trait analysis);
TGCT	cis	rs804280	1.000	rs804280	chr8:11612698	G/T	cg02840367	chr8:11660030	FDFT1	-0.59	-4.67	-0.39	7.57e-6	Myopia (pathological);
TGCT	cis	rs11122272	0.735	rs2808602	chr1:231537303	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-6.5	-0.5	1.77e-9	Hemoglobin concentration;
TGCT	cis	rs12530845	1.000	rs12540688	chr7:135329690	T/C	cg23117316	chr7:135346802	PL-5283	-0.51	-4.83	-0.4	3.98e-6	Red blood cell traits;
TGCT	cis	rs806215	0.951	rs327516	chr7:127255795	C/G	cg25922125	chr7:127225783	GCC1	0.6	6.26	0.49	5.75e-9	Type 2 diabetes;
TGCT	cis	rs4851254	0.660	rs58683655	chr2:100686519	G/C	cg07810366	chr2:100720526	AFF3	-0.49	-5.22	-0.42	7.36e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg03760483	chr17:6899297	ALOX12	0.45	5.36	0.43	3.87e-7	Tonsillectomy;
TGCT	cis	rs9325144	0.534	rs4882283	chr12:38710249	C/T	cg26384229	chr12:38710491	ALG10B	0.7	6.61	0.51	1.02e-9	Morning vs. evening chronotype;
TGCT	cis	rs6770219	0.516	rs56228685	chr3:186140644	C/T	cg20306810	chr3:186501757	SNORD2;EIF4A2	0.73	4.46	0.37	1.81e-5	Cerebrospinal T-tau levels;
TGCT	cis	rs9926296	0.632	rs7206546	chr16:89799079	C/T	cg26513180	chr16:89883248	FANCA	-0.68	-6.62	-0.51	9.49e-10	Vitiligo;
TGCT	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg19635926	chr16:89946313	TCF25	0.28	4.8	0.4	4.47e-6	Skin colour saturation;
TGCT	cis	rs2153535	0.580	rs6914276	chr6:8450435	A/T	cg23788917	chr6:8435910	SLC35B3	-0.61	-5.61	-0.45	1.23e-7	Motion sickness;
TGCT	cis	rs11098499	0.505	rs75122014	chr4:120362426	G/C	cg09307838	chr4:120376055	NA	0.68	6.53	0.51	1.54e-9	Corneal astigmatism;
TGCT	cis	rs7666738	0.546	rs28444809	chr4:98916934	C/T	cg17366294	chr4:99064904	C4orf37	0.65	5.98	0.47	2.24e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9393777	0.513	rs13215020	chr6:26656073	G/A	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.53	-4.88	-0.4	3.19e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7647973	1.000	rs7644148	chr3:49545241	G/A	cg05785598	chr3:49045655	WDR6	-0.38	-4.5	-0.37	1.57e-5	Menarche (age at onset);
TGCT	cis	rs7772486	0.875	rs12194437	chr6:146411440	A/G	cg23711669	chr6:146136114	FBXO30	0.91	9.95	0.67	1.67e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs8068544	0.748	rs75881902	chr17:40156612	C/A	cg13092355	chr17:39992602	KLHL10;NT5C3L	-0.95	-4.55	-0.38	1.24e-5	Reticulocyte fraction of red cells;Reticulocyte count;
TGCT	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-6.54	-0.51	1.42e-9	Alzheimer's disease;
TGCT	trans	rs4650994	1.000	rs10913568	chr1:178513411	C/T	cg05059571	chr16:84539110	KIAA1609	-0.42	-7.74	-0.57	3.02e-12	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs2832191	0.740	rs2832168	chr21:30463695	G/A	cg08807101	chr21:30365312	RNF160	0.66	6.18	0.49	8.49e-9	Dental caries;
TGCT	cis	rs4689388	0.750	rs10001190	chr4:6284633	C/T	cg00701064	chr4:6280414	WFS1	-0.39	-5.01	-0.41	1.79e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs9303401	0.659	rs34351230	chr17:56782555	C/A	cg25039879	chr17:56429692	SUPT4H1	0.52	4.62	0.38	9.48e-6	Cognitive test performance;
TGCT	cis	rs6933660	0.646	rs9383899	chr6:151781022	G/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.49	4.68	0.39	7.39e-6	Menarche (age at onset);
TGCT	cis	rs2594989	0.943	rs2244617	chr3:11503097	T/C	cg26283222	chr3:11613257	VGLL4	-0.21	-4.49	-0.37	1.58e-5	Circulating chemerin levels;
TGCT	cis	rs2227564	0.620	rs11000785	chr10:75575963	T/C	cg19442545	chr10:75533431	FUT11	-0.31	-4.48	-0.37	1.65e-5	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.7	-0.39	6.79e-6	Prudent dietary pattern;
TGCT	cis	rs10503709	0.581	rs17580809	chr8:21409341	A/G	cg21031128	chr8:21771278	DOK2	-0.27	-4.54	-0.38	1.29e-5	Blood protein levels;
TGCT	cis	rs11779988	0.500	rs208023	chr8:17878882	G/A	cg08627089	chr8:17753878	FGL1	-0.28	-4.5	-0.37	1.55e-5	Breast cancer;
TGCT	cis	rs79349575	0.687	rs12602179	chr17:47010034	G/T	cg26022315	chr17:47021804	SNF8	0.49	4.9	0.4	2.94e-6	Type 2 diabetes;
TGCT	cis	rs6598955	0.627	rs12143920	chr1:26575834	A/G	cg04990556	chr1:26633338	UBXN11	0.62	4.73	0.39	6.12e-6	Obesity-related traits;
TGCT	cis	rs1008375	0.966	rs3733581	chr4:17695206	C/G	cg10189774	chr4:17578691	LAP3	-0.55	-4.56	-0.38	1.19e-5	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs736408	1.000	rs736408	chr3:52835354	C/T	cg10802521	chr3:52805072	NEK4	-0.65	-7.19	-0.54	5.37e-11	Bipolar disorder;
TGCT	cis	rs1008375	0.966	rs3775923	chr4:17585625	T/C	cg16339924	chr4:17578868	LAP3	0.83	7.21	0.54	4.92e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg08280861	chr8:58055591	NA	0.4	4.73	0.39	5.97e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6032067	0.516	rs761367	chr20:43913317	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.37	-5.93	-0.47	2.79e-8	Blood protein levels;
TGCT	cis	rs17376456	1.000	rs59472588	chr5:93511981	A/G	cg21475434	chr5:93447410	FAM172A	0.62	4.55	0.38	1.28e-5	Diabetic retinopathy;
TGCT	cis	rs8180040	0.966	rs2101247	chr3:47494303	G/A	cg27129171	chr3:47204927	SETD2	-0.65	-7.68	-0.57	4.2e-12	Colorectal cancer;
TGCT	cis	rs3780378	0.682	rs7861763	chr9:5273194	C/T	cg02405213	chr9:5042618	JAK2	-0.54	-6.85	-0.52	3.01e-10	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs981844	0.890	rs62325115	chr4:154694847	A/G	cg14289246	chr4:154710475	SFRP2	1.05	9.32	0.64	5.44e-16	Response to statins (LDL cholesterol change);
TGCT	cis	rs12681287	0.752	rs12681438	chr8:87293089	G/A	cg27223183	chr8:87520930	FAM82B	-0.82	-5.86	-0.47	3.98e-8	Caudate activity during reward;
TGCT	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg10802521	chr3:52805072	NEK4	-0.76	-9.36	-0.64	4.51e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs4722166	0.630	rs7781534	chr7:22778592	A/C	cg26061582	chr7:22766209	IL6	0.57	7.36	0.55	2.27e-11	Lung cancer;
TGCT	cis	rs1406084	0.636	rs10167490	chr2:154718155	T/C	cg25703346	chr2:154729189	GALNT13	0.77	4.6	0.38	1.03e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9372498	0.536	rs62663261	chr6:118900553	T/C	cg07617317	chr6:118971624	C6orf204	0.49	5.19	0.42	8.37e-7	Diastolic blood pressure;
TGCT	cis	rs9611565	0.592	rs6519270	chr22:42078666	A/G	cg03806693	chr22:41940476	POLR3H	1.0	10.29	0.68	2.52e-18	Vitiligo;
TGCT	cis	rs910316	0.737	rs175049	chr14:75481368	C/T	cg11812906	chr14:75593930	NEK9	-0.59	-5.59	-0.45	1.38e-7	Height;
TGCT	cis	rs9393777	0.513	rs3999471	chr6:26650306	T/C	cg15659132	chr6:26577336	NA	-0.75	-5.25	-0.43	6.33e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs11711311	1.000	rs34475696	chr3:113458293	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.78	-7.13	-0.54	7.14e-11	IgG glycosylation;
TGCT	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.48	-4.64	-0.38	8.55e-6	Bipolar disorder;
TGCT	cis	rs5769765	0.908	rs9616370	chr22:50306316	A/G	cg26441486	chr22:50317300	CRELD2	-0.28	-4.45	-0.37	1.92e-5	Schizophrenia;
TGCT	cis	rs1129187	0.702	rs2395943	chr6:42940673	A/G	cg10862848	chr6:42927986	GNMT	-0.37	-4.47	-0.37	1.75e-5	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs9522267	0.535	rs9522298	chr13:112234457	C/A	cg10483660	chr13:112241077	NA	-0.27	-4.61	-0.38	9.78e-6	Hepatitis;
TGCT	cis	rs1670533	0.932	rs13108207	chr4:1054218	C/T	cg27284194	chr4:1044797	NA	0.67	5.98	0.47	2.21e-8	Recombination rate (females);
TGCT	trans	rs3780486	0.505	rs10813959	chr9:33166234	C/T	cg04842962	chr6:43655489	MRPS18A	-0.81	-8.78	-0.62	1.1e-14	IgG glycosylation;
TGCT	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	8.55	0.61	3.84e-14	Platelet count;
TGCT	cis	rs10751667	0.643	rs10902237	chr11:944801	C/A	cg06064525	chr11:970664	AP2A2	-0.35	-8.09	-0.59	4.54e-13	Alzheimer's disease (late onset);
TGCT	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg06028808	chr11:68637592	NA	0.52	6.84	0.52	3.18e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9916302	0.904	rs4357971	chr17:37717280	C/T	cg07936489	chr17:37558343	FBXL20	-0.61	-4.87	-0.4	3.29e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs6543140	0.964	rs2080288	chr2:103022166	G/A	cg09003973	chr2:102972529	NA	0.56	4.7	0.39	6.84e-6	Blood protein levels;
TGCT	cis	rs4253772	0.591	rs6008384	chr22:46655948	T/C	cg09491104	chr22:46646882	C22orf40	-0.65	-6.6	-0.51	1.05e-9	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg10802521	chr3:52805072	NEK4	-0.79	-10.32	-0.68	2.06e-18	Bipolar disorder;
TGCT	cis	rs854765	0.583	rs2350977	chr17:17802779	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.74	7.73	0.57	3.24e-12	Total body bone mineral density;
TGCT	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg06873352	chr17:61820015	STRADA	0.55	6.13	0.48	1.09e-8	Prudent dietary pattern;
TGCT	cis	rs6671200	0.920	rs7555236	chr1:95631314	G/A	cg03123541	chr1:95699097	RWDD3	0.87	6.17	0.48	8.81e-9	Stearic acid (18:0) levels;
TGCT	cis	rs9611519	1.000	rs2057070	chr22:41564287	T/C	cg13695892	chr22:41940480	POLR3H	-0.5	-4.51	-0.38	1.5e-5	Neuroticism;
TGCT	cis	rs4819052	0.684	rs914216	chr21:46698298	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	7.02	0.53	1.27e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs79349575	0.783	rs318096	chr17:46975370	G/A	cg26022315	chr17:47021804	SNF8	0.49	4.89	0.4	3.04e-6	Type 2 diabetes;
TGCT	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg21285383	chr16:89894308	SPIRE2	0.42	6.61	0.51	1.01e-9	Vitiligo;
TGCT	cis	rs2456568	0.803	rs10831141	chr11:93640728	C/T	cg16099599	chr11:93583650	C11orf90	-0.4	-4.87	-0.4	3.38e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs3008870	1.000	rs2755240	chr1:67477339	T/G	cg03991309	chr1:68237761	GNG12	0.26	4.46	0.37	1.83e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs829418	0.901	rs947334	chr1:21938897	A/G	cg04260293	chr1:22924330	EPHA8	0.35	4.45	0.37	1.88e-5	Neurocognitive impairment in HIV-1 infection (continuous);
TGCT	cis	rs7179456	0.547	rs6494036	chr15:59015961	A/T	cg05156742	chr15:59063176	FAM63B	0.51	5.05	0.41	1.52e-6	Asperger disorder;
TGCT	cis	rs425277	0.958	rs262688	chr1:2113565	T/G	cg03732007	chr1:2071316	PRKCZ	0.25	5.27	0.43	5.86e-7	Height;
TGCT	cis	rs7226408	0.857	rs59634585	chr18:34437032	T/C	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs9486719	0.857	rs1157316	chr6:96869710	G/A	cg06623918	chr6:96969491	KIAA0776	1.03	10.94	0.7	6.47e-20	Migraine;Coronary artery disease;
TGCT	cis	rs1532993	0.518	rs28874284	chr4:98616319	T/A	cg05340658	chr4:99064831	C4orf37	-0.41	-4.96	-0.41	2.3e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg18402987	chr7:1209562	NA	0.74	6.21	0.49	7.23e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs10782582	0.609	rs1796815	chr1:76396793	T/G	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.54	4.64	0.38	8.58e-6	Daytime sleep phenotypes;
TGCT	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg24060327	chr5:131705240	SLC22A5	-0.77	-8.17	-0.59	3.05e-13	Breast cancer;
TGCT	cis	rs8180040	0.966	rs34634681	chr3:47579102	G/A	cg27129171	chr3:47204927	SETD2	-0.64	-7.34	-0.55	2.41e-11	Colorectal cancer;
TGCT	cis	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg25427524	chr10:38739819	LOC399744	-0.39	-8.04	-0.59	5.95e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs6500602	0.701	rs4785968	chr16:4535307	T/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.43	6.45	0.5	2.24e-9	Schizophrenia;
TGCT	cis	rs16957091	0.647	rs28494835	chr15:43281391	C/T	cg17935677	chr15:44119062	WDR76	0.53	4.74	0.39	5.73e-6	MGMT methylation in smokers;
TGCT	cis	rs6500602	0.701	rs4786500	chr16:4525265	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	-0.3	-5.32	-0.43	4.76e-7	Schizophrenia;
TGCT	cis	rs7246657	0.943	rs4417644	chr19:37852472	A/G	cg18154014	chr19:37997991	ZNF793	0.97	6.49	0.5	1.82e-9	Coronary artery calcification;
TGCT	cis	rs2730245	0.645	rs4909282	chr7:158699797	T/C	cg11984989	chr7:158649758	WDR60	1.07	10.3	0.68	2.36e-18	Height;
TGCT	trans	rs1496653	0.602	rs13076412	chr3:23554950	T/C	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg11494091	chr17:61959527	GH2	0.61	14.49	0.79	1.92e-28	Prudent dietary pattern;
TGCT	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg24531977	chr5:56204891	C5orf35	-0.77	-7.61	-0.56	5.83e-12	Initial pursuit acceleration;
TGCT	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg18876405	chr7:65276391	NA	0.38	5.89	0.47	3.32e-8	Calcium levels;
TGCT	cis	rs644799	1.000	rs593665	chr11:95574302	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	9.9	0.66	2.27e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs10892173	0.678	rs4537790	chr11:117661356	A/G	cg21640587	chr11:117668038	DSCAML1	0.47	4.97	0.41	2.18e-6	Myopia;
TGCT	cis	rs1670533	0.769	rs6814833	chr4:1057679	A/C	cg20887711	chr4:1340912	KIAA1530	0.68	5.25	0.43	6.4e-7	Recombination rate (females);
TGCT	cis	rs11809207	1.000	rs55695238	chr1:26521931	C/G	cg03844060	chr1:26490628	NA	0.25	4.62	0.38	9.44e-6	Height;
TGCT	cis	rs2760061	0.626	rs672907	chr1:228120345	G/A	cg18477163	chr1:228402036	OBSCN	-0.32	-6.37	-0.5	3.31e-9	Diastolic blood pressure;
TGCT	cis	rs9443645	0.901	rs1960542	chr6:79566643	C/T	cg05283184	chr6:79620031	NA	-0.21	-4.71	-0.39	6.66e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7954584	0.520	rs1169094	chr12:122465535	A/G	cg13699009	chr12:122356056	WDR66	-0.22	-4.59	-0.38	1.05e-5	Mean corpuscular volume;
TGCT	cis	rs9467711	0.516	rs501220	chr6:25873025	C/A	cg12310025	chr6:25882481	NA	-0.75	-5.0	-0.41	1.88e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs10782582	0.532	rs78106188	chr1:76137836	A/G	cg10523679	chr1:76189770	ACADM	-0.69	-7.16	-0.54	6.4e-11	Daytime sleep phenotypes;
TGCT	cis	rs6495122	0.699	rs4886410	chr15:75065644	G/C	cg13906792	chr15:75199810	C15orf17	-0.22	-4.5	-0.37	1.55e-5	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
TGCT	cis	rs4499344	0.696	rs2868154	chr19:33099305	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	8.54	0.61	4.15e-14	Mean platelet volume;
TGCT	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg03264133	chr6:25882463	NA	-0.66	-6.11	-0.48	1.19e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs11955175	1.000	rs112239156	chr5:40649478	A/C	cg17351974	chr5:40835760	RPL37	0.76	4.8	0.4	4.43e-6	Bipolar disorder and schizophrenia;
TGCT	trans	rs4332037	0.950	rs62442895	chr7:1936938	G/A	cg10840412	chr1:235813424	GNG4	1.04	8.16	0.59	3.22e-13	Bipolar disorder;
TGCT	cis	rs798766	1.000	rs1665362	chr4:1726367	T/A	cg05874882	chr4:1763078	NA	-0.36	-4.87	-0.4	3.27e-6	Bladder cancer;Urinary bladder cancer;
TGCT	cis	rs12142240	0.698	rs7548675	chr1:46809321	C/G	cg00530320	chr1:46809349	NSUN4	0.29	5.88	0.47	3.63e-8	Menopause (age at onset);
TGCT	cis	rs10791097	0.720	rs4936121	chr11:130733878	A/G	cg14779329	chr11:130786720	SNX19	0.31	5.09	0.42	1.31e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs2153535	0.580	rs6938071	chr6:8464845	A/T	cg07606381	chr6:8435919	SLC35B3	0.55	5.16	0.42	9.35e-7	Motion sickness;
TGCT	cis	rs62064224	0.589	rs2041306	chr17:30665675	T/C	cg18200150	chr17:30822561	MYO1D	0.39	4.58	0.38	1.09e-5	Schizophrenia;
TGCT	cis	rs7635838	0.596	rs4684765	chr3:11261085	G/C	cg00170343	chr3:11313890	ATG7	0.65	6.15	0.48	9.62e-9	HDL cholesterol;
TGCT	cis	rs709400	1.000	rs861531	chr14:104172807	C/A	cg26031613	chr14:104095156	KLC1	1.13	16.72	0.83	1.42e-33	Body mass index;
TGCT	cis	rs1008375	0.932	rs4698628	chr4:17608620	A/G	cg16339924	chr4:17578868	LAP3	0.64	5.22	0.42	7.4e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs174601	0.864	rs174545	chr11:61569306	C/G	cg19610905	chr11:61596333	FADS2	-1.09	-11.84	-0.73	4.21e-22	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
TGCT	cis	rs13217239	0.646	rs2142685	chr6:27054497	C/T	cg26531700	chr6:26746687	NA	-0.68	-6.72	-0.52	5.79e-10	Schizophrenia;
TGCT	cis	rs7267979	0.932	rs6138588	chr20:25487523	C/T	cg03522245	chr20:25566470	NINL	0.6	6.46	0.5	2.14e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs910316	0.967	rs2268619	chr14:75640354	C/G	cg11812906	chr14:75593930	NEK9	-0.73	-6.79	-0.52	4.1e-10	Height;
TGCT	cis	rs1729951	0.575	rs361241	chr3:136699561	C/A	cg21827317	chr3:136751795	NA	0.4	5.61	0.45	1.28e-7	Neuroticism;
TGCT	cis	rs7677751	0.806	rs7673853	chr4:55096606	T/C	cg17187183	chr4:55093834	PDGFRA	0.53	6.92	0.53	2.19e-10	Corneal astigmatism;
TGCT	cis	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg21775007	chr8:11205619	TDH	-0.46	-4.49	-0.37	1.64e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg06238570	chr21:40685208	BRWD1	0.68	6.32	0.49	4.3e-9	Cognitive function;
TGCT	cis	rs9916302	0.808	rs12947281	chr17:37652210	G/T	cg07936489	chr17:37558343	FBXL20	-0.62	-4.91	-0.4	2.85e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs10992471	0.603	rs12336415	chr9:95195458	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.62	-5.94	-0.47	2.62e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs7216064	1.000	rs62084249	chr17:65874998	A/G	cg12091567	chr17:66097778	LOC651250	-0.83	-6.49	-0.5	1.9e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs7552404	0.691	rs5745449	chr1:76344711	A/T	cg10523679	chr1:76189770	ACADM	-0.83	-7.8	-0.57	2.24e-12	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs1997103	1.000	rs2331065	chr7:55408392	A/G	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs1215050	0.740	rs1084777	chr4:99017542	C/T	cg05340658	chr4:99064831	C4orf37	-0.41	-4.99	-0.41	1.95e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg18252515	chr7:66147081	NA	-1.2	-7.16	-0.54	6.16e-11	Diabetic kidney disease;
TGCT	cis	rs208520	0.661	rs851466	chr6:66840476	A/G	cg07460842	chr6:66804631	NA	-0.92	-9.58	-0.65	1.29e-16	Exhaled nitric oxide output;
TGCT	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.41	7.12	0.54	7.77e-11	Schizophrenia;
TGCT	cis	rs9916302	0.861	rs7503514	chr17:37669884	G/C	cg15445000	chr17:37608096	MED1	0.32	4.66	0.39	8.18e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs2439831	0.850	rs28413881	chr15:44174099	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	6.16	0.48	9.29e-9	Lung cancer in ever smokers;
TGCT	cis	rs60843830	0.661	rs6755432	chr2:106692	T/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.63	5.58	0.45	1.41e-7	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs1075232	0.826	rs12438813	chr15:31705913	C/T	cg01030201	chr15:31746330	NA	-1.01	-5.26	-0.43	6.07e-7	Survival in colorectal cancer (non-distant metastatic);
TGCT	cis	rs6570726	0.905	rs430248	chr6:145874104	A/G	cg23711669	chr6:146136114	FBXO30	0.71	7.03	0.53	1.25e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1372520	0.748	rs1471484	chr4:90754313	C/T	cg14346243	chr4:90757452	SNCA	-0.65	-5.37	-0.43	3.8e-7	Neuroticism;
TGCT	cis	rs3617	0.573	rs56383738	chr3:52908398	T/C	cg10802521	chr3:52805072	NEK4	0.56	6.3	0.49	4.72e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg08736216	chr1:53307985	ZYG11A	-0.24	-4.89	-0.4	3e-6	Monocyte count;
TGCT	cis	rs6500602	0.701	rs8053770	chr16:4539030	T/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.42	6.28	0.49	5.18e-9	Schizophrenia;
TGCT	cis	rs904251	0.797	rs2776878	chr6:37487273	G/A	cg25019722	chr6:37503610	NA	-0.51	-7.03	-0.53	1.24e-10	Cognitive performance;
TGCT	cis	rs6500602	0.592	rs4785966	chr16:4518754	C/T	cg08645402	chr16:4508243	NA	-0.22	-5.17	-0.42	9e-7	Schizophrenia;
TGCT	cis	rs12579753	0.833	rs12579530	chr12:82163930	A/C	cg07988820	chr12:82153109	PPFIA2	-0.67	-7.61	-0.56	5.92e-12	Resting heart rate;
TGCT	cis	rs908922	0.676	rs526099	chr1:152497811	T/C	cg20991723	chr1:152506922	NA	0.46	6.28	0.49	5.26e-9	Hair morphology;
TGCT	cis	rs36051895	0.632	rs12337904	chr9:5144606	C/G	cg02405213	chr9:5042618	JAK2	-0.72	-10.05	-0.67	9.59e-18	Pediatric autoimmune diseases;
TGCT	cis	rs8062405	0.789	rs240704	chr16:28529949	T/C	cg09754948	chr16:28834200	ATXN2L	0.56	4.46	0.37	1.78e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs7394190	0.748	rs4114992	chr10:75566829	A/G	cg07699608	chr10:75541558	CHCHD1	0.79	5.44	0.44	2.72e-7	Incident atrial fibrillation;
TGCT	cis	rs4466137	0.830	rs6886442	chr5:82973210	A/C	cg16102102	chr5:83017553	HAPLN1	0.8	8.55	0.61	3.86e-14	Prostate cancer;
TGCT	cis	rs986417	0.901	rs8020084	chr14:61001495	C/T	cg27398547	chr14:60952738	C14orf39	1.52	9.5	0.65	2.04e-16	Gut microbiota (bacterial taxa);
TGCT	cis	rs644799	0.965	rs10831430	chr11:95509638	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	10.82	0.7	1.31e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	trans	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg21659725	chr3:3221576	CRBN	-0.99	-15.57	-0.81	5.76e-31	Intelligence (multi-trait analysis);
TGCT	cis	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg09021430	chr5:549028	NA	-0.45	-6.13	-0.48	1.08e-8	Obesity-related traits;
TGCT	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg01238044	chr22:24384105	GSTT1	0.49	4.64	0.38	8.71e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	trans	rs9951602	0.512	rs1599636	chr18:76643916	G/A	cg02800362	chr5:177631904	HNRNPAB	1.13	12.94	0.76	9.39e-25	Obesity-related traits;
TGCT	cis	rs6977955	0.877	rs9648346	chr7:28160113	C/G	cg23620719	chr7:28220237	JAZF1	0.65	4.95	0.41	2.36e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs1903068	0.785	rs10020668	chr4:55996903	C/T	cg01777861	chr4:56023843	NA	0.53	6.17	0.48	8.85e-9	Endometriosis;
TGCT	cis	rs9467711	0.516	rs1324087	chr6:25841408	A/G	cg03517284	chr6:25882590	NA	0.73	4.85	0.4	3.62e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9611565	0.512	rs964899	chr22:42142386	G/A	cg06481639	chr22:41940642	POLR3H	0.67	5.82	0.46	4.74e-8	Vitiligo;
TGCT	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg04772025	chr11:68637568	NA	0.6	6.67	0.51	7.4e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs4499344	0.664	rs7258278	chr19:33099523	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	8.81	0.62	9.52e-15	Mean platelet volume;
TGCT	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg19729930	chr2:74357872	NA	0.51	6.1	0.48	1.24e-8	Gestational age at birth (maternal effect);
TGCT	cis	rs7647973	0.731	rs13084037	chr3:49214066	G/A	cg07636037	chr3:49044803	WDR6	0.65	4.84	0.4	3.75e-6	Menarche (age at onset);
TGCT	trans	rs1814175	0.529	rs10839396	chr11:49852406	G/T	cg03929089	chr4:120376271	NA	0.62	6.79	0.52	4.07e-10	Height;
TGCT	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg03806693	chr22:41940476	POLR3H	-1.09	-12.4	-0.74	1.86e-23	Vitiligo;
TGCT	cis	rs7439150	0.954	rs4681	chr4:155490832	C/T	cg22130008	chr4:155548532	NA	-0.51	-6.18	-0.49	8.4e-9	Fibrinogen levels;
TGCT	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg10295955	chr4:187884368	NA	-0.97	-14.76	-0.8	4.41e-29	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs950169	0.723	rs17589320	chr15:84919996	C/A	cg11189052	chr15:85197271	WDR73	0.83	6.67	0.51	7.71e-10	Schizophrenia;
TGCT	cis	rs2692947	0.696	rs2576437	chr2:96800417	T/C	cg23100626	chr2:96804247	ASTL	0.41	5.06	0.41	1.46e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs7819412	1.000	rs7819412	chr8:11045161	A/G	cg21775007	chr8:11205619	TDH	0.51	4.88	0.4	3.2e-6	Triglycerides;
TGCT	cis	rs9926296	0.586	rs1800359	chr16:89805261	A/G	cg26513180	chr16:89883248	FANCA	0.71	6.93	0.53	2.07e-10	Vitiligo;
TGCT	cis	rs7681440	0.904	rs6816305	chr4:90772902	C/G	cg20003494	chr4:90757398	SNCA	-0.59	-5.52	-0.44	1.9e-7	Dementia with Lewy bodies;
TGCT	cis	rs11690935	0.885	rs6727017	chr2:172766847	T/A	cg13550731	chr2:172543902	DYNC1I2	-0.92	-8.36	-0.6	1.11e-13	Schizophrenia;
TGCT	cis	rs6570726	0.599	rs9403725	chr6:145897622	A/T	cg05347473	chr6:146136440	FBXO30	-0.62	-5.73	-0.46	7.35e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2235642	0.750	rs763152	chr16:1658056	T/C	cg00463982	chr16:1583984	IFT140;TMEM204	-0.27	-4.56	-0.38	1.22e-5	Coronary artery disease;
TGCT	cis	rs6831352	0.918	rs29001209	chr4:100052340	C/A	cg12011299	chr4:100065546	ADH4	-0.41	-4.92	-0.4	2.72e-6	Alcohol dependence;
TGCT	cis	rs13188771	0.690	rs164621	chr5:100873520	A/G	cg18665594	chr5:101119420	NA	0.44	4.46	0.37	1.83e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs7845219	0.544	rs4735332	chr8:95923660	C/T	cg16049864	chr8:95962084	TP53INP1	-0.48	-5.25	-0.43	6.29e-7	Type 2 diabetes;
TGCT	cis	rs10791097	0.547	rs12365680	chr11:130749059	C/T	cg05962950	chr11:130786565	SNX19	0.93	12.26	0.74	3.95e-23	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9926296	0.712	rs447735	chr16:89734349	T/C	cg01097406	chr16:89675127	NA	0.35	6.09	0.48	1.29e-8	Vitiligo;
TGCT	cis	rs919433	0.679	rs61155920	chr2:198528881	C/T	cg00792783	chr2:198669748	PLCL1	0.55	4.88	0.4	3.24e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.24	-0.43	6.7e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs75059851	0.756	rs11223654	chr11:133841579	C/T	cg14047540	chr11:133829660	NA	-0.55	-5.45	-0.44	2.57e-7	Schizophrenia;
TGCT	cis	rs6964587	1.000	rs61244255	chr7:91751662	C/T	cg22709100	chr7:91322751	NA	0.29	4.69	0.39	6.98e-6	Breast cancer;
TGCT	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg06481639	chr22:41940642	POLR3H	0.73	6.49	0.5	1.83e-9	Vitiligo;
TGCT	cis	rs1045714	0.836	rs73033691	chr7:2636522	T/G	cg17215154	chr7:2644645	IQCE	0.29	5.12	0.42	1.12e-6	Urate levels in lean individuals;
TGCT	cis	rs6570726	0.967	rs439017	chr6:145806123	T/C	cg23711669	chr6:146136114	FBXO30	0.64	6.08	0.48	1.37e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs61990749	0.597	rs2112136	chr14:78248952	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	0.6	4.45	0.37	1.88e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs7104764	0.957	rs3829998	chr11:230751	A/G	cg18336825	chr11:236787	PSMD13;SIRT3	1.05	10.79	0.7	1.48e-19	Menarche (age at onset);
TGCT	cis	rs2675609	0.647	rs2675595	chr10:63616669	A/C	cg10604396	chr10:64577901	EGR2	0.47	4.45	0.37	1.91e-5	Serum total protein level;
TGCT	cis	rs922182	0.556	rs10851734	chr15:64216247	C/T	cg02919090	chr15:64263738	DAPK2	-0.37	-6.77	-0.52	4.69e-10	Blood protein levels;
TGCT	cis	rs10927875	0.541	rs1763607	chr1:16337509	G/A	cg22431228	chr1:16359049	CLCNKA	-0.29	-5.97	-0.47	2.33e-8	Dilated cardiomyopathy;
TGCT	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg12756686	chr19:29218302	NA	0.68	6.39	0.5	3.07e-9	Methadone dose in opioid dependence;
TGCT	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg06221963	chr1:154839813	KCNN3	-0.75	-12.65	-0.75	4.66e-24	Prostate cancer;
TGCT	cis	rs12134245	0.776	rs13447526	chr1:91983174	A/G	cg07090678	chr1:91966139	CDC7	-0.37	-5.05	-0.41	1.56e-6	Breast cancer;
TGCT	cis	rs7804356	1.000	rs10267950	chr7:26826757	T/A	cg03456212	chr7:26904342	SKAP2	-0.64	-4.88	-0.4	3.16e-6	Type 1 diabetes;
TGCT	cis	rs7937682	0.889	rs542424	chr11:111477698	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.04	-11.09	-0.71	2.89e-20	Primary sclerosing cholangitis;
TGCT	cis	rs3820928	0.874	rs1917122	chr2:227835681	C/T	cg11843606	chr2:227700838	RHBDD1	-0.52	-4.58	-0.38	1.1e-5	Pulmonary function;
TGCT	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs617219	0.671	rs13165414	chr5:78548873	C/T	cg09550809	chr5:78407562	BHMT	0.37	5.24	0.43	6.65e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs6539288	0.589	rs1037013	chr12:107219308	A/G	cg15890332	chr12:107067104	RFX4	0.23	4.7	0.39	6.84e-6	Total body bone mineral density;
TGCT	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg00343986	chr7:65444356	GUSB	-0.2	-4.51	-0.38	1.51e-5	Aortic root size;
TGCT	cis	rs2204008	0.702	rs3849999	chr12:38483498	G/A	cg26384229	chr12:38710491	ALG10B	-0.54	-4.79	-0.4	4.57e-6	Bladder cancer;
TGCT	cis	rs11190604	1.000	rs10883505	chr10:102280772	C/T	cg16342193	chr10:102329863	NA	-0.42	-5.37	-0.43	3.74e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs12142240	0.698	rs12385697	chr1:46818898	T/C	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs7666738	0.830	rs17558151	chr4:99048699	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.49	0.56	1.11e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2180341	0.883	rs6904630	chr6:127696869	A/G	cg27446573	chr6:127587934	RNF146	1.16	10.52	0.69	6.95e-19	Breast cancer;
TGCT	cis	rs6977660	0.714	rs10228783	chr7:19789290	C/T	cg07541023	chr7:19748670	TWISTNB	0.83	4.69	0.39	7.01e-6	Thyroid stimulating hormone;
TGCT	trans	rs9467711	1.000	rs9467701	chr6:26312170	G/C	cg20516262	chr7:155325649	CNPY1	0.54	6.63	0.51	9.34e-10	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.18	0.49	8.32e-9	Electroencephalogram traits;
TGCT	cis	rs9796	0.621	rs58109657	chr15:41471750	A/G	cg18705301	chr15:41695430	NDUFAF1	0.52	7.17	0.54	5.94e-11	Menopause (age at onset);
TGCT	cis	rs9436747	0.803	rs1751490	chr1:66007430	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.5	4.86	0.4	3.51e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg11062466	chr8:58055876	NA	0.38	4.62	0.38	9.5e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg18876405	chr7:65276391	NA	0.33	4.97	0.41	2.13e-6	Aortic root size;
TGCT	cis	rs7819412	0.678	rs11991716	chr8:10948575	A/T	cg27411982	chr8:10470053	RP1L1	-0.22	-4.58	-0.38	1.11e-5	Triglycerides;
TGCT	cis	rs7949030	0.591	rs35880596	chr11:62369884	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.7	8.76	0.62	1.26e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs12048904	0.619	rs12239082	chr1:101330077	G/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.67	-5.76	-0.46	6.18e-8	Multiple sclerosis;
TGCT	cis	rs9291683	0.546	rs12504565	chr4:10045145	G/A	cg00071950	chr4:10020882	SLC2A9	0.57	6.47	0.5	2.01e-9	Bone mineral density;
TGCT	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg27170947	chr2:26402098	FAM59B	-0.39	-4.46	-0.37	1.8e-5	Gut microbiome composition (summer);
TGCT	cis	rs9653442	0.628	rs12474386	chr2:100857017	G/A	cg07810366	chr2:100720526	AFF3	-0.42	-6.52	-0.51	1.62e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs28595532	0.920	rs114314373	chr4:119639128	G/A	cg14228332	chr4:119757509	SEC24D	1.04	5.37	0.43	3.66e-7	Cannabis dependence symptom count;
TGCT	cis	rs4819852	0.958	rs9606204	chr22:19976510	C/A	cg07821417	chr22:19972146	ARVCF	0.19	4.79	0.4	4.7e-6	Pulse pressure;
TGCT	cis	rs7107174	1.000	rs7104222	chr11:78007169	G/A	cg12700464	chr11:78128424	GAB2	-0.68	-4.64	-0.38	8.71e-6	Testicular germ cell tumor;
TGCT	cis	rs9467773	1.000	rs1321481	chr6:26538210	A/T	cg05738196	chr6:26577821	NA	0.88	12.5	0.75	1.03e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs4595586	0.546	rs11169801	chr12:39241429	G/A	cg26384229	chr12:38710491	ALG10B	0.65	5.29	0.43	5.43e-7	Morning vs. evening chronotype;
TGCT	cis	rs7826238	0.535	rs2979179	chr8:8320029	C/T	cg06636001	chr8:8085503	FLJ10661	0.79	7.37	0.55	2.1e-11	Systolic blood pressure;
TGCT	cis	rs4595586	0.545	rs12815047	chr12:39380901	A/G	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs35146811	0.695	rs1727132	chr7:99812297	T/C	cg13334819	chr7:99746414	C7orf59	0.74	6.31	0.49	4.4e-9	Coronary artery disease;
TGCT	cis	rs7786808	0.544	rs6971888	chr7:158193835	G/A	cg01191920	chr7:158217561	PTPRN2	0.36	5.26	0.43	6.23e-7	Obesity-related traits;
TGCT	cis	rs6671200	0.831	rs9659908	chr1:95656127	C/T	cg03123541	chr1:95699097	RWDD3	0.87	6.17	0.48	8.81e-9	Stearic acid (18:0) levels;
TGCT	cis	rs7267979	1.000	rs34645895	chr20:25368373	A/G	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs711245	0.670	rs7560321	chr2:36822318	C/G	cg15105969	chr2:36825350	FEZ2	-0.61	-6.07	-0.48	1.43e-8	Height;
TGCT	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg03303774	chr4:1407052	NA	0.29	4.67	0.39	7.71e-6	Obesity-related traits;
TGCT	cis	rs35771425	0.536	rs6656860	chr1:211620805	A/G	cg26515805	chr1:211431828	RCOR3	-0.44	-5.09	-0.42	1.27e-6	Educational attainment (years of education);
TGCT	cis	rs9467773	0.620	rs2504566	chr6:26660488	G/C	cg15659132	chr6:26577336	NA	0.87	10.72	0.69	2.19e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg00814883	chr7:100076585	TSC22D4	-0.85	-8.62	-0.61	2.62e-14	Platelet count;
TGCT	cis	rs17221829	0.965	rs10830359	chr11:89455444	A/G	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.66	-0.39	7.9e-6	Anxiety in major depressive disorder;
TGCT	cis	rs2847281	0.614	rs2847262	chr18:12775295	T/G	cg23598886	chr18:12777645	NA	0.37	4.69	0.39	7.07e-6	C-reactive protein levels;Esophageal cancer (squamous cell);
TGCT	cis	rs896854	0.654	rs13274945	chr8:95986626	C/T	cg23172400	chr8:95962367	TP53INP1	-0.36	-6.14	-0.48	1.04e-8	Type 2 diabetes;
TGCT	cis	rs950169	1.000	rs79318564	chr15:84786150	G/A	cg17173187	chr15:85201210	NMB	0.51	5.6	0.45	1.3e-7	Schizophrenia;
TGCT	cis	rs2288278	0.601	rs12450225	chr17:46592413	A/G	cg25032089	chr17:46643351	HOXB3	-0.42	-5.0	-0.41	1.87e-6	Hand grip strength;
TGCT	cis	rs2439831	0.850	rs524417	chr15:43772374	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.98	7.72	0.57	3.37e-12	Lung cancer in ever smokers;
TGCT	cis	rs5769707	0.642	rs4824070	chr22:50031521	T/C	cg05373962	chr22:49881684	NA	-0.31	-5.28	-0.43	5.72e-7	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs10465746	0.725	rs4907185	chr1:84336047	T/C	cg10977910	chr1:84465055	TTLL7	0.68	6.7	0.52	6.46e-10	Obesity-related traits;
TGCT	cis	rs4824093	0.610	rs3761496	chr22:50246466	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.48	4.93	0.41	2.53e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs7635838	0.617	rs367745	chr3:11309274	T/C	cg00170343	chr3:11313890	ATG7	0.63	6.19	0.49	7.96e-9	HDL cholesterol;
TGCT	cis	rs36051895	0.555	rs6476953	chr9:5248742	C/T	cg02405213	chr9:5042618	JAK2	-0.7	-8.98	-0.63	3.67e-15	Pediatric autoimmune diseases;
TGCT	cis	rs7824557	0.583	rs4448232	chr8:11231354	G/T	cg21775007	chr8:11205619	TDH	0.69	6.99	0.53	1.46e-10	Retinal vascular caliber;
TGCT	cis	rs3858526	0.959	rs10838901	chr11:5959128	G/A	cg13902645	chr11:5959945	NA	-0.44	-4.72	-0.39	6.39e-6	DNA methylation (variation);
TGCT	cis	rs2404602	0.716	rs7164060	chr15:76707694	T/C	cg22467129	chr15:76604101	ETFA	-0.59	-7.13	-0.54	7.33e-11	Blood metabolite levels;
TGCT	cis	rs9467711	0.591	rs41266779	chr6:26021872	C/T	cg16898833	chr6:26189333	HIST1H4D	1.34	6.07	0.48	1.47e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg11644478	chr21:40555479	PSMG1	-0.63	-5.92	-0.47	2.95e-8	Cognitive function;
TGCT	cis	rs11792861	0.890	rs57387569	chr9:111920392	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.48	4.49	0.37	1.63e-5	Menarche (age at onset);
TGCT	cis	rs1475911	0.708	rs56185023	chr21:43521538	T/C	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.31	-5.88	-0.47	3.64e-8	IgG glycosylation;
TGCT	cis	rs7914558	0.505	rs12260436	chr10:104741114	A/C	cg04362960	chr10:104952993	NT5C2	0.64	5.33	0.43	4.48e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs4919669	0.777	rs12415043	chr10:104467609	C/G	cg05855489	chr10:104503620	C10orf26	-0.71	-4.5	-0.37	1.57e-5	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs77106637	1.000	rs11605166	chr11:72669777	T/C	cg03713592	chr11:72463424	ARAP1	0.79	5.13	0.42	1.09e-6	Type 2 diabetes;
TGCT	trans	rs17685	0.784	rs1637043	chr7:75699099	G/A	cg19862616	chr7:65841803	NCRNA00174	0.51	8.59	0.61	3.07e-14	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs265548	0.586	rs265542	chr19:17904388	T/G	cg03316864	chr19:17906309	B3GNT3	0.43	5.0	0.41	1.88e-6	Tumor biomarkers;
TGCT	cis	rs7909074	1.000	rs10900128	chr10:45393201	G/T	cg04218760	chr10:45406644	TMEM72	-0.27	-5.55	-0.45	1.64e-7	Mean corpuscular volume;
TGCT	cis	rs7666738	0.791	rs7684521	chr4:99071219	A/G	cg17366294	chr4:99064904	C4orf37	0.74	7.42	0.55	1.63e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4803468	1.000	rs4803463	chr19:41911040	C/G	cg09537434	chr19:41945824	ATP5SL	-0.92	-10.69	-0.69	2.72e-19	Height;
TGCT	cis	rs9430161	0.579	rs6696575	chr1:11037136	G/A	cg27631724	chr1:11040367	C1orf127	0.54	6.28	0.49	5.3300000000000004e-09	Ewing sarcoma;
TGCT	cis	rs1008375	0.800	rs28754811	chr4:17612312	C/T	cg18681998	chr4:17616180	MED28	1.0	10.67	0.69	3.01e-19	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2288278	0.619	rs10853100	chr17:46602432	T/C	cg25032089	chr17:46643351	HOXB3	-0.42	-5.0	-0.41	1.89e-6	Hand grip strength;
TGCT	cis	rs4803468	1.000	rs2569754	chr19:41936734	A/G	cg09537434	chr19:41945824	ATP5SL	-0.91	-10.05	-0.67	9.48e-18	Height;
TGCT	cis	rs61861422	0.516	rs12412216	chr10:134393338	C/T	cg22868943	chr10:134019008	DPYSL4	0.3	5.31	0.43	4.86e-7	Primary sclerosing cholangitis;
TGCT	cis	rs3806843	0.576	rs246029	chr5:140333226	G/A	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs858239	0.899	rs28458177	chr7:23294872	G/A	cg05602783	chr7:23145260	KLHL7	-0.63	-4.96	-0.41	2.31e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9653442	0.545	rs11123810	chr2:100759285	T/C	cg22139774	chr2:100720529	AFF3	-0.36	-5.63	-0.45	1.16e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg20607798	chr8:58055168	NA	0.5	4.66	0.39	8.04e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7552404	0.960	rs61797339	chr1:76189946	G/T	cg03433033	chr1:76189801	ACADM	0.83	9.91	0.66	2.13e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7772486	0.875	rs9322044	chr6:146369608	T/C	cg13319975	chr6:146136371	FBXO30	-0.5	-4.46	-0.37	1.83e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9787249	0.957	rs6670841	chr1:40220284	C/G	cg19912559	chr1:40204330	PPIE	0.47	5.52	0.44	1.88e-7	Blood protein levels;
TGCT	cis	rs7523273	0.565	rs2761420	chr1:207889368	G/T	cg22525895	chr1:207977042	MIR29B2	-0.35	-5.67	-0.45	9.4e-8	Schizophrenia;
TGCT	cis	rs28735056	0.904	rs35201860	chr18:77628719	T/C	cg20368463	chr18:77673604	PQLC1	0.4	4.89	0.4	3.09e-6	Schizophrenia;
TGCT	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg22891161	chr3:195456627	MUC20	-0.23	-5.38	-0.44	3.53e-7	Pancreatic cancer;
TGCT	cis	rs9325144	0.624	rs7309400	chr12:39150369	G/C	cg26384229	chr12:38710491	ALG10B	-0.61	-5.69	-0.46	8.63e-8	Morning vs. evening chronotype;
TGCT	trans	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	1.03	13.16	0.76	2.65e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs4478858	0.735	rs10914361	chr1:31817542	T/G	cg07478791	chr1:31886160	SERINC2	-0.51	-4.95	-0.41	2.33e-6	Alcohol dependence;
TGCT	cis	rs4906332	0.966	rs12588705	chr14:103865477	T/A	cg26031613	chr14:104095156	KLC1	-0.51	-4.65	-0.39	8.49e-6	Coronary artery disease;
TGCT	cis	rs72781680	0.898	rs111460347	chr2:24018833	G/A	cg08917208	chr2:24149416	ATAD2B	0.81	5.01	0.41	1.8e-6	Lymphocyte counts;
TGCT	cis	rs2233152	0.656	rs10405633	chr19:41291703	G/A	cg23743927	chr19:41304969	EGLN2	-0.7	-4.69	-0.39	7.06e-6	Kawasaki disease;
TGCT	cis	rs2235642	0.691	rs2281235	chr16:1603535	T/C	cg11375102	chr16:1583810	IFT140;TMEM204	-0.3	-5.42	-0.44	2.97e-7	Coronary artery disease;
TGCT	cis	rs7824557	0.778	rs3808502	chr8:11179458	G/T	cg21775007	chr8:11205619	TDH	0.55	5.11	0.42	1.2e-6	Retinal vascular caliber;
TGCT	cis	rs10791097	0.694	rs4264159	chr11:130755784	G/T	cg05962950	chr11:130786565	SNX19	0.9	11.06	0.7	3.32e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs2303745	0.544	rs6512180	chr19:17399153	C/T	cg04248312	chr19:17393744	ANKLE1	-0.33	-5.51	-0.44	1.96e-7	Systemic lupus erythematosus;
TGCT	cis	rs7523273	0.526	rs2724394	chr1:208017072	T/A	cg22525895	chr1:207977042	MIR29B2	-0.53	-8.98	-0.63	3.6e-15	Schizophrenia;
TGCT	cis	rs3015497	0.616	rs4901044	chr14:51090295	A/G	cg04730355	chr14:51134070	SAV1	-0.64	-6.04	-0.48	1.64e-8	Mean platelet volume;
TGCT	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg10802521	chr3:52805072	NEK4	-0.79	-9.98	-0.67	1.39e-17	Bipolar disorder;
TGCT	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.81	0.46	4.96e-8	Height;
TGCT	cis	rs477895	0.713	rs7952318	chr11:63961242	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.78	6.33	0.49	4.14e-9	Mean platelet volume;
TGCT	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg27588902	chr6:42928151	GNMT	-0.56	-6.99	-0.53	1.48e-10	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg07424592	chr7:64974309	NA	1.31	8.14	0.59	3.55e-13	Diabetic kidney disease;
TGCT	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg11965913	chr1:205819406	PM20D1	0.48	6.26	0.49	5.7e-9	Menarche (age at onset);
TGCT	cis	rs67072384	1.000	rs67072384	chr11:72450724	C/T	cg03713592	chr11:72463424	ARAP1	-0.93	-4.66	-0.39	7.89e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs42648	0.596	rs194518	chr7:89853149	G/A	cg25739043	chr7:89950458	NA	-0.51	-4.85	-0.4	3.65e-6	Homocysteine levels;
TGCT	cis	rs950027	0.549	rs12909409	chr15:45608582	T/G	cg26924012	chr15:45694286	SPATA5L1	-0.72	-7.44	-0.56	1.48e-11	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg03213289	chr20:61660250	NA	0.68	9.99	0.67	1.36e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9372253	1.000	rs9386894	chr6:110718853	A/G	cg00083206	chr6:110721305	DDO	-0.44	-6.68	-0.51	7.27e-10	Platelet distribution width;
TGCT	cis	rs7772486	0.597	rs2246132	chr6:146182515	C/G	cg23711669	chr6:146136114	FBXO30	0.74	6.88	0.53	2.65e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11085466	1.000	rs73552468	chr19:21772097	G/A	cg23026602	chr19:21646605	NA	-0.55	-4.82	-0.4	4.2e-6	Colorectal or endometrial cancer;
TGCT	cis	rs2075371	1.000	rs1421486	chr7:133985196	T/C	cg11752832	chr7:134001865	SLC35B4	0.69	6.32	0.49	4.19e-9	Mean platelet volume;
TGCT	cis	rs4499344	0.556	rs259220	chr19:33137629	T/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.82	8.26	0.6	1.84e-13	Mean platelet volume;
TGCT	cis	rs10464366	0.746	rs11760807	chr7:39142377	G/A	cg15212455	chr7:39170539	POU6F2	0.26	5.62	0.45	1.19e-7	IgG glycosylation;
TGCT	cis	rs950776	0.684	rs692780	chr15:78876505	C/G	cg06917634	chr15:78832804	PSMA4	-0.68	-5.48	-0.44	2.24e-7	Sudden cardiac arrest;
TGCT	cis	rs2013441	0.965	rs2703790	chr17:20163209	G/A	cg18979559	chr17:20280153	CCDC144C	-0.45	-4.67	-0.39	7.61e-6	Obesity-related traits;
TGCT	cis	rs72781680	0.898	rs72790310	chr2:24116716	C/T	cg08917208	chr2:24149416	ATAD2B	0.78	4.79	0.4	4.69e-6	Lymphocyte counts;
TGCT	cis	rs7394190	0.748	rs4746151	chr10:75578720	G/T	cg07699608	chr10:75541558	CHCHD1	0.79	4.95	0.41	2.42e-6	Incident atrial fibrillation;
TGCT	cis	rs250677	0.687	rs171636	chr5:148434545	G/A	cg18129178	chr5:148520854	ABLIM3	-0.45	-6.06	-0.48	1.54e-8	Breast cancer;
TGCT	cis	rs7698623	0.867	rs4693191	chr4:88797873	C/T	cg27387453	chr4:88533842	DSPP	-0.61	-4.6	-0.38	1.03e-5	Cardiovascular disease risk factors;
TGCT	cis	rs362272	0.545	rs3135146	chr4:3307638	C/G	cg06533319	chr4:3265114	C4orf44	0.24	4.88	0.4	3.24e-6	Serum sulfate level;
TGCT	cis	rs35934224	0.783	rs58195087	chr22:19858547	A/G	cg11182965	chr22:19864308	TXNRD2	-0.38	-5.22	-0.42	7.16e-7	Glaucoma (primary open-angle);
TGCT	cis	rs9325144	0.650	rs6582624	chr12:38733475	A/T	cg26384229	chr12:38710491	ALG10B	-0.6	-5.73	-0.46	7.06e-8	Morning vs. evening chronotype;
TGCT	cis	rs513349	1.000	rs513349	chr6:33541719	A/G	cg24505687	chr6:33548425	BAK1	0.53	6.9	0.53	2.42e-10	Platelet count;
TGCT	cis	rs12042938	0.600	rs823161	chr1:231775017	G/A	cg04892437	chr1:231737901	TSNAX-DISC1	0.46	4.79	0.4	4.68e-6	Neuranatomic and neurocognitive phenotypes;
TGCT	cis	rs77106637	0.860	rs1552224	chr11:72433098	A/C	cg03713592	chr11:72463424	ARAP1	1.21	9.04	0.63	2.56e-15	Type 2 diabetes;
TGCT	cis	rs938554	0.513	rs3775947	chr4:9995240	C/T	cg11266682	chr4:10021025	SLC2A9	0.54	4.8	0.4	4.55e-6	Blood metabolite levels;
TGCT	cis	rs9443645	0.901	rs9361466	chr6:79618352	T/C	cg05283184	chr6:79620031	NA	-0.21	-4.71	-0.39	6.61e-6	Intelligence (multi-trait analysis);
TGCT	trans	rs1814175	0.817	rs11040700	chr11:50023832	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.26	-0.55	3.77e-11	Height;
TGCT	cis	rs78456975	0.657	rs116217838	chr2:1569173	T/C	cg12573674	chr2:1569213	NA	-0.49	-5.38	-0.44	3.52e-7	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs17473412	0.609	rs1004434	chr5:122871486	A/T	cg15125798	chr5:122621645	NA	0.53	4.93	0.41	2.54e-6	Total body bone mineral density;
TGCT	cis	rs9926296	0.581	rs2108838	chr16:89904426	A/G	cg21285383	chr16:89894308	SPIRE2	0.33	4.71	0.39	6.6e-6	Vitiligo;
TGCT	cis	rs826838	1.000	rs826891	chr12:39100824	A/G	cg26384229	chr12:38710491	ALG10B	-0.85	-8.1	-0.59	4.39e-13	Heart rate;
TGCT	cis	rs2013441	1.000	rs2703816	chr17:20118887	A/G	cg18979559	chr17:20280153	CCDC144C	-0.44	-4.61	-0.38	9.78e-6	Obesity-related traits;
TGCT	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	16.07	0.82	4.16e-32	Prudent dietary pattern;
TGCT	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg06618935	chr21:46677482	NA	-0.38	-4.89	-0.4	3.07e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7267979	0.934	rs2482913	chr20:25405086	T/A	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3806843	0.576	rs246007	chr5:140338748	C/T	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg03732007	chr1:2071316	PRKCZ	0.27	6.23	0.49	6.77e-9	Height;
TGCT	cis	rs9341808	0.727	rs4706834	chr6:81012605	G/T	cg08355045	chr6:80787529	NA	0.26	4.48	0.37	1.64e-5	Sitting height ratio;
TGCT	cis	rs2404602	0.647	rs11072619	chr15:77043242	A/C	cg23625390	chr15:77176239	SCAPER	-0.38	-4.79	-0.39	4.75e-6	Blood metabolite levels;
TGCT	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg11247378	chr22:39784982	NA	-0.74	-9.72	-0.66	5.95e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7208859	0.673	rs9899349	chr17:29200122	C/T	cg14008862	chr17:28927542	LRRC37B2	0.72	4.66	0.39	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7666738	0.791	rs34437628	chr4:99029232	C/G	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2455799	0.613	rs13060772	chr3:15896795	C/T	cg16303742	chr3:15540471	COLQ	-0.25	-4.73	-0.39	5.89e-6	Mean platelet volume;
TGCT	cis	rs2153535	0.580	rs9505455	chr6:8478622	A/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	trans	rs1496653	0.512	rs35649850	chr3:23481508	A/G	cg02770683	chr12:57597238	LRP1	0.38	6.89	0.53	2.53e-10	Type 2 diabetes;
TGCT	cis	rs425277	1.000	rs425277	chr1:2069172	C/T	cg03732007	chr1:2071316	PRKCZ	0.23	4.48	0.37	1.69e-5	Height;
TGCT	cis	rs60154123	0.730	rs679042	chr1:210457122	A/G	cg22029157	chr1:209979665	IRF6	0.6	4.46	0.37	1.81e-5	Coronary artery disease;
TGCT	cis	rs6921919	0.583	rs740622	chr6:28398291	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.55	-5.21	-0.42	7.65e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs899997	1.000	rs1814880	chr15:79021140	T/C	cg04896959	chr15:78267971	NA	0.36	5.31	0.43	4.94e-7	Coronary artery disease or large artery stroke;
TGCT	cis	rs2456568	0.802	rs10831136	chr11:93636860	T/C	cg17595323	chr11:93583763	C11orf90	-0.47	-6.44	-0.5	2.38e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs68170813	0.523	rs7777976	chr7:106888594	C/T	cg02696742	chr7:106810147	HBP1	-0.69	-5.61	-0.45	1.27e-7	Coronary artery disease;
TGCT	trans	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg17830980	chr10:43048298	ZNF37B	-0.83	-10.33	-0.68	2.02e-18	Extrinsic epigenetic age acceleration;
TGCT	cis	rs734999	0.545	rs10910111	chr1:2542653	A/G	cg18854424	chr1:2615690	NA	0.46	5.32	0.43	4.62e-7	Ulcerative colitis;
TGCT	cis	rs9443645	1.000	rs9443645	chr6:79822924	C/T	cg09184832	chr6:79620586	NA	-0.47	-5.12	-0.42	1.13e-6	Intelligence (multi-trait analysis);
TGCT	trans	rs77457752	0.690	rs12349396	chr9:13912144	T/C	cg18948646	chr4:83674694	SCD5;MIR575	0.55	6.62	0.51	9.75e-10	Breast cancer;
TGCT	cis	rs2404602	0.692	rs7163397	chr15:76940315	A/G	cg22467129	chr15:76604101	ETFA	-0.45	-5.11	-0.42	1.18e-6	Blood metabolite levels;
TGCT	trans	rs208520	0.690	rs12209753	chr6:66703951	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	11.22	0.71	1.34e-20	Exhaled nitric oxide output;
TGCT	cis	rs716804	0.691	rs1442738	chr11:10278772	C/G	cg17061862	chr11:9590431	NA	-0.36	-4.55	-0.38	1.28e-5	Neuroticism;
TGCT	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg03264133	chr6:25882463	NA	-0.62	-6.65	-0.51	8.55e-10	Blood metabolite levels;
TGCT	cis	rs6782228	1.000	rs34890930	chr3:128329223	T/C	cg15113803	chr3:129247119	RHO	0.18	4.7	0.39	6.88e-6	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
TGCT	cis	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg20637647	chr7:64974828	NA	0.94	5.17	0.42	9.06e-7	Diabetic kidney disease;
TGCT	cis	rs9948	0.655	rs62156232	chr2:97431161	C/A	cg01990225	chr2:97406019	LMAN2L	-1.01	-5.13	-0.42	1.08e-6	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs12681288	0.823	rs2701905	chr8:1003482	T/C	cg04851639	chr8:1020857	NA	-0.36	-6.47	-0.5	2.01e-9	Schizophrenia;
TGCT	cis	rs13242816	1.000	rs56298491	chr7:116116687	C/T	cg02799643	chr7:116139180	CAV2	-0.48	-5.52	-0.44	1.87e-7	P wave duration;
TGCT	cis	rs2249625	0.584	rs2496506	chr6:72891324	A/C	cg08500200	chr6:72892038	RIMS1	-0.42	-4.55	-0.38	1.27e-5	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
TGCT	cis	rs35883536	0.609	rs10783142	chr1:101043902	C/G	cg10298815	chr1:101004474	GPR88	-0.25	-4.7	-0.39	6.67e-6	Monocyte count;
TGCT	cis	rs2637266	1.000	rs12251543	chr10:78345465	G/A	cg18941641	chr10:78392320	NA	0.4	5.02	0.41	1.77e-6	Pulmonary function;
TGCT	cis	rs344364	0.511	rs1742460	chr16:1945441	G/C	cg26617929	chr16:1858877	NA	-0.27	-4.9	-0.4	2.99e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs7208859	0.673	rs216411	chr17:28903493	T/C	cg04154034	chr17:28927549	LRRC37B2	-0.87	-5.22	-0.42	7.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs1008375	1.000	rs6818639	chr4:17633049	A/G	cg16339924	chr4:17578868	LAP3	0.66	5.49	0.44	2.22e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7208859	0.623	rs11657777	chr17:29091785	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7959452	0.557	rs899224	chr12:69784774	A/G	cg14784868	chr12:69753453	YEATS4	0.83	8.96	0.63	4.14e-15	Blood protein levels;
TGCT	trans	rs7726839	0.561	rs4957048	chr5:583442	G/A	cg11887960	chr12:57824829	NA	0.98	7.81	0.57	2.09e-12	Obesity-related traits;
TGCT	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7772486	0.713	rs2328704	chr6:146020494	T/C	cg05347473	chr6:146136440	FBXO30	-0.49	-4.67	-0.39	7.63e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs12477438	0.798	rs1349779	chr2:99645055	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-6.18	-0.49	8.51e-9	Chronic sinus infection;
TGCT	cis	rs9467773	0.596	rs2451750	chr6:26646579	A/T	cg26531700	chr6:26746687	NA	0.51	4.61	0.38	9.86e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7584330	0.554	rs74001386	chr2:238425333	T/A	cg08992911	chr2:238395768	MLPH	0.73	4.95	0.41	2.37e-6	Prostate cancer;
TGCT	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.6	0.51	1.05e-9	Bipolar disorder;
TGCT	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.47	4.56	0.38	1.19e-5	Cerebrospinal P-tau181p levels;
TGCT	cis	rs12549025	0.536	rs35742726	chr8:23366942	G/C	cg00472375	chr8:23315376	ENTPD4	0.66	5.21	0.42	7.67e-7	Reticulocyte fraction of red cells;
TGCT	cis	rs763121	0.853	rs5750672	chr22:39104168	C/T	cg06022373	chr22:39101656	GTPBP1	-0.76	-7.23	-0.54	4.46e-11	Menopause (age at onset);
TGCT	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg17554472	chr22:41940697	POLR3H	-0.49	-5.27	-0.43	5.9e-7	Vitiligo;
TGCT	cis	rs4455778	0.860	rs9969372	chr7:49067276	A/C	cg26309511	chr7:48887640	NA	-0.45	-5.32	-0.43	4.78e-7	Lung cancer in never smokers;
TGCT	cis	rs7666738	0.830	rs1967979	chr4:98966201	G/T	cg18180107	chr4:99064573	C4orf37	0.57	5.19	0.42	8.47e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs5769707	0.521	rs7285764	chr22:50058561	T/C	cg05373962	chr22:49881684	NA	-0.32	-5.46	-0.44	2.46e-7	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs7659604	0.540	rs10007956	chr4:122700669	A/T	cg19748678	chr4:122722346	EXOSC9	-0.55	-5.55	-0.45	1.62e-7	Type 2 diabetes;
TGCT	cis	rs7727544	0.645	rs272857	chr5:131685297	G/A	cg24060327	chr5:131705240	SLC22A5	-0.59	-6.53	-0.51	1.54e-9	Blood metabolite levels;
TGCT	cis	rs7666738	0.830	rs6532723	chr4:99052147	A/T	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg21548813	chr6:291882	DUSP22	-0.65	-6.89	-0.53	2.46e-10	Menopause (age at onset);
TGCT	cis	rs6088590	0.965	rs6087639	chr20:33443866	G/A	cg06115741	chr20:33292138	TP53INP2	0.64	5.21	0.42	7.77e-7	Coronary artery disease;
TGCT	cis	rs1401999	0.966	rs2313212	chr3:183700928	A/G	cg01324343	chr3:183735012	ABCC5	0.82	10.97	0.7	5.41e-20	Anterior chamber depth;
TGCT	cis	rs523522	0.962	rs4767905	chr12:120930835	C/T	cg27279351	chr12:120934652	DYNLL1	0.76	6.59	0.51	1.15e-9	High light scatter reticulocyte count;
TGCT	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg08280861	chr8:58055591	NA	0.37	5.03	0.41	1.66e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9467773	0.901	rs1407045	chr6:26476155	A/G	cg02458000	chr6:26745757	NA	0.47	4.46	0.37	1.81e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs2230307	0.536	rs7518943	chr1:100463422	G/T	cg24955406	chr1:100503596	HIAT1	0.8	5.73	0.46	7.35e-8	Carotid intima media thickness;
TGCT	cis	rs3806843	0.900	rs2563286	chr5:140125199	T/A	cg19875535	chr5:140030758	IK	-0.35	-5.92	-0.47	2.89e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7828089	0.522	rs4872484	chr8:22255859	C/T	cg12081754	chr8:22256438	SLC39A14	0.31	4.97	0.41	2.18e-6	Verbal declarative memory;
TGCT	cis	rs9291683	0.595	rs35501905	chr4:10053431	C/T	cg11266682	chr4:10021025	SLC2A9	0.65	8.68	0.61	1.85e-14	Bone mineral density;
TGCT	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg22920501	chr2:26401640	FAM59B	-0.74	-6.4	-0.5	2.86e-9	Gut microbiome composition (summer);
TGCT	cis	rs13102973	0.965	rs4535381	chr4:135861313	A/T	cg14419869	chr4:135874104	NA	0.24	4.49	0.37	1.6e-5	Subjective well-being;
TGCT	trans	rs931812	0.825	rs6993937	chr8:101898707	A/G	cg20993868	chr7:22813445	NA	0.42	9.22	0.64	9.5e-16	Attention deficit hyperactivity disorder and conduct disorder;
TGCT	cis	rs9916302	0.904	rs2168785	chr17:37407135	C/T	cg07936489	chr17:37558343	FBXL20	-0.64	-5.2	-0.42	7.92e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs12210905	0.688	rs12209174	chr6:27443952	G/A	cg08851530	chr6:28072375	NA	1.34	6.29	0.49	5.02e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs9611565	0.512	rs2899347	chr22:42158204	T/C	cg17554472	chr22:41940697	POLR3H	0.46	4.69	0.39	7.09e-6	Vitiligo;
TGCT	cis	rs9467773	0.967	rs6924865	chr6:26521353	A/G	cg09904177	chr6:26538194	HMGN4	0.65	6.53	0.51	1.53e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs4294134	0.608	rs11535258	chr7:135247547	A/G	cg08396481	chr7:135194601	CNOT4	-0.58	-4.68	-0.39	7.53e-6	Paget's disease;
TGCT	cis	rs2730245	1.000	rs2657365	chr7:158722753	A/T	cg24397884	chr7:158709396	WDR60	-0.38	-5.16	-0.42	9.34e-7	Height;
TGCT	cis	rs9611565	0.592	rs5751129	chr22:42015765	C/T	cg13695892	chr22:41940480	POLR3H	0.83	8.02	0.58	6.86e-13	Vitiligo;
TGCT	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg20203395	chr5:56204925	C5orf35	-0.59	-5.12	-0.42	1.12e-6	Initial pursuit acceleration;
TGCT	cis	rs9611565	0.546	rs5758426	chr22:42098763	T/G	cg06634786	chr22:41940651	POLR3H	0.84	8.08	0.59	4.86e-13	Vitiligo;
TGCT	cis	rs72781680	1.000	rs72781675	chr2:24232092	G/A	cg08917208	chr2:24149416	ATAD2B	0.82	4.92	0.4	2.68e-6	Lymphocyte counts;
TGCT	cis	rs2456568	0.805	rs55784864	chr11:93682887	G/A	cg26875233	chr11:93583750	C11orf90	-0.45	-5.65	-0.45	1.04e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7666738	0.830	rs13122456	chr4:98936011	A/G	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12200560	0.505	rs211179	chr6:97074103	A/G	cg06623918	chr6:96969491	KIAA0776	0.59	5.03	0.41	1.71e-6	Coronary heart disease;
TGCT	cis	rs9486719	1.000	rs12205728	chr6:96891838	T/C	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.21	-0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg10207240	chr12:122356781	WDR66	0.35	4.9	0.4	2.97e-6	Mean corpuscular volume;
TGCT	cis	rs79387448	0.576	rs11902044	chr2:102972534	C/T	cg09003973	chr2:102972529	NA	1.47	10.36	0.68	1.69e-18	Gut microbiota (bacterial taxa);
TGCT	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg04944784	chr2:26401820	FAM59B	-0.68	-6.04	-0.48	1.7e-8	Gut microbiome composition (summer);
TGCT	cis	rs7772486	0.743	rs62433835	chr6:146032688	C/G	cg23711669	chr6:146136114	FBXO30	-0.83	-8.95	-0.63	4.23e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7552404	0.690	rs2029681	chr1:76333846	G/A	cg22875332	chr1:76189707	ACADM	-0.57	-6.14	-0.48	1.05e-8	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9814567	1.000	rs3846055	chr3:134203973	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.99	-10.02	-0.67	1.12e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs6570726	0.935	rs386823	chr6:145841365	C/T	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7940866	0.803	rs10894307	chr11:130876350	G/A	cg05962950	chr11:130786565	SNX19	0.67	6.51	0.5	1.65e-9	Schizophrenia;
TGCT	cis	rs7528419	1.000	rs629301	chr1:109818306	G/T	cg00908766	chr1:109817496	CELSR2	0.5	5.08	0.42	1.35e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
TGCT	cis	rs739496	0.518	rs10744775	chr12:112096215	T/C	cg10833066	chr12:111807467	FAM109A	0.32	4.83	0.4	3.91e-6	Platelet count;
TGCT	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg17264618	chr3:40429014	ENTPD3	-0.32	-4.6	-0.38	1.04e-5	Renal cell carcinoma;
TGCT	cis	rs6089584	0.830	rs4925331	chr20:60580174	T/C	cg13770153	chr20:60521292	NA	-0.53	-7.2	-0.54	5.01e-11	Body mass index;
TGCT	cis	rs9411298	0.550	rs4880192	chr9:139927062	A/G	cg14024893	chr9:139943146	ENTPD2	0.36	5.91	0.47	3.08e-8	Monocyte percentage of white cells;
TGCT	cis	rs9443645	0.901	rs9352675	chr6:79612800	G/A	cg05283184	chr6:79620031	NA	-0.21	-4.71	-0.39	6.61e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs62244186	0.566	rs3762636	chr3:44854563	A/G	cg18722847	chr3:44754129	ZNF502	-0.4	-4.58	-0.38	1.12e-5	Depressive symptoms;
TGCT	cis	rs7666738	0.753	rs13120995	chr4:98972762	A/G	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9902453	0.868	rs8066731	chr17:28523121	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	6.9	0.53	2.37e-10	Coffee consumption (cups per day);
TGCT	cis	rs7772486	0.597	rs6570732	chr6:146245151	G/A	cg13319975	chr6:146136371	FBXO30	0.63	5.67	0.45	9.51e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs854765	0.649	rs4924821	chr17:17735952	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.6	-5.62	-0.45	1.19e-7	Total body bone mineral density;
TGCT	cis	rs2050392	0.517	rs603072	chr10:30755778	C/T	cg13289132	chr10:30722225	MAP3K8	0.41	4.93	0.41	2.53e-6	Inflammatory bowel disease;
TGCT	cis	rs9926296	0.581	rs12598477	chr16:89902482	T/C	cg26513180	chr16:89883248	FANCA	0.76	7.62	0.56	5.81e-12	Vitiligo;
TGCT	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.48	-0.37	1.66e-5	Bipolar disorder;
TGCT	cis	rs7647973	0.925	rs4955421	chr3:49218888	G/A	cg07636037	chr3:49044803	WDR6	0.63	5.09	0.42	1.27e-6	Menarche (age at onset);
TGCT	cis	rs2380220	0.516	rs7748108	chr6:96008082	T/C	cg04719120	chr6:96025338	MANEA	0.62	5.01	0.41	1.8e-6	Behavioural disinhibition (generation interaction);
TGCT	cis	rs9467711	0.790	rs41266839	chr6:26409890	G/C	cg12315302	chr6:26189340	HIST1H4D	0.99	4.44	0.37	1.93e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2201728	0.967	rs28914783	chr4:100231602	C/T	cg07219303	chr4:100140905	ADH6	-0.35	-5.14	-0.42	1.04e-6	Cardiac Troponin-T levels;
TGCT	cis	rs1555895	0.599	rs997615	chr10:865214	A/G	cg02193355	chr10:851439	NA	0.22	4.78	0.39	4.86e-6	Survival in rectal cancer;
TGCT	cis	rs909674	0.775	rs8138462	chr22:39839670	G/C	cg01416388	chr22:39784598	NA	-0.73	-6.89	-0.53	2.45e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs6570726	0.935	rs419854	chr6:145844085	A/C	cg23711669	chr6:146136114	FBXO30	0.69	6.69	0.51	7.01e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg04156016	chr5:1868137	NA	0.33	4.66	0.39	8.06e-6	Cardiovascular disease risk factors;
TGCT	cis	rs10876993	0.928	rs1678532	chr12:58055197	T/G	cg15848620	chr12:58087721	OS9	-0.73	-5.94	-0.47	2.74e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs7100689	0.646	rs1572819	chr10:82112488	A/G	cg01528321	chr10:82214614	TSPAN14	0.76	7.57	0.56	7.56e-12	Post bronchodilator FEV1;
TGCT	cis	rs77741769	0.571	rs34009825	chr12:121326183	A/G	cg02419362	chr12:121203948	SPPL3	0.19	4.5	0.37	1.56e-5	Mean corpuscular volume;
TGCT	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg27286337	chr10:134555280	INPP5A	0.41	4.9	0.4	2.97e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs9467711	0.606	rs34550936	chr6:26361985	A/G	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2439831	1.000	rs2256764	chr15:43735763	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	7.11	0.54	8.14e-11	Lung cancer in ever smokers;
TGCT	cis	rs2535633	0.631	rs2245424	chr3:53003021	G/C	cg10802521	chr3:52805072	NEK4	0.54	5.83	0.46	4.45e-8	Body mass index;
TGCT	cis	rs7249142	0.549	rs7260127	chr19:19280499	C/T	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	-0.56	-5.54	-0.45	1.69e-7	IgG glycosylation;
TGCT	cis	rs4478858	0.735	rs6687819	chr1:31801112	G/A	cg07478791	chr1:31886160	SERINC2	-0.51	-4.95	-0.41	2.33e-6	Alcohol dependence;
TGCT	cis	rs2562456	0.876	rs2681370	chr19:21736838	T/C	cg01304269	chr19:21688519	ZNF429	0.57	4.74	0.39	5.86e-6	Pain;
TGCT	cis	rs11122272	0.701	rs2491402	chr1:231494338	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-6.7	-0.52	6.67e-10	Hemoglobin concentration;
TGCT	cis	rs7666738	0.830	rs35531558	chr4:98938217	A/G	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9906944	0.707	rs1523136	chr17:47144532	A/G	cg07075026	chr17:47091521	IGF2BP1	-0.45	-4.81	-0.4	4.38e-6	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs36051895	0.560	rs1575281	chr9:5219131	T/C	cg02405213	chr9:5042618	JAK2	-0.67	-8.35	-0.6	1.16e-13	Pediatric autoimmune diseases;
TGCT	cis	rs79387448	0.745	rs1159509	chr2:103169073	T/A	cg09003973	chr2:102972529	NA	0.95	6.15	0.48	9.95e-9	Gut microbiota (bacterial taxa);
TGCT	cis	rs1056107	0.863	rs7041663	chr9:115002818	T/A	cg02332936	chr9:115140584	NA	-0.25	-4.44	-0.37	1.96e-5	Colorectal cancer;
TGCT	cis	rs2224391	0.628	rs2773319	chr6:5258941	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	0.96	6.01	0.47	1.93e-8	Height;
TGCT	cis	rs11190604	1.000	rs10509744	chr10:102271579	C/T	cg16342193	chr10:102329863	NA	-0.38	-4.84	-0.4	3.77e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2439831	0.867	rs2245176	chr15:43750762	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.81	5.66	0.45	9.81e-8	Lung cancer in ever smokers;
TGCT	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs854765	0.551	rs56886154	chr17:17831473	C/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	7.91	0.58	1.2e-12	Total body bone mineral density;
TGCT	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	5.45	0.44	2.66e-7	Height;
TGCT	cis	rs36051895	0.632	rs12344116	chr9:5142216	G/A	cg02405213	chr9:5042618	JAK2	-0.72	-10.05	-0.67	9.59e-18	Pediatric autoimmune diseases;
TGCT	cis	rs806215	1.000	rs712701	chr7:127251188	T/G	cg25922125	chr7:127225783	GCC1	0.58	5.89	0.47	3.35e-8	Type 2 diabetes;
TGCT	trans	rs7615952	0.932	rs7629977	chr3:125649573	T/G	cg07211511	chr3:129823064	LOC729375	-0.47	-7.69	-0.57	4e-12	Blood pressure (smoking interaction);
TGCT	cis	rs2956278	0.677	rs2947121	chr12:84681525	G/A	cg25678815	chr12:85673915	ALX1	-0.54	-4.83	-0.4	3.96e-6	Depressive symptoms;Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg07424592	chr7:64974309	NA	1.34	8.08	0.59	4.95e-13	Diabetic kidney disease;
TGCT	cis	rs9611565	0.802	rs132916	chr22:41806768	C/G	cg06634786	chr22:41940651	POLR3H	0.69	6.64	0.51	8.61e-10	Vitiligo;
TGCT	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg22963979	chr7:1858916	MAD1L1	-0.41	-6.67	-0.51	7.66e-10	Schizophrenia;
TGCT	cis	rs9894429	0.621	rs7502337	chr17:79588470	T/C	cg21028142	chr17:79581711	NPLOC4	0.29	6.08	0.48	1.39e-8	Eye color traits;
TGCT	cis	rs4886920	0.537	rs6495247	chr15:78069431	C/T	cg25212270	chr15:78015279	NA	0.23	4.51	0.38	1.47e-5	Neuroticism;
TGCT	cis	rs11190604	1.000	rs4919464	chr10:102221195	A/G	cg23241863	chr10:102295624	HIF1AN	0.62	4.87	0.4	3.27e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.54	4.73	0.39	5.92e-6	Prudent dietary pattern;
TGCT	cis	rs422249	0.547	rs174537	chr11:61552680	G/T	cg19610905	chr11:61596333	FADS2	-1.06	-10.7	-0.69	2.47e-19	Trans fatty acid levels;
TGCT	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.71	-0.39	6.54e-6	Prudent dietary pattern;
TGCT	cis	rs2046867	0.818	rs62249879	chr3:72917171	A/G	cg25664220	chr3:72788482	NA	-0.54	-6.88	-0.53	2.65e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg02725872	chr8:58115012	NA	-0.37	-4.99	-0.41	1.99e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg11494091	chr17:61959527	GH2	0.61	14.43	0.79	2.59e-28	Prudent dietary pattern;
TGCT	cis	rs7582180	0.629	rs11123827	chr2:100951248	C/G	cg14675211	chr2:100938903	LONRF2	0.5	4.78	0.39	4.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2820315	1.000	rs2820314	chr1:201872209	A/C	cg12730843	chr1:201915899	LMOD1	-0.27	-4.78	-0.39	4.82e-6	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
TGCT	cis	rs782590	0.774	rs782630	chr2:55899425	T/C	cg18811423	chr2:55921094	PNPT1	0.65	6.76	0.52	4.79e-10	Metabolic syndrome;
TGCT	cis	rs12369179	1.000	rs12369179	chr12:122963550	C/T	cg18578876	chr12:123200353	GPR109B	-0.43	-4.75	-0.39	5.47e-6	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;
TGCT	cis	rs11122272	0.735	rs2486728	chr1:231535883	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-6.5	-0.5	1.77e-9	Hemoglobin concentration;
TGCT	cis	rs7201929	1.000	rs7201929	chr16:28871966	C/T	cg09754948	chr16:28834200	ATXN2L	0.63	4.99	0.41	2.03e-6	QT interval;
TGCT	cis	rs6938	0.575	rs12902515	chr15:75160998	G/C	cg10253484	chr15:75165896	SCAMP2	-0.53	-4.88	-0.4	3.15e-6	Breast cancer;
TGCT	cis	rs12620999	0.941	rs62183342	chr2:237979140	C/A	cg23555395	chr2:238036564	NA	0.27	4.76	0.39	5.28e-6	Systemic lupus erythematosus;
TGCT	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.0	-7.42	-0.55	1.64e-11	Gut microbiome composition (summer);
TGCT	cis	rs7584330	0.740	rs12471291	chr2:238441751	T/G	cg14458575	chr2:238380390	NA	0.41	6.22	0.49	6.9e-9	Prostate cancer;
TGCT	cis	rs704	0.585	rs2227735	chr17:26693258	C/T	cg10494684	chr17:26645200	TMEM97	-0.46	-4.95	-0.41	2.33e-6	Osteoprotegerin levels;
TGCT	cis	rs74233809	1.000	rs9633712	chr10:104873761	G/C	cg05855489	chr10:104503620	C10orf26	0.82	4.44	0.37	1.97e-5	Birth weight;
TGCT	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg01802117	chr1:53393560	SCP2	0.48	5.9	0.47	3.21e-8	Monocyte count;
TGCT	cis	rs9858542	0.537	rs9863142	chr3:49366741	C/G	cg00383909	chr3:49044727	WDR6	0.7	4.81	0.4	4.22e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs35306767	0.903	rs12763396	chr10:927357	C/A	cg26597838	chr10:835615	NA	0.75	10.54	0.69	6.3e-19	Eosinophil percentage of granulocytes;
TGCT	cis	rs13191362	0.507	rs2849527	chr6:163117932	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.6	5.7	0.46	8.3e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs1023500	0.505	rs2143139	chr22:42614401	G/C	cg15557168	chr22:42548783	NA	-0.21	-4.8	-0.4	4.45e-6	Schizophrenia;
TGCT	cis	rs8103278	0.507	rs10404220	chr19:46248407	G/A	cg11657440	chr19:46296263	DMWD	0.75	7.74	0.57	3.02e-12	Coronary artery disease;
TGCT	cis	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg05590025	chr7:65112418	INTS4L2	-0.77	-4.5	-0.37	1.52e-5	Diabetic kidney disease;
TGCT	cis	rs2075671	0.857	rs11772849	chr7:100308412	G/A	cg16850897	chr7:100343110	ZAN	-0.47	-4.44	-0.37	1.98e-5	Other erythrocyte phenotypes;
TGCT	cis	rs2594989	0.887	rs2454498	chr3:11500953	A/G	cg26283222	chr3:11613257	VGLL4	-0.21	-4.49	-0.37	1.58e-5	Circulating chemerin levels;
TGCT	cis	rs7044106	0.762	rs1530370	chr9:123424552	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	4.56	0.38	1.21e-5	Hip circumference adjusted for BMI;
TGCT	cis	rs75059851	0.756	rs11223649	chr11:133840471	T/C	cg14047540	chr11:133829660	NA	-0.57	-5.69	-0.45	8.72e-8	Schizophrenia;
TGCT	cis	rs2842992	0.830	rs2758320	chr6:160070676	T/G	cg11366901	chr6:160182831	ACAT2	1.02	6.71	0.52	6.06e-10	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs10782582	0.593	rs11579752	chr1:76178694	C/T	cg03433033	chr1:76189801	ACADM	-0.59	-6.73	-0.52	5.46e-10	Daytime sleep phenotypes;
TGCT	cis	rs9790314	0.846	rs899275	chr3:161042104	T/C	cg03342759	chr3:160939853	NMD3	-0.5	-5.63	-0.45	1.13e-7	Morning vs. evening chronotype;
TGCT	cis	rs4494114	1.000	rs7539067	chr1:39359694	A/G	cg25970120	chr1:39325951	RRAGC	-0.62	-6.55	-0.51	1.41e-9	Blood protein levels;
TGCT	cis	rs7666738	0.861	rs5014702	chr4:99052102	C/A	cg17366294	chr4:99064904	C4orf37	0.74	7.54	0.56	8.44e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs17376456	0.825	rs13161885	chr5:93071242	A/C	cg21475434	chr5:93447410	FAM172A	0.62	4.67	0.39	7.58e-6	Diabetic retinopathy;
TGCT	cis	rs12500482	1.000	rs12500482	chr4:2430235	A/G	cg01601518	chr4:2404284	ZFYVE28	-0.29	-4.66	-0.39	8.08e-6	Cognitive function;
TGCT	cis	rs4805272	0.512	rs66830923	chr19:29321277	C/T	cg12756686	chr19:29218302	NA	0.63	4.53	0.38	1.34e-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
TGCT	cis	rs7666738	0.830	rs3896704	chr4:99034252	C/T	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11718455	0.920	rs13084408	chr3:44008967	G/A	cg08738300	chr3:44038990	NA	0.86	6.55	0.51	1.4e-9	Coronary artery disease;
TGCT	cis	rs9467773	0.596	rs2494693	chr6:26619226	T/C	cg11502198	chr6:26597334	ABT1	0.53	4.9	0.4	2.95e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg18867708	chr6:26865862	GUSBL1	0.4	5.32	0.43	4.75e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6815814	0.950	rs5743789	chr4:38833173	A/T	cg02016764	chr4:38805732	TLR1	-0.32	-4.91	-0.4	2.75e-6	Breast cancer;
TGCT	cis	rs2075371	0.501	rs1643057	chr7:134027521	A/G	cg11752832	chr7:134001865	SLC35B4	0.59	5.08	0.41	1.36e-6	Mean platelet volume;
TGCT	cis	rs589448	0.538	rs683790	chr12:69751434	T/G	cg11871910	chr12:69753446	YEATS4	0.6	5.27	0.43	5.85e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs806215	0.526	rs17151470	chr7:127517965	A/G	cg11539674	chr7:127291444	SND1	-0.36	-4.65	-0.39	8.46e-6	Type 2 diabetes;
TGCT	trans	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg27523141	chr10:43048294	ZNF37B	0.74	8.61	0.61	2.7e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs208520	0.690	rs207094	chr6:66799009	G/A	cg07460842	chr6:66804631	NA	-0.94	-9.91	-0.66	2.15e-17	Exhaled nitric oxide output;
TGCT	cis	rs9325144	0.534	rs4882350	chr12:38686979	A/G	cg26384229	chr12:38710491	ALG10B	0.66	6.12	0.48	1.11e-8	Morning vs. evening chronotype;
TGCT	cis	rs682748	1.000	rs297171	chr5:17150901	A/C	cg23987134	chr5:17158319	LOC285696	-0.23	-5.42	-0.44	2.93e-7	Hippocampal atrophy;
TGCT	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg08859206	chr1:53392774	SCP2	0.35	5.04	0.41	1.62e-6	Monocyte count;
TGCT	trans	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg17470723	chr8:74884337	TCEB1	0.71	6.77	0.52	4.48e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg02953382	chr22:24373134	LOC391322	0.82	9.18	0.64	1.24e-15	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs910316	0.967	rs175479	chr14:75561871	A/C	cg08847533	chr14:75593920	NEK9	-0.94	-10.04	-0.67	1.03e-17	Height;
TGCT	cis	rs1023500	1.000	rs6002548	chr22:42337040	T/G	cg04692870	chr22:42525206	CYP2D6	-0.35	-5.21	-0.42	7.53e-7	Schizophrenia;
TGCT	trans	rs10506458	0.834	rs58821476	chr12:63389425	T/C	cg22491629	chr6:157744540	C6orf35	-0.99	-8.5	-0.61	5.08e-14	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs10782582	0.593	rs12129523	chr1:76129223	C/A	cg10523679	chr1:76189770	ACADM	-0.68	-7.05	-0.53	1.11e-10	Daytime sleep phenotypes;
TGCT	cis	rs10779751	0.960	rs1883965	chr1:11322156	A/G	cg08854313	chr1:11322531	MTOR	0.97	9.18	0.64	1.24e-15	Body mass index;
TGCT	cis	rs9467773	1.000	rs1321479	chr6:26501897	C/T	cg09904177	chr6:26538194	HMGN4	-0.63	-6.42	-0.5	2.58e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg18876405	chr7:65276391	NA	0.35	5.2	0.42	7.81e-7	Aortic root size;
TGCT	cis	rs8017423	0.845	rs8005870	chr14:90723172	A/C	cg04374321	chr14:90722782	PSMC1	0.76	7.7	0.57	3.68e-12	Mortality in heart failure;
TGCT	cis	rs7017914	0.869	rs2639954	chr8:71925575	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.56	-5.11	-0.42	1.21e-6	Bone mineral density;
TGCT	cis	rs2295359	0.824	rs12060309	chr1:67604219	T/C	cg03340356	chr1:67600835	NA	0.39	4.65	0.39	8.41e-6	Psoriasis;
TGCT	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.62	5.11	0.42	1.2e-6	Tonsillectomy;
TGCT	cis	rs5769765	0.955	rs2295406	chr22:50260169	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.4	-6.01	-0.47	1.96e-8	Schizophrenia;
TGCT	cis	rs3796352	1.000	rs75217232	chr3:53132373	A/C	cg07884673	chr3:53033167	SFMBT1	0.54	5.76	0.46	6.2e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs11190604	0.767	rs11190513	chr10:102165238	A/G	cg16005271	chr10:102321736	NA	0.45	4.57	0.38	1.15e-5	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs8141529	0.843	rs1065497	chr22:29279991	C/T	cg02153584	chr22:29168773	CCDC117	0.66	4.84	0.4	3.79e-6	Lymphocyte counts;
TGCT	cis	rs2404602	1.000	rs12594212	chr15:76802014	T/A	cg26408565	chr15:76604113	ETFA	-0.41	-5.28	-0.43	5.48e-7	Blood metabolite levels;
TGCT	cis	rs12477438	0.798	rs9308816	chr2:99637230	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-8.44	-0.6	6.88e-14	Chronic sinus infection;
TGCT	cis	rs10871290	0.650	rs2288054	chr16:74491733	A/G	cg01733217	chr16:74700730	RFWD3	0.58	4.64	0.38	8.59e-6	Breast cancer;
TGCT	cis	rs9818758	0.545	rs11717978	chr3:48969036	T/A	cg00383909	chr3:49044727	WDR6	1.26	6.52	0.51	1.58e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs1008375	1.000	rs1558377	chr4:17650758	A/G	cg16339924	chr4:17578868	LAP3	0.67	5.55	0.45	1.68e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2486288	0.656	rs11637364	chr15:45579238	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.46	-5.43	-0.44	2.8e-7	Glomerular filtration rate;
TGCT	cis	rs6504663	1.000	rs6504661	chr17:48580126	A/T	cg22571038	chr17:48585470	MYCBPAP	-0.56	-5.11	-0.42	1.2e-6	Visceral fat;
TGCT	cis	rs7267979	0.816	rs6037158	chr20:25595466	C/A	cg16686733	chr20:25566563	NINL	0.51	4.91	0.4	2.81e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6901004	0.570	rs783084	chr6:111477887	T/C	cg15721981	chr6:111408429	SLC16A10	0.65	5.43	0.44	2.88e-7	Blood metabolite levels;
TGCT	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg20203395	chr5:56204925	C5orf35	0.53	4.89	0.4	3.03e-6	Initial pursuit acceleration;
TGCT	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg24846343	chr22:24311635	DDTL	-0.22	-5.78	-0.46	5.68e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg14784868	chr12:69753453	YEATS4	0.9	10.55	0.69	5.67e-19	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs12765878	1.000	rs11191849	chr10:105650880	T/A	cg11005552	chr10:105648138	OBFC1	0.44	7.7	0.57	3.69e-12	Coronary artery disease;
TGCT	cis	rs617219	0.726	rs1275105	chr5:78444148	T/C	cg23514016	chr5:78407564	BHMT	0.34	5.15	0.42	9.83e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs2688608	0.967	rs2688609	chr10:75658181	A/G	cg02947784	chr10:75434997	AGAP5	-0.16	-4.49	-0.37	1.61e-5	Inflammatory bowel disease;
TGCT	cis	rs651907	0.535	rs11919389	chr3:101424458	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.89	10.59	0.69	4.52e-19	Colorectal cancer;
TGCT	cis	rs11779988	0.545	rs208753	chr8:17814915	A/G	cg01800426	chr8:17659068	MTUS1	-0.64	-4.8	-0.4	4.41e-6	Breast cancer;
TGCT	cis	rs10206020	0.885	rs11887527	chr2:1578080	A/G	cg12573674	chr2:1569213	NA	-0.46	-5.2	-0.42	7.88e-7	IgG glycosylation;
TGCT	cis	rs3091242	0.904	rs6661533	chr1:25771715	A/G	cg23205692	chr1:25664452	TMEM50A	0.48	5.07	0.41	1.42e-6	Erythrocyte sedimentation rate;
TGCT	cis	rs12477438	0.798	rs2123686	chr2:99690135	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-4.62	-0.38	9.47e-6	Chronic sinus infection;
TGCT	cis	rs986417	1.000	rs10148202	chr14:61055940	C/T	cg27398547	chr14:60952738	C14orf39	-1.41	-8.43	-0.6	7.41e-14	Gut microbiota (bacterial taxa);
TGCT	cis	rs4783244	0.897	rs3865188	chr16:82650717	A/T	cg09415485	chr16:82663111	CDH13	0.25	4.91	0.4	2.78e-6	Adiponectin levels;
TGCT	cis	rs6565180	1.000	rs11646130	chr16:30376959	T/C	cg17640201	chr16:30407289	ZNF48	-0.85	-8.07	-0.59	5.22e-13	Tonsillectomy;
TGCT	cis	rs6545883	0.801	rs778142	chr2:61681428	G/T	cg15711740	chr2:61764176	XPO1	-0.53	-4.79	-0.4	4.59e-6	Tuberculosis;
TGCT	cis	rs933688	1.000	rs6869717	chr5:90694797	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.96	8.05	0.59	5.84e-13	Smoking behavior;
TGCT	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg15242686	chr22:24348715	GSTTP1	0.42	5.68	0.45	9.1e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs17376456	0.825	rs17314825	chr5:93234937	A/G	cg21475434	chr5:93447410	FAM172A	0.78	5.28	0.43	5.6e-7	Diabetic retinopathy;
TGCT	cis	rs2456568	0.548	rs7105031	chr11:93661207	C/T	cg17595323	chr11:93583763	C11orf90	-0.42	-5.26	-0.43	6.25e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs61990749	0.597	rs176944	chr14:78176211	G/T	cg23188588	chr14:78226832	SNW1;C14orf178	-0.66	-4.65	-0.39	8.45e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs10057188	1.000	rs6877631	chr5:77867941	T/C	cg06873401	chr5:77792105	LHFPL2	-0.23	-4.53	-0.38	1.39e-5	Pulse pressure;
TGCT	cis	rs6430585	0.941	rs12469551	chr2:136510012	T/G	cg07169764	chr2:136633963	MCM6	-0.88	-7.8	-0.57	2.16e-12	Corneal structure;
TGCT	cis	rs73058052	1.000	rs2288920	chr19:50091798	G/T	cg09250473	chr19:50168907	IRF3;BCL2L12	0.86	6.53	0.51	1.52e-9	Fibrinogen levels;
TGCT	cis	rs425277	0.628	rs3128340	chr1:2047496	C/G	cg24578937	chr1:2090814	PRKCZ	-0.26	-6.17	-0.48	9e-9	Height;
TGCT	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg24829409	chr8:58192753	C8orf71	-0.59	-4.97	-0.41	2.17e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7095607	0.560	rs2101484	chr10:69927711	T/C	cg18986048	chr10:69913749	MYPN	0.6	6.39	0.5	2.98e-9	Lung function (FVC);
TGCT	cis	rs3935685	0.874	rs35028279	chr15:78003542	T/C	cg25212270	chr15:78015279	NA	0.26	5.6	0.45	1.32e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1857353	1.000	rs61083115	chr1:75909323	G/C	cg11838876	chr1:75668600	SLC44A5	-0.47	-4.56	-0.38	1.2e-5	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg06618935	chr21:46677482	NA	-0.37	-5.85	-0.47	4.04e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs600231	0.706	rs1111934	chr11:65329392	A/G	cg17120908	chr11:65337727	SSSCA1	-0.56	-5.36	-0.43	3.86e-7	Bone mineral density;
TGCT	cis	rs9640161	0.711	rs60268791	chr7:150023800	G/T	cg17279839	chr7:150038598	RARRES2	0.43	4.6	0.38	1.02e-5	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.03	0.41	1.68e-6	Prudent dietary pattern;
TGCT	cis	rs7666738	0.830	rs13110410	chr4:98920018	T/C	cg05340658	chr4:99064831	C4orf37	0.53	6.11	0.48	1.21e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs763121	0.853	rs6001173	chr22:39015302	A/G	cg06022373	chr22:39101656	GTPBP1	0.78	7.99	0.58	8.12e-13	Menopause (age at onset);
TGCT	cis	rs7267979	0.868	rs6138553	chr20:25239233	G/A	cg16686733	chr20:25566563	NINL	0.6	6.12	0.48	1.11e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg08564027	chr20:61660810	NA	0.37	6.85	0.52	3.1e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7169223	0.653	rs3743057	chr15:79089007	T/C	cg03762349	chr15:79060523	ADAMTS7	-0.24	-4.82	-0.4	4.03e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
TGCT	cis	rs6988636	0.710	rs73339623	chr8:124140288	A/G	cg27053337	chr8:124217698	FAM83A	0.77	5.55	0.45	1.65e-7	Urinary uromodulin levels;
TGCT	cis	rs28595532	0.920	rs114420700	chr4:119751297	T/C	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs10782582	0.632	rs11810154	chr1:76239973	C/G	cg03433033	chr1:76189801	ACADM	-0.46	-4.64	-0.38	8.83e-6	Daytime sleep phenotypes;
TGCT	cis	rs4455778	0.580	rs6583508	chr7:49122331	C/A	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs7727544	0.735	rs273914	chr5:131660431	A/T	cg14196790	chr5:131705035	SLC22A5	0.32	4.56	0.38	1.19e-5	Blood metabolite levels;
TGCT	cis	rs9468199	0.523	rs9468152	chr6:27492906	A/C	cg11744777	chr6:27799370	HIST1H4K	-0.67	-4.51	-0.38	1.49e-5	Parkinson's disease;
TGCT	cis	rs3749237	0.595	rs1464567	chr3:49459252	C/G	cg03060546	chr3:49711283	APEH	-0.77	-8.78	-0.62	1.11e-14	Resting heart rate;
TGCT	cis	rs1406084	0.636	rs3843320	chr2:154717638	A/C	cg25703346	chr2:154729189	GALNT13	0.82	4.6	0.38	1.03e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1568889	0.838	rs4614434	chr11:28302234	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.93	10.99	0.7	4.8e-20	Bipolar disorder;
TGCT	cis	rs2073300	1.000	rs6132623	chr20:23442324	T/A	cg09953122	chr20:23471693	CST8	-0.64	-4.56	-0.38	1.19e-5	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs8179	0.645	rs7804293	chr7:92287849	T/G	cg15732164	chr7:92237376	CDK6	-0.3	-5.11	-0.42	1.17e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
TGCT	trans	rs1814175	0.817	rs7932683	chr11:49983640	G/A	cg03929089	chr4:120376271	NA	-0.72	-8.53	-0.61	4.24e-14	Height;
TGCT	cis	rs801193	0.904	rs4718405	chr7:66254646	A/G	cg00343986	chr7:65444356	GUSB	0.24	5.18	0.42	8.62e-7	Aortic root size;
TGCT	cis	rs6681544	0.760	rs4970653	chr1:82429979	T/C	cg04226724	chr1:82268649	LPHN2	-0.48	-4.95	-0.41	2.42e-6	Metabolite levels  (X-11787);
TGCT	cis	rs751728	0.965	rs9394165	chr6:33731408	G/A	cg13859433	chr6:33739653	LEMD2	-0.39	-7.32	-0.55	2.67e-11	Crohn's disease;
TGCT	cis	rs4689388	0.853	rs6817447	chr4:6286847	G/T	cg14416269	chr4:6271139	WFS1	0.41	5.42	0.44	2.99e-7	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs11098499	0.738	rs10026493	chr4:120384194	C/G	cg09307838	chr4:120376055	NA	0.68	6.53	0.51	1.54e-9	Corneal astigmatism;
TGCT	cis	rs7100689	0.646	rs1538823	chr10:82088040	C/A	cg01528321	chr10:82214614	TSPAN14	0.75	7.49	0.56	1.15e-11	Post bronchodilator FEV1;
TGCT	cis	rs7904368	1.000	rs7904368	chr10:16858587	C/T	cg14835575	chr10:16859367	RSU1	0.61	6.84	0.52	3.29e-10	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
TGCT	cis	rs2290402	0.572	rs3736087	chr4:876318	C/T	cg11315544	chr4:1222440	CTBP1	0.27	4.62	0.38	9.36e-6	Type 2 diabetes;
TGCT	cis	rs34245846	0.769	rs12089942	chr1:154827522	T/C	cg06418219	chr1:154948305	SHC1;CKS1B	0.73	5.86	0.47	3.83e-8	Atrial fibrillation;
TGCT	cis	rs7584330	0.704	rs72620821	chr2:238362615	C/A	cg14458575	chr2:238380390	NA	0.59	8.88	0.62	6.18e-15	Prostate cancer;
TGCT	cis	rs68170813	0.559	rs17429146	chr7:106964281	A/G	cg02696742	chr7:106810147	HBP1	-0.68	-5.52	-0.44	1.9e-7	Coronary artery disease;
TGCT	cis	rs11209002	0.567	rs2755269	chr1:67541065	T/C	cg02640540	chr1:67518911	SLC35D1	0.53	4.45	0.37	1.86e-5	Crohn's disease;
TGCT	cis	rs12142240	0.660	rs7520497	chr1:46824919	C/A	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs8032315	0.965	rs35346340	chr15:91427872	G/C	cg04510874	chr15:91427884	FES	0.52	5.77	0.46	6e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg08859206	chr1:53392774	SCP2	-0.42	-6.8	-0.52	3.92e-10	Monocyte count;
TGCT	trans	rs17685	0.753	rs869806	chr7:75688623	C/T	cg19862616	chr7:65841803	NCRNA00174	0.51	8.69	0.62	1.78e-14	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg05368731	chr17:41323189	NBR1	1.2	14.59	0.79	1.08e-28	Menopause (age at onset);
TGCT	cis	rs9517313	0.615	rs4772079	chr13:99090837	C/G	cg07423050	chr13:99094983	FARP1	-0.33	-6.67	-0.51	7.67e-10	Neuroticism;
TGCT	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg23131131	chr22:24373011	LOC391322	0.77	7.24	0.55	4.12e-11	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg17971929	chr21:40555470	PSMG1	-0.51	-4.64	-0.38	8.88e-6	Menarche (age at onset);
TGCT	cis	rs3862260	0.509	rs2281493	chr1:120162787	T/C	cg11530693	chr1:120165357	ZNF697	0.2	4.53	0.38	1.38e-5	Systemic lupus erythematosus;
TGCT	cis	rs2070488	0.965	rs2051216	chr3:38562288	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.83	-8.45	-0.6	6.78e-14	Electrocardiographic conduction measures;
TGCT	trans	rs731174	0.592	rs12121777	chr1:38188841	C/T	cg19725343	chr19:51830960	IGLON5	-0.63	-7.18	-0.54	5.57e-11	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs73198271	0.740	rs28521727	chr8:8647217	T/C	cg06671706	chr8:8559999	CLDN23	-0.35	-4.5	-0.37	1.52e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs12134133	1.000	rs4844590	chr1:207496129	C/T	cg08855249	chr1:207975363	MIR29C	0.2	4.61	0.38	1e-5	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs1997103	1.000	rs6949222	chr7:55411264	C/T	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs6088590	0.561	rs2295444	chr20:33173883	C/T	cg06115741	chr20:33292138	TP53INP2	0.51	4.47	0.37	1.76e-5	Coronary artery disease;
TGCT	cis	rs62244186	0.520	rs9311361	chr3:44796132	T/G	cg15687855	chr3:44754131	ZNF502	-0.52	-6.39	-0.5	2.99e-9	Depressive symptoms;
TGCT	cis	rs2760061	0.819	rs1745416	chr1:228204497	G/A	cg02753203	chr1:228287806	NA	0.32	6.14	0.48	1e-8	Diastolic blood pressure;
TGCT	cis	rs854765	0.619	rs1101727	chr17:18016148	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	7.52	0.56	9.35e-12	Total body bone mineral density;
TGCT	cis	rs17539620	0.624	rs62432738	chr6:154835674	T/C	cg20019720	chr6:154832845	CNKSR3	0.57	5.02	0.41	1.72e-6	Lipoprotein (a) levels;
TGCT	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg24531977	chr5:56204891	C5orf35	0.88	7.52	0.56	9.39e-12	Initial pursuit acceleration;
TGCT	cis	rs2639990	1.000	rs655156	chr18:72898181	T/C	cg18449964	chr18:72917101	ZADH2	0.93	6.3	0.49	4.62e-9	Vascular endothelial growth factor levels;
TGCT	cis	rs864537	0.590	rs1214596	chr1:167427170	A/T	cg22356347	chr1:167427500	CD247	0.18	4.69	0.39	6.98e-6	Celiac disease or Rheumatoid arthritis;Celiac disease;
TGCT	cis	rs4766566	0.704	rs11065861	chr12:111752211	A/G	cg10833066	chr12:111807467	FAM109A	0.36	6.36	0.5	3.6e-9	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
TGCT	cis	rs6543140	0.964	rs2141781	chr2:103082906	G/A	cg09003973	chr2:102972529	NA	0.54	4.46	0.37	1.83e-5	Blood protein levels;
TGCT	cis	rs858239	0.600	rs6967475	chr7:23128982	C/T	cg05602783	chr7:23145260	KLHL7	-0.57	-4.67	-0.39	7.64e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg11494091	chr17:61959527	GH2	-0.61	-15.24	-0.81	3.34e-30	Prudent dietary pattern;
TGCT	cis	rs9942416	0.660	rs2307113	chr5:74998264	C/T	cg19683494	chr5:74908142	NA	0.57	6.37	0.5	3.33e-9	Age-related disease endophenotypes;
TGCT	cis	rs79349575	0.783	rs903567	chr17:46980318	C/T	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.44	-0.37	1.95e-5	Type 2 diabetes;
TGCT	cis	rs986417	0.901	rs1884094	chr14:61016933	C/G	cg27398547	chr14:60952738	C14orf39	1.42	8.85	0.62	7.44e-15	Gut microbiota (bacterial taxa);
TGCT	cis	rs7824557	0.836	rs2736378	chr8:11119760	G/A	cg21775007	chr8:11205619	TDH	-0.6	-5.91	-0.47	3.16e-8	Retinal vascular caliber;
TGCT	cis	rs3733585	0.775	rs13124007	chr4:10043931	G/C	cg00071950	chr4:10020882	SLC2A9	0.57	6.47	0.5	2.01e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs6752107	0.870	rs13418066	chr2:234145944	A/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.2	4.89	0.4	3.02e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs4273100	0.688	rs4924967	chr17:19172196	T/G	cg03910582	chr17:19030146	GRAPL	0.51	6.15	0.48	9.7e-9	Schizophrenia;
TGCT	cis	rs1971256	0.500	rs17081325	chr6:151817992	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.75	-4.58	-0.38	1.1e-5	Endometriosis;
TGCT	cis	rs2486012	0.579	rs4660750	chr1:44250381	T/C	cg12908607	chr1:44402522	ARTN	-0.71	-5.61	-0.45	1.26e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs35938349	chr4:98974998	T/C	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs921968	0.643	rs832801	chr2:219488698	G/A	cg02176678	chr2:219576539	TTLL4	0.43	6.11	0.48	1.19e-8	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs17133449	0.696	rs10904325	chr10:4751327	G/T	cg04530666	chr10:3759553	NA	0.31	4.74	0.39	5.82e-6	Major depressive disorder;
TGCT	cis	rs6701037	0.566	rs1014555	chr1:175134249	C/T	cg08873628	chr1:175162347	KIAA0040	0.48	4.57	0.38	1.15e-5	Alcohol dependence;
TGCT	cis	rs5760092	0.842	rs5760103	chr22:24248781	A/G	cg00024416	chr22:24240387	NA	-0.39	-6.62	-0.51	9.68e-10	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs7937682	0.632	rs11214015	chr11:111719417	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.8	-7.0	-0.53	1.46e-10	Primary sclerosing cholangitis;
TGCT	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.79	7.56	0.56	7.67e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs60843830	1.000	rs11553746	chr2:272203	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.71	6.79	0.52	4.24e-10	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6695640	0.819	rs2762887	chr1:17731440	A/G	cg25979543	chr1:17888104	ARHGEF10L	-0.25	-4.57	-0.38	1.14e-5	Mean platelet volume;
TGCT	cis	rs7927771	0.832	rs11039212	chr11:47393303	A/T	cg21462715	chr11:47870315	NUP160	-0.57	-4.58	-0.38	1.11e-5	Subjective well-being;
TGCT	trans	rs2688608	0.647	rs2633319	chr10:75691247	A/T	cg13918328	chr10:52500089	ASAH2B	0.68	6.68	0.51	7.27e-10	Inflammatory bowel disease;
TGCT	cis	rs17221829	0.673	rs1962257	chr11:89380737	G/T	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.63	-0.38	9.04e-6	Anxiety in major depressive disorder;
TGCT	cis	rs7666738	0.924	rs62318940	chr4:99064768	C/T	cg18180107	chr4:99064573	C4orf37	0.57	4.51	0.38	1.49e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg06873352	chr17:61820015	STRADA	0.56	6.22	0.49	7.1e-9	Prudent dietary pattern;
TGCT	cis	rs11190604	0.767	rs10509743	chr10:102190406	C/T	cg16342193	chr10:102329863	NA	-0.4	-5.02	-0.41	1.74e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs362296	0.698	rs362282	chr4:3259671	G/A	cg06533319	chr4:3265114	C4orf44	0.24	4.45	0.37	1.86e-5	Parental longevity (mother's age at death);
TGCT	cis	rs1395	0.922	rs11608	chr2:27435374	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.48	-6.35	-0.5	3.72e-9	Blood metabolite levels;
TGCT	cis	rs6570726	0.577	rs441982	chr6:145842848	A/G	cg13319975	chr6:146136371	FBXO30	-0.69	-6.08	-0.48	1.38e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6582630	0.555	rs1969362	chr12:38514843	C/T	cg13010199	chr12:38710504	ALG10B	0.6	4.77	0.39	5e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs9300255	0.602	rs1716168	chr12:123651966	C/G	cg00376283	chr12:123451042	ABCB9	-0.72	-5.55	-0.45	1.65e-7	Neutrophil percentage of white cells;
TGCT	cis	rs9372498	0.536	rs55899435	chr6:118812099	C/T	cg07617317	chr6:118971624	C6orf204	0.46	5.08	0.41	1.36e-6	Diastolic blood pressure;
TGCT	cis	rs7829975	0.606	rs7833171	chr8:8699761	C/T	cg06636001	chr8:8085503	FLJ10661	0.71	6.25	0.49	6.17e-9	Mood instability;
TGCT	cis	rs7666738	0.761	rs1456210	chr4:98645932	T/G	cg17366294	chr4:99064904	C4orf37	0.57	5.85	0.47	4.02e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12580194	0.593	rs12099808	chr12:55731178	T/A	cg10672482	chr12:55725839	OR6C3	-0.54	-4.77	-0.39	5.17e-6	Cancer;
TGCT	cis	rs8017423	0.647	rs12590712	chr14:90822481	T/C	cg04374321	chr14:90722782	PSMC1	-0.54	-5.41	-0.44	3.13e-7	Mortality in heart failure;
TGCT	cis	rs9303542	0.625	rs4793889	chr17:46592352	A/G	cg25032089	chr17:46643351	HOXB3	-0.52	-5.56	-0.45	1.6e-7	Ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs6061231	0.571	rs482010	chr20:60927551	A/G	cg06026331	chr20:60912101	LAMA5	-0.26	-4.69	-0.39	7.23e-6	Colorectal cancer;
TGCT	cis	rs9435341	0.930	rs61798463	chr1:107565934	G/A	cg09367891	chr1:107599246	PRMT6	0.62	5.4	0.44	3.22e-7	Facial morphology (factor 21, depth of nasal alae);
TGCT	cis	rs80282103	0.764	rs10047382	chr10:1102868	T/C	cg08668510	chr10:1095578	IDI1	1.01	4.51	0.38	1.48e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs6598955	0.543	rs881578	chr1:26536141	G/A	cg04990556	chr1:26633338	UBXN11	0.82	7.9	0.58	1.31e-12	Obesity-related traits;
TGCT	cis	rs9913156	0.793	rs72835642	chr17:4573407	T/C	cg19197139	chr17:4613644	ARRB2	0.86	7.97	0.58	8.69e-13	Lymphocyte counts;
TGCT	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg27286337	chr10:134555280	INPP5A	0.42	5.3	0.43	5.03e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs12615966	0.932	rs17030310	chr2:105391647	C/T	cg16465502	chr2:105461796	NA	-0.79	-5.07	-0.41	1.42e-6	Pancreatic cancer;
TGCT	cis	rs67311347	1.000	rs9822909	chr3:40457084	G/T	cg17264618	chr3:40429014	ENTPD3	0.32	4.72	0.39	6.22e-6	Renal cell carcinoma;
TGCT	cis	rs80282103	0.764	rs7093915	chr10:1107341	A/G	cg08668510	chr10:1095578	IDI1	-0.98	-5.31	-0.43	4.82e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs473651	0.837	rs563458	chr2:239345613	T/A	cg21699342	chr2:239360505	ASB1	0.17	4.75	0.39	5.46e-6	Multiple system atrophy;
TGCT	cis	rs9611565	0.506	rs2024567	chr22:41699206	G/C	cg06634786	chr22:41940651	POLR3H	-0.63	-5.66	-0.45	1.01e-7	Vitiligo;
TGCT	cis	rs4911253	0.509	rs66499347	chr20:31448696	C/T	cg13636640	chr20:31349939	DNMT3B	-0.78	-8.09	-0.59	4.68e-13	Lymphocyte counts;
TGCT	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg00149659	chr3:10157352	C3orf10	0.98	6.24	0.49	6.21e-9	Alzheimer's disease;
TGCT	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg18135555	chr8:22132992	PIWIL2	0.29	5.84	0.46	4.32e-8	Hypertriglyceridemia;
TGCT	cis	rs2153535	0.580	rs965706	chr6:8464708	G/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs2197308	0.765	rs12824529	chr12:37931656	T/C	cg26384229	chr12:38710491	ALG10B	0.87	7.83	0.58	1.85e-12	Morning vs. evening chronotype;
TGCT	cis	rs71435601	0.628	rs4591370	chr2:21383742	C/T	cg25035485	chr2:21266500	APOB	-0.51	-4.48	-0.37	1.64e-5	Cholesterol, total;
TGCT	cis	rs9325144	0.560	rs11182952	chr12:38636278	C/A	cg26384229	chr12:38710491	ALG10B	-0.66	-5.98	-0.47	2.23e-8	Morning vs. evening chronotype;
TGCT	cis	rs7786808	0.608	rs6978352	chr7:158209802	T/C	cg01191920	chr7:158217561	PTPRN2	0.38	5.73	0.46	7.25e-8	Obesity-related traits;
TGCT	cis	rs7246657	0.943	rs10415937	chr19:37830064	T/G	cg18154014	chr19:37997991	ZNF793	0.72	5.19	0.42	8.31e-7	Coronary artery calcification;
TGCT	cis	rs1536827	0.541	rs11101814	chr10:135355702	C/G	cg12448312	chr10:135032219	KNDC1	-0.49	-4.91	-0.4	2.87e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs35146811	0.700	rs858513	chr7:99825558	G/A	cg22906224	chr7:99728672	NA	-0.5	-4.51	-0.38	1.48e-5	Coronary artery disease;
TGCT	trans	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg21659725	chr3:3221576	CRBN	-0.73	-8.48	-0.61	5.64e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs10089	1.000	rs10463838	chr5:127518305	C/T	cg19767477	chr5:127420684	SLC12A2	-0.45	-4.77	-0.39	5.08e-6	Ileal carcinoids;
TGCT	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.48	-0.37	1.66e-5	Bipolar disorder;
TGCT	cis	rs10946940	0.965	rs6910838	chr6:27515519	A/C	cg10876282	chr6:28092338	ZSCAN16	-0.46	-4.63	-0.38	9.22e-6	Systemic lupus erythematosus;
TGCT	cis	rs7666738	0.830	rs17486413	chr4:99060544	G/T	cg17366294	chr4:99064904	C4orf37	0.69	6.89	0.53	2.54e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg20007245	chr22:24372913	LOC391322	-0.78	-8.42	-0.6	7.69e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg23708337	chr7:1209742	NA	0.6	5.57	0.45	1.53e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs8072100	0.713	rs1912486	chr17:45515167	A/G	cg08085267	chr17:45401833	C17orf57	-0.52	-5.75	-0.46	6.48e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg17179660	chr6:151773299	C6orf211;RMND1	-0.54	-4.88	-0.4	3.17e-6	Menarche (age at onset);
TGCT	cis	rs28595532	0.920	rs115320476	chr4:119759680	G/A	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs1499614	1.000	rs1267817	chr7:66110040	G/T	cg18252515	chr7:66147081	NA	-1.23	-7.53	-0.56	9.12e-12	Gout;
TGCT	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.58	-5.83	-0.46	4.44e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7208859	0.673	rs73265624	chr17:29232066	G/A	cg14008862	chr17:28927542	LRRC37B2	0.72	4.66	0.39	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs6831352	0.918	rs29001231	chr4:100046680	T/C	cg12011299	chr4:100065546	ADH4	-0.41	-4.92	-0.4	2.72e-6	Alcohol dependence;
TGCT	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg04414720	chr1:150670196	GOLPH3L	0.38	5.0	0.41	1.88e-6	Tonsillectomy;
TGCT	cis	rs6674176	0.932	rs7412307	chr1:44433864	C/G	cg12908607	chr1:44402522	ARTN	0.74	8.47	0.61	5.88e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs2070433	0.539	rs56157650	chr21:47957959	T/C	cg12379764	chr21:47803548	PCNT	0.54	5.44	0.44	2.69e-7	Lymphocyte counts;
TGCT	cis	rs2692947	0.673	rs1168965	chr2:96787899	C/G	cg23100626	chr2:96804247	ASTL	-0.41	-4.99	-0.41	1.96e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs2338224	1.000	rs10942301	chr5:71745457	G/A	cg01187920	chr5:71015162	CARTPT	-0.53	-4.57	-0.38	1.15e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Granulocyte count;Myeloid white cell count;
TGCT	cis	rs7017914	0.875	rs2732107	chr8:71925308	A/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.56	-5.11	-0.42	1.19e-6	Bone mineral density;
TGCT	cis	rs4727027	0.933	rs1468369	chr7:148839840	G/C	cg23583168	chr7:148888333	NA	-0.72	-9.18	-0.64	1.18e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs739496	0.579	rs12296574	chr12:112322777	T/C	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	trans	rs6762477	0.748	rs34877766	chr3:50234126	A/G	cg21659725	chr3:3221576	CRBN	0.67	7.32	0.55	2.78e-11	Menarche (age at onset);
TGCT	cis	rs72634258	0.554	rs1012477	chr1:7858135	C/G	cg26816564	chr1:7831052	VAMP3	-0.9	-6.76	-0.52	4.86e-10	Inflammatory bowel disease;
TGCT	cis	rs6977660	0.652	rs12673842	chr7:19747437	T/C	cg07541023	chr7:19748670	TWISTNB	1.15	7.28	0.55	3.33e-11	Thyroid stimulating hormone;
TGCT	cis	rs938554	0.513	rs4529048	chr4:9997112	G/T	cg11266682	chr4:10021025	SLC2A9	0.62	4.92	0.4	2.7e-6	Blood metabolite levels;
TGCT	cis	rs931127	0.624	rs2306364	chr11:65412467	G/A	cg17480646	chr11:65405466	SIPA1	-0.51	-6.44	-0.5	2.33e-9	Systemic lupus erythematosus;
TGCT	cis	rs3096299	0.658	rs12443705	chr16:89547054	C/G	cg06640241	chr16:89574553	SPG7	0.8	9.04	0.63	2.63e-15	Multiple myeloma (IgH translocation);
TGCT	cis	rs7647973	0.710	rs11130208	chr3:49615624	G/T	cg03060546	chr3:49711283	APEH	0.63	5.14	0.42	1.03e-6	Menarche (age at onset);
TGCT	trans	rs941408	1.000	rs2260416	chr19:2796355	G/A	cg22153745	chr1:153894579	GATAD2B	-0.64	-7.01	-0.53	1.39e-10	Total cholesterol levels;
TGCT	cis	rs7727544	0.661	rs273900	chr5:131694606	G/A	cg24060327	chr5:131705240	SLC22A5	-0.57	-6.43	-0.5	2.55e-9	Blood metabolite levels;
TGCT	cis	rs7267979	0.816	rs6138593	chr20:25504492	A/G	cg14121845	chr20:25566513	NINL	0.46	4.76	0.39	5.36e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10751667	0.857	rs6597961	chr11:976677	T/C	cg06064525	chr11:970664	AP2A2	-0.33	-6.51	-0.5	1.71e-9	Alzheimer's disease (late onset);
TGCT	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg07870213	chr5:140052090	DND1	-0.59	-6.89	-0.53	2.5e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7666738	0.716	rs13136721	chr4:99085602	G/A	cg17366294	chr4:99064904	C4orf37	0.68	6.69	0.51	6.92e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4389656	0.857	rs2279657	chr5:6737571	A/G	cg10857441	chr5:6722123	POLS	-0.22	-4.74	-0.39	5.75e-6	Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs10031751	chr4:98939134	G/A	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs40363	1.000	rs1690444	chr16:3518350	G/A	cg05754148	chr16:3507555	NAT15	0.48	4.68	0.39	7.32e-6	Tuberculosis;
TGCT	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg07298985	chr8:22133076	PIWIL2	0.33	5.14	0.42	1.04e-6	Hypertriglyceridemia;
TGCT	cis	rs6722750	0.818	rs13411753	chr2:64394417	A/G	cg22352474	chr2:64371530	PELI1	0.65	6.02	0.48	1.79e-8	Neuroticism;
TGCT	cis	rs832540	0.669	rs832539	chr5:56199386	A/C	cg24531977	chr5:56204891	C5orf35	-0.68	-6.83	-0.52	3.47e-10	Coronary artery disease;
TGCT	cis	rs524281	0.861	rs10896086	chr11:65914764	T/A	cg00563793	chr11:65837595	PACS1	0.57	4.68	0.39	7.4e-6	Electroencephalogram traits;
TGCT	cis	rs6570726	0.764	rs9386125	chr6:145911677	C/T	cg05347473	chr6:146136440	FBXO30	0.51	4.75	0.39	5.42e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3540	0.512	rs8033818	chr15:91075535	C/T	cg22089800	chr15:90895588	ZNF774	-0.74	-7.58	-0.56	7.14e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs2439831	0.850	rs12441984	chr15:44126285	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.44	0.37	1.99e-5	Lung cancer in ever smokers;
TGCT	cis	rs2153535	0.521	rs6939827	chr6:8461360	C/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs11175492	0.528	rs11175480	chr12:65028492	G/A	cg18624581	chr12:65153313	GNS	-0.85	-4.64	-0.38	8.76e-6	Platelet count;
TGCT	cis	rs10479542	0.806	rs4700835	chr5:178976313	A/G	cg19723775	chr5:179050963	HNRNPH1	0.48	4.64	0.38	8.71e-6	Lung cancer;
TGCT	cis	rs7822232	1.000	rs6558296	chr8:145143802	G/A	cg06239191	chr8:145163136	KIAA1875	-0.88	-6.45	-0.5	2.26e-9	Blood metabolite levels;
TGCT	cis	rs7824557	0.724	rs2251473	chr8:11177126	C/A	cg21775007	chr8:11205619	TDH	0.56	5.14	0.42	1.05e-6	Retinal vascular caliber;
TGCT	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg05896524	chr21:47604654	C21orf56	0.4	4.5	0.37	1.54e-5	Testicular germ cell tumor;
TGCT	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg06212747	chr3:49208901	KLHDC8B	0.61	5.51	0.44	2e-7	Parkinson's disease;
TGCT	cis	rs7249142	0.549	rs12975253	chr19:19279745	A/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.56	5.62	0.45	1.18e-7	IgG glycosylation;
TGCT	cis	rs7666738	0.830	rs7679961	chr4:99000202	C/T	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10751667	1.000	rs6597972	chr11:928402	C/T	cg06064525	chr11:970664	AP2A2	-0.33	-6.4	-0.5	2.96e-9	Alzheimer's disease (late onset);
TGCT	cis	rs854765	0.583	rs12452254	chr17:17829434	G/A	cg09796270	chr17:17721594	SREBF1	0.27	5.53	0.44	1.84e-7	Total body bone mineral density;
TGCT	trans	rs561341	0.941	rs8066156	chr17:30361629	A/G	cg20587970	chr11:113659929	NA	-0.96	-12.63	-0.75	5.23e-24	Hip circumference adjusted for BMI;
TGCT	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg03732007	chr1:2071316	PRKCZ	-0.26	-5.92	-0.47	2.9e-8	Height;
TGCT	cis	rs7010267	0.602	rs7822098	chr8:120020129	A/T	cg17171407	chr8:119960777	TNFRSF11B	0.26	4.59	0.38	1.06e-5	Total body bone mineral density (age 45-60);
TGCT	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	6.75	0.52	5.02e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9910055	0.529	rs368328	chr17:42170289	G/A	cg19774624	chr17:42201019	HDAC5	0.77	6.98	0.53	1.61e-10	Total body bone mineral density;
TGCT	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg11871910	chr12:69753446	YEATS4	0.89	10.53	0.69	6.39e-19	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs7829975	0.567	rs6601273	chr8:8796519	T/G	cg15556689	chr8:8085844	FLJ10661	-0.69	-6.14	-0.48	1.01e-8	Mood instability;
TGCT	cis	rs9486719	0.857	rs13208321	chr6:96860354	C/T	cg06623918	chr6:96969491	KIAA0776	-0.97	-9.58	-0.65	1.3e-16	Migraine;Coronary artery disease;
TGCT	cis	rs9291683	0.620	rs4383618	chr4:10125151	T/C	cg00071950	chr4:10020882	SLC2A9	-0.43	-4.7	-0.39	6.69e-6	Bone mineral density;
TGCT	cis	rs2070488	0.965	rs7372386	chr3:38484175	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.92	9.68	0.66	7.36e-17	Electrocardiographic conduction measures;
TGCT	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg08859206	chr1:53392774	SCP2	-0.43	-6.71	-0.52	6.34e-10	Monocyte count;
TGCT	cis	rs9467711	0.606	rs9393705	chr6:26361011	G/A	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4862307	0.514	rs7696176	chr4:185014390	A/G	cg06737308	chr4:185021514	ENPP6	0.47	7.56	0.56	7.6e-12	Serum dimethylarginine levels (asymmetric/symetric ratio);
TGCT	cis	rs12497850	0.765	rs12487580	chr3:49182932	G/A	cg07636037	chr3:49044803	WDR6	0.94	10.1	0.67	7.08e-18	Parkinson's disease;
TGCT	cis	rs7647973	0.593	rs59684465	chr3:49874246	C/T	cg03034192	chr3:50606346	HEMK1;C3orf18	-0.34	-4.51	-0.38	1.5e-5	Menarche (age at onset);
TGCT	cis	rs9583531	0.660	rs34523940	chr13:111350205	C/T	cg15747390	chr13:111297551	CARS2	0.73	5.03	0.41	1.65e-6	Coronary artery disease;
TGCT	cis	rs910316	1.000	rs12889472	chr14:75543979	A/G	cg08847533	chr14:75593920	NEK9	0.96	10.54	0.69	6.25e-19	Height;
TGCT	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg08859206	chr1:53392774	SCP2	-0.4	-4.52	-0.38	1.4e-5	Monocyte count;
TGCT	cis	rs9611565	0.559	rs13056262	chr22:42081921	A/G	cg03806693	chr22:41940476	POLR3H	1.08	11.79	0.73	5.53e-22	Vitiligo;
TGCT	cis	rs7267979	0.816	rs405822	chr20:25501314	A/G	cg14121845	chr20:25566513	NINL	0.46	4.76	0.39	5.36e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10028773	0.556	rs4473640	chr4:120260437	G/A	cg09307838	chr4:120376055	NA	0.53	5.16	0.42	9.36e-7	Educational attainment;
TGCT	cis	rs12950390	0.853	rs59513807	chr17:45867925	G/A	cg06532163	chr17:45867833	NA	0.37	5.96	0.47	2.45e-8	IgG glycosylation;
TGCT	cis	rs9916302	0.851	rs6503518	chr17:37660469	A/G	cg15445000	chr17:37608096	MED1	0.31	4.59	0.38	1.06e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs9291683	0.588	rs3756237	chr4:10013378	G/A	cg11266682	chr4:10021025	SLC2A9	0.73	11.04	0.7	3.63e-20	Bone mineral density;
TGCT	cis	rs2153535	0.541	rs4637688	chr6:8446501	A/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.29e-6	Motion sickness;
TGCT	cis	rs2404602	0.716	rs17460201	chr15:76673627	C/T	cg22467129	chr15:76604101	ETFA	0.56	6.56	0.51	1.32e-9	Blood metabolite levels;
TGCT	cis	rs8078723	0.933	rs4794822	chr17:38156712	C/T	cg17467752	chr17:38218738	THRA	0.55	5.34	0.43	4.24e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs7659604	0.502	rs13108419	chr4:122687238	A/G	cg05802129	chr4:122689817	NA	0.29	4.46	0.37	1.84e-5	Type 2 diabetes;
TGCT	cis	rs11662586	0.517	rs11663082	chr18:77713494	C/T	cg20368463	chr18:77673604	PQLC1	0.6	7.0	0.53	1.39e-10	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
TGCT	cis	rs13082711	0.522	rs574955	chr3:27351000	T/C	cg02860705	chr3:27208620	NA	0.32	5.24	0.43	6.6e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs9388451	0.903	rs7758115	chr6:126061502	C/T	cg05901451	chr6:126070800	HEY2	-0.97	-12.85	-0.76	1.53e-24	Brugada syndrome;
TGCT	cis	rs11264213	0.901	rs631202	chr1:36449099	G/C	cg26235710	chr1:36184717	C1orf216	0.97	4.55	0.38	1.25e-5	Schizophrenia;
TGCT	cis	rs12681287	0.604	rs28378899	chr8:87434500	G/C	cg27223183	chr8:87520930	FAM82B	0.89	6.43	0.5	2.54e-9	Caudate activity during reward;
TGCT	cis	rs739496	0.615	rs11609628	chr12:112217208	G/A	cg10833066	chr12:111807467	FAM109A	0.36	4.67	0.39	7.74e-6	Platelet count;
TGCT	cis	rs75229567	0.618	rs10219700	chr12:70201730	A/G	cg10114359	chr12:70132523	RAB3IP	-1.06	-5.95	-0.47	2.6e-8	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
TGCT	cis	rs362296	0.698	rs3095081	chr4:3263776	C/T	cg06533319	chr4:3265114	C4orf44	0.23	4.85	0.4	3.67e-6	Parental longevity (mother's age at death);
TGCT	cis	rs7666738	0.830	rs6846739	chr4:99016647	G/A	cg17366294	chr4:99064904	C4orf37	0.68	7.04	0.53	1.17e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg11764359	chr7:65958608	NA	0.54	4.85	0.4	3.67e-6	Aortic root size;
TGCT	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs1729951	0.575	rs16844362	chr3:136704008	T/C	cg21827317	chr3:136751795	NA	0.4	5.61	0.45	1.24e-7	Neuroticism;
TGCT	cis	rs910316	1.000	rs12435391	chr14:75601737	A/G	cg08847533	chr14:75593920	NEK9	0.92	9.91	0.66	2.1e-17	Height;
TGCT	cis	rs7914558	0.966	rs10786719	chr10:104637992	C/T	cg15744005	chr10:104629667	AS3MT	0.41	5.3	0.43	5.14e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs12950390	0.853	rs8071192	chr17:45856141	A/G	cg06532163	chr17:45867833	NA	0.37	5.89	0.47	3.46e-8	IgG glycosylation;
TGCT	cis	rs8180040	0.932	rs11711265	chr3:47558448	T/C	cg27129171	chr3:47204927	SETD2	0.62	7.36	0.55	2.26e-11	Colorectal cancer;
TGCT	cis	rs559928	0.569	rs7103915	chr11:63944370	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.75	-4.85	-0.4	3.58e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
TGCT	cis	rs4972806	0.668	rs2072588	chr2:177042930	G/C	cg13092806	chr2:177043255	NA	0.6	5.24	0.43	6.62e-7	IgG glycosylation;
TGCT	cis	rs9902453	0.967	rs8082175	chr17:28430303	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.74	6.57	0.51	1.22e-9	Coffee consumption (cups per day);
TGCT	cis	rs34684276	1	rs34684276	chr15:78813155	G/A	cg18825076	chr15:78729989	IREB2	-0.3	-4.5	-0.37	1.58e-5	Nicotine dependence;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
TGCT	cis	rs6748734	0.901	rs6720357	chr2:241830296	A/C	cg04034577	chr2:241836375	C2orf54	-0.4	-6.32	-0.49	4.22e-9	Urinary metabolites;
TGCT	cis	rs6490294	0.904	rs60217649	chr12:112410920	C/T	cg10833066	chr12:111807467	FAM109A	0.39	5.53	0.44	1.83e-7	Mean platelet volume;
TGCT	trans	rs17685	0.725	rs1044483	chr7:75659815	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.52	-8.78	-0.62	1.07e-14	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs2463822	1.000	rs1881534	chr11:62085083	A/G	cg06239285	chr11:62104954	ASRGL1	0.95	6.58	0.51	1.18e-9	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs2486012	1.000	rs2486014	chr1:44419546	T/C	cg12908607	chr1:44402522	ARTN	0.77	6.02	0.48	1.79e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs6582630	0.555	rs11613249	chr12:38519339	T/C	cg26384229	chr12:38710491	ALG10B	0.84	7.68	0.57	4.16e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs6598955	0.671	rs10159433	chr1:26618370	A/G	cg04990556	chr1:26633338	UBXN11	0.64	4.91	0.4	2.78e-6	Obesity-related traits;
TGCT	trans	rs10506458	0.915	rs56321182	chr12:63392023	C/T	cg22491629	chr6:157744540	C6orf35	-0.99	-8.55	-0.61	3.94e-14	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs986417	0.901	rs11158292	chr14:61043183	G/T	cg27398547	chr14:60952738	C14orf39	1.48	11.08	0.71	2.96e-20	Gut microbiota (bacterial taxa);
TGCT	cis	rs68170813	0.559	rs12533767	chr7:106860245	A/C	cg02696742	chr7:106810147	HBP1	-0.69	-5.61	-0.45	1.27e-7	Coronary artery disease;
TGCT	cis	rs2456568	0.867	rs7935801	chr11:93658000	G/A	cg16099599	chr11:93583650	C11orf90	-0.41	-4.78	-0.39	4.87e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7647973	1.000	rs1009051	chr3:49521549	G/A	cg05785598	chr3:49045655	WDR6	0.37	4.52	0.38	1.42e-5	Menarche (age at onset);
TGCT	cis	rs9611565	0.512	rs4822052	chr22:42193741	G/A	cg03806693	chr22:41940476	POLR3H	-0.96	-9.99	-0.67	1.36e-17	Vitiligo;
TGCT	cis	rs2842992	0.830	rs2758312	chr6:160153452	G/A	cg11366901	chr6:160182831	ACAT2	1.03	6.92	0.53	2.14e-10	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg18188782	chr20:61659543	NA	0.44	5.29	0.43	5.3e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1461503	0.932	rs6589962	chr11:122843535	G/A	cg27398637	chr11:122830231	C11orf63	-0.43	-5.31	-0.43	5e-7	Menarche (age at onset);
TGCT	cis	rs478304	0.903	rs61895677	chr11:65549415	T/C	cg27068330	chr11:65405492	SIPA1	0.74	7.34	0.55	2.48e-11	Acne (severe);
TGCT	cis	rs17376456	0.877	rs10060462	chr5:93455073	C/T	cg21475434	chr5:93447410	FAM172A	0.6	4.62	0.38	9.48e-6	Diabetic retinopathy;
TGCT	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg18230493	chr5:56204884	C5orf35	-0.68	-5.92	-0.47	2.92e-8	Initial pursuit acceleration;
TGCT	cis	rs35146811	0.700	rs4729579	chr7:99780282	C/G	cg13334819	chr7:99746414	C7orf59	-0.74	-6.31	-0.49	4.4e-9	Coronary artery disease;
TGCT	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.57	-5.77	-0.46	5.91e-8	Electroencephalogram traits;
TGCT	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6089584	0.528	rs881994	chr20:60623931	G/A	cg06108461	chr20:60628389	TAF4	-0.45	-5.37	-0.43	3.78e-7	Body mass index;
TGCT	cis	rs60154123	0.505	rs76101197	chr1:210044089	T/C	cg23283495	chr1:209979779	IRF6	0.67	4.99	0.41	1.96e-6	Coronary artery disease;
TGCT	cis	rs10751667	1.000	rs10902246	chr11:953674	T/C	cg06064525	chr11:970664	AP2A2	-0.33	-6.49	-0.5	1.83e-9	Alzheimer's disease (late onset);
TGCT	cis	rs10751667	0.666	rs7396059	chr11:970490	C/A	cg06064525	chr11:970664	AP2A2	-0.36	-8.28	-0.6	1.67e-13	Alzheimer's disease (late onset);
TGCT	cis	rs6088590	1.000	rs6087626	chr20:33347328	C/T	cg24642439	chr20:33292090	TP53INP2	0.69	6.17	0.48	8.94e-9	Coronary artery disease;
TGCT	cis	rs10131894	0.529	rs10162358	chr14:75429593	A/G	cg06637938	chr14:75390232	RPS6KL1	0.55	4.77	0.39	5.16e-6	Coronary artery disease;
TGCT	cis	rs7954584	0.616	rs10743185	chr12:122356435	G/A	cg13699009	chr12:122356056	WDR66	0.32	7.33	0.55	2.6e-11	Mean corpuscular volume;
TGCT	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg21016266	chr12:122356598	WDR66	0.53	6.62	0.51	9.84e-10	Mean corpuscular volume;
TGCT	cis	rs12579753	1.000	rs7963577	chr12:82174115	T/C	cg07988820	chr12:82153109	PPFIA2	-0.65	-6.79	-0.52	4.09e-10	Resting heart rate;
TGCT	cis	rs732765	1.000	rs10134885	chr14:75373475	C/T	cg06637938	chr14:75390232	RPS6KL1	0.62	5.37	0.43	3.7e-7	Non-small cell lung cancer;
TGCT	cis	rs9911578	1.000	rs4793952	chr17:56608465	C/T	cg05425664	chr17:57184151	TRIM37	0.63	6.26	0.49	5.86e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs734999	0.967	rs7515633	chr1:2496653	A/G	cg18854424	chr1:2615690	NA	0.47	5.78	0.46	5.71e-8	Ulcerative colitis;
TGCT	cis	rs185694	1.000	rs595449	chr13:30896852	T/C	cg07600127	chr13:30881527	KATNAL1	-0.82	-6.75	-0.52	4.95e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
TGCT	cis	rs1355023	0.547	rs7767248	chr6:106228397	G/A	cg17356964	chr6:106582638	NA	0.26	4.92	0.4	2.7e-6	Age-related macular degeneration;
TGCT	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg10295955	chr4:187884368	NA	-0.96	-14.48	-0.79	2.04e-28	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2404602	0.692	rs12910734	chr15:77149931	A/G	cg26408565	chr15:76604113	ETFA	-0.36	-4.54	-0.38	1.33e-5	Blood metabolite levels;
TGCT	cis	rs4919694	1.000	rs12266291	chr10:104806884	G/A	cg04362960	chr10:104952993	NT5C2	1.07	7.09	0.54	8.9e-11	Arsenic metabolism;
TGCT	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.75	5.44	0.44	2.75e-7	Platelet count;
TGCT	cis	rs919433	0.680	rs2565163	chr2:198354414	T/C	cg00792783	chr2:198669748	PLCL1	0.52	4.73	0.39	5.98e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs9381040	0.655	rs6939989	chr6:41020205	A/G	cg03526776	chr6:41159608	TREML2	0.27	5.28	0.43	5.66e-7	Alzheimer's disease (late onset);
TGCT	cis	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg06636001	chr8:8085503	FLJ10661	-0.77	-7.37	-0.55	2.13e-11	Mood instability;
TGCT	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg27454412	chr7:1067447	C7orf50	0.6	4.72	0.39	6.32e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs11190604	1.000	rs7070776	chr10:102264672	A/G	cg23241863	chr10:102295624	HIF1AN	0.7	5.38	0.43	3.59e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs78487399	0.808	rs1388387	chr2:43736969	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-4.84	-0.4	3.79e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs3820068	0.603	rs72645900	chr1:15931980	A/T	cg05660106	chr1:15850417	CASP9	0.74	7.27	0.55	3.53e-11	Systolic blood pressure;
TGCT	cis	rs3820928	0.934	rs66959645	chr2:227761582	C/A	cg11843606	chr2:227700838	RHBDD1	-0.51	-4.51	-0.38	1.47e-5	Pulmonary function;
TGCT	cis	rs981844	0.796	rs17030437	chr4:154704225	A/C	cg14289246	chr4:154710475	SFRP2	-1.07	-9.0	-0.63	3.18e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg21724239	chr8:58056113	NA	0.33	4.54	0.38	1.31e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs28595532	0.920	rs115853212	chr4:119765354	C/T	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs4951018	0.821	rs11240547	chr1:205632932	A/G	cg26354017	chr1:205819088	PM20D1	0.4	4.59	0.38	1.06e-5	Prostate-specific antigen levels;
TGCT	cis	rs7582180	0.627	rs2099611	chr2:101021090	A/G	cg14675211	chr2:100938903	LONRF2	0.47	4.47	0.37	1.75e-5	Intelligence (multi-trait analysis);
TGCT	trans	rs1496653	0.602	rs35347265	chr3:23420397	T/C	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs28595532	0.920	rs116046128	chr4:119741990	C/T	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10984561	0.881	rs73540223	chr9:122250259	A/G	cg14242995	chr9:122249943	NA	0.75	6.12	0.48	1.16e-8	Pulmonary function decline;
TGCT	cis	rs6430585	0.527	rs2254780	chr2:136435526	C/T	cg07169764	chr2:136633963	MCM6	0.92	8.17	0.59	3.08e-13	Corneal structure;
TGCT	cis	rs4711350	0.765	rs756138	chr6:33755711	G/C	cg18005901	chr6:33739558	LEMD2	-0.59	-6.61	-0.51	1.01e-9	Schizophrenia;
TGCT	cis	rs7917772	0.636	rs7911747	chr10:104528890	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.6	-4.92	-0.4	2.67e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs3796352	1.000	rs71301804	chr3:53073314	C/A	cg15956490	chr3:53032818	SFMBT1	0.59	6.75	0.52	5.19e-10	Immune reponse to smallpox (secreted IL-2);
TGCT	trans	rs7618501	0.521	rs2352984	chr3:49948728	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.83	8.48	0.61	5.54e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs2836950	0.501	rs35994303	chr21:40686020	C/T	cg06238570	chr21:40685208	BRWD1	-0.63	-6.4	-0.5	2.96e-9	Menarche (age at onset);
TGCT	cis	rs8103278	1.000	rs1548029	chr19:46309203	A/C	cg11657440	chr19:46296263	DMWD	-0.59	-5.63	-0.45	1.17e-7	Coronary artery disease;
TGCT	cis	rs7104764	0.507	rs7121085	chr11:258523	A/G	cg18336825	chr11:236787	PSMD13;SIRT3	0.76	5.68	0.45	8.96e-8	Menarche (age at onset);
TGCT	cis	rs4886920	0.694	rs12902298	chr15:78085418	C/T	cg25212270	chr15:78015279	NA	-0.23	-4.75	-0.39	5.57e-6	Neuroticism;
TGCT	cis	rs782590	0.837	rs809732	chr2:55914621	T/C	cg03859395	chr2:55845619	SMEK2	0.81	9.36	0.64	4.35e-16	Metabolic syndrome;
TGCT	cis	rs7044106	0.762	rs1324473	chr9:123404610	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.42	-4.46	-0.37	1.8e-5	Hip circumference adjusted for BMI;
TGCT	cis	rs360798	0.532	rs189671	chr2:62959308	T/A	cg17519650	chr2:63277830	OTX1	-0.54	-4.58	-0.38	1.14e-5	Coronary artery disease;
TGCT	cis	rs931127	0.502	rs1466462	chr11:65419364	C/G	cg12758867	chr11:65354231	EHBP1L1	-0.26	-5.09	-0.42	1.3e-6	Systemic lupus erythematosus;
TGCT	cis	rs2645424	0.635	rs62495697	chr8:11709007	G/A	cg21281001	chr8:11725306	CTSB	0.55	4.49	0.37	1.64e-5	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
TGCT	cis	rs4505848	0.606	rs7676523	chr4:123523279	G/A	cg10583651	chr4:123538969	IL21	-0.36	-5.27	-0.43	5.97e-7	Type 1 diabetes;
TGCT	cis	rs1008375	1.000	rs2872959	chr4:17677163	G/A	cg10189774	chr4:17578691	LAP3	-0.56	-4.95	-0.41	2.37e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2404602	0.967	rs7174096	chr15:77072400	A/G	cg26408565	chr15:76604113	ETFA	-0.37	-4.65	-0.39	8.34e-6	Blood metabolite levels;
TGCT	cis	rs2730245	1.000	rs2730241	chr7:158723014	T/C	cg24397884	chr7:158709396	WDR60	-0.37	-4.98	-0.41	2.1e-6	Height;
TGCT	cis	rs7674212	0.539	rs6854709	chr4:104129786	A/G	cg16532752	chr4:104119610	CENPE	-0.61	-5.49	-0.44	2.17e-7	Type 2 diabetes;
TGCT	cis	rs2762353	0.603	rs12201071	chr6:25778055	C/T	cg03517284	chr6:25882590	NA	0.5	4.96	0.41	2.24e-6	Blood metabolite levels;
TGCT	cis	rs7264396	0.690	rs2425178	chr20:34446395	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.04	-0.41	1.58e-6	Total cholesterol levels;
TGCT	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.98	0.41	2.05e-6	Bipolar disorder;
TGCT	cis	rs4700695	0.841	rs36301	chr5:65348940	A/G	cg21114390	chr5:65439923	SFRS12	0.62	4.57	0.38	1.18e-5	Facial morphology (factor 19);
TGCT	cis	rs35264875	1.000	rs72919432	chr11:68829954	C/T	cg02660097	chr11:68866761	NA	0.32	4.8	0.4	4.55e-6	Blond vs. brown hair color;
TGCT	trans	rs731174	0.559	rs10908375	chr1:38194094	G/C	cg19725343	chr19:51830960	IGLON5	-0.63	-7.18	-0.54	5.57e-11	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9916302	0.706	rs8069074	chr17:37685401	C/T	cg07936489	chr17:37558343	FBXL20	0.84	6.23	0.49	6.68e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs6860806	0.507	rs169256	chr5:131688533	A/G	cg24060327	chr5:131705240	SLC22A5	-0.68	-7.33	-0.55	2.64e-11	Breast cancer;
TGCT	cis	rs7824557	0.527	rs11785394	chr8:11238029	C/T	cg21775007	chr8:11205619	TDH	-0.6	-5.61	-0.45	1.23e-7	Retinal vascular caliber;
TGCT	cis	rs35883536	0.609	rs10783142	chr1:101043902	C/G	cg06223162	chr1:101003688	GPR88	-0.42	-7.93	-0.58	1.11e-12	Monocyte count;
TGCT	cis	rs9549367	0.713	rs9549691	chr13:113861606	A/C	cg09473364	chr13:112927190	NA	-0.31	-4.62	-0.38	9.3e-6	Platelet distribution width;
TGCT	cis	rs916888	0.610	rs199453	chr17:44800946	C/T	cg17911788	chr17:44343683	NA	-0.48	-5.66	-0.45	9.83e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs12049351	0.774	rs12125978	chr1:229627722	T/C	cg12130225	chr1:229698885	NA	0.39	4.59	0.38	1.06e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs11677370	0.561	rs10191326	chr2:3827524	G/C	cg17052675	chr2:3827356	NA	-0.43	-7.81	-0.57	2.04e-12	Type 2 diabetes;
TGCT	cis	rs6912958	0.667	rs7746545	chr6:88090225	A/G	cg10393598	chr6:87862264	NA	-0.31	-4.5	-0.37	1.56e-5	Monocyte percentage of white cells;
TGCT	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg21862992	chr11:68658383	NA	0.47	6.61	0.51	1.03e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs3796352	1.000	rs10510761	chr3:52965255	A/G	cg15956490	chr3:53032818	SFMBT1	-0.63	-6.65	-0.51	8.26e-10	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs9486715	1.000	rs3798297	chr6:97062835	C/T	cg18709589	chr6:96969512	KIAA0776	-0.78	-7.13	-0.54	7.19e-11	Headache;
TGCT	cis	rs1568079	0.516	rs1571424	chr10:125220311	G/A	cg02353154	chr10:124578028	NA	-0.37	-4.72	-0.39	6.34e-6	Body mass index;
TGCT	cis	rs12681288	0.550	rs4410933	chr8:959581	A/G	cg04851639	chr8:1020857	NA	-0.27	-4.44	-0.37	1.94e-5	Schizophrenia;
TGCT	cis	rs2842992	0.830	rs2842966	chr6:160141592	C/T	cg11366901	chr6:160182831	ACAT2	0.95	6.33	0.49	4.14e-9	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs4642101	0.618	rs11128614	chr3:12819212	A/G	cg05775895	chr3:12838266	CAND2	0.89	9.52	0.65	1.87e-16	QRS complex (12-leadsum);
TGCT	cis	rs9486719	0.857	rs11751075	chr6:97065751	G/A	cg06623918	chr6:96969491	KIAA0776	-1.06	-9.8	-0.66	3.95e-17	Migraine;Coronary artery disease;
TGCT	cis	rs6088580	0.634	rs6059878	chr20:33087166	A/T	cg08999081	chr20:33150536	PIGU	0.29	5.57	0.45	1.54e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs7255374	0.566	rs7255904	chr19:41529020	C/T	cg27089200	chr19:41531976	NA	0.49	6.58	0.51	1.18e-9	DDT metabolite (p,p'-DDE levels);
TGCT	cis	rs911555	0.755	rs2756128	chr14:103974964	C/T	cg12935359	chr14:103987150	CKB	0.33	4.57	0.38	1.15e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs9368481	0.761	rs7775041	chr6:27009512	T/A	cg18867708	chr6:26865862	GUSBL1	-0.43	-5.63	-0.45	1.15e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9921338	0.961	rs77552156	chr16:11426399	C/A	cg00044050	chr16:11439710	C16orf75	-0.88	-6.75	-0.52	5.08e-10	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg08219700	chr8:58056026	NA	0.38	4.69	0.39	6.95e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg03517284	chr6:25882590	NA	-0.66	-5.82	-0.46	4.67e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs1008375	0.800	rs62296338	chr4:17613425	G/T	cg10189774	chr4:17578691	LAP3	0.63	5.29	0.43	5.25e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6866344	0.697	rs11748497	chr5:178130012	C/G	cg03877680	chr5:178157825	ZNF354A	0.72	5.84	0.46	4.2e-8	Neutrophil percentage of white cells;
TGCT	cis	rs864537	0.676	rs1773560	chr1:167421763	A/G	cg22356347	chr1:167427500	CD247	-0.22	-5.47	-0.44	2.35e-7	Celiac disease or Rheumatoid arthritis;Celiac disease;
TGCT	cis	rs964184	0.638	rs3741298	chr11:116657561	C/T	cg23217865	chr11:117376295	DSCAML1	0.27	4.44	0.37	2e-5	Age-related disease endophenotypes;Metabolic syndrome;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);LDL cholesterol;Response to Vitamin E supplementation;High light scatter reticulocyte count;Cholesterol, total;Coronary artery disease or large artery stroke;Mean platelet volume;Triglyceride levels;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Very low density lipoprotein cholesterol levels;Hypertriglyceridemia;Metabolite levels (lipoprotein measures);Triglycerides;Coronary artery disease;HDL cholesterol;Blood metabolite levels;Vitamin E levels;LDL cholesterol levels;Circulating phylloquinone levels;Very long-chain saturated fatty acid levels (fatty acid 20:0);Postprandial triglyceride response to high fat diet meal;Coronary heart disease;Metabolite levels;Reticulocyte fraction of red cells;Red cell distribution width;Platelet distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Mean corpuscular hemoglobin concentration;Total cholesterol levels;Phospholipid levels (plasma);Age-related diseases, mortality and associated endophenotypes;
TGCT	cis	rs453301	0.606	rs6981060	chr8:8908235	C/A	cg15556689	chr8:8085844	FLJ10661	-0.68	-5.58	-0.45	1.44e-7	Joint mobility (Beighton score);
TGCT	cis	rs3829109	0.564	rs12378717	chr9:139286060	G/C	cg13741927	chr9:139327495	INPP5E	-0.23	-4.97	-0.41	2.14e-6	Peak insulin response;Acute insulin response;
TGCT	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg03264133	chr6:25882463	NA	0.6	6.49	0.5	1.89e-9	Blood metabolite levels;
TGCT	cis	rs2486288	0.656	rs1719236	chr15:45577783	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.83	-8.77	-0.62	1.16e-14	Glomerular filtration rate;
TGCT	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg27454412	chr7:1067447	C7orf50	0.6	4.7	0.39	6.76e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7666738	0.830	rs6832209	chr4:98994120	A/G	cg17366294	chr4:99064904	C4orf37	0.68	6.96	0.53	1.75e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs881375	0.967	rs1860823	chr9:123659304	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	5.2	0.42	8.09e-7	Rheumatoid arthritis;
TGCT	cis	rs10744422	0.764	rs3852535	chr12:123293656	G/A	cg18912006	chr12:123335444	HIP1R	0.56	4.78	0.39	4.84e-6	Schizophrenia;
TGCT	cis	rs9905704	0.647	rs11659035	chr17:56966052	C/T	cg12560992	chr17:57184187	TRIM37	0.58	4.93	0.4	2.57e-6	Testicular germ cell tumor;
TGCT	cis	rs2455799	0.613	rs7614204	chr3:15792748	A/G	cg16303742	chr3:15540471	COLQ	-0.25	-4.88	-0.4	3.18e-6	Mean platelet volume;
TGCT	cis	rs146201400	1	rs146201400	chr1:26645955	G/GA	cg12733254	chr1:26682999	NA	-0.21	-4.58	-0.38	1.12e-5	Monocyte percentage of white cells;
TGCT	cis	rs6879260	1.000	rs1035411	chr5:179729519	A/G	cg23221052	chr5:179740743	GFPT2	-0.36	-5.76	-0.46	6.13e-8	Height;
TGCT	cis	rs6088580	0.584	rs2378203	chr20:32993846	A/T	cg08999081	chr20:33150536	PIGU	-0.28	-5.51	-0.44	2.03e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs6570726	0.791	rs422099	chr6:145806936	C/T	cg23711669	chr6:146136114	FBXO30	0.89	9.83	0.66	3.33e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs66561647	0.661	rs890442	chr8:128931207	G/T	cg11792826	chr8:129160931	MIR1208	0.22	5.05	0.41	1.53e-6	Hemoglobin concentration;
TGCT	cis	rs2797160	0.837	rs1739364	chr6:126022383	A/G	cg05901451	chr6:126070800	HEY2	-0.69	-6.06	-0.48	1.51e-8	Endometrial cancer;
TGCT	cis	rs832540	0.898	rs331498	chr5:56249842	C/G	cg24531977	chr5:56204891	C5orf35	0.53	5.42	0.44	3e-7	Coronary artery disease;
TGCT	cis	rs929596	0.755	rs4148324	chr2:234672722	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.33	-5.42	-0.44	2.95e-7	Total bilirubin levels in HIV-1 infection;
TGCT	cis	rs2153535	0.601	rs2143353	chr6:8530111	T/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.01	0.41	1.86e-6	Motion sickness;
TGCT	cis	rs13082711	0.522	rs11927257	chr3:27334294	C/T	cg02860705	chr3:27208620	NA	0.33	5.45	0.44	2.62e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs2115630	0.936	rs6496318	chr15:85215229	C/T	cg17173187	chr15:85201210	NMB	-0.41	-5.2	-0.42	7.89e-7	P wave terminal force;
TGCT	cis	rs9549367	0.712	rs2316443	chr13:113864837	G/A	cg00898013	chr13:113819073	PROZ	-0.43	-5.42	-0.44	2.94e-7	Platelet distribution width;
TGCT	cis	rs12188164	0.686	rs56279338	chr5:416118	G/A	cg22025206	chr5:502436	SLC9A3	-0.26	-4.69	-0.39	7.2e-6	Cystic fibrosis severity;
TGCT	cis	rs10186029	0.676	rs4673721	chr2:213941643	T/G	cg08319019	chr2:214017104	IKZF2	0.63	5.81	0.46	5.05e-8	Systemic sclerosis;
TGCT	cis	rs12019136	1	rs12019136	chr19:5835677	G/A	cg25387410	chr19:5844109	FUT3	-0.54	-6.45	-0.5	2.27e-9	Advanced age-related macular degeneration;IgG N-glycosylation phenotypes (multivariate analysis);
TGCT	cis	rs4824093	0.610	rs4141437	chr22:50243719	C/G	cg20569369	chr22:51173646	NA	-0.27	-4.57	-0.38	1.18e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs2277425	0.755	rs2277424	chr13:111522420	A/G	cg16032841	chr13:111522222	C13orf29	-0.52	-7.11	-0.54	8.27e-11	Sitting height ratio;
TGCT	cis	rs2228479	0.557	rs12933317	chr16:89828220	A/G	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs11118844	0.793	rs11118854	chr1:221943678	T/C	cg04222084	chr1:221915650	DUSP10	-0.8	-5.55	-0.45	1.62e-7	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
TGCT	cis	rs8133974	0.878	rs56045941	chr21:36421331	T/C	cg06758350	chr21:36259460	RUNX1	-0.4	-4.48	-0.37	1.67e-5	Eosinophil counts;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;
TGCT	cis	rs2153535	0.580	rs7753192	chr6:8482637	G/A	cg07606381	chr6:8435919	SLC35B3	0.53	4.89	0.4	3.08e-6	Motion sickness;
TGCT	cis	rs7260538	0.509	rs10420194	chr19:41529781	A/T	cg20630647	chr19:41531805	NA	0.39	6.2	0.49	7.68e-9	DDT metabolite (p,p'-DDE levels);
TGCT	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg03709012	chr19:19516395	GATAD2A	0.75	6.16	0.48	9.21e-9	Tonsillectomy;
TGCT	cis	rs12478296	1.000	rs6732595	chr2:243035338	T/C	cg06360820	chr2:242988706	NA	-0.59	-4.61	-0.38	9.95e-6	Obesity-related traits;
TGCT	cis	rs539096	0.915	rs2842194	chr1:44028962	G/A	cg12908607	chr1:44402522	ARTN	0.49	5.13	0.42	1.07e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1692580	0.870	rs262680	chr1:2167149	C/T	cg21194808	chr1:2205498	SKI	0.31	5.95	0.47	2.55e-8	Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs13102369	chr4:99045912	A/G	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs79387448	0.638	rs6741230	chr2:103069631	C/T	cg09003973	chr2:102972529	NA	1.28	9.8	0.66	3.95e-17	Gut microbiota (bacterial taxa);
TGCT	trans	rs208520	0.661	rs207079	chr6:66770462	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.97	-11.24	-0.71	1.23e-20	Exhaled nitric oxide output;
TGCT	cis	rs2075671	0.903	rs11979818	chr7:100293639	A/G	cg20848291	chr7:100343083	ZAN	0.54	4.58	0.38	1.12e-5	Other erythrocyte phenotypes;
TGCT	cis	rs35306767	0.855	rs61830932	chr10:934183	T/C	cg26597838	chr10:835615	NA	0.75	10.54	0.69	6.3e-19	Eosinophil percentage of granulocytes;
TGCT	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.55	4.92	0.4	2.74e-6	Prudent dietary pattern;
TGCT	cis	rs2013441	1.000	rs17759923	chr17:20022035	G/A	cg18979559	chr17:20280153	CCDC144C	0.47	4.9	0.4	2.96e-6	Obesity-related traits;
TGCT	cis	rs3935685	0.874	rs4076998	chr15:78025420	T/G	cg03457338	chr15:78040120	NA	-0.22	-5.85	-0.46	4.17e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs1568889	1.000	rs34140872	chr11:28335872	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	8.75	0.62	1.27e-14	Bipolar disorder;
TGCT	cis	rs9638182	0.830	rs34346326	chr7:73016181	T/C	cg14087351	chr7:73037990	MLXIPL	-0.54	-4.5	-0.37	1.55e-5	Triglycerides;
TGCT	cis	rs10875746	0.680	rs4760610	chr12:48418225	C/T	cg20731937	chr12:48336164	NA	0.72	6.1	0.48	1.23e-8	Longevity (90 years and older);
TGCT	cis	rs739496	0.579	rs7294902	chr12:112354531	T/C	cg10833066	chr12:111807467	FAM109A	0.38	5.42	0.44	2.97e-7	Platelet count;
TGCT	cis	rs6669384	0.723	rs4844395	chr1:208037967	A/G	cg22525895	chr1:207977042	MIR29B2	0.4	5.28	0.43	5.67e-7	Immune response to measles vaccine (measles-specific neutralising antibody titre);
TGCT	cis	rs6088590	1.000	rs6120750	chr20:33465289	A/C	cg24642439	chr20:33292090	TP53INP2	0.7	5.98	0.47	2.17e-8	Coronary artery disease;
TGCT	cis	rs9914544	0.524	rs7209853	chr17:18798600	G/A	cg26378065	chr17:18585709	ZNF286B	0.51	4.59	0.38	1.09e-5	Educational attainment (years of education);
TGCT	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.66	0.39	8.18e-6	Prudent dietary pattern;
TGCT	cis	rs11585357	0.689	rs2977293	chr1:17599444	C/T	cg08277548	chr1:17600880	PADI3	-0.67	-6.67	-0.51	7.75e-10	Hair shape;
TGCT	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg17554472	chr22:41940697	POLR3H	-0.42	-4.56	-0.38	1.19e-5	Vitiligo;
TGCT	cis	rs9527	0.590	rs7074395	chr10:104844928	A/C	cg04362960	chr10:104952993	NT5C2	-0.65	-5.59	-0.45	1.36e-7	Arsenic metabolism;
TGCT	cis	rs6088580	0.584	rs2378203	chr20:32993846	A/T	cg06115741	chr20:33292138	TP53INP2	-0.53	-4.63	-0.38	8.94e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs1541995	0.824	rs1822246	chr15:96245020	A/G	cg00882281	chr15:96346592	NA	0.29	4.83	0.4	3.88e-6	Photic sneeze reflex;
TGCT	cis	rs1158570	0.500	rs2791342	chr8:131314429	C/T	cg16277922	chr8:131349729	ASAP1	-0.4	-5.11	-0.42	1.2e-6	Platelet count;
TGCT	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg21285383	chr16:89894308	SPIRE2	0.44	6.91	0.53	2.24e-10	Vitiligo;
TGCT	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2115630	1.000	rs10220733	chr15:85280864	G/A	cg17173187	chr15:85201210	NMB	-0.39	-4.76	-0.39	5.4e-6	P wave terminal force;
TGCT	cis	rs9916302	0.904	rs8079303	chr17:37530755	G/C	cg15445000	chr17:37608096	MED1	-0.33	-4.71	-0.39	6.46e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs9787249	0.957	rs12239844	chr1:40217258	T/C	cg19912559	chr1:40204330	PPIE	0.49	5.68	0.45	9.03e-8	Blood protein levels;
TGCT	cis	rs2050392	0.965	rs1543725	chr10:30698873	A/G	cg13289132	chr10:30722225	MAP3K8	-0.4	-5.1	-0.42	1.22e-6	Inflammatory bowel disease;
TGCT	cis	rs4455778	0.659	rs10264682	chr7:49038952	C/T	cg26309511	chr7:48887640	NA	0.44	5.13	0.42	1.07e-6	Lung cancer in never smokers;
TGCT	cis	rs2798269	0.604	rs2488803	chr13:22159277	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.5	-4.45	-0.37	1.88e-5	PR segment;
TGCT	cis	rs10504229	0.680	rs11777459	chr8:58044241	A/T	cg08280861	chr8:58055591	NA	0.39	5.44	0.44	2.74e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7681440	0.904	rs28415623	chr4:90767110	C/T	cg01966878	chr4:90757139	SNCA	-0.25	-4.56	-0.38	1.2e-5	Dementia with Lewy bodies;
TGCT	cis	rs208520	0.690	rs1776365	chr6:66834474	G/T	cg07460842	chr6:66804631	NA	-0.92	-9.58	-0.65	1.29e-16	Exhaled nitric oxide output;
TGCT	cis	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg02380750	chr20:61661411	NA	0.37	6.64	0.51	8.85e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs981844	0.683	rs1037653	chr4:154749992	A/T	cg14289246	chr4:154710475	SFRP2	-0.99	-9.12	-0.63	1.65e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs6558530	0.653	rs6984632	chr8:1700434	G/A	cg09410841	chr8:1729607	CLN8	0.72	6.44	0.5	2.41e-9	Systolic blood pressure;
TGCT	cis	rs7312933	0.584	rs7974654	chr12:42630466	C/A	cg19980929	chr12:42632907	YAF2	0.41	5.86	0.47	3.85e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg04944784	chr2:26401820	FAM59B	0.76	6.24	0.49	6.46e-9	Gut microbiome composition (summer);
TGCT	cis	rs1670533	1.000	rs6827357	chr4:1059202	A/C	cg20887711	chr4:1340912	KIAA1530	0.67	5.17	0.42	9.27e-7	Recombination rate (females);
TGCT	cis	rs2075371	1.000	rs2598291	chr7:133988313	C/G	cg11752832	chr7:134001865	SLC35B4	0.69	6.32	0.49	4.36e-9	Mean platelet volume;
TGCT	cis	rs35306767	0.903	rs12763396	chr10:927357	C/A	cg20503657	chr10:835505	NA	0.74	10.3	0.68	2.41e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs28595532	0.623	rs34958556	chr4:119222074	C/T	cg21605333	chr4:119757512	SEC24D	0.75	4.58	0.38	1.1e-5	Cannabis dependence symptom count;
TGCT	cis	rs7100689	0.646	rs4468295	chr10:82119276	C/G	cg01528321	chr10:82214614	TSPAN14	0.8	7.76	0.57	2.7e-12	Post bronchodilator FEV1;
TGCT	cis	rs244731	0.920	rs244707	chr5:176555636	A/T	cg17509989	chr5:176798049	RGS14	0.59	6.73	0.52	5.55e-10	Urate levels in lean individuals;
TGCT	cis	rs74181299	0.571	rs2302647	chr2:65283174	G/A	cg05010058	chr2:65284262	CEP68	0.49	5.01	0.41	1.79e-6	Pulse pressure;
TGCT	cis	rs4563143	0.675	rs55849754	chr19:29279665	G/A	cg14983838	chr19:29218262	NA	0.86	7.07	0.54	9.71e-11	Methadone dose in opioid dependence;
TGCT	cis	rs3008870	0.959	rs4655658	chr1:67389608	C/T	cg11518657	chr1:67396239	MIER1	0.52	4.53	0.38	1.39e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs2692947	0.673	rs2917662	chr2:96794957	G/A	cg05933789	chr2:97190408	NA	0.16	4.64	0.38	8.81e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs7172971	0.655	rs7170413	chr15:42344505	C/T	cg05886115	chr15:42349113	NA	0.31	4.88	0.4	3.21e-6	3-hydroxypropylmercapturic acid levels in smokers;
TGCT	cis	rs11096990	0.634	rs17754	chr4:39289308	G/C	cg20847110	chr4:39482781	LOC401127	0.16	4.51	0.38	1.48e-5	Cognitive function;
TGCT	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.12	0.54	7.79e-11	Prudent dietary pattern;
TGCT	cis	rs60154123	0.686	rs227222	chr1:210191272	T/C	cg22029157	chr1:209979665	IRF6	-0.73	-4.58	-0.38	1.11e-5	Coronary artery disease;
TGCT	cis	rs2204008	0.658	rs11181310	chr12:38315963	C/A	cg13010199	chr12:38710504	ALG10B	0.59	4.59	0.38	1.07e-5	Bladder cancer;
TGCT	cis	rs7917772	0.582	rs10786696	chr10:104378134	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	5.36	0.43	3.84e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs910316	1.000	rs10873275	chr14:75531460	A/T	cg11812906	chr14:75593930	NEK9	0.74	7.25	0.55	3.9e-11	Height;
TGCT	cis	rs28735056	0.596	rs3744879	chr18:77679006	G/C	cg20368463	chr18:77673604	PQLC1	-0.53	-6.45	-0.5	2.27e-9	Schizophrenia;
TGCT	trans	rs2688608	0.967	rs1815076	chr10:75659886	C/T	cg13918328	chr10:52500089	ASAH2B	0.64	6.65	0.51	8.42e-10	Inflammatory bowel disease;
TGCT	trans	rs7618501	1.000	rs695238	chr3:49869158	A/C	cg21659725	chr3:3221576	CRBN	0.98	15.33	0.81	2.1000000000000002e-30	Intelligence (multi-trait analysis);
TGCT	cis	rs868036	0.681	rs4776977	chr15:68108219	C/T	cg05925327	chr15:68127851	NA	-0.5	-4.85	-0.4	3.57e-6	Restless legs syndrome;
TGCT	cis	rs1801251	1.000	rs6745879	chr2:233590007	A/G	cg25237894	chr2:233734115	C2orf82	0.32	5.81	0.46	4.94e-8	Coronary artery disease;
TGCT	cis	rs295140	0.903	rs7605146	chr2:201183888	A/G	cg04283868	chr2:201171347	SPATS2L	-0.62	-6.26	-0.49	5.69e-9	QT interval;
TGCT	cis	rs9807989	0.507	rs6726985	chr2:103048580	G/A	cg03938978	chr2:103052716	IL18RAP	0.27	5.41	0.44	3.17e-7	Asthma;
TGCT	cis	rs79149102	0.579	rs74023936	chr15:75362084	C/T	cg09165964	chr15:75287851	SCAMP5	-1.04	-5.78	-0.46	5.77e-8	Lung cancer;
TGCT	cis	rs3849570	0.925	rs1464791	chr3:81893929	A/C	cg07356753	chr3:81810745	GBE1	0.74	6.77	0.52	4.57e-10	Waist circumference;Body mass index;
TGCT	cis	rs2046867	0.819	rs34132129	chr3:72829100	A/G	cg25664220	chr3:72788482	NA	-0.56	-6.89	-0.53	2.49e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg26338869	chr17:61819248	STRADA	-0.53	-4.94	-0.41	2.48e-6	Prudent dietary pattern;
TGCT	cis	rs12893668	0.697	rs67899457	chr14:104060066	A/T	cg26031613	chr14:104095156	KLC1	-0.55	-4.61	-0.38	9.69e-6	Reticulocyte count;
TGCT	cis	rs56114371	0.530	rs2056923	chr6:27689939	T/C	cg20933634	chr6:27740509	NA	0.42	4.78	0.39	4.81e-6	Breast cancer;
TGCT	trans	rs3780486	0.718	rs7859454	chr9:33119583	T/A	cg04842962	chr6:43655489	MRPS18A	1.0	7.22	0.54	4.61e-11	IgG glycosylation;
TGCT	cis	rs4824093	0.610	rs73441745	chr22:50237606	G/A	cg14114931	chr22:50943910	LMF2	0.36	4.57	0.38	1.14e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs36051895	0.659	rs62541539	chr9:5038180	C/T	cg02405213	chr9:5042618	JAK2	-0.78	-10.74	-0.69	2.01e-19	Pediatric autoimmune diseases;
TGCT	cis	rs1577917	1.000	rs1995688	chr6:86632319	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.22	-0.42	7.27e-7	Response to antipsychotic treatment;
TGCT	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg13395646	chr4:1353034	KIAA1530	-0.41	-4.6	-0.38	1.01e-5	Longevity;
TGCT	cis	rs9653442	0.564	rs4850924	chr2:100782273	A/G	cg22139774	chr2:100720529	AFF3	-0.35	-5.44	-0.44	2.79e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs778371	0.578	rs2675956	chr2:233753340	G/A	cg08000102	chr2:233561755	GIGYF2	-0.48	-4.83	-0.4	3.92e-6	Schizophrenia;
TGCT	cis	rs3091242	0.900	rs35345536	chr1:25766488	A/G	cg00786635	chr1:25594202	NA	0.55	5.74	0.46	6.71e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs9911578	0.967	rs2333410	chr17:57137129	G/A	cg12560992	chr17:57184187	TRIM37	-0.79	-9.71	-0.66	6.56e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs2239547	0.607	rs9836178	chr3:52925403	T/C	cg10802521	chr3:52805072	NEK4	0.63	5.67	0.45	9.48e-8	Schizophrenia;
TGCT	cis	rs4773860	0.512	rs2892715	chr13:95894329	A/G	cg22859289	chr13:95358476	NA	0.26	4.53	0.38	1.38e-5	Plateletcrit;
TGCT	cis	rs4478858	0.684	rs7544946	chr1:31749736	T/C	cg00250761	chr1:31883323	NA	-0.25	-4.52	-0.38	1.45e-5	Alcohol dependence;
TGCT	cis	rs2072499	0.931	rs1052053	chr1:156202173	A/G	cg24450063	chr1:156163899	SLC25A44	1.02	12.94	0.76	9.07e-25	Testicular germ cell tumor;
TGCT	trans	rs2727020	0.521	rs7946190	chr11:49521964	T/A	cg11707556	chr5:10655725	ANKRD33B	0.42	8.63	0.61	2.5e-14	Coronary artery disease;
TGCT	cis	rs751728	1.000	rs4713682	chr6:33757047	G/C	cg13859433	chr6:33739653	LEMD2	-0.39	-7.13	-0.54	7.23e-11	Crohn's disease;
TGCT	trans	rs7618501	1.000	rs3811696	chr3:49761605	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-1.03	-13.16	-0.76	2.65e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs1670533	0.872	rs935969	chr4:1062588	A/G	cg20887711	chr4:1340912	KIAA1530	0.65	5.11	0.42	1.16e-6	Recombination rate (females);
TGCT	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9868809	0.881	rs2286652	chr3:48689192	G/A	cg00383909	chr3:49044727	WDR6	1.11	5.97	0.47	2.28e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs2404602	0.647	rs3812908	chr15:77176158	C/T	cg23625390	chr15:77176239	SCAPER	0.39	5.04	0.41	1.6e-6	Blood metabolite levels;
TGCT	cis	rs854765	0.547	rs4072739	chr17:17884660	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.74	7.29	0.55	3.14e-11	Total body bone mineral density;
TGCT	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg04287289	chr16:89883240	FANCA	0.91	11.74	0.73	7.21e-22	Vitiligo;
TGCT	cis	rs9611565	0.546	rs34077262	chr22:42061639	A/G	cg17554472	chr22:41940697	POLR3H	0.46	4.87	0.4	3.34e-6	Vitiligo;
TGCT	cis	rs2153535	0.580	rs1889715	chr6:8443475	G/A	cg07606381	chr6:8435919	SLC35B3	0.57	5.25	0.43	6.46e-7	Motion sickness;
TGCT	cis	rs4722166	0.630	rs10950916	chr7:22799667	C/T	cg13104385	chr7:22767384	IL6	0.2	4.59	0.38	1.08e-5	Lung cancer;
TGCT	trans	rs11218343	1.000	rs2276412	chr11:121460846	C/T	cg21762680	chr3:195295723	APOD	0.68	6.63	0.51	9.32e-10	Alzheimer's disease in APOE e4- carriers;Alzheimer's disease (late onset);
TGCT	cis	rs11190604	0.767	rs35508946	chr10:102191156	A/G	cg16005271	chr10:102321736	NA	0.45	4.7	0.39	6.81e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg18538332	chr22:24372958	LOC391322	0.84	9.55	0.65	1.54e-16	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7772486	0.686	rs1415744	chr6:146022531	C/T	cg23711669	chr6:146136114	FBXO30	0.85	9.73	0.66	5.58e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7089973	0.584	rs758585	chr10:116582560	C/A	cg03647239	chr10:116582469	FAM160B1	0.6	5.75	0.46	6.7e-8	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs10465746	0.653	rs11163877	chr1:84441848	T/A	cg10977910	chr1:84465055	TTLL7	0.69	7.1	0.54	8.59e-11	Obesity-related traits;
TGCT	cis	rs67478160	0.529	rs12880413	chr14:104267407	A/G	cg26031613	chr14:104095156	KLC1	-0.64	-6.58	-0.51	1.2e-9	Schizophrenia;
TGCT	cis	rs4803468	1.000	rs11883104	chr19:41923799	T/C	cg09537434	chr19:41945824	ATP5SL	-0.92	-10.72	-0.69	2.21e-19	Height;
TGCT	cis	rs7662987	0.517	rs2602878	chr4:100039953	T/G	cg12011299	chr4:100065546	ADH4	0.41	4.91	0.4	2.81e-6	Smoking initiation;
TGCT	cis	rs10779751	1.000	rs1010447	chr1:11269796	A/G	cg08854313	chr1:11322531	MTOR	1.0	10.26	0.68	2.99e-18	Body mass index;
TGCT	cis	rs2050392	0.792	rs303434	chr10:30714440	G/A	cg13289132	chr10:30722225	MAP3K8	-0.39	-4.68	-0.39	7.52e-6	Inflammatory bowel disease;
TGCT	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg23156509	chr2:114033830	PAX8;LOC440839	-0.3	-4.45	-0.37	1.88e-5	Lymphocyte counts;
TGCT	cis	rs2594989	1.000	rs2606740	chr3:11392441	G/A	cg00170343	chr3:11313890	ATG7	0.66	4.68	0.39	7.32e-6	Circulating chemerin levels;
TGCT	trans	rs2727020	0.514	rs4980444	chr11:49550764	T/A	cg03929089	chr4:120376271	NA	-0.66	-7.6	-0.56	6.24e-12	Coronary artery disease;
TGCT	cis	rs2760061	0.626	rs2527614	chr1:228126470	A/G	cg02753203	chr1:228287806	NA	-0.34	-6.56	-0.51	1.31e-9	Diastolic blood pressure;
TGCT	cis	rs6089829	0.888	rs4809268	chr20:61675249	C/G	cg08564027	chr20:61660810	NA	0.37	5.98	0.47	2.26e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9296661	0.522	rs10948647	chr6:51664212	T/A	cg20180370	chr6:50691003	TFAP2D	0.48	4.58	0.38	1.1e-5	Weight loss (gastric bypass surgery);
TGCT	cis	rs7833790	0.660	rs10091077	chr8:82705464	A/G	cg17211192	chr8:82754475	SNX16	-0.89	-7.96	-0.58	9.36e-13	Diastolic blood pressure;
TGCT	cis	rs909674	0.909	rs1557541	chr22:39851970	C/A	cg05872129	chr22:39784769	NA	-0.98	-9.6	-0.65	1.19e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs797680	0.861	rs612037	chr1:93682878	G/A	cg17826107	chr1:92977322	EVI5	0.24	5.3	0.43	5.16e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg02725872	chr8:58115012	NA	-0.39	-4.8	-0.4	4.54e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6598955	0.671	rs12089149	chr1:26638500	C/A	cg04990556	chr1:26633338	UBXN11	0.64	4.91	0.4	2.78e-6	Obesity-related traits;
TGCT	cis	rs8179	1.000	rs42031	chr7:92237396	A/T	cg15732164	chr7:92237376	CDK6	-0.33	-4.87	-0.4	3.3e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
TGCT	cis	rs9811920	0.638	rs704581	chr3:99556160	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.6	7.02	0.53	1.32e-10	Axial length;
TGCT	cis	rs7599312	0.534	rs7607373	chr2:213409719	G/A	cg16329650	chr2:213403929	ERBB4	1.07	16.1	0.82	3.58e-32	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7647973	0.925	rs9834003	chr3:49216472	T/C	cg07636037	chr3:49044803	WDR6	0.63	5.09	0.42	1.27e-6	Menarche (age at onset);
TGCT	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs909002	0.772	rs10798876	chr1:32074514	C/G	cg11573219	chr1:32083031	HCRTR1	-0.45	-5.87	-0.47	3.67e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs12681287	0.752	rs13262673	chr8:87293600	G/A	cg27223183	chr8:87520930	FAM82B	-0.82	-5.86	-0.47	3.98e-8	Caudate activity during reward;
TGCT	cis	rs9611565	0.568	rs5758441	chr22:42132888	C/A	cg17554472	chr22:41940697	POLR3H	0.43	4.54	0.38	1.31e-5	Vitiligo;
TGCT	cis	rs8141529	0.732	rs5762788	chr22:29174770	G/T	cg02153584	chr22:29168773	CCDC117	0.63	5.38	0.43	3.58e-7	Lymphocyte counts;
TGCT	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.5	-4.87	-0.4	3.35e-6	Longevity;Endometriosis;
TGCT	cis	rs9910055	0.615	rs189049	chr17:42197213	A/C	cg19774624	chr17:42201019	HDAC5	0.81	9.74	0.66	5.37e-17	Total body bone mineral density;
TGCT	cis	rs2019216	0.500	rs7502283	chr17:21878561	G/C	cg22648282	chr17:21454238	C17orf51	-0.57	-5.13	-0.42	1.08e-6	Pelvic organ prolapse;
TGCT	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg23758822	chr17:41437982	NA	0.77	7.21	0.54	4.92e-11	Menopause (age at onset);
TGCT	cis	rs9303401	0.659	rs35539277	chr17:56853833	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs4253772	0.591	rs6007748	chr22:46657798	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.55	4.46	0.37	1.84e-5	LDL cholesterol;Cholesterol, total;
TGCT	trans	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg27523141	chr10:43048294	ZNF37B	0.73	8.5	0.61	5.09e-14	Extrinsic epigenetic age acceleration;
TGCT	trans	rs1814175	0.935	rs7925863	chr11:49615802	C/A	cg15704280	chr7:45808275	SEPT13	-0.61	-6.8	-0.52	4.02e-10	Height;
TGCT	cis	rs4711350	0.734	rs9380379	chr6:33766131	A/G	cg13859433	chr6:33739653	LEMD2	-0.31	-4.64	-0.38	8.54e-6	Schizophrenia;
TGCT	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	6.13	0.48	1.06e-8	Height;
TGCT	cis	rs617219	0.726	rs2364596	chr5:78434291	C/T	cg05890484	chr5:78407552	BHMT	0.4	5.53	0.44	1.85e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs9467773	1.000	rs6925703	chr6:26521589	G/A	cg15659132	chr6:26577336	NA	0.86	12.21	0.74	5.3e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs9457247	1.000	rs385863	chr6:167386615	C/G	cg25258033	chr6:167368657	RNASET2	0.18	4.49	0.37	1.63e-5	Crohn's disease;
TGCT	cis	rs7246657	0.722	rs2075284	chr19:38189616	T/C	cg03611452	chr19:38183253	ZNF781	-0.56	-4.63	-0.38	8.97e-6	Coronary artery calcification;
TGCT	cis	rs10882165	0.779	rs57708198	chr10:94910526	G/T	cg15980076	chr10:94822747	CYP26C1	0.44	4.77	0.39	5.13e-6	Refractive error;
TGCT	cis	rs3820068	0.822	rs2901964	chr1:15792426	C/G	cg05660106	chr1:15850417	CASP9	0.88	7.92	0.58	1.13e-12	Systolic blood pressure;
TGCT	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg17179660	chr6:151773299	C6orf211;RMND1	0.59	5.43	0.44	2.84e-7	Menarche (age at onset);
TGCT	cis	rs6430585	0.528	rs75753154	chr2:136665711	T/C	cg07169764	chr2:136633963	MCM6	1.25	12.45	0.75	1.36e-23	Corneal structure;
TGCT	cis	rs8013055	0.898	rs8004007	chr14:105971435	G/C	cg19700328	chr14:106028568	NA	-0.53	-5.87	-0.47	3.76e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs17076896	0.748	rs7325676	chr13:19933749	T/G	cg00777926	chr13:20807375	GJB6	-0.37	-4.53	-0.38	1.36e-5	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.5	-4.81	-0.4	4.26e-6	Bipolar disorder;
TGCT	cis	rs7208859	0.673	rs11657270	chr17:29214387	A/G	cg14008862	chr17:28927542	LRRC37B2	0.71	4.71	0.39	6.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg27170947	chr2:26402098	FAM59B	-0.39	-4.46	-0.37	1.8e-5	Gut microbiome composition (summer);
TGCT	cis	rs10779751	1.000	rs4845859	chr1:11304873	A/G	cg08854313	chr1:11322531	MTOR	0.98	9.12	0.63	1.65e-15	Body mass index;
TGCT	cis	rs7246657	0.722	rs2287229	chr19:38188652	G/A	cg03611452	chr19:38183253	ZNF781	-0.56	-4.63	-0.38	8.97e-6	Coronary artery calcification;
TGCT	cis	rs17253792	0.822	rs113350960	chr14:56087713	G/A	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs12220898	0.749	rs3996894	chr10:50484369	G/A	cg06072769	chr10:50146962	WDFY4	0.38	5.07	0.41	1.38e-6	Inflammatory biomarkers;
TGCT	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg10207240	chr12:122356781	WDR66	0.34	4.68	0.39	7.53e-6	Mean corpuscular volume;
TGCT	cis	rs2663905	0.706	rs2683260	chr15:81385552	A/C	cg09236163	chr15:81426669	C15orf26	-0.6	-5.71	-0.46	7.81e-8	QT interval (drug interaction);
TGCT	trans	rs941408	1.000	rs1736176	chr19:2790394	G/A	cg22153745	chr1:153894579	GATAD2B	-0.61	-6.84	-0.52	3.28e-10	Total cholesterol levels;
TGCT	cis	rs2153535	0.580	rs6900007	chr6:8474035	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg25767906	chr1:53392781	SCP2	-0.55	-6.25	-0.49	5.98e-9	Monocyte count;
TGCT	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg00684032	chr4:1343700	KIAA1530	0.23	4.9	0.4	2.87e-6	Obesity-related traits;
TGCT	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.07	-9.63	-0.65	1.01e-16	Platelet count;
TGCT	cis	rs6964587	1.000	rs2157747	chr7:91750578	A/G	cg17063962	chr7:91808500	NA	0.87	9.26	0.64	7.82e-16	Breast cancer;
TGCT	cis	rs13191362	1.000	rs13210412	chr6:163019478	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.68	5.79	0.46	5.33e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs1215050	0.755	rs7696354	chr4:98820330	T/C	cg17366294	chr4:99064904	C4orf37	0.56	6.06	0.48	1.53e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	7.17	0.54	5.86e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.37	4.46	0.37	1.81e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs611744	0.810	rs619227	chr8:109215100	C/A	cg21045802	chr8:109455806	TTC35	0.7	6.26	0.49	5.73e-9	Dupuytren's disease;
TGCT	cis	rs7786808	0.741	rs7789415	chr7:158227617	C/T	cg01191920	chr7:158217561	PTPRN2	-0.42	-6.29	-0.49	4.94e-9	Obesity-related traits;
TGCT	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg23302884	chr18:44338147	ST8SIA5	-0.4	-4.58	-0.38	1.11e-5	Personality dimensions;
TGCT	cis	rs7666738	0.791	rs60028147	chr4:99046618	G/A	cg17366294	chr4:99064904	C4orf37	0.73	7.49	0.56	1.11e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg07061783	chr6:25882402	NA	-0.56	-5.34	-0.43	4.28e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs524023	1.000	rs9734313	chr11:64358311	C/T	cg07733098	chr11:64478343	NRXN2	0.31	4.63	0.38	8.93e-6	Urate levels in obese individuals;
TGCT	trans	rs13064411	0.542	rs9877649	chr3:113226874	C/T	cg00307254	chr3:126706825	PLXNA1	0.34	6.78	0.52	4.36e-10	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs992157	0.672	rs2382829	chr2:219184617	G/A	cg00012203	chr2:219082015	ARPC2	0.7	6.58	0.51	1.16e-9	Colorectal cancer;
TGCT	cis	rs10892173	0.846	rs2298647	chr11:117671641	A/T	cg07621104	chr11:117668040	DSCAML1	0.48	5.02	0.41	1.78e-6	Myopia;
TGCT	cis	rs611744	0.563	rs7815105	chr8:109298794	C/T	cg21045802	chr8:109455806	TTC35	0.7	6.96	0.53	1.76e-10	Dupuytren's disease;
TGCT	cis	rs7843479	1.000	rs10503715	chr8:21850687	G/A	cg17168535	chr8:21777572	XPO7	0.63	5.76	0.46	6.15e-8	Mean corpuscular volume;
TGCT	cis	rs977747	1.000	rs2984618	chr1:47690438	G/T	cg03885399	chr1:47691550	TAL1	0.37	4.44	0.37	1.95e-5	Body mass index;
TGCT	cis	rs60871478	0.787	rs4720928	chr7:808002	T/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.46	4.6	0.38	1.04e-5	Cerebrospinal P-tau181p levels;
TGCT	cis	rs28735056	0.967	rs8091497	chr18:77632565	G/A	cg20368463	chr18:77673604	PQLC1	-0.45	-5.55	-0.45	1.65e-7	Schizophrenia;
TGCT	cis	rs28595532	0.748	rs115651241	chr4:119363509	C/T	cg11846333	chr4:119757529	SEC24D	0.72	4.51	0.38	1.48e-5	Cannabis dependence symptom count;
TGCT	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg06212747	chr3:49208901	KLHDC8B	0.67	6.36	0.5	3.57e-9	Menarche (age at onset);
TGCT	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-8.64	-0.61	2.39e-14	Platelet count;
TGCT	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg11644478	chr21:40555479	PSMG1	-0.6	-5.37	-0.43	3.72e-7	Cognitive function;
TGCT	cis	rs4523957	0.614	rs7219693	chr17:2061101	C/A	cg16513277	chr17:2031491	SMG6	-0.2	-4.61	-0.38	9.88e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9549367	0.789	rs2287244	chr13:113887173	C/G	cg00898013	chr13:113819073	PROZ	0.4	4.95	0.41	2.4e-6	Platelet distribution width;
TGCT	cis	rs9443645	0.901	rs9448596	chr6:79629429	T/C	cg09184832	chr6:79620586	NA	-0.49	-5.29	-0.43	5.29e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2153535	0.580	rs6921964	chr6:8446395	A/G	cg07606381	chr6:8435919	SLC35B3	0.55	5.17	0.42	9.24e-7	Motion sickness;
TGCT	cis	rs250677	0.522	rs56309414	chr5:148376026	C/G	cg18129178	chr5:148520854	ABLIM3	-0.36	-4.69	-0.39	7.23e-6	Breast cancer;
TGCT	cis	rs12477438	1.000	rs11897712	chr2:99735697	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-5.89	-0.47	3.32e-8	Chronic sinus infection;
TGCT	cis	rs7193541	0.662	rs8052367	chr16:74658867	G/A	cg01733217	chr16:74700730	RFWD3	1.01	13.89	0.78	4.94e-27	Multiple myeloma;
TGCT	cis	rs362272	0.524	rs881816	chr4:3365366	A/G	cg18352616	chr4:3374830	RGS12	0.23	4.54	0.38	1.31e-5	Serum sulfate level;
TGCT	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg22891161	chr3:195456627	MUC20	-0.23	-5.38	-0.44	3.53e-7	Pancreatic cancer;
TGCT	cis	rs62244186	0.748	rs12635624	chr3:44678498	G/A	cg25151919	chr3:44754333	ZNF502	-0.4	-4.59	-0.38	1.06e-5	Depressive symptoms;
TGCT	cis	rs7179456	0.545	rs2250583	chr15:59050382	C/T	cg05156742	chr15:59063176	FAM63B	-0.51	-4.89	-0.4	3.05e-6	Asperger disorder;
TGCT	cis	rs6840360	0.571	rs11729136	chr4:152529227	C/A	cg17479576	chr4:152424074	FAM160A1	-0.71	-7.72	-0.57	3.41e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs1982963	1.000	rs753050	chr14:52505375	A/G	cg10843707	chr14:52510701	NID2	-0.43	-6.6	-0.51	1.09e-9	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2404602	1.000	rs6495206	chr15:76870963	C/T	cg26408565	chr15:76604113	ETFA	-0.38	-4.88	-0.4	3.24e-6	Blood metabolite levels;
TGCT	cis	rs12478296	0.892	rs11897561	chr2:243014976	C/A	cg06360820	chr2:242988706	NA	-0.59	-4.83	-0.4	3.89e-6	Obesity-related traits;
TGCT	trans	rs10504390	0.656	rs17302765	chr8:66474459	A/G	cg26037026	chr7:1641922	NA	-0.64	-6.84	-0.52	3.26e-10	IgG glycosylation;
TGCT	cis	rs2120019	1.000	rs35736167	chr15:75332002	T/G	cg11632617	chr15:75315747	PPCDC	-0.3	-4.47	-0.37	1.71e-5	Blood trace element (Zn levels);
TGCT	cis	rs9549260	0.753	rs9549238	chr13:41179321	G/A	cg21288729	chr13:41239152	FOXO1	0.67	4.68	0.39	7.31e-6	Red blood cell count;
TGCT	cis	rs595982	0.559	rs17206700	chr19:49361255	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.68	-9.12	-0.63	1.67e-15	Red cell distribution width;
TGCT	cis	rs7607369	0.617	rs12987009	chr2:219658170	A/T	cg02176678	chr2:219576539	TTLL4	-0.48	-6.16	-0.48	9.24e-9	Red blood cell count;Amyotrophic lateral sclerosis;
TGCT	cis	rs459571	0.959	rs465535	chr9:136910905	C/T	cg14405625	chr9:136855902	VAV2	-0.3	-4.54	-0.38	1.3e-5	Platelet distribution width;
TGCT	cis	rs7208859	0.573	rs73277960	chr17:29177441	T/C	cg18442181	chr17:29233375	C17orf42	-0.79	-4.71	-0.39	6.66e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs2458413	0.935	rs2514667	chr8:105358590	C/T	cg04554929	chr8:105342491	NA	0.55	7.92	0.58	1.18e-12	Paget's disease;
TGCT	cis	rs1153858	1.000	rs16952714	chr15:45650358	G/A	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.62e-8	Homoarginine levels;
TGCT	cis	rs9818758	0.607	rs9837237	chr3:49215583	G/T	cg07636037	chr3:49044803	WDR6	-1.04	-5.15	-0.42	1.01e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs7568458	0.837	rs12714145	chr2:85787341	C/T	cg17127132	chr2:85788382	GGCX	0.67	6.08	0.48	1.35e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs9467773	1.000	rs9467773	chr6:26498426	A/G	cg09904177	chr6:26538194	HMGN4	0.64	6.49	0.5	1.89e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs372883	0.600	rs2832294	chr21:30739671	A/C	cg24692254	chr21:30365293	RNF160	0.51	4.6	0.38	1.02e-5	Pancreatic cancer;
TGCT	cis	rs4654899	0.865	rs6664532	chr1:21515800	G/A	cg01072550	chr1:21505969	NA	-0.48	-7.14	-0.54	7.03e-11	Superior frontal gyrus grey matter volume;
TGCT	cis	rs7552404	0.883	rs11161493	chr1:76206254	T/A	cg22875332	chr1:76189707	ACADM	0.77	9.49	0.65	2.13e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg17264618	chr3:40429014	ENTPD3	0.34	4.94	0.41	2.52e-6	Renal cell carcinoma;
TGCT	trans	rs208520	0.802	rs208516	chr6:66946119	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-9.93	-0.67	1.84e-17	Exhaled nitric oxide output;
TGCT	cis	rs3087591	1.000	rs2905791	chr17:29472888	T/C	cg24425628	chr17:29625626	OMG;NF1	0.47	7.52	0.56	9.75e-12	Hip circumference;
TGCT	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg11301795	chr4:187892539	NA	-0.33	-5.07	-0.41	1.4e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11190604	0.943	rs7900678	chr10:102229016	T/C	cg16342193	chr10:102329863	NA	-0.4	-5.31	-0.43	4.85e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg11247378	chr22:39784982	NA	-0.63	-8.71	-0.62	1.64e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg22920501	chr2:26401640	FAM59B	0.81	6.31	0.49	4.52e-9	Gut microbiome composition (summer);
TGCT	cis	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg07424592	chr7:64974309	NA	-1.34	-8.08	-0.59	4.95e-13	Diabetic kidney disease;
TGCT	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg01017244	chr2:74357527	NA	0.5	8.29	0.6	1.58e-13	Gestational age at birth (maternal effect);
TGCT	cis	rs17376456	0.825	rs17372649	chr5:93126096	C/G	cg25358565	chr5:93447407	FAM172A	0.9	7.65	0.57	4.86e-12	Diabetic retinopathy;
TGCT	cis	rs11792861	0.781	rs72607159	chr9:111764270	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.5	4.69	0.39	7.21e-6	Menarche (age at onset);
TGCT	cis	rs8054556	0.787	rs12921753	chr16:30018720	C/T	cg06015834	chr16:30021696	DOC2A	-0.27	-4.44	-0.37	1.94e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7582180	0.652	rs11687865	chr2:100947000	T/A	cg14675211	chr2:100938903	LONRF2	0.5	4.78	0.39	4.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs17473412	0.677	rs7737667	chr5:122875622	T/G	cg15125798	chr5:122621645	NA	-0.53	-4.9	-0.4	2.93e-6	Total body bone mineral density;
TGCT	cis	rs447735	0.565	rs10852626	chr16:89914633	T/G	cg03388025	chr16:89894329	SPIRE2	0.35	4.92	0.4	2.72e-6	Hemoglobin concentration;
TGCT	trans	rs9951602	0.512	rs6506872	chr18:76649695	T/C	cg02800362	chr5:177631904	HNRNPAB	1.15	13.03	0.76	5.64e-25	Obesity-related traits;
TGCT	cis	rs7917772	0.536	rs12357172	chr10:104388549	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.8	7.61	0.56	5.87e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs8077889	0.719	rs4793033	chr17:41879627	C/T	cg26893861	chr17:41843967	DUSP3	1.13	19.78	0.87	3.55e-40	Triglycerides;
TGCT	cis	rs1215050	0.740	rs1214994	chr4:99035577	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.26	0.49	5.76e-9	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.52	-4.83	-0.4	3.92e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7412746	0.658	rs4970986	chr1:150907955	A/G	cg04414720	chr1:150670196	GOLPH3L	0.37	4.46	0.37	1.81e-5	Melanoma;
TGCT	cis	rs2463822	1.000	rs118049526	chr11:62107508	C/T	cg23876832	chr11:62092739	NA	-0.65	-4.56	-0.38	1.19e-5	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs28595532	0.920	rs115294251	chr4:119772833	C/T	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs7659604	0.521	rs9993206	chr4:122686957	A/G	cg19748678	chr4:122722346	EXOSC9	-0.53	-5.3	-0.43	5.11e-7	Type 2 diabetes;
TGCT	cis	rs950169	0.800	rs4842847	chr15:84931199	G/A	cg11189052	chr15:85197271	WDR73	0.81	6.22	0.49	6.89e-9	Schizophrenia;
TGCT	cis	rs2404602	0.647	rs11633869	chr15:77133322	G/T	cg23625390	chr15:77176239	SCAPER	0.37	4.87	0.4	3.27e-6	Blood metabolite levels;
TGCT	cis	rs2050392	0.829	rs306589	chr10:30723831	A/G	cg13289132	chr10:30722225	MAP3K8	-0.4	-4.83	-0.4	4e-6	Inflammatory bowel disease;
TGCT	cis	rs62064224	0.589	rs9910731	chr17:30784034	A/G	cg18200150	chr17:30822561	MYO1D	0.43	5.46	0.44	2.52e-7	Schizophrenia;
TGCT	cis	rs7044106	0.791	rs2416797	chr9:123480600	C/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	4.98	0.41	2.12e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg13665807	chr20:60559372	TAF4	-0.45	-4.78	-0.39	4.89e-6	Body mass index;
TGCT	cis	rs35306767	0.859	rs11817793	chr10:878895	C/T	cg26597838	chr10:835615	NA	0.72	10.38	0.68	1.54e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs778371	0.871	rs2675954	chr2:233750627	C/G	cg08000102	chr2:233561755	GIGYF2	-0.58	-6.24	-0.49	6.27e-9	Schizophrenia;
TGCT	cis	rs933688	1.000	rs4382199	chr5:90744228	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.99	8.31	0.6	1.43e-13	Smoking behavior;
TGCT	cis	rs950169	0.580	rs11636189	chr15:85193554	G/A	cg11189052	chr15:85197271	WDR73	0.76	6.33	0.49	4.04e-9	Schizophrenia;
TGCT	cis	rs112591243	0.570	rs79100421	chr21:47969962	T/C	cg10657630	chr21:48055338	PRMT2	1.03	4.63	0.38	9.08e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs2067615	0.560	rs1882542	chr12:107070049	A/C	cg15890332	chr12:107067104	RFX4	0.29	5.81	0.46	4.97e-8	Heart rate;
TGCT	cis	rs6121246	0.633	rs6060986	chr20:30426297	G/A	cg13852791	chr20:30311386	BCL2L1	0.87	8.18	0.59	2.85e-13	Mean corpuscular hemoglobin;
TGCT	cis	rs4242434	0.757	rs2280104	chr8:22525980	C/T	cg21658235	chr8:22456391	C8orf58	0.43	4.75	0.39	5.48e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs7809950	0.637	rs3801964	chr7:106836242	T/C	cg23024343	chr7:107201750	COG5	-0.44	-6.03	-0.48	1.74e-8	Coronary artery disease;
TGCT	cis	rs9457247	1.000	rs422562	chr6:167406318	A/G	cg23791538	chr6:167370224	RNASET2	-0.5	-4.99	-0.41	2.01e-6	Crohn's disease;
TGCT	cis	rs28595532	0.920	rs114639588	chr4:119736176	T/C	cg11846333	chr4:119757529	SEC24D	0.93	4.44	0.37	2e-5	Cannabis dependence symptom count;
TGCT	cis	rs586688	1.000	rs632081	chr1:201643512	T/C	cg05779441	chr1:201574716	NA	0.29	4.72	0.39	6.21e-6	Obesity-related traits;
TGCT	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg13342137	chr4:2252803	MXD4	-0.17	-4.51	-0.38	1.5e-5	Obesity-related traits;
TGCT	cis	rs3809566	0.559	rs4775605	chr15:63324048	C/G	cg08198488	chr15:63333792	TPM1	-0.35	-5.35	-0.43	4.02e-7	Platelet count;
TGCT	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg00814883	chr7:100076585	TSC22D4	-0.82	-8.37	-0.6	1.03e-13	Platelet count;
TGCT	cis	rs8077577	0.895	rs62072500	chr17:18126918	A/C	cg09161412	chr17:18057145	MYO15A	-0.58	-4.73	-0.39	5.9e-6	Obesity-related traits;
TGCT	cis	rs4499344	0.622	rs2903752	chr19:33049943	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.67	5.74	0.46	6.86e-8	Mean platelet volume;
TGCT	cis	rs9467711	0.659	rs13216828	chr6:26373507	G/A	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.61	6.45	0.5	2.28e-9	Height;
TGCT	cis	rs9911578	1.000	rs11870671	chr17:56605360	A/G	cg12560992	chr17:57184187	TRIM37	-0.76	-9.34	-0.64	4.88e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg04944784	chr2:26401820	FAM59B	0.76	6.24	0.49	6.46e-9	Gut microbiome composition (summer);
TGCT	cis	rs74054849	0.850	rs60513147	chr1:15962974	A/G	cg05660106	chr1:15850417	CASP9	0.86	4.48	0.37	1.68e-5	Alcoholic chronic pancreatitis;
TGCT	cis	rs921968	0.643	rs1516086	chr2:219431535	C/T	cg02176678	chr2:219576539	TTLL4	0.38	5.66	0.45	1.01e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs35883536	0.647	rs11166485	chr1:101048805	G/C	cg10298815	chr1:101004474	GPR88	-0.25	-4.5	-0.37	1.54e-5	Monocyte count;
TGCT	cis	rs2468186	0.583	rs2465403	chr8:120090827	A/G	cg02248809	chr8:120845432	TAF2	0.44	4.7	0.39	6.79e-6	Osteoprotegerin levels;
TGCT	cis	rs7572733	0.534	rs700678	chr2:198705820	T/C	cg00792783	chr2:198669748	PLCL1	0.56	5.08	0.42	1.35e-6	Dermatomyositis;
TGCT	cis	rs28595532	0.920	rs116106661	chr4:119749794	A/G	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs1552244	0.748	rs9862221	chr3:10059658	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.4	-5.13	-0.42	1.09e-6	Alzheimer's disease;
TGCT	trans	rs1864729	1.000	rs2439700	chr8:98277168	G/A	cg08679828	chr8:102218111	ZNF706	-1.09	-7.6	-0.56	6.34e-12	Estradiol plasma levels (breast cancer);
TGCT	cis	rs6690583	0.623	rs1371140	chr1:85455362	A/C	cg20280350	chr1:85513789	MCOLN3	-0.74	-5.11	-0.42	1.2e-6	Serum sulfate level;
TGCT	cis	rs8032315	0.965	rs1894400	chr15:91428955	C/T	cg04510874	chr15:91427884	FES	0.53	6.01	0.48	1.91e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12142240	0.698	rs41294478	chr1:46818442	G/A	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs12142240	0.660	rs6679080	chr1:46819779	A/T	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg12311346	chr5:56204834	C5orf35	-0.67	-6.77	-0.52	4.59e-10	Initial pursuit acceleration;
TGCT	cis	rs2688608	0.592	rs11000759	chr10:75493726	G/A	cg15838173	chr10:75533400	FUT11	-0.31	-5.02	-0.41	1.73e-6	Inflammatory bowel disease;
TGCT	cis	rs3087591	0.960	rs2952991	chr17:29526742	T/C	cg24425628	chr17:29625626	OMG;NF1	0.46	7.39	0.55	1.91e-11	Hip circumference;
TGCT	cis	rs7772486	0.754	rs4896841	chr6:146041522	T/C	cg23711669	chr6:146136114	FBXO30	-0.95	-11.14	-0.71	2.17e-20	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7975161	1.000	rs4964728	chr12:104649733	G/A	cg25273343	chr12:104657179	TXNRD1	-0.31	-4.86	-0.4	3.45e-6	Toenail selenium levels;
TGCT	cis	rs78487399	0.808	rs17031005	chr2:43761299	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.42	-5.19	-0.42	8.39e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs7100689	0.646	rs1934694	chr10:82125325	G/A	cg01528321	chr10:82214614	TSPAN14	0.8	7.76	0.57	2.7e-12	Post bronchodilator FEV1;
TGCT	cis	rs9549367	0.789	rs2302754	chr13:113898385	C/T	cg18105134	chr13:113819100	PROZ	0.34	5.53	0.44	1.81e-7	Platelet distribution width;
TGCT	cis	rs2594989	0.832	rs13325556	chr3:11566961	T/G	cg26283222	chr3:11613257	VGLL4	0.22	4.57	0.38	1.18e-5	Circulating chemerin levels;
TGCT	cis	rs2637266	1.000	rs2395390	chr10:78357734	C/G	cg18941641	chr10:78392320	NA	0.37	4.5	0.37	1.53e-5	Pulmonary function;
TGCT	cis	rs950169	0.580	rs11636189	chr15:85193554	G/A	cg12863693	chr15:85201151	NMB	0.46	5.51	0.44	1.97e-7	Schizophrenia;
TGCT	cis	rs6840360	0.606	rs2709814	chr4:152360870	T/C	cg17479576	chr4:152424074	FAM160A1	-0.57	-5.91	-0.47	3.07e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs6582630	0.576	rs4882258	chr12:38453686	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-4.79	-0.4	4.57e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.46	-6.36	-0.5	3.55e-9	Alzheimer's disease;
TGCT	cis	rs7772486	0.658	rs4895683	chr6:146113654	T/A	cg23711669	chr6:146136114	FBXO30	-0.86	-9.74	-0.66	5.4e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg20203395	chr5:56204925	C5orf35	-0.59	-5.12	-0.42	1.12e-6	Initial pursuit acceleration;
TGCT	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg22166914	chr1:53195759	ZYG11B	0.41	7.17	0.54	6.04e-11	Monocyte count;
TGCT	cis	rs4074961	0.527	rs10908356	chr1:38038388	G/A	cg17933807	chr1:38061675	GNL2	1.04	14.78	0.8	3.92e-29	Axial length;
TGCT	cis	rs7103648	0.669	rs10437655	chr11:47391948	G/A	cg20307385	chr11:47447363	PSMC3	0.95	11.08	0.71	2.98e-20	Diastolic blood pressure;Systolic blood pressure;
TGCT	cis	rs4252435	0.520	rs7797896	chr7:142641189	T/C	cg21621906	chr7:142494914	NA	-1.08	-4.53	-0.38	1.36e-5	Cancer;
TGCT	cis	rs4972806	0.849	rs2113561	chr2:177030925	G/A	cg03152288	chr2:177042942	NA	0.6	5.18	0.42	8.72e-7	IgG glycosylation;
TGCT	cis	rs10782582	0.569	rs74090722	chr1:76197262	A/G	cg03433033	chr1:76189801	ACADM	-0.6	-6.61	-0.51	1e-9	Daytime sleep phenotypes;
TGCT	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.71	5.14	0.42	1.02e-6	Platelet count;
TGCT	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg18876405	chr7:65276391	NA	0.37	5.89	0.47	3.34e-8	Aortic root size;
TGCT	cis	rs7666738	0.830	rs11727612	chr4:99001662	T/C	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs1814175	0.781	rs11040681	chr11:49981654	G/T	cg15704280	chr7:45808275	SEPT13	-0.73	-8.48	-0.61	5.58e-14	Height;
TGCT	cis	rs7264396	0.790	rs6060530	chr20:34227663	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.28	-4.74	-0.39	5.75e-6	Total cholesterol levels;
TGCT	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg24399712	chr22:39784796	NA	-1.04	-13.27	-0.77	1.44e-25	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs36051895	0.659	rs57204002	chr9:5062610	T/C	cg02405213	chr9:5042618	JAK2	-0.72	-9.69	-0.66	7.17e-17	Pediatric autoimmune diseases;
TGCT	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs9311474	0.607	rs2015971	chr3:52546820	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.85	0.4	3.63e-6	Electroencephalogram traits;
TGCT	cis	rs6840360	0.642	rs10857260	chr4:152424056	C/G	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.82e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.66	5.43	0.44	2.84e-7	Tonsillectomy;
TGCT	cis	rs28595532	0.920	rs115154776	chr4:119774803	A/G	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg20637647	chr7:64974828	NA	0.89	4.99	0.41	2.01e-6	Diabetic kidney disease;
TGCT	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg23156509	chr2:114033830	PAX8;LOC440839	-0.3	-4.56	-0.38	1.2e-5	Lymphocyte counts;
TGCT	cis	rs6835098	1.000	rs10011724	chr4:174088865	A/G	cg08422745	chr4:174089978	GALNT7	-0.95	-11.46	-0.72	3.51e-21	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs78456975	0.527	rs11884165	chr2:1561052	A/G	cg01028140	chr2:1542097	TPO	-0.33	-5.12	-0.42	1.14e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg22920501	chr2:26401640	FAM59B	0.8	5.02	0.41	1.78e-6	Gut microbiome composition (summer);
TGCT	cis	rs17376456	0.877	rs12153506	chr5:93360953	T/G	cg21475434	chr5:93447410	FAM172A	0.6	4.73	0.39	6.08e-6	Diabetic retinopathy;
TGCT	cis	rs56104184	0.887	rs4801778	chr19:49370609	G/T	cg15549821	chr19:49342101	PLEKHA4	-0.64	-8.96	-0.63	4.09e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs11190604	1.000	rs2489049	chr10:102350732	G/A	cg16342193	chr10:102329863	NA	-0.4	-5.12	-0.42	1.12e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2486288	0.656	rs9921025	chr15:45546602	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.72	-7.46	-0.56	1.34e-11	Glomerular filtration rate;
TGCT	cis	rs6993813	0.589	rs4397431	chr8:120018413	G/A	cg17171407	chr8:119960777	TNFRSF11B	0.26	4.66	0.39	8.02e-6	Bone mineral density (hip);
TGCT	cis	rs6940638	0.606	rs6456771	chr6:27232395	G/A	cg05738196	chr6:26577821	NA	-0.55	-4.48	-0.37	1.7e-5	Intelligence (multi-trait analysis);
TGCT	trans	rs7824557	0.564	rs2736304	chr8:11236964	C/T	cg15556689	chr8:8085844	FLJ10661	-0.74	-6.69	-0.51	6.84e-10	Retinal vascular caliber;
TGCT	cis	rs10779751	0.960	rs4845988	chr1:11319587	A/G	cg08854313	chr1:11322531	MTOR	0.93	10.22	0.68	3.75e-18	Body mass index;
TGCT	cis	rs74417235	0.684	rs13185173	chr5:154055081	A/G	cg08754654	chr5:154026448	NA	0.58	5.53	0.44	1.84e-7	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
TGCT	cis	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg08045932	chr20:61659980	NA	0.48	9.28	0.64	7.07e-16	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2997447	0.846	rs55912918	chr1:26409801	C/T	cg03844060	chr1:26490628	NA	0.28	4.57	0.38	1.17e-5	QRS complex (12-leadsum);
TGCT	cis	rs9534288	0.830	rs3783202	chr13:46631869	G/A	cg15192986	chr13:46630673	CPB2	-0.5	-6.23	-0.49	6.66e-9	Blood protein levels;
TGCT	cis	rs17767294	0.708	rs72846802	chr6:28164842	A/G	cg08851530	chr6:28072375	NA	1.47	6.82	0.52	3.64e-10	Parkinson's disease;
TGCT	cis	rs9457247	1.000	rs421214	chr6:167396629	A/G	cg25258033	chr6:167368657	RNASET2	0.18	4.52	0.38	1.42e-5	Crohn's disease;
TGCT	cis	rs4824093	0.545	rs58876234	chr22:50258868	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.11	-6.79	-0.52	4.13e-10	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg21724239	chr8:58056113	NA	0.34	4.54	0.38	1.31e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs28595532	0.764	rs115916994	chr4:119688758	A/G	cg21605333	chr4:119757512	SEC24D	1.41	7.28	0.55	3.45e-11	Cannabis dependence symptom count;
TGCT	cis	rs9902453	0.967	rs4325622	chr17:28526475	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	6.51	0.5	1.66e-9	Coffee consumption (cups per day);
TGCT	cis	rs75686122	0.892	rs79477585	chr8:104571733	G/A	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs911263	0.603	rs12890124	chr14:68781614	A/C	cg18825221	chr14:68749962	RAD51L1	-0.22	-4.56	-0.38	1.22e-5	Primary biliary cholangitis;
TGCT	cis	rs11190604	1.000	rs75063298	chr10:102213600	C/A	cg16342193	chr10:102329863	NA	-0.4	-5.31	-0.43	4.85e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg11890956	chr21:40555474	PSMG1	1.12	12.59	0.75	6.25e-24	Cognitive function;
TGCT	cis	rs1048238	0.506	rs7525608	chr1:16141901	A/G	cg22431228	chr1:16359049	CLCNKA	-0.23	-4.52	-0.38	1.43e-5	Systolic blood pressure;
TGCT	cis	rs11190604	1.000	rs74650218	chr10:102293830	C/T	cg16342193	chr10:102329863	NA	-0.41	-5.37	-0.43	3.78e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs523522	0.962	rs4767914	chr12:120993817	C/T	cg12219531	chr12:120966889	COQ5	0.83	7.27	0.55	3.46e-11	High light scatter reticulocyte count;
TGCT	cis	rs7829975	0.774	rs1703982	chr8:8598388	A/T	cg15556689	chr8:8085844	FLJ10661	-0.64	-5.68	-0.45	9.17e-8	Mood instability;
TGCT	cis	rs68170813	0.559	rs79543528	chr7:106891090	C/T	cg02696742	chr7:106810147	HBP1	-0.69	-5.61	-0.45	1.27e-7	Coronary artery disease;
TGCT	cis	rs12142240	0.698	rs17413694	chr1:46818416	A/C	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs6835098	0.692	rs7657374	chr4:174065756	A/T	cg08422745	chr4:174089978	GALNT7	-0.77	-8.95	-0.63	4.19e-15	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs6121246	0.909	rs6060923	chr20:30336655	A/C	cg13852791	chr20:30311386	BCL2L1	0.8	6.12	0.48	1.15e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs4383453	0.539	rs4678015	chr3:123100463	A/G	cg04890266	chr3:123102914	ADCY5	-0.5	-8.19	-0.59	2.68e-13	Gestational age at birth (maternal effect);
TGCT	cis	rs6460942	0.915	rs62447642	chr7:12489147	T/C	cg06484146	chr7:12443880	VWDE	-0.61	-5.43	-0.44	2.87e-7	Coronary artery disease;
TGCT	cis	rs2153535	0.601	rs1855765	chr6:8444325	C/T	cg07606381	chr6:8435919	SLC35B3	0.57	5.25	0.43	6.46e-7	Motion sickness;
TGCT	cis	rs17122693	0.748	rs72681609	chr14:51117376	A/G	cg04730355	chr14:51134070	SAV1	1.33	10.91	0.7	7.71e-20	Cognitive performance;
TGCT	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs3749237	0.555	rs2117939	chr3:49415179	C/A	cg02487422	chr3:49467188	NICN1	0.59	6.01	0.47	1.92e-8	Resting heart rate;
TGCT	cis	rs1008375	0.900	rs4698622	chr4:17589557	C/T	cg10189774	chr4:17578691	LAP3	0.62	5.2	0.42	8.05e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2013441	0.760	rs8080827	chr17:20173936	G/A	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.55	-0.38	1.27e-5	Obesity-related traits;
TGCT	cis	rs2404602	0.692	rs58889902	chr15:77173070	A/C	cg22467129	chr15:76604101	ETFA	-0.47	-5.39	-0.44	3.44e-7	Blood metabolite levels;
TGCT	cis	rs73198271	0.722	rs488566	chr8:8639575	A/G	cg06671706	chr8:8559999	CLDN23	-0.35	-4.57	-0.38	1.15e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs1008375	1.000	rs28545485	chr4:17645376	C/T	cg18681998	chr4:17616180	MED28	1.01	11.89	0.73	3.17e-22	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg10876282	chr6:28092338	ZSCAN16	0.5	4.6	0.38	1.01e-5	Parkinson's disease;
TGCT	cis	rs782590	0.935	rs6739513	chr2:55749902	G/A	cg18811423	chr2:55921094	PNPT1	0.67	7.1	0.54	8.6e-11	Metabolic syndrome;
TGCT	cis	rs904251	0.600	rs11756241	chr6:37445101	C/T	cg25019722	chr6:37503610	NA	-0.48	-6.95	-0.53	1.88e-10	Cognitive performance;
TGCT	cis	rs2050392	0.771	rs303446	chr10:30728489	C/T	cg13289132	chr10:30722225	MAP3K8	-0.41	-4.97	-0.41	2.15e-6	Inflammatory bowel disease;
TGCT	cis	rs6754311	0.773	rs188680	chr2:136630989	A/G	cg07169764	chr2:136633963	MCM6	-0.65	-6.06	-0.48	1.5e-8	Mosquito bite size;
TGCT	cis	rs936229	1.000	rs936228	chr15:75132164	T/C	cg10253484	chr15:75165896	SCAMP2	-0.78	-6.45	-0.5	2.28e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
TGCT	cis	rs40363	1.000	rs28401	chr16:3515354	C/G	cg00484396	chr16:3507460	NAT15	0.44	5.08	0.41	1.36e-6	Tuberculosis;
TGCT	cis	rs7614311	0.636	rs77639204	chr3:64005452	C/T	cg22134162	chr3:63841271	THOC7	-0.43	-5.54	-0.45	1.74e-7	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs7267979	0.903	rs2474769	chr20:25248725	C/T	cg03522245	chr20:25566470	NINL	0.6	6.58	0.51	1.21e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs916888	0.610	rs199453	chr17:44800946	C/T	cg15921436	chr17:44337874	NA	0.41	6.25	0.49	5.98e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg12419862	chr22:24373484	LOC391322	-0.79	-8.04	-0.59	6.11e-13	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg19010396	chr19:19431384	KIAA0892;SF4	0.54	4.47	0.37	1.77e-5	Tonsillectomy;
TGCT	cis	rs2249625	0.508	rs60020363	chr6:72844706	C/T	cg08500200	chr6:72892038	RIMS1	0.45	4.84	0.4	3.79e-6	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
TGCT	cis	rs7267979	0.565	rs4815432	chr20:25556403	A/C	cg03522245	chr20:25566470	NINL	-0.44	-4.59	-0.38	1.06e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2204008	0.580	rs11174421	chr12:38105138	A/G	cg26384229	chr12:38710491	ALG10B	0.79	7.43	0.56	1.52e-11	Bladder cancer;
TGCT	cis	rs6598955	0.666	rs12759434	chr1:26607123	C/T	cg04990556	chr1:26633338	UBXN11	-0.9	-11.45	-0.72	3.7e-21	Obesity-related traits;
TGCT	cis	rs2637266	0.739	rs2583040	chr10:78439388	A/C	cg18941641	chr10:78392320	NA	0.4	4.88	0.4	3.24e-6	Pulmonary function;
TGCT	cis	rs6138458	1.000	rs2387361	chr20:24899905	C/T	cg26195577	chr20:24973756	C20orf3	-1.2	-12.04	-0.73	1.35e-22	Blood protein levels;
TGCT	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg24531977	chr5:56204891	C5orf35	-0.77	-7.61	-0.56	5.83e-12	Initial pursuit acceleration;
TGCT	cis	rs28374715	0.578	rs13313520	chr15:41629127	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.9	-14.93	-0.8	1.76e-29	Ulcerative colitis;
TGCT	cis	rs1903068	0.853	rs10012701	chr4:56002776	A/G	cg01777861	chr4:56023843	NA	0.53	6.21	0.49	7.2e-9	Endometriosis;
TGCT	cis	rs7666738	0.830	rs28729647	chr4:99059552	T/C	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.44e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9911578	1.000	rs2055779	chr17:57030561	A/G	cg12560992	chr17:57184187	TRIM37	0.76	9.21	0.64	1.03e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs7647973	0.925	rs6808036	chr3:49236439	T/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.57	-4.79	-0.4	4.63e-6	Menarche (age at onset);
TGCT	cis	rs12188164	1.000	rs34453673	chr5:434722	G/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.39	-4.62	-0.38	9.37e-6	Cystic fibrosis severity;
TGCT	cis	rs9309473	0.606	rs79234109	chr2:73848354	G/A	cg07208825	chr2:73871855	ALMS1P	0.27	5.25	0.43	6.34e-7	Metabolite levels;
TGCT	cis	rs7267979	0.509	rs6115218	chr20:25566485	A/G	cg14121845	chr20:25566513	NINL	0.86	10.74	0.69	1.97e-19	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9296092	0.517	rs76662639	chr6:33508476	G/A	cg13560919	chr6:33536144	NA	-0.21	-4.52	-0.38	1.41e-5	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs6901250	0.655	rs1117046	chr6:117136978	G/C	cg12892004	chr6:117198278	RFX6	0.45	5.65	0.45	1.04e-7	C-reactive protein levels;
TGCT	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg03303774	chr4:1407052	NA	0.28	4.52	0.38	1.42e-5	Obesity-related traits;
TGCT	cis	rs4919669	0.668	rs3934495	chr10:104361711	C/T	cg05855489	chr10:104503620	C10orf26	0.73	4.71	0.39	6.65e-6	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs7666738	0.830	rs28769113	chr4:98950371	T/G	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7731657	0.537	rs2107334	chr5:130292773	T/C	cg08523029	chr5:130500466	HINT1	-0.58	-4.84	-0.4	3.8e-6	Fasting plasma glucose;
TGCT	cis	rs4319547	0.695	rs1803290	chr12:122865029	T/C	cg05707623	chr12:122985044	ZCCHC8	0.62	4.87	0.4	3.32e-6	Body mass index;
TGCT	cis	rs10464366	0.544	rs2280667	chr7:39172228	A/C	cg18850127	chr7:39170497	POU6F2	0.37	8.18	0.59	2.89e-13	IgG glycosylation;
TGCT	cis	rs9831754	0.906	rs4680929	chr3:78387591	T/A	cg06138941	chr3:78371609	NA	-0.5	-5.46	-0.44	2.5e-7	Calcium levels;
TGCT	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	5.93	0.47	2.85e-8	Bipolar disorder;
TGCT	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	6.65	0.51	8.45e-10	Platelet count;
TGCT	cis	rs7666738	0.830	rs13101352	chr4:98957544	C/T	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs13177918	0.677	rs57890152	chr5:149821472	T/C	cg14059543	chr5:149831962	NA	-0.72	-9.49	-0.65	2.17e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs17253792	0.822	rs10483643	chr14:56089931	G/C	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs9486719	1.000	rs2092096	chr6:96870919	A/G	cg06623918	chr6:96969491	KIAA0776	0.98	8.77	0.62	1.15e-14	Migraine;Coronary artery disease;
TGCT	cis	rs7246657	0.943	rs7257672	chr19:37823859	G/C	cg18154014	chr19:37997991	ZNF793	0.74	5.08	0.42	1.34e-6	Coronary artery calcification;
TGCT	cis	rs4566357	1.000	rs1917129	chr2:227927951	A/T	cg11843606	chr2:227700838	RHBDD1	-0.52	-4.7	-0.39	6.81e-6	Coronary artery disease;
TGCT	cis	rs599083	0.502	rs113307519	chr11:68212641	C/T	cg16797656	chr11:68205561	LRP5	0.36	4.86	0.4	3.51e-6	Bone mineral density (spine);
TGCT	cis	rs3092073	0.617	rs56324610	chr20:44564030	G/C	cg23252815	chr20:44420276	WFDC3;DNTTIP1	-0.27	-4.5	-0.37	1.53e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs554111	0.963	rs710312	chr1:21042462	A/G	cg08890418	chr1:21044141	KIF17	0.57	6.03	0.48	1.73e-8	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs17345786	0.861	rs74768235	chr3:101142821	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.84	8.78	0.62	1.09e-14	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs523522	0.962	rs4766968	chr12:120947788	G/C	cg12219531	chr12:120966889	COQ5	0.83	7.27	0.55	3.46e-11	High light scatter reticulocyte count;
TGCT	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg13342137	chr4:2252803	MXD4	0.17	4.47	0.37	1.71e-5	Obesity-related traits;
TGCT	cis	rs11696501	0.688	rs6094197	chr20:44316492	C/T	cg11783356	chr20:44313418	WFDC10B	-0.33	-4.49	-0.37	1.6e-5	Brain structure;
TGCT	cis	rs617219	0.710	rs2591386	chr5:78561373	C/T	cg23987322	chr5:78407566	BHMT	0.35	4.67	0.39	7.64e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs28595532	0.841	rs115987912	chr4:119737085	C/T	cg11846333	chr4:119757529	SEC24D	0.93	4.44	0.37	2e-5	Cannabis dependence symptom count;
TGCT	cis	rs992157	0.764	rs2891076	chr2:219184398	C/T	cg00012203	chr2:219082015	ARPC2	0.7	6.59	0.51	1.11e-9	Colorectal cancer;
TGCT	cis	rs7586879	0.796	rs10187348	chr2:25078415	G/C	cg01884057	chr2:25150051	NA	0.26	4.56	0.38	1.2e-5	Body mass index;
TGCT	cis	rs72781680	1.000	rs72796357	chr2:24160131	A/G	cg08917208	chr2:24149416	ATAD2B	0.73	4.5	0.37	1.58e-5	Lymphocyte counts;
TGCT	cis	rs66573146	1.000	rs67405518	chr4:6965930	C/T	cg05069807	chr4:6945702	TBC1D14	0.31	4.6	0.38	1.03e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs9325144	0.577	rs12314639	chr12:39119869	T/C	cg26384229	chr12:38710491	ALG10B	-0.62	-5.86	-0.47	3.95e-8	Morning vs. evening chronotype;
TGCT	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.79	6.34	0.49	3.93e-9	Mean platelet volume;
TGCT	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.44	7.56	0.56	7.89e-12	Schizophrenia;
TGCT	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg24829409	chr8:58192753	C8orf71	-0.59	-4.97	-0.41	2.17e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs854765	0.522	rs63721860	chr17:17829576	T/C	cg09796270	chr17:17721594	SREBF1	0.24	4.78	0.39	4.92e-6	Total body bone mineral density;
TGCT	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg01802117	chr1:53393560	SCP2	-0.43	-5.2	-0.42	8.03e-7	Monocyte count;
TGCT	cis	rs4499344	0.633	rs259251	chr19:33149768	G/A	cg26639809	chr19:33781782	NA	0.22	4.47	0.37	1.75e-5	Mean platelet volume;
TGCT	trans	rs4650994	0.525	rs2811295	chr1:178551267	C/T	cg05059571	chr16:84539110	KIAA1609	0.53	10.64	0.69	3.57e-19	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg22963979	chr7:1858916	MAD1L1	-0.33	-5.07	-0.41	1.44e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs6906287	0.647	rs12207209	chr6:118850375	T/G	cg21191810	chr6:118973309	C6orf204	0.26	4.49	0.37	1.58e-5	Electrocardiographic conduction measures;
TGCT	cis	rs9883204	0.817	rs71330995	chr3:123124513	G/A	cg04890266	chr3:123102914	ADCY5	0.36	5.15	0.42	9.78e-7	Birth weight;
TGCT	cis	rs1887596	0.663	rs9551307	chr13:27258256	A/G	cg01312412	chr13:27282625	NA	0.3	5.46	0.44	2.45e-7	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs10791323	0.633	rs2171006	chr11:133728323	T/C	cg15485101	chr11:133734466	NA	0.35	4.59	0.38	1.09e-5	Childhood ear infection;
TGCT	cis	rs2070488	0.775	rs4407366	chr3:38521425	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.69	6.13	0.48	1.09e-8	Electrocardiographic conduction measures;
TGCT	cis	rs804280	0.638	rs36038176	chr8:11609995	C/T	cg26752888	chr8:11627280	NEIL2	0.71	5.39	0.44	3.44e-7	Myopia (pathological);
TGCT	cis	rs8180040	0.690	rs7640397	chr3:46989828	C/T	cg27129171	chr3:47204927	SETD2	0.71	9.04	0.63	2.58e-15	Colorectal cancer;
TGCT	cis	rs9325144	0.560	rs7304568	chr12:38632408	G/A	cg26384229	chr12:38710491	ALG10B	-0.66	-6.17	-0.48	8.94e-9	Morning vs. evening chronotype;
TGCT	cis	rs111803315	0.744	rs113568656	chr14:60011922	C/T	cg22995959	chr14:59931024	GPR135	0.66	4.8	0.4	4.39e-6	Schizophrenia;
TGCT	cis	rs12188164	0.965	rs56146525	chr5:442571	A/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.4	-4.71	-0.39	6.42e-6	Cystic fibrosis severity;
TGCT	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg00908189	chr16:619842	PIGQ	0.87	10.61	0.69	4.21e-19	Height;
TGCT	cis	rs2847281	0.796	rs11876290	chr18:12777607	G/A	cg23598886	chr18:12777645	NA	0.36	4.54	0.38	1.3e-5	C-reactive protein levels;Esophageal cancer (squamous cell);
TGCT	cis	rs28595532	0.920	rs114420700	chr4:119751297	T/C	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs6831352	0.918	rs13129488	chr4:100053025	G/T	cg12011299	chr4:100065546	ADH4	-0.4	-4.88	-0.4	3.26e-6	Alcohol dependence;
TGCT	cis	rs6687430	0.562	rs6676491	chr1:10633421	A/C	cg17425144	chr1:10567563	PEX14	0.48	5.32	0.43	4.66e-7	Hand grip strength;
TGCT	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg04025307	chr7:1156635	C7orf50	0.24	5.59	0.45	1.37e-7	Longevity;Endometriosis;
TGCT	cis	rs9457247	0.967	rs2015864	chr6:167381476	T/C	cg25258033	chr6:167368657	RNASET2	-0.18	-4.49	-0.37	1.63e-5	Crohn's disease;
TGCT	trans	rs10809457	0.869	rs1414202	chr9:11359656	T/C	cg12218771	chr1:6696166	DNAJC11	0.27	6.61	0.51	1.01e-9	Palmitic acid (16:0) levels;
TGCT	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg00420450	chr8:22132641	PIWIL2	0.23	4.56	0.38	1.22e-5	Hypertriglyceridemia;
TGCT	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg05368731	chr17:41323189	NBR1	1.16	13.48	0.77	4.59e-26	Menopause (age at onset);
TGCT	cis	rs9325144	0.624	rs10783329	chr12:39113951	C/T	cg10518543	chr12:38710700	ALG10B	-0.49	-4.48	-0.37	1.64e-5	Morning vs. evening chronotype;
TGCT	cis	rs60871478	1.000	rs4721124	chr7:823761	T/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.48	4.66	0.39	7.91e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs17076896	0.748	rs79332942	chr13:19929058	A/G	cg00777926	chr13:20807375	GJB6	-0.37	-4.51	-0.38	1.5e-5	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs13064411	0.696	rs7624994	chr3:113228009	T/C	cg18753928	chr3:113234510	CCDC52	-0.71	-5.78	-0.46	5.63e-8	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs9814567	1.000	rs13096604	chr3:134250099	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.96	9.11	0.63	1.79e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs35160687	0.901	rs10200186	chr2:86527423	C/T	cg04877910	chr2:85804641	VAMP8	0.34	4.51	0.38	1.49e-5	Night sleep phenotypes;
TGCT	cis	rs2153535	0.562	rs6901765	chr6:8455436	A/T	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs4293393	1.000	rs28362063	chr16:20365012	T/C	cg26923810	chr16:20935690	LYRM1	0.22	4.76	0.39	5.28e-6	Chronic kidney disease and serum creatinine levels;
TGCT	cis	rs59107033	0.607	rs1000368	chr3:123117165	C/T	cg04890266	chr3:123102914	ADCY5	-0.36	-5.24	-0.43	6.58e-7	Lymphocyte counts;
TGCT	cis	rs7824557	0.707	rs3808519	chr8:11142970	C/G	cg21775007	chr8:11205619	TDH	0.6	5.86	0.47	3.99e-8	Retinal vascular caliber;
TGCT	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg20607798	chr8:58055168	NA	0.44	4.54	0.38	1.33e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7659604	0.592	rs56077950	chr4:122721412	C/T	cg20573242	chr4:122745356	CCNA2	0.64	5.71	0.46	7.81e-8	Type 2 diabetes;
TGCT	cis	rs7178572	0.633	rs4886875	chr15:77838419	C/T	cg22256960	chr15:77711686	NA	0.8	7.5	0.56	1.08e-11	Type 2 diabetes;
TGCT	cis	rs700590	0.662	rs304154	chr5:88120416	T/C	cg22951263	chr5:87985283	NA	0.56	5.4	0.44	3.27e-7	Educational attainment (years of education);
TGCT	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg24549020	chr5:56110836	MAP3K1	0.67	5.78	0.46	5.74e-8	Initial pursuit acceleration;
TGCT	cis	rs7324557	0.717	rs9510870	chr13:24384485	C/T	cg16602799	chr13:25254742	ATP12A	0.57	4.45	0.37	1.93e-5	Visceral adipose tissue adjusted for BMI;
TGCT	trans	rs4650994	0.816	rs1074896	chr1:178591190	A/G	cg05059571	chr16:84539110	KIAA1609	0.41	7.51	0.56	1e-11	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs9462846	0.658	rs9471970	chr6:42913646	G/A	cg13397359	chr6:42928475	GNMT	0.6	4.59	0.38	1.06e-5	Blood protein levels;
TGCT	trans	rs797680	0.786	rs9432465	chr1:93780591	G/A	cg27528825	chr2:159282178	CCDC148	-0.33	-6.67	-0.51	7.68e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs6665290	0.669	rs12406714	chr1:227177061	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.9	-14.92	-0.8	1.84e-29	Myeloid white cell count;
TGCT	cis	rs6714788	0.565	rs12712063	chr2:100663281	C/T	cg22139774	chr2:100720529	AFF3	-0.4	-6.5	-0.5	1.73e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs68170813	0.641	rs12538848	chr7:106984569	G/T	cg02696742	chr7:106810147	HBP1	-0.71	-5.96	-0.47	2.38e-8	Coronary artery disease;
TGCT	cis	rs2688608	0.967	rs2675663	chr10:75660270	T/G	cg19442545	chr10:75533431	FUT11	-0.3	-4.86	-0.4	3.55e-6	Inflammatory bowel disease;
TGCT	trans	rs877282	0.583	rs7072970	chr10:822757	G/A	cg22713356	chr15:30763199	NA	0.89	6.64	0.51	8.63e-10	Uric acid levels;
TGCT	cis	rs3008870	0.755	rs2815380	chr1:67510857	A/G	cg02640540	chr1:67518911	SLC35D1	-0.64	-5.71	-0.46	7.93e-8	Lymphocyte percentage of white cells;
TGCT	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs2439831	0.681	rs825740	chr15:43592408	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	6.39	0.5	3.1e-9	Lung cancer in ever smokers;
TGCT	cis	rs12497850	0.829	rs8926	chr3:49052785	T/A	cg05785598	chr3:49045655	WDR6	0.36	4.77	0.39	5.17e-6	Parkinson's disease;
TGCT	cis	rs7647973	0.516	rs4955419	chr3:49200692	T/A	cg18654377	chr3:49208889	KLHDC8B	-0.38	-4.95	-0.41	2.38e-6	Menarche (age at onset);
TGCT	cis	rs3096299	0.719	rs2911265	chr16:89511328	G/A	cg06640241	chr16:89574553	SPG7	0.76	8.51	0.61	4.88e-14	Multiple myeloma (IgH translocation);
TGCT	cis	rs8056742	0.730	rs79334537	chr16:85084390	G/A	cg00229868	chr16:85520891	NA	0.36	4.83	0.4	3.96e-6	Amyotrophic lateral sclerosis;
TGCT	cis	rs9291683	0.567	rs12499857	chr4:9995376	G/A	cg00071950	chr4:10020882	SLC2A9	0.71	8.83	0.62	8.21e-15	Bone mineral density;
TGCT	cis	rs9486719	0.948	rs11153059	chr6:97014537	T/A	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.0	-0.41	1.9e-6	Migraine;Coronary artery disease;
TGCT	cis	rs2153535	0.563	rs6942177	chr6:8534460	A/G	cg07606381	chr6:8435919	SLC35B3	-0.54	-5.01	-0.41	1.86e-6	Motion sickness;
TGCT	cis	rs4319547	0.508	rs10846826	chr12:122894987	C/T	cg08088222	chr12:122070432	ORAI1	0.25	4.43	0.37	2.01e-5	Body mass index;
TGCT	cis	rs10464366	0.746	rs6945402	chr7:39145385	A/T	cg15212455	chr7:39170539	POU6F2	0.26	5.9	0.47	3.21e-8	IgG glycosylation;
TGCT	cis	rs8037137	0.749	rs12594925	chr15:91520287	G/A	cg22570213	chr15:91497863	RCCD1	0.51	4.83	0.4	3.91e-6	Platelet count;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
TGCT	cis	rs614226	0.872	rs787827	chr12:120937794	A/G	cg01236616	chr12:121019343	POP5	1.26	13.01	0.76	6.14e-25	Type 1 diabetes nephropathy;
TGCT	cis	rs2730245	0.569	rs842692	chr7:158657228	T/C	cg11984989	chr7:158649758	WDR60	1.01	8.96	0.63	4.14e-15	Height;
TGCT	cis	rs3733585	0.699	rs6449159	chr4:9960498	G/A	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.7	-0.57	3.69e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	trans	rs4919669	0.668	rs10883760	chr10:104419465	G/T	cg16267304	chr21:44985357	HSF2BP	0.65	6.69	0.51	6.85e-10	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs2806561	0.765	rs2776815	chr1:23510584	C/T	cg12483005	chr1:23474871	LUZP1	-0.37	-4.78	-0.39	4.97e-6	Height;
TGCT	cis	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg18252515	chr7:66147081	NA	-1.21	-7.89	-0.58	1.36e-12	Diabetic kidney disease;
TGCT	cis	rs7267979	0.789	rs62213729	chr20:25363426	C/T	cg13486641	chr20:25479848	NINL	0.16	4.57	0.38	1.17e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs13326165	0.760	rs1077142	chr3:52403526	A/G	cg27565382	chr3:53032988	SFMBT1	0.38	5.06	0.41	1.5e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs7267979	0.932	rs6107052	chr20:25530838	G/A	cg03522245	chr20:25566470	NINL	0.6	6.46	0.5	2.14e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10493773	0.748	rs12758511	chr1:86165987	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.43	-6.18	-0.49	8.29e-9	Urate levels in overweight individuals;
TGCT	cis	rs2721195	0.683	rs6989368	chr8:145813457	A/G	cg11211951	chr8:145729740	GPT	0.22	4.75	0.39	5.55e-6	Age at first birth;
TGCT	cis	rs295140	0.597	rs1653301	chr2:201076401	A/G	cg04283868	chr2:201171347	SPATS2L	-0.55	-5.54	-0.45	1.69e-7	QT interval;
TGCT	cis	rs56104184	0.775	rs117744769	chr19:49402686	G/T	cg17863274	chr19:49399704	TULP2	-0.54	-7.43	-0.55	1.58e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs754133	0.964	rs4759318	chr12:54420098	C/T	cg16264616	chr12:54390824	NA	0.33	5.11	0.42	1.19e-6	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;
TGCT	cis	rs10782582	0.609	rs1498311	chr1:76254726	A/C	cg10523679	chr1:76189770	ACADM	0.55	5.06	0.41	1.46e-6	Daytime sleep phenotypes;
TGCT	cis	rs2230307	0.536	rs11166384	chr1:100439890	C/T	cg24955406	chr1:100503596	HIAT1	0.75	4.88	0.4	3.2e-6	Carotid intima media thickness;
TGCT	cis	rs651907	0.535	rs58658478	chr3:101511667	G/A	cg12386194	chr3:101231763	SENP7	0.46	4.5	0.37	1.57e-5	Colorectal cancer;
TGCT	cis	rs7647973	0.577	rs6446247	chr3:49102001	A/T	cg07636037	chr3:49044803	WDR6	0.81	6.68	0.51	7.37e-10	Menarche (age at onset);
TGCT	cis	rs3796352	1.000	rs58660500	chr3:53086573	C/T	cg07884673	chr3:53033167	SFMBT1	0.61	6.25	0.49	6e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs6570726	0.791	rs379040	chr6:145889035	T/C	cg23711669	chr6:146136114	FBXO30	0.85	9.24	0.64	8.9e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1023500	1.000	rs1023497	chr22:42340508	C/G	cg04692870	chr22:42525206	CYP2D6	-0.31	-4.71	-0.39	6.46e-6	Schizophrenia;
TGCT	cis	rs6598955	0.543	rs12125620	chr1:26552238	G/A	cg04990556	chr1:26633338	UBXN11	0.8	7.3	0.55	3.01e-11	Obesity-related traits;
TGCT	cis	rs7267979	0.966	rs2227890	chr20:25260931	A/G	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7264396	0.790	rs6121026	chr20:34266883	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.25	-0.43	6.33e-7	Total cholesterol levels;
TGCT	cis	rs7267979	1.000	rs6515651	chr20:25414539	T/G	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs708547	0.836	rs1277287	chr4:57853147	C/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.55	-4.87	-0.4	3.32e-6	Response to bleomycin (chromatid breaks);
TGCT	cis	rs477895	0.838	rs7111278	chr11:64016284	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.83	6.93	0.53	2.04e-10	Mean platelet volume;
TGCT	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	16.07	0.82	4.16e-32	Prudent dietary pattern;
TGCT	cis	rs28595532	0.920	rs116516492	chr4:119734247	C/G	cg14228332	chr4:119757509	SEC24D	1.32	6.38	0.5	3.2e-9	Cannabis dependence symptom count;
TGCT	cis	rs78456975	0.527	rs11901028	chr2:1557972	A/G	cg12573674	chr2:1569213	NA	-0.45	-4.76	-0.39	5.37e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs4319547	0.656	rs9788145	chr12:122899522	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.64	-4.98	-0.41	2.08e-6	Body mass index;
TGCT	cis	rs422249	0.512	rs174577	chr11:61604814	A/C	cg19610905	chr11:61596333	FADS2	0.96	9.71	0.66	6.42e-17	Trans fatty acid levels;
TGCT	cis	rs3125734	0.572	rs3864794	chr10:64041956	A/C	cg19640130	chr10:64028056	RTKN2	-0.38	-4.76	-0.39	5.25e-6	Rheumatoid arthritis;
TGCT	cis	rs78366141	0.649	rs10428273	chr4:89672738	G/A	cg01026744	chr4:89619053	NAP1L5;HERC3	1.15	5.23	0.43	6.86e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
TGCT	cis	rs896854	0.738	rs527234	chr8:95963798	C/G	cg09323728	chr8:95962352	TP53INP1	0.45	5.32	0.43	4.6e-7	Type 2 diabetes;
TGCT	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.03	0.41	1.68e-6	Prudent dietary pattern;
TGCT	cis	rs669446	0.591	rs617521	chr1:44114199	G/T	cg12908607	chr1:44402522	ARTN	-0.52	-5.74	-0.46	6.79e-8	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs10089	1.000	rs4836370	chr5:127499224	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.85	8.27	0.6	1.75e-13	Ileal carcinoids;
TGCT	cis	rs854765	0.583	rs12603148	chr17:17865257	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.74	7.55	0.56	8.23e-12	Total body bone mineral density;
TGCT	cis	rs8070128	0.583	rs7406982	chr17:17942613	C/T	cg09796270	chr17:17721594	SREBF1	0.24	4.7	0.39	6.87e-6	Total body bone mineral density;
TGCT	cis	rs2075371	0.933	rs1421481	chr7:133964380	A/C	cg11752832	chr7:134001865	SLC35B4	0.69	6.1	0.48	1.24e-8	Mean platelet volume;
TGCT	cis	rs77972916	0.536	rs6751209	chr2:43588302	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.37	-5.8	-0.46	5.19e-8	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg02487422	chr3:49467188	NICN1	0.53	4.94	0.41	2.43e-6	Menarche (age at onset);
TGCT	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg10802521	chr3:52805072	NEK4	-0.78	-10.0	-0.67	1.26e-17	Bipolar disorder;
TGCT	cis	rs617219	0.710	rs10054122	chr5:78581371	A/T	cg09550809	chr5:78407562	BHMT	-0.39	-5.5	-0.44	2.03e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg21724239	chr8:58056113	NA	0.41	4.87	0.4	3.33e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs748404	0.578	rs512628	chr15:43618734	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	4.75	0.39	5.5e-6	Lung cancer;
TGCT	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg13012494	chr21:47604986	C21orf56	0.38	4.56	0.38	1.21e-5	Testicular germ cell tumor;
TGCT	cis	rs8103278	0.507	rs16939	chr19:46276056	C/A	cg14061069	chr19:46274453	DMPK	0.62	10.94	0.7	6.57e-20	Coronary artery disease;
TGCT	cis	rs10057188	0.814	rs10075895	chr5:77874443	C/G	cg06873401	chr5:77792105	LHFPL2	-0.23	-4.51	-0.38	1.45e-5	Pulse pressure;
TGCT	cis	rs7216064	0.953	rs9890629	chr17:65871559	G/A	cg12091567	chr17:66097778	LOC651250	-0.86	-6.75	-0.52	5.09e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	trans	rs12655019	0.920	rs7731829	chr5:56207711	T/C	cg25190722	chr1:3801660	DFFB	0.62	7.17	0.54	5.87e-11	Breast cancer (early onset);
TGCT	cis	rs7178572	0.568	rs12907847	chr15:77493174	C/T	cg15453836	chr15:77711506	NA	-0.44	-4.91	-0.4	2.86e-6	Type 2 diabetes;
TGCT	cis	rs644799	0.582	rs473157	chr11:95596874	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.54	5.42	0.44	3e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs10493773	0.566	rs11161659	chr1:86183967	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.52	-8.15	-0.59	3.45e-13	Urate levels in overweight individuals;
TGCT	cis	rs7781977	0.554	rs7804185	chr7:50353144	T/C	cg01139861	chr7:50343298	IKZF1	0.47	5.57	0.45	1.48e-7	IgG glycosylation;
TGCT	cis	rs35306767	0.903	rs12250936	chr10:870109	C/T	cg26597838	chr10:835615	NA	0.71	10.12	0.67	6.47e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs854765	0.583	rs62064156	chr17:17822480	C/T	cg09796270	chr17:17721594	SREBF1	0.28	5.66	0.45	9.89e-8	Total body bone mineral density;
TGCT	cis	rs9972944	0.756	rs7218844	chr17:63768289	G/A	cg07283582	chr17:63770753	CCDC46	-0.26	-5.27	-0.43	5.91e-7	Total body bone mineral density;
TGCT	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg02353165	chr6:42928485	GNMT	0.97	10.15	0.67	5.35e-18	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs7474896	0.537	rs2749588	chr10:38269457	C/G	cg13720705	chr10:37990370	NA	0.34	4.54	0.38	1.31e-5	Obesity (extreme);
TGCT	cis	rs6460942	1.000	rs6948314	chr7:12418363	T/A	cg06484146	chr7:12443880	VWDE	-0.59	-5.6	-0.45	1.28e-7	Coronary artery disease;
TGCT	cis	rs7953508	0.506	rs12425869	chr12:93961353	A/G	cg18151635	chr12:93972918	NA	-0.19	-4.54	-0.38	1.33e-5	Pubertal anthropometrics;
TGCT	trans	rs2970818	0.831	rs7304949	chr12:4609625	A/G	cg03310518	chr7:30954522	AQP1	0.3	6.73	0.52	5.56e-10	Phosphorus levels;
TGCT	cis	rs2197308	0.765	rs68029712	chr12:37906585	T/G	cg26384229	chr12:38710491	ALG10B	0.89	8.03	0.58	6.52e-13	Morning vs. evening chronotype;
TGCT	cis	rs13188771	0.651	rs114484620	chr5:100889920	T/C	cg10455971	chr5:101119566	NA	0.44	4.45	0.37	1.87e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs8051149	0.688	rs16943320	chr16:87870379	A/G	cg01412419	chr16:87856264	NA	0.49	6.1	0.48	1.24e-8	Blood metabolite levels;
TGCT	cis	rs1505368	0.567	rs2054617	chr2:213355890	T/C	cg20637307	chr2:213403960	ERBB4	0.66	7.01	0.53	1.35e-10	Symmetrical dimethylarginine levels;
TGCT	cis	rs2075371	1.000	rs2598288	chr7:133977304	A/T	cg11752832	chr7:134001865	SLC35B4	0.7	6.51	0.5	1.68e-9	Mean platelet volume;
TGCT	cis	rs6540559	0.673	rs11805830	chr1:209984969	C/T	cg23283495	chr1:209979779	IRF6	0.65	5.04	0.41	1.63e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	8.0	0.58	7.67e-13	Platelet count;
TGCT	cis	rs7666738	0.830	rs13108422	chr4:99059267	G/A	cg18180107	chr4:99064573	C4orf37	0.56	5.08	0.41	1.37e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6424115	0.830	rs2502991	chr1:24202318	A/G	cg15997130	chr1:24165203	NA	0.85	9.25	0.64	8.02e-16	Immature fraction of reticulocytes;
TGCT	cis	rs11948739	0.501	rs3981332	chr5:130372203	A/T	cg08523029	chr5:130500466	HINT1	-0.61	-5.08	-0.42	1.34e-6	Pediatric bone mineral content (hip);
TGCT	cis	rs1008375	1.000	rs4698634	chr4:17630192	A/C	cg16339924	chr4:17578868	LAP3	-0.62	-5.11	-0.42	1.17e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.97	10.53	0.69	6.35e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs2404602	0.662	rs908817	chr15:76639191	G/A	cg22467129	chr15:76604101	ETFA	0.45	4.72	0.39	6.38e-6	Blood metabolite levels;
TGCT	cis	rs477895	0.713	rs7952318	chr11:63961242	G/A	cg23719950	chr11:63933701	MACROD1	-0.72	-6.06	-0.48	1.52e-8	Mean platelet volume;
TGCT	cis	rs713587	0.875	rs6746013	chr2:25143649	C/G	cg01884057	chr2:25150051	NA	0.4	8.18	0.59	2.88e-13	Body mass index in non-asthmatics;
TGCT	cis	rs713587	0.967	rs10182181	chr2:25150296	C/T	cg15423357	chr2:25149977	NA	-0.66	-6.81	-0.52	3.78e-10	Body mass index in non-asthmatics;
TGCT	cis	rs78487399	0.803	rs75275342	chr2:43762885	T/G	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.79	4.82	0.4	4.14e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs73198271	1.000	rs73198272	chr8:8606808	A/C	ch.8.214553F	chr8:8189620	PRAGMIN	-0.27	-4.57	-0.38	1.17e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs6735179	0.565	rs736870	chr2:1748702	T/C	cg08534653	chr2:1747700	PXDN	0.54	4.45	0.37	1.92e-5	Response to antipsychotic treatment;
TGCT	cis	rs7914558	0.966	rs11191438	chr10:104637864	C/G	cg04362960	chr10:104952993	NT5C2	0.59	5.29	0.43	5.4e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	trans	rs2727020	0.521	rs10839285	chr11:49496852	T/G	cg11707556	chr5:10655725	ANKRD33B	0.45	9.83	0.66	3.25e-17	Coronary artery disease;
TGCT	cis	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg03213289	chr20:61660250	NA	0.68	9.9	0.66	2.25e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7824557	0.564	rs11782430	chr8:11226071	A/G	cg21775007	chr8:11205619	TDH	-0.63	-5.8	-0.46	5.24e-8	Retinal vascular caliber;
TGCT	cis	rs7568458	0.870	rs2366639	chr2:85809955	A/G	cg02493740	chr2:85810744	VAMP5	-0.27	-4.64	-0.38	8.64e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs346785	1.000	rs346785	chr17:74283769	C/T	cg09812376	chr17:74270190	QRICH2	0.4	6.26	0.49	5.88e-9	White matter hyperintensities in ischemic stroke;
TGCT	cis	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg06697600	chr4:7070879	GRPEL1	-0.47	-4.94	-0.41	2.42e-6	Monocyte percentage of white cells;
TGCT	cis	rs7833790	0.963	rs1451997	chr8:82774053	A/T	cg17211192	chr8:82754475	SNX16	1.06	9.09	0.63	2e-15	Diastolic blood pressure;
TGCT	cis	rs11792861	0.591	rs10979632	chr9:111732140	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	7.35	0.55	2.38e-11	Menarche (age at onset);
TGCT	cis	rs17345786	0.511	rs1138818	chr3:101399583	C/G	cg11279151	chr3:101281821	RG9MTD1	-0.35	-7.28	-0.55	3.4e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs709400	1.000	rs58133129	chr14:104104759	A/G	cg26031613	chr14:104095156	KLC1	1.14	17.16	0.84	1.53e-34	Body mass index;
TGCT	cis	rs8072100	0.738	rs9900123	chr17:45549055	T/C	cg08085267	chr17:45401833	C17orf57	-0.47	-5.17	-0.42	8.98e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg06896619	chr17:61851486	DDX42;CCDC47	0.49	4.98	0.41	2.06e-6	Prudent dietary pattern;
TGCT	cis	rs6901250	0.807	rs339303	chr6:117176691	C/T	cg12892004	chr6:117198278	RFX6	-0.55	-6.76	-0.52	4.74e-10	C-reactive protein levels;
TGCT	cis	rs6964587	0.692	rs7807490	chr7:91773359	A/G	cg17063962	chr7:91808500	NA	0.74	6.94	0.53	1.93e-10	Breast cancer;
TGCT	cis	rs7264396	0.790	rs11697903	chr20:34272224	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.25	-0.43	6.33e-7	Total cholesterol levels;
TGCT	cis	rs55883249	1.000	rs62119391	chr2:9712272	A/G	cg23886495	chr2:9695866	ADAM17	0.82	4.8	0.4	4.47e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	trans	rs1496653	0.602	rs34743949	chr3:23371636	T/C	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs9467711	0.720	rs7749823	chr6:26158079	A/C	cg16898833	chr6:26189333	HIST1H4D	1.0	5.27	0.43	5.73e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs459571	0.715	rs401826	chr9:136890591	C/T	cg13789015	chr9:136890014	NCRNA00094	0.41	7.53	0.56	9.26e-12	Platelet distribution width;
TGCT	cis	rs710216	0.917	rs3754223	chr1:43419091	A/T	cg03128534	chr1:43423976	SLC2A1	0.57	4.81	0.4	4.34e-6	Red cell distribution width;
TGCT	cis	rs17345786	0.906	rs11708616	chr3:101231731	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.42	-8.89	-0.62	5.99e-15	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2404602	1.000	rs2056544	chr15:76826003	G/A	cg22467129	chr15:76604101	ETFA	-0.5	-5.64	-0.45	1.09e-7	Blood metabolite levels;
TGCT	cis	rs6088580	0.634	rs1205344	chr20:32918298	G/A	cg06115741	chr20:33292138	TP53INP2	-0.5	-4.46	-0.37	1.8e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs4129767	0.869	rs4969142	chr17:76398304	G/A	cg05887092	chr17:76393375	PGS1	0.22	4.64	0.38	8.72e-6	HDL cholesterol;
TGCT	cis	rs11148252	0.574	rs3742297	chr13:53278067	T/C	cg00495681	chr13:53174319	NA	0.71	7.41	0.55	1.69e-11	Lewy body disease;
TGCT	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg10150615	chr22:24372951	LOC391322	-0.8	-8.71	-0.62	1.62e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.61	0.38	9.85e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg12310025	chr6:25882481	NA	-0.67	-6.09	-0.48	1.32e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs6754311	0.593	rs7608045	chr2:136413359	T/C	cg07169764	chr2:136633963	MCM6	0.67	6.1	0.48	1.24e-8	Mosquito bite size;
TGCT	cis	rs2282802	0.635	rs199152	chr5:139539235	C/T	cg01081189	chr5:139537190	NA	-0.29	-5.31	-0.43	4.81e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2862064	0.929	rs2862062	chr5:156445677	C/T	cg12943317	chr5:156479607	HAVCR1	-0.4	-5.05	-0.41	1.56e-6	Platelet count;
TGCT	cis	rs3809566	1.000	rs4775610	chr15:63332057	C/T	cg00520135	chr15:63333846	TPM1	0.45	5.51	0.44	1.98e-7	Platelet count;
TGCT	cis	rs6860806	0.507	rs272878	chr5:131671769	C/T	cg24060327	chr5:131705240	SLC22A5	0.76	8.64	0.61	2.38e-14	Breast cancer;
TGCT	cis	rs7904368	0.951	rs7905776	chr10:16853609	C/T	cg14835575	chr10:16859367	RSU1	0.63	6.73	0.52	5.61e-10	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
TGCT	cis	rs4711350	0.954	rs943464	chr6:33731469	A/G	cg13859433	chr6:33739653	LEMD2	0.33	4.49	0.37	1.58e-5	Schizophrenia;
TGCT	cis	rs2070488	0.775	rs6599204	chr3:38525734	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.69	6.13	0.48	1.09e-8	Electrocardiographic conduction measures;
TGCT	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg12667521	chr19:29218732	NA	0.54	5.72	0.46	7.65e-8	Methadone dose in opioid dependence;
TGCT	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg14893161	chr1:205819251	PM20D1	0.37	4.52	0.38	1.42e-5	Menarche (age at onset);
TGCT	cis	rs4654899	0.802	rs1530946	chr1:21182540	A/G	cg01072550	chr1:21505969	NA	0.45	6.64	0.51	8.8e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs6752107	0.935	rs10929325	chr2:234151031	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.2	4.88	0.4	3.13e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs11122272	0.735	rs2486729	chr1:231535584	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-6.5	-0.5	1.77e-9	Hemoglobin concentration;
TGCT	cis	rs6547741	1.000	rs10205364	chr2:27794233	C/T	cg27432699	chr2:27873401	GPN1	0.18	4.66	0.39	8.09e-6	Oral cavity cancer;
TGCT	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.46	-6.43	-0.5	2.53e-9	Alzheimer's disease;
TGCT	cis	rs7523050	0.643	rs17621851	chr1:109400835	C/T	cg08274380	chr1:109419600	GPSM2	1.3	6.39	0.5	2.99e-9	Fat distribution (HIV);
TGCT	cis	rs68170813	0.527	rs78133594	chr7:107025260	T/C	cg02696742	chr7:106810147	HBP1	-0.7	-5.68	-0.45	8.91e-8	Coronary artery disease;
TGCT	cis	rs7666738	0.791	rs11097610	chr4:99011795	C/G	cg18180107	chr4:99064573	C4orf37	0.52	4.69	0.39	7e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg18538332	chr22:24372958	LOC391322	0.84	7.23	0.54	4.44e-11	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	trans	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg13615516	chr5:77269221	NA	0.68	8.54	0.61	3.97e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs6504663	0.586	rs60117965	chr17:48569755	G/A	cg22571038	chr17:48585470	MYCBPAP	0.56	4.78	0.39	4.79e-6	Visceral fat;
TGCT	cis	rs9653442	0.500	rs72819191	chr2:100826572	A/G	cg22139774	chr2:100720529	AFF3	0.36	5.2	0.42	8.11e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs950776	1.000	rs950776	chr15:78926018	A/G	cg06917634	chr15:78832804	PSMA4	0.65	4.92	0.4	2.72e-6	Sudden cardiac arrest;
TGCT	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.62	-5.11	-0.42	1.17e-6	Tonsillectomy;
TGCT	cis	rs2243480	1.000	rs316315	chr7:65591205	C/T	cg18252515	chr7:66147081	NA	1.15	8.2	0.59	2.63e-13	Diabetic kidney disease;
TGCT	cis	rs9393692	0.905	rs7747133	chr6:26293470	C/T	cg00631329	chr6:26305371	NA	-0.44	-6.59	-0.51	1.13e-9	Educational attainment;
TGCT	cis	rs2072499	0.932	rs2736613	chr1:156196016	T/C	cg25208724	chr1:156163844	SLC25A44	1.11	12.8	0.75	1.94e-24	Testicular germ cell tumor;
TGCT	cis	rs6570726	0.791	rs443628	chr6:145883484	T/C	cg23711669	chr6:146136114	FBXO30	0.9	10.01	0.67	1.19e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs17221829	0.931	rs10160803	chr11:89461859	C/T	cg02982614	chr11:89391479	FOLH1B	-0.3	-5.29	-0.43	5.47e-7	Anxiety in major depressive disorder;
TGCT	cis	rs35160687	0.901	rs35281683	chr2:86526372	T/C	cg03171300	chr2:86307199	POLR1A	0.32	5.56	0.45	1.61e-7	Night sleep phenotypes;
TGCT	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg09737314	chr17:6899359	ALOX12	-0.46	-4.88	-0.4	3.23e-6	Tonsillectomy;
TGCT	cis	rs1044826	0.642	rs4607068	chr3:139162994	A/G	cg00490450	chr3:139108681	COPB2	0.53	4.59	0.38	1.06e-5	Obesity-related traits;
TGCT	cis	rs9291683	0.935	rs1860911	chr4:10275057	C/T	cg00071950	chr4:10020882	SLC2A9	0.42	4.57	0.38	1.16e-5	Bone mineral density;
TGCT	cis	rs10776733	0.613	rs2364815	chr1:112106247	G/T	cg21869440	chr1:111888833	C1orf88	-0.49	-4.5	-0.37	1.55e-5	Obesity-related traits;
TGCT	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg11890956	chr21:40555474	PSMG1	-0.68	-6.59	-0.51	1.15e-9	Menarche (age at onset);
TGCT	cis	rs892961	1.000	rs11077907	chr17:75400706	G/A	cg05865280	chr17:75406074	SEPT9	0.29	6.82	0.52	3.6e-10	Airflow obstruction;
TGCT	cis	rs7020830	0.931	rs13293916	chr9:37136359	C/G	cg14294708	chr9:37120828	ZCCHC7	1.29	19.83	0.87	2.81e-40	Schizophrenia;
TGCT	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg01802117	chr1:53393560	SCP2	0.45	5.37	0.43	3.73e-7	Monocyte count;
TGCT	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg16049864	chr8:95962084	TP53INP1	-0.74	-10.56	-0.69	5.52e-19	Type 2 diabetes;
TGCT	cis	rs1532993	0.518	rs13150153	chr4:98629384	T/C	cg05340658	chr4:99064831	C4orf37	-0.38	-4.54	-0.38	1.32e-5	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg20607798	chr8:58055168	NA	0.61	5.06	0.41	1.5e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6988636	1.000	rs11988157	chr8:124194740	A/G	cg22384356	chr8:124195192	FAM83A	0.44	5.98	0.47	2.26e-8	Urinary uromodulin levels;
TGCT	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs3774830	0.714	rs7657964	chr4:5466327	C/G	cg26943120	chr4:5472116	STK32B	-0.23	-5.08	-0.42	1.34e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs12210905	1.000	rs116005859	chr6:27155485	G/A	cg08851530	chr6:28072375	NA	1.12	5.43	0.44	2.82e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs76096589	0.557	rs3783409	chr14:50990400	C/T	cg04730355	chr14:51134070	SAV1	1.05	4.49	0.37	1.58e-5	Diisocyanate-induced asthma;
TGCT	trans	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.83	-8.69	-0.62	1.76e-14	Body mass index;
TGCT	cis	rs7589728	0.858	rs1914734	chr2:88529509	T/C	cg04511125	chr2:88470314	THNSL2	0.57	4.74	0.39	5.67e-6	Plasma clusterin levels;
TGCT	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg18305652	chr10:134549665	INPP5A	0.34	5.83	0.46	4.5e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs7819412	0.838	rs4840544	chr8:10960572	C/T	cg21775007	chr8:11205619	TDH	-0.57	-5.6	-0.45	1.3e-7	Triglycerides;
TGCT	trans	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg24694675	chr1:76082066	NA	0.66	6.81	0.52	3.7e-10	Bipolar disorder and schizophrenia;
TGCT	cis	rs2404602	0.716	rs12440815	chr15:76627328	C/A	cg26408565	chr15:76604113	ETFA	-0.45	-6.09	-0.48	1.28e-8	Blood metabolite levels;
TGCT	cis	rs6754311	0.773	rs309125	chr2:136643555	C/T	cg07169764	chr2:136633963	MCM6	0.62	5.47	0.44	2.41e-7	Mosquito bite size;
TGCT	cis	rs7772486	0.875	rs932522	chr6:146374026	A/G	cg05347473	chr6:146136440	FBXO30	-0.52	-4.88	-0.4	3.13e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11190604	0.767	rs11190513	chr10:102165238	A/G	cg16342193	chr10:102329863	NA	-0.4	-5.06	-0.41	1.5e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs11098499	0.708	rs10005237	chr4:120237897	T/C	cg09307838	chr4:120376055	NA	0.61	5.91	0.47	3.14e-8	Corneal astigmatism;
TGCT	cis	rs7412746	0.658	rs1027699	chr1:150811712	T/C	cg04414720	chr1:150670196	GOLPH3L	0.38	4.69	0.39	7.01e-6	Melanoma;
TGCT	cis	rs826838	1.000	rs12366971	chr12:38737687	T/G	cg26384229	chr12:38710491	ALG10B	1.08	10.88	0.7	9.18e-20	Heart rate;
TGCT	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg11644478	chr21:40555479	PSMG1	-0.53	-4.55	-0.38	1.28e-5	Cognitive function;
TGCT	cis	rs12497850	0.897	rs7432989	chr3:49105136	A/G	cg05785598	chr3:49045655	WDR6	0.36	4.8	0.4	4.48e-6	Parkinson's disease;
TGCT	cis	rs28830936	0.510	rs7174099	chr15:42099059	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.19	-5.23	-0.43	7e-7	Diastolic blood pressure;
TGCT	trans	rs17173637	0.764	rs1044616	chr7:150502075	G/C	cg00050224	chr17:78327956	RNF213;LOC100294362	0.37	6.68	0.51	7.29e-10	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg07157834	chr1:205819609	PM20D1	0.43	7.03	0.53	1.25e-10	Menarche (age at onset);
TGCT	cis	rs2204008	0.702	rs8175764	chr12:38363690	T/C	cg13010199	chr12:38710504	ALG10B	0.59	4.58	0.38	1.14e-5	Bladder cancer;
TGCT	cis	rs7681440	0.869	rs894280	chr4:90760883	C/T	cg26578617	chr4:90757533	SNCA	-0.49	-5.12	-0.42	1.13e-6	Dementia with Lewy bodies;
TGCT	cis	rs9677476	0.542	rs7595464	chr2:231967610	A/G	cg07929768	chr2:232055508	NA	0.33	5.25	0.43	6.36e-7	Food antigen IgG levels;
TGCT	cis	rs5769765	0.773	rs9616751	chr22:50222236	T/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.2	-12.89	-0.76	1.18e-24	Schizophrenia;
TGCT	cis	rs6700896	0.522	rs4655793	chr1:66159278	C/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.54	4.44	0.37	1.98e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs4409675	0.576	rs2474470	chr1:28234999	C/T	cg23691781	chr1:28212827	C1orf38	0.26	5.44	0.44	2.76e-7	Corneal astigmatism;
TGCT	cis	rs11249608	0.548	rs11960161	chr5:178453837	A/G	cg01312482	chr5:178451176	ZNF879	-0.49	-4.76	-0.39	5.2e-6	Pubertal anthropometrics;
TGCT	cis	rs9611565	0.546	rs2092274	chr22:42123737	A/G	cg03806693	chr22:41940476	POLR3H	1.06	11.92	0.73	2.7e-22	Vitiligo;
TGCT	cis	rs709400	0.663	rs17679475	chr14:103916958	A/G	cg26031613	chr14:104095156	KLC1	0.84	9.19	0.64	1.13e-15	Body mass index;
TGCT	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.63	-6.54	-0.51	1.45e-9	Longevity;Endometriosis;
TGCT	cis	rs155076	1.000	rs261423	chr13:21852331	A/C	cg14456004	chr13:21872349	NA	-1.34	-11.21	-0.71	1.42e-20	White matter hyperintensity burden;
TGCT	cis	rs763121	0.925	rs5757251	chr22:39100128	G/A	cg06022373	chr22:39101656	GTPBP1	0.69	6.65	0.51	8.39e-10	Menopause (age at onset);
TGCT	cis	rs6430585	0.591	rs309170	chr2:136672775	C/T	cg07169764	chr2:136633963	MCM6	1.19	11.56	0.72	2.02e-21	Corneal structure;
TGCT	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg26513180	chr16:89883248	FANCA	1.05	14.87	0.8	2.47e-29	Vitiligo;
TGCT	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg05368731	chr17:41323189	NBR1	1.11	11.14	0.71	2.11e-20	Menopause (age at onset);
TGCT	cis	rs514406	0.505	rs436363	chr1:53172163	T/C	cg08859206	chr1:53392774	SCP2	-0.34	-4.86	-0.4	3.53e-6	Monocyte count;
TGCT	cis	rs12477438	0.520	rs6542870	chr2:99796638	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.82	0.62	8.67e-15	Chronic sinus infection;
TGCT	cis	rs9811920	0.535	rs704571	chr3:99481946	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.39	4.6	0.38	1.04e-5	Axial length;
TGCT	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg00024416	chr22:24240387	NA	-0.26	-5.11	-0.42	1.2e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs5769707	0.667	rs4824069	chr22:50030325	T/C	cg05373962	chr22:49881684	NA	-0.31	-5.37	-0.43	3.8e-7	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs6570726	0.967	rs9403706	chr6:145795187	C/T	cg23711669	chr6:146136114	FBXO30	-0.66	-6.06	-0.48	1.52e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6586111	1.000	rs6586111	chr10:82377590	T/C	cg03086067	chr10:82368399	SH2D4B	-0.23	-4.51	-0.38	1.51e-5	Capecitabine sensitivity;
TGCT	cis	rs2288073	0.965	rs6545340	chr2:24422269	C/G	cg05570707	chr2:24270316	C2orf44	-0.5	-4.47	-0.37	1.72e-5	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs2120019	1.000	rs12910644	chr15:75358388	A/G	cg11632617	chr15:75315747	PPCDC	-0.33	-4.59	-0.38	1.07e-5	Blood trace element (Zn levels);
TGCT	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg08219700	chr8:58056026	NA	0.3	4.53	0.38	1.35e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7312933	0.558	rs11181501	chr12:42822671	G/A	cg19980929	chr12:42632907	YAF2	0.42	5.91	0.47	3.05e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs9419702	0.568	rs7075233	chr10:133545170	A/G	cg23460707	chr10:133558971	NA	-0.42	-4.94	-0.41	2.43e-6	Survival in rectal cancer;
TGCT	cis	rs3741404	0.537	rs1123251	chr11:63917601	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.68	-5.92	-0.47	2.98e-8	Platelet count;
TGCT	cis	rs12136530	0.774	rs4912097	chr1:19784410	C/G	cg18923740	chr1:19971790	NBL1	0.36	4.44	0.37	1.96e-5	Lead levels in blood;
TGCT	cis	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.67	6.68	0.51	7.19e-10	Eosinophil percentage of white cells;
TGCT	cis	rs77972916	0.536	rs11679731	chr2:43589064	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.32	-4.53	-0.38	1.36e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.35	0.43	4.08e-7	Prudent dietary pattern;
TGCT	cis	rs1150668	0.768	rs1233713	chr6:28198281	A/G	cg13525197	chr6:28411240	ZSCAN23	-0.47	-4.61	-0.38	9.84e-6	Pubertal anthropometrics;
TGCT	cis	rs11671005	0.779	rs11670125	chr19:58987390	G/T	cg07764513	chr19:58919909	ZNF584	-0.71	-4.59	-0.38	1.06e-5	Mean platelet volume;
TGCT	cis	rs4936891	1.000	rs4936890	chr11:123914742	G/A	cg22125253	chr11:123886957	OR10G4	-0.2	-4.51	-0.38	1.47e-5	Male fertility;
TGCT	cis	rs7267979	1.000	rs6050632	chr20:25432601	A/G	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7772486	0.558	rs62435775	chr6:146136415	G/C	cg13319975	chr6:146136371	FBXO30	-0.69	-6.28	-0.49	5.18e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7647973	0.769	rs6772452	chr3:49040462	A/G	cg07636037	chr3:49044803	WDR6	0.8	6.69	0.51	6.94e-10	Menarche (age at onset);
TGCT	cis	rs12188164	0.965	rs72717438	chr5:448663	C/T	cg21144161	chr5:423903	AHRR	0.25	4.79	0.4	4.59e-6	Cystic fibrosis severity;
TGCT	cis	rs4975616	0.804	rs459961	chr5:1337106	T/A	cg07493874	chr5:1342172	CLPTM1L	-0.28	-6.85	-0.52	3.06e-10	Lung cancer;
TGCT	cis	rs1580019	0.921	rs1580023	chr7:32497881	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.81	7.61	0.56	5.93e-12	Cognitive ability;
TGCT	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg11247378	chr22:39784982	NA	-0.65	-9.02	-0.63	2.89e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs74233809	1.000	rs74233296	chr10:104655350	T/C	cg05855489	chr10:104503620	C10orf26	0.74	4.45	0.37	1.87e-5	Birth weight;
TGCT	cis	rs2439831	0.867	rs6493082	chr15:43634808	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	8.65	0.61	2.26e-14	Lung cancer in ever smokers;
TGCT	cis	rs7822232	0.908	rs7821112	chr8:145147169	G/A	cg14631276	chr8:145163102	KIAA1875	0.56	5.05	0.41	1.55e-6	Blood metabolite levels;
TGCT	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg25036284	chr2:26402008	FAM59B	0.58	4.58	0.38	1.12e-5	Gut microbiome composition (summer);
TGCT	cis	rs73198271	0.653	rs10087633	chr8:8660444	A/G	cg06671706	chr8:8559999	CLDN23	-0.36	-4.61	-0.38	9.98e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs10501293	1.000	rs1559762	chr11:43128541	C/T	cg03447554	chr11:43094025	NA	0.49	6.9	0.53	2.37e-10	Cognitive performance;
TGCT	trans	rs208515	0.525	rs10944859	chr6:66665197	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.9	9.56	0.65	1.46e-16	Exhaled nitric oxide levels;
TGCT	cis	rs9308731	0.644	rs1837369	chr2:111874276	C/T	cg04202892	chr2:111875749	ACOXL	0.54	6.22	0.49	6.93e-9	Chronic lymphocytic leukemia;
TGCT	cis	rs1912483	0.505	rs11079772	chr17:45393739	A/C	cg08085267	chr17:45401833	C17orf57	0.67	8.23	0.59	2.19e-13	Coronary artery disease;
TGCT	cis	rs6500602	0.727	rs11076836	chr16:4569331	G/A	cg09549813	chr16:4587862	C16orf5	-0.28	-4.51	-0.38	1.5e-5	Schizophrenia;
TGCT	cis	rs929354	0.742	rs3808316	chr7:156944787	C/G	cg05182265	chr7:156933206	UBE3C	-0.38	-8.43	-0.6	7.5e-14	Body mass index;
TGCT	cis	rs554111	0.636	rs10916935	chr1:21432112	T/C	cg01072550	chr1:21505969	NA	0.36	5.46	0.44	2.51e-7	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg03188948	chr7:1209495	NA	0.59	4.82	0.4	4.06e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2235642	0.821	rs2281234	chr16:1602938	A/G	cg11375102	chr16:1583810	IFT140;TMEM204	-0.3	-5.42	-0.44	2.97e-7	Coronary artery disease;
TGCT	cis	rs4925386	0.959	rs6121989	chr20:60916713	A/T	cg06026331	chr20:60912101	LAMA5	-0.3	-5.4	-0.44	3.2e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg06481639	chr22:41940642	POLR3H	-0.74	-6.74	-0.52	5.38e-10	Vitiligo;
TGCT	cis	rs9393692	0.846	rs9366651	chr6:26336696	G/T	cg13736514	chr6:26305472	NA	-0.35	-4.95	-0.41	2.4e-6	Educational attainment;
TGCT	cis	rs210152	0.588	rs3119024	chr6:33450034	T/C	cg16739976	chr6:34101401	GRM4	-0.57	-4.72	-0.39	6.15e-6	Schizophrenia;
TGCT	cis	rs10858047	0.883	rs6701427	chr1:115216886	C/T	cg12756093	chr1:115239321	AMPD1	-0.49	-5.13	-0.42	1.08e-6	Autism;
TGCT	cis	rs11167764	1.000	rs6887599	chr5:141484349	G/A	cg02659431	chr5:141694439	SPRY4	-0.21	-4.6	-0.38	1.03e-5	Crohn's disease;
TGCT	cis	rs1670533	1.000	rs10084890	chr4:1053934	C/G	cg27284194	chr4:1044797	NA	-0.7	-6.08	-0.48	1.34e-8	Recombination rate (females);
TGCT	cis	rs9527	0.615	rs10883800	chr10:104671212	A/C	cg04362960	chr10:104952993	NT5C2	0.64	5.4	0.44	3.33e-7	Arsenic metabolism;
TGCT	cis	rs6582630	0.519	rs4002438	chr12:38484880	C/T	cg13010199	chr12:38710504	ALG10B	0.58	4.72	0.39	6.16e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs7617773	0.780	rs11720026	chr3:48377921	T/C	cg11946769	chr3:48343235	NME6	0.82	6.99	0.53	1.49e-10	Coronary artery disease;
TGCT	cis	rs3796352	1.000	rs13072457	chr3:53102389	G/A	cg27565382	chr3:53032988	SFMBT1	0.45	4.76	0.39	5.25e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs11935103	0.636	rs9997314	chr4:187297232	T/C	cg16785698	chr4:186456103	PDLIM3	0.44	4.47	0.37	1.74e-5	Response to citalopram treatment;
TGCT	trans	rs66573146	1.000	rs7686186	chr4:6986094	C/T	cg07817883	chr1:32538562	TMEM39B	1.66	8.29	0.6	1.56e-13	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg06873352	chr17:61820015	STRADA	0.58	6.37	0.5	3.32e-9	Prudent dietary pattern;
TGCT	cis	rs9926296	0.712	rs258319	chr16:89732024	A/T	cg03388025	chr16:89894329	SPIRE2	-0.35	-5.05	-0.41	1.54e-6	Vitiligo;
TGCT	cis	rs950169	0.959	rs66801143	chr15:84736657	C/T	cg11189052	chr15:85197271	WDR73	0.69	5.91	0.47	3.14e-8	Schizophrenia;
TGCT	cis	rs7474896	0.583	rs10827817	chr10:37997974	A/G	cg25427524	chr10:38739819	LOC399744	-0.28	-4.45	-0.37	1.91e-5	Obesity (extreme);
TGCT	cis	rs6582630	0.519	rs11495724	chr12:38337507	T/C	cg26384229	chr12:38710491	ALG10B	0.83	7.27	0.55	3.51e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs17376456	0.569	rs13186432	chr5:93336940	G/A	cg21475434	chr5:93447410	FAM172A	-0.65	-5.93	-0.47	2.75e-8	Diabetic retinopathy;
TGCT	cis	rs35306767	0.623	rs12354710	chr10:1114020	C/T	cg20503657	chr10:835505	NA	0.53	5.6	0.45	1.33e-7	Eosinophil percentage of granulocytes;
TGCT	cis	rs9611565	0.918	rs28638318	chr22:41753059	G/A	cg03806693	chr22:41940476	POLR3H	-1.12	-12.62	-0.75	5.47e-24	Vitiligo;
TGCT	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg11845111	chr2:191398756	TMEM194B	-0.36	-5.44	-0.44	2.73e-7	Pulse pressure;
TGCT	cis	rs9372253	1.000	rs11153232	chr6:110716252	G/T	cg19196401	chr6:110721138	DDO	0.5	7.33	0.55	2.59e-11	Platelet distribution width;
TGCT	cis	rs17826219	0.561	rs4085382	chr17:29071202	T/C	cg13385521	chr17:29058706	SUZ12P	0.82	5.04	0.41	1.61e-6	Body mass index;
TGCT	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg09222892	chr1:25734099	RHCE	-0.44	-7.08	-0.54	9.31e-11	Erythrocyte sedimentation rate;
TGCT	cis	rs9467773	0.620	rs1027204	chr6:26639613	T/C	cg15659132	chr6:26577336	NA	0.86	11.04	0.7	3.71e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs17741873	1.000	rs17741873	chr10:75653800	G/T	cg07699608	chr10:75541558	CHCHD1	0.66	5.04	0.41	1.59e-6	Paclitaxel disposition in epithelial ovarian cancer;
TGCT	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.53	4.94	0.41	2.44e-6	Prudent dietary pattern;
TGCT	cis	rs7927592	0.731	rs7108376	chr11:68347870	A/G	cg16797656	chr11:68205561	LRP5	-0.25	-4.5	-0.37	1.53e-5	Total body bone mineral density;
TGCT	cis	rs3096299	0.679	rs3102338	chr16:89442250	C/G	cg06640241	chr16:89574553	SPG7	0.63	5.73	0.46	7.09e-8	Multiple myeloma (IgH translocation);
TGCT	cis	rs57920188	0.537	rs72852529	chr1:4076373	A/G	cg20703997	chr1:4087676	NA	0.47	5.8	0.46	5.14e-8	Interleukin-17 levels;
TGCT	cis	rs17767294	0.708	rs72849206	chr6:28172704	A/G	cg08851530	chr6:28072375	NA	1.47	6.82	0.52	3.64e-10	Parkinson's disease;
TGCT	cis	rs7267979	0.899	rs2104734	chr20:25526668	A/G	cg03522245	chr20:25566470	NINL	0.6	6.46	0.5	2.14e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs931812	0.895	rs4734013	chr8:101908687	A/C	cg20993868	chr7:22813445	NA	0.4	8.85	0.62	7.57e-15	Attention deficit hyperactivity disorder and conduct disorder;
TGCT	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.51	-4.48	-0.37	1.66e-5	Prudent dietary pattern;
TGCT	cis	rs7584330	0.910	rs6757376	chr2:238400036	G/C	cg14458575	chr2:238380390	NA	0.39	5.56	0.45	1.61e-7	Prostate cancer;
TGCT	cis	rs9894429	0.608	rs7406382	chr17:79597786	T/C	cg18240062	chr17:79603768	NPLOC4	0.58	5.12	0.42	1.15e-6	Eye color traits;
TGCT	cis	rs10791097	0.720	rs4936121	chr11:130733878	A/G	cg05962950	chr11:130786565	SNX19	0.92	10.76	0.69	1.76e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs4455778	0.580	rs7783068	chr7:49120791	A/G	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg22920501	chr2:26401640	FAM59B	0.78	6.23	0.49	6.54e-9	Gut microbiome composition (summer);
TGCT	cis	rs2688608	0.620	rs12253408	chr10:75495956	G/T	cg19442545	chr10:75533431	FUT11	-0.37	-5.77	-0.46	5.89e-8	Inflammatory bowel disease;
TGCT	cis	rs9467603	0.592	rs1184498	chr6:25864882	G/C	cg03517284	chr6:25882590	NA	-0.73	-4.73	-0.39	5.97e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4499344	0.730	rs417823	chr19:33104561	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	8.66	0.61	2.12e-14	Mean platelet volume;
TGCT	cis	rs2050392	0.624	rs2489842	chr10:30721991	T/C	cg13289132	chr10:30722225	MAP3K8	-0.46	-5.57	-0.45	1.47e-7	Inflammatory bowel disease;
TGCT	cis	rs9486719	1.000	rs11152968	chr6:96908653	A/G	cg06623918	chr6:96969491	KIAA0776	0.98	8.77	0.62	1.15e-14	Migraine;Coronary artery disease;
TGCT	cis	rs9311474	0.652	rs352161	chr3:52221849	C/A	cg07507251	chr3:52567010	NT5DC2	0.35	4.52	0.38	1.42e-5	Electroencephalogram traits;
TGCT	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg21963583	chr11:68658836	MRPL21	0.38	6.24	0.49	6.45e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg03396347	chr1:1875803	NA	-0.37	-6.62	-0.51	9.64e-10	Body mass index;
TGCT	cis	rs112217694	1.000	rs75159306	chr4:104649474	G/C	cg24090629	chr4:104641072	TACR3	-0.97	-4.81	-0.4	4.25e-6	Menarche (age at onset);
TGCT	cis	rs4523957	0.620	rs1565764	chr17:2074303	G/A	cg16513277	chr17:2031491	SMG6	-0.2	-4.46	-0.37	1.8e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs6684514	1.000	rs12117903	chr1:156311165	G/T	cg20302342	chr1:156215951	PAQR6	0.36	4.77	0.39	5.1e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs523522	0.962	rs3742052	chr12:120966921	A/G	cg27279351	chr12:120934652	DYNLL1	0.76	6.59	0.51	1.15e-9	High light scatter reticulocyte count;
TGCT	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg11644478	chr21:40555479	PSMG1	1.02	10.59	0.69	4.75e-19	Cognitive function;
TGCT	cis	rs17401966	0.540	rs6541094	chr1:10467074	G/A	cg19773385	chr1:10388646	KIF1B	-0.23	-5.46	-0.44	2.52e-7	Hepatocellular carcinoma;
TGCT	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg23758822	chr17:41437982	NA	0.79	7.39	0.55	1.87e-11	Menopause (age at onset);
TGCT	cis	rs12497850	1.000	rs4858828	chr3:48724811	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.5	-4.78	-0.39	4.87e-6	Parkinson's disease;
TGCT	cis	rs7666738	0.830	rs11932942	chr4:98998939	T/C	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg05985448	chr10:134359359	INPP5A	0.22	4.83	0.4	3.89e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs12497850	0.931	rs6446196	chr3:49004723	A/G	cg06212747	chr3:49208901	KLHDC8B	0.61	5.5	0.44	2.06e-7	Parkinson's disease;
TGCT	cis	rs3003334	1	rs3003334	chr1:24199869	G/A	cg15997130	chr1:24165203	NA	0.85	9.35	0.64	4.75e-16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;
TGCT	cis	rs2153535	0.580	rs915352	chr6:8442766	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.58	0.45	1.42e-7	Motion sickness;
TGCT	cis	rs1153858	1.000	rs1820518	chr15:45694579	C/T	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.62e-8	Homoarginine levels;
TGCT	cis	rs6450176	0.909	rs7732139	chr5:53292017	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.49	-4.59	-0.38	1.08e-5	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs2806561	0.734	rs2143156	chr1:23374629	T/G	cg12483005	chr1:23474871	LUZP1	0.38	4.76	0.39	5.3e-6	Height;
TGCT	cis	rs66561647	0.597	rs34390452	chr8:128940141	G/A	cg05480350	chr8:128972681	MIR1205;PVT1	0.23	4.71	0.39	6.62e-6	Hemoglobin concentration;
TGCT	cis	rs10089	1.000	rs3805612	chr5:127505316	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.85	8.27	0.6	1.8e-13	Ileal carcinoids;
TGCT	cis	rs11785400	0.793	rs7000765	chr8:143722457	G/A	cg24634471	chr8:143751801	JRK	0.54	5.27	0.43	5.82e-7	Schizophrenia;
TGCT	trans	rs57221529	0.713	rs56328416	chr5:591138	G/A	cg25482853	chr8:67687455	SGK3	1.21	10.3	0.68	2.37e-18	Lung disease severity in cystic fibrosis;
TGCT	cis	rs2075371	0.965	rs1862049	chr7:133978344	A/T	cg11752832	chr7:134001865	SLC35B4	0.7	6.51	0.5	1.68e-9	Mean platelet volume;
TGCT	cis	rs6879260	0.963	rs11738924	chr5:179727308	A/G	cg23248424	chr5:179741104	GFPT2	-0.35	-6.32	-0.49	4.31e-9	Height;
TGCT	cis	rs7043114	0.525	rs7045409	chr9:95201540	A/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.54	-5.46	-0.44	2.48e-7	Height;
TGCT	cis	rs611744	0.836	rs684412	chr8:109210905	T/A	cg21045802	chr8:109455806	TTC35	0.52	4.72	0.39	6.21e-6	Dupuytren's disease;
TGCT	cis	rs909674	0.818	rs8137426	chr22:39844350	T/G	cg24399712	chr22:39784796	NA	-1.05	-10.97	-0.7	5.63e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg09359103	chr1:154839909	KCNN3	-0.67	-12.42	-0.74	1.61e-23	Prostate cancer;
TGCT	cis	rs9399137	0.507	rs61738647	chr6:135282735	T/C	cg24558204	chr6:135376177	HBS1L	0.46	4.68	0.39	7.32e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
TGCT	cis	rs11098499	0.542	rs10440343	chr4:120309787	G/C	cg09307838	chr4:120376055	NA	0.65	6.39	0.5	3.02e-9	Corneal astigmatism;
TGCT	cis	rs66823261	0.741	rs7841786	chr8:191746	A/C	cg27532244	chr8:182981	ZNF596;RPL23AP53	-0.83	-7.04	-0.53	1.16e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
TGCT	cis	rs854765	0.583	rs8078583	chr17:17811465	C/T	cg09796270	chr17:17721594	SREBF1	0.28	5.66	0.45	1.02e-7	Total body bone mineral density;
TGCT	cis	rs67311347	1.000	rs9874006	chr3:40471596	G/A	cg13683864	chr3:40499215	RPL14	-1.04	-10.79	-0.7	1.54e-19	Renal cell carcinoma;
TGCT	cis	rs10927875	0.541	rs1048245	chr1:16341354	T/G	cg21385522	chr1:16154831	NA	0.46	4.85	0.4	3.64e-6	Dilated cardiomyopathy;
TGCT	cis	rs2014572	0.967	rs8112572	chr19:57759612	T/C	cg24459738	chr19:57751996	ZNF805	-0.56	-5.6	-0.45	1.29e-7	Hyperactive-impulsive symptoms;
TGCT	cis	rs9611565	0.649	rs2413659	chr22:42164862	A/G	cg17554472	chr22:41940697	POLR3H	0.43	4.54	0.38	1.3e-5	Vitiligo;
TGCT	cis	rs11085466	1.000	rs73552479	chr19:21778816	G/T	cg01048962	chr19:21646470	NA	-0.59	-4.61	-0.38	9.72e-6	Colorectal or endometrial cancer;
TGCT	cis	rs11235843	0.636	rs10736793	chr11:73402576	A/C	cg18195628	chr11:73498948	MRPL48	-0.64	-4.52	-0.38	1.42e-5	Hand grip strength;
TGCT	cis	rs7336332	0.598	rs7669	chr13:28009851	C/T	cg22138327	chr13:27999177	GTF3A	0.79	6.44	0.5	2.37e-9	Weight;
TGCT	cis	rs2228479	0.850	rs62056068	chr16:89909737	C/T	cg06558623	chr16:89946397	TCF25	0.55	4.86	0.4	3.55e-6	Skin colour saturation;
TGCT	cis	rs9921338	0.961	rs9937269	chr16:11416679	A/G	cg00044050	chr16:11439710	C16orf75	0.97	7.45	0.56	1.4e-11	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs2730245	0.527	rs842695	chr7:158662182	G/A	cg11984989	chr7:158649758	WDR60	1.01	7.87	0.58	1.48e-12	Height;
TGCT	cis	rs6964587	1.000	rs13230588	chr7:91615427	C/A	cg17063962	chr7:91808500	NA	0.91	9.99	0.67	1.32e-17	Breast cancer;
TGCT	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg11366901	chr6:160182831	ACAT2	0.79	5.81	0.46	4.92e-8	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs9733	0.596	rs12086472	chr1:150697710	G/A	cg09365446	chr1:150670422	GOLPH3L	0.3	4.52	0.38	1.4e-5	Tonsillectomy;
TGCT	cis	rs933688	1.000	rs6867091	chr5:90734333	C/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.91	8.42	0.6	7.74e-14	Smoking behavior;
TGCT	cis	rs9910055	0.529	rs183462	chr17:42183376	G/C	cg19774624	chr17:42201019	HDAC5	0.73	6.89	0.53	2.53e-10	Total body bone mineral density;
TGCT	cis	rs853679	0.546	rs175597	chr6:27810626	T/C	cg08798685	chr6:27730294	NA	-0.34	-4.77	-0.39	5.13e-6	Depression;
TGCT	cis	rs1775715	0.737	rs2778650	chr10:32106851	A/G	cg14930904	chr10:32216787	ARHGAP12	0.52	5.07	0.41	1.38e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs5758659	0.714	rs5758589	chr22:42518382	A/G	cg15557168	chr22:42548783	NA	0.18	4.56	0.38	1.23e-5	Cognitive function;
TGCT	cis	rs2549003	0.966	rs2706385	chr5:131831766	T/G	cg02551604	chr5:131831745	NA	0.9	12.32	0.74	2.92e-23	Asthma (sex interaction);
TGCT	cis	rs4824093	0.610	rs4141437	chr22:50243719	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	1.06	6.46	0.5	2.18e-9	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs2404602	0.669	rs12916324	chr15:77179603	G/A	cg22467129	chr15:76604101	ETFA	-0.47	-5.39	-0.44	3.44e-7	Blood metabolite levels;
TGCT	cis	rs10832963	0.924	rs10500834	chr11:18638712	A/T	cg09201001	chr11:18656081	SPTY2D1	1.05	11.63	0.72	1.34e-21	Breast cancer;
TGCT	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg08859206	chr1:53392774	SCP2	0.4	5.96	0.47	2.46e-8	Monocyte count;
TGCT	cis	rs1348850	0.567	rs1405714	chr2:178538584	A/G	cg22681709	chr2:178499509	PDE11A	0.5	6.59	0.51	1.11e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs9831754	1.000	rs9831754	chr3:78353591	A/C	cg06138941	chr3:78371609	NA	-0.44	-4.46	-0.37	1.78e-5	Calcium levels;
TGCT	cis	rs11190604	0.767	rs11190520	chr10:102175309	T/C	cg16005271	chr10:102321736	NA	0.45	4.57	0.38	1.15e-5	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs11785400	0.731	rs4736363	chr8:143742112	C/A	cg10596483	chr8:143751796	JRK	0.55	5.48	0.44	2.29e-7	Schizophrenia;
TGCT	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg20607798	chr8:58055168	NA	0.5	4.66	0.39	8.04e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2295359	1.000	rs4655524	chr1:67629469	G/A	cg12940439	chr1:67600707	NA	0.54	5.78	0.46	5.78e-8	Psoriasis;
TGCT	cis	rs17601876	0.814	rs12050767	chr15:51557257	T/C	cg19946085	chr15:51559439	CYP19A1	-0.33	-5.04	-0.41	1.64e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg04287289	chr16:89883240	FANCA	0.92	11.67	0.72	1.11e-21	Vitiligo;
TGCT	cis	rs6933660	0.646	rs9383899	chr6:151781022	G/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.58	-5.47	-0.44	2.41e-7	Menarche (age at onset);
TGCT	cis	rs6095298	0.595	rs6095325	chr20:47453602	G/T	cg12307787	chr20:48099359	KCNB1	-0.44	-4.56	-0.38	1.19e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7312933	0.558	rs11181422	chr12:42718552	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.59	-5.7	-0.46	8.16e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs6484504	0.532	rs2761589	chr11:31311429	C/G	cg14844989	chr11:31128820	NA	0.23	4.56	0.38	1.23e-5	Red blood cell count;
TGCT	cis	rs7523273	0.565	rs2796280	chr1:207889345	C/T	cg22525895	chr1:207977042	MIR29B2	-0.35	-5.72	-0.46	7.49e-8	Schizophrenia;
TGCT	cis	rs1784581	0.651	rs1784589	chr6:162389571	A/G	cg17173639	chr6:162384350	PARK2	-0.47	-8.16	-0.59	3.15e-13	Itch intensity from mosquito bite;
TGCT	cis	rs11030122	0.547	rs12270732	chr11:3952901	C/A	cg18678763	chr11:4115507	RRM1	-0.39	-4.76	-0.39	5.24e-6	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg12042659	chr19:58951599	ZNF132	0.52	4.82	0.4	4.18e-6	Uric acid clearance;
TGCT	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg11764359	chr7:65958608	NA	-0.55	-5.08	-0.42	1.34e-6	Aortic root size;
TGCT	cis	rs514406	0.505	rs856721	chr1:53162156	C/A	cg24675658	chr1:53192096	ZYG11B	-0.74	-8.28	-0.6	1.65e-13	Monocyte count;
TGCT	cis	rs10197940	0.624	rs4461258	chr2:152429679	A/G	cg19508488	chr2:152266495	RIF1	-0.68	-6.33	-0.49	4.02e-9	Lung cancer;
TGCT	cis	rs854765	0.583	rs9913724	chr17:17819101	A/G	cg09796270	chr17:17721594	SREBF1	0.24	4.7	0.39	6.83e-6	Total body bone mineral density;
TGCT	cis	rs10992471	0.528	rs2296666	chr9:95274261	C/T	cg13798575	chr9:95087839	CENPP;NOL8	0.52	4.99	0.41	1.98e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg01765077	chr12:122356316	WDR66	0.32	4.64	0.38	8.82e-6	Mean corpuscular volume;
TGCT	cis	rs9309473	0.606	rs78941213	chr2:73885137	C/T	cg07208825	chr2:73871855	ALMS1P	0.29	5.72	0.46	7.52e-8	Metabolite levels;
TGCT	cis	rs11148252	0.553	rs9536219	chr13:53227301	C/T	cg00495681	chr13:53174319	NA	0.64	6.46	0.5	2.15e-9	Lewy body disease;
TGCT	cis	rs9926296	0.687	rs258317	chr16:89732238	C/T	cg03388025	chr16:89894329	SPIRE2	-0.36	-5.28	-0.43	5.54e-7	Vitiligo;
TGCT	cis	rs208515	0.556	rs10455193	chr6:66691456	G/A	cg07460842	chr6:66804631	NA	0.88	9.35	0.64	4.63e-16	Exhaled nitric oxide levels;
TGCT	cis	rs17125944	0.615	rs7145392	chr14:53321016	G/A	cg00686598	chr14:53173677	PSMC6	-0.82	-4.85	-0.4	3.68e-6	Alzheimer's disease (late onset);
TGCT	cis	rs3008870	0.959	rs1886686	chr1:67390468	C/G	cg11518657	chr1:67396239	MIER1	0.52	4.53	0.38	1.39e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs651907	0.535	rs13094911	chr3:101519021	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.86	10.4	0.68	1.35e-18	Colorectal cancer;
TGCT	cis	rs453301	0.522	rs2929455	chr8:9083433	A/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-4.57	-0.38	1.14e-5	Joint mobility (Beighton score);
TGCT	cis	rs12762955	0.529	rs2387213	chr10:1051420	C/T	cg18964960	chr10:1102726	WDR37	0.68	5.99	0.47	2.12e-8	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs7937682	0.575	rs1346180	chr11:111715570	G/C	cg09085632	chr11:111637200	PPP2R1B	0.94	8.94	0.63	4.57e-15	Primary sclerosing cholangitis;
TGCT	cis	rs11252926	0.537	rs4881274	chr10:459940	G/A	cg18196295	chr10:418757	DIP2C	0.29	4.76	0.39	5.4e-6	Psychosis in Alzheimer's disease;
TGCT	cis	rs4689388	0.926	rs11732178	chr4:6292643	G/C	cg00701064	chr4:6280414	WFS1	0.44	5.74	0.46	6.95e-8	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs6964587	1.000	rs12537846	chr7:91721581	C/T	cg17063962	chr7:91808500	NA	-0.86	-9.39	-0.64	3.79e-16	Breast cancer;
TGCT	cis	rs10504229	0.593	rs4738567	chr8:57997033	A/C	cg08280861	chr8:58055591	NA	0.34	4.79	0.39	4.75e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg04944784	chr2:26401820	FAM59B	-0.67	-6.05	-0.48	1.62e-8	Gut microbiome composition (summer);
TGCT	cis	rs2282802	0.685	rs6893253	chr5:139661279	T/C	cg01081189	chr5:139537190	NA	0.28	5.06	0.41	1.46e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs3540	0.533	rs4932342	chr15:90982923	C/T	cg22089800	chr15:90895588	ZNF774	0.76	8.11	0.59	4.19e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs9916302	0.706	rs4488484	chr17:37717377	A/T	cg07936489	chr17:37558343	FBXL20	0.84	6.08	0.48	1.35e-8	Glomerular filtration rate (creatinine);
TGCT	cis	rs9457247	1.000	rs430477	chr6:167389851	T/C	cg25258033	chr6:167368657	RNASET2	0.18	4.49	0.37	1.63e-5	Crohn's disease;
TGCT	cis	rs1062177	0.826	rs1549920	chr5:151140844	A/T	cg00977110	chr5:151150581	G3BP1	0.41	4.66	0.39	8.17e-6	Preschool internalizing problems;
TGCT	cis	rs78487399	0.634	rs77881454	chr2:43757293	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.09	-0.42	1.29e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs7617773	0.817	rs9847953	chr3:48282695	A/G	cg11946769	chr3:48343235	NME6	0.72	6.23	0.49	6.77e-9	Coronary artery disease;
TGCT	cis	rs7412746	0.611	rs4970931	chr1:150910727	G/A	cg04414720	chr1:150670196	GOLPH3L	0.37	4.46	0.37	1.81e-5	Melanoma;
TGCT	cis	rs2742417	1.000	rs2742436	chr3:45741397	T/C	cg04837898	chr3:45731254	SACM1L	-0.51	-5.22	-0.42	7.15e-7	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs7178572	0.568	rs1493700	chr15:77629060	T/C	cg15453836	chr15:77711506	NA	-0.42	-4.79	-0.4	4.68e-6	Type 2 diabetes;
TGCT	cis	rs17001868	0.892	rs73167023	chr22:40799954	T/C	cg07138101	chr22:40742427	ADSL	0.71	4.72	0.39	6.31e-6	Mammographic density (dense area);
TGCT	cis	rs2467099	0.504	rs2608881	chr17:73936653	C/G	cg02678768	chr17:74002944	EVPL	0.28	4.85	0.4	3.58e-6	Systolic blood pressure;
TGCT	cis	rs9611565	0.729	rs203320	chr22:41913477	T/C	cg06634786	chr22:41940651	POLR3H	-0.76	-7.51	-0.56	1e-11	Vitiligo;
TGCT	cis	rs68170813	0.523	rs79607134	chr7:107033619	A/T	cg02696742	chr7:106810147	HBP1	-0.7	-5.68	-0.45	8.91e-8	Coronary artery disease;
TGCT	cis	rs5769707	0.967	rs4524218	chr22:50018639	G/A	cg05373962	chr22:49881684	NA	-0.3	-6.29	-0.49	5.08e-9	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs11209002	0.614	rs4655515	chr1:67566898	T/C	cg02640540	chr1:67518911	SLC35D1	0.59	5.0	0.41	1.92e-6	Crohn's disease;
TGCT	cis	rs1784581	0.588	rs9885762	chr6:162411954	G/A	cg17173639	chr6:162384350	PARK2	0.39	6.51	0.5	1.7e-9	Itch intensity from mosquito bite;
TGCT	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg11890956	chr21:40555474	PSMG1	0.76	7.42	0.55	1.64e-11	Cognitive function;
TGCT	cis	rs8062405	0.757	rs2411453	chr16:28632021	A/C	cg09754948	chr16:28834200	ATXN2L	-0.57	-4.6	-0.38	1.04e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs9467773	0.565	rs6925047	chr6:26521435	C/G	cg05738196	chr6:26577821	NA	0.75	9.2	0.64	1.09e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs7246657	0.943	rs10405407	chr19:37839164	C/T	cg18154014	chr19:37997991	ZNF793	0.72	5.19	0.42	8.3e-7	Coronary artery calcification;
TGCT	cis	rs10466239	0.730	rs12221341	chr10:43857330	C/G	cg08951903	chr10:44070173	ZNF239	-0.79	-4.92	-0.4	2.72e-6	Telomere length;
TGCT	cis	rs7255045	0.788	rs1124820	chr19:12957114	G/A	cg23899408	chr19:12877188	HOOK2	-0.59	-4.79	-0.4	4.63e-6	Mean corpuscular volume;
TGCT	cis	rs60843830	1.000	rs17714252	chr2:285471	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.72	6.7	0.52	6.46e-10	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs7524258	0.900	rs12035586	chr1:7273020	C/T	cg04342483	chr1:7259290	CAMTA1	0.32	4.81	0.4	4.36e-6	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs73001065	0.636	rs56241616	chr19:19506092	C/T	cg03709012	chr19:19516395	GATAD2A	0.88	4.69	0.39	7.11e-6	LDL cholesterol;
TGCT	cis	rs1215050	0.740	rs6855827	chr4:99065706	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.15	0.48	9.93e-9	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9814567	1.000	rs9289476	chr3:134237103	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.92	-9.2	-0.64	1.11e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs13064411	0.591	rs7628945	chr3:113201754	A/T	cg18753928	chr3:113234510	CCDC52	-0.54	-4.58	-0.38	1.12e-5	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs12497850	0.829	rs8926	chr3:49052785	T/A	cg06212747	chr3:49208901	KLHDC8B	0.61	5.66	0.45	9.84e-8	Parkinson's disease;
TGCT	cis	rs28374715	0.681	rs7168307	chr15:41620534	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.87	-13.89	-0.78	4.85e-27	Ulcerative colitis;
TGCT	cis	rs9517320	0.534	rs9554474	chr13:99140871	G/A	cg07423050	chr13:99094983	FARP1	-0.3	-5.8	-0.46	5.15e-8	Longevity;
TGCT	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg24846343	chr22:24311635	DDTL	0.24	6.05	0.48	1.57e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg11941060	chr3:133502564	NA	-0.29	-6.14	-0.48	1.02e-8	Iron status biomarkers;
TGCT	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.27	4.85	0.4	3.56e-6	Schizophrenia;
TGCT	trans	rs561341	0.941	rs2428338	chr17:30299629	T/C	cg20587970	chr11:113659929	NA	-1.03	-12.7	-0.75	3.52e-24	Hip circumference adjusted for BMI;
TGCT	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	4.89	0.4	3e-6	Menopause (age at onset);
TGCT	cis	rs765787	0.530	rs2458224	chr15:45522130	T/C	cg24006582	chr15:45444508	DUOX1	-0.26	-5.63	-0.45	1.15e-7	Uric acid levels;
TGCT	cis	rs858239	0.539	rs6955726	chr7:23186691	A/G	cg05602783	chr7:23145260	KLHL7	-0.62	-5.03	-0.41	1.67e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg06238570	chr21:40685208	BRWD1	-0.8	-9.1	-0.63	1.91e-15	Cognitive function;
TGCT	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.38	-4.92	-0.4	2.69e-6	Menarche (age at onset);
TGCT	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg23719950	chr11:63933701	MACROD1	-0.69	-5.67	-0.45	9.32e-8	Mean platelet volume;
TGCT	cis	rs9581857	0.615	rs3759435	chr13:27996813	T/G	cg22138327	chr13:27999177	GTF3A	0.8	6.55	0.51	1.38e-9	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs6570726	0.516	rs9322025	chr6:145729196	C/T	cg23711669	chr6:146136114	FBXO30	0.62	5.63	0.45	1.14e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg01802117	chr1:53393560	SCP2	0.44	5.31	0.43	4.89e-7	Monocyte count;
TGCT	cis	rs2742417	1.000	rs2249357	chr3:45758381	C/A	cg04837898	chr3:45731254	SACM1L	-0.51	-5.27	-0.43	5.85e-7	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg09436375	chr6:42928200	GNMT	-0.4	-5.16	-0.42	9.7e-7	Plasma homocysteine levels (post-methionine load test);
TGCT	cis	rs6459804	0.588	rs78762416	chr7:157511142	G/A	cg14168080	chr7:157504135	PTPRN2	-0.41	-4.86	-0.4	3.43e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs7179456	0.547	rs653765	chr15:59042012	T/C	cg05156742	chr15:59063176	FAM63B	0.51	5.01	0.41	1.8e-6	Asperger disorder;
TGCT	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg05368731	chr17:41323189	NBR1	1.2	14.48	0.79	1.98e-28	Menopause (age at onset);
TGCT	cis	rs60843830	0.661	rs7561648	chr2:105171	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.62	5.52	0.44	1.92e-7	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs6582630	0.502	rs11520279	chr12:38360871	A/G	cg26384229	chr12:38710491	ALG10B	0.79	6.98	0.53	1.61e-10	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs9640161	0.663	rs1916932	chr7:150021644	T/C	cg17279839	chr7:150038598	RARRES2	0.43	4.6	0.38	1.02e-5	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs3008870	0.727	rs4582760	chr1:67464394	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-0.82	-8.51	-0.61	4.69e-14	Lymphocyte percentage of white cells;
TGCT	cis	rs1322512	0.677	rs2695254	chr6:152926021	A/C	cg03415253	chr6:152958462	SYNE1	-0.55	-5.25	-0.43	6.43e-7	Tonometry;
TGCT	cis	rs858239	0.539	rs6976957	chr7:23187333	T/A	cg05602783	chr7:23145260	KLHL7	-0.62	-5.03	-0.41	1.67e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs13082711	0.522	rs479302	chr3:27363033	A/G	cg02860705	chr3:27208620	NA	0.29	4.71	0.39	6.43e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs13191362	1.000	rs35424047	chr6:163029715	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.66	5.11	0.42	1.18e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs2455799	0.559	rs7629968	chr3:15915864	C/T	cg12172478	chr3:16357591	RFTN1	-0.36	-5.3	-0.43	5.07e-7	Mean platelet volume;
TGCT	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg12310025	chr6:25882481	NA	-0.66	-5.92	-0.47	3.01e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs155076	1.000	rs261404	chr13:21858162	T/G	cg11317459	chr13:21872234	NA	-1.39	-11.7	-0.72	9.04e-22	White matter hyperintensity burden;
TGCT	cis	rs68170813	0.652	rs17482543	chr7:107169174	C/G	cg02696742	chr7:106810147	HBP1	-0.58	-4.47	-0.37	1.74e-5	Coronary artery disease;
TGCT	cis	rs7267979	0.932	rs6115200	chr20:25487377	G/T	cg14121845	chr20:25566513	NINL	0.49	5.36	0.43	3.83e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs711830	0.965	rs2072590	chr2:177042633	A/C	cg13092806	chr2:177043255	NA	0.78	6.27	0.49	5.46e-9	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
TGCT	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg11494091	chr17:61959527	GH2	-0.42	-7.27	-0.55	3.52e-11	Height;
TGCT	cis	rs35306767	0.903	rs12769873	chr10:936526	G/T	cg26597838	chr10:835615	NA	0.75	10.54	0.69	6.3e-19	Eosinophil percentage of granulocytes;
TGCT	cis	rs910316	0.783	rs11850751	chr14:75590113	A/T	cg23033748	chr14:75592666	NEK9	0.29	4.9	0.4	2.95e-6	Height;
TGCT	cis	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg22857025	chr5:266934	NA	-0.34	-6.7	-0.52	6.65e-10	Breast cancer;
TGCT	trans	rs1814175	0.817	rs28525029	chr11:50045815	A/G	cg15704280	chr7:45808275	SEPT13	-0.72	-8.47	-0.61	6.02e-14	Height;
TGCT	cis	rs1163251	0.837	rs658442	chr1:120244858	T/G	cg19096424	chr1:120255104	PHGDH	0.6	5.93	0.47	2.76e-8	Blood metabolite levels;
TGCT	cis	rs669446	0.561	rs530201	chr1:44102257	T/C	cg12908607	chr1:44402522	ARTN	-0.55	-5.9	-0.47	3.25e-8	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs889312	0.500	rs832552	chr5:56113850	A/C	cg24531977	chr5:56204891	C5orf35	0.48	4.8	0.4	4.5e-6	Breast cancer;Breast cancer (early onset);
TGCT	cis	rs13082711	1.000	rs34234262	chr3:27539188	G/A	cg02860705	chr3:27208620	NA	0.34	4.64	0.38	8.68e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs13427251	0.903	rs6746402	chr2:100150443	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.59	-5.52	-0.44	1.88e-7	Chronic sinus infection;
TGCT	cis	rs4986172	0.734	rs60289499	chr17:43218677	G/A	cg10701640	chr17:43249399	NA	0.53	6.38	0.5	3.15e-9	Height;
TGCT	cis	rs2658782	0.951	rs72972357	chr11:93118840	T/C	cg18152523	chr11:93063302	CCDC67	0.77	6.18	0.49	8.42e-9	Pulmonary function decline;
TGCT	cis	rs2439831	0.867	rs16957627	chr15:43642657	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	8.65	0.61	2.26e-14	Lung cancer in ever smokers;
TGCT	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg19774624	chr17:42201019	HDAC5	-0.83	-8.49	-0.61	5.19e-14	Total body bone mineral density;
TGCT	cis	rs896854	0.715	rs12548874	chr8:95935164	A/C	cg23172400	chr8:95962367	TP53INP1	0.33	4.99	0.41	1.98e-6	Type 2 diabetes;
TGCT	cis	rs7727544	0.735	rs272894	chr5:131662460	C/T	cg14196790	chr5:131705035	SLC22A5	0.32	4.56	0.38	1.19e-5	Blood metabolite levels;
TGCT	cis	rs2963155	0.518	rs174048	chr5:142650404	T/C	cg17617527	chr5:142782415	NR3C1	0.86	6.49	0.5	1.82e-9	Breast cancer;
TGCT	cis	rs17401966	0.931	rs2236678	chr1:10471789	A/T	cg19773385	chr1:10388646	KIF1B	-0.23	-5.42	-0.44	2.97e-7	Hepatocellular carcinoma;
TGCT	cis	rs10883723	0.773	rs7917402	chr10:104246690	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs10089	0.953	rs1036171	chr5:127402798	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	6.81	0.52	3.74e-10	Ileal carcinoids;
TGCT	cis	rs17076896	0.786	rs74034965	chr13:19928097	G/A	cg00777926	chr13:20807375	GJB6	-0.37	-4.51	-0.38	1.5e-5	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs1691799	0.863	rs1168291	chr12:66732488	T/C	cg16791601	chr12:66731901	HELB	-0.28	-6.11	-0.48	1.19e-8	White blood cell count (basophil);
TGCT	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs77948430	0.748	rs113823977	chr8:13151121	G/A	cg25598624	chr8:12235727	FAM66A	0.32	4.69	0.39	6.97e-6	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs1670533	0.932	rs2045067	chr4:1052355	C/T	cg20887711	chr4:1340912	KIAA1530	0.72	5.71	0.46	7.8e-8	Recombination rate (females);
TGCT	cis	rs2549003	1.000	rs2549004	chr5:131827825	C/G	cg02551604	chr5:131831745	NA	0.9	11.87	0.73	3.59e-22	Asthma (sex interaction);
TGCT	cis	rs1153858	0.725	rs74572151	chr15:45647526	T/G	cg26924012	chr15:45694286	SPATA5L1	1.09	15.16	0.81	5.15e-30	Homoarginine levels;
TGCT	cis	rs806215	0.526	rs4728079	chr7:127480364	A/G	cg11539674	chr7:127291444	SND1	-0.36	-4.67	-0.39	7.77e-6	Type 2 diabetes;
TGCT	trans	rs1814175	0.791	rs10769593	chr11:49616217	T/C	cg15704280	chr7:45808275	SEPT13	-0.73	-8.57	-0.61	3.46e-14	Height;
TGCT	cis	rs1472147	0.696	rs1532222	chr7:128516945	A/C	cg00260937	chr7:128520193	KCP	-0.43	-5.75	-0.46	6.46e-8	Calcium levels;
TGCT	trans	rs1814175	0.645	rs847632	chr11:49926097	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.51	-0.69	7.2e-19	Height;
TGCT	cis	rs9902453	0.765	rs2628191	chr17:28051140	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.84	-8.39	-0.6	9.14e-14	Coffee consumption (cups per day);
TGCT	cis	rs8014204	0.935	rs2853779	chr14:75368508	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.73	-6.94	-0.53	1.96e-10	Caffeine consumption;
TGCT	cis	rs6570726	0.846	rs7762536	chr6:145923145	T/C	cg05347473	chr6:146136440	FBXO30	0.5	4.61	0.38	9.98e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7772486	0.790	rs9403756	chr6:146257761	C/G	cg05347473	chr6:146136440	FBXO30	-0.48	-4.71	-0.39	6.44e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg03188948	chr7:1209495	NA	0.46	6.1	0.48	1.24e-8	Longevity;Endometriosis;
TGCT	cis	rs9467773	1.000	rs9467778	chr6:26534743	T/C	cg15659132	chr6:26577336	NA	0.86	12.21	0.74	5.3e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs6429082	0.715	rs2131923	chr1:235580821	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.57	-5.03	-0.41	1.7e-6	Adiposity;
TGCT	cis	rs6424115	0.545	rs11576333	chr1:24065770	C/T	cg15997130	chr1:24165203	NA	-0.66	-6.1	-0.48	1.24e-8	Immature fraction of reticulocytes;
TGCT	cis	rs1018836	0.884	rs7008765	chr8:91632589	C/T	cg16814680	chr8:91681699	NA	-0.87	-9.49	-0.65	2.12e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9425766	0.640	rs1322774	chr1:173839240	C/T	cg07177756	chr1:173836307	SNORD75;SNORD78;ZBTB37;SNORD76;GAS5;SNORD77;SNORD44	0.53	4.61	0.38	9.73e-6	Life satisfaction;
TGCT	cis	rs9790314	1.000	rs6794601	chr3:160946769	C/T	cg03342759	chr3:160939853	NMD3	-0.43	-4.55	-0.38	1.25e-5	Morning vs. evening chronotype;
TGCT	cis	rs7572733	0.555	rs2342558	chr2:198920142	T/C	cg00792783	chr2:198669748	PLCL1	0.59	5.15	0.42	1.01e-6	Dermatomyositis;
TGCT	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg22029157	chr1:209979665	IRF6	0.76	6.24	0.49	6.3e-9	Cleft lip with or without cleft palate;
TGCT	cis	rs1775715	0.835	rs113450267	chr10:32223728	G/A	cg14930904	chr10:32216787	ARHGAP12	0.52	4.82	0.4	4.16e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs67460515	0.892	rs10513564	chr3:161059762	A/G	cg03342759	chr3:160939853	NMD3	-0.52	-5.68	-0.45	9.16e-8	Parkinson's disease;
TGCT	cis	rs2060793	0.741	rs4344519	chr11:14722893	G/C	cg00085434	chr11:14927489	NA	0.34	4.68	0.39	7.45e-6	Vitamin D levels;
TGCT	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg11890956	chr21:40555474	PSMG1	-0.72	-6.47	-0.5	2.07e-9	Cognitive function;
TGCT	trans	rs4919669	0.720	rs729025	chr10:104342206	C/T	cg24066601	chr6:26271455	HIST1H3G	0.66	6.81	0.52	3.7e-10	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs6988636	1.000	rs58177772	chr8:124188067	T/C	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs7100689	0.646	rs10736356	chr10:82148325	A/G	cg01528321	chr10:82214614	TSPAN14	0.79	7.93	0.58	1.11e-12	Post bronchodilator FEV1;
TGCT	cis	rs16865717	0.513	rs6431837	chr2:7036811	C/T	cg20486407	chr2:7037101	RSAD2	-0.39	-5.11	-0.42	1.17e-6	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs7223966	1.000	rs56057198	chr17:61733332	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	4.83	0.4	3.93e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs858239	0.600	rs7776644	chr7:23119307	C/T	cg05602783	chr7:23145260	KLHL7	-0.61	-5.03	-0.41	1.68e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs11969893	0.850	rs9404055	chr6:101302260	C/T	cg12253828	chr6:101329408	ASCC3	1.36	6.32	0.49	4.33e-9	Economic and political preferences (immigration/crime);
TGCT	cis	rs2282802	0.685	rs12717951	chr5:139589309	A/G	cg01081189	chr5:139537190	NA	0.29	5.41	0.44	3.19e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs6570726	0.935	rs374000	chr6:145855290	C/T	cg05347473	chr6:146136440	FBXO30	0.49	4.54	0.38	1.29e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs66573146	1.000	rs28729690	chr4:6962061	C/T	cg05069807	chr4:6945702	TBC1D14	0.31	4.6	0.38	1.03e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs4144743	0.938	rs55677902	chr17:45322572	G/T	cg18085866	chr17:45331354	ITGB3	-0.72	-4.8	-0.4	4.39e-6	Body mass index;
TGCT	cis	rs72949976	0.564	rs4673730	chr2:214024836	G/T	cg08319019	chr2:214017104	IKZF2	0.84	8.38	0.6	9.58e-14	Lung cancer;Squamous cell lung carcinoma;
TGCT	cis	rs3096299	0.719	rs2911265	chr16:89511328	G/A	cg02187348	chr16:89574699	SPG7	0.62	6.66	0.51	8.13e-10	Multiple myeloma (IgH translocation);
TGCT	cis	rs7666738	0.606	rs13108868	chr4:99083753	C/T	cg17366294	chr4:99064904	C4orf37	0.57	5.34	0.43	4.31e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7818688	0.697	rs3802192	chr8:95987471	C/T	cg16049864	chr8:95962084	TP53INP1	0.54	4.64	0.38	8.87e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs763121	0.889	rs1837988	chr22:38901094	A/G	cg06022373	chr22:39101656	GTPBP1	0.79	7.78	0.57	2.45e-12	Menopause (age at onset);
TGCT	cis	rs6912958	0.559	rs451829	chr6:88041919	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.73	7.63	0.57	5.25e-12	Monocyte percentage of white cells;
TGCT	cis	rs2580764	0.598	rs7340476	chr2:55227346	G/C	cg09592903	chr2:55203963	RTN4	-0.24	-5.32	-0.43	4.73e-7	Mean platelet volume;
TGCT	cis	rs2224391	0.590	rs2773298	chr6:5242067	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-1.0	-6.12	-0.48	1.16e-8	Height;
TGCT	cis	rs11190604	1.000	rs2489039	chr10:102328036	T/A	cg16342193	chr10:102329863	NA	-0.42	-5.39	-0.44	3.47e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7267979	1.000	rs7268053	chr20:25328286	A/T	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6693567	0.545	rs2275246	chr1:150460168	A/G	cg09579323	chr1:150459698	TARS2	0.52	4.58	0.38	1.12e-5	Migraine;
TGCT	cis	rs112217694	1.000	rs77617156	chr4:104648984	G/A	cg24090629	chr4:104641072	TACR3	-0.97	-4.81	-0.4	4.25e-6	Menarche (age at onset);
TGCT	cis	rs9457247	0.565	rs12193698	chr6:167512073	C/A	cg07741184	chr6:167504864	NA	0.28	5.6	0.45	1.33e-7	Crohn's disease;
TGCT	cis	rs17331151	0.573	rs77223362	chr3:52865125	G/A	cg07884673	chr3:53033167	SFMBT1	0.49	5.66	0.45	1.01e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg22105103	chr4:187893119	NA	0.34	4.76	0.39	5.33e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4713118	0.619	rs200486	chr6:27779506	C/T	cg10876282	chr6:28092338	ZSCAN16	0.58	4.9	0.4	2.98e-6	Parkinson's disease;
TGCT	cis	rs1541995	1.000	rs35504206	chr15:96392333	G/C	cg00882281	chr15:96346592	NA	0.29	4.68	0.39	7.42e-6	Photic sneeze reflex;
TGCT	cis	rs2153535	0.563	rs1737586	chr6:8535897	C/T	cg07606381	chr6:8435919	SLC35B3	0.56	5.16	0.42	9.56e-7	Motion sickness;
TGCT	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2066819	1.000	rs2643626	chr12:56726518	C/T	cg26714650	chr12:56694279	CS	1.53	8.28	0.6	1.67e-13	Psoriasis vulgaris;
TGCT	cis	rs7937682	0.883	rs549143	chr11:111463779	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.99	-10.02	-0.67	1.16e-17	Primary sclerosing cholangitis;
TGCT	cis	rs7100689	0.784	rs4934139	chr10:82177023	C/A	cg01528321	chr10:82214614	TSPAN14	0.91	9.58	0.65	1.3e-16	Post bronchodilator FEV1;
TGCT	cis	rs4704846	1.000	rs1036200	chr5:156531865	A/G	cg12943317	chr5:156479607	HAVCR1	-0.34	-4.75	-0.39	5.43e-6	Blood protein levels;
TGCT	cis	rs9291683	0.546	rs4529049	chr4:10045389	C/T	cg00071950	chr4:10020882	SLC2A9	0.57	6.47	0.5	2.01e-9	Bone mineral density;
TGCT	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg06618935	chr21:46677482	NA	-0.37	-5.87	-0.47	3.72e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs3008870	0.755	rs6657065	chr1:67384639	T/G	cg08660285	chr1:67390436	MIER1;WDR78	0.8	8.47	0.61	5.86e-14	Lymphocyte percentage of white cells;
TGCT	cis	rs13394619	0.840	rs11674605	chr2:11722575	A/G	cg07314298	chr2:11723111	GREB1	-0.3	-5.13	-0.42	1.09e-6	Endometriosis;
TGCT	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg07061783	chr6:25882402	NA	-0.56	-5.56	-0.45	1.55e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1055129	0.560	rs2305913	chr17:73922941	T/C	cg10935138	chr17:73851978	WBP2	0.54	4.71	0.39	6.44e-6	White matter hyperintensity burden;
TGCT	cis	rs7027203	0.797	rs4744294	chr9:96612114	C/G	cg13679303	chr9:96623674	NA	-0.66	-10.76	-0.69	1.84e-19	DNA methylation (variation);
TGCT	cis	rs11122272	0.638	rs2739514	chr1:231514806	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-6.83	-0.52	3.3e-10	Hemoglobin concentration;
TGCT	cis	rs478304	0.627	rs11604568	chr11:65511336	G/A	cg10518572	chr11:65560635	OVOL1	-0.23	-4.52	-0.38	1.42e-5	Acne (severe);
TGCT	cis	rs7681440	0.669	rs7693616	chr4:90792230	G/T	cg20003494	chr4:90757398	SNCA	0.51	4.48	0.37	1.69e-5	Dementia with Lewy bodies;
TGCT	cis	rs9677476	0.657	rs7604042	chr2:232135541	A/T	cg07929768	chr2:232055508	NA	0.28	4.48	0.37	1.65e-5	Food antigen IgG levels;
TGCT	cis	rs2836974	0.800	rs73221174	chr21:40540939	T/C	cg06238570	chr21:40685208	BRWD1	0.69	6.3	0.49	4.63e-9	Cognitive function;
TGCT	cis	rs7760949	0.963	rs7453814	chr6:13918291	C/G	cg27413430	chr6:13925136	RNF182	0.62	5.79	0.46	5.31e-8	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs9814567	1.000	rs1880376	chr3:134270347	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.96	9.11	0.63	1.79e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs523522	0.926	rs10849766	chr12:121025894	G/A	cg27279351	chr12:120934652	DYNLL1	0.72	6.05	0.48	1.62e-8	High light scatter reticulocyte count;
TGCT	cis	rs9858542	0.953	rs11926781	chr3:49603289	C/T	cg03060546	chr3:49711283	APEH	-0.63	-5.48	-0.44	2.28e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs7809950	1.000	rs2712201	chr7:107145564	T/C	cg23024343	chr7:107201750	COG5	-0.35	-5.43	-0.44	2.88e-7	Coronary artery disease;
TGCT	cis	rs295140	1.000	rs13005573	chr2:201164696	G/C	cg04283868	chr2:201171347	SPATS2L	0.63	6.43	0.5	2.46e-9	QT interval;
TGCT	cis	rs6770219	0.516	rs7650292	chr3:186166085	T/C	cg15503553	chr3:185216877	TMEM41A	0.63	4.78	0.39	4.88e-6	Cerebrospinal T-tau levels;
TGCT	cis	rs9457247	1.000	rs9457247	chr6:167392174	C/T	cg23791538	chr6:167370224	RNASET2	-0.5	-4.98	-0.41	2.08e-6	Crohn's disease;
TGCT	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg10802521	chr3:52805072	NEK4	-0.7	-8.67	-0.61	2.04e-14	Bipolar disorder;
TGCT	cis	rs4727027	0.870	rs62507512	chr7:148799338	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	4.68	0.39	7.53e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs7223966	1.000	rs15637	chr17:61772050	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	5.17	0.42	8.94e-7	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs73058052	0.867	rs57940349	chr19:50097607	C/T	cg09250473	chr19:50168907	IRF3;BCL2L12	0.88	6.61	0.51	1.01e-9	Fibrinogen levels;
TGCT	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.65	6.31	0.49	4.45e-9	Bipolar disorder;
TGCT	cis	rs12220898	0.749	rs7913851	chr10:50482996	C/G	cg09603381	chr10:49954066	WDFY4	0.38	4.45	0.37	1.88e-5	Inflammatory biomarkers;
TGCT	cis	rs2760061	0.598	rs658238	chr1:228121291	A/G	cg18477163	chr1:228402036	OBSCN	-0.32	-6.37	-0.5	3.31e-9	Diastolic blood pressure;
TGCT	cis	rs3733585	0.673	rs10018204	chr4:9964570	C/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.67	-0.51	7.44e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs67311347	0.955	rs2085114	chr3:40497437	T/A	cg13683864	chr3:40499215	RPL14	-1.2	-13.3	-0.77	1.27e-25	Renal cell carcinoma;
TGCT	cis	rs9357506	1.000	rs1372569	chr6:46305542	G/A	cg21115430	chr6:46460003	NA	-0.26	-5.16	-0.42	9.37e-7	Body mass index;
TGCT	cis	rs775227	0.574	rs16860849	chr3:113049993	C/T	cg18753928	chr3:113234510	CCDC52	0.65	4.61	0.38	9.88e-6	Dental caries;
TGCT	cis	rs10838634	1.000	rs7111760	chr11:46828273	T/C	cg18332754	chr11:46939436	LRP4	0.9	4.59	0.38	1.05e-5	Schizophrenia;
TGCT	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg20203395	chr5:56204925	C5orf35	0.53	4.92	0.4	2.67e-6	Initial pursuit acceleration;
TGCT	cis	rs3617	0.625	rs2245647	chr3:52862753	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.6	-0.38	1.02e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg18252515	chr7:66147081	NA	1.25	7.75	0.57	2.92e-12	Diabetic kidney disease;
TGCT	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg07507251	chr3:52567010	NT5DC2	0.49	6.71	0.52	6.33e-10	Bipolar disorder;
TGCT	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg07061783	chr6:25882402	NA	-0.45	-4.82	-0.4	4.15e-6	Blood metabolite levels;
TGCT	cis	rs4689388	0.890	rs4688989	chr4:6290594	T/C	cg00701064	chr4:6280414	WFS1	0.39	5.03	0.41	1.68e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs7226408	0.802	rs55889065	chr18:34425307	G/A	cg06757138	chr18:34340585	FHOD3	0.25	4.83	0.4	4.02e-6	Obesity-related traits;
TGCT	cis	rs912057	0.585	rs1745341	chr6:6744990	T/C	cg06612196	chr6:6737390	NA	0.47	6.77	0.52	4.57e-10	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs7940866	0.804	rs10894287	chr11:130808483	C/T	cg05962950	chr11:130786565	SNX19	0.67	6.8	0.52	3.99e-10	Schizophrenia;
TGCT	cis	rs2050392	0.771	rs303446	chr10:30728489	C/T	cg18806716	chr10:30721971	MAP3K8	-0.51	-6.0	-0.47	2.05e-8	Inflammatory bowel disease;
TGCT	cis	rs7666738	0.830	rs13113899	chr4:99050422	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.94	0.47	2.68e-8	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg01341218	chr17:43662625	NA	-0.85	-7.57	-0.56	7.46e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg07507251	chr3:52567010	NT5DC2	0.46	6.68	0.51	7.37e-10	Bipolar disorder;
TGCT	cis	rs4319547	0.774	rs10773394	chr12:123124778	C/A	cg05707623	chr12:122985044	ZCCHC8	-0.59	-4.95	-0.41	2.42e-6	Body mass index;
TGCT	cis	rs6430585	0.527	rs62168830	chr2:136443900	A/T	cg07169764	chr2:136633963	MCM6	1.0	9.14	0.63	1.51e-15	Corneal structure;
TGCT	cis	rs9640161	0.750	rs17173617	chr7:150038023	G/C	cg10018233	chr7:150070692	REPIN1	0.32	4.62	0.38	9.29e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs250677	0.687	rs250674	chr5:148438597	A/G	cg23229984	chr5:148520753	ABLIM3	-0.2	-4.87	-0.4	3.26e-6	Breast cancer;
TGCT	cis	rs751728	1.000	rs747695	chr6:33736672	G/A	cg13859433	chr6:33739653	LEMD2	-0.4	-7.55	-0.56	8.33e-12	Crohn's disease;
TGCT	trans	rs7618501	1.000	rs35261599	chr3:49773236	G/A	cg21659725	chr3:3221576	CRBN	-0.98	-15.33	-0.81	2.1000000000000002e-30	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2485376	0.842	rs11593146	chr10:104184981	A/G	cg26089160	chr10:104170217	PSD	0.51	5.04	0.41	1.62e-6	QT interval;
TGCT	trans	rs1814175	0.791	rs1722011	chr11:49899340	G/C	cg15704280	chr7:45808275	SEPT13	-0.71	-8.02	-0.58	6.85e-13	Height;
TGCT	cis	rs600231	0.665	rs1784859	chr11:65220749	A/G	cg11802864	chr11:65308245	LTBP3	-0.46	-4.55	-0.38	1.24e-5	Bone mineral density;
TGCT	cis	rs11105298	0.891	rs4842662	chr12:89933446	T/C	cg00757033	chr12:89920650	WDR51B	0.29	4.6	0.38	1.01e-5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs9393777	0.513	rs1104871	chr6:26665235	T/G	cg15659132	chr6:26577336	NA	-0.73	-5.25	-0.43	6.5e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs6714788	0.546	rs12712062	chr2:100654307	A/T	cg22139774	chr2:100720529	AFF3	-0.41	-6.5	-0.5	1.74e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs62244186	0.520	rs9311361	chr3:44796132	T/G	cg02073558	chr3:44770973	ZNF501	0.73	7.37	0.55	2.08e-11	Depressive symptoms;
TGCT	cis	rs8180040	0.966	rs2062278	chr3:47416761	C/T	cg27129171	chr3:47204927	SETD2	0.65	7.67	0.57	4.29e-12	Colorectal cancer;
TGCT	cis	rs8002180	0.959	rs8001475	chr13:95922407	T/C	cg24476569	chr13:95954382	ABCC4	0.41	5.07	0.41	1.42e-6	Blood metabolite levels;
TGCT	trans	rs1496653	0.602	rs71322189	chr3:23481899	A/C	cg02770683	chr12:57597238	LRP1	0.38	6.89	0.53	2.53e-10	Type 2 diabetes;
TGCT	cis	rs208515	0.560	rs207084	chr6:66776966	T/C	cg07460842	chr6:66804631	NA	-1.06	-15.57	-0.81	5.81e-31	Exhaled nitric oxide levels;
TGCT	cis	rs12134245	0.747	rs11164912	chr1:92005191	A/T	cg07090678	chr1:91966139	CDC7	0.36	4.96	0.41	2.25e-6	Breast cancer;
TGCT	cis	rs765787	0.530	rs3759895	chr15:45543870	G/A	cg24006582	chr15:45444508	DUOX1	-0.25	-5.49	-0.44	2.13e-7	Uric acid levels;
TGCT	cis	rs4689592	0.554	rs66925245	chr4:7071999	C/T	cg26116260	chr4:7069785	GRPEL1	-0.97	-7.88	-0.58	1.4e-12	Monocyte percentage of white cells;
TGCT	cis	rs1008375	0.966	rs758483	chr4:17703614	G/T	cg10189774	chr4:17578691	LAP3	-0.57	-4.85	-0.4	3.7e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2762353	0.904	rs13197601	chr6:25785935	G/A	cg03517284	chr6:25882590	NA	0.51	5.33	0.43	4.47e-7	Blood metabolite levels;
TGCT	cis	rs9583531	0.600	rs6492305	chr13:111361400	C/T	cg24331049	chr13:111365604	ING1	0.76	7.31	0.55	2.95e-11	Coronary artery disease;
TGCT	cis	rs7918232	0.825	rs4749233	chr10:27467967	G/A	cg14442939	chr10:27389572	ANKRD26	0.82	5.75	0.46	6.69e-8	Breast cancer;
TGCT	cis	rs416603	0.967	rs11640138	chr16:11362729	A/G	cg00044050	chr16:11439710	C16orf75	0.8	8.05	0.59	5.64e-13	Type 1 diabetes;
TGCT	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg21724239	chr8:58056113	NA	0.41	4.87	0.4	3.33e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs911263	0.603	rs2180770	chr14:68773353	G/A	cg18825221	chr14:68749962	RAD51L1	0.22	4.44	0.37	1.97e-5	Primary biliary cholangitis;
TGCT	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg03806693	chr22:41940476	POLR3H	1.01	11.44	0.72	3.94e-21	Vitiligo;
TGCT	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg06873352	chr17:61820015	STRADA	0.55	6.13	0.48	1.09e-8	Prudent dietary pattern;
TGCT	cis	rs9393777	0.513	rs926300	chr6:27059443	A/T	cg16898833	chr6:26189333	HIST1H4D	0.8	4.85	0.4	3.57e-6	Intelligence (multi-trait analysis);
TGCT	trans	rs2469997	1.000	rs2470024	chr8:120363181	C/A	cg01792902	chr3:178864926	PIK3CA	0.83	6.77	0.52	4.49e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs8062405	0.754	rs28410083	chr16:28631360	A/T	cg09754948	chr16:28834200	ATXN2L	-0.59	-4.78	-0.39	4.82e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs3092073	0.617	rs17448680	chr20:44594726	T/C	cg23252815	chr20:44420276	WFDC3;DNTTIP1	-0.27	-4.44	-0.37	1.93e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs10489525	0.556	rs11102882	chr1:115612222	T/A	cg12756093	chr1:115239321	AMPD1	-0.33	-4.5	-0.37	1.52e-5	Autism;
TGCT	cis	rs858239	0.508	rs7805085	chr7:23190243	C/T	cg05602783	chr7:23145260	KLHL7	-0.68	-5.62	-0.45	1.2e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg23172400	chr8:95962367	TP53INP1	-0.38	-6.38	-0.5	3.13e-9	Type 2 diabetes;
TGCT	cis	rs13191362	1.000	rs35092540	chr6:163090778	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.17	9.9	0.66	2.27e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs4072705	0.614	rs7020027	chr9:127241414	G/A	cg13476313	chr9:127244764	NR5A1	-0.29	-4.81	-0.4	4.35e-6	Menarche (age at onset);
TGCT	cis	rs6964587	0.620	rs6967588	chr7:91643402	G/T	cg17063962	chr7:91808500	NA	0.75	7.1	0.54	8.68e-11	Breast cancer;
TGCT	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg18402987	chr7:1209562	NA	0.76	6.26	0.49	5.67e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs919433	0.617	rs700645	chr2:198605514	A/G	cg00792783	chr2:198669748	PLCL1	0.56	5.01	0.41	1.84e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs7586879	0.639	rs6545776	chr2:25099357	A/C	cg01884057	chr2:25150051	NA	0.33	6.3	0.49	4.82e-9	Body mass index;
TGCT	cis	rs2963155	0.518	rs2963151	chr5:142734151	T/C	cg17617527	chr5:142782415	NR3C1	0.81	6.3	0.49	4.84e-9	Breast cancer;
TGCT	cis	rs8177179	0.967	rs6782434	chr3:133438834	C/G	cg16262614	chr3:133464971	TF	0.35	4.72	0.39	6.28e-6	Iron status biomarkers (transferrin levels);
TGCT	cis	rs763014	0.865	rs8909	chr16:633851	T/C	cg27436995	chr16:743998	FBXL16	-0.45	-4.82	-0.4	4.17e-6	Height;
TGCT	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs11711311	0.955	rs1048892	chr3:113464859	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.79	-7.32	-0.55	2.75e-11	IgG glycosylation;
TGCT	cis	rs929354	0.739	rs1182439	chr7:157027367	G/A	cg05182265	chr7:156933206	UBE3C	0.4	9.05	0.63	2.54e-15	Body mass index;
TGCT	cis	rs75059851	0.756	rs56241440	chr11:133840830	A/C	cg14047540	chr11:133829660	NA	-0.57	-5.69	-0.45	8.72e-8	Schizophrenia;
TGCT	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg11644478	chr21:40555479	PSMG1	1.02	11.16	0.71	1.86e-20	Cognitive function;
TGCT	cis	rs3784262	0.669	rs4646580	chr15:58329211	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.43	-6.28	-0.49	5.31e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg21862992	chr11:68658383	NA	0.49	6.65	0.51	8.54e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs453301	0.686	rs28482034	chr8:8869664	G/A	cg11995313	chr8:8860691	ERI1	0.51	4.46	0.37	1.84e-5	Joint mobility (Beighton score);
TGCT	cis	rs7727544	0.571	rs12521097	chr5:131575338	G/A	cg24060327	chr5:131705240	SLC22A5	-0.56	-5.37	-0.43	3.7e-7	Blood metabolite levels;
TGCT	cis	rs6450176	0.830	rs7718193	chr5:53291591	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.49	-4.59	-0.38	1.08e-5	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg11366901	chr6:160182831	ACAT2	0.79	5.81	0.46	4.92e-8	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs2440129	0.611	rs2292352	chr17:6902887	A/G	cg03760483	chr17:6899297	ALOX12	0.47	5.34	0.43	4.2e-7	Tonsillectomy;
TGCT	trans	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg20587970	chr11:113659929	NA	0.8	9.3	0.64	6.34e-16	Hip circumference adjusted for BMI;
TGCT	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg24250549	chr1:154909240	PMVK	0.63	6.25	0.49	6.03e-9	Prostate cancer;
TGCT	cis	rs9858542	0.953	rs7648841	chr3:49416825	G/A	cg03060546	chr3:49711283	APEH	-0.64	-5.61	-0.45	1.27e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs1371867	0.846	rs1660332	chr8:101309490	A/G	cg00191853	chr8:101177733	SPAG1	0.23	4.76	0.39	5.2e-6	Atrioventricular conduction;
TGCT	cis	rs11711311	0.955	rs9851812	chr3:113412362	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.75	-6.84	-0.52	3.21e-10	IgG glycosylation;
TGCT	cis	rs3784262	0.904	rs3784260	chr15:58253269	T/G	cg12031962	chr15:58353849	ALDH1A2	-0.49	-7.57	-0.56	7.27e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs6840360	0.582	rs2724555	chr4:152341878	A/G	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.38	-0.5	3.17e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg04772025	chr11:68637568	NA	0.59	6.69	0.52	6.73e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs2456568	0.867	rs2511375	chr11:93671117	T/G	cg17595323	chr11:93583763	C11orf90	-0.46	-5.86	-0.47	3.88e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg00484396	chr16:3507460	NAT15	0.41	6.19	0.49	8.06e-9	Tuberculosis;
TGCT	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg03352830	chr11:487213	PTDSS2	0.26	4.58	0.38	1.12e-5	Body mass index;
TGCT	cis	rs7772486	0.790	rs9386141	chr6:146268623	T/A	cg23711669	chr6:146136114	FBXO30	-0.85	-9.7	-0.66	6.82e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg11644478	chr21:40555479	PSMG1	0.96	9.75	0.66	5.14e-17	Cognitive function;
TGCT	cis	rs7412746	0.658	rs1546376	chr1:150937661	A/G	cg04414720	chr1:150670196	GOLPH3L	0.38	4.5	0.37	1.52e-5	Melanoma;
TGCT	cis	rs17270561	0.779	rs17271767	chr6:25886921	C/T	cg17042849	chr6:26104293	HIST1H4C	-0.78	-5.52	-0.44	1.92e-7	Iron status biomarkers;
TGCT	cis	rs7772486	0.764	rs7745696	chr6:146162829	T/C	cg23711669	chr6:146136114	FBXO30	0.92	10.44	0.68	1.06e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs12410462	0.579	rs78343168	chr1:227621090	G/A	cg23173402	chr1:227635558	NA	0.65	4.49	0.37	1.61e-5	Major depressive disorder;
TGCT	cis	rs7412746	0.658	rs59988025	chr1:150940358	C/T	cg04414720	chr1:150670196	GOLPH3L	0.38	4.54	0.38	1.3e-5	Melanoma;
TGCT	cis	rs12681287	0.640	rs13256765	chr8:87457833	C/T	cg27223183	chr8:87520930	FAM82B	-0.89	-6.43	-0.5	2.54e-9	Caudate activity during reward;
TGCT	cis	rs155076	0.938	rs9509633	chr13:21844482	G/C	cg11317459	chr13:21872234	NA	-1.42	-12.02	-0.73	1.53e-22	White matter hyperintensity burden;
TGCT	cis	rs72781680	1.000	rs72781679	chr2:24237712	G/A	cg08917208	chr2:24149416	ATAD2B	0.83	5.08	0.42	1.35e-6	Lymphocyte counts;
TGCT	cis	rs11690935	0.959	rs10207085	chr2:172585885	T/G	cg13550731	chr2:172543902	DYNC1I2	-1.18	-12.58	-0.75	6.59e-24	Schizophrenia;
TGCT	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs17473412	1.000	rs75449813	chr5:122730653	C/G	cg15125798	chr5:122621645	NA	-0.6	-5.23	-0.43	7.01e-7	Total body bone mineral density;
TGCT	cis	rs6981523	0.553	rs11989369	chr8:11055385	A/G	cg21775007	chr8:11205619	TDH	0.5	4.61	0.38	1e-5	Neuroticism;
TGCT	cis	rs7772486	0.720	rs991507	chr6:146023609	G/A	cg13319975	chr6:146136371	FBXO30	0.53	4.8	0.4	4.49e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9325144	0.647	rs7980932	chr12:38921583	G/T	cg26384229	chr12:38710491	ALG10B	-0.56	-5.02	-0.41	1.76e-6	Morning vs. evening chronotype;
TGCT	cis	rs6074578	0.679	rs13043289	chr20:137114	A/G	cg16931068	chr20:139680	DEFB127	0.27	4.8	0.4	4.52e-6	Hirschsprung disease;
TGCT	cis	rs62380364	0.774	rs2362108	chr5:88147771	G/A	cg22951263	chr5:87985283	NA	-0.48	-4.62	-0.38	9.39e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs11673344	0.523	rs2385415	chr19:37526193	G/A	cg08039142	chr19:36980659	ZNF566	0.5	4.64	0.38	8.58e-6	Obesity-related traits;
TGCT	cis	rs2832191	1.000	rs2832185	chr21:30483761	C/G	cg24692254	chr21:30365293	RNF160	-0.83	-8.72	-0.62	1.56e-14	Dental caries;
TGCT	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs9814567	1.000	rs9864346	chr3:134312352	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.91	-8.83	-0.62	8.17e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs7843479	0.601	rs11785043	chr8:21810377	C/T	cg17168535	chr8:21777572	XPO7	0.81	8.33	0.6	1.25e-13	Mean corpuscular volume;
TGCT	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg20607798	chr8:58055168	NA	0.56	4.7	0.39	6.67e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs11676348	0.818	rs7425447	chr2:218980183	T/C	cg00012203	chr2:219082015	ARPC2	-0.51	-4.8	-0.4	4.39e-6	Ulcerative colitis;
TGCT	cis	rs12048904	0.964	rs12027668	chr1:101330984	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.55	5.14	0.42	1.04e-6	Multiple sclerosis;
TGCT	cis	rs2251381	0.750	rs2251186	chr21:30528880	G/A	cg08807101	chr21:30365312	RNF160	0.51	4.49	0.37	1.63e-5	Selective IgA deficiency;
TGCT	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg02725872	chr8:58115012	NA	-0.38	-4.76	-0.39	5.39e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6909430	0.539	rs13196732	chr6:98799148	A/G	cg20000812	chr6:99276697	NA	-0.51	-4.46	-0.37	1.79e-5	Quantitative traits;
TGCT	cis	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.22	4.54	0.38	1.32e-5	Eosinophil percentage of white cells;
TGCT	cis	rs7552404	0.731	rs931507	chr1:76401577	G/A	cg22875332	chr1:76189707	ACADM	-0.66	-6.78	-0.52	4.38e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs12477438	0.520	rs13012481	chr2:99754290	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.05	12.89	0.76	1.24e-24	Chronic sinus infection;
TGCT	cis	rs1670533	0.932	rs13137819	chr4:1042115	T/C	cg20887711	chr4:1340912	KIAA1530	0.71	5.16	0.42	9.34e-7	Recombination rate (females);
TGCT	cis	rs1865760	0.865	rs9393677	chr6:25945815	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.64	6.31	0.49	4.56e-9	Height;
TGCT	cis	rs2832191	0.791	rs28633762	chr21:30500070	C/T	cg24692254	chr21:30365293	RNF160	-0.86	-9.11	-0.63	1.83e-15	Dental caries;
TGCT	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg07157834	chr1:205819609	PM20D1	-0.33	-4.72	-0.39	6.19e-6	Menarche (age at onset);
TGCT	cis	rs1784581	0.651	rs1784588	chr6:162390027	T/A	cg17173639	chr6:162384350	PARK2	-0.47	-8.16	-0.59	3.15e-13	Itch intensity from mosquito bite;
TGCT	cis	rs514406	0.929	rs12145105	chr1:53340564	T/C	cg24675658	chr1:53192096	ZYG11B	-0.69	-7.86	-0.58	1.55e-12	Monocyte count;
TGCT	cis	rs1395	0.744	rs1122227	chr2:27544285	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.6	7.62	0.56	5.61e-12	Blood metabolite levels;
TGCT	cis	rs7772486	0.754	rs6570708	chr6:145989428	C/T	cg05347473	chr6:146136440	FBXO30	-0.51	-4.77	-0.39	5.07e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs17376456	0.877	rs10072592	chr5:93405989	C/G	cg25358565	chr5:93447407	FAM172A	0.93	8.37	0.6	1.04e-13	Diabetic retinopathy;
TGCT	cis	rs2997447	0.846	rs3008225	chr1:26390181	T/A	cg19633962	chr1:26362018	EXTL1	-0.68	-4.62	-0.38	9.47e-6	QRS complex (12-leadsum);
TGCT	cis	rs10791097	0.720	rs6590518	chr11:130733530	C/T	cg14779329	chr11:130786720	SNX19	0.28	4.78	0.39	4.88e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs1691799	0.899	rs1168304	chr12:66738667	A/C	cg16791601	chr12:66731901	HELB	-0.28	-6.1	-0.48	1.25e-8	White blood cell count (basophil);
TGCT	cis	rs6088590	0.561	rs6088527	chr20:33155841	C/T	cg08999081	chr20:33150536	PIGU	0.25	4.99	0.41	1.97e-6	Coronary artery disease;
TGCT	cis	rs733175	0.857	rs7666545	chr4:10012372	C/T	cg11266682	chr4:10021025	SLC2A9	0.52	4.68	0.39	7.48e-6	Psychosis and Alzheimer's disease;
TGCT	cis	rs614226	1.000	rs12310837	chr12:120880572	C/T	cg10072921	chr12:121022843	NA	-0.42	-4.47	-0.37	1.77e-5	Type 1 diabetes nephropathy;
TGCT	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg09033563	chr22:24373618	LOC391322	-0.48	-4.63	-0.38	8.97e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1005277	0.540	rs2145487	chr10:38010077	A/G	cg25427524	chr10:38739819	LOC399744	-0.33	-6.6	-0.51	1.07e-9	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg20637647	chr7:64974828	NA	-0.9	-5.06	-0.41	1.45e-6	Diabetic kidney disease;
TGCT	cis	rs9914544	1.000	rs6502677	chr17:18803658	A/G	cg26306683	chr17:18585705	ZNF286B	0.54	4.82	0.4	4.11e-6	Educational attainment (years of education);
TGCT	trans	rs2727020	0.617	rs7102702	chr11:49401125	T/G	cg03929089	chr4:120376271	NA	-0.68	-7.23	-0.54	4.35e-11	Coronary artery disease;
TGCT	cis	rs12216125	0.549	rs9358905	chr6:26077839	T/A	cg16482183	chr6:26056742	HIST1H1C	0.57	4.99	0.41	1.96e-6	Iron status biomarkers;
TGCT	cis	rs2640806	0.505	rs7837495	chr8:97359508	T/C	cg04026948	chr8:97953330	PGCP	-0.26	-4.64	-0.38	8.63e-6	Obesity-related traits;
TGCT	cis	rs6964587	1.000	rs6952389	chr7:91657994	A/G	cg17063962	chr7:91808500	NA	0.91	9.99	0.67	1.32e-17	Breast cancer;
TGCT	cis	rs11696501	0.688	rs6073854	chr20:44309605	A/G	cg11783356	chr20:44313418	WFDC10B	-0.33	-4.49	-0.37	1.6e-5	Brain structure;
TGCT	cis	rs4499344	0.730	rs7250272	chr19:33100338	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	8.81	0.62	9.52e-15	Mean platelet volume;
TGCT	cis	rs11190604	1.000	rs11190589	chr10:102275471	A/G	cg23241863	chr10:102295624	HIF1AN	0.7	5.39	0.44	3.36e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs922182	0.569	rs6494457	chr15:64263532	C/A	cg02919090	chr15:64263738	DAPK2	0.36	6.87	0.53	2.76e-10	Blood protein levels;
TGCT	cis	rs67311347	0.544	rs4974047	chr3:40339653	G/T	cg13683864	chr3:40499215	RPL14	-0.78	-7.5	-0.56	1.06e-11	Renal cell carcinoma;
TGCT	cis	rs3806933	0.522	rs13153937	chr5:110434307	C/T	cg04022379	chr5:110408740	TSLP	0.61	6.35	0.5	3.79e-9	Eosinophilic esophagitis;
TGCT	cis	rs7666738	0.830	rs7659006	chr4:98934529	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6490294	0.851	rs1016079	chr12:112410186	G/T	cg10833066	chr12:111807467	FAM109A	-0.37	-5.53	-0.44	1.79e-7	Mean platelet volume;
TGCT	cis	rs12136530	0.577	rs12120180	chr1:19791441	C/T	cg18923740	chr1:19971790	NBL1	0.45	4.9	0.4	2.91e-6	Lead levels in blood;
TGCT	cis	rs4822044	0.617	rs13054514	chr22:42130383	A/G	cg06481639	chr22:41940642	POLR3H	0.54	4.57	0.38	1.17e-5	Cannabis dependence symptom count;
TGCT	cis	rs11098499	0.954	rs28572238	chr4:120316686	T/G	cg09307838	chr4:120376055	NA	0.68	6.7	0.52	6.46e-10	Corneal astigmatism;
TGCT	cis	rs6456156	0.586	rs4710176	chr6:167491639	T/C	cg07741184	chr6:167504864	NA	0.24	4.72	0.39	6.21e-6	Primary biliary cholangitis;
TGCT	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg21724239	chr8:58056113	NA	0.45	5.26	0.43	6.08e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2777491	0.574	rs316616	chr15:41746276	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.94	-17.35	-0.84	5.64e-35	Ulcerative colitis;
TGCT	cis	rs2204008	0.744	rs11519905	chr12:38222959	G/A	cg26384229	chr12:38710491	ALG10B	0.84	7.38	0.55	2e-11	Bladder cancer;
TGCT	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg17971929	chr21:40555470	PSMG1	-0.51	-4.6	-0.38	1.04e-5	Menarche (age at onset);
TGCT	cis	rs3806843	0.576	rs246072	chr5:140320426	C/T	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.42	-5.37	-0.43	3.69e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs3796352	1.000	rs11713206	chr3:52999243	A/G	cg07884673	chr3:53033167	SFMBT1	0.63	5.74	0.46	6.83e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg08975724	chr8:8085496	FLJ10661	0.59	5.74	0.46	7.01e-8	Mood instability;
TGCT	cis	rs17125944	0.505	rs80211268	chr14:53265483	C/G	cg00686598	chr14:53173677	PSMC6	1.08	6.32	0.49	4.37e-9	Alzheimer's disease (late onset);
TGCT	cis	rs9650657	0.737	rs4551304	chr8:10665069	A/G	cg27411982	chr8:10470053	RP1L1	-0.23	-5.17	-0.42	9.17e-7	Neuroticism;
TGCT	cis	rs11098499	1.000	rs6837898	chr4:120179154	C/T	cg09307838	chr4:120376055	NA	0.49	4.48	0.37	1.67e-5	Corneal astigmatism;
TGCT	cis	rs12681288	0.550	rs12675410	chr8:957845	T/C	cg04851639	chr8:1020857	NA	-0.27	-4.45	-0.37	1.85e-5	Schizophrenia;
TGCT	cis	rs992157	0.735	rs13392177	chr2:219112956	C/T	cg00012203	chr2:219082015	ARPC2	-0.81	-10.28	-0.68	2.67e-18	Colorectal cancer;
TGCT	cis	rs527409	1.000	rs12083021	chr1:58712791	A/T	cg26345888	chr1:58716257	DAB1	0.81	4.51	0.38	1.51e-5	Kawasaki disease;
TGCT	cis	rs1008375	0.902	rs6844984	chr4:17651304	C/G	cg16339924	chr4:17578868	LAP3	0.63	5.26	0.43	6.22e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9300255	0.569	rs1790115	chr12:123620270	C/G	cg00376283	chr12:123451042	ABCB9	0.71	5.54	0.45	1.7e-7	Neutrophil percentage of white cells;
TGCT	cis	rs7208859	0.673	rs1347359	chr17:28914529	T/C	cg04154034	chr17:28927549	LRRC37B2	0.8	4.99	0.41	1.99e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs3751972	0.911	rs9630740	chr17:26242756	C/G	cg02948944	chr17:26242737	NA	0.51	7.32	0.55	2.78e-11	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs25422	0.887	rs9320666	chr6:118989181	C/T	cg07617317	chr6:118971624	C6orf204	0.45	5.1	0.42	1.26e-6	Renal cell carcinoma;
TGCT	trans	rs210152	0.531	rs4713634	chr6:33514708	T/C	cg08795360	chr21:41033440	B3GALT5	-0.43	-6.64	-0.51	8.94e-10	Schizophrenia;
TGCT	cis	rs77106637	1.000	rs11600585	chr11:72727840	A/G	cg03713592	chr11:72463424	ARAP1	0.83	5.49	0.44	2.12e-7	Type 2 diabetes;
TGCT	cis	rs2050392	1.000	rs7077496	chr10:30692028	G/A	cg18806716	chr10:30721971	MAP3K8	0.48	6.0	0.47	2.05e-8	Inflammatory bowel disease;
TGCT	cis	rs2933343	0.729	rs1680786	chr3:128644840	T/C	cg11901034	chr3:128598214	ACAD9	-0.65	-6.05	-0.48	1.55e-8	IgG glycosylation;
TGCT	cis	rs12220898	0.526	rs4838505	chr10:50556797	T/C	cg06072769	chr10:50146962	WDFY4	0.32	4.65	0.39	8.38e-6	Inflammatory biomarkers;
TGCT	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.94	7.92	0.58	1.17e-12	Platelet count;
TGCT	cis	rs765787	0.530	rs2413780	chr15:45538866	A/G	cg24006582	chr15:45444508	DUOX1	-0.25	-5.54	-0.45	1.76e-7	Uric acid levels;
TGCT	cis	rs7829975	0.535	rs4841005	chr8:8501230	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-4.74	-0.39	5.79e-6	Mood instability;
TGCT	cis	rs2832191	0.791	rs4817270	chr21:30480368	G/A	cg24692254	chr21:30365293	RNF160	-0.95	-10.52	-0.69	7.06e-19	Dental caries;
TGCT	cis	rs7095607	0.721	rs10997950	chr10:69912278	G/A	cg18986048	chr10:69913749	MYPN	0.47	5.38	0.43	3.64e-7	Lung function (FVC);
TGCT	cis	rs79349575	0.594	rs62078375	chr17:47034974	A/G	cg07967210	chr17:47022446	SNF8	0.43	5.88	0.47	3.51e-8	Type 2 diabetes;
TGCT	cis	rs79057730	0.599	rs4721086	chr7:821123	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.65	6.12	0.48	1.14e-8	Initial pursuit acceleration;
TGCT	cis	rs1215050	0.567	rs4699317	chr4:98602032	G/A	cg05340658	chr4:99064831	C4orf37	-0.38	-4.49	-0.37	1.59e-5	Waist-to-hip ratio adjusted for body mass index;
TGCT	trans	rs1496653	0.602	rs115867975	chr3:23346046	A/G	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs9436747	0.641	rs10443259	chr1:66051350	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.56	5.04	0.41	1.59e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs3947	1.000	rs1736083	chr8:11703497	G/T	cg02840367	chr8:11660030	FDFT1	0.91	6.66	0.51	7.98e-10	Blood protein levels;
TGCT	cis	rs9399135	0.967	rs12527707	chr6:135324511	G/A	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.36e-6	Red blood cell count;
TGCT	cis	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg19635926	chr16:89946313	TCF25	0.27	4.6	0.38	1.02e-5	Skin colour saturation;
TGCT	cis	rs752010	0.574	rs6671999	chr1:42120416	G/A	cg06885757	chr1:42089581	HIVEP3	0.24	4.56	0.38	1.21e-5	Lupus nephritis in systemic lupus erythematosus;
TGCT	cis	rs2235642	0.750	rs763152	chr16:1658056	T/C	cg07639376	chr16:1584516	IFT140;TMEM204	-0.29	-4.95	-0.41	2.38e-6	Coronary artery disease;
TGCT	cis	rs12908161	1.000	rs34900908	chr15:85257599	G/A	cg11189052	chr15:85197271	WDR73	0.75	6.29	0.49	5.02e-9	Schizophrenia;
TGCT	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.72	5.19	0.42	8.33e-7	Platelet count;
TGCT	cis	rs826838	0.967	rs1719852	chr12:39128531	A/G	cg13010199	chr12:38710504	ALG10B	-0.59	-4.66	-0.39	8.16e-6	Heart rate;
TGCT	trans	rs1814175	0.817	rs3974439	chr11:50022607	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.26	-0.55	3.77e-11	Height;
TGCT	trans	rs6052484	0.602	rs6076649	chr20:4258071	A/G	cg25044834	chr11:68177524	LRP5	0.32	6.87	0.53	2.7e-10	Sense of smell;
TGCT	trans	rs797680	0.927	rs1000607	chr1:93772001	T/C	cg27528825	chr2:159282178	CCDC148	-0.34	-6.71	-0.52	6.19e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg13695892	chr22:41940480	POLR3H	0.92	9.08	0.63	2.08e-15	Vitiligo;
TGCT	cis	rs9467773	1.000	rs4713006	chr6:26519872	A/G	cg09904177	chr6:26538194	HMGN4	0.65	6.53	0.51	1.53e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7819412	0.774	rs34208825	chr8:11014616	T/G	cg21775007	chr8:11205619	TDH	-0.55	-4.92	-0.4	2.71e-6	Triglycerides;
TGCT	cis	rs5771225	0.505	rs5771111	chr22:50695946	C/G	cg16473166	chr22:50639996	SELO	0.69	5.69	0.45	8.74e-8	Late-onset Alzheimer's disease;
TGCT	cis	rs739496	0.895	rs7965040	chr12:111920295	A/C	cg10833066	chr12:111807467	FAM109A	0.37	5.39	0.44	3.49e-7	Platelet count;
TGCT	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg21724239	chr8:58056113	NA	0.42	5.04	0.41	1.59e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs868036	0.718	rs28463100	chr15:68078769	T/C	cg05925327	chr15:68127851	NA	-0.5	-4.85	-0.4	3.57e-6	Restless legs syndrome;
TGCT	cis	rs3820928	1.000	rs3731593	chr2:227773924	A/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-4.64	-0.38	8.58e-6	Pulmonary function;
TGCT	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg26818010	chr10:134567672	INPP5A	-0.38	-5.19	-0.42	8.5e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs8078723	1.000	rs709592	chr17:38175553	C/T	cg17467752	chr17:38218738	THRA	0.52	4.93	0.41	2.54e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs3947	1.000	rs709821	chr8:11702594	G/C	cg02840367	chr8:11660030	FDFT1	0.91	6.7	0.52	6.58e-10	Blood protein levels;
TGCT	cis	rs12428086	1.000	rs17181551	chr13:36436924	T/C	cg09072216	chr13:36919344	SPG20	0.27	4.5	0.37	1.56e-5	Obesity-related traits;
TGCT	cis	rs231513	1.000	rs231513	chr17:41965200	C/G	cg26893861	chr17:41843967	DUSP3	-0.74	-5.21	-0.42	7.52e-7	Cognitive function;
TGCT	cis	rs546131	0.642	rs7946980	chr11:34820438	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.57	5.0	0.41	1.87e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	16.05	0.82	4.59e-32	Prudent dietary pattern;
TGCT	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg06634786	chr22:41940651	POLR3H	-0.83	-7.9	-0.58	1.31e-12	Vitiligo;
TGCT	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg26118208	chr10:134322334	NA	0.25	4.65	0.39	8.37e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs231513	0.906	rs11657681	chr17:42005363	G/A	cg26893861	chr17:41843967	DUSP3	0.73	5.1	0.42	1.25e-6	Cognitive function;
TGCT	cis	rs854765	0.547	rs4643387	chr17:17972973	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	8.63	0.61	2.42e-14	Total body bone mineral density;
TGCT	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg02725872	chr8:58115012	NA	-0.41	-5.42	-0.44	3.01e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7552404	0.960	rs12085123	chr1:76149749	G/A	cg22875332	chr1:76189707	ACADM	0.79	9.77	0.66	4.68e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs4783244	0.897	rs4597315	chr16:82652931	T/C	cg09415485	chr16:82663111	CDH13	-0.25	-4.66	-0.39	7.97e-6	Adiponectin levels;
TGCT	cis	rs3099143	1.000	rs3099143	chr15:77104856	A/C	cg21673338	chr15:77095150	SCAPER	-0.52	-4.87	-0.4	3.28e-6	Recalcitrant atopic dermatitis;
TGCT	cis	rs56104184	0.779	rs4802513	chr19:49357656	T/A	cg15549821	chr19:49342101	PLEKHA4	-0.76	-8.76	-0.62	1.2e-14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs4555082	1.000	rs4277291	chr14:105759009	A/G	cg10792982	chr14:105748885	BRF1	0.22	4.48	0.37	1.7e-5	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs6866344	0.601	rs12187838	chr5:178099833	T/C	cg10224037	chr5:178157518	ZNF354A	0.63	5.36	0.43	3.93e-7	Neutrophil percentage of white cells;
TGCT	trans	rs7618501	1.000	rs1491986	chr3:49739086	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-1.04	-13.29	-0.77	1.33e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs66887589	0.592	rs62320740	chr4:120279486	C/A	cg09307838	chr4:120376055	NA	0.46	4.59	0.38	1.09e-5	Diastolic blood pressure;
TGCT	cis	rs453301	0.571	rs2929305	chr8:9085217	G/A	cg15556689	chr8:8085844	FLJ10661	-0.64	-6.05	-0.48	1.6e-8	Joint mobility (Beighton score);
TGCT	cis	rs986417	1.000	rs8021348	chr14:60952777	G/T	cg27398547	chr14:60952738	C14orf39	1.39	10.61	0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs208520	0.690	rs12204512	chr6:66710486	C/T	cg07460842	chr6:66804631	NA	0.96	10.26	0.68	2.92e-18	Exhaled nitric oxide output;
TGCT	cis	rs4820792	0.725	rs5752777	chr22:29110002	T/C	cg03733026	chr22:29445468	ZNRF3	0.25	4.85	0.4	3.67e-6	Breast size;
TGCT	cis	rs4808199	0.895	rs10421505	chr19:19459554	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.65	4.91	0.4	2.77e-6	Nonalcoholic fatty liver disease;
TGCT	cis	rs477895	0.713	rs1059440	chr11:63991801	C/T	cg23719950	chr11:63933701	MACROD1	0.71	5.86	0.47	3.99e-8	Mean platelet volume;
TGCT	cis	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg20362242	chr5:692897	TPPP	0.51	4.7	0.39	6.92e-6	Obesity-related traits;
TGCT	cis	rs2302045	1.000	rs6732666	chr2:242055918	G/A	cg04553960	chr2:241721320	KIF1A	-0.7	-4.68	-0.39	7.4e-6	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio);
TGCT	cis	rs2354432	0.607	rs894469	chr1:146672906	C/T	cg25205988	chr1:146714368	CHD1L	1.33	6.35	0.5	3.68e-9	Mitochondrial DNA levels;
TGCT	cis	rs4808199	0.948	rs7259434	chr19:19428805	A/T	cg03709012	chr19:19516395	GATAD2A	0.81	6.55	0.51	1.4e-9	Nonalcoholic fatty liver disease;
TGCT	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg02187348	chr16:89574699	SPG7	0.6	6.51	0.5	1.69e-9	Multiple myeloma (IgH translocation);
TGCT	cis	rs981844	0.857	rs56198877	chr4:154718970	A/G	cg14289246	chr4:154710475	SFRP2	1.01	8.9	0.62	5.71e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs6988636	1.000	rs4282551	chr8:124185916	G/A	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg10295955	chr4:187884368	NA	-0.97	-14.67	-0.8	7e-29	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3892630	0.878	rs1559177	chr19:33210646	A/G	cg22980127	chr19:33182716	NUDT19	0.71	5.15	0.42	9.79e-7	Red blood cell traits;
TGCT	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg03303774	chr4:1407052	NA	-0.31	-4.93	-0.4	2.6e-6	Obesity-related traits;
TGCT	cis	rs5769765	0.865	rs9616369	chr22:50304591	A/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.11	-10.96	-0.7	5.67e-20	Schizophrenia;
TGCT	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg12311346	chr5:56204834	C5orf35	-0.57	-4.53	-0.38	1.38e-5	Type 2 diabetes;
TGCT	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg16325326	chr1:53192061	ZYG11B	-0.7	-8.72	-0.62	1.53e-14	Monocyte count;
TGCT	cis	rs8037137	0.822	rs2890156	chr15:91513157	T/A	cg22570213	chr15:91497863	RCCD1	0.51	4.76	0.39	5.32e-6	Platelet count;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
TGCT	cis	rs1008375	0.544	rs7685265	chr4:17568510	C/T	cg16339924	chr4:17578868	LAP3	0.74	5.95	0.47	2.61e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2404618	0.561	rs9918765	chr8:1484467	C/T	cg13402656	chr8:1511478	DLGAP2	-0.37	-6.17	-0.48	8.74e-9	Lung cancer;
TGCT	cis	rs7918232	0.891	rs10443987	chr10:27375377	A/T	cg14442939	chr10:27389572	ANKRD26	0.73	5.37	0.43	3.69e-7	Breast cancer;
TGCT	cis	rs6121246	0.559	rs6119728	chr20:30413121	G/A	cg13852791	chr20:30311386	BCL2L1	0.81	7.58	0.56	7.06e-12	Mean corpuscular hemoglobin;
TGCT	cis	rs2637266	0.765	rs2438993	chr10:78414604	A/C	cg18941641	chr10:78392320	NA	0.4	4.99	0.41	1.95e-6	Pulmonary function;
TGCT	cis	rs8177253	0.509	rs6762415	chr3:133478557	T/G	cg16414030	chr3:133502952	NA	-0.57	-7.19	-0.54	5.32e-11	Iron status biomarkers;
TGCT	cis	rs1451375	0.755	rs6969081	chr7:50624505	A/T	cg18232548	chr7:50535776	DDC	0.44	7.22	0.54	4.6e-11	Malaria;
TGCT	trans	rs1496653	0.602	rs34474714	chr3:23536891	T/C	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs2404602	0.669	rs17367297	chr15:77158026	A/C	cg26408565	chr15:76604113	ETFA	-0.36	-4.52	-0.38	1.41e-5	Blood metabolite levels;
TGCT	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg07507251	chr3:52567010	NT5DC2	0.48	6.67	0.51	7.55e-10	Bipolar disorder;
TGCT	cis	rs425277	0.585	rs3107143	chr1:2045372	G/C	cg03732007	chr1:2071316	PRKCZ	-0.24	-5.38	-0.44	3.57e-7	Height;
TGCT	cis	rs4642101	0.824	rs3889514	chr3:12844072	T/C	cg05775895	chr3:12838266	CAND2	0.73	7.24	0.55	4.1e-11	QRS complex (12-leadsum);
TGCT	cis	rs2033711	0.755	rs4801587	chr19:58936679	C/A	cg12042659	chr19:58951599	ZNF132	0.52	4.81	0.4	4.24e-6	Uric acid clearance;
TGCT	cis	rs6722750	0.506	rs12612392	chr2:64373635	G/A	cg22352474	chr2:64371530	PELI1	0.76	7.09	0.54	9.13e-11	Neuroticism;
TGCT	cis	rs992157	0.798	rs2382817	chr2:219151218	A/C	cg00012203	chr2:219082015	ARPC2	0.8	7.98	0.58	8.26e-13	Colorectal cancer;
TGCT	cis	rs7192750	0.586	rs12447045	chr16:71914617	C/G	cg06353428	chr16:71660113	MARVELD3	0.8	6.93	0.53	2.04e-10	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs67311347	1.000	rs66841330	chr3:40531123	G/A	cg02782426	chr3:40428986	ENTPD3	0.43	4.88	0.4	3.18e-6	Renal cell carcinoma;
TGCT	cis	rs1865760	0.963	rs3846838	chr6:25911775	T/C	cg17042849	chr6:26104293	HIST1H4C	-0.52	-4.68	-0.39	7.33e-6	Height;
TGCT	cis	rs826838	0.967	rs6580726	chr12:39108623	T/C	cg13010199	chr12:38710504	ALG10B	-0.6	-4.9	-0.4	2.95e-6	Heart rate;
TGCT	cis	rs593982	0.858	rs537385	chr11:65504900	G/A	cg08755490	chr11:65554678	OVOL1	1.42	12.09	0.74	1.03e-22	Atopic dermatitis;
TGCT	cis	rs2760061	0.626	rs592736	chr1:228116831	A/G	cg18477163	chr1:228402036	OBSCN	-0.32	-6.32	-0.49	4.19e-9	Diastolic blood pressure;
TGCT	cis	rs13256369	0.708	rs11783670	chr8:8559394	G/A	cg17143192	chr8:8559678	CLDN23	0.53	4.82	0.4	4.03e-6	Obesity-related traits;
TGCT	cis	rs10170846	0.731	rs10180632	chr2:223526384	G/A	cg25565276	chr2:223520875	FARSB	0.55	4.58	0.38	1.11e-5	Schizophrenia (inflammation and infection response interaction);
TGCT	cis	rs2070488	0.775	rs1073505	chr3:38566722	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.71	-6.89	-0.53	2.46e-10	Electrocardiographic conduction measures;
TGCT	cis	rs6952808	0.792	rs12537914	chr7:1948359	C/T	cg04267008	chr7:1944627	MAD1L1	-0.4	-5.44	-0.44	2.71e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs9787249	0.957	rs11206754	chr1:40216234	A/G	cg19912559	chr1:40204330	PPIE	0.49	5.71	0.46	7.84e-8	Blood protein levels;
TGCT	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg18230493	chr5:56204884	C5orf35	-0.7	-5.03	-0.41	1.7e-6	Type 2 diabetes;
TGCT	cis	rs10992471	0.603	rs13301537	chr9:95229047	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.62	-5.74	-0.46	6.79e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs7582180	0.764	rs4851293	chr2:100925106	A/T	cg08017756	chr2:100939284	LONRF2	-0.32	-5.26	-0.43	6.1e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs10823500	0.523	rs12774848	chr10:71932436	T/C	cg02100629	chr10:71892760	AIFM2	-0.47	-4.57	-0.38	1.18e-5	Blood protein levels;
TGCT	cis	rs2836950	0.565	rs3171465	chr21:40552307	A/G	cg06238570	chr21:40685208	BRWD1	-0.62	-6.3	-0.49	4.82e-9	Menarche (age at onset);
TGCT	cis	rs5769765	1.000	rs2092982	chr22:50282204	C/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.4	-6.07	-0.48	1.46e-8	Schizophrenia;
TGCT	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg10802521	chr3:52805072	NEK4	-0.78	-9.99	-0.67	1.3e-17	Bipolar disorder;
TGCT	cis	rs2840044	1.000	rs11653310	chr17:33893378	C/G	cg05299278	chr17:33885742	SLFN14	0.23	5.1	0.42	1.22e-6	Response to radiotherapy in cancer (late toxicity);
TGCT	cis	rs4631830	0.869	rs7896437	chr10:51529593	A/C	cg10326726	chr10:51549505	MSMB	-0.24	-4.87	-0.4	3.35e-6	Prostate-specific antigen levels;
TGCT	cis	rs35306767	0.855	rs12774985	chr10:904245	C/T	cg26597838	chr10:835615	NA	0.8	12.11	0.74	9.26e-23	Eosinophil percentage of granulocytes;
TGCT	cis	rs1865760	0.964	rs3799373	chr6:25929173	A/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.65	6.21	0.49	7.27e-9	Height;
TGCT	cis	rs9549367	0.789	rs9549705	chr13:113888425	T/C	cg18105134	chr13:113819100	PROZ	-0.34	-5.49	-0.44	2.18e-7	Platelet distribution width;
TGCT	cis	rs6964587	1.000	rs10234290	chr7:91716951	T/C	cg17063962	chr7:91808500	NA	0.86	9.47	0.65	2.39e-16	Breast cancer;
TGCT	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg23758822	chr17:41437982	NA	0.71	6.77	0.52	4.56e-10	Menopause (age at onset);
TGCT	cis	rs76878669	0.917	rs10219183	chr11:66090032	A/C	cg18002602	chr11:66138449	SLC29A2	0.48	5.52	0.44	1.94e-7	Educational attainment (years of education);
TGCT	cis	rs17376456	0.569	rs7735009	chr5:93260865	T/C	cg21475434	chr5:93447410	FAM172A	-0.62	-5.97	-0.47	2.3e-8	Diabetic retinopathy;
TGCT	cis	rs7100689	0.599	rs6585968	chr10:82139807	T/C	cg01528321	chr10:82214614	TSPAN14	0.81	8.27	0.6	1.71e-13	Post bronchodilator FEV1;
TGCT	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg13206674	chr6:150067644	NUP43	0.53	4.65	0.39	8.3e-6	Lung cancer;
TGCT	cis	rs3749237	0.576	rs62259939	chr3:49386047	G/A	cg02487422	chr3:49467188	NICN1	0.66	6.89	0.53	2.45e-10	Resting heart rate;
TGCT	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	5.07	0.41	1.4e-6	Height;
TGCT	trans	rs17277593	0.517	rs35592667	chr9:13875829	T/C	cg24852548	chr4:57522632	HOPX	0.73	6.94	0.53	1.9e-10	Endometriosis;
TGCT	cis	rs12210905	0.841	rs28410967	chr6:27265235	T/C	cg08851530	chr6:28072375	NA	1.29	5.45	0.44	2.65e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs67311347	1.000	rs9849992	chr3:40402140	C/T	cg13409248	chr3:40428643	ENTPD3	0.54	4.52	0.38	1.41e-5	Renal cell carcinoma;
TGCT	cis	rs11822910	0.737	rs2584858	chr11:57207077	C/T	cg00522883	chr11:57194120	SLC43A3	0.32	4.78	0.39	4.86e-6	Platelet distribution width;
TGCT	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg11890956	chr21:40555474	PSMG1	0.79	7.78	0.57	2.47e-12	Cognitive function;
TGCT	cis	rs7949030	0.626	rs71490390	chr11:62329185	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.64	9.42	0.65	3.17e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg03303774	chr4:1407052	NA	0.29	4.54	0.38	1.33e-5	Obesity-related traits;
TGCT	cis	rs11690935	0.959	rs10167419	chr2:172649826	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.18	-12.58	-0.75	6.59e-24	Schizophrenia;
TGCT	cis	rs4253772	0.591	rs10854854	chr22:46684706	C/G	cg24881330	chr22:46731750	TRMU	0.99	5.45	0.44	2.64e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.76	-7.54	-0.56	8.59e-12	Prudent dietary pattern;
TGCT	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg12310025	chr6:25882481	NA	0.9	9.22	0.64	9.6e-16	Blood metabolite levels;
TGCT	trans	rs7819412	0.745	rs28464654	chr8:11080665	T/A	cg15556689	chr8:8085844	FLJ10661	-0.87	-8.34	-0.6	1.2e-13	Triglycerides;
TGCT	cis	rs425277	1.000	rs262667	chr1:2082722	T/C	cg03732007	chr1:2071316	PRKCZ	0.26	5.52	0.44	1.89e-7	Height;
TGCT	cis	rs7937682	0.587	rs571594	chr11:111359334	A/G	cg09085632	chr11:111637200	PPP2R1B	0.65	6.03	0.48	1.74e-8	Primary sclerosing cholangitis;
TGCT	cis	rs13108904	0.775	rs2279282	chr4:1216033	G/C	cg05665937	chr4:1216051	CTBP1	0.26	5.16	0.42	9.54e-7	Obesity-related traits;
TGCT	cis	rs17387100	0.901	rs55808189	chr4:15983246	T/C	cg13480465	chr4:16795757	LDB2	-0.44	-5.08	-0.42	1.35e-6	Suicide attempts in depression or bipolar disorder;
TGCT	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg11764359	chr7:65958608	NA	0.61	5.53	0.44	1.84e-7	Aortic root size;
TGCT	cis	rs864745	0.967	rs1635852	chr7:28189411	T/C	cg23620719	chr7:28220237	JAZF1	-0.53	-4.79	-0.4	4.63e-6	Crohn's disease;Type 2 diabetes;
TGCT	cis	rs892961	0.932	rs3987887	chr17:75414862	T/C	cg05865280	chr17:75406074	SEPT9	0.3	6.97	0.53	1.65e-10	Airflow obstruction;
TGCT	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg02725872	chr8:58115012	NA	-0.41	-5.42	-0.44	3.01e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs35000415	0.515	rs13240595	chr7:128731777	C/A	cg06242719	chr7:129414860	MIR183;MIR96	-0.31	-4.7	-0.39	6.77e-6	Systemic lupus erythematosus;
TGCT	cis	rs9818758	0.545	rs55921200	chr3:49189316	T/C	cg00383909	chr3:49044727	WDR6	1.56	6.29	0.49	5.06e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	trans	rs731174	0.559	rs10908376	chr1:38196026	G/A	cg19725343	chr19:51830960	IGLON5	-0.62	-7.0	-0.53	1.44e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs624899	1.000	rs624899	chr19:11612498	C/T	cg21515159	chr19:11639617	ECSIT	0.84	4.64	0.38	8.77e-6	Presence of antiphospholipid antibodies;
TGCT	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg00814883	chr7:100076585	TSC22D4	-0.89	-9.26	-0.64	7.79e-16	Platelet count;
TGCT	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.15	0.82	2.71e-32	Prudent dietary pattern;
TGCT	cis	rs6087771	0.851	rs6087775	chr20:30325765	G/A	cg10886678	chr20:30946050	ASXL1	-0.52	-4.44	-0.37	1.97e-5	Subcortical brain region volumes;Putamen volume;
TGCT	cis	rs13256369	0.851	rs13254997	chr8:8563753	G/C	cg17143192	chr8:8559678	CLDN23	0.57	5.35	0.43	4.09e-7	Obesity-related traits;
TGCT	cis	rs7617773	0.780	rs71323395	chr3:48374077	G/A	cg11946769	chr3:48343235	NME6	0.81	6.96	0.53	1.71e-10	Coronary artery disease;
TGCT	cis	rs1406084	0.636	rs12693842	chr2:154724833	G/C	cg25703346	chr2:154729189	GALNT13	0.8	4.72	0.39	6.29e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9913156	0.802	rs4538065	chr17:4566015	G/A	cg00122941	chr17:4613640	ARRB2	-0.89	-7.56	-0.56	7.65e-12	Lymphocyte counts;
TGCT	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg15242686	chr22:24348715	GSTTP1	0.48	6.94	0.53	1.97e-10	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs12220238	0.722	rs10762635	chr10:76403131	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.59	4.54	0.38	1.29e-5	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs1552244	0.554	rs17050705	chr3:10046398	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.33	-4.95	-0.41	2.39e-6	Alzheimer's disease;
TGCT	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg14159672	chr1:205819179	PM20D1	0.71	10.1	0.67	7.19e-18	Menarche (age at onset);
TGCT	cis	rs76419734	0.558	rs4235415	chr4:106593850	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.65	4.6	0.38	1.03e-5	Post bronchodilator FEV1;
TGCT	cis	rs4689388	0.581	rs1801212	chr4:6302519	C/T	cg14416269	chr4:6271139	WFS1	0.47	5.74	0.46	7.01e-8	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs9393692	0.905	rs6916289	chr6:26289122	A/T	cg05868516	chr6:26286170	HIST1H4H	0.56	5.35	0.43	4.01e-7	Educational attainment;
TGCT	cis	rs7666738	0.830	rs4699603	chr4:99056172	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.79	0.46	5.32e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2066819	0.818	rs773652	chr12:56674766	G/A	cg26714650	chr12:56694279	CS	1.57	8.21	0.59	2.5e-13	Psoriasis vulgaris;
TGCT	cis	rs7666738	0.830	rs6819177	chr4:99040907	T/C	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11626933	0.959	rs8005973	chr14:90774951	C/T	cg14092571	chr14:90743983	NA	-0.29	-6.06	-0.48	1.51e-8	Gut microbiota (bacterial taxa);
TGCT	cis	rs921968	0.643	rs611203	chr2:219472325	G/A	cg02176678	chr2:219576539	TTLL4	0.45	6.48	0.5	1.93e-9	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs3087591	0.960	rs2905883	chr17:29550141	G/A	cg24425628	chr17:29625626	OMG;NF1	0.46	7.15	0.54	6.46e-11	Hip circumference;
TGCT	cis	rs11623869	0.553	rs11627567	chr14:103851775	C/T	cg12935359	chr14:103987150	CKB	-0.47	-6.09	-0.48	1.34e-8	Bone mineral density;
TGCT	cis	rs8180040	0.620	rs6768722	chr3:47079112	G/A	cg27129171	chr3:47204927	SETD2	0.71	8.51	0.61	4.8e-14	Colorectal cancer;
TGCT	cis	rs2806561	0.606	rs10917335	chr1:23294136	A/G	cg12483005	chr1:23474871	LUZP1	0.38	4.96	0.41	2.31e-6	Height;
TGCT	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg11905131	chr22:24372483	LOC391322	0.95	11.1	0.71	2.66e-20	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs921968	0.643	rs539451	chr2:219426972	T/C	cg02176678	chr2:219576539	TTLL4	0.38	5.48	0.44	2.31e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs13217239	0.646	rs12523820	chr6:27001502	A/G	cg05738196	chr6:26577821	NA	0.49	4.75	0.39	5.45e-6	Schizophrenia;
TGCT	cis	rs11585357	0.947	rs11584287	chr1:17607501	G/C	cg08277548	chr1:17600880	PADI3	-0.97	-9.95	-0.67	1.7e-17	Hair shape;
TGCT	cis	rs514406	0.505	rs269287	chr1:53168842	T/C	cg24675658	chr1:53192096	ZYG11B	-0.74	-8.31	-0.6	1.4e-13	Monocyte count;
TGCT	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg26338869	chr17:61819248	STRADA	-0.55	-5.08	-0.41	1.37e-6	Prudent dietary pattern;
TGCT	cis	rs6460942	0.908	rs74801929	chr7:12232715	C/G	cg06484146	chr7:12443880	VWDE	-0.52	-4.52	-0.38	1.44e-5	Coronary artery disease;
TGCT	cis	rs7568458	0.875	rs2044474	chr2:85758790	G/A	cg02493740	chr2:85810744	VAMP5	-0.27	-4.83	-0.4	4e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs362272	0.524	rs2749781	chr4:3346617	T/C	cg06533319	chr4:3265114	C4orf44	-0.26	-5.15	-0.42	1.01e-6	Serum sulfate level;
TGCT	cis	rs523522	0.962	rs12371550	chr12:120987643	C/T	cg12219531	chr12:120966889	COQ5	0.83	7.27	0.55	3.46e-11	High light scatter reticulocyte count;
TGCT	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg13012494	chr21:47604986	C21orf56	-0.37	-4.55	-0.38	1.26e-5	Testicular germ cell tumor;
TGCT	cis	rs8077889	0.917	rs9894873	chr17:41911832	A/G	cg26893861	chr17:41843967	DUSP3	1.11	13.43	0.77	6.22e-26	Triglycerides;
TGCT	cis	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg03213289	chr20:61660250	NA	0.68	9.9	0.66	2.25e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7267979	0.816	rs3746337	chr20:25208272	C/T	cg03522245	chr20:25566470	NINL	0.55	5.48	0.44	2.31e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs79387448	0.745	rs72993754	chr2:103151136	A/G	cg09003973	chr2:102972529	NA	0.92	6.03	0.48	1.73e-8	Gut microbiota (bacterial taxa);
TGCT	cis	rs12220238	1.000	rs10824099	chr10:75943625	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.06	0.54	1.05e-10	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs7226408	0.590	rs72894348	chr18:34730549	C/A	cg06757138	chr18:34340585	FHOD3	0.26	4.68	0.39	7.43e-6	Obesity-related traits;
TGCT	cis	rs1150668	0.796	rs728122	chr6:28399124	G/A	cg13525197	chr6:28411240	ZSCAN23	-0.53	-5.14	-0.42	1.06e-6	Pubertal anthropometrics;
TGCT	cis	rs10892173	0.566	rs10892174	chr11:117672565	A/C	cg04064380	chr11:117688259	NA	-0.5	-4.48	-0.37	1.66e-5	Myopia;
TGCT	cis	rs4273100	0.512	rs2233072	chr17:19281828	T/G	cg01534423	chr17:18965556	NA	-0.75	-7.86	-0.58	1.6e-12	Schizophrenia;
TGCT	cis	rs2242116	0.932	rs7646906	chr3:46949379	G/A	cg02527881	chr3:46936655	PTH1R	-0.31	-5.79	-0.46	5.41e-8	Birth weight;
TGCT	cis	rs7666738	0.830	rs28729647	chr4:99059552	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.45	0.56	1.4e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9910055	0.530	rs2269906	chr17:42294337	G/T	cg13607699	chr17:42295918	UBTF	-0.9	-10.34	-0.68	1.93e-18	Total body bone mineral density;
TGCT	cis	rs7772486	0.806	rs2247317	chr6:146217570	C/T	cg05347473	chr6:146136440	FBXO30	0.53	5.23	0.43	6.96e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs514406	0.505	rs437954	chr1:53173321	C/G	cg22166914	chr1:53195759	ZYG11B	0.45	7.82	0.57	2.01e-12	Monocyte count;
TGCT	cis	rs72945132	0.882	rs947781	chr11:70212755	G/A	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs9611519	0.857	rs4820434	chr22:41637119	G/T	cg13695892	chr22:41940480	POLR3H	-0.63	-5.96	-0.47	2.42e-8	Neuroticism;
TGCT	cis	rs12142240	0.698	rs1475389	chr1:46816429	T/C	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs3008870	0.917	rs12044492	chr1:67461667	T/C	cg03991309	chr1:68237761	GNG12	-0.27	-4.53	-0.38	1.36e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs12477438	0.798	rs6705821	chr2:99602832	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-6.1	-0.48	1.22e-8	Chronic sinus infection;
TGCT	cis	rs10256972	0.514	rs2140578	chr7:1214003	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.52	-6.08	-0.48	1.39e-8	Longevity;Endometriosis;
TGCT	cis	rs1008375	0.933	rs4698637	chr4:17632843	A/T	cg16339924	chr4:17578868	LAP3	0.64	5.19	0.42	8.36e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs854765	0.624	rs8078756	chr17:17744725	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.71	-6.69	-0.51	6.87e-10	Total body bone mineral density;
TGCT	cis	rs72781680	0.898	rs72782126	chr2:24039901	A/C	cg08917208	chr2:24149416	ATAD2B	0.8	4.93	0.4	2.62e-6	Lymphocyte counts;
TGCT	cis	rs9915657	0.660	rs1558748	chr17:70066502	T/C	cg06234051	chr17:70120541	SOX9	-0.25	-5.44	-0.44	2.71e-7	Thyroid hormone levels;
TGCT	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg13395646	chr4:1353034	KIAA1530	0.4	4.95	0.41	2.34e-6	Obesity-related traits;
TGCT	cis	rs2180341	0.855	rs4308584	chr6:127714874	A/G	cg27446573	chr6:127587934	RNF146	0.92	8.5	0.61	5.15e-14	Breast cancer;
TGCT	cis	rs2204008	0.837	rs11514225	chr12:38076270	G/A	cg26384229	chr12:38710491	ALG10B	0.86	7.72	0.57	3.39e-12	Bladder cancer;
TGCT	cis	rs860295	0.500	rs34995046	chr1:155988485	G/T	cg05700447	chr1:155978627	NA	-0.19	-4.67	-0.39	7.55e-6	Body mass index;
TGCT	cis	rs6964587	1.000	rs2301559	chr7:91746727	T/C	cg17063962	chr7:91808500	NA	0.88	9.42	0.65	3.2e-16	Breast cancer;
TGCT	cis	rs11098499	0.691	rs2136911	chr4:120265859	G/A	cg09307838	chr4:120376055	NA	0.56	5.5	0.44	2.08e-7	Corneal astigmatism;
TGCT	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs11650494	0.516	rs9907942	chr17:47513891	C/T	cg08112188	chr17:47440006	ZNF652	0.89	4.47	0.37	1.73e-5	Prostate cancer;
TGCT	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg04287289	chr16:89883240	FANCA	0.93	11.83	0.73	4.42e-22	Vitiligo;
TGCT	cis	rs1215050	0.791	rs165252	chr4:98758728	A/C	cg17366294	chr4:99064904	C4orf37	0.52	5.61	0.45	1.27e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9467773	0.620	rs2451744	chr6:26633463	G/T	cg09904177	chr6:26538194	HMGN4	0.67	6.48	0.5	1.94e-9	Intelligence (multi-trait analysis);
TGCT	trans	rs2727020	0.615	rs10128582	chr11:49447424	C/T	cg15704280	chr7:45808275	SEPT13	-0.77	-8.75	-0.62	1.29e-14	Coronary artery disease;
TGCT	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg03188948	chr7:1209495	NA	0.71	6.04	0.48	1.68e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2836950	0.501	rs4818019	chr21:40694456	T/A	cg11890956	chr21:40555474	PSMG1	-0.65	-6.12	-0.48	1.15e-8	Menarche (age at onset);
TGCT	cis	rs6912958	0.630	rs9450726	chr6:88236728	A/G	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.79	-0.39	4.75e-6	Monocyte percentage of white cells;
TGCT	cis	rs911555	0.511	rs8007489	chr14:104054572	A/G	cg26031613	chr14:104095156	KLC1	-0.54	-4.99	-0.41	2.01e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs17221829	0.965	rs11018745	chr11:89443808	A/C	cg02982614	chr11:89391479	FOLH1B	-0.29	-5.08	-0.41	1.36e-6	Anxiety in major depressive disorder;
TGCT	cis	rs916888	0.647	rs199523	chr17:44848517	C/A	cg17911788	chr17:44343683	NA	0.51	5.9	0.47	3.3e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7824557	0.679	rs10110008	chr8:11133736	G/T	cg21775007	chr8:11205619	TDH	-0.57	-5.37	-0.43	3.66e-7	Retinal vascular caliber;
TGCT	cis	rs10484885	0.824	rs72919981	chr6:90528977	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.46	-4.49	-0.37	1.63e-5	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs4523957	0.651	rs7214741	chr17:2085598	C/T	cg16513277	chr17:2031491	SMG6	-0.2	-4.51	-0.38	1.47e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs2153535	0.584	rs9502721	chr6:8541379	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.61	0.45	1.23e-7	Motion sickness;
TGCT	cis	rs2455799	0.613	rs4685264	chr3:15858347	G/A	cg16303742	chr3:15540471	COLQ	-0.25	-4.88	-0.4	3.19e-6	Mean platelet volume;
TGCT	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg18876405	chr7:65276391	NA	0.29	4.65	0.39	8.32e-6	Aortic root size;
TGCT	cis	rs7552404	0.727	rs2172508	chr1:76320215	A/G	cg03433033	chr1:76189801	ACADM	0.59	5.9	0.47	3.21e-8	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg12963246	chr6:28129442	ZNF389	0.52	5.01	0.41	1.85e-6	Depression;
TGCT	cis	rs17376456	0.569	rs7729807	chr5:93104089	C/T	cg25358565	chr5:93447407	FAM172A	0.76	6.61	0.51	1e-9	Diabetic retinopathy;
TGCT	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg18402987	chr7:1209562	NA	0.47	4.69	0.39	7.03e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg12667521	chr19:29218732	NA	0.5	5.84	0.46	4.26e-8	Methadone dose in opioid dependence;
TGCT	cis	rs76878669	0.561	rs7110944	chr11:66118217	C/T	cg18002602	chr11:66138449	SLC29A2	-0.54	-6.62	-0.51	9.76e-10	Educational attainment (years of education);
TGCT	cis	rs12681288	0.676	rs1562921	chr8:1021986	G/T	cg04851639	chr8:1020857	NA	-0.36	-6.82	-0.52	3.56e-10	Schizophrenia;
TGCT	cis	rs9467773	0.967	rs6941022	chr6:26553531	T/C	cg05738196	chr6:26577821	NA	0.91	13.14	0.76	2.99e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs600550	0.963	rs4939328	chr11:60021506	C/A	cg18570331	chr11:60101691	MS4A6E	0.52	4.48	0.37	1.67e-5	Lipoprotein-associated phospholipase A2 activity and mass;
TGCT	trans	rs7615952	0.932	rs1976458	chr3:125647512	T/G	cg07211511	chr3:129823064	LOC729375	-0.47	-7.55	-0.56	8.34e-12	Blood pressure (smoking interaction);
TGCT	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg26338869	chr17:61819248	STRADA	-0.54	-4.92	-0.4	2.64e-6	Prudent dietary pattern;
TGCT	cis	rs981844	1.000	rs2606341	chr4:154658702	T/C	cg14289246	chr4:154710475	SFRP2	1.01	8.46	0.6	6.31e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs4713118	0.513	rs202908	chr6:28011551	C/G	cg10876282	chr6:28092338	ZSCAN16	0.51	4.56	0.38	1.19e-5	Parkinson's disease;
TGCT	cis	rs4887140	0.867	rs9806165	chr15:74063723	A/G	cg05195566	chr15:74465209	ISLR	-0.44	-4.5	-0.37	1.53e-5	Glucose homeostasis traits;
TGCT	cis	rs2742417	1.000	rs2673025	chr3:45760483	A/G	cg04837898	chr3:45731254	SACM1L	-0.52	-5.28	-0.43	5.58e-7	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs1670533	0.932	rs610218	chr4:1080083	C/G	cg27284194	chr4:1044797	NA	0.68	5.84	0.46	4.28e-8	Recombination rate (females);
TGCT	trans	rs8073060	0.586	rs35542792	chr17:33903886	A/G	cg19694781	chr19:47549865	TMEM160	0.6	13.28	0.77	1.39e-25	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg25427524	chr10:38739819	LOC399744	-0.4	-8.23	-0.59	2.17e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs611744	0.934	rs624311	chr8:109204437	A/G	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs2180341	0.842	rs9372860	chr6:127546605	G/A	cg24812749	chr6:127587940	RNF146	0.93	6.53	0.51	1.55e-9	Breast cancer;
TGCT	cis	rs1005277	0.540	rs4934907	chr10:38015230	A/C	cg25427524	chr10:38739819	LOC399744	-0.33	-6.6	-0.51	1.07e-9	Extrinsic epigenetic age acceleration;
TGCT	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg01802117	chr1:53393560	SCP2	0.43	5.12	0.42	1.14e-6	Monocyte count;
TGCT	cis	rs854765	0.583	rs9635697	chr17:17870394	T/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	7.69	0.57	3.98e-12	Total body bone mineral density;
TGCT	cis	rs35883536	0.626	rs7545966	chr1:101047633	G/A	cg06223162	chr1:101003688	GPR88	-0.41	-7.64	-0.57	5.04e-12	Monocyte count;
TGCT	cis	rs34065801	0.584	rs1171085	chr13:36512489	A/G	cg03563146	chr13:37393157	RFXAP	-0.48	-4.49	-0.37	1.6e-5	Breast size;
TGCT	cis	rs2456568	0.802	rs1574515	chr11:93629643	T/C	cg26875233	chr11:93583750	C11orf90	-0.48	-6.5	-0.5	1.76e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7267979	0.903	rs2474766	chr20:25246153	A/G	cg14121845	chr20:25566513	NINL	0.5	5.51	0.44	1.95e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2758596	1.000	rs2758617	chr1:156160693	A/G	cg25208724	chr1:156163844	SLC25A44	0.84	5.09	0.42	1.27e-6	Paclitaxel disposition in epithelial ovarian cancer;
TGCT	cis	rs57994353	0.659	rs76259794	chr9:139377405	C/A	cg13741927	chr9:139327495	INPP5E	-0.23	-5.16	-0.42	9.54e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs710216	0.536	rs710221	chr1:43414200	G/A	cg03128534	chr1:43423976	SLC2A1	0.7	7.41	0.55	1.74e-11	Red cell distribution width;
TGCT	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg08859206	chr1:53392774	SCP2	-0.42	-6.8	-0.52	3.92e-10	Monocyte count;
TGCT	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg04944784	chr2:26401820	FAM59B	-0.75	-5.29	-0.43	5.46e-7	Gut microbiome composition (summer);
TGCT	cis	rs7959452	0.649	rs4761239	chr12:69776886	T/A	cg14784868	chr12:69753453	YEATS4	0.84	8.84	0.62	7.88e-15	Blood protein levels;
TGCT	cis	rs308403	0.640	rs13110096	chr4:123633932	T/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.67	5.75	0.46	6.58e-8	Blood protein levels;
TGCT	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg01448562	chr3:133502909	NA	-0.33	-6.71	-0.52	6.3e-10	Iron status biomarkers;
TGCT	cis	rs35146811	0.625	rs858514	chr7:99825748	A/G	cg00553149	chr7:99775558	STAG3;GPC2	-0.32	-4.81	-0.4	4.28e-6	Coronary artery disease;
TGCT	cis	rs17221829	0.673	rs10741307	chr11:89367271	G/C	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.63	-0.38	9.04e-6	Anxiety in major depressive disorder;
TGCT	cis	rs617219	0.671	rs2591388	chr5:78557241	A/G	cg23514016	chr5:78407564	BHMT	0.32	4.66	0.39	7.88e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs12497850	0.966	rs6792510	chr3:48723302	G/C	cg16497277	chr3:49208875	KLHDC8B	-0.5	-4.69	-0.39	6.97e-6	Parkinson's disease;
TGCT	cis	rs9325144	0.560	rs1843910	chr12:38677408	T/C	cg13010199	chr12:38710504	ALG10B	-0.53	-4.63	-0.38	9.02e-6	Morning vs. evening chronotype;
TGCT	cis	rs9952991	0.941	rs2847280	chr18:12779342	A/G	cg23544223	chr18:12777786	NA	0.64	6.12	0.48	1.15e-8	Inflammatory skin disease;
TGCT	trans	rs2727020	0.595	rs11040416	chr11:49566429	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.36	-7.12	-0.54	7.81e-11	Coronary artery disease;
TGCT	cis	rs12477438	0.834	rs6757019	chr2:99676936	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-5.87	-0.47	3.74e-8	Chronic sinus infection;
TGCT	cis	rs7582180	0.585	rs12999151	chr2:100939333	G/A	cg14675211	chr2:100938903	LONRF2	0.51	4.95	0.41	2.32e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg03264133	chr6:25882463	NA	0.69	7.63	0.57	5.51e-12	Blood metabolite levels;
TGCT	cis	rs2120019	1.000	rs12898259	chr15:75369780	G/A	cg17294928	chr15:75287854	SCAMP5	-0.86	-6.62	-0.51	9.55e-10	Blood trace element (Zn levels);
TGCT	cis	rs7666738	0.830	rs6834014	chr4:98951431	G/A	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7017914	0.967	rs13257800	chr8:71714133	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.51	-4.72	-0.39	6.18e-6	Bone mineral density;
TGCT	cis	rs10193935	1.000	rs10180528	chr2:42436723	T/A	cg27598129	chr2:42591480	NA	-0.39	-5.14	-0.42	1.05e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7772486	0.686	rs9373473	chr6:146082282	A/G	cg05347473	chr6:146136440	FBXO30	0.5	4.83	0.4	3.97e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs675209	0.680	rs12530084	chr6:7214676	C/T	cg27097018	chr6:6320614	F13A1	0.36	4.92	0.4	2.67e-6	Urate levels;
TGCT	cis	rs12510870	0.599	rs12507775	chr4:74451073	C/T	cg05868023	chr4:75230803	EREG	0.53	4.7	0.39	6.81e-6	Iris color (b* coordinate);
TGCT	cis	rs1941023	0.568	rs1373064	chr11:60168200	C/T	cg08716584	chr11:60157161	MS4A7	-0.31	-4.69	-0.39	7.18e-6	Congenital heart disease (maternal effect);
TGCT	cis	rs7914558	0.966	rs10450373	chr10:104728616	T/C	cg15744005	chr10:104629667	AS3MT	-0.4	-4.99	-0.41	1.97e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs7914558	0.966	rs56946876	chr10:104653545	T/C	cg04362960	chr10:104952993	NT5C2	0.58	5.16	0.42	9.65e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs2762353	0.574	rs9467570	chr6:25699283	C/A	cg12310025	chr6:25882481	NA	0.94	9.38	0.64	4.07e-16	Blood metabolite levels;
TGCT	cis	rs10504229	1.000	rs59843034	chr8:58195756	T/G	cg08280861	chr8:58055591	NA	0.36	4.61	0.38	9.98e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9916302	0.861	rs8081033	chr17:37506650	A/G	cg07936489	chr17:37558343	FBXL20	0.65	5.08	0.41	1.36e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs2404602	0.716	rs117129193	chr15:76656803	A/G	cg26408565	chr15:76604113	ETFA	-0.4	-5.08	-0.41	1.37e-6	Blood metabolite levels;
TGCT	cis	rs2932538	0.744	rs6537742	chr1:113085197	G/T	cg10983938	chr1:113465962	AFARP1;SLC16A1	0.24	4.61	0.38	9.89e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs9916302	0.768	rs11078900	chr17:37614641	C/T	cg15445000	chr17:37608096	MED1	0.31	4.59	0.38	1.06e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs9611565	0.592	rs5758406	chr22:42076641	A/G	cg13695892	chr22:41940480	POLR3H	0.9	9.02	0.63	2.89e-15	Vitiligo;
TGCT	cis	rs12510870	0.729	rs10213305	chr4:74360642	C/A	cg05868023	chr4:75230803	EREG	0.53	4.55	0.38	1.25e-5	Iris color (b* coordinate);
TGCT	cis	rs4319547	0.626	rs12423420	chr12:122938466	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.67	-5.41	-0.44	3.08e-7	Body mass index;
TGCT	trans	rs8073060	0.561	rs225260	chr17:33958422	T/C	cg19694781	chr19:47549865	TMEM160	-0.61	-13.51	-0.77	3.85e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg22920501	chr2:26401640	FAM59B	0.8	6.34	0.49	3.84e-9	Gut microbiome composition (summer);
TGCT	trans	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg23505145	chr19:12996616	KLF1	0.79	8.3	0.6	1.47e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg21862992	chr11:68658383	NA	0.47	6.6	0.51	1.09e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs6988636	0.710	rs73339621	chr8:124138936	C/T	cg22384356	chr8:124195192	FAM83A	-0.42	-4.59	-0.38	1.06e-5	Urinary uromodulin levels;
TGCT	cis	rs2180341	0.722	rs9388555	chr6:127576363	G/A	cg24812749	chr6:127587940	RNF146	0.83	6.69	0.51	6.91e-10	Breast cancer;
TGCT	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg26119090	chr2:26468346	HADHA;HADHB	1.0	7.42	0.55	1.64e-11	Gut microbiome composition (summer);
TGCT	cis	rs9906944	0.707	rs11655950	chr17:47129121	C/T	cg20966754	chr17:47091339	IGF2BP1	-0.49	-5.67	-0.45	9.38e-8	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs981844	0.712	rs897611	chr4:154755519	T/C	cg14289246	chr4:154710475	SFRP2	-0.96	-8.97	-0.63	3.91e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs3087591	0.922	rs2905805	chr17:29502856	C/A	cg24425628	chr17:29625626	OMG;NF1	0.45	6.95	0.53	1.84e-10	Hip circumference;
TGCT	cis	rs1878931	0.858	rs3760083	chr16:3450052	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.97	-10.31	-0.68	2.26e-18	Body mass index (adult);
TGCT	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg11062466	chr8:58055876	NA	0.46	4.81	0.4	4.29e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs12042938	0.507	rs2570408	chr1:231732934	C/T	cg04892437	chr1:231737901	TSNAX-DISC1	-0.38	-4.45	-0.37	1.85e-5	Neuranatomic and neurocognitive phenotypes;
TGCT	cis	rs7439150	1.000	rs72681213	chr4:155479689	G/A	cg22130008	chr4:155548532	NA	-0.44	-5.59	-0.45	1.36e-7	Fibrinogen levels;
TGCT	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg11764359	chr7:65958608	NA	0.55	5.08	0.42	1.34e-6	Aortic root size;
TGCT	cis	rs9868809	1.000	rs9868809	chr3:48681053	C/T	cg00383909	chr3:49044727	WDR6	0.93	4.52	0.38	1.4e-5	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs7191700	0.836	rs10163410	chr16:11430615	G/C	cg00044050	chr16:11439710	C16orf75	0.68	5.7	0.46	8.46e-8	Multiple sclerosis;
TGCT	cis	rs11122272	0.735	rs2474631	chr1:231541341	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-6.24	-0.49	6.23e-9	Hemoglobin concentration;
TGCT	cis	rs2204008	0.837	rs7315255	chr12:37949279	G/A	cg13010199	chr12:38710504	ALG10B	0.65	5.29	0.43	5.47e-7	Bladder cancer;
TGCT	cis	rs1018836	0.663	rs4735190	chr8:91509601	A/G	cg16814680	chr8:91681699	NA	-0.84	-8.49	-0.61	5.44e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs12477438	0.798	rs6542849	chr2:99578493	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-5.97	-0.47	2.3e-8	Chronic sinus infection;
TGCT	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg27588902	chr6:42928151	GNMT	-0.49	-5.93	-0.47	2.85e-8	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.62	5.25	0.43	6.3e-7	Tonsillectomy;
TGCT	cis	rs9443645	0.901	rs9361480	chr6:79724429	C/T	cg05283184	chr6:79620031	NA	-0.2	-4.63	-0.38	9.08e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1497406	0.744	rs12562207	chr1:16508059	G/A	cg20430773	chr1:16534157	ARHGEF19	0.56	6.28	0.49	5.24e-9	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9859260	0.744	rs557527	chr3:195780709	G/A	cg02975922	chr3:195473998	MUC4	0.25	5.09	0.42	1.3e-6	Mean corpuscular volume;
TGCT	cis	rs1552244	0.554	rs3846167	chr3:9996426	T/C	cg00149659	chr3:10157352	C3orf10	0.66	4.89	0.4	3.04e-6	Alzheimer's disease;
TGCT	cis	rs7267979	0.932	rs928121	chr20:25534818	A/G	cg16686733	chr20:25566563	NINL	0.56	5.69	0.46	8.49e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs748404	0.578	rs573615	chr15:43614281	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	4.82	0.4	4.07e-6	Lung cancer;
TGCT	trans	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg17470723	chr8:74884337	TCEB1	0.74	6.92	0.53	2.19e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs8062405	1.000	rs11861174	chr16:28871989	A/G	cg09754948	chr16:28834200	ATXN2L	0.59	4.45	0.37	1.91e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs2180341	0.781	rs7760652	chr6:127572096	A/G	cg27446573	chr6:127587934	RNF146	0.91	8.5	0.61	5.12e-14	Breast cancer;
TGCT	cis	rs13102973	0.965	rs55967588	chr4:135860189	G/A	cg14419869	chr4:135874104	NA	0.24	4.49	0.37	1.6e-5	Subjective well-being;
TGCT	cis	rs67478160	0.643	rs8005594	chr14:104279889	T/C	cg26031613	chr14:104095156	KLC1	-0.63	-6.56	-0.51	1.3e-9	Schizophrenia;
TGCT	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg13409248	chr3:40428643	ENTPD3	0.57	4.53	0.38	1.37e-5	Renal cell carcinoma;
TGCT	cis	rs367615	0.679	rs11241021	chr5:108812090	T/G	cg17395555	chr5:108820864	NA	0.31	5.85	0.47	4.07e-8	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs11239930	0.517	rs4950354	chr1:146554223	T/C	cg00044796	chr1:146552390	NA	-0.34	-4.46	-0.37	1.84e-5	AIDS progression;
TGCT	trans	rs28735056	0.967	rs11662248	chr18:77619009	C/T	cg05926928	chr17:57297772	GDPD1	-0.7	-7.61	-0.56	5.93e-12	Schizophrenia;
TGCT	cis	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg03213289	chr20:61660250	NA	0.68	9.9	0.66	2.25e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9341808	0.754	rs3805885	chr6:80996751	C/G	cg08355045	chr6:80787529	NA	-0.26	-4.54	-0.38	1.34e-5	Sitting height ratio;
TGCT	cis	rs11578119	0.836	rs12130520	chr1:170539500	G/A	cg09767346	chr1:170501363	GORAB	0.58	4.61	0.38	9.77e-6	Male-pattern baldness;
TGCT	cis	rs4589502	0.512	rs4395023	chr15:67097208	G/A	cg12317470	chr15:67143691	NA	0.56	4.97	0.41	2.16e-6	Lung cancer (smoking interaction);
TGCT	cis	rs651907	0.557	rs2318090	chr3:101474933	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	4.68	0.39	7.44e-6	Colorectal cancer;
TGCT	cis	rs7017914	0.905	rs4434651	chr8:71947187	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.55	-5.27	-0.43	5.81e-7	Bone mineral density;
TGCT	cis	rs17539620	0.628	rs62432728	chr6:154829511	G/C	cg20019720	chr6:154832845	CNKSR3	0.48	4.45	0.37	1.88e-5	Lipoprotein (a) levels;
TGCT	cis	rs4824093	0.610	rs73443906	chr22:50274293	A/G	cg20569369	chr22:51173646	NA	0.28	4.69	0.39	7.23e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs7209700	0.862	rs2015729	chr17:45354493	G/A	cg21624342	chr17:45890973	OSBPL7	0.16	4.6	0.38	1.04e-5	IgG glycosylation;
TGCT	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2188554	0.785	rs213952	chr7:117203417	A/G	cg09181792	chr7:117119393	CFTR	0.48	4.47	0.37	1.74e-5	Esophageal adenocarcinoma;
TGCT	cis	rs909002	0.962	rs10798883	chr1:32140305	C/T	cg11573219	chr1:32083031	HCRTR1	-0.39	-4.72	-0.39	6.21e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg18876405	chr7:65276391	NA	-0.36	-5.41	-0.44	3.12e-7	Aortic root size;
TGCT	cis	rs2180341	0.781	rs7742161	chr6:127571676	T/C	cg27446573	chr6:127587934	RNF146	0.91	8.5	0.61	5.12e-14	Breast cancer;
TGCT	cis	rs3617	0.522	rs6773650	chr3:52897095	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	4.59	0.38	1.08e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7172809	0.561	rs74026923	chr15:77797927	C/T	cg22256960	chr15:77711686	NA	-0.5	-4.8	-0.4	4.45e-6	Glucose homeostasis traits;
TGCT	cis	rs1215050	0.704	rs783915	chr4:99023151	C/G	cg17366294	chr4:99064904	C4orf37	0.56	5.9	0.47	3.25e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs28595532	0.920	rs116098781	chr4:119771613	G/A	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs28595532	1.000	rs56225646	chr4:119651217	T/C	cg21605333	chr4:119757512	SEC24D	1.36	7.39	0.55	1.89e-11	Cannabis dependence symptom count;
TGCT	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg08280861	chr8:58055591	NA	0.37	5.04	0.41	1.59e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.69	-6.95	-0.53	1.82e-10	Prostate cancer;
TGCT	cis	rs8038465	0.622	rs17185525	chr15:73885539	T/C	cg15420318	chr15:73925796	NPTN	0.64	6.8	0.52	3.9e-10	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs3096299	0.900	rs744327	chr16:89439270	C/T	cg06640241	chr16:89574553	SPG7	0.69	6.7	0.52	6.6e-10	Multiple myeloma (IgH translocation);
TGCT	cis	rs4409675	0.619	rs12070173	chr1:28231955	G/C	cg23691781	chr1:28212827	C1orf38	0.25	5.38	0.43	3.59e-7	Corneal astigmatism;
TGCT	cis	rs6987853	0.830	rs12542919	chr8:42356035	C/T	cg20539142	chr8:42623718	CHRNA6	0.19	4.52	0.38	1.44e-5	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs9303401	0.659	rs56162835	chr17:56687315	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg12310025	chr6:25882481	NA	-0.62	-6.42	-0.5	2.63e-9	Blood metabolite levels;
TGCT	cis	rs2242116	0.727	rs4683298	chr3:46966387	C/G	cg02527881	chr3:46936655	PTH1R	-0.3	-5.59	-0.45	1.4e-7	Birth weight;
TGCT	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg11941060	chr3:133502564	NA	-0.26	-5.32	-0.43	4.74e-7	Iron status biomarkers;
TGCT	cis	rs4509693	1.000	rs4509693	chr10:102501571	C/T	cg24127310	chr10:102502104	NA	0.7	5.86	0.47	3.84e-8	Alzheimer's disease;
TGCT	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg24250549	chr1:154909240	PMVK	0.66	6.44	0.5	2.33e-9	Prostate cancer;
TGCT	cis	rs11080466	0.928	rs11659686	chr18:10898527	A/C	cg02393756	chr18:9912783	VAPA	-0.27	-4.74	-0.39	5.68e-6	Non-small cell lung cancer;
TGCT	cis	rs7552404	0.727	rs1159214	chr1:76317910	G/T	cg03433033	chr1:76189801	ACADM	-0.59	-6.06	-0.48	1.51e-8	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs13217239	0.621	rs12527231	chr6:27001288	G/A	cg02458000	chr6:26745757	NA	0.5	4.61	0.38	1e-5	Schizophrenia;
TGCT	cis	rs10089	1.000	rs17764954	chr5:127514436	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	7.83	0.58	1.83e-12	Ileal carcinoids;
TGCT	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg18110333	chr6:292329	DUSP22	-0.66	-7.25	-0.55	3.97e-11	Menopause (age at onset);
TGCT	cis	rs7824557	0.591	rs2043510	chr8:11225168	G/A	cg21775007	chr8:11205619	TDH	-0.74	-7.38	-0.55	2.02e-11	Retinal vascular caliber;
TGCT	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg10150615	chr22:24372951	LOC391322	0.76	6.37	0.5	3.44e-9	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs11722228	1.000	rs6823877	chr4:9921931	T/C	cg00071950	chr4:10020882	SLC2A9	-0.49	-5.04	-0.41	1.58e-6	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs4319547	0.915	rs1473553	chr12:122985057	G/T	cg23029597	chr12:123009494	RSRC2	-0.29	-4.87	-0.4	3.34e-6	Body mass index;
TGCT	cis	rs7296418	0.636	rs11057261	chr12:123797567	T/C	cg00376283	chr12:123451042	ABCB9	0.62	5.32	0.43	4.7e-7	Platelet count;
TGCT	cis	rs2180341	1.000	rs6903878	chr6:127638600	C/G	cg27446573	chr6:127587934	RNF146	1.12	10.11	0.67	6.87e-18	Breast cancer;
TGCT	cis	rs6598955	0.671	rs7551557	chr1:26596614	G/A	cg04990556	chr1:26633338	UBXN11	0.66	5.0	0.41	1.88e-6	Obesity-related traits;
TGCT	cis	rs11190604	0.943	rs9420792	chr10:102258439	C/T	cg23241863	chr10:102295624	HIF1AN	0.69	5.3	0.43	5.05e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7209700	0.821	rs4634	chr17:45369789	G/A	cg21624342	chr17:45890973	OSBPL7	0.19	5.09	0.42	1.32e-6	IgG glycosylation;
TGCT	cis	rs12049351	0.722	rs4148763	chr1:229654960	A/T	cg12130225	chr1:229698885	NA	0.35	4.46	0.37	1.85e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs78487399	0.808	rs75321787	chr2:43843071	G/C	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.69	4.73	0.39	6.01e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs28595532	0.702	rs72670250	chr4:119337134	T/C	cg11846333	chr4:119757529	SEC24D	0.72	4.51	0.38	1.48e-5	Cannabis dependence symptom count;
TGCT	cis	rs950169	0.580	rs17532346	chr15:85171495	A/C	cg17173187	chr15:85201210	NMB	0.61	6.95	0.53	1.84e-10	Schizophrenia;
TGCT	cis	rs7572733	0.534	rs700685	chr2:198715972	A/G	cg00792783	chr2:198669748	PLCL1	0.56	5.08	0.42	1.35e-6	Dermatomyositis;
TGCT	cis	rs3617	0.598	rs56214994	chr3:52878600	G/C	cg11645453	chr3:52864694	ITIH4	-0.29	-5.71	-0.46	7.84e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs35306767	0.903	rs12250937	chr10:900209	C/T	cg20503657	chr10:835505	NA	0.75	10.39	0.68	1.41e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs1971762	0.730	rs7963016	chr12:54072819	T/A	cg22997177	chr12:54070527	ATP5G2	-0.33	-4.47	-0.37	1.76e-5	Height;
TGCT	cis	rs28595532	0.920	rs114093638	chr4:119729819	T/C	cg21605333	chr4:119757512	SEC24D	1.66	8.33	0.6	1.28e-13	Cannabis dependence symptom count;
TGCT	cis	rs1670533	0.697	rs658846	chr4:1084723	G/C	cg19318889	chr4:1322082	MAEA	0.21	4.5	0.37	1.56e-5	Recombination rate (females);
TGCT	cis	rs10465746	0.967	rs4907191	chr1:84444165	A/G	cg10977910	chr1:84465055	TTLL7	-0.65	-6.57	-0.51	1.27e-9	Obesity-related traits;
TGCT	cis	rs13082711	0.554	rs6804440	chr3:27398150	C/T	cg02860705	chr3:27208620	NA	0.42	5.81	0.46	4.86e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs881375	0.967	rs1930778	chr9:123641369	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	5.63	0.45	1.14e-7	Rheumatoid arthritis;
TGCT	cis	rs1903068	0.657	rs73236104	chr4:55990954	G/C	cg16572876	chr4:56024045	NA	0.42	4.43	0.37	2.01e-5	Endometriosis;
TGCT	cis	rs763121	0.962	rs6001159	chr22:38966487	A/G	cg06022373	chr22:39101656	GTPBP1	0.76	7.34	0.55	2.45e-11	Menopause (age at onset);
TGCT	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg10295955	chr4:187884368	NA	-0.97	-14.7	-0.8	6.19e-29	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1865760	0.865	rs9467645	chr6:25955176	G/C	cg17042849	chr6:26104293	HIST1H4C	-0.52	-4.78	-0.39	4.88e-6	Height;
TGCT	cis	rs6964587	1.000	rs6956431	chr7:91750016	T/C	cg17063962	chr7:91808500	NA	0.87	9.18	0.64	1.18e-15	Breast cancer;
TGCT	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg00080972	chr5:178986291	RUFY1	-0.59	-7.58	-0.56	6.89e-12	Lung cancer;
TGCT	cis	rs17102423	0.661	rs11627540	chr14:65614892	C/T	cg11161011	chr14:65562177	MAX	-0.46	-5.83	-0.46	4.56e-8	Obesity-related traits;
TGCT	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg01802117	chr1:53393560	SCP2	0.43	5.12	0.42	1.14e-6	Monocyte count;
TGCT	cis	rs767764	0.592	rs17091944	chr8:13202480	G/A	cg23717764	chr8:12526205	NA	0.25	4.61	0.38	9.93e-6	Nose size;
TGCT	cis	rs6977940	0.512	rs11765726	chr7:2850878	A/G	cg19731401	chr7:2775893	GNA12	0.35	4.74	0.39	5.81e-6	White matter integrity;
TGCT	cis	rs72781680	0.821	rs72790304	chr2:24108557	G/A	cg08917208	chr2:24149416	ATAD2B	0.8	5.09	0.42	1.28e-6	Lymphocyte counts;
TGCT	cis	rs13242816	1.000	rs62468978	chr7:116127099	A/G	cg02799643	chr7:116139180	CAV2	-0.45	-5.46	-0.44	2.49e-7	P wave duration;
TGCT	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg03188948	chr7:1209495	NA	0.71	6.04	0.48	1.68e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9303401	0.614	rs68100606	chr17:56500898	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.58	6.12	0.48	1.15e-8	Cognitive test performance;
TGCT	cis	rs2982552	0.967	rs2982558	chr6:152056146	A/G	cg22157087	chr6:152012887	ESR1	0.18	4.59	0.38	1.08e-5	Bone properties (heel);
TGCT	cis	rs56104184	0.723	rs73063515	chr19:49407715	C/T	cg21252483	chr19:49399788	TULP2	-0.42	-5.89	-0.47	3.47e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs28595532	0.920	rs116331303	chr4:119754542	T/C	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs12497850	0.863	rs4974084	chr3:48939080	G/A	cg16497277	chr3:49208875	KLHDC8B	-0.55	-5.08	-0.41	1.36e-6	Parkinson's disease;
TGCT	cis	rs1867631	1.000	rs7546090	chr1:67083981	G/A	cg13052034	chr1:66999238	SGIP1	0.58	4.88	0.4	3.26e-6	Menopause (age at onset);
TGCT	cis	rs1005277	0.522	rs289648	chr10:37971837	T/C	cg25427524	chr10:38739819	LOC399744	-0.33	-6.48	-0.5	1.99e-9	Extrinsic epigenetic age acceleration;
TGCT	cis	rs28493229	0.708	rs111410535	chr19:41158441	C/T	cg11601297	chr19:41224147	ITPKC;ADCK4	0.57	5.15	0.42	9.78e-7	Kawasaki disease;
TGCT	cis	rs9457247	0.529	rs6907666	chr6:167523395	A/G	cg07741184	chr6:167504864	NA	-0.27	-5.52	-0.44	1.92e-7	Crohn's disease;
TGCT	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg16423285	chr20:60520624	NA	-0.69	-7.11	-0.54	7.98e-11	Body mass index;
TGCT	cis	rs9640161	0.830	rs3735165	chr7:150068371	T/C	cg21361702	chr7:150065534	REPIN1	0.5	4.6	0.38	1.01e-5	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg11062466	chr8:58055876	NA	0.44	4.62	0.38	9.46e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs3087591	0.919	rs7406870	chr17:29590617	G/A	cg24425628	chr17:29625626	OMG;NF1	0.42	6.14	0.48	1.04e-8	Hip circumference;
TGCT	cis	rs12893668	0.572	rs34000399	chr14:104101417	T/C	cg26031613	chr14:104095156	KLC1	-0.59	-5.08	-0.42	1.34e-6	Reticulocyte count;
TGCT	cis	rs858239	0.536	rs6961109	chr7:23252413	C/T	cg05602783	chr7:23145260	KLHL7	-0.72	-5.79	-0.46	5.36e-8	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs1008375	0.966	rs2315553	chr4:17627332	T/C	cg16339924	chr4:17578868	LAP3	0.71	5.77	0.46	6.04e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7666738	0.830	rs7662948	chr4:99020132	G/C	cg18180107	chr4:99064573	C4orf37	0.51	4.64	0.38	8.77e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.21	0.49	7.27e-9	Bipolar disorder;
TGCT	cis	rs9302065	0.565	rs2992908	chr13:95960600	G/A	cg26751094	chr13:95954534	ABCC4	-0.4	-6.74	-0.52	5.33e-10	Blood metabolite levels;
TGCT	cis	rs7113874	0.569	rs10160805	chr11:8600393	C/T	cg14521421	chr11:8862019	ST5	-0.28	-4.44	-0.37	1.96e-5	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg22618164	chr12:122356400	WDR66	0.62	6.43	0.5	2.53e-9	Mean corpuscular volume;
TGCT	cis	rs11031096	0.754	rs3817657	chr11:4142592	T/C	cg18678763	chr11:4115507	RRM1	-0.46	-5.73	-0.46	7.29e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs7267979	1.000	rs2257808	chr20:25266450	G/C	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2777491	0.915	rs9302109	chr15:41612180	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.75	-10.44	-0.68	1.07e-18	Ulcerative colitis;
TGCT	cis	rs4727443	0.866	rs13243708	chr7:99616291	T/C	cg13334819	chr7:99746414	C7orf59	0.56	4.71	0.39	6.63e-6	Interstitial lung disease;
TGCT	cis	rs7267979	0.844	rs2424703	chr20:25270124	G/A	cg16686733	chr20:25566563	NINL	0.52	4.93	0.4	2.61e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1146942	0.590	rs9531035	chr13:80824788	T/A	cg11599984	chr13:80914014	SPRY2	0.79	4.82	0.4	4.19e-6	Diastolic blood pressure;
TGCT	cis	rs7267979	1.000	rs4813562	chr20:25352588	G/A	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7570971	1.000	rs1375131	chr2:135954797	T/C	cg07169764	chr2:136633963	MCM6	0.53	4.77	0.39	5.03e-6	Blood metabolite levels;Body mass index;Cholesterol, total;
TGCT	cis	rs12479064	0.703	rs28382977	chr2:100018304	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.73	-6.44	-0.5	2.42e-9	Chronic sinus infection;
TGCT	cis	rs2535633	0.631	rs2245424	chr3:53003021	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.48	-4.45	-0.37	1.91e-5	Body mass index;
TGCT	cis	rs1691799	0.899	rs1168351	chr12:66752505	A/G	cg16791601	chr12:66731901	HELB	-0.29	-6.17	-0.48	8.77e-9	White blood cell count (basophil);
TGCT	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs367943	0.901	rs348951	chr5:112822017	G/C	cg12552261	chr5:112820674	MCC	-0.24	-4.91	-0.4	2.81e-6	Type 2 diabetes;
TGCT	cis	rs7586879	0.616	rs876186	chr2:25125585	C/T	cg15423357	chr2:25149977	NA	0.5	4.89	0.4	3.06e-6	Body mass index;
TGCT	cis	rs17253792	0.822	rs74720318	chr14:56099828	G/T	cg01858014	chr14:56050164	KTN1	-0.35	-4.5	-0.37	1.53e-5	Putamen volume;
TGCT	cis	rs1008375	1.000	rs10939744	chr4:17664473	G/T	cg10189774	chr4:17578691	LAP3	0.54	5.08	0.41	1.38e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg22433210	chr17:43662623	NA	1.0	7.13	0.54	7.26e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg05368731	chr17:41323189	NBR1	1.2	14.48	0.79	1.98e-28	Menopause (age at onset);
TGCT	cis	rs4722166	0.695	rs35779989	chr7:22800314	A/C	cg26061582	chr7:22766209	IL6	0.48	6.25	0.49	6.15e-9	Lung cancer;
TGCT	cis	rs9399137	0.507	rs11759077	chr6:135381351	A/G	cg24558204	chr6:135376177	HBS1L	0.47	4.73	0.39	5.98e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
TGCT	trans	rs7618501	0.521	rs6774354	chr3:49961780	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.83	8.58	0.61	3.34e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs4925386	0.681	rs2427296	chr20:60927475	G/A	cg24112000	chr20:60950667	NA	-0.37	-4.45	-0.37	1.9e-5	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs7923609	1.000	rs4400684	chr10:65012687	A/G	cg08743896	chr10:65200160	JMJD1C	-0.34	-4.54	-0.38	1.32e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg03213289	chr20:61660250	NA	0.68	9.9	0.66	2.25e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs17767294	0.708	rs72851158	chr6:28060485	G/C	cg08851530	chr6:28072375	NA	1.56	7.21	0.54	4.9e-11	Parkinson's disease;
TGCT	cis	rs11578119	0.866	rs11586686	chr1:170354846	C/T	cg09767346	chr1:170501363	GORAB	0.61	4.57	0.38	1.18e-5	Male-pattern baldness;
TGCT	cis	rs78487399	0.808	rs78481334	chr2:43796135	T/A	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.68	4.51	0.38	1.51e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs798554	0.704	rs798513	chr7:2782493	C/T	cg25467336	chr7:2757616	NA	-0.24	-4.62	-0.38	9.58e-6	Height;
TGCT	cis	rs7089973	0.668	rs61868024	chr10:116637939	A/G	cg03647239	chr10:116582469	FAM160B1	0.58	5.28	0.43	5.7e-7	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs4273100	0.541	rs973649	chr17:19292068	A/G	cg01534423	chr17:18965556	NA	-0.75	-7.83	-0.58	1.83e-12	Schizophrenia;
TGCT	cis	rs62103177	0.673	rs62096717	chr18:77616819	C/T	cg12964065	chr18:77638022	KCNG2	0.31	4.46	0.37	1.84e-5	Opioid sensitivity;
TGCT	cis	rs858239	0.539	rs4295546	chr7:23191021	C/T	cg05602783	chr7:23145260	KLHL7	-0.63	-4.98	-0.41	2.09e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs6547741	1.000	rs4666007	chr2:27856495	T/C	cg27432699	chr2:27873401	GPN1	0.18	4.63	0.38	9.05e-6	Oral cavity cancer;
TGCT	cis	rs748404	0.587	rs9920879	chr15:43639770	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	4.72	0.39	6.3e-6	Lung cancer;
TGCT	cis	rs6964587	1.000	rs7800582	chr7:91701346	G/A	cg17063962	chr7:91808500	NA	0.88	9.65	0.66	8.73e-17	Breast cancer;
TGCT	cis	rs2549003	0.870	rs10053046	chr5:131821558	A/G	cg02551604	chr5:131831745	NA	-0.89	-11.95	-0.73	2.33e-22	Asthma (sex interaction);
TGCT	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6089584	0.566	rs6061401	chr20:60607482	G/A	cg13770153	chr20:60521292	NA	-0.39	-4.67	-0.39	7.61e-6	Body mass index;
TGCT	cis	rs7845219	0.544	rs10956932	chr8:95948202	C/T	cg13393036	chr8:95962371	TP53INP1	0.45	5.31	0.43	4.91e-7	Type 2 diabetes;
TGCT	cis	rs7552404	0.690	rs7549863	chr1:76327923	T/C	cg03433033	chr1:76189801	ACADM	-0.59	-5.97	-0.47	2.34e-8	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs6835098	0.924	rs12639929	chr4:174156538	C/T	cg08422745	chr4:174089978	GALNT7	-0.9	-9.71	-0.66	6.56e-17	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs2455799	0.559	rs10514667	chr3:15915154	C/T	cg12172478	chr3:16357591	RFTN1	-0.36	-5.29	-0.43	5.33e-7	Mean platelet volume;
TGCT	cis	rs7666738	0.830	rs4699589	chr4:98973889	A/G	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1691799	0.867	rs6581677	chr12:66770379	C/G	cg16791601	chr12:66731901	HELB	-0.29	-6.02	-0.48	1.82e-8	White blood cell count (basophil);
TGCT	cis	rs698813	0.637	rs4952706	chr2:44500536	T/C	cg00619915	chr2:44497795	NA	-0.22	-4.91	-0.4	2.79e-6	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
TGCT	cis	rs1865760	0.566	rs1539183	chr6:26075051	G/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.78	7.49	0.56	1.15e-11	Height;
TGCT	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg04772025	chr11:68637568	NA	0.62	6.63	0.51	9.08e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs636291	0.517	rs11121579	chr1:10541824	G/C	cg17425144	chr1:10567563	PEX14	0.53	7.5	0.56	1.06e-11	Prostate cancer;
TGCT	cis	rs8068544	0.606	rs77681389	chr17:40154419	T/C	cg13092355	chr17:39992602	KLHL10;NT5C3L	-0.95	-4.55	-0.38	1.24e-5	Reticulocyte fraction of red cells;Reticulocyte count;
TGCT	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.46	-6.7	-0.52	6.44e-10	Alzheimer's disease;
TGCT	cis	rs2073300	1.000	rs6114138	chr20:23457350	G/A	cg09953122	chr20:23471693	CST8	-0.59	-4.71	-0.39	6.5e-6	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs2718812	0.792	rs1867504	chr3:133410661	C/T	cg08048268	chr3:133502702	NA	-0.38	-4.63	-0.38	9.04e-6	Iron status biomarkers;
TGCT	cis	rs11190604	1.000	rs2495741	chr10:102331795	A/G	cg16342193	chr10:102329863	NA	-0.43	-5.39	-0.44	3.42e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs589448	0.538	rs622656	chr12:69753595	C/T	cg11871910	chr12:69753446	YEATS4	0.61	5.37	0.43	3.67e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs1451375	0.785	rs10278338	chr7:50630270	C/T	cg18232548	chr7:50535776	DDC	0.44	6.85	0.52	3.08e-10	Malaria;
TGCT	cis	rs9394841	0.646	rs9471676	chr6:41815192	C/T	cg08135965	chr6:41755394	TOMM6	0.54	4.94	0.41	2.46e-6	Mean corpuscular hemoglobin;Red cell distribution width;
TGCT	cis	rs854765	0.624	rs1889018	chr17:17734740	G/A	cg09796270	chr17:17721594	SREBF1	-0.27	-5.19	-0.42	8.39e-7	Total body bone mineral density;
TGCT	cis	rs10423674	0.526	rs11085241	chr19:18828546	G/A	cg14292368	chr19:18793705	CRTC1	-0.53	-4.89	-0.4	3.1e-6	Menarche (age at onset);
TGCT	cis	rs7172809	0.573	rs13380152	chr15:77436386	A/T	cg22256960	chr15:77711686	NA	-0.48	-4.63	-0.38	9.17e-6	Glucose homeostasis traits;
TGCT	cis	rs10782582	0.609	rs5745469	chr1:76347394	G/A	cg03433033	chr1:76189801	ACADM	-0.5	-4.98	-0.41	2.11e-6	Daytime sleep phenotypes;
TGCT	cis	rs7949030	0.626	rs61296092	chr11:62320838	T/C	cg22862634	chr11:62369728	EML3;MTA2	0.71	9.06	0.63	2.33e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs4478858	0.684	rs11578407	chr1:31728543	A/G	cg00250761	chr1:31883323	NA	-0.27	-4.88	-0.4	3.13e-6	Alcohol dependence;
TGCT	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg01802117	chr1:53393560	SCP2	0.46	5.52	0.44	1.85e-7	Monocyte count;
TGCT	cis	rs2046867	0.862	rs62252360	chr3:72838551	C/T	cg25664220	chr3:72788482	NA	-0.52	-6.66	-0.51	7.86e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg11764359	chr7:65958608	NA	-0.6	-5.32	-0.43	4.68e-7	Aortic root size;
TGCT	cis	rs7917772	0.636	rs7894154	chr10:104524647	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.56	-4.59	-0.38	1.07e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	trans	rs28735056	0.846	rs12958903	chr18:77628996	A/G	cg05926928	chr17:57297772	GDPD1	0.65	6.74	0.52	5.44e-10	Schizophrenia;
TGCT	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	8.55	0.61	3.84e-14	Platelet count;
TGCT	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg18538332	chr22:24372958	LOC391322	-1.01	-12.94	-0.76	9.13e-25	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs919433	0.617	rs13018267	chr2:198545592	G/C	cg00792783	chr2:198669748	PLCL1	-0.55	-5.04	-0.41	1.62e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs12477438	0.765	rs7605218	chr2:99593080	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-4.62	-0.38	9.47e-6	Chronic sinus infection;
TGCT	cis	rs909674	0.775	rs4821896	chr22:39833437	T/C	cg11247378	chr22:39784982	NA	-0.73	-8.6	-0.61	3e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs2657888	0.965	rs2694909	chr12:56934928	T/C	cg23002907	chr12:56915593	RBMS2	0.44	6.15	0.48	9.65e-9	Adiponectin levels;
TGCT	cis	rs6752107	0.901	rs28454240	chr2:234145618	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.21	4.97	0.41	2.16e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs1375194	0.509	rs62150473	chr2:33822320	G/A	cg04131969	chr2:33951647	MYADML	-0.56	-4.86	-0.4	3.51e-6	Response to antidepressants in depression;
TGCT	cis	rs854765	0.647	rs9303144	chr17:17977355	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	7.32	0.55	2.74e-11	Total body bone mineral density;
TGCT	cis	rs1964356	0.524	rs7839585	chr8:8854235	C/G	cg06636001	chr8:8085503	FLJ10661	-0.68	-5.79	-0.46	5.53e-8	Mean corpuscular volume;
TGCT	cis	rs2115630	0.846	rs8024538	chr15:85368419	A/T	cg12863693	chr15:85201151	NMB	-0.38	-4.95	-0.41	2.32e-6	P wave terminal force;
TGCT	cis	rs2197308	0.667	rs11181073	chr12:37898543	A/G	cg26384229	chr12:38710491	ALG10B	0.85	7.82	0.57	1.94e-12	Morning vs. evening chronotype;
TGCT	trans	rs10802346	0.545	rs10802345	chr1:246372834	C/T	cg13514129	chr1:39547527	MACF1	0.84	7.49	0.56	1.12e-11	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs9660992	0.573	rs1172161	chr1:205206495	C/T	cg00857998	chr1:205179979	DSTYK	0.51	4.67	0.39	7.77e-6	Mean corpuscular volume;Mean platelet volume;
TGCT	cis	rs9372498	0.536	rs9489452	chr6:118910868	G/C	cg21191810	chr6:118973309	C6orf204	-0.39	-5.13	-0.42	1.07e-6	Diastolic blood pressure;
TGCT	cis	rs6740322	0.748	rs6755601	chr2:43483044	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.4	-6.3	-0.49	4.81e-9	Coronary artery disease;
TGCT	cis	rs76419734	0.558	rs73837046	chr4:106523319	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.81	4.53	0.38	1.35e-5	Post bronchodilator FEV1;
TGCT	cis	rs4824093	0.610	rs73441745	chr22:50237606	G/A	cg20569369	chr22:51173646	NA	0.27	4.54	0.38	1.3e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs208520	0.526	rs7775830	chr6:66755249	A/G	cg07460842	chr6:66804631	NA	1.03	13.88	0.78	5.09e-27	Exhaled nitric oxide output;
TGCT	cis	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg25427524	chr10:38739819	LOC399744	-0.41	-8.56	-0.61	3.6e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs1018836	0.923	rs11784529	chr8:91640956	C/A	cg16814680	chr8:91681699	NA	-0.9	-9.65	-0.65	8.98e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs13082711	0.953	rs13096477	chr3:27490194	T/C	cg02860705	chr3:27208620	NA	0.34	4.77	0.39	5.18e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs939658	0.728	rs12904789	chr15:79412589	G/A	cg17916960	chr15:79447300	NA	-0.46	-6.38	-0.5	3.24e-9	Refractive error;
TGCT	trans	rs561341	0.882	rs28649357	chr17:30367190	A/G	cg20587970	chr11:113659929	NA	-0.96	-12.59	-0.75	6.48e-24	Hip circumference adjusted for BMI;
TGCT	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg24675658	chr1:53192096	ZYG11B	-0.7	-7.91	-0.58	1.22e-12	Monocyte count;
TGCT	cis	rs2074585	0.647	rs2601172	chr15:90915666	A/G	cg22089800	chr15:90895588	ZNF774	0.82	9.2	0.64	1.07e-15	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
TGCT	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg01802117	chr1:53393560	SCP2	-0.44	-5.52	-0.44	1.86e-7	Monocyte count;
TGCT	cis	rs903263	0.601	rs953197	chr1:84541286	T/C	cg09664975	chr1:84543551	PRKACB	0.5	4.92	0.4	2.73e-6	Breast cancer (male);
TGCT	cis	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg18252515	chr7:66147081	NA	-1.22	-8.04	-0.59	6.02e-13	Diabetic kidney disease;
TGCT	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6545883	0.929	rs2421203	chr2:61669248	C/A	cg15711740	chr2:61764176	XPO1	-0.56	-5.12	-0.42	1.12e-6	Tuberculosis;
TGCT	cis	rs3806843	0.619	rs2569160	chr5:140028774	T/C	cg19875535	chr5:140030758	IK	-0.36	-6.34	-0.49	3.84e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs17401966	0.964	rs2027331	chr1:10276718	C/T	cg21474053	chr1:11182049	MTOR	0.18	4.43	0.37	2.01e-5	Hepatocellular carcinoma;
TGCT	cis	rs477895	0.838	rs1058735	chr11:64000410	C/G	cg04317338	chr11:64019027	PLCB3	0.81	6.93	0.53	2.07e-10	Mean platelet volume;
TGCT	cis	rs4819052	0.840	rs914217	chr21:46698299	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	5.47	0.44	2.34e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2228479	0.717	rs9282682	chr16:89805794	A/G	cg04287289	chr16:89883240	FANCA	0.74	4.47	0.37	1.74e-5	Skin colour saturation;
TGCT	cis	rs7089973	0.604	rs17663670	chr10:116596269	A/C	cg03647239	chr10:116582469	FAM160B1	-0.59	-5.74	-0.46	6.72e-8	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs9549260	0.755	rs4941987	chr13:41195992	T/C	cg21288729	chr13:41239152	FOXO1	1.0	10.23	0.68	3.52e-18	Red blood cell count;
TGCT	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg25036284	chr2:26402008	FAM59B	0.65	5.19	0.42	8.36e-7	Gut microbiome composition (summer);
TGCT	cis	rs6089829	0.888	rs6011559	chr20:61675620	C/T	cg02380750	chr20:61661411	NA	-0.33	-5.11	-0.42	1.2e-6	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs3008870	1.000	rs2985822	chr1:67404910	T/G	cg11518657	chr1:67396239	MIER1	0.54	4.68	0.39	7.24e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs9427116	0.502	rs9427104	chr1:154589232	C/T	cg17218026	chr1:154582156	ADAR	0.31	7.97	0.58	8.71e-13	Blood protein levels;
TGCT	cis	rs4722585	0.533	rs12334205	chr7:26202490	G/A	cg07876897	chr7:26191696	NFE2L3	0.4	5.57	0.45	1.53e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
TGCT	cis	rs1008375	0.966	rs10939736	chr4:17581617	T/A	cg10189774	chr4:17578691	LAP3	0.64	5.61	0.45	1.28e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7769051	1.000	rs9493438	chr6:133098349	T/C	cg07930552	chr6:133119739	C6orf192	0.93	5.0	0.41	1.87e-6	Type 2 diabetes nephropathy;
TGCT	cis	rs6988636	1.000	rs17323510	chr8:124186089	A/G	cg22384356	chr8:124195192	FAM83A	0.42	5.68	0.45	9.09e-8	Urinary uromodulin levels;
TGCT	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg13397359	chr6:42928475	GNMT	0.73	6.54	0.51	1.43e-9	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs11711311	0.712	rs10804510	chr3:113340700	T/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.68	-5.77	-0.46	5.99e-8	IgG glycosylation;
TGCT	cis	rs6088590	0.550	rs12624640	chr20:32952125	G/A	cg24642439	chr20:33292090	TP53INP2	0.6	5.1	0.42	1.23e-6	Coronary artery disease;
TGCT	cis	rs9393692	1.000	rs2393593	chr6:26285683	T/C	cg13736514	chr6:26305472	NA	-0.43	-6.28	-0.49	5.32e-9	Educational attainment;
TGCT	cis	rs11249608	0.548	rs2132672	chr5:178457742	A/C	cg21905437	chr5:178450457	ZNF879	0.44	4.62	0.38	9.35e-6	Pubertal anthropometrics;
TGCT	cis	rs7666738	0.716	rs11097615	chr4:99092773	T/C	cg17366294	chr4:99064904	C4orf37	0.71	6.95	0.53	1.86e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7267979	0.966	rs6083818	chr20:25346082	G/A	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg00684032	chr4:1343700	KIAA1530	0.23	4.95	0.41	2.36e-6	Obesity-related traits;
TGCT	cis	rs9436116	1	rs9436116	chr1:150454724	G/T	cg09579323	chr1:150459698	TARS2	0.52	4.58	0.38	1.12e-5	Morning vs. evening chronotype;
TGCT	cis	rs6693567	0.545	rs5011187	chr1:150422761	T/C	cg09579323	chr1:150459698	TARS2	0.52	4.62	0.38	9.55e-6	Migraine;
TGCT	cis	rs9393777	0.513	rs9368450	chr6:26652489	A/C	cg15659132	chr6:26577336	NA	-0.75	-5.25	-0.43	6.33e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs4911259	0.552	rs6058926	chr20:31465450	T/C	cg13636640	chr20:31349939	DNMT3B	-0.89	-9.83	-0.66	3.33e-17	Inflammatory bowel disease;
TGCT	cis	rs4975709	0.569	rs931509	chr5:1858821	A/T	cg14773178	chr5:1868261	NA	0.34	5.62	0.45	1.18e-7	Cardiovascular disease risk factors;
TGCT	cis	rs317865	0.867	rs73234637	chr4:16178866	C/T	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.75	4.86	0.4	3.46e-6	Kidney disease (early stage) in type 1 diabetes;
TGCT	cis	rs2153535	0.580	rs1319169	chr6:8464456	G/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs751728	0.931	rs2296746	chr6:33744711	C/T	cg13859433	chr6:33739653	LEMD2	-0.39	-7.13	-0.54	7.29e-11	Crohn's disease;
TGCT	cis	rs2956278	0.717	rs2956294	chr12:84678552	C/T	cg25678815	chr12:85673915	ALX1	-0.54	-4.83	-0.4	3.96e-6	Depressive symptoms;Depressive symptoms (multi-trait analysis);
TGCT	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg14159672	chr1:205819179	PM20D1	0.63	7.92	0.58	1.16e-12	Menarche (age at onset);
TGCT	cis	rs854765	0.583	rs11078406	chr17:17840823	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	7.6	0.56	6.32e-12	Total body bone mineral density;
TGCT	cis	rs739496	0.615	rs7978737	chr12:112196611	C/T	cg10833066	chr12:111807467	FAM109A	0.37	5.01	0.41	1.84e-6	Platelet count;
TGCT	cis	rs2404602	0.735	rs3765115	chr15:76673716	T/C	cg22467129	chr15:76604101	ETFA	0.46	4.68	0.39	7.38e-6	Blood metabolite levels;
TGCT	cis	rs9291683	0.510	rs4318649	chr4:10016815	T/C	cg00071950	chr4:10020882	SLC2A9	0.66	7.75	0.57	2.83e-12	Bone mineral density;
TGCT	cis	rs11690935	1.000	rs6757773	chr2:172549630	T/A	cg13550731	chr2:172543902	DYNC1I2	1.2	12.95	0.76	8.62e-25	Schizophrenia;
TGCT	cis	rs10206020	0.885	rs11899557	chr2:1576123	G/T	cg01028140	chr2:1542097	TPO	-0.28	-4.51	-0.38	1.47e-5	IgG glycosylation;
TGCT	cis	rs12682352	0.602	rs1473029	chr8:8668917	A/C	cg06636001	chr8:8085503	FLJ10661	0.6	5.07	0.41	1.43e-6	Neuroticism;
TGCT	cis	rs6840360	0.615	rs12647586	chr4:152607568	G/C	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.13	-0.48	1.07e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7246657	0.639	rs3112434	chr19:38198148	G/T	cg18154014	chr19:37997991	ZNF793	-0.72	-5.06	-0.41	1.48e-6	Coronary artery calcification;
TGCT	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	5.8	0.46	5.19e-8	Alzheimer's disease;
TGCT	cis	rs6586111	1.000	rs7915642	chr10:82377861	T/C	cg03086067	chr10:82368399	SH2D4B	-0.24	-4.71	-0.39	6.6e-6	Capecitabine sensitivity;
TGCT	cis	rs367615	0.506	rs2963021	chr5:108800365	C/T	cg17395555	chr5:108820864	NA	0.23	4.54	0.38	1.32e-5	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs6901250	0.587	rs339357	chr6:117198291	G/C	cg12892004	chr6:117198278	RFX6	-0.57	-6.94	-0.53	1.92e-10	C-reactive protein levels;
TGCT	cis	rs7666738	0.830	rs11944107	chr4:98931638	G/C	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7336332	0.598	rs9581850	chr13:28012265	A/G	cg22138327	chr13:27999177	GTF3A	0.81	6.35	0.5	3.66e-9	Weight;
TGCT	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg06675538	chr2:114033490	PAX8;LOC440839	-0.44	-4.88	-0.4	3.18e-6	Lymphocyte counts;
TGCT	cis	rs6952808	0.858	rs12671113	chr7:1965255	G/A	cg22963979	chr7:1858916	MAD1L1	-0.35	-5.43	-0.44	2.9e-7	Bipolar disorder and schizophrenia;
TGCT	trans	rs1499614	0.901	rs2178742	chr7:66197799	G/A	cg07424592	chr7:64974309	NA	1.31	7.65	0.57	4.73e-12	Gout;
TGCT	cis	rs10984561	0.881	rs10984554	chr9:122247659	A/G	cg14242995	chr9:122249943	NA	-0.75	-6.41	-0.5	2.7e-9	Pulmonary function decline;
TGCT	cis	rs2851682	0.706	rs2524299	chr11:61604782	A/T	cg20584555	chr11:61717780	BEST1	-0.32	-4.56	-0.38	1.21e-5	Gestational age at birth (child effect);Trans fatty acid levels;
TGCT	cis	rs3008870	1.000	rs3008874	chr1:67431365	A/T	cg11518657	chr1:67396239	MIER1	0.54	4.61	0.38	9.72e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs17001868	0.568	rs9611310	chr22:40733777	A/G	cg07138101	chr22:40742427	ADSL	0.73	5.38	0.44	3.57e-7	Mammographic density (dense area);
TGCT	cis	rs9914988	0.943	rs4795457	chr17:27087929	C/T	cg20469991	chr17:27169893	C17orf63	-0.76	-5.56	-0.45	1.55e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs1023500	1.000	rs1023498	chr22:42340569	C/T	cg04692870	chr22:42525206	CYP2D6	-0.33	-4.95	-0.41	2.37e-6	Schizophrenia;
TGCT	cis	rs6484504	0.576	rs158144	chr11:31211795	A/C	cg26647111	chr11:31128758	NA	-0.34	-4.62	-0.38	9.36e-6	Red blood cell count;
TGCT	cis	rs727505	1.000	rs68007199	chr7:124491307	T/C	cg23710748	chr7:124431027	NA	-0.26	-4.49	-0.37	1.6e-5	Lewy body disease;
TGCT	cis	rs35146811	0.735	rs2272344	chr7:99786819	C/T	cg13334819	chr7:99746414	C7orf59	-0.74	-6.31	-0.49	4.4e-9	Coronary artery disease;
TGCT	cis	rs7681440	0.804	rs1442135	chr4:90819093	C/T	cg26578617	chr4:90757533	SNCA	0.45	4.89	0.4	3.04e-6	Dementia with Lewy bodies;
TGCT	cis	rs3782455	1.000	rs76258123	chr12:114402449	G/C	cg23502203	chr12:113549970	RASAL1	-0.55	-4.92	-0.4	2.7e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg23708337	chr7:1209742	NA	0.56	5.1	0.42	1.25e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs4808199	0.895	rs6511036	chr19:19582651	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.72	5.15	0.42	9.94e-7	Nonalcoholic fatty liver disease;
TGCT	cis	rs2692947	0.537	rs72821437	chr2:96200799	C/T	cg23100626	chr2:96804247	ASTL	0.45	5.34	0.43	4.21e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs55823223	0.564	rs12103594	chr17:73855279	C/T	cg10935138	chr17:73851978	WBP2	0.82	7.3	0.55	3.03e-11	Psoriasis;
TGCT	cis	rs11030122	0.702	rs12281293	chr11:3963814	C/T	cg18678763	chr11:4115507	RRM1	-0.49	-6.14	-0.48	1.01e-8	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs17345786	1.000	rs3762729	chr3:101308874	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.87	9.09	0.63	2.03e-15	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg03517284	chr6:25882590	NA	-1.08	-13.96	-0.78	3.4e-27	Urate levels;
TGCT	cis	rs1941023	0.503	rs4939348	chr11:60135871	A/C	cg08716584	chr11:60157161	MS4A7	-0.31	-4.56	-0.38	1.21e-5	Congenital heart disease (maternal effect);
TGCT	cis	rs36051895	0.589	rs7869015	chr9:5199750	C/T	cg02405213	chr9:5042618	JAK2	-0.76	-10.36	-0.68	1.68e-18	Pediatric autoimmune diseases;
TGCT	cis	rs4654899	0.525	rs12035087	chr1:21471606	T/A	cg01072550	chr1:21505969	NA	0.57	9.48	0.65	2.23e-16	Superior frontal gyrus grey matter volume;
TGCT	cis	rs854765	0.616	rs8070624	chr17:17843396	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.65	6.36	0.5	3.58e-9	Total body bone mineral density;
TGCT	cis	rs526231	0.781	rs2569015	chr5:102608847	A/G	cg05225461	chr5:102596755	C5orf30	0.23	4.65	0.39	8.39e-6	Primary biliary cholangitis;
TGCT	cis	rs7659604	0.702	rs58649165	chr4:122693752	C/A	cg06713675	chr4:122721982	EXOSC9	-0.56	-7.58	-0.56	7.18e-12	Type 2 diabetes;
TGCT	cis	rs7104764	0.957	rs6598064	chr11:243557	G/A	cg18336825	chr11:236787	PSMD13;SIRT3	1.07	11.19	0.71	1.61e-20	Menarche (age at onset);
TGCT	cis	rs2172802	0.570	rs6820960	chr4:62518033	A/T	cg04118610	chr4:62707027	LPHN3	-0.39	-4.58	-0.38	1.12e-5	Partial epilepsies;
TGCT	cis	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg20637647	chr7:64974828	NA	0.94	5.17	0.42	9.06e-7	Diabetic kidney disease;
TGCT	cis	rs6750795	0.569	rs1797387	chr2:232414692	A/G	cg19187155	chr2:232395269	NMUR1	0.4	4.53	0.38	1.35e-5	Height;
TGCT	cis	rs7249142	0.562	rs1050544	chr19:19287901	A/G	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.47	-4.83	-0.4	3.93e-6	IgG glycosylation;
TGCT	cis	rs2760061	0.626	rs2527615	chr1:228119283	A/G	cg18477163	chr1:228402036	OBSCN	-0.32	-6.37	-0.5	3.31e-9	Diastolic blood pressure;
TGCT	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg16325326	chr1:53192061	ZYG11B	0.7	8.23	0.59	2.19e-13	Monocyte count;
TGCT	cis	rs832540	0.656	rs832567	chr5:56152416	C/A	cg24531977	chr5:56204891	C5orf35	-0.54	-5.34	-0.43	4.33e-7	Coronary artery disease;
TGCT	cis	rs12711979	0.765	rs13030772	chr2:3821280	T/C	cg17052675	chr2:3827356	NA	-0.4	-7.82	-0.57	2.02e-12	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs1371867	0.875	rs1612773	chr8:101337818	G/C	cg06636551	chr8:101224915	SPAG1	-0.44	-5.82	-0.46	4.61e-8	Atrioventricular conduction;
TGCT	cis	rs763014	0.932	rs7204439	chr16:661335	T/C	cg07343612	chr16:622815	PIGQ	-0.42	-8.41	-0.6	8.2e-14	Height;
TGCT	cis	rs2688608	0.592	rs3849967	chr10:75483366	C/T	cg15838173	chr10:75533400	FUT11	-0.31	-5.02	-0.41	1.73e-6	Inflammatory bowel disease;
TGCT	cis	rs7635838	0.892	rs9838141	chr3:11488639	C/T	cg00170343	chr3:11313890	ATG7	0.64	6.08	0.48	1.38e-8	HDL cholesterol;
TGCT	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg01570182	chr17:44337453	NA	1.08	9.36	0.64	4.36e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs4074961	0.604	rs4411102	chr1:38063424	C/G	cg11397548	chr1:38022522	DNALI1	0.46	5.08	0.42	1.33e-6	Axial length;
TGCT	cis	rs9911578	1.000	rs12940681	chr17:56933622	T/C	cg12560992	chr17:57184187	TRIM37	0.76	9.29	0.64	6.74e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs13082711	0.595	rs17317435	chr3:27339326	A/G	cg02860705	chr3:27208620	NA	0.46	6.95	0.53	1.8e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs7246657	1.000	rs6508710	chr19:37749886	A/G	cg24025825	chr19:37761650	NA	-0.25	-4.53	-0.38	1.34e-5	Coronary artery calcification;
TGCT	cis	rs13326165	0.760	rs11706108	chr3:52372366	T/C	cg27565382	chr3:53032988	SFMBT1	0.38	5.06	0.41	1.5e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs7752195	0.643	rs77951490	chr6:25236645	G/A	cg16898833	chr6:26189333	HIST1H4D	0.97	4.58	0.38	1.1e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs651907	0.557	rs11924013	chr3:101366698	G/A	cg12386194	chr3:101231763	SENP7	0.51	5.01	0.41	1.84e-6	Colorectal cancer;
TGCT	cis	rs877282	0.733	rs11253342	chr10:765072	A/G	cg17470449	chr10:769945	NA	0.37	5.59	0.45	1.37e-7	Uric acid levels;
TGCT	cis	rs611744	0.967	rs682007	chr8:109210326	G/C	cg21045802	chr8:109455806	TTC35	0.52	4.72	0.39	6.21e-6	Dupuytren's disease;
TGCT	cis	rs7666738	0.830	rs60391193	chr4:98933912	T/G	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9400467	0.537	rs17663278	chr6:111504881	A/C	cg15721981	chr6:111408429	SLC16A10	0.71	4.6	0.38	1.04e-5	Blood metabolite levels;Amino acid levels;
TGCT	cis	rs2413583	0.591	rs115263847	chr22:39729777	C/T	cg24399712	chr22:39784796	NA	0.82	4.48	0.37	1.69e-5	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg23248424	chr5:179741104	GFPT2	-0.38	-7.07	-0.54	9.78e-11	Height;
TGCT	cis	rs6121246	0.609	rs6060955	chr20:30385071	A/G	cg13852791	chr20:30311386	BCL2L1	0.8	7.55	0.56	8.29e-12	Mean corpuscular hemoglobin;
TGCT	cis	rs1538970	1.000	rs11211101	chr1:45849311	C/G	cg05343316	chr1:45956843	TESK2	0.65	5.12	0.42	1.12e-6	Platelet count;
TGCT	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.18	0.49	8.33e-9	Electroencephalogram traits;
TGCT	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg23758822	chr17:41437982	NA	0.72	6.81	0.52	3.83e-10	Menopause (age at onset);
TGCT	cis	rs881375	0.900	rs1008383	chr9:123683579	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.38	4.5	0.37	1.57e-5	Rheumatoid arthritis;
TGCT	cis	rs9467711	0.606	rs9379855	chr6:26364930	C/T	cg16898833	chr6:26189333	HIST1H4D	-1.09	-5.27	-0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2307449	0.731	rs62020354	chr15:89818342	C/T	cg24365117	chr15:89879190	POLG	0.33	4.6	0.38	1.01e-5	Menopause (age at onset);
TGCT	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg26119090	chr2:26468346	HADHA;HADHB	0.97	7.19	0.54	5.48e-11	Gut microbiome composition (summer);
TGCT	cis	rs2075371	0.863	rs1421479	chr7:133949345	T/G	cg11752832	chr7:134001865	SLC35B4	0.66	5.51	0.44	1.95e-7	Mean platelet volume;
TGCT	cis	rs11098499	0.535	rs10005542	chr4:120268302	T/C	cg09307838	chr4:120376055	NA	0.56	5.57	0.45	1.51e-7	Corneal astigmatism;
TGCT	cis	rs55882075	0.723	rs56227602	chr5:179179472	A/G	cg14593053	chr5:179126677	CANX	0.51	5.9	0.47	3.23e-8	Monocyte percentage of white cells;
TGCT	cis	rs11190604	1.000	rs2495750	chr10:102327708	A/G	cg23241863	chr10:102295624	HIF1AN	0.67	5.1	0.42	1.23e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg06112835	chr11:68658793	MRPL21	0.48	8.17	0.59	3.09e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7927592	0.763	rs2513277	chr11:68360887	T/G	cg16797656	chr11:68205561	LRP5	0.25	4.5	0.37	1.53e-5	Total body bone mineral density;
TGCT	cis	rs3784262	0.869	rs4646628	chr15:58255282	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.49	-7.64	-0.57	5.03e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg05872129	chr22:39784769	NA	-0.98	-10.82	-0.7	1.27e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs2235642	0.785	rs1057983	chr16:1660274	A/G	cg11375102	chr16:1583810	IFT140;TMEM204	-0.26	-4.52	-0.38	1.45e-5	Coronary artery disease;
TGCT	cis	rs4849975	0.510	rs28548099	chr2:3710938	G/A	cg21484315	chr2:2712669	NA	-0.42	-4.96	-0.41	2.26e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
TGCT	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg00814883	chr7:100076585	TSC22D4	-0.61	-5.66	-0.45	1.01e-7	Lung function (FEV1/FVC);
TGCT	cis	rs6430585	0.528	rs6430594	chr2:136719173	C/T	cg07169764	chr2:136633963	MCM6	-1.26	-12.74	-0.75	2.79e-24	Corneal structure;
TGCT	cis	rs1903068	0.853	rs28838369	chr4:56007249	A/G	cg09978860	chr4:56023921	NA	0.58	6.22	0.49	7.14e-9	Endometriosis;
TGCT	cis	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg18252515	chr7:66147081	NA	-1.31	-8.18	-0.59	2.87e-13	Diabetic kidney disease;
TGCT	cis	rs12048904	0.595	rs10493937	chr1:101342650	A/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.62	-6.1	-0.48	1.24e-8	Multiple sclerosis;
TGCT	cis	rs1488864	1.000	rs4758096	chr11:6348614	C/G	cg12755421	chr11:6342214	PRKCDBP	-0.56	-4.48	-0.37	1.7e-5	Smooth-surface caries;
TGCT	cis	rs3099143	1.000	rs2046415	chr15:77085253	A/G	cg21673338	chr15:77095150	SCAPER	-0.53	-5.22	-0.42	7.33e-7	Recalcitrant atopic dermatitis;
TGCT	cis	rs72843506	0.722	rs9897161	chr17:20034270	T/C	cg18979559	chr17:20280153	CCDC144C	-0.65	-4.87	-0.4	3.33e-6	Schizophrenia;
TGCT	cis	rs4689388	0.819	rs12649341	chr4:6294759	G/A	cg25554036	chr4:6271136	WFS1	0.54	7.37	0.55	2.11e-11	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs7113874	0.610	rs11041924	chr11:8463107	C/T	cg14521421	chr11:8862019	ST5	0.29	4.5	0.37	1.54e-5	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs986417	0.681	rs1254329	chr14:60912870	G/A	cg27398547	chr14:60952738	C14orf39	-1.39	-10.61	-0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg11764359	chr7:65958608	NA	-0.54	-4.86	-0.4	3.45e-6	Aortic root size;
TGCT	cis	rs7809950	0.817	rs58052742	chr7:107210003	A/G	cg23024343	chr7:107201750	COG5	0.46	6.42	0.5	2.67e-9	Coronary artery disease;
TGCT	cis	rs7010267	0.692	rs3102732	chr8:119960547	A/C	cg17171407	chr8:119960777	TNFRSF11B	0.28	5.1	0.42	1.25e-6	Total body bone mineral density (age 45-60);
TGCT	cis	rs12579753	0.879	rs7958566	chr12:82131478	A/T	cg21231944	chr12:82153410	PPFIA2	-0.36	-4.7	-0.39	6.72e-6	Resting heart rate;
TGCT	cis	rs1729951	0.575	rs2163896	chr3:136691177	G/A	cg12473912	chr3:136751656	NA	0.39	6.18	0.49	8.36e-9	Neuroticism;
TGCT	cis	rs9911578	1.000	rs4482353	chr17:56896834	A/G	cg05425664	chr17:57184151	TRIM37	-0.63	-6.26	-0.49	5.86e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs854765	0.547	rs9896837	chr17:17924868	A/G	cg04398451	chr17:18023971	MYO15A	-0.32	-5.12	-0.42	1.15e-6	Total body bone mineral density;
TGCT	cis	rs7208859	0.614	rs7216394	chr17:28825756	T/C	cg13385521	chr17:29058706	SUZ12P	-0.69	-4.57	-0.38	1.18e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs2760061	0.819	rs3094913	chr1:228206980	T/C	cg18477163	chr1:228402036	OBSCN	0.34	7.24	0.55	4.1e-11	Diastolic blood pressure;
TGCT	cis	rs7959452	0.590	rs56054057	chr12:69775972	C/T	cg11871910	chr12:69753446	YEATS4	0.82	8.95	0.63	4.38e-15	Blood protein levels;
TGCT	cis	rs7567389	0.719	rs4150404	chr2:128050000	A/G	cg09760422	chr2:128146352	NA	-0.34	-4.45	-0.37	1.87e-5	Self-rated health;
TGCT	cis	rs66561647	0.597	rs34390452	chr8:128940141	G/A	cg11792826	chr8:129160931	MIR1208	0.23	5.22	0.42	7.31e-7	Hemoglobin concentration;
TGCT	trans	rs4919669	0.719	rs17114803	chr10:104386934	A/G	cg24066601	chr6:26271455	HIST1H3G	0.66	6.81	0.52	3.7e-10	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs7412746	0.658	rs10305714	chr1:150800655	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.36	-4.6	-0.38	1.04e-5	Melanoma;
TGCT	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.05	8.69	0.62	1.83e-14	Platelet count;
TGCT	cis	rs9894429	0.634	rs9709130	chr17:79583948	C/T	cg21028142	chr17:79581711	NPLOC4	0.29	5.95	0.47	2.56e-8	Eye color traits;
TGCT	cis	rs3812831	0.695	rs423237	chr13:114930955	C/T	cg08824895	chr13:115047677	UPF3A	0.51	4.98	0.41	2.07e-6	Schizophrenia;
TGCT	cis	rs904251	0.523	rs2797794	chr6:37480604	T/C	cg08126542	chr6:37504118	NA	-0.46	-6.64	-0.51	8.96e-10	Cognitive performance;
TGCT	cis	rs9383153	1.000	rs9370888	chr6:16335544	A/G	cg18081338	chr6:17212963	NA	0.55	5.58	0.45	1.43e-7	Gambling;
TGCT	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg11764359	chr7:65958608	NA	-0.62	-5.53	-0.44	1.81e-7	Aortic root size;
TGCT	cis	rs6089584	0.627	rs55875402	chr20:60559925	G/A	cg06108461	chr20:60628389	TAF4	-0.4	-4.8	-0.4	4.4e-6	Body mass index;
TGCT	cis	rs4478858	0.735	rs7523438	chr1:31788313	C/T	cg00250761	chr1:31883323	NA	0.27	4.82	0.4	4.15e-6	Alcohol dependence;
TGCT	cis	rs7666738	0.830	rs13118892	chr4:98968497	T/C	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs80282103	0.717	rs41299206	chr10:1120236	T/C	cg18964960	chr10:1102726	WDR37	0.98	4.47	0.37	1.71e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs12477438	0.765	rs2167930	chr2:99592551	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-8.65	-0.61	2.22e-14	Chronic sinus infection;
TGCT	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg26338869	chr17:61819248	STRADA	-0.52	-4.86	-0.4	3.52e-6	Prudent dietary pattern;
TGCT	cis	rs6921919	0.583	rs7740351	chr6:28399412	A/C	cg18815343	chr6:28367644	ZSCAN12	-0.55	-5.16	-0.42	9.34e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs912057	0.671	rs1024246	chr6:6743505	A/T	cg06612196	chr6:6737390	NA	0.48	6.95	0.53	1.82e-10	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs7666738	0.830	rs1426664	chr4:98988264	A/C	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1371867	0.846	rs1788180	chr8:101333368	A/G	cg06636551	chr8:101224915	SPAG1	-0.42	-5.65	-0.45	1.06e-7	Atrioventricular conduction;
TGCT	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg21016266	chr12:122356598	WDR66	-0.52	-6.5	-0.5	1.75e-9	Mean corpuscular volume;
TGCT	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg18876405	chr7:65276391	NA	0.32	4.93	0.4	2.61e-6	Aortic root size;
TGCT	cis	rs79149102	0.579	rs6495137	chr15:75295541	G/A	cg09165964	chr15:75287851	SCAMP5	-1.04	-5.71	-0.46	7.93e-8	Lung cancer;
TGCT	cis	rs9487051	0.872	rs9487043	chr6:109610474	C/T	cg01475377	chr6:109611718	NA	-0.3	-4.68	-0.39	7.46e-6	Reticulocyte fraction of red cells;
TGCT	cis	rs10927875	0.632	rs4661667	chr1:16162731	C/T	cg21385522	chr1:16154831	NA	-1.0	-17.73	-0.85	8.56e-36	Dilated cardiomyopathy;
TGCT	cis	rs9916302	0.904	rs7223438	chr17:37521355	T/C	cg07936489	chr17:37558343	FBXL20	0.63	4.91	0.4	2.83e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7552404	0.824	rs1251077	chr1:76189745	C/G	cg10523679	chr1:76189770	ACADM	-0.98	-14.22	-0.79	8.25e-28	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2544527	0.819	rs2544523	chr2:15920323	T/C	cg26669897	chr2:15909070	NA	0.42	4.98	0.41	2.09e-6	Pulmonary function (smoking interaction);Pulmonary function;
TGCT	cis	rs2980439	0.557	rs2921056	chr8:8319182	T/C	cg08975724	chr8:8085496	FLJ10661	0.6	5.45	0.44	2.59e-7	Neuroticism;
TGCT	cis	rs67311347	1.000	rs9829800	chr3:40443927	T/C	cg17264618	chr3:40429014	ENTPD3	0.32	4.76	0.39	5.36e-6	Renal cell carcinoma;
TGCT	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg07507251	chr3:52567010	NT5DC2	0.51	7.63	0.57	5.48e-12	Electroencephalogram traits;
TGCT	cis	rs707040	0.961	rs10210987	chr2:155233967	G/A	cg18104148	chr2:154337490	NA	0.19	4.57	0.38	1.17e-5	Sudden cardiac arrest;
TGCT	cis	rs1215050	0.791	rs165237	chr4:98712029	T/C	cg17366294	chr4:99064904	C4orf37	0.52	5.61	0.45	1.27e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs11696501	0.688	rs6124727	chr20:44325623	T/C	cg11783356	chr20:44313418	WFDC10B	-0.33	-4.49	-0.37	1.6e-5	Brain structure;
TGCT	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg03303774	chr4:1407052	NA	0.31	4.96	0.41	2.25e-6	Obesity-related traits;
TGCT	cis	rs3905510	0.658	rs17150506	chr5:122943848	A/G	cg15125798	chr5:122621645	NA	0.55	4.94	0.41	2.5e-6	Total body bone mineral density;
TGCT	cis	rs6500602	0.826	rs9925719	chr16:4461861	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.45	5.75	0.46	6.66e-8	Schizophrenia;
TGCT	cis	rs1048238	0.846	rs945419	chr1:16344858	C/T	cg21385522	chr1:16154831	NA	0.43	4.52	0.38	1.43e-5	Systolic blood pressure;
TGCT	cis	rs904251	0.600	rs12211110	chr6:37466232	A/G	cg25019722	chr6:37503610	NA	-0.49	-7.08	-0.54	9.21e-11	Cognitive performance;
TGCT	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg11494091	chr17:61959527	GH2	0.43	7.47	0.56	1.23e-11	Height;
TGCT	cis	rs1729951	0.575	rs361248	chr3:136709066	G/A	cg21827317	chr3:136751795	NA	0.4	5.61	0.45	1.24e-7	Neuroticism;
TGCT	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg25767906	chr1:53392781	SCP2	0.49	5.64	0.45	1.09e-7	Monocyte count;
TGCT	cis	rs7843479	0.562	rs2127206	chr8:21786989	C/T	cg17168535	chr8:21777572	XPO7	0.92	9.4	0.65	3.52e-16	Mean corpuscular volume;
TGCT	cis	rs3125734	0.633	rs4979772	chr10:63967600	C/T	cg05499367	chr10:63213510	TMEM26	0.35	4.75	0.39	5.57e-6	Rheumatoid arthritis;
TGCT	cis	rs2832191	0.740	rs2832175	chr21:30475606	A/G	cg24692254	chr21:30365293	RNF160	-1.03	-12.06	-0.73	1.25e-22	Dental caries;
TGCT	cis	rs6988636	1.000	rs13260775	chr8:124190167	G/A	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs2594989	0.943	rs2606748	chr3:11373989	T/C	cg00170343	chr3:11313890	ATG7	0.67	4.99	0.41	2.04e-6	Circulating chemerin levels;
TGCT	cis	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg18252515	chr7:66147081	NA	-1.13	-6.81	-0.52	3.7e-10	Diabetic kidney disease;
TGCT	cis	rs2836974	0.830	rs2735309	chr21:40715313	C/T	cg06238570	chr21:40685208	BRWD1	0.67	5.84	0.46	4.4e-8	Cognitive function;
TGCT	cis	rs2455601	0.638	rs2568092	chr11:8987438	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.44	4.53	0.38	1.38e-5	Schizophrenia;
TGCT	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg11644478	chr21:40555479	PSMG1	-0.63	-5.93	-0.47	2.79e-8	Cognitive function;
TGCT	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	8.16	0.59	3.1400000000000003e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs12200560	0.505	rs4839849	chr6:97076673	T/C	cg06623918	chr6:96969491	KIAA0776	0.59	5.03	0.41	1.71e-6	Coronary heart disease;
TGCT	cis	rs7833790	0.724	rs6473310	chr8:82707981	A/G	cg17211192	chr8:82754475	SNX16	-0.93	-8.71	-0.62	1.62e-14	Diastolic blood pressure;
TGCT	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg16497277	chr3:49208875	KLHDC8B	-0.6	-5.62	-0.45	1.21e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs1008375	1.000	rs3815414	chr4:17606659	A/G	cg18681998	chr4:17616180	MED28	-0.97	-10.99	-0.7	5.01e-20	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2847297	1.000	rs2847297	chr18:12797694	A/G	cg23544223	chr18:12777786	NA	-0.4	-4.77	-0.39	5.12e-6	Rheumatoid arthritis;
TGCT	cis	rs9527	0.615	rs4919685	chr10:104587362	G/T	cg15744005	chr10:104629667	AS3MT	-0.46	-5.59	-0.45	1.38e-7	Arsenic metabolism;
TGCT	cis	rs62244186	0.659	rs6441844	chr3:44503579	C/T	cg02073558	chr3:44770973	ZNF501	0.61	5.79	0.46	5.34e-8	Depressive symptoms;
TGCT	cis	rs9916302	0.861	rs752314	chr17:37410700	C/T	cg15445000	chr17:37608096	MED1	0.33	4.84	0.4	3.8e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7772486	0.754	rs13214277	chr6:146136125	G/T	cg05347473	chr6:146136440	FBXO30	0.54	5.11	0.42	1.2e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10875746	0.903	rs11168370	chr12:48435280	A/C	cg20731937	chr12:48336164	NA	0.58	4.79	0.4	4.66e-6	Longevity (90 years and older);
TGCT	cis	rs6882046	0.513	rs639725	chr5:88001969	A/G	cg24804195	chr5:87968844	LOC645323	-0.59	-5.71	-0.46	7.96e-8	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs2249625	0.844	rs1015944	chr6:72925747	A/G	cg24401219	chr6:72892597	RIMS1	-0.56	-4.51	-0.38	1.47e-5	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
TGCT	cis	rs11734570	0.581	rs4461531	chr4:38603576	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.61	5.21	0.42	7.55e-7	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs2637266	1.000	rs1907317	chr10:78337849	C/A	cg18941641	chr10:78392320	NA	0.4	4.93	0.41	2.54e-6	Pulmonary function;
TGCT	cis	rs7714584	1.000	rs2345001	chr5:150266518	G/T	cg22134413	chr5:150180641	NA	0.78	6.12	0.48	1.16e-8	Crohn's disease;
TGCT	cis	rs9341808	0.718	rs9359408	chr6:80820132	T/G	cg08355045	chr6:80787529	NA	0.32	5.83	0.46	4.48e-8	Sitting height ratio;
TGCT	cis	rs9381040	0.610	rs2235679	chr6:41020577	G/T	cg03526776	chr6:41159608	TREML2	0.27	5.27	0.43	5.78e-7	Alzheimer's disease (late onset);
TGCT	cis	rs7772486	0.658	rs9403737	chr6:145962193	G/T	cg13319975	chr6:146136371	FBXO30	-0.53	-4.85	-0.4	3.6e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs231513	0.871	rs231522	chr17:41954602	A/G	cg26893861	chr17:41843967	DUSP3	-0.78	-5.58	-0.45	1.47e-7	Cognitive function;
TGCT	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg05368731	chr17:41323189	NBR1	1.21	14.63	0.8	8.89e-29	Menopause (age at onset);
TGCT	cis	rs28595532	0.920	rs56046676	chr4:119766733	A/G	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs9291683	0.507	rs3796837	chr4:10011321	C/G	cg00071950	chr4:10020882	SLC2A9	0.63	7.37	0.55	2.12e-11	Bone mineral density;
TGCT	cis	rs1865760	0.566	rs1971509	chr6:26085777	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.78	7.49	0.56	1.15e-11	Height;
TGCT	cis	rs832540	0.618	rs2548663	chr5:56172778	G/A	cg12311346	chr5:56204834	C5orf35	-0.49	-5.05	-0.41	1.55e-6	Coronary artery disease;
TGCT	cis	rs7659604	0.502	rs11098640	chr4:122675875	G/A	cg19748678	chr4:122722346	EXOSC9	-0.51	-5.0	-0.41	1.89e-6	Type 2 diabetes;
TGCT	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg03351412	chr1:154909251	PMVK	0.53	4.93	0.4	2.6e-6	Prostate cancer;
TGCT	cis	rs67311347	1.000	rs11720360	chr3:40448397	G/A	cg13683864	chr3:40499215	RPL14	-1.19	-13.15	-0.76	2.94e-25	Renal cell carcinoma;
TGCT	cis	rs4819052	0.580	rs419322	chr21:46551702	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.66	5.18	0.42	8.61e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9291683	0.588	rs3796829	chr4:10019138	C/G	cg11266682	chr4:10021025	SLC2A9	0.73	10.98	0.7	5.33e-20	Bone mineral density;
TGCT	cis	rs1865760	0.865	rs9467647	chr6:25957642	A/G	cg17042849	chr6:26104293	HIST1H4C	-0.52	-4.78	-0.39	4.88e-6	Height;
TGCT	cis	rs2549003	1.000	rs2070726	chr5:131821738	C/A	cg02551604	chr5:131831745	NA	-0.9	-12.1	-0.74	9.75e-23	Asthma (sex interaction);
TGCT	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg24829409	chr8:58192753	C8orf71	-0.54	-4.8	-0.4	4.42e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4253772	0.550	rs6007818	chr22:46703776	C/T	cg24881330	chr22:46731750	TRMU	1.03	5.38	0.43	3.61e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs9814567	1.000	rs2373865	chr3:134291556	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.95	8.76	0.62	1.21e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs270601	0.837	rs367805	chr5:131701279	T/C	cg16647868	chr5:131706066	SLC22A5	0.31	4.48	0.37	1.67e-5	Acylcarnitine levels;
TGCT	cis	rs17345786	1.000	rs7641261	chr3:101279006	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	4.48	0.37	1.65e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs727505	0.954	rs1568883	chr7:124710761	G/A	cg23710748	chr7:124431027	NA	-0.27	-4.59	-0.38	1.07e-5	Lewy body disease;
TGCT	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg21724239	chr8:58056113	NA	0.42	5.04	0.41	1.59e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs274567	0.501	rs272855	chr5:131687175	C/T	cg24060327	chr5:131705240	SLC22A5	-0.75	-8.12	-0.59	3.87e-13	Blood metabolite levels;
TGCT	cis	rs250677	0.522	rs55732303	chr5:148392538	C/T	cg18129178	chr5:148520854	ABLIM3	-0.35	-4.58	-0.38	1.12e-5	Breast cancer;
TGCT	cis	rs138491296	1	rs138491296	chr17:27961561	GATTATT/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.93	-9.13	-0.63	1.58e-15	White blood cell count;
TGCT	cis	rs6754311	0.608	rs3739020	chr2:136602491	T/G	cg07169764	chr2:136633963	MCM6	0.77	7.06	0.54	1.06e-10	Mosquito bite size;
TGCT	cis	rs9807989	0.839	rs4988955	chr2:102967928	A/G	cg09003973	chr2:102972529	NA	0.59	5.21	0.42	7.58e-7	Asthma;
TGCT	cis	rs2945232	1	rs2945232	chr8:8098038	T/C	cg08975724	chr8:8085496	FLJ10661	0.63	5.81	0.46	4.85e-8	Schizophrenia;
TGCT	cis	rs2777491	1.000	rs7167729	chr15:41721042	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.75	-11.01	-0.7	4.47e-20	Ulcerative colitis;
TGCT	cis	rs797680	0.856	rs10874764	chr1:93661342	C/A	cg17826107	chr1:92977322	EVI5	-0.24	-5.23	-0.43	6.89e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg20203395	chr5:56204925	C5orf35	-0.54	-4.86	-0.4	3.42e-6	Coronary artery disease;
TGCT	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg23172400	chr8:95962367	TP53INP1	-0.39	-6.52	-0.51	1.59e-9	Type 2 diabetes;
TGCT	cis	rs12762955	0.561	rs11253567	chr10:1054444	A/G	cg18964960	chr10:1102726	WDR37	0.67	5.84	0.46	4.3e-8	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs6964587	0.626	rs4729014	chr7:91550707	A/G	cg17063962	chr7:91808500	NA	-0.76	-7.25	-0.55	3.94e-11	Breast cancer;
TGCT	cis	rs66573146	0.901	rs55659111	chr4:7012338	G/T	cg05069807	chr4:6945702	TBC1D14	0.41	5.42	0.44	3.05e-7	Granulocyte percentage of myeloid white cells;
TGCT	trans	rs2970818	0.831	rs7304949	chr12:4609625	A/G	cg11755803	chr12:129000542	TMEM132C	0.52	6.84	0.52	3.22e-10	Phosphorus levels;
TGCT	cis	rs6988636	0.584	rs75096144	chr8:124131225	C/T	cg27053337	chr8:124217698	FAM83A	0.54	4.69	0.39	7.01e-6	Urinary uromodulin levels;
TGCT	cis	rs6591182	0.504	rs7130955	chr11:65372580	C/T	cg17480646	chr11:65405466	SIPA1	-0.52	-6.73	-0.52	5.48e-10	Non-alcoholic fatty liver disease histology (lobular);
TGCT	cis	rs651907	0.557	rs3094296	chr3:101400167	A/G	cg12386194	chr3:101231763	SENP7	0.52	4.92	0.4	2.68e-6	Colorectal cancer;
TGCT	cis	rs7819412	0.642	rs11250117	chr8:10972740	C/A	cg21775007	chr8:11205619	TDH	-0.49	-4.77	-0.39	5e-6	Triglycerides;
TGCT	cis	rs2658782	1.000	rs2605582	chr11:93163799	C/T	cg18152523	chr11:93063302	CCDC67	-0.65	-5.27	-0.43	5.74e-7	Pulmonary function decline;
TGCT	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	0.45	6.71	0.52	6.15e-10	Alzheimer's disease;
TGCT	trans	rs28735056	1.000	rs4798923	chr18:77629373	G/A	cg05926928	chr17:57297772	GDPD1	-0.71	-7.6	-0.56	6.2e-12	Schizophrenia;
TGCT	cis	rs11105298	0.891	rs10858889	chr12:89902604	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.7	-5.02	-0.41	1.79e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs9611565	0.918	rs4822024	chr22:41757647	G/A	cg06634786	chr22:41940651	POLR3H	-0.89	-8.27	-0.6	1.71e-13	Vitiligo;
TGCT	cis	rs1903068	0.785	rs12331538	chr4:55998086	A/C	cg01777861	chr4:56023843	NA	0.55	6.37	0.5	3.34e-9	Endometriosis;
TGCT	cis	rs514406	0.893	rs1242317	chr1:53414766	T/C	cg16325326	chr1:53192061	ZYG11B	0.59	6.94	0.53	1.89e-10	Monocyte count;
TGCT	cis	rs2346177	1.000	rs11125074	chr2:46655260	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.45	-5.1	-0.42	1.24e-6	HDL cholesterol;
TGCT	cis	rs7786808	0.552	rs2878456	chr7:158182129	A/T	cg01191920	chr7:158217561	PTPRN2	-0.34	-5.06	-0.41	1.45e-6	Obesity-related traits;
TGCT	cis	rs1372520	0.684	rs2619347	chr4:90745770	G/A	cg14346243	chr4:90757452	SNCA	-0.67	-5.64	-0.45	1.09e-7	Neuroticism;
TGCT	cis	rs7511006	1.000	rs5771109	chr22:50678571	T/C	cg08875078	chr22:50639485	SELO	0.52	5.11	0.42	1.2e-6	Obesity-related traits;
TGCT	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg01802117	chr1:53393560	SCP2	-0.42	-4.86	-0.4	3.45e-6	Monocyte count;
TGCT	cis	rs919433	0.617	rs700643	chr2:198601370	A/G	cg00792783	chr2:198669748	PLCL1	0.55	4.96	0.41	2.29e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs7100689	0.646	rs7894762	chr10:82086779	C/G	cg01528321	chr10:82214614	TSPAN14	0.75	7.49	0.56	1.15e-11	Post bronchodilator FEV1;
TGCT	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg23708337	chr7:1209742	NA	0.6	5.56	0.45	1.58e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg03188948	chr7:1209495	NA	0.43	5.67	0.45	9.5e-8	Longevity;Endometriosis;
TGCT	cis	rs6570726	0.935	rs400968	chr6:145819718	A/G	cg23711669	chr6:146136114	FBXO30	0.69	6.22	0.49	6.89e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9467773	0.525	rs1535274	chr6:26520747	A/C	cg05738196	chr6:26577821	NA	0.75	9.2	0.64	1.09e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs12464483	0.524	rs1348898	chr2:30888026	C/A	cg17749961	chr2:30669863	LCLAT1	0.59	4.58	0.38	1.12e-5	Pre-treatment pain in head and neck squamous cell carcinoma;
TGCT	cis	rs10791097	0.592	rs7116068	chr11:130732739	A/C	cg05962950	chr11:130786565	SNX19	-0.9	-11.73	-0.73	7.96e-22	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs807669	0.742	rs1206544	chr22:19215039	C/T	cg02655711	chr22:19163373	SLC25A1	0.33	7.25	0.55	3.9e-11	Metabolite levels;
TGCT	cis	rs12134245	0.719	rs61798831	chr1:91996588	C/T	cg25838465	chr1:92012736	NA	-0.41	-6.57	-0.51	1.23e-9	Breast cancer;
TGCT	cis	rs12510870	0.599	rs10029673	chr4:74451917	G/A	cg05868023	chr4:75230803	EREG	-0.55	-4.74	-0.39	5.71e-6	Iris color (b* coordinate);
TGCT	cis	rs2075371	0.897	rs10488428	chr7:133997560	C/T	cg11752832	chr7:134001865	SLC35B4	0.67	5.96	0.47	2.46e-8	Mean platelet volume;
TGCT	cis	rs7666738	0.924	rs62318940	chr4:99064768	C/T	cg05340658	chr4:99064831	C4orf37	0.49	4.75	0.39	5.56e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7959452	0.868	rs10878967	chr12:69740869	T/C	cg11871910	chr12:69753446	YEATS4	0.76	8.31	0.6	1.44e-13	Blood protein levels;
TGCT	cis	rs7647973	1.000	rs6783003	chr3:49524778	G/C	cg07636037	chr3:49044803	WDR6	-0.73	-5.87	-0.47	3.65e-8	Menarche (age at onset);
TGCT	cis	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg16624210	chr5:671434	TPPP	0.4	4.52	0.38	1.44e-5	Obesity-related traits;
TGCT	cis	rs2486288	0.656	rs2413774	chr15:45549423	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.46	-5.59	-0.45	1.38e-7	Glomerular filtration rate;
TGCT	trans	rs17685	0.753	rs2108274	chr7:75781636	C/A	cg19862616	chr7:65841803	NCRNA00174	0.51	8.59	0.61	3.07e-14	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs4561483	0.549	rs154149	chr16:11956118	T/A	cg08843971	chr16:11963173	GSPT1	-0.25	-4.55	-0.38	1.24e-5	Testicular germ cell tumor;
TGCT	cis	rs4908768	0.512	rs4908784	chr1:8900568	C/T	cg13202082	chr1:9882851	CLSTN1	0.34	4.5	0.37	1.54e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
TGCT	cis	rs7017914	0.905	rs2639896	chr8:71920783	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.55	-5.1	-0.42	1.24e-6	Bone mineral density;
TGCT	cis	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg07424592	chr7:64974309	NA	1.27	7.84	0.58	1.8e-12	Diabetic kidney disease;
TGCT	cis	rs2115630	0.641	rs11073613	chr15:85185893	G/A	cg12501888	chr15:85177176	SCAND2	-0.47	-4.48	-0.37	1.69e-5	P wave terminal force;
TGCT	cis	rs6964587	0.869	rs10242792	chr7:91492103	A/C	cg17063962	chr7:91808500	NA	0.87	9.22	0.64	9.9e-16	Breast cancer;
TGCT	cis	rs4372836	0.681	rs4477866	chr2:29009089	C/A	cg09522027	chr2:28974177	PPP1CB	-0.64	-6.42	-0.5	2.68e-9	Body mass index;
TGCT	trans	rs34421088	0.559	rs12386974	chr8:11400628	C/G	cg15556689	chr8:8085844	FLJ10661	0.78	7.88	0.58	1.46e-12	Neuroticism;
TGCT	cis	rs76878669	0.606	rs2282531	chr11:66099494	C/T	cg18002602	chr11:66138449	SLC29A2	-0.52	-6.47	-0.5	2.06e-9	Educational attainment (years of education);
TGCT	cis	rs9357506	1.000	rs9296492	chr6:46315573	A/G	cg21115430	chr6:46460003	NA	0.25	5.1	0.42	1.26e-6	Body mass index;
TGCT	cis	rs79387448	0.655	rs77763678	chr2:102916749	G/A	cg09003973	chr2:102972529	NA	1.34	8.26	0.6	1.89e-13	Gut microbiota (bacterial taxa);
TGCT	cis	rs7666738	0.830	rs6832209	chr4:98994120	A/G	cg05340658	chr4:99064831	C4orf37	0.49	5.6	0.45	1.31e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg10802521	chr3:52805072	NEK4	-0.72	-9.1	-0.63	1.91e-15	Bipolar disorder;
TGCT	cis	rs7726839	0.540	rs58599998	chr5:596087	A/G	cg20362242	chr5:692897	TPPP	0.53	4.56	0.38	1.22e-5	Obesity-related traits;
TGCT	cis	rs12142240	0.660	rs112560929	chr1:46822297	A/G	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	trans	rs1814175	0.817	rs7950856	chr11:49976394	C/T	cg15704280	chr7:45808275	SEPT13	-0.73	-8.48	-0.61	5.58e-14	Height;
TGCT	cis	rs477895	0.838	rs7111278	chr11:64016284	G/A	cg04317338	chr11:64019027	PLCB3	0.81	6.9	0.53	2.35e-10	Mean platelet volume;
TGCT	cis	rs765787	0.530	rs13329228	chr15:45533017	C/T	cg24006582	chr15:45444508	DUOX1	-0.24	-5.28	-0.43	5.51e-7	Uric acid levels;
TGCT	cis	rs7809950	1.000	rs2520268	chr7:107191161	T/A	cg23024343	chr7:107201750	COG5	-0.35	-5.36	-0.43	3.99e-7	Coronary artery disease;
TGCT	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs35883536	0.967	rs1981134	chr1:101111205	G/T	cg06223162	chr1:101003688	GPR88	-0.28	-4.56	-0.38	1.22e-5	Monocyte count;
TGCT	cis	rs2067615	0.579	rs66716938	chr12:107196825	T/C	cg15890332	chr12:107067104	RFX4	0.28	5.61	0.45	1.27e-7	Heart rate;
TGCT	cis	rs10114408	0.959	rs10992960	chr9:96653178	A/G	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs6840360	0.615	rs10021407	chr4:152465002	A/G	cg17479576	chr4:152424074	FAM160A1	-0.72	-7.98	-0.58	8.25e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs10779751	1.000	rs11121710	chr1:11313244	T/C	cg08854313	chr1:11322531	MTOR	0.95	8.63	0.61	2.54e-14	Body mass index;
TGCT	cis	rs4689388	0.856	rs10016157	chr4:6294414	T/C	cg14416269	chr4:6271139	WFS1	0.37	4.9	0.4	2.95e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs7647973	1.000	rs74471041	chr3:49542543	T/G	cg05785598	chr3:49045655	WDR6	-0.38	-4.5	-0.37	1.57e-5	Menarche (age at onset);
TGCT	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg06028808	chr11:68637592	NA	0.5	6.59	0.51	1.12e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs11718455	0.960	rs34019365	chr3:44004735	G/A	cg08738300	chr3:44038990	NA	0.85	6.34	0.49	3.94e-9	Coronary artery disease;
TGCT	cis	rs9916302	0.800	rs9892675	chr17:37549200	C/T	cg15445000	chr17:37608096	MED1	-0.34	-4.84	-0.4	3.75e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs76878669	0.561	rs2279862	chr11:66135179	C/T	cg18002602	chr11:66138449	SLC29A2	0.53	6.49	0.5	1.89e-9	Educational attainment (years of education);
TGCT	cis	rs6598955	0.670	rs7531518	chr1:26539749	T/C	cg04990556	chr1:26633338	UBXN11	-0.89	-11.24	-0.71	1.2e-20	Obesity-related traits;
TGCT	cis	rs1577917	0.545	rs9344548	chr6:86487337	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.6	4.94	0.41	2.47e-6	Response to antipsychotic treatment;
TGCT	cis	rs9467773	0.572	rs62394558	chr6:26604650	G/A	cg26531700	chr6:26746687	NA	0.66	6.42	0.5	2.68e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7095607	0.606	rs10998015	chr10:69959624	A/G	cg18986048	chr10:69913749	MYPN	0.57	5.92	0.47	2.89e-8	Lung function (FVC);
TGCT	cis	rs4660261	0.526	rs2040950	chr1:44315113	G/C	cg12908607	chr1:44402522	ARTN	-0.64	-7.66	-0.57	4.69e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs3617	0.573	rs9860296	chr3:52913781	A/G	cg10802521	chr3:52805072	NEK4	-0.56	-6.4	-0.5	2.87e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs131777	0.708	rs131749	chr22:51024624	C/T	cg25309564	chr22:51001381	C22orf41	-0.53	-4.96	-0.41	2.23e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs7267979	0.873	rs6083853	chr20:25404541	T/C	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs611744	0.967	rs688746	chr8:109225725	G/A	cg21045802	chr8:109455806	TTC35	0.52	4.72	0.39	6.21e-6	Dupuytren's disease;
TGCT	cis	rs9467711	1.000	rs6923139	chr6:26313348	C/T	cg16898833	chr6:26189333	HIST1H4D	1.04	5.51	0.44	1.97e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs938554	0.558	rs4697701	chr4:9946095	C/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-5.03	-0.41	1.67e-6	Blood metabolite levels;
TGCT	cis	rs903263	0.965	rs11163905	chr1:84594399	C/T	cg09664975	chr1:84543551	PRKACB	0.48	4.56	0.38	1.19e-5	Breast cancer (male);
TGCT	cis	rs478607	0.764	rs2666558	chr11:64481579	G/A	cg19395706	chr11:64412079	NRXN2	-0.47	-5.02	-0.41	1.73e-6	Urate levels;
TGCT	cis	rs11673344	0.523	rs8110158	chr19:37554393	C/A	cg08039142	chr19:36980659	ZNF566	0.5	4.64	0.38	8.63e-6	Obesity-related traits;
TGCT	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.06	-9.57	-0.65	1.41e-16	Platelet count;
TGCT	cis	rs1371867	0.846	rs2919469	chr8:101233896	C/T	cg06002616	chr8:101225028	SPAG1	-0.54	-6.46	-0.5	2.15e-9	Atrioventricular conduction;
TGCT	cis	rs7666738	0.830	rs13118945	chr4:98968586	T/G	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg21724239	chr8:58056113	NA	0.41	4.87	0.4	3.33e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs938554	0.513	rs3775948	chr4:9995182	G/C	cg11266682	chr4:10021025	SLC2A9	0.54	4.8	0.4	4.55e-6	Blood metabolite levels;
TGCT	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg13699009	chr12:122356056	WDR66	0.29	5.72	0.46	7.44e-8	Mean corpuscular volume;
TGCT	cis	rs514406	0.584	rs7524702	chr1:53197830	G/A	cg22166914	chr1:53195759	ZYG11B	-0.5	-9.4	-0.65	3.56e-16	Monocyte count;
TGCT	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg00149659	chr3:10157352	C3orf10	0.91	5.89	0.47	3.32e-8	Alzheimer's disease;
TGCT	cis	rs55794721	0.509	rs7554255	chr1:25778106	C/T	cg09222892	chr1:25734099	RHCE	-0.41	-6.8	-0.52	3.99e-10	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs7909074	1.000	rs1408814	chr10:45399088	A/G	cg04218760	chr10:45406644	TMEM72	-0.27	-5.38	-0.44	3.57e-7	Mean corpuscular volume;
TGCT	cis	rs7267979	0.903	rs2500400	chr20:25354705	A/G	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6141769	0.518	rs6058834	chr20:31316862	C/T	cg13636640	chr20:31349939	DNMT3B	-0.52	-4.54	-0.38	1.34e-5	Subjective well-being;
TGCT	trans	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg15556689	chr8:8085844	FLJ10661	-0.81	-8.68	-0.61	1.93e-14	Neuroticism;
TGCT	cis	rs12579753	0.827	rs7311917	chr12:82187551	G/T	cg07988820	chr12:82153109	PPFIA2	-0.59	-6.19	-0.49	7.93e-9	Resting heart rate;
TGCT	cis	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg20637647	chr7:64974828	NA	1.0	5.59	0.45	1.4e-7	Diabetic kidney disease;
TGCT	cis	rs4906332	1.000	rs3783397	chr14:103947289	A/G	cg26031613	chr14:104095156	KLC1	-0.53	-4.86	-0.4	3.42e-6	Coronary artery disease;
TGCT	cis	rs9303401	0.659	rs12150264	chr17:56939927	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs12477438	0.798	rs6704766	chr2:99642818	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-6.1	-0.48	1.22e-8	Chronic sinus infection;
TGCT	cis	rs1568889	0.838	rs11030230	chr11:28174631	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.93	11.12	0.71	2.31e-20	Bipolar disorder;
TGCT	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg27535305	chr1:53392650	SCP2	-0.27	-5.29	-0.43	5.24e-7	Monocyte count;
TGCT	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	6.39	0.5	3.08e-9	Alzheimer's disease;
TGCT	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg18876405	chr7:65276391	NA	-0.36	-5.41	-0.44	3.12e-7	Aortic root size;
TGCT	cis	rs909674	0.818	rs7364148	chr22:39842165	T/C	cg11247378	chr22:39784982	NA	-0.71	-8.33	-0.6	1.25e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg09359103	chr1:154839909	KCNN3	0.66	12.26	0.74	3.95e-23	Prostate cancer;
TGCT	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg11764359	chr7:65958608	NA	-0.59	-5.2	-0.42	8.12e-7	Aortic root size;
TGCT	cis	rs11264213	0.901	rs72661641	chr1:36448130	A/G	cg27506609	chr1:36549197	TEKT2	0.41	4.61	0.38	9.88e-6	Schizophrenia;
TGCT	cis	rs1903068	0.925	rs1551643	chr4:55994226	T/A	cg09978860	chr4:56023921	NA	0.58	6.38	0.5	3.16e-9	Endometriosis;
TGCT	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg12310025	chr6:25882481	NA	-0.51	-5.25	-0.43	6.43e-7	Height;
TGCT	cis	rs4727027	0.866	rs3927307	chr7:148774869	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	4.99	0.41	2.02e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs896854	0.654	rs13281625	chr8:95972738	T/C	cg09323728	chr8:95962352	TP53INP1	-0.52	-6.6	-0.51	1.07e-9	Type 2 diabetes;
TGCT	cis	rs77972916	0.536	rs7589361	chr2:43589328	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.38	-6.09	-0.48	1.3e-8	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	5.44	0.44	2.76e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9341808	0.718	rs2179842	chr6:80979053	T/C	cg08355045	chr6:80787529	NA	0.29	4.99	0.41	2.03e-6	Sitting height ratio;
TGCT	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs8014204	0.967	rs4903266	chr14:75344941	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.74	-7.12	-0.54	7.82e-11	Caffeine consumption;
TGCT	cis	rs12477438	0.520	rs11883676	chr2:99800814	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.82	0.62	8.67e-15	Chronic sinus infection;
TGCT	cis	rs854765	0.964	rs854762	chr17:18009102	G/A	cg04398451	chr17:18023971	MYO15A	0.3	4.79	0.39	4.75e-6	Total body bone mineral density;
TGCT	cis	rs6964587	1.000	rs7797834	chr7:91743150	C/T	cg17063962	chr7:91808500	NA	-0.9	-9.76	-0.66	4.92e-17	Breast cancer;
TGCT	cis	rs4665630	0.522	rs4665235	chr2:23878102	C/G	cg08063864	chr2:24346004	PFN4;LOC375190	-1.25	-5.71	-0.46	7.73e-8	Hypertension;
TGCT	cis	rs2692947	0.567	rs4907276	chr2:96391109	G/T	cg23100626	chr2:96804247	ASTL	-0.44	-5.41	-0.44	3.19e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs4886920	0.563	rs8037968	chr15:78077762	C/T	cg25212270	chr15:78015279	NA	-0.23	-4.87	-0.4	3.37e-6	Neuroticism;
TGCT	cis	rs11098499	0.754	rs4107728	chr4:120253910	G/A	cg09307838	chr4:120376055	NA	0.61	5.91	0.47	3.14e-8	Corneal astigmatism;
TGCT	cis	rs11711311	1.000	rs3773682	chr3:113520576	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.7	-6.64	-0.51	8.96e-10	IgG glycosylation;
TGCT	cis	rs62103177	0.608	rs4799115	chr18:77736365	A/T	cg07235805	chr18:78004237	PARD6G	-0.5	-4.9	-0.4	2.98e-6	Opioid sensitivity;
TGCT	cis	rs7267979	0.934	rs6037085	chr20:25305202	C/T	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg11764359	chr7:65958608	NA	-0.61	-5.36	-0.43	3.96e-7	Aortic root size;
TGCT	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg00684032	chr4:1343700	KIAA1530	0.24	5.01	0.41	1.83e-6	Obesity-related traits;
TGCT	cis	rs7412746	0.611	rs12410869	chr1:150856153	G/T	cg04414720	chr1:150670196	GOLPH3L	0.4	4.82	0.4	4.06e-6	Melanoma;
TGCT	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg05368731	chr17:41323189	NBR1	1.16	13.76	0.78	1.03e-26	Menopause (age at onset);
TGCT	cis	rs9942416	0.660	rs61173369	chr5:74997995	A/G	cg19683494	chr5:74908142	NA	0.57	6.37	0.5	3.33e-9	Age-related disease endophenotypes;
TGCT	cis	rs2816062	0.813	rs2816053	chr1:18895819	A/G	cg18795169	chr1:18902165	NA	-0.58	-13.28	-0.77	1.36e-25	Urate levels in lean individuals;
TGCT	cis	rs6570726	0.755	rs2092297	chr6:145893765	A/G	cg13319975	chr6:146136371	FBXO30	-0.5	-4.51	-0.38	1.48e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1568889	0.877	rs7933326	chr11:28288416	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.81	7.87	0.58	1.54e-12	Bipolar disorder;
TGCT	cis	rs7666738	0.830	rs17486413	chr4:99060544	G/T	cg05340658	chr4:99064831	C4orf37	0.5	5.67	0.45	9.63e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9796	0.689	rs28497404	chr15:41449510	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.52	-6.76	-0.52	4.71e-10	Menopause (age at onset);
TGCT	cis	rs5769765	0.862	rs138857	chr22:50199589	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.07	-10.91	-0.7	7.73e-20	Schizophrenia;
TGCT	cis	rs17607347	0.542	rs62051133	chr16:72466151	C/T	cg06220725	chr16:72042591	DHODH	-0.74	-4.83	-0.4	3.94e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg09436375	chr6:42928200	GNMT	-0.43	-5.55	-0.45	1.63e-7	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg04352962	chr1:209979756	IRF6	0.64	4.89	0.4	3.12e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs9527	0.590	rs10509764	chr10:104776475	G/A	cg04362960	chr10:104952993	NT5C2	0.65	5.54	0.45	1.73e-7	Arsenic metabolism;
TGCT	cis	rs380904	1.000	rs12543128	chr8:144595042	G/A	cg09317036	chr8:144635547	GSDMD	0.5	4.77	0.39	5.06e-6	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg10295955	chr4:187884368	NA	-0.95	-14.86	-0.8	2.58e-29	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4455778	0.659	rs7808091	chr7:49071344	A/G	cg26309511	chr7:48887640	NA	0.51	4.57	0.38	1.14e-5	Lung cancer in never smokers;
TGCT	cis	rs9583531	0.509	rs9521923	chr13:111405462	C/T	cg24331049	chr13:111365604	ING1	-0.84	-5.68	-0.45	9.25e-8	Coronary artery disease;
TGCT	cis	rs7568458	0.837	rs6547624	chr2:85802134	A/T	cg02493740	chr2:85810744	VAMP5	-0.27	-4.83	-0.4	4e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs6121246	0.909	rs6089058	chr20:30326338	T/G	cg18721089	chr20:30220636	NA	-0.43	-4.75	-0.39	5.54e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs9443189	0.526	rs9359124	chr6:76200514	G/A	cg01950844	chr6:76311363	SENP6	0.96	5.81	0.46	4.91e-8	Prostate cancer;
TGCT	cis	rs4148883	0.504	rs4585310	chr4:100120233	T/C	cg12011299	chr4:100065546	ADH4	-0.35	-5.04	-0.41	1.57e-6	Alcohol dependence;
TGCT	cis	rs926938	0.563	rs360655	chr1:115447867	T/C	cg12756093	chr1:115239321	AMPD1	0.4	6.33	0.49	4.02e-9	Autism;
TGCT	cis	rs6977660	0.562	rs2189566	chr7:19768960	G/A	cg07541023	chr7:19748670	TWISTNB	1.01	6.64	0.51	8.88e-10	Thyroid stimulating hormone;
TGCT	cis	rs682748	0.967	rs297172	chr5:17150524	T/C	cg23987134	chr5:17158319	LOC285696	-0.23	-5.42	-0.44	2.93e-7	Hippocampal atrophy;
TGCT	cis	rs12540874	0.698	rs3807566	chr7:50564204	G/T	cg18232548	chr7:50535776	DDC	-0.36	-6.18	-0.49	8.57e-9	Systemic sclerosis;
TGCT	trans	rs877282	0.898	rs12359731	chr10:759497	A/G	cg22713356	chr15:30763199	NA	1.08	9.15	0.63	1.46e-15	Uric acid levels;
TGCT	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg03709012	chr19:19516395	GATAD2A	-0.79	-6.75	-0.52	4.97e-10	Tonsillectomy;
TGCT	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg11644478	chr21:40555479	PSMG1	1.01	10.47	0.69	8.99e-19	Cognitive function;
TGCT	cis	rs9303401	0.659	rs62083362	chr17:56846464	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs7666738	0.927	rs4699328	chr4:99055890	C/T	cg05340658	chr4:99064831	C4orf37	0.49	5.53	0.44	1.85e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9527	0.590	rs7898770	chr10:104756636	A/G	cg04362960	chr10:104952993	NT5C2	-0.69	-5.84	-0.46	4.23e-8	Arsenic metabolism;
TGCT	cis	rs9814567	0.752	rs9848254	chr3:134330374	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-6.41	-0.5	2.8e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs3733585	0.699	rs7437120	chr4:9967683	T/A	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.67	-0.57	4.29e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg06238570	chr21:40685208	BRWD1	-0.83	-9.32	-0.64	5.46e-16	Cognitive function;
TGCT	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg11890956	chr21:40555474	PSMG1	1.03	10.89	0.7	8.59e-20	Cognitive function;
TGCT	cis	rs6430585	0.536	rs60397494	chr2:136470219	C/T	cg07169764	chr2:136633963	MCM6	1.12	10.49	0.69	8.04e-19	Corneal structure;
TGCT	cis	rs7804356	0.651	rs1123156	chr7:26817044	C/T	cg03456212	chr7:26904342	SKAP2	-0.54	-4.54	-0.38	1.3e-5	Type 1 diabetes;
TGCT	cis	rs6701037	0.748	rs2685	chr1:175127771	A/G	cg00321850	chr1:175162397	KIAA0040	0.39	5.28	0.43	5.55e-7	Alcohol dependence;
TGCT	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg21963583	chr11:68658836	MRPL21	0.37	6.08	0.48	1.39e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7737716	0.500	rs73790355	chr5:118235990	C/G	cg21035905	chr5:118964330	FAM170A	0.41	4.69	0.39	7.18e-6	Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;
TGCT	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg21285383	chr16:89894308	SPIRE2	-0.44	-7.14	-0.54	7e-11	Vitiligo;
TGCT	cis	rs5769765	0.955	rs8135963	chr22:50301476	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.09	-10.56	-0.69	5.6e-19	Schizophrenia;
TGCT	cis	rs6912958	0.712	rs2754260	chr6:88397666	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.46	-4.46	-0.37	1.81e-5	Monocyte percentage of white cells;
TGCT	cis	rs9921338	0.961	rs7193278	chr16:11445831	A/C	cg00044050	chr16:11439710	C16orf75	-0.73	-5.69	-0.45	8.72e-8	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs40363	1.000	rs37769	chr16:3514580	C/G	cg22508957	chr16:3507546	NAT15	0.57	5.15	0.42	1.01e-6	Tuberculosis;
TGCT	cis	rs10751667	0.666	rs7396473	chr11:966181	T/C	cg06064525	chr11:970664	AP2A2	-0.36	-8.28	-0.6	1.66e-13	Alzheimer's disease (late onset);
TGCT	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg17054783	chr10:134559939	INPP5A	0.23	4.64	0.38	8.89e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs459571	0.804	rs448918	chr9:136885979	G/A	cg13789015	chr9:136890014	NCRNA00094	0.4	7.21	0.54	4.93e-11	Platelet distribution width;
TGCT	cis	rs2456568	0.802	rs10831139	chr11:93640537	G/A	cg14065697	chr11:93583672	C11orf90	-0.36	-4.45	-0.37	1.85e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7617773	0.743	rs13071960	chr3:48367537	A/G	cg11946769	chr3:48343235	NME6	0.8	6.91	0.53	2.26e-10	Coronary artery disease;
TGCT	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg20607798	chr8:58055168	NA	0.49	4.52	0.38	1.43e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs854765	0.724	rs2955371	chr17:17967397	G/A	cg09796270	chr17:17721594	SREBF1	-0.28	-5.56	-0.45	1.6e-7	Total body bone mineral density;
TGCT	cis	rs9634489	0.502	rs12431147	chr13:97112598	T/C	cg11411106	chr13:97107445	HS6ST3	0.25	4.48	0.37	1.7e-5	Body mass index;
TGCT	cis	rs9549367	0.789	rs9549715	chr13:113908240	G/C	cg18105134	chr13:113819100	PROZ	-0.34	-5.58	-0.45	1.41e-7	Platelet distribution width;
TGCT	cis	rs10540	1.000	rs61742833	chr11:490035	C/T	cg03934478	chr11:495069	RNH1	0.34	5.38	0.44	3.54e-7	Body mass index;
TGCT	cis	rs981844	1.000	rs2606342	chr4:154659980	C/A	cg14289246	chr4:154710475	SFRP2	1.01	8.46	0.6	6.31e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs892961	0.932	rs3987886	chr17:75414980	A/G	cg05865280	chr17:75406074	SEPT9	0.29	6.98	0.53	1.61e-10	Airflow obstruction;
TGCT	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg11494091	chr17:61959527	GH2	-0.53	-11.85	-0.73	4e-22	Prudent dietary pattern;
TGCT	cis	rs3733585	0.673	rs4447861	chr4:9953940	C/T	cg00071950	chr4:10020882	SLC2A9	-0.55	-6.58	-0.51	1.21e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs2066819	1.000	rs75265219	chr12:56640341	G/A	cg26714650	chr12:56694279	CS	-1.32	-6.2	-0.49	7.69e-9	Psoriasis vulgaris;
TGCT	cis	rs6901250	0.851	rs339324	chr6:117195024	C/T	cg12892004	chr6:117198278	RFX6	-0.57	-6.94	-0.53	1.92e-10	C-reactive protein levels;
TGCT	cis	rs447735	0.537	rs7190341	chr16:89917537	T/C	cg03388025	chr16:89894329	SPIRE2	0.36	4.94	0.41	2.42e-6	Hemoglobin concentration;
TGCT	cis	rs4455778	0.580	rs6976152	chr7:49087711	A/G	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs9467711	0.720	rs75782365	chr6:26408551	T/G	cg16898833	chr6:26189333	HIST1H4D	1.37	6.2	0.49	7.83e-9	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2251381	0.750	rs8129616	chr21:30520085	C/T	cg24692254	chr21:30365293	RNF160	-0.69	-6.6	-0.51	1.08e-9	Selective IgA deficiency;
TGCT	trans	rs2233152	0.519	rs11083567	chr19:41318306	C/T	cg23963070	chr1:1162176	SDF4	0.32	6.74	0.52	5.22e-10	Kawasaki disease;
TGCT	cis	rs9522267	0.535	rs9522303	chr13:112237301	T/C	cg10483660	chr13:112241077	NA	-0.28	-4.65	-0.39	8.46e-6	Hepatitis;
TGCT	cis	rs2404602	0.716	rs17461634	chr15:76764107	G/A	cg26408565	chr15:76604113	ETFA	-0.39	-5.23	-0.43	6.85e-7	Blood metabolite levels;
TGCT	cis	rs7178572	0.568	rs11630689	chr15:77520094	C/T	cg22256960	chr15:77711686	NA	-0.87	-8.8	-0.62	9.73e-15	Type 2 diabetes;
TGCT	cis	rs9653442	0.564	rs10175599	chr2:100787635	C/T	cg22139774	chr2:100720529	AFF3	-0.35	-5.46	-0.44	2.53e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg13531842	chr10:38383804	ZNF37A	-0.38	-4.51	-0.38	1.49e-5	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7662987	0.517	rs1154410	chr4:100006645	A/G	cg12011299	chr4:100065546	ADH4	0.38	4.6	0.38	1.04e-5	Smoking initiation;
TGCT	cis	rs12142240	0.698	rs4372193	chr1:46853233	G/T	cg00530320	chr1:46809349	NSUN4	0.29	5.79	0.46	5.34e-8	Menopause (age at onset);
TGCT	cis	rs7681440	0.904	rs6816469	chr4:90772885	G/C	cg14346243	chr4:90757452	SNCA	-0.57	-5.5	-0.44	2.04e-7	Dementia with Lewy bodies;
TGCT	cis	rs8180040	0.966	rs7649234	chr3:47494380	G/C	cg27129171	chr3:47204927	SETD2	0.68	8.08	0.59	4.77e-13	Colorectal cancer;
TGCT	cis	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg18252515	chr7:66147081	NA	-1.2	-7.83	-0.58	1.89e-12	Diabetic kidney disease;
TGCT	cis	rs3125734	0.633	rs3852412	chr10:64050288	C/T	cg19640130	chr10:64028056	RTKN2	-0.38	-4.79	-0.39	4.73e-6	Rheumatoid arthritis;
TGCT	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.31	-4.76	-0.39	5.36e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7666738	0.830	rs10022389	chr4:99022229	T/C	cg05340658	chr4:99064831	C4orf37	0.48	5.43	0.44	2.92e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7726839	0.540	rs57306627	chr5:597643	T/C	cg16624210	chr5:671434	TPPP	0.44	4.85	0.4	3.68e-6	Obesity-related traits;
TGCT	cis	rs2242116	1.000	rs1138518	chr3:46944274	T/C	cg02527881	chr3:46936655	PTH1R	-0.32	-6.08	-0.48	1.36e-8	Birth weight;
TGCT	cis	rs1018836	0.892	rs10103198	chr8:91579436	A/T	cg16814680	chr8:91681699	NA	-0.77	-8.22	-0.59	2.28e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9611565	0.512	rs9607842	chr22:42192722	G/A	cg06481639	chr22:41940642	POLR3H	-0.68	-6.01	-0.48	1.89e-8	Vitiligo;
TGCT	cis	rs7666738	0.546	rs62320963	chr4:98839297	A/G	cg17366294	chr4:99064904	C4orf37	0.66	6.14	0.48	1.02e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7914558	1.000	rs1926030	chr10:104855656	T/C	cg04362960	chr10:104952993	NT5C2	0.62	5.55	0.45	1.66e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs3784262	0.669	rs4646603	chr15:58290024	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.42	-5.96	-0.47	2.49e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs7843479	0.965	rs733544	chr8:21835628	A/G	cg17168535	chr8:21777572	XPO7	0.63	5.8	0.46	5.08e-8	Mean corpuscular volume;
TGCT	cis	rs9486719	1.000	rs12205728	chr6:96891838	T/C	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.86	-0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg00343986	chr7:65444356	GUSB	-0.24	-5.81	-0.46	4.87e-8	Aortic root size;
TGCT	cis	rs3806843	0.576	rs246028	chr5:140333513	C/T	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs1903068	1.000	rs73236109	chr4:56007425	C/T	cg16572876	chr4:56024045	NA	0.46	5.24	0.43	6.65e-7	Endometriosis;
TGCT	cis	rs854765	0.583	rs11871899	chr17:17826748	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.76	7.94	0.58	1.04e-12	Total body bone mineral density;
TGCT	cis	rs35146811	0.735	rs11764176	chr7:99786964	G/T	cg13334819	chr7:99746414	C7orf59	-0.74	-6.31	-0.49	4.4e-9	Coronary artery disease;
TGCT	cis	rs9985766	1.000	rs28896206	chr4:151034907	T/C	cg05926478	chr4:151174724	DCLK2	-0.27	-4.81	-0.4	4.35e-6	Coronary artery disease;Myocardial infarction;
TGCT	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg27588902	chr6:42928151	GNMT	-0.56	-6.81	-0.52	3.8e-10	Alzheimer's disease in APOE e4+ carriers;
TGCT	trans	rs208520	0.754	rs851592	chr6:66875175	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-10.31	-0.68	2.29e-18	Exhaled nitric oxide output;
TGCT	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg23719950	chr11:63933701	MACROD1	-0.71	-5.87	-0.47	3.82e-8	Mean platelet volume;
TGCT	trans	rs2898290	0.500	rs11998678	chr8:11830150	A/G	cg15556689	chr8:8085844	FLJ10661	-0.73	-6.63	-0.51	9.2e-10	Systolic blood pressure;
TGCT	cis	rs6901004	0.688	rs34151782	chr6:111574537	T/A	cg15721981	chr6:111408429	SLC16A10	0.53	4.61	0.38	9.85e-6	Blood metabolite levels;
TGCT	cis	rs7926906	0.679	rs7933305	chr11:90522199	A/T	cg26138821	chr11:89956704	CHORDC1	-0.48	-4.94	-0.41	2.49e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs28595532	0.920	rs116559327	chr4:119754526	T/G	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs2180341	0.842	rs9372860	chr6:127546605	G/A	cg27446573	chr6:127587934	RNF146	1.07	8.4	0.6	8.9e-14	Breast cancer;
TGCT	trans	rs208520	0.874	rs208518	chr6:66948501	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	9.89	0.66	2.33e-17	Exhaled nitric oxide output;
TGCT	cis	rs4788570	0.566	rs8051439	chr16:71495793	A/T	cg06353428	chr16:71660113	MARVELD3	-1.2	-7.67	-0.57	4.25e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs42648	0.748	rs12673914	chr7:89943389	C/T	cg25739043	chr7:89950458	NA	-0.63	-6.12	-0.48	1.12e-8	Homocysteine levels;
TGCT	cis	rs7666738	0.830	rs6831219	chr4:98993576	C/A	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7599312	0.534	rs6435711	chr2:213410065	G/A	cg20637307	chr2:213403960	ERBB4	0.89	10.96	0.7	5.75e-20	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs644799	1.000	rs3177463	chr11:95502128	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	8.53	0.61	4.41e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9486715	0.867	rs4839828	chr6:96863326	G/A	cg18709589	chr6:96969512	KIAA0776	0.79	7.77	0.57	2.5e-12	Headache;
TGCT	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg01416388	chr22:39784598	NA	-0.63	-5.27	-0.43	5.87e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1865760	0.566	rs9358902	chr6:26058570	C/G	cg16482183	chr6:26056742	HIST1H1C	0.58	4.98	0.41	2.12e-6	Height;
TGCT	trans	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg27523141	chr10:43048294	ZNF37B	-0.73	-8.38	-0.6	9.87e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs6746896	1.000	rs56361249	chr2:97380229	T/G	cg26085987	chr2:97230376	NA	0.19	4.66	0.39	8.15e-6	Bipolar disorder;
TGCT	cis	rs854765	0.964	rs72827413	chr17:17988299	C/T	cg09796270	chr17:17721594	SREBF1	-0.26	-5.02	-0.41	1.73e-6	Total body bone mineral density;
TGCT	cis	rs6752107	1.000	rs13009506	chr2:234175706	A/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	-0.19	-4.65	-0.39	8.35e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs854765	0.693	rs9907287	chr17:17774118	C/T	cg09796270	chr17:17721594	SREBF1	-0.24	-4.8	-0.4	4.56e-6	Total body bone mineral density;
TGCT	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg21280719	chr6:42927975	GNMT	-0.37	-4.59	-0.38	1.07e-5	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs2224391	0.628	rs2753238	chr6:5252795	A/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.99	-6.43	-0.5	2.46e-9	Height;
TGCT	cis	rs4788570	0.566	rs3886947	chr16:71483958	G/C	cg06353428	chr16:71660113	MARVELD3	-1.32	-7.86	-0.58	1.6e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs12643440	0.538	rs62296722	chr4:17140970	T/G	cg22650099	chr4:17144496	NA	-0.46	-4.7	-0.39	6.79e-6	Metabolite levels (Pyroglutamine);
TGCT	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg22920501	chr2:26401640	FAM59B	-0.72	-6.19	-0.49	8.23e-9	Gut microbiome composition (summer);
TGCT	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg11890956	chr21:40555474	PSMG1	-1.1	-12.05	-0.73	1.27e-22	Cognitive function;
TGCT	cis	rs308403	0.568	rs13102440	chr4:123664919	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.7	6.51	0.5	1.66e-9	Blood protein levels;
TGCT	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	6.75	0.52	5.02e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6674970	1.000	rs4970941	chr1:151068546	A/G	cg00003202	chr1:151319512	RFX5	-0.51	-4.46	-0.37	1.84e-5	Childhood ear infection;
TGCT	cis	rs3091242	0.836	rs35346083	chr1:25788425	C/A	cg10117171	chr1:25599238	RHD	0.32	5.16	0.42	9.43e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs1372520	0.577	rs748849	chr4:90734961	G/A	cg14346243	chr4:90757452	SNCA	-0.66	-5.56	-0.45	1.55e-7	Neuroticism;
TGCT	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.62	5.25	0.43	6.3e-7	Tonsillectomy;
TGCT	cis	rs7000551	0.751	rs2461490	chr8:22370115	G/C	cg12081754	chr8:22256438	SLC39A14	0.27	4.51	0.38	1.48e-5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs6459788	0.502	rs9692347	chr7:157232659	C/T	cg03453431	chr7:157225567	NA	-0.54	-8.9	-0.62	5.77e-15	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs7760949	0.889	rs9475787	chr6:13926102	G/C	cg27413430	chr6:13925136	RNF182	0.74	6.82	0.52	3.64e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs524281	0.861	rs580891	chr11:65954681	A/C	cg00563793	chr11:65837595	PACS1	0.56	4.88	0.4	3.22e-6	Electroencephalogram traits;
TGCT	cis	rs6500602	0.627	rs4786494	chr16:4506232	G/A	cg08645402	chr16:4508243	NA	0.2	4.78	0.39	4.87e-6	Schizophrenia;
TGCT	cis	rs7246657	0.943	rs10417844	chr19:37837587	C/T	cg18154014	chr19:37997991	ZNF793	0.72	5.19	0.42	8.3e-7	Coronary artery calcification;
TGCT	cis	rs9905704	0.647	rs11659035	chr17:56966052	C/T	cg05425664	chr17:57184151	TRIM37	-0.57	-4.44	-0.37	1.97e-5	Testicular germ cell tumor;
TGCT	cis	rs12510870	0.599	rs2103323	chr4:74422785	A/T	cg05868023	chr4:75230803	EREG	0.62	5.03	0.41	1.68e-6	Iris color (b* coordinate);
TGCT	cis	rs6964587	0.900	rs6972027	chr7:91781380	T/C	cg17063962	chr7:91808500	NA	0.93	10.08	0.67	8.03e-18	Breast cancer;
TGCT	cis	rs4711350	0.765	rs943476	chr6:33750086	A/G	cg00334056	chr6:33755658	LEMD2	-0.28	-4.47	-0.37	1.73e-5	Schizophrenia;
TGCT	cis	rs33794	0.901	rs33786	chr3:45293379	C/T	cg18645101	chr3:44551900	NA	0.54	4.74	0.39	5.75e-6	Lung function (forced expiratory volume in 1 second);
TGCT	cis	rs73198271	1.000	rs73198271	chr8:8606807	A/T	ch.8.214553F	chr8:8189620	PRAGMIN	-0.27	-4.57	-0.38	1.17e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs3733585	0.736	rs4543113	chr4:10008305	G/A	cg11266682	chr4:10021025	SLC2A9	0.64	8.27	0.6	1.75e-13	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs9677476	0.516	rs1035620	chr2:232008305	C/T	cg07929768	chr2:232055508	NA	0.33	5.24	0.43	6.78e-7	Food antigen IgG levels;
TGCT	cis	rs76935404	0.811	rs11083589	chr19:41428416	A/T	cg19493303	chr19:41414353	NA	0.41	5.05	0.41	1.57e-6	nicotine metabolite ratio in current smokers;
TGCT	cis	rs9902453	0.730	rs2020939	chr17:28550732	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.58	-5.41	-0.44	3.14e-7	Coffee consumption (cups per day);
TGCT	cis	rs2594989	0.831	rs66488222	chr3:11576289	C/T	cg00170343	chr3:11313890	ATG7	-0.65	-4.92	-0.4	2.71e-6	Circulating chemerin levels;
TGCT	cis	rs67311347	0.956	rs11714871	chr3:40428938	T/G	cg17264618	chr3:40429014	ENTPD3	0.32	4.76	0.39	5.29e-6	Renal cell carcinoma;
TGCT	cis	rs1348850	0.837	rs4243388	chr2:178284604	T/G	cg22681709	chr2:178499509	PDE11A	-0.35	-4.6	-0.38	1.03e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs1577917	1.000	rs1999852	chr6:86705738	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.54	-0.45	1.73e-7	Response to antipsychotic treatment;
TGCT	cis	rs3617	0.625	rs2071042	chr3:52864584	A/G	cg10802521	chr3:52805072	NEK4	-0.62	-7.17	-0.54	6e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9902453	0.808	rs8069669	chr17:28239502	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.88	8.32	0.6	1.33e-13	Coffee consumption (cups per day);
TGCT	cis	rs2832077	0.527	rs2832116	chr21:30228368	C/A	cg24692254	chr21:30365293	RNF160	-0.59	-5.05	-0.41	1.53e-6	Cognitive test performance;
TGCT	cis	rs4253772	0.550	rs9615913	chr22:46668515	A/T	cg24881330	chr22:46731750	TRMU	-0.67	-4.49	-0.37	1.6e-5	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs2296887	0.722	rs10883715	chr10:103960817	C/T	cg26089160	chr10:104170217	PSD	-0.53	-4.82	-0.4	4.08e-6	Parkinson's disease;
TGCT	cis	rs60871478	0.898	rs4720929	chr7:808009	T/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.46	4.6	0.38	1.04e-5	Cerebrospinal P-tau181p levels;
TGCT	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg07507251	chr3:52567010	NT5DC2	0.48	6.76	0.52	4.9e-10	Bipolar disorder;
TGCT	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.65	-6.31	-0.49	4.42e-9	Bipolar disorder;
TGCT	cis	rs6840360	0.593	rs10016160	chr4:152693998	A/G	cg17479576	chr4:152424074	FAM160A1	-0.53	-5.26	-0.43	5.99e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs3087591	0.919	rs2940180	chr17:29409347	G/T	cg24425628	chr17:29625626	OMG;NF1	0.46	6.91	0.53	2.23e-10	Hip circumference;
TGCT	cis	rs7568458	0.837	rs35565292	chr2:85790316	T/A	cg17127132	chr2:85788382	GGCX	0.72	6.86	0.52	2.87e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs2836974	0.799	rs8129303	chr21:40711959	G/A	cg17971929	chr21:40555470	PSMG1	0.89	7.75	0.57	2.88e-12	Cognitive function;
TGCT	cis	rs7192750	0.586	rs8063324	chr16:71967599	T/G	cg06353428	chr16:71660113	MARVELD3	0.76	6.91	0.53	2.2e-10	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs981844	0.712	rs1037648	chr4:154737877	T/C	cg14289246	chr4:154710475	SFRP2	-1.0	-9.32	-0.64	5.46e-16	Response to statins (LDL cholesterol change);
TGCT	cis	rs9818758	0.556	rs11716614	chr3:49017208	C/G	cg00383909	chr3:49044727	WDR6	1.54	5.91	0.47	3.14e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs4953076	0.573	rs2053456	chr2:44448632	G/A	cg04920474	chr2:44395004	PPM1B	0.6	6.06	0.48	1.51e-8	Height;
TGCT	cis	rs2836974	0.897	rs2836923	chr21:40524236	T/C	cg17971929	chr21:40555470	PSMG1	0.98	9.08	0.63	2.09e-15	Cognitive function;
TGCT	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg06896619	chr17:61851486	DDX42;CCDC47	-0.5	-4.69	-0.39	7.05e-6	Prudent dietary pattern;
TGCT	cis	rs12142240	0.698	rs6659228	chr1:46811027	C/G	cg00530320	chr1:46809349	NSUN4	0.29	5.83	0.46	4.47e-8	Menopause (age at onset);
TGCT	cis	rs514406	0.584	rs11205997	chr1:53195271	G/C	cg16325326	chr1:53192061	ZYG11B	-0.89	-13.12	-0.76	3.31e-25	Monocyte count;
TGCT	cis	rs854765	0.718	rs7224815	chr17:17845800	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.65	6.41	0.5	2.72e-9	Total body bone mineral density;
TGCT	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg21724239	chr8:58056113	NA	0.52	5.53	0.44	1.8e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6752107	1.000	rs3828309	chr2:234180410	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	-0.2	-4.82	-0.4	4.11e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs929354	0.742	rs10274687	chr7:156933181	T/G	cg05182265	chr7:156933206	UBE3C	-0.39	-8.98	-0.63	3.72e-15	Body mass index;
TGCT	cis	rs56235845	0.964	rs11746443	chr5:176798306	G/A	cg16006841	chr5:176797999	RGS14	0.75	12.79	0.75	2.1e-24	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs2216164	1.000	rs2069718	chr12:68550162	A/G	cg17065850	chr12:67807625	NA	0.24	4.48	0.37	1.64e-5	Alopecia areata;
TGCT	cis	rs17384381	0.953	rs3768223	chr1:85809183	T/C	cg16011679	chr1:85725395	C1orf52	0.84	6.5	0.5	1.74e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2066819	1.000	rs11171806	chr12:56733531	A/G	cg26714650	chr12:56694279	CS	1.35	5.71	0.46	7.97e-8	Psoriasis vulgaris;
TGCT	cis	rs4788570	0.615	rs7190487	chr16:71648617	A/G	cg06353428	chr16:71660113	MARVELD3	1.54	12.75	0.75	2.57e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs1005277	0.540	rs7903942	chr10:37929276	C/T	cg25427524	chr10:38739819	LOC399744	0.36	7.13	0.54	7.4e-11	Extrinsic epigenetic age acceleration;
TGCT	cis	rs826838	0.834	rs2387842	chr12:38736442	T/C	cg26384229	chr12:38710491	ALG10B	1.09	10.99	0.7	4.95e-20	Heart rate;
TGCT	cis	rs6582630	0.502	rs11520234	chr12:38255005	G/A	cg26384229	chr12:38710491	ALG10B	0.86	7.48	0.56	1.17e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs6728642	1.000	rs7580504	chr2:97605597	C/G	cg26665480	chr2:98280029	ACTR1B	-0.95	-5.35	-0.43	4.15e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	cis	rs78487399	0.808	rs17030925	chr2:43713808	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.41	-4.68	-0.39	7.4e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs9910055	0.659	rs8079310	chr17:42270291	A/G	cg13607699	chr17:42295918	UBTF	0.56	5.15	0.42	1.01e-6	Total body bone mineral density;
TGCT	cis	rs9486715	0.867	rs7451950	chr6:96879974	T/C	cg18709589	chr6:96969512	KIAA0776	0.79	7.77	0.57	2.5e-12	Headache;
TGCT	cis	rs11623869	0.772	rs12587310	chr14:103907286	G/A	cg26031613	chr14:104095156	KLC1	-0.87	-9.58	-0.65	1.3e-16	Bone mineral density;
TGCT	trans	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg21659725	chr3:3221576	CRBN	0.67	7.53	0.56	9.05e-12	Body mass index;
TGCT	cis	rs2997447	0.739	rs60141220	chr1:26395741	G/A	cg19633962	chr1:26362018	EXTL1	-0.68	-4.7	-0.39	6.68e-6	QRS complex (12-leadsum);
TGCT	cis	rs3008870	0.755	rs2815374	chr1:67507387	G/A	cg02640540	chr1:67518911	SLC35D1	0.51	4.56	0.38	1.23e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs7267979	1.000	rs6050630	chr20:25430745	A/G	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1008375	1.000	rs7673500	chr4:17621383	C/T	cg16339924	chr4:17578868	LAP3	0.65	5.21	0.42	7.61e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg03517284	chr6:25882590	NA	-0.71	-6.48	-0.5	1.94e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.52	5.54	0.45	1.73e-7	Lymphocyte counts;
TGCT	cis	rs3617	0.573	rs6795646	chr3:52922621	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	0.53	5.22	0.42	7.26e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg16680214	chr1:154839983	KCNN3	-0.36	-7.13	-0.54	7.13e-11	Prostate cancer;
TGCT	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg07061783	chr6:25882402	NA	-0.45	-4.82	-0.4	4.14e-6	Blood metabolite levels;
TGCT	cis	rs7860634	1.000	rs7860634	chr9:139089679	C/T	cg04455058	chr9:139085579	NA	0.49	5.45	0.44	2.56e-7	Thyroid hormone levels;
TGCT	cis	rs3809566	0.963	rs3809565	chr15:63333619	A/G	cg08198488	chr15:63333792	TPM1	-0.35	-5.15	-0.42	1e-6	Platelet count;
TGCT	cis	rs28595532	0.920	rs115485705	chr4:119733286	G/C	cg14228332	chr4:119757509	SEC24D	1.32	6.38	0.5	3.2e-9	Cannabis dependence symptom count;
TGCT	cis	rs6740322	0.793	rs9808360	chr2:43546835	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.41	-7.0	-0.53	1.42e-10	Coronary artery disease;
TGCT	cis	rs858239	0.669	rs1990365	chr7:23115966	T/C	cg05602783	chr7:23145260	KLHL7	-0.54	-4.54	-0.38	1.33e-5	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs151997	0.830	rs27282	chr5:50198970	G/A	cg06027927	chr5:50259733	NA	0.54	5.58	0.45	1.46e-7	Callous-unemotional behaviour;
TGCT	cis	rs2836950	0.772	rs62222988	chr21:40569508	T/C	cg06238570	chr21:40685208	BRWD1	-0.56	-5.63	-0.45	1.12e-7	Menarche (age at onset);
TGCT	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg20607798	chr8:58055168	NA	0.49	4.67	0.39	7.56e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg23758822	chr17:41437982	NA	-0.67	-6.57	-0.51	1.23e-9	Menopause (age at onset);
TGCT	cis	rs3749237	0.576	rs3877784	chr3:49539417	C/T	cg07636037	chr3:49044803	WDR6	0.63	6.07	0.48	1.47e-8	Resting heart rate;
TGCT	cis	rs7267979	0.966	rs2387882	chr20:25378802	C/T	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9929218	0.551	rs2274239	chr16:68725783	G/A	cg01251360	chr16:68772225	CDH1	-0.29	-5.42	-0.44	2.97e-7	Colorectal cancer;
TGCT	cis	rs7246657	0.943	rs7255996	chr19:37971699	G/A	cg18154014	chr19:37997991	ZNF793	0.74	5.44	0.44	2.71e-7	Coronary artery calcification;
TGCT	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg03609598	chr5:56110824	MAP3K1	-0.56	-4.57	-0.38	1.14e-5	Initial pursuit acceleration;
TGCT	cis	rs739496	0.947	rs11608565	chr12:111921926	T/A	cg10833066	chr12:111807467	FAM109A	0.37	5.2	0.42	8.1e-7	Platelet count;
TGCT	cis	rs1577917	1.000	rs10944161	chr6:86630376	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.54	-0.45	1.73e-7	Response to antipsychotic treatment;
TGCT	cis	rs669446	0.561	rs664728	chr1:44101714	A/T	cg12908607	chr1:44402522	ARTN	-0.55	-5.9	-0.47	3.25e-8	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs10509586	1.000	rs76543761	chr10:91808407	T/C	cg25278353	chr10:91717815	NA	0.48	4.53	0.38	1.35e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
TGCT	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg13607699	chr17:42295918	UBTF	0.59	5.31	0.43	4.88e-7	Total body bone mineral density;
TGCT	cis	rs7647973	0.626	rs1352889	chr3:49652148	T/C	cg03060546	chr3:49711283	APEH	0.63	5.63	0.45	1.12e-7	Menarche (age at onset);
TGCT	cis	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg20637647	chr7:64974828	NA	0.89	4.99	0.41	2.01e-6	Diabetic kidney disease;
TGCT	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg18876405	chr7:65276391	NA	0.31	4.79	0.4	4.58e-6	Aortic root size;
TGCT	cis	rs588177	0.522	rs34358026	chr11:64015422	T/C	cg23719950	chr11:63933701	MACROD1	-0.68	-5.65	-0.45	1.03e-7	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs2439831	0.850	rs28513374	chr15:44125495	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.9	6.3	0.49	4.62e-9	Lung cancer in ever smokers;
TGCT	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg16325326	chr1:53192061	ZYG11B	-0.71	-8.81	-0.62	9.22e-15	Monocyte count;
TGCT	cis	rs7829975	0.582	rs11783950	chr8:8597831	A/C	cg17143192	chr8:8559678	CLDN23	-0.51	-5.11	-0.42	1.21e-6	Mood instability;
TGCT	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg11764359	chr7:65958608	NA	-0.56	-5.09	-0.42	1.31e-6	Aortic root size;
TGCT	cis	rs60871478	0.579	rs56109762	chr7:925967	G/A	cg00475322	chr7:917719	C7orf20	0.56	5.37	0.43	3.72e-7	Cerebrospinal P-tau181p levels;
TGCT	cis	rs7681423	1.000	rs2066861	chr4:155527436	C/T	cg20735720	chr4:155535218	FGG	-0.46	-6.8	-0.52	4e-10	Fibrinogen;
TGCT	cis	rs7940866	0.740	rs7131121	chr11:130806424	A/G	cg12179176	chr11:130786555	SNX19	0.59	5.89	0.47	3.41e-8	Schizophrenia;
TGCT	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg21963583	chr11:68658836	MRPL21	0.37	6.18	0.48	8.66e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	trans	rs4650994	0.789	rs2476559	chr1:178592919	A/G	cg05059571	chr16:84539110	KIAA1609	0.41	7.51	0.56	1e-11	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs6831352	0.879	rs29001208	chr4:100052539	A/C	cg12011299	chr4:100065546	ADH4	-0.41	-4.92	-0.4	2.72e-6	Alcohol dependence;
TGCT	cis	rs6867032	1.000	rs16902318	chr5:2013568	A/G	cg26168224	chr5:2018326	NA	0.46	8.36	0.6	1.08e-13	Gut microbiome composition (winter);
TGCT	cis	rs9660992	0.710	rs1668872	chr1:205236069	G/A	cg00857998	chr1:205179979	DSTYK	0.52	4.56	0.38	1.19e-5	Mean corpuscular volume;Mean platelet volume;
TGCT	cis	rs9611565	0.559	rs7290990	chr22:41964357	C/A	cg13695892	chr22:41940480	POLR3H	-0.87	-8.17	-0.59	2.95e-13	Vitiligo;
TGCT	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.62	4.82	0.4	4.1e-6	Lung function (FEV1/FVC);
TGCT	cis	rs2010099	0.775	rs73191624	chr3:124308208	C/T	cg17170942	chr3:124452405	UMPS	-0.38	-4.51	-0.38	1.47e-5	Thyroid peroxidase antibody levels;
TGCT	cis	rs7726839	0.540	rs11738281	chr5:662547	T/C	cg16035780	chr5:759353	NA	0.44	4.49	0.37	1.63e-5	Obesity-related traits;
TGCT	cis	rs698813	0.604	rs2340813	chr2:44487398	T/C	cg00619915	chr2:44497795	NA	-0.25	-5.7	-0.46	8.4e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
TGCT	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg23758822	chr17:41437982	NA	0.62	6.16	0.48	9.19e-9	Menopause (age at onset);
TGCT	cis	rs910187	0.605	rs8184673	chr20:45806262	C/T	cg27589058	chr20:45804311	EYA2	-0.38	-8.4	-0.6	8.83e-14	Migraine;
TGCT	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg22963979	chr7:1858916	MAD1L1	-0.41	-6.4	-0.5	2.92e-9	Bipolar disorder and schizophrenia;
TGCT	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.55	4.92	0.4	2.74e-6	Prudent dietary pattern;
TGCT	cis	rs5769765	0.542	rs1033666	chr22:50252783	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.97	6.35	0.5	3.69e-9	Schizophrenia;
TGCT	cis	rs2637266	1.000	rs2637264	chr10:78322794	A/C	cg18941641	chr10:78392320	NA	0.39	4.84	0.4	3.73e-6	Pulmonary function;
TGCT	cis	rs4746818	1.000	rs6480383	chr10:70890482	C/T	cg11621586	chr10:70884670	VPS26A	1.21	10.66	0.69	3.17e-19	Left atrial antero-posterior diameter;
TGCT	cis	rs35306767	0.903	rs11816064	chr10:931176	A/C	cg26597838	chr10:835615	NA	0.75	10.54	0.69	6.3e-19	Eosinophil percentage of granulocytes;
TGCT	cis	rs4975616	0.869	rs466502	chr5:1325767	C/T	cg07493874	chr5:1342172	CLPTM1L	0.29	6.87	0.53	2.72e-10	Lung cancer;
TGCT	cis	rs3849570	0.925	rs9841087	chr3:81907949	A/G	cg07356753	chr3:81810745	GBE1	-0.72	-6.62	-0.51	9.51e-10	Waist circumference;Body mass index;
TGCT	cis	rs13082711	0.555	rs7627508	chr3:27252495	A/C	cg02860705	chr3:27208620	NA	0.46	7.16	0.54	6.15e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs12188164	1.000	rs72717410	chr5:428785	A/T	cg26850624	chr5:429559	AHRR	-0.2	-4.82	-0.4	4.15e-6	Cystic fibrosis severity;
TGCT	cis	rs7677751	0.806	rs67432867	chr4:55104454	A/T	cg17187183	chr4:55093834	PDGFRA	0.54	7.0	0.53	1.45e-10	Corneal astigmatism;
TGCT	cis	rs9527	0.590	rs7917650	chr10:104937100	G/C	cg04362960	chr10:104952993	NT5C2	0.65	5.59	0.45	1.36e-7	Arsenic metabolism;
TGCT	cis	rs4389656	0.775	rs274668	chr5:6711630	C/T	cg10857441	chr5:6722123	POLS	-0.22	-4.87	-0.4	3.27e-6	Coronary artery disease;
TGCT	cis	rs9818758	0.556	rs9813813	chr3:49207093	T/A	cg07636037	chr3:49044803	WDR6	-1.03	-5.08	-0.41	1.37e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs1245541	0.776	rs1678613	chr10:73866511	T/C	cg10983208	chr10:73848320	SPOCK2	-0.27	-4.57	-0.38	1.14e-5	Insulin-like growth factors;
TGCT	cis	rs9372498	0.505	rs17080456	chr6:118985938	G/C	cg07617317	chr6:118971624	C6orf204	0.49	5.15	0.42	9.91e-7	Diastolic blood pressure;
TGCT	cis	rs8020441	0.945	rs67713610	chr14:51168830	C/T	cg04730355	chr14:51134070	SAV1	0.73	6.02	0.48	1.84e-8	Cognitive performance;
TGCT	cis	rs7731657	0.509	rs916956	chr5:130331705	C/G	cg08523029	chr5:130500466	HINT1	-0.59	-4.84	-0.4	3.76e-6	Fasting plasma glucose;
TGCT	cis	rs7267979	0.966	rs2257712	chr20:25264910	T/C	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3617	0.573	rs9880978	chr3:52923251	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.95	0.41	2.4e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7666738	0.791	rs34088022	chr4:99001508	G/T	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6570726	0.764	rs9322028	chr6:145895797	G/T	cg13319975	chr6:146136371	FBXO30	-0.5	-4.51	-0.38	1.48e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6831352	0.734	rs2602856	chr4:100029145	C/A	cg12011299	chr4:100065546	ADH4	0.41	5.67	0.45	9.34e-8	Alcohol dependence;
TGCT	cis	rs11677416	1.000	rs3783559	chr2:113529837	A/G	cg27083787	chr2:113543245	IL1A	0.18	4.5	0.37	1.53e-5	Response to antipsychotic treatment in schizophrenia (working memory);
TGCT	cis	rs4803468	1.000	rs2288871	chr19:41917868	C/T	cg09537434	chr19:41945824	ATP5SL	-0.9	-10.87	-0.7	9.43e-20	Height;
TGCT	cis	rs9357506	1.000	rs12055793	chr6:46306389	T/A	cg21115430	chr6:46460003	NA	-0.26	-5.17	-0.42	9.2e-7	Body mass index;
TGCT	cis	rs56309584	0.560	rs3027169	chr17:8058814	A/C	cg08322244	chr17:8066669	VAMP2	-0.52	-4.88	-0.4	3.14e-6	Initial pursuit acceleration;
TGCT	cis	rs9362426	0.608	rs6912875	chr6:88133503	A/T	cg10919329	chr6:88182879	SLC35A1	-0.61	-4.61	-0.38	9.99e-6	Depressive episodes in bipolar disorder;
TGCT	cis	rs7949030	0.688	rs11231155	chr11:62365619	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.62	9.04	0.63	2.68e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs514406	0.548	rs6670871	chr1:53212082	A/C	cg16325326	chr1:53192061	ZYG11B	-0.9	-13.21	-0.76	2.07e-25	Monocyte count;
TGCT	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg18230493	chr5:56204884	C5orf35	-0.72	-6.07	-0.48	1.44e-8	Initial pursuit acceleration;
TGCT	cis	rs28595532	0.920	rs17324968	chr4:119772316	A/G	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs13064411	0.696	rs1386336	chr3:113144153	C/T	cg18753928	chr3:113234510	CCDC52	-0.71	-4.98	-0.41	2.06e-6	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs778371	0.752	rs283487	chr2:233644011	A/G	cg08000102	chr2:233561755	GIGYF2	0.69	7.78	0.57	2.37e-12	Schizophrenia;
TGCT	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg22963979	chr7:1858916	MAD1L1	-0.37	-5.67	-0.45	9.59e-8	Bipolar disorder and schizophrenia;
TGCT	cis	rs10992471	0.528	rs10761158	chr9:95205322	T/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.52	-4.91	-0.4	2.8e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs7224685	0.569	rs8065660	chr17:4000858	A/G	cg09580393	chr17:4869866	SPAG7	-0.38	-4.48	-0.37	1.64e-5	Type 2 diabetes;
TGCT	cis	rs3772130	0.527	rs2141614	chr3:121590173	G/A	cg20356878	chr3:121714668	ILDR1	0.38	4.83	0.4	3.93e-6	Cognitive performance;
TGCT	cis	rs7106204	0.748	rs2403888	chr11:24208071	C/G	ch.11.24196551F	chr11:24239977	NA	-0.5	-4.64	-0.38	8.82e-6	Response to Homoharringtonine (cytotoxicity);
TGCT	cis	rs6430585	0.527	rs2278731	chr2:136396300	T/C	cg07169764	chr2:136633963	MCM6	0.98	8.33	0.6	1.3e-13	Corneal structure;
TGCT	cis	rs4689388	0.926	rs28420833	chr4:6279504	G/A	cg25554036	chr4:6271136	WFS1	0.55	8.09	0.59	4.65e-13	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs736408	0.812	rs2240920	chr3:52831009	A/G	cg10802521	chr3:52805072	NEK4	0.65	7.13	0.54	7.35e-11	Bipolar disorder;
TGCT	cis	rs7666738	0.753	rs10029372	chr4:98859002	T/C	cg17366294	chr4:99064904	C4orf37	0.7	7.27	0.55	3.62e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs270601	0.866	rs460271	chr5:131630062	C/G	cg24060327	chr5:131705240	SLC22A5	-0.71	-7.2	-0.54	5.07e-11	Acylcarnitine levels;
TGCT	cis	rs7119	0.635	rs2682910	chr15:77880114	C/A	cg27398640	chr15:77910606	LINGO1	0.31	6.19	0.49	8.26e-9	Type 2 diabetes;
TGCT	cis	rs2066819	1.000	rs77032009	chr12:56679971	A/G	cg26714650	chr12:56694279	CS	-1.36	-6.06	-0.48	1.54e-8	Psoriasis vulgaris;
TGCT	cis	rs7666738	0.830	rs17548431	chr4:98923768	C/G	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9296661	0.868	rs1326577	chr6:51667838	A/G	cg00593404	chr6:52377740	TRAM2	-0.27	-4.49	-0.37	1.62e-5	Weight loss (gastric bypass surgery);
TGCT	cis	rs77972916	0.536	rs11694173	chr2:43590899	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.34	4.89	0.4	3.01e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg08048268	chr3:133502702	NA	-0.7	-11.01	-0.7	4.4e-20	Iron status biomarkers;
TGCT	cis	rs1865760	0.551	rs9461230	chr6:26019240	G/C	cg16482183	chr6:26056742	HIST1H1C	0.59	5.16	0.42	9.65e-7	Height;
TGCT	cis	rs67311347	1.000	rs13324109	chr3:40460767	T/C	cg17264618	chr3:40429014	ENTPD3	0.32	4.76	0.39	5.36e-6	Renal cell carcinoma;
TGCT	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg02953382	chr22:24373134	LOC391322	0.77	7.96	0.58	9.07e-13	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg12311346	chr5:56204834	C5orf35	0.67	6.82	0.52	3.63e-10	Initial pursuit acceleration;
TGCT	cis	rs35934224	0.783	rs7289343	chr22:19860990	G/T	cg11182965	chr22:19864308	TXNRD2	-0.38	-5.3	-0.43	5.04e-7	Glaucoma (primary open-angle);
TGCT	cis	rs2562456	0.917	rs9304987	chr19:21682274	A/T	cg25650185	chr19:21324782	ZNF431	0.59	5.18	0.42	8.79e-7	Pain;
TGCT	cis	rs7681440	0.904	rs3806789	chr4:90759556	C/T	cg14346243	chr4:90757452	SNCA	-0.59	-5.74	-0.46	6.87e-8	Dementia with Lewy bodies;
TGCT	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg00343986	chr7:65444356	GUSB	0.22	5.0	0.41	1.9e-6	Aortic root size;
TGCT	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg20607798	chr8:58055168	NA	0.45	4.62	0.38	9.54e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs8016982	0.630	rs61980900	chr14:81686436	T/C	cg01989461	chr14:81687754	GTF2A1	0.81	8.55	0.61	3.82e-14	Schizophrenia;
TGCT	cis	rs79349575	0.777	rs28517720	chr17:46976756	C/G	cg07967210	chr17:47022446	SNF8	0.43	6.08	0.48	1.4e-8	Type 2 diabetes;
TGCT	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.54	-6.95	-0.53	1.86e-10	Longevity;Endometriosis;
TGCT	cis	rs9291683	0.632	rs12508991	chr4:10041104	C/T	cg00071950	chr4:10020882	SLC2A9	0.68	8.73	0.62	1.45e-14	Bone mineral density;
TGCT	cis	rs11997175	0.574	rs12156280	chr8:33650277	C/T	ch.8.33884649F	chr8:33765107	NA	0.28	4.53	0.38	1.35e-5	Body mass index;
TGCT	cis	rs10197940	0.662	rs6735771	chr2:152273503	G/A	cg06191203	chr2:152266755	RIF1	0.71	6.28	0.49	5.14e-9	Lung cancer;
TGCT	cis	rs7119	0.651	rs12904823	chr15:77837662	G/A	cg27398640	chr15:77910606	LINGO1	-0.28	-5.11	-0.42	1.16e-6	Type 2 diabetes;
TGCT	cis	rs1670533	1.000	rs604597	chr4:1094151	G/A	cg20887711	chr4:1340912	KIAA1530	-0.7	-5.53	-0.45	1.77e-7	Recombination rate (females);
TGCT	cis	rs13191362	0.810	rs66921603	chr6:162996982	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs13040088	0.580	rs11905041	chr20:61563408	C/T	cg23096297	chr20:61557774	DIDO1	0.8	6.41	0.5	2.81e-9	Menopause (age at onset);
TGCT	trans	rs2727020	0.656	rs7925524	chr11:49437542	G/A	cg03929089	chr4:120376271	NA	-0.68	-7.15	-0.54	6.64e-11	Coronary artery disease;
TGCT	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg19774624	chr17:42201019	HDAC5	-0.85	-10.09	-0.67	7.79e-18	Total body bone mineral density;
TGCT	cis	rs1784581	0.532	rs7767219	chr6:162423088	T/C	cg17173639	chr6:162384350	PARK2	0.4	6.6	0.51	1.08e-9	Itch intensity from mosquito bite;
TGCT	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.7	-0.39	6.79e-6	Prudent dietary pattern;
TGCT	cis	rs8017423	0.669	rs7153190	chr14:90703904	T/G	cg04374321	chr14:90722782	PSMC1	0.78	8.1	0.59	4.38e-13	Mortality in heart failure;
TGCT	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg01416388	chr22:39784598	NA	0.64	6.16	0.48	9.43e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs1008375	0.932	rs6449321	chr4:17644472	A/G	cg10189774	chr4:17578691	LAP3	0.58	4.99	0.41	1.96e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	trans	rs208520	0.690	rs12201219	chr6:66748862	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	10.83	0.7	1.19e-19	Exhaled nitric oxide output;
TGCT	cis	rs2456568	0.900	rs877340	chr11:93689292	A/T	cg17595323	chr11:93583763	C11orf90	-0.47	-6.05	-0.48	1.55e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs933688	1.000	rs933688	chr5:90762748	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.98	9.34	0.64	4.9e-16	Smoking behavior;
TGCT	cis	rs4771122	0.740	rs1006353	chr13:28047269	A/G	cg22138327	chr13:27999177	GTF3A	-0.78	-7.46	-0.56	1.32e-11	Body mass index;
TGCT	cis	rs6964587	0.626	rs409	chr7:91556355	C/T	cg17063962	chr7:91808500	NA	0.76	7.24	0.55	4.11e-11	Breast cancer;
TGCT	cis	rs6969780	0.722	rs4722666	chr7:27197601	C/G	cg11410718	chr7:27170412	HOXA4	-0.46	-4.57	-0.38	1.18e-5	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs210138	0.832	rs375555	chr6:33557741	T/C	cg07679836	chr6:33548423	BAK1	0.35	4.62	0.38	9.34e-6	Testicular germ cell tumor;
TGCT	cis	rs11997175	0.574	rs4733453	chr8:33650745	A/G	ch.8.33884649F	chr8:33765107	NA	0.28	4.54	0.38	1.33e-5	Body mass index;
TGCT	trans	rs3780486	0.541	rs10738909	chr9:33148834	T/C	cg04842962	chr6:43655489	MRPS18A	0.8	8.61	0.61	2.79e-14	IgG glycosylation;
TGCT	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg02891314	chr5:179741120	GFPT2	-0.41	-7.12	-0.54	7.59e-11	Height;
TGCT	trans	rs10802346	0.545	rs10924568	chr1:246385482	C/A	cg22732515	chr19:44031385	ETHE1	0.83	6.62	0.51	9.79e-10	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs1997103	1.000	rs2331063	chr7:55408914	A/G	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs4455778	0.561	rs6952745	chr7:49122762	C/A	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs1670533	1.000	rs6852155	chr4:1067638	T/G	cg20887711	chr4:1340912	KIAA1530	0.65	5.19	0.42	8.29e-7	Recombination rate (females);
TGCT	cis	rs453301	0.653	rs1562211	chr8:8902424	A/G	cg08975724	chr8:8085496	FLJ10661	-0.59	-5.13	-0.42	1.09e-6	Joint mobility (Beighton score);
TGCT	cis	rs12908161	1.000	rs12910012	chr15:85298662	T/C	cg17173187	chr15:85201210	NMB	0.57	6.41	0.5	2.81e-9	Schizophrenia;
TGCT	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg07092213	chr7:1199455	ZFAND2A	-0.45	-4.85	-0.4	3.58e-6	Longevity;Endometriosis;
TGCT	cis	rs1532993	0.518	rs1508462	chr4:98582307	G/C	cg05340658	chr4:99064831	C4orf37	-0.41	-4.8	-0.4	4.45e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs6426558	0.537	rs10799381	chr1:227239746	G/T	cg10327440	chr1:227177885	CDC42BPA	0.61	7.41	0.55	1.72e-11	Neutrophil percentage of white cells;
TGCT	cis	rs28595532	0.920	rs114696063	chr4:119760624	T/A	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs4273100	0.541	rs973649	chr17:19292068	A/G	cg03910582	chr17:19030146	GRAPL	-0.45	-6.22	-0.49	6.97e-9	Schizophrenia;
TGCT	cis	rs67366981	0.720	rs4447349	chr14:77685381	G/A	cg22824376	chr14:77648248	TMEM63C	0.74	4.75	0.39	5.58e-6	Obsessive-compulsive symptoms;
TGCT	cis	rs4727027	0.833	rs2107846	chr7:148832774	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	4.58	0.38	1.13e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7547997	0.615	rs12038925	chr1:158319449	G/A	cg07950803	chr1:158223934	CD1A	0.31	4.71	0.39	6.42e-6	QRS duration;
TGCT	cis	rs611744	0.934	rs672408	chr8:109224390	A/G	cg21045802	chr8:109455806	TTC35	0.52	4.72	0.39	6.21e-6	Dupuytren's disease;
TGCT	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg09436375	chr6:42928200	GNMT	-0.4	-5.2	-0.42	8.08e-7	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs12464483	0.524	rs1348898	chr2:30888026	C/A	cg12454169	chr2:30669597	LCLAT1	0.45	4.91	0.4	2.75e-6	Pre-treatment pain in head and neck squamous cell carcinoma;
TGCT	cis	rs155076	1.000	rs155076	chr13:21870114	A/G	cg14456004	chr13:21872349	NA	-1.18	-10.19	-0.68	4.35e-18	White matter hyperintensity burden;
TGCT	cis	rs4713118	0.629	rs203889	chr6:28021775	T/G	cg12963246	chr6:28129442	ZNF389	0.45	4.55	0.38	1.27e-5	Parkinson's disease;
TGCT	cis	rs7681440	0.804	rs763443	chr4:90819961	T/C	cg20003494	chr4:90757398	SNCA	-0.54	-5.1	-0.42	1.22e-6	Dementia with Lewy bodies;
TGCT	cis	rs11112613	0.609	rs11112585	chr12:105933442	A/G	cg03607813	chr12:105948248	NA	-0.44	-4.96	-0.41	2.32e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	cis	rs4455778	0.596	rs7777887	chr7:49020978	C/T	cg26309511	chr7:48887640	NA	-0.43	-5.07	-0.41	1.4e-6	Lung cancer in never smokers;
TGCT	cis	rs12510870	0.634	rs4694173	chr4:74382790	T/A	cg05868023	chr4:75230803	EREG	-0.55	-4.7	-0.39	6.84e-6	Iris color (b* coordinate);
TGCT	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg21724239	chr8:58056113	NA	0.4	5.01	0.41	1.8e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2235642	0.928	rs9932984	chr16:1605051	A/G	cg11375102	chr16:1583810	IFT140;TMEM204	-0.3	-5.26	-0.43	6.24e-7	Coronary artery disease;
TGCT	cis	rs7394190	0.748	rs11000780	chr10:75559077	G/A	cg07699608	chr10:75541558	CHCHD1	0.79	5.45	0.44	2.63e-7	Incident atrial fibrillation;
TGCT	cis	rs2228479	0.867	rs12919804	chr16:89945369	G/A	cg06558623	chr16:89946397	TCF25	0.56	6.83	0.52	3.38e-10	Skin colour saturation;
TGCT	cis	rs9788682	1.000	rs2036534	chr15:78826948	T/C	cg24631222	chr15:78858424	CHRNA5	0.92	7.54	0.56	8.79e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs131805	1.000	rs131805	chr22:50964153	T/C	cg25309564	chr22:51001381	C22orf41	0.57	4.77	0.39	5.06e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs422249	0.819	rs174608	chr11:61627484	A/G	cg01500311	chr11:61656094	FADS3	-0.32	-5.3	-0.43	5.2e-7	Trans fatty acid levels;
TGCT	cis	rs9325144	0.560	rs11182979	chr12:38642562	C/A	cg26384229	chr12:38710491	ALG10B	-0.66	-6.0	-0.47	1.97e-8	Morning vs. evening chronotype;
TGCT	cis	rs709400	0.663	rs11624367	chr14:103892818	T/A	cg26031613	chr14:104095156	KLC1	0.88	9.61	0.65	1.09e-16	Body mass index;
TGCT	cis	rs12188164	1.000	rs72717410	chr5:428785	A/T	cg21144161	chr5:423903	AHRR	0.25	4.75	0.39	5.57e-6	Cystic fibrosis severity;
TGCT	cis	rs7824557	0.564	rs2437152	chr8:11235497	G/A	cg21775007	chr8:11205619	TDH	-0.65	-6.4	-0.5	2.95e-9	Retinal vascular caliber;
TGCT	cis	rs56104184	0.779	rs17206686	chr19:49356317	A/G	cg21252483	chr19:49399788	TULP2	-0.36	-4.5	-0.37	1.56e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs11711311	1.000	rs9826465	chr3:113432254	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.71	-6.58	-0.51	1.19e-9	IgG glycosylation;
TGCT	cis	rs9467773	0.595	rs9366657	chr6:26434914	C/G	cg05738196	chr6:26577821	NA	0.51	5.44	0.44	2.74e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2070488	0.965	rs1046048	chr3:38524742	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.88	8.99	0.63	3.5e-15	Electrocardiographic conduction measures;
TGCT	cis	rs7027203	0.595	rs2398876	chr9:96536853	T/C	cg14598338	chr9:96623480	NA	0.49	7.07	0.54	1e-10	DNA methylation (variation);
TGCT	cis	rs4478858	0.647	rs4949380	chr1:31764160	A/G	cg07478791	chr1:31886160	SERINC2	-0.52	-5.02	-0.41	1.73e-6	Alcohol dependence;
TGCT	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg09359103	chr1:154839909	KCNN3	-0.73	-15.86	-0.82	1.28e-31	Prostate cancer;
TGCT	trans	rs1814175	0.647	rs4881649	chr11:49845560	A/G	cg03929089	chr4:120376271	NA	-0.58	-6.73	-0.52	5.65e-10	Height;
TGCT	cis	rs7584330	0.744	rs10929234	chr2:238380034	C/G	cg14458575	chr2:238380390	NA	-0.62	-9.64	-0.65	9.41e-17	Prostate cancer;
TGCT	cis	rs7959452	0.562	rs11177630	chr12:69767963	G/C	cg14784868	chr12:69753453	YEATS4	0.83	8.85	0.62	7.59e-15	Blood protein levels;
TGCT	cis	rs3008870	0.755	rs2065002	chr1:67487119	A/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.78	-8.26	-0.6	1.84e-13	Lymphocyte percentage of white cells;
TGCT	cis	rs2153535	0.580	rs6914276	chr6:8450435	A/T	cg07606381	chr6:8435919	SLC35B3	-0.52	-4.88	-0.4	3.18e-6	Motion sickness;
TGCT	cis	rs2657888	0.529	rs118166110	chr12:56887783	G/A	cg23002907	chr12:56915593	RBMS2	-0.37	-4.66	-0.39	7.9e-6	Adiponectin levels;
TGCT	cis	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg06558623	chr16:89946397	TCF25	0.45	4.52	0.38	1.42e-5	Skin colour saturation;
TGCT	cis	rs12765878	0.603	rs10786773	chr10:105644275	A/T	cg11005552	chr10:105648138	OBFC1	-0.42	-6.49	-0.5	1.85e-9	Coronary artery disease;
TGCT	cis	rs1538970	0.924	rs1826691	chr1:45881262	A/G	cg05343316	chr1:45956843	TESK2	-0.7	-5.77	-0.46	5.93e-8	Platelet count;
TGCT	cis	rs7258465	1.000	rs271621	chr19:18631332	C/A	cg06462663	chr19:18546047	ISYNA1	0.22	5.17	0.42	9.29e-7	Breast cancer;
TGCT	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg07507251	chr3:52567010	NT5DC2	0.48	6.91	0.53	2.24e-10	Bipolar disorder;
TGCT	cis	rs9372253	0.967	rs9400379	chr6:110713783	A/G	cg13266496	chr6:110720918	DDO	-0.42	-5.18	-0.42	8.77e-7	Platelet distribution width;
TGCT	cis	rs748404	0.660	rs2249952	chr15:43720533	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	4.75	0.39	5.51e-6	Lung cancer;
TGCT	cis	rs7681440	0.904	rs58864428	chr4:90766986	T/C	cg26578617	chr4:90757533	SNCA	-0.47	-4.87	-0.4	3.34e-6	Dementia with Lewy bodies;
TGCT	cis	rs10193935	1.000	rs62144748	chr2:42419468	C/T	cg27598129	chr2:42591480	NA	-0.39	-5.16	-0.42	9.46e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7714584	1.000	rs61270113	chr5:150226263	G/A	cg22134413	chr5:150180641	NA	0.89	6.96	0.53	1.73e-10	Crohn's disease;
TGCT	cis	rs5757676	0.858	rs6001585	chr22:39812986	G/T	cg02038168	chr22:39784481	NA	-0.71	-5.0	-0.41	1.9e-6	IgG glycosylation;
TGCT	cis	rs9534288	0.797	rs1326401	chr13:46571602	A/G	cg15192986	chr13:46630673	CPB2	0.52	7.57	0.56	7.35e-12	Blood protein levels;
TGCT	cis	rs12477438	0.765	rs6735801	chr2:99657995	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-7.6	-0.56	6.26e-12	Chronic sinus infection;
TGCT	cis	rs1799949	0.931	rs9891977	chr17:41437398	A/G	cg23758822	chr17:41437982	NA	0.65	6.14	0.48	1.04e-8	Menopause (age at onset);
TGCT	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2816958	0.803	rs2821337	chr1:200097743	A/G	cg07971716	chr1:199773294	NA	0.46	4.52	0.38	1.45e-5	Ulcerative colitis;Inflammatory bowel disease;
TGCT	cis	rs6570726	0.738	rs4495284	chr6:145916617	T/A	cg05347473	chr6:146136440	FBXO30	0.53	4.91	0.4	2.87e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7677751	0.806	rs7673984	chr4:55088761	C/T	cg17187183	chr4:55093834	PDGFRA	0.55	7.01	0.53	1.34e-10	Corneal astigmatism;
TGCT	cis	rs4879913	0.801	rs10758314	chr9:35594724	G/A	cg18130437	chr9:35658183	CCDC107;RMRP	-0.5	-4.95	-0.41	2.38e-6	Electroencephalogram traits;
TGCT	cis	rs12188164	0.930	rs72717436	chr5:448291	C/A	cg21144161	chr5:423903	AHRR	0.25	4.79	0.4	4.59e-6	Cystic fibrosis severity;
TGCT	cis	rs1580019	0.961	rs1610143	chr7:32498331	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.81	7.61	0.56	5.93e-12	Cognitive ability;
TGCT	cis	rs9907295	0.688	rs2526327	chr17:34256906	A/G	cg24520589	chr17:33415888	RFFL	-0.65	-4.48	-0.37	1.68e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs9325144	0.624	rs10783329	chr12:39113951	C/T	cg26384229	chr12:38710491	ALG10B	-0.62	-5.68	-0.45	8.87e-8	Morning vs. evening chronotype;
TGCT	cis	rs763014	0.898	rs8050792	chr16:656033	T/C	cg00908189	chr16:619842	PIGQ	0.86	10.25	0.68	3.12e-18	Height;
TGCT	cis	rs7666738	0.830	rs7674095	chr4:99048158	T/A	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12422267	0.536	rs58521339	chr12:132609486	T/C	cg09764611	chr12:132620959	NA	-0.38	-5.71	-0.46	7.88e-8	Plasma amyloid beta peptide concentrations (ABx-40);
TGCT	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg27121462	chr16:89883253	FANCA	-0.83	-9.15	-0.63	1.46e-15	Vitiligo;
TGCT	cis	rs1775715	0.677	rs2491272	chr10:32186783	A/G	cg14930904	chr10:32216787	ARHGAP12	0.52	5.07	0.41	1.39e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs765787	0.530	rs2554454	chr15:45521536	A/G	cg24006582	chr15:45444508	DUOX1	-0.26	-5.76	-0.46	6.31e-8	Uric acid levels;
TGCT	cis	rs11098499	0.908	rs28559989	chr4:120386627	C/T	cg09307838	chr4:120376055	NA	0.68	6.51	0.5	1.66e-9	Corneal astigmatism;
TGCT	cis	rs2594989	0.943	rs2454509	chr3:11489653	C/T	cg00170343	chr3:11313890	ATG7	-0.69	-5.1	-0.42	1.26e-6	Circulating chemerin levels;
TGCT	cis	rs8103278	0.507	rs1865116	chr19:46294510	G/A	cg11657440	chr19:46296263	DMWD	0.78	8.52	0.61	4.56e-14	Coronary artery disease;
TGCT	cis	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg09021430	chr5:549028	NA	-0.37	-4.98	-0.41	2.07e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs9611565	0.506	rs2024567	chr22:41699206	G/C	cg03806693	chr22:41940476	POLR3H	-0.82	-7.85	-0.58	1.7e-12	Vitiligo;
TGCT	cis	rs7267979	1.000	rs6050542	chr20:25318879	T/C	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7635838	0.557	rs347615	chr3:11277284	T/A	cg00170343	chr3:11313890	ATG7	0.62	6.09	0.48	1.28e-8	HDL cholesterol;
TGCT	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.63	-0.51	9.04e-10	Alzheimer's disease;
TGCT	cis	rs1971762	0.527	rs2365343	chr12:54038149	C/T	cg16917193	chr12:54089295	NA	-0.98	-11.98	-0.73	1.93e-22	Height;
TGCT	cis	rs6426558	0.537	rs2670462	chr1:227432923	C/G	cg10327440	chr1:227177885	CDC42BPA	-0.6	-6.93	-0.53	2.03e-10	Neutrophil percentage of white cells;
TGCT	cis	rs9611565	0.512	rs2899349	chr22:42164660	T/C	cg17554472	chr22:41940697	POLR3H	0.46	4.8	0.4	4.46e-6	Vitiligo;
TGCT	cis	rs67311347	1.000	rs17078511	chr3:40396254	A/G	cg13409248	chr3:40428643	ENTPD3	0.55	4.59	0.38	1.06e-5	Renal cell carcinoma;
TGCT	cis	rs698813	0.674	rs6759891	chr2:44496005	C/T	cg00619915	chr2:44497795	NA	-0.24	-5.41	-0.44	3.11e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
TGCT	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg07424592	chr7:64974309	NA	-0.65	-6.34	-0.49	3.89e-9	Calcium levels;
TGCT	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg17554472	chr22:41940697	POLR3H	-0.49	-5.06	-0.41	1.46e-6	Vitiligo;
TGCT	cis	rs4455778	0.580	rs62454353	chr7:49087900	C/A	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg14159672	chr1:205819179	PM20D1	0.72	9.93	0.67	1.88e-17	Menarche (age at onset);
TGCT	cis	rs1372520	0.808	rs1372518	chr4:90757294	A/C	cg15133208	chr4:90757351	SNCA	-0.47	-5.34	-0.43	4.3e-7	Neuroticism;
TGCT	cis	rs3806843	1.000	rs10057161	chr5:140156831	C/T	cg19875535	chr5:140030758	IK	0.37	6.33	0.49	4.09e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs10883723	0.810	rs6584507	chr10:104254623	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg11211951	chr8:145729740	GPT	0.23	5.5	0.44	2.09e-7	Age at first birth;
TGCT	cis	rs1865760	0.613	rs7749342	chr6:25920265	T/C	cg12310025	chr6:25882481	NA	-0.48	-4.79	-0.4	4.63e-6	Height;
TGCT	cis	rs3096299	0.933	rs747485	chr16:89474094	T/C	cg06640241	chr16:89574553	SPG7	0.66	6.39	0.5	3.06e-9	Multiple myeloma (IgH translocation);
TGCT	cis	rs7647973	1.000	rs892974	chr3:49398514	C/A	cg06212747	chr3:49208901	KLHDC8B	0.6	4.71	0.39	6.54e-6	Menarche (age at onset);
TGCT	cis	rs523522	0.962	rs603574	chr12:120998443	A/G	cg12219531	chr12:120966889	COQ5	0.82	7.38	0.55	2.05e-11	High light scatter reticulocyte count;
TGCT	cis	rs7044106	0.762	rs1547268	chr9:123408688	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	4.75	0.39	5.55e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg10802521	chr3:52805072	NEK4	-0.71	-8.79	-0.62	1.04e-14	Bipolar disorder;
TGCT	cis	rs11190604	0.943	rs2495744	chr10:102329409	C/T	cg16342193	chr10:102329863	NA	-0.42	-5.35	-0.43	4.16e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs17376456	1.000	rs13154249	chr5:93550508	C/T	cg25358565	chr5:93447407	FAM172A	0.94	7.65	0.57	4.96e-12	Diabetic retinopathy;
TGCT	cis	rs9611565	0.918	rs6002351	chr22:41757223	C/T	cg03806693	chr22:41940476	POLR3H	-1.02	-11.06	-0.7	3.31e-20	Vitiligo;
TGCT	cis	rs77106637	1.000	rs76793820	chr11:72619860	G/A	cg03713592	chr11:72463424	ARAP1	0.83	5.43	0.44	2.87e-7	Type 2 diabetes;
TGCT	cis	rs3806843	1.000	rs3733708	chr5:140181734	A/G	cg19875535	chr5:140030758	IK	0.37	6.34	0.49	3.89e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs4629710	0.592	rs13200165	chr6:131549167	G/C	cg12606694	chr6:131520996	AKAP7	0.39	4.63	0.38	9.14e-6	Multiple myeloma (IgH translocation);
TGCT	cis	rs3796352	1.000	rs114562844	chr3:52991584	C/T	cg15956490	chr3:53032818	SFMBT1	0.59	6.04	0.48	1.65e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs7666738	0.606	rs3846446	chr4:99099768	C/A	cg17366294	chr4:99064904	C4orf37	0.53	4.9	0.4	2.89e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6570726	0.791	rs448939	chr6:145808320	T/C	cg23711669	chr6:146136114	FBXO30	0.76	7.2	0.54	5.03e-11	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1153858	0.945	rs7182300	chr15:45634928	G/A	cg26924012	chr15:45694286	SPATA5L1	1.07	14.56	0.79	1.32e-28	Homoarginine levels;
TGCT	cis	rs6089829	0.888	rs4809467	chr20:61671688	A/G	cg18188782	chr20:61659543	NA	0.44	4.88	0.4	3.17e-6	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2841277	0.645	rs28380382	chr14:105410827	C/T	cg19901468	chr14:105411992	AHNAK2	-0.27	-5.76	-0.46	6.14e-8	Rheumatoid arthritis;
TGCT	cis	rs2072499	0.932	rs3001790	chr1:156165290	T/G	cg06970220	chr1:156163860	SLC25A44	0.71	6.27	0.49	5.6e-9	Testicular germ cell tumor;
TGCT	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg12756686	chr19:29218302	NA	0.78	6.68	0.51	7.13e-10	Methadone dose in opioid dependence;
TGCT	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg22920501	chr2:26401640	FAM59B	-0.72	-6.38	-0.5	3.19e-9	Gut microbiome composition (summer);
TGCT	cis	rs12497850	1.000	rs12497850	chr3:48748989	G/T	cg16497277	chr3:49208875	KLHDC8B	-0.5	-4.78	-0.39	4.87e-6	Parkinson's disease;
TGCT	cis	rs682748	0.846	rs1964566	chr5:17143610	C/T	cg23987134	chr5:17158319	LOC285696	0.21	5.12	0.42	1.15e-6	Hippocampal atrophy;
TGCT	cis	rs716316	1.000	rs716316	chr20:14908741	C/T	cg04470754	chr20:14904432	MACROD2	0.34	5.03	0.41	1.67e-6	Advanced glycation end-product levels;
TGCT	cis	rs1878931	1.000	rs1878931	chr16:3450907	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.96	10.59	0.69	4.56e-19	Body mass index (adult);
TGCT	cis	rs6500602	0.627	rs860891	chr16:4586529	C/T	cg06139259	chr16:4526053	HMOX2;NMRAL1	-0.27	-4.9	-0.4	2.87e-6	Schizophrenia;
TGCT	cis	rs6460942	0.908	rs6979046	chr7:12232744	A/G	cg06484146	chr7:12443880	VWDE	-0.52	-4.52	-0.38	1.44e-5	Coronary artery disease;
TGCT	cis	rs36405	1.000	rs36409	chr14:72357200	C/T	cg10066683	chr14:71515513	PCNX	0.24	4.7	0.39	6.69e-6	Yang-deficiency constitution;
TGCT	cis	rs3125734	0.633	rs1368157	chr10:64001114	T/C	cg19640130	chr10:64028056	RTKN2	-0.39	-5.02	-0.41	1.78e-6	Rheumatoid arthritis;
TGCT	cis	rs7769051	0.711	rs9493436	chr6:133088275	T/C	cg07930552	chr6:133119739	C6orf192	0.87	4.55	0.38	1.27e-5	Type 2 diabetes nephropathy;
TGCT	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg01570182	chr17:44337453	NA	1.09	9.86	0.66	2.72e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs78487399	0.808	rs6737882	chr2:43731908	A/G	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.76	4.65	0.39	8.53e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs11031096	0.727	rs7932702	chr11:4124372	C/T	cg18678763	chr11:4115507	RRM1	-0.5	-6.56	-0.51	1.34e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs34526934	0.608	rs7591820	chr2:177028144	G/T	cg26754761	chr2:177040938	NA	-0.28	-5.22	-0.42	7.15e-7	Obstructive sleep apnea trait (apnea hypopnea index);
TGCT	cis	rs28595532	0.748	rs72670248	chr4:119335536	A/C	cg11846333	chr4:119757529	SEC24D	0.72	4.51	0.38	1.48e-5	Cannabis dependence symptom count;
TGCT	cis	rs7729723	0.591	rs11242426	chr5:137817243	T/C	cg19169342	chr5:137827400	NA	0.35	4.99	0.41	1.97e-6	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);
TGCT	cis	rs344364	0.511	rs2982453	chr16:1949520	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.45	-5.08	-0.42	1.35e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.82	7.52	0.56	9.42e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs1971762	0.522	rs10747680	chr12:54077776	T/G	cg16917193	chr12:54089295	NA	1.37	17.65	0.85	1.25e-35	Height;
TGCT	cis	rs2439831	0.867	rs16957632	chr15:43642897	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	8.65	0.61	2.26e-14	Lung cancer in ever smokers;
TGCT	cis	rs11249608	0.548	rs6867208	chr5:178455575	G/A	cg01312482	chr5:178451176	ZNF879	-0.49	-4.76	-0.39	5.2e-6	Pubertal anthropometrics;
TGCT	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg17971929	chr21:40555470	PSMG1	-0.68	-5.99	-0.47	2.08e-8	Cognitive function;
TGCT	cis	rs7027203	0.538	rs2244395	chr9:96520723	A/G	cg13679303	chr9:96623674	NA	-0.53	-7.48	-0.56	1.18e-11	DNA methylation (variation);
TGCT	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg06238570	chr21:40685208	BRWD1	0.82	8.95	0.63	4.29e-15	Cognitive function;
TGCT	cis	rs40363	1.000	rs1690443	chr16:3517787	C/G	cg05754148	chr16:3507555	NAT15	0.46	4.56	0.38	1.22e-5	Tuberculosis;
TGCT	cis	rs769267	0.965	rs2965198	chr19:19473030	A/G	cg03709012	chr19:19516395	GATAD2A	-0.77	-6.35	-0.5	3.64e-9	Tonsillectomy;
TGCT	cis	rs12497850	0.931	rs7626445	chr3:49114544	C/T	cg06212747	chr3:49208901	KLHDC8B	0.61	5.66	0.45	9.84e-8	Parkinson's disease;
TGCT	cis	rs10540	1.000	rs116876680	chr11:517473	G/T	cg03934478	chr11:495069	RNH1	0.32	4.82	0.4	4.16e-6	Body mass index;
TGCT	cis	rs748404	0.660	rs2467742	chr15:43750237	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	4.71	0.39	6.65e-6	Lung cancer;
TGCT	cis	rs3749237	0.595	rs4855864	chr3:49521974	C/T	cg02487422	chr3:49467188	NICN1	0.58	5.92	0.47	3e-8	Resting heart rate;
TGCT	cis	rs7698623	0.702	rs1599722	chr4:88782786	A/G	cg27387453	chr4:88533842	DSPP	-0.61	-4.6	-0.38	1.03e-5	Cardiovascular disease risk factors;
TGCT	cis	rs5769765	0.862	rs138857	chr22:50199589	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.36	5.26	0.43	6.2e-7	Schizophrenia;
TGCT	cis	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg18252515	chr7:66147081	NA	1.25	7.75	0.57	2.92e-12	Diabetic kidney disease;
TGCT	cis	rs9388451	0.874	rs1159974	chr6:126090277	C/T	cg10911889	chr6:126070802	HEY2	-0.55	-5.76	-0.46	6.23e-8	Brugada syndrome;
TGCT	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg11494091	chr17:61959527	GH2	0.43	7.4	0.55	1.84e-11	Height;
TGCT	cis	rs13191362	1.000	rs13195226	chr6:163006421	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.57	4.94	0.41	2.45e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs8014204	0.836	rs888413	chr14:75267396	C/T	cg06637938	chr14:75390232	RPS6KL1	0.64	6.12	0.48	1.13e-8	Caffeine consumption;
TGCT	cis	rs4845570	1.000	rs6683364	chr1:151746202	T/A	cg07092448	chr1:151763213	TDRKH	-1.12	-8.18	-0.59	2.84e-13	Coronary artery disease;
TGCT	cis	rs11031096	0.535	rs10767886	chr11:4218391	T/C	cg18678763	chr11:4115507	RRM1	-0.43	-5.52	-0.44	1.92e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs9911578	0.967	rs2643124	chr17:56741672	T/C	cg12560992	chr17:57184187	TRIM37	0.76	9.34	0.64	4.88e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs73110464	0.609	rs6580923	chr12:53358352	A/G	cg25025879	chr12:53359317	NA	-0.52	-5.7	-0.46	8.29e-8	Cancer (pleiotropy);
TGCT	cis	rs7819412	0.643	rs7829396	chr8:10999583	C/T	cg21775007	chr8:11205619	TDH	-0.55	-5.05	-0.41	1.53e-6	Triglycerides;
TGCT	cis	rs7587476	0.765	rs2121284	chr2:215656260	T/C	cg04004882	chr2:215674386	BARD1	-0.62	-4.73	-0.39	6.11e-6	Neuroblastoma;
TGCT	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.54	4.88	0.4	3.18e-6	Prudent dietary pattern;
TGCT	cis	rs2249625	0.545	rs2249021	chr6:72889472	A/G	cg08500200	chr6:72892038	RIMS1	-0.42	-4.55	-0.38	1.27e-5	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
TGCT	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg12310025	chr6:25882481	NA	-1.13	-14.49	-0.79	1.86e-28	Urate levels;
TGCT	cis	rs514406	0.763	rs7535088	chr1:53215042	A/G	cg16325326	chr1:53192061	ZYG11B	-0.74	-9.11	-0.63	1.79e-15	Monocyte count;
TGCT	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg07061783	chr6:25882402	NA	-0.64	-6.06	-0.48	1.53e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7095607	0.842	rs2130097	chr10:69919422	A/T	cg18986048	chr10:69913749	MYPN	0.41	4.48	0.37	1.66e-5	Lung function (FVC);
TGCT	cis	rs1982963	1.000	rs10139288	chr14:52506486	T/C	cg10843707	chr14:52510701	NID2	-0.43	-6.6	-0.51	1.09e-9	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7172809	0.573	rs11853633	chr15:77466024	T/C	cg22256960	chr15:77711686	NA	-0.48	-4.63	-0.38	9.17e-6	Glucose homeostasis traits;
TGCT	cis	rs28595532	0.841	rs114768988	chr4:119744451	T/C	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs9291683	0.538	rs11727199	chr4:10036190	C/T	cg00071950	chr4:10020882	SLC2A9	0.68	8.74	0.62	1.35e-14	Bone mineral density;
TGCT	cis	rs17376456	1.000	rs17323433	chr5:93551028	G/A	cg21475434	chr5:93447410	FAM172A	0.65	4.66	0.39	8.09e-6	Diabetic retinopathy;
TGCT	cis	rs62244186	0.566	rs6766221	chr3:44882784	C/T	cg10108389	chr3:44770937	ZNF501	-0.49	-4.9	-0.4	2.96e-6	Depressive symptoms;
TGCT	cis	rs3796352	1.000	rs34340609	chr3:53077276	A/G	cg15956490	chr3:53032818	SFMBT1	0.53	6.11	0.48	1.19e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs4664308	1.000	rs56297666	chr2:160902023	G/C	cg03641300	chr2:160917029	PLA2R1	-0.27	-6.57	-0.51	1.27e-9	Idiopathic membranous nephropathy;
TGCT	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg13665807	chr20:60559372	TAF4	-0.46	-4.94	-0.41	2.48e-6	Body mass index;
TGCT	cis	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg08564027	chr20:61660810	NA	0.38	7.08	0.54	9.36e-11	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs6558530	0.965	rs7460287	chr8:1708274	G/C	cg09410841	chr8:1729607	CLN8	0.91	10.31	0.68	2.23e-18	Systolic blood pressure;
TGCT	cis	rs1670533	1.000	rs6812596	chr4:1069866	A/G	cg27284194	chr4:1044797	NA	0.69	5.94	0.47	2.66e-8	Recombination rate (females);
TGCT	cis	rs1577917	0.958	rs6921315	chr6:86471668	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-5.18	-0.42	8.84e-7	Response to antipsychotic treatment;
TGCT	cis	rs9534288	0.797	rs2404729	chr13:46617368	C/T	cg15192986	chr13:46630673	CPB2	-0.4	-5.52	-0.44	1.9e-7	Blood protein levels;
TGCT	cis	rs9527	0.518	rs7899608	chr10:104727304	C/T	cg15744005	chr10:104629667	AS3MT	-0.6	-4.84	-0.4	3.71e-6	Arsenic metabolism;
TGCT	cis	rs2046867	0.818	rs62251647	chr3:72805789	G/A	cg25664220	chr3:72788482	NA	-0.56	-7.15	-0.54	6.59e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7666738	0.791	rs28858828	chr4:98950442	C/G	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg02891314	chr5:179741120	GFPT2	-0.41	-7.06	-0.54	1.04e-10	Height;
TGCT	cis	rs2463822	0.583	rs72919467	chr11:62040102	G/A	cg06239285	chr11:62104954	ASRGL1	-0.88	-5.49	-0.44	2.15e-7	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs4237845	0.551	rs116263297	chr12:58273445	A/C	cg23860436	chr12:58378763	NA	0.33	4.54	0.38	1.32e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs6570726	0.764	rs367065	chr6:145882309	T/G	cg13319975	chr6:146136371	FBXO30	-0.51	-4.6	-0.38	1.01e-5	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs10506458	1.000	rs1009539	chr12:63414655	A/G	cg22491629	chr6:157744540	C6orf35	0.99	8.53	0.61	4.35e-14	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs4478858	0.735	rs10914360	chr1:31817476	G/A	cg00250761	chr1:31883323	NA	-0.27	-4.9	-0.4	2.92e-6	Alcohol dependence;
TGCT	cis	rs6964587	0.967	rs34344935	chr7:91835436	G/A	cg17063962	chr7:91808500	NA	0.91	9.26	0.64	7.79e-16	Breast cancer;
TGCT	cis	rs66573146	0.539	rs56659624	chr4:7069377	G/C	cg02503808	chr4:7069936	GRPEL1	-0.9	-4.56	-0.38	1.2e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs2677744	0.719	rs2002739	chr15:91452106	C/T	cg22570213	chr15:91497863	RCCD1	0.39	4.52	0.38	1.4e-5	Attention deficit hyperactivity disorder;
TGCT	cis	rs7731657	0.537	rs10053245	chr5:130353033	G/A	cg08523029	chr5:130500466	HINT1	-0.61	-5.08	-0.42	1.34e-6	Fasting plasma glucose;
TGCT	cis	rs7666738	0.830	rs4699331	chr4:99059816	T/C	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.44e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2230307	0.536	rs11166385	chr1:100443462	A/G	cg24955406	chr1:100503596	HIAT1	0.75	4.88	0.4	3.2e-6	Carotid intima media thickness;
TGCT	cis	rs889312	0.500	rs252906	chr5:56119190	G/T	cg24531977	chr5:56204891	C5orf35	-0.52	-5.33	-0.43	4.49e-7	Breast cancer;Breast cancer (early onset);
TGCT	cis	rs236907	0.859	rs17649609	chr1:171738453	G/A	cg20598894	chr1:171756153	METTL13	-0.19	-4.49	-0.37	1.61e-5	Mean platelet volume;
TGCT	cis	rs6570726	0.791	rs4332001	chr6:145934841	T/C	cg05347473	chr6:146136440	FBXO30	0.5	4.61	0.38	9.8200000000000008e-06	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs951366	0.677	rs1775140	chr1:205672107	C/A	cg14893161	chr1:205819251	PM20D1	0.54	7.19	0.54	5.3e-11	Menarche (age at onset);
TGCT	cis	rs7267979	0.586	rs6083776	chr20:25186116	G/A	cg14121845	chr20:25566513	NINL	0.45	4.86	0.4	3.51e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs911263	0.603	rs3784109	chr14:68789911	T/G	cg18825221	chr14:68749962	RAD51L1	0.22	4.5	0.37	1.52e-5	Primary biliary cholangitis;
TGCT	cis	rs9814567	1.000	rs4955485	chr3:134295843	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.91	-8.83	-0.62	8.17e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.98	-7.22	-0.54	4.68e-11	Gut microbiome composition (summer);
TGCT	cis	rs3820068	0.608	rs58140482	chr1:16043979	A/G	cg17385448	chr1:15911702	AGMAT	0.36	4.92	0.4	2.67e-6	Systolic blood pressure;
TGCT	cis	rs4148883	0.645	rs2851287	chr4:100014548	G/A	cg12011299	chr4:100065546	ADH4	0.4	5.89	0.47	3.32e-8	Alcohol dependence;
TGCT	cis	rs4851254	0.660	rs77023845	chr2:100712346	G/A	cg22139774	chr2:100720529	AFF3	-0.41	-4.52	-0.38	1.41e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs9300255	0.506	rs61388686	chr12:123810873	G/A	cg00376283	chr12:123451042	ABCB9	0.62	5.29	0.43	5.46e-7	Neutrophil percentage of white cells;
TGCT	cis	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg07424592	chr7:64974309	NA	1.36	8.15	0.59	3.36e-13	Diabetic kidney disease;
TGCT	trans	rs7615952	0.932	rs11922218	chr3:125631289	C/T	cg07211511	chr3:129823064	LOC729375	-0.45	-7.36	-0.55	2.2e-11	Blood pressure (smoking interaction);
TGCT	cis	rs2404602	0.536	rs12915248	chr15:76765615	A/T	cg26408565	chr15:76604113	ETFA	-0.36	-4.93	-0.4	2.62e-6	Blood metabolite levels;
TGCT	cis	rs877282	0.898	rs10904547	chr10:766283	C/T	cg17470449	chr10:769945	NA	0.37	5.59	0.45	1.37e-7	Uric acid levels;
TGCT	cis	rs57994353	0.568	rs10747044	chr9:139319129	G/T	cg13741927	chr9:139327495	INPP5E	-0.24	-5.63	-0.45	1.14e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs61677309	1.000	rs1599809	chr11:118179200	G/A	cg11038285	chr11:118016290	SCN4B	-0.49	-4.52	-0.38	1.41e-5	Lung cancer in ever smokers;
TGCT	cis	rs17102423	0.559	rs7160037	chr14:65490948	T/C	cg11161011	chr14:65562177	MAX	-0.46	-5.33	-0.43	4.45e-7	Obesity-related traits;
TGCT	cis	rs9677476	0.516	rs6706191	chr2:232040047	T/G	cg07929768	chr2:232055508	NA	0.33	5.24	0.43	6.78e-7	Food antigen IgG levels;
TGCT	cis	rs7959452	0.562	rs10878975	chr12:69782044	G/C	cg20891283	chr12:69753455	YEATS4	0.83	8.7	0.62	1.68e-14	Blood protein levels;
TGCT	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg06618935	chr21:46677482	NA	-0.37	-5.83	-0.46	4.48e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2840044	1.000	rs225277	chr17:33973311	G/A	cg05299278	chr17:33885742	SLFN14	0.22	4.98	0.41	2.07e-6	Response to radiotherapy in cancer (late toxicity);
TGCT	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg14784868	chr12:69753453	YEATS4	0.89	10.43	0.68	1.11e-18	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs62064224	0.791	rs11654833	chr17:30667728	C/T	cg18200150	chr17:30822561	MYO1D	0.59	7.64	0.57	5.14e-12	Schizophrenia;
TGCT	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.49	-5.82	-0.46	4.68e-8	Longevity;Endometriosis;
TGCT	cis	rs7666738	0.830	rs35644814	chr4:98886111	G/C	cg18180107	chr4:99064573	C4orf37	0.53	4.84	0.4	3.83e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs13168506	0.552	rs889010	chr5:135572910	C/A	cg16684184	chr5:135415129	NA	0.25	4.76	0.39	5.4e-6	Stroke;
TGCT	cis	rs9868809	0.505	rs13316551	chr3:48745167	A/C	cg00383909	chr3:49044727	WDR6	1.06	6.28	0.49	5.26e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs35934224	0.783	rs34675706	chr22:19847618	G/A	cg11182965	chr22:19864308	TXNRD2	-0.36	-4.95	-0.41	2.33e-6	Glaucoma (primary open-angle);
TGCT	trans	rs877282	0.891	rs34383514	chr10:800181	T/C	cg22713356	chr15:30763199	NA	1.18	9.92	0.67	1.96e-17	Uric acid levels;
TGCT	cis	rs7095607	0.785	rs4746731	chr10:69920924	C/A	cg18986048	chr10:69913749	MYPN	0.41	4.48	0.37	1.66e-5	Lung function (FVC);
TGCT	cis	rs514406	0.763	rs7535088	chr1:53215042	A/G	cg08736216	chr1:53307985	ZYG11A	0.25	4.77	0.39	4.98e-6	Monocyte count;
TGCT	cis	rs4767364	0.961	rs10850024	chr12:112718510	C/A	cg10833066	chr12:111807467	FAM109A	0.33	5.13	0.42	1.08e-6	Oral cavity and pharyngeal cancer;
TGCT	cis	rs427394	0.802	rs274721	chr5:6719164	C/T	cg10857441	chr5:6722123	POLS	-0.32	-7.8	-0.57	2.17e-12	Menopause (age at onset);
TGCT	cis	rs7044106	0.708	rs1324472	chr9:123375110	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.58	6.29	0.49	5.01e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg11301795	chr4:187892539	NA	0.35	5.35	0.43	4.08e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6674176	0.569	rs34830883	chr1:44405339	T/C	cg13606994	chr1:44402422	ARTN	-0.53	-5.69	-0.46	8.53e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs9372498	0.536	rs724868	chr6:118795152	C/T	cg21191810	chr6:118973309	C6orf204	-0.37	-4.76	-0.39	5.36e-6	Diastolic blood pressure;
TGCT	cis	rs1577917	0.727	rs9444361	chr6:86400900	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.57	5.13	0.42	1.07e-6	Response to antipsychotic treatment;
TGCT	cis	rs362272	0.524	rs13150241	chr4:3367281	A/G	cg06533319	chr4:3265114	C4orf44	-0.28	-5.69	-0.46	8.58e-8	Serum sulfate level;
TGCT	cis	rs71636778	0.509	rs17356923	chr1:27282676	G/A	cg23921621	chr1:27994728	IFI6	-0.43	-4.61	-0.38	9.92e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
TGCT	cis	rs9611565	0.512	rs4820444	chr22:42202606	A/G	cg17554472	chr22:41940697	POLR3H	0.46	4.69	0.39	7.09e-6	Vitiligo;
TGCT	cis	rs9486715	0.867	rs9373829	chr6:96897201	A/C	cg06623918	chr6:96969491	KIAA0776	-1.07	-15.72	-0.82	2.66e-31	Headache;
TGCT	cis	rs4499344	0.604	rs259245	chr19:33145106	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.76	7.52	0.56	9.49e-12	Mean platelet volume;
TGCT	trans	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg21659725	chr3:3221576	CRBN	0.76	9.35	0.64	4.6e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs9372253	1.000	rs7740028	chr6:110719180	A/G	cg01119278	chr6:110721349	DDO	-0.37	-5.92	-0.47	2.88e-8	Platelet distribution width;
TGCT	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg23708337	chr7:1209742	NA	0.44	4.87	0.4	3.27e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs12776158	0.901	rs59262400	chr10:71216310	G/A	cg12610070	chr10:71211762	TSPAN15	-0.55	-4.83	-0.4	3.87e-6	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs910316	0.934	rs7141705	chr14:75655352	G/C	cg11812906	chr14:75593930	NEK9	-0.71	-6.83	-0.52	3.43e-10	Height;
TGCT	cis	rs7772486	0.719	rs7753770	chr6:146066161	G/A	cg23711669	chr6:146136114	FBXO30	-0.97	-11.03	-0.7	4.03e-20	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7394190	0.748	rs34163229	chr10:75406912	G/T	cg07699608	chr10:75541558	CHCHD1	0.6	4.49	0.37	1.59e-5	Incident atrial fibrillation;
TGCT	cis	rs6121246	0.529	rs6060291	chr20:30198043	T/G	cg13852791	chr20:30311386	BCL2L1	0.7	4.58	0.38	1.1e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs9914544	1.000	rs1037036	chr17:18764077	C/T	cg26378065	chr17:18585709	ZNF286B	0.51	4.57	0.38	1.17e-5	Educational attainment (years of education);
TGCT	cis	rs11098499	0.863	rs1383532	chr4:120434404	A/T	cg09307838	chr4:120376055	NA	-0.71	-6.43	-0.5	2.53e-9	Corneal astigmatism;
TGCT	cis	rs916888	0.821	rs199512	chr17:44857352	T/C	cg01570182	chr17:44337453	NA	-1.01	-9.1	-0.63	1.83e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg20607798	chr8:58055168	NA	0.7	5.94	0.47	2.66e-8	Developmental language disorder (linguistic errors);
TGCT	trans	rs9951602	0.512	rs1599634	chr18:76643645	T/C	cg02800362	chr5:177631904	HNRNPAB	1.13	12.94	0.76	9.39e-25	Obesity-related traits;
TGCT	cis	rs938554	0.735	rs11942223	chr4:9962765	T/C	cg11197905	chr4:10459435	ZNF518B	-0.29	-4.44	-0.37	1.98e-5	Blood metabolite levels;
TGCT	cis	rs885389	1.000	rs867411	chr12:131621789	T/G	cg07124762	chr12:131619285	GPR133	-0.31	-6.33	-0.49	4.15e-9	RR interval (heart rate);
TGCT	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg12310025	chr6:25882481	NA	-0.59	-6.04	-0.48	1.63e-8	Blood metabolite levels;
TGCT	trans	rs208520	0.690	rs12213561	chr6:66705646	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	11.22	0.71	1.34e-20	Exhaled nitric oxide output;
TGCT	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs4780355	1.000	rs4780355	chr16:11347858	T/C	cg00044050	chr16:11439710	C16orf75	0.55	4.78	0.39	4.93e-6	Crohn's disease and psoriasis;
TGCT	cis	rs473651	0.904	rs10929275	chr2:239323169	A/G	cg18131467	chr2:239335373	ASB1	0.99	13.63	0.77	2.02e-26	Multiple system atrophy;
TGCT	cis	rs1580019	0.563	rs4723169	chr7:32567577	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.14	14.94	0.8	1.6800000000000001e-29	Cognitive ability;
TGCT	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.69	-5.47	-0.44	2.41e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9583531	0.527	rs6492302	chr13:111352354	C/T	cg24331049	chr13:111365604	ING1	-0.75	-7.31	-0.55	2.9100000000000002e-11	Coronary artery disease;
TGCT	cis	rs12893668	0.703	rs35498576	chr14:104025893	T/C	cg26031613	chr14:104095156	KLC1	-0.54	-4.55	-0.38	1.28e-5	Reticulocyte count;
TGCT	cis	rs72634258	0.554	rs4908704	chr1:7918904	A/G	cg26816564	chr1:7831052	VAMP3	0.64	4.94	0.41	2.46e-6	Inflammatory bowel disease;
TGCT	cis	rs4499344	0.633	rs259282	chr19:33163043	C/T	cg26639809	chr19:33781782	NA	0.22	4.56	0.38	1.22e-5	Mean platelet volume;
TGCT	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg07507251	chr3:52567010	NT5DC2	0.47	6.7	0.52	6.47e-10	Bipolar disorder;
TGCT	cis	rs17345786	1.000	rs3804775	chr3:101306507	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.86	8.79	0.62	1.01e-14	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg06481639	chr22:41940642	POLR3H	0.75	6.66	0.51	8.03e-10	Vitiligo;
TGCT	cis	rs78487399	0.731	rs6747229	chr2:43712610	T/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.42	-4.95	-0.41	2.34e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg09517075	chr8:22133004	PIWIL2	0.25	4.76	0.39	5.21e-6	Hypertriglyceridemia;
TGCT	cis	rs2404602	0.563	rs12914005	chr15:76765667	A/G	cg22467129	chr15:76604101	ETFA	-0.48	-6.01	-0.48	1.91e-8	Blood metabolite levels;
TGCT	cis	rs4888262	0.526	rs4887772	chr16:74537591	C/T	cg01733217	chr16:74700730	RFWD3	0.68	6.88	0.53	2.6200000000000003e-10	Testicular germ cell tumor;
TGCT	cis	rs7829975	0.533	rs1039917	chr8:8718850	C/T	cg15556689	chr8:8085844	FLJ10661	0.78	7.48	0.56	1.21e-11	Mood instability;
TGCT	cis	rs6582630	0.519	rs11495724	chr12:38337507	T/C	cg13010199	chr12:38710504	ALG10B	0.58	4.55	0.38	1.26e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs6061231	0.631	rs2427318	chr20:60975727	G/T	cg24112000	chr20:60950667	NA	-0.35	-4.91	-0.4	2.77e-6	Colorectal cancer;
TGCT	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg03609598	chr5:56110824	MAP3K1	-0.59	-4.78	-0.39	4.81e-6	Initial pursuit acceleration;
TGCT	cis	rs62244186	0.659	rs1806579	chr3:44509281	T/C	cg10263370	chr3:44754102	ZNF502	-0.4	-4.8	-0.4	4.4e-6	Depressive symptoms;
TGCT	cis	rs10465746	0.725	rs12070578	chr1:84349607	A/G	cg10977910	chr1:84465055	TTLL7	0.68	6.7	0.52	6.46e-10	Obesity-related traits;
TGCT	cis	rs2456568	0.867	rs10501810	chr11:93666589	C/G	cg17595323	chr11:93583763	C11orf90	-0.45	-5.85	-0.46	4.13e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs1577917	0.876	rs12190735	chr6:86686467	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-4.94	-0.41	2.43e-6	Response to antipsychotic treatment;
TGCT	cis	rs7178572	0.524	rs1473922	chr15:77656798	G/T	cg15453836	chr15:77711506	NA	-0.42	-4.79	-0.4	4.68e-6	Type 2 diabetes;
TGCT	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg11764359	chr7:65958608	NA	0.55	5.08	0.42	1.34e-6	Aortic root size;
TGCT	cis	rs7829975	0.744	rs2409092	chr8:8682192	A/T	cg15556689	chr8:8085844	FLJ10661	0.69	6.43	0.5	2.56e-9	Mood instability;
TGCT	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg21724239	chr8:58056113	NA	0.47	5.05	0.41	1.54e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs700651	0.753	rs10207232	chr2:198893813	A/G	cg00792783	chr2:198669748	PLCL1	0.59	5.19	0.42	8.27e-7	Intracranial aneurysm;
TGCT	cis	rs3087591	0.960	rs11080146	chr17:29578724	C/T	cg24425628	chr17:29625626	OMG;NF1	-0.46	-7.19	-0.54	5.31e-11	Hip circumference;
TGCT	cis	rs2243480	1.000	rs465359	chr7:65558164	C/T	cg07424592	chr7:64974309	NA	1.26	8.11	0.59	4.17e-13	Diabetic kidney disease;
TGCT	cis	rs892961	0.932	rs8066646	chr17:75414192	C/T	cg05865280	chr17:75406074	SEPT9	0.28	6.71	0.52	6.16e-10	Airflow obstruction;
TGCT	cis	rs2228479	0.850	rs11639788	chr16:89807543	G/A	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs6815814	0.861	rs73142654	chr4:38785697	T/A	cg02016764	chr4:38805732	TLR1	-0.27	-4.46	-0.37	1.78e-5	Breast cancer;
TGCT	cis	rs7209700	0.547	rs16941776	chr17:45343141	C/T	cg21624342	chr17:45890973	OSBPL7	0.19	4.77	0.39	5.02e-6	IgG glycosylation;
TGCT	cis	rs6977660	0.507	rs72591448	chr7:19775298	C/T	cg07541023	chr7:19748670	TWISTNB	0.98	6.33	0.49	4.02e-9	Thyroid stimulating hormone;
TGCT	cis	rs16910800	0.731	rs55908012	chr11:23191640	G/A	cg20040320	chr11:23191996	NA	-0.51	-4.47	-0.37	1.71e-5	Cancer;
TGCT	cis	rs1941023	0.584	rs6591578	chr11:60158649	G/A	cg08716584	chr11:60157161	MS4A7	-0.32	-4.92	-0.4	2.7e-6	Congenital heart disease (maternal effect);
TGCT	cis	rs7617773	0.638	rs7644414	chr3:48299079	A/T	cg11946769	chr3:48343235	NME6	0.69	5.64	0.45	1.1e-7	Coronary artery disease;
TGCT	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg06112835	chr11:68658793	MRPL21	0.46	8.07	0.59	5.25e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg17554472	chr22:41940697	POLR3H	0.49	5.07	0.41	1.38e-6	Vitiligo;
TGCT	cis	rs12681287	0.609	rs13279850	chr8:87477800	C/T	cg27223183	chr8:87520930	FAM82B	-0.84	-6.11	-0.48	1.19e-8	Caudate activity during reward;
TGCT	cis	rs1538970	0.810	rs12067642	chr1:45927517	G/T	cg05343316	chr1:45956843	TESK2	0.79	6.38	0.5	3.23e-9	Platelet count;
TGCT	cis	rs240764	0.697	rs846799	chr6:101270345	A/G	cg21058520	chr6:100914733	NA	-0.35	-4.56	-0.38	1.22e-5	Neuroticism;
TGCT	cis	rs3733631	1.000	rs6831087	chr4:104619090	C/A	cg24090629	chr4:104641072	TACR3	-0.73	-5.72	-0.46	7.65e-8	Menarche (age at onset);
TGCT	cis	rs1843834	0.539	rs6749402	chr2:225443901	T/G	cg12698349	chr2:225449008	CUL3	0.78	6.41	0.5	2.77e-9	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs7647973	0.626	rs2329021	chr3:49679072	G/A	cg03060546	chr3:49711283	APEH	0.63	5.63	0.45	1.12e-7	Menarche (age at onset);
TGCT	cis	rs433852	0.718	rs386551	chr19:49138286	C/G	cg07996880	chr19:49339085	HSD17B14	-0.28	-4.69	-0.39	7.03e-6	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs17539620	0.534	rs7768635	chr6:154827861	C/T	cg17771515	chr6:154831774	CNKSR3	0.67	4.6	0.38	1.02e-5	Lipoprotein (a) levels;
TGCT	cis	rs7945705	0.935	rs11042103	chr11:8888700	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.42	4.73	0.39	5.99e-6	Hemoglobin concentration;
TGCT	cis	rs6121246	0.609	rs6060948	chr20:30376393	C/G	cg10886678	chr20:30946050	ASXL1	-0.53	-4.5	-0.37	1.55e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs72647484	0.730	rs72647483	chr1:22587009	T/C	cg21876283	chr1:22149684	LDLRAD2;HSPG2	0.27	4.52	0.38	1.42e-5	Colorectal cancer;
TGCT	cis	rs3806843	0.735	rs778597	chr5:140040665	A/G	cg19875535	chr5:140030758	IK	0.37	6.28	0.49	5.14e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7698623	0.850	rs10011586	chr4:88798921	C/T	cg27387453	chr4:88533842	DSPP	-0.6	-4.53	-0.38	1.35e-5	Cardiovascular disease risk factors;
TGCT	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg13206674	chr6:150067644	NUP43	0.52	4.51	0.38	1.5e-5	Lung cancer;
TGCT	cis	rs9916302	0.904	rs68178216	chr17:37526241	A/C	cg15445000	chr17:37608096	MED1	-0.35	-5.05	-0.41	1.53e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs1018836	0.923	rs34126139	chr8:91572045	T/G	cg16814680	chr8:91681699	NA	-0.88	-9.4	-0.65	3.57e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10479542	0.806	rs4700836	chr5:178976393	A/G	cg19723775	chr5:179050963	HNRNPH1	0.48	4.64	0.38	8.71e-6	Lung cancer;
TGCT	cis	rs10875746	0.903	rs12306451	chr12:48483241	T/C	cg20731937	chr12:48336164	NA	0.62	4.95	0.41	2.36e-6	Longevity (90 years and older);
TGCT	cis	rs9906944	0.707	rs4794019	chr17:47107290	G/T	cg07075026	chr17:47091521	IGF2BP1	-0.43	-4.76	-0.39	5.4e-6	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs1215050	0.791	rs165242	chr4:98686482	A/C	cg05340658	chr4:99064831	C4orf37	-0.44	-5.18	-0.42	8.76e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs10782582	0.609	rs6656501	chr1:76266126	A/C	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.52	4.54	0.38	1.31e-5	Daytime sleep phenotypes;
TGCT	cis	rs11644362	1.000	rs4781349	chr16:12987249	T/C	cg06890432	chr16:12997467	SHISA9	-0.6	-6.49	-0.5	1.88e-9	Positive affect;Subjective well-being;
TGCT	cis	rs6598541	0.505	rs2175795	chr15:99312854	A/G	cg18742785	chr15:100270048	LYSMD4	-0.26	-4.55	-0.38	1.25e-5	Urate levels;
TGCT	cis	rs6500602	0.647	rs4786519	chr16:4584406	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.3	5.51	0.44	1.95e-7	Schizophrenia;
TGCT	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg24060327	chr5:131705240	SLC22A5	-0.74	-7.96	-0.58	9.5e-13	Acylcarnitine levels;
TGCT	cis	rs9902453	0.868	rs12944395	chr17:28323499	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.81	-7.33	-0.55	2.6e-11	Coffee consumption (cups per day);
TGCT	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg06618935	chr21:46677482	NA	-0.37	-5.56	-0.45	1.58e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2180341	1.000	rs7756336	chr6:127650299	T/C	cg27446573	chr6:127587934	RNF146	1.12	10.11	0.67	6.87e-18	Breast cancer;
TGCT	cis	rs4727027	0.901	rs10952792	chr7:148760501	C/T	cg23583168	chr7:148888333	NA	-0.69	-8.67	-0.61	2.04e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs10992471	0.580	rs10992304	chr9:95085365	G/A	cg14631576	chr9:95140430	CENPP	-0.3	-4.49	-0.37	1.62e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg03452623	chr4:187889614	NA	-0.36	-5.43	-0.44	2.85e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9611565	0.592	rs57102627	chr22:41987627	T/C	cg06634786	chr22:41940651	POLR3H	-0.83	-7.66	-0.57	4.6e-12	Vitiligo;
TGCT	cis	rs10791097	0.694	rs7125622	chr11:130743388	T/C	cg12179176	chr11:130786555	SNX19	0.84	10.17	0.67	4.95e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs7772486	0.817	rs2748491	chr6:146327759	T/C	cg05347473	chr6:146136440	FBXO30	0.52	4.98	0.41	2.12e-6	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs9329221	0.741	rs13264066	chr8:9804075	C/G	cg06636001	chr8:8085503	FLJ10661	-0.77	-6.93	-0.53	2.02e-10	Neuroticism;
TGCT	cis	rs6424115	0.830	rs3003336	chr1:24201448	C/T	cg15997130	chr1:24165203	NA	0.85	9.25	0.64	8.02e-16	Immature fraction of reticulocytes;
TGCT	cis	rs2836633	0.931	rs2836635	chr21:40069850	A/G	cg05519781	chr21:40033154	ERG	0.51	4.97	0.41	2.17e-6	Coronary artery disease;
TGCT	cis	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg18200150	chr17:30822561	MYO1D	-0.55	-7.33	-0.55	2.65e-11	Schizophrenia;
TGCT	cis	rs459571	0.959	rs456205	chr9:136911146	G/A	cg13789015	chr9:136890014	NCRNA00094	0.4	7.15	0.54	6.64e-11	Platelet distribution width;
TGCT	cis	rs9868809	0.505	rs9811027	chr3:48725014	G/C	cg00383909	chr3:49044727	WDR6	1.06	6.28	0.49	5.26e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs7582180	0.614	rs1530030	chr2:101009600	G/A	cg08017756	chr2:100939284	LONRF2	-0.3	-4.73	-0.39	6.02e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1997103	1.000	rs2177802	chr7:55410789	G/A	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs228437	0.586	rs7763955	chr6:134939628	C/A	cg09872934	chr6:134495829	SGK1	-0.55	-4.65	-0.39	8.39e-6	Melanoma;
TGCT	cis	rs72781680	0.898	rs17762651	chr2:24115922	A/G	cg08917208	chr2:24149416	ATAD2B	0.78	4.79	0.4	4.69e-6	Lymphocyte counts;
TGCT	cis	rs9341808	0.718	rs9443735	chr6:80820474	G/T	cg08355045	chr6:80787529	NA	0.32	5.83	0.46	4.48e-8	Sitting height ratio;
TGCT	cis	rs7267979	1.000	rs2259837	chr20:25280205	T/C	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2702888	0.502	rs2702935	chr8:6751827	A/G	cg26795848	chr8:6756730	NA	-0.31	-6.13	-0.48	1.1e-8	Blood pressure;
TGCT	cis	rs1005224	0.926	rs12892551	chr14:76159902	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.63	-5.61	-0.45	1.28e-7	Large artery stroke;
TGCT	cis	rs55692411	0.537	rs62262118	chr3:50003586	G/A	cg14019146	chr3:50243930	SLC38A3	-0.21	-4.44	-0.37	1.98e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs2075371	1.000	rs2241334	chr7:133979225	C/G	cg11752832	chr7:134001865	SLC35B4	0.69	6.32	0.49	4.36e-9	Mean platelet volume;
TGCT	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg18402987	chr7:1209562	NA	0.7	5.67	0.45	9.66e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1163251	0.837	rs839612	chr1:120247176	T/C	cg19096424	chr1:120255104	PHGDH	0.6	5.93	0.47	2.76e-8	Blood metabolite levels;
TGCT	cis	rs861020	0.630	rs616544	chr1:210007368	T/C	cg05527609	chr1:210001259	C1orf107	0.86	7.54	0.56	8.69e-12	Orofacial clefts;
TGCT	trans	rs8073060	0.586	rs7208672	chr17:33989759	G/A	cg19694781	chr19:47549865	TMEM160	-0.6	-13.37	-0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs62244186	0.541	rs9859879	chr3:44840166	G/A	cg10108389	chr3:44770937	ZNF501	-0.48	-4.83	-0.4	4.02e-6	Depressive symptoms;
TGCT	cis	rs9549367	0.774	rs2287246	chr13:113889127	A/G	cg18105134	chr13:113819100	PROZ	-0.34	-5.49	-0.44	2.18e-7	Platelet distribution width;
TGCT	cis	rs739496	0.579	rs3741998	chr12:112339843	A/G	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	5.53	0.44	1.8e-7	Alzheimer's disease;
TGCT	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg21724239	chr8:58056113	NA	0.48	5.17	0.42	9.18e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs71597109	0.957	rs13136796	chr4:102736743	A/T	cg14855874	chr4:102712397	BANK1	0.42	4.47	0.37	1.77e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs7552404	0.883	rs2185436	chr1:76203783	A/G	cg10523679	chr1:76189770	ACADM	0.89	9.88	0.66	2.42e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs10435719	0.902	rs4840599	chr8:11805380	C/T	cg02840367	chr8:11660030	FDFT1	0.54	4.54	0.38	1.31e-5	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg09021430	chr5:549028	NA	-0.37	-5.29	-0.43	5.46e-7	Lung disease severity in cystic fibrosis;
TGCT	cis	rs136211	0.577	rs9610498	chr22:36777739	C/T	cg16924664	chr22:36878180	TXN2	0.51	4.83	0.4	3.99e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs9326248	0.501	rs4938351	chr11:117022352	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.6	5.6	0.45	1.33e-7	Blood protein levels;
TGCT	cis	rs2760061	0.583	rs708118	chr1:228201801	A/G	cg18477163	chr1:228402036	OBSCN	-0.32	-6.62	-0.51	9.85e-10	Diastolic blood pressure;
TGCT	cis	rs12368653	0.641	rs11172300	chr12:58076515	C/T	cg12615879	chr12:58013172	SLC26A10	0.48	5.76	0.46	6.37e-8	Multiple sclerosis;
TGCT	cis	rs6460942	1.000	rs62448568	chr7:12407445	A/G	cg06484146	chr7:12443880	VWDE	-0.57	-5.34	-0.43	4.36e-7	Coronary artery disease;
TGCT	trans	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg27523141	chr10:43048294	ZNF37B	0.73	8.58	0.61	3.32e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs617219	0.710	rs16876598	chr5:78573970	T/C	cg23514016	chr5:78407564	BHMT	-0.32	-4.87	-0.4	3.38e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg12667521	chr19:29218732	NA	0.51	6.21	0.49	7.46e-9	Methadone dose in opioid dependence;
TGCT	cis	rs3771570	0.892	rs62186433	chr2:242257835	A/G	cg21155796	chr2:242212141	HDLBP	0.96	6.36	0.5	3.5e-9	Prostate cancer;
TGCT	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.36	4.58	0.38	1.12e-5	Total body bone mineral density;
TGCT	cis	rs9303401	0.659	rs35103007	chr17:56900738	G/A	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs4664308	0.810	rs62175552	chr2:160937220	T/G	cg03641300	chr2:160917029	PLA2R1	-0.28	-6.83	-0.52	3.43e-10	Idiopathic membranous nephropathy;
TGCT	cis	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg07424592	chr7:64974309	NA	-1.27	-7.84	-0.58	1.8e-12	Diabetic kidney disease;
TGCT	cis	rs739496	0.947	rs2301622	chr12:111895203	C/G	cg10833066	chr12:111807467	FAM109A	0.36	5.51	0.44	2.01e-7	Platelet count;
TGCT	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg10047753	chr17:41438598	NA	0.97	9.99	0.67	1.37e-17	Menopause (age at onset);
TGCT	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg08736216	chr1:53307985	ZYG11A	-0.24	-4.74	-0.39	5.75e-6	Monocyte count;
TGCT	cis	rs13256369	0.901	rs13251887	chr8:8568678	G/A	cg18904891	chr8:8559673	CLDN23	0.59	5.54	0.45	1.73e-7	Obesity-related traits;
TGCT	trans	rs6089829	0.851	rs6089827	chr20:61668845	C/T	cg17470723	chr8:74884337	TCEB1	0.77	7.4	0.55	1.82e-11	Prostate cancer (SNP x SNP interaction);
TGCT	trans	rs1075232	0.677	rs72714666	chr15:31492226	T/C	cg18108818	chr7:102574475	FBXL13;LRRC17	0.83	6.81	0.52	3.83e-10	Survival in colorectal cancer (non-distant metastatic);
TGCT	cis	rs12220238	0.841	rs7919010	chr10:76111137	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.87	6.32	0.49	4.31e-9	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs9303401	0.659	rs62083436	chr17:57031742	G/A	cg25039879	chr17:56429692	SUPT4H1	0.52	4.62	0.38	9.48e-6	Cognitive test performance;
TGCT	cis	rs319204	1.000	rs319231	chr5:146242245	C/T	cg25021259	chr5:146258546	PPP2R2B	0.36	4.53	0.38	1.37e-5	Schizophrenia;
TGCT	cis	rs929354	0.742	rs7806775	chr7:156947199	A/G	cg05182265	chr7:156933206	UBE3C	-0.39	-8.98	-0.63	3.72e-15	Body mass index;
TGCT	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg16325326	chr1:53192061	ZYG11B	-0.7	-8.6	-0.61	2.87e-14	Monocyte count;
TGCT	cis	rs6665290	0.901	rs3795453	chr1:227205331	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.93	-16.65	-0.83	2.06e-33	Myeloid white cell count;
TGCT	cis	rs5769707	0.706	rs763128	chr22:50018045	G/A	cg05373962	chr22:49881684	NA	-0.31	-5.31	-0.43	4.95e-7	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs7666738	0.830	rs28594127	chr4:99001121	T/G	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7044106	0.762	rs3904197	chr9:123480378	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.61	6.53	0.51	1.52e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs651907	0.535	rs34648996	chr3:101511202	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	4.85	0.4	3.68e-6	Colorectal cancer;
TGCT	cis	rs7772486	0.875	rs9390377	chr6:146386932	G/A	cg05347473	chr6:146136440	FBXO30	0.56	5.22	0.42	7.31e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg05785598	chr3:49045655	WDR6	-0.36	-4.68	-0.39	7.35e-6	Menarche (age at onset);
TGCT	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg11062466	chr8:58055876	NA	0.38	4.62	0.38	9.5e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg05665937	chr4:1216051	CTBP1	0.25	4.68	0.39	7.33e-6	Obesity-related traits;
TGCT	cis	rs17376456	1.000	rs17376456	chr5:93557702	C/T	cg21475434	chr5:93447410	FAM172A	-0.63	-4.62	-0.38	9.66e-6	Diabetic retinopathy;
TGCT	cis	rs6540559	0.673	rs11803382	chr1:209986426	G/A	cg21951975	chr1:209979733	IRF6	0.69	5.42	0.44	2.99e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs4409675	0.597	rs1467464	chr1:28211650	T/C	cg23691781	chr1:28212827	C1orf38	0.26	5.27	0.43	5.89e-7	Corneal astigmatism;
TGCT	cis	rs9325144	0.647	rs11169189	chr12:39097078	A/T	cg26384229	chr12:38710491	ALG10B	-0.51	-4.89	-0.4	3.1e-6	Morning vs. evening chronotype;
TGCT	cis	rs7429990	0.930	rs13072132	chr3:47866161	A/G	cg11946769	chr3:48343235	NME6	0.59	4.45	0.37	1.87e-5	Educational attainment (years of education);
TGCT	cis	rs10858047	0.883	rs1564824	chr1:115123747	A/G	cg12756093	chr1:115239321	AMPD1	0.47	4.96	0.41	2.27e-6	Autism;
TGCT	cis	rs3617	0.532	rs9836499	chr3:52904524	G/T	cg11645453	chr3:52864694	ITIH4	-0.27	-5.16	-0.42	9.4e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2639990	1.000	rs655156	chr18:72898181	T/C	cg02750262	chr18:72916776	ZADH2	0.88	6.67	0.51	7.46e-10	Vascular endothelial growth factor levels;
TGCT	cis	rs704	0.739	rs2027993	chr17:26706946	G/T	cg10342447	chr17:26645325	TMEM97	-0.48	-4.67	-0.39	7.82e-6	Osteoprotegerin levels;
TGCT	cis	rs2652822	0.504	rs2134263	chr15:63365394	C/T	cg12855773	chr15:63363890	TPM1	-0.17	-4.7	-0.39	6.82e-6	Metabolic traits;
TGCT	cis	rs9549367	0.713	rs9577211	chr13:113830718	G/C	cg09473364	chr13:112927190	NA	-0.3	-4.64	-0.38	8.7e-6	Platelet distribution width;
TGCT	cis	rs2070488	1.000	rs13072809	chr3:38468171	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	9.66	0.66	8.59e-17	Electrocardiographic conduction measures;
TGCT	cis	rs33794	0.935	rs33789	chr3:45296367	A/G	cg18645101	chr3:44551900	NA	0.53	4.67	0.39	7.84e-6	Lung function (forced expiratory volume in 1 second);
TGCT	trans	rs208520	1.000	rs12190187	chr6:66973207	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.86	7.83	0.58	1.85e-12	Exhaled nitric oxide output;
TGCT	cis	rs2290402	0.572	rs3736087	chr4:876318	C/T	cg23332689	chr4:987652	IDUA;SLC26A1	0.36	5.44	0.44	2.77e-7	Type 2 diabetes;
TGCT	cis	rs78487399	0.908	rs12475503	chr2:43831319	A/G	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.66	4.67	0.39	7.66e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs9611519	0.929	rs9611469	chr22:41433319	T/C	cg03806693	chr22:41940476	POLR3H	-0.7	-6.22	-0.49	6.88e-9	Neuroticism;
TGCT	trans	rs208515	0.592	rs10944862	chr6:66674215	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.93	10.3	0.68	2.34e-18	Exhaled nitric oxide levels;
TGCT	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg04772025	chr11:68637568	NA	0.59	6.7	0.52	6.48e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs12049351	0.675	rs754024	chr1:229637414	C/T	cg12130225	chr1:229698885	NA	0.39	4.58	0.38	1.12e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs2677744	0.688	rs7183098	chr15:91452294	A/G	cg23684204	chr15:91497937	RCCD1	0.33	4.82	0.4	4.1e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs9291683	0.588	rs35866697	chr4:10018604	C/A	cg11266682	chr4:10021025	SLC2A9	0.73	10.8	0.7	1.4e-19	Bone mineral density;
TGCT	cis	rs7582180	0.675	rs4851313	chr2:101029002	A/G	cg08017756	chr2:100939284	LONRF2	0.3	4.52	0.38	1.44e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs17767294	0.708	rs72845897	chr6:27699357	T/C	cg08851530	chr6:28072375	NA	1.56	7.38	0.55	1.95e-11	Parkinson's disease;
TGCT	cis	rs7267979	0.789	rs4815400	chr20:25292560	T/C	cg16686733	chr20:25566563	NINL	-0.52	-4.93	-0.4	2.61e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7223966	1.000	rs11657306	chr17:61704822	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	5.17	0.42	9.12e-7	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs7528684	0.752	rs2050568	chr1:157770241	C/T	cg17134153	chr1:157670328	FCRL3	-0.27	-4.86	-0.4	3.51e-6	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;
TGCT	cis	rs7267979	0.966	rs6037097	chr20:25347221	C/T	cg03522245	chr20:25566470	NINL	0.59	6.21	0.49	7.19e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9296092	0.517	rs78978280	chr6:33520747	T/A	cg13560919	chr6:33536144	NA	-0.2	-4.64	-0.38	8.68e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs61990749	0.597	rs1048147	chr14:78139988	C/A	cg02301378	chr14:78227641	SNW1;C14orf178	-0.61	-4.45	-0.37	1.89e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg09323728	chr8:95962352	TP53INP1	-0.52	-6.6	-0.51	1.05e-9	Type 2 diabetes;
TGCT	cis	rs2880765	0.835	rs730372	chr15:86038193	G/T	cg13263323	chr15:86062960	AKAP13	0.22	4.79	0.4	4.68e-6	Coronary artery disease;
TGCT	cis	rs2299587	0.610	rs7001974	chr8:17773295	C/T	cg01800426	chr8:17659068	MTUS1	-0.7	-6.03	-0.48	1.72e-8	Economic and political preferences;
TGCT	cis	rs7809950	1.000	rs10258385	chr7:107243350	T/C	cg23024343	chr7:107201750	COG5	0.33	5.29	0.43	5.36e-7	Coronary artery disease;
TGCT	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg20573242	chr4:122745356	CCNA2	0.63	5.59	0.45	1.37e-7	Type 2 diabetes;
TGCT	cis	rs9398235	0.929	rs4945860	chr6:110728383	A/G	cg00083206	chr6:110721305	DDO	0.46	4.64	0.38	8.68e-6	Systemic lupus erythematosus;
TGCT	cis	rs2806561	0.704	rs664301	chr1:23522522	C/T	cg12483005	chr1:23474871	LUZP1	0.42	5.41	0.44	3.15e-7	Height;
TGCT	cis	rs240764	0.658	rs12213201	chr6:101176285	C/A	cg09795085	chr6:101329169	ASCC3	-0.51	-4.51	-0.38	1.46e-5	Neuroticism;
TGCT	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg19729930	chr2:74357872	NA	0.65	9.55	0.65	1.56e-16	Gestational age at birth (maternal effect);
TGCT	cis	rs9467773	1.000	rs2208331	chr6:26507319	A/G	cg15659132	chr6:26577336	NA	0.86	12.18	0.74	6.14e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs910316	1.000	rs12588240	chr14:75612083	C/A	cg11812906	chr14:75593930	NEK9	0.74	7.37	0.55	2.12e-11	Height;
TGCT	cis	rs2439831	0.867	rs4583210	chr15:43660925	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	8.65	0.61	2.26e-14	Lung cancer in ever smokers;
TGCT	cis	rs57590327	0.555	rs6767749	chr3:81725513	G/A	cg07356753	chr3:81810745	GBE1	-0.77	-7.15	-0.54	6.47e-11	Extraversion;
TGCT	cis	rs137603	0.623	rs470075	chr22:39686806	G/A	cg17798944	chr22:39715225	SNORD43;RPL3	-0.68	-6.96	-0.53	1.75e-10	Primary biliary cholangitis;
TGCT	cis	rs752010	0.714	rs2148635	chr1:42082452	C/T	cg06885757	chr1:42089581	HIVEP3	-0.25	-4.45	-0.37	1.92e-5	Lupus nephritis in systemic lupus erythematosus;
TGCT	trans	rs1499614	1.000	rs2707828	chr7:66171377	G/A	cg07424592	chr7:64974309	NA	1.35	8.11	0.59	4.14e-13	Gout;
TGCT	cis	rs9467773	0.620	rs1490488	chr6:26614808	T/C	cg05738196	chr6:26577821	NA	0.88	11.4	0.72	5.07e-21	Intelligence (multi-trait analysis);
TGCT	cis	rs11891	0.685	rs9891726	chr17:76992101	C/T	cg25730791	chr17:76457213	DNAH17	0.42	4.76	0.39	5.4e-6	Magnesium levels;
TGCT	cis	rs6582630	0.519	rs12368889	chr12:38315160	G/A	cg26384229	chr12:38710491	ALG10B	0.83	7.22	0.54	4.62e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs7119038	0.818	rs10892294	chr11:118667357	C/G	cg19308663	chr11:118741387	NA	-0.29	-5.91	-0.47	3.12e-8	Sjögren's syndrome;
TGCT	cis	rs2663905	0.611	rs2663924	chr15:81392903	T/G	cg09236163	chr15:81426669	C15orf26	-0.46	-4.68	-0.39	7.42e-6	QT interval (drug interaction);
TGCT	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg22433210	chr17:43662623	NA	-0.94	-7.99	-0.58	7.87e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg11764359	chr7:65958608	NA	-0.57	-4.99	-0.41	2.03e-6	Aortic root size;
TGCT	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-8.64	-0.61	2.39e-14	Platelet count;
TGCT	cis	rs9399137	0.507	rs13214669	chr6:135299959	T/C	cg24558204	chr6:135376177	HBS1L	0.47	4.76	0.39	5.27e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
TGCT	cis	rs12477438	0.520	rs11695379	chr2:99742161	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.12	17.33	0.84	6.27e-35	Chronic sinus infection;
TGCT	cis	rs7726839	0.574	rs72705014	chr5:619815	C/G	cg16624210	chr5:671434	TPPP	0.43	4.68	0.39	7.5e-6	Obesity-related traits;
TGCT	cis	rs10492096	0.947	rs10849484	chr12:6637941	C/T	cg00459232	chr12:6309025	CD9	0.36	4.46	0.37	1.84e-5	Hip geometry;
TGCT	cis	rs28595532	0.920	rs56291421	chr4:119732294	G/A	cg21605333	chr4:119757512	SEC24D	1.66	8.33	0.6	1.28e-13	Cannabis dependence symptom count;
TGCT	trans	rs2727020	0.615	rs35423199	chr11:49514914	T/C	cg03929089	chr4:120376271	NA	-0.77	-9.31	-0.64	5.82e-16	Coronary artery disease;
TGCT	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg22920501	chr2:26401640	FAM59B	-0.79	-6.31	-0.49	4.58e-9	Gut microbiome composition (summer);
TGCT	cis	rs2066819	1.000	rs78149779	chr12:56694817	A/G	cg26714650	chr12:56694279	CS	-1.36	-6.06	-0.48	1.54e-8	Psoriasis vulgaris;
TGCT	cis	rs7833790	1.000	rs7834808	chr8:82704996	A/G	cg27398817	chr8:82754497	SNX16	-0.89	-6.25	-0.49	5.89e-9	Diastolic blood pressure;
TGCT	cis	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg18180107	chr4:99064573	C4orf37	0.58	5.1	0.42	1.25e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs4845570	0.834	rs1196467	chr1:151710038	T/C	cg07092448	chr1:151763213	TDRKH	1.05	8.06	0.59	5.43e-13	Coronary artery disease;
TGCT	cis	rs12681288	0.792	rs12678495	chr8:1000858	C/G	cg04851639	chr8:1020857	NA	-0.36	-6.43	-0.5	2.55e-9	Schizophrenia;
TGCT	cis	rs911555	0.755	rs12432803	chr14:103930032	C/T	cg23461800	chr14:103021989	NA	-0.35	-4.56	-0.38	1.23e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs1843834	0.716	rs6716600	chr2:225481991	A/T	cg22455342	chr2:225449267	CUL3	0.8	8.03	0.58	6.56e-13	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs6912958	0.781	rs13193380	chr6:88297057	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-5.06	-0.41	1.45e-6	Monocyte percentage of white cells;
TGCT	cis	rs7914558	0.966	rs7921574	chr10:104840970	T/C	cg15744005	chr10:104629667	AS3MT	-0.39	-4.69	-0.39	7.05e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs3087591	1.000	rs2854322	chr17:29699416	C/T	cg24425628	chr17:29625626	OMG;NF1	0.45	6.65	0.51	8.31e-10	Hip circumference;
TGCT	cis	rs709400	0.663	rs72708893	chr14:103929535	G/A	cg12935359	chr14:103987150	CKB	-0.37	-5.61	-0.45	1.25e-7	Body mass index;
TGCT	cis	rs6754311	0.509	rs13412397	chr2:136470714	G/A	cg07169764	chr2:136633963	MCM6	-0.67	-6.08	-0.48	1.41e-8	Mosquito bite size;
TGCT	cis	rs244731	0.959	rs11740250	chr5:176721272	G/C	cg16006841	chr5:176797999	RGS14	0.55	7.12	0.54	7.52e-11	Urate levels in lean individuals;
TGCT	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9486719	1.000	rs12212614	chr6:97036466	T/G	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.32	-0.6	1.32e-13	Migraine;Coronary artery disease;
TGCT	trans	rs62264129	0.500	rs11923402	chr3:112050148	G/T	cg13345683	chr7:154003305	DPP6	0.4	6.64	0.51	8.88e-10	Sum eosinophil basophil counts;Eosinophil counts;
TGCT	cis	rs7772486	0.875	rs9322048	chr6:146400439	A/G	cg05347473	chr6:146136440	FBXO30	0.53	5.03	0.41	1.71e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6540559	0.673	rs17015330	chr1:210012795	T/G	cg23283495	chr1:209979779	IRF6	0.6	4.5	0.37	1.54e-5	Cleft lip with or without cleft palate;
TGCT	cis	rs4769475	0.629	rs55752743	chr13:26697104	T/C	cg19000612	chr13:26506281	ATP8A2	0.33	4.52	0.38	1.44e-5	Response to Homoharringtonine (cytotoxicity);
TGCT	cis	rs7824557	0.527	rs2736298	chr8:11235136	C/G	cg21775007	chr8:11205619	TDH	-0.65	-6.4	-0.5	2.97e-9	Retinal vascular caliber;
TGCT	cis	rs7248779	0.532	rs10153475	chr19:2413961	G/C	cg22729335	chr19:2427816	TIMM13	1.13	13.48	0.77	4.71e-26	Cortisol levels (saliva);
TGCT	cis	rs9972944	0.756	rs1421032	chr17:63766368	A/C	cg07283582	chr17:63770753	CCDC46	-0.26	-5.3	-0.43	5.02e-7	Total body bone mineral density;
TGCT	cis	rs6087771	0.781	rs6089067	chr20:30358894	G/C	cg13852791	chr20:30311386	BCL2L1	0.8	7.57	0.56	7.42e-12	Subcortical brain region volumes;Putamen volume;
TGCT	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg10047753	chr17:41438598	NA	0.96	9.86	0.66	2.71e-17	Menopause (age at onset);
TGCT	cis	rs7772486	0.776	rs4316025	chr6:146238032	C/T	cg23711669	chr6:146136114	FBXO30	-0.8	-8.9	-0.62	5.72e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7617480	0.616	rs9873227	chr3:48773108	G/C	cg07636037	chr3:49044803	WDR6	0.78	6.39	0.5	3.02e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs7103648	1.000	rs10838705	chr11:47424931	G/A	cg20307385	chr11:47447363	PSMC3	1.0	12.09	0.74	1.06e-22	Diastolic blood pressure;Systolic blood pressure;
TGCT	cis	rs9611565	0.592	rs4822040	chr22:41963553	C/G	cg06481639	chr22:41940642	POLR3H	-0.6	-5.14	-0.42	1.03e-6	Vitiligo;
TGCT	cis	rs9611565	0.512	rs2050033	chr22:42159229	G/T	cg06481639	chr22:41940642	POLR3H	0.69	6.05	0.48	1.59e-8	Vitiligo;
TGCT	cis	rs7772486	0.875	rs9403768	chr6:146406458	A/C	cg23711669	chr6:146136114	FBXO30	0.89	9.73	0.66	5.56e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2070488	0.804	rs13063978	chr3:38476538	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.78	7.96	0.58	9.56e-13	Electrocardiographic conduction measures;
TGCT	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg10047753	chr17:41438598	NA	0.96	9.6	0.65	1.16e-16	Menopause (age at onset);
TGCT	cis	rs2070433	0.752	rs60290737	chr21:47837630	C/A	cg12379764	chr21:47803548	PCNT	0.57	4.86	0.4	3.52e-6	Lymphocyte counts;
TGCT	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg07747251	chr5:1868357	NA	0.38	5.43	0.44	2.84e-7	Cardiovascular disease risk factors;
TGCT	cis	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg02380750	chr20:61661411	NA	0.35	6.1	0.48	1.25e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg05368731	chr17:41323189	NBR1	1.16	13.44	0.77	5.9e-26	Menopause (age at onset);
TGCT	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.48	-0.37	1.66e-5	Bipolar disorder;
TGCT	cis	rs4285028	0.580	rs12496036	chr3:121640362	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.61	-5.22	-0.42	7.38e-7	Multiple sclerosis;
TGCT	cis	rs7223966	1.000	rs9899491	chr17:61934384	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	4.68	0.39	7.5e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs9549260	0.599	rs12870023	chr13:41244222	T/A	cg21288729	chr13:41239152	FOXO1	1.01	10.56	0.69	5.52e-19	Red blood cell count;
TGCT	cis	rs9473924	0.580	rs60100577	chr6:50816134	C/T	cg14470998	chr6:50812995	TFAP2B	1.36	8.61	0.61	2.74e-14	Body mass index;
TGCT	cis	rs35264875	1.000	rs1542334	chr11:68850773	G/C	cg02660097	chr11:68866761	NA	0.32	4.96	0.41	2.3e-6	Blond vs. brown hair color;
TGCT	cis	rs2718812	0.607	rs12497433	chr3:133388584	C/G	cg08048268	chr3:133502702	NA	-0.38	-4.81	-0.4	4.21e-6	Iron status biomarkers;
TGCT	cis	rs9914544	0.545	rs4924940	chr17:18800092	T/C	cg26378065	chr17:18585709	ZNF286B	0.51	4.59	0.38	1.09e-5	Educational attainment (years of education);
TGCT	cis	rs10875746	0.903	rs61918806	chr12:48484433	G/A	cg20731937	chr12:48336164	NA	0.62	4.95	0.41	2.36e-6	Longevity (90 years and older);
TGCT	cis	rs13242816	1.000	rs35515812	chr7:116156032	C/G	cg16553024	chr7:116138462	CAV2	-0.45	-5.27	-0.43	5.81e-7	P wave duration;
TGCT	cis	rs8084125	0.832	rs62105182	chr18:74951407	T/C	cg07390210	chr18:74961196	GALR1	0.37	4.51	0.38	1.49e-5	Obesity-related traits;
TGCT	cis	rs76954792	0.826	rs11080166	chr17:30028469	C/A	cg18427091	chr17:30115417	NA	-0.36	-4.67	-0.39	7.61e-6	Coronary artery disease;
TGCT	cis	rs7432375	0.610	rs28458819	chr3:136522314	A/G	cg15507776	chr3:136538369	TMEM22	0.55	5.63	0.45	1.15e-7	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	trans	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg12575136	chr18:32820987	ZNF397	0.75	8.86	0.62	6.89e-15	White blood cell count;
TGCT	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg08736216	chr1:53307985	ZYG11A	-0.3	-5.99	-0.47	2.09e-8	Monocyte count;
TGCT	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg06618935	chr21:46677482	NA	-0.37	-5.56	-0.45	1.58e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs56339712	0.802	rs4495524	chr9:92025336	C/G	ch.9.1233470F	chr9:91626629	NA	0.25	4.78	0.39	4.93e-6	Reticulocyte fraction of red cells;Reticulocyte count;
TGCT	cis	rs9611565	0.592	rs4481089	chr22:41980892	T/C	cg06634786	chr22:41940651	POLR3H	-0.83	-7.66	-0.57	4.6e-12	Vitiligo;
TGCT	cis	rs6500602	0.592	rs4785966	chr16:4518754	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	-0.39	-5.29	-0.43	5.27e-7	Schizophrenia;
TGCT	cis	rs651907	0.535	rs17412601	chr3:101499275	T/C	cg12386194	chr3:101231763	SENP7	0.47	4.7	0.39	6.87e-6	Colorectal cancer;
TGCT	cis	rs7927771	0.800	rs11039200	chr11:47379646	A/C	cg21462715	chr11:47870315	NUP160	0.55	4.46	0.37	1.84e-5	Subjective well-being;
TGCT	cis	rs3820068	0.608	rs7514858	chr1:16035246	G/A	cg05660106	chr1:15850417	CASP9	0.69	6.45	0.5	2.28e-9	Systolic blood pressure;
TGCT	cis	rs9467603	1.000	rs9461216	chr6:25808743	A/T	cg16898833	chr6:26189333	HIST1H4D	1.16	5.5	0.44	2.08e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg11764359	chr7:65958608	NA	-0.55	-5.0	-0.41	1.94e-6	Aortic root size;
TGCT	cis	rs17376456	0.877	rs10476601	chr5:93402522	G/A	cg21475434	chr5:93447410	FAM172A	0.59	4.66	0.39	8.09e-6	Diabetic retinopathy;
TGCT	cis	rs8072100	0.967	rs8078880	chr17:45676526	G/C	cg08085267	chr17:45401833	C17orf57	0.43	4.64	0.38	8.8e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs208520	0.690	rs10455194	chr6:66743356	A/G	cg07460842	chr6:66804631	NA	0.94	9.91	0.66	2.15e-17	Exhaled nitric oxide output;
TGCT	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg09060608	chr5:178986726	RUFY1	-0.62	-7.62	-0.56	5.63e-12	Lung cancer;
TGCT	cis	rs7547997	0.685	rs1575172	chr1:158345279	A/G	cg07950803	chr1:158223934	CD1A	0.32	4.78	0.39	4.95e-6	QRS duration;
TGCT	cis	rs4730250	0.708	rs3801965	chr7:106825628	G/T	cg02696742	chr7:106810147	HBP1	-0.7	-6.05	-0.48	1.59e-8	Osteoarthritis;
TGCT	cis	rs3096299	0.967	rs28644774	chr16:89472181	G/C	cg06640241	chr16:89574553	SPG7	0.66	6.3	0.49	4.82e-9	Multiple myeloma (IgH translocation);
TGCT	cis	rs7044106	0.762	rs10760110	chr9:123412563	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.43	-4.56	-0.38	1.22e-5	Hip circumference adjusted for BMI;
TGCT	cis	rs9399137	0.507	rs4895437	chr6:135317354	G/A	cg24558204	chr6:135376177	HBS1L	0.47	4.78	0.39	4.95e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
TGCT	cis	rs6570726	0.791	rs392612	chr6:145881586	C/G	cg13319975	chr6:146136371	FBXO30	0.51	4.6	0.38	1.01e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4919694	0.572	rs12262258	chr10:104900272	G/A	cg04362960	chr10:104952993	NT5C2	0.98	6.88	0.53	2.66e-10	Arsenic metabolism;
TGCT	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg05368731	chr17:41323189	NBR1	1.2	14.48	0.79	1.98e-28	Menopause (age at onset);
TGCT	cis	rs17030434	1.000	rs1456391	chr4:154720485	A/G	cg14289246	chr4:154710475	SFRP2	-0.91	-7.2	-0.54	5.18e-11	Electrocardiographic conduction measures;
TGCT	cis	rs9677476	0.515	rs13430145	chr2:231931133	T/C	cg07929768	chr2:232055508	NA	0.34	5.34	0.43	4.37e-7	Food antigen IgG levels;
TGCT	cis	rs4478037	0.822	rs59834381	chr3:33116313	G/A	cg19404215	chr3:33155277	CRTAP	1.25	6.05	0.48	1.59e-8	Major depressive disorder;
TGCT	cis	rs453301	0.624	rs7014430	chr8:8827737	T/G	cg11995313	chr8:8860691	ERI1	-0.58	-5.21	-0.42	7.59e-7	Joint mobility (Beighton score);
TGCT	cis	rs7258465	1.000	rs7252707	chr19:18612257	G/A	cg22489759	chr19:18572700	ELL	0.21	4.63	0.38	9e-6	Breast cancer;
TGCT	cis	rs7829975	0.840	rs572366	chr8:8578794	A/T	cg15556689	chr8:8085844	FLJ10661	0.67	5.67	0.45	9.6e-8	Mood instability;
TGCT	cis	rs7714584	1.000	rs1000113	chr5:150240076	C/T	cg22134413	chr5:150180641	NA	1.11	7.97	0.58	8.78e-13	Crohn's disease;
TGCT	cis	rs67311347	1.000	rs2168111	chr3:40395325	T/G	cg17264618	chr3:40429014	ENTPD3	0.31	4.65	0.39	8.38e-6	Renal cell carcinoma;
TGCT	cis	rs1691799	0.899	rs1168358	chr12:66748664	A/G	cg16791601	chr12:66731901	HELB	-0.27	-5.8	-0.46	5.22e-8	White blood cell count (basophil);
TGCT	cis	rs7614311	0.731	rs56263032	chr3:63863022	G/A	cg22134162	chr3:63841271	THOC7	-0.4	-5.27	-0.43	5.98e-7	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs16958440	0.867	rs77615793	chr18:44684464	C/G	cg17192377	chr18:44677553	HDHD2	0.63	4.7	0.39	6.74e-6	Sitting height ratio;
TGCT	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg03452623	chr4:187889614	NA	-0.37	-5.65	-0.45	1.06e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg04317338	chr11:64019027	PLCB3	0.79	6.5	0.5	1.77e-9	Mean platelet volume;
TGCT	cis	rs28374715	0.662	rs28587487	chr15:41495460	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.81	-11.6	-0.72	1.65e-21	Ulcerative colitis;
TGCT	cis	rs8077889	1.000	rs2880329	chr17:41866168	T/A	cg26893861	chr17:41843967	DUSP3	1.08	13.1	0.76	3.73e-25	Triglycerides;
TGCT	cis	rs16958440	0.867	rs12326221	chr18:44682893	G/T	cg17192377	chr18:44677553	HDHD2	0.64	4.57	0.38	1.15e-5	Sitting height ratio;
TGCT	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg11890956	chr21:40555474	PSMG1	-0.75	-6.99	-0.53	1.51e-10	Cognitive function;
TGCT	cis	rs7542091	0.704	rs7537294	chr1:210043777	A/G	cg00989853	chr1:209979345	IRF6	0.43	4.58	0.38	1.12e-5	Monobrow;
TGCT	cis	rs4654899	0.965	rs61779124	chr1:21513306	C/T	cg01072550	chr1:21505969	NA	-0.5	-8.03	-0.59	6.27e-13	Superior frontal gyrus grey matter volume;
TGCT	cis	rs3812831	0.669	rs7327370	chr13:114946858	A/G	cg06611532	chr13:114900021	NA	0.34	6.0	0.47	2.02e-8	Schizophrenia;
TGCT	cis	rs4746818	0.901	rs7914719	chr10:70903832	T/C	cg04149295	chr10:70884716	VPS26A	0.79	5.39	0.44	3.47e-7	Left atrial antero-posterior diameter;
TGCT	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg11764359	chr7:65958608	NA	0.55	5.08	0.42	1.34e-6	Aortic root size;
TGCT	cis	rs7666738	0.753	rs35194639	chr4:99053819	G/C	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs1908814	0.516	rs4367597	chr8:11793529	C/T	cg15556689	chr8:8085844	FLJ10661	0.75	7.26	0.55	3.66e-11	Neuroticism;
TGCT	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg11235426	chr6:292522	DUSP22	-0.72	-7.3	-0.55	2.98e-11	Menopause (age at onset);
TGCT	cis	rs1865760	0.827	rs9461227	chr6:25960815	C/T	cg16482183	chr6:26056742	HIST1H1C	0.52	4.84	0.4	3.78e-6	Height;
TGCT	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg27121462	chr16:89883253	FANCA	0.79	8.46	0.6	6.35e-14	Vitiligo;
TGCT	cis	rs208520	0.565	rs1385222	chr6:66753013	C/T	cg07460842	chr6:66804631	NA	1.03	13.89	0.78	4.83e-27	Exhaled nitric oxide output;
TGCT	cis	rs6598955	0.724	rs12726972	chr1:26639634	A/G	cg04990556	chr1:26633338	UBXN11	0.9	11.83	0.73	4.36e-22	Obesity-related traits;
TGCT	cis	rs8177253	0.665	rs12493887	chr3:133440737	T/C	cg16414030	chr3:133502952	NA	-0.52	-7.29	-0.55	3.17e-11	Iron status biomarkers;
TGCT	cis	rs3733585	0.673	rs4627861	chr4:9954238	T/G	cg00071950	chr4:10020882	SLC2A9	-0.55	-6.58	-0.51	1.21e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs295140	1.000	rs1367857	chr2:201160765	T/C	cg04283868	chr2:201171347	SPATS2L	0.63	6.36	0.5	3.56e-9	QT interval;
TGCT	cis	rs9807989	0.501	rs11903946	chr2:103005330	A/G	cg03938978	chr2:103052716	IL18RAP	0.26	5.22	0.42	7.15e-7	Asthma;
TGCT	cis	rs5750830	0.594	rs9611165	chr22:39775250	A/G	cg01416388	chr22:39784598	NA	-0.59	-5.8	-0.46	5.09e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs3820068	0.581	rs72645879	chr1:15928199	A/G	cg05660106	chr1:15850417	CASP9	0.82	8.02	0.58	6.63e-13	Systolic blood pressure;
TGCT	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg05985448	chr10:134359359	INPP5A	0.24	5.13	0.42	1.1e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs11874712	1.000	rs8089150	chr18:43674300	A/G	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	5.23	0.42	7.11e-7	Migraine - clinic-based;
TGCT	cis	rs6969780	0.545	rs983184	chr7:27188379	C/T	cg06942814	chr7:27170819	HOXA4	-0.39	-4.46	-0.37	1.8e-5	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs3902035	0.964	rs62423995	chr6:119011836	G/A	cg07617317	chr6:118971624	C6orf204	0.43	5.01	0.41	1.79e-6	QT interval;
TGCT	cis	rs2153904	0.793	rs12118655	chr1:205663478	A/G	cg23034840	chr1:205782522	SLC41A1	-0.72	-4.76	-0.39	5.23e-6	Prostate-specific antigen levels;
TGCT	cis	rs17001868	0.568	rs9611318	chr22:40739414	C/G	cg07138101	chr22:40742427	ADSL	0.73	5.38	0.44	3.57e-7	Mammographic density (dense area);
TGCT	cis	rs6570726	0.791	rs436498	chr6:145876347	G/A	cg23711669	chr6:146136114	FBXO30	0.89	9.93	0.67	1.82e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg07424592	chr7:64974309	NA	1.36	8.15	0.59	3.36e-13	Diabetic kidney disease;
TGCT	cis	rs7666738	0.830	rs6839277	chr4:99015563	C/T	cg17366294	chr4:99064904	C4orf37	0.68	7.04	0.53	1.17e-10	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs7618501	0.519	rs3774749	chr3:50207227	C/T	cg21659725	chr3:3221576	CRBN	-0.7	-7.99	-0.58	8.03e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs7178572	0.633	rs4886876	chr15:77838491	C/T	cg22256960	chr15:77711686	NA	-0.78	-7.45	-0.56	1.42e-11	Type 2 diabetes;
TGCT	cis	rs9303401	0.614	rs7215900	chr17:56654850	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.61	5.86	0.47	3.87e-8	Cognitive test performance;
TGCT	cis	rs9787249	0.957	rs2274949	chr1:40221067	G/A	cg24920358	chr1:40204285	PPIE	0.57	10.63	0.69	3.68e-19	Blood protein levels;
TGCT	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg11764359	chr7:65958608	NA	0.57	5.28	0.43	5.64e-7	Aortic root size;
TGCT	cis	rs2456568	0.867	rs1395384	chr11:93663250	C/T	cg26875233	chr11:93583750	C11orf90	0.46	5.75	0.46	6.47e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs832540	0.656	rs702689	chr5:56177443	G/A	cg12311346	chr5:56204834	C5orf35	-0.5	-5.11	-0.42	1.2e-6	Coronary artery disease;
TGCT	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg22105103	chr4:187893119	NA	0.35	4.89	0.4	3.02e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7659604	0.689	rs59131059	chr4:122666357	C/T	cg19748678	chr4:122722346	EXOSC9	0.55	5.31	0.43	4.92e-7	Type 2 diabetes;
TGCT	trans	rs1814175	0.817	rs1851858	chr11:49855638	G/A	cg03929089	chr4:120376271	NA	-0.72	-8.26	-0.6	1.84e-13	Height;
TGCT	cis	rs9443645	0.901	rs10455356	chr6:79664748	T/C	cg09184832	chr6:79620586	NA	-0.49	-5.29	-0.43	5.29e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg17971929	chr21:40555470	PSMG1	0.98	9.51	0.65	1.95e-16	Cognitive function;
TGCT	cis	rs9419702	0.639	rs4367873	chr10:133533485	C/T	cg04492858	chr10:133558786	NA	0.55	5.71	0.46	7.96e-8	Survival in rectal cancer;
TGCT	cis	rs9993613	0.875	rs12639746	chr4:73513026	C/T	cg15102770	chr4:73434591	ADAMTS3	0.5	4.6	0.38	1.03e-5	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg13732083	chr21:47605072	C21orf56	0.35	4.75	0.39	5.51e-6	Testicular germ cell tumor;
TGCT	cis	rs7809950	0.678	rs2301801	chr7:106870746	T/C	cg23024343	chr7:107201750	COG5	-0.44	-6.17	-0.48	8.73e-9	Coronary artery disease;
TGCT	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg23156509	chr2:114033830	PAX8;LOC440839	-0.32	-4.93	-0.4	2.58e-6	Lymphocyte counts;
TGCT	cis	rs2404602	0.583	rs12913096	chr15:76551852	C/T	cg26408565	chr15:76604113	ETFA	-0.45	-6.36	-0.5	3.6e-9	Blood metabolite levels;
TGCT	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.86	5.42	0.44	3.05e-7	Alzheimer's disease;
TGCT	cis	rs7020830	0.928	rs11544336	chr9:37089150	A/G	cg14294708	chr9:37120828	ZCCHC7	1.28	20.28	0.88	3.46e-41	Schizophrenia;
TGCT	cis	rs2277425	0.755	rs2277424	chr13:111522420	A/G	cg13698168	chr13:111522651	C13orf29	-0.33	-4.62	-0.38	9.53e-6	Sitting height ratio;
TGCT	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.44	-4.57	-0.38	1.18e-5	Longevity;Endometriosis;
TGCT	cis	rs727563	0.552	rs4822045	chr22:41985958	C/A	cg03806693	chr22:41940476	POLR3H	-1.11	-11.64	-0.72	1.26e-21	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs1153858	1.000	rs4395020	chr15:45652889	A/C	cg26924012	chr15:45694286	SPATA5L1	1.1	14.88	0.8	2.26e-29	Homoarginine levels;
TGCT	cis	rs8141529	0.748	rs5762882	chr22:29290680	C/A	cg02153584	chr22:29168773	CCDC117	0.63	4.87	0.4	3.3e-6	Lymphocyte counts;
TGCT	cis	rs2456568	0.802	rs1395387	chr11:93639307	A/T	cg26875233	chr11:93583750	C11orf90	-0.47	-6.1	-0.48	1.27e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs6546537	1.000	rs6546537	chr2:69839633	T/C	cg10773587	chr2:69614142	GFPT1	-0.62	-5.21	-0.42	7.66e-7	Serum thyroid-stimulating hormone levels;
TGCT	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg19774624	chr17:42201019	HDAC5	-0.84	-10.39	-0.68	1.44e-18	Total body bone mineral density;
TGCT	cis	rs17102423	0.755	rs4902358	chr14:65542477	A/G	cg11161011	chr14:65562177	MAX	-0.55	-7.71	-0.57	3.47e-12	Obesity-related traits;
TGCT	cis	rs933688	1.000	rs10073935	chr5:90742188	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.96	8.43	0.6	7.52e-14	Smoking behavior;
TGCT	cis	rs6938	0.618	rs11857695	chr15:75165751	G/T	cg10253484	chr15:75165896	SCAMP2	-0.53	-4.88	-0.4	3.15e-6	Breast cancer;
TGCT	cis	rs2204008	0.782	rs117824012	chr12:38215517	T/C	cg26384229	chr12:38710491	ALG10B	0.84	7.43	0.56	1.51e-11	Bladder cancer;
TGCT	cis	rs9296092	0.538	rs9461875	chr6:33516644	C/T	cg13560919	chr6:33536144	NA	-0.2	-4.63	-0.38	9.08e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs6087771	0.662	rs6058298	chr20:30247916	C/T	cg13852791	chr20:30311386	BCL2L1	0.8	7.16	0.54	6.39e-11	Subcortical brain region volumes;Putamen volume;
TGCT	cis	rs4711350	0.862	rs570749	chr6:33710229	C/T	cg18005901	chr6:33739558	LEMD2	0.57	5.9	0.47	3.23e-8	Schizophrenia;
TGCT	cis	rs7267979	1.000	rs4813563	chr20:25365340	T/C	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6732795	0.854	rs6546486	chr2:69413892	A/T	cg10773587	chr2:69614142	GFPT1	-0.52	-4.82	-0.4	4.05e-6	Intraocular pressure;
TGCT	cis	rs11105298	0.786	rs10777186	chr12:89921277	G/A	cg00757033	chr12:89920650	WDR51B	0.32	5.13	0.42	1.11e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs41271951	0.512	rs116666233	chr1:151056058	C/T	cg00666978	chr1:150947442	LASS2	0.89	4.64	0.38	8.54e-6	Blood protein levels;
TGCT	cis	rs9549367	0.789	rs12584813	chr13:113895443	C/G	cg18105134	chr13:113819100	PROZ	-0.37	-5.0	-0.41	1.89e-6	Platelet distribution width;
TGCT	cis	rs9818758	0.607	rs67831908	chr3:49313513	T/G	cg00383909	chr3:49044727	WDR6	1.28	6.57	0.51	1.23e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg07404485	chr7:94953653	PON1	-0.27	-4.78	-0.39	4.92e-6	Paraoxonase activity;
TGCT	cis	rs909674	0.818	rs5757680	chr22:39844793	C/T	cg24399712	chr22:39784796	NA	1.01	10.46	0.68	9.83e-19	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	trans	rs1814175	0.676	rs1851859	chr11:49860405	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.45	-11.09	-0.71	2.8e-20	Height;
TGCT	cis	rs950027	0.620	rs1145076	chr15:45684508	G/T	cg26924012	chr15:45694286	SPATA5L1	0.78	8.83	0.62	8.22e-15	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg08736216	chr1:53307985	ZYG11A	0.29	5.89	0.47	3.41e-8	Monocyte count;
TGCT	cis	rs10197940	0.686	rs12616688	chr2:152242099	C/G	cg19508488	chr2:152266495	RIF1	0.73	6.58	0.51	1.2e-9	Lung cancer;
TGCT	cis	rs4936891	0.601	rs7929503	chr11:123916160	A/G	cg22125253	chr11:123886957	OR10G4	0.21	4.82	0.4	4.13e-6	Male fertility;
TGCT	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg27454412	chr7:1067447	C7orf50	0.6	4.7	0.39	6.76e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs35934224	0.843	rs1139795	chr22:19867771	C/T	cg11182965	chr22:19864308	TXNRD2	-0.38	-5.37	-0.43	3.79e-7	Glaucoma (primary open-angle);
TGCT	cis	rs9788682	0.747	rs8042374	chr15:78908032	A/G	cg24631222	chr15:78858424	CHRNA5	0.78	5.71	0.46	8.03e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs4253772	0.591	rs6008545	chr22:46686375	C/T	cg26492175	chr22:47022658	GRAMD4	0.2	4.57	0.38	1.15e-5	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs35306767	0.903	rs34847097	chr10:902252	A/T	cg26597838	chr10:835615	NA	0.75	10.61	0.69	4.13e-19	Eosinophil percentage of granulocytes;
TGCT	cis	rs2031577	1.000	rs4881271	chr10:4047125	G/T	cg19231290	chr10:3827321	KLF6	0.41	4.47	0.37	1.71e-5	Longevity;
TGCT	cis	rs6089584	1.000	rs6089581	chr20:60562394	G/A	cg06108461	chr20:60628389	TAF4	-0.57	-8.01	-0.58	7.25e-13	Body mass index;
TGCT	cis	rs265548	0.586	rs265542	chr19:17904388	T/G	cg04517722	chr19:17905589	B3GNT3	0.46	5.96	0.47	2.42e-8	Tumor biomarkers;
TGCT	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg06112835	chr11:68658793	MRPL21	0.47	8.18	0.59	2.86e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs5769765	0.865	rs3788730	chr22:50244695	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	-0.35	-5.41	-0.44	3.05e-7	Schizophrenia;
TGCT	cis	rs9467711	0.606	rs34104395	chr6:26478252	C/T	cg16898833	chr6:26189333	HIST1H4D	1.13	5.05	0.41	1.56e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6840360	0.571	rs6811676	chr4:152562726	T/C	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.0	-0.58	7.69e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs3749237	1.000	rs2307021	chr3:49765483	C/G	cg07636037	chr3:49044803	WDR6	0.61	5.32	0.43	4.68e-7	Resting heart rate;
TGCT	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.75	5.41	0.44	3.09e-7	Platelet count;
TGCT	cis	rs6460942	0.915	rs1595802	chr7:12439672	C/T	cg06484146	chr7:12443880	VWDE	-0.57	-5.46	-0.44	2.47e-7	Coronary artery disease;
TGCT	cis	rs611744	0.967	rs612265	chr8:109188650	A/G	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg12963246	chr6:28129442	ZNF389	0.52	5.01	0.41	1.85e-6	Depression;
TGCT	cis	rs7829975	0.617	rs4841071	chr8:8791144	G/T	cg15556689	chr8:8085844	FLJ10661	0.63	5.94	0.47	2.69e-8	Mood instability;
TGCT	cis	rs240764	0.658	rs7740783	chr6:101263516	C/T	cg21058520	chr6:100914733	NA	-0.35	-4.51	-0.38	1.48e-5	Neuroticism;
TGCT	cis	rs11971779	0.793	rs4732366	chr7:139027845	G/C	cg07862535	chr7:139043722	LUC7L2	0.75	6.01	0.47	1.95e-8	Diisocyanate-induced asthma;
TGCT	trans	rs208520	0.779	rs208446	chr6:66903515	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.93	-9.78	-0.66	4.3e-17	Exhaled nitric oxide output;
TGCT	cis	rs7666738	0.830	rs6819047	chr4:98866902	G/A	cg05340658	chr4:99064831	C4orf37	0.52	6.0	0.47	1.98e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs17534004	1.000	rs17534004	chr13:31469665	C/T	cg13251181	chr13:31481184	C13orf33	0.37	4.6	0.38	1.04e-5	3-hydroxypropylmercapturic acid levels in smokers;
TGCT	cis	rs11148252	0.538	rs2408611	chr13:52709742	C/T	cg00495681	chr13:53174319	NA	0.57	5.86	0.47	3.84e-8	Lewy body disease;
TGCT	cis	rs1949733	1.000	rs6837429	chr4:8502374	A/G	cg13073564	chr4:8508604	NA	-0.47	-5.05	-0.41	1.55e-6	Response to antineoplastic agents;
TGCT	cis	rs13064447	0.967	rs113886525	chr3:12762356	A/G	cg20675869	chr3:12750130	NA	-0.18	-4.6	-0.38	1.01e-5	Major depression and alcohol dependence;
TGCT	cis	rs473651	0.935	rs540636	chr2:239358341	T/C	cg21699342	chr2:239360505	ASB1	0.17	4.65	0.39	8.49e-6	Multiple system atrophy;
TGCT	cis	rs4148883	0.651	rs4147547	chr4:100127311	G/T	cg12011299	chr4:100065546	ADH4	0.36	5.39	0.44	3.38e-7	Alcohol dependence;
TGCT	cis	rs12579753	0.789	rs1343933	chr12:82123301	A/C	cg07988820	chr12:82153109	PPFIA2	-0.67	-7.13	-0.54	7.42e-11	Resting heart rate;
TGCT	cis	rs7949030	0.504	rs2516633	chr11:62371773	A/C	cg22862634	chr11:62369728	EML3;MTA2	-0.59	-6.11	-0.48	1.17e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9914544	0.545	rs8078993	chr17:18797126	A/G	cg26378065	chr17:18585709	ZNF286B	0.51	4.59	0.38	1.09e-5	Educational attainment (years of education);
TGCT	cis	rs2721195	0.967	rs1985022	chr8:145684031	C/T	cg13257436	chr8:145726034	PPP1R16A	-0.34	-5.16	-0.42	9.7e-7	Age at first birth;
TGCT	cis	rs7267979	0.844	rs6083851	chr20:25401235	G/A	cg14121845	chr20:25566513	NINL	-0.45	-4.6	-0.38	1.02e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10114408	0.959	rs10761298	chr9:96648815	G/C	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs7429990	0.965	rs5016900	chr3:47822877	G/C	cg11946769	chr3:48343235	NME6	0.59	4.45	0.37	1.87e-5	Educational attainment (years of education);
TGCT	cis	rs2932538	0.922	rs6673930	chr1:113104887	A/G	cg22162597	chr1:113214053	CAPZA1	0.27	5.98	0.47	2.24e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg03609598	chr5:56110824	MAP3K1	-0.58	-4.7	-0.39	6.72e-6	Initial pursuit acceleration;
TGCT	cis	rs4722166	0.508	rs1474347	chr7:22768124	A/C	cg26061582	chr7:22766209	IL6	-0.52	-6.5	-0.5	1.77e-9	Lung cancer;
TGCT	cis	rs208520	1.000	rs12189683	chr6:66977716	A/C	cg07460842	chr6:66804631	NA	-0.78	-6.82	-0.52	3.61e-10	Exhaled nitric oxide output;
TGCT	cis	rs10744422	0.764	rs11060152	chr12:123298932	G/A	cg18912006	chr12:123335444	HIP1R	0.56	4.78	0.39	4.84e-6	Schizophrenia;
TGCT	cis	rs9527	0.544	rs1572578	chr10:104822431	C/G	cg04362960	chr10:104952993	NT5C2	0.66	5.55	0.45	1.62e-7	Arsenic metabolism;
TGCT	cis	rs6570726	0.935	rs447247	chr6:145812678	G/T	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.16e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6545883	0.826	rs777593	chr2:61419103	C/A	cg15711740	chr2:61764176	XPO1	-0.58	-5.09	-0.42	1.3e-6	Tuberculosis;
TGCT	cis	rs7914558	1.000	rs11191577	chr10:104902165	A/G	cg04362960	chr10:104952993	NT5C2	0.62	5.55	0.45	1.66e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs71435601	0.574	rs522963	chr2:21386957	T/C	cg25035485	chr2:21266500	APOB	0.51	4.48	0.37	1.64e-5	Cholesterol, total;
TGCT	cis	rs9653442	0.564	rs7593261	chr2:100789907	A/G	cg22139774	chr2:100720529	AFF3	-0.34	-5.21	-0.42	7.55e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs734999	0.967	rs10752745	chr1:2507938	A/G	cg18854424	chr1:2615690	NA	0.44	5.37	0.43	3.77e-7	Ulcerative colitis;
TGCT	cis	rs7772486	0.790	rs2265472	chr6:146220758	G/C	cg05347473	chr6:146136440	FBXO30	0.52	5.0	0.41	1.89e-6	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs1814175	0.817	rs11493756	chr11:50017885	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.26	-0.55	3.77e-11	Height;
TGCT	cis	rs634534	0.622	rs1308733	chr11:65720841	T/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.47	-4.68	-0.39	7.38e-6	Sum eosinophil basophil counts;Eosinophil counts;
TGCT	cis	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg08975724	chr8:8085496	FLJ10661	0.5	4.52	0.38	1.45e-5	Mood instability;
TGCT	trans	rs941408	1.000	rs1736183	chr19:2809672	A/G	cg19676328	chr12:49525230	TUBA1B	-0.72	-7.19	-0.54	5.31e-11	Total cholesterol levels;
TGCT	cis	rs988712	0.705	rs11030099	chr11:27677583	C/A	cg10635145	chr11:27742435	BDNF	-0.4	-5.55	-0.45	1.65e-7	Obesity;
TGCT	cis	rs2013441	0.965	rs6587063	chr17:20193940	T/C	cg18979559	chr17:20280153	CCDC144C	-0.45	-4.67	-0.39	7.61e-6	Obesity-related traits;
TGCT	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg14784868	chr12:69753453	YEATS4	0.9	10.6	0.69	4.47e-19	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs8180040	0.764	rs6794193	chr3:47114904	T/C	cg27129171	chr3:47204927	SETD2	0.74	9.79	0.66	4.15e-17	Colorectal cancer;
TGCT	cis	rs9733	0.650	rs12125672	chr1:150554470	A/T	cg13175981	chr1:150552382	MCL1	0.51	5.66	0.45	9.73e-8	Tonsillectomy;
TGCT	trans	rs7698623	0.850	rs1477604	chr4:88771060	C/T	cg01186725	chr1:53905612	FLJ40434	-0.47	-6.65	-0.51	8.29e-10	Cardiovascular disease risk factors;
TGCT	cis	rs7647973	0.626	rs1078341	chr3:49685592	A/G	cg05785598	chr3:49045655	WDR6	0.42	5.24	0.43	6.67e-7	Menarche (age at onset);
TGCT	cis	rs600231	0.706	rs4244811	chr11:65320780	G/A	cg21890820	chr11:65308645	LTBP3	-0.36	-4.64	-0.38	8.63e-6	Bone mineral density;
TGCT	cis	rs854765	0.647	rs854817	chr17:18021882	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	7.51	0.56	1.01e-11	Total body bone mineral density;
TGCT	cis	rs2235642	0.826	rs8048410	chr16:1614097	A/G	cg00463982	chr16:1583984	IFT140;TMEM204	-0.32	-5.2	-0.42	8.15e-7	Coronary artery disease;
TGCT	cis	rs941873	0.868	rs2233718	chr10:81108956	A/G	cg09469691	chr10:81107165	PPIF	0.56	5.43	0.44	2.9e-7	Height;
TGCT	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg09436375	chr6:42928200	GNMT	-0.41	-5.39	-0.44	3.46e-7	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg21433313	chr16:3507492	NAT15	0.38	5.06	0.41	1.5e-6	Tuberculosis;
TGCT	cis	rs71435601	0.699	rs515135	chr2:21286057	T/C	cg16306978	chr2:21266953	APOB	0.59	4.63	0.38	9.24e-6	Cholesterol, total;
TGCT	cis	rs601339	1.000	rs2454722	chr12:123171218	A/G	cg11919336	chr12:123188078	GPR109A	0.66	7.7	0.57	3.69e-12	Adiponectin levels;
TGCT	cis	rs7119038	0.818	rs6589684	chr11:118610957	A/G	cg19308663	chr11:118741387	NA	-0.23	-4.78	-0.39	4.83e-6	Sjögren's syndrome;
TGCT	cis	rs5769707	0.935	rs739239	chr22:50050468	G/A	cg10356904	chr22:49881777	NA	-0.23	-4.66	-0.39	7.88e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg09060608	chr5:178986726	RUFY1	0.5	5.64	0.45	1.12e-7	Lung cancer;
TGCT	cis	rs4819052	0.851	rs1056100	chr21:46678711	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	6.87	0.53	2.77e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg14820908	chr5:178986412	RUFY1	0.6	6.71	0.52	6.31e-10	Lung cancer;
TGCT	cis	rs8072100	0.905	rs11651766	chr17:45574931	G/T	cg08085267	chr17:45401833	C17orf57	-0.44	-4.72	-0.39	6.17e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs1153858	1.000	rs12593370	chr15:45617417	C/T	cg26924012	chr15:45694286	SPATA5L1	1.05	13.95	0.78	3.56e-27	Homoarginine levels;
TGCT	cis	rs9611565	0.879	rs5758307	chr22:41750219	A/G	cg13695892	chr22:41940480	POLR3H	-0.84	-8.22	-0.59	2.28e-13	Vitiligo;
TGCT	cis	rs9611519	0.603	rs9607764	chr22:41411804	G/C	cg06634786	chr22:41940651	POLR3H	-0.49	-4.53	-0.38	1.38e-5	Neuroticism;
TGCT	cis	rs17376456	0.877	rs67066109	chr5:93494101	G/C	cg21475434	chr5:93447410	FAM172A	0.63	4.63	0.38	8.98e-6	Diabetic retinopathy;
TGCT	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	4.78	0.39	4.86e-6	Prudent dietary pattern;
TGCT	cis	rs17152411	0.947	rs733400	chr10:126594340	G/A	cg07906193	chr10:126599966	NA	0.42	5.28	0.43	5.6e-7	Height;
TGCT	cis	rs11190604	1.000	rs7100386	chr10:102301417	C/T	cg16342193	chr10:102329863	NA	-0.4	-4.97	-0.41	2.14e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs909674	0.734	rs5757675	chr22:39838892	G/T	cg24399712	chr22:39784796	NA	-1.05	-11.41	-0.72	4.79e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs1670533	0.932	rs3796620	chr4:1095079	A/G	cg20887711	chr4:1340912	KIAA1530	-0.68	-5.47	-0.44	2.33e-7	Recombination rate (females);
TGCT	cis	rs9926296	0.609	rs4785714	chr16:89798404	G/T	cg08627397	chr16:89984028	MC1R	0.29	4.5	0.37	1.52e-5	Vitiligo;
TGCT	cis	rs986417	1.000	rs1254298	chr14:60883842	C/T	cg27398547	chr14:60952738	C14orf39	-1.58	-8.33	-0.6	1.24e-13	Gut microbiota (bacterial taxa);
TGCT	cis	rs858239	0.863	rs274058	chr7:23391509	C/G	cg05602783	chr7:23145260	KLHL7	-0.56	-4.58	-0.38	1.13e-5	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs8014252	0.803	rs12587714	chr14:71004376	G/C	cg11204974	chr14:71022665	NA	-0.53	-4.46	-0.37	1.79e-5	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
TGCT	cis	rs4803468	1.000	rs284658	chr19:41929988	G/A	cg09537434	chr19:41945824	ATP5SL	-0.93	-10.96	-0.7	5.8e-20	Height;
TGCT	cis	rs4700695	0.841	rs706679	chr5:65317181	A/G	cg21114390	chr5:65439923	SFRS12	-0.59	-4.44	-0.37	1.99e-5	Facial morphology (factor 19);
TGCT	cis	rs9916302	0.706	rs7503081	chr17:37482673	A/G	cg07936489	chr17:37558343	FBXL20	0.84	6.23	0.49	6.68e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs2067615	0.579	rs10861663	chr12:107183589	G/A	cg15890332	chr12:107067104	RFX4	0.3	6.06	0.48	1.54e-8	Heart rate;
TGCT	cis	rs9467773	0.620	rs1490488	chr6:26614808	T/C	cg15659132	chr6:26577336	NA	0.85	10.93	0.7	7e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs7000551	0.689	rs2122878	chr8:22311916	T/C	cg12081754	chr8:22256438	SLC39A14	0.31	5.17	0.42	8.96e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg02353165	chr6:42928485	GNMT	0.94	9.24	0.64	8.85e-16	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs7824557	0.603	rs2249804	chr8:11215617	C/G	cg21775007	chr8:11205619	TDH	0.63	5.85	0.47	4.03e-8	Retinal vascular caliber;
TGCT	cis	rs10479542	0.683	rs7380706	chr5:178961872	C/T	cg21226059	chr5:178986404	RUFY1	0.41	4.49	0.37	1.61e-5	Lung cancer;
TGCT	cis	rs10782582	0.609	rs1630587	chr1:76399787	T/C	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.52	4.46	0.37	1.83e-5	Daytime sleep phenotypes;
TGCT	cis	rs514406	0.763	rs7535088	chr1:53215042	A/G	cg25767906	chr1:53392781	SCP2	0.48	5.36	0.43	3.95e-7	Monocyte count;
TGCT	cis	rs3617	0.573	rs12492391	chr3:52912296	C/A	cg10802521	chr3:52805072	NEK4	-0.54	-5.99	-0.47	2.09e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7267979	1.000	rs884613	chr20:25288505	C/T	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs992157	0.835	rs10932769	chr2:219147245	T/G	cg00012203	chr2:219082015	ARPC2	-0.8	-7.98	-0.58	8.26e-13	Colorectal cancer;
TGCT	trans	rs7726839	0.540	rs56325086	chr5:640728	G/A	cg11887960	chr12:57824829	NA	1.09	8.89	0.62	6.07e-15	Obesity-related traits;
TGCT	cis	rs7726839	0.507	rs111707179	chr5:593308	T/A	cg20362242	chr5:692897	TPPP	0.53	4.62	0.38	9.42e-6	Obesity-related traits;
TGCT	cis	rs1577917	0.545	rs1335443	chr6:86478737	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-4.66	-0.39	7.89e-6	Response to antipsychotic treatment;
TGCT	cis	rs1375194	0.606	rs17657783	chr2:33814590	A/G	cg04131969	chr2:33951647	MYADML	-0.58	-5.07	-0.41	1.41e-6	Response to antidepressants in depression;
TGCT	cis	rs10089	0.953	rs6879970	chr5:127387178	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	6.93	0.53	2e-10	Ileal carcinoids;
TGCT	cis	rs2204008	0.811	rs2139752	chr12:38370398	C/T	cg13010199	chr12:38710504	ALG10B	0.6	4.68	0.39	7.36e-6	Bladder cancer;
TGCT	cis	rs1372520	0.684	rs2583978	chr4:90750326	A/C	cg14346243	chr4:90757452	SNCA	-0.67	-5.64	-0.45	1.09e-7	Neuroticism;
TGCT	cis	rs9640161	0.750	rs1983440	chr7:150023941	G/C	cg10018233	chr7:150070692	REPIN1	0.32	4.63	0.38	8.94e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs7027203	0.663	rs4428726	chr9:96623559	T/G	cg13679303	chr9:96623674	NA	-0.69	-11.4	-0.72	4.94e-21	DNA methylation (variation);
TGCT	cis	rs798766	0.779	rs3134866	chr4:1723265	A/G	cg05874882	chr4:1763078	NA	-0.36	-4.87	-0.4	3.27e-6	Bladder cancer;Urinary bladder cancer;
TGCT	cis	rs7591446	0.517	rs7596942	chr2:45839700	G/T	cg15146906	chr2:45838581	SRBD1	0.7	5.2	0.42	7.98e-7	Squamous cell lung carcinoma;
TGCT	cis	rs617219	0.684	rs2896766	chr5:78586493	A/G	cg09550809	chr5:78407562	BHMT	-0.37	-5.25	-0.43	6.49e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs9796	0.870	rs4244584	chr15:41259523	A/G	cg18705301	chr15:41695430	NDUFAF1	0.4	5.24	0.43	6.58e-7	Menopause (age at onset);
TGCT	cis	rs12653946	0.846	rs10866528	chr5:1891821	A/G	cg22472608	chr5:1891194	NA	-0.67	-8.59	-0.61	3.06e-14	Prostate cancer;
TGCT	cis	rs9443645	0.901	rs1354831	chr6:79613576	T/C	cg05283184	chr6:79620031	NA	-0.21	-4.71	-0.39	6.61e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6586111	0.967	rs6586106	chr10:82372300	A/C	cg03086067	chr10:82368399	SH2D4B	-0.24	-4.72	-0.39	6.14e-6	Capecitabine sensitivity;
TGCT	cis	rs9549260	0.564	rs9549279	chr13:41315582	C/G	cg21288729	chr13:41239152	FOXO1	-0.94	-9.29	-0.64	6.57e-16	Red blood cell count;
TGCT	cis	rs7666738	0.830	rs13125930	chr4:98654695	G/A	cg18180107	chr4:99064573	C4orf37	0.53	5.07	0.41	1.41e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7829975	0.777	rs560544	chr8:8637429	G/A	cg15556689	chr8:8085844	FLJ10661	-0.69	-6.15	-0.48	9.85e-9	Mood instability;
TGCT	cis	rs7647973	1.000	rs3870339	chr3:49536863	T/A	cg07690219	chr3:49449608	TCTA;RHOA	-0.53	-4.45	-0.37	1.87e-5	Menarche (age at onset);
TGCT	cis	rs7772486	0.686	rs4896833	chr6:145965673	T/G	cg13319975	chr6:146136371	FBXO30	-0.5	-4.49	-0.37	1.63e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2050392	0.590	rs303433	chr10:30714963	A/T	cg13289132	chr10:30722225	MAP3K8	-0.45	-5.48	-0.44	2.25e-7	Inflammatory bowel disease;
TGCT	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg11764359	chr7:65958608	NA	0.59	5.09	0.42	1.28e-6	Aortic root size;
TGCT	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg24829409	chr8:58192753	C8orf71	-0.59	-4.97	-0.41	2.17e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs13256369	0.851	rs13271698	chr8:8567539	C/A	cg06671706	chr8:8559999	CLDN23	0.34	4.59	0.38	1.09e-5	Obesity-related traits;
TGCT	cis	rs28735056	0.620	rs12456484	chr18:77677315	C/G	cg20368463	chr18:77673604	PQLC1	0.48	5.73	0.46	7.27e-8	Schizophrenia;
TGCT	trans	rs4332037	1.000	rs6947019	chr7:1950337	G/A	cg25206134	chr2:45395956	NA	1.11	9.39	0.64	3.79e-16	Bipolar disorder;
TGCT	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs12791968	0.765	rs12794751	chr11:44998769	C/G	cg11846598	chr11:44996168	LOC221122	-0.31	-4.8	-0.4	4.4e-6	Inhibitory control;
TGCT	cis	rs1008375	0.966	rs28750296	chr4:17685826	A/T	cg10189774	chr4:17578691	LAP3	0.52	4.74	0.39	5.82e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	trans	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.88	9.92	0.67	1.95e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs6938	0.534	rs12907898	chr15:75207872	C/T	cg10253484	chr15:75165896	SCAMP2	-0.57	-5.28	-0.43	5.69e-7	Breast cancer;
TGCT	cis	rs13191362	1.000	rs35754151	chr6:163074867	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.89	6.36	0.5	3.55e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs9926296	0.568	rs417323	chr16:89746277	T/G	cg04287289	chr16:89883240	FANCA	-0.54	-5.09	-0.42	1.32e-6	Vitiligo;
TGCT	cis	rs17376456	0.825	rs17372057	chr5:93071916	C/A	cg21475434	chr5:93447410	FAM172A	0.64	5.05	0.41	1.52e-6	Diabetic retinopathy;
TGCT	cis	rs79349575	0.749	rs58838744	chr17:46998902	A/G	cg07967210	chr17:47022446	SNF8	0.44	6.12	0.48	1.13e-8	Type 2 diabetes;
TGCT	cis	rs1371867	0.846	rs1788167	chr8:101319996	C/T	cg06636551	chr8:101224915	SPAG1	-0.42	-5.65	-0.45	1.06e-7	Atrioventricular conduction;
TGCT	cis	rs6892003	0.857	rs58936790	chr5:174179520	T/C	cg06056415	chr5:174162510	NA	0.44	4.6	0.38	1.04e-5	Clopidogrel active metabolite levels;
TGCT	trans	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg21659725	chr3:3221576	CRBN	0.98	15.33	0.81	2.1000000000000002e-30	Intelligence (multi-trait analysis);
TGCT	cis	rs10876993	0.855	rs1678520	chr12:58049319	C/G	cg15848620	chr12:58087721	OS9	-0.72	-5.82	-0.46	4.71e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs7943191	0.810	rs7942991	chr11:62337203	A/G	cg13298116	chr11:62369859	EML3;MTA2	-0.57	-6.84	-0.52	3.19e-10	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg05985448	chr10:134359359	INPP5A	0.23	5.11	0.42	1.2e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs17601876	0.814	rs8029537	chr15:51557698	A/G	cg19946085	chr15:51559439	CYP19A1	-0.33	-5.06	-0.41	1.45e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs4951018	0.853	rs1573104	chr1:205636907	A/C	cg14893161	chr1:205819251	PM20D1	-0.36	-4.76	-0.39	5.39e-6	Prostate-specific antigen levels;
TGCT	cis	rs60154123	0.505	rs2206043	chr1:210042983	G/A	cg21951975	chr1:209979733	IRF6	0.69	5.18	0.42	8.74e-7	Coronary artery disease;
TGCT	cis	rs713587	0.571	rs2917916	chr2:25316336	A/C	cg01884057	chr2:25150051	NA	-0.26	-4.88	-0.4	3.16e-6	Body mass index in non-asthmatics;
TGCT	cis	rs7937612	1.000	rs7117063	chr11:120238824	T/C	cg24566217	chr11:120254723	ARHGEF12	-0.29	-4.7	-0.39	6.76e-6	Intraocular pressure;
TGCT	cis	rs17739794	0.557	rs7823711	chr8:814529	A/G	cg01971667	chr8:817044	NA	-0.29	-4.44	-0.37	1.97e-5	Clozapine-induced cytotoxicity;
TGCT	cis	rs17741873	0.836	rs12221230	chr10:75604972	T/C	cg07699608	chr10:75541558	CHCHD1	0.71	4.81	0.4	4.26e-6	Paclitaxel disposition in epithelial ovarian cancer;
TGCT	cis	rs2964802	0.505	rs7729989	chr5:10822246	A/G	cg14521931	chr5:10832172	NA	-0.28	-4.74	-0.39	5.78e-6	Major depressive disorder;Recurrent major depressive disorder;
TGCT	cis	rs12049351	0.774	rs3767327	chr1:229659310	C/G	cg12130225	chr1:229698885	NA	0.35	4.46	0.37	1.85e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs7192750	0.539	rs12599192	chr16:71979097	G/A	cg06353428	chr16:71660113	MARVELD3	0.75	6.74	0.52	5.43e-10	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs6964587	1.000	rs10488510	chr7:91660225	G/T	cg17063962	chr7:91808500	NA	0.91	9.97	0.67	1.53e-17	Breast cancer;
TGCT	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg11764359	chr7:65958608	NA	0.61	5.53	0.44	1.84e-7	Aortic root size;
TGCT	cis	rs35306767	0.903	rs12764024	chr10:922861	A/G	cg20503657	chr10:835505	NA	0.73	9.79	0.66	4.03e-17	Eosinophil percentage of granulocytes;
TGCT	cis	rs2050392	1.000	rs2250714	chr10:30697396	G/C	cg18806716	chr10:30721971	MAP3K8	-0.46	-5.35	-0.43	4.06e-7	Inflammatory bowel disease;
TGCT	cis	rs7914558	0.966	rs10786745	chr10:104956827	A/G	cg05855489	chr10:104503620	C10orf26	0.52	4.58	0.38	1.1e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs1903068	0.819	rs17711320	chr4:56000053	A/C	cg16572876	chr4:56024045	NA	0.43	4.94	0.41	2.43e-6	Endometriosis;
TGCT	cis	rs4523957	0.651	rs7223390	chr17:2085653	T/C	cg16513277	chr17:2031491	SMG6	-0.2	-4.64	-0.38	8.83e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg10560079	chr2:191398806	TMEM194B	0.37	5.35	0.43	4.14e-7	Pulse pressure;
TGCT	cis	rs8070740	0.836	rs4444392	chr17:5324588	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.49	4.88	0.4	3.15e-6	Menopause (age at onset);
TGCT	cis	rs9291683	0.588	rs17247314	chr4:10004743	C/G	cg00071950	chr4:10020882	SLC2A9	0.67	9.01	0.63	3.02e-15	Bone mineral density;
TGCT	cis	rs2073300	1.000	rs6114098	chr20:23444276	G/A	cg09953122	chr20:23471693	CST8	-0.61	-4.45	-0.37	1.9e-5	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs11148252	0.574	rs9536247	chr13:53279542	T/C	cg00495681	chr13:53174319	NA	0.71	7.41	0.55	1.69e-11	Lewy body disease;
TGCT	cis	rs9549260	0.755	rs7985364	chr13:41179580	C/G	cg21288729	chr13:41239152	FOXO1	1.0	10.06	0.67	9.29e-18	Red blood cell count;
TGCT	cis	rs3820068	0.705	rs11577225	chr1:15864242	T/C	cg05660106	chr1:15850417	CASP9	1.16	14.82	0.8	3.11e-29	Systolic blood pressure;
TGCT	cis	rs734999	0.588	rs10910099	chr1:2533552	G/T	cg18854424	chr1:2615690	NA	-0.46	-5.33	-0.43	4.38e-7	Ulcerative colitis;
TGCT	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg06221963	chr1:154839813	KCNN3	-0.75	-12.65	-0.75	4.66e-24	Prostate cancer;
TGCT	cis	rs2153535	0.580	rs9406161	chr6:8466144	G/T	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs1062177	0.756	rs2915817	chr5:151115517	T/C	cg00977110	chr5:151150581	G3BP1	-0.4	-4.6	-0.38	1.03e-5	Preschool internalizing problems;
TGCT	cis	rs2303745	0.544	rs6512181	chr19:17399213	T/G	cg02221750	chr19:17393354	ANKLE1	-0.46	-5.87	-0.47	3.73e-8	Systemic lupus erythematosus;
TGCT	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg23982607	chr1:1823379	GNB1	-0.55	-8.35	-0.6	1.15e-13	Body mass index;
TGCT	cis	rs881375	0.967	rs1930781	chr9:123687834	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	4.99	0.41	2.03e-6	Rheumatoid arthritis;
TGCT	cis	rs7833790	0.724	rs1054078	chr8:82712153	A/G	cg06027949	chr8:82754900	SNX16	-0.65	-5.03	-0.41	1.69e-6	Diastolic blood pressure;
TGCT	cis	rs2777491	1.000	rs2777491	chr15:41735710	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.75	-11.01	-0.7	4.47e-20	Ulcerative colitis;
TGCT	cis	rs6570726	0.689	rs411785	chr6:145888398	G/A	cg05347473	chr6:146136440	FBXO30	0.54	5.15	0.42	1.01e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6669919	0.510	rs4951758	chr1:211690631	A/G	cg26515805	chr1:211431828	RCOR3	-0.43	-4.63	-0.38	8.96e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs11677370	0.561	rs4849990	chr2:3819558	A/G	cg17052675	chr2:3827356	NA	-0.45	-7.33	-0.55	2.63e-11	Type 2 diabetes;
TGCT	cis	rs9372253	1.000	rs9372253	chr6:110716136	C/T	cg19196401	chr6:110721138	DDO	-0.5	-7.33	-0.55	2.59e-11	Platelet distribution width;
TGCT	cis	rs514406	0.505	rs374662	chr1:53164549	C/A	cg16325326	chr1:53192061	ZYG11B	0.85	11.53	0.72	2.38e-21	Monocyte count;
TGCT	cis	rs1008375	1.000	rs11947857	chr4:17691047	T/C	cg10189774	chr4:17578691	LAP3	-0.58	-4.94	-0.41	2.52e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7772486	0.692	rs1577916	chr6:146069789	G/A	cg05347473	chr6:146136440	FBXO30	-0.54	-4.95	-0.41	2.33e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4888262	0.526	rs12921903	chr16:74625575	C/T	cg01733217	chr16:74700730	RFWD3	0.74	7.48	0.56	1.16e-11	Testicular germ cell tumor;
TGCT	cis	rs1577917	0.958	rs12209668	chr6:86566517	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.29	-0.43	5.34e-7	Response to antipsychotic treatment;
TGCT	cis	rs589448	0.538	rs683790	chr12:69751434	T/G	cg20891283	chr12:69753455	YEATS4	0.66	5.73	0.46	7.22e-8	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg03160526	chr17:80928410	B3GNTL1	0.33	4.61	0.38	9.86e-6	Glycated hemoglobin levels;
TGCT	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg06481639	chr22:41940642	POLR3H	-0.74	-6.74	-0.52	5.38e-10	Vitiligo;
TGCT	cis	rs2811893	1.000	rs232861	chr1:59120399	T/G	cg26196860	chr1:59745563	NA	0.24	4.44	0.37	1.96e-5	Diabetic retinopathy;
TGCT	cis	rs9611565	0.559	rs4822049	chr22:41993496	G/A	cg17554472	chr22:41940697	POLR3H	-0.52	-5.37	-0.43	3.79e-7	Vitiligo;
TGCT	cis	rs3617	0.652	rs7630552	chr3:52891570	G/C	cg11645453	chr3:52864694	ITIH4	-0.29	-5.68	-0.45	9.09e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2204008	0.806	rs11520229	chr12:38246448	C/A	cg26384229	chr12:38710491	ALG10B	0.86	7.42	0.55	1.6e-11	Bladder cancer;
TGCT	cis	rs12220898	0.833	rs3996895	chr10:50484365	G/A	cg09603381	chr10:49954066	WDFY4	0.38	4.45	0.37	1.88e-5	Inflammatory biomarkers;
TGCT	cis	rs739496	0.947	rs2301621	chr12:111895272	C/T	cg10833066	chr12:111807467	FAM109A	0.37	5.2	0.42	8.01e-7	Platelet count;
TGCT	cis	rs9534288	0.762	rs1571053	chr13:46554854	G/A	cg15192986	chr13:46630673	CPB2	-0.53	-7.66	-0.57	4.65e-12	Blood protein levels;
TGCT	cis	rs782590	0.935	rs10460508	chr2:55882565	A/C	cg18811423	chr2:55921094	PNPT1	0.63	6.49	0.5	1.84e-9	Metabolic syndrome;
TGCT	cis	rs9911578	0.741	rs2611776	chr17:56819636	G/T	cg12560992	chr17:57184187	TRIM37	0.76	9.34	0.64	4.88e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs28595532	0.841	rs114465037	chr4:119778165	A/G	cg11846333	chr4:119757529	SEC24D	0.92	4.64	0.38	8.74e-6	Cannabis dependence symptom count;
TGCT	cis	rs4319547	0.656	rs2173582	chr12:122824694	A/G	cg08088222	chr12:122070432	ORAI1	0.26	4.64	0.38	8.63e-6	Body mass index;
TGCT	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg02187348	chr16:89574699	SPG7	0.62	6.66	0.51	7.77e-10	Multiple myeloma (IgH translocation);
TGCT	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	5.97	0.47	2.36e-8	Bipolar disorder;
TGCT	cis	rs1357245	0.503	rs9816609	chr3:27100459	A/G	cg02860705	chr3:27208620	NA	0.32	5.09	0.42	1.3e-6	Breast cancer;
TGCT	cis	rs4919694	1.000	rs3740394	chr10:104634474	A/G	cg04362960	chr10:104952993	NT5C2	1.03	6.98	0.53	1.61e-10	Arsenic metabolism;
TGCT	cis	rs6088580	0.634	rs945673	chr20:32964265	C/A	cg08999081	chr20:33150536	PIGU	-0.28	-5.51	-0.44	1.98e-7	Glomerular filtration rate (creatinine);
TGCT	trans	rs877282	0.853	rs7092652	chr10:756109	G/A	cg22713356	chr15:30763199	NA	1.07	8.27	0.6	1.75e-13	Uric acid levels;
TGCT	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg11764359	chr7:65958608	NA	0.58	5.27	0.43	5.77e-7	Aortic root size;
TGCT	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.86	7.29	0.55	3.13e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs832540	0.931	rs331499	chr5:56210923	C/T	cg17801930	chr5:56009405	NA	-0.21	-4.43	-0.37	2.01e-5	Coronary artery disease;
TGCT	cis	rs1008375	1.000	rs12507142	chr4:17656103	A/G	cg16339924	chr4:17578868	LAP3	0.63	5.26	0.43	6.22e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs782590	0.967	rs1084522	chr2:55843294	A/G	cg03859395	chr2:55845619	SMEK2	0.88	10.82	0.7	1.31e-19	Metabolic syndrome;
TGCT	trans	rs1973993	0.691	rs6658131	chr1:96889314	C/T	cg10631902	chr5:14652156	NA	0.39	10.65	0.69	3.39e-19	Weight;
TGCT	cis	rs210152	0.588	rs1755040	chr6:33495175	A/C	cg07735790	chr6:34101545	GRM4	-0.52	-4.79	-0.4	4.68e-6	Schizophrenia;
TGCT	cis	rs6969780	0.722	rs4722666	chr7:27197601	C/G	cg22997113	chr7:27170241	HOXA4	-0.44	-4.46	-0.37	1.79e-5	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs752010	0.574	rs2148636	chr1:42119844	C/T	cg06885757	chr1:42089581	HIVEP3	-0.25	-4.89	-0.4	3.08e-6	Lupus nephritis in systemic lupus erythematosus;
TGCT	cis	rs1801251	1.000	rs6717841	chr2:233590255	C/T	cg08000102	chr2:233561755	GIGYF2	0.63	6.53	0.51	1.51e-9	Coronary artery disease;
TGCT	cis	rs7772486	0.790	rs6917135	chr6:146152426	T/C	cg23711669	chr6:146136114	FBXO30	0.89	10.12	0.67	6.38e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1008375	1.000	rs10939746	chr4:17684951	A/G	cg18681998	chr4:17616180	MED28	-0.96	-10.78	-0.7	1.61e-19	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7666738	0.530	rs2865992	chr4:99067181	A/T	cg17366294	chr4:99064904	C4orf37	0.58	6.15	0.48	9.93e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7246657	0.712	rs4803263	chr19:38066782	G/A	cg03611452	chr19:38183253	ZNF781	0.58	4.64	0.38	8.62e-6	Coronary artery calcification;
TGCT	cis	rs2404602	0.692	rs35999717	chr15:77193367	G/C	cg26408565	chr15:76604113	ETFA	-0.36	-4.68	-0.39	7.39e-6	Blood metabolite levels;
TGCT	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg17747265	chr1:1875780	NA	-0.39	-7.32	-0.55	2.73e-11	Body mass index;
TGCT	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg27454412	chr7:1067447	C7orf50	0.57	4.46	0.37	1.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs17270561	0.541	rs17586946	chr6:25939053	C/T	cg16482183	chr6:26056742	HIST1H1C	0.95	7.23	0.54	4.29e-11	Iron status biomarkers;
TGCT	cis	rs7615952	0.736	rs11921945	chr3:125643719	A/G	cg05084668	chr3:125655381	ALG1L	-0.7	-5.64	-0.45	1.08e-7	Blood pressure (smoking interaction);
TGCT	cis	rs55940216	0.615	rs2027924	chr8:17983723	C/T	cg24613644	chr8:18387969	PSD3	0.3	4.77	0.39	5.16e-6	Facial morphology (factor 14, intercanthal width);
TGCT	cis	rs28595532	0.841	rs114175487	chr4:119733580	C/G	cg14228332	chr4:119757509	SEC24D	1.32	6.38	0.5	3.2e-9	Cannabis dependence symptom count;
TGCT	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg05896524	chr21:47604654	C21orf56	0.43	4.58	0.38	1.13e-5	Testicular germ cell tumor;
TGCT	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	8.04	0.59	5.91e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	trans	rs1005277	0.522	rs1208681	chr10:38092975	C/T	cg17830980	chr10:43048298	ZNF37B	-0.65	-7.49	-0.56	1.11e-11	Extrinsic epigenetic age acceleration;
TGCT	cis	rs3749237	0.595	rs10865955	chr3:49499829	G/A	cg02487422	chr3:49467188	NICN1	0.61	6.29	0.49	5.08e-9	Resting heart rate;
TGCT	cis	rs3821902	0.606	rs73119095	chr3:64018177	G/T	cg22134162	chr3:63841271	THOC7	-0.32	-4.77	-0.39	5.15e-6	Breast cancer;
TGCT	cis	rs854765	0.686	rs8065497	chr17:17782649	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.65	-6.47	-0.5	2.03e-9	Total body bone mineral density;
TGCT	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	trans	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg21659725	chr3:3221576	CRBN	0.7	7.96	0.58	9.35e-13	Body mass index;
TGCT	cis	rs60843830	1.000	rs56167434	chr2:282137	G/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.72	6.95	0.53	1.86e-10	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs9733	0.543	rs72702558	chr1:150683251	G/A	cg09365446	chr1:150670422	GOLPH3L	0.3	4.52	0.38	1.4e-5	Tonsillectomy;
TGCT	cis	rs9383153	0.590	rs2072736	chr6:16328068	T/C	cg20052079	chr6:15504923	JARID2	0.92	5.01	0.41	1.82e-6	Gambling;
TGCT	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.46	-6.7	-0.52	6.44e-10	Alzheimer's disease;
TGCT	cis	rs4631830	0.683	rs10763193	chr10:51504938	G/A	cg10326726	chr10:51549505	MSMB	0.23	4.54	0.38	1.33e-5	Prostate-specific antigen levels;
TGCT	cis	rs7824557	0.564	rs2736301	chr8:11236413	C/T	cg21775007	chr8:11205619	TDH	-0.65	-6.39	-0.5	3.07e-9	Retinal vascular caliber;
TGCT	cis	rs7833790	1.000	rs28696138	chr8:82770794	G/A	cg27398817	chr8:82754497	SNX16	0.84	5.98	0.47	2.18e-8	Diastolic blood pressure;
TGCT	cis	rs12291225	0.679	rs4757245	chr11:14297872	A/C	cg19336497	chr11:14380999	RRAS2	-0.38	-5.9	-0.47	3.23e-8	Sense of smell;
TGCT	cis	rs1062177	1.000	rs41494545	chr5:151235094	A/G	cg00977110	chr5:151150581	G3BP1	-0.4	-4.5	-0.38	1.51e-5	Preschool internalizing problems;
TGCT	cis	rs7175404	0.591	rs17708628	chr15:94060378	T/C	cg18324227	chr15:93584571	NA	0.49	4.56	0.38	1.2e-5	Attention deficit hyperactivity disorder;
TGCT	cis	rs8031584	0.652	rs2691683	chr15:31135060	A/G	cg08704250	chr15:31115839	NA	0.43	6.31	0.49	4.47e-9	Huntington's disease progression;
TGCT	cis	rs372883	0.613	rs1153289	chr21:30686212	G/T	cg24692254	chr21:30365293	RNF160	-0.5	-4.55	-0.38	1.25e-5	Pancreatic cancer;
TGCT	cis	rs7698623	0.850	rs4693896	chr4:88797897	T/C	cg27387453	chr4:88533842	DSPP	-0.61	-4.6	-0.38	1.03e-5	Cardiovascular disease risk factors;
TGCT	cis	rs6722750	0.933	rs1370390	chr2:64410193	G/T	cg22352474	chr2:64371530	PELI1	0.58	5.18	0.42	8.78e-7	Neuroticism;
TGCT	cis	rs12477438	0.798	rs6704766	chr2:99642818	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-5.87	-0.47	3.74e-8	Chronic sinus infection;
TGCT	cis	rs1475911	1.000	rs34421316	chr21:43513989	C/T	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.26	-5.08	-0.42	1.32e-6	IgG glycosylation;
TGCT	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg07507251	chr3:52567010	NT5DC2	0.48	6.91	0.53	2.24e-10	Bipolar disorder;
TGCT	cis	rs7267979	0.966	rs6083817	chr20:25343998	G/C	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7937682	0.632	rs4441050	chr11:111772506	C/T	cg09085632	chr11:111637200	PPP2R1B	0.84	7.34	0.55	2.4e-11	Primary sclerosing cholangitis;
TGCT	cis	rs4132699	0.683	rs9410474	chr9:92012720	C/T	cg00420568	chr9:91794904	SHC3	0.41	4.68	0.39	7.41e-6	Orofacial clefts;Nonsyndromic cleft lip with or without cleft palate;
TGCT	cis	rs1975974	1.000	rs4889732	chr17:21721443	T/C	cg18423549	chr17:21743878	NA	-0.49	-4.65	-0.39	8.23e-6	Psoriasis;
TGCT	cis	rs7666738	0.861	rs5014702	chr4:99052102	C/A	cg05340658	chr4:99064831	C4orf37	0.51	5.67	0.45	9.57e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7412746	0.658	rs6677420	chr1:150946490	G/A	cg09365446	chr1:150670422	GOLPH3L	0.34	4.72	0.39	6.28e-6	Melanoma;
TGCT	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg06618935	chr21:46677482	NA	-0.37	-5.56	-0.45	1.58e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs8017423	0.647	rs11623736	chr14:90746471	G/T	cg04374321	chr14:90722782	PSMC1	-0.73	-6.99	-0.53	1.53e-10	Mortality in heart failure;
TGCT	cis	rs7178424	0.516	rs12917535	chr15:62325518	A/T	cg00456672	chr15:62358751	C2CD4A	-0.29	-4.5	-0.37	1.52e-5	Height;
TGCT	cis	rs12049351	0.613	rs10799535	chr1:229657794	T/C	cg12130225	chr1:229698885	NA	0.35	4.46	0.37	1.85e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs11098499	0.863	rs3775849	chr4:120450908	G/C	cg09307838	chr4:120376055	NA	0.69	6.53	0.51	1.49e-9	Corneal astigmatism;
TGCT	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg02353165	chr6:42928485	GNMT	0.99	10.14	0.67	5.65e-18	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs2075371	0.863	rs12672691	chr7:133954431	C/T	cg11752832	chr7:134001865	SLC35B4	0.66	5.52	0.44	1.93e-7	Mean platelet volume;
TGCT	cis	rs57590327	0.503	rs9866374	chr3:81615311	T/C	cg07356753	chr3:81810745	GBE1	-0.61	-5.1	-0.42	1.24e-6	Extraversion;
TGCT	cis	rs6912958	0.515	rs381782	chr6:88040649	C/T	cg10393598	chr6:87862264	NA	-0.31	-4.5	-0.37	1.54e-5	Monocyte percentage of white cells;
TGCT	trans	rs210152	0.531	rs4713634	chr6:33514708	T/C	cg22108809	chr5:56777663	ACTBL2	-0.54	-6.67	-0.51	7.5e-10	Schizophrenia;
TGCT	cis	rs4689388	0.926	rs4689394	chr4:6291003	C/G	cg25554036	chr4:6271136	WFS1	-0.54	-7.55	-0.56	8.15e-12	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg00149659	chr3:10157352	C3orf10	0.94	6.0	0.47	2e-8	Alzheimer's disease;
TGCT	cis	rs3125734	0.633	rs1864836	chr10:64028538	C/G	cg09941381	chr10:64027924	RTKN2	-0.37	-5.64	-0.45	1.1e-7	Rheumatoid arthritis;
TGCT	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg13732083	chr21:47605072	C21orf56	-0.36	-4.72	-0.39	6.26e-6	Testicular germ cell tumor;
TGCT	cis	rs7647973	1.000	rs62259933	chr3:49469703	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.57	-4.56	-0.38	1.21e-5	Menarche (age at onset);
TGCT	cis	rs3849570	0.643	rs9870954	chr3:81978850	A/G	cg07356753	chr3:81810745	GBE1	-0.64	-5.59	-0.45	1.4e-7	Waist circumference;Body mass index;
TGCT	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg06481639	chr22:41940642	POLR3H	-0.73	-6.64	-0.51	8.91e-10	Vitiligo;
TGCT	cis	rs1008375	1.000	rs6846238	chr4:17629939	A/G	cg16339924	chr4:17578868	LAP3	0.62	5.11	0.42	1.17e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs13242816	1.000	rs6968230	chr7:116137049	G/T	cg16553024	chr7:116138462	CAV2	-0.44	-5.31	-0.43	4.81e-7	P wave duration;
TGCT	cis	rs2637266	0.935	rs7921790	chr10:78368253	T/C	cg18941641	chr10:78392320	NA	0.4	4.73	0.39	6.03e-6	Pulmonary function;
TGCT	cis	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg20362242	chr5:692897	TPPP	0.48	4.51	0.38	1.47e-5	Lung disease severity in cystic fibrosis;
TGCT	cis	rs6725041	0.522	rs10172782	chr2:213089415	C/G	cg16329650	chr2:213403929	ERBB4	-0.55	-4.78	-0.39	4.82e-6	QT interval (ambient particulate matter interaction);
TGCT	cis	rs42648	0.869	rs42614	chr7:89950363	C/G	cg25739043	chr7:89950458	NA	-0.74	-7.3	-0.55	2.98e-11	Homocysteine levels;
TGCT	cis	rs3806843	0.933	rs2240696	chr5:140168070	A/G	cg19875535	chr5:140030758	IK	0.37	6.34	0.49	3.89e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg03806693	chr22:41940476	POLR3H	1.02	11.39	0.72	5.21e-21	Vitiligo;
TGCT	cis	rs7267979	1.000	rs2257985	chr20:25269743	G/T	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9818758	0.607	rs9847839	chr3:49289003	T/C	cg00383909	chr3:49044727	WDR6	1.28	6.57	0.51	1.23e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs9911578	0.934	rs8081967	chr17:57072701	T/C	cg05425664	chr17:57184151	TRIM37	-0.68	-6.89	-0.53	2.55e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs4808199	0.947	rs10401193	chr19:19591066	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.69	4.99	0.41	1.96e-6	Nonalcoholic fatty liver disease;
TGCT	cis	rs9790314	0.846	rs13083229	chr3:161008125	G/A	cg03342759	chr3:160939853	NMD3	-0.51	-5.66	-0.45	9.96e-8	Morning vs. evening chronotype;
TGCT	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg02187348	chr16:89574699	SPG7	0.63	6.99	0.53	1.47e-10	Multiple myeloma (IgH translocation);
TGCT	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg02725872	chr8:58115012	NA	-0.35	-4.67	-0.39	7.82e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7614311	0.681	rs73117083	chr3:63948455	G/C	cg22134162	chr3:63841271	THOC7	-0.46	-5.87	-0.47	3.73e-8	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs56399783	0.901	rs17300022	chr7:2808517	C/T	cg19731401	chr7:2775893	GNA12	-0.37	-5.15	-0.42	1.01e-6	Childhood ear infection;
TGCT	cis	rs2486012	1.000	rs2485989	chr1:44408454	T/C	cg12908607	chr1:44402522	ARTN	0.77	6.02	0.48	1.79e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs3935685	0.934	rs11630598	chr15:78006095	C/T	cg25212270	chr15:78015279	NA	0.3	6.08	0.48	1.38e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs6912958	0.754	rs1051131	chr6:88221546	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-5.06	-0.41	1.45e-6	Monocyte percentage of white cells;
TGCT	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg22963979	chr7:1858916	MAD1L1	-0.34	-5.39	-0.44	3.43e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs6540559	0.551	rs17389436	chr1:209972297	A/T	cg21951975	chr1:209979733	IRF6	0.73	4.68	0.39	7.53e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg08975724	chr8:8085496	FLJ10661	0.64	6.03	0.48	1.77e-8	Mood instability;
TGCT	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs76096589	0.557	rs59230713	chr14:50995729	A/C	cg04730355	chr14:51134070	SAV1	1.05	4.49	0.37	1.58e-5	Diisocyanate-induced asthma;
TGCT	cis	rs1372520	0.577	rs748849	chr4:90734961	G/A	cg20003494	chr4:90757398	SNCA	-0.65	-5.2	-0.42	8.15e-7	Neuroticism;
TGCT	cis	rs72781680	0.898	rs72782113	chr2:24024952	G/C	cg08917208	chr2:24149416	ATAD2B	0.81	5.01	0.41	1.8e-6	Lymphocyte counts;
TGCT	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg03060546	chr3:49711283	APEH	-0.51	-4.92	-0.4	2.75e-6	Menarche (age at onset);
TGCT	cis	rs3774830	0.743	rs6810392	chr4:5459932	C/T	cg26943120	chr4:5472116	STK32B	0.22	4.78	0.39	4.95e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs1949733	0.701	rs871768	chr4:8454938	G/A	cg11789530	chr4:8429930	ACOX3	0.54	5.13	0.42	1.08e-6	Response to antineoplastic agents;
TGCT	cis	rs7208859	0.673	rs216411	chr17:28903493	T/C	cg13385521	chr17:29058706	SUZ12P	-0.76	-4.71	-0.39	6.4e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg10295955	chr4:187884368	NA	-0.99	-14.5	-0.79	1.78e-28	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs8077889	0.956	rs4793026	chr17:41850508	A/G	cg26893861	chr17:41843967	DUSP3	1.09	13.68	0.78	1.57e-26	Triglycerides;
TGCT	cis	rs13256369	0.901	rs12681327	chr8:8566414	G/T	cg06671706	chr8:8559999	CLDN23	0.34	4.59	0.38	1.09e-5	Obesity-related traits;
TGCT	cis	rs7267979	1.000	rs6050542	chr20:25318879	T/C	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9457247	1.000	rs393558	chr6:167397750	A/C	cg23791538	chr6:167370224	RNASET2	-0.49	-4.96	-0.41	2.26e-6	Crohn's disease;
TGCT	cis	rs12142240	0.698	rs72677594	chr1:46824371	A/C	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs7542091	0.748	rs2357231	chr1:210028454	A/C	cg22029157	chr1:209979665	IRF6	-0.48	-4.83	-0.4	4.03e-6	Monobrow;
TGCT	cis	rs826838	0.935	rs3886109	chr12:39189243	C/T	cg26384229	chr12:38710491	ALG10B	0.98	8.78	0.62	1.07e-14	Heart rate;
TGCT	trans	rs6089829	0.888	rs6011559	chr20:61675620	C/T	cg13615516	chr5:77269221	NA	-0.73	-8.16	-0.59	3.24e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs908922	0.676	rs1856119	chr1:152512483	A/G	cg20991723	chr1:152506922	NA	0.46	6.18	0.48	8.66e-9	Hair morphology;
TGCT	cis	rs4822044	0.568	rs1883370	chr22:42143740	C/A	cg06481639	chr22:41940642	POLR3H	0.67	5.81	0.46	5.06e-8	Cannabis dependence symptom count;
TGCT	trans	rs57221529	0.766	rs72703064	chr5:587825	T/C	cg11887960	chr12:57824829	NA	1.14	9.3	0.64	6.29e-16	Lung disease severity in cystic fibrosis;
TGCT	cis	rs9527	0.590	rs12415388	chr10:104796345	T/C	cg15744005	chr10:104629667	AS3MT	-0.4	-4.63	-0.38	9.04e-6	Arsenic metabolism;
TGCT	cis	rs1150668	0.799	rs7206	chr6:28201138	A/G	cg13525197	chr6:28411240	ZSCAN23	-0.47	-4.61	-0.38	9.84e-6	Pubertal anthropometrics;
TGCT	cis	rs8002180	0.918	rs7322318	chr13:95923688	T/C	cg24476569	chr13:95954382	ABCC4	0.41	5.09	0.42	1.31e-6	Blood metabolite levels;
TGCT	cis	rs11648796	0.879	rs12448432	chr16:778820	G/A	cg00908189	chr16:619842	PIGQ	0.68	5.44	0.44	2.68e-7	Height;
TGCT	cis	rs78456975	1.000	rs10189336	chr2:1558015	G/A	cg01028140	chr2:1542097	TPO	-0.33	-4.53	-0.38	1.37e-5	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg00024416	chr22:24240387	NA	0.3	5.49	0.44	2.2e-7	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs17376456	0.741	rs7718842	chr5:93480568	G/A	cg21475434	chr5:93447410	FAM172A	0.62	4.57	0.38	1.16e-5	Diabetic retinopathy;
TGCT	cis	rs2739330	0.576	rs2858912	chr22:24297197	A/G	cg10819733	chr22:24237672	NA	-0.3	-5.01	-0.41	1.87e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs10057188	0.545	rs13162495	chr5:77929230	C/T	cg17456851	chr5:78090622	ARSB	-0.28	-4.51	-0.38	1.49e-5	Pulse pressure;
TGCT	cis	rs1355223	0.583	rs1828298	chr11:34870439	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.78	8.67	0.61	2.03e-14	Systemic lupus erythematosus and Systemic sclerosis;
TGCT	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg25036284	chr2:26402008	FAM59B	0.65	5.18	0.42	8.59e-7	Gut microbiome composition (summer);
TGCT	cis	rs7666738	0.830	rs4699588	chr4:98973789	A/G	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs57920188	0.535	rs4295856	chr1:4094842	C/T	cg20703997	chr1:4087676	NA	0.48	5.7	0.46	8.27e-8	Interleukin-17 levels;
TGCT	cis	rs61931739	0.517	rs7139189	chr12:34319757	T/C	cg06521331	chr12:34319734	NA	-0.35	-5.74	-0.46	6.71e-8	Morning vs. evening chronotype;
TGCT	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.68	5.62	0.45	1.18e-7	Tonsillectomy;
TGCT	cis	rs9486715	0.790	rs2971602	chr6:97022468	C/T	cg06623918	chr6:96969491	KIAA0776	-1.1	-14.44	-0.79	2.5e-28	Headache;
TGCT	cis	rs11785400	0.793	rs6996760	chr8:143722386	G/A	cg24634471	chr8:143751801	JRK	0.53	5.24	0.43	6.7e-7	Schizophrenia;
TGCT	cis	rs4938534	0.683	rs1944930	chr11:111290238	G/A	cg24049888	chr11:111250129	POU2AF1	-0.25	-4.44	-0.37	1.98e-5	Primary biliary cholangitis;
TGCT	cis	rs1008375	0.966	rs2302393	chr4:17654341	G/A	cg10189774	chr4:17578691	LAP3	0.55	4.91	0.4	2.81e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2120019	0.935	rs12591119	chr15:75355944	A/G	cg09165964	chr15:75287851	SCAMP5	-1.18	-9.83	-0.66	3.33e-17	Blood trace element (Zn levels);
TGCT	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg08859206	chr1:53392774	SCP2	-0.48	-7.66	-0.57	4.69e-12	Monocyte count;
TGCT	cis	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg20637647	chr7:64974828	NA	-0.92	-5.09	-0.42	1.26e-6	Diabetic kidney disease;
TGCT	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg15691649	chr6:25882328	NA	-0.41	-4.77	-0.39	4.99e-6	Intelligence (multi-trait analysis);
TGCT	trans	rs6762477	0.748	rs2073726	chr3:50223593	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.78	-8.11	-0.59	4.24e-13	Menarche (age at onset);
TGCT	cis	rs1568889	1.000	rs1464897	chr11:28034844	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.87	8.85	0.62	7.64e-15	Bipolar disorder;
TGCT	cis	rs28493229	0.708	rs10407431	chr19:41160870	T/C	cg11601297	chr19:41224147	ITPKC;ADCK4	0.57	5.15	0.42	9.94e-7	Kawasaki disease;
TGCT	trans	rs1814175	0.935	rs10839317	chr11:49657228	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.34	-6.67	-0.51	7.47e-10	Height;
TGCT	cis	rs2663905	0.611	rs2663924	chr15:81392903	T/G	cg27045999	chr15:81426544	C15orf26	-0.51	-5.02	-0.41	1.78e-6	QT interval (drug interaction);
TGCT	cis	rs3806843	0.766	rs801176	chr5:140087010	A/G	cg19875535	chr5:140030758	IK	0.36	6.02	0.48	1.85e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs1505368	0.781	rs10197836	chr2:213274278	T/C	cg16329650	chr2:213403929	ERBB4	0.61	5.92	0.47	2.88e-8	Symmetrical dimethylarginine levels;
TGCT	cis	rs7980687	0.527	rs1727295	chr12:123616861	G/A	cg00376283	chr12:123451042	ABCB9	0.76	6.75	0.52	5.13e-10	Height;Educational attainment;Head circumference (infant);
TGCT	cis	rs17473412	0.677	rs6887967	chr5:122884414	A/G	cg15125798	chr5:122621645	NA	-0.53	-4.9	-0.4	2.93e-6	Total body bone mineral density;
TGCT	cis	rs28595532	0.920	rs28837152	chr4:119782868	G/A	cg21605333	chr4:119757512	SEC24D	1.44	8.24	0.6	2.03e-13	Cannabis dependence symptom count;
TGCT	cis	rs2456568	0.867	rs1827931	chr11:93663170	T/C	cg26875233	chr11:93583750	C11orf90	-0.46	-5.74	-0.46	7.02e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs8077889	0.956	rs58242860	chr17:41847300	T/C	cg26893861	chr17:41843967	DUSP3	1.09	13.68	0.78	1.57e-26	Triglycerides;
TGCT	cis	rs3806843	0.545	rs251375	chr5:140252960	T/G	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	0.43	5.17	0.42	8.91e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2242116	1.000	rs2242116	chr3:46941116	A/G	cg23352942	chr3:46931381	PTH1R	-0.36	-5.48	-0.44	2.27e-7	Birth weight;
TGCT	cis	rs8017423	0.967	rs11623275	chr14:90721335	C/T	cg04374321	chr14:90722782	PSMC1	0.76	7.71	0.57	3.49e-12	Mortality in heart failure;
TGCT	cis	rs7772486	0.748	rs2748484	chr6:146333653	C/T	cg23711669	chr6:146136114	FBXO30	0.84	9.12	0.63	1.72e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11098499	0.954	rs10006877	chr4:120242793	C/T	cg09307838	chr4:120376055	NA	0.63	5.89	0.47	3.41e-8	Corneal astigmatism;
TGCT	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg00343986	chr7:65444356	GUSB	-0.24	-5.3	-0.43	5.16e-7	Aortic root size;
TGCT	cis	rs12477438	0.765	rs6750876	chr2:99679673	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-4.62	-0.38	9.47e-6	Chronic sinus infection;
TGCT	cis	rs10791323	0.569	rs2282602	chr11:133714522	G/A	cg03690763	chr11:133734501	NA	-0.31	-4.82	-0.4	4.08e-6	Childhood ear infection;
TGCT	cis	rs644799	0.544	rs687559	chr11:95598629	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.49	-4.98	-0.41	2.09e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs2354432	0.556	rs34602039	chr1:146850972	G/A	cg25205988	chr1:146714368	CHD1L	-1.34	-5.79	-0.46	5.52e-8	Mitochondrial DNA levels;
TGCT	cis	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg18252515	chr7:66147081	NA	-1.2	-7.83	-0.58	1.89e-12	Diabetic kidney disease;
TGCT	cis	rs7605378	0.528	rs281787	chr2:200784238	C/T	cg23649088	chr2:200775458	C2orf69	-0.47	-9.83	-0.66	3.23e-17	Osteoporosis;
TGCT	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg13395646	chr4:1353034	KIAA1530	-0.55	-7.57	-0.56	7.56e-12	Obesity-related traits;
TGCT	cis	rs4478858	0.684	rs4949202	chr1:31736800	T/C	cg00250761	chr1:31883323	NA	-0.25	-4.52	-0.38	1.45e-5	Alcohol dependence;
TGCT	cis	rs67311347	0.577	rs2887951	chr3:40282104	C/G	cg13683864	chr3:40499215	RPL14	-0.8	-7.63	-0.57	5.39e-12	Renal cell carcinoma;
TGCT	cis	rs6740322	0.895	rs10166994	chr2:43557977	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.38	-6.54	-0.51	1.45e-9	Coronary artery disease;
TGCT	cis	rs644148	0.781	rs630469	chr19:44970167	T/C	cg15540054	chr19:45004280	ZNF180	-0.59	-5.21	-0.42	7.8e-7	Personality dimensions;
TGCT	cis	rs12497850	0.797	rs61583136	chr3:49189195	C/T	cg07636037	chr3:49044803	WDR6	0.94	10.1	0.67	7.08e-18	Parkinson's disease;
TGCT	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg22166914	chr1:53195759	ZYG11B	-0.36	-5.96	-0.47	2.44e-8	Monocyte count;
TGCT	cis	rs6121246	0.567	rs6087700	chr20:30217560	A/G	cg21427119	chr20:30132790	HM13	-0.43	-6.17	-0.48	8.86e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs13064411	0.735	rs7636128	chr3:113133701	A/T	cg18753928	chr3:113234510	CCDC52	-0.67	-5.12	-0.42	1.14e-6	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs1552244	0.554	rs59465469	chr3:9990800	G/C	cg00149659	chr3:10157352	C3orf10	0.67	4.96	0.41	2.28e-6	Alzheimer's disease;
TGCT	cis	rs1372520	0.684	rs2197120	chr4:90729602	A/G	cg14346243	chr4:90757452	SNCA	-0.68	-5.64	-0.45	1.12e-7	Neuroticism;
TGCT	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg14820908	chr5:178986412	RUFY1	0.61	6.78	0.52	4.37e-10	Lung cancer;
TGCT	cis	rs909002	0.830	rs1356803	chr1:32131163	C/G	cg11573219	chr1:32083031	HCRTR1	-0.42	-5.36	-0.43	3.92e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs921522	chr4:98841608	C/T	cg17366294	chr4:99064904	C4orf37	0.66	6.12	0.48	1.11e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10791323	0.572	rs1114367	chr11:133737304	G/T	cg15485101	chr11:133734466	NA	0.43	6.26	0.49	5.61e-9	Childhood ear infection;
TGCT	cis	rs60871478	0.947	rs62432255	chr7:804219	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.48	4.88	0.4	3.21e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs4972806	0.849	rs2857535	chr2:177036211	G/A	cg13092806	chr2:177043255	NA	0.54	4.66	0.39	7.93e-6	IgG glycosylation;
TGCT	cis	rs9914988	0.943	rs9890155	chr17:27125467	A/G	cg20469991	chr17:27169893	C17orf63	-0.72	-5.09	-0.42	1.29e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg22535103	chr8:58192502	C8orf71	-0.41	-4.81	-0.4	4.27e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs35306767	0.953	rs12259801	chr10:959306	C/G	cg26597838	chr10:835615	NA	0.66	9.01	0.63	3.04e-15	Eosinophil percentage of granulocytes;
TGCT	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg10802521	chr3:52805072	NEK4	0.72	9.04	0.63	2.63e-15	Bipolar disorder;
TGCT	cis	rs7666738	0.791	rs1426661	chr4:98874303	C/G	cg17366294	chr4:99064904	C4orf37	0.7	7.27	0.55	3.62e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9467773	1.000	rs6925703	chr6:26521589	G/A	cg05738196	chr6:26577821	NA	0.88	12.5	0.75	1.03e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs6540559	0.673	rs7525951	chr1:210018306	C/T	cg21951975	chr1:209979733	IRF6	-0.63	-4.76	-0.39	5.36e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs7119	0.604	rs907383	chr15:77870646	A/G	cg27398640	chr15:77910606	LINGO1	0.27	4.93	0.4	2.57e-6	Type 2 diabetes;
TGCT	cis	rs7949030	0.725	rs12808829	chr11:62378660	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.66	9.9	0.66	2.21e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9330316	0.632	rs56364682	chr2:110321230	A/G	cg25199208	chr2:109402912	CCDC138	-0.42	-4.56	-0.38	1.19e-5	Schizophrenia;
TGCT	cis	rs7085104	0.660	rs7902804	chr10:104585405	A/T	cg05855489	chr10:104503620	C10orf26	0.52	4.64	0.38	8.83e-6	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs2658782	1.000	rs2658779	chr11:93163137	G/T	cg15737290	chr11:93063684	CCDC67	-0.77	-5.41	-0.44	3.09e-7	Pulmonary function decline;
TGCT	cis	rs9467711	0.659	rs66941101	chr6:26530376	C/T	cg16898833	chr6:26189333	HIST1H4D	1.25	5.86	0.47	3.88e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6570726	0.935	rs452552	chr6:145820781	G/A	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4689388	0.750	rs12642481	chr4:6301058	G/A	cg25554036	chr4:6271136	WFS1	0.57	7.14	0.54	6.76e-11	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs12893668	0.572	rs4906350	chr14:104111794	C/T	cg26031613	chr14:104095156	KLC1	-0.59	-5.08	-0.42	1.34e-6	Reticulocyte count;
TGCT	cis	rs10089	0.904	rs2228112	chr5:127469859	A/G	cg19767477	chr5:127420684	SLC12A2	-0.43	-4.56	-0.38	1.21e-5	Ileal carcinoids;
TGCT	cis	rs6460942	0.915	rs62448623	chr7:12464122	A/G	cg06484146	chr7:12443880	VWDE	-0.57	-5.54	-0.45	1.71e-7	Coronary artery disease;
TGCT	trans	rs797680	0.856	rs7553465	chr1:93644410	C/T	cg27528825	chr2:159282178	CCDC148	-0.35	-6.85	-0.52	3.08e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs4478858	0.684	rs4949202	chr1:31736800	T/C	cg07478791	chr1:31886160	SERINC2	-0.49	-4.91	-0.4	2.82e-6	Alcohol dependence;
TGCT	cis	rs2180341	1.000	rs6569482	chr6:127631371	C/T	cg24812749	chr6:127587940	RNF146	0.98	7.64	0.57	5.06e-12	Breast cancer;
TGCT	cis	rs4568518	0.530	rs6967917	chr7:17984297	A/G	cg03009463	chr7:17980271	SNX13	0.57	4.61	0.38	9.88e-6	Measles;
TGCT	cis	rs11031096	0.803	rs2099875	chr11:4173173	A/C	cg18678763	chr11:4115507	RRM1	0.39	5.29	0.43	5.36e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs34779708	0.931	rs12771399	chr10:35452377	C/T	cg04310649	chr10:35416472	CREM	-0.53	-4.8	-0.4	4.46e-6	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs28595532	0.920	rs17257039	chr4:119603703	G/A	cg21605333	chr4:119757512	SEC24D	1.36	7.24	0.55	4.12e-11	Cannabis dependence symptom count;
TGCT	cis	rs17102423	0.788	rs11158575	chr14:65581665	T/C	cg11161011	chr14:65562177	MAX	-0.54	-7.62	-0.56	5.58e-12	Obesity-related traits;
TGCT	cis	rs7027203	0.557	rs2487015	chr9:96521240	T/G	cg14598338	chr9:96623480	NA	-0.49	-7.04	-0.53	1.18e-10	DNA methylation (variation);
TGCT	cis	rs782590	0.967	rs6545506	chr2:55798108	A/G	cg03859395	chr2:55845619	SMEK2	-0.88	-10.87	-0.7	9.74e-20	Metabolic syndrome;
TGCT	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg24531977	chr5:56204891	C5orf35	-0.68	-7.22	-0.54	4.69e-11	Initial pursuit acceleration;
TGCT	cis	rs10883723	0.738	rs3781290	chr10:104244948	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	8.62	0.61	2.63e-14	Allergic disease (asthma, hay fever or eczema);
TGCT	trans	rs1814175	0.715	rs1722007	chr11:49897319	T/C	cg03929089	chr4:120376271	NA	-0.72	-8.26	-0.6	1.86e-13	Height;
TGCT	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.46	-6.7	-0.52	6.44e-10	Alzheimer's disease;
TGCT	cis	rs12681287	0.608	rs13272148	chr8:87481853	T/C	cg27223183	chr8:87520930	FAM82B	-0.89	-6.41	-0.5	2.8e-9	Caudate activity during reward;
TGCT	cis	rs7267979	0.966	rs2257233	chr20:25265984	A/C	cg16686733	chr20:25566563	NINL	-0.56	-5.53	-0.44	1.84e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9796	0.653	rs28516683	chr15:41446645	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.53	-6.83	-0.52	3.38e-10	Menopause (age at onset);
TGCT	cis	rs9733	0.650	rs6698495	chr1:150564476	T/C	cg13175981	chr1:150552382	MCL1	0.53	5.93	0.47	2.8e-8	Tonsillectomy;
TGCT	cis	rs2836950	0.565	rs7279497	chr21:40531306	A/G	cg06238570	chr21:40685208	BRWD1	0.56	5.77	0.46	5.85e-8	Menarche (age at onset);
TGCT	cis	rs2216164	0.966	rs7137814	chr12:68571378	A/G	cg17065850	chr12:67807625	NA	-0.23	-4.48	-0.37	1.69e-5	Alopecia areata;
TGCT	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg10802521	chr3:52805072	NEK4	-0.71	-8.79	-0.62	1.04e-14	Bipolar disorder;
TGCT	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.6	5.75	0.46	6.48e-8	Prudent dietary pattern;
TGCT	cis	rs7772486	0.743	rs9390344	chr6:146012755	C/G	cg23711669	chr6:146136114	FBXO30	-0.81	-8.65	-0.61	2.25e-14	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs67311347	0.866	rs9826419	chr3:40352051	G/A	cg13683864	chr3:40499215	RPL14	-0.91	-8.78	-0.62	1.08e-14	Renal cell carcinoma;
TGCT	cis	rs11792861	0.926	rs72607174	chr9:111899132	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.48	4.47	0.37	1.73e-5	Menarche (age at onset);
TGCT	cis	rs11098499	0.662	rs13108589	chr4:120268102	G/C	cg09307838	chr4:120376055	NA	0.62	6.26	0.49	5.61e-9	Corneal astigmatism;
TGCT	cis	rs2948294	0.588	rs4840913	chr8:8116906	A/C	cg15556689	chr8:8085844	FLJ10661	0.69	6.05	0.48	1.56e-8	Red cell distribution width;
TGCT	cis	rs6088580	0.634	rs4911422	chr20:32999345	T/C	cg06115741	chr20:33292138	TP53INP2	-0.55	-4.81	-0.4	4.28e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs28595532	0.920	rs56162974	chr4:119742333	T/C	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs986417	1.000	rs1254303	chr14:60886301	A/G	cg27398547	chr14:60952738	C14orf39	-1.42	-8.68	-0.61	1.89e-14	Gut microbiota (bacterial taxa);
TGCT	cis	rs9393777	0.557	rs7759741	chr6:27241043	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.58	-5.0	-0.41	1.95e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9308731	0.623	rs2241841	chr2:111879467	G/A	cg04202892	chr2:111875749	ACOXL	0.54	6.25	0.49	6.18e-9	Chronic lymphocytic leukemia;
TGCT	cis	rs3820928	0.874	rs116652884	chr2:227902285	C/T	cg11843606	chr2:227700838	RHBDD1	-0.54	-4.96	-0.41	2.29e-6	Pulmonary function;
TGCT	cis	rs590121	0.876	rs6704	chr11:75283653	C/A	cg26104986	chr11:75275303	SERPINH1	-0.24	-4.53	-0.38	1.35e-5	Coronary artery disease;
TGCT	cis	rs28595532	0.920	rs114051506	chr4:119772893	A/T	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs6964587	1.000	rs12537846	chr7:91721581	C/T	cg22709100	chr7:91322751	NA	-0.29	-4.82	-0.4	4.04e-6	Breast cancer;
TGCT	cis	rs42648	0.792	rs4236517	chr7:89963465	A/T	cg25739043	chr7:89950458	NA	-0.67	-6.52	-0.51	1.63e-9	Homocysteine levels;
TGCT	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg24675658	chr1:53192096	ZYG11B	-0.73	-8.62	-0.61	2.59e-14	Monocyte count;
TGCT	cis	rs3806843	0.931	rs13168670	chr5:140146899	T/C	cg19875535	chr5:140030758	IK	0.37	6.23	0.49	6.53e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.82	-7.67	-0.57	4.3e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9467711	0.606	rs9357006	chr6:26364628	A/C	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs10858047	0.883	rs7539721	chr1:115171649	C/T	cg12756093	chr1:115239321	AMPD1	-0.45	-4.73	-0.39	6.09e-6	Autism;
TGCT	cis	rs473651	0.901	rs563282	chr2:239329736	T/C	cg18131467	chr2:239335373	ASB1	1.01	13.17	0.76	2.51e-25	Multiple system atrophy;
TGCT	cis	rs10791323	0.572	rs10791334	chr11:133735810	A/C	cg03690763	chr11:133734501	NA	-0.28	-4.69	-0.39	7.17e-6	Childhood ear infection;
TGCT	cis	rs57590327	0.716	rs4352391	chr3:81802318	T/C	cg07356753	chr3:81810745	GBE1	-0.75	-6.83	-0.52	3.4e-10	Extraversion;
TGCT	cis	rs10197940	0.571	rs13393021	chr2:152413258	A/C	cg06191203	chr2:152266755	RIF1	-0.75	-7.03	-0.53	1.21e-10	Lung cancer;
TGCT	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg11062466	chr8:58055876	NA	0.37	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs6121246	0.529	rs6060144	chr20:30178624	A/G	cg13852791	chr20:30311386	BCL2L1	0.71	4.54	0.38	1.31e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs9486719	0.857	rs6568392	chr6:96861476	G/T	cg06623918	chr6:96969491	KIAA0776	1.0	11.25	0.71	1.12e-20	Migraine;Coronary artery disease;
TGCT	cis	rs2657888	0.628	rs3809122	chr12:56882710	A/T	cg23002907	chr12:56915593	RBMS2	-0.4	-5.24	-0.43	6.7e-7	Adiponectin levels;
TGCT	trans	rs10435719	0.899	rs9693925	chr8:11789963	A/G	cg15556689	chr8:8085844	FLJ10661	0.74	7.04	0.53	1.17e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	trans	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.85	8.84	0.62	7.83e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs9682041	0.736	rs34237232	chr3:170063753	C/T	cg11886554	chr3:170076028	SKIL	-0.79	-5.52	-0.44	1.92e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs8180040	0.966	rs6800271	chr3:47470787	A/T	cg27129171	chr3:47204927	SETD2	-0.68	-8.11	-0.59	4.16e-13	Colorectal cancer;
TGCT	cis	rs9926296	0.712	rs447735	chr16:89734349	T/C	cg27121462	chr16:89883253	FANCA	-0.55	-5.11	-0.42	1.2e-6	Vitiligo;
TGCT	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	5.53	0.44	1.8e-7	Alzheimer's disease;
TGCT	cis	rs6964587	0.933	rs28671255	chr7:91770705	A/G	cg17063962	chr7:91808500	NA	0.91	9.8	0.66	3.89e-17	Breast cancer;
TGCT	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg03388025	chr16:89894329	SPIRE2	-0.49	-8.45	-0.6	6.47e-14	Vitiligo;
TGCT	cis	rs854765	0.724	rs62072049	chr17:17906520	T/C	cg04398451	chr17:18023971	MYO15A	-0.29	-4.54	-0.38	1.33e-5	Total body bone mineral density;
TGCT	cis	rs9894429	1.000	rs7222241	chr17:79574714	C/G	cg21028142	chr17:79581711	NPLOC4	0.29	6.81	0.52	3.83e-10	Eye color traits;
TGCT	trans	rs4650994	0.544	rs2811306	chr1:178599248	C/G	cg05059571	chr16:84539110	KIAA1609	0.52	10.37	0.68	1.56e-18	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs7822232	1.000	rs6558296	chr8:145143802	G/A	cg06495924	chr8:145149574	CYC1	-1.04	-4.49	-0.37	1.6e-5	Blood metabolite levels;
TGCT	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	5.19	0.42	8.51e-7	Tonsillectomy;
TGCT	cis	rs1008375	1.000	rs6854733	chr4:17640526	C/T	cg16339924	chr4:17578868	LAP3	0.63	5.33	0.43	4.49e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs453301	0.686	rs11785819	chr8:8870378	T/G	cg15556689	chr8:8085844	FLJ10661	-0.64	-5.29	-0.43	5.37e-7	Joint mobility (Beighton score);
TGCT	cis	rs13188771	0.651	rs12520498	chr5:100881358	G/A	cg18665594	chr5:101119420	NA	0.45	4.5	0.37	1.55e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg03452623	chr4:187889614	NA	0.34	4.58	0.38	1.11e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs67311347	0.956	rs9822870	chr3:40514890	A/C	cg13683864	chr3:40499215	RPL14	1.14	12.22	0.74	4.89e-23	Renal cell carcinoma;
TGCT	cis	rs2046867	0.818	rs34582798	chr3:72882778	A/C	cg25664220	chr3:72788482	NA	-0.57	-6.33	-0.49	4.08e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6570726	0.791	rs9403729	chr6:145907007	C/T	cg05347473	chr6:146136440	FBXO30	0.54	5.12	0.42	1.14e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6681544	0.760	rs2172285	chr1:82411874	C/T	cg04226724	chr1:82268649	LPHN2	-0.48	-4.95	-0.41	2.42e-6	Metabolite levels  (X-11787);
TGCT	cis	rs17331151	0.505	rs79993196	chr3:52697566	T/C	cg07884673	chr3:53033167	SFMBT1	0.75	5.59	0.45	1.35e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.46	-4.74	-0.39	5.68e-6	Longevity;Endometriosis;
TGCT	cis	rs8056742	0.730	rs71386886	chr16:85065488	G/C	cg00229868	chr16:85520891	NA	0.42	5.17	0.42	9.14e-7	Amyotrophic lateral sclerosis;
TGCT	cis	rs28595532	0.920	rs55726697	chr4:119742863	G/A	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg03806693	chr22:41940476	POLR3H	-1.15	-12.98	-0.76	7.24e-25	Vitiligo;
TGCT	cis	rs10892173	0.846	rs7943887	chr11:117670282	C/G	cg21640587	chr11:117668038	DSCAML1	0.41	4.58	0.38	1.13e-5	Myopia;
TGCT	cis	rs4654899	0.785	rs9426656	chr1:21505932	T/G	cg01072550	chr1:21505969	NA	-0.57	-9.4	-0.64	3.62e-16	Superior frontal gyrus grey matter volume;
TGCT	cis	rs7666738	1.000	rs13106934	chr4:99028685	C/T	cg05340658	chr4:99064831	C4orf37	0.46	4.57	0.38	1.18e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6460942	0.915	rs62448596	chr7:12446869	C/T	cg06484146	chr7:12443880	VWDE	-0.57	-5.52	-0.44	1.92e-7	Coronary artery disease;
TGCT	cis	rs7582180	0.625	rs11892034	chr2:100938952	T/C	cg08017756	chr2:100939284	LONRF2	-0.3	-4.78	-0.39	4.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4072705	0.616	rs915033	chr9:127245558	C/G	cg13476313	chr9:127244764	NR5A1	0.31	5.09	0.42	1.29e-6	Menarche (age at onset);
TGCT	cis	rs854765	0.583	rs9912895	chr17:17826020	C/T	cg09796270	chr17:17721594	SREBF1	-0.24	-4.86	-0.4	3.44e-6	Total body bone mineral density;
TGCT	cis	rs12472274	0.817	rs12621791	chr2:239104061	G/A	cg17459225	chr2:239074497	NA	0.33	4.84	0.4	3.79e-6	Phospholipid levels (plasma);
TGCT	cis	rs2456568	0.802	rs7101791	chr11:93638998	A/G	cg14065697	chr11:93583672	C11orf90	-0.38	-4.74	-0.39	5.65e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs9399135	0.967	rs9389251	chr6:135325717	A/G	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.36e-6	Red blood cell count;
TGCT	cis	rs727505	1.000	rs10241173	chr7:124453258	A/G	cg23710748	chr7:124431027	NA	-0.26	-4.5	-0.37	1.54e-5	Lewy body disease;
TGCT	cis	rs644799	1.000	rs516551	chr11:95588626	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	8.55	0.61	3.94e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9549367	1.000	rs9549367	chr13:113911532	C/G	cg18105134	chr13:113819100	PROZ	-0.32	-5.2	-0.42	7.84e-7	Platelet distribution width;
TGCT	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.94	9.46	0.65	2.58e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs897984	0.806	rs1046276	chr16:30914626	A/G	cg02466173	chr16:30829666	NA	0.27	4.51	0.38	1.47e-5	Dementia with Lewy bodies;
TGCT	trans	rs941408	1.000	rs1076448	chr19:2792343	G/A	cg22153745	chr1:153894579	GATAD2B	-0.64	-7.26	-0.55	3.67e-11	Total cholesterol levels;
TGCT	cis	rs473651	0.935	rs472357	chr2:239355454	A/G	cg18131467	chr2:239335373	ASB1	-1.01	-14.84	-0.8	2.9e-29	Multiple system atrophy;
TGCT	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg26338869	chr17:61819248	STRADA	-0.56	-5.11	-0.42	1.17e-6	Prudent dietary pattern;
TGCT	cis	rs12477438	0.765	rs12468807	chr2:99691994	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-8.52	-0.61	4.5e-14	Chronic sinus infection;
TGCT	cis	rs17376456	0.569	rs1349711	chr5:93179032	C/T	cg21475434	chr5:93447410	FAM172A	-0.64	-4.75	-0.39	5.47e-6	Diabetic retinopathy;
TGCT	cis	rs28374715	0.681	rs7163989	chr15:41614621	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.87	-13.41	-0.77	7e-26	Ulcerative colitis;
TGCT	cis	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg08564027	chr20:61660810	NA	0.37	6.85	0.52	3.1e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs66561647	0.719	rs4733582	chr8:128947967	C/T	cg11792826	chr8:129160931	MIR1208	0.21	4.73	0.39	6.13e-6	Hemoglobin concentration;
TGCT	cis	rs7044106	0.648	rs2031369	chr9:123360294	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.55	5.59	0.45	1.36e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs9303401	0.659	rs34426768	chr17:56683385	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs10782582	0.609	rs6656501	chr1:76266126	A/C	cg03433033	chr1:76189801	ACADM	-0.5	-4.95	-0.41	2.39e-6	Daytime sleep phenotypes;
TGCT	cis	rs9611565	0.608	rs202652	chr22:41838792	A/G	cg03806693	chr22:41940476	POLR3H	1.11	12.05	0.73	1.3e-22	Vitiligo;
TGCT	cis	rs1903068	0.853	rs9312657	chr4:56003502	G/A	cg16572876	chr4:56024045	NA	0.42	4.79	0.39	4.75e-6	Endometriosis;
TGCT	cis	rs7666738	0.830	rs4699584	chr4:98952019	A/G	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10193935	0.786	rs72796504	chr2:42406728	T/C	cg27598129	chr2:42591480	NA	-0.39	-5.14	-0.42	1.05e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg17554472	chr22:41940697	POLR3H	0.49	5.06	0.41	1.44e-6	Vitiligo;
TGCT	cis	rs5769707	0.605	rs6009791	chr22:50025265	T/C	cg05373962	chr22:49881684	NA	-0.31	-5.37	-0.43	3.8e-7	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg00149659	chr3:10157352	C3orf10	0.94	6.0	0.47	2e-8	Alzheimer's disease;
TGCT	cis	rs6940638	0.662	rs7759694	chr6:27240956	C/T	cg15659132	chr6:26577336	NA	-0.61	-5.84	-0.46	4.2e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs853679	0.550	rs6901017	chr6:28152583	T/C	cg12963246	chr6:28129442	ZNF389	0.49	4.8	0.4	4.53e-6	Depression;
TGCT	cis	rs62064224	0.530	rs8073708	chr17:30680493	T/C	cg18200150	chr17:30822561	MYO1D	0.39	4.69	0.39	7.12e-6	Schizophrenia;
TGCT	cis	rs7565124	1.000	rs12472043	chr2:20256838	G/A	cg00462460	chr2:20212509	MATN3	-0.43	-4.67	-0.39	7.65e-6	Major depressive disorder;
TGCT	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg01416388	chr22:39784598	NA	0.64	6.62	0.51	9.94e-10	IgG glycosylation;
TGCT	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg16405210	chr4:1374714	KIAA1530	-0.24	-4.44	-0.37	1.98e-5	Longevity;
TGCT	cis	rs1775715	0.737	rs11008695	chr10:32216887	T/G	cg14930904	chr10:32216787	ARHGAP12	0.53	5.05	0.41	1.51e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs7772486	0.790	rs6926657	chr6:146255794	G/A	cg05347473	chr6:146136440	FBXO30	-0.51	-4.95	-0.41	2.32e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs62244186	0.659	rs9835270	chr3:44553722	G/A	cg21672276	chr3:44754072	ZNF502	-0.44	-4.89	-0.4	3.02e-6	Depressive symptoms;
TGCT	trans	rs28735056	0.609	rs4799099	chr18:77639585	A/G	cg05926928	chr17:57297772	GDPD1	0.83	9.68	0.66	7.66e-17	Schizophrenia;
TGCT	cis	rs909002	0.800	rs2176807	chr1:32092735	T/G	cg11573219	chr1:32083031	HCRTR1	-0.43	-5.6	-0.45	1.33e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7804356	0.954	rs4722641	chr7:26838677	C/G	cg03456212	chr7:26904342	SKAP2	-0.61	-4.7	-0.39	6.82e-6	Type 1 diabetes;
TGCT	cis	rs35306767	0.714	rs12783621	chr10:1083304	C/T	cg20503657	chr10:835505	NA	0.44	4.99	0.41	1.96e-6	Eosinophil percentage of granulocytes;
TGCT	cis	rs79349575	0.749	rs2270574	chr17:47022270	C/T	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.52	-0.38	1.44e-5	Type 2 diabetes;
TGCT	cis	rs4925386	0.625	rs3810550	chr20:60912117	C/T	cg06026331	chr20:60912101	LAMA5	0.35	5.55	0.45	1.65e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs2458413	0.771	rs7010076	chr8:105342827	C/G	cg04554929	chr8:105342491	NA	-0.52	-7.4	-0.55	1.82e-11	Paget's disease;
TGCT	cis	rs2594989	0.779	rs13353407	chr3:11585299	C/T	cg00170343	chr3:11313890	ATG7	-0.68	-5.04	-0.41	1.64e-6	Circulating chemerin levels;
TGCT	trans	rs6446298	1.000	rs6446298	chr3:49860854	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.77	6.88	0.53	2.69e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs5769765	0.908	rs9616217	chr22:50318946	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.21	-8.49	-0.61	5.29e-14	Schizophrenia;
TGCT	cis	rs902774	0.585	rs7399070	chr12:53355678	G/T	cg16329197	chr12:53359506	NA	-0.56	-4.71	-0.39	6.44e-6	Prostate cancer;
TGCT	cis	rs45509595	0.841	rs9368531	chr6:27781872	G/C	cg08798685	chr6:27730294	NA	-0.35	-4.76	-0.39	5.24e-6	Breast cancer;
TGCT	cis	rs1865760	0.566	rs1800702	chr6:26086463	C/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.78	7.49	0.56	1.15e-11	Height;
TGCT	cis	rs9467773	0.869	rs1796520	chr6:26410800	C/T	cg24010402	chr6:26660753	ZNF322A	0.23	4.46	0.37	1.8e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs5769707	0.967	rs9616333	chr22:50050847	G/A	cg10356904	chr22:49881777	NA	-0.23	-4.53	-0.38	1.35e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs10206020	0.921	rs72776302	chr2:1571383	G/A	cg01028140	chr2:1542097	TPO	-0.32	-4.99	-0.41	1.97e-6	IgG glycosylation;
TGCT	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg03188948	chr7:1209495	NA	0.62	5.66	0.45	9.97e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7937682	0.924	rs564601	chr11:111594077	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.17	-13.93	-0.78	3.92e-27	Primary sclerosing cholangitis;
TGCT	cis	rs7267979	1.000	rs2482927	chr20:25327151	T/C	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg21659725	chr3:3221576	CRBN	0.76	9.35	0.64	4.85e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs2013441	1.000	rs11871945	chr17:20206883	A/G	cg18979559	chr17:20280153	CCDC144C	-0.49	-4.99	-0.41	1.97e-6	Obesity-related traits;
TGCT	cis	rs62064224	0.614	rs11656445	chr17:30694164	T/C	cg18200150	chr17:30822561	MYO1D	0.39	4.65	0.39	8.31e-6	Schizophrenia;
TGCT	cis	rs72781680	0.821	rs17038360	chr2:24095798	A/G	cg08917208	chr2:24149416	ATAD2B	0.77	4.89	0.4	3e-6	Lymphocyte counts;
TGCT	cis	rs796364	0.587	rs7588746	chr2:200986345	A/G	cg17644776	chr2:200775616	C2orf69	0.3	4.88	0.4	3.22e-6	Schizophrenia;
TGCT	cis	rs79349575	0.783	rs4399576	chr17:47009835	G/A	cg07967210	chr17:47022446	SNF8	0.44	6.13	0.48	1.1e-8	Type 2 diabetes;
TGCT	cis	rs12701220	0.894	rs10263252	chr7:1049949	G/A	cg07217954	chr7:1067459	C7orf50	-0.49	-4.9	-0.4	2.95e-6	Bronchopulmonary dysplasia;
TGCT	cis	rs9457247	0.967	rs2769346	chr6:167370999	A/G	cg23791538	chr6:167370224	RNASET2	0.51	4.98	0.41	2.05e-6	Crohn's disease;
TGCT	cis	rs62103177	0.789	rs7242289	chr18:77603291	C/T	cg12964065	chr18:77638022	KCNG2	0.41	5.48	0.44	2.31e-7	Opioid sensitivity;
TGCT	cis	rs11122272	0.735	rs2790889	chr1:231520240	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.13	-0.54	7.33e-11	Hemoglobin concentration;
TGCT	cis	rs6519955	0.897	rs4073601	chr22:46434686	A/G	cg05468064	chr22:46423449	NA	0.58	6.22	0.49	6.97e-9	Dupuytren's disease;
TGCT	cis	rs7267979	1.000	rs4815417	chr20:25379526	C/T	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2204008	0.571	rs1117803	chr12:38281007	C/G	cg26384229	chr12:38710491	ALG10B	-0.54	-4.7	-0.39	6.68e-6	Bladder cancer;
TGCT	cis	rs6725041	0.792	rs1533768	chr2:213089875	T/A	cg16329650	chr2:213403929	ERBB4	-0.53	-4.52	-0.38	1.44e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs904251	0.504	rs12202664	chr6:37481198	A/G	cg25019722	chr6:37503610	NA	-0.53	-7.98	-0.58	8.46e-13	Cognitive performance;
TGCT	cis	rs7914558	0.901	rs1926034	chr10:104829102	G/A	cg15744005	chr10:104629667	AS3MT	-0.38	-4.66	-0.39	7.94e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs6500602	0.893	rs6500596	chr16:4470027	G/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.43	5.29	0.43	5.42e-7	Schizophrenia;
TGCT	cis	rs1887596	0.705	rs498498	chr13:27221206	G/A	cg01312412	chr13:27282625	NA	0.28	4.91	0.4	2.87e-6	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs919433	0.617	rs4850436	chr2:198541398	C/T	cg00792783	chr2:198669748	PLCL1	-0.55	-5.04	-0.41	1.62e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs17539620	0.519	rs12665532	chr6:154835182	C/G	cg20019720	chr6:154832845	CNKSR3	0.63	5.77	0.46	6.02e-8	Lipoprotein (a) levels;
TGCT	cis	rs9486719	0.843	rs2499797	chr6:96848669	C/T	cg18709589	chr6:96969512	KIAA0776	0.75	5.13	0.42	1.1e-6	Migraine;Coronary artery disease;
TGCT	trans	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.87	-9.71	-0.66	6.56e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.76	-7.36	-0.55	2.25e-11	Prudent dietary pattern;
TGCT	cis	rs931608	0.640	rs2957824	chr19:22579316	T/C	cg15554505	chr19:22123728	NA	0.63	4.89	0.4	3.06e-6	Dental caries;Response to statins (LDL cholesterol change);
TGCT	cis	rs11098499	0.697	rs10020027	chr4:120381879	G/C	cg09307838	chr4:120376055	NA	0.71	6.98	0.53	1.57e-10	Corneal astigmatism;
TGCT	cis	rs7681440	0.874	rs1372524	chr4:90776045	A/G	cg14346243	chr4:90757452	SNCA	-0.56	-5.47	-0.44	2.41e-7	Dementia with Lewy bodies;
TGCT	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg06221963	chr1:154839813	KCNN3	0.73	11.91	0.73	2.91e-22	Prostate cancer;
TGCT	cis	rs57221529	0.709	rs72703090	chr5:598314	C/T	cg16624210	chr5:671434	TPPP	0.44	4.85	0.4	3.68e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg24250549	chr1:154909240	PMVK	0.53	4.89	0.4	3.05e-6	Prostate cancer;
TGCT	cis	rs12681287	0.547	rs13260345	chr8:87483721	T/C	cg27223183	chr8:87520930	FAM82B	-0.89	-6.41	-0.5	2.8e-9	Caudate activity during reward;
TGCT	cis	rs4733781	0.765	rs62524625	chr8:131084728	C/T	cg16277922	chr8:131349729	ASAP1	0.39	4.94	0.41	2.42e-6	Tuberculosis;
TGCT	cis	rs10114408	0.959	rs7853178	chr9:96648007	C/T	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs2249625	0.526	rs17781511	chr6:72845455	C/T	cg08500200	chr6:72892038	RIMS1	0.45	4.84	0.4	3.79e-6	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
TGCT	cis	rs858239	0.539	rs10225608	chr7:23188908	A/G	cg05602783	chr7:23145260	KLHL7	-0.62	-5.03	-0.41	1.67e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs1799949	0.965	rs8071278	chr17:41193910	A/T	cg23758822	chr17:41437982	NA	0.66	6.44	0.5	2.36e-9	Menopause (age at onset);
TGCT	cis	rs4455778	0.600	rs4282517	chr7:49115450	C/T	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs11098499	0.826	rs12511640	chr4:120251248	T/C	cg09307838	chr4:120376055	NA	0.61	5.91	0.47	3.14e-8	Corneal astigmatism;
TGCT	cis	rs12510870	0.634	rs13120998	chr4:74378422	C/T	cg05868023	chr4:75230803	EREG	-0.55	-4.7	-0.39	6.84e-6	Iris color (b* coordinate);
TGCT	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg25767906	chr1:53392781	SCP2	0.48	5.55	0.45	1.62e-7	Monocyte count;
TGCT	cis	rs881375	0.967	rs2239658	chr9:123671837	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	5.28	0.43	5.56e-7	Rheumatoid arthritis;
TGCT	cis	rs2506155	0.585	rs72790215	chr10:33521398	G/C	cg25928881	chr10:32632685	EPC1	0.3	4.98	0.41	2.05e-6	Migraine;
TGCT	cis	rs763121	0.853	rs1065201	chr22:39069510	T/C	cg06022373	chr22:39101656	GTPBP1	0.77	7.46	0.56	1.35e-11	Menopause (age at onset);
TGCT	cis	rs72781680	0.950	rs72796343	chr2:24147631	G/A	cg08917208	chr2:24149416	ATAD2B	0.85	5.28	0.43	5.53e-7	Lymphocyte counts;
TGCT	cis	rs3916	0.955	rs2066938	chr12:121160615	A/G	cg21892295	chr12:121157589	UNC119B	-0.22	-4.51	-0.38	1.46e-5	Urinary metabolites (H-NMR features);
TGCT	cis	rs1055129	0.682	rs7217432	chr17:73834604	A/G	cg08125733	chr17:73851984	WBP2	0.51	4.65	0.39	8.21e-6	White matter hyperintensity burden;
TGCT	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg22891161	chr3:195456627	MUC20	0.23	5.35	0.43	4.12e-7	Pancreatic cancer;
TGCT	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg21724239	chr8:58056113	NA	0.42	5.04	0.41	1.59e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs595982	0.559	rs17272680	chr19:49364511	A/G	cg17863274	chr19:49399704	TULP2	0.46	6.54	0.51	1.46e-9	Red cell distribution width;
TGCT	cis	rs4273100	0.688	rs4924967	chr17:19172196	T/G	cg01534423	chr17:18965556	NA	0.79	7.13	0.54	7.34e-11	Schizophrenia;
TGCT	cis	rs308403	0.532	rs309386	chr4:123665991	C/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.83	12.16	0.74	6.83e-23	Blood protein levels;
TGCT	cis	rs17108533	0.588	rs12878094	chr14:71303542	A/G	cg23900759	chr14:71108106	TTC9	-1.15	-4.79	-0.39	4.73e-6	Response to antipsychotic treatment in schizophrenia (reasoning);
TGCT	cis	rs7208859	0.524	rs8069400	chr17:29075967	G/T	cg13385521	chr17:29058706	SUZ12P	0.8	4.66	0.39	8.04e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs17001868	0.568	rs12484697	chr22:40736472	A/G	cg07138101	chr22:40742427	ADSL	-0.73	-5.38	-0.44	3.57e-7	Mammographic density (dense area);
TGCT	cis	rs10504229	1.000	rs67096506	chr8:58195655	G/A	cg24829409	chr8:58192753	C8orf71	-0.55	-4.77	-0.39	5.18e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg11941060	chr3:133502564	NA	-0.29	-6.16	-0.48	9.45e-9	Iron status biomarkers;
TGCT	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg26354017	chr1:205819088	PM20D1	0.56	6.86	0.52	2.9e-10	Menarche (age at onset);
TGCT	cis	rs2456568	0.835	rs8181533	chr11:93638614	C/T	cg16099599	chr11:93583650	C11orf90	-0.4	-5.12	-0.42	1.13e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs6964587	0.967	rs6970743	chr7:91744311	C/G	cg17063962	chr7:91808500	NA	0.89	9.53	0.65	1.78e-16	Breast cancer;
TGCT	cis	rs2439831	1.000	rs7173487	chr15:43750239	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.98	7.06	0.54	1.07e-10	Lung cancer in ever smokers;
TGCT	cis	rs3820928	0.934	rs16822890	chr2:227761477	G/A	cg11843606	chr2:227700838	RHBDD1	-0.53	-4.68	-0.39	7.31e-6	Pulmonary function;
TGCT	cis	rs12620999	0.555	rs4078064	chr2:238110296	C/T	cg23555395	chr2:238036564	NA	-0.27	-4.75	-0.39	5.57e-6	Systemic lupus erythematosus;
TGCT	cis	rs9611565	0.694	rs202641	chr22:41833116	C/T	cg13695892	chr22:41940480	POLR3H	0.89	8.48	0.61	5.62e-14	Vitiligo;
TGCT	cis	rs259991	0.661	rs236711	chr20:57694059	C/G	cg01712452	chr20:56736072	C20orf85	-0.53	-4.61	-0.38	9.71e-6	Attention function in attention deficit hyperactive disorder;
TGCT	cis	rs1008375	1.000	rs28545485	chr4:17645376	C/T	cg10189774	chr4:17578691	LAP3	0.57	5.15	0.42	9.95e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs11920354	0.642	rs9812878	chr3:47182787	T/C	cg27129171	chr3:47204927	SETD2	0.67	7.67	0.57	4.3e-12	Granulocyte count;Sum neutrophil eosinophil counts;
TGCT	cis	rs4918072	0.667	rs1342212	chr10:105708813	A/C	cg11005552	chr10:105648138	OBFC1	0.34	4.74	0.39	5.86e-6	Coronary artery disease;
TGCT	cis	rs7818688	0.697	rs76815619	chr8:95981330	G/A	cg16049864	chr8:95962084	TP53INP1	0.54	4.64	0.38	8.87e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs7119	0.717	rs12916515	chr15:77818518	G/T	cg27398640	chr15:77910606	LINGO1	-0.25	-4.59	-0.38	1.08e-5	Type 2 diabetes;
TGCT	cis	rs13102973	0.965	rs13108037	chr4:135885643	A/G	cg14419869	chr4:135874104	NA	-0.25	-4.79	-0.39	4.71e-6	Subjective well-being;
TGCT	cis	rs9467773	1.000	rs2393670	chr6:26535541	A/G	cg05738196	chr6:26577821	NA	0.88	12.5	0.75	1.03e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs950169	0.845	rs4502182	chr15:84923520	A/G	cg11189052	chr15:85197271	WDR73	0.83	6.67	0.51	7.71e-10	Schizophrenia;
TGCT	cis	rs17102423	1.000	rs17102423	chr14:65604728	G/T	cg11161011	chr14:65562177	MAX	-0.49	-6.72	-0.52	5.81e-10	Obesity-related traits;
TGCT	trans	rs1814175	0.645	rs11040702	chr11:50024827	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.84	-0.7	1.13e-19	Height;
TGCT	cis	rs11148252	0.538	rs9526842	chr13:52727723	T/G	cg00495681	chr13:53174319	NA	0.57	5.86	0.47	3.85e-8	Lewy body disease;
TGCT	cis	rs2046867	0.818	rs1502754	chr3:72895345	G/T	cg25664220	chr3:72788482	NA	-0.54	-5.82	-0.46	4.76e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs933688	1.000	rs332529	chr5:90789470	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.06	8.83	0.62	8.11e-15	Smoking behavior;
TGCT	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg09263875	chr16:632152	PIGQ	0.31	6.88	0.53	2.65e-10	Height;
TGCT	cis	rs651907	0.557	rs13077925	chr3:101488181	T/A	cg12386194	chr3:101231763	SENP7	0.47	4.63	0.38	8.99e-6	Colorectal cancer;
TGCT	cis	rs4888262	0.526	rs7193423	chr16:74626340	A/C	cg05423758	chr16:74752063	FA2H	0.18	4.79	0.39	4.72e-6	Testicular germ cell tumor;
TGCT	cis	rs9486715	1.000	rs9398148	chr6:97063555	A/G	cg06623918	chr6:96969491	KIAA0776	-1.08	-13.52	-0.77	3.67e-26	Headache;
TGCT	cis	rs68170813	0.559	rs17427123	chr7:106823661	G/A	cg02696742	chr7:106810147	HBP1	-0.72	-6.28	-0.49	5.29e-9	Coronary artery disease;
TGCT	cis	rs2663905	0.706	rs7162859	chr15:81360038	C/T	cg09236163	chr15:81426669	C15orf26	0.6	5.61	0.45	1.27e-7	QT interval (drug interaction);
TGCT	cis	rs7822232	0.908	rs1127096	chr8:145140472	A/G	cg06495924	chr8:145149574	CYC1	-1.04	-4.49	-0.37	1.6e-5	Blood metabolite levels;
TGCT	cis	rs7666738	0.791	rs2865958	chr4:99040732	G/T	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1635	0.826	rs3800327	chr6:28264928	G/C	cg15743358	chr6:28303923	ZNF323	-1.36	-5.89	-0.47	3.47e-8	Schizophrenia;
TGCT	cis	rs1975974	0.935	rs41361749	chr17:21732693	A/G	cg18423549	chr17:21743878	NA	0.5	4.65	0.39	8.52e-6	Psoriasis;
TGCT	cis	rs3784262	0.967	rs12148907	chr15:58296450	T/A	cg12031962	chr15:58353849	ALDH1A2	-0.5	-7.82	-0.57	1.98e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs919433	0.647	rs2045242	chr2:198507649	G/A	cg00792783	chr2:198669748	PLCL1	0.56	5.03	0.41	1.68e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs10206020	0.921	rs72778009	chr2:1573322	G/T	cg12573674	chr2:1569213	NA	-0.49	-5.3	-0.43	5.1e-7	IgG glycosylation;
TGCT	cis	rs826838	0.967	rs2069211	chr12:39128892	C/T	cg26384229	chr12:38710491	ALG10B	-0.86	-7.7	-0.57	3.65e-12	Heart rate;
TGCT	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg05665937	chr4:1216051	CTBP1	0.24	4.63	0.38	8.9e-6	Obesity-related traits;
TGCT	cis	rs1008375	0.966	rs4698621	chr4:17587565	C/T	cg10189774	chr4:17578691	LAP3	0.64	5.61	0.45	1.28e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs259282	0.605	rs8100423	chr19:33109003	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.51	4.66	0.39	7.93e-6	Schizophrenia;
TGCT	cis	rs2404602	0.735	rs2436996	chr15:76817420	C/T	cg22467129	chr15:76604101	ETFA	0.47	4.88	0.4	3.19e-6	Blood metabolite levels;
TGCT	cis	rs6426558	0.572	rs2670471	chr1:227454328	T/C	cg10327440	chr1:227177885	CDC42BPA	0.58	6.76	0.52	4.75e-10	Neutrophil percentage of white cells;
TGCT	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg13012494	chr21:47604986	C21orf56	0.36	4.5	0.37	1.54e-5	Testicular germ cell tumor;
TGCT	cis	rs7980687	0.628	rs1609520	chr12:123735937	A/G	cg00376283	chr12:123451042	ABCB9	-0.66	-5.35	-0.43	4.08e-7	Height;Educational attainment;Head circumference (infant);
TGCT	cis	rs7572733	0.555	rs1435569	chr2:198718667	G/C	cg00792783	chr2:198669748	PLCL1	0.56	5.08	0.42	1.35e-6	Dermatomyositis;
TGCT	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg06481639	chr22:41940642	POLR3H	0.74	6.55	0.51	1.41e-9	Vitiligo;
TGCT	cis	rs611744	0.967	rs695028	chr8:109239324	T/C	cg21045802	chr8:109455806	TTC35	0.52	4.72	0.39	6.21e-6	Dupuytren's disease;
TGCT	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg11890956	chr21:40555474	PSMG1	-0.76	-7.08	-0.54	9.53e-11	Cognitive function;
TGCT	cis	rs9346649	0.967	rs6920748	chr6:168490047	T/G	cg02770688	chr6:168491649	NA	-0.27	-5.08	-0.41	1.36e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
TGCT	cis	rs950169	0.922	rs62021167	chr15:85118051	T/A	cg11189052	chr15:85197271	WDR73	0.78	6.5	0.5	1.77e-9	Schizophrenia;
TGCT	cis	rs12497850	0.865	rs13072911	chr3:48962128	T/G	cg06212747	chr3:49208901	KLHDC8B	0.61	5.62	0.45	1.2e-7	Parkinson's disease;
TGCT	cis	rs13191362	1.000	rs35593345	chr6:163174981	G/C	cg06582575	chr6:163149167	PACRG;PARK2	0.94	6.77	0.52	4.6e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	trans	rs7618501	1.000	rs1491986	chr3:49739086	C/T	cg21659725	chr3:3221576	CRBN	-0.99	-15.57	-0.81	5.76e-31	Intelligence (multi-trait analysis);
TGCT	cis	rs854765	0.583	rs4077198	chr17:17834563	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.74	7.73	0.57	3.18e-12	Total body bone mineral density;
TGCT	cis	rs6121246	0.567	rs2889488	chr20:30185758	G/A	cg10886678	chr20:30946050	ASXL1	-0.71	-4.8	-0.4	4.42e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg13683864	chr3:40499215	RPL14	-1.18	-13.68	-0.78	1.54e-26	Renal cell carcinoma;
TGCT	cis	rs8017423	0.967	rs11159957	chr14:90715972	A/G	cg04374321	chr14:90722782	PSMC1	-0.72	-7.54	-0.56	8.86e-12	Mortality in heart failure;
TGCT	cis	rs75686122	0.892	rs75117899	chr8:104582618	A/G	cg04852977	chr8:104510831	NA	0.59	4.45	0.37	1.92e-5	Cocaine dependence;
TGCT	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg14159672	chr1:205819179	PM20D1	-0.57	-7.12	-0.54	7.6e-11	Menarche (age at onset);
TGCT	cis	rs2204008	0.805	rs10881112	chr12:37956611	G/A	cg26384229	chr12:38710491	ALG10B	-0.73	-6.26	-0.49	5.88e-9	Bladder cancer;
TGCT	cis	rs9467711	0.651	rs35378061	chr6:26059157	C/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.6	-4.67	-0.39	7.83e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1534166	0.647	rs13321680	chr3:133507119	G/T	cg08048268	chr3:133502702	NA	0.45	5.54	0.45	1.7e-7	Alcohol consumption (transferrin glycosylation);
TGCT	cis	rs72615157	0.634	rs11762932	chr7:99792666	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	-0.64	-5.12	-0.42	1.15e-6	Lung function (FEV1/FVC);
TGCT	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.51	-4.94	-0.41	2.52e-6	Bipolar disorder;
TGCT	cis	rs2404602	0.647	rs11072625	chr15:77084984	A/G	cg22467129	chr15:76604101	ETFA	-0.49	-5.08	-0.42	1.32e-6	Blood metabolite levels;
TGCT	cis	rs6840360	1.000	rs6535810	chr4:152592953	C/T	cg17479576	chr4:152424074	FAM160A1	-0.5	-5.4	-0.44	3.33e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1198872	0.526	rs57282335	chr2:10928207	G/A	cg15705551	chr2:10952987	PDIA6	0.55	4.81	0.4	4.38e-6	Cardiac Troponin-T levels;
TGCT	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg06618935	chr21:46677482	NA	-0.36	-5.5	-0.44	2.06e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7666738	0.861	rs13139309	chr4:99020916	A/G	cg17366294	chr4:99064904	C4orf37	0.68	7.04	0.53	1.17e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3796352	1.000	rs34121720	chr3:53072167	C/T	cg27565382	chr3:53032988	SFMBT1	0.43	4.62	0.38	9.64e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs7949030	0.626	rs71490390	chr11:62329185	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.71	9.07	0.63	2.23e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2153535	0.526	rs7748404	chr6:8472500	A/T	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs250677	0.687	rs36043	chr5:148440983	G/A	cg18129178	chr5:148520854	ABLIM3	-0.44	-6.57	-0.51	1.27e-9	Breast cancer;
TGCT	cis	rs9308731	0.644	rs7577824	chr2:111876763	G/A	cg04202892	chr2:111875749	ACOXL	0.54	6.25	0.49	6.1e-9	Chronic lymphocytic leukemia;
TGCT	cis	rs9534288	0.797	rs7990238	chr13:46578379	T/C	cg15192986	chr13:46630673	CPB2	-0.53	-7.62	-0.56	5.82e-12	Blood protein levels;
TGCT	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg22963979	chr7:1858916	MAD1L1	-0.46	-7.65	-0.57	4.73e-12	Bipolar disorder and schizophrenia;
TGCT	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg01874867	chr7:94954059	PON1	-0.4	-5.85	-0.47	4.06e-8	Paraoxonase activity;
TGCT	cis	rs929596	0.755	rs3771341	chr2:234673239	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.35	-5.68	-0.45	9.25e-8	Total bilirubin levels in HIV-1 infection;
TGCT	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg22168489	chr12:122356033	WDR66	0.2	4.74	0.39	5.87e-6	Mean corpuscular volume;
TGCT	cis	rs9527	0.590	rs12415199	chr10:104895536	T/C	cg04362960	chr10:104952993	NT5C2	0.69	5.82	0.46	4.78e-8	Arsenic metabolism;
TGCT	cis	rs9581857	0.547	rs4612914	chr13:28049128	A/G	cg22138327	chr13:27999177	GTF3A	0.77	5.12	0.42	1.16e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs67385638	0.792	rs16912979	chr11:5309695	T/C	cg12559170	chr11:5275217	HBG2	0.42	7.33	0.55	2.57e-11	Hemoglobin levels;
TGCT	cis	rs17102423	0.685	rs7156617	chr14:65541381	G/A	cg11161011	chr14:65562177	MAX	-0.51	-7.28	-0.55	3.3e-11	Obesity-related traits;
TGCT	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg01416388	chr22:39784598	NA	-0.73	-7.54	-0.56	8.5e-12	Intelligence (multi-trait analysis);
TGCT	trans	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg17830980	chr10:43048298	ZNF37B	-0.81	-10.13	-0.67	6.19e-18	Extrinsic epigenetic age acceleration;
TGCT	cis	rs6815814	0.950	rs66922907	chr4:38812537	A/G	cg02016764	chr4:38805732	TLR1	-0.36	-5.67	-0.45	9.33e-8	Breast cancer;
TGCT	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs11578119	0.689	rs1591148	chr1:170386703	G/T	cg09767346	chr1:170501363	GORAB	-0.6	-4.97	-0.41	2.2e-6	Male-pattern baldness;
TGCT	cis	rs7917772	0.636	rs2253709	chr10:104542745	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.58	4.73	0.39	6.1e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs71435601	0.628	rs533211	chr2:21381702	G/A	cg25035485	chr2:21266500	APOB	0.51	4.48	0.37	1.66e-5	Cholesterol, total;
TGCT	cis	rs7208859	0.623	rs58908911	chr17:29244558	C/T	cg14008862	chr17:28927542	LRRC37B2	0.73	4.8	0.4	4.43e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs514406	0.505	rs437954	chr1:53173321	C/G	cg08859206	chr1:53392774	SCP2	-0.35	-4.98	-0.41	2.12e-6	Monocyte count;
TGCT	cis	rs2404602	0.647	rs10851892	chr15:77176491	T/C	cg22467129	chr15:76604101	ETFA	0.47	4.79	0.4	4.69e-6	Blood metabolite levels;
TGCT	cis	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg27121462	chr16:89883253	FANCA	-0.55	-5.05	-0.41	1.52e-6	Vitiligo;
TGCT	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.33	-5.17	-0.42	9.08e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg16325326	chr1:53192061	ZYG11B	-0.71	-8.81	-0.62	9.22e-15	Monocyte count;
TGCT	cis	rs2594989	1.000	rs2606747	chr3:11374955	T/C	cg00170343	chr3:11313890	ATG7	0.67	5.06	0.41	1.44e-6	Circulating chemerin levels;
TGCT	cis	rs73198271	0.740	rs28521727	chr8:8647217	T/C	cg15556689	chr8:8085844	FLJ10661	-0.6	-4.46	-0.37	1.8e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs881375	0.967	rs2109895	chr9:123677827	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	5.02	0.41	1.74e-6	Rheumatoid arthritis;
TGCT	cis	rs877282	0.733	rs7092976	chr10:756358	G/A	cg17470449	chr10:769945	NA	0.32	4.91	0.4	2.76e-6	Uric acid levels;
TGCT	cis	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg22857025	chr5:266934	NA	-0.31	-6.36	-0.5	3.45e-9	Breast cancer;
TGCT	cis	rs861020	0.630	rs9308411	chr1:210005713	C/T	cg05527609	chr1:210001259	C1orf107	0.86	7.9	0.58	1.28e-12	Orofacial clefts;
TGCT	cis	rs13272623	0.502	rs268599	chr8:71517401	G/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.58	-5.1	-0.42	1.23e-6	IgG glycosylation;
TGCT	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg14784868	chr12:69753453	YEATS4	-0.9	-10.6	-0.69	4.47e-19	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs916888	0.647	rs199524	chr17:44848438	G/T	cg01570182	chr17:44337453	NA	-0.84	-8.15	-0.59	3.41e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7666738	0.830	rs114722517	chr4:99042061	G/A	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg17345569	chr6:42928274	GNMT	-0.47	-4.86	-0.4	3.48e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg01516881	chr6:292596	DUSP22	-0.71	-7.6	-0.56	6.19e-12	Menopause (age at onset);
TGCT	cis	rs6671200	0.607	rs1927043	chr1:95667251	G/A	cg20701556	chr1:95698924	RWDD3	-0.54	-5.36	-0.43	3.98e-7	Stearic acid (18:0) levels;
TGCT	cis	rs61990749	0.597	rs1006039	chr14:78263196	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	-0.63	-4.46	-0.37	1.8e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs9467711	0.606	rs12173854	chr6:26371679	A/G	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg01802117	chr1:53393560	SCP2	0.49	6.02	0.48	1.86e-8	Monocyte count;
TGCT	cis	rs9393692	0.902	rs6456711	chr6:26302572	A/C	cg05868516	chr6:26286170	HIST1H4H	0.62	5.85	0.46	4.17e-8	Educational attainment;
TGCT	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	trans	rs2727020	0.729	rs1164685	chr11:49293660	G/A	cg03929089	chr4:120376271	NA	0.73	8.5	0.61	4.94e-14	Coronary artery disease;
TGCT	cis	rs9435341	0.826	rs17496332	chr1:107546375	C/T	cg09367891	chr1:107599246	PRMT6	-0.63	-5.47	-0.44	2.35e-7	Facial morphology (factor 21, depth of nasal alae);
TGCT	cis	rs10464366	0.560	rs11763728	chr7:39145862	C/T	cg15212455	chr7:39170539	POU6F2	0.23	5.24	0.43	6.54e-7	IgG glycosylation;
TGCT	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg23574427	chr4:122746245	BBS7;CCNA2	-0.34	-5.63	-0.45	1.15e-7	Type 2 diabetes;
TGCT	cis	rs10782582	0.609	rs1770889	chr1:76401166	A/G	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.52	4.46	0.37	1.83e-5	Daytime sleep phenotypes;
TGCT	cis	rs7647973	1.000	rs6446275	chr3:49466871	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.57	-4.56	-0.38	1.21e-5	Menarche (age at onset);
TGCT	cis	rs514406	0.698	rs1775540	chr1:53407893	C/A	cg25767906	chr1:53392781	SCP2	-0.58	-7.3	-0.55	3.08e-11	Monocyte count;
TGCT	cis	rs26868	0.816	rs26873	chr16:2247362	C/T	cg02248941	chr16:2239361	CASKIN1	0.17	4.48	0.37	1.69e-5	Height;
TGCT	cis	rs3741151	1.000	rs78433080	chr11:73067565	G/A	cg17517138	chr11:73019481	ARHGEF17	0.91	4.63	0.38	9e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
TGCT	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg06873352	chr17:61820015	STRADA	0.55	6.13	0.48	1.09e-8	Prudent dietary pattern;
TGCT	cis	rs6540559	0.673	rs6540561	chr1:209982255	C/T	cg21951975	chr1:209979733	IRF6	0.69	5.42	0.44	2.99e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs6459680	0.583	rs6957065	chr7:156268046	G/A	cg02321112	chr7:156810523	NA	-0.31	-4.65	-0.39	8.2e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs151997	1.000	rs152817	chr5:50230879	T/A	cg06027927	chr5:50259733	NA	-0.47	-4.86	-0.4	3.47e-6	Callous-unemotional behaviour;
TGCT	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg03609598	chr5:56110824	MAP3K1	-0.58	-4.7	-0.39	6.72e-6	Initial pursuit acceleration;
TGCT	cis	rs7582180	0.629	rs7597615	chr2:100954828	T/C	cg14675211	chr2:100938903	LONRF2	0.5	4.78	0.39	4.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs854765	0.547	rs4368210	chr17:17896090	A/G	cg04398451	chr17:18023971	MYO15A	0.32	5.15	0.42	1.01e-6	Total body bone mineral density;
TGCT	cis	rs4742903	1.000	rs3780535	chr9:106894211	A/C	cg21169611	chr9:106856078	SMC2	0.51	4.84	0.4	3.81e-6	High-grade serous ovarian cancer;Breast cancer;
TGCT	cis	rs12788102	0.522	rs1865282	chr11:4830652	A/C	cg17625643	chr11:3845204	PGAP2	0.22	4.45	0.37	1.9e-5	Malaria;
TGCT	cis	rs7772486	0.754	rs4896832	chr6:145964151	G/A	cg13319975	chr6:146136371	FBXO30	-0.53	-4.85	-0.4	3.6e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	trans	rs7726839	0.540	rs58599998	chr5:596087	A/G	cg25482853	chr8:67687455	SGK3	1.27	10.56	0.69	5.48e-19	Obesity-related traits;
TGCT	cis	rs3796352	1.000	rs10510761	chr3:52965255	A/G	cg07884673	chr3:53033167	SFMBT1	-0.63	-6.1	-0.48	1.23e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs76878669	0.561	rs905770	chr11:66156765	A/G	cg18002602	chr11:66138449	SLC29A2	0.53	6.54	0.51	1.43e-9	Educational attainment (years of education);
TGCT	cis	rs2456568	0.835	rs7936182	chr11:93665532	T/A	cg17595323	chr11:93583763	C11orf90	-0.46	-5.86	-0.47	3.97e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs8033133	0.581	rs8042796	chr15:25327396	A/C	cg14481604	chr15:25334117	SNORD116-22	-0.21	-4.64	-0.38	8.82e-6	Blood osmolality (transformed sodium);
TGCT	cis	rs2243480	1.000	rs10807702	chr7:65767843	C/T	cg18252515	chr7:66147081	NA	-1.26	-7.23	-0.54	4.43e-11	Diabetic kidney disease;
TGCT	cis	rs75686122	0.892	rs117473860	chr8:104710816	C/A	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs7659604	0.643	rs6839375	chr4:122663610	G/C	cg06713675	chr4:122721982	EXOSC9	-0.45	-5.24	-0.43	6.75e-7	Type 2 diabetes;
TGCT	cis	rs7312933	0.558	rs11181467	chr12:42765250	C/T	cg19980929	chr12:42632907	YAF2	0.43	6.03	0.48	1.79e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs35306767	0.903	rs11253485	chr10:919362	C/T	cg26597838	chr10:835615	NA	0.75	10.54	0.69	6.3e-19	Eosinophil percentage of granulocytes;
TGCT	cis	rs7552404	0.731	rs931507	chr1:76401577	G/A	cg03433033	chr1:76189801	ACADM	-0.74	-7.49	-0.56	1.14e-11	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs8177253	0.665	rs6774822	chr3:133442012	G/T	cg08048268	chr3:133502702	NA	-0.54	-7.2	-0.54	5.06e-11	Iron status biomarkers;
TGCT	cis	rs36051895	0.622	rs12335546	chr9:5072182	C/T	cg02405213	chr9:5042618	JAK2	-0.85	-12.71	-0.75	3.36e-24	Pediatric autoimmune diseases;
TGCT	cis	rs6684514	1.000	rs12038203	chr1:156248265	C/T	cg20302342	chr1:156215951	PAQR6	0.34	4.6	0.38	1.01e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs631288	0.557	rs7546434	chr1:146676339	A/G	cg25205988	chr1:146714368	CHD1L	1.33	5.42	0.44	2.97e-7	PR interval in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7659604	0.521	rs4833235	chr4:122695136	C/A	cg06713675	chr4:122721982	EXOSC9	0.35	4.48	0.37	1.64e-5	Type 2 diabetes;
TGCT	trans	rs6089829	0.926	rs6011552	chr20:61667894	T/C	cg23505145	chr19:12996616	KLF1	0.8	8.37	0.6	1.05e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg25036284	chr2:26402008	FAM59B	-0.65	-5.19	-0.42	8.36e-7	Gut microbiome composition (summer);
TGCT	cis	rs9858542	1.000	rs9882740	chr3:49702484	T/C	cg03060546	chr3:49711283	APEH	-0.67	-6.09	-0.48	1.28e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs11098499	0.954	rs11940028	chr4:120411907	T/C	cg09307838	chr4:120376055	NA	0.69	6.64	0.51	8.97e-10	Corneal astigmatism;
TGCT	cis	rs6089829	0.962	rs6089825	chr20:61668447	C/T	cg18188782	chr20:61659543	NA	0.46	5.61	0.45	1.23e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg25427524	chr10:38739819	LOC399744	-0.4	-8.22	-0.59	2.3e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs317689	0.819	rs317660	chr12:69686203	G/A	cg14784868	chr12:69753453	YEATS4	0.57	4.9	0.4	2.96e-6	Response to diuretic therapy;
TGCT	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg03806693	chr22:41940476	POLR3H	-1.12	-13.03	-0.76	5.66e-25	Vitiligo;
TGCT	cis	rs7511006	0.893	rs2038049	chr22:50654888	G/C	cg08875078	chr22:50639485	SELO	0.53	5.05	0.41	1.51e-6	Obesity-related traits;
TGCT	cis	rs6570726	0.791	rs7765687	chr6:145915100	A/C	cg05347473	chr6:146136440	FBXO30	0.51	4.74	0.39	5.8e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6429082	0.818	rs704706	chr1:235614378	G/A	cg26050004	chr1:235667680	B3GALNT2	0.58	4.98	0.41	2.08e-6	Adiposity;
TGCT	cis	rs4700695	0.614	rs40194	chr5:65219842	G/A	cg21114390	chr5:65439923	SFRS12	0.65	4.54	0.38	1.3e-5	Facial morphology (factor 19);
TGCT	cis	rs17102423	0.559	rs11624169	chr14:65481710	C/G	cg11161011	chr14:65562177	MAX	-0.46	-5.33	-0.43	4.45e-7	Obesity-related traits;
TGCT	cis	rs3733585	0.638	rs17185835	chr4:9958180	T/G	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.7	-0.57	3.71e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs2637266	1.000	rs12260379	chr10:78365036	C/T	cg18941641	chr10:78392320	NA	0.39	4.88	0.4	3.24e-6	Pulmonary function;
TGCT	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.6	-5.9	-0.47	3.28e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs8177253	0.632	rs6782523	chr3:133438917	C/T	cg08439880	chr3:133502540	NA	-0.26	-4.69	-0.39	7.05e-6	Iron status biomarkers;
TGCT	cis	rs7666738	0.830	rs1115616	chr4:99006603	A/C	cg18180107	chr4:99064573	C4orf37	0.54	4.98	0.41	2.1e-6	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.88	9.9	0.66	2.18e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs1451375	0.698	rs11489734	chr7:50635730	A/T	cg18232548	chr7:50535776	DDC	0.44	6.72	0.52	5.81e-10	Malaria;
TGCT	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg12751644	chr20:60527061	NA	-0.4	-4.63	-0.38	9.23e-6	Body mass index;
TGCT	cis	rs77972916	0.561	rs4372955	chr2:43566146	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.41	-5.03	-0.41	1.66e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs4727027	0.901	rs12671341	chr7:148805282	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	4.6	0.38	1.04e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs9372498	0.536	rs9489433	chr6:118867006	G/A	cg07617317	chr6:118971624	C6orf204	0.52	5.55	0.45	1.69e-7	Diastolic blood pressure;
TGCT	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg02953382	chr22:24373134	LOC391322	-0.81	-8.91	-0.62	5.26e-15	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs4455778	0.580	rs6583501	chr7:49077636	A/T	cg26309511	chr7:48887640	NA	0.5	6.47	0.5	2.07e-9	Lung cancer in never smokers;
TGCT	cis	rs7264396	0.528	rs7273880	chr20:34551507	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.04	-0.41	1.58e-6	Total cholesterol levels;
TGCT	cis	rs17401966	0.540	rs3748581	chr1:10441664	T/C	cg19773385	chr1:10388646	KIF1B	-0.22	-5.27	-0.43	5.96e-7	Hepatocellular carcinoma;
TGCT	cis	rs62244186	0.593	rs9814298	chr3:44871899	T/A	cg10263370	chr3:44754102	ZNF502	-0.44	-5.23	-0.42	7.06e-7	Depressive symptoms;
TGCT	cis	rs7267979	0.966	rs7270835	chr20:25435067	C/T	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9457247	0.534	rs933243	chr6:167403873	A/C	cg23791538	chr6:167370224	RNASET2	-0.58	-5.76	-0.46	6.13e-8	Crohn's disease;
TGCT	cis	rs68092024	0.731	rs792841	chr3:99471308	G/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.51	6.19	0.49	8.23e-9	Cleft lip with or without cleft palate;
TGCT	cis	rs7726839	0.574	rs11134149	chr5:637277	A/G	cg20362242	chr5:692897	TPPP	0.49	4.81	0.4	4.21e-6	Obesity-related traits;
TGCT	cis	rs7666738	0.830	rs13145011	chr4:98993410	G/A	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7027203	0.576	rs7855940	chr9:96535966	C/G	cg14598338	chr9:96623480	NA	-0.48	-6.99	-0.53	1.54e-10	DNA methylation (variation);
TGCT	cis	rs492146	0.729	rs316130	chr6:52848200	G/A	cg06706454	chr6:52930286	FBXO9	-0.53	-4.95	-0.41	2.37e-6	Epilepsy (remission after treatment);
TGCT	cis	rs826838	0.935	rs1684407	chr12:39127270	C/T	cg26384229	chr12:38710491	ALG10B	-0.86	-7.72	-0.57	3.37e-12	Heart rate;
TGCT	cis	rs4889911	0.544	rs1285273	chr17:77830885	A/G	cg00646381	chr17:77835854	NA	0.44	6.6	0.51	1.06e-9	Electroencephalogram traits;
TGCT	cis	rs910316	1.000	rs4903289	chr14:75623988	C/T	cg23033748	chr14:75592666	NEK9	-0.29	-4.84	-0.4	3.86e-6	Height;
TGCT	cis	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg08045932	chr20:61659980	NA	0.48	9.16	0.64	1.36e-15	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2742234	0.759	rs12241923	chr10:43713047	T/C	cg02780029	chr10:43622663	RET	0.26	5.04	0.41	1.58e-6	Hirschsprung disease;
TGCT	cis	rs7666738	0.830	rs35644814	chr4:98886111	G/C	cg05340658	chr4:99064831	C4orf37	0.52	6.02	0.48	1.81e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28595532	0.920	rs114916728	chr4:119776886	G/A	cg11846333	chr4:119757529	SEC24D	0.92	4.64	0.38	8.74e-6	Cannabis dependence symptom count;
TGCT	cis	rs7267979	1.000	rs448396	chr20:25440269	G/A	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9611519	1.000	rs5758267	chr22:41619350	A/T	cg03806693	chr22:41940476	POLR3H	0.67	6.4	0.5	2.94e-9	Neuroticism;
TGCT	cis	rs6860806	0.507	rs635619	chr5:131720265	G/A	cg24060327	chr5:131705240	SLC22A5	0.77	8.48	0.61	5.57e-14	Breast cancer;
TGCT	trans	rs9859260	0.744	rs406271	chr3:195776976	T/C	cg17074656	chr11:63784126	MACROD1	0.52	6.67	0.51	7.49e-10	Mean corpuscular volume;
TGCT	cis	rs7829975	0.774	rs35039922	chr8:8675325	A/T	cg06636001	chr8:8085503	FLJ10661	0.66	5.78	0.46	5.66e-8	Mood instability;
TGCT	cis	rs2204008	0.594	rs11531211	chr12:37998007	T/G	cg26384229	chr12:38710491	ALG10B	-0.7	-6.1	-0.48	1.27e-8	Bladder cancer;
TGCT	cis	rs11874712	0.932	rs8092674	chr18:43665982	C/T	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	5.23	0.42	7.11e-7	Migraine - clinic-based;
TGCT	cis	rs7043114	0.525	rs710162	chr9:95059790	A/T	cg14631576	chr9:95140430	CENPP	0.29	4.7	0.39	6.71e-6	Height;
TGCT	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.07	0.82	4.17e-32	Prudent dietary pattern;
TGCT	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	7.99	0.58	8.01e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs10466239	0.730	rs2243492	chr10:43849358	C/T	cg12891252	chr10:43902500	HNRNPF	-0.69	-4.55	-0.38	1.28e-5	Telomere length;
TGCT	cis	rs1008375	1.000	rs28497813	chr4:17685503	A/G	cg18681998	chr4:17616180	MED28	0.92	10.51	0.69	7.15e-19	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10791097	0.694	rs2236711	chr11:130739284	G/A	cg14779329	chr11:130786720	SNX19	0.28	4.82	0.4	4.09e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9372253	0.818	rs2207360	chr6:110706337	G/C	cg00083206	chr6:110721305	DDO	-0.36	-5.22	-0.42	7.19e-7	Platelet distribution width;
TGCT	cis	rs17376456	0.877	rs13156865	chr5:93390908	C/A	cg21475434	chr5:93447410	FAM172A	0.59	4.66	0.39	8.09e-6	Diabetic retinopathy;
TGCT	trans	rs941408	1.000	rs1640274	chr19:2807375	G/A	cg19676328	chr12:49525230	TUBA1B	-0.87	-7.92	-0.58	1.13e-12	Total cholesterol levels;
TGCT	cis	rs34638657	0.500	rs12446210	chr16:82185762	G/A	cg09439754	chr16:82129088	HSD17B2	-0.23	-4.8	-0.4	4.55e-6	Lung adenocarcinoma;
TGCT	cis	rs2562456	0.682	rs11085464	chr19:21751778	C/G	cg25650185	chr19:21324782	ZNF431	-0.66	-5.85	-0.46	4.18e-8	Pain;
TGCT	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	7.22	0.54	4.57e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg18876405	chr7:65276391	NA	0.37	5.58	0.45	1.47e-7	Aortic root size;
TGCT	cis	rs9810089	0.814	rs1279424	chr3:136007333	A/G	cg12473912	chr3:136751656	NA	0.35	4.91	0.4	2.77e-6	Gestational age at birth (child effect);
TGCT	cis	rs7666738	0.830	rs17027058	chr4:98864671	G/A	cg05340658	chr4:99064831	C4orf37	0.52	6.03	0.48	1.78e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs694739	0.657	rs11231770	chr11:64140625	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.7	6.8	0.52	4.02e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs6426558	0.502	rs2813965	chr1:227445733	A/G	cg10327440	chr1:227177885	CDC42BPA	0.58	6.76	0.52	4.75e-10	Neutrophil percentage of white cells;
TGCT	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg11062466	chr8:58055876	NA	0.37	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs12477438	0.501	rs11692336	chr2:99740606	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.75	7.25	0.55	3.92e-11	Chronic sinus infection;
TGCT	cis	rs1008375	0.863	rs10003291	chr4:17600728	A/C	cg10189774	chr4:17578691	LAP3	0.62	4.99	0.41	2e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6121246	0.821	rs6121209	chr20:30311258	G/C	cg10886678	chr20:30946050	ASXL1	-0.62	-4.5	-0.37	1.54e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs11264213	0.901	rs72661646	chr1:36454954	A/T	cg27506609	chr1:36549197	TEKT2	0.41	4.61	0.38	9.88e-6	Schizophrenia;
TGCT	cis	rs1580019	0.587	rs2392069	chr7:32547154	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.58	4.96	0.41	2.25e-6	Cognitive ability;
TGCT	cis	rs79349575	0.783	rs12453374	chr17:46994846	G/C	cg26022315	chr17:47021804	SNF8	0.49	4.89	0.4	3.03e-6	Type 2 diabetes;
TGCT	cis	rs6840360	0.515	rs11099811	chr4:152320532	C/A	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.35	-0.5	3.68e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs12049351	0.719	rs6587338	chr1:229632638	G/T	cg12130225	chr1:229698885	NA	0.39	4.59	0.38	1.06e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs265548	0.586	rs265542	chr19:17904388	T/G	cg16744531	chr19:17905626	B3GNT3	0.41	5.03	0.41	1.69e-6	Tumor biomarkers;
TGCT	cis	rs11085466	0.948	rs76881507	chr19:21762189	A/T	cg23026602	chr19:21646605	NA	-0.57	-4.59	-0.38	1.05e-5	Colorectal or endometrial cancer;
TGCT	cis	rs11249608	0.548	rs7709054	chr5:178462757	C/T	cg01312482	chr5:178451176	ZNF879	-0.49	-4.83	-0.4	3.96e-6	Pubertal anthropometrics;
TGCT	cis	rs453301	0.658	rs6983877	chr8:8904639	T/C	cg08975724	chr8:8085496	FLJ10661	-0.54	-4.46	-0.37	1.8e-5	Joint mobility (Beighton score);
TGCT	cis	rs40363	1.000	rs1690444	chr16:3518350	G/A	cg22508957	chr16:3507546	NAT15	0.57	5.29	0.43	5.31e-7	Tuberculosis;
TGCT	cis	rs2115630	0.641	rs11073613	chr15:85185893	G/A	cg17173187	chr15:85201210	NMB	-0.38	-4.69	-0.39	7.04e-6	P wave terminal force;
TGCT	cis	rs3125734	0.572	rs3864794	chr10:64041956	A/C	cg09941381	chr10:64027924	RTKN2	-0.33	-4.91	-0.4	2.76e-6	Rheumatoid arthritis;
TGCT	cis	rs7523050	0.730	rs12079547	chr1:109469314	A/C	cg08274380	chr1:109419600	GPSM2	1.29	6.93	0.53	2.02e-10	Fat distribution (HIV);
TGCT	cis	rs9611565	0.500	rs10775759	chr22:42088158	T/C	cg06634786	chr22:41940651	POLR3H	0.9	9.03	0.63	2.7e-15	Vitiligo;
TGCT	cis	rs11190604	0.747	rs11190516	chr10:102173525	G/A	cg16005271	chr10:102321736	NA	0.45	4.57	0.38	1.15e-5	Palmitoleic acid (16:1n-7) levels;
TGCT	trans	rs7819412	0.715	rs2409727	chr8:11043236	C/T	cg15556689	chr8:8085844	FLJ10661	-0.74	-6.66	-0.51	7.84e-10	Triglycerides;
TGCT	cis	rs10507380	0.824	rs80030408	chr13:27919648	C/A	cg25543773	chr13:27185723	WASF3	0.34	4.83	0.4	3.97e-6	Electrocardiographic traits;
TGCT	cis	rs7824557	0.564	rs2736300	chr8:11235579	T/G	cg21775007	chr8:11205619	TDH	-0.65	-6.4	-0.5	2.95e-9	Retinal vascular caliber;
TGCT	cis	rs9911578	1.000	rs7216680	chr17:56988243	G/C	cg05425664	chr17:57184151	TRIM37	-0.62	-6.18	-0.49	8.33e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs4820539	0.933	rs2267004	chr22:23459863	G/A	cg21100191	chr22:23484243	RTDR1	0.93	10.72	0.69	2.21e-19	Bone mineral density;
TGCT	cis	rs11190604	1.000	rs7078799	chr10:102301447	G/A	cg23241863	chr10:102295624	HIF1AN	0.69	5.1	0.42	1.26e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg12963246	chr6:28129442	ZNF389	0.51	5.02	0.41	1.73e-6	Depression;
TGCT	cis	rs35160687	0.901	rs35762338	chr2:86513553	G/A	cg03171300	chr2:86307199	POLR1A	0.32	5.54	0.45	1.73e-7	Night sleep phenotypes;
TGCT	cis	rs4786125	0.542	rs2345826	chr16:6916235	G/T	cg03623568	chr16:6915990	A2BP1	-0.44	-6.55	-0.51	1.38e-9	Heart rate variability traits (SDNN);
TGCT	cis	rs6125597	0.935	rs6067034	chr20:47900164	G/A	cg11220565	chr20:47934802	NA	-0.3	-4.61	-0.38	9.77e-6	Intelligence (multi-trait analysis);
TGCT	trans	rs1814175	0.817	rs12295885	chr11:50036762	T/G	cg03929089	chr4:120376271	NA	-0.72	-8.55	-0.61	3.8e-14	Height;
TGCT	cis	rs6076065	0.748	rs2253834	chr20:23387816	C/T	cg11657817	chr20:23433608	CST11	-0.29	-5.15	-0.42	1.01e-6	Facial morphology (factor 15, philtrum width);
TGCT	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg27286337	chr10:134555280	INPP5A	0.37	4.52	0.38	1.4e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs4654899	1.000	rs7537072	chr1:21434533	T/C	cg01072550	chr1:21505969	NA	-0.51	-8.27	-0.6	1.76e-13	Superior frontal gyrus grey matter volume;
TGCT	cis	rs9911578	1.000	rs4636974	chr17:56965373	C/G	cg05425664	chr17:57184151	TRIM37	-0.62	-6.18	-0.49	8.33e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs6912958	0.754	rs4707374	chr6:88255438	T/C	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.91	-0.4	2.78e-6	Monocyte percentage of white cells;
TGCT	cis	rs2688608	0.592	rs3933085	chr10:75483331	C/T	cg19442545	chr10:75533431	FUT11	-0.37	-5.77	-0.46	5.89e-8	Inflammatory bowel disease;
TGCT	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg13395646	chr4:1353034	KIAA1530	-0.39	-4.96	-0.41	2.3e-6	Obesity-related traits;
TGCT	cis	rs2456568	0.802	rs1574515	chr11:93629643	T/C	cg14065697	chr11:93583672	C11orf90	-0.37	-4.64	-0.38	8.58e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7208859	0.573	rs11656278	chr17:29075188	C/T	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs6912958	0.712	rs6930600	chr6:88349787	G/A	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.98	-0.41	2.06e-6	Monocyte percentage of white cells;
TGCT	cis	rs7666738	0.830	rs7664169	chr4:99037859	C/T	cg05340658	chr4:99064831	C4orf37	-0.49	-5.52	-0.44	1.93e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3902035	0.964	rs62422254	chr6:119004249	A/T	cg07617317	chr6:118971624	C6orf204	0.43	5.08	0.41	1.37e-6	QT interval;
TGCT	cis	rs9399135	1.000	rs6569988	chr6:135352303	C/A	cg24558204	chr6:135376177	HBS1L	0.48	4.83	0.4	3.88e-6	Red blood cell count;
TGCT	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	9.52	0.65	1.86e-16	Platelet count;
TGCT	cis	rs1008375	1.000	rs3815413	chr4:17654648	T/C	cg10189774	chr4:17578691	LAP3	0.6	5.29	0.43	5.23e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2721195	0.845	rs3816732	chr8:145724275	T/C	cg15320075	chr8:145703422	NA	0.69	6.73	0.52	5.6e-10	Age at first birth;
TGCT	cis	rs1801239	1.000	rs78625146	chr10:16933839	T/A	cg00939682	chr10:16933505	CUBN	0.48	4.49	0.37	1.59e-5	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin excretion;
TGCT	cis	rs896854	0.654	rs2011566	chr8:95971921	G/A	cg09323728	chr8:95962352	TP53INP1	-0.49	-6.29	-0.49	4.86e-9	Type 2 diabetes;
TGCT	cis	rs7617773	0.778	rs11707997	chr3:48377875	A/G	cg11946769	chr3:48343235	NME6	0.82	6.99	0.53	1.49e-10	Coronary artery disease;
TGCT	cis	rs1971762	0.545	rs10783586	chr12:53980821	C/T	cg16917193	chr12:54089295	NA	0.93	9.72	0.66	5.91e-17	Height;
TGCT	cis	rs2115630	0.691	rs2292462	chr15:85200754	G/T	cg17173187	chr15:85201210	NMB	-0.47	-5.72	-0.46	7.45e-8	P wave terminal force;
TGCT	cis	rs4730250	0.669	rs6466160	chr7:106793175	T/A	cg02696742	chr7:106810147	HBP1	0.72	5.89	0.47	3.44e-8	Osteoarthritis;
TGCT	trans	rs208520	0.770	rs2153941	chr6:66885521	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.95	-10.37	-0.68	1.58e-18	Exhaled nitric oxide output;
TGCT	cis	rs7666738	0.611	rs34982650	chr4:98819530	T/A	cg05340658	chr4:99064831	C4orf37	0.51	6.03	0.48	1.76e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs735396	0.770	rs1169314	chr12:121443116	A/G	cg02403541	chr12:121454288	C12orf43	0.76	7.38	0.55	2.05e-11	N-glycan levels;
TGCT	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg27170947	chr2:26402098	FAM59B	-0.39	-4.46	-0.37	1.8e-5	Gut microbiome composition (summer);
TGCT	cis	rs7635838	0.892	rs9870881	chr3:11447082	A/G	cg00170343	chr3:11313890	ATG7	0.65	6.15	0.48	9.98e-9	HDL cholesterol;
TGCT	trans	rs931812	1.000	rs4734495	chr8:101917817	C/A	cg20993868	chr7:22813445	NA	0.36	8.02	0.58	6.78e-13	Attention deficit hyperactivity disorder and conduct disorder;
TGCT	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg22166914	chr1:53195759	ZYG11B	-0.36	-5.93	-0.47	2.78e-8	Monocyte count;
TGCT	cis	rs60843830	1.000	rs2126129	chr2:212548	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.71	6.4	0.5	2.83e-9	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs514406	0.505	rs416968	chr1:53183513	A/G	cg22166914	chr1:53195759	ZYG11B	0.44	7.85	0.58	1.67e-12	Monocyte count;
TGCT	cis	rs4595586	0.545	rs7976609	chr12:39394317	T/C	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs11250098	0.583	rs7001456	chr8:10804865	C/G	cg21775007	chr8:11205619	TDH	-0.56	-5.09	-0.42	1.3e-6	Morning vs. evening chronotype;
TGCT	trans	rs4957048	0.891	rs11960196	chr5:568857	C/A	cg11887960	chr12:57824829	NA	1.02	7.74	0.57	3.07e-12	Ulcerative colitis;
TGCT	cis	rs6674176	1.000	rs6674176	chr1:44379957	G/A	cg13606994	chr1:44402422	ARTN	-0.46	-4.71	-0.39	6.45e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg08219700	chr8:58056026	NA	0.38	4.61	0.38	1e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs1406084	0.541	rs1822208	chr2:154630981	C/G	cg25703346	chr2:154729189	GALNT13	0.91	4.49	0.37	1.59e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs473651	0.935	rs541128	chr2:239336449	A/G	cg18131467	chr2:239335373	ASB1	1.02	15.09	0.8	7.51e-30	Multiple system atrophy;
TGCT	cis	rs7192750	0.539	rs7193731	chr16:71897399	T/C	cg06353428	chr16:71660113	MARVELD3	0.83	7.37	0.55	2.07e-11	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs7226408	0.857	rs11664715	chr18:34435068	T/C	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs6570726	0.791	rs405206	chr6:145836873	C/A	cg23711669	chr6:146136114	FBXO30	0.89	9.72	0.66	6.02e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9388451	0.839	rs11154331	chr6:126111429	A/T	cg05901451	chr6:126070800	HEY2	-1.0	-14.26	-0.79	6.67e-28	Brugada syndrome;
TGCT	cis	rs34014631	0.892	rs7919455	chr10:103689176	T/C	cg22630918	chr10:102748988	C10orf2	0.42	4.78	0.39	4.86e-6	Coronary artery calcification;
TGCT	cis	rs78487399	0.710	rs75514072	chr2:43750224	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.07	-0.41	1.41e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs55823223	0.646	rs55868394	chr17:73851113	C/A	cg06969265	chr17:73775802	H3F3B	0.65	4.6	0.38	1.03e-5	Psoriasis;
TGCT	cis	rs28595532	0.925	rs28627331	chr4:119665345	T/C	cg11846333	chr4:119757529	SEC24D	0.95	4.9	0.4	2.97e-6	Cannabis dependence symptom count;
TGCT	cis	rs926938	1.000	rs926938	chr1:115239816	A/G	cg12756093	chr1:115239321	AMPD1	-0.48	-6.78	-0.52	4.36e-10	Autism;
TGCT	cis	rs2153535	0.580	rs6912193	chr6:8456306	T/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs7666738	0.830	rs3846443	chr4:99032666	G/A	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2842992	0.789	rs4235925	chr6:160202860	C/T	cg11366901	chr6:160182831	ACAT2	1.03	6.92	0.53	2.14e-10	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs7666738	0.830	rs1426670	chr4:98923572	A/G	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6543140	0.855	rs4851591	chr2:103077423	T/C	cg09003973	chr2:102972529	NA	0.55	4.67	0.39	7.71e-6	Blood protein levels;
TGCT	cis	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg18252515	chr7:66147081	NA	1.2	7.83	0.58	1.89e-12	Diabetic kidney disease;
TGCT	cis	rs1153858	1.000	rs56806728	chr15:45637814	A/G	cg26924012	chr15:45694286	SPATA5L1	1.07	14.56	0.79	1.32e-28	Homoarginine levels;
TGCT	trans	rs7819412	0.875	rs6981523	chr8:11061792	C/T	cg15556689	chr8:8085844	FLJ10661	-0.78	-7.71	-0.57	3.6e-12	Triglycerides;
TGCT	cis	rs9910055	0.529	rs190144	chr17:42164584	A/G	cg19774624	chr17:42201019	HDAC5	0.69	6.13	0.48	1.05e-8	Total body bone mineral density;
TGCT	cis	rs2797160	1.000	rs1954361	chr6:126001423	C/G	cg05901451	chr6:126070800	HEY2	-0.73	-6.27	-0.49	5.51e-9	Endometrial cancer;
TGCT	cis	rs10858047	0.883	rs72698008	chr1:115086264	A/G	cg12756093	chr1:115239321	AMPD1	0.45	4.63	0.38	9.24e-6	Autism;
TGCT	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg13732083	chr21:47605072	C21orf56	0.35	4.64	0.38	8.64e-6	Testicular germ cell tumor;
TGCT	cis	rs422249	0.819	rs174611	chr11:61627881	T/C	cg19610905	chr11:61596333	FADS2	-0.63	-4.84	-0.4	3.71e-6	Trans fatty acid levels;
TGCT	cis	rs6964587	1.000	rs17164263	chr7:91581566	T/A	cg17063962	chr7:91808500	NA	-0.91	-9.99	-0.67	1.32e-17	Breast cancer;
TGCT	cis	rs9443645	0.901	rs56057971	chr6:79607182	G/A	cg05283184	chr6:79620031	NA	-0.22	-4.98	-0.41	2.11e-6	Intelligence (multi-trait analysis);
TGCT	trans	rs2610739	0.554	rs9353573	chr6:89223517	G/C	cg05764691	chr16:22927585	HS3ST2	0.4	6.62	0.51	9.76e-10	IgG glycosylation;
TGCT	cis	rs9911578	1.000	rs7207693	chr17:57016525	C/T	cg05425664	chr17:57184151	TRIM37	-0.62	-6.18	-0.49	8.33e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs644799	1.000	rs586238	chr11:95560371	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	8.99	0.63	3.53e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7617773	0.963	rs12494304	chr3:48178029	C/T	cg11946769	chr3:48343235	NME6	-0.59	-5.27	-0.43	5.75e-7	Coronary artery disease;
TGCT	cis	rs1670533	0.932	rs3796620	chr4:1095079	A/G	cg20518497	chr4:1046821	NA	0.27	4.46	0.37	1.84e-5	Recombination rate (females);
TGCT	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg16325326	chr1:53192061	ZYG11B	-0.71	-8.82	-0.62	8.9e-15	Monocyte count;
TGCT	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg06618935	chr21:46677482	NA	0.37	5.56	0.45	1.58e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs8014252	0.803	rs1959477	chr14:71034216	A/G	cg11204974	chr14:71022665	NA	-0.55	-4.66	-0.39	7.98e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
TGCT	cis	rs12681288	0.676	rs2701927	chr8:995886	G/A	cg04851639	chr8:1020857	NA	-0.32	-5.37	-0.43	3.81e-7	Schizophrenia;
TGCT	cis	rs600231	0.665	rs1784858	chr11:65222952	T/C	cg17120908	chr11:65337727	SSSCA1	-0.51	-4.71	-0.39	6.59e-6	Bone mineral density;
TGCT	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg24250549	chr1:154909240	PMVK	0.56	5.27	0.43	5.95e-7	Prostate cancer;
TGCT	cis	rs4988958	0.565	rs1420100	chr2:103037002	C/A	cg03938978	chr2:103052716	IL18RAP	0.27	5.4	0.44	3.31e-7	Asthma (childhood onset);
TGCT	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg08280861	chr8:58055591	NA	0.48	5.11	0.42	1.21e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1857353	0.803	rs2040082	chr1:75906874	A/G	cg11838876	chr1:75668600	SLC44A5	-0.47	-4.56	-0.38	1.2e-5	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs7524258	0.900	rs1476047	chr1:7312172	C/T	cg04342483	chr1:7259290	CAMTA1	-0.31	-4.51	-0.38	1.47e-5	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9650657	0.655	rs10093774	chr8:10703293	C/T	cg27411982	chr8:10470053	RP1L1	0.23	4.67	0.39	7.71e-6	Neuroticism;
TGCT	cis	rs2739330	0.576	rs2858912	chr22:24297197	A/G	cg15242686	chr22:24348715	GSTTP1	0.43	5.95	0.47	2.54e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1971762	0.545	rs10747676	chr12:54049930	T/C	cg16917193	chr12:54089295	NA	1.05	10.91	0.7	7.89e-20	Height;
TGCT	cis	rs2404602	0.967	rs2083762	chr15:76907376	T/C	cg22467129	chr15:76604101	ETFA	-0.45	-4.95	-0.41	2.35e-6	Blood metabolite levels;
TGCT	cis	rs10114408	0.959	rs1933672	chr9:96654908	A/C	cg13679303	chr9:96623674	NA	-0.35	-4.45	-0.37	1.86e-5	Colorectal cancer (SNP x SNP interaction);
TGCT	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg01341218	chr17:43662625	NA	-0.79	-7.11	-0.54	7.91e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs1008375	1.000	rs9291659	chr4:17662360	A/C	cg10189774	chr4:17578691	LAP3	0.54	4.97	0.41	2.21e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg18402987	chr7:1209562	NA	0.45	4.56	0.38	1.23e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2066819	1.000	rs11575229	chr12:56750737	C/T	cg26714650	chr12:56694279	CS	-1.36	-5.89	-0.47	3.4e-8	Psoriasis vulgaris;
TGCT	cis	rs9486719	1.000	rs9486719	chr6:97060124	G/A	cg06623918	chr6:96969491	KIAA0776	-0.97	-8.46	-0.61	6.24e-14	Migraine;Coronary artery disease;
TGCT	cis	rs939574	0.799	rs1109867	chr2:220083453	G/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-1.04	-6.24	-0.49	6.22e-9	Platelet distribution width;
TGCT	cis	rs12477438	0.798	rs1580068	chr2:99649969	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-5.87	-0.47	3.74e-8	Chronic sinus infection;
TGCT	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.29	-4.49	-0.37	1.64e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2013441	0.786	rs4003797	chr17:20288900	T/C	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.52	-0.38	1.4e-5	Obesity-related traits;
TGCT	cis	rs35306767	0.714	rs28512382	chr10:1092195	G/C	cg18964960	chr10:1102726	WDR37	0.66	4.57	0.38	1.14e-5	Eosinophil percentage of granulocytes;
TGCT	cis	rs7909074	0.798	rs914699	chr10:45377066	A/C	cg05187965	chr10:45406764	TMEM72	-0.28	-5.9	-0.47	3.3e-8	Mean corpuscular volume;
TGCT	cis	rs79349575	0.749	rs2270574	chr17:47022270	C/T	cg26022315	chr17:47021804	SNF8	0.49	4.9	0.4	2.94e-6	Type 2 diabetes;
TGCT	cis	rs36051895	0.664	rs62543877	chr9:5093465	C/A	cg02405213	chr9:5042618	JAK2	-0.72	-9.52	-0.65	1.85e-16	Pediatric autoimmune diseases;
TGCT	cis	rs7220401	0.512	rs2289629	chr17:27959903	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.76	6.77	0.52	4.6e-10	Coronary artery disease;
TGCT	cis	rs13242816	1.000	rs56309428	chr7:116150137	G/T	cg02799643	chr7:116139180	CAV2	-0.42	-5.46	-0.44	2.45e-7	P wave duration;
TGCT	cis	rs7226408	0.739	rs115893729	chr18:34343144	C/T	cg06757138	chr18:34340585	FHOD3	0.3	5.09	0.42	1.3e-6	Obesity-related traits;
TGCT	cis	rs902774	0.554	rs4503623	chr12:53353759	T/C	cg14581129	chr12:53358946	NA	-0.56	-6.08	-0.48	1.34e-8	Prostate cancer;
TGCT	cis	rs926938	0.527	rs360684	chr1:115499001	A/G	cg12756093	chr1:115239321	AMPD1	0.35	5.1	0.42	1.25e-6	Autism;
TGCT	cis	rs2178146	0.535	rs4843370	chr16:86450509	G/A	cg11165158	chr16:86613094	FOXL1	0.35	4.69	0.39	7.09e-6	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Esophageal adenocarcinoma;
TGCT	trans	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.88	-9.5	-0.65	2.02e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs3796352	0.892	rs11718388	chr3:53076415	G/A	cg27565382	chr3:53032988	SFMBT1	0.43	4.62	0.38	9.64e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs62103177	0.608	rs551643	chr18:77838970	C/G	cg07235805	chr18:78004237	PARD6G	-0.51	-4.98	-0.41	2.11e-6	Opioid sensitivity;
TGCT	cis	rs6558530	0.836	rs11136424	chr8:1717036	C/T	cg09410841	chr8:1729607	CLN8	0.89	10.54	0.69	6.17e-19	Systolic blood pressure;
TGCT	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg11890956	chr21:40555474	PSMG1	-0.68	-6.58	-0.51	1.21e-9	Menarche (age at onset);
TGCT	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs813218	0.523	rs10935917	chr3:99441241	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.42	5.13	0.42	1.07e-6	Orofacial clefts;
TGCT	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.34	0.55	2.43e-11	Prudent dietary pattern;
TGCT	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg00149659	chr3:10157352	C3orf10	0.73	4.72	0.39	6.17e-6	Alzheimer's disease;
TGCT	cis	rs60843830	1.000	rs79716074	chr2:277003	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.73	7.33	0.55	2.65e-11	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg21724239	chr8:58056113	NA	-0.39	-4.96	-0.41	2.29e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7923609	0.967	rs7076310	chr10:65135672	C/A	cg08743896	chr10:65200160	JMJD1C	-0.34	-4.57	-0.38	1.15e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7226408	0.857	rs72887034	chr18:34474187	A/G	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg11062466	chr8:58055876	NA	0.37	4.63	0.38	9.01e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7580717	0.540	rs62197320	chr2:232060366	T/G	cg07929768	chr2:232055508	NA	0.31	4.93	0.41	2.55e-6	Multiple myeloma;
TGCT	cis	rs854765	0.583	rs9908832	chr17:17871068	C/T	cg09796270	chr17:17721594	SREBF1	0.23	4.56	0.38	1.22e-5	Total body bone mineral density;
TGCT	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg22963979	chr7:1858916	MAD1L1	-0.41	-6.74	-0.52	5.43e-10	Schizophrenia;
TGCT	trans	rs1814175	0.817	rs11493756	chr11:50017885	T/C	cg03929089	chr4:120376271	NA	-0.72	-8.55	-0.61	3.8e-14	Height;
TGCT	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg08280861	chr8:58055591	NA	0.4	4.73	0.39	5.97e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs11690935	1.000	rs312918	chr2:172569587	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.18	-12.58	-0.75	6.59e-24	Schizophrenia;
TGCT	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg13695892	chr22:41940480	POLR3H	-0.92	-9.23	-0.64	9.18e-16	Vitiligo;
TGCT	cis	rs12681287	0.577	rs11992955	chr8:87530485	A/G	cg27223183	chr8:87520930	FAM82B	0.94	6.91	0.53	2.24e-10	Caudate activity during reward;
TGCT	cis	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg20637647	chr7:64974828	NA	0.89	4.99	0.41	2.01e-6	Diabetic kidney disease;
TGCT	cis	rs2016266	0.855	rs6580941	chr12:53662199	T/C	cg16917193	chr12:54089295	NA	0.69	5.24	0.43	6.71e-7	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs6540559	0.673	rs114467813	chr1:210017785	G/A	cg22029157	chr1:209979665	IRF6	0.7	4.96	0.41	2.26e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg07507251	chr3:52567010	NT5DC2	-0.43	-5.82	-0.46	4.67e-8	Bipolar disorder;
TGCT	cis	rs2762353	0.574	rs4419666	chr6:25693274	C/T	cg15691649	chr6:25882328	NA	0.48	5.64	0.45	1.11e-7	Blood metabolite levels;
TGCT	cis	rs7772486	0.790	rs2814880	chr6:146208937	T/G	cg23711669	chr6:146136114	FBXO30	0.89	10.18	0.67	4.61e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg07424592	chr7:64974309	NA	1.4	8.42	0.6	7.87e-14	Diabetic kidney disease;
TGCT	cis	rs10540	0.730	rs12789735	chr11:518509	G/A	cg03934478	chr11:495069	RNH1	0.32	4.82	0.4	4.16e-6	Body mass index;
TGCT	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg06634786	chr22:41940651	POLR3H	0.87	8.2	0.59	2.56e-13	Vitiligo;
TGCT	cis	rs3617	0.573	rs2336667	chr3:52916363	C/T	cg10802521	chr3:52805072	NEK4	0.57	6.57	0.51	1.27e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12220898	0.749	rs6537520	chr10:50484107	T/C	cg06072769	chr10:50146962	WDFY4	0.38	5.07	0.41	1.38e-6	Inflammatory biomarkers;
TGCT	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9787249	0.957	rs12086750	chr1:40210468	G/C	cg19912559	chr1:40204330	PPIE	0.49	5.7	0.46	8.41e-8	Blood protein levels;
TGCT	cis	rs2439831	1.000	rs2467743	chr15:43750346	T/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.01	8.18	0.59	2.83e-13	Lung cancer in ever smokers;
TGCT	cis	rs9807989	0.839	rs1420099	chr2:102980543	C/G	cg09003973	chr2:102972529	NA	0.67	6.03	0.48	1.75e-8	Asthma;
TGCT	cis	rs9300255	0.507	rs1727302	chr12:123632930	G/A	cg00376283	chr12:123451042	ABCB9	0.78	6.66	0.51	8.08e-10	Neutrophil percentage of white cells;
TGCT	cis	rs6912958	0.781	rs9444519	chr6:88290398	T/C	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.91	-0.4	2.78e-6	Monocyte percentage of white cells;
TGCT	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg00080972	chr5:178986291	RUFY1	0.46	5.39	0.44	3.46e-7	Lung cancer;
TGCT	cis	rs6845621	0.901	rs7697728	chr4:18922514	C/T	cg12196642	chr4:18937545	NA	-0.25	-4.5	-0.38	1.52e-5	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
TGCT	cis	rs9905704	0.647	rs12940492	chr17:56954655	C/G	cg12560992	chr17:57184187	TRIM37	0.57	4.9	0.4	2.87e-6	Testicular germ cell tumor;
TGCT	cis	rs9638182	0.945	rs13247874	chr7:73010442	C/T	cg14087351	chr7:73037990	MLXIPL	-0.55	-4.6	-0.38	1.01e-5	Triglycerides;
TGCT	cis	rs11247915	1.000	rs11247915	chr1:26650550	G/T	cg23732845	chr1:26663426	AIM1L	0.31	4.46	0.37	1.82e-5	Obesity-related traits;
TGCT	cis	rs7666738	0.830	rs35235971	chr4:98999833	G/T	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs1814175	0.817	rs12277258	chr11:49940216	T/C	cg03929089	chr4:120376271	NA	-0.71	-8.09	-0.59	4.74e-13	Height;
TGCT	cis	rs13191362	0.935	rs34063386	chr6:163041271	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.07	8.5	0.61	5.17e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs6061231	0.571	rs482010	chr20:60927551	A/G	cg24112000	chr20:60950667	NA	0.34	4.76	0.39	5.24e-6	Colorectal cancer;
TGCT	cis	rs1334894	0.901	rs56353810	chr6:35521086	G/T	cg24281267	chr6:35479648	TULP1	-0.43	-4.47	-0.37	1.78e-5	Coronary artery disease;
TGCT	cis	rs2032447	0.641	rs442601	chr6:25934524	G/A	cg03264133	chr6:25882463	NA	-0.62	-5.72	-0.46	7.56e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg04287289	chr16:89883240	FANCA	0.93	11.83	0.73	4.42e-22	Vitiligo;
TGCT	cis	rs11626933	0.885	rs28517514	chr14:90788709	G/A	cg14092571	chr14:90743983	NA	-0.27	-5.49	-0.44	2.14e-7	Gut microbiota (bacterial taxa);
TGCT	cis	rs2637266	0.905	rs10824428	chr10:78346041	G/A	cg18941641	chr10:78392320	NA	0.42	5.45	0.44	2.62e-7	Pulmonary function;
TGCT	cis	rs6088580	0.634	rs4911151	chr20:32932273	T/C	cg06115741	chr20:33292138	TP53INP2	-0.55	-4.9	-0.4	2.97e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs877282	0.945	rs11253391	chr10:788752	G/A	cg17470449	chr10:769945	NA	0.3	4.71	0.39	6.53e-6	Uric acid levels;
TGCT	cis	rs263156	1.000	rs263158	chr6:142909049	G/T	cg18419694	chr6:143832440	FUCA2	0.4	4.65	0.39	8.22e-6	Ear morphology;Lobe size;Lobe attachment;
TGCT	cis	rs6500602	0.527	rs13338333	chr16:4443250	T/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.41	5.05	0.41	1.53e-6	Schizophrenia;
TGCT	cis	rs67311347	0.544	rs9821440	chr3:40342347	T/C	cg13683864	chr3:40499215	RPL14	-0.78	-7.5	-0.56	1.06e-11	Renal cell carcinoma;
TGCT	cis	rs12477438	0.520	rs4851187	chr2:99745860	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-1.05	-12.95	-0.76	8.61e-25	Chronic sinus infection;
TGCT	cis	rs1355223	0.552	rs2421743	chr11:34882840	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.8	8.94	0.63	4.49e-15	Systemic lupus erythematosus and Systemic sclerosis;
TGCT	cis	rs7010267	0.740	rs1872426	chr8:119949756	A/C	cg17171407	chr8:119960777	TNFRSF11B	-0.25	-4.44	-0.37	2e-5	Total body bone mineral density (age 45-60);
TGCT	cis	rs2795502	1.000	rs2795497	chr10:43339475	C/A	cg20628663	chr10:43360327	NA	-0.44	-6.37	-0.5	3.4e-9	Blood protein levels;
TGCT	cis	rs473651	0.935	rs1103770	chr2:239339281	G/C	cg08773314	chr2:239334832	ASB1	0.45	6.39	0.5	3.05e-9	Multiple system atrophy;
TGCT	cis	rs7937682	0.881	rs4936678	chr11:111625085	C/T	cg03242880	chr11:111382915	BTG4;MIR34C;MIR34B	-0.25	-4.49	-0.37	1.58e-5	Primary sclerosing cholangitis;
TGCT	cis	rs700651	0.624	rs12105927	chr2:198937258	G/A	cg00792783	chr2:198669748	PLCL1	0.58	5.16	0.42	9.47e-7	Intracranial aneurysm;
TGCT	cis	rs7666738	0.791	rs6853608	chr4:99047916	A/G	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4383453	0.539	rs2332509	chr3:123100177	T/C	cg04890266	chr3:123102914	ADCY5	-0.5	-8.19	-0.59	2.68e-13	Gestational age at birth (maternal effect);
TGCT	cis	rs12220898	0.749	rs4497321	chr10:50475018	C/T	cg06072769	chr10:50146962	WDFY4	0.36	4.67	0.39	7.64e-6	Inflammatory biomarkers;
TGCT	trans	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg17830980	chr10:43048298	ZNF37B	-0.87	-11.3	-0.71	8.5e-21	Extrinsic epigenetic age acceleration;
TGCT	trans	rs11088226	0.681	rs11700670	chr21:33938615	T/C	cg09050820	chr6:167586206	TCP10L2	0.79	7.04	0.53	1.13e-10	Gastritis;
TGCT	cis	rs8037137	0.915	rs112770790	chr15:91507495	G/A	cg22570213	chr15:91497863	RCCD1	0.52	4.84	0.4	3.85e-6	Platelet count;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
TGCT	cis	rs9467773	0.869	rs9295689	chr6:26455811	T/C	cg09904177	chr6:26538194	HMGN4	0.56	5.43	0.44	2.8e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs290268	0.838	rs290993	chr9:93559572	G/A	cg02608019	chr9:93564028	SYK	0.46	4.69	0.39	7.07e-6	Platelet count;
TGCT	cis	rs7582180	0.676	rs4264577	chr2:100930662	T/C	cg08017756	chr2:100939284	LONRF2	-0.3	-4.98	-0.41	2.11e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs78487399	0.808	rs7578597	chr2:43732823	T/C	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.74	4.5	0.37	1.57e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs7226408	0.857	rs55992510	chr18:34519130	G/C	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs4805272	0.512	rs66830923	chr19:29321277	C/T	cg14983838	chr19:29218262	NA	0.69	4.7	0.39	6.67e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
TGCT	cis	rs986417	0.901	rs1955698	chr14:61029936	C/T	cg27398547	chr14:60952738	C14orf39	1.33	10.37	0.68	1.56e-18	Gut microbiota (bacterial taxa);
TGCT	cis	rs2235642	0.750	rs763152	chr16:1658056	T/C	cg08296037	chr16:1584118	IFT140;TMEM204	-0.29	-5.01	-0.41	1.8e-6	Coronary artery disease;
TGCT	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg03934478	chr11:495069	RNH1	0.33	5.08	0.42	1.33e-6	Body mass index;
TGCT	trans	rs3780486	0.846	rs3780487	chr9:33139237	T/C	cg04842962	chr6:43655489	MRPS18A	1.24	15.76	0.82	2.18e-31	IgG glycosylation;
TGCT	cis	rs12477438	0.520	rs13018891	chr2:99755099	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	17.43	0.84	3.73e-35	Chronic sinus infection;
TGCT	cis	rs1878931	0.501	rs37800	chr16:3423648	T/G	cg22508957	chr16:3507546	NAT15	0.4	5.24	0.43	6.71e-7	Body mass index (adult);
TGCT	cis	rs6964587	1.000	rs2188154	chr7:91595138	T/A	cg17063962	chr7:91808500	NA	0.91	9.99	0.67	1.32e-17	Breast cancer;
TGCT	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg19723775	chr5:179050963	HNRNPH1	0.53	5.29	0.43	5.29e-7	Lung cancer;
TGCT	cis	rs10791323	0.604	rs2723607	chr11:133711018	C/G	cg03690763	chr11:133734501	NA	-0.31	-4.79	-0.39	4.72e-6	Childhood ear infection;
TGCT	cis	rs4851266	1.000	rs4583487	chr2:100837126	G/T	cg22139774	chr2:100720529	AFF3	-0.34	-5.09	-0.42	1.28e-6	Educational attainment;
TGCT	cis	rs3617	0.625	rs2239548	chr3:52854186	A/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.6	-0.38	1.02e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	trans	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg27523141	chr10:43048294	ZNF37B	0.74	8.66	0.61	2.13e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2469997	0.925	rs2470011	chr8:120359937	G/C	cg00681363	chr8:120844660	TAF2	0.69	4.48	0.37	1.64e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs79121401	0.744	rs6592813	chr11:78696828	A/G	cg25632648	chr11:77899776	KCTD21;USP35	1.14	4.69	0.39	7.22e-6	Interleukin-12p70 levels;
TGCT	cis	rs713587	0.967	rs10865320	chr2:25159780	A/G	cg15423357	chr2:25149977	NA	0.58	5.85	0.46	4.18e-8	Body mass index in non-asthmatics;
TGCT	cis	rs11190604	1.000	rs12219158	chr10:102302923	T/C	cg23241863	chr10:102295624	HIF1AN	0.7	5.14	0.42	1.02e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg11905131	chr22:24372483	LOC391322	-1.03	-13.34	-0.77	9.82e-26	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9914544	1.000	rs1634409	chr17:18836177	C/T	cg26306683	chr17:18585705	ZNF286B	0.59	5.26	0.43	5.99e-7	Educational attainment (years of education);
TGCT	cis	rs473651	0.935	rs483166	chr2:239346641	C/T	cg08773314	chr2:239334832	ASB1	-0.45	-7.5	-0.56	1.07e-11	Multiple system atrophy;
TGCT	cis	rs1577917	1.000	rs6914463	chr6:86653415	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.05	-0.41	1.57e-6	Response to antipsychotic treatment;
TGCT	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg13683864	chr3:40499215	RPL14	-1.19	-13.2	-0.76	2.17e-25	Renal cell carcinoma;
TGCT	cis	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg12570787	chr5:219185	SDHA;CCDC127	0.65	4.46	0.37	1.83e-5	Breast cancer;
TGCT	cis	rs1801251	0.963	rs13424351	chr2:233573629	A/G	cg25237894	chr2:233734115	C2orf82	0.3	5.3	0.43	5.08e-7	Coronary artery disease;
TGCT	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.67	-6.89	-0.53	2.53e-10	Prostate cancer;
TGCT	cis	rs12049351	0.774	rs1053513	chr1:229652587	T/C	cg12130225	chr1:229698885	NA	0.35	4.46	0.37	1.85e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs7666738	0.830	rs13134819	chr4:98919885	G/C	cg17366294	chr4:99064904	C4orf37	0.73	7.51	0.56	1e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs13102973	0.646	rs4428339	chr4:135886187	C/T	cg14419869	chr4:135874104	NA	0.26	4.6	0.38	1.03e-5	Subjective well-being;
TGCT	cis	rs13082711	0.648	rs13085782	chr3:27404390	C/G	cg02860705	chr3:27208620	NA	0.51	7.37	0.55	2.09e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs12780845	0.540	rs10795451	chr10:17179195	T/C	cg01003015	chr10:17271136	VIM	-0.59	-5.5	-0.44	2.11e-7	Homocysteine levels;
TGCT	cis	rs6964587	0.935	rs9770444	chr7:91783162	T/G	cg17063962	chr7:91808500	NA	0.93	10.08	0.67	8.03e-18	Breast cancer;
TGCT	cis	rs7945705	0.967	rs34842234	chr11:8891894	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.43	4.86	0.4	3.42e-6	Hemoglobin concentration;
TGCT	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg17971929	chr21:40555470	PSMG1	0.97	9.54	0.65	1.67e-16	Cognitive function;
TGCT	cis	rs28595532	0.920	rs10025640	chr4:119787451	G/A	cg14228332	chr4:119757509	SEC24D	1.19	6.66	0.51	8.07e-10	Cannabis dependence symptom count;
TGCT	cis	rs12188164	0.965	rs72717430	chr5:444502	T/C	cg21144161	chr5:423903	AHRR	0.25	4.79	0.4	4.59e-6	Cystic fibrosis severity;
TGCT	cis	rs1997103	0.954	rs9649780	chr7:55411741	A/C	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs9916302	0.904	rs11869109	chr17:37518205	G/T	cg15445000	chr17:37608096	MED1	-0.33	-4.74	-0.39	5.87e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs295140	0.605	rs3769471	chr2:201195403	G/A	cg04283868	chr2:201171347	SPATS2L	0.48	4.59	0.38	1.07e-5	QT interval;
TGCT	cis	rs2859741	0.935	rs2782410	chr1:37509489	G/C	cg09363841	chr1:37513479	NA	-0.19	-4.48	-0.37	1.65e-5	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
TGCT	cis	rs7100689	0.784	rs17678947	chr10:82136333	T/C	cg01528321	chr10:82214614	TSPAN14	0.87	8.35	0.6	1.14e-13	Post bronchodilator FEV1;
TGCT	cis	rs6089584	0.507	rs28545731	chr20:60634102	C/T	cg13665807	chr20:60559372	TAF4	-0.48	-5.08	-0.42	1.35e-6	Body mass index;
TGCT	cis	rs6964587	1.000	rs7785971	chr7:91736794	T/A	cg22709100	chr7:91322751	NA	0.28	4.56	0.38	1.21e-5	Breast cancer;
TGCT	trans	rs75565482	0.546	rs12090359	chr1:168458546	G/A	cg15721615	chr1:100771427	NA	0.49	6.84	0.52	3.23e-10	Emphysema imaging phenotypes;
TGCT	cis	rs12681287	0.547	rs9942823	chr8:87509177	A/G	cg27223183	chr8:87520930	FAM82B	-0.95	-6.95	-0.53	1.81e-10	Caudate activity during reward;
TGCT	cis	rs2235642	0.893	rs2076440	chr16:1587322	G/A	cg00463982	chr16:1583984	IFT140;TMEM204	-0.29	-4.96	-0.41	2.27e-6	Coronary artery disease;
TGCT	cis	rs8017423	0.935	rs2104704	chr14:90696609	A/G	cg04374321	chr14:90722782	PSMC1	-0.76	-7.85	-0.58	1.64e-12	Mortality in heart failure;
TGCT	cis	rs9357506	1.000	rs9369611	chr6:46313249	G/A	cg21115430	chr6:46460003	NA	-0.26	-5.16	-0.42	9.6e-7	Body mass index;
TGCT	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg23708337	chr7:1209742	NA	0.51	4.46	0.37	1.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9393692	0.676	rs1543681	chr6:26187783	G/T	cg05868516	chr6:26286170	HIST1H4H	0.53	5.13	0.42	1.06e-6	Educational attainment;
TGCT	cis	rs3099143	0.908	rs6495222	chr15:77180015	A/C	cg21673338	chr15:77095150	SCAPER	0.52	5.05	0.41	1.54e-6	Recalcitrant atopic dermatitis;
TGCT	cis	rs748404	0.660	rs2467741	chr15:43742626	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	4.77	0.39	5.17e-6	Lung cancer;
TGCT	cis	rs28595532	0.920	rs115681185	chr4:119757700	G/A	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.45	-5.43	-0.44	2.85e-7	Longevity;Endometriosis;
TGCT	trans	rs2688608	0.617	rs6480709	chr10:75479125	T/C	cg13918328	chr10:52500089	ASAH2B	0.68	6.73	0.52	5.68e-10	Inflammatory bowel disease;
TGCT	cis	rs7949030	0.626	rs7943191	chr11:62328551	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.71	9.07	0.63	2.23e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs4268898	0.560	rs78711174	chr2:24496531	G/A	cg06627628	chr2:24431161	ITSN2	-0.2	-4.46	-0.37	1.82e-5	Asthma;
TGCT	cis	rs3749237	0.537	rs4459909	chr3:49469217	T/C	cg03060546	chr3:49711283	APEH	0.77	8.86	0.62	6.92e-15	Resting heart rate;
TGCT	cis	rs6089829	0.888	rs4809465	chr20:61671156	G/C	cg08045932	chr20:61659980	NA	0.5	8.69	0.62	1.75e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg10802521	chr3:52805072	NEK4	-0.7	-8.64	-0.61	2.37e-14	Bipolar disorder;
TGCT	cis	rs9467711	0.790	rs45527431	chr6:26599509	A/G	cg16898833	chr6:26189333	HIST1H4D	1.37	6.2	0.49	7.83e-9	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs611744	0.967	rs608115	chr8:109231948	T/A	cg21045802	chr8:109455806	TTC35	0.52	4.72	0.39	6.21e-6	Dupuytren's disease;
TGCT	cis	rs7833790	0.660	rs1451995	chr8:82746123	G/C	cg27398817	chr8:82754497	SNX16	0.67	5.34	0.43	4.27e-7	Diastolic blood pressure;
TGCT	cis	rs6540559	0.546	rs735694	chr1:210034029	T/C	cg12034118	chr1:209979487	IRF6	0.65	4.56	0.38	1.2e-5	Cleft lip with or without cleft palate;
TGCT	cis	rs3902035	0.964	rs62423960	chr6:119008133	T/C	cg07617317	chr6:118971624	C6orf204	0.43	5.01	0.41	1.79e-6	QT interval;
TGCT	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg21862992	chr11:68658383	NA	-0.45	-6.19	-0.49	7.89e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs17345786	0.511	rs13061565	chr3:101392270	T/C	cg12386194	chr3:101231763	SENP7	0.53	5.13	0.42	1.08e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4563143	0.592	rs12151001	chr19:29283386	C/G	cg04546413	chr19:29218101	NA	0.86	7.0	0.53	1.45e-10	Methadone dose in opioid dependence;
TGCT	cis	rs6782228	1.000	rs35871360	chr3:128336129	G/A	cg15113803	chr3:129247119	RHO	0.17	4.47	0.37	1.72e-5	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
TGCT	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg05368731	chr17:41323189	NBR1	1.01	9.03	0.63	2.83e-15	Menopause (age at onset);
TGCT	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg06028808	chr11:68637592	NA	0.51	6.55	0.51	1.38e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7666738	0.515	rs10015315	chr4:98700137	A/G	cg17366294	chr4:99064904	C4orf37	0.59	5.57	0.45	1.48e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs36051895	0.632	rs1581927	chr9:5177462	C/T	cg02405213	chr9:5042618	JAK2	-0.77	-10.92	-0.7	7.2e-20	Pediatric autoimmune diseases;
TGCT	cis	rs9916302	0.851	rs11078906	chr17:37662767	C/T	cg07936489	chr17:37558343	FBXL20	-0.62	-4.91	-0.4	2.85e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs4072705	1.000	rs10760372	chr9:127468816	T/C	cg13476313	chr9:127244764	NR5A1	0.29	4.65	0.39	8.5e-6	Menarche (age at onset);
TGCT	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg14784868	chr12:69753453	YEATS4	0.89	10.48	0.69	8.4e-19	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg11301795	chr4:187892539	NA	-0.36	-5.55	-0.45	1.66e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg24531977	chr5:56204891	C5orf35	-0.72	-7.31	-0.55	2.9e-11	Initial pursuit acceleration;
TGCT	cis	rs7246657	0.639	rs12459015	chr19:38083189	T/A	cg03611452	chr19:38183253	ZNF781	0.58	4.64	0.38	8.62e-6	Coronary artery calcification;
TGCT	cis	rs28374715	0.532	rs28584379	chr15:41670408	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.93	-16.21	-0.82	2.08e-32	Ulcerative colitis;
TGCT	cis	rs763014	0.931	rs710925	chr16:633354	G/A	cg09263875	chr16:632152	PIGQ	0.3	6.4	0.5	2.88e-9	Height;
TGCT	cis	rs3812049	0.667	rs6888037	chr5:127406259	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.6	5.57	0.45	1.47e-7	Lymphocyte counts;Red cell distribution width;
TGCT	cis	rs3796352	1.000	rs34121720	chr3:53072167	C/T	cg15956490	chr3:53032818	SFMBT1	0.59	6.75	0.52	5.19e-10	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs2996428	0.667	rs111640545	chr1:3752792	G/A	cg17848003	chr1:3704513	LRRC47	0.19	5.14	0.42	1.04e-6	Red cell distribution width;
TGCT	trans	rs7618501	0.669	rs3774758	chr3:49938227	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.89	9.83	0.66	3.36e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs9291683	0.588	rs4697705	chr4:10108127	G/A	cg00071950	chr4:10020882	SLC2A9	-0.42	-4.6	-0.38	1.01e-5	Bone mineral density;
TGCT	cis	rs1048238	0.506	rs1262788	chr1:16215608	G/C	cg21385522	chr1:16154831	NA	-0.61	-6.88	-0.53	2.64e-10	Systolic blood pressure;
TGCT	cis	rs7246657	0.882	rs59224125	chr19:37963205	T/C	cg18154014	chr19:37997991	ZNF793	0.73	5.33	0.43	4.4e-7	Coronary artery calcification;
TGCT	cis	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg06697600	chr4:7070879	GRPEL1	0.43	4.55	0.38	1.24e-5	Monocyte percentage of white cells;
TGCT	cis	rs2153535	0.580	rs969421	chr6:8451949	A/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.76	0.46	6.39e-8	Motion sickness;
TGCT	cis	rs7772486	0.590	rs1890170	chr6:146071839	G/C	cg05347473	chr6:146136440	FBXO30	-0.68	-6.22	-0.49	7.01e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs13315871	1.000	rs9869576	chr3:58401262	G/A	cg12435725	chr3:58293450	RPP14	-0.43	-4.47	-0.37	1.71e-5	Cholesterol, total;
TGCT	cis	rs3733585	0.725	rs6449201	chr4:9973894	C/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.72	-0.52	5.74e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs11690935	0.798	rs13018768	chr2:172598592	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.17	-12.41	-0.74	1.75e-23	Schizophrenia;
TGCT	cis	rs6964587	1.000	rs2285333	chr7:91667692	T/G	cg17063962	chr7:91808500	NA	0.88	9.65	0.66	8.73e-17	Breast cancer;
TGCT	cis	rs7584330	0.910	rs66509917	chr2:238395394	T/G	cg08992911	chr2:238395768	MLPH	0.63	5.2	0.42	8.03e-7	Prostate cancer;
TGCT	cis	rs2440129	0.611	rs1042357	chr17:6905061	T/G	cg03404566	chr17:6899310	ALOX12	0.47	5.26	0.43	6.17e-7	Tonsillectomy;
TGCT	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg18876405	chr7:65276391	NA	-0.37	-5.58	-0.45	1.47e-7	Aortic root size;
TGCT	cis	rs12681287	0.752	rs4288357	chr8:87251833	C/T	cg27223183	chr8:87520930	FAM82B	-0.8	-5.67	-0.45	9.58e-8	Caudate activity during reward;
TGCT	cis	rs6547741	1.000	rs6547734	chr2:27830990	G/T	cg27432699	chr2:27873401	GPN1	0.18	4.65	0.38	8.53e-6	Oral cavity cancer;
TGCT	cis	rs782590	0.967	rs11125581	chr2:55796527	C/G	cg18811423	chr2:55921094	PNPT1	0.65	6.92	0.53	2.12e-10	Metabolic syndrome;
TGCT	cis	rs12410462	0.502	rs114121935	chr1:227959336	A/G	cg23173402	chr1:227635558	NA	0.7	4.81	0.4	4.31e-6	Major depressive disorder;
TGCT	cis	rs11690935	0.589	rs2271758	chr2:172701157	T/G	cg13550731	chr2:172543902	DYNC1I2	0.72	6.32	0.49	4.2e-9	Schizophrenia;
TGCT	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg17971929	chr21:40555470	PSMG1	-0.68	-5.96	-0.47	2.42e-8	Cognitive function;
TGCT	cis	rs6598955	0.671	rs12354062	chr1:26608761	C/T	cg04990556	chr1:26633338	UBXN11	0.66	5.0	0.41	1.88e-6	Obesity-related traits;
TGCT	cis	rs713587	0.520	rs493090	chr2:25303772	G/A	cg01884057	chr2:25150051	NA	-0.25	-4.64	-0.38	8.56e-6	Body mass index in non-asthmatics;
TGCT	cis	rs7681440	0.904	rs6816736	chr4:90765746	G/A	cg20003494	chr4:90757398	SNCA	-0.62	-5.93	-0.47	2.74e-8	Dementia with Lewy bodies;
TGCT	cis	rs7666738	0.716	rs28792413	chr4:99083707	G/A	cg17366294	chr4:99064904	C4orf37	0.68	6.69	0.51	6.92e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9467773	0.620	rs1027204	chr6:26639613	T/C	cg09904177	chr6:26538194	HMGN4	0.67	6.48	0.5	1.94e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs13108705	chr4:99044438	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs988712	0.705	rs4074134	chr11:27647285	C/T	cg10635145	chr11:27742435	BDNF	-0.38	-5.23	-0.43	7e-7	Obesity;
TGCT	cis	rs67311347	1.000	rs1454497	chr3:40496326	C/T	cg13683864	chr3:40499215	RPL14	1.16	12.09	0.74	1.04e-22	Renal cell carcinoma;
TGCT	cis	rs78487399	0.808	rs6731980	chr2:43703183	T/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-5.45	-0.44	2.63e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs4730250	0.708	rs4730242	chr7:107057373	G/C	cg02696742	chr7:106810147	HBP1	-0.68	-5.44	-0.44	2.69e-7	Osteoarthritis;
TGCT	cis	rs7917772	0.502	rs4919670	chr10:104515799	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.57	-4.73	-0.39	6.01e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9467773	0.804	rs2073526	chr6:26374658	C/T	cg26531700	chr6:26746687	NA	-0.54	-5.2	-0.42	8.06e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9894429	1.000	rs7213129	chr17:79581573	C/T	cg21028142	chr17:79581711	NPLOC4	0.29	6.81	0.52	3.83e-10	Eye color traits;
TGCT	cis	rs1577917	1.000	rs12199784	chr6:86726808	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.22	-0.42	7.27e-7	Response to antipsychotic treatment;
TGCT	cis	rs904251	0.525	rs12200378	chr6:37425304	A/G	cg01843034	chr6:37503916	NA	-0.48	-6.04	-0.48	1.65e-8	Cognitive performance;
TGCT	cis	rs9653442	1.000	rs6712515	chr2:100806514	T/C	cg22139774	chr2:100720529	AFF3	-0.48	-8.71	-0.62	1.57e-14	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs13242816	1.000	rs34424131	chr7:116119002	G/A	cg02799643	chr7:116139180	CAV2	-0.49	-5.61	-0.45	1.27e-7	P wave duration;
TGCT	cis	rs9905704	0.647	rs11079367	chr17:57009024	A/G	cg05425664	chr17:57184151	TRIM37	-0.57	-4.44	-0.37	1.97e-5	Testicular germ cell tumor;
TGCT	cis	rs9486719	0.857	rs11759769	chr6:97065212	G/A	cg06623918	chr6:96969491	KIAA0776	-1.06	-9.8	-0.66	3.95e-17	Migraine;Coronary artery disease;
TGCT	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	5.23	0.43	6.92e-7	Menopause (age at onset);
TGCT	trans	rs7726839	0.540	rs72703092	chr5:599269	G/A	cg25482853	chr8:67687455	SGK3	1.27	10.56	0.69	5.48e-19	Obesity-related traits;
TGCT	cis	rs9303401	0.659	rs61291849	chr17:56909867	T/C	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs1801251	0.778	rs812383	chr2:233737132	C/A	cg25237894	chr2:233734115	C2orf82	-0.31	-5.98	-0.47	2.2e-8	Coronary artery disease;
TGCT	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.53	-5.01	-0.41	1.81e-6	Longevity;Endometriosis;
TGCT	cis	rs3617	0.572	rs2245538	chr3:52852060	T/C	cg11645453	chr3:52864694	ITIH4	0.28	5.45	0.44	2.63e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1129187	0.935	rs9462859	chr6:42946943	G/A	cg02353165	chr6:42928485	GNMT	0.98	10.18	0.67	4.7e-18	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs6540559	0.673	rs11805830	chr1:209984969	C/T	cg04352962	chr1:209979756	IRF6	0.65	4.6	0.38	1.05e-5	Cleft lip with or without cleft palate;
TGCT	cis	rs2692947	0.537	rs4907274	chr2:96363682	G/A	cg23100626	chr2:96804247	ASTL	0.46	5.53	0.44	1.79e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg11764359	chr7:65958608	NA	-0.58	-5.27	-0.43	5.83e-7	Aortic root size;
TGCT	cis	rs916888	0.610	rs199536	chr17:44820425	T/C	cg15921436	chr17:44337874	NA	-0.41	-6.27	-0.49	5.47e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2013441	1.000	rs2526475	chr17:20136216	T/C	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.63	-0.38	9.19e-6	Obesity-related traits;
TGCT	cis	rs2060793	0.741	rs10741653	chr11:14704840	C/A	cg00085434	chr11:14927489	NA	0.34	4.78	0.39	4.8e-6	Vitamin D levels;
TGCT	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg00484396	chr16:3507460	NAT15	0.42	6.36	0.5	3.59e-9	Tuberculosis;
TGCT	cis	rs17376456	0.877	rs34184666	chr5:93444584	T/C	cg21475434	chr5:93447410	FAM172A	0.59	4.66	0.39	8.09e-6	Diabetic retinopathy;
TGCT	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg08859206	chr1:53392774	SCP2	-0.46	-7.42	-0.55	1.64e-11	Monocyte count;
TGCT	cis	rs7267979	1.000	rs2387884	chr20:25379069	C/T	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg21724239	chr8:58056113	NA	0.44	4.81	0.4	4.36e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6671200	0.541	rs7555339	chr1:95691579	G/A	cg20701556	chr1:95698924	RWDD3	-0.53	-5.37	-0.43	3.7e-7	Stearic acid (18:0) levels;
TGCT	cis	rs7681440	0.835	rs6532198	chr4:90798870	C/T	cg26578617	chr4:90757533	SNCA	-0.45	-4.63	-0.38	9.12e-6	Dementia with Lewy bodies;
TGCT	cis	rs17345786	1.000	rs17345528	chr3:101294830	A/C	cg11279151	chr3:101281821	RG9MTD1	0.45	9.64	0.65	9.35e-17	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4919044	0.735	rs835245	chr10:94759873	A/T	cg05127821	chr10:94822908	CYP26C1	-0.57	-4.44	-0.37	1.95e-5	Coronary artery disease;
TGCT	cis	rs7937682	0.924	rs7938360	chr11:111539875	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.14	-12.06	-0.73	1.22e-22	Primary sclerosing cholangitis;
TGCT	cis	rs7698623	0.850	rs4693896	chr4:88797897	T/C	cg02735620	chr4:88950514	PKD2	-0.44	-4.81	-0.4	4.22e-6	Cardiovascular disease risk factors;
TGCT	cis	rs72781680	0.821	rs2176265	chr2:24158638	C/G	cg08917208	chr2:24149416	ATAD2B	0.74	4.66	0.39	7.9e-6	Lymphocyte counts;
TGCT	cis	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg20637647	chr7:64974828	NA	-0.9	-5.31	-0.43	4.87e-7	Diabetic kidney disease;
TGCT	cis	rs7772486	0.875	rs2814874	chr6:146305895	C/T	cg05347473	chr6:146136440	FBXO30	0.55	5.11	0.42	1.2e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6089584	1.000	rs3787425	chr20:60559256	C/T	cg06108461	chr20:60628389	TAF4	-0.57	-8.01	-0.58	7.25e-13	Body mass index;
TGCT	cis	rs7659604	0.539	rs72680779	chr4:122797263	C/T	cg20573242	chr4:122745356	CCNA2	0.6	5.22	0.42	7.17e-7	Type 2 diabetes;
TGCT	cis	rs9905704	0.624	rs8080071	chr17:57093825	C/T	cg12560992	chr17:57184187	TRIM37	-0.62	-5.52	-0.44	1.9e-7	Testicular germ cell tumor;
TGCT	cis	rs4689592	0.523	rs4256224	chr4:7074583	T/C	cg26116260	chr4:7069785	GRPEL1	1.12	10.96	0.7	5.83e-20	Monocyte percentage of white cells;
TGCT	cis	rs425277	0.958	rs262660	chr1:2086757	A/G	cg03732007	chr1:2071316	PRKCZ	0.26	5.52	0.44	1.89e-7	Height;
TGCT	cis	rs1865760	0.593	rs9295678	chr6:25937033	G/A	cg03264133	chr6:25882463	NA	-0.5	-5.2	-0.42	8.12e-7	Height;
TGCT	cis	rs7666738	0.535	rs6850010	chr4:98971601	A/T	cg05340658	chr4:99064831	C4orf37	0.5	5.55	0.45	1.63e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1971762	0.583	rs12810378	chr12:54091838	G/T	cg16917193	chr12:54089295	NA	1.32	17.62	0.85	1.5e-35	Height;
TGCT	cis	rs524023	0.874	rs518053	chr11:64456099	C/T	cg19395706	chr11:64412079	NRXN2	-0.36	-4.44	-0.37	1.96e-5	Urate levels in obese individuals;
TGCT	cis	rs9894429	0.816	rs7406040	chr17:79597583	A/C	cg18240062	chr17:79603768	NPLOC4	0.84	9.67	0.66	8.03e-17	Eye color traits;
TGCT	cis	rs9399135	0.967	rs9376085	chr6:135371224	T/C	cg24558204	chr6:135376177	HBS1L	0.46	4.55	0.38	1.24e-5	Red blood cell count;
TGCT	cis	rs13242816	1.000	rs67982517	chr7:116075363	A/G	cg16553024	chr7:116138462	CAV2	-0.47	-5.25	-0.43	6.52e-7	P wave duration;
TGCT	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.97	7.19	0.54	5.48e-11	Gut microbiome composition (summer);
TGCT	cis	rs854765	0.583	rs11650649	chr17:17790319	C/A	cg09796270	chr17:17721594	SREBF1	-0.27	-5.5	-0.44	2.04e-7	Total body bone mineral density;
TGCT	cis	rs2458413	0.522	rs2514657	chr8:105331215	T/C	cg23108931	chr8:105342351	NA	-0.34	-5.74	-0.46	6.76e-8	Paget's disease;
TGCT	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg13206674	chr6:150067644	NUP43	0.52	4.46	0.37	1.78e-5	Lung cancer;
TGCT	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.36	0.55	2.25e-11	Prudent dietary pattern;
TGCT	cis	rs17401966	0.540	rs4846219	chr1:10463888	C/A	cg19773385	chr1:10388646	KIF1B	-0.23	-5.46	-0.44	2.52e-7	Hepatocellular carcinoma;
TGCT	cis	rs1903068	0.785	rs28584303	chr4:55997622	C/T	cg09978860	chr4:56023921	NA	0.56	6.24	0.49	6.22e-9	Endometriosis;
TGCT	cis	rs11785400	0.612	rs10110864	chr8:143750072	A/G	cg24634471	chr8:143751801	JRK	0.57	5.96	0.47	2.38e-8	Schizophrenia;
TGCT	cis	rs6840360	0.638	rs6816002	chr4:152589439	C/T	cg17479576	chr4:152424074	FAM160A1	-0.61	-6.29	-0.49	4.94e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7044106	0.762	rs10984974	chr9:123421556	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	6.29	0.49	4.98e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs7542091	0.666	rs7537070	chr1:210043565	A/G	cg00989853	chr1:209979345	IRF6	0.43	4.58	0.38	1.12e-5	Monobrow;
TGCT	trans	rs7618501	0.966	rs9882639	chr3:49799475	A/C	cg21659725	chr3:3221576	CRBN	0.98	15.33	0.81	2.1000000000000002e-30	Intelligence (multi-trait analysis);
TGCT	cis	rs12421382	0.511	rs2212430	chr11:109289538	C/T	cg27471124	chr11:109292789	C11orf87	0.48	5.73	0.46	7.32e-8	Schizophrenia;
TGCT	cis	rs10901296	0.660	rs11789055	chr9:133766295	T/C	cg01000188	chr9:133769184	QRFP	0.33	4.46	0.37	1.84e-5	Bilirubin levels;
TGCT	cis	rs7726839	0.540	rs11739847	chr5:609661	G/A	cg09021430	chr5:549028	NA	-0.46	-6.09	-0.48	1.3e-8	Obesity-related traits;
TGCT	cis	rs9291683	1.000	rs9291683	chr4:10324160	C/T	cg00071950	chr4:10020882	SLC2A9	0.46	4.85	0.4	3.6e-6	Bone mineral density;
TGCT	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg25811766	chr13:21894605	NA	0.32	4.53	0.38	1.36e-5	White matter hyperintensity burden;
TGCT	cis	rs735396	0.770	rs2259820	chr12:121435342	C/T	cg15155738	chr12:121454335	C12orf43	0.52	4.56	0.38	1.19e-5	N-glycan levels;
TGCT	cis	rs7647973	0.516	rs12490393	chr3:49196132	C/T	cg06212747	chr3:49208901	KLHDC8B	0.65	6.08	0.48	1.36e-8	Menarche (age at onset);
TGCT	cis	rs2688608	0.620	rs7080350	chr10:75577843	A/G	cg19442545	chr10:75533431	FUT11	0.36	5.87	0.47	3.69e-8	Inflammatory bowel disease;
TGCT	cis	rs67072384	0.892	rs67034709	chr11:72451004	T/C	cg03713592	chr11:72463424	ARAP1	-0.93	-4.66	-0.39	7.89e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs1395	0.778	rs1439767	chr2:27389634	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.66	8.95	0.63	4.24e-15	Blood metabolite levels;
TGCT	cis	rs13217239	0.646	rs62401067	chr6:27018101	T/A	cg05738196	chr6:26577821	NA	0.49	4.71	0.39	6.47e-6	Schizophrenia;
TGCT	cis	rs9467773	0.620	rs9295701	chr6:26627508	T/C	cg05738196	chr6:26577821	NA	0.88	11.22	0.71	1.33e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.61	0.38	9.85e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs4803468	1.000	rs2241708	chr19:41912270	C/T	cg09537434	chr19:41945824	ATP5SL	-0.92	-10.83	-0.7	1.18e-19	Height;
TGCT	cis	rs514406	0.683	rs6588440	chr1:53209587	C/T	cg16325326	chr1:53192061	ZYG11B	-0.9	-13.17	-0.76	2.58e-25	Monocyte count;
TGCT	cis	rs7044106	0.791	rs10818473	chr9:123484155	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	4.96	0.41	2.28e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs9790314	0.934	rs455386	chr3:161102495	A/T	cg03342759	chr3:160939853	NMD3	-0.44	-4.59	-0.38	1.06e-5	Morning vs. evening chronotype;
TGCT	cis	rs78487399	0.908	rs6725688	chr2:43846553	G/T	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.65	4.58	0.38	1.12e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs7611238	0.560	rs10439946	chr3:195080101	T/C	cg27323046	chr3:195102265	ACAP2	0.37	5.01	0.41	1.86e-6	Body mass index;
TGCT	cis	rs72781680	0.898	rs718139	chr2:23975911	G/A	cg08917208	chr2:24149416	ATAD2B	0.95	6.09	0.48	1.28e-8	Lymphocyte counts;
TGCT	cis	rs12477438	0.798	rs13409996	chr2:99575497	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-5.97	-0.47	2.3e-8	Chronic sinus infection;
TGCT	cis	rs210152	0.588	rs210131	chr6:33535466	T/C	cg16739976	chr6:34101401	GRM4	-0.61	-4.95	-0.41	2.4e-6	Schizophrenia;
TGCT	cis	rs9653442	0.545	rs11900482	chr2:100758709	G/C	cg22139774	chr2:100720529	AFF3	-0.36	-5.63	-0.45	1.16e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs2458413	0.500	rs2514665	chr8:105351531	C/T	cg04554929	chr8:105342491	NA	0.5	6.07	0.48	1.42e-8	Paget's disease;
TGCT	cis	rs7617773	0.780	rs79089926	chr3:48348564	A/C	cg11946769	chr3:48343235	NME6	0.82	7.09	0.54	9.1e-11	Coronary artery disease;
TGCT	cis	rs10892173	0.566	rs10892174	chr11:117672565	A/C	cg21640587	chr11:117668038	DSCAML1	0.71	8.27	0.6	1.73e-13	Myopia;
TGCT	cis	rs7085104	0.700	rs10786712	chr10:104596396	A/G	cg05855489	chr10:104503620	C10orf26	-0.54	-4.94	-0.41	2.47e-6	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs12220238	0.915	rs61045754	chr10:76153125	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.88	5.86	0.47	3.87e-8	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs35883536	0.566	rs4908086	chr1:101088124	C/T	cg06223162	chr1:101003688	GPR88	0.33	5.33	0.43	4.55e-7	Monocyte count;
TGCT	cis	rs7216064	1.000	rs11079706	chr17:65835470	G/T	cg12091567	chr17:66097778	LOC651250	-0.83	-6.49	-0.5	1.9e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs7086627	0.515	rs12245180	chr10:82211897	C/G	cg01528321	chr10:82214614	TSPAN14	0.65	6.21	0.49	7.21e-9	Post bronchodilator FEV1;
TGCT	cis	rs2486012	0.649	rs1354261	chr1:44256682	A/C	cg12908607	chr1:44402522	ARTN	-0.69	-5.74	-0.46	7.02e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs36051895	0.554	rs11789744	chr9:5134213	G/A	cg02405213	chr9:5042618	JAK2	-0.71	-9.55	-0.65	1.57e-16	Pediatric autoimmune diseases;
TGCT	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg18538332	chr22:24372958	LOC391322	-1.01	-12.84	-0.76	1.6e-24	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9611565	0.512	rs4512	chr22:42206084	G/C	cg06634786	chr22:41940651	POLR3H	-0.86	-8.01	-0.58	7.16e-13	Vitiligo;
TGCT	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg16325326	chr1:53192061	ZYG11B	0.64	7.11	0.54	8.1e-11	Monocyte count;
TGCT	cis	rs7647973	0.588	rs4855848	chr3:49653457	C/T	cg03060546	chr3:49711283	APEH	0.63	5.63	0.45	1.12e-7	Menarche (age at onset);
TGCT	cis	rs6582630	0.555	rs2004152	chr12:38478951	C/T	cg13010199	chr12:38710504	ALG10B	0.64	5.09	0.42	1.27e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs654950	0.901	rs594656	chr1:41999873	C/T	cg06885757	chr1:42089581	HIVEP3	-0.26	-4.46	-0.37	1.83e-5	Airway imaging phenotypes;
TGCT	cis	rs12477438	0.798	rs1580068	chr2:99649969	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-8.52	-0.61	4.5e-14	Chronic sinus infection;
TGCT	cis	rs2657888	0.628	rs2638335	chr12:56880672	C/T	cg23002907	chr12:56915593	RBMS2	-0.41	-5.41	-0.44	3.15e-7	Adiponectin levels;
TGCT	cis	rs3820068	0.608	rs12734937	chr1:16047726	T/C	cg17385448	chr1:15911702	AGMAT	0.35	4.66	0.39	8.1e-6	Systolic blood pressure;
TGCT	cis	rs6121246	0.529	rs6060145	chr20:30178631	T/C	cg21427119	chr20:30132790	HM13	-0.44	-6.39	-0.5	3.11e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs7681440	0.967	rs920624	chr4:90748195	T/A	cg14346243	chr4:90757452	SNCA	-0.57	-5.55	-0.45	1.64e-7	Dementia with Lewy bodies;
TGCT	cis	rs35306767	0.903	rs12249634	chr10:872744	G/A	cg20503657	chr10:835505	NA	0.7	9.83	0.66	3.22e-17	Eosinophil percentage of granulocytes;
TGCT	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.63	-0.51	9.04e-10	Alzheimer's disease;
TGCT	cis	rs6831352	0.879	rs7434491	chr4:100069847	G/C	cg12011299	chr4:100065546	ADH4	-0.46	-5.22	-0.42	7.38e-7	Alcohol dependence;
TGCT	cis	rs11874712	1.000	rs9783887	chr18:43651272	C/A	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.52	5.0	0.41	1.94e-6	Migraine - clinic-based;
TGCT	cis	rs12908161	0.959	rs34028043	chr15:85231585	G/A	cg17173187	chr15:85201210	NMB	0.59	6.74	0.52	5.44e-10	Schizophrenia;
TGCT	cis	rs9467711	0.606	rs9358930	chr6:26357011	C/T	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2228479	0.850	rs62056103	chr16:89942781	G/A	cg06558623	chr16:89946397	TCF25	0.59	6.73	0.52	5.69e-10	Skin colour saturation;
TGCT	cis	rs2456568	0.900	rs2511373	chr11:93671414	T/C	cg26875233	chr11:93583750	C11orf90	-0.45	-5.61	-0.45	1.28e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs11031096	0.655	rs10835736	chr11:4212013	G/A	cg18678763	chr11:4115507	RRM1	-0.45	-5.77	-0.46	6.11e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	5.71	0.46	8.05e-8	Alzheimer's disease;
TGCT	cis	rs1008375	0.966	rs6833808	chr4:17652526	T/A	cg18681998	chr4:17616180	MED28	1.06	12.42	0.74	1.62e-23	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs526231	0.543	rs183752	chr5:102507812	T/C	cg23492399	chr5:102201601	PAM	-0.51	-4.49	-0.37	1.6e-5	Primary biliary cholangitis;
TGCT	cis	rs7917772	0.503	rs1536308	chr10:104288777	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	8.36	0.6	1.1e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs6500602	0.701	rs8053770	chr16:4539030	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.39	6.9	0.53	2.38e-10	Schizophrenia;
TGCT	cis	rs2486288	0.656	rs11632777	chr15:45551045	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.46	-5.59	-0.45	1.38e-7	Glomerular filtration rate;
TGCT	cis	rs9611519	1.000	rs5751069	chr22:41627775	C/G	cg03806693	chr22:41940476	POLR3H	-0.68	-6.51	-0.5	1.65e-9	Neuroticism;
TGCT	cis	rs3796352	0.667	rs11720228	chr3:52877270	G/A	cg07884673	chr3:53033167	SFMBT1	0.62	5.35	0.43	4.16e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	trans	rs2624839	0.704	rs13064381	chr3:50233317	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.82	7.15	0.54	6.61e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs2299587	0.554	rs2073565	chr8:17743649	T/C	cg01800426	chr8:17659068	MTUS1	-0.55	-4.96	-0.41	2.25e-6	Economic and political preferences;
TGCT	cis	rs6840360	0.642	rs56301462	chr4:152452128	T/G	cg17479576	chr4:152424074	FAM160A1	-0.65	-7.11	-0.54	8.02e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs651907	0.535	rs9830943	chr3:101428899	T/G	cg11279151	chr3:101281821	RG9MTD1	-0.35	-7.36	-0.55	2.23e-11	Colorectal cancer;
TGCT	cis	rs2046867	0.862	rs9827405	chr3:72827115	C/T	cg25664220	chr3:72788482	NA	-0.54	-6.72	-0.52	5.99e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs3733585	0.781	rs4292328	chr4:9970962	C/T	cg11266682	chr4:10021025	SLC2A9	-0.62	-8.62	-0.61	2.56e-14	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs1050631	1.000	rs3110564	chr18:33701589	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	-0.49	-4.78	-0.39	4.85e-6	Esophageal squamous cell cancer (length of survival);
TGCT	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg08280861	chr8:58055591	NA	0.38	4.81	0.4	4.36e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs245880	0.740	rs245897	chr7:29193940	C/T	cg17163760	chr7:29186267	CPVL	0.41	5.18	0.42	8.89e-7	Warfarin maintenance dose;
TGCT	cis	rs11696501	0.688	rs6130897	chr20:44330004	C/T	cg11783356	chr20:44313418	WFDC10B	-0.33	-4.49	-0.37	1.6e-5	Brain structure;
TGCT	cis	rs2688608	0.967	rs2675663	chr10:75660270	T/G	cg23231163	chr10:75533350	FUT11	-0.27	-4.82	-0.4	4.04e-6	Inflammatory bowel disease;
TGCT	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.73	-0.39	5.93e-6	Prudent dietary pattern;
TGCT	cis	rs11122272	0.732	rs999010	chr1:231495316	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.74	-7.08	-0.54	9.42e-11	Hemoglobin concentration;
TGCT	cis	rs9611565	0.512	rs132784	chr22:42052363	G/A	cg06634786	chr22:41940651	POLR3H	0.86	7.82	0.57	1.92e-12	Vitiligo;
TGCT	cis	rs4654899	0.865	rs12130841	chr1:21067051	C/T	cg01072550	chr1:21505969	NA	-0.49	-7.85	-0.58	1.67e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg13695892	chr22:41940480	POLR3H	-0.92	-9.33	-0.64	5.22e-16	Vitiligo;
TGCT	cis	rs35160687	0.901	rs12478653	chr2:86535394	A/C	cg12542933	chr2:85804724	VAMP8	-0.39	-4.76	-0.39	5.26e-6	Night sleep phenotypes;
TGCT	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	8.99	0.63	3.48e-15	Platelet count;
TGCT	cis	rs941408	1.000	rs1736177	chr19:2791624	C/T	cg06609049	chr19:2785107	THOP1	0.77	7.55	0.56	8.09e-12	Total cholesterol levels;
TGCT	cis	rs1062177	1.000	rs2915878	chr5:151149662	A/G	cg12924095	chr5:151150029	G3BP1	0.35	5.07	0.41	1.41e-6	Preschool internalizing problems;
TGCT	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg21951975	chr1:209979733	IRF6	0.71	6.04	0.48	1.7e-8	Cleft lip with or without cleft palate;
TGCT	cis	rs9473924	0.542	rs9463650	chr6:50822081	C/T	cg14470998	chr6:50812995	TFAP2B	1.38	8.58	0.61	3.33e-14	Body mass index;
TGCT	cis	rs9611565	0.513	rs739135	chr22:42090069	A/C	cg17554472	chr22:41940697	POLR3H	0.49	5.22	0.42	7.4e-7	Vitiligo;
TGCT	cis	rs7772486	0.875	rs1331644	chr6:146398660	T/C	cg23711669	chr6:146136114	FBXO30	0.89	9.47	0.65	2.36e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs796364	0.664	rs3106089	chr2:200884615	A/C	cg17644776	chr2:200775616	C2orf69	0.33	5.0	0.41	1.91e-6	Schizophrenia;
TGCT	cis	rs2404602	0.716	rs12438077	chr15:76863601	T/C	cg22467129	chr15:76604101	ETFA	-0.44	-5.05	-0.41	1.51e-6	Blood metabolite levels;
TGCT	cis	rs35306767	0.855	rs34251037	chr10:867884	C/T	cg26597838	chr10:835615	NA	0.8	12.0	0.73	1.67e-22	Eosinophil percentage of granulocytes;
TGCT	cis	rs28595532	0.920	rs114168088	chr4:119772666	G/A	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs10949834	0.793	rs810534	chr7:73505045	A/G	cg07137043	chr7:73588983	EIF4H	0.63	4.61	0.38	1.01e-5	Verbal memory performance (residualized delayed recall change);
TGCT	cis	rs9911578	1.000	rs9897326	chr17:56902297	A/G	cg12560992	chr17:57184187	TRIM37	0.76	9.21	0.64	1.03e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs2797160	1.000	rs78602343	chr6:126019768	T/C	cg05901451	chr6:126070800	HEY2	0.73	6.29	0.49	4.85e-9	Endometrial cancer;
TGCT	cis	rs66731853	0.769	rs477679	chr1:20894618	A/G	cg04087271	chr1:20915334	CDA	0.57	6.89	0.53	2.46e-10	Mean corpuscular volume;
TGCT	cis	rs66561647	0.661	rs890442	chr8:128931207	G/T	cg05480350	chr8:128972681	MIR1205;PVT1	0.22	4.55	0.38	1.27e-5	Hemoglobin concentration;
TGCT	cis	rs7772486	0.875	rs9390372	chr6:146363638	G/C	cg23711669	chr6:146136114	FBXO30	0.87	9.53	0.65	1.75e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs35146811	0.961	rs1880949	chr7:99722266	A/C	cg13334819	chr7:99746414	C7orf59	0.82	7.34	0.55	2.49e-11	Coronary artery disease;
TGCT	cis	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg06636001	chr8:8085503	FLJ10661	0.77	7.37	0.55	2.12e-11	Mood instability;
TGCT	cis	rs12210905	0.688	rs10456051	chr6:27463436	T/C	cg08851530	chr6:28072375	NA	1.34	6.29	0.49	5.02e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	4.96	0.41	2.3e-6	Electroencephalogram traits;
TGCT	cis	rs12579753	0.869	rs12366921	chr12:82223024	G/A	cg07988820	chr12:82153109	PPFIA2	-0.6	-6.48	-0.5	1.91e-9	Resting heart rate;
TGCT	cis	rs3784262	0.669	rs4646597	chr15:58300768	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.42	-6.19	-0.49	8.05e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs9467773	0.549	rs9461273	chr6:26584526	A/G	cg02458000	chr6:26745757	NA	-0.52	-4.85	-0.4	3.62e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.515	rs13142498	chr4:98792443	G/T	cg18180107	chr4:99064573	C4orf37	0.54	4.74	0.39	5.8e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6500602	0.627	rs860891	chr16:4586529	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.41	-7.45	-0.56	1.42e-11	Schizophrenia;
TGCT	cis	rs7528684	0.816	rs1977710	chr1:157693722	A/G	cg17134153	chr1:157670328	FCRL3	-0.26	-4.68	-0.39	7.53e-6	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;
TGCT	cis	rs7731657	0.537	rs10073197	chr5:130373090	C/T	cg08523029	chr5:130500466	HINT1	-0.61	-5.08	-0.42	1.34e-6	Fasting plasma glucose;
TGCT	cis	rs478304	0.754	rs2004649	chr11:65380916	G/A	cg27068330	chr11:65405492	SIPA1	-0.81	-8.01	-0.58	7.19e-13	Acne (severe);
TGCT	cis	rs6988636	1.000	rs16898097	chr8:124195034	G/C	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs806215	0.526	rs62481416	chr7:127478125	C/T	cg11539674	chr7:127291444	SND1	-0.37	-4.73	-0.39	6.02e-6	Type 2 diabetes;
TGCT	cis	rs4268898	0.686	rs2042468	chr2:24398446	A/T	cg02683114	chr2:24398427	C2orf84	0.2	4.91	0.4	2.83e-6	Asthma;
TGCT	cis	rs4319547	0.915	rs7316734	chr12:123117425	A/G	cg23029597	chr12:123009494	RSRC2	-0.3	-4.92	-0.4	2.74e-6	Body mass index;
TGCT	cis	rs16966142	0.786	rs2238533	chr16:89871344	T/C	cg04287289	chr16:89883240	FANCA	0.8	5.03	0.41	1.71e-6	Caffeine consumption;
TGCT	cis	rs74233809	1.000	rs3740390	chr10:104638480	C/T	cg05855489	chr10:104503620	C10orf26	0.86	4.99	0.41	2.02e-6	Birth weight;
TGCT	cis	rs1865760	0.827	rs9295681	chr6:25944117	T/G	cg16482183	chr6:26056742	HIST1H1C	0.53	4.93	0.4	2.57e-6	Height;
TGCT	cis	rs3749237	0.964	rs11717463	chr3:49808981	C/T	cg00174179	chr3:49450293	RHOA;TCTA	0.19	4.6	0.38	1.04e-5	Resting heart rate;
TGCT	cis	rs2204008	0.837	rs7974888	chr12:37945215	A/G	cg13010199	chr12:38710504	ALG10B	0.61	4.91	0.4	2.77e-6	Bladder cancer;
TGCT	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.84	7.5	0.56	1.08e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2469997	0.623	rs2470023	chr8:120362995	T/A	cg00681363	chr8:120844660	TAF2	0.69	4.49	0.37	1.63e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs10927875	0.632	rs1122068	chr1:16127480	G/C	cg21385522	chr1:16154831	NA	-0.96	-15.62	-0.81	4.59e-31	Dilated cardiomyopathy;
TGCT	cis	rs854765	0.693	rs8080061	chr17:17776389	C/T	cg04398451	chr17:18023971	MYO15A	0.28	4.51	0.38	1.49e-5	Total body bone mineral density;
TGCT	cis	rs11085466	1.000	rs11085466	chr19:21751811	G/C	cg02997983	chr19:21646781	NA	-0.62	-4.45	-0.37	1.92e-5	Colorectal or endometrial cancer;
TGCT	cis	rs56235845	0.694	rs9313758	chr5:176773091	T/G	cg17509989	chr5:176798049	RGS14	0.57	7.96	0.58	9.47e-13	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs35146811	0.961	rs11771139	chr7:99736059	C/T	cg13334819	chr7:99746414	C7orf59	-0.83	-7.62	-0.56	5.61e-12	Coronary artery disease;
TGCT	cis	rs62244186	0.715	rs13321717	chr3:44667455	C/A	cg10108389	chr3:44770937	ZNF501	-0.47	-4.69	-0.39	7.03e-6	Depressive symptoms;
TGCT	cis	rs6912958	0.712	rs4498321	chr6:88339251	G/C	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.98	-0.41	2.06e-6	Monocyte percentage of white cells;
TGCT	cis	rs2204008	0.837	rs11168341	chr12:37961951	C/T	cg26384229	chr12:38710491	ALG10B	0.86	7.77	0.57	2.55e-12	Bladder cancer;
TGCT	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg26818010	chr10:134567672	INPP5A	-0.36	-4.69	-0.39	7.12e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs11107903	1.000	rs12817989	chr12:95512389	T/A	cg10621809	chr12:95840313	NA	0.7	4.61	0.38	9.89e-6	Coronary artery disease;
TGCT	cis	rs896854	0.625	rs13281709	chr8:95972819	T/A	cg13393036	chr8:95962371	TP53INP1	-0.63	-8.52	-0.61	4.51e-14	Type 2 diabetes;
TGCT	cis	rs55910451	0.779	rs55837307	chr10:5799144	A/G	cg09234995	chr10:5726438	C10orf18	0.48	4.43	0.37	2.01e-5	Breast cancer;
TGCT	cis	rs2204008	0.777	rs2387813	chr12:38382091	A/C	cg26384229	chr12:38710491	ALG10B	0.81	7.13	0.54	7.23e-11	Bladder cancer;
TGCT	cis	rs7017914	0.967	rs7018381	chr8:71670117	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.53	-4.9	-0.4	2.87e-6	Bone mineral density;
TGCT	cis	rs12497850	0.931	rs7626445	chr3:49114544	C/T	cg07636037	chr3:49044803	WDR6	0.96	10.9	0.7	8.39e-20	Parkinson's disease;
TGCT	cis	rs765787	0.530	rs12905246	chr15:45500841	C/T	cg24006582	chr15:45444508	DUOX1	0.25	5.31	0.43	4.79e-7	Uric acid levels;
TGCT	cis	rs853679	0.546	rs200950	chr6:27835772	A/G	cg01031101	chr6:28227091	NKAPL	-0.49	-4.66	-0.39	8.09e-6	Depression;
TGCT	cis	rs3181245	0.641	rs3756821	chr6:24646821	C/T	cg18428180	chr6:24646492	KIAA0319	0.76	7.07	0.54	1.02e-10	Colorectal or endometrial cancer;
TGCT	cis	rs6546537	0.840	rs34743816	chr2:69813345	A/C	cg10773587	chr2:69614142	GFPT1	-0.75	-6.92	-0.53	2.19e-10	Serum thyroid-stimulating hormone levels;
TGCT	cis	rs2243480	1.000	rs160639	chr7:65579987	C/G	cg18252515	chr7:66147081	NA	-1.24	-8.1	-0.59	4.35e-13	Diabetic kidney disease;
TGCT	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg13342137	chr4:2252803	MXD4	0.16	4.46	0.37	1.79e-5	Obesity-related traits;
TGCT	cis	rs185694	1.000	rs202099	chr13:30896874	C/T	cg07600127	chr13:30881527	KATNAL1	-0.81	-6.53	-0.51	1.53e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
TGCT	cis	rs2862064	1.000	rs1948760	chr5:156442784	T/A	cg12943317	chr5:156479607	HAVCR1	-0.39	-5.25	-0.43	6.27e-7	Platelet count;
TGCT	cis	rs62244186	0.659	rs9873072	chr3:44516496	G/A	cg15687855	chr3:44754131	ZNF502	-0.43	-5.27	-0.43	5.98e-7	Depressive symptoms;
TGCT	cis	rs7267979	1.000	rs2297496	chr20:25295787	T/C	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1215050	0.791	rs1215055	chr4:98865454	C/T	cg05340658	chr4:99064831	C4orf37	-0.47	-5.9	-0.47	3.18e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9911578	1.000	rs12449365	chr17:56600660	C/G	cg12560992	chr17:57184187	TRIM37	-0.76	-9.34	-0.64	4.88e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs7617480	0.648	rs10865953	chr3:48759562	C/T	cg07636037	chr3:49044803	WDR6	0.75	6.03	0.48	1.76e-8	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs9928842	0.712	rs10871304	chr16:75223491	G/T	cg09066997	chr16:75300724	BCAR1	0.24	4.56	0.38	1.22e-5	Alcoholic chronic pancreatitis;
TGCT	cis	rs6665290	0.935	rs6693535	chr1:227197685	G/A	cg10327440	chr1:227177885	CDC42BPA	-0.99	-20.13	-0.88	6.85e-41	Myeloid white cell count;
TGCT	cis	rs12048904	0.647	rs7528268	chr1:101329295	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.84	8.12	0.59	3.9e-13	Multiple sclerosis;
TGCT	cis	rs17345786	0.861	rs79181492	chr3:101216021	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.84	8.92	0.63	5.05e-15	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12286929	0.607	rs10891808	chr11:115071301	T/C	cg04017736	chr11:115827165	NA	0.18	4.48	0.37	1.7e-5	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg22968622	chr17:43663579	NA	1.3	11.87	0.73	3.46e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs34638657	0.732	rs12597534	chr16:82200276	G/T	cg09439754	chr16:82129088	HSD17B2	-0.25	-4.75	-0.39	5.63e-6	Lung adenocarcinoma;
TGCT	cis	rs524281	0.861	rs2177053	chr11:65966145	A/C	cg00563793	chr11:65837595	PACS1	0.53	4.67	0.39	7.6e-6	Electroencephalogram traits;
TGCT	cis	rs7666738	0.830	rs28615340	chr4:98896922	T/C	cg05340658	chr4:99064831	C4orf37	0.51	5.93	0.47	2.84e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg04632378	chr13:21900426	NA	0.4	4.92	0.4	2.68e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	cis	rs114540395	0.925	rs76197608	chr10:103392896	T/C	cg03300883	chr10:102748874	C10orf2	0.42	4.63	0.38	9.24e-6	Schizophrenia;
TGCT	cis	rs1023500	0.505	rs134899	chr22:42683030	T/G	cg15557168	chr22:42548783	NA	-0.2	-4.79	-0.4	4.6e-6	Schizophrenia;
TGCT	cis	rs57590327	0.583	rs13062245	chr3:81833718	G/T	cg07356753	chr3:81810745	GBE1	-0.73	-6.73	-0.52	5.57e-10	Extraversion;
TGCT	cis	rs11148252	0.574	rs7139495	chr13:53283318	A/G	cg00495681	chr13:53174319	NA	0.62	6.27	0.49	5.35e-9	Lewy body disease;
TGCT	cis	rs10883723	0.810	rs2281879	chr10:104268877	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	9.06	0.63	2.36e-15	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs17152411	0.793	rs12569669	chr10:126592671	A/G	cg07906193	chr10:126599966	NA	0.42	5.16	0.42	9.36e-7	Height;
TGCT	cis	rs7267979	0.932	rs6037125	chr20:25463382	G/A	cg14121845	chr20:25566513	NINL	0.49	5.36	0.43	3.83e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2486012	1.000	rs61770291	chr1:44383123	A/G	cg12908607	chr1:44402522	ARTN	0.71	5.86	0.47	3.87e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7267979	0.816	rs6037158	chr20:25595466	C/A	cg14121845	chr20:25566513	NINL	0.45	4.69	0.39	7.14e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6840360	0.967	rs6535812	chr4:152599374	C/A	cg17479576	chr4:152424074	FAM160A1	-0.5	-5.4	-0.44	3.26e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg12963246	chr6:28129442	ZNF389	0.52	5.1	0.42	1.23e-6	Depression;
TGCT	cis	rs3892630	0.588	rs8106748	chr19:33282797	G/A	cg22980127	chr19:33182716	NUDT19	0.74	6.09	0.48	1.3e-8	Red blood cell traits;
TGCT	cis	rs62244186	0.659	rs7649834	chr3:44503732	C/T	cg02073558	chr3:44770973	ZNF501	0.58	5.68	0.45	8.89e-8	Depressive symptoms;
TGCT	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg11644478	chr21:40555479	PSMG1	1.03	11.12	0.71	2.32e-20	Cognitive function;
TGCT	cis	rs2354432	0.882	rs11576360	chr1:146740576	G/A	cg25205988	chr1:146714368	CHD1L	1.34	10.54	0.69	6.14e-19	Mitochondrial DNA levels;
TGCT	cis	rs1372520	0.684	rs2737010	chr4:90746466	G/A	cg15133208	chr4:90757351	SNCA	-0.5	-5.86	-0.47	4e-8	Neuroticism;
TGCT	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg06753367	chr22:24256600	NA	-0.24	-4.54	-0.38	1.31e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs4975616	0.839	rs2447853	chr5:1333077	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.32	-4.77	-0.39	5.09e-6	Lung cancer;
TGCT	cis	rs7267979	0.873	rs7453	chr20:25207074	A/G	cg14121845	chr20:25566513	NINL	0.47	5.15	0.42	1e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs1496653	0.602	rs13090335	chr3:23463722	A/C	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs2070488	1.000	rs17733640	chr3:38446742	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	9.65	0.65	9.06e-17	Electrocardiographic conduction measures;
TGCT	cis	rs8031584	0.663	rs1917421	chr15:31187663	C/T	cg08109568	chr15:31115862	NA	-0.35	-4.79	-0.4	4.66e-6	Huntington's disease progression;
TGCT	cis	rs514406	0.825	rs12089511	chr1:53436427	A/T	cg24675658	chr1:53192096	ZYG11B	0.7	8.03	0.58	6.54e-13	Monocyte count;
TGCT	cis	rs651907	0.557	rs7629753	chr3:101371922	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.89	-11.14	-0.71	2.09e-20	Colorectal cancer;
TGCT	cis	rs4973397	0.883	rs4973392	chr2:232286552	G/A	cg09339159	chr2:232260559	B3GNT7	0.55	4.54	0.38	1.3e-5	Anti-saccade response;
TGCT	cis	rs7191700	0.511	rs8043625	chr16:11361895	C/G	cg00044050	chr16:11439710	C16orf75	-0.81	-8.38	-0.6	9.95e-14	Multiple sclerosis;
TGCT	cis	rs72615157	0.645	rs76281814	chr7:99846414	T/C	cg00814883	chr7:100076585	TSC22D4	-0.59	-5.7	-0.46	8.45e-8	Lung function (FEV1/FVC);
TGCT	cis	rs7666738	0.830	rs9884501	chr4:98893721	A/C	cg05340658	chr4:99064831	C4orf37	0.52	6.02	0.48	1.81e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs73001065	0.818	rs58847337	chr19:19726022	G/A	cg03709012	chr19:19516395	GATAD2A	1.08	5.32	0.43	4.76e-7	LDL cholesterol;
TGCT	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg00080972	chr5:178986291	RUFY1	0.46	5.59	0.45	1.36e-7	Lung cancer;
TGCT	cis	rs7267979	0.586	rs6050439	chr20:25192331	T/C	cg14121845	chr20:25566513	NINL	0.45	4.86	0.4	3.51e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.58	4.69	0.39	7.01e-6	Renal function-related traits (BUN);
TGCT	cis	rs2404602	0.716	rs12441247	chr15:76812316	T/C	cg22467129	chr15:76604101	ETFA	-0.56	-6.65	-0.51	8.35e-10	Blood metabolite levels;
TGCT	cis	rs149866169	1	rs149866169	chr6:27441723	T/A	cg08798685	chr6:27730294	NA	-0.38	-4.57	-0.38	1.15e-5	Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Subjective well-being (multi-trait analysis);Lung cancer;Squamous cell lung carcinoma;
TGCT	trans	rs208520	0.690	rs12213581	chr6:66735818	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	11.06	0.7	3.28e-20	Exhaled nitric oxide output;
TGCT	cis	rs9549367	0.756	rs3861723	chr13:113910926	A/G	cg18105134	chr13:113819100	PROZ	-0.31	-5.42	-0.44	3.01e-7	Platelet distribution width;
TGCT	cis	rs763121	0.853	rs7289577	chr22:39042214	C/G	cg06022373	chr22:39101656	GTPBP1	0.77	7.46	0.56	1.35e-11	Menopause (age at onset);
TGCT	cis	rs72945132	0.882	rs7116059	chr11:70159690	G/T	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs950776	0.790	rs2067808	chr15:78911780	G/A	cg06917634	chr15:78832804	PSMA4	0.65	5.03	0.41	1.68e-6	Sudden cardiac arrest;
TGCT	cis	rs2274459	0.500	rs34517899	chr6:33635309	C/G	cg00898486	chr6:34006557	GRM4	0.32	4.96	0.41	2.31e-6	Obesity (extreme);
TGCT	cis	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg08045932	chr20:61659980	NA	0.48	9.16	0.64	1.36e-15	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2239547	0.657	rs4687672	chr3:52880543	G/A	cg10802521	chr3:52805072	NEK4	-0.65	-6.12	-0.48	1.16e-8	Schizophrenia;
TGCT	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg00908189	chr16:619842	PIGQ	0.86	10.29	0.68	2.54e-18	Height;
TGCT	cis	rs7267979	0.528	rs34485039	chr20:25583763	G/T	cg03522245	chr20:25566470	NINL	-0.44	-4.57	-0.38	1.18e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9467773	0.935	rs11752946	chr6:26560364	C/A	cg15659132	chr6:26577336	NA	0.86	11.69	0.72	9.65e-22	Intelligence (multi-trait analysis);
TGCT	cis	rs7027203	1.000	rs7856374	chr9:96529791	G/A	cg14396892	chr9:96623032	NA	0.23	4.54	0.38	1.33e-5	DNA methylation (variation);
TGCT	cis	rs10744422	0.920	rs10773657	chr12:123327900	C/A	cg25930673	chr12:123319894	HIP1R	-0.85	-5.01	-0.41	1.86e-6	Schizophrenia;
TGCT	cis	rs546131	0.642	rs2915186	chr11:34851183	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.52	4.5	0.37	1.52e-5	Lung disease severity in cystic fibrosis;
TGCT	cis	rs950027	0.620	rs1145077	chr15:45683795	A/C	cg14582100	chr15:45693742	SPATA5L1	-0.48	-5.86	-0.47	3.88e-8	Response to fenofibrate (adiponectin levels);
TGCT	trans	rs208515	0.556	rs1872309	chr6:66660432	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.77	7.97	0.58	9.03e-13	Exhaled nitric oxide levels;
TGCT	cis	rs7666738	0.680	rs11726233	chr4:99079773	G/A	cg05340658	chr4:99064831	C4orf37	0.49	5.37	0.43	3.81e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg13699009	chr12:122356056	WDR66	0.29	5.72	0.46	7.44e-8	Mean corpuscular volume;
TGCT	trans	rs751984	0.706	rs3802951	chr11:61273700	T/C	cg03305746	chr2:106927199	NA	-0.58	-6.8	-0.52	3.93e-10	Diastolic blood pressure;Systolic blood pressure;Mean arterial pressure;
TGCT	cis	rs9650657	0.513	rs4841459	chr8:10782442	A/C	cg27411982	chr8:10470053	RP1L1	-0.23	-4.86	-0.4	3.47e-6	Neuroticism;
TGCT	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg18230493	chr5:56204884	C5orf35	0.72	5.56	0.45	1.59e-7	Initial pursuit acceleration;
TGCT	cis	rs2777491	0.574	rs2730056	chr15:41735785	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.93	-17.17	-0.84	1.44e-34	Ulcerative colitis;
TGCT	cis	rs2239547	0.522	rs9846976	chr3:53007995	T/C	cg10802521	chr3:52805072	NEK4	-0.6	-5.43	-0.44	2.88e-7	Schizophrenia;
TGCT	cis	rs9534288	0.577	rs2897029	chr13:46682821	T/C	cg15192986	chr13:46630673	CPB2	-0.51	-6.11	-0.48	1.17e-8	Blood protein levels;
TGCT	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg12963246	chr6:28129442	ZNF389	0.51	5.02	0.41	1.73e-6	Depression;
TGCT	cis	rs9911578	1.000	rs2531729	chr17:56539890	C/T	cg12560992	chr17:57184187	TRIM37	0.76	9.28	0.64	7.12e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs1784581	0.674	rs1784592	chr6:162387365	T/A	cg17173639	chr6:162384350	PARK2	-0.47	-8.16	-0.59	3.15e-13	Itch intensity from mosquito bite;
TGCT	cis	rs245880	0.740	rs245885	chr7:29188554	A/G	cg17163760	chr7:29186267	CPVL	-0.44	-5.54	-0.45	1.73e-7	Warfarin maintenance dose;
TGCT	cis	rs6669919	0.570	rs34293509	chr1:211690673	C/A	cg25617285	chr1:211431773	RCOR3	-0.39	-4.44	-0.37	1.93e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs11644362	1.000	rs12918494	chr16:12988455	C/T	cg06890432	chr16:12997467	SHISA9	-0.61	-6.7	-0.52	6.46e-10	Positive affect;Subjective well-being;
TGCT	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg02725872	chr8:58115012	NA	-0.38	-5.16	-0.42	9.32e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs782590	0.537	rs12619903	chr2:55884106	T/A	cg18811423	chr2:55921094	PNPT1	-0.62	-5.23	-0.43	6.84e-7	Metabolic syndrome;
TGCT	cis	rs6748734	1.000	rs6748734	chr2:241837452	A/G	cg04034577	chr2:241836375	C2orf54	-0.4	-6.27	-0.49	5.35e-9	Urinary metabolites;
TGCT	cis	rs35883536	0.588	rs72977389	chr1:101107053	A/C	cg06223162	chr1:101003688	GPR88	0.34	5.67	0.45	9.44e-8	Monocyte count;
TGCT	cis	rs12615966	0.651	rs58796108	chr2:105408088	T/A	cg16465502	chr2:105461796	NA	0.85	5.6	0.45	1.34e-7	Pancreatic cancer;
TGCT	cis	rs56036086	0.887	rs73187244	chr22:50625271	T/C	cg01548456	chr22:50352384	NA	0.36	5.16	0.42	9.67e-7	Platelet count;Plateletcrit;
TGCT	cis	rs6969780	1.000	rs6969780	chr7:27159136	G/C	cg04321618	chr7:27170880	HOXA4	0.55	4.9	0.4	2.97e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs5769707	0.609	rs2007024	chr22:49988815	C/T	cg05373962	chr22:49881684	NA	-0.29	-5.12	-0.42	1.13e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg09359103	chr1:154839909	KCNN3	-0.66	-12.15	-0.74	7.27e-23	Prostate cancer;
TGCT	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg03351412	chr1:154909251	PMVK	0.52	4.92	0.4	2.66e-6	Prostate cancer;
TGCT	cis	rs6089584	1.000	rs6089581	chr20:60562394	G/A	cg16423285	chr20:60520624	NA	-0.52	-5.45	-0.44	2.6e-7	Body mass index;
TGCT	cis	rs6424115	1.000	rs6424115	chr1:24153231	A/G	cg15997130	chr1:24165203	NA	-0.9	-10.23	-0.68	3.51e-18	Immature fraction of reticulocytes;
TGCT	cis	rs9486715	0.867	rs9373887	chr6:96957004	C/T	cg06623918	chr6:96969491	KIAA0776	1.1	15.44	0.81	1.17e-30	Headache;
TGCT	cis	rs896854	0.715	rs12548874	chr8:95935164	A/C	cg13393036	chr8:95962371	TP53INP1	0.6	7.7	0.57	3.67e-12	Type 2 diabetes;
TGCT	cis	rs7312933	0.618	rs12366848	chr12:42682215	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.57	5.4	0.44	3.2e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs10493773	1.000	rs3767163	chr1:86121895	T/G	cg17807903	chr1:86174739	ZNHIT6	-0.37	-4.69	-0.39	7.01e-6	Urate levels in overweight individuals;
TGCT	cis	rs2070488	0.804	rs7372452	chr3:38444298	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.77	7.49	0.56	1.12e-11	Electrocardiographic conduction measures;
TGCT	cis	rs514406	0.505	rs387436	chr1:53179376	C/T	cg16325326	chr1:53192061	ZYG11B	-0.85	-12.13	-0.74	8.13e-23	Monocyte count;
TGCT	cis	rs13242816	1.000	rs35538349	chr7:116117896	C/T	cg02799643	chr7:116139180	CAV2	-0.49	-5.61	-0.45	1.27e-7	P wave duration;
TGCT	cis	rs7772486	0.806	rs7740785	chr6:146171299	C/A	cg05347473	chr6:146136440	FBXO30	0.54	5.09	0.42	1.27e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7769051	1.000	rs12204027	chr6:133122831	A/G	cg07930552	chr6:133119739	C6orf192	0.94	5.04	0.41	1.6e-6	Type 2 diabetes nephropathy;
TGCT	cis	rs910316	1.000	rs12589376	chr14:75561152	C/T	cg11812906	chr14:75593930	NEK9	0.74	7.25	0.55	3.9e-11	Height;
TGCT	cis	rs6558530	0.799	rs62477060	chr8:1706498	A/T	cg09410841	chr8:1729607	CLN8	0.9	10.08	0.67	8.29e-18	Systolic blood pressure;
TGCT	cis	rs6570726	0.935	rs407721	chr6:145871354	A/C	cg05347473	chr6:146136440	FBXO30	0.49	4.54	0.38	1.29e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg13397359	chr6:42928475	GNMT	0.73	6.54	0.51	1.45e-9	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs2180341	0.782	rs6912750	chr6:127723081	A/T	cg27446573	chr6:127587934	RNF146	0.8	7.08	0.54	9.53e-11	Breast cancer;
TGCT	cis	rs2204008	0.630	rs12306932	chr12:38242029	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-4.7	-0.39	6.68e-6	Bladder cancer;
TGCT	cis	rs3782123	1.000	rs3782123	chr11:205198	C/A	cg18336825	chr11:236787	PSMD13;SIRT3	-0.51	-4.65	-0.39	8.41e-6	Glycated hemoglobin levels;Red cell distribution width;
TGCT	cis	rs1023500	0.573	rs2269524	chr22:42475703	T/G	cg15557168	chr22:42548783	NA	0.22	5.58	0.45	1.47e-7	Schizophrenia;
TGCT	cis	rs9303542	0.559	rs1042818	chr17:46620111	T/C	cg25032089	chr17:46643351	HOXB3	0.56	5.27	0.43	5.97e-7	Ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs9291683	0.546	rs13120348	chr4:10053155	C/G	cg00071950	chr4:10020882	SLC2A9	-0.58	-6.53	-0.51	1.52e-9	Bone mineral density;
TGCT	cis	rs826838	1.000	rs860400	chr12:39081279	A/G	cg13010199	chr12:38710504	ALG10B	-0.59	-4.89	-0.4	3e-6	Heart rate;
TGCT	cis	rs9467773	0.620	rs2504566	chr6:26660488	G/C	cg02458000	chr6:26745757	NA	0.51	4.59	0.38	1.08e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs11209002	0.614	rs6670381	chr1:67562106	G/T	cg02640540	chr1:67518911	SLC35D1	0.61	5.09	0.42	1.29e-6	Crohn's disease;
TGCT	trans	rs7726839	0.540	rs72705097	chr5:655067	G/A	cg11887960	chr12:57824829	NA	1.16	9.4	0.65	3.51e-16	Obesity-related traits;
TGCT	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg13683864	chr3:40499215	RPL14	-1.19	-13.2	-0.76	2.17e-25	Renal cell carcinoma;
TGCT	cis	rs7412746	0.611	rs4970931	chr1:150910727	G/A	cg09365446	chr1:150670422	GOLPH3L	0.34	4.71	0.39	6.58e-6	Melanoma;
TGCT	cis	rs2204008	0.657	rs8186888	chr12:38334260	T/G	cg26384229	chr12:38710491	ALG10B	0.61	5.63	0.45	1.15e-7	Bladder cancer;
TGCT	cis	rs1372520	0.684	rs1811442	chr4:90747751	C/T	cg14346243	chr4:90757452	SNCA	-0.67	-5.64	-0.45	1.09e-7	Neuroticism;
TGCT	cis	rs58722170	0.659	rs12023270	chr1:38086578	A/G	cg17933807	chr1:38061675	GNL2	0.85	8.73	0.62	1.42e-14	High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs6500602	0.702	rs1051308	chr16:4560301	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.31	-5.71	-0.46	7.88e-8	Schizophrenia;
TGCT	cis	rs854765	0.565	rs854768	chr17:18018806	T/C	cg04398451	chr17:18023971	MYO15A	-0.39	-6.75	-0.52	5e-10	Total body bone mineral density;
TGCT	cis	rs1801251	1.000	rs1867778	chr2:233679644	C/T	cg25237894	chr2:233734115	C2orf82	-0.3	-5.44	-0.44	2.74e-7	Coronary artery disease;
TGCT	cis	rs6674176	0.660	rs6801	chr1:44396646	C/G	cg12908607	chr1:44402522	ARTN	0.72	9.08	0.63	2.12e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg14983838	chr19:29218262	NA	0.81	7.62	0.56	5.68e-12	Methadone dose in opioid dependence;
TGCT	cis	rs7267979	0.528	rs6076366	chr20:25564626	G/T	cg03522245	chr20:25566470	NINL	-0.44	-4.59	-0.38	1.06e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3749237	0.576	rs4241406	chr3:49600426	C/T	cg02487422	chr3:49467188	NICN1	0.56	5.53	0.44	1.81e-7	Resting heart rate;
TGCT	trans	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg17830980	chr10:43048298	ZNF37B	-0.86	-11.18	-0.71	1.68e-20	Extrinsic epigenetic age acceleration;
TGCT	cis	rs950776	0.620	rs7181405	chr15:78948152	A/G	cg21242079	chr15:79101063	ADAMTS7	-0.3	-4.91	-0.4	2.77e-6	Sudden cardiac arrest;
TGCT	cis	rs79349575	0.756	rs2291726	chr17:47039254	T/C	cg07967210	chr17:47022446	SNF8	-0.44	-5.94	-0.47	2.68e-8	Type 2 diabetes;
TGCT	cis	rs8032315	0.965	rs1894400	chr15:91428955	C/T	cg05211768	chr15:91427848	FES	0.51	5.11	0.42	1.2e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs11648796	0.757	rs6600231	chr16:766485	A/G	cg00908189	chr16:619842	PIGQ	-0.66	-5.41	-0.44	3.14e-7	Height;
TGCT	cis	rs2130392	0.962	rs35613786	chr4:185625657	A/G	cg14471096	chr4:185570637	CCDC111;CASP3	-0.56	-5.06	-0.41	1.49e-6	Kawasaki disease;
TGCT	trans	rs2727020	0.930	rs1164686	chr11:49291822	C/T	cg03929089	chr4:120376271	NA	0.71	7.73	0.57	3.16e-12	Coronary artery disease;
TGCT	cis	rs6988636	0.901	rs16898076	chr8:124187721	T/C	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs1997103	1.000	rs12532070	chr7:55407698	A/G	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs1371867	0.846	rs1660330	chr8:101305015	T/A	cg06002616	chr8:101225028	SPAG1	-0.56	-6.58	-0.51	1.2e-9	Atrioventricular conduction;
TGCT	cis	rs41271951	0.512	rs79122717	chr1:151093526	G/A	cg00666978	chr1:150947442	LASS2	0.89	4.64	0.38	8.54e-6	Blood protein levels;
TGCT	cis	rs9611565	0.649	rs5758442	chr22:42133060	T/C	cg17554472	chr22:41940697	POLR3H	0.43	4.54	0.38	1.31e-5	Vitiligo;
TGCT	cis	rs1971762	0.762	rs7976793	chr12:54073069	G/T	cg22997177	chr12:54070527	ATP5G2	-0.33	-4.47	-0.37	1.76e-5	Height;
TGCT	cis	rs1541995	0.964	rs12917406	chr15:96298442	A/G	cg00882281	chr15:96346592	NA	0.29	4.77	0.39	5.12e-6	Photic sneeze reflex;
TGCT	cis	rs174601	0.861	rs174580	chr11:61606642	A/G	cg01500311	chr11:61656094	FADS3	-0.33	-5.8	-0.46	5.23e-8	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
TGCT	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg06028808	chr11:68637592	NA	0.53	6.87	0.53	2.75e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg06896619	chr17:61851486	DDX42;CCDC47	-0.5	-4.72	-0.39	6.33e-6	Prudent dietary pattern;
TGCT	cis	rs11247915	0.540	rs11582416	chr1:26677721	A/G	cg23732845	chr1:26663426	AIM1L	0.35	4.68	0.39	7.43e-6	Obesity-related traits;
TGCT	cis	rs2486288	0.656	rs11632778	chr15:45551056	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.46	-5.59	-0.45	1.38e-7	Glomerular filtration rate;
TGCT	cis	rs7020830	0.867	rs7852593	chr9:37332380	A/T	cg14294708	chr9:37120828	ZCCHC7	1.24	16.92	0.84	5.14e-34	Schizophrenia;
TGCT	cis	rs62244186	0.627	rs3935212	chr3:44460954	G/A	cg10263370	chr3:44754102	ZNF502	-0.38	-4.58	-0.38	1.1e-5	Depressive symptoms;
TGCT	cis	rs3803170	0.513	rs7299142	chr12:111829513	G/A	cg10833066	chr12:111807467	FAM109A	0.36	5.41	0.44	3.09e-7	Mean corpuscular hemoglobin;
TGCT	cis	rs344364	0.602	rs12719796	chr16:1921197	A/G	cg01422476	chr16:1922425	C16orf73	-0.46	-4.45	-0.37	1.92e-5	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs751728	1.000	rs751728	chr6:33764033	C/T	cg13859433	chr6:33739653	LEMD2	-0.39	-7.1	-0.54	8.43e-11	Crohn's disease;
TGCT	cis	rs3820068	0.705	rs57440988	chr1:15879034	T/C	cg05660106	chr1:15850417	CASP9	1.17	14.8	0.8	3.47e-29	Systolic blood pressure;
TGCT	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	15.79	0.82	1.81e-31	Prudent dietary pattern;
TGCT	cis	rs10028773	0.700	rs7671797	chr4:120248157	A/G	cg09307838	chr4:120376055	NA	0.61	5.92	0.47	3.01e-8	Educational attainment;
TGCT	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg13695892	chr22:41940480	POLR3H	0.93	9.17	0.64	1.31e-15	Vitiligo;
TGCT	cis	rs56399783	0.708	rs56208415	chr7:2813806	G/A	cg19731401	chr7:2775893	GNA12	0.35	4.9	0.4	2.97e-6	Childhood ear infection;
TGCT	cis	rs7226408	0.857	rs56308574	chr18:34586293	C/A	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs6964587	0.692	rs10271430	chr7:91710466	G/C	cg17063962	chr7:91808500	NA	0.74	6.96	0.53	1.75e-10	Breast cancer;
TGCT	cis	rs8031584	0.958	rs7176569	chr15:31244495	G/T	cg08704250	chr15:31115839	NA	0.36	4.96	0.41	2.29e-6	Huntington's disease progression;
TGCT	cis	rs2549003	0.674	rs960757	chr5:131826310	G/A	cg02551604	chr5:131831745	NA	-0.85	-10.74	-0.69	1.98e-19	Asthma (sex interaction);
TGCT	cis	rs986417	0.901	rs12883305	chr14:61006690	A/G	cg27398547	chr14:60952738	C14orf39	1.38	10.8	0.7	1.4e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs9916302	0.861	rs9903363	chr17:37499604	C/G	cg07936489	chr17:37558343	FBXL20	0.65	5.08	0.41	1.36e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs8038465	0.874	rs2291011	chr15:74000839	G/A	cg15420318	chr15:73925796	NPTN	0.57	5.11	0.42	1.17e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs478304	0.654	rs6591187	chr11:65460086	C/G	cg17480646	chr11:65405466	SIPA1	-0.61	-8.27	-0.6	1.79e-13	Acne (severe);
TGCT	cis	rs11170631	0.504	rs12817180	chr12:54035448	A/G	cg16917193	chr12:54089295	NA	1.04	11.51	0.72	2.68e-21	Height;
TGCT	cis	rs79387448	0.810	rs76229479	chr2:103123912	A/C	cg09003973	chr2:102972529	NA	1.02	6.11	0.48	1.19e-8	Gut microbiota (bacterial taxa);
TGCT	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs739496	0.653	rs10744773	chr12:112086810	C/A	cg10833066	chr12:111807467	FAM109A	0.36	5.22	0.42	7.28e-7	Platelet count;
TGCT	cis	rs739496	0.947	rs7299849	chr12:111855461	A/T	cg10833066	chr12:111807467	FAM109A	0.37	5.2	0.42	8.01e-7	Platelet count;
TGCT	cis	rs7666738	0.791	rs2865953	chr4:99040319	C/T	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6701037	0.566	rs729675	chr1:175136946	T/C	cg08873628	chr1:175162347	KIAA0040	0.48	4.57	0.38	1.15e-5	Alcohol dependence;
TGCT	cis	rs16867321	0.671	rs10189871	chr2:181515623	G/T	cg23363182	chr2:181467187	NA	-0.44	-4.59	-0.38	1.09e-5	Obesity;
TGCT	cis	rs7914558	0.933	rs10786729	chr10:104719378	A/G	cg15744005	chr10:104629667	AS3MT	-0.4	-4.99	-0.41	1.97e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs4253772	0.530	rs11704350	chr22:46671507	C/T	cg24881330	chr22:46731750	TRMU	0.92	4.55	0.38	1.27e-5	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs42648	0.748	rs6972119	chr7:89894008	T/C	cg25739043	chr7:89950458	NA	-0.63	-6.12	-0.48	1.16e-8	Homocysteine levels;
TGCT	cis	rs4237845	0.537	rs11172367	chr12:58272486	T/G	cg23860436	chr12:58378763	NA	0.33	4.45	0.37	1.86e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7760949	0.548	rs280151	chr6:13942831	C/G	cg27413430	chr6:13925136	RNF182	-0.56	-4.56	-0.38	1.21e-5	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs7582180	0.715	rs1866198	chr2:100917739	C/A	cg08017756	chr2:100939284	LONRF2	-0.32	-5.31	-0.43	4.89e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1403694	0.695	rs67173199	chr3:186432858	G/A	cg12454167	chr3:186435060	KNG1	0.5	8.56	0.61	3.65e-14	Blood protein levels;
TGCT	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg06028808	chr11:68637592	NA	0.55	7.3	0.55	3.1e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg22920501	chr2:26401640	FAM59B	-0.71	-5.88	-0.47	3.63e-8	Gut microbiome composition (summer);
TGCT	cis	rs3829109	0.504	rs11145890	chr9:139293851	C/G	cg13741927	chr9:139327495	INPP5E	-0.24	-5.18	-0.42	8.84e-7	Peak insulin response;Acute insulin response;
TGCT	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	5.45	0.44	2.66e-7	Height;
TGCT	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg24675658	chr1:53192096	ZYG11B	0.74	8.65	0.61	2.2e-14	Monocyte count;
TGCT	cis	rs12477438	0.798	rs2084987	chr2:99587885	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-5.87	-0.47	3.74e-8	Chronic sinus infection;
TGCT	cis	rs71435601	0.628	rs312979	chr2:21377705	A/T	cg25035485	chr2:21266500	APOB	0.51	4.48	0.37	1.66e-5	Cholesterol, total;
TGCT	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs11098499	0.644	rs7676296	chr4:120555687	A/G	cg09307838	chr4:120376055	NA	0.62	5.86	0.47	3.86e-8	Corneal astigmatism;
TGCT	cis	rs8031584	0.578	rs1088473	chr15:31139298	A/G	cg08704250	chr15:31115839	NA	0.43	6.31	0.49	4.47e-9	Huntington's disease progression;
TGCT	cis	rs7119038	0.774	rs11217038	chr11:118677355	G/A	cg19308663	chr11:118741387	NA	0.31	6.42	0.5	2.65e-9	Sjögren's syndrome;
TGCT	cis	rs614226	0.935	rs3887875	chr12:120895749	A/G	cg10072921	chr12:121022843	NA	0.45	4.69	0.39	7.09e-6	Type 1 diabetes nephropathy;
TGCT	trans	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg23505145	chr19:12996616	KLF1	0.79	8.3	0.6	1.47e-13	Prostate cancer (SNP x SNP interaction);
TGCT	trans	rs62103177	0.810	rs62096746	chr18:77619556	T/A	cg05926928	chr17:57297772	GDPD1	1.22	11.16	0.71	1.85e-20	Opioid sensitivity;
TGCT	cis	rs80262450	1	rs80262450	chr18:12818922	G/A	cg23598886	chr18:12777645	NA	-0.61	-4.5	-0.37	1.52e-5	Inflammatory bowel disease;Crohn's disease;
TGCT	trans	rs2727020	0.658	rs1851992	chr11:49438110	C/T	cg03929089	chr4:120376271	NA	-0.74	-8.55	-0.61	3.78e-14	Coronary artery disease;
TGCT	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg06238570	chr21:40685208	BRWD1	-0.6	-6.22	-0.49	6.89e-9	Menarche (age at onset);
TGCT	cis	rs2204008	0.818	rs1589389	chr12:38416041	G/A	cg13010199	chr12:38710504	ALG10B	-0.55	-4.47	-0.37	1.76e-5	Bladder cancer;
TGCT	cis	rs2229238	0.868	rs12408461	chr1:154512710	T/C	cg13067139	chr1:155221277	FAM189B	0.2	4.46	0.37	1.85e-5	Coronary heart disease;
TGCT	cis	rs12681287	0.640	rs13253515	chr8:87458596	T/A	cg27223183	chr8:87520930	FAM82B	-0.89	-6.43	-0.5	2.54e-9	Caudate activity during reward;
TGCT	cis	rs4077468	1.000	rs11801695	chr1:205916175	A/C	cg14982357	chr1:205744203	RAB7L1	0.44	4.45	0.37	1.91e-5	Cystic fibrosis-related diabetes;
TGCT	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg08219700	chr8:58056026	NA	0.39	4.73	0.39	5.99e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6545883	0.831	rs2592356	chr2:61810428	G/C	cg15711740	chr2:61764176	XPO1	-0.6	-5.76	-0.46	6.27e-8	Tuberculosis;
TGCT	cis	rs9467711	0.524	rs13216484	chr6:26762087	C/T	cg16898833	chr6:26189333	HIST1H4D	1.27	6.03	0.48	1.76e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs453301	0.506	rs686189	chr8:8623637	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-4.51	-0.38	1.46e-5	Joint mobility (Beighton score);
TGCT	cis	rs137603	0.901	rs137612	chr22:39698010	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	-0.54	-5.1	-0.42	1.26e-6	Primary biliary cholangitis;
TGCT	cis	rs11098499	0.863	rs13134665	chr4:120426430	T/C	cg09307838	chr4:120376055	NA	0.68	6.45	0.5	2.28e-9	Corneal astigmatism;
TGCT	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg11644478	chr21:40555479	PSMG1	-0.63	-5.92	-0.47	2.93e-8	Cognitive function;
TGCT	cis	rs11785400	0.793	rs4301430	chr8:143737416	A/G	cg24634471	chr8:143751801	JRK	0.54	5.44	0.44	2.77e-7	Schizophrenia;
TGCT	cis	rs8180040	0.701	rs62248439	chr3:46996448	A/G	cg27129171	chr3:47204927	SETD2	-0.71	-8.9	-0.62	5.58e-15	Colorectal cancer;
TGCT	cis	rs4629710	0.568	rs67021539	chr6:131552900	A/G	cg12606694	chr6:131520996	AKAP7	0.39	4.57	0.38	1.17e-5	Multiple myeloma (IgH translocation);
TGCT	cis	rs9291683	1.000	rs9291683	chr4:10324160	C/T	cg11266682	chr4:10021025	SLC2A9	0.48	5.65	0.45	1.04e-7	Bone mineral density;
TGCT	cis	rs9467773	0.620	rs2498351	chr6:26659642	C/T	cg09904177	chr6:26538194	HMGN4	0.68	6.27	0.49	5.41e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg27286337	chr10:134555280	INPP5A	0.46	5.55	0.45	1.62e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs9910055	0.529	rs228767	chr17:42188311	C/G	cg13607699	chr17:42295918	UBTF	-0.66	-5.46	-0.44	2.51e-7	Total body bone mineral density;
TGCT	cis	rs7474896	0.583	rs10740950	chr10:38003496	C/T	cg13720705	chr10:37990370	NA	0.34	4.9	0.4	2.9e-6	Obesity (extreme);
TGCT	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.75	5.41	0.44	3.09e-7	Platelet count;
TGCT	cis	rs6840360	0.642	rs28666858	chr4:152416382	T/C	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.82e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg03732007	chr1:2071316	PRKCZ	-0.25	-5.73	-0.46	7.25e-8	Height;
TGCT	cis	rs350251	0.868	rs350232	chr16:12190947	G/C	cg02910054	chr16:12241554	SNX29	0.37	4.74	0.39	5.66e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs3784262	0.904	rs4646616	chr15:58261349	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.5	-7.78	-0.57	2.39e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs6088580	0.634	rs6120642	chr20:33012531	A/G	cg08999081	chr20:33150536	PIGU	0.29	5.67	0.45	9.68e-8	Glomerular filtration rate (creatinine);
TGCT	cis	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg20637647	chr7:64974828	NA	0.94	5.17	0.42	9.06e-7	Diabetic kidney disease;
TGCT	cis	rs6835098	1.000	rs10031414	chr4:174084953	A/C	cg08422745	chr4:174089978	GALNT7	-0.94	-11.2	-0.71	1.48e-20	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg06112835	chr11:68658793	MRPL21	0.46	8.12	0.59	3.91e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	trans	rs3780486	0.846	rs7864705	chr9:33140352	A/C	cg20290983	chr6:43655470	MRPS18A	1.19	14.6	0.8	1.02e-28	IgG glycosylation;
TGCT	cis	rs2242194	0.816	rs2242193	chr1:154995503	A/G	cg06221963	chr1:154839813	KCNN3	0.48	5.97	0.47	2.33e-8	Schizophrenia;
TGCT	cis	rs1008375	1.000	rs55939327	chr4:17642937	T/A	cg16339924	chr4:17578868	LAP3	0.63	5.33	0.43	4.49e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2120019	0.938	rs59094290	chr15:75308561	G/T	cg09165964	chr15:75287851	SCAMP5	-1.17	-10.03	-0.67	1.05e-17	Blood trace element (Zn levels);
TGCT	cis	rs9303542	0.625	rs7222242	chr17:46565486	C/A	cg25032089	chr17:46643351	HOXB3	0.58	5.96	0.47	2.45e-8	Ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs3027009	0.881	rs56184975	chr1:159149253	G/T	cg27303699	chr1:158224869	CD1A	-0.4	-4.59	-0.38	1.07e-5	Lean body mass and age at menarche (combined);
TGCT	cis	rs586688	0.625	rs601757	chr1:201657508	A/G	cg07139329	chr1:201708558	NAV1	-0.48	-5.18	-0.42	8.83e-7	Obesity-related traits;
TGCT	cis	rs58788809	1	rs58788809	chr9:5038596	ATTT/A	cg02405213	chr9:5042618	JAK2	-0.57	-7.2	-0.54	5.12e-11	Platelet count;
TGCT	cis	rs7727544	0.684	rs274561	chr5:131719228	A/C	cg24060327	chr5:131705240	SLC22A5	-0.61	-6.68	-0.51	7.09e-10	Blood metabolite levels;
TGCT	cis	rs7027203	0.759	rs10761282	chr9:96586175	G/A	cg14396892	chr9:96623032	NA	-0.29	-5.97	-0.47	2.3e-8	DNA methylation (variation);
TGCT	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg00343986	chr7:65444356	GUSB	0.26	5.95	0.47	2.56e-8	Calcium levels;
TGCT	cis	rs7752195	0.643	rs116090114	chr6:25257785	C/T	cg16898833	chr6:26189333	HIST1H4D	0.99	4.81	0.4	4.21e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs77669868	0.929	rs3782004	chr11:114070250	T/C	cg01914181	chr11:114070210	ZBTB16	0.33	5.73	0.46	7.25e-8	Monocyte percentage of white cells;
TGCT	cis	rs854765	0.624	rs9891957	chr17:17744439	G/A	cg09796270	chr17:17721594	SREBF1	-0.24	-4.49	-0.37	1.59e-5	Total body bone mineral density;
TGCT	cis	rs4076764	0.958	rs6688997	chr1:163411562	G/A	cg24596788	chr1:163392923	NA	-0.17	-4.83	-0.4	3.96e-6	Motion sickness;
TGCT	cis	rs4891159	0.548	rs2554830	chr18:74127702	A/G	cg24786174	chr18:74118243	ZNF516	0.67	13.58	0.77	2.65e-26	Longevity;
TGCT	cis	rs9634489	0.560	rs601674	chr13:97081460	T/G	cg11411106	chr13:97107445	HS6ST3	-0.27	-5.07	-0.41	1.42e-6	Body mass index;
TGCT	cis	rs9902453	0.791	rs2729451	chr17:28131334	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-7.18	-0.54	5.76e-11	Coffee consumption (cups per day);
TGCT	cis	rs2760061	0.819	rs3094913	chr1:228206980	T/C	cg02753203	chr1:228287806	NA	0.3	5.71	0.46	8.06e-8	Diastolic blood pressure;
TGCT	trans	rs208520	0.690	rs207081	chr6:66773742	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-11.08	-0.71	3.01e-20	Exhaled nitric oxide output;
TGCT	cis	rs75686122	0.892	rs1895899	chr8:104602625	G/T	cg04852977	chr8:104510831	NA	0.59	4.45	0.37	1.92e-5	Cocaine dependence;
TGCT	cis	rs7100689	0.784	rs7081903	chr10:82162509	T/C	cg01528321	chr10:82214614	TSPAN14	0.87	8.71	0.62	1.62e-14	Post bronchodilator FEV1;
TGCT	cis	rs7412746	0.634	rs72704658	chr1:150833010	T/C	cg04414720	chr1:150670196	GOLPH3L	0.39	4.83	0.4	3.97e-6	Melanoma;
TGCT	cis	rs3820068	0.581	rs56128111	chr1:15928948	T/G	cg05660106	chr1:15850417	CASP9	0.82	8.02	0.58	6.63e-13	Systolic blood pressure;
TGCT	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	7.12	0.54	7.55e-11	Platelet count;
TGCT	cis	rs2153535	0.580	rs1414345	chr6:8471537	T/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs1062177	0.950	rs892005	chr5:151180621	A/G	cg00977110	chr5:151150581	G3BP1	0.4	4.5	0.38	1.51e-5	Preschool internalizing problems;
TGCT	cis	rs7769051	1.000	rs3813347	chr6:133119778	G/A	cg22852734	chr6:133119734	C6orf192	1.22	6.9	0.53	2.34e-10	Type 2 diabetes nephropathy;
TGCT	cis	rs1580019	0.563	rs34319173	chr7:32585904	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.6	4.97	0.41	2.17e-6	Cognitive ability;
TGCT	cis	rs4722166	0.573	rs35436671	chr7:22775508	G/A	cg26061582	chr7:22766209	IL6	0.59	7.61	0.56	5.85e-12	Lung cancer;
TGCT	cis	rs3808502	0.585	rs4549730	chr8:11239078	T/G	cg21775007	chr8:11205619	TDH	-0.68	-6.6	-0.51	1.08e-9	Neuroticism;
TGCT	cis	rs2153535	0.601	rs9393030	chr6:8516489	C/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.55e-8	Motion sickness;
TGCT	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg18230493	chr5:56204884	C5orf35	-0.68	-5.85	-0.46	4.13e-8	Initial pursuit acceleration;
TGCT	cis	rs8077577	1.000	rs62073605	chr17:18066791	C/T	cg09161412	chr17:18057145	MYO15A	-0.67	-5.44	-0.44	2.69e-7	Obesity-related traits;
TGCT	cis	rs9560113	0.960	rs4773378	chr13:112174154	G/A	cg14154082	chr13:112174009	NA	0.34	4.67	0.39	7.79e-6	Menarche (age at onset);
TGCT	cis	rs2115630	1.000	rs2879828	chr15:85361977	G/T	cg11189052	chr15:85197271	WDR73	-0.63	-6.03	-0.48	1.71e-8	P wave terminal force;
TGCT	cis	rs6582630	0.555	rs11180986	chr12:38264486	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-4.52	-0.38	1.44e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs2795502	1.000	rs3121279	chr10:43378449	T/A	cg20628663	chr10:43360327	NA	0.43	6.2	0.49	7.57e-9	Blood protein levels;
TGCT	cis	rs6545883	0.929	rs2593626	chr2:61665184	C/A	cg15711740	chr2:61764176	XPO1	-0.56	-5.07	-0.41	1.42e-6	Tuberculosis;
TGCT	cis	rs7666738	0.830	rs7679299	chr4:99057620	C/A	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.44e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg05368731	chr17:41323189	NBR1	1.16	14.14	0.79	1.28e-27	Menopause (age at onset);
TGCT	cis	rs2762353	0.935	rs11754288	chr6:25776949	G/A	cg03517284	chr6:25882590	NA	0.5	5.19	0.42	8.42e-7	Blood metabolite levels;
TGCT	cis	rs533581	0.873	rs579740	chr16:88973937	A/G	cg16701003	chr16:89028210	CBFA2T3	-0.39	-5.61	-0.45	1.26e-7	Social autistic-like traits;
TGCT	cis	rs7914558	0.902	rs7092200	chr10:104844872	T/C	cg15744005	chr10:104629667	AS3MT	-0.39	-4.75	-0.39	5.57e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs7617773	0.780	rs4511916	chr3:48350366	G/A	cg11946769	chr3:48343235	NME6	0.82	7.09	0.54	9.1e-11	Coronary artery disease;
TGCT	cis	rs1348850	0.789	rs13027959	chr2:178275887	G/A	cg22681709	chr2:178499509	PDE11A	-0.35	-4.73	-0.39	6.08e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs981844	0.714	rs6822142	chr4:154683524	C/T	cg14289246	chr4:154710475	SFRP2	-0.89	-8.19	-0.59	2.73e-13	Response to statins (LDL cholesterol change);
TGCT	cis	rs7511006	1.000	rs7290710	chr22:50677454	C/T	cg16473166	chr22:50639996	SELO	0.61	5.95	0.47	2.51e-8	Obesity-related traits;
TGCT	cis	rs10504229	0.906	rs2270608	chr8:58194688	T/C	cg22535103	chr8:58192502	C8orf71	-0.39	-4.5	-0.37	1.54e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs950169	0.840	rs2896002	chr15:84945121	A/G	cg17173187	chr15:85201210	NMB	0.58	5.93	0.47	2.77e-8	Schizophrenia;
TGCT	cis	rs6426558	0.559	rs7549520	chr1:227258858	G/C	cg10327440	chr1:227177885	CDC42BPA	0.61	7.41	0.55	1.72e-11	Neutrophil percentage of white cells;
TGCT	cis	rs35306767	0.903	rs11253492	chr10:936873	T/C	cg20503657	chr10:835505	NA	0.74	10.3	0.68	2.41e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.57	-5.67	-0.45	9.59e-8	Electroencephalogram traits;
TGCT	cis	rs7017914	0.905	rs3098879	chr8:71938460	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-4.97	-0.41	2.16e-6	Bone mineral density;
TGCT	cis	rs2455799	0.613	rs2345736	chr3:15824860	T/G	cg16303742	chr3:15540471	COLQ	-0.24	-4.56	-0.38	1.21e-5	Mean platelet volume;
TGCT	cis	rs9611565	0.512	rs9607841	chr22:42186838	G/A	cg03806693	chr22:41940476	POLR3H	-1.01	-10.3	-0.68	2.33e-18	Vitiligo;
TGCT	cis	rs986417	0.901	rs4640083	chr14:61097779	G/A	cg27398547	chr14:60952738	C14orf39	1.56	8.73	0.62	1.45e-14	Gut microbiota (bacterial taxa);
TGCT	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs3087591	1.000	rs2905870	chr17:29521833	G/A	cg24425628	chr17:29625626	OMG;NF1	0.46	7.04	0.53	1.17e-10	Hip circumference;
TGCT	cis	rs9913156	0.515	rs11658808	chr17:4577112	C/T	cg19197139	chr17:4613644	ARRB2	-0.68	-6.7	-0.52	6.62e-10	Lymphocyte counts;
TGCT	cis	rs7809950	0.834	rs2712199	chr7:107140239	A/G	cg23024343	chr7:107201750	COG5	-0.36	-5.51	-0.44	1.97e-7	Coronary artery disease;
TGCT	cis	rs6988636	1.000	rs58741168	chr8:124191852	G/A	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs1577917	1.000	rs1337850	chr6:86729103	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.13	-0.42	1.07e-6	Response to antipsychotic treatment;
TGCT	cis	rs6835098	0.923	rs9997477	chr4:174112543	C/T	cg08422745	chr4:174089978	GALNT7	-0.93	-10.96	-0.7	5.82e-20	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs7567389	0.704	rs4662714	chr2:127995213	A/G	cg09760422	chr2:128146352	NA	-0.35	-4.43	-0.37	2.01e-5	Self-rated health;
TGCT	cis	rs7769051	1.000	rs58832890	chr6:133127139	C/T	cg22852734	chr6:133119734	C6orf192	1.23	6.98	0.53	1.58e-10	Type 2 diabetes nephropathy;
TGCT	cis	rs6598955	0.670	rs12733645	chr1:26540356	G/T	cg01614726	chr1:26633154	UBXN11	0.49	4.69	0.39	7.09e-6	Obesity-related traits;
TGCT	cis	rs9640161	0.789	rs1047207	chr7:150037660	A/G	cg17279839	chr7:150038598	RARRES2	0.45	4.84	0.4	3.81e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs6071524	0.508	rs2247983	chr20:37397909	C/T	cg09937324	chr20:37376998	ACTR5	-0.58	-4.56	-0.38	1.19e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12477438	0.520	rs11123764	chr2:99750677	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	16.87	0.83	6.81e-34	Chronic sinus infection;
TGCT	cis	rs12477438	0.735	rs12474477	chr2:99690408	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-6.09	-0.48	1.32e-8	Chronic sinus infection;
TGCT	cis	rs7611238	0.538	rs6806763	chr3:195109760	A/C	cg27323046	chr3:195102265	ACAP2	0.37	4.93	0.4	2.56e-6	Body mass index;
TGCT	cis	rs9517320	0.534	rs3858776	chr13:99161457	C/T	cg07423050	chr13:99094983	FARP1	-0.29	-5.83	-0.46	4.43e-8	Longevity;
TGCT	cis	rs4285028	0.747	rs9820511	chr3:121361345	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.92	-7.3	-0.55	3.03e-11	Multiple sclerosis;
TGCT	cis	rs4689592	0.503	rs2292461	chr4:7058473	C/T	cg02503808	chr4:7069936	GRPEL1	0.88	7.48	0.56	1.2e-11	Monocyte percentage of white cells;
TGCT	cis	rs6666258	0.924	rs12754189	chr1:154812630	T/C	cg06418219	chr1:154948305	SHC1;CKS1B	0.65	5.22	0.42	7.23e-7	Atrial fibrillation;
TGCT	trans	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg25482853	chr8:67687455	SGK3	1.17	11.24	0.71	1.19e-20	Lung disease severity in cystic fibrosis;
TGCT	cis	rs9611519	0.808	rs5751074	chr22:41665722	G/A	cg03806693	chr22:41940476	POLR3H	-0.77	-7.46	-0.56	1.3e-11	Neuroticism;
TGCT	cis	rs7085104	0.684	rs7092690	chr10:104609365	T/C	cg04362960	chr10:104952993	NT5C2	0.58	5.14	0.42	1.04e-6	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs7824557	0.736	rs6601578	chr8:11136604	A/G	cg21775007	chr8:11205619	TDH	-0.59	-5.57	-0.45	1.54e-7	Retinal vascular caliber;
TGCT	cis	rs9443645	0.868	rs9443643	chr6:79798838	A/G	cg09184832	chr6:79620586	NA	-0.48	-5.23	-0.43	6.99e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	7.12	0.54	7.55e-11	Platelet count;
TGCT	trans	rs797680	0.856	rs535760	chr1:93728758	T/A	cg27528825	chr2:159282178	CCDC148	0.35	6.88	0.53	2.65e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs7829975	0.626	rs332040	chr8:8730488	G/A	cg06636001	chr8:8085503	FLJ10661	0.71	6.57	0.51	1.26e-9	Mood instability;
TGCT	cis	rs8070128	0.637	rs4925133	chr17:17884801	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.76	7.5	0.56	1.05e-11	Total body bone mineral density;
TGCT	cis	rs9788721	0.836	rs11858836	chr15:78783277	G/A	cg18825076	chr15:78729989	IREB2	-0.35	-5.19	-0.42	8.3e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
TGCT	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg25036284	chr2:26402008	FAM59B	-0.54	-4.7	-0.39	6.93e-6	Gut microbiome composition (summer);
TGCT	cis	rs3784262	0.679	rs11071366	chr15:58334244	A/T	cg12031962	chr15:58353849	ALDH1A2	-0.55	-8.46	-0.6	6.31e-14	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs10088262	0.629	rs7833650	chr8:124822969	C/T	cg20713898	chr8:124780851	FAM91A1	-0.89	-7.32	-0.55	2.8e-11	Pancreatic cancer;
TGCT	cis	rs7959452	0.640	rs11177599	chr12:69721970	G/A	cg14784868	chr12:69753453	YEATS4	0.67	6.93	0.53	2.07e-10	Blood protein levels;
TGCT	cis	rs1018836	0.851	rs7014073	chr8:91618548	T/C	cg16814680	chr8:91681699	NA	-0.83	-8.65	-0.61	2.22e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9467711	0.606	rs9393711	chr6:26370659	C/T	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs79976124	0.837	rs10455591	chr6:66650584	A/G	cg07460842	chr6:66804631	NA	0.58	5.29	0.43	5.33e-7	Type 2 diabetes;
TGCT	cis	rs11230394	0.916	rs17627788	chr11:60384540	C/T	cg24026212	chr11:59952134	MS4A6A	0.29	4.64	0.38	8.85e-6	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
TGCT	cis	rs854765	0.583	rs67253360	chr17:17828973	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.74	7.73	0.57	3.18e-12	Total body bone mineral density;
TGCT	cis	rs35146811	0.735	rs1727139	chr7:99815367	C/T	cg22906224	chr7:99728672	NA	-0.49	-4.45	-0.37	1.88e-5	Coronary artery disease;
TGCT	cis	rs6570726	0.791	rs401331	chr6:145831408	A/G	cg23711669	chr6:146136114	FBXO30	0.89	9.72	0.66	6.02e-17	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs2469997	1.000	rs2470009	chr8:120359377	T/C	cg01792902	chr3:178864926	PIK3CA	0.83	6.77	0.52	4.49e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs13256369	0.755	rs11776987	chr8:8559401	C/G	cg17143192	chr8:8559678	CLDN23	0.53	4.82	0.4	4.03e-6	Obesity-related traits;
TGCT	cis	rs68170813	0.559	rs17350182	chr7:106909637	T/A	cg02696742	chr7:106810147	HBP1	-0.69	-5.61	-0.45	1.27e-7	Coronary artery disease;
TGCT	cis	rs9611519	1.000	rs9611519	chr22:41613188	C/T	cg13695892	chr22:41940480	POLR3H	-0.5	-4.5	-0.37	1.56e-5	Neuroticism;
TGCT	cis	rs1475911	0.947	rs67055914	chr21:43510427	T/C	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.23	-4.69	-0.39	7.13e-6	IgG glycosylation;
TGCT	cis	rs7659604	0.840	rs6821305	chr4:122713863	A/C	cg19748678	chr4:122722346	EXOSC9	0.73	7.4	0.55	1.82e-11	Type 2 diabetes;
TGCT	cis	rs1903068	0.962	rs17773813	chr4:56008969	G/A	cg09978860	chr4:56023921	NA	0.58	6.61	0.51	1.02e-9	Endometriosis;
TGCT	cis	rs2180341	0.920	rs9401951	chr6:127671632	A/C	cg24812749	chr6:127587940	RNF146	1.02	7.59	0.56	6.71e-12	Breast cancer;
TGCT	cis	rs240764	0.853	rs17303769	chr6:100967531	G/A	cg21058520	chr6:100914733	NA	0.35	4.63	0.38	9.07e-6	Neuroticism;
TGCT	cis	rs1976403	0.659	rs10799700	chr1:21820968	G/C	cg17800788	chr1:21766015	NBPF3	0.24	4.51	0.38	1.46e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7582180	0.614	rs2241809	chr2:101014363	C/T	cg08017756	chr2:100939284	LONRF2	-0.29	-4.67	-0.39	7.68e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs950776	0.518	rs11636131	chr15:78821606	C/T	cg06917634	chr15:78832804	PSMA4	0.95	9.52	0.65	1.81e-16	Sudden cardiac arrest;
TGCT	cis	rs7666738	0.830	rs10028692	chr4:98962585	C/T	cg05340658	chr4:99064831	C4orf37	0.53	5.93	0.47	2.85e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7681440	0.904	rs6816736	chr4:90765746	G/A	cg14346243	chr4:90757452	SNCA	-0.57	-5.6	-0.45	1.31e-7	Dementia with Lewy bodies;
TGCT	trans	rs11088226	0.681	rs4547609	chr21:33953542	G/A	cg09050820	chr6:167586206	TCP10L2	0.76	7.31	0.55	2.88e-11	Gastritis;
TGCT	cis	rs7572733	0.534	rs6760891	chr2:198768166	T/G	cg00792783	chr2:198669748	PLCL1	0.56	5.11	0.42	1.21e-6	Dermatomyositis;
TGCT	cis	rs7833790	0.963	rs28823280	chr8:82777716	G/A	cg17211192	chr8:82754475	SNX16	1.01	8.69	0.62	1.77e-14	Diastolic blood pressure;
TGCT	cis	rs9807989	0.507	rs2110659	chr2:103043867	G/A	cg03938978	chr2:103052716	IL18RAP	0.27	5.41	0.44	3.17e-7	Asthma;
TGCT	cis	rs7681440	0.904	rs1822217	chr4:90765052	C/T	cg20003494	chr4:90757398	SNCA	-0.62	-5.93	-0.47	2.74e-8	Dementia with Lewy bodies;
TGCT	cis	rs17376456	0.825	rs28534784	chr5:93063332	C/A	cg25358565	chr5:93447407	FAM172A	0.9	7.98	0.58	8.23e-13	Diabetic retinopathy;
TGCT	cis	rs6671200	0.607	rs3767315	chr1:95705972	A/G	cg03123541	chr1:95699097	RWDD3	-0.81	-7.26	-0.55	3.81e-11	Stearic acid (18:0) levels;
TGCT	cis	rs2717559	0.522	rs2572925	chr8:143867905	C/T	cg07661805	chr8:143867942	LY6D	0.23	4.47	0.37	1.77e-5	Urinary tract infection frequency;
TGCT	cis	rs7226408	0.790	rs55935783	chr18:34346120	A/C	cg06757138	chr18:34340585	FHOD3	0.29	4.97	0.41	2.14e-6	Obesity-related traits;
TGCT	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg11062466	chr8:58055876	NA	0.38	4.62	0.38	9.5e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs11711311	0.822	rs9850256	chr3:113408382	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.67	-5.9	-0.47	3.26e-8	IgG glycosylation;
TGCT	cis	rs921968	0.541	rs17462853	chr2:219345637	T/G	cg02176678	chr2:219576539	TTLL4	-0.48	-6.84	-0.52	3.21e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs8064299	0.967	rs878906	chr17:72769334	T/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.79	8.01	0.58	7.17e-13	Monocyte count;
TGCT	cis	rs6912958	0.781	rs9444524	chr6:88311260	T/C	cg06598631	chr6:88300029	RARS2;ORC3L	-0.55	-5.04	-0.41	1.62e-6	Monocyte percentage of white cells;
TGCT	cis	rs7027203	0.797	rs3996254	chr9:96591239	A/G	cg13679303	chr9:96623674	NA	-0.66	-10.78	-0.7	1.64e-19	DNA methylation (variation);
TGCT	cis	rs2730245	0.550	rs2709860	chr7:158651156	A/T	cg24397884	chr7:158709396	WDR60	0.39	5.24	0.43	6.56e-7	Height;
TGCT	cis	rs4478858	0.735	rs4949384	chr1:31792141	A/G	cg00250761	chr1:31883323	NA	-0.27	-4.78	-0.39	4.86e-6	Alcohol dependence;
TGCT	cis	rs4478858	0.746	rs12136121	chr1:31689743	G/C	cg00250761	chr1:31883323	NA	0.29	4.88	0.4	3.25e-6	Alcohol dependence;
TGCT	cis	rs7949030	0.626	rs72927213	chr11:62351198	G/C	cg13298116	chr11:62369859	EML3;MTA2	0.63	9.39	0.64	3.71e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9926296	0.712	rs459920	chr16:89730827	T/C	cg01097406	chr16:89675127	NA	0.34	5.88	0.47	3.54e-8	Vitiligo;
TGCT	cis	rs11190604	0.767	rs10883481	chr10:102165021	G/A	cg16005271	chr10:102321736	NA	0.45	4.57	0.38	1.15e-5	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs6433895	1.000	rs11893821	chr2:182017148	A/G	cg16904960	chr2:182549928	NA	0.34	4.47	0.37	1.77e-5	Lymphocyte counts;
TGCT	trans	rs459571	1.000	rs459571	chr9:136912626	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.77	-8.3	-0.6	1.47e-13	Platelet distribution width;
TGCT	cis	rs12681287	0.570	rs10956830	chr8:87430483	T/A	cg27223183	chr8:87520930	FAM82B	0.89	6.43	0.5	2.54e-9	Caudate activity during reward;
TGCT	cis	rs2816062	0.775	rs2816046	chr1:18893708	A/G	cg18795169	chr1:18902165	NA	-0.59	-13.32	-0.77	1.12e-25	Urate levels in lean individuals;
TGCT	cis	rs909674	0.818	rs5750833	chr22:39843091	C/A	cg02038168	chr22:39784481	NA	-0.71	-5.56	-0.45	1.54e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg06618935	chr21:46677482	NA	-0.37	-5.68	-0.45	9.06e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7017914	0.967	rs1493198	chr8:71851957	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.07	-0.41	1.39e-6	Bone mineral density;
TGCT	cis	rs79724016	1.000	rs1105414	chr1:42144764	C/T	cg07578001	chr1:42501544	NA	-0.99	-4.45	-0.37	1.91e-5	Breast cancer;
TGCT	cis	rs9486719	0.843	rs2499789	chr6:96844510	T/C	cg06623918	chr6:96969491	KIAA0776	0.93	7.08	0.54	9.59e-11	Migraine;Coronary artery disease;
TGCT	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg00814883	chr7:100076585	TSC22D4	-0.82	-8.23	-0.59	2.14e-13	Platelet count;
TGCT	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg27170947	chr2:26402098	FAM59B	-0.39	-4.46	-0.37	1.8e-5	Gut microbiome composition (summer);
TGCT	cis	rs1008375	0.932	rs6814465	chr4:17659034	C/T	cg16339924	chr4:17578868	LAP3	0.66	5.52	0.44	1.89e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7727544	0.684	rs611084	chr5:131709739	A/C	cg24060327	chr5:131705240	SLC22A5	0.62	6.77	0.52	4.69e-10	Blood metabolite levels;
TGCT	cis	rs2742417	1.000	rs2673058	chr3:45735618	A/C	cg04837898	chr3:45731254	SACM1L	-0.55	-5.68	-0.45	9.14e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs2777491	0.915	rs16971767	chr15:41623308	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.75	-10.44	-0.68	1.07e-18	Ulcerative colitis;
TGCT	cis	rs8031584	0.678	rs798125	chr15:31116800	C/T	cg08704250	chr15:31115839	NA	0.44	6.43	0.5	2.47e-9	Huntington's disease progression;
TGCT	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg11965913	chr1:205819406	PM20D1	0.53	7.4	0.55	1.82e-11	Menarche (age at onset);
TGCT	trans	rs208520	0.837	rs208509	chr6:66941706	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-9.85	-0.66	3e-17	Exhaled nitric oxide output;
TGCT	cis	rs796364	0.906	rs281766	chr2:200820505	T/G	cg17644776	chr2:200775616	C2orf69	0.31	4.85	0.4	3.58e-6	Schizophrenia;
TGCT	cis	rs2288884	1.000	rs76768215	chr19:52572623	C/T	cg15405931	chr19:52693188	PPP2R1A	-0.69	-4.5	-0.37	1.56e-5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg11965913	chr1:205819406	PM20D1	-0.47	-6.5	-0.5	1.8e-9	Monocyte percentage of white cells;
TGCT	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg01802117	chr1:53393560	SCP2	-0.42	-4.85	-0.4	3.63e-6	Monocyte count;
TGCT	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg05368731	chr17:41323189	NBR1	1.1	11.12	0.71	2.38e-20	Menopause (age at onset);
TGCT	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg07507251	chr3:52567010	NT5DC2	0.47	6.53	0.51	1.55e-9	Bipolar disorder;
TGCT	cis	rs9611565	0.572	rs139569	chr22:42211141	A/G	cg03806693	chr22:41940476	POLR3H	-0.88	-8.45	-0.6	6.8e-14	Vitiligo;
TGCT	cis	rs35146811	0.624	rs1727134	chr7:99813672	T/C	cg04778012	chr7:99775508	STAG3;GPC2	-0.36	-5.1	-0.42	1.22e-6	Coronary artery disease;
TGCT	cis	rs6540559	0.611	rs6540563	chr1:210019858	C/G	cg23283495	chr1:209979779	IRF6	0.6	4.5	0.37	1.54e-5	Cleft lip with or without cleft palate;
TGCT	trans	rs1814175	0.645	rs1851845	chr11:49982396	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.67	-0.69	2.92e-19	Height;
TGCT	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs76878669	0.561	rs12416747	chr11:66135614	A/G	cg18002602	chr11:66138449	SLC29A2	0.53	6.49	0.5	1.89e-9	Educational attainment (years of education);
TGCT	cis	rs12681288	0.748	rs7000148	chr8:1016383	G/C	cg04851639	chr8:1020857	NA	-0.37	-6.84	-0.52	3.24e-10	Schizophrenia;
TGCT	cis	rs939658	0.805	rs11634679	chr15:79432475	T/C	cg17916960	chr15:79447300	NA	-0.49	-7.59	-0.56	6.76e-12	Refractive error;
TGCT	cis	rs8179	1.000	rs42033	chr7:92237533	A/T	cg15732164	chr7:92237376	CDK6	-0.33	-4.9	-0.4	2.99e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
TGCT	cis	rs1532993	0.518	rs12512518	chr4:98633283	G/C	cg05340658	chr4:99064831	C4orf37	-0.4	-4.91	-0.4	2.77e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs8056742	0.643	rs12926648	chr16:85092970	T/C	cg00229868	chr16:85520891	NA	0.34	4.8	0.4	4.39e-6	Amyotrophic lateral sclerosis;
TGCT	cis	rs10510102	0.745	rs7076882	chr10:123706554	A/G	cg23691251	chr10:123688108	ATE1	-0.59	-4.7	-0.39	6.75e-6	Breast cancer;
TGCT	cis	rs4455778	0.580	rs4917197	chr7:49075894	C/T	cg26309511	chr7:48887640	NA	0.5	6.36	0.5	3.57e-9	Lung cancer in never smokers;
TGCT	cis	rs1348850	0.632	rs12471621	chr2:178502353	T/C	cg22681709	chr2:178499509	PDE11A	-0.53	-6.64	-0.51	8.93e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs12908161	1.000	rs35524990	chr15:85258203	T/C	cg11189052	chr15:85197271	WDR73	0.75	6.29	0.49	5.02e-9	Schizophrenia;
TGCT	cis	rs1008375	0.931	rs10939733	chr4:17570658	T/C	cg16339924	chr4:17578868	LAP3	0.82	7.13	0.54	7.32e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9296092	0.538	rs112113649	chr6:33524529	A/G	cg13560919	chr6:33536144	NA	-0.21	-4.75	-0.39	5.5e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs76878669	0.561	rs7948058	chr11:66148111	T/A	cg18002602	chr11:66138449	SLC29A2	-0.54	-6.59	-0.51	1.15e-9	Educational attainment (years of education);
TGCT	cis	rs981844	0.816	rs56413502	chr4:154721784	T/A	cg14289246	chr4:154710475	SFRP2	1.03	9.03	0.63	2.72e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs61990749	0.597	rs17106157	chr14:78146878	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.63	-4.62	-0.38	9.34e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs4689388	0.926	rs4688987	chr4:6287329	C/T	cg14416269	chr4:6271139	WFS1	0.39	5.22	0.42	7.41e-7	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs4509693	0.943	rs4917907	chr10:102498140	A/G	cg24127310	chr10:102502104	NA	0.7	5.86	0.47	3.84e-8	Alzheimer's disease;
TGCT	cis	rs4704846	1.000	rs4704851	chr5:156533174	C/T	cg12943317	chr5:156479607	HAVCR1	-0.34	-4.7	-0.39	6.82e-6	Blood protein levels;
TGCT	cis	rs670523	0.532	rs6427297	chr1:155975493	C/T	cg13795986	chr1:155880507	RIT1	0.37	4.61	0.38	9.72e-6	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs78707713	0.560	rs61848398	chr10:71226103	G/A	cg12610070	chr10:71211762	TSPAN15	-0.62	-7.37	-0.55	2.14e-11	Venous thromboembolism;
TGCT	cis	rs10883723	0.810	rs7090034	chr10:104281155	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs4319547	0.626	rs11057882	chr12:122875046	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.62	-4.87	-0.4	3.32e-6	Body mass index;
TGCT	cis	rs2721195	0.816	rs4925826	chr8:145706276	G/A	cg15857475	chr8:145742913	RECQL4;LRRC14	0.88	9.59	0.65	1.22e-16	Age at first birth;
TGCT	cis	rs9583531	0.891	rs9521911	chr13:111370615	A/G	cg24331049	chr13:111365604	ING1	-0.74	-5.05	-0.41	1.54e-6	Coronary artery disease;
TGCT	cis	rs4851266	1.000	rs1160543	chr2:100832182	C/T	cg22139774	chr2:100720529	AFF3	-0.35	-5.19	-0.42	8.51e-7	Educational attainment;
TGCT	cis	rs12971120	0.891	rs11151960	chr18:72177232	G/A	cg26446133	chr18:72167187	CNDP2	-0.35	-5.89	-0.47	3.42e-8	Refractive error;
TGCT	cis	rs6450176	0.909	rs80213371	chr5:53300874	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.53	-5.1	-0.42	1.23e-6	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs4653663	0.785	rs4653662	chr1:225921655	A/G	cg06802365	chr1:225117676	DNAH14	-0.51	-4.46	-0.37	1.82e-5	Neuroticism;
TGCT	cis	rs9916302	0.851	rs12936996	chr17:37665554	A/G	cg07936489	chr17:37558343	FBXL20	0.61	4.81	0.4	4.25e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.76	5.6	0.45	1.28e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9916302	0.706	rs649180	chr17:37464959	A/C	cg03321784	chr17:37729644	NA	-0.43	-4.46	-0.37	1.84e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs7772486	0.743	rs111332144	chr6:146056681	C/T	cg23711669	chr6:146136114	FBXO30	-0.77	-7.33	-0.55	2.65e-11	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11864453	0.826	rs12448315	chr16:72147242	G/T	cg14768367	chr16:72042858	DHODH	0.48	4.47	0.37	1.77e-5	Fibrinogen levels;
TGCT	cis	rs4662750	0.674	rs777437	chr2:128357647	C/T	cg20053821	chr2:127529534	NA	0.23	4.47	0.37	1.74e-5	Renal cell carcinoma;
TGCT	cis	rs7647973	0.626	rs9835157	chr3:49797769	G/A	cg05785598	chr3:49045655	WDR6	-0.42	-5.24	-0.43	6.67e-7	Menarche (age at onset);
TGCT	cis	rs9534288	0.797	rs7982998	chr13:46601535	C/T	cg15192986	chr13:46630673	CPB2	-0.52	-7.53	-0.56	9.22e-12	Blood protein levels;
TGCT	cis	rs6121246	0.779	rs6060763	chr20:30282223	A/G	cg18721089	chr20:30220636	NA	-0.42	-4.65	-0.39	8.2e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs2153535	0.580	rs7742689	chr6:8452433	C/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.76	0.46	6.39e-8	Motion sickness;
TGCT	cis	rs1348850	0.567	rs4893838	chr2:178531436	T/C	cg22681709	chr2:178499509	PDE11A	-0.46	-5.95	-0.47	2.58e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg09359103	chr1:154839909	KCNN3	-0.65	-12.35	-0.74	2.43e-23	Prostate cancer;
TGCT	cis	rs62244186	0.566	rs6766221	chr3:44882784	C/T	cg21672276	chr3:44754072	ZNF502	-0.55	-6.31	-0.49	4.58e-9	Depressive symptoms;
TGCT	cis	rs288326	0.561	rs78745965	chr2:183848475	T/C	cg09997497	chr2:183902928	NCKAP1	1.11	4.95	0.41	2.38e-6	Blood protein levels;
TGCT	cis	rs2455799	0.613	rs2470542	chr3:15724133	A/C	cg16303742	chr3:15540471	COLQ	-0.24	-4.52	-0.38	1.4e-5	Mean platelet volume;
TGCT	cis	rs7568458	0.870	rs2366639	chr2:85809955	A/G	cg17127132	chr2:85788382	GGCX	0.68	6.2	0.49	7.54e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs7226408	0.857	rs72885294	chr18:34450941	T/A	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs6867032	0.917	rs10474734	chr5:2004208	A/G	cg26168224	chr5:2018326	NA	0.33	5.04	0.41	1.64e-6	Gut microbiome composition (winter);
TGCT	cis	rs2153535	0.601	rs9328487	chr6:8529378	G/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.55e-8	Motion sickness;
TGCT	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg26119090	chr2:26468346	HADHA;HADHB	1.0	7.42	0.55	1.64e-11	Gut microbiome composition (summer);
TGCT	cis	rs939658	1.000	rs8027411	chr15:79461029	G/T	cg17916960	chr15:79447300	NA	0.52	8.38	0.6	9.77e-14	Refractive error;
TGCT	cis	rs11785400	0.793	rs4736366	chr8:143742413	C/T	cg24634471	chr8:143751801	JRK	0.55	5.45	0.44	2.6e-7	Schizophrenia;
TGCT	cis	rs7772486	0.875	rs863820	chr6:146347402	C/T	cg05347473	chr6:146136440	FBXO30	-0.57	-5.51	-0.44	2.02e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4595586	0.545	rs12819061	chr12:39386976	C/T	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs9993613	0.875	rs6812147	chr4:73475839	T/G	cg15102770	chr4:73434591	ADAMTS3	0.54	4.96	0.41	2.26e-6	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs4901869	0.902	rs10149194	chr14:59308198	A/G	cg02291164	chr14:59296302	NA	-0.25	-4.69	-0.39	7.15e-6	Panic disorder;
TGCT	cis	rs3820928	0.874	rs10183633	chr2:227887828	A/G	cg11843606	chr2:227700838	RHBDD1	-0.57	-5.23	-0.42	7.12e-7	Pulmonary function;
TGCT	cis	rs709400	0.659	rs7160366	chr14:103944137	C/T	cg12935359	chr14:103987150	CKB	-0.36	-5.55	-0.45	1.67e-7	Body mass index;
TGCT	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg03188948	chr7:1209495	NA	0.48	5.12	0.42	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg11644478	chr21:40555479	PSMG1	-0.62	-5.88	-0.47	3.5e-8	Cognitive function;
TGCT	cis	rs7208859	0.623	rs7220999	chr17:29149298	C/T	cg13385521	chr17:29058706	SUZ12P	0.81	4.85	0.4	3.68e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs735396	0.770	rs2264782	chr12:121432603	C/T	cg02403541	chr12:121454288	C12orf43	0.64	5.88	0.47	3.6e-8	N-glycan levels;
TGCT	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg15242686	chr22:24348715	GSTTP1	-0.5	-7.57	-0.56	7.42e-12	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7647973	0.710	rs6797299	chr3:49609794	G/T	cg03060546	chr3:49711283	APEH	0.63	5.14	0.42	1.03e-6	Menarche (age at onset);
TGCT	cis	rs2239547	0.522	rs4519686	chr3:52997871	C/T	cg10802521	chr3:52805072	NEK4	-0.63	-6.05	-0.48	1.59e-8	Schizophrenia;
TGCT	trans	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg17830980	chr10:43048298	ZNF37B	-0.86	-11.18	-0.71	1.68e-20	Extrinsic epigenetic age acceleration;
TGCT	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg06618935	chr21:46677482	NA	-0.36	-5.61	-0.45	1.25e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9972944	0.756	rs7221131	chr17:63764848	G/A	cg07283582	chr17:63770753	CCDC46	-0.26	-5.3	-0.43	5.02e-7	Total body bone mineral density;
TGCT	cis	rs10751667	0.666	rs6597958	chr11:978087	C/T	cg06064525	chr11:970664	AP2A2	-0.36	-8.28	-0.6	1.67e-13	Alzheimer's disease (late onset);
TGCT	cis	rs5769707	0.681	rs4622843	chr22:50036916	T/G	cg06623630	chr22:50017776	C22orf34	-0.26	-4.52	-0.38	1.42e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	trans	rs7819412	0.805	rs2409710	chr8:10979821	A/G	cg15556689	chr8:8085844	FLJ10661	-0.82	-8.29	-0.6	1.61e-13	Triglycerides;
TGCT	cis	rs10984561	0.881	rs73540255	chr9:122255508	T/C	cg14242995	chr9:122249943	NA	0.72	5.82	0.46	4.75e-8	Pulmonary function decline;
TGCT	cis	rs6728642	0.908	rs10207116	chr2:98018281	G/A	cg26665480	chr2:98280029	ACTR1B	-0.95	-5.3	-0.43	5.14e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	cis	rs7216169	1	rs7216169	chr17:5219511	C/T	cg02842197	chr17:5389625	DERL2;MIS12	0.8	4.56	0.38	1.21e-5	Red blood cell density in sickle cell anemia;
TGCT	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg04944784	chr2:26401820	FAM59B	-0.7	-6.49	-0.5	1.89e-9	Gut microbiome composition (summer);
TGCT	cis	rs12477438	0.501	rs34272114	chr2:99737443	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.75	7.25	0.55	3.92e-11	Chronic sinus infection;
TGCT	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	5.5	0.44	2.06e-7	Height;
TGCT	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg18402987	chr7:1209562	NA	0.48	4.79	0.39	4.72e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7611238	0.560	rs9879305	chr3:195074094	T/C	cg27323046	chr3:195102265	ACAP2	0.35	4.82	0.4	4.11e-6	Body mass index;
TGCT	cis	rs6674176	0.597	rs4031031	chr1:44393533	C/T	cg13606994	chr1:44402422	ARTN	-0.52	-5.47	-0.44	2.33e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg12963246	chr6:28129442	ZNF389	0.52	5.04	0.41	1.61e-6	Depression;
TGCT	cis	rs78707713	0.560	rs2394563	chr10:71238618	G/A	cg14388049	chr10:71211838	TSPAN15	-0.39	-4.64	-0.38	8.84e-6	Venous thromboembolism;
TGCT	cis	rs7267979	1.000	rs3761117	chr20:25388070	G/A	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7617773	0.780	rs6782166	chr3:48351683	A/G	cg11946769	chr3:48343235	NME6	0.82	7.09	0.54	9.1e-11	Coronary artery disease;
TGCT	cis	rs7267979	0.932	rs6115215	chr20:25562500	C/T	cg14121845	chr20:25566513	NINL	0.49	5.36	0.43	3.83e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg00149659	chr3:10157352	C3orf10	1.17	7.24	0.55	4.13e-11	Alzheimer's disease;
TGCT	cis	rs7666738	0.830	rs11935588	chr4:98979862	A/G	cg05340658	chr4:99064831	C4orf37	-0.53	-6.01	-0.47	1.93e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-6.54	-0.51	1.42e-9	Alzheimer's disease;
TGCT	cis	rs7547997	0.649	rs7543890	chr1:158342937	A/G	cg07950803	chr1:158223934	CD1A	0.32	4.78	0.39	4.95e-6	QRS duration;
TGCT	cis	rs7772486	0.805	rs4896831	chr6:145959481	T/C	cg23711669	chr6:146136114	FBXO30	0.79	8.38	0.6	9.86e-14	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11578119	0.872	rs17350312	chr1:170377400	T/C	cg09767346	chr1:170501363	GORAB	0.74	5.92	0.47	2.94e-8	Male-pattern baldness;
TGCT	cis	rs7100689	0.622	rs1340383	chr10:82095968	T/G	cg01528321	chr10:82214614	TSPAN14	0.75	7.49	0.56	1.15e-11	Post bronchodilator FEV1;
TGCT	cis	rs7666738	0.830	rs7678250	chr4:98922109	G/A	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9527	0.590	rs3861984	chr10:104916980	T/C	cg15744005	chr10:104629667	AS3MT	-0.41	-4.73	-0.39	6.06e-6	Arsenic metabolism;
TGCT	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg03303774	chr4:1407052	NA	0.31	4.93	0.4	2.58e-6	Obesity-related traits;
TGCT	trans	rs7618501	0.699	rs2681780	chr3:49897830	C/T	cg21659725	chr3:3221576	CRBN	0.79	9.28	0.64	6.9e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs6089829	0.851	rs6089827	chr20:61668845	C/T	cg18188782	chr20:61659543	NA	0.47	5.63	0.45	1.15e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs67311347	1.000	rs6795475	chr3:40489281	A/G	cg17264618	chr3:40429014	ENTPD3	0.32	4.73	0.39	5.9e-6	Renal cell carcinoma;
TGCT	cis	rs7829975	0.593	rs2921051	chr8:8320104	C/A	cg08975724	chr8:8085496	FLJ10661	0.62	6.02	0.48	1.87e-8	Mood instability;
TGCT	cis	rs9393777	0.844	rs35909544	chr6:27163456	G/A	cg16898833	chr6:26189333	HIST1H4D	0.87	4.89	0.4	3.06e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7100689	0.646	rs7077854	chr10:82124070	C/T	cg01528321	chr10:82214614	TSPAN14	0.8	7.76	0.57	2.7e-12	Post bronchodilator FEV1;
TGCT	cis	rs427394	0.582	rs274665	chr5:6707981	C/T	cg10857441	chr5:6722123	POLS	-0.3	-6.4	-0.5	2.95e-9	Menopause (age at onset);
TGCT	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg11494091	chr17:61959527	GH2	0.61	14.78	0.8	4.02e-29	Prudent dietary pattern;
TGCT	cis	rs6500602	0.826	rs11076831	chr16:4460133	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	-0.44	-5.71	-0.46	7.83e-8	Schizophrenia;
TGCT	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs8013055	0.796	rs28733392	chr14:105993258	G/A	cg23356831	chr14:105996513	TMEM121	0.35	5.1	0.42	1.22e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs4812048	0.793	rs7266693	chr20:57593158	T/C	cg24457521	chr20:57607420	ATP5E	-0.69	-4.56	-0.38	1.22e-5	Mean platelet volume;
TGCT	cis	rs7726839	0.540	rs72705097	chr5:655067	G/A	cg16624210	chr5:671434	TPPP	0.41	4.6	0.38	1.02e-5	Obesity-related traits;
TGCT	cis	rs72781680	0.716	rs2712050	chr2:24059408	A/C	cg08917208	chr2:24149416	ATAD2B	0.77	4.8	0.4	4.46e-6	Lymphocyte counts;
TGCT	cis	rs7119038	0.629	rs11216994	chr11:118603520	C/T	cg19308663	chr11:118741387	NA	0.23	4.49	0.37	1.62e-5	Sjögren's syndrome;
TGCT	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg27454412	chr7:1067447	C7orf50	0.6	4.72	0.39	6.32e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg22166914	chr1:53195759	ZYG11B	-0.47	-8.62	-0.61	2.66e-14	Monocyte count;
TGCT	cis	rs611744	0.901	rs673981	chr8:109191917	G/A	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs9611565	0.512	rs5751153	chr22:42156561	T/C	cg06481639	chr22:41940642	POLR3H	0.69	6.02	0.48	1.83e-8	Vitiligo;
TGCT	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg24531977	chr5:56204891	C5orf35	-0.66	-6.67	-0.51	7.66e-10	Coronary artery disease;
TGCT	cis	rs2075371	1.000	rs1421484	chr7:133979795	T/C	cg11752832	chr7:134001865	SLC35B4	0.69	6.32	0.49	4.19e-9	Mean platelet volume;
TGCT	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg13409248	chr3:40428643	ENTPD3	0.57	4.64	0.38	8.8e-6	Renal cell carcinoma;
TGCT	cis	rs10782582	0.545	rs12138018	chr1:76186794	T/C	cg10523679	chr1:76189770	ACADM	-0.67	-6.62	-0.51	9.61e-10	Daytime sleep phenotypes;
TGCT	cis	rs4654899	0.895	rs10916866	chr1:21137768	C/A	cg01072550	chr1:21505969	NA	0.55	8.83	0.62	8.24e-15	Superior frontal gyrus grey matter volume;
TGCT	cis	rs12693043	0.817	rs10930673	chr2:175375315	G/A	cg11778734	chr2:175439522	WIPF1	-0.35	-4.48	-0.37	1.68e-5	Urate levels (BMI interaction);
TGCT	cis	rs17076896	0.786	rs74038129	chr13:19932807	A/T	cg00777926	chr13:20807375	GJB6	-0.37	-4.53	-0.38	1.36e-5	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.57	-5.67	-0.45	9.34e-8	Electroencephalogram traits;
TGCT	cis	rs11577318	0.853	rs3795684	chr1:26632781	C/T	cg12733254	chr1:26682999	NA	-0.2	-4.49	-0.37	1.62e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs9527	0.567	rs6584539	chr10:104879402	G/C	cg15744005	chr10:104629667	AS3MT	-0.43	-4.9	-0.4	2.89e-6	Arsenic metabolism;
TGCT	cis	rs7267979	0.738	rs2892409	chr20:25638138	C/T	cg16686733	chr20:25566563	NINL	0.48	4.62	0.38	9.4e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs12776158	0.901	rs12413873	chr10:71212091	C/G	cg12610070	chr10:71211762	TSPAN15	-0.56	-4.73	-0.39	6.07e-6	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs6693567	0.586	rs9661040	chr1:150483236	A/C	cg07843065	chr1:150265600	MRPS21	-0.17	-4.47	-0.37	1.72e-5	Migraine;
TGCT	trans	rs7618501	0.633	rs2008877	chr3:50162291	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.88	-9.75	-0.66	5.11e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs155076	1.000	rs564685	chr13:21846879	A/G	cg11317459	chr13:21872234	NA	-1.42	-12.02	-0.73	1.53e-22	White matter hyperintensity burden;
TGCT	cis	rs12142240	0.698	rs72677600	chr1:46834449	G/A	cg14993813	chr1:46806288	NSUN4	-0.58	-4.87	-0.4	3.31e-6	Menopause (age at onset);
TGCT	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg22963979	chr7:1858916	MAD1L1	-0.36	-5.63	-0.45	1.13e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs7729723	0.568	rs6885225	chr5:137824837	T/C	cg19169342	chr5:137827400	NA	0.32	4.47	0.37	1.74e-5	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);
TGCT	trans	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg27523141	chr10:43048294	ZNF37B	0.7	8.15	0.59	3.36e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs12368653	0.557	rs903067	chr12:58011857	G/A	cg00700412	chr12:58011837	NA	-0.24	-4.73	-0.39	5.97e-6	Multiple sclerosis;
TGCT	cis	rs1801251	0.778	rs2250654	chr2:233752376	A/T	cg25237894	chr2:233734115	C2orf82	-0.31	-5.84	-0.46	4.25e-8	Coronary artery disease;
TGCT	cis	rs4478858	0.735	rs12563669	chr1:31858067	A/G	cg07478791	chr1:31886160	SERINC2	-0.52	-5.29	-0.43	5.27e-7	Alcohol dependence;
TGCT	cis	rs9457247	0.555	rs2247325	chr6:167369992	A/G	cg23791538	chr6:167370224	RNASET2	0.64	6.0	0.47	2.04e-8	Crohn's disease;
TGCT	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg13665807	chr20:60559372	TAF4	-0.46	-4.94	-0.41	2.48e-6	Body mass index;
TGCT	cis	rs10883723	0.810	rs7072351	chr10:104265047	C/T	cg05855489	chr10:104503620	C10orf26	-0.58	-5.06	-0.41	1.47e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs72720396	0.803	rs114328297	chr1:91190854	T/G	cg13456504	chr1:91191583	NA	0.74	5.83	0.46	4.57e-8	Morning vs. evening chronotype;Chronotype;
TGCT	cis	rs585510	1	rs585510	chr12:121000133	A/G	cg12219531	chr12:120966889	COQ5	0.82	7.38	0.55	2.05e-11	Reticulocyte fraction of red cells;
TGCT	cis	rs933688	0.938	rs1477348	chr5:90707823	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.98	8.03	0.58	6.35e-13	Smoking behavior;
TGCT	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg04154034	chr17:28927549	LRRC37B2	-0.87	-5.53	-0.44	1.81e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs6087990	0.835	rs4911106	chr20:31331330	A/G	cg13636640	chr20:31349939	DNMT3B	1.03	14.85	0.8	2.67e-29	Ulcerative colitis;
TGCT	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg25036284	chr2:26402008	FAM59B	0.57	4.49	0.37	1.59e-5	Gut microbiome composition (summer);
TGCT	cis	rs35883536	0.647	rs10875312	chr1:101042320	G/C	cg06223162	chr1:101003688	GPR88	-0.42	-7.93	-0.58	1.1e-12	Monocyte count;
TGCT	cis	rs7312933	0.584	rs6582391	chr12:42634686	G/A	cg19980929	chr12:42632907	YAF2	0.41	5.86	0.47	3.85e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	trans	rs66573146	0.634	rs55633489	chr4:6988745	C/A	cg07817883	chr1:32538562	TMEM39B	1.3	6.83	0.52	3.41e-10	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs35306767	0.715	rs17221463	chr10:1038040	T/C	cg20503657	chr10:835505	NA	0.63	6.98	0.53	1.57e-10	Eosinophil percentage of granulocytes;
TGCT	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg22535103	chr8:58192502	C8orf71	-0.39	-4.73	-0.39	5.97e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6681544	0.760	rs2026597	chr1:82425956	T/A	cg04226724	chr1:82268649	LPHN2	-0.48	-4.95	-0.41	2.42e-6	Metabolite levels  (X-11787);
TGCT	cis	rs2996428	0.667	rs61768933	chr1:3766587	G/A	cg17848003	chr1:3704513	LRRC47	0.18	5.15	0.42	9.99e-7	Red cell distribution width;
TGCT	cis	rs9325144	0.600	rs1817648	chr12:38733424	C/T	cg13010199	chr12:38710504	ALG10B	-0.51	-4.47	-0.37	1.76e-5	Morning vs. evening chronotype;
TGCT	cis	rs2594989	1.000	rs346077	chr3:11326102	A/C	cg00170343	chr3:11313890	ATG7	0.67	5.06	0.41	1.44e-6	Circulating chemerin levels;
TGCT	cis	rs651907	0.535	rs34161138	chr3:101510388	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.86	10.4	0.68	1.35e-18	Colorectal cancer;
TGCT	cis	rs2637266	1.000	rs2130798	chr10:78329563	C/T	cg18941641	chr10:78392320	NA	0.41	4.97	0.41	2.17e-6	Pulmonary function;
TGCT	cis	rs7714584	1.000	rs7732643	chr5:150261436	A/T	cg22134413	chr5:150180641	NA	0.78	6.12	0.48	1.16e-8	Crohn's disease;
TGCT	cis	rs13242816	1.000	rs13242816	chr7:116189376	C/T	cg16553024	chr7:116138462	CAV2	-0.44	-5.26	-0.43	6.11e-7	P wave duration;
TGCT	cis	rs40363	0.620	rs1137454	chr16:3533577	C/G	cg21433313	chr16:3507492	NAT15	-0.35	-4.53	-0.38	1.36e-5	Tuberculosis;
TGCT	cis	rs7582180	0.614	rs4851309	chr2:100975390	C/T	cg08017756	chr2:100939284	LONRF2	-0.3	-4.87	-0.4	3.38e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10779751	1.000	rs2253213	chr1:11265785	A/G	cg08854313	chr1:11322531	MTOR	1.0	9.07	0.63	2.26e-15	Body mass index;
TGCT	cis	rs6964587	1.000	rs13245393	chr7:91641928	A/G	cg17063962	chr7:91808500	NA	0.91	9.99	0.67	1.32e-17	Breast cancer;
TGCT	cis	rs3806843	0.868	rs2531352	chr5:140119534	A/G	cg19875535	chr5:140030758	IK	-0.35	-5.94	-0.47	2.67e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2019216	0.500	rs7359613	chr17:21944028	T/C	cg22648282	chr17:21454238	C17orf51	-0.58	-4.95	-0.41	2.37e-6	Pelvic organ prolapse;
TGCT	cis	rs4765905	0.610	rs2238053	chr12:2317096	C/T	cg07807026	chr12:2041581	NA	0.24	4.51	0.38	1.47e-5	Schizophrenia;
TGCT	cis	rs6570726	0.935	rs409121	chr6:145839793	G/A	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11785400	1.000	rs7459630	chr8:143738585	A/C	cg24634471	chr8:143751801	JRK	0.57	6.18	0.49	8.56e-9	Schizophrenia;
TGCT	cis	rs10782582	0.609	rs1630587	chr1:76399787	T/C	cg10523679	chr1:76189770	ACADM	-0.58	-5.21	-0.42	7.7e-7	Daytime sleep phenotypes;
TGCT	cis	rs2404602	0.716	rs67920045	chr15:76800084	G/A	cg22467129	chr15:76604101	ETFA	-0.48	-5.7	-0.46	8.38e-8	Blood metabolite levels;
TGCT	cis	rs4273100	1.000	rs4924986	chr17:19242467	C/T	cg01534423	chr17:18965556	NA	-0.9	-6.22	-0.49	7.01e-9	Schizophrenia;
TGCT	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg03188948	chr7:1209495	NA	0.43	5.33	0.43	4.54e-7	Longevity;Endometriosis;
TGCT	cis	rs3772130	0.962	rs6768621	chr3:121530274	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.72	0.39	6.25e-6	Cognitive performance;
TGCT	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg10295955	chr4:187884368	NA	0.96	14.31	0.79	5.09e-28	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg05590025	chr7:65112418	INTS4L2	-0.76	-4.56	-0.38	1.21e-5	Diabetic kidney disease;
TGCT	cis	rs10089	1.000	rs7713877	chr5:127428825	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	8.19	0.59	2.7e-13	Ileal carcinoids;
TGCT	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg22168489	chr12:122356033	WDR66	0.21	4.63	0.38	9.2e-6	Mean platelet volume;
TGCT	cis	rs34526934	0.608	rs13017511	chr2:177035395	A/G	cg26754761	chr2:177040938	NA	-0.29	-5.43	-0.44	2.86e-7	Obstructive sleep apnea trait (apnea hypopnea index);
TGCT	cis	rs4253772	0.550	rs6007830	chr22:46711323	C/T	cg24881330	chr22:46731750	TRMU	1.04	5.41	0.44	3.12e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs7044106	0.791	rs4837793	chr9:123483621	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	7.01	0.53	1.37e-10	Hip circumference adjusted for BMI;
TGCT	cis	rs4478858	0.735	rs68008576	chr1:31805905	T/C	cg07478791	chr1:31886160	SERINC2	-0.51	-4.95	-0.41	2.33e-6	Alcohol dependence;
TGCT	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg11301795	chr4:187892539	NA	-0.35	-5.41	-0.44	3.11e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs734999	0.588	rs745368	chr1:2524205	C/T	cg18854424	chr1:2615690	NA	0.46	5.23	0.43	6.92e-7	Ulcerative colitis;
TGCT	cis	rs826838	1.000	rs10880785	chr12:38655405	T/G	cg13010199	chr12:38710504	ALG10B	0.77	6.31	0.49	4.59e-9	Heart rate;
TGCT	cis	rs13191362	0.688	rs73035006	chr6:162997083	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs9527	0.590	rs3740386	chr10:104931051	C/T	cg04362960	chr10:104952993	NT5C2	0.67	5.64	0.45	1.07e-7	Arsenic metabolism;
TGCT	cis	rs16854884	0.770	rs1530477	chr3:143819506	A/G	cg06585982	chr3:143692056	C3orf58	-0.59	-4.64	-0.38	8.56e-6	Economic and political preferences (feminism/equality);
TGCT	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.31	0.43	4.9e-7	Prudent dietary pattern;
TGCT	cis	rs4566357	1.000	rs10933167	chr2:227925969	T/C	cg11843606	chr2:227700838	RHBDD1	-0.5	-4.49	-0.37	1.59e-5	Coronary artery disease;
TGCT	cis	rs11696501	0.688	rs6094192	chr20:44297796	G/A	cg11783356	chr20:44313418	WFDC10B	-0.32	-4.63	-0.38	9.25e-6	Brain structure;
TGCT	cis	rs7267979	1.000	rs4815405	chr20:25317492	T/C	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7267979	0.966	rs2500417	chr20:25383287	A/G	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg25482853	chr8:67687455	SGK3	1.26	10.61	0.69	4.22e-19	Obesity-related traits;
TGCT	cis	rs6570726	0.935	rs388394	chr6:145852689	C/T	cg05347473	chr6:146136440	FBXO30	0.48	4.5	0.37	1.55e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs12579753	1.000	rs11115030	chr12:82203021	A/T	cg07988820	chr12:82153109	PPFIA2	-0.65	-6.87	-0.52	2.82e-10	Resting heart rate;
TGCT	trans	rs73411413	0.608	rs7126170	chr11:1539387	C/A	cg13381631	chr10:46776799	NA	-0.38	-6.68	-0.51	7.16e-10	Myringotomy;
TGCT	cis	rs2072499	0.966	rs2244144	chr1:156184598	G/A	cg24450063	chr1:156163899	SLC25A44	1.18	13.56	0.77	2.93e-26	Testicular germ cell tumor;
TGCT	cis	rs5769707	0.681	rs2319346	chr22:50029640	A/G	cg06623630	chr22:50017776	C22orf34	-0.27	-4.6	-0.38	1.04e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs6089584	0.888	rs6142927	chr20:60605848	A/G	cg06108461	chr20:60628389	TAF4	-0.64	-9.17	-0.64	1.27e-15	Body mass index;
TGCT	cis	rs9650657	0.707	rs2005309	chr8:10652170	T/C	cg27411982	chr8:10470053	RP1L1	-0.23	-4.99	-0.41	2.03e-6	Neuroticism;
TGCT	cis	rs6459788	0.685	rs13226469	chr7:157235777	G/A	cg06271696	chr7:157225062	NA	-0.31	-5.45	-0.44	2.56e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs2721195	0.845	rs1063739	chr8:145729727	C/A	cg11211951	chr8:145729740	GPT	0.28	6.65	0.51	8.38e-10	Age at first birth;
TGCT	cis	rs79349575	0.783	rs4793995	chr17:47019399	A/C	cg07967210	chr17:47022446	SNF8	0.44	6.13	0.48	1.1e-8	Type 2 diabetes;
TGCT	cis	rs910316	1.000	rs7156105	chr14:75541954	C/A	cg11812906	chr14:75593930	NEK9	0.74	7.31	0.55	2.88e-11	Height;
TGCT	cis	rs12791968	1.000	rs10838397	chr11:45009133	A/G	cg11846598	chr11:44996168	LOC221122	0.31	5.97	0.47	2.33e-8	Inhibitory control;
TGCT	cis	rs2404602	0.716	rs12917430	chr15:76674360	T/C	cg22467129	chr15:76604101	ETFA	-0.57	-6.7	-0.52	6.39e-10	Blood metabolite levels;
TGCT	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.72	-6.26	-0.49	5.89e-9	Mean platelet volume;
TGCT	cis	rs9911578	0.935	rs420878	chr17:56709077	A/G	cg12560992	chr17:57184187	TRIM37	0.75	9.21	0.64	1.04e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs7312933	0.607	rs7965392	chr12:42540280	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.56	5.14	0.42	1.03e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg00684032	chr4:1343700	KIAA1530	-0.22	-4.72	-0.39	6.18e-6	Obesity-related traits;
TGCT	cis	rs2230307	0.536	rs11166409	chr1:100641411	T/C	cg24955406	chr1:100503596	HIAT1	-0.73	-4.94	-0.41	2.5e-6	Carotid intima media thickness;
TGCT	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.0	8.27	0.6	1.74e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg06028808	chr11:68637592	NA	0.51	6.66	0.51	7.87e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs8074700	0.539	rs3096649	chr17:46751157	A/T	cg24803719	chr17:45855879	NA	0.39	4.5	0.38	1.51e-5	Body mass index in non-asthmatics;
TGCT	cis	rs6933660	0.745	rs3800272	chr6:151744283	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	0.83	8.97	0.63	3.86e-15	Menarche (age at onset);
TGCT	cis	rs734999	0.549	rs2764845	chr1:2528999	G/T	cg18854424	chr1:2615690	NA	-0.5	-5.78	-0.46	5.64e-8	Ulcerative colitis;
TGCT	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg09060608	chr5:178986726	RUFY1	-0.62	-7.68	-0.57	4.22e-12	Lung cancer;
TGCT	cis	rs73001065	0.901	rs73004967	chr19:19717056	A/G	cg03709012	chr19:19516395	GATAD2A	1.19	5.43	0.44	2.88e-7	LDL cholesterol;
TGCT	cis	rs9372498	0.536	rs62422229	chr6:118959288	T/C	cg07617317	chr6:118971624	C6orf204	0.48	5.08	0.42	1.32e-6	Diastolic blood pressure;
TGCT	cis	rs4073582	0.595	rs801736	chr11:65928430	A/T	cg16950941	chr11:66035639	RAB1B	0.55	5.42	0.44	2.94e-7	Gout;
TGCT	cis	rs17384381	1.000	rs12140457	chr1:85860170	G/A	cg16011679	chr1:85725395	C1orf52	0.8	6.44	0.5	2.39e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs8180040	0.966	rs12636851	chr3:47463567	C/T	cg27129171	chr3:47204927	SETD2	0.64	7.39	0.55	1.89e-11	Colorectal cancer;
TGCT	cis	rs11190604	1.000	rs11190552	chr10:102206607	G/A	cg16342193	chr10:102329863	NA	-0.4	-5.31	-0.43	4.85e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7924176	0.564	rs34868542	chr10:75986157	C/T	cg19889307	chr10:75911429	ADK;AP3M1	-0.46	-4.52	-0.38	1.44e-5	Primary tooth development (time to first tooth eruption);Permanent tooth development;Primary tooth development (number of teeth);
TGCT	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg24060327	chr5:131705240	SLC22A5	-0.61	-6.32	-0.49	4.29e-9	Acylcarnitine levels;
TGCT	cis	rs514406	0.698	rs1775540	chr1:53407893	C/A	cg08736216	chr1:53307985	ZYG11A	-0.23	-4.56	-0.38	1.19e-5	Monocyte count;
TGCT	cis	rs7937612	1.000	rs11601535	chr11:120333801	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.29	-4.48	-0.37	1.66e-5	Intraocular pressure;
TGCT	cis	rs911186	0.891	rs6914824	chr6:27139048	C/T	cg16898833	chr6:26189333	HIST1H4D	0.74	4.48	0.37	1.71e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6087990	0.568	rs853854	chr20:31420757	T/A	cg13636640	chr20:31349939	DNMT3B	0.85	9.01	0.63	3.16e-15	Ulcerative colitis;
TGCT	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg03517284	chr6:25882590	NA	-0.58	-5.3	-0.43	5.05e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7267979	0.933	rs2424708	chr20:25281398	C/T	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6586163	0.872	rs1926200	chr10:90746533	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.38	-4.78	-0.39	4.79e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs12497850	0.931	rs7628719	chr3:48995487	C/T	cg05785598	chr3:49045655	WDR6	0.37	4.83	0.4	3.98e-6	Parkinson's disease;
TGCT	cis	rs933688	1.000	rs12188467	chr5:90765632	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.06	10.48	0.69	8.43e-19	Smoking behavior;
TGCT	cis	rs5769765	1.000	rs2295408	chr22:50261051	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	1.09	11.03	0.7	4e-20	Schizophrenia;
TGCT	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg26338869	chr17:61819248	STRADA	-0.55	-5.08	-0.42	1.34e-6	Prudent dietary pattern;
TGCT	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg08859206	chr1:53392774	SCP2	-0.45	-6.66	-0.51	7.99e-10	Monocyte count;
TGCT	cis	rs2239547	0.657	rs6445538	chr3:52874288	T/C	cg10802521	chr3:52805072	NEK4	-0.65	-6.12	-0.48	1.16e-8	Schizophrenia;
TGCT	cis	rs2070488	0.662	rs7372545	chr3:38507570	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.65	5.11	0.42	1.19e-6	Electrocardiographic conduction measures;
TGCT	cis	rs6964587	1.000	rs1063243	chr7:91726927	A/C	cg22709100	chr7:91322751	NA	0.29	4.8	0.4	4.45e-6	Breast cancer;
TGCT	cis	rs939658	0.935	rs2204069	chr15:79449335	A/G	cg17916960	chr15:79447300	NA	0.55	8.82	0.62	8.87e-15	Refractive error;
TGCT	cis	rs6570726	0.935	rs416987	chr6:145847005	G/C	cg23711669	chr6:146136114	FBXO30	0.68	6.67	0.51	7.58e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2562456	0.652	rs62110214	chr19:21775208	G/A	cg13978929	chr19:21580086	ZNF493	-0.56	-4.72	-0.39	6.29e-6	Pain;
TGCT	cis	rs3862435	0.610	rs2589942	chr15:90935181	T/C	cg14166756	chr15:90894880	ZNF774	-0.28	-4.64	-0.38	8.87e-6	Response to exercise (triglyceride level interaction);
TGCT	cis	rs1843834	0.755	rs10197382	chr2:225574650	T/C	cg22455342	chr2:225449267	CUL3	0.66	6.28	0.49	5.25e-9	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs6701037	0.681	rs34370567	chr1:175131340	C/T	cg00321850	chr1:175162397	KIAA0040	-0.4	-5.71	-0.46	7.97e-8	Alcohol dependence;
TGCT	cis	rs7582180	0.764	rs7425449	chr2:100928393	A/G	cg08017756	chr2:100939284	LONRF2	-0.3	-4.91	-0.4	2.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2235642	0.891	rs2281231	chr16:1601879	A/G	cg11375102	chr16:1583810	IFT140;TMEM204	-0.29	-5.33	-0.43	4.51e-7	Coronary artery disease;
TGCT	cis	rs2692947	0.740	rs11695514	chr2:96548068	C/T	cg23100626	chr2:96804247	ASTL	0.37	4.44	0.37	1.93e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs10892173	0.703	rs1014034	chr11:117661734	G/C	cg07621104	chr11:117668040	DSCAML1	0.5	5.06	0.41	1.46e-6	Myopia;
TGCT	cis	rs72945132	0.882	rs56770826	chr11:70128874	A/G	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs2075371	0.830	rs1421478	chr7:133922793	T/A	cg11752832	chr7:134001865	SLC35B4	0.67	5.53	0.44	1.78e-7	Mean platelet volume;
TGCT	cis	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg20637647	chr7:64974828	NA	1.0	5.59	0.45	1.4e-7	Diabetic kidney disease;
TGCT	cis	rs13256369	0.950	rs13248096	chr8:8577476	C/T	cg06671706	chr8:8559999	CLDN23	0.34	4.52	0.38	1.4e-5	Obesity-related traits;
TGCT	cis	rs7208859	0.623	rs73267858	chr17:29059737	A/G	cg13385521	chr17:29058706	SUZ12P	0.79	4.77	0.39	5.16e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs10892173	0.566	rs10892175	chr11:117674355	G/A	cg21014159	chr11:117668035	DSCAML1	0.61	5.86	0.47	3.95e-8	Myopia;
TGCT	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg22920501	chr2:26401640	FAM59B	-0.74	-6.4	-0.5	2.86e-9	Gut microbiome composition (summer);
TGCT	cis	rs35883536	0.584	rs56112014	chr1:101037431	A/G	cg10298815	chr1:101004474	GPR88	-0.25	-4.49	-0.37	1.63e-5	Monocyte count;
TGCT	cis	rs459571	0.959	rs2073818	chr9:136918662	C/A	cg14405625	chr9:136855902	VAV2	-0.32	-4.79	-0.39	4.71e-6	Platelet distribution width;
TGCT	cis	rs1371867	0.846	rs1788182	chr8:101334620	C/T	cg06636551	chr8:101224915	SPAG1	-0.42	-5.65	-0.45	1.06e-7	Atrioventricular conduction;
TGCT	trans	rs986417	0.818	rs761557	chr14:61077484	C/T	cg04611801	chr17:56402029	BZRAP1	0.88	7.29	0.55	3.2e-11	Gut microbiota (bacterial taxa);
TGCT	cis	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg25660036	chr4:7070649	GRPEL1	-0.64	-5.55	-0.45	1.68e-7	Monocyte percentage of white cells;
TGCT	cis	rs7772486	0.686	rs9390349	chr6:146054430	T/G	cg23711669	chr6:146136114	FBXO30	-0.87	-9.51	-0.65	1.94e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg11247378	chr22:39784982	NA	-0.73	-9.59	-0.65	1.22e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs2816062	0.721	rs2816047	chr1:18893728	A/C	cg18795169	chr1:18902165	NA	-0.6	-14.18	-0.79	1.01e-27	Urate levels in lean individuals;
TGCT	cis	rs11948739	0.501	rs79115810	chr5:130374516	A/G	cg08523029	chr5:130500466	HINT1	-0.61	-5.08	-0.42	1.34e-6	Pediatric bone mineral content (hip);
TGCT	cis	rs11997175	0.716	rs7460818	chr8:33816362	A/G	ch.8.33884649F	chr8:33765107	NA	0.34	5.28	0.43	5.56e-7	Body mass index;
TGCT	cis	rs950027	0.620	rs1153862	chr15:45631868	A/G	cg26924012	chr15:45694286	SPATA5L1	0.79	8.86	0.62	6.92e-15	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs10514758	0.744	rs1521564	chr3:114853163	A/G	cg05943254	chr3:114009756	NA	-0.85	-5.06	-0.41	1.48e-6	Urate levels in obese individuals;
TGCT	cis	rs1865760	0.566	rs3752419	chr6:26027433	C/T	cg17042849	chr6:26104293	HIST1H4C	-0.6	-5.28	-0.43	5.54e-7	Height;
TGCT	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg12288994	chr5:1860383	NA	0.23	4.57	0.38	1.18e-5	Cardiovascular disease risk factors;
TGCT	cis	rs2276314	0.857	rs59649576	chr18:33616075	G/T	cg19628046	chr18:33552617	C18orf21	0.52	4.56	0.38	1.2e-5	Endometriosis;Drug-induced torsades de pointes;
TGCT	cis	rs459571	1.000	rs467387	chr9:136907005	G/A	cg14405625	chr9:136855902	VAV2	-0.31	-4.72	-0.39	6.32e-6	Platelet distribution width;
TGCT	cis	rs6912958	0.754	rs4587143	chr6:88292291	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-5.06	-0.41	1.45e-6	Monocyte percentage of white cells;
TGCT	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg07061783	chr6:25882402	NA	-0.45	-4.82	-0.4	4.14e-6	Blood metabolite levels;
TGCT	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg15242686	chr22:24348715	GSTTP1	-0.5	-5.91	-0.47	3.07e-8	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs1552244	0.554	rs2272120	chr3:10046703	C/T	cg00149659	chr3:10157352	C3orf10	0.69	4.99	0.41	2.03e-6	Alzheimer's disease;
TGCT	cis	rs8062405	1.000	rs3888190	chr16:28889486	C/A	cg09754948	chr16:28834200	ATXN2L	0.59	4.45	0.37	1.9e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs79057730	0.599	rs6951032	chr7:794092	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.7	6.6	0.51	1.1e-9	Initial pursuit acceleration;
TGCT	cis	rs514406	0.644	rs928451	chr1:53195800	A/G	cg22166914	chr1:53195759	ZYG11B	-0.5	-9.42	-0.65	3.19e-16	Monocyte count;
TGCT	cis	rs933688	1.000	rs7715402	chr5:90679504	T/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.95	8.76	0.62	1.19e-14	Smoking behavior;
TGCT	cis	rs7714584	1.000	rs6874560	chr5:150182713	A/C	cg22134413	chr5:150180641	NA	1.13	8.18	0.59	2.91e-13	Crohn's disease;
TGCT	cis	rs10504229	1.000	rs76270388	chr8:58195605	T/A	cg24829409	chr8:58192753	C8orf71	-0.55	-4.77	-0.39	5.18e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7681440	0.904	rs6816469	chr4:90772885	G/C	cg26578617	chr4:90757533	SNCA	-0.46	-4.73	-0.39	6.01e-6	Dementia with Lewy bodies;
TGCT	cis	rs17331151	0.541	rs11709430	chr3:52862055	G/A	cg07884673	chr3:53033167	SFMBT1	0.5	5.97	0.47	2.3e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs9910055	0.529	rs368328	chr17:42170289	G/A	cg13607699	chr17:42295918	UBTF	-0.62	-4.87	-0.4	3.38e-6	Total body bone mineral density;
TGCT	cis	rs4563143	0.675	rs17498203	chr19:29279734	G/T	cg12667521	chr19:29218732	NA	0.55	5.9	0.47	3.29e-8	Methadone dose in opioid dependence;
TGCT	cis	rs4824093	0.610	rs73441787	chr22:50269646	A/G	cg20569369	chr22:51173646	NA	0.28	4.69	0.39	7.23e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs1375194	0.582	rs4670735	chr2:33801456	C/T	cg04131969	chr2:33951647	MYADML	-0.57	-5.03	-0.41	1.65e-6	Response to antidepressants in depression;
TGCT	cis	rs2982552	0.773	rs62442016	chr6:152056053	C/A	cg22157087	chr6:152012887	ESR1	0.21	5.17	0.42	8.93e-7	Bone properties (heel);
TGCT	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg26531700	chr6:26746687	NA	-0.57	-5.21	-0.42	7.62e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs11167764	0.895	rs9324865	chr5:141488792	T/C	cg08523384	chr5:141488047	NDFIP1	-0.25	-5.37	-0.43	3.72e-7	Crohn's disease;
TGCT	cis	rs7666738	0.830	rs1534318	chr4:98965058	C/T	cg05340658	chr4:99064831	C4orf37	0.53	6.04	0.48	1.64e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9291683	0.507	rs6827754	chr4:10018153	A/C	cg00071950	chr4:10020882	SLC2A9	-0.59	-4.88	-0.4	3.24e-6	Bone mineral density;
TGCT	cis	rs13191362	1.000	rs35044651	chr6:163004142	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs2153535	0.580	rs9328488	chr6:8529411	G/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.01	0.41	1.86e-6	Motion sickness;
TGCT	cis	rs12497850	0.931	rs4974085	chr3:48924900	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.41	-5.49	-0.44	2.15e-7	Parkinson's disease;
TGCT	cis	rs3096299	0.967	rs3102341	chr16:89450744	G/A	cg02187348	chr16:89574699	SPG7	0.49	4.6	0.38	1.04e-5	Multiple myeloma (IgH translocation);
TGCT	cis	rs9649213	0.614	rs4236537	chr7:97996593	T/C	cg09267113	chr7:98030324	BAIAP2L1	-0.93	-8.73	-0.62	1.45e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1903068	0.925	rs1551642	chr4:55994210	T/C	cg09978860	chr4:56023921	NA	0.58	6.38	0.5	3.16e-9	Endometriosis;
TGCT	cis	rs11677370	1.000	rs11677370	chr2:3841420	T/A	cg17052675	chr2:3827356	NA	-0.28	-4.73	-0.39	5.9e-6	Type 2 diabetes;
TGCT	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg11764359	chr7:65958608	NA	0.61	5.53	0.44	1.84e-7	Aortic root size;
TGCT	cis	rs2050392	0.624	rs303450	chr10:30725337	C/A	cg18806716	chr10:30721971	MAP3K8	-0.7	-9.39	-0.64	3.84e-16	Inflammatory bowel disease;
TGCT	cis	rs2562456	0.561	rs12610883	chr19:21750059	A/G	cg01304269	chr19:21688519	ZNF429	0.58	4.73	0.39	5.93e-6	Pain;
TGCT	cis	rs9549260	0.564	rs9549270	chr13:41284193	G/T	cg21288729	chr13:41239152	FOXO1	0.86	7.76	0.57	2.68e-12	Red blood cell count;
TGCT	cis	rs4654899	0.931	rs4654730	chr1:21229286	A/T	cg01072550	chr1:21505969	NA	-0.49	-7.94	-0.58	1.03e-12	Superior frontal gyrus grey matter volume;
TGCT	trans	rs7864133	1.000	rs11139251	chr9:84063141	A/G	cg23451063	chr7:1059876	C7orf50	0.55	6.93	0.53	2.02e-10	Post bronchodilator FEV1 in COPD;
TGCT	cis	rs28714278	0.609	rs12899936	chr15:40298068	G/A	cg21830797	chr15:40226279	EIF2AK4	-0.52	-4.66	-0.39	7.94e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.09	13.7	0.78	1.38e-26	Height;
TGCT	cis	rs3821902	0.597	rs73119079	chr3:64015399	G/A	cg22134162	chr3:63841271	THOC7	-0.32	-4.73	-0.39	6.09e-6	Breast cancer;
TGCT	cis	rs4819052	0.684	rs914216	chr21:46698298	T/G	cg06618935	chr21:46677482	NA	-0.37	-5.64	-0.45	1.1e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs13102973	0.682	rs11938038	chr4:135894258	T/C	cg14419869	chr4:135874104	NA	0.26	4.6	0.38	1.03e-5	Subjective well-being;
TGCT	cis	rs4642101	0.686	rs9822382	chr3:12828828	T/G	cg05775895	chr3:12838266	CAND2	0.78	8.9	0.62	5.77e-15	QRS complex (12-leadsum);
TGCT	trans	rs7618501	0.699	rs9862795	chr3:49915506	A/T	cg21659725	chr3:3221576	CRBN	0.78	9.34	0.64	4.99e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs11190604	1.000	rs10883503	chr10:102275504	C/A	cg16342193	chr10:102329863	NA	-0.44	-5.65	-0.45	1.06e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7666738	0.830	rs6819177	chr4:99040907	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs155076	0.938	rs9509630	chr13:21844314	G/A	cg11317459	chr13:21872234	NA	-1.42	-12.02	-0.73	1.53e-22	White matter hyperintensity burden;
TGCT	cis	rs9611519	0.780	rs9611542	chr22:41677317	C/T	cg06634786	chr22:41940651	POLR3H	-0.63	-5.84	-0.46	4.26e-8	Neuroticism;
TGCT	cis	rs6570726	0.846	rs6914304	chr6:145921017	T/C	cg05347473	chr6:146136440	FBXO30	0.5	4.59	0.38	1.07e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10744422	0.764	rs6489241	chr12:123288739	C/G	cg18912006	chr12:123335444	HIP1R	0.56	4.78	0.39	4.84e-6	Schizophrenia;
TGCT	cis	rs651907	0.557	rs13077925	chr3:101488181	T/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.87	10.51	0.69	7.46e-19	Colorectal cancer;
TGCT	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg05368731	chr17:41323189	NBR1	1.08	11.0	0.7	4.76e-20	Menopause (age at onset);
TGCT	cis	rs6121246	0.529	rs6060145	chr20:30178631	T/C	cg13852791	chr20:30311386	BCL2L1	0.71	4.54	0.38	1.31e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs13108904	0.517	rs7671242	chr4:1339875	G/A	cg03303774	chr4:1407052	NA	0.35	5.41	0.44	3.17e-7	Obesity-related traits;
TGCT	cis	rs9581857	0.685	rs9319373	chr13:28042835	A/G	cg22138327	chr13:27999177	GTF3A	0.68	4.57	0.38	1.14e-5	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9814567	1.000	rs62271514	chr3:134298554	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.92	8.42	0.6	7.71e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg22963979	chr7:1858916	MAD1L1	-0.35	-5.51	-0.44	2.01e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs17608059	0.679	rs9898056	chr17:13951966	C/G	cg11395062	chr17:14139857	CDRT15	0.39	5.08	0.41	1.36e-6	Temperament;
TGCT	cis	rs9733	0.596	rs72702556	chr1:150680115	C/T	cg09365446	chr1:150670422	GOLPH3L	0.3	4.52	0.38	1.4e-5	Tonsillectomy;
TGCT	cis	rs739496	0.579	rs12423041	chr12:112324846	A/G	cg10833066	chr12:111807467	FAM109A	0.38	5.44	0.44	2.7e-7	Platelet count;
TGCT	cis	rs782590	1.000	rs782594	chr2:55844445	T/C	cg03859395	chr2:55845619	SMEK2	0.92	11.37	0.71	5.88e-21	Metabolic syndrome;
TGCT	cis	rs10504229	1.000	rs59275611	chr8:58195191	G/A	cg24829409	chr8:58192753	C8orf71	-0.55	-4.79	-0.39	4.77e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7681440	1.000	rs1471483	chr4:90754292	A/G	cg14346243	chr4:90757452	SNCA	-0.57	-5.37	-0.43	3.77e-7	Dementia with Lewy bodies;
TGCT	cis	rs1371867	0.817	rs1788208	chr8:101312515	T/C	cg00191853	chr8:101177733	SPAG1	-0.22	-4.47	-0.37	1.75e-5	Atrioventricular conduction;
TGCT	cis	rs10791097	0.694	rs4457753	chr11:130755575	A/G	cg12179176	chr11:130786555	SNX19	0.83	10.36	0.68	1.73e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs7666738	0.544	rs35160902	chr4:98974690	A/T	cg05340658	chr4:99064831	C4orf37	0.51	5.83	0.46	4.56e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs35306767	0.807	rs34885925	chr10:919032	G/C	cg20503657	chr10:835505	NA	0.77	11.34	0.71	6.95e-21	Eosinophil percentage of granulocytes;
TGCT	cis	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg15556689	chr8:8085844	FLJ10661	-0.67	-6.23	-0.49	6.75e-9	Mood instability;
TGCT	cis	rs7681440	0.904	rs58864428	chr4:90766986	T/C	cg14346243	chr4:90757452	SNCA	-0.57	-5.6	-0.45	1.31e-7	Dementia with Lewy bodies;
TGCT	cis	rs9921222	1.000	rs9921222	chr16:375782	A/G	cg00101154	chr16:420108	MRPL28	0.57	6.84	0.52	3.28e-10	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs7524258	0.868	rs8179413	chr1:7267729	T/G	cg07173049	chr1:7289937	CAMTA1	0.31	5.29	0.43	5.39e-7	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs7727544	0.735	rs272867	chr5:131681057	G/A	cg24060327	chr5:131705240	SLC22A5	-0.56	-6.26	-0.49	5.61e-9	Blood metabolite levels;
TGCT	cis	rs9381040	0.674	rs3747742	chr6:41162518	C/T	cg03526776	chr6:41159608	TREML2	-0.28	-5.68	-0.45	9.15e-8	Alzheimer's disease (late onset);
TGCT	cis	rs17473412	0.677	rs9327298	chr5:122850321	G/A	cg15125798	chr5:122621645	NA	-0.57	-5.2	-0.42	8.05e-7	Total body bone mineral density;
TGCT	cis	rs11190604	1.000	rs10786598	chr10:102291579	G/A	cg23241863	chr10:102295624	HIF1AN	0.68	5.17	0.42	9.14e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.5	5.34	0.43	4.3e-7	Lymphocyte counts;
TGCT	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg07507251	chr3:52567010	NT5DC2	0.48	6.59	0.51	1.11e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs3806843	0.933	rs2879087	chr5:140188575	G/C	cg19875535	chr5:140030758	IK	0.35	5.85	0.47	4.01e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7824557	0.614	rs2736286	chr8:11227104	A/G	cg21775007	chr8:11205619	TDH	-0.69	-6.92	-0.53	2.1e-10	Retinal vascular caliber;
TGCT	cis	rs2739330	0.615	rs2858911	chr22:24297195	G/T	cg12419862	chr22:24373484	LOC391322	-0.8	-8.67	-0.61	1.97e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs3784262	1.000	rs4646622	chr15:58257199	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.49	-7.7	-0.57	3.78e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs7586879	0.593	rs11689546	chr2:25130451	A/G	cg15423357	chr2:25149977	NA	0.5	4.88	0.4	3.13e-6	Body mass index;
TGCT	cis	rs10782582	0.609	rs1796827	chr1:76391536	A/T	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.53	4.66	0.39	7.96e-6	Daytime sleep phenotypes;
TGCT	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2404602	0.536	rs7165025	chr15:76766434	G/A	cg26408565	chr15:76604113	ETFA	-0.37	-4.99	-0.41	2.03e-6	Blood metabolite levels;
TGCT	cis	rs6089584	0.888	rs6061405	chr20:60617033	A/G	cg13770153	chr20:60521292	NA	-0.54	-7.13	-0.54	7.45e-11	Body mass index;
TGCT	cis	rs7666738	0.546	rs62320963	chr4:98839297	A/G	cg05340658	chr4:99064831	C4orf37	0.55	6.01	0.48	1.91e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1371867	0.875	rs1612773	chr8:101337818	G/C	cg00191853	chr8:101177733	SPAG1	-0.23	-4.68	-0.39	7.34e-6	Atrioventricular conduction;
TGCT	cis	rs727563	0.565	rs132774	chr22:42031953	C/G	cg17554472	chr22:41940697	POLR3H	-0.47	-5.04	-0.41	1.61e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs8177253	0.633	rs10935073	chr3:133439184	T/C	cg11941060	chr3:133502564	NA	-0.27	-5.42	-0.44	2.94e-7	Iron status biomarkers;
TGCT	cis	rs35264875	1.000	rs35264875	chr11:68846399	A/T	cg02660097	chr11:68866761	NA	0.32	4.96	0.41	2.3e-6	Blond vs. brown hair color;
TGCT	cis	rs2153535	0.580	rs4365970	chr6:8453813	C/T	cg07606381	chr6:8435919	SLC35B3	-0.51	-4.86	-0.4	3.45e-6	Motion sickness;
TGCT	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg05368731	chr17:41323189	NBR1	1.16	14.14	0.79	1.28e-27	Menopause (age at onset);
TGCT	cis	rs12142240	0.659	rs17361873	chr1:46832686	A/G	cg14993813	chr1:46806288	NSUN4	-0.58	-4.8	-0.4	4.46e-6	Menopause (age at onset);
TGCT	cis	rs9303401	0.659	rs17822735	chr17:56620167	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.85	0.47	4.05e-8	Height;
TGCT	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg11494091	chr17:61959527	GH2	0.61	14.81	0.8	3.37e-29	Prudent dietary pattern;
TGCT	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg08280861	chr8:58055591	NA	0.55	6.23	0.49	6.59e-9	Developmental language disorder (linguistic errors);
TGCT	cis	rs3935685	0.874	rs28406214	chr15:77996537	G/A	cg25212270	chr15:78015279	NA	0.26	5.61	0.45	1.23e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs13394619	1.000	rs2884374	chr2:11731846	C/T	cg07314298	chr2:11723111	GREB1	0.29	5.12	0.42	1.14e-6	Endometriosis;
TGCT	cis	rs7666738	0.830	rs6825211	chr4:98807698	A/T	cg05340658	chr4:99064831	C4orf37	0.49	5.75	0.46	6.46e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4713118	0.955	rs9368528	chr6:27683798	G/A	cg10876282	chr6:28092338	ZSCAN16	0.5	4.62	0.38	9.35e-6	Parkinson's disease;
TGCT	trans	rs551517	0.541	rs1751242	chr9:113641783	T/A	cg18410444	chr5:89825535	LYSMD3	0.66	6.73	0.52	5.51e-10	Post bronchodilator FEV1 in COPD;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
TGCT	cis	rs6969780	1.000	rs6461985	chr7:27150634	T/C	cg04317399	chr7:27170313	HOXA4	0.45	4.47	0.37	1.77e-5	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs7772486	0.714	rs1883365	chr6:146076749	C/T	cg23711669	chr6:146136114	FBXO30	-0.88	-9.63	-0.65	1.01e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9303401	0.614	rs34550282	chr17:57092788	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.63	5.87	0.47	3.77e-8	Cognitive test performance;
TGCT	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg06028808	chr11:68637592	NA	0.53	6.86	0.52	2.9e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs67478160	0.595	rs12879501	chr14:104272634	G/T	cg26031613	chr14:104095156	KLC1	-0.64	-6.58	-0.51	1.2e-9	Schizophrenia;
TGCT	cis	rs6500602	0.963	rs7201012	chr16:4480682	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.31	5.19	0.42	8.2e-7	Schizophrenia;
TGCT	cis	rs7772486	0.521	rs9485017	chr6:146023326	C/T	cg05347473	chr6:146136440	FBXO30	0.61	5.76	0.46	6.18e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7666738	0.830	rs4699592	chr4:98974202	A/C	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9467603	1.000	rs1892250	chr6:25769024	T/C	cg16898833	chr6:26189333	HIST1H4D	-0.99	-4.75	-0.39	5.62e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs79057730	0.599	rs4721086	chr7:821123	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.73	5.59	0.45	1.36e-7	Initial pursuit acceleration;
TGCT	cis	rs9467773	1.000	rs1056667	chr6:26510564	T/C	cg09904177	chr6:26538194	HMGN4	0.65	6.53	0.51	1.5e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs13185784	0.667	rs4700924	chr5:179645870	A/C	cg04734276	chr5:178882605	NA	0.29	4.46	0.37	1.79e-5	TRAIL levels;
TGCT	cis	rs910187	0.605	rs6063079	chr20:45804275	C/G	cg27589058	chr20:45804311	EYA2	-0.36	-8.65	-0.61	2.2e-14	Migraine;
TGCT	cis	rs2439831	0.867	rs28461955	chr15:43661459	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	8.65	0.61	2.26e-14	Lung cancer in ever smokers;
TGCT	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg06873352	chr17:61820015	STRADA	0.58	6.39	0.5	3.01e-9	Prudent dietary pattern;
TGCT	cis	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg08975724	chr8:8085496	FLJ10661	0.64	6.03	0.48	1.77e-8	Mood instability;
TGCT	cis	rs10791323	0.604	rs2851116	chr11:133705759	G/A	cg15485101	chr11:133734466	NA	0.41	5.18	0.42	8.59e-7	Childhood ear infection;
TGCT	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg02788857	chr8:22132959	PIWIL2	-0.26	-4.87	-0.4	3.26e-6	Hypertriglyceridemia;
TGCT	cis	rs7666738	0.830	rs13133355	chr4:98919415	A/G	cg05340658	chr4:99064831	C4orf37	0.53	6.12	0.48	1.13e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2456568	0.771	rs8181530	chr11:93638678	G/A	cg16099599	chr11:93583650	C11orf90	-0.4	-5.12	-0.42	1.13e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg06618935	chr21:46677482	NA	-0.36	-5.39	-0.44	3.38e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs36051895	0.623	rs7043634	chr9:5263146	G/A	cg02405213	chr9:5042618	JAK2	-0.72	-9.47	-0.65	2.37e-16	Pediatric autoimmune diseases;
TGCT	cis	rs7000551	0.556	rs13258367	chr8:22235759	C/A	cg12081754	chr8:22256438	SLC39A14	0.32	4.96	0.41	2.23e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs377070	0.934	rs309407	chr4:123619335	T/C	cg10495464	chr4:123653540	BBS12;LOC729338	0.48	5.32	0.43	4.61e-7	Mosquito bite size;
TGCT	cis	rs9393692	0.645	rs2179152	chr6:26325888	T/C	cg00631329	chr6:26305371	NA	-0.46	-6.91	-0.53	2.23e-10	Educational attainment;
TGCT	cis	rs1395	1.000	rs1275501	chr2:27419282	A/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.5	-6.65	-0.51	8.47e-10	Blood metabolite levels;
TGCT	cis	rs71435601	0.628	rs563696	chr2:21389430	T/A	cg25035485	chr2:21266500	APOB	0.51	4.48	0.37	1.64e-5	Cholesterol, total;
TGCT	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.18	0.49	8.33e-9	Electroencephalogram traits;
TGCT	cis	rs12477438	0.520	rs11123763	chr2:99750673	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	13.05	0.76	4.93e-25	Chronic sinus infection;
TGCT	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg23758822	chr17:41437982	NA	0.72	6.77	0.52	4.51e-10	Menopause (age at onset);
TGCT	cis	rs12579753	0.917	rs10129029	chr12:82180324	G/A	cg07988820	chr12:82153109	PPFIA2	-0.59	-6.19	-0.49	7.93e-9	Resting heart rate;
TGCT	cis	rs9549367	0.713	rs3024776	chr13:113827075	A/G	cg00898013	chr13:113819073	PROZ	0.57	7.24	0.55	4.08e-11	Platelet distribution width;
TGCT	cis	rs6088580	0.634	rs2184836	chr20:32963369	A/G	cg08999081	chr20:33150536	PIGU	-0.29	-5.65	-0.45	1.02e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg23302884	chr18:44338147	ST8SIA5	-0.41	-4.68	-0.39	7.26e-6	Personality dimensions;
TGCT	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg02953382	chr22:24373134	LOC391322	-0.82	-9.12	-0.63	1.73e-15	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9902453	0.904	rs7213076	chr17:28419428	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-7.31	-0.55	2.88e-11	Coffee consumption (cups per day);
TGCT	cis	rs9611565	0.921	rs2281332	chr22:41746212	T/C	cg03806693	chr22:41940476	POLR3H	-0.87	-9.3	-0.64	6.07e-16	Vitiligo;
TGCT	cis	rs17331151	0.573	rs28552648	chr3:52865593	G/A	cg11137980	chr3:52469226	SEMA3G	0.29	5.14	0.42	1.04e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs6951245	0.542	rs28460147	chr7:1217192	G/A	cg03188948	chr7:1209495	NA	0.71	6.11	0.48	1.18e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg11494091	chr17:61959527	GH2	-0.53	-11.85	-0.73	4e-22	Prudent dietary pattern;
TGCT	cis	rs7829975	0.508	rs1594437	chr8:8825875	T/C	cg11995313	chr8:8860691	ERI1	-0.56	-4.95	-0.41	2.35e-6	Mood instability;
TGCT	cis	rs11098499	1.000	rs7659194	chr4:120207147	T/G	cg09307838	chr4:120376055	NA	0.49	4.47	0.37	1.78e-5	Corneal astigmatism;
TGCT	cis	rs2404602	0.669	rs12916324	chr15:77179603	G/A	cg26408565	chr15:76604113	ETFA	-0.36	-4.52	-0.38	1.41e-5	Blood metabolite levels;
TGCT	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg10295955	chr4:187884368	NA	-0.97	-14.89	-0.8	2.14e-29	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg07424592	chr7:64974309	NA	-1.27	-7.84	-0.58	1.8e-12	Diabetic kidney disease;
TGCT	cis	rs1215050	0.740	rs1084784	chr4:98961711	T/G	cg17366294	chr4:99064904	C4orf37	-0.57	-6.12	-0.48	1.12e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.07	0.82	4.17e-32	Prudent dietary pattern;
TGCT	cis	rs4285028	0.747	rs9852845	chr3:121390618	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.92	-7.3	-0.55	3.03e-11	Multiple sclerosis;
TGCT	cis	rs3617	0.573	rs12638968	chr3:52919447	T/A	cg10802521	chr3:52805072	NEK4	0.57	6.57	0.51	1.27e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg20637647	chr7:64974828	NA	0.91	5.09	0.42	1.29e-6	Diabetic kidney disease;
TGCT	cis	rs4253772	0.513	rs6008700	chr22:46722560	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.69	5.31	0.43	4.82e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs7945705	0.902	rs1560569	chr11:8939887	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-5.44	-0.44	2.75e-7	Hemoglobin concentration;
TGCT	cis	rs2242116	0.796	rs4683297	chr3:46973673	T/C	cg27129171	chr3:47204927	SETD2	-0.64	-6.32	-0.49	4.39e-9	Birth weight;
TGCT	trans	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg13565492	chr6:43139072	SRF	-0.81	-7.66	-0.57	4.5e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2050392	0.557	rs306588	chr10:30723593	G/A	cg13289132	chr10:30722225	MAP3K8	-0.46	-5.57	-0.45	1.47e-7	Inflammatory bowel disease;
TGCT	cis	rs4936891	0.563	rs78158860	chr11:123890220	A/G	cg22125253	chr11:123886957	OR10G4	0.21	4.74	0.39	5.66e-6	Male fertility;
TGCT	cis	rs7666738	0.830	rs13137808	chr4:99047095	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs938554	0.513	rs3775946	chr4:9995256	A/G	cg02734326	chr4:10020555	SLC2A9	0.52	4.8	0.4	4.41e-6	Blood metabolite levels;
TGCT	cis	rs9467773	0.620	rs4368798	chr6:26593471	A/G	cg15659132	chr6:26577336	NA	0.87	11.0	0.7	4.77e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs2204008	0.870	rs12369578	chr12:38444227	C/T	cg26384229	chr12:38710491	ALG10B	0.85	7.59	0.56	6.74e-12	Bladder cancer;
TGCT	cis	rs362272	0.545	rs3129308	chr4:3309272	C/T	cg18352616	chr4:3374830	RGS12	0.27	5.49	0.44	2.19e-7	Serum sulfate level;
TGCT	cis	rs1812835	1	rs1812835	chr15:73507504	C/A	cg25046953	chr15:73611614	NA	0.25	4.6	0.38	1.03e-5	Heart rate variability traits (RMSSD);Heart rate variability traits (pvRSA/HF);Heart rate variability traits (SDNN);
TGCT	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.67	-0.39	7.73e-6	Prudent dietary pattern;
TGCT	cis	rs7666738	0.830	rs28728124	chr4:99001116	G/T	cg18180107	chr4:99064573	C4orf37	0.51	4.53	0.38	1.38e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs68170813	0.559	rs12532967	chr7:106937418	T/C	cg02696742	chr7:106810147	HBP1	-0.69	-5.81	-0.46	4.85e-8	Coronary artery disease;
TGCT	cis	rs1371867	0.875	rs962451	chr8:101331010	C/T	cg00191853	chr8:101177733	SPAG1	-0.22	-4.47	-0.37	1.75e-5	Atrioventricular conduction;
TGCT	cis	rs3820068	0.532	rs72645862	chr1:15920366	A/G	cg05660106	chr1:15850417	CASP9	0.84	8.27	0.6	1.8e-13	Systolic blood pressure;
TGCT	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.51	-4.48	-0.37	1.66e-5	Prudent dietary pattern;
TGCT	cis	rs10080237	0.564	rs2490224	chr6:80809833	G/A	cg08355045	chr6:80787529	NA	0.33	5.52	0.44	1.91e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
TGCT	cis	rs10927875	0.691	rs1048302	chr1:16340879	T/G	cg21385522	chr1:16154831	NA	0.6	6.34	0.49	3.95e-9	Dilated cardiomyopathy;
TGCT	cis	rs12477438	0.520	rs6741773	chr2:99738962	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.85	8.41	0.6	8.43e-14	Chronic sinus infection;
TGCT	cis	rs1532993	0.518	rs2865936	chr4:98553780	C/T	cg05340658	chr4:99064831	C4orf37	-0.38	-4.53	-0.38	1.36e-5	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs9660992	0.710	rs7367930	chr1:205235512	A/G	cg00857998	chr1:205179979	DSTYK	0.51	4.47	0.37	1.73e-5	Mean corpuscular volume;Mean platelet volume;
TGCT	cis	rs11874712	0.966	rs8094902	chr18:43666774	T/C	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	5.23	0.42	7.11e-7	Migraine - clinic-based;
TGCT	cis	rs28595532	0.841	rs114966236	chr4:119733437	T/C	cg14228332	chr4:119757509	SEC24D	1.32	6.38	0.5	3.2e-9	Cannabis dependence symptom count;
TGCT	cis	rs9393692	0.905	rs6931391	chr6:26279235	G/C	cg13736514	chr6:26305472	NA	-0.41	-5.77	-0.46	6.09e-8	Educational attainment;
TGCT	cis	rs4820539	1.000	rs4822362	chr22:23482744	C/A	cg14186256	chr22:23484241	RTDR1	0.98	12.77	0.75	2.31e-24	Bone mineral density;
TGCT	cis	rs11264213	0.901	rs72661636	chr1:36426483	T/C	cg27506609	chr1:36549197	TEKT2	0.41	4.61	0.38	9.88e-6	Schizophrenia;
TGCT	cis	rs7824557	0.651	rs6601582	chr8:11207367	C/A	cg21775007	chr8:11205619	TDH	0.73	7.14	0.54	7.09e-11	Retinal vascular caliber;
TGCT	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg12963246	chr6:28129442	ZNF389	0.53	5.19	0.42	8.46e-7	Depression;
TGCT	cis	rs10992471	0.676	rs13286566	chr9:95473178	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.58	-5.48	-0.44	2.27e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs2354432	0.607	rs9782976	chr1:146825049	A/G	cg25205988	chr1:146714368	CHD1L	1.21	7.2	0.54	5.05e-11	Mitochondrial DNA levels;
TGCT	cis	rs6840360	0.550	rs6836343	chr4:152497564	A/G	cg17479576	chr4:152424074	FAM160A1	-0.73	-7.94	-0.58	1.03e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs7216064	1.000	rs9897982	chr17:65879592	G/T	cg12091567	chr17:66097778	LOC651250	-0.84	-6.8	-0.52	4.01e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs7917772	0.582	rs4917976	chr10:104360518	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-5.36	-0.43	3.84e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs478304	0.654	rs7947604	chr11:65442059	G/C	cg17480646	chr11:65405466	SIPA1	-0.62	-8.13	-0.59	3.73e-13	Acne (severe);
TGCT	cis	rs7267979	0.789	rs1983974	chr20:25530619	A/C	cg03522245	chr20:25566470	NINL	-0.56	-5.74	-0.46	6.76e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9357506	1.000	rs935106	chr6:46304657	G/A	cg21115430	chr6:46460003	NA	-0.26	-5.16	-0.42	9.37e-7	Body mass index;
TGCT	cis	rs28374715	0.662	rs72737792	chr15:41515589	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.78	-10.91	-0.7	7.59e-20	Ulcerative colitis;
TGCT	cis	rs12458462	0.892	rs58675823	chr18:77463672	G/A	cg11879182	chr18:77439856	CTDP1	0.71	7.86	0.58	1.61e-12	Monocyte count;
TGCT	cis	rs1865760	0.532	rs2006736	chr6:26086017	C/T	cg17042849	chr6:26104293	HIST1H4C	-0.63	-5.47	-0.44	2.43e-7	Height;
TGCT	cis	rs1005277	0.540	rs289638	chr10:37923731	G/A	cg25427524	chr10:38739819	LOC399744	-0.36	-7.13	-0.54	7.28e-11	Extrinsic epigenetic age acceleration;
TGCT	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg22968622	chr17:43663579	NA	-1.09	-9.69	-0.66	7.23e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg13683864	chr3:40499215	RPL14	-1.18	-13.68	-0.78	1.54e-26	Renal cell carcinoma;
TGCT	cis	rs7926906	0.631	rs6483075	chr11:90520310	C/T	cg26138821	chr11:89956704	CHORDC1	-0.48	-4.91	-0.4	2.76e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2197308	0.740	rs11182967	chr12:37935140	A/C	cg13010199	chr12:38710504	ALG10B	0.66	5.33	0.43	4.41e-7	Morning vs. evening chronotype;
TGCT	cis	rs9486719	1.000	rs12193732	chr6:96942609	G/A	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.21	-0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs68170813	0.559	rs76299183	chr7:106904859	A/G	cg02696742	chr7:106810147	HBP1	-0.69	-5.61	-0.45	1.27e-7	Coronary artery disease;
TGCT	cis	rs7119	0.604	rs2458035	chr15:77862806	G/A	cg27398640	chr15:77910606	LINGO1	0.27	4.78	0.39	4.84e-6	Type 2 diabetes;
TGCT	cis	rs13242816	1.000	rs987791	chr7:116134701	A/G	cg16553024	chr7:116138462	CAV2	-0.45	-5.06	-0.41	1.49e-6	P wave duration;
TGCT	cis	rs10804591	1.000	rs2625984	chr3:129339101	A/G	cg07730360	chr3:128845626	NA	0.2	4.62	0.38	9.34e-6	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Hip circumference adjusted for BMI;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs6725041	0.819	rs1546718	chr2:213088329	A/G	cg16329650	chr2:213403929	ERBB4	-0.53	-4.52	-0.38	1.44e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs7617773	0.780	rs13079728	chr3:48339360	A/G	cg11946769	chr3:48343235	NME6	0.82	7.06	0.54	1.03e-10	Coronary artery disease;
TGCT	cis	rs1862618	0.525	rs2662019	chr5:56263104	A/G	cg24531977	chr5:56204891	C5orf35	0.77	6.8	0.52	3.94e-10	Initial pursuit acceleration;
TGCT	cis	rs62064224	0.593	rs916663	chr17:30835833	A/C	cg24550644	chr17:30846204	MYO1D	0.43	4.46	0.37	1.81e-5	Schizophrenia;
TGCT	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg27535305	chr1:53392650	SCP2	0.28	5.71	0.46	8.04e-8	Monocyte count;
TGCT	cis	rs10791097	0.609	rs3751039	chr11:130773076	A/G	cg12179176	chr11:130786555	SNX19	-0.92	-11.98	-0.73	1.88e-22	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	trans	rs931812	0.895	rs4236763	chr8:101913022	G/A	cg20993868	chr7:22813445	NA	0.4	8.7	0.62	1.66e-14	Attention deficit hyperactivity disorder and conduct disorder;
TGCT	cis	rs9291683	0.595	rs35250962	chr4:10048271	C/T	cg11266682	chr4:10021025	SLC2A9	0.65	8.87	0.62	6.58e-15	Bone mineral density;
TGCT	trans	rs17685	0.664	rs9801113	chr7:75792031	C/T	cg19862616	chr7:65841803	NCRNA00174	0.51	8.88	0.62	6.28e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	trans	rs877282	0.898	rs11253340	chr10:764786	G/T	cg22713356	chr15:30763199	NA	1.2	9.39	0.64	3.76e-16	Uric acid levels;
TGCT	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg08736216	chr1:53307985	ZYG11A	-0.3	-5.99	-0.47	2.09e-8	Monocyte count;
TGCT	cis	rs9303401	0.659	rs16943176	chr17:56769887	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.67	6.3	0.49	4.7e-9	Cognitive test performance;
TGCT	cis	rs2658782	1.000	rs2658781	chr11:93166368	C/T	cg18152523	chr11:93063302	CCDC67	0.55	4.8	0.4	4.49e-6	Pulmonary function decline;
TGCT	cis	rs9549367	0.774	rs9549364	chr13:113903745	T/C	cg00898013	chr13:113819073	PROZ	-0.4	-5.03	-0.41	1.64e-6	Platelet distribution width;
TGCT	cis	rs713587	0.571	rs564667	chr2:25310860	A/T	cg01884057	chr2:25150051	NA	-0.25	-4.81	-0.4	4.36e-6	Body mass index in non-asthmatics;
TGCT	trans	rs62103177	0.564	rs2115996	chr18:77701007	C/G	cg05926928	chr17:57297772	GDPD1	0.98	8.96	0.63	4.08e-15	Opioid sensitivity;
TGCT	trans	rs1814175	0.817	rs7924619	chr11:49620632	G/A	cg15704280	chr7:45808275	SEPT13	-0.73	-8.64	-0.61	2.32e-14	Height;
TGCT	cis	rs9611565	0.592	rs5758427	chr22:42099688	A/G	cg03806693	chr22:41940476	POLR3H	1.06	11.92	0.73	2.7e-22	Vitiligo;
TGCT	trans	rs9388451	0.839	rs4897157	chr6:126102981	A/T	cg05039488	chr6:79577232	IRAK1BP1	-0.72	-8.04	-0.59	6.03e-13	Brugada syndrome;
TGCT	cis	rs2288884	0.806	rs11084141	chr19:52587907	G/A	cg13540795	chr19:52551618	ZNF432	-0.64	-5.42	-0.44	2.98e-7	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs7843479	0.898	rs13282562	chr8:21869727	G/A	cg17168535	chr8:21777572	XPO7	0.62	5.62	0.45	1.18e-7	Mean corpuscular volume;
TGCT	cis	rs244731	1.000	rs244730	chr5:176539212	A/G	cg16006841	chr5:176797999	RGS14	-0.48	-6.3	-0.49	4.7e-9	Urate levels in lean individuals;
TGCT	cis	rs13256369	0.901	rs12679831	chr8:8566411	T/G	cg17143192	chr8:8559678	CLDN23	0.58	5.55	0.45	1.64e-7	Obesity-related traits;
TGCT	cis	rs73252553	0.513	rs315684	chr4:25374197	A/G	cg04009456	chr4:25379436	ANAPC4	0.42	4.72	0.39	6.24e-6	Cannabis dependence symptom count;
TGCT	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	8.39	0.6	9.03e-14	Platelet count;
TGCT	cis	rs4665630	0.522	rs1862902	chr2:23886622	A/C	cg08063864	chr2:24346004	PFN4;LOC375190	-1.13	-5.45	-0.44	2.64e-7	Hypertension;
TGCT	cis	rs3125734	0.660	rs10733769	chr10:63974255	G/T	cg05499367	chr10:63213510	TMEM26	-0.35	-4.73	-0.39	6.06e-6	Rheumatoid arthritis;
TGCT	cis	rs3751972	0.911	rs11657699	chr17:26242726	C/G	cg02948944	chr17:26242737	NA	0.48	6.79	0.52	4.09e-10	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs56309584	0.596	rs117854193	chr17:8178467	G/A	cg08322244	chr17:8066669	VAMP2	-0.57	-5.31	-0.43	4.89e-7	Initial pursuit acceleration;
TGCT	cis	rs7267979	0.899	rs442834	chr20:25458096	A/G	cg03522245	chr20:25566470	NINL	0.6	6.46	0.5	2.14e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs8064299	0.967	rs880827	chr17:72767435	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	-0.76	-7.6	-0.56	6.16e-12	Monocyte count;
TGCT	cis	rs7843479	0.582	rs7818254	chr8:21798316	C/T	cg17168535	chr8:21777572	XPO7	0.81	8.33	0.6	1.25e-13	Mean corpuscular volume;
TGCT	cis	rs259282	0.584	rs10416758	chr19:33107716	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.53	4.82	0.4	4.09e-6	Schizophrenia;
TGCT	cis	rs76878669	0.538	rs4930360	chr11:66143247	T/A	cg18002602	chr11:66138449	SLC29A2	0.54	6.62	0.51	9.7e-10	Educational attainment (years of education);
TGCT	trans	rs17471911	0.708	rs9633708	chr10:100807933	G/A	cg03484267	chr2:207988651	KLF7	-0.52	-6.67	-0.51	7.53e-10	Neuroticism;
TGCT	cis	rs10751667	1.000	rs7396366	chr11:986185	C/A	cg06064525	chr11:970664	AP2A2	-0.32	-6.43	-0.5	2.45e-9	Alzheimer's disease (late onset);
TGCT	cis	rs3806843	0.576	rs246029	chr5:140333226	G/A	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg13012494	chr21:47604986	C21orf56	0.39	4.77	0.39	5.19e-6	Testicular germ cell tumor;
TGCT	cis	rs6688613	0.685	rs61815130	chr1:166910465	T/C	cg07049167	chr1:166818506	POGK	0.25	5.15	0.42	9.73e-7	Refractive astigmatism;
TGCT	cis	rs1801251	1.000	rs36007169	chr2:233621834	A/G	cg08000102	chr2:233561755	GIGYF2	0.64	6.56	0.51	1.34e-9	Coronary artery disease;
TGCT	cis	rs1372520	0.684	rs2619341	chr4:90741773	A/G	cg01966878	chr4:90757139	SNCA	-0.3	-4.69	-0.39	7.05e-6	Neuroticism;
TGCT	cis	rs35146811	0.731	rs2257213	chr7:99810113	T/C	cg22906224	chr7:99728672	NA	-0.5	-4.51	-0.38	1.48e-5	Coronary artery disease;
TGCT	cis	rs7809950	0.861	rs2701682	chr7:107295835	G/A	cg23024343	chr7:107201750	COG5	0.43	5.98	0.47	2.23e-8	Coronary artery disease;
TGCT	cis	rs10876993	0.928	rs1689596	chr12:58053029	T/C	cg15848620	chr12:58087721	OS9	-0.72	-5.86	-0.47	3.95e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs10934753	0.632	rs2001273	chr3:125926110	C/T	cg01346077	chr3:125931526	NA	0.37	6.11	0.48	1.21e-8	Plasma homocysteine levels (post-methionine load test);
TGCT	cis	rs56104184	0.723	rs116909499	chr19:49407733	C/T	cg17863274	chr19:49399704	TULP2	-0.54	-7.43	-0.55	1.58e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs2816062	0.813	rs2745323	chr1:18882385	C/T	cg18795169	chr1:18902165	NA	-0.59	-13.16	-0.76	2.73e-25	Urate levels in lean individuals;
TGCT	cis	rs6191	0.838	rs6877893	chr5:142727193	C/T	cg17617527	chr5:142782415	NR3C1	-0.48	-4.6	-0.38	1.03e-5	Night sleep phenotypes;
TGCT	cis	rs7193541	0.965	rs7199068	chr16:74698263	C/G	cg01733217	chr16:74700730	RFWD3	0.83	7.92	0.58	1.13e-12	Multiple myeloma;
TGCT	cis	rs4077468	0.963	rs1342064	chr1:205913073	T/C	cg24503407	chr1:205819492	PM20D1	-0.39	-4.57	-0.38	1.14e-5	Cystic fibrosis-related diabetes;
TGCT	cis	rs6448317	1.000	rs11934149	chr4:24938953	T/C	cg21108841	chr4:24914750	CCDC149	-0.65	-4.95	-0.41	2.33e-6	Heschl's gyrus morphology;
TGCT	cis	rs7020830	0.931	rs7851239	chr9:37138672	A/G	cg14294708	chr9:37120828	ZCCHC7	-1.26	-13.54	-0.77	3.27e-26	Schizophrenia;
TGCT	cis	rs2456568	0.570	rs1827932	chr11:93663319	A/T	cg17595323	chr11:93583763	C11orf90	-0.43	-5.34	-0.43	4.33e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg18876405	chr7:65276391	NA	0.31	4.79	0.4	4.58e-6	Aortic root size;
TGCT	cis	rs4455778	0.538	rs9642332	chr7:49113177	T/G	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs7226408	0.857	rs55752284	chr18:34447175	G/A	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs4253772	0.530	rs9615349	chr22:46732418	T/G	cg24881330	chr22:46731750	TRMU	0.96	4.7	0.39	6.75e-6	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs782590	0.935	rs2586954	chr2:55892261	A/C	cg03859395	chr2:55845619	SMEK2	0.89	10.38	0.68	1.49e-18	Metabolic syndrome;
TGCT	cis	rs763014	0.898	rs1045277	chr16:633125	T/C	cg27436995	chr16:743998	FBXL16	-0.45	-4.82	-0.4	4.17e-6	Height;
TGCT	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg13732083	chr21:47605072	C21orf56	0.35	4.69	0.39	7.17e-6	Testicular germ cell tumor;
TGCT	cis	rs9814567	0.806	rs4955534	chr3:134319723	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.76	-7.11	-0.54	8.15e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs904251	0.600	rs9380673	chr6:37415125	T/C	cg25019722	chr6:37503610	NA	-0.46	-6.86	-0.52	2.94e-10	Cognitive performance;
TGCT	cis	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg18188782	chr20:61659543	NA	0.46	5.55	0.45	1.61e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs6495122	0.699	rs2168518	chr15:75081078	G/A	cg10253484	chr15:75165896	SCAMP2	-0.68	-6.01	-0.48	1.87e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
TGCT	cis	rs4742903	0.904	rs7028408	chr9:106859811	G/A	cg21169611	chr9:106856078	SMC2	0.49	4.6	0.38	1.03e-5	High-grade serous ovarian cancer;Breast cancer;
TGCT	cis	rs250677	0.687	rs250666	chr5:148454622	A/G	cg23229984	chr5:148520753	ABLIM3	0.21	4.89	0.4	3.11e-6	Breast cancer;
TGCT	cis	rs4713675	0.553	rs943465	chr6:33731663	G/A	cg13859433	chr6:33739653	LEMD2	-0.3	-4.65	-0.39	8.23e-6	Plateletcrit;
TGCT	cis	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg22857025	chr5:266934	NA	-0.34	-6.7	-0.52	6.65e-10	Breast cancer;
TGCT	cis	rs314370	0.951	rs3757868	chr7:100482720	G/A	cg10426581	chr7:100472382	SRRT	1.0	10.93	0.7	6.98e-20	Resting heart rate;
TGCT	cis	rs7208859	0.673	rs8077116	chr17:29140162	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs9486715	1.000	rs9373985	chr6:97063522	C/G	cg18709589	chr6:96969512	KIAA0776	-0.77	-7.12	-0.54	7.74e-11	Headache;
TGCT	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg24250549	chr1:154909240	PMVK	0.65	6.46	0.5	2.11e-9	Prostate cancer;
TGCT	cis	rs2842992	0.747	rs1547093	chr6:160205991	C/A	cg11366901	chr6:160182831	ACAT2	1.07	7.21	0.54	4.75e-11	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs10883723	0.810	rs10786669	chr10:104256094	C/G	cg05855489	chr10:104503620	C10orf26	-0.57	-4.96	-0.41	2.29e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs61931739	0.500	rs7137392	chr12:34447074	T/C	cg06521331	chr12:34319734	NA	-0.28	-4.51	-0.38	1.47e-5	Morning vs. evening chronotype;
TGCT	cis	rs6767049	0.528	rs17006724	chr3:20231788	A/G	cg00235661	chr3:20228976	SGOL1	0.32	4.93	0.4	2.58e-6	Temperament (bipolar disorder);
TGCT	cis	rs2562456	0.958	rs2562508	chr19:21726281	G/A	cg25650185	chr19:21324782	ZNF431	0.64	5.7	0.46	8.3e-8	Pain;
TGCT	cis	rs2204008	0.653	rs11182569	chr12:38572452	G/A	cg26384229	chr12:38710491	ALG10B	0.89	8.1	0.59	4.28e-13	Bladder cancer;
TGCT	cis	rs9611565	0.802	rs9611577	chr22:41793090	T/G	cg03806693	chr22:41940476	POLR3H	-1.01	-11.18	-0.71	1.71e-20	Vitiligo;
TGCT	cis	rs427394	0.632	rs169285	chr5:6736587	G/C	cg10857441	chr5:6722123	POLS	-0.28	-6.08	-0.48	1.38e-8	Menopause (age at onset);
TGCT	cis	rs11690935	0.885	rs6752812	chr2:172851502	C/A	cg13550731	chr2:172543902	DYNC1I2	-0.89	-7.89	-0.58	1.33e-12	Schizophrenia;
TGCT	cis	rs5757676	1.000	rs5757676	chr22:39841700	T/C	cg11247378	chr22:39784982	NA	-0.73	-7.55	-0.56	8.36e-12	IgG glycosylation;
TGCT	cis	rs4273100	0.605	rs28591622	chr17:19175317	A/G	cg03910582	chr17:19030146	GRAPL	0.51	6.15	0.48	9.7e-9	Schizophrenia;
TGCT	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	8.0	0.58	7.67e-13	Platelet count;
TGCT	cis	rs13191362	1.000	rs13220048	chr6:163004325	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.86	-10.09	-0.67	7.49e-18	Prudent dietary pattern;
TGCT	cis	rs11190604	1.000	rs11190557	chr10:102209369	G/A	cg23241863	chr10:102295624	HIF1AN	0.62	4.87	0.4	3.27e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7552404	1.000	rs437298	chr1:76113770	T/C	cg03433033	chr1:76189801	ACADM	-0.84	-10.0	-0.67	1.28e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs523522	0.962	rs10849753	chr12:120910813	C/T	cg12219531	chr12:120966889	COQ5	0.83	7.25	0.55	4.02e-11	High light scatter reticulocyte count;
TGCT	cis	rs6831352	0.879	rs2602879	chr4:100040652	G/A	cg12011299	chr4:100065546	ADH4	0.39	4.81	0.4	4.36e-6	Alcohol dependence;
TGCT	cis	rs208520	0.874	rs208470	chr6:66916402	G/A	cg07460842	chr6:66804631	NA	-0.9	-9.16	-0.64	1.34e-15	Exhaled nitric oxide output;
TGCT	cis	rs11252926	0.574	rs7068976	chr10:453112	A/G	cg13477178	chr10:375248	DIP2C	-0.25	-4.72	-0.39	6.33e-6	Psychosis in Alzheimer's disease;
TGCT	cis	rs7973719	0.868	rs12825629	chr12:7355583	T/C	cg07052231	chr12:7363540	PEX5	0.36	5.6	0.45	1.34e-7	IgG glycosylation;
TGCT	cis	rs9467711	0.560	rs6900665	chr6:26487169	C/T	cg16898833	chr6:26189333	HIST1H4D	0.94	4.58	0.38	1.12e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1538970	1.000	rs4660853	chr1:45849090	C/T	cg05343316	chr1:45956843	TESK2	0.66	5.06	0.41	1.47e-6	Platelet count;
TGCT	cis	rs13191362	1.000	rs13207671	chr6:162979056	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.68	5.79	0.46	5.33e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs2180341	0.814	rs9321085	chr6:127735361	T/C	cg27446573	chr6:127587934	RNF146	0.88	8.07	0.59	5.22e-13	Breast cancer;
TGCT	cis	rs7726839	0.540	rs7434	chr5:660804	A/G	cg20362242	chr5:692897	TPPP	-0.52	-4.92	-0.4	2.7e-6	Obesity-related traits;
TGCT	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg04025307	chr7:1156635	C7orf50	0.22	5.23	0.43	6.97e-7	Longevity;Endometriosis;
TGCT	cis	rs1949733	1.000	rs1949733	chr4:8503359	C/T	cg11789530	chr4:8429930	ACOX3	-0.63	-5.8	-0.46	5.2e-8	Response to antineoplastic agents;
TGCT	cis	rs9611565	0.592	rs9611612	chr22:41961189	T/C	cg03806693	chr22:41940476	POLR3H	-1.07	-11.34	-0.71	7.07e-21	Vitiligo;
TGCT	cis	rs9467773	0.935	rs4573	chr6:26546808	A/G	cg15659132	chr6:26577336	NA	0.81	10.65	0.69	3.23e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs7822232	0.908	rs6558295	chr8:145139522	C/G	cg06495924	chr8:145149574	CYC1	-1.04	-4.49	-0.37	1.6e-5	Blood metabolite levels;
TGCT	cis	rs1371867	0.846	rs1692007	chr8:101268343	T/C	cg00191853	chr8:101177733	SPAG1	0.23	4.8	0.4	4.44e-6	Atrioventricular conduction;
TGCT	cis	rs6088580	0.634	rs6058051	chr20:33044862	G/A	cg08999081	chr20:33150536	PIGU	0.29	5.6	0.45	1.31e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs10791097	0.720	rs4936121	chr11:130733878	A/G	cg12179176	chr11:130786555	SNX19	0.83	9.45	0.65	2.77e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs910187	0.678	rs7352690	chr20:45815352	C/G	cg27589058	chr20:45804311	EYA2	-0.34	-7.21	-0.54	4.78e-11	Migraine;
TGCT	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg20203395	chr5:56204925	C5orf35	-0.58	-4.87	-0.4	3.34e-6	Initial pursuit acceleration;
TGCT	cis	rs9486715	0.659	rs9399930	chr6:96854444	G/T	cg06623918	chr6:96969491	KIAA0776	1.02	12.09	0.74	1.01e-22	Headache;
TGCT	cis	rs4631830	1.000	rs4631830	chr10:51543344	C/T	cg10326726	chr10:51549505	MSMB	-0.24	-4.64	-0.38	8.63e-6	Prostate-specific antigen levels;
TGCT	cis	rs62344088	0.590	rs73016637	chr5:172462	G/A	cg10601043	chr5:1076365	SLC12A7	0.58	4.74	0.39	5.71e-6	Asthma (childhood onset);
TGCT	cis	rs4285028	1.000	rs4285028	chr3:121660664	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.78	-6.63	-0.51	9.43e-10	Multiple sclerosis;
TGCT	cis	rs4906332	0.966	rs12885786	chr14:103972503	C/T	cg26031613	chr14:104095156	KLC1	-0.54	-4.66	-0.39	8.15e-6	Coronary artery disease;
TGCT	cis	rs12681287	0.570	rs4961188	chr8:87383033	T/C	cg27223183	chr8:87520930	FAM82B	0.89	6.61	0.51	1.04e-9	Caudate activity during reward;
TGCT	cis	rs12257961	0.521	rs7899540	chr10:15382782	G/A	cg10616319	chr10:15468812	NA	0.25	4.71	0.39	6.49e-6	Selective IgA deficiency;
TGCT	cis	rs17030434	0.911	rs75822357	chr4:154738258	T/C	cg14289246	chr4:154710475	SFRP2	-0.88	-7.02	-0.53	1.3100000000000001e-10	Electrocardiographic conduction measures;
TGCT	cis	rs2956278	0.717	rs7973519	chr12:84684752	A/G	cg25678815	chr12:85673915	ALX1	-0.51	-4.64	-0.38	8.9e-6	Depressive symptoms;Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7824557	0.527	rs2572376	chr8:11237756	C/A	cg21775007	chr8:11205619	TDH	-0.7	-6.8	-0.52	3.92e-10	Retinal vascular caliber;
TGCT	trans	rs28735056	0.904	rs9967107	chr18:77633343	C/T	cg05926928	chr17:57297772	GDPD1	0.65	6.81	0.52	3.65e-10	Schizophrenia;
TGCT	cis	rs2070488	0.804	rs6764551	chr3:38460305	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.8	7.95	0.58	1e-12	Electrocardiographic conduction measures;
TGCT	cis	rs7264396	0.561	rs66483315	chr20:34573575	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.27	-4.76	-0.39	5.19e-6	Total cholesterol levels;
TGCT	cis	rs8002180	0.959	rs9590228	chr13:95923390	C/T	cg24476569	chr13:95954382	ABCC4	0.41	5.07	0.41	1.42e-6	Blood metabolite levels;
TGCT	cis	rs1008375	0.902	rs6844984	chr4:17651304	C/G	cg10189774	chr4:17578691	LAP3	0.55	4.9	0.4	2.96e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg00684032	chr4:1343700	KIAA1530	0.22	4.88	0.4	3.21e-6	Obesity-related traits;
TGCT	cis	rs5769707	0.967	rs739248	chr22:50025205	T/C	cg20744362	chr22:50050164	C22orf34	0.27	4.57	0.38	1.18e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs651907	0.535	rs61396602	chr3:101509046	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.31	-6.4	-0.5	2.91e-9	Colorectal cancer;
TGCT	cis	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg07424592	chr7:64974309	NA	1.27	7.86	0.58	1.61e-12	Diabetic kidney disease;
TGCT	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg03188948	chr7:1209495	NA	0.71	6.04	0.48	1.68e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs12580194	0.593	rs60230359	chr12:55736550	T/C	cg10672482	chr12:55725839	OR6C3	-0.51	-4.46	-0.37	1.79e-5	Cancer;
TGCT	cis	rs7208859	0.673	rs11650305	chr17:29229361	A/C	cg18442181	chr17:29233375	C17orf42	-0.79	-4.78	-0.39	4.95e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs6701037	0.566	rs1883102	chr1:175136793	T/A	cg00321850	chr1:175162397	KIAA0040	0.38	5.04	0.41	1.61e-6	Alcohol dependence;
TGCT	cis	rs17152411	0.895	rs11245422	chr10:126588143	T/C	cg07906193	chr10:126599966	NA	0.41	5.05	0.41	1.52e-6	Height;
TGCT	cis	rs453301	0.686	rs4840389	chr8:8884503	G/C	cg06636001	chr8:8085503	FLJ10661	-0.69	-5.67	-0.45	9.36e-8	Joint mobility (Beighton score);
TGCT	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg12963246	chr6:28129442	ZNF389	0.52	5.1	0.42	1.23e-6	Depression;
TGCT	cis	rs59698941	0.527	rs1910075	chr5:132180089	A/T	cg27099455	chr5:132201840	GDF9;UQCRQ	0.28	4.76	0.39	5.3e-6	Apolipoprotein A-IV levels;
TGCT	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.88	8.56	0.61	3.63e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs9911578	1.000	rs1971659	chr17:57004787	A/G	cg05425664	chr17:57184151	TRIM37	-0.62	-6.18	-0.49	8.33e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg00431813	chr7:1051703	C7orf50	-0.2	-4.43	-0.37	2.01e-5	Longevity;Endometriosis;
TGCT	cis	rs6752107	1.000	rs2289472	chr2:234182240	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.2	4.81	0.4	4.36e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs782590	0.837	rs782573	chr2:55912961	T/C	cg18811423	chr2:55921094	PNPT1	0.7	7.83	0.58	1.88e-12	Metabolic syndrome;
TGCT	cis	rs4919044	0.545	rs9420603	chr10:94777490	T/C	cg05127821	chr10:94822908	CYP26C1	-0.77	-5.03	-0.41	1.71e-6	Coronary artery disease;
TGCT	cis	rs231513	0.681	rs8079623	chr17:42027330	C/G	cg26893861	chr17:41843967	DUSP3	-0.69	-4.59	-0.38	1.08e-5	Cognitive function;
TGCT	cis	rs9916302	0.706	rs8075737	chr17:37727316	C/T	cg03321784	chr17:37729644	NA	-0.44	-4.95	-0.41	2.4e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs6688613	1.000	rs7533688	chr1:166944123	G/A	cg07049167	chr1:166818506	POGK	0.22	4.55	0.38	1.25e-5	Refractive astigmatism;
TGCT	cis	rs7193541	0.684	rs7201320	chr16:74694058	T/G	cg01733217	chr16:74700730	RFWD3	0.99	13.35	0.77	9.31e-26	Multiple myeloma;
TGCT	cis	rs79349575	0.783	rs4794000	chr17:47022755	C/G	cg26022315	chr17:47021804	SNF8	0.49	4.9	0.4	2.94e-6	Type 2 diabetes;
TGCT	cis	rs829883	0.664	rs829864	chr12:98850195	C/T	cg25150519	chr12:98850993	NA	0.64	7.54	0.56	8.56e-12	Colorectal adenoma (advanced);
TGCT	cis	rs896854	0.818	rs13262110	chr8:95926890	C/T	cg09323728	chr8:95962352	TP53INP1	-0.5	-6.36	-0.5	3.51e-9	Type 2 diabetes;
TGCT	cis	rs7843479	1.000	rs7843479	chr8:21820813	G/T	cg17168535	chr8:21777572	XPO7	0.62	5.49	0.44	2.13e-7	Mean corpuscular volume;
TGCT	cis	rs9388451	0.591	rs1268792	chr6:126042124	G/A	cg05901451	chr6:126070800	HEY2	0.89	8.8	0.62	9.88e-15	Brugada syndrome;
TGCT	cis	rs12681288	0.676	rs17740799	chr8:1014327	C/T	cg04851639	chr8:1020857	NA	0.36	6.82	0.52	3.62e-10	Schizophrenia;
TGCT	cis	rs17221829	0.932	rs4753236	chr11:89448147	C/T	cg02982614	chr11:89391479	FOLH1B	-0.29	-5.09	-0.42	1.3e-6	Anxiety in major depressive disorder;
TGCT	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg00149659	chr3:10157352	C3orf10	0.91	5.89	0.47	3.32e-8	Alzheimer's disease;
TGCT	cis	rs1153858	0.943	rs67045941	chr15:45677011	A/G	cg26924012	chr15:45694286	SPATA5L1	1.09	15.16	0.81	5.15e-30	Homoarginine levels;
TGCT	cis	rs7654585	0.782	rs2309288	chr4:25947097	C/A	cg10409131	chr4:25915609	C4orf52	0.75	7.81	0.57	2.06e-12	Obesity-related traits;
TGCT	cis	rs35160687	0.901	rs12620833	chr2:86472870	T/C	cg04877910	chr2:85804641	VAMP8	0.35	4.6	0.38	1.04e-5	Night sleep phenotypes;
TGCT	cis	rs28595532	0.920	rs115103359	chr4:119739608	A/T	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs2072499	0.966	rs2842864	chr1:156159217	G/A	cg24450063	chr1:156163899	SLC25A44	1.19	17.21	0.84	1.15e-34	Testicular germ cell tumor;
TGCT	cis	rs9858542	0.953	rs6997	chr3:49453834	C/T	cg03060546	chr3:49711283	APEH	-0.64	-5.55	-0.45	1.64e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs10197940	0.638	rs2288193	chr2:152348842	T/A	cg19508488	chr2:152266495	RIF1	0.73	6.69	0.51	6.91e-10	Lung cancer;
TGCT	cis	rs3749237	0.964	rs2234385	chr3:49846041	G/A	cg10152585	chr3:50297680	NA	0.51	4.84	0.4	3.79e-6	Resting heart rate;
TGCT	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg00149659	chr3:10157352	C3orf10	0.73	4.72	0.39	6.17e-6	Alzheimer's disease;
TGCT	trans	rs4332037	0.575	rs55952733	chr7:2070680	G/A	cg10840412	chr1:235813424	GNG4	0.95	6.94	0.53	1.97e-10	Bipolar disorder;
TGCT	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg06896619	chr17:61851486	DDX42;CCDC47	-0.51	-4.96	-0.41	2.24e-6	Prudent dietary pattern;
TGCT	trans	rs3107575	0.572	rs73169365	chr3:165319778	T/C	cg20820622	chr15:70354647	TLE3	0.97	6.63	0.51	9.3e-10	Morning vs. evening chronotype;
TGCT	cis	rs12681288	0.862	rs7015529	chr8:1020249	A/G	cg21347738	chr8:1310380	NA	-0.22	-4.57	-0.38	1.14e-5	Schizophrenia;
TGCT	cis	rs910316	0.934	rs7141705	chr14:75655352	G/C	cg08847533	chr14:75593920	NEK9	-0.91	-9.71	-0.66	6.33e-17	Height;
TGCT	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.91	0.4	2.83e-6	Height;
TGCT	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg00343986	chr7:65444356	GUSB	-0.23	-5.15	-0.42	9.77e-7	Aortic root size;
TGCT	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg03806693	chr22:41940476	POLR3H	-1.11	-12.05	-0.73	1.3e-22	Vitiligo;
TGCT	cis	rs7772486	0.875	rs1331637	chr6:146337087	T/C	cg13319975	chr6:146136371	FBXO30	-0.51	-4.56	-0.38	1.23e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11874712	0.932	rs34907121	chr18:43677793	G/A	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	5.23	0.42	7.04e-7	Migraine - clinic-based;
TGCT	cis	rs9814567	1.000	rs9829092	chr3:134229866	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.96	-9.19	-0.64	1.16e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg05665937	chr4:1216051	CTBP1	0.24	4.61	0.38	1e-5	Obesity-related traits;
TGCT	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	16.7	0.83	1.62e-33	Prudent dietary pattern;
TGCT	cis	rs4851254	0.618	rs4851243	chr2:100639482	G/A	cg07810366	chr2:100720526	AFF3	-0.46	-4.64	-0.38	8.78e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs8078723	0.714	rs3859187	chr17:38150613	C/A	cg17467752	chr17:38218738	THRA	-0.53	-5.36	-0.43	3.83e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs11195062	0.693	rs11195033	chr10:111980235	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.26	-4.44	-0.37	2e-5	Multiple myeloma;
TGCT	cis	rs12142240	0.698	rs13374893	chr1:46843800	A/G	cg00530320	chr1:46809349	NSUN4	0.29	5.88	0.47	3.51e-8	Menopause (age at onset);
TGCT	cis	rs78487399	0.808	rs72865297	chr2:43743248	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-5.2	-0.42	8.11e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	trans	rs797680	0.930	rs622608	chr1:93715219	G/A	cg27528825	chr2:159282178	CCDC148	0.34	6.7	0.52	6.63e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs10540	1.000	rs35231079	chr11:515224	G/A	cg03934478	chr11:495069	RNH1	0.32	4.82	0.4	4.16e-6	Body mass index;
TGCT	cis	rs9916302	0.904	rs34363096	chr17:37594294	G/A	cg15445000	chr17:37608096	MED1	0.33	4.78	0.39	4.93e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs514406	0.505	rs405208	chr1:53176674	C/T	cg01802117	chr1:53393560	SCP2	-0.42	-4.88	-0.4	3.24e-6	Monocyte count;
TGCT	cis	rs2016266	0.787	rs61928080	chr12:53752204	G/A	cg16917193	chr12:54089295	NA	-0.71	-4.6	-0.38	1.04e-5	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs2797160	0.935	rs6940748	chr6:125994080	C/T	cg05901451	chr6:126070800	HEY2	-0.74	-6.49	-0.5	1.84e-9	Endometrial cancer;
TGCT	cis	rs11098499	1.000	rs12506395	chr4:120185094	C/T	cg09307838	chr4:120376055	NA	0.49	4.52	0.38	1.43e-5	Corneal astigmatism;
TGCT	cis	rs11711311	1.000	rs9865435	chr3:113450046	G/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.78	-7.13	-0.54	7.14e-11	IgG glycosylation;
TGCT	cis	rs1865760	0.865	rs2164485	chr6:25952106	G/A	cg17042849	chr6:26104293	HIST1H4C	-0.52	-4.78	-0.39	4.97e-6	Height;
TGCT	cis	rs9303401	0.659	rs9303399	chr17:56672309	C/T	cg25039879	chr17:56429692	SUPT4H1	0.51	4.49	0.37	1.6e-5	Cognitive test performance;
TGCT	cis	rs6570726	0.791	rs9403729	chr6:145907007	C/T	cg13319975	chr6:146136371	FBXO30	-0.51	-4.58	-0.38	1.13e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs113577745	0.725	rs73913928	chr2:10093003	G/A	cg17603321	chr2:9696605	ADAM17	-1.15	-5.09	-0.42	1.31e-6	Breast cancer;
TGCT	cis	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg18252515	chr7:66147081	NA	-1.09	-6.4	-0.5	2.88e-9	Diabetic kidney disease;
TGCT	cis	rs9303401	0.625	rs10515159	chr17:56802693	G/C	cg25039879	chr17:56429692	SUPT4H1	0.52	4.62	0.38	9.48e-6	Cognitive test performance;
TGCT	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg01341218	chr17:43662625	NA	1.11	9.15	0.63	1.43e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs10791097	0.667	rs1893019	chr11:130756664	C/G	cg14779329	chr11:130786720	SNX19	0.29	4.94	0.41	2.45e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs2439831	0.867	rs2260160	chr15:43895643	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.84	5.57	0.45	1.49e-7	Lung cancer in ever smokers;
TGCT	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg17971929	chr21:40555470	PSMG1	0.98	9.65	0.65	9.11e-17	Cognitive function;
TGCT	cis	rs10782582	0.586	rs1856791	chr1:76308942	C/T	cg10523679	chr1:76189770	ACADM	-0.59	-5.42	-0.44	2.94e-7	Daytime sleep phenotypes;
TGCT	cis	rs35883536	0.647	rs945329	chr1:101084273	C/T	cg06223162	chr1:101003688	GPR88	-0.42	-7.66	-0.57	4.51e-12	Monocyte count;
TGCT	cis	rs7010267	0.602	rs4313185	chr8:120052549	G/A	cg17171407	chr8:119960777	TNFRSF11B	0.26	4.62	0.38	9.52e-6	Total body bone mineral density (age 45-60);
TGCT	cis	rs4851266	1.000	rs11686280	chr2:100827718	C/A	cg22139774	chr2:100720529	AFF3	-0.36	-5.34	-0.43	4.23e-7	Educational attainment;
TGCT	trans	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg27523141	chr10:43048294	ZNF37B	0.71	8.17	0.59	3.03e-13	Extrinsic epigenetic age acceleration;
TGCT	trans	rs11722228	0.549	rs56146302	chr4:10081052	C/T	cg26043149	chr18:55253948	FECH	1.15	11.34	0.71	6.89e-21	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs12188164	0.762	rs11745923	chr5:475408	T/G	cg17553881	chr5:443987	EXOC3;C5orf55	-0.4	-4.58	-0.38	1.13e-5	Cystic fibrosis severity;
TGCT	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.68	5.62	0.45	1.18e-7	Tonsillectomy;
TGCT	cis	rs9486719	0.522	rs4839683	chr6:96851933	A/G	cg06623918	chr6:96969491	KIAA0776	0.87	6.99	0.53	1.52e-10	Migraine;Coronary artery disease;
TGCT	trans	rs10504390	0.656	rs78310018	chr8:66486522	T/C	cg18118147	chr19:51128640	SYT3	-0.77	-6.81	-0.52	3.71e-10	IgG glycosylation;
TGCT	cis	rs6940638	0.956	rs12190473	chr6:27024687	C/T	cg16898833	chr6:26189333	HIST1H4D	0.7	5.34	0.43	4.27e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg16228356	chr17:43848958	NA	-0.26	-4.53	-0.38	1.37e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7944584	0.545	rs7118178	chr11:47659135	G/A	cg20307385	chr11:47447363	PSMC3	0.92	8.52	0.61	4.56e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
TGCT	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg07507251	chr3:52567010	NT5DC2	0.48	6.91	0.53	2.24e-10	Bipolar disorder;
TGCT	cis	rs67311347	1.000	rs73080138	chr3:40516417	A/G	cg13683864	chr3:40499215	RPL14	-1.14	-12.15	-0.74	7.25e-23	Renal cell carcinoma;
TGCT	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg17054783	chr10:134559939	INPP5A	0.26	5.13	0.42	1.06e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.91	9.82	0.66	3.52e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs4234284	0.556	rs34147515	chr3:126965137	G/C	cg26312807	chr3:127057048	NA	-0.5	-4.57	-0.38	1.17e-5	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
TGCT	cis	rs4851254	0.584	rs56935201	chr2:100637788	G/A	cg07810366	chr2:100720526	AFF3	-0.46	-4.64	-0.38	8.78e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg06112835	chr11:68658793	MRPL21	0.46	8.12	0.59	3.91e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7193541	0.585	rs3851729	chr16:74485529	A/G	cg01733217	chr16:74700730	RFWD3	-0.82	-9.48	-0.65	2.24e-16	Multiple myeloma;
TGCT	cis	rs1552244	0.554	rs6443275	chr3:10008819	G/A	cg00149659	chr3:10157352	C3orf10	0.63	4.65	0.39	8.35e-6	Alzheimer's disease;
TGCT	cis	rs62209	0.752	rs11256935	chr10:11004177	C/T	cg26901096	chr10:10994189	LOC254312	0.4	6.3	0.49	4.64e-9	Alzheimer's disease (late onset);
TGCT	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg11871910	chr12:69753446	YEATS4	0.87	10.07	0.67	8.72e-18	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs7267979	0.932	rs13040655	chr20:25582197	C/T	cg03522245	chr20:25566470	NINL	0.6	6.12	0.48	1.11e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9467773	0.620	rs2451731	chr6:26624822	A/C	cg26531700	chr6:26746687	NA	0.5	4.68	0.39	7.52e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4638749	1.000	rs2123694	chr2:108857505	A/G	cg06795125	chr2:108905320	SULT1C2	-0.39	-4.81	-0.4	4.26e-6	Blood pressure;
TGCT	cis	rs6988636	1.000	rs9987357	chr8:124187620	T/G	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs6003958	1	rs6003958	chr22:24264089	T/G	cg11905131	chr22:24372483	LOC391322	0.7	5.63	0.45	1.14e-7	S-phenylmercapturic acid levels in smokers;
TGCT	cis	rs2153535	0.580	rs1119689	chr6:8460754	C/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs9303401	0.659	rs1864754	chr17:56688789	G/T	cg25039879	chr17:56429692	SUPT4H1	-0.51	-4.5	-0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs950027	0.584	rs1145086	chr15:45654327	A/G	cg26924012	chr15:45694286	SPATA5L1	0.79	8.86	0.62	6.92e-15	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs17221829	0.965	rs1967075	chr11:89447256	A/G	cg02982614	chr11:89391479	FOLH1B	-0.29	-5.09	-0.42	1.3e-6	Anxiety in major depressive disorder;
TGCT	cis	rs11249608	0.510	rs6861539	chr5:178452307	A/G	cg01312482	chr5:178451176	ZNF879	-0.56	-5.5	-0.44	2.09e-7	Pubertal anthropometrics;
TGCT	cis	rs2235642	0.750	rs763152	chr16:1658056	T/C	cg11375102	chr16:1583810	IFT140;TMEM204	-0.27	-4.66	-0.39	7.88e-6	Coronary artery disease;
TGCT	cis	rs4727027	0.899	rs4727025	chr7:148862863	A/G	cg23583168	chr7:148888333	NA	-0.76	-10.09	-0.67	7.46e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	trans	rs9354352	0.935	rs9354354	chr6:66699333	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.72	-7.84	-0.58	1.77e-12	Initial pursuit acceleration in psychotic disorders;
TGCT	cis	rs896854	0.654	rs10429443	chr8:95971164	A/G	cg16049864	chr8:95962084	TP53INP1	-0.75	-10.47	-0.69	9.05e-19	Type 2 diabetes;
TGCT	cis	rs4595586	0.615	rs11169838	chr12:39253108	C/T	cg10518543	chr12:38710700	ALG10B	-0.52	-4.48	-0.37	1.68e-5	Morning vs. evening chronotype;
TGCT	cis	rs1915146	0.546	rs2454055	chr10:126859832	T/C	cg23000734	chr10:126850823	CTBP2	0.48	5.21	0.42	7.76e-7	Menarche (age at onset);
TGCT	cis	rs12579753	0.789	rs35448307	chr12:82165817	A/G	cg21231944	chr12:82153410	PPFIA2	-0.34	-4.62	-0.38	9.52e-6	Resting heart rate;
TGCT	cis	rs7258465	0.965	rs271628	chr19:18624333	A/G	cg06462663	chr19:18546047	ISYNA1	0.2	4.67	0.39	7.74e-6	Breast cancer;
TGCT	cis	rs10501293	0.662	rs7929773	chr11:42999551	C/G	cg03447554	chr11:43094025	NA	-0.44	-6.34	-0.49	3.9e-9	Cognitive performance;
TGCT	cis	rs7678296	0.649	rs60691639	chr4:37239925	T/C	cg18431856	chr4:37245254	KIAA1239	0.68	4.49	0.37	1.64e-5	3-hydroxypropylmercapturic acid levels in smokers;
TGCT	cis	rs8038465	0.622	rs60696711	chr15:73873005	C/A	cg15420318	chr15:73925796	NPTN	0.64	6.8	0.52	3.87e-10	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2404602	0.716	rs1874944	chr15:76863928	A/G	cg22467129	chr15:76604101	ETFA	-0.44	-5.05	-0.41	1.51e-6	Blood metabolite levels;
TGCT	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.77	-7.46	-0.56	1.33e-11	Prudent dietary pattern;
TGCT	cis	rs2737273	1.000	rs2737273	chr9:35716066	T/C	cg12717594	chr9:36037454	RECK	0.53	4.54	0.38	1.3e-5	Platelet distribution width;
TGCT	cis	rs3734905	1.000	rs79846353	chr6:169894834	C/T	cg20469989	chr6:170102314	C6orf120;WDR27	-0.88	-4.67	-0.39	7.59e-6	HIV-1 control;
TGCT	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.0	-7.42	-0.55	1.64e-11	Gut microbiome composition (summer);
TGCT	cis	rs12681287	0.640	rs13264364	chr8:87466385	G/T	cg27223183	chr8:87520930	FAM82B	-0.89	-6.43	-0.5	2.54e-9	Caudate activity during reward;
TGCT	cis	rs7829975	0.510	rs332037	chr8:8722675	C/T	cg15556689	chr8:8085844	FLJ10661	0.64	5.81	0.46	5.01e-8	Mood instability;
TGCT	cis	rs6665290	0.669	rs3768419	chr1:227173477	C/G	cg10327440	chr1:227177885	CDC42BPA	-0.88	-14.6	-0.8	1.04e-28	Myeloid white cell count;
TGCT	cis	rs909341	0.678	rs2738778	chr20:62291830	C/T	cg14758556	chr20:62440591	NA	0.37	5.05	0.41	1.57e-6	Atopic dermatitis;
TGCT	trans	rs4332037	0.851	rs1403175	chr7:1964357	A/T	cg10840412	chr1:235813424	GNG4	-1.05	-8.44	-0.6	7.18e-14	Bipolar disorder;
TGCT	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg06634786	chr22:41940651	POLR3H	-0.72	-6.8	-0.52	3.99e-10	Vitiligo;
TGCT	cis	rs6121246	0.647	rs6088855	chr20:30225792	C/T	cg18721089	chr20:30220636	NA	-0.57	-5.73	-0.46	7.05e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg18876405	chr7:65276391	NA	-0.36	-5.41	-0.44	3.12e-7	Aortic root size;
TGCT	cis	rs1975974	0.539	rs58796614	chr17:21733767	C/T	cg18423549	chr17:21743878	NA	-0.61	-5.99	-0.47	2.14e-8	Psoriasis;
TGCT	cis	rs1903068	0.925	rs1551642	chr4:55994210	T/C	cg16572876	chr4:56024045	NA	0.45	5.08	0.42	1.34e-6	Endometriosis;
TGCT	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.75	5.41	0.44	3.09e-7	Platelet count;
TGCT	cis	rs9868809	0.505	rs73080312	chr3:48737847	C/T	cg00383909	chr3:49044727	WDR6	1.54	5.91	0.47	3.14e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs4499344	0.730	rs2903755	chr19:33098870	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	8.81	0.62	9.52e-15	Mean platelet volume;
TGCT	cis	rs10465746	0.967	rs12759527	chr1:84434425	T/C	cg10977910	chr1:84465055	TTLL7	0.63	6.23	0.49	6.49e-9	Obesity-related traits;
TGCT	cis	rs7100689	0.646	rs10736345	chr10:82134140	C/T	cg01528321	chr10:82214614	TSPAN14	0.8	7.72	0.57	3.42e-12	Post bronchodilator FEV1;
TGCT	cis	rs2455799	0.613	rs2470548	chr3:15737689	G/A	cg16303742	chr3:15540471	COLQ	-0.25	-4.62	-0.38	9.34e-6	Mean platelet volume;
TGCT	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg14773178	chr5:1868261	NA	0.34	5.57	0.45	1.54e-7	Cardiovascular disease risk factors;
TGCT	cis	rs2404602	0.583	rs35707798	chr15:76565026	G/C	cg26408565	chr15:76604113	ETFA	-0.45	-6.35	-0.5	3.66e-9	Blood metabolite levels;
TGCT	cis	rs10479542	0.929	rs7718673	chr5:178980009	C/T	cg19723775	chr5:179050963	HNRNPH1	-0.52	-5.13	-0.42	1.08e-6	Lung cancer;
TGCT	cis	rs3091242	0.933	rs35497030	chr1:25783066	A/G	cg09222892	chr1:25734099	RHCE	0.42	7.16	0.54	6.34e-11	Erythrocyte sedimentation rate;
TGCT	cis	rs7772486	0.840	rs2814867	chr6:146334030	C/A	cg23711669	chr6:146136114	FBXO30	0.87	9.3	0.64	6.21e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4076764	1.000	rs6683181	chr1:163417077	C/T	cg24596788	chr1:163392923	NA	-0.17	-4.81	-0.4	4.22e-6	Motion sickness;
TGCT	cis	rs5769765	0.773	rs9616208	chr22:50313359	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.24	-13.17	-0.76	2.52e-25	Schizophrenia;
TGCT	cis	rs12188164	0.965	rs11743639	chr5:450710	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.4	-4.71	-0.39	6.42e-6	Cystic fibrosis severity;
TGCT	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg03517284	chr6:25882590	NA	-0.58	-6.03	-0.48	1.76e-8	Blood metabolite levels;
TGCT	cis	rs7909074	1.000	rs1408814	chr10:45399088	A/G	cg05187965	chr10:45406764	TMEM72	-0.25	-5.3	-0.43	5.07e-7	Mean corpuscular volume;
TGCT	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg07507251	chr3:52567010	NT5DC2	0.49	7.07	0.54	1e-10	Bipolar disorder;
TGCT	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	16.05	0.82	4.59e-32	Prudent dietary pattern;
TGCT	cis	rs3947	0.789	rs6990033	chr8:11693378	G/T	cg02840367	chr8:11660030	FDFT1	-0.94	-6.9	-0.53	2.43e-10	Blood protein levels;
TGCT	cis	rs3849570	0.643	rs10779986	chr3:81970818	C/G	cg07356753	chr3:81810745	GBE1	0.72	6.76	0.52	4.82e-10	Waist circumference;Body mass index;
TGCT	cis	rs7246657	0.943	rs9917081	chr19:37876616	T/C	cg18154014	chr19:37997991	ZNF793	1.0	6.69	0.52	6.81e-10	Coronary artery calcification;
TGCT	cis	rs832540	0.898	rs331497	chr5:56251660	G/T	cg24531977	chr5:56204891	C5orf35	0.49	5.21	0.42	7.8e-7	Coronary artery disease;
TGCT	cis	rs727505	0.821	rs73225498	chr7:124704197	C/T	cg23710748	chr7:124431027	NA	-0.27	-4.59	-0.38	1.07e-5	Lewy body disease;
TGCT	cis	rs2224391	0.628	rs2753234	chr6:5251050	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-1.04	-6.69	-0.51	6.87e-10	Height;
TGCT	cis	rs920590	0.500	rs7819535	chr8:19689058	A/G	cg03894339	chr8:19674705	INTS10	0.99	6.24	0.49	6.4e-9	Acute lymphoblastic leukemia (childhood);
TGCT	cis	rs7829975	0.511	rs2921028	chr8:8340477	T/C	cg15556689	chr8:8085844	FLJ10661	0.66	6.39	0.5	2.98e-9	Mood instability;
TGCT	cis	rs13188771	0.690	rs164622	chr5:100874123	C/G	cg18665594	chr5:101119420	NA	0.44	4.46	0.37	1.83e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	trans	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.86	-9.4	-0.65	3.49e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs3087591	0.960	rs2905872	chr17:29525027	C/A	cg24425628	chr17:29625626	OMG;NF1	0.48	7.29	0.55	3.25e-11	Hip circumference;
TGCT	cis	rs765787	0.530	rs4775837	chr15:45537684	G/T	cg24006582	chr15:45444508	DUOX1	-0.25	-5.54	-0.45	1.76e-7	Uric acid levels;
TGCT	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg18402987	chr7:1209562	NA	0.7	5.67	0.45	9.66e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7772486	0.764	rs2265471	chr6:146220250	G/A	cg23711669	chr6:146136114	FBXO30	0.89	10.16	0.67	5.28e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7666738	0.962	rs1527515	chr4:99025733	C/A	cg05340658	chr4:99064831	C4orf37	0.46	4.57	0.38	1.18e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10114408	0.959	rs11792740	chr9:96653951	C/A	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg27436995	chr16:743998	FBXL16	-0.47	-5.13	-0.42	1.07e-6	Height;
TGCT	cis	rs9911578	1.000	rs304292	chr17:56824123	G/A	cg05425664	chr17:57184151	TRIM37	-0.63	-6.26	-0.49	5.86e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7208859	0.623	rs11652358	chr17:29205480	T/C	cg14008862	chr17:28927542	LRRC37B2	0.72	4.66	0.39	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs9381040	0.610	rs2235678	chr6:41020510	G/T	cg03526776	chr6:41159608	TREML2	0.27	5.27	0.43	5.78e-7	Alzheimer's disease (late onset);
TGCT	trans	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg21659725	chr3:3221576	CRBN	0.77	9.27	0.64	7.26e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs6460942	0.915	rs75732743	chr7:12454095	C/T	cg06484146	chr7:12443880	VWDE	-0.57	-5.52	-0.44	1.92e-7	Coronary artery disease;
TGCT	trans	rs114540395	0.858	rs74415794	chr10:103238858	A/G	cg10198749	chr1:39920707	MACF1	0.55	7.12	0.54	7.73e-11	Schizophrenia;
TGCT	cis	rs2440129	0.611	rs10852889	chr17:6900845	C/T	cg05215272	chr17:6899095	ALOX12	0.54	6.63	0.51	9.29e-10	Tonsillectomy;
TGCT	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg12310025	chr6:25882481	NA	-0.59	-6.04	-0.48	1.65e-8	Blood metabolite levels;
TGCT	cis	rs1941184	0.500	rs7234091	chr18:29019829	C/T	cg14871544	chr18:29027885	DSG3	0.44	4.63	0.38	9.18e-6	Parkinson's disease (age of onset);
TGCT	cis	rs910316	1.000	rs12889309	chr14:75593902	C/T	cg23033748	chr14:75592666	NEK9	0.28	4.79	0.39	4.73e-6	Height;
TGCT	cis	rs4951018	0.821	rs11240547	chr1:205632932	A/G	cg24503407	chr1:205819492	PM20D1	0.38	4.82	0.4	4.05e-6	Prostate-specific antigen levels;
TGCT	cis	rs17473412	0.677	rs7703751	chr5:122831981	A/T	cg15125798	chr5:122621645	NA	-0.57	-5.05	-0.41	1.56e-6	Total body bone mineral density;
TGCT	cis	rs2239785	0.883	rs136157	chr22:36656443	C/A	cg15716373	chr22:36655542	APOL1	-0.41	-4.94	-0.41	2.44e-6	Glomerulosclerosis;
TGCT	cis	rs62380364	0.626	rs618741	chr5:88064012	C/T	cg22951263	chr5:87985283	NA	-0.59	-6.27	-0.49	5.5e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs988712	0.705	rs35051342	chr11:27634373	G/C	cg10635145	chr11:27742435	BDNF	-0.38	-5.25	-0.43	6.38e-7	Obesity;
TGCT	cis	rs2147959	0.824	rs10799479	chr1:228678510	G/A	cg22700015	chr1:228743131	NA	-0.63	-4.82	-0.4	4.2e-6	Adult asthma;
TGCT	cis	rs6901004	0.803	rs9320360	chr6:111462272	G/T	cg15721981	chr6:111408429	SLC16A10	-0.53	-4.64	-0.38	8.82e-6	Blood metabolite levels;
TGCT	cis	rs60843830	0.928	rs2306060	chr2:230912	A/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.79	8.04	0.59	5.94e-13	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs73252553	0.547	rs315683	chr4:25375455	C/G	cg04009456	chr4:25379436	ANAPC4	0.4	4.46	0.37	1.84e-5	Cannabis dependence symptom count;
TGCT	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg12923728	chr3:195709715	SDHAP1	-0.36	-7.43	-0.55	1.56e-11	Pancreatic cancer;
TGCT	cis	rs7666738	0.830	rs732299	chr4:98995389	C/T	cg05340658	chr4:99064831	C4orf37	0.49	5.6	0.45	1.31e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2204008	0.777	rs114096617	chr12:38342557	A/C	cg26384229	chr12:38710491	ALG10B	0.82	7.22	0.54	4.5e-11	Bladder cancer;
TGCT	cis	rs826838	1.000	rs11610522	chr12:38687575	C/T	cg13010199	chr12:38710504	ALG10B	0.82	6.65	0.51	8.46e-10	Heart rate;
TGCT	cis	rs2658782	1.000	rs2658781	chr11:93166368	C/T	cg15737290	chr11:93063684	CCDC67	-0.74	-5.71	-0.46	7.94e-8	Pulmonary function decline;
TGCT	cis	rs6540559	1.000	rs1044516	chr1:209959614	G/T	cg23283495	chr1:209979779	IRF6	0.67	5.64	0.45	1.08e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs17376456	0.877	rs34673483	chr5:93315079	C/A	cg21475434	chr5:93447410	FAM172A	0.65	4.85	0.4	3.58e-6	Diabetic retinopathy;
TGCT	cis	rs3960554	0.529	rs7800970	chr7:75880198	C/T	cg19105122	chr7:75896889	SRRM3	-0.58	-4.91	-0.4	2.85e-6	Eotaxin levels;
TGCT	cis	rs28595532	0.764	rs116788606	chr4:119748849	G/C	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs7914558	0.966	rs12569617	chr10:104729996	T/C	cg05855489	chr10:104503620	C10orf26	0.51	4.53	0.38	1.37e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs1552244	0.554	rs34391585	chr3:9999208	G/C	cg00149659	chr3:10157352	C3orf10	0.65	4.8	0.4	4.49e-6	Alzheimer's disease;
TGCT	cis	rs651907	0.535	rs2290859	chr3:101525625	C/T	cg12386194	chr3:101231763	SENP7	0.48	4.65	0.39	8.26e-6	Colorectal cancer;
TGCT	cis	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg22891161	chr3:195456627	MUC20	-0.21	-4.48	-0.37	1.7e-5	Pancreatic cancer;
TGCT	cis	rs4727027	0.804	rs13231262	chr7:148886058	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	4.75	0.39	5.54e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs4851266	1.000	rs11693324	chr2:100827753	T/C	cg22139774	chr2:100720529	AFF3	-0.35	-5.31	-0.43	4.92e-7	Educational attainment;
TGCT	trans	rs4332037	0.851	rs73050128	chr7:1961882	C/A	cg25206134	chr2:45395956	NA	1.1	9.53	0.65	1.75e-16	Bipolar disorder;
TGCT	cis	rs992157	0.710	rs6752254	chr2:219058743	C/T	cg00012203	chr2:219082015	ARPC2	0.83	10.62	0.69	4.01e-19	Colorectal cancer;
TGCT	cis	rs11585357	0.793	rs112597506	chr1:17628832	A/G	cg08277548	chr1:17600880	PADI3	-0.95	-9.6	-0.65	1.15e-16	Hair shape;
TGCT	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.85	7.0	0.53	1.44e-10	Platelet count;
TGCT	cis	rs367943	0.966	rs364738	chr5:112808329	A/G	cg12552261	chr5:112820674	MCC	-0.24	-4.91	-0.4	2.81e-6	Type 2 diabetes;
TGCT	cis	rs10791323	0.572	rs4353292	chr11:133742656	A/G	cg03690763	chr11:133734501	NA	-0.29	-4.98	-0.41	2.09e-6	Childhood ear infection;
TGCT	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-8.64	-0.61	2.39e-14	Platelet count;
TGCT	cis	rs524281	1.000	rs547087	chr11:65846264	A/G	cg00563793	chr11:65837595	PACS1	-0.52	-4.46	-0.37	1.82e-5	Electroencephalogram traits;
TGCT	cis	rs1981331	1.000	rs77587985	chr21:47993897	A/G	cg23283320	chr21:48055893	PRMT2	1.29	6.09	0.48	1.31e-8	Cerebrospinal fluid t-tau:AB1-42 ratio;
TGCT	trans	rs10435719	0.809	rs77601743	chr8:11790569	G/A	cg15556689	chr8:8085844	FLJ10661	0.76	7.18	0.54	5.62e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs7267979	1.000	rs2259928	chr20:25281834	G/C	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs35306767	0.953	rs1539174	chr10:974870	C/G	cg26597838	chr10:835615	NA	0.56	7.7	0.57	3.77e-12	Eosinophil percentage of granulocytes;
TGCT	cis	rs9611565	0.559	rs5758428	chr22:42106216	G/A	cg03806693	chr22:41940476	POLR3H	1.08	11.99	0.73	1.84e-22	Vitiligo;
TGCT	cis	rs10992471	0.603	rs10992349	chr9:95233887	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.62	-5.79	-0.46	5.39e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs6684514	0.845	rs12138564	chr1:156291600	G/T	cg20302342	chr1:156215951	PAQR6	0.35	4.74	0.39	5.77e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs289997	0.920	rs2999569	chr7:25582362	A/G	cg14064488	chr7:26331273	SNX10	0.34	4.93	0.4	2.57e-6	Breast cancer;
TGCT	trans	rs77457752	0.690	rs12349345	chr9:13912075	T/C	cg18948646	chr4:83674694	SCD5;MIR575	0.55	6.62	0.51	9.75e-10	Breast cancer;
TGCT	cis	rs13191362	1.000	rs35449999	chr6:163023465	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs3091242	0.781	rs71652378	chr1:25721457	G/C	cg09222892	chr1:25734099	RHCE	-0.45	-7.33	-0.55	2.63e-11	Erythrocyte sedimentation rate;
TGCT	cis	rs60843830	1.000	rs3828165	chr2:220889	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.74	6.76	0.52	4.93e-10	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs7296418	0.885	rs1716184	chr12:123637509	G/C	cg05973401	chr12:123451056	ABCB9	0.54	4.47	0.37	1.71e-5	Platelet count;
TGCT	cis	rs939658	0.805	rs34478496	chr15:79440997	C/A	cg17916960	chr15:79447300	NA	-0.49	-7.41	-0.55	1.73e-11	Refractive error;
TGCT	cis	rs8038465	0.874	rs11574495	chr15:74003936	C/T	cg15420318	chr15:73925796	NPTN	0.53	4.89	0.4	3.1e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7226408	0.948	rs11662148	chr18:34408423	A/C	cg06757138	chr18:34340585	FHOD3	0.26	4.79	0.4	4.62e-6	Obesity-related traits;
TGCT	cis	rs9916302	0.904	rs8065879	chr17:37515978	G/A	cg07936489	chr17:37558343	FBXL20	0.65	5.09	0.42	1.3e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg03264133	chr6:25882463	NA	-0.57	-6.07	-0.48	1.45e-8	Blood metabolite levels;
TGCT	cis	rs8013055	0.846	rs10152050	chr14:105984145	C/G	cg23356831	chr14:105996513	TMEM121	0.33	4.83	0.4	3.86e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs7220711	0.934	rs7217502	chr17:41801246	A/C	cg26893861	chr17:41843967	DUSP3	0.55	4.98	0.41	2.09e-6	Bone mineral density (spine);Bone mineral density (hip);
TGCT	cis	rs986417	0.892	rs11628559	chr14:61038153	G/C	cg27398547	chr14:60952738	C14orf39	1.55	8.76	0.62	1.22e-14	Gut microbiota (bacterial taxa);
TGCT	cis	rs478304	0.654	rs12289836	chr11:65436888	C/T	cg17480646	chr11:65405466	SIPA1	0.62	8.19	0.59	2.69e-13	Acne (severe);
TGCT	cis	rs67311347	1.000	rs2276871	chr3:40499273	C/T	cg13683864	chr3:40499215	RPL14	-1.17	-13.15	-0.76	2.93e-25	Renal cell carcinoma;
TGCT	cis	rs6912958	0.754	rs6918909	chr6:88247251	A/C	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.92	-0.4	2.7e-6	Monocyte percentage of white cells;
TGCT	cis	rs968451	0.619	rs2267407	chr22:39747050	G/A	cg17798944	chr22:39715225	SNORD43;RPL3	0.76	6.89	0.53	2.47e-10	Primary biliary cholangitis;
TGCT	cis	rs9611565	0.694	rs202641	chr22:41833116	C/T	cg17554472	chr22:41940697	POLR3H	0.46	4.71	0.39	6.63e-6	Vitiligo;
TGCT	cis	rs7949030	0.591	rs11231156	chr11:62366454	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.61	8.75	0.62	1.29e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1336900	0.513	rs56253522	chr1:150614869	C/A	cg04414720	chr1:150670196	GOLPH3L	0.39	4.84	0.4	3.74e-6	Blood protein levels;
TGCT	cis	rs137603	0.644	rs137636	chr22:39722477	C/A	cg01093212	chr22:39715156	SNORD43;RPL3	-0.53	-5.16	-0.42	9.64e-7	Primary biliary cholangitis;
TGCT	cis	rs7523273	0.565	rs2761422	chr1:207893266	A/T	cg22525895	chr1:207977042	MIR29B2	0.34	5.76	0.46	6.15e-8	Schizophrenia;
TGCT	trans	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.87	9.66	0.66	8.25e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg23205692	chr1:25664452	TMEM50A	0.5	5.21	0.42	7.72e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs9467711	0.790	rs35162296	chr6:26318262	C/T	cg16898833	chr6:26189333	HIST1H4D	1.2	5.52	0.44	1.87e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7666738	0.546	rs10010088	chr4:98655945	C/T	cg17366294	chr4:99064904	C4orf37	0.58	5.36	0.43	3.87e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9486715	0.867	rs9486444	chr6:96963619	A/G	cg18709589	chr6:96969512	KIAA0776	0.82	8.01	0.58	7.14e-13	Headache;
TGCT	cis	rs8077577	0.895	rs16960990	chr17:18108601	A/G	cg09161412	chr17:18057145	MYO15A	-0.64	-5.22	-0.42	7.2e-7	Obesity-related traits;
TGCT	cis	rs62064224	0.658	rs62065460	chr17:30715007	A/G	cg18200150	chr17:30822561	MYO1D	0.58	7.69	0.57	3.92e-12	Schizophrenia;
TGCT	cis	rs9372498	0.536	rs9489458	chr6:118920503	G/A	cg21191810	chr6:118973309	C6orf204	-0.39	-5.13	-0.42	1.07e-6	Diastolic blood pressure;
TGCT	cis	rs9972944	0.756	rs7207587	chr17:63766307	C/T	cg07283582	chr17:63770753	CCDC46	-0.26	-5.3	-0.43	5.02e-7	Total body bone mineral density;
TGCT	cis	rs7208859	0.623	rs11657391	chr17:29194287	G/A	cg14008862	chr17:28927542	LRRC37B2	0.72	4.66	0.39	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs12049351	0.774	rs4925457	chr1:229633571	C/T	cg12130225	chr1:229698885	NA	0.39	4.59	0.38	1.06e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs17331151	0.505	rs13086936	chr3:52659079	T/C	cg07884673	chr3:53033167	SFMBT1	0.75	5.59	0.45	1.35e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs8084125	0.832	rs2156646	chr18:74946660	C/T	cg05528293	chr18:74961138	GALR1	0.5	4.88	0.4	3.17e-6	Obesity-related traits;
TGCT	cis	rs13177918	0.626	rs13175436	chr5:149830537	A/T	cg14059543	chr5:149831962	NA	-0.68	-9.13	-0.63	1.6e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs12681287	0.547	rs7461366	chr8:87511685	C/T	cg19078186	chr8:87526527	CPNE3	-0.37	-4.57	-0.38	1.15e-5	Caudate activity during reward;
TGCT	cis	rs1163251	0.837	rs2764886	chr1:120241771	C/T	cg19096424	chr1:120255104	PHGDH	0.6	5.94	0.47	2.66e-8	Blood metabolite levels;
TGCT	cis	rs6570726	0.791	rs447992	chr6:145817184	C/T	cg05347473	chr6:146136440	FBXO30	0.53	4.95	0.41	2.4e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11696501	0.688	rs11696685	chr20:44295134	A/G	cg11783356	chr20:44313418	WFDC10B	-0.32	-4.63	-0.38	9.25e-6	Brain structure;
TGCT	cis	rs12579753	0.956	rs11115038	chr12:82214660	T/G	cg07988820	chr12:82153109	PPFIA2	-0.64	-6.68	-0.51	7.15e-10	Resting heart rate;
TGCT	cis	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg22857025	chr5:266934	NA	-0.34	-6.64	-0.51	8.6e-10	Breast cancer;
TGCT	cis	rs7666738	0.830	rs2019163	chr4:99022747	C/T	cg05340658	chr4:99064831	C4orf37	0.49	5.54	0.45	1.72e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7267979	0.966	rs2482948	chr20:25296499	T/C	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7267979	0.528	rs2387976	chr20:25599560	C/T	cg03522245	chr20:25566470	NINL	-0.45	-4.69	-0.39	6.99e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6490294	0.561	rs10744777	chr12:112233018	C/T	cg10833066	chr12:111807467	FAM109A	-0.29	-4.84	-0.4	3.85e-6	Mean platelet volume;
TGCT	cis	rs896854	0.608	rs6991067	chr8:95875676	A/G	cg09323728	chr8:95962352	TP53INP1	-0.42	-5.01	-0.41	1.83e-6	Type 2 diabetes;
TGCT	cis	rs35306767	0.807	rs61831436	chr10:837882	G/A	cg20503657	chr10:835505	NA	0.78	11.16	0.71	1.88e-20	Eosinophil percentage of granulocytes;
TGCT	cis	rs2153535	0.580	rs6941670	chr6:8446346	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.65	0.45	1.02e-7	Motion sickness;
TGCT	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg20276088	chr3:133502917	NA	-0.24	-5.17	-0.42	9.11e-7	Iron status biomarkers;
TGCT	cis	rs3020333	0.653	rs851984	chr6:152023191	G/A	cg22157087	chr6:152012887	ESR1	0.25	6.03	0.48	1.76e-8	Total body bone mineral density;
TGCT	cis	rs6700896	0.522	rs12042379	chr1:66158464	G/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.54	4.44	0.37	1.98e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg22920501	chr2:26401640	FAM59B	-0.72	-6.38	-0.5	3.19e-9	Gut microbiome composition (summer);
TGCT	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg06558623	chr16:89946397	TCF25	-0.55	-7.35	-0.55	2.28e-11	Skin colour saturation;
TGCT	cis	rs3734729	1.000	rs3734730	chr6:150570940	T/C	cg16439130	chr6:149658548	MAP3K7IP2	0.52	4.96	0.41	2.25e-6	Pulmonary function;Pulmonary function (smoking interaction);
TGCT	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg11890956	chr21:40555474	PSMG1	-0.7	-6.8	-0.52	3.87e-10	Menarche (age at onset);
TGCT	cis	rs2688608	0.592	rs11000757	chr10:75486815	T/C	cg19442545	chr10:75533431	FUT11	-0.37	-5.77	-0.46	5.89e-8	Inflammatory bowel disease;
TGCT	cis	rs2742417	0.967	rs9877499	chr3:45734404	G/A	cg04837898	chr3:45731254	SACM1L	-0.55	-5.68	-0.45	9.07e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs7666738	0.830	rs1349757	chr4:99058763	C/G	cg17366294	chr4:99064904	C4orf37	0.72	7.39	0.55	1.9e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1552244	0.515	rs28853661	chr3:10177659	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.35	-4.75	-0.39	5.62e-6	Alzheimer's disease;
TGCT	cis	rs7824557	0.518	rs11777007	chr8:10801857	C/T	cg27411982	chr8:10470053	RP1L1	-0.24	-5.04	-0.41	1.62e-6	Retinal vascular caliber;
TGCT	cis	rs11190604	0.767	rs10786590	chr10:102164604	T/C	cg16342193	chr10:102329863	NA	-0.39	-5.05	-0.41	1.54e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7824557	0.767	rs2060463	chr8:11161610	T/G	cg21775007	chr8:11205619	TDH	0.58	5.46	0.44	2.46e-7	Retinal vascular caliber;
TGCT	cis	rs4494114	0.875	rs7518432	chr1:39363522	G/C	cg25970120	chr1:39325951	RRAGC	-0.6	-6.19	-0.49	8.18e-9	Blood protein levels;
TGCT	cis	rs4242434	0.892	rs34269854	chr8:22465160	G/C	cg03733263	chr8:22462867	KIAA1967	1.14	20.09	0.87	8.18e-41	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs10838634	1.000	rs12287376	chr11:46857059	C/T	cg18332754	chr11:46939436	LRP4	0.9	4.58	0.38	1.11e-5	Schizophrenia;
TGCT	trans	rs6089829	0.962	rs6089826	chr20:61668595	G/A	cg13615516	chr5:77269221	NA	0.72	9.08	0.63	2.05e-15	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.72	5.19	0.42	8.33e-7	Platelet count;
TGCT	cis	rs11122272	0.668	rs2790874	chr1:231537988	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-6.28	-0.49	5.32e-9	Hemoglobin concentration;
TGCT	cis	rs908922	0.676	rs7545336	chr1:152527863	A/G	cg20991723	chr1:152506922	NA	0.45	6.06	0.48	1.55e-8	Hair morphology;
TGCT	cis	rs9611565	0.546	rs739132	chr22:42123099	A/T	cg06634786	chr22:41940651	POLR3H	0.89	8.81	0.62	9.46e-15	Vitiligo;
TGCT	cis	rs55962025	1.000	rs2285087	chr4:3088211	A/G	cg06533319	chr4:3265114	C4orf44	0.22	4.66	0.39	8.19e-6	Parental longevity (mother's age at death);
TGCT	cis	rs7666738	0.645	rs10013290	chr4:99082799	G/A	cg05340658	chr4:99064831	C4orf37	0.52	5.64	0.45	1.08e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2153535	0.580	rs1115079	chr6:8449615	G/C	cg07606381	chr6:8435919	SLC35B3	0.53	5.02	0.41	1.79e-6	Motion sickness;
TGCT	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg12667521	chr19:29218732	NA	0.51	6.05	0.48	1.57e-8	Methadone dose in opioid dependence;
TGCT	cis	rs3902035	0.964	rs28710027	chr6:119009295	G/A	cg07617317	chr6:118971624	C6orf204	0.42	5.08	0.42	1.35e-6	QT interval;
TGCT	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg05368731	chr17:41323189	NBR1	1.2	14.2	0.79	8.98e-28	Menopause (age at onset);
TGCT	cis	rs7647973	0.677	rs11130211	chr3:49645209	C/T	cg03060546	chr3:49711283	APEH	0.63	5.14	0.42	1.03e-6	Menarche (age at onset);
TGCT	cis	rs6964587	0.869	rs11769294	chr7:91549937	C/T	cg17063962	chr7:91808500	NA	0.73	5.62	0.45	1.19e-7	Breast cancer;
TGCT	cis	rs11650494	0.901	rs117087923	chr17:47364913	G/A	cg08112188	chr17:47440006	ZNF652	1.05	5.4	0.44	3.32e-7	Prostate cancer;
TGCT	cis	rs4654899	0.931	rs4654880	chr1:21186608	C/A	cg01072550	chr1:21505969	NA	0.5	7.93	0.58	1.08e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs62244186	0.516	rs11922470	chr3:44777795	C/T	cg15687855	chr3:44754131	ZNF502	-0.42	-4.68	-0.39	7.42e-6	Depressive symptoms;
TGCT	cis	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg22121687	chr7:65037720	NA	-0.76	-4.45	-0.37	1.87e-5	Diabetic kidney disease;
TGCT	cis	rs4727027	0.933	rs2158633	chr7:148832652	C/T	cg23583168	chr7:148888333	NA	-0.72	-9.18	-0.64	1.18e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs6939532	0.544	rs10946816	chr6:26361946	C/G	cg05738196	chr6:26577821	NA	-0.53	-5.03	-0.41	1.68e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9796	0.870	rs7169375	chr15:41311046	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.41	-5.41	-0.44	3.06e-7	Menopause (age at onset);
TGCT	cis	rs7809950	1.000	rs2520249	chr7:107146748	A/G	cg23024343	chr7:107201750	COG5	-0.35	-5.54	-0.45	1.72e-7	Coronary artery disease;
TGCT	cis	rs72949976	0.864	rs10176806	chr2:214022596	T/G	cg08319019	chr2:214017104	IKZF2	-0.76	-7.04	-0.53	1.14e-10	Lung cancer;Squamous cell lung carcinoma;
TGCT	cis	rs7010267	0.596	rs1905778	chr8:120021848	A/C	cg17171407	chr8:119960777	TNFRSF11B	0.25	4.45	0.37	1.87e-5	Total body bone mineral density (age 45-60);
TGCT	cis	rs7617773	0.563	rs62263035	chr3:48391569	C/T	cg11946769	chr3:48343235	NME6	0.57	4.89	0.4	3.05e-6	Coronary artery disease;
TGCT	cis	rs7568458	0.837	rs3731827	chr2:85806068	T/C	cg02493740	chr2:85810744	VAMP5	-0.27	-4.85	-0.4	3.63e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs422249	0.512	rs174578	chr11:61605499	T/A	cg19610905	chr11:61596333	FADS2	-0.95	-9.31	-0.64	6.01e-16	Trans fatty acid levels;
TGCT	cis	rs72781680	0.821	rs2339887	chr2:24198376	G/A	cg08917208	chr2:24149416	ATAD2B	0.72	4.5	0.37	1.56e-5	Lymphocyte counts;
TGCT	cis	rs1005277	0.522	rs1208681	chr10:38092975	C/T	cg25427524	chr10:38739819	LOC399744	-0.32	-6.45	-0.5	2.22e-9	Extrinsic epigenetic age acceleration;
TGCT	cis	rs35146811	0.735	rs6948729	chr7:99787372	A/G	cg13334819	chr7:99746414	C7orf59	-0.74	-6.31	-0.49	4.4e-9	Coronary artery disease;
TGCT	cis	rs9911578	1.000	rs12947785	chr17:57045160	A/C	cg12560992	chr17:57184187	TRIM37	0.76	9.21	0.64	1.03e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs362272	0.505	rs3129310	chr4:3301388	T/G	cg18352616	chr4:3374830	RGS12	0.24	4.7	0.39	6.93e-6	Serum sulfate level;
TGCT	cis	rs939658	0.875	rs2177057	chr15:79441441	G/C	cg17916960	chr15:79447300	NA	-0.49	-7.41	-0.55	1.73e-11	Refractive error;
TGCT	cis	rs9911578	1.000	rs304299	chr17:56838472	C/G	cg05425664	chr17:57184151	TRIM37	-0.63	-6.26	-0.49	5.86e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs13147768	chr4:98833675	A/T	cg05340658	chr4:99064831	C4orf37	0.53	6.18	0.49	8.5e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs739496	0.615	rs56884502	chr12:112207300	T/A	cg10833066	chr12:111807467	FAM109A	0.36	4.67	0.39	7.74e-6	Platelet count;
TGCT	cis	rs3796352	1.000	rs11714876	chr3:53101640	C/G	cg15956490	chr3:53032818	SFMBT1	-0.59	-6.67	-0.51	7.64e-10	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs3749237	0.615	rs55957735	chr3:49438158	G/A	cg02487422	chr3:49467188	NICN1	0.59	6.01	0.47	1.92e-8	Resting heart rate;
TGCT	cis	rs644799	1.000	rs494829	chr11:95571750	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	9.73	0.66	5.62e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9527	0.615	rs4917991	chr10:104783833	T/C	cg15744005	chr10:104629667	AS3MT	-0.42	-4.92	-0.4	2.74e-6	Arsenic metabolism;
TGCT	cis	rs13064411	0.696	rs6798938	chr3:113218206	C/T	cg18753928	chr3:113234510	CCDC52	-0.7	-5.75	-0.46	6.6e-8	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs9393692	0.840	rs9358915	chr6:26277268	G/A	cg13736514	chr6:26305472	NA	-0.37	-5.42	-0.44	3.01e-7	Educational attainment;
TGCT	trans	rs57221529	0.766	rs72706608	chr5:559203	C/T	cg11887960	chr12:57824829	NA	1.15	9.35	0.64	4.71e-16	Lung disease severity in cystic fibrosis;
TGCT	cis	rs12477438	0.798	rs7606635	chr2:99644782	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-7.6	-0.56	6.47e-12	Chronic sinus infection;
TGCT	cis	rs6430585	0.528	rs56064699	chr2:136595706	G/A	cg07169764	chr2:136633963	MCM6	1.21	11.6	0.72	1.59e-21	Corneal structure;
TGCT	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg22105103	chr4:187893119	NA	0.35	4.89	0.4	3.02e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6460942	0.915	rs17324858	chr7:12305792	G/T	cg06484146	chr7:12443880	VWDE	-0.43	-4.58	-0.38	1.12e-5	Coronary artery disease;
TGCT	cis	rs9640161	0.789	rs60283368	chr7:150023258	G/A	cg10018233	chr7:150070692	REPIN1	0.32	4.63	0.38	9.08e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs12210905	0.688	rs12212389	chr6:27326397	T/C	cg08851530	chr6:28072375	NA	1.25	5.39	0.44	3.38e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs7617773	0.539	rs35460860	chr3:48392085	A/T	cg11946769	chr3:48343235	NME6	0.59	4.91	0.4	2.83e-6	Coronary artery disease;
TGCT	cis	rs2657888	0.529	rs34287864	chr12:56858317	G/A	cg23002907	chr12:56915593	RBMS2	-0.45	-5.72	-0.46	7.37e-8	Adiponectin levels;
TGCT	cis	rs9372498	0.536	rs62663261	chr6:118900553	T/C	cg21191810	chr6:118973309	C6orf204	-0.39	-5.06	-0.41	1.5e-6	Diastolic blood pressure;
TGCT	cis	rs2204008	0.837	rs11169157	chr12:37980047	T/C	cg26384229	chr12:38710491	ALG10B	0.85	7.77	0.57	2.56e-12	Bladder cancer;
TGCT	cis	rs1577917	1.000	rs2816821	chr6:86657084	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.05	-0.41	1.57e-6	Response to antipsychotic treatment;
TGCT	cis	rs941873	0.900	rs4979862	chr10:81131599	G/A	cg09469691	chr10:81107165	PPIF	0.66	6.87	0.53	2.75e-10	Height;
TGCT	cis	rs6500602	0.627	rs860891	chr16:4586529	C/T	cg08645402	chr16:4508243	NA	-0.21	-5.47	-0.44	2.4e-7	Schizophrenia;
TGCT	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg01802117	chr1:53393560	SCP2	-0.39	-4.61	-0.38	1e-5	Monocyte count;
TGCT	cis	rs9457247	1.000	rs439553	chr6:167391212	A/G	cg23791538	chr6:167370224	RNASET2	-0.5	-4.98	-0.41	2.08e-6	Crohn's disease;
TGCT	cis	rs3858526	0.916	rs11039551	chr11:5930773	C/T	cg05234568	chr11:5960015	NA	-0.44	-4.6	-0.38	1.03e-5	DNA methylation (variation);
TGCT	cis	rs6087990	0.765	rs6058900	chr20:31400673	T/C	cg13636640	chr20:31349939	DNMT3B	0.96	11.62	0.72	1.4e-21	Ulcerative colitis;
TGCT	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg05896524	chr21:47604654	C21orf56	-0.43	-4.54	-0.38	1.31e-5	Testicular germ cell tumor;
TGCT	cis	rs7781977	0.575	rs7782210	chr7:50348745	A/G	cg14216940	chr7:50343131	IKZF1	0.37	4.65	0.39	8.31e-6	IgG glycosylation;
TGCT	cis	rs9894429	0.671	rs6565616	chr17:79612161	C/T	cg21028142	chr17:79581711	NPLOC4	0.28	5.87	0.47	3.73e-8	Eye color traits;
TGCT	cis	rs16867321	0.507	rs2013577	chr2:181370505	C/T	cg23363182	chr2:181467187	NA	-0.33	-4.98	-0.41	2.05e-6	Obesity;
TGCT	cis	rs7819412	0.838	rs3021494	chr8:10983534	A/G	cg27411982	chr8:10470053	RP1L1	-0.21	-4.6	-0.38	1.02e-5	Triglycerides;
TGCT	cis	rs7208859	0.623	rs216436	chr17:28922900	G/A	cg14008862	chr17:28927542	LRRC37B2	0.93	5.64	0.45	1.11e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg23719950	chr11:63933701	MACROD1	-0.71	-5.91	-0.47	3.06e-8	Mean platelet volume;
TGCT	cis	rs3748682	0.861	rs72661832	chr1:38260733	C/T	cg04496824	chr1:38276835	MTF1	0.21	4.63	0.38	9.22e-6	Hypothyroidism;
TGCT	cis	rs2463822	1.000	rs2463822	chr11:62103420	T/C	cg06239285	chr11:62104954	ASRGL1	0.95	6.56	0.51	1.33e-9	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs9399135	0.967	rs6923827	chr6:135335382	C/T	cg24558204	chr6:135376177	HBS1L	0.46	4.59	0.38	1.09e-5	Red blood cell count;
TGCT	cis	rs62244186	0.659	rs62251383	chr3:44552421	A/G	cg02073558	chr3:44770973	ZNF501	0.58	5.57	0.45	1.5e-7	Depressive symptoms;
TGCT	cis	rs1670533	1.000	rs3816474	chr4:1050653	G/A	cg27284194	chr4:1044797	NA	0.63	4.9	0.4	2.87e-6	Recombination rate (females);
TGCT	cis	rs1059312	1.000	rs7136092	chr12:129280164	G/C	cg09035930	chr12:129282057	SLC15A4	0.59	11.76	0.73	6.45e-22	Systemic lupus erythematosus;
TGCT	cis	rs11711311	1.000	rs9811353	chr3:113483979	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.79	-7.32	-0.55	2.75e-11	IgG glycosylation;
TGCT	cis	rs7772486	0.817	rs12198065	chr6:146385286	G/C	cg13319975	chr6:146136371	FBXO30	-0.51	-4.48	-0.37	1.69e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs28493229	0.708	rs10408309	chr19:41161189	T/G	cg11601297	chr19:41224147	ITPKC;ADCK4	0.57	5.15	0.42	9.78e-7	Kawasaki disease;
TGCT	cis	rs288326	0.561	rs77184695	chr2:183802573	G/A	cg09997497	chr2:183902928	NCKAP1	1.11	4.95	0.41	2.38e-6	Blood protein levels;
TGCT	cis	rs11648796	0.721	rs743987	chr16:769566	C/G	cg27144592	chr16:783916	NARFL	0.43	5.82	0.46	4.73e-8	Height;
TGCT	cis	rs72781680	0.950	rs72798404	chr2:24180125	C/T	cg08917208	chr2:24149416	ATAD2B	0.9	5.45	0.44	2.62e-7	Lymphocyte counts;
TGCT	cis	rs7786877	0.521	rs4729606	chr7:100321790	T/C	cg20848291	chr7:100343083	ZAN	-0.52	-4.49	-0.37	1.63e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs4850410	0.559	rs13013812	chr2:197908178	C/G	cg19149314	chr2:197065128	HECW2	0.23	4.51	0.38	1.46e-5	Interferon alpha levels in systemic lupus erythematosus;
TGCT	cis	rs870825	0.615	rs2696038	chr4:185610903	C/T	cg14471096	chr4:185570637	CCDC111;CASP3	-0.67	-4.62	-0.38	9.41e-6	Blood protein levels;
TGCT	cis	rs7829975	0.514	rs2920983	chr8:8268063	G/C	cg15556689	chr8:8085844	FLJ10661	0.75	6.8	0.52	4e-10	Mood instability;
TGCT	cis	rs1451375	0.712	rs11974297	chr7:50618260	A/G	cg18232548	chr7:50535776	DDC	0.44	7.05	0.53	1.13e-10	Malaria;
TGCT	cis	rs7953249	0.564	rs11065385	chr12:121423386	A/G	cg02403541	chr12:121454288	C12orf43	-0.7	-6.33	-0.49	4.11e-9	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs4285028	0.699	rs2689290	chr3:121585146	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.75	-6.71	-0.52	6.29e-10	Multiple sclerosis;
TGCT	cis	rs35306767	0.903	rs61833260	chr10:975148	T/G	cg26597838	chr10:835615	NA	0.69	9.59	0.65	1.25e-16	Eosinophil percentage of granulocytes;
TGCT	cis	rs9926296	0.572	rs8047581	chr16:89884502	C/T	cg04287289	chr16:89883240	FANCA	0.71	7.57	0.56	7.42e-12	Vitiligo;
TGCT	cis	rs7917772	0.512	rs11594073	chr10:104308193	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.54	-5.31	-0.43	4.96e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs910316	1.000	rs10138183	chr14:75615227	T/C	cg08847533	chr14:75593920	NEK9	0.94	10.16	0.67	5.21e-18	Height;
TGCT	cis	rs8072100	0.967	rs8075411	chr17:45676760	C/T	cg08085267	chr17:45401833	C17orf57	0.43	4.63	0.38	9.02e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs11122272	0.735	rs2491403	chr1:231511185	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.14	-0.54	6.86e-11	Hemoglobin concentration;
TGCT	cis	rs3008870	0.883	rs2755249	chr1:67493662	A/G	cg03991309	chr1:68237761	GNG12	0.27	4.5	0.37	1.56e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs1059312	0.808	rs2170989	chr12:129291317	T/C	cg09035930	chr12:129282057	SLC15A4	-0.55	-10.73	-0.69	2.06e-19	Systemic lupus erythematosus;
TGCT	cis	rs4727027	0.680	rs6464941	chr7:148826352	A/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.57	4.72	0.39	6.24e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs3806843	1.000	rs1476768	chr5:140173597	G/A	cg19875535	chr5:140030758	IK	0.37	6.34	0.49	3.89e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs17108533	0.588	rs12882665	chr14:71300599	C/T	cg23900759	chr14:71108106	TTC9	1.13	4.56	0.38	1.19e-5	Response to antipsychotic treatment in schizophrenia (reasoning);
TGCT	cis	rs1580019	0.844	rs1584615	chr7:32503258	G/C	cg06627557	chr7:32535165	LSM5;AVL9	0.88	8.63	0.61	2.55e-14	Cognitive ability;
TGCT	cis	rs919433	0.679	rs10931788	chr2:198531084	A/G	cg00792783	chr2:198669748	PLCL1	0.55	4.93	0.4	2.56e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.71	-0.39	6.54e-6	Prudent dietary pattern;
TGCT	cis	rs6088590	1.000	rs2076668	chr20:33437621	G/A	cg24642439	chr20:33292090	TP53INP2	0.72	6.38	0.5	3.18e-9	Coronary artery disease;
TGCT	cis	rs9517320	0.515	rs4772101	chr13:99207554	G/A	cg07423050	chr13:99094983	FARP1	-0.22	-4.46	-0.37	1.79e-5	Longevity;
TGCT	cis	rs922182	0.617	rs55694045	chr15:64245943	T/C	cg02919090	chr15:64263738	DAPK2	0.37	6.84	0.52	3.28e-10	Blood protein levels;
TGCT	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg23248424	chr5:179741104	GFPT2	-0.37	-7.04	-0.53	1.17e-10	Height;
TGCT	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg26354017	chr1:205819088	PM20D1	0.56	6.79	0.52	4.16e-10	Menarche (age at onset);
TGCT	cis	rs12477438	0.765	rs13406288	chr2:99589585	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-7.6	-0.56	6.47e-12	Chronic sinus infection;
TGCT	cis	rs3862030	0.503	rs10786673	chr10:104280537	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
TGCT	cis	rs112591243	0.685	rs2839366	chr21:48026443	A/T	cg10657630	chr21:48055338	PRMT2	-1.08	-6.4	-0.5	2.96e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs350251	0.899	rs350277	chr16:12232547	C/T	cg02910054	chr16:12241554	SNX29	0.33	4.57	0.38	1.18e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs753778	0.628	rs1045248	chr8:142204326	C/G	cg18755752	chr8:142205143	DENND3	-0.28	-5.02	-0.41	1.78e-6	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs9393777	0.841	rs67092078	chr6:27054772	G/A	cg16898833	chr6:26189333	HIST1H4D	1.3	5.86	0.47	3.92e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs12479064	0.724	rs4851203	chr2:99986932	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-4.96	-0.41	2.29e-6	Chronic sinus infection;
TGCT	cis	rs7674212	0.570	rs6810571	chr4:104086787	G/T	cg16532752	chr4:104119610	CENPE	-0.61	-5.67	-0.45	9.45e-8	Type 2 diabetes;
TGCT	cis	rs12477438	0.765	rs12470471	chr2:99689141	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.52	4.45	0.37	1.85e-5	Chronic sinus infection;
TGCT	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	-1.08	-9.05	-0.63	2.43e-15	Platelet count;
TGCT	cis	rs6922617	0.892	rs6922692	chr6:41336319	C/G	cg07798131	chr6:41471673	NA	-0.81	-4.46	-0.37	1.8e-5	Alzheimer's disease biomarkers;
TGCT	cis	rs3935685	0.874	rs4886898	chr15:78004743	T/C	cg03457338	chr15:78040120	NA	-0.21	-5.54	-0.45	1.72e-7	Intelligence (multi-trait analysis);
TGCT	trans	rs1814175	0.817	rs1621090	chr11:49895868	C/A	cg03929089	chr4:120376271	NA	-0.72	-8.26	-0.6	1.86e-13	Height;
TGCT	cis	rs9677476	0.657	rs9679430	chr2:232122482	C/T	cg27665808	chr2:232055229	NA	-0.34	-4.45	-0.37	1.89e-5	Food antigen IgG levels;
TGCT	cis	rs11098499	0.697	rs35280960	chr4:120257059	G/A	cg09307838	chr4:120376055	NA	0.66	6.21	0.49	7.37e-9	Corneal astigmatism;
TGCT	cis	rs1635	0.655	rs60568488	chr6:28309511	T/C	cg15743358	chr6:28303923	ZNF323	-1.29	-6.5	-0.5	1.73e-9	Schizophrenia;
TGCT	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg01516881	chr6:292596	DUSP22	-0.72	-7.61	-0.56	5.89e-12	Menopause (age at onset);
TGCT	cis	rs12464483	0.591	rs4952170	chr2:30885429	G/A	cg17749961	chr2:30669863	LCLAT1	0.69	5.18	0.42	8.66e-7	Pre-treatment pain in head and neck squamous cell carcinoma;
TGCT	trans	rs3780486	0.505	rs7868663	chr9:33141229	A/G	cg04842962	chr6:43655489	MRPS18A	0.8	8.6	0.61	2.9e-14	IgG glycosylation;
TGCT	cis	rs72945132	0.882	rs12279046	chr11:70130388	A/G	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs3617	0.522	rs6773650	chr3:52897095	A/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.5	-4.92	-0.4	2.74e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs28595532	0.764	rs116158926	chr4:119730572	C/T	cg14228332	chr4:119757509	SEC24D	1.32	6.38	0.5	3.2e-9	Cannabis dependence symptom count;
TGCT	trans	rs208520	0.690	rs7739253	chr6:66861052	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-10.43	-0.68	1.13e-18	Exhaled nitric oxide output;
TGCT	cis	rs7267979	1.000	rs761025	chr20:25426968	G/A	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs57590327	0.644	rs7624045	chr3:81510799	A/G	cg07356753	chr3:81810745	GBE1	-0.53	-4.44	-0.37	1.97e-5	Extraversion;
TGCT	cis	rs523522	0.885	rs524735	chr12:121022099	T/C	cg27279351	chr12:120934652	DYNLL1	0.74	6.46	0.5	2.19e-9	High light scatter reticulocyte count;
TGCT	cis	rs910316	0.935	rs11159119	chr14:75636967	C/T	cg11812906	chr14:75593930	NEK9	-0.75	-7.44	-0.56	1.43e-11	Height;
TGCT	cis	rs7772486	0.875	rs10457794	chr6:146415608	A/G	cg13319975	chr6:146136371	FBXO30	-0.51	-4.48	-0.37	1.69e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs8017423	0.791	rs7146250	chr14:90711703	A/G	cg04374321	chr14:90722782	PSMC1	0.75	7.71	0.57	3.51e-12	Mortality in heart failure;
TGCT	cis	rs1801251	1.000	rs7592717	chr2:233577038	G/A	cg25237894	chr2:233734115	C2orf82	0.32	5.78	0.46	5.59e-8	Coronary artery disease;
TGCT	cis	rs9443645	0.901	rs10943605	chr6:79655477	G/A	cg09184832	chr6:79620586	NA	-0.49	-5.29	-0.43	5.29e-7	Intelligence (multi-trait analysis);
TGCT	trans	rs57221529	0.766	rs12522303	chr5:555564	A/C	cg25482853	chr8:67687455	SGK3	1.2	10.16	0.67	5.25e-18	Lung disease severity in cystic fibrosis;
TGCT	cis	rs9905704	0.647	rs2286299	chr17:57043367	T/G	cg12560992	chr17:57184187	TRIM37	0.59	5.24	0.43	6.8e-7	Testicular germ cell tumor;
TGCT	cis	rs8031584	0.706	rs798084	chr15:31126935	C/T	cg08704250	chr15:31115839	NA	-0.46	-6.85	-0.52	3.08e-10	Huntington's disease progression;
TGCT	cis	rs10779751	1.000	rs2300093	chr1:11266392	G/C	cg08854313	chr1:11322531	MTOR	0.92	10.28	0.68	2.6e-18	Body mass index;
TGCT	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs13393800	0.536	rs2741292	chr2:233380999	T/A	cg26635044	chr2:233757626	NGEF	0.18	5.0	0.41	1.92e-6	Height;
TGCT	cis	rs4478858	0.735	rs1566964	chr1:31792794	C/A	cg00250761	chr1:31883323	NA	-0.27	-4.84	-0.4	3.76e-6	Alcohol dependence;
TGCT	cis	rs8084125	0.832	rs62105173	chr18:74947147	A/G	cg05528293	chr18:74961138	GALR1	0.48	4.8	0.4	4.45e-6	Obesity-related traits;
TGCT	cis	rs17401966	0.931	rs11587854	chr1:10447622	G/A	cg19773385	chr1:10388646	KIF1B	-0.24	-5.49	-0.44	2.16e-7	Hepatocellular carcinoma;
TGCT	cis	rs933688	1.000	rs332529	chr5:90789470	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.93	7.33	0.55	2.63e-11	Smoking behavior;
TGCT	cis	rs6762	0.550	rs8672	chr11:838634	C/G	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.45	-4.55	-0.38	1.27e-5	Mean platelet volume;
TGCT	cis	rs2832191	0.729	rs2832201	chr21:30499841	A/G	cg24692254	chr21:30365293	RNF160	-0.99	-10.91	-0.7	7.71e-20	Dental caries;
TGCT	cis	rs7666738	0.830	rs13148324	chr4:98833616	G/A	cg17366294	chr4:99064904	C4orf37	0.72	7.47	0.56	1.23e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2836633	0.929	rs11701577	chr21:40028906	C/T	cg12884169	chr21:40033163	ERG	0.42	4.54	0.38	1.34e-5	Coronary artery disease;
TGCT	cis	rs6967414	0.685	rs6944332	chr7:6758018	G/A	cg00387323	chr7:6746715	ZNF12	0.76	4.65	0.39	8.23e-6	Hematocrit;Hemoglobin concentration;
TGCT	cis	rs1008375	0.933	rs6847966	chr4:17634255	G/A	cg10189774	chr4:17578691	LAP3	0.65	5.64	0.45	1.08e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs3733585	0.699	rs1122142	chr4:9947548	G/C	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.45	-0.5	2.22e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7975161	0.572	rs7132418	chr12:104603591	C/A	cg25273343	chr12:104657179	TXNRD1	-0.35	-5.13	-0.42	1.07e-6	Toenail selenium levels;
TGCT	cis	rs7523273	0.586	rs2796264	chr1:207919968	A/G	cg22525895	chr1:207977042	MIR29B2	0.54	8.81	0.62	9.48e-15	Schizophrenia;
TGCT	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg25036284	chr2:26402008	FAM59B	-0.61	-4.9	-0.4	2.92e-6	Gut microbiome composition (summer);
TGCT	cis	rs2243480	1.000	rs383402	chr7:65586653	A/C	cg18252515	chr7:66147081	NA	1.22	7.98	0.58	8.46e-13	Diabetic kidney disease;
TGCT	cis	rs1453308	0.938	rs2084953	chr2:237178578	T/A	cg19324714	chr2:237145437	ASB18	0.58	5.08	0.41	1.36e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs10820904	1.000	rs4743852	chr9:94558126	C/T	cg26478992	chr9:95245965	CENPP;ASPN	-0.32	-4.47	-0.37	1.77e-5	Body mass index;
TGCT	cis	rs3125734	0.633	rs7100297	chr10:63985100	T/C	cg09941381	chr10:64027924	RTKN2	-0.36	-5.53	-0.44	1.83e-7	Rheumatoid arthritis;
TGCT	cis	rs2997447	0.706	rs61776574	chr1:26429492	C/T	cg03844060	chr1:26490628	NA	0.28	4.57	0.38	1.17e-5	QRS complex (12-leadsum);
TGCT	cis	rs60843830	0.517	rs58416198	chr2:175580	T/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.66	5.12	0.42	1.13e-6	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs2456568	0.867	rs4753111	chr11:93658410	A/G	cg17595323	chr11:93583763	C11orf90	-0.47	-5.96	-0.47	2.49e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs727563	0.562	rs5758458	chr22:42154132	G/A	cg17554472	chr22:41940697	POLR3H	0.46	4.69	0.39	7.09e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs7542091	0.704	rs1108628	chr1:210041150	A/G	cg23283495	chr1:209979779	IRF6	0.56	5.59	0.45	1.36e-7	Monobrow;
TGCT	cis	rs933688	1.000	rs1035476	chr5:90745976	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.93	7.95	0.58	1.01e-12	Smoking behavior;
TGCT	cis	rs3741151	1.000	rs74776668	chr11:73065909	G/A	cg17517138	chr11:73019481	ARHGEF17	1.08	5.32	0.43	4.75e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
TGCT	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg03395511	chr6:291903	DUSP22	-0.65	-6.76	-0.52	4.71e-10	Menopause (age at onset);
TGCT	cis	rs7267979	1.000	rs398036	chr20:25439850	C/T	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg21659725	chr3:3221576	CRBN	0.7	7.95	0.58	9.9e-13	Body mass index;
TGCT	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg03709012	chr19:19516395	GATAD2A	0.75	6.2	0.49	7.59e-9	Tonsillectomy;
TGCT	cis	rs4074961	0.565	rs4415526	chr1:38071728	T/C	cg11397548	chr1:38022522	DNALI1	0.41	4.67	0.39	7.69e-6	Axial length;
TGCT	cis	rs9372498	0.536	rs17080292	chr6:118850266	A/G	cg07617317	chr6:118971624	C6orf204	0.52	5.55	0.45	1.69e-7	Diastolic blood pressure;
TGCT	cis	rs2019216	0.500	rs4325621	chr17:21926257	T/G	cg22648282	chr17:21454238	C17orf51	-0.59	-5.39	-0.44	3.41e-7	Pelvic organ prolapse;
TGCT	cis	rs881375	0.967	rs1008381	chr9:123681116	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.38	4.5	0.37	1.57e-5	Rheumatoid arthritis;
TGCT	cis	rs259282	0.605	rs8101007	chr19:33109557	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.53	4.84	0.4	3.8e-6	Schizophrenia;
TGCT	cis	rs9341808	0.718	rs2322631	chr6:80843956	A/C	cg08355045	chr6:80787529	NA	0.32	5.83	0.46	4.48e-8	Sitting height ratio;
TGCT	cis	rs644799	1.000	rs505220	chr11:95563228	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	10.52	0.69	6.94e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs10465746	0.967	rs12120160	chr1:84342835	T/G	cg10977910	chr1:84465055	TTLL7	0.63	6.19	0.49	8.08e-9	Obesity-related traits;
TGCT	cis	rs918629	0.679	rs57471342	chr5:95272429	A/C	cg16656078	chr5:95278638	ELL2	-0.32	-5.06	-0.41	1.49e-6	IgG glycosylation;
TGCT	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg10802521	chr3:52805072	NEK4	-0.73	-8.95	-0.63	4.39e-15	Electroencephalogram traits;
TGCT	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg10802521	chr3:52805072	NEK4	-0.78	-10.0	-0.67	1.26e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs9517320	0.515	rs72646416	chr13:99232916	C/G	cg07423050	chr13:99094983	FARP1	-0.23	-4.54	-0.38	1.31e-5	Longevity;
TGCT	trans	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg20587970	chr11:113659929	NA	-1.04	-12.57	-0.75	6.97e-24	Hip circumference adjusted for BMI;
TGCT	cis	rs4727027	0.870	rs11525060	chr7:148801091	G/A	cg23583168	chr7:148888333	NA	-0.72	-9.11	-0.63	1.8e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs3812831	0.662	rs407531	chr13:114929218	G/A	cg15513719	chr13:114904418	NA	0.38	4.65	0.39	8.37e-6	Schizophrenia;
TGCT	cis	rs138857	0.515	rs9616373	chr22:50308597	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.21	-7.42	-0.55	1.6e-11	Mean platelet volume;
TGCT	trans	rs7819412	0.505	rs34031674	chr8:10809490	G/C	cg06636001	chr8:8085503	FLJ10661	-0.79	-6.87	-0.53	2.69e-10	Triglycerides;
TGCT	cis	rs4268898	0.795	rs12470303	chr2:24619883	C/T	cg02683114	chr2:24398427	C2orf84	-0.19	-4.46	-0.37	1.79e-5	Asthma;
TGCT	cis	rs2180341	1.000	rs9398837	chr6:127635217	G/A	cg27446573	chr6:127587934	RNF146	1.12	10.11	0.67	6.87e-18	Breast cancer;
TGCT	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg13393036	chr8:95962371	TP53INP1	-0.61	-8.31	-0.6	1.42e-13	Type 2 diabetes;
TGCT	cis	rs2948294	0.566	rs13274039	chr8:8111659	A/G	cg15462221	chr8:8086144	FLJ10661	-0.58	-4.75	-0.39	5.5e-6	Red cell distribution width;
TGCT	cis	rs1797885	0.546	rs2450855	chr3:12602494	G/A	cg05775895	chr3:12838266	CAND2	0.49	4.75	0.39	5.53e-6	Immature fraction of reticulocytes;
TGCT	cis	rs7617480	0.648	rs9864243	chr3:48982732	G/A	cg07636037	chr3:49044803	WDR6	0.81	6.68	0.51	7.37e-10	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs244731	0.959	rs9313752	chr5:176645435	G/T	cg16006841	chr5:176797999	RGS14	-0.56	-7.2	-0.54	5e-11	Urate levels in lean individuals;
TGCT	cis	rs911263	0.603	rs11626138	chr14:68786993	A/G	cg18825221	chr14:68749962	RAD51L1	0.22	4.46	0.37	1.82e-5	Primary biliary cholangitis;
TGCT	cis	rs1609391	0.543	rs6761993	chr3:136625902	C/T	cg15507776	chr3:136538369	TMEM22	0.66	6.84	0.52	3.27e-10	Neuroticism;
TGCT	cis	rs17345786	0.906	rs72946021	chr3:101250008	T/G	cg12386194	chr3:101231763	SENP7	0.6	5.52	0.44	1.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3008870	1.000	rs3008870	chr1:67418027	C/T	cg11518657	chr1:67396239	MIER1	0.54	4.65	0.39	8.44e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs4924935	0.781	rs2472694	chr17:18848498	A/G	cg26378065	chr17:18585709	ZNF286B	0.61	4.96	0.41	2.29e-6	Pancreatic cancer;
TGCT	cis	rs4711350	0.954	rs1536501	chr6:33727885	C/T	cg00334056	chr6:33755658	LEMD2	0.31	4.82	0.4	4.18e-6	Schizophrenia;
TGCT	cis	rs2594989	0.943	rs2454504	chr3:11498423	G/A	cg00170343	chr3:11313890	ATG7	0.67	5.03	0.41	1.69e-6	Circulating chemerin levels;
TGCT	cis	rs79149102	0.579	rs6495135	chr15:75295030	T/C	cg09165964	chr15:75287851	SCAMP5	-1.04	-5.71	-0.46	7.93e-8	Lung cancer;
TGCT	cis	rs1322512	1.000	rs9371620	chr6:152949230	T/G	cg03415253	chr6:152958462	SYNE1	-0.57	-4.99	-0.41	2e-6	Tonometry;
TGCT	cis	rs6671200	0.541	rs7555339	chr1:95691579	G/A	cg26537280	chr1:95699037	RWDD3	-0.52	-4.93	-0.4	2.62e-6	Stearic acid (18:0) levels;
TGCT	cis	rs9300255	0.508	rs1716176	chr12:123655467	T/G	cg00376283	chr12:123451042	ABCB9	0.66	4.85	0.4	3.59e-6	Neutrophil percentage of white cells;
TGCT	cis	rs76473307	1.000	rs80031754	chr20:57376626	A/G	cg06163629	chr20:57414884	GNASAS;GNAS	-0.7	-4.61	-0.38	1.01e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs826838	0.935	rs1684406	chr12:39127265	A/G	cg13010199	chr12:38710504	ALG10B	-0.63	-5.04	-0.41	1.6e-6	Heart rate;
TGCT	cis	rs61931739	0.517	rs10844830	chr12:34308133	C/T	cg06521331	chr12:34319734	NA	-0.28	-4.7	-0.39	6.74e-6	Morning vs. evening chronotype;
TGCT	trans	rs8073060	0.586	rs6505487	chr17:33996850	A/G	cg19694781	chr19:47549865	TMEM160	-0.58	-12.73	-0.75	2.87e-24	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs986417	0.688	rs6573321	chr14:61101710	A/G	cg27398547	chr14:60952738	C14orf39	1.57	10.0	0.67	1.28e-17	Gut microbiota (bacterial taxa);
TGCT	cis	rs12908161	0.683	rs12903256	chr15:85308141	G/T	cg11189052	chr15:85197271	WDR73	0.62	5.67	0.45	9.56e-8	Schizophrenia;
TGCT	cis	rs7617773	0.643	rs78159520	chr3:48349023	T/C	cg11946769	chr3:48343235	NME6	0.82	7.09	0.54	9.1e-11	Coronary artery disease;
TGCT	cis	rs1401999	0.690	rs1402001	chr3:183642751	A/G	cg01324343	chr3:183735012	ABCC5	0.69	8.34	0.6	1.23e-13	Anterior chamber depth;
TGCT	cis	rs3008870	0.958	rs12131222	chr1:67438535	A/T	cg11518657	chr1:67396239	MIER1	-0.54	-4.61	-0.38	9.72e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg05368731	chr17:41323189	NBR1	1.1	11.08	0.71	2.94e-20	Menopause (age at onset);
TGCT	cis	rs9467773	0.967	rs9295694	chr6:26512994	A/T	cg15659132	chr6:26577336	NA	0.86	12.21	0.74	5.3e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs554111	0.656	rs964466	chr1:21375163	T/G	cg01072550	chr1:21505969	NA	0.36	5.46	0.44	2.51e-7	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs909674	0.775	rs4821896	chr22:39833437	T/C	cg01416388	chr22:39784598	NA	-0.74	-6.74	-0.52	5.2e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs3902035	0.964	rs1891713	chr6:119009564	A/G	cg07617317	chr6:118971624	C6orf204	-0.43	-5.01	-0.41	1.79e-6	QT interval;
TGCT	cis	rs2046867	0.908	rs11928067	chr3:72796340	T/C	cg25664220	chr3:72788482	NA	-0.56	-7.15	-0.54	6.59e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs4930561	0.677	rs7946212	chr11:67982187	T/A	cg04465784	chr11:67976953	SUV420H1	-0.38	-5.5	-0.44	2.07e-7	Breast cancer in childhood cancer survivors;IgG glycosylation;
TGCT	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg10047753	chr17:41438598	NA	0.96	9.49	0.65	2.15e-16	Menopause (age at onset);
TGCT	cis	rs4680	0.737	rs2239393	chr22:19950428	A/G	cg23601416	chr22:19950040	COMT	-0.39	-5.02	-0.41	1.75e-6	Blood metabolite levels;
TGCT	cis	rs2404602	0.735	rs4886805	chr15:76739384	A/G	cg22467129	chr15:76604101	ETFA	-0.47	-4.87	-0.4	3.26e-6	Blood metabolite levels;
TGCT	cis	rs782590	0.556	rs782579	chr2:55917604	A/G	cg18811423	chr2:55921094	PNPT1	0.56	5.63	0.45	1.13e-7	Metabolic syndrome;
TGCT	cis	rs3806843	0.606	rs251377	chr5:140255792	C/A	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	0.43	5.17	0.42	8.91e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2180341	0.532	rs6933893	chr6:127707250	A/G	cg27446573	chr6:127587934	RNF146	0.67	6.07	0.48	1.41e-8	Breast cancer;
TGCT	cis	rs2862064	0.932	rs1995378	chr5:156421132	G/A	cg12943317	chr5:156479607	HAVCR1	-0.44	-5.8	-0.46	5.28e-8	Platelet count;
TGCT	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg16680214	chr1:154839983	KCNN3	-0.36	-7.12	-0.54	7.57e-11	Prostate cancer;
TGCT	cis	rs6460942	0.915	rs62447641	chr7:12488764	G/A	cg06484146	chr7:12443880	VWDE	-0.61	-5.43	-0.44	2.87e-7	Coronary artery disease;
TGCT	cis	rs9915657	0.715	rs34624256	chr17:70105848	C/T	cg06234051	chr17:70120541	SOX9	-0.24	-5.14	-0.42	1.03e-6	Thyroid hormone levels;
TGCT	cis	rs13217239	0.608	rs6930508	chr6:27053142	T/C	cg05738196	chr6:26577821	NA	-0.51	-4.92	-0.4	2.71e-6	Schizophrenia;
TGCT	cis	rs9906944	0.603	rs10853104	chr17:47092076	C/T	cg20966754	chr17:47091339	IGF2BP1	-0.45	-5.11	-0.42	1.17e-6	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg10150615	chr22:24372951	LOC391322	-1.01	-13.22	-0.76	1.94e-25	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6906287	0.647	rs13217710	chr6:118843601	A/G	cg21191810	chr6:118973309	C6orf204	0.26	4.49	0.37	1.58e-5	Electrocardiographic conduction measures;
TGCT	cis	rs12532214	1.000	rs12532214	chr7:3169890	C/G	cg19214707	chr7:3157722	NA	-0.45	-6.11	-0.48	1.19e-8	Itch intensity from mosquito bite;
TGCT	cis	rs4766566	0.501	rs3742004	chr12:111798553	A/G	cg10833066	chr12:111807467	FAM109A	0.45	7.72	0.57	3.32e-12	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
TGCT	cis	rs7666738	0.606	rs7663216	chr4:99088385	A/C	cg17366294	chr4:99064904	C4orf37	0.57	5.31	0.43	4.89e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3796352	0.892	rs2581807	chr3:53088844	G/A	cg15956490	chr3:53032818	SFMBT1	-0.54	-6.44	-0.5	2.33e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs1322512	1.000	rs1322512	chr6:152947953	C/A	cg03415253	chr6:152958462	SYNE1	-0.57	-4.99	-0.41	2e-6	Tonometry;
TGCT	cis	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg20362242	chr5:692897	TPPP	0.48	4.51	0.38	1.47e-5	Lung disease severity in cystic fibrosis;
TGCT	cis	rs4822044	0.561	rs132781	chr22:42046122	T/G	cg06481639	chr22:41940642	POLR3H	0.73	6.26	0.49	5.81e-9	Cannabis dependence symptom count;
TGCT	cis	rs2832191	0.791	rs2832182	chr21:30481612	G/A	cg24692254	chr21:30365293	RNF160	-0.95	-10.52	-0.69	7.06e-19	Dental caries;
TGCT	cis	rs1153858	1.000	rs1346266	chr15:45694516	G/T	cg26924012	chr15:45694286	SPATA5L1	0.99	12.23	0.74	4.74e-23	Homoarginine levels;
TGCT	cis	rs12682352	0.535	rs12677550	chr8:8644322	A/G	cg06636001	chr8:8085503	FLJ10661	-0.6	-5.11	-0.42	1.2e-6	Neuroticism;
TGCT	cis	rs716804	0.740	rs7115944	chr11:10279712	T/C	cg17061862	chr11:9590431	NA	-0.35	-4.52	-0.38	1.4e-5	Neuroticism;
TGCT	cis	rs7647973	0.667	rs6446286	chr3:49681704	A/G	cg03060546	chr3:49711283	APEH	0.63	5.63	0.45	1.12e-7	Menarche (age at onset);
TGCT	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg12963246	chr6:28129442	ZNF389	0.52	5.1	0.42	1.23e-6	Depression;
TGCT	cis	rs921968	0.643	rs485765	chr2:219480804	C/G	cg02176678	chr2:219576539	TTLL4	0.41	6.14	0.48	1.04e-8	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs7614311	0.509	rs73119034	chr3:63993025	G/A	cg22134162	chr3:63841271	THOC7	-0.48	-5.14	-0.42	1.05e-6	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.68	5.73	0.46	7.3e-8	Tonsillectomy;
TGCT	cis	rs9467711	0.606	rs9393713	chr6:26373678	C/T	cg10795676	chr6:26370623	BTN3A2	-0.48	-4.91	-0.4	2.83e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg11644478	chr21:40555479	PSMG1	1.0	9.88	0.66	2.54e-17	Cognitive function;
TGCT	cis	rs12142240	1.000	rs12142240	chr1:46747301	T/C	cg00530320	chr1:46809349	NSUN4	0.25	4.81	0.4	4.3e-6	Menopause (age at onset);
TGCT	cis	rs7666738	1.000	rs2865983	chr4:99033352	C/T	cg17366294	chr4:99064904	C4orf37	0.7	6.56	0.51	1.29e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10779751	1.000	rs4845987	chr1:11306279	G/C	cg08854313	chr1:11322531	MTOR	0.94	10.5	0.69	7.65e-19	Body mass index;
TGCT	cis	rs9527	0.590	rs3740386	chr10:104931051	C/T	cg15744005	chr10:104629667	AS3MT	-0.4	-4.59	-0.38	1.08e-5	Arsenic metabolism;
TGCT	cis	rs79349575	0.756	rs3848460	chr17:47047114	A/G	cg07967210	chr17:47022446	SNF8	-0.44	-5.94	-0.47	2.68e-8	Type 2 diabetes;
TGCT	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg12564285	chr5:131593104	PDLIM4	0.4	4.75	0.39	5.41e-6	Acylcarnitine levels;
TGCT	cis	rs6860806	0.507	rs273901	chr5:131694360	G/T	cg24060327	chr5:131705240	SLC22A5	-0.77	-8.46	-0.6	6.27e-14	Breast cancer;
TGCT	cis	rs3008870	0.755	rs1024229	chr1:67512903	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.79	7.31	0.55	2.83e-11	Lymphocyte percentage of white cells;
TGCT	cis	rs968451	1.000	rs5750784	chr22:39664180	C/A	cg17798944	chr22:39715225	SNORD43;RPL3	0.78	6.76	0.52	4.85e-10	Primary biliary cholangitis;
TGCT	trans	rs12339966	0.550	rs73644521	chr9:11283648	G/T	cg03488587	chr11:64876988	C11orf2	0.29	6.64	0.51	8.59e-10	Systolic blood pressure;
TGCT	cis	rs6964587	1.000	rs6950470	chr7:91680641	G/A	cg17063962	chr7:91808500	NA	0.88	9.63	0.65	9.8e-17	Breast cancer;
TGCT	cis	rs12477438	0.798	rs6712338	chr2:99585457	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-8.52	-0.61	4.5e-14	Chronic sinus infection;
TGCT	cis	rs67311347	1.000	rs28536038	chr3:40496382	A/C	cg13683864	chr3:40499215	RPL14	-1.2	-13.25	-0.77	1.68e-25	Renal cell carcinoma;
TGCT	cis	rs826838	0.967	rs7970069	chr12:38810631	T/C	cg13010199	chr12:38710504	ALG10B	0.82	6.85	0.52	3e-10	Heart rate;
TGCT	cis	rs9611565	0.512	rs5758436	chr22:42124265	C/T	cg13695892	chr22:41940480	POLR3H	0.88	8.63	0.61	2.45e-14	Vitiligo;
TGCT	cis	rs78487399	0.808	rs6732766	chr2:43712785	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-5.14	-0.42	1.04e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs10057188	0.967	rs13181597	chr5:77862388	C/G	cg06873401	chr5:77792105	LHFPL2	-0.22	-4.46	-0.37	1.79e-5	Pulse pressure;
TGCT	cis	rs2153535	0.580	rs2225766	chr6:8481833	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.61	0.45	1.24e-7	Motion sickness;
TGCT	cis	rs9467773	1.000	rs4871	chr6:26545632	G/A	cg05738196	chr6:26577821	NA	0.88	12.31	0.74	3.11e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs28595532	0.920	rs114611353	chr4:119736607	C/T	cg21605333	chr4:119757512	SEC24D	1.61	8.95	0.63	4.36e-15	Cannabis dependence symptom count;
TGCT	cis	rs9443645	0.901	rs2174743	chr6:79591805	G/A	cg09184832	chr6:79620586	NA	-0.51	-5.52	-0.44	1.9e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2769264	0.546	rs12047617	chr1:151392597	G/A	cg18801370	chr1:151430492	POGZ	0.64	6.17	0.48	8.77e-9	Blood trace element (Cu levels);
TGCT	cis	rs2439831	0.867	rs935901	chr15:43651256	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.1	7.37	0.55	2.1e-11	Lung cancer in ever smokers;
TGCT	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg03452623	chr4:187889614	NA	-0.36	-5.24	-0.43	6.6e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4654899	1.000	rs6659152	chr1:21355841	C/G	cg01072550	chr1:21505969	NA	-0.48	-7.68	-0.57	4.11e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs263156	0.874	rs263131	chr6:142943747	G/T	cg18419694	chr6:143832440	FUCA2	0.4	4.69	0.39	7.21e-6	Ear morphology;Lobe size;Lobe attachment;
TGCT	cis	rs748404	0.604	rs2278857	chr15:43632549	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.48	5.0	0.41	1.93e-6	Lung cancer;
TGCT	cis	rs9325144	0.560	rs10506125	chr12:39120287	C/T	cg26384229	chr12:38710491	ALG10B	0.67	6.47	0.5	2.05e-9	Morning vs. evening chronotype;
TGCT	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.61	0.38	9.85e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9549367	0.713	rs2480949	chr13:113853149	T/C	cg09473364	chr13:112927190	NA	0.29	4.64	0.38	8.73e-6	Platelet distribution width;
TGCT	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg06873352	chr17:61820015	STRADA	0.56	6.22	0.49	7.1e-9	Prudent dietary pattern;
TGCT	cis	rs782590	0.935	rs782568	chr2:55881538	T/C	cg18811423	chr2:55921094	PNPT1	0.64	6.61	0.51	1.04e-9	Metabolic syndrome;
TGCT	cis	rs6582630	0.519	rs8189461	chr12:38374870	G/T	cg13010199	chr12:38710504	ALG10B	0.58	4.55	0.38	1.26e-5	Drug-induced liver injury (flucloxacillin);
TGCT	trans	rs2688608	0.620	rs12253408	chr10:75495956	G/T	cg13918328	chr10:52500089	ASAH2B	0.68	6.7	0.52	6.48e-10	Inflammatory bowel disease;
TGCT	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg03709012	chr19:19516395	GATAD2A	0.74	6.04	0.48	1.65e-8	Tonsillectomy;
TGCT	cis	rs2235649	0.592	rs2429186	chr16:1969939	C/T	cg02432467	chr16:1963432	HS3ST6	-0.3	-4.5	-0.37	1.53e-5	Blood metabolite levels;
TGCT	cis	rs4372836	0.928	rs55836936	chr2:28922833	T/C	cg09522027	chr2:28974177	PPP1CB	0.55	4.48	0.37	1.66e-5	Body mass index;
TGCT	cis	rs6981523	0.553	rs2409730	chr8:11060638	C/A	cg21775007	chr8:11205619	TDH	-0.51	-4.64	-0.38	8.68e-6	Neuroticism;
TGCT	trans	rs8073060	0.586	rs3859284	chr17:34012792	C/T	cg19694781	chr19:47549865	TMEM160	-0.6	-13.37	-0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs2594989	0.733	rs9811482	chr3:11578591	C/T	cg00170343	chr3:11313890	ATG7	-0.62	-4.64	-0.38	8.66e-6	Circulating chemerin levels;
TGCT	cis	rs262147	0.610	rs2657363	chr7:158684273	C/T	cg11984989	chr7:158649758	WDR60	0.91	5.09	0.42	1.32e-6	Hippocampal volume;
TGCT	cis	rs992157	0.730	rs2382828	chr2:219184492	A/G	cg00012203	chr2:219082015	ARPC2	0.69	6.51	0.5	1.7e-9	Colorectal cancer;
TGCT	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg08736216	chr1:53307985	ZYG11A	0.25	4.84	0.4	3.82e-6	Monocyte count;
TGCT	cis	rs10276381	0.786	rs10255700	chr7:28220228	C/T	cg23620719	chr7:28220237	JAZF1	0.95	5.75	0.46	6.52e-8	Crohn's disease;
TGCT	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg13628971	chr7:2884303	GNA12	0.56	4.71	0.39	6.49e-6	Height;
TGCT	cis	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg08975724	chr8:8085496	FLJ10661	0.52	4.69	0.39	7.08e-6	Joint mobility (Beighton score);
TGCT	cis	rs62244186	0.659	rs9850129	chr3:44532047	C/T	cg21672276	chr3:44754072	ZNF502	-0.41	-4.68	-0.39	7.51e-6	Depressive symptoms;
TGCT	cis	rs9653442	0.712	rs6714788	chr2:100686173	A/G	cg07810366	chr2:100720526	AFF3	0.43	7.3	0.55	3.03e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs1023500	0.573	rs6002592	chr22:42476754	A/C	cg15557168	chr22:42548783	NA	0.22	5.58	0.45	1.47e-7	Schizophrenia;
TGCT	cis	rs317689	0.819	rs317685	chr12:69715457	A/G	cg20891283	chr12:69753455	YEATS4	-0.55	-4.58	-0.38	1.13e-5	Response to diuretic therapy;
TGCT	cis	rs644799	1.000	rs473148	chr11:95628606	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	7.67	0.57	4.37e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs35306767	0.761	rs11253540	chr10:1011958	C/T	cg18964960	chr10:1102726	WDR37	-0.67	-4.86	-0.4	3.5e-6	Eosinophil percentage of granulocytes;
TGCT	cis	rs7647973	0.626	rs11130217	chr3:49737323	A/G	cg03034192	chr3:50606346	HEMK1;C3orf18	0.36	4.75	0.39	5.61e-6	Menarche (age at onset);
TGCT	cis	rs7937682	0.632	rs11214028	chr11:111761149	T/C	cg09085632	chr11:111637200	PPP2R1B	0.84	7.26	0.55	3.75e-11	Primary sclerosing cholangitis;
TGCT	cis	rs8077889	0.917	rs72836547	chr17:41902799	G/T	cg26893861	chr17:41843967	DUSP3	1.08	12.97	0.76	7.86e-25	Triglycerides;
TGCT	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg15857475	chr8:145742913	RECQL4;LRRC14	0.8	8.47	0.61	6.05e-14	Age at first birth;
TGCT	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg13695892	chr22:41940480	POLR3H	-0.9	-9.01	-0.63	3.17e-15	Vitiligo;
TGCT	cis	rs7100689	0.542	rs10887869	chr10:82194689	A/G	cg01528321	chr10:82214614	TSPAN14	0.64	5.35	0.43	4.09e-7	Post bronchodilator FEV1;
TGCT	cis	rs7524258	0.900	rs12035586	chr1:7273020	C/T	cg07173049	chr1:7289937	CAMTA1	-0.27	-4.57	-0.38	1.16e-5	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs2153904	0.793	rs12132270	chr1:205660940	C/T	cg23034840	chr1:205782522	SLC41A1	-0.72	-4.64	-0.38	8.68e-6	Prostate-specific antigen levels;
TGCT	cis	rs526231	0.543	rs27698	chr5:102526175	C/T	cg23492399	chr5:102201601	PAM	0.52	4.49	0.37	1.59e-5	Primary biliary cholangitis;
TGCT	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg05872129	chr22:39784769	NA	-1.01	-11.09	-0.71	2.82e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs10791097	0.694	rs10791103	chr11:130757161	G/A	cg14779329	chr11:130786720	SNX19	0.29	5.02	0.41	1.74e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9807989	0.839	rs4988956	chr2:102968007	G/A	cg09003973	chr2:102972529	NA	0.64	5.7	0.46	8.28e-8	Asthma;
TGCT	cis	rs514406	0.505	rs835609	chr1:53170494	T/C	cg16325326	chr1:53192061	ZYG11B	0.86	11.87	0.73	3.45e-22	Monocyte count;
TGCT	cis	rs7267979	0.966	rs2257705	chr20:25264664	T/C	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1372520	0.627	rs2737025	chr4:90719192	A/G	cg26578617	chr4:90757533	SNCA	-0.52	-4.44	-0.37	1.99e-5	Neuroticism;
TGCT	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg24675658	chr1:53192096	ZYG11B	0.7	7.98	0.58	8.59e-13	Monocyte count;
TGCT	cis	rs3733585	0.699	rs2018643	chr4:9947121	C/T	cg00071950	chr4:10020882	SLC2A9	0.54	6.25	0.49	5.99e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs9811920	0.570	rs1021102	chr3:99603780	T/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.6	-6.82	-0.52	3.63e-10	Axial length;
TGCT	cis	rs9790314	0.905	rs4856739	chr3:160986710	A/C	cg03342759	chr3:160939853	NMD3	-0.42	-4.51	-0.38	1.5e-5	Morning vs. evening chronotype;
TGCT	cis	rs2282802	0.685	rs11750229	chr5:139559014	T/G	cg01081189	chr5:139537190	NA	-0.3	-5.37	-0.43	3.82e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg18402987	chr7:1209562	NA	0.78	6.64	0.51	8.96e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2440129	0.611	rs2292352	chr17:6902887	A/G	cg03404566	chr17:6899310	ALOX12	0.45	5.1	0.42	1.25e-6	Tonsillectomy;
TGCT	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg00684032	chr4:1343700	KIAA1530	0.22	4.9	0.4	2.93e-6	Obesity-related traits;
TGCT	cis	rs1129187	0.782	rs9462860	chr6:42947013	G/C	cg10862848	chr6:42927986	GNMT	-0.38	-4.67	-0.39	7.6e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs7666738	0.830	rs4699577	chr4:98846513	G/A	cg18180107	chr4:99064573	C4orf37	0.57	5.34	0.43	4.23e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg23708337	chr7:1209742	NA	0.31	4.47	0.37	1.77e-5	Longevity;Endometriosis;
TGCT	cis	rs17030434	1.000	rs12646124	chr4:154718084	G/T	cg14289246	chr4:154710475	SFRP2	-0.93	-7.08	-0.54	9.34e-11	Electrocardiographic conduction measures;
TGCT	cis	rs346785	0.965	rs164009	chr17:74283669	C/T	cg09812376	chr17:74270190	QRICH2	0.39	6.06	0.48	1.51e-8	White matter hyperintensities in ischemic stroke;
TGCT	cis	rs34172651	0.517	rs2303084	chr16:24834581	G/C	cg06028605	chr16:24865363	SLC5A11	0.41	4.47	0.37	1.76e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg09165964	chr15:75287851	SCAMP5	0.51	4.57	0.38	1.16e-5	Breast cancer;
TGCT	cis	rs11741688	0.557	rs2004503	chr5:178337122	C/T	cg08270223	chr5:178322770	ZFP2	-0.37	-5.54	-0.45	1.74e-7	Sleep duration;
TGCT	cis	rs6558530	0.863	rs4595147	chr8:1703569	G/T	cg09410841	chr8:1729607	CLN8	0.9	10.36	0.68	1.65e-18	Systolic blood pressure;
TGCT	cis	rs1062177	1.000	rs62394155	chr5:151248069	G/A	cg12924095	chr5:151150029	G3BP1	0.34	4.6	0.38	1.04e-5	Preschool internalizing problems;
TGCT	cis	rs12477438	0.798	rs6705821	chr2:99602832	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-8.52	-0.61	4.5e-14	Chronic sinus infection;
TGCT	cis	rs2766692	1.000	rs2766692	chr14:100684192	C/T	cg14866419	chr14:100704911	YY1	0.57	4.56	0.38	1.21e-5	Electroencephalographic traits in alcoholism;
TGCT	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg03806693	chr22:41940476	POLR3H	-1.12	-13.03	-0.76	5.66e-25	Vitiligo;
TGCT	cis	rs7909074	0.651	rs10900127	chr10:45390103	C/A	cg04218760	chr10:45406644	TMEM72	-0.25	-4.69	-0.39	7.03e-6	Mean corpuscular volume;
TGCT	cis	rs2637266	1.000	rs1907314	chr10:78337948	G/A	cg18941641	chr10:78392320	NA	0.4	4.89	0.4	3.07e-6	Pulmonary function;
TGCT	cis	rs2153535	0.580	rs1414340	chr6:8491139	G/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs1372520	0.873	rs2583990	chr4:90771499	A/G	cg14346243	chr4:90757452	SNCA	-0.63	-5.4	-0.44	3.23e-7	Neuroticism;
TGCT	cis	rs11673344	0.523	rs10420330	chr19:37602171	G/A	cg08039142	chr19:36980659	ZNF566	0.52	4.78	0.39	4.96e-6	Obesity-related traits;
TGCT	cis	rs651907	0.535	rs36060163	chr3:101360963	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.35	-7.31	-0.55	2.86e-11	Colorectal cancer;
TGCT	cis	rs7772486	0.875	rs2814872	chr6:146310234	T/C	cg05347473	chr6:146136440	FBXO30	0.54	5.0	0.41	1.91e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1670533	1.000	rs935971	chr4:1045265	G/A	cg27284194	chr4:1044797	NA	0.68	5.45	0.44	2.57e-7	Recombination rate (females);
TGCT	cis	rs7586879	0.639	rs2033654	chr2:25103108	C/A	cg15423357	chr2:25149977	NA	0.5	4.75	0.39	5.43e-6	Body mass index;
TGCT	cis	rs12188164	0.965	rs72717430	chr5:444502	T/C	cg26850624	chr5:429559	AHRR	-0.2	-4.84	-0.4	3.78e-6	Cystic fibrosis severity;
TGCT	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg11905131	chr22:24372483	LOC391322	-0.88	-9.98	-0.67	1.38e-17	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs17376456	0.825	rs10075217	chr5:93176774	C/G	cg21475434	chr5:93447410	FAM172A	0.73	4.92	0.4	2.66e-6	Diabetic retinopathy;
TGCT	cis	rs911555	0.723	rs4906324	chr14:103923099	A/G	cg23461800	chr14:103021989	NA	-0.35	-4.56	-0.38	1.23e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7909074	1.000	rs10736831	chr10:45402311	G/A	cg05187965	chr10:45406764	TMEM72	-0.24	-5.01	-0.41	1.82e-6	Mean corpuscular volume;
TGCT	trans	rs1814175	0.645	rs7123448	chr11:49764865	T/G	cg11707556	chr5:10655725	ANKRD33B	-0.45	-11.14	-0.71	2.17e-20	Height;
TGCT	cis	rs704	0.523	rs11080054	chr17:26645991	G/A	cg10494684	chr17:26645200	TMEM97	-0.46	-4.96	-0.41	2.32e-6	Osteoprotegerin levels;
TGCT	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg02891314	chr5:179741120	GFPT2	-0.41	-7.09	-0.54	8.78e-11	Height;
TGCT	cis	rs8050907	0.744	rs56235717	chr16:4524374	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.53	4.57	0.38	1.15e-5	Obesity-related traits;
TGCT	cis	rs7772486	0.875	rs2748485	chr6:146332421	T/C	cg05347473	chr6:146136440	FBXO30	0.52	4.98	0.41	2.12e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7613051	0.947	rs13093698	chr3:33063050	A/G	cg19000631	chr3:33138515	GLB1;TMPPE	0.64	4.64	0.38	8.56e-6	Atopic dermatitis;
TGCT	cis	rs853679	0.567	rs2232427	chr6:28359709	T/G	cg18815343	chr6:28367644	ZSCAN12	-0.52	-4.74	-0.39	5.68e-6	Depression;
TGCT	cis	rs7829975	0.577	rs17684466	chr8:8545233	G/A	cg08975724	chr8:8085496	FLJ10661	-0.51	-4.44	-0.37	1.96e-5	Mood instability;
TGCT	cis	rs11190604	1.000	rs4604805	chr10:102261409	C/G	cg23241863	chr10:102295624	HIF1AN	0.7	5.33	0.43	4.46e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9611565	0.729	rs505533	chr22:41864216	A/C	cg06634786	chr22:41940651	POLR3H	0.81	7.71	0.57	3.43e-12	Vitiligo;
TGCT	cis	rs9814567	0.865	rs9834981	chr3:134282279	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.98	-9.53	-0.65	1.7e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs11264213	0.901	rs10796876	chr1:36424985	A/G	cg07093915	chr1:36184400	C1orf216	0.66	4.61	0.38	9.71e-6	Schizophrenia;
TGCT	cis	rs9457247	1.000	rs385863	chr6:167386615	C/G	cg23791538	chr6:167370224	RNASET2	-0.5	-4.98	-0.41	2.08e-6	Crohn's disease;
TGCT	cis	rs11644362	1.000	rs35325771	chr16:12985138	A/C	cg06890432	chr16:12997467	SHISA9	-0.61	-6.72	-0.52	5.93e-10	Positive affect;Subjective well-being;
TGCT	cis	rs9443645	0.869	rs9343848	chr6:79621101	C/T	cg05283184	chr6:79620031	NA	-0.21	-4.71	-0.39	6.61e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7772486	0.686	rs9373473	chr6:146082282	A/G	cg23711669	chr6:146136114	FBXO30	0.8	8.56	0.61	3.71e-14	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg12311346	chr5:56204834	C5orf35	-0.57	-6.13	-0.48	1.07e-8	Initial pursuit acceleration;
TGCT	cis	rs2806561	0.765	rs605367	chr1:23518524	T/C	cg12483005	chr1:23474871	LUZP1	0.38	4.82	0.4	4.09e-6	Height;
TGCT	cis	rs10510102	0.872	rs12240306	chr10:123722906	C/T	cg23691251	chr10:123688108	ATE1	-0.59	-4.7	-0.39	6.75e-6	Breast cancer;
TGCT	cis	rs981844	0.666	rs7691303	chr4:154684198	T/C	cg14289246	chr4:154710475	SFRP2	-0.89	-8.19	-0.59	2.73e-13	Response to statins (LDL cholesterol change);
TGCT	cis	rs7937682	0.847	rs11213948	chr11:111464401	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.99	-10.02	-0.67	1.16e-17	Primary sclerosing cholangitis;
TGCT	cis	rs6746896	0.843	rs72809827	chr2:97390953	C/T	cg26085987	chr2:97230376	NA	0.19	4.72	0.39	6.2e-6	Bipolar disorder;
TGCT	cis	rs11190604	1.000	rs7085439	chr10:102210100	C/T	cg16342193	chr10:102329863	NA	-0.4	-5.31	-0.43	4.85e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs904251	0.523	rs1776454	chr6:37482099	C/T	cg08126542	chr6:37504118	NA	-0.44	-6.51	-0.5	1.71e-9	Cognitive performance;
TGCT	cis	rs72781680	0.898	rs72796154	chr2:23933839	G/A	cg08917208	chr2:24149416	ATAD2B	0.89	5.41	0.44	3.11e-7	Lymphocyte counts;
TGCT	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg18876405	chr7:65276391	NA	0.31	4.78	0.39	4.81e-6	Aortic root size;
TGCT	cis	rs9911578	0.803	rs8069033	chr17:57131581	T/A	cg05425664	chr17:57184151	TRIM37	0.66	6.66	0.51	7.78e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs3617	0.573	rs13072537	chr3:52896032	C/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.5	-4.89	-0.4	3e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1372520	0.684	rs2583963	chr4:90727088	C/T	cg20003494	chr4:90757398	SNCA	-0.66	-5.21	-0.42	7.59e-7	Neuroticism;
TGCT	cis	rs10507380	0.824	rs117209028	chr13:27921999	A/G	cg25543773	chr13:27185723	WASF3	0.34	4.83	0.4	3.97e-6	Electrocardiographic traits;
TGCT	cis	rs4242434	0.857	rs11777808	chr8:22462755	A/C	cg03733263	chr8:22462867	KIAA1967	1.14	20.09	0.87	8.14e-41	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs17490626	0.568	rs12416520	chr10:71211945	A/G	cg14388049	chr10:71211838	TSPAN15	-0.38	-4.48	-0.37	1.7e-5	Thrombosis;
TGCT	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.04	0.53	1.16e-10	Prudent dietary pattern;
TGCT	cis	rs611744	0.647	rs13280487	chr8:109270263	G/C	cg21045802	chr8:109455806	TTC35	0.7	7.13	0.54	7.42e-11	Dupuytren's disease;
TGCT	trans	rs4332037	0.906	rs6461009	chr7:1952139	T/C	cg25206134	chr2:45395956	NA	-1.13	-9.64	-0.65	9.5e-17	Bipolar disorder;
TGCT	cis	rs9309473	0.660	rs79370894	chr2:73683515	C/A	cg07208825	chr2:73871855	ALMS1P	0.25	4.53	0.38	1.34e-5	Metabolite levels;
TGCT	cis	rs933688	1.000	rs12654787	chr5:90713259	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.98	8.03	0.58	6.35e-13	Smoking behavior;
TGCT	cis	rs12701220	0.847	rs10272002	chr7:1047615	A/G	cg07217954	chr7:1067459	C7orf50	-0.49	-4.76	-0.39	5.27e-6	Bronchopulmonary dysplasia;
TGCT	cis	rs7833790	0.700	rs28390260	chr8:82769175	A/T	cg23324259	chr8:82754387	SNX16	0.62	4.71	0.39	6.47e-6	Diastolic blood pressure;
TGCT	cis	rs7617773	1.000	rs6771889	chr3:48194326	C/T	cg11946769	chr3:48343235	NME6	-0.6	-5.37	-0.43	3.69e-7	Coronary artery disease;
TGCT	cis	rs7226408	0.857	rs72888908	chr18:34517789	G/C	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs9467711	0.651	rs67554133	chr6:25866232	T/A	cg16898833	chr6:26189333	HIST1H4D	1.19	5.48	0.44	2.29e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7714584	1.000	rs57001853	chr5:150272452	A/G	cg22134413	chr5:150180641	NA	0.78	6.12	0.48	1.16e-8	Crohn's disease;
TGCT	cis	rs7834745	0.578	rs1032128	chr8:119951773	G/A	cg17171407	chr8:119960777	TNFRSF11B	0.27	4.45	0.37	1.91e-5	Eosinophil counts;Sum eosinophil basophil counts;
TGCT	cis	rs7666738	0.830	rs11941961	chr4:99065654	G/T	cg18180107	chr4:99064573	C4orf37	0.56	5.08	0.41	1.37e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg04944784	chr2:26401820	FAM59B	0.69	5.68	0.45	8.93e-8	Gut microbiome composition (summer);
TGCT	cis	rs78487399	0.710	rs7561114	chr2:43701951	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-5.45	-0.44	2.63e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs72843506	0.656	rs9913018	chr17:20064072	T/C	cg18979559	chr17:20280153	CCDC144C	-0.65	-4.87	-0.4	3.33e-6	Schizophrenia;
TGCT	cis	rs2296887	0.673	rs60154233	chr10:104075217	A/G	cg26089160	chr10:104170217	PSD	-0.56	-5.66	-0.45	9.94e-8	Parkinson's disease;
TGCT	cis	rs17345786	0.906	rs72946021	chr3:101250008	T/G	cg11279151	chr3:101281821	RG9MTD1	-0.42	-8.72	-0.62	1.48e-14	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12220238	0.908	rs10824077	chr10:75887038	C/T	cg19889307	chr10:75911429	ADK;AP3M1	-0.91	-7.77	-0.57	2.63e-12	Soluble interleukin-2 receptor subunit alpha;
TGCT	trans	rs72913475	0.579	rs112094677	chr18:44180253	T/C	cg11874627	chr6:46703554	PLA2G7	0.61	6.7	0.52	6.51e-10	Midgestational circulating levels of PBDEs (fetal genetic effect);
TGCT	cis	rs2153535	0.580	rs6421949	chr6:8531769	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.55e-8	Motion sickness;
TGCT	cis	rs1691799	0.899	rs1168315	chr12:66746694	A/G	cg16791601	chr12:66731901	HELB	-0.28	-6.17	-0.48	8.87e-9	White blood cell count (basophil);
TGCT	cis	rs5769765	0.773	rs9616378	chr22:50311973	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.44	6.12	0.48	1.13e-8	Schizophrenia;
TGCT	cis	rs9467711	0.675	rs58825580	chr6:26365679	T/G	cg16898833	chr6:26189333	HIST1H4D	1.0	5.22	0.42	7.46e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7267979	0.586	rs1007708	chr20:25190959	C/T	cg03522245	chr20:25566470	NINL	0.51	5.23	0.43	6.97e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs17539620	0.519	rs4077066	chr6:154838448	C/G	cg20019720	chr6:154832845	CNKSR3	0.63	5.69	0.45	8.68e-8	Lipoprotein (a) levels;
TGCT	cis	rs7829975	0.777	rs486781	chr8:8639740	A/G	cg06636001	chr8:8085503	FLJ10661	-0.68	-5.85	-0.46	4.19e-8	Mood instability;
TGCT	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg13012494	chr21:47604986	C21orf56	0.35	4.5	0.37	1.57e-5	Testicular germ cell tumor;
TGCT	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg13342137	chr4:2252803	MXD4	0.16	4.46	0.37	1.79e-5	Obesity-related traits;
TGCT	cis	rs6912958	0.712	rs7772561	chr6:88331299	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-4.55	-0.38	1.26e-5	Monocyte percentage of white cells;
TGCT	cis	rs826838	1.000	rs55828987	chr12:39056421	A/C	cg13010199	chr12:38710504	ALG10B	0.77	6.3	0.49	4.68e-9	Heart rate;
TGCT	cis	rs1903068	0.657	rs10026340	chr4:55998136	G/A	cg16572876	chr4:56024045	NA	0.44	4.71	0.39	6.48e-6	Endometriosis;
TGCT	cis	rs7666738	0.830	rs34916200	chr4:98851593	C/T	cg17366294	chr4:99064904	C4orf37	0.7	7.27	0.55	3.62e-11	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs66573146	1.000	rs28384174	chr4:6961107	G/T	cg07817883	chr1:32538562	TMEM39B	1.56	8.31	0.6	1.45e-13	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs7666738	0.830	rs28522896	chr4:99008243	C/T	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs78456975	0.506	rs10206900	chr2:1552841	T/C	cg12573674	chr2:1569213	NA	-0.48	-4.83	-0.4	3.96e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg25036284	chr2:26402008	FAM59B	-0.58	-4.61	-0.38	1.01e-5	Gut microbiome composition (summer);
TGCT	cis	rs2549003	1.000	rs2070726	chr5:131821738	C/A	cg21138405	chr5:131827807	IRF1	0.19	4.79	0.39	4.76e-6	Asthma (sex interaction);
TGCT	cis	rs910316	1.000	rs1047418	chr14:75605792	A/G	cg23033748	chr14:75592666	NEK9	0.29	4.9	0.4	2.95e-6	Height;
TGCT	cis	rs9916302	0.904	rs2024073	chr17:37471330	T/G	cg07936489	chr17:37558343	FBXL20	0.65	5.08	0.41	1.36e-6	Glomerular filtration rate (creatinine);
TGCT	trans	rs10802346	0.545	rs2362253	chr1:246371676	G/A	cg13514129	chr1:39547527	MACF1	0.86	7.71	0.57	3.54e-12	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs6570726	0.791	rs414297	chr6:145887556	C/T	cg05347473	chr6:146136440	FBXO30	0.5	4.63	0.38	9.22e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7224685	0.569	rs12950310	chr17:4001980	T/C	cg09580393	chr17:4869866	SPAG7	-0.38	-4.48	-0.37	1.64e-5	Type 2 diabetes;
TGCT	cis	rs11122272	0.735	rs2250704	chr1:231486647	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-6.88	-0.53	2.66e-10	Hemoglobin concentration;
TGCT	cis	rs6088580	0.602	rs6059840	chr20:33030405	G/A	cg08999081	chr20:33150536	PIGU	0.29	5.67	0.45	9.68e-8	Glomerular filtration rate (creatinine);
TGCT	cis	rs9400467	0.537	rs12202411	chr6:111488518	G/A	cg15721981	chr6:111408429	SLC16A10	0.69	4.5	0.37	1.56e-5	Blood metabolite levels;Amino acid levels;
TGCT	cis	rs4919694	0.611	rs75182663	chr10:105058104	A/G	cg04362960	chr10:104952993	NT5C2	0.91	6.05	0.48	1.59e-8	Arsenic metabolism;
TGCT	cis	rs4499344	0.730	rs259286	chr19:33164759	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.89	9.69	0.66	7.28e-17	Mean platelet volume;
TGCT	cis	rs12701220	0.894	rs12701406	chr7:1050283	G/A	cg07217954	chr7:1067459	C7orf50	-0.49	-4.76	-0.39	5.27e-6	Bronchopulmonary dysplasia;
TGCT	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg12311346	chr5:56204834	C5orf35	-0.67	-6.82	-0.52	3.63e-10	Initial pursuit acceleration;
TGCT	cis	rs208520	0.802	rs1342959	chr6:66883329	A/G	cg07460842	chr6:66804631	NA	-0.9	-9.33	-0.64	5.29e-16	Exhaled nitric oxide output;
TGCT	cis	rs62244186	0.659	rs6441844	chr3:44503579	C/T	cg04389838	chr3:44770851	ZNF501	-0.38	-4.94	-0.41	2.42e-6	Depressive symptoms;
TGCT	cis	rs4654899	0.629	rs7515279	chr1:21172774	C/T	cg01072550	chr1:21505969	NA	0.53	8.28	0.6	1.66e-13	Superior frontal gyrus grey matter volume;
TGCT	trans	rs66573146	0.831	rs56320732	chr4:6974319	G/A	cg07817883	chr1:32538562	TMEM39B	1.42	7.53	0.56	8.92e-12	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs12989701	0.877	rs34854727	chr2:127855392	C/T	cg08168897	chr2:127865431	BIN1	0.52	5.53	0.45	1.78e-7	Alzheimer's disease (late onset);
TGCT	cis	rs2811893	1.000	rs232781	chr1:59127637	T/G	cg26196860	chr1:59745563	NA	0.25	4.68	0.39	7.49e-6	Diabetic retinopathy;
TGCT	cis	rs10927875	0.662	rs848309	chr1:16308447	T/C	cg21385522	chr1:16154831	NA	0.47	5.07	0.41	1.4e-6	Dilated cardiomyopathy;
TGCT	cis	rs13096760	1	rs13096760	chr3:49476806	T/C	cg07636037	chr3:49044803	WDR6	0.63	6.07	0.48	1.47e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs6586163	0.872	rs1800682	chr10:90749963	A/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.38	-4.75	-0.39	5.61e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs9291683	0.609	rs13149985	chr4:10028390	G/A	cg11266682	chr4:10021025	SLC2A9	0.66	9.54	0.65	1.61e-16	Bone mineral density;
TGCT	cis	rs554111	0.660	rs667687	chr1:21072577	A/G	cg01072550	chr1:21505969	NA	-0.31	-4.62	-0.38	9.39e-6	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg04317338	chr11:64019027	PLCB3	0.72	5.52	0.44	1.85e-7	Mean platelet volume;
TGCT	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg04414720	chr1:150670196	GOLPH3L	0.37	4.92	0.4	2.65e-6	Tonsillectomy;
TGCT	cis	rs9611565	0.512	rs2050031	chr22:42152266	A/G	cg06481639	chr22:41940642	POLR3H	0.69	6.02	0.48	1.83e-8	Vitiligo;
TGCT	cis	rs6882046	0.513	rs34318	chr5:88027149	G/A	cg24804195	chr5:87968844	LOC645323	-0.61	-6.24	-0.49	6.2e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs12497850	0.897	rs6795025	chr3:49081247	T/C	cg06212747	chr3:49208901	KLHDC8B	0.61	5.51	0.44	2e-7	Parkinson's disease;
TGCT	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg12310025	chr6:25882481	NA	0.79	8.09	0.59	4.59e-13	Blood metabolite levels;
TGCT	cis	rs8028182	0.636	rs12708519	chr15:75803200	T/C	cg20655648	chr15:75932815	IMP3	0.6	4.65	0.38	8.54e-6	Sudden cardiac arrest;
TGCT	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg26119090	chr2:26468346	HADHA;HADHB	1.0	7.42	0.55	1.64e-11	Gut microbiome composition (summer);
TGCT	cis	rs838147	0.537	rs503279	chr19:49209010	C/T	cg05248581	chr19:49925731	PTH2	-0.42	-4.62	-0.38	9.55e-6	Dietary macronutrient intake;
TGCT	cis	rs9653442	0.866	rs12712065	chr2:100761105	C/G	cg22139774	chr2:100720529	AFF3	-0.45	-8.11	-0.59	4.08e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs13326165	0.715	rs34355561	chr3:52383120	G/A	cg07884673	chr3:53033167	SFMBT1	0.38	4.65	0.39	8.36e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs295140	0.546	rs295119	chr2:201117944	C/T	cg23649088	chr2:200775458	C2orf69	0.33	5.62	0.45	1.21e-7	QT interval;
TGCT	cis	rs7027203	0.828	rs3957506	chr9:96588133	C/T	cg14396892	chr9:96623032	NA	-0.29	-5.97	-0.47	2.29e-8	DNA methylation (variation);
TGCT	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg23708337	chr7:1209742	NA	0.59	5.37	0.43	3.71e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs6088580	0.634	rs11700221	chr20:32940320	T/C	cg06115741	chr20:33292138	TP53INP2	-0.55	-4.8	-0.4	4.5e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs881375	0.967	rs7864019	chr9:123692868	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	4.99	0.41	2.03e-6	Rheumatoid arthritis;
TGCT	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.48	-4.59	-0.38	1.06e-5	Bipolar disorder;
TGCT	cis	rs36051895	0.695	rs10974915	chr9:5016818	A/G	cg02405213	chr9:5042618	JAK2	-0.75	-9.96	-0.67	1.62e-17	Pediatric autoimmune diseases;
TGCT	cis	rs2274273	0.592	rs2878174	chr14:55470624	T/C	cg01923255	chr14:55878535	KIAA0831	0.58	5.14	0.42	1.06e-6	Protein biomarker;
TGCT	cis	rs797680	0.964	rs1932314	chr1:93638400	G/A	cg17826107	chr1:92977322	EVI5	-0.24	-5.31	-0.43	4.87e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs9653442	0.712	rs7582731	chr2:100686486	T/C	cg07810366	chr2:100720526	AFF3	-0.43	-7.27	-0.55	3.53e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs78487399	0.808	rs6544669	chr2:43736171	T/C	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.74	4.5	0.37	1.57e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs1045714	0.848	rs73033686	chr7:2635085	C/G	cg17215154	chr7:2644645	IQCE	0.29	5.12	0.42	1.12e-6	Urate levels in lean individuals;
TGCT	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg23574427	chr4:122746245	BBS7;CCNA2	-0.35	-5.3	-0.43	5.06e-7	Type 2 diabetes;
TGCT	cis	rs4319547	0.661	rs10773172	chr12:122939655	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.62	-5.02	-0.41	1.72e-6	Body mass index;
TGCT	cis	rs11971779	0.680	rs2355787	chr7:139089928	G/T	cg07862535	chr7:139043722	LUC7L2	-0.58	-4.69	-0.39	6.97e-6	Diisocyanate-induced asthma;
TGCT	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg00475322	chr7:917719	C7orf20	0.52	6.95	0.53	1.8e-10	Perceived unattractiveness to mosquitoes;
TGCT	cis	rs7949030	0.590	rs12225213	chr11:62350248	T/A	cg22862634	chr11:62369728	EML3;MTA2	0.7	8.83	0.62	8.36e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg12310025	chr6:25882481	NA	-0.63	-5.8	-0.46	5.23e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	4.67	0.39	7.7e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2204008	0.811	rs11520277	chr12:38359611	G/A	cg26384229	chr12:38710491	ALG10B	0.78	6.94	0.53	1.91e-10	Bladder cancer;
TGCT	cis	rs9653442	0.564	rs10175599	chr2:100787635	C/T	cg07810366	chr2:100720526	AFF3	-0.35	-5.18	-0.42	8.69e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs12893668	0.603	rs61637848	chr14:104096031	C/T	cg26031613	chr14:104095156	KLC1	-0.58	-4.86	-0.4	3.5e-6	Reticulocyte count;
TGCT	cis	rs9911578	0.967	rs11079354	chr17:56594460	G/A	cg12560992	chr17:57184187	TRIM37	-0.76	-9.34	-0.64	4.88e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs644799	1.000	rs680134	chr11:95559517	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	10.52	0.69	6.94e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs3091242	0.900	rs1811832	chr1:25753565	G/A	cg23205692	chr1:25664452	TMEM50A	0.51	5.32	0.43	4.69e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs2153535	0.541	rs9328471	chr6:8468842	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs877282	0.838	rs11253373	chr10:774857	A/G	cg17470449	chr10:769945	NA	0.3	4.73	0.39	6e-6	Uric acid levels;
TGCT	cis	rs6920965	0.527	rs7763515	chr6:126174714	C/G	cg05901451	chr6:126070800	HEY2	-0.58	-5.11	-0.42	1.16e-6	High light scatter reticulocyte count;
TGCT	cis	rs11098499	0.954	rs35091806	chr4:120325529	G/A	cg09307838	chr4:120376055	NA	0.68	6.53	0.51	1.54e-9	Corneal astigmatism;
TGCT	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg22683308	chr4:1340831	KIAA1530	-0.61	-5.7	-0.46	8.14e-8	Longevity;
TGCT	cis	rs6840360	0.901	rs1443094	chr4:152456724	C/T	cg17479576	chr4:152424074	FAM160A1	-0.57	-6.34	-0.49	3.96e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs9393777	0.547	rs2893910	chr6:27283254	A/T	cg11262757	chr6:27280423	POM121L2	0.62	4.56	0.38	1.19e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7172809	0.573	rs1446313	chr15:77475380	G/T	cg22256960	chr15:77711686	NA	-0.49	-4.63	-0.38	9.01e-6	Glucose homeostasis traits;
TGCT	cis	rs11711311	1.000	rs9854504	chr3:113532381	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.7	-6.72	-0.52	5.98e-10	IgG glycosylation;
TGCT	cis	rs7666738	0.830	rs4401456	chr4:98959902	C/T	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs698813	0.604	rs10865200	chr2:44482884	G/C	cg00619915	chr2:44497795	NA	-0.24	-5.63	-0.45	1.14e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
TGCT	cis	rs6121246	0.909	rs6060821	chr20:30294034	C/T	cg18721089	chr20:30220636	NA	-0.42	-4.65	-0.39	8.2e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs6933660	0.646	rs6915598	chr6:151778664	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.8	-6.59	-0.51	1.11e-9	Menarche (age at onset);
TGCT	cis	rs4478037	0.558	rs73826343	chr3:33067676	C/A	cg19404215	chr3:33155277	CRTAP	0.97	4.91	0.4	2.82e-6	Major depressive disorder;
TGCT	cis	rs7769051	1.000	rs7761365	chr6:133101561	T/A	cg22852734	chr6:133119734	C6orf192	1.22	7.01	0.53	1.38e-10	Type 2 diabetes nephropathy;
TGCT	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs3784262	0.669	rs12912093	chr15:58332583	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.43	-6.19	-0.49	8.07e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs1801251	1.000	rs1446311	chr2:233705071	G/A	cg08000102	chr2:233561755	GIGYF2	-0.63	-6.46	-0.5	2.2e-9	Coronary artery disease;
TGCT	cis	rs13064411	0.696	rs1486897	chr3:113215818	G/A	cg18753928	chr3:113234510	CCDC52	-0.69	-5.57	-0.45	1.47e-7	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs9303401	0.527	rs7224468	chr17:56749943	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.53	5.05	0.41	1.55e-6	Cognitive test performance;
TGCT	cis	rs34526934	0.608	rs13017511	chr2:177035395	A/G	cg14324370	chr2:177042789	NA	-0.89	-8.46	-0.61	6.16e-14	Obstructive sleep apnea trait (apnea hypopnea index);
TGCT	cis	rs7267979	0.966	rs454723	chr20:25438928	G/C	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg13206674	chr6:150067644	NUP43	0.52	4.51	0.38	1.5e-5	Lung cancer;
TGCT	cis	rs2361718	0.500	rs4889818	chr17:78085228	A/G	cg21238619	chr17:78079768	GAA	-0.35	-4.47	-0.37	1.73e-5	Yeast infection;
TGCT	cis	rs25422	0.938	rs114309775	chr6:118838782	G/A	cg07617317	chr6:118971624	C6orf204	0.52	5.55	0.45	1.69e-7	Renal cell carcinoma;
TGCT	cis	rs10751667	0.666	rs10902241	chr11:949129	G/A	cg06064525	chr11:970664	AP2A2	-0.35	-8.22	-0.59	2.29e-13	Alzheimer's disease (late onset);
TGCT	cis	rs2658782	1.000	rs2605583	chr11:93164957	T/A	cg15737290	chr11:93063684	CCDC67	0.78	5.51	0.44	1.94e-7	Pulmonary function decline;
TGCT	trans	rs7618501	0.521	rs868891	chr3:49949071	A/G	cg21659725	chr3:3221576	CRBN	0.68	7.55	0.56	8.1e-12	Intelligence (multi-trait analysis);
TGCT	trans	rs1814175	0.509	rs60698301	chr11:49877672	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.45	-11.09	-0.71	2.8e-20	Height;
TGCT	cis	rs2066819	1.000	rs2695789	chr12:56694261	C/A	cg26714650	chr12:56694279	CS	1.53	8.28	0.6	1.67e-13	Psoriasis vulgaris;
TGCT	trans	rs561341	0.556	rs542244	chr17:30307242	T/C	cg20587970	chr11:113659929	NA	-1.03	-12.39	-0.74	1.92e-23	Hip circumference adjusted for BMI;
TGCT	cis	rs10540	0.908	rs12792111	chr11:520921	G/C	cg03934478	chr11:495069	RNH1	0.32	4.82	0.4	4.08e-6	Body mass index;
TGCT	cis	rs3091242	0.902	rs36003018	chr1:25784318	A/G	cg00786635	chr1:25594202	NA	-0.52	-5.56	-0.45	1.59e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs11674184	0.743	rs12470971	chr2:11725241	A/G	cg07314298	chr2:11723111	GREB1	0.4	7.58	0.56	7.09e-12	Endometriosis;
TGCT	cis	rs4253772	0.591	rs9627324	chr22:46656511	A/G	cg09491104	chr22:46646882	C22orf40	-0.63	-6.39	-0.5	3.05e-9	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg18230493	chr5:56204884	C5orf35	-0.67	-5.75	-0.46	6.54e-8	Initial pursuit acceleration;
TGCT	cis	rs3820068	0.705	rs4646096	chr1:15820758	A/G	cg05660106	chr1:15850417	CASP9	1.16	14.82	0.8	3.11e-29	Systolic blood pressure;
TGCT	cis	rs10744422	0.858	rs7980541	chr12:123379477	C/T	cg25930673	chr12:123319894	HIP1R	-0.85	-5.03	-0.41	1.69e-6	Schizophrenia;
TGCT	cis	rs1532993	0.518	rs11097571	chr4:98623861	C/T	cg05340658	chr4:99064831	C4orf37	-0.41	-4.96	-0.41	2.3e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs10791097	0.694	rs11222369	chr11:130744670	A/G	cg05962950	chr11:130786565	SNX19	0.92	11.55	0.72	2.13e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9330316	0.632	rs919941	chr2:110357351	C/T	cg25199208	chr2:109402912	CCDC138	-0.41	-4.44	-0.37	1.99e-5	Schizophrenia;
TGCT	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg06238570	chr21:40685208	BRWD1	-0.65	-5.73	-0.46	7.14e-8	Cognitive function;
TGCT	cis	rs7017914	0.905	rs2732113	chr8:71928549	G/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.56	-5.11	-0.42	1.21e-6	Bone mineral density;
TGCT	cis	rs644799	1.000	rs627568	chr11:95569253	A/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.82	8.16	0.59	3.25e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs559928	0.606	rs56311067	chr11:63931607	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	4.56	0.38	1.22e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
TGCT	cis	rs9733	0.818	rs12130363	chr1:150688596	T/C	cg13175981	chr1:150552382	MCL1	0.43	4.78	0.39	4.88e-6	Tonsillectomy;
TGCT	cis	rs709400	0.832	rs10145755	chr14:104121984	C/T	cg26031613	chr14:104095156	KLC1	1.14	17.16	0.84	1.53e-34	Body mass index;
TGCT	cis	rs151997	0.538	rs1345777	chr5:50263788	A/G	cg06027927	chr5:50259733	NA	-0.57	-5.66	-0.45	9.98e-8	Callous-unemotional behaviour;
TGCT	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	5.03	0.41	1.69e-6	Prudent dietary pattern;
TGCT	cis	rs12477438	0.765	rs1453564	chr2:99564428	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-4.88	-0.4	3.17e-6	Chronic sinus infection;
TGCT	cis	rs4409675	0.576	rs6700473	chr1:28236682	C/T	cg23691781	chr1:28212827	C1orf38	0.26	5.32	0.43	4.67e-7	Corneal astigmatism;
TGCT	trans	rs2727020	0.702	rs609054	chr11:49219725	C/G	cg15704280	chr7:45808275	SEPT13	0.7	7.71	0.57	3.59e-12	Coronary artery disease;
TGCT	cis	rs6088580	0.634	rs6059897	chr20:33113224	A/G	cg06115741	chr20:33292138	TP53INP2	0.54	4.63	0.38	9.06e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs10791097	0.694	rs1893017	chr11:130756253	C/T	cg05962950	chr11:130786565	SNX19	0.9	11.06	0.7	3.32e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs6714710	0.603	rs2044458	chr2:98377512	A/T	cg26665480	chr2:98280029	ACTR1B	0.66	6.24	0.49	6.33e-9	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg26531700	chr6:26746687	NA	-0.57	-5.21	-0.42	7.62e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7072216	0.727	rs942809	chr10:100168001	G/A	cg26618903	chr10:100175079	PYROXD2	-0.41	-4.5	-0.38	1.51e-5	Metabolite levels;
TGCT	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg11764359	chr7:65958608	NA	0.59	5.28	0.43	5.64e-7	Aortic root size;
TGCT	cis	rs1868673	0.623	rs9844184	chr3:150132039	G/A	cg24290546	chr3:150134309	TSC22D2	-0.25	-4.67	-0.39	7.66e-6	Waist circumference;
TGCT	cis	rs10984561	0.881	rs10984559	chr9:122256836	G/A	cg14242995	chr9:122249943	NA	0.77	6.19	0.49	7.92e-9	Pulmonary function decline;
TGCT	cis	rs13102973	0.646	rs7670551	chr4:135895130	C/T	cg14419869	chr4:135874104	NA	0.26	4.6	0.38	1.03e-5	Subjective well-being;
TGCT	cis	rs11190604	0.767	rs10883479	chr10:102162860	A/G	cg23241863	chr10:102295624	HIF1AN	0.6	4.57	0.38	1.17e-5	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs908922	0.676	rs4845441	chr1:152485421	C/T	cg20991723	chr1:152506922	NA	0.47	6.64	0.51	8.74e-10	Hair morphology;
TGCT	cis	rs77633900	0.614	rs1443110	chr15:76928322	C/T	cg21673338	chr15:77095150	SCAPER	0.5	4.82	0.4	4.07e-6	Non-glioblastoma glioma;Glioma;
TGCT	cis	rs7917772	0.503	rs7093285	chr10:104374815	G/C	cg05855489	chr10:104503620	C10orf26	-0.6	-5.28	-0.43	5.49e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.49	-4.58	-0.38	1.09e-5	Prudent dietary pattern;
TGCT	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg10295955	chr4:187884368	NA	-0.98	-15.16	-0.81	5.3e-30	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs208520	0.661	rs1776361	chr6:66822270	G/A	cg07460842	chr6:66804631	NA	-0.93	-9.63	-0.65	1e-16	Exhaled nitric oxide output;
TGCT	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg22963979	chr7:1858916	MAD1L1	-0.45	-7.61	-0.56	5.9e-12	Schizophrenia;
TGCT	cis	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg22857025	chr5:266934	NA	-0.33	-6.57	-0.51	1.22e-9	Breast cancer;
TGCT	cis	rs2303745	0.544	rs6512180	chr19:17399153	C/T	cg02221750	chr19:17393354	ANKLE1	-0.46	-5.8	-0.46	5.09e-8	Systemic lupus erythematosus;
TGCT	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg00149659	chr3:10157352	C3orf10	0.73	4.72	0.39	6.17e-6	Alzheimer's disease;
TGCT	cis	rs11122272	0.735	rs2486746	chr1:231497324	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-6.68	-0.51	7.25e-10	Hemoglobin concentration;
TGCT	cis	rs4836694	0.574	rs4837476	chr9:132937533	T/C	cg05251000	chr9:132935664	FREQ	0.55	6.08	0.48	1.36e-8	Alzheimer's disease (cognitive decline);
TGCT	cis	rs854765	0.663	rs4925120	chr17:17754633	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.74	-7.26	-0.55	3.78e-11	Total body bone mineral density;
TGCT	cis	rs11711311	1.000	rs9811746	chr3:113515060	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.76	-7.16	-0.54	6.29e-11	IgG glycosylation;
TGCT	cis	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg25427524	chr10:38739819	LOC399744	-0.39	-8.04	-0.59	5.95e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs6500602	0.739	rs4786502	chr16:4537104	T/C	cg08645402	chr16:4508243	NA	0.18	4.88	0.4	3.23e-6	Schizophrenia;
TGCT	cis	rs67072384	0.786	rs58424437	chr11:72448256	C/T	cg03713592	chr11:72463424	ARAP1	-0.94	-4.8	-0.4	4.41e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs12210905	0.688	rs72839474	chr6:27324757	T/C	cg08851530	chr6:28072375	NA	1.25	5.39	0.44	3.38e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs9611519	0.780	rs2284079	chr22:41658632	C/T	cg06634786	chr22:41940651	POLR3H	-0.54	-4.92	-0.4	2.7e-6	Neuroticism;
TGCT	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg24250549	chr1:154909240	PMVK	-0.57	-5.55	-0.45	1.67e-7	Prostate cancer;
TGCT	cis	rs12142240	0.698	rs17361833	chr1:46828700	A/G	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg12658694	chr1:38397304	INPP5B	0.55	5.78	0.46	5.71e-8	Coronary artery disease;
TGCT	cis	rs1885364	0.574	rs134086	chr22:28067235	A/G	cg17187762	chr22:28070120	NA	-0.25	-4.57	-0.38	1.15e-5	Facial morphology (factor 8, orbital inclination due to vertical and horizontal position of exocanthion);
TGCT	cis	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg22857025	chr5:266934	NA	-0.34	-6.7	-0.52	6.65e-10	Breast cancer;
TGCT	cis	rs2692947	0.537	rs12468117	chr2:96194583	C/G	cg23100626	chr2:96804247	ASTL	0.45	5.34	0.43	4.21e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs736801	0.538	rs2548998	chr5:131832514	G/A	cg02551604	chr5:131831745	NA	0.77	8.55	0.61	3.85e-14	Breast cancer;Mosquito bite size;
TGCT	cis	rs2456568	0.548	rs10765647	chr11:93662459	T/C	cg26875233	chr11:93583750	C11orf90	-0.41	-4.94	-0.41	2.43e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs13040088	1.000	rs6090159	chr20:61531351	C/G	cg23096297	chr20:61557774	DIDO1	1.17	9.71	0.66	6.25e-17	Menopause (age at onset);
TGCT	cis	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg03213289	chr20:61660250	NA	0.68	9.99	0.67	1.36e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs12478296	0.681	rs56357900	chr2:243033966	A/C	cg06360820	chr2:242988706	NA	-0.61	-4.75	-0.39	5.52e-6	Obesity-related traits;
TGCT	cis	rs950027	0.620	rs1145080	chr15:45681338	C/T	cg14582100	chr15:45693742	SPATA5L1	0.47	6.02	0.48	1.8e-8	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs9814567	0.752	rs4955547	chr3:134334975	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.75	-6.75	-0.52	4.98e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg13397359	chr6:42928475	GNMT	0.71	7.16	0.54	6.35e-11	Alzheimer's disease in APOE e4+ carriers;
TGCT	trans	rs9650657	0.524	rs10088408	chr8:10817197	C/T	cg15556689	chr8:8085844	FLJ10661	-0.95	-10.16	-0.67	5.22e-18	Neuroticism;
TGCT	cis	rs9611565	0.592	rs1811113	chr22:42073134	C/T	cg06634786	chr22:41940651	POLR3H	0.9	8.74	0.62	1.34e-14	Vitiligo;
TGCT	cis	rs3784262	0.527	rs4646557	chr15:58354697	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.38	-5.57	-0.45	1.53e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg06873352	chr17:61820015	STRADA	0.55	6.1	0.48	1.26e-8	Prudent dietary pattern;
TGCT	cis	rs7647973	0.626	rs35129566	chr3:49866584	T/G	cg03060546	chr3:49711283	APEH	-0.62	-5.56	-0.45	1.59e-7	Menarche (age at onset);
TGCT	cis	rs12549902	0.800	rs7825337	chr8:41507237	C/T	cg21772509	chr8:41503840	NKX6-3	0.8	8.97	0.63	3.91e-15	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
TGCT	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg05368731	chr17:41323189	NBR1	0.9	8.95	0.63	4.4e-15	Menopause (age at onset);
TGCT	cis	rs7104764	1.000	rs7481993	chr11:237875	C/T	cg18336825	chr11:236787	PSMD13;SIRT3	1.07	11.15	0.71	2.05e-20	Menarche (age at onset);
TGCT	cis	rs3820928	0.845	rs2177596	chr2:227890283	A/T	cg11843606	chr2:227700838	RHBDD1	-0.55	-4.97	-0.41	2.19e-6	Pulmonary function;
TGCT	cis	rs9733	0.596	rs6692960	chr1:150695965	G/A	cg09365446	chr1:150670422	GOLPH3L	0.3	4.52	0.38	1.4e-5	Tonsillectomy;
TGCT	cis	rs7617773	0.780	rs7632297	chr3:48348163	A/C	cg11946769	chr3:48343235	NME6	0.82	7.09	0.54	9.1e-11	Coronary artery disease;
TGCT	cis	rs9911578	1.000	rs4793950	chr17:56593111	T/C	cg05425664	chr17:57184151	TRIM37	0.63	6.26	0.49	5.86e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs709400	0.628	rs2273700	chr14:103923414	A/G	cg12935359	chr14:103987150	CKB	-0.36	-5.47	-0.44	2.42e-7	Body mass index;
TGCT	cis	rs7677751	0.806	rs4864857	chr4:55089814	T/C	cg17187183	chr4:55093834	PDGFRA	0.55	6.99	0.53	1.48e-10	Corneal astigmatism;
TGCT	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg01802117	chr1:53393560	SCP2	0.47	5.77	0.46	5.88e-8	Monocyte count;
TGCT	cis	rs9393777	0.513	rs7759969	chr6:26663096	T/A	cg15659132	chr6:26577336	NA	-0.75	-5.25	-0.43	6.33e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs853679	0.546	rs200954	chr6:27838764	C/G	cg08798685	chr6:27730294	NA	-0.35	-5.18	-0.42	8.64e-7	Depression;
TGCT	cis	rs2242194	0.816	rs11264296	chr1:154994750	T/C	cg06221963	chr1:154839813	KCNN3	-0.49	-6.13	-0.48	1.08e-8	Schizophrenia;
TGCT	cis	rs3858526	0.959	rs61876223	chr11:5943393	G/A	cg13902645	chr11:5959945	NA	-0.46	-4.8	-0.4	4.44e-6	DNA methylation (variation);
TGCT	cis	rs7264396	0.676	rs6058383	chr20:34556005	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.04	-0.41	1.58e-6	Total cholesterol levels;
TGCT	cis	rs1371867	0.875	rs1371868	chr8:101330267	C/T	cg06636551	chr8:101224915	SPAG1	-0.48	-6.52	-0.51	1.62e-9	Atrioventricular conduction;
TGCT	cis	rs7147624	1.000	rs2411821	chr14:65896914	G/T	cg03016385	chr14:66212404	NA	-0.5	-7.18	-0.54	5.64e-11	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs12983728	0.831	rs79222418	chr19:58664418	T/C	cg07378217	chr19:58662286	ZNF329	-0.82	-4.65	-0.39	8.47e-6	Cholesterol, total;
TGCT	cis	rs4494114	1.000	rs9438984	chr1:39361615	G/A	cg25970120	chr1:39325951	RRAGC	-0.6	-6.19	-0.49	8.18e-9	Blood protein levels;
TGCT	cis	rs4886920	0.722	rs3935182	chr15:78094807	G/C	cg25212270	chr15:78015279	NA	-0.24	-4.83	-0.4	3.99e-6	Neuroticism;
TGCT	cis	rs854765	0.583	rs4925129	chr17:17807186	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	7.76	0.57	2.7e-12	Total body bone mineral density;
TGCT	cis	rs775227	0.574	rs13083453	chr3:113096943	G/A	cg18753928	chr3:113234510	CCDC52	-0.65	-4.77	-0.39	5.12e-6	Dental caries;
TGCT	cis	rs71435601	0.628	rs548506	chr2:21385541	A/G	cg25035485	chr2:21266500	APOB	0.51	4.48	0.37	1.64e-5	Cholesterol, total;
TGCT	cis	rs11148252	0.634	rs1571189	chr13:52731004	A/T	cg00495681	chr13:53174319	NA	0.5	4.51	0.38	1.45e-5	Lewy body disease;
TGCT	cis	rs637571	0.565	rs633800	chr11:65638719	G/A	cg26695010	chr11:65641043	EFEMP2	0.58	5.85	0.46	4.15e-8	Eosinophil percentage of white cells;
TGCT	cis	rs7267979	0.903	rs2500423	chr20:25374882	G/A	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs2727020	0.734	rs1164664	chr11:49295542	T/G	cg03929089	chr4:120376271	NA	0.67	6.89	0.53	2.44e-10	Coronary artery disease;
TGCT	cis	rs11098499	0.954	rs12506546	chr4:120301618	T/C	cg09307838	chr4:120376055	NA	0.62	5.88	0.47	3.64e-8	Corneal astigmatism;
TGCT	cis	rs4072705	0.562	rs7855918	chr9:127239939	T/C	cg13476313	chr9:127244764	NR5A1	0.3	4.81	0.4	4.29e-6	Menarche (age at onset);
TGCT	cis	rs992157	0.717	rs11692780	chr2:219149163	A/G	cg00012203	chr2:219082015	ARPC2	-0.8	-7.98	-0.58	8.26e-13	Colorectal cancer;
TGCT	cis	rs73058052	0.531	rs3745475	chr19:50100295	A/G	cg09250473	chr19:50168907	IRF3;BCL2L12	0.68	5.62	0.45	1.19e-7	Fibrinogen levels;
TGCT	cis	rs7178572	0.625	rs12905285	chr15:77845812	T/C	cg22256960	chr15:77711686	NA	-0.79	-9.06	-0.63	2.33e-15	Type 2 diabetes;
TGCT	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg07507251	chr3:52567010	NT5DC2	0.47	6.7	0.52	6.47e-10	Bipolar disorder;
TGCT	cis	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg08975724	chr8:8085496	FLJ10661	0.64	6.03	0.48	1.77e-8	Mood instability;
TGCT	cis	rs151997	0.925	rs27260	chr5:50166696	C/T	cg06027927	chr5:50259733	NA	0.47	4.77	0.39	5e-6	Callous-unemotional behaviour;
TGCT	cis	rs8014204	0.720	rs34752362	chr14:75232306	G/A	cg06637938	chr14:75390232	RPS6KL1	0.71	6.72	0.52	5.98e-10	Caffeine consumption;
TGCT	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.49	-6.5	-0.5	1.76e-9	Alzheimer's disease;
TGCT	cis	rs3091242	0.933	rs35530120	chr1:25785451	A/G	cg23205692	chr1:25664452	TMEM50A	-0.47	-5.0	-0.41	1.88e-6	Erythrocyte sedimentation rate;
TGCT	cis	rs172166	0.516	rs1225618	chr6:28129713	A/C	cg13525197	chr6:28411240	ZSCAN23	-0.48	-4.68	-0.39	7.36e-6	Cardiac Troponin-T levels;
TGCT	cis	rs7439150	0.779	rs80170133	chr4:155476251	C/T	cg22130008	chr4:155548532	NA	-0.43	-5.43	-0.44	2.87e-7	Fibrinogen levels;
TGCT	cis	rs6933660	0.745	rs6912830	chr6:151743629	A/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.49	4.64	0.38	8.89e-6	Menarche (age at onset);
TGCT	cis	rs7914558	1.000	rs10786740	chr10:104935593	G/C	cg05855489	chr10:104503620	C10orf26	0.5	4.47	0.37	1.71e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg25767906	chr1:53392781	SCP2	-0.59	-7.49	-0.56	1.12e-11	Monocyte count;
TGCT	cis	rs7666738	0.830	rs28456179	chr4:98991439	A/G	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs629535	0.814	rs652483	chr8:70055083	G/A	cg21567404	chr3:27674614	NA	0.57	8.67	0.61	2.01e-14	Dupuytren's disease;
TGCT	cis	rs6540559	1.000	rs1044516	chr1:209959614	G/T	cg04352962	chr1:209979756	IRF6	0.63	4.74	0.39	5.76e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg22857025	chr5:266934	NA	0.34	6.7	0.52	6.46e-10	Breast cancer;
TGCT	cis	rs10927875	0.578	rs10927859	chr1:16141862	C/T	cg21385522	chr1:16154831	NA	-0.98	-16.54	-0.83	3.72e-33	Dilated cardiomyopathy;
TGCT	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	4.84	0.4	3.8e-6	Menopause (age at onset);
TGCT	trans	rs11722228	0.508	rs3822246	chr4:10094698	G/A	cg26043149	chr18:55253948	FECH	1.16	11.23	0.71	1.26e-20	Gout;Urate levels;Serum uric acid levels;
TGCT	trans	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg27523141	chr10:43048294	ZNF37B	0.73	8.39	0.6	9.23e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs6570726	0.599	rs9403725	chr6:145897622	A/T	cg23711669	chr6:146136114	FBXO30	-0.74	-6.97	-0.53	1.62e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10811516	0.501	rs10757193	chr9:21157373	A/G	cg23029519	chr9:21187344	IFNA4	-0.29	-4.56	-0.38	1.22e-5	Response to mepolizumab in severe asthma;
TGCT	cis	rs910316	0.763	rs175016	chr14:75459633	C/T	cg11812906	chr14:75593930	NEK9	-0.59	-5.69	-0.45	8.84e-8	Height;
TGCT	cis	rs2797160	0.967	rs1578793	chr6:126015057	A/G	cg05901451	chr6:126070800	HEY2	0.73	6.29	0.49	5.01e-9	Endometrial cancer;
TGCT	cis	rs17376456	0.569	rs7721668	chr5:93290995	G/A	cg21475434	chr5:93447410	FAM172A	-0.62	-5.97	-0.47	2.3e-8	Diabetic retinopathy;
TGCT	cis	rs7552404	0.727	rs5745433	chr1:76333163	T/G	cg10523679	chr1:76189770	ACADM	0.68	6.27	0.49	5.37e-9	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg06112835	chr11:68658793	MRPL21	0.47	8.01	0.58	7.09e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs2980439	0.807	rs2980438	chr8:8094825	T/C	cg06636001	chr8:8085503	FLJ10661	0.83	8.25	0.6	1.99e-13	Neuroticism;
TGCT	cis	rs4730250	0.707	rs10253291	chr7:106786550	C/A	cg02696742	chr7:106810147	HBP1	0.72	5.93	0.47	2.86e-8	Osteoarthritis;
TGCT	cis	rs1949733	0.701	rs2688222	chr4:8473735	C/A	cg13073564	chr4:8508604	NA	-0.46	-4.84	-0.4	3.82e-6	Response to antineoplastic agents;
TGCT	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg26668828	chr6:292823	DUSP22	-0.76	-7.94	-0.58	1.05e-12	Menopause (age at onset);
TGCT	cis	rs9894429	1.000	rs11652797	chr17:79574124	A/G	cg21028142	chr17:79581711	NPLOC4	0.29	6.81	0.52	3.83e-10	Eye color traits;
TGCT	cis	rs7917772	0.503	rs7904955	chr10:104367092	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.78	7.97	0.58	9.02e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs11690462	0.963	rs12471849	chr2:26559825	C/G	cg04726446	chr2:26624865	C2orf39	-0.45	-4.87	-0.4	3.3e-6	Coronary artery disease;
TGCT	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg00684032	chr4:1343700	KIAA1530	0.23	4.93	0.41	2.55e-6	Obesity-related traits;
TGCT	cis	rs1670533	1.000	rs13119276	chr4:1051574	T/C	cg20887711	chr4:1340912	KIAA1530	0.72	5.73	0.46	7.16e-8	Recombination rate (females);
TGCT	cis	rs9291683	0.645	rs11557743	chr4:10118377	C/G	cg00071950	chr4:10020882	SLC2A9	-0.44	-4.77	-0.39	5.07e-6	Bone mineral density;
TGCT	cis	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg03213289	chr20:61660250	NA	0.68	9.99	0.67	1.36e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7267979	0.932	rs431579	chr20:25470056	T/C	cg03522245	chr20:25566470	NINL	0.6	6.46	0.5	2.14e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9811920	0.638	rs2452321	chr3:99638836	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.6	-7.02	-0.53	1.32e-10	Axial length;
TGCT	trans	rs3780486	0.846	rs7850878	chr9:33126570	A/G	cg04842962	chr6:43655489	MRPS18A	1.24	15.83	0.82	1.46e-31	IgG glycosylation;
TGCT	cis	rs7829975	0.606	rs891570	chr8:8794454	G/A	cg06636001	chr8:8085503	FLJ10661	-0.73	-6.47	-0.5	2.01e-9	Mood instability;
TGCT	cis	rs7772486	0.902	rs2144476	chr6:146322484	G/A	cg23711669	chr6:146136114	FBXO30	0.76	7.98	0.58	8.6e-13	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2338224	1.000	rs6452474	chr5:71742179	C/T	cg01187920	chr5:71015162	CARTPT	-0.53	-4.57	-0.38	1.15e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Granulocyte count;Myeloid white cell count;
TGCT	cis	rs4237845	0.844	rs7306124	chr12:58303349	A/T	cg02175503	chr12:58329896	NA	0.61	6.16	0.48	9.31e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg20637647	chr7:64974828	NA	0.99	5.38	0.44	3.53e-7	Diabetic kidney disease;
TGCT	cis	rs7017914	0.870	rs2639953	chr8:71925660	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.56	-5.11	-0.42	1.21e-6	Bone mineral density;
TGCT	cis	rs77972916	0.611	rs10495899	chr2:43602304	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.39	-6.04	-0.48	1.69e-8	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.93	7.44	0.56	1.44e-11	Platelet count;
TGCT	cis	rs2456568	0.802	rs11020586	chr11:93638547	G/A	cg16099599	chr11:93583650	C11orf90	-0.4	-5.12	-0.42	1.13e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs6545883	0.929	rs1900572	chr2:61650715	T/G	cg15711740	chr2:61764176	XPO1	0.52	4.62	0.38	9.55e-6	Tuberculosis;
TGCT	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg04234412	chr22:24373322	LOC391322	-0.92	-10.83	-0.7	1.2e-19	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs651907	0.557	rs1056579	chr3:101397877	T/G	cg11279151	chr3:101281821	RG9MTD1	-0.35	-7.28	-0.55	3.4e-11	Colorectal cancer;
TGCT	cis	rs986417	0.901	rs1061108	chr14:60978071	C/G	cg27398547	chr14:60952738	C14orf39	1.48	11.21	0.71	1.46e-20	Gut microbiota (bacterial taxa);
TGCT	cis	rs3749237	1.000	rs2307021	chr3:49765483	C/G	cg03060546	chr3:49711283	APEH	0.73	7.58	0.56	7.07e-12	Resting heart rate;
TGCT	cis	rs5750830	0.594	rs5757647	chr22:39775047	C/A	cg11247378	chr22:39784982	NA	-0.64	-8.48	-0.61	5.71e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs7635838	0.654	rs4684766	chr3:11285474	G/A	cg00170343	chr3:11313890	ATG7	0.68	6.58	0.51	1.19e-9	HDL cholesterol;
TGCT	cis	rs7611238	0.538	rs6800221	chr3:195157490	C/G	cg27323046	chr3:195102265	ACAP2	0.37	4.97	0.41	2.19e-6	Body mass index;
TGCT	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg12756686	chr19:29218302	NA	0.76	6.45	0.5	2.29e-9	Methadone dose in opioid dependence;
TGCT	cis	rs3125734	0.633	rs10761616	chr10:64009076	G/A	cg19640130	chr10:64028056	RTKN2	-0.39	-5.02	-0.41	1.78e-6	Rheumatoid arthritis;
TGCT	cis	rs4273100	0.605	rs28591622	chr17:19175317	A/G	cg01534423	chr17:18965556	NA	0.79	7.13	0.54	7.34e-11	Schizophrenia;
TGCT	cis	rs7119	0.667	rs2867312	chr15:77902293	A/G	cg27398640	chr15:77910606	LINGO1	-0.32	-6.82	-0.52	3.54e-10	Type 2 diabetes;
TGCT	cis	rs11779988	0.543	rs379066	chr8:17881835	T/C	cg08627089	chr8:17753878	FGL1	-0.29	-4.57	-0.38	1.18e-5	Breast cancer;
TGCT	cis	rs9811920	0.609	rs4928232	chr3:99694217	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.59	6.56	0.51	1.34e-9	Axial length;
TGCT	cis	rs57920188	0.585	rs6703103	chr1:4068320	C/T	cg20703997	chr1:4087676	NA	0.48	5.91	0.47	3.14e-8	Interleukin-17 levels;
TGCT	cis	rs17376456	0.877	rs10476526	chr5:93461916	G/A	cg25358565	chr5:93447407	FAM172A	0.92	8.38	0.6	9.58e-14	Diabetic retinopathy;
TGCT	cis	rs6424115	1.000	rs2256179	chr1:24132305	A/G	cg15997130	chr1:24165203	NA	-0.91	-10.39	-0.68	1.4e-18	Immature fraction of reticulocytes;
TGCT	cis	rs13188771	0.690	rs67093064	chr5:100893715	A/T	cg10455971	chr5:101119566	NA	0.44	4.45	0.37	1.87e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs7635838	0.892	rs9852530	chr3:11466469	C/T	cg00170343	chr3:11313890	ATG7	0.66	6.25	0.49	6.1e-9	HDL cholesterol;
TGCT	cis	rs7914558	0.966	rs3902934	chr10:104746649	A/G	cg04362960	chr10:104952993	NT5C2	0.62	5.51	0.44	2.03e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs514406	0.548	rs6670871	chr1:53212082	A/C	cg25767906	chr1:53392781	SCP2	0.46	5.11	0.42	1.17e-6	Monocyte count;
TGCT	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.08	0.48	1.37e-8	Bipolar disorder;
TGCT	cis	rs9581857	0.547	rs9579096	chr13:28084069	T/C	cg22138327	chr13:27999177	GTF3A	0.73	4.54	0.38	1.34e-5	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	trans	rs1814175	0.817	rs7932683	chr11:49983640	G/A	cg15704280	chr7:45808275	SEPT13	-0.73	-8.48	-0.61	5.58e-14	Height;
TGCT	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg27170947	chr2:26402098	FAM59B	-0.39	-4.46	-0.37	1.8e-5	Gut microbiome composition (summer);
TGCT	cis	rs1008375	1.000	rs2058337	chr4:17678649	C/T	cg10189774	chr4:17578691	LAP3	0.58	5.3	0.43	5.12e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4819052	0.851	rs2236443	chr21:46678174	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	6.45	0.5	2.32e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg13395646	chr4:1353034	KIAA1530	-0.35	-4.44	-0.37	1.95e-5	Obesity-related traits;
TGCT	cis	rs6545883	0.895	rs6545871	chr2:61692203	G/T	cg15711740	chr2:61764176	XPO1	-0.59	-5.43	-0.44	2.79e-7	Tuberculosis;
TGCT	cis	rs13102973	0.720	rs13129730	chr4:135888329	G/A	cg14419869	chr4:135874104	NA	0.26	4.6	0.38	1.03e-5	Subjective well-being;
TGCT	cis	rs346785	0.692	rs4789274	chr17:74286106	C/T	cg09812376	chr17:74270190	QRICH2	-0.37	-5.62	-0.45	1.2e-7	White matter hyperintensities in ischemic stroke;
TGCT	cis	rs6089584	0.566	rs7274240	chr20:60622004	C/T	cg06108461	chr20:60628389	TAF4	-0.49	-6.13	-0.48	1.1e-8	Body mass index;
TGCT	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg17554472	chr22:41940697	POLR3H	0.53	5.28	0.43	5.58e-7	Vitiligo;
TGCT	cis	rs1570884	0.516	rs2146144	chr13:50170245	C/T	cg03651054	chr13:50194643	NA	0.32	5.26	0.43	6.06e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
TGCT	cis	rs56235845	0.694	rs4976643	chr5:176760227	A/C	cg17509989	chr5:176798049	RGS14	0.55	7.58	0.56	6.89e-12	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs1729951	0.575	rs75976	chr3:136700455	G/A	cg21827317	chr3:136751795	NA	0.41	5.78	0.46	5.58e-8	Neuroticism;
TGCT	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg27588902	chr6:42928151	GNMT	-0.56	-6.87	-0.53	2.77e-10	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs9354352	0.784	rs2062327	chr6:66689923	C/G	cg07460842	chr6:66804631	NA	-0.54	-5.52	-0.44	1.93e-7	Initial pursuit acceleration in psychotic disorders;
TGCT	cis	rs1008375	1.000	rs3733579	chr4:17694943	A/G	cg18681998	chr4:17616180	MED28	0.75	7.12	0.54	7.64e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9902453	0.715	rs2628176	chr17:28139292	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-6.75	-0.52	5.16e-10	Coffee consumption (cups per day);
TGCT	cis	rs3617	0.572	rs2245538	chr3:52852060	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	4.59	0.38	1.08e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs5769765	0.526	rs5770722	chr22:50253220	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.97	6.35	0.5	3.69e-9	Schizophrenia;
TGCT	cis	rs28493229	0.522	rs2287692	chr19:41289756	G/A	cg11601297	chr19:41224147	ITPKC;ADCK4	0.58	5.1	0.42	1.25e-6	Kawasaki disease;
TGCT	cis	rs1048238	0.818	rs945421	chr1:16345393	T/C	cg22431228	chr1:16359049	CLCNKA	-0.3	-6.25	-0.49	6.09e-9	Systolic blood pressure;
TGCT	cis	rs6969780	1.000	rs73071550	chr7:27149099	T/C	cg04321618	chr7:27170880	HOXA4	0.62	5.21	0.42	7.48e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg06873352	chr17:61820015	STRADA	0.56	6.22	0.49	6.93e-9	Prudent dietary pattern;
TGCT	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg08736216	chr1:53307985	ZYG11A	0.25	4.93	0.4	2.59e-6	Monocyte count;
TGCT	cis	rs4631830	0.965	rs7070301	chr10:51543070	T/G	cg10326726	chr10:51549505	MSMB	-0.25	-4.89	-0.4	3e-6	Prostate-specific antigen levels;
TGCT	cis	rs4776059	0.761	rs61731670	chr15:52901283	T/C	cg25063058	chr15:52860530	ARPP19	-0.56	-4.44	-0.37	1.98e-5	Schizophrenia;
TGCT	cis	rs67311347	1.000	rs4128740	chr3:40519532	C/A	cg13409248	chr3:40428643	ENTPD3	0.56	4.45	0.37	1.91e-5	Renal cell carcinoma;
TGCT	cis	rs7647973	1.000	rs940045	chr3:49449638	G/A	cg07636037	chr3:49044803	WDR6	0.64	5.26	0.43	6.12e-7	Menarche (age at onset);
TGCT	cis	rs62244186	0.566	rs3762636	chr3:44854563	A/G	cg21672276	chr3:44754072	ZNF502	-0.53	-6.25	-0.49	5.98e-9	Depressive symptoms;
TGCT	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg06618935	chr21:46677482	NA	-0.37	-5.58	-0.45	1.41e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	trans	rs57221529	0.664	rs72704802	chr5:554211	C/T	cg25482853	chr8:67687455	SGK3	1.21	10.12	0.67	6.64e-18	Lung disease severity in cystic fibrosis;
TGCT	trans	rs561341	1.000	rs55962687	chr17:30260369	C/T	cg20587970	chr11:113659929	NA	-0.9	-7.84	-0.58	1.78e-12	Hip circumference adjusted for BMI;
TGCT	cis	rs28595532	0.920	rs114019902	chr4:119755564	G/A	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs6906287	0.647	rs973944	chr6:118850956	T/G	cg21191810	chr6:118973309	C6orf204	0.26	4.49	0.37	1.58e-5	Electrocardiographic conduction measures;
TGCT	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.73	6.64	0.51	8.93e-10	Prudent dietary pattern;
TGCT	trans	rs931812	0.691	rs884488	chr8:101898523	C/G	cg20993868	chr7:22813445	NA	0.34	7.01	0.53	1.37e-10	Attention deficit hyperactivity disorder and conduct disorder;
TGCT	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg26338869	chr17:61819248	STRADA	-0.53	-4.85	-0.4	3.68e-6	Prudent dietary pattern;
TGCT	cis	rs208520	0.954	rs12190073	chr6:66983740	T/C	cg07460842	chr6:66804631	NA	0.78	6.82	0.52	3.61e-10	Exhaled nitric oxide output;
TGCT	trans	rs17685	0.775	rs11761172	chr7:75761547	C/T	cg19862616	chr7:65841803	NCRNA00174	0.52	9.01	0.63	3.02e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs1801251	1.000	rs56777991	chr2:233635388	A/C	cg08000102	chr2:233561755	GIGYF2	0.64	6.45	0.5	2.22e-9	Coronary artery disease;
TGCT	trans	rs61931739	0.500	rs28692887	chr12:34457075	G/A	cg26384229	chr12:38710491	ALG10B	0.73	6.92	0.53	2.09e-10	Morning vs. evening chronotype;
TGCT	cis	rs1949733	0.701	rs940134	chr4:8454870	C/T	cg11789530	chr4:8429930	ACOX3	0.54	5.13	0.42	1.08e-6	Response to antineoplastic agents;
TGCT	cis	rs3806843	0.520	rs265312	chr5:140296272	T/G	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.43	-5.31	-0.43	4.89e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7267979	0.966	rs2151144	chr20:25414924	G/C	cg03522245	chr20:25566470	NINL	-0.63	-6.77	-0.52	4.62e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1775715	0.737	rs2808078	chr10:32172552	C/T	cg14930904	chr10:32216787	ARHGAP12	0.54	5.3	0.43	5.12e-7	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs1448094	0.556	rs11610627	chr12:86167752	C/T	cg02569458	chr12:86230093	RASSF9	0.38	4.49	0.37	1.61e-5	Major depressive disorder;
TGCT	cis	rs67311347	0.544	rs2278929	chr3:40351008	C/G	cg13683864	chr3:40499215	RPL14	0.82	7.63	0.57	5.42e-12	Renal cell carcinoma;
TGCT	cis	rs910316	0.967	rs175451	chr14:75589729	C/T	cg11812906	chr14:75593930	NEK9	-0.73	-7.13	-0.54	7.35e-11	Height;
TGCT	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.83	5.72	0.46	7.43e-8	Alzheimer's disease;
TGCT	cis	rs7666738	0.830	rs6843777	chr4:98866635	T/A	cg17366294	chr4:99064904	C4orf37	0.7	7.26	0.55	3.74e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12541335	0.639	rs4565458	chr8:22154133	T/C	cg02463440	chr8:22132932	PIWIL2	0.25	4.88	0.4	3.22e-6	Hypertriglyceridemia;
TGCT	cis	rs2067615	0.524	rs4964187	chr12:107080313	C/A	cg15890332	chr12:107067104	RFX4	0.29	5.77	0.46	5.9e-8	Heart rate;
TGCT	cis	rs6570726	0.846	rs371186	chr6:145886971	T/C	cg05347473	chr6:146136440	FBXO30	0.51	4.78	0.39	4.8e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7954584	0.710	rs10840641	chr12:122465831	G/T	cg13699009	chr12:122356056	WDR66	0.23	4.52	0.38	1.43e-5	Mean corpuscular volume;
TGCT	cis	rs13256369	0.851	rs11249889	chr8:8564992	G/T	cg06671706	chr8:8559999	CLDN23	0.34	4.53	0.38	1.38e-5	Obesity-related traits;
TGCT	cis	rs208520	0.526	rs9363522	chr6:66816642	C/T	cg07460842	chr6:66804631	NA	-1.07	-15.41	-0.81	1.34e-30	Exhaled nitric oxide output;
TGCT	cis	rs12681287	0.640	rs13258126	chr8:87453378	G/T	cg27223183	chr8:87520930	FAM82B	-0.89	-6.43	-0.5	2.54e-9	Caudate activity during reward;
TGCT	cis	rs6087990	0.806	rs4911108	chr20:31375311	A/G	cg13636640	chr20:31349939	DNMT3B	1.05	12.8	0.75	1.94e-24	Ulcerative colitis;
TGCT	cis	rs28595532	0.720	rs72670233	chr4:119316237	C/G	cg21605333	chr4:119757512	SEC24D	0.78	4.48	0.37	1.68e-5	Cannabis dependence symptom count;
TGCT	cis	rs476633	0.691	rs28409265	chr15:41539404	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.57	-7.34	-0.55	2.47e-11	Glomerular filtration rate (creatinine);
TGCT	cis	rs7267979	0.565	rs3752273	chr20:25594783	A/T	cg03522245	chr20:25566470	NINL	-0.45	-4.66	-0.39	8.06e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11209002	0.592	rs6672126	chr1:67558063	C/G	cg02640540	chr1:67518911	SLC35D1	0.61	5.09	0.42	1.29e-6	Crohn's disease;
TGCT	cis	rs4925386	0.921	rs11204472	chr20:60920887	G/A	cg06026331	chr20:60912101	LAMA5	-0.29	-5.38	-0.43	3.61e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs7666738	0.830	rs2865977	chr4:99017916	C/T	cg17366294	chr4:99064904	C4orf37	0.68	7.06	0.54	1.06e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg22920501	chr2:26401640	FAM59B	-0.73	-6.28	-0.49	5.18e-9	Gut microbiome composition (summer);
TGCT	cis	rs7267979	0.844	rs2474780	chr20:25285835	G/A	cg16686733	chr20:25566563	NINL	0.52	4.93	0.4	2.61e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9916302	0.851	rs11078907	chr17:37662954	C/T	cg15445000	chr17:37608096	MED1	0.31	4.59	0.38	1.06e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg22166914	chr1:53195759	ZYG11B	-0.42	-7.46	-0.56	1.33e-11	Monocyte count;
TGCT	trans	rs1866967	0.811	rs4949268	chr1:30186956	C/T	cg02311534	chr13:41345535	MRPS31	0.61	6.79	0.52	4.22e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2120019	1.000	rs12910644	chr15:75358388	A/G	cg17294928	chr15:75287854	SCAMP5	-0.84	-6.3	-0.49	4.75e-9	Blood trace element (Zn levels);
TGCT	cis	rs12220898	0.703	rs2377977	chr10:50478947	C/T	cg06072769	chr10:50146962	WDFY4	0.35	4.5	0.37	1.56e-5	Inflammatory biomarkers;
TGCT	cis	rs259282	0.562	rs28505804	chr19:33110047	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.54	4.91	0.4	2.76e-6	Schizophrenia;
TGCT	cis	rs1865760	0.865	rs9467652	chr6:25959127	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.64	6.29	0.49	4.91e-9	Height;
TGCT	cis	rs1372520	0.684	rs2583963	chr4:90727088	C/T	cg14346243	chr4:90757452	SNCA	-0.68	-5.64	-0.45	1.12e-7	Neuroticism;
TGCT	cis	rs62244186	0.715	rs10212378	chr3:44667286	C/G	cg04389838	chr3:44770851	ZNF501	-0.39	-5.15	-0.42	1e-6	Depressive symptoms;
TGCT	cis	rs12950390	1.000	rs8068453	chr17:45852354	A/G	cg24803719	chr17:45855879	NA	0.54	4.96	0.41	2.24e-6	IgG glycosylation;
TGCT	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg24531977	chr5:56204891	C5orf35	-0.76	-7.34	-0.55	2.45e-11	Initial pursuit acceleration;
TGCT	cis	rs10493773	0.928	rs12741600	chr1:86191172	A/C	cg17807903	chr1:86174739	ZNHIT6	-0.42	-5.6	-0.45	1.29e-7	Urate levels in overweight individuals;
TGCT	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.9	-6.54	-0.51	1.47e-9	Gut microbiome composition (summer);
TGCT	cis	rs770189	0.628	rs244749	chr5:88140962	T/C	cg24804195	chr5:87968844	LOC645323	0.68	4.71	0.39	6.5e-6	Tonometry;
TGCT	cis	rs11098499	0.866	rs7677068	chr4:120291704	C/T	cg09307838	chr4:120376055	NA	0.58	5.75	0.46	6.63e-8	Corneal astigmatism;
TGCT	cis	rs6582630	0.519	rs80226845	chr12:38528231	C/A	cg13010199	chr12:38710504	ALG10B	0.62	4.95	0.41	2.37e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs6840360	0.642	rs11735957	chr4:152427506	G/A	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.82e-9	Intelligence (multi-trait analysis);
TGCT	trans	rs208520	1.000	rs72884025	chr6:66994185	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.83	7.47	0.56	1.27e-11	Exhaled nitric oxide output;
TGCT	cis	rs1953600	1.000	rs2573346	chr10:81918041	G/A	cg04850286	chr10:81895943	PLAC9	-0.39	-4.65	-0.39	8.44e-6	Sarcoidosis;
TGCT	cis	rs7267979	0.808	rs84816	chr20:25459919	G/A	cg16686733	chr20:25566563	NINL	0.56	5.57	0.45	1.48e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4253772	0.530	rs715518	chr22:46754177	C/G	cg24881330	chr22:46731750	TRMU	1.05	5.39	0.44	3.36e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs473651	1.000	rs473651	chr2:239335401	A/C	cg21699342	chr2:239360505	ASB1	0.18	5.01	0.41	1.8e-6	Multiple system atrophy;
TGCT	cis	rs651907	0.557	rs2303474	chr3:101371899	G/T	cg12386194	chr3:101231763	SENP7	0.51	4.8	0.4	4.45e-6	Colorectal cancer;
TGCT	cis	rs8103278	1.000	rs7258283	chr19:46335511	C/T	cg11657440	chr19:46296263	DMWD	-0.6	-5.75	-0.46	6.51e-8	Coronary artery disease;
TGCT	cis	rs295140	0.546	rs295137	chr2:201150040	C/T	cg23649088	chr2:200775458	C2orf69	0.27	4.5	0.37	1.53e-5	QT interval;
TGCT	cis	rs7621025	0.500	rs16844241	chr3:136635171	A/G	cg15507776	chr3:136538369	TMEM22	-0.68	-6.39	-0.5	3.11e-9	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
TGCT	cis	rs28595532	0.920	rs56252481	chr4:119754023	C/T	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.13	14.74	0.8	4.88e-29	Height;
TGCT	trans	rs66573146	1.000	rs6838250	chr4:6973184	C/G	cg07817883	chr1:32538562	TMEM39B	1.66	8.29	0.6	1.56e-13	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg19774624	chr17:42201019	HDAC5	-0.87	-10.74	-0.69	1.99e-19	Total body bone mineral density;
TGCT	trans	rs2624839	0.704	rs11919418	chr3:50233215	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.84	8.12	0.59	3.98e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs6430585	0.583	rs9636213	chr2:136589278	G/A	cg07169764	chr2:136633963	MCM6	-1.05	-9.58	-0.65	1.28e-16	Corneal structure;
TGCT	cis	rs1857353	1.000	rs114865780	chr1:75871055	T/C	cg11838876	chr1:75668600	SLC44A5	-0.47	-4.56	-0.38	1.2e-5	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs8141529	0.719	rs5762880	chr22:29287816	T/G	cg02153584	chr22:29168773	CCDC117	0.63	4.87	0.4	3.3e-6	Lymphocyte counts;
TGCT	cis	rs2439831	1.000	rs101094	chr15:43787322	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.01	8.19	0.59	2.67e-13	Lung cancer in ever smokers;
TGCT	cis	rs7178572	0.568	rs12901739	chr15:77395491	C/T	cg22256960	chr15:77711686	NA	-0.86	-8.84	-0.62	8.05e-15	Type 2 diabetes;
TGCT	cis	rs12477438	0.559	rs6733285	chr2:99725575	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.75	7.25	0.55	3.92e-11	Chronic sinus infection;
TGCT	cis	rs6500602	0.627	rs860891	chr16:4586529	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	-0.39	-5.68	-0.45	9.26e-8	Schizophrenia;
TGCT	trans	rs1814175	0.935	rs11040463	chr11:49685574	C/T	cg03929089	chr4:120376271	NA	-0.63	-7.04	-0.53	1.14e-10	Height;
TGCT	cis	rs6815814	0.851	rs73235002	chr4:38769018	A/G	cg02016764	chr4:38805732	TLR1	-0.33	-5.25	-0.43	6.31e-7	Breast cancer;
TGCT	cis	rs1497406	0.773	rs7538833	chr1:16504381	T/C	cg20430773	chr1:16534157	ARHGEF19	0.51	5.65	0.45	1.04e-7	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7662987	0.540	rs2851278	chr4:100021253	G/C	cg12011299	chr4:100065546	ADH4	0.42	4.92	0.4	2.64e-6	Smoking initiation;
TGCT	cis	rs610932	0.517	rs676309	chr11:60001573	A/G	cg18570331	chr11:60101691	MS4A6E	0.51	4.6	0.38	1.04e-5	Alzheimer's disease;
TGCT	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg12963246	chr6:28129442	ZNF389	-0.48	-4.89	-0.4	3.01e-6	Parkinson's disease;
TGCT	cis	rs7714584	1.000	rs2004711	chr5:150225068	C/T	cg22134413	chr5:150180641	NA	0.89	6.96	0.53	1.73e-10	Crohn's disease;
TGCT	cis	rs6674176	0.628	rs7556565	chr1:44416090	C/T	cg13606994	chr1:44402422	ARTN	-0.46	-4.98	-0.41	2.12e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs74181299	0.571	rs12990465	chr2:65281401	C/T	cg05010058	chr2:65284262	CEP68	0.49	5.01	0.41	1.79e-6	Pulse pressure;
TGCT	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg17345569	chr6:42928274	GNMT	-0.47	-4.92	-0.4	2.65e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs4851266	1.000	rs11123817	chr2:100835032	C/T	cg07810366	chr2:100720526	AFF3	-0.39	-5.73	-0.46	7.19e-8	Educational attainment;
TGCT	cis	rs4478858	0.698	rs4949385	chr1:31793256	C/T	cg00250761	chr1:31883323	NA	-0.27	-4.84	-0.4	3.76e-6	Alcohol dependence;
TGCT	cis	rs2658782	0.789	rs56091149	chr11:93073640	A/C	cg18152523	chr11:93063302	CCDC67	0.71	5.2	0.42	8.11e-7	Pulmonary function decline;
TGCT	cis	rs11671005	0.735	rs34873624	chr19:58943402	G/A	cg13877915	chr19:58951672	ZNF132	0.63	5.0	0.41	1.95e-6	Mean platelet volume;
TGCT	cis	rs72634258	0.503	rs71637401	chr1:7837012	G/A	cg26816564	chr1:7831052	VAMP3	0.97	6.95	0.53	1.88e-10	Inflammatory bowel disease;
TGCT	cis	rs933688	0.938	rs7720235	chr5:90659329	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.13	10.03	0.67	1.06e-17	Smoking behavior;
TGCT	cis	rs1372520	0.766	rs2583961	chr4:90779758	A/G	cg01966878	chr4:90757139	SNCA	-0.3	-4.77	-0.39	5.1e-6	Neuroticism;
TGCT	cis	rs2832191	0.791	rs2832196	chr21:30497412	G/A	cg08807101	chr21:30365312	RNF160	-0.62	-5.8	-0.46	5.14e-8	Dental caries;
TGCT	cis	rs17001868	0.568	rs9607702	chr22:40739177	A/G	cg07138101	chr22:40742427	ADSL	0.73	5.38	0.44	3.57e-7	Mammographic density (dense area);
TGCT	cis	rs9467773	0.523	rs2498399	chr6:26706544	T/C	cg09904177	chr6:26538194	HMGN4	0.6	5.15	0.42	1.01e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7647973	1.000	rs13088309	chr3:49368317	A/G	cg07636037	chr3:49044803	WDR6	0.72	5.84	0.46	4.25e-8	Menarche (age at onset);
TGCT	cis	rs514406	0.698	rs1672913	chr1:53408326	A/T	cg01802117	chr1:53393560	SCP2	-0.44	-5.45	-0.44	2.6e-7	Monocyte count;
TGCT	cis	rs7246657	0.765	rs7247259	chr19:37851090	T/C	cg18154014	chr19:37997991	ZNF793	0.72	5.19	0.42	8.3e-7	Coronary artery calcification;
TGCT	cis	rs9972944	0.589	rs11870559	chr17:63772633	G/A	cg07283582	chr17:63770753	CCDC46	0.25	4.57	0.38	1.14e-5	Total body bone mineral density;
TGCT	cis	rs7647973	0.710	rs11130207	chr3:49611666	T/G	cg05785598	chr3:49045655	WDR6	0.41	4.66	0.39	8.03e-6	Menarche (age at onset);
TGCT	cis	rs7412746	0.634	rs3754212	chr1:150738200	A/G	cg09365446	chr1:150670422	GOLPH3L	0.36	5.19	0.42	8.25e-7	Melanoma;
TGCT	cis	rs7731657	0.537	rs13355768	chr5:130360245	C/T	cg08523029	chr5:130500466	HINT1	-0.61	-5.08	-0.42	1.34e-6	Fasting plasma glucose;
TGCT	cis	rs4888262	0.545	rs7193959	chr16:74664969	T/A	cg01733217	chr16:74700730	RFWD3	0.74	7.38	0.55	1.99e-11	Testicular germ cell tumor;
TGCT	cis	rs9527	0.615	rs7899622	chr10:104727333	C/T	cg15744005	chr10:104629667	AS3MT	-0.44	-5.19	-0.42	8.3e-7	Arsenic metabolism;
TGCT	cis	rs319204	0.885	rs575571	chr5:146287354	A/C	cg25021259	chr5:146258546	PPP2R2B	0.35	4.45	0.37	1.89e-5	Schizophrenia;
TGCT	cis	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg03213289	chr20:61660250	NA	0.68	9.59	0.65	1.23e-16	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs295140	1.000	rs11696001	chr2:201162433	G/A	cg04283868	chr2:201171347	SPATS2L	0.63	6.43	0.5	2.46e-9	QT interval;
TGCT	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg11764359	chr7:65958608	NA	0.56	4.7	0.39	6.69e-6	Aortic root size;
TGCT	cis	rs6912958	0.515	rs381782	chr6:88040649	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.7	7.17	0.54	5.95e-11	Monocyte percentage of white cells;
TGCT	cis	rs7927771	0.832	rs10838699	chr11:47386073	T/C	cg21462715	chr11:47870315	NUP160	-0.56	-4.52	-0.38	1.4e-5	Subjective well-being;
TGCT	cis	rs7014346	0.767	rs11778075	chr8:128421128	G/T	cg04263511	chr8:128962092	PVT1	-0.31	-4.55	-0.38	1.25e-5	Colorectal cancer;
TGCT	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs8042680	0.592	rs11073960	chr15:91483257	C/G	cg23684204	chr15:91497937	RCCD1	0.29	4.44	0.37	1.98e-5	Type 2 diabetes;
TGCT	cis	rs2078087	0.790	rs12035803	chr1:183466305	T/C	cg16263152	chr1:183287819	NMNAT2	0.41	4.83	0.4	3.99e-6	Obesity-related traits;
TGCT	cis	rs72781680	1.000	rs72798408	chr2:24181845	G/C	cg08917208	chr2:24149416	ATAD2B	0.84	5.13	0.42	1.1e-6	Lymphocyte counts;
TGCT	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.95	9.63	0.65	9.9900000000000006e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs13191362	0.935	rs13215748	chr6:163010710	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs9527	0.590	rs3781282	chr10:104852419	C/T	cg15744005	chr10:104629667	AS3MT	0.45	5.29	0.43	5.44e-7	Arsenic metabolism;
TGCT	cis	rs12145833	0.538	rs4658547	chr1:243391131	T/G	cg02356786	chr1:243265016	LOC731275	-0.59	-5.11	-0.42	1.18e-6	Obesity (early onset extreme);
TGCT	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg11764359	chr7:65958608	NA	-0.53	-4.7	-0.39	6.81e-6	Aortic root size;
TGCT	cis	rs13188771	0.690	rs67093064	chr5:100893715	A/T	cg18665594	chr5:101119420	NA	0.44	4.47	0.37	1.74e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs13242816	1.000	rs34234085	chr7:116114066	G/A	cg02799643	chr7:116139180	CAV2	-0.48	-5.52	-0.44	1.87e-7	P wave duration;
TGCT	cis	rs2072499	0.931	rs1052053	chr1:156202173	A/G	cg06970220	chr1:156163860	SLC25A44	0.65	5.95	0.47	2.51e-8	Testicular germ cell tumor;
TGCT	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.21	0.49	7.27e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs9467773	0.549	rs9461273	chr6:26584526	A/G	cg11502198	chr6:26597334	ABT1	-0.54	-4.96	-0.41	2.25e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6964587	0.708	rs38800	chr7:92046191	C/G	cg17063962	chr7:91808500	NA	-0.59	-4.99	-0.41	2.03e-6	Breast cancer;
TGCT	cis	rs9611565	0.649	rs5751144	chr22:42128097	A/G	cg06634786	chr22:41940651	POLR3H	-0.82	-7.9	-0.58	1.3e-12	Vitiligo;
TGCT	cis	rs13217239	0.646	rs4403259	chr6:26997617	C/T	cg02458000	chr6:26745757	NA	0.5	4.61	0.38	1e-5	Schizophrenia;
TGCT	cis	rs2455799	0.559	rs11128768	chr3:15923990	A/G	cg12172478	chr3:16357591	RFTN1	-0.36	-5.3	-0.43	5.07e-7	Mean platelet volume;
TGCT	cis	rs13191362	1.000	rs13214516	chr6:163121583	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.99	8.17	0.59	3.08e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	7.96	0.58	9.51e-13	Platelet count;
TGCT	cis	rs4664308	0.710	rs13001911	chr2:161020703	G/C	cg03641300	chr2:160917029	PLA2R1	-0.21	-4.84	-0.4	3.83e-6	Idiopathic membranous nephropathy;
TGCT	cis	rs6684514	1.000	rs7522948	chr1:156275308	C/T	cg20302342	chr1:156215951	PAQR6	0.33	4.54	0.38	1.34e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs1215050	0.682	rs6839343	chr4:98839732	G/A	cg05340658	chr4:99064831	C4orf37	0.47	4.9	0.4	2.94e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs3772130	0.962	rs9812137	chr3:121539103	T/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.72	0.39	6.25e-6	Cognitive performance;
TGCT	cis	rs10465746	0.780	rs12145258	chr1:84401211	G/A	cg10977910	chr1:84465055	TTLL7	0.69	7.07	0.54	9.97e-11	Obesity-related traits;
TGCT	cis	rs7666738	0.830	rs11731478	chr4:99001686	A/G	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg06873352	chr17:61820015	STRADA	0.58	6.39	0.5	3.01e-9	Prudent dietary pattern;
TGCT	cis	rs2239815	0.515	rs6005917	chr22:29233486	A/G	cg02153584	chr22:29168773	CCDC117	0.67	4.57	0.38	1.17e-5	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
TGCT	cis	rs933688	1.000	rs1541674	chr5:90660447	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	9.32	0.64	5.44e-16	Smoking behavior;
TGCT	cis	rs3617	0.591	rs11918800	chr3:52868145	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	-0.48	-4.53	-0.38	1.35e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12142240	0.698	rs72677596	chr1:46833930	C/T	cg14993813	chr1:46806288	NSUN4	-0.58	-4.87	-0.4	3.31e-6	Menopause (age at onset);
TGCT	cis	rs7193541	0.684	rs4888262	chr16:74670458	C/T	cg01733217	chr16:74700730	RFWD3	1.02	14.05	0.78	2.05e-27	Multiple myeloma;
TGCT	cis	rs832540	0.931	rs832529	chr5:56229288	C/T	cg24531977	chr5:56204891	C5orf35	-0.49	-5.03	-0.41	1.66e-6	Coronary artery disease;
TGCT	cis	rs617219	0.710	rs10474578	chr5:78542290	T/C	cg05890484	chr5:78407552	BHMT	0.34	4.63	0.38	9.24e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs12421382	0.659	rs56410856	chr11:109382455	T/G	cg16359550	chr11:109292809	C11orf87	0.4	4.5	0.37	1.54e-5	Schizophrenia;
TGCT	cis	rs6095298	0.595	rs34280360	chr20:47454171	G/A	cg12307787	chr20:48099359	KCNB1	0.42	4.51	0.38	1.51e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs981844	0.775	rs62323977	chr4:154746141	G/A	cg14289246	chr4:154710475	SFRP2	1.0	8.63	0.61	2.53e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs7617773	0.778	rs11715776	chr3:48377611	G/C	cg11946769	chr3:48343235	NME6	0.82	6.99	0.53	1.49e-10	Coronary artery disease;
TGCT	cis	rs4595586	0.545	rs11609541	chr12:39378331	T/C	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs2688608	1.000	rs2688608	chr10:75658349	G/T	cg04320760	chr10:75533139	FUT11	-0.3	-4.63	-0.38	9.21e-6	Inflammatory bowel disease;
TGCT	cis	rs7267979	0.816	rs422148	chr20:25512604	G/C	cg16686733	chr20:25566563	NINL	0.52	5.05	0.41	1.52e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg24399712	chr22:39784796	NA	-1.04	-12.23	-0.74	4.8e-23	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs9914544	0.545	rs1037037	chr17:18765021	A/G	cg26378065	chr17:18585709	ZNF286B	0.52	4.5	0.37	1.55e-5	Educational attainment (years of education);
TGCT	cis	rs9868809	0.772	rs9877501	chr3:48718390	C/G	cg00383909	chr3:49044727	WDR6	0.88	5.29	0.43	5.32e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs7769051	0.522	rs60631157	chr6:133094817	G/A	cg22852734	chr6:133119734	C6orf192	1.16	4.48	0.37	1.67e-5	Type 2 diabetes nephropathy;
TGCT	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg18876405	chr7:65276391	NA	0.31	4.8	0.4	4.53e-6	Aortic root size;
TGCT	cis	rs10883723	0.669	rs2001595	chr10:104395085	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.8	7.62	0.56	5.71e-12	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs986417	1.000	rs1956557	chr14:60972569	G/A	cg27398547	chr14:60952738	C14orf39	1.49	10.81	0.7	1.38e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs13191362	1.000	rs13213408	chr6:162998049	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs6598955	0.585	rs6659822	chr1:26626408	C/A	cg04990556	chr1:26633338	UBXN11	0.64	4.91	0.4	2.78e-6	Obesity-related traits;
TGCT	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg13395646	chr4:1353034	KIAA1530	-0.4	-4.66	-0.39	7.96e-6	Longevity;
TGCT	cis	rs1519814	0.696	rs7386139	chr8:121027419	C/T	cg22335954	chr8:121166405	COL14A1	-0.36	-4.56	-0.38	1.21e-5	Breast cancer;
TGCT	cis	rs1372520	1.000	rs1372520	chr4:90757505	T/C	cg20003494	chr4:90757398	SNCA	-0.67	-5.31	-0.43	4.84e-7	Neuroticism;
TGCT	cis	rs12478296	0.681	rs73007114	chr2:242984903	T/C	cg06360820	chr2:242988706	NA	-0.91	-5.53	-0.44	1.83e-7	Obesity-related traits;
TGCT	cis	rs1008375	1.000	rs11722037	chr4:17683811	G/A	cg10189774	chr4:17578691	LAP3	0.51	4.77	0.39	5.04e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4803468	1.000	rs10409485	chr19:41920765	C/T	cg09537434	chr19:41945824	ATP5SL	0.88	10.19	0.68	4.28e-18	Height;
TGCT	cis	rs61990749	0.597	rs759808	chr14:78250845	T/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.64	4.5	0.37	1.54e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs35883536	1.000	rs1577508	chr1:101089289	T/C	cg06223162	chr1:101003688	GPR88	0.29	4.56	0.38	1.22e-5	Monocyte count;
TGCT	trans	rs2727020	0.729	rs2204366	chr11:49349367	A/C	cg15704280	chr7:45808275	SEPT13	0.72	7.95	0.58	9.78e-13	Coronary artery disease;
TGCT	cis	rs72720396	0.803	rs115552537	chr1:91190856	C/A	cg13456504	chr1:91191583	NA	0.74	5.83	0.46	4.57e-8	Morning vs. evening chronotype;Chronotype;
TGCT	cis	rs501916	1.000	rs599111	chr15:48053334	G/T	cg16110827	chr15:48056943	SEMA6D	-0.17	-5.15	-0.42	9.79e-7	Inflammatory bowel disease;Ulcerative colitis;
TGCT	trans	rs2727020	0.576	rs12293522	chr11:49558425	T/A	cg03929089	chr4:120376271	NA	-0.77	-9.31	-0.64	5.96e-16	Coronary artery disease;
TGCT	cis	rs4455778	0.659	rs7796932	chr7:49057745	C/T	cg26309511	chr7:48887640	NA	0.44	5.12	0.42	1.13e-6	Lung cancer in never smokers;
TGCT	cis	rs1171582	0.526	rs1913507	chr10:61518989	C/T	cg23572703	chr10:62241191	NA	-0.26	-4.46	-0.37	1.84e-5	Alopecia areata;
TGCT	trans	rs208520	0.955	rs17644076	chr6:67004973	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.73	-6.63	-0.51	9.12e-10	Exhaled nitric oxide output;
TGCT	cis	rs651907	0.557	rs7612283	chr3:101434919	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.89	10.45	0.68	1.02e-18	Colorectal cancer;
TGCT	cis	rs7213347	0.610	rs8077194	chr17:2119475	A/G	cg13315690	chr17:1944831	OVCA2;DPH1	-0.39	-4.97	-0.41	2.16e-6	Total body bone mineral density;
TGCT	cis	rs308403	0.568	rs13138426	chr4:123652580	C/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.7	6.41	0.5	2.8e-9	Blood protein levels;
TGCT	cis	rs79996792	0.736	rs79299044	chr2:162494182	T/A	cg22496339	chr2:162101262	NA	0.54	4.54	0.38	1.3e-5	Neuroticism;
TGCT	cis	rs9611565	1.000	rs1109151	chr22:41752944	A/G	cg06634786	chr22:41940651	POLR3H	-0.78	-7.47	-0.56	1.23e-11	Vitiligo;
TGCT	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg10802521	chr3:52805072	NEK4	-0.65	-7.63	-0.57	5.37e-12	Hemoglobin concentration;
TGCT	cis	rs2594989	0.943	rs2454501	chr3:11500089	A/G	cg26283222	chr3:11613257	VGLL4	-0.21	-4.49	-0.37	1.58e-5	Circulating chemerin levels;
TGCT	cis	rs61867294	0.794	rs7901022	chr10:106656680	A/G	cg08000847	chr10:105880925	C10orf78	-0.57	-4.6	-0.38	1.04e-5	Schizophrenia;
TGCT	cis	rs7772486	0.686	rs702305	chr6:145973840	A/G	cg23711669	chr6:146136114	FBXO30	-0.83	-9.29	-0.64	6.68e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7829975	0.572	rs28730413	chr8:8795447	A/C	cg06636001	chr8:8085503	FLJ10661	-0.76	-7.17	-0.54	5.83e-11	Mood instability;
TGCT	cis	rs112591243	0.685	rs73379602	chr21:48027317	G/A	cg10657630	chr21:48055338	PRMT2	0.95	6.19	0.49	8.21e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs936229	0.668	rs67411922	chr15:75187612	A/G	cg10253484	chr15:75165896	SCAMP2	-0.77	-6.49	-0.5	1.85e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
TGCT	cis	rs595982	0.527	rs12151238	chr19:49368613	T/C	cg21252483	chr19:49399788	TULP2	-0.42	-6.39	-0.5	3.02e-9	Red cell distribution width;
TGCT	cis	rs826838	1.000	rs1684416	chr12:39130301	G/A	cg26384229	chr12:38710491	ALG10B	-0.86	-7.7	-0.57	3.65e-12	Heart rate;
TGCT	cis	rs4455778	0.508	rs38776	chr7:48938570	G/C	cg26309511	chr7:48887640	NA	0.54	6.06	0.48	1.54e-8	Lung cancer in never smokers;
TGCT	cis	rs6901250	0.819	rs9374623	chr6:117127312	C/A	cg12892004	chr6:117198278	RFX6	0.54	6.6	0.51	1.05e-9	C-reactive protein levels;
TGCT	cis	rs6933660	0.683	rs8180642	chr6:151756612	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.6	5.71	0.46	7.95e-8	Menarche (age at onset);
TGCT	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg23758822	chr17:41437982	NA	0.69	6.71	0.52	6.07e-10	Menopause (age at onset);
TGCT	cis	rs1205863	1.000	rs1205866	chr6:11943775	C/A	cg07106625	chr6:11870215	NA	0.51	5.05	0.41	1.51e-6	Disc degeneration (lumbar);
TGCT	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg11965913	chr1:205819406	PM20D1	0.47	6.39	0.5	3.09e-9	Menarche (age at onset);
TGCT	cis	rs6088580	0.634	rs6119497	chr20:33012529	T/A	cg06115741	chr20:33292138	TP53INP2	0.55	4.82	0.4	4.15e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7584330	0.554	rs6706729	chr2:238398580	T/C	cg14458575	chr2:238380390	NA	0.67	5.5	0.44	2.09e-7	Prostate cancer;
TGCT	cis	rs11955175	1.000	rs75929994	chr5:40821816	T/C	cg17351974	chr5:40835760	RPL37	0.87	5.92	0.47	2.98e-8	Bipolar disorder and schizophrenia;
TGCT	cis	rs2120019	0.938	rs1867150	chr15:75321139	T/C	cg11632617	chr15:75315747	PPCDC	-0.3	-4.44	-0.37	1.95e-5	Blood trace element (Zn levels);
TGCT	cis	rs62012628	0.527	rs12437868	chr15:79088460	T/C	cg04896959	chr15:78267971	NA	-0.33	-5.73	-0.46	7.28e-8	Diastolic blood pressure;
TGCT	cis	rs6430585	0.583	rs2839740	chr2:136648883	G/T	cg07169764	chr2:136633963	MCM6	1.22	11.92	0.73	2.63e-22	Corneal structure;
TGCT	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg12963246	chr6:28129442	ZNF389	0.48	4.79	0.4	4.58e-6	Parkinson's disease;
TGCT	cis	rs926938	0.765	rs12407408	chr1:115234275	A/G	cg12756093	chr1:115239321	AMPD1	0.42	6.23	0.49	6.61e-9	Autism;
TGCT	cis	rs9611565	0.592	rs80477	chr22:42001183	C/T	cg03806693	chr22:41940476	POLR3H	1.02	10.38	0.68	1.54e-18	Vitiligo;
TGCT	cis	rs9354352	0.967	rs6455062	chr6:66694131	T/A	cg07460842	chr6:66804631	NA	0.65	6.68	0.51	7.29e-10	Initial pursuit acceleration in psychotic disorders;
TGCT	cis	rs9902453	0.845	rs62068583	chr17:28001482	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	7.18	0.54	5.76e-11	Coffee consumption (cups per day);
TGCT	cis	rs9653442	0.900	rs2309837	chr2:100837567	T/C	cg07810366	chr2:100720526	AFF3	-0.4	-6.06	-0.48	1.49e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs477895	1.000	rs2286614	chr11:64068310	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.65	4.95	0.41	2.36e-6	Mean platelet volume;
TGCT	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg15691649	chr6:25882328	NA	0.49	5.98	0.47	2.17e-8	Blood metabolite levels;
TGCT	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg07424592	chr7:64974309	NA	0.65	6.41	0.5	2.8e-9	Calcium levels;
TGCT	cis	rs6076065	0.630	rs6083127	chr20:23424886	T/C	cg11657817	chr20:23433608	CST11	0.35	6.59	0.51	1.14e-9	Facial morphology (factor 15, philtrum width);
TGCT	cis	rs2692947	0.673	rs2917662	chr2:96794957	G/A	cg23100626	chr2:96804247	ASTL	0.47	5.61	0.45	1.28e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs78545713	1.000	rs3734534	chr6:26240649	A/G	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	0.61	4.61	0.38	9.8200000000000008e-06	Iron status biomarkers (total iron binding capacity);
TGCT	cis	rs10832169	0.933	rs1406356	chr11:14077511	A/T	cg04547675	chr11:13986162	SPON1	-0.5	-4.5	-0.37	1.57e-5	Blood protein levels;
TGCT	cis	rs2898681	0.511	rs881743	chr4:53727450	A/G	cg00791764	chr4:53727839	RASL11B	0.45	4.45	0.37	1.91e-5	Optic nerve measurement (cup area);
TGCT	cis	rs2862064	1.000	rs9313400	chr5:156433341	A/G	cg12943317	chr5:156479607	HAVCR1	-0.45	-5.77	-0.46	5.83e-8	Platelet count;
TGCT	cis	rs13082711	0.640	rs66941564	chr3:27259702	C/A	cg02860705	chr3:27208620	NA	0.46	7.22	0.54	4.63e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs2439831	0.850	rs2228368	chr15:44102010	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.69	4.53	0.38	1.38e-5	Lung cancer in ever smokers;
TGCT	trans	rs10435719	0.902	rs7459545	chr8:11804389	G/T	cg15556689	chr8:8085844	FLJ10661	0.76	7.28	0.55	3.36e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs10170846	0.861	rs6740452	chr2:223518452	C/T	cg25565276	chr2:223520875	FARSB	0.55	4.58	0.38	1.11e-5	Schizophrenia (inflammation and infection response interaction);
TGCT	trans	rs1499614	1.000	rs1882655	chr7:66147057	T/C	cg07424592	chr7:64974309	NA	-1.35	-8.11	-0.59	4.14e-13	Gout;
TGCT	cis	rs2204008	0.748	rs11514352	chr12:38246954	C/T	cg13010199	chr12:38710504	ALG10B	0.64	5.01	0.41	1.85e-6	Bladder cancer;
TGCT	cis	rs2204008	0.527	rs1315367	chr12:38177487	G/T	cg26384229	chr12:38710491	ALG10B	-0.58	-5.09	-0.42	1.28e-6	Bladder cancer;
TGCT	cis	rs912057	0.965	rs1294415	chr6:6740633	G/A	cg06612196	chr6:6737390	NA	0.38	4.81	0.4	4.25e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs4711336	0.967	rs4711338	chr6:33660188	T/C	cg14003231	chr6:33640908	ITPR3	0.28	4.52	0.38	1.41e-5	Height;
TGCT	cis	rs13191362	1.000	rs67094146	chr6:163145412	G/C	cg21926612	chr6:163149169	PACRG;PARK2	1.18	9.34	0.64	5.08e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg17971929	chr21:40555470	PSMG1	-0.54	-4.92	-0.4	2.71e-6	Menarche (age at onset);
TGCT	cis	rs2832191	0.655	rs2247110	chr21:30323888	G/A	cg24692254	chr21:30365293	RNF160	-0.95	-10.73	-0.69	2.09e-19	Dental caries;
TGCT	cis	rs9916302	0.808	rs12947281	chr17:37652210	G/T	cg15445000	chr17:37608096	MED1	0.31	4.59	0.38	1.06e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg10862848	chr6:42927986	GNMT	-0.4	-4.98	-0.41	2.11e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs11696501	0.591	rs6065854	chr20:44288816	T/C	cg11783356	chr20:44313418	WFDC10B	-0.32	-4.63	-0.38	9.25e-6	Brain structure;
TGCT	cis	rs58688157	0.960	rs702966	chr11:611919	C/G	cg16486109	chr11:613632	IRF7	0.35	5.18	0.42	8.82e-7	Systemic lupus erythematosus;
TGCT	cis	rs78456975	0.527	rs11886696	chr2:1567841	A/G	cg12573674	chr2:1569213	NA	-0.48	-5.1	-0.42	1.25e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs813218	0.523	rs1711554	chr3:99428998	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.42	5.12	0.42	1.13e-6	Orofacial clefts;
TGCT	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg17554472	chr22:41940697	POLR3H	-0.49	-5.27	-0.43	5.9e-7	Vitiligo;
TGCT	cis	rs9611565	0.765	rs132914	chr22:41805749	T/C	cg13695892	chr22:41940480	POLR3H	0.8	8.01	0.58	7.2e-13	Vitiligo;
TGCT	cis	rs36051895	0.664	rs3780370	chr9:5095167	A/C	cg02405213	chr9:5042618	JAK2	-0.72	-9.4	-0.65	3.59e-16	Pediatric autoimmune diseases;
TGCT	cis	rs4499344	0.633	rs259256	chr19:33151802	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.85	9.09	0.63	2.01e-15	Mean platelet volume;
TGCT	cis	rs7246657	0.722	rs1975937	chr19:38091932	A/T	cg18154014	chr19:37997991	ZNF793	0.69	4.67	0.39	7.71e-6	Coronary artery calcification;
TGCT	cis	rs7191439	0.584	rs8048897	chr16:88744470	T/G	cg27087555	chr16:88793112	FAM38A	-0.47	-4.72	-0.39	6.27e-6	Plateletcrit;
TGCT	cis	rs1150668	0.768	rs1233713	chr6:28198281	A/G	cg11262757	chr6:27280423	POM121L2	0.45	4.44	0.37	1.94e-5	Pubertal anthropometrics;
TGCT	cis	rs6570726	0.764	rs367065	chr6:145882309	T/G	cg23711669	chr6:146136114	FBXO30	0.89	9.93	0.67	1.82e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7584330	0.697	rs9287620	chr2:238368730	C/T	cg08992911	chr2:238395768	MLPH	0.61	4.7	0.39	6.79e-6	Prostate cancer;
TGCT	cis	rs9858542	1.000	rs9823546	chr3:49705512	T/A	cg03060546	chr3:49711283	APEH	-0.67	-6.09	-0.48	1.28e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg05985448	chr10:134359359	INPP5A	0.21	4.74	0.39	5.74e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs185694	1.000	rs202082	chr13:30881026	G/A	cg07600127	chr13:30881527	KATNAL1	-0.87	-6.77	-0.52	4.55e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
TGCT	cis	rs12765878	0.812	rs10786776	chr10:105662994	A/G	cg11005552	chr10:105648138	OBFC1	-0.44	-7.29	-0.55	3.12e-11	Coronary artery disease;
TGCT	cis	rs3784262	0.739	rs1530293	chr15:58210398	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.53	-7.68	-0.57	4.11e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs7681440	0.835	rs6839608	chr4:90805493	T/C	cg20003494	chr4:90757398	SNCA	-0.62	-5.94	-0.47	2.7e-8	Dementia with Lewy bodies;
TGCT	cis	rs7584330	0.868	rs13386290	chr2:238393136	G/C	cg14458575	chr2:238380390	NA	0.56	8.29	0.6	1.61e-13	Prostate cancer;
TGCT	cis	rs9362426	1.000	rs9450662	chr6:88088593	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.46	5.19	0.42	8.5e-7	Depressive episodes in bipolar disorder;
TGCT	cis	rs6500602	0.855	rs1139652	chr16:4476089	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.43	6.44	0.5	2.4e-9	Schizophrenia;
TGCT	cis	rs2153535	0.601	rs9406160	chr6:8464907	A/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.67	0.45	9.42e-8	Motion sickness;
TGCT	cis	rs72781680	1.000	rs72781632	chr2:24198342	A/C	cg08917208	chr2:24149416	ATAD2B	0.84	5.13	0.42	1.1e-6	Lymphocyte counts;
TGCT	cis	rs9527	0.518	rs11191487	chr10:104734623	A/G	cg15744005	chr10:104629667	AS3MT	-0.61	-4.76	-0.39	5.37e-6	Arsenic metabolism;
TGCT	cis	rs7246657	0.722	rs11083432	chr19:38182633	A/G	cg03611452	chr19:38183253	ZNF781	-0.6	-5.16	-0.42	9.49e-7	Coronary artery calcification;
TGCT	cis	rs9372253	1.000	rs9372253	chr6:110716136	C/T	cg01119278	chr6:110721349	DDO	-0.35	-5.68	-0.45	9e-8	Platelet distribution width;
TGCT	cis	rs7249142	0.562	rs2314035	chr19:19284920	T/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.33	-4.51	-0.38	1.48e-5	IgG glycosylation;
TGCT	cis	rs12682352	0.652	rs3827806	chr8:8724276	C/T	cg17143192	chr8:8559678	CLDN23	0.46	4.66	0.39	7.92e-6	Neuroticism;
TGCT	cis	rs7572733	0.534	rs1436131	chr2:198731230	A/C	cg00792783	chr2:198669748	PLCL1	0.56	5.08	0.42	1.32e-6	Dermatomyositis;
TGCT	cis	rs61931739	0.500	rs11053194	chr12:34440841	A/G	cg06521331	chr12:34319734	NA	-0.28	-4.51	-0.38	1.47e-5	Morning vs. evening chronotype;
TGCT	cis	rs7172809	0.599	rs74026918	chr15:77762851	G/C	cg22256960	chr15:77711686	NA	-0.51	-4.86	-0.4	3.47e-6	Glucose homeostasis traits;
TGCT	cis	rs4689388	0.926	rs3821940	chr4:6286711	C/A	cg14416269	chr4:6271139	WFS1	0.39	5.19	0.42	8.22e-7	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs4803468	1.000	rs4803469	chr19:41922775	A/C	cg09537434	chr19:41945824	ATP5SL	-0.92	-10.71	-0.69	2.31e-19	Height;
TGCT	cis	rs10114408	0.921	rs1890376	chr9:96661535	A/C	cg13679303	chr9:96623674	NA	-0.36	-4.63	-0.38	9.04e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg12310025	chr6:25882481	NA	0.54	4.65	0.39	8.23e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs67311347	0.605	rs1880762	chr3:40283215	A/G	cg13683864	chr3:40499215	RPL14	-0.85	-7.24	-0.55	4.08e-11	Renal cell carcinoma;
TGCT	cis	rs651907	0.935	rs2929922	chr3:101587934	A/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.46	4.79	0.4	4.6e-6	Colorectal cancer;
TGCT	cis	rs6840360	0.571	rs2406976	chr4:152541056	G/C	cg17479576	chr4:152424074	FAM160A1	-0.73	-7.94	-0.58	1.03e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs4730430	0.537	rs6960599	chr7:110157254	T/C	cg14239618	chr7:110281356	NA	0.26	5.45	0.44	2.63e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs3008870	0.785	rs10889651	chr1:67463513	A/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.83	-8.65	-0.61	2.21e-14	Lymphocyte percentage of white cells;
TGCT	cis	rs11673344	0.523	rs2082010	chr19:37530776	A/G	cg08039142	chr19:36980659	ZNF566	0.49	4.5	0.37	1.57e-5	Obesity-related traits;
TGCT	cis	rs7523050	0.643	rs17621922	chr1:109404454	C/T	cg08274380	chr1:109419600	GPSM2	1.3	6.55	0.51	1.4e-9	Fat distribution (HIV);
TGCT	cis	rs9467773	0.596	rs2494693	chr6:26619226	T/C	cg05738196	chr6:26577821	NA	0.87	11.3	0.71	8.47e-21	Intelligence (multi-trait analysis);
TGCT	cis	rs4730430	0.557	rs10953661	chr7:110135479	T/C	cg14239618	chr7:110281356	NA	0.24	4.65	0.39	8.25e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg22963979	chr7:1858916	MAD1L1	-0.4	-6.31	-0.49	4.57e-9	Bipolar disorder and schizophrenia;
TGCT	cis	rs9486719	1.000	rs2472884	chr6:96863965	C/T	cg18709589	chr6:96969512	KIAA0776	0.71	5.21	0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs899997	0.954	rs4887091	chr15:79043580	T/C	cg00061860	chr15:78953028	NA	-0.27	-4.67	-0.39	7.62e-6	Coronary artery disease or large artery stroke;
TGCT	cis	rs9400467	0.506	rs12214933	chr6:111558006	A/G	cg15721981	chr6:111408429	SLC16A10	0.72	4.66	0.39	8.09e-6	Blood metabolite levels;Amino acid levels;
TGCT	cis	rs12210905	0.688	rs12202956	chr6:27356476	T/C	cg08851530	chr6:28072375	NA	1.32	5.79	0.46	5.48e-8	Hip circumference adjusted for BMI;
TGCT	cis	rs3749237	1.000	rs11130214	chr3:49735746	C/G	cg07636037	chr3:49044803	WDR6	-0.63	-5.61	-0.45	1.24e-7	Resting heart rate;
TGCT	cis	rs11785400	0.701	rs9297967	chr8:143723002	A/C	cg24634471	chr8:143751801	JRK	0.53	5.24	0.43	6.7e-7	Schizophrenia;
TGCT	cis	rs17376456	0.569	rs6556839	chr5:93206292	T/C	cg25358565	chr5:93447407	FAM172A	-0.8	-6.09	-0.48	1.31e-8	Diabetic retinopathy;
TGCT	cis	rs2688608	0.592	rs11000758	chr10:75493610	A/T	cg04320760	chr10:75533139	FUT11	-0.4	-6.25	-0.49	6.11e-9	Inflammatory bowel disease;
TGCT	cis	rs7582180	0.629	rs4851298	chr2:100949827	G/A	cg08017756	chr2:100939284	LONRF2	-0.3	-4.87	-0.4	3.27e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6752107	1.000	rs6738490	chr2:234161583	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.2	4.86	0.4	3.46e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg24330042	chr22:24384159	GSTT1	-0.46	-4.56	-0.38	1.21e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg04414720	chr1:150670196	GOLPH3L	0.39	5.04	0.41	1.58e-6	Tonsillectomy;
TGCT	cis	rs17253792	0.822	rs11546	chr14:56146357	G/A	cg01858014	chr14:56050164	KTN1	-0.35	-4.62	-0.38	9.37e-6	Putamen volume;
TGCT	cis	rs7726839	0.540	rs11750321	chr5:599196	C/T	cg16624210	chr5:671434	TPPP	0.44	4.85	0.4	3.68e-6	Obesity-related traits;
TGCT	cis	rs4654899	0.802	rs2167811	chr1:21194510	A/G	cg01072550	chr1:21505969	NA	0.46	6.86	0.52	2.89e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg06481639	chr22:41940642	POLR3H	-0.76	-6.97	-0.53	1.65e-10	Vitiligo;
TGCT	cis	rs6714710	0.603	rs12988571	chr2:98405695	C/T	cg26665480	chr2:98280029	ACTR1B	0.66	6.31	0.49	4.56e-9	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs7091068	0.754	rs6583903	chr10:95422174	T/C	cg20715218	chr10:95462985	C10orf4	0.55	5.16	0.42	9.49e-7	Urinary tract infection frequency;
TGCT	cis	rs11785400	0.793	rs4336593	chr8:143739647	A/C	cg10596483	chr8:143751796	JRK	-0.56	-5.64	-0.45	1.11e-7	Schizophrenia;
TGCT	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg13665807	chr20:60559372	TAF4	-0.54	-5.47	-0.44	2.39e-7	Body mass index;
TGCT	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg07332563	chr6:291687	DUSP22	-0.66	-6.76	-0.52	4.88e-10	Menopause (age at onset);
TGCT	cis	rs11190604	1.000	rs4919466	chr10:102241213	T/C	cg23241863	chr10:102295624	HIF1AN	0.64	5.04	0.41	1.59e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	14.26	0.79	6.49e-28	Height;
TGCT	cis	rs13191362	0.935	rs34009353	chr6:163007668	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.68	5.79	0.46	5.33e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs9644630	0.804	rs11783263	chr8:19371674	C/G	cg06699216	chr8:19333253	CSGALNACT1	-0.27	-4.72	-0.39	6.21e-6	Oropharynx cancer;
TGCT	cis	rs7681440	0.904	rs7671549	chr4:90771147	T/A	cg14346243	chr4:90757452	SNCA	-0.57	-5.5	-0.44	2.04e-7	Dementia with Lewy bodies;
TGCT	cis	rs7614311	0.681	rs3774708	chr3:63881549	A/C	cg22134162	chr3:63841271	THOC7	-0.39	-5.15	-0.42	1e-6	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs4654899	0.758	rs9426652	chr1:21458151	G/A	cg01072550	chr1:21505969	NA	-0.58	-9.57	-0.65	1.41e-16	Superior frontal gyrus grey matter volume;
TGCT	cis	rs4319547	0.656	rs1553179	chr12:122831073	A/G	cg08088222	chr12:122070432	ORAI1	0.26	4.66	0.39	8.01e-6	Body mass index;
TGCT	cis	rs35306767	0.714	rs12762955	chr10:1078782	A/C	cg26597838	chr10:835615	NA	0.52	5.98	0.47	2.22e-8	Eosinophil percentage of granulocytes;
TGCT	cis	rs3782455	0.793	rs77365057	chr12:114404294	G/A	cg23502203	chr12:113549970	RASAL1	-0.55	-4.92	-0.4	2.7e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs854765	0.718	rs12943500	chr17:17790588	C/T	cg09796270	chr17:17721594	SREBF1	-0.27	-5.45	-0.44	2.66e-7	Total body bone mineral density;
TGCT	cis	rs1552244	0.832	rs115415687	chr3:10195704	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.55	-6.53	-0.51	1.5e-9	Alzheimer's disease;
TGCT	cis	rs6426558	0.537	rs498020	chr1:227304180	G/A	cg10327440	chr1:227177885	CDC42BPA	0.58	6.91	0.53	2.21e-10	Neutrophil percentage of white cells;
TGCT	cis	rs10875746	0.951	rs10875747	chr12:48525861	A/G	cg20731937	chr12:48336164	NA	0.61	4.82	0.4	4.14e-6	Longevity (90 years and older);
TGCT	trans	rs7615952	0.932	rs13325495	chr3:125637416	T/G	cg07211511	chr3:129823064	LOC729375	-0.46	-6.73	-0.52	5.49e-10	Blood pressure (smoking interaction);
TGCT	cis	rs7937612	1.000	rs7924963	chr11:120233536	G/A	cg24566217	chr11:120254723	ARHGEF12	-0.29	-4.62	-0.38	9.5e-6	Intraocular pressure;
TGCT	cis	rs4891159	0.790	rs17059325	chr18:74119567	A/C	cg24786174	chr18:74118243	ZNF516	-0.57	-7.72	-0.57	3.3e-12	Longevity;
TGCT	cis	rs4925386	0.681	rs2427295	chr20:60927431	G/A	cg24112000	chr20:60950667	NA	-0.37	-4.45	-0.37	1.9e-5	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs6964587	0.692	rs6953256	chr7:91575417	C/T	cg17063962	chr7:91808500	NA	-0.75	-7.1	-0.54	8.63e-11	Breast cancer;
TGCT	cis	rs16966142	1.000	rs16966142	chr16:89851033	C/T	cg04287289	chr16:89883240	FANCA	0.95	5.33	0.43	4.49e-7	Caffeine consumption;
TGCT	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg10295955	chr4:187884368	NA	-1.02	-15.6	-0.81	5.02e-31	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7267979	1.000	rs2258769	chr20:25276680	G/C	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9527	0.545	rs7915816	chr10:104881750	A/G	cg04362960	chr10:104952993	NT5C2	0.7	5.88	0.47	3.57e-8	Arsenic metabolism;
TGCT	cis	rs7666738	0.830	rs13148913	chr4:99009732	C/T	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg27535305	chr1:53392650	SCP2	-0.25	-5.06	-0.41	1.47e-6	Monocyte count;
TGCT	cis	rs4808199	0.948	rs757001	chr19:19448808	G/A	cg03709012	chr19:19516395	GATAD2A	0.81	6.32	0.49	4.32e-9	Nonalcoholic fatty liver disease;
TGCT	cis	rs7267979	0.714	rs6132825	chr20:25238309	A/T	cg14121845	chr20:25566513	NINL	0.46	4.57	0.38	1.17e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs60843830	1.000	rs62114548	chr2:274672	C/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.7	6.56	0.51	1.33e-9	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs16958440	0.867	rs80064497	chr18:44669653	A/G	cg17192377	chr18:44677553	HDHD2	0.63	4.7	0.39	6.74e-6	Sitting height ratio;
TGCT	cis	rs1018836	0.608	rs1033348	chr8:91464169	C/G	cg16814680	chr8:91681699	NA	-0.71	-7.27	-0.55	3.49e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9325144	0.555	rs4550281	chr12:38689937	A/G	cg26384229	chr12:38710491	ALG10B	0.66	6.13	0.48	1.09e-8	Morning vs. evening chronotype;
TGCT	cis	rs3793683	0.965	rs3829131	chr10:134564627	A/G	cg27286337	chr10:134555280	INPP5A	-0.46	-7.05	-0.53	1.1e-10	Migraine;
TGCT	trans	rs7819412	0.749	rs11991118	chr8:10939273	A/C	cg15556689	chr8:8085844	FLJ10661	0.69	6.63	0.51	9.08e-10	Triglycerides;
TGCT	cis	rs12615966	1.000	rs72830442	chr2:105375329	G/C	cg16465502	chr2:105461796	NA	0.81	4.47	0.37	1.76e-5	Pancreatic cancer;
TGCT	cis	rs2239815	0.576	rs10427628	chr22:29239766	T/C	cg02153584	chr22:29168773	CCDC117	0.6	4.53	0.38	1.38e-5	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
TGCT	cis	rs7666738	0.830	rs17484966	chr4:99014432	T/C	cg18180107	chr4:99064573	C4orf37	0.56	5.28	0.43	5.54e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg10802521	chr3:52805072	NEK4	-0.74	-9.02	-0.63	2.87e-15	Bipolar disorder;
TGCT	trans	rs7618501	1.000	rs7431106	chr3:49808374	G/A	cg21659725	chr3:3221576	CRBN	0.98	15.33	0.81	2.1000000000000002e-30	Intelligence (multi-trait analysis);
TGCT	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg13206674	chr6:150067644	NUP43	0.53	4.56	0.38	1.23e-5	Lung cancer;
TGCT	cis	rs72781680	0.898	rs79023848	chr2:24038174	C/A	cg08917208	chr2:24149416	ATAD2B	0.92	5.75	0.46	6.55e-8	Lymphocyte counts;
TGCT	cis	rs2153535	0.580	rs9392223	chr6:8468650	G/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.12	0.42	1.12e-6	Motion sickness;
TGCT	cis	rs1981331	0.609	rs59121565	chr21:48043023	A/G	cg23283320	chr21:48055893	PRMT2	1.35	6.43	0.5	2.51e-9	Cerebrospinal fluid t-tau:AB1-42 ratio;
TGCT	cis	rs7929679	0.875	rs2217480	chr11:34811928	G/A	cg18414381	chr11:34642885	EHF	-0.23	-4.51	-0.38	1.47e-5	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
TGCT	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg03609598	chr5:56110824	MAP3K1	-0.58	-4.7	-0.39	6.72e-6	Initial pursuit acceleration;
TGCT	cis	rs7681440	0.904	rs35424815	chr4:90767877	C/T	cg26578617	chr4:90757533	SNCA	-0.47	-4.87	-0.4	3.34e-6	Dementia with Lewy bodies;
TGCT	cis	rs7809950	1.000	rs2057837	chr7:107222725	C/G	cg23024343	chr7:107201750	COG5	0.33	5.07	0.41	1.42e-6	Coronary artery disease;
TGCT	cis	rs9372498	0.536	rs62422228	chr6:118957276	T/C	cg21191810	chr6:118973309	C6orf204	-0.38	-4.97	-0.41	2.14e-6	Diastolic blood pressure;
TGCT	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg03188948	chr7:1209495	NA	0.52	5.4	0.44	3.29e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs904251	0.600	rs2270687	chr6:37418263	A/G	cg25019722	chr6:37503610	NA	-0.48	-6.98	-0.53	1.57e-10	Cognitive performance;
TGCT	cis	rs57994353	0.865	rs13290734	chr9:139330701	G/A	cg13741927	chr9:139327495	INPP5E	-0.27	-6.41	-0.5	2.72e-9	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs2594989	0.721	rs9860504	chr3:11573615	G/T	cg26283222	chr3:11613257	VGLL4	0.2	4.45	0.37	1.89e-5	Circulating chemerin levels;
TGCT	cis	rs7726839	0.540	rs61731455	chr5:665295	A/G	cg20362242	chr5:692897	TPPP	0.51	4.66	0.39	8.11e-6	Obesity-related traits;
TGCT	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg01802117	chr1:53393560	SCP2	-0.39	-4.61	-0.38	1e-5	Monocyte count;
TGCT	cis	rs7666738	0.830	rs1426662	chr4:98990319	C/T	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7267979	0.816	rs6138593	chr20:25504492	A/G	cg03522245	chr20:25566470	NINL	0.56	5.79	0.46	5.51e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg23708337	chr7:1209742	NA	0.51	4.46	0.37	1.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	16.07	0.82	4.21e-32	Prudent dietary pattern;
TGCT	cis	rs933688	1.000	rs60513756	chr5:90727692	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	8.73	0.62	1.47e-14	Smoking behavior;
TGCT	cis	rs13217239	0.646	rs9393789	chr6:27067028	G/T	cg06035815	chr6:26189597	HIST1H4D	0.44	4.52	0.38	1.41e-5	Schizophrenia;
TGCT	cis	rs7267979	0.866	rs2424698	chr20:25256106	C/T	cg14121845	chr20:25566513	NINL	0.53	5.88	0.47	3.57e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg06108461	chr20:60628389	TAF4	-0.69	-10.64	-0.69	3.59e-19	Body mass index;
TGCT	cis	rs4074961	0.527	rs10908355	chr1:38035286	G/T	cg11397548	chr1:38022522	DNALI1	0.42	4.95	0.41	2.39e-6	Axial length;
TGCT	cis	rs7698623	0.850	rs4147244	chr4:88779168	C/T	cg02735620	chr4:88950514	PKD2	-0.44	-4.81	-0.4	4.22e-6	Cardiovascular disease risk factors;
TGCT	cis	rs514406	0.505	rs269287	chr1:53168842	T/C	cg16325326	chr1:53192061	ZYG11B	0.85	11.49	0.72	2.95e-21	Monocyte count;
TGCT	cis	rs7267979	1.000	rs6050599	chr20:25400240	T/C	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs938554	0.513	rs10939650	chr4:9998440	C/T	cg02734326	chr4:10020555	SLC2A9	0.48	4.85	0.4	3.6e-6	Blood metabolite levels;
TGCT	cis	rs9300255	0.639	rs1716171	chr12:123716376	C/T	cg00376283	chr12:123451042	ABCB9	0.67	5.26	0.43	6.13e-7	Neutrophil percentage of white cells;
TGCT	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg04025307	chr7:1156635	C7orf50	0.24	5.78	0.46	5.71e-8	Longevity;Endometriosis;
TGCT	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg12419862	chr22:24373484	LOC391322	-0.84	-9.57	-0.65	1.36e-16	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1153858	0.621	rs2413769	chr15:45561868	A/C	cg14582100	chr15:45693742	SPATA5L1	0.48	5.09	0.42	1.32e-6	Homoarginine levels;
TGCT	cis	rs6089829	0.888	rs4809465	chr20:61671156	G/C	cg02380750	chr20:61661411	NA	0.35	5.68	0.45	9.19e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg24503407	chr1:205819492	PM20D1	0.57	7.77	0.57	2.53e-12	Menarche (age at onset);
TGCT	cis	rs34891900	0.507	rs2535707	chr22:18181869	C/T	cg19898043	chr22:18121309	BCL2L13	-0.56	-4.76	-0.39	5.31e-6	Sum neutrophil eosinophil counts;
TGCT	cis	rs208520	0.874	rs208518	chr6:66948501	C/G	cg07460842	chr6:66804631	NA	0.91	9.18	0.64	1.21e-15	Exhaled nitric oxide output;
TGCT	cis	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg27411982	chr8:10470053	RP1L1	-0.21	-4.56	-0.38	1.21e-5	Neuroticism;
TGCT	cis	rs7959452	0.535	rs1350166	chr12:69636314	G/T	cg20891283	chr12:69753455	YEATS4	0.65	6.32	0.49	4.36e-9	Blood protein levels;
TGCT	cis	rs4253772	0.591	rs9615935	chr22:46686115	T/G	cg24881330	chr22:46731750	TRMU	1.04	5.38	0.44	3.54e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs4727027	0.745	rs10952801	chr7:148864757	T/C	cg23583168	chr7:148888333	NA	-0.76	-10.09	-0.67	7.46e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs116095464	0.558	rs9312978	chr5:221930	C/G	cg12570787	chr5:219185	SDHA;CCDC127	0.71	4.75	0.39	5.44e-6	Breast cancer;
TGCT	cis	rs854765	0.647	rs6502637	chr17:17986098	A/G	cg04398451	chr17:18023971	MYO15A	-0.37	-6.51	-0.5	1.71e-9	Total body bone mineral density;
TGCT	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg13695892	chr22:41940480	POLR3H	0.8	8.01	0.58	7.2e-13	Vitiligo;
TGCT	cis	rs7582180	0.764	rs11691684	chr2:100921776	T/A	cg08017756	chr2:100939284	LONRF2	-0.32	-5.31	-0.43	4.86e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2180341	1.000	rs2144742	chr6:127595786	C/A	cg24812749	chr6:127587940	RNF146	0.99	7.72	0.57	3.33e-12	Breast cancer;
TGCT	cis	rs7208859	0.623	rs56812022	chr17:29068733	A/G	cg14008862	chr17:28927542	LRRC37B2	0.76	4.52	0.38	1.42e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7085104	0.513	rs192569	chr10:104577915	T/C	cg05855489	chr10:104503620	C10orf26	-0.59	-5.61	-0.45	1.24e-7	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs6088590	1.000	rs2295354	chr20:33356541	T/C	cg24642439	chr20:33292090	TP53INP2	0.7	6.22	0.49	7.12e-9	Coronary artery disease;
TGCT	cis	rs11031096	0.803	rs11031142	chr11:4174375	C/T	cg18678763	chr11:4115507	RRM1	0.39	5.24	0.43	6.69e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs3791556	1.000	rs3791562	chr2:240113436	C/T	cg03281426	chr2:240109471	HDAC4	0.28	4.46	0.37	1.82e-5	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg01341218	chr17:43662625	NA	-1.11	-9.34	-0.64	5.11e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs11030122	0.702	rs10835311	chr11:3949027	G/T	cg18678763	chr11:4115507	RRM1	-0.49	-6.14	-0.48	1.01e-8	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs9467773	0.836	rs1624440	chr6:26433329	G/A	cg15659132	chr6:26577336	NA	-0.55	-5.77	-0.46	5.89e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs1372520	0.684	rs2619368	chr4:90729747	T/G	cg14346243	chr4:90757452	SNCA	-0.68	-5.64	-0.45	1.12e-7	Neuroticism;
TGCT	cis	rs6088580	0.634	rs6120644	chr20:33023810	G/A	cg08999081	chr20:33150536	PIGU	0.29	5.67	0.45	9.68e-8	Glomerular filtration rate (creatinine);
TGCT	cis	rs7772486	0.754	rs9399561	chr6:145955687	C/G	cg23711669	chr6:146136114	FBXO30	0.92	10.45	0.68	1.03e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11030122	0.673	rs11030639	chr11:4039056	A/G	cg18678763	chr11:4115507	RRM1	-0.48	-5.96	-0.47	2.39e-8	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs734999	0.524	rs4648448	chr1:2695687	C/T	cg18854424	chr1:2615690	NA	0.45	5.01	0.41	1.82e-6	Ulcerative colitis;
TGCT	cis	rs9534288	0.731	rs7981685	chr13:46605495	G/A	cg15192986	chr13:46630673	CPB2	-0.52	-7.5	-0.56	1.06e-11	Blood protein levels;
TGCT	cis	rs6426558	0.537	rs7523167	chr1:227365304	G/A	cg10327440	chr1:227177885	CDC42BPA	-0.6	-6.95	-0.53	1.84e-10	Neutrophil percentage of white cells;
TGCT	cis	rs473651	0.692	rs579511	chr2:239334914	C/G	cg18131467	chr2:239335373	ASB1	0.99	13.74	0.78	1.09e-26	Multiple system atrophy;
TGCT	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs12497850	0.931	rs9867373	chr3:48960938	A/T	cg06212747	chr3:49208901	KLHDC8B	0.61	5.62	0.45	1.2e-7	Parkinson's disease;
TGCT	cis	rs7267979	1.000	rs6050564	chr20:25344231	G/A	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2180341	1.000	rs3798852	chr6:127636733	A/G	cg24812749	chr6:127587940	RNF146	0.98	7.64	0.57	5.06e-12	Breast cancer;
TGCT	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7605378	1.000	rs769954	chr2:200692159	C/G	cg23649088	chr2:200775458	C2orf69	-0.34	-5.63	-0.45	1.12e-7	Osteoporosis;
TGCT	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.97	-8.51	-0.61	4.86e-14	Platelet count;
TGCT	cis	rs9389248	0.728	rs1022491	chr6:135259366	C/T	cg24558204	chr6:135376177	HBS1L	-0.51	-5.11	-0.42	1.21e-6	High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs9788682	0.747	rs3743078	chr15:78894759	C/G	cg24631222	chr15:78858424	CHRNA5	-0.79	-5.84	-0.46	4.39e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs7959452	0.719	rs57954211	chr12:69748397	C/A	cg14784868	chr12:69753453	YEATS4	0.85	9.43	0.65	3.01e-16	Blood protein levels;
TGCT	cis	rs3824867	0.920	rs7948705	chr11:47447955	C/G	cg20307385	chr11:47447363	PSMC3	-0.69	-5.86	-0.47	3.99e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs2721173	0.619	rs997258	chr8:145903077	C/A	cg17328964	chr8:145687451	CYHR1	0.44	5.83	0.46	4.54e-8	Educational attainment;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
TGCT	cis	rs651907	0.535	rs17347156	chr3:101504674	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.86	10.15	0.67	5.47e-18	Colorectal cancer;
TGCT	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.93	7.53	0.56	9.26e-12	Platelet count;
TGCT	cis	rs7523273	0.927	rs2796275	chr1:207950490	C/T	cg22525895	chr1:207977042	MIR29B2	0.48	8.31	0.6	1.42e-13	Schizophrenia;
TGCT	cis	rs3733585	0.673	rs4560411	chr4:9953361	A/G	cg11266682	chr4:10021025	SLC2A9	-0.57	-7.6	-0.56	6.21e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg21724239	chr8:58056113	NA	0.46	5.0	0.41	1.89e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1185460	0.967	rs11217133	chr11:118928249	G/A	cg01677386	chr11:118938358	VPS11	-0.55	-4.61	-0.38	9.95e-6	Coronary artery disease;
TGCT	cis	rs6570726	0.935	rs380883	chr6:145822992	A/G	cg23711669	chr6:146136114	FBXO30	0.71	6.77	0.52	4.64e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7552404	0.727	rs11161626	chr1:76260837	C/T	cg03433033	chr1:76189801	ACADM	0.64	6.5	0.5	1.75e-9	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs8180040	0.726	rs11130112	chr3:47024495	G/T	cg27129171	chr3:47204927	SETD2	0.75	9.49	0.65	2.15e-16	Colorectal cancer;
TGCT	cis	rs904251	0.504	rs2797795	chr6:37480683	T/C	cg08126542	chr6:37504118	NA	-0.44	-6.51	-0.5	1.71e-9	Cognitive performance;
TGCT	cis	rs5769765	0.913	rs8135071	chr22:50299587	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.37	5.21	0.42	7.51e-7	Schizophrenia;
TGCT	cis	rs11792861	0.926	rs56899598	chr9:111867271	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.48	4.48	0.37	1.66e-5	Menarche (age at onset);
TGCT	cis	rs6910741	0.641	rs1892247	chr6:25887657	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.76	5.22	0.42	7.19e-7	Blood pressure;
TGCT	trans	rs9929218	0.529	rs11075694	chr16:68730366	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.54	6.75	0.52	4.98e-10	Colorectal cancer;
TGCT	cis	rs9549260	0.564	rs9315784	chr13:41289166	G/A	cg21288729	chr13:41239152	FOXO1	0.87	7.86	0.58	1.59e-12	Red blood cell count;
TGCT	cis	rs5769707	0.632	rs1476037	chr22:49991377	G/A	cg05373962	chr22:49881684	NA	-0.3	-5.14	-0.42	1.04e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg22433210	chr17:43662623	NA	-1.0	-7.13	-0.54	7.26e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg07157834	chr1:205819609	PM20D1	0.51	8.84	0.62	7.96e-15	Menarche (age at onset);
TGCT	cis	rs983545	0.573	rs9872060	chr3:16920117	A/G	cg21767191	chr3:17082105	PLCL2	0.22	4.5	0.37	1.52e-5	Blood protein levels;
TGCT	cis	rs6450176	0.625	rs3776725	chr5:53290138	C/A	ch.5.1024479R	chr5:53302184	ARL15	-0.69	-5.58	-0.45	1.45e-7	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg21171335	chr12:122356390	WDR66	0.66	6.65	0.51	8.56e-10	Mean corpuscular volume;
TGCT	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg22535103	chr8:58192502	C8orf71	-0.41	-5.24	-0.43	6.7e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6519955	0.866	rs9626920	chr22:46428993	A/G	cg05468064	chr22:46423449	NA	-0.56	-5.87	-0.47	3.67e-8	Dupuytren's disease;
TGCT	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg20203395	chr5:56204925	C5orf35	0.59	4.5	0.37	1.57e-5	Initial pursuit acceleration;
TGCT	cis	rs17376456	0.877	rs9314099	chr5:93447375	T/C	cg21475434	chr5:93447410	FAM172A	0.59	4.66	0.39	8.09e-6	Diabetic retinopathy;
TGCT	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg14784868	chr12:69753453	YEATS4	0.9	10.55	0.69	5.67e-19	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs7829975	0.653	rs13259070	chr8:8690787	C/T	cg15556689	chr8:8085844	FLJ10661	0.69	6.15	0.48	9.66e-9	Mood instability;
TGCT	cis	rs854765	0.583	rs7222480	chr17:17818817	G/T	cg09796270	chr17:17721594	SREBF1	0.27	5.55	0.45	1.69e-7	Total body bone mineral density;
TGCT	cis	rs6450176	1.000	rs7735253	chr5:53297611	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.53	-5.12	-0.42	1.15e-6	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	trans	rs2727020	0.521	rs7126835	chr11:49594658	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.4	-7.69	-0.57	3.92e-12	Coronary artery disease;
TGCT	cis	rs6722750	0.782	rs7608530	chr2:64412043	T/A	cg22352474	chr2:64371530	PELI1	-0.57	-4.94	-0.41	2.52e-6	Neuroticism;
TGCT	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg08392591	chr16:89556376	ANKRD11	0.58	5.26	0.43	6.25e-7	Multiple myeloma (IgH translocation);
TGCT	cis	rs1635	0.655	rs16893973	chr6:28302113	C/T	cg15743358	chr6:28303923	ZNF323	-1.27	-6.2	-0.49	7.86e-9	Schizophrenia;
TGCT	cis	rs7772486	0.790	rs2485632	chr6:146193228	A/G	cg13319975	chr6:146136371	FBXO30	-0.51	-4.46	-0.37	1.83e-5	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs4650994	0.507	rs12141152	chr1:178514165	C/T	cg05059571	chr16:84539110	KIAA1609	-0.54	-11.05	-0.7	3.43e-20	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs933688	1.000	rs10045280	chr5:90717675	T/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.99	9.38	0.64	4.06e-16	Smoking behavior;
TGCT	cis	rs7923609	1.000	rs12355784	chr10:65121565	G/T	cg08743896	chr10:65200160	JMJD1C	-0.34	-4.61	-0.38	9.73e-6	Educational attainment;Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs12142240	0.583	rs5013330	chr1:46815154	G/A	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs7172809	0.599	rs116981387	chr15:77753231	G/A	cg22256960	chr15:77711686	NA	-0.51	-4.86	-0.4	3.47e-6	Glucose homeostasis traits;
TGCT	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.48	-0.37	1.66e-5	Bipolar disorder;
TGCT	trans	rs4650994	0.544	rs2811314	chr1:178619183	C/T	cg05059571	chr16:84539110	KIAA1609	0.51	9.71	0.66	6.42e-17	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs6088590	0.561	rs3891369	chr20:33161127	C/T	cg06115741	chr20:33292138	TP53INP2	0.54	4.72	0.39	6.32e-6	Coronary artery disease;
TGCT	cis	rs1153858	1.000	rs2467863	chr15:45641880	G/A	cg26924012	chr15:45694286	SPATA5L1	1.05	13.63	0.77	2.04e-26	Homoarginine levels;
TGCT	trans	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg23505145	chr19:12996616	KLF1	0.89	9.92	0.67	1.94e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs12477438	0.520	rs36071868	chr2:99737120	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.06	13.26	0.77	1.59e-25	Chronic sinus infection;
TGCT	cis	rs28595532	0.920	rs116047800	chr4:119773569	G/T	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs4919669	0.777	rs10883766	chr10:104464763	G/A	cg05855489	chr10:104503620	C10orf26	0.73	4.45	0.37	1.91e-5	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs4332037	0.539	rs11764780	chr7:2020904	G/C	cg25834613	chr7:1915315	MAD1L1	-0.47	-4.51	-0.38	1.48e-5	Bipolar disorder;
TGCT	cis	rs57221529	0.766	rs12519469	chr5:581772	A/G	cg20362242	chr5:692897	TPPP	0.49	4.7	0.39	6.76e-6	Lung disease severity in cystic fibrosis;
TGCT	trans	rs941408	1.000	rs1624295	chr19:2792034	G/A	cg22153745	chr1:153894579	GATAD2B	-0.65	-7.5	-0.56	1.08e-11	Total cholesterol levels;
TGCT	cis	rs7412746	0.611	rs12410869	chr1:150856153	G/T	cg09365446	chr1:150670422	GOLPH3L	0.35	5.0	0.41	1.87e-6	Melanoma;
TGCT	cis	rs77686669	1	rs77686669	chr7:99744572	T/C	cg13334819	chr7:99746414	C7orf59	0.54	4.57	0.38	1.16e-5	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
TGCT	cis	rs1367858	0.661	rs3856513	chr2:201234216	G/A	cg04283868	chr2:201171347	SPATS2L	0.52	4.96	0.41	2.32e-6	Schizophrenia;
TGCT	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg10802521	chr3:52805072	NEK4	-0.78	-10.01	-0.67	1.23e-17	Electroencephalogram traits;
TGCT	cis	rs9682041	0.696	rs9872796	chr3:170099393	T/G	cg07589077	chr3:170072950	NA	0.31	4.7	0.39	6.94e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	trans	rs62103177	0.733	rs62096748	chr18:77619699	T/C	cg05926928	chr17:57297772	GDPD1	1.22	11.16	0.71	1.85e-20	Opioid sensitivity;
TGCT	cis	rs7833790	0.963	rs72686466	chr8:82758928	G/T	cg17211192	chr8:82754475	SNX16	1.06	8.51	0.61	4.89e-14	Diastolic blood pressure;
TGCT	cis	rs9911578	1.000	rs9892795	chr17:57023054	G/C	cg05425664	chr17:57184151	TRIM37	-0.62	-6.18	-0.49	8.33e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs4237845	0.837	rs7971877	chr12:58287630	T/G	cg02175503	chr12:58329896	NA	0.49	5.01	0.41	1.85e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.546	rs10018080	chr4:98758436	C/A	cg18180107	chr4:99064573	C4orf37	0.54	4.78	0.39	4.93e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg25703541	chr22:24373054	LOC391322	-0.85	-9.07	-0.63	2.28e-15	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1857353	1.000	rs74089238	chr1:75888220	G/A	cg11838876	chr1:75668600	SLC44A5	-0.51	-4.81	-0.4	4.23e-6	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs1448094	0.556	rs61930626	chr12:86167445	A/G	cg02569458	chr12:86230093	RASSF9	0.38	4.49	0.37	1.61e-5	Major depressive disorder;
TGCT	cis	rs928736	0.599	rs1000005	chr21:34433051	C/G	cg04836472	chr21:34405997	NA	0.48	5.96	0.47	2.46e-8	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs7043114	0.525	rs2274966	chr9:95155563	C/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-5.59	-0.45	1.36e-7	Height;
TGCT	cis	rs4925386	1.000	rs6089351	chr20:60916153	G/A	cg06026331	chr20:60912101	LAMA5	-0.29	-5.44	-0.44	2.74e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs5769765	0.773	rs9616208	chr22:50313359	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.42	5.93	0.47	2.77e-8	Schizophrenia;
TGCT	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg20607798	chr8:58055168	NA	0.45	4.68	0.39	7.52e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1008375	0.932	rs1008894	chr4:17704667	C/T	cg18681998	chr4:17616180	MED28	-0.8	-7.85	-0.58	1.68e-12	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg20637647	chr7:64974828	NA	-0.95	-5.3	-0.43	5.09e-7	Diabetic kidney disease;
TGCT	cis	rs9467773	0.620	rs2504592	chr6:26640951	C/G	cg26531700	chr6:26746687	NA	0.51	4.71	0.39	6.4e-6	Intelligence (multi-trait analysis);
TGCT	trans	rs804280	0.535	rs10435719	chr8:11776904	C/T	cg15556689	chr8:8085844	FLJ10661	0.8	7.46	0.56	1.34e-11	Myopia (pathological);
TGCT	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg04944784	chr2:26401820	FAM59B	-0.68	-6.07	-0.48	1.45e-8	Gut microbiome composition (summer);
TGCT	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.31	-4.82	-0.4	4.12e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs28595532	0.920	rs115118317	chr4:119736613	C/T	cg11846333	chr4:119757529	SEC24D	0.93	4.44	0.37	2e-5	Cannabis dependence symptom count;
TGCT	cis	rs60871478	0.898	rs62432225	chr7:789433	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.53	4.55	0.38	1.26e-5	Cerebrospinal P-tau181p levels;
TGCT	cis	rs9818758	0.607	rs11710247	chr3:49249800	G/T	cg07636037	chr3:49044803	WDR6	-1.04	-5.13	-0.42	1.09e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs57221529	0.600	rs11750269	chr5:666270	G/A	cg16624210	chr5:671434	TPPP	0.43	4.98	0.41	2.11e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg08219700	chr8:58056026	NA	0.38	4.69	0.39	6.95e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10114408	0.959	rs10761299	chr9:96649537	T/C	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs344364	0.511	rs62040569	chr16:1948137	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.45	-5.08	-0.42	1.35e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs12477438	0.715	rs6724476	chr2:99627316	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-4.88	-0.4	3.17e-6	Chronic sinus infection;
TGCT	cis	rs10782582	0.586	rs5745383	chr1:76288590	G/C	cg10523679	chr1:76189770	ACADM	-0.59	-5.42	-0.44	2.94e-7	Daytime sleep phenotypes;
TGCT	cis	rs3540	0.533	rs12708585	chr15:91052285	C/T	cg22089800	chr15:90895588	ZNF774	-0.76	-7.83	-0.58	1.83e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs3091242	0.933	rs909833	chr1:25754140	C/G	cg23205692	chr1:25664452	TMEM50A	0.5	5.21	0.42	7.56e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs10871290	0.881	rs7498574	chr16:74472661	A/G	cg01733217	chr16:74700730	RFWD3	-0.6	-5.66	-0.45	1.02e-7	Breast cancer;
TGCT	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9467773	0.620	rs2494694	chr6:26619328	A/T	cg11502198	chr6:26597334	ABT1	0.53	4.9	0.4	2.95e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7829975	0.606	rs11776838	chr8:8794801	C/T	cg15556689	chr8:8085844	FLJ10661	-0.67	-6.02	-0.48	1.84e-8	Mood instability;
TGCT	cis	rs6570726	1.000	rs441477	chr6:145848243	C/T	cg23711669	chr6:146136114	FBXO30	0.69	6.5	0.5	1.78e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs896854	0.654	rs1453377	chr8:95969947	C/T	cg23172400	chr8:95962367	TP53INP1	-0.37	-6.1	-0.48	1.27e-8	Type 2 diabetes;
TGCT	cis	rs9611565	0.729	rs137831	chr22:41903813	A/C	cg02107564	chr22:41488750	EP300	-0.56	-4.55	-0.38	1.28e-5	Vitiligo;
TGCT	cis	rs7937682	0.632	rs4935811	chr11:111679262	C/T	cg09085632	chr11:111637200	PPP2R1B	0.81	7.16	0.54	6.29e-11	Primary sclerosing cholangitis;
TGCT	cis	rs10744422	0.764	rs4307760	chr12:123293048	C/G	cg18912006	chr12:123335444	HIP1R	0.56	4.78	0.39	4.84e-6	Schizophrenia;
TGCT	cis	rs1670533	1.000	rs6852558	chr4:1059944	C/T	cg20887711	chr4:1340912	KIAA1530	0.65	5.14	0.42	1.05e-6	Recombination rate (females);
TGCT	cis	rs4845570	1.000	rs11585294	chr1:151769887	A/C	cg07092448	chr1:151763213	TDRKH	-1.12	-8.62	-0.61	2.64e-14	Coronary artery disease;
TGCT	trans	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg17830980	chr10:43048298	ZNF37B	-0.87	-11.04	-0.7	3.63e-20	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2120019	0.638	rs12050628	chr15:75333494	G/A	cg09165964	chr15:75287851	SCAMP5	1.13	11.66	0.72	1.13e-21	Blood trace element (Zn levels);
TGCT	cis	rs7954584	0.813	rs1523261	chr12:122462877	C/A	cg21171335	chr12:122356390	WDR66	0.48	4.86	0.4	3.55e-6	Mean corpuscular volume;
TGCT	cis	rs78487399	0.908	rs12474102	chr2:43835570	A/C	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.68	4.85	0.4	3.7e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs28735056	0.584	rs11664834	chr18:77644876	G/T	cg20368463	chr18:77673604	PQLC1	0.47	5.4	0.44	3.26e-7	Schizophrenia;
TGCT	cis	rs9467773	0.620	rs3800303	chr6:26598188	A/G	cg02458000	chr6:26745757	NA	0.52	4.8	0.4	4.48e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9653442	0.900	rs6740838	chr2:100813499	T/G	cg07810366	chr2:100720526	AFF3	-0.4	-6.09	-0.48	1.3e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	trans	rs1814175	0.817	rs1794164	chr11:49899610	T/C	cg03929089	chr4:120376271	NA	-0.71	-8.06	-0.59	5.34e-13	Height;
TGCT	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg06238570	chr21:40685208	BRWD1	0.81	8.67	0.61	2e-14	Cognitive function;
TGCT	cis	rs4699052	0.662	rs6848091	chr4:104250101	A/G	cg16532752	chr4:104119610	CENPE	-0.49	-4.89	-0.4	3.07e-6	Testicular germ cell tumor;
TGCT	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg06896619	chr17:61851486	DDX42;CCDC47	0.49	4.83	0.4	4e-6	Prudent dietary pattern;
TGCT	cis	rs4851266	1.000	rs11689201	chr2:100820431	A/G	cg22139774	chr2:100720529	AFF3	-0.35	-5.23	-0.43	6.83e-7	Educational attainment;
TGCT	cis	rs7267979	0.966	rs2482923	chr20:25308981	T/C	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9467773	0.620	rs2504599	chr6:26641060	C/T	cg15659132	chr6:26577336	NA	0.86	10.81	0.7	1.36e-19	Intelligence (multi-trait analysis);
TGCT	trans	rs8073060	0.614	rs225275	chr17:33972567	G/C	cg19694781	chr19:47549865	TMEM160	-0.6	-13.37	-0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg24531977	chr5:56204891	C5orf35	-0.77	-7.61	-0.56	5.83e-12	Initial pursuit acceleration;
TGCT	cis	rs595982	0.559	rs17272680	chr19:49364511	A/G	cg15549821	chr19:49342101	PLEKHA4	0.69	9.3	0.64	6.08e-16	Red cell distribution width;
TGCT	cis	rs7659604	1.000	rs6814995	chr4:122664963	A/T	cg19748678	chr4:122722346	EXOSC9	-0.55	-5.3	-0.43	5.2e-7	Type 2 diabetes;
TGCT	cis	rs2204008	0.623	rs4882302	chr12:38415608	T/A	cg26384229	chr12:38710491	ALG10B	-0.53	-4.64	-0.38	8.67e-6	Bladder cancer;
TGCT	cis	rs2721195	0.967	rs11777703	chr8:145703508	G/A	cg15320075	chr8:145703422	NA	-0.72	-7.46	-0.56	1.32e-11	Age at first birth;
TGCT	cis	rs62244186	0.659	rs7649834	chr3:44503732	C/T	cg10108389	chr3:44770937	ZNF501	-0.47	-4.87	-0.4	3.34e-6	Depressive symptoms;
TGCT	cis	rs4953076	0.573	rs67537903	chr2:44422111	G/A	cg00619915	chr2:44497795	NA	-0.23	-5.14	-0.42	1.02e-6	Height;
TGCT	cis	rs2204008	0.641	rs66876045	chr12:38205713	G/A	cg13010199	chr12:38710504	ALG10B	0.62	4.89	0.4	3.09e-6	Bladder cancer;
TGCT	cis	rs11098499	0.604	rs2389886	chr4:120570422	C/T	cg09307838	chr4:120376055	NA	0.65	6.32	0.49	4.22e-9	Corneal astigmatism;
TGCT	cis	rs2692947	0.726	rs13019188	chr2:96774199	A/G	cg23100626	chr2:96804247	ASTL	-0.39	-4.67	-0.39	7.56e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs921968	0.643	rs2243911	chr2:219529348	C/T	cg02176678	chr2:219576539	TTLL4	-0.38	-5.47	-0.44	2.34e-7	Mean corpuscular hemoglobin concentration;
TGCT	trans	rs561341	1.000	rs7216102	chr17:30259450	A/G	cg20587970	chr11:113659929	NA	-0.93	-10.95	-0.7	6.29e-20	Hip circumference adjusted for BMI;
TGCT	cis	rs922182	0.557	rs8039736	chr15:64188251	G/A	cg02919090	chr15:64263738	DAPK2	0.31	5.6	0.45	1.33e-7	Blood protein levels;
TGCT	cis	rs561341	0.769	rs9899093	chr17:30191954	C/G	cg08728848	chr17:30437958	NA	0.3	4.79	0.4	4.68e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs7258465	0.965	rs7254249	chr19:18591745	G/A	cg06462663	chr19:18546047	ISYNA1	0.2	4.63	0.38	9.01e-6	Breast cancer;
TGCT	cis	rs1775715	0.966	rs1251386	chr10:32319114	C/T	cg14930904	chr10:32216787	ARHGAP12	-0.5	-4.63	-0.38	8.96e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	5.19	0.42	8.48e-7	Menopause (age at onset);
TGCT	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg07061783	chr6:25882402	NA	0.51	5.57	0.45	1.51e-7	Blood metabolite levels;
TGCT	cis	rs17221829	0.965	rs28614109	chr11:89460943	A/G	cg02982614	chr11:89391479	FOLH1B	-0.3	-5.15	-0.42	9.89e-7	Anxiety in major depressive disorder;
TGCT	cis	rs1371867	0.846	rs1660317	chr8:101333252	G/T	cg06636551	chr8:101224915	SPAG1	-0.48	-6.52	-0.51	1.62e-9	Atrioventricular conduction;
TGCT	cis	rs7193541	0.684	rs8062783	chr16:74691264	C/T	cg01733217	chr16:74700730	RFWD3	-1.0	-13.57	-0.77	2.84e-26	Multiple myeloma;
TGCT	cis	rs1577917	0.740	rs2842604	chr6:86336300	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.58	-0.45	1.43e-7	Response to antipsychotic treatment;
TGCT	cis	rs826838	0.616	rs10880751	chr12:38627485	C/T	cg26384229	chr12:38710491	ALG10B	0.51	4.54	0.38	1.3e-5	Heart rate;
TGCT	cis	rs28595532	0.920	rs116697254	chr4:119733603	T/C	cg21605333	chr4:119757512	SEC24D	1.66	8.33	0.6	1.28e-13	Cannabis dependence symptom count;
TGCT	cis	rs10504229	0.679	rs12675340	chr8:58035501	T/A	cg08280861	chr8:58055591	NA	0.35	5.07	0.41	1.43e-6	Developmental language disorder (linguistic errors);
TGCT	trans	rs9388451	0.874	rs1159974	chr6:126090277	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.74	8.31	0.6	1.4e-13	Brugada syndrome;
TGCT	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	15.94	0.82	8.5e-32	Prudent dietary pattern;
TGCT	cis	rs7586879	0.616	rs11900505	chr2:25131986	A/C	cg15423357	chr2:25149977	NA	0.52	5.03	0.41	1.65e-6	Body mass index;
TGCT	cis	rs12893668	0.667	rs71417869	chr14:104077434	A/G	cg26031613	chr14:104095156	KLC1	-0.55	-4.54	-0.38	1.3e-5	Reticulocyte count;
TGCT	cis	rs9295536	0.651	rs6921113	chr6:22136879	G/T	cg25792714	chr6:21666554	FLJ22536	-0.52	-4.55	-0.38	1.27e-5	Neuroblastoma;
TGCT	cis	rs9611565	1.000	rs9611565	chr22:41767486	T/C	cg13695892	chr22:41940480	POLR3H	-0.72	-6.9	-0.53	2.32e-10	Vitiligo;
TGCT	cis	rs2120019	1.000	rs7168680	chr15:75369212	G/A	cg17294928	chr15:75287854	SCAMP5	-0.86	-6.62	-0.51	9.55e-10	Blood trace element (Zn levels);
TGCT	cis	rs9513593	0.901	rs7330165	chr13:99889427	C/T	cg21788972	chr13:99853209	UBAC2	-0.55	-4.46	-0.37	1.79e-5	Psoriasis;
TGCT	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg00684032	chr4:1343700	KIAA1530	0.25	5.28	0.43	5.47e-7	Obesity-related traits;
TGCT	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg02038168	chr22:39784481	NA	0.7	5.75	0.46	6.64e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs425277	0.959	rs77665022	chr1:2065958	C/T	cg03732007	chr1:2071316	PRKCZ	0.25	5.01	0.41	1.81e-6	Height;
TGCT	cis	rs9926296	0.632	rs7184315	chr16:89799373	C/G	cg03388025	chr16:89894329	SPIRE2	-0.32	-4.77	-0.39	5.09e-6	Vitiligo;
TGCT	trans	rs10802346	0.545	rs2362252	chr1:246371574	A/C	cg13514129	chr1:39547527	MACF1	0.86	7.71	0.57	3.54e-12	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs7811142	0.945	rs6978739	chr7:100098680	C/G	cg00814883	chr7:100076585	TSC22D4	-0.89	-9.03	-0.63	2.76e-15	Platelet count;
TGCT	cis	rs1008375	0.898	rs61047804	chr4:17593965	G/A	cg10189774	chr4:17578691	LAP3	0.71	6.05	0.48	1.59e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7312933	0.531	rs2406674	chr12:42720150	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.59	-5.7	-0.46	8.16e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs10501293	0.917	rs10838003	chr11:43071988	T/A	cg03447554	chr11:43094025	NA	0.44	6.52	0.51	1.61e-9	Cognitive performance;
TGCT	cis	rs7091068	0.536	rs6583901	chr10:95409998	C/T	cg20715218	chr10:95462985	C10orf4	-0.51	-5.52	-0.44	1.9e-7	Urinary tract infection frequency;
TGCT	cis	rs950027	0.620	rs1426932	chr15:45687256	T/C	cg14582100	chr15:45693742	SPATA5L1	0.43	5.38	0.44	3.52e-7	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs11098499	0.863	rs11098531	chr4:120465001	G/A	cg09307838	chr4:120376055	NA	0.72	6.87	0.52	2.81e-10	Corneal astigmatism;
TGCT	cis	rs12519773	0.597	rs4308464	chr5:92468867	G/C	cg18783429	chr5:92414398	NA	0.31	4.65	0.39	8.41e-6	Migraine;
TGCT	cis	rs4654899	0.812	rs7539512	chr1:21410791	A/G	cg01072550	chr1:21505969	NA	-0.56	-9.08	-0.63	2.14e-15	Superior frontal gyrus grey matter volume;
TGCT	cis	rs7829975	0.846	rs11779061	chr8:8549432	G/A	cg06636001	chr8:8085503	FLJ10661	-0.61	-5.1	-0.42	1.22e-6	Mood instability;
TGCT	cis	rs986417	0.818	rs2057135	chr14:61077022	G/A	cg27398547	chr14:60952738	C14orf39	1.33	9.79	0.66	4e-17	Gut microbiota (bacterial taxa);
TGCT	cis	rs3087591	0.708	rs2854307	chr17:29652147	G/A	cg24425628	chr17:29625626	OMG;NF1	0.4	5.63	0.45	1.14e-7	Hip circumference;
TGCT	cis	rs72615157	0.595	rs112241539	chr7:99847237	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.62	4.82	0.4	4.1e-6	Lung function (FEV1/FVC);
TGCT	cis	rs4148883	0.629	rs2602899	chr4:100010128	C/T	cg12011299	chr4:100065546	ADH4	0.38	5.72	0.46	7.41e-8	Alcohol dependence;
TGCT	cis	rs9457247	1.000	rs2769354	chr6:167379771	G/T	cg23791538	chr6:167370224	RNASET2	0.5	4.98	0.41	2.08e-6	Crohn's disease;
TGCT	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.54	4.7	0.39	6.81e-6	Prudent dietary pattern;
TGCT	cis	rs9467773	1.000	rs9295695	chr6:26528250	C/T	cg05738196	chr6:26577821	NA	-0.89	-12.7	-0.75	3.46e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs17539620	0.624	rs871069	chr6:154837578	A/C	cg20019720	chr6:154832845	CNKSR3	0.57	5.02	0.41	1.72e-6	Lipoprotein (a) levels;
TGCT	cis	rs748404	0.631	rs1133395	chr15:43650384	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	4.72	0.39	6.3e-6	Lung cancer;
TGCT	cis	rs28595532	0.841	rs10019311	chr4:119785458	G/A	cg21605333	chr4:119757512	SEC24D	1.44	8.24	0.6	2.03e-13	Cannabis dependence symptom count;
TGCT	cis	rs992157	0.764	rs10193189	chr2:219187603	C/A	cg00012203	chr2:219082015	ARPC2	0.71	6.44	0.5	2.41e-9	Colorectal cancer;
TGCT	cis	rs739496	0.579	rs7959619	chr12:112376597	G/A	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs694739	0.654	rs10897488	chr11:64140806	T/C	cg23796481	chr11:64053134	BAD;GPR137	0.63	6.54	0.51	1.44e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs9942416	0.601	rs114547168	chr5:74991903	A/G	cg19683494	chr5:74908142	NA	0.57	5.96	0.47	2.39e-8	Age-related disease endophenotypes;
TGCT	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg23574427	chr4:122746245	BBS7;CCNA2	-0.34	-5.31	-0.43	4.82e-7	Type 2 diabetes;
TGCT	cis	rs7552404	1.000	rs7552404	chr1:76135946	A/G	cg10523679	chr1:76189770	ACADM	0.92	10.14	0.67	5.73e-18	Blood metabolite levels;Acylcarnitine levels;
TGCT	trans	rs9951602	0.512	rs8089108	chr18:76651361	C/T	cg02800362	chr5:177631904	HNRNPAB	1.15	13.03	0.76	5.64e-25	Obesity-related traits;
TGCT	cis	rs3733585	0.806	rs11723382	chr4:9954660	T/C	cg11266682	chr4:10021025	SLC2A9	-0.61	-8.42	-0.6	7.65e-14	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs6964587	1.000	rs2188155	chr7:91599825	A/C	cg22709100	chr7:91322751	NA	0.27	4.48	0.37	1.68e-5	Breast cancer;
TGCT	cis	rs11098499	0.863	rs2291185	chr4:120434833	C/A	cg09307838	chr4:120376055	NA	0.69	6.53	0.51	1.49e-9	Corneal astigmatism;
TGCT	cis	rs12681287	0.547	rs35871312	chr8:87543219	T/C	cg27223183	chr8:87520930	FAM82B	0.94	6.91	0.53	2.24e-10	Caudate activity during reward;
TGCT	cis	rs4478037	0.558	rs59482503	chr3:33077163	G/A	cg19404215	chr3:33155277	CRTAP	1.04	4.99	0.41	2e-6	Major depressive disorder;
TGCT	cis	rs6674176	0.696	rs4448553	chr1:44411589	A/G	cg13606994	chr1:44402422	ARTN	-0.49	-5.38	-0.44	3.51e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg09359103	chr1:154839909	KCNN3	-0.67	-12.42	-0.74	1.61e-23	Prostate cancer;
TGCT	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/T	cg06395469	chr6:27635558	NA	0.37	4.62	0.38	9.33e-6	Parkinson's disease;
TGCT	cis	rs4906332	1.000	rs35344594	chr14:103955792	A/G	cg26031613	chr14:104095156	KLC1	-0.51	-4.51	-0.38	1.48e-5	Coronary artery disease;
TGCT	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg01802117	chr1:53393560	SCP2	-0.41	-4.87	-0.4	3.32e-6	Monocyte count;
TGCT	cis	rs7213347	0.780	rs9892016	chr17:2146422	A/G	cg22033759	chr17:1182267	TUSC5	-0.22	-4.62	-0.38	9.53e-6	Total body bone mineral density;
TGCT	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg10047753	chr17:41438598	NA	0.84	7.61	0.56	5.9e-12	Menopause (age at onset);
TGCT	cis	rs5769765	0.819	rs9616377	chr22:50310880	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.43	6.08	0.48	1.35e-8	Schizophrenia;
TGCT	cis	rs28595532	0.764	rs56071514	chr4:119761833	T/C	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs72781680	0.898	rs7589440	chr2:24038595	G/A	cg08917208	chr2:24149416	ATAD2B	0.8	4.93	0.4	2.62e-6	Lymphocyte counts;
TGCT	cis	rs9486719	1.000	rs12214469	chr6:97019471	G/T	cg06623918	chr6:96969491	KIAA0776	-0.99	-8.05	-0.59	5.65e-13	Migraine;Coronary artery disease;
TGCT	cis	rs9486715	0.867	rs211159	chr6:97023026	G/A	cg18709589	chr6:96969512	KIAA0776	-0.85	-8.16	-0.59	3.2e-13	Headache;
TGCT	cis	rs7095607	0.538	rs2673796	chr10:69917242	A/G	cg18986048	chr10:69913749	MYPN	0.53	5.12	0.42	1.12e-6	Lung function (FVC);
TGCT	cis	rs11792861	0.816	rs28361111	chr9:111761012	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.5	4.69	0.39	6.99e-6	Menarche (age at onset);
TGCT	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg03709012	chr19:19516395	GATAD2A	0.67	5.74	0.46	6.83e-8	Tonsillectomy;
TGCT	trans	rs1814175	0.702	rs4881644	chr11:49786367	C/T	cg15704280	chr7:45808275	SEPT13	-0.69	-8.05	-0.59	5.61e-13	Height;
TGCT	cis	rs7312933	0.670	rs2406568	chr12:42552297	G/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	5.06	0.41	1.45e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs7819412	0.511	rs2409799	chr8:11435927	G/C	cg21775007	chr8:11205619	TDH	-0.53	-5.01	-0.41	1.8e-6	Triglycerides;
TGCT	cis	rs17767294	0.708	rs72849204	chr6:28170943	G/A	cg08851530	chr6:28072375	NA	1.47	6.82	0.52	3.64e-10	Parkinson's disease;
TGCT	cis	rs587847	0.558	rs614443	chr15:37683804	G/A	cg16890051	chr15:37175029	LOC145845	-0.38	-4.52	-0.38	1.43e-5	Intraocular pressure;
TGCT	cis	rs7568458	0.837	rs6547624	chr2:85802134	A/T	cg17127132	chr2:85788382	GGCX	0.72	6.68	0.51	7.16e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs6964587	1.000	rs2299232	chr7:91626699	A/C	cg17063962	chr7:91808500	NA	0.88	9.54	0.65	1.69e-16	Breast cancer;
TGCT	cis	rs10493773	0.928	rs12751296	chr1:86176968	G/A	cg17807903	chr1:86174739	ZNHIT6	-0.38	-4.61	-0.38	9.67e-6	Urate levels in overweight individuals;
TGCT	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg03188948	chr7:1209495	NA	0.47	5.81	0.46	4.9e-8	Longevity;Endometriosis;
TGCT	cis	rs10927875	0.864	rs12744578	chr1:16173110	A/T	cg14742211	chr1:16348397	CLCNKA	-0.2	-4.46	-0.37	1.82e-5	Dilated cardiomyopathy;
TGCT	cis	rs12134133	1.000	rs2802235	chr1:207471799	G/A	cg02152968	chr1:207494213	CD55	0.57	4.51	0.38	1.48e-5	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs2456568	0.564	rs4608039	chr11:93624799	C/G	cg26875233	chr11:93583750	C11orf90	0.44	5.83	0.46	4.55e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs9467711	0.606	rs9348726	chr6:26605206	G/A	cg16898833	chr6:26189333	HIST1H4D	1.02	5.25	0.43	6.32e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7666738	0.830	rs28594127	chr4:99001121	T/G	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg17830980	chr10:43048298	ZNF37B	-0.85	-11.06	-0.7	3.31e-20	Extrinsic epigenetic age acceleration;
TGCT	cis	rs13064411	0.735	rs6778800	chr3:113149236	A/G	cg18753928	chr3:113234510	CCDC52	-0.67	-5.12	-0.42	1.14e-6	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs7666738	0.648	rs33988750	chr4:98985386	T/C	cg17366294	chr4:99064904	C4orf37	0.65	4.68	0.39	7.36e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs72945132	0.882	rs67093918	chr11:70198999	C/A	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs8030485	0.728	rs13379886	chr15:79394894	A/G	cg17916960	chr15:79447300	NA	-0.32	-4.52	-0.38	1.41e-5	Left ventricle wall thickness;
TGCT	cis	rs595982	0.527	rs35023389	chr19:49377873	G/A	cg21252483	chr19:49399788	TULP2	-0.48	-7.32	-0.55	2.8e-11	Red cell distribution width;
TGCT	cis	rs8017423	0.967	rs11159958	chr14:90716051	T/C	cg04374321	chr14:90722782	PSMC1	0.72	7.54	0.56	8.86e-12	Mortality in heart failure;
TGCT	cis	rs2836974	0.897	rs2776308	chr21:40715175	A/G	cg17971929	chr21:40555470	PSMG1	0.91	7.93	0.58	1.07e-12	Cognitive function;
TGCT	cis	rs1008375	0.618	rs13129002	chr4:17567513	A/G	cg18681998	chr4:17616180	MED28	0.73	6.58	0.51	1.16e-9	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs17741873	0.779	rs3812635	chr10:75594302	T/G	cg07699608	chr10:75541558	CHCHD1	0.72	5.15	0.42	1.02e-6	Paclitaxel disposition in epithelial ovarian cancer;
TGCT	cis	rs2996428	0.601	rs59414187	chr1:3762815	T/C	cg17848003	chr1:3704513	LRRC47	0.19	5.21	0.42	7.56e-7	Red cell distribution width;
TGCT	cis	rs7666738	0.791	rs10005118	chr4:99038196	A/C	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs950776	0.612	rs8038920	chr15:78974545	A/G	cg21242079	chr15:79101063	ADAMTS7	0.3	5.04	0.41	1.64e-6	Sudden cardiac arrest;
TGCT	cis	rs1541995	0.931	rs12437634	chr15:96322790	T/A	cg00882281	chr15:96346592	NA	0.28	4.56	0.38	1.2e-5	Photic sneeze reflex;
TGCT	trans	rs561341	1.000	rs72821952	chr17:30248133	T/A	cg20587970	chr11:113659929	NA	-0.9	-8.59	-0.61	3.08e-14	Hip circumference adjusted for BMI;
TGCT	cis	rs2346177	0.638	rs34186951	chr2:46657659	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.43	-4.62	-0.38	9.52e-6	HDL cholesterol;
TGCT	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg24846343	chr22:24311635	DDTL	0.23	5.86	0.47	3.94e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg18252515	chr7:66147081	NA	-1.2	-7.16	-0.54	6.16e-11	Diabetic kidney disease;
TGCT	cis	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg22857025	chr5:266934	NA	-0.34	-6.7	-0.52	6.65e-10	Breast cancer;
TGCT	cis	rs6582630	0.519	rs1607868	chr12:38385512	G/T	cg26384229	chr12:38710491	ALG10B	0.85	7.58	0.56	7.17e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs909674	0.818	rs8137426	chr22:39844350	T/G	cg01416388	chr22:39784598	NA	-0.69	-6.32	-0.49	4.37e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs17601876	0.814	rs28674681	chr15:51559917	A/C	cg19946085	chr15:51559439	CYP19A1	-0.33	-5.06	-0.41	1.45e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs2479724	0.935	rs7753507	chr6:41784094	C/T	cg08135965	chr6:41755394	TOMM6	-0.48	-4.74	-0.39	5.77e-6	Menarche (age at onset);
TGCT	cis	rs2455799	0.634	rs13085226	chr3:15923750	C/T	cg16303742	chr3:15540471	COLQ	-0.23	-4.52	-0.38	1.42e-5	Mean platelet volume;
TGCT	cis	rs9814567	1.000	rs62271513	chr3:134298412	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.92	8.42	0.6	7.71e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg22166914	chr1:53195759	ZYG11B	0.35	5.78	0.46	5.7e-8	Monocyte count;
TGCT	trans	rs1005277	0.522	rs7072977	chr10:37940440	C/A	cg17830980	chr10:43048298	ZNF37B	-0.67	-7.46	-0.56	1.32e-11	Extrinsic epigenetic age acceleration;
TGCT	cis	rs6976053	0.875	rs7783543	chr7:100468398	T/C	cg05669210	chr7:100450634	SLC12A9	0.51	4.5	0.37	1.56e-5	Plasminogen activator inhibitor type 1 levels (PAI-1);
TGCT	cis	rs7542091	0.704	rs1883331	chr1:210043483	A/G	cg21951975	chr1:209979733	IRF6	0.6	6.1	0.48	1.24e-8	Monobrow;
TGCT	cis	rs11191270	0.554	rs77616533	chr10:104055983	A/G	cg15320455	chr10:103880129	LDB1	0.85	5.35	0.43	4.09e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs394563	0.591	rs237018	chr6:149743930	A/G	cg03678062	chr6:149772716	ZC3H12D	-0.37	-4.79	-0.39	4.75e-6	Dupuytren's disease;
TGCT	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg07507251	chr3:52567010	NT5DC2	0.48	6.67	0.51	7.55e-10	Bipolar disorder;
TGCT	cis	rs36051895	0.659	rs10815150	chr9:5067301	C/A	cg02405213	chr9:5042618	JAK2	-0.82	-12.07	-0.74	1.15e-22	Pediatric autoimmune diseases;
TGCT	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg10819733	chr22:24237672	NA	0.32	5.55	0.45	1.62e-7	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg18252515	chr7:66147081	NA	-1.3	-7.93	-0.58	1.1e-12	Diabetic kidney disease;
TGCT	cis	rs2887571	0.821	rs11613567	chr12:1637740	G/C	cg01940102	chr12:1095972	NA	0.25	4.67	0.39	7.69e-6	Bone mineral density;
TGCT	cis	rs1401999	0.668	rs6806313	chr3:183642152	G/C	cg01324343	chr3:183735012	ABCC5	0.73	8.92	0.63	5.17e-15	Anterior chamber depth;
TGCT	cis	rs4730250	0.707	rs257387	chr7:106808480	G/A	cg02696742	chr7:106810147	HBP1	-0.71	-5.83	-0.46	4.6e-8	Osteoarthritis;
TGCT	cis	rs6448317	0.954	rs11946846	chr4:24922703	G/A	cg21108841	chr4:24914750	CCDC149	-0.63	-4.81	-0.4	4.29e-6	Heschl's gyrus morphology;
TGCT	cis	rs858239	0.539	rs6975852	chr7:23186654	T/C	cg05602783	chr7:23145260	KLHL7	-0.69	-5.71	-0.46	7.93e-8	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg11644478	chr21:40555479	PSMG1	-0.54	-4.7	-0.39	6.69e-6	Cognitive function;
TGCT	cis	rs7666738	0.830	rs17550610	chr4:99008273	T/C	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs854765	0.647	rs4365346	chr17:17989373	G/T	cg04398451	chr17:18023971	MYO15A	-0.37	-6.51	-0.5	1.71e-9	Total body bone mineral density;
TGCT	cis	rs651907	0.557	rs3094296	chr3:101400167	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.9	10.42	0.68	1.23e-18	Colorectal cancer;
TGCT	cis	rs7666738	0.830	rs13144564	chr4:98939276	A/G	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs921968	0.643	rs559722	chr2:219398159	A/G	cg02176678	chr2:219576539	TTLL4	0.44	6.33	0.49	4.17e-9	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs9914544	1.000	rs1037036	chr17:18764077	C/T	cg26306683	chr17:18585705	ZNF286B	0.56	5.03	0.41	1.67e-6	Educational attainment (years of education);
TGCT	cis	rs17125944	0.686	rs6572868	chr14:53325090	C/T	cg00686598	chr14:53173677	PSMC6	-0.89	-4.62	-0.38	9.56e-6	Alzheimer's disease (late onset);
TGCT	cis	rs514406	0.505	rs436363	chr1:53172163	T/C	cg16325326	chr1:53192061	ZYG11B	0.86	12.09	0.74	1.05e-22	Monocyte count;
TGCT	cis	rs11098499	0.818	rs7688802	chr4:120451668	G/A	cg09307838	chr4:120376055	NA	0.69	6.53	0.51	1.49e-9	Corneal astigmatism;
TGCT	cis	rs11671005	0.735	rs45617039	chr19:58951096	G/A	cg13877915	chr19:58951672	ZNF132	0.63	5.0	0.41	1.95e-6	Mean platelet volume;
TGCT	cis	rs6088590	0.965	rs6120730	chr20:33385102	G/C	cg06115741	chr20:33292138	TP53INP2	0.65	5.45	0.44	2.66e-7	Coronary artery disease;
TGCT	cis	rs17473412	0.926	rs114335122	chr5:122652820	A/G	cg15125798	chr5:122621645	NA	-0.66	-5.93	-0.47	2.84e-8	Total body bone mineral density;
TGCT	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg12751644	chr20:60527061	NA	-0.49	-6.43	-0.5	2.5e-9	Obesity-related traits;
TGCT	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg04944784	chr2:26401820	FAM59B	0.76	6.24	0.49	6.46e-9	Gut microbiome composition (summer);
TGCT	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg03188948	chr7:1209495	NA	0.68	5.8	0.46	5.09e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg10876282	chr6:28092338	ZSCAN16	0.49	4.54	0.38	1.33e-5	Parkinson's disease;
TGCT	cis	rs9393777	0.513	rs7740197	chr6:26663478	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.58	4.63	0.38	9.02e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4595586	0.545	rs2388175	chr12:39389217	A/G	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs6089584	0.526	rs6089619	chr20:60610916	C/T	cg13770153	chr20:60521292	NA	-0.41	-5.09	-0.42	1.28e-6	Body mass index;
TGCT	cis	rs11118844	0.739	rs12070192	chr1:221945870	A/T	cg04222084	chr1:221915650	DUSP10	-0.71	-5.03	-0.41	1.67e-6	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
TGCT	cis	rs7772486	0.875	rs1960885	chr6:146325930	G/T	cg05347473	chr6:146136440	FBXO30	0.52	4.9	0.4	2.93e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4654899	0.758	rs6693055	chr1:21421813	C/T	cg01072550	chr1:21505969	NA	-0.56	-9.08	-0.63	2.14e-15	Superior frontal gyrus grey matter volume;
TGCT	cis	rs68170813	0.559	rs79978998	chr7:106845482	C/T	cg02696742	chr7:106810147	HBP1	-0.67	-5.43	-0.44	2.88e-7	Coronary artery disease;
TGCT	cis	rs7017914	0.905	rs1353058	chr8:71922018	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.55	-5.13	-0.42	1.06e-6	Bone mineral density;
TGCT	cis	rs2742417	0.967	rs6800556	chr3:45752229	G/T	cg04837898	chr3:45731254	SACM1L	-0.55	-5.72	-0.46	7.45e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs317689	0.819	rs317667	chr12:69703754	G/T	cg14784868	chr12:69753453	YEATS4	0.57	4.9	0.4	2.96e-6	Response to diuretic therapy;
TGCT	cis	rs12893668	0.572	rs4900591	chr14:104154878	G/A	cg26031613	chr14:104095156	KLC1	-0.59	-5.05	-0.41	1.53e-6	Reticulocyte count;
TGCT	cis	rs7773004	0.601	rs13210340	chr6:26326314	G/C	cg16898833	chr6:26189333	HIST1H4D	1.34	5.61	0.45	1.23e-7	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
TGCT	cis	rs7589728	0.563	rs78685993	chr2:88447026	T/C	cg04511125	chr2:88470314	THNSL2	0.79	6.55	0.51	1.37e-9	Plasma clusterin levels;
TGCT	cis	rs17001868	0.568	rs9611311	chr22:40733951	T/C	cg07138101	chr22:40742427	ADSL	0.73	5.38	0.44	3.57e-7	Mammographic density (dense area);
TGCT	cis	rs2120019	0.938	rs13056	chr15:75312187	A/G	cg11632617	chr15:75315747	PPCDC	-0.3	-4.44	-0.37	1.95e-5	Blood trace element (Zn levels);
TGCT	cis	rs7914558	0.752	rs7896519	chr10:104866863	C/T	cg04362960	chr10:104952993	NT5C2	0.64	5.54	0.45	1.71e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs7267979	0.966	rs416745	chr20:25438868	T/C	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6121246	0.697	rs6060446	chr20:30231637	T/C	cg18721089	chr20:30220636	NA	-0.53	-5.43	-0.44	2.86e-7	Mean corpuscular hemoglobin;
TGCT	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg21724239	chr8:58056113	NA	0.39	4.59	0.38	1.07e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs295137	0.798	rs1900706	chr2:201214071	A/C	cg23649088	chr2:200775458	C2orf69	0.28	4.73	0.39	6.03e-6	Asthma (bronchodilator response);
TGCT	cis	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg20637647	chr7:64974828	NA	1.0	5.59	0.45	1.4e-7	Diabetic kidney disease;
TGCT	cis	rs4820539	1.000	rs3788347	chr22:23467804	G/A	cg21100191	chr22:23484243	RTDR1	0.88	9.99	0.67	1.36e-17	Bone mineral density;
TGCT	cis	rs7267979	0.549	rs11698185	chr20:25181998	T/C	cg03522245	chr20:25566470	NINL	0.52	5.46	0.44	2.52e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1729951	0.546	rs12054219	chr3:136677472	G/A	cg12473912	chr3:136751656	NA	0.39	6.18	0.49	8.36e-9	Neuroticism;
TGCT	cis	rs4689388	0.926	rs4688987	chr4:6287329	C/T	cg25554036	chr4:6271136	WFS1	0.57	8.21	0.59	2.47e-13	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs10791097	1.000	rs10791097	chr11:130718630	G/T	cg12179176	chr11:130786555	SNX19	-0.6	-5.63	-0.45	1.15e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs11931598	0.511	rs4689576	chr4:7025523	T/C	cg02503808	chr4:7069936	GRPEL1	0.54	5.13	0.42	1.07e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs1670533	1.000	rs6850784	chr4:1059809	G/A	cg20887711	chr4:1340912	KIAA1530	0.65	5.14	0.42	1.05e-6	Recombination rate (females);
TGCT	cis	rs10949834	0.730	rs2237503	chr7:73509326	G/C	cg07137043	chr7:73588983	EIF4H	-0.63	-4.64	-0.38	8.73e-6	Verbal memory performance (residualized delayed recall change);
TGCT	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg18876405	chr7:65276391	NA	0.35	5.66	0.45	1.01e-7	Aortic root size;
TGCT	trans	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg20587970	chr11:113659929	NA	-1.09	-13.5	-0.77	4.23e-26	Hip circumference adjusted for BMI;
TGCT	cis	rs523522	0.962	rs4766966	chr12:120942911	G/C	cg12219531	chr12:120966889	COQ5	0.83	7.27	0.55	3.46e-11	High light scatter reticulocyte count;
TGCT	cis	rs11098499	0.863	rs7664986	chr4:120429952	A/C	cg09307838	chr4:120376055	NA	0.68	6.45	0.5	2.28e-9	Corneal astigmatism;
TGCT	cis	rs4555082	0.794	rs2735827	chr14:105710600	T/A	cg01266790	chr14:105781312	PACS2	0.54	4.44	0.37	1.95e-5	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs854765	0.547	rs2955377	chr17:17932818	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.78	8.1	0.59	4.3e-13	Total body bone mineral density;
TGCT	cis	rs2652822	0.550	rs72747098	chr15:63525249	G/A	cg12855773	chr15:63363890	TPM1	-0.17	-5.09	-0.42	1.29e-6	Metabolic traits;
TGCT	cis	rs68170813	0.617	rs2283041	chr7:107190415	A/G	cg02696742	chr7:106810147	HBP1	-0.6	-4.66	-0.39	8.15e-6	Coronary artery disease;
TGCT	cis	rs72949976	1.000	rs72949976	chr2:214034104	C/T	cg08319019	chr2:214017104	IKZF2	-0.79	-7.3	-0.55	2.97e-11	Lung cancer;Squamous cell lung carcinoma;
TGCT	cis	rs7647973	1.000	rs56127630	chr3:49438036	C/G	cg05785598	chr3:49045655	WDR6	-0.4	-4.67	-0.39	7.57e-6	Menarche (age at onset);
TGCT	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.54	4.95	0.41	2.35e-6	Prudent dietary pattern;
TGCT	cis	rs12200560	0.505	rs211162	chr6:97067344	G/A	cg06623918	chr6:96969491	KIAA0776	0.61	5.19	0.42	8.52e-7	Coronary heart disease;
TGCT	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg06873352	chr17:61820015	STRADA	-0.5	-5.61	-0.45	1.23e-7	Prudent dietary pattern;
TGCT	trans	rs4332037	0.539	rs11764780	chr7:2020904	G/C	cg10840412	chr1:235813424	GNG4	0.93	6.69	0.51	6.97e-10	Bipolar disorder;
TGCT	cis	rs36093844	0.898	rs11512932	chr11:85591130	T/G	cg25872744	chr11:85566296	CCDC83	-0.52	-4.73	-0.39	6.09e-6	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
TGCT	cis	rs4704846	1.000	rs4704846	chr5:156513344	G/A	cg12943317	chr5:156479607	HAVCR1	-0.29	-4.44	-0.37	1.96e-5	Blood protein levels;
TGCT	cis	rs7312933	0.607	rs7965392	chr12:42540280	G/A	cg19980929	chr12:42632907	YAF2	0.47	6.43	0.5	2.47e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs3733585	0.566	rs35955619	chr4:9918986	T/A	cg11266682	chr4:10021025	SLC2A9	-0.49	-5.86	-0.47	3.86e-8	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs617219	0.591	rs1840805	chr5:78565563	T/A	cg23514016	chr5:78407564	BHMT	-0.32	-4.88	-0.4	3.26e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs11031096	0.782	rs4910889	chr11:4153231	T/C	cg18678763	chr11:4115507	RRM1	-0.46	-5.79	-0.46	5.36e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs2204008	0.640	rs2320744	chr12:38162389	A/G	cg13010199	chr12:38710504	ALG10B	0.64	5.16	0.42	9.41e-7	Bladder cancer;
TGCT	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	7.45	0.56	1.41e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs933688	1.000	rs12655973	chr5:90736537	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.01	8.92	0.63	4.99e-15	Smoking behavior;
TGCT	cis	rs35146811	0.700	rs4729579	chr7:99780282	C/G	cg00553149	chr7:99775558	STAG3;GPC2	0.31	4.61	0.38	9.75e-6	Coronary artery disease;
TGCT	cis	rs9677476	0.516	rs2175147	chr2:232008473	A/G	cg07929768	chr2:232055508	NA	0.33	5.24	0.43	6.78e-7	Food antigen IgG levels;
TGCT	cis	rs10114408	0.918	rs10992954	chr9:96647025	T/G	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.67	-0.39	7.73e-6	Prudent dietary pattern;
TGCT	cis	rs2956278	0.747	rs2929751	chr12:84677765	T/C	cg25678815	chr12:85673915	ALX1	-0.54	-4.83	-0.4	3.96e-6	Depressive symptoms;Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2230307	0.536	rs684519	chr1:100604715	T/G	cg24955406	chr1:100503596	HIAT1	-0.73	-4.96	-0.41	2.27e-6	Carotid intima media thickness;
TGCT	cis	rs849210	0.517	rs3845806	chr2:206198319	A/G	cg11793701	chr2:206547163	NRP2	-0.56	-4.51	-0.38	1.47e-5	Tonsillectomy;
TGCT	cis	rs2153535	0.580	rs1577470	chr6:8462426	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs10892173	0.935	rs7108548	chr11:117674072	A/T	cg21640587	chr11:117668038	DSCAML1	0.43	4.56	0.38	1.21e-5	Myopia;
TGCT	cis	rs9811920	0.809	rs793475	chr3:99543764	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.45	5.03	0.41	1.7e-6	Axial length;
TGCT	cis	rs7772486	0.875	rs2814863	chr6:146347299	C/T	cg05347473	chr6:146136440	FBXO30	-0.56	-5.42	-0.44	2.96e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7666738	0.830	rs991169	chr4:98928567	C/A	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11958404	0.789	rs72800604	chr5:157502940	C/T	cg05962755	chr5:157440814	NA	0.36	4.66	0.39	7.94e-6	IgG glycosylation;
TGCT	cis	rs2188554	0.740	rs213948	chr7:117194470	G/A	cg08576598	chr7:116962626	WNT2	-0.35	-4.48	-0.37	1.68e-5	Esophageal adenocarcinoma;
TGCT	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg18876405	chr7:65276391	NA	0.31	4.78	0.39	4.81e-6	Aortic root size;
TGCT	cis	rs2067615	0.507	rs10746063	chr12:107086240	G/T	cg15890332	chr12:107067104	RFX4	0.29	5.77	0.46	5.9e-8	Heart rate;
TGCT	cis	rs2204008	0.775	rs8186812	chr12:38305055	C/T	cg26384229	chr12:38710491	ALG10B	0.78	6.9	0.53	2.33e-10	Bladder cancer;
TGCT	cis	rs9435341	0.860	rs12406721	chr1:107563243	G/T	cg09367891	chr1:107599246	PRMT6	0.66	5.79	0.46	5.32e-8	Facial morphology (factor 21, depth of nasal alae);
TGCT	cis	rs4820539	0.966	rs2283803	chr22:23454881	G/A	cg21100191	chr22:23484243	RTDR1	0.9	10.8	0.7	1.43e-19	Bone mineral density;
TGCT	cis	rs797680	0.822	rs2297707	chr1:93646207	T/C	cg17826107	chr1:92977322	EVI5	-0.24	-5.24	-0.43	6.59e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs2115630	1.000	rs4633690	chr15:85361960	C/T	cg12501888	chr15:85177176	SCAND2	-0.53	-4.92	-0.4	2.69e-6	P wave terminal force;
TGCT	cis	rs7681440	0.904	rs7680761	chr4:90763510	A/T	cg20003494	chr4:90757398	SNCA	-0.63	-6.09	-0.48	1.3e-8	Dementia with Lewy bodies;
TGCT	cis	rs6121246	0.909	rs6060979	chr20:30417522	C/T	cg13852791	chr20:30311386	BCL2L1	0.77	5.69	0.46	8.57e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs28735056	1.000	rs4798922	chr18:77628953	G/C	cg20368463	chr18:77673604	PQLC1	-0.45	-5.55	-0.45	1.65e-7	Schizophrenia;
TGCT	cis	rs797680	0.856	rs1535701	chr1:93805201	T/G	cg17826107	chr1:92977322	EVI5	-0.23	-5.16	-0.42	9.63e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs7208859	0.673	rs9915963	chr17:29019643	C/T	cg04154034	chr17:28927549	LRRC37B2	0.75	4.47	0.37	1.73e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs12477438	0.520	rs11883676	chr2:99800814	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	13.05	0.76	4.93e-25	Chronic sinus infection;
TGCT	cis	rs3027234	0.727	rs79107119	chr17:8208481	G/C	cg08322244	chr17:8066669	VAMP2	-0.57	-5.33	-0.43	4.55e-7	Telomere length;
TGCT	cis	rs1982963	1.000	rs3818187	chr14:52509788	A/G	cg10843707	chr14:52510701	NID2	0.43	6.57	0.51	1.22e-9	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2762353	0.904	rs13197514	chr6:25785991	C/T	cg12310025	chr6:25882481	NA	0.52	5.34	0.43	4.19e-7	Blood metabolite levels;
TGCT	cis	rs9902453	0.933	rs7221154	chr17:28505024	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-5.47	-0.44	2.42e-7	Coffee consumption (cups per day);
TGCT	cis	rs6121246	0.697	rs6088856	chr20:30226543	C/G	cg18721089	chr20:30220636	NA	-0.55	-5.72	-0.46	7.56e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs11098499	0.909	rs1809406	chr4:120377122	G/A	cg09307838	chr4:120376055	NA	0.71	6.98	0.53	1.57e-10	Corneal astigmatism;
TGCT	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg22433210	chr17:43662623	NA	1.04	7.37	0.55	2.07e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs909674	0.731	rs6001594	chr22:39837472	C/T	cg01416388	chr22:39784598	NA	-0.74	-6.73	-0.52	5.61e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg08439880	chr3:133502540	NA	-0.37	-7.01	-0.53	1.39e-10	Iron status biomarkers;
TGCT	cis	rs7216064	1.000	rs59950564	chr17:65860859	A/G	cg12091567	chr17:66097778	LOC651250	-0.83	-6.49	-0.5	1.9e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs2730260	0.537	rs73169239	chr7:158884305	C/A	cg27122614	chr7:157913741	PTPRN2	0.42	4.47	0.37	1.74e-5	Myopia (pathological);
TGCT	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.96	-11.08	-0.71	3.04e-20	Menarche (age at onset);
TGCT	cis	rs11864453	0.749	rs7192730	chr16:72124219	T/C	cg14768367	chr16:72042858	DHODH	0.5	4.8	0.4	4.5e-6	Fibrinogen levels;
TGCT	cis	rs12478296	1.000	rs73007140	chr2:243010756	T/C	cg06360820	chr2:242988706	NA	-0.6	-4.96	-0.41	2.23e-6	Obesity-related traits;
TGCT	cis	rs9467773	1.000	rs9467778	chr6:26534743	T/C	cg05738196	chr6:26577821	NA	0.88	12.5	0.75	1.03e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs611744	0.967	rs645070	chr8:109216345	A/C	cg21045802	chr8:109455806	TTC35	0.52	4.72	0.39	6.21e-6	Dupuytren's disease;
TGCT	cis	rs4699052	0.963	rs6533066	chr4:104163607	C/G	cg16532752	chr4:104119610	CENPE	-0.62	-5.78	-0.46	5.79e-8	Testicular germ cell tumor;
TGCT	cis	rs9796	0.621	rs690733	chr15:41476465	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.52	-7.17	-0.54	5.94e-11	Menopause (age at onset);
TGCT	cis	rs9611565	0.512	rs5758450	chr22:42141640	G/A	cg06481639	chr22:41940642	POLR3H	0.68	6.01	0.48	1.9e-8	Vitiligo;
TGCT	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.76	5.05	0.41	1.51e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs1124769	0.525	rs11070812	chr15:51062492	G/T	cg23028286	chr15:51614521	CYP19A1	0.19	4.47	0.37	1.75e-5	Cognitive performance;
TGCT	cis	rs6088580	0.634	rs6087579	chr20:32985155	A/G	cg06115741	chr20:33292138	TP53INP2	-0.55	-4.81	-0.4	4.28e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs586688	1.000	rs647130	chr1:201637982	A/G	cg07139329	chr1:201708558	NAV1	-0.41	-4.52	-0.38	1.41e-5	Obesity-related traits;
TGCT	cis	rs6977955	1.000	rs67250450	chr7:28174986	T/C	cg23620719	chr7:28220237	JAZF1	0.65	4.9	0.4	2.94e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs16958440	0.867	rs78854354	chr18:44666924	C/G	cg17192377	chr18:44677553	HDHD2	0.65	4.67	0.39	7.78e-6	Sitting height ratio;
TGCT	cis	rs2404602	0.716	rs12594577	chr15:76828793	A/C	cg22467129	chr15:76604101	ETFA	-0.56	-6.65	-0.51	8.35e-10	Blood metabolite levels;
TGCT	cis	rs910316	1.000	rs4903279	chr14:75546583	C/T	cg11812906	chr14:75593930	NEK9	0.74	7.25	0.55	3.9e-11	Height;
TGCT	cis	rs9467711	1.000	rs6939978	chr6:26328462	G/C	cg26531700	chr6:26746687	NA	-0.94	-5.09	-0.42	1.28e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs644799	0.965	rs3789960	chr11:95509037	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	10.82	0.7	1.31e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs12210905	1.000	rs12198077	chr6:27169307	A/C	cg08851530	chr6:28072375	NA	1.12	5.43	0.44	2.82e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs11718455	0.653	rs28533958	chr3:43974179	C/A	cg08738300	chr3:44038990	NA	0.75	5.71	0.46	7.9e-8	Coronary artery disease;
TGCT	cis	rs6840360	0.615	rs4696267	chr4:152464500	A/G	cg17479576	chr4:152424074	FAM160A1	-0.72	-7.98	-0.58	8.25e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg09222892	chr1:25734099	RHCE	-0.44	-7.17	-0.54	5.87e-11	Erythrocyte sedimentation rate;
TGCT	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs4555082	1.000	rs7146012	chr14:105757566	G/A	cg10792982	chr14:105748885	BRF1	0.22	4.48	0.37	1.7e-5	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs10465746	0.780	rs2147392	chr1:84404154	C/A	cg10977910	chr1:84465055	TTLL7	0.69	7.07	0.54	9.97e-11	Obesity-related traits;
TGCT	cis	rs7429990	0.813	rs7627568	chr3:48093052	A/T	cg11946769	chr3:48343235	NME6	-0.52	-4.51	-0.38	1.48e-5	Educational attainment (years of education);
TGCT	cis	rs12220238	0.915	rs7922519	chr10:75976573	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.78	0.57	2.42e-12	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs1865760	1.000	rs9358895	chr6:25924655	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.65	6.21	0.49	7.42e-9	Height;
TGCT	cis	rs587847	0.737	rs28672197	chr15:37628310	G/C	cg00216138	chr15:37171175	LOC145845	0.31	4.52	0.38	1.41e-5	Intraocular pressure;
TGCT	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg23758822	chr17:41437982	NA	0.72	6.85	0.52	3.09e-10	Menopause (age at onset);
TGCT	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg23758822	chr17:41437982	NA	0.54	4.45	0.37	1.92e-5	Menopause (age at onset);
TGCT	trans	rs1814175	0.817	rs11040474	chr11:49708441	G/A	cg03929089	chr4:120376271	NA	-0.71	-8.36	-0.6	1.09e-13	Height;
TGCT	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg17971929	chr21:40555470	PSMG1	0.96	9.05	0.63	2.44e-15	Cognitive function;
TGCT	cis	rs4601821	0.858	rs2298489	chr11:113235419	C/T	cg14159747	chr11:113255604	NA	-0.43	-4.86	-0.4	3.53e-6	Alcoholic chronic pancreatitis;
TGCT	cis	rs78456975	1.000	rs11883965	chr2:1560062	T/C	cg01028140	chr2:1542097	TPO	-0.33	-4.53	-0.38	1.37e-5	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs2708977	1.000	rs2708977	chr2:97230074	G/A	cg01950434	chr2:97203154	ARID5A	-0.66	-6.09	-0.48	1.34e-8	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs6835098	1.000	rs2332654	chr4:174088399	C/T	cg08422745	chr4:174089978	GALNT7	-0.95	-11.46	-0.72	3.51e-21	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs2688608	0.620	rs7076525	chr10:75512797	C/T	cg23231163	chr10:75533350	FUT11	-0.28	-4.86	-0.4	3.51e-6	Inflammatory bowel disease;
TGCT	cis	rs7017914	0.967	rs7000647	chr8:71688408	C/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.53	-4.98	-0.41	2.09e-6	Bone mineral density;
TGCT	cis	rs7208859	0.623	rs216439	chr17:28927884	T/C	cg14008862	chr17:28927542	LRRC37B2	0.88	5.32	0.43	4.75e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7091068	0.616	rs7920366	chr10:95497178	A/T	cg20715218	chr10:95462985	C10orf4	0.52	4.62	0.38	9.33e-6	Urinary tract infection frequency;
TGCT	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg22764044	chr5:178986830	RUFY1	0.43	4.87	0.4	3.38e-6	Lung cancer;
TGCT	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.75	5.41	0.44	3.09e-7	Platelet count;
TGCT	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg02463440	chr8:22132932	PIWIL2	0.26	5.14	0.42	1.05e-6	Hypertriglyceridemia;
TGCT	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg22963979	chr7:1858916	MAD1L1	-0.41	-6.43	-0.5	2.5e-9	Bipolar disorder and schizophrenia;
TGCT	cis	rs7100689	0.784	rs7895042	chr10:82095276	G/A	cg01528321	chr10:82214614	TSPAN14	0.8	7.92	0.58	1.15e-12	Post bronchodilator FEV1;
TGCT	cis	rs2797160	1.000	rs6569435	chr6:125998186	T/C	cg05901451	chr6:126070800	HEY2	-0.74	-6.58	-0.51	1.18e-9	Endometrial cancer;
TGCT	cis	rs7746199	0.736	rs6904596	chr6:27491299	G/A	cg01031101	chr6:28227091	NKAPL	-0.53	-4.53	-0.38	1.39e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7829975	0.577	rs7816329	chr8:8543843	G/A	cg15556689	chr8:8085844	FLJ10661	-0.53	-4.5	-0.37	1.53e-5	Mood instability;
TGCT	cis	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg18252515	chr7:66147081	NA	1.13	6.81	0.52	3.7e-10	Diabetic kidney disease;
TGCT	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg05665937	chr4:1216051	CTBP1	0.25	4.68	0.39	7.33e-6	Obesity-related traits;
TGCT	cis	rs4689388	0.926	rs4689394	chr4:6291003	C/G	cg00701064	chr4:6280414	WFS1	-0.38	-4.86	-0.4	3.47e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.62	-6.05	-0.48	1.62e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9400467	0.537	rs55643604	chr6:111490648	T/G	cg15721981	chr6:111408429	SLC16A10	0.69	4.5	0.37	1.56e-5	Blood metabolite levels;Amino acid levels;
TGCT	cis	rs4689388	0.824	rs6446482	chr4:6295693	C/G	cg00701064	chr4:6280414	WFS1	0.4	5.09	0.42	1.28e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs2070488	1.000	rs3792528	chr3:38493303	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.93	9.84	0.66	3.06e-17	Electrocardiographic conduction measures;
TGCT	cis	rs6540559	0.808	rs11119358	chr1:210042456	T/C	cg22442454	chr1:209979470	IRF6	0.63	4.65	0.39	8.22e-6	Cleft lip with or without cleft palate;
TGCT	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg01516881	chr6:292596	DUSP22	-0.81	-8.52	-0.61	4.63e-14	Menopause (age at onset);
TGCT	cis	rs514406	0.547	rs377808	chr1:53190359	T/G	cg08859206	chr1:53392774	SCP2	-0.34	-4.9	-0.4	2.93e-6	Monocyte count;
TGCT	cis	rs11190604	1.000	rs2489040	chr10:102331298	G/A	cg23241863	chr10:102295624	HIF1AN	0.67	5.1	0.42	1.23e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2692947	0.644	rs2969491	chr2:96794982	C/T	cg22654517	chr2:96458247	NA	0.22	4.58	0.38	1.11e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs2204008	0.560	rs4129033	chr12:38301897	A/T	cg26384229	chr12:38710491	ALG10B	-0.54	-4.7	-0.39	6.68e-6	Bladder cancer;
TGCT	cis	rs6840360	0.539	rs1443087	chr4:152450095	C/A	cg17479576	chr4:152424074	FAM160A1	-0.57	-6.02	-0.48	1.85e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs6964587	1.000	rs2282970	chr7:91584281	A/G	cg17063962	chr7:91808500	NA	0.9	9.92	0.67	2e-17	Breast cancer;
TGCT	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg10117171	chr1:25599238	RHD	-0.35	-5.72	-0.46	7.6e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.7	-0.39	6.79e-6	Prudent dietary pattern;
TGCT	cis	rs9807989	0.524	rs7591246	chr2:102999403	C/A	cg03938978	chr2:103052716	IL18RAP	0.26	5.22	0.42	7.15e-7	Asthma;
TGCT	cis	rs13242816	1.000	rs56275709	chr7:116108489	A/G	cg16553024	chr7:116138462	CAV2	-0.43	-4.8	-0.4	4.41e-6	P wave duration;
TGCT	cis	rs6912958	0.712	rs6454640	chr6:88370352	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.49	4.76	0.39	5.4e-6	Monocyte percentage of white cells;
TGCT	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg27588902	chr6:42928151	GNMT	-0.5	-5.96	-0.47	2.49e-8	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs12136530	0.577	rs4481878	chr1:19791086	C/A	cg18923740	chr1:19971790	NBL1	-0.45	-4.9	-0.4	2.91e-6	Lead levels in blood;
TGCT	cis	rs1971256	0.563	rs76363440	chr6:151767483	A/G	cg03627880	chr6:151815985	C6orf97	0.47	4.76	0.39	5.36e-6	Endometriosis;
TGCT	cis	rs28595532	0.920	rs56124677	chr4:119772213	C/T	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs72945132	0.882	rs72949076	chr11:70217695	T/C	cg00319359	chr11:70116639	PPFIA1	0.99	7.21	0.54	4.95e-11	Coronary artery disease;
TGCT	cis	rs13064411	0.735	rs13098166	chr3:113210038	A/G	cg18753928	chr3:113234510	CCDC52	-0.7	-5.75	-0.46	6.6e-8	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs7829975	0.501	rs2980769	chr8:8320291	G/A	cg08975724	chr8:8085496	FLJ10661	0.6	5.44	0.44	2.72e-7	Mood instability;
TGCT	cis	rs1215050	0.791	rs968854	chr4:98837863	T/C	cg17366294	chr4:99064904	C4orf37	0.57	6.13	0.48	1.08e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs4805272	0.512	rs11879141	chr19:29320335	G/A	cg14983838	chr19:29218262	NA	0.69	4.7	0.39	6.67e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
TGCT	cis	rs11190604	1.000	rs2489040	chr10:102331298	G/A	cg16342193	chr10:102329863	NA	-0.42	-5.39	-0.44	3.47e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs10782582	0.609	rs2029680	chr1:76363505	A/C	cg03433033	chr1:76189801	ACADM	-0.5	-4.92	-0.4	2.7e-6	Daytime sleep phenotypes;
TGCT	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg12140144	chr1:2984275	FLJ42875;PRDM16	-0.32	-4.54	-0.38	1.34e-5	Height;
TGCT	cis	rs9329289	0.510	rs12356215	chr10:2545390	C/G	cg07014206	chr10:2547000	NA	-0.28	-4.53	-0.38	1.36e-5	Age-related hearing impairment;
TGCT	cis	rs896854	0.573	rs11996455	chr8:95853708	G/A	cg13393036	chr8:95962371	TP53INP1	-0.51	-6.26	-0.49	5.79e-9	Type 2 diabetes;
TGCT	cis	rs35883536	0.588	rs955337	chr1:101108834	A/T	cg06223162	chr1:101003688	GPR88	0.33	5.61	0.45	1.27e-7	Monocyte count;
TGCT	cis	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg22857025	chr5:266934	NA	-0.31	-6.32	-0.49	4.33e-9	Breast cancer;
TGCT	cis	rs7091068	0.536	rs7893369	chr10:95410147	A/G	cg20715218	chr10:95462985	C10orf4	0.51	5.79	0.46	5.52e-8	Urinary tract infection frequency;
TGCT	cis	rs1799949	0.965	rs4792989	chr17:41437552	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.17	0.42	9.27e-7	Menopause (age at onset);
TGCT	trans	rs1974653	0.672	rs28610569	chr22:20071351	A/G	cg08822737	chr17:71088851	SLC39A11	-0.93	-7.61	-0.56	5.97e-12	Schizophrenia;
TGCT	cis	rs10504229	0.679	rs72649107	chr8:58030453	C/A	cg08280861	chr8:58055591	NA	0.35	5.07	0.41	1.43e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs36051895	0.587	rs7036761	chr9:5198781	A/C	cg02405213	chr9:5042618	JAK2	0.7	8.48	0.61	5.5e-14	Pediatric autoimmune diseases;
TGCT	cis	rs969413	0.624	rs9914093	chr17:79260653	C/G	cg27412613	chr17:79183705	AZI1	-0.23	-4.57	-0.38	1.16e-5	Frontotemporal dementia;
TGCT	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg08280861	chr8:58055591	NA	0.38	4.81	0.4	4.36e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6450176	0.857	rs1541680	chr5:53304725	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.49	-4.6	-0.38	1.03e-5	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.31	-4.76	-0.39	5.36e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs910316	1.000	rs10146482	chr14:75574087	C/T	cg23033748	chr14:75592666	NEK9	0.27	4.66	0.39	8.07e-6	Height;
TGCT	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg11764359	chr7:65958608	NA	0.54	5.02	0.41	1.73e-6	Aortic root size;
TGCT	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg08280861	chr8:58055591	NA	0.39	4.86	0.4	3.45e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6500602	0.819	rs3747580	chr16:4455675	G/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.44	5.65	0.45	1.05e-7	Schizophrenia;
TGCT	cis	rs9916302	0.706	rs2302073	chr17:37457342	A/G	cg07936489	chr17:37558343	FBXL20	0.84	6.23	0.49	6.68e-9	Glomerular filtration rate (creatinine);
TGCT	trans	rs1415174	0.958	rs10873836	chr1:87844420	A/G	cg23065576	chr20:25207247	ENTPD6	-0.27	-6.8	-0.52	3.88e-10	Breast cancer;
TGCT	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg06873352	chr17:61820015	STRADA	0.58	6.39	0.5	3.01e-9	Prudent dietary pattern;
TGCT	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	6.75	0.52	5.18e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs62103177	0.733	rs62096747	chr18:77619568	A/G	cg12964065	chr18:77638022	KCNG2	0.37	4.76	0.39	5.4e-6	Opioid sensitivity;
TGCT	cis	rs7172809	0.573	rs1374201	chr15:77477873	G/A	cg22256960	chr15:77711686	NA	-0.49	-4.63	-0.38	9.01e-6	Glucose homeostasis traits;
TGCT	cis	rs8180040	1.000	rs807936	chr3:47322496	C/T	cg27129171	chr3:47204927	SETD2	0.7	8.89	0.62	5.88e-15	Colorectal cancer;
TGCT	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg04414720	chr1:150670196	GOLPH3L	0.38	4.84	0.4	3.83e-6	Tonsillectomy;
TGCT	cis	rs727563	0.593	rs5758461	chr22:42162189	G/C	cg06481639	chr22:41940642	POLR3H	0.69	6.05	0.48	1.59e-8	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs9913156	0.707	rs9902000	chr17:4582426	A/C	cg00122941	chr17:4613640	ARRB2	-0.84	-7.41	-0.55	1.72e-11	Lymphocyte counts;
TGCT	cis	rs6912958	0.781	rs3757368	chr6:88224495	T/C	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.91	-0.4	2.78e-6	Monocyte percentage of white cells;
TGCT	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg24531977	chr5:56204891	C5orf35	-0.78	-7.67	-0.57	4.41e-12	Initial pursuit acceleration;
TGCT	cis	rs67311347	1.000	rs6599102	chr3:40468406	G/A	cg13683864	chr3:40499215	RPL14	-1.04	-10.79	-0.7	1.54e-19	Renal cell carcinoma;
TGCT	cis	rs360798	0.532	rs360797	chr2:62942840	C/T	cg17519650	chr2:63277830	OTX1	-0.55	-4.73	-0.39	5.96e-6	Coronary artery disease;
TGCT	cis	rs9494142	0.592	rs1547247	chr6:135390836	C/T	cg22676075	chr6:135203613	NA	0.49	4.53	0.38	1.38e-5	Lymphocyte counts;Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg21285383	chr16:89894308	SPIRE2	0.46	7.16	0.54	6.15e-11	Vitiligo;
TGCT	cis	rs7172809	0.897	rs16968895	chr15:77825121	A/G	cg22256960	chr15:77711686	NA	-0.44	-4.48	-0.37	1.67e-5	Glucose homeostasis traits;
TGCT	cis	rs1497406	0.744	rs7538216	chr1:16509671	T/C	cg20430773	chr1:16534157	ARHGEF19	0.55	6.11	0.48	1.18e-8	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg10047753	chr17:41438598	NA	0.96	9.64	0.65	9.37e-17	Menopause (age at onset);
TGCT	cis	rs35306767	0.623	rs34034003	chr10:1143435	G/A	cg20503657	chr10:835505	NA	0.51	5.41	0.44	3.18e-7	Eosinophil percentage of granulocytes;
TGCT	cis	rs41271951	0.512	rs12068365	chr1:151015868	G/A	cg00666978	chr1:150947442	LASS2	0.89	4.64	0.38	8.54e-6	Blood protein levels;
TGCT	cis	rs7829975	0.560	rs6994131	chr8:8550958	G/A	cg06636001	chr8:8085503	FLJ10661	-0.61	-5.31	-0.43	4.81e-7	Mood instability;
TGCT	cis	rs2594989	0.943	rs2454502	chr3:11499331	T/C	cg26283222	chr3:11613257	VGLL4	-0.21	-4.49	-0.37	1.58e-5	Circulating chemerin levels;
TGCT	cis	rs7666738	0.830	rs7662596	chr4:99019962	G/T	cg18180107	chr4:99064573	C4orf37	0.54	5.03	0.41	1.7e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9811920	0.770	rs4928237	chr3:99731330	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.46	5.18	0.42	8.58e-7	Axial length;
TGCT	cis	rs13191362	1.000	rs73035025	chr6:163000988	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs4455778	0.600	rs4244233	chr7:49130572	T/A	cg26309511	chr7:48887640	NA	0.51	6.59	0.51	1.12e-9	Lung cancer in never smokers;
TGCT	cis	rs12477438	0.501	rs7349217	chr2:99815146	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	17.06	0.84	2.55e-34	Chronic sinus infection;
TGCT	cis	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg18252515	chr7:66147081	NA	1.17	7.17	0.54	5.94e-11	Diabetic kidney disease;
TGCT	cis	rs1372520	0.935	rs2245801	chr4:90757840	T/C	cg20003494	chr4:90757398	SNCA	-0.65	-4.89	-0.4	3.12e-6	Neuroticism;
TGCT	cis	rs2072499	0.966	rs2842869	chr1:156160696	A/G	cg24450063	chr1:156163899	SLC25A44	1.19	17.21	0.84	1.15e-34	Testicular germ cell tumor;
TGCT	cis	rs933688	1.000	rs6452951	chr5:90653868	T/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.03	9.42	0.65	3.21e-16	Smoking behavior;
TGCT	cis	rs17345786	1.000	rs997739	chr3:101313940	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.88	9.32	0.64	5.46e-16	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2235642	0.717	rs2236269	chr16:1652614	T/A	cg00463982	chr16:1583984	IFT140;TMEM204	-0.26	-4.46	-0.37	1.79e-5	Coronary artery disease;
TGCT	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg10802521	chr3:52805072	NEK4	-0.7	-8.75	-0.62	1.28e-14	Bipolar disorder;
TGCT	cis	rs7085104	0.700	rs3740397	chr10:104592675	G/C	cg15744005	chr10:104629667	AS3MT	-0.42	-5.22	-0.42	7.24e-7	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs7113874	0.524	rs9300090	chr11:8585384	G/A	cg14521421	chr11:8862019	ST5	0.3	4.6	0.38	1.01e-5	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg20007245	chr22:24372913	LOC391322	0.82	7.03	0.53	1.2e-10	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs78487399	0.614	rs10166376	chr2:43622472	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-4.8	-0.4	4.39e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs11098499	0.954	rs10006525	chr4:120408931	T/G	cg09307838	chr4:120376055	NA	0.69	6.64	0.51	8.97e-10	Corneal astigmatism;
TGCT	cis	rs16854884	0.683	rs2053211	chr3:143774592	C/T	cg06585982	chr3:143692056	C3orf58	-0.53	-4.47	-0.37	1.72e-5	Economic and political preferences (feminism/equality);
TGCT	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	8.99	0.63	3.48e-15	Platelet count;
TGCT	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg11062466	chr8:58055876	NA	0.43	4.52	0.38	1.45e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs709400	0.663	rs7145113	chr14:103945414	A/G	cg26031613	chr14:104095156	KLC1	0.84	9.64	0.65	9.34e-17	Body mass index;
TGCT	trans	rs7726839	0.540	rs4957083	chr5:659343	T/C	cg25482853	chr8:67687455	SGK3	1.2	10.13	0.67	6.02e-18	Obesity-related traits;
TGCT	cis	rs7267979	1.000	rs2259956	chr20:25282433	A/G	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs9951602	0.512	rs8085719	chr18:76649111	A/G	cg02800362	chr5:177631904	HNRNPAB	1.15	13.03	0.76	5.64e-25	Obesity-related traits;
TGCT	cis	rs17345786	0.798	rs4257518	chr3:101281709	C/T	cg12386194	chr3:101231763	SENP7	-0.56	-5.39	-0.44	3.41e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg05665937	chr4:1216051	CTBP1	0.24	4.63	0.38	8.9e-6	Obesity-related traits;
TGCT	cis	rs9296092	0.517	rs9461877	chr6:33516667	C/T	cg13560919	chr6:33536144	NA	-0.2	-4.63	-0.38	9.08e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs13315871	1.000	rs71311870	chr3:58399283	T/C	cg12435725	chr3:58293450	RPP14	-0.43	-4.47	-0.37	1.71e-5	Cholesterol, total;
TGCT	cis	rs2777491	0.957	rs6493002	chr15:41709195	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.75	-11.01	-0.7	4.47e-20	Ulcerative colitis;
TGCT	cis	rs73001065	0.901	rs73004933	chr19:19675696	C/T	cg03709012	chr19:19516395	GATAD2A	1.03	5.03	0.41	1.65e-6	LDL cholesterol;
TGCT	cis	rs7772486	0.692	rs2265915	chr6:146194332	A/T	cg23711669	chr6:146136114	FBXO30	0.97	11.36	0.71	6.35e-21	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9527	0.590	rs34104646	chr10:104896078	T/A	cg04362960	chr10:104952993	NT5C2	0.69	5.82	0.46	4.78e-8	Arsenic metabolism;
TGCT	cis	rs61990749	0.597	rs1048147	chr14:78139988	C/A	cg23188588	chr14:78226832	SNW1;C14orf178	-0.68	-4.76	-0.39	5.29e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs4648739	0.613	rs13303201	chr1:1903712	G/T	cg14196676	chr1:1911069	KIAA1751	-0.48	-7.47	-0.56	1.26e-11	Severe influenza A (H1N1) infection;
TGCT	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg11890956	chr21:40555474	PSMG1	1.12	12.45	0.75	1.39e-23	Cognitive function;
TGCT	cis	rs4663866	0.908	rs35093813	chr2:239153765	T/A	cg17283117	chr2:239148619	HES6	0.98	4.5	0.37	1.55e-5	Irritable bowel syndrome;
TGCT	cis	rs11644362	1.000	rs12934970	chr16:12988077	G/C	cg06890432	chr16:12997467	SHISA9	-0.59	-6.47	-0.5	2.04e-9	Positive affect;Subjective well-being;
TGCT	cis	rs4886920	0.563	rs8037968	chr15:78077762	C/T	cg03457338	chr15:78040120	NA	0.18	4.51	0.38	1.48e-5	Neuroticism;
TGCT	cis	rs9534288	0.797	rs7998854	chr13:46592174	C/A	cg15192986	chr13:46630673	CPB2	-0.53	-7.62	-0.56	5.82e-12	Blood protein levels;
TGCT	cis	rs12479064	0.724	rs112900993	chr2:99948805	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.74	-6.33	-0.49	4.06e-9	Chronic sinus infection;
TGCT	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg00149659	chr3:10157352	C3orf10	0.73	4.72	0.39	6.17e-6	Alzheimer's disease;
TGCT	cis	rs17376456	0.741	rs12374432	chr5:93481348	C/A	cg21475434	chr5:93447410	FAM172A	0.64	4.76	0.39	5.35e-6	Diabetic retinopathy;
TGCT	trans	rs2469997	1.000	rs2469999	chr8:120354695	G/A	cg01792902	chr3:178864926	PIK3CA	0.78	6.66	0.51	7.93e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs78487399	0.908	rs80144434	chr2:43844640	G/C	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.65	4.58	0.38	1.12e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs3733585	0.699	rs6856127	chr4:9965443	T/C	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.67	-0.51	7.44e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs2115630	1.000	rs4633690	chr15:85361960	C/T	cg11189052	chr15:85197271	WDR73	-0.64	-5.97	-0.47	2.31e-8	P wave terminal force;
TGCT	cis	rs2710642	0.888	rs2539985	chr2:63134507	T/A	cg17519650	chr2:63277830	OTX1	0.58	5.07	0.41	1.4e-6	LDL cholesterol levels;LDL cholesterol;
TGCT	cis	rs7809950	0.678	rs3801966	chr7:106824580	G/A	cg23024343	chr7:107201750	COG5	-0.44	-5.82	-0.46	4.67e-8	Coronary artery disease;
TGCT	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg10047753	chr17:41438598	NA	0.97	9.99	0.67	1.37e-17	Menopause (age at onset);
TGCT	cis	rs13242816	1.000	rs4292624	chr7:116102724	A/C	cg16553024	chr7:116138462	CAV2	-0.43	-4.8	-0.4	4.41e-6	P wave duration;
TGCT	cis	rs7917772	0.582	rs10786680	chr10:104317192	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	5.36	0.43	3.84e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2153535	0.563	rs7739249	chr6:8534590	C/G	cg23788917	chr6:8435910	SLC35B3	0.64	5.8	0.46	5.23e-8	Motion sickness;
TGCT	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.46	-6.7	-0.52	6.44e-10	Alzheimer's disease;
TGCT	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2974760	0.606	rs6600143	chr16:201389	A/C	cg08400316	chr16:204221	HBZ	-0.71	-7.56	-0.56	7.85e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs9549367	0.789	rs9549695	chr13:113874814	A/G	cg18105134	chr13:113819100	PROZ	0.29	5.09	0.42	1.31e-6	Platelet distribution width;
TGCT	cis	rs9653442	0.593	rs7597861	chr2:100853187	G/A	cg07810366	chr2:100720526	AFF3	-0.41	-6.21	-0.49	7.19e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs2932538	0.922	rs12136781	chr1:113090655	C/T	cg22162597	chr1:113214053	CAPZA1	0.27	5.89	0.47	3.46e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs3774830	0.714	rs12509727	chr4:5470800	T/G	cg26943120	chr4:5472116	STK32B	0.29	7.0	0.53	1.39e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9902453	0.791	rs57719820	chr17:28335088	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.74	-6.59	-0.51	1.12e-9	Coffee consumption (cups per day);
TGCT	cis	rs2688608	0.560	rs10128354	chr10:75470045	T/C	cg23231163	chr10:75533350	FUT11	-0.27	-4.56	-0.38	1.19e-5	Inflammatory bowel disease;
TGCT	cis	rs67311347	1.000	rs9865348	chr3:40397658	A/C	cg17264618	chr3:40429014	ENTPD3	0.31	4.59	0.38	1.09e-5	Renal cell carcinoma;
TGCT	cis	rs7552404	0.731	rs7523573	chr1:76372020	G/T	cg10523679	chr1:76189770	ACADM	0.82	7.13	0.54	7.21e-11	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2249625	0.545	rs2496495	chr6:72882414	G/A	cg08500200	chr6:72892038	RIMS1	-0.42	-4.54	-0.38	1.33e-5	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
TGCT	trans	rs7618501	0.602	rs7642934	chr3:50174848	G/A	cg21659725	chr3:3221576	CRBN	-0.76	-9.11	-0.63	1.8e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs587847	0.737	rs56383924	chr15:37604790	C/T	cg00216138	chr15:37171175	LOC145845	0.3	4.52	0.38	1.43e-5	Intraocular pressure;
TGCT	cis	rs1483890	0.723	rs6419767	chr3:69412505	G/A	cg22125112	chr3:69402811	FRMD4B	0.29	4.74	0.39	5.85e-6	Resting heart rate;
TGCT	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg02953382	chr22:24373134	LOC391322	0.82	7.01	0.53	1.37e-10	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs854765	0.619	rs1101727	chr17:18016148	T/C	cg04398451	chr17:18023971	MYO15A	-0.38	-6.51	-0.5	1.65e-9	Total body bone mineral density;
TGCT	cis	rs11098499	0.866	rs9991221	chr4:120292107	G/C	cg09307838	chr4:120376055	NA	0.58	5.75	0.46	6.63e-8	Corneal astigmatism;
TGCT	cis	rs228437	0.507	rs440170	chr6:134904442	C/T	cg09872934	chr6:134495829	SGK1	0.51	4.63	0.38	9e-6	Melanoma;
TGCT	cis	rs6831352	0.851	rs1230164	chr4:99986023	C/G	cg12011299	chr4:100065546	ADH4	0.4	4.57	0.38	1.18e-5	Alcohol dependence;
TGCT	cis	rs3858526	0.796	rs9645652	chr11:5944264	C/T	cg05234568	chr11:5960015	NA	-0.45	-4.46	-0.37	1.84e-5	DNA methylation (variation);
TGCT	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg11141652	chr22:24348549	GSTTP1	0.33	4.53	0.38	1.39e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs986417	0.818	rs8005621	chr14:61106699	G/A	cg18240143	chr14:60952599	C14orf39	0.88	4.57	0.38	1.15e-5	Gut microbiota (bacterial taxa);
TGCT	cis	rs7666738	0.830	rs9998682	chr4:98939009	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2932538	0.961	rs12126494	chr1:113228623	G/A	cg22162597	chr1:113214053	CAPZA1	0.24	4.97	0.41	2.21e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	trans	rs8073060	0.505	rs225276	chr17:33973034	T/C	cg19694781	chr19:47549865	TMEM160	-0.6	-13.37	-0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs11148252	0.774	rs7334583	chr13:52930352	G/T	cg00495681	chr13:53174319	NA	-0.57	-5.51	-0.44	1.96e-7	Lewy body disease;
TGCT	cis	rs807669	0.505	rs8142503	chr22:19166717	G/T	cg02655711	chr22:19163373	SLC25A1	0.25	4.67	0.39	7.78e-6	Metabolite levels;
TGCT	trans	rs1814175	0.817	rs10839318	chr11:49657511	G/C	cg15704280	chr7:45808275	SEPT13	-0.73	-8.64	-0.61	2.33e-14	Height;
TGCT	cis	rs2242116	0.932	rs4683301	chr3:46931478	A/T	cg02527881	chr3:46936655	PTH1R	0.31	6.27	0.49	5.55e-9	Birth weight;
TGCT	cis	rs2070433	0.948	rs2839304	chr21:47952650	C/G	cg12379764	chr21:47803548	PCNT	-0.51	-4.56	-0.38	1.22e-5	Lymphocyte counts;
TGCT	cis	rs1371867	0.846	rs1660351	chr8:101275034	C/T	cg00191853	chr8:101177733	SPAG1	-0.22	-4.5	-0.37	1.53e-5	Atrioventricular conduction;
TGCT	cis	rs240764	0.687	rs1336245	chr6:101197640	A/T	cg09795085	chr6:101329169	ASCC3	-0.51	-4.51	-0.38	1.45e-5	Neuroticism;
TGCT	cis	rs7043114	0.525	rs10283572	chr9:95133074	G/A	cg14311495	chr9:95764742	FGD3	-0.22	-4.47	-0.37	1.75e-5	Height;
TGCT	cis	rs9296092	0.538	rs7761464	chr6:33519417	C/A	cg13560919	chr6:33536144	NA	-0.21	-4.75	-0.39	5.5e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs7943191	0.768	rs34065644	chr11:62371938	C/T	cg13298116	chr11:62369859	EML3;MTA2	0.6	7.25	0.55	3.98e-11	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs35146811	0.696	rs1727124	chr7:99804104	T/G	cg00553149	chr7:99775558	STAG3;GPC2	-0.31	-4.62	-0.38	9.32e-6	Coronary artery disease;
TGCT	cis	rs796364	0.762	rs13030712	chr2:200973569	G/A	cg23649088	chr2:200775458	C2orf69	0.43	6.93	0.53	1.98e-10	Schizophrenia;
TGCT	cis	rs3020736	0.500	rs11090076	chr22:42514190	T/C	cg05082376	chr22:42548792	NA	0.23	5.43	0.44	2.83e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12049351	0.774	rs6678721	chr1:229623131	G/C	cg12130225	chr1:229698885	NA	0.39	4.59	0.38	1.06e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs9611565	0.512	rs4820446	chr22:42215684	C/T	cg03806693	chr22:41940476	POLR3H	-1.03	-10.47	-0.68	9.18e-19	Vitiligo;
TGCT	cis	rs79976124	0.876	rs17511913	chr6:66644361	C/T	cg07460842	chr6:66804631	NA	0.57	5.22	0.42	7.44e-7	Type 2 diabetes;
TGCT	cis	rs2440129	0.632	rs13396	chr17:6905624	T/C	cg05215272	chr17:6899095	ALOX12	0.57	6.79	0.52	4.04e-10	Tonsillectomy;
TGCT	cis	rs9549367	0.826	rs35306827	chr13:113869045	G/A	cg00898013	chr13:113819073	PROZ	-0.42	-5.19	-0.42	8.26e-7	Platelet distribution width;
TGCT	cis	rs950027	0.620	rs1145084	chr15:45675440	G/A	cg26924012	chr15:45694286	SPATA5L1	0.8	8.85	0.62	7.53e-15	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs910316	0.967	rs35446981	chr14:75637351	A/T	cg23033748	chr14:75592666	NEK9	-0.28	-4.84	-0.4	3.84e-6	Height;
TGCT	cis	rs10464366	0.746	rs17171537	chr7:39145647	C/T	cg18850127	chr7:39170497	POU6F2	0.3	6.61	0.51	1e-9	IgG glycosylation;
TGCT	cis	rs208520	0.586	rs208442	chr6:66900618	T/A	cg07460842	chr6:66804631	NA	-0.67	-6.69	-0.52	6.82e-10	Exhaled nitric oxide output;
TGCT	cis	rs56104184	0.723	rs73063522	chr19:49408358	C/G	cg17863274	chr19:49399704	TULP2	-0.54	-7.43	-0.55	1.58e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.69	-7.06	-0.54	1.07e-10	Prostate cancer;
TGCT	cis	rs7507204	0.680	rs12975645	chr19:3419132	A/G	cg08380311	chr19:3435252	NFIC	0.96	8.22	0.59	2.32e-13	Height;
TGCT	cis	rs73001065	0.591	rs56273306	chr19:19621004	T/C	cg03709012	chr19:19516395	GATAD2A	0.93	4.98	0.41	2.1e-6	LDL cholesterol;
TGCT	cis	rs11098499	0.863	rs3775854	chr4:120471971	C/T	cg09307838	chr4:120376055	NA	0.72	6.9	0.53	2.41e-10	Corneal astigmatism;
TGCT	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg13695892	chr22:41940480	POLR3H	-0.89	-8.88	-0.62	6.27e-15	Vitiligo;
TGCT	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	15.94	0.82	8.5e-32	Prudent dietary pattern;
TGCT	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg19318889	chr4:1322082	MAEA	0.27	6.66	0.51	8.13e-10	Longevity;
TGCT	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg27170947	chr2:26402098	FAM59B	-0.39	-4.46	-0.37	1.8e-5	Gut microbiome composition (summer);
TGCT	cis	rs17601876	0.843	rs28490942	chr15:51559845	G/C	cg19946085	chr15:51559439	CYP19A1	-0.33	-4.98	-0.41	2.04e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs6671200	1.000	rs34037437	chr1:95660921	C/G	cg20701556	chr1:95698924	RWDD3	0.65	5.58	0.45	1.43e-7	Stearic acid (18:0) levels;
TGCT	cis	rs2832191	1.000	rs6516891	chr21:30483070	C/T	cg08807101	chr21:30365312	RNF160	-0.49	-4.48	-0.37	1.65e-5	Dental caries;
TGCT	cis	rs7617480	0.587	rs9311431	chr3:48848787	T/A	cg07636037	chr3:49044803	WDR6	0.79	6.43	0.5	2.54e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs7267979	0.873	rs6115093	chr20:25210730	C/T	cg16686733	chr20:25566563	NINL	0.59	6.06	0.48	1.52e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs5769707	0.846	rs5770610	chr22:50036897	A/C	cg05373962	chr22:49881684	NA	-0.31	-6.42	-0.5	2.6e-9	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs910316	0.874	rs61980828	chr14:75630378	G/A	cg11812906	chr14:75593930	NEK9	-0.75	-7.44	-0.56	1.43e-11	Height;
TGCT	cis	rs2439831	0.867	rs2242068	chr15:43699304	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.06	7.75	0.57	2.79e-12	Lung cancer in ever smokers;
TGCT	cis	rs6964587	1.000	rs2282975	chr7:91761638	A/G	cg22709100	chr7:91322751	NA	0.28	4.52	0.38	1.44e-5	Breast cancer;
TGCT	cis	rs6589563	0.609	rs56224630	chr11:116627097	G/A	cg20660624	chr11:117307972	DSCAML1	-0.38	-4.99	-0.41	2.02e-6	Eosinophil counts;
TGCT	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg18230493	chr5:56204884	C5orf35	0.85	6.61	0.51	1.05e-9	Initial pursuit acceleration;
TGCT	cis	rs4888262	0.508	rs7189123	chr16:74540097	C/A	cg01733217	chr16:74700730	RFWD3	0.68	6.88	0.53	2.6200000000000003e-10	Testicular germ cell tumor;
TGCT	cis	rs9467711	0.538	rs35942482	chr6:26444938	T/A	cg10795676	chr6:26370623	BTN3A2	-0.45	-4.56	-0.38	1.23e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1891498	0.602	rs10793706	chr1:147243753	C/G	cg17941330	chr1:147245494	GJA5	0.36	4.81	0.4	4.36e-6	Cognitive performance;
TGCT	cis	rs2594989	0.836	rs1546231	chr3:11513678	T/G	cg00170343	chr3:11313890	ATG7	0.7	5.22	0.42	7.17e-7	Circulating chemerin levels;
TGCT	cis	rs7666738	0.830	rs10470894	chr4:99039107	G/A	cg17366294	chr4:99064904	C4orf37	0.73	7.49	0.56	1.11e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9611565	0.568	rs2413656	chr22:42129357	G/T	cg06481639	chr22:41940642	POLR3H	0.55	4.62	0.38	9.38e-6	Vitiligo;
TGCT	cis	rs4689388	0.889	rs13128674	chr4:6294517	C/T	cg14416269	chr4:6271139	WFS1	0.37	4.9	0.4	2.95e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs1865760	0.865	rs9467641	chr6:25947236	T/C	cg17042849	chr6:26104293	HIST1H4C	-0.52	-4.78	-0.39	4.97e-6	Height;
TGCT	cis	rs9341808	0.718	rs9352806	chr6:80980057	G/T	cg08355045	chr6:80787529	NA	0.28	4.75	0.39	5.41e-6	Sitting height ratio;
TGCT	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg03517284	chr6:25882590	NA	0.53	5.48	0.44	2.3e-7	Blood metabolite levels;
TGCT	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg17971929	chr21:40555470	PSMG1	-0.67	-6.27	-0.49	5.46e-9	Cognitive function;
TGCT	cis	rs2075671	0.903	rs11983334	chr7:100302434	C/T	cg20848291	chr7:100343083	ZAN	-0.52	-4.56	-0.38	1.21e-5	Other erythrocyte phenotypes;
TGCT	cis	rs11190604	1.000	rs2489037	chr10:102319918	A/G	cg16342193	chr10:102329863	NA	0.43	5.39	0.44	3.43e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs59107033	0.563	rs6802207	chr3:123124811	A/C	cg04890266	chr3:123102914	ADCY5	-0.37	-5.59	-0.45	1.39e-7	Lymphocyte counts;
TGCT	cis	rs9549260	0.651	rs57735994	chr13:41226561	C/G	cg21288729	chr13:41239152	FOXO1	0.99	10.42	0.68	1.22e-18	Red blood cell count;
TGCT	cis	rs9911578	0.935	rs34523895	chr17:57034095	T/C	cg12560992	chr17:57184187	TRIM37	0.73	8.7	0.62	1.69e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs2050392	0.517	rs603072	chr10:30755778	C/T	cg18806716	chr10:30721971	MAP3K8	0.56	6.76	0.52	4.92e-10	Inflammatory bowel disease;
TGCT	cis	rs56104184	0.725	rs1466896	chr19:49385253	C/G	cg21252483	chr19:49399788	TULP2	-0.42	-5.89	-0.47	3.47e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs2074585	0.647	rs2601178	chr15:90919333	T/C	cg22089800	chr15:90895588	ZNF774	0.82	9.04	0.63	2.61e-15	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
TGCT	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg05368731	chr17:41323189	NBR1	1.08	11.0	0.7	4.76e-20	Menopause (age at onset);
TGCT	cis	rs35306767	0.903	rs10508208	chr10:910983	C/T	cg20503657	chr10:835505	NA	0.74	10.3	0.68	2.41e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs2075371	0.796	rs1978504	chr7:134006933	C/T	cg11752832	chr7:134001865	SLC35B4	-0.69	-6.15	-0.48	9.86e-9	Mean platelet volume;
TGCT	cis	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg06671706	chr8:8559999	CLDN23	0.33	4.48	0.37	1.65e-5	Obesity-related traits;
TGCT	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg23758822	chr17:41437982	NA	0.68	6.6	0.51	1.06e-9	Menopause (age at onset);
TGCT	cis	rs7267979	1.000	rs401166	chr20:25446308	C/G	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2832191	0.692	rs2245517	chr21:30357968	C/T	cg24692254	chr21:30365293	RNF160	1.01	11.79	0.73	5.45e-22	Dental caries;
TGCT	cis	rs3087591	1.000	rs4541129	chr17:29442878	T/C	cg24425628	chr17:29625626	OMG;NF1	0.46	7.29	0.55	3.12e-11	Hip circumference;
TGCT	cis	rs9467773	0.967	rs6456732	chr6:26514445	T/C	cg15659132	chr6:26577336	NA	0.86	12.21	0.74	5.3e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs9379850	0.730	rs9393738	chr6:26620658	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.55	-5.08	-0.42	1.35e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg10876282	chr6:28092338	ZSCAN16	0.5	4.6	0.38	1.01e-5	Parkinson's disease;
TGCT	cis	rs9915657	0.773	rs9900977	chr17:70110438	A/G	cg06234051	chr17:70120541	SOX9	-0.26	-5.23	-0.43	6.84e-7	Thyroid hormone levels;
TGCT	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg05985448	chr10:134359359	INPP5A	0.21	4.5	0.37	1.52e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs1344694	0.548	rs12468812	chr2:216905867	C/T	cg12620499	chr2:216877984	MREG	0.82	8.57	0.61	3.44e-14	Alcohol dependence;
TGCT	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg22535103	chr8:58192502	C8orf71	-0.41	-4.81	-0.4	4.27e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs778371	0.871	rs2675954	chr2:233750627	C/G	cg25237894	chr2:233734115	C2orf82	-0.25	-4.53	-0.38	1.37e-5	Schizophrenia;
TGCT	cis	rs2075371	1.000	rs378358	chr7:133970628	A/G	cg11752832	chr7:134001865	SLC35B4	0.66	6.11	0.48	1.19e-8	Mean platelet volume;
TGCT	cis	rs939658	0.567	rs11631829	chr15:79446529	C/T	cg17916960	chr15:79447300	NA	-0.4	-5.65	-0.45	1.03e-7	Refractive error;
TGCT	cis	rs868036	0.681	rs28670272	chr15:68109907	C/T	cg05925327	chr15:68127851	NA	0.5	4.85	0.4	3.57e-6	Restless legs syndrome;
TGCT	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg04944784	chr2:26401820	FAM59B	0.76	6.24	0.49	6.46e-9	Gut microbiome composition (summer);
TGCT	cis	rs5769765	0.865	rs4824108	chr22:50271428	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	1.11	11.76	0.73	6.5e-22	Schizophrenia;
TGCT	cis	rs7552404	0.691	rs61770550	chr1:76366966	C/T	cg10523679	chr1:76189770	ACADM	0.85	7.54	0.56	8.71e-12	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg04944784	chr2:26401820	FAM59B	-0.68	-6.04	-0.48	1.7e-8	Gut microbiome composition (summer);
TGCT	cis	rs56104184	0.779	rs17272666	chr19:49356294	T/C	cg17863274	chr19:49399704	TULP2	-0.45	-5.4	-0.44	3.22e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg06481639	chr22:41940642	POLR3H	0.73	6.61	0.51	1.03e-9	Vitiligo;
TGCT	cis	rs2013441	1.000	rs2703794	chr17:20073338	T/C	cg23224458	chr17:20280056	CCDC144C	0.38	4.61	0.38	9.96e-6	Obesity-related traits;
TGCT	cis	rs4819852	1.000	rs4819852	chr22:19988167	G/A	cg07821417	chr22:19972146	ARVCF	0.2	5.14	0.42	1.04e-6	Pulse pressure;
TGCT	cis	rs524281	0.637	rs7126075	chr11:65940563	T/G	cg00563793	chr11:65837595	PACS1	0.56	4.72	0.39	6.28e-6	Electroencephalogram traits;
TGCT	cis	rs3924048	0.574	rs11121925	chr1:12613130	A/C	cg00291366	chr1:12616550	NA	0.33	4.95	0.41	2.41e-6	Optic cup area;
TGCT	cis	rs3820068	0.603	rs6429767	chr1:15963334	G/A	cg05660106	chr1:15850417	CASP9	0.83	8.19	0.59	2.78e-13	Systolic blood pressure;
TGCT	cis	rs12681288	0.862	rs2600487	chr8:1016903	C/T	cg04851639	chr8:1020857	NA	-0.4	-7.51	-0.56	9.9e-12	Schizophrenia;
TGCT	cis	rs11931598	0.514	rs10937779	chr4:7039326	G/A	cg02503808	chr4:7069936	GRPEL1	0.65	6.65	0.51	8.57e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs68170813	0.559	rs2189501	chr7:106942766	A/T	cg02696742	chr7:106810147	HBP1	-0.69	-5.81	-0.46	4.85e-8	Coronary artery disease;
TGCT	cis	rs10744422	1.000	rs937766	chr12:123331094	G/T	cg25930673	chr12:123319894	HIP1R	-0.86	-5.02	-0.41	1.72e-6	Schizophrenia;
TGCT	cis	rs9653442	0.704	rs10211595	chr2:100726476	G/C	cg22139774	chr2:100720529	AFF3	-0.42	-7.49	-0.56	1.1e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs7208859	0.673	rs216411	chr17:28903493	T/C	cg14008862	chr17:28927542	LRRC37B2	-0.76	-4.71	-0.39	6.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg21280719	chr6:42927975	GNMT	0.37	4.59	0.38	1.07e-5	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs13082711	0.522	rs515402	chr3:27331022	G/T	cg02860705	chr3:27208620	NA	0.34	5.58	0.45	1.43e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs7312774	0.618	rs61061573	chr12:107372758	T/C	cg16260113	chr12:107380972	MTERFD3	1.0	5.13	0.42	1.07e-6	Severe influenza A (H1N1) infection;
TGCT	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg14820908	chr5:178986412	RUFY1	0.61	6.78	0.52	4.37e-10	Lung cancer;
TGCT	cis	rs4819052	0.620	rs421619	chr21:46546115	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.53	0.38	1.39e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6570726	1.000	rs405622	chr6:145871897	G/T	cg05347473	chr6:146136440	FBXO30	0.5	4.46	0.37	1.82e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7681440	0.904	rs28734152	chr4:90767359	C/T	cg20003494	chr4:90757398	SNCA	-0.62	-5.93	-0.47	2.74e-8	Dementia with Lewy bodies;
TGCT	cis	rs889312	0.500	rs832585	chr5:56125904	T/C	cg12311346	chr5:56204834	C5orf35	-0.47	-5.03	-0.41	1.7e-6	Breast cancer;Breast cancer (early onset);
TGCT	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg10047753	chr17:41438598	NA	0.71	6.47	0.5	2.02e-9	Menopause (age at onset);
TGCT	cis	rs2290416	0.688	rs62522171	chr8:144690832	C/A	cg08017634	chr8:144659831	NAPRT1	0.51	4.68	0.39	7.36e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs1008375	0.966	rs2286773	chr4:17616214	C/A	cg10189774	chr4:17578691	LAP3	0.61	5.34	0.43	4.35e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs938554	0.501	rs7671266	chr4:10056376	C/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-5.17	-0.42	8.92e-7	Blood metabolite levels;
TGCT	cis	rs227917	1.000	rs10253843	chr7:23684965	C/T	cg12601843	chr7:23510954	IGF2BP3	0.59	4.67	0.39	7.83e-6	Common carotid intima-media thickness in HIV negative individuals;
TGCT	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg26338869	chr17:61819248	STRADA	-0.53	-4.9	-0.4	2.95e-6	Prudent dietary pattern;
TGCT	cis	rs11190604	1.000	rs3750720	chr10:102248884	C/T	cg16342193	chr10:102329863	NA	-0.42	-5.46	-0.44	2.49e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs911555	0.723	rs6575986	chr14:103886671	G/A	cg23461800	chr14:103021989	NA	0.33	4.46	0.37	1.83e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg11494091	chr17:61959527	GH2	0.42	7.02	0.53	1.3e-10	Height;
TGCT	cis	rs910316	0.664	rs2098252	chr14:75492732	T/C	cg11812906	chr14:75593930	NEK9	0.59	5.59	0.45	1.36e-7	Height;
TGCT	cis	rs1801251	1.000	rs2100053	chr2:233719516	G/T	cg25237894	chr2:233734115	C2orf82	-0.33	-5.91	-0.47	3.13e-8	Coronary artery disease;
TGCT	cis	rs7917772	0.502	rs2296583	chr10:104244322	T/G	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg24675658	chr1:53192096	ZYG11B	0.76	8.75	0.62	1.3e-14	Monocyte count;
TGCT	cis	rs734999	0.588	rs867435	chr1:2523706	C/T	cg18854424	chr1:2615690	NA	0.45	5.17	0.42	9.18e-7	Ulcerative colitis;
TGCT	cis	rs3796352	1.000	rs13072395	chr3:52980573	T/C	cg07884673	chr3:53033167	SFMBT1	0.63	5.74	0.46	6.83e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg11644478	chr21:40555479	PSMG1	1.0	10.04	0.67	9.98e-18	Cognitive function;
TGCT	cis	rs6545883	0.929	rs2264100	chr2:61670829	G/A	cg15711740	chr2:61764176	XPO1	-0.56	-5.07	-0.41	1.42e-6	Tuberculosis;
TGCT	cis	rs2455799	0.594	rs11128769	chr3:15926230	C/T	cg16303742	chr3:15540471	COLQ	-0.24	-4.51	-0.38	1.51e-5	Mean platelet volume;
TGCT	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.8	6.5	0.5	1.75e-9	Mean platelet volume;
TGCT	cis	rs7666738	0.822	rs6815312	chr4:99058220	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.45	0.56	1.4e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs727563	0.636	rs2413653	chr22:42106996	T/C	cg03806693	chr22:41940476	POLR3H	1.08	11.99	0.73	1.84e-22	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg00684032	chr4:1343700	KIAA1530	0.23	4.93	0.41	2.55e-6	Obesity-related traits;
TGCT	trans	rs629535	0.590	rs62513427	chr8:70138891	A/T	cg21567404	chr3:27674614	NA	-0.52	-7.76	-0.57	2.74e-12	Dupuytren's disease;
TGCT	cis	rs60871478	0.636	rs55663559	chr7:884057	G/A	cg00475322	chr7:917719	C7orf20	0.49	4.79	0.39	4.72e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs362272	0.545	rs2236052	chr4:3318413	C/T	cg06533319	chr4:3265114	C4orf44	0.26	5.32	0.43	4.74e-7	Serum sulfate level;
TGCT	cis	rs35306767	0.855	rs61830931	chr10:932497	T/C	cg26597838	chr10:835615	NA	0.81	12.42	0.74	1.61e-23	Eosinophil percentage of granulocytes;
TGCT	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg20607798	chr8:58055168	NA	0.66	5.58	0.45	1.46e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs78487399	0.808	rs7599799	chr2:43685493	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-5.19	-0.42	8.37e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs7553864	0.614	rs4559475	chr1:87614236	T/C	cg17420885	chr1:87600446	LOC339524	-0.37	-4.89	-0.4	3.04e-6	Smoking behavior;
TGCT	cis	rs3008870	1.000	rs3008854	chr1:67385951	T/C	cg03991309	chr1:68237761	GNG12	0.27	4.56	0.38	1.23e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs79976124	0.800	rs10944857	chr6:66637078	C/T	cg07460842	chr6:66804631	NA	0.58	5.12	0.42	1.14e-6	Type 2 diabetes;
TGCT	cis	rs12711979	0.509	rs13000873	chr2:3823705	T/C	cg17052675	chr2:3827356	NA	-0.55	-12.73	-0.75	2.94e-24	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs3772130	0.545	rs7340674	chr3:121574215	T/C	cg20356878	chr3:121714668	ILDR1	0.38	4.84	0.4	3.71e-6	Cognitive performance;
TGCT	trans	rs941408	1.000	rs1736180	chr19:2796021	C/T	cg19676328	chr12:49525230	TUBA1B	-0.74	-7.25	-0.55	3.98e-11	Total cholesterol levels;
TGCT	cis	rs2677744	0.657	rs11073961	chr15:91483392	A/G	cg23684204	chr15:91497937	RCCD1	0.32	4.71	0.39	6.47e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs1475911	1.000	rs2839466	chr21:43512324	A/G	cg14562523	chr21:43528734	C21orf128;UMODL1	0.24	4.73	0.39	5.99e-6	IgG glycosylation;
TGCT	cis	rs2997457	1.000	rs2997457	chr1:26343112	A/G	cg07766612	chr1:26372887	SLC30A2	-0.64	-4.78	-0.39	4.93e-6	Facial morphology (factor 16);
TGCT	cis	rs1801251	0.964	rs10933411	chr2:233706847	A/G	cg25237894	chr2:233734115	C2orf82	-0.33	-5.94	-0.47	2.71e-8	Coronary artery disease;
TGCT	cis	rs2820315	1.000	rs2820312	chr1:201869257	G/A	cg12730843	chr1:201915899	LMOD1	-0.27	-4.73	-0.39	6.07e-6	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
TGCT	cis	rs78487399	0.808	rs13405776	chr2:43739121	C/T	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.76	4.68	0.39	7.27e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs7635838	0.617	rs347590	chr3:11289561	G/A	cg00170343	chr3:11313890	ATG7	0.65	6.44	0.5	2.4e-9	HDL cholesterol;
TGCT	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg24846343	chr22:24311635	DDTL	0.19	4.47	0.37	1.77e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6840360	0.692	rs1838043	chr4:152411462	T/C	cg17479576	chr4:152424074	FAM160A1	-0.5	-5.03	-0.41	1.65e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1008375	0.897	rs67455495	chr4:17665238	A/T	cg18681998	chr4:17616180	MED28	-0.94	-9.83	-0.66	3.2e-17	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2276314	1.000	rs58054756	chr18:33554053	G/C	cg05985134	chr18:33552581	C18orf21	0.54	4.82	0.4	4.12e-6	Endometriosis;Drug-induced torsades de pointes;
TGCT	cis	rs78487399	0.808	rs17030845	chr2:43687879	C/T	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.74	4.77	0.39	5.16e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs854765	0.647	rs741782	chr17:18019712	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	7.37	0.55	2.15e-11	Total body bone mineral density;
TGCT	cis	rs7647973	0.925	rs6446256	chr3:49224210	A/G	cg05785598	chr3:49045655	WDR6	0.38	4.68	0.39	7.48e-6	Menarche (age at onset);
TGCT	cis	rs7647973	1.000	rs9871024	chr3:49554241	T/C	cg07636037	chr3:49044803	WDR6	-0.65	-5.35	-0.43	4.01e-7	Menarche (age at onset);
TGCT	cis	rs4455778	0.580	rs7808082	chr7:49124973	T/C	cg26309511	chr7:48887640	NA	0.51	6.62	0.51	9.97e-10	Lung cancer in never smokers;
TGCT	cis	rs7586879	0.575	rs6706316	chr2:25128351	C/G	cg01884057	chr2:25150051	NA	0.35	6.9	0.53	2.39e-10	Body mass index;
TGCT	cis	rs861020	0.771	rs1962735	chr1:210012102	A/G	cg05527609	chr1:210001259	C1orf107	0.99	9.24	0.64	8.92e-16	Orofacial clefts;
TGCT	cis	rs6725041	0.792	rs4638732	chr2:213090070	A/C	cg20637307	chr2:213403960	ERBB4	-0.52	-4.47	-0.37	1.72e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs9910055	0.529	rs228767	chr17:42188311	C/G	cg19774624	chr17:42201019	HDAC5	0.75	7.13	0.54	7.4e-11	Total body bone mineral density;
TGCT	cis	rs644799	0.526	rs542509	chr11:95641602	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.47	5.01	0.41	1.87e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs1552244	0.554	rs13079240	chr3:10047246	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.33	-4.95	-0.41	2.39e-6	Alzheimer's disease;
TGCT	cis	rs6815814	0.898	rs2174284	chr4:38859339	C/T	cg02016764	chr4:38805732	TLR1	-0.36	-5.4	-0.44	3.33e-7	Breast cancer;
TGCT	cis	rs1534166	0.647	rs9853615	chr3:133519981	C/T	cg16414030	chr3:133502952	NA	-0.46	-6.0	-0.47	2.01e-8	Alcohol consumption (transferrin glycosylation);
TGCT	cis	rs9611565	0.765	rs727563	chr22:41867377	C/T	cg02107564	chr22:41488750	EP300	0.56	4.61	0.38	9.88e-6	Vitiligo;
TGCT	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg20607798	chr8:58055168	NA	0.65	5.43	0.44	2.86e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7264396	0.635	rs6121073	chr20:34457513	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.04	-0.41	1.58e-6	Total cholesterol levels;
TGCT	cis	rs11122272	0.766	rs2790872	chr1:231540543	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-6.09	-0.48	1.32e-8	Hemoglobin concentration;
TGCT	cis	rs6438424	0.521	rs12634615	chr3:117748947	A/G	cg15509235	chr3:117715573	NA	0.54	5.37	0.43	3.79e-7	Menarche (age at onset);
TGCT	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg12310025	chr6:25882481	NA	-0.65	-5.67	-0.45	9.54e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs11030122	0.661	rs12290747	chr11:3939650	T/C	cg18678763	chr11:4115507	RRM1	-0.49	-6.14	-0.48	1.01e-8	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs17376456	0.542	rs10061069	chr5:93071630	G/C	cg21475434	chr5:93447410	FAM172A	0.64	6.04	0.48	1.69e-8	Diabetic retinopathy;
TGCT	cis	rs7674212	0.570	rs2711899	chr4:104062414	T/C	cg16532752	chr4:104119610	CENPE	-0.66	-6.02	-0.48	1.86e-8	Type 2 diabetes;
TGCT	cis	rs3784262	1.000	rs11855259	chr15:58249377	C/G	cg12031962	chr15:58353849	ALDH1A2	-0.5	-7.76	-0.57	2.71e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs4332037	0.552	rs11773627	chr7:2002733	A/G	cg25834613	chr7:1915315	MAD1L1	-0.46	-4.73	-0.39	6.06e-6	Bipolar disorder;
TGCT	cis	rs2046867	0.862	rs6766747	chr3:72856551	T/C	cg25664220	chr3:72788482	NA	-0.56	-7.05	-0.53	1.1e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs11644362	0.966	rs1433747	chr16:12992147	C/A	cg06890432	chr16:12997467	SHISA9	-0.6	-6.35	-0.5	3.77e-9	Positive affect;Subjective well-being;
TGCT	cis	rs6977660	0.714	rs17141882	chr7:19790217	C/T	cg07541023	chr7:19748670	TWISTNB	0.85	4.84	0.4	3.74e-6	Thyroid stimulating hormone;
TGCT	cis	rs12580194	0.593	rs58254871	chr12:55750281	G/A	cg10672482	chr12:55725839	OR6C3	-0.51	-4.43	-0.37	2.01e-5	Cancer;
TGCT	cis	rs2708977	0.965	rs13019986	chr2:97243058	C/T	cg01950434	chr2:97203154	ARID5A	0.64	5.85	0.47	4.09e-8	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs7772486	0.875	rs9373485	chr6:146401429	A/T	cg23711669	chr6:146136114	FBXO30	0.91	9.95	0.67	1.67e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg06558623	chr16:89946397	TCF25	0.57	6.89	0.53	2.56e-10	Skin colour saturation;
TGCT	cis	rs506338	0.517	rs530775	chr11:64426933	A/G	cg19395706	chr11:64412079	NRXN2	0.49	5.98	0.47	2.2e-8	Body mass index;Urate levels;
TGCT	cis	rs6450176	0.909	rs11742688	chr5:53291081	C/T	ch.5.1024479R	chr5:53302184	ARL15	-0.49	-4.59	-0.38	1.09e-5	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs35160687	0.901	rs12999029	chr2:86502913	G/A	cg03171300	chr2:86307199	POLR1A	0.32	5.49	0.44	2.18e-7	Night sleep phenotypes;
TGCT	cis	rs3213545	0.700	rs2260399	chr12:121469653	C/T	cg15155738	chr12:121454335	C12orf43	0.47	4.61	0.38	9.85e-6	Subjective well-being;Cardiovascular disease risk factors;
TGCT	cis	rs1475911	0.708	rs66994219	chr21:43521647	G/A	cg19766460	chr21:43528205	UMODL1;C21orf128	0.65	9.36	0.64	4.41e-16	IgG glycosylation;
TGCT	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg23708337	chr7:1209742	NA	0.61	5.52	0.44	1.89e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1005224	0.853	rs9323616	chr14:76151697	T/C	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.54	-4.72	-0.39	6.23e-6	Large artery stroke;
TGCT	cis	rs40363	1.000	rs1690444	chr16:3518350	G/A	cg00484396	chr16:3507460	NAT15	0.43	5.04	0.41	1.57e-6	Tuberculosis;
TGCT	cis	rs28493229	0.708	rs10407650	chr19:41160970	T/C	cg11601297	chr19:41224147	ITPKC;ADCK4	0.57	5.15	0.42	9.78e-7	Kawasaki disease;
TGCT	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg27535305	chr1:53392650	SCP2	-0.24	-4.69	-0.39	6.96e-6	Monocyte count;
TGCT	cis	rs428668	0.681	rs428064	chr5:150696498	G/A	cg11125805	chr5:150678162	SLC36A3	0.27	6.12	0.48	1.12e-8	Skin aging (microtopography measurement);
TGCT	cis	rs7044106	0.791	rs4837792	chr9:123483559	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.61	6.55	0.51	1.37e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs12780845	0.505	rs10795460	chr10:17244253	A/G	cg01003015	chr10:17271136	VIM	-0.59	-5.45	-0.44	2.65e-7	Homocysteine levels;
TGCT	cis	rs8032315	0.895	rs4932370	chr15:91404705	A/G	cg05211768	chr15:91427848	FES	-0.52	-5.22	-0.42	7.17e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12134245	0.742	rs17501381	chr1:92003919	A/G	cg25838465	chr1:92012736	NA	-0.41	-6.57	-0.51	1.23e-9	Breast cancer;
TGCT	cis	rs7714584	1.000	rs11746560	chr5:150185925	T/G	cg22134413	chr5:150180641	NA	1.13	8.18	0.59	2.91e-13	Crohn's disease;
TGCT	cis	rs6570726	0.935	rs453609	chr6:145812332	T/C	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.16e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11578119	0.772	rs1333142	chr1:170466454	A/G	cg09767346	chr1:170501363	GORAB	-0.67	-5.36	-0.43	3.85e-7	Male-pattern baldness;
TGCT	cis	rs2013441	1.000	rs2703782	chr17:20144799	A/G	cg18979559	chr17:20280153	CCDC144C	-0.45	-4.67	-0.39	7.61e-6	Obesity-related traits;
TGCT	cis	rs12681287	1.000	rs12681287	chr8:87269536	A/C	cg27223183	chr8:87520930	FAM82B	0.78	5.7	0.46	8.18e-8	Caudate activity during reward;
TGCT	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg04546413	chr19:29218101	NA	0.82	7.84	0.58	1.72e-12	Methadone dose in opioid dependence;
TGCT	cis	rs1629083	0.875	rs11216819	chr11:118084980	G/A	cg16594165	chr11:118135105	MPZL2	-0.33	-4.52	-0.38	1.4e-5	Lung cancer;
TGCT	cis	rs2346177	0.844	rs34791442	chr2:46655169	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.43	-4.63	-0.38	9.01e-6	HDL cholesterol;
TGCT	cis	rs1475911	1.000	rs2839466	chr21:43512324	A/G	cg24372256	chr21:43528868	UMODL1;C21orf128	0.25	4.55	0.38	1.25e-5	IgG glycosylation;
TGCT	cis	rs28785552	0.769	rs7253672	chr19:53243212	G/C	cg04754360	chr19:53238445	ZNF611	-0.64	-5.24	-0.43	6.75e-7	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.47	-0.37	1.72e-5	Bipolar disorder;
TGCT	cis	rs911555	0.755	rs2403192	chr14:103974235	C/T	cg12935359	chr14:103987150	CKB	-0.33	-4.66	-0.39	7.91e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10114408	0.760	rs35590214	chr9:96643844	A/G	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs981844	0.816	rs56109239	chr4:154726500	A/G	cg14289246	chr4:154710475	SFRP2	1.02	8.96	0.63	4.15e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs8180040	0.620	rs11709660	chr3:47074927	G/A	cg27129171	chr3:47204927	SETD2	-0.71	-8.51	-0.61	4.8e-14	Colorectal cancer;
TGCT	cis	rs739496	0.615	rs12427276	chr12:112113508	G/A	cg10833066	chr12:111807467	FAM109A	0.37	4.79	0.39	4.76e-6	Platelet count;
TGCT	cis	rs7647973	1.000	rs62259947	chr3:49439924	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.59	-4.68	-0.39	7.32e-6	Menarche (age at onset);
TGCT	cis	rs10883723	0.810	rs10786669	chr10:104256094	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.74	0.62	1.4e-14	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs7267979	1.000	rs453329	chr20:25440593	G/A	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7647973	0.587	rs10452032	chr3:49680973	G/A	cg03034192	chr3:50606346	HEMK1;C3orf18	0.36	4.75	0.39	5.61e-6	Menarche (age at onset);
TGCT	cis	rs68170813	0.559	rs58663672	chr7:106949444	T/C	cg02696742	chr7:106810147	HBP1	-0.69	-5.81	-0.46	4.85e-8	Coronary artery disease;
TGCT	cis	rs9905704	0.647	rs8077332	chr17:57105223	A/G	cg05425664	chr17:57184151	TRIM37	-0.68	-5.65	-0.45	1.06e-7	Testicular germ cell tumor;
TGCT	trans	rs1496653	0.602	rs35928592	chr3:23389659	A/G	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.73	-0.39	5.93e-6	Prudent dietary pattern;
TGCT	cis	rs11676855	1.000	rs11676855	chr2:235900171	C/T	cg14917874	chr2:235941519	SH3BP4	-0.22	-4.82	-0.4	4.19e-6	Dialysis-related mortality;
TGCT	cis	rs4319547	0.619	rs7973869	chr12:122874284	G/C	cg08088222	chr12:122070432	ORAI1	0.25	4.49	0.37	1.58e-5	Body mass index;
TGCT	cis	rs9911578	1.000	rs8067571	chr17:56868856	C/T	cg05425664	chr17:57184151	TRIM37	-0.63	-6.26	-0.49	5.86e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs6121246	0.567	rs6120815	chr20:30184866	T/C	cg21427119	chr20:30132790	HM13	-0.42	-6.17	-0.48	8.75e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs12477438	0.520	rs6542864	chr2:99725223	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	13.05	0.76	4.93e-25	Chronic sinus infection;
TGCT	cis	rs2562456	0.755	rs2914646	chr19:21637161	A/C	cg01304269	chr19:21688519	ZNF429	-0.58	-4.61	-0.38	1e-5	Pain;
TGCT	cis	rs1519814	0.592	rs4870969	chr8:121006548	G/A	cg22335954	chr8:121166405	COL14A1	-0.36	-4.48	-0.37	1.67e-5	Breast cancer;
TGCT	cis	rs2594989	0.943	rs9830784	chr3:11434605	A/G	cg00170343	chr3:11313890	ATG7	0.78	5.36	0.43	3.92e-7	Circulating chemerin levels;
TGCT	cis	rs7412746	0.658	rs59024312	chr1:150909005	T/G	cg09365446	chr1:150670422	GOLPH3L	0.34	4.71	0.39	6.58e-6	Melanoma;
TGCT	cis	rs4478037	0.822	rs9817393	chr3:33117069	A/G	cg19404215	chr3:33155277	CRTAP	1.27	6.16	0.48	9.36e-9	Major depressive disorder;
TGCT	cis	rs9902453	0.967	rs12602065	chr17:28482488	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	6.39	0.5	3.03e-9	Coffee consumption (cups per day);
TGCT	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg10074409	chr1:209979377	IRF6	0.51	5.89	0.47	3.45e-8	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
TGCT	cis	rs9517313	0.591	rs17574543	chr13:99172893	G/A	cg20487152	chr13:99095054	FARP1	-0.29	-5.39	-0.44	3.39e-7	Neuroticism;
TGCT	cis	rs6912958	0.712	rs4587138	chr6:88356915	G/C	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.98	-0.41	2.06e-6	Monocyte percentage of white cells;
TGCT	cis	rs7103411	0.592	rs11030087	chr11:27646246	T/C	cg10635145	chr11:27742435	BDNF	0.32	4.47	0.37	1.72e-5	Menarche (age at onset);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
TGCT	cis	rs2070488	1.000	rs1002675	chr3:38445226	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.93	9.76	0.66	4.77e-17	Electrocardiographic conduction measures;
TGCT	cis	rs7523273	0.606	rs2488254	chr1:207941539	A/G	cg22525895	chr1:207977042	MIR29B2	0.53	8.71	0.62	1.62e-14	Schizophrenia;
TGCT	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg06873352	chr17:61820015	STRADA	0.58	6.42	0.5	2.65e-9	Prudent dietary pattern;
TGCT	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg22433210	chr17:43662623	NA	-0.94	-7.99	-0.58	7.87e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs9811920	0.695	rs793497	chr3:99505610	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.42	4.73	0.39	6.09e-6	Axial length;
TGCT	cis	rs10256972	0.669	rs10229964	chr7:1051776	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.47	-5.47	-0.44	2.35e-7	Longevity;Endometriosis;
TGCT	cis	rs7819412	0.522	rs4642600	chr8:11013025	C/A	cg21775007	chr8:11205619	TDH	-0.52	-4.63	-0.38	8.99e-6	Triglycerides;
TGCT	cis	rs2075671	0.810	rs12531792	chr7:100280624	G/A	cg20848291	chr7:100343083	ZAN	-0.52	-4.56	-0.38	1.21e-5	Other erythrocyte phenotypes;
TGCT	cis	rs1018836	0.739	rs4734247	chr8:91569144	A/G	cg16814680	chr8:91681699	NA	-0.8	-8.57	-0.61	3.46e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10197940	0.578	rs2432957	chr2:152287897	A/C	cg06191203	chr2:152266755	RIF1	-0.58	-4.92	-0.4	2.7e-6	Lung cancer;
TGCT	cis	rs68190844	1	rs68190844	chr17:4568953	CTA/C	cg23387401	chr17:4582204	PELP1	-0.31	-4.63	-0.38	8.97e-6	Eosinophil percentage of white cells;
TGCT	cis	rs1372520	0.684	rs356162	chr4:90697157	T/C	cg14346243	chr4:90757452	SNCA	0.62	5.29	0.43	5.26e-7	Neuroticism;
TGCT	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	8.39	0.6	9.03e-14	Platelet count;
TGCT	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg10047753	chr17:41438598	NA	0.96	9.86	0.66	2.71e-17	Menopause (age at onset);
TGCT	cis	rs4319547	1.000	rs10998	chr12:122989412	G/A	cg23029597	chr12:123009494	RSRC2	-0.31	-4.99	-0.41	1.96e-6	Body mass index;
TGCT	cis	rs9467773	1.000	rs3736781	chr6:26505362	G/A	cg09904177	chr6:26538194	HMGN4	0.65	6.53	0.51	1.5e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs62244186	0.566	rs55901755	chr3:44834707	C/T	cg15687855	chr3:44754131	ZNF502	-0.55	-6.8	-0.52	3.9e-10	Depressive symptoms;
TGCT	cis	rs12497850	0.931	rs9840684	chr3:48893780	T/C	cg06212747	chr3:49208901	KLHDC8B	0.61	5.62	0.45	1.2e-7	Parkinson's disease;
TGCT	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg12963246	chr6:28129442	ZNF389	0.52	5.01	0.41	1.85e-6	Depression;
TGCT	cis	rs1113500	0.787	rs11185266	chr1:108642664	G/A	cg22161131	chr1:109420278	GPSM2	0.49	4.45	0.37	1.88e-5	Growth-regulated protein alpha levels;
TGCT	cis	rs3741151	0.892	rs76854106	chr11:73027110	G/A	cg17517138	chr11:73019481	ARHGEF17	0.9	4.51	0.38	1.45e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
TGCT	trans	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg13565492	chr6:43139072	SRF	-0.82	-7.72	-0.57	3.43e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9910055	0.529	rs2523161	chr17:42179405	C/T	cg13607699	chr17:42295918	UBTF	-0.61	-5.09	-0.42	1.32e-6	Total body bone mineral density;
TGCT	cis	rs9611565	0.559	rs9611619	chr22:41986714	C/T	cg06481639	chr22:41940642	POLR3H	-0.75	-6.47	-0.5	2.1e-9	Vitiligo;
TGCT	cis	rs13177918	0.677	rs13183077	chr5:149826572	G/A	cg14059543	chr5:149831962	NA	-0.71	-9.35	-0.64	4.68e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs9486715	0.867	rs2223238	chr6:96871855	G/A	cg18709589	chr6:96969512	KIAA0776	0.79	7.77	0.57	2.5e-12	Headache;
TGCT	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.46	-6.7	-0.52	6.44e-10	Alzheimer's disease;
TGCT	cis	rs2549003	0.966	rs2070730	chr5:131819800	G/A	cg21138405	chr5:131827807	IRF1	0.19	4.79	0.4	4.64e-6	Asthma (sex interaction);
TGCT	cis	rs7772486	0.654	rs6906402	chr6:146089307	C/G	cg23711669	chr6:146136114	FBXO30	-0.92	-10.41	-0.68	1.3e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs74233809	1.000	rs112390216	chr10:104741031	C/T	cg05855489	chr10:104503620	C10orf26	0.74	4.44	0.37	1.96e-5	Birth weight;
TGCT	cis	rs17376456	0.504	rs6898507	chr5:93082343	C/T	cg25358565	chr5:93447407	FAM172A	0.74	6.42	0.5	2.66e-9	Diabetic retinopathy;
TGCT	cis	rs6460942	0.908	rs78682952	chr7:12284886	C/A	cg06484146	chr7:12443880	VWDE	-0.57	-4.9	-0.4	2.91e-6	Coronary artery disease;
TGCT	cis	rs610932	0.517	rs688460	chr11:59986710	C/T	cg18570331	chr11:60101691	MS4A6E	0.53	4.86	0.4	3.5e-6	Alzheimer's disease;
TGCT	cis	rs6088580	0.634	rs6059860	chr20:33063830	A/C	cg06115741	chr20:33292138	TP53INP2	0.55	4.68	0.39	7.39e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs12042938	0.507	rs1765778	chr1:231732356	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-6.16	-0.48	9.54e-9	Neuranatomic and neurocognitive phenotypes;
TGCT	cis	rs10992471	0.756	rs10992319	chr9:95127895	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.61	-6.26	-0.49	5.73e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs7647973	0.506	rs11920251	chr3:49356671	C/T	cg06212747	chr3:49208901	KLHDC8B	0.53	4.58	0.38	1.13e-5	Menarche (age at onset);
TGCT	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg10047753	chr17:41438598	NA	0.96	9.62	0.65	1.04e-16	Menopause (age at onset);
TGCT	cis	rs4478037	0.642	rs77202692	chr3:33115776	A/C	cg19404215	chr3:33155277	CRTAP	1.2	6.68	0.51	7.34e-10	Major depressive disorder;
TGCT	cis	rs7647973	0.626	rs1491985	chr3:49739507	G/C	cg03060546	chr3:49711283	APEH	0.63	5.63	0.45	1.12e-7	Menarche (age at onset);
TGCT	cis	rs7666738	0.830	rs62321597	chr4:99014221	C/A	cg17366294	chr4:99064904	C4orf37	0.66	6.75	0.52	5.04e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9611565	0.545	rs5758432	chr22:42111693	T/C	cg06634786	chr22:41940651	POLR3H	0.89	8.68	0.61	1.88e-14	Vitiligo;
TGCT	cis	rs8031584	0.651	rs28664821	chr15:31172323	G/A	cg08109568	chr15:31115862	NA	0.37	4.91	0.4	2.8e-6	Huntington's disease progression;
TGCT	cis	rs1401999	0.565	rs4912515	chr3:183653718	A/G	cg01324343	chr3:183735012	ABCC5	0.49	5.58	0.45	1.46e-7	Anterior chamber depth;
TGCT	cis	rs7681440	0.838	rs1348224	chr4:90761946	G/A	cg26578617	chr4:90757533	SNCA	-0.49	-5.12	-0.42	1.15e-6	Dementia with Lewy bodies;
TGCT	cis	rs10927875	0.541	rs1048334	chr1:16340761	T/C	cg22431228	chr1:16359049	CLCNKA	-0.29	-6.07	-0.48	1.42e-8	Dilated cardiomyopathy;
TGCT	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg06481639	chr22:41940642	POLR3H	0.75	6.86	0.52	2.84e-10	Vitiligo;
TGCT	cis	rs9611565	0.802	rs4822028	chr22:41789408	A/G	cg06481639	chr22:41940642	POLR3H	-0.61	-5.49	-0.44	2.17e-7	Vitiligo;
TGCT	cis	rs9611565	0.525	rs9611549	chr22:41705909	C/G	cg13695892	chr22:41940480	POLR3H	-0.67	-6.28	-0.49	5.18e-9	Vitiligo;
TGCT	cis	rs7086627	0.515	rs10887895	chr10:82210011	A/G	cg00277334	chr10:82204260	NA	-0.54	-8.46	-0.61	6.23e-14	Post bronchodilator FEV1;
TGCT	cis	rs17376456	0.569	rs7701114	chr5:93096028	T/C	cg25358565	chr5:93447407	FAM172A	0.76	6.68	0.51	7.23e-10	Diabetic retinopathy;
TGCT	cis	rs3749237	1.000	rs6804655	chr3:49738945	C/T	cg03060546	chr3:49711283	APEH	0.74	7.6	0.56	6.37e-12	Resting heart rate;
TGCT	cis	rs514406	0.505	rs447581	chr1:53177098	T/C	cg16325326	chr1:53192061	ZYG11B	0.86	12.25	0.74	4.3e-23	Monocyte count;
TGCT	trans	rs11082438	0.786	rs11660485	chr18:42866471	A/C	cg06374610	chr10:50328992	NA	-0.83	-6.79	-0.52	4.09e-10	Follicular lymphoma;
TGCT	cis	rs807669	0.504	rs8141941	chr22:19166263	G/A	cg02655711	chr22:19163373	SLC25A1	0.27	5.16	0.42	9.53e-7	Metabolite levels;
TGCT	cis	rs1729951	0.575	rs10935213	chr3:136693459	A/G	cg12473912	chr3:136751656	NA	0.39	6.16	0.48	9.31e-9	Neuroticism;
TGCT	cis	rs853679	0.546	rs34295134	chr6:27828151	T/A	cg10876282	chr6:28092338	ZSCAN16	0.75	4.45	0.37	1.88e-5	Depression;
TGCT	cis	rs1348850	0.872	rs2084233	chr2:178331206	G/A	cg22681709	chr2:178499509	PDE11A	-0.36	-4.71	-0.39	6.46e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs1915146	0.967	rs7086481	chr10:126844523	A/T	cg10402121	chr10:126487101	NA	-0.25	-4.63	-0.38	9.07e-6	Menarche (age at onset);
TGCT	cis	rs6582630	0.519	rs11520262	chr12:38333051	A/G	cg26384229	chr12:38710491	ALG10B	0.83	7.19	0.54	5.37e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs7659604	0.521	rs4833773	chr4:122689245	C/T	cg06713675	chr4:122721982	EXOSC9	0.36	4.57	0.38	1.16e-5	Type 2 diabetes;
TGCT	cis	rs9467711	0.722	rs35825164	chr6:26117404	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.57	-4.54	-0.38	1.33e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2404602	0.563	rs12914005	chr15:76765667	A/G	cg26408565	chr15:76604113	ETFA	-0.37	-5.1	-0.42	1.21e-6	Blood metabolite levels;
TGCT	cis	rs10197940	0.662	rs10173699	chr2:152281561	C/G	cg06191203	chr2:152266755	RIF1	0.79	7.27	0.55	3.55e-11	Lung cancer;
TGCT	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	8.0	0.58	7.67e-13	Platelet count;
TGCT	cis	rs5769707	0.967	rs1018812	chr22:50010073	C/T	cg20744362	chr22:50050164	C22orf34	0.29	4.74	0.39	5.83e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs12477438	0.520	rs11883676	chr2:99800814	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	17.43	0.84	3.73e-35	Chronic sinus infection;
TGCT	cis	rs6952809	0.532	rs2057840	chr7:2432797	C/G	cg23289794	chr7:2394357	EIF3B	-0.8	-6.81	-0.52	3.79e-10	Multiple sclerosis;
TGCT	cis	rs9796	0.636	rs1983400	chr15:41373029	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.52	-6.77	-0.52	4.58e-10	Menopause (age at onset);
TGCT	cis	rs5750830	0.594	rs9611166	chr22:39775268	T/C	cg02038168	chr22:39784481	NA	-0.64	-5.48	-0.44	2.32e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs72700829	0.518	rs34755378	chr1:150242340	G/A	cg18798344	chr1:149336151	NA	0.56	4.5	0.37	1.52e-5	Schizophrenia;
TGCT	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg05457628	chr5:178986728	RUFY1	0.44	4.67	0.39	7.56e-6	Lung cancer;
TGCT	cis	rs17102423	0.896	rs8004805	chr14:65579720	T/C	cg11161011	chr14:65562177	MAX	-0.49	-6.47	-0.5	2.02e-9	Obesity-related traits;
TGCT	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg13628971	chr7:2884303	GNA12	0.62	5.24	0.43	6.8e-7	Height;
TGCT	cis	rs1348850	0.846	rs4893962	chr2:178421106	A/G	cg22681709	chr2:178499509	PDE11A	-0.38	-5.24	-0.43	6.57e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs2153535	0.580	rs9328488	chr6:8529411	G/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.55e-8	Motion sickness;
TGCT	cis	rs3091242	0.728	rs706845	chr1:25730713	G/A	cg23205692	chr1:25664452	TMEM50A	0.53	5.48	0.44	2.32e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs3812831	0.543	rs389108	chr13:114925389	A/G	cg06611532	chr13:114900021	NA	0.34	6.16	0.48	9.55e-9	Schizophrenia;
TGCT	cis	rs13191362	0.872	rs13213421	chr6:163203805	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.94	6.76	0.52	4.71e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7666738	0.791	rs10033994	chr4:98969582	C/T	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2153535	0.580	rs2143355	chr6:8517856	T/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.55e-8	Motion sickness;
TGCT	cis	rs758117	0.744	rs7312107	chr12:2523370	C/T	cg07128330	chr12:2921958	ITFG2	-0.44	-4.45	-0.37	1.91e-5	Schizophrenia;
TGCT	cis	rs10875595	0.836	rs1363453	chr5:140657864	G/A	cg20560182	chr5:140700478	TAF7	-0.66	-5.06	-0.41	1.49e-6	Pulmonary function decline;
TGCT	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.56	-5.57	-0.45	1.52e-7	Electroencephalogram traits;
TGCT	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg21548813	chr6:291882	DUSP22	-0.71	-7.45	-0.56	1.36e-11	Menopause (age at onset);
TGCT	cis	rs2070488	1.000	rs13074160	chr3:38455650	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	9.65	0.65	9.06e-17	Electrocardiographic conduction measures;
TGCT	cis	rs910316	0.967	rs10142770	chr14:75525449	G/A	cg11812906	chr14:75593930	NEK9	0.73	7.08	0.54	9.26e-11	Height;
TGCT	cis	rs28595532	0.920	rs114564223	chr4:119729953	A/G	cg21605333	chr4:119757512	SEC24D	1.66	8.33	0.6	1.28e-13	Cannabis dependence symptom count;
TGCT	cis	rs9653442	0.564	rs4851261	chr2:100786717	A/G	cg22139774	chr2:100720529	AFF3	-0.36	-5.69	-0.46	8.67e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg11764359	chr7:65958608	NA	0.61	5.54	0.45	1.76e-7	Aortic root size;
TGCT	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg08859206	chr1:53392774	SCP2	0.4	5.96	0.47	2.46e-8	Monocyte count;
TGCT	cis	rs60871478	0.636	rs4276575	chr7:900035	C/T	cg00475322	chr7:917719	C7orf20	0.49	4.87	0.4	3.3e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs67311347	1.000	rs2887995	chr3:40409029	C/G	cg13683864	chr3:40499215	RPL14	-1.04	-10.79	-0.7	1.54e-19	Renal cell carcinoma;
TGCT	cis	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg08975724	chr8:8085496	FLJ10661	-0.54	-5.03	-0.41	1.71e-6	Mood instability;
TGCT	cis	rs9291683	0.588	rs13121211	chr4:9999539	A/G	cg00071950	chr4:10020882	SLC2A9	0.71	9.08	0.63	2.11e-15	Bone mineral density;
TGCT	cis	rs12142240	0.731	rs12385693	chr1:46818921	A/C	cg00530320	chr1:46809349	NSUN4	0.25	4.7	0.39	6.79e-6	Menopause (age at onset);
TGCT	cis	rs7659604	0.540	rs11098643	chr4:122701507	C/A	cg19748678	chr4:122722346	EXOSC9	-0.59	-5.86	-0.47	3.97e-8	Type 2 diabetes;
TGCT	cis	rs2486012	1.000	rs1766964	chr1:44381847	T/C	cg12908607	chr1:44402522	ARTN	0.71	5.86	0.47	3.87e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs864643	0.773	rs13064980	chr3:39545464	A/G	cg14968361	chr3:39543547	MOBP	0.43	4.54	0.38	1.3e-5	Attention deficit hyperactivity disorder;
TGCT	cis	rs11711311	0.955	rs12634241	chr3:113397685	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.76	-6.88	-0.53	2.6200000000000003e-10	IgG glycosylation;
TGCT	cis	rs17345786	0.861	rs11711808	chr3:101235101	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.84	8.43	0.6	7.33e-14	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9611565	0.918	rs6002351	chr22:41757223	C/T	cg17554472	chr22:41940697	POLR3H	-0.45	-4.91	-0.4	2.84e-6	Vitiligo;
TGCT	cis	rs6570726	0.791	rs414600	chr6:145879606	G/A	cg05347473	chr6:146136440	FBXO30	0.54	5.15	0.42	1.01e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg12311346	chr5:56204834	C5orf35	-0.64	-6.98	-0.53	1.57e-10	Initial pursuit acceleration;
TGCT	cis	rs2404602	0.716	rs4886817	chr15:76877702	C/T	cg22467129	chr15:76604101	ETFA	-0.44	-4.98	-0.41	2.08e-6	Blood metabolite levels;
TGCT	cis	rs7772486	0.625	rs2050027	chr6:146116113	C/G	cg13319975	chr6:146136371	FBXO30	0.5	4.62	0.38	9.6e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9318086	0.935	rs2025701	chr13:24440581	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.67	6.78	0.52	4.27e-10	Myopia (pathological);
TGCT	cis	rs11190604	0.767	rs3750723	chr10:102172989	T/C	cg16342193	chr10:102329863	NA	-0.4	-5.06	-0.41	1.5e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs10186029	0.676	rs4673720	chr2:213941581	G/A	cg08319019	chr2:214017104	IKZF2	0.63	5.94	0.47	2.67e-8	Systemic sclerosis;
TGCT	cis	rs17155006	0.702	rs399290	chr7:107725977	T/C	cg05962710	chr7:107745446	LAMB4	-0.18	-4.52	-0.38	1.4e-5	Pneumococcal bacteremia;
TGCT	cis	rs4642101	0.793	rs3889513	chr3:12844070	G/A	cg05775895	chr3:12838266	CAND2	0.73	7.24	0.55	4.1e-11	QRS complex (12-leadsum);
TGCT	cis	rs17331151	0.573	rs11718060	chr3:52875546	G/A	cg27565382	chr3:53032988	SFMBT1	0.47	5.82	0.46	4.71e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs5769765	1.000	rs34774661	chr22:50267508	C/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.41	-6.13	-0.48	1.08e-8	Schizophrenia;
TGCT	cis	rs3617	0.625	rs11922961	chr3:52868610	T/C	cg11645453	chr3:52864694	ITIH4	-0.29	-5.71	-0.46	7.84e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs910316	1.000	rs12590452	chr14:75548756	T/C	cg08847533	chr14:75593920	NEK9	0.96	10.9	0.7	8.37e-20	Height;
TGCT	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg07507251	chr3:52567010	NT5DC2	0.47	6.61	0.51	1.05e-9	Bipolar disorder;
TGCT	cis	rs4595586	0.545	rs4411311	chr12:39363612	C/G	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	trans	rs9329221	0.617	rs615632	chr8:9796321	C/T	cg15556689	chr8:8085844	FLJ10661	-0.81	-8.45	-0.6	6.76e-14	Neuroticism;
TGCT	cis	rs7267979	1.000	rs2257808	chr20:25266450	G/C	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs62064224	0.509	rs2302276	chr17:30791503	C/T	cg18200150	chr17:30822561	MYO1D	0.42	5.02	0.41	1.77e-6	Schizophrenia;
TGCT	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg27535305	chr1:53392650	SCP2	-0.28	-5.93	-0.47	2.85e-8	Monocyte count;
TGCT	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg01802117	chr1:53393560	SCP2	-0.41	-4.98	-0.41	2.12e-6	Monocyte count;
TGCT	cis	rs4930561	1.000	rs10896298	chr11:67931459	C/T	cg04465784	chr11:67976953	SUV420H1	-0.34	-4.49	-0.37	1.62e-5	Breast cancer in childhood cancer survivors;IgG glycosylation;
TGCT	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg23172400	chr8:95962367	TP53INP1	-0.4	-6.56	-0.51	1.33e-9	Type 2 diabetes;
TGCT	cis	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg25427524	chr10:38739819	LOC399744	-0.4	-8.2	-0.59	2.5e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs10791097	0.694	rs4436551	chr11:130755739	A/G	cg05962950	chr11:130786565	SNX19	-0.89	-11.41	-0.72	4.79e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9362426	0.708	rs7753821	chr6:88100010	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.45	4.98	0.41	2.07e-6	Depressive episodes in bipolar disorder;
TGCT	cis	rs12780845	0.540	rs2273736	chr10:17195428	G/C	cg01003015	chr10:17271136	VIM	-0.51	-4.65	-0.39	8.46e-6	Homocysteine levels;
TGCT	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg03303774	chr4:1407052	NA	0.38	6.07	0.48	1.45e-8	Obesity-related traits;
TGCT	cis	rs9653442	0.609	rs2576678	chr2:100704810	T/C	cg22139774	chr2:100720529	AFF3	-0.43	-7.75	-0.57	2.79e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	5.8	0.46	5.19e-8	Alzheimer's disease;
TGCT	cis	rs7611238	0.583	rs13317782	chr3:195153635	C/T	cg27323046	chr3:195102265	ACAP2	0.33	4.44	0.37	1.96e-5	Body mass index;
TGCT	cis	rs9611565	0.512	rs4820446	chr22:42215684	C/T	cg06481639	chr22:41940642	POLR3H	-0.68	-5.87	-0.47	3.77e-8	Vitiligo;
TGCT	cis	rs1348850	0.567	rs3770012	chr2:178538023	A/G	cg22681709	chr2:178499509	PDE11A	0.48	6.24	0.49	6.25e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg24060327	chr5:131705240	SLC22A5	0.78	8.46	0.61	6.22e-14	Blood metabolite levels;
TGCT	cis	rs11673344	0.504	rs1667377	chr19:37491868	G/A	cg08039142	chr19:36980659	ZNF566	0.59	5.58	0.45	1.41e-7	Obesity-related traits;
TGCT	cis	rs10088262	0.629	rs7827665	chr8:124804190	G/A	cg20713898	chr8:124780851	FAM91A1	-0.84	-7.19	-0.54	5.3e-11	Pancreatic cancer;
TGCT	cis	rs7246657	0.639	rs12459015	chr19:38083189	T/A	cg18154014	chr19:37997991	ZNF793	0.69	4.63	0.38	9.25e-6	Coronary artery calcification;
TGCT	cis	rs782590	0.967	rs35504023	chr2:55806503	C/T	cg18811423	chr2:55921094	PNPT1	-0.65	-6.93	-0.53	2.02e-10	Metabolic syndrome;
TGCT	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg20276088	chr3:133502917	NA	-0.24	-5.02	-0.41	1.74e-6	Iron status biomarkers;
TGCT	cis	rs4664308	1.000	rs17341301	chr2:160902420	G/A	cg03641300	chr2:160917029	PLA2R1	-0.27	-6.54	-0.51	1.46e-9	Idiopathic membranous nephropathy;
TGCT	cis	rs2932538	0.883	rs6537740	chr1:113080084	T/G	cg22162597	chr1:113214053	CAPZA1	0.28	5.93	0.47	2.84e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.42	5.78	0.46	5.68e-8	Lymphocyte counts;
TGCT	cis	rs736408	0.812	rs746694	chr3:52826620	C/T	cg10802521	chr3:52805072	NEK4	-0.68	-7.79	-0.57	2.28e-12	Bipolar disorder;
TGCT	cis	rs9467711	0.516	rs501220	chr6:25873025	C/A	cg03264133	chr6:25882463	NA	-0.7	-4.71	-0.39	6.45e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12220238	1.000	rs10824112	chr10:75969003	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.78	0.57	2.42e-12	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs6570726	0.818	rs952405	chr6:145925952	T/C	cg13319975	chr6:146136371	FBXO30	-0.51	-4.5	-0.37	1.53e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs57994353	0.568	rs10870151	chr9:139309584	G/A	cg13741927	chr9:139327495	INPP5E	-0.24	-5.42	-0.44	2.99e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg00343986	chr7:65444356	GUSB	-0.2	-4.51	-0.38	1.51e-5	Aortic root size;
TGCT	cis	rs7818688	0.697	rs75349998	chr8:95990918	G/A	cg16049864	chr8:95962084	TP53INP1	0.54	4.64	0.38	8.87e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs60871478	0.636	rs7792072	chr7:886239	C/T	cg00475322	chr7:917719	C7orf20	0.5	4.87	0.4	3.37e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs734999	0.870	rs2985858	chr1:2483298	C/G	cg18854424	chr1:2615690	NA	0.49	5.88	0.47	3.6e-8	Ulcerative colitis;
TGCT	cis	rs2836950	0.545	rs2836956	chr21:40623018	C/G	cg11890956	chr21:40555474	PSMG1	0.68	6.58	0.51	1.17e-9	Menarche (age at onset);
TGCT	cis	rs62244186	0.627	rs3935212	chr3:44460954	G/A	cg10108389	chr3:44770937	ZNF501	-0.46	-4.7	-0.39	6.86e-6	Depressive symptoms;
TGCT	cis	rs7666738	0.830	rs11725652	chr4:98878362	G/A	cg17366294	chr4:99064904	C4orf37	0.71	7.28	0.55	3.33e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6088580	0.602	rs6059840	chr20:33030405	G/A	cg06115741	chr20:33292138	TP53INP2	0.55	4.82	0.4	4.15e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs2288073	0.965	rs6545335	chr2:24422011	G/A	cg02683114	chr2:24398427	C2orf84	-0.25	-5.67	-0.45	9.72e-8	Venous thromboembolism (SNP x SNP interaction);
TGCT	trans	rs11082438	0.786	rs11660485	chr18:42866471	A/C	cg03885119	chr10:117885028	GFRA1	-0.86	-6.85	-0.52	3.06e-10	Follicular lymphoma;
TGCT	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg10935138	chr17:73851978	WBP2	1.05	9.62	0.65	1.08e-16	Psoriasis;
TGCT	cis	rs826838	0.868	rs12322306	chr12:39130021	A/G	cg26384229	chr12:38710491	ALG10B	-0.86	-7.7	-0.57	3.65e-12	Heart rate;
TGCT	cis	rs2288884	0.767	rs3752119	chr19:52551498	C/T	cg15405931	chr19:52693188	PPP2R1A	-0.64	-4.5	-0.38	1.51e-5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs6988636	1.000	rs59601467	chr8:124193488	C/T	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs1061377	0.501	rs62308278	chr4:39162658	G/T	cg20847110	chr4:39482781	LOC401127	0.17	4.86	0.4	3.49e-6	Uric acid levels;
TGCT	cis	rs1008375	1.000	rs6449319	chr4:17640283	T/A	cg18681998	chr4:17616180	MED28	1.07	12.28	0.74	3.52e-23	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6693567	0.565	rs834238	chr1:150366469	G/T	cg09579323	chr1:150459698	TARS2	0.53	4.71	0.39	6.56e-6	Migraine;
TGCT	cis	rs9467773	0.620	rs1027204	chr6:26639613	T/C	cg02458000	chr6:26745757	NA	0.53	5.02	0.41	1.76e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs137603	0.602	rs137654	chr22:39732413	C/T	cg01093212	chr22:39715156	SNORD43;RPL3	-0.52	-5.09	-0.42	1.29e-6	Primary biliary cholangitis;
TGCT	cis	rs2204008	0.684	rs11514164	chr12:38036494	C/T	cg13010199	chr12:38710504	ALG10B	0.61	4.89	0.4	3.05e-6	Bladder cancer;
TGCT	cis	rs11122272	0.735	rs2749717	chr1:231489353	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-6.6	-0.51	1.09e-9	Hemoglobin concentration;
TGCT	cis	rs6121246	0.865	rs6058421	chr20:30295013	G/C	cg13852791	chr20:30311386	BCL2L1	0.78	5.8	0.46	5.15e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs6088580	0.634	rs6088484	chr20:32985961	T/C	cg24642439	chr20:33292090	TP53INP2	-0.49	-4.49	-0.37	1.59e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs7833790	0.700	rs28390260	chr8:82769175	A/T	cg06027949	chr8:82754900	SNX16	0.67	5.14	0.42	1.06e-6	Diastolic blood pressure;
TGCT	cis	rs2153535	0.580	rs6597337	chr6:8531652	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.55e-8	Motion sickness;
TGCT	cis	rs75059851	0.756	rs11223651	chr11:133841034	A/G	cg14047540	chr11:133829660	NA	0.53	5.47	0.44	2.33e-7	Schizophrenia;
TGCT	cis	rs12615966	0.651	rs72830473	chr2:105411202	C/A	cg16465502	chr2:105461796	NA	0.85	5.6	0.45	1.34e-7	Pancreatic cancer;
TGCT	cis	rs9560113	0.959	rs4771756	chr13:112176083	T/G	cg14154082	chr13:112174009	NA	0.34	4.65	0.39	8.49e-6	Menarche (age at onset);
TGCT	cis	rs78545713	1.000	rs78661760	chr6:26250033	A/T	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.71	-4.68	-0.39	7.39e-6	Iron status biomarkers (total iron binding capacity);
TGCT	cis	rs2456568	0.805	rs55649862	chr11:93682888	G/T	cg26875233	chr11:93583750	C11orf90	-0.45	-5.65	-0.45	1.04e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs6500602	0.647	rs1659497	chr16:4594635	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.31	-5.9	-0.47	3.25e-8	Schizophrenia;
TGCT	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg08280861	chr8:58055591	NA	0.37	5.03	0.41	1.66e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.69	4.91	0.4	2.75e-6	Platelet count;
TGCT	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg06238570	chr21:40685208	BRWD1	-0.62	-6.42	-0.5	2.58e-9	Menarche (age at onset);
TGCT	cis	rs6964587	0.967	rs7781221	chr7:91664645	A/G	cg17063962	chr7:91808500	NA	0.88	9.65	0.66	8.73e-17	Breast cancer;
TGCT	cis	rs11098499	0.604	rs2389887	chr4:120570644	T/C	cg09307838	chr4:120376055	NA	0.64	6.23	0.49	6.81e-9	Corneal astigmatism;
TGCT	cis	rs950027	0.595	rs2486288	chr15:45712339	T/C	cg26924012	chr15:45694286	SPATA5L1	0.8	9.1	0.63	1.83e-15	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs6582630	0.555	rs12372536	chr12:38400864	C/G	cg13010199	chr12:38710504	ALG10B	0.59	4.68	0.39	7.35e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs78545713	0.881	rs74608402	chr6:26240474	C/T	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.79	-4.45	-0.37	1.87e-5	Iron status biomarkers (total iron binding capacity);
TGCT	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg17747265	chr1:1875780	NA	-0.38	-7.18	-0.54	5.67e-11	Body mass index;
TGCT	cis	rs295140	0.668	rs3769482	chr2:201173100	C/G	cg04283868	chr2:201171347	SPATS2L	0.6	5.68	0.45	9.27e-8	QT interval;
TGCT	cis	rs1372520	0.684	rs1442148	chr4:90748846	T/A	cg01966878	chr4:90757139	SNCA	-0.3	-4.76	-0.39	5.2e-6	Neuroticism;
TGCT	cis	rs3780378	0.875	rs4587378	chr9:5002011	C/T	cg02405213	chr9:5042618	JAK2	-0.54	-6.42	-0.5	2.57e-9	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg11764359	chr7:65958608	NA	0.61	5.53	0.44	1.84e-7	Aortic root size;
TGCT	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg20849893	chr7:64541193	NA	0.49	5.1	0.42	1.24e-6	Calcium levels;
TGCT	cis	rs7677751	0.747	rs1800809	chr4:55093914	A/G	cg17187183	chr4:55093834	PDGFRA	0.55	7.06	0.54	1.05e-10	Corneal astigmatism;
TGCT	cis	rs7666738	0.649	rs28865589	chr4:98954279	C/A	cg17366294	chr4:99064904	C4orf37	0.73	7.3	0.55	2.96e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs317689	0.581	rs160829	chr12:69769538	G/C	cg11871910	chr12:69753446	YEATS4	0.58	5.18	0.42	8.72e-7	Response to diuretic therapy;
TGCT	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg11941060	chr3:133502564	NA	0.29	6.43	0.5	2.51e-9	Iron status biomarkers;
TGCT	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg04944784	chr2:26401820	FAM59B	-0.68	-6.09	-0.48	1.28e-8	Gut microbiome composition (summer);
TGCT	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9457247	1.000	rs444988	chr6:167389674	A/T	cg23791538	chr6:167370224	RNASET2	-0.53	-5.18	-0.42	8.72e-7	Crohn's disease;
TGCT	cis	rs727563	0.635	rs5751141	chr22:42107745	A/G	cg03806693	chr22:41940476	POLR3H	1.07	11.53	0.72	2.33e-21	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs2153535	0.580	rs1034272	chr6:8469335	G/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs3960554	0.673	rs112680895	chr7:75623520	G/A	cg17325771	chr7:75508891	RHBDD2	-0.59	-4.68	-0.39	7.44e-6	Eotaxin levels;
TGCT	cis	rs4654899	0.758	rs35913932	chr1:21423025	G/T	cg01072550	chr1:21505969	NA	-0.57	-9.35	-0.64	4.68e-16	Superior frontal gyrus grey matter volume;
TGCT	cis	rs6964587	0.869	rs406	chr7:91546526	C/A	cg17063962	chr7:91808500	NA	-0.86	-9.28	-0.64	6.82e-16	Breast cancer;
TGCT	cis	rs11122272	0.614	rs78172021	chr1:231525160	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-6.94	-0.53	1.98e-10	Hemoglobin concentration;
TGCT	cis	rs62244186	0.748	rs2888410	chr3:44655476	A/C	cg10108389	chr3:44770937	ZNF501	-0.47	-4.67	-0.39	7.6e-6	Depressive symptoms;
TGCT	cis	rs7829975	0.514	rs2979139	chr8:8268313	A/G	cg08975724	chr8:8085496	FLJ10661	0.59	5.21	0.42	7.78e-7	Mood instability;
TGCT	cis	rs4953076	0.574	rs4953074	chr2:44464629	C/T	cg00619915	chr2:44497795	NA	-0.23	-5.07	-0.41	1.41e-6	Height;
TGCT	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs826838	0.616	rs10880738	chr12:38617762	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-4.74	-0.39	5.87e-6	Heart rate;
TGCT	cis	rs66573146	0.634	rs55633489	chr4:6988745	C/A	cg05069807	chr4:6945702	TBC1D14	0.31	4.83	0.4	3.91e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs4087296	0.671	rs3859076	chr16:82379801	G/A	cg05453434	chr16:83371223	CDH13	0.31	4.44	0.37	1.93e-5	Bone mineral density;
TGCT	cis	rs6500602	0.727	rs2160567	chr16:4535557	C/T	cg08645402	chr16:4508243	NA	0.18	4.92	0.4	2.74e-6	Schizophrenia;
TGCT	cis	rs17376456	0.877	rs10044066	chr5:93437580	T/C	cg25358565	chr5:93447407	FAM172A	0.92	8.38	0.6	9.58e-14	Diabetic retinopathy;
TGCT	cis	rs7219021	0.705	rs2270576	chr17:47007963	C/T	cg26022315	chr17:47021804	SNF8	-0.54	-4.65	-0.39	8.2e-6	Schizophrenia or bipolar disorder;
TGCT	cis	rs7246657	0.722	rs2972430	chr19:38182111	C/T	cg03611452	chr19:38183253	ZNF781	-0.59	-4.69	-0.39	7.15e-6	Coronary artery calcification;
TGCT	cis	rs10832963	0.961	rs10832954	chr11:18643559	G/A	cg09201001	chr11:18656081	SPTY2D1	1.03	11.22	0.71	1.32e-20	Breast cancer;
TGCT	cis	rs1670533	0.872	rs11727136	chr4:1051804	G/A	cg20887711	chr4:1340912	KIAA1530	0.63	5.03	0.41	1.65e-6	Recombination rate (females);
TGCT	cis	rs1453308	0.507	rs2219062	chr2:237149375	C/T	cg19324714	chr2:237145437	ASB18	0.44	4.46	0.37	1.84e-5	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs7208859	0.623	rs9906957	chr17:29157755	C/T	cg14008862	chr17:28927542	LRRC37B2	0.75	5.1	0.42	1.26e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs5769765	0.862	rs9616381	chr22:50312382	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.43	6.08	0.48	1.35e-8	Schizophrenia;
TGCT	cis	rs7726839	0.540	rs28364691	chr5:664084	G/A	cg20362242	chr5:692897	TPPP	0.51	4.66	0.39	8.11e-6	Obesity-related traits;
TGCT	cis	rs10992471	0.603	rs11792019	chr9:95195229	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.62	-5.94	-0.47	2.62e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs7681440	0.904	rs7672979	chr4:90767873	A/G	cg26578617	chr4:90757533	SNCA	-0.47	-4.87	-0.4	3.34e-6	Dementia with Lewy bodies;
TGCT	cis	rs3087591	0.960	rs8067021	chr17:29555078	T/A	cg24425628	chr17:29625626	OMG;NF1	-0.46	-7.15	-0.54	6.46e-11	Hip circumference;
TGCT	cis	rs6964587	1.000	rs7800582	chr7:91701346	G/A	cg22709100	chr7:91322751	NA	0.28	4.56	0.38	1.19e-5	Breast cancer;
TGCT	cis	rs10779751	0.922	rs4845985	chr1:11288618	G/A	cg08854313	chr1:11322531	MTOR	0.96	10.11	0.67	6.65e-18	Body mass index;
TGCT	cis	rs727563	0.608	rs2076200	chr22:41985956	G/T	cg13695892	chr22:41940480	POLR3H	-0.87	-8.01	-0.58	6.94e-13	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg12570787	chr5:219185	SDHA;CCDC127	0.66	4.48	0.37	1.64e-5	Breast cancer;
TGCT	cis	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg08564027	chr20:61660810	NA	0.38	7.08	0.54	9.36e-11	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs727479	0.523	rs8034835	chr15:51512664	A/G	cg19946085	chr15:51559439	CYP19A1	-0.31	-4.48	-0.37	1.7e-5	Estradiol levels;
TGCT	cis	rs7674212	0.570	rs1031804	chr4:104066049	C/T	cg16532752	chr4:104119610	CENPE	-0.6	-5.47	-0.44	2.34e-7	Type 2 diabetes;
TGCT	cis	rs3091242	0.933	rs28633797	chr1:25741629	C/A	cg00786635	chr1:25594202	NA	0.58	6.07	0.48	1.43e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs271674	1.000	rs271674	chr17:47978986	A/G	cg05310240	chr17:47979069	NA	-0.37	-5.99	-0.47	2.07e-8	White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy;
TGCT	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg10876282	chr6:28092338	ZSCAN16	0.51	4.69	0.39	6.99e-6	Cardiac Troponin-T levels;
TGCT	cis	rs2153535	0.580	rs9393019	chr6:8462091	G/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs9902453	0.765	rs3115087	chr17:28030267	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.76	6.84	0.52	3.17e-10	Coffee consumption (cups per day);
TGCT	cis	rs8077577	0.895	rs11871491	chr17:18105656	T/C	cg09161412	chr17:18057145	MYO15A	-0.64	-5.22	-0.42	7.2e-7	Obesity-related traits;
TGCT	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg05872129	chr22:39784769	NA	-1.01	-11.09	-0.71	2.82e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs1568889	1.000	rs9783281	chr11:28033786	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.87	8.12	0.59	3.93e-13	Bipolar disorder;
TGCT	cis	rs11696501	0.688	rs4812955	chr20:44324638	G/C	cg11783356	chr20:44313418	WFDC10B	-0.33	-4.49	-0.37	1.6e-5	Brain structure;
TGCT	cis	rs2204008	0.713	rs12366709	chr12:38210179	G/A	cg26384229	chr12:38710491	ALG10B	0.84	7.43	0.56	1.51e-11	Bladder cancer;
TGCT	cis	rs9653442	0.527	rs13003982	chr2:100759078	T/C	cg07810366	chr2:100720526	AFF3	-0.35	-5.03	-0.41	1.69e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs67460515	0.892	rs11718905	chr3:161051793	G/A	cg03342759	chr3:160939853	NMD3	-0.48	-5.16	-0.42	9.65e-7	Parkinson's disease;
TGCT	cis	rs1801251	0.896	rs6719061	chr2:233695885	C/T	cg08000102	chr2:233561755	GIGYF2	-0.59	-6.22	-0.49	6.86e-9	Coronary artery disease;
TGCT	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg20607798	chr8:58055168	NA	0.49	4.67	0.39	7.56e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs36051895	0.664	rs7847141	chr9:5097171	A/T	cg02405213	chr9:5042618	JAK2	-0.76	-10.67	-0.69	3.05e-19	Pediatric autoimmune diseases;
TGCT	cis	rs7211079	0.581	rs66994322	chr17:78131240	G/T	cg09238746	chr17:78121135	EIF4A3	-0.74	-5.11	-0.42	1.16e-6	Myocardial infarction;
TGCT	cis	rs3809566	0.534	rs4775609	chr15:63332009	A/C	cg08198488	chr15:63333792	TPM1	-0.32	-4.63	-0.38	9.22e-6	Platelet count;
TGCT	cis	rs62244186	0.659	rs4431151	chr3:44510906	G/C	cg15687855	chr3:44754131	ZNF502	-0.44	-5.11	-0.42	1.18e-6	Depressive symptoms;
TGCT	cis	rs10114408	0.959	rs7852292	chr9:96648085	C/T	cg13679303	chr9:96623674	NA	-0.36	-4.6	-0.38	1.04e-5	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs2445762	1.000	rs2445762	chr15:51617708	T/C	cg00184732	chr15:51633821	GLDN	0.41	4.59	0.38	1.08e-5	Hormone measurements;
TGCT	cis	rs7666738	0.791	rs12233867	chr4:98950233	A/G	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs868036	0.609	rs2127163	chr15:68090842	C/T	cg27219399	chr15:67835830	MAP2K5	0.34	4.49	0.37	1.6e-5	Restless legs syndrome;
TGCT	cis	rs1023500	0.505	rs134889	chr22:42674350	A/T	cg15557168	chr22:42548783	NA	-0.21	-4.99	-0.41	2.03e-6	Schizophrenia;
TGCT	cis	rs611744	0.905	rs610891	chr8:109161003	C/T	cg21045802	chr8:109455806	TTC35	-0.49	-4.5	-0.37	1.53e-5	Dupuytren's disease;
TGCT	cis	rs514406	0.505	rs146750	chr1:53183447	C/G	cg08859206	chr1:53392774	SCP2	-0.35	-5.18	-0.42	8.58e-7	Monocyte count;
TGCT	cis	rs71191701	1.000	rs71191701	chr9:139322257	G/C	cg13741927	chr9:139327495	INPP5E	-0.29	-6.75	-0.52	4.99e-10	Myeloid white cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
TGCT	cis	rs10751667	0.643	rs10751671	chr11:944479	T/G	cg06064525	chr11:970664	AP2A2	-0.35	-8.28	-0.6	1.65e-13	Alzheimer's disease (late onset);
TGCT	cis	rs8017423	0.647	rs12882575	chr14:90820454	C/G	cg04374321	chr14:90722782	PSMC1	-0.56	-5.62	-0.45	1.19e-7	Mortality in heart failure;
TGCT	cis	rs992157	0.560	rs6738394	chr2:219110625	G/A	cg00012203	chr2:219082015	ARPC2	-0.81	-9.21	-0.64	1.03e-15	Colorectal cancer;
TGCT	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg13395646	chr4:1353034	KIAA1530	-0.47	-5.77	-0.46	5.99e-8	Obesity-related traits;
TGCT	cis	rs11696501	0.694	rs2171371	chr20:44273482	T/C	cg11783356	chr20:44313418	WFDC10B	-0.32	-4.63	-0.38	9.25e-6	Brain structure;
TGCT	cis	rs3096299	0.685	rs3803681	chr16:89544756	C/T	cg02187348	chr16:89574699	SPG7	0.6	6.26	0.49	5.79e-9	Multiple myeloma (IgH translocation);
TGCT	cis	rs2067615	0.579	rs10746066	chr12:107129108	G/A	cg15890332	chr12:107067104	RFX4	0.28	5.55	0.45	1.68e-7	Heart rate;
TGCT	cis	rs1062177	1.000	rs2964584	chr5:151142878	T/C	cg00977110	chr5:151150581	G3BP1	0.4	4.55	0.38	1.26e-5	Preschool internalizing problems;
TGCT	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg11247378	chr22:39784982	NA	-0.73	-9.59	-0.65	1.22e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs12477438	1.000	rs12466388	chr2:99916538	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.81	-6.3	-0.49	4.62e-9	Chronic sinus infection;
TGCT	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg18402987	chr7:1209562	NA	0.39	4.48	0.37	1.68e-5	Longevity;Endometriosis;
TGCT	cis	rs6684514	1.000	rs10752615	chr1:156248609	T/C	cg20302342	chr1:156215951	PAQR6	0.34	4.6	0.38	1.01e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs6665290	0.901	rs61834004	chr1:227202782	G/A	cg10327440	chr1:227177885	CDC42BPA	-0.99	-20.19	-0.88	5.19e-41	Myeloid white cell count;
TGCT	cis	rs3770081	1.000	rs60479377	chr2:86283948	A/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.17	-4.56	-0.38	1.21e-5	Facial emotion recognition (sad faces);
TGCT	cis	rs2370759	1.000	rs75984055	chr10:32591276	T/C	cg01819863	chr10:32635814	EPC1	1.03	10.03	0.67	1.05e-17	Sexual dysfunction (female);
TGCT	cis	rs6570726	0.791	rs6915094	chr6:145883540	C/G	cg05347473	chr6:146136440	FBXO30	0.54	5.15	0.42	1.01e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs116095464	0.558	rs10059907	chr5:205360	G/C	cg22857025	chr5:266934	NA	-0.34	-6.42	-0.5	2.63e-9	Breast cancer;
TGCT	cis	rs911555	1.000	rs754287	chr14:103997525	T/A	cg12935359	chr14:103987150	CKB	0.35	4.96	0.41	2.23e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2760061	0.583	rs1774757	chr1:228211135	C/G	cg18477163	chr1:228402036	OBSCN	0.36	7.28	0.55	3.39e-11	Diastolic blood pressure;
TGCT	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg06221963	chr1:154839813	KCNN3	-0.71	-11.68	-0.72	1.06e-21	Prostate cancer;
TGCT	cis	rs9811920	0.809	rs796976	chr3:99621002	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.46	-5.2	-0.42	7.88e-7	Axial length;
TGCT	cis	rs11098499	0.754	rs12507565	chr4:120251121	G/A	cg09307838	chr4:120376055	NA	0.61	5.91	0.47	3.14e-8	Corneal astigmatism;
TGCT	cis	rs394563	0.591	rs6570964	chr6:149691859	G/A	cg16235748	chr6:149772707	ZC3H12D	0.44	5.03	0.41	1.66e-6	Dupuytren's disease;
TGCT	cis	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg08564027	chr20:61660810	NA	0.37	6.85	0.52	3.1e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs854765	0.562	rs2955381	chr17:17945500	G/C	cg09796270	chr17:17721594	SREBF1	-0.24	-4.7	-0.39	6.8e-6	Total body bone mineral density;
TGCT	cis	rs6840360	0.615	rs7669761	chr4:152609304	G/A	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.15	-0.48	9.82e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs4285028	0.699	rs4676758	chr3:121583415	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.79	6.75	0.52	5.11e-10	Multiple sclerosis;
TGCT	cis	rs9611565	0.694	rs4822032	chr22:41925535	T/C	cg06481639	chr22:41940642	POLR3H	-0.58	-5.26	-0.43	6.02e-7	Vitiligo;
TGCT	cis	rs425277	1.000	rs262641	chr1:2104981	C/T	cg03732007	chr1:2071316	PRKCZ	-0.23	-4.85	-0.4	3.56e-6	Height;
TGCT	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg11764359	chr7:65958608	NA	0.58	5.32	0.43	4.62e-7	Aortic root size;
TGCT	cis	rs9527	0.590	rs7894959	chr10:104756182	C/T	cg15744005	chr10:104629667	AS3MT	-0.42	-5.0	-0.41	1.93e-6	Arsenic metabolism;
TGCT	cis	rs9611519	1.000	rs5758268	chr22:41622419	A/T	cg03806693	chr22:41940476	POLR3H	-0.67	-6.4	-0.5	2.9e-9	Neuroticism;
TGCT	cis	rs9913156	0.748	rs72835619	chr17:4557285	G/A	cg23387401	chr17:4582204	PELP1	0.31	4.57	0.38	1.14e-5	Lymphocyte counts;
TGCT	cis	rs655029	0.837	rs632964	chr2:31463866	G/C	cg14018959	chr2:31480232	EHD3	-0.36	-4.88	-0.4	3.25e-6	Mean platelet volume;Platelet distribution width;Platelet count;Plateletcrit;
TGCT	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg25767906	chr1:53392781	SCP2	0.48	5.55	0.45	1.62e-7	Monocyte count;
TGCT	cis	rs9926296	0.607	rs2079672	chr16:89884917	A/G	cg27121462	chr16:89883253	FANCA	-0.54	-5.07	-0.41	1.41e-6	Vitiligo;
TGCT	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg08280861	chr8:58055591	NA	0.42	4.82	0.4	4.15e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg03213289	chr20:61660250	NA	0.68	9.99	0.67	1.36e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1059312	0.808	rs10847693	chr12:129292006	G/A	cg09035930	chr12:129282057	SLC15A4	0.55	10.73	0.69	2.06e-19	Systemic lupus erythematosus;
TGCT	cis	rs1865760	0.865	rs9467652	chr6:25959127	A/G	cg17042849	chr6:26104293	HIST1H4C	-0.52	-4.78	-0.39	4.88e-6	Height;
TGCT	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.82	7.39	0.55	1.85e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs3796352	1.000	rs35849389	chr3:53005235	A/G	cg07884673	chr3:53033167	SFMBT1	0.62	6.19	0.49	8.26e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs2153535	0.580	rs9406167	chr6:8502852	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.28	4.92	0.4	2.73e-6	Schizophrenia;
TGCT	cis	rs950027	0.620	rs1153855	chr15:45660758	C/G	cg26924012	chr15:45694286	SPATA5L1	0.79	8.86	0.62	6.92e-15	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs7727544	0.684	rs272869	chr5:131677997	A/G	cg24060327	chr5:131705240	SLC22A5	-0.59	-6.53	-0.51	1.54e-9	Blood metabolite levels;
TGCT	cis	rs45509595	0.822	rs200484	chr6:27775674	A/G	cg10876282	chr6:28092338	ZSCAN16	0.76	4.53	0.38	1.38e-5	Breast cancer;
TGCT	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg21724239	chr8:58056113	NA	0.4	5.01	0.41	1.8e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1635	0.655	rs75885713	chr6:28312356	G/A	cg15743358	chr6:28303923	ZNF323	-1.3	-4.94	-0.41	2.45e-6	Schizophrenia;
TGCT	cis	rs9811920	0.695	rs1287284	chr3:99516962	C/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.44	4.98	0.41	2.08e-6	Axial length;
TGCT	cis	rs9611565	0.592	rs8779	chr22:42070276	T/C	cg03806693	chr22:41940476	POLR3H	1.08	11.79	0.73	5.53e-22	Vitiligo;
TGCT	cis	rs7829975	0.564	rs2921057	chr8:8318667	C/T	cg08975724	chr8:8085496	FLJ10661	0.64	6.16	0.48	9.49e-9	Mood instability;
TGCT	cis	rs3796352	1.000	rs11718752	chr3:53130745	T/C	cg15956490	chr3:53032818	SFMBT1	0.49	5.58	0.45	1.41e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs9611565	0.649	rs738422	chr22:42123399	C/T	cg06634786	chr22:41940651	POLR3H	0.82	7.9	0.58	1.3e-12	Vitiligo;
TGCT	cis	rs7027203	0.964	rs6479512	chr9:96556985	G/A	cg13679303	chr9:96623674	NA	0.66	9.82	0.66	3.55e-17	DNA methylation (variation);
TGCT	cis	rs2067615	0.579	rs10778509	chr12:107162918	G/A	cg15890332	chr12:107067104	RFX4	0.29	5.89	0.47	3.34e-8	Heart rate;
TGCT	cis	rs908922	0.676	rs4845782	chr1:152492225	A/G	cg20991723	chr1:152506922	NA	0.46	6.28	0.49	5.16e-9	Hair morphology;
TGCT	cis	rs2230307	0.536	rs522696	chr1:100476662	G/A	cg24955406	chr1:100503596	HIAT1	0.75	4.88	0.4	3.2e-6	Carotid intima media thickness;
TGCT	cis	rs2688608	0.588	rs10128205	chr10:75469648	C/G	cg19442545	chr10:75533431	FUT11	-0.38	-5.91	-0.47	3.03e-8	Inflammatory bowel disease;
TGCT	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg13395646	chr4:1353034	KIAA1530	0.4	4.98	0.41	2.1e-6	Obesity-related traits;
TGCT	cis	rs7843479	0.965	rs13269198	chr8:21823025	G/A	cg17168535	chr8:21777572	XPO7	0.65	5.99	0.47	2.14e-8	Mean corpuscular volume;
TGCT	cis	rs7714584	1.000	rs10058821	chr5:150226385	A/G	cg22134413	chr5:150180641	NA	0.89	6.96	0.53	1.73e-10	Crohn's disease;
TGCT	trans	rs621559	0.535	rs665462	chr1:43672011	T/C	cg19324027	chr2:74699582	MRPL53	0.87	6.75	0.52	5.12e-10	Telomere length;
TGCT	cis	rs7666738	0.515	rs13131874	chr4:98779183	A/G	cg17366294	chr4:99064904	C4orf37	0.62	5.78	0.46	5.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg00343986	chr7:65444356	GUSB	0.26	6.12	0.48	1.15e-8	Calcium levels;
TGCT	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg13866156	chr1:1669148	SLC35E2	-0.23	-5.53	-0.44	1.8e-7	Body mass index;
TGCT	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg00343986	chr7:65444356	GUSB	0.23	5.14	0.42	1.06e-6	Aortic root size;
TGCT	cis	rs13256369	0.851	rs13266562	chr8:8564065	T/C	cg06671706	chr8:8559999	CLDN23	0.34	4.53	0.38	1.38e-5	Obesity-related traits;
TGCT	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg18230493	chr5:56204884	C5orf35	-0.84	-6.45	-0.5	2.23e-9	Initial pursuit acceleration;
TGCT	cis	rs7772486	0.846	rs2748499	chr6:146315002	T/C	cg13319975	chr6:146136371	FBXO30	-0.51	-4.55	-0.38	1.28e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6569992	0.500	rs12660713	chr6:135517996	G/A	cg22676075	chr6:135203613	NA	0.77	4.86	0.4	3.51e-6	Red blood cell traits;
TGCT	trans	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg23505145	chr19:12996616	KLF1	0.79	8.3	0.6	1.47e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs200895692	1	rs200895692	chr1:43421956	CGCCTGTAATCCCAG/C	cg00102166	chr1:43425337	SLC2A1	-0.73	-6.36	-0.5	3.58e-9	Monocyte count;
TGCT	cis	rs6969780	0.722	rs4722666	chr7:27197601	C/G	cg04321618	chr7:27170880	HOXA4	-0.52	-5.18	-0.42	8.67e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs1532993	0.518	rs11097566	chr4:98587459	C/T	cg05340658	chr4:99064831	C4orf37	0.41	4.84	0.4	3.8e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg11764359	chr7:65958608	NA	0.57	5.28	0.43	5.64e-7	Aortic root size;
TGCT	trans	rs7698623	0.850	rs7678318	chr4:88768888	C/T	cg01186725	chr1:53905612	FLJ40434	-0.48	-6.63	-0.51	9.21e-10	Cardiovascular disease risk factors;
TGCT	trans	rs17685	0.743	rs10277259	chr7:75802674	A/C	cg19862616	chr7:65841803	NCRNA00174	0.51	8.88	0.62	6.28e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs1348850	0.651	rs1901826	chr2:178225266	G/A	cg22681709	chr2:178499509	PDE11A	-0.35	-4.51	-0.38	1.5e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs526231	0.578	rs10463553	chr5:102249207	T/C	cg23492399	chr5:102201601	PAM	-0.51	-4.49	-0.37	1.62e-5	Primary biliary cholangitis;
TGCT	cis	rs614226	0.872	rs787827	chr12:120937794	A/G	cg10072921	chr12:121022843	NA	-0.45	-4.76	-0.39	5.27e-6	Type 1 diabetes nephropathy;
TGCT	cis	rs2228479	0.850	rs62054610	chr16:89816920	G/A	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg02725872	chr8:58115012	NA	-0.38	-5.05	-0.41	1.55e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2180341	0.814	rs6569488	chr6:127726256	C/T	cg27446573	chr6:127587934	RNF146	0.88	8.07	0.59	5.22e-13	Breast cancer;
TGCT	cis	rs9549260	0.755	rs7324319	chr13:41233505	G/C	cg21288729	chr13:41239152	FOXO1	0.98	10.14	0.67	5.74e-18	Red blood cell count;
TGCT	cis	rs12681288	0.782	rs2600497	chr8:1026220	A/G	cg04851639	chr8:1020857	NA	-0.33	-5.71	-0.46	7.82e-8	Schizophrenia;
TGCT	cis	rs3091242	0.933	rs7541095	chr1:25761291	T/C	cg00786635	chr1:25594202	NA	0.54	5.7	0.46	8.3e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs9467773	1.000	rs6456733	chr6:26566804	C/T	cg05738196	chr6:26577821	NA	0.9	12.48	0.75	1.16e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs4891159	0.790	rs9950025	chr18:74113596	C/G	cg24786174	chr18:74118243	ZNF516	0.63	9.98	0.67	1.38e-17	Longevity;
TGCT	cis	rs11098499	0.865	rs28753180	chr4:120405367	A/T	cg09307838	chr4:120376055	NA	0.69	6.64	0.51	8.97e-10	Corneal astigmatism;
TGCT	cis	rs2228479	0.717	rs9282682	chr16:89805794	A/G	cg26513180	chr16:89883248	FANCA	0.78	4.56	0.38	1.23e-5	Skin colour saturation;
TGCT	cis	rs7336332	0.628	rs9581855	chr13:28018014	G/A	cg22138327	chr13:27999177	GTF3A	0.83	6.64	0.51	9e-10	Weight;
TGCT	cis	rs832540	0.864	rs832576	chr5:56163255	C/A	cg24531977	chr5:56204891	C5orf35	-0.51	-5.21	-0.42	7.61e-7	Coronary artery disease;
TGCT	cis	rs10833905	0.680	rs10833894	chr11:23027476	A/G	cg06387204	chr11:22647648	FANCF	-0.52	-4.69	-0.39	7.07e-6	Sudden cardiac arrest;
TGCT	cis	rs12530845	1.000	rs12540325	chr7:135334111	T/C	cg23117316	chr7:135346802	PL-5283	-0.51	-4.83	-0.4	3.98e-6	Red blood cell traits;
TGCT	cis	rs950169	0.840	rs62029595	chr15:84955301	C/T	cg17173187	chr15:85201210	NMB	0.58	5.93	0.47	2.77e-8	Schizophrenia;
TGCT	cis	rs10197940	0.578	rs6718653	chr2:152346118	C/A	cg19508488	chr2:152266495	RIF1	0.59	4.98	0.41	2.11e-6	Lung cancer;
TGCT	cis	rs7772486	0.681	rs9390343	chr6:146010527	A/T	cg05347473	chr6:146136440	FBXO30	-0.49	-4.67	-0.39	7.63e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs17539620	0.624	rs62432735	chr6:154834055	T/C	cg20019720	chr6:154832845	CNKSR3	0.56	4.75	0.39	5.5e-6	Lipoprotein (a) levels;
TGCT	cis	rs28493229	0.708	rs73546845	chr19:41158717	C/T	cg11601297	chr19:41224147	ITPKC;ADCK4	0.57	5.15	0.42	9.78e-7	Kawasaki disease;
TGCT	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg21017887	chr14:105400489	NA	-0.38	-5.42	-0.44	3.03e-7	Rheumatoid arthritis;
TGCT	cis	rs7246657	0.943	rs10405407	chr19:37839164	C/T	cg03233940	chr19:37894644	NA	-0.34	-4.49	-0.37	1.59e-5	Coronary artery calcification;
TGCT	cis	rs806215	1.000	rs806196	chr7:127248414	A/G	cg25922125	chr7:127225783	GCC1	0.59	5.98	0.47	2.21e-8	Type 2 diabetes;
TGCT	cis	rs732765	0.734	rs10133860	chr14:75186425	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.55	-4.48	-0.37	1.71e-5	Non-small cell lung cancer;
TGCT	cis	rs7829975	0.533	rs35900578	chr8:8719513	G/A	cg06636001	chr8:8085503	FLJ10661	0.77	6.9	0.53	2.4e-10	Mood instability;
TGCT	cis	rs11264213	0.901	rs645123	chr1:36458075	T/C	cg27506609	chr1:36549197	TEKT2	0.39	4.64	0.38	8.67e-6	Schizophrenia;
TGCT	cis	rs71435601	0.657	rs490757	chr2:21388224	C/T	cg25035485	chr2:21266500	APOB	0.51	4.48	0.37	1.64e-5	Cholesterol, total;
TGCT	cis	rs6988636	0.534	rs62521770	chr8:124104070	G/A	cg27053337	chr8:124217698	FAM83A	0.56	4.82	0.4	4.1e-6	Urinary uromodulin levels;
TGCT	cis	rs7267979	1.000	rs2257496	chr20:25279315	A/G	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs28595532	0.920	rs114678295	chr4:119756281	C/T	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	trans	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg21659725	chr3:3221576	CRBN	-0.75	-8.83	-0.62	8.16e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg24675658	chr1:53192096	ZYG11B	-0.84	-10.27	-0.68	2.8e-18	Monocyte count;
TGCT	cis	rs6089584	0.927	rs2281734	chr20:60582401	C/A	cg16423285	chr20:60520624	NA	-0.63	-7.09	-0.54	8.93e-11	Body mass index;
TGCT	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.52	4.48	0.37	1.69e-5	Prudent dietary pattern;
TGCT	cis	rs11264213	0.901	rs688833	chr1:36455600	C/T	cg07093915	chr1:36184400	C1orf216	0.65	4.47	0.37	1.77e-5	Schizophrenia;
TGCT	cis	rs3733585	0.637	rs6850684	chr4:9964380	G/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.58	-0.51	1.2e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs11098499	0.954	rs59866101	chr4:120296591	T/G	cg09307838	chr4:120376055	NA	0.66	6.48	0.5	1.98e-9	Corneal astigmatism;
TGCT	cis	rs7666738	0.830	rs10440379	chr4:98902822	G/T	cg05340658	chr4:99064831	C4orf37	0.51	5.93	0.47	2.84e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs68170813	0.559	rs76145119	chr7:107052368	C/T	cg02696742	chr7:106810147	HBP1	-0.68	-5.44	-0.44	2.69e-7	Coronary artery disease;
TGCT	cis	rs1008375	1.000	rs10939742	chr4:17659936	G/T	cg18681998	chr4:17616180	MED28	1.01	11.93	0.73	2.52e-22	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7178572	1.000	rs2055901	chr15:77759295	G/A	cg15453836	chr15:77711506	NA	-0.4	-4.59	-0.38	1.07e-5	Type 2 diabetes;
TGCT	cis	rs4285028	0.796	rs12638492	chr3:121711763	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.75	-6.28	-0.49	5.3300000000000004e-09	Multiple sclerosis;
TGCT	cis	rs12541335	0.639	rs68063696	chr8:22153236	A/G	cg02463440	chr8:22132932	PIWIL2	0.25	4.85	0.4	3.6e-6	Hypertriglyceridemia;
TGCT	cis	rs6540559	0.611	rs61747285	chr1:210004332	G/A	cg21951975	chr1:209979733	IRF6	0.64	4.82	0.4	4.12e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg03188948	chr7:1209495	NA	0.68	5.8	0.46	5.09e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs6815814	0.861	rs10004195	chr4:38784724	T/A	cg02016764	chr4:38805732	TLR1	-0.28	-4.52	-0.38	1.41e-5	Breast cancer;
TGCT	cis	rs7605378	1.000	rs7605378	chr2:200676926	A/C	cg17644776	chr2:200775616	C2orf69	0.26	5.1	0.42	1.25e-6	Osteoporosis;
TGCT	cis	rs67311347	1.000	rs73076046	chr3:40447724	C/T	cg13683864	chr3:40499215	RPL14	-1.19	-13.2	-0.76	2.17e-25	Renal cell carcinoma;
TGCT	cis	rs6921919	0.609	rs67211468	chr6:28391987	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.53	-5.16	-0.42	9.45e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs10791097	0.720	rs7119425	chr11:130733185	C/T	cg14779329	chr11:130786720	SNX19	0.28	4.81	0.4	4.27e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg10047753	chr17:41438598	NA	0.79	7.48	0.56	1.19e-11	Menopause (age at onset);
TGCT	cis	rs10791097	0.677	rs11222359	chr11:130730648	A/G	cg05962950	chr11:130786565	SNX19	0.82	9.91	0.66	2.06e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg13866156	chr1:1669148	SLC35E2	-0.21	-5.01	-0.41	1.81e-6	Body mass index;
TGCT	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg20573242	chr4:122745356	CCNA2	0.51	4.69	0.39	7.21e-6	Type 2 diabetes;
TGCT	cis	rs7179456	0.544	rs2555357	chr15:59087115	A/G	cg05156742	chr15:59063176	FAM63B	0.56	5.26	0.43	6.22e-7	Asperger disorder;
TGCT	cis	rs7655841	0.704	rs7671508	chr4:129977667	G/T	cg26347359	chr4:129759716	PHF17	-0.43	-4.98	-0.41	2.07e-6	Chronic obstructive pulmonary disease (moderate to severe);
TGCT	cis	rs2492301	0.506	rs11264049	chr1:37902135	A/G	cg17933807	chr1:38061675	GNL2	-0.56	-5.57	-0.45	1.52e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs16854884	0.837	rs4380409	chr3:143800896	A/G	cg06585982	chr3:143692056	C3orf58	0.61	4.72	0.39	6.19e-6	Economic and political preferences (feminism/equality);
TGCT	cis	rs4886920	0.563	rs55726435	chr15:78071083	C/T	cg03457338	chr15:78040120	NA	0.19	4.76	0.39	5.22e-6	Neuroticism;
TGCT	cis	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg08564027	chr20:61660810	NA	0.37	6.85	0.52	3.1e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs533581	0.866	rs2968474	chr16:88970566	A/G	cg16701003	chr16:89028210	CBFA2T3	-0.39	-5.1	-0.42	1.25e-6	Social autistic-like traits;
TGCT	cis	rs35146811	0.660	rs3779045	chr7:99779259	T/C	cg00553149	chr7:99775558	STAG3;GPC2	0.31	4.61	0.38	9.75e-6	Coronary artery disease;
TGCT	trans	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg21659725	chr3:3221576	CRBN	-0.98	-15.33	-0.81	2.1000000000000002e-30	Intelligence (multi-trait analysis);
TGCT	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg09359103	chr1:154839909	KCNN3	-0.66	-12.15	-0.74	7.27e-23	Prostate cancer;
TGCT	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg08736216	chr1:53307985	ZYG11A	-0.25	-4.83	-0.4	4.01e-6	Monocyte count;
TGCT	cis	rs56399783	0.901	rs73051415	chr7:2850643	C/T	cg19731401	chr7:2775893	GNA12	0.37	4.97	0.41	2.14e-6	Childhood ear infection;
TGCT	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.51	-4.94	-0.41	2.52e-6	Bipolar disorder;
TGCT	cis	rs7043114	0.525	rs2516567	chr9:95187418	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-5.59	-0.45	1.36e-7	Height;
TGCT	cis	rs9394841	0.692	rs9357371	chr6:41885319	A/C	cg08135965	chr6:41755394	TOMM6	0.57	5.11	0.42	1.21e-6	Mean corpuscular hemoglobin;Red cell distribution width;
TGCT	cis	rs11098499	0.818	rs12498599	chr4:120468503	C/T	cg09307838	chr4:120376055	NA	0.72	6.87	0.52	2.81e-10	Corneal astigmatism;
TGCT	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg05985448	chr10:134359359	INPP5A	0.22	5.1	0.42	1.26e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs642803	0.591	rs620088	chr11:65508986	G/A	cg27068330	chr11:65405492	SIPA1	0.64	5.68	0.45	8.87e-8	Urate levels;
TGCT	cis	rs8031584	0.663	rs1917421	chr15:31187663	C/T	cg08704250	chr15:31115839	NA	-0.42	-6.28	-0.49	5.27e-9	Huntington's disease progression;
TGCT	cis	rs4654899	0.802	rs12401413	chr1:21236503	T/C	cg01072550	chr1:21505969	NA	-0.46	-6.94	-0.53	1.96e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs2997447	0.761	rs17257093	chr1:26436231	C/A	cg03844060	chr1:26490628	NA	0.28	4.56	0.38	1.19e-5	QRS complex (12-leadsum);
TGCT	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg13409248	chr3:40428643	ENTPD3	0.57	4.6	0.38	1.03e-5	Renal cell carcinoma;
TGCT	trans	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg20587970	chr11:113659929	NA	-1.04	-12.57	-0.75	6.97e-24	Hip circumference adjusted for BMI;
TGCT	cis	rs7804356	0.954	rs10225924	chr7:26839954	C/T	cg03456212	chr7:26904342	SKAP2	-0.61	-4.7	-0.39	6.82e-6	Type 1 diabetes;
TGCT	cis	rs12681288	0.676	rs34435811	chr8:990630	T/A	cg04851639	chr8:1020857	NA	-0.29	-4.68	-0.39	7.51e-6	Schizophrenia;
TGCT	cis	rs858239	0.570	rs10271613	chr7:23162586	G/A	cg05602783	chr7:23145260	KLHL7	-0.65	-5.52	-0.44	1.93e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg20607798	chr8:58055168	NA	0.67	5.62	0.45	1.22e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7666738	0.830	rs11942114	chr4:99066261	C/G	cg05340658	chr4:99064831	C4orf37	0.52	5.92	0.47	2.91e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7267979	0.966	rs2261784	chr20:25262396	G/C	cg14121845	chr20:25566513	NINL	0.51	5.5	0.44	2.04e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs62244186	0.659	rs12489887	chr3:44547124	A/T	cg10108389	chr3:44770937	ZNF501	-0.48	-4.94	-0.41	2.48e-6	Depressive symptoms;
TGCT	cis	rs7772486	0.776	rs2265467	chr6:146218339	T/A	cg23711669	chr6:146136114	FBXO30	0.83	9.16	0.64	1.32e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9372498	0.536	rs1319988	chr6:118782379	G/A	cg21191810	chr6:118973309	C6orf204	-0.37	-4.77	-0.39	5.03e-6	Diastolic blood pressure;
TGCT	cis	rs10089	1.000	rs72794401	chr5:127517626	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.82	7.66	0.57	4.61e-12	Ileal carcinoids;
TGCT	cis	rs9787249	0.957	rs11206754	chr1:40216234	A/G	cg24920358	chr1:40204285	PPIE	0.58	10.58	0.69	4.85e-19	Blood protein levels;
TGCT	cis	rs12477438	0.520	rs6542866	chr2:99764592	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	10.3	0.68	2.42e-18	Chronic sinus infection;
TGCT	cis	rs7542091	0.704	rs7550330	chr1:210044587	G/A	cg23283495	chr1:209979779	IRF6	0.55	5.47	0.44	2.34e-7	Monobrow;
TGCT	cis	rs6121246	0.609	rs6087783	chr20:30421224	T/G	cg18721089	chr20:30220636	NA	-0.37	-4.46	-0.37	1.79e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs1891275	0.509	rs76313529	chr10:93443076	T/C	cg07889827	chr10:93443413	NA	-0.33	-6.88	-0.53	2.59e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs6032067	0.673	rs13042474	chr20:43893068	G/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.45	-6.37	-0.5	3.36e-9	Blood protein levels;
TGCT	cis	rs1472147	0.518	rs1565629	chr7:128445370	G/A	cg00260937	chr7:128520193	KCP	0.46	5.12	0.42	1.15e-6	Calcium levels;
TGCT	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg04944784	chr2:26401820	FAM59B	-0.67	-6.16	-0.48	9.54e-9	Gut microbiome composition (summer);
TGCT	cis	rs6074578	0.679	rs1434789	chr20:137900	T/G	cg16931068	chr20:139680	DEFB127	0.28	4.82	0.4	4.11e-6	Hirschsprung disease;
TGCT	cis	rs2836950	0.501	rs2836984	chr21:40700949	A/C	cg17971929	chr21:40555470	PSMG1	-0.51	-4.48	-0.37	1.7e-5	Menarche (age at onset);
TGCT	cis	rs11203032	0.710	rs10887923	chr10:90930404	C/T	cg16672925	chr10:90967113	CH25H	0.73	4.5	0.37	1.55e-5	Heart failure;
TGCT	cis	rs7552167	0.925	rs11249020	chr1:24512804	A/G	cg01960748	chr1:24522592	NA	-0.49	-5.49	-0.44	2.13e-7	Psoriasis vulgaris;
TGCT	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg17054783	chr10:134559939	INPP5A	0.26	4.91	0.4	2.78e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs2228479	0.850	rs2283565	chr16:89827556	G/T	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs3733585	0.673	rs4580649	chr4:9948461	G/A	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.37	-0.5	3.33e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs9467773	1.000	rs9467774	chr6:26505036	C/A	cg15659132	chr6:26577336	NA	0.86	12.18	0.74	6.14e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs3213545	0.700	rs2260399	chr12:121469653	C/T	cg02403541	chr12:121454288	C12orf43	0.71	8.0	0.58	7.62e-13	Subjective well-being;Cardiovascular disease risk factors;
TGCT	cis	rs981844	0.775	rs17299246	chr4:154743504	C/T	cg14289246	chr4:154710475	SFRP2	0.88	6.17	0.48	9.07e-9	Response to statins (LDL cholesterol change);
TGCT	cis	rs3820928	1.000	rs4675119	chr2:227774635	A/C	cg11843606	chr2:227700838	RHBDD1	-0.53	-4.73	-0.39	5.89e-6	Pulmonary function;
TGCT	cis	rs3008870	0.727	rs4582760	chr1:67464394	G/A	cg02640540	chr1:67518911	SLC35D1	-0.49	-4.44	-0.37	1.94e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs950027	0.595	rs2486288	chr15:45712339	T/C	cg14582100	chr15:45693742	SPATA5L1	0.43	5.38	0.44	3.52e-7	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs9611565	0.649	rs139553	chr22:42187199	A/G	cg13695892	chr22:41940480	POLR3H	0.86	8.19	0.59	2.67e-13	Vitiligo;
TGCT	cis	rs11671005	0.735	rs11881000	chr19:58932788	C/T	cg13877915	chr19:58951672	ZNF132	0.65	5.14	0.42	1.04e-6	Mean platelet volume;
TGCT	cis	rs7547997	0.685	rs11264963	chr1:158335533	A/G	cg07950803	chr1:158223934	CD1A	0.32	4.98	0.41	2.04e-6	QRS duration;
TGCT	cis	rs7927771	0.832	rs10838698	chr11:47385923	G/A	cg21462715	chr11:47870315	NUP160	-0.56	-4.52	-0.38	1.4e-5	Subjective well-being;
TGCT	trans	rs561341	0.700	rs886223	chr17:30229877	G/T	cg20587970	chr11:113659929	NA	-0.6	-9.12	-0.63	1.65e-15	Hip circumference adjusted for BMI;
TGCT	cis	rs10791323	0.604	rs2257010	chr11:133712348	G/A	cg15485101	chr11:133734466	NA	0.42	5.45	0.44	2.62e-7	Childhood ear infection;
TGCT	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg23283495	chr1:209979779	IRF6	0.67	5.7	0.46	8.12e-8	Cleft lip with or without cleft palate;
TGCT	cis	rs10170846	0.924	rs3768973	chr2:223436402	C/T	cg25565276	chr2:223520875	FARSB	0.75	5.73	0.46	7.09e-8	Schizophrenia (inflammation and infection response interaction);
TGCT	cis	rs3862260	0.509	rs1045827	chr1:120162442	C/T	cg11530693	chr1:120165357	ZNF697	-0.2	-4.48	-0.37	1.67e-5	Systemic lupus erythematosus;
TGCT	cis	rs36051895	0.664	rs10115518	chr9:5094559	T/C	cg02405213	chr9:5042618	JAK2	-0.72	-9.52	-0.65	1.85e-16	Pediatric autoimmune diseases;
TGCT	trans	rs114540395	0.858	rs116357148	chr10:103352082	T/A	cg10198749	chr1:39920707	MACF1	0.55	7.03	0.53	1.2e-10	Schizophrenia;
TGCT	cis	rs11190604	1.000	rs10883508	chr10:102294413	G/A	cg16342193	chr10:102329863	NA	-0.42	-5.37	-0.43	3.76e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs1887596	0.554	rs547756	chr13:27114904	G/C	cg01312412	chr13:27282625	NA	-0.28	-4.96	-0.41	2.26e-6	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs7829975	0.711	rs4481596	chr8:8704330	G/C	cg06636001	chr8:8085503	FLJ10661	0.75	6.95	0.53	1.82e-10	Mood instability;
TGCT	cis	rs6089829	0.962	rs57684920	chr20:61662639	G/A	cg03213289	chr20:61660250	NA	-0.63	-8.36	-0.6	1.06e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs10056811	0.556	rs55810502	chr5:74380959	A/G	cg00601450	chr5:74908170	NA	0.42	4.44	0.37	1.97e-5	Coronary artery disease;
TGCT	cis	rs763121	0.814	rs5757212	chr22:39053757	G/C	cg06022373	chr22:39101656	GTPBP1	0.8	8.25	0.6	1.95e-13	Menopause (age at onset);
TGCT	cis	rs13177918	0.677	rs13177970	chr5:149826010	A/G	cg14059543	chr5:149831962	NA	-0.71	-9.45	-0.65	2.77e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	trans	rs459571	0.839	rs10993895	chr9:136887726	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	0.72	7.87	0.58	1.48e-12	Platelet distribution width;
TGCT	cis	rs12681287	0.640	rs4961193	chr8:87486168	C/T	cg27223183	chr8:87520930	FAM82B	0.87	6.33	0.49	4.05e-9	Caudate activity during reward;
TGCT	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg11494091	chr17:61959527	GH2	0.43	7.51	0.56	9.88e-12	Height;
TGCT	cis	rs2688608	0.592	rs11000760	chr10:75493734	G/A	cg23231163	chr10:75533350	FUT11	-0.28	-4.68	-0.39	7.4e-6	Inflammatory bowel disease;
TGCT	cis	rs7829975	0.623	rs7010753	chr8:8373956	A/G	cg06636001	chr8:8085503	FLJ10661	0.81	7.9	0.58	1.27e-12	Mood instability;
TGCT	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs17401966	0.558	rs17402762	chr1:10414470	T/C	cg19773385	chr1:10388646	KIF1B	-0.22	-5.27	-0.43	5.96e-7	Hepatocellular carcinoma;
TGCT	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg07636037	chr3:49044803	WDR6	0.88	9.28	0.64	6.89e-16	Menarche (age at onset);
TGCT	cis	rs908922	0.676	rs6658925	chr1:152482801	C/T	cg20991723	chr1:152506922	NA	-0.49	-6.89	-0.53	2.43e-10	Hair morphology;
TGCT	cis	rs2762353	0.845	rs1937130	chr6:25787554	T/A	cg12310025	chr6:25882481	NA	0.5	5.17	0.42	8.96e-7	Blood metabolite levels;
TGCT	cis	rs7010267	0.902	rs7006553	chr8:119970779	C/T	cg17171407	chr8:119960777	TNFRSF11B	0.33	6.26	0.49	5.67e-9	Total body bone mineral density (age 45-60);
TGCT	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg25767906	chr1:53392781	SCP2	-0.55	-6.58	-0.51	1.21e-9	Monocyte count;
TGCT	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg03188948	chr7:1209495	NA	0.71	6.3	0.49	4.79e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs6882046	0.513	rs625970	chr5:88042296	A/G	cg22951263	chr5:87985283	NA	-0.57	-6.02	-0.48	1.79e-8	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs67311347	1.000	rs11706148	chr3:40407243	A/C	cg17264618	chr3:40429014	ENTPD3	0.33	4.73	0.39	6.1e-6	Renal cell carcinoma;
TGCT	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg19723775	chr5:179050963	HNRNPH1	0.48	4.57	0.38	1.16e-5	Lung cancer;
TGCT	cis	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg18252515	chr7:66147081	NA	1.2	7.83	0.58	1.89e-12	Diabetic kidney disease;
TGCT	cis	rs5769707	0.605	rs6009791	chr22:50025265	T/C	cg06623630	chr22:50017776	C22orf34	-0.27	-4.7	-0.39	6.81e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.07	0.82	4.17e-32	Prudent dietary pattern;
TGCT	cis	rs8078723	0.763	rs4433838	chr17:38143532	C/T	cg17467752	chr17:38218738	THRA	-0.53	-5.37	-0.43	3.69e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs4332037	0.539	rs4470910	chr7:2071723	C/T	cg25834613	chr7:1915315	MAD1L1	-0.53	-5.2	-0.42	7.98e-7	Bipolar disorder;
TGCT	cis	rs6840360	0.615	rs66852535	chr4:152472227	C/A	cg17479576	chr4:152424074	FAM160A1	-0.72	-7.98	-0.58	8.25e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs3540	0.618	rs2301832	chr15:91040725	A/T	cg22089800	chr15:90895588	ZNF774	-0.75	-7.58	-0.56	7.16e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs4665809	0.525	rs10865402	chr2:26535383	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-5.86	-0.47	3.97e-8	Gut microbiome composition (summer);
TGCT	cis	rs7917772	0.636	rs7079231	chr10:104527341	A/G	cg05855489	chr10:104503620	C10orf26	-0.63	-5.04	-0.41	1.59e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs478304	0.651	rs4930319	chr11:65555458	G/C	cg17480646	chr11:65405466	SIPA1	-0.55	-6.49	-0.5	1.88e-9	Acne (severe);
TGCT	cis	rs12477438	0.798	rs10202452	chr2:99569409	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-8.69	-0.62	1.75e-14	Chronic sinus infection;
TGCT	cis	rs11030122	0.702	rs7950153	chr11:3951337	T/C	cg18678763	chr11:4115507	RRM1	-0.48	-5.99	-0.47	2.15e-8	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs10782582	0.609	rs1628063	chr1:76391646	A/G	cg10523679	chr1:76189770	ACADM	-0.52	-4.73	-0.39	5.94e-6	Daytime sleep phenotypes;
TGCT	cis	rs926938	0.527	rs360679	chr1:115494121	G/T	cg12756093	chr1:115239321	AMPD1	0.34	4.96	0.41	2.28e-6	Autism;
TGCT	cis	rs35306767	0.761	rs11253559	chr10:1044809	T/C	cg20503657	chr10:835505	NA	0.61	6.71	0.52	6.11e-10	Eosinophil percentage of granulocytes;
TGCT	cis	rs1008375	0.863	rs4590022	chr4:17614434	T/C	cg16339924	chr4:17578868	LAP3	0.74	5.88	0.47	3.64e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9534288	0.956	rs2094244	chr13:46605803	T/C	cg15192986	chr13:46630673	CPB2	-0.51	-6.62	-0.51	9.95e-10	Blood protein levels;
TGCT	cis	rs7208859	0.623	rs55811708	chr17:29104731	G/T	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs6840360	1.000	rs4696104	chr4:152600451	A/G	cg17479576	chr4:152424074	FAM160A1	-0.52	-5.66	-0.45	9.86e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9303401	0.614	rs2007993	chr17:56590643	T/C	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs11676348	0.818	rs7426289	chr2:218966315	C/T	cg00012203	chr2:219082015	ARPC2	-0.52	-4.82	-0.4	4.13e-6	Ulcerative colitis;
TGCT	cis	rs9739682	0.636	rs1920101	chr12:62522638	G/A	cg10589851	chr12:62653931	USP15	-0.59	-4.49	-0.37	1.62e-5	Post bronchodilator FEV1/FVC ratio in COPD;
TGCT	cis	rs35000415	0.688	rs34350562	chr7:128718708	A/G	cg06242719	chr7:129414860	MIR183;MIR96	-0.3	-4.58	-0.38	1.1e-5	Systemic lupus erythematosus;
TGCT	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg13695892	chr22:41940480	POLR3H	-0.91	-9.07	-0.63	2.18e-15	Vitiligo;
TGCT	cis	rs9926296	0.568	rs417323	chr16:89746277	T/G	cg27121462	chr16:89883253	FANCA	-0.56	-5.18	-0.42	8.56e-7	Vitiligo;
TGCT	cis	rs7584330	0.518	rs74003104	chr2:238446823	C/T	cg14458575	chr2:238380390	NA	0.43	4.51	0.38	1.48e-5	Prostate cancer;
TGCT	cis	rs10089	0.953	rs4836359	chr5:127385518	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	6.93	0.53	2e-10	Ileal carcinoids;
TGCT	cis	rs7246657	0.722	rs16958863	chr19:38124235	A/G	cg18154014	chr19:37997991	ZNF793	0.69	4.67	0.39	7.7e-6	Coronary artery calcification;
TGCT	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg00814883	chr7:100076585	TSC22D4	-0.92	-9.76	-0.66	4.73e-17	Platelet count;
TGCT	cis	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg07424592	chr7:64974309	NA	-1.28	-7.3	-0.55	2.98e-11	Diabetic kidney disease;
TGCT	cis	rs2180341	1.000	rs2144743	chr6:127633810	A/T	cg24812749	chr6:127587940	RNF146	0.98	7.64	0.57	5.06e-12	Breast cancer;
TGCT	cis	rs7568458	0.905	rs10172544	chr2:85788270	C/A	cg17127132	chr2:85788382	GGCX	0.68	6.1	0.48	1.27e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs9549367	0.713	rs2480949	chr13:113853149	T/C	cg00898013	chr13:113819073	PROZ	0.53	7.2	0.54	5.17e-11	Platelet distribution width;
TGCT	cis	rs11785400	0.793	rs13248524	chr8:143739343	T/C	cg24634471	chr8:143751801	JRK	0.55	5.51	0.44	1.99e-7	Schizophrenia;
TGCT	cis	rs7267979	1.000	rs2258719	chr20:25275843	C/T	cg16686733	chr20:25566563	NINL	0.6	5.97	0.47	2.29e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7824557	0.679	rs4840554	chr8:11134105	T/C	cg21775007	chr8:11205619	TDH	-0.56	-5.13	-0.42	1.07e-6	Retinal vascular caliber;
TGCT	trans	rs9951602	0.512	rs12607938	chr18:76651887	A/C	cg02800362	chr5:177631904	HNRNPAB	1.12	12.75	0.75	2.64e-24	Obesity-related traits;
TGCT	cis	rs2637266	1.000	rs7900616	chr10:78367075	C/T	cg18941641	chr10:78392320	NA	0.39	4.88	0.4	3.24e-6	Pulmonary function;
TGCT	cis	rs457287	0.772	rs438405	chr9:4824607	G/T	cg21184111	chr9:4792285	RCL1	0.48	4.8	0.4	4.55e-6	Platelet count;
TGCT	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.04	0.53	1.16e-10	Prudent dietary pattern;
TGCT	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.46	-4.98	-0.41	2.1e-6	Longevity;Endometriosis;
TGCT	cis	rs8077577	0.943	rs62073603	chr17:18064316	C/T	cg09161412	chr17:18057145	MYO15A	-0.67	-5.44	-0.44	2.69e-7	Obesity-related traits;
TGCT	cis	rs3733606	0.775	rs66514314	chr4:6827238	C/T	cg26167625	chr4:7770639	AFAP1;LOC84740	0.37	5.25	0.43	6.5e-7	Platelet count;
TGCT	cis	rs10488029	0.646	rs34699952	chr7:37045543	G/A	cg06458904	chr7:36312573	EEPD1	0.39	4.48	0.37	1.64e-5	IgG glycosylation;
TGCT	cis	rs2816062	0.760	rs2745319	chr1:18895078	G/A	cg18795169	chr1:18902165	NA	-0.6	-14.18	-0.79	1.04e-27	Urate levels in lean individuals;
TGCT	cis	rs62244186	0.659	rs12489887	chr3:44547124	A/T	cg02073558	chr3:44770973	ZNF501	0.57	5.5	0.44	2.05e-7	Depressive symptoms;
TGCT	cis	rs6725041	0.819	rs10048796	chr2:213083326	C/G	cg20637307	chr2:213403960	ERBB4	-0.51	-4.48	-0.37	1.68e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs6460942	0.915	rs10267801	chr7:12451931	G/A	cg06484146	chr7:12443880	VWDE	-0.59	-5.88	-0.47	3.51e-8	Coronary artery disease;
TGCT	cis	rs7178572	0.849	rs1005752	chr15:77818128	C/A	cg22256960	chr15:77711686	NA	-0.97	-11.03	-0.7	3.83e-20	Type 2 diabetes;
TGCT	cis	rs910187	0.678	rs6122562	chr20:45813847	A/G	cg27589058	chr20:45804311	EYA2	-0.34	-7.21	-0.54	4.78e-11	Migraine;
TGCT	cis	rs10875595	0.775	rs66998469	chr5:140659960	T/C	cg20560182	chr5:140700478	TAF7	-0.66	-5.06	-0.41	1.49e-6	Pulmonary function decline;
TGCT	cis	rs1401999	1.000	rs6443926	chr3:183706630	A/C	cg01324343	chr3:183735012	ABCC5	0.82	10.97	0.7	5.41e-20	Anterior chamber depth;
TGCT	cis	rs6901004	0.803	rs4947107	chr6:111442505	C/T	cg15721981	chr6:111408429	SLC16A10	-0.51	-4.49	-0.37	1.6e-5	Blood metabolite levels;
TGCT	cis	rs9302065	1.000	rs7490267	chr13:95970258	T/C	cg26751094	chr13:95954534	ABCC4	-0.32	-5.27	-0.43	5.79e-7	Blood metabolite levels;
TGCT	cis	rs2562456	0.792	rs2562398	chr19:21722949	A/G	cg01304269	chr19:21688519	ZNF429	-0.57	-4.77	-0.39	5.02e-6	Pain;
TGCT	cis	rs35883536	0.647	rs10875315	chr1:101044062	G/A	cg06223162	chr1:101003688	GPR88	-0.41	-7.55	-0.56	7.99e-12	Monocyte count;
TGCT	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg17971929	chr21:40555470	PSMG1	0.98	9.65	0.65	9.11e-17	Cognitive function;
TGCT	cis	rs10791323	0.569	rs1944734	chr11:133720077	G/A	cg03690763	chr11:133734501	NA	-0.32	-4.76	-0.39	5.35e-6	Childhood ear infection;
TGCT	cis	rs2072499	0.966	rs6427304	chr1:156156789	A/G	cg06970220	chr1:156163860	SLC25A44	0.6	5.1	0.42	1.22e-6	Testicular germ cell tumor;
TGCT	cis	rs9913156	0.793	rs55677157	chr17:4576620	C/T	cg19197139	chr17:4613644	ARRB2	0.9	7.7	0.57	3.76e-12	Lymphocyte counts;
TGCT	cis	rs4499344	0.881	rs35447302	chr19:33068499	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.7	-6.08	-0.48	1.4e-8	Mean platelet volume;
TGCT	cis	rs79149102	0.579	rs12593542	chr15:75282147	C/G	cg09165964	chr15:75287851	SCAMP5	-1.08	-6.26	-0.49	5.66e-9	Lung cancer;
TGCT	cis	rs9611565	0.571	rs2050032	chr22:42152429	C/T	cg13695892	chr22:41940480	POLR3H	0.81	7.4	0.55	1.77e-11	Vitiligo;
TGCT	cis	rs617791	0.508	rs10896074	chr11:65776304	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.49	4.49	0.37	1.64e-5	Breast cancer;
TGCT	trans	rs829418	0.582	rs747662	chr1:21947218	C/G	cg26917367	chr19:57352807	PEG3;ZIM2;MIMT1	-0.87	-6.68	-0.51	7.11e-10	Neurocognitive impairment in HIV-1 infection (continuous);
TGCT	cis	rs4148883	0.629	rs2602899	chr4:100010128	C/T	cg13256891	chr4:100009986	ADH5	0.42	4.49	0.37	1.64e-5	Alcohol dependence;
TGCT	cis	rs2404602	0.647	rs11631394	chr15:76973209	G/T	cg23625390	chr15:77176239	SCAPER	-0.37	-4.73	-0.39	5.88e-6	Blood metabolite levels;
TGCT	cis	rs16866061	1.000	rs72974205	chr2:225408468	C/T	cg12698349	chr2:225449008	CUL3	1.0	9.83	0.66	3.23e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	cis	rs11731606	0.508	rs28497379	chr4:95283789	G/T	cg00507259	chr4:95128692	SMARCAD1	0.66	4.93	0.41	2.55e-6	Mean platelet volume;
TGCT	cis	rs10875595	0.779	rs4912746	chr5:140673969	T/C	cg20560182	chr5:140700478	TAF7	-0.64	-4.91	-0.4	2.76e-6	Pulmonary function decline;
TGCT	cis	rs6484504	0.576	rs2065208	chr11:31239457	C/T	cg14844989	chr11:31128820	NA	-0.24	-4.58	-0.38	1.13e-5	Red blood cell count;
TGCT	cis	rs7599312	0.553	rs6710653	chr2:213404893	A/G	cg16329650	chr2:213403929	ERBB4	1.06	16.47	0.83	5.13e-33	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs56309584	0.673	rs7219471	chr17:8121594	G/T	cg08322244	chr17:8066669	VAMP2	-0.56	-5.2	-0.42	7.95e-7	Initial pursuit acceleration;
TGCT	trans	rs561341	1.000	rs757009	chr17:30243937	A/G	cg20587970	chr11:113659929	NA	-0.93	-11.69	-0.72	9.7e-22	Hip circumference adjusted for BMI;
TGCT	cis	rs7614311	0.636	rs56165216	chr3:63916620	C/T	cg22134162	chr3:63841271	THOC7	-0.42	-5.58	-0.45	1.44e-7	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs7226408	0.857	rs72887014	chr18:34463771	T/G	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs7752195	0.558	rs77914161	chr6:25233485	T/C	cg16898833	chr6:26189333	HIST1H4D	1.27	5.88	0.47	3.55e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg09060608	chr5:178986726	RUFY1	0.53	5.87	0.47	3.66e-8	Lung cancer;
TGCT	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.55	4.92	0.4	2.74e-6	Prudent dietary pattern;
TGCT	cis	rs9486719	0.843	rs3860229	chr6:97036559	T/C	cg06623918	chr6:96969491	KIAA0776	-1.04	-10.25	-0.68	3.11e-18	Migraine;Coronary artery disease;
TGCT	cis	rs6484504	0.532	rs11031330	chr11:31275073	G/A	cg14844989	chr11:31128820	NA	-0.25	-4.84	-0.4	3.76e-6	Red blood cell count;
TGCT	cis	rs7666738	0.830	rs2903154	chr4:99048151	A/G	cg18180107	chr4:99064573	C4orf37	0.56	5.08	0.41	1.37e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7599312	0.534	rs7355673	chr2:213404389	T/C	cg16329650	chr2:213403929	ERBB4	1.06	16.47	0.83	5.13e-33	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs950169	0.845	rs4106951	chr15:84833394	C/G	cg11189052	chr15:85197271	WDR73	0.81	6.5	0.5	1.78e-9	Schizophrenia;
TGCT	cis	rs2239547	0.657	rs4687554	chr3:52864135	T/C	cg10802521	chr3:52805072	NEK4	-0.63	-5.95	-0.47	2.6e-8	Schizophrenia;
TGCT	cis	rs2404602	0.716	rs67418609	chr15:76627089	C/A	cg22467129	chr15:76604101	ETFA	-0.6	-7.44	-0.56	1.45e-11	Blood metabolite levels;
TGCT	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.51	-4.97	-0.41	2.18e-6	Prudent dietary pattern;
TGCT	cis	rs939658	0.805	rs35832166	chr15:79417994	G/T	cg17916960	chr15:79447300	NA	-0.5	-7.7	-0.57	3.74e-12	Refractive error;
TGCT	cis	rs2012796	0.785	rs61986597	chr14:81853107	T/C	cg02996355	chr14:81879375	NA	0.54	5.35	0.43	4.07e-7	Night sleep phenotypes;
TGCT	cis	rs9486715	0.867	rs9373833	chr6:96904998	A/G	cg06623918	chr6:96969491	KIAA0776	-1.1	-16.66	-0.83	1.99e-33	Headache;
TGCT	cis	rs9926296	0.643	rs12596429	chr16:89841374	T/C	cg27121462	chr16:89883253	FANCA	0.57	5.32	0.43	4.76e-7	Vitiligo;
TGCT	cis	rs7726839	0.794	rs6883536	chr5:599274	G/A	cg09021430	chr5:549028	NA	-0.42	-6.04	-0.48	1.66e-8	Obesity-related traits;
TGCT	cis	rs12497850	0.866	rs6791234	chr3:48996137	A/G	cg07636037	chr3:49044803	WDR6	0.96	10.52	0.69	6.9e-19	Parkinson's disease;
TGCT	cis	rs910187	0.901	rs6124969	chr20:45816277	C/T	cg27589058	chr20:45804311	EYA2	-0.34	-6.27	-0.49	5.61e-9	Migraine;
TGCT	cis	rs9611565	0.921	rs761366	chr22:41744022	C/G	cg17554472	chr22:41940697	POLR3H	-0.42	-4.58	-0.38	1.13e-5	Vitiligo;
TGCT	cis	rs2549003	0.966	rs2706385	chr5:131831766	T/G	cg00255919	chr5:131827918	IRF1	-0.21	-4.9	-0.4	2.89e-6	Asthma (sex interaction);
TGCT	cis	rs6663390	0.510	rs2267896	chr1:208080972	C/T	cg03990033	chr1:208084030	CD34	-0.73	-6.41	-0.5	2.77e-9	Facial morphology (factor 18);
TGCT	cis	rs9650657	0.740	rs11250077	chr8:10656437	T/C	cg27411982	chr8:10470053	RP1L1	-0.24	-5.09	-0.42	1.3e-6	Neuroticism;
TGCT	cis	rs66573146	0.831	rs1048009	chr4:6988677	G/A	cg00086871	chr4:6988644	TBC1D14	0.95	4.78	0.39	4.89e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs6722750	0.933	rs4671554	chr2:64411122	T/A	cg22352474	chr2:64371530	PELI1	-0.58	-5.16	-0.42	9.64e-7	Neuroticism;
TGCT	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	13.57	0.77	2.91e-26	Prudent dietary pattern;
TGCT	cis	rs6831352	1.000	rs6532798	chr4:100054827	C/T	cg12011299	chr4:100065546	ADH4	0.41	5.16	0.42	9.55e-7	Alcohol dependence;
TGCT	cis	rs240764	0.853	rs12374612	chr6:100955752	C/T	cg21058520	chr6:100914733	NA	0.35	4.56	0.38	1.19e-5	Neuroticism;
TGCT	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.5	5.64	0.45	1.08e-7	Lymphocyte counts;
TGCT	cis	rs9400467	0.506	rs12192718	chr6:111569151	T/A	cg15721981	chr6:111408429	SLC16A10	0.7	4.46	0.37	1.83e-5	Blood metabolite levels;Amino acid levels;
TGCT	cis	rs1127311	0.901	rs11264223	chr1:154565519	G/A	cg17218026	chr1:154582156	ADAR	0.31	7.75	0.57	2.86e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs80282103	0.618	rs59377495	chr10:1157019	C/T	cg08668510	chr10:1095578	IDI1	0.98	4.51	0.38	1.46e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg03709012	chr19:19516395	GATAD2A	0.75	6.16	0.48	9.21e-9	Tonsillectomy;
TGCT	cis	rs2204008	0.776	rs8186824	chr12:38316537	A/C	cg26384229	chr12:38710491	ALG10B	0.77	6.88	0.53	2.6200000000000003e-10	Bladder cancer;
TGCT	cis	rs9952991	0.883	rs2542148	chr18:12777573	C/G	cg09945482	chr18:12777974	NA	0.5	4.75	0.39	5.61e-6	Inflammatory skin disease;
TGCT	cis	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg22121687	chr7:65037720	NA	-0.78	-4.7	-0.39	6.74e-6	Diabetic kidney disease;
TGCT	cis	rs3782455	1.000	rs16943528	chr12:114403582	A/C	cg23502203	chr12:113549970	RASAL1	-0.55	-4.92	-0.4	2.7e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs3617	0.652	rs60332615	chr3:52867595	C/A	cg05573699	chr3:52720067	GNL3;PBRM1	0.49	4.77	0.39	5.04e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7647973	1.000	rs2177268	chr3:49439725	A/T	cg06212747	chr3:49208901	KLHDC8B	-0.59	-4.72	-0.39	6.19e-6	Menarche (age at onset);
TGCT	cis	rs1843834	0.734	rs1908251	chr2:225487865	T/C	cg22455342	chr2:225449267	CUL3	0.79	7.98	0.58	8.35e-13	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs2153535	0.580	rs9392220	chr6:8457946	G/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs8103278	0.864	rs2070737	chr19:46282890	A/T	cg11657440	chr19:46296263	DMWD	-0.58	-5.73	-0.46	7.03e-8	Coronary artery disease;
TGCT	cis	rs67460515	0.859	rs7610800	chr3:161002582	C/T	cg03342759	chr3:160939853	NMD3	-0.49	-5.3	-0.43	5.16e-7	Parkinson's disease;
TGCT	cis	rs9972944	0.756	rs6416948	chr17:63767131	T/G	cg07283582	chr17:63770753	CCDC46	-0.26	-5.3	-0.43	5.02e-7	Total body bone mineral density;
TGCT	cis	rs986417	0.901	rs1010052	chr14:61003071	G/A	cg27398547	chr14:60952738	C14orf39	1.38	10.8	0.7	1.4e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs9611565	0.802	rs9611571	chr22:41784867	G/A	cg06634786	chr22:41940651	POLR3H	-0.72	-6.68	-0.51	7.15e-10	Vitiligo;
TGCT	cis	rs7552404	1.000	rs441109	chr1:76120430	T/G	cg10523679	chr1:76189770	ACADM	-0.93	-10.18	-0.67	4.69e-18	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs3820928	0.904	rs2396432	chr2:227765891	C/T	cg11843606	chr2:227700838	RHBDD1	-0.51	-4.49	-0.37	1.59e-5	Pulmonary function;
TGCT	cis	rs35934224	0.657	rs9606169	chr22:19856472	G/A	cg11182965	chr22:19864308	TXNRD2	-0.36	-4.53	-0.38	1.34e-5	Glaucoma (primary open-angle);
TGCT	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.72	5.19	0.42	8.33e-7	Platelet count;
TGCT	trans	rs1974653	0.672	rs112629076	chr22:20079688	T/C	cg08822737	chr17:71088851	SLC39A11	-0.93	-7.61	-0.56	5.97e-12	Schizophrenia;
TGCT	cis	rs981844	0.736	rs1036614	chr4:154639105	G/A	cg14289246	chr4:154710475	SFRP2	0.98	7.59	0.56	6.55e-12	Response to statins (LDL cholesterol change);
TGCT	cis	rs12541335	0.639	rs3923439	chr8:22170079	G/A	cg02788857	chr8:22132959	PIWIL2	0.27	4.96	0.41	2.25e-6	Hypertriglyceridemia;
TGCT	cis	rs1975974	0.511	rs17052375	chr17:21743877	G/A	cg18423549	chr17:21743878	NA	-0.69	-6.64	-0.51	8.59e-10	Psoriasis;
TGCT	cis	rs7926906	0.846	rs10830578	chr11:90539319	A/G	cg26138821	chr11:89956704	CHORDC1	-0.48	-5.07	-0.41	1.38e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4727027	0.835	rs6959224	chr7:148784495	A/G	cg23583168	chr7:148888333	NA	-0.65	-8.05	-0.59	5.66e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs453301	0.652	rs2043129	chr8:8825504	C/G	cg06636001	chr8:8085503	FLJ10661	0.68	5.58	0.45	1.46e-7	Joint mobility (Beighton score);
TGCT	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg06896619	chr17:61851486	DDX42;CCDC47	-0.51	-4.97	-0.41	2.18e-6	Prudent dietary pattern;
TGCT	cis	rs1887596	0.630	rs1276045	chr13:27246216	T/C	cg01312412	chr13:27282625	NA	0.28	5.01	0.41	1.79e-6	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs9217	0.841	rs7225954	chr17:7397274	G/A	cg17892169	chr17:7452644	TNFSF12;TNFSF12-TNFSF13	-0.23	-4.44	-0.37	1.99e-5	Height;
TGCT	cis	rs6570726	0.577	rs867056	chr6:145784805	A/C	cg13319975	chr6:146136371	FBXO30	0.65	5.75	0.46	6.54e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.07	0.82	4.17e-32	Prudent dietary pattern;
TGCT	cis	rs7666738	0.830	rs1527517	chr4:98931907	C/T	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg22683308	chr4:1340831	KIAA1530	-0.66	-6.2	-0.49	7.68e-9	Longevity;
TGCT	cis	rs3741151	0.892	rs3741152	chr11:73008914	G/A	cg17517138	chr11:73019481	ARHGEF17	0.93	5.04	0.41	1.59e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
TGCT	cis	rs36051895	0.587	rs16922785	chr9:5200409	C/G	cg02405213	chr9:5042618	JAK2	-0.72	-8.77	-0.62	1.14e-14	Pediatric autoimmune diseases;
TGCT	cis	rs6860806	0.507	rs635620	chr5:131720263	A/G	cg24060327	chr5:131705240	SLC22A5	0.77	8.48	0.61	5.57e-14	Breast cancer;
TGCT	cis	rs7213347	0.780	rs170041	chr17:2170216	C/T	cg20777128	chr17:1945076	DPH1;OVCA2	0.5	4.46	0.37	1.84e-5	Total body bone mineral density;
TGCT	cis	rs7824557	0.602	rs7820895	chr8:11206262	T/C	cg21775007	chr8:11205619	TDH	0.73	7.01	0.53	1.32e-10	Retinal vascular caliber;
TGCT	cis	rs2463822	1.000	rs2513076	chr11:62103711	A/G	cg06239285	chr11:62104954	ASRGL1	0.93	6.71	0.52	6.27e-10	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs9911578	1.000	rs12449365	chr17:56600660	C/G	cg05425664	chr17:57184151	TRIM37	0.63	6.26	0.49	5.86e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs2228479	0.867	rs12919804	chr16:89945369	G/A	cg19635926	chr16:89946313	TCF25	0.28	4.8	0.4	4.47e-6	Skin colour saturation;
TGCT	cis	rs3749237	0.595	rs4855873	chr3:49459114	A/C	cg03060546	chr3:49711283	APEH	0.77	8.86	0.62	6.92e-15	Resting heart rate;
TGCT	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.47	-0.5	2.01e-9	Alzheimer's disease;
TGCT	cis	rs611744	0.967	rs686251	chr8:109198907	C/A	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs9372498	0.505	rs62424202	chr6:118851027	T/C	cg21191810	chr6:118973309	C6orf204	-0.37	-4.8	-0.4	4.4e-6	Diastolic blood pressure;
TGCT	cis	rs3812831	0.695	rs8000778	chr13:114944310	T/C	cg08824895	chr13:115047677	UPF3A	0.51	4.99	0.41	1.98e-6	Schizophrenia;
TGCT	cis	rs1801251	1.000	rs1446308	chr2:233639309	T/C	cg25237894	chr2:233734115	C2orf82	0.33	5.95	0.47	2.53e-8	Coronary artery disease;
TGCT	cis	rs3020736	0.500	rs6002616	chr22:42504679	A/G	cg15557168	chr22:42548783	NA	0.22	5.58	0.45	1.47e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7681440	0.904	rs28734152	chr4:90767359	C/T	cg14346243	chr4:90757452	SNCA	-0.57	-5.6	-0.45	1.31e-7	Dementia with Lewy bodies;
TGCT	cis	rs782590	0.574	rs12991445	chr2:55675939	C/T	cg03859395	chr2:55845619	SMEK2	0.61	5.35	0.43	4.07e-7	Metabolic syndrome;
TGCT	cis	rs13256369	0.802	rs13256404	chr8:8562974	T/C	cg18904891	chr8:8559673	CLDN23	0.58	5.4	0.44	3.23e-7	Obesity-related traits;
TGCT	cis	rs2832191	0.755	rs2832193	chr21:30493589	T/C	cg24692254	chr21:30365293	RNF160	-0.91	-9.65	-0.65	8.88e-17	Dental caries;
TGCT	cis	rs950776	0.518	rs12906284	chr15:78825105	C/T	cg06917634	chr15:78832804	PSMA4	0.95	9.52	0.65	1.81e-16	Sudden cardiac arrest;
TGCT	cis	rs3617	0.625	rs7612624	chr3:52893426	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.49	-4.58	-0.38	1.09e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs789852	1.000	rs711980	chr3:194324558	G/C	cg18000598	chr3:194342907	TMEM44	-0.81	-5.31	-0.43	4.83e-7	QT interval;
TGCT	cis	rs1670533	1.000	rs10026482	chr4:1051128	C/G	cg27284194	chr4:1044797	NA	0.68	5.87	0.47	3.76e-8	Recombination rate (females);
TGCT	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg11644478	chr21:40555479	PSMG1	-0.6	-5.65	-0.45	1.03e-7	Cognitive function;
TGCT	cis	rs72634258	0.945	rs12727642	chr1:8046672	C/A	cg23986158	chr1:8847014	RERE	0.28	4.51	0.38	1.47e-5	Inflammatory bowel disease;
TGCT	cis	rs9467773	1.000	rs10214634	chr6:26564582	T/A	cg05738196	chr6:26577821	NA	0.91	13.19	0.76	2.28e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs2456568	0.803	rs10831140	chr11:93640689	G/A	cg16099599	chr11:93583650	C11orf90	-0.39	-4.78	-0.39	4.94e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	trans	rs114540395	0.858	rs3730467	chr10:103342783	G/T	cg10198749	chr1:39920707	MACF1	0.55	7.06	0.54	1.06e-10	Schizophrenia;
TGCT	cis	rs28374715	0.783	rs1866399	chr15:41571139	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.83	-11.36	-0.71	6.08e-21	Ulcerative colitis;
TGCT	cis	rs735396	0.627	rs2264778	chr12:121450354	C/A	cg15155738	chr12:121454335	C12orf43	0.62	5.59	0.45	1.39e-7	N-glycan levels;
TGCT	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg04944784	chr2:26401820	FAM59B	-0.68	-6.04	-0.48	1.7e-8	Gut microbiome composition (summer);
TGCT	cis	rs1008375	0.900	rs13144986	chr4:17675019	C/A	cg18681998	chr4:17616180	MED28	-0.86	-8.72	-0.62	1.53e-14	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs57506017	0.585	rs5011437	chr7:12268792	A/T	cg07541786	chr7:12610355	SCIN	0.45	4.58	0.38	1.12e-5	Neuroticism;
TGCT	cis	rs9611519	0.929	rs9611466	chr22:41426299	A/T	cg13695892	chr22:41940480	POLR3H	-0.53	-4.62	-0.38	9.54e-6	Neuroticism;
TGCT	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg10047753	chr17:41438598	NA	0.91	8.44	0.6	6.86e-14	Menopause (age at onset);
TGCT	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg08280861	chr8:58055591	NA	0.37	5.03	0.41	1.66e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10507380	0.824	rs9512633	chr13:27919246	C/T	cg25543773	chr13:27185723	WASF3	0.34	4.83	0.4	3.97e-6	Electrocardiographic traits;
TGCT	cis	rs9611565	0.921	rs4822021	chr22:41726053	G/A	cg13695892	chr22:41940480	POLR3H	-0.76	-7.25	-0.55	3.83e-11	Vitiligo;
TGCT	cis	rs7568458	0.709	rs2592551	chr2:85780131	G/A	cg02493740	chr2:85810744	VAMP5	-0.28	-5.37	-0.43	3.67e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs651907	0.514	rs34301719	chr3:101417993	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.89	9.87	0.66	2.65e-17	Colorectal cancer;
TGCT	cis	rs727505	0.954	rs1383748	chr7:124638201	A/T	cg23710748	chr7:124431027	NA	-0.26	-4.55	-0.38	1.27e-5	Lewy body disease;
TGCT	cis	rs9394169	0.709	rs6919321	chr6:33724004	G/A	cg13859433	chr6:33739653	LEMD2	-0.33	-5.52	-0.44	1.93e-7	Essential tremor;
TGCT	cis	rs60871478	0.636	rs10245785	chr7:894422	T/C	cg15782153	chr7:917662	C7orf20	0.54	4.92	0.4	2.74e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs9952991	0.883	rs2847260	chr18:12775591	C/T	cg23544223	chr18:12777786	NA	0.63	6.02	0.48	1.85e-8	Inflammatory skin disease;
TGCT	cis	rs4794202	0.629	rs7214694	chr17:45895353	C/T	cg02219949	chr17:45927392	SP6	0.39	4.45	0.37	1.93e-5	Alzheimer's disease (cognitive decline);
TGCT	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg13395646	chr4:1353034	KIAA1530	-0.38	-4.72	-0.39	6.28e-6	Obesity-related traits;
TGCT	cis	rs34526934	0.566	rs34028621	chr2:177042779	C/T	cg00278547	chr2:177037212	HOXD3	-0.36	-4.45	-0.37	1.85e-5	Obstructive sleep apnea trait (apnea hypopnea index);
TGCT	cis	rs7714584	1.000	rs10053750	chr5:150270051	A/G	cg22134413	chr5:150180641	NA	0.78	6.12	0.48	1.16e-8	Crohn's disease;
TGCT	cis	rs775227	0.528	rs775231	chr3:113027214	A/C	cg18753928	chr3:113234510	CCDC52	0.64	4.91	0.4	2.77e-6	Dental caries;
TGCT	cis	rs2486012	1.000	rs2428963	chr1:44373439	C/T	cg12908607	chr1:44402522	ARTN	0.71	5.86	0.47	3.87e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs10431058	0.930	rs7948142	chr11:107478703	T/G	cg18204760	chr11:107461044	ELMOD1;LOC643923	0.72	6.9	0.53	2.36e-10	Common traits (Other);
TGCT	cis	rs77372450	0.515	rs2277948	chr5:157098233	T/C	cg19063654	chr5:156516798	HAVCR2	-0.37	-4.6	-0.38	1.02e-5	Bipolar disorder (body mass index interaction);
TGCT	cis	rs36051895	0.623	rs11506292	chr9:5257048	C/A	cg02405213	chr9:5042618	JAK2	-0.71	-8.41	-0.6	8.29e-14	Pediatric autoimmune diseases;
TGCT	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg22166914	chr1:53195759	ZYG11B	0.36	5.71	0.46	8.05e-8	Monocyte count;
TGCT	cis	rs7095607	0.654	rs7081017	chr10:69954451	A/G	cg18986048	chr10:69913749	MYPN	0.56	6.0	0.47	2e-8	Lung function (FVC);
TGCT	cis	rs2658782	0.901	rs11604909	chr11:93218355	C/G	cg18152523	chr11:93063302	CCDC67	-0.67	-5.6	-0.45	1.3e-7	Pulmonary function decline;
TGCT	cis	rs7845219	0.544	rs34293080	chr8:95908078	G/T	cg16049864	chr8:95962084	TP53INP1	-0.5	-5.39	-0.44	3.35e-7	Type 2 diabetes;
TGCT	cis	rs12210905	0.688	rs72843177	chr6:27367414	A/G	cg08851530	chr6:28072375	NA	1.33	5.85	0.47	4.08e-8	Hip circumference adjusted for BMI;
TGCT	cis	rs2677744	0.626	rs11857545	chr15:91489705	G/A	cg23684204	chr15:91497937	RCCD1	0.36	5.37	0.43	3.79e-7	Attention deficit hyperactivity disorder;
TGCT	cis	rs7547997	0.615	rs73029766	chr1:158320989	G/A	cg03528325	chr1:158223921	CD1A	0.34	4.71	0.39	6.65e-6	QRS duration;
TGCT	cis	rs9549367	0.789	rs12584008	chr13:113881228	C/T	cg00898013	chr13:113819073	PROZ	-0.4	-4.88	-0.4	3.18e-6	Platelet distribution width;
TGCT	cis	rs4389656	0.857	rs416847	chr5:6739567	A/G	cg10857441	chr5:6722123	POLS	-0.22	-4.76	-0.39	5.28e-6	Coronary artery disease;
TGCT	cis	rs9419702	0.568	rs9419635	chr10:133546164	C/T	cg04492858	chr10:133558786	NA	0.57	6.06	0.48	1.52e-8	Survival in rectal cancer;
TGCT	cis	rs6570726	0.846	rs441575	chr6:145849205	A/C	cg23711669	chr6:146136114	FBXO30	0.68	6.67	0.51	7.58e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3015497	0.934	rs2934691	chr14:51121333	C/A	cg04730355	chr14:51134070	SAV1	-0.52	-4.6	-0.38	1.01e-5	Mean platelet volume;
TGCT	cis	rs9894429	1.000	rs7223613	chr17:79574803	C/T	cg18240062	chr17:79603768	NPLOC4	-0.67	-6.84	-0.52	3.23e-10	Eye color traits;
TGCT	cis	rs17221829	0.673	rs10830324	chr11:89388845	C/T	cg02982614	chr11:89391479	FOLH1B	-0.25	-4.46	-0.37	1.8e-5	Anxiety in major depressive disorder;
TGCT	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg24549020	chr5:56110836	MAP3K1	0.63	5.5	0.44	2.05e-7	Initial pursuit acceleration;
TGCT	cis	rs1775715	0.737	rs1419171	chr10:32214831	C/A	cg14930904	chr10:32216787	ARHGAP12	0.52	5.07	0.41	1.39e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs10875746	0.625	rs2898065	chr12:48644619	C/A	cg20731937	chr12:48336164	NA	0.59	4.52	0.38	1.45e-5	Longevity (90 years and older);
TGCT	cis	rs7267979	1.000	rs4815408	chr20:25346678	C/T	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg12311346	chr5:56204834	C5orf35	-0.68	-6.87	-0.52	2.83e-10	Type 2 diabetes;
TGCT	cis	rs7617773	0.539	rs6779517	chr3:48384388	C/T	cg11946769	chr3:48343235	NME6	0.6	5.09	0.42	1.28e-6	Coronary artery disease;
TGCT	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg12311346	chr5:56204834	C5orf35	-0.67	-6.82	-0.52	3.63e-10	Initial pursuit acceleration;
TGCT	cis	rs36051895	0.659	rs7859390	chr9:5062473	A/T	cg02405213	chr9:5042618	JAK2	-0.72	-9.42	-0.65	3.29e-16	Pediatric autoimmune diseases;
TGCT	cis	rs7017914	0.967	rs34409123	chr8:71662116	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.03	-0.41	1.69e-6	Bone mineral density;
TGCT	cis	rs13223928	0.651	rs4722435	chr7:3152962	C/T	cg19214707	chr7:3157722	NA	0.49	7.05	0.53	1.09e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
TGCT	cis	rs1008375	1.000	rs1860596	chr4:17660082	C/T	cg10189774	chr4:17578691	LAP3	0.56	4.95	0.41	2.39e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2836633	0.895	rs2836597	chr21:40024424	A/G	cg12884169	chr21:40033163	ERG	0.44	4.64	0.38	8.68e-6	Coronary artery disease;
TGCT	cis	rs4319547	0.737	rs10773176	chr12:122944713	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.63	-4.94	-0.41	2.49e-6	Body mass index;
TGCT	cis	rs16966142	0.786	rs2238533	chr16:89871344	T/C	cg03388025	chr16:89894329	SPIRE2	0.46	4.46	0.37	1.81e-5	Caffeine consumption;
TGCT	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg10207240	chr12:122356781	WDR66	-0.37	-5.31	-0.43	4.95e-7	Mean corpuscular volume;
TGCT	cis	rs17102423	0.588	rs7150646	chr14:65540463	G/T	cg11161011	chr14:65562177	MAX	-0.46	-6.54	-0.51	1.45e-9	Obesity-related traits;
TGCT	cis	rs3540	0.960	rs1505936	chr15:91010776	T/C	cg22089800	chr15:90895588	ZNF774	0.74	6.74	0.52	5.32e-10	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.81	5.6	0.45	1.32e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7772486	0.754	rs4896839	chr6:146019689	T/G	cg05347473	chr6:146136440	FBXO30	-0.51	-4.8	-0.4	4.44e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2228479	0.867	rs12930606	chr16:89946682	A/G	cg06558623	chr16:89946397	TCF25	0.56	6.83	0.52	3.38e-10	Skin colour saturation;
TGCT	trans	rs797680	0.822	rs7541304	chr1:93757838	T/A	cg27528825	chr2:159282178	CCDC148	0.34	6.71	0.52	6.32e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs79724016	0.744	rs7539225	chr1:42113523	A/G	cg14093106	chr1:42503579	NA	-0.63	-4.51	-0.38	1.47e-5	Breast cancer;
TGCT	cis	rs3849570	1.000	rs3860595	chr3:81811784	A/G	cg07356753	chr3:81810745	GBE1	-0.68	-5.75	-0.46	6.51e-8	Waist circumference;Body mass index;
TGCT	cis	rs2075371	1.000	rs2598296	chr7:133992985	C/T	cg11752832	chr7:134001865	SLC35B4	0.69	6.26	0.49	5.87e-9	Mean platelet volume;
TGCT	cis	rs4654899	0.802	rs57351360	chr1:21229538	T/A	cg01072550	chr1:21505969	NA	-0.47	-7.06	-0.54	1.03e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs9549260	0.564	rs7997896	chr13:41268823	T/A	cg21288729	chr13:41239152	FOXO1	0.92	8.97	0.63	3.82e-15	Red blood cell count;
TGCT	cis	rs265548	0.538	rs36688	chr19:17911212	A/C	cg04517722	chr19:17905589	B3GNT3	0.47	6.31	0.49	4.46e-9	Tumor biomarkers;
TGCT	cis	rs2120019	0.938	rs8036573	chr15:75308690	C/T	cg09165964	chr15:75287851	SCAMP5	-1.18	-10.31	-0.68	2.22e-18	Blood trace element (Zn levels);
TGCT	cis	rs2204008	0.774	rs11180977	chr12:38263094	G/T	cg13010199	chr12:38710504	ALG10B	0.64	4.97	0.41	2.15e-6	Bladder cancer;
TGCT	cis	rs10876993	0.928	rs2169988	chr12:58071165	G/A	cg15848620	chr12:58087721	OS9	-0.72	-5.83	-0.46	4.52e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.51	5.37	0.43	3.71e-7	Menopause (age at onset);
TGCT	cis	rs6540234	0.701	rs9933690	chr16:85993295	T/C	cg01145317	chr16:86542838	FOXF1	0.48	4.44	0.37	1.96e-5	Granulocyte percentage of myeloid white cells;Monocyte count;
TGCT	cis	rs587847	0.540	rs668644	chr15:37669606	G/A	cg16890051	chr15:37175029	LOC145845	-0.38	-4.49	-0.37	1.6e-5	Intraocular pressure;
TGCT	cis	rs7264396	0.779	rs2425162	chr20:34429974	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.28	-4.74	-0.39	5.7e-6	Total cholesterol levels;
TGCT	cis	rs12497850	0.931	rs9311433	chr3:48863835	T/C	cg07636037	chr3:49044803	WDR6	0.95	10.74	0.69	2e-19	Parkinson's disease;
TGCT	cis	rs79976124	0.842	rs1548154	chr6:66624910	G/A	cg07460842	chr6:66804631	NA	0.6	5.3	0.43	5.2e-7	Type 2 diabetes;
TGCT	cis	rs6845621	0.600	rs35850168	chr4:18913277	T/A	cg12196642	chr4:18937545	NA	-0.25	-4.48	-0.37	1.69e-5	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
TGCT	cis	rs6556937	0.562	rs31248	chr5:96014683	A/G	cg01741836	chr5:95996644	CAST	0.33	4.52	0.38	1.45e-5	Blood protein levels;
TGCT	cis	rs1008375	0.966	rs2302393	chr4:17654341	G/A	cg18681998	chr4:17616180	MED28	1.0	11.67	0.72	1.11e-21	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7927592	0.513	rs901823	chr11:68205578	T/C	cg16797656	chr11:68205561	LRP5	0.32	5.62	0.45	1.22e-7	Total body bone mineral density;
TGCT	cis	rs17270561	0.562	rs12199626	chr6:26013604	G/A	cg17691542	chr6:26056736	HIST1H1C	0.99	6.89	0.53	2.55e-10	Iron status biomarkers;
TGCT	cis	rs6940638	0.662	rs6915678	chr6:27235866	T/G	cg05738196	chr6:26577821	NA	-0.53	-4.74	-0.39	5.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs8033133	1.000	rs8033133	chr15:25350474	A/G	cg14481604	chr15:25334117	SNORD116-22	-0.31	-6.42	-0.5	2.67e-9	Blood osmolality (transformed sodium);
TGCT	cis	rs7666738	0.830	rs28622458	chr4:98916651	A/G	cg05340658	chr4:99064831	C4orf37	0.54	6.51	0.5	1.7e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg14893161	chr1:205819251	PM20D1	0.57	8.22	0.59	2.36e-13	Menarche (age at onset);
TGCT	cis	rs9906944	0.545	rs2088140	chr17:47094599	T/C	cg07075026	chr17:47091521	IGF2BP1	-0.43	-4.51	-0.38	1.47e-5	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs7264396	0.690	rs2425171	chr20:34443173	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.04	-0.41	1.58e-6	Total cholesterol levels;
TGCT	cis	rs2816062	0.786	rs742486	chr1:18900829	G/A	cg18795169	chr1:18902165	NA	-0.6	-13.92	-0.78	4.23e-27	Urate levels in lean individuals;
TGCT	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg13695892	chr22:41940480	POLR3H	0.78	7.62	0.56	5.73e-12	Vitiligo;
TGCT	cis	rs4824093	0.545	rs58876234	chr22:50258868	G/A	cg20569369	chr22:51173646	NA	0.28	4.69	0.39	7.23e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs554111	0.656	rs12021529	chr1:21306161	C/T	cg01072550	chr1:21505969	NA	-0.32	-4.99	-0.41	2.03e-6	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.51	-4.82	-0.4	4.16e-6	Bipolar disorder;
TGCT	cis	rs3091242	0.933	rs10903129	chr1:25768937	A/G	cg23205692	chr1:25664452	TMEM50A	0.45	4.78	0.39	4.77e-6	Erythrocyte sedimentation rate;
TGCT	cis	rs9291683	0.525	rs12506455	chr4:10031569	T/A	cg00071950	chr4:10020882	SLC2A9	0.68	8.84	0.62	7.71e-15	Bone mineral density;
TGCT	cis	rs10782582	0.609	rs56159153	chr1:76353498	T/G	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.52	4.54	0.38	1.31e-5	Daytime sleep phenotypes;
TGCT	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg18876405	chr7:65276391	NA	0.31	4.79	0.4	4.58e-6	Aortic root size;
TGCT	cis	rs11992186	0.597	rs77717027	chr8:8591632	T/C	cg15556689	chr8:8085844	FLJ10661	-0.55	-4.67	-0.39	7.8e-6	Neuroticism;
TGCT	cis	rs10465746	0.780	rs1324486	chr1:84384825	A/G	cg10977910	chr1:84465055	TTLL7	-0.71	-7.16	-0.54	6.15e-11	Obesity-related traits;
TGCT	cis	rs73001065	0.901	rs10401969	chr19:19407718	A/G	cg03709012	chr19:19516395	GATAD2A	1.01	5.04	0.41	1.6e-6	LDL cholesterol;
TGCT	cis	rs6460942	0.915	rs62448598	chr7:12453762	T/C	cg06484146	chr7:12443880	VWDE	-0.57	-5.52	-0.44	1.92e-7	Coronary artery disease;
TGCT	cis	rs1577917	0.771	rs7762321	chr6:86412146	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.52	4.63	0.38	9.12e-6	Response to antipsychotic treatment;
TGCT	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg11644478	chr21:40555479	PSMG1	-0.56	-5.23	-0.42	7.09e-7	Menarche (age at onset);
TGCT	cis	rs6695640	0.854	rs1555660	chr1:17731117	T/C	cg25979543	chr1:17888104	ARHGEF10L	-0.25	-4.57	-0.38	1.14e-5	Mean platelet volume;
TGCT	cis	rs9677476	0.516	rs7607338	chr2:231987955	C/A	cg27665808	chr2:232055229	NA	0.36	4.5	0.37	1.52e-5	Food antigen IgG levels;
TGCT	cis	rs1887596	0.639	rs581728	chr13:27202054	T/A	cg01312412	chr13:27282625	NA	0.29	5.13	0.42	1.1e-6	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.39	-5.04	-0.41	1.6e-6	Menarche (age at onset);
TGCT	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.63	-0.51	9.04e-10	Alzheimer's disease;
TGCT	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg06238570	chr21:40685208	BRWD1	0.72	6.58	0.51	1.16e-9	Cognitive function;
TGCT	cis	rs1568889	1.000	rs12796293	chr11:28177723	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.83	-8.75	-0.62	1.26e-14	Bipolar disorder;
TGCT	cis	rs13191362	1.000	rs13213408	chr6:162998049	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs9557207	1.000	rs9557192	chr13:99944165	C/T	cg24509225	chr13:100037070	UBAC2	-0.23	-4.55	-0.38	1.26e-5	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
TGCT	cis	rs11148252	0.904	rs9568732	chr13:52993412	A/G	cg00495681	chr13:53174319	NA	-0.57	-5.97	-0.47	2.37e-8	Lewy body disease;
TGCT	cis	rs9357506	0.905	rs4714928	chr6:46309843	T/C	cg21115430	chr6:46460003	NA	-0.26	-5.16	-0.42	9.6e-7	Body mass index;
TGCT	cis	rs1023500	0.552	rs133368	chr22:42463689	T/C	cg15557168	chr22:42548783	NA	-0.22	-5.6	-0.45	1.33e-7	Schizophrenia;
TGCT	cis	rs514406	0.861	rs35581164	chr1:53271373	C/G	cg24675658	chr1:53192096	ZYG11B	-0.7	-7.96	-0.58	9.19e-13	Monocyte count;
TGCT	cis	rs28374715	0.662	rs28493087	chr15:41486504	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.81	-11.6	-0.72	1.65e-21	Ulcerative colitis;
TGCT	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg11890956	chr21:40555474	PSMG1	-0.69	-6.59	-0.51	1.13e-9	Menarche (age at onset);
TGCT	cis	rs71435601	0.600	rs544450	chr2:21384358	T/C	cg25035485	chr2:21266500	APOB	0.51	4.48	0.37	1.64e-5	Cholesterol, total;
TGCT	cis	rs7208859	0.673	rs55658077	chr17:29156519	A/G	cg14008862	chr17:28927542	LRRC37B2	0.75	5.1	0.42	1.26e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs35883536	0.647	rs10875315	chr1:101044062	G/A	cg10298815	chr1:101004474	GPR88	-0.24	-4.44	-0.37	1.95e-5	Monocyte count;
TGCT	cis	rs2303745	0.589	rs1465576	chr19:17398487	G/A	cg02221750	chr19:17393354	ANKLE1	-0.46	-5.81	-0.46	5.05e-8	Systemic lupus erythematosus;
TGCT	cis	rs7772486	0.641	rs9390374	chr6:146368175	A/T	cg23711669	chr6:146136114	FBXO30	0.71	6.86	0.52	2.89e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7809950	0.678	rs12672451	chr7:106853817	C/G	cg23024343	chr7:107201750	COG5	-0.43	-5.84	-0.46	4.2e-8	Coronary artery disease;
TGCT	cis	rs4733781	0.509	rs6470811	chr8:131338933	G/T	cg16277922	chr8:131349729	ASAP1	-0.53	-8.76	-0.62	1.24e-14	Tuberculosis;
TGCT	cis	rs6570726	0.764	rs366673	chr6:145814628	T/A	cg23711669	chr6:146136114	FBXO30	0.89	9.73	0.66	5.62e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9892942	1	rs9892942	chr17:27178761	C/T	cg06745955	chr17:27038470	PROCA1	-0.58	-4.55	-0.38	1.27e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs10089	0.680	rs3805616	chr5:127520897	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	7.0	0.53	1.41e-10	Ileal carcinoids;
TGCT	cis	rs11098499	0.954	rs3733523	chr4:120423719	C/T	cg09307838	chr4:120376055	NA	0.68	6.37	0.5	3.41e-9	Corneal astigmatism;
TGCT	cis	rs9611565	0.559	rs5751160	chr22:42175695	A/G	cg17554472	chr22:41940697	POLR3H	0.46	4.8	0.4	4.46e-6	Vitiligo;
TGCT	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg23758822	chr17:41437982	NA	0.72	6.81	0.52	3.77e-10	Menopause (age at onset);
TGCT	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.47	0.56	1.28e-11	Prudent dietary pattern;
TGCT	cis	rs13326165	0.760	rs2016575	chr3:52477080	T/C	cg07884673	chr3:53033167	SFMBT1	-0.39	-4.69	-0.39	7e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs4711350	0.765	rs943473	chr6:33743651	G/C	cg13859433	chr6:33739653	LEMD2	-0.33	-4.98	-0.41	2.12e-6	Schizophrenia;
TGCT	cis	rs13067306	1.000	rs13087299	chr3:94229344	T/C	cg16274205	chr3:94243571	NA	0.32	4.68	0.39	7.38e-6	Blood pressure measurement (high sodium intervention);
TGCT	cis	rs2777491	0.915	rs8032838	chr15:41605632	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.75	-10.44	-0.68	1.07e-18	Ulcerative colitis;
TGCT	cis	rs9467711	0.516	rs555460	chr6:25870655	C/T	cg03264133	chr6:25882463	NA	-0.71	-4.82	-0.4	4.07e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1357245	0.534	rs6766181	chr3:27100290	A/G	cg02860705	chr3:27208620	NA	-0.31	-5.02	-0.41	1.73e-6	Breast cancer;
TGCT	cis	rs7043114	0.525	rs7863406	chr9:95053381	T/C	cg14311495	chr9:95764742	FGD3	-0.22	-4.44	-0.37	1.95e-5	Height;
TGCT	cis	rs793571	0.590	rs442495	chr15:59022615	T/C	cg05156742	chr15:59063176	FAM63B	0.47	4.48	0.37	1.7e-5	Schizophrenia;
TGCT	cis	rs2836974	0.583	rs2735307	chr21:40713358	C/T	cg11644478	chr21:40555479	PSMG1	0.65	6.27	0.49	5.38e-9	Cognitive function;
TGCT	cis	rs7772486	0.790	rs9485024	chr6:146142487	A/G	cg05347473	chr6:146136440	FBXO30	-0.49	-4.78	-0.39	4.92e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1215050	0.791	rs165239	chr4:98682549	C/T	cg17366294	chr4:99064904	C4orf37	0.52	5.51	0.44	1.97e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs12971120	0.891	rs2278158	chr18:72178300	G/T	cg26446133	chr18:72167187	CNDP2	-0.35	-5.89	-0.47	3.42e-8	Refractive error;
TGCT	cis	rs12681287	0.604	rs34227066	chr8:87449366	C/T	cg27223183	chr8:87520930	FAM82B	-0.89	-6.43	-0.5	2.54e-9	Caudate activity during reward;
TGCT	cis	rs72627509	0.680	rs73165962	chr4:57740533	G/A	cg26694713	chr4:57773883	REST	0.82	6.68	0.51	7.07e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs6598955	0.627	rs6684875	chr1:26567044	A/G	cg04990556	chr1:26633338	UBXN11	0.64	5.11	0.42	1.19e-6	Obesity-related traits;
TGCT	cis	rs11734570	0.581	rs73811716	chr4:38590773	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.65	4.96	0.41	2.24e-6	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs11718455	0.767	rs9861276	chr3:43989595	C/T	cg08738300	chr3:44038990	NA	0.74	5.62	0.45	1.22e-7	Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs1025204	chr4:99023441	G/A	cg05340658	chr4:99064831	C4orf37	0.49	5.51	0.44	2.01e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.39	5.24	0.43	6.78e-7	Lymphocyte counts;
TGCT	cis	rs4478858	0.735	rs6681286	chr1:31799384	G/C	cg00250761	chr1:31883323	NA	-0.28	-4.96	-0.41	2.32e-6	Alcohol dependence;
TGCT	cis	rs9611519	0.780	rs2235852	chr22:41661154	G/T	cg13695892	chr22:41940480	POLR3H	-0.68	-4.8	-0.4	4.55e-6	Neuroticism;
TGCT	cis	rs1048238	0.506	rs10927867	chr1:16177285	A/G	cg21385522	chr1:16154831	NA	0.58	6.5	0.5	1.72e-9	Systolic blood pressure;
TGCT	cis	rs9364220	0.623	rs6940507	chr6:168493719	T/C	cg02770688	chr6:168491649	NA	-0.3	-5.51	-0.44	2.02e-7	Attention deficit hyperactivity disorder (inattention symptoms);Attention deficit hyperactivity disorder (combined symptoms);
TGCT	cis	rs10779751	0.734	rs6701726	chr1:11126941	C/T	cg08854313	chr1:11322531	MTOR	0.82	7.04	0.53	1.19e-10	Body mass index;
TGCT	cis	rs1008375	0.618	rs13129002	chr4:17567513	A/G	cg16339924	chr4:17578868	LAP3	0.7	5.82	0.46	4.63e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6840360	0.638	rs2406974	chr4:152601841	G/A	cg22705602	chr4:152727874	NA	-0.33	-5.5	-0.44	2.11e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs933688	1.000	rs9293568	chr5:90737845	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.0	8.49	0.61	5.31e-14	Smoking behavior;
TGCT	cis	rs6840360	0.642	rs1899550	chr4:152407236	T/C	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.82e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs546131	0.928	rs558967	chr11:34827168	T/A	cg06937548	chr11:34938143	PDHX;APIP	0.65	5.91	0.47	3.14e-8	Lung disease severity in cystic fibrosis;
TGCT	cis	rs45509595	0.822	rs200484	chr6:27775674	A/G	cg08798685	chr6:27730294	NA	-0.33	-4.53	-0.38	1.34e-5	Breast cancer;
TGCT	cis	rs12188164	0.965	rs77101200	chr5:443059	G/T	cg21144161	chr5:423903	AHRR	0.25	4.79	0.4	4.61e-6	Cystic fibrosis severity;
TGCT	cis	rs7523273	0.606	rs2796283	chr1:207978732	C/T	cg22525895	chr1:207977042	MIR29B2	-0.55	-9.57	-0.65	1.36e-16	Schizophrenia;
TGCT	cis	rs9467711	0.790	rs13195402	chr6:26463575	G/T	cg12315302	chr6:26189340	HIST1H4D	0.99	4.44	0.37	1.93e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs79387448	0.745	rs723292	chr2:103166804	A/G	cg09003973	chr2:102972529	NA	0.95	6.15	0.48	9.95e-9	Gut microbiota (bacterial taxa);
TGCT	cis	rs236907	0.812	rs17596025	chr1:171746247	T/C	cg20598894	chr1:171756153	METTL13	-0.19	-4.52	-0.38	1.42e-5	Mean platelet volume;
TGCT	cis	rs12950390	0.814	rs4794099	chr17:45838358	T/C	cg06532163	chr17:45867833	NA	0.34	5.31	0.43	4.82e-7	IgG glycosylation;
TGCT	cis	rs79349575	0.811	rs60708039	chr17:46999373	C/G	cg26022315	chr17:47021804	SNF8	0.49	4.89	0.4	3.03e-6	Type 2 diabetes;
TGCT	cis	rs875971	0.564	rs313804	chr7:65514622	A/G	cg11764359	chr7:65958608	NA	0.54	4.66	0.39	7.88e-6	Aortic root size;
TGCT	cis	rs9650657	0.589	rs6985109	chr8:10761585	A/G	cg27411982	chr8:10470053	RP1L1	0.21	4.51	0.38	1.51e-5	Neuroticism;
TGCT	cis	rs1372520	0.748	rs990085	chr4:90754771	A/G	cg14346243	chr4:90757452	SNCA	-0.67	-5.64	-0.45	1.09e-7	Neuroticism;
TGCT	cis	rs7264396	0.561	rs6060750	chr20:34596371	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.28	-5.02	-0.41	1.79e-6	Total cholesterol levels;
TGCT	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg13409248	chr3:40428643	ENTPD3	-0.55	-4.47	-0.37	1.74e-5	Renal cell carcinoma;
TGCT	cis	rs7611238	0.583	rs11706218	chr3:195055790	A/T	cg27323046	chr3:195102265	ACAP2	0.37	4.9	0.4	2.9e-6	Body mass index;
TGCT	cis	rs2243480	1.000	rs1267820	chr7:66050295	C/G	cg18252515	chr7:66147081	NA	-1.22	-8.04	-0.59	6.02e-13	Diabetic kidney disease;
TGCT	cis	rs10986311	0.713	rs10986292	chr9:127016876	T/G	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.2	-4.57	-0.38	1.15e-5	Vitiligo;
TGCT	trans	rs2727020	0.595	rs10466496	chr11:49501514	C/T	cg15704280	chr7:45808275	SEPT13	-0.74	-8.49	-0.61	5.28e-14	Coronary artery disease;
TGCT	cis	rs921968	0.648	rs538483	chr2:219458656	T/C	cg02176678	chr2:219576539	TTLL4	0.44	6.33	0.49	4.17e-9	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs6500602	0.702	rs17761816	chr16:4548832	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.3	5.65	0.45	1.06e-7	Schizophrenia;
TGCT	cis	rs10170846	0.572	rs12620873	chr2:223419528	A/C	cg25565276	chr2:223520875	FARSB	0.86	5.92	0.47	2.93e-8	Schizophrenia (inflammation and infection response interaction);
TGCT	cis	rs2243480	1.000	rs313831	chr7:65551226	C/T	cg20637647	chr7:64974828	NA	0.88	5.34	0.43	4.19e-7	Diabetic kidney disease;
TGCT	cis	rs7666738	0.830	rs17550610	chr4:99008273	T/C	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4788570	0.584	rs7204608	chr16:71678679	C/G	cg06353428	chr16:71660113	MARVELD3	-1.51	-11.87	-0.73	3.6e-22	Intelligence (multi-trait analysis);
TGCT	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg03517284	chr6:25882590	NA	-0.65	-5.87	-0.47	3.78e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg18135555	chr8:22132992	PIWIL2	0.29	5.69	0.45	8.74e-8	Hypertriglyceridemia;
TGCT	cis	rs344364	0.511	rs62040569	chr16:1948137	C/T	cg26617929	chr16:1858877	NA	-0.27	-4.9	-0.4	2.99e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs1215050	0.791	rs11729826	chr4:98657190	G/T	cg05340658	chr4:99064831	C4orf37	-0.43	-5.4	-0.44	3.2e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9868809	0.772	rs12107418	chr3:48689787	A/G	cg00383909	chr3:49044727	WDR6	0.9	5.42	0.44	3.05e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs9926296	0.632	rs2011925	chr16:89814064	T/G	cg26513180	chr16:89883248	FANCA	0.73	6.92	0.53	2.1e-10	Vitiligo;
TGCT	cis	rs9300255	0.739	rs4759371	chr12:123742563	T/C	cg00376283	chr12:123451042	ABCB9	0.72	5.54	0.45	1.76e-7	Neutrophil percentage of white cells;
TGCT	cis	rs1153858	0.621	rs2687512	chr15:45581495	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.48	-5.28	-0.43	5.67e-7	Homoarginine levels;
TGCT	cis	rs12497850	0.897	rs6781790	chr3:49044767	C/T	cg05785598	chr3:49045655	WDR6	0.36	4.77	0.39	5.17e-6	Parkinson's disease;
TGCT	cis	rs9467773	0.620	rs2494694	chr6:26619328	A/T	cg15659132	chr6:26577336	NA	0.84	10.91	0.7	7.83e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs6840360	0.615	rs7669761	chr4:152609304	G/A	cg22705602	chr4:152727874	NA	-0.32	-5.44	-0.44	2.76e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs595982	0.702	rs609985	chr19:49370648	A/G	cg21252483	chr19:49399788	TULP2	-0.26	-4.48	-0.37	1.67e-5	Red cell distribution width;
TGCT	cis	rs4233949	0.832	rs6734097	chr2:54651933	C/T	cg14634210	chr2:54682758	SPTBN1	0.58	4.83	0.4	3.97e-6	Bone mineral density;
TGCT	cis	rs9902453	0.967	rs56326816	chr17:28492805	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	6.51	0.5	1.66e-9	Coffee consumption (cups per day);
TGCT	cis	rs1153858	1.000	rs12440038	chr15:45706739	A/G	cg26924012	chr15:45694286	SPATA5L1	1.1	15.34	0.81	2.01e-30	Homoarginine levels;
TGCT	trans	rs2469997	1.000	rs2447168	chr8:120365613	A/T	cg01792902	chr3:178864926	PIK3CA	0.78	6.64	0.51	8.85e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.55	-5.41	-0.44	3.15e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs362296	0.661	rs3095078	chr4:3265479	C/T	cg06533319	chr4:3265114	C4orf44	0.23	4.52	0.38	1.43e-5	Parental longevity (mother's age at death);
TGCT	cis	rs4285028	0.747	rs7647351	chr3:121422109	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.92	-7.3	-0.55	3.03e-11	Multiple sclerosis;
TGCT	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg06873352	chr17:61820015	STRADA	0.55	6.13	0.48	1.09e-8	Prudent dietary pattern;
TGCT	cis	rs7617773	0.817	rs13100815	chr3:48287449	A/C	cg11946769	chr3:48343235	NME6	0.76	6.67	0.51	7.64e-10	Coronary artery disease;
TGCT	cis	rs611744	0.647	rs2298603	chr8:109271426	C/T	cg21045802	chr8:109455806	TTC35	0.67	6.99	0.53	1.53e-10	Dupuytren's disease;
TGCT	cis	rs9929218	1.000	rs13333528	chr16:68790502	C/T	cg01251360	chr16:68772225	CDH1	0.29	4.89	0.4	3.01e-6	Colorectal cancer;
TGCT	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg14773178	chr5:1868261	NA	0.35	6.17	0.48	9.08e-9	Cardiovascular disease risk factors;
TGCT	cis	rs7698623	0.850	rs4693894	chr4:88797798	C/T	cg02735620	chr4:88950514	PKD2	-0.44	-4.81	-0.4	4.22e-6	Cardiovascular disease risk factors;
TGCT	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg06238570	chr21:40685208	BRWD1	0.61	5.44	0.44	2.79e-7	Cognitive function;
TGCT	cis	rs12950390	0.853	rs11655336	chr17:45858836	A/G	cg03474202	chr17:45855739	NA	0.44	4.64	0.38	8.66e-6	IgG glycosylation;
TGCT	cis	rs514406	0.547	rs377808	chr1:53190359	T/G	cg04995860	chr1:53192072	ZYG11B	-0.41	-4.61	-0.38	1e-5	Monocyte count;
TGCT	cis	rs8180040	0.627	rs6442059	chr3:47187075	C/G	cg27129171	chr3:47204927	SETD2	0.71	8.5	0.61	5.06e-14	Colorectal cancer;
TGCT	cis	rs9503598	1.000	rs9503598	chr6:3446263	A/G	cg00476032	chr6:3446245	SLC22A23	-0.18	-5.37	-0.43	3.79e-7	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
TGCT	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg17971929	chr21:40555470	PSMG1	0.95	9.06	0.63	2.31e-15	Cognitive function;
TGCT	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg01802117	chr1:53393560	SCP2	0.43	5.14	0.42	1.02e-6	Monocyte count;
TGCT	cis	rs9914988	0.943	rs2874253	chr17:27157863	A/T	cg20469991	chr17:27169893	C17orf63	-0.72	-5.09	-0.42	1.28e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs2070856	0.655	rs6049057	chr20:23725528	A/G	cg07394064	chr20:23346232	GZF1	0.44	4.58	0.38	1.09e-5	Blood protein levels;
TGCT	cis	rs763121	0.853	rs4821808	chr22:39065739	A/G	cg06022373	chr22:39101656	GTPBP1	0.77	7.57	0.56	7.47e-12	Menopause (age at onset);
TGCT	cis	rs35146811	0.735	rs11764176	chr7:99786964	G/T	cg00553149	chr7:99775558	STAG3;GPC2	0.31	4.61	0.38	9.75e-6	Coronary artery disease;
TGCT	cis	rs11190604	1.000	rs11292	chr10:102313607	A/G	cg23241863	chr10:102295624	HIF1AN	0.66	4.99	0.41	2.01e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs4722166	0.568	rs1880241	chr7:22759469	A/G	cg26061582	chr7:22766209	IL6	0.37	4.93	0.41	2.54e-6	Lung cancer;
TGCT	cis	rs9653442	0.564	rs4850924	chr2:100782273	A/G	cg07810366	chr2:100720526	AFF3	-0.35	-5.1	-0.42	1.26e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs2948294	0.566	rs13274039	chr8:8111659	A/G	cg06636001	chr8:8085503	FLJ10661	0.82	6.7	0.52	6.46e-10	Red cell distribution width;
TGCT	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg21856205	chr7:94953877	PON1	0.62	7.12	0.54	7.72e-11	Paraoxonase activity;
TGCT	cis	rs6570726	0.837	rs636894	chr6:145864122	T/C	cg05347473	chr6:146136440	FBXO30	0.49	4.51	0.38	1.46e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9682041	0.932	rs1525362	chr3:170070702	C/T	cg11886554	chr3:170076028	SKIL	0.71	5.62	0.45	1.2e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg11494091	chr17:61959527	GH2	0.61	14.8	0.8	3.65e-29	Prudent dietary pattern;
TGCT	cis	rs7412746	0.658	rs12405726	chr1:150956128	G/A	cg04414720	chr1:150670196	GOLPH3L	0.4	4.85	0.4	3.66e-6	Melanoma;
TGCT	cis	rs12477438	0.765	rs7591794	chr2:99567514	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.6	-5.24	-0.43	6.6e-7	Chronic sinus infection;
TGCT	cis	rs73058052	0.709	rs10416310	chr19:50079846	G/A	cg09250473	chr19:50168907	IRF3;BCL2L12	0.68	5.85	0.46	4.13e-8	Fibrinogen levels;
TGCT	cis	rs10791097	0.694	rs7942621	chr11:130751308	C/G	cg14779329	chr11:130786720	SNX19	0.29	5.01	0.41	1.85e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs7586879	0.616	rs6545809	chr2:25126715	C/T	cg15423357	chr2:25149977	NA	0.5	4.89	0.4	3.06e-6	Body mass index;
TGCT	cis	rs9303401	0.659	rs62081316	chr17:56781499	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.67	6.3	0.49	4.7e-9	Cognitive test performance;
TGCT	cis	rs8044995	0.501	rs73613999	chr16:68390099	C/A	cg05110241	chr16:68378359	PRMT7	-0.36	-4.45	-0.37	1.89e-5	Schizophrenia;
TGCT	cis	rs2147959	0.882	rs4653552	chr1:228628138	A/G	cg22700015	chr1:228743131	NA	-0.57	-4.53	-0.38	1.35e-5	Adult asthma;
TGCT	cis	rs6089584	0.507	rs28545731	chr20:60634102	C/T	cg13770153	chr20:60521292	NA	-0.43	-5.24	-0.43	6.83e-7	Body mass index;
TGCT	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg18876405	chr7:65276391	NA	0.38	5.89	0.47	3.4e-8	Calcium levels;
TGCT	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7552167	1.000	rs7552167	chr1:24518643	A/G	cg01960748	chr1:24522592	NA	-0.53	-5.83	-0.46	4.54e-8	Psoriasis vulgaris;
TGCT	cis	rs981844	0.714	rs6853529	chr4:154706267	C/T	cg14289246	chr4:154710475	SFRP2	0.77	5.87	0.47	3.77e-8	Response to statins (LDL cholesterol change);
TGCT	cis	rs12188164	1.000	rs55842567	chr5:437586	G/A	cg26850624	chr5:429559	AHRR	-0.2	-4.82	-0.4	4.05e-6	Cystic fibrosis severity;
TGCT	cis	rs9899728	0.539	rs113775187	chr17:73047290	A/G	cg27626185	chr17:73056755	KCTD2	-0.92	-8.01	-0.58	7.17e-13	Alzheimer's disease or small vessel stroke;
TGCT	cis	rs1153858	1.000	rs7171577	chr15:45627979	G/A	cg14582100	chr15:45693742	SPATA5L1	0.48	5.7	0.46	8.17e-8	Homoarginine levels;
TGCT	cis	rs11031096	0.711	rs61899755	chr11:4201317	G/T	cg18678763	chr11:4115507	RRM1	-0.46	-6.03	-0.48	1.78e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs6500602	0.826	rs7205189	chr16:4460114	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.43	6.39	0.5	3.09e-9	Schizophrenia;
TGCT	cis	rs7917772	0.536	rs3961456	chr10:104425304	A/T	cg05855489	chr10:104503620	C10orf26	0.57	4.74	0.39	5.82e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	trans	rs3780486	0.757	rs10813949	chr9:33123464	G/A	cg20290983	chr6:43655470	MRPS18A	1.17	14.54	0.79	1.43e-28	IgG glycosylation;
TGCT	cis	rs2153535	0.580	rs9405391	chr6:8466548	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs4986172	0.690	rs11657325	chr17:43242694	C/T	cg10701640	chr17:43249399	NA	0.51	6.13	0.48	1.07e-8	Height;
TGCT	cis	rs9486719	1.000	rs12201449	chr6:96959382	C/T	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.21	-0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs9527	0.545	rs7100369	chr10:104956218	C/A	cg15744005	chr10:104629667	AS3MT	-0.41	-4.78	-0.39	4.88e-6	Arsenic metabolism;
TGCT	cis	rs12477438	0.798	rs2084987	chr2:99587885	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-6.1	-0.48	1.22e-8	Chronic sinus infection;
TGCT	cis	rs950027	0.620	rs872192	chr15:45614502	A/G	cg26924012	chr15:45694286	SPATA5L1	0.82	9.11	0.63	1.78e-15	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs11874712	0.899	rs56075249	chr18:43670863	T/C	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	5.23	0.42	7.04e-7	Migraine - clinic-based;
TGCT	cis	rs10875746	0.951	rs2286021	chr12:48528220	C/T	cg20731937	chr12:48336164	NA	0.61	4.82	0.4	4.14e-6	Longevity (90 years and older);
TGCT	cis	rs586688	0.625	rs654631	chr1:201658449	C/T	cg07139329	chr1:201708558	NAV1	0.42	4.58	0.38	1.13e-5	Obesity-related traits;
TGCT	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg11062466	chr8:58055876	NA	0.38	4.62	0.38	9.5e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7829975	0.514	rs2920983	chr8:8268063	G/C	cg08975724	chr8:8085496	FLJ10661	0.58	5.14	0.42	1.04e-6	Mood instability;
TGCT	cis	rs9818758	0.607	rs12715434	chr3:49295025	G/C	cg07636037	chr3:49044803	WDR6	-1.04	-5.13	-0.42	1.09e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs11122272	0.733	rs2749700	chr1:231522734	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.73	-7.29	-0.55	3.25e-11	Hemoglobin concentration;
TGCT	cis	rs9894429	0.646	rs7406522	chr17:79615396	G/T	cg18240062	chr17:79603768	NPLOC4	0.56	4.9	0.4	2.95e-6	Eye color traits;
TGCT	cis	rs7829975	0.755	rs3789849	chr8:8687054	G/C	cg06636001	chr8:8085503	FLJ10661	0.68	6.09	0.48	1.29e-8	Mood instability;
TGCT	cis	rs8180040	1.000	rs811115	chr3:47322133	C/T	cg27129171	chr3:47204927	SETD2	0.7	8.89	0.62	5.88e-15	Colorectal cancer;
TGCT	cis	rs4862307	0.754	rs6846208	chr4:184991703	C/T	cg06737308	chr4:185021514	ENPP6	0.41	5.9	0.47	3.31e-8	Serum dimethylarginine levels (asymmetric/symetric ratio);
TGCT	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg05665937	chr4:1216051	CTBP1	0.24	4.54	0.38	1.32e-5	Obesity-related traits;
TGCT	cis	rs78487399	0.710	rs76857293	chr2:43591676	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.07	-0.41	1.41e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.5	-6.61	-0.51	1.02e-9	Alzheimer's disease;
TGCT	trans	rs62103177	0.810	rs62103188	chr18:77627661	G/A	cg05926928	chr17:57297772	GDPD1	1.22	11.16	0.71	1.85e-20	Opioid sensitivity;
TGCT	cis	rs11031096	0.727	rs2056853	chr11:4142172	C/T	cg18678763	chr11:4115507	RRM1	-0.46	-5.73	-0.46	7.29e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs9921222	0.585	rs7195617	chr16:376781	A/G	cg10349874	chr16:420996	TMEM8A;MRPL28	0.29	5.16	0.42	9.56e-7	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs6964587	0.967	rs7801058	chr7:91784381	C/T	cg17063962	chr7:91808500	NA	0.95	8.85	0.62	7.26e-15	Breast cancer;
TGCT	cis	rs8078723	0.966	rs57065891	chr17:38168227	C/T	cg17467752	chr17:38218738	THRA	0.52	4.93	0.41	2.54e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs9916302	0.706	rs439537	chr17:37734482	T/C	cg03321784	chr17:37729644	NA	0.44	4.58	0.38	1.1e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs2075371	0.637	rs13245165	chr7:133951492	A/T	cg11752832	chr7:134001865	SLC35B4	0.66	5.52	0.44	1.93e-7	Mean platelet volume;
TGCT	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg06896619	chr17:61851486	DDX42;CCDC47	0.55	5.81	0.46	4.84e-8	Prudent dietary pattern;
TGCT	cis	rs6938	0.534	rs11072512	chr15:75204026	C/T	cg09165964	chr15:75287851	SCAMP5	0.54	5.07	0.41	1.39e-6	Breast cancer;
TGCT	cis	rs17270561	1.000	rs79867288	chr6:25828416	A/G	cg16482183	chr6:26056742	HIST1H1C	0.79	5.25	0.43	6.49e-7	Iron status biomarkers;
TGCT	cis	rs317689	0.918	rs610192	chr12:69739941	T/C	cg14784868	chr12:69753453	YEATS4	0.57	4.79	0.39	4.73e-6	Response to diuretic therapy;
TGCT	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg21285383	chr16:89894308	SPIRE2	0.43	6.69	0.52	6.81e-10	Vitiligo;
TGCT	cis	rs7208859	0.623	rs79607958	chr17:28934548	T/G	cg14008862	chr17:28927542	LRRC37B2	0.88	5.32	0.43	4.75e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs3008870	0.583	rs11208985	chr1:67464666	G/A	cg11518657	chr1:67396239	MIER1	-0.6	-4.76	-0.39	5.32e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs4246215	1	rs4246215	chr11:61564299	G/T	cg01500311	chr11:61656094	FADS3	-0.3	-5.04	-0.41	1.64e-6	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);Platelet count;Inflammatory bowel disease;Trans fatty acid levels;Crohn's disease;Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);Red blood cell fatty acid levels;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);
TGCT	cis	rs10892173	0.566	rs12364667	chr11:117675286	A/C	cg21014159	chr11:117668035	DSCAML1	0.62	5.98	0.47	2.21e-8	Myopia;
TGCT	cis	rs1538970	0.961	rs884962	chr1:45847981	G/A	cg05343316	chr1:45956843	TESK2	0.64	5.06	0.41	1.47e-6	Platelet count;
TGCT	cis	rs4478858	0.735	rs6425737	chr1:31790288	T/C	cg07478791	chr1:31886160	SERINC2	-0.51	-4.94	-0.41	2.47e-6	Alcohol dependence;
TGCT	cis	rs12477438	0.798	rs6704766	chr2:99642818	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-8.52	-0.61	4.5e-14	Chronic sinus infection;
TGCT	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg08280861	chr8:58055591	NA	0.54	6.15	0.48	9.82e-9	Developmental language disorder (linguistic errors);
TGCT	cis	rs1994135	0.715	rs11052742	chr12:33692290	A/C	cg06521331	chr12:34319734	NA	-0.31	-4.7	-0.39	6.83e-6	Resting heart rate;
TGCT	cis	rs838147	0.537	rs503279	chr19:49209010	C/T	cg13540341	chr19:49222985	MAMSTR	0.36	4.85	0.4	3.68e-6	Dietary macronutrient intake;
TGCT	cis	rs12580194	0.593	rs55898514	chr12:55736238	G/A	cg10672482	chr12:55725839	OR6C3	-0.51	-4.57	-0.38	1.17e-5	Cancer;
TGCT	cis	rs832540	0.931	rs331499	chr5:56210923	C/T	cg24531977	chr5:56204891	C5orf35	-0.5	-4.86	-0.4	3.48e-6	Coronary artery disease;
TGCT	cis	rs7652177	1.000	rs7652177	chr3:171969077	C/G	cg03587978	chr3:172165696	GHSR	-0.28	-4.61	-0.38	9.77e-6	Height;
TGCT	cis	rs595982	0.527	rs35087747	chr19:49377918	G/T	cg15549821	chr19:49342101	PLEKHA4	-0.66	-7.99	-0.58	7.91e-13	Red cell distribution width;
TGCT	cis	rs739496	0.579	rs7314870	chr12:112276464	T/C	cg10833066	chr12:111807467	FAM109A	0.39	5.25	0.43	6.47e-7	Platelet count;
TGCT	cis	rs9419702	0.568	rs9419635	chr10:133546164	C/T	cg20568497	chr10:133558893	NA	0.47	5.21	0.42	7.48e-7	Survival in rectal cancer;
TGCT	cis	rs514406	0.505	rs447581	chr1:53177098	T/C	cg24675658	chr1:53192096	ZYG11B	-0.78	-9.29	-0.64	6.63e-16	Monocyte count;
TGCT	cis	rs1150668	0.796	rs213236	chr6:28324397	T/C	cg19488431	chr6:28601329	NA	0.2	4.44	0.37	1.99e-5	Pubertal anthropometrics;
TGCT	cis	rs453301	0.624	rs7014430	chr8:8827737	T/G	cg06636001	chr8:8085503	FLJ10661	0.68	5.61	0.45	1.23e-7	Joint mobility (Beighton score);
TGCT	cis	rs6456156	0.792	rs4710183	chr6:167514083	A/G	cg07741184	chr6:167504864	NA	-0.23	-4.66	-0.39	8.06e-6	Primary biliary cholangitis;
TGCT	cis	rs6969780	0.915	rs10085570	chr7:27151188	C/T	cg04321618	chr7:27170880	HOXA4	-0.5	-4.81	-0.4	4.35e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs6089584	0.566	rs55881457	chr20:60608424	G/A	cg06108461	chr20:60628389	TAF4	-0.44	-5.58	-0.45	1.44e-7	Body mass index;
TGCT	cis	rs17681684	0.541	rs17810219	chr17:9764998	A/G	cg15743799	chr17:9805578	RCVRN	-0.27	-5.83	-0.46	4.61e-8	GIP levels in response to oral glucose tolerance test (fasting);
TGCT	cis	rs3096299	0.967	rs2965830	chr16:89460290	T/C	cg02187348	chr16:89574699	SPG7	0.47	4.45	0.37	1.93e-5	Multiple myeloma (IgH translocation);
TGCT	cis	rs66561647	0.929	rs67423398	chr8:128972220	C/T	cg05480350	chr8:128972681	MIR1205;PVT1	0.21	4.5	0.37	1.52e-5	Hemoglobin concentration;
TGCT	cis	rs314370	0.621	rs314312	chr7:100422642	G/C	cg10426581	chr7:100472382	SRRT	0.72	7.41	0.55	1.69e-11	Resting heart rate;
TGCT	cis	rs7432375	0.610	rs7621932	chr3:136517016	C/T	cg15507776	chr3:136538369	TMEM22	0.55	5.64	0.45	1.1e-7	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9534288	0.702	rs7331472	chr13:46644173	C/T	cg15192986	chr13:46630673	CPB2	-0.53	-6.57	-0.51	1.28e-9	Blood protein levels;
TGCT	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg18305652	chr10:134549665	INPP5A	-0.33	-5.67	-0.45	9.3e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	trans	rs10953454	1.000	rs10953454	chr7:104503813	G/A	cg04208666	chr6:19734707	NA	-0.57	-6.89	-0.53	2.52e-10	Obesity;
TGCT	cis	rs4285028	0.747	rs9817818	chr3:121466826	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.92	-7.3	-0.55	3.03e-11	Multiple sclerosis;
TGCT	cis	rs2836633	0.929	rs2836610	chr21:40044502	C/T	cg05519781	chr21:40033154	ERG	0.68	6.68	0.51	7.2e-10	Coronary artery disease;
TGCT	cis	rs62169186	0.655	rs13383608	chr2:145093066	G/A	cg15345847	chr2:145146928	ZEB2	-0.67	-4.54	-0.38	1.33e-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs9467711	0.591	rs3752417	chr6:26045905	G/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.6	-4.66	-0.39	7.95e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12220238	1.000	rs11000902	chr10:75920483	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.83	5.66	0.45	9.98e-8	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs317689	0.684	rs315125	chr12:69758884	C/T	cg11871910	chr12:69753446	YEATS4	0.55	4.72	0.39	6.38e-6	Response to diuretic therapy;
TGCT	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg11764359	chr7:65958608	NA	0.61	5.53	0.44	1.84e-7	Aortic root size;
TGCT	cis	rs2486288	0.656	rs2413768	chr15:45561984	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.74	-7.37	-0.55	2.13e-11	Glomerular filtration rate;
TGCT	cis	rs2439831	0.850	rs694985	chr15:43813387	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	5.58	0.45	1.46e-7	Lung cancer in ever smokers;
TGCT	cis	rs4727027	0.901	rs1137432	chr7:148801658	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	4.68	0.39	7.53e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs2204008	0.604	rs2320521	chr12:38253789	A/G	cg13010199	chr12:38710504	ALG10B	0.61	4.67	0.39	7.69e-6	Bladder cancer;
TGCT	cis	rs1062177	0.774	rs2964574	chr5:151155711	G/A	cg00977110	chr5:151150581	G3BP1	0.4	4.62	0.38	9.33e-6	Preschool internalizing problems;
TGCT	cis	rs35883536	0.740	rs4604711	chr1:101089492	A/C	cg06223162	chr1:101003688	GPR88	0.29	4.56	0.38	1.22e-5	Monocyte count;
TGCT	cis	rs28595532	0.920	rs114333298	chr4:119765305	C/A	cg14228332	chr4:119757509	SEC24D	1.28	6.65	0.51	8.36e-10	Cannabis dependence symptom count;
TGCT	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg22963979	chr7:1858916	MAD1L1	-0.32	-4.95	-0.41	2.39e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs2718812	0.607	rs12497433	chr3:133388584	C/G	cg16414030	chr3:133502952	NA	-0.4	-5.3	-0.43	5.16e-7	Iron status biomarkers;
TGCT	cis	rs6964587	1.000	rs6951972	chr7:91689446	T/G	cg22709100	chr7:91322751	NA	0.28	4.56	0.38	1.19e-5	Breast cancer;
TGCT	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg06713675	chr4:122721982	EXOSC9	-0.68	-9.21	-0.64	1.05e-15	Type 2 diabetes;
TGCT	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg11890956	chr21:40555474	PSMG1	-0.75	-6.81	-0.52	3.82e-10	Cognitive function;
TGCT	cis	rs4727027	0.754	rs11764892	chr7:148858916	G/A	cg23583168	chr7:148888333	NA	-0.72	-8.22	-0.59	2.36e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs6714710	0.603	rs58546246	chr2:98521823	C/A	cg26665480	chr2:98280029	ACTR1B	0.64	6.03	0.48	1.71e-8	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs17102423	0.826	rs10873182	chr14:65605408	C/T	cg11161011	chr14:65562177	MAX	-0.47	-6.33	-0.49	4.15e-9	Obesity-related traits;
TGCT	cis	rs131777	0.575	rs963980	chr22:51022117	C/A	cg25309564	chr22:51001381	C22orf41	0.55	5.22	0.42	7.17e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs12142240	0.698	rs112068407	chr1:46822291	T/C	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs59197085	0.636	rs754920	chr7:128468412	A/G	cg00260937	chr7:128520193	KCP	-0.45	-4.66	-0.39	8.04e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
TGCT	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg18876405	chr7:65276391	NA	0.31	4.79	0.39	4.74e-6	Aortic root size;
TGCT	cis	rs10986311	0.802	rs7045589	chr9:127110354	C/T	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.19	4.97	0.41	2.19e-6	Vitiligo;
TGCT	cis	rs2013441	1.000	rs2703792	chr17:20166950	G/A	cg18979559	chr17:20280153	CCDC144C	-0.44	-4.56	-0.38	1.22e-5	Obesity-related traits;
TGCT	cis	rs2251381	0.750	rs2776250	chr21:30528094	T/G	cg24692254	chr21:30365293	RNF160	0.74	7.03	0.53	1.23e-10	Selective IgA deficiency;
TGCT	cis	rs7552404	0.961	rs1767458	chr1:76219155	A/G	cg22875332	chr1:76189707	ACADM	0.69	8.32	0.6	1.32e-13	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9467773	0.526	rs12199613	chr6:26367218	C/T	cg05738196	chr6:26577821	NA	-0.63	-6.61	-0.51	1.01e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs644799	0.965	rs3016295	chr11:95554311	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	10.57	0.69	5.17e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs17331151	0.573	rs11718060	chr3:52875546	G/A	cg15956490	chr3:53032818	SFMBT1	0.46	5.51	0.44	2.02e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg10047753	chr17:41438598	NA	0.91	8.44	0.6	6.86e-14	Menopause (age at onset);
TGCT	cis	rs12472274	0.941	rs4663861	chr2:239105203	C/T	cg17459225	chr2:239074497	NA	0.33	4.84	0.4	3.79e-6	Phospholipid levels (plasma);
TGCT	cis	rs2370759	1.000	rs11008865	chr10:32574842	C/T	cg01819863	chr10:32635814	EPC1	1.03	10.03	0.67	1.05e-17	Sexual dysfunction (female);
TGCT	cis	rs6918586	0.658	rs13161	chr6:26114702	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.7	-6.6	-0.51	1.09e-9	Schizophrenia;
TGCT	cis	rs7666738	0.752	rs62318905	chr4:99036103	T/G	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9325144	0.647	rs4616077	chr12:39092364	T/C	cg26384229	chr12:38710491	ALG10B	-0.55	-5.16	-0.42	9.52e-7	Morning vs. evening chronotype;
TGCT	cis	rs6733011	0.628	rs6542838	chr2:99452458	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.48	-4.81	-0.4	4.31e-6	Bipolar disorder;
TGCT	cis	rs7674212	0.556	rs223401	chr4:103738972	T/C	cg16532752	chr4:104119610	CENPE	-0.61	-5.39	-0.44	3.41e-7	Type 2 diabetes;
TGCT	cis	rs12200560	0.505	rs2387378	chr6:97077504	C/A	cg06623918	chr6:96969491	KIAA0776	0.59	5.03	0.41	1.71e-6	Coronary heart disease;
TGCT	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg11494091	chr17:61959527	GH2	0.43	7.44	0.56	1.49e-11	Height;
TGCT	cis	rs13242816	1.000	rs4292624	chr7:116102724	A/C	cg02799643	chr7:116139180	CAV2	-0.45	-5.38	-0.44	3.5e-7	P wave duration;
TGCT	cis	rs6570726	0.935	rs451349	chr6:145820894	A/G	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs62064224	0.533	rs11657826	chr17:30790386	T/A	cg25809561	chr17:30822961	MYO1D	0.28	4.96	0.41	2.29e-6	Schizophrenia;
TGCT	cis	rs7666738	0.830	rs17484966	chr4:99014432	T/C	cg05340658	chr4:99064831	C4orf37	0.47	5.33	0.43	4.51e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2562456	0.833	rs2562507	chr19:21726337	C/T	cg25650185	chr19:21324782	ZNF431	0.59	5.28	0.43	5.71e-7	Pain;
TGCT	cis	rs28374715	0.662	rs691906	chr15:41474636	T/A	cg18705301	chr15:41695430	NDUFAF1	0.74	11.02	0.7	4.25e-20	Ulcerative colitis;
TGCT	cis	rs2456568	0.803	rs10831141	chr11:93640728	C/T	cg26875233	chr11:93583750	C11orf90	-0.49	-6.36	-0.5	3.47e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs12711979	0.729	rs6714956	chr2:3820454	T/C	cg17052675	chr2:3827356	NA	-0.4	-7.79	-0.57	2.27e-12	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs9926296	0.632	rs1800286	chr16:89869761	T/C	cg26513180	chr16:89883248	FANCA	0.76	7.1	0.54	8.68e-11	Vitiligo;
TGCT	cis	rs1055129	0.560	rs2666003	chr17:73942976	G/A	cg10935138	chr17:73851978	WBP2	0.55	4.87	0.4	3.35e-6	White matter hyperintensity burden;
TGCT	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-6.54	-0.51	1.42e-9	Alzheimer's disease;
TGCT	cis	rs12983728	0.831	rs34503352	chr19:58651296	G/A	cg07378217	chr19:58662286	ZNF329	-0.82	-4.65	-0.39	8.28e-6	Cholesterol, total;
TGCT	cis	rs2066819	1.000	rs2020854	chr12:56743367	T/C	cg26714650	chr12:56694279	CS	-1.44	-7.53	-0.56	8.91e-12	Psoriasis vulgaris;
TGCT	cis	rs644799	1.000	rs644799	chr11:95564259	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	8.3	0.6	1.51e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9811920	0.715	rs1017967	chr3:99905803	C/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.38	-4.47	-0.37	1.71e-5	Axial length;
TGCT	cis	rs7617773	0.963	rs6800730	chr3:48174210	C/T	cg11946769	chr3:48343235	NME6	0.58	5.21	0.42	7.54e-7	Coronary artery disease;
TGCT	cis	rs6840360	0.615	rs1561916	chr4:152479234	C/T	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.03	-0.58	6.46e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs1865760	1.000	rs3752421	chr6:25918688	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.65	6.11	0.48	1.17e-8	Height;
TGCT	cis	rs2197308	0.565	rs4123923	chr12:37857684	T/C	cg26384229	chr12:38710491	ALG10B	0.85	7.64	0.57	5e-12	Morning vs. evening chronotype;
TGCT	cis	rs938554	0.657	rs7660895	chr4:9985445	A/G	cg11266682	chr4:10021025	SLC2A9	0.45	4.46	0.37	1.81e-5	Blood metabolite levels;
TGCT	cis	rs11098499	0.780	rs7692994	chr4:120427489	C/A	cg09307838	chr4:120376055	NA	0.62	6.07	0.48	1.46e-8	Corneal astigmatism;
TGCT	cis	rs7824557	0.628	rs7841394	chr8:11185671	G/T	cg21775007	chr8:11205619	TDH	0.63	6.14	0.48	1.02e-8	Retinal vascular caliber;
TGCT	cis	rs12048904	0.541	rs6699536	chr1:101276544	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.71	5.7	0.46	8.15e-8	Multiple sclerosis;
TGCT	cis	rs71017072	1	rs71017072	chr7:19794295	G/GA	cg05791153	chr7:19748676	TWISTNB	0.72	4.56	0.38	1.21e-5	Rubella;
TGCT	cis	rs7072216	0.763	rs7923729	chr10:100169465	C/T	cg26618903	chr10:100175079	PYROXD2	-0.4	-4.49	-0.37	1.64e-5	Metabolite levels;
TGCT	cis	rs6964587	1.000	rs12533199	chr7:91757393	C/T	cg17063962	chr7:91808500	NA	0.89	9.51	0.65	1.95e-16	Breast cancer;
TGCT	cis	rs2404602	0.598	rs11634019	chr15:76634680	A/G	cg22467129	chr15:76604101	ETFA	0.47	4.71	0.39	6.44e-6	Blood metabolite levels;
TGCT	cis	rs6840360	0.615	rs4696266	chr4:152463421	A/G	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.03	-0.58	6.46e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs7833790	0.724	rs1054078	chr8:82712153	A/G	cg23324259	chr8:82754387	SNX16	-0.61	-4.71	-0.39	6.42e-6	Diastolic blood pressure;
TGCT	cis	rs250677	0.958	rs43147	chr5:148417103	C/G	cg18129178	chr5:148520854	ABLIM3	0.4	5.57	0.45	1.5e-7	Breast cancer;
TGCT	cis	rs6138458	1.000	rs7268095	chr20:24972333	C/T	cg26195577	chr20:24973756	C20orf3	1.22	12.1	0.74	9.98e-23	Blood protein levels;
TGCT	cis	rs4819052	0.580	rs419322	chr21:46551702	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	4.49	0.37	1.63e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg18252515	chr7:66147081	NA	1.2	7.83	0.58	1.89e-12	Diabetic kidney disease;
TGCT	trans	rs797680	0.856	rs6682670	chr1:93649732	A/G	cg27528825	chr2:159282178	CCDC148	-0.35	-6.82	-0.52	3.53e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg20849893	chr7:64541193	NA	-0.44	-4.62	-0.38	9.47e-6	Calcium levels;
TGCT	trans	rs877282	0.947	rs4133015	chr10:774131	T/C	cg22713356	chr15:30763199	NA	1.11	9.86	0.66	2.79e-17	Uric acid levels;
TGCT	cis	rs13242816	1.000	rs66985071	chr7:116130433	C/T	cg16553024	chr7:116138462	CAV2	-0.45	-5.04	-0.41	1.57e-6	P wave duration;
TGCT	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg25036284	chr2:26402008	FAM59B	-0.54	-4.7	-0.39	6.93e-6	Gut microbiome composition (summer);
TGCT	cis	rs2562456	0.917	rs10420016	chr19:21688602	C/G	cg01304269	chr19:21688519	ZNF429	-0.55	-4.59	-0.38	1.06e-5	Pain;
TGCT	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg00684032	chr4:1343700	KIAA1530	0.23	5.01	0.41	1.79e-6	Obesity-related traits;
TGCT	cis	rs9534288	0.797	rs4294711	chr13:46575557	C/T	cg15192986	chr13:46630673	CPB2	-0.53	-7.62	-0.56	5.82e-12	Blood protein levels;
TGCT	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg08736216	chr1:53307985	ZYG11A	-0.28	-5.73	-0.46	7.33e-8	Monocyte count;
TGCT	cis	rs904251	0.772	rs2776906	chr6:37431757	A/G	cg25019722	chr6:37503610	NA	-0.45	-5.33	-0.43	4.42e-7	Cognitive performance;
TGCT	cis	rs896854	0.654	rs4735337	chr8:95973465	T/C	cg23172400	chr8:95962367	TP53INP1	-0.39	-6.52	-0.51	1.59e-9	Type 2 diabetes;
TGCT	cis	rs2535633	0.631	rs2336670	chr3:52998504	T/G	cg10802521	chr3:52805072	NEK4	0.56	5.92	0.47	2.9e-8	Body mass index;
TGCT	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg01448562	chr3:133502909	NA	-0.28	-5.27	-0.43	5.8e-7	Iron status biomarkers;
TGCT	cis	rs11696501	0.637	rs3746596	chr20:44312028	C/T	cg11783356	chr20:44313418	WFDC10B	-0.33	-4.66	-0.39	7.97e-6	Brain structure;
TGCT	cis	rs7412746	0.658	rs10305704	chr1:150804429	A/C	cg09365446	chr1:150670422	GOLPH3L	0.35	5.13	0.42	1.1e-6	Melanoma;
TGCT	cis	rs2836950	0.545	rs2836922	chr21:40516308	C/T	cg11890956	chr21:40555474	PSMG1	-0.72	-7.21	-0.54	4.91e-11	Menarche (age at onset);
TGCT	cis	rs3087591	1.000	rs3087591	chr17:29630970	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.43	-6.35	-0.5	3.73e-9	Hip circumference;
TGCT	cis	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg20637647	chr7:64974828	NA	0.93	5.2	0.42	8.11e-7	Diabetic kidney disease;
TGCT	cis	rs9581857	0.547	rs9579094	chr13:28081495	G/A	cg22138327	chr13:27999177	GTF3A	0.73	4.54	0.38	1.34e-5	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs2204008	0.744	rs12099650	chr12:38317140	C/G	cg26384229	chr12:38710491	ALG10B	0.79	6.97	0.53	1.67e-10	Bladder cancer;
TGCT	cis	rs2948294	0.566	rs13261997	chr8:8112295	C/T	cg06636001	chr8:8085503	FLJ10661	0.84	7.05	0.53	1.13e-10	Red cell distribution width;
TGCT	cis	rs72945132	0.882	rs7114200	chr11:70186099	C/A	cg00319359	chr11:70116639	PPFIA1	0.97	7.07	0.54	1.01e-10	Coronary artery disease;
TGCT	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg20203395	chr5:56204925	C5orf35	0.53	4.89	0.4	3.03e-6	Initial pursuit acceleration;
TGCT	cis	rs1023500	0.505	rs134888	chr22:42674281	C/T	cg15557168	chr22:42548783	NA	-0.21	-4.84	-0.4	3.82e-6	Schizophrenia;
TGCT	cis	rs7635838	1.000	rs7635838	chr3:11412604	A/G	cg00170343	chr3:11313890	ATG7	0.57	5.5	0.44	2.07e-7	HDL cholesterol;
TGCT	cis	rs9649213	0.533	rs1541409	chr7:98027580	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.95	-8.89	-0.62	5.83e-15	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs6141600	0.627	rs2746100	chr20:34686075	A/C	cg09179691	chr20:35094251	DLGAP4	0.19	4.58	0.38	1.1e-5	Height;Hip circumference;
TGCT	cis	rs7666738	0.830	rs13147195	chr4:98893334	G/T	cg05340658	chr4:99064831	C4orf37	0.52	6.02	0.48	1.81e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7917772	0.619	rs2251772	chr10:104470918	T/C	cg05855489	chr10:104503620	C10orf26	-0.63	-4.94	-0.41	2.52e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs3772130	0.583	rs6767409	chr3:121564989	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.58	5.35	0.43	4.05e-7	Cognitive performance;
TGCT	cis	rs6750047	0.691	rs336032	chr2:38264788	T/C	cg07380506	chr2:38303506	CYP1B1	-0.55	-4.86	-0.4	3.5e-6	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9486719	0.948	rs11152953	chr6:96894305	C/T	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.21	-0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs7666738	0.791	rs11097601	chr4:98960103	C/T	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg03188948	chr7:1209495	NA	0.68	5.8	0.46	5.09e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2594989	1.000	rs346081	chr3:11329085	A/G	cg00170343	chr3:11313890	ATG7	0.67	5.06	0.41	1.44e-6	Circulating chemerin levels;
TGCT	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.91	7.47	0.56	1.26e-11	Platelet count;
TGCT	cis	rs2050392	0.931	rs2265187	chr10:30690844	C/T	cg18806716	chr10:30721971	MAP3K8	-0.44	-5.17	-0.42	9.28e-7	Inflammatory bowel disease;
TGCT	cis	rs7666738	0.830	rs7657497	chr4:99044028	A/G	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2688608	0.592	rs10824032	chr10:75528130	G/A	cg15838173	chr10:75533400	FUT11	-0.3	-4.9	-0.4	2.89e-6	Inflammatory bowel disease;
TGCT	cis	rs12541335	0.615	rs4872464	chr8:22153381	G/A	cg26039829	chr8:22132926	PIWIL2	0.26	4.73	0.39	5.97e-6	Hypertriglyceridemia;
TGCT	cis	rs17376456	0.877	rs12153788	chr5:93405437	A/G	cg25358565	chr5:93447407	FAM172A	0.92	8.38	0.6	9.58e-14	Diabetic retinopathy;
TGCT	cis	rs12188164	1.000	rs72717412	chr5:429381	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.4	-4.76	-0.39	5.27e-6	Cystic fibrosis severity;
TGCT	cis	rs3845702	0.736	rs9288045	chr2:180814194	G/A	cg01881094	chr2:180872142	CWC22	-1.05	-6.78	-0.52	4.27e-10	Schizophrenia;
TGCT	cis	rs2439831	1.000	rs9920763	chr15:43760508	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	6.79	0.52	4.19e-10	Lung cancer in ever smokers;
TGCT	cis	rs858239	0.932	rs1728313	chr7:23271031	A/C	cg05602783	chr7:23145260	KLHL7	-0.64	-5.41	-0.44	3.17e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs11874712	0.527	rs9965812	chr18:43702733	A/G	cg20479805	chr18:43684716	ATP5A1;HAUS1	-0.48	-4.68	-0.39	7.33e-6	Migraine - clinic-based;
TGCT	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg11494091	chr17:61959527	GH2	0.61	14.49	0.79	1.92e-28	Prudent dietary pattern;
TGCT	cis	rs12681287	0.640	rs13280468	chr8:87338452	C/T	cg27223183	chr8:87520930	FAM82B	-0.9	-6.71	-0.52	6.12e-10	Caudate activity during reward;
TGCT	cis	rs8072100	1.000	rs8065669	chr17:45724996	G/A	cg08085267	chr17:45401833	C17orf57	-0.47	-5.13	-0.42	1.07e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg04772025	chr11:68637568	NA	0.6	6.75	0.52	5.08e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs763121	0.853	rs4820345	chr22:39091151	T/C	cg06022373	chr22:39101656	GTPBP1	0.77	7.45	0.56	1.41e-11	Menopause (age at onset);
TGCT	cis	rs7666738	0.515	rs13142498	chr4:98792443	G/T	cg05340658	chr4:99064831	C4orf37	0.52	5.73	0.46	7.24e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7926906	0.875	rs2213084	chr11:90518158	G/A	cg26138821	chr11:89956704	CHORDC1	-0.51	-5.52	-0.44	1.9e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9393692	0.645	rs4145910	chr6:26313305	T/C	cg00631329	chr6:26305371	NA	-0.46	-6.91	-0.53	2.23e-10	Educational attainment;
TGCT	cis	rs12142240	0.698	rs45517837	chr1:46859225	A/G	cg14993813	chr1:46806288	NSUN4	-0.59	-4.86	-0.4	3.45e-6	Menopause (age at onset);
TGCT	trans	rs2727020	0.576	rs1814175	chr11:49559172	T/C	cg03929089	chr4:120376271	NA	-0.66	-7.6	-0.56	6.24e-12	Coronary artery disease;
TGCT	trans	rs1814175	0.817	rs10769613	chr11:49769692	G/A	cg15704280	chr7:45808275	SEPT13	-0.69	-8.05	-0.59	5.61e-13	Height;
TGCT	cis	rs9486719	0.843	rs2472876	chr6:96845723	A/G	cg18709589	chr6:96969512	KIAA0776	0.75	5.13	0.42	1.1e-6	Migraine;Coronary artery disease;
TGCT	cis	rs1371867	0.846	rs1613453	chr8:101244215	G/T	cg00191853	chr8:101177733	SPAG1	0.22	4.51	0.38	1.48e-5	Atrioventricular conduction;
TGCT	cis	rs425277	1.000	rs436045	chr1:2071556	A/G	cg03732007	chr1:2071316	PRKCZ	-0.26	-5.25	-0.43	6.29e-7	Height;
TGCT	trans	rs11722228	0.522	rs12503195	chr4:10082772	T/C	cg26043149	chr18:55253948	FECH	0.82	8.42	0.6	7.82e-14	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs7772486	0.875	rs2474356	chr6:146296798	G/A	cg23711669	chr6:146136114	FBXO30	0.89	9.66	0.66	8.33e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs5769707	0.604	rs1018814	chr22:50036900	T/C	cg05373962	chr22:49881684	NA	-0.31	-5.31	-0.43	4.99e-7	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs12042938	0.600	rs823163	chr1:231771108	A/G	cg04892437	chr1:231737901	TSNAX-DISC1	0.46	4.81	0.4	4.38e-6	Neuranatomic and neurocognitive phenotypes;
TGCT	cis	rs617219	0.698	rs7379187	chr5:78521354	T/C	cg23514016	chr5:78407564	BHMT	0.34	5.25	0.43	6.28e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg22963979	chr7:1858916	MAD1L1	-0.36	-5.53	-0.45	1.78e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg22920501	chr2:26401640	FAM59B	-0.78	-6.28	-0.49	5.18e-9	Gut microbiome composition (summer);
TGCT	cis	rs4680	0.737	rs6269	chr22:19949952	A/G	cg23601416	chr22:19950040	COMT	-0.39	-5.07	-0.41	1.44e-6	Blood metabolite levels;
TGCT	cis	rs295140	0.605	rs159321	chr2:201184713	C/T	cg23649088	chr2:200775458	C2orf69	-0.27	-4.5	-0.37	1.55e-5	QT interval;
TGCT	cis	rs9911578	0.902	rs12948746	chr17:57071892	A/G	cg05425664	chr17:57184151	TRIM37	-0.67	-6.86	-0.52	2.88e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs7809950	0.678	rs79902674	chr7:106866498	A/C	cg23024343	chr7:107201750	COG5	-0.43	-5.91	-0.47	3.13e-8	Coronary artery disease;
TGCT	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg12419862	chr22:24373484	LOC391322	-0.83	-9.3	-0.64	6.27e-16	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs72945132	0.825	rs947811	chr11:70209142	A/T	cg00319359	chr11:70116639	PPFIA1	0.98	7.13	0.54	7.33e-11	Coronary artery disease;
TGCT	cis	rs6964587	0.967	rs2299235	chr7:91627500	C/T	cg22709100	chr7:91322751	NA	0.27	4.48	0.37	1.68e-5	Breast cancer;
TGCT	cis	rs6540559	0.673	rs1073150	chr1:210017083	G/A	cg22029157	chr1:209979665	IRF6	0.68	4.88	0.4	3.22e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs12540874	0.895	rs4245556	chr7:50661661	C/T	cg18232548	chr7:50535776	DDC	-0.31	-5.27	-0.43	5.96e-7	Systemic sclerosis;
TGCT	cis	rs7917772	0.582	rs10786698	chr10:104378750	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	5.36	0.43	3.84e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg13695892	chr22:41940480	POLR3H	0.78	7.58	0.56	7.01e-12	Vitiligo;
TGCT	cis	rs739496	0.579	rs11066051	chr12:112301760	G/C	cg10833066	chr12:111807467	FAM109A	0.38	5.61	0.45	1.24e-7	Platelet count;
TGCT	cis	rs13191362	1.000	rs36107456	chr6:162997399	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.68	5.79	0.46	5.33e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs11190604	1.000	rs2495732	chr10:102357780	T/C	cg23241863	chr10:102295624	HIF1AN	0.69	4.93	0.4	2.58e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9674544	0.757	rs9896443	chr17:47125982	A/G	cg20966754	chr17:47091339	IGF2BP1	-0.44	-5.43	-0.44	2.91e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
TGCT	cis	rs13082711	0.522	rs480646	chr3:27327143	C/T	cg02860705	chr3:27208620	NA	0.34	5.66	0.45	9.82e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs1371867	0.875	rs1788168	chr8:101324960	G/T	cg00191853	chr8:101177733	SPAG1	-0.23	-4.76	-0.39	5.2e-6	Atrioventricular conduction;
TGCT	cis	rs6671200	0.573	rs3738171	chr1:95699594	A/G	cg26537280	chr1:95699037	RWDD3	-0.54	-4.94	-0.41	2.42e-6	Stearic acid (18:0) levels;
TGCT	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg12310025	chr6:25882481	NA	-0.69	-7.5	-0.56	1.08e-11	Blood metabolite levels;
TGCT	cis	rs3733585	0.699	rs6449171	chr4:9965998	C/T	cg00071950	chr4:10020882	SLC2A9	0.54	6.48	0.5	1.97e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs9486715	0.867	rs9384628	chr6:96960232	T/C	cg18709589	chr6:96969512	KIAA0776	0.82	8.01	0.58	7.14e-13	Headache;
TGCT	cis	rs2456568	0.741	rs10831137	chr11:93636912	C/T	cg14065697	chr11:93583672	C11orf90	-0.38	-4.74	-0.39	5.69e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs12532214	0.690	rs6971710	chr7:3140173	G/A	cg19214707	chr7:3157722	NA	-0.38	-4.57	-0.38	1.17e-5	Itch intensity from mosquito bite;
TGCT	cis	rs427394	0.659	rs274674	chr5:6755460	C/T	cg10857441	chr5:6722123	POLS	-0.29	-6.12	-0.48	1.16e-8	Menopause (age at onset);
TGCT	cis	rs7666738	0.830	rs3846445	chr4:99032939	T/A	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10927875	0.722	rs6696912	chr1:16338474	T/C	cg21385522	chr1:16154831	NA	0.6	6.38	0.5	3.14e-9	Dilated cardiomyopathy;
TGCT	cis	rs3806843	0.576	rs246030	chr5:140333154	C/G	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9291683	0.588	rs3756237	chr4:10013378	G/A	cg00071950	chr4:10020882	SLC2A9	0.76	10.38	0.68	1.55e-18	Bone mineral density;
TGCT	cis	rs2840044	1.000	rs11656138	chr17:33910218	T/C	cg05299278	chr17:33885742	SLFN14	-0.23	-5.05	-0.41	1.53e-6	Response to radiotherapy in cancer (late toxicity);
TGCT	cis	rs68170813	0.559	rs78553765	chr7:106930787	C/T	cg02696742	chr7:106810147	HBP1	-0.69	-5.81	-0.46	4.85e-8	Coronary artery disease;
TGCT	cis	rs644799	0.526	rs542509	chr11:95641602	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.49	4.97	0.41	2.19e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7949030	0.523	rs12223627	chr11:62368557	G/C	cg13298116	chr11:62369859	EML3;MTA2	0.6	7.25	0.55	3.98e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	trans	rs1496653	0.557	rs13087563	chr3:23322626	A/G	cg02770683	chr12:57597238	LRP1	0.36	6.66	0.51	8.06e-10	Type 2 diabetes;
TGCT	cis	rs8017423	0.647	rs12882973	chr14:90820502	G/A	cg04374321	chr14:90722782	PSMC1	-0.56	-5.62	-0.45	1.19e-7	Mortality in heart failure;
TGCT	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg18876405	chr7:65276391	NA	0.31	4.79	0.4	4.58e-6	Aortic root size;
TGCT	cis	rs3784262	0.935	rs4646563	chr15:58353335	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.5	-7.84	-0.58	1.81e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs35883536	0.647	rs10875312	chr1:101042320	G/C	cg10298815	chr1:101004474	GPR88	-0.25	-4.73	-0.39	6.03e-6	Monocyte count;
TGCT	cis	rs7584330	0.910	rs6757376	chr2:238400036	G/C	cg08992911	chr2:238395768	MLPH	0.58	4.51	0.38	1.49e-5	Prostate cancer;
TGCT	cis	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg12570787	chr5:219185	SDHA;CCDC127	0.65	4.46	0.37	1.83e-5	Breast cancer;
TGCT	cis	rs2549003	1.000	rs7701588	chr5:131819970	T/C	cg21138405	chr5:131827807	IRF1	0.19	4.79	0.4	4.64e-6	Asthma (sex interaction);
TGCT	cis	rs4824093	0.541	rs8142132	chr22:50211294	C/T	cg03660710	chr22:50631079	TRABD	0.36	4.49	0.37	1.59e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs9302065	0.565	rs2993584	chr13:95961678	C/A	cg24476569	chr13:95954382	ABCC4	-0.54	-8.26	-0.6	1.9e-13	Blood metabolite levels;
TGCT	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg10295955	chr4:187884368	NA	-1.0	-14.26	-0.79	6.69e-28	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6964587	0.900	rs7783674	chr7:91784212	T/A	cg17063962	chr7:91808500	NA	0.91	9.83	0.66	3.33e-17	Breast cancer;
TGCT	cis	rs10791097	0.678	rs10894272	chr11:130731081	A/G	cg14779329	chr11:130786720	SNX19	0.27	4.64	0.38	8.6e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs634534	0.561	rs655744	chr11:65776585	G/T	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.62	-6.11	-0.48	1.2e-8	Sum eosinophil basophil counts;Eosinophil counts;
TGCT	cis	rs4654899	1.000	rs6683542	chr1:21369610	T/C	cg01072550	chr1:21505969	NA	-0.49	-7.87	-0.58	1.47e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs2180341	0.618	rs6683	chr6:127610021	G/A	cg27446573	chr6:127587934	RNF146	0.65	5.79	0.46	5.52e-8	Breast cancer;
TGCT	cis	rs34526934	0.608	rs7591820	chr2:177028144	G/T	cg00278547	chr2:177037212	HOXD3	-0.4	-4.98	-0.41	2.09e-6	Obstructive sleep apnea trait (apnea hypopnea index);
TGCT	cis	rs35306767	0.715	rs17293580	chr10:1034895	T/C	cg20503657	chr10:835505	NA	0.64	7.06	0.54	1.04e-10	Eosinophil percentage of granulocytes;
TGCT	cis	rs17473412	1.000	rs17473342	chr5:122697009	C/T	cg15125798	chr5:122621645	NA	0.55	5.09	0.42	1.28e-6	Total body bone mineral density;
TGCT	cis	rs12142240	0.698	rs17361791	chr1:46812519	A/G	cg14993813	chr1:46806288	NSUN4	-0.58	-4.79	-0.4	4.68e-6	Menopause (age at onset);
TGCT	cis	rs1460583	0.961	rs1460582	chr8:106108281	C/T	cg13963735	chr8:106810858	ZFPM2	0.27	4.44	0.37	1.98e-5	Schizophrenia;
TGCT	cis	rs3091242	0.728	rs706845	chr1:25730713	G/A	cg09222892	chr1:25734099	RHCE	-0.44	-7.09	-0.54	9.15e-11	Erythrocyte sedimentation rate;
TGCT	cis	rs6426551	1.000	rs6426551	chr1:226542049	A/G	cg18564989	chr1:226411057	MIXL1	-0.49	-4.95	-0.41	2.4e-6	Coronary artery disease;
TGCT	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg10047753	chr17:41438598	NA	0.94	9.11	0.63	1.81e-15	Menopause (age at onset);
TGCT	cis	rs7095607	0.538	rs2255027	chr10:69920911	T/C	cg18986048	chr10:69913749	MYPN	0.61	5.85	0.46	4.16e-8	Lung function (FVC);
TGCT	cis	rs2721195	1.000	rs2721195	chr8:145677011	T/C	cg17328964	chr8:145687451	CYHR1	0.48	6.95	0.53	1.84e-10	Age at first birth;
TGCT	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg25660036	chr4:7070649	GRPEL1	-0.67	-5.89	-0.47	3.39e-8	Monocyte percentage of white cells;
TGCT	cis	rs2130392	0.924	rs873687	chr4:185638853	G/A	cg14471096	chr4:185570637	CCDC111;CASP3	-0.52	-4.91	-0.4	2.85e-6	Kawasaki disease;
TGCT	cis	rs12497850	0.931	rs9311430	chr3:48845251	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.41	-5.49	-0.44	2.15e-7	Parkinson's disease;
TGCT	cis	rs1371867	0.775	rs3020183	chr8:101233297	A/T	cg06636551	chr8:101224915	SPAG1	0.53	7.24	0.54	4.19e-11	Atrioventricular conduction;
TGCT	cis	rs11249608	0.548	rs7707587	chr5:178462590	G/C	cg21905437	chr5:178450457	ZNF879	0.44	4.55	0.38	1.25e-5	Pubertal anthropometrics;
TGCT	cis	rs854765	0.693	rs11657074	chr17:17770355	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.76	-7.95	-0.58	9.74e-13	Total body bone mineral density;
TGCT	trans	rs1814175	0.803	rs11040451	chr11:49650639	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.34	-6.67	-0.51	7.47e-10	Height;
TGCT	cis	rs7172809	0.573	rs1015813	chr15:77533274	C/T	cg22256960	chr15:77711686	NA	-0.49	-4.62	-0.38	9.51e-6	Glucose homeostasis traits;
TGCT	cis	rs7089973	0.584	rs4752322	chr10:116613258	A/C	cg03647239	chr10:116582469	FAM160B1	0.59	5.61	0.45	1.26e-7	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs704	0.790	rs708100	chr17:26688663	G/A	cg10342447	chr17:26645325	TMEM97	-0.56	-5.44	-0.44	2.73e-7	Osteoprotegerin levels;
TGCT	cis	rs7267979	0.932	rs6115200	chr20:25487377	G/T	cg03522245	chr20:25566470	NINL	0.6	6.46	0.5	2.14e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10858047	0.831	rs10776787	chr1:115210161	A/T	cg12756093	chr1:115239321	AMPD1	0.46	5.05	0.41	1.55e-6	Autism;
TGCT	cis	rs55883249	0.957	rs17362839	chr2:9754439	T/C	cg23886495	chr2:9695866	ADAM17	0.79	4.66	0.39	8.09e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs1670533	1.000	rs7660779	chr4:1075940	A/G	cg20887711	chr4:1340912	KIAA1530	0.72	5.8	0.46	5.25e-8	Recombination rate (females);
TGCT	cis	rs7772486	0.625	rs2050027	chr6:146116113	C/G	cg23711669	chr6:146136114	FBXO30	-0.86	-9.74	-0.66	5.4e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10206020	0.885	rs6746052	chr2:1576811	T/C	cg01028140	chr2:1542097	TPO	-0.28	-4.51	-0.38	1.47e-5	IgG glycosylation;
TGCT	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.44	0.44	2.74e-7	Tonsillectomy;
TGCT	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg10560079	chr2:191398806	TMEM194B	0.37	5.33	0.43	4.5e-7	Pulse pressure;
TGCT	cis	rs17376456	0.825	rs10038831	chr5:93124115	C/T	cg25358565	chr5:93447407	FAM172A	0.91	8.22	0.59	2.27e-13	Diabetic retinopathy;
TGCT	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg03188948	chr7:1209495	NA	0.46	6.3	0.49	4.7e-9	Longevity;Endometriosis;
TGCT	cis	rs9913156	0.576	rs2036656	chr17:4622071	C/G	cg19197139	chr17:4613644	ARRB2	-0.59	-5.37	-0.43	3.82e-7	Lymphocyte counts;
TGCT	cis	rs7731657	0.537	rs12332151	chr5:130344771	T/C	cg08523029	chr5:130500466	HINT1	-0.61	-5.08	-0.42	1.34e-6	Fasting plasma glucose;
TGCT	cis	rs13217239	0.608	rs6930508	chr6:27053142	T/C	cg15659132	chr6:26577336	NA	-0.56	-5.55	-0.45	1.62e-7	Schizophrenia;
TGCT	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg08280861	chr8:58055591	NA	0.52	5.97	0.47	2.35e-8	Developmental language disorder (linguistic errors);
TGCT	cis	rs7582180	0.638	rs7581011	chr2:100954659	A/G	cg08017756	chr2:100939284	LONRF2	0.3	4.92	0.4	2.7e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs12477438	0.798	rs6542848	chr2:99573732	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-8.58	-0.61	3.24e-14	Chronic sinus infection;
TGCT	cis	rs1857353	1.000	rs116436237	chr1:75931742	G/A	cg11838876	chr1:75668600	SLC44A5	-0.51	-4.7	-0.39	6.94e-6	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs77633900	0.614	rs2468116	chr15:76870998	G/A	cg21673338	chr15:77095150	SCAPER	-0.5	-4.71	-0.39	6.49e-6	Non-glioblastoma glioma;Glioma;
TGCT	cis	rs3784262	0.967	rs11630835	chr15:58269462	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.49	-7.74	-0.57	3.01e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs9467711	0.606	rs34622023	chr6:26362119	A/T	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7726839	0.540	rs55929359	chr5:595956	C/G	cg16624210	chr5:671434	TPPP	0.43	4.66	0.39	8.1e-6	Obesity-related traits;
TGCT	cis	rs67478160	0.643	rs6575999	chr14:104250609	C/G	cg26031613	chr14:104095156	KLC1	-0.63	-6.36	-0.5	3.46e-9	Schizophrenia;
TGCT	cis	rs36051895	0.589	rs62543573	chr9:5201675	A/G	cg02405213	chr9:5042618	JAK2	-0.72	-9.21	-0.64	1.05e-15	Pediatric autoimmune diseases;
TGCT	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg21856205	chr7:94953877	PON1	-0.63	-7.31	-0.55	2.86e-11	Paraoxonase activity;
TGCT	cis	rs7412746	0.611	rs4970984	chr1:150887377	T/C	cg09365446	chr1:150670422	GOLPH3L	0.34	4.71	0.39	6.58e-6	Melanoma;
TGCT	cis	rs10089	0.953	rs1432614	chr5:127416919	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.81	7.51	0.56	1e-11	Ileal carcinoids;
TGCT	trans	rs61931739	0.500	rs11524949	chr12:34435551	C/T	cg26384229	chr12:38710491	ALG10B	0.73	6.92	0.53	2.11e-10	Morning vs. evening chronotype;
TGCT	cis	rs2455799	0.517	rs6442553	chr3:15927193	A/G	cg12172478	chr3:16357591	RFTN1	-0.34	-4.98	-0.41	2.09e-6	Mean platelet volume;
TGCT	cis	rs79349575	0.651	rs4378658	chr17:46993370	G/A	cg26022315	chr17:47021804	SNF8	0.49	4.89	0.4	3.03e-6	Type 2 diabetes;
TGCT	cis	rs9467773	0.572	rs62394558	chr6:26604650	G/A	cg09904177	chr6:26538194	HMGN4	0.63	5.65	0.45	1.05e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs12421382	0.659	rs60143378	chr11:109385513	T/C	cg16359550	chr11:109292809	C11orf87	0.43	4.79	0.39	4.73e-6	Schizophrenia;
TGCT	cis	rs7100689	0.622	rs10736344	chr10:82133955	T/C	cg01528321	chr10:82214614	TSPAN14	0.8	7.72	0.57	3.42e-12	Post bronchodilator FEV1;
TGCT	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	4.93	0.4	2.63e-6	Menopause (age at onset);
TGCT	cis	rs9611565	0.592	rs12484467	chr22:41957610	T/C	cg17554472	chr22:41940697	POLR3H	-0.46	-4.72	-0.39	6.27e-6	Vitiligo;
TGCT	cis	rs2019216	0.542	rs7217513	chr17:21933536	C/A	cg22648282	chr17:21454238	C17orf51	-0.59	-5.89	-0.47	3.46e-8	Pelvic organ prolapse;
TGCT	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg09436375	chr6:42928200	GNMT	-0.4	-5.23	-0.42	7.13e-7	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs2486288	0.656	rs11632778	chr15:45551056	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.72	-7.46	-0.56	1.34e-11	Glomerular filtration rate;
TGCT	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg11890956	chr21:40555474	PSMG1	0.8	7.6	0.56	6.2e-12	Cognitive function;
TGCT	cis	rs651907	0.514	rs12636046	chr3:101434448	T/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.89	10.45	0.68	1.02e-18	Colorectal cancer;
TGCT	cis	rs28595532	0.920	rs116717907	chr4:119762568	A/G	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs1059312	0.772	rs11609637	chr12:129300202	T/G	cg09035930	chr12:129282057	SLC15A4	0.56	10.49	0.69	8.05e-19	Systemic lupus erythematosus;
TGCT	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg20891283	chr12:69753455	YEATS4	0.9	10.36	0.68	1.69e-18	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs3087591	0.960	rs2953009	chr17:29498387	A/C	cg24425628	chr17:29625626	OMG;NF1	0.45	6.95	0.53	1.84e-10	Hip circumference;
TGCT	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.19e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs28595532	0.920	rs56389935	chr4:119683571	G/A	cg21605333	chr4:119757512	SEC24D	1.4	7.38	0.55	1.97e-11	Cannabis dependence symptom count;
TGCT	cis	rs2242116	0.900	rs4683300	chr3:46934292	C/A	cg27129171	chr3:47204927	SETD2	0.61	6.15	0.48	9.79e-9	Birth weight;
TGCT	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg11301795	chr4:187892539	NA	-0.33	-5.11	-0.42	1.2e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs12497850	0.931	rs4072859	chr3:49032205	G/C	cg05785598	chr3:49045655	WDR6	0.37	4.83	0.4	3.97e-6	Parkinson's disease;
TGCT	trans	rs2727020	0.576	rs12293522	chr11:49558425	T/A	cg15704280	chr7:45808275	SEPT13	-0.75	-8.8	-0.62	9.9e-15	Coronary artery disease;
TGCT	cis	rs3806843	0.801	rs2531358	chr5:140117437	A/G	cg19875535	chr5:140030758	IK	-0.35	-5.92	-0.47	2.9e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs72945132	0.882	rs7123602	chr11:70181489	C/T	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs3096299	0.642	rs12934829	chr16:89523349	T/A	cg06640241	chr16:89574553	SPG7	0.77	8.65	0.61	2.25e-14	Multiple myeloma (IgH translocation);
TGCT	cis	rs7412746	0.611	rs11204726	chr1:150743492	T/C	cg09365446	chr1:150670422	GOLPH3L	0.36	5.19	0.42	8.25e-7	Melanoma;
TGCT	cis	rs782590	0.967	rs1975484	chr2:55803167	T/A	cg18811423	chr2:55921094	PNPT1	0.65	6.93	0.53	2.04e-10	Metabolic syndrome;
TGCT	cis	rs2153535	0.580	rs2327056	chr6:8443305	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.58	0.45	1.42e-7	Motion sickness;
TGCT	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg02953382	chr22:24373134	LOC391322	-0.77	-7.98	-0.58	8.41e-13	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9911578	0.839	rs7208505	chr17:57187729	C/T	cg05425664	chr17:57184151	TRIM37	-0.65	-6.6	-0.51	1.09e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs66561647	0.518	rs4733806	chr8:128909539	C/T	cg11792826	chr8:129160931	MIR1208	0.23	5.04	0.41	1.62e-6	Hemoglobin concentration;
TGCT	cis	rs11252926	0.537	rs6560836	chr10:444997	C/T	cg13477178	chr10:375248	DIP2C	-0.24	-4.52	-0.38	1.45e-5	Psychosis in Alzheimer's disease;
TGCT	cis	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.67	6.57	0.51	1.27e-9	Eosinophil percentage of white cells;
TGCT	cis	rs6748734	1.000	rs7604393	chr2:241825034	T/G	cg04034577	chr2:241836375	C2orf54	-0.4	-6.32	-0.49	4.22e-9	Urinary metabolites;
TGCT	cis	rs7552404	0.924	rs1313071	chr1:76195542	C/G	cg10523679	chr1:76189770	ACADM	0.85	9.41	0.65	3.37e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs8064299	0.597	rs6501737	chr17:72780830	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	-0.83	-9.62	-0.65	1.08e-16	Monocyte count;
TGCT	cis	rs1691799	0.867	rs1168333	chr12:66761377	G/A	cg16791601	chr12:66731901	HELB	-0.27	-5.66	-0.45	9.92e-8	White blood cell count (basophil);
TGCT	cis	rs12681287	0.547	rs10087788	chr8:87544174	G/A	cg27223183	chr8:87520930	FAM82B	0.94	6.91	0.53	2.24e-10	Caudate activity during reward;
TGCT	cis	rs6671200	0.915	rs259334	chr1:95739701	C/T	cg03123541	chr1:95699097	RWDD3	-1.0	-6.44	-0.5	2.43e-9	Stearic acid (18:0) levels;
TGCT	cis	rs6565180	0.962	rs35480350	chr16:30366039	G/A	cg17640201	chr16:30407289	ZNF48	-0.87	-8.21	-0.59	2.4e-13	Tonsillectomy;
TGCT	trans	rs3790455	0.804	rs1109751	chr1:156439000	C/T	cg16443977	chr5:115884994	SEMA6A	-0.36	-6.65	-0.51	8.53e-10	Migraine;
TGCT	cis	rs7772486	0.754	rs697055	chr6:146003790	C/G	cg13319975	chr6:146136371	FBXO30	-0.55	-5.14	-0.42	1.03e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1062177	1.000	rs2964578	chr5:151147198	T/A	cg12924095	chr5:151150029	G3BP1	0.35	5.04	0.41	1.6e-6	Preschool internalizing problems;
TGCT	cis	rs765787	0.530	rs11636404	chr15:45535861	C/G	cg24006582	chr15:45444508	DUOX1	-0.24	-5.29	-0.43	5.34e-7	Uric acid levels;
TGCT	cis	rs453301	0.509	rs7000323	chr8:8792273	G/A	cg06636001	chr8:8085503	FLJ10661	-0.6	-4.85	-0.4	3.56e-6	Joint mobility (Beighton score);
TGCT	cis	rs61774743	0.714	rs2364543	chr1:41833089	T/G	cg01193554	chr1:41846683	NA	0.41	4.91	0.4	2.84e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs12220238	0.915	rs10824164	chr10:76137032	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.88	5.86	0.47	3.87e-8	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs9611565	0.614	rs4822053	chr22:42212936	C/A	cg06481639	chr22:41940642	POLR3H	-0.55	-4.69	-0.39	6.98e-6	Vitiligo;
TGCT	cis	rs7552404	0.921	rs10873685	chr1:76218818	A/C	cg10523679	chr1:76189770	ACADM	0.92	9.67	0.66	8.16e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs3751972	0.668	rs9903233	chr17:26216356	G/A	cg02948944	chr17:26242737	NA	0.33	4.8	0.4	4.48e-6	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs12497850	0.644	rs11928552	chr3:48739883	T/C	cg06212747	chr3:49208901	KLHDC8B	0.62	5.7	0.46	8.17e-8	Parkinson's disease;
TGCT	cis	rs12971120	0.947	rs4891559	chr18:72170397	C/T	cg26446133	chr18:72167187	CNDP2	-0.4	-7.73	-0.57	3.15e-12	Refractive error;
TGCT	cis	rs3806843	0.520	rs265312	chr5:140296272	T/G	cg09824255	chr5:140014002	CD14	0.25	4.48	0.37	1.69e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs763121	0.853	rs1569716	chr22:38998519	C/A	cg06022373	chr22:39101656	GTPBP1	0.81	8.26	0.6	1.84e-13	Menopause (age at onset);
TGCT	cis	rs3008870	1.000	rs2985821	chr1:67403787	G/A	cg03991309	chr1:68237761	GNG12	0.27	4.55	0.38	1.26e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs6977940	0.818	rs73033466	chr7:2902617	G/C	cg19731401	chr7:2775893	GNA12	0.37	4.44	0.37	1.94e-5	White matter integrity;
TGCT	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg05368731	chr17:41323189	NBR1	1.07	12.07	0.73	1.17e-22	Menopause (age at onset);
TGCT	cis	rs1577917	0.958	rs1816937	chr6:86557251	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.29	-0.43	5.34e-7	Response to antipsychotic treatment;
TGCT	cis	rs3733585	0.648	rs7376155	chr4:9952588	C/T	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.65	-0.57	4.78e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg03806693	chr22:41940476	POLR3H	1.11	12.05	0.73	1.3e-22	Cannabis dependence symptom count;
TGCT	cis	rs6921919	0.609	rs1005127	chr6:28367658	G/A	cg18815343	chr6:28367644	ZSCAN12	-0.56	-5.27	-0.43	5.78e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg07167872	chr1:205819463	PM20D1	0.67	9.56	0.65	1.49e-16	Menarche (age at onset);
TGCT	cis	rs28595532	0.841	rs116587722	chr4:119790517	T/C	cg14228332	chr4:119757509	SEC24D	1.31	6.68	0.51	7.27e-10	Cannabis dependence symptom count;
TGCT	cis	rs6754311	0.773	rs4988226	chr2:136610598	A/G	cg07169764	chr2:136633963	MCM6	-0.62	-5.74	-0.46	7e-8	Mosquito bite size;
TGCT	cis	rs7103648	0.669	rs12577383	chr11:47774238	C/T	cg20307385	chr11:47447363	PSMC3	0.77	7.25	0.55	3.99e-11	Diastolic blood pressure;Systolic blood pressure;
TGCT	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg06481639	chr22:41940642	POLR3H	0.86	6.43	0.5	2.5e-9	Vitiligo;
TGCT	cis	rs9677476	0.516	rs10169827	chr2:232049722	A/G	cg07929768	chr2:232055508	NA	0.32	5.05	0.41	1.53e-6	Food antigen IgG levels;
TGCT	cis	rs3096299	0.935	rs3102387	chr16:89432276	A/C	cg02187348	chr16:89574699	SPG7	0.48	4.69	0.39	7.11e-6	Multiple myeloma (IgH translocation);
TGCT	cis	rs4478858	0.735	rs7526095	chr1:31797581	C/T	cg07478791	chr1:31886160	SERINC2	-0.51	-4.95	-0.41	2.33e-6	Alcohol dependence;
TGCT	cis	rs9913156	0.789	rs72824966	chr17:4596679	T/C	cg23387401	chr17:4582204	PELP1	0.31	4.68	0.39	7.44e-6	Lymphocyte counts;
TGCT	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg00684032	chr4:1343700	KIAA1530	0.23	4.93	0.41	2.55e-6	Obesity-related traits;
TGCT	cis	rs13256369	1.000	rs4841016	chr8:8572561	C/T	cg06671706	chr8:8559999	CLDN23	0.34	4.44	0.37	1.99e-5	Obesity-related traits;
TGCT	cis	rs7248779	1.000	rs7248779	chr19:2403564	G/T	cg22729335	chr19:2427816	TIMM13	-0.67	-6.83	-0.52	3.4e-10	Cortisol levels (saliva);
TGCT	cis	rs1403694	1.000	rs2304451	chr3:186437661	G/C	cg12454167	chr3:186435060	KNG1	0.43	7.53	0.56	9.3e-12	Blood protein levels;
TGCT	cis	rs6700896	0.500	rs4655566	chr1:66088951	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.59	4.56	0.38	1.22e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs7659604	0.539	rs72680779	chr4:122797263	C/T	cg19748678	chr4:122722346	EXOSC9	0.85	8.39	0.6	9.24e-14	Type 2 diabetes;
TGCT	cis	rs7666738	0.791	rs1559860	chr4:99024422	C/T	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7524258	0.868	rs6577428	chr1:7314655	C/T	cg07173049	chr1:7289937	CAMTA1	-0.29	-4.83	-0.4	3.96e-6	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg00149659	chr3:10157352	C3orf10	-0.89	-5.76	-0.46	6.17e-8	Alzheimer's disease;
TGCT	cis	rs7937682	0.632	rs57414412	chr11:111769431	G/A	cg09085632	chr11:111637200	PPP2R1B	0.83	7.15	0.54	6.45e-11	Primary sclerosing cholangitis;
TGCT	cis	rs7246657	0.722	rs12974225	chr19:38240098	G/T	cg03611452	chr19:38183253	ZNF781	-0.59	-4.94	-0.41	2.45e-6	Coronary artery calcification;
TGCT	cis	rs2235642	0.928	rs2076435	chr16:1607574	C/T	cg00463982	chr16:1583984	IFT140;TMEM204	-0.28	-4.74	-0.39	5.81e-6	Coronary artery disease;
TGCT	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7949030	0.626	rs7124057	chr11:62334096	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.61	8.71	0.62	1.65e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7552404	0.765	rs211717	chr1:76106969	G/A	cg22875332	chr1:76189707	ACADM	-0.79	-9.72	-0.66	6.2e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg03160526	chr17:80928410	B3GNTL1	0.33	4.46	0.37	1.8e-5	Glycated hemoglobin levels;
TGCT	cis	rs854765	0.583	rs6502625	chr17:17848286	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.69	6.93	0.53	1.99e-10	Total body bone mineral density;
TGCT	cis	rs6430585	0.640	rs6716070	chr2:136544651	G/T	cg07169764	chr2:136633963	MCM6	-1.19	-11.11	-0.71	2.49e-20	Corneal structure;
TGCT	cis	rs12762955	0.529	rs2387213	chr10:1051420	C/T	cg20503657	chr10:835505	NA	0.41	5.24	0.43	6.54e-7	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs9372253	0.678	rs6568644	chr6:110707820	C/T	cg01119278	chr6:110721349	DDO	-0.3	-4.54	-0.38	1.32e-5	Platelet distribution width;
TGCT	cis	rs2046867	0.818	rs62249866	chr3:72878632	T/C	cg25664220	chr3:72788482	NA	-0.57	-6.33	-0.49	4.08e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs1008375	1.000	rs4698634	chr4:17630192	A/C	cg10189774	chr4:17578691	LAP3	-0.59	-5.13	-0.42	1.06e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2734839	0.537	rs11214603	chr11:113279922	G/A	cg14159747	chr11:113255604	NA	0.37	4.75	0.39	5.46e-6	Information processing speed;
TGCT	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg11301795	chr4:187892539	NA	-0.33	-4.82	-0.4	4.14e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3213545	0.700	rs2260445	chr12:121468863	C/A	cg15155738	chr12:121454335	C12orf43	0.47	4.64	0.38	8.71e-6	Subjective well-being;Cardiovascular disease risk factors;
TGCT	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg11644478	chr21:40555479	PSMG1	-0.51	-4.77	-0.39	5.15e-6	Menarche (age at onset);
TGCT	cis	rs8020441	0.541	rs72681652	chr14:51156155	C/T	cg04730355	chr14:51134070	SAV1	1.23	9.65	0.66	8.78e-17	Cognitive performance;
TGCT	cis	rs7439150	0.954	rs72679193	chr4:155470398	A/G	cg22130008	chr4:155548532	NA	-0.45	-5.5	-0.44	2.03e-7	Fibrinogen levels;
TGCT	cis	rs72945132	0.638	rs627079	chr11:70165505	G/T	cg00319359	chr11:70116639	PPFIA1	0.84	6.75	0.52	5.05e-10	Coronary artery disease;
TGCT	cis	rs6545883	0.929	rs3732170	chr2:61749716	C/T	cg15711740	chr2:61764176	XPO1	-0.57	-5.23	-0.43	6.89e-7	Tuberculosis;
TGCT	cis	rs17376456	0.542	rs1453003	chr5:93151611	T/C	cg25358565	chr5:93447407	FAM172A	-0.76	-6.72	-0.52	5.94e-10	Diabetic retinopathy;
TGCT	cis	rs13191362	1.000	rs28360546	chr6:163210973	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.93	5.86	0.47	3.91e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs55794721	0.509	rs909834	chr1:25757996	A/G	cg09222892	chr1:25734099	RHCE	-0.43	-7.0	-0.53	1.43e-10	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs6674176	0.628	rs3791119	chr1:44431362	C/G	cg13606994	chr1:44402422	ARTN	-0.46	-4.95	-0.41	2.36e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs9308731	1.000	rs6750599	chr2:111893869	A/T	cg04202892	chr2:111875749	ACOXL	-0.42	-4.45	-0.37	1.9e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs7959452	0.590	rs28778648	chr12:69771911	C/A	cg11871910	chr12:69753446	YEATS4	0.82	8.95	0.63	4.38e-15	Blood protein levels;
TGCT	cis	rs4478858	0.735	rs11583123	chr1:31751772	T/C	cg07478791	chr1:31886160	SERINC2	-0.52	-5.02	-0.41	1.73e-6	Alcohol dependence;
TGCT	cis	rs28735056	0.935	rs11662267	chr18:77641902	C/G	cg20368463	chr18:77673604	PQLC1	-0.45	-5.58	-0.45	1.43e-7	Schizophrenia;
TGCT	cis	rs1348850	0.567	rs1527401	chr2:178522104	C/T	cg22681709	chr2:178499509	PDE11A	-0.5	-6.33	-0.49	4.17e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs9796	0.689	rs13329537	chr15:41449211	C/G	cg18705301	chr15:41695430	NDUFAF1	0.54	7.13	0.54	7.14e-11	Menopause (age at onset);
TGCT	cis	rs6674970	0.966	rs10788800	chr1:151104950	G/A	cg00003202	chr1:151319512	RFX5	-0.51	-4.46	-0.37	1.84e-5	Childhood ear infection;
TGCT	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg22166914	chr1:53195759	ZYG11B	-0.42	-7.46	-0.56	1.33e-11	Monocyte count;
TGCT	cis	rs2832191	0.597	rs8127842	chr21:30516461	G/A	cg24692254	chr21:30365293	RNF160	-0.62	-5.46	-0.44	2.44e-7	Dental caries;
TGCT	cis	rs114540395	1.000	rs114540395	chr10:103479062	C/T	cg03300883	chr10:102748874	C10orf2	0.44	4.87	0.4	3.32e-6	Schizophrenia;
TGCT	cis	rs55704346	1.000	rs1032684	chr4:25198523	C/T	cg26487582	chr4:25322200	ZCCHC4	0.18	4.57	0.38	1.18e-5	Tonsillectomy;
TGCT	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.37	-4.5	-0.37	1.52e-5	Total body bone mineral density;
TGCT	cis	rs11122272	0.525	rs61835222	chr1:231537917	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-6.28	-0.49	5.32e-9	Hemoglobin concentration;
TGCT	cis	rs10256972	0.647	rs10233430	chr7:1051664	T/C	cg00431813	chr7:1051703	C7orf50	-0.26	-5.59	-0.45	1.35e-7	Longevity;Endometriosis;
TGCT	cis	rs7917772	0.503	rs6584510	chr10:104299868	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	8.36	0.6	1.1e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs4819052	0.851	rs7275468	chr21:46656499	C/A	cg06618935	chr21:46677482	NA	-0.34	-5.35	-0.43	4.13e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9443645	0.901	rs4706077	chr6:79548845	G/A	cg05283184	chr6:79620031	NA	-0.21	-4.77	-0.39	5.11e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs11690935	0.959	rs6738445	chr2:172599615	T/C	cg13550731	chr2:172543902	DYNC1I2	1.21	13.23	0.77	1.87e-25	Schizophrenia;
TGCT	cis	rs7211079	0.833	rs7220523	chr17:78127695	G/A	cg09238746	chr17:78121135	EIF4A3	-0.73	-5.86	-0.47	3.98e-8	Myocardial infarction;
TGCT	cis	rs79387448	0.638	rs7600961	chr2:103035455	G/A	cg09003973	chr2:102972529	NA	1.27	9.82	0.66	3.37e-17	Gut microbiota (bacterial taxa);
TGCT	cis	rs35146811	0.695	rs1618851	chr7:99810643	T/G	cg04778012	chr7:99775508	STAG3;GPC2	-0.35	-4.93	-0.41	2.55e-6	Coronary artery disease;
TGCT	cis	rs6840360	1.000	rs6823194	chr4:152604543	T/C	cg17479576	chr4:152424074	FAM160A1	-0.44	-4.6	-0.38	1.03e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs789859	1.000	rs789860	chr3:194405630	A/T	cg21106136	chr3:194405973	FAM43A	-0.36	-5.11	-0.42	1.21e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
TGCT	cis	rs11578119	1.000	rs10919426	chr1:170501746	C/G	cg09767346	chr1:170501363	GORAB	0.65	5.17	0.42	9.21e-7	Male-pattern baldness;
TGCT	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg26818010	chr10:134567672	INPP5A	-0.37	-5.17	-0.42	9.23e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.93	7.44	0.56	1.44e-11	Platelet count;
TGCT	cis	rs4851251	1.000	rs4851251	chr2:100753490	C/T	cg22139774	chr2:100720529	AFF3	0.4	5.42	0.44	2.98e-7	Educational attainment (years of education);
TGCT	cis	rs7772486	0.764	rs7762562	chr6:146158994	T/C	cg05347473	chr6:146136440	FBXO30	0.53	4.99	0.41	2.01e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs34526934	0.608	rs34720456	chr2:177027292	G/A	cg14324370	chr2:177042789	NA	-0.9	-8.57	-0.61	3.41e-14	Obstructive sleep apnea trait (apnea hypopnea index);
TGCT	cis	rs9467773	0.620	rs2504599	chr6:26641060	C/T	cg09904177	chr6:26538194	HMGN4	0.68	6.36	0.5	3.55e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs5769707	0.568	rs2011097	chr22:50018069	A/G	cg05373962	chr22:49881684	NA	-0.31	-5.31	-0.43	4.95e-7	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs66573146	0.803	rs59742225	chr4:6969942	C/T	cg01220768	chr4:7056774	TADA2B	0.35	4.63	0.38	8.96e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs651907	0.557	rs62284199	chr3:101478531	T/G	cg12386194	chr3:101231763	SENP7	0.49	4.81	0.4	4.29e-6	Colorectal cancer;
TGCT	cis	rs981844	0.712	rs3925717	chr4:154750917	C/G	cg14289246	chr4:154710475	SFRP2	-0.99	-9.12	-0.63	1.65e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs1467026	0.719	rs17037220	chr3:12818103	A/G	cg05775895	chr3:12838266	CAND2	0.79	7.85	0.58	1.67e-12	P wave duration;
TGCT	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg06481639	chr22:41940642	POLR3H	0.75	6.66	0.51	8.03e-10	Vitiligo;
TGCT	cis	rs877282	1.000	rs12763443	chr10:771941	G/A	cg17470449	chr10:769945	NA	0.31	4.89	0.4	3.03e-6	Uric acid levels;
TGCT	cis	rs12458462	0.851	rs2169249	chr18:77489649	G/A	cg11879182	chr18:77439856	CTDP1	0.71	8.07	0.59	5.19e-13	Monocyte count;
TGCT	cis	rs9393692	1.000	rs9393692	chr6:26276650	A/G	cg13736514	chr6:26305472	NA	-0.43	-6.32	-0.49	4.38e-9	Educational attainment;
TGCT	cis	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg18252515	chr7:66147081	NA	-1.1	-6.4	-0.5	2.85e-9	Diabetic kidney disease;
TGCT	cis	rs8180040	0.726	rs7610636	chr3:47064436	A/C	cg27129171	chr3:47204927	SETD2	-0.77	-10.59	-0.69	4.55e-19	Colorectal cancer;
TGCT	cis	rs6964587	0.933	rs10271174	chr7:91785970	A/G	cg22709100	chr7:91322751	NA	0.29	4.71	0.39	6.62e-6	Breast cancer;
TGCT	cis	rs9326248	0.581	rs7120515	chr11:116991926	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.58	5.34	0.43	4.35e-7	Blood protein levels;
TGCT	cis	rs926938	0.563	rs360661	chr1:115455280	G/A	cg12756093	chr1:115239321	AMPD1	0.4	6.33	0.49	4.02e-9	Autism;
TGCT	cis	rs919433	0.617	rs10931791	chr2:198573612	A/C	cg00792783	chr2:198669748	PLCL1	-0.51	-4.83	-0.4	3.87e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs9910055	0.530	rs2269906	chr17:42294337	G/T	cg19774624	chr17:42201019	HDAC5	0.68	7.51	0.56	1.02e-11	Total body bone mineral density;
TGCT	cis	rs11676348	0.846	rs4674259	chr2:218991005	C/T	cg00012203	chr2:219082015	ARPC2	-0.52	-4.94	-0.41	2.5e-6	Ulcerative colitis;
TGCT	cis	rs617219	0.710	rs2166344	chr5:78534134	T/G	cg09550809	chr5:78407562	BHMT	0.37	5.24	0.43	6.65e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs6840360	0.653	rs13136369	chr4:152731283	T/G	cg22705602	chr4:152727874	NA	0.27	5.06	0.41	1.46e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	16.05	0.82	4.59e-32	Prudent dietary pattern;
TGCT	cis	rs2013441	0.965	rs7207611	chr17:20204516	C/T	cg23224458	chr17:20280056	CCDC144C	0.41	4.88	0.4	3.25e-6	Obesity-related traits;
TGCT	cis	rs2282802	0.685	rs10077671	chr5:139689505	C/T	cg01081189	chr5:139537190	NA	0.27	4.93	0.4	2.55e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2153535	0.580	rs2327060	chr6:8447111	G/A	cg07606381	chr6:8435919	SLC35B3	0.53	5.02	0.41	1.79e-6	Motion sickness;
TGCT	cis	rs79387448	0.638	rs78123896	chr2:103075417	T/C	cg09003973	chr2:102972529	NA	1.28	9.8	0.66	3.95e-17	Gut microbiota (bacterial taxa);
TGCT	cis	rs986417	1.000	rs11158293	chr14:61109020	G/C	cg27398547	chr14:60952738	C14orf39	1.56	8.73	0.62	1.45e-14	Gut microbiota (bacterial taxa);
TGCT	cis	rs704	0.764	rs3093692	chr17:26670627	G/A	cg10342447	chr17:26645325	TMEM97	-0.55	-5.2	-0.42	7.94e-7	Osteoprotegerin levels;
TGCT	cis	rs8072100	0.905	rs9901869	chr17:45575206	G/A	cg10024583	chr17:45772800	TBKBP1	0.43	4.47	0.37	1.74e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs2469997	1.000	rs2470012	chr8:120360488	T/G	cg00681363	chr8:120844660	TAF2	0.69	4.48	0.37	1.64e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs3093024	1.000	rs3093024	chr6:167532793	C/T	cg07741184	chr6:167504864	NA	0.23	4.66	0.39	7.98e-6	Rheumatoid arthritis;
TGCT	cis	rs11190604	0.767	rs4559620	chr10:102199935	C/T	cg16005271	chr10:102321736	NA	0.47	4.66	0.39	8.14e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs933688	0.759	rs1423593	chr5:90752351	T/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.08	9.29	0.64	6.55e-16	Smoking behavior;
TGCT	cis	rs12753569	0.934	rs10430051	chr1:76491628	T/G	cg00791851	chr1:76518896	NA	-0.4	-5.49	-0.44	2.2e-7	Personality dimensions;
TGCT	cis	rs1891275	0.515	rs4244930	chr10:93466849	T/C	cg07889827	chr10:93443413	NA	-0.32	-6.75	-0.52	5.12e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs6831352	0.918	rs1042364	chr4:100045574	T/C	cg12011299	chr4:100065546	ADH4	0.41	4.92	0.4	2.72e-6	Alcohol dependence;
TGCT	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg22618164	chr12:122356400	WDR66	0.53	5.18	0.42	8.83e-7	Mean corpuscular volume;
TGCT	cis	rs73058052	0.709	rs10416310	chr19:50079846	G/A	cg14048834	chr19:49990801	RPL13AP5;RPL13A	-0.52	-4.48	-0.37	1.66e-5	Fibrinogen levels;
TGCT	cis	rs9611519	0.780	rs9611542	chr22:41677317	C/T	cg03806693	chr22:41940476	POLR3H	-0.81	-8.15	-0.59	3.41e-13	Neuroticism;
TGCT	cis	rs3617	0.573	rs2336668	chr3:52919096	G/T	cg11645453	chr3:52864694	ITIH4	-0.27	-5.17	-0.42	9.18e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1008375	1.000	rs1860597	chr4:17657650	C/T	cg16339924	chr4:17578868	LAP3	0.63	5.33	0.43	4.49e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs12220898	0.749	rs2377976	chr10:50479493	A/G	cg12697796	chr10:49954016	WDFY4	0.52	4.81	0.4	4.3e-6	Inflammatory biomarkers;
TGCT	cis	rs6866344	0.697	rs17184344	chr5:178129281	A/G	cg10224037	chr5:178157518	ZNF354A	0.93	8.22	0.59	2.25e-13	Neutrophil percentage of white cells;
TGCT	cis	rs8177253	0.511	rs9830001	chr3:133433470	A/G	cg11941060	chr3:133502564	NA	0.23	4.66	0.39	7.97e-6	Iron status biomarkers;
TGCT	cis	rs250677	0.652	rs36042	chr5:148439782	G/T	cg23229984	chr5:148520753	ABLIM3	0.22	4.98	0.41	2.05e-6	Breast cancer;
TGCT	cis	rs372883	0.648	rs368322	chr21:30717151	C/T	cg24692254	chr21:30365293	RNF160	-0.52	-4.64	-0.38	8.89e-6	Pancreatic cancer;
TGCT	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	6.23	0.49	6.56e-9	Bipolar disorder;
TGCT	cis	rs751728	0.638	rs4713686	chr6:33787506	C/T	cg13859433	chr6:33739653	LEMD2	-0.33	-5.53	-0.44	1.83e-7	Crohn's disease;
TGCT	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg24060327	chr5:131705240	SLC22A5	0.78	8.46	0.61	6.22e-14	Breast cancer;
TGCT	cis	rs950027	0.620	rs1145093	chr15:45649813	C/A	cg14582100	chr15:45693742	SPATA5L1	0.47	6.02	0.48	1.8e-8	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs7572733	0.534	rs13026569	chr2:198783330	C/G	cg00792783	chr2:198669748	PLCL1	-0.57	-5.14	-0.42	1.03e-6	Dermatomyositis;
TGCT	cis	rs11673344	0.504	rs10402907	chr19:37603776	G/T	cg08039142	chr19:36980659	ZNF566	0.51	4.72	0.39	6.29e-6	Obesity-related traits;
TGCT	cis	rs9611565	0.546	rs739132	chr22:42123099	A/T	cg03806693	chr22:41940476	POLR3H	1.08	11.99	0.73	1.84e-22	Vitiligo;
TGCT	cis	rs9814567	0.806	rs2293293	chr3:134322742	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.74	-6.86	-0.52	2.97e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs6545883	0.929	rs778155	chr2:61647901	A/G	cg15711740	chr2:61764176	XPO1	0.58	5.2	0.42	7.96e-7	Tuberculosis;
TGCT	cis	rs9581857	0.547	rs9581876	chr13:28101113	T/C	cg22138327	chr13:27999177	GTF3A	0.72	4.75	0.39	5.45e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs6893807	1.000	rs3814424	chr5:87968953	C/T	cg24804195	chr5:87968844	LOC645323	0.73	5.29	0.43	5.39e-7	Body mass index;
TGCT	cis	rs8179	0.645	rs11764331	chr7:92282624	C/T	cg15732164	chr7:92237376	CDK6	-0.29	-5.06	-0.41	1.46e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
TGCT	trans	rs208520	0.955	rs208532	chr6:66961280	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.88	-8.21	-0.59	2.37e-13	Exhaled nitric oxide output;
TGCT	cis	rs950169	0.840	rs4842853	chr15:84942304	G/T	cg11189052	chr15:85197271	WDR73	0.81	6.22	0.49	6.89e-9	Schizophrenia;
TGCT	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.52	-5.04	-0.41	1.61e-6	Bipolar disorder;
TGCT	cis	rs4727027	0.704	rs7784122	chr7:148904624	A/G	cg23583168	chr7:148888333	NA	0.8	10.65	0.69	3.31e-19	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs7917772	0.636	rs4919674	chr10:104522226	T/C	cg05855489	chr10:104503620	C10orf26	0.67	5.32	0.43	4.77e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs6977660	0.607	rs12113916	chr7:19781424	G/T	cg05791153	chr7:19748676	TWISTNB	0.84	4.86	0.4	3.49e-6	Thyroid stimulating hormone;
TGCT	cis	rs8111998	0.826	rs7245719	chr19:22768952	A/T	cg19914732	chr19:22715077	NA	-0.56	-4.53	-0.38	1.36e-5	Corneal structure;
TGCT	cis	rs425277	0.585	rs2222217	chr1:2063164	G/A	cg24578937	chr1:2090814	PRKCZ	-0.26	-6.24	-0.49	6.22e-9	Height;
TGCT	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg00149659	chr3:10157352	C3orf10	0.91	5.89	0.47	3.32e-8	Alzheimer's disease;
TGCT	cis	rs13242816	1.000	rs62471198	chr7:116107963	T/C	cg16553024	chr7:116138462	CAV2	-0.43	-4.8	-0.4	4.41e-6	P wave duration;
TGCT	cis	rs7524258	0.903	rs4908449	chr1:7292700	T/C	cg04342483	chr1:7259290	CAMTA1	-0.31	-4.49	-0.37	1.6e-5	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs2506155	0.715	rs2474712	chr10:33497709	T/C	cg25928881	chr10:32632685	EPC1	0.28	4.89	0.4	3.04e-6	Migraine;
TGCT	cis	rs2535633	0.631	rs9823697	chr3:53002150	A/G	cg10802521	chr3:52805072	NEK4	-0.53	-5.74	-0.46	6.85e-8	Body mass index;
TGCT	cis	rs9611565	0.592	rs4481089	chr22:41980892	T/C	cg03806693	chr22:41940476	POLR3H	-1.01	-10.2	-0.68	4.07e-18	Vitiligo;
TGCT	cis	rs523522	0.962	rs10849757	chr12:120964014	G/A	cg27279351	chr12:120934652	DYNLL1	0.76	6.59	0.51	1.15e-9	High light scatter reticulocyte count;
TGCT	cis	rs28595532	1.000	rs115004746	chr4:119642137	C/T	cg14228332	chr4:119757509	SEC24D	1.02	5.37	0.43	3.78e-7	Cannabis dependence symptom count;
TGCT	cis	rs28374715	0.662	rs28382348	chr15:41487934	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.81	-11.6	-0.72	1.65e-21	Ulcerative colitis;
TGCT	cis	rs7923452	0.938	rs67812762	chr10:30759479	G/T	cg18806716	chr10:30721971	MAP3K8	0.66	6.06	0.48	1.48e-8	Itch intensity from mosquito bite;
TGCT	cis	rs3820068	0.608	rs6668919	chr1:16049893	A/G	cg17385448	chr1:15911702	AGMAT	-0.35	-4.64	-0.38	8.6e-6	Systolic blood pressure;
TGCT	cis	rs2997447	0.792	rs61775432	chr1:26416376	A/G	cg03844060	chr1:26490628	NA	0.28	4.57	0.38	1.16e-5	QRS complex (12-leadsum);
TGCT	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg00149659	chr3:10157352	C3orf10	0.93	5.98	0.47	2.25e-8	Alzheimer's disease;
TGCT	cis	rs2180341	0.842	rs6569476	chr6:127553539	G/A	cg24812749	chr6:127587940	RNF146	0.92	6.46	0.5	2.18e-9	Breast cancer;
TGCT	cis	rs28595532	0.920	rs116791817	chr4:119763303	C/T	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs72781680	1.000	rs72781671	chr2:24231123	A/G	cg08917208	chr2:24149416	ATAD2B	0.82	4.92	0.4	2.68e-6	Lymphocyte counts;
TGCT	cis	rs6893807	1.000	rs16903275	chr5:87950543	A/C	cg24804195	chr5:87968844	LOC645323	-0.76	-5.82	-0.46	4.69e-8	Body mass index;
TGCT	cis	rs1568657	1.000	rs1568657	chr15:83726179	A/G	cg10025586	chr15:83501699	WHAMM	-0.24	-4.57	-0.38	1.15e-5	Kawasaki disease;
TGCT	cis	rs8177253	0.665	rs6774822	chr3:133442012	G/T	cg08439880	chr3:133502540	NA	-0.29	-5.42	-0.44	2.93e-7	Iron status biomarkers;
TGCT	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg20203395	chr5:56204925	C5orf35	0.54	5.04	0.41	1.58e-6	Initial pursuit acceleration;
TGCT	cis	rs4372836	1.000	rs7562170	chr2:28943516	T/C	cg09522027	chr2:28974177	PPP1CB	0.6	5.06	0.41	1.46e-6	Body mass index;
TGCT	cis	rs55883249	1.000	rs17453724	chr2:9764001	A/G	cg23886495	chr2:9695866	ADAM17	0.74	4.45	0.37	1.9e-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs8179	0.645	rs11767704	chr7:92256375	C/T	cg15732164	chr7:92237376	CDK6	-0.29	-5.05	-0.41	1.57e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
TGCT	cis	rs13427251	0.903	rs6746402	chr2:100150443	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.58	-5.51	-0.44	1.97e-7	Chronic sinus infection;
TGCT	cis	rs5769707	0.874	rs9616714	chr22:50050859	G/A	cg20744362	chr22:50050164	C22orf34	0.28	4.62	0.38	9.53e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs9549367	0.789	rs2287251	chr13:113889499	A/G	cg00898013	chr13:113819073	PROZ	-0.4	-4.92	-0.4	2.7e-6	Platelet distribution width;
TGCT	cis	rs9341808	0.718	rs12208016	chr6:80823563	G/A	cg08355045	chr6:80787529	NA	0.32	5.83	0.46	4.48e-8	Sitting height ratio;
TGCT	trans	rs114540395	0.858	rs77325250	chr10:103320638	G/A	cg10198749	chr1:39920707	MACF1	0.55	7.05	0.53	1.11e-10	Schizophrenia;
TGCT	cis	rs1215050	0.740	rs1214994	chr4:99035577	C/T	cg05340658	chr4:99064831	C4orf37	0.42	5.2	0.42	7.82e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	trans	rs2727020	0.681	rs2866362	chr11:49379316	A/G	cg15704280	chr7:45808275	SEPT13	-0.73	-8.33	-0.6	1.3e-13	Coronary artery disease;
TGCT	cis	rs595982	0.559	rs73061643	chr19:49368151	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.69	-9.25	-0.64	8.09e-16	Red cell distribution width;
TGCT	cis	rs9894429	0.634	rs11655346	chr17:79572399	A/G	cg18240062	chr17:79603768	NPLOC4	-0.56	-4.92	-0.4	2.67e-6	Eye color traits;
TGCT	cis	rs7584330	0.868	rs13408361	chr2:238382899	A/G	cg08992911	chr2:238395768	MLPH	0.64	5.13	0.42	1.07e-6	Prostate cancer;
TGCT	cis	rs9611565	0.918	rs4822024	chr22:41757647	G/A	cg06481639	chr22:41940642	POLR3H	-0.68	-5.81	-0.46	4.87e-8	Vitiligo;
TGCT	cis	rs500492	0.618	rs2473158	chr16:1075241	G/A	cg01366354	chr16:1075121	NA	0.35	5.12	0.42	1.11e-6	Polycystic ovary syndrome;
TGCT	cis	rs12681288	0.832	rs2123060	chr8:1009313	T/C	cg04851639	chr8:1020857	NA	-0.36	-6.29	-0.49	5.07e-9	Schizophrenia;
TGCT	cis	rs10782582	0.593	rs17647178	chr1:76210524	A/G	cg03433033	chr1:76189801	ACADM	-0.6	-6.63	-0.51	9.16e-10	Daytime sleep phenotypes;
TGCT	cis	rs8072100	0.934	rs6504872	chr17:45438952	C/T	cg08085267	chr17:45401833	C17orf57	-0.46	-5.1	-0.42	1.25e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs2180341	1.000	rs6569478	chr6:127598619	G/A	cg27446573	chr6:127587934	RNF146	1.13	10.12	0.67	6.64e-18	Breast cancer;
TGCT	cis	rs73099903	0.611	rs7957445	chr12:53408580	A/G	cg24505307	chr12:53448429	TENC1	0.39	5.14	0.42	1.06e-6	Systolic blood pressure;
TGCT	cis	rs13256369	0.950	rs13255655	chr8:8577736	C/T	cg17143192	chr8:8559678	CLDN23	0.63	5.6	0.45	1.33e-7	Obesity-related traits;
TGCT	cis	rs13188771	0.527	rs365366	chr5:100877873	A/T	cg18665594	chr5:101119420	NA	0.44	4.49	0.37	1.62e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs2197308	0.692	rs67352173	chr12:37906912	A/T	cg13010199	chr12:38710504	ALG10B	0.61	4.93	0.4	2.57e-6	Morning vs. evening chronotype;
TGCT	cis	rs7225537	0.559	rs11870483	chr17:17016012	G/A	cg26176665	chr17:16994978	MPRIP	0.25	5.81	0.46	4.93e-8	Mean platelet volume;
TGCT	cis	rs13242816	1.000	rs987791	chr7:116134701	A/G	cg02799643	chr7:116139180	CAV2	-0.46	-5.52	-0.44	1.87e-7	P wave duration;
TGCT	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg10883421	chr6:151773342	RMND1;C6orf211	-0.65	-6.37	-0.5	3.3e-9	Menarche (age at onset);
TGCT	cis	rs17376456	0.877	rs2290937	chr5:93356515	A/T	cg21475434	chr5:93447410	FAM172A	0.69	4.79	0.39	4.76e-6	Diabetic retinopathy;
TGCT	cis	rs951366	0.870	rs3747973	chr1:205677148	A/G	cg07167872	chr1:205819463	PM20D1	0.41	4.53	0.38	1.39e-5	Menarche (age at onset);
TGCT	cis	rs3749237	0.595	rs11720264	chr3:49580347	C/T	cg02487422	chr3:49467188	NICN1	0.61	6.29	0.49	5.08e-9	Resting heart rate;
TGCT	cis	rs4822044	0.680	rs8138780	chr22:42097462	A/T	cg13695892	chr22:41940480	POLR3H	0.89	8.6	0.61	2.92e-14	Cannabis dependence symptom count;
TGCT	cis	rs9790314	0.818	rs6797066	chr3:161008725	T/A	cg03342759	chr3:160939853	NMD3	-0.51	-5.66	-0.45	9.96e-8	Morning vs. evening chronotype;
TGCT	cis	rs7647973	0.961	rs10154992	chr3:49276077	C/T	cg05785598	chr3:49045655	WDR6	0.39	4.61	0.38	9.91e-6	Menarche (age at onset);
TGCT	cis	rs3784262	0.528	rs34556514	chr15:58333769	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.43	-6.39	-0.5	3.11e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs9733	0.519	rs11587444	chr1:150722844	A/G	cg04414720	chr1:150670196	GOLPH3L	0.4	5.21	0.42	7.77e-7	Tonsillectomy;
TGCT	cis	rs7312933	0.558	rs11181422	chr12:42718552	G/A	cg19980929	chr12:42632907	YAF2	-0.41	-5.76	-0.46	6.3e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs8141529	0.764	rs5762824	chr22:29222930	C/T	cg02153584	chr22:29168773	CCDC117	0.66	5.64	0.45	1.08e-7	Lymphocyte counts;
TGCT	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg03806693	chr22:41940476	POLR3H	-1.13	-13.36	-0.77	8.87e-26	Vitiligo;
TGCT	cis	rs9291683	0.595	rs13150928	chr4:10052961	G/T	cg11266682	chr4:10021025	SLC2A9	0.65	8.81	0.62	9.38e-15	Bone mineral density;
TGCT	cis	rs73198271	0.628	rs11783944	chr8:8597801	A/G	cg06671706	chr8:8559999	CLDN23	-0.41	-4.46	-0.37	1.8e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs1865760	1.000	rs6905887	chr6:25912103	T/C	cg17042849	chr6:26104293	HIST1H4C	-0.52	-4.68	-0.39	7.33e-6	Height;
TGCT	cis	rs926938	0.527	rs360685	chr1:115499795	G/C	cg12756093	chr1:115239321	AMPD1	0.34	4.97	0.41	2.19e-6	Autism;
TGCT	cis	rs2354432	0.607	rs3766524	chr1:146729093	A/G	cg25205988	chr1:146714368	CHD1L	-1.34	-6.07	-0.48	1.44e-8	Mitochondrial DNA levels;
TGCT	cis	rs7914558	1.000	rs7081075	chr10:104929191	C/T	cg05855489	chr10:104503620	C10orf26	0.5	4.47	0.37	1.71e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs539096	0.872	rs674725	chr1:44061795	C/T	cg12908607	chr1:44402522	ARTN	-0.52	-5.43	-0.44	2.84e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1008375	0.932	rs6845288	chr4:17665498	A/T	cg18681998	chr4:17616180	MED28	-0.94	-9.83	-0.66	3.2e-17	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs3008870	1.000	rs2755245	chr1:67487964	C/G	cg08660285	chr1:67390436	MIER1;WDR78	1.1	11.13	0.71	2.26e-20	Lymphocyte percentage of white cells;
TGCT	cis	rs6693567	0.545	rs11205382	chr1:150442466	G/A	cg09579323	chr1:150459698	TARS2	-0.52	-4.62	-0.38	9.55e-6	Migraine;
TGCT	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.49	-4.76	-0.39	5.34e-6	Bipolar disorder;
TGCT	cis	rs7772486	0.720	rs1890171	chr6:146072114	T/C	cg05347473	chr6:146136440	FBXO30	-0.54	-4.95	-0.41	2.33e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg06634786	chr22:41940651	POLR3H	0.87	8.08	0.59	4.79e-13	Cannabis dependence symptom count;
TGCT	cis	rs11644362	0.631	rs8054655	chr16:12965215	T/A	cg06890432	chr16:12997467	SHISA9	-0.46	-4.64	-0.38	8.64e-6	Positive affect;Subjective well-being;
TGCT	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg06028808	chr11:68637592	NA	0.56	7.3	0.55	2.99e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7666738	0.830	rs11097606	chr4:99011486	C/T	cg18180107	chr4:99064573	C4orf37	0.51	4.64	0.38	8.77e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs858239	0.601	rs11982002	chr7:23163270	C/T	cg05602783	chr7:23145260	KLHL7	-0.65	-5.52	-0.44	1.93e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs1401999	0.724	rs1016752	chr3:183665062	C/G	cg01324343	chr3:183735012	ABCC5	-0.68	-8.24	-0.59	2.08e-13	Anterior chamber depth;
TGCT	cis	rs782590	0.967	rs1975484	chr2:55803167	T/A	cg03859395	chr2:55845619	SMEK2	0.92	11.39	0.72	5.08e-21	Metabolic syndrome;
TGCT	cis	rs11112613	0.713	rs11112589	chr12:105951226	C/G	cg03607813	chr12:105948248	NA	-0.49	-5.87	-0.47	3.8e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.09	0.42	1.3e-6	Prudent dietary pattern;
TGCT	cis	rs7267979	0.873	rs6115093	chr20:25210730	C/T	cg14121845	chr20:25566513	NINL	0.5	5.52	0.44	1.9e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs17253792	0.822	rs80085988	chr14:56096173	A/G	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs709400	0.633	rs1136165	chr14:103988180	G/T	cg12935359	chr14:103987150	CKB	0.4	5.86	0.47	3.96e-8	Body mass index;
TGCT	cis	rs13217239	0.646	rs7747454	chr6:27034253	T/G	cg15659132	chr6:26577336	NA	-0.56	-5.55	-0.45	1.62e-7	Schizophrenia;
TGCT	cis	rs16854884	0.770	rs1445417	chr3:143808972	A/T	cg06585982	chr3:143692056	C3orf58	0.57	4.49	0.37	1.63e-5	Economic and political preferences (feminism/equality);
TGCT	cis	rs2688608	0.592	rs2306328	chr10:75579510	C/T	cg19442545	chr10:75533431	FUT11	-0.36	-5.67	-0.45	9.61e-8	Inflammatory bowel disease;
TGCT	cis	rs7552404	0.924	rs7544117	chr1:76158246	A/G	cg03433033	chr1:76189801	ACADM	0.82	9.89	0.66	2.31e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2239547	0.563	rs9839035	chr3:52909877	C/T	cg11645453	chr3:52864694	ITIH4	0.34	5.72	0.46	7.68e-8	Schizophrenia;
TGCT	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg01802117	chr1:53393560	SCP2	0.38	4.6	0.38	1.04e-5	Monocyte count;
TGCT	cis	rs12477438	0.520	rs8179690	chr2:99795300	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.88	-8.77	-0.62	1.17e-14	Chronic sinus infection;
TGCT	cis	rs9549367	0.713	rs3024744	chr13:113821477	A/C	cg00898013	chr13:113819073	PROZ	-0.53	-6.77	-0.52	4.62e-10	Platelet distribution width;
TGCT	trans	rs73411413	0.661	rs11599981	chr11:1520063	C/T	cg13381631	chr10:46776799	NA	-0.39	-6.85	-0.52	3.08e-10	Myringotomy;
TGCT	cis	rs13242816	1.000	rs987790	chr7:116134633	T/A	cg16553024	chr7:116138462	CAV2	-0.45	-5.06	-0.41	1.49e-6	P wave duration;
TGCT	cis	rs10782582	0.593	rs6704444	chr1:76205108	T/C	cg03433033	chr1:76189801	ACADM	-0.61	-6.63	-0.51	9.47e-10	Daytime sleep phenotypes;
TGCT	cis	rs3812831	0.695	rs3118895	chr13:114931742	G/A	cg08824895	chr13:115047677	UPF3A	0.51	4.98	0.41	2.07e-6	Schizophrenia;
TGCT	cis	rs4372836	0.615	rs61407258	chr2:29046909	A/G	cg09522027	chr2:28974177	PPP1CB	-0.67	-6.97	-0.53	1.66e-10	Body mass index;
TGCT	cis	rs6733011	0.578	rs6714243	chr2:99510039	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.51	-4.78	-0.39	4.87e-6	Bipolar disorder;
TGCT	cis	rs10791097	0.694	rs11222370	chr11:130744767	T/G	cg14779329	chr11:130786720	SNX19	0.28	4.82	0.4	4.09e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs765787	0.530	rs4775831	chr15:45534722	A/C	cg24006582	chr15:45444508	DUOX1	-0.25	-5.53	-0.44	1.82e-7	Uric acid levels;
TGCT	cis	rs138249	0.527	rs138251	chr22:50570852	A/G	cg16473166	chr22:50639996	SELO	0.64	4.51	0.38	1.48e-5	Gestational age at birth in labor-initiated deliveries (child effect);
TGCT	cis	rs7100689	0.646	rs1340380	chr10:82115619	T/C	cg01528321	chr10:82214614	TSPAN14	0.81	7.83	0.58	1.9e-12	Post bronchodilator FEV1;
TGCT	cis	rs7552404	0.727	rs5745427	chr1:76332637	C/A	cg22875332	chr1:76189707	ACADM	-0.57	-6.14	-0.48	1.05e-8	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs10791097	0.694	rs4370948	chr11:130755700	A/C	cg12179176	chr11:130786555	SNX19	0.83	10.34	0.68	1.85e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg19318889	chr4:1322082	MAEA	0.28	6.71	0.52	6.05e-10	Longevity;
TGCT	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	8.4	0.6	8.57e-14	Platelet count;
TGCT	cis	rs9902453	0.612	rs2617868	chr17:28073247	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.84	-8.4	-0.6	8.88e-14	Coffee consumption (cups per day);
TGCT	cis	rs9486715	0.838	rs7770889	chr6:96858453	C/T	cg18709589	chr6:96969512	KIAA0776	-0.73	-6.59	-0.51	1.13e-9	Headache;
TGCT	cis	rs4851254	0.961	rs11677607	chr2:100751150	C/T	cg04109781	chr2:100722022	AFF3	0.45	4.8	0.4	4.51e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7100689	0.646	rs1934696	chr10:82124966	T/C	cg01528321	chr10:82214614	TSPAN14	0.8	7.76	0.57	2.7e-12	Post bronchodilator FEV1;
TGCT	cis	rs8017423	0.967	rs12896540	chr14:90729392	T/C	cg04374321	chr14:90722782	PSMC1	-0.75	-7.37	-0.55	2.14e-11	Mortality in heart failure;
TGCT	cis	rs7714584	1.000	rs10057988	chr5:150272062	A/G	cg22134413	chr5:150180641	NA	0.78	6.12	0.48	1.16e-8	Crohn's disease;
TGCT	cis	rs611744	0.647	rs702808	chr8:109252554	T/C	cg21045802	chr8:109455806	TTC35	0.72	7.28	0.55	3.32e-11	Dupuytren's disease;
TGCT	cis	rs6121246	0.567	rs7266471	chr20:30220599	T/A	cg21427119	chr20:30132790	HM13	-0.43	-6.02	-0.48	1.86e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs7666738	0.800	rs2839836	chr4:98970512	A/G	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg08280861	chr8:58055591	NA	0.41	4.63	0.38	8.93e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg27436995	chr16:743998	FBXL16	-0.45	-4.86	-0.4	3.48e-6	Height;
TGCT	cis	rs7833790	0.632	rs6473308	chr8:82707708	G/A	cg17211192	chr8:82754475	SNX16	-0.95	-8.69	-0.62	1.78e-14	Diastolic blood pressure;
TGCT	cis	rs11673344	0.504	rs8111285	chr19:37623649	A/G	cg08039142	chr19:36980659	ZNF566	0.51	4.68	0.39	7.31e-6	Obesity-related traits;
TGCT	cis	rs6460942	0.908	rs59410610	chr7:12282847	A/G	cg06484146	chr7:12443880	VWDE	-0.54	-4.71	-0.39	6.5e-6	Coronary artery disease;
TGCT	cis	rs17345786	0.906	rs12638137	chr3:101150964	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.4	-8.36	-0.6	1.09e-13	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs8073060	0.671	rs9894813	chr17:33873848	C/T	cg19694781	chr19:47549865	TMEM160	0.48	9.37	0.64	4.24e-16	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg08859206	chr1:53392774	SCP2	0.41	5.98	0.47	2.19e-8	Monocyte count;
TGCT	cis	rs6484504	0.600	rs12796587	chr11:31266443	T/C	cg26647111	chr11:31128758	NA	-0.35	-4.85	-0.4	3.58e-6	Red blood cell count;
TGCT	cis	rs6087771	0.781	rs6089067	chr20:30358894	G/C	cg18721089	chr20:30220636	NA	-0.35	-4.52	-0.38	1.4e-5	Subcortical brain region volumes;Putamen volume;
TGCT	cis	rs9303401	0.659	rs7223708	chr17:56896398	A/G	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs11098499	0.754	rs2036860	chr4:120248934	A/G	cg09307838	chr4:120376055	NA	0.61	5.91	0.47	3.14e-8	Corneal astigmatism;
TGCT	cis	rs13242816	1.000	rs35364754	chr7:116109716	T/G	cg16553024	chr7:116138462	CAV2	-0.44	-4.53	-0.38	1.34e-5	P wave duration;
TGCT	cis	rs35146811	0.624	rs1727134	chr7:99813672	T/C	cg13334819	chr7:99746414	C7orf59	0.74	6.41	0.5	2.82e-9	Coronary artery disease;
TGCT	cis	rs1008375	1.000	rs4235388	chr4:17682030	G/A	cg18681998	chr4:17616180	MED28	0.91	10.3	0.68	2.41e-18	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	4.9	0.4	2.9e-6	Menopause (age at onset);
TGCT	cis	rs5771225	0.563	rs5771281	chr22:50693479	A/G	cg16473166	chr22:50639996	SELO	0.69	5.69	0.45	8.74e-8	Late-onset Alzheimer's disease;
TGCT	cis	rs10791097	0.703	rs11222360	chr11:130730871	C/T	cg14779329	chr11:130786720	SNX19	0.26	4.61	0.38	9.93e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9952991	0.566	rs534911	chr18:12857335	G/A	cg23544223	chr18:12777786	NA	0.54	4.71	0.39	6.43e-6	Inflammatory skin disease;
TGCT	cis	rs75686122	0.772	rs79344235	chr8:104509998	G/C	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs1891275	0.515	rs10881957	chr10:93501876	C/T	cg07889827	chr10:93443413	NA	-0.32	-6.85	-0.52	3.03e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg06238570	chr21:40685208	BRWD1	-0.76	-6.96	-0.53	1.74e-10	Cognitive function;
TGCT	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.66	0.39	8.18e-6	Prudent dietary pattern;
TGCT	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg10295955	chr4:187884368	NA	-0.97	-14.69	-0.8	6.27e-29	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9583531	0.689	rs6492308	chr13:111377829	T/C	cg24331049	chr13:111365604	ING1	0.88	8.89	0.62	6e-15	Coronary artery disease;
TGCT	cis	rs9435341	0.965	rs1730862	chr1:107614003	G/A	cg09367891	chr1:107599246	PRMT6	-0.62	-5.17	-0.42	8.93e-7	Facial morphology (factor 21, depth of nasal alae);
TGCT	cis	rs9443189	0.570	rs775072	chr6:76377998	G/A	cg01950844	chr6:76311363	SENP6	-1.0	-6.24	-0.49	6.35e-9	Prostate cancer;
TGCT	cis	rs250677	0.958	rs17109282	chr5:148416677	A/G	cg23229984	chr5:148520753	ABLIM3	-0.2	-4.66	-0.39	8.06e-6	Breast cancer;
TGCT	cis	rs71435601	0.657	rs67599264	chr2:21418083	G/A	cg25035485	chr2:21266500	APOB	-0.52	-4.45	-0.37	1.92e-5	Cholesterol, total;
TGCT	cis	rs2239547	0.522	rs2581797	chr3:52972468	C/T	cg11645453	chr3:52864694	ITIH4	-0.33	-5.34	-0.43	4.35e-7	Schizophrenia;
TGCT	cis	rs2180341	1.000	rs9385419	chr6:127597591	A/G	cg27446573	chr6:127587934	RNF146	1.13	10.12	0.67	6.64e-18	Breast cancer;
TGCT	cis	rs12497850	0.931	rs13064911	chr3:48952385	A/G	cg05785598	chr3:49045655	WDR6	0.36	4.75	0.39	5.46e-6	Parkinson's disease;
TGCT	cis	rs6582630	0.555	rs10880624	chr12:38526316	C/T	cg13010199	chr12:38710504	ALG10B	0.62	4.95	0.41	2.37e-6	Drug-induced liver injury (flucloxacillin);
TGCT	trans	rs1814175	0.781	rs2866734	chr11:49886338	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.35	-0.55	2.38e-11	Height;
TGCT	cis	rs4730250	0.595	rs7789500	chr7:106915723	A/C	cg02696742	chr7:106810147	HBP1	-0.68	-5.2	-0.42	8.03e-7	Osteoarthritis;
TGCT	cis	rs6666258	1.000	rs6426986	chr1:154814045	G/A	cg06418219	chr1:154948305	SHC1;CKS1B	0.62	5.04	0.41	1.59e-6	Atrial fibrillation;
TGCT	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.52	-4.9	-0.4	2.9e-6	Bipolar disorder;
TGCT	cis	rs12291225	0.679	rs11023172	chr11:14295367	C/G	cg19336497	chr11:14380999	RRAS2	-0.38	-5.9	-0.47	3.23e-8	Sense of smell;
TGCT	cis	rs17345786	1.000	rs3762729	chr3:101308874	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.56	4.76	0.39	5.25e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2180341	0.814	rs7768435	chr6:127737038	A/C	cg27446573	chr6:127587934	RNF146	0.88	8.07	0.59	5.22e-13	Breast cancer;
TGCT	cis	rs12451471	0.667	rs12942002	chr17:78101629	C/G	cg06718696	chr17:78121285	EIF4A3	0.77	6.43	0.5	2.47e-9	Plateletcrit;Mean corpuscular hemoglobin concentration;
TGCT	cis	rs11018874	0.532	rs11018867	chr11:89862345	C/T	cg05041596	chr11:89867385	NAALAD2	0.52	5.21	0.42	7.6e-7	White blood cell types;
TGCT	trans	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg23505145	chr19:12996616	KLF1	0.78	8.12	0.59	4.03e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs12950390	0.893	rs4239165	chr17:45847272	A/T	cg06532163	chr17:45867833	NA	0.34	5.31	0.43	4.82e-7	IgG glycosylation;
TGCT	cis	rs12049351	0.774	rs4925456	chr1:229623896	A/T	cg12130225	chr1:229698885	NA	0.39	4.59	0.38	1.06e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs7095607	0.813	rs7895737	chr10:69924146	A/G	cg18986048	chr10:69913749	MYPN	0.48	5.57	0.45	1.54e-7	Lung function (FVC);
TGCT	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg09323728	chr8:95962352	TP53INP1	-0.54	-6.91	-0.53	2.26e-10	Type 2 diabetes;
TGCT	cis	rs1371867	0.875	rs1788174	chr8:101330957	C/G	cg06002616	chr8:101225028	SPAG1	0.54	6.37	0.5	3.31e-9	Atrioventricular conduction;
TGCT	cis	rs892961	1.000	rs1075457	chr17:75400737	A/G	cg05865280	chr17:75406074	SEPT9	-0.28	-6.6	-0.51	1.06e-9	Airflow obstruction;
TGCT	cis	rs13191362	1.000	rs67094146	chr6:163145412	G/C	cg06582575	chr6:163149167	PACRG;PARK2	1.0	7.64	0.57	5.11e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs12477438	0.520	rs4347885	chr2:99804007	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	14.89	0.8	2.21e-29	Chronic sinus infection;
TGCT	cis	rs2760061	0.626	rs2527614	chr1:228126470	A/G	cg18477163	chr1:228402036	OBSCN	-0.32	-6.38	-0.5	3.25e-9	Diastolic blood pressure;
TGCT	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg19626725	chr5:178986131	RUFY1	-0.51	-6.84	-0.52	3.22e-10	Lung cancer;
TGCT	cis	rs7666738	0.830	rs1813642	chr4:98852225	G/A	cg18180107	chr4:99064573	C4orf37	0.58	5.38	0.43	3.58e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg11211951	chr8:145729740	GPT	-0.21	-4.71	-0.39	6.53e-6	Age at first birth;
TGCT	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg00343986	chr7:65444356	GUSB	0.24	5.29	0.43	5.43e-7	Aortic root size;
TGCT	cis	rs7666738	0.546	rs1863602	chr4:98909304	T/C	cg17366294	chr4:99064904	C4orf37	0.66	6.02	0.48	1.83e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6500602	0.627	rs841231	chr16:4583147	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	-0.39	-5.69	-0.45	8.79e-8	Schizophrenia;
TGCT	cis	rs12210905	1.000	rs3800310	chr6:27206843	C/G	cg08851530	chr6:28072375	NA	1.05	5.07	0.41	1.42e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs3806843	0.966	rs7737424	chr5:140146345	C/T	cg19875535	chr5:140030758	IK	0.36	6.17	0.48	8.74e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7586879	0.789	rs36029941	chr2:25127801	C/T	cg01884057	chr2:25150051	NA	0.27	4.72	0.39	6.29e-6	Body mass index;
TGCT	cis	rs12762955	0.561	rs7918118	chr10:1042823	C/A	cg18964960	chr10:1102726	WDR37	-0.69	-6.08	-0.48	1.35e-8	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs8135665	0.600	rs8139025	chr22:38450881	G/C	cg13116946	chr22:38479732	SLC16A8	0.28	5.55	0.45	1.63e-7	Advanced age-related macular degeneration;Age-related macular degeneration;
TGCT	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg15242686	chr22:24348715	GSTTP1	0.48	6.96	0.53	1.77e-10	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs904251	0.504	rs2797795	chr6:37480683	T/C	cg25019722	chr6:37503610	NA	-0.53	-8.19	-0.59	2.75e-13	Cognitive performance;
TGCT	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.55	4.89	0.4	3.01e-6	Prudent dietary pattern;
TGCT	cis	rs8077577	0.895	rs62072468	chr17:18118179	A/G	cg09161412	chr17:18057145	MYO15A	-0.6	-4.79	-0.4	4.61e-6	Obesity-related traits;
TGCT	cis	rs2742417	0.603	rs2742374	chr3:45784082	T/C	cg04837898	chr3:45731254	SACM1L	-0.67	-7.3	-0.55	3.06e-11	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs7226408	0.948	rs4368229	chr18:34395243	A/G	cg06757138	chr18:34340585	FHOD3	-0.25	-4.57	-0.38	1.17e-5	Obesity-related traits;
TGCT	cis	rs78487399	0.808	rs6544668	chr2:43732488	T/C	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.74	4.5	0.37	1.57e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs10782582	0.609	rs78776851	chr1:76424845	T/C	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.56	4.95	0.41	2.4e-6	Daytime sleep phenotypes;
TGCT	cis	rs1129187	0.702	rs2395943	chr6:42940673	A/G	cg13397359	chr6:42928475	GNMT	0.58	4.89	0.4	3.02e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs36051895	0.589	rs11790596	chr9:5198335	T/C	cg02405213	chr9:5042618	JAK2	-0.76	-9.91	-0.66	2.13e-17	Pediatric autoimmune diseases;
TGCT	cis	rs9467711	0.606	rs28362606	chr6:26365586	T/C	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2075371	0.796	rs1646644	chr7:134011817	A/T	cg11752832	chr7:134001865	SLC35B4	0.72	6.22	0.49	7.09e-9	Mean platelet volume;
TGCT	cis	rs10489202	0.632	rs202268	chr1:167927339	T/C	cg24449463	chr1:168025552	DCAF6	-0.59	-7.02	-0.53	1.29e-10	Schizophrenia;
TGCT	cis	rs9372498	0.536	rs62424199	chr6:118827252	G/A	cg07617317	chr6:118971624	C6orf204	0.47	5.1	0.42	1.23e-6	Diastolic blood pressure;
TGCT	cis	rs2404618	0.557	rs2906578	chr8:1508963	T/C	cg13402656	chr8:1511478	DLGAP2	-0.45	-8.95	-0.63	4.26e-15	Lung cancer;
TGCT	cis	rs4851266	0.966	rs4851270	chr2:100832656	T/C	cg22139774	chr2:100720529	AFF3	-0.34	-5.09	-0.42	1.28e-6	Educational attainment;
TGCT	cis	rs13242816	1.000	rs6979182	chr7:116119345	T/G	cg02799643	chr7:116139180	CAV2	-0.49	-5.55	-0.45	1.66e-7	P wave duration;
TGCT	cis	rs9811920	0.638	rs1688782	chr3:99630527	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.57	6.77	0.52	4.59e-10	Axial length;
TGCT	cis	rs6424115	0.737	rs10917430	chr1:24170458	C/T	cg15997130	chr1:24165203	NA	-0.71	-7.19	-0.54	5.43e-11	Immature fraction of reticulocytes;
TGCT	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg27535305	chr1:53392650	SCP2	-0.28	-5.36	-0.43	3.92e-7	Monocyte count;
TGCT	cis	rs77633900	0.614	rs280005	chr15:77009185	G/C	cg21673338	chr15:77095150	SCAPER	-0.51	-5.12	-0.42	1.11e-6	Non-glioblastoma glioma;Glioma;
TGCT	cis	rs6696846	0.765	rs2836	chr1:205111761	G/T	cg03948781	chr1:205179583	DSTYK	-0.34	-4.51	-0.38	1.51e-5	Red blood cell count;
TGCT	cis	rs6121246	0.909	rs6060644	chr20:30265652	G/A	cg18721089	chr20:30220636	NA	-0.42	-4.65	-0.39	8.2e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs8180040	0.593	rs12715421	chr3:47084859	A/G	cg27129171	chr3:47204927	SETD2	0.71	8.51	0.61	4.8e-14	Colorectal cancer;
TGCT	cis	rs72781680	0.898	rs72782106	chr2:24022009	A/G	cg08917208	chr2:24149416	ATAD2B	0.93	5.84	0.46	4.22e-8	Lymphocyte counts;
TGCT	cis	rs4916646	0.668	rs13117158	chr4:11516839	A/G	cg16957523	chr4:11431359	HS3ST1	-0.47	-4.66	-0.39	8.08e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs35306767	0.855	rs12761180	chr10:872086	C/T	cg26597838	chr10:835615	NA	0.8	12.11	0.74	9.26e-23	Eosinophil percentage of granulocytes;
TGCT	trans	rs1864729	0.688	rs1540434	chr8:98305351	A/G	cg08679828	chr8:102218111	ZNF706	-1.02	-6.67	-0.51	7.5e-10	Estradiol plasma levels (breast cancer);
TGCT	cis	rs231513	1.000	rs231519	chr17:41961051	C/T	cg26893861	chr17:41843967	DUSP3	0.73	5.35	0.43	4.16e-7	Cognitive function;
TGCT	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg24531977	chr5:56204891	C5orf35	-0.76	-7.66	-0.57	4.53e-12	Initial pursuit acceleration;
TGCT	cis	rs72634258	0.554	rs12061787	chr1:7888730	G/C	cg26816564	chr1:7831052	VAMP3	0.87	6.44	0.5	2.34e-9	Inflammatory bowel disease;
TGCT	cis	rs151997	0.671	rs152926	chr5:50201787	G/A	cg06027927	chr5:50259733	NA	-0.54	-5.49	-0.44	2.14e-7	Callous-unemotional behaviour;
TGCT	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg03264133	chr6:25882463	NA	-0.65	-5.98	-0.47	2.26e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2932538	0.922	rs6537745	chr1:113154080	T/C	cg22162597	chr1:113214053	CAPZA1	0.25	5.6	0.45	1.34e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs2013441	0.804	rs1811453	chr17:20232193	A/C	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.63	-0.38	9.19e-6	Obesity-related traits;
TGCT	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.64	-6.63	-0.51	9.03e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg17063962	chr7:91808500	NA	0.83	8.16	0.59	3.1e-13	Breast cancer;
TGCT	cis	rs3749237	0.964	rs2234385	chr3:49846041	G/A	cg03060546	chr3:49711283	APEH	0.69	7.12	0.54	7.8e-11	Resting heart rate;
TGCT	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg21171335	chr12:122356390	WDR66	0.59	6.19	0.49	8.15e-9	Mean corpuscular volume;
TGCT	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg04267008	chr7:1944627	MAD1L1	-0.36	-4.72	-0.39	6.26e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs6831352	0.918	rs35784540	chr4:100061692	T/A	cg12011299	chr4:100065546	ADH4	-0.41	-4.97	-0.41	2.21e-6	Alcohol dependence;
TGCT	cis	rs10791097	0.694	rs10791100	chr11:130738946	T/A	cg12179176	chr11:130786555	SNX19	0.84	10.17	0.67	4.95e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs2153535	0.580	rs9406172	chr6:8515464	T/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.55e-8	Motion sickness;
TGCT	cis	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg08975724	chr8:8085496	FLJ10661	0.57	4.96	0.41	2.22e-6	Mood instability;
TGCT	cis	rs74544699	1.000	rs353029	chr4:74776804	C/T	cg16072462	chr4:74847758	PF4	0.99	4.52	0.38	1.4e-5	Growth-regulated protein alpha levels;
TGCT	cis	rs2594989	0.943	rs2454508	chr3:11493232	T/C	cg26283222	chr3:11613257	VGLL4	-0.21	-4.46	-0.37	1.84e-5	Circulating chemerin levels;
TGCT	cis	rs6977955	1.000	rs917117	chr7:28176305	G/A	cg23620719	chr7:28220237	JAZF1	0.67	5.05	0.41	1.52e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs12900413	0.603	rs2351494	chr15:90299541	C/T	cg24249390	chr15:90295951	MESP1	-0.29	-5.03	-0.41	1.7e-6	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs7429990	0.895	rs35790549	chr3:48071488	A/T	cg11946769	chr3:48343235	NME6	0.64	5.12	0.42	1.13e-6	Educational attainment (years of education);
TGCT	cis	rs9985766	1.000	rs9992748	chr4:151037795	C/A	cg05926478	chr4:151174724	DCLK2	-0.27	-4.81	-0.4	4.35e-6	Coronary artery disease;Myocardial infarction;
TGCT	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg23758822	chr17:41437982	NA	0.72	6.81	0.52	3.83e-10	Menopause (age at onset);
TGCT	cis	rs289997	0.920	rs905385	chr7:25576737	G/C	cg14064488	chr7:26331273	SNX10	0.36	5.19	0.42	8.28e-7	Breast cancer;
TGCT	cis	rs11098499	0.575	rs907205	chr4:120238664	G/C	cg09307838	chr4:120376055	NA	0.61	5.84	0.46	4.35e-8	Corneal astigmatism;
TGCT	cis	rs9611565	0.512	rs2050033	chr22:42159229	G/T	cg06634786	chr22:41940651	POLR3H	0.85	8.15	0.59	3.41e-13	Vitiligo;
TGCT	cis	rs4888262	0.545	rs4588013	chr16:74703388	C/T	cg01733217	chr16:74700730	RFWD3	0.77	7.77	0.57	2.57e-12	Testicular germ cell tumor;
TGCT	cis	rs4727027	0.870	rs13237714	chr7:148884083	A/G	cg23583168	chr7:148888333	NA	-0.74	-9.81	-0.66	3.64e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs9399135	0.622	rs3817776	chr6:135256756	C/T	cg24558204	chr6:135376177	HBS1L	-0.46	-5.0	-0.41	1.92e-6	Red blood cell count;
TGCT	cis	rs7226408	0.948	rs11664088	chr18:34380417	C/A	cg06757138	chr18:34340585	FHOD3	0.26	4.79	0.4	4.62e-6	Obesity-related traits;
TGCT	cis	rs2486288	0.656	rs8039138	chr15:45551592	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.46	-5.59	-0.45	1.38e-7	Glomerular filtration rate;
TGCT	cis	rs10875746	0.951	rs7485355	chr12:48548342	G/A	cg20731937	chr12:48336164	NA	0.62	4.94	0.41	2.46e-6	Longevity (90 years and older);
TGCT	cis	rs807669	0.565	rs5746682	chr22:19185526	C/T	cg02655711	chr22:19163373	SLC25A1	0.33	6.81	0.52	3.82e-10	Metabolite levels;
TGCT	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg02725872	chr8:58115012	NA	-0.38	-5.16	-0.42	9.32e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7666738	0.830	rs13119995	chr4:99026790	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4253772	0.638	rs6007845	chr22:46718417	A/T	cg26492175	chr22:47022658	GRAMD4	-0.19	-4.5	-0.37	1.54e-5	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs7666738	0.830	rs13138063	chr4:99050438	A/C	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7824557	0.606	rs2736273	chr8:11199938	C/A	cg21775007	chr8:11205619	TDH	0.73	6.81	0.52	3.72e-10	Retinal vascular caliber;
TGCT	cis	rs367943	0.966	rs451425	chr5:112808637	A/G	cg12552261	chr5:112820674	MCC	-0.24	-4.91	-0.4	2.81e-6	Type 2 diabetes;
TGCT	cis	rs11599315	0.507	rs12218307	chr10:1341914	G/A	cg27336068	chr10:1336103	ADARB2	-0.34	-5.47	-0.44	2.41e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	cis	rs10791323	0.569	rs1944734	chr11:133720077	G/A	cg15485101	chr11:133734466	NA	0.43	5.39	0.44	3.41e-7	Childhood ear infection;
TGCT	cis	rs4727027	0.782	rs10245343	chr7:148796333	T/C	cg15662616	chr7:148823355	ZNF425;ZNF398	0.57	4.74	0.39	5.72e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs9393777	0.546	rs9366673	chr6:26893329	C/G	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.54	-5.03	-0.41	1.7e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs13256369	0.851	rs13254997	chr8:8563753	G/C	cg18904891	chr8:8559673	CLDN23	0.59	5.46	0.44	2.54e-7	Obesity-related traits;
TGCT	cis	rs7586879	0.681	rs6545790	chr2:25109302	A/G	cg01884057	chr2:25150051	NA	0.35	6.55	0.51	1.39e-9	Body mass index;
TGCT	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7666738	0.830	rs13122456	chr4:98936011	A/G	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs477895	0.838	rs2070765	chr11:64010085	A/G	cg04317338	chr11:64019027	PLCB3	0.8	6.81	0.52	3.73e-10	Mean platelet volume;
TGCT	cis	rs3772130	0.962	rs28660600	chr3:121482637	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.72	0.39	6.25e-6	Cognitive performance;
TGCT	cis	rs377070	0.844	rs309415	chr4:123621228	C/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.44	4.94	0.41	2.49e-6	Mosquito bite size;
TGCT	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg13206674	chr6:150067644	NUP43	0.52	4.51	0.38	1.5e-5	Lung cancer;
TGCT	cis	rs7833790	0.632	rs6473308	chr8:82707708	G/A	cg27398817	chr8:82754497	SNX16	-0.66	-5.22	-0.42	7.25e-7	Diastolic blood pressure;
TGCT	cis	rs1403694	1.000	rs1624230	chr3:186438935	A/C	cg12454167	chr3:186435060	KNG1	-0.42	-7.26	-0.55	3.73e-11	Blood protein levels;
TGCT	cis	rs9921338	0.961	rs17605444	chr16:11413589	A/C	cg00044050	chr16:11439710	C16orf75	-0.93	-6.96	-0.53	1.7e-10	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs12048904	0.512	rs932798	chr1:101249355	G/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.8	-7.06	-0.54	1.06e-10	Multiple sclerosis;
TGCT	cis	rs7412746	0.611	rs6660084	chr1:150748803	T/C	cg09365446	chr1:150670422	GOLPH3L	0.36	5.19	0.42	8.25e-7	Melanoma;
TGCT	cis	rs2839186	0.504	rs11702278	chr21:47936295	T/G	cg10657630	chr21:48055338	PRMT2	0.49	4.73	0.39	5.91e-6	Testicular germ cell tumor;
TGCT	cis	rs62380364	0.565	rs617944	chr5:88057915	T/C	cg22951263	chr5:87985283	NA	-0.59	-6.27	-0.49	5.5e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg23131131	chr22:24373011	LOC391322	0.62	6.24	0.49	6.18e-9	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2594989	0.943	rs2442780	chr3:11510568	A/G	cg00170343	chr3:11313890	ATG7	0.69	5.1	0.42	1.21e-6	Circulating chemerin levels;
TGCT	cis	rs7226408	0.857	rs72890574	chr18:34623479	T/G	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs11969893	0.649	rs9485415	chr6:101279459	C/T	cg12253828	chr6:101329408	ASCC3	1.08	5.24	0.43	6.59e-7	Economic and political preferences (immigration/crime);
TGCT	cis	rs9810089	0.843	rs11717954	chr3:136112109	A/G	cg12473912	chr3:136751656	NA	0.37	5.15	0.42	9.8e-7	Gestational age at birth (child effect);
TGCT	cis	rs3617	0.573	rs12638968	chr3:52919447	T/A	cg11645453	chr3:52864694	ITIH4	-0.27	-5.17	-0.42	9.18e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg17775962	chr7:1200435	ZFAND2A	0.28	4.86	0.4	3.46e-6	Longevity;Endometriosis;
TGCT	cis	rs425277	0.565	rs2480711	chr1:2111376	A/G	cg12140144	chr1:2984275	FLJ42875;PRDM16	-0.32	-4.48	-0.37	1.7e-5	Height;
TGCT	cis	rs6762	0.748	rs28735718	chr11:839629	A/G	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.45	-4.5	-0.37	1.53e-5	Mean platelet volume;
TGCT	cis	rs10089	0.904	rs2195921	chr5:127489754	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	8.19	0.59	2.64e-13	Ileal carcinoids;
TGCT	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg06753367	chr22:24256600	NA	0.24	4.51	0.38	1.5e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs3733585	0.673	rs6843873	chr4:9958788	A/C	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.67	-0.51	7.44e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs10197940	0.662	rs72860233	chr2:152289767	G/A	cg06191203	chr2:152266755	RIF1	-0.78	-7.31	-0.55	2.89e-11	Lung cancer;
TGCT	cis	rs6545883	0.895	rs2442029	chr2:61679552	G/T	cg15711740	chr2:61764176	XPO1	-0.56	-5.1	-0.42	1.23e-6	Tuberculosis;
TGCT	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg05872129	chr22:39784769	NA	0.99	11.49	0.72	2.91e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs4654899	0.865	rs6693020	chr1:21378057	A/G	cg01072550	chr1:21505969	NA	-0.47	-6.96	-0.53	1.72e-10	Superior frontal gyrus grey matter volume;
TGCT	trans	rs551517	0.560	rs547116	chr9:113640132	T/A	cg18410444	chr5:89825535	LYSMD3	0.67	6.83	0.52	3.39e-10	Post bronchodilator FEV1 in COPD;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
TGCT	cis	rs9929218	0.953	rs3118227	chr16:68734855	G/A	cg01251360	chr16:68772225	CDH1	0.3	4.8	0.4	4.45e-6	Colorectal cancer;
TGCT	cis	rs62244186	0.748	rs2888410	chr3:44655476	A/C	cg04389838	chr3:44770851	ZNF501	-0.4	-5.36	-0.43	3.92e-7	Depressive symptoms;
TGCT	cis	rs7133214	0.510	rs4931479	chr12:27948615	A/G	cg16706260	chr12:27849370	REP15	0.28	5.18	0.42	8.76e-7	Gut microbiota (functional units);
TGCT	cis	rs634534	0.591	rs688862	chr11:65733393	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.24	5.23	0.43	6.85e-7	Sum eosinophil basophil counts;Eosinophil counts;
TGCT	cis	rs7614311	0.731	rs1053338	chr3:63967900	A/G	cg22134162	chr3:63841271	THOC7	-0.45	-5.73	-0.46	7.3e-8	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs7666738	0.830	rs17558193	chr4:99049593	A/G	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg18876405	chr7:65276391	NA	-0.32	-4.93	-0.4	2.63e-6	Aortic root size;
TGCT	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.06	-9.57	-0.65	1.41e-16	Platelet count;
TGCT	cis	rs11785400	0.963	rs6990126	chr8:143728387	T/C	cg24634471	chr8:143751801	JRK	0.55	5.92	0.47	2.93e-8	Schizophrenia;
TGCT	trans	rs4650994	0.544	rs2476561	chr1:178619900	C/T	cg05059571	chr16:84539110	KIAA1609	-0.5	-9.61	-0.65	1.14e-16	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs4975709	0.609	rs2232373	chr5:1882280	C/G	cg14773178	chr5:1868261	NA	0.36	4.88	0.4	3.16e-6	Cardiovascular disease risk factors;
TGCT	cis	rs12477438	0.520	rs6708576	chr2:99801308	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	16.87	0.83	6.81e-34	Chronic sinus infection;
TGCT	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg08736216	chr1:53307985	ZYG11A	-0.29	-6.09	-0.48	1.32e-8	Monocyte count;
TGCT	cis	rs6570726	0.902	rs373321	chr6:145854150	T/A	cg23711669	chr6:146136114	FBXO30	0.71	7.03	0.53	1.25e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6722750	0.846	rs34923691	chr2:64395183	C/T	cg22352474	chr2:64371530	PELI1	0.7	6.63	0.51	9.46e-10	Neuroticism;
TGCT	cis	rs12477438	0.748	rs10200974	chr2:99675227	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-4.88	-0.4	3.17e-6	Chronic sinus infection;
TGCT	cis	rs2463822	0.748	rs2513038	chr11:62081329	A/C	cg06239285	chr11:62104954	ASRGL1	0.92	6.16	0.48	9.2e-9	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs1171582	0.545	rs10821585	chr10:61516587	G/A	cg23572703	chr10:62241191	NA	-0.28	-4.58	-0.38	1.1e-5	Alopecia areata;
TGCT	cis	rs4494114	1.000	rs9439084	chr1:39345017	A/C	cg25970120	chr1:39325951	RRAGC	-0.6	-6.23	-0.49	6.58e-9	Blood protein levels;
TGCT	cis	rs6430585	0.702	rs3213890	chr2:136552188	G/A	cg07169764	chr2:136633963	MCM6	1.21	11.47	0.72	3.36e-21	Corneal structure;
TGCT	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg06418219	chr1:154948305	SHC1;CKS1B	-0.69	-7.09	-0.54	8.92e-11	Prostate cancer;
TGCT	cis	rs7666738	0.830	rs6853266	chr4:99047528	G/T	cg17366294	chr4:99064904	C4orf37	0.78	8.09	0.59	4.52e-13	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.12	0.54	7.78e-11	Prudent dietary pattern;
TGCT	cis	rs62064224	0.614	rs9916114	chr17:30766950	T/C	cg18200150	chr17:30822561	MYO1D	0.44	5.28	0.43	5.61e-7	Schizophrenia;
TGCT	cis	rs9549260	0.564	rs9549280	chr13:41322660	T/C	cg21288729	chr13:41239152	FOXO1	0.91	8.25	0.6	2.01e-13	Red blood cell count;
TGCT	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.44	6.19	0.49	7.91e-9	Schizophrenia;
TGCT	cis	rs11112613	0.713	rs73184084	chr12:105952615	T/A	cg03607813	chr12:105948248	NA	0.47	5.72	0.46	7.49e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	cis	rs950169	0.541	rs10795	chr15:85177297	G/A	cg17173187	chr15:85201210	NMB	0.62	7.09	0.54	8.99e-11	Schizophrenia;
TGCT	cis	rs524023	0.957	rs552307	chr11:64357539	G/A	cg07733098	chr11:64478343	NRXN2	-0.31	-4.64	-0.38	8.56e-6	Urate levels in obese individuals;
TGCT	cis	rs12776158	0.901	rs61848384	chr10:71215225	T/G	cg12610070	chr10:71211762	TSPAN15	-0.55	-4.83	-0.4	3.87e-6	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg10117171	chr1:25599238	RHD	-0.36	-5.86	-0.47	3.99e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs245880	0.702	rs245884	chr7:29188475	T/G	cg17163760	chr7:29186267	CPVL	-0.44	-5.54	-0.45	1.73e-7	Warfarin maintenance dose;
TGCT	cis	rs593982	1.000	rs1941746	chr11:65502413	A/G	cg08755490	chr11:65554678	OVOL1	1.42	12.09	0.74	1.03e-22	Atopic dermatitis;
TGCT	cis	rs3892630	0.824	rs35654350	chr19:33223766	T/C	cg22980127	chr19:33182716	NUDT19	0.71	5.15	0.42	9.79e-7	Red blood cell traits;
TGCT	cis	rs10193935	0.901	rs10490552	chr2:42559947	C/T	cg27598129	chr2:42591480	NA	0.36	5.22	0.42	7.19e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs911263	0.603	rs11628954	chr14:68782604	C/T	cg18825221	chr14:68749962	RAD51L1	0.22	4.46	0.37	1.82e-5	Primary biliary cholangitis;
TGCT	cis	rs9788682	1.000	rs57064725	chr15:78833036	C/A	cg24631222	chr15:78858424	CHRNA5	0.92	7.57	0.56	7.51e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs7246657	0.663	rs4803276	chr19:38072330	C/A	cg03611452	chr19:38183253	ZNF781	0.6	4.83	0.4	3.97e-6	Coronary artery calcification;
TGCT	cis	rs2280018	0.538	rs7404526	chr16:15129162	A/G	cg07549590	chr16:15018862	NA	-0.31	-4.57	-0.38	1.15e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs8077889	0.871	rs7212648	chr17:41917962	A/C	cg26893861	chr17:41843967	DUSP3	1.11	12.84	0.76	1.62e-24	Triglycerides;
TGCT	cis	rs896854	0.846	rs13254283	chr8:95914103	G/T	cg23172400	chr8:95962367	TP53INP1	-0.34	-5.61	-0.45	1.27e-7	Type 2 diabetes;
TGCT	cis	rs12135062	0.901	rs2651928	chr1:3101722	C/T	cg21609526	chr1:3105151	PRDM16	-0.38	-6.34	-0.5	3.79e-9	Migraine;
TGCT	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg17345569	chr6:42928274	GNMT	-0.48	-4.97	-0.41	2.22e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs7666738	0.791	rs34790496	chr4:98930516	C/T	cg17366294	chr4:99064904	C4orf37	0.72	7.39	0.55	1.87e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs137699	1.000	rs5757632	chr22:39756097	A/C	cg05872129	chr22:39784769	NA	-0.56	-4.85	-0.4	3.64e-6	IgG glycosylation;
TGCT	cis	rs492146	0.935	rs316135	chr6:52846777	C/T	cg06706454	chr6:52930286	FBXO9	-0.47	-4.54	-0.38	1.32e-5	Epilepsy (remission after treatment);
TGCT	cis	rs1969363	0.509	rs8189633	chr12:38065155	C/G	cg13010199	chr12:38710504	ALG10B	0.65	5.29	0.43	5.47e-7	Morning vs. evening chronotype;
TGCT	cis	rs7027203	0.828	rs3996239	chr9:96611290	T/A	cg14598338	chr9:96623480	NA	-0.61	-9.56	-0.65	1.44e-16	DNA methylation (variation);
TGCT	cis	rs9527	0.637	rs7085104	chr10:104628873	A/G	cg15744005	chr10:104629667	AS3MT	-0.51	-6.54	-0.51	1.47e-9	Arsenic metabolism;
TGCT	cis	rs826838	0.586	rs1843903	chr12:38627524	C/T	cg26384229	chr12:38710491	ALG10B	0.62	5.71	0.46	8e-8	Heart rate;
TGCT	cis	rs71435601	0.689	rs10169543	chr2:21423989	T/C	cg25035485	chr2:21266500	APOB	-0.55	-4.68	-0.39	7.46e-6	Cholesterol, total;
TGCT	cis	rs78707713	0.524	rs10823377	chr10:71213327	G/A	cg12610070	chr10:71211762	TSPAN15	-0.58	-7.0	-0.53	1.41e-10	Venous thromboembolism;
TGCT	cis	rs6921919	0.583	rs13201726	chr6:28385551	T/A	cg18815343	chr6:28367644	ZSCAN12	-0.54	-5.25	-0.43	6.29e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9372498	0.831	rs62421532	chr6:118705454	A/T	cg21191810	chr6:118973309	C6orf204	-0.5	-4.57	-0.38	1.14e-5	Diastolic blood pressure;
TGCT	cis	rs8111998	0.826	rs4932775	chr19:22766651	A/G	cg19914732	chr19:22715077	NA	-0.56	-4.51	-0.38	1.46e-5	Corneal structure;
TGCT	cis	rs3733585	0.781	rs6449183	chr4:9970691	C/A	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.92	-0.58	1.15e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs2115630	0.936	rs8033459	chr15:85253258	C/T	cg17173187	chr15:85201210	NMB	-0.4	-5.02	-0.41	1.78e-6	P wave terminal force;
TGCT	cis	rs1218582	0.741	rs705094	chr1:154917314	G/A	cg24250549	chr1:154909240	PMVK	0.61	6.04	0.48	1.63e-8	Prostate cancer;
TGCT	cis	rs950169	0.724	rs11632668	chr15:84948687	T/C	cg17173187	chr15:85201210	NMB	0.58	5.93	0.47	2.77e-8	Schizophrenia;
TGCT	cis	rs10949662	1.000	rs10949662	chr7:157534105	A/G	cg14168080	chr7:157504135	PTPRN2	0.39	4.75	0.39	5.6e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs826838	1.000	rs826892	chr12:39100790	T/C	cg26384229	chr12:38710491	ALG10B	-0.85	-8.1	-0.59	4.39e-13	Heart rate;
TGCT	cis	rs9372253	0.678	rs9372251	chr6:110700656	A/G	cg00083206	chr6:110721305	DDO	-0.38	-5.56	-0.45	1.59e-7	Platelet distribution width;
TGCT	cis	rs10256972	0.504	rs3735687	chr7:1066297	A/G	cg00431813	chr7:1051703	C7orf50	-0.29	-6.33	-0.49	4.13e-9	Longevity;Endometriosis;
TGCT	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg05457628	chr5:178986728	RUFY1	0.54	6.29	0.49	4.98e-9	Lung cancer;
TGCT	cis	rs7681440	0.835	rs6831847	chr4:90785341	A/G	cg10208370	chr4:90758469	SNCA	0.49	4.61	0.38	9.7e-6	Dementia with Lewy bodies;
TGCT	cis	rs2404602	0.672	rs35374222	chr15:77071394	G/T	cg22467129	chr15:76604101	ETFA	0.47	4.62	0.38	9.31e-6	Blood metabolite levels;
TGCT	cis	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg12570787	chr5:219185	SDHA;CCDC127	0.66	4.48	0.37	1.64e-5	Breast cancer;
TGCT	cis	rs2798269	0.604	rs2798275	chr13:22159035	T/A	cg18095732	chr13:22033692	ZDHHC20	-0.5	-4.45	-0.37	1.88e-5	PR segment;
TGCT	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg22963979	chr7:1858916	MAD1L1	-0.4	-6.23	-0.49	6.81e-9	Bipolar disorder and schizophrenia;
TGCT	cis	rs929354	0.651	rs6951298	chr7:156949149	T/C	cg05182265	chr7:156933206	UBE3C	-0.39	-8.98	-0.63	3.72e-15	Body mass index;
TGCT	cis	rs4642101	0.512	rs12629892	chr3:12818920	A/G	cg05775895	chr3:12838266	CAND2	0.78	7.72	0.57	3.34e-12	QRS complex (12-leadsum);
TGCT	cis	rs12477438	0.520	rs6743355	chr2:99732360	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.82	0.62	8.67e-15	Chronic sinus infection;
TGCT	cis	rs1008375	1.000	rs1860597	chr4:17657650	C/T	cg10189774	chr4:17578691	LAP3	0.57	5.15	0.42	9.95e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs858239	0.600	rs61292332	chr7:23131862	C/T	cg05602783	chr7:23145260	KLHL7	-0.58	-4.85	-0.4	3.68e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs17767294	0.708	rs41269275	chr6:27833315	C/G	cg08851530	chr6:28072375	NA	1.58	7.16	0.54	6.15e-11	Parkinson's disease;
TGCT	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg04234412	chr22:24373322	LOC391322	-0.94	-11.92	-0.73	2.73e-22	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7666738	0.962	rs4699596	chr4:99012924	C/T	cg05340658	chr4:99064831	C4orf37	0.44	4.48	0.37	1.65e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.47	-0.37	1.72e-5	Bipolar disorder;
TGCT	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg05368731	chr17:41323189	NBR1	1.2	14.48	0.79	1.98e-28	Menopause (age at onset);
TGCT	cis	rs116095464	0.558	rs10057299	chr5:242135	C/T	cg22857025	chr5:266934	NA	-0.34	-6.72	-0.52	5.96e-10	Breast cancer;
TGCT	cis	rs9549260	0.755	rs2151785	chr13:41243660	G/A	cg21288729	chr13:41239152	FOXO1	1.0	10.25	0.68	3.06e-18	Red blood cell count;
TGCT	cis	rs8103278	0.860	rs11669073	chr19:46324880	C/T	cg11657440	chr19:46296263	DMWD	-0.6	-5.7	-0.46	8.16e-8	Coronary artery disease;
TGCT	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.5	5.41	0.44	3.18e-7	Lymphocyte counts;
TGCT	cis	rs9467711	0.516	rs523383	chr6:25869848	A/G	cg03517284	chr6:25882590	NA	-0.76	-5.17	-0.42	9.19e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2982552	0.805	rs2982557	chr6:152056369	G/A	cg22157087	chr6:152012887	ESR1	0.21	5.25	0.43	6.29e-7	Bone properties (heel);
TGCT	cis	rs6076065	0.775	rs6083114	chr20:23379528	G/T	cg11657817	chr20:23433608	CST11	0.31	5.42	0.44	3.02e-7	Facial morphology (factor 15, philtrum width);
TGCT	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg05785598	chr3:49045655	WDR6	0.36	4.78	0.39	4.78e-6	Menarche (age at onset);
TGCT	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg22166914	chr1:53195759	ZYG11B	0.36	5.71	0.46	8.05e-8	Monocyte count;
TGCT	trans	rs7726839	0.574	rs12517345	chr5:628294	G/A	cg25482853	chr8:67687455	SGK3	1.22	10.53	0.69	6.33e-19	Obesity-related traits;
TGCT	cis	rs4808199	1.000	rs60003758	chr19:19557353	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.7	5.07	0.41	1.41e-6	Nonalcoholic fatty liver disease;
TGCT	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg10802521	chr3:52805072	NEK4	-0.71	-8.79	-0.62	1.04e-14	Bipolar disorder;
TGCT	cis	rs7666738	0.830	rs1426665	chr4:99027764	C/T	cg18180107	chr4:99064573	C4orf37	0.55	5.13	0.42	1.1e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs66573146	0.831	rs56300156	chr4:6990813	G/C	cg00086871	chr4:6988644	TBC1D14	0.95	4.69	0.39	7.15e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs8017423	0.967	rs11621364	chr14:90709115	A/G	cg04374321	chr14:90722782	PSMC1	0.77	8.05	0.59	5.68e-13	Mortality in heart failure;
TGCT	cis	rs2836950	0.509	rs4816618	chr21:40599529	G/A	cg06238570	chr21:40685208	BRWD1	-0.6	-6.21	-0.49	7.27e-9	Menarche (age at onset);
TGCT	cis	rs7412746	0.611	rs3768018	chr1:150723747	T/C	cg04414720	chr1:150670196	GOLPH3L	0.37	4.47	0.37	1.77e-5	Melanoma;
TGCT	cis	rs9916302	0.752	rs9901219	chr17:37558369	T/G	cg15445000	chr17:37608096	MED1	-0.33	-4.64	-0.38	8.86e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7267979	1.000	rs6037086	chr20:25306338	A/G	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs12500482	1.000	rs12500482	chr4:2430235	A/G	cg08330972	chr4:2403930	ZFYVE28	-0.33	-4.54	-0.38	1.34e-5	Cognitive function;
TGCT	cis	rs7246657	0.722	rs2909098	chr19:38204248	G/A	cg18154014	chr19:37997991	ZNF793	-0.72	-5.06	-0.41	1.48e-6	Coronary artery calcification;
TGCT	cis	rs4713118	0.955	rs9393847	chr6:27687973	G/A	cg10876282	chr6:28092338	ZSCAN16	0.5	4.62	0.38	9.35e-6	Parkinson's disease;
TGCT	cis	rs1215050	0.740	rs13134479	chr4:99067723	G/A	cg05340658	chr4:99064831	C4orf37	0.44	5.3	0.43	5.03e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs881375	0.967	rs1548783	chr9:123658639	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.4	4.49	0.37	1.63e-5	Rheumatoid arthritis;
TGCT	cis	rs13401104	0.587	rs62190972	chr2:237145164	T/C	cg26422059	chr2:237146110	ASB18	0.57	4.56	0.38	1.19e-5	Educational attainment;
TGCT	cis	rs7119	0.931	rs12901998	chr15:77833524	G/T	cg27398640	chr15:77910606	LINGO1	-0.25	-4.7	-0.39	6.77e-6	Type 2 diabetes;
TGCT	trans	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.83	-8.69	-0.62	1.76e-14	Body mass index;
TGCT	cis	rs151997	0.569	rs62367393	chr5:50270360	C/A	cg06027927	chr5:50259733	NA	0.54	5.44	0.44	2.76e-7	Callous-unemotional behaviour;
TGCT	cis	rs2073300	1.000	rs6048835	chr20:23462343	G/C	cg09953122	chr20:23471693	CST8	-0.59	-4.75	-0.39	5.62e-6	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs12579753	1.000	rs12830268	chr12:82233627	A/C	cg07988820	chr12:82153109	PPFIA2	-0.6	-6.48	-0.5	1.91e-9	Resting heart rate;
TGCT	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg22105103	chr4:187893119	NA	-0.35	-4.98	-0.41	2.07e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2304069	0.550	rs216144	chr5:149445480	T/C	cg05650999	chr5:148883763	CSNK1A1	-0.22	-4.52	-0.38	1.44e-5	HIV-1 control;
TGCT	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg06618935	chr21:46677482	NA	0.37	5.59	0.45	1.37e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs10514758	0.744	rs72491128	chr3:114910078	G/C	cg05943254	chr3:114009756	NA	-0.76	-4.53	-0.38	1.39e-5	Urate levels in obese individuals;
TGCT	cis	rs7119	0.700	rs7497168	chr15:77886231	A/C	cg27398640	chr15:77910606	LINGO1	0.33	6.85	0.52	2.99e-10	Type 2 diabetes;
TGCT	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg08859206	chr1:53392774	SCP2	-0.41	-6.13	-0.48	1.05e-8	Monocyte count;
TGCT	cis	rs6429082	0.811	rs291348	chr1:235667690	A/G	cg26050004	chr1:235667680	B3GALNT2	0.82	8.69	0.62	1.84e-14	Adiposity;
TGCT	cis	rs7772486	0.774	rs6930181	chr6:146180974	A/T	cg23711669	chr6:146136114	FBXO30	-0.77	-7.5	-0.56	1.08e-11	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9303401	0.659	rs7210700	chr17:56668186	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs7246657	0.943	rs8109632	chr19:37931125	A/T	cg18154014	chr19:37997991	ZNF793	0.73	5.38	0.44	3.53e-7	Coronary artery calcification;
TGCT	cis	rs6939532	0.522	rs4712980	chr6:26355758	G/T	cg05738196	chr6:26577821	NA	0.5	4.77	0.39	4.98e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2224391	0.784	rs67285271	chr6:5279267	T/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.79	-4.8	-0.4	4.54e-6	Height;
TGCT	cis	rs12142240	0.698	rs67941619	chr1:46838219	A/G	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs7666738	0.830	rs10009943	chr4:99021475	G/A	cg17366294	chr4:99064904	C4orf37	0.68	7.04	0.53	1.17e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs911555	0.755	rs8016676	chr14:103904842	C/A	cg23461800	chr14:103021989	NA	-0.35	-4.56	-0.38	1.23e-5	Intelligence (multi-trait analysis);
TGCT	trans	rs208515	0.525	rs10944870	chr6:66687757	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.93	10.3	0.68	2.34e-18	Exhaled nitric oxide levels;
TGCT	cis	rs7647973	1.000	rs3870339	chr3:49536863	T/A	cg07636037	chr3:49044803	WDR6	0.64	5.26	0.43	6.12e-7	Menarche (age at onset);
TGCT	cis	rs2295359	0.892	rs12029362	chr1:67624231	G/A	cg12940439	chr1:67600707	NA	0.58	5.9	0.47	3.2e-8	Psoriasis;
TGCT	cis	rs9549367	0.789	rs9577220	chr13:113908294	T/A	cg18105134	chr13:113819100	PROZ	-0.35	-5.94	-0.47	2.68e-8	Platelet distribution width;
TGCT	cis	rs66573146	1.000	rs56350643	chr4:7017591	G/A	cg05069807	chr4:6945702	TBC1D14	0.37	5.2	0.42	8.07e-7	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs2455799	0.634	rs11128765	chr3:15903331	G/T	cg16303742	chr3:15540471	COLQ	-0.24	-4.59	-0.38	1.07e-5	Mean platelet volume;
TGCT	cis	rs1552244	0.554	rs3846167	chr3:9996426	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.32	-4.84	-0.4	3.76e-6	Alzheimer's disease;
TGCT	cis	rs1577917	0.958	rs6454487	chr6:86446868	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.63	5.09	0.42	1.32e-6	Response to antipsychotic treatment;
TGCT	cis	rs7674212	0.531	rs4698876	chr4:103933567	T/G	cg16532752	chr4:104119610	CENPE	-0.6	-5.29	-0.43	5.33e-7	Type 2 diabetes;
TGCT	cis	rs5769765	0.908	rs9616370	chr22:50306316	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	1.15	11.32	0.71	7.79e-21	Schizophrenia;
TGCT	cis	rs8072100	0.713	rs57427906	chr17:45494014	G/A	cg08085267	chr17:45401833	C17orf57	-0.52	-5.75	-0.46	6.48e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs368755101	1	rs368755101	chr2:100762215	AG/A	cg07810366	chr2:100720526	AFF3	-0.37	-5.28	-0.43	5.54e-7	Plateletcrit;Red blood cell count;
TGCT	cis	rs72627509	0.857	rs56155140	chr4:57824451	G/A	cg26694713	chr4:57773883	REST	0.72	6.38	0.5	3.21e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs7312933	0.558	rs1669886	chr12:42838240	A/G	cg19980929	chr12:42632907	YAF2	-0.41	-5.8	-0.46	5.14e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg15691649	chr6:25882328	NA	-0.58	-7.44	-0.56	1.43e-11	Urate levels;
TGCT	cis	rs698813	0.572	rs6544749	chr2:44478077	G/A	cg00619915	chr2:44497795	NA	-0.25	-5.7	-0.46	8.13e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
TGCT	cis	rs9788721	0.806	rs951985	chr15:78720923	T/G	cg18825076	chr15:78729989	IREB2	-0.33	-5.05	-0.41	1.55e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
TGCT	cis	rs7552404	1.000	rs7518038	chr1:76154430	G/A	cg10523679	chr1:76189770	ACADM	0.9	9.82	0.66	3.52e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg18402987	chr7:1209562	NA	0.81	6.94	0.53	1.9e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7772486	0.806	rs4075695	chr6:146250959	A/G	cg23711669	chr6:146136114	FBXO30	-0.8	-8.9	-0.62	5.72e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs62380364	0.542	rs2457979	chr5:88039660	T/A	cg24804195	chr5:87968844	LOC645323	-0.6	-6.05	-0.48	1.59e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs1483890	0.723	rs1483888	chr3:69413329	G/T	cg22125112	chr3:69402811	FRMD4B	0.29	4.8	0.4	4.57e-6	Resting heart rate;
TGCT	cis	rs2204008	0.837	rs8189467	chr12:38241956	T/C	cg13010199	chr12:38710504	ALG10B	0.6	4.64	0.38	8.72e-6	Bladder cancer;
TGCT	cis	rs7666738	0.830	rs4699590	chr4:98974030	A/C	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6074578	0.648	rs12624954	chr20:139456	G/A	cg16931068	chr20:139680	DEFB127	0.27	4.52	0.38	1.4e-5	Hirschsprung disease;
TGCT	cis	rs7681440	0.845	rs6843084	chr4:90766230	T/C	cg01966878	chr4:90757139	SNCA	-0.25	-4.56	-0.38	1.2e-5	Dementia with Lewy bodies;
TGCT	cis	rs4689388	0.824	rs6446482	chr4:6295693	C/G	cg25554036	chr4:6271136	WFS1	0.57	7.87	0.58	1.54e-12	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs9733	0.526	rs6587542	chr1:150907701	G/T	cg04414720	chr1:150670196	GOLPH3L	0.37	4.46	0.37	1.81e-5	Tonsillectomy;
TGCT	cis	rs732765	1.000	rs709888	chr14:75369346	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.65	-5.51	-0.44	1.99e-7	Non-small cell lung cancer;
TGCT	trans	rs3780486	0.846	rs10113903	chr9:33122645	C/G	cg20290983	chr6:43655470	MRPS18A	-1.2	-15.17	-0.81	4.92e-30	IgG glycosylation;
TGCT	cis	rs7945705	1.000	rs10840134	chr11:8865363	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.4	4.47	0.37	1.72e-5	Hemoglobin concentration;
TGCT	cis	rs931127	0.624	rs2306364	chr11:65412467	G/A	cg27068330	chr11:65405492	SIPA1	-0.96	-10.8	-0.7	1.42e-19	Systemic lupus erythematosus;
TGCT	cis	rs9911578	0.967	rs12938821	chr17:56959422	T/C	cg12560992	chr17:57184187	TRIM37	0.76	9.21	0.64	1.03e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg13732083	chr21:47605072	C21orf56	0.35	4.69	0.39	7.17e-6	Testicular germ cell tumor;
TGCT	cis	rs7224685	0.569	rs12940782	chr17:3992712	T/C	cg09580393	chr17:4869866	SPAG7	-0.38	-4.48	-0.37	1.64e-5	Type 2 diabetes;
TGCT	cis	rs7267979	1.000	rs6050547	chr20:25326012	C/T	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg11301795	chr4:187892539	NA	0.33	4.79	0.39	4.75e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7655841	0.524	rs189236	chr4:130028412	C/T	cg26347359	chr4:129759716	PHF17	-0.45	-6.09	-0.48	1.3e-8	Chronic obstructive pulmonary disease (moderate to severe);
TGCT	cis	rs367943	0.965	rs463249	chr5:112797430	A/C	cg12552261	chr5:112820674	MCC	-0.24	-4.89	-0.4	3.04e-6	Type 2 diabetes;
TGCT	cis	rs4494114	1.000	rs9439082	chr1:39344055	G/A	cg25970120	chr1:39325951	RRAGC	-0.6	-6.23	-0.49	6.58e-9	Blood protein levels;
TGCT	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg13012494	chr21:47604986	C21orf56	0.37	4.68	0.39	7.49e-6	Testicular germ cell tumor;
TGCT	cis	rs61990749	0.597	rs1008988	chr14:78260795	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.6	4.45	0.37	1.88e-5	Fibroblast growth factor basic levels;
TGCT	trans	rs10435719	0.764	rs10103485	chr8:11787563	C/T	cg15556689	chr8:8085844	FLJ10661	0.78	7.33	0.55	2.63e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs6500602	0.727	rs7193136	chr16:4580034	C/T	cg08645402	chr16:4508243	NA	0.19	5.3	0.43	5.14e-7	Schizophrenia;
TGCT	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg10150615	chr22:24372951	LOC391322	-1.0	-12.91	-0.76	1.1e-24	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs16867321	0.671	rs4666665	chr2:181463705	A/G	cg23363182	chr2:181467187	NA	-0.42	-4.46	-0.37	1.8e-5	Obesity;
TGCT	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg18305652	chr10:134549665	INPP5A	0.33	5.86	0.47	3.93e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs11190604	1.000	rs3750626	chr10:102266316	C/T	cg16342193	chr10:102329863	NA	-0.38	-4.89	-0.4	3.06e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs8016982	0.651	rs9806027	chr14:81668707	G/C	cg01989461	chr14:81687754	GTF2A1	0.71	6.46	0.5	2.2e-9	Schizophrenia;
TGCT	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg14159672	chr1:205819179	PM20D1	0.61	7.57	0.56	7.33e-12	Menarche (age at onset);
TGCT	cis	rs7819412	0.618	rs34772085	chr8:10964906	C/T	cg03192020	chr8:11204681	TDH	-0.56	-5.22	-0.42	7.31e-7	Triglycerides;
TGCT	cis	rs7267979	1.000	rs6050626	chr20:25428261	T/C	cg16686733	chr20:25566563	NINL	0.58	5.84	0.46	4.39e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs666930	0.967	rs637868	chr1:120257110	A/G	cg19096424	chr1:120255104	PHGDH	0.55	5.18	0.42	8.78e-7	Breast cancer;
TGCT	cis	rs67311347	1.000	rs9860162	chr3:40403875	C/T	cg13683864	chr3:40499215	RPL14	-1.1	-11.83	-0.73	4.49e-22	Renal cell carcinoma;
TGCT	cis	rs6589563	0.609	rs12280724	chr11:116613423	A/C	cg15855170	chr11:116574279	NA	0.34	4.54	0.38	1.3e-5	Eosinophil counts;
TGCT	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.01	0.41	1.86e-6	Prudent dietary pattern;
TGCT	cis	rs9467711	0.606	rs9379851	chr6:26354780	A/C	cg10795676	chr6:26370623	BTN3A2	-0.45	-4.93	-0.4	2.6e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7103648	0.864	rs12801188	chr11:47388214	G/A	cg20307385	chr11:47447363	PSMC3	0.99	11.74	0.73	7.18e-22	Diastolic blood pressure;Systolic blood pressure;
TGCT	trans	rs9929218	0.551	rs2274239	chr16:68725783	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.96	0.58	9.54e-13	Colorectal cancer;
TGCT	cis	rs7666738	0.830	rs6839277	chr4:99015563	C/T	cg05340658	chr4:99064831	C4orf37	0.48	5.43	0.44	2.92e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4786125	0.516	rs7203888	chr16:6915483	T/C	cg03623568	chr16:6915990	A2BP1	-0.44	-6.63	-0.51	9.34e-10	Heart rate variability traits (SDNN);
TGCT	trans	rs4332037	0.950	rs11767515	chr7:1941051	C/T	cg25206134	chr2:45395956	NA	1.1	9.34	0.64	5.11e-16	Bipolar disorder;
TGCT	cis	rs11105298	0.891	rs3741898	chr12:89933763	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.67	-4.85	-0.4	3.63e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg18252515	chr7:66147081	NA	-1.22	-7.33	-0.55	2.53e-11	Diabetic kidney disease;
TGCT	cis	rs2300747	0.932	rs2300746	chr1:117082183	C/G	cg26677431	chr1:117075710	CD58	-0.23	-4.56	-0.38	1.23e-5	Primary biliary cholangitis;Multiple sclerosis;
TGCT	cis	rs3796352	1.000	rs9874517	chr3:53128371	A/G	cg15956490	chr3:53032818	SFMBT1	0.49	5.58	0.45	1.41e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs10883723	0.810	rs7090034	chr10:104281155	C/G	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs4918072	0.637	rs61861138	chr10:105613417	G/A	cg11005552	chr10:105648138	OBFC1	0.41	5.16	0.42	9.36e-7	Coronary artery disease;
TGCT	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.57	-5.67	-0.45	9.59e-8	Electroencephalogram traits;
TGCT	cis	rs12210905	0.688	rs72841400	chr6:27489911	T/G	cg08851530	chr6:28072375	NA	1.34	6.29	0.49	5.02e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg06221963	chr1:154839813	KCNN3	-0.78	-14.77	-0.8	4.24e-29	Prostate cancer;
TGCT	cis	rs9372498	0.505	rs17427284	chr6:118991953	A/T	cg07617317	chr6:118971624	C6orf204	0.47	4.65	0.39	8.43e-6	Diastolic blood pressure;
TGCT	cis	rs1008375	1.000	rs4235388	chr4:17682030	G/A	cg10189774	chr4:17578691	LAP3	0.54	4.97	0.41	2.14e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg00684032	chr4:1343700	KIAA1530	0.21	4.52	0.38	1.44e-5	Obesity-related traits;
TGCT	cis	rs7752195	0.643	rs77006546	chr6:25219582	T/C	cg16898833	chr6:26189333	HIST1H4D	1.21	4.7	0.39	6.82e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs514406	0.800	rs4926930	chr1:53217335	A/G	cg01802117	chr1:53393560	SCP2	0.44	5.26	0.43	6.2e-7	Monocyte count;
TGCT	trans	rs2727020	0.729	rs10742932	chr11:49173234	T/C	cg03929089	chr4:120376271	NA	-0.71	-8.05	-0.59	5.64e-13	Coronary artery disease;
TGCT	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.73	5.55	0.45	1.68e-7	Lung function (FEV1/FVC);
TGCT	cis	rs3772130	0.962	rs11715951	chr3:121522968	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.72	0.39	6.25e-6	Cognitive performance;
TGCT	trans	rs8073060	0.586	rs225300	chr17:33922428	C/T	cg19694781	chr19:47549865	TMEM160	-0.6	-13.04	-0.76	5.29e-25	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg06873352	chr17:61820015	STRADA	0.58	6.39	0.5	3.01e-9	Prudent dietary pattern;
TGCT	cis	rs11030122	0.673	rs10767767	chr11:4003678	C/T	cg18678763	chr11:4115507	RRM1	-0.47	-5.68	-0.45	8.88e-8	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs4319547	0.698	rs10773178	chr12:122944752	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.63	-4.94	-0.41	2.49e-6	Body mass index;
TGCT	cis	rs8002180	0.959	rs2027445	chr13:95921388	C/T	cg24476569	chr13:95954382	ABCC4	0.39	4.97	0.41	2.2e-6	Blood metabolite levels;
TGCT	cis	rs644799	0.582	rs473157	chr11:95596874	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.56	5.96	0.47	2.44e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs11098499	0.775	rs10021601	chr4:120282563	G/A	cg09307838	chr4:120376055	NA	0.58	5.76	0.46	6.16e-8	Corneal astigmatism;
TGCT	cis	rs2180341	0.618	rs12210968	chr6:127596985	A/G	cg24812749	chr6:127587940	RNF146	0.63	5.33	0.43	4.51e-7	Breast cancer;
TGCT	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.31	-4.82	-0.4	4.12e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.04	0.53	1.16e-10	Prudent dietary pattern;
TGCT	trans	rs208520	1.000	rs12192261	chr6:66985268	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.83	7.46	0.56	1.31e-11	Exhaled nitric oxide output;
TGCT	cis	rs1023500	0.505	rs134874	chr22:42661144	A/G	cg05082376	chr22:42548792	NA	-0.21	-4.61	-0.38	9.93e-6	Schizophrenia;
TGCT	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg04317338	chr11:64019027	PLCB3	0.81	6.89	0.53	2.49e-10	Mean platelet volume;
TGCT	cis	rs7000551	0.581	rs11136030	chr8:22254235	C/T	cg12081754	chr8:22256438	SLC39A14	0.33	4.77	0.39	5.04e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs6684514	1.000	rs10908495	chr1:156263940	T/C	cg20302342	chr1:156215951	PAQR6	0.34	4.6	0.38	1.01e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs3806843	0.576	rs246017	chr5:140335060	C/T	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.52	-6.44	-0.5	2.34e-9	Longevity;Endometriosis;
TGCT	cis	rs2245008	0.671	rs907036	chr16:83989850	A/T	cg27171569	chr16:83987465	OSGIN1	0.56	7.89	0.58	1.35e-12	Pursuit maintenance gain;
TGCT	cis	rs7547997	0.654	rs10158210	chr1:158311985	A/G	cg07950803	chr1:158223934	CD1A	0.32	5.08	0.42	1.35e-6	QRS duration;
TGCT	cis	rs7027203	0.576	rs7855940	chr9:96535966	C/G	cg13679303	chr9:96623674	NA	-0.52	-7.52	-0.56	9.69e-12	DNA methylation (variation);
TGCT	cis	rs4975616	0.804	rs457130	chr5:1336178	A/T	cg06550200	chr5:1325588	CLPTM1L	-0.31	-4.86	-0.4	3.44e-6	Lung cancer;
TGCT	cis	rs4851266	1.000	rs1122231	chr2:100834546	C/T	cg22139774	chr2:100720529	AFF3	-0.35	-5.41	-0.44	3.1e-7	Educational attainment;
TGCT	cis	rs1451375	0.698	rs11238226	chr7:50645827	A/G	cg18232548	chr7:50535776	DDC	0.46	7.1	0.54	8.31e-11	Malaria;
TGCT	cis	rs76419734	0.558	rs72669984	chr4:106544702	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.83	4.67	0.39	7.6e-6	Post bronchodilator FEV1;
TGCT	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.21	0.49	7.27e-9	Bipolar disorder;
TGCT	cis	rs2692947	0.727	rs1657502	chr2:96795608	A/C	cg22654517	chr2:96458247	NA	0.22	5.07	0.41	1.41e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs7666738	0.830	rs4440224	chr4:99044924	G/A	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11264213	0.591	rs274755	chr1:36544237	T/C	cg27506609	chr1:36549197	TEKT2	-0.49	-5.82	-0.46	4.73e-8	Schizophrenia;
TGCT	cis	rs6964587	0.967	rs1978061	chr7:91779242	G/A	cg17063962	chr7:91808500	NA	0.93	10.08	0.67	8.03e-18	Breast cancer;
TGCT	cis	rs1348850	0.874	rs12996447	chr2:178283592	C/T	cg22681709	chr2:178499509	PDE11A	-0.35	-4.73	-0.39	5.89e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs9926296	0.682	rs645019	chr16:89716883	C/T	cg21285383	chr16:89894308	SPIRE2	-0.33	-4.64	-0.38	8.56e-6	Vitiligo;
TGCT	cis	rs9818758	0.607	rs34580506	chr3:49113713	C/A	cg00383909	chr3:49044727	WDR6	1.3	6.73	0.52	5.74e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs9443645	0.869	rs4706080	chr6:79760997	C/T	cg09184832	chr6:79620586	NA	-0.48	-5.34	-0.43	4.21e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs3924048	0.559	rs4075303	chr1:12626593	C/G	cg00291366	chr1:12616550	NA	0.32	5.03	0.41	1.66e-6	Optic cup area;
TGCT	cis	rs9611565	0.512	rs2899347	chr22:42158204	T/C	cg03806693	chr22:41940476	POLR3H	1.04	10.57	0.69	5.2e-19	Vitiligo;
TGCT	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg11494091	chr17:61959527	GH2	0.6	14.51	0.79	1.71e-28	Prudent dietary pattern;
TGCT	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.1	0.42	1.24e-6	Menopause (age at onset);
TGCT	cis	rs11122272	0.735	rs973254	chr1:231521149	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.73	-7.29	-0.55	3.25e-11	Hemoglobin concentration;
TGCT	cis	rs1008375	1.000	rs4698635	chr4:17630242	C/A	cg18681998	chr4:17616180	MED28	1.02	11.4	0.72	4.89e-21	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1461503	0.966	rs10790547	chr11:122842110	T/A	cg27398637	chr11:122830231	C11orf63	-0.42	-5.25	-0.43	6.42e-7	Menarche (age at onset);
TGCT	cis	rs3803170	0.513	rs10849942	chr12:111818637	T/C	cg10833066	chr12:111807467	FAM109A	0.35	5.51	0.44	1.94e-7	Mean corpuscular hemoglobin;
TGCT	cis	rs2439831	0.867	rs2447208	chr15:43933895	C/T	cg19166733	chr15:44192098	FRMD5	-0.24	-4.89	-0.4	3.08e-6	Lung cancer in ever smokers;
TGCT	cis	rs9926296	0.712	rs258330	chr16:89729574	T/G	cg26513180	chr16:89883248	FANCA	-0.67	-6.37	-0.5	3.32e-9	Vitiligo;
TGCT	cis	rs28595532	0.920	rs114057512	chr4:119750179	G/A	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs62244186	0.659	rs62251383	chr3:44552421	A/G	cg10263370	chr3:44754102	ZNF502	-0.41	-4.94	-0.41	2.47e-6	Depressive symptoms;
TGCT	cis	rs10751667	0.621	rs7396107	chr11:970029	C/T	cg06064525	chr11:970664	AP2A2	-0.36	-8.28	-0.6	1.67e-13	Alzheimer's disease (late onset);
TGCT	cis	rs12479064	0.724	rs3792150	chr2:100041849	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.7	-6.28	-0.49	5.1e-9	Chronic sinus infection;
TGCT	cis	rs6840360	0.607	rs1561918	chr4:152446832	T/A	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.82e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs6570726	0.791	rs446362	chr6:145878716	G/T	cg05347473	chr6:146136440	FBXO30	0.54	5.15	0.42	1.01e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs12477438	1.000	rs6542873	chr2:99824965	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.67	-5.73	-0.46	7.13e-8	Chronic sinus infection;
TGCT	cis	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg18188782	chr20:61659543	NA	0.44	5.38	0.43	3.6e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg18252515	chr7:66147081	NA	-1.31	-8.18	-0.59	2.87e-13	Diabetic kidney disease;
TGCT	cis	rs9787249	0.874	rs7520588	chr1:40214525	T/A	cg24920358	chr1:40204285	PPIE	0.57	10.56	0.69	5.57e-19	Blood protein levels;
TGCT	cis	rs7666738	0.716	rs6814353	chr4:99074202	A/G	cg05340658	chr4:99064831	C4orf37	0.51	5.62	0.45	1.18e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9399137	0.507	rs28384513	chr6:135376209	T/G	cg24558204	chr6:135376177	HBS1L	0.47	4.73	0.39	5.98e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
TGCT	cis	rs204693	0.623	rs204687	chr20:541855	A/G	cg15180867	chr20:591076	TCF15	0.65	4.48	0.37	1.69e-5	Pursuit maintenance gain;
TGCT	cis	rs62244186	0.659	rs9873072	chr3:44516496	G/A	cg10108389	chr3:44770937	ZNF501	-0.48	-4.96	-0.41	2.31e-6	Depressive symptoms;
TGCT	cis	rs669446	0.533	rs2158956	chr1:44211697	T/C	cg12908607	chr1:44402522	ARTN	-0.63	-7.43	-0.56	1.52e-11	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs362272	0.545	rs3135146	chr4:3307638	C/G	cg22655196	chr4:3374909	RGS12	-0.25	-5.02	-0.41	1.73e-6	Serum sulfate level;
TGCT	cis	rs910316	1.000	rs13099	chr14:75599155	G/A	cg23033748	chr14:75592666	NEK9	-0.28	-4.76	-0.39	5.33e-6	Height;
TGCT	cis	rs6912958	0.712	rs6454638	chr6:88329427	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.5	4.73	0.39	6.12e-6	Monocyte percentage of white cells;
TGCT	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg01570182	chr17:44337453	NA	1.08	9.48	0.65	2.25e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg03161606	chr19:29218774	NA	0.59	6.5	0.5	1.75e-9	Methadone dose in opioid dependence;
TGCT	cis	rs2032447	0.677	rs199737	chr6:25933538	A/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.67	-6.86	-0.52	2.92e-10	Intelligence (multi-trait analysis);
TGCT	trans	rs1814175	0.817	rs12287396	chr11:49819798	G/C	cg15704280	chr7:45808275	SEPT13	-0.72	-8.14	-0.59	3.61e-13	Height;
TGCT	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.77	-7.97	-0.58	8.65e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg13695892	chr22:41940480	POLR3H	0.92	9.08	0.63	2.08e-15	Vitiligo;
TGCT	cis	rs4711350	0.862	rs487835	chr6:33710933	G/A	cg18005901	chr6:33739558	LEMD2	0.57	5.9	0.47	3.23e-8	Schizophrenia;
TGCT	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg11494091	chr17:61959527	GH2	0.61	14.9	0.8	2.04e-29	Prudent dietary pattern;
TGCT	cis	rs9436747	0.641	rs11208675	chr1:66045424	T/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.52	4.65	0.39	8.37e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg00149659	chr3:10157352	C3orf10	0.92	5.57	0.45	1.5e-7	Alzheimer's disease;
TGCT	cis	rs7681440	0.715	rs17016305	chr4:90791381	A/G	cg20003494	chr4:90757398	SNCA	-0.53	-4.74	-0.39	5.65e-6	Dementia with Lewy bodies;
TGCT	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg11764359	chr7:65958608	NA	-0.57	-4.99	-0.41	2.02e-6	Aortic root size;
TGCT	cis	rs114540395	0.858	rs78446856	chr10:103119815	T/A	cg18276125	chr10:102749041	C10orf2	0.36	4.44	0.37	1.98e-5	Schizophrenia;
TGCT	cis	rs7681440	0.835	rs1899389	chr4:90802998	G/A	cg14346243	chr4:90757452	SNCA	-0.5	-4.75	-0.39	5.46e-6	Dementia with Lewy bodies;
TGCT	cis	rs7010267	0.669	rs2073617	chr8:119964283	G/A	cg17171407	chr8:119960777	TNFRSF11B	0.28	5.16	0.42	9.44e-7	Total body bone mineral density (age 45-60);
TGCT	cis	rs9359856	0.510	rs6937244	chr6:90468465	C/A	cg13799429	chr6:90582589	CASP8AP2	0.46	4.78	0.39	4.95e-6	Bipolar disorder;
TGCT	cis	rs694739	1.000	rs694739	chr11:64097233	A/G	cg23796481	chr11:64053134	BAD;GPR137	0.68	6.95	0.53	1.88e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs73198271	0.653	rs3827811	chr8:8659038	C/T	cg06636001	chr8:8085503	FLJ10661	-0.61	-4.62	-0.38	9.61e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs6938	0.534	rs12913293	chr15:75184458	G/C	cg09165964	chr15:75287851	SCAMP5	0.56	5.29	0.43	5.38e-7	Breast cancer;
TGCT	cis	rs12765878	0.627	rs1265166	chr10:105671248	C/A	cg11005552	chr10:105648138	OBFC1	-0.4	-6.2	-0.49	7.61e-9	Coronary artery disease;
TGCT	cis	rs9911578	1.000	rs6503887	chr17:56993320	T/C	cg05425664	chr17:57184151	TRIM37	-0.62	-6.18	-0.49	8.33e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs17539620	0.624	rs4566892	chr6:154837346	C/T	cg20019720	chr6:154832845	CNKSR3	0.57	5.02	0.41	1.72e-6	Lipoprotein (a) levels;
TGCT	cis	rs6674176	0.569	rs11210935	chr1:44369444	G/A	cg12908607	chr1:44402522	ARTN	-0.68	-7.81	-0.57	2.09e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs9527	0.590	rs7067663	chr10:104883650	A/G	cg04362960	chr10:104952993	NT5C2	0.7	5.88	0.47	3.57e-8	Arsenic metabolism;
TGCT	cis	rs4478037	0.558	rs72854780	chr3:33072557	C/T	cg19404215	chr3:33155277	CRTAP	0.99	4.98	0.41	2.08e-6	Major depressive disorder;
TGCT	cis	rs514406	0.893	rs1242315	chr1:53417181	A/G	cg08736216	chr1:53307985	ZYG11A	-0.29	-5.9	-0.47	3.29e-8	Monocyte count;
TGCT	trans	rs3780486	0.505	rs10813958	chr9:33165985	A/G	cg20290983	chr6:43655470	MRPS18A	0.78	8.52	0.61	4.46e-14	IgG glycosylation;
TGCT	cis	rs4237845	0.780	rs3751331	chr12:58290278	G/A	cg23860436	chr12:58378763	NA	0.35	4.92	0.4	2.7e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7824557	0.510	rs4841524	chr8:11243126	C/G	cg21775007	chr8:11205619	TDH	-0.67	-6.58	-0.51	1.17e-9	Retinal vascular caliber;
TGCT	cis	rs7674212	0.570	rs2251634	chr4:104082349	C/T	cg16532752	chr4:104119610	CENPE	-0.61	-5.67	-0.45	9.45e-8	Type 2 diabetes;
TGCT	cis	rs9942416	0.660	rs34905687	chr5:74997736	A/G	cg02573091	chr5:74908125	NA	0.39	4.6	0.38	1.03e-5	Age-related disease endophenotypes;
TGCT	cis	rs17376456	0.569	rs10076965	chr5:93094972	G/A	cg25358565	chr5:93447407	FAM172A	0.74	6.42	0.5	2.66e-9	Diabetic retinopathy;
TGCT	cis	rs2997447	0.761	rs55960411	chr1:26437741	G/C	cg03844060	chr1:26490628	NA	0.28	4.55	0.38	1.27e-5	QRS complex (12-leadsum);
TGCT	cis	rs6693567	0.545	rs1566225	chr1:150415990	G/C	cg09579323	chr1:150459698	TARS2	0.52	4.62	0.38	9.56e-6	Migraine;
TGCT	cis	rs6582630	0.555	rs56228141	chr12:38518652	T/G	cg13010199	chr12:38710504	ALG10B	0.59	4.77	0.39	5.14e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs7655441	1.000	rs11098965	chr4:80888040	C/T	cg02241357	chr4:80885279	ANTXR2	-0.23	-4.52	-0.38	1.45e-5	Neutrophil percentage of white cells;
TGCT	cis	rs6840360	0.642	rs2709831	chr4:152379651	G/A	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.82e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs763014	0.966	rs4144003	chr16:645968	C/T	cg27436995	chr16:743998	FBXL16	-0.46	-4.97	-0.41	2.17e-6	Height;
TGCT	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg22920501	chr2:26401640	FAM59B	0.81	6.36	0.5	3.52e-9	Gut microbiome composition (summer);
TGCT	cis	rs2288073	1.000	rs2288073	chr2:24413298	C/T	cg02683114	chr2:24398427	C2orf84	0.26	5.98	0.47	2.2e-8	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg17971929	chr21:40555470	PSMG1	-0.51	-4.6	-0.38	1.02e-5	Menarche (age at onset);
TGCT	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.6	-6.31	-0.49	4.58e-9	Longevity;Endometriosis;
TGCT	cis	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg07424592	chr7:64974309	NA	1.35	7.66	0.57	4.49e-12	Diabetic kidney disease;
TGCT	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg05457628	chr5:178986728	RUFY1	-0.53	-6.09	-0.48	1.34e-8	Lung cancer;
TGCT	cis	rs59107033	0.607	rs56156664	chr3:123118720	T/C	cg04890266	chr3:123102914	ADCY5	-0.37	-5.12	-0.42	1.13e-6	Lymphocyte counts;
TGCT	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.46	0.56	1.3e-11	Prudent dietary pattern;
TGCT	cis	rs7586879	0.593	rs11689546	chr2:25130451	A/G	cg01884057	chr2:25150051	NA	0.35	6.87	0.53	2.76e-10	Body mass index;
TGCT	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.18	0.49	8.32e-9	Bipolar disorder;
TGCT	cis	rs7714584	1.000	rs4958848	chr5:150271122	G/C	cg22134413	chr5:150180641	NA	0.78	6.12	0.48	1.16e-8	Crohn's disease;
TGCT	cis	rs4727027	0.800	rs12530946	chr7:148887942	A/G	cg23583168	chr7:148888333	NA	-0.82	-11.32	-0.71	7.58e-21	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	trans	rs751984	0.636	rs11607904	chr11:61263029	A/C	cg03305746	chr2:106927199	NA	-0.58	-7.01	-0.53	1.32e-10	Diastolic blood pressure;Systolic blood pressure;Mean arterial pressure;
TGCT	cis	rs1008375	0.966	rs10939736	chr4:17581617	T/A	cg18681998	chr4:17616180	MED28	0.94	9.56	0.65	1.44e-16	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg00343986	chr7:65444356	GUSB	-0.23	-5.13	-0.42	1.07e-6	Aortic root size;
TGCT	cis	rs9393692	0.846	rs7771202	chr6:26279907	A/G	cg13736514	chr6:26305472	NA	-0.41	-5.77	-0.46	6.09e-8	Educational attainment;
TGCT	cis	rs1801251	0.963	rs66549961	chr2:233602293	A/G	cg08000102	chr2:233561755	GIGYF2	0.64	6.5	0.5	1.78e-9	Coronary artery disease;
TGCT	cis	rs5762813	0.524	rs5752815	chr22:29230733	C/A	cg02153584	chr22:29168773	CCDC117	0.78	5.31	0.43	4.91e-7	Hematocrit;Hemoglobin concentration;
TGCT	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.07	-9.63	-0.65	1.01e-16	Platelet count;
TGCT	cis	rs655029	0.714	rs649729	chr2:31464385	A/T	cg14018959	chr2:31480232	EHD3	0.32	4.51	0.38	1.5e-5	Mean platelet volume;Platelet distribution width;Platelet count;Plateletcrit;
TGCT	cis	rs6125597	0.904	rs2273146	chr20:47839653	C/T	cg11220565	chr20:47934802	NA	-0.3	-4.58	-0.38	1.13e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs116095464	0.558	rs12173015	chr5:269967	A/C	cg22857025	chr5:266934	NA	0.3	6.35	0.5	3.76e-9	Breast cancer;
TGCT	cis	rs1532993	0.518	rs9993179	chr4:98634314	A/G	cg05340658	chr4:99064831	C4orf37	0.41	4.94	0.41	2.49e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs9372498	0.536	rs9489394	chr6:118758234	T/C	cg21191810	chr6:118973309	C6orf204	-0.37	-4.77	-0.39	5.03e-6	Diastolic blood pressure;
TGCT	cis	rs1580019	0.961	rs2392056	chr7:32498953	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.81	7.66	0.57	4.58e-12	Cognitive ability;
TGCT	cis	rs67311347	1.000	rs6762251	chr3:40531136	A/G	cg13409248	chr3:40428643	ENTPD3	-0.61	-4.99	-0.41	2.01e-6	Renal cell carcinoma;
TGCT	cis	rs7120118	0.517	rs56825896	chr11:47326184	A/G	cg13308137	chr11:47528955	CUGBP1	0.33	5.19	0.42	8.26e-7	HDL cholesterol;
TGCT	trans	rs7248779	0.512	rs7250002	chr19:2413188	A/G	cg25835954	chr13:50160062	RCBTB1	0.76	6.88	0.53	2.6200000000000003e-10	Cortisol levels (saliva);
TGCT	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg06238570	chr21:40685208	BRWD1	-0.82	-8.78	-0.62	1.11e-14	Cognitive function;
TGCT	cis	rs9467773	0.620	rs2451738	chr6:26618459	A/T	cg05738196	chr6:26577821	NA	-0.83	-10.61	-0.69	4.07e-19	Intelligence (multi-trait analysis);
TGCT	trans	rs1814175	0.765	rs1722003	chr11:49895896	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.39	-7.59	-0.56	6.59e-12	Height;
TGCT	cis	rs6121246	0.567	rs6060262	chr20:30193071	A/C	cg18721089	chr20:30220636	NA	-0.57	-6.22	-0.49	6.83e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs763121	0.853	rs4821810	chr22:39072098	C/G	cg06022373	chr22:39101656	GTPBP1	0.8	8.25	0.6	1.95e-13	Menopause (age at onset);
TGCT	cis	rs7267979	0.727	rs2474765	chr20:25245950	G/T	cg03522245	chr20:25566470	NINL	0.52	5.4	0.44	3.22e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.68	-7.06	-0.54	1.03e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.72	-5.71	-0.46	7.86e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7439150	0.954	rs72679195	chr4:155473386	A/G	cg22130008	chr4:155548532	NA	-0.43	-5.38	-0.44	3.5e-7	Fibrinogen levels;
TGCT	cis	rs6121246	0.567	rs6087700	chr20:30217560	A/G	cg18721089	chr20:30220636	NA	-0.64	-6.86	-0.52	2.84e-10	Mean corpuscular hemoglobin;
TGCT	cis	rs904251	0.523	rs9366935	chr6:37480404	C/T	cg08126542	chr6:37504118	NA	-0.46	-6.46	-0.5	2.11e-9	Cognitive performance;
TGCT	cis	rs797680	0.822	rs7541304	chr1:93757838	T/A	cg17826107	chr1:92977322	EVI5	0.23	5.11	0.42	1.2e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs2997447	0.601	rs61776580	chr1:26432719	C/T	cg03844060	chr1:26490628	NA	0.28	4.56	0.38	1.19e-5	QRS complex (12-leadsum);
TGCT	cis	rs2120019	1.000	rs8036197	chr15:75370232	T/C	cg09165964	chr15:75287851	SCAMP5	-1.07	-8.58	-0.61	3.34e-14	Blood trace element (Zn levels);
TGCT	cis	rs9611519	0.780	rs5751072	chr22:41656509	C/T	cg03806693	chr22:41940476	POLR3H	-0.76	-7.37	-0.55	2.05e-11	Neuroticism;
TGCT	cis	rs3540	0.513	rs2589957	chr15:90903311	A/G	cg22089800	chr15:90895588	ZNF774	0.82	9.06	0.63	2.29e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs854765	0.547	rs2955372	chr17:17970229	T/C	cg04398451	chr17:18023971	MYO15A	0.34	5.46	0.44	2.48e-7	Total body bone mineral density;
TGCT	cis	rs2243480	1.000	rs313820	chr7:65574466	A/C	cg18252515	chr7:66147081	NA	-1.24	-8.13	-0.59	3.76e-13	Diabetic kidney disease;
TGCT	cis	rs61332075	0.531	rs11885695	chr2:239338632	G/A	cg18131467	chr2:239335373	ASB1	-0.84	-5.8	-0.46	5.07e-8	Lung function (FEV1/FVC);
TGCT	cis	rs3847687	1.000	rs3847687	chr12:131525053	C/T	cg25772418	chr12:131519998	GPR133	-0.33	-6.1	-0.48	1.26e-8	Longevity;
TGCT	cis	rs1008375	0.932	rs9291660	chr4:17663414	A/G	cg10189774	chr4:17578691	LAP3	0.53	4.62	0.38	9.31e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7100689	0.646	rs10736346	chr10:82134281	A/C	cg01528321	chr10:82214614	TSPAN14	0.8	7.72	0.57	3.42e-12	Post bronchodilator FEV1;
TGCT	cis	rs896854	0.517	rs896851	chr8:95950251	T/C	cg09323728	chr8:95962352	TP53INP1	-0.43	-4.9	-0.4	2.98e-6	Type 2 diabetes;
TGCT	cis	rs7582180	0.627	rs2241811	chr2:101011724	C/T	cg08017756	chr2:100939284	LONRF2	-0.31	-5.01	-0.41	1.86e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4294134	0.608	rs12707239	chr7:135247183	C/T	cg08396481	chr7:135194601	CNOT4	-0.58	-4.68	-0.39	7.53e-6	Paget's disease;
TGCT	cis	rs13256369	0.802	rs34762800	chr8:8559294	G/A	cg17143192	chr8:8559678	CLDN23	0.54	4.86	0.4	3.53e-6	Obesity-related traits;
TGCT	cis	rs12134245	0.747	rs35654098	chr1:92001452	T/A	cg07090678	chr1:91966139	CDC7	0.35	4.75	0.39	5.58e-6	Breast cancer;
TGCT	cis	rs4622507	0.773	rs62034614	chr16:55046548	A/G	cg04853843	chr16:55358461	IRX6	-0.57	-4.95	-0.41	2.4e-6	Social communication problems;
TGCT	cis	rs3733585	0.631	rs4697707	chr4:10119787	G/T	cg00071950	chr4:10020882	SLC2A9	-0.51	-5.28	-0.43	5.7e-7	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7647973	0.626	rs9824435	chr3:49674343	A/G	cg03034192	chr3:50606346	HEMK1;C3orf18	-0.39	-5.13	-0.42	1.1e-6	Menarche (age at onset);
TGCT	cis	rs7178572	0.633	rs12900004	chr15:77844904	A/G	cg22256960	chr15:77711686	NA	-0.82	-7.48	-0.56	1.19e-11	Type 2 diabetes;
TGCT	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.84	7.5	0.56	1.08e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs478304	0.651	rs11604451	chr11:65551710	C/T	cg27068330	chr11:65405492	SIPA1	-0.95	-9.42	-0.65	3.19e-16	Acne (severe);
TGCT	cis	rs8072100	0.934	rs8067286	chr17:45594590	A/G	cg08085267	chr17:45401833	C17orf57	0.48	5.3	0.43	5.03e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	8.39	0.6	9.03e-14	Platelet count;
TGCT	cis	rs6504663	1.000	rs6504661	chr17:48580126	A/T	cg03168497	chr17:48586147	MYCBPAP	-0.62	-7.07	-0.54	9.84e-11	Visceral fat;
TGCT	cis	rs2067615	0.524	rs1922436	chr12:107065258	A/G	cg15890332	chr12:107067104	RFX4	0.3	5.88	0.47	3.6e-8	Heart rate;
TGCT	cis	rs2204008	0.748	rs7312204	chr12:38334909	T/C	cg26384229	chr12:38710491	ALG10B	0.76	6.89	0.53	2.46e-10	Bladder cancer;
TGCT	cis	rs1008375	0.932	rs6449317	chr4:17631253	T/C	cg10189774	chr4:17578691	LAP3	0.6	5.08	0.42	1.33e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs17197710	0.673	rs41301449	chr11:47303821	C/T	cg13308137	chr11:47528955	CUGBP1	0.41	5.82	0.46	4.71e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs17374749	0.916	rs9855601	chr3:136768482	T/C	cg21827317	chr3:136751795	NA	-0.52	-7.56	-0.56	7.86e-12	Anxiety in major depressive disorder;
TGCT	cis	rs7681440	0.904	rs1372521	chr4:90765223	G/A	cg26578617	chr4:90757533	SNCA	-0.47	-4.87	-0.4	3.34e-6	Dementia with Lewy bodies;
TGCT	cis	rs793571	0.543	rs11854073	chr15:58972995	G/A	cg05156742	chr15:59063176	FAM63B	0.48	4.47	0.37	1.77e-5	Schizophrenia;
TGCT	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg23302884	chr18:44338147	ST8SIA5	0.39	4.55	0.38	1.28e-5	Personality dimensions;
TGCT	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg13206674	chr6:150067644	NUP43	0.53	4.65	0.39	8.3e-6	Lung cancer;
TGCT	cis	rs9926296	0.712	rs459920	chr16:89730827	T/C	cg03388025	chr16:89894329	SPIRE2	-0.36	-5.33	-0.43	4.49e-7	Vitiligo;
TGCT	cis	rs2580764	0.565	rs7562292	chr2:55230219	C/T	cg09592903	chr2:55203963	RTN4	-0.25	-5.45	-0.44	2.58e-7	Mean platelet volume;
TGCT	cis	rs9532580	0.620	rs2755210	chr13:41141282	C/G	cg21288729	chr13:41239152	FOXO1	0.92	7.73	0.57	3.14e-12	Mean corpuscular hemoglobin;
TGCT	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg24675658	chr1:53192096	ZYG11B	-0.7	-7.91	-0.58	1.22e-12	Monocyte count;
TGCT	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg04944784	chr2:26401820	FAM59B	-0.67	-5.98	-0.47	2.23e-8	Gut microbiome composition (summer);
TGCT	cis	rs2456568	0.900	rs2511399	chr11:93682156	C/T	cg14065697	chr11:93583672	C11orf90	0.37	4.62	0.38	9.53e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg14827481	chr10:134361889	INPP5A	0.31	5.03	0.41	1.71e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs66573146	0.831	rs66645969	chr4:6985614	G/A	cg05069807	chr4:6945702	TBC1D14	0.32	5.01	0.41	1.83e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs7647973	1.000	rs4241407	chr3:49600319	C/T	cg06212747	chr3:49208901	KLHDC8B	0.54	4.45	0.37	1.87e-5	Menarche (age at onset);
TGCT	cis	rs6752107	1.000	rs3792112	chr2:234176609	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.2	4.8	0.4	4.57e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs4478858	0.647	rs1007013	chr1:31710270	C/T	cg00250761	chr1:31883323	NA	-0.28	-4.92	-0.4	2.66e-6	Alcohol dependence;
TGCT	cis	rs3008870	1.000	rs2755256	chr1:67471692	A/T	cg03991309	chr1:68237761	GNG12	0.27	4.53	0.38	1.36e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs727563	0.636	rs2187795	chr22:42092225	C/A	cg13695892	chr22:41940480	POLR3H	0.89	8.6	0.61	2.92e-14	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs2629540	0.765	rs11245387	chr10:126537825	C/T	cg08799069	chr10:126477246	METTL10	-0.28	-4.6	-0.38	1.04e-5	Cocaine dependence;
TGCT	cis	rs12900413	0.562	rs28557101	chr15:90298149	C/T	cg24249390	chr15:90295951	MESP1	-0.29	-5.11	-0.42	1.19e-6	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs5760092	0.755	rs6003959	chr22:24264395	C/T	cg25703541	chr22:24373054	LOC391322	0.81	6.9	0.53	2.34e-10	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs910316	0.967	rs4899545	chr14:75568138	A/G	cg23033748	chr14:75592666	NEK9	0.27	4.57	0.38	1.16e-5	Height;
TGCT	cis	rs6964587	0.839	rs2049314	chr7:91464134	C/T	cg17063962	chr7:91808500	NA	0.81	8.39	0.6	9.37e-14	Breast cancer;
TGCT	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg07507251	chr3:52567010	NT5DC2	0.47	6.6	0.51	1.05e-9	Bipolar disorder;
TGCT	cis	rs9787249	0.957	rs12086750	chr1:40210468	G/C	cg20968010	chr1:40505947	CAP1	-0.53	-5.0	-0.41	1.91e-6	Blood protein levels;
TGCT	cis	rs61990749	0.597	rs2267758	chr14:78147429	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	-0.6	-4.45	-0.37	1.88e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs9611565	0.512	rs9607842	chr22:42192722	G/A	cg06634786	chr22:41940651	POLR3H	-0.84	-7.98	-0.58	8.5e-13	Vitiligo;
TGCT	cis	rs1059312	0.808	rs12831705	chr12:129294905	G/A	cg09035930	chr12:129282057	SLC15A4	0.55	10.73	0.69	2.06e-19	Systemic lupus erythematosus;
TGCT	cis	rs2834081	0.536	rs11702285	chr21:34474294	G/A	cg00274965	chr21:34405681	NA	0.49	4.51	0.38	1.5e-5	Sum eosinophil basophil counts;
TGCT	cis	rs2594989	0.943	rs2442769	chr3:11491086	A/G	cg26283222	chr3:11613257	VGLL4	0.22	4.48	0.37	1.68e-5	Circulating chemerin levels;
TGCT	cis	rs6089584	1.000	rs3787424	chr20:60559219	G/A	cg13770153	chr20:60521292	NA	-0.44	-5.62	-0.45	1.21e-7	Body mass index;
TGCT	cis	rs7666738	0.791	rs6840669	chr4:99016020	G/T	cg18180107	chr4:99064573	C4orf37	0.54	5.03	0.41	1.7e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11190604	1.000	rs4919471	chr10:102299239	A/G	cg16342193	chr10:102329863	NA	-0.44	-5.04	-0.41	1.58e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs28595532	0.920	rs116834347	chr4:119774155	C/A	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs1476679	0.830	rs6971558	chr7:100079857	A/T	cg13334819	chr7:99746414	C7orf59	0.56	4.53	0.38	1.35e-5	Alzheimer's disease (late onset);
TGCT	trans	rs7615952	0.800	rs12489350	chr3:125644116	T/C	cg07211511	chr3:129823064	LOC729375	-0.48	-7.98	-0.58	8.36e-13	Blood pressure (smoking interaction);
TGCT	cis	rs6121246	0.697	rs45557936	chr20:30226690	G/A	cg21427119	chr20:30132790	HM13	-0.37	-5.19	-0.42	8.51e-7	Mean corpuscular hemoglobin;
TGCT	cis	rs7000551	0.715	rs1530874	chr8:22347777	G/C	cg12081754	chr8:22256438	SLC39A14	0.28	4.69	0.39	7.11e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs6430585	0.583	rs4988163	chr2:136628121	G/T	cg07169764	chr2:136633963	MCM6	1.22	10.62	0.69	3.95e-19	Corneal structure;
TGCT	cis	rs28595532	1.000	rs114039398	chr4:119631627	T/C	cg14228332	chr4:119757509	SEC24D	1.02	5.37	0.43	3.75e-7	Cannabis dependence symptom count;
TGCT	cis	rs4906332	1.000	rs3783400	chr14:103967045	G/A	cg26031613	chr14:104095156	KLC1	-0.51	-4.51	-0.38	1.48e-5	Coronary artery disease;
TGCT	cis	rs12477438	0.765	rs4851183	chr2:99629149	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-4.62	-0.38	9.47e-6	Chronic sinus infection;
TGCT	cis	rs7192750	0.586	rs4788449	chr16:71931219	G/A	cg06353428	chr16:71660113	MARVELD3	0.8	7.2	0.54	5.05e-11	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg06212747	chr3:49208901	KLHDC8B	0.71	6.56	0.51	1.32e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs1008375	1.000	rs2159584	chr4:17620568	G/A	cg16339924	chr4:17578868	LAP3	0.63	5.13	0.42	1.07e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs5769707	0.568	rs2011097	chr22:50018069	A/G	cg06623630	chr22:50017776	C22orf34	-0.27	-4.64	-0.38	8.67e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs11098499	0.532	rs12512646	chr4:120585733	G/A	cg09307838	chr4:120376055	NA	0.59	5.6	0.45	1.31e-7	Corneal astigmatism;
TGCT	cis	rs10791097	0.694	rs2155750	chr11:130751261	A/C	cg14779329	chr11:130786720	SNX19	0.29	5.01	0.41	1.85e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs17221829	0.733	rs1844199	chr11:89376368	A/G	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.63	-0.38	9.04e-6	Anxiety in major depressive disorder;
TGCT	cis	rs896854	0.608	rs6991067	chr8:95875676	A/G	cg13393036	chr8:95962371	TP53INP1	-0.52	-6.58	-0.51	1.21e-9	Type 2 diabetes;
TGCT	cis	rs4851266	1.000	rs13013169	chr2:100814087	A/C	cg07810366	chr2:100720526	AFF3	-0.41	-5.79	-0.46	5.35e-8	Educational attainment;
TGCT	cis	rs9611565	0.729	rs203320	chr22:41913477	T/C	cg06481639	chr22:41940642	POLR3H	-0.57	-5.17	-0.42	9.14e-7	Vitiligo;
TGCT	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg11871910	chr12:69753446	YEATS4	0.89	10.53	0.69	6.39e-19	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs9653442	0.545	rs12987209	chr2:100761148	C/T	cg07810366	chr2:100720526	AFF3	-0.36	-5.31	-0.43	4.89e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs9650657	0.524	rs11787278	chr8:10492611	G/C	cg27411982	chr8:10470053	RP1L1	0.21	4.69	0.39	7.21e-6	Neuroticism;
TGCT	cis	rs7666738	0.830	rs34892904	chr4:98938097	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10193935	0.786	rs13399052	chr2:42385151	G/A	cg27598129	chr2:42591480	NA	-0.39	-5.14	-0.42	1.05e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6582630	0.513	rs1596446	chr12:38282160	C/T	cg26384229	chr12:38710491	ALG10B	-0.84	-7.33	-0.55	2.58e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs11719291	0.833	rs13074318	chr3:48816725	C/T	cg00383909	chr3:49044727	WDR6	1.3	6.72	0.52	5.98e-10	Cognitive function;
TGCT	cis	rs7666738	0.606	rs6839946	chr4:99076132	A/C	cg05340658	chr4:99064831	C4orf37	0.46	4.99	0.41	2.03e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10392	0.516	rs4141892	chr20:37590758	T/C	cg27552599	chr20:37590471	DHX35	0.38	4.79	0.39	4.77e-6	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
TGCT	cis	rs854765	0.575	rs2955357	chr17:17946401	T/C	cg09796270	chr17:17721594	SREBF1	-0.26	-5.17	-0.42	8.95e-7	Total body bone mineral density;
TGCT	cis	rs9303401	0.659	rs12944971	chr17:56988801	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.68	6.48	0.5	1.94e-9	Cognitive test performance;
TGCT	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg00814883	chr7:100076585	TSC22D4	-0.92	-9.76	-0.66	4.73e-17	Platelet count;
TGCT	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg11494091	chr17:61959527	GH2	0.6	14.54	0.79	1.46e-28	Prudent dietary pattern;
TGCT	cis	rs2120019	1.000	rs8036197	chr15:75370232	T/C	cg11632617	chr15:75315747	PPCDC	-0.33	-4.78	-0.39	4.82e-6	Blood trace element (Zn levels);
TGCT	cis	rs9467711	0.651	rs34043431	chr6:25875084	T/C	cg16898833	chr6:26189333	HIST1H4D	1.34	6.07	0.48	1.47e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2797160	1.000	rs1777194	chr6:126004883	G/A	cg05901451	chr6:126070800	HEY2	-0.74	-6.3	-0.49	4.62e-9	Endometrial cancer;
TGCT	cis	rs9527	0.590	rs7912517	chr10:104905529	G/A	cg15744005	chr10:104629667	AS3MT	-0.4	-4.63	-0.38	9.04e-6	Arsenic metabolism;
TGCT	cis	rs7927592	0.546	rs638076	chr11:68202580	A/G	cg16797656	chr11:68205561	LRP5	0.28	5.11	0.42	1.16e-6	Total body bone mineral density;
TGCT	cis	rs3892630	0.878	rs66788054	chr19:33190146	G/T	cg22980127	chr19:33182716	NUDT19	0.7	5.18	0.42	8.9e-7	Red blood cell traits;
TGCT	cis	rs12291225	0.679	rs4756786	chr11:14285900	C/A	cg19336497	chr11:14380999	RRAS2	-0.39	-6.09	-0.48	1.31e-8	Sense of smell;
TGCT	cis	rs1865760	0.534	rs2032444	chr6:26046744	T/G	cg16482183	chr6:26056742	HIST1H1C	0.68	5.61	0.45	1.24e-7	Height;
TGCT	cis	rs4455778	0.536	rs887451	chr7:48943352	T/C	cg26309511	chr7:48887640	NA	-0.46	-5.51	-0.44	1.98e-7	Lung cancer in never smokers;
TGCT	cis	rs7226408	0.857	rs56822468	chr18:34448917	C/T	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs7582180	0.629	rs12621892	chr2:100947124	G/C	cg08017756	chr2:100939284	LONRF2	-0.3	-4.87	-0.4	3.29e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.04	6.35	0.5	3.65e-9	Gut microbiome composition (summer);
TGCT	cis	rs7095607	1.000	rs12415303	chr10:69964141	C/T	cg18986048	chr10:69913749	MYPN	0.45	4.89	0.4	3.07e-6	Lung function (FVC);
TGCT	cis	rs3008870	1.000	rs1925411	chr1:67370292	C/T	cg11518657	chr1:67396239	MIER1	0.53	4.72	0.39	6.16e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs9467711	0.790	rs34107459	chr6:26328353	T/C	cg05948654	chr6:25930507	SLC17A2	0.36	4.68	0.39	7.48e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs826838	0.967	rs1719856	chr12:39127201	C/T	cg13010199	chr12:38710504	ALG10B	-0.63	-5.04	-0.41	1.6e-6	Heart rate;
TGCT	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg04944784	chr2:26401820	FAM59B	-0.68	-6.07	-0.48	1.45e-8	Gut microbiome composition (summer);
TGCT	cis	rs9911578	1.000	rs11079365	chr17:56945430	T/C	cg12560992	chr17:57184187	TRIM37	0.76	9.21	0.64	1.03e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg13770153	chr20:60521292	NA	0.52	6.68	0.51	7.32e-10	Body mass index;
TGCT	cis	rs250677	0.652	rs168751	chr5:148438264	C/T	cg18129178	chr5:148520854	ABLIM3	-0.42	-5.74	-0.46	6.77e-8	Breast cancer;
TGCT	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg13257436	chr8:145726034	PPP1R16A	0.34	5.47	0.44	2.43e-7	Age at first birth;
TGCT	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.31	0.43	4.9e-7	Prudent dietary pattern;
TGCT	cis	rs9486715	0.867	rs1127175	chr6:96999725	C/T	cg18709589	chr6:96969512	KIAA0776	-0.8	-7.35	-0.55	2.35e-11	Headache;
TGCT	cis	rs7666738	0.830	rs1120708	chr4:98931260	G/C	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11874712	0.899	rs11872954	chr18:43686450	A/G	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	5.15	0.42	1.01e-6	Migraine - clinic-based;
TGCT	cis	rs12681287	0.927	rs7003059	chr8:87330713	C/T	cg27223183	chr8:87520930	FAM82B	-0.88	-6.82	-0.52	3.62e-10	Caudate activity during reward;
TGCT	cis	rs933688	1.000	rs10474353	chr5:90732285	A/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.08	9.6	0.65	1.2e-16	Smoking behavior;
TGCT	cis	rs7772486	0.875	rs969694	chr6:146394655	A/G	cg05347473	chr6:146136440	FBXO30	0.53	4.97	0.41	2.21e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg06873352	chr17:61820015	STRADA	0.56	6.22	0.49	7.1e-9	Prudent dietary pattern;
TGCT	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg13342137	chr4:2252803	MXD4	0.17	4.47	0.37	1.71e-5	Obesity-related traits;
TGCT	cis	rs265548	0.646	rs36689	chr19:17910639	A/G	cg16744531	chr19:17905626	B3GNT3	0.42	5.34	0.43	4.26e-7	Tumor biomarkers;
TGCT	cis	rs2439831	0.764	rs12324584	chr15:43683446	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	6.11	0.48	1.19e-8	Lung cancer in ever smokers;
TGCT	cis	rs921968	0.643	rs832799	chr2:219490111	C/A	cg02176678	chr2:219576539	TTLL4	0.43	6.11	0.48	1.19e-8	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs13217239	0.646	rs7747454	chr6:27034253	T/G	cg06035815	chr6:26189597	HIST1H4D	0.44	4.53	0.38	1.39e-5	Schizophrenia;
TGCT	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg03806693	chr22:41940476	POLR3H	1.14	12.91	0.76	1.07e-24	Vitiligo;
TGCT	cis	rs7809950	1.000	rs2712189	chr7:107195747	G/A	cg23024343	chr7:107201750	COG5	-0.34	-5.16	-0.42	9.35e-7	Coronary artery disease;
TGCT	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg22920501	chr2:26401640	FAM59B	-0.74	-6.4	-0.5	2.86e-9	Gut microbiome composition (summer);
TGCT	cis	rs17030434	0.784	rs72617459	chr4:154661686	T/C	cg14289246	chr4:154710475	SFRP2	-0.85	-7.27	-0.55	3.6e-11	Electrocardiographic conduction measures;
TGCT	cis	rs2440129	0.591	rs312466	chr17:6899221	G/A	cg21237687	chr17:6899380	ALOX12	-0.52	-5.88	-0.47	3.54e-8	Tonsillectomy;
TGCT	trans	rs1814175	0.650	rs6486000	chr11:49659090	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.43	-10.19	-0.68	4.28e-18	Height;
TGCT	cis	rs6089829	0.962	rs6089825	chr20:61668447	C/T	cg08045932	chr20:61659980	NA	0.48	9.01	0.63	3.09e-15	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7095607	0.560	rs2673794	chr10:69926097	T/C	cg18986048	chr10:69913749	MYPN	0.54	5.83	0.46	4.48e-8	Lung function (FVC);
TGCT	trans	rs7819412	0.806	rs2409689	chr8:10932868	A/G	cg15556689	chr8:8085844	FLJ10661	-0.84	-8.16	-0.59	3.19e-13	Triglycerides;
TGCT	trans	rs1496653	0.602	rs13060251	chr3:23337221	A/G	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs28595532	0.920	rs115994609	chr4:119777273	G/A	cg11846333	chr4:119757529	SEC24D	0.92	4.64	0.38	8.74e-6	Cannabis dependence symptom count;
TGCT	cis	rs7666738	0.830	rs62318504	chr4:98935558	T/G	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs751728	0.931	rs2296746	chr6:33744711	C/T	cg00334056	chr6:33755658	LEMD2	-0.25	-4.59	-0.38	1.08e-5	Crohn's disease;
TGCT	cis	rs265548	0.586	rs265542	chr19:17904388	T/G	cg21960279	chr19:17905606	B3GNT3	0.49	5.48	0.44	2.3e-7	Tumor biomarkers;
TGCT	cis	rs9611565	0.921	rs761366	chr22:41744022	C/G	cg06634786	chr22:41940651	POLR3H	-0.7	-6.54	-0.51	1.42e-9	Vitiligo;
TGCT	cis	rs910316	0.967	rs4384542	chr14:75658013	A/C	cg08847533	chr14:75593920	NEK9	-0.94	-10.1	-0.67	7.14e-18	Height;
TGCT	cis	rs735396	0.731	rs1182933	chr12:121454622	C/T	cg02403541	chr12:121454288	C12orf43	0.77	7.58	0.56	6.97e-12	N-glycan levels;
TGCT	cis	rs7267979	1.000	rs2297497	chr20:25297909	C/T	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9467603	1.000	rs9467609	chr6:25809751	A/G	cg16898833	chr6:26189333	HIST1H4D	1.16	5.51	0.44	2.03e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg11871910	chr12:69753446	YEATS4	0.88	10.41	0.68	1.28e-18	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs9467773	1.000	rs9393729	chr6:26514166	C/T	cg09904177	chr6:26538194	HMGN4	0.65	6.53	0.51	1.53e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg17971929	chr21:40555470	PSMG1	0.98	9.67	0.66	8.18e-17	Cognitive function;
TGCT	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg23719950	chr11:63933701	MACROD1	-0.71	-5.87	-0.47	3.72e-8	Mean platelet volume;
TGCT	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.82	7.31	0.55	2.82e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg08975724	chr8:8085496	FLJ10661	0.66	5.99	0.47	2.09e-8	Neuroticism;
TGCT	cis	rs2675662	0.525	rs12264025	chr10:75494450	A/G	cg04320760	chr10:75533139	FUT11	-0.4	-6.25	-0.49	6.11e-9	Psoriasis vulgaris;Psoriasis;
TGCT	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg00080972	chr5:178986291	RUFY1	0.47	5.51	0.44	2.02e-7	Lung cancer;
TGCT	trans	rs941408	1.000	rs2260416	chr19:2796355	G/A	cg19676328	chr12:49525230	TUBA1B	-0.74	-7.15	-0.54	6.67e-11	Total cholesterol levels;
TGCT	cis	rs3820068	0.581	rs58567918	chr1:15925823	A/G	cg05660106	chr1:15850417	CASP9	0.76	7.33	0.55	2.56e-11	Systolic blood pressure;
TGCT	cis	rs1421811	0.606	rs981001	chr5:32721545	G/A	cg16267343	chr5:32710456	NPR3	0.82	6.98	0.53	1.61e-10	Blood pressure;
TGCT	cis	rs10411936	0.924	rs8110761	chr19:16501005	A/G	cg19006008	chr19:16999768	F2RL3	0.27	4.84	0.4	3.85e-6	White blood cell count;Multiple sclerosis;
TGCT	cis	rs950880	0.560	rs1558622	chr2:102930147	G/A	cg09003973	chr2:102972529	NA	-0.51	-4.49	-0.37	1.59e-5	Serum protein levels (sST2);
TGCT	cis	rs9291683	0.609	rs3796836	chr4:10011345	A/G	cg11266682	chr4:10021025	SLC2A9	0.69	9.99	0.67	1.34e-17	Bone mineral density;
TGCT	cis	rs8056742	0.730	rs11644038	chr16:85097945	T/G	cg00229868	chr16:85520891	NA	0.38	4.77	0.39	5.03e-6	Amyotrophic lateral sclerosis;
TGCT	cis	rs9393777	0.513	rs61240102	chr6:27124904	G/C	cg16898833	chr6:26189333	HIST1H4D	0.74	4.48	0.37	1.71e-5	Intelligence (multi-trait analysis);
TGCT	trans	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg17952111	chr19:54960355	LENG8	-0.81	-6.68	-0.51	7.14e-10	Lung disease severity in cystic fibrosis;
TGCT	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	4.93	0.4	2.6e-6	Menopause (age at onset);
TGCT	cis	rs7666738	0.785	rs11097614	chr4:99092175	G/C	cg17366294	chr4:99064904	C4orf37	0.71	5.48	0.44	2.27e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1971762	0.762	rs7976793	chr12:54073069	G/T	cg16917193	chr12:54089295	NA	0.6	4.81	0.4	4.22e-6	Height;
TGCT	cis	rs208520	0.690	rs12202913	chr6:66734198	C/T	cg07460842	chr6:66804631	NA	0.95	10.11	0.67	6.77e-18	Exhaled nitric oxide output;
TGCT	cis	rs7216064	0.906	rs8074644	chr17:65878217	G/C	cg12091567	chr17:66097778	LOC651250	-0.87	-6.85	-0.52	3.1e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs7439150	1.000	rs72681211	chr4:155479261	T/A	cg22130008	chr4:155548532	NA	-0.44	-5.59	-0.45	1.36e-7	Fibrinogen levels;
TGCT	cis	rs6901250	0.655	rs636252	chr6:117157774	A/G	cg12892004	chr6:117198278	RFX6	-0.41	-5.11	-0.42	1.2e-6	C-reactive protein levels;
TGCT	cis	rs7267979	1.000	rs3002702	chr20:25268920	T/C	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11971779	0.680	rs4077889	chr7:139033914	A/G	cg07862535	chr7:139043722	LUC7L2	0.56	4.46	0.37	1.82e-5	Diisocyanate-induced asthma;
TGCT	cis	rs12510870	0.599	rs28612539	chr4:74450728	A/G	cg05868023	chr4:75230803	EREG	-0.54	-4.76	-0.39	5.33e-6	Iris color (b* coordinate);
TGCT	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg03303774	chr4:1407052	NA	0.34	5.43	0.44	2.91e-7	Obesity-related traits;
TGCT	cis	rs10858047	0.941	rs116185978	chr1:115118982	C/T	cg12756093	chr1:115239321	AMPD1	0.47	4.96	0.41	2.27e-6	Autism;
TGCT	cis	rs1838472	0.607	rs9880957	chr3:123979651	C/T	cg19008133	chr3:123124015	ADCY5	0.18	4.58	0.38	1.12e-5	Schizophrenia;
TGCT	cis	rs7666738	0.830	rs4699597	chr4:99019031	G/A	cg18180107	chr4:99064573	C4orf37	0.54	5.03	0.41	1.7e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2797780	1.000	rs2797780	chr6:37506415	T/C	cg00985040	chr6:37553208	NA	0.24	4.77	0.39	5.04e-6	Systemic lupus erythematosus;
TGCT	cis	rs7399018	0.643	rs6580810	chr12:51610478	C/T	cg25754956	chr12:51612065	POU6F1	0.94	8.81	0.62	9.47e-15	Cisplatin-induced ototoxicity;
TGCT	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg11764359	chr7:65958608	NA	0.58	5.49	0.44	2.2e-7	Aortic root size;
TGCT	trans	rs2727020	0.729	rs2299650	chr11:49174007	A/C	cg03929089	chr4:120376271	NA	-0.7	-8.1	-0.59	4.3e-13	Coronary artery disease;
TGCT	cis	rs7267979	0.844	rs2257649	chr20:25263457	T/G	cg14121845	chr20:25566513	NINL	0.45	4.6	0.38	1.02e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2115536	0.967	rs934137	chr15:80211768	T/C	cg00225070	chr15:80189496	MTHFS	0.58	5.01	0.41	1.8e-6	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs968567	0.539	rs174556	chr11:61580635	C/T	cg19610905	chr11:61596333	FADS2	-1.05	-11.51	-0.72	2.6e-21	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
TGCT	cis	rs12497850	0.931	rs3774628	chr3:48801840	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.41	-5.52	-0.44	1.89e-7	Parkinson's disease;
TGCT	cis	rs6674176	0.628	rs3791119	chr1:44431362	C/G	cg12908607	chr1:44402522	ARTN	-0.67	-8.15	-0.59	3.4e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs453301	0.522	rs1964356	chr8:8853270	G/T	cg15556689	chr8:8085844	FLJ10661	0.69	6.25	0.49	6.13e-9	Joint mobility (Beighton score);
TGCT	cis	rs10501293	1.000	rs10768913	chr11:43060750	T/C	cg03447554	chr11:43094025	NA	0.46	6.64	0.51	8.85e-10	Cognitive performance;
TGCT	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg25036284	chr2:26402008	FAM59B	0.54	4.7	0.39	6.93e-6	Gut microbiome composition (summer);
TGCT	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg02953382	chr22:24373134	LOC391322	-0.78	-8.09	-0.59	4.76e-13	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs12935418	0.616	rs7184568	chr16:80964848	G/C	cg07676361	chr16:80966860	NA	-0.36	-4.73	-0.39	6.04e-6	Mean corpuscular volume;
TGCT	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.97	-8.51	-0.61	4.86e-14	Platelet count;
TGCT	cis	rs4478037	0.558	rs72854778	chr3:33071945	G/T	cg19404215	chr3:33155277	CRTAP	1.05	5.04	0.41	1.58e-6	Major depressive disorder;
TGCT	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg08439880	chr3:133502540	NA	-0.34	-6.61	-0.51	1e-9	Iron status biomarkers;
TGCT	cis	rs346785	0.610	rs347674	chr17:74278548	C/G	cg09812376	chr17:74270190	QRICH2	-0.48	-7.35	-0.55	2.35e-11	White matter hyperintensities in ischemic stroke;
TGCT	cis	rs4689388	0.890	rs13130845	chr4:6297646	A/C	cg25554036	chr4:6271136	WFS1	0.54	7.32	0.55	2.66e-11	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs1401999	0.606	rs7644687	chr3:183753353	A/G	cg20387954	chr3:183756860	HTR3D	0.22	4.67	0.39	7.69e-6	Anterior chamber depth;
TGCT	cis	rs6087771	0.651	rs6060775	chr20:30286191	A/G	cg13852791	chr20:30311386	BCL2L1	0.54	4.74	0.39	5.76e-6	Subcortical brain region volumes;Putamen volume;
TGCT	cis	rs11105298	0.891	rs10506972	chr12:89861529	T/C	cg00757033	chr12:89920650	WDR51B	0.34	5.37	0.43	3.75e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg02380750	chr20:61661411	NA	0.33	5.96	0.47	2.4e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs10411936	0.962	rs2607278	chr19:16568197	C/T	cg14704714	chr19:15740395	CYP4F8	-0.27	-4.7	-0.39	6.86e-6	White blood cell count;Multiple sclerosis;
TGCT	cis	rs12479064	0.724	rs62153852	chr2:99934713	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-6.37	-0.5	3.43e-9	Chronic sinus infection;
TGCT	cis	rs708686	0.553	rs778805	chr19:5832209	G/A	cg25387410	chr19:5844109	FUT3	-0.19	-4.44	-0.37	1.99e-5	Vitamin B12 levels;
TGCT	cis	rs6570726	0.791	rs9373466	chr6:145912016	T/C	cg13319975	chr6:146136371	FBXO30	-0.52	-4.68	-0.39	7.45e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg02487422	chr3:49467188	NICN1	0.55	5.32	0.43	4.77e-7	Menarche (age at onset);
TGCT	cis	rs9611565	0.592	rs28750375	chr22:41990644	A/C	cg13695892	chr22:41940480	POLR3H	-0.83	-7.82	-0.57	1.94e-12	Vitiligo;
TGCT	trans	rs57221529	0.766	rs72703026	chr5:572383	G/A	cg11887960	chr12:57824829	NA	1.13	9.15	0.63	1.44e-15	Lung disease severity in cystic fibrosis;
TGCT	cis	rs6089584	0.586	rs1079755	chr20:60615262	G/A	cg13770153	chr20:60521292	NA	-0.41	-5.09	-0.42	1.28e-6	Body mass index;
TGCT	cis	rs611744	0.967	rs702801	chr8:109211802	T/C	cg21045802	chr8:109455806	TTC35	0.52	4.72	0.39	6.21e-6	Dupuytren's disease;
TGCT	cis	rs2153535	0.580	rs9393033	chr6:8521446	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.55e-8	Motion sickness;
TGCT	cis	rs3020333	1.000	rs3020333	chr6:152010254	A/G	cg22157087	chr6:152012887	ESR1	0.19	4.64	0.38	8.67e-6	Total body bone mineral density;
TGCT	cis	rs858239	0.632	rs13438452	chr7:23174182	A/G	cg05602783	chr7:23145260	KLHL7	-0.63	-5.28	-0.43	5.64e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs1729951	0.546	rs835632	chr3:136676525	A/T	cg21827317	chr3:136751795	NA	0.4	5.61	0.45	1.28e-7	Neuroticism;
TGCT	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg03388025	chr16:89894329	SPIRE2	0.49	8.27	0.6	1.71e-13	Vitiligo;
TGCT	cis	rs7590720	1.000	rs4674048	chr2:216900023	G/A	cg12620499	chr2:216877984	MREG	0.89	9.07	0.63	2.27e-15	Alcohol dependence;
TGCT	cis	rs3770752	0.654	rs3770754	chr2:37575381	C/G	cg20091297	chr2:37572423	QPCT	-0.36	-4.46	-0.37	1.82e-5	Schizophrenia;
TGCT	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg05025164	chr4:1340916	KIAA1530	0.78	6.44	0.5	2.36e-9	Longevity;
TGCT	cis	rs7731657	0.509	rs2250348	chr5:130243531	T/A	cg08523029	chr5:130500466	HINT1	-0.58	-4.84	-0.4	3.8e-6	Fasting plasma glucose;
TGCT	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	7.43	0.55	1.56e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs1538970	0.962	rs9429077	chr1:45820667	C/A	cg05343316	chr1:45956843	TESK2	0.64	5.06	0.41	1.47e-6	Platelet count;
TGCT	cis	rs6430585	0.528	rs614193	chr2:136653925	A/T	cg07169764	chr2:136633963	MCM6	1.17	10.98	0.7	5.18e-20	Corneal structure;
TGCT	cis	rs12142240	0.698	rs72677592	chr1:46818288	A/G	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs7267979	0.789	rs62213729	chr20:25363426	C/T	cg16686733	chr20:25566563	NINL	-0.49	-4.62	-0.38	9.44e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6961102	0.548	rs2402968	chr7:129321647	T/C	cg02041484	chr7:129266958	NRF1	-0.28	-5.1	-0.42	1.26e-6	Platelet distribution width;
TGCT	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg18876405	chr7:65276391	NA	0.35	5.66	0.45	1.01e-7	Calcium levels;
TGCT	cis	rs425277	1.000	rs262676	chr1:2078482	T/A	cg24578937	chr1:2090814	PRKCZ	0.32	8.03	0.58	6.41e-13	Height;
TGCT	cis	rs4253772	0.515	rs7287164	chr22:46781008	T/C	cg26008785	chr22:46428396	NA	0.43	4.44	0.37	1.99e-5	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs3885907	0.542	rs4147064	chr13:31320118	A/G	cg22282089	chr13:30686841	NA	-0.22	-4.55	-0.38	1.25e-5	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU);
TGCT	cis	rs9400467	0.506	rs12196873	chr6:111598058	G/T	cg15721981	chr6:111408429	SLC16A10	-0.68	-4.45	-0.37	1.92e-5	Blood metabolite levels;Amino acid levels;
TGCT	cis	rs4851254	0.920	rs11686599	chr2:100753475	A/G	cg23118464	chr2:100721844	AFF3	0.74	5.52	0.44	1.86e-7	Intelligence (multi-trait analysis);
TGCT	trans	rs17685	0.816	rs11763076	chr7:75765963	C/T	cg19862616	chr7:65841803	NCRNA00174	0.52	9.01	0.63	3.02e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs9300255	0.699	rs11057204	chr12:123725827	T/C	cg00376283	chr12:123451042	ABCB9	0.72	5.52	0.44	1.88e-7	Neutrophil percentage of white cells;
TGCT	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg09359103	chr1:154839909	KCNN3	-0.62	-11.25	-0.71	1.15e-20	Prostate cancer;
TGCT	cis	rs514406	0.536	rs878957	chr1:53197559	C/T	cg24675658	chr1:53192096	ZYG11B	0.94	13.04	0.76	5.2e-25	Monocyte count;
TGCT	cis	rs908922	0.584	rs71626721	chr1:152532745	A/G	cg20991723	chr1:152506922	NA	0.44	5.89	0.47	3.34e-8	Hair morphology;
TGCT	cis	rs7772486	0.790	rs1062067	chr6:146207563	A/G	cg05347473	chr6:146136440	FBXO30	0.52	5.0	0.41	1.87e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg06221963	chr1:154839813	KCNN3	-0.79	-15.15	-0.81	5.4e-30	Prostate cancer;
TGCT	cis	rs6460942	0.687	rs74753576	chr7:12463926	G/A	cg06484146	chr7:12443880	VWDE	-0.53	-5.59	-0.45	1.36e-7	Coronary artery disease;
TGCT	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg17054783	chr10:134559939	INPP5A	0.26	5.0	0.41	1.94e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	trans	rs11088226	0.598	rs79634586	chr21:33959363	A/G	cg09050820	chr6:167586206	TCP10L2	0.76	7.31	0.55	2.88e-11	Gastritis;
TGCT	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg19723775	chr5:179050963	HNRNPH1	-0.52	-5.2	-0.42	8.05e-7	Lung cancer;
TGCT	cis	rs7267979	1.000	rs1046073	chr20:25281333	G/A	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3091242	0.900	rs4649086	chr1:25778967	T/A	cg23205692	chr1:25664452	TMEM50A	0.47	4.97	0.41	2.22e-6	Erythrocyte sedimentation rate;
TGCT	cis	rs6988636	1.000	rs17323510	chr8:124186089	A/G	cg27053337	chr8:124217698	FAM83A	-0.58	-4.82	-0.4	4.13e-6	Urinary uromodulin levels;
TGCT	cis	rs873917	0.577	rs784611	chr1:40125988	T/A	cg18438793	chr1:40149837	HPCAL4	0.53	4.72	0.39	6.17e-6	Amyotrophic lateral sclerosis;
TGCT	cis	rs2290416	0.688	rs62522171	chr8:144690832	C/A	cg17524265	chr8:144659883	NAPRT1	0.71	5.5	0.44	2.05e-7	Attention deficit hyperactivity disorder;
TGCT	cis	rs12541335	0.639	rs3923433	chr8:22169798	A/T	cg07298985	chr8:22133076	PIWIL2	0.33	5.32	0.43	4.73e-7	Hypertriglyceridemia;
TGCT	cis	rs13256369	1.000	rs9329166	chr8:8576655	C/T	cg06671706	chr8:8559999	CLDN23	0.34	4.83	0.4	3.92e-6	Obesity-related traits;
TGCT	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.8	6.47	0.5	2.06e-9	Mean platelet volume;
TGCT	cis	rs367943	1.000	rs348948	chr5:112822452	A/C	cg12552261	chr5:112820674	MCC	-0.24	-4.91	-0.4	2.81e-6	Type 2 diabetes;
TGCT	trans	rs1496653	0.602	rs34134134	chr3:23441604	A/G	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs1691799	0.899	rs1168310	chr12:66726355	A/G	cg16791601	chr12:66731901	HELB	0.28	5.96	0.47	2.39e-8	White blood cell count (basophil);
TGCT	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg08280861	chr8:58055591	NA	0.53	5.96	0.47	2.44e-8	Developmental language disorder (linguistic errors);
TGCT	cis	rs1577917	0.876	rs1582127	chr6:86697204	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.19	-0.42	8.51e-7	Response to antipsychotic treatment;
TGCT	cis	rs5769765	0.740	rs2103932	chr22:50272515	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	1.11	11.76	0.73	6.5e-22	Schizophrenia;
TGCT	cis	rs7027203	0.576	rs7848045	chr9:96551824	G/A	cg13679303	chr9:96623674	NA	0.53	7.66	0.57	4.68e-12	DNA methylation (variation);
TGCT	cis	rs7523273	0.526	rs12132176	chr1:207884287	A/T	cg22525895	chr1:207977042	MIR29B2	0.35	5.73	0.46	7.22e-8	Schizophrenia;
TGCT	cis	rs6430585	0.528	rs309159	chr2:136684940	C/T	cg07169764	chr2:136633963	MCM6	1.18	11.35	0.71	6.37e-21	Corneal structure;
TGCT	cis	rs4563143	0.675	rs56407818	chr19:29279379	G/A	cg04546413	chr19:29218101	NA	0.86	7.0	0.53	1.45e-10	Methadone dose in opioid dependence;
TGCT	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg00149659	chr3:10157352	C3orf10	0.96	6.1	0.48	1.26e-8	Alzheimer's disease;
TGCT	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg03303774	chr4:1407052	NA	0.28	4.64	0.38	8.56e-6	Obesity-related traits;
TGCT	cis	rs796364	0.806	rs11688168	chr2:200916004	G/A	cg17644776	chr2:200775616	C2orf69	-0.33	-5.0	-0.41	1.91e-6	Schizophrenia;
TGCT	trans	rs797680	0.789	rs531514	chr1:93700212	C/T	cg27528825	chr2:159282178	CCDC148	0.35	6.88	0.53	2.65e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs1048238	0.506	rs848212	chr1:16263452	A/G	cg22431228	chr1:16359049	CLCNKA	0.23	4.49	0.37	1.61e-5	Systolic blood pressure;
TGCT	cis	rs10051787	0.754	rs890928	chr5:122696367	A/C	cg15125798	chr5:122621645	NA	-0.55	-5.01	-0.41	1.84e-6	Waist circumference;
TGCT	cis	rs9457247	1.000	rs389956	chr6:167407254	T/G	cg23791538	chr6:167370224	RNASET2	-0.49	-4.96	-0.41	2.26e-6	Crohn's disease;
TGCT	cis	rs2354432	0.607	rs1530336	chr1:146685121	G/A	cg25205988	chr1:146714368	CHD1L	1.33	6.31	0.49	4.44e-9	Mitochondrial DNA levels;
TGCT	cis	rs56339712	0.802	rs11265838	chr9:92029453	T/G	ch.9.1233470F	chr9:91626629	NA	0.25	4.74	0.39	5.82e-6	Reticulocyte fraction of red cells;Reticulocyte count;
TGCT	cis	rs11190604	1.000	rs7099965	chr10:102301165	A/G	cg23241863	chr10:102295624	HIF1AN	0.69	5.1	0.42	1.26e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs12134133	0.962	rs11120512	chr1:207413715	C/G	cg02152968	chr1:207494213	CD55	-0.6	-4.67	-0.39	7.74e-6	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg11644478	chr21:40555479	PSMG1	-0.55	-4.77	-0.39	5.12e-6	Cognitive function;
TGCT	cis	rs12530134	0.519	rs3920484	chr6:170746081	A/G	cg18217622	chr6:170732253	NA	0.72	4.58	0.38	1.1e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg27425262	chr2:113953981	PSD4;LOC440839	0.46	6.66	0.51	7.82e-10	Lymphocyte counts;
TGCT	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.62	5.25	0.43	6.3e-7	Tonsillectomy;
TGCT	cis	rs2239547	0.563	rs4302374	chr3:52905802	T/C	cg11645453	chr3:52864694	ITIH4	0.34	5.72	0.46	7.68e-8	Schizophrenia;
TGCT	cis	rs6752107	0.967	rs11694081	chr2:234148586	A/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.2	4.91	0.4	2.8e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs11648796	0.765	rs61112891	chr16:783156	G/C	cg27144592	chr16:783916	NARFL	0.46	6.19	0.49	8.14e-9	Height;
TGCT	cis	rs7208859	0.573	rs28779471	chr17:29084369	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs6693567	0.565	rs1260408	chr1:150307270	T/G	cg09579323	chr1:150459698	TARS2	0.54	4.79	0.4	4.59e-6	Migraine;
TGCT	cis	rs1023500	0.596	rs133350	chr22:42429049	A/G	cg15557168	chr22:42548783	NA	-0.19	-4.91	-0.4	2.78e-6	Schizophrenia;
TGCT	cis	rs17030434	0.728	rs16998891	chr4:154646419	T/G	cg14289246	chr4:154710475	SFRP2	-0.81	-6.12	-0.48	1.14e-8	Electrocardiographic conduction measures;
TGCT	cis	rs1153858	1.000	rs61365925	chr15:45650311	T/C	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.62e-8	Homoarginine levels;
TGCT	cis	rs4919669	0.843	rs11191379	chr10:104482330	C/T	cg05855489	chr10:104503620	C10orf26	0.71	4.5	0.37	1.57e-5	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs9393777	0.513	rs13195210	chr6:26646521	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.63	-5.75	-0.46	6.58e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg18402987	chr7:1209562	NA	0.64	5.2	0.42	8.07e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs911555	0.570	rs11625397	chr14:104027557	A/G	cg26031613	chr14:104095156	KLC1	-0.57	-5.42	-0.44	3e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7618915	0.547	rs11719685	chr3:52676065	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	5.84	0.46	4.38e-8	Bipolar disorder;
TGCT	cis	rs68170813	0.559	rs7803290	chr7:106907353	T/C	cg02696742	chr7:106810147	HBP1	-0.69	-5.61	-0.45	1.27e-7	Coronary artery disease;
TGCT	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	5.26	0.43	6.08e-7	Menopause (age at onset);
TGCT	cis	rs644799	0.932	rs480079	chr11:95643777	A/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.69	-7.64	-0.57	5.09e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs644799	0.965	rs607039	chr11:95547086	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	8.74	0.62	1.39e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7666738	0.791	rs2903151	chr4:99027218	T/C	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.8	-7.22	-0.54	4.49e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2239547	0.522	rs2564947	chr3:53046216	C/T	cg11645453	chr3:52864694	ITIH4	-0.34	-5.7	-0.46	8.3e-8	Schizophrenia;
TGCT	cis	rs9527	0.641	rs4919684	chr10:104587024	A/G	cg15744005	chr10:104629667	AS3MT	-0.48	-5.82	-0.46	4.72e-8	Arsenic metabolism;
TGCT	cis	rs6582630	0.538	rs12304844	chr12:38335870	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-4.51	-0.38	1.5e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	5.74	0.46	6.73e-8	Alzheimer's disease;
TGCT	cis	rs9368481	0.761	rs7775041	chr6:27009512	T/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.51	-5.56	-0.45	1.61e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs11785400	0.731	rs4294163	chr8:143730830	G/T	cg10596483	chr8:143751796	JRK	0.53	5.21	0.42	7.5e-7	Schizophrenia;
TGCT	cis	rs919433	0.679	rs6741314	chr2:198526088	G/A	cg00792783	chr2:198669748	PLCL1	0.55	4.88	0.4	3.24e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs3858526	1.000	rs11039787	chr11:5965611	C/T	cg13902645	chr11:5959945	NA	-0.42	-4.6	-0.38	1.02e-5	DNA methylation (variation);
TGCT	cis	rs826838	1.000	rs11183941	chr12:38851692	G/C	cg13010199	chr12:38710504	ALG10B	0.82	6.85	0.52	3e-10	Heart rate;
TGCT	cis	rs4455778	0.659	rs2058267	chr7:49015951	C/T	cg26309511	chr7:48887640	NA	0.43	5.07	0.41	1.4e-6	Lung cancer in never smokers;
TGCT	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg21862992	chr11:68658383	NA	0.44	6.12	0.48	1.14e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs17376456	0.877	rs66696214	chr5:93424533	G/A	cg21475434	chr5:93447410	FAM172A	0.6	4.62	0.38	9.48e-6	Diabetic retinopathy;
TGCT	cis	rs2692947	0.589	rs810057	chr2:97015073	T/C	cg22654517	chr2:96458247	NA	0.22	5.01	0.41	1.87e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs67311347	0.955	rs4974067	chr3:40374551	C/T	cg13409248	chr3:40428643	ENTPD3	0.54	4.52	0.38	1.41e-5	Renal cell carcinoma;
TGCT	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg11494091	chr17:61959527	GH2	0.61	14.49	0.79	1.92e-28	Prudent dietary pattern;
TGCT	cis	rs2066819	1.000	rs2066808	chr12:56737973	A/G	cg26714650	chr12:56694279	CS	-1.55	-8.12	-0.59	4e-13	Psoriasis vulgaris;
TGCT	cis	rs3733585	0.673	rs9994937	chr4:9964799	G/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.6	-0.51	1.07e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg08439880	chr3:133502540	NA	-0.31	-5.88	-0.47	3.57e-8	Iron status biomarkers;
TGCT	cis	rs3617	0.573	rs9850563	chr3:52912214	G/A	cg10802521	chr3:52805072	NEK4	0.57	6.45	0.5	2.29e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg03351412	chr1:154909251	PMVK	0.52	4.89	0.4	3.05e-6	Prostate cancer;
TGCT	cis	rs2562456	0.793	rs2562474	chr19:21646282	A/C	cg01304269	chr19:21688519	ZNF429	-0.57	-4.76	-0.39	5.22e-6	Pain;
TGCT	cis	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg03213289	chr20:61660250	NA	0.68	9.99	0.67	1.36e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9397585	0.626	rs13215045	chr6:153447516	C/T	cg24028809	chr6:153414101	RGS17	0.22	4.66	0.39	8.15e-6	Body mass index;
TGCT	cis	rs4073582	0.595	rs708472	chr11:65930990	A/G	cg16950941	chr11:66035639	RAB1B	0.55	5.42	0.44	2.94e-7	Gout;
TGCT	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg05368731	chr17:41323189	NBR1	1.0	11.08	0.71	2.91e-20	Menopause (age at onset);
TGCT	cis	rs79149102	0.579	rs7167415	chr15:75302570	C/T	cg09165964	chr15:75287851	SCAMP5	-1.04	-5.71	-0.46	7.93e-8	Lung cancer;
TGCT	cis	rs1784581	0.721	rs9365356	chr6:162414789	A/G	cg17173639	chr6:162384350	PARK2	0.42	7.3	0.55	3.02e-11	Itch intensity from mosquito bite;
TGCT	cis	rs2282802	0.685	rs7717563	chr5:139689968	A/G	cg01081189	chr5:139537190	NA	-0.27	-5.04	-0.41	1.6e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs12899618	0.915	rs7170506	chr15:71676235	C/T	cg15179472	chr15:70736858	NA	0.31	5.22	0.42	7.29e-7	Pulmonary function (smoking interaction);Pulmonary function;
TGCT	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg03188948	chr7:1209495	NA	0.59	4.82	0.4	4.06e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7615952	0.932	rs3811679	chr3:125648283	A/G	cg05084668	chr3:125655381	ALG1L	-0.76	-6.08	-0.48	1.39e-8	Blood pressure (smoking interaction);
TGCT	cis	rs9341808	0.690	rs9448909	chr6:80909031	G/A	cg08355045	chr6:80787529	NA	0.32	5.6	0.45	1.29e-7	Sitting height ratio;
TGCT	cis	rs10782582	0.593	rs11801414	chr1:76124517	G/A	cg03433033	chr1:76189801	ACADM	-0.63	-7.27	-0.55	3.6e-11	Daytime sleep phenotypes;
TGCT	cis	rs2721195	0.614	rs12719778	chr8:145879883	T/C	cg17328964	chr8:145687451	CYHR1	-0.44	-5.83	-0.46	4.54e-8	Age at first birth;
TGCT	cis	rs9443645	0.901	rs9361451	chr6:79555055	T/C	cg09184832	chr6:79620586	NA	-0.48	-5.35	-0.43	4.01e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs79349575	0.783	rs4793992	chr17:47008207	A/G	cg00947319	chr17:47005597	UBE2Z	-0.2	-4.74	-0.39	5.83e-6	Type 2 diabetes;
TGCT	cis	rs447735	0.565	rs10852626	chr16:89914633	T/G	cg26513180	chr16:89883248	FANCA	0.7	6.45	0.5	2.27e-9	Hemoglobin concentration;
TGCT	cis	rs12497850	0.931	rs7623023	chr3:48914238	G/A	cg07636037	chr3:49044803	WDR6	0.95	10.74	0.69	2e-19	Parkinson's disease;
TGCT	cis	rs2439831	1.000	rs2251538	chr15:43767209	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.8	5.7	0.46	8.33e-8	Lung cancer in ever smokers;
TGCT	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg12963246	chr6:28129442	ZNF389	0.52	5.1	0.42	1.23e-6	Depression;
TGCT	cis	rs1891275	0.515	rs7475294	chr10:93508199	T/C	cg07889827	chr10:93443413	NA	-0.32	-6.8	-0.52	3.95e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs2073300	1.000	rs6114137	chr20:23457264	G/A	cg09953122	chr20:23471693	CST8	-0.59	-4.71	-0.39	6.5e-6	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs10838634	0.803	rs61898529	chr11:46905731	G/A	cg18332754	chr11:46939436	LRP4	0.87	4.48	0.37	1.68e-5	Schizophrenia;
TGCT	cis	rs7611238	0.583	rs59004692	chr3:195151174	G/A	cg27323046	chr3:195102265	ACAP2	0.37	4.97	0.41	2.17e-6	Body mass index;
TGCT	cis	rs2836974	0.545	rs8128901	chr21:40710419	G/A	cg11644478	chr21:40555479	PSMG1	0.65	6.26	0.49	5.75e-9	Cognitive function;
TGCT	cis	rs9814567	0.929	rs1534027	chr3:134284662	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.94	-9.18	-0.64	1.2e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs9611565	0.506	rs4822020	chr22:41700203	C/T	cg03806693	chr22:41940476	POLR3H	-0.82	-7.85	-0.58	1.7e-12	Vitiligo;
TGCT	cis	rs7647973	1.000	rs3448	chr3:49396751	T/C	cg05785598	chr3:49045655	WDR6	0.39	4.66	0.39	7.89e-6	Menarche (age at onset);
TGCT	cis	rs12477438	0.520	rs13035311	chr2:99717322	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	8.52	0.61	4.42e-14	Chronic sinus infection;
TGCT	cis	rs9302001	0.920	rs9516478	chr13:95459696	T/C	cg07483244	chr13:95358924	NA	0.37	4.81	0.4	4.22e-6	Panic disorder;
TGCT	cis	rs2354432	0.556	rs2275249	chr1:146759320	C/G	cg25205988	chr1:146714368	CHD1L	1.19	6.06	0.48	1.51e-8	Mitochondrial DNA levels;
TGCT	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg21724239	chr8:58056113	NA	0.41	4.87	0.4	3.33e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4654899	0.897	rs10799668	chr1:21169385	T/C	cg01072550	chr1:21505969	NA	0.48	7.58	0.56	7.09e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs9611565	0.649	rs9623450	chr22:42175231	G/A	cg13695892	chr22:41940480	POLR3H	0.8	7.65	0.57	4.87e-12	Vitiligo;
TGCT	cis	rs11969893	0.737	rs1358758	chr6:101411891	T/C	cg12253828	chr6:101329408	ASCC3	1.08	5.14	0.42	1.06e-6	Economic and political preferences (immigration/crime);
TGCT	cis	rs35160687	0.865	rs10189492	chr2:86478902	G/A	cg03171300	chr2:86307199	POLR1A	0.32	5.53	0.44	1.83e-7	Night sleep phenotypes;
TGCT	cis	rs7772486	0.754	rs1055212	chr6:146058315	A/T	cg13319975	chr6:146136371	FBXO30	0.56	5.0	0.41	1.9e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9787249	0.957	rs56064244	chr1:40213890	C/T	cg24920358	chr1:40204285	PPIE	0.57	10.56	0.69	5.57e-19	Blood protein levels;
TGCT	cis	rs10501293	1.000	rs4755695	chr11:43108344	C/A	cg03447554	chr11:43094025	NA	-0.5	-6.92	-0.53	2.09e-10	Cognitive performance;
TGCT	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg22968622	chr17:43663579	NA	1.06	10.16	0.67	5.09e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs9348721	0.673	rs9358934	chr6:26363755	G/C	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs12188164	0.714	rs11741954	chr5:421455	G/T	cg22025206	chr5:502436	SLC9A3	-0.25	-4.44	-0.37	1.94e-5	Cystic fibrosis severity;
TGCT	cis	rs28595532	0.920	rs114094671	chr4:119753540	G/A	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs7666738	0.962	rs2865985	chr4:99068009	T/C	cg18180107	chr4:99064573	C4orf37	0.56	4.54	0.38	1.33e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4730250	0.634	rs11767623	chr7:106792332	C/T	cg02696742	chr7:106810147	HBP1	0.72	5.89	0.47	3.44e-8	Osteoarthritis;
TGCT	cis	rs826838	0.935	rs11183940	chr12:38851642	A/G	cg26384229	chr12:38710491	ALG10B	1.06	10.68	0.69	2.84e-19	Heart rate;
TGCT	cis	rs7666738	0.830	rs1025203	chr4:99023073	G/A	cg05340658	chr4:99064831	C4orf37	0.5	5.56	0.45	1.59e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7819412	0.643	rs7829396	chr8:10999583	C/T	cg03192020	chr8:11204681	TDH	-0.52	-4.5	-0.37	1.53e-5	Triglycerides;
TGCT	cis	rs9660180	0.967	rs12040325	chr1:1702436	G/A	cg03396347	chr1:1875803	NA	-0.36	-6.58	-0.51	1.17e-9	Body mass index;
TGCT	cis	rs137603	0.644	rs137619	chr22:39706360	A/C	cg17798944	chr22:39715225	SNORD43;RPL3	-0.69	-7.04	-0.53	1.16e-10	Primary biliary cholangitis;
TGCT	cis	rs8017423	0.630	rs12589687	chr14:90819570	C/G	cg04374321	chr14:90722782	PSMC1	-0.56	-5.59	-0.45	1.38e-7	Mortality in heart failure;
TGCT	cis	rs644799	0.526	rs506180	chr11:95623109	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.49	5.08	0.41	1.38e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg11494091	chr17:61959527	GH2	0.44	7.33	0.55	2.58e-11	Height;
TGCT	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg20276088	chr3:133502917	NA	-0.27	-5.59	-0.45	1.38e-7	Iron status biomarkers;
TGCT	cis	rs7937682	0.575	rs7107213	chr11:111750430	A/G	cg09085632	chr11:111637200	PPP2R1B	0.88	8.5	0.61	5.19e-14	Primary sclerosing cholangitis;
TGCT	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg05872129	chr22:39784769	NA	-1.01	-11.01	-0.7	4.35e-20	Intelligence (multi-trait analysis);
TGCT	trans	rs1499614	1.000	rs1267817	chr7:66110040	G/T	cg07424592	chr7:64974309	NA	1.31	7.65	0.57	4.73e-12	Gout;
TGCT	cis	rs56309584	0.715	rs11651199	chr17:8142644	G/A	cg08322244	chr17:8066669	VAMP2	-0.55	-4.98	-0.41	2.08e-6	Initial pursuit acceleration;
TGCT	cis	rs7255045	0.752	rs10404876	chr19:12987605	T/C	cg23899408	chr19:12877188	HOOK2	-0.61	-5.01	-0.41	1.79e-6	Mean corpuscular volume;
TGCT	cis	rs6430585	0.583	rs111837148	chr2:136612036	G/A	cg07169764	chr2:136633963	MCM6	1.23	11.92	0.73	2.66e-22	Corneal structure;
TGCT	cis	rs1215050	0.765	rs644839	chr4:98716357	C/A	cg05340658	chr4:99064831	C4orf37	0.44	5.51	0.44	1.95e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs12188164	0.965	rs77101200	chr5:443059	G/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.4	-4.73	-0.39	6.02e-6	Cystic fibrosis severity;
TGCT	cis	rs33794	0.934	rs33796	chr3:45302287	C/T	cg18645101	chr3:44551900	NA	0.53	4.64	0.38	8.89e-6	Lung function (forced expiratory volume in 1 second);
TGCT	cis	rs28595532	0.920	rs116091383	chr4:119635518	A/G	cg21605333	chr4:119757512	SEC24D	1.36	7.39	0.55	1.89e-11	Cannabis dependence symptom count;
TGCT	cis	rs986417	0.818	rs7156317	chr14:61087740	G/A	cg18240143	chr14:60952599	C14orf39	0.88	4.57	0.38	1.15e-5	Gut microbiota (bacterial taxa);
TGCT	cis	rs6540559	0.546	rs74991018	chr1:210033790	T/G	cg23283495	chr1:209979779	IRF6	0.67	4.99	0.41	1.96e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs453301	0.606	rs6601279	chr8:8908231	G/A	cg15556689	chr8:8085844	FLJ10661	-0.68	-5.58	-0.45	1.44e-7	Joint mobility (Beighton score);
TGCT	cis	rs1008375	0.932	rs6844593	chr4:17659039	T/C	cg10189774	chr4:17578691	LAP3	0.55	4.83	0.4	3.89e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9611565	0.525	rs9611548	chr22:41704143	G/T	cg03806693	chr22:41940476	POLR3H	-0.82	-8.35	-0.6	1.13e-13	Vitiligo;
TGCT	cis	rs7208859	0.614	rs28758251	chr17:29223312	A/T	cg18442181	chr17:29233375	C17orf42	-0.78	-4.61	-0.38	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs9677476	0.516	rs6746156	chr2:231967210	A/G	cg07929768	chr2:232055508	NA	0.34	5.31	0.43	4.92e-7	Food antigen IgG levels;
TGCT	cis	rs1577917	0.958	rs13201730	chr6:86556647	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-5.02	-0.41	1.74e-6	Response to antipsychotic treatment;
TGCT	cis	rs709400	0.663	rs62007681	chr14:103884651	G/A	cg12935359	chr14:103987150	CKB	-0.36	-5.47	-0.44	2.42e-7	Body mass index;
TGCT	cis	rs4767364	0.961	rs10850031	chr12:112771063	T/G	cg10833066	chr12:111807467	FAM109A	0.33	5.1	0.42	1.23e-6	Oral cavity and pharyngeal cancer;
TGCT	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg13395646	chr4:1353034	KIAA1530	-0.39	-4.96	-0.41	2.3e-6	Obesity-related traits;
TGCT	cis	rs208520	1.000	rs9453663	chr6:66976077	A/G	cg07460842	chr6:66804631	NA	0.77	6.83	0.52	3.34e-10	Exhaled nitric oxide output;
TGCT	cis	rs651907	0.557	rs17347644	chr3:101547733	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.86	10.37	0.68	1.61e-18	Colorectal cancer;
TGCT	cis	rs4689592	0.503	rs59640165	chr4:7051661	G/A	cg25660036	chr4:7070649	GRPEL1	0.59	4.49	0.37	1.62e-5	Monocyte percentage of white cells;
TGCT	cis	rs5760092	0.755	rs3884794	chr22:24251766	C/A	cg10150615	chr22:24372951	LOC391322	-0.77	-6.8	-0.52	3.96e-10	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs1062177	0.826	rs1549920	chr5:151140844	A/T	cg12924095	chr5:151150029	G3BP1	0.35	5.02	0.41	1.75e-6	Preschool internalizing problems;
TGCT	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg06896619	chr17:61851486	DDX42;CCDC47	-0.5	-4.78	-0.39	4.77e-6	Prudent dietary pattern;
TGCT	cis	rs1403694	1.000	rs1648716	chr3:186439529	C/T	cg12454167	chr3:186435060	KNG1	0.42	7.32	0.55	2.77e-11	Blood protein levels;
TGCT	cis	rs3020736	0.500	rs4147640	chr22:42485292	T/C	cg05082376	chr22:42548792	NA	0.23	5.43	0.44	2.83e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2816062	0.813	rs2745325	chr1:18880442	C/A	cg18795169	chr1:18902165	NA	-0.59	-13.16	-0.76	2.73e-25	Urate levels in lean individuals;
TGCT	cis	rs7914558	1.000	rs2275271	chr10:104814162	T/C	cg05855489	chr10:104503620	C10orf26	0.51	4.48	0.37	1.67e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs782590	0.748	rs782634	chr2:55897700	T/C	cg03859395	chr2:55845619	SMEK2	0.76	7.72	0.57	3.36e-12	Metabolic syndrome;
TGCT	cis	rs11031096	0.536	rs894459	chr11:4213590	A/G	cg18678763	chr11:4115507	RRM1	-0.39	-5.0	-0.41	1.92e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg23221052	chr5:179740743	GFPT2	-0.35	-5.54	-0.45	1.74e-7	Height;
TGCT	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.51	-6.55	-0.51	1.37e-9	Longevity;Endometriosis;
TGCT	cis	rs1453308	0.766	rs1470861	chr2:237176942	A/G	cg19324714	chr2:237145437	ASB18	0.59	5.22	0.42	7.18e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs910187	0.678	rs3818006	chr20:45816328	A/G	cg27589058	chr20:45804311	EYA2	-0.35	-7.6	-0.56	6.23e-12	Migraine;
TGCT	cis	rs8016982	0.633	rs8019108	chr14:81716781	A/T	cg01989461	chr14:81687754	GTF2A1	0.76	7.5	0.56	1.09e-11	Schizophrenia;
TGCT	cis	rs12220898	0.679	rs12254955	chr10:50480763	T/G	cg09603381	chr10:49954066	WDFY4	0.39	4.48	0.37	1.68e-5	Inflammatory biomarkers;
TGCT	cis	rs9325144	0.723	rs1586373	chr12:39181582	G/A	cg26384229	chr12:38710491	ALG10B	-0.61	-5.67	-0.45	9.5e-8	Morning vs. evening chronotype;
TGCT	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.45	-4.89	-0.4	3.04e-6	Blood metabolite levels;
TGCT	cis	rs4285028	0.747	rs7610298	chr3:121419100	T/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.92	-7.3	-0.55	3.03e-11	Multiple sclerosis;
TGCT	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg10047753	chr17:41438598	NA	0.96	9.86	0.66	2.71e-17	Menopause (age at onset);
TGCT	cis	rs28595532	0.920	rs116548907	chr4:119735285	G/A	cg14228332	chr4:119757509	SEC24D	1.32	6.4	0.5	2.94e-9	Cannabis dependence symptom count;
TGCT	cis	rs6570726	0.935	rs12663204	chr6:145818373	G/A	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9853921	0.674	rs9843209	chr3:117966601	C/T	cg15509235	chr3:117715573	NA	-0.53	-4.51	-0.38	1.46e-5	JT interval (sulfonylurea treatment interaction);
TGCT	cis	rs4269383	0.692	rs4513805	chr6:156224697	G/A	cg15940508	chr6:156885744	NA	-0.29	-4.47	-0.37	1.73e-5	Pancreatic cancer;
TGCT	cis	rs7267979	0.816	rs6076358	chr20:25519403	G/T	cg03522245	chr20:25566470	NINL	-0.56	-5.79	-0.46	5.51e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9611565	0.513	rs739135	chr22:42090069	A/C	cg06481639	chr22:41940642	POLR3H	0.73	6.57	0.51	1.27e-9	Vitiligo;
TGCT	cis	rs79349575	0.783	rs4793995	chr17:47019399	A/C	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.52	-0.38	1.44e-5	Type 2 diabetes;
TGCT	cis	rs78487399	0.808	rs6746610	chr2:43677253	T/A	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.72	4.62	0.38	9.53e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs28595532	0.920	rs114724233	chr4:119754918	T/A	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg20637647	chr7:64974828	NA	0.92	5.09	0.42	1.26e-6	Diabetic kidney disease;
TGCT	cis	rs7523273	0.606	rs2761433	chr1:207917361	G/A	cg22525895	chr1:207977042	MIR29B2	0.54	8.77	0.62	1.16e-14	Schizophrenia;
TGCT	cis	rs1865760	0.532	rs1061482	chr6:26086699	G/T	cg17042849	chr6:26104293	HIST1H4C	-0.63	-5.46	-0.44	2.52e-7	Height;
TGCT	cis	rs4253772	0.550	rs738444	chr22:46721088	C/T	cg26492175	chr22:47022658	GRAMD4	0.19	4.5	0.37	1.54e-5	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs1371867	0.875	rs7830342	chr8:101327738	T/A	cg06002616	chr8:101225028	SPAG1	-0.53	-6.21	-0.49	7.16e-9	Atrioventricular conduction;
TGCT	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg23758822	chr17:41437982	NA	0.69	6.37	0.5	3.34e-9	Menopause (age at onset);
TGCT	cis	rs10779751	0.686	rs2791656	chr1:11128329	A/G	cg08854313	chr1:11322531	MTOR	0.85	6.96	0.53	1.74e-10	Body mass index;
TGCT	cis	rs1215050	0.740	rs783924	chr4:98969234	C/T	cg05340658	chr4:99064831	C4orf37	-0.43	-5.27	-0.43	5.8e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg03388025	chr16:89894329	SPIRE2	-0.32	-4.76	-0.39	5.26e-6	Vitiligo;
TGCT	cis	rs6964587	0.934	rs6973792	chr7:91749798	C/A	cg22709100	chr7:91322751	NA	0.29	4.66	0.39	8e-6	Breast cancer;
TGCT	cis	rs11098499	0.775	rs2002049	chr4:120257417	A/G	cg09307838	chr4:120376055	NA	0.63	6.07	0.48	1.44e-8	Corneal astigmatism;
TGCT	cis	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg18252515	chr7:66147081	NA	-1.17	-7.49	-0.56	1.13e-11	Diabetic kidney disease;
TGCT	cis	rs5750830	0.620	rs1007337	chr22:39781585	C/T	cg24399712	chr22:39784796	NA	-1.03	-11.98	-0.73	1.92e-22	Intelligence (multi-trait analysis);
TGCT	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.72	5.22	0.42	7.44e-7	Platelet count;
TGCT	cis	rs1215050	0.904	rs890469	chr4:98923293	T/C	cg17366294	chr4:99064904	C4orf37	-0.49	-4.91	-0.4	2.87e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs13256369	0.774	rs13248423	chr8:8577602	C/G	cg18904891	chr8:8559673	CLDN23	0.56	4.95	0.41	2.38e-6	Obesity-related traits;
TGCT	cis	rs2233152	0.520	rs56101381	chr19:41272902	T/C	cg23743927	chr19:41304969	EGLN2	-0.7	-4.69	-0.39	7.06e-6	Kawasaki disease;
TGCT	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg05890377	chr2:74357713	NA	0.5	6.63	0.51	9.26e-10	Gestational age at birth (maternal effect);
TGCT	cis	rs35306767	0.714	rs28512382	chr10:1092195	G/C	cg26597838	chr10:835615	NA	0.61	7.02	0.53	1.3100000000000001e-10	Eosinophil percentage of granulocytes;
TGCT	cis	rs9341808	0.935	rs2322633	chr6:80845989	C/T	cg08355045	chr6:80787529	NA	-0.34	-5.67	-0.45	9.48e-8	Sitting height ratio;
TGCT	cis	rs2188554	0.740	rs213948	chr7:117194470	G/A	cg09181792	chr7:117119393	CFTR	0.48	4.44	0.37	1.99e-5	Esophageal adenocarcinoma;
TGCT	cis	rs4808199	0.895	rs10419672	chr19:19471241	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.66	4.91	0.4	2.86e-6	Nonalcoholic fatty liver disease;
TGCT	cis	rs7635838	0.654	rs347585	chr3:11286220	C/T	cg00170343	chr3:11313890	ATG7	0.69	6.8	0.52	4.01e-10	HDL cholesterol;
TGCT	cis	rs7666738	0.830	rs58367603	chr4:99015350	T/C	cg17366294	chr4:99064904	C4orf37	0.68	7.04	0.53	1.17e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg22920501	chr2:26401640	FAM59B	-0.78	-6.16	-0.48	9.43e-9	Gut microbiome composition (summer);
TGCT	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.62	-5.07	-0.41	1.42e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs12681287	0.547	rs60982560	chr8:87515046	C/T	cg19078186	chr8:87526527	CPNE3	-0.36	-4.49	-0.37	1.59e-5	Caudate activity during reward;
TGCT	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg08645402	chr16:4508243	NA	0.21	5.05	0.41	1.57e-6	Schizophrenia;
TGCT	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs9291683	0.530	rs73227883	chr4:9979279	T/C	cg00071950	chr4:10020882	SLC2A9	0.65	8.35	0.6	1.17e-13	Bone mineral density;
TGCT	cis	rs6866344	0.697	rs61247551	chr5:178133503	G/A	cg10224037	chr5:178157518	ZNF354A	0.95	8.47	0.61	6.06e-14	Neutrophil percentage of white cells;
TGCT	cis	rs13191362	1.000	rs36113695	chr6:163004733	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs8016982	0.633	rs9944085	chr14:81717620	A/T	cg01989461	chr14:81687754	GTF2A1	-0.76	-7.5	-0.56	1.09e-11	Schizophrenia;
TGCT	cis	rs7542091	0.813	rs2049999	chr1:210031331	A/G	cg22029157	chr1:209979665	IRF6	0.55	5.35	0.43	4e-7	Monobrow;
TGCT	cis	rs739496	0.793	rs1557685	chr12:111901204	C/A	cg10833066	chr12:111807467	FAM109A	0.37	5.65	0.45	1.05e-7	Platelet count;
TGCT	cis	rs1784581	0.674	rs1789989	chr6:162408138	C/T	cg17173639	chr6:162384350	PARK2	0.42	7.17	0.54	6e-11	Itch intensity from mosquito bite;
TGCT	cis	rs2072499	0.695	rs112223391	chr1:156156094	G/A	cg25208724	chr1:156163844	SLC25A44	1.0	9.0	0.63	3.2e-15	Testicular germ cell tumor;
TGCT	cis	rs4409675	0.576	rs2749110	chr1:28235010	T/C	cg23691781	chr1:28212827	C1orf38	0.26	5.52	0.44	1.9e-7	Corneal astigmatism;
TGCT	cis	rs4273100	0.688	rs28582509	chr17:19165179	T/C	cg03910582	chr17:19030146	GRAPL	0.51	6.18	0.49	8.57e-9	Schizophrenia;
TGCT	cis	rs13191362	1.000	rs67840803	chr6:163049048	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.07	8.5	0.61	5.17e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs1008375	1.000	rs13148861	chr4:17688338	G/A	cg18681998	chr4:17616180	MED28	-0.91	-8.93	-0.63	4.82e-15	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs501916	0.743	rs3743281	chr15:48056958	C/T	cg16110827	chr15:48056943	SEMA6D	-0.16	-4.49	-0.37	1.63e-5	Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg27121462	chr16:89883253	FANCA	0.76	7.93	0.58	1.07e-12	Vitiligo;
TGCT	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg05025164	chr4:1340916	KIAA1530	0.79	6.65	0.51	8.3e-10	Longevity;
TGCT	cis	rs4699052	0.963	rs7679365	chr4:104212980	G/C	cg16532752	chr4:104119610	CENPE	-0.56	-5.1	-0.42	1.26e-6	Testicular germ cell tumor;
TGCT	trans	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg25482853	chr8:67687455	SGK3	1.22	10.56	0.69	5.48e-19	Lung disease severity in cystic fibrosis;
TGCT	cis	rs11030122	0.702	rs67300156	chr11:3953949	C/T	cg18678763	chr11:4115507	RRM1	-0.49	-6.14	-0.48	1.01e-8	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs12712073	0.845	rs6729966	chr2:100781566	A/G	cg22139774	chr2:100720529	AFF3	-0.35	-5.55	-0.45	1.63e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1005224	0.963	rs2303345	chr14:76156609	A/G	cg04684003	chr14:76127793	TTLL5;C14orf1	0.61	5.57	0.45	1.51e-7	Large artery stroke;
TGCT	cis	rs9911578	1.000	rs11079365	chr17:56945430	T/C	cg05425664	chr17:57184151	TRIM37	-0.62	-6.18	-0.49	8.33e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs2153535	0.521	rs6939827	chr6:8461360	C/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs10986311	0.962	rs10818943	chr9:127087740	C/T	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.19	-4.44	-0.37	1.97e-5	Vitiligo;
TGCT	cis	rs11098499	1.000	rs11098499	chr4:120187611	C/T	cg09307838	chr4:120376055	NA	0.49	4.48	0.37	1.67e-5	Corneal astigmatism;
TGCT	cis	rs7917772	0.503	rs746552	chr10:104342501	A/G	cg05855489	chr10:104503620	C10orf26	-0.61	-5.41	-0.44	3.16e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	trans	rs365060	0.818	rs154998	chr2:109577205	C/T	cg13735819	chr19:2253850	JSRP1	0.7	6.65	0.51	8.52e-10	Beard thickness;
TGCT	cis	rs453301	0.592	rs4841084	chr8:8883905	C/T	cg06636001	chr8:8085503	FLJ10661	0.81	7.06	0.54	1.06e-10	Joint mobility (Beighton score);
TGCT	cis	rs4654899	0.827	rs12564330	chr1:21207495	A/C	cg01072550	chr1:21505969	NA	0.49	7.75	0.57	2.82e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs750134	0.901	rs1549087	chr12:109201326	T/C	cg14311481	chr12:108920534	SART3	0.57	4.48	0.37	1.7e-5	Low high density lipoprotein cholesterol levels;
TGCT	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg24060327	chr5:131705240	SLC22A5	0.78	8.46	0.61	6.22e-14	Breast cancer;
TGCT	cis	rs4783244	0.862	rs7198176	chr16:82647971	C/T	cg09415485	chr16:82663111	CDH13	-0.26	-4.82	-0.4	4.05e-6	Adiponectin levels;
TGCT	cis	rs3087591	0.659	rs757377	chr17:29720426	G/A	cg24425628	chr17:29625626	OMG;NF1	0.41	6.03	0.48	1.73e-8	Hip circumference;
TGCT	cis	rs73198271	0.813	rs56007835	chr8:8610026	G/A	cg06671706	chr8:8559999	CLDN23	-0.37	-4.75	-0.39	5.45e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg25036284	chr2:26402008	FAM59B	0.58	4.58	0.38	1.12e-5	Gut microbiome composition (summer);
TGCT	trans	rs1814175	0.519	rs10839291	chr11:49514321	G/A	cg11707556	chr5:10655725	ANKRD33B	0.42	8.63	0.61	2.5e-14	Height;
TGCT	cis	rs7394190	0.748	rs11000766	chr10:75512952	C/T	cg07699608	chr10:75541558	CHCHD1	0.77	4.86	0.4	3.48e-6	Incident atrial fibrillation;
TGCT	cis	rs910316	1.000	rs8017642	chr14:75590822	G/A	cg11812906	chr14:75593930	NEK9	0.73	7.23	0.54	4.36e-11	Height;
TGCT	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	6.14	0.48	1.03e-8	Bipolar disorder;
TGCT	cis	rs3885907	0.520	rs9671182	chr13:31321138	C/G	cg22282089	chr13:30686841	NA	0.22	4.54	0.38	1.33e-5	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU);
TGCT	cis	rs3772130	0.885	rs9816844	chr3:121496324	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.72	0.39	6.25e-6	Cognitive performance;
TGCT	cis	rs76878669	0.561	rs1892940	chr11:66111251	A/G	cg18002602	chr11:66138449	SLC29A2	-0.51	-6.25	-0.49	6.06e-9	Educational attainment (years of education);
TGCT	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	7.76	0.57	2.67e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg05368731	chr17:41323189	NBR1	1.08	11.0	0.7	4.76e-20	Menopause (age at onset);
TGCT	trans	rs2727020	0.553	rs4103567	chr11:49255389	C/T	cg15704280	chr7:45808275	SEPT13	-0.6	-6.71	-0.52	6.07e-10	Coronary artery disease;
TGCT	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg06238570	chr21:40685208	BRWD1	-0.81	-8.52	-0.61	4.45e-14	Cognitive function;
TGCT	cis	rs3781684	1.000	rs2233551	chr11:76814471	A/G	cg17957640	chr11:76839205	MYO7A	-0.48	-4.75	-0.39	5.46e-6	Cognitive performance;
TGCT	cis	rs734999	0.967	rs10797434	chr1:2511280	C/T	cg18854424	chr1:2615690	NA	0.46	5.84	0.46	4.22e-8	Ulcerative colitis;
TGCT	cis	rs10782582	0.586	rs112368938	chr1:76336339	C/T	cg10523679	chr1:76189770	ACADM	-0.59	-5.42	-0.44	2.94e-7	Daytime sleep phenotypes;
TGCT	cis	rs7647973	0.626	rs1352889	chr3:49652148	T/C	cg05785598	chr3:49045655	WDR6	0.42	5.24	0.43	6.67e-7	Menarche (age at onset);
TGCT	cis	rs7937682	0.602	rs11214036	chr11:111773169	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.98	-9.59	-0.65	1.21e-16	Primary sclerosing cholangitis;
TGCT	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.48	0.56	1.17e-11	Prudent dietary pattern;
TGCT	cis	rs3796352	1.000	rs71301809	chr3:53090312	C/T	cg15956490	chr3:53032818	SFMBT1	0.6	6.78	0.52	4.31e-10	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs7617480	0.558	rs12715430	chr3:48942855	A/C	cg07636037	chr3:49044803	WDR6	0.78	6.5	0.5	1.73e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs9436747	0.641	rs7413467	chr1:66047893	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.56	5.03	0.41	1.69e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs7666738	0.800	rs28427190	chr4:98989106	A/G	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg04267008	chr7:1944627	MAD1L1	-0.37	-4.85	-0.4	3.56e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs2404602	0.583	rs2176623	chr15:76568579	C/T	cg26408565	chr15:76604113	ETFA	-0.44	-5.88	-0.47	3.6e-8	Blood metabolite levels;
TGCT	cis	rs2857078	0.720	rs9901595	chr17:42305699	G/A	cg19774624	chr17:42201019	HDAC5	-0.69	-7.14	-0.54	6.91e-11	Red cell distribution width;Reticulocyte count;
TGCT	cis	rs854765	0.547	rs9912096	chr17:17896673	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.78	8.27	0.6	1.72e-13	Total body bone mineral density;
TGCT	cis	rs79349575	0.716	rs46522	chr17:46988597	C/T	cg26022315	chr17:47021804	SNF8	0.49	4.97	0.41	2.22e-6	Type 2 diabetes;
TGCT	cis	rs7666738	0.581	rs34205844	chr4:98887494	C/A	cg18180107	chr4:99064573	C4orf37	0.51	4.51	0.38	1.47e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2439831	0.867	rs3213990	chr15:43670226	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	6.61	0.51	1e-9	Lung cancer in ever smokers;
TGCT	cis	rs7267979	1.000	rs2297496	chr20:25295787	T/C	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2777491	1.000	rs316609	chr15:41743828	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.75	-11.07	-0.71	3.15e-20	Ulcerative colitis;
TGCT	cis	rs67311347	0.956	rs6771527	chr3:40506548	T/C	cg13683864	chr3:40499215	RPL14	1.17	13.19	0.76	2.34e-25	Renal cell carcinoma;
TGCT	cis	rs2439831	0.850	rs67541383	chr15:44172548	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	5.54	0.45	1.72e-7	Lung cancer in ever smokers;
TGCT	cis	rs473651	0.904	rs501333	chr2:239336045	G/A	cg21699342	chr2:239360505	ASB1	0.17	4.78	0.39	4.78e-6	Multiple system atrophy;
TGCT	cis	rs13256369	1.000	rs13282915	chr8:8570891	T/G	cg17143192	chr8:8559678	CLDN23	0.58	5.56	0.45	1.56e-7	Obesity-related traits;
TGCT	cis	rs600231	0.708	rs682845	chr11:65254201	A/G	cg21890820	chr11:65308645	LTBP3	0.35	4.44	0.37	1.93e-5	Bone mineral density;
TGCT	cis	rs7213347	0.581	rs2873195	chr17:2064702	A/T	cg22033759	chr17:1182267	TUSC5	-0.23	-4.65	-0.39	8.44e-6	Total body bone mineral density;
TGCT	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg22963979	chr7:1858916	MAD1L1	0.41	6.66	0.51	7.94e-10	Bipolar disorder and schizophrenia;
TGCT	cis	rs2050392	0.829	rs306589	chr10:30723831	A/G	cg18806716	chr10:30721971	MAP3K8	-0.49	-5.65	-0.45	1.04e-7	Inflammatory bowel disease;
TGCT	cis	rs8017423	0.647	rs1958346	chr14:90824011	G/T	cg04374321	chr14:90722782	PSMC1	-0.54	-5.41	-0.44	3.13e-7	Mortality in heart failure;
TGCT	cis	rs3008870	0.755	rs2815366	chr1:67499930	C/T	cg11518657	chr1:67396239	MIER1	0.47	4.61	0.38	9.68e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs4849845	0.678	rs3896632	chr2:121023496	C/T	cg24070213	chr2:121070622	NA	0.35	4.64	0.38	8.58e-6	Mean platelet volume;
TGCT	cis	rs3820928	0.933	rs1429267	chr2:227767593	G/C	cg11843606	chr2:227700838	RHBDD1	-0.51	-4.49	-0.37	1.6e-5	Pulmonary function;
TGCT	cis	rs13242816	1.000	rs3807988	chr7:116180735	A/C	cg02799643	chr7:116139180	CAV2	-0.43	-5.29	-0.43	5.24e-7	P wave duration;
TGCT	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg23758822	chr17:41437982	NA	0.67	6.5	0.5	1.8e-9	Menopause (age at onset);
TGCT	cis	rs28374715	0.609	rs8043237	chr15:41514298	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.78	-10.91	-0.7	7.59e-20	Ulcerative colitis;
TGCT	cis	rs67311347	1.000	rs56303661	chr3:40520778	C/G	cg13683864	chr3:40499215	RPL14	-1.2	-13.3	-0.77	1.27e-25	Renal cell carcinoma;
TGCT	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg12310025	chr6:25882481	NA	-0.68	-6.01	-0.47	1.96e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9611565	0.918	rs9538	chr22:41755857	G/T	cg06634786	chr22:41940651	POLR3H	-0.91	-8.79	-0.62	1.02e-14	Vitiligo;
TGCT	trans	rs7824557	0.564	rs2736300	chr8:11235579	T/G	cg15556689	chr8:8085844	FLJ10661	-0.74	-6.7	-0.52	6.48e-10	Retinal vascular caliber;
TGCT	cis	rs7617773	0.707	rs13061269	chr3:48373343	C/T	cg11946769	chr3:48343235	NME6	0.81	6.96	0.53	1.71e-10	Coronary artery disease;
TGCT	cis	rs12210905	0.688	rs12205044	chr6:27478990	A/G	cg08851530	chr6:28072375	NA	1.34	6.29	0.49	5.02e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs56309584	0.560	rs3027160	chr17:8057572	T/C	cg08322244	chr17:8066669	VAMP2	-0.52	-4.88	-0.4	3.14e-6	Initial pursuit acceleration;
TGCT	cis	rs66573146	1.000	rs7686168	chr4:6986057	C/A	cg01220768	chr4:7056774	TADA2B	0.39	4.91	0.4	2.77e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs13102973	0.720	rs7687463	chr4:135885773	G/T	cg14419869	chr4:135874104	NA	0.26	4.79	0.39	4.72e-6	Subjective well-being;
TGCT	cis	rs12478296	0.901	rs7603560	chr2:243043256	C/T	cg06360820	chr2:242988706	NA	-0.81	-5.39	-0.44	3.36e-7	Obesity-related traits;
TGCT	cis	rs7681440	0.904	rs6532193	chr4:90764188	G/A	cg26578617	chr4:90757533	SNCA	-0.49	-5.1	-0.42	1.26e-6	Dementia with Lewy bodies;
TGCT	cis	rs10927875	0.541	rs1763599	chr1:16342602	C/T	cg21385522	chr1:16154831	NA	0.46	4.75	0.39	5.5e-6	Dilated cardiomyopathy;
TGCT	cis	rs4906332	0.868	rs4900578	chr14:103926010	A/T	cg26031613	chr14:104095156	KLC1	-0.53	-4.71	-0.39	6.62e-6	Coronary artery disease;
TGCT	cis	rs651907	0.535	rs34063583	chr3:101509948	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.86	10.4	0.68	1.35e-18	Colorectal cancer;
TGCT	cis	rs3796352	1.000	rs35163227	chr3:53127876	A/G	cg07884673	chr3:53033167	SFMBT1	0.53	5.23	0.43	6.94e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg21017887	chr14:105400489	NA	0.37	5.19	0.42	8.23e-7	Rheumatoid arthritis;
TGCT	cis	rs4803468	0.935	rs12602	chr19:41889748	T/C	cg09537434	chr19:41945824	ATP5SL	-0.89	-9.97	-0.67	1.47e-17	Height;
TGCT	cis	rs3796619	1.000	rs4974601	chr4:1095410	G/A	cg27284194	chr4:1044797	NA	0.47	4.57	0.38	1.17e-5	Recombination rate (males);
TGCT	cis	rs7172809	0.573	rs2292594	chr15:77515140	T/C	cg22256960	chr15:77711686	NA	-0.49	-4.62	-0.38	9.51e-6	Glucose homeostasis traits;
TGCT	cis	rs912057	0.833	rs1294418	chr6:6742185	A/G	cg06612196	chr6:6737390	NA	0.37	4.88	0.4	3.17e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs9549367	0.756	rs2316463	chr13:113901406	C/T	cg18105134	chr13:113819100	PROZ	-0.34	-5.61	-0.45	1.28e-7	Platelet distribution width;
TGCT	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg06028605	chr16:24865363	SLC5A11	0.41	4.58	0.38	1.13e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg18735214	chr6:43276756	CRIP3	-0.56	-4.88	-0.4	3.24e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs9467711	0.538	rs35934643	chr6:26355094	G/A	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7552404	1.000	rs4949879	chr1:76237143	G/A	cg03433033	chr1:76189801	ACADM	0.82	9.39	0.64	3.73e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg03609598	chr5:56110824	MAP3K1	-0.59	-4.78	-0.39	4.81e-6	Initial pursuit acceleration;
TGCT	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg21862992	chr11:68658383	NA	0.49	6.65	0.51	8.18e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg13699009	chr12:122356056	WDR66	0.26	5.44	0.44	2.72e-7	Mean corpuscular volume;
TGCT	cis	rs4654899	0.567	rs9426735	chr1:21505472	A/T	cg01072550	chr1:21505969	NA	-0.53	-8.49	-0.61	5.22e-14	Superior frontal gyrus grey matter volume;
TGCT	cis	rs782590	0.764	rs2054728	chr2:55818419	C/T	cg18811423	chr2:55921094	PNPT1	0.55	5.65	0.45	1.03e-7	Metabolic syndrome;
TGCT	cis	rs6594499	0.500	rs12514810	chr5:110455357	T/A	cg04022379	chr5:110408740	TSLP	0.56	5.89	0.47	3.43e-8	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs950169	0.922	rs2033284	chr15:84946273	C/T	cg17173187	chr15:85201210	NMB	0.57	5.74	0.46	6.94e-8	Schizophrenia;
TGCT	cis	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg20637647	chr7:64974828	NA	0.96	5.29	0.43	5.33e-7	Diabetic kidney disease;
TGCT	cis	rs860554	0.640	rs2268153	chr1:201262184	A/G	cg01022117	chr1:201258280	PKP1	-0.35	-6.72	-0.52	5.78e-10	Panic disorder;
TGCT	cis	rs9303401	0.614	rs8081058	chr17:57160513	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.64	5.87	0.47	3.79e-8	Cognitive test performance;
TGCT	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg06112835	chr11:68658793	MRPL21	-0.45	-7.67	-0.57	4.3e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs10504229	1.000	rs73591706	chr8:58195633	C/T	cg08280861	chr8:58055591	NA	0.36	4.61	0.38	9.98e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs12042938	0.579	rs980394	chr1:231779507	A/G	cg04892437	chr1:231737901	TSNAX-DISC1	-0.43	-4.6	-0.38	1.01e-5	Neuranatomic and neurocognitive phenotypes;
TGCT	cis	rs7769051	0.521	rs9321367	chr6:133084359	G/T	cg22852734	chr6:133119734	C6orf192	1.26	5.6	0.45	1.33e-7	Type 2 diabetes nephropathy;
TGCT	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg27425262	chr2:113953981	PSD4;LOC440839	-0.52	-8.2	-0.59	2.52e-13	Lymphocyte counts;
TGCT	cis	rs7267979	0.833	rs6138556	chr20:25243310	C/T	cg16686733	chr20:25566563	NINL	0.56	5.76	0.46	6.24e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs1908814	0.516	rs11996277	chr8:11800031	G/A	cg15556689	chr8:8085844	FLJ10661	0.79	7.38	0.55	1.96e-11	Neuroticism;
TGCT	cis	rs6594499	0.542	rs4530809	chr5:110462230	A/G	cg04022379	chr5:110408740	TSLP	0.61	5.64	0.45	1.11e-7	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg07507251	chr3:52567010	NT5DC2	0.48	6.67	0.51	7.55e-10	Bipolar disorder;
TGCT	cis	rs13343954	0.778	rs10425798	chr19:33541539	C/G	cg07624008	chr19:33672378	NA	-0.27	-4.61	-0.38	9.73e-6	Colorectal cancer;
TGCT	cis	rs3027009	0.881	rs61828178	chr1:159159041	G/T	cg17025555	chr1:158724362	OR6K6	-0.46	-4.46	-0.37	1.81e-5	Lean body mass and age at menarche (combined);
TGCT	cis	rs2797160	1.000	rs1612249	chr6:126014916	C/A	cg05901451	chr6:126070800	HEY2	0.73	6.29	0.49	5.01e-9	Endometrial cancer;
TGCT	cis	rs2730260	0.537	rs3793223	chr7:158863574	C/A	cg12144100	chr7:157890277	PTPRN2	0.35	4.45	0.37	1.87e-5	Myopia (pathological);
TGCT	cis	rs35146811	0.735	rs858505	chr7:99819577	G/A	cg04778012	chr7:99775508	STAG3;GPC2	-0.36	-5.1	-0.42	1.22e-6	Coronary artery disease;
TGCT	cis	rs1843834	0.539	rs12694643	chr2:225446603	A/G	cg12698349	chr2:225449008	CUL3	0.82	6.88	0.53	2.68e-10	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs9486715	0.867	rs9480700	chr6:96965056	A/G	cg06623918	chr6:96969491	KIAA0776	1.1	15.44	0.81	1.17e-30	Headache;
TGCT	cis	rs2996428	0.601	rs10909804	chr1:3770929	A/G	cg17848003	chr1:3704513	LRRC47	-0.18	-5.15	-0.42	9.99e-7	Red cell distribution width;
TGCT	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.49	-4.67	-0.39	7.79e-6	Bipolar disorder;
TGCT	cis	rs6570726	0.791	rs9376953	chr6:145912226	G/T	cg23711669	chr6:146136114	FBXO30	0.89	9.62	0.65	1.06e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7523050	0.554	rs34086470	chr1:109485991	C/A	cg08274380	chr1:109419600	GPSM2	1.12	6.19	0.49	8.06e-9	Fat distribution (HIV);
TGCT	cis	rs6977940	0.818	rs73033460	chr7:2900662	C/T	cg19731401	chr7:2775893	GNA12	0.38	4.61	0.38	9.91e-6	White matter integrity;
TGCT	cis	rs17401966	0.931	rs11584023	chr1:10302596	A/G	cg19773385	chr1:10388646	KIF1B	-0.21	-4.6	-0.38	1.02e-5	Hepatocellular carcinoma;
TGCT	cis	rs9325144	0.752	rs12300353	chr12:39154492	G/C	cg13010199	chr12:38710504	ALG10B	-0.52	-4.63	-0.38	9.18e-6	Morning vs. evening chronotype;
TGCT	cis	rs4478037	0.822	rs9875140	chr3:33117068	T/A	cg19404215	chr3:33155277	CRTAP	1.27	6.16	0.48	9.36e-9	Major depressive disorder;
TGCT	cis	rs13191362	1.000	rs35820211	chr6:163046252	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.07	8.5	0.61	5.17e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs9611565	0.608	rs2003816	chr22:42095140	T/G	cg17554472	chr22:41940697	POLR3H	0.46	4.91	0.4	2.82e-6	Vitiligo;
TGCT	cis	rs2180341	0.640	rs11154395	chr6:127629138	T/C	cg24812749	chr6:127587940	RNF146	0.64	5.4	0.44	3.31e-7	Breast cancer;
TGCT	cis	rs826838	1.000	rs1684395	chr12:39083161	T/G	cg26384229	chr12:38710491	ALG10B	-0.85	-8.09	-0.59	4.68e-13	Heart rate;
TGCT	cis	rs7605378	0.528	rs281791	chr2:200850402	A/G	cg23649088	chr2:200775458	C2orf69	-0.46	-9.85	-0.66	2.88e-17	Osteoporosis;
TGCT	cis	rs6604026	0.656	rs2255723	chr1:93368309	A/C	cg17283838	chr1:93427260	FAM69A	0.56	4.44	0.37	1.96e-5	Multiple sclerosis;
TGCT	cis	rs7017914	0.905	rs2956610	chr8:71929533	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.56	-5.11	-0.42	1.21e-6	Bone mineral density;
TGCT	cis	rs7829975	0.533	rs1039917	chr8:8718850	C/T	cg08975724	chr8:8085496	FLJ10661	0.53	4.76	0.39	5.28e-6	Mood instability;
TGCT	cis	rs61774743	0.754	rs11578963	chr1:41834183	A/G	cg01193554	chr1:41846683	NA	0.43	5.36	0.43	3.91e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs425277	1.000	rs55826501	chr1:2059143	G/A	cg03732007	chr1:2071316	PRKCZ	0.25	5.0	0.41	1.92e-6	Height;
TGCT	cis	rs478304	0.651	rs11537193	chr11:65500003	A/C	cg17480646	chr11:65405466	SIPA1	-0.57	-6.93	-0.53	2.05e-10	Acne (severe);
TGCT	cis	rs2404602	0.716	rs17461634	chr15:76764107	G/A	cg22467129	chr15:76604101	ETFA	-0.55	-6.71	-0.52	6.26e-10	Blood metabolite levels;
TGCT	cis	rs748404	0.660	rs2444251	chr15:43788595	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	4.71	0.39	6.47e-6	Lung cancer;
TGCT	cis	rs2050392	0.789	rs303438	chr10:30733493	C/T	cg13289132	chr10:30722225	MAP3K8	0.4	4.97	0.41	2.21e-6	Inflammatory bowel disease;
TGCT	cis	rs13082711	0.863	rs66743193	chr3:27471958	G/A	cg02860705	chr3:27208620	NA	0.35	4.83	0.4	3.9e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs2404602	0.622	rs9635380	chr15:77103479	A/G	cg22467129	chr15:76604101	ETFA	0.47	4.65	0.39	8.39e-6	Blood metabolite levels;
TGCT	trans	rs1496653	0.602	rs13085173	chr3:23605263	A/G	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs6988636	1.000	rs11993411	chr8:124180537	T/C	cg23067535	chr8:124195133	FAM83A	-0.34	-5.13	-0.42	1.09e-6	Urinary uromodulin levels;
TGCT	trans	rs4650994	0.507	rs56229230	chr1:178526563	G/A	cg05059571	chr16:84539110	KIAA1609	-0.54	-11.05	-0.7	3.58e-20	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs36051895	0.664	rs11788834	chr9:5092466	G/A	cg02405213	chr9:5042618	JAK2	-0.72	-9.52	-0.65	1.85e-16	Pediatric autoimmune diseases;
TGCT	cis	rs7528419	1.000	rs646776	chr1:109818530	C/T	cg00908766	chr1:109817496	CELSR2	0.52	5.36	0.43	4e-7	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
TGCT	cis	rs7666738	1.000	rs880473	chr4:98922596	C/T	cg17366294	chr4:99064904	C4orf37	0.8	7.2	0.54	5.04e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10779751	0.690	rs2791646	chr1:11133242	C/T	cg08854313	chr1:11322531	MTOR	0.82	7.04	0.53	1.19e-10	Body mass index;
TGCT	cis	rs6121246	0.559	rs6060919	chr20:30331922	A/T	cg13852791	chr20:30311386	BCL2L1	0.82	8.0	0.58	7.65e-13	Mean corpuscular hemoglobin;
TGCT	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg10802521	chr3:52805072	NEK4	-0.73	-9.09	-0.63	2.03e-15	Electroencephalogram traits;
TGCT	cis	rs2153535	0.526	rs1796689	chr6:8536433	A/C	cg07606381	chr6:8435919	SLC35B3	0.54	4.83	0.4	3.9e-6	Motion sickness;
TGCT	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.69	5.32	0.43	4.67e-7	Lung function (FEV1/FVC);
TGCT	cis	rs9902453	0.933	rs4470197	chr17:28464474	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	5.41	0.44	3.08e-7	Coffee consumption (cups per day);
TGCT	cis	rs2204008	0.744	rs11514358	chr12:38255526	G/A	cg13010199	chr12:38710504	ALG10B	0.64	4.97	0.41	2.15e-6	Bladder cancer;
TGCT	cis	rs7586879	0.662	rs2384059	chr2:25100338	C/T	cg15423357	chr2:25149977	NA	0.5	4.75	0.39	5.43e-6	Body mass index;
TGCT	cis	rs137603	0.644	rs94852	chr22:39712334	T/C	cg01093212	chr22:39715156	SNORD43;RPL3	-0.51	-4.98	-0.41	2.09e-6	Primary biliary cholangitis;
TGCT	cis	rs11190604	1.000	rs7078799	chr10:102301447	G/A	cg16342193	chr10:102329863	NA	-0.4	-4.97	-0.41	2.14e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs782590	0.837	rs809732	chr2:55914621	T/C	cg18811423	chr2:55921094	PNPT1	0.7	7.83	0.58	1.88e-12	Metabolic syndrome;
TGCT	cis	rs7666738	0.753	rs13111199	chr4:98953705	A/G	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs739401	0.572	rs739400	chr11:3016520	G/A	cg05729581	chr11:3078854	CARS	-0.59	-5.39	-0.44	3.47e-7	Longevity;
TGCT	cis	rs11122272	0.705	rs2486742	chr1:231507254	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.14	-0.54	6.86e-11	Hemoglobin concentration;
TGCT	cis	rs3784262	0.565	rs12914414	chr15:58318757	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.39	-5.63	-0.45	1.16e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs62244186	0.659	rs7649834	chr3:44503732	C/T	cg15687855	chr3:44754131	ZNF502	-0.43	-5.23	-0.42	7.08e-7	Depressive symptoms;
TGCT	cis	rs12188164	0.515	rs11744936	chr5:412112	C/T	cg26850624	chr5:429559	AHRR	-0.2	-4.45	-0.37	1.9e-5	Cystic fibrosis severity;
TGCT	cis	rs1215050	0.791	rs1215054	chr4:98863009	T/G	cg17366294	chr4:99064904	C4orf37	-0.57	-6.12	-0.48	1.13e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1371867	0.846	rs924057	chr8:101266157	A/G	cg00191853	chr8:101177733	SPAG1	0.23	4.8	0.4	4.44e-6	Atrioventricular conduction;
TGCT	cis	rs9902453	1.000	rs7223786	chr17:28332107	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.74	-6.59	-0.51	1.12e-9	Coffee consumption (cups per day);
TGCT	cis	rs7267979	0.834	rs6115100	chr20:25225938	C/A	cg16686733	chr20:25566563	NINL	0.59	6.06	0.48	1.53e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7635838	0.539	rs430353	chr3:11254071	G/A	cg00170343	chr3:11313890	ATG7	0.58	5.5	0.44	2.11e-7	HDL cholesterol;
TGCT	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.56	4.9	0.4	2.92e-6	Height;
TGCT	trans	rs1814175	0.566	rs1811673	chr11:49602134	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.4	-7.77	-0.57	2.55e-12	Height;
TGCT	cis	rs2075371	0.501	rs1646654	chr7:134027547	G/C	cg11752832	chr7:134001865	SLC35B4	0.59	5.09	0.42	1.31e-6	Mean platelet volume;
TGCT	cis	rs7267979	0.932	rs1985737	chr20:25591468	T/A	cg03522245	chr20:25566470	NINL	0.6	6.47	0.5	2.1e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs797680	0.930	rs12128131	chr1:93546299	T/G	cg17826107	chr1:92977322	EVI5	-0.21	-4.78	-0.39	4.89e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg12288994	chr5:1860383	NA	0.24	4.65	0.39	8.32e-6	Cardiovascular disease risk factors;
TGCT	cis	rs911263	0.540	rs7158493	chr14:68812330	C/G	cg18825221	chr14:68749962	RAD51L1	0.22	4.46	0.37	1.82e-5	Primary biliary cholangitis;
TGCT	cis	rs7808935	0.768	rs757138	chr7:27989403	T/G	cg00453374	chr7:27701825	HIBADH	-0.45	-4.47	-0.37	1.72e-5	Prostate cancer;
TGCT	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg17264618	chr3:40429014	ENTPD3	0.33	4.71	0.39	6.47e-6	Renal cell carcinoma;
TGCT	cis	rs2964802	0.505	rs13180011	chr5:10824615	T/C	cg14521931	chr5:10832172	NA	-0.28	-4.71	-0.39	6.44e-6	Major depressive disorder;Recurrent major depressive disorder;
TGCT	cis	rs62244186	0.659	rs7649834	chr3:44503732	C/T	cg17546649	chr3:44802566	KIF15;KIAA1143	-0.36	-4.44	-0.37	1.99e-5	Depressive symptoms;
TGCT	cis	rs7605378	0.752	rs769960	chr2:200710706	G/T	cg19045956	chr2:200819837	C2orf60;C2orf47	-0.48	-4.65	-0.39	8.51e-6	Osteoporosis;
TGCT	cis	rs3812831	0.669	rs382913	chr13:114928255	G/T	cg06611532	chr13:114900021	NA	0.35	6.26	0.49	5.63e-9	Schizophrenia;
TGCT	cis	rs727563	0.635	rs2899348	chr22:42164516	C/G	cg06481639	chr22:41940642	POLR3H	0.69	6.05	0.48	1.59e-8	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs483180	0.532	rs561931	chr1:120254506	A/G	cg19096424	chr1:120255104	PHGDH	0.62	5.66	0.45	9.8e-8	Macular telangiectasia type 2;
TGCT	cis	rs854765	0.693	rs4924822	chr17:17748013	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.69	-6.46	-0.5	2.17e-9	Total body bone mineral density;
TGCT	cis	rs3824867	0.920	rs7105122	chr11:47449544	A/G	cg20307385	chr11:47447363	PSMC3	0.66	5.68	0.45	9.16e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg00149659	chr3:10157352	C3orf10	0.91	5.89	0.47	3.32e-8	Alzheimer's disease;
TGCT	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.62	-4.57	-0.38	1.14e-5	Tuberculosis;
TGCT	cis	rs1805008	0.561	rs8046635	chr16:90123493	C/T	cg08547343	chr16:90038815	CENPBD1;AFG3L1	-0.77	-4.45	-0.37	1.89e-5	Skin colour saturation;
TGCT	cis	rs4077468	0.927	rs1342063	chr1:205912859	C/T	cg24503407	chr1:205819492	PM20D1	-0.39	-4.61	-0.38	1e-5	Cystic fibrosis-related diabetes;
TGCT	cis	rs2404602	0.735	rs11638767	chr15:76655938	T/C	cg22467129	chr15:76604101	ETFA	0.45	4.57	0.38	1.14e-5	Blood metabolite levels;
TGCT	cis	rs6754311	0.593	rs313518	chr2:136439090	C/T	cg07169764	chr2:136633963	MCM6	0.63	5.62	0.45	1.19e-7	Mosquito bite size;
TGCT	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.8	5.54	0.45	1.72e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2153535	0.580	rs7767926	chr6:8453557	A/G	cg07606381	chr6:8435919	SLC35B3	0.53	5.02	0.41	1.79e-6	Motion sickness;
TGCT	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.31	-4.82	-0.4	4.12e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs854765	0.693	rs35451946	chr17:17764061	C/G	cg04398451	chr17:18023971	MYO15A	0.28	4.51	0.38	1.49e-5	Total body bone mineral density;
TGCT	cis	rs7647973	0.922	rs57273516	chr3:49483074	A/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.53	-4.45	-0.37	1.87e-5	Menarche (age at onset);
TGCT	cis	rs9303401	0.659	rs72828726	chr17:56951217	C/G	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs7727544	0.647	rs72793280	chr5:131562900	C/T	cg24060327	chr5:131705240	SLC22A5	-0.55	-5.12	-0.42	1.14e-6	Blood metabolite levels;
TGCT	cis	rs12142240	0.920	rs6697623	chr1:46757542	G/A	cg00530320	chr1:46809349	NSUN4	0.25	4.81	0.4	4.3e-6	Menopause (age at onset);
TGCT	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.31	0.43	4.9e-7	Prudent dietary pattern;
TGCT	cis	rs2456568	1.000	rs2456568	chr11:93691332	A/T	cg17595323	chr11:93583763	C11orf90	-0.46	-6.1	-0.48	1.25e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs4730250	0.581	rs3779500	chr7:106792704	T/C	cg02696742	chr7:106810147	HBP1	0.72	5.89	0.47	3.44e-8	Osteoarthritis;
TGCT	cis	rs12210905	0.925	rs12193820	chr6:27113811	A/G	cg08851530	chr6:28072375	NA	1.08	5.25	0.43	6.28e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg11644478	chr21:40555479	PSMG1	1.03	11.12	0.71	2.32e-20	Cognitive function;
TGCT	cis	rs78487399	0.808	rs75126888	chr2:43664007	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.24	-0.43	6.79e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs7617773	0.743	rs11716371	chr3:48362750	C/T	cg11946769	chr3:48343235	NME6	0.8	6.91	0.53	2.26e-10	Coronary artery disease;
TGCT	cis	rs3820928	0.839	rs12470666	chr2:227876525	G/A	cg11843606	chr2:227700838	RHBDD1	-0.55	-4.83	-0.4	3.97e-6	Pulmonary function;
TGCT	cis	rs2075371	0.932	rs2598290	chr7:133987736	C/G	cg11752832	chr7:134001865	SLC35B4	0.69	6.32	0.49	4.19e-9	Mean platelet volume;
TGCT	cis	rs302668	0.651	rs12295227	chr11:87870556	C/A	cg01568784	chr11:87908783	RAB38	0.34	4.52	0.38	1.4e-5	Frontotemporal dementia;
TGCT	cis	rs7208859	0.623	rs9912440	chr17:29148772	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg11764359	chr7:65958608	NA	0.63	5.68	0.45	8.88e-8	Aortic root size;
TGCT	cis	rs9916302	0.904	rs2061338	chr17:37421767	T/C	cg15445000	chr17:37608096	MED1	0.32	4.69	0.39	7.11e-6	Glomerular filtration rate (creatinine);
TGCT	trans	rs7618501	0.699	rs11713193	chr3:49924424	G/A	cg21659725	chr3:3221576	CRBN	0.76	8.86	0.62	6.99e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs12765878	0.967	rs11598018	chr10:105661315	C/A	cg11005552	chr10:105648138	OBFC1	0.44	7.7	0.57	3.69e-12	Coronary artery disease;
TGCT	cis	rs6121246	0.909	rs6060679	chr20:30270772	C/G	cg18721089	chr20:30220636	NA	0.42	4.65	0.39	8.2e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg08509172	chr19:19383838	TM6SF2	-0.35	-4.6	-0.38	1.02e-5	Tonsillectomy;
TGCT	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg13770153	chr20:60521292	NA	0.6	8.67	0.61	2.02e-14	Obesity-related traits;
TGCT	cis	rs7647973	0.925	rs7429661	chr3:49228800	G/A	cg05785598	chr3:49045655	WDR6	0.39	4.69	0.39	7.2e-6	Menarche (age at onset);
TGCT	trans	rs66573146	1.000	rs56178503	chr4:6961748	C/T	cg07817883	chr1:32538562	TMEM39B	1.56	8.31	0.6	1.45e-13	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs5769765	0.874	rs4624	chr22:50281917	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.4	-6.07	-0.48	1.46e-8	Schizophrenia;
TGCT	cis	rs7824557	0.545	rs34482136	chr8:11227885	C/T	cg21775007	chr8:11205619	TDH	-0.59	-5.48	-0.44	2.29e-7	Retinal vascular caliber;
TGCT	cis	rs9682041	0.877	rs10755126	chr3:170071694	C/G	cg07589077	chr3:170072950	NA	-0.29	-5.06	-0.41	1.48e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs947211	0.898	rs10900524	chr1:205748309	G/A	cg14893161	chr1:205819251	PM20D1	0.43	4.44	0.37	1.96e-5	Parkinson's disease;
TGCT	cis	rs9810089	0.903	rs7432375	chr3:136288405	G/A	cg12473912	chr3:136751656	NA	0.34	4.83	0.4	3.9e-6	Gestational age at birth (child effect);
TGCT	cis	rs6964587	1.000	rs28927678	chr7:91715662	C/T	cg22709100	chr7:91322751	NA	0.28	4.69	0.39	6.96e-6	Breast cancer;
TGCT	cis	rs10465746	0.682	rs55693838	chr1:84359081	G/A	cg10977910	chr1:84465055	TTLL7	0.65	6.37	0.5	3.39e-9	Obesity-related traits;
TGCT	cis	rs9894429	0.505	rs35570626	chr17:79611084	A/G	cg18240062	chr17:79603768	NPLOC4	0.56	4.9	0.4	2.95e-6	Eye color traits;
TGCT	cis	rs7086627	0.515	rs2125040	chr10:82208422	G/C	cg01528321	chr10:82214614	TSPAN14	0.65	6.21	0.49	7.21e-9	Post bronchodilator FEV1;
TGCT	cis	rs79387448	0.614	rs6719130	chr2:102958236	C/T	cg09003973	chr2:102972529	NA	1.34	10.63	0.69	3.78e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs1348850	0.567	rs880899	chr2:178532416	A/G	cg22681709	chr2:178499509	PDE11A	-0.47	-5.94	-0.47	2.69e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs295140	0.605	rs159320	chr2:201187775	A/G	cg04283868	chr2:201171347	SPATS2L	-0.47	-4.45	-0.37	1.87e-5	QT interval;
TGCT	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg06618935	chr21:46677482	NA	-0.37	-5.56	-0.45	1.58e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg11494091	chr17:61959527	GH2	0.6	14.37	0.79	3.65e-28	Prudent dietary pattern;
TGCT	cis	rs1215050	0.904	rs165246	chr4:98688541	C/T	cg05340658	chr4:99064831	C4orf37	0.44	4.67	0.39	7.64e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs4689388	0.926	rs10937719	chr4:6295322	C/G	cg14416269	chr4:6271139	WFS1	0.42	5.43	0.44	2.91e-7	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs826838	1.000	rs11168505	chr12:38939057	A/T	cg26384229	chr12:38710491	ALG10B	-0.81	-7.45	-0.56	1.38e-11	Heart rate;
TGCT	cis	rs6429082	0.667	rs10802800	chr1:235706283	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.55	-4.63	-0.38	9.13e-6	Adiposity;
TGCT	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg27211696	chr2:191398769	TMEM194B	0.28	5.2	0.42	8.06e-7	Pulse pressure;
TGCT	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg03303774	chr4:1407052	NA	0.32	4.73	0.39	6.03e-6	Obesity-related traits;
TGCT	cis	rs950169	0.580	rs35516100	chr15:85195430	C/T	cg17173187	chr15:85201210	NMB	0.59	6.75	0.52	5.05e-10	Schizophrenia;
TGCT	cis	rs1406084	0.636	rs6750165	chr2:154727830	T/C	cg25703346	chr2:154729189	GALNT13	0.79	4.63	0.38	9.04e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2427308	0.643	rs477859	chr20:60937597	A/G	cg06026331	chr20:60912101	LAMA5	-0.29	-4.65	-0.39	8.25e-6	Colorectal cancer;
TGCT	cis	rs68170813	0.523	rs3757713	chr7:107042750	A/C	cg02696742	chr7:106810147	HBP1	-0.68	-5.44	-0.44	2.69e-7	Coronary artery disease;
TGCT	cis	rs263156	1.000	rs839554	chr6:142907051	T/C	cg18419694	chr6:143832440	FUCA2	-0.4	-4.65	-0.39	8.22e-6	Ear morphology;Lobe size;Lobe attachment;
TGCT	cis	rs7104764	1.000	rs6598074	chr11:219398	G/A	cg18336825	chr11:236787	PSMD13;SIRT3	1.07	10.47	0.69	8.98e-19	Menarche (age at onset);
TGCT	cis	rs13191362	0.507	rs2846536	chr6:163033492	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.61	5.87	0.47	3.79e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7178424	0.606	rs1000598	chr15:62141611	G/C	cg00456672	chr15:62358751	C2CD4A	-0.29	-4.51	-0.38	1.51e-5	Height;
TGCT	cis	rs4733781	0.865	rs17284725	chr8:131282724	A/T	cg16277922	chr8:131349729	ASAP1	0.38	4.82	0.4	4.05e-6	Tuberculosis;
TGCT	cis	rs6570726	0.935	rs1883406	chr6:145823205	A/G	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs4650994	1.000	rs17361251	chr1:178520577	C/A	cg05059571	chr16:84539110	KIAA1609	-0.41	-7.6	-0.56	6.42e-12	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs7474896	0.583	rs10740950	chr10:38003496	C/T	cg25427524	chr10:38739819	LOC399744	-0.34	-5.47	-0.44	2.43e-7	Obesity (extreme);
TGCT	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg07061783	chr6:25882402	NA	-0.47	-4.95	-0.41	2.37e-6	Blood metabolite levels;
TGCT	cis	rs1577917	0.958	rs2660576	chr6:86651603	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.05	-0.41	1.57e-6	Response to antipsychotic treatment;
TGCT	cis	rs7539409	0.651	rs979757	chr1:84296605	T/C	cg10977910	chr1:84465055	TTLL7	0.9	5.47	0.44	2.39e-7	Alzheimer's disease;
TGCT	cis	rs9457247	0.967	rs2149083	chr6:167370971	G/C	cg23791538	chr6:167370224	RNASET2	0.51	4.98	0.41	2.09e-6	Crohn's disease;
TGCT	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg06238570	chr21:40685208	BRWD1	0.68	6.32	0.49	4.3e-9	Cognitive function;
TGCT	cis	rs1949733	0.523	rs55977448	chr4:8542918	G/T	cg13073564	chr4:8508604	NA	0.5	4.9	0.4	2.96e-6	Response to antineoplastic agents;
TGCT	cis	rs2594989	0.943	rs2454512	chr3:11487506	A/G	cg00170343	chr3:11313890	ATG7	0.69	5.1	0.42	1.26e-6	Circulating chemerin levels;
TGCT	cis	rs9894429	0.809	rs9889642	chr17:79591762	T/C	cg21028142	chr17:79581711	NPLOC4	0.29	6.81	0.52	3.83e-10	Eye color traits;
TGCT	cis	rs12142240	0.698	rs56358525	chr1:46849520	C/T	cg14993813	chr1:46806288	NSUN4	-0.59	-4.86	-0.4	3.45e-6	Menopause (age at onset);
TGCT	cis	rs7666738	0.962	rs17027204	chr4:98997049	G/A	cg17366294	chr4:99064904	C4orf37	0.69	6.39	0.5	3.1e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs62064224	0.703	rs62065493	chr17:30822620	C/G	cg18200150	chr17:30822561	MYO1D	0.57	8.04	0.59	6.08e-13	Schizophrenia;
TGCT	cis	rs12220898	0.679	rs10857458	chr10:50477906	A/G	cg06072769	chr10:50146962	WDFY4	0.35	4.5	0.37	1.56e-5	Inflammatory biomarkers;
TGCT	cis	rs1401999	1.000	rs2176824	chr3:183654029	C/G	cg01324343	chr3:183735012	ABCC5	0.85	11.33	0.71	7.12e-21	Anterior chamber depth;
TGCT	cis	rs3820068	0.608	rs6668919	chr1:16049893	A/G	cg05660106	chr1:15850417	CASP9	-0.72	-6.7	-0.52	6.62e-10	Systolic blood pressure;
TGCT	cis	rs1008375	0.932	rs2302394	chr4:17641188	A/G	cg16339924	chr4:17578868	LAP3	0.66	5.52	0.44	1.89e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7666738	0.830	rs2114426	chr4:98933130	C/T	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28735056	0.609	rs4799099	chr18:77639585	A/G	cg20368463	chr18:77673604	PQLC1	0.45	5.5	0.44	2.04e-7	Schizophrenia;
TGCT	cis	rs73384572	1.000	rs2123421	chr10:130931444	G/T	cg00886512	chr10:131637291	EBF3	0.4	4.57	0.38	1.15e-5	Neuroticism;
TGCT	cis	rs10782582	0.586	rs11161902	chr1:76392498	C/G	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.56	4.84	0.4	3.71e-6	Daytime sleep phenotypes;
TGCT	cis	rs7666738	0.546	rs13105521	chr4:98734419	C/T	cg05340658	chr4:99064831	C4orf37	0.5	5.57	0.45	1.5e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2832191	0.935	rs11910475	chr21:30519702	T/C	cg08807101	chr21:30365312	RNF160	-0.54	-5.02	-0.41	1.78e-6	Dental caries;
TGCT	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg13770153	chr20:60521292	NA	-0.54	-7.12	-0.54	7.73e-11	Body mass index;
TGCT	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg20203395	chr5:56204925	C5orf35	-0.51	-4.65	-0.39	8.42e-6	Initial pursuit acceleration;
TGCT	cis	rs7017914	0.905	rs2732094	chr8:71919918	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.55	-5.1	-0.42	1.24e-6	Bone mineral density;
TGCT	cis	rs526231	0.578	rs59323174	chr5:102267869	T/C	cg23492399	chr5:102201601	PAM	-0.51	-4.51	-0.38	1.47e-5	Primary biliary cholangitis;
TGCT	cis	rs2404602	0.598	rs11855999	chr15:76627333	A/C	cg22467129	chr15:76604101	ETFA	0.51	4.97	0.41	2.16e-6	Blood metabolite levels;
TGCT	cis	rs2594989	0.831	rs7651790	chr3:11572610	C/T	cg26283222	chr3:11613257	VGLL4	0.2	4.45	0.37	1.89e-5	Circulating chemerin levels;
TGCT	cis	rs265548	0.646	rs36692	chr19:17906839	C/T	cg21960279	chr19:17905606	B3GNT3	0.48	5.41	0.44	3.15e-7	Tumor biomarkers;
TGCT	cis	rs28595532	0.844	rs116721336	chr4:119536538	A/G	cg21605333	chr4:119757512	SEC24D	1.33	8.01	0.58	7.07e-13	Cannabis dependence symptom count;
TGCT	cis	rs1062177	0.547	rs2915818	chr5:151115290	T/A	cg12924095	chr5:151150029	G3BP1	-0.33	-4.82	-0.4	4.07e-6	Preschool internalizing problems;
TGCT	cis	rs3733585	0.673	rs7375587	chr4:9954758	A/T	cg00071950	chr4:10020882	SLC2A9	0.54	6.36	0.5	3.54e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7208859	0.623	rs8080882	chr17:29081146	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg27436995	chr16:743998	FBXL16	-0.46	-5.08	-0.42	1.35e-6	Height;
TGCT	cis	rs9549367	0.789	rs3850451	chr13:113905812	C/G	cg18105134	chr13:113819100	PROZ	-0.34	-5.58	-0.45	1.41e-7	Platelet distribution width;
TGCT	cis	rs13191362	0.507	rs6936804	chr6:163069424	A/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.6	-5.24	-0.43	6.77e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs1153858	1.000	rs16942568	chr15:45677390	T/C	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.62e-8	Homoarginine levels;
TGCT	cis	rs2338224	1.000	rs12697710	chr5:71747245	T/A	cg01187920	chr5:71015162	CARTPT	-0.53	-4.57	-0.38	1.15e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Granulocyte count;Myeloid white cell count;
TGCT	cis	rs1215050	0.740	rs700740	chr4:98976003	A/C	cg05340658	chr4:99064831	C4orf37	-0.43	-5.27	-0.43	5.8e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs3809566	1.000	rs4775610	chr15:63332057	C/T	cg05507819	chr15:63340323	TPM1	-0.49	-4.57	-0.38	1.16e-5	Platelet count;
TGCT	cis	rs7937682	0.889	rs493810	chr11:111491888	G/T	cg09085632	chr11:111637200	PPP2R1B	-1.05	-11.36	-0.71	6.21e-21	Primary sclerosing cholangitis;
TGCT	cis	rs7647973	0.696	rs7100	chr3:49053219	A/G	cg07636037	chr3:49044803	WDR6	0.81	6.68	0.51	7.37e-10	Menarche (age at onset);
TGCT	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg04772025	chr11:68637568	NA	-0.61	-6.86	-0.52	2.95e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg21285383	chr16:89894308	SPIRE2	0.43	6.48	0.5	1.93e-9	Vitiligo;
TGCT	cis	rs1153858	0.943	rs8038342	chr15:45651537	T/C	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.62e-8	Homoarginine levels;
TGCT	cis	rs11696501	0.739	rs6073843	chr20:44293956	G/A	cg11783356	chr20:44313418	WFDC10B	-0.32	-4.63	-0.38	9.25e-6	Brain structure;
TGCT	cis	rs4886920	0.573	rs11854573	chr15:78108112	C/A	cg25212270	chr15:78015279	NA	0.24	4.62	0.38	9.48e-6	Neuroticism;
TGCT	cis	rs2739330	0.576	rs2858912	chr22:24297197	A/G	cg25703541	chr22:24373054	LOC391322	-0.81	-8.7	-0.62	1.68e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg02380750	chr20:61661411	NA	0.33	5.96	0.47	2.4e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9467773	1.000	rs1535277	chr6:26567802	G/T	cg05738196	chr6:26577821	NA	0.9	12.48	0.75	1.16e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs6728302	0.557	rs73001973	chr2:233241575	G/A	cg06555452	chr2:233241558	NA	0.37	4.99	0.41	2.01e-6	Height;
TGCT	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg03264133	chr6:25882463	NA	-0.61	-6.51	-0.5	1.69e-9	Blood metabolite levels;
TGCT	cis	rs9325144	0.624	rs10506126	chr12:39123244	G/A	cg10518543	chr12:38710700	ALG10B	-0.48	-4.44	-0.37	1.94e-5	Morning vs. evening chronotype;
TGCT	cis	rs11690935	1.000	rs34542126	chr2:172542705	C/T	cg13550731	chr2:172543902	DYNC1I2	1.2	12.95	0.76	8.62e-25	Schizophrenia;
TGCT	cis	rs10972341	1.000	rs7856842	chr9:35145157	C/T	cg00812861	chr9:35114699	KIAA1539	0.33	5.0	0.41	1.88e-6	Weight;
TGCT	cis	rs2228479	0.850	rs2238527	chr16:89840708	C/A	cg06558623	chr16:89946397	TCF25	0.45	4.52	0.38	1.42e-5	Skin colour saturation;
TGCT	cis	rs4808199	0.842	rs11085259	chr19:19445856	C/T	cg03709012	chr19:19516395	GATAD2A	0.81	6.32	0.49	4.32e-9	Nonalcoholic fatty liver disease;
TGCT	cis	rs7552404	0.883	rs7513363	chr1:76143443	A/G	cg03433033	chr1:76189801	ACADM	0.82	9.89	0.66	2.31e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7666738	0.830	rs6851253	chr4:99029980	A/G	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg13206674	chr6:150067644	NUP43	0.52	4.46	0.37	1.78e-5	Lung cancer;
TGCT	cis	rs9302065	0.681	rs59108692	chr13:95962424	C/A	cg26751094	chr13:95954534	ABCC4	-0.33	-5.31	-0.43	4.91e-7	Blood metabolite levels;
TGCT	cis	rs7192750	0.517	rs9932922	chr16:71918178	T/C	cg06353428	chr16:71660113	MARVELD3	0.82	7.26	0.55	3.82e-11	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs5769765	0.954	rs5770709	chr22:50245196	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	1.08	11.84	0.73	4.29e-22	Schizophrenia;
TGCT	cis	rs11118844	0.696	rs11118859	chr1:221953193	A/T	cg04222084	chr1:221915650	DUSP10	-0.78	-4.66	-0.39	8.03e-6	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
TGCT	cis	rs79387448	0.745	rs9677607	chr2:103149520	A/T	cg09003973	chr2:102972529	NA	0.97	6.32	0.49	4.33e-9	Gut microbiota (bacterial taxa);
TGCT	cis	rs2073300	1.000	rs6137984	chr20:23469864	T/A	cg09953122	chr20:23471693	CST8	-0.7	-4.76	-0.39	5.31e-6	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	trans	rs28735056	0.967	rs11660941	chr18:77630600	G/C	cg05926928	chr17:57297772	GDPD1	-0.71	-7.6	-0.56	6.2e-12	Schizophrenia;
TGCT	cis	rs7208859	0.623	rs11652533	chr17:29060601	A/C	cg13385521	chr17:29058706	SUZ12P	0.79	4.77	0.39	5.16e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs4242434	0.597	rs1877675	chr8:22533947	C/T	cg21658235	chr8:22456391	C8orf58	-0.45	-4.74	-0.39	5.8e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs7044106	0.791	rs7036196	chr9:123479457	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	4.85	0.4	3.57e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs3091242	0.967	rs3093614	chr1:25677844	T/A	cg10117171	chr1:25599238	RHD	0.35	5.71	0.46	7.87e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs7666738	0.791	rs11729596	chr4:99045461	A/G	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7582180	0.606	rs11684004	chr2:100954783	C/T	cg14675211	chr2:100938903	LONRF2	0.5	4.78	0.39	4.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9649213	0.614	rs4729432	chr7:97947055	G/C	cg09267113	chr7:98030324	BAIAP2L1	-0.94	-8.69	-0.62	1.83e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9291683	0.530	rs11723970	chr4:9980462	T/C	cg00071950	chr4:10020882	SLC2A9	0.65	8.23	0.59	2.21e-13	Bone mineral density;
TGCT	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs259282	0.563	rs596394	chr19:33111162	T/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.73	7.36	0.55	2.2e-11	Schizophrenia;
TGCT	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg10802521	chr3:52805072	NEK4	-0.72	-9.11	-0.63	1.76e-15	Bipolar disorder;
TGCT	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg22920501	chr2:26401640	FAM59B	-0.81	-6.36	-0.5	3.52e-9	Gut microbiome composition (summer);
TGCT	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg11644478	chr21:40555479	PSMG1	0.88	8.03	0.59	6.26e-13	Cognitive function;
TGCT	cis	rs6665290	0.835	rs7549465	chr1:227214399	A/C	cg10327440	chr1:227177885	CDC42BPA	-0.92	-16.53	-0.83	3.84e-33	Myeloid white cell count;
TGCT	cis	rs4970988	0.501	rs11204713	chr1:150694623	T/A	cg09365446	chr1:150670422	GOLPH3L	0.3	4.52	0.38	1.4e-5	Urate levels;
TGCT	cis	rs17030434	1.000	rs10026531	chr4:154727070	C/T	cg14289246	chr4:154710475	SFRP2	-0.88	-6.96	-0.53	1.78e-10	Electrocardiographic conduction measures;
TGCT	cis	rs1570884	0.890	rs6561541	chr13:50127280	C/T	cg08779649	chr13:50194554	NA	0.32	4.78	0.39	4.77e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
TGCT	cis	rs9581857	0.685	rs9319369	chr13:28042323	A/T	cg22138327	chr13:27999177	GTF3A	0.72	4.6	0.38	1.03e-5	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs7552404	0.628	rs5745442	chr1:76342858	T/G	cg22875332	chr1:76189707	ACADM	0.68	6.91	0.53	2.23e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs17376456	1.000	rs6867042	chr5:93555761	C/T	cg25358565	chr5:93447407	FAM172A	0.94	7.65	0.57	4.72e-12	Diabetic retinopathy;
TGCT	cis	rs4642101	0.534	rs13316229	chr3:12807371	C/T	cg05775895	chr3:12838266	CAND2	0.51	5.11	0.42	1.16e-6	QRS complex (12-leadsum);
TGCT	cis	rs892961	0.836	rs35077273	chr17:75412415	T/C	cg05865280	chr17:75406074	SEPT9	0.28	6.86	0.52	2.9e-10	Airflow obstruction;
TGCT	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg09359103	chr1:154839909	KCNN3	-0.63	-11.36	-0.71	6.16e-21	Prostate cancer;
TGCT	cis	rs394563	0.591	rs237035	chr6:149710848	C/T	cg03678062	chr6:149772716	ZC3H12D	-0.38	-4.74	-0.39	5.87e-6	Dupuytren's disease;
TGCT	cis	rs2658782	0.724	rs2658769	chr11:93252030	T/C	cg15737290	chr11:93063684	CCDC67	0.63	4.72	0.39	6.22e-6	Pulmonary function decline;
TGCT	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg22963979	chr7:1858916	MAD1L1	-0.36	-5.77	-0.46	6.08e-8	Bipolar disorder and schizophrenia;
TGCT	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg11764359	chr7:65958608	NA	0.61	5.54	0.45	1.76e-7	Aortic root size;
TGCT	cis	rs682748	0.846	rs13178413	chr5:17151456	G/A	cg23987134	chr5:17158319	LOC285696	-0.22	-5.4	-0.44	3.21e-7	Hippocampal atrophy;
TGCT	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg13395646	chr4:1353034	KIAA1530	-0.36	-4.45	-0.37	1.91e-5	Obesity-related traits;
TGCT	cis	rs1371867	0.839	rs1788186	chr8:101335686	T/C	cg06636551	chr8:101224915	SPAG1	-0.42	-5.65	-0.45	1.06e-7	Atrioventricular conduction;
TGCT	cis	rs524281	0.684	rs7946447	chr11:65864338	T/C	cg00563793	chr11:65837595	PACS1	0.55	4.64	0.38	8.89e-6	Electroencephalogram traits;
TGCT	cis	rs7267979	0.966	rs6050567	chr20:25354561	C/T	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs12142240	0.698	rs6697123	chr1:46811310	A/C	cg14993813	chr1:46806288	NSUN4	-0.58	-4.81	-0.4	4.34e-6	Menopause (age at onset);
TGCT	cis	rs7746199	0.736	rs6904596	chr6:27491299	G/A	cg10876282	chr6:28092338	ZSCAN16	0.87	4.72	0.39	6.19e-6	Gait speed in old age;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9388451	0.537	rs1739383	chr6:126098915	G/T	cg05901451	chr6:126070800	HEY2	-0.94	-11.89	-0.73	3.1e-22	Brugada syndrome;
TGCT	cis	rs9611565	0.512	rs139561	chr22:42195410	C/T	cg13695892	chr22:41940480	POLR3H	0.79	7.51	0.56	9.92e-12	Vitiligo;
TGCT	trans	rs561341	0.883	rs4450460	chr17:30201309	C/T	cg20587970	chr11:113659929	NA	0.8	9.3	0.64	6.34e-16	Hip circumference adjusted for BMI;
TGCT	cis	rs2549003	0.811	rs10035166	chr5:131823927	C/T	cg02551604	chr5:131831745	NA	0.66	7.02	0.53	1.27e-10	Asthma (sex interaction);
TGCT	cis	rs7772486	0.713	rs1986729	chr6:146194831	G/A	cg05347473	chr6:146136440	FBXO30	0.54	5.06	0.41	1.44e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7772486	0.875	rs2748497	chr6:146319417	C/T	cg23711669	chr6:146136114	FBXO30	0.8	8.06	0.59	5.4e-13	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg19010396	chr19:19431384	KIAA0892;SF4	-0.55	-4.56	-0.38	1.22e-5	Tonsillectomy;
TGCT	cis	rs13242816	1.000	rs1049334	chr7:116200380	A/G	cg02799643	chr7:116139180	CAV2	0.45	5.67	0.45	9.71e-8	P wave duration;
TGCT	cis	rs2458413	0.500	rs2458418	chr8:105350851	A/G	cg04554929	chr8:105342491	NA	0.52	6.13	0.48	1.1e-8	Paget's disease;
TGCT	cis	rs4689388	0.890	rs6446481	chr4:6295583	C/A	cg00701064	chr4:6280414	WFS1	0.39	4.78	0.39	4.97e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs7264396	0.616	rs6060744	chr20:34581555	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.28	-4.96	-0.41	2.25e-6	Total cholesterol levels;
TGCT	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg11494091	chr17:61959527	GH2	0.6	13.05	0.76	5.09e-25	Prudent dietary pattern;
TGCT	cis	rs9549260	0.712	rs1334241	chr13:41223110	C/T	cg21288729	chr13:41239152	FOXO1	0.69	4.87	0.4	3.31e-6	Red blood cell count;
TGCT	cis	rs2549003	1.000	rs7701588	chr5:131819970	T/C	cg00255919	chr5:131827918	IRF1	0.2	4.7	0.39	6.92e-6	Asthma (sex interaction);
TGCT	cis	rs6570726	0.791	rs6570693	chr6:145910841	C/T	cg13319975	chr6:146136371	FBXO30	-0.52	-4.68	-0.39	7.45e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7772486	0.846	rs2492856	chr6:146323928	A/G	cg23711669	chr6:146136114	FBXO30	0.82	8.92	0.63	5.14e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9900497	0.504	rs2228100	chr17:19642952	C/G	cg15323506	chr17:19619410	SLC47A2	0.19	4.91	0.4	2.86e-6	Response to paliperidone in schizophrenia (CGI-S score);
TGCT	cis	rs9926296	0.581	rs1108064	chr16:89894150	G/C	cg26513180	chr16:89883248	FANCA	0.74	7.25	0.55	3.87e-11	Vitiligo;
TGCT	cis	rs7926906	1.000	rs10734138	chr11:90538063	A/C	cg26138821	chr11:89956704	CHORDC1	-0.51	-5.39	-0.44	3.46e-7	Intelligence (multi-trait analysis);
TGCT	trans	rs9650657	0.501	rs3021500	chr8:11023997	G/C	cg06636001	chr8:8085503	FLJ10661	-0.83	-7.83	-0.58	1.84e-12	Neuroticism;
TGCT	cis	rs12497850	0.931	rs13316620	chr3:49045355	T/C	cg06212747	chr3:49208901	KLHDC8B	0.61	5.51	0.44	2e-7	Parkinson's disease;
TGCT	cis	rs9383153	0.625	rs1886349	chr6:16320320	G/A	cg14009473	chr6:15502099	JARID2	0.68	5.14	0.42	1.03e-6	Gambling;
TGCT	cis	rs12497850	0.931	rs9755490	chr3:48871664	A/C	cg05785598	chr3:49045655	WDR6	0.36	4.75	0.39	5.46e-6	Parkinson's disease;
TGCT	cis	rs7000551	0.689	rs6984908	chr8:22316901	A/G	cg12081754	chr8:22256438	SLC39A14	-0.29	-4.89	-0.4	3.01e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs1372520	0.684	rs184810	chr4:90697979	T/C	cg20003494	chr4:90757398	SNCA	0.56	4.46	0.37	1.83e-5	Neuroticism;
TGCT	cis	rs1997103	0.911	rs9642575	chr7:55399090	C/T	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs7940866	0.774	rs12420126	chr11:130834811	C/T	cg12179176	chr11:130786555	SNX19	0.61	5.72	0.46	7.47e-8	Schizophrenia;
TGCT	cis	rs9926296	0.572	rs8047581	chr16:89884502	C/T	cg26513180	chr16:89883248	FANCA	0.75	7.67	0.57	4.42e-12	Vitiligo;
TGCT	cis	rs12477438	0.798	rs4851179	chr2:99568774	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-6.46	-0.5	2.2e-9	Chronic sinus infection;
TGCT	cis	rs13256369	1.000	rs4840351	chr8:8573148	A/G	cg18904891	chr8:8559673	CLDN23	0.62	5.67	0.45	9.47e-8	Obesity-related traits;
TGCT	cis	rs9611565	0.879	rs5758311	chr22:41759375	G/T	cg06481639	chr22:41940642	POLR3H	-0.58	-5.01	-0.41	1.81e-6	Vitiligo;
TGCT	trans	rs2727020	0.521	rs10839285	chr11:49496852	T/G	cg03929089	chr4:120376271	NA	0.63	6.88	0.53	2.59e-10	Coronary artery disease;
TGCT	cis	rs2046867	0.862	rs6788139	chr3:72835630	A/G	cg25664220	chr3:72788482	NA	0.49	6.52	0.51	1.57e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs4803468	0.935	rs13346603	chr19:41945837	T/A	cg09537434	chr19:41945824	ATP5SL	0.91	10.11	0.67	6.81e-18	Height;
TGCT	cis	rs62244186	0.520	rs2372828	chr3:44784949	A/G	cg10263370	chr3:44754102	ZNF502	0.45	5.35	0.43	4.08e-7	Depressive symptoms;
TGCT	cis	rs12142240	0.731	rs6681857	chr1:46850124	T/C	cg14993813	chr1:46806288	NSUN4	-0.59	-4.9	-0.4	2.94e-6	Menopause (age at onset);
TGCT	cis	rs265548	0.608	rs36690	chr19:17910483	C/T	cg03316864	chr19:17906309	B3GNT3	0.46	5.55	0.45	1.62e-7	Tumor biomarkers;
TGCT	cis	rs6912958	0.514	rs7767449	chr6:87887985	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.66	-6.67	-0.51	7.5e-10	Monocyte percentage of white cells;
TGCT	cis	rs5769765	0.862	rs9616385	chr22:50313124	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.24	-12.97	-0.76	7.81e-25	Schizophrenia;
TGCT	cis	rs2486012	0.737	rs37457	chr1:44291191	G/A	cg12908607	chr1:44402522	ARTN	-0.69	-5.35	-0.43	4.16e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg04944784	chr2:26401820	FAM59B	0.76	6.24	0.49	6.46e-9	Gut microbiome composition (summer);
TGCT	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.4	-4.76	-0.39	5.24e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs10782582	0.609	rs5745469	chr1:76347394	G/A	cg10523679	chr1:76189770	ACADM	-0.59	-5.42	-0.44	2.94e-7	Daytime sleep phenotypes;
TGCT	cis	rs4506170	1.000	rs60163266	chr8:128323157	G/A	cg07795030	chr8:128802207	NA	-0.21	-4.61	-0.38	9.75e-6	Prostate cancer;
TGCT	cis	rs986417	0.748	rs12436632	chr14:61034416	T/C	cg27398547	chr14:60952738	C14orf39	1.33	10.37	0.68	1.56e-18	Gut microbiota (bacterial taxa);
TGCT	cis	rs2032447	0.670	rs198801	chr6:26139741	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.83	-8.54	-0.61	4.12e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs7208859	0.524	rs77498725	chr17:29063986	C/T	cg13385521	chr17:29058706	SUZ12P	0.8	4.87	0.4	3.36e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs425277	0.917	rs262656	chr1:2088754	A/C	cg03732007	chr1:2071316	PRKCZ	0.26	5.41	0.44	3.07e-7	Height;
TGCT	cis	rs17767294	0.708	rs113741085	chr6:27849982	C/A	cg08851530	chr6:28072375	NA	1.58	7.16	0.54	6.15e-11	Parkinson's disease;
TGCT	cis	rs6500602	0.727	rs11076837	chr16:4569440	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.31	5.78	0.46	5.58e-8	Schizophrenia;
TGCT	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg05368731	chr17:41323189	NBR1	1.04	11.28	0.71	9.71e-21	Menopause (age at onset);
TGCT	cis	rs9467773	0.620	rs9461275	chr6:26590801	C/T	cg02458000	chr6:26745757	NA	0.51	4.77	0.39	5.08e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg11941060	chr3:133502564	NA	-0.26	-5.32	-0.43	4.74e-7	Iron status biomarkers;
TGCT	cis	rs10771431	0.597	rs10843142	chr12:9357502	A/G	cg08997352	chr12:9597637	DDX12	-0.25	-5.04	-0.41	1.63e-6	Breast size;
TGCT	cis	rs6688613	0.694	rs1476347	chr1:166815587	G/T	cg07049167	chr1:166818506	POGK	0.24	5.08	0.42	1.34e-6	Refractive astigmatism;
TGCT	cis	rs9467711	0.606	rs2073531	chr6:26375256	A/G	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6430585	1.000	rs73958618	chr2:136500475	A/G	cg07169764	chr2:136633963	MCM6	0.88	7.84	0.58	1.78e-12	Corneal structure;
TGCT	cis	rs11098499	0.954	rs11734241	chr4:120416872	A/G	cg09307838	chr4:120376055	NA	0.69	6.64	0.51	8.97e-10	Corneal astigmatism;
TGCT	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg07424592	chr7:64974309	NA	-0.56	-5.36	-0.43	3.83e-7	Calcium levels;
TGCT	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg19774624	chr17:42201019	HDAC5	-0.87	-10.86	-0.7	1.02e-19	Total body bone mineral density;
TGCT	cis	rs10791097	0.582	rs2282578	chr11:130735691	A/T	cg12179176	chr11:130786555	SNX19	0.81	9.76	0.66	4.74e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs10876993	0.890	rs12302350	chr12:58062589	T/G	cg15848620	chr12:58087721	OS9	-0.71	-5.63	-0.45	1.13e-7	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs6582630	0.519	rs4002440	chr12:38485012	A/G	cg13010199	chr12:38710504	ALG10B	0.58	4.72	0.39	6.16e-6	Drug-induced liver injury (flucloxacillin);
TGCT	trans	rs6762477	0.748	rs3755831	chr3:50228767	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.78	-7.85	-0.58	1.68e-12	Menarche (age at onset);
TGCT	cis	rs17443541	0.507	rs6435020	chr2:200448356	C/T	cg00055341	chr2:200446845	NA	-0.34	-4.63	-0.38	9.15e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs8072100	0.764	rs2644349	chr17:45641743	G/A	cg08085267	chr17:45401833	C17orf57	0.42	4.62	0.38	9.57e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs9611519	0.929	rs4820423	chr22:41430338	A/T	cg03806693	chr22:41940476	POLR3H	-0.7	-6.22	-0.49	6.88e-9	Neuroticism;
TGCT	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg18876405	chr7:65276391	NA	0.4	6.37	0.5	3.34e-9	Calcium levels;
TGCT	cis	rs131805	1.000	rs3091397	chr22:50957520	C/T	cg25309564	chr22:51001381	C22orf41	0.5	4.67	0.39	7.67e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs77972916	0.611	rs61552842	chr2:43584036	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.37	-5.45	-0.44	2.61e-7	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs8141529	0.748	rs5762881	chr22:29289346	C/A	cg02153584	chr22:29168773	CCDC117	0.63	4.87	0.4	3.3e-6	Lymphocyte counts;
TGCT	cis	rs11651000	0.761	rs11657388	chr17:45820707	C/G	cg06532163	chr17:45867833	NA	0.33	4.82	0.4	4.05e-6	IgG glycosylation;
TGCT	cis	rs79057730	0.527	rs35316052	chr7:802954	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.76	5.84	0.46	4.31e-8	Initial pursuit acceleration;
TGCT	cis	rs3796352	1.000	rs13074524	chr3:52974184	A/G	cg15956490	chr3:53032818	SFMBT1	0.59	6.04	0.48	1.65e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs7208859	0.524	rs73263982	chr17:28920624	T/C	cg14008862	chr17:28927542	LRRC37B2	0.72	4.59	0.38	1.08e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs62244186	0.632	rs1402751	chr3:44594030	C/A	cg04389838	chr3:44770851	ZNF501	-0.42	-5.69	-0.45	8.77e-8	Depressive symptoms;
TGCT	cis	rs274567	0.602	rs272853	chr5:131688561	A/G	cg16647868	chr5:131706066	SLC22A5	0.32	4.77	0.39	4.97e-6	Blood metabolite levels;
TGCT	cis	rs1008375	0.932	rs6449317	chr4:17631253	T/C	cg18681998	chr4:17616180	MED28	0.97	9.68	0.66	7.47e-17	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs75686122	0.892	rs17807953	chr8:104638505	A/G	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs7829975	0.902	rs485107	chr8:8581408	C/G	cg08975724	chr8:8085496	FLJ10661	-0.52	-4.53	-0.38	1.39e-5	Mood instability;
TGCT	cis	rs9467773	1.000	rs4713006	chr6:26519872	A/G	cg15659132	chr6:26577336	NA	0.86	12.21	0.74	5.3e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs9357506	1.000	rs6940825	chr6:46304945	C/T	cg21115430	chr6:46460003	NA	-0.26	-5.16	-0.42	9.37e-7	Body mass index;
TGCT	cis	rs35306767	1.000	rs35306767	chr10:989437	A/T	cg20503657	chr10:835505	NA	0.62	8.19	0.59	2.64e-13	Eosinophil percentage of granulocytes;
TGCT	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg08736216	chr1:53307985	ZYG11A	-0.28	-5.58	-0.45	1.44e-7	Monocyte count;
TGCT	cis	rs2227564	0.620	rs3812637	chr10:75568846	C/T	cg04320760	chr10:75533139	FUT11	-0.32	-4.53	-0.38	1.35e-5	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs11809207	0.719	rs4659415	chr1:26580790	C/T	cg03844060	chr1:26490628	NA	0.27	5.22	0.42	7.22e-7	Height;
TGCT	cis	rs394563	0.775	rs399673	chr6:149783221	T/C	cg03678062	chr6:149772716	ZC3H12D	-0.36	-4.45	-0.37	1.87e-5	Dupuytren's disease;
TGCT	cis	rs526231	0.819	rs2288788	chr5:102600569	A/C	cg05225461	chr5:102596755	C5orf30	0.24	4.79	0.4	4.7e-6	Primary biliary cholangitis;
TGCT	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	5.68	0.45	9.24e-8	Height;
TGCT	trans	rs4332037	0.552	rs11773627	chr7:2002733	A/G	cg10840412	chr1:235813424	GNG4	0.87	6.66	0.51	7.87e-10	Bipolar disorder;
TGCT	cis	rs9915657	1.000	rs9910864	chr17:70123028	T/A	cg06234051	chr17:70120541	SOX9	-0.29	-5.62	-0.45	1.17e-7	Thyroid hormone levels;
TGCT	cis	rs4975616	0.773	rs414965	chr5:1324121	G/A	cg07493874	chr5:1342172	CLPTM1L	-0.28	-6.77	-0.52	4.62e-10	Lung cancer;
TGCT	cis	rs9611565	0.649	rs9623450	chr22:42175231	G/A	cg03806693	chr22:41940476	POLR3H	0.9	8.76	0.62	1.2e-14	Vitiligo;
TGCT	cis	rs7715806	0.500	rs17649332	chr5:75003878	T/C	cg19683494	chr5:74908142	NA	0.57	5.02	0.41	1.76e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs7044106	0.791	rs10984997	chr9:123481206	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	7.21	0.54	4.88e-11	Hip circumference adjusted for BMI;
TGCT	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg26398791	chr1:38455867	SF3A3	-0.62	-6.23	-0.49	6.65e-9	Coronary artery disease;
TGCT	cis	rs4689388	0.727	rs1801213	chr4:6293696	C/G	cg14416269	chr4:6271139	WFS1	0.46	5.77	0.46	5.93e-8	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg09359103	chr1:154839909	KCNN3	-0.62	-11.25	-0.71	1.15e-20	Prostate cancer;
TGCT	cis	rs1577917	0.874	rs1838954	chr6:86565478	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.29	-0.43	5.34e-7	Response to antipsychotic treatment;
TGCT	cis	rs6831352	0.918	rs29001216	chr4:100051556	A/T	cg12011299	chr4:100065546	ADH4	-0.41	-4.92	-0.4	2.72e-6	Alcohol dependence;
TGCT	cis	rs12049351	0.774	rs12030128	chr1:229622863	A/G	cg12130225	chr1:229698885	NA	0.39	4.59	0.38	1.06e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs4319547	0.695	rs4758643	chr12:122924819	A/T	cg05707623	chr12:122985044	ZCCHC8	-0.69	-5.38	-0.44	3.58e-7	Body mass index;
TGCT	cis	rs9399135	0.933	rs28384512	chr6:135376232	C/T	cg24558204	chr6:135376177	HBS1L	0.46	4.55	0.38	1.24e-5	Red blood cell count;
TGCT	cis	rs752010	0.574	rs10890157	chr1:42117689	C/G	cg06885757	chr1:42089581	HIVEP3	0.24	4.48	0.37	1.69e-5	Lupus nephritis in systemic lupus erythematosus;
TGCT	cis	rs899997	1.000	rs11632672	chr15:79044330	A/G	cg00061860	chr15:78953028	NA	-0.27	-4.67	-0.39	7.62e-6	Coronary artery disease or large artery stroke;
TGCT	cis	rs9549260	0.755	rs9549255	chr13:41235213	C/T	cg21288729	chr13:41239152	FOXO1	1.01	10.71	0.69	2.36e-19	Red blood cell count;
TGCT	cis	rs2580764	0.632	rs2588510	chr2:55199248	A/G	cg09592903	chr2:55203963	RTN4	-0.24	-5.53	-0.44	1.84e-7	Mean platelet volume;
TGCT	cis	rs7666738	0.830	rs10017557	chr4:98983969	G/A	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2439831	0.850	rs12441127	chr15:44021175	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	5.91	0.47	3.05e-8	Lung cancer in ever smokers;
TGCT	cis	rs9814567	1.000	rs9809619	chr3:134280948	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.95	-9.34	-0.64	4.93e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs2486288	0.586	rs12909883	chr15:45572054	G/C	cg26924012	chr15:45694286	SPATA5L1	-0.79	-7.73	-0.57	3.24e-12	Glomerular filtration rate;
TGCT	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.47	0.56	1.28e-11	Prudent dietary pattern;
TGCT	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg20064778	chr22:24384315	GSTT1	-0.49	-4.58	-0.38	1.12e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg13665807	chr20:60559372	TAF4	-0.5	-5.21	-0.42	7.51e-7	Body mass index;
TGCT	cis	rs9443645	0.808	rs2050661	chr6:79661125	T/C	cg09184832	chr6:79620586	NA	-0.49	-5.29	-0.43	5.29e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs4700695	0.668	rs253214	chr5:65499401	A/G	cg21114390	chr5:65439923	SFRS12	-0.81	-7.63	-0.57	5.36e-12	Facial morphology (factor 19);
TGCT	cis	rs10791323	0.511	rs4937837	chr11:133731134	T/C	cg15485101	chr11:133734466	NA	0.42	5.26	0.43	6.25e-7	Childhood ear infection;
TGCT	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg06873352	chr17:61820015	STRADA	0.58	6.37	0.5	3.32e-9	Prudent dietary pattern;
TGCT	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg11062466	chr8:58055876	NA	0.44	5.02	0.41	1.73e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg03709012	chr19:19516395	GATAD2A	0.64	5.38	0.43	3.65e-7	Tonsillectomy;
TGCT	cis	rs17376456	1.000	rs61132622	chr5:93539684	G/A	cg21475434	chr5:93447410	FAM172A	0.65	4.66	0.39	8.09e-6	Diabetic retinopathy;
TGCT	cis	rs7103648	0.630	rs7120548	chr11:47662932	A/G	cg20307385	chr11:47447363	PSMC3	0.9	8.62	0.61	2.58e-14	Diastolic blood pressure;Systolic blood pressure;
TGCT	cis	rs7666738	0.830	rs11947027	chr4:99005941	T/C	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs981844	0.775	rs1037656	chr4:154750786	A/G	cg14289246	chr4:154710475	SFRP2	-0.96	-8.42	-0.6	7.72e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs9372498	0.536	rs9481808	chr6:118784571	G/A	cg07617317	chr6:118971624	C6orf204	0.5	5.39	0.44	3.37e-7	Diastolic blood pressure;
TGCT	cis	rs3008870	1.000	rs2985822	chr1:67404910	T/G	cg03991309	chr1:68237761	GNG12	0.27	4.55	0.38	1.26e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs7598759	0.548	rs1584462	chr2:232369798	A/G	cg19187155	chr2:232395269	NMUR1	0.52	6.2	0.49	7.61e-9	Noise-induced hearing loss;
TGCT	cis	rs12148488	0.816	rs4886655	chr15:75385568	C/T	cg10253484	chr15:75165896	SCAMP2	-0.52	-4.5	-0.37	1.56e-5	Caffeine consumption;
TGCT	cis	rs4654899	0.865	rs12130664	chr1:21332812	G/T	cg01072550	chr1:21505969	NA	-0.46	-6.77	-0.52	4.63e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs7614311	0.689	rs73122704	chr3:63841228	C/T	cg22134162	chr3:63841271	THOC7	-0.41	-4.58	-0.38	1.1e-5	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs2742417	0.935	rs1468543	chr3:45776900	A/G	cg04837898	chr3:45731254	SACM1L	-0.53	-5.52	-0.44	1.92e-7	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs3806843	1.000	rs7732179	chr5:140199039	G/A	cg19875535	chr5:140030758	IK	0.36	5.82	0.46	4.74e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9291683	0.546	rs6829727	chr4:10051672	A/C	cg00071950	chr4:10020882	SLC2A9	0.56	6.29	0.49	4.98e-9	Bone mineral density;
TGCT	cis	rs4319547	0.695	rs7301515	chr12:122949673	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.64	-4.94	-0.41	2.45e-6	Body mass index;
TGCT	cis	rs739496	0.579	rs3213628	chr12:112280773	G/T	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs1011108	0.622	rs744539	chr2:26804122	T/G	cg18742855	chr2:26800399	C2orf70	-0.25	-5.7	-0.46	8.12e-8	Periodontal microbiota;
TGCT	cis	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg22709100	chr7:91322751	NA	0.3	4.77	0.39	5.15e-6	Breast cancer;
TGCT	cis	rs67072384	0.901	rs72964856	chr11:72473299	T/G	cg03713592	chr11:72463424	ARAP1	-0.88	-4.49	-0.37	1.62e-5	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg22920501	chr2:26401640	FAM59B	-0.73	-6.44	-0.5	2.35e-9	Gut microbiome composition (summer);
TGCT	cis	rs473651	0.904	rs10929275	chr2:239323169	A/G	cg21699342	chr2:239360505	ASB1	0.18	4.81	0.4	4.28e-6	Multiple system atrophy;
TGCT	cis	rs9916302	0.904	rs4794814	chr17:37696852	G/A	cg07936489	chr17:37558343	FBXL20	-0.61	-4.87	-0.4	3.29e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg22857025	chr5:266934	NA	-0.34	-6.72	-0.52	5.96e-10	Breast cancer;
TGCT	cis	rs17268829	0.927	rs10234392	chr7:94082994	T/C	cg06439941	chr7:93550756	GNG11	-0.24	-4.47	-0.37	1.74e-5	Breast cancer;
TGCT	cis	rs2980439	0.517	rs712253	chr8:8103782	C/T	cg06636001	chr8:8085503	FLJ10661	-0.61	-5.33	-0.43	4.51e-7	Neuroticism;
TGCT	cis	rs4654899	0.865	rs10916951	chr1:21528835	A/G	cg01072550	chr1:21505969	NA	0.47	7.02	0.53	1.27e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs10744422	0.686	rs967281	chr12:123292179	A/G	cg18912006	chr12:123335444	HIP1R	0.56	4.78	0.39	4.84e-6	Schizophrenia;
TGCT	cis	rs10791097	0.702	rs10894267	chr11:130714861	C/T	cg12179176	chr11:130786555	SNX19	-0.61	-6.34	-0.49	3.95e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	trans	rs1814175	0.935	rs11040438	chr11:49622521	G/A	cg03929089	chr4:120376271	NA	-0.65	-7.44	-0.56	1.46e-11	Height;
TGCT	cis	rs2404602	0.647	rs920712	chr15:77033934	G/A	cg23625390	chr15:77176239	SCAPER	-0.36	-4.52	-0.38	1.42e-5	Blood metabolite levels;
TGCT	cis	rs9486719	1.000	rs2179126	chr6:96871350	A/G	cg06623918	chr6:96969491	KIAA0776	1.01	8.86	0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg23302884	chr18:44338147	ST8SIA5	0.39	4.62	0.38	9.65e-6	Personality dimensions;
TGCT	cis	rs3760776	0.522	rs78060698	chr19:5832773	G/A	cg25387410	chr19:5844109	FUT3	-0.56	-6.47	-0.5	2.08e-9	N-glycan levels;Tumor biomarkers;Vitamin B12 levels;
TGCT	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg23758822	chr17:41437982	NA	0.69	6.82	0.52	3.55e-10	Menopause (age at onset);
TGCT	cis	rs8056742	0.643	rs12932104	chr16:85090182	C/G	cg00229868	chr16:85520891	NA	0.36	4.83	0.4	3.96e-6	Amyotrophic lateral sclerosis;
TGCT	cis	rs6867032	0.687	rs4998338	chr5:2015910	A/G	cg26168224	chr5:2018326	NA	0.43	7.96	0.58	9.31e-13	Gut microbiome composition (winter);
TGCT	cis	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg08564027	chr20:61660810	NA	0.37	6.85	0.52	3.1e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs11676348	0.729	rs13013361	chr2:218947515	A/T	cg00012203	chr2:219082015	ARPC2	-0.48	-4.51	-0.38	1.46e-5	Ulcerative colitis;
TGCT	cis	rs2243480	0.522	rs73150635	chr7:65972490	C/T	cg07424592	chr7:64974309	NA	1.44	8.81	0.62	9.18e-15	Diabetic kidney disease;
TGCT	cis	rs2486288	0.656	rs6493144	chr15:45573489	C/G	cg26924012	chr15:45694286	SPATA5L1	0.77	8.0	0.58	7.59e-13	Glomerular filtration rate;
TGCT	trans	rs7618501	0.966	rs7372966	chr3:49788969	T/C	cg21659725	chr3:3221576	CRBN	-0.98	-15.33	-0.81	2.1000000000000002e-30	Intelligence (multi-trait analysis);
TGCT	cis	rs1385374	0.858	rs10847692	chr12:129289679	A/T	cg09035930	chr12:129282057	SLC15A4	-0.55	-4.76	-0.39	5.27e-6	Systemic lupus erythematosus;
TGCT	cis	rs4242434	0.672	rs10113779	chr8:22485934	G/C	cg03733263	chr8:22462867	KIAA1967	0.98	13.14	0.76	2.97e-25	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs7772486	0.686	rs9497380	chr6:145955305	T/C	cg13319975	chr6:146136371	FBXO30	-0.5	-4.49	-0.37	1.63e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs739496	0.579	rs57046217	chr12:112285116	T/C	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	trans	rs3780486	0.505	rs1411609	chr9:33137303	C/T	cg04842962	chr6:43655489	MRPS18A	0.82	8.79	0.62	1.03e-14	IgG glycosylation;
TGCT	cis	rs116095464	0.558	rs55833259	chr5:286728	G/A	cg22857025	chr5:266934	NA	-0.35	-6.87	-0.53	2.7e-10	Breast cancer;
TGCT	trans	rs2727020	0.930	rs1164688	chr11:49290604	C/G	cg15704280	chr7:45808275	SEPT13	0.72	7.71	0.57	3.47e-12	Coronary artery disease;
TGCT	cis	rs9486719	1.000	rs4078038	chr6:96904366	A/G	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.35	-0.43	4.14e-7	Migraine;Coronary artery disease;
TGCT	cis	rs7647973	0.961	rs11130186	chr3:49275828	A/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.55	-4.48	-0.37	1.68e-5	Menarche (age at onset);
TGCT	cis	rs2050392	0.517	rs656600	chr10:30765654	G/A	cg18806716	chr10:30721971	MAP3K8	-0.47	-5.42	-0.44	3.04e-7	Inflammatory bowel disease;
TGCT	cis	rs910316	0.967	rs119076	chr14:75572419	G/T	cg23033748	chr14:75592666	NEK9	-0.29	-4.83	-0.4	3.97e-6	Height;
TGCT	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg03609598	chr5:56110824	MAP3K1	-0.6	-4.48	-0.37	1.69e-5	Initial pursuit acceleration;
TGCT	cis	rs9393692	0.645	rs6939048	chr6:26327953	G/A	cg13736514	chr6:26305472	NA	-0.45	-6.65	-0.51	8.17e-10	Educational attainment;
TGCT	cis	rs854765	0.647	rs6826	chr17:18011140	C/T	cg04398451	chr17:18023971	MYO15A	-0.38	-6.48	-0.5	1.91e-9	Total body bone mineral density;
TGCT	cis	rs9894429	0.546	rs9906979	chr17:79608765	A/G	cg18240062	chr17:79603768	NPLOC4	0.75	7.08	0.54	9.3e-11	Eye color traits;
TGCT	cis	rs854765	0.693	rs12936037	chr17:17777245	A/G	cg09796270	chr17:17721594	SREBF1	-0.27	-5.52	-0.44	1.94e-7	Total body bone mineral density;
TGCT	cis	rs1903068	0.819	rs17711320	chr4:56000053	A/C	cg09978860	chr4:56023921	NA	0.57	6.47	0.5	2.1e-9	Endometriosis;
TGCT	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg17747265	chr1:1875780	NA	-0.42	-7.92	-0.58	1.16e-12	Body mass index;
TGCT	cis	rs10149470	0.549	rs9652403	chr14:104036024	G/C	cg26031613	chr14:104095156	KLC1	0.56	4.99	0.41	2.02e-6	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
TGCT	cis	rs12477438	0.953	rs3851334	chr2:99794704	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-5.89	-0.47	3.32e-8	Chronic sinus infection;
TGCT	cis	rs782590	0.902	rs782595	chr2:55845596	C/G	cg18811423	chr2:55921094	PNPT1	0.64	6.52	0.51	1.6e-9	Metabolic syndrome;
TGCT	cis	rs9486719	0.843	rs2472875	chr6:96844691	G/A	cg06623918	chr6:96969491	KIAA0776	0.93	7.08	0.54	9.59e-11	Migraine;Coronary artery disease;
TGCT	cis	rs7017914	0.934	rs62530826	chr8:71641643	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.03	-0.41	1.69e-6	Bone mineral density;
TGCT	cis	rs6582630	0.555	rs34145279	chr12:38405588	T/C	cg13010199	chr12:38710504	ALG10B	0.61	4.82	0.4	4.12e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs9467773	0.620	rs2451731	chr6:26624822	A/C	cg09904177	chr6:26538194	HMGN4	0.67	6.48	0.5	1.94e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg01802117	chr1:53393560	SCP2	0.43	5.13	0.42	1.1e-6	Monocyte count;
TGCT	cis	rs12049351	0.665	rs1838464	chr1:229616693	T/C	cg12130225	chr1:229698885	NA	0.39	4.5	0.37	1.55e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs28595532	0.920	rs17323877	chr4:119671188	A/G	cg14228332	chr4:119757509	SEC24D	1.06	5.67	0.45	9.69e-8	Cannabis dependence symptom count;
TGCT	cis	rs7937682	0.889	rs7948236	chr11:111499933	C/A	cg09085632	chr11:111637200	PPP2R1B	-1.09	-11.56	-0.72	2.06e-21	Primary sclerosing cholangitis;
TGCT	cis	rs9467711	0.606	rs72836482	chr6:26359241	A/T	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12620999	0.838	rs7589198	chr2:237967615	C/T	cg23555395	chr2:238036564	NA	0.27	4.81	0.4	4.35e-6	Systemic lupus erythematosus;
TGCT	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	7.24	0.55	4.17e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs798766	1.000	rs2166580	chr4:1743169	G/A	cg05874882	chr4:1763078	NA	-0.36	-4.83	-0.4	3.87e-6	Bladder cancer;Urinary bladder cancer;
TGCT	cis	rs6138458	1.000	rs6114984	chr20:24976610	A/G	cg26195577	chr20:24973756	C20orf3	1.22	12.1	0.74	9.98e-23	Blood protein levels;
TGCT	trans	rs2688608	0.839	rs2675662	chr10:75599127	A/G	cg13918328	chr10:52500089	ASAH2B	-0.69	-6.72	-0.52	5.91e-10	Inflammatory bowel disease;
TGCT	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	4.67	0.39	7.7e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs35849525	0.776	rs7615318	chr3:49987475	C/T	cg14019146	chr3:50243930	SLC38A3	-0.21	-4.44	-0.37	1.98e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs9486719	1.000	rs34236778	chr6:96884556	C/A	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.86	-0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs13336428	0.730	rs28653458	chr16:1525850	T/C	cg08008072	chr16:1524255	CLCN7	-0.61	-9.03	-0.63	2.77e-15	Bone mineral density;
TGCT	cis	rs2012796	0.743	rs61986598	chr14:81856865	G/A	cg02996355	chr14:81879375	NA	0.56	5.45	0.44	2.66e-7	Night sleep phenotypes;
TGCT	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.77	6.05	0.48	1.56e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6570726	0.935	rs424263	chr6:145840073	A/C	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs514406	0.560	rs1889033	chr1:53211887	A/G	cg08859206	chr1:53392774	SCP2	0.36	5.12	0.42	1.14e-6	Monocyte count;
TGCT	cis	rs7043114	0.525	rs6479417	chr9:95064562	G/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-5.57	-0.45	1.53e-7	Height;
TGCT	cis	rs916888	0.821	rs415430	chr17:44859144	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.7	-4.82	-0.4	4.1e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs9611565	0.694	rs5758324	chr22:41787950	G/T	cg06634786	chr22:41940651	POLR3H	-0.8	-7.61	-0.56	6.1e-12	Vitiligo;
TGCT	cis	rs9527	0.615	rs17725614	chr10:104685493	G/C	cg04362960	chr10:104952993	NT5C2	0.64	5.4	0.44	3.33e-7	Arsenic metabolism;
TGCT	cis	rs9486715	0.867	rs9373829	chr6:96897201	A/C	cg18709589	chr6:96969512	KIAA0776	-0.69	-6.69	-0.51	7.02e-10	Headache;
TGCT	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs344364	0.511	rs12596510	chr16:1949480	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.45	-5.08	-0.42	1.35e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	trans	rs1814175	0.645	rs4598671	chr11:50003191	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.84	-0.7	1.13e-19	Height;
TGCT	cis	rs459571	0.839	rs2519831	chr9:136886257	T/A	cg14405625	chr9:136855902	VAV2	-0.3	-4.5	-0.37	1.52e-5	Platelet distribution width;
TGCT	cis	rs228437	0.657	rs6902569	chr6:134947804	G/C	cg09872934	chr6:134495829	SGK1	-0.57	-4.54	-0.38	1.33e-5	Melanoma;
TGCT	cis	rs2637266	0.739	rs2583041	chr10:78439219	C/T	cg18941641	chr10:78392320	NA	-0.41	-4.91	-0.4	2.86e-6	Pulmonary function;
TGCT	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg06212747	chr3:49208901	KLHDC8B	0.65	6.24	0.49	6.24e-9	Menarche (age at onset);
TGCT	cis	rs2361718	0.631	rs12601637	chr17:78142455	T/C	cg21238619	chr17:78079768	GAA	-0.31	-4.57	-0.38	1.16e-5	Yeast infection;
TGCT	cis	rs9549367	0.713	rs4907598	chr13:113861385	C/T	cg18105134	chr13:113819100	PROZ	0.47	8.38	0.6	9.82e-14	Platelet distribution width;
TGCT	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg22166914	chr1:53195759	ZYG11B	0.29	4.89	0.4	3.09e-6	Monocyte count;
TGCT	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg22166914	chr1:53195759	ZYG11B	-0.42	-7.46	-0.56	1.29e-11	Monocyte count;
TGCT	cis	rs7714584	1.000	rs3857422	chr5:150268609	A/G	cg22134413	chr5:150180641	NA	0.78	6.12	0.48	1.16e-8	Crohn's disease;
TGCT	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg03806693	chr22:41940476	POLR3H	-1.12	-12.12	-0.74	8.54e-23	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs7666738	0.830	rs13112131	chr4:98976784	G/A	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs924607	1.000	rs924607	chr5:610093	C/T	cg18765565	chr5:669397	TPPP	-0.62	-6.97	-0.53	1.66e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs17345786	1.000	rs73863360	chr3:101316837	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.88	9.32	0.64	5.46e-16	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7192750	0.539	rs12926300	chr16:71978997	C/T	cg06353428	chr16:71660113	MARVELD3	0.77	6.82	0.52	3.61e-10	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs6684514	1.000	rs3806408	chr1:156252137	C/A	cg16558208	chr1:156270281	VHLL	0.46	9.38	0.64	3.92e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs2439831	0.867	rs496584	chr15:43831923	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.94	7.22	0.54	4.65e-11	Lung cancer in ever smokers;
TGCT	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg18876405	chr7:65276391	NA	0.33	4.96	0.41	2.24e-6	Aortic root size;
TGCT	cis	rs13102973	0.617	rs11734991	chr4:135885411	T/G	cg14419869	chr4:135874104	NA	0.26	4.55	0.38	1.28e-5	Subjective well-being;
TGCT	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg01802117	chr1:53393560	SCP2	0.43	5.12	0.42	1.14e-6	Monocyte count;
TGCT	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg06238570	chr21:40685208	BRWD1	0.69	6.47	0.5	2.08e-9	Cognitive function;
TGCT	cis	rs7267979	1.000	rs4813562	chr20:25352588	G/A	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11971779	0.688	rs1862880	chr7:139020100	T/C	cg07862535	chr7:139043722	LUC7L2	0.71	5.69	0.46	8.6e-8	Diisocyanate-induced asthma;
TGCT	cis	rs9814567	0.896	rs7653880	chr3:134345788	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-7.29	-0.55	3.14e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs2404602	0.716	rs8030411	chr15:76699855	A/G	cg22467129	chr15:76604101	ETFA	-0.59	-7.38	-0.55	2.02e-11	Blood metabolite levels;
TGCT	cis	rs6582630	0.584	rs12832156	chr12:38419435	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-4.81	-0.4	4.32e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs651907	0.535	rs13084113	chr3:101534039	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	4.87	0.4	3.32e-6	Colorectal cancer;
TGCT	cis	rs7945705	0.935	rs11042102	chr11:8882164	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.43	4.94	0.41	2.5e-6	Hemoglobin concentration;
TGCT	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg12310025	chr6:25882481	NA	-0.54	-5.7	-0.46	8.31e-8	Height;
TGCT	cis	rs2688608	0.933	rs2688614	chr10:75652876	G/A	cg04320760	chr10:75533139	FUT11	-0.29	-4.55	-0.38	1.27e-5	Inflammatory bowel disease;
TGCT	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg19774624	chr17:42201019	HDAC5	-0.87	-10.86	-0.7	1.02e-19	Total body bone mineral density;
TGCT	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.31	0.43	4.9e-7	Prudent dietary pattern;
TGCT	cis	rs7474896	0.583	rs10827818	chr10:38000856	T/C	cg25427524	chr10:38739819	LOC399744	-0.34	-5.47	-0.44	2.43e-7	Obesity (extreme);
TGCT	cis	rs826838	1.000	rs1963562	chr12:38662896	C/T	cg13010199	chr12:38710504	ALG10B	0.77	6.31	0.49	4.59e-9	Heart rate;
TGCT	cis	rs79057730	0.528	rs4719313	chr7:822501	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.65	6.04	0.48	1.67e-8	Initial pursuit acceleration;
TGCT	cis	rs10540	1.000	rs12786555	chr11:506229	C/T	cg03934478	chr11:495069	RNH1	0.35	5.77	0.46	6.03e-8	Body mass index;
TGCT	cis	rs6087990	0.735	rs1040555	chr20:31380201	A/T	cg13636640	chr20:31349939	DNMT3B	-0.97	-13.01	-0.76	6.33e-25	Ulcerative colitis;
TGCT	cis	rs939574	0.512	rs55908154	chr2:220145960	G/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.78	5.54	0.45	1.71e-7	Platelet distribution width;
TGCT	cis	rs8070740	0.786	rs34856659	chr17:5327572	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	4.55	0.38	1.27e-5	Menopause (age at onset);
TGCT	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg20203395	chr5:56204925	C5orf35	-0.67	-4.62	-0.38	9.56e-6	Type 2 diabetes;
TGCT	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg08280861	chr8:58055591	NA	0.38	4.81	0.4	4.36e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg24675658	chr1:53192096	ZYG11B	0.87	11.29	0.71	9.39e-21	Monocyte count;
TGCT	cis	rs4417704	0.551	rs10169006	chr2:241898824	A/G	cg04034577	chr2:241836375	C2orf54	-0.31	-4.45	-0.37	1.86e-5	Joint mobility (Beighton score);
TGCT	cis	rs1062177	1.000	rs2016409	chr5:151126324	G/T	cg12924095	chr5:151150029	G3BP1	-0.35	-5.04	-0.41	1.6e-6	Preschool internalizing problems;
TGCT	cis	rs17513268	0.808	rs112823227	chr17:59333956	C/T	cg12597983	chr17:59531696	NA	-0.4	-4.52	-0.38	1.45e-5	Obesity-related traits;
TGCT	cis	rs854765	0.663	rs16960744	chr17:17755259	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.74	-7.26	-0.55	3.78e-11	Total body bone mineral density;
TGCT	cis	rs4780401	0.546	rs3743588	chr16:11836508	G/A	cg01061890	chr16:11836724	TXNDC11	0.6	4.95	0.41	2.36e-6	Rheumatoid arthritis;
TGCT	cis	rs7617773	0.780	rs34749846	chr3:48347168	T/G	cg11946769	chr3:48343235	NME6	0.82	7.09	0.54	9.1e-11	Coronary artery disease;
TGCT	cis	rs769267	0.792	rs4808961	chr19:19577215	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.72	6.06	0.48	1.53e-8	Tonsillectomy;
TGCT	cis	rs2235642	0.821	rs2281236	chr16:1603576	G/A	cg08296037	chr16:1584118	IFT140;TMEM204	-0.31	-5.64	-0.45	1.08e-7	Coronary artery disease;
TGCT	cis	rs782590	0.683	rs782633	chr2:55898203	A/G	cg18811423	chr2:55921094	PNPT1	0.65	6.76	0.52	4.79e-10	Metabolic syndrome;
TGCT	cis	rs7216064	1.000	rs7208663	chr17:65885171	T/C	cg12091567	chr17:66097778	LOC651250	-0.87	-6.85	-0.52	3.07e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs1371867	0.846	rs1788189	chr8:101249762	G/T	cg00191853	chr8:101177733	SPAG1	0.23	4.67	0.39	7.55e-6	Atrioventricular conduction;
TGCT	cis	rs950027	0.620	rs2467862	chr15:45643843	T/G	cg14582100	chr15:45693742	SPATA5L1	0.47	6.02	0.48	1.8e-8	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs758129	0.501	rs2856268	chr15:89878391	T/C	cg24365117	chr15:89879190	POLG	0.34	4.63	0.38	9.16e-6	Schizophrenia;
TGCT	cis	rs667920	0.512	rs13071085	chr3:136014923	G/A	cg15507776	chr3:136538369	TMEM22	-0.62	-4.6	-0.38	1.01e-5	Coronary artery disease;
TGCT	cis	rs317689	0.581	rs315132	chr12:69761996	G/C	cg14784868	chr12:69753453	YEATS4	0.64	5.72	0.46	7.3900000000000007e-08	Response to diuretic therapy;
TGCT	cis	rs7674212	0.541	rs2623064	chr4:104030792	C/A	cg16532752	chr4:104119610	CENPE	-0.62	-5.36	-0.43	3.83e-7	Type 2 diabetes;
TGCT	cis	rs2730260	0.537	rs73169234	chr7:158882366	C/T	cg02078164	chr7:157982224	PTPRN2	0.41	4.58	0.38	1.11e-5	Myopia (pathological);
TGCT	cis	rs981844	1.000	rs62325093	chr4:154669733	G/A	cg14289246	chr4:154710475	SFRP2	1.01	8.67	0.61	2.02e-14	Response to statins (LDL cholesterol change);
TGCT	trans	rs1814175	0.645	rs28478790	chr11:50054322	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.84	-0.7	1.13e-19	Height;
TGCT	cis	rs6987853	0.966	rs2974342	chr8:42436651	A/C	cg20539142	chr8:42623718	CHRNA6	-0.2	-4.84	-0.4	3.76e-6	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs7647973	0.626	rs7637711	chr3:49829653	A/G	cg05785598	chr3:49045655	WDR6	-0.42	-5.24	-0.43	6.67e-7	Menarche (age at onset);
TGCT	cis	rs11578119	0.933	rs1928716	chr1:170482301	T/C	cg09767346	chr1:170501363	GORAB	-0.67	-5.36	-0.43	3.85e-7	Male-pattern baldness;
TGCT	cis	rs9926296	0.546	rs9935541	chr16:89905925	G/C	cg21285383	chr16:89894308	SPIRE2	0.34	4.73	0.39	6.11e-6	Vitiligo;
TGCT	cis	rs8062405	0.792	rs12446550	chr16:28543381	G/A	cg09754948	chr16:28834200	ATXN2L	0.59	4.59	0.38	1.05e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.0	0.41	1.89e-6	Menopause (age at onset);
TGCT	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg22963979	chr7:1858916	MAD1L1	-0.45	-7.41	-0.55	1.74e-11	Bipolar disorder and schizophrenia;
TGCT	cis	rs2290402	0.536	rs60492656	chr4:875008	C/T	cg23332689	chr4:987652	IDUA;SLC26A1	0.29	4.52	0.38	1.41e-5	Type 2 diabetes;
TGCT	cis	rs68170813	0.559	rs4730239	chr7:107056960	A/T	cg02696742	chr7:106810147	HBP1	-0.68	-5.44	-0.44	2.69e-7	Coronary artery disease;
TGCT	cis	rs6663390	0.831	rs2267894	chr1:208085735	G/A	cg03990033	chr1:208084030	CD34	0.54	5.61	0.45	1.26e-7	Facial morphology (factor 18);
TGCT	cis	rs7666738	0.830	rs13149404	chr4:99070236	A/G	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.44e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9611565	0.512	rs5758450	chr22:42141640	G/A	cg06634786	chr22:41940651	POLR3H	0.86	8.27	0.6	1.76e-13	Vitiligo;
TGCT	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg11301795	chr4:187892539	NA	-0.35	-5.28	-0.43	5.6e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9926296	0.656	rs4522419	chr16:89853307	T/C	cg21285383	chr16:89894308	SPIRE2	0.33	4.57	0.38	1.14e-5	Vitiligo;
TGCT	cis	rs4595586	1.000	rs1523118	chr12:39229699	C/T	cg10518543	chr12:38710700	ALG10B	-0.51	-5.09	-0.42	1.32e-6	Morning vs. evening chronotype;
TGCT	cis	rs71435601	0.628	rs1652418	chr2:21388456	T/C	cg25035485	chr2:21266500	APOB	0.51	4.48	0.37	1.64e-5	Cholesterol, total;
TGCT	cis	rs11671005	0.735	rs11668814	chr19:58946833	T/C	cg13877915	chr19:58951672	ZNF132	0.63	5.0	0.41	1.95e-6	Mean platelet volume;
TGCT	cis	rs6785206	0.554	rs12054283	chr3:128505829	A/G	cg25356066	chr3:128598488	ACAD9	-0.78	-4.45	-0.37	1.91e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs6121246	0.542	rs2376990	chr20:30238744	G/A	cg18721089	chr20:30220636	NA	-0.5	-5.05	-0.41	1.57e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs5769765	1.000	rs768618	chr22:50286827	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.11	-12.1	-0.74	9.56e-23	Schizophrenia;
TGCT	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg05368731	chr17:41323189	NBR1	1.08	11.0	0.7	4.76e-20	Menopause (age at onset);
TGCT	cis	rs9291683	0.632	rs13101785	chr4:10042915	T/A	cg00071950	chr4:10020882	SLC2A9	0.68	8.74	0.62	1.38e-14	Bone mineral density;
TGCT	cis	rs2180341	0.961	rs9375501	chr6:127652539	C/T	cg24812749	chr6:127587940	RNF146	0.98	7.64	0.57	5.06e-12	Breast cancer;
TGCT	cis	rs7412746	0.658	rs4970987	chr1:150949682	T/C	cg09365446	chr1:150670422	GOLPH3L	0.34	4.7	0.39	6.78e-6	Melanoma;
TGCT	cis	rs9796	0.558	rs11855102	chr15:41513257	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.53	-7.11	-0.54	8.15e-11	Menopause (age at onset);
TGCT	cis	rs11209185	0.545	rs1926284	chr1:68446291	T/C	cg22082780	chr1:68452167	NA	0.32	4.81	0.4	4.35e-6	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs508618	0.731	rs576462	chr1:231544607	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.6	-4.92	-0.4	2.64e-6	Red blood cell count;
TGCT	cis	rs7249142	0.549	rs2239369	chr19:19292405	A/T	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	-0.54	-5.44	-0.44	2.73e-7	IgG glycosylation;
TGCT	cis	rs17376456	0.569	rs10057664	chr5:93182274	C/T	cg25358565	chr5:93447407	FAM172A	-0.81	-6.54	-0.51	1.47e-9	Diabetic retinopathy;
TGCT	cis	rs9532580	0.619	rs2755211	chr13:41142223	C/T	cg21288729	chr13:41239152	FOXO1	0.89	7.47	0.56	1.24e-11	Mean corpuscular hemoglobin;
TGCT	cis	rs4409675	0.576	rs2295367	chr1:28224312	C/T	cg23691781	chr1:28212827	C1orf38	0.25	5.26	0.43	6.19e-7	Corneal astigmatism;
TGCT	cis	rs4851254	0.579	rs78633727	chr2:100669457	T/C	cg07810366	chr2:100720526	AFF3	-0.49	-5.04	-0.41	1.61e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg23758822	chr17:41437982	NA	0.69	6.37	0.5	3.34e-9	Menopause (age at onset);
TGCT	trans	rs208520	0.690	rs12213575	chr6:66735989	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	11.06	0.7	3.28e-20	Exhaled nitric oxide output;
TGCT	cis	rs9534288	0.797	rs9526132	chr13:46609364	A/G	cg15192986	chr13:46630673	CPB2	-0.53	-7.66	-0.57	4.65e-12	Blood protein levels;
TGCT	cis	rs7216064	1.000	rs58551145	chr17:65837235	A/G	cg12091567	chr17:66097778	LOC651250	-0.83	-6.49	-0.5	1.9e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs988712	0.622	rs2030323	chr11:27728539	A/C	cg10635145	chr11:27742435	BDNF	0.44	6.37	0.5	3.35e-9	Obesity;
TGCT	cis	rs6695640	0.854	rs942458	chr1:17739313	A/C	cg25979543	chr1:17888104	ARHGEF10L	-0.26	-4.62	-0.38	9.41e-6	Mean platelet volume;
TGCT	cis	rs7824557	0.602	rs7817658	chr8:11206543	A/G	cg21775007	chr8:11205619	TDH	0.73	7.01	0.53	1.32e-10	Retinal vascular caliber;
TGCT	cis	rs7267979	0.966	rs2257461	chr20:25265554	A/G	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs763121	0.853	rs5757253	chr22:39104320	C/T	cg06022373	chr22:39101656	GTPBP1	0.78	8.1	0.59	4.34e-13	Menopause (age at onset);
TGCT	cis	rs13064411	0.696	rs6786974	chr3:113190149	T/A	cg18753928	chr3:113234510	CCDC52	-0.71	-5.59	-0.45	1.35e-7	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg23758822	chr17:41437982	NA	-0.59	-5.89	-0.47	3.41e-8	Menopause (age at onset);
TGCT	cis	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg26116260	chr4:7069785	GRPEL1	1.12	11.07	0.7	3.2e-20	Monocyte percentage of white cells;
TGCT	cis	rs427394	0.659	rs274695	chr5:6732252	G/C	cg10857441	chr5:6722123	POLS	-0.28	-6.08	-0.48	1.38e-8	Menopause (age at onset);
TGCT	cis	rs9906944	0.678	rs56015440	chr17:47136631	C/G	cg20966754	chr17:47091339	IGF2BP1	-0.46	-5.12	-0.42	1.12e-6	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs4654899	0.865	rs6658526	chr1:21391314	A/G	cg01072550	chr1:21505969	NA	0.44	6.12	0.48	1.12e-8	Superior frontal gyrus grey matter volume;
TGCT	cis	rs28493229	0.522	rs17713068	chr19:41270055	A/C	cg00475131	chr19:41117096	LTBP4	0.29	4.49	0.37	1.61e-5	Kawasaki disease;
TGCT	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg06634786	chr22:41940651	POLR3H	-0.88	-8.27	-0.6	1.75e-13	Vitiligo;
TGCT	cis	rs8177253	0.633	rs10935073	chr3:133439184	T/C	cg08048268	chr3:133502702	NA	-0.56	-7.47	-0.56	1.27e-11	Iron status biomarkers;
TGCT	trans	rs17471911	0.708	rs9633709	chr10:100807955	C/T	cg03484267	chr2:207988651	KLF7	-0.52	-6.67	-0.51	7.53e-10	Neuroticism;
TGCT	cis	rs9916302	0.904	rs650106	chr17:37451559	A/G	cg07936489	chr17:37558343	FBXL20	0.62	4.91	0.4	2.85e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs694739	0.628	rs617051	chr11:64133638	C/A	cg02228329	chr11:64053129	BAD;GPR137	0.69	6.71	0.52	6.1e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs9393777	0.513	rs13210025	chr6:26654817	A/C	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.53	-4.88	-0.4	3.19e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6088580	0.634	rs4911422	chr20:32999345	T/C	cg24642439	chr20:33292090	TP53INP2	-0.49	-4.49	-0.37	1.59e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs9430161	0.579	rs7542164	chr1:11040223	G/A	cg27631724	chr1:11040367	C1orf127	0.55	6.58	0.51	1.2e-9	Ewing sarcoma;
TGCT	cis	rs10927875	0.691	rs1048302	chr1:16340879	T/G	cg14742211	chr1:16348397	CLCNKA	0.19	4.48	0.37	1.7e-5	Dilated cardiomyopathy;
TGCT	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg23574427	chr4:122746245	BBS7;CCNA2	-0.34	-5.31	-0.43	4.82e-7	Type 2 diabetes;
TGCT	cis	rs601339	1.000	rs35683065	chr12:123164062	G/C	cg11919336	chr12:123188078	GPR109A	0.64	7.49	0.56	1.1e-11	Adiponectin levels;
TGCT	cis	rs4455778	0.557	rs4289754	chr7:49116730	C/A	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs9634489	0.502	rs7336870	chr13:97084677	G/A	cg11411106	chr13:97107445	HS6ST3	-0.27	-5.05	-0.41	1.56e-6	Body mass index;
TGCT	cis	rs10992471	0.756	rs10992319	chr9:95127895	G/A	cg14631576	chr9:95140430	CENPP	-0.29	-4.82	-0.4	4.17e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs476633	0.708	rs28547298	chr15:41446951	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.66	-8.77	-0.62	1.18e-14	Glomerular filtration rate (creatinine);
TGCT	cis	rs6570726	0.764	rs9403726	chr6:145901686	G/T	cg23711669	chr6:146136114	FBXO30	0.85	9.24	0.64	8.9e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7267979	1.000	rs6115153	chr20:25325567	T/C	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs889312	0.500	rs252920	chr5:56148741	C/A	cg24531977	chr5:56204891	C5orf35	-0.52	-5.39	-0.44	3.44e-7	Breast cancer;Breast cancer (early onset);
TGCT	cis	rs28595532	0.920	rs115690307	chr4:119768289	C/T	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg05368731	chr17:41323189	NBR1	1.2	14.59	0.79	1.08e-28	Menopause (age at onset);
TGCT	cis	rs2777491	0.522	rs7169278	chr15:41696932	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.49	-6.8	-0.52	3.93e-10	Ulcerative colitis;
TGCT	cis	rs4253772	0.513	rs6008612	chr22:46707907	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.7	5.14	0.42	1.02e-6	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs9811920	0.898	rs7636776	chr3:99840446	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.41	-4.55	-0.38	1.27e-5	Axial length;
TGCT	cis	rs12286929	0.687	rs6589487	chr11:115089927	T/C	cg04580443	chr11:115547056	NA	0.24	4.51	0.38	1.47e-5	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg25767906	chr1:53392781	SCP2	0.47	5.26	0.43	6.03e-7	Monocyte count;
TGCT	cis	rs4653767	0.573	rs708772	chr1:226912891	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.43	-4.85	-0.4	3.59e-6	Parkinson's disease;
TGCT	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg02353165	chr6:42928485	GNMT	0.97	9.95	0.67	1.66e-17	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs7072216	0.690	rs113195335	chr10:100175532	A/C	cg26618903	chr10:100175079	PYROXD2	-0.4	-4.49	-0.37	1.64e-5	Metabolite levels;
TGCT	cis	rs597480	0.853	rs580459	chr11:85436500	T/C	cg11817631	chr11:85522609	SYTL2	-0.47	-4.66	-0.39	8.18e-6	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);
TGCT	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg00484396	chr16:3507460	NAT15	0.44	6.53	0.51	1.51e-9	Tuberculosis;
TGCT	cis	rs1129187	0.702	rs2395943	chr6:42940673	A/G	cg17345569	chr6:42928274	GNMT	-0.49	-5.05	-0.41	1.55e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg11644478	chr21:40555479	PSMG1	1.0	10.6	0.69	4.32e-19	Cognitive function;
TGCT	trans	rs9859260	0.710	rs419068	chr3:195782176	C/T	cg17074656	chr11:63784126	MACROD1	0.52	6.67	0.51	7.49e-10	Mean corpuscular volume;
TGCT	cis	rs7568458	0.837	rs35565292	chr2:85790316	T/A	cg02493740	chr2:85810744	VAMP5	-0.27	-4.89	-0.4	3.04e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs11719291	0.833	rs11713694	chr3:48833615	G/T	cg07636037	chr3:49044803	WDR6	-1.0	-4.98	-0.41	2.11e-6	Cognitive function;
TGCT	cis	rs7226408	0.802	rs117913067	chr18:34454822	A/G	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs11098499	0.821	rs3775852	chr4:120454556	A/G	cg09307838	chr4:120376055	NA	0.69	6.53	0.51	1.49e-9	Corneal astigmatism;
TGCT	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg24549020	chr5:56110836	MAP3K1	0.66	5.79	0.46	5.56e-8	Initial pursuit acceleration;
TGCT	cis	rs4665630	0.803	rs1007195	chr2:23889614	A/G	cg08063864	chr2:24346004	PFN4;LOC375190	-0.88	-4.55	-0.38	1.25e-5	Hypertension;
TGCT	cis	rs6866344	0.697	rs56159071	chr5:178127246	T/A	cg10224037	chr5:178157518	ZNF354A	0.94	7.97	0.58	8.92e-13	Neutrophil percentage of white cells;
TGCT	cis	rs7568458	0.811	rs10175792	chr2:85761654	A/G	cg17127132	chr2:85788382	GGCX	0.62	5.92	0.47	2.97e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs2692947	0.800	rs2692936	chr2:96745729	G/A	cg23100626	chr2:96804247	ASTL	0.4	4.75	0.39	5.55e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.72	5.14	0.42	1.06e-6	Platelet count;
TGCT	cis	rs2188554	0.785	rs213952	chr7:117203417	A/G	cg08576598	chr7:116962626	WNT2	-0.35	-4.52	-0.38	1.43e-5	Esophageal adenocarcinoma;
TGCT	cis	rs601339	1.000	rs645491	chr12:123181661	T/C	cg11919336	chr12:123188078	GPR109A	0.64	7.74	0.57	3.07e-12	Adiponectin levels;
TGCT	cis	rs7666738	0.830	rs9307218	chr4:99024885	T/C	cg18180107	chr4:99064573	C4orf37	0.55	5.13	0.42	1.1e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2013441	0.932	rs3850782	chr17:20181940	A/C	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.63	-0.38	9.19e-6	Obesity-related traits;
TGCT	cis	rs6448317	1.000	rs7698504	chr4:24939386	A/T	cg21108841	chr4:24914750	CCDC149	-0.65	-4.94	-0.41	2.51e-6	Heschl's gyrus morphology;
TGCT	cis	rs11167764	0.945	rs4912619	chr5:141471847	G/A	cg08523384	chr5:141488047	NDFIP1	-0.25	-4.96	-0.41	2.24e-6	Crohn's disease;
TGCT	cis	rs9393777	0.778	rs35741362	chr6:27007687	T/C	cg16898833	chr6:26189333	HIST1H4D	1.0	5.82	0.46	4.65e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs12681288	0.862	rs7814070	chr8:1020991	A/G	cg04851639	chr8:1020857	NA	-0.37	-6.84	-0.52	3.27e-10	Schizophrenia;
TGCT	cis	rs9811920	0.625	rs9847283	chr3:99910320	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.4	4.7	0.39	6.7e-6	Axial length;
TGCT	cis	rs682748	1.000	rs297180	chr5:17157291	A/C	cg23987134	chr5:17158319	LOC285696	0.23	5.51	0.44	2e-7	Hippocampal atrophy;
TGCT	cis	rs17030434	1.000	rs78249279	chr4:154718783	C/T	cg14289246	chr4:154710475	SFRP2	-0.92	-7.14	-0.54	6.89e-11	Electrocardiographic conduction measures;
TGCT	cis	rs548181	0.536	rs503288	chr11:125461787	C/T	cg03464685	chr11:125439445	EI24	-1.18	-9.15	-0.63	1.43e-15	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs910316	1.000	rs10142865	chr14:75555624	G/A	cg11812906	chr14:75593930	NEK9	0.74	7.38	0.55	1.97e-11	Height;
TGCT	cis	rs7833790	0.963	rs10958046	chr8:82729210	A/G	cg17211192	chr8:82754475	SNX16	-1.06	-8.51	-0.61	4.89e-14	Diastolic blood pressure;
TGCT	cis	rs9311474	1.000	rs7614727	chr3:52295895	C/T	cg07507251	chr3:52567010	NT5DC2	0.43	5.84	0.46	4.21e-8	Electroencephalogram traits;
TGCT	cis	rs185694	1.000	rs200505	chr13:30900868	G/T	cg07600127	chr13:30881527	KATNAL1	-0.81	-6.53	-0.51	1.53e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
TGCT	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg19318889	chr4:1322082	MAEA	0.27	6.55	0.51	1.38e-9	Longevity;
TGCT	cis	rs9486715	0.825	rs211158	chr6:97022938	C/G	cg06623918	chr6:96969491	KIAA0776	-1.08	-13.6	-0.77	2.39e-26	Headache;
TGCT	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg02725872	chr8:58115012	NA	-0.38	-4.76	-0.39	5.39e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6545883	0.860	rs13023037	chr2:61620989	C/T	cg15711740	chr2:61764176	XPO1	0.56	5.04	0.41	1.59e-6	Tuberculosis;
TGCT	cis	rs1205863	1.000	rs1205863	chr6:11943526	T/G	cg07106625	chr6:11870215	NA	0.51	5.05	0.41	1.51e-6	Disc degeneration (lumbar);
TGCT	cis	rs9486719	1.000	rs12213426	chr6:96896035	T/C	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.86	-0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs2153535	0.580	rs7769020	chr6:8457724	G/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs3820068	0.608	rs2057304	chr1:16017710	A/G	cg05660106	chr1:15850417	CASP9	0.64	5.96	0.47	2.41e-8	Systolic blood pressure;
TGCT	cis	rs28595532	0.920	rs116668854	chr4:119707642	A/G	cg21605333	chr4:119757512	SEC24D	1.37	6.56	0.51	1.3e-9	Cannabis dependence symptom count;
TGCT	cis	rs9914544	0.545	rs8071458	chr17:18790840	C/A	cg26378065	chr17:18585709	ZNF286B	0.53	4.63	0.38	9.01e-6	Educational attainment (years of education);
TGCT	cis	rs60843830	0.661	rs62116681	chr2:104197	A/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.54	4.51	0.38	1.45e-5	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs10501293	0.746	rs7944338	chr11:43015799	A/G	cg03447554	chr11:43094025	NA	0.44	6.32	0.49	4.2e-9	Cognitive performance;
TGCT	cis	rs6484504	0.532	rs2774403	chr11:31320530	A/T	cg14844989	chr11:31128820	NA	0.22	4.51	0.38	1.49e-5	Red blood cell count;
TGCT	cis	rs4629710	0.592	rs13205441	chr6:131575069	G/A	cg12606694	chr6:131520996	AKAP7	0.41	4.86	0.4	3.55e-6	Multiple myeloma (IgH translocation);
TGCT	cis	rs4808199	0.948	rs2301668	chr19:19452249	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.63	4.56	0.38	1.23e-5	Nonalcoholic fatty liver disease;
TGCT	cis	rs2404602	0.669	rs1875884	chr15:76638161	C/T	cg26408565	chr15:76604113	ETFA	-0.41	-5.3	-0.43	5.1e-7	Blood metabolite levels;
TGCT	cis	rs6674176	0.561	rs4660263	chr1:44421433	A/C	cg13606994	chr1:44402422	ARTN	-0.46	-4.98	-0.41	2.12e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs1568079	0.516	rs1571424	chr10:125220311	G/A	cg02936953	chr10:124639892	FAM24B;LOC399815	-0.35	-5.29	-0.43	5.31e-7	Body mass index;
TGCT	cis	rs11098499	0.863	rs7678400	chr4:120461957	G/A	cg09307838	chr4:120376055	NA	0.7	6.6	0.51	1.06e-9	Corneal astigmatism;
TGCT	cis	rs7819412	0.745	rs2898260	chr8:10939490	G/T	cg27411982	chr8:10470053	RP1L1	-0.22	-4.87	-0.4	3.39e-6	Triglycerides;
TGCT	cis	rs7172809	0.573	rs75657134	chr15:77532885	C/G	cg22256960	chr15:77711686	NA	-0.49	-4.62	-0.38	9.51e-6	Glucose homeostasis traits;
TGCT	cis	rs72843506	0.722	rs78041331	chr17:20208846	G/T	cg18979559	chr17:20280153	CCDC144C	-0.64	-4.8	-0.4	4.49e-6	Schizophrenia;
TGCT	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.5	5.64	0.45	1.11e-7	Lymphocyte counts;
TGCT	cis	rs7666738	0.962	rs11932892	chr4:99072967	C/T	cg05340658	chr4:99064831	C4orf37	0.52	4.85	0.4	3.68e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs56036086	0.877	rs73187247	chr22:50629872	C/T	cg01548456	chr22:50352384	NA	0.37	4.82	0.4	4.15e-6	Platelet count;Plateletcrit;
TGCT	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.77	-6.99	-0.53	1.54e-10	Prudent dietary pattern;
TGCT	trans	rs7615952	0.800	rs11914298	chr3:125643772	G/A	cg07211511	chr3:129823064	LOC729375	-0.48	-8.05	-0.59	5.62e-13	Blood pressure (smoking interaction);
TGCT	cis	rs7714584	1.000	rs12659118	chr5:150324622	T/C	cg22134413	chr5:150180641	NA	0.9	5.5	0.44	2.05e-7	Crohn's disease;
TGCT	cis	rs2153535	0.580	rs6597322	chr6:8449952	T/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.76	0.46	6.39e-8	Motion sickness;
TGCT	trans	rs1864729	1.000	rs2583504	chr8:98283404	G/C	cg08679828	chr8:102218111	ZNF706	-1.08	-7.52	-0.56	9.47e-12	Estradiol plasma levels (breast cancer);
TGCT	cis	rs2562456	0.793	rs2650819	chr19:21638873	C/T	cg01304269	chr19:21688519	ZNF429	-0.6	-4.89	-0.4	3.07e-6	Pain;
TGCT	cis	rs3091242	0.900	rs4649086	chr1:25778967	T/A	cg09222892	chr1:25734099	RHCE	-0.42	-7.15	-0.54	6.72e-11	Erythrocyte sedimentation rate;
TGCT	cis	rs9787249	0.957	rs7518431	chr1:40214944	C/T	cg24920358	chr1:40204285	PPIE	-0.54	-10.0	-0.67	1.24e-17	Blood protein levels;
TGCT	cis	rs10832169	0.967	rs2403709	chr11:14072538	C/T	cg04547675	chr11:13986162	SPON1	0.51	4.51	0.38	1.49e-5	Blood protein levels;
TGCT	cis	rs986417	0.818	rs7156317	chr14:61087740	G/A	cg27398547	chr14:60952738	C14orf39	1.45	9.82	0.66	3.5e-17	Gut microbiota (bacterial taxa);
TGCT	cis	rs4713118	0.955	rs9468201	chr6:27687035	C/T	cg10876282	chr6:28092338	ZSCAN16	0.5	4.68	0.39	7.42e-6	Parkinson's disease;
TGCT	cis	rs2115630	0.645	rs4842978	chr15:85197253	T/C	cg12863693	chr15:85201151	NMB	-0.4	-5.31	-0.43	4.92e-7	P wave terminal force;
TGCT	cis	rs17376456	0.825	rs10079708	chr5:93261796	G/C	cg21475434	chr5:93447410	FAM172A	0.65	4.47	0.37	1.72e-5	Diabetic retinopathy;
TGCT	cis	rs11578119	0.933	rs1888173	chr1:170530657	A/G	cg09767346	chr1:170501363	GORAB	0.58	4.56	0.38	1.19e-5	Male-pattern baldness;
TGCT	trans	rs7824557	0.564	rs2572394	chr8:11235393	A/G	cg15556689	chr8:8085844	FLJ10661	-0.74	-6.7	-0.52	6.48e-10	Retinal vascular caliber;
TGCT	cis	rs7618915	0.547	rs11719685	chr3:52676065	C/T	cg10802521	chr3:52805072	NEK4	-0.71	-8.51	-0.61	4.8e-14	Bipolar disorder;
TGCT	cis	rs2982552	0.775	rs2982562	chr6:152052601	C/T	cg22157087	chr6:152012887	ESR1	0.21	5.19	0.42	8.32e-7	Bone properties (heel);
TGCT	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg04608855	chr19:58913158	NA	0.58	5.76	0.46	6.36e-8	Uric acid clearance;
TGCT	cis	rs7582180	0.591	rs11674569	chr2:101010860	G/A	cg14675211	chr2:100938903	LONRF2	0.5	4.69	0.39	6.95e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs3008870	1.000	rs2985818	chr1:67398916	G/A	cg11518657	chr1:67396239	MIER1	0.54	4.68	0.39	7.24e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs8177253	0.665	rs12493887	chr3:133440737	T/C	cg11941060	chr3:133502564	NA	-0.26	-5.43	-0.44	2.88e-7	Iron status biomarkers;
TGCT	cis	rs7714584	1.000	rs7736873	chr5:150258482	T/C	cg22134413	chr5:150180641	NA	0.78	6.12	0.48	1.16e-8	Crohn's disease;
TGCT	cis	rs6750047	0.771	rs1056836	chr2:38298203	C/G	cg07380506	chr2:38303506	CYP1B1	-0.71	-6.51	-0.5	1.71e-9	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs319204	1.000	rs2082405	chr5:146258596	C/T	cg13983063	chr5:146258615	PPP2R2B	0.32	4.55	0.38	1.25e-5	Schizophrenia;
TGCT	cis	rs858239	0.665	rs858306	chr7:23242754	A/T	cg05407003	chr7:23246146	NA	-0.29	-4.59	-0.38	1.05e-5	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs9467773	1.000	rs9467796	chr6:26568411	A/G	cg26531700	chr6:26746687	NA	0.5	4.85	0.4	3.64e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9527	0.545	rs10883847	chr10:104958284	C/T	cg15744005	chr10:104629667	AS3MT	-0.41	-4.78	-0.39	4.88e-6	Arsenic metabolism;
TGCT	cis	rs7772486	0.754	rs4896838	chr6:146015451	T/C	cg13319975	chr6:146136371	FBXO30	0.52	4.68	0.39	7.31e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7172809	0.573	rs60863150	chr15:77515940	C/A	cg22256960	chr15:77711686	NA	-0.49	-4.62	-0.38	9.51e-6	Glucose homeostasis traits;
TGCT	trans	rs1496653	0.602	rs35121170	chr3:23516614	C/T	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg02725872	chr8:58115012	NA	-0.41	-5.38	-0.44	3.5e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7772486	0.875	rs2814875	chr6:146305810	G/A	cg05347473	chr6:146136440	FBXO30	0.55	5.11	0.42	1.2e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7017914	0.905	rs2732103	chr8:71923496	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.56	-5.11	-0.42	1.2e-6	Bone mineral density;
TGCT	cis	rs12478296	0.818	rs57194240	chr2:243011545	A/G	cg06360820	chr2:242988706	NA	-0.62	-5.23	-0.43	6.93e-7	Obesity-related traits;
TGCT	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.51	-6.37	-0.5	3.42e-9	Longevity;Endometriosis;
TGCT	trans	rs7726839	0.507	rs111707179	chr5:593308	T/A	cg25482853	chr8:67687455	SGK3	1.26	10.61	0.69	4.22e-19	Obesity-related traits;
TGCT	cis	rs17473412	0.765	rs10044880	chr5:122663671	G/A	cg15125798	chr5:122621645	NA	-0.6	-5.34	-0.43	4.24e-7	Total body bone mineral density;
TGCT	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.61	5.06	0.41	1.5e-6	Tonsillectomy;
TGCT	cis	rs2742417	0.603	rs2742395	chr3:45758595	A/G	cg04837898	chr3:45731254	SACM1L	-0.65	-7.06	-0.54	1.03e-10	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs79387448	0.655	rs79144324	chr2:102932814	G/A	cg09003973	chr2:102972529	NA	1.4	9.4	0.64	3.64e-16	Gut microbiota (bacterial taxa);
TGCT	cis	rs1215050	0.791	rs7688942	chr4:98832048	T/C	cg17366294	chr4:99064904	C4orf37	0.57	6.14	0.48	1.04e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	trans	rs17685	0.753	rs2302438	chr7:75677065	C/A	cg19862616	chr7:65841803	NCRNA00174	0.52	8.84	0.62	7.72e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs3820068	0.603	rs41270279	chr1:15988878	A/G	cg05660106	chr1:15850417	CASP9	0.81	7.67	0.57	4.28e-12	Systolic blood pressure;
TGCT	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg11644478	chr21:40555479	PSMG1	1.04	10.72	0.69	2.25e-19	Cognitive function;
TGCT	cis	rs35306767	0.715	rs17221463	chr10:1038040	T/C	cg18964960	chr10:1102726	WDR37	0.78	5.4	0.44	3.21e-7	Eosinophil percentage of granulocytes;
TGCT	cis	rs56309584	0.599	rs117347460	chr17:8097171	C/T	cg08322244	chr17:8066669	VAMP2	-0.55	-5.19	-0.42	8.23e-7	Initial pursuit acceleration;
TGCT	cis	rs12497850	0.931	rs7616815	chr3:48779715	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.42	-5.64	-0.45	1.1e-7	Parkinson's disease;
TGCT	cis	rs61990749	0.597	rs13379065	chr14:78141295	C/A	cg23188588	chr14:78226832	SNW1;C14orf178	-0.66	-4.65	-0.39	8.45e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs12510870	0.599	rs7695946	chr4:74453111	T/A	cg05868023	chr4:75230803	EREG	-0.55	-4.74	-0.39	5.71e-6	Iris color (b* coordinate);
TGCT	cis	rs4906332	1.000	rs2065018	chr14:103879187	C/T	cg26031613	chr14:104095156	KLC1	0.5	4.57	0.38	1.16e-5	Coronary artery disease;
TGCT	cis	rs6879260	0.963	rs11738924	chr5:179727308	A/G	cg13944838	chr5:179740914	GFPT2	-0.38	-5.87	-0.47	3.7e-8	Height;
TGCT	cis	rs8031584	0.958	rs3512	chr15:31235005	G/C	cg08704250	chr15:31115839	NA	-0.36	-4.96	-0.41	2.28e-6	Huntington's disease progression;
TGCT	cis	rs2692947	0.727	rs749459	chr2:96795714	G/A	cg23100626	chr2:96804247	ASTL	0.41	4.9	0.4	2.91e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.34	0.43	4.23e-7	Prudent dietary pattern;
TGCT	cis	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg03060546	chr3:49711283	APEH	0.74	7.6	0.56	6.37e-12	Resting heart rate;
TGCT	cis	rs5769765	0.865	rs3788730	chr22:50244695	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	1.06	11.57	0.72	1.91e-21	Schizophrenia;
TGCT	cis	rs12950390	0.853	rs11079790	chr17:45853626	G/A	cg24803719	chr17:45855879	NA	-0.48	-4.82	-0.4	4.11e-6	IgG glycosylation;
TGCT	cis	rs67311347	0.544	rs9864664	chr3:40336226	T/C	cg13683864	chr3:40499215	RPL14	-0.79	-7.55	-0.56	8.28e-12	Renal cell carcinoma;
TGCT	cis	rs6490294	0.799	rs12426566	chr12:112315172	T/C	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Mean platelet volume;
TGCT	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg16325326	chr1:53192061	ZYG11B	-0.72	-8.65	-0.61	2.28e-14	Monocyte count;
TGCT	cis	rs2046867	0.908	rs62251640	chr3:72801605	T/C	cg25664220	chr3:72788482	NA	-0.56	-7.03	-0.53	1.25e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7666738	0.830	rs11722272	chr4:99000839	C/T	cg18180107	chr4:99064573	C4orf37	0.57	5.04	0.41	1.61e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg16680214	chr1:154839983	KCNN3	-0.35	-7.11	-0.54	8.04e-11	Prostate cancer;
TGCT	cis	rs9677476	0.516	rs2175147	chr2:232008473	A/G	cg27665808	chr2:232055229	NA	0.35	4.43	0.37	2.01e-5	Food antigen IgG levels;
TGCT	cis	rs7715806	0.500	rs34355	chr5:74959970	G/A	cg19683494	chr5:74908142	NA	-0.52	-4.8	-0.4	4.49e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs4253772	0.591	rs11703848	chr22:46685131	A/G	cg24881330	chr22:46731750	TRMU	1.04	5.38	0.44	3.54e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs735396	1.000	rs1169309	chr12:121439192	G/T	cg02403541	chr12:121454288	C12orf43	0.66	6.27	0.49	5.35e-9	N-glycan levels;
TGCT	cis	rs7917772	0.536	rs4919667	chr10:104426011	A/G	cg05855489	chr10:104503620	C10orf26	0.59	4.97	0.41	2.18e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9302065	0.681	rs9524902	chr13:95963518	C/T	cg26751094	chr13:95954534	ABCC4	-0.34	-5.44	-0.44	2.78e-7	Blood metabolite levels;
TGCT	cis	rs4654899	0.897	rs7548649	chr1:21090081	A/G	cg01072550	chr1:21505969	NA	-0.49	-7.89	-0.58	1.37e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs2617583	0.530	rs905201	chr5:1457986	C/T	cg13982541	chr5:1466431	LPCAT1	0.2	4.78	0.39	4.96e-6	Breast cancer;
TGCT	trans	rs77457752	0.525	rs1923350	chr9:13898880	T/A	cg25510823	chr7:47085976	NA	0.45	6.68	0.51	7.21e-10	Breast cancer;
TGCT	cis	rs12042938	0.507	rs1655299	chr1:231732161	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-6.16	-0.48	9.54e-9	Neuranatomic and neurocognitive phenotypes;
TGCT	cis	rs4478858	0.775	rs6685868	chr1:31706956	C/T	cg00250761	chr1:31883323	NA	-0.3	-5.52	-0.44	1.88e-7	Alcohol dependence;
TGCT	cis	rs2130392	1.000	rs4862406	chr4:185629339	G/A	cg14471096	chr4:185570637	CCDC111;CASP3	-0.57	-5.25	-0.43	6.46e-7	Kawasaki disease;
TGCT	cis	rs9399137	0.507	rs13209780	chr6:135344795	G/C	cg24558204	chr6:135376177	HBS1L	0.48	4.97	0.41	2.22e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
TGCT	cis	rs1670533	0.932	rs935968	chr4:1063187	G/T	cg27284194	chr4:1044797	NA	0.67	5.79	0.46	5.55e-8	Recombination rate (females);
TGCT	cis	rs17331151	0.573	rs76029595	chr3:52868523	C/T	cg15956490	chr3:53032818	SFMBT1	0.46	5.75	0.46	6.57e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs7296418	0.922	rs12425009	chr12:123502044	C/T	cg00376283	chr12:123451042	ABCB9	0.86	8.06	0.59	5.57e-13	Platelet count;
TGCT	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg17775962	chr7:1200435	ZFAND2A	0.27	4.56	0.38	1.21e-5	Longevity;Endometriosis;
TGCT	cis	rs10883723	0.773	rs1326193	chr10:104271674	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	8.36	0.6	1.1e-13	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs7715806	0.500	rs17563610	chr5:74981322	A/T	cg19683494	chr5:74908142	NA	0.57	4.95	0.41	2.35e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs2594989	0.733	rs9861286	chr3:11568144	C/T	cg00170343	chr3:11313890	ATG7	-0.66	-5.3	-0.43	5.19e-7	Circulating chemerin levels;
TGCT	cis	rs7246657	0.943	rs12709813	chr19:37844983	G/A	cg03233940	chr19:37894644	NA	-0.34	-4.49	-0.37	1.59e-5	Coronary artery calcification;
TGCT	cis	rs10761750	1	rs10761750	chr10:65128619	G/A	cg08743896	chr10:65200160	JMJD1C	-0.34	-4.51	-0.38	1.48e-5	Vascular endothelial growth factor levels;
TGCT	cis	rs586688	0.929	rs587180	chr1:201631088	G/A	cg05779441	chr1:201574716	NA	0.29	4.7	0.39	6.78e-6	Obesity-related traits;
TGCT	cis	rs2658782	0.951	rs72972364	chr11:93122128	C/T	cg18152523	chr11:93063302	CCDC67	0.76	6.25	0.49	6.04e-9	Pulmonary function decline;
TGCT	trans	rs1908814	0.516	rs7825529	chr8:11794444	C/T	cg15556689	chr8:8085844	FLJ10661	0.75	7.26	0.55	3.66e-11	Neuroticism;
TGCT	cis	rs3617	0.625	rs2240917	chr3:52851137	T/C	cg11645453	chr3:52864694	ITIH4	0.28	5.45	0.44	2.63e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs77441887	0.636	rs17043283	chr12:77690281	A/T	cg12013332	chr12:76741916	BBS10	0.84	4.46	0.37	1.85e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs8180040	0.966	rs60369822	chr3:47479735	A/C	cg27129171	chr3:47204927	SETD2	-0.65	-7.68	-0.57	4.2e-12	Colorectal cancer;
TGCT	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	6.11	0.48	1.17e-8	Alzheimer's disease;
TGCT	cis	rs6088580	0.634	rs2184836	chr20:32963369	A/G	cg06115741	chr20:33292138	TP53INP2	-0.55	-4.81	-0.4	4.28e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs16866061	1.000	rs34345163	chr2:225459080	A/G	cg12698349	chr2:225449008	CUL3	1.0	9.4	0.64	3.62e-16	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	cis	rs6095298	0.557	rs6012538	chr20:47441883	G/A	cg12307787	chr20:48099359	KCNB1	0.44	4.67	0.39	7.75e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7267979	0.932	rs1541061	chr20:25521057	G/A	cg14121845	chr20:25566513	NINL	0.49	5.36	0.43	3.83e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3008870	0.755	rs2815349	chr1:67472280	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.81	8.43	0.6	7.53e-14	Lymphocyte percentage of white cells;
TGCT	cis	rs4925386	0.959	rs6121989	chr20:60916713	A/T	cg24112000	chr20:60950667	NA	0.35	4.84	0.4	3.85e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs7017914	0.902	rs13269513	chr8:71578079	A/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.53	-4.9	-0.4	2.87e-6	Bone mineral density;
TGCT	trans	rs1814175	0.781	rs28681334	chr11:50051177	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.26	-0.55	3.77e-11	Height;
TGCT	cis	rs9393692	0.905	rs9393694	chr6:26279296	T/C	cg13736514	chr6:26305472	NA	-0.37	-5.42	-0.44	3.01e-7	Educational attainment;
TGCT	cis	rs7714584	1.000	rs77698001	chr5:150250367	C/T	cg22134413	chr5:150180641	NA	0.89	6.87	0.53	2.72e-10	Crohn's disease;
TGCT	cis	rs7246657	0.663	rs9304568	chr19:38054508	C/A	cg03611452	chr19:38183253	ZNF781	0.56	4.68	0.39	7.54e-6	Coronary artery calcification;
TGCT	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg11764359	chr7:65958608	NA	0.62	5.57	0.45	1.51e-7	Aortic root size;
TGCT	cis	rs9611565	0.694	rs9611591	chr22:41830212	G/A	cg13695892	chr22:41940480	POLR3H	0.85	8.53	0.61	4.33e-14	Vitiligo;
TGCT	cis	rs7772486	0.811	rs2777475	chr6:146304603	G/A	cg23711669	chr6:146136114	FBXO30	0.7	6.38	0.5	3.2e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7829975	0.514	rs2976926	chr8:8261624	T/C	cg15556689	chr8:8085844	FLJ10661	0.75	6.78	0.52	4.26e-10	Mood instability;
TGCT	cis	rs7829975	0.522	rs6601689	chr8:8172283	C/T	cg06636001	chr8:8085503	FLJ10661	0.54	4.87	0.4	3.37e-6	Mood instability;
TGCT	cis	rs4722166	0.541	rs1800795	chr7:22766645	C/G	cg13104385	chr7:22767384	IL6	0.21	4.88	0.4	3.19e-6	Lung cancer;
TGCT	cis	rs2721195	0.626	rs59464125	chr8:145857786	G/A	cg11211951	chr8:145729740	GPT	-0.21	-4.72	-0.39	6.28e-6	Age at first birth;
TGCT	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg03517284	chr6:25882590	NA	-1.08	-13.96	-0.78	3.4e-27	Urate levels;
TGCT	cis	rs2075371	1.000	rs2244700	chr7:133987374	A/G	cg11752832	chr7:134001865	SLC35B4	0.7	6.44	0.5	2.39e-9	Mean platelet volume;
TGCT	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg03188948	chr7:1209495	NA	0.45	5.7	0.46	8.09e-8	Longevity;Endometriosis;
TGCT	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg19748678	chr4:122722346	EXOSC9	0.88	8.89	0.62	5.97e-15	Type 2 diabetes;
TGCT	cis	rs11671005	0.737	rs11671033	chr19:58963669	G/T	cg18639983	chr19:58920768	ZNF584	0.33	4.54	0.38	1.34e-5	Mean platelet volume;
TGCT	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs950169	0.919	rs12915589	chr15:84734464	T/C	cg11189052	chr15:85197271	WDR73	0.69	5.91	0.47	3.14e-8	Schizophrenia;
TGCT	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg27121462	chr16:89883253	FANCA	0.79	8.71	0.62	1.62e-14	Vitiligo;
TGCT	cis	rs12579753	0.917	rs7954438	chr12:82184419	T/C	cg07988820	chr12:82153109	PPFIA2	-0.59	-6.19	-0.49	7.93e-9	Resting heart rate;
TGCT	trans	rs8073060	0.544	rs225244	chr17:33946581	A/G	cg19694781	chr19:47549865	TMEM160	0.6	13.04	0.76	5.29e-25	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg16590910	chr6:42928470	GNMT	-0.49	-4.52	-0.38	1.41e-5	Plasma homocysteine levels (post-methionine load test);
TGCT	cis	rs1371867	0.846	rs1660328	chr8:101303450	A/G	cg06636551	chr8:101224915	SPAG1	-0.42	-5.65	-0.45	1.06e-7	Atrioventricular conduction;
TGCT	cis	rs7582180	0.629	rs12612809	chr2:100951616	G/T	cg08017756	chr2:100939284	LONRF2	-0.3	-4.87	-0.4	3.27e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.72	6.45	0.5	2.28e-9	Tonsillectomy;
TGCT	trans	rs28735056	1.000	rs4798922	chr18:77628953	G/C	cg05926928	chr17:57297772	GDPD1	-0.71	-7.6	-0.56	6.2e-12	Schizophrenia;
TGCT	cis	rs3617	0.573	rs2336668	chr3:52919096	G/T	cg10802521	chr3:52805072	NEK4	0.57	6.57	0.51	1.27e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9653442	0.675	rs12995420	chr2:100652578	T/C	cg22139774	chr2:100720529	AFF3	-0.41	-7.3	-0.55	3.02e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs9549367	0.865	rs3861721	chr13:113906308	C/T	cg00898013	chr13:113819073	PROZ	-0.4	-5.03	-0.41	1.64e-6	Platelet distribution width;
TGCT	cis	rs727563	0.594	rs132807	chr22:42071584	T/C	cg06481639	chr22:41940642	POLR3H	0.73	6.57	0.51	1.27e-9	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs1511802	0.591	rs6810892	chr4:187123941	C/T	cg19358738	chr4:186734530	SORBS2	0.17	4.43	0.37	2.01e-5	Blood protein levels;
TGCT	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg03709012	chr19:19516395	GATAD2A	0.66	5.68	0.45	9.28e-8	Tonsillectomy;
TGCT	cis	rs9611565	0.592	rs9611612	chr22:41961189	T/C	cg06481639	chr22:41940642	POLR3H	-0.67	-5.8	-0.46	5.24e-8	Vitiligo;
TGCT	cis	rs11764561	0.503	rs1922086	chr7:156016226	C/T	cg13324311	chr7:156111445	NA	-0.26	-4.49	-0.37	1.62e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	cis	rs67311347	0.955	rs4974067	chr3:40374551	C/T	cg13683864	chr3:40499215	RPL14	-1.1	-11.83	-0.73	4.49e-22	Renal cell carcinoma;
TGCT	cis	rs12643440	0.538	rs62296684	chr4:17137455	A/T	cg22650099	chr4:17144496	NA	-0.46	-4.66	-0.39	8.14e-6	Metabolite levels (Pyroglutamine);
TGCT	trans	rs1814175	0.588	rs10466497	chr11:49864381	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.45	-11.09	-0.71	2.8e-20	Height;
TGCT	cis	rs2921036	0.529	rs2979192	chr8:8338147	C/T	cg06636001	chr8:8085503	FLJ10661	0.64	5.66	0.45	1.01e-7	Neuroticism;
TGCT	cis	rs447735	0.537	rs7190341	chr16:89917537	T/C	cg26513180	chr16:89883248	FANCA	0.7	6.13	0.48	1.09e-8	Hemoglobin concentration;
TGCT	cis	rs7940866	0.874	rs7111478	chr11:130819628	A/G	cg05962950	chr11:130786565	SNX19	0.68	6.93	0.53	2.03e-10	Schizophrenia;
TGCT	cis	rs2721195	1.000	rs750472	chr8:145701453	A/C	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.85	-9.23	-0.64	9.23e-16	Age at first birth;
TGCT	cis	rs2932538	0.922	rs12402929	chr1:113072293	G/C	cg22162597	chr1:113214053	CAPZA1	0.28	6.0	0.47	1.99e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs9788682	0.948	rs905739	chr15:78845110	A/G	cg06917634	chr15:78832804	PSMA4	-0.69	-4.69	-0.39	7.24e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs2361718	0.500	rs4889818	chr17:78085228	A/G	cg17882374	chr17:78041429	CCDC40	0.29	4.64	0.38	8.71e-6	Yeast infection;
TGCT	cis	rs4478858	0.735	rs6425737	chr1:31790288	T/C	cg00250761	chr1:31883323	NA	-0.27	-4.84	-0.4	3.76e-6	Alcohol dependence;
TGCT	trans	rs62103177	0.673	rs36087369	chr18:77589596	C/G	cg05926928	chr17:57297772	GDPD1	1.03	9.74	0.66	5.52e-17	Opioid sensitivity;
TGCT	cis	rs2702888	0.501	rs2702936	chr8:6751434	T/C	cg26795848	chr8:6756730	NA	-0.31	-6.21	-0.49	7.26e-9	Blood pressure;
TGCT	cis	rs76866386	1.000	rs4953023	chr2:44074000	C/T	cg18957751	chr2:43448938	NA	-0.65	-4.67	-0.39	7.8e-6	Cholesterol, total;
TGCT	cis	rs1153858	1.000	rs4775909	chr15:45643042	T/C	cg26924012	chr15:45694286	SPATA5L1	1.09	15.03	0.8	1.02e-29	Homoarginine levels;
TGCT	cis	rs11098499	0.562	rs2389879	chr4:120557684	G/A	cg09307838	chr4:120376055	NA	-0.57	-5.3	-0.43	5.13e-7	Corneal astigmatism;
TGCT	cis	rs6598955	0.543	rs881578	chr1:26536141	G/A	cg24519413	chr1:26490540	NA	-0.25	-4.61	-0.38	9.99e-6	Obesity-related traits;
TGCT	cis	rs67311347	0.568	rs9864544	chr3:40336204	T/C	cg13683864	chr3:40499215	RPL14	-0.79	-7.55	-0.56	8.28e-12	Renal cell carcinoma;
TGCT	cis	rs9309473	0.539	rs7574268	chr2:73904872	C/T	cg20560298	chr2:73613845	ALMS1	0.43	4.66	0.39	7.98e-6	Metabolite levels;
TGCT	cis	rs589249	0.825	rs4653213	chr1:37179503	C/A	cg04012535	chr1:37176647	NA	0.36	5.65	0.45	1.03e-7	Neuroticism (multi-trait analysis);Schizophrenia;
TGCT	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg02038168	chr22:39784481	NA	-0.74	-6.44	-0.5	2.36e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs739496	0.579	rs10849984	chr12:112347728	T/C	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs514406	0.861	rs35581164	chr1:53271373	C/G	cg08859206	chr1:53392774	SCP2	-0.38	-5.72	-0.46	7.61e-8	Monocyte count;
TGCT	cis	rs1215050	0.740	rs700739	chr4:99022546	A/G	cg05340658	chr4:99064831	C4orf37	-0.41	-4.99	-0.41	1.95e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2835872	0.869	rs73203821	chr21:39046744	C/T	cg20424643	chr21:39039972	KCNJ6	0.23	4.64	0.38	8.75e-6	Electroencephalographic traits in alcoholism;
TGCT	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg03161606	chr19:29218774	NA	0.56	6.06	0.48	1.51e-8	Methadone dose in opioid dependence;
TGCT	cis	rs427394	1.000	rs182135	chr5:6747453	G/A	cg10857441	chr5:6722123	POLS	-0.27	-6.63	-0.51	9.35e-10	Menopause (age at onset);
TGCT	cis	rs4144743	1.000	rs4144745	chr17:45323349	T/C	cg18085866	chr17:45331354	ITGB3	-0.72	-4.8	-0.4	4.39e-6	Body mass index;
TGCT	cis	rs707040	0.810	rs6435165	chr2:155218550	T/G	cg18104148	chr2:154337490	NA	0.19	4.79	0.4	4.63e-6	Sudden cardiac arrest;
TGCT	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.5	-4.75	-0.39	5.6e-6	Prudent dietary pattern;
TGCT	trans	rs10506458	0.915	rs12426017	chr12:63396272	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.47	-7.58	-0.56	6.97e-12	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs1541995	0.754	rs71396826	chr15:96236968	T/G	cg00882281	chr15:96346592	NA	0.3	4.63	0.38	9.12e-6	Photic sneeze reflex;
TGCT	cis	rs9928842	0.679	rs4888361	chr16:75267676	A/G	cg09066997	chr16:75300724	BCAR1	0.28	5.09	0.42	1.31e-6	Alcoholic chronic pancreatitis;
TGCT	cis	rs410644	0.717	rs436064	chr5:81069494	C/T	cg09496599	chr5:80383224	RASGRF2	-0.16	-4.65	-0.39	8.39e-6	Anorexia nervosa;
TGCT	cis	rs41271951	0.542	rs11584761	chr1:150250991	G/A	cg18798344	chr1:149336151	NA	0.56	4.5	0.37	1.52e-5	Blood protein levels;
TGCT	cis	rs3782455	0.793	rs2290801	chr12:114404424	C/G	cg10631684	chr12:113795897	PLBD2	-0.7	-4.61	-0.38	1e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs10927875	0.632	rs4661666	chr1:16162471	C/A	cg14742211	chr1:16348397	CLCNKA	-0.2	-4.79	-0.39	4.75e-6	Dilated cardiomyopathy;
TGCT	cis	rs2404602	0.716	rs8030411	chr15:76699855	A/G	cg26408565	chr15:76604113	ETFA	-0.43	-5.76	-0.46	6.17e-8	Blood metabolite levels;
TGCT	cis	rs2458413	0.542	rs2514669	chr8:105362842	A/C	cg04554929	chr8:105342491	NA	0.49	5.88	0.47	3.59e-8	Paget's disease;
TGCT	cis	rs2650000	0.536	rs1169286	chr12:121419056	T/C	cg02403541	chr12:121454288	C12orf43	0.58	5.55	0.45	1.65e-7	Metabolic traits;LDL cholesterol;
TGCT	cis	rs911555	0.755	rs2756132	chr14:103967820	C/G	cg12935359	chr14:103987150	CKB	0.33	4.59	0.38	1.05e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg22857025	chr5:266934	NA	-0.32	-6.4	-0.5	2.83e-9	Breast cancer;
TGCT	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg11644478	chr21:40555479	PSMG1	-1.05	-10.79	-0.7	1.53e-19	Cognitive function;
TGCT	cis	rs10088262	0.629	rs7015861	chr8:124795613	C/T	cg20713898	chr8:124780851	FAM91A1	-0.83	-7.14	-0.54	6.79e-11	Pancreatic cancer;
TGCT	cis	rs7811142	0.945	rs34989573	chr7:100097895	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.04	8.56	0.61	3.72e-14	Platelet count;
TGCT	cis	rs1843834	0.721	rs6436507	chr2:225598242	T/A	cg22455342	chr2:225449267	CUL3	0.65	6.26	0.49	5.64e-9	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs6880778	0.505	rs10072596	chr5:40407033	A/G	cg01087697	chr5:40835557	RPL37	0.55	4.96	0.41	2.22e-6	Inflammatory bowel disease;
TGCT	cis	rs6901004	0.803	rs168522	chr6:111506628	A/G	cg15721981	chr6:111408429	SLC16A10	-0.53	-4.64	-0.38	8.82e-6	Blood metabolite levels;
TGCT	cis	rs9926296	0.609	rs4785714	chr16:89798404	G/T	cg26513180	chr16:89883248	FANCA	-0.68	-6.56	-0.51	1.29e-9	Vitiligo;
TGCT	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg18402987	chr7:1209562	NA	0.65	5.32	0.43	4.65e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs4566357	1.000	rs2396444	chr2:227921314	T/G	cg11843606	chr2:227700838	RHBDD1	-0.58	-5.31	-0.43	4.92e-7	Coronary artery disease;
TGCT	cis	rs568617	0.716	rs77779142	chr11:65599656	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.64	5.1	0.42	1.22e-6	Crohn's disease;
TGCT	trans	rs62103177	0.608	rs4799115	chr18:77736365	A/T	cg05926928	chr17:57297772	GDPD1	-0.77	-6.81	-0.52	3.73e-10	Opioid sensitivity;
TGCT	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg21724239	chr8:58056113	NA	0.42	5.04	0.41	1.59e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2562456	0.516	rs56072098	chr19:21651960	G/T	cg25650185	chr19:21324782	ZNF431	0.54	4.68	0.39	7.27e-6	Pain;
TGCT	cis	rs9611565	0.546	rs739129	chr22:42118249	G/A	cg06481639	chr22:41940642	POLR3H	0.71	6.43	0.5	2.56e-9	Vitiligo;
TGCT	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg11764359	chr7:65958608	NA	-0.57	-5.12	-0.42	1.12e-6	Aortic root size;
TGCT	cis	rs6582630	0.502	rs1115515	chr12:38279830	C/T	cg13010199	chr12:38710504	ALG10B	0.61	4.67	0.39	7.69e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs922182	0.607	rs8030264	chr15:64271496	C/T	cg02919090	chr15:64263738	DAPK2	-0.29	-5.21	-0.42	7.69e-7	Blood protein levels;
TGCT	cis	rs7975161	0.630	rs4964732	chr12:104652705	A/T	cg25273343	chr12:104657179	TXNRD1	-0.47	-5.85	-0.46	4.13e-8	Toenail selenium levels;
TGCT	cis	rs2637266	0.875	rs115333453	chr10:78369011	G/A	cg18941641	chr10:78392320	NA	0.43	5.57	0.45	1.49e-7	Pulmonary function;
TGCT	cis	rs950169	0.763	rs35372971	chr15:84941795	G/A	cg11189052	chr15:85197271	WDR73	0.81	6.22	0.49	6.89e-9	Schizophrenia;
TGCT	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg26338869	chr17:61819248	STRADA	-0.53	-4.87	-0.4	3.29e-6	Prudent dietary pattern;
TGCT	trans	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg21659725	chr3:3221576	CRBN	0.67	7.24	0.55	4.07e-11	Body mass index;
TGCT	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg08048268	chr3:133502702	NA	-0.63	-8.65	-0.61	2.25e-14	Iron status biomarkers;
TGCT	cis	rs2880765	0.805	rs11858817	chr15:86031260	C/T	cg13263323	chr15:86062960	AKAP13	-0.22	-4.79	-0.4	4.68e-6	Coronary artery disease;
TGCT	cis	rs10986311	0.802	rs3780201	chr9:127104775	C/T	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.19	-4.65	-0.39	8.24e-6	Vitiligo;
TGCT	cis	rs10927875	0.632	rs10927864	chr1:16165661	C/G	cg21385522	chr1:16154831	NA	-1.01	-18.14	-0.85	1.06e-36	Dilated cardiomyopathy;
TGCT	cis	rs9902453	0.904	rs9900112	chr17:28282910	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.82	7.62	0.56	5.54e-12	Coffee consumption (cups per day);
TGCT	cis	rs9905704	0.647	rs2286299	chr17:57043367	T/G	cg05425664	chr17:57184151	TRIM37	-0.58	-4.68	-0.39	7.49e-6	Testicular germ cell tumor;
TGCT	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg21433313	chr16:3507492	NAT15	0.37	4.74	0.39	5.76e-6	Tuberculosis;
TGCT	cis	rs12477438	0.520	rs6717729	chr2:99756941	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.85	8.52	0.61	4.53e-14	Chronic sinus infection;
TGCT	cis	rs1153858	1.000	rs7402650	chr15:45701895	C/T	cg14582100	chr15:45693742	SPATA5L1	0.48	5.67	0.45	9.65e-8	Homoarginine levels;
TGCT	cis	rs11105298	0.891	rs3741898	chr12:89933763	G/C	cg00757033	chr12:89920650	WDR51B	0.29	4.6	0.38	1.01e-5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs9443645	0.901	rs10455356	chr6:79664748	T/C	cg05283184	chr6:79620031	NA	-0.21	-4.71	-0.39	6.61e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg25427524	chr10:38739819	LOC399744	-0.4	-8.23	-0.59	2.17e-13	Extrinsic epigenetic age acceleration;
TGCT	trans	rs1496653	0.602	rs36082634	chr3:23554688	G/C	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs10901296	0.702	rs11244178	chr9:133766008	C/T	cg01000188	chr9:133769184	QRFP	-0.33	-4.5	-0.37	1.55e-5	Bilirubin levels;
TGCT	cis	rs7647973	0.925	rs6446257	chr3:49253492	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.61	-5.14	-0.42	1.06e-6	Menarche (age at onset);
TGCT	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	7.62	0.56	5.6e-12	Schizophrenia;
TGCT	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg18305652	chr10:134549665	INPP5A	0.35	5.93	0.47	2.87e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	trans	rs564343	0.545	rs2241303	chr11:65819661	C/A	cg26701943	chr11:108369231	KDELC2	-0.74	-6.87	-0.53	2.81e-10	Obesity (early onset extreme);
TGCT	cis	rs7267979	1.000	rs6083844	chr20:25386832	C/T	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1729951	0.575	rs1654904	chr3:136681149	T/C	cg12473912	chr3:136751656	NA	0.39	6.18	0.49	8.36e-9	Neuroticism;
TGCT	cis	rs3791556	0.853	rs35245395	chr2:240107661	C/T	cg03281426	chr2:240109471	HDAC4	0.28	4.79	0.39	4.76e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg10802521	chr3:52805072	NEK4	-0.71	-8.43	-0.6	7.23e-14	Bipolar disorder;
TGCT	cis	rs3617	0.625	rs3774364	chr3:52863605	G/A	cg11645453	chr3:52864694	ITIH4	0.26	4.86	0.4	3.42e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs11585357	0.843	rs113593167	chr1:17613355	G/A	cg08277548	chr1:17600880	PADI3	-0.96	-9.72	-0.66	5.97e-17	Hair shape;
TGCT	cis	rs1371867	0.846	rs1788180	chr8:101333368	A/G	cg00191853	chr8:101177733	SPAG1	-0.23	-4.76	-0.39	5.2e-6	Atrioventricular conduction;
TGCT	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.07	-9.63	-0.65	1.01e-16	Platelet count;
TGCT	cis	rs7914558	1.000	rs10786740	chr10:104935593	G/C	cg04362960	chr10:104952993	NT5C2	0.61	5.45	0.44	2.6e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs3020333	0.875	rs3020331	chr6:152008780	C/T	cg22157087	chr6:152012887	ESR1	0.2	4.83	0.4	4.01e-6	Total body bone mineral density;
TGCT	cis	rs60733400	0.667	rs4385650	chr1:2499898	G/A	cg18854424	chr1:2615690	NA	0.43	4.81	0.4	4.3e-6	Multiple sclerosis;
TGCT	cis	rs13191362	0.938	rs13213746	chr6:163167777	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.88	7.89	0.58	1.34e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs6831352	0.918	rs34876213	chr4:100062216	G/A	cg12011299	chr4:100065546	ADH4	-0.42	-5.05	-0.41	1.56e-6	Alcohol dependence;
TGCT	cis	rs4901869	0.864	rs12891575	chr14:59334342	T/A	cg02291164	chr14:59296302	NA	0.24	4.62	0.38	9.4e-6	Panic disorder;
TGCT	cis	rs12681288	0.823	rs2701906	chr8:1003316	T/C	cg04851639	chr8:1020857	NA	-0.36	-6.47	-0.5	2.01e-9	Schizophrenia;
TGCT	trans	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg13615516	chr5:77269221	NA	0.67	8.38	0.6	9.45e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg10802521	chr3:52805072	NEK4	-0.78	-9.99	-0.67	1.3e-17	Bipolar disorder;
TGCT	cis	rs6049375	1.000	rs6036631	chr20:24046423	A/G	cg14741141	chr20:24973699	C20orf3	0.84	4.92	0.4	2.68e-6	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs2832191	0.791	rs9983651	chr21:30491227	T/A	cg08807101	chr21:30365312	RNF160	-0.62	-5.74	-0.46	6.74e-8	Dental caries;
TGCT	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg11764359	chr7:65958608	NA	-0.57	-4.86	-0.4	3.5e-6	Aortic root size;
TGCT	cis	rs9381040	0.655	rs2268194	chr6:41024447	T/C	cg03526776	chr6:41159608	TREML2	0.27	5.29	0.43	5.37e-7	Alzheimer's disease (late onset);
TGCT	cis	rs9790314	0.586	rs11710916	chr3:161130070	A/G	cg03342759	chr3:160939853	NMD3	-0.55	-5.7	-0.46	8.15e-8	Morning vs. evening chronotype;
TGCT	cis	rs1372520	0.684	rs184810	chr4:90697979	T/C	cg14346243	chr4:90757452	SNCA	0.62	5.29	0.43	5.26e-7	Neuroticism;
TGCT	cis	rs892961	0.899	rs312911	chr17:75414585	A/C	cg05865280	chr17:75406074	SEPT9	0.28	6.73	0.52	5.56e-10	Airflow obstruction;
TGCT	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg04267008	chr7:1944627	MAD1L1	-0.37	-5.03	-0.41	1.71e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg03934478	chr11:495069	RNH1	0.35	5.77	0.46	6.03e-8	Body mass index;
TGCT	trans	rs6561151	0.957	rs1932990	chr13:44460242	C/T	cg12856521	chr11:46389249	DGKZ	0.63	6.88	0.53	2.6200000000000003e-10	Crohn's disease;
TGCT	cis	rs6088580	0.713	rs1884669	chr20:33171287	G/A	cg06115741	chr20:33292138	TP53INP2	0.51	4.47	0.37	1.76e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs72781680	0.898	rs72782136	chr2:24047344	A/G	cg08917208	chr2:24149416	ATAD2B	0.8	4.93	0.4	2.62e-6	Lymphocyte counts;
TGCT	cis	rs7552404	0.696	rs10518521	chr1:76461214	G/A	cg10523679	chr1:76189770	ACADM	0.81	6.84	0.52	3.19e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2749592	0.550	rs7917262	chr10:37874602	A/C	cg25427524	chr10:38739819	LOC399744	0.3	5.53	0.44	1.79e-7	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs1555895	0.566	rs11253451	chr10:852885	C/T	cg02193355	chr10:851439	NA	0.2	4.51	0.38	1.47e-5	Survival in rectal cancer;
TGCT	cis	rs62064224	0.791	rs11656289	chr17:30761160	T/C	cg25809561	chr17:30822961	MYO1D	0.28	4.71	0.39	6.66e-6	Schizophrenia;
TGCT	cis	rs7666738	0.830	rs6854919	chr4:98947326	C/T	cg05340658	chr4:99064831	C4orf37	0.47	5.19	0.42	8.24e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7043114	0.525	rs10992374	chr9:95336327	A/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.53	-5.19	-0.42	8.23e-7	Height;
TGCT	cis	rs7226408	0.857	rs72894323	chr18:34710125	A/C	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs611744	0.517	rs62537573	chr8:109269281	C/T	cg21045802	chr8:109455806	TTC35	0.82	8.65	0.61	2.19e-14	Dupuytren's disease;
TGCT	cis	rs12595025	1	rs12595025	chr15:91520131	C/T	cg22570213	chr15:91497863	RCCD1	0.49	4.77	0.39	5e-6	Mean platelet volume;
TGCT	cis	rs3793917	0.948	rs3750846	chr10:124215565	T/C	cg09507567	chr10:124027408	NA	0.38	4.71	0.39	6.62e-6	Age-related macular degeneration;
TGCT	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs62244186	0.748	rs4682987	chr3:44674996	C/T	cg15687855	chr3:44754131	ZNF502	-0.44	-5.27	-0.43	5.87e-7	Depressive symptoms;
TGCT	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2153535	0.563	rs1796688	chr6:8536423	A/T	cg07606381	chr6:8435919	SLC35B3	0.54	4.83	0.4	3.9e-6	Motion sickness;
TGCT	cis	rs2692947	0.599	rs7561198	chr2:96774981	C/G	cg05933789	chr2:97190408	NA	-0.16	-4.74	-0.39	5.75e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs2354432	0.660	rs10751415	chr1:146830785	T/A	cg25205988	chr1:146714368	CHD1L	1.36	6.23	0.49	6.77e-9	Mitochondrial DNA levels;
TGCT	cis	rs2014572	0.967	rs10413671	chr19:57763489	G/A	cg24459738	chr19:57751996	ZNF805	-0.58	-5.7	-0.46	8.38e-8	Hyperactive-impulsive symptoms;
TGCT	cis	rs2013441	1.000	rs2703817	chr17:20119677	A/C	cg18979559	chr17:20280153	CCDC144C	-0.42	-4.48	-0.37	1.67e-5	Obesity-related traits;
TGCT	cis	rs826838	0.967	rs1719853	chr12:39128515	A/G	cg13010199	chr12:38710504	ALG10B	-0.59	-4.66	-0.39	8.16e-6	Heart rate;
TGCT	cis	rs9325144	0.647	rs17518186	chr12:38883665	T/C	cg10518543	chr12:38710700	ALG10B	-0.49	-4.51	-0.38	1.5e-5	Morning vs. evening chronotype;
TGCT	cis	rs7666738	0.830	rs9307218	chr4:99024885	T/C	cg05340658	chr4:99064831	C4orf37	0.51	5.82	0.46	4.75e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1577917	1.000	rs7766645	chr6:86622238	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.05	-0.41	1.57e-6	Response to antipsychotic treatment;
TGCT	cis	rs644799	0.610	rs1255179	chr11:95472097	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.51	5.17	0.42	9.05e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9534288	0.700	rs7331032	chr13:46609040	C/T	cg15192986	chr13:46630673	CPB2	-0.53	-7.66	-0.57	4.65e-12	Blood protein levels;
TGCT	trans	rs629535	0.859	rs55803226	chr8:70108965	T/C	cg21567404	chr3:27674614	NA	-0.55	-8.44	-0.6	6.92e-14	Dupuytren's disease;
TGCT	cis	rs11098499	0.663	rs28369503	chr4:120238925	G/A	cg09307838	chr4:120376055	NA	0.63	6.22	0.49	7.01e-9	Corneal astigmatism;
TGCT	cis	rs263156	0.903	rs263116	chr6:142885834	G/A	cg18419694	chr6:143832440	FUCA2	-0.4	-4.71	-0.39	6.56e-6	Ear morphology;Lobe size;Lobe attachment;
TGCT	cis	rs6671200	0.850	rs259345	chr1:95729649	A/G	cg03123541	chr1:95699097	RWDD3	-0.91	-6.4	-0.5	2.93e-9	Stearic acid (18:0) levels;
TGCT	cis	rs6759518	0.655	rs1659700	chr2:27414134	T/C	cg26210250	chr2:26863503	CIB4	-0.78	-4.46	-0.37	1.79e-5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
TGCT	cis	rs950169	1.000	rs11638297	chr15:84782417	A/C	cg11189052	chr15:85197271	WDR73	0.64	5.3	0.43	5.13e-7	Schizophrenia;
TGCT	cis	rs72945132	0.714	rs66542029	chr11:70196302	A/T	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs394563	0.591	rs237019	chr6:149727064	G/A	cg16235748	chr6:149772707	ZC3H12D	-0.44	-4.92	-0.4	2.74e-6	Dupuytren's disease;
TGCT	cis	rs2147959	0.941	rs4653960	chr1:228631719	T/C	cg22700015	chr1:228743131	NA	-0.56	-4.61	-0.38	9.67e-6	Adult asthma;
TGCT	cis	rs11688237	0.601	rs12613801	chr2:144548368	G/A	cg07409629	chr2:144282743	ARHGAP15	-0.38	-4.71	-0.39	6.43e-6	Chin dimples;
TGCT	cis	rs1048466	0.664	rs2041298	chr12:539038	C/G	cg26458557	chr12:285704	IQSEC3	-0.24	-4.5	-0.37	1.56e-5	Obesity (early onset extreme);
TGCT	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg05665937	chr4:1216051	CTBP1	0.25	4.7	0.39	6.84e-6	Obesity-related traits;
TGCT	cis	rs7267979	0.966	rs2261720	chr20:25260641	T/G	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg20607798	chr8:58055168	NA	0.49	4.52	0.38	1.43e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2204008	0.744	rs1115514	chr12:38280140	C/T	cg26384229	chr12:38710491	ALG10B	0.84	7.33	0.55	2.58e-11	Bladder cancer;
TGCT	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs6558530	0.666	rs4242538	chr8:1694010	G/C	cg09410841	chr8:1729607	CLN8	0.64	5.7	0.46	8.43e-8	Systolic blood pressure;
TGCT	cis	rs910316	0.726	rs61979167	chr14:75663610	C/T	cg11812906	chr14:75593930	NEK9	-0.61	-5.5	-0.44	2.04e-7	Height;
TGCT	cis	rs478304	0.934	rs506853	chr11:65521247	C/T	cg17480646	chr11:65405466	SIPA1	0.43	5.35	0.43	4.01e-7	Acne (severe);
TGCT	cis	rs2456568	0.802	rs1108910	chr11:93629677	C/T	cg14065697	chr11:93583672	C11orf90	0.39	4.79	0.4	4.69e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs6088580	0.634	rs2424992	chr20:33012060	C/T	cg24642439	chr20:33292090	TP53INP2	0.49	4.5	0.37	1.55e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs854765	0.647	rs6826	chr17:18011140	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	7.52	0.56	9.79e-12	Total body bone mineral density;
TGCT	cis	rs78456975	0.941	rs6755875	chr2:1557109	T/C	cg01028140	chr2:1542097	TPO	-0.33	-4.53	-0.38	1.37e-5	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs3862435	0.764	rs28545005	chr15:90954131	A/G	cg14166756	chr15:90894880	ZNF774	-0.29	-4.68	-0.39	7.31e-6	Response to exercise (triglyceride level interaction);
TGCT	cis	rs6430585	0.793	rs11684545	chr2:136539122	G/T	cg07169764	chr2:136633963	MCM6	-0.68	-6.21	-0.49	7.42e-9	Corneal structure;
TGCT	cis	rs13191362	1.000	rs34066731	chr6:163011047	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7943203	0.524	rs227060	chr11:108204881	C/T	cg04873221	chr11:107992290	ACAT1	-0.61	-5.18	-0.42	8.85e-7	Red blood cell count;Mean corpuscular volume;
TGCT	cis	rs7914558	1.000	rs12780843	chr10:104769335	G/C	cg04362960	chr10:104952993	NT5C2	0.6	5.36	0.43	3.97e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs12477438	0.539	rs12999417	chr2:99865548	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-1.0	-12.33	-0.74	2.72e-23	Chronic sinus infection;
TGCT	cis	rs2832191	0.791	rs2065270	chr21:30485420	T/C	cg24692254	chr21:30365293	RNF160	-0.95	-10.52	-0.69	7.01e-19	Dental caries;
TGCT	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg16325326	chr1:53192061	ZYG11B	0.52	5.95	0.47	2.6e-8	Monocyte count;
TGCT	cis	rs933688	1.000	rs1363839	chr5:90671274	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.0	9.41	0.65	3.47e-16	Smoking behavior;
TGCT	cis	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg11764359	chr7:65958608	NA	0.54	4.85	0.4	3.67e-6	Aortic root size;
TGCT	cis	rs9818758	0.607	rs34326553	chr3:49134429	A/G	cg00383909	chr3:49044727	WDR6	1.3	6.73	0.52	5.74e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs769267	0.864	rs7245983	chr19:19657632	A/C	cg03709012	chr19:19516395	GATAD2A	0.69	5.65	0.45	1.06e-7	Tonsillectomy;
TGCT	cis	rs3796352	0.881	rs34238610	chr3:53026480	A/T	cg15956490	chr3:53032818	SFMBT1	0.62	6.82	0.52	3.6e-10	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg13395646	chr4:1353034	KIAA1530	-0.36	-4.75	-0.39	5.64e-6	Obesity-related traits;
TGCT	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg01416388	chr22:39784598	NA	-0.7	-6.92	-0.53	2.11e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs9653442	0.545	rs12987212	chr2:100761156	C/T	cg07810366	chr2:100720526	AFF3	-0.36	-5.31	-0.43	4.89e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg13342137	chr4:2252803	MXD4	0.16	4.46	0.37	1.79e-5	Obesity-related traits;
TGCT	cis	rs2115630	1.000	rs4633690	chr15:85361960	C/T	cg17173187	chr15:85201210	NMB	-0.41	-4.93	-0.4	2.61e-6	P wave terminal force;
TGCT	cis	rs7246657	0.882	rs6508719	chr19:37877419	A/G	cg18154014	chr19:37997991	ZNF793	0.74	5.33	0.43	4.48e-7	Coronary artery calcification;
TGCT	cis	rs9567349	1.000	rs9567352	chr13:44637493	C/T	cg12694124	chr13:45013657	TSC22D1	-0.46	-4.65	-0.39	8.2e-6	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs10504229	0.679	rs12679920	chr8:58051710	G/T	cg20607798	chr8:58055168	NA	0.44	4.6	0.38	1.01e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs6964587	0.633	rs13231620	chr7:91507859	G/A	cg17063962	chr7:91808500	NA	-0.84	-8.62	-0.61	2.6e-14	Breast cancer;
TGCT	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg23188684	chr11:67383651	NA	-0.33	-5.12	-0.42	1.16e-6	Mean corpuscular volume;
TGCT	cis	rs7727544	0.606	rs10060615	chr5:131708877	T/C	cg14196790	chr5:131705035	SLC22A5	0.34	4.67	0.39	7.69e-6	Blood metabolite levels;
TGCT	cis	rs9325144	0.624	rs7312879	chr12:39150752	G/A	cg26384229	chr12:38710491	ALG10B	-0.61	-5.69	-0.46	8.63e-8	Morning vs. evening chronotype;
TGCT	cis	rs1568889	0.592	rs17652117	chr11:28483645	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.7	-5.65	-0.45	1.06e-7	Bipolar disorder;
TGCT	cis	rs7267979	1.000	rs4813566	chr20:25386465	G/T	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7829975	0.533	rs35900578	chr8:8719513	G/A	cg15556689	chr8:8085844	FLJ10661	0.74	6.66	0.51	8.04e-10	Mood instability;
TGCT	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg00343986	chr7:65444356	GUSB	0.22	5.38	0.44	3.53e-7	Calcium levels;
TGCT	cis	rs7826238	0.543	rs2976908	chr8:8345774	T/G	cg06636001	chr8:8085503	FLJ10661	0.59	5.04	0.41	1.59e-6	Systolic blood pressure;
TGCT	cis	rs3126085	0.867	rs11204948	chr1:152218473	A/G	cg03465714	chr1:152285911	FLG	-0.41	-4.79	-0.39	4.75e-6	Atopic dermatitis;
TGCT	cis	rs8050907	0.744	rs17879291	chr16:4526104	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.53	4.57	0.38	1.15e-5	Obesity-related traits;
TGCT	cis	rs2282802	0.660	rs2436390	chr5:139586501	G/A	cg01081189	chr5:139537190	NA	-0.29	-5.41	-0.44	3.19e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg20637647	chr7:64974828	NA	1.0	5.59	0.45	1.4e-7	Diabetic kidney disease;
TGCT	cis	rs796364	1.000	rs1658807	chr2:200767512	C/T	cg17644776	chr2:200775616	C2orf69	0.31	4.76	0.39	5.39e-6	Schizophrenia;
TGCT	cis	rs933688	1.000	rs12656350	chr5:90751343	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.03	8.55	0.61	3.8e-14	Smoking behavior;
TGCT	cis	rs4851254	0.660	rs74340261	chr2:100696827	C/T	cg04109781	chr2:100722022	AFF3	0.46	4.59	0.38	1.08e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg11211951	chr8:145729740	GPT	-0.24	-5.7	-0.46	8.4e-8	Age at first birth;
TGCT	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg07507251	chr3:52567010	NT5DC2	0.47	6.7	0.52	6.47e-10	Bipolar disorder;
TGCT	cis	rs933688	0.532	rs997737	chr5:90567031	C/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.56	-4.73	-0.39	5.91e-6	Smoking behavior;
TGCT	cis	rs7666738	0.830	rs1593569	chr4:99017485	C/G	cg05340658	chr4:99064831	C4orf37	0.49	5.62	0.45	1.18e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs929354	0.742	rs3808317	chr7:156944460	A/G	cg05182265	chr7:156933206	UBE3C	-0.39	-8.98	-0.63	3.72e-15	Body mass index;
TGCT	cis	rs9473924	0.542	rs2245173	chr6:50810540	T/C	cg14470998	chr6:50812995	TFAP2B	1.36	8.61	0.61	2.74e-14	Body mass index;
TGCT	cis	rs7107174	0.892	rs4291702	chr11:78001248	C/T	cg12700464	chr11:78128424	GAB2	-0.63	-4.49	-0.37	1.62e-5	Testicular germ cell tumor;
TGCT	cis	rs5769765	1.000	rs4824106	chr22:50267822	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	-0.41	-6.13	-0.48	1.08e-8	Schizophrenia;
TGCT	cis	rs12615966	0.932	rs4013898	chr2:105369671	C/T	cg16465502	chr2:105461796	NA	0.78	4.54	0.38	1.29e-5	Pancreatic cancer;
TGCT	cis	rs12286929	0.610	rs12807135	chr11:115053508	G/C	cg04017736	chr11:115827165	NA	-0.21	-4.7	-0.39	6.78e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg07167872	chr1:205819463	PM20D1	0.66	9.2	0.64	1.07e-15	Menarche (age at onset);
TGCT	cis	rs78456975	1.000	rs72776251	chr2:1525097	G/A	cg01028140	chr2:1542097	TPO	-0.35	-4.67	-0.39	7.82e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs67478160	0.584	rs2295148	chr14:104195610	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.19	-4.61	-0.38	9.97e-6	Schizophrenia;
TGCT	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg04772025	chr11:68637568	NA	0.6	6.78	0.52	4.36e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7208859	0.623	rs7219361	chr17:29080393	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs10986311	0.775	rs10760359	chr9:127174353	G/A	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.21	-4.87	-0.4	3.37e-6	Vitiligo;
TGCT	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg05368731	chr17:41323189	NBR1	1.2	14.2	0.79	9.05e-28	Menopause (age at onset);
TGCT	cis	rs17376456	0.569	rs35878747	chr5:93094070	C/A	cg25358565	chr5:93447407	FAM172A	0.74	6.42	0.5	2.66e-9	Diabetic retinopathy;
TGCT	cis	rs5769765	0.908	rs4074304	chr22:50309446	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.44	6.24	0.49	6.27e-9	Schizophrenia;
TGCT	trans	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg27523141	chr10:43048294	ZNF37B	0.74	8.61	0.61	2.7e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs782590	0.517	rs13013133	chr2:55889466	G/A	cg18811423	chr2:55921094	PNPT1	-0.6	-5.19	-0.42	8.37e-7	Metabolic syndrome;
TGCT	cis	rs8031584	0.752	rs2001686	chr15:31185772	G/A	cg08704250	chr15:31115839	NA	-0.42	-6.28	-0.49	5.27e-9	Huntington's disease progression;
TGCT	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.93	-6.89	-0.53	2.52e-10	Gut microbiome composition (summer);
TGCT	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg11644478	chr21:40555479	PSMG1	0.65	6.04	0.48	1.65e-8	Cognitive function;
TGCT	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg04772025	chr11:68637568	NA	0.6	6.77	0.52	4.48e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs600231	0.706	rs3782091	chr11:65336483	G/T	cg17120908	chr11:65337727	SSSCA1	0.57	5.78	0.46	5.72e-8	Bone mineral density;
TGCT	cis	rs2762353	0.574	rs4409177	chr6:25694491	T/G	cg15691649	chr6:25882328	NA	0.52	6.06	0.48	1.51e-8	Blood metabolite levels;
TGCT	cis	rs6728642	0.572	rs60621865	chr2:97598001	T/C	cg26665480	chr2:98280029	ACTR1B	-0.94	-6.74	-0.52	5.4e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	cis	rs782590	0.783	rs7594279	chr2:55812073	T/G	cg18811423	chr2:55921094	PNPT1	0.64	6.67	0.51	7.52e-10	Metabolic syndrome;
TGCT	cis	rs10743315	0.599	rs11044451	chr12:19365798	C/T	cg02471346	chr12:19282374	PLEKHA5	-0.61	-4.59	-0.38	1.06e-5	Gut microbiota (bacterial taxa);
TGCT	cis	rs4845570	0.920	rs10788809	chr1:151760792	A/G	cg07092448	chr1:151763213	TDRKH	1.19	9.81	0.66	3.59e-17	Coronary artery disease;
TGCT	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg11062466	chr8:58055876	NA	0.38	4.62	0.38	9.5e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs3087591	0.920	rs2905881	chr17:29547862	T/C	cg24425628	chr17:29625626	OMG;NF1	0.47	7.45	0.56	1.37e-11	Hip circumference;
TGCT	cis	rs7953249	0.791	rs10774579	chr12:121405210	T/C	cg00044289	chr12:121019603	POP5	-0.4	-4.44	-0.37	1.97e-5	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs12497850	0.931	rs9846123	chr3:49088112	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.61	-5.66	-0.45	9.84e-8	Parkinson's disease;
TGCT	cis	rs9325144	0.678	rs7315271	chr12:39164731	A/G	cg13010199	chr12:38710504	ALG10B	-0.52	-4.58	-0.38	1.12e-5	Morning vs. evening chronotype;
TGCT	cis	rs611744	0.934	rs2848619	chr8:109198185	T/C	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs9486715	0.867	rs4839834	chr6:96882109	C/A	cg18709589	chr6:96969512	KIAA0776	0.79	7.77	0.57	2.5e-12	Headache;
TGCT	cis	rs4919044	0.808	rs1238178	chr10:94804043	G/A	cg05127821	chr10:94822908	CYP26C1	-0.75	-4.85	-0.4	3.67e-6	Coronary artery disease;
TGCT	cis	rs7607369	0.648	rs17470271	chr2:219651995	A/T	cg02176678	chr2:219576539	TTLL4	0.46	6.07	0.48	1.43e-8	Red blood cell count;Amyotrophic lateral sclerosis;
TGCT	cis	rs79149102	0.579	rs58068887	chr15:75286140	G/A	cg09165964	chr15:75287851	SCAMP5	-1.07	-5.89	-0.47	3.42e-8	Lung cancer;
TGCT	cis	rs6121246	0.609	rs6089054	chr20:30323141	A/G	cg13852791	chr20:30311386	BCL2L1	0.84	8.15	0.59	3.38e-13	Mean corpuscular hemoglobin;
TGCT	cis	rs7568458	0.684	rs1048740	chr2:85764966	A/T	cg02493740	chr2:85810744	VAMP5	-0.28	-5.26	-0.43	6.1e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs4820539	1.000	rs4822360	chr22:23482460	A/G	cg14186256	chr22:23484241	RTDR1	0.99	12.69	0.75	3.59e-24	Bone mineral density;
TGCT	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg08280861	chr8:58055591	NA	0.4	4.73	0.39	5.97e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6845621	0.901	rs1452554	chr4:18920164	A/G	cg12196642	chr4:18937545	NA	0.25	4.48	0.37	1.7e-5	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
TGCT	cis	rs7617773	0.780	rs34523942	chr3:48342669	C/T	cg11946769	chr3:48343235	NME6	0.81	7.01	0.53	1.35e-10	Coronary artery disease;
TGCT	cis	rs4689388	0.581	rs4476672	chr4:6281496	A/G	cg14416269	chr4:6271139	WFS1	0.47	5.6	0.45	1.32e-7	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs9894429	1.000	rs11651264	chr17:79576394	A/G	cg21028142	chr17:79581711	NPLOC4	-0.29	-6.81	-0.52	3.83e-10	Eye color traits;
TGCT	cis	rs9993613	0.778	rs7689931	chr4:73423124	C/T	cg15102770	chr4:73434591	ADAMTS3	-0.5	-4.65	-0.39	8.51e-6	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg11890956	chr21:40555474	PSMG1	1.04	11.03	0.7	3.96e-20	Cognitive function;
TGCT	trans	rs1814175	0.645	rs11040661	chr11:49952146	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.49	-0.69	7.94e-19	Height;
TGCT	cis	rs3091242	0.900	rs35345536	chr1:25766488	A/G	cg23205692	chr1:25664452	TMEM50A	0.47	4.87	0.4	3.27e-6	Erythrocyte sedimentation rate;
TGCT	cis	rs12477438	0.765	rs7591794	chr2:99567514	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.83	-8.29	-0.6	1.56e-13	Chronic sinus infection;
TGCT	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg03264133	chr6:25882463	NA	0.74	7.71	0.57	3.43e-12	Blood metabolite levels;
TGCT	cis	rs6490294	0.500	rs4767284	chr12:112440731	G/A	cg10833066	chr12:111807467	FAM109A	0.34	5.32	0.43	4.69e-7	Mean platelet volume;
TGCT	cis	rs10088262	0.629	rs12549683	chr8:124798276	G/C	cg02993010	chr8:124780839	FAM91A1	-0.63	-5.13	-0.42	1.08e-6	Pancreatic cancer;
TGCT	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg25036284	chr2:26402008	FAM59B	0.65	5.19	0.42	8.36e-7	Gut microbiome composition (summer);
TGCT	cis	rs2295359	1.000	rs4655684	chr1:67611772	A/G	cg12940439	chr1:67600707	NA	-0.58	-6.01	-0.47	1.95e-8	Psoriasis;
TGCT	cis	rs6725041	0.792	rs1533769	chr2:213089956	A/C	cg16329650	chr2:213403929	ERBB4	-0.53	-4.52	-0.38	1.44e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs17102423	0.755	rs942627	chr14:65550025	A/G	cg11161011	chr14:65562177	MAX	-0.55	-7.7	-0.57	3.74e-12	Obesity-related traits;
TGCT	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg07636037	chr3:49044803	WDR6	0.88	9.05	0.63	2.49e-15	Menarche (age at onset);
TGCT	trans	rs208520	0.754	rs1100989	chr6:66880532	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-10.31	-0.68	2.29e-18	Exhaled nitric oxide output;
TGCT	cis	rs11671005	0.693	rs11668821	chr19:58955813	G/A	cg07777224	chr19:58919807	ZNF584	-0.63	-4.47	-0.37	1.77e-5	Mean platelet volume;
TGCT	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg09365446	chr1:150670422	GOLPH3L	0.31	4.56	0.38	1.23e-5	Tonsillectomy;
TGCT	cis	rs9436747	0.714	rs1186403	chr1:66000533	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	-0.49	-4.54	-0.38	1.32e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs12477438	0.798	rs6542849	chr2:99578493	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-6.25	-0.49	5.98e-9	Chronic sinus infection;
TGCT	cis	rs854765	0.547	rs7223696	chr17:17915791	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.79	8.41	0.6	8.09e-14	Total body bone mineral density;
TGCT	cis	rs7677751	0.943	rs9991165	chr4:55124591	A/G	cg17187183	chr4:55093834	PDGFRA	0.5	5.18	0.42	8.8e-7	Corneal astigmatism;
TGCT	cis	rs778371	0.522	rs10205801	chr2:233597196	G/A	cg08000102	chr2:233561755	GIGYF2	0.61	6.92	0.53	2.12e-10	Schizophrenia;
TGCT	cis	rs9611565	0.921	rs5751077	chr22:41720728	G/C	cg03806693	chr22:41940476	POLR3H	-0.86	-9.19	-0.64	1.16e-15	Vitiligo;
TGCT	cis	rs782590	1.000	rs782594	chr2:55844445	T/C	cg18811423	chr2:55921094	PNPT1	0.65	6.88	0.53	2.6e-10	Metabolic syndrome;
TGCT	cis	rs6121246	0.697	rs6087716	chr20:30229040	C/T	cg13852791	chr20:30311386	BCL2L1	0.74	4.84	0.4	3.77e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs2069837	0.515	rs12535219	chr7:22806159	C/G	cg00365470	chr7:22893924	NA	-0.64	-4.71	-0.39	6.64e-6	Longevity;
TGCT	cis	rs12477438	0.520	rs4340581	chr2:99725025	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.06	13.26	0.77	1.59e-25	Chronic sinus infection;
TGCT	cis	rs28595532	0.920	rs113034745	chr4:119750044	T/C	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs3125734	0.633	rs4979754	chr10:64048959	G/A	cg19640130	chr10:64028056	RTKN2	-0.38	-4.79	-0.39	4.75e-6	Rheumatoid arthritis;
TGCT	cis	rs9534288	0.797	rs7996875	chr13:46612836	C/T	cg15192986	chr13:46630673	CPB2	0.5	6.97	0.53	1.7e-10	Blood protein levels;
TGCT	cis	rs7681440	0.835	rs6831847	chr4:90785341	A/G	cg20003494	chr4:90757398	SNCA	0.59	5.55	0.45	1.64e-7	Dementia with Lewy bodies;
TGCT	cis	rs9814567	1.000	rs9841212	chr3:134191938	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.94	-9.38	-0.64	3.97e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs12908161	0.959	rs35557864	chr15:85331629	A/G	cg11189052	chr15:85197271	WDR73	0.71	5.85	0.47	4.1e-8	Schizophrenia;
TGCT	cis	rs2180341	0.618	rs11154398	chr6:127654281	C/A	cg24812749	chr6:127587940	RNF146	0.63	5.33	0.43	4.51e-7	Breast cancer;
TGCT	cis	rs9914988	0.943	rs7215310	chr17:27088626	G/T	cg20469991	chr17:27169893	C17orf63	-0.69	-5.04	-0.41	1.61e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs2243480	1.000	rs316315	chr7:65591205	C/T	cg20637647	chr7:64974828	NA	-0.77	-4.78	-0.39	4.87e-6	Diabetic kidney disease;
TGCT	cis	rs587847	0.558	rs619235	chr15:37664924	A/G	cg16890051	chr15:37175029	LOC145845	-0.38	-4.49	-0.37	1.6e-5	Intraocular pressure;
TGCT	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg21862992	chr11:68658383	NA	0.47	6.54	0.51	1.42e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs13256369	0.950	rs12548792	chr8:8568031	T/C	cg06671706	chr8:8559999	CLDN23	0.34	4.57	0.38	1.18e-5	Obesity-related traits;
TGCT	cis	rs7731657	0.537	rs10076495	chr5:130362953	A/C	cg08523029	chr5:130500466	HINT1	-0.61	-5.08	-0.42	1.34e-6	Fasting plasma glucose;
TGCT	cis	rs10791097	0.506	rs10750446	chr11:130706918	T/C	cg12179176	chr11:130786555	SNX19	-0.48	-4.76	-0.39	5.2e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs1448094	0.511	rs59858864	chr12:86166404	G/A	cg02569458	chr12:86230093	RASSF9	0.38	4.5	0.37	1.57e-5	Major depressive disorder;
TGCT	cis	rs7914558	0.966	rs4532960	chr10:104667406	C/T	cg15744005	chr10:104629667	AS3MT	-0.41	-5.11	-0.42	1.16e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs9611565	0.592	rs57102627	chr22:41987627	T/C	cg17554472	chr22:41940697	POLR3H	-0.49	-5.15	-0.42	9.88e-7	Vitiligo;
TGCT	cis	rs981844	0.775	rs17299561	chr4:154765480	C/T	cg14289246	chr4:154710475	SFRP2	0.95	8.45	0.6	6.67e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg24675658	chr1:53192096	ZYG11B	0.7	7.98	0.58	8.59e-13	Monocyte count;
TGCT	cis	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg18188782	chr20:61659543	NA	0.44	5.37	0.43	3.73e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1801251	1.000	rs1022330	chr2:233577330	G/A	cg25237894	chr2:233734115	C2orf82	0.31	5.45	0.44	2.63e-7	Coronary artery disease;
TGCT	cis	rs6429082	0.585	rs7524848	chr1:235711688	G/C	cg26050004	chr1:235667680	B3GALNT2	-0.56	-4.9	-0.4	2.98e-6	Adiposity;
TGCT	cis	rs916888	0.821	rs199512	chr17:44857352	T/C	cg17911788	chr17:44343683	NA	0.59	6.13	0.48	1.09e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7043114	0.525	rs7847929	chr9:95154244	C/T	cg14311495	chr9:95764742	FGD3	-0.22	-4.52	-0.38	1.41e-5	Height;
TGCT	cis	rs6684514	0.961	rs12048077	chr1:156299916	T/A	cg16558208	chr1:156270281	VHLL	0.48	9.6	0.65	1.19e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs7246657	0.722	rs2972437	chr19:38210511	G/T	cg03611452	chr19:38183253	ZNF781	0.56	4.63	0.38	8.97e-6	Coronary artery calcification;
TGCT	cis	rs11190604	1.000	rs7100386	chr10:102301417	C/T	cg23241863	chr10:102295624	HIF1AN	0.69	5.1	0.42	1.26e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg06238570	chr21:40685208	BRWD1	0.72	6.84	0.52	3.16e-10	Cognitive function;
TGCT	cis	rs9291683	0.609	rs12500810	chr4:10031068	G/A	cg11266682	chr4:10021025	SLC2A9	0.63	8.67	0.61	2.04e-14	Bone mineral density;
TGCT	cis	rs4663866	1.000	rs6741269	chr2:239179418	A/G	cg17283117	chr2:239148619	HES6	0.98	4.52	0.38	1.42e-5	Irritable bowel syndrome;
TGCT	cis	rs1775715	0.737	rs2799015	chr10:32107712	C/T	cg14930904	chr10:32216787	ARHGAP12	0.5	4.85	0.4	3.62e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs2153535	0.547	rs9505475	chr6:8542890	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.63	0.45	1.14e-7	Motion sickness;
TGCT	cis	rs1933488	0.931	rs3870364	chr6:153426679	G/A	cg24028809	chr6:153414101	RGS17	0.21	4.69	0.39	7.12e-6	Prostate cancer;
TGCT	cis	rs4664308	0.967	rs17241973	chr2:160918601	A/G	cg03641300	chr2:160917029	PLA2R1	-0.27	-6.66	-0.51	7.81e-10	Idiopathic membranous nephropathy;
TGCT	cis	rs7726839	0.794	rs10053310	chr5:595661	C/G	cg09021430	chr5:549028	NA	-0.41	-5.83	-0.46	4.48e-8	Obesity-related traits;
TGCT	cis	rs7552404	0.731	rs1770887	chr1:76401812	A/G	cg10523679	chr1:76189770	ACADM	-0.85	-7.88	-0.58	1.42e-12	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7647973	0.626	rs7637711	chr3:49829653	A/G	cg03034192	chr3:50606346	HEMK1;C3orf18	-0.36	-4.75	-0.39	5.61e-6	Menarche (age at onset);
TGCT	trans	rs2749592	0.550	rs9733309	chr10:37882405	G/A	cg17830980	chr10:43048298	ZNF37B	0.65	6.85	0.52	2.99e-10	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs9527	0.590	rs10786738	chr10:104869451	C/T	cg04362960	chr10:104952993	NT5C2	0.7	5.88	0.47	3.57e-8	Arsenic metabolism;
TGCT	cis	rs2836974	0.549	rs34160989	chr21:40554118	C/G	cg17971929	chr21:40555470	PSMG1	0.68	4.67	0.39	7.78e-6	Cognitive function;
TGCT	cis	rs9467773	0.620	rs2101582	chr6:26622734	C/T	cg26531700	chr6:26746687	NA	0.54	5.28	0.43	5.71e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	15.74	0.82	2.39e-31	Prudent dietary pattern;
TGCT	cis	rs4906332	1.000	rs8004501	chr14:103981662	G/A	cg26031613	chr14:104095156	KLC1	-0.54	-4.67	-0.39	7.66e-6	Coronary artery disease;
TGCT	cis	rs3733585	0.664	rs17245436	chr4:9958169	A/G	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.68	-0.51	7.16e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs1018836	0.608	rs1033347	chr8:91464137	G/A	cg16814680	chr8:91681699	NA	-0.77	-7.8	-0.57	2.21e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg11494091	chr17:61959527	GH2	0.6	14.36	0.79	3.83e-28	Prudent dietary pattern;
TGCT	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg17554472	chr22:41940697	POLR3H	0.46	4.71	0.39	6.63e-6	Vitiligo;
TGCT	cis	rs1538970	0.962	rs2185549	chr1:45814103	C/T	cg05343316	chr1:45956843	TESK2	-0.67	-5.02	-0.41	1.77e-6	Platelet count;
TGCT	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg23574427	chr4:122746245	BBS7;CCNA2	-0.35	-5.3	-0.43	5.06e-7	Type 2 diabetes;
TGCT	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg03760483	chr17:6899297	ALOX12	-0.46	-5.22	-0.42	7.34e-7	Tonsillectomy;
TGCT	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg19010396	chr19:19431384	KIAA0892;SF4	-0.54	-4.54	-0.38	1.3e-5	Tonsillectomy;
TGCT	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg08125733	chr17:73851984	WBP2	1.09	12.95	0.76	8.9e-25	Psoriasis;
TGCT	cis	rs7727544	0.716	rs7720230	chr5:131592405	T/G	cg22598563	chr5:131563921	P4HA2	-0.29	-4.67	-0.39	7.72e-6	Blood metabolite levels;
TGCT	cis	rs2224391	0.628	rs2753244	chr6:5257610	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-1.0	-6.14	-0.48	1.01e-8	Height;
TGCT	cis	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg13732083	chr21:47605072	C21orf56	0.35	4.5	0.37	1.55e-5	Testicular germ cell tumor;
TGCT	cis	rs3821902	0.646	rs17344653	chr3:64015989	C/T	cg22134162	chr3:63841271	THOC7	-0.32	-4.85	-0.4	3.7e-6	Breast cancer;
TGCT	cis	rs9311474	0.713	rs181274	chr3:52233861	T/A	cg07507251	chr3:52567010	NT5DC2	0.39	5.12	0.42	1.14e-6	Electroencephalogram traits;
TGCT	cis	rs2153535	0.580	rs7763190	chr6:8484197	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs290268	0.874	rs290997	chr9:93559351	G/A	cg02608019	chr9:93564028	SYK	0.46	4.65	0.39	8.23e-6	Platelet count;
TGCT	cis	rs3892630	0.824	rs7247264	chr19:33239846	T/G	cg22980127	chr19:33182716	NUDT19	0.7	5.07	0.41	1.44e-6	Red blood cell traits;
TGCT	cis	rs919433	0.617	rs4850809	chr2:198583403	C/T	cg00792783	chr2:198669748	PLCL1	-0.54	-4.96	-0.41	2.25e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs7829975	0.606	rs7833171	chr8:8699761	C/T	cg08975724	chr8:8085496	FLJ10661	0.55	4.86	0.4	3.5e-6	Mood instability;
TGCT	cis	rs4072705	0.967	rs4836986	chr9:127408059	C/T	cg13476313	chr9:127244764	NR5A1	0.28	4.62	0.38	9.66e-6	Menarche (age at onset);
TGCT	cis	rs1891498	0.602	rs10900396	chr1:147242596	C/T	cg17941330	chr1:147245494	GJA5	0.33	4.51	0.38	1.48e-5	Cognitive performance;
TGCT	cis	rs78487399	0.908	rs10186441	chr2:43840048	G/A	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.67	4.8	0.4	4.52e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs11969893	0.850	rs9404058	chr6:101323078	T/C	cg12253828	chr6:101329408	ASCC3	1.36	6.32	0.49	4.33e-9	Economic and political preferences (immigration/crime);
TGCT	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg09263875	chr16:632152	PIGQ	0.31	6.88	0.53	2.65e-10	Height;
TGCT	cis	rs10751667	0.961	rs7395928	chr11:952605	T/G	cg06064525	chr11:970664	AP2A2	-0.33	-6.49	-0.5	1.83e-9	Alzheimer's disease (late onset);
TGCT	cis	rs7267979	0.899	rs2179459	chr20:25456141	C/A	cg14121845	chr20:25566513	NINL	0.46	5.05	0.41	1.56e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.63	0.38	9.2e-6	Prudent dietary pattern;
TGCT	cis	rs896854	0.738	rs1713669	chr8:95958637	C/G	cg16049864	chr8:95962084	TP53INP1	-0.63	-7.75	-0.57	2.82e-12	Type 2 diabetes;
TGCT	cis	rs9894429	0.646	rs8080391	chr17:79566319	A/T	cg21028142	chr17:79581711	NPLOC4	-0.3	-7.03	-0.53	1.2e-10	Eye color traits;
TGCT	cis	rs11148252	0.595	rs9526968	chr13:53240183	T/C	cg00495681	chr13:53174319	NA	0.62	6.27	0.49	5.35e-9	Lewy body disease;
TGCT	cis	rs9677476	0.516	rs10199752	chr2:231969554	A/C	cg27665808	chr2:232055229	NA	0.35	4.43	0.37	2.01e-5	Food antigen IgG levels;
TGCT	cis	rs7296418	0.961	rs1790121	chr12:123604492	G/A	cg13010344	chr12:123464640	ARL6IP4	-0.31	-4.44	-0.37	2e-5	Platelet count;
TGCT	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg15691649	chr6:25882328	NA	-0.41	-4.71	-0.39	6.41e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.61	0.38	9.85e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2204008	0.774	rs11514062	chr12:38332297	A/C	cg26384229	chr12:38710491	ALG10B	0.76	6.89	0.53	2.46e-10	Bladder cancer;
TGCT	cis	rs11249608	0.548	rs62393074	chr5:178450476	G/C	cg01312482	chr5:178451176	ZNF879	-0.56	-5.5	-0.44	2.09e-7	Pubertal anthropometrics;
TGCT	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg20007245	chr22:24372913	LOC391322	-0.71	-7.04	-0.53	1.16e-10	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7178572	0.889	rs869301	chr15:77830633	T/C	cg22256960	chr15:77711686	NA	-0.95	-10.69	-0.69	2.58e-19	Type 2 diabetes;
TGCT	cis	rs6496667	0.642	rs12148876	chr15:91065208	G/A	cg22089800	chr15:90895588	ZNF774	0.64	4.46	0.37	1.81e-5	Rheumatoid arthritis;
TGCT	cis	rs7909074	1.000	rs4948926	chr10:45392604	G/C	cg05187965	chr10:45406764	TMEM72	-0.25	-5.34	-0.43	4.2e-7	Mean corpuscular volume;
TGCT	cis	rs3027009	0.881	rs56184975	chr1:159149253	G/T	cg11719576	chr1:158153771	CD1D	-0.39	-4.52	-0.38	1.41e-5	Lean body mass and age at menarche (combined);
TGCT	cis	rs7772486	0.875	rs10457793	chr6:146415403	A/G	cg05347473	chr6:146136440	FBXO30	0.56	5.22	0.42	7.31e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9611565	0.546	rs132793	chr22:42063681	A/G	cg06634786	chr22:41940651	POLR3H	0.87	8.3	0.6	1.49e-13	Vitiligo;
TGCT	cis	rs7772486	0.754	rs4360151	chr6:146255079	A/C	cg23711669	chr6:146136114	FBXO30	-0.85	-9.7	-0.66	6.73e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7020830	0.516	rs36047049	chr9:37375472	G/T	cg14294708	chr9:37120828	ZCCHC7	0.97	9.42	0.65	3.14e-16	Schizophrenia;
TGCT	cis	rs4455778	0.580	rs4304291	chr7:49116983	T/C	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg09359103	chr1:154839909	KCNN3	-0.71	-15.31	-0.81	2.37e-30	Prostate cancer;
TGCT	cis	rs3820928	0.904	rs2195487	chr2:227759720	G/C	cg11843606	chr2:227700838	RHBDD1	-0.58	-5.15	-0.42	9.93e-7	Pulmonary function;
TGCT	cis	rs2075371	0.933	rs2244548	chr7:133986234	A/G	cg11752832	chr7:134001865	SLC35B4	0.69	6.32	0.49	4.19e-9	Mean platelet volume;
TGCT	cis	rs950169	1.000	rs1911155	chr15:84787635	A/G	cg12863693	chr15:85201151	NMB	0.39	4.65	0.38	8.54e-6	Schizophrenia;
TGCT	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg11062466	chr8:58055876	NA	0.38	4.5	0.37	1.56e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9921338	0.961	rs8056282	chr16:11407236	T/C	cg00044050	chr16:11439710	C16orf75	-0.93	-6.89	-0.53	2.5e-10	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg18876405	chr7:65276391	NA	0.31	4.78	0.39	4.81e-6	Aortic root size;
TGCT	cis	rs4713675	0.624	rs482786	chr6:33707599	T/C	cg18005901	chr6:33739558	LEMD2	0.54	6.37	0.5	3.33e-9	Plateletcrit;
TGCT	cis	rs2594989	0.943	rs7646500	chr3:11478000	A/G	cg00170343	chr3:11313890	ATG7	0.67	5.12	0.42	1.13e-6	Circulating chemerin levels;
TGCT	cis	rs778371	1.000	rs778370	chr2:233743363	C/T	cg08000102	chr2:233561755	GIGYF2	-0.59	-6.56	-0.51	1.29e-9	Schizophrenia;
TGCT	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg06221963	chr1:154839813	KCNN3	0.82	15.81	0.82	1.62e-31	Prostate cancer;
TGCT	cis	rs9308731	0.623	rs6708784	chr2:111927379	A/G	cg04202892	chr2:111875749	ACOXL	0.55	6.42	0.5	2.64e-9	Chronic lymphocytic leukemia;
TGCT	cis	rs6754311	0.589	rs2011724	chr2:136818006	A/G	cg07169764	chr2:136633963	MCM6	-0.56	-5.48	-0.44	2.29e-7	Mosquito bite size;
TGCT	cis	rs896854	0.517	rs1011796	chr8:95951273	A/G	cg13393036	chr8:95962371	TP53INP1	0.5	5.8	0.46	5.2100000000000003e-08	Type 2 diabetes;
TGCT	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9467711	0.606	rs9379875	chr6:26444732	C/T	cg10795676	chr6:26370623	BTN3A2	-0.45	-4.56	-0.38	1.23e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs319204	0.918	rs2963080	chr5:146261089	C/T	cg13983063	chr5:146258615	PPP2R2B	0.32	4.59	0.38	1.06e-5	Schizophrenia;
TGCT	cis	rs11098499	0.863	rs3822195	chr4:120471660	C/T	cg09307838	chr4:120376055	NA	0.72	6.9	0.53	2.41e-10	Corneal astigmatism;
TGCT	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.51	-5.81	-0.46	4.97e-8	Lymphocyte counts;
TGCT	cis	rs7267979	1.000	rs2424710	chr20:25283886	C/G	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6500596	0.506	rs1530088	chr16:4439131	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.3	4.61	0.38	9.75e-6	Schizophrenia;
TGCT	cis	rs2204008	0.837	rs4432085	chr12:38181146	C/T	cg26384229	chr12:38710491	ALG10B	0.86	7.65	0.57	4.87e-12	Bladder cancer;
TGCT	cis	rs7224685	0.569	rs67533014	chr17:3993910	C/T	cg09580393	chr17:4869866	SPAG7	-0.38	-4.48	-0.37	1.64e-5	Type 2 diabetes;
TGCT	cis	rs1475911	1.000	rs2839467	chr21:43513200	A/G	cg14562523	chr21:43528734	C21orf128;UMODL1	0.25	4.95	0.41	2.35e-6	IgG glycosylation;
TGCT	cis	rs6952809	0.516	rs6952959	chr7:2440722	C/T	cg23289794	chr7:2394357	EIF3B	-0.84	-7.21	-0.54	4.72e-11	Multiple sclerosis;
TGCT	cis	rs2637266	0.703	rs7920374	chr10:78455861	T/C	cg18941641	chr10:78392320	NA	0.41	4.9	0.4	2.95e-6	Pulmonary function;
TGCT	cis	rs11864453	0.647	rs3764314	chr16:72127078	T/C	cg14768367	chr16:72042858	DHODH	0.52	5.21	0.42	7.61e-7	Fibrinogen levels;
TGCT	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg26818010	chr10:134567672	INPP5A	-0.38	-5.19	-0.42	8.5e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs9583531	0.629	rs7991766	chr13:111380684	A/G	cg24331049	chr13:111365604	ING1	0.85	8.25	0.6	1.97e-13	Coronary artery disease;
TGCT	cis	rs796364	0.616	rs6710393	chr2:200697246	G/A	cg17644776	chr2:200775616	C2orf69	0.35	4.99	0.41	1.97e-6	Schizophrenia;
TGCT	cis	rs7937682	0.883	rs1611989	chr11:111456299	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.97	-9.75	-0.66	5.24e-17	Primary sclerosing cholangitis;
TGCT	cis	rs950169	0.922	rs12915832	chr15:85111457	C/T	cg11189052	chr15:85197271	WDR73	0.77	6.42	0.5	2.68e-9	Schizophrenia;
TGCT	trans	rs9567307	1	rs9567307	chr13:44471877	A/G	cg12856521	chr11:46389249	DGKZ	0.66	7.29	0.55	3.14e-11	Leprosy;
TGCT	cis	rs1670533	1.000	rs629261	chr4:1086763	A/C	cg20887711	chr4:1340912	KIAA1530	0.66	5.33	0.43	4.49e-7	Recombination rate (females);
TGCT	cis	rs28595532	0.920	rs73842253	chr4:119721856	G/A	cg21605333	chr4:119757512	SEC24D	1.53	7.83	0.58	1.83e-12	Cannabis dependence symptom count;
TGCT	cis	rs11971779	0.752	rs4732371	chr7:139077317	T/A	cg07862535	chr7:139043722	LUC7L2	0.72	5.61	0.45	1.24e-7	Diisocyanate-induced asthma;
TGCT	cis	rs46522	0.585	rs79049364	chr17:47014991	T/A	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.5	-0.37	1.53e-5	Coronary heart disease;
TGCT	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg22168489	chr12:122356033	WDR66	0.2	4.74	0.39	5.87e-6	Mean corpuscular volume;
TGCT	cis	rs751728	0.965	rs4713681	chr6:33754817	T/C	cg13859433	chr6:33739653	LEMD2	-0.4	-7.16	-0.54	6.32e-11	Crohn's disease;
TGCT	cis	rs151997	0.925	rs26090	chr5:50170071	C/T	cg06027927	chr5:50259733	NA	-0.45	-4.59	-0.38	1.08e-5	Callous-unemotional behaviour;
TGCT	cis	rs651907	0.557	rs3094295	chr3:101401995	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.91	10.9	0.7	8.24e-20	Colorectal cancer;
TGCT	cis	rs1865760	0.613	rs2071300	chr6:25914572	C/T	cg07061783	chr6:25882402	NA	-0.43	-4.76	-0.39	5.23e-6	Height;
TGCT	cis	rs17221829	0.645	rs4002142	chr11:89374013	G/T	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.63	-0.38	9.04e-6	Anxiety in major depressive disorder;
TGCT	cis	rs7666738	0.830	rs9995370	chr4:98732145	T/G	cg05340658	chr4:99064831	C4orf37	0.49	5.77	0.46	6.02e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2885056	0.830	rs2018810	chr19:10669172	A/G	cg04833646	chr19:10679720	CDKN2D	0.95	9.16	0.64	1.36e-15	Red cell distribution width;
TGCT	cis	rs8070740	0.617	rs1058117	chr17:5323206	T/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.64	6.3	0.49	4.68e-9	Menopause (age at onset);
TGCT	cis	rs2777491	0.574	rs316611	chr15:41751678	A/G	cg18705301	chr15:41695430	NDUFAF1	0.95	16.29	0.83	1.36e-32	Ulcerative colitis;
TGCT	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg00814883	chr7:100076585	TSC22D4	-0.92	-9.76	-0.66	4.73e-17	Platelet count;
TGCT	cis	rs4705962	0.878	rs2023823	chr5:132032806	A/G	cg13566430	chr5:131992455	IL13	-0.28	-4.44	-0.37	1.97e-5	Atopic dermatitis;
TGCT	cis	rs9326248	0.954	rs8521	chr11:117067699	C/T	cg11861562	chr11:117069780	TAGLN	0.27	4.46	0.37	1.78e-5	Blood protein levels;
TGCT	cis	rs7043114	0.525	rs7869742	chr9:95256174	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-5.41	-0.44	3.1e-7	Height;
TGCT	cis	rs10984561	0.881	rs80242897	chr9:122248625	A/G	cg14242995	chr9:122249943	NA	0.75	6.12	0.48	1.16e-8	Pulmonary function decline;
TGCT	cis	rs7809950	1.000	rs4727680	chr7:107087407	T/G	cg23024343	chr7:107201750	COG5	-0.35	-5.54	-0.45	1.71e-7	Coronary artery disease;
TGCT	cis	rs2227564	0.620	rs11000765	chr10:75512452	G/C	cg19442545	chr10:75533431	FUT11	-0.31	-4.55	-0.38	1.26e-5	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs4654899	0.802	rs10916906	chr1:21255675	C/A	cg01072550	chr1:21505969	NA	-0.47	-7.02	-0.53	1.3100000000000001e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs911186	0.786	rs3800307	chr6:27185792	A/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.55	-4.81	-0.4	4.35e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9326248	1.000	rs4938354	chr11:117051165	A/G	cg16524733	chr11:117070046	TAGLN	0.32	4.54	0.38	1.3e-5	Blood protein levels;
TGCT	cis	rs1150668	0.835	rs203869	chr6:28040819	T/A	cg13525197	chr6:28411240	ZSCAN23	-0.48	-4.67	-0.39	7.63e-6	Pubertal anthropometrics;
TGCT	cis	rs9926296	0.656	rs2376884	chr16:89826922	C/T	cg08627397	chr16:89984028	MC1R	-0.29	-4.55	-0.38	1.26e-5	Vitiligo;
TGCT	cis	rs2242116	0.896	rs724448	chr3:46935734	A/C	cg27129171	chr3:47204927	SETD2	0.61	6.15	0.48	9.79e-9	Birth weight;
TGCT	cis	rs7829975	0.600	rs1719381	chr8:8602344	T/C	cg06636001	chr8:8085503	FLJ10661	-0.58	-4.79	-0.39	4.72e-6	Mood instability;
TGCT	cis	rs16854884	0.690	rs35885310	chr3:143771333	A/G	cg06585982	chr3:143692056	C3orf58	0.64	5.17	0.42	9.12e-7	Economic and political preferences (feminism/equality);
TGCT	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg18402987	chr7:1209562	NA	0.78	6.64	0.51	8.96e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7917772	0.636	rs2482499	chr10:104516246	G/A	cg05855489	chr10:104503620	C10orf26	-0.65	-5.17	-0.42	9.16e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.5	-4.75	-0.39	5.44e-6	Prudent dietary pattern;
TGCT	cis	rs2486012	1.000	rs1766966	chr1:44382515	A/G	cg12908607	chr1:44402522	ARTN	0.68	5.76	0.46	6.14e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs854765	0.583	rs8070722	chr17:17813562	C/T	cg09796270	chr17:17721594	SREBF1	0.24	4.72	0.39	6.36e-6	Total body bone mineral density;
TGCT	cis	rs4253772	0.591	rs9615934	chr22:46682310	C/G	cg24881330	chr22:46731750	TRMU	1.02	5.07	0.41	1.4e-6	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs7647973	0.922	rs6809851	chr3:49309787	C/A	cg06212747	chr3:49208901	KLHDC8B	0.56	4.46	0.37	1.78e-5	Menarche (age at onset);
TGCT	cis	rs7666738	0.830	rs1559859	chr4:99024325	C/T	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg07157834	chr1:205819609	PM20D1	0.36	5.55	0.45	1.63e-7	Monocyte percentage of white cells;
TGCT	cis	rs8013055	0.796	rs4075104	chr14:106000214	C/A	cg19700328	chr14:106028568	NA	-0.46	-5.14	-0.42	1.05e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs9291683	0.526	rs12506122	chr4:10033538	C/A	cg11266682	chr4:10021025	SLC2A9	0.61	7.76	0.57	2.67e-12	Bone mineral density;
TGCT	cis	rs3008870	0.958	rs12143044	chr1:67460054	A/T	cg11518657	chr1:67396239	MIER1	-0.54	-4.61	-0.38	9.72e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs7927997	0.757	rs2212434	chr11:76281593	C/T	cg17647271	chr11:76299819	NA	0.54	6.47	0.5	2.01e-9	Gut microbiota (functional units);Crohn's disease;
TGCT	cis	rs12220238	1.000	rs12358614	chr10:75906173	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.28	0.55	3.4e-11	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs7020830	0.898	rs7038219	chr9:37182892	C/A	cg14294708	chr9:37120828	ZCCHC7	1.17	16.15	0.82	2.76e-32	Schizophrenia;
TGCT	cis	rs3733631	0.895	rs28592258	chr4:104621036	C/A	cg24090629	chr4:104641072	TACR3	-0.73	-5.72	-0.46	7.65e-8	Menarche (age at onset);
TGCT	cis	rs6460942	1.000	rs6944134	chr7:12418036	T/C	cg06484146	chr7:12443880	VWDE	-0.59	-5.6	-0.45	1.28e-7	Coronary artery disease;
TGCT	cis	rs6952809	0.561	rs1548598	chr7:2438912	T/C	cg23289794	chr7:2394357	EIF3B	-0.84	-7.17	-0.54	5.84e-11	Multiple sclerosis;
TGCT	cis	rs10507380	0.824	rs9512641	chr13:27922574	C/T	cg25543773	chr13:27185723	WASF3	0.34	4.83	0.4	3.97e-6	Electrocardiographic traits;
TGCT	cis	rs7291412	0.600	rs7511013	chr22:46447132	C/G	cg05468064	chr22:46423449	NA	0.51	4.64	0.38	8.68e-6	Dupuytren's disease;Subjective well-being;
TGCT	cis	rs782590	0.537	rs7575170	chr2:55886780	C/T	cg18811423	chr2:55921094	PNPT1	-0.63	-5.34	-0.43	4.26e-7	Metabolic syndrome;
TGCT	cis	rs10838634	1.000	rs7102474	chr11:46833092	T/C	cg18332754	chr11:46939436	LRP4	0.89	4.46	0.37	1.82e-5	Schizophrenia;
TGCT	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.53	4.72	0.39	6.34e-6	Prudent dietary pattern;
TGCT	cis	rs2153535	0.580	rs962590	chr6:8450899	A/G	cg07606381	chr6:8435919	SLC35B3	0.53	5.02	0.41	1.79e-6	Motion sickness;
TGCT	cis	rs7584330	0.737	rs1390985	chr2:238367420	G/A	cg14458575	chr2:238380390	NA	0.51	8.25	0.6	1.91e-13	Prostate cancer;
TGCT	trans	rs2832077	0.527	rs9981922	chr21:30212718	A/G	cg14791747	chr16:20752902	THUMPD1	1.07	12.57	0.75	7.04e-24	Cognitive test performance;
TGCT	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg11062466	chr8:58055876	NA	0.43	4.52	0.38	1.45e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2235642	0.785	rs1057983	chr16:1660274	A/G	cg07639376	chr16:1584516	IFT140;TMEM204	-0.28	-4.96	-0.41	2.28e-6	Coronary artery disease;
TGCT	cis	rs6964587	0.935	rs9770444	chr7:91783162	T/G	cg22709100	chr7:91322751	NA	0.29	4.62	0.38	9.33e-6	Breast cancer;
TGCT	cis	rs7119	0.667	rs1058129	chr15:77905661	A/G	cg27398640	chr15:77910606	LINGO1	0.31	6.62	0.51	9.78e-10	Type 2 diabetes;
TGCT	cis	rs2692947	0.726	rs13019188	chr2:96774199	A/G	cg05933789	chr2:97190408	NA	-0.15	-4.53	-0.38	1.35e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg10876282	chr6:28092338	ZSCAN16	0.5	4.6	0.38	1.01e-5	Parkinson's disease;
TGCT	cis	rs12681288	0.748	rs2123054	chr8:1028227	C/G	cg04851639	chr8:1020857	NA	-0.34	-6.11	-0.48	1.18e-8	Schizophrenia;
TGCT	cis	rs60871478	0.636	rs12534606	chr7:895928	A/G	cg15782153	chr7:917662	C7orf20	0.54	4.92	0.4	2.74e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs4478858	0.684	rs2050816	chr1:31721708	G/T	cg00250761	chr1:31883323	NA	-0.27	-4.79	-0.4	4.59e-6	Alcohol dependence;
TGCT	cis	rs3820928	0.605	rs4675124	chr2:227802354	G/A	cg11843606	chr2:227700838	RHBDD1	-0.51	-4.82	-0.4	4.1e-6	Pulmonary function;
TGCT	cis	rs2997447	0.761	rs61776596	chr1:26454968	T/C	cg03844060	chr1:26490628	NA	0.27	4.44	0.37	2e-5	QRS complex (12-leadsum);
TGCT	cis	rs5769765	0.908	rs4824109	chr22:50271460	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	1.11	11.76	0.73	6.5e-22	Schizophrenia;
TGCT	cis	rs2204008	0.729	rs2892365	chr12:38446760	G/C	cg26384229	chr12:38710491	ALG10B	-0.8	-7.45	-0.56	1.42e-11	Bladder cancer;
TGCT	cis	rs11098499	0.863	rs34308924	chr4:120481431	T/C	cg09307838	chr4:120376055	NA	0.72	6.9	0.53	2.41e-10	Corneal astigmatism;
TGCT	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg18876405	chr7:65276391	NA	-0.36	-5.41	-0.44	3.12e-7	Aortic root size;
TGCT	cis	rs9303401	0.659	rs12946397	chr17:56769979	C/T	cg25039879	chr17:56429692	SUPT4H1	0.52	4.62	0.38	9.48e-6	Cognitive test performance;
TGCT	cis	rs4499344	0.622	rs73573371	chr19:33047095	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.7	-6.14	-0.48	1.01e-8	Mean platelet volume;
TGCT	cis	rs586688	0.582	rs550365	chr1:201665278	A/G	cg07139329	chr1:201708558	NAV1	-0.55	-5.47	-0.44	2.37e-7	Obesity-related traits;
TGCT	cis	rs644799	0.687	rs3748252	chr11:95519195	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.81	-9.5	-0.65	2.06e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7659604	1.000	rs73844281	chr4:122664688	A/G	cg19748678	chr4:122722346	EXOSC9	0.57	5.5	0.44	2.07e-7	Type 2 diabetes;
TGCT	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg00908189	chr16:619842	PIGQ	0.87	10.61	0.69	4.21e-19	Height;
TGCT	cis	rs7727544	0.618	rs2631367	chr5:131705458	C/G	cg24060327	chr5:131705240	SLC22A5	0.52	5.38	0.44	3.55e-7	Blood metabolite levels;
TGCT	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg07507251	chr3:52567010	NT5DC2	0.47	6.63	0.51	9.08e-10	Electroencephalogram traits;
TGCT	cis	rs7772486	0.686	rs702314	chr6:146003510	G/A	cg13319975	chr6:146136371	FBXO30	0.49	4.44	0.37	1.99e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6582630	0.502	rs11520261	chr12:38332019	T/G	cg26384229	chr12:38710491	ALG10B	0.76	6.89	0.53	2.46e-10	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg02725872	chr8:58115012	NA	-0.38	-4.76	-0.39	5.39e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs17102423	1.000	rs4902365	chr14:65602064	T/C	cg11161011	chr14:65562177	MAX	-0.48	-6.46	-0.5	2.18e-9	Obesity-related traits;
TGCT	cis	rs7246657	0.722	rs1531549	chr19:38088009	T/C	cg03611452	chr19:38183253	ZNF781	0.59	4.72	0.39	6.14e-6	Coronary artery calcification;
TGCT	cis	rs4794202	0.629	rs59111282	chr17:45902414	G/T	cg02219949	chr17:45927392	SP6	0.42	4.52	0.38	1.4e-5	Alzheimer's disease (cognitive decline);
TGCT	cis	rs1008375	0.900	rs6812675	chr4:17597549	A/G	cg18681998	chr4:17616180	MED28	0.87	7.67	0.57	4.29e-12	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7909074	0.899	rs2026428	chr10:45389452	T/C	cg04218760	chr10:45406644	TMEM72	-0.28	-5.66	-0.45	1.01e-7	Mean corpuscular volume;
TGCT	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg10047753	chr17:41438598	NA	0.95	9.61	0.65	1.12e-16	Menopause (age at onset);
TGCT	cis	rs2486012	0.737	rs6691988	chr1:44254402	A/G	cg12908607	chr1:44402522	ARTN	0.59	5.17	0.42	9.14e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs950169	0.810	rs62029594	chr15:84955252	T/C	cg12863693	chr15:85201151	NMB	0.45	4.96	0.41	2.28e-6	Schizophrenia;
TGCT	cis	rs4631830	0.812	rs11593361	chr10:51539156	A/G	cg10326726	chr10:51549505	MSMB	-0.26	-5.29	-0.43	5.44e-7	Prostate-specific antigen levels;
TGCT	cis	rs6586163	0.527	rs3824730	chr10:90752128	A/T	cg03111039	chr10:90751583	FAS;ACTA2	0.6	7.77	0.57	2.59e-12	Chronic lymphocytic leukemia;
TGCT	cis	rs7428	0.527	rs1061782	chr2:85546615	A/G	cg24342717	chr2:85555507	TGOLN2	0.48	8.12	0.59	3.89e-13	Ear protrusion;
TGCT	cis	rs62244186	0.541	rs62244226	chr3:44831831	G/A	cg10263370	chr3:44754102	ZNF502	-0.47	-5.67	-0.45	9.54e-8	Depressive symptoms;
TGCT	cis	rs4727027	0.933	rs34578816	chr7:148847606	G/A	cg23583168	chr7:148888333	NA	-0.76	-9.83	-0.66	3.29e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs138024639	1	rs138024639	chr6:28436014	TAAACATA/T	cg10876282	chr6:28092338	ZSCAN16	0.86	4.46	0.37	1.8e-5	Breast cancer;
TGCT	cis	rs17384381	0.861	rs12736004	chr1:85901367	G/A	cg16011679	chr1:85725395	C1orf52	0.82	6.56	0.51	1.28e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3749237	0.595	rs3870337	chr3:49557095	G/T	cg03060546	chr3:49711283	APEH	0.75	8.62	0.61	2.66e-14	Resting heart rate;
TGCT	cis	rs2439831	0.571	rs689883	chr15:43812596	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.97	7.38	0.55	1.96e-11	Lung cancer in ever smokers;
TGCT	cis	rs7833790	1.000	rs7460277	chr8:82709777	T/C	cg27398817	chr8:82754497	SNX16	-0.82	-5.86	-0.47	3.96e-8	Diastolic blood pressure;
TGCT	cis	rs7267979	1.000	rs4815406	chr20:25341316	C/G	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg12310025	chr6:25882481	NA	0.51	4.62	0.38	9.56e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10782582	0.593	rs6664254	chr1:76235084	G/T	cg22875332	chr1:76189707	ACADM	-0.45	-4.93	-0.4	2.55e-6	Daytime sleep phenotypes;
TGCT	cis	rs1568889	1.000	rs7112860	chr11:28151609	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	8.68	0.61	1.88e-14	Bipolar disorder;
TGCT	trans	rs1814175	0.669	rs11040473	chr11:49703813	C/T	cg15704280	chr7:45808275	SEPT13	-0.6	-6.94	-0.53	1.92e-10	Height;
TGCT	cis	rs10992471	0.603	rs12342019	chr9:95192508	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.62	-5.94	-0.47	2.62e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs7568458	0.870	rs1972297	chr2:85808573	T/C	cg02493740	chr2:85810744	VAMP5	-0.26	-4.75	-0.39	5.51e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs1497406	0.590	rs6676143	chr1:16528218	G/T	cg20430773	chr1:16534157	ARHGEF19	0.48	5.55	0.45	1.68e-7	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7845219	0.525	rs3019175	chr8:95949013	G/A	cg13393036	chr8:95962371	TP53INP1	-0.46	-5.28	-0.43	5.52e-7	Type 2 diabetes;
TGCT	cis	rs3008870	0.755	rs2208577	chr1:67513574	A/C	cg02640540	chr1:67518911	SLC35D1	0.65	5.88	0.47	3.62e-8	Lymphocyte percentage of white cells;
TGCT	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg21285383	chr16:89894308	SPIRE2	0.46	7.19	0.54	5.44e-11	Vitiligo;
TGCT	cis	rs11779988	0.516	rs426498	chr8:17897158	T/C	cg01800426	chr8:17659068	MTUS1	-0.6	-4.63	-0.38	9.07e-6	Breast cancer;
TGCT	cis	rs5769765	1.000	rs2295409	chr22:50261060	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	1.09	11.03	0.7	4e-20	Schizophrenia;
TGCT	cis	rs765787	0.530	rs2899381	chr15:45529630	C/T	cg24006582	chr15:45444508	DUOX1	-0.25	-5.54	-0.45	1.75e-7	Uric acid levels;
TGCT	cis	rs73110464	0.505	rs2638503	chr12:53307369	C/G	cg25025879	chr12:53359317	NA	-0.37	-4.78	-0.39	4.78e-6	Cancer (pleiotropy);
TGCT	cis	rs7945705	0.870	rs1109305	chr11:8955272	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.46	5.18	0.42	8.66e-7	Hemoglobin concentration;
TGCT	cis	rs10193935	0.901	rs92303	chr2:42656337	A/G	cg27598129	chr2:42591480	NA	0.33	4.97	0.41	2.13e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7681440	0.835	rs7656954	chr4:90784670	G/A	cg20003494	chr4:90757398	SNCA	-0.6	-5.54	-0.45	1.71e-7	Dementia with Lewy bodies;
TGCT	cis	rs2180341	1.000	rs6937287	chr6:127645719	T/A	cg24812749	chr6:127587940	RNF146	0.98	7.64	0.57	5.06e-12	Breast cancer;
TGCT	cis	rs425277	1.000	rs421992	chr1:2077260	C/T	cg24578937	chr1:2090814	PRKCZ	0.32	8.03	0.58	6.41e-13	Height;
TGCT	cis	rs3780378	0.967	rs7043371	chr9:5040203	T/A	cg02405213	chr9:5042618	JAK2	-0.59	-7.69	-0.57	3.87e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs1570884	0.684	rs7326825	chr13:50113450	G/A	cg08779649	chr13:50194554	NA	0.3	4.72	0.39	6.29e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
TGCT	cis	rs9473924	0.505	rs34793301	chr6:50859462	G/T	cg14470998	chr6:50812995	TFAP2B	1.34	7.08	0.54	9.62e-11	Body mass index;
TGCT	cis	rs9549367	0.713	rs3024745	chr13:113821598	A/G	cg18105134	chr13:113819100	PROZ	-0.46	-7.76	-0.57	2.75e-12	Platelet distribution width;
TGCT	cis	rs1670533	1.000	rs2045068	chr4:1052212	G/A	cg27284194	chr4:1044797	NA	0.7	5.88	0.47	3.62e-8	Recombination rate (females);
TGCT	cis	rs2997447	0.761	rs17356867	chr1:26448849	C/T	cg03844060	chr1:26490628	NA	-0.28	-4.57	-0.38	1.17e-5	QRS complex (12-leadsum);
TGCT	cis	rs861020	0.677	rs2049998	chr1:210031154	C/T	cg05527609	chr1:210001259	C1orf107	-0.95	-8.13	-0.59	3.74e-13	Orofacial clefts;
TGCT	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	5.56	0.45	1.56e-7	Height;
TGCT	cis	rs2180341	0.960	rs9398839	chr6:127665863	G/A	cg27446573	chr6:127587934	RNF146	1.2	10.61	0.69	4.11e-19	Breast cancer;
TGCT	cis	rs1903068	0.785	rs10013228	chr4:55997340	A/G	cg01777861	chr4:56023843	NA	0.53	6.16	0.48	9.28e-9	Endometriosis;
TGCT	cis	rs734999	0.588	rs4648562	chr1:2535613	C/A	cg18854424	chr1:2615690	NA	0.43	4.96	0.41	2.31e-6	Ulcerative colitis;
TGCT	cis	rs2066819	1.000	rs77120931	chr12:56646213	A/C	cg26714650	chr12:56694279	CS	-1.33	-6.24	-0.49	6.46e-9	Psoriasis vulgaris;
TGCT	cis	rs12602172	1	rs12602172	chr17:38163567	G/A	cg17467752	chr17:38218738	THRA	0.54	5.22	0.42	7.25e-7	Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;
TGCT	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg20203395	chr5:56204925	C5orf35	-0.57	-4.84	-0.4	3.85e-6	Initial pursuit acceleration;
TGCT	cis	rs9952991	0.941	rs2014857	chr18:12774326	C/T	cg23598886	chr18:12777645	NA	0.62	5.78	0.46	5.63e-8	Inflammatory skin disease;
TGCT	cis	rs10791097	0.694	rs7942621	chr11:130751308	C/G	cg05962950	chr11:130786565	SNX19	0.91	11.68	0.72	1.01e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs644799	0.965	rs607039	chr11:95547086	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	10.57	0.69	5.17e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7714584	1.000	rs11955172	chr5:150254378	T/C	cg22134413	chr5:150180641	NA	0.83	6.53	0.51	1.54e-9	Crohn's disease;
TGCT	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg18876405	chr7:65276391	NA	0.31	4.79	0.4	4.58e-6	Aortic root size;
TGCT	cis	rs6543140	0.964	rs4851592	chr2:103087641	C/T	cg09003973	chr2:102972529	NA	0.54	4.46	0.37	1.83e-5	Blood protein levels;
TGCT	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg21963583	chr11:68658836	MRPL21	0.36	6.01	0.47	1.94e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg10047753	chr17:41438598	NA	0.95	9.5	0.65	2.09e-16	Menopause (age at onset);
TGCT	cis	rs113352275	1	rs113352275	chr15:78840567	C/T	cg24631222	chr15:78858424	CHRNA5	0.93	7.58	0.56	7.12e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs62244186	1.000	rs62244186	chr3:44739783	G/A	cg02073558	chr3:44770973	ZNF501	0.69	6.94	0.53	1.92e-10	Depressive symptoms;
TGCT	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg22105103	chr4:187893119	NA	0.35	4.94	0.41	2.49e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	7.28	0.55	3.36e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7027203	0.828	rs7037960	chr9:96584028	G/A	cg13679303	chr9:96623674	NA	-0.66	-10.64	-0.69	3.54e-19	DNA methylation (variation);
TGCT	cis	rs7027203	0.557	rs2487015	chr9:96521240	T/G	cg13679303	chr9:96623674	NA	-0.53	-7.48	-0.56	1.18e-11	DNA methylation (variation);
TGCT	cis	rs4924935	0.851	rs17743944	chr17:18809268	A/G	cg26378065	chr17:18585709	ZNF286B	-0.56	-4.64	-0.38	8.86e-6	Pancreatic cancer;
TGCT	cis	rs76878669	0.793	rs10791867	chr11:66081211	C/G	cg18002602	chr11:66138449	SLC29A2	-0.53	-6.05	-0.48	1.62e-8	Educational attainment (years of education);
TGCT	cis	rs6570726	0.791	rs379040	chr6:145889035	T/C	cg05347473	chr6:146136440	FBXO30	0.52	4.93	0.41	2.54e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs72949976	0.966	rs6752061	chr2:214027818	C/T	cg08319019	chr2:214017104	IKZF2	-0.83	-7.74	-0.57	2.99e-12	Lung cancer;Squamous cell lung carcinoma;
TGCT	cis	rs67311347	0.577	rs1317217	chr3:40271697	T/G	cg13683864	chr3:40499215	RPL14	-0.79	-7.58	-0.56	7.16e-12	Renal cell carcinoma;
TGCT	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	5.23	0.43	6.92e-7	Menopause (age at onset);
TGCT	cis	rs7769051	0.522	rs7775241	chr6:133109022	T/C	cg22852734	chr6:133119734	C6orf192	1.22	4.65	0.39	8.32e-6	Type 2 diabetes nephropathy;
TGCT	cis	rs909002	0.849	rs10914456	chr1:32088171	T/C	cg11573219	chr1:32083031	HCRTR1	-0.49	-6.39	-0.5	3.06e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs116161686	0.500	rs76610459	chr1:210050756	T/G	cg21951975	chr1:209979733	IRF6	0.63	4.96	0.41	2.23e-6	Coronary artery disease;
TGCT	cis	rs208515	0.525	rs4145045	chr6:66678949	T/C	cg07460842	chr6:66804631	NA	0.87	9.16	0.64	1.32e-15	Exhaled nitric oxide levels;
TGCT	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg10802521	chr3:52805072	NEK4	-0.72	-9.1	-0.63	1.91e-15	Bipolar disorder;
TGCT	cis	rs2458413	0.903	rs2669448	chr8:105372324	T/G	cg13045555	chr8:105342365	NA	0.34	5.04	0.41	1.6e-6	Paget's disease;
TGCT	cis	rs36051895	0.659	rs57299248	chr9:5062932	C/G	cg02405213	chr9:5042618	JAK2	-0.79	-11.54	-0.72	2.28e-21	Pediatric autoimmune diseases;
TGCT	cis	rs35306767	0.668	rs12356612	chr10:1055055	C/T	cg18964960	chr10:1102726	WDR37	0.75	5.48	0.44	2.23e-7	Eosinophil percentage of granulocytes;
TGCT	cis	rs9928842	0.771	rs2870471	chr16:75274282	A/G	cg09066997	chr16:75300724	BCAR1	-0.23	-4.44	-0.37	2e-5	Alcoholic chronic pancreatitis;
TGCT	cis	rs9291683	0.588	rs11732054	chr4:9999877	C/T	cg11266682	chr4:10021025	SLC2A9	0.66	9.23	0.64	9.39e-16	Bone mineral density;
TGCT	cis	rs1050631	0.960	rs1789503	chr18:33696865	T/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.51	4.95	0.41	2.33e-6	Esophageal squamous cell cancer (length of survival);
TGCT	cis	rs9473924	0.542	rs4294001	chr6:50850065	G/A	cg14470998	chr6:50812995	TFAP2B	1.35	8.39	0.6	9.05e-14	Body mass index;
TGCT	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg12963246	chr6:28129442	ZNF389	-0.53	-5.09	-0.42	1.27e-6	Depression;
TGCT	cis	rs61990749	0.597	rs176943	chr14:78175797	T/G	cg02301378	chr14:78227641	SNW1;C14orf178	-0.6	-4.45	-0.37	1.88e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs7542091	0.704	rs7537294	chr1:210043777	A/G	cg22029157	chr1:209979665	IRF6	0.64	6.1	0.48	1.23e-8	Monobrow;
TGCT	cis	rs3793917	0.901	rs36212732	chr10:124215198	A/G	cg09507567	chr10:124027408	NA	0.4	4.89	0.4	3.12e-6	Age-related macular degeneration;
TGCT	cis	rs3820068	0.580	rs36100011	chr1:16046920	C/T	cg17385448	chr1:15911702	AGMAT	0.35	4.63	0.38	8.97e-6	Systolic blood pressure;
TGCT	cis	rs3820928	0.874	rs11685983	chr2:227799853	A/G	cg11843606	chr2:227700838	RHBDD1	-0.53	-4.73	-0.39	5.9e-6	Pulmonary function;
TGCT	cis	rs2455601	0.529	rs2653569	chr11:8986978	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.46	-4.73	-0.39	6.02e-6	Schizophrenia;
TGCT	cis	rs2637266	0.654	rs846576	chr10:78500388	T/A	cg18941641	chr10:78392320	NA	0.42	5.03	0.41	1.7e-6	Pulmonary function;
TGCT	cis	rs12477438	0.798	rs4850894	chr2:99629396	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-5.87	-0.47	3.74e-8	Chronic sinus infection;
TGCT	cis	rs1371867	0.875	rs1788173	chr8:101330939	A/G	cg06002616	chr8:101225028	SPAG1	0.53	6.34	0.49	3.9e-9	Atrioventricular conduction;
TGCT	cis	rs7635838	0.859	rs6786166	chr3:11511424	T/C	cg00170343	chr3:11313890	ATG7	0.65	5.97	0.47	2.33e-8	HDL cholesterol;
TGCT	cis	rs12478296	0.792	rs6755390	chr2:243012998	C/T	cg06360820	chr2:242988706	NA	-0.64	-5.02	-0.41	1.73e-6	Obesity-related traits;
TGCT	cis	rs1215050	0.791	rs6813619	chr4:98830768	C/T	cg17366294	chr4:99064904	C4orf37	-0.55	-5.92	-0.47	2.97e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	trans	rs8073060	0.821	rs11080355	chr17:33872694	T/A	cg19694781	chr19:47549865	TMEM160	0.43	7.9	0.58	1.27e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs1008375	0.931	rs6449309	chr4:17573208	C/T	cg10189774	chr4:17578691	LAP3	0.61	5.35	0.43	4.06e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs319204	0.959	rs525418	chr5:146285437	G/A	cg25021259	chr5:146258546	PPP2R2B	0.35	4.51	0.38	1.5e-5	Schizophrenia;
TGCT	cis	rs2404602	0.692	rs12910382	chr15:77053442	A/C	cg22467129	chr15:76604101	ETFA	-0.45	-5.11	-0.42	1.18e-6	Blood metabolite levels;
TGCT	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg11062466	chr8:58055876	NA	0.42	4.49	0.37	1.61e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2594989	1.000	rs2594990	chr3:11317897	G/T	cg00170343	chr3:11313890	ATG7	0.66	4.99	0.41	2.02e-6	Circulating chemerin levels;
TGCT	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs8051431	0.876	rs4788452	chr16:72012847	C/A	cg06353428	chr16:71660113	MARVELD3	0.59	5.02	0.41	1.73e-6	LDL cholesterol levels;
TGCT	cis	rs7917772	0.502	rs2296583	chr10:104244322	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg03517284	chr6:25882590	NA	0.55	4.81	0.4	4.33e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg27588902	chr6:42928151	GNMT	-0.49	-5.94	-0.47	2.69e-8	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs4988958	0.565	rs1035125	chr2:103033839	C/A	cg03938978	chr2:103052716	IL18RAP	0.27	5.41	0.44	3.17e-7	Asthma (childhood onset);
TGCT	cis	rs6570726	0.846	rs9399559	chr6:145945778	C/T	cg13319975	chr6:146136371	FBXO30	-0.5	-4.49	-0.37	1.63e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg01448562	chr3:133502909	NA	0.34	7.06	0.54	1.07e-10	Iron status biomarkers;
TGCT	trans	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg20587970	chr11:113659929	NA	-1.04	-12.57	-0.75	6.97e-24	Hip circumference adjusted for BMI;
TGCT	cis	rs9916302	0.904	rs801420	chr17:37466103	C/G	cg07936489	chr17:37558343	FBXL20	0.65	5.08	0.41	1.36e-6	Glomerular filtration rate (creatinine);
TGCT	trans	rs1814175	0.817	rs10769648	chr11:50013992	T/C	cg15704280	chr7:45808275	SEPT13	-0.72	-8.47	-0.61	6.02e-14	Height;
TGCT	cis	rs6840360	0.642	rs4696092	chr4:152412603	T/C	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.82e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7953249	0.656	rs2178463	chr12:121389721	A/G	cg02403541	chr12:121454288	C12orf43	-0.62	-5.3	-0.43	5.11e-7	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs78487399	0.614	rs13422551	chr2:43724682	G/A	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.74	4.49	0.37	1.59e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs2243480	1.000	rs160634	chr7:65528664	C/T	cg20637647	chr7:64974828	NA	-0.84	-5.5	-0.44	2.07e-7	Diabetic kidney disease;
TGCT	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg15595755	chr5:1867978	NA	0.45	5.09	0.42	1.3e-6	Cardiovascular disease risk factors;
TGCT	cis	rs7666738	0.830	rs13119913	chr4:98977983	G/T	cg18180107	chr4:99064573	C4orf37	0.53	4.89	0.4	3.01e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.0	-7.42	-0.55	1.64e-11	Gut microbiome composition (summer);
TGCT	cis	rs2204008	0.744	rs66474616	chr12:38461564	G/A	cg26384229	chr12:38710491	ALG10B	0.88	8.04	0.59	5.98e-13	Bladder cancer;
TGCT	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg00684032	chr4:1343700	KIAA1530	-0.22	-4.73	-0.39	6.06e-6	Obesity-related traits;
TGCT	cis	rs6088590	0.687	rs8115656	chr20:33282780	G/C	cg08999081	chr20:33150536	PIGU	0.26	4.88	0.4	3.17e-6	Coronary artery disease;
TGCT	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg03188948	chr7:1209495	NA	0.68	5.8	0.46	5.09e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2216164	1.000	rs7304531	chr12:68521687	C/T	cg17065850	chr12:67807625	NA	0.25	4.61	0.38	9.76e-6	Alopecia areata;
TGCT	trans	rs7824557	0.564	rs4631424	chr8:11236809	T/C	cg15556689	chr8:8085844	FLJ10661	-0.74	-6.68	-0.51	7.12e-10	Retinal vascular caliber;
TGCT	cis	rs9611565	0.546	rs5758430	chr22:42109844	G/T	cg13695892	chr22:41940480	POLR3H	0.89	9.04	0.63	2.55e-15	Vitiligo;
TGCT	cis	rs35934224	0.891	rs73148965	chr22:19872935	G/A	cg11182965	chr22:19864308	TXNRD2	-0.35	-4.68	-0.39	7.54e-6	Glaucoma (primary open-angle);
TGCT	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg00684032	chr4:1343700	KIAA1530	0.22	4.73	0.39	6.04e-6	Obesity-related traits;
TGCT	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.55	4.85	0.4	3.59e-6	Prudent dietary pattern;
TGCT	cis	rs11874712	0.899	rs11664764	chr18:43675364	T/C	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	5.23	0.42	7.11e-7	Migraine - clinic-based;
TGCT	cis	rs6088590	1.000	rs2076668	chr20:33437621	G/A	cg06115741	chr20:33292138	TP53INP2	0.63	5.08	0.42	1.32e-6	Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs7663661	chr4:99014761	A/G	cg17366294	chr4:99064904	C4orf37	0.68	7.04	0.53	1.17e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1488864	1.000	rs1552515	chr11:6354524	G/A	cg12755421	chr11:6342214	PRKCDBP	-0.65	-4.66	-0.39	8.1e-6	Smooth-surface caries;
TGCT	cis	rs8084125	0.832	rs62105182	chr18:74951407	T/C	cg05528293	chr18:74961138	GALR1	0.52	5.18	0.42	8.65e-7	Obesity-related traits;
TGCT	cis	rs3125734	0.608	rs7905731	chr10:64018472	T/C	cg19640130	chr10:64028056	RTKN2	-0.4	-5.14	-0.42	1.02e-6	Rheumatoid arthritis;
TGCT	cis	rs7772486	0.875	rs2777479	chr6:146309178	C/A	cg23711669	chr6:146136114	FBXO30	0.86	9.13	0.63	1.59e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg21017887	chr14:105400489	NA	0.37	5.19	0.42	8.23e-7	Rheumatoid arthritis;
TGCT	cis	rs1568889	0.712	rs10835306	chr11:28302410	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.93	10.99	0.7	4.8e-20	Bipolar disorder;
TGCT	cis	rs2070488	1.000	rs13058903	chr3:38513365	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.88	-9.49	-0.65	2.13e-16	Electrocardiographic conduction measures;
TGCT	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg06558623	chr16:89946397	TCF25	0.5	5.99	0.47	2.14e-8	Skin colour saturation;
TGCT	cis	rs478304	0.654	rs6591187	chr11:65460086	C/G	cg27068330	chr11:65405492	SIPA1	-0.99	-11.36	-0.71	6.13e-21	Acne (severe);
TGCT	cis	rs1153858	1.000	rs4774579	chr15:45651803	G/A	cg26924012	chr15:45694286	SPATA5L1	1.09	15.16	0.81	5.15e-30	Homoarginine levels;
TGCT	cis	rs3101457	0.515	rs4658632	chr1:244516949	G/T	cg09033006	chr1:244517177	C1orf100	-0.42	-4.59	-0.38	1.06e-5	Smoking behavior;
TGCT	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	8.55	0.61	3.84e-14	Platelet count;
TGCT	cis	rs829661	0.947	rs829665	chr2:30724701	T/A	cg07150166	chr2:30669952	LCLAT1	0.9	5.7	0.46	8.09e-8	Midgestational circulating levels of PBDEs (fetal genetic effect);
TGCT	cis	rs6088580	0.634	rs1205338	chr20:32925625	C/G	cg06115741	chr20:33292138	TP53INP2	-0.55	-4.84	-0.4	3.85e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs9894429	0.646	rs7220310	chr17:79606056	C/A	cg18240062	chr17:79603768	NPLOC4	0.56	4.92	0.4	2.67e-6	Eye color traits;
TGCT	cis	rs1371867	0.846	rs1788167	chr8:101319996	C/T	cg00191853	chr8:101177733	SPAG1	-0.23	-4.76	-0.39	5.2e-6	Atrioventricular conduction;
TGCT	cis	rs4730250	0.707	rs257386	chr7:106807783	C/G	cg02696742	chr7:106810147	HBP1	-0.71	-5.83	-0.46	4.6e-8	Osteoarthritis;
TGCT	trans	rs17685	0.725	rs6467993	chr7:75719350	G/A	cg19862616	chr7:65841803	NCRNA00174	0.52	9.01	0.63	3.02e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs9902453	0.765	rs2874505	chr17:28037923	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.83	8.49	0.61	5.34e-14	Coffee consumption (cups per day);
TGCT	cis	rs7617773	0.780	rs2541	chr3:48339618	A/G	cg11946769	chr3:48343235	NME6	0.82	7.06	0.54	1.03e-10	Coronary artery disease;
TGCT	cis	rs11190604	1.000	rs11190602	chr10:102297256	T/C	cg23241863	chr10:102295624	HIF1AN	0.69	5.1	0.42	1.24e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs4455778	0.580	rs7808248	chr7:49125067	T/A	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs7824557	0.527	rs4634600	chr8:11239017	T/A	cg21775007	chr8:11205619	TDH	-0.68	-6.6	-0.51	1.08e-9	Retinal vascular caliber;
TGCT	cis	rs4975709	1.000	rs4975709	chr5:1877280	A/C	cg14773178	chr5:1868261	NA	0.35	5.12	0.42	1.14e-6	Cardiovascular disease risk factors;
TGCT	cis	rs12142240	0.698	rs17361915	chr1:46847321	C/T	cg00530320	chr1:46809349	NSUN4	0.29	5.79	0.46	5.34e-8	Menopause (age at onset);
TGCT	cis	rs2153535	0.580	rs2184584	chr6:8468407	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs10782582	0.593	rs6675076	chr1:76118503	A/C	cg03433033	chr1:76189801	ACADM	-0.63	-7.39	-0.55	1.89e-11	Daytime sleep phenotypes;
TGCT	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.31	-4.84	-0.4	3.85e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2073300	1.000	rs6036422	chr20:23456962	A/T	cg09953122	chr20:23471693	CST8	-0.59	-4.71	-0.39	6.5e-6	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs6558174	0.965	rs1564595	chr8:22488939	A/G	cg03733263	chr8:22462867	KIAA1967	0.67	5.4	0.44	3.33e-7	Breast cancer;
TGCT	cis	rs8031584	1.000	rs35607976	chr15:31277788	T/C	cg08704250	chr15:31115839	NA	-0.35	-4.53	-0.38	1.38e-5	Huntington's disease progression;
TGCT	cis	rs12220898	0.679	rs7082585	chr10:50486747	G/T	cg12697796	chr10:49954016	WDFY4	0.51	4.58	0.38	1.1e-5	Inflammatory biomarkers;
TGCT	cis	rs611744	0.870	rs634216	chr8:109174803	A/G	cg21045802	chr8:109455806	TTC35	0.7	6.19	0.49	8.14e-9	Dupuytren's disease;
TGCT	cis	rs2050392	0.792	rs684395	chr10:30719112	C/G	cg13289132	chr10:30722225	MAP3K8	-0.39	-4.65	-0.39	8.2e-6	Inflammatory bowel disease;
TGCT	cis	rs1878931	0.580	rs3848355	chr16:3407489	A/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.91	10.22	0.68	3.6e-18	Body mass index (adult);
TGCT	cis	rs7267979	1.000	rs6115168	chr20:25372891	C/A	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	4.54	0.38	1.34e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7666738	0.830	rs34164616	chr4:99015251	G/A	cg05340658	chr4:99064831	C4orf37	0.48	5.43	0.44	2.92e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs595982	0.559	rs117227130	chr19:49367959	A/G	cg17863274	chr19:49399704	TULP2	-0.47	-6.78	-0.52	4.43e-10	Red cell distribution width;
TGCT	cis	rs7296418	0.961	rs7957096	chr12:123544878	A/G	cg00376283	chr12:123451042	ABCB9	0.78	7.16	0.54	6.27e-11	Platelet count;
TGCT	cis	rs1245541	0.681	rs1245579	chr10:73883550	C/T	cg09661010	chr10:73848153	SPOCK2	-0.37	-4.53	-0.38	1.39e-5	Insulin-like growth factors;
TGCT	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg24531977	chr5:56204891	C5orf35	-0.76	-7.34	-0.55	2.45e-11	Initial pursuit acceleration;
TGCT	cis	rs3849570	0.961	rs3772896	chr3:81751968	C/T	cg07356753	chr3:81810745	GBE1	-0.85	-8.16	-0.59	3.13e-13	Waist circumference;Body mass index;
TGCT	cis	rs17401966	1.000	rs17401966	chr1:10385471	C/T	cg19773385	chr1:10388646	KIF1B	0.21	4.54	0.38	1.31e-5	Hepatocellular carcinoma;
TGCT	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg23131131	chr22:24373011	LOC391322	-0.79	-8.48	-0.61	5.68e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs12210905	1.000	rs6931711	chr6:27145586	C/T	cg08851530	chr6:28072375	NA	1.12	5.43	0.44	2.82e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs9314614	0.865	rs2978898	chr8:6692378	T/C	cg27319216	chr8:6693540	XKR5	-0.31	-5.13	-0.42	1.07e-6	IgA nephropathy;White blood cell count (basophil);
TGCT	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg19626725	chr5:178986131	RUFY1	-0.54	-7.3	-0.55	3.09e-11	Lung cancer;
TGCT	cis	rs9443645	0.901	rs10943605	chr6:79655477	G/A	cg05283184	chr6:79620031	NA	-0.21	-4.71	-0.39	6.61e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs950169	0.919	rs17300292	chr15:84762568	G/C	cg17173187	chr15:85201210	NMB	0.47	5.23	0.43	7.01e-7	Schizophrenia;
TGCT	cis	rs2456568	0.741	rs2102332	chr11:93635281	G/T	cg16099599	chr11:93583650	C11orf90	-0.4	-4.98	-0.41	2.04e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs10876993	0.789	rs1689600	chr12:58049645	A/T	cg15848620	chr12:58087721	OS9	-0.72	-5.82	-0.46	4.71e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs4975616	0.869	rs380286	chr5:1320247	G/A	cg07493874	chr5:1342172	CLPTM1L	-0.28	-6.52	-0.51	1.59e-9	Lung cancer;
TGCT	cis	rs6582630	0.555	rs7301250	chr12:38596244	G/T	cg26384229	chr12:38710491	ALG10B	0.89	7.82	0.57	2e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.15	0.82	2.71e-32	Prudent dietary pattern;
TGCT	trans	rs57221529	0.766	rs28563961	chr5:554498	C/G	cg11887960	chr12:57824829	NA	1.14	9.17	0.64	1.26e-15	Lung disease severity in cystic fibrosis;
TGCT	cis	rs7833790	0.724	rs72603871	chr8:82754460	C/G	cg06027949	chr8:82754900	SNX16	0.67	5.14	0.42	1.06e-6	Diastolic blood pressure;
TGCT	cis	rs11203032	0.831	rs10887920	chr10:90924415	C/T	cg16672925	chr10:90967113	CH25H	0.73	4.5	0.37	1.55e-5	Heart failure;
TGCT	cis	rs2281845	0.965	rs3738263	chr1:201083506	A/G	cg22815214	chr1:201083145	CACNA1S	0.25	4.65	0.39	8.33e-6	Permanent tooth development;
TGCT	cis	rs655029	0.816	rs711229	chr2:31460932	G/A	cg14018959	chr2:31480232	EHD3	-0.34	-4.58	-0.38	1.11e-5	Mean platelet volume;Platelet distribution width;Platelet count;Plateletcrit;
TGCT	cis	rs7402982	0.934	rs8028620	chr15:99202875	C/T	cg03437748	chr15:99193247	IGF1R	0.57	6.08	0.48	1.35e-8	Birth weight;
TGCT	cis	rs6732795	0.896	rs6546485	chr2:69413745	A/G	cg10773587	chr2:69614142	GFPT1	-0.51	-4.74	-0.39	5.77e-6	Intraocular pressure;
TGCT	cis	rs10744422	1.000	rs1532835	chr12:123330665	G/A	cg25930673	chr12:123319894	HIP1R	-0.85	-4.94	-0.41	2.45e-6	Schizophrenia;
TGCT	cis	rs910316	0.763	rs6574205	chr14:75453039	G/C	cg08847533	chr14:75593920	NEK9	0.82	8.81	0.62	9.21e-15	Height;
TGCT	cis	rs2387326	1.000	rs2387328	chr10:129925986	C/T	cg03458096	chr10:129105057	DOCK1	-0.3	-4.67	-0.39	7.78e-6	Select biomarker traits;
TGCT	cis	rs9291683	0.507	rs6827754	chr4:10018153	A/C	cg11266682	chr4:10021025	SLC2A9	-0.68	-6.44	-0.5	2.41e-9	Bone mineral density;
TGCT	cis	rs427394	0.772	rs274689	chr5:6736215	G/C	cg10857441	chr5:6722123	POLS	-0.32	-7.93	-0.58	1.08e-12	Menopause (age at onset);
TGCT	cis	rs950169	0.920	rs12915390	chr15:84792069	T/C	cg12863693	chr15:85201151	NMB	0.38	4.45	0.37	1.9e-5	Schizophrenia;
TGCT	cis	rs4506170	0.887	rs56736364	chr8:128323724	C/T	cg07795030	chr8:128802207	NA	-0.21	-4.61	-0.38	9.75e-6	Prostate cancer;
TGCT	cis	rs4635969	1.000	rs4635969	chr5:1308552	C/T	cg00059399	chr5:2008272	NA	-0.33	-4.6	-0.38	1.01e-5	Testicular germ cell tumor;Testicular germ cell cancer;
TGCT	cis	rs7267979	0.934	rs4815423	chr20:25387521	A/G	cg14121845	chr20:25566513	NINL	-0.5	-5.4	-0.44	3.23e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs78366141	0.536	rs76432068	chr4:89624219	G/A	cg01026744	chr4:89619053	NAP1L5;HERC3	1.28	5.48	0.44	2.32e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
TGCT	cis	rs9467773	1.000	rs28558133	chr6:26531433	G/C	cg15659132	chr6:26577336	NA	0.86	12.21	0.74	5.3e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs9467773	0.620	rs9295701	chr6:26627508	T/C	cg15659132	chr6:26577336	NA	0.86	11.04	0.7	3.71e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs896854	0.654	rs13281625	chr8:95972738	T/C	cg13393036	chr8:95962371	TP53INP1	-0.63	-8.52	-0.61	4.51e-14	Type 2 diabetes;
TGCT	cis	rs7104764	1.000	rs6598065	chr11:243211	A/G	cg18336825	chr11:236787	PSMD13;SIRT3	1.07	11.19	0.71	1.61e-20	Menarche (age at onset);
TGCT	cis	rs6940638	0.715	rs9348751	chr6:27067190	T/A	cg26531700	chr6:26746687	NA	-0.56	-4.88	-0.4	3.25e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7267979	0.844	rs2474780	chr20:25285835	G/A	cg03522245	chr20:25566470	NINL	0.55	5.55	0.45	1.68e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs595982	0.517	rs4801779	chr19:49406651	T/G	cg17863274	chr19:49399704	TULP2	-0.28	-4.49	-0.37	1.64e-5	Red cell distribution width;
TGCT	cis	rs9393777	0.778	rs35526527	chr6:27042287	C/A	cg16898833	chr6:26189333	HIST1H4D	1.0	5.74	0.46	6.81e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs35306767	0.807	rs11253513	chr10:968450	C/T	cg20503657	chr10:835505	NA	0.65	9.44	0.65	2.93e-16	Eosinophil percentage of granulocytes;
TGCT	cis	rs9300255	0.739	rs1533703	chr12:123742093	T/G	cg00376283	chr12:123451042	ABCB9	0.72	5.54	0.45	1.76e-7	Neutrophil percentage of white cells;
TGCT	cis	rs7085104	0.700	rs10786712	chr10:104596396	A/G	cg04362960	chr10:104952993	NT5C2	-0.55	-4.92	-0.4	2.7e-6	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg12311346	chr5:56204834	C5orf35	-0.65	-6.48	-0.5	1.99e-9	Initial pursuit acceleration;
TGCT	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg02725872	chr8:58115012	NA	-0.41	-5.38	-0.44	3.5e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs910316	0.737	rs175080	chr14:75513828	G/A	cg11812906	chr14:75593930	NEK9	-0.63	-5.74	-0.46	6.72e-8	Height;
TGCT	cis	rs12497850	0.864	rs12493001	chr3:49181885	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.38	-4.81	-0.4	4.25e-6	Parkinson's disease;
TGCT	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	8.22	0.59	2.28e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs3806843	0.576	rs246009	chr5:140338069	A/G	cg07102913	chr5:140593443	PCDHB13	0.47	4.7	0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	7.86	0.58	1.55e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs3935685	0.967	rs62009151	chr15:77999264	C/A	cg25212270	chr15:78015279	NA	0.3	6.03	0.48	1.71e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7178424	0.516	rs8023668	chr15:62334705	T/A	cg00456672	chr15:62358751	C2CD4A	-0.29	-4.5	-0.37	1.57e-5	Height;
TGCT	trans	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg27523141	chr10:43048294	ZNF37B	0.7	8.15	0.59	3.36e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg25703541	chr22:24373054	LOC391322	0.82	6.94	0.53	1.89e-10	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs7826238	0.594	rs2948285	chr8:8130538	A/T	cg15556689	chr8:8085844	FLJ10661	0.83	7.78	0.57	2.46e-12	Systolic blood pressure;
TGCT	trans	rs2727020	0.729	rs34647977	chr11:49195543	G/A	cg03929089	chr4:120376271	NA	-0.69	-7.78	-0.57	2.48e-12	Coronary artery disease;
TGCT	cis	rs2455799	0.613	rs6772879	chr3:15741793	G/A	cg16303742	chr3:15540471	COLQ	-0.25	-4.57	-0.38	1.15e-5	Mean platelet volume;
TGCT	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg18876405	chr7:65276391	NA	-0.33	-4.99	-0.41	1.98e-6	Aortic root size;
TGCT	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg20607798	chr8:58055168	NA	0.5	4.66	0.39	8.04e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7511006	0.893	rs2038049	chr22:50654888	G/C	cg16473166	chr22:50639996	SELO	0.63	6.1	0.48	1.24e-8	Obesity-related traits;
TGCT	cis	rs9914544	0.545	rs8066636	chr17:18761109	G/A	cg26378065	chr17:18585709	ZNF286B	0.52	4.5	0.37	1.56e-5	Educational attainment (years of education);
TGCT	cis	rs11577318	0.812	rs3795683	chr1:26632831	C/A	cg12733254	chr1:26682999	NA	-0.2	-4.49	-0.37	1.62e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs2120019	1.000	rs7167285	chr15:75368769	A/G	cg09165964	chr15:75287851	SCAMP5	-1.09	-8.86	-0.62	7.08e-15	Blood trace element (Zn levels);
TGCT	trans	rs561341	0.843	rs4795666	chr17:30241409	A/G	cg20587970	chr11:113659929	NA	-0.86	-11.09	-0.71	2.74e-20	Hip circumference adjusted for BMI;
TGCT	cis	rs2204008	0.547	rs12318267	chr12:38250905	T/G	cg26384229	chr12:38710491	ALG10B	-0.54	-4.7	-0.39	6.68e-6	Bladder cancer;
TGCT	cis	rs933688	0.877	rs1477349	chr5:90707773	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.02	8.35	0.6	1.17e-13	Smoking behavior;
TGCT	cis	rs3125734	0.633	rs4979772	chr10:63967600	C/T	cg09941381	chr10:64027924	RTKN2	0.37	5.61	0.45	1.24e-7	Rheumatoid arthritis;
TGCT	cis	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg20637647	chr7:64974828	NA	1.0	5.59	0.45	1.4e-7	Diabetic kidney disease;
TGCT	cis	rs9916302	0.706	rs7503377	chr17:37708841	A/G	cg07936489	chr17:37558343	FBXL20	-0.74	-5.76	-0.46	6.13e-8	Glomerular filtration rate (creatinine);
TGCT	trans	rs114540395	0.858	rs79010936	chr10:103300909	T/C	cg10198749	chr1:39920707	MACF1	0.55	7.05	0.53	1.11e-10	Schizophrenia;
TGCT	cis	rs7666738	0.830	rs17550630	chr4:99008332	G/T	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs67311347	0.866	rs2371183	chr3:40334247	C/T	cg13683864	chr3:40499215	RPL14	0.87	8.55	0.61	3.92e-14	Renal cell carcinoma;
TGCT	cis	rs2742234	0.868	rs2505512	chr10:43633596	G/A	cg02780029	chr10:43622663	RET	-0.26	-5.03	-0.41	1.67e-6	Hirschsprung disease;
TGCT	cis	rs1062177	0.855	rs6896664	chr5:151265274	A/G	cg12924095	chr5:151150029	G3BP1	0.32	4.48	0.37	1.67e-5	Preschool internalizing problems;
TGCT	cis	rs4845570	1.000	rs3790514	chr1:151744168	T/C	cg07092448	chr1:151763213	TDRKH	-1.14	-8.5	-0.61	5.08e-14	Coronary artery disease;
TGCT	cis	rs778371	0.630	rs13007579	chr2:233725364	G/A	cg08000102	chr2:233561755	GIGYF2	-0.68	-7.7	-0.57	3.81e-12	Schizophrenia;
TGCT	cis	rs2469997	1.000	rs2469998	chr8:120354022	G/A	cg00681363	chr8:120844660	TAF2	0.65	4.52	0.38	1.45e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg25767906	chr1:53392781	SCP2	-0.62	-7.65	-0.57	4.78e-12	Monocyte count;
TGCT	trans	rs225245	0.541	rs321612	chr17:33881631	T/C	cg19694781	chr19:47549865	TMEM160	-0.36	-6.69	-0.51	6.94e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs12477438	0.501	rs2632284	chr2:99775865	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.9	9.33	0.64	5.15e-16	Chronic sinus infection;
TGCT	cis	rs17345786	1.000	rs17345528	chr3:101294830	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.55	-4.69	-0.39	7.21e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg00684032	chr4:1343700	KIAA1530	0.23	4.93	0.4	2.56e-6	Obesity-related traits;
TGCT	cis	rs7267979	0.789	rs62213729	chr20:25363426	C/T	cg03522245	chr20:25566470	NINL	-0.52	-5.23	-0.43	6.85e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs9388451	0.869	rs7764016	chr6:126070789	T/G	cg05039488	chr6:79577232	IRAK1BP1	-0.75	-8.53	-0.61	4.37e-14	Brugada syndrome;
TGCT	cis	rs7959452	0.562	rs10878975	chr12:69782044	G/C	cg11871910	chr12:69753446	YEATS4	0.82	8.95	0.63	4.38e-15	Blood protein levels;
TGCT	cis	rs2243480	1.000	rs709607	chr7:65449541	C/G	cg07424592	chr7:64974309	NA	-1.41	-8.37	-0.6	1.03e-13	Diabetic kidney disease;
TGCT	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.18	0.49	8.42e-9	Bipolar disorder;
TGCT	cis	rs13188771	0.614	rs66592082	chr5:100914515	T/C	cg18665594	chr5:101119420	NA	0.44	4.57	0.38	1.17e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs6684514	1.000	rs11264462	chr1:156241728	G/A	cg16558208	chr1:156270281	VHLL	0.48	9.46	0.65	2.55e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs2404602	0.716	rs67418609	chr15:76627089	C/A	cg26408565	chr15:76604113	ETFA	-0.45	-6.09	-0.48	1.28e-8	Blood metabolite levels;
TGCT	cis	rs7714584	1.000	rs17800886	chr5:150309539	C/G	cg22134413	chr5:150180641	NA	1.04	7.44	0.56	1.48e-11	Crohn's disease;
TGCT	cis	rs344364	0.511	rs2982452	chr16:1949511	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.45	-5.08	-0.42	1.35e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs938554	0.513	rs11943372	chr4:9999346	T/A	cg11266682	chr4:10021025	SLC2A9	0.5	4.88	0.4	3.23e-6	Blood metabolite levels;
TGCT	cis	rs2832191	0.692	rs8134627	chr21:30349069	C/T	cg08807101	chr21:30365312	RNF160	-0.65	-6.01	-0.47	1.96e-8	Dental caries;
TGCT	cis	rs17376456	0.877	rs9314093	chr5:93333347	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.62	4.44	0.37	1.98e-5	Diabetic retinopathy;
TGCT	cis	rs12541335	0.692	rs2290274	chr8:22214374	C/T	cg07298985	chr8:22133076	PIWIL2	0.34	5.22	0.42	7.46e-7	Hypertriglyceridemia;
TGCT	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg16049864	chr8:95962084	TP53INP1	-0.75	-10.73	-0.69	2.15e-19	Type 2 diabetes;
TGCT	cis	rs9814567	0.727	rs7430034	chr3:134342127	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-6.29	-0.49	4.95e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs17152411	0.895	rs7914206	chr10:126585397	G/A	cg07906193	chr10:126599966	NA	0.41	5.06	0.41	1.46e-6	Height;
TGCT	cis	rs3733585	0.648	rs13125029	chr4:9982029	A/G	cg00071950	chr4:10020882	SLC2A9	0.57	6.62	0.51	9.8e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs57994353	0.826	rs34619169	chr9:139327277	G/A	cg13741927	chr9:139327495	INPP5E	-0.27	-6.3	-0.49	4.64e-9	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs6450176	0.953	rs3776724	chr5:53292270	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.49	-4.59	-0.38	1.08e-5	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs8084125	0.832	rs56301307	chr18:74942711	A/G	cg05528293	chr18:74961138	GALR1	0.5	4.75	0.39	5.61e-6	Obesity-related traits;
TGCT	cis	rs3784262	1.000	rs4646629	chr15:58255215	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.49	-7.7	-0.57	3.78e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs986417	1.000	rs1313243	chr14:60876398	C/T	cg27398547	chr14:60952738	C14orf39	-1.42	-8.68	-0.61	1.89e-14	Gut microbiota (bacterial taxa);
TGCT	cis	rs11650494	0.908	rs111834333	chr17:47411814	C/T	cg08112188	chr17:47440006	ZNF652	1.04	5.34	0.43	4.3e-7	Prostate cancer;
TGCT	cis	rs12643440	0.538	rs12641321	chr4:17141393	G/C	cg22650099	chr4:17144496	NA	-0.45	-4.65	-0.39	8.28e-6	Metabolite levels (Pyroglutamine);
TGCT	cis	rs6671200	0.510	rs35556400	chr1:95916885	G/A	cg20701556	chr1:95698924	RWDD3	0.72	5.36	0.43	3.95e-7	Stearic acid (18:0) levels;
TGCT	cis	rs394563	0.591	rs237026	chr6:149720681	G/A	cg03678062	chr6:149772716	ZC3H12D	-0.38	-4.82	-0.4	4.12e-6	Dupuytren's disease;
TGCT	cis	rs6088580	0.634	rs13041646	chr20:33082881	T/A	cg08999081	chr20:33150536	PIGU	0.28	5.56	0.45	1.6e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg12311346	chr5:56204834	C5orf35	0.57	6.13	0.48	1.07e-8	Initial pursuit acceleration;
TGCT	cis	rs9479482	1.000	rs9479482	chr6:150358012	T/C	cg03788504	chr6:150331562	NA	-0.24	-4.58	-0.38	1.12e-5	Alopecia areata;
TGCT	cis	rs67311347	1.000	rs17078916	chr3:40445438	C/T	cg13409248	chr3:40428643	ENTPD3	0.57	4.53	0.38	1.37e-5	Renal cell carcinoma;
TGCT	cis	rs1005224	0.520	rs6574249	chr14:76087152	A/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.61	-4.63	-0.38	9.26e-6	Large artery stroke;
TGCT	cis	rs7959452	0.640	rs4274230	chr12:69700772	T/G	cg20891283	chr12:69753455	YEATS4	0.66	6.57	0.51	1.26e-9	Blood protein levels;
TGCT	cis	rs2153904	0.793	rs1891091	chr1:205661418	A/G	cg23034840	chr1:205782522	SLC41A1	0.82	5.08	0.41	1.36e-6	Prostate-specific antigen levels;
TGCT	cis	rs586688	0.543	rs1267115	chr1:201676312	A/G	cg07139329	chr1:201708558	NAV1	-0.44	-4.76	-0.39	5.2e-6	Obesity-related traits;
TGCT	cis	rs10089	1.000	rs1962291	chr5:127445373	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.84	-8.19	-0.59	2.7e-13	Ileal carcinoids;
TGCT	cis	rs7412746	0.658	rs4537557	chr1:150734436	A/G	cg04414720	chr1:150670196	GOLPH3L	0.37	4.63	0.38	9.12e-6	Melanoma;
TGCT	cis	rs13108904	0.846	rs9631805	chr4:1283035	T/C	cg13395646	chr4:1353034	KIAA1530	0.38	4.58	0.38	1.1e-5	Obesity-related traits;
TGCT	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.61	-5.07	-0.41	1.42e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.09	-15.68	-0.82	3.31e-31	Prudent dietary pattern;
TGCT	cis	rs7584330	0.554	rs6739456	chr2:238385092	G/C	cg14458575	chr2:238380390	NA	0.48	4.47	0.37	1.73e-5	Prostate cancer;
TGCT	cis	rs11650494	0.908	rs57390430	chr17:47374886	G/A	cg08112188	chr17:47440006	ZNF652	1.04	5.35	0.43	4.09e-7	Prostate cancer;
TGCT	cis	rs36051895	0.658	rs10815145	chr9:5013309	G/A	cg02405213	chr9:5042618	JAK2	-0.78	-10.83	-0.7	1.2e-19	Pediatric autoimmune diseases;
TGCT	cis	rs2242116	1.000	rs2242116	chr3:46941116	A/G	cg02527881	chr3:46936655	PTH1R	-0.31	-5.84	-0.46	4.36e-8	Birth weight;
TGCT	cis	rs7208859	0.673	rs216424	chr17:28943064	T/G	cg19761014	chr17:28927070	LRRC37B2	0.55	4.7	0.39	6.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs2412819	0.597	rs78282429	chr15:43922003	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	4.68	0.39	7.31e-6	Lung cancer;
TGCT	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg06618935	chr21:46677482	NA	-0.39	-5.08	-0.42	1.34e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs1008375	0.897	rs1006723	chr4:17618524	G/A	cg10189774	chr4:17578691	LAP3	0.62	5.24	0.43	6.72e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2535633	0.602	rs2581816	chr3:53014657	C/T	cg11645453	chr3:52864694	ITIH4	0.27	5.08	0.41	1.37e-6	Body mass index;
TGCT	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.84	7.5	0.56	1.08e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs35306767	0.761	rs34480046	chr10:1027440	A/G	cg26597838	chr10:835615	NA	0.58	6.55	0.51	1.35e-9	Eosinophil percentage of granulocytes;
TGCT	cis	rs1670533	1.000	rs2290410	chr4:1052078	A/T	cg27284194	chr4:1044797	NA	0.63	5.03	0.41	1.68e-6	Recombination rate (females);
TGCT	cis	rs78487399	0.908	rs77613902	chr2:43843991	T/G	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.65	4.58	0.38	1.12e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs10791097	0.694	rs2155752	chr11:130755998	C/T	cg05962950	chr11:130786565	SNX19	0.9	11.06	0.7	3.32e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs7296418	0.580	rs78455769	chr12:123856443	G/A	cg00376283	chr12:123451042	ABCB9	0.64	5.49	0.44	2.18e-7	Platelet count;
TGCT	cis	rs3924048	0.559	rs6541037	chr1:12626155	A/G	cg00291366	chr1:12616550	NA	0.31	4.88	0.4	3.17e-6	Optic cup area;
TGCT	cis	rs2404602	1.000	rs2056544	chr15:76826003	G/A	cg26408565	chr15:76604113	ETFA	-0.41	-5.18	-0.42	8.71e-7	Blood metabolite levels;
TGCT	cis	rs854765	0.647	rs7406744	chr17:17981938	C/G	cg09796270	chr17:17721594	SREBF1	0.23	4.71	0.39	6.6e-6	Total body bone mineral density;
TGCT	cis	rs17221829	0.764	rs7945447	chr11:89386070	A/G	cg02982614	chr11:89391479	FOLH1B	-0.25	-4.46	-0.37	1.8e-5	Anxiety in major depressive disorder;
TGCT	cis	rs10207060	0.778	rs6543581	chr2:240702308	C/T	cg20800816	chr2:241070422	MYEOV2	-0.18	-4.46	-0.37	1.81e-5	Obesity-related traits;
TGCT	cis	rs1505368	0.567	rs2054617	chr2:213355890	T/C	cg16329650	chr2:213403929	ERBB4	0.83	9.72	0.66	6.19e-17	Symmetrical dimethylarginine levels;
TGCT	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg06634786	chr22:41940651	POLR3H	-0.9	-8.98	-0.63	3.59e-15	Vitiligo;
TGCT	cis	rs727505	0.954	rs67870530	chr7:124591878	A/G	cg23710748	chr7:124431027	NA	-0.26	-4.52	-0.38	1.41e-5	Lewy body disease;
TGCT	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg08736216	chr1:53307985	ZYG11A	-0.25	-4.82	-0.4	4.11e-6	Monocyte count;
TGCT	cis	rs9399137	0.507	rs12664898	chr6:135288663	T/C	cg24558204	chr6:135376177	HBS1L	0.47	4.78	0.39	4.95e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
TGCT	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg03709012	chr19:19516395	GATAD2A	0.75	6.51	0.5	1.71e-9	Tonsillectomy;
TGCT	cis	rs6964587	0.869	rs6964050	chr7:91482418	C/T	cg17063962	chr7:91808500	NA	-0.85	-9.05	-0.63	2.54e-15	Breast cancer;
TGCT	trans	rs2727020	0.612	rs603672	chr11:49234566	T/A	cg15704280	chr7:45808275	SEPT13	0.7	7.64	0.57	5e-12	Coronary artery disease;
TGCT	cis	rs67340775	0.541	rs200975	chr6:27855625	G/T	cg26587870	chr6:27730563	NA	-0.34	-4.62	-0.38	9.28e-6	Lung cancer in ever smokers;
TGCT	cis	rs11190604	0.943	rs3750632	chr10:102279295	G/C	cg23241863	chr10:102295624	HIF1AN	0.68	5.17	0.42	9.14e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs589448	0.538	rs622656	chr12:69753595	C/T	cg14784868	chr12:69753453	YEATS4	0.66	5.92	0.47	2.97e-8	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs9611565	0.512	rs4512	chr22:42206084	G/C	cg06481639	chr22:41940642	POLR3H	-0.69	-6.02	-0.48	1.83e-8	Vitiligo;
TGCT	cis	rs1048238	0.525	rs848214	chr1:16265422	A/G	cg22431228	chr1:16359049	CLCNKA	0.23	4.48	0.37	1.67e-5	Systolic blood pressure;
TGCT	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg13395646	chr4:1353034	KIAA1530	-0.4	-5.0	-0.41	1.93e-6	Obesity-related traits;
TGCT	cis	rs11874712	0.933	rs8097521	chr18:43666952	C/A	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	5.23	0.42	7.11e-7	Migraine - clinic-based;
TGCT	cis	rs9581857	0.579	rs75326986	chr13:27997758	C/T	cg22138327	chr13:27999177	GTF3A	0.79	5.51	0.44	1.99e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs6088580	0.634	rs6088478	chr20:32971719	T/C	cg06115741	chr20:33292138	TP53INP2	-0.55	-4.81	-0.4	4.28e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs17384381	0.859	rs12130591	chr1:85904985	C/T	cg16011679	chr1:85725395	C1orf52	0.83	6.77	0.52	4.61e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg25036284	chr2:26402008	FAM59B	-0.54	-4.7	-0.39	6.93e-6	Gut microbiome composition (summer);
TGCT	trans	rs208515	0.556	rs12214562	chr6:66681011	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.93	10.3	0.68	2.34e-18	Exhaled nitric oxide levels;
TGCT	cis	rs7043114	0.525	rs4744134	chr9:95246833	A/G	cg13798575	chr9:95087839	CENPP;NOL8	0.53	5.14	0.42	1.03e-6	Height;
TGCT	cis	rs5769765	0.778	rs8137331	chr22:50313358	G/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.4	5.67	0.45	9.72e-8	Schizophrenia;
TGCT	cis	rs7264396	0.561	rs6142474	chr20:34574914	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.28	4.83	0.4	3.95e-6	Total cholesterol levels;
TGCT	cis	rs9858542	0.953	rs6446272	chr3:49463287	G/A	cg03060546	chr3:49711283	APEH	-0.61	-5.37	-0.43	3.78e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs7666738	0.830	rs62318503	chr4:98935479	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7829975	0.600	rs1719381	chr8:8602344	T/C	cg15556689	chr8:8085844	FLJ10661	-0.65	-5.67	-0.45	9.37e-8	Mood instability;
TGCT	cis	rs7666738	0.800	rs11941885	chr4:99072921	A/C	cg17366294	chr4:99064904	C4orf37	0.76	7.61	0.56	6.06e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2204008	0.811	rs12368410	chr12:38305705	C/T	cg13010199	chr12:38710504	ALG10B	0.61	4.81	0.4	4.2e-6	Bladder cancer;
TGCT	cis	rs8062405	1.000	rs1987472	chr16:28825777	C/T	cg09754948	chr16:28834200	ATXN2L	0.62	4.69	0.39	6.95e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg10047753	chr17:41438598	NA	0.9	8.32	0.6	1.37e-13	Menopause (age at onset);
TGCT	cis	rs17534004	1.000	rs71436418	chr13:31455888	G/A	cg13251181	chr13:31481184	C13orf33	0.35	4.71	0.39	6.65e-6	3-hydroxypropylmercapturic acid levels in smokers;
TGCT	cis	rs17221829	0.733	rs11600976	chr11:89360842	A/T	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.65	-0.39	8.43e-6	Anxiety in major depressive disorder;
TGCT	cis	rs61990749	0.597	rs176946	chr14:78178439	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	0.69	5.02	0.41	1.72e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs12497850	1.000	rs4858798	chr3:48727112	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.43	-5.94	-0.47	2.74e-8	Parkinson's disease;
TGCT	cis	rs9291683	0.585	rs12648479	chr4:10104571	G/A	cg00071950	chr4:10020882	SLC2A9	-0.49	-5.27	-0.43	5.88e-7	Bone mineral density;
TGCT	cis	rs910316	0.967	rs8013444	chr14:75661981	A/G	cg11812906	chr14:75593930	NEK9	-0.71	-6.8	-0.52	3.94e-10	Height;
TGCT	trans	rs7618501	1.000	rs60205400	chr3:49800272	C/T	cg21659725	chr3:3221576	CRBN	0.98	15.33	0.81	2.1000000000000002e-30	Intelligence (multi-trait analysis);
TGCT	cis	rs11690935	0.595	rs788171	chr2:172921832	A/G	cg13550731	chr2:172543902	DYNC1I2	0.69	6.36	0.5	3.49e-9	Schizophrenia;
TGCT	cis	rs826838	0.559	rs1843891	chr12:38617018	T/C	cg26384229	chr12:38710491	ALG10B	0.55	5.0	0.41	1.93e-6	Heart rate;
TGCT	cis	rs877282	0.891	rs34383514	chr10:800181	T/C	cg17470449	chr10:769945	NA	0.31	4.64	0.38	8.88e-6	Uric acid levels;
TGCT	cis	rs12681288	0.782	rs2600498	chr8:1026520	A/G	cg04851639	chr8:1020857	NA	-0.32	-5.75	-0.46	6.63e-8	Schizophrenia;
TGCT	cis	rs11105298	0.786	rs10858897	chr12:89922032	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.67	-4.91	-0.4	2.78e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs2836633	0.895	rs2836598	chr21:40024758	C/G	cg12884169	chr21:40033163	ERG	0.42	4.44	0.37	1.95e-5	Coronary artery disease;
TGCT	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg22968622	chr17:43663579	NA	1.29	11.46	0.72	3.61e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs9341808	0.718	rs9352801	chr6:80817468	G/T	cg08355045	chr6:80787529	NA	0.32	5.83	0.46	4.48e-8	Sitting height ratio;
TGCT	cis	rs797680	0.786	rs1593512	chr1:93858374	G/A	cg17826107	chr1:92977322	EVI5	-0.23	-5.47	-0.44	2.34e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs2562456	0.876	rs11668606	chr19:21737420	T/G	cg01304269	chr19:21688519	ZNF429	0.57	4.74	0.39	5.86e-6	Pain;
TGCT	trans	rs2624839	0.704	rs12637671	chr3:50224562	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.77	-6.89	-0.53	2.47e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs7044106	0.762	rs1470307	chr9:123433039	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.61	6.43	0.5	2.55e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs12220238	0.722	rs7921187	chr10:76377501	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.59	4.54	0.38	1.29e-5	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs7980687	0.628	rs2851443	chr12:123694250	C/T	cg00376283	chr12:123451042	ABCB9	0.79	6.8	0.52	3.88e-10	Height;Educational attainment;Head circumference (infant);
TGCT	cis	rs2742417	0.935	rs2742393	chr3:45757417	T/A	cg04837898	chr3:45731254	SACM1L	-0.55	-5.72	-0.46	7.45e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg13395646	chr4:1353034	KIAA1530	0.4	4.95	0.41	2.34e-6	Obesity-related traits;
TGCT	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg10047753	chr17:41438598	NA	0.96	9.64	0.65	9.37e-17	Menopause (age at onset);
TGCT	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	6.0	0.47	1.98e-8	Alzheimer's disease;
TGCT	cis	rs6088590	0.930	rs6120723	chr20:33364655	C/T	cg24642439	chr20:33292090	TP53INP2	0.7	6.22	0.49	7.12e-9	Coronary artery disease;
TGCT	cis	rs478304	0.934	rs570954	chr11:65498261	A/G	cg27068330	chr11:65405492	SIPA1	0.75	7.39	0.55	1.93e-11	Acne (severe);
TGCT	cis	rs7000551	0.556	rs12674913	chr8:22263617	G/C	cg12081754	chr8:22256438	SLC39A14	0.37	5.38	0.44	3.57e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs10206020	0.842	rs7609325	chr2:1574718	G/A	cg12573674	chr2:1569213	NA	-0.46	-5.2	-0.42	7.88e-7	IgG glycosylation;
TGCT	cis	rs933688	1.000	rs6867219	chr5:90718008	T/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.98	8.36	0.6	1.11e-13	Smoking behavior;
TGCT	cis	rs813218	0.523	rs497868	chr3:99450187	G/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.42	5.04	0.41	1.59e-6	Orofacial clefts;
TGCT	cis	rs28595532	0.920	rs55671478	chr4:119753811	A/G	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg05457628	chr5:178986728	RUFY1	-0.53	-6.0	-0.47	1.99e-8	Lung cancer;
TGCT	cis	rs4689388	0.929	rs1046320	chr4:6304344	C/T	cg14416269	chr4:6271139	WFS1	0.36	4.73	0.39	6.02e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs478607	1.000	rs60159753	chr11:64479112	G/T	cg19395706	chr11:64412079	NRXN2	0.52	5.43	0.44	2.79e-7	Urate levels;
TGCT	cis	rs6725041	0.547	rs61696052	chr2:213201295	G/C	cg20637307	chr2:213403960	ERBB4	-0.53	-4.49	-0.37	1.63e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs208520	0.690	rs1318604	chr6:66825278	A/C	cg07460842	chr6:66804631	NA	-0.95	-9.88	-0.66	2.43e-17	Exhaled nitric oxide output;
TGCT	trans	rs7248779	0.512	rs3848635	chr19:2410332	T/C	cg25835954	chr13:50160062	RCBTB1	0.75	6.89	0.53	2.52e-10	Cortisol levels (saliva);
TGCT	cis	rs7570971	1.000	rs6730157	chr2:135907088	C/T	cg07169764	chr2:136633963	MCM6	-0.55	-4.9	-0.4	2.94e-6	Blood metabolite levels;Body mass index;Cholesterol, total;
TGCT	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	8.39	0.6	9.03e-14	Platelet count;
TGCT	cis	rs899997	1.000	rs4887078	chr15:79011073	C/T	cg00061860	chr15:78953028	NA	-0.25	-4.67	-0.39	7.76e-6	Coronary artery disease or large artery stroke;
TGCT	cis	rs66573146	0.831	rs6832482	chr4:7023433	A/T	cg00086871	chr4:6988644	TBC1D14	0.93	4.53	0.38	1.35e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs11096990	0.634	rs2062229	chr4:39286766	A/C	cg20847110	chr4:39482781	LOC401127	0.16	4.46	0.37	1.81e-5	Cognitive function;
TGCT	cis	rs9303401	0.659	rs12600349	chr17:57054245	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.66	-6.09	-0.48	1.32e-8	Cognitive test performance;
TGCT	cis	rs9303401	0.614	rs56284918	chr17:57178838	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.58	5.74	0.46	6.76e-8	Cognitive test performance;
TGCT	cis	rs7914558	0.966	rs1971589	chr10:104744406	A/G	cg04362960	chr10:104952993	NT5C2	0.6	5.42	0.44	2.99e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs3770081	1.000	rs2278086	chr2:86281905	G/A	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.17	-4.56	-0.38	1.21e-5	Facial emotion recognition (sad faces);
TGCT	cis	rs9430161	0.644	rs34365965	chr1:11034442	G/A	cg27631724	chr1:11040367	C1orf127	0.52	5.95	0.47	2.57e-8	Ewing sarcoma;
TGCT	cis	rs175714	0.845	rs175702	chr14:75971133	G/T	cg01624173	chr14:75981868	NA	-0.38	-7.07	-0.54	9.92e-11	Lymphocyte counts;
TGCT	cis	rs6570726	0.599	rs426371	chr6:145886469	A/G	cg13319975	chr6:146136371	FBXO30	0.69	6.27	0.49	5.34e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.75	5.41	0.44	3.09e-7	Platelet count;
TGCT	cis	rs17253792	0.822	rs77315200	chr14:56072643	C/A	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs6912958	0.559	rs242280	chr6:88048714	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.72	7.53	0.56	9.05e-12	Monocyte percentage of white cells;
TGCT	cis	rs11030122	0.702	rs17081	chr11:3987830	A/G	cg18678763	chr11:4115507	RRM1	0.49	6.13	0.48	1.08e-8	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs13242816	0.881	rs13235183	chr7:116140149	G/T	cg02799643	chr7:116139180	CAV2	-0.42	-5.45	-0.44	2.55e-7	P wave duration;
TGCT	cis	rs899997	1.000	rs7182694	chr15:79045030	C/T	cg00061860	chr15:78953028	NA	-0.27	-4.67	-0.39	7.62e-6	Coronary artery disease or large artery stroke;
TGCT	cis	rs4727027	0.870	rs62507485	chr7:148764182	C/T	cg23583168	chr7:148888333	NA	-0.69	-8.72	-0.62	1.5e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs6088580	0.634	rs6058052	chr20:33047084	A/G	cg08999081	chr20:33150536	PIGU	0.28	5.6	0.45	1.3e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs7772486	0.754	rs702324	chr6:146008793	A/G	cg23711669	chr6:146136114	FBXO30	-0.93	-10.4	-0.68	1.33e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs559928	0.606	rs7941773	chr11:63952759	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	4.57	0.38	1.18e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
TGCT	cis	rs875971	0.666	rs13242072	chr7:65765988	A/G	cg00343986	chr7:65444356	GUSB	-0.21	-4.57	-0.38	1.15e-5	Aortic root size;
TGCT	cis	rs7666738	0.830	rs28416660	chr4:98899525	C/G	cg18180107	chr4:99064573	C4orf37	0.53	4.81	0.4	4.23e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7572733	0.534	rs700674	chr2:198693703	C/T	cg00792783	chr2:198669748	PLCL1	0.56	5.08	0.42	1.35e-6	Dermatomyositis;
TGCT	trans	rs3107575	0.572	rs73169366	chr3:165320307	C/T	cg03961853	chr1:230384989	GALNT2	0.64	6.9	0.53	2.41e-10	Morning vs. evening chronotype;
TGCT	cis	rs6964587	0.967	rs34344935	chr7:91835436	G/A	cg22709100	chr7:91322751	NA	0.29	4.49	0.37	1.59e-5	Breast cancer;
TGCT	cis	rs2153535	0.580	rs2327051	chr6:8441150	A/G	cg23788917	chr6:8435910	SLC35B3	-0.54	-4.61	-0.38	9.84e-6	Motion sickness;
TGCT	cis	rs6964587	1.000	rs10225885	chr7:91671007	A/G	cg17063962	chr7:91808500	NA	0.88	9.65	0.66	8.73e-17	Breast cancer;
TGCT	cis	rs9296661	0.522	rs9474070	chr6:51647813	C/T	cg20180370	chr6:50691003	TFAP2D	-0.48	-4.68	-0.39	7.35e-6	Weight loss (gastric bypass surgery);
TGCT	cis	rs7666738	0.925	rs34423396	chr4:99049031	T/A	cg17366294	chr4:99064904	C4orf37	0.71	6.53	0.51	1.55e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1018836	0.851	rs7007129	chr8:91629790	T/G	cg16814680	chr8:91681699	NA	-0.82	-8.6	-0.61	2.86e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs137603	0.644	rs137620	chr22:39709776	T/C	cg01093212	chr22:39715156	SNORD43;RPL3	-0.5	-4.75	-0.39	5.59e-6	Primary biliary cholangitis;
TGCT	cis	rs11586313	0.507	rs6658967	chr1:152870372	C/G	cg07796016	chr1:152779584	LCE1C	-0.44	-5.0	-0.41	1.91e-6	Vitamin D levels;
TGCT	cis	rs2692947	0.550	rs4613327	chr2:96583823	G/A	cg23100626	chr2:96804247	ASTL	0.38	4.61	0.38	9.79e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs6424115	0.708	rs11803575	chr1:24182348	A/T	cg15997130	chr1:24165203	NA	-0.69	-6.99	-0.53	1.51e-10	Immature fraction of reticulocytes;
TGCT	cis	rs6933660	0.745	rs9397405	chr6:151736084	G/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.65	6.4	0.5	2.88e-9	Menarche (age at onset);
TGCT	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg25036284	chr2:26402008	FAM59B	-0.57	-4.99	-0.41	2e-6	Gut microbiome composition (summer);
TGCT	cis	rs4074961	0.692	rs11264075	chr1:38083941	C/G	cg11397548	chr1:38022522	DNALI1	0.45	5.01	0.41	1.84e-6	Axial length;
TGCT	trans	rs4650994	0.524	rs2209170	chr1:178607388	C/A	cg05059571	chr16:84539110	KIAA1609	0.52	10.36	0.68	1.73e-18	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs17221829	0.702	rs12360859	chr11:89359887	A/G	cg02982614	chr11:89391479	FOLH1B	-0.28	-4.87	-0.4	3.35e-6	Anxiety in major depressive disorder;
TGCT	cis	rs13217239	0.646	rs7768407	chr6:27016795	G/A	cg15659132	chr6:26577336	NA	0.59	6.0	0.47	1.97e-8	Schizophrenia;
TGCT	cis	rs12142240	0.698	rs1475389	chr1:46816429	T/C	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs10504229	0.906	rs2270607	chr8:58194699	A/G	cg24829409	chr8:58192753	C8orf71	-0.5	-4.64	-0.38	8.89e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6933660	0.745	rs9397405	chr6:151736084	G/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.5	4.66	0.39	7.87e-6	Menarche (age at onset);
TGCT	cis	rs2806561	0.734	rs7548692	chr1:23354877	T/A	cg12483005	chr1:23474871	LUZP1	0.38	4.76	0.39	5.3e-6	Height;
TGCT	cis	rs797680	0.964	rs797668	chr1:93694789	C/G	cg17826107	chr1:92977322	EVI5	0.24	5.3	0.43	5.16e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg27286337	chr10:134555280	INPP5A	0.41	4.98	0.41	2.05e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs17122693	0.748	rs72679596	chr14:51103595	C/T	cg04730355	chr14:51134070	SAV1	1.34	11.9	0.73	2.97e-22	Cognitive performance;
TGCT	cis	rs922182	0.633	rs4776698	chr15:64267534	C/A	cg02919090	chr15:64263738	DAPK2	-0.29	-5.08	-0.42	1.33e-6	Blood protein levels;
TGCT	cis	rs9400467	0.537	rs17606672	chr6:111546833	G/C	cg15721981	chr6:111408429	SLC16A10	0.73	4.79	0.4	4.71e-6	Blood metabolite levels;Amino acid levels;
TGCT	cis	rs2688608	0.592	rs12253482	chr10:75496130	G/A	cg04320760	chr10:75533139	FUT11	-0.39	-5.94	-0.47	2.64e-8	Inflammatory bowel disease;
TGCT	cis	rs2204008	0.805	rs4882575	chr12:37940573	G/A	cg26384229	chr12:38710491	ALG10B	-0.73	-6.33	-0.49	4.02e-9	Bladder cancer;
TGCT	cis	rs10493389	0.673	rs4310419	chr1:66286459	A/G	cg08716655	chr1:66257732	PDE4B	-0.42	-4.59	-0.38	1.06e-5	Echocardiographic traits;
TGCT	cis	rs977747	0.843	rs4134058	chr1:47670911	T/C	cg03885399	chr1:47691550	TAL1	-0.43	-5.42	-0.44	2.97e-7	Body mass index;
TGCT	cis	rs1577917	0.958	rs6454488	chr6:86450842	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.17	-0.42	9.02e-7	Response to antipsychotic treatment;
TGCT	cis	rs7917772	0.582	rs10786683	chr10:104320476	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	5.36	0.43	3.84e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7772486	0.686	rs2328708	chr6:146095739	G/A	cg23711669	chr6:146136114	FBXO30	-0.84	-9.35	-0.64	4.84e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1371867	0.875	rs1612773	chr8:101337818	G/C	cg06002616	chr8:101225028	SPAG1	-0.54	-6.21	-0.49	7.43e-9	Atrioventricular conduction;
TGCT	cis	rs6940638	0.956	rs12190473	chr6:27024687	C/T	cg26531700	chr6:26746687	NA	-0.6	-4.58	-0.38	1.1e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs6988636	1.000	rs57322232	chr8:124193532	A/G	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs4824093	0.545	rs58876234	chr22:50258868	G/A	cg14114931	chr22:50943910	LMF2	0.37	4.58	0.38	1.11e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg18188782	chr20:61659543	NA	-0.43	-5.11	-0.42	1.17e-6	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7666738	0.830	rs7678911	chr4:99057430	C/T	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.44e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7178572	0.568	rs11072653	chr15:77693934	C/T	cg22256960	chr15:77711686	NA	-0.88	-9.16	-0.64	1.32e-15	Type 2 diabetes;
TGCT	cis	rs6840360	0.571	rs7685697	chr4:152558849	A/G	cg17479576	chr4:152424074	FAM160A1	-0.73	-7.94	-0.58	1.03e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs9549367	0.664	rs9549689	chr13:113848387	G/A	cg09473364	chr13:112927190	NA	-0.3	-4.6	-0.38	1.01e-5	Platelet distribution width;
TGCT	cis	rs11696501	0.789	rs1487319	chr20:44295943	A/G	cg11783356	chr20:44313418	WFDC10B	-0.32	-4.63	-0.38	9.25e-6	Brain structure;
TGCT	cis	rs853679	0.546	rs200989	chr6:27816442	A/G	cg08798685	chr6:27730294	NA	-0.34	-4.77	-0.39	5.13e-6	Depression;
TGCT	cis	rs3617	0.559	rs11915546	chr3:52866845	A/C	cg05573699	chr3:52720067	GNL3;PBRM1	0.49	4.77	0.39	5.04e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs16986825	0.664	rs5997409	chr22:29222096	T/C	cg02153584	chr22:29168773	CCDC117	0.78	5.37	0.43	3.81e-7	Pancreatic cancer;
TGCT	cis	rs8180040	0.966	rs11130129	chr3:47489885	G/C	cg27129171	chr3:47204927	SETD2	-0.66	-7.84	-0.58	1.75e-12	Colorectal cancer;
TGCT	cis	rs2070488	1.000	rs2070488	chr3:38442490	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.9	-9.65	-0.66	8.79e-17	Electrocardiographic conduction measures;
TGCT	cis	rs10883723	0.962	rs1056741	chr10:104236640	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	7.52	0.56	9.74e-12	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs8031584	0.958	rs34909055	chr15:31284170	C/T	cg19680485	chr15:31195859	MTMR15	-0.51	-4.54	-0.38	1.31e-5	Huntington's disease progression;
TGCT	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg04267008	chr7:1944627	MAD1L1	-0.35	-4.53	-0.38	1.35e-5	Bipolar disorder and schizophrenia;
TGCT	cis	rs8177179	0.967	rs9820225	chr3:133449189	A/G	cg16262614	chr3:133464971	TF	0.35	4.72	0.39	6.28e-6	Iron status biomarkers (transferrin levels);
TGCT	cis	rs6121246	0.529	rs6120862	chr20:30199459	T/C	cg13852791	chr20:30311386	BCL2L1	0.7	4.58	0.38	1.1e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs13191362	1.000	rs13210756	chr6:163009030	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.57	4.94	0.41	2.45e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg22764044	chr5:178986830	RUFY1	0.44	4.76	0.39	5.36e-6	Lung cancer;
TGCT	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg27454412	chr7:1067447	C7orf50	0.6	4.7	0.39	6.76e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs4601821	1.000	rs6589375	chr11:113255111	C/A	cg14159747	chr11:113255604	NA	0.38	4.43	0.37	2.01e-5	Alcoholic chronic pancreatitis;
TGCT	cis	rs6669384	0.774	rs7551724	chr1:208030856	C/T	cg22525895	chr1:207977042	MIR29B2	-0.38	-5.31	-0.43	4.83e-7	Immune response to measles vaccine (measles-specific neutralising antibody titre);
TGCT	cis	rs344364	0.511	rs1742467	chr16:1950187	G/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.45	-5.08	-0.42	1.35e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs727563	0.635	rs5751149	chr22:42139501	A/G	cg06481639	chr22:41940642	POLR3H	0.7	6.1	0.48	1.24e-8	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs739401	0.572	rs7111857	chr11:3068106	A/G	cg25174290	chr11:3078921	CARS	-0.49	-4.87	-0.4	3.34e-6	Longevity;
TGCT	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg20607798	chr8:58055168	NA	0.5	4.66	0.39	8.04e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4517514	0.509	rs4385851	chr11:89870750	C/T	cg14505434	chr11:89522851	NA	0.45	4.45	0.37	1.87e-5	Trans fatty acid levels;
TGCT	cis	rs12135062	0.755	rs1553287	chr1:3101277	G/A	cg25382214	chr1:3105252	PRDM16	-0.27	-4.58	-0.38	1.12e-5	Migraine;
TGCT	cis	rs12510870	0.599	rs7682201	chr4:74450830	C/T	cg05868023	chr4:75230803	EREG	-0.54	-4.76	-0.39	5.33e-6	Iris color (b* coordinate);
TGCT	cis	rs112591243	0.685	rs78443123	chr21:47953331	G/T	cg10657630	chr21:48055338	PRMT2	1.06	5.21	0.42	7.69e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs2230307	0.536	rs640030	chr1:100574992	C/T	cg24955406	chr1:100503596	HIAT1	-0.75	-5.11	-0.42	1.19e-6	Carotid intima media thickness;
TGCT	cis	rs4711350	0.862	rs487835	chr6:33710933	G/A	cg00334056	chr6:33755658	LEMD2	0.31	4.81	0.4	4.31e-6	Schizophrenia;
TGCT	cis	rs7528419	1.000	rs12740374	chr1:109817590	G/T	cg00908766	chr1:109817496	CELSR2	-0.52	-5.38	-0.43	3.62e-7	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
TGCT	cis	rs765787	0.530	rs1706837	chr15:45519036	A/G	cg24006582	chr15:45444508	DUOX1	-0.26	-5.75	-0.46	6.51e-8	Uric acid levels;
TGCT	cis	rs3733585	0.699	rs6449177	chr4:9968050	T/C	cg11266682	chr4:10021025	SLC2A9	-0.57	-7.38	-0.55	2.03e-11	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs1775715	0.677	rs2808105	chr10:32110907	C/T	cg14930904	chr10:32216787	ARHGAP12	0.52	5.07	0.41	1.38e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs7727544	0.735	rs274566	chr5:131715011	A/G	cg24060327	chr5:131705240	SLC22A5	0.59	6.62	0.51	9.73e-10	Blood metabolite levels;
TGCT	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg05368731	chr17:41323189	NBR1	1.04	11.64	0.72	1.25e-21	Menopause (age at onset);
TGCT	cis	rs7909074	1.000	rs7909074	chr10:45395839	G/A	cg05187965	chr10:45406764	TMEM72	-0.24	-5.23	-0.42	7.12e-7	Mean corpuscular volume;
TGCT	trans	rs1496653	0.602	rs35902312	chr3:23387013	T/C	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs3796352	1.000	rs2564926	chr3:53094730	G/A	cg27565382	chr3:53032988	SFMBT1	-0.42	-4.48	-0.37	1.68e-5	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs7428	0.545	rs2366404	chr2:85551779	G/A	cg24342717	chr2:85555507	TGOLN2	-0.48	-8.09	-0.59	4.64e-13	Ear protrusion;
TGCT	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg22968622	chr17:43663579	NA	-1.19	-10.3	-0.68	2.4e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	trans	rs4332037	0.539	rs55988458	chr7:2059761	G/A	cg25206134	chr2:45395956	NA	0.96	7.31	0.55	2.89e-11	Bipolar disorder;
TGCT	cis	rs9811920	0.732	rs7613864	chr3:99602470	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.46	-5.2	-0.42	7.88e-7	Axial length;
TGCT	cis	rs9831754	0.865	rs9842838	chr3:78387904	A/C	cg06138941	chr3:78371609	NA	-0.49	-5.4	-0.44	3.25e-7	Calcium levels;
TGCT	cis	rs35883536	0.588	rs955338	chr1:101108794	G/C	cg06223162	chr1:101003688	GPR88	0.34	5.67	0.45	9.44e-8	Monocyte count;
TGCT	cis	rs2012796	1.000	rs10450939	chr14:81825202	A/T	cg02996355	chr14:81879375	NA	0.47	4.61	0.38	9.68e-6	Night sleep phenotypes;
TGCT	cis	rs4851266	1.000	rs4851267	chr2:100824104	G/A	cg22139774	chr2:100720529	AFF3	-0.36	-5.4	-0.44	3.26e-7	Educational attainment;
TGCT	cis	rs73001065	0.901	rs73002956	chr19:19578743	A/G	cg03709012	chr19:19516395	GATAD2A	1.04	5.02	0.41	1.74e-6	LDL cholesterol;
TGCT	cis	rs10744422	1.000	rs3852536	chr12:123333824	C/T	cg25930673	chr12:123319894	HIP1R	-0.86	-5.02	-0.41	1.72e-6	Schizophrenia;
TGCT	cis	rs6903823	0.508	rs1150726	chr6:28243042	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.44	-4.58	-0.38	1.13e-5	Pulmonary function;
TGCT	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg11890956	chr21:40555474	PSMG1	1.05	11.11	0.71	2.44e-20	Cognitive function;
TGCT	cis	rs1371867	0.875	rs1788173	chr8:101330939	A/G	cg06636551	chr8:101224915	SPAG1	0.42	5.63	0.45	1.15e-7	Atrioventricular conduction;
TGCT	cis	rs7119	0.717	rs12902912	chr15:77809170	A/G	cg27398640	chr15:77910606	LINGO1	-0.25	-4.59	-0.38	1.06e-5	Type 2 diabetes;
TGCT	cis	rs12681287	0.640	rs12541793	chr8:87462558	G/A	cg27223183	chr8:87520930	FAM82B	-0.89	-6.43	-0.5	2.54e-9	Caudate activity during reward;
TGCT	cis	rs13088645	0.652	rs13074557	chr3:134153526	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.64	6.02	0.48	1.83e-8	Coronary artery disease;
TGCT	cis	rs3849570	0.961	rs11710970	chr3:81693489	T/C	cg07356753	chr3:81810745	GBE1	-0.84	-7.74	-0.57	3.01e-12	Waist circumference;Body mass index;
TGCT	cis	rs1568889	0.838	rs6484359	chr11:28262328	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.91	9.93	0.67	1.82e-17	Bipolar disorder;
TGCT	cis	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg25427524	chr10:38739819	LOC399744	-0.39	-8.04	-0.59	5.95e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7829975	0.539	rs4841012	chr8:8551710	C/A	cg06636001	chr8:8085503	FLJ10661	-0.61	-5.31	-0.43	4.81e-7	Mood instability;
TGCT	cis	rs9611519	0.894	rs4821998	chr22:41468273	C/G	cg13695892	chr22:41940480	POLR3H	-0.54	-4.78	-0.39	4.93e-6	Neuroticism;
TGCT	cis	rs7666738	0.830	rs28867388	chr4:98962794	A/T	cg17366294	chr4:99064904	C4orf37	0.74	7.56	0.56	7.89e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.12	15.17	0.81	4.81e-30	Height;
TGCT	cis	rs6988636	1.000	rs28624331	chr8:124190768	G/A	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs7432375	0.610	rs56695781	chr3:136510601	G/T	cg15507776	chr3:136538369	TMEM22	0.55	5.64	0.45	1.1e-7	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9486715	0.838	rs7452350	chr6:96883326	C/A	cg06623918	chr6:96969491	KIAA0776	1.11	16.62	0.83	2.35e-33	Headache;
TGCT	cis	rs67311347	0.955	rs11717036	chr3:40379578	G/T	cg17264618	chr3:40429014	ENTPD3	-0.3	-4.48	-0.37	1.65e-5	Renal cell carcinoma;
TGCT	cis	rs1670533	0.932	rs9992925	chr4:1050909	A/T	cg27284194	chr4:1044797	NA	0.68	5.87	0.47	3.76e-8	Recombination rate (females);
TGCT	cis	rs11971779	0.648	rs66463279	chr7:139118661	A/G	cg07862535	chr7:139043722	LUC7L2	0.66	5.07	0.41	1.42e-6	Diisocyanate-induced asthma;
TGCT	cis	rs4820792	0.725	rs1884816	chr22:29106733	T/C	cg03733026	chr22:29445468	ZNRF3	0.25	4.85	0.4	3.67e-6	Breast size;
TGCT	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg04546413	chr19:29218101	NA	0.84	6.76	0.52	4.71e-10	Methadone dose in opioid dependence;
TGCT	cis	rs877282	0.898	rs11253348	chr10:765852	C/T	cg17470449	chr10:769945	NA	0.37	5.59	0.45	1.37e-7	Uric acid levels;
TGCT	cis	rs7822232	0.908	rs6558297	chr8:145143934	C/T	cg06239191	chr8:145163136	KIAA1875	-0.88	-6.45	-0.5	2.26e-9	Blood metabolite levels;
TGCT	cis	rs35306767	0.623	rs12354710	chr10:1114020	C/T	cg26597838	chr10:835615	NA	0.49	5.12	0.42	1.15e-6	Eosinophil percentage of granulocytes;
TGCT	cis	rs4460629	0.712	rs11264313	chr1:155076505	A/G	cg23973274	chr1:155060172	NA	-0.26	-4.66	-0.39	8.1e-6	Serum magnesium levels;
TGCT	cis	rs509477	1.000	rs505763	chr18:32558879	G/A	cg23791764	chr18:32556832	MAPRE2	0.59	4.83	0.4	3.9e-6	Cerebrospinal fluid AB1-42 levels;
TGCT	cis	rs4808199	0.948	rs7250368	chr19:19452763	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.64	4.75	0.39	5.58e-6	Nonalcoholic fatty liver disease;
TGCT	cis	rs12681288	0.550	rs4272405	chr8:959014	C/G	cg04851639	chr8:1020857	NA	-0.27	-4.44	-0.37	1.94e-5	Schizophrenia;
TGCT	cis	rs1401999	1.000	rs1402003	chr3:183642879	C/T	cg01324343	chr3:183735012	ABCC5	0.82	10.35	0.68	1.81e-18	Anterior chamber depth;
TGCT	cis	rs11577318	0.626	rs11806568	chr1:26686837	C/A	cg15090202	chr1:26687087	NA	0.59	4.58	0.38	1.1e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs826838	0.967	rs11169142	chr12:39085773	A/T	cg26384229	chr12:38710491	ALG10B	-0.85	-8.09	-0.59	4.68e-13	Heart rate;
TGCT	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs36051895	0.695	rs10815147	chr9:5016145	C/T	cg02405213	chr9:5042618	JAK2	-0.72	-9.2	-0.64	1.06e-15	Pediatric autoimmune diseases;
TGCT	cis	rs2241685	0.850	rs7591787	chr2:1942841	C/T	cg21862353	chr2:1801628	MYT1L	-0.52	-4.77	-0.39	5.05e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs9393692	1.000	rs2393593	chr6:26285683	T/C	cg00631329	chr6:26305371	NA	-0.46	-6.82	-0.52	3.51e-10	Educational attainment;
TGCT	cis	rs1215050	0.791	rs2658477	chr4:98850993	G/A	cg17366294	chr4:99064904	C4orf37	-0.57	-6.12	-0.48	1.13e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg24675658	chr1:53192096	ZYG11B	-0.71	-7.99	-0.58	8e-13	Monocyte count;
TGCT	cis	rs9303542	0.571	rs2202895	chr17:46584657	T/C	cg25032089	chr17:46643351	HOXB3	-0.52	-5.82	-0.46	4.61e-8	Ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs4372836	0.897	rs6707130	chr2:28973276	A/G	cg09522027	chr2:28974177	PPP1CB	-0.6	-5.18	-0.42	8.74e-7	Body mass index;
TGCT	cis	rs12210905	1.000	rs3531	chr6:27095313	T/C	cg08851530	chr6:28072375	NA	1.21	5.58	0.45	1.43e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg25036284	chr2:26402008	FAM59B	-0.65	-5.19	-0.42	8.36e-7	Gut microbiome composition (summer);
TGCT	cis	rs6433857	0.536	rs1971135	chr2:181351508	G/A	cg23363182	chr2:181467187	NA	-0.32	-4.85	-0.4	3.59e-6	Body mass index;
TGCT	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.64	0.51	8.85e-10	Bipolar disorder;
TGCT	cis	rs9818758	0.545	rs9853352	chr3:49813258	C/T	cg08550065	chr3:50336684	HYAL3;NAT6	-1.08	-5.44	-0.44	2.72e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg18252515	chr7:66147081	NA	-1.2	-7.16	-0.54	6.16e-11	Diabetic kidney disease;
TGCT	cis	rs2153535	0.580	rs1335636	chr6:8465047	T/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs61990749	0.544	rs1477259	chr14:78256138	C/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.64	4.5	0.37	1.54e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs6988636	1.000	rs28624331	chr8:124190768	G/A	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	trans	rs877282	0.898	rs12357016	chr10:765675	C/T	cg22713356	chr15:30763199	NA	1.2	9.39	0.64	3.76e-16	Uric acid levels;
TGCT	cis	rs2233152	0.656	rs10405633	chr19:41291703	G/A	cg11601297	chr19:41224147	ITPKC;ADCK4	0.53	4.86	0.4	3.46e-6	Kawasaki disease;
TGCT	cis	rs13394619	0.562	rs34532804	chr2:11746003	G/A	cg07314298	chr2:11723111	GREB1	0.29	4.93	0.4	2.59e-6	Endometriosis;
TGCT	cis	rs11673344	0.563	rs4805199	chr19:37606429	A/G	cg08039142	chr19:36980659	ZNF566	0.51	4.76	0.39	5.26e-6	Obesity-related traits;
TGCT	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg20607798	chr8:58055168	NA	0.45	4.68	0.39	7.47e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6460942	0.915	rs2216051	chr7:12304054	G/A	cg20607287	chr7:12443886	VWDE	-0.47	-4.51	-0.38	1.5e-5	Coronary artery disease;
TGCT	cis	rs6540559	0.673	rs6540564	chr1:210019910	T/C	cg22029157	chr1:209979665	IRF6	0.71	5.09	0.42	1.3e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs6901004	0.716	rs35312643	chr6:111574536	C/A	cg15721981	chr6:111408429	SLC16A10	0.53	4.61	0.38	9.85e-6	Blood metabolite levels;
TGCT	cis	rs7020830	0.898	rs7038219	chr9:37182892	C/A	cg14235030	chr9:37121269	ZCCHC7	0.39	4.47	0.37	1.75e-5	Schizophrenia;
TGCT	cis	rs2153535	0.580	rs9406170	chr6:8514153	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.55e-8	Motion sickness;
TGCT	cis	rs926938	0.765	rs2268701	chr1:115233046	C/T	cg12756093	chr1:115239321	AMPD1	-0.42	-6.03	-0.48	1.72e-8	Autism;
TGCT	cis	rs992157	1.000	rs11554825	chr2:219125809	C/T	cg00012203	chr2:219082015	ARPC2	0.77	8.2	0.59	2.56e-13	Colorectal cancer;
TGCT	cis	rs7698623	0.850	rs7678318	chr4:88768888	C/T	cg27387453	chr4:88533842	DSPP	-0.61	-4.6	-0.38	1.03e-5	Cardiovascular disease risk factors;
TGCT	cis	rs858239	0.600	rs7784929	chr7:23124277	T/C	cg05602783	chr7:23145260	KLHL7	-0.6	-4.99	-0.41	2.02e-6	Cerebrospinal fluid biomarker levels;
TGCT	trans	rs11722228	0.549	rs55848383	chr4:10081117	C/A	cg26043149	chr18:55253948	FECH	1.15	11.34	0.71	6.89e-21	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs7666738	0.830	rs11932887	chr4:99072965	C/G	cg05340658	chr4:99064831	C4orf37	0.55	6.22	0.49	7.09e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.69	4.91	0.4	2.75e-6	Platelet count;
TGCT	cis	rs9611565	0.512	rs45500192	chr22:42177899	A/G	cg03806693	chr22:41940476	POLR3H	-1.01	-10.3	-0.68	2.33e-18	Vitiligo;
TGCT	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg26531700	chr6:26746687	NA	-0.54	-4.87	-0.4	3.36e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs346785	0.692	rs2279052	chr17:74287204	C/G	cg09812376	chr17:74270190	QRICH2	-0.37	-5.63	-0.45	1.17e-7	White matter hyperintensities in ischemic stroke;
TGCT	cis	rs7674212	0.570	rs6841136	chr4:104103509	A/C	cg16532752	chr4:104119610	CENPE	-0.55	-5.09	-0.42	1.32e-6	Type 2 diabetes;
TGCT	cis	rs4494114	0.967	rs9438978	chr1:39355058	G/T	cg25970120	chr1:39325951	RRAGC	-0.6	-6.31	-0.49	4.61e-9	Blood protein levels;
TGCT	cis	rs7666738	0.830	rs7679299	chr4:99057620	C/A	cg17366294	chr4:99064904	C4orf37	0.73	7.45	0.56	1.4e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1215050	0.626	rs1010190	chr4:98585818	A/G	cg05340658	chr4:99064831	C4orf37	-0.42	-5.02	-0.41	1.75e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1997103	1.000	rs4948012	chr7:55412578	A/C	cg17469321	chr7:55412551	NA	0.65	6.75	0.52	5.08e-10	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs9796	0.870	rs2412574	chr15:41259707	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.44	-5.84	-0.46	4.27e-8	Menopause (age at onset);
TGCT	cis	rs861020	0.527	rs614662	chr1:209962419	C/T	cg21951975	chr1:209979733	IRF6	-0.45	-4.83	-0.4	3.98e-6	Orofacial clefts;
TGCT	cis	rs61884328	0.777	rs17790420	chr11:47169555	G/A	cg13308137	chr11:47528955	CUGBP1	0.38	4.48	0.37	1.65e-5	Total body bone mineral density (age over 60);
TGCT	cis	rs60843830	1.000	rs3791224	chr2:221981	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.77	7.47	0.56	1.22e-11	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs1878931	0.501	rs9921169	chr16:3421261	A/T	cg22508957	chr16:3507546	NAT15	-0.38	-4.98	-0.41	2.1e-6	Body mass index (adult);
TGCT	cis	rs1008375	1.000	rs6854733	chr4:17640526	C/T	cg10189774	chr4:17578691	LAP3	0.57	5.15	0.42	9.95e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs11190604	1.000	rs57025426	chr10:102205868	A/G	cg16342193	chr10:102329863	NA	-0.4	-5.31	-0.43	4.85e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7100689	0.826	rs7098414	chr10:82214586	A/C	cg01528321	chr10:82214614	TSPAN14	1.12	12.32	0.74	2.82e-23	Post bronchodilator FEV1;
TGCT	cis	rs9868809	0.505	rs9882549	chr3:48749358	C/T	cg00383909	chr3:49044727	WDR6	0.98	5.67	0.45	9.63e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs17102423	0.731	rs7145112	chr14:65534084	A/C	cg11161011	chr14:65562177	MAX	-0.47	-6.24	-0.49	6.38e-9	Obesity-related traits;
TGCT	cis	rs2718798	1	rs2718798	chr3:133492088	A/C	cg16414030	chr3:133502952	NA	-0.45	-6.27	-0.49	5.39e-9	Ankle injury;
TGCT	cis	rs2354432	1.000	rs6680778	chr1:146747153	T/C	cg25205988	chr1:146714368	CHD1L	1.4	12.0	0.73	1.76e-22	Mitochondrial DNA levels;
TGCT	cis	rs727563	0.608	rs2076200	chr22:41985956	G/T	cg06481639	chr22:41940642	POLR3H	-0.75	-6.47	-0.5	2.1e-9	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs55665837	0.524	rs61884009	chr11:14426462	C/T	cg19336497	chr11:14380999	RRAS2	-0.31	-4.85	-0.4	3.57e-6	Vitamin D levels;
TGCT	cis	rs72627509	0.857	rs2227901	chr4:57798189	A/G	cg26694713	chr4:57773883	REST	-0.72	-6.33	-0.49	4.07e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs2404618	0.561	rs4242536	chr8:1477225	A/G	cg13402656	chr8:1511478	DLGAP2	-0.34	-5.68	-0.45	9.12e-8	Lung cancer;
TGCT	cis	rs7523050	0.643	rs35924015	chr1:109404626	T/C	cg08274380	chr1:109419600	GPSM2	1.15	5.85	0.47	4.11e-8	Fat distribution (HIV);
TGCT	cis	rs3820068	0.524	rs34094056	chr1:15824154	G/T	cg05660106	chr1:15850417	CASP9	1.16	14.82	0.8	3.11e-29	Systolic blood pressure;
TGCT	cis	rs3733585	0.673	rs4311316	chr4:9955971	A/C	cg00071950	chr4:10020882	SLC2A9	0.56	6.73	0.52	5.62e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9291683	0.620	rs4383618	chr4:10125151	T/C	cg11266682	chr4:10021025	SLC2A9	-0.45	-5.32	-0.43	4.65e-7	Bone mineral density;
TGCT	cis	rs4803468	0.967	rs284661	chr19:41932120	C/T	cg09537434	chr19:41945824	ATP5SL	-0.92	-10.44	-0.68	1.1e-18	Height;
TGCT	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg24250549	chr1:154909240	PMVK	0.62	6.28	0.49	5.29e-9	Prostate cancer;
TGCT	cis	rs2303745	0.544	rs12710308	chr19:17395879	T/A	cg02221750	chr19:17393354	ANKLE1	-0.48	-6.28	-0.49	5.17e-9	Systemic lupus erythematosus;
TGCT	trans	rs656319	0.591	rs17734690	chr8:9713196	T/C	cg15556689	chr8:8085844	FLJ10661	-0.71	-6.99	-0.53	1.51e-10	Myopia (pathological);
TGCT	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg08859206	chr1:53392774	SCP2	-0.43	-6.56	-0.51	1.31e-9	Monocyte count;
TGCT	cis	rs4285028	0.699	rs2689285	chr3:121586486	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.78	6.72	0.52	5.95e-10	Multiple sclerosis;
TGCT	cis	rs11190604	1.000	rs2489046	chr10:102346282	A/C	cg23241863	chr10:102295624	HIF1AN	0.71	5.43	0.44	2.82e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7605378	0.528	rs281767	chr2:200823281	C/A	cg19045956	chr2:200819837	C2orf60;C2orf47	0.54	5.82	0.46	4.81e-8	Osteoporosis;
TGCT	cis	rs9303401	0.573	rs34097494	chr17:57171917	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.64	5.87	0.47	3.79e-8	Cognitive test performance;
TGCT	cis	rs17681684	0.565	rs62066034	chr17:9758829	A/G	cg15743799	chr17:9805578	RCVRN	-0.27	-5.9	-0.47	3.19e-8	GIP levels in response to oral glucose tolerance test (fasting);
TGCT	cis	rs7726839	0.540	rs72703080	chr5:595238	A/G	cg16624210	chr5:671434	TPPP	0.45	4.92	0.4	2.71e-6	Obesity-related traits;
TGCT	cis	rs10875746	0.669	rs11168516	chr12:48702065	C/T	cg20731937	chr12:48336164	NA	0.61	4.63	0.38	9.26e-6	Longevity (90 years and older);
TGCT	cis	rs11711311	0.747	rs11928590	chr3:113343478	T/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.7	-5.88	-0.47	3.5e-8	IgG glycosylation;
TGCT	cis	rs35771425	0.619	rs7529900	chr1:211442661	C/T	cg25617285	chr1:211431773	RCOR3	-0.48	-5.48	-0.44	2.27e-7	Educational attainment (years of education);
TGCT	cis	rs6835098	1.000	rs6826412	chr4:174109622	C/T	cg08422745	chr4:174089978	GALNT7	-0.9	-10.08	-0.67	7.91e-18	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs7172809	0.573	rs8035526	chr15:77683247	T/G	cg22256960	chr15:77711686	NA	-0.5	-4.74	-0.39	5.82e-6	Glucose homeostasis traits;
TGCT	cis	rs875971	0.666	rs13242072	chr7:65765988	A/G	cg18876405	chr7:65276391	NA	-0.4	-6.11	-0.48	1.2e-8	Aortic root size;
TGCT	cis	rs68170813	0.559	rs78079372	chr7:106934548	T/G	cg02696742	chr7:106810147	HBP1	-0.69	-5.81	-0.46	4.85e-8	Coronary artery disease;
TGCT	trans	rs986417	0.818	rs761557	chr14:61077484	C/T	cg06338710	chr1:92946187	GFI1	0.73	7.02	0.53	1.3100000000000001e-10	Gut microbiota (bacterial taxa);
TGCT	cis	rs17221829	0.610	rs1844195	chr11:89389332	G/A	cg02982614	chr11:89391479	FOLH1B	-0.25	-4.46	-0.37	1.8e-5	Anxiety in major depressive disorder;
TGCT	trans	rs28595532	0.516	rs28552458	chr4:119288363	T/C	cg26518628	chr1:97050305	NA	-0.6	-7.07	-0.54	1.01e-10	Cannabis dependence symptom count;
TGCT	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg08645402	chr16:4508243	NA	0.2	5.01	0.41	1.86e-6	Schizophrenia;
TGCT	cis	rs35306767	0.579	rs7091502	chr10:1154979	C/T	cg20503657	chr10:835505	NA	0.54	5.8	0.46	5.25e-8	Eosinophil percentage of granulocytes;
TGCT	cis	rs9814567	0.752	rs6779294	chr3:134329821	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-6.41	-0.5	2.8e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg04317338	chr11:64019027	PLCB3	0.74	6.01	0.48	1.89e-8	Mean platelet volume;
TGCT	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg17971929	chr21:40555470	PSMG1	0.52	4.74	0.39	5.74e-6	Menarche (age at onset);
TGCT	cis	rs7523050	0.643	rs7551313	chr1:109399881	G/A	cg08274380	chr1:109419600	GPSM2	1.3	6.39	0.5	2.99e-9	Fat distribution (HIV);
TGCT	cis	rs514406	0.505	rs425520	chr1:53179805	C/G	cg16325326	chr1:53192061	ZYG11B	0.85	12.13	0.74	8.13e-23	Monocyte count;
TGCT	cis	rs10193935	0.582	rs13394853	chr2:42630900	T/C	cg27598129	chr2:42591480	NA	-0.37	-5.23	-0.42	7.1e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4888262	0.508	rs12598701	chr16:74539904	G/A	cg01733217	chr16:74700730	RFWD3	0.68	6.88	0.53	2.6200000000000003e-10	Testicular germ cell tumor;
TGCT	cis	rs752092	0.802	rs2412005	chr15:101767591	T/A	cg19997662	chr15:101784653	CHSY1	-0.27	-5.0	-0.41	1.9e-6	Corneal structure;
TGCT	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg20203395	chr5:56204925	C5orf35	-0.59	-5.12	-0.42	1.12e-6	Initial pursuit acceleration;
TGCT	cis	rs35883536	1.000	rs2297712	chr1:101092813	C/T	cg06223162	chr1:101003688	GPR88	0.29	4.56	0.38	1.19e-5	Monocyte count;
TGCT	cis	rs8031584	0.678	rs4779497	chr15:31151365	T/A	cg14829155	chr15:31115871	NA	-0.36	-4.72	-0.39	6.14e-6	Huntington's disease progression;
TGCT	cis	rs763014	0.898	rs916416	chr16:632198	T/A	cg00908189	chr16:619842	PIGQ	0.87	10.5	0.69	7.53e-19	Height;
TGCT	cis	rs7655441	1.000	rs7686031	chr4:80908268	T/C	cg02241357	chr4:80885279	ANTXR2	-0.24	-4.59	-0.38	1.07e-5	Neutrophil percentage of white cells;
TGCT	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg10047753	chr17:41438598	NA	0.7	6.5	0.5	1.75e-9	Menopause (age at onset);
TGCT	cis	rs2197308	0.765	rs117216293	chr12:37882982	T/C	cg26384229	chr12:38710491	ALG10B	-0.7	-6.15	-0.48	9.71e-9	Morning vs. evening chronotype;
TGCT	cis	rs9325144	0.505	rs7138977	chr12:38642109	G/A	cg13010199	chr12:38710504	ALG10B	0.62	5.54	0.45	1.71e-7	Morning vs. evening chronotype;
TGCT	cis	rs2730245	0.527	rs62476462	chr7:158686619	A/G	cg11984989	chr7:158649758	WDR60	1.01	7.85	0.58	1.65e-12	Height;
TGCT	cis	rs11148252	0.574	rs61958118	chr13:53170226	C/T	cg00495681	chr13:53174319	NA	0.7	7.09	0.54	9.05e-11	Lewy body disease;
TGCT	cis	rs10876993	0.928	rs1689594	chr12:58057156	T/C	cg15848620	chr12:58087721	OS9	-0.72	-5.86	-0.47	3.95e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs2956278	0.717	rs2956285	chr12:84690194	C/T	cg25678815	chr12:85673915	ALX1	-0.53	-4.76	-0.39	5.4e-6	Depressive symptoms;Depressive symptoms (multi-trait analysis);
TGCT	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg12667521	chr19:29218732	NA	0.54	5.72	0.46	7.65e-8	Methadone dose in opioid dependence;
TGCT	cis	rs6988636	0.818	rs1713733	chr8:124199458	A/G	cg23067535	chr8:124195133	FAM83A	0.32	4.82	0.4	4.11e-6	Urinary uromodulin levels;
TGCT	cis	rs6460942	1.000	rs112996286	chr7:12315741	G/C	cg06484146	chr7:12443880	VWDE	-0.55	-4.56	-0.38	1.22e-5	Coronary artery disease;
TGCT	cis	rs12540874	0.728	rs3807563	chr7:50566390	C/T	cg18232548	chr7:50535776	DDC	-0.37	-6.48	-0.5	1.97e-9	Systemic sclerosis;
TGCT	cis	rs796364	0.760	rs2202922	chr2:200882610	C/T	cg17644776	chr2:200775616	C2orf69	0.33	5.0	0.41	1.91e-6	Schizophrenia;
TGCT	cis	rs2153535	0.580	rs1577466	chr6:8444192	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.58	0.45	1.42e-7	Motion sickness;
TGCT	cis	rs4455778	0.538	rs7795732	chr7:49127493	T/C	cg26309511	chr7:48887640	NA	0.5	6.51	0.5	1.66e-9	Lung cancer in never smokers;
TGCT	cis	rs57920188	0.584	rs12068729	chr1:4091650	A/G	cg20703997	chr1:4087676	NA	0.49	6.2	0.49	7.57e-9	Interleukin-17 levels;
TGCT	cis	rs7586879	0.575	rs6712981	chr2:25126230	A/G	cg15423357	chr2:25149977	NA	0.5	4.89	0.4	3.06e-6	Body mass index;
TGCT	cis	rs9549367	0.756	rs9549702	chr13:113881944	T/G	cg18105134	chr13:113819100	PROZ	-0.34	-5.67	-0.45	9.36e-8	Platelet distribution width;
TGCT	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-5.09	-0.42	1.27e-6	Bipolar disorder;
TGCT	cis	rs12477438	1.000	rs12477438	chr2:99841085	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-6.39	-0.5	2.97e-9	Chronic sinus infection;
TGCT	cis	rs4688759	0.719	rs73079018	chr3:49875327	T/C	cg08550065	chr3:50336684	HYAL3;NAT6	1.04	5.12	0.42	1.13e-6	Blood protein levels;
TGCT	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg08280861	chr8:58055591	NA	0.39	4.76	0.39	5.35e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9348739	1	rs9348739	chr6:26923099	G/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.57	-4.71	-0.39	6.52e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9467711	0.606	rs9358930	chr6:26357011	C/T	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg18252515	chr7:66147081	NA	-1.2	-7.83	-0.58	1.89e-12	Diabetic kidney disease;
TGCT	cis	rs10479542	0.896	rs10078712	chr5:178978805	C/T	cg00080972	chr5:178986291	RUFY1	-0.44	-5.03	-0.41	1.65e-6	Lung cancer;
TGCT	trans	rs8073060	0.586	rs17638867	chr17:34052513	C/T	cg19694781	chr19:47549865	TMEM160	0.6	13.38	0.77	8.17e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs2229238	0.911	rs59239860	chr1:154492107	G/T	cg13067139	chr1:155221277	FAM189B	0.2	4.49	0.37	1.63e-5	Coronary heart disease;
TGCT	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg13732083	chr21:47605072	C21orf56	0.34	4.59	0.38	1.05e-5	Testicular germ cell tumor;
TGCT	cis	rs116095464	0.558	rs9312956	chr5:201812	T/C	cg12570787	chr5:219185	SDHA;CCDC127	0.73	4.63	0.38	9.01e-6	Breast cancer;
TGCT	cis	rs7226408	0.790	rs58099133	chr18:34332333	C/T	cg06757138	chr18:34340585	FHOD3	0.29	4.95	0.41	2.4e-6	Obesity-related traits;
TGCT	cis	rs377070	1.000	rs377070	chr4:123629002	G/C	cg10495464	chr4:123653540	BBS12;LOC729338	0.47	5.1	0.42	1.23e-6	Mosquito bite size;
TGCT	cis	rs10927875	0.562	rs10803401	chr1:16147377	G/A	cg21385522	chr1:16154831	NA	-1.0	-17.61	-0.85	1.57e-35	Dilated cardiomyopathy;
TGCT	cis	rs317689	0.690	rs317656	chr12:69681101	T/A	cg14784868	chr12:69753453	YEATS4	0.55	4.76	0.39	5.2e-6	Response to diuretic therapy;
TGCT	cis	rs8051431	0.876	rs8053841	chr16:72012072	C/T	cg06353428	chr16:71660113	MARVELD3	0.59	5.02	0.41	1.73e-6	LDL cholesterol levels;
TGCT	cis	rs909002	0.759	rs10914454	chr1:32078940	G/A	cg11573219	chr1:32083031	HCRTR1	-0.44	-5.58	-0.45	1.46e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9467773	0.572	rs3846846	chr6:26445039	A/G	cg15659132	chr6:26577336	NA	-0.43	-4.51	-0.38	1.47e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs5769765	0.908	rs138891	chr22:50227741	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.04	-10.95	-0.7	6.06e-20	Schizophrenia;
TGCT	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg17054783	chr10:134559939	INPP5A	0.23	4.69	0.39	7.22e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs67072384	1.000	rs67075228	chr11:72450775	C/T	cg03713592	chr11:72463424	ARAP1	-0.93	-4.66	-0.39	7.89e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs7000551	0.556	rs35359294	chr8:22249755	G/A	cg12081754	chr8:22256438	SLC39A14	0.33	4.77	0.39	5.06e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs4654899	0.931	rs12723255	chr1:21233570	C/T	cg01072550	chr1:21505969	NA	0.51	8.18	0.59	2.84e-13	Superior frontal gyrus grey matter volume;
TGCT	cis	rs9300255	0.544	rs1716174	chr12:123660717	T/C	cg00376283	chr12:123451042	ABCB9	0.74	5.1	0.42	1.22e-6	Neutrophil percentage of white cells;
TGCT	cis	rs2455799	0.613	rs1976479	chr3:15729714	C/G	cg16303742	chr3:15540471	COLQ	-0.25	-4.74	-0.39	5.65e-6	Mean platelet volume;
TGCT	cis	rs593982	0.920	rs1108922	chr11:65423930	C/T	cg08755490	chr11:65554678	OVOL1	-1.15	-6.32	-0.49	4.28e-9	Atopic dermatitis;
TGCT	cis	rs7666738	0.830	rs34671152	chr4:98978177	C/T	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1577917	0.771	rs12205013	chr6:86333029	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.58	-0.45	1.43e-7	Response to antipsychotic treatment;
TGCT	cis	rs314370	0.904	rs13244629	chr7:100509253	A/C	cg10426581	chr7:100472382	SRRT	1.0	10.93	0.7	6.98e-20	Resting heart rate;
TGCT	cis	rs6089584	1.000	rs6142910	chr20:60562181	C/A	cg06108461	chr20:60628389	TAF4	-0.57	-8.01	-0.58	7.25e-13	Body mass index;
TGCT	cis	rs1334894	0.892	rs72911394	chr6:35525164	T/C	cg24281267	chr6:35479648	TULP1	-0.43	-4.54	-0.38	1.34e-5	Coronary artery disease;
TGCT	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg10802521	chr3:52805072	NEK4	-0.64	-7.66	-0.57	4.56e-12	Electroencephalogram traits;
TGCT	cis	rs3741151	1.000	rs76887714	chr11:73045500	C/T	cg17517138	chr11:73019481	ARHGEF17	1.01	5.08	0.42	1.34e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
TGCT	cis	rs72781680	0.679	rs718138	chr2:23976324	G/A	cg08917208	chr2:24149416	ATAD2B	0.75	5.04	0.41	1.59e-6	Lymphocyte counts;
TGCT	cis	rs12477438	0.501	rs12995473	chr2:99764884	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	12.84	0.76	1.57e-24	Chronic sinus infection;
TGCT	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg17971929	chr21:40555470	PSMG1	0.98	9.13	0.63	1.6e-15	Cognitive function;
TGCT	cis	rs9296092	0.517	rs56206922	chr6:33522567	C/T	cg13560919	chr6:33536144	NA	-0.21	-4.75	-0.39	5.5e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs508618	0.697	rs7534248	chr1:231554531	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.62	5.11	0.42	1.18e-6	Red blood cell count;
TGCT	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg17554472	chr22:41940697	POLR3H	-0.48	-4.95	-0.41	2.39e-6	Vitiligo;
TGCT	cis	rs12142240	0.698	rs6696777	chr1:46810970	A/G	cg14993813	chr1:46806288	NSUN4	-0.58	-4.81	-0.4	4.34e-6	Menopause (age at onset);
TGCT	cis	rs651907	0.535	rs13094911	chr3:101519021	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.31	-6.4	-0.5	2.91e-9	Colorectal cancer;
TGCT	cis	rs1401999	1.000	rs1401999	chr3:183678342	C/G	cg01324343	chr3:183735012	ABCC5	0.82	10.97	0.7	5.41e-20	Anterior chamber depth;
TGCT	cis	rs9427116	0.702	rs9427108	chr1:154607914	G/A	cg17218026	chr1:154582156	ADAR	0.28	7.02	0.53	1.3e-10	Blood protein levels;
TGCT	cis	rs1448094	0.511	rs10863083	chr12:86226739	C/A	cg02569458	chr12:86230093	RASSF9	0.36	4.53	0.38	1.36e-5	Major depressive disorder;
TGCT	cis	rs6893807	0.778	rs13173305	chr5:87945377	A/G	cg24804195	chr5:87968844	LOC645323	0.78	4.57	0.38	1.14e-5	Body mass index;
TGCT	cis	rs4478858	0.735	rs1566963	chr1:31772206	G/A	cg00250761	chr1:31883323	NA	-0.28	-5.01	-0.41	1.86e-6	Alcohol dependence;
TGCT	cis	rs524281	0.817	rs7115081	chr11:65853541	A/G	cg00563793	chr11:65837595	PACS1	0.55	4.62	0.38	9.44e-6	Electroencephalogram traits;
TGCT	cis	rs6912958	0.559	rs445434	chr6:88041849	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.45	5.88	0.47	3.49e-8	Monocyte percentage of white cells;
TGCT	cis	rs208520	0.802	rs208499	chr6:66932146	C/T	cg07460842	chr6:66804631	NA	-0.9	-9.15	-0.63	1.45e-15	Exhaled nitric oxide output;
TGCT	cis	rs644799	1.000	rs580255	chr11:95577929	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	8.11	0.59	4.26e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs3784262	0.669	rs3204690	chr15:58246768	A/C	cg12031962	chr15:58353849	ALDH1A2	-0.43	-5.97	-0.47	2.3e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg12310025	chr6:25882481	NA	-0.83	-8.49	-0.61	5.24e-14	Blood metabolite levels;
TGCT	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.55	4.92	0.4	2.68e-6	Prudent dietary pattern;
TGCT	cis	rs2016266	0.826	rs61928079	chr12:53741468	T/C	cg16917193	chr12:54089295	NA	-0.7	-4.68	-0.39	7.49e-6	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs9914544	0.545	rs7222748	chr17:18787976	T/C	cg26378065	chr17:18585709	ZNF286B	0.53	4.63	0.38	9.01e-6	Educational attainment (years of education);
TGCT	cis	rs12477438	0.520	rs4340581	chr2:99725025	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.89	9.0	0.63	3.26e-15	Chronic sinus infection;
TGCT	cis	rs2338224	1.000	rs4703887	chr5:71746038	C/T	cg01187920	chr5:71015162	CARTPT	-0.53	-4.57	-0.38	1.15e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Granulocyte count;Myeloid white cell count;
TGCT	cis	rs3617	0.573	rs9880978	chr3:52923251	C/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.51	-4.86	-0.4	3.44e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12681287	0.640	rs10086340	chr8:87446789	G/T	cg19078186	chr8:87526527	CPNE3	-0.34	-4.55	-0.38	1.26e-5	Caudate activity during reward;
TGCT	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg01802117	chr1:53393560	SCP2	-0.42	-5.25	-0.43	6.33e-7	Monocyte count;
TGCT	cis	rs17387100	0.901	rs73230220	chr4:15982382	G/A	cg14577840	chr4:16257979	FLJ39653	0.5	4.85	0.4	3.56e-6	Suicide attempts in depression or bipolar disorder;
TGCT	cis	rs3809566	0.676	rs9806544	chr15:63328360	G/A	cg00520135	chr15:63333846	TPM1	-0.4	-4.92	-0.4	2.68e-6	Platelet count;
TGCT	cis	rs12142240	0.698	rs77185326	chr1:46818417	T/C	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs79387448	0.745	rs75644281	chr2:103151316	A/T	cg09003973	chr2:102972529	NA	0.97	6.32	0.49	4.33e-9	Gut microbiota (bacterial taxa);
TGCT	cis	rs147649347	1	rs147649347	chr2:24210076	GATAA/G	cg08917208	chr2:24149416	ATAD2B	0.79	4.78	0.39	4.83e-6	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs453301	0.653	rs7853	chr8:8890814	A/G	cg00184457	chr8:8946301	NA	0.24	4.49	0.37	1.64e-5	Joint mobility (Beighton score);
TGCT	cis	rs13191362	0.935	rs66962088	chr6:162963891	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.66	5.11	0.42	1.17e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs5769765	0.913	rs2319462	chr22:50263370	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	-0.41	-6.13	-0.48	1.08e-8	Schizophrenia;
TGCT	cis	rs727563	0.565	rs132774	chr22:42031953	C/G	cg06481639	chr22:41940642	POLR3H	-0.6	-5.25	-0.43	6.35e-7	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs7666738	0.830	rs4443295	chr4:99044935	G/A	cg05340658	chr4:99064831	C4orf37	0.52	5.94	0.47	2.68e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2172802	0.693	rs7660566	chr4:62481231	G/T	cg04118610	chr4:62707027	LPHN3	0.46	4.96	0.41	2.3e-6	Partial epilepsies;
TGCT	cis	rs778371	0.723	rs6710294	chr2:233579634	T/C	cg08000102	chr2:233561755	GIGYF2	0.75	8.99	0.63	3.42e-15	Schizophrenia;
TGCT	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg07507251	chr3:52567010	NT5DC2	0.42	5.92	0.47	2.94e-8	Bipolar disorder;
TGCT	cis	rs877282	1.000	rs11253362	chr10:770979	G/T	cg17470449	chr10:769945	NA	0.34	5.4	0.44	3.34e-7	Uric acid levels;
TGCT	cis	rs17030434	0.871	rs78151744	chr4:154730266	C/T	cg14289246	chr4:154710475	SFRP2	-0.9	-7.58	-0.56	7.16e-12	Electrocardiographic conduction measures;
TGCT	trans	rs629535	0.821	rs660144	chr8:70035629	T/C	cg21567404	chr3:27674614	NA	0.58	9.18	0.64	1.22e-15	Dupuytren's disease;
TGCT	cis	rs10791323	0.511	rs4937837	chr11:133731134	T/C	cg03690763	chr11:133734501	NA	-0.3	-4.53	-0.38	1.38e-5	Childhood ear infection;
TGCT	cis	rs559928	0.553	rs1320628	chr11:64175986	C/T	cg12453748	chr11:64085041	PRDX5;TRMT112	0.56	4.85	0.4	3.6e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
TGCT	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg00343986	chr7:65444356	GUSB	-0.2	-4.51	-0.38	1.51e-5	Aortic root size;
TGCT	cis	rs10197940	0.510	rs7602715	chr2:152421937	A/G	cg19508488	chr2:152266495	RIF1	0.62	5.48	0.44	2.27e-7	Lung cancer;
TGCT	cis	rs8072100	0.840	rs9893901	chr17:45506682	T/G	cg08085267	chr17:45401833	C17orf57	-0.5	-5.51	-0.44	2.02e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg06221963	chr1:154839813	KCNN3	-0.74	-12.65	-0.75	4.56e-24	Prostate cancer;
TGCT	cis	rs8038465	0.874	rs11574488	chr15:73999379	T/A	cg15420318	chr15:73925796	NPTN	0.57	5.12	0.42	1.12e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9926296	0.715	rs467035	chr16:89740285	C/G	cg27121462	chr16:89883253	FANCA	0.52	4.96	0.41	2.25e-6	Vitiligo;
TGCT	cis	rs7246657	0.882	rs8112610	chr19:37928730	C/A	cg18154014	chr19:37997991	ZNF793	0.73	5.4	0.44	3.23e-7	Coronary artery calcification;
TGCT	cis	rs17076896	0.786	rs74038130	chr13:19933634	T/C	cg00777926	chr13:20807375	GJB6	-0.37	-4.53	-0.38	1.36e-5	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs9926296	0.744	rs164748	chr16:89708292	C/G	cg04287289	chr16:89883240	FANCA	-0.5	-4.79	-0.39	4.73e-6	Vitiligo;
TGCT	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-1.0	-10.76	-0.69	1.79e-19	Height;
TGCT	cis	rs860554	0.546	rs2239845	chr1:201292488	C/T	cg01022117	chr1:201258280	PKP1	-0.28	-4.96	-0.41	2.28e-6	Panic disorder;
TGCT	cis	rs72634258	0.554	rs34020118	chr1:7895015	C/T	cg26816564	chr1:7831052	VAMP3	0.88	6.53	0.51	1.52e-9	Inflammatory bowel disease;
TGCT	cis	rs10479542	0.642	rs6879665	chr5:178974581	T/A	cg14851468	chr5:179071604	C5orf60	0.25	4.86	0.4	3.46e-6	Lung cancer;
TGCT	cis	rs7666738	0.800	rs12163918	chr4:98835794	T/C	cg17366294	chr4:99064904	C4orf37	0.72	7.47	0.56	1.23e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12413816	0.963	rs12359348	chr10:13765950	C/T	cg16485048	chr10:13749193	FRMD4A	-0.25	-5.03	-0.41	1.64e-6	Red cell distribution width;
TGCT	cis	rs12765878	1.000	rs11191848	chr10:105650837	T/C	cg11005552	chr10:105648138	OBFC1	0.44	7.7	0.57	3.69e-12	Coronary artery disease;
TGCT	cis	rs950776	0.647	rs495956	chr15:78869930	C/T	cg06917634	chr15:78832804	PSMA4	-0.66	-5.29	-0.43	5.47e-7	Sudden cardiac arrest;
TGCT	cis	rs2458413	0.500	rs2251930	chr8:105357764	G/A	cg04554929	chr8:105342491	NA	0.49	5.84	0.46	4.26e-8	Paget's disease;
TGCT	cis	rs10876993	0.784	rs1871417	chr12:58018979	C/T	cg15848620	chr12:58087721	OS9	0.72	5.38	0.44	3.52e-7	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs748404	0.578	rs478028	chr15:43610772	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	4.75	0.39	5.46e-6	Lung cancer;
TGCT	cis	rs11122272	0.735	rs11122280	chr1:231519816	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.13	-0.54	7.33e-11	Hemoglobin concentration;
TGCT	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg17264618	chr3:40429014	ENTPD3	0.32	4.57	0.38	1.18e-5	Renal cell carcinoma;
TGCT	cis	rs2637266	1.000	rs7475638	chr10:78358586	G/T	cg18941641	chr10:78392320	NA	-0.37	-4.67	-0.39	7.71e-6	Pulmonary function;
TGCT	cis	rs9291683	0.595	rs3733585	chr4:10036339	A/G	cg11266682	chr4:10021025	SLC2A9	0.64	8.92	0.63	5e-15	Bone mineral density;
TGCT	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg19318889	chr4:1322082	MAEA	-0.16	-4.46	-0.37	1.84e-5	Obesity-related traits;
TGCT	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg10047753	chr17:41438598	NA	0.96	9.64	0.65	9.37e-17	Menopause (age at onset);
TGCT	cis	rs797680	0.820	rs10874773	chr1:93798496	T/G	cg17826107	chr1:92977322	EVI5	-0.23	-5.14	-0.42	1.05e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs713587	0.607	rs6725517	chr2:25129473	A/G	cg01884057	chr2:25150051	NA	0.34	6.57	0.51	1.24e-9	Body mass index in non-asthmatics;
TGCT	cis	rs9467711	0.606	rs9379855	chr6:26364930	C/T	cg10795676	chr6:26370623	BTN3A2	0.46	4.75	0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7104764	0.957	rs6598071	chr11:219800	T/C	cg18336825	chr11:236787	PSMD13;SIRT3	1.05	10.74	0.69	2e-19	Menarche (age at onset);
TGCT	cis	rs6570726	0.791	rs9403730	chr6:145907233	C/T	cg05347473	chr6:146136440	FBXO30	0.52	4.95	0.41	2.33e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg18876405	chr7:65276391	NA	0.32	4.89	0.4	3.12e-6	Aortic root size;
TGCT	cis	rs950169	1.000	rs11638394	chr15:84778928	G/A	cg11189052	chr15:85197271	WDR73	0.69	5.91	0.47	3.07e-8	Schizophrenia;
TGCT	cis	rs11874712	1.000	rs9944637	chr18:43655239	G/A	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	5.23	0.42	7.04e-7	Migraine - clinic-based;
TGCT	cis	rs151997	0.777	rs6870880	chr5:50256207	G/A	cg06027927	chr5:50259733	NA	0.56	5.92	0.47	2.88e-8	Callous-unemotional behaviour;
TGCT	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg03388025	chr16:89894329	SPIRE2	-0.46	-7.98	-0.58	8.26e-13	Vitiligo;
TGCT	cis	rs459571	0.959	rs465724	chr9:136910097	C/T	cg13789015	chr9:136890014	NCRNA00094	0.4	7.28	0.55	3.41e-11	Platelet distribution width;
TGCT	cis	rs7359276	1	rs7359276	chr15:78892661	C/T	cg24631222	chr15:78858424	CHRNA5	-0.8	-5.84	-0.46	4.29e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs7044106	0.762	rs7044226	chr9:123466328	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	4.7	0.39	6.66e-6	Hip circumference adjusted for BMI;
TGCT	trans	rs77457752	0.525	rs10120720	chr9:13897929	G/C	cg23609682	chr1:3070786	PRDM16	0.5	6.79	0.52	4.09e-10	Breast cancer;
TGCT	cis	rs7666738	0.830	rs11944855	chr4:99068258	G/A	cg05340658	chr4:99064831	C4orf37	0.52	5.79	0.46	5.32e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8067545	1.000	rs4925066	chr17:19915292	A/G	cg13482628	chr17:19912719	NA	0.55	4.83	0.4	3.98e-6	Schizophrenia;
TGCT	cis	rs651907	1.000	rs665211	chr3:101600028	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.47	4.8	0.4	4.46e-6	Colorectal cancer;
TGCT	cis	rs9372498	0.536	rs62422227	chr6:118957200	C/G	cg21191810	chr6:118973309	C6orf204	-0.38	-4.97	-0.41	2.14e-6	Diastolic blood pressure;
TGCT	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.05	8.69	0.62	1.83e-14	Platelet count;
TGCT	cis	rs9534288	0.762	rs9534292	chr13:46611340	T/C	cg15192986	chr13:46630673	CPB2	-0.53	-7.66	-0.57	4.65e-12	Blood protein levels;
TGCT	cis	rs79149102	0.579	rs61166993	chr15:75306644	C/A	cg09165964	chr15:75287851	SCAMP5	-1.04	-5.73	-0.46	7.2e-8	Lung cancer;
TGCT	cis	rs4629710	0.592	rs67399092	chr6:131582936	G/A	cg12606694	chr6:131520996	AKAP7	0.4	4.77	0.39	5.05e-6	Multiple myeloma (IgH translocation);
TGCT	cis	rs187455071	1	rs187455071	chr4:106805884	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	1.01	4.61	0.38	9.71e-6	Post bronchodilator FEV1;
TGCT	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9549367	0.713	rs2146750	chr13:113822530	A/G	cg00898013	chr13:113819073	PROZ	0.4	4.58	0.38	1.12e-5	Platelet distribution width;
TGCT	cis	rs6671200	0.573	rs6666528	chr1:95697490	C/A	cg06440946	chr1:95699313	RWDD3	-0.62	-5.3	-0.43	5.09e-7	Stearic acid (18:0) levels;
TGCT	cis	rs12615966	0.651	rs72830470	chr2:105406694	C/T	cg16465502	chr2:105461796	NA	0.85	5.6	0.45	1.34e-7	Pancreatic cancer;
TGCT	cis	rs62244186	0.659	rs4682745	chr3:44508967	T/C	cg10108389	chr3:44770937	ZNF501	-0.47	-4.87	-0.4	3.34e-6	Depressive symptoms;
TGCT	cis	rs7647973	0.769	rs7434187	chr3:49032967	C/T	cg07636037	chr3:49044803	WDR6	0.82	6.59	0.51	1.12e-9	Menarche (age at onset);
TGCT	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg17554472	chr22:41940697	POLR3H	-0.51	-5.5	-0.44	2.09e-7	Vitiligo;
TGCT	cis	rs2067615	0.579	rs10861667	chr12:107194776	T/G	cg15890332	chr12:107067104	RFX4	0.28	5.53	0.44	1.8e-7	Heart rate;
TGCT	cis	rs6582630	0.533	rs2120464	chr12:38280289	A/C	cg26384229	chr12:38710491	ALG10B	0.53	4.67	0.39	7.65e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs7523050	0.643	rs71655970	chr1:109403895	A/G	cg08274380	chr1:109419600	GPSM2	1.3	6.39	0.5	2.99e-9	Fat distribution (HIV);
TGCT	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.36	-4.45	-0.37	1.9e-5	Total body bone mineral density;
TGCT	cis	rs9500256	0.934	rs1343391	chr6:58344154	C/G	cg16251399	chr6:58287822	GUSBL2	0.63	5.75	0.46	6.49e-8	Eosinophilic esophagitis (pediatric);
TGCT	cis	rs11031096	0.769	rs12803541	chr11:4208906	G/A	cg18678763	chr11:4115507	RRM1	0.4	5.19	0.42	8.27e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	trans	rs1814175	0.715	rs10839409	chr11:49884647	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.35	-0.55	2.38e-11	Height;
TGCT	cis	rs933688	1.000	rs12188467	chr5:90765632	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.87	8.03	0.58	6.54e-13	Smoking behavior;
TGCT	trans	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg25482853	chr8:67687455	SGK3	1.19	10.3	0.68	2.4e-18	Obesity-related traits;
TGCT	cis	rs67478160	0.634	rs7141928	chr14:104219949	C/T	cg26031613	chr14:104095156	KLC1	-0.64	-6.49	-0.5	1.89e-9	Schizophrenia;
TGCT	cis	rs975739	0.669	rs7986312	chr13:78584793	T/G	cg07847733	chr13:78271382	SLAIN1	0.5	4.44	0.37	1.96e-5	Hair color;
TGCT	cis	rs1997103	1.000	rs6949244	chr7:55411301	C/G	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs2677744	0.626	rs11207	chr15:91497239	C/T	cg22570213	chr15:91497863	RCCD1	0.41	4.96	0.41	2.24e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs77633900	0.614	rs280029	chr15:77031235	A/G	cg21673338	chr15:77095150	SCAPER	-0.53	-5.22	-0.42	7.33e-7	Non-glioblastoma glioma;Glioma;
TGCT	cis	rs7412746	0.611	rs7532045	chr1:150821847	G/A	cg09365446	chr1:150670422	GOLPH3L	0.34	4.69	0.39	7.24e-6	Melanoma;
TGCT	cis	rs2456568	0.900	rs1518571	chr11:93667420	C/A	cg26875233	chr11:93583750	C11orf90	-0.45	-5.61	-0.45	1.27e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7267979	0.816	rs376742	chr20:25487417	A/C	cg14121845	chr20:25566513	NINL	0.45	4.69	0.39	7.14e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9381040	1.000	rs2093395	chr6:41155026	C/G	cg03526776	chr6:41159608	TREML2	-0.34	-6.94	-0.53	1.92e-10	Alzheimer's disease (late onset);
TGCT	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.68	4.84	0.4	3.86e-6	Platelet count;
TGCT	cis	rs7845219	0.597	rs7002058	chr8:95873993	G/C	cg16049864	chr8:95962084	TP53INP1	-0.55	-6.29	-0.49	4.98e-9	Type 2 diabetes;
TGCT	cis	rs7666738	0.791	rs6833691	chr4:98951508	A/G	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7714584	1.000	rs4958842	chr5:150224877	G/A	cg22134413	chr5:150180641	NA	1.12	8.12	0.59	3.99e-13	Crohn's disease;
TGCT	cis	rs595982	0.501	rs112370206	chr19:49396623	C/T	cg11637076	chr19:49575188	KCNA7	-0.44	-5.23	-0.43	6.99e-7	Red cell distribution width;
TGCT	cis	rs6121246	0.821	rs6121209	chr20:30311258	G/C	cg13852791	chr20:30311386	BCL2L1	0.81	6.27	0.49	5.38e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs587847	0.737	rs28373878	chr15:37664826	G/A	cg00216138	chr15:37171175	LOC145845	0.31	4.45	0.37	1.91e-5	Intraocular pressure;
TGCT	cis	rs11096990	0.656	rs6531709	chr4:39302249	T/G	cg20847110	chr4:39482781	LOC401127	-0.16	-4.52	-0.38	1.43e-5	Cognitive function;
TGCT	cis	rs1994135	0.565	rs11052767	chr12:33731194	A/G	cg06521331	chr12:34319734	NA	-0.31	-4.79	-0.4	4.71e-6	Resting heart rate;
TGCT	cis	rs7726839	0.540	rs4957083	chr5:659343	T/C	cg16624210	chr5:671434	TPPP	0.41	4.6	0.38	1.02e-5	Obesity-related traits;
TGCT	cis	rs600231	0.708	rs682845	chr11:65254201	A/G	cg17120908	chr11:65337727	SSSCA1	-0.57	-5.39	-0.44	3.46e-7	Bone mineral density;
TGCT	cis	rs2070488	1.000	rs6772046	chr3:38479660	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.92	9.68	0.66	7.36e-17	Electrocardiographic conduction measures;
TGCT	cis	rs7208859	0.673	rs17826219	chr17:29161845	G/A	cg14008862	chr17:28927542	LRRC37B2	0.72	4.66	0.39	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	trans	rs1814175	0.727	rs2140597	chr11:49873946	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.35	-0.55	2.38e-11	Height;
TGCT	cis	rs1669338	0.588	rs3749360	chr3:3213775	G/A	cg16797762	chr3:3221439	CRBN	-0.92	-5.82	-0.46	4.76e-8	White matter integrity;
TGCT	cis	rs7208859	0.673	rs73277967	chr17:29184166	T/A	cg14008862	chr17:28927542	LRRC37B2	0.72	4.66	0.39	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs9611519	0.780	rs1983631	chr22:41644074	C/T	cg06634786	chr22:41940651	POLR3H	-0.54	-4.83	-0.4	3.87e-6	Neuroticism;
TGCT	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	9.52	0.65	1.86e-16	Platelet count;
TGCT	cis	rs4776059	0.958	rs35505902	chr15:52888493	A/G	cg25063058	chr15:52860530	ARPP19	0.52	4.71	0.39	6.66e-6	Schizophrenia;
TGCT	cis	rs7659604	0.502	rs10212738	chr4:122675724	G/A	cg19748678	chr4:122722346	EXOSC9	-0.51	-5.0	-0.41	1.89e-6	Type 2 diabetes;
TGCT	cis	rs1218582	0.741	rs11264291	chr1:154914797	C/T	cg06221963	chr1:154839813	KCNN3	-0.71	-11.94	-0.73	2.43e-22	Prostate cancer;
TGCT	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg13607699	chr17:42295918	UBTF	-0.73	-7.05	-0.53	1.1e-10	Total body bone mineral density;
TGCT	cis	rs2242116	0.796	rs4683296	chr3:46973820	G/C	cg27129171	chr3:47204927	SETD2	-0.65	-6.37	-0.5	3.28e-9	Birth weight;
TGCT	cis	rs6141769	0.518	rs6057631	chr20:31319149	A/G	cg13636640	chr20:31349939	DNMT3B	-0.52	-4.55	-0.38	1.26e-5	Subjective well-being;
TGCT	cis	rs9303401	0.659	rs12935851	chr17:56600244	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs11578119	0.898	rs6427253	chr1:170433401	C/T	cg09767346	chr1:170501363	GORAB	0.71	5.68	0.45	9.07e-8	Male-pattern baldness;
TGCT	cis	rs17331151	0.505	rs35225119	chr3:52623465	A/T	cg24616795	chr3:53032891	SFMBT1	0.6	4.9	0.4	2.97e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs9796	0.621	rs9972349	chr15:41491656	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.52	-7.18	-0.54	5.68e-11	Menopause (age at onset);
TGCT	cis	rs2180341	1.000	rs2038378	chr6:127590400	C/T	cg24812749	chr6:127587940	RNF146	0.97	7.52	0.56	9.68e-12	Breast cancer;
TGCT	cis	rs7772486	0.754	rs6906258	chr6:146089356	A/G	cg05347473	chr6:146136440	FBXO30	-0.53	-5.01	-0.41	1.84e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2562456	0.917	rs2650793	chr19:21676115	C/G	cg01304269	chr19:21688519	ZNF429	-0.59	-5.04	-0.41	1.64e-6	Pain;
TGCT	cis	rs13064411	0.696	rs6773497	chr3:113186514	T/C	cg18753928	chr3:113234510	CCDC52	-0.69	-5.57	-0.45	1.47e-7	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs2073300	1.000	rs6048827	chr20:23458080	T/C	cg09953122	chr20:23471693	CST8	-0.6	-4.72	-0.39	6.22e-6	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs4689388	0.853	rs13114527	chr4:6294655	T/G	cg25554036	chr4:6271136	WFS1	0.54	7.37	0.55	2.11e-11	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs9302001	0.920	rs6492751	chr13:95460383	C/T	cg07483244	chr13:95358924	NA	0.37	4.79	0.4	4.65e-6	Panic disorder;
TGCT	cis	rs1475911	0.708	rs56109792	chr21:43520060	A/G	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.31	-5.88	-0.47	3.64e-8	IgG glycosylation;
TGCT	cis	rs9952991	0.709	rs71353225	chr18:12759183	T/C	cg23598886	chr18:12777645	NA	-0.65	-4.66	-0.39	8.08e-6	Inflammatory skin disease;
TGCT	cis	rs79057730	0.527	rs34519158	chr7:811114	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.65	6.07	0.48	1.41e-8	Initial pursuit acceleration;
TGCT	cis	rs1480597	0.518	rs1480603	chr10:45197977	G/T	cg12063947	chr10:45878068	ALOX5	0.26	4.44	0.37	2e-5	Parkinson's disease;
TGCT	cis	rs6964587	1.000	rs4644173	chr7:91759597	A/G	cg22709100	chr7:91322751	NA	0.28	4.46	0.37	1.81e-5	Breast cancer;
TGCT	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg19635926	chr16:89946313	TCF25	0.25	4.46	0.37	1.84e-5	Skin colour saturation;
TGCT	cis	rs1023500	0.573	rs13057094	chr22:42470317	T/C	cg15557168	chr22:42548783	NA	-0.21	-5.27	-0.43	5.81e-7	Schizophrenia;
TGCT	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg18230493	chr5:56204884	C5orf35	-0.67	-5.71	-0.46	8e-8	Initial pursuit acceleration;
TGCT	cis	rs9443645	0.901	rs1542977	chr6:79550307	G/T	cg09184832	chr6:79620586	NA	-0.48	-5.3	-0.43	5.19e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs4851266	0.933	rs6709656	chr2:100806719	A/G	cg22139774	chr2:100720529	AFF3	-0.35	-5.29	-0.43	5.24e-7	Educational attainment;
TGCT	cis	rs2115630	1.000	rs2115630	chr15:85364516	C/T	cg09876464	chr15:85330779	ZNF592	0.19	4.47	0.37	1.76e-5	P wave terminal force;
TGCT	cis	rs9926296	0.609	rs4785714	chr16:89798404	G/T	cg27121462	chr16:89883253	FANCA	-0.53	-4.95	-0.41	2.38e-6	Vitiligo;
TGCT	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg18876405	chr7:65276391	NA	0.32	4.87	0.4	3.29e-6	Aortic root size;
TGCT	cis	rs9354352	0.935	rs7766730	chr6:66697003	C/A	cg07460842	chr6:66804631	NA	0.65	6.68	0.51	7.29e-10	Initial pursuit acceleration in psychotic disorders;
TGCT	cis	rs2708977	0.933	rs6576972	chr2:97152446	C/T	cg01950434	chr2:97203154	ARID5A	-0.72	-6.77	-0.52	4.6e-10	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs1215050	0.791	rs1727278	chr4:98853576	A/G	cg05340658	chr4:99064831	C4orf37	-0.47	-5.9	-0.47	3.18e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg06873352	chr17:61820015	STRADA	0.58	6.39	0.5	3.01e-9	Prudent dietary pattern;
TGCT	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg03517284	chr6:25882590	NA	0.78	8.11	0.59	4.26e-13	Blood metabolite levels;
TGCT	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg01577475	chr2:114033581	PAX8;LOC440839	-0.44	-4.75	-0.39	5.42e-6	Lymphocyte counts;
TGCT	cis	rs2228479	0.717	rs11644967	chr16:89806614	T/A	cg27121462	chr16:89883253	FANCA	0.78	4.65	0.39	8.51e-6	Skin colour saturation;
TGCT	cis	rs9640161	0.830	rs17173681	chr7:150059414	A/G	cg10018233	chr7:150070692	REPIN1	-0.31	-4.62	-0.38	9.57e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs3125734	0.653	rs1007976	chr10:63970144	C/T	cg05499367	chr10:63213510	TMEM26	0.34	4.54	0.38	1.32e-5	Rheumatoid arthritis;
TGCT	cis	rs10782582	0.532	rs12132503	chr1:76137762	C/G	cg22875332	chr1:76189707	ACADM	-0.55	-6.28	-0.49	5.25e-9	Daytime sleep phenotypes;
TGCT	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg11235426	chr6:292522	DUSP22	-0.68	-6.94	-0.53	1.92e-10	Menopause (age at onset);
TGCT	cis	rs2677744	0.626	rs11207	chr15:91497239	C/T	cg23684204	chr15:91497937	RCCD1	0.4	6.12	0.48	1.15e-8	Attention deficit hyperactivity disorder;
TGCT	cis	rs9467773	1.000	rs6933176	chr6:26540178	G/A	cg15659132	chr6:26577336	NA	0.86	12.21	0.74	5.3e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs2980439	0.525	rs1850511	chr8:8170329	T/A	cg15556689	chr8:8085844	FLJ10661	0.67	5.79	0.46	5.4e-8	Neuroticism;
TGCT	cis	rs7524258	0.868	rs4908607	chr1:7269323	A/G	cg04342483	chr1:7259290	CAMTA1	-0.3	-4.45	-0.37	1.89e-5	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs7655841	0.504	rs10028974	chr4:129871442	C/A	cg26347359	chr4:129759716	PHF17	0.46	6.16	0.48	9.24e-9	Chronic obstructive pulmonary disease (moderate to severe);
TGCT	cis	rs9894429	1.000	rs9894429	chr17:79596811	C/T	cg18240062	chr17:79603768	NPLOC4	0.69	7.22	0.54	4.67e-11	Eye color traits;
TGCT	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg12310025	chr6:25882481	NA	-0.59	-6.04	-0.48	1.65e-8	Blood metabolite levels;
TGCT	cis	rs8141529	0.719	rs9625619	chr22:29272328	T/A	cg02153584	chr22:29168773	CCDC117	0.63	4.87	0.4	3.3e-6	Lymphocyte counts;
TGCT	cis	rs2806561	0.695	rs67238799	chr1:23335012	G/A	cg12483005	chr1:23474871	LUZP1	0.37	4.72	0.39	6.21e-6	Height;
TGCT	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.47	0.56	1.28e-11	Prudent dietary pattern;
TGCT	cis	rs71718386	1	rs71718386	chr13:41224287	CTATA/C	cg21288729	chr13:41239152	FOXO1	1.01	10.71	0.69	2.36e-19	Eosinophil counts;
TGCT	cis	rs896854	0.684	rs10098778	chr8:95992020	C/T	cg23172400	chr8:95962367	TP53INP1	-0.36	-6.22	-0.49	6.97e-9	Type 2 diabetes;
TGCT	cis	rs7772486	0.686	rs9497380	chr6:145955305	T/C	cg05347473	chr6:146136440	FBXO30	0.48	4.53	0.38	1.35e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11122272	0.603	rs2998427	chr1:231528112	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-6.12	-0.48	1.12e-8	Hemoglobin concentration;
TGCT	cis	rs17767294	0.708	rs17693877	chr6:27707046	G/A	cg08851530	chr6:28072375	NA	0.95	4.64	0.38	8.79e-6	Parkinson's disease;
TGCT	cis	rs31872	0.520	rs246053	chr5:140326290	T/A	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Visceral adipose tissue adjusted for BMI;
TGCT	cis	rs57590327	0.679	rs13071810	chr3:81618478	T/C	cg07356753	chr3:81810745	GBE1	-0.57	-4.72	-0.39	6.37e-6	Extraversion;
TGCT	cis	rs9814567	0.752	rs13075253	chr3:134329600	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.75	6.83	0.52	3.43e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs644799	0.930	rs631099	chr11:95563482	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	10.52	0.69	6.94e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg25427524	chr10:38739819	LOC399744	-0.39	-8.04	-0.59	5.95e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs6582630	0.537	rs35336822	chr12:38346251	T/C	cg26384229	chr12:38710491	ALG10B	0.78	6.94	0.53	1.94e-10	Drug-induced liver injury (flucloxacillin);
TGCT	trans	rs751984	0.706	rs11605791	chr11:61263116	C/G	cg03305746	chr2:106927199	NA	-0.58	-7.01	-0.53	1.32e-10	Diastolic blood pressure;Systolic blood pressure;Mean arterial pressure;
TGCT	cis	rs1018836	0.923	rs6986689	chr8:91626709	A/C	cg16814680	chr8:91681699	NA	-0.85	-9.22	-0.64	9.9e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9372498	0.536	rs1319987	chr6:118782236	A/G	cg07617317	chr6:118971624	C6orf204	0.5	5.39	0.44	3.37e-7	Diastolic blood pressure;
TGCT	cis	rs7258465	1.000	rs10409483	chr19:18590223	C/G	cg06462663	chr19:18546047	ISYNA1	0.2	4.63	0.38	9.01e-6	Breast cancer;
TGCT	cis	rs11948739	0.501	rs971699	chr5:130361558	A/G	cg08523029	chr5:130500466	HINT1	-0.61	-5.08	-0.42	1.34e-6	Pediatric bone mineral content (hip);
TGCT	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg03188948	chr7:1209495	NA	0.65	5.39	0.44	3.36e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1800682	0.528	rs11202918	chr10:90742008	A/G	cg03111039	chr10:90751583	FAS;ACTA2	0.62	8.71	0.62	1.58e-14	Chronic lymphocytic leukemia;
TGCT	cis	rs35306767	0.903	rs35567307	chr10:915804	G/C	cg26597838	chr10:835615	NA	0.75	10.54	0.69	6.3e-19	Eosinophil percentage of granulocytes;
TGCT	cis	rs13326165	0.760	rs56357549	chr3:52374516	T/G	cg27565382	chr3:53032988	SFMBT1	0.37	4.9	0.4	2.97e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs8078723	0.714	rs12940405	chr17:38143768	C/T	cg17467752	chr17:38218738	THRA	-0.53	-5.37	-0.43	3.69e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs11105298	0.891	rs10858881	chr12:89891474	T/G	cg00757033	chr12:89920650	WDR51B	0.34	5.37	0.43	3.75e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.51	-4.96	-0.41	2.24e-6	Prudent dietary pattern;
TGCT	cis	rs9513593	0.892	rs7320298	chr13:99875666	G/T	cg21788972	chr13:99853209	UBAC2	0.59	4.7	0.39	6.68e-6	Psoriasis;
TGCT	cis	rs78487399	0.710	rs7607777	chr2:43629931	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-4.87	-0.4	3.39e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs5769707	0.933	rs2157444	chr22:49994292	A/G	cg05373962	chr22:49881684	NA	-0.3	-6.13	-0.48	1.06e-8	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs2404602	0.735	rs11632222	chr15:76712927	C/G	cg26408565	chr15:76604113	ETFA	0.38	4.49	0.37	1.58e-5	Blood metabolite levels;
TGCT	cis	rs9650657	0.801	rs7018334	chr8:10612075	G/A	cg27411982	chr8:10470053	RP1L1	-0.22	-4.51	-0.38	1.49e-5	Neuroticism;
TGCT	cis	rs3008870	1.000	rs35365746	chr1:67438900	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-1.1	-11.8	-0.73	5.15e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs2882877	0.648	rs13018571	chr2:190395126	A/T	cg10752008	chr2:190445175	SLC40A1	0.63	4.67	0.39	7.72e-6	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg24675658	chr1:53192096	ZYG11B	-0.75	-9.11	-0.63	1.78e-15	Monocyte count;
TGCT	cis	rs4566357	0.615	rs4675140	chr2:227908665	C/T	cg11843606	chr2:227700838	RHBDD1	-0.54	-5.09	-0.42	1.28e-6	Coronary artery disease;
TGCT	cis	rs9910055	0.530	rs8072954	chr17:42294722	G/A	cg13607699	chr17:42295918	UBTF	0.97	11.16	0.71	1.87e-20	Total body bone mineral density;
TGCT	trans	rs7726839	0.574	rs72705014	chr5:619815	C/G	cg11887960	chr12:57824829	NA	1.19	9.29	0.64	6.45e-16	Obesity-related traits;
TGCT	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg12042659	chr19:58951599	ZNF132	-0.5	-4.5	-0.37	1.57e-5	Uric acid clearance;
TGCT	cis	rs9611565	0.729	rs202654	chr22:41841034	G/A	cg03806693	chr22:41940476	POLR3H	1.03	11.32	0.71	7.58e-21	Vitiligo;
TGCT	cis	rs6964587	0.610	rs10953056	chr7:91466700	C/T	cg17063962	chr7:91808500	NA	0.73	6.7	0.52	6.48e-10	Breast cancer;
TGCT	cis	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg20637647	chr7:64974828	NA	0.89	4.99	0.41	2.01e-6	Diabetic kidney disease;
TGCT	cis	rs2066819	0.901	rs773665	chr12:56717466	C/T	cg26714650	chr12:56694279	CS	1.53	8.28	0.6	1.67e-13	Psoriasis vulgaris;
TGCT	trans	rs4576506	0.536	rs35433184	chr9:31502795	A/G	cg11445191	chr5:140227765	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA5;PCDHA9;PCDHA3;PCDHA4;PCDHA8	0.98	6.69	0.51	6.76e-10	Psychosis and Alzheimer's disease;
TGCT	cis	rs10206020	0.921	rs72776302	chr2:1571383	G/A	cg12573674	chr2:1569213	NA	-0.49	-5.3	-0.43	5.1e-7	IgG glycosylation;
TGCT	cis	rs1005277	0.522	rs289649	chr10:37975384	T/C	cg25427524	chr10:38739819	LOC399744	-0.33	-6.48	-0.5	1.99e-9	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2637266	1.000	rs2637266	chr10:78331318	C/T	cg18941641	chr10:78392320	NA	-0.39	-4.58	-0.38	1.1e-5	Pulmonary function;
TGCT	cis	rs62244186	0.541	rs62244226	chr3:44831831	G/A	cg15687855	chr3:44754131	ZNF502	-0.54	-6.78	-0.52	4.27e-10	Depressive symptoms;
TGCT	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.28	4.89	0.4	3.05e-6	Schizophrenia;
TGCT	cis	rs11098499	0.909	rs7681214	chr4:120385320	C/A	cg09307838	chr4:120376055	NA	0.68	6.53	0.51	1.54e-9	Corneal astigmatism;
TGCT	cis	rs10782582	0.532	rs12132503	chr1:76137762	C/G	cg03433033	chr1:76189801	ACADM	-0.64	-7.35	-0.55	2.29e-11	Daytime sleep phenotypes;
TGCT	cis	rs6684514	1.000	rs12130361	chr1:156260301	C/T	cg20302342	chr1:156215951	PAQR6	0.34	4.6	0.38	1.01e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.07	0.82	4.17e-32	Prudent dietary pattern;
TGCT	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg18402987	chr7:1209562	NA	0.4	5.17	0.42	9.07e-7	Longevity;Endometriosis;
TGCT	cis	rs6570726	0.935	rs406343	chr6:145874388	A/G	cg05347473	chr6:146136440	FBXO30	0.49	4.54	0.38	1.29e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs17401966	1.000	rs17401924	chr1:10384439	A/G	cg19773385	chr1:10388646	KIF1B	-0.21	-4.5	-0.37	1.57e-5	Hepatocellular carcinoma;
TGCT	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.62	5.25	0.43	6.3e-7	Tonsillectomy;
TGCT	cis	rs1729951	0.575	rs10935214	chr3:136693485	G/A	cg12473912	chr3:136751656	NA	0.39	6.18	0.49	8.36e-9	Neuroticism;
TGCT	cis	rs6582630	0.519	rs8189623	chr12:38351436	G/A	cg26384229	chr12:38710491	ALG10B	0.83	7.23	0.54	4.33e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs2839186	0.732	rs8131458	chr21:47694712	G/A	cg12516959	chr21:47718080	NA	-0.3	-4.46	-0.37	1.85e-5	Testicular germ cell tumor;
TGCT	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.66	-6.43	-0.5	2.47e-9	Prostate cancer;
TGCT	cis	rs7226408	0.857	rs74682538	chr18:34473572	G/A	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs6534347	0.573	rs7676741	chr4:123523441	G/A	cg10583651	chr4:123538969	IL21	-0.36	-5.27	-0.43	5.97e-7	Type 1 diabetes;
TGCT	cis	rs9926296	0.581	rs12598477	chr16:89902482	T/C	cg27121462	chr16:89883253	FANCA	0.64	6.14	0.48	1.05e-8	Vitiligo;
TGCT	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg24531977	chr5:56204891	C5orf35	-0.77	-7.61	-0.56	5.83e-12	Initial pursuit acceleration;
TGCT	cis	rs5769765	0.913	rs8135071	chr22:50299587	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.09	-10.56	-0.69	5.6e-19	Schizophrenia;
TGCT	cis	rs17345786	1.000	rs11715368	chr3:101336380	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	4.72	0.39	6.29e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs5758659	0.714	rs2284087	chr22:42485671	T/C	cg15557168	chr22:42548783	NA	0.18	4.56	0.38	1.23e-5	Cognitive function;
TGCT	cis	rs7833790	0.724	rs6473299	chr8:82676936	A/G	cg17211192	chr8:82754475	SNX16	-1.03	-8.39	-0.6	9.37e-14	Diastolic blood pressure;
TGCT	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg06221963	chr1:154839813	KCNN3	-0.8	-14.79	-0.8	3.73e-29	Prostate cancer;
TGCT	cis	rs2301573	1.000	rs2301573	chr3:129305919	A/G	cg07730360	chr3:128845626	NA	0.32	5.04	0.41	1.63e-6	Hip circumference;
TGCT	cis	rs1878931	0.535	rs7188903	chr16:3412861	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.73	6.0	0.47	2.01e-8	Body mass index (adult);
TGCT	cis	rs7843479	0.601	rs4872209	chr8:21848832	A/T	cg17168535	chr8:21777572	XPO7	0.79	7.79	0.57	2.32e-12	Mean corpuscular volume;
TGCT	cis	rs7412746	0.658	rs1027699	chr1:150811712	T/C	cg09365446	chr1:150670422	GOLPH3L	0.35	5.13	0.42	1.1e-6	Melanoma;
TGCT	cis	rs17221829	0.626	rs10830305	chr11:89366794	T/C	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.65	-0.39	8.43e-6	Anxiety in major depressive disorder;
TGCT	cis	rs3733585	0.578	rs6837224	chr4:9955255	G/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.7	-0.52	6.62e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs2486288	0.656	rs8024620	chr15:45574329	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.45	-5.33	-0.43	4.53e-7	Glomerular filtration rate;
TGCT	cis	rs7909074	0.691	rs11239274	chr10:45393219	A/C	cg05187965	chr10:45406764	TMEM72	0.23	4.8	0.4	4.46e-6	Mean corpuscular volume;
TGCT	cis	rs2235642	0.821	rs2281236	chr16:1603576	G/A	cg00463982	chr16:1583984	IFT140;TMEM204	-0.29	-5.06	-0.41	1.46e-6	Coronary artery disease;
TGCT	cis	rs12472274	1.000	rs12472274	chr2:239095422	G/A	cg17459225	chr2:239074497	NA	0.33	4.84	0.4	3.79e-6	Phospholipid levels (plasma);
TGCT	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg06238570	chr21:40685208	BRWD1	0.67	5.95	0.47	2.5e-8	Cognitive function;
TGCT	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg14159672	chr1:205819179	PM20D1	0.6	7.24	0.55	4.04e-11	Menarche (age at onset);
TGCT	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg24846343	chr22:24311635	DDTL	0.23	5.96	0.47	2.47e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.46	0.56	1.3e-11	Prudent dietary pattern;
TGCT	cis	rs2303759	0.918	rs8107548	chr19:49870643	T/C	cg22307029	chr19:49891270	CCDC155	0.56	5.28	0.43	5.56e-7	Multiple sclerosis;
TGCT	cis	rs6987853	0.931	rs3099936	chr8:42384331	C/T	cg20539142	chr8:42623718	CHRNA6	0.21	5.03	0.41	1.69e-6	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg13395646	chr4:1353034	KIAA1530	-0.41	-5.04	-0.41	1.58e-6	Longevity;
TGCT	cis	rs6665290	0.904	rs1186	chr1:227177731	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.01	-20.94	-0.88	1.57e-42	Myeloid white cell count;
TGCT	cis	rs12579753	1.000	rs11115017	chr12:82176914	C/A	cg07988820	chr12:82153109	PPFIA2	-0.65	-6.79	-0.52	4.09e-10	Resting heart rate;
TGCT	cis	rs6840360	1.000	rs2840130	chr4:152600699	T/C	cg17479576	chr4:152424074	FAM160A1	-0.52	-5.59	-0.45	1.37e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs36093844	0.898	rs12361645	chr11:85595106	C/G	cg25872744	chr11:85566296	CCDC83	-0.51	-4.98	-0.41	2.11e-6	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
TGCT	cis	rs473651	0.935	rs540636	chr2:239358341	T/C	cg08773314	chr2:239334832	ASB1	0.44	7.18	0.54	5.53e-11	Multiple system atrophy;
TGCT	cis	rs1150668	0.799	rs9301	chr6:28292706	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.47	-4.65	-0.39	8.37e-6	Pubertal anthropometrics;
TGCT	cis	rs2762353	0.806	rs6909187	chr6:25785925	C/T	cg03264133	chr6:25882463	NA	0.48	4.97	0.41	2.19e-6	Blood metabolite levels;
TGCT	cis	rs7772486	0.790	rs9403749	chr6:146162239	A/G	cg05347473	chr6:146136440	FBXO30	0.52	4.87	0.4	3.39e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2153535	0.580	rs1932285	chr6:8477719	T/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs2836974	0.831	rs4375956	chr21:40521788	G/A	cg11644478	chr21:40555479	PSMG1	1.05	11.19	0.71	1.6e-20	Cognitive function;
TGCT	cis	rs72945132	1.000	rs72945127	chr11:70107650	A/G	cg00319359	chr11:70116639	PPFIA1	0.98	7.06	0.54	1.04e-10	Coronary artery disease;
TGCT	cis	rs2180341	0.924	rs877661	chr6:127587915	T/G	cg24812749	chr6:127587940	RNF146	0.98	7.64	0.57	5.06e-12	Breast cancer;
TGCT	cis	rs7267979	1.000	rs13038834	chr20:25441433	C/T	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg00343986	chr7:65444356	GUSB	0.23	5.14	0.42	1.06e-6	Aortic root size;
TGCT	cis	rs4808199	0.895	rs2285628	chr19:19467996	T/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.65	4.79	0.39	4.73e-6	Nonalcoholic fatty liver disease;
TGCT	cis	rs9911578	0.765	rs66954617	chr17:56999427	A/G	cg12560992	chr17:57184187	TRIM37	0.76	9.21	0.64	1.03e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg04155289	chr7:94953770	PON1	-0.37	-5.97	-0.47	2.28e-8	Paraoxonase activity;
TGCT	cis	rs6547741	1.000	rs6750943	chr2:27777904	T/G	cg27432699	chr2:27873401	GPN1	0.18	4.66	0.39	8.09e-6	Oral cavity cancer;
TGCT	cis	rs6840360	1.000	rs10019048	chr4:152603615	A/G	cg17479576	chr4:152424074	FAM160A1	-0.45	-4.72	-0.39	6.36e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs12286929	0.576	rs2275997	chr11:115100186	A/G	cg04580443	chr11:115547056	NA	-0.24	-4.67	-0.39	7.86e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs10927875	0.894	rs34957618	chr1:16320499	G/C	cg21385522	chr1:16154831	NA	-0.63	-7.07	-0.54	9.8e-11	Dilated cardiomyopathy;
TGCT	cis	rs8038465	0.638	rs12594175	chr15:73973186	C/T	cg15420318	chr15:73925796	NPTN	0.72	7.93	0.58	1.09e-12	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg24531977	chr5:56204891	C5orf35	-0.77	-7.61	-0.56	5.83e-12	Initial pursuit acceleration;
TGCT	cis	rs2075371	1.000	rs2544218	chr7:133992315	C/A	cg11752832	chr7:134001865	SLC35B4	0.69	6.32	0.49	4.19e-9	Mean platelet volume;
TGCT	trans	rs797680	0.856	rs11164880	chr1:93658096	A/C	cg27528825	chr2:159282178	CCDC148	-0.35	-6.81	-0.52	3.79e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs5769765	0.837	rs8142737	chr22:50291889	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.39	5.92	0.47	2.96e-8	Schizophrenia;
TGCT	cis	rs12142240	0.698	rs6703374	chr1:46862332	C/G	cg00530320	chr1:46809349	NSUN4	0.29	5.79	0.46	5.34e-8	Menopause (age at onset);
TGCT	cis	rs76878669	0.561	rs4930179	chr11:66157432	C/T	cg18002602	chr11:66138449	SLC29A2	0.53	6.49	0.5	1.87e-9	Educational attainment (years of education);
TGCT	cis	rs6430585	0.697	rs115944351	chr2:136515458	G/A	cg07169764	chr2:136633963	MCM6	1.21	11.47	0.72	3.36e-21	Corneal structure;
TGCT	cis	rs35146811	0.735	rs1727133	chr7:99812870	C/T	cg13334819	chr7:99746414	C7orf59	0.74	6.31	0.49	4.4e-9	Coronary artery disease;
TGCT	cis	rs13191362	0.507	rs2849518	chr6:163134248	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.58	-5.27	-0.43	5.86e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg22857025	chr5:266934	NA	-0.34	-6.67	-0.51	7.72e-10	Breast cancer;
TGCT	cis	rs62388641	0.539	rs56016631	chr6:1542575	T/G	cg01806741	chr6:1527072	NA	-0.31	-4.72	-0.39	6.14e-6	Daytime sleep phenotypes;
TGCT	cis	rs6964587	0.626	rs35849169	chr7:91507313	A/G	cg17063962	chr7:91808500	NA	0.72	6.92	0.53	2.16e-10	Breast cancer;
TGCT	cis	rs16867321	0.639	rs12466770	chr2:181441312	C/G	cg23363182	chr2:181467187	NA	0.41	6.04	0.48	1.69e-8	Obesity;
TGCT	cis	rs938554	0.513	rs10939650	chr4:9998440	C/T	cg11266682	chr4:10021025	SLC2A9	0.51	5.09	0.42	1.28e-6	Blood metabolite levels;
TGCT	cis	rs7267979	0.966	rs6083817	chr20:25343998	G/C	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.79	6.02	0.48	1.83e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs62244186	0.566	rs6766221	chr3:44882784	C/T	cg25151919	chr3:44754333	ZNF502	-0.47	-5.44	-0.44	2.77e-7	Depressive symptoms;
TGCT	cis	rs1371867	0.846	rs1788205	chr8:101306546	G/C	cg06636551	chr8:101224915	SPAG1	-0.48	-6.52	-0.51	1.62e-9	Atrioventricular conduction;
TGCT	trans	rs10504390	0.656	rs76479008	chr8:66486620	G/T	cg26037026	chr7:1641922	NA	-0.64	-6.84	-0.52	3.26e-10	IgG glycosylation;
TGCT	cis	rs11190604	0.673	rs10883498	chr10:102228709	T/A	cg23241863	chr10:102295624	HIF1AN	0.62	4.87	0.4	3.27e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs8072100	0.667	rs1912485	chr17:45515678	T/G	cg08085267	chr17:45401833	C17orf57	-0.52	-5.75	-0.46	6.48e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs2933343	1.000	rs6785869	chr3:128643144	G/A	cg11901034	chr3:128598214	ACAD9	-0.63	-5.13	-0.42	1.08e-6	IgG glycosylation;
TGCT	cis	rs707040	1.000	rs10175148	chr2:155215213	T/C	cg18104148	chr2:154337490	NA	0.19	4.76	0.39	5.21e-6	Sudden cardiac arrest;
TGCT	cis	rs1153858	1.000	rs12101539	chr15:45650666	C/G	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.62e-8	Homoarginine levels;
TGCT	cis	rs3862030	0.503	rs10786673	chr10:104280537	G/A	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
TGCT	cis	rs6988636	0.901	rs16898076	chr8:124187721	T/C	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg14893161	chr1:205819251	PM20D1	0.55	7.8	0.57	2.23e-12	Menarche (age at onset);
TGCT	cis	rs1865760	0.516	rs9358903	chr6:26061949	A/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.77	7.45	0.56	1.42e-11	Height;
TGCT	cis	rs7312933	0.703	rs11181380	chr12:42616040	A/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.53	4.62	0.38	9.51e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs2880765	0.835	rs11633604	chr15:86031579	T/G	cg13263323	chr15:86062960	AKAP13	-0.22	-4.79	-0.4	4.68e-6	Coronary artery disease;
TGCT	cis	rs4566357	1.000	rs7567789	chr2:227922104	T/C	cg11843606	chr2:227700838	RHBDD1	-0.58	-5.31	-0.43	4.92e-7	Coronary artery disease;
TGCT	cis	rs3008870	0.727	rs11208971	chr1:67383901	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.8	8.47	0.61	5.86e-14	Lymphocyte percentage of white cells;
TGCT	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.31	-4.82	-0.4	4.12e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2486012	0.649	rs39722	chr1:44285663	G/C	cg12908607	chr1:44402522	ARTN	-0.73	-5.32	-0.43	4.64e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7100689	0.646	rs1340384	chr10:82088702	T/A	cg01528321	chr10:82214614	TSPAN14	0.75	7.49	0.56	1.15e-11	Post bronchodilator FEV1;
TGCT	cis	rs17767294	0.708	rs72851138	chr6:28042654	C/T	cg08851530	chr6:28072375	NA	1.56	7.21	0.54	4.9e-11	Parkinson's disease;
TGCT	cis	rs11031096	0.542	rs7924984	chr11:3974588	C/T	cg18678763	chr11:4115507	RRM1	-0.43	-5.24	-0.43	6.8e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs11122272	0.735	rs2749699	chr1:231520279	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.13	-0.54	7.33e-11	Hemoglobin concentration;
TGCT	cis	rs7777754	0.512	rs7785224	chr7:50562361	T/C	cg18232548	chr7:50535776	DDC	-0.4	-6.23	-0.49	6.7e-9	Response to zileuton treatment in asthma (FEV1 change interaction);
TGCT	cis	rs881375	0.867	rs6478487	chr9:123672777	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	4.97	0.41	2.19e-6	Rheumatoid arthritis;
TGCT	cis	rs4242434	0.672	rs3758041	chr8:22486987	A/G	cg03733263	chr8:22462867	KIAA1967	0.98	13.14	0.76	2.97e-25	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs2921073	0.510	rs2976945	chr8:8270871	G/T	cg15556689	chr8:8085844	FLJ10661	0.71	6.24	0.49	6.43e-9	Parkinson's disease;
TGCT	cis	rs1801251	1.000	rs6717841	chr2:233590255	C/T	cg25237894	chr2:233734115	C2orf82	0.32	5.81	0.46	4.94e-8	Coronary artery disease;
TGCT	cis	rs68170813	0.652	rs763386	chr7:107196723	T/C	cg02696742	chr7:106810147	HBP1	-0.59	-4.71	-0.39	6.61e-6	Coronary artery disease;
TGCT	cis	rs1215050	0.791	rs548892	chr4:98724701	C/T	cg05340658	chr4:99064831	C4orf37	0.44	5.63	0.45	1.15e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2404602	0.647	rs11072620	chr15:77048770	T/A	cg23625390	chr15:77176239	SCAPER	-0.38	-4.79	-0.39	4.75e-6	Blood metabolite levels;
TGCT	cis	rs986417	0.818	rs10142842	chr14:61085205	C/T	cg27398547	chr14:60952738	C14orf39	-1.33	-9.93	-0.67	1.82e-17	Gut microbiota (bacterial taxa);
TGCT	cis	rs40363	0.723	rs2379831	chr16:3538927	T/C	cg22508957	chr16:3507546	NAT15	-0.54	-4.89	-0.4	3.04e-6	Tuberculosis;
TGCT	cis	rs10493773	0.748	rs6576784	chr1:86149476	G/A	cg17807903	chr1:86174739	ZNHIT6	-0.43	-6.18	-0.49	8.29e-9	Urate levels in overweight individuals;
TGCT	cis	rs8020441	0.588	rs45558232	chr14:51188754	C/T	cg04730355	chr14:51134070	SAV1	1.04	7.27	0.55	3.55e-11	Cognitive performance;
TGCT	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7666738	0.830	rs6817645	chr4:99016054	T/C	cg17366294	chr4:99064904	C4orf37	0.68	7.04	0.53	1.17e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4803455	0.565	rs1025497	chr19:41871254	A/G	cg09537434	chr19:41945824	ATP5SL	-0.55	-5.44	-0.44	2.76e-7	Migraine;Coronary artery disease;
TGCT	cis	rs244731	1.000	rs244731	chr5:176539679	C/T	cg16006841	chr5:176797999	RGS14	0.49	6.28	0.49	5.12e-9	Urate levels in lean individuals;
TGCT	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg11644478	chr21:40555479	PSMG1	0.64	5.85	0.47	4.05e-8	Cognitive function;
TGCT	cis	rs2688608	0.617	rs6480709	chr10:75479125	T/C	cg15838173	chr10:75533400	FUT11	-0.31	-5.16	-0.42	9.66e-7	Inflammatory bowel disease;
TGCT	cis	rs12497850	0.897	rs6446252	chr3:48911125	C/T	cg06212747	chr3:49208901	KLHDC8B	0.61	5.62	0.45	1.2e-7	Parkinson's disease;
TGCT	cis	rs9611565	0.546	rs739134	chr22:42089623	T/C	cg06634786	chr22:41940651	POLR3H	0.9	9.03	0.63	2.7e-15	Vitiligo;
TGCT	cis	rs514406	0.683	rs10157120	chr1:53210888	A/G	cg24675658	chr1:53192096	ZYG11B	-0.81	-9.87	-0.66	2.57e-17	Monocyte count;
TGCT	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg25767906	chr1:53392781	SCP2	0.49	5.52	0.44	1.87e-7	Monocyte count;
TGCT	cis	rs12188164	0.965	rs72717435	chr5:448202	G/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.4	-4.6	-0.38	1.01e-5	Cystic fibrosis severity;
TGCT	cis	rs9549367	0.826	rs35306827	chr13:113869045	G/A	cg18105134	chr13:113819100	PROZ	-0.36	-5.81	-0.46	4.84e-8	Platelet distribution width;
TGCT	cis	rs6430585	0.702	rs2015532	chr2:136555525	G/T	cg07169764	chr2:136633963	MCM6	-1.2	-11.43	-0.72	4.14e-21	Corneal structure;
TGCT	cis	rs7959452	0.640	rs4761154	chr12:69705362	A/G	cg20891283	chr12:69753455	YEATS4	-0.66	-6.57	-0.51	1.26e-9	Blood protein levels;
TGCT	cis	rs968451	1.000	rs57078777	chr22:39697458	A/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.87	7.73	0.57	3.17e-12	Primary biliary cholangitis;
TGCT	cis	rs752590	0.806	rs4849174	chr2:113973467	T/C	cg27425262	chr2:113953981	PSD4;LOC440839	0.39	4.6	0.38	1.01e-5	Mucinous ovarian carcinoma;
TGCT	cis	rs9467773	0.836	rs1977198	chr6:26466225	A/C	cg05738196	chr6:26577821	NA	0.66	7.01	0.53	1.35e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg26116260	chr4:7069785	GRPEL1	0.83	6.2	0.49	7.55e-9	Monocyte percentage of white cells;
TGCT	cis	rs9952991	0.566	rs7241016	chr18:12880206	A/G	cg23544223	chr18:12777786	NA	-0.5	-4.51	-0.38	1.51e-5	Inflammatory skin disease;
TGCT	cis	rs60871478	0.545	rs35400476	chr7:795686	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.44	4.44	0.37	1.96e-5	Cerebrospinal P-tau181p levels;
TGCT	cis	rs3796352	1.000	rs11707780	chr3:53084326	A/G	cg07884673	chr3:53033167	SFMBT1	-0.54	-5.95	-0.47	2.57e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs4689388	0.609	rs4234729	chr4:6286087	T/C	cg25554036	chr4:6271136	WFS1	0.56	6.72	0.52	5.99e-10	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs1903068	0.785	rs10020668	chr4:55996903	C/T	cg09978860	chr4:56023921	NA	0.55	6.11	0.48	1.17e-8	Endometriosis;
TGCT	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg18305652	chr10:134549665	INPP5A	0.31	4.98	0.41	2.09e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs11018874	0.597	rs4393275	chr11:89886397	C/T	cg14505434	chr11:89522851	NA	0.39	4.5	0.37	1.52e-5	White blood cell types;
TGCT	cis	rs9467773	0.869	rs1796520	chr6:26410800	C/T	cg15659132	chr6:26577336	NA	-0.53	-5.59	-0.45	1.35e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs732765	0.774	rs67212334	chr14:75317699	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.61	-5.19	-0.42	8.27e-7	Non-small cell lung cancer;
TGCT	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg17747265	chr1:1875780	NA	-0.42	-8.11	-0.59	4.18e-13	Body mass index;
TGCT	cis	rs4972806	0.814	rs6710370	chr2:177045969	T/C	cg13092806	chr2:177043255	NA	0.54	4.88	0.4	3.23e-6	IgG glycosylation;
TGCT	cis	rs11172134	0.508	rs7398426	chr12:57576370	A/C	cg19258868	chr12:57585184	LRP1	-0.31	-5.93	-0.47	2.76e-8	Urate levels in overweight individuals;
TGCT	cis	rs2637266	0.905	rs60809084	chr10:78374431	A/C	cg18941641	chr10:78392320	NA	0.43	5.37	0.43	3.74e-7	Pulmonary function;
TGCT	cis	rs9814567	1.000	rs6801596	chr3:134252114	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.92	-9.2	-0.64	1.11e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs2708977	0.665	rs772173	chr2:97000396	C/T	cg14837825	chr2:96917567	TMEM127	-0.28	-4.46	-0.37	1.81e-5	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs727563	0.635	rs5758444	chr22:42133921	T/A	cg17554472	chr22:41940697	POLR3H	0.46	4.72	0.39	6.36e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs854765	0.929	rs854766	chr17:18012775	A/G	cg04398451	chr17:18023971	MYO15A	-0.3	-4.72	-0.39	6.32e-6	Total body bone mineral density;
TGCT	cis	rs4319547	0.956	rs10744275	chr12:123048618	A/G	cg23029597	chr12:123009494	RSRC2	-0.31	-5.1	-0.42	1.24e-6	Body mass index;
TGCT	cis	rs17761864	1.000	rs1555569	chr17:2149425	A/C	cg02171503	chr17:1588363	PRPF8	-0.47	-4.48	-0.37	1.64e-5	Esophageal cancer (squamous cell);
TGCT	cis	rs11971779	0.941	rs4732368	chr7:139034207	A/C	cg07862535	chr7:139043722	LUC7L2	0.79	5.97	0.47	2.38e-8	Diisocyanate-induced asthma;
TGCT	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg11494091	chr17:61959527	GH2	-0.61	-14.81	-0.8	3.39e-29	Prudent dietary pattern;
TGCT	cis	rs7666738	0.830	rs13129479	chr4:98987860	T/C	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3099143	1.000	rs1913001	chr15:77179408	A/C	cg21673338	chr15:77095150	SCAPER	0.54	5.15	0.42	1.01e-6	Recalcitrant atopic dermatitis;
TGCT	cis	rs12477438	0.798	rs12468419	chr2:99579680	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-5.43	-0.44	2.89e-7	Chronic sinus infection;
TGCT	cis	rs12971120	0.947	rs34676212	chr18:72170006	A/G	cg26446133	chr18:72167187	CNDP2	-0.4	-7.74	-0.57	3.07e-12	Refractive error;
TGCT	cis	rs9393692	0.676	rs806977	chr6:26189615	A/G	cg00631329	chr6:26305371	NA	-0.32	-4.65	-0.39	8.31e-6	Educational attainment;
TGCT	cis	rs9611565	1.000	rs5758314	chr22:41762523	T/G	cg13695892	chr22:41940480	POLR3H	-0.71	-6.96	-0.53	1.71e-10	Vitiligo;
TGCT	cis	rs2303745	0.589	rs7246262	chr19:17392483	C/G	cg04248312	chr19:17393744	ANKLE1	-0.33	-5.55	-0.45	1.62e-7	Systemic lupus erythematosus;
TGCT	cis	rs17102423	0.533	rs3783715	chr14:65490018	C/G	cg11161011	chr14:65562177	MAX	-0.46	-5.33	-0.43	4.45e-7	Obesity-related traits;
TGCT	cis	rs2153535	0.580	rs1119688	chr6:8460850	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg17054783	chr10:134559939	INPP5A	0.25	4.74	0.39	5.75e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs1843834	0.539	rs3912999	chr2:225390089	C/T	cg22455342	chr2:225449267	CUL3	1.01	10.41	0.68	1.25e-18	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs9611565	0.512	rs1983576	chr22:42166486	G/A	cg06634786	chr22:41940651	POLR3H	0.85	8.15	0.59	3.41e-13	Vitiligo;
TGCT	cis	rs1348850	0.872	rs12991272	chr2:178457339	T/C	cg22681709	chr2:178499509	PDE11A	-0.45	-5.28	-0.43	5.7e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs2692947	0.726	rs13009727	chr2:96769883	C/G	cg23100626	chr2:96804247	ASTL	-0.39	-4.59	-0.38	1.05e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs698813	0.674	rs6544753	chr2:44501895	A/T	cg00619915	chr2:44497795	NA	-0.22	-5.06	-0.41	1.48e-6	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
TGCT	cis	rs200810	0.694	rs13211103	chr6:98022156	T/A	cg16511841	chr6:97730490	C6orf167;MIR548H3	-0.64	-4.45	-0.37	1.91e-5	Body mass index;
TGCT	cis	rs35306767	0.715	rs11253550	chr10:1028288	C/G	cg20503657	chr10:835505	NA	0.59	6.67	0.51	7.75e-10	Eosinophil percentage of granulocytes;
TGCT	cis	rs74233809	1.000	rs11191472	chr10:104707016	A/T	cg05855489	chr10:104503620	C10orf26	0.75	4.47	0.37	1.72e-5	Birth weight;
TGCT	cis	rs11098499	0.865	rs28845498	chr4:120405186	G/A	cg09307838	chr4:120376055	NA	0.69	6.64	0.51	8.97e-10	Corneal astigmatism;
TGCT	cis	rs7312933	0.703	rs11181378	chr12:42600658	T/C	cg19980929	chr12:42632907	YAF2	0.47	6.46	0.5	2.13e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.01	8.32	0.6	1.34e-13	Platelet count;
TGCT	cis	rs425277	1.000	rs262665	chr1:2083173	A/G	cg03732007	chr1:2071316	PRKCZ	0.26	5.44	0.44	2.77e-7	Height;
TGCT	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.73	-0.39	5.93e-6	Prudent dietary pattern;
TGCT	cis	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg07636037	chr3:49044803	WDR6	0.65	5.75	0.46	6.7e-8	Resting heart rate;
TGCT	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg20607798	chr8:58055168	NA	0.44	4.45	0.37	1.9e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9443645	0.808	rs9361484	chr6:79758218	C/A	cg09184832	chr6:79620586	NA	-0.47	-5.11	-0.42	1.19e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9467711	0.606	rs16891727	chr6:26488860	C/A	cg16898833	chr6:26189333	HIST1H4D	0.94	4.58	0.38	1.12e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs79349575	0.811	rs12601072	chr17:46997998	T/C	cg26022315	chr17:47021804	SNF8	0.49	4.89	0.4	3.03e-6	Type 2 diabetes;
TGCT	cis	rs9394438	0.529	rs10947681	chr6:37547073	C/A	cg00985040	chr6:37553208	NA	-0.28	-5.67	-0.45	9.41e-8	IgG glycosylation;
TGCT	cis	rs6665290	0.669	rs3768423	chr1:227177293	G/A	cg10327440	chr1:227177885	CDC42BPA	-0.9	-14.92	-0.8	1.84e-29	Myeloid white cell count;
TGCT	cis	rs7267979	1.000	rs4815408	chr20:25346678	C/T	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg20637647	chr7:64974828	NA	1.0	5.59	0.45	1.4e-7	Diabetic kidney disease;
TGCT	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	16.07	0.82	4.21e-32	Prudent dietary pattern;
TGCT	cis	rs877282	0.786	rs10904558	chr10:797509	C/T	cg17470449	chr10:769945	NA	0.29	4.64	0.38	8.77e-6	Uric acid levels;
TGCT	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg04414720	chr1:150670196	GOLPH3L	0.39	5.04	0.41	1.58e-6	Tonsillectomy;
TGCT	cis	rs13088281	1.000	rs13088281	chr3:53147576	A/C	cg27565382	chr3:53032988	SFMBT1	-0.49	-5.82	-0.46	4.68e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7666738	0.791	rs1115615	chr4:99006614	G/A	cg17366294	chr4:99064904	C4orf37	0.71	7.3	0.55	3.08e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7208859	0.623	rs73269988	chr17:29118145	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs939574	1.000	rs9989854	chr2:220086280	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-1.03	-6.63	-0.51	9.19e-10	Platelet distribution width;
TGCT	cis	rs2439831	1.000	rs2264239	chr15:43765533	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.01	8.37	0.6	1.02e-13	Lung cancer in ever smokers;
TGCT	cis	rs12548874	0.618	rs10100651	chr8:95887225	G/C	cg13393036	chr8:95962371	TP53INP1	-0.53	-6.28	-0.49	5.19e-9	Hemoglobin concentration;
TGCT	cis	rs860554	0.960	rs832143	chr1:201262755	G/T	cg01022117	chr1:201258280	PKP1	0.31	4.85	0.4	3.6e-6	Panic disorder;
TGCT	cis	rs12048904	0.505	rs10493936	chr1:101213335	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.63	-5.4	-0.44	3.27e-7	Multiple sclerosis;
TGCT	cis	rs4731207	0.561	rs12706631	chr7:124586580	G/A	cg10503827	chr7:124401702	GPR37	-0.21	-4.53	-0.38	1.37e-5	Cutaneous malignant melanoma;
TGCT	cis	rs11190604	1.000	rs7073586	chr10:102307671	A/G	cg16342193	chr10:102329863	NA	-0.43	-4.94	-0.41	2.47e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	trans	rs12001652	0.579	rs7029792	chr9:14018144	C/G	cg16456503	chr16:67943052	PSKH1	-0.44	-6.75	-0.52	5.03e-10	Carotid plaque burden;
TGCT	cis	rs1865760	0.534	rs2032444	chr6:26046744	T/G	cg17042849	chr6:26104293	HIST1H4C	-0.82	-7.09	-0.54	8.83e-11	Height;
TGCT	cis	rs546131	0.642	rs523246	chr11:34845011	C/G	cg06937548	chr11:34938143	PDHX;APIP	0.54	4.76	0.39	5.38e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs2673604	0.513	rs2673606	chr8:133409932	C/T	cg05740582	chr8:133573933	HPYR1	-0.31	-4.48	-0.37	1.65e-5	Interleukin-8 levels;
TGCT	cis	rs877282	0.945	rs10904555	chr10:787740	C/A	cg17470449	chr10:769945	NA	0.3	4.71	0.39	6.53e-6	Uric acid levels;
TGCT	cis	rs2014572	0.967	rs10426174	chr19:57756055	G/A	cg24459738	chr19:57751996	ZNF805	-0.54	-5.4	-0.44	3.21e-7	Hyperactive-impulsive symptoms;
TGCT	cis	rs57994353	0.793	rs35531907	chr9:139327143	C/T	cg13741927	chr9:139327495	INPP5E	-0.27	-6.26	-0.49	5.81e-9	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs9916302	0.904	rs4795359	chr17:37573146	C/T	cg15445000	chr17:37608096	MED1	0.34	4.8	0.4	4.43e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs77808099	0.590	rs74654914	chr1:15936119	T/C	cg05660106	chr1:15850417	CASP9	0.86	4.47	0.37	1.71e-5	Alcoholic chronic pancreatitis;
TGCT	cis	rs7208859	0.673	rs11080135	chr17:29176481	A/G	cg18442181	chr17:29233375	C17orf42	-0.78	-4.61	-0.38	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7655841	0.504	rs337279	chr4:130028426	G/T	cg26347359	chr4:129759716	PHF17	-0.45	-6.09	-0.48	1.3e-8	Chronic obstructive pulmonary disease (moderate to severe);
TGCT	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.55	4.92	0.4	2.74e-6	Prudent dietary pattern;
TGCT	cis	rs10782582	0.569	rs1770892	chr1:76389359	T/C	cg03433033	chr1:76189801	ACADM	-0.46	-4.56	-0.38	1.19e-5	Daytime sleep phenotypes;
TGCT	cis	rs16957091	0.647	rs4274403	chr15:43345047	T/C	cg17935677	chr15:44119062	WDR76	0.56	4.9	0.4	2.93e-6	MGMT methylation in smokers;
TGCT	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg17178900	chr1:205818956	PM20D1	0.67	8.98	0.63	3.58e-15	Menarche (age at onset);
TGCT	cis	rs4506170	1.000	rs16902102	chr8:128340221	C/A	cg07795030	chr8:128802207	NA	-0.21	-4.61	-0.38	9.7e-6	Prostate cancer;
TGCT	cis	rs1552244	0.608	rs6764807	chr3:9998803	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.31	-4.82	-0.4	4.12e-6	Alzheimer's disease;
TGCT	cis	rs2075371	1.000	rs2075373	chr7:133984683	A/C	cg11752832	chr7:134001865	SLC35B4	0.69	6.32	0.49	4.19e-9	Mean platelet volume;
TGCT	cis	rs4919694	1.000	rs112809537	chr10:104670346	C/T	cg04362960	chr10:104952993	NT5C2	1.06	7.07	0.54	9.73e-11	Arsenic metabolism;
TGCT	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg20203395	chr5:56204925	C5orf35	-0.58	-4.87	-0.4	3.34e-6	Initial pursuit acceleration;
TGCT	cis	rs7666738	0.830	rs2865951	chr4:99040191	C/T	cg18180107	chr4:99064573	C4orf37	0.55	5.02	0.41	1.79e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs617219	0.737	rs12659709	chr5:78458257	C/G	cg23987322	chr5:78407566	BHMT	0.37	4.95	0.41	2.38e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs7681440	0.775	rs6848181	chr4:90807252	T/C	cg20003494	chr4:90757398	SNCA	-0.62	-5.94	-0.47	2.7e-8	Dementia with Lewy bodies;
TGCT	cis	rs7937682	0.889	rs516263	chr11:111484719	A/C	cg09085632	chr11:111637200	PPP2R1B	-1.06	-11.52	-0.72	2.48e-21	Primary sclerosing cholangitis;
TGCT	cis	rs9303401	0.659	rs17822837	chr17:56737838	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.58	5.83	0.46	4.6e-8	Cognitive test performance;
TGCT	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg06481639	chr22:41940642	POLR3H	0.62	5.59	0.45	1.4e-7	Vitiligo;
TGCT	cis	rs651907	0.514	rs12636047	chr3:101434449	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.89	10.45	0.68	1.02e-18	Colorectal cancer;
TGCT	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs1805008	0.568	rs76888998	chr16:89884310	G/T	cg08547343	chr16:90038815	CENPBD1;AFG3L1	-0.95	-4.75	-0.39	5.61e-6	Skin colour saturation;
TGCT	cis	rs9325144	0.556	rs34565156	chr12:39028239	G/A	cg13010199	chr12:38710504	ALG10B	-0.51	-4.63	-0.38	9.17e-6	Morning vs. evening chronotype;
TGCT	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg10253484	chr15:75165896	SCAMP2	-0.6	-5.51	-0.44	2.02e-7	Breast cancer;
TGCT	cis	rs5760092	0.755	rs6003959	chr22:24264395	C/T	cg20007245	chr22:24372913	LOC391322	0.8	6.8	0.52	3.87e-10	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs6430585	0.528	rs3098102	chr2:136654833	C/T	cg07169764	chr2:136633963	MCM6	1.16	10.95	0.7	6.06e-20	Corneal structure;
TGCT	cis	rs903263	0.520	rs12756327	chr1:84664640	T/G	cg09664975	chr1:84543551	PRKACB	0.68	5.77	0.46	6.07e-8	Breast cancer (male);
TGCT	cis	rs11098499	0.789	rs12498994	chr4:120250818	A/C	cg09307838	chr4:120376055	NA	0.61	5.91	0.47	3.14e-8	Corneal astigmatism;
TGCT	cis	rs7666738	0.830	rs7663438	chr4:99014582	C/T	cg17366294	chr4:99064904	C4orf37	0.66	6.55	0.51	1.41e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9436747	0.641	rs3790428	chr1:66042078	G/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.55	4.96	0.41	2.32e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs60843830	1.000	rs17713729	chr2:249092	A/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.72	6.76	0.52	4.84e-10	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs7772486	0.738	rs9485039	chr6:146319387	C/T	cg05347473	chr6:146136440	FBXO30	0.55	4.92	0.4	2.68e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7267979	1.000	rs2500424	chr20:25391969	C/T	cg14121845	chr20:25566513	NINL	-0.5	-5.43	-0.44	2.83e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg03351412	chr1:154909251	PMVK	0.53	4.93	0.4	2.6e-6	Prostate cancer;
TGCT	cis	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg22857025	chr5:266934	NA	-0.33	-6.6	-0.51	1.1e-9	Breast cancer;
TGCT	cis	rs28374715	0.578	rs7169543	chr15:41620405	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.9	-14.93	-0.8	1.76e-29	Ulcerative colitis;
TGCT	cis	rs6933660	0.745	rs6912830	chr6:151743629	A/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.5	-4.63	-0.38	8.93e-6	Menarche (age at onset);
TGCT	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs17376456	1.000	rs13185608	chr5:93509688	T/G	cg21475434	chr5:93447410	FAM172A	0.62	4.5	0.37	1.54e-5	Diabetic retinopathy;
TGCT	cis	rs11190604	0.806	rs11190510	chr10:102157175	G/A	cg16005271	chr10:102321736	NA	0.46	4.72	0.39	6.25e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg25660036	chr4:7070649	GRPEL1	-0.67	-5.81	-0.46	4.85e-8	Monocyte percentage of white cells;
TGCT	cis	rs926938	0.527	rs360672	chr1:115483836	C/T	cg12756093	chr1:115239321	AMPD1	0.34	4.97	0.41	2.19e-6	Autism;
TGCT	cis	rs6565180	0.783	rs9888967	chr16:30407979	G/C	cg17640201	chr16:30407289	ZNF48	1.02	10.01	0.67	1.19e-17	Tonsillectomy;
TGCT	cis	rs9291683	0.632	rs11734786	chr4:10041499	A/C	cg11266682	chr4:10021025	SLC2A9	0.64	8.75	0.62	1.31e-14	Bone mineral density;
TGCT	cis	rs1577917	0.958	rs13213899	chr6:86473140	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.48	-0.44	2.28e-7	Response to antipsychotic treatment;
TGCT	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg07507251	chr3:52567010	NT5DC2	0.47	6.88	0.53	2.59e-10	Electroencephalogram traits;
TGCT	cis	rs9372253	0.645	rs7753212	chr6:110700229	T/C	cg00083206	chr6:110721305	DDO	-0.37	-5.33	-0.43	4.43e-7	Platelet distribution width;
TGCT	cis	rs909674	0.731	rs6001594	chr22:39837472	C/T	cg05872129	chr22:39784769	NA	-0.99	-9.43	-0.65	3.04e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs35934224	0.891	rs12158214	chr22:19871691	C/T	cg11182965	chr22:19864308	TXNRD2	-0.31	-4.62	-0.38	9.29e-6	Glaucoma (primary open-angle);
TGCT	cis	rs7208859	0.673	rs11656462	chr17:29160700	G/A	cg18442181	chr17:29233375	C17orf42	-0.8	-4.78	-0.39	4.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.57	-5.01	-0.41	1.79e-6	Prudent dietary pattern;
TGCT	cis	rs864643	0.947	rs704962	chr3:39557120	C/T	cg14968361	chr3:39543547	MOBP	0.46	4.49	0.37	1.62e-5	Attention deficit hyperactivity disorder;
TGCT	cis	rs1153858	0.943	rs28605551	chr15:45641720	C/T	cg14582100	chr15:45693742	SPATA5L1	0.48	5.7	0.46	8.17e-8	Homoarginine levels;
TGCT	cis	rs9952991	0.941	rs2847278	chr18:12778715	C/T	cg23544223	chr18:12777786	NA	0.64	6.12	0.48	1.15e-8	Inflammatory skin disease;
TGCT	cis	rs9291683	0.546	rs10939672	chr4:10052136	A/G	cg11266682	chr4:10021025	SLC2A9	0.59	7.25	0.55	3.92e-11	Bone mineral density;
TGCT	cis	rs9549367	0.789	rs9549698	chr13:113877701	A/G	cg18105134	chr13:113819100	PROZ	-0.36	-5.85	-0.46	4.16e-8	Platelet distribution width;
TGCT	cis	rs9807989	0.507	rs10204757	chr2:102998974	A/C	cg03938978	chr2:103052716	IL18RAP	0.26	5.22	0.42	7.15e-7	Asthma;
TGCT	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg10047753	chr17:41438598	NA	0.95	9.5	0.65	2.09e-16	Menopause (age at onset);
TGCT	cis	rs4727027	0.901	rs66800495	chr7:148763702	T/C	cg23583168	chr7:148888333	NA	-0.69	-8.72	-0.62	1.5e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs7714584	1.000	rs10051804	chr5:150226424	T/C	cg22134413	chr5:150180641	NA	0.87	6.89	0.53	2.52e-10	Crohn's disease;
TGCT	cis	rs11696845	0.666	rs6103849	chr20:43365687	C/T	cg25301532	chr20:43378953	KCNK15	-0.48	-5.03	-0.41	1.68e-6	Obesity-related traits;
TGCT	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg06873352	chr17:61820015	STRADA	0.58	6.37	0.5	3.32e-9	Prudent dietary pattern;
TGCT	cis	rs9325144	0.560	rs10506127	chr12:39126686	C/G	cg26384229	chr12:38710491	ALG10B	-0.62	-5.99	-0.47	2.14e-8	Morning vs. evening chronotype;
TGCT	cis	rs11577318	0.579	rs11247936	chr1:26698884	A/G	cg15090202	chr1:26687087	NA	0.57	4.49	0.37	1.64e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs6490294	0.904	rs9971871	chr12:112408376	T/C	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Mean platelet volume;
TGCT	cis	rs7027203	0.964	rs7854075	chr9:96571211	G/A	cg14598338	chr9:96623480	NA	0.62	8.9	0.62	5.79e-15	DNA methylation (variation);
TGCT	cis	rs28595532	0.844	rs55845920	chr4:119490085	C/T	cg21605333	chr4:119757512	SEC24D	1.33	8.01	0.58	7.07e-13	Cannabis dependence symptom count;
TGCT	cis	rs954108	0.584	rs9314922	chr13:29379229	A/G	cg11788234	chr13:29393811	NA	0.5	7.13	0.54	7.46e-11	Obesity-related traits;
TGCT	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg08048268	chr3:133502702	NA	-0.65	-9.79	-0.66	3.99e-17	Iron status biomarkers;
TGCT	cis	rs9916302	0.904	rs755500	chr17:37409865	C/T	cg07936489	chr17:37558343	FBXL20	-0.56	-4.51	-0.38	1.47e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.44	-5.51	-0.44	2e-7	Alzheimer's disease;
TGCT	cis	rs681343	0.746	rs633372	chr19:49209226	G/A	cg13540341	chr19:49222985	MAMSTR	-0.36	-4.9	-0.4	2.92e-6	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
TGCT	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg06238570	chr21:40685208	BRWD1	0.69	6.41	0.5	2.71e-9	Cognitive function;
TGCT	cis	rs2842992	0.747	rs733319	chr6:160221475	A/G	cg11366901	chr6:160182831	ACAT2	1.03	6.98	0.53	1.59e-10	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs916888	0.821	rs199506	chr17:44859031	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.7	-4.82	-0.4	4.1e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs6988636	0.710	rs73339623	chr8:124140288	A/G	cg23067535	chr8:124195133	FAM83A	-0.38	-4.8	-0.4	4.53e-6	Urinary uromodulin levels;
TGCT	cis	rs7267979	0.903	rs1118963	chr20:25247449	G/A	cg14121845	chr20:25566513	NINL	0.5	5.51	0.44	1.95e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs8020441	1.000	rs72681677	chr14:51173590	T/G	cg04730355	chr14:51134070	SAV1	0.68	5.42	0.44	2.96e-7	Cognitive performance;
TGCT	cis	rs7945705	0.869	rs2742471	chr11:9003953	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.52	-6.01	-0.47	1.93e-8	Hemoglobin concentration;
TGCT	trans	rs1814175	0.817	rs1615305	chr11:49895222	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.34	-0.55	2.4e-11	Height;
TGCT	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg03264133	chr6:25882463	NA	-0.57	-6.08	-0.48	1.37e-8	Blood metabolite levels;
TGCT	cis	rs896854	0.573	rs11996455	chr8:95853708	G/A	cg23172400	chr8:95962367	TP53INP1	-0.29	-4.44	-0.37	1.97e-5	Type 2 diabetes;
TGCT	cis	rs12135062	1.000	rs12135062	chr1:3103312	A/C	cg21609526	chr1:3105151	PRDM16	0.39	6.62	0.51	9.78e-10	Migraine;
TGCT	cis	rs17384381	0.953	rs11161597	chr1:85784936	G/A	cg16011679	chr1:85725395	C1orf52	0.87	6.73	0.52	5.65e-10	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg13615516	chr5:77269221	NA	0.68	8.54	0.61	3.97e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9549367	0.789	rs12584008	chr13:113881228	C/T	cg18105134	chr13:113819100	PROZ	-0.34	-5.45	-0.44	2.63e-7	Platelet distribution width;
TGCT	cis	rs17331151	0.541	rs11709430	chr3:52862055	G/A	cg11137980	chr3:52469226	SEMA3G	0.27	4.83	0.4	3.98e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	trans	rs629535	0.767	rs62513418	chr8:70114376	G/T	cg21567404	chr3:27674614	NA	-0.56	-9.04	-0.63	2.69e-15	Dupuytren's disease;
TGCT	cis	rs644799	0.544	rs499637	chr11:95569183	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.56	5.43	0.44	2.83e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs1062177	1.000	rs2915869	chr5:151171509	C/T	cg00977110	chr5:151150581	G3BP1	0.4	4.57	0.38	1.16e-5	Preschool internalizing problems;
TGCT	cis	rs35934224	0.783	rs9754418	chr22:19854733	A/G	cg11182965	chr22:19864308	TXNRD2	-0.36	-4.95	-0.41	2.33e-6	Glaucoma (primary open-angle);
TGCT	cis	rs911555	0.755	rs4906329	chr14:103942669	A/G	cg23461800	chr14:103021989	NA	-0.35	-4.56	-0.38	1.23e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs12216125	0.537	rs12207059	chr6:25922385	C/T	cg16482183	chr6:26056742	HIST1H1C	0.94	7.28	0.55	3.36e-11	Iron status biomarkers;
TGCT	cis	rs610932	0.517	rs599862	chr11:59972888	G/A	cg18570331	chr11:60101691	MS4A6E	0.52	4.79	0.4	4.6e-6	Alzheimer's disease;
TGCT	cis	rs6121246	0.542	rs6059761	chr20:30110522	G/C	cg13852791	chr20:30311386	BCL2L1	0.68	4.5	0.37	1.52e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg24399712	chr22:39784796	NA	-1.06	-12.58	-0.75	6.72e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs7714584	1.000	rs1863998	chr5:150271753	A/T	cg22134413	chr5:150180641	NA	0.78	6.12	0.48	1.16e-8	Crohn's disease;
TGCT	cis	rs7246657	0.663	rs9304568	chr19:38054508	C/A	cg18154014	chr19:37997991	ZNF793	0.67	4.65	0.39	8.34e-6	Coronary artery calcification;
TGCT	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg13695892	chr22:41940480	POLR3H	-0.91	-9.07	-0.63	2.18e-15	Vitiligo;
TGCT	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg18876405	chr7:65276391	NA	0.31	4.78	0.39	4.81e-6	Aortic root size;
TGCT	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg03188948	chr7:1209495	NA	0.65	5.4	0.44	3.26e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1075232	1.000	rs12440544	chr15:32096504	C/T	cg01030201	chr15:31746330	NA	-0.99	-4.98	-0.41	2.11e-6	Survival in colorectal cancer (non-distant metastatic);
TGCT	cis	rs1538970	1.000	rs2492840	chr1:45849792	C/A	cg05343316	chr1:45956843	TESK2	0.66	5.2	0.42	8.13e-7	Platelet count;
TGCT	trans	rs877282	0.891	rs11253355	chr10:768367	C/G	cg22713356	chr15:30763199	NA	1.19	9.81	0.66	3.75e-17	Uric acid levels;
TGCT	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs11190604	0.767	rs872290	chr10:102198879	G/A	cg16005271	chr10:102321736	NA	0.46	4.68	0.39	7.39e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg10047753	chr17:41438598	NA	0.96	9.49	0.65	2.15e-16	Menopause (age at onset);
TGCT	cis	rs854765	0.547	rs2955383	chr17:17941364	A/G	cg04398451	chr17:18023971	MYO15A	-0.32	-5.15	-0.42	9.85e-7	Total body bone mineral density;
TGCT	cis	rs9467773	0.565	rs4343916	chr6:26522675	A/T	cg05738196	chr6:26577821	NA	0.75	9.2	0.64	1.09e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs2836633	0.929	rs58120977	chr21:40037346	C/T	cg05519781	chr21:40033154	ERG	0.69	6.81	0.52	3.81e-10	Coronary artery disease;
TGCT	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg13695892	chr22:41940480	POLR3H	-0.91	-9.07	-0.63	2.18e-15	Vitiligo;
TGCT	cis	rs131777	0.575	rs131760	chr22:51011936	T/C	cg25309564	chr22:51001381	C22orf41	0.57	5.45	0.44	2.58e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.59	-4.9	-0.4	2.88e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs611744	0.573	rs629996	chr8:109255206	C/T	cg21045802	chr8:109455806	TTC35	0.83	8.71	0.62	1.57e-14	Dupuytren's disease;
TGCT	cis	rs7119	0.634	rs2667782	chr15:77862296	A/C	cg27398640	chr15:77910606	LINGO1	0.27	4.78	0.39	4.84e-6	Type 2 diabetes;
TGCT	cis	rs9916302	0.808	rs12948906	chr17:37644854	C/T	cg15445000	chr17:37608096	MED1	0.31	4.59	0.38	1.06e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs700651	0.675	rs1371665	chr2:198942568	C/T	cg00792783	chr2:198669748	PLCL1	0.54	4.55	0.38	1.28e-5	Intracranial aneurysm;
TGCT	trans	rs208515	0.525	rs10944871	chr6:66690306	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.93	10.3	0.68	2.34e-18	Exhaled nitric oxide levels;
TGCT	cis	rs6460942	1.000	rs77010200	chr7:12290724	G/A	cg06484146	chr7:12443880	VWDE	-0.54	-4.81	-0.4	4.36e-6	Coronary artery disease;
TGCT	cis	rs6570726	0.791	rs436498	chr6:145876347	G/A	cg13319975	chr6:146136371	FBXO30	-0.51	-4.6	-0.38	1.01e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7635838	0.929	rs7638724	chr3:11413387	T/G	cg00170343	chr3:11313890	ATG7	0.61	5.78	0.46	5.68e-8	HDL cholesterol;
TGCT	cis	rs6815814	0.904	rs3924113	chr4:38796255	G/T	cg02016764	chr4:38805732	TLR1	-0.35	-5.27	-0.43	5.82e-7	Breast cancer;
TGCT	cis	rs507506	0.771	rs929229	chr17:7105399	C/T	cg25256661	chr17:7137939	DVL2	0.53	5.1	0.42	1.22e-6	Adiponectin levels;
TGCT	cis	rs7659604	0.540	rs11934307	chr4:122677514	G/A	cg19748678	chr4:122722346	EXOSC9	-0.51	-5.0	-0.41	1.89e-6	Type 2 diabetes;
TGCT	cis	rs1018836	0.892	rs4140680	chr8:91584157	G/A	cg16814680	chr8:91681699	NA	-0.73	-7.41	-0.55	1.67e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs12422267	0.536	rs12303484	chr12:132609558	G/A	cg09764611	chr12:132620959	NA	-0.38	-5.71	-0.46	7.88e-8	Plasma amyloid beta peptide concentrations (ABx-40);
TGCT	cis	rs11585357	0.895	rs72646797	chr1:17613838	C/G	cg08277548	chr1:17600880	PADI3	-0.96	-9.72	-0.66	5.97e-17	Hair shape;
TGCT	cis	rs2243480	0.708	rs13242216	chr7:65898277	T/C	cg07424592	chr7:64974309	NA	1.29	8.01	0.58	7.16e-13	Diabetic kidney disease;
TGCT	cis	rs1018836	0.886	rs10112242	chr8:91642631	G/C	cg16814680	chr8:91681699	NA	-0.8	-8.6	-0.61	2.89e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg08509172	chr19:19383838	TM6SF2	-0.35	-4.63	-0.38	9.18e-6	Tonsillectomy;
TGCT	cis	rs1008375	0.932	rs4698627	chr4:17605959	T/C	cg16339924	chr4:17578868	LAP3	0.68	5.4	0.44	3.24e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs28437878	1	rs28437878	chr15:78807872	C/T	cg06917634	chr15:78832804	PSMA4	-0.69	-5.08	-0.42	1.34e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs782590	0.967	rs17798852	chr2:55805172	A/C	cg18811423	chr2:55921094	PNPT1	0.65	6.93	0.53	2.04e-10	Metabolic syndrome;
TGCT	cis	rs2016266	0.684	rs4759021	chr12:53714868	G/A	cg16917193	chr12:54089295	NA	-0.72	-5.33	-0.43	4.41e-7	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs7524258	0.903	rs6577424	chr1:7292417	C/T	cg04342483	chr1:7259290	CAMTA1	0.31	4.49	0.37	1.6e-5	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs6088580	0.634	rs4911419	chr20:32995873	G/A	cg08999081	chr20:33150536	PIGU	-0.29	-5.65	-0.45	1.02e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs6840360	1.000	rs7439465	chr4:152594814	C/T	cg17479576	chr4:152424074	FAM160A1	0.5	5.19	0.42	8.24e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs786425	0.585	rs10773034	chr12:124234253	A/G	cg10461218	chr12:124144432	GTF2H3	0.22	4.67	0.39	7.73e-6	Pubertal anthropometrics;
TGCT	cis	rs8111998	0.793	rs10411767	chr19:22757883	A/G	cg19914732	chr19:22715077	NA	-0.61	-4.66	-0.39	7.87e-6	Corneal structure;
TGCT	cis	rs11122272	0.735	rs2808600	chr1:231534723	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-6.64	-0.51	8.59e-10	Hemoglobin concentration;
TGCT	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg17554472	chr22:41940697	POLR3H	-0.43	-4.59	-0.38	1.05e-5	Vitiligo;
TGCT	trans	rs1814175	0.817	rs10839358	chr11:49770972	G/A	cg15704280	chr7:45808275	SEPT13	-0.69	-8.05	-0.59	5.61e-13	Height;
TGCT	cis	rs9611565	0.592	rs8779	chr22:42070276	T/C	cg17554472	chr22:41940697	POLR3H	0.49	5.22	0.42	7.4e-7	Vitiligo;
TGCT	cis	rs9486719	0.741	rs2049927	chr6:96848958	C/G	cg18709589	chr6:96969512	KIAA0776	-0.68	-4.67	-0.39	7.79e-6	Migraine;Coronary artery disease;
TGCT	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg03161606	chr19:29218774	NA	0.6	5.79	0.46	5.33e-8	Methadone dose in opioid dependence;
TGCT	cis	rs10782582	0.564	rs17647711	chr1:76241710	C/G	cg10523679	chr1:76189770	ACADM	-0.53	-4.98	-0.41	2.04e-6	Daytime sleep phenotypes;
TGCT	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs34526934	0.566	rs62624470	chr2:177040907	C/T	cg14324370	chr2:177042789	NA	-0.92	-8.73	-0.62	1.45e-14	Obstructive sleep apnea trait (apnea hypopnea index);
TGCT	cis	rs1670533	1.000	rs6857085	chr4:1095920	C/A	cg20887711	chr4:1340912	KIAA1530	-0.7	-5.53	-0.45	1.77e-7	Recombination rate (females);
TGCT	cis	rs6750047	0.546	rs2082255	chr2:38273758	C/A	cg07380506	chr2:38303506	CYP1B1	0.6	5.41	0.44	3.07e-7	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs7552404	0.961	rs211710	chr1:76109038	G/A	cg22875332	chr1:76189707	ACADM	-0.79	-9.64	-0.65	9.57e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs1008375	1.000	rs28693609	chr4:17645233	C/T	cg16339924	chr4:17578868	LAP3	0.61	5.19	0.42	8.41e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs11971779	0.680	rs4728465	chr7:139069061	G/A	cg07862535	chr7:139043722	LUC7L2	0.71	5.55	0.45	1.63e-7	Diisocyanate-induced asthma;
TGCT	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg13695892	chr22:41940480	POLR3H	0.93	9.06	0.63	2.34e-15	Vitiligo;
TGCT	cis	rs2204008	0.837	rs11169157	chr12:37980047	T/C	cg13010199	chr12:38710504	ALG10B	0.61	4.89	0.4	3.05e-6	Bladder cancer;
TGCT	cis	rs16837677	0.826	rs3795737	chr1:156697056	A/G	cg17331738	chr1:156647236	NES	0.73	5.0	0.41	1.9e-6	Sjögren's syndrome;
TGCT	cis	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs7809950	0.953	rs2253271	chr7:107201252	G/C	cg23024343	chr7:107201750	COG5	-0.34	-5.26	-0.43	6.08e-7	Coronary artery disease;
TGCT	cis	rs2933343	0.951	rs9871612	chr3:128570402	C/T	cg11901034	chr3:128598214	ACAD9	-0.6	-4.74	-0.39	5.76e-6	IgG glycosylation;
TGCT	cis	rs533581	0.866	rs865102	chr16:88969969	A/G	cg05579598	chr16:88989069	CBFA2T3	0.34	4.44	0.37	1.94e-5	Social autistic-like traits;
TGCT	cis	rs4746818	0.892	rs2394505	chr10:70871598	A/G	cg11621586	chr10:70884670	VPS26A	-1.07	-8.75	-0.62	1.32e-14	Left atrial antero-posterior diameter;
TGCT	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg05064044	chr6:292385	DUSP22	-0.7	-7.29	-0.55	3.15e-11	Menopause (age at onset);
TGCT	cis	rs3780378	0.967	rs62543876	chr9:5085859	G/C	cg02405213	chr9:5042618	JAK2	-0.58	-7.4	-0.55	1.78e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs10791323	0.627	rs2723614	chr11:133705871	T/G	cg03690763	chr11:133734501	NA	-0.35	-5.32	-0.43	4.6e-7	Childhood ear infection;
TGCT	cis	rs7267979	1.000	rs6037095	chr20:25335687	A/G	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs3780486	0.505	rs10217267	chr9:33146528	T/C	cg20290983	chr6:43655470	MRPS18A	0.77	8.33	0.6	1.28e-13	IgG glycosylation;
TGCT	cis	rs2721195	0.549	rs2620666	chr8:145703413	T/C	cg17328964	chr8:145687451	CYHR1	-0.44	-6.66	-0.51	7.97e-10	Age at first birth;
TGCT	cis	rs1156327	0.655	rs4441251	chr16:19325239	C/T	cg02978544	chr16:19716338	NA	-0.42	-4.46	-0.37	1.82e-5	Periodontal disease-related phenotypes;
TGCT	cis	rs28595532	0.920	rs115154263	chr4:119765307	G/A	cg14228332	chr4:119757509	SEC24D	1.28	6.64	0.51	8.6e-10	Cannabis dependence symptom count;
TGCT	cis	rs2302045	1.000	rs55938551	chr2:242033593	G/A	cg04553960	chr2:241721320	KIF1A	-0.68	-4.61	-0.38	9.94e-6	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio);
TGCT	cis	rs2806561	0.828	rs604030	chr1:23518227	T/C	cg12483005	chr1:23474871	LUZP1	0.38	4.73	0.39	5.93e-6	Height;
TGCT	cis	rs11650494	0.908	rs75092916	chr17:47412578	T/C	cg08112188	chr17:47440006	ZNF652	1.04	5.3	0.43	5.13e-7	Prostate cancer;
TGCT	cis	rs2562456	0.876	rs11085467	chr19:21751843	A/G	cg01304269	chr19:21688519	ZNF429	0.58	4.74	0.39	5.78e-6	Pain;
TGCT	cis	rs3754214	0.857	rs9126	chr1:150259400	A/C	cg09579323	chr1:150459698	TARS2	-0.53	-4.8	-0.4	4.48e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs4566357	0.615	rs2272202	chr2:227914625	C/T	cg11843606	chr2:227700838	RHBDD1	0.54	5.09	0.42	1.27e-6	Coronary artery disease;
TGCT	cis	rs1799899	0.826	rs1800276	chr3:133461551	C/T	cg18342939	chr3:134203408	ANAPC13;CEP63	0.43	4.45	0.37	1.86e-5	Alcohol consumption (transferrin glycosylation);
TGCT	cis	rs8016982	0.674	rs3815953	chr14:81685482	G/A	cg01989461	chr14:81687754	GTF2A1	0.81	8.55	0.61	3.82e-14	Schizophrenia;
TGCT	cis	rs9653442	0.835	rs11885529	chr2:100746935	A/G	cg22139774	chr2:100720529	AFF3	-0.43	-7.47	-0.56	1.27e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs11190604	1.000	rs11190604	chr10:102302457	A/G	cg23241863	chr10:102295624	HIF1AN	0.69	5.06	0.41	1.46e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg08048268	chr3:133502702	NA	-0.65	-9.83	-0.66	3.21e-17	Iron status biomarkers;
TGCT	cis	rs682748	1.000	rs682748	chr5:17148911	A/G	cg23987134	chr5:17158319	LOC285696	-0.23	-5.42	-0.44	2.93e-7	Hippocampal atrophy;
TGCT	cis	rs76419734	1.000	rs111248783	chr4:106770998	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	1.09	4.45	0.37	1.9e-5	Post bronchodilator FEV1;
TGCT	cis	rs3796352	1.000	rs7645611	chr3:53125297	G/C	cg15956490	chr3:53032818	SFMBT1	0.53	6.22	0.49	6.92e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs7809950	1.000	rs7809950	chr7:107237807	T/C	cg23024343	chr7:107201750	COG5	0.33	5.23	0.42	7.06e-7	Coronary artery disease;
TGCT	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg10802521	chr3:52805072	NEK4	-0.78	-10.0	-0.67	1.26e-17	Bipolar disorder;
TGCT	cis	rs4689388	0.926	rs4689391	chr4:6280449	G/A	cg14416269	chr4:6271139	WFS1	0.38	5.23	0.42	7.12e-7	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs2963155	0.518	rs72801090	chr5:142774692	C/T	cg17617527	chr5:142782415	NR3C1	0.86	5.51	0.44	2.02e-7	Breast cancer;
TGCT	cis	rs4788570	0.538	rs72797728	chr16:71552789	C/T	cg06353428	chr16:71660113	MARVELD3	-1.32	-7.58	-0.56	6.9e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs79349575	0.783	rs58591767	chr17:47026076	G/A	cg07967210	chr17:47022446	SNF8	0.44	6.13	0.48	1.1e-8	Type 2 diabetes;
TGCT	trans	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg23505145	chr19:12996616	KLF1	0.79	8.3	0.6	1.47e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2070488	0.775	rs2186457	chr3:38553965	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.65	6.21	0.49	7.21e-9	Electrocardiographic conduction measures;
TGCT	cis	rs60871478	0.636	rs56393680	chr7:885696	A/G	cg00475322	chr7:917719	C7orf20	0.5	4.97	0.41	2.2e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs28595532	0.920	rs115226628	chr4:119639818	A/G	cg14228332	chr4:119757509	SEC24D	1.02	5.37	0.43	3.75e-7	Cannabis dependence symptom count;
TGCT	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg06238570	chr21:40685208	BRWD1	-0.81	-8.52	-0.61	4.6e-14	Cognitive function;
TGCT	cis	rs7474896	0.559	rs10740949	chr10:37978435	A/G	cg25427524	chr10:38739819	LOC399744	-0.31	-4.83	-0.4	3.98e-6	Obesity (extreme);
TGCT	cis	rs16854884	0.837	rs13083068	chr3:143801642	G/T	cg06585982	chr3:143692056	C3orf58	0.62	4.82	0.4	4.11e-6	Economic and political preferences (feminism/equality);
TGCT	cis	rs6714710	0.663	rs71429376	chr2:98534412	T/C	cg26665480	chr2:98280029	ACTR1B	0.64	6.03	0.48	1.71e-8	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs7267979	1.000	rs7343481	chr20:25300113	C/T	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs13256369	0.802	rs13256404	chr8:8562974	T/C	cg17143192	chr8:8559678	CLDN23	0.56	5.31	0.43	4.9e-7	Obesity-related traits;
TGCT	cis	rs6879260	1.000	rs1035411	chr5:179729519	A/G	cg23248424	chr5:179741104	GFPT2	-0.37	-7.04	-0.53	1.16e-10	Height;
TGCT	cis	rs10088262	0.629	rs6990565	chr8:124785645	C/A	cg20713898	chr8:124780851	FAM91A1	-0.83	-6.7	-0.52	6.41e-10	Pancreatic cancer;
TGCT	cis	rs7552404	0.727	rs2172508	chr1:76320215	A/G	cg22875332	chr1:76189707	ACADM	0.58	6.04	0.48	1.7e-8	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs6558530	0.666	rs6558518	chr8:1697309	G/T	cg09410841	chr8:1729607	CLN8	0.69	6.2	0.49	7.73e-9	Systolic blood pressure;
TGCT	cis	rs2228479	0.541	rs62052173	chr16:89950739	T/C	cg06558623	chr16:89946397	TCF25	0.4	4.73	0.39	5.89e-6	Skin colour saturation;
TGCT	cis	rs2956278	0.717	rs2947128	chr12:84689866	C/T	cg25678815	chr12:85673915	ALX1	-0.53	-4.76	-0.39	5.4e-6	Depressive symptoms;Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2721195	0.967	rs1985022	chr8:145684031	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.79	8.23	0.59	2.13e-13	Age at first birth;
TGCT	cis	rs6088580	0.634	rs6059875	chr20:33086090	T/G	cg08999081	chr20:33150536	PIGU	0.28	5.56	0.45	1.61e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs9611565	0.512	rs4820446	chr22:42215684	C/T	cg06634786	chr22:41940651	POLR3H	-0.84	-7.87	-0.58	1.51e-12	Vitiligo;
TGCT	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg18230493	chr5:56204884	C5orf35	0.8	5.92	0.47	2.95e-8	Initial pursuit acceleration;
TGCT	cis	rs6964587	0.967	rs4626516	chr7:91807153	G/C	cg17063962	chr7:91808500	NA	0.88	8.95	0.63	4.42e-15	Breast cancer;
TGCT	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg05368731	chr17:41323189	NBR1	1.21	14.63	0.8	8.89e-29	Menopause (age at onset);
TGCT	cis	rs12458462	0.851	rs3859317	chr18:77443093	A/C	cg11879182	chr18:77439856	CTDP1	0.67	7.67	0.57	4.39e-12	Monocyte count;
TGCT	cis	rs12048904	0.964	rs3188491	chr1:101338482	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.55	5.14	0.42	1.04e-6	Multiple sclerosis;
TGCT	cis	rs78487399	0.710	rs11899863	chr2:43618819	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.42	-4.46	-0.37	1.78e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg25703541	chr22:24373054	LOC391322	-0.91	-11.18	-0.71	1.69e-20	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg05368731	chr17:41323189	NBR1	1.16	13.45	0.77	5.44e-26	Menopause (age at onset);
TGCT	trans	rs1496653	0.602	rs35273607	chr3:23460017	A/G	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs425277	1.000	rs262665	chr1:2083173	A/G	cg24578937	chr1:2090814	PRKCZ	0.32	8.03	0.58	6.41e-13	Height;
TGCT	cis	rs904251	0.802	rs2646933	chr6:37402070	C/G	cg08126542	chr6:37504118	NA	-0.42	-4.74	-0.39	5.8e-6	Cognitive performance;
TGCT	cis	rs9309473	0.607	rs6546826	chr2:73599808	A/G	cg20560298	chr2:73613845	ALMS1	0.41	4.54	0.38	1.31e-5	Metabolite levels;
TGCT	cis	rs11874712	1.000	rs7244950	chr18:43676523	G/C	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	5.23	0.42	7.11e-7	Migraine - clinic-based;
TGCT	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg11494091	chr17:61959527	GH2	0.6	14.51	0.79	1.71e-28	Prudent dietary pattern;
TGCT	cis	rs12643440	0.538	rs1522081	chr4:17135357	T/C	cg22650099	chr4:17144496	NA	-0.46	-4.66	-0.39	8.14e-6	Metabolite levels (Pyroglutamine);
TGCT	cis	rs1008375	0.966	rs2098152	chr4:17684392	G/T	cg18681998	chr4:17616180	MED28	0.92	10.46	0.68	9.72e-19	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2688608	0.592	rs13013	chr10:75562161	C/A	cg04320760	chr10:75533139	FUT11	-0.38	-5.82	-0.46	4.8e-8	Inflammatory bowel disease;
TGCT	cis	rs2797160	0.967	rs2747715	chr6:126007719	A/T	cg05901451	chr6:126070800	HEY2	0.75	6.33	0.49	4.14e-9	Endometrial cancer;
TGCT	cis	rs59197085	0.515	rs73238147	chr7:128469917	T/C	cg00260937	chr7:128520193	KCP	0.48	5.22	0.42	7.33e-7	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
TGCT	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs6840360	0.615	rs2406973	chr4:152608339	G/T	cg22705602	chr4:152727874	NA	0.34	5.7	0.46	8.09e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs1075232	1.000	rs34959140	chr15:31725223	G/A	cg01030201	chr15:31746330	NA	-1.01	-5.26	-0.43	6.07e-7	Survival in colorectal cancer (non-distant metastatic);
TGCT	cis	rs8141529	0.504	rs6005915	chr22:29233262	A/G	cg02153584	chr22:29168773	CCDC117	0.61	4.46	0.37	1.81e-5	Lymphocyte counts;
TGCT	cis	rs7010267	0.596	rs1485285	chr8:120036138	T/C	cg17171407	chr8:119960777	TNFRSF11B	0.26	4.59	0.38	1.06e-5	Total body bone mineral density (age 45-60);
TGCT	cis	rs7666738	0.830	rs2865978	chr4:99017946	G/T	cg18180107	chr4:99064573	C4orf37	0.54	5.03	0.41	1.7e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3087591	1.000	rs2057769	chr17:29691368	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.48	-7.08	-0.54	9.25e-11	Hip circumference;
TGCT	cis	rs6840360	0.615	rs55932132	chr4:152463897	G/T	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.03	-0.58	6.46e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs854765	0.547	rs2955383	chr17:17941364	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.79	8.46	0.6	6.36e-14	Total body bone mineral density;
TGCT	cis	rs9534288	0.659	rs7996394	chr13:46653503	A/C	cg15192986	chr13:46630673	CPB2	-0.53	-6.39	-0.5	3.01e-9	Blood protein levels;
TGCT	cis	rs208520	0.690	rs207077	chr6:66769855	A/C	cg07460842	chr6:66804631	NA	-0.96	-10.26	-0.68	2.92e-18	Exhaled nitric oxide output;
TGCT	cis	rs4517514	0.509	rs10765252	chr11:89875664	C/T	cg05041596	chr11:89867385	NAALAD2	0.52	4.61	0.38	9.86e-6	Trans fatty acid levels;
TGCT	cis	rs2721195	0.549	rs2620666	chr8:145703413	T/C	cg15857475	chr8:145742913	RECQL4;LRRC14	0.86	10.01	0.67	1.17e-17	Age at first birth;
TGCT	cis	rs9733	0.596	rs12063547	chr1:150674053	G/T	cg04414720	chr1:150670196	GOLPH3L	-0.37	-4.99	-0.41	1.95e-6	Tonsillectomy;
TGCT	cis	rs9487051	0.714	rs9487058	chr6:109631060	A/C	cg01475377	chr6:109611718	NA	-0.31	-4.73	-0.39	6.12e-6	Reticulocyte fraction of red cells;
TGCT	cis	rs9325144	0.513	rs7977596	chr12:38649067	C/A	cg26384229	chr12:38710491	ALG10B	-0.66	-6.0	-0.47	2.06e-8	Morning vs. evening chronotype;
TGCT	cis	rs2456568	0.867	rs7114457	chr11:93657817	C/T	cg26875233	chr11:93583750	C11orf90	-0.46	-5.63	-0.45	1.16e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs9814567	0.896	rs1357764	chr3:134344928	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.85	7.73	0.57	3.19e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	trans	rs2727020	0.729	rs2866328	chr11:49282421	A/G	cg03929089	chr4:120376271	NA	0.73	8.48	0.61	5.75e-14	Coronary artery disease;
TGCT	cis	rs6582630	0.555	rs10880602	chr12:38505660	T/C	cg13010199	chr12:38710504	ALG10B	0.56	4.55	0.38	1.25e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs2299587	0.585	rs2285304	chr8:17797931	T/A	cg01800426	chr8:17659068	MTUS1	-0.65	-5.66	-0.45	9.98e-8	Economic and political preferences;
TGCT	cis	rs806215	0.951	rs327521	chr7:127249143	G/A	cg25922125	chr7:127225783	GCC1	0.46	4.74	0.39	5.85e-6	Type 2 diabetes;
TGCT	cis	rs3796352	1.000	rs35737577	chr3:53002557	G/C	cg07884673	chr3:53033167	SFMBT1	0.62	6.19	0.49	8.26e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs9443189	0.570	rs276687	chr6:76429995	G/T	cg01950844	chr6:76311363	SENP6	-0.94	-6.03	-0.48	1.78e-8	Prostate cancer;
TGCT	cis	rs854765	0.647	rs854809	chr17:18006539	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	7.52	0.56	9.79e-12	Total body bone mineral density;
TGCT	cis	rs1053338	0.529	rs17654237	chr3:63735585	C/A	cg22134162	chr3:63841271	THOC7	-0.31	-4.78	-0.39	4.89e-6	Breast cancer;
TGCT	cis	rs3733631	0.947	rs2189220	chr4:104598099	T/A	cg24090629	chr4:104641072	TACR3	-0.73	-5.72	-0.46	7.65e-8	Menarche (age at onset);
TGCT	cis	rs12210905	1.000	rs9379970	chr6:27255231	T/C	cg08851530	chr6:28072375	NA	1.29	5.49	0.44	2.19e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg26338869	chr17:61819248	STRADA	-0.55	-4.95	-0.41	2.35e-6	Prudent dietary pattern;
TGCT	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs1372520	0.684	rs2619356	chr4:90750844	C/T	cg01966878	chr4:90757139	SNCA	-0.3	-4.76	-0.39	5.2e-6	Neuroticism;
TGCT	cis	rs10089	1.000	rs4835944	chr5:127490870	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.83	-7.68	-0.57	4.19e-12	Ileal carcinoids;
TGCT	cis	rs7824557	0.527	rs2572447	chr8:11239510	G/A	cg21775007	chr8:11205619	TDH	-0.68	-6.6	-0.51	1.08e-9	Retinal vascular caliber;
TGCT	cis	rs1113500	0.787	rs12047429	chr1:108633239	C/T	cg22161131	chr1:109420278	GPSM2	0.49	4.54	0.38	1.34e-5	Growth-regulated protein alpha levels;
TGCT	cis	rs28595532	0.920	rs115242199	chr4:119728652	A/C	cg21605333	chr4:119757512	SEC24D	1.66	8.33	0.6	1.28e-13	Cannabis dependence symptom count;
TGCT	cis	rs6088590	0.965	rs6087619	chr20:33288511	C/G	cg24642439	chr20:33292090	TP53INP2	0.69	6.31	0.49	4.55e-9	Coronary artery disease;
TGCT	cis	rs12887734	0.546	rs66676135	chr14:104271504	G/A	cg26031613	chr14:104095156	KLC1	-0.71	-6.13	-0.48	1.06e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg23131131	chr22:24373011	LOC391322	-0.69	-7.06	-0.54	1.07e-10	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7309	0.622	rs4664396	chr2:161901650	C/T	cg22496339	chr2:162101262	NA	-0.59	-5.59	-0.45	1.36e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
TGCT	cis	rs9517313	0.770	rs9517301	chr13:99095088	A/G	cg07423050	chr13:99094983	FARP1	-0.33	-6.88	-0.53	2.6e-10	Neuroticism;
TGCT	trans	rs7819412	0.775	rs34094119	chr8:10935898	A/G	cg06636001	chr8:8085503	FLJ10661	-0.77	-7.07	-0.54	1.01e-10	Triglycerides;
TGCT	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg06238570	chr21:40685208	BRWD1	0.69	6.41	0.5	2.71e-9	Cognitive function;
TGCT	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.51	-4.82	-0.4	4.16e-6	Bipolar disorder;
TGCT	cis	rs11105298	0.891	rs3741899	chr12:89933931	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.67	-4.85	-0.4	3.63e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs2243480	0.522	rs431168	chr7:65511604	G/T	cg20637647	chr7:64974828	NA	0.99	5.12	0.42	1.14e-6	Diabetic kidney disease;
TGCT	cis	rs2153535	0.563	rs7739249	chr6:8534590	C/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.03	0.41	1.71e-6	Motion sickness;
TGCT	cis	rs11190604	1.000	rs10883512	chr10:102308516	A/G	cg16342193	chr10:102329863	NA	-0.39	-4.95	-0.41	2.36e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg24531977	chr5:56204891	C5orf35	-0.76	-7.56	-0.56	7.68e-12	Initial pursuit acceleration;
TGCT	cis	rs854765	0.505	rs4924832	chr17:17897739	A/G	cg09796270	chr17:17721594	SREBF1	0.24	4.67	0.39	7.85e-6	Total body bone mineral density;
TGCT	cis	rs2072499	0.966	rs2842865	chr1:156159532	G/A	cg25208724	chr1:156163844	SLC25A44	1.14	16.72	0.83	1.43e-33	Testicular germ cell tumor;
TGCT	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg08736216	chr1:53307985	ZYG11A	0.25	4.93	0.4	2.59e-6	Monocyte count;
TGCT	trans	rs13064411	0.542	rs9846539	chr3:113228688	A/G	cg00307254	chr3:126706825	PLXNA1	0.34	6.78	0.52	4.36e-10	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs2933343	0.700	rs789238	chr3:128636715	A/G	cg11901034	chr3:128598214	ACAD9	-0.63	-6.04	-0.48	1.68e-8	IgG glycosylation;
TGCT	cis	rs2455799	0.593	rs2047852	chr3:15732539	T/G	cg16303742	chr3:15540471	COLQ	-0.25	-4.67	-0.39	7.72e-6	Mean platelet volume;
TGCT	cis	rs7666738	0.687	rs6839454	chr4:99073914	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.16	0.54	6.13e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg11764359	chr7:65958608	NA	0.54	4.79	0.4	4.68e-6	Aortic root size;
TGCT	cis	rs13256369	0.851	rs12541477	chr8:8563895	G/A	cg18904891	chr8:8559673	CLDN23	0.59	5.46	0.44	2.54e-7	Obesity-related traits;
TGCT	cis	rs2070488	0.965	rs7433277	chr3:38529818	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.88	8.99	0.63	3.5e-15	Electrocardiographic conduction measures;
TGCT	cis	rs11025559	0.812	rs10766678	chr11:20507180	A/G	cg19653624	chr11:20408972	PRMT3	-0.62	-4.86	-0.4	3.47e-6	Pursuit maintenance gain;
TGCT	cis	rs12477438	0.520	rs6542865	chr2:99764521	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.82	0.62	8.67e-15	Chronic sinus infection;
TGCT	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg02975922	chr3:195473998	MUC4	-0.25	-5.65	-0.45	1.03e-7	Pancreatic cancer;
TGCT	cis	rs7666738	0.830	rs10000573	chr4:99048785	G/C	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9399135	0.967	rs7741515	chr6:135374368	C/G	cg24558204	chr6:135376177	HBS1L	-0.49	-4.97	-0.41	2.15e-6	Red blood cell count;
TGCT	trans	rs10504390	0.585	rs80151640	chr8:66537841	C/T	cg26037026	chr7:1641922	NA	-0.64	-6.84	-0.52	3.29e-10	IgG glycosylation;
TGCT	cis	rs9527	0.571	rs12765337	chr10:104635344	G/C	cg15744005	chr10:104629667	AS3MT	-0.47	-5.86	-0.47	3.9e-8	Arsenic metabolism;
TGCT	cis	rs35146811	0.660	rs3779045	chr7:99779259	T/C	cg04778012	chr7:99775508	STAG3;GPC2	0.35	4.93	0.41	2.55e-6	Coronary artery disease;
TGCT	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg01341218	chr17:43662625	NA	1.08	9.0	0.63	3.23e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs10875746	0.669	rs11168499	chr12:48662670	A/G	cg20731937	chr12:48336164	NA	0.59	4.49	0.37	1.61e-5	Longevity (90 years and older);
TGCT	cis	rs9611565	0.644	rs2413652	chr22:42097238	C/T	cg13695892	chr22:41940480	POLR3H	0.84	8.14	0.59	3.45e-13	Vitiligo;
TGCT	cis	rs12477438	0.501	rs13000731	chr2:99795231	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.75	7.25	0.55	3.92e-11	Chronic sinus infection;
TGCT	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.68	-6.98	-0.53	1.62e-10	Prostate cancer;
TGCT	cis	rs854765	0.583	rs2350977	chr17:17802779	A/G	cg09796270	chr17:17721594	SREBF1	0.24	4.71	0.39	6.54e-6	Total body bone mineral density;
TGCT	cis	rs1215050	0.740	rs783941	chr4:99008235	T/C	cg17366294	chr4:99064904	C4orf37	-0.54	-5.81	-0.46	4.85e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg03934478	chr11:495069	RNH1	0.35	5.89	0.47	3.34e-8	Body mass index;
TGCT	cis	rs6740322	0.748	rs13402621	chr2:43458611	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.39	-5.65	-0.45	1.03e-7	Coronary artery disease;
TGCT	cis	rs9811920	0.609	rs793467	chr3:99539664	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.6	-6.91	-0.53	2.21e-10	Axial length;
TGCT	cis	rs2075371	0.611	rs35428392	chr7:134019645	G/A	cg11752832	chr7:134001865	SLC35B4	0.69	5.52	0.44	1.86e-7	Mean platelet volume;
TGCT	cis	rs3026101	0.624	rs1065483	chr17:5284770	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.5	4.88	0.4	3.14e-6	Body mass index;
TGCT	cis	rs7104764	1.000	rs10902112	chr11:244106	A/G	cg18336825	chr11:236787	PSMD13;SIRT3	1.07	11.19	0.71	1.61e-20	Menarche (age at onset);
TGCT	cis	rs2147959	0.766	rs728964	chr1:228731895	T/A	cg22700015	chr1:228743131	NA	-0.61	-5.15	-0.42	9.77e-7	Adult asthma;
TGCT	cis	rs11190604	0.767	rs7090150	chr10:102173446	G/T	cg16005271	chr10:102321736	NA	0.45	4.74	0.39	5.87e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	trans	rs797680	0.856	rs6680107	chr1:93770880	G/A	cg27528825	chr2:159282178	CCDC148	-0.34	-6.71	-0.52	6.19e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs12039431	0.746	rs61776184	chr1:38008523	C/T	cg17933807	chr1:38061675	GNL2	-0.8	-7.64	-0.57	5.24e-12	Epithelial ovarian cancer;
TGCT	cis	rs6882076	1.000	rs4704825	chr5:156382308	A/G	cg12943317	chr5:156479607	HAVCR1	-0.31	-5.63	-0.45	1.17e-7	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
TGCT	cis	rs700590	0.515	rs62380364	chr5:88107337	C/A	cg22951263	chr5:87985283	NA	-0.54	-5.35	-0.43	4.16e-7	Educational attainment (years of education);
TGCT	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg10047753	chr17:41438598	NA	-0.77	-7.28	-0.55	3.43e-11	Menopause (age at onset);
TGCT	cis	rs3812049	0.784	rs6889311	chr5:127431285	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	5.87	0.47	3.81e-8	Lymphocyte counts;Red cell distribution width;
TGCT	trans	rs77457752	0.690	rs75036580	chr9:13912781	C/T	cg23609682	chr1:3070786	PRDM16	0.48	6.96	0.53	1.78e-10	Breast cancer;
TGCT	cis	rs7216064	0.636	rs4638	chr17:66039350	A/G	cg12091567	chr17:66097778	LOC651250	1.08	8.86	0.62	7.21e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs9303401	0.538	rs2240259	chr17:56458129	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.56	5.24	0.43	6.54e-7	Cognitive test performance;
TGCT	cis	rs7666738	0.830	rs11932887	chr4:99072965	C/G	cg17366294	chr4:99064904	C4orf37	0.76	7.61	0.56	6.06e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1867631	0.958	rs7536188	chr1:67087926	A/T	cg13052034	chr1:66999238	SGIP1	-0.58	-4.88	-0.4	3.23e-6	Menopause (age at onset);
TGCT	cis	rs7312933	0.703	rs10880268	chr12:42599122	C/T	cg19980929	chr12:42632907	YAF2	0.47	6.46	0.5	2.13e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs7017914	0.967	rs1471114	chr8:71675547	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.53	-4.9	-0.4	2.87e-6	Bone mineral density;
TGCT	cis	rs950169	0.920	rs12915390	chr15:84792069	T/C	cg17173187	chr15:85201210	NMB	0.5	5.56	0.45	1.61e-7	Schizophrenia;
TGCT	cis	rs1033284	0.666	rs7424161	chr2:141942235	C/T	cg20443778	chr2:142887886	LRP1B	-0.44	-4.47	-0.37	1.74e-5	Blood pressure (smoking interaction);
TGCT	cis	rs10804591	0.524	rs2811462	chr3:129303436	T/G	cg07730360	chr3:128845626	NA	0.21	4.63	0.38	9.19e-6	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Hip circumference adjusted for BMI;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7043114	0.525	rs7847929	chr9:95154244	C/T	cg14631576	chr9:95140430	CENPP	-0.29	-4.79	-0.39	4.76e-6	Height;
TGCT	cis	rs9912789	0.807	rs9896850	chr17:79191726	C/T	cg14413466	chr17:79170920	AZI1	-0.25	-4.55	-0.38	1.25e-5	Frontotemporal dementia;
TGCT	cis	rs3087591	0.683	rs2040792	chr17:29628549	G/T	cg24425628	chr17:29625626	OMG;NF1	0.42	6.2	0.49	7.68e-9	Hip circumference;
TGCT	cis	rs10089	1.000	rs7703634	chr5:127509223	A/C	cg19767477	chr5:127420684	SLC12A2	-0.43	-4.55	-0.38	1.25e-5	Ileal carcinoids;
TGCT	cis	rs7954584	0.546	rs10840630	chr12:122352445	C/T	cg22168489	chr12:122356033	WDR66	0.22	4.79	0.4	4.59e-6	Mean corpuscular volume;
TGCT	trans	rs17685	0.671	rs60303271	chr7:75760008	A/G	cg19862616	chr7:65841803	NCRNA00174	0.52	9.01	0.63	3.02e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs6589563	0.609	rs59455853	chr11:116607874	A/T	cg01124546	chr11:117515332	DSCAML1	-0.43	-4.54	-0.38	1.31e-5	Eosinophil counts;
TGCT	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg22166914	chr1:53195759	ZYG11B	0.42	7.35	0.55	2.33e-11	Monocyte count;
TGCT	cis	rs10992471	0.756	rs1121979	chr9:95140218	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.61	-6.31	-0.49	4.46e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg22963979	chr7:1858916	MAD1L1	-0.39	-6.17	-0.48	8.78e-9	Bipolar disorder and schizophrenia;
TGCT	cis	rs7246657	0.722	rs28512414	chr19:38056574	T/A	cg03611452	chr19:38183253	ZNF781	0.58	4.64	0.38	8.62e-6	Coronary artery calcification;
TGCT	cis	rs4499344	0.730	rs34270210	chr19:33103945	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.83	8.63	0.61	2.53e-14	Mean platelet volume;
TGCT	cis	rs17253792	0.822	rs10083303	chr14:56068521	T/C	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg13683864	chr3:40499215	RPL14	-1.19	-13.2	-0.76	2.17e-25	Renal cell carcinoma;
TGCT	cis	rs7666738	0.830	rs13122054	chr4:98972974	G/A	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11190604	1.000	rs2489034	chr10:102319192	C/T	cg23241863	chr10:102295624	HIF1AN	0.69	5.21	0.42	7.75e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs17401966	0.838	rs12120191	chr1:10345772	A/G	cg19773385	chr1:10388646	KIF1B	-0.2	-4.5	-0.37	1.54e-5	Hepatocellular carcinoma;
TGCT	cis	rs11711311	1.000	rs9811200	chr3:113531180	A/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.76	-7.16	-0.54	6.29e-11	IgG glycosylation;
TGCT	cis	rs896854	0.625	rs13281709	chr8:95972819	T/A	cg16049864	chr8:95962084	TP53INP1	-0.75	-10.47	-0.69	9.05e-19	Type 2 diabetes;
TGCT	cis	rs2762353	0.603	rs4145221	chr6:25763192	A/G	cg12310025	chr6:25882481	NA	0.49	4.78	0.39	4.77e-6	Blood metabolite levels;
TGCT	cis	rs12701220	0.948	rs10275712	chr7:1082918	G/A	cg07217954	chr7:1067459	C7orf50	-0.48	-4.7	-0.39	6.84e-6	Bronchopulmonary dysplasia;
TGCT	cis	rs1467026	0.563	rs58674721	chr3:12811233	G/A	cg05775895	chr3:12838266	CAND2	0.72	7.41	0.55	1.73e-11	P wave duration;
TGCT	cis	rs7666738	0.830	rs13149779	chr4:99010145	G/T	cg05340658	chr4:99064831	C4orf37	0.5	5.58	0.45	1.42e-7	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg01341218	chr17:43662625	NA	-1.05	-9.43	-0.65	3.03e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs11874712	0.623	rs3753069	chr18:43678035	T/C	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.49	4.9	0.4	2.91e-6	Migraine - clinic-based;
TGCT	cis	rs9916302	0.851	rs12947620	chr17:37605364	T/C	cg07936489	chr17:37558343	FBXL20	-0.62	-4.91	-0.4	2.85e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs17826219	0.706	rs61643715	chr17:29057762	A/G	cg14008862	chr17:28927542	LRRC37B2	0.77	4.59	0.38	1.08e-5	Body mass index;
TGCT	cis	rs1153858	1.000	rs7181167	chr15:45686236	C/G	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.62e-8	Homoarginine levels;
TGCT	cis	rs2236918	0.664	rs1776158	chr1:242017658	C/T	cg04158730	chr1:242011433	EXO1	0.49	4.55	0.38	1.25e-5	Menopause (age at onset);
TGCT	cis	rs2692947	0.537	rs11682182	chr2:96378210	A/G	cg23100626	chr2:96804247	ASTL	0.4	4.7	0.39	6.69e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg07424592	chr7:64974309	NA	1.27	7.86	0.58	1.61e-12	Diabetic kidney disease;
TGCT	cis	rs4788570	0.615	rs6499531	chr16:71731485	T/C	cg06353428	chr16:71660113	MARVELD3	1.55	12.69	0.75	3.63e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs28374715	0.528	rs28492932	chr15:41624397	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.9	-14.93	-0.8	1.76e-29	Ulcerative colitis;
TGCT	cis	rs9611565	0.681	rs5751094	chr22:41803279	C/T	cg06634786	chr22:41940651	POLR3H	0.7	6.65	0.51	8.51e-10	Vitiligo;
TGCT	cis	rs860554	0.546	rs1543806	chr1:201292844	C/T	cg01022117	chr1:201258280	PKP1	-0.27	-4.93	-0.4	2.57e-6	Panic disorder;
TGCT	cis	rs35306767	0.761	rs11253557	chr10:1043667	C/T	cg26597838	chr10:835615	NA	0.61	6.72	0.52	5.82e-10	Eosinophil percentage of granulocytes;
TGCT	cis	rs8072100	0.840	rs1912482	chr17:45454883	G/A	cg08085267	chr17:45401833	C17orf57	-0.46	-5.08	-0.42	1.33e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs6964587	1.000	rs3753109	chr7:91630001	G/C	cg17063962	chr7:91808500	NA	0.91	9.99	0.67	1.32e-17	Breast cancer;
TGCT	cis	rs72949976	0.606	rs1922797	chr2:214027642	G/A	cg08319019	chr2:214017104	IKZF2	0.84	8.21	0.59	2.46e-13	Lung cancer;Squamous cell lung carcinoma;
TGCT	cis	rs2502731	1.000	rs2502731	chr9:130976557	A/G	cg13642260	chr9:130955380	CIZ1	-0.47	-5.37	-0.43	3.72e-7	Attention deficit hyperactivity disorder;
TGCT	cis	rs9911578	1.000	rs12952832	chr17:56906254	T/C	cg12560992	chr17:57184187	TRIM37	0.75	9.07	0.63	2.26e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs8077889	1.000	rs113919636	chr17:41877740	A/C	cg26893861	chr17:41843967	DUSP3	1.1	13.31	0.77	1.17e-25	Triglycerides;
TGCT	cis	rs910316	0.934	rs8016330	chr14:75657507	G/T	cg11812906	chr14:75593930	NEK9	-0.72	-6.79	-0.52	4.14e-10	Height;
TGCT	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg13607699	chr17:42295918	UBTF	0.84	7.76	0.57	2.72e-12	Total body bone mineral density;
TGCT	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg11247378	chr22:39784982	NA	-0.68	-7.44	-0.56	1.44e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs6429082	0.683	rs2131920	chr1:235579912	T/A	cg26050004	chr1:235667680	B3GALNT2	-0.57	-5.03	-0.41	1.7e-6	Adiposity;
TGCT	cis	rs7666738	0.581	rs34205844	chr4:98887494	C/A	cg17366294	chr4:99064904	C4orf37	0.67	6.66	0.51	7.79e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs477895	1.000	rs7939107	chr11:64034773	C/T	cg04317338	chr11:64019027	PLCB3	0.71	5.75	0.46	6.48e-8	Mean platelet volume;
TGCT	cis	rs145445141	1	rs145445141	chr1:67489169	ATT/A	cg08660285	chr1:67390436	MIER1;WDR78	1.1	10.32	0.68	2.06e-18	Neutrophil percentage of white cells;
TGCT	cis	rs9928842	0.770	rs4888364	chr16:75279510	A/G	cg09066997	chr16:75300724	BCAR1	0.25	4.63	0.38	9.24e-6	Alcoholic chronic pancreatitis;
TGCT	cis	rs3087591	0.922	rs2905806	chr17:29502507	A/G	cg24425628	chr17:29625626	OMG;NF1	0.45	7.23	0.54	4.41e-11	Hip circumference;
TGCT	cis	rs2455799	0.505	rs2028989	chr3:15934874	C/T	cg12172478	chr3:16357591	RFTN1	-0.33	-4.81	-0.4	4.31e-6	Mean platelet volume;
TGCT	cis	rs1865760	0.516	rs10807007	chr6:26048931	A/C	cg17042849	chr6:26104293	HIST1H4C	-0.65	-5.76	-0.46	6.19e-8	Height;
TGCT	cis	rs826838	0.616	rs1601746	chr12:38626195	G/T	cg26384229	chr12:38710491	ALG10B	-0.54	-4.88	-0.4	3.24e-6	Heart rate;
TGCT	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.78	6.11	0.48	1.2e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs8062405	1.000	rs8055138	chr16:28891465	C/T	cg09754948	chr16:28834200	ATXN2L	0.6	4.46	0.37	1.79e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs7552404	0.731	rs1689275	chr1:76409655	T/C	cg03433033	chr1:76189801	ACADM	-0.76	-7.81	-0.57	2.07e-12	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs13102973	0.710	rs4428340	chr4:135886451	C/T	cg14419869	chr4:135874104	NA	0.26	4.6	0.38	1.03e-5	Subjective well-being;
TGCT	cis	rs919433	0.679	rs6757632	chr2:198530266	C/T	cg00792783	chr2:198669748	PLCL1	0.55	4.93	0.4	2.56e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs10782582	0.569	rs74090722	chr1:76197262	A/G	cg10523679	chr1:76189770	ACADM	-0.67	-6.67	-0.51	7.54e-10	Daytime sleep phenotypes;
TGCT	cis	rs2115630	0.875	rs8039472	chr15:85361644	A/G	cg12863693	chr15:85201151	NMB	-0.37	-4.78	-0.39	4.77e-6	P wave terminal force;
TGCT	cis	rs1371867	0.846	rs1660347	chr8:101314980	G/A	cg00191853	chr8:101177733	SPAG1	-0.22	-4.47	-0.37	1.75e-5	Atrioventricular conduction;
TGCT	cis	rs4478037	0.749	rs9311003	chr3:33131070	A/G	cg19404215	chr3:33155277	CRTAP	-0.94	-5.93	-0.47	2.84e-8	Major depressive disorder;
TGCT	cis	rs10875595	0.836	rs758346	chr5:140674734	C/A	cg20560182	chr5:140700478	TAF7	-0.64	-4.91	-0.4	2.76e-6	Pulmonary function decline;
TGCT	cis	rs478304	0.903	rs1151502	chr11:65503485	G/C	cg17480646	chr11:65405466	SIPA1	0.43	5.35	0.43	4.18e-7	Acne (severe);
TGCT	cis	rs12477438	0.798	rs12468419	chr2:99579680	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.56	-4.86	-0.4	3.51e-6	Chronic sinus infection;
TGCT	cis	rs7937682	0.855	rs571462	chr11:111487106	C/G	cg09085632	chr11:111637200	PPP2R1B	-1.05	-11.36	-0.71	6.21e-21	Primary sclerosing cholangitis;
TGCT	cis	rs35849525	0.814	rs35491931	chr3:49993462	T/A	cg14019146	chr3:50243930	SLC38A3	-0.21	-4.44	-0.37	1.98e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs1048238	0.506	rs698889	chr1:16267040	A/C	cg21385522	chr1:16154831	NA	-0.57	-6.33	-0.49	4.18e-9	Systolic blood pressure;
TGCT	cis	rs12118280	0.531	rs12402496	chr1:108732781	G/A	cg11967332	chr1:108735228	SLC25A24	0.3	4.45	0.37	1.87e-5	Myeloid white cell count;
TGCT	cis	rs6674176	0.660	rs2108202	chr1:44395786	A/G	cg13606994	chr1:44402422	ARTN	0.5	5.48	0.44	2.3e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg23758822	chr17:41437982	NA	0.72	6.85	0.52	3.09e-10	Menopause (age at onset);
TGCT	cis	rs9303401	0.704	rs740605	chr17:56604811	C/T	cg12560992	chr17:57184187	TRIM37	0.58	6.34	0.49	3.93e-9	Cognitive test performance;
TGCT	cis	rs7223966	1.000	rs11657081	chr17:61792339	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	4.92	0.4	2.74e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.49	-4.75	-0.39	5.6e-6	Bipolar disorder;
TGCT	cis	rs854765	0.520	rs7219324	chr17:17909775	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.71	-6.93	-0.53	2e-10	Total body bone mineral density;
TGCT	cis	rs9911578	0.967	rs302843	chr17:56727986	C/T	cg12560992	chr17:57184187	TRIM37	0.75	9.21	0.64	1.04e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs9325144	0.560	rs1601745	chr12:38647828	G/A	cg26384229	chr12:38710491	ALG10B	-0.63	-5.92	-0.47	2.9e-8	Morning vs. evening chronotype;
TGCT	cis	rs7027203	0.828	rs4743934	chr9:96581893	A/G	cg13679303	chr9:96623674	NA	-0.66	-10.64	-0.69	3.54e-19	DNA methylation (variation);
TGCT	cis	rs2455799	0.517	rs3843387	chr3:15938909	A/C	cg12172478	chr3:16357591	RFTN1	0.33	4.82	0.4	4.09e-6	Mean platelet volume;
TGCT	cis	rs1532993	0.518	rs28566098	chr4:98569438	C/T	cg05340658	chr4:99064831	C4orf37	-0.38	-4.53	-0.38	1.36e-5	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs2228479	0.850	rs62052711	chr16:89855100	C/A	cg06558623	chr16:89946397	TCF25	0.47	4.58	0.38	1.14e-5	Skin colour saturation;
TGCT	cis	rs1403694	0.695	rs13095338	chr3:186435583	T/C	cg12454167	chr3:186435060	KNG1	0.51	8.67	0.61	1.95e-14	Blood protein levels;
TGCT	cis	rs739496	0.579	rs9971942	chr12:112256042	C/T	cg10833066	chr12:111807467	FAM109A	0.38	5.61	0.45	1.24e-7	Platelet count;
TGCT	cis	rs17001868	0.568	rs742140	chr22:40781586	G/A	cg07138101	chr22:40742427	ADSL	0.73	5.47	0.44	2.38e-7	Mammographic density (dense area);
TGCT	cis	rs9400467	0.537	rs354533	chr6:111487104	T/G	cg15721981	chr6:111408429	SLC16A10	0.68	4.48	0.37	1.69e-5	Blood metabolite levels;Amino acid levels;
TGCT	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg00343986	chr7:65444356	GUSB	0.26	6.14	0.48	1.02e-8	Aortic root size;
TGCT	cis	rs28595532	0.688	rs116580819	chr4:119767362	T/A	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs931608	1.000	rs10408585	chr19:22613247	A/G	cg23859931	chr19:22123797	NA	0.6	4.66	0.39	7.99e-6	Dental caries;Response to statins (LDL cholesterol change);
TGCT	trans	rs11722228	0.539	rs62287552	chr4:10153197	C/T	cg26043149	chr18:55253948	FECH	1.1	12.23	0.74	4.63e-23	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg08736216	chr1:53307985	ZYG11A	-0.3	-6.06	-0.48	1.48e-8	Monocyte count;
TGCT	cis	rs2153535	0.580	rs9505467	chr6:8520219	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.55e-8	Motion sickness;
TGCT	cis	rs17473412	1.000	rs7713551	chr5:122721253	G/T	cg15125798	chr5:122621645	NA	-0.57	-5.15	-0.42	9.93e-7	Total body bone mineral density;
TGCT	cis	rs1448094	0.511	rs59668915	chr12:86197170	C/T	cg02569458	chr12:86230093	RASSF9	0.39	4.97	0.41	2.16e-6	Major depressive disorder;
TGCT	cis	rs2050392	0.517	rs2771242	chr10:30762973	C/T	cg13289132	chr10:30722225	MAP3K8	-0.42	-5.02	-0.41	1.79e-6	Inflammatory bowel disease;
TGCT	cis	rs2395909	1	rs2395909	chr7:107292663	G/A	cg23024343	chr7:107201750	COG5	0.3	4.75	0.39	5.42e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs9308731	0.644	rs7602904	chr2:111880600	C/T	cg04202892	chr2:111875749	ACOXL	0.54	6.25	0.49	6.18e-9	Chronic lymphocytic leukemia;
TGCT	cis	rs3806843	0.576	rs246049	chr5:140327590	T/G	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs6964587	0.933	rs13230837	chr7:91779017	A/G	cg22709100	chr7:91322751	NA	0.29	4.62	0.38	9.32e-6	Breast cancer;
TGCT	cis	rs7552404	0.731	rs12090849	chr1:76400261	A/G	cg22875332	chr1:76189707	ACADM	0.65	6.36	0.5	3.56e-9	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs736408	1.000	rs4687552	chr3:52838402	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	4.7	0.39	6.76e-6	Bipolar disorder;
TGCT	cis	rs9952991	0.941	rs1893217	chr18:12809340	A/G	cg23598886	chr18:12777645	NA	-0.61	-5.47	-0.44	2.35e-7	Inflammatory skin disease;
TGCT	cis	rs8103278	0.507	rs10404220	chr19:46248407	G/A	cg14061069	chr19:46274453	DMPK	0.62	10.19	0.68	4.35e-18	Coronary artery disease;
TGCT	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg08219700	chr8:58056026	NA	0.3	4.57	0.38	1.14e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg13206674	chr6:150067644	NUP43	0.52	4.51	0.38	1.5e-5	Lung cancer;
TGCT	cis	rs2274273	0.774	rs9323278	chr14:55541574	C/G	cg01923255	chr14:55878535	KIAA0831	0.57	4.89	0.4	3.03e-6	Protein biomarker;
TGCT	trans	rs7618501	0.699	rs1317154	chr3:49910084	T/C	cg21659725	chr3:3221576	CRBN	0.78	9.37	0.64	4.19e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs11105298	0.891	rs1054807	chr12:89913419	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.7	-5.02	-0.41	1.75e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs4906332	0.933	rs35999760	chr14:103924481	A/C	cg26031613	chr14:104095156	KLC1	-0.53	-4.71	-0.39	6.62e-6	Coronary artery disease;
TGCT	cis	rs2562456	0.793	rs2562420	chr19:21631305	T/A	cg01304269	chr19:21688519	ZNF429	-0.61	-4.81	-0.4	4.22e-6	Pain;
TGCT	cis	rs2236918	1.000	rs735943	chr1:242030151	C/T	cg04158730	chr1:242011433	EXO1	-0.53	-4.62	-0.38	9.28e-6	Menopause (age at onset);
TGCT	cis	rs1348850	0.874	rs4893822	chr2:178285727	G/T	cg22681709	chr2:178499509	PDE11A	-0.36	-4.59	-0.38	1.06e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg27454412	chr7:1067447	C7orf50	0.57	4.43	0.37	2.01e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs6582630	0.585	rs12422588	chr12:38478675	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-4.79	-0.4	4.57e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs2463822	0.920	rs7924998	chr11:62073980	C/G	cg06239285	chr11:62104954	ASRGL1	-0.89	-5.52	-0.44	1.89e-7	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs7552404	0.961	rs1767458	chr1:76219155	A/G	cg03433033	chr1:76189801	ACADM	0.75	8.76	0.62	1.19e-14	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg20607798	chr8:58055168	NA	0.5	4.66	0.39	8.04e-6	Developmental language disorder (linguistic errors);
TGCT	trans	rs1814175	0.645	rs847627	chr11:49927177	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.51	-0.69	7.2e-19	Height;
TGCT	cis	rs9486719	1.000	rs34209750	chr6:96882215	G/T	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.21	-0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg01416388	chr22:39784598	NA	-0.72	-7.11	-0.54	8.03e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs3181245	0.641	rs3756821	chr6:24646821	C/T	cg16906346	chr6:24646782	KIAA0319	-0.51	-5.78	-0.46	5.63e-8	Colorectal or endometrial cancer;
TGCT	cis	rs7666738	0.830	rs7686456	chr4:99019695	T/C	cg05340658	chr4:99064831	C4orf37	0.48	5.43	0.44	2.92e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7178572	0.889	rs7177055	chr15:77832762	A/G	cg22256960	chr15:77711686	NA	0.92	10.82	0.7	1.27e-19	Type 2 diabetes;
TGCT	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.75	5.41	0.44	3.09e-7	Platelet count;
TGCT	cis	rs832540	0.629	rs6888317	chr5:56093307	A/G	cg24531977	chr5:56204891	C5orf35	0.51	5.0	0.41	1.89e-6	Coronary artery disease;
TGCT	trans	rs114540395	0.777	rs9420863	chr10:103362726	C/T	cg10198749	chr1:39920707	MACF1	0.55	7.03	0.53	1.2e-10	Schizophrenia;
TGCT	cis	rs1171582	0.564	rs6479648	chr10:61510559	G/A	cg23572703	chr10:62241191	NA	-0.29	-4.8	-0.4	4.55e-6	Alopecia areata;
TGCT	cis	rs9427116	0.502	rs6699825	chr1:154582970	A/G	cg17218026	chr1:154582156	ADAR	0.31	7.7	0.57	3.72e-12	Blood protein levels;
TGCT	cis	rs7666738	0.791	rs1115615	chr4:99006614	G/A	cg18180107	chr4:99064573	C4orf37	0.54	4.98	0.41	2.1e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs904251	0.772	rs1812186	chr6:37465916	T/C	cg08126542	chr6:37504118	NA	-0.39	-4.55	-0.38	1.28e-5	Cognitive performance;
TGCT	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.47	0.56	1.28e-11	Prudent dietary pattern;
TGCT	cis	rs11585357	1.000	rs11203346	chr1:17600822	A/G	cg08277548	chr1:17600880	PADI3	-0.97	-9.78	-0.66	4.23e-17	Hair shape;
TGCT	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg22920501	chr2:26401640	FAM59B	-0.74	-6.4	-0.5	2.86e-9	Gut microbiome composition (summer);
TGCT	cis	rs2354432	0.556	rs4295925	chr1:146857335	T/C	cg25205988	chr1:146714368	CHD1L	1.32	5.88	0.47	3.62e-8	Mitochondrial DNA levels;
TGCT	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg24549020	chr5:56110836	MAP3K1	0.71	6.15	0.48	9.56e-9	Initial pursuit acceleration;
TGCT	cis	rs7192750	0.586	rs4788584	chr16:71993386	A/T	cg06353428	chr16:71660113	MARVELD3	0.76	6.52	0.51	1.6e-9	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs2072499	0.966	rs2244144	chr1:156184598	G/A	cg06970220	chr1:156163860	SLC25A44	0.74	5.91	0.47	3.05e-8	Testicular germ cell tumor;
TGCT	cis	rs7666738	0.830	rs10049985	chr4:99023517	C/T	cg17366294	chr4:99064904	C4orf37	0.68	7.04	0.53	1.17e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12220238	1.000	rs10824090	chr10:75923446	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.78	0.57	2.42e-12	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg06108461	chr20:60628389	TAF4	-0.69	-10.64	-0.69	3.59e-19	Body mass index;
TGCT	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/A	cg15659132	chr6:26577336	NA	0.84	10.28	0.68	2.58e-18	Intelligence (multi-trait analysis);
TGCT	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg10802521	chr3:52805072	NEK4	-0.78	-10.0	-0.67	1.26e-17	Electroencephalogram traits;
TGCT	cis	rs7267979	0.789	rs1983974	chr20:25530619	A/C	cg16686733	chr20:25566563	NINL	-0.51	-4.91	-0.4	2.82e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs17221829	0.733	rs11018686	chr11:89365241	G/A	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.65	-0.39	8.43e-6	Anxiety in major depressive disorder;
TGCT	cis	rs7511006	0.859	rs7292228	chr22:50649560	C/G	cg08875078	chr22:50639485	SELO	0.56	5.41	0.44	3.12e-7	Obesity-related traits;
TGCT	cis	rs7772486	0.701	rs7772717	chr6:145954854	T/C	cg13319975	chr6:146136371	FBXO30	-0.56	-5.06	-0.41	1.46e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1215050	0.791	rs700738	chr4:98907909	C/A	cg05340658	chr4:99064831	C4orf37	-0.46	-5.82	-0.46	4.74e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg03396347	chr1:1875803	NA	-0.3	-5.08	-0.42	1.32e-6	Body mass index;
TGCT	cis	rs9915657	0.966	rs8071717	chr17:70128705	C/T	cg06234051	chr17:70120541	SOX9	-0.28	-5.54	-0.45	1.72e-7	Thyroid hormone levels;
TGCT	cis	rs10507380	0.843	rs74615458	chr13:27859246	C/T	cg25543773	chr13:27185723	WASF3	0.29	4.45	0.37	1.86e-5	Electrocardiographic traits;
TGCT	cis	rs951366	0.677	rs1775140	chr1:205672107	C/CA	cg23034840	chr1:205782522	SLC41A1	-0.76	-4.92	-0.4	2.7e-6	Menarche (age at onset);
TGCT	cis	rs9611565	0.559	rs5758397	chr22:42019251	C/T	cg17554472	chr22:41940697	POLR3H	0.5	5.26	0.43	6.02e-7	Vitiligo;
TGCT	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg18876405	chr7:65276391	NA	0.32	4.87	0.4	3.29e-6	Aortic root size;
TGCT	cis	rs7223966	0.691	rs9893518	chr17:62006997	A/G	cg18032289	chr17:61959525	GH2	-0.31	-4.69	-0.39	7.12e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs7172971	0.808	rs55905344	chr15:42340178	C/T	cg05886115	chr15:42349113	NA	0.32	4.92	0.4	2.71e-6	3-hydroxypropylmercapturic acid levels in smokers;
TGCT	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg06112835	chr11:68658793	MRPL21	0.45	7.64	0.57	5.19e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	trans	rs877282	0.945	rs877280	chr10:771599	C/T	cg22713356	chr15:30763199	NA	1.2	10.36	0.68	1.66e-18	Uric acid levels;
TGCT	cis	rs568617	0.953	rs583887	chr11:65644027	T/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.57	-5.22	-0.42	7.39e-7	Crohn's disease;
TGCT	cis	rs4819052	0.655	rs2330102	chr21:46690968	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.64	6.19	0.49	8.26e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7267979	0.932	rs449703	chr20:25458559	C/T	cg16686733	chr20:25566563	NINL	0.56	5.69	0.46	8.49e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg21548813	chr6:291882	DUSP22	-0.72	-7.59	-0.56	6.53e-12	Menopause (age at onset);
TGCT	cis	rs35306767	0.953	rs34405399	chr10:981015	G/A	cg26597838	chr10:835615	NA	0.56	7.7	0.57	3.66e-12	Eosinophil percentage of granulocytes;
TGCT	cis	rs12765878	1.000	rs2273698	chr10:105649158	G/A	cg11005552	chr10:105648138	OBFC1	0.44	7.69	0.57	4.01e-12	Coronary artery disease;
TGCT	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg05665937	chr4:1216051	CTBP1	0.24	4.47	0.37	1.72e-5	Obesity-related traits;
TGCT	cis	rs7412746	0.621	rs72704656	chr1:150828307	A/G	cg04414720	chr1:150670196	GOLPH3L	0.39	4.75	0.39	5.55e-6	Melanoma;
TGCT	cis	rs2295359	0.892	rs4655687	chr1:67649946	C/T	cg08029281	chr1:67600428	NA	0.4	4.68	0.39	7.42e-6	Psoriasis;
TGCT	cis	rs7255045	0.752	rs2418568	chr19:12987881	A/G	cg23899408	chr19:12877188	HOOK2	-0.61	-5.01	-0.41	1.79e-6	Mean corpuscular volume;
TGCT	cis	rs9443645	0.901	rs9443622	chr6:79582790	C/T	cg09184832	chr6:79620586	NA	-0.48	-5.17	-0.42	9.23e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9473924	0.542	rs2857482	chr6:50790642	C/T	cg14470998	chr6:50812995	TFAP2B	1.34	7.28	0.55	3.38e-11	Body mass index;
TGCT	cis	rs5769765	0.542	rs1535189	chr22:50249131	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.97	6.35	0.5	3.69e-9	Schizophrenia;
TGCT	cis	rs793108	0.869	rs1624116	chr10:31435153	G/A	cg24861272	chr10:31607153	ZEB1;LOC220930	0.29	4.46	0.37	1.84e-5	Multiple sclerosis;Rheumatoid arthritis;
TGCT	cis	rs4144743	1.000	rs34182248	chr17:45321359	T/C	cg18085866	chr17:45331354	ITGB3	-0.72	-4.85	-0.4	3.61e-6	Body mass index;
TGCT	cis	rs367615	0.659	rs13435970	chr5:108884660	C/T	cg17395555	chr5:108820864	NA	0.3	4.92	0.4	2.73e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg07806771	chr7:64541737	NA	0.45	4.59	0.38	1.06e-5	Calcium levels;
TGCT	cis	rs6893300	0.524	rs6601073	chr5:179177271	A/G	cg14593053	chr5:179126677	CANX	-0.49	-5.63	-0.45	1.16e-7	Resting heart rate;
TGCT	cis	rs7178572	0.568	rs28524916	chr15:77599002	T/A	cg15453836	chr15:77711506	NA	0.42	4.79	0.4	4.68e-6	Type 2 diabetes;
TGCT	cis	rs9649213	0.614	rs3801258	chr7:97988428	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.93	-8.73	-0.62	1.45e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2404602	0.692	rs34272342	chr15:77012276	A/C	cg22467129	chr15:76604101	ETFA	-0.45	-5.11	-0.42	1.2e-6	Blood metabolite levels;
TGCT	cis	rs4761974	1.000	rs74583309	chr12:51880093	A/G	cg09925572	chr12:51518419	TFCP2	0.5	4.53	0.38	1.35e-5	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
TGCT	cis	rs2153535	0.601	rs9406160	chr6:8464907	A/C	cg07606381	chr6:8435919	SLC35B3	0.55	5.16	0.42	9.35e-7	Motion sickness;
TGCT	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg22166914	chr1:53195759	ZYG11B	-0.42	-7.46	-0.56	1.29e-11	Monocyte count;
TGCT	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg22963979	chr7:1858916	MAD1L1	-0.45	-7.41	-0.55	1.74e-11	Bipolar disorder and schizophrenia;
TGCT	cis	rs1891275	0.515	rs1986941	chr10:93444343	C/T	cg07889827	chr10:93443413	NA	-0.33	-6.99	-0.53	1.53e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs10489202	0.612	rs3820401	chr1:168074753	T/C	cg24449463	chr1:168025552	DCAF6	-0.53	-5.49	-0.44	2.16e-7	Schizophrenia;
TGCT	trans	rs7819412	0.838	rs3021494	chr8:10983534	A/G	cg15556689	chr8:8085844	FLJ10661	-0.8	-7.94	-0.58	1.03e-12	Triglycerides;
TGCT	cis	rs7666738	0.791	rs6532725	chr4:99061479	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.45	0.56	1.4e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7772486	0.720	rs7752286	chr6:146072662	C/T	cg13319975	chr6:146136371	FBXO30	0.56	4.93	0.4	2.56e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6840360	0.617	rs2724563	chr4:152349959	G/C	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.83e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7772486	0.764	rs2247211	chr6:146216379	G/A	cg23711669	chr6:146136114	FBXO30	0.87	9.97	0.67	1.48e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs151997	0.925	rs27847	chr5:50176197	G/T	cg06027927	chr5:50259733	NA	0.46	4.63	0.38	9.01e-6	Callous-unemotional behaviour;
TGCT	cis	rs6450176	0.625	rs16881958	chr5:53288201	C/G	ch.5.1024479R	chr5:53302184	ARL15	-0.69	-5.53	-0.44	1.8e-7	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.98	10.79	0.7	1.55e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs4642101	0.535	rs55692304	chr3:12840057	C/T	cg05775895	chr3:12838266	CAND2	0.84	9.56	0.65	1.45e-16	QRS complex (12-leadsum);
TGCT	cis	rs344364	0.511	rs1657134	chr16:1953127	A/G	cg26617929	chr16:1858877	NA	-0.26	-4.66	-0.39	8.04e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs12477438	1.000	rs1922624	chr2:99909958	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.8	-6.4	-0.5	2.92e-9	Chronic sinus infection;
TGCT	trans	rs57221529	0.713	rs56328416	chr5:591138	G/A	cg11887960	chr12:57824829	NA	1.17	9.69	0.66	6.98e-17	Lung disease severity in cystic fibrosis;
TGCT	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg06873352	chr17:61820015	STRADA	0.58	6.36	0.5	3.51e-9	Prudent dietary pattern;
TGCT	cis	rs7119038	0.818	rs3889239	chr11:118619960	C/T	cg19308663	chr11:118741387	NA	0.29	5.39	0.44	3.41e-7	Sjögren's syndrome;
TGCT	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg00343986	chr7:65444356	GUSB	-0.25	-5.8	-0.46	5.09e-8	Aortic root size;
TGCT	cis	rs7246657	0.722	rs8100646	chr19:38107943	T/C	cg18154014	chr19:37997991	ZNF793	0.69	4.63	0.38	9.25e-6	Coronary artery calcification;
TGCT	cis	rs10504229	1.000	rs68114352	chr8:58196081	C/T	cg21724239	chr8:58056113	NA	0.38	4.76	0.39	5.41e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9517313	0.523	rs4772104	chr13:99235677	G/A	cg07423050	chr13:99094983	FARP1	-0.23	-4.53	-0.38	1.39e-5	Neuroticism;
TGCT	cis	rs4700695	0.511	rs29443	chr5:65504927	G/A	cg21114390	chr5:65439923	SFRS12	-0.79	-7.28	-0.55	3.36e-11	Facial morphology (factor 19);
TGCT	cis	rs7208859	0.673	rs78799101	chr17:29215160	A/T	cg14008862	chr17:28927542	LRRC37B2	0.72	4.66	0.39	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs2235642	1.000	rs2076438	chr16:1584618	T/C	cg07341220	chr16:1583899	IFT140;TMEM204	-0.29	-4.64	-0.38	8.66e-6	Coronary artery disease;
TGCT	cis	rs6121246	0.954	rs6060989	chr20:30429763	C/T	cg13852791	chr20:30311386	BCL2L1	0.76	5.67	0.45	9.7e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs2070488	0.689	rs6809352	chr3:38544349	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.71	-6.55	-0.51	1.4e-9	Electrocardiographic conduction measures;
TGCT	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg02725872	chr8:58115012	NA	-0.4	-4.83	-0.4	3.92e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.5	-5.96	-0.47	2.45e-8	Longevity;Endometriosis;
TGCT	cis	rs1048238	0.846	rs945417	chr1:16344625	C/G	cg22431228	chr1:16359049	CLCNKA	-0.29	-6.2	-0.49	7.76e-9	Systolic blood pressure;
TGCT	cis	rs7954584	0.583	rs6486782	chr12:122359172	T/C	cg10207240	chr12:122356781	WDR66	0.34	4.68	0.39	7.53e-6	Mean corpuscular volume;
TGCT	cis	rs9926296	0.581	rs2108838	chr16:89904426	A/G	cg26513180	chr16:89883248	FANCA	0.76	7.62	0.56	5.81e-12	Vitiligo;
TGCT	cis	rs79976124	0.797	rs78317899	chr6:66652896	C/A	cg07460842	chr6:66804631	NA	0.58	5.29	0.43	5.33e-7	Type 2 diabetes;
TGCT	cis	rs6831352	0.879	rs56295995	chr4:100060899	C/T	cg12011299	chr4:100065546	ADH4	-0.41	-4.97	-0.41	2.21e-6	Alcohol dependence;
TGCT	cis	rs9914544	1.000	rs9914544	chr17:18787828	A/C	cg26306683	chr17:18585705	ZNF286B	0.57	5.08	0.41	1.36e-6	Educational attainment (years of education);
TGCT	cis	rs10875595	0.836	rs6889723	chr5:140676524	C/T	cg24830062	chr5:140700576	TAF7	-0.75	-6.26	-0.49	5.78e-9	Pulmonary function decline;
TGCT	cis	rs7017914	0.934	rs7009297	chr8:71672366	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.53	-4.9	-0.4	2.87e-6	Bone mineral density;
TGCT	cis	rs3091242	0.900	rs1811832	chr1:25753565	G/A	cg00786635	chr1:25594202	NA	0.59	6.21	0.49	7.4e-9	Erythrocyte sedimentation rate;
TGCT	cis	rs1568889	0.548	rs34906813	chr11:28508819	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.66	4.62	0.38	9.62e-6	Bipolar disorder;
TGCT	trans	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.85	8.89	0.62	6.01e-15	Body mass index;
TGCT	cis	rs6754311	0.861	rs12475139	chr2:136786651	A/T	cg07169764	chr2:136633963	MCM6	0.51	4.54	0.38	1.3e-5	Mosquito bite size;
TGCT	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg12963246	chr6:28129442	ZNF389	0.51	5.02	0.41	1.73e-6	Depression;
TGCT	cis	rs877282	0.947	rs7904978	chr10:768078	C/T	cg17470449	chr10:769945	NA	0.34	5.13	0.42	1.1e-6	Uric acid levels;
TGCT	cis	rs11190604	1.000	rs2489036	chr10:102319581	A/G	cg16342193	chr10:102329863	NA	-0.39	-5.0	-0.41	1.92e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.14	0.42	1.06e-6	Prudent dietary pattern;
TGCT	cis	rs9393777	0.513	rs6904071	chr6:27047256	G/A	cg16898833	chr6:26189333	HIST1H4D	0.8	4.85	0.4	3.57e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9914988	0.832	rs4795462	chr17:27130991	C/T	cg20469991	chr17:27169893	C17orf63	-0.72	-5.09	-0.42	1.29e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs16866061	0.816	rs115900205	chr2:225467840	G/C	cg12698349	chr2:225449008	CUL3	1.0	9.08	0.63	2.11e-15	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	cis	rs2404602	0.536	rs7163946	chr15:76766049	C/G	cg26408565	chr15:76604113	ETFA	-0.37	-4.99	-0.41	2.03e-6	Blood metabolite levels;
TGCT	cis	rs7666738	0.830	rs2865949	chr4:99039967	A/G	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2742417	0.967	rs1969625	chr3:45734975	A/G	cg04837898	chr3:45731254	SACM1L	-0.55	-5.68	-0.45	9.14e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs6723226	0.806	rs2249109	chr2:32750879	G/A	cg02381751	chr2:32503542	YIPF4	0.55	5.05	0.41	1.56e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9816226	0.590	rs869401	chr3:185826546	G/A	cg00760338	chr3:185826511	ETV5	0.69	6.17	0.48	8.7e-9	Obesity;Body mass index;
TGCT	cis	rs77741769	0.507	rs11065264	chr12:121218380	T/G	cg02419362	chr12:121203948	SPPL3	0.19	4.47	0.37	1.74e-5	Mean corpuscular volume;
TGCT	cis	rs67311347	1.000	rs1466236	chr3:40462162	C/T	cg17264618	chr3:40429014	ENTPD3	0.32	4.76	0.39	5.36e-6	Renal cell carcinoma;
TGCT	cis	rs6714788	0.503	rs2309748	chr2:100681449	A/T	cg22139774	chr2:100720529	AFF3	-0.4	-6.15	-0.48	9.58e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg00343986	chr7:65444356	GUSB	-0.23	-5.16	-0.42	9.66e-7	Aortic root size;
TGCT	cis	rs4242434	0.927	rs7843828	chr8:22463623	C/T	cg03733263	chr8:22462867	KIAA1967	1.14	20.27	0.88	3.6e-41	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs651907	0.535	rs35799195	chr3:101521927	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	4.85	0.4	3.68e-6	Colorectal cancer;
TGCT	cis	rs981844	0.775	rs62323976	chr4:154739032	A/G	cg14289246	chr4:154710475	SFRP2	1.01	8.8	0.62	9.72e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs950169	0.519	rs7237	chr15:85186577	C/T	cg11189052	chr15:85197271	WDR73	0.68	5.82	0.46	4.72e-8	Schizophrenia;
TGCT	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg16414030	chr3:133502952	NA	-0.65	-10.6	-0.69	4.35e-19	Iron status biomarkers;
TGCT	cis	rs12142240	0.698	rs17361819	chr1:46828109	A/G	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs11677416	1.000	rs2856836	chr2:113532083	A/G	cg27083787	chr2:113543245	IL1A	0.18	4.5	0.37	1.53e-5	Response to antipsychotic treatment in schizophrenia (working memory);
TGCT	cis	rs13256369	1.000	rs873063	chr8:8572447	A/G	cg17143192	chr8:8559678	CLDN23	0.62	5.83	0.46	4.57e-8	Obesity-related traits;
TGCT	cis	rs2730245	0.583	rs2788473	chr7:158649280	T/C	cg11984989	chr7:158649758	WDR60	1.04	9.33	0.64	5.3e-16	Height;
TGCT	cis	rs6088590	1.000	rs11696546	chr20:33452999	C/G	cg06115741	chr20:33292138	TP53INP2	0.64	5.1	0.42	1.25e-6	Coronary artery disease;
TGCT	cis	rs12510870	0.599	rs34773614	chr4:74452245	A/G	cg05868023	chr4:75230803	EREG	-0.55	-4.74	-0.39	5.71e-6	Iris color (b* coordinate);
TGCT	cis	rs9921222	1.000	rs9921222	chr16:375782	A/G	cg08923669	chr16:420230	MRPL28	0.48	5.03	0.41	1.71e-6	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs2243480	1.000	rs160634	chr7:65528664	C/T	cg07424592	chr7:64974309	NA	-1.17	-8.11	-0.59	4.19e-13	Diabetic kidney disease;
TGCT	cis	rs13256369	1.000	rs10088439	chr8:8576699	T/G	cg18904891	chr8:8559673	CLDN23	0.63	5.82	0.46	4.83e-8	Obesity-related traits;
TGCT	cis	rs72781680	0.660	rs72780104	chr2:23983715	A/G	cg08917208	chr2:24149416	ATAD2B	0.83	5.24	0.43	6.62e-7	Lymphocyte counts;
TGCT	cis	rs17253792	0.822	rs17253723	chr14:56154015	A/G	cg01858014	chr14:56050164	KTN1	-0.35	-4.62	-0.38	9.37e-6	Putamen volume;
TGCT	cis	rs7666738	0.791	rs7658177	chr4:99035192	T/C	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7809950	0.773	rs62483722	chr7:107186349	C/T	cg23024343	chr7:107201750	COG5	-0.35	-5.54	-0.45	1.72e-7	Coronary artery disease;
TGCT	cis	rs2688608	0.592	rs7923045	chr10:75487498	A/T	cg23231163	chr10:75533350	FUT11	-0.27	-4.67	-0.39	7.62e-6	Inflammatory bowel disease;
TGCT	cis	rs889312	0.500	rs252905	chr5:56118875	C/T	cg24531977	chr5:56204891	C5orf35	-0.53	-5.43	-0.44	2.89e-7	Breast cancer;Breast cancer (early onset);
TGCT	cis	rs1150668	0.796	rs1005125	chr6:28367355	G/A	cg19488431	chr6:28601329	NA	0.2	4.54	0.38	1.33e-5	Pubertal anthropometrics;
TGCT	cis	rs4660261	0.526	rs3011228	chr1:44325995	A/G	cg12908607	chr1:44402522	ARTN	-0.64	-7.74	-0.57	3e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs9733	0.519	rs1336900	chr1:150679033	C/T	cg04414720	chr1:150670196	GOLPH3L	0.34	4.56	0.38	1.23e-5	Tonsillectomy;
TGCT	cis	rs2204008	0.694	rs1672436	chr12:38132547	G/T	cg26384229	chr12:38710491	ALG10B	-0.58	-5.09	-0.42	1.28e-6	Bladder cancer;
TGCT	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs7523050	0.730	rs67312582	chr1:109423976	A/G	cg08274380	chr1:109419600	GPSM2	1.35	6.86	0.52	2.89e-10	Fat distribution (HIV);
TGCT	cis	rs7213347	1.000	rs7213347	chr17:2153257	G/C	cg20777128	chr17:1945076	DPH1;OVCA2	-0.49	-4.48	-0.37	1.67e-5	Total body bone mineral density;
TGCT	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg03517284	chr6:25882590	NA	0.52	5.29	0.43	5.39e-7	Blood metabolite levels;
TGCT	cis	rs3020736	0.500	rs2413672	chr22:42513261	C/T	cg15557168	chr22:42548783	NA	0.22	5.58	0.45	1.47e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs113084984	0.718	rs1865574	chr2:11681438	A/G	cg25804072	chr2:10829725	NOL10	0.56	4.69	0.39	7.01e-6	Breast cancer;
TGCT	cis	rs78487399	0.808	rs7587268	chr2:43673892	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.42	-5.04	-0.41	1.62e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs7829975	0.511	rs2980426	chr8:8145609	T/C	cg06636001	chr8:8085503	FLJ10661	0.78	6.9	0.53	2.37e-10	Mood instability;
TGCT	cis	rs9372498	0.536	rs17424234	chr6:118808521	A/G	cg21191810	chr6:118973309	C6orf204	-0.37	-4.76	-0.39	5.36e-6	Diastolic blood pressure;
TGCT	cis	rs7614311	0.639	rs111234932	chr3:63842449	C/T	cg22134162	chr3:63841271	THOC7	-0.42	-4.68	-0.39	7.4e-6	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs11650494	0.908	rs79768864	chr17:47446968	C/A	cg08112188	chr17:47440006	ZNF652	1.04	5.31	0.43	4.85e-7	Prostate cancer;
TGCT	cis	rs9811920	0.928	rs2130369	chr3:99873317	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.41	-4.58	-0.38	1.14e-5	Axial length;
TGCT	cis	rs910316	1.000	rs876402	chr14:75601862	C/T	cg23033748	chr14:75592666	NEK9	-0.26	-4.52	-0.38	1.44e-5	Height;
TGCT	cis	rs9527	0.590	rs7920868	chr10:104795409	C/T	cg15744005	chr10:104629667	AS3MT	-0.41	-4.8	-0.4	4.43e-6	Arsenic metabolism;
TGCT	cis	rs7666738	0.830	rs1426666	chr4:99030887	A/G	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg13531842	chr10:38383804	ZNF37A	-0.38	-4.51	-0.38	1.49e-5	Extrinsic epigenetic age acceleration;
TGCT	cis	rs3806843	0.900	rs2563254	chr5:140142701	T/C	cg19875535	chr5:140030758	IK	-0.36	-6.17	-0.48	8.74e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs73198271	0.563	rs11783487	chr8:8541247	C/T	ch.8.214553F	chr8:8189620	PRAGMIN	-0.34	-5.51	-0.44	1.94e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs12780845	0.505	rs973307	chr10:17246333	C/T	cg01003015	chr10:17271136	VIM	-0.51	-4.54	-0.38	1.3e-5	Homocysteine levels;
TGCT	cis	rs7826238	0.653	rs2979202	chr8:8344127	T/C	cg15556689	chr8:8085844	FLJ10661	0.59	5.53	0.44	1.79e-7	Systolic blood pressure;
TGCT	cis	rs941408	1.000	rs1736176	chr19:2790394	G/A	cg06609049	chr19:2785107	THOP1	0.78	7.74	0.57	3.06e-12	Total cholesterol levels;
TGCT	cis	rs3845624	0.531	rs59012264	chr1:159251511	A/G	cg12277145	chr1:160232707	DCAF8	-0.36	-4.44	-0.37	1.97e-5	Inflammatory biomarkers;
TGCT	cis	rs1568889	1.000	rs12803716	chr11:28055111	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	8.86	0.62	7.07e-15	Bipolar disorder;
TGCT	cis	rs2153535	0.580	rs9406163	chr6:8466642	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs12497850	0.865	rs7649458	chr3:48920127	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.41	-5.49	-0.44	2.15e-7	Parkinson's disease;
TGCT	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg16325326	chr1:53192061	ZYG11B	0.62	6.85	0.52	3.05e-10	Monocyte count;
TGCT	cis	rs9914988	0.943	rs7217547	chr17:27106872	C/G	cg20469991	chr17:27169893	C17orf63	-0.66	-5.03	-0.41	1.65e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs7927592	0.731	rs11228288	chr11:68353550	A/G	cg16797656	chr11:68205561	LRP5	0.25	4.5	0.37	1.53e-5	Total body bone mineral density;
TGCT	trans	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg17830980	chr10:43048298	ZNF37B	-0.85	-10.98	-0.7	5.08e-20	Extrinsic epigenetic age acceleration;
TGCT	trans	rs148330122	1	rs148330122	chr19:38520324	C/T	cg12224730	chr15:35384648	NA	0.67	6.81	0.52	3.8e-10	Gut microbiota (bacterial taxa);
TGCT	cis	rs9549367	0.789	rs71446682	chr13:113894908	A/G	cg00898013	chr13:113819073	PROZ	-0.4	-5.03	-0.41	1.64e-6	Platelet distribution width;
TGCT	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.69	-7.06	-0.54	1.07e-10	Prostate cancer;
TGCT	cis	rs3806843	0.868	rs2563281	chr5:140131219	T/A	cg19875535	chr5:140030758	IK	-0.35	-5.97	-0.47	2.27e-8	Depressive symptoms (multi-trait analysis);
TGCT	trans	rs561341	1.000	rs68140514	chr17:30335781	T/C	cg20587970	chr11:113659929	NA	-1.05	-13.14	-0.76	3.03e-25	Hip circumference adjusted for BMI;
TGCT	cis	rs11098499	0.774	rs73842616	chr4:120290683	G/A	cg09307838	chr4:120376055	NA	0.58	5.75	0.46	6.63e-8	Corneal astigmatism;
TGCT	cis	rs7568458	0.870	rs1562323	chr2:85809711	T/C	cg02493740	chr2:85810744	VAMP5	-0.29	-5.06	-0.41	1.49e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs7666738	0.830	rs79075162	chr4:98960674	A/T	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2243480	1.000	rs160655	chr7:65533214	T/C	cg18252515	chr7:66147081	NA	-1.13	-7.39	-0.55	1.94e-11	Diabetic kidney disease;
TGCT	cis	rs2153535	0.580	rs7767780	chr6:8453462	A/G	cg07606381	chr6:8435919	SLC35B3	0.53	5.02	0.41	1.79e-6	Motion sickness;
TGCT	cis	rs2153535	0.601	rs2327091	chr6:8540369	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.67	0.45	9.45e-8	Motion sickness;
TGCT	cis	rs7635838	0.819	rs12714866	chr3:11539058	C/T	cg00170343	chr3:11313890	ATG7	0.68	6.36	0.5	3.46e-9	HDL cholesterol;
TGCT	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg13665807	chr20:60559372	TAF4	-0.46	-5.0	-0.41	1.92e-6	Body mass index;
TGCT	cis	rs35934224	0.783	rs34143881	chr22:19860093	A/G	cg11182965	chr22:19864308	TXNRD2	-0.38	-5.3	-0.43	5.04e-7	Glaucoma (primary open-angle);
TGCT	cis	rs6684514	1.000	rs6684514	chr1:156255456	G/A	cg16558208	chr1:156270281	VHLL	0.46	9.38	0.64	3.92e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs1475911	0.744	rs12481958	chr21:43517269	A/G	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.27	-5.43	-0.44	2.89e-7	IgG glycosylation;
TGCT	cis	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg18252515	chr7:66147081	NA	-1.31	-8.18	-0.59	2.87e-13	Diabetic kidney disease;
TGCT	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.66	-6.91	-0.53	2.3e-10	Longevity;Endometriosis;
TGCT	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg10047753	chr17:41438598	NA	0.96	9.6	0.65	1.16e-16	Menopause (age at onset);
TGCT	cis	rs6701037	0.566	rs1883102	chr1:175136793	T/A	cg08873628	chr1:175162347	KIAA0040	0.48	4.57	0.38	1.15e-5	Alcohol dependence;
TGCT	cis	rs7647973	0.593	rs9870755	chr3:49809841	A/G	cg05785598	chr3:49045655	WDR6	0.43	5.23	0.43	6.99e-7	Menarche (age at onset);
TGCT	cis	rs9807841	0.670	rs2569512	chr19:10790162	A/G	cg17848348	chr19:10766748	ILF3	-0.4	-4.58	-0.38	1.12e-5	Inflammatory skin disease;
TGCT	cis	rs6688613	1.000	rs12130629	chr1:166953284	C/T	cg07049167	chr1:166818506	POGK	0.21	4.52	0.38	1.43e-5	Refractive astigmatism;
TGCT	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg07806771	chr7:64541737	NA	0.44	4.55	0.38	1.26e-5	Calcium levels;
TGCT	cis	rs2404602	0.692	rs12902452	chr15:76921465	T/C	cg22467129	chr15:76604101	ETFA	-0.44	-4.98	-0.41	2.07e-6	Blood metabolite levels;
TGCT	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg07061783	chr6:25882402	NA	-0.55	-5.34	-0.43	4.34e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg22920501	chr2:26401640	FAM59B	-0.81	-6.36	-0.5	3.52e-9	Gut microbiome composition (summer);
TGCT	cis	rs7677751	0.806	rs4864861	chr4:55097685	C/T	cg17187183	chr4:55093834	PDGFRA	0.55	7.05	0.54	1.08e-10	Corneal astigmatism;
TGCT	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg10802521	chr3:52805072	NEK4	-0.71	-8.79	-0.62	1.04e-14	Bipolar disorder;
TGCT	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	5.11	0.42	1.18e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs4803468	0.901	rs3745292	chr19:41888506	A/G	cg09537434	chr19:41945824	ATP5SL	-0.88	-9.98	-0.67	1.4e-17	Height;
TGCT	cis	rs7611238	0.538	rs4677833	chr3:195091449	G/T	cg27323046	chr3:195102265	ACAP2	0.39	5.09	0.42	1.29e-6	Body mass index;
TGCT	cis	rs67478160	0.643	rs6576005	chr14:104292369	C/T	cg26031613	chr14:104095156	KLC1	-0.63	-6.35	-0.5	3.78e-9	Schizophrenia;
TGCT	cis	rs9478217	1	rs9478217	chr6:151874122	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	0.52	4.48	0.37	1.68e-5	Total body bone mineral density (age 30-45);
TGCT	cis	rs9911578	1.000	rs12947785	chr17:57045160	A/C	cg05425664	chr17:57184151	TRIM37	-0.62	-6.18	-0.49	8.33e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs12908161	1.000	rs56864281	chr15:85357649	C/A	cg11189052	chr15:85197271	WDR73	0.71	5.9	0.47	3.2e-8	Schizophrenia;
TGCT	cis	rs751728	0.965	rs756137	chr6:33755890	T/C	cg13859433	chr6:33739653	LEMD2	-0.43	-7.94	-0.58	1.04e-12	Crohn's disease;
TGCT	trans	rs980000	0.557	rs3784611	chr15:60910223	C/G	cg17159698	chr8:142842030	NA	-0.81	-6.63	-0.51	9.42e-10	Menarche (age at onset);
TGCT	cis	rs9611565	0.649	rs5758466	chr22:42176059	G/A	cg17554472	chr22:41940697	POLR3H	0.43	4.61	0.38	9.67e-6	Vitiligo;
TGCT	cis	rs7647973	0.626	rs2131108	chr3:49665390	C/T	cg05785598	chr3:49045655	WDR6	0.43	5.34	0.43	4.37e-7	Menarche (age at onset);
TGCT	cis	rs896854	0.654	rs16893776	chr8:95973604	C/T	cg16049864	chr8:95962084	TP53INP1	-0.73	-10.23	-0.68	3.4e-18	Type 2 diabetes;
TGCT	cis	rs8180040	0.701	rs11130111	chr3:47009805	C/T	cg27129171	chr3:47204927	SETD2	0.73	9.4	0.65	3.57e-16	Colorectal cancer;
TGCT	cis	rs12477438	0.520	rs2516835	chr2:99779131	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	14.89	0.8	2.21e-29	Chronic sinus infection;
TGCT	cis	rs9894429	0.527	rs7405469	chr17:79566596	G/C	cg21028142	chr17:79581711	NPLOC4	-0.27	-4.79	-0.39	4.75e-6	Eye color traits;
TGCT	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg10047753	chr17:41438598	NA	0.95	9.5	0.65	2.09e-16	Menopause (age at onset);
TGCT	cis	rs3806843	0.735	rs778596	chr5:140037272	G/A	cg19875535	chr5:140030758	IK	-0.36	-6.15	-0.48	9.57e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs4891159	1.000	rs4891159	chr18:74101941	A/G	cg24786174	chr18:74118243	ZNF516	0.52	7.21	0.54	4.72e-11	Longevity;
TGCT	cis	rs6121246	0.567	rs6060262	chr20:30193071	A/C	cg21427119	chr20:30132790	HM13	-0.38	-5.63	-0.45	1.14e-7	Mean corpuscular hemoglobin;
TGCT	cis	rs10488031	0.557	rs13232698	chr7:37119973	G/A	cg06458904	chr7:36312573	EEPD1	0.58	4.8	0.4	4.49e-6	QT interval;
TGCT	cis	rs55692411	0.537	rs35375092	chr3:50065274	G/A	cg14019146	chr3:50243930	SLC38A3	-0.21	-4.44	-0.37	1.98e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs12044355	0.516	rs2356383	chr1:231742973	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.6	-4.76	-0.39	5.25e-6	Alzheimer's disease;
TGCT	cis	rs7044106	0.537	rs10818474	chr9:123489964	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.62	6.52	0.51	1.59e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs6121246	0.567	rs6120890	chr20:30207659	T/G	cg10886678	chr20:30946050	ASXL1	-0.71	-4.8	-0.4	4.39e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs727563	0.648	rs6002406	chr22:41965237	A/T	cg13695892	chr22:41940480	POLR3H	-0.87	-8.08	-0.59	4.83e-13	Crohn's disease;Inflammatory bowel disease;
TGCT	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg01516881	chr6:292596	DUSP22	-0.7	-7.47	-0.56	1.27e-11	Menopause (age at onset);
TGCT	cis	rs3820928	0.874	rs3769646	chr2:227896330	C/T	cg11843606	chr2:227700838	RHBDD1	-0.54	-4.96	-0.41	2.29e-6	Pulmonary function;
TGCT	cis	rs12048904	0.619	rs10875346	chr1:101328083	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.91	8.36	0.6	1.07e-13	Multiple sclerosis;
TGCT	cis	rs4319547	0.695	rs11058034	chr12:122894936	G/T	cg08088222	chr12:122070432	ORAI1	-0.27	-4.62	-0.38	9.48e-6	Body mass index;
TGCT	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.5	-6.19	-0.49	8.15e-9	Longevity;Endometriosis;
TGCT	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg18305652	chr10:134549665	INPP5A	0.34	5.75	0.46	6.52e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	trans	rs797680	0.856	rs7535628	chr1:93648728	T/C	cg27528825	chr2:159282178	CCDC148	-0.35	-6.81	-0.52	3.79e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs4072980	0.527	rs11210825	chr1:38446986	G/A	cg26398791	chr1:38455867	SF3A3	-0.47	-4.56	-0.38	1.19e-5	Coronary artery disease;
TGCT	cis	rs7085104	0.591	rs4919683	chr10:104585125	G/T	cg15744005	chr10:104629667	AS3MT	-0.45	-5.66	-0.45	9.88e-8	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs12477438	0.501	rs34272114	chr2:99737443	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	14.89	0.8	2.21e-29	Chronic sinus infection;
TGCT	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg26338869	chr17:61819248	STRADA	-0.53	-4.85	-0.4	3.68e-6	Prudent dietary pattern;
TGCT	cis	rs6940638	0.531	rs12211984	chr6:26986054	G/C	cg02458000	chr6:26745757	NA	0.5	4.61	0.38	9.84e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	6.94	0.53	1.91e-10	Prudent dietary pattern;
TGCT	cis	rs6582630	0.555	rs11181053	chr12:38271364	T/C	cg26384229	chr12:38710491	ALG10B	-0.52	-4.6	-0.38	1.02e-5	Drug-induced liver injury (flucloxacillin);
TGCT	trans	rs1814175	0.647	rs1404157	chr11:49917301	G/C	cg15704280	chr7:45808275	SEPT13	-0.59	-6.82	-0.52	3.49e-10	Height;
TGCT	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs10789491	1.000	rs1258061	chr1:47105000	G/A	cg15501359	chr1:47185051	KIAA0494	-0.84	-8.4	-0.6	8.53e-14	Response to hepatitis C treatment;
TGCT	cis	rs9916302	0.706	rs1877030	chr17:37740161	T/C	cg07936489	chr17:37558343	FBXL20	-0.82	-5.57	-0.45	1.48e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs1577917	0.958	rs2225754	chr6:86449698	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-5.35	-0.43	4.17e-7	Response to antipsychotic treatment;
TGCT	cis	rs832540	0.866	rs832579	chr5:56164943	A/G	cg24531977	chr5:56204891	C5orf35	-0.5	-5.09	-0.42	1.28e-6	Coronary artery disease;
TGCT	cis	rs9733	0.503	rs7556451	chr1:150913142	A/G	cg09365446	chr1:150670422	GOLPH3L	0.34	4.71	0.39	6.58e-6	Tonsillectomy;
TGCT	cis	rs853679	0.585	rs201000	chr6:27809159	C/T	cg10876282	chr6:28092338	ZSCAN16	0.58	4.79	0.39	4.76e-6	Depression;
TGCT	cis	rs7714584	1.000	rs73282234	chr5:150195924	G/C	cg22134413	chr5:150180641	NA	1.17	8.69	0.62	1.76e-14	Crohn's disease;
TGCT	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg07507251	chr3:52567010	NT5DC2	0.47	6.7	0.52	6.47e-10	Bipolar disorder;
TGCT	cis	rs950169	0.840	rs4842853	chr15:84942304	G/T	cg12863693	chr15:85201151	NMB	0.45	4.96	0.41	2.28e-6	Schizophrenia;
TGCT	cis	rs6671200	1.000	rs71654418	chr1:95662658	G/T	cg03123541	chr1:95699097	RWDD3	0.87	6.17	0.48	8.81e-9	Stearic acid (18:0) levels;
TGCT	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg11644478	chr21:40555479	PSMG1	0.64	5.85	0.47	4.05e-8	Cognitive function;
TGCT	cis	rs1609391	0.543	rs6800690	chr3:136623026	G/A	cg15507776	chr3:136538369	TMEM22	0.66	6.84	0.52	3.27e-10	Neuroticism;
TGCT	cis	rs7264396	0.635	rs6058358	chr20:34492560	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.06	-0.41	1.47e-6	Total cholesterol levels;
TGCT	cis	rs9549260	0.816	rs7337995	chr13:41249040	A/G	cg21288729	chr13:41239152	FOXO1	0.97	10.0	0.67	1.24e-17	Red blood cell count;
TGCT	cis	rs1580019	0.587	rs1597555	chr7:32546118	T/G	cg07520158	chr7:32535189	LSM5;AVL9	0.58	4.96	0.41	2.25e-6	Cognitive ability;
TGCT	cis	rs2228479	0.850	rs57267516	chr16:89903552	G/A	cg06558623	chr16:89946397	TCF25	0.55	4.86	0.4	3.55e-6	Skin colour saturation;
TGCT	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg25036284	chr2:26402008	FAM59B	-0.58	-4.61	-0.38	1.01e-5	Gut microbiome composition (summer);
TGCT	cis	rs2549003	0.966	rs10072571	chr5:131816711	A/C	cg21138405	chr5:131827807	IRF1	0.2	5.08	0.41	1.36e-6	Asthma (sex interaction);
TGCT	cis	rs11190604	1.000	rs4919470	chr10:102298920	C/T	cg16342193	chr10:102329863	NA	-0.43	-5.3	-0.43	5.03e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7772486	0.875	rs2492855	chr6:146296926	A/G	cg05347473	chr6:146136440	FBXO30	0.53	5.02	0.41	1.72e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs911555	0.855	rs2071408	chr14:103987078	G/A	cg12935359	chr14:103987150	CKB	0.38	5.39	0.44	3.44e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs789859	0.897	rs1675923	chr3:194393208	A/G	cg21106136	chr3:194405973	FAM43A	-0.39	-5.16	-0.42	9.56e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
TGCT	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs35160687	0.901	rs7571424	chr2:86539160	A/G	cg12542933	chr2:85804724	VAMP8	0.37	4.46	0.37	1.8e-5	Night sleep phenotypes;
TGCT	cis	rs524281	0.817	rs10896092	chr11:65958046	A/C	cg00563793	chr11:65837595	PACS1	0.52	4.57	0.38	1.18e-5	Electroencephalogram traits;
TGCT	cis	rs62244186	0.545	rs9284880	chr3:44759389	C/T	cg02073558	chr3:44770973	ZNF501	0.73	7.31	0.55	2.82e-11	Depressive symptoms;
TGCT	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg01802117	chr1:53393560	SCP2	-0.43	-5.2	-0.42	7.91e-7	Monocyte count;
TGCT	cis	rs10501293	0.746	rs7944392	chr11:43006672	T/G	cg03447554	chr11:43094025	NA	0.44	6.28	0.49	5.2e-9	Cognitive performance;
TGCT	cis	rs78456975	1.000	rs55761535	chr2:1561450	A/G	cg01028140	chr2:1542097	TPO	-0.33	-4.53	-0.38	1.37e-5	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs72949976	0.864	rs13389834	chr2:214025112	G/A	cg08319019	chr2:214017104	IKZF2	-0.8	-7.47	-0.56	1.22e-11	Lung cancer;Squamous cell lung carcinoma;
TGCT	cis	rs56104184	0.615	rs73061693	chr19:49399941	C/A	cg17863274	chr19:49399704	TULP2	-0.54	-7.43	-0.55	1.58e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg20276088	chr3:133502917	NA	-0.24	-5.12	-0.42	1.15e-6	Iron status biomarkers;
TGCT	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	9.52	0.65	1.86e-16	Platelet count;
TGCT	cis	rs8017423	0.845	rs80167706	chr14:90727629	G/C	cg04374321	chr14:90722782	PSMC1	0.76	7.63	0.57	5.3e-12	Mortality in heart failure;
TGCT	cis	rs7914558	1.000	rs7094843	chr10:104806654	A/C	cg05855489	chr10:104503620	C10orf26	0.51	4.48	0.37	1.67e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs17376456	0.877	rs10059230	chr5:93450347	A/G	cg21475434	chr5:93447410	FAM172A	0.59	4.66	0.39	8.09e-6	Diabetic retinopathy;
TGCT	cis	rs3771570	1.000	rs62193205	chr2:242316512	C/T	cg21155796	chr2:242212141	HDLBP	0.94	6.69	0.51	6.9e-10	Prostate cancer;
TGCT	cis	rs2243480	1.000	rs160652	chr7:65538431	A/G	cg18252515	chr7:66147081	NA	-1.13	-7.39	-0.55	1.94e-11	Diabetic kidney disease;
TGCT	cis	rs10493773	0.532	rs1889919	chr1:86180034	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.52	-8.2	-0.59	2.63e-13	Urate levels in overweight individuals;
TGCT	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg23708337	chr7:1209742	NA	0.59	5.37	0.43	3.71e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7666738	0.830	rs13124689	chr4:98961182	A/T	cg17366294	chr4:99064904	C4orf37	0.74	7.56	0.56	7.89e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs858239	0.601	rs1981665	chr7:23167969	T/C	cg05602783	chr7:23145260	KLHL7	-0.65	-5.48	-0.44	2.32e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs185694	0.817	rs12874839	chr13:30891541	G/C	cg07600127	chr13:30881527	KATNAL1	0.63	5.49	0.44	2.21e-7	Antineutrophil cytoplasmic antibody-associated vasculitis;
TGCT	cis	rs7267979	0.844	rs6083824	chr20:25363057	G/A	cg16686733	chr20:25566563	NINL	-0.52	-4.93	-0.4	2.61e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7731657	0.537	rs2097797	chr5:130355151	C/T	cg08523029	chr5:130500466	HINT1	-0.61	-5.08	-0.42	1.34e-6	Fasting plasma glucose;
TGCT	cis	rs2629540	0.847	rs10901811	chr10:126417914	G/A	cg08799069	chr10:126477246	METTL10	0.29	4.45	0.37	1.9e-5	Cocaine dependence;
TGCT	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg24549020	chr5:56110836	MAP3K1	0.68	5.8	0.46	5.22e-8	Initial pursuit acceleration;
TGCT	cis	rs2455799	0.533	rs2470513	chr3:15750056	G/A	cg16303742	chr3:15540471	COLQ	-0.26	-4.86	-0.4	3.48e-6	Mean platelet volume;
TGCT	cis	rs9796	0.870	rs3101436	chr15:41287689	A/G	cg18705301	chr15:41695430	NDUFAF1	0.41	5.3	0.43	5.07e-7	Menopause (age at onset);
TGCT	trans	rs57221529	0.766	rs72706606	chr5:558609	T/C	cg25482853	chr8:67687455	SGK3	1.2	10.16	0.67	5.25e-18	Lung disease severity in cystic fibrosis;
TGCT	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs4664308	0.840	rs17218566	chr2:161054748	C/T	cg03641300	chr2:160917029	PLA2R1	-0.27	-6.81	-0.52	3.82e-10	Idiopathic membranous nephropathy;
TGCT	cis	rs7100689	0.577	rs873395	chr10:82037215	C/T	cg01528321	chr10:82214614	TSPAN14	-0.71	-6.88	-0.53	2.56e-10	Post bronchodilator FEV1;
TGCT	cis	rs28595532	0.920	rs116062544	chr4:119735548	G/C	cg14228332	chr4:119757509	SEC24D	1.32	6.38	0.5	3.2e-9	Cannabis dependence symptom count;
TGCT	cis	rs1371867	0.846	rs2439458	chr8:101297984	T/C	cg00191853	chr8:101177733	SPAG1	-0.23	-4.76	-0.39	5.2e-6	Atrioventricular conduction;
TGCT	cis	rs12477438	0.520	rs11695751	chr2:99708247	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.06	13.26	0.77	1.59e-25	Chronic sinus infection;
TGCT	cis	rs425277	0.583	rs3107151	chr1:2051513	T/G	cg03732007	chr1:2071316	PRKCZ	-0.26	-5.85	-0.46	4.16e-8	Height;
TGCT	cis	rs9814567	1.000	rs2177601	chr3:134245434	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.96	9.11	0.63	1.79e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs6964587	1.000	rs2269727	chr7:91752690	C/A	cg17063962	chr7:91808500	NA	0.89	9.51	0.65	1.95e-16	Breast cancer;
TGCT	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg11890956	chr21:40555474	PSMG1	1.15	12.32	0.74	2.88e-23	Cognitive function;
TGCT	cis	rs7192750	0.586	rs12444829	chr16:71959727	A/G	cg06353428	chr16:71660113	MARVELD3	0.82	7.38	0.55	2.03e-11	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs7267979	0.933	rs1130694	chr20:25276297	G/A	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1018836	0.923	rs12680211	chr8:91633434	C/T	cg16814680	chr8:91681699	NA	-0.84	-8.94	-0.63	4.67e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7149242	0.697	rs12882815	chr14:101183142	C/G	cg11193865	chr14:101193038	DLK1	-0.49	-5.44	-0.44	2.74e-7	Platelet count;
TGCT	cis	rs7439150	1.000	rs2227402	chr4:155486470	T/A	cg22130008	chr4:155548532	NA	-0.47	-5.8	-0.46	5.25e-8	Fibrinogen levels;
TGCT	cis	rs669446	0.561	rs641351	chr1:44083519	G/A	cg12908607	chr1:44402522	ARTN	-0.55	-5.9	-0.47	3.25e-8	Amyotrophic lateral sclerosis (age of onset);
TGCT	trans	rs877282	1.000	rs11253366	chr10:773386	C/T	cg22713356	chr15:30763199	NA	1.15	10.1	0.67	7.07e-18	Uric acid levels;
TGCT	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	5.84	0.46	4.3e-8	Bipolar disorder;
TGCT	cis	rs7429990	0.932	rs11720151	chr3:48140634	G/A	cg11946769	chr3:48343235	NME6	-0.55	-4.46	-0.37	1.81e-5	Educational attainment (years of education);
TGCT	cis	rs2404602	0.716	rs1125932	chr15:76820540	C/T	cg26408565	chr15:76604113	ETFA	-0.37	-4.74	-0.39	5.83e-6	Blood metabolite levels;
TGCT	cis	rs10791323	0.569	rs11223609	chr11:133741766	C/T	cg03690763	chr11:133734501	NA	-0.3	-5.16	-0.42	9.36e-7	Childhood ear infection;
TGCT	cis	rs1775715	0.737	rs12256714	chr10:32216262	A/G	cg14930904	chr10:32216787	ARHGAP12	-0.55	-5.31	-0.43	4.79e-7	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs6429082	0.749	rs3819974	chr1:235601958	G/T	cg26050004	chr1:235667680	B3GALNT2	-0.56	-4.81	-0.4	4.22e-6	Adiposity;
TGCT	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7044106	0.762	rs1158554	chr9:123400898	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.61	6.56	0.51	1.33e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs7552404	0.727	rs7547056	chr1:76279267	C/T	cg10523679	chr1:76189770	ACADM	0.75	7.21	0.54	4.89e-11	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs308403	0.506	rs309365	chr4:123659343	C/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.73	6.85	0.52	3e-10	Blood protein levels;
TGCT	cis	rs9914988	0.943	rs4794836	chr17:27082710	C/G	cg20469991	chr17:27169893	C17orf63	0.62	4.7	0.39	6.77e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs7666738	0.830	rs13133355	chr4:98919415	A/G	cg18180107	chr4:99064573	C4orf37	0.55	5.02	0.41	1.78e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6570726	0.967	rs373704	chr6:145860618	C/A	cg23711669	chr6:146136114	FBXO30	0.71	6.66	0.51	7.78e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg03609598	chr5:56110824	MAP3K1	-0.62	-4.46	-0.37	1.82e-5	Type 2 diabetes;
TGCT	cis	rs151997	1.000	rs27284	chr5:50198086	A/G	cg06027927	chr5:50259733	NA	0.49	5.03	0.41	1.68e-6	Callous-unemotional behaviour;
TGCT	cis	rs6088590	1.000	rs6119530	chr20:33403930	A/G	cg24642439	chr20:33292090	TP53INP2	0.68	6.06	0.48	1.48e-8	Coronary artery disease;
TGCT	cis	rs28595532	0.841	rs114155681	chr4:119736427	A/G	cg14228332	chr4:119757509	SEC24D	1.31	7.06	0.54	1.06e-10	Cannabis dependence symptom count;
TGCT	cis	rs2075165	0.901	rs6701440	chr1:156249505	A/G	cg16558208	chr1:156270281	VHLL	0.27	4.83	0.4	3.87e-6	Tonsillectomy;
TGCT	cis	rs1005224	0.853	rs61980778	chr14:76151532	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	0.67	5.96	0.47	2.45e-8	Large artery stroke;
TGCT	cis	rs709400	0.663	rs62007683	chr14:103894071	G/T	cg12935359	chr14:103987150	CKB	-0.34	-4.9	-0.4	2.95e-6	Body mass index;
TGCT	cis	rs7666738	0.830	rs4492007	chr4:98959848	A/T	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1580019	0.563	rs2392071	chr7:32572536	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.59	5.06	0.41	1.47e-6	Cognitive ability;
TGCT	cis	rs137699	0.958	rs137705	chr22:39751394	T/C	cg11247378	chr22:39784982	NA	-0.44	-4.69	-0.39	7.08e-6	IgG glycosylation;
TGCT	cis	rs3091242	0.806	rs35189848	chr1:25788422	A/G	cg09222892	chr1:25734099	RHCE	0.4	6.43	0.5	2.46e-9	Erythrocyte sedimentation rate;
TGCT	cis	rs208520	0.634	rs3909071	chr6:66836947	T/C	cg07460842	chr6:66804631	NA	-0.92	-9.51	-0.65	1.97e-16	Exhaled nitric oxide output;
TGCT	cis	rs929354	0.772	rs6954050	chr7:156978554	A/G	cg05182265	chr7:156933206	UBE3C	-0.39	-8.79	-0.62	1.03e-14	Body mass index;
TGCT	cis	rs2016266	0.859	rs10783575	chr12:53742885	C/T	cg16917193	chr12:54089295	NA	-0.6	-4.53	-0.38	1.34e-5	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs7584330	0.554	rs3751110	chr2:238427142	T/C	cg08992911	chr2:238395768	MLPH	0.7	4.72	0.39	6.32e-6	Prostate cancer;
TGCT	cis	rs2692947	0.683	rs1813381	chr2:96422939	C/T	cg22654517	chr2:96458247	NA	-0.23	-4.8	-0.4	4.44e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs10791097	0.668	rs10791102	chr11:130744977	G/A	cg12179176	chr11:130786555	SNX19	0.84	10.17	0.67	4.95e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs3008870	0.959	rs2815353	chr1:67483372	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.08	11.47	0.72	3.32e-21	Lymphocyte percentage of white cells;
TGCT	cis	rs11585357	0.895	rs112208664	chr1:17632010	G/A	cg08277548	chr1:17600880	PADI3	-0.95	-9.6	-0.65	1.15e-16	Hair shape;
TGCT	cis	rs12579753	0.879	rs7131927	chr12:82166313	T/C	cg07988820	chr12:82153109	PPFIA2	-0.69	-7.77	-0.57	2.56e-12	Resting heart rate;
TGCT	cis	rs854765	0.583	rs6502627	chr17:17849671	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.76	7.85	0.58	1.65e-12	Total body bone mineral density;
TGCT	cis	rs12220238	1.000	rs10824085	chr10:75911984	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.91	7.98	0.58	8.43e-13	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs17345786	0.906	rs58835747	chr3:101243634	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.42	-8.88	-0.62	6.33e-15	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2880765	0.545	rs17553734	chr15:86013059	C/G	cg13263323	chr15:86062960	AKAP13	0.22	4.8	0.4	4.41e-6	Coronary artery disease;
TGCT	cis	rs707040	1.000	rs2177672	chr2:155232079	C/G	cg18104148	chr2:154337490	NA	0.19	4.57	0.38	1.17e-5	Sudden cardiac arrest;
TGCT	cis	rs8078723	0.714	rs2241244	chr17:38153554	G/C	cg17467752	chr17:38218738	THRA	-0.55	-5.52	-0.44	1.93e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs2072499	0.966	rs887953	chr1:156191149	T/C	cg06970220	chr1:156163860	SLC25A44	0.74	5.94	0.47	2.71e-8	Testicular germ cell tumor;
TGCT	cis	rs7772486	0.654	rs6906402	chr6:146089307	C/G	cg13319975	chr6:146136371	FBXO30	0.58	5.29	0.43	5.27e-7	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg07870213	chr5:140052090	DND1	0.65	7.75	0.57	2.79e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs6840360	1.000	rs6535811	chr4:152598992	C/T	cg17479576	chr4:152424074	FAM160A1	-0.5	-5.4	-0.44	3.26e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9467773	0.620	rs9461275	chr6:26590801	C/T	cg11502198	chr6:26597334	ABT1	0.54	4.95	0.41	2.42e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg10150615	chr22:24372951	LOC391322	-0.71	-7.34	-0.55	2.5e-11	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9467773	0.933	rs2024970	chr6:26497520	T/A	cg26531700	chr6:26746687	NA	0.58	5.5	0.44	2.07e-7	Intelligence (multi-trait analysis);
TGCT	trans	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg21659725	chr3:3221576	CRBN	0.98	15.33	0.81	2.1000000000000002e-30	Intelligence (multi-trait analysis);
TGCT	cis	rs7394190	0.748	rs11000775	chr10:75539010	T/C	cg07699608	chr10:75541558	CHCHD1	0.79	5.44	0.44	2.72e-7	Incident atrial fibrillation;
TGCT	cis	rs526231	0.819	rs2288787	chr5:102600706	A/G	cg05225461	chr5:102596755	C5orf30	0.23	4.62	0.38	9.51e-6	Primary biliary cholangitis;
TGCT	cis	rs9650657	0.615	rs12541110	chr8:10695125	A/T	cg16664915	chr8:10907788	XKR6	-0.29	-4.71	-0.39	6.47e-6	Neuroticism;
TGCT	trans	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.82	8.44	0.6	6.82e-14	Body mass index;
TGCT	cis	rs2729354	0.817	rs2467327	chr11:57279228	A/G	cg24343310	chr11:57249947	NA	0.28	4.69	0.39	7.03e-6	Blood protein levels;
TGCT	cis	rs12103	0.749	rs2649599	chr1:1305493	A/G	cg16590012	chr1:1265354	TAS1R3	0.41	5.79	0.46	5.41e-8	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs539096	0.500	rs2527776	chr1:44345292	G/A	cg13606994	chr1:44402422	ARTN	-0.42	-4.52	-0.38	1.44e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg08280861	chr8:58055591	NA	0.39	5.61	0.45	1.26e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7666738	0.830	rs28761309	chr4:98867393	C/T	cg05340658	chr4:99064831	C4orf37	0.52	6.0	0.47	1.98e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs999943	0.846	rs1570760	chr6:33622933	C/T	cg14003231	chr6:33640908	ITPR3	0.4	4.86	0.4	3.48e-6	Obesity (extreme);
TGCT	cis	rs3096299	0.967	rs3102341	chr16:89450744	G/A	cg06640241	chr16:89574553	SPG7	0.69	6.77	0.52	4.56e-10	Multiple myeloma (IgH translocation);
TGCT	cis	rs853679	0.527	rs853690	chr6:28285482	G/A	cg18815343	chr6:28367644	ZSCAN12	-0.47	-4.87	-0.4	3.32e-6	Depression;
TGCT	cis	rs2067615	0.579	rs3910854	chr12:107165669	T/C	cg15890332	chr12:107067104	RFX4	0.29	5.63	0.45	1.15e-7	Heart rate;
TGCT	cis	rs9653442	0.527	rs2164712	chr2:100745404	C/G	cg22139774	chr2:100720529	AFF3	-0.38	-5.61	-0.45	1.23e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs77106637	0.769	rs11603313	chr11:72588177	G/A	cg03713592	chr11:72463424	ARAP1	0.9	6.14	0.48	1.05e-8	Type 2 diabetes;
TGCT	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg12419862	chr22:24373484	LOC391322	-0.79	-8.14	-0.59	3.55e-13	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg11301795	chr4:187892539	NA	-0.34	-5.26	-0.43	6.21e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10504229	0.861	rs57314710	chr8:58196051	T/C	cg24829409	chr8:58192753	C8orf71	-0.55	-4.77	-0.39	5.18e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg04267008	chr7:1944627	MAD1L1	-0.37	-4.87	-0.4	3.39e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs1997103	1.000	rs9649857	chr7:55411777	C/T	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs6977660	0.714	rs10260866	chr7:19793151	T/C	cg05791153	chr7:19748676	TWISTNB	0.88	5.05	0.41	1.52e-6	Thyroid stimulating hormone;
TGCT	cis	rs6570726	0.791	rs6913727	chr6:145899826	A/G	cg05347473	chr6:146136440	FBXO30	0.52	4.95	0.41	2.33e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4851266	0.898	rs13026143	chr2:100865406	A/G	cg22139774	chr2:100720529	AFF3	0.3	4.54	0.38	1.31e-5	Educational attainment;
TGCT	cis	rs8028182	0.636	rs4886715	chr15:75831449	C/T	cg20655648	chr15:75932815	IMP3	0.58	4.61	0.38	1e-5	Sudden cardiac arrest;
TGCT	trans	rs2469997	1.000	rs2469997	chr8:120353267	C/G	cg01792902	chr3:178864926	PIK3CA	-0.8	-6.64	-0.51	8.76e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs9462846	0.691	rs67059212	chr6:42913269	T/G	cg13397359	chr6:42928475	GNMT	0.6	4.59	0.38	1.06e-5	Blood protein levels;
TGCT	cis	rs17376456	0.597	rs7733142	chr5:93322795	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.53	-4.48	-0.37	1.68e-5	Diabetic retinopathy;
TGCT	cis	rs2303745	0.589	rs1465576	chr19:17398487	G/A	cg04248312	chr19:17393744	ANKLE1	-0.34	-5.54	-0.45	1.72e-7	Systemic lupus erythematosus;
TGCT	cis	rs78456975	0.527	rs72778003	chr2:1571487	G/A	cg12573674	chr2:1569213	NA	-0.48	-5.0	-0.41	1.91e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg16680214	chr1:154839983	KCNN3	-0.42	-9.25	-0.64	8.37e-16	Prostate cancer;
TGCT	cis	rs2354432	0.607	rs4950385	chr1:146656292	A/G	cg25205988	chr1:146714368	CHD1L	1.34	6.29	0.49	4.92e-9	Mitochondrial DNA levels;
TGCT	cis	rs1577917	1.000	rs10455158	chr6:86672825	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.48	-0.44	2.27e-7	Response to antipsychotic treatment;
TGCT	cis	rs9372498	0.536	rs9481825	chr6:118876092	C/T	cg07617317	chr6:118971624	C6orf204	0.5	5.42	0.44	3.03e-7	Diastolic blood pressure;
TGCT	cis	rs1801251	1.000	rs11555646	chr2:233599904	A/C	cg08000102	chr2:233561755	GIGYF2	0.63	6.35	0.5	3.77e-9	Coronary artery disease;
TGCT	cis	rs9611519	0.603	rs9607764	chr22:41411804	G/C	cg03806693	chr22:41940476	POLR3H	-0.64	-6.08	-0.48	1.36e-8	Neuroticism;
TGCT	cis	rs1577917	1.000	rs12212733	chr6:86726013	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.54	-0.45	1.73e-7	Response to antipsychotic treatment;
TGCT	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg02953382	chr22:24373134	LOC391322	0.82	7.01	0.53	1.37e-10	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs2172802	0.924	rs10018746	chr4:62445246	T/C	cg04118610	chr4:62707027	LPHN3	-0.39	-4.53	-0.38	1.39e-5	Partial epilepsies;
TGCT	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.72	-6.47	-0.5	2.04e-9	Tonsillectomy;
TGCT	cis	rs6866344	0.697	rs62392833	chr5:178135452	T/A	cg10224037	chr5:178157518	ZNF354A	0.92	8.04	0.59	6.16e-13	Neutrophil percentage of white cells;
TGCT	cis	rs6752107	0.935	rs10929326	chr2:234151045	T/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.2	4.88	0.4	3.13e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs1401999	1.000	rs869417	chr3:183689138	T/C	cg01324343	chr3:183735012	ABCC5	0.82	10.97	0.7	5.41e-20	Anterior chamber depth;
TGCT	cis	rs4638749	0.953	rs4676033	chr2:108869368	G/A	cg06795125	chr2:108905320	SULT1C2	-0.36	-4.55	-0.38	1.25e-5	Blood pressure;
TGCT	cis	rs7412746	0.611	rs16827671	chr1:150738759	T/C	cg09365446	chr1:150670422	GOLPH3L	0.33	4.75	0.39	5.64e-6	Melanoma;
TGCT	cis	rs7267979	0.966	rs6083855	chr20:25405118	A/G	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7209700	0.889	rs11079769	chr17:45349731	A/T	cg17185639	chr17:45330862	ITGB3	0.19	4.83	0.4	3.98e-6	IgG glycosylation;
TGCT	cis	rs9467711	0.606	rs9379858	chr6:26367689	T/C	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	trans	rs28735056	1.000	rs56376220	chr18:77609462	C/T	cg05926928	chr17:57297772	GDPD1	-0.7	-7.71	-0.57	3.52e-12	Schizophrenia;
TGCT	cis	rs2797160	0.651	rs1343121	chr6:126036184	C/T	cg05901451	chr6:126070800	HEY2	0.77	6.91	0.53	2.27e-10	Endometrial cancer;
TGCT	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg22166914	chr1:53195759	ZYG11B	-0.42	-7.46	-0.56	1.29e-11	Monocyte count;
TGCT	cis	rs981844	0.890	rs55917677	chr4:154701051	C/T	cg14289246	chr4:154710475	SFRP2	1.05	9.32	0.64	5.44e-16	Response to statins (LDL cholesterol change);
TGCT	cis	rs7043114	0.525	rs9299404	chr9:95170338	A/G	cg14631576	chr9:95140430	CENPP	0.28	4.64	0.38	8.9e-6	Height;
TGCT	cis	rs7584330	0.697	rs60278044	chr2:238357118	A/G	cg14458575	chr2:238380390	NA	0.52	7.84	0.58	1.79e-12	Prostate cancer;
TGCT	cis	rs6684514	1.000	rs10494304	chr1:156285764	C/G	cg20302342	chr1:156215951	PAQR6	-0.35	-4.74	-0.39	5.77e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg06238570	chr21:40685208	BRWD1	-0.83	-8.83	-0.62	8.44e-15	Cognitive function;
TGCT	cis	rs12220238	0.722	rs12360087	chr10:76373904	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.67	5.11	0.42	1.17e-6	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg12667521	chr19:29218732	NA	0.54	5.72	0.46	7.65e-8	Methadone dose in opioid dependence;
TGCT	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg11062466	chr8:58055876	NA	0.34	4.67	0.39	7.79e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs758747	0.531	rs13332500	chr16:3575270	A/C	cg07396092	chr16:3662230	BTBD12	0.53	4.75	0.39	5.6e-6	Body mass index;
TGCT	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg07636037	chr3:49044803	WDR6	0.96	10.59	0.69	4.61e-19	Parkinson's disease;
TGCT	cis	rs2046867	0.818	rs17690720	chr3:72866030	T/C	cg25664220	chr3:72788482	NA	-0.56	-7.04	-0.53	1.16e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9473924	1.000	rs9473932	chr6:50857995	G/A	cg14470998	chr6:50812995	TFAP2B	0.61	4.48	0.37	1.7e-5	Body mass index;
TGCT	cis	rs854765	0.663	rs1108648	chr17:17750558	G/A	cg04398451	chr17:18023971	MYO15A	0.3	4.59	0.38	1.09e-5	Total body bone mineral density;
TGCT	cis	rs9818758	0.556	rs9835439	chr3:49220330	G/C	cg00383909	chr3:49044727	WDR6	1.26	6.33	0.49	4.1e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs7017914	0.967	rs13261712	chr8:71732264	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.55	-5.1	-0.42	1.24e-6	Bone mineral density;
TGCT	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg00484396	chr16:3507460	NAT15	0.43	6.52	0.51	1.62e-9	Tuberculosis;
TGCT	cis	rs36051895	0.658	rs62541531	chr9:5011795	C/T	cg02405213	chr9:5042618	JAK2	-0.8	-11.07	-0.7	3.18e-20	Pediatric autoimmune diseases;
TGCT	cis	rs6089584	0.566	rs11699442	chr20:60623268	A/G	cg13770153	chr20:60521292	NA	-0.4	-4.85	-0.4	3.65e-6	Body mass index;
TGCT	cis	rs9653442	0.527	rs2118280	chr2:100746395	G/A	cg07810366	chr2:100720526	AFF3	-0.37	-5.2	-0.42	8.01e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs360798	0.532	rs2136737	chr2:62969310	G/C	cg17519650	chr2:63277830	OTX1	-0.55	-4.66	-0.39	8.12e-6	Coronary artery disease;
TGCT	cis	rs10791323	0.604	rs2723615	chr11:133704567	C/T	cg15485101	chr11:133734466	NA	0.42	5.29	0.43	5.28e-7	Childhood ear infection;
TGCT	trans	rs208520	0.690	rs1738970	chr6:66809491	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.97	-10.61	-0.69	4.11e-19	Exhaled nitric oxide output;
TGCT	cis	rs6740322	0.841	rs10211126	chr2:43551416	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.4	-6.77	-0.52	4.47e-10	Coronary artery disease;
TGCT	cis	rs925228	0.504	rs7568272	chr2:24313785	T/C	cg01493198	chr2:24299560	SF3B14	0.73	4.75	0.39	5.43e-6	Reticulocyte fraction of red cells;Reticulocyte count;
TGCT	cis	rs6964587	0.934	rs6973792	chr7:91749798	C/A	cg17063962	chr7:91808500	NA	0.88	9.42	0.65	3.2e-16	Breast cancer;
TGCT	cis	rs910316	0.737	rs175072	chr14:75502827	T/C	cg11812906	chr14:75593930	NEK9	-0.58	-5.52	-0.44	1.92e-7	Height;
TGCT	cis	rs11626933	1.000	rs3825661	chr14:90767607	C/T	cg14092571	chr14:90743983	NA	0.32	6.73	0.52	5.73e-10	Gut microbiota (bacterial taxa);
TGCT	cis	rs1153858	1.000	rs12593370	chr15:45617417	C/T	cg14582100	chr15:45693742	SPATA5L1	0.48	5.66	0.45	9.96e-8	Homoarginine levels;
TGCT	cis	rs2060793	0.712	rs11023310	chr11:14725263	T/G	cg00085434	chr11:14927489	NA	0.34	4.68	0.39	7.45e-6	Vitamin D levels;
TGCT	cis	rs637571	0.522	rs566590	chr11:65754062	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.65	6.38	0.5	3.14e-9	Eosinophil percentage of white cells;
TGCT	cis	rs826838	0.967	rs826855	chr12:39114888	T/C	cg13010199	chr12:38710504	ALG10B	-0.64	-5.07	-0.41	1.39e-6	Heart rate;
TGCT	cis	rs42648	0.837	rs42615	chr7:89950501	G/T	cg25739043	chr7:89950458	NA	-0.73	-7.29	-0.55	3.2e-11	Homocysteine levels;
TGCT	cis	rs2115630	0.967	rs12595786	chr15:85336670	T/C	cg11189052	chr15:85197271	WDR73	-0.59	-5.56	-0.45	1.59e-7	P wave terminal force;
TGCT	cis	rs6940638	0.688	rs9393790	chr6:27114052	A/C	cg15659132	chr6:26577336	NA	0.52	4.6	0.38	1.02e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg08280861	chr8:58055591	NA	0.47	5.28	0.43	5.6e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9467711	0.606	rs9379856	chr6:26366836	A/C	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12142240	0.698	rs6684274	chr1:46810842	A/G	cg00530320	chr1:46809349	NSUN4	-0.3	-6.32	-0.49	4.24e-9	Menopause (age at onset);
TGCT	cis	rs7119038	0.818	rs11826521	chr11:118610549	G/T	cg19308663	chr11:118741387	NA	0.28	5.25	0.43	6.5e-7	Sjögren's syndrome;
TGCT	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg24399712	chr22:39784796	NA	-1.07	-13.49	-0.77	4.49e-26	Intelligence (multi-trait analysis);
TGCT	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg22683308	chr4:1340831	KIAA1530	-0.65	-6.14	-0.48	1.02e-8	Longevity;
TGCT	cis	rs4253772	0.550	rs738444	chr22:46721088	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.69	5.31	0.43	4.82e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs9325144	0.650	rs6582631	chr12:38744135	T/C	cg26384229	chr12:38710491	ALG10B	0.61	5.61	0.45	1.26e-7	Morning vs. evening chronotype;
TGCT	cis	rs6089829	0.888	rs4809268	chr20:61675249	C/G	cg03213289	chr20:61660250	NA	0.72	9.45	0.65	2.69e-16	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7568458	0.846	rs2028900	chr2:85767735	A/G	cg17127132	chr2:85788382	GGCX	-0.67	-6.29	-0.49	5.04e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs11785400	0.793	rs4336593	chr8:143739647	A/C	cg24634471	chr8:143751801	JRK	-0.56	-5.7	-0.46	8.27e-8	Schizophrenia;
TGCT	cis	rs6912958	0.559	rs376633	chr6:88042785	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.48	6.35	0.5	3.65e-9	Monocyte percentage of white cells;
TGCT	cis	rs12681287	0.927	rs2953517	chr8:87332013	C/T	cg27223183	chr8:87520930	FAM82B	-0.88	-6.82	-0.52	3.62e-10	Caudate activity during reward;
TGCT	cis	rs6860806	0.507	rs183898	chr5:131716902	C/G	cg24060327	chr5:131705240	SLC22A5	0.78	8.53	0.61	4.27e-14	Breast cancer;
TGCT	cis	rs4851266	1.000	rs7566527	chr2:100811970	C/T	cg07810366	chr2:100720526	AFF3	-0.37	-5.3	-0.43	5.04e-7	Educational attainment;
TGCT	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg22535103	chr8:58192502	C8orf71	-0.39	-4.73	-0.39	5.97e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs11673344	0.504	rs35162188	chr19:37579810	G/A	cg08039142	chr19:36980659	ZNF566	0.5	4.6	0.38	1.02e-5	Obesity-related traits;
TGCT	cis	rs26868	0.742	rs26848	chr16:2263516	A/G	cg07762234	chr16:2261099	C16orf79	-0.29	-5.19	-0.42	8.36e-7	Height;
TGCT	cis	rs12368653	0.591	rs1552842	chr12:58012163	A/G	cg12615879	chr12:58013172	SLC26A10	-0.52	-6.24	-0.49	6.47e-9	Multiple sclerosis;
TGCT	cis	rs76878669	0.561	rs2279861	chr11:66133336	A/G	cg18002602	chr11:66138449	SLC29A2	0.54	6.62	0.51	9.76e-10	Educational attainment (years of education);
TGCT	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	5.79	0.46	5.36e-8	Bipolar disorder;
TGCT	cis	rs9308731	0.583	rs2165107	chr2:111931350	C/G	cg04202892	chr2:111875749	ACOXL	0.46	5.14	0.42	1.02e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.07	0.82	4.17e-32	Prudent dietary pattern;
TGCT	cis	rs1670533	1.000	rs13135215	chr4:1054364	A/G	cg27284194	chr4:1044797	NA	0.69	5.71	0.46	7.76e-8	Recombination rate (females);
TGCT	cis	rs6500550	0.597	rs2285814	chr16:3565123	G/T	cg07396092	chr16:3662230	BTBD12	0.53	4.72	0.39	6.24e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;White blood cell count;Neutrophil count;
TGCT	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.34	0.55	2.43e-11	Prudent dietary pattern;
TGCT	cis	rs3806843	0.735	rs702394	chr5:140086786	A/G	cg19875535	chr5:140030758	IK	-0.37	-6.23	-0.49	6.51e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs17253792	0.822	rs17685102	chr14:56129214	A/G	cg01858014	chr14:56050164	KTN1	-0.35	-4.65	-0.39	8.23e-6	Putamen volume;
TGCT	cis	rs476633	0.691	rs28568756	chr15:41539371	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.55	-7.43	-0.56	1.54e-11	Glomerular filtration rate (creatinine);
TGCT	cis	rs9486719	1.000	rs12191653	chr6:96903898	T/C	cg18709589	chr6:96969512	KIAA0776	-0.68	-5.05	-0.41	1.55e-6	Migraine;Coronary artery disease;
TGCT	cis	rs295137	0.836	rs10804097	chr2:201104924	A/T	cg23649088	chr2:200775458	C2orf69	0.34	5.82	0.46	4.79e-8	Asthma (bronchodilator response);
TGCT	cis	rs752092	0.925	rs8032007	chr15:101790817	C/T	cg25114630	chr15:101792522	CHSY1	-0.53	-5.1	-0.42	1.22e-6	Corneal structure;
TGCT	cis	rs3806843	0.576	rs155361	chr5:140307284	G/A	cg09824255	chr5:140014002	CD14	0.25	4.59	0.38	1.09e-5	Depressive symptoms (multi-trait analysis);
TGCT	trans	rs797680	0.786	rs555161	chr1:93676314	A/G	cg27528825	chr2:159282178	CCDC148	-0.35	-6.88	-0.53	2.65e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs16910800	0.731	rs59845980	chr11:23191511	T/G	cg20040320	chr11:23191996	NA	-0.51	-4.47	-0.37	1.71e-5	Cancer;
TGCT	cis	rs17401966	0.838	rs4846207	chr1:10313811	T/C	cg19773385	chr1:10388646	KIF1B	-0.2	-4.5	-0.37	1.54e-5	Hepatocellular carcinoma;
TGCT	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg00080972	chr5:178986291	RUFY1	-0.57	-7.22	-0.54	4.63e-11	Lung cancer;
TGCT	cis	rs950169	0.920	rs2135551	chr15:84707851	A/G	cg11189052	chr15:85197271	WDR73	0.7	5.94	0.47	2.64e-8	Schizophrenia;
TGCT	trans	rs877282	0.853	rs12777155	chr10:754731	G/C	cg22713356	chr15:30763199	NA	1.07	8.27	0.6	1.75e-13	Uric acid levels;
TGCT	cis	rs62244186	0.545	rs725866	chr3:44765533	A/G	cg10263370	chr3:44754102	ZNF502	-0.45	-5.35	-0.43	4.08e-7	Depressive symptoms;
TGCT	cis	rs734999	0.545	rs10910105	chr1:2538209	G/A	cg18854424	chr1:2615690	NA	0.41	4.58	0.38	1.13e-5	Ulcerative colitis;
TGCT	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg03303774	chr4:1407052	NA	0.31	4.96	0.41	2.25e-6	Obesity-related traits;
TGCT	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg18135555	chr8:22132992	PIWIL2	0.3	6.09	0.48	1.29e-8	Hypertriglyceridemia;
TGCT	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.49	-6.87	-0.53	2.72e-10	Alzheimer's disease;
TGCT	trans	rs2727020	0.658	rs10839269	chr11:49385596	A/G	cg15704280	chr7:45808275	SEPT13	-0.74	-8.25	-0.6	1.97e-13	Coronary artery disease;
TGCT	cis	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg08975724	chr8:8085496	FLJ10661	0.64	5.92	0.47	2.89e-8	Mood instability;
TGCT	cis	rs4319547	0.585	rs7953007	chr12:122816977	A/C	cg08088222	chr12:122070432	ORAI1	0.26	4.69	0.39	7.14e-6	Body mass index;
TGCT	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg10047753	chr17:41438598	NA	0.96	9.6	0.65	1.16e-16	Menopause (age at onset);
TGCT	cis	rs2033711	0.905	rs1077420	chr19:58968875	A/C	cg12042659	chr19:58951599	ZNF132	0.56	4.99	0.41	2.03e-6	Uric acid clearance;
TGCT	cis	rs2228479	0.850	rs17226980	chr16:89825065	G/A	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs6121246	0.529	rs6060134	chr20:30176794	A/G	cg18721089	chr20:30220636	NA	-0.63	-6.86	-0.52	2.95e-10	Mean corpuscular hemoglobin;
TGCT	cis	rs3020736	0.500	rs6002616	chr22:42504679	A/G	cg05082376	chr22:42548792	NA	0.23	5.43	0.44	2.83e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs933688	1.000	rs1541674	chr5:90660447	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.08	10.13	0.67	6.16e-18	Smoking behavior;
TGCT	cis	rs7949030	0.596	rs11231138	chr11:62316195	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.6	8.45	0.6	6.5e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9811920	0.715	rs6810262	chr3:99906342	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.39	-4.57	-0.38	1.17e-5	Axial length;
TGCT	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg19761014	chr17:28927070	LRRC37B2	-0.54	-4.67	-0.39	7.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs796364	0.694	rs1653299	chr2:201075611	A/G	cg23649088	chr2:200775458	C2orf69	0.33	4.77	0.39	5.01e-6	Schizophrenia;
TGCT	cis	rs986417	0.901	rs1007152	chr14:60999493	C/T	cg27398547	chr14:60952738	C14orf39	1.49	10.78	0.7	1.64e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg07424592	chr7:64974309	NA	1.27	7.84	0.58	1.8e-12	Diabetic kidney disease;
TGCT	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg03934478	chr11:495069	RNH1	0.35	5.82	0.46	4.66e-8	Body mass index;
TGCT	trans	rs629535	0.862	rs662725	chr8:70029616	C/T	cg21567404	chr3:27674614	NA	0.58	9.18	0.64	1.22e-15	Dupuytren's disease;
TGCT	cis	rs72843506	0.722	rs9897168	chr17:20034274	T/G	cg18979559	chr17:20280153	CCDC144C	-0.65	-4.87	-0.4	3.33e-6	Schizophrenia;
TGCT	cis	rs9913156	0.793	rs55677157	chr17:4576620	C/T	cg00122941	chr17:4613640	ARRB2	0.88	6.88	0.53	2.6200000000000003e-10	Lymphocyte counts;
TGCT	cis	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg20637647	chr7:64974828	NA	1.0	5.59	0.45	1.4e-7	Diabetic kidney disease;
TGCT	cis	rs72843506	0.652	rs28550747	chr17:20178312	A/G	cg18979559	chr17:20280153	CCDC144C	-0.65	-4.93	-0.4	2.61e-6	Schizophrenia;
TGCT	cis	rs77669868	0.929	rs76761091	chr11:114067058	A/G	cg01914181	chr11:114070210	ZBTB16	0.34	5.72	0.46	7.53e-8	Monocyte percentage of white cells;
TGCT	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg23758822	chr17:41437982	NA	0.72	6.99	0.53	1.51e-10	Menopause (age at onset);
TGCT	cis	rs826838	0.616	rs4418873	chr12:38625473	C/A	cg26384229	chr12:38710491	ALG10B	0.55	5.0	0.41	1.93e-6	Heart rate;
TGCT	cis	rs797680	0.822	rs1057257	chr1:93621483	A/G	cg17826107	chr1:92977322	EVI5	-0.24	-5.19	-0.42	8.19e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs7674212	0.507	rs223361	chr4:103769304	T/C	cg16532752	chr4:104119610	CENPE	-0.62	-5.59	-0.45	1.41e-7	Type 2 diabetes;
TGCT	cis	rs950169	0.922	rs17531523	chr15:85132449	C/G	cg12863693	chr15:85201151	NMB	0.39	4.44	0.37	1.98e-5	Schizophrenia;
TGCT	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.68	5.62	0.45	1.18e-7	Tonsillectomy;
TGCT	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.48	-0.37	1.66e-5	Bipolar disorder;
TGCT	cis	rs9682041	0.696	rs6774380	chr3:170091644	T/A	cg11886554	chr3:170076028	SKIL	0.61	4.78	0.39	4.77e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs910316	1.000	rs175426	chr14:75624134	C/T	cg11812906	chr14:75593930	NEK9	-0.74	-7.23	-0.54	4.25e-11	Height;
TGCT	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg00343986	chr7:65444356	GUSB	-0.23	-5.16	-0.42	9.66e-7	Aortic root size;
TGCT	cis	rs3809566	0.963	rs4775608	chr15:63331940	A/G	cg00520135	chr15:63333846	TPM1	-0.44	-5.46	-0.44	2.44e-7	Platelet count;
TGCT	cis	rs2637266	0.935	rs12259550	chr10:78352843	A/G	cg18941641	chr10:78392320	NA	0.42	5.2	0.42	8.09e-7	Pulmonary function;
TGCT	cis	rs79057730	0.599	rs6951032	chr7:794092	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.68	5.55	0.45	1.67e-7	Initial pursuit acceleration;
TGCT	cis	rs912057	0.833	rs1294424	chr6:6744135	G/A	cg06612196	chr6:6737390	NA	0.37	4.88	0.4	3.17e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	5.99	0.47	2.09e-8	Bipolar disorder;
TGCT	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg12516959	chr21:47718080	NA	0.33	4.89	0.4	3.07e-6	Testicular germ cell tumor;
TGCT	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg17554472	chr22:41940697	POLR3H	0.46	4.71	0.39	6.63e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs13191362	1.000	rs35126854	chr6:163012443	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.57	4.94	0.41	2.45e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs11031096	0.516	rs7113845	chr11:3989226	C/G	cg18678763	chr11:4115507	RRM1	-0.42	-5.14	-0.42	1.04e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	7.24	0.55	4.17e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7666738	0.830	rs10856936	chr4:99011319	T/C	cg18180107	chr4:99064573	C4orf37	0.52	4.85	0.4	3.57e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3806843	0.548	rs246038	chr5:140331699	A/G	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs911555	0.713	rs1107070	chr14:103970508	G/T	cg12935359	chr14:103987150	CKB	0.33	4.47	0.37	1.73e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs514406	0.505	rs387436	chr1:53179376	C/T	cg08859206	chr1:53392774	SCP2	0.36	5.23	0.42	7.05e-7	Monocyte count;
TGCT	cis	rs6762	0.642	rs28692469	chr11:839675	T/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.45	-4.5	-0.37	1.53e-5	Mean platelet volume;
TGCT	cis	rs172166	0.560	rs203878	chr6:28048996	T/G	cg13525197	chr6:28411240	ZSCAN23	-0.48	-4.71	-0.39	6.43e-6	Cardiac Troponin-T levels;
TGCT	cis	rs11096990	0.656	rs2066788	chr4:39301605	G/C	cg20847110	chr4:39482781	LOC401127	-0.16	-4.52	-0.38	1.43e-5	Cognitive function;
TGCT	cis	rs9467711	0.790	rs1979	chr6:26377591	G/T	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs13315871	1.000	rs71311869	chr3:58398922	C/T	cg12435725	chr3:58293450	RPP14	-0.43	-4.47	-0.37	1.71e-5	Cholesterol, total;
TGCT	cis	rs3796352	1.000	rs11713859	chr3:53042080	C/A	cg15956490	chr3:53032818	SFMBT1	0.62	6.82	0.52	3.6e-10	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs933688	1.000	rs10058025	chr5:90689052	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.99	8.15	0.59	3.39e-13	Smoking behavior;
TGCT	cis	rs7565124	1.000	rs60676431	chr2:20263863	G/A	cg00462460	chr2:20212509	MATN3	-0.43	-4.64	-0.38	8.68e-6	Major depressive disorder;
TGCT	cis	rs10791097	0.694	rs4936123	chr11:130740967	G/A	cg05962950	chr11:130786565	SNX19	0.9	11.18	0.71	1.72e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs12477438	0.520	rs7572660	chr2:99788582	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.02	11.79	0.73	5.47e-22	Chronic sinus infection;
TGCT	cis	rs4273100	0.646	rs4924987	chr17:19247075	G/A	cg03910582	chr17:19030146	GRAPL	-0.51	-6.21	-0.49	7.47e-9	Schizophrenia;
TGCT	trans	rs797680	0.821	rs7551485	chr1:93751280	G/A	cg27528825	chr2:159282178	CCDC148	0.34	6.71	0.52	6.32e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs10510102	0.872	rs7916008	chr10:123703093	A/G	cg23691251	chr10:123688108	ATE1	-0.58	-4.58	-0.38	1.11e-5	Breast cancer;
TGCT	cis	rs2224391	0.628	rs2753231	chr6:5248915	C/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.98	-6.21	-0.49	7.43e-9	Height;
TGCT	cis	rs35306767	0.903	rs12769002	chr10:927666	C/G	cg20503657	chr10:835505	NA	-0.8	-11.26	-0.71	1.05e-20	Eosinophil percentage of granulocytes;
TGCT	cis	rs734999	0.505	rs4648659	chr1:2560903	T/G	cg18854424	chr1:2615690	NA	-0.45	-5.15	-0.42	1e-6	Ulcerative colitis;
TGCT	cis	rs6582630	0.555	rs10785443	chr12:38463792	A/C	cg26384229	chr12:38710491	ALG10B	0.82	7.5	0.56	1.09e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs6089584	0.507	rs6061990	chr20:60628429	T/G	cg06108461	chr20:60628389	TAF4	-0.41	-5.11	-0.42	1.2e-6	Body mass index;
TGCT	cis	rs7772486	0.754	rs857881	chr6:145970793	C/A	cg13319975	chr6:146136371	FBXO30	0.56	4.97	0.41	2.22e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs910316	1.000	rs3742780	chr14:75505008	G/C	cg11812906	chr14:75593930	NEK9	0.74	7.25	0.55	3.97e-11	Height;
TGCT	cis	rs7172809	0.573	rs11854466	chr15:77584733	T/C	cg22256960	chr15:77711686	NA	-0.47	-4.61	-0.38	9.99e-6	Glucose homeostasis traits;
TGCT	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg06238570	chr21:40685208	BRWD1	0.79	8.66	0.61	2.14e-14	Cognitive function;
TGCT	cis	rs6964587	0.839	rs13229273	chr7:91444472	G/A	cg17063962	chr7:91808500	NA	0.83	8.41	0.6	8.35e-14	Breast cancer;
TGCT	cis	rs986417	1.000	rs713336	chr14:60974958	T/G	cg27398547	chr14:60952738	C14orf39	1.39	10.61	0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs1163251	0.869	rs487884	chr1:120217330	C/T	cg19096424	chr1:120255104	PHGDH	0.56	5.29	0.43	5.46e-7	Blood metabolite levels;
TGCT	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	5.08	0.42	1.34e-6	Bipolar disorder;
TGCT	cis	rs11578119	0.933	rs12124515	chr1:170452501	C/T	cg09767346	chr1:170501363	GORAB	0.66	5.29	0.43	5.27e-7	Male-pattern baldness;
TGCT	cis	rs7727544	0.716	rs10058655	chr5:131570896	A/T	cg24060327	chr5:131705240	SLC22A5	-0.55	-5.23	-0.42	7.13e-7	Blood metabolite levels;
TGCT	cis	rs765787	0.530	rs1648286	chr15:45517386	G/C	cg24006582	chr15:45444508	DUOX1	-0.26	-5.62	-0.45	1.19e-7	Uric acid levels;
TGCT	cis	rs11096990	0.634	rs7564	chr4:39287322	C/T	cg20847110	chr4:39482781	LOC401127	-0.16	-4.51	-0.38	1.46e-5	Cognitive function;
TGCT	cis	rs6998277	1.000	rs62523306	chr8:103640752	C/A	cg10187029	chr8:103597600	NA	0.47	5.91	0.47	3.05e-8	Migraine;
TGCT	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg01448562	chr3:133502909	NA	-0.33	-6.71	-0.52	6.3e-10	Iron status biomarkers;
TGCT	cis	rs17076896	0.609	rs77801871	chr13:19929336	A/G	cg00777926	chr13:20807375	GJB6	-0.37	-4.51	-0.38	1.5e-5	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg13206674	chr6:150067644	NUP43	0.51	4.45	0.37	1.91e-5	Lung cancer;
TGCT	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg18867708	chr6:26865862	GUSBL1	-0.39	-5.16	-0.42	9.66e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs734999	0.967	rs2495365	chr1:2498027	A/G	cg18854424	chr1:2615690	NA	0.47	5.78	0.46	5.71e-8	Ulcerative colitis;
TGCT	cis	rs4808199	1.000	rs4808199	chr19:19545099	C/T	cg03709012	chr19:19516395	GATAD2A	0.97	7.64	0.57	5.05e-12	Nonalcoholic fatty liver disease;
TGCT	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.6	-5.38	-0.43	3.65e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs9976767	0.637	rs11909930	chr21:43822200	C/A	cg23042151	chr21:43824109	UBASH3A	-0.22	-4.75	-0.39	5.46e-6	Type 1 diabetes;
TGCT	cis	rs7267979	1.000	rs6107047	chr20:25442097	G/A	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4595586	0.545	rs12816546	chr12:39398913	C/T	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs7937682	0.632	rs11823089	chr11:111673539	A/G	cg09085632	chr11:111637200	PPP2R1B	0.81	7.16	0.54	6.29e-11	Primary sclerosing cholangitis;
TGCT	cis	rs6138458	0.626	rs6050259	chr20:25011423	A/G	cg26195577	chr20:24973756	C20orf3	0.99	9.24	0.64	8.46e-16	Blood protein levels;
TGCT	cis	rs72843506	0.591	rs117720402	chr17:20347611	C/T	cg18052601	chr17:19850474	AKAP10	0.28	4.6	0.38	1.02e-5	Schizophrenia;
TGCT	cis	rs7412746	0.611	rs72704679	chr1:150897477	C/T	cg09365446	chr1:150670422	GOLPH3L	0.34	4.71	0.39	6.58e-6	Melanoma;
TGCT	cis	rs11971779	0.818	rs12056045	chr7:139025430	C/G	cg07862535	chr7:139043722	LUC7L2	0.76	5.74	0.46	6.98e-8	Diisocyanate-induced asthma;
TGCT	cis	rs600231	0.708	rs3132767	chr11:65234860	C/T	cg17120908	chr11:65337727	SSSCA1	-0.55	-5.16	-0.42	9.53e-7	Bone mineral density;
TGCT	cis	rs2302045	1.000	rs2240539	chr2:242035544	G/C	cg04553960	chr2:241721320	KIF1A	-0.7	-4.68	-0.39	7.4e-6	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio);
TGCT	cis	rs853679	0.546	rs200949	chr6:27835435	A/G	cg08798685	chr6:27730294	NA	-0.34	-4.69	-0.39	7.2e-6	Depression;
TGCT	cis	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg06636001	chr8:8085503	FLJ10661	0.68	6.01	0.47	1.94e-8	Mood instability;
TGCT	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg24531977	chr5:56204891	C5orf35	-0.74	-7.14	-0.54	7.06e-11	Initial pursuit acceleration;
TGCT	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg22166914	chr1:53195759	ZYG11B	0.38	6.18	0.49	8.32e-9	Monocyte count;
TGCT	cis	rs12549025	0.536	rs9644077	chr8:23360332	C/T	cg00472375	chr8:23315376	ENTPD4	0.67	5.23	0.42	7.07e-7	Reticulocyte fraction of red cells;
TGCT	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg03188948	chr7:1209495	NA	0.59	4.82	0.4	4.06e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs3771570	0.901	rs10190033	chr2:242412358	A/C	cg21155796	chr2:242212141	HDLBP	0.89	6.86	0.52	2.88e-10	Prostate cancer;
TGCT	cis	rs4689388	0.926	rs11725500	chr4:6293919	C/G	cg25554036	chr4:6271136	WFS1	0.54	7.37	0.55	2.11e-11	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	trans	rs1814175	0.754	rs10219245	chr11:49645052	C/T	cg15704280	chr7:45808275	SEPT13	-0.73	-8.64	-0.61	2.33e-14	Height;
TGCT	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg00814883	chr7:100076585	TSC22D4	-0.9	-9.56	-0.65	1.5e-16	Platelet count;
TGCT	cis	rs9952991	0.883	rs2542147	chr18:12775851	G/T	cg09945482	chr18:12777974	NA	0.5	4.75	0.39	5.61e-6	Inflammatory skin disease;
TGCT	cis	rs10875595	0.836	rs758346	chr5:140674734	C/A	cg24830062	chr5:140700576	TAF7	-0.61	-5.14	-0.42	1.04e-6	Pulmonary function decline;
TGCT	cis	rs6663390	0.510	rs6540445	chr1:208081467	A/G	cg03990033	chr1:208084030	CD34	-0.7	-6.08	-0.48	1.36e-8	Facial morphology (factor 18);
TGCT	cis	rs8013055	0.796	rs4075104	chr14:106000214	C/A	cg23356831	chr14:105996513	TMEM121	0.34	5.31	0.43	4.91e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs2760061	0.598	rs1774755	chr1:228115282	T/G	cg18477163	chr1:228402036	OBSCN	-0.31	-6.27	-0.49	5.55e-9	Diastolic blood pressure;
TGCT	cis	rs2708977	0.965	rs12717781	chr2:97249142	G/A	cg01950434	chr2:97203154	ARID5A	0.64	5.84	0.46	4.38e-8	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs666930	0.519	rs477992	chr1:120257576	A/G	cg19096424	chr1:120255104	PHGDH	0.64	5.88	0.47	3.62e-8	Breast cancer;
TGCT	trans	rs6740731	0.518	rs35766785	chr2:145295628	C/T	cg19463199	chr3:197401858	MIR922;KIAA0226	0.38	6.77	0.52	4.64e-10	Coronary artery disease;
TGCT	trans	rs1974653	0.672	rs9606231	chr22:20065276	T/C	cg08822737	chr17:71088851	SLC39A11	-0.9	-7.22	-0.54	4.57e-11	Schizophrenia;
TGCT	cis	rs2629540	0.765	rs12221075	chr10:126534855	G/A	cg08799069	chr10:126477246	METTL10	-0.28	-4.58	-0.38	1.12e-5	Cocaine dependence;
TGCT	cis	rs4808199	1.000	rs17288409	chr19:19504167	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.7	5.07	0.41	1.41e-6	Nonalcoholic fatty liver disease;
TGCT	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	8.39	0.6	9.03e-14	Platelet count;
TGCT	cis	rs10782582	0.609	rs10873797	chr1:76377191	G/T	cg03433033	chr1:76189801	ACADM	-0.5	-4.88	-0.4	3.15e-6	Daytime sleep phenotypes;
TGCT	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4455778	0.501	rs10250970	chr7:49052491	T/C	cg26309511	chr7:48887640	NA	0.51	6.67	0.51	7.54e-10	Lung cancer in never smokers;
TGCT	cis	rs968567	0.559	rs174544	chr11:61567753	C/A	cg01500311	chr11:61656094	FADS3	-0.32	-5.34	-0.43	4.25e-7	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
TGCT	cis	rs2153535	0.580	rs7767756	chr6:8453428	A/C	cg07606381	chr6:8435919	SLC35B3	0.53	5.02	0.41	1.79e-6	Motion sickness;
TGCT	cis	rs13326165	0.760	rs1077142	chr3:52403526	A/G	cg07884673	chr3:53033167	SFMBT1	0.4	4.86	0.4	3.45e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs11208691	0.513	rs72480644	chr1:66159417	C/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.63	4.85	0.4	3.63e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs2688608	0.592	rs11000758	chr10:75493610	A/T	cg15838173	chr10:75533400	FUT11	-0.31	-5.02	-0.41	1.73e-6	Inflammatory bowel disease;
TGCT	cis	rs7103648	0.695	rs11039290	chr11:47572279	G/A	cg20307385	chr11:47447363	PSMC3	0.88	8.56	0.61	3.56e-14	Diastolic blood pressure;Systolic blood pressure;
TGCT	cis	rs4268898	0.697	rs10445892	chr2:24406958	T/C	cg05570707	chr2:24270316	C2orf44	0.49	4.84	0.4	3.73e-6	Asthma;
TGCT	cis	rs611744	0.967	rs655707	chr8:109197530	T/C	cg21045802	chr8:109455806	TTC35	0.5	4.5	0.37	1.53e-5	Dupuytren's disease;
TGCT	cis	rs13202913	0.837	rs9397054	chr6:151789912	C/T	cg03627880	chr6:151815985	C6orf97	-0.76	-5.84	-0.46	4.24e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs7267979	0.899	rs442834	chr20:25458096	A/G	cg14121845	chr20:25566513	NINL	0.49	5.36	0.43	3.83e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg17345569	chr6:42928274	GNMT	-0.47	-4.81	-0.4	4.25e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs2050392	0.799	rs2907	chr10:30728250	A/G	cg18806716	chr10:30721971	MAP3K8	-0.51	-6.0	-0.47	2.05e-8	Inflammatory bowel disease;
TGCT	cis	rs7267979	0.932	rs367666	chr20:25449818	T/C	cg14121845	chr20:25566513	NINL	0.5	5.42	0.44	3.01e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6426558	0.537	rs488104	chr1:227300277	G/A	cg10327440	chr1:227177885	CDC42BPA	0.58	6.91	0.53	2.21e-10	Neutrophil percentage of white cells;
TGCT	trans	rs561341	0.609	rs2051810	chr17:30195841	C/T	cg20587970	chr11:113659929	NA	0.67	8.22	0.59	2.35e-13	Hip circumference adjusted for BMI;
TGCT	cis	rs7147624	0.572	rs2411813	chr14:66023906	G/A	cg03016385	chr14:66212404	NA	-0.49	-6.56	-0.51	1.32e-9	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs10089	0.953	rs72794400	chr5:127516028	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	8.06	0.59	5.58e-13	Ileal carcinoids;
TGCT	cis	rs4654899	0.785	rs7531381	chr1:21403348	A/G	cg01072550	chr1:21505969	NA	-0.56	-9.15	-0.63	1.42e-15	Superior frontal gyrus grey matter volume;
TGCT	cis	rs7503807	0.967	rs4889867	chr17:78593058	C/T	cg06872548	chr17:78716983	RPTOR	0.25	4.56	0.38	1.2e-5	Obesity;
TGCT	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.71	6.36	0.5	3.53e-9	Tonsillectomy;
TGCT	cis	rs4689388	0.926	rs4343789	chr4:6285228	C/G	cg00701064	chr4:6280414	WFS1	0.46	6.31	0.49	4.55e-9	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs11644362	0.966	rs12933348	chr16:12991081	C/T	cg06890432	chr16:12997467	SHISA9	-0.61	-6.87	-0.52	2.78e-10	Positive affect;Subjective well-being;
TGCT	cis	rs10744422	0.858	rs4759389	chr12:123308615	A/G	cg25930673	chr12:123319894	HIP1R	-0.85	-4.97	-0.41	2.13e-6	Schizophrenia;
TGCT	cis	rs7209700	0.547	rs10514919	chr17:45342129	G/T	cg21624342	chr17:45890973	OSBPL7	0.19	4.77	0.39	5.02e-6	IgG glycosylation;
TGCT	cis	rs4478858	0.735	rs4949393	chr1:31851875	G/A	cg00250761	chr1:31883323	NA	-0.25	-4.46	-0.37	1.83e-5	Alcohol dependence;
TGCT	cis	rs35883536	0.647	rs2783702	chr1:101040836	G/A	cg06223162	chr1:101003688	GPR88	0.42	8.0	0.58	7.5e-13	Monocyte count;
TGCT	cis	rs8180040	0.966	rs3816779	chr3:47543389	C/T	cg27129171	chr3:47204927	SETD2	0.64	7.68	0.57	4.17e-12	Colorectal cancer;
TGCT	cis	rs3796352	1.000	rs3796352	chr3:52913279	C/T	cg15956490	chr3:53032818	SFMBT1	0.56	4.94	0.41	2.52e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs3099143	0.908	rs3102716	chr15:77051003	T/G	cg21673338	chr15:77095150	SCAPER	-0.51	-5.12	-0.42	1.11e-6	Recalcitrant atopic dermatitis;
TGCT	cis	rs1050631	1.000	rs1050631	chr18:33694120	A/G	cg25426722	chr18:33708991	SLC39A6;ELP2	-0.49	-4.86	-0.4	3.43e-6	Esophageal squamous cell cancer (length of survival);
TGCT	cis	rs916888	0.610	rs199452	chr17:44801340	C/T	cg15921436	chr17:44337874	NA	0.41	6.25	0.49	5.98e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs11190604	0.767	rs11190519	chr10:102175133	C/T	cg16005271	chr10:102321736	NA	0.45	4.74	0.39	5.87e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7178572	0.688	rs12591335	chr15:77774894	A/G	cg22256960	chr15:77711686	NA	0.83	6.95	0.53	1.88e-10	Type 2 diabetes;
TGCT	cis	rs28595532	0.920	rs116108618	chr4:119763585	C/T	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs3008870	1.000	rs2985811	chr1:67377722	G/T	cg03991309	chr1:68237761	GNG12	0.27	4.68	0.39	7.28e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs7777754	0.734	rs4947709	chr7:50672907	A/G	cg18232548	chr7:50535776	DDC	-0.31	-4.96	-0.41	2.29e-6	Response to zileuton treatment in asthma (FEV1 change interaction);
TGCT	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs1008375	0.966	rs3733576	chr4:17586703	T/C	cg18681998	chr4:17616180	MED28	0.85	8.18	0.59	2.86e-13	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs67311347	1.000	rs7625736	chr3:40441345	C/G	cg13683864	chr3:40499215	RPL14	1.01	10.44	0.68	1.1e-18	Renal cell carcinoma;
TGCT	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	6.14	0.48	1.03e-8	Bipolar disorder;
TGCT	cis	rs62380364	0.602	rs665324	chr5:88055517	T/C	cg22951263	chr5:87985283	NA	-0.59	-6.32	-0.49	4.3e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs4919044	0.866	rs835265	chr10:94786259	A/G	cg05127821	chr10:94822908	CYP26C1	-0.74	-4.83	-0.4	3.95e-6	Coronary artery disease;
TGCT	cis	rs853679	0.585	rs201004	chr6:27804934	T/C	cg10876282	chr6:28092338	ZSCAN16	0.58	4.79	0.39	4.76e-6	Depression;
TGCT	cis	rs4711350	0.953	rs942496	chr6:33788055	A/G	cg18005901	chr6:33739558	LEMD2	-0.59	-6.08	-0.48	1.36e-8	Schizophrenia;
TGCT	cis	rs2236918	0.710	rs1776138	chr1:242027075	G/A	cg04158730	chr1:242011433	EXO1	0.56	5.36	0.43	3.88e-7	Menopause (age at onset);
TGCT	cis	rs8077577	0.945	rs34474249	chr17:18074525	T/C	cg09161412	chr17:18057145	MYO15A	-0.67	-5.44	-0.44	2.69e-7	Obesity-related traits;
TGCT	cis	rs9611565	0.649	rs5751144	chr22:42128097	A/G	cg13695892	chr22:41940480	POLR3H	-0.83	-8.18	-0.59	2.79e-13	Vitiligo;
TGCT	cis	rs75059851	0.756	rs7127156	chr11:133839857	T/C	cg14047540	chr11:133829660	NA	-0.57	-5.69	-0.45	8.72e-8	Schizophrenia;
TGCT	cis	rs7017914	0.967	rs12680166	chr8:71678638	G/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.53	-4.9	-0.4	2.87e-6	Bone mineral density;
TGCT	cis	rs9467773	0.935	rs9461270	chr6:26544110	A/G	cg15659132	chr6:26577336	NA	0.86	12.17	0.74	6.67e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs4689388	0.890	rs6838400	chr4:6295427	C/G	cg25554036	chr4:6271136	WFS1	0.53	7.33	0.55	2.58e-11	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs17376456	0.569	rs6879620	chr5:93119893	G/A	cg25358565	chr5:93447407	FAM172A	-0.76	-6.68	-0.51	7.23e-10	Diabetic retinopathy;
TGCT	cis	rs854765	0.718	rs6502629	chr17:17869642	A/G	cg09796270	chr17:17721594	SREBF1	0.26	5.13	0.42	1.09e-6	Total body bone mineral density;
TGCT	cis	rs9527	0.637	rs12219247	chr10:104613361	A/G	cg04362960	chr10:104952993	NT5C2	0.55	4.74	0.39	5.7e-6	Arsenic metabolism;
TGCT	cis	rs3749237	0.595	rs1464566	chr3:49459376	T/C	cg02487422	chr3:49467188	NICN1	0.58	5.92	0.47	3e-8	Resting heart rate;
TGCT	cis	rs7523050	0.730	rs41279678	chr1:109440215	G/A	cg08274380	chr1:109419600	GPSM2	1.35	6.86	0.52	2.89e-10	Fat distribution (HIV);
TGCT	cis	rs7208859	0.673	rs9913782	chr17:29237384	A/G	cg18442181	chr17:29233375	C17orf42	-0.78	-4.61	-0.38	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7760949	0.889	rs9475806	chr6:13934527	A/G	cg27413430	chr6:13925136	RNF182	0.73	6.79	0.52	4.22e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs35146811	0.735	rs1727130	chr7:99811464	C/G	cg22906224	chr7:99728672	NA	-0.49	-4.45	-0.37	1.88e-5	Coronary artery disease;
TGCT	cis	rs2688608	0.592	rs11814282	chr10:75490217	T/C	cg04320760	chr10:75533139	FUT11	-0.4	-6.25	-0.49	6.11e-9	Inflammatory bowel disease;
TGCT	cis	rs2243480	1.000	rs10807702	chr7:65767843	C/T	cg07424592	chr7:64974309	NA	1.35	7.47	0.56	1.27e-11	Diabetic kidney disease;
TGCT	cis	rs35306767	0.903	rs12761424	chr10:967295	C/T	cg20503657	chr10:835505	NA	0.65	9.44	0.65	2.93e-16	Eosinophil percentage of granulocytes;
TGCT	cis	rs10782582	0.609	rs79835994	chr1:76287508	G/T	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.52	4.53	0.38	1.37e-5	Daytime sleep phenotypes;
TGCT	cis	rs1372520	0.684	rs2619356	chr4:90750844	C/T	cg14346243	chr4:90757452	SNCA	-0.67	-5.64	-0.45	1.09e-7	Neuroticism;
TGCT	cis	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg08045932	chr20:61659980	NA	0.48	9.28	0.64	7.07e-16	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7809950	0.817	rs4727678	chr7:107083635	C/G	cg23024343	chr7:107201750	COG5	-0.48	-7.05	-0.54	1.08e-10	Coronary artery disease;
TGCT	cis	rs72781680	0.898	rs56179550	chr2:23934867	C/T	cg08917208	chr2:24149416	ATAD2B	0.89	5.41	0.44	3.11e-7	Lymphocyte counts;
TGCT	cis	rs11167764	0.945	rs7720832	chr5:141473097	T/G	cg08523384	chr5:141488047	NDFIP1	-0.24	-4.91	-0.4	2.85e-6	Crohn's disease;
TGCT	cis	rs2692947	0.567	rs4907276	chr2:96391109	G/T	cg00336220	chr2:96940284	SNRNP200	-0.16	-4.44	-0.37	1.96e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs500492	0.542	rs2744148	chr16:1073552	A/G	cg01366354	chr16:1075121	NA	0.34	5.02	0.41	1.77e-6	Polycystic ovary syndrome;
TGCT	cis	rs7267979	0.966	rs2500433	chr20:25296335	A/G	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1061377	1.000	rs7676008	chr4:39121774	G/C	cg24403649	chr4:39172243	NA	0.18	4.44	0.37	1.99e-5	Uric acid levels;
TGCT	cis	rs4689388	0.890	rs4342257	chr4:6290037	G/C	cg25554036	chr4:6271136	WFS1	0.54	7.54	0.56	8.85e-12	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs6964587	1.000	rs10234434	chr7:91673308	A/T	cg17063962	chr7:91808500	NA	0.88	9.65	0.66	8.73e-17	Breast cancer;
TGCT	cis	rs7937682	0.889	rs551825	chr11:111480116	C/G	cg09085632	chr11:111637200	PPP2R1B	-1.05	-11.39	-0.72	5.21e-21	Primary sclerosing cholangitis;
TGCT	cis	rs7666738	0.830	rs13139078	chr4:99020774	C/T	cg05340658	chr4:99064831	C4orf37	0.48	5.43	0.44	2.92e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg11965913	chr1:205819406	PM20D1	0.63	9.98	0.67	1.38e-17	Menarche (age at onset);
TGCT	cis	rs7726839	0.574	rs72705014	chr5:619815	C/G	cg20362242	chr5:692897	TPPP	0.52	4.48	0.37	1.68e-5	Obesity-related traits;
TGCT	cis	rs10791097	0.694	rs4459316	chr11:130756176	T/C	cg05962950	chr11:130786565	SNX19	0.9	11.06	0.7	3.32e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg07424592	chr7:64974309	NA	0.54	5.29	0.43	5.44e-7	Calcium levels;
TGCT	cis	rs9942416	0.601	rs40059	chr5:74964582	A/G	cg02573091	chr5:74908125	NA	-0.39	-4.56	-0.38	1.22e-5	Age-related disease endophenotypes;
TGCT	cis	rs9457247	1.000	rs376551	chr6:167384923	G/A	cg23791538	chr6:167370224	RNASET2	-0.5	-4.98	-0.41	2.08e-6	Crohn's disease;
TGCT	cis	rs1577917	0.958	rs4707229	chr6:86546237	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.29	-0.43	5.34e-7	Response to antipsychotic treatment;
TGCT	cis	rs9911578	1.000	rs8071916	chr17:56660279	A/G	cg05425664	chr17:57184151	TRIM37	-0.63	-6.28	-0.49	5.09e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs12580194	0.593	rs55637917	chr12:55747565	T/C	cg10672482	chr12:55725839	OR6C3	-0.51	-4.43	-0.37	2.01e-5	Cancer;
TGCT	cis	rs2204008	0.749	rs4579984	chr12:38166266	A/G	cg26384229	chr12:38710491	ALG10B	0.85	7.68	0.57	4.21e-12	Bladder cancer;
TGCT	cis	rs17030434	0.682	rs1339	chr4:154631563	T/C	cg14289246	chr4:154710475	SFRP2	-0.73	-5.39	-0.44	3.41e-7	Electrocardiographic conduction measures;
TGCT	cis	rs4746818	0.793	rs2008553	chr10:70860475	C/G	cg11621586	chr10:70884670	VPS26A	1.07	8.98	0.63	3.62e-15	Left atrial antero-posterior diameter;
TGCT	cis	rs7674212	0.570	rs6813563	chr4:104099110	G/A	cg16532752	chr4:104119610	CENPE	-0.59	-5.37	-0.43	3.76e-7	Type 2 diabetes;
TGCT	cis	rs7772486	0.875	rs9390371	chr6:146363180	A/G	cg05347473	chr6:146136440	FBXO30	0.52	4.93	0.41	2.54e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9916302	0.784	rs4795361	chr17:37573446	G/A	cg07936489	chr17:37558343	FBXL20	-0.65	-4.98	-0.41	2.11e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs9381040	0.655	rs7775972	chr6:41038116	A/C	cg03526776	chr6:41159608	TREML2	0.27	5.37	0.43	3.78e-7	Alzheimer's disease (late onset);
TGCT	cis	rs1348850	0.626	rs1901825	chr2:178225331	A/T	cg22681709	chr2:178499509	PDE11A	-0.35	-4.54	-0.38	1.3e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs6920364	1	rs6920364	chr6:167376466	G/C	cg23791538	chr6:167370224	RNASET2	0.53	5.19	0.42	8.41e-7	Lung cancer;
TGCT	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg00814883	chr7:100076585	TSC22D4	-0.85	-8.62	-0.61	2.62e-14	Platelet count;
TGCT	cis	rs11098499	0.691	rs9995716	chr4:120264996	T/C	cg09307838	chr4:120376055	NA	0.55	5.41	0.44	3.16e-7	Corneal astigmatism;
TGCT	cis	rs1150668	0.796	rs1124132	chr6:28380321	T/G	cg13525197	chr6:28411240	ZSCAN23	-0.51	-5.0	-0.41	1.93e-6	Pubertal anthropometrics;
TGCT	cis	rs6964587	1.000	rs2282971	chr7:91584356	A/G	cg17063962	chr7:91808500	NA	0.85	9.43	0.65	2.97e-16	Breast cancer;
TGCT	cis	rs12291225	0.585	rs10832242	chr11:14340504	C/T	cg19336497	chr11:14380999	RRAS2	0.45	7.25	0.55	3.87e-11	Sense of smell;
TGCT	cis	rs10465746	0.780	rs11163872	chr1:84421969	G/T	cg10977910	chr1:84465055	TTLL7	0.66	6.73	0.52	5.71e-10	Obesity-related traits;
TGCT	cis	rs5760092	0.755	rs6003959	chr22:24264395	C/T	cg23131131	chr22:24373011	LOC391322	0.57	4.52	0.38	1.41e-5	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	trans	rs11722228	0.522	rs7681250	chr4:10133013	G/T	cg26043149	chr18:55253948	FECH	1.23	14.06	0.78	1.97e-27	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs941408	0.515	rs7253128	chr19:2776982	C/T	cg26465405	chr19:3039745	TLE2	-0.22	-4.52	-0.38	1.44e-5	Total cholesterol levels;
TGCT	cis	rs7772486	0.790	rs6917135	chr6:146152426	T/C	cg05347473	chr6:146136440	FBXO30	0.5	4.72	0.39	6.31e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs739401	0.611	rs3782069	chr11:3033275	G/A	cg25174290	chr11:3078921	CARS	0.49	4.81	0.4	4.28e-6	Longevity;
TGCT	cis	rs10779751	0.770	rs2486922	chr1:11124885	T/C	cg08854313	chr1:11322531	MTOR	0.82	7.04	0.53	1.19e-10	Body mass index;
TGCT	cis	rs7726839	0.540	rs3792720	chr5:643028	T/G	cg16624210	chr5:671434	TPPP	0.4	4.52	0.38	1.44e-5	Obesity-related traits;
TGCT	cis	rs10927875	0.722	rs945425	chr1:16348412	T/C	cg21385522	chr1:16154831	NA	0.62	6.41	0.5	2.76e-9	Dilated cardiomyopathy;
TGCT	cis	rs11249608	0.636	rs6888567	chr5:178449074	C/T	cg21905437	chr5:178450457	ZNF879	-0.46	-4.63	-0.38	9.21e-6	Pubertal anthropometrics;
TGCT	cis	rs68170813	0.559	rs17427849	chr7:106864237	A/G	cg02696742	chr7:106810147	HBP1	-0.71	-5.83	-0.46	4.43e-8	Coronary artery disease;
TGCT	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg11247378	chr22:39784982	NA	-0.74	-10.33	-0.68	1.98e-18	Intelligence (multi-trait analysis);
TGCT	cis	rs950169	0.922	rs62029585	chr15:84951874	C/G	cg12863693	chr15:85201151	NMB	0.45	4.7	0.39	6.73e-6	Schizophrenia;
TGCT	cis	rs9926296	0.535	rs36022917	chr16:89893238	A/G	cg04287289	chr16:89883240	FANCA	0.67	6.82	0.52	3.63e-10	Vitiligo;
TGCT	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg21285383	chr16:89894308	SPIRE2	0.46	7.23	0.54	4.35e-11	Vitiligo;
TGCT	cis	rs7474896	0.515	rs688608	chr10:38331624	G/A	cg25427524	chr10:38739819	LOC399744	0.34	4.52	0.38	1.4e-5	Obesity (extreme);
TGCT	trans	rs4824093	0.610	rs73443923	chr22:50285348	C/T	cg09872104	chr7:134855509	C7orf49	-1.07	-8.89	-0.62	5.98e-15	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs2010099	0.759	rs116358073	chr3:124299095	G/A	cg04915618	chr3:124304960	KALRN	0.52	4.73	0.39	6.01e-6	Thyroid peroxidase antibody levels;
TGCT	cis	rs858239	0.600	rs9691762	chr7:23125922	G/C	cg05602783	chr7:23145260	KLHL7	-0.64	-5.4	-0.44	3.21e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs2956278	0.717	rs2956286	chr12:84689964	T/C	cg25678815	chr12:85673915	ALX1	-0.53	-4.76	-0.39	5.4e-6	Depressive symptoms;Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7727544	0.716	rs3844312	chr5:131582356	C/T	cg24060327	chr5:131705240	SLC22A5	-0.56	-5.5	-0.44	2.06e-7	Blood metabolite levels;
TGCT	cis	rs3820928	1.000	rs3820928	chr2:227773466	A/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-4.78	-0.39	4.77e-6	Pulmonary function;
TGCT	cis	rs1903068	0.853	rs10012701	chr4:56002776	A/G	cg09978860	chr4:56023921	NA	0.56	6.34	0.49	3.88e-9	Endometriosis;
TGCT	cis	rs72945132	0.678	rs35733235	chr11:70235595	C/T	cg00319359	chr11:70116639	PPFIA1	0.99	7.17	0.54	5.79e-11	Coronary artery disease;
TGCT	cis	rs7811142	0.945	rs34989573	chr7:100097895	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	7.77	0.57	2.61e-12	Platelet count;
TGCT	trans	rs4332037	0.707	rs56070303	chr7:1891015	C/T	cg25206134	chr2:45395956	NA	0.96	8.1	0.59	4.34e-13	Bipolar disorder;
TGCT	cis	rs2274273	0.522	rs2251366	chr14:55518156	A/G	cg01923255	chr14:55878535	KIAA0831	0.56	4.76	0.39	5.24e-6	Protein biomarker;
TGCT	cis	rs838147	0.537	rs485073	chr19:49207255	A/G	cg13540341	chr19:49222985	MAMSTR	-0.37	-4.79	-0.4	4.69e-6	Dietary macronutrient intake;
TGCT	cis	rs477895	1.000	rs477895	chr11:64048912	C/T	cg04317338	chr11:64019027	PLCB3	-0.73	-5.88	-0.47	3.49e-8	Mean platelet volume;
TGCT	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg03517284	chr6:25882590	NA	0.51	5.32	0.43	4.74e-7	Blood metabolite levels;
TGCT	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.64	0.51	8.85e-10	Electroencephalogram traits;
TGCT	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg17971929	chr21:40555470	PSMG1	-0.68	-5.96	-0.47	2.47e-8	Cognitive function;
TGCT	cis	rs2816062	0.786	rs2816055	chr1:18898248	A/G	cg18795169	chr1:18902165	NA	-0.6	-14.18	-0.79	1.04e-27	Urate levels in lean individuals;
TGCT	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg08280861	chr8:58055591	NA	0.54	6.0	0.47	2.05e-8	Developmental language disorder (linguistic errors);
TGCT	cis	rs10782582	0.609	rs5745543	chr1:76365111	A/T	cg10523679	chr1:76189770	ACADM	-0.58	-5.31	-0.43	4.92e-7	Daytime sleep phenotypes;
TGCT	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg21285383	chr16:89894308	SPIRE2	0.44	6.97	0.53	1.69e-10	Vitiligo;
TGCT	cis	rs6964587	0.967	rs9656003	chr7:91766322	A/C	cg22709100	chr7:91322751	NA	0.28	4.44	0.37	1.96e-5	Breast cancer;
TGCT	cis	rs9467773	0.506	rs9393709	chr6:26365147	C/T	cg05738196	chr6:26577821	NA	-0.63	-6.61	-0.51	1.01e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs11711311	0.955	rs11715350	chr3:113418376	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.76	-6.69	-0.52	6.78e-10	IgG glycosylation;
TGCT	cis	rs10782582	0.593	rs11589276	chr1:76105545	G/A	cg10523679	chr1:76189770	ACADM	-0.68	-7.45	-0.56	1.4e-11	Daytime sleep phenotypes;
TGCT	cis	rs797680	0.786	rs10874772	chr1:93787770	G/A	cg17826107	chr1:92977322	EVI5	-0.22	-5.05	-0.41	1.53e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs11190604	1.000	rs2295773	chr10:102265815	A/G	cg16342193	chr10:102329863	NA	-0.38	-4.89	-0.4	3.06e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs6424115	1.000	rs6697805	chr1:24151996	C/A	cg15997130	chr1:24165203	NA	-0.92	-10.57	-0.69	5.26e-19	Immature fraction of reticulocytes;
TGCT	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg06634786	chr22:41940651	POLR3H	-0.86	-8.32	-0.6	1.34e-13	Vitiligo;
TGCT	cis	rs7582180	0.663	rs2309800	chr2:100992086	C/T	cg14675211	chr2:100938903	LONRF2	0.46	4.44	0.37	1.97e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs478304	0.651	rs10896037	chr11:65503424	A/G	cg17480646	chr11:65405466	SIPA1	-0.57	-6.93	-0.53	2.05e-10	Acne (severe);
TGCT	trans	rs10953454	1.000	rs35324592	chr7:104480715	A/G	cg04208666	chr6:19734707	NA	-0.57	-6.89	-0.53	2.52e-10	Obesity;
TGCT	cis	rs1857353	1.000	rs60194830	chr1:75888706	C/T	cg11838876	chr1:75668600	SLC44A5	-0.51	-4.81	-0.4	4.23e-6	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs11792861	0.591	rs10979613	chr9:111687584	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.66	7.51	0.56	1.01e-11	Menarche (age at onset);
TGCT	cis	rs9303401	0.659	rs34878689	chr17:56694330	G/A	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg24829409	chr8:58192753	C8orf71	-0.55	-5.2	-0.42	8.06e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9527	0.569	rs78193706	chr10:104780564	T/C	cg15744005	chr10:104629667	AS3MT	-0.42	-4.92	-0.4	2.74e-6	Arsenic metabolism;
TGCT	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg22618164	chr12:122356400	WDR66	0.6	5.71	0.46	7.75e-8	Mean platelet volume;
TGCT	cis	rs7819412	0.775	rs6601564	chr8:10982051	A/G	cg27411982	chr8:10470053	RP1L1	-0.21	-4.62	-0.38	9.44e-6	Triglycerides;
TGCT	cis	rs72627509	0.723	rs67043033	chr4:57739233	A/G	cg26694713	chr4:57773883	REST	0.81	6.35	0.5	3.7e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg23758822	chr17:41437982	NA	0.7	6.6	0.51	1.1e-9	Menopause (age at onset);
TGCT	cis	rs4654899	0.680	rs4233274	chr1:21121678	C/T	cg01072550	chr1:21505969	NA	-0.53	-8.53	-0.61	4.4e-14	Superior frontal gyrus grey matter volume;
TGCT	cis	rs67311347	0.506	rs55962832	chr3:40244451	T/C	cg13683864	chr3:40499215	RPL14	-0.79	-7.4	-0.55	1.83e-11	Renal cell carcinoma;
TGCT	cis	rs10779751	0.632	rs2748876	chr1:11134157	T/G	cg08854313	chr1:11322531	MTOR	0.85	6.96	0.53	1.74e-10	Body mass index;
TGCT	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg13665807	chr20:60559372	TAF4	-0.51	-5.28	-0.43	5.63e-7	Body mass index;
TGCT	cis	rs7772486	0.875	rs12194437	chr6:146411440	A/G	cg13319975	chr6:146136371	FBXO30	-0.51	-4.48	-0.37	1.69e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7590720	0.819	rs1344694	chr2:216893637	T/G	cg12620499	chr2:216877984	MREG	0.91	10.87	0.7	9.89e-20	Alcohol dependence;
TGCT	cis	rs600231	0.706	rs3782091	chr11:65336483	G/T	cg13974409	chr11:65292307	SCYL1	-0.45	-4.53	-0.38	1.35e-5	Bone mineral density;
TGCT	cis	rs9913156	0.789	rs55999196	chr17:4600655	A/G	cg23387401	chr17:4582204	PELP1	0.31	4.68	0.39	7.44e-6	Lymphocyte counts;
TGCT	cis	rs7572733	0.555	rs1837495	chr2:198921201	A/G	cg00792783	chr2:198669748	PLCL1	-0.56	-4.83	-0.4	3.97e-6	Dermatomyositis;
TGCT	cis	rs4319547	0.774	rs7307233	chr12:123124301	C/G	cg23029597	chr12:123009494	RSRC2	-0.27	-4.73	-0.39	6.11e-6	Body mass index;
TGCT	cis	rs2933343	0.649	rs789214	chr3:128594995	A/G	cg11901034	chr3:128598214	ACAD9	-0.65	-6.04	-0.48	1.65e-8	IgG glycosylation;
TGCT	cis	rs17401966	0.540	rs4846216	chr1:10447792	A/T	cg19773385	chr1:10388646	KIF1B	0.22	5.27	0.43	5.96e-7	Hepatocellular carcinoma;
TGCT	cis	rs6921919	0.525	rs16894095	chr6:28390230	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.54	-5.29	-0.43	5.35e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs492146	0.935	rs316128	chr6:52849146	G/T	cg06706454	chr6:52930286	FBXO9	-0.47	-4.54	-0.38	1.29e-5	Epilepsy (remission after treatment);
TGCT	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg18402987	chr7:1209562	NA	0.78	6.64	0.51	8.96e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1395	0.813	rs11685326	chr2:27453679	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.7	9.47	0.65	2.4e-16	Blood metabolite levels;
TGCT	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg05368731	chr17:41323189	NBR1	1.16	13.7	0.78	1.41e-26	Menopause (age at onset);
TGCT	cis	rs13256369	1.000	rs885000	chr8:8568875	G/T	cg18904891	chr8:8559673	CLDN23	0.59	5.54	0.45	1.73e-7	Obesity-related traits;
TGCT	cis	rs4654899	0.865	rs7532667	chr1:21438239	A/G	cg01072550	chr1:21505969	NA	-0.47	-7.02	-0.53	1.27e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs6681544	0.760	rs3790895	chr1:82401515	T/C	cg04226724	chr1:82268649	LPHN2	0.48	4.97	0.41	2.19e-6	Metabolite levels  (X-11787);
TGCT	cis	rs920590	0.527	rs79929516	chr8:19650050	G/C	cg03894339	chr8:19674705	INTS10	0.82	5.29	0.43	5.28e-7	Acute lymphoblastic leukemia (childhood);
TGCT	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.98	10.7	0.69	2.47e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs4788570	0.624	rs9929985	chr16:71838458	A/G	cg06353428	chr16:71660113	MARVELD3	1.53	12.59	0.75	6.48e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs9788682	0.747	rs6495308	chr15:78907656	A/G	cg24631222	chr15:78858424	CHRNA5	0.78	5.84	0.46	4.22e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg22508957	chr16:3507546	NAT15	0.48	5.42	0.44	3.04e-7	Tuberculosis;
TGCT	cis	rs763121	0.819	rs5750658	chr22:39060917	C/T	cg06022373	chr22:39101656	GTPBP1	0.77	7.51	0.56	9.9e-12	Menopause (age at onset);
TGCT	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg22920501	chr2:26401640	FAM59B	-0.72	-6.38	-0.5	3.19e-9	Gut microbiome composition (summer);
TGCT	cis	rs9910055	0.530	rs11656758	chr17:42301541	A/G	cg19774624	chr17:42201019	HDAC5	-0.7	-7.46	-0.56	1.29e-11	Total body bone mineral density;
TGCT	cis	rs2230307	0.536	rs687513	chr1:100598867	C/T	cg24955406	chr1:100503596	HIAT1	-0.74	-5.03	-0.41	1.68e-6	Carotid intima media thickness;
TGCT	cis	rs9527	0.590	rs7901197	chr10:104840433	C/T	cg15744005	chr10:104629667	AS3MT	-0.42	-4.87	-0.4	3.29e-6	Arsenic metabolism;
TGCT	cis	rs8031584	0.752	rs7174744	chr15:31183747	G/A	cg08109568	chr15:31115862	NA	0.33	4.45	0.37	1.89e-5	Huntington's disease progression;
TGCT	cis	rs11190604	0.767	rs11190534	chr10:102190930	G/A	cg16342193	chr10:102329863	NA	-0.38	-5.0	-0.41	1.93e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs3774830	0.846	rs11731730	chr4:5454545	C/T	cg26943120	chr4:5472116	STK32B	0.21	4.68	0.39	7.48e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg22535103	chr8:58192502	C8orf71	-0.42	-4.79	-0.4	4.7e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs921968	0.542	rs630858	chr2:219409689	C/A	cg02176678	chr2:219576539	TTLL4	0.48	6.78	0.52	4.32e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs9467773	1.000	rs11756120	chr6:26529808	G/C	cg09904177	chr6:26538194	HMGN4	0.65	6.53	0.51	1.53e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs6570726	0.846	rs446031	chr6:145885592	C/T	cg23711669	chr6:146136114	FBXO30	0.85	9.23	0.64	9.21e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3806843	0.576	rs155361	chr5:140307284	G/A	cg07102913	chr5:140593443	PCDHB13	-0.46	-4.6	-0.38	1.01e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7017914	0.967	rs6993115	chr8:71699183	G/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.53	-4.98	-0.41	2.09e-6	Bone mineral density;
TGCT	cis	rs9916302	0.706	rs4795385	chr17:37733148	A/G	cg03321784	chr17:37729644	NA	-0.44	-4.58	-0.38	1.1e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs9790314	0.740	rs4856767	chr3:161004379	C/T	cg03342759	chr3:160939853	NMD3	-0.5	-5.53	-0.44	1.79e-7	Morning vs. evening chronotype;
TGCT	cis	rs861020	0.606	rs2184919	chr1:210000015	C/T	cg05527609	chr1:210001259	C1orf107	-0.88	-8.37	-0.6	1.05e-13	Orofacial clefts;
TGCT	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	14.26	0.79	6.49e-28	Height;
TGCT	cis	rs10193935	0.892	rs12622152	chr2:42482929	C/A	cg27598129	chr2:42591480	NA	-0.39	-5.41	-0.44	3.06e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6964587	1.000	rs2282972	chr7:91666369	C/T	cg17063962	chr7:91808500	NA	0.88	9.65	0.66	8.73e-17	Breast cancer;
TGCT	cis	rs2832191	0.903	rs11700687	chr21:30486767	A/G	cg24692254	chr21:30365293	RNF160	-0.83	-8.71	-0.62	1.58e-14	Dental caries;
TGCT	cis	rs10791323	0.628	rs10750543	chr11:133718467	G/A	cg15485101	chr11:133734466	NA	0.42	5.28	0.43	5.54e-7	Childhood ear infection;
TGCT	cis	rs9303401	0.614	rs3803753	chr17:56540110	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.77	0.52	4.6e-10	Cognitive test performance;
TGCT	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg13395646	chr4:1353034	KIAA1530	-0.48	-6.12	-0.48	1.16e-8	Obesity-related traits;
TGCT	cis	rs7010267	0.935	rs10955915	chr8:119963547	A/G	cg17171407	chr8:119960777	TNFRSF11B	0.33	6.18	0.49	8.29e-9	Total body bone mineral density (age 45-60);
TGCT	cis	rs13191362	0.810	rs28360533	chr6:162996742	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs2050392	0.792	rs9338188	chr10:30721963	G/C	cg18806716	chr10:30721971	MAP3K8	-0.48	-5.53	-0.44	1.85e-7	Inflammatory bowel disease;
TGCT	cis	rs10089	0.953	rs10463839	chr5:127519675	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	7.83	0.58	1.83e-12	Ileal carcinoids;
TGCT	cis	rs8070740	0.617	rs1058119	chr17:5323125	C/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.64	6.3	0.49	4.68e-9	Menopause (age at onset);
TGCT	cis	rs7542091	0.704	rs7550330	chr1:210044587	G/A	cg22029157	chr1:209979665	IRF6	0.64	6.1	0.48	1.23e-8	Monobrow;
TGCT	cis	rs3820068	0.580	rs36100011	chr1:16046920	C/T	cg05660106	chr1:15850417	CASP9	0.73	6.75	0.52	5.18e-10	Systolic blood pressure;
TGCT	cis	rs3947	0.738	rs1293328	chr8:11695060	C/T	cg02840367	chr8:11660030	FDFT1	0.89	6.56	0.51	1.3e-9	Blood protein levels;
TGCT	cis	rs3809566	0.654	rs6494384	chr15:63325607	C/G	cg08198488	chr15:63333792	TPM1	-0.35	-5.25	-0.43	6.5e-7	Platelet count;
TGCT	cis	rs7926906	1.000	rs7926906	chr11:90524290	C/A	cg26138821	chr11:89956704	CHORDC1	-0.51	-5.52	-0.44	1.92e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs4886920	0.518	rs12902224	chr15:78076272	T/C	cg25212270	chr15:78015279	NA	-0.29	-5.17	-0.42	8.99e-7	Neuroticism;
TGCT	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg11890956	chr21:40555474	PSMG1	-0.72	-6.44	-0.5	2.33e-9	Cognitive function;
TGCT	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg04234412	chr22:24373322	LOC391322	-0.91	-10.67	-0.69	2.98e-19	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs250677	0.522	rs10038913	chr5:148354224	A/G	cg18129178	chr5:148520854	ABLIM3	0.36	4.62	0.38	9.43e-6	Breast cancer;
TGCT	cis	rs8077577	0.895	rs1563371	chr17:18111793	C/T	cg09161412	chr17:18057145	MYO15A	-0.64	-5.22	-0.42	7.2e-7	Obesity-related traits;
TGCT	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg04546413	chr19:29218101	NA	0.83	6.68	0.51	7.35e-10	Methadone dose in opioid dependence;
TGCT	cis	rs78487399	0.808	rs7581586	chr2:43668176	T/C	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.72	4.62	0.38	9.53e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs11031096	0.542	rs10835337	chr11:3958828	A/G	cg08557956	chr11:4115526	RRM1	0.49	4.44	0.37	1.97e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs42648	0.905	rs42641	chr7:89972764	T/C	cg25739043	chr7:89950458	NA	-0.77	-7.82	-0.57	1.96e-12	Homocysteine levels;
TGCT	cis	rs9549367	0.713	rs3024761	chr13:113824090	C/G	cg00898013	chr13:113819073	PROZ	0.52	6.5	0.5	1.75e-9	Platelet distribution width;
TGCT	cis	rs60843830	1.000	rs3791224	chr2:221981	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.75	6.86	0.52	2.9e-10	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs3849570	0.643	rs1969433	chr3:81968869	T/C	cg07356753	chr3:81810745	GBE1	-0.64	-5.62	-0.45	1.19e-7	Waist circumference;Body mass index;
TGCT	cis	rs7909074	0.899	rs2026428	chr10:45389452	T/C	cg05187965	chr10:45406764	TMEM72	-0.25	-5.31	-0.43	4.96e-7	Mean corpuscular volume;
TGCT	cis	rs6088580	0.624	rs6120645	chr20:33025171	C/T	cg08999081	chr20:33150536	PIGU	0.29	5.67	0.45	9.68e-8	Glomerular filtration rate (creatinine);
TGCT	cis	rs1371867	0.846	rs2439458	chr8:101297984	T/C	cg06002616	chr8:101225028	SPAG1	-0.53	-6.21	-0.49	7.16e-9	Atrioventricular conduction;
TGCT	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg17554472	chr22:41940697	POLR3H	0.51	5.52	0.44	1.9e-7	Vitiligo;
TGCT	cis	rs35934224	0.783	rs5993849	chr22:19866194	G/C	cg11182965	chr22:19864308	TXNRD2	-0.38	-5.4	-0.44	3.27e-7	Glaucoma (primary open-angle);
TGCT	cis	rs1691799	0.899	rs1168308	chr12:66742183	A/G	cg16791601	chr12:66731901	HELB	-0.28	-6.11	-0.48	1.19e-8	White blood cell count (basophil);
TGCT	cis	rs2084898	0.891	rs2511023	chr11:120009145	A/G	cg00437969	chr11:120009135	TRIM29	0.34	4.47	0.37	1.77e-5	Stroke (pediatric);
TGCT	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg06238570	chr21:40685208	BRWD1	0.75	7.06	0.54	1.07e-10	Cognitive function;
TGCT	cis	rs7681440	0.874	rs1372522	chr4:90765280	A/G	cg01966878	chr4:90757139	SNCA	-0.25	-4.56	-0.38	1.2e-5	Dementia with Lewy bodies;
TGCT	cis	rs367615	0.679	rs10070786	chr5:108815081	T/G	cg17395555	chr5:108820864	NA	0.31	5.85	0.47	4.07e-8	Colorectal cancer (SNP x SNP interaction);
TGCT	trans	rs2257129	1.000	rs7904102	chr10:122916891	C/G	cg11273493	chr8:10928985	XKR6	-0.81	-7.69	-0.57	3.88e-12	Coronary artery disease;Body mass index;
TGCT	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.68	5.73	0.46	7.3e-8	Tonsillectomy;
TGCT	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg24578937	chr1:2090814	PRKCZ	-0.23	-5.42	-0.44	3e-7	Height;
TGCT	trans	rs629535	0.734	rs542288	chr8:70057149	G/T	cg21567404	chr3:27674614	NA	-0.56	-8.82	-0.62	8.75e-15	Dupuytren's disease;
TGCT	cis	rs9473924	0.542	rs66834257	chr6:50809141	G/A	cg14470998	chr6:50812995	TFAP2B	1.36	8.61	0.61	2.74e-14	Body mass index;
TGCT	cis	rs9581857	0.685	rs79699519	chr13:28023241	C/T	cg22138327	chr13:27999177	GTF3A	0.7	5.01	0.41	1.85e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs7439150	0.954	rs2227399	chr4:155485853	T/G	cg22130008	chr4:155548532	NA	-0.48	-5.93	-0.47	2.8e-8	Fibrinogen levels;
TGCT	cis	rs4889855	0.530	rs11654265	chr17:78602697	G/A	cg16591659	chr17:78472290	NA	0.28	4.45	0.37	1.89e-5	Fractional excretion of uric acid;
TGCT	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.49	-6.61	-0.51	9.98e-10	Alzheimer's disease;
TGCT	trans	rs9388451	0.903	rs7758115	chr6:126061502	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.74	-8.26	-0.6	1.87e-13	Brugada syndrome;
TGCT	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg11764359	chr7:65958608	NA	0.61	5.53	0.44	1.84e-7	Aortic root size;
TGCT	cis	rs4786125	0.581	rs7193000	chr16:6918270	G/C	cg03623568	chr16:6915990	A2BP1	-0.44	-6.57	-0.51	1.27e-9	Heart rate variability traits (SDNN);
TGCT	cis	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg18252515	chr7:66147081	NA	-1.31	-8.18	-0.59	2.87e-13	Diabetic kidney disease;
TGCT	cis	rs68170813	0.652	rs17481621	chr7:107113852	G/C	cg02696742	chr7:106810147	HBP1	-0.65	-4.93	-0.4	2.55e-6	Coronary artery disease;
TGCT	cis	rs9341808	0.667	rs2490239	chr6:80826289	G/A	cg08355045	chr6:80787529	NA	0.32	5.31	0.43	4.88e-7	Sitting height ratio;
TGCT	cis	rs1322512	0.959	rs2758798	chr6:152943980	A/G	cg03415253	chr6:152958462	SYNE1	-0.57	-4.98	-0.41	2.05e-6	Tonometry;
TGCT	cis	rs651907	0.557	rs3806653	chr3:101396972	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.35	-7.28	-0.55	3.4e-11	Colorectal cancer;
TGCT	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg00149659	chr3:10157352	C3orf10	0.97	5.98	0.47	2.19e-8	Alzheimer's disease;
TGCT	cis	rs55910451	0.723	rs3736461	chr10:5855403	G/C	cg09234995	chr10:5726438	C10orf18	0.49	4.65	0.39	8.26e-6	Breast cancer;
TGCT	cis	rs9399135	0.935	rs9376086	chr6:135371329	T/C	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.21e-6	Red blood cell count;
TGCT	cis	rs3796352	0.686	rs1560333	chr3:53138254	T/C	cg07884673	chr3:53033167	SFMBT1	-0.51	-5.82	-0.46	4.73e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs1878931	0.501	rs9635547	chr16:3416664	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.76	7.12	0.54	7.61e-11	Body mass index (adult);
TGCT	cis	rs2479724	0.870	rs6902650	chr6:41764080	G/A	cg08135965	chr6:41755394	TOMM6	-0.49	-4.82	-0.4	4.06e-6	Menarche (age at onset);
TGCT	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg13409248	chr3:40428643	ENTPD3	0.57	4.53	0.38	1.37e-5	Renal cell carcinoma;
TGCT	cis	rs2463822	0.925	rs1528730	chr11:62081181	A/C	cg06239285	chr11:62104954	ASRGL1	0.92	6.16	0.48	9.2e-9	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs2439831	0.867	rs45585139	chr15:43700427	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.05	6.66	0.51	8.08e-10	Lung cancer in ever smokers;
TGCT	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg06238570	chr21:40685208	BRWD1	0.69	6.39	0.5	3.07e-9	Cognitive function;
TGCT	cis	rs5769765	1.000	rs2092982	chr22:50282204	C/A	cg22709217	chr22:50311962	ALG12;CRELD2	1.11	11.81	0.73	5.03e-22	Schizophrenia;
TGCT	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg08439880	chr3:133502540	NA	-0.29	-5.42	-0.44	2.93e-7	Iron status biomarkers;
TGCT	trans	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg17830980	chr10:43048298	ZNF37B	-0.82	-10.29	-0.68	2.47e-18	Extrinsic epigenetic age acceleration;
TGCT	cis	rs4699052	0.626	rs10017383	chr4:104249957	G/A	cg16532752	chr4:104119610	CENPE	-0.49	-4.89	-0.4	3.07e-6	Testicular germ cell tumor;
TGCT	cis	rs7829975	0.560	rs17154599	chr8:8551418	C/T	cg15556689	chr8:8085844	FLJ10661	-0.54	-4.72	-0.39	6.39e-6	Mood instability;
TGCT	cis	rs7937682	0.961	rs7119563	chr11:111543916	T/A	cg09085632	chr11:111637200	PPP2R1B	1.04	9.57	0.65	1.36e-16	Primary sclerosing cholangitis;
TGCT	cis	rs7666738	0.830	rs1813972	chr4:98886828	C/A	cg18180107	chr4:99064573	C4orf37	0.53	4.84	0.4	3.83e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs904251	0.772	rs1224127	chr6:37417556	G/A	cg25019722	chr6:37503610	NA	-0.46	-5.32	-0.43	4.71e-7	Cognitive performance;
TGCT	cis	rs244731	0.959	rs7724098	chr5:176659570	G/A	cg06060754	chr5:176797920	RGS14	-0.45	-6.34	-0.49	3.93e-9	Urate levels in lean individuals;
TGCT	cis	rs9430161	0.644	rs6685766	chr1:11037051	T/C	cg02454025	chr1:11042201	C1orf127	0.92	11.24	0.71	1.21e-20	Ewing sarcoma;
TGCT	cis	rs7954584	0.583	rs6486782	chr12:122359172	T/C	cg13699009	chr12:122356056	WDR66	0.32	7.33	0.55	2.6e-11	Mean corpuscular volume;
TGCT	cis	rs9393777	0.513	rs1104871	chr6:26665235	T/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.61	-4.95	-0.41	2.33e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7523050	0.643	rs34801874	chr1:109404382	C/T	cg08274380	chr1:109419600	GPSM2	1.3	6.39	0.5	2.99e-9	Fat distribution (HIV);
TGCT	cis	rs9303401	0.614	rs12947982	chr17:57140301	A/G	cg25039879	chr17:56429692	SUPT4H1	0.54	4.84	0.4	3.85e-6	Cognitive test performance;
TGCT	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.5	-4.81	-0.4	4.26e-6	Bipolar disorder;
TGCT	cis	rs10186029	0.676	rs1025820	chr2:213933778	T/G	cg08319019	chr2:214017104	IKZF2	0.63	5.94	0.47	2.67e-8	Systemic sclerosis;
TGCT	cis	rs921968	0.541	rs687747	chr2:219399627	T/C	cg02176678	chr2:219576539	TTLL4	0.48	6.78	0.52	4.32e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs3824662	0.592	rs9746	chr10:8116503	A/G	cg20314737	chr10:8096579	FLJ45983;GATA3	0.66	4.61	0.38	9.73e-6	Acute lymphoblastic leukemia (B-cell precursor);Acute lymphoblastic leukemia (adolescents and young adults);
TGCT	cis	rs7662987	0.517	rs2602882	chr4:100040765	C/T	cg12011299	chr4:100065546	ADH4	0.4	4.77	0.39	5.18e-6	Smoking initiation;
TGCT	cis	rs34734847	1.000	rs3021338	chr12:121162989	A/G	cg21892295	chr12:121157589	UNC119B	-0.23	-5.59	-0.45	1.4e-7	Mean corpuscular volume;
TGCT	trans	rs4824093	0.610	rs56810176	chr22:50303149	G/C	cg09872104	chr7:134855509	C7orf49	-0.93	-6.91	-0.53	2.29e-10	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs3806843	1.000	rs3756340	chr5:140180451	T/G	cg19875535	chr5:140030758	IK	0.36	6.11	0.48	1.21e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7523050	0.730	rs72984628	chr1:109460808	G/A	cg08274380	chr1:109419600	GPSM2	1.27	6.86	0.52	2.9e-10	Fat distribution (HIV);
TGCT	cis	rs11098499	0.644	rs10009566	chr4:120558608	A/G	cg09307838	chr4:120376055	NA	0.66	6.09	0.48	1.31e-8	Corneal astigmatism;
TGCT	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs208520	0.909	rs9354411	chr6:67019930	A/G	cg07460842	chr6:66804631	NA	0.73	5.91	0.47	3.07e-8	Exhaled nitric oxide output;
TGCT	cis	rs3771570	0.579	rs62190373	chr2:242388685	G/A	cg21155796	chr2:242212141	HDLBP	0.93	6.65	0.51	8.25e-10	Prostate cancer;
TGCT	cis	rs7666738	0.830	rs1349757	chr4:99058763	C/G	cg05340658	chr4:99064831	C4orf37	0.52	5.92	0.47	2.91e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs13242816	1.000	rs2191498	chr7:116138569	C/T	cg02799643	chr7:116139180	CAV2	-0.45	-5.85	-0.47	4.03e-8	P wave duration;
TGCT	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg04414720	chr1:150670196	GOLPH3L	0.37	4.81	0.4	4.38e-6	Tonsillectomy;
TGCT	cis	rs9381040	0.655	rs2294696	chr6:41036988	A/G	cg03526776	chr6:41159608	TREML2	-0.27	-5.28	-0.43	5.66e-7	Alzheimer's disease (late onset);
TGCT	cis	rs2239547	0.603	rs6805298	chr3:53096552	A/G	cg11645453	chr3:52864694	ITIH4	-0.29	-4.59	-0.38	1.08e-5	Schizophrenia;
TGCT	cis	rs6701037	0.681	rs6664840	chr1:175128726	A/G	cg00321850	chr1:175162397	KIAA0040	-0.42	-5.83	-0.46	4.61e-8	Alcohol dependence;
TGCT	cis	rs881375	0.678	rs2269060	chr9:123683569	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	5.86	0.47	3.95e-8	Rheumatoid arthritis;
TGCT	cis	rs1371867	0.775	rs6511	chr8:101252680	T/C	cg00191853	chr8:101177733	SPAG1	0.24	4.83	0.4	3.87e-6	Atrioventricular conduction;
TGCT	cis	rs4713118	0.669	rs200997	chr6:27811815	G/A	cg10876282	chr6:28092338	ZSCAN16	0.5	4.78	0.39	4.84e-6	Parkinson's disease;
TGCT	cis	rs7267979	0.966	rs2263204	chr20:25377688	A/T	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs151997	0.962	rs27844	chr5:50190680	T/G	cg06027927	chr5:50259733	NA	0.47	4.83	0.4	4e-6	Callous-unemotional behaviour;
TGCT	cis	rs12791968	1.000	rs12791968	chr11:45001490	C/T	cg11846598	chr11:44996168	LOC221122	0.34	6.74	0.52	5.25e-10	Inhibitory control;
TGCT	cis	rs7949030	0.688	rs11231155	chr11:62365619	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.64	9.52	0.65	1.88e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2657888	0.628	rs2638285	chr12:56886361	A/G	cg23002907	chr12:56915593	RBMS2	0.4	5.26	0.43	6.06e-7	Adiponectin levels;
TGCT	cis	rs727563	0.593	rs5758461	chr22:42162189	G/C	cg06634786	chr22:41940651	POLR3H	0.85	8.15	0.59	3.41e-13	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs9611565	0.765	rs132914	chr22:41805749	T/C	cg06481639	chr22:41940642	POLR3H	0.6	5.48	0.44	2.23e-7	Vitiligo;
TGCT	cis	rs35146811	0.735	rs1727139	chr7:99815367	C/T	cg13334819	chr7:99746414	C7orf59	0.74	6.31	0.49	4.4e-9	Coronary artery disease;
TGCT	cis	rs2463822	0.925	rs17157227	chr11:62169772	A/G	cg06239285	chr11:62104954	ASRGL1	0.75	4.91	0.4	2.8e-6	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs742614	0.935	rs6057930	chr20:32477972	C/T	cg03217337	chr20:32447030	NA	-0.22	-4.64	-0.38	8.88e-6	Stearic acid (18:0) levels;
TGCT	cis	rs3784262	0.715	rs1994927	chr15:58347949	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.43	-6.34	-0.49	3.96e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs7119	0.717	rs12910513	chr15:77817258	C/T	cg27398640	chr15:77910606	LINGO1	-0.25	-4.6	-0.38	1.05e-5	Type 2 diabetes;
TGCT	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg07747251	chr5:1868357	NA	0.38	5.43	0.44	2.84e-7	Cardiovascular disease risk factors;
TGCT	cis	rs10882165	0.636	rs12357018	chr10:94903515	C/T	cg15980076	chr10:94822747	CYP26C1	-0.43	-4.83	-0.4	3.94e-6	Refractive error;
TGCT	cis	rs4730250	0.707	rs3729877	chr7:106787065	T/G	cg02696742	chr7:106810147	HBP1	0.73	5.99	0.47	2.09e-8	Osteoarthritis;
TGCT	cis	rs10504229	1.000	rs68114352	chr8:58196081	C/T	cg08280861	chr8:58055591	NA	0.36	4.61	0.38	9.98e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs8017423	0.935	rs11159959	chr14:90733656	C/T	cg04374321	chr14:90722782	PSMC1	-0.76	-7.36	-0.55	2.2e-11	Mortality in heart failure;
TGCT	cis	rs1865760	0.566	rs2858993	chr6:26087856	T/A	cg16482183	chr6:26056742	HIST1H1C	0.57	4.79	0.39	4.76e-6	Height;
TGCT	cis	rs317689	0.718	rs160827	chr12:69770147	G/A	cg14784868	chr12:69753453	YEATS4	0.55	4.68	0.39	7.24e-6	Response to diuretic therapy;
TGCT	cis	rs9467773	0.935	rs11752946	chr6:26560364	C/A	cg09904177	chr6:26538194	HMGN4	0.61	5.89	0.47	3.42e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs4517514	0.509	rs11018870	chr11:89871409	T/G	cg05041596	chr11:89867385	NAALAD2	0.53	4.7	0.39	6.89e-6	Trans fatty acid levels;
TGCT	cis	rs6598955	0.627	rs7550127	chr1:26592871	C/T	cg04990556	chr1:26633338	UBXN11	0.66	5.0	0.41	1.88e-6	Obesity-related traits;
TGCT	cis	rs3749237	1.000	rs4768	chr3:49758764	A/G	cg07636037	chr3:49044803	WDR6	0.65	5.75	0.46	6.7e-8	Resting heart rate;
TGCT	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	-0.93	-7.4	-0.55	1.79e-11	Platelet count;
TGCT	cis	rs4253772	0.832	rs6008259	chr22:46633782	G/A	cg09491104	chr22:46646882	C22orf40	-0.49	-4.77	-0.39	5.1e-6	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs6964587	0.755	rs13229505	chr7:91444679	G/T	cg17063962	chr7:91808500	NA	0.82	8.31	0.6	1.43e-13	Breast cancer;
TGCT	cis	rs611744	0.604	rs6469170	chr8:109305277	T/C	cg21045802	chr8:109455806	TTC35	0.75	7.99	0.58	8.06e-13	Dupuytren's disease;
TGCT	cis	rs7772486	0.738	rs2246334	chr6:146183635	G/A	cg13319975	chr6:146136371	FBXO30	-0.52	-4.64	-0.38	8.61e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs28595532	1.000	rs115915387	chr4:119640854	C/T	cg21605333	chr4:119757512	SEC24D	1.36	7.39	0.55	1.89e-11	Cannabis dependence symptom count;
TGCT	cis	rs2115630	0.645	rs3825878	chr15:85174755	C/T	cg17173187	chr15:85201210	NMB	-0.48	-5.78	-0.46	5.69e-8	P wave terminal force;
TGCT	cis	rs2239785	0.959	rs136163	chr22:36657628	T/G	cg15716373	chr22:36655542	APOL1	-0.43	-4.92	-0.4	2.64e-6	Glomerulosclerosis;
TGCT	cis	rs11578119	0.836	rs12130105	chr1:170357956	T/A	cg09767346	chr1:170501363	GORAB	0.61	4.58	0.38	1.1e-5	Male-pattern baldness;
TGCT	cis	rs7666738	0.830	rs13119995	chr4:99026790	T/C	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6545883	0.965	rs1992765	chr2:61751333	A/G	cg15711740	chr2:61764176	XPO1	-0.57	-5.31	-0.43	4.99e-7	Tuberculosis;
TGCT	cis	rs7216064	0.817	rs28609796	chr17:65855104	T/A	cg12091567	chr17:66097778	LOC651250	-0.84	-6.56	-0.51	1.29e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs1865760	0.865	rs9467650	chr6:25958235	A/G	cg17042849	chr6:26104293	HIST1H4C	-0.52	-4.78	-0.39	4.88e-6	Height;
TGCT	cis	rs7027203	1.000	rs7864114	chr9:96551954	A/G	cg14396892	chr9:96623032	NA	0.24	4.81	0.4	4.27e-6	DNA methylation (variation);
TGCT	cis	rs1971762	0.583	rs3852561	chr12:54085842	C/T	cg16917193	chr12:54089295	NA	1.38	18.38	0.86	3.23e-37	Height;
TGCT	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg07061783	chr6:25882402	NA	-0.5	-5.47	-0.44	2.33e-7	Blood metabolite levels;
TGCT	cis	rs7772486	0.790	rs4075694	chr6:146251108	G/C	cg05347473	chr6:146136440	FBXO30	-0.52	-5.03	-0.41	1.67e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs8014204	0.762	rs12889665	chr14:75234830	T/G	cg06637938	chr14:75390232	RPS6KL1	0.58	5.13	0.42	1.11e-6	Caffeine consumption;
TGCT	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg12311346	chr5:56204834	C5orf35	-0.65	-6.44	-0.5	2.37e-9	Initial pursuit acceleration;
TGCT	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg23205692	chr1:25664452	TMEM50A	-0.53	-5.67	-0.45	9.31e-8	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs317689	0.690	rs10878946	chr12:69642315	C/T	cg11871910	chr12:69753446	YEATS4	0.53	4.47	0.37	1.77e-5	Response to diuretic therapy;
TGCT	cis	rs231513	0.822	rs231520	chr17:41956983	T/C	cg26893861	chr17:41843967	DUSP3	-0.71	-5.33	-0.43	4.45e-7	Cognitive function;
TGCT	cis	rs4824093	0.535	rs73443931	chr22:50291603	G/A	cg20569369	chr22:51173646	NA	0.28	4.58	0.38	1.13e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs4455778	0.519	rs6583488	chr7:49039939	A/G	cg26309511	chr7:48887640	NA	0.51	6.66	0.51	7.85e-10	Lung cancer in never smokers;
TGCT	cis	rs7726839	0.540	rs7558	chr5:660491	C/T	cg16624210	chr5:671434	TPPP	0.41	4.54	0.38	1.31e-5	Obesity-related traits;
TGCT	cis	rs854765	0.693	rs8079418	chr17:17924060	C/T	cg09796270	chr17:17721594	SREBF1	0.26	5.19	0.42	8.52e-7	Total body bone mineral density;
TGCT	cis	rs317689	0.718	rs160827	chr12:69770147	G/A	cg20891283	chr12:69753455	YEATS4	0.56	4.71	0.39	6.52e-6	Response to diuretic therapy;
TGCT	trans	rs4650994	1.000	rs4650999	chr1:178532188	A/C	cg05059571	chr16:84539110	KIAA1609	0.41	7.7	0.57	3.78e-12	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.14	0.42	1.06e-6	Prudent dietary pattern;
TGCT	cis	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg20637647	chr7:64974828	NA	0.92	5.38	0.44	3.53e-7	Diabetic kidney disease;
TGCT	cis	rs1371867	0.846	rs1660353	chr8:101250907	C/T	cg06636551	chr8:101224915	SPAG1	0.44	6.11	0.48	1.19e-8	Atrioventricular conduction;
TGCT	cis	rs7677751	0.848	rs7673625	chr4:55088586	C/T	cg17187183	chr4:55093834	PDGFRA	0.53	6.87	0.52	2.83e-10	Corneal astigmatism;
TGCT	cis	rs2153535	0.580	rs2327053	chr6:8443127	A/G	cg07606381	chr6:8435919	SLC35B3	0.57	5.25	0.43	6.46e-7	Motion sickness;
TGCT	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.66	5.42	0.44	3.01e-7	Tonsillectomy;
TGCT	cis	rs7617480	0.648	rs6796790	chr3:48780317	G/A	cg07636037	chr3:49044803	WDR6	0.76	6.36	0.5	3.6e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs17767294	0.614	rs72854506	chr6:28252497	T/C	cg08851530	chr6:28072375	NA	1.54	6.89	0.53	2.51e-10	Parkinson's disease;
TGCT	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg06618935	chr21:46677482	NA	-0.37	-5.81	-0.46	5.06e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2204008	0.728	rs12369538	chr12:38443942	C/T	cg26384229	chr12:38710491	ALG10B	0.85	7.59	0.56	6.74e-12	Bladder cancer;
TGCT	cis	rs12142240	0.698	rs17357621	chr1:46807697	C/T	cg14993813	chr1:46806288	NSUN4	-0.58	-4.81	-0.4	4.34e-6	Menopause (age at onset);
TGCT	trans	rs10506458	0.915	rs17763441	chr12:63418335	T/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.47	-7.48	-0.56	1.18e-11	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs904251	0.504	rs1757188	chr6:37483808	A/G	cg01843034	chr6:37503916	NA	-0.54	-7.33	-0.55	2.57e-11	Cognitive performance;
TGCT	cis	rs4988958	0.565	rs3771154	chr2:103039360	C/T	cg03938978	chr2:103052716	IL18RAP	0.27	5.41	0.44	3.17e-7	Asthma (childhood onset);
TGCT	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg14893161	chr1:205819251	PM20D1	0.66	10.84	0.7	1.13e-19	Menarche (age at onset);
TGCT	cis	rs9291683	0.554	rs7668175	chr4:10125782	T/C	cg11266682	chr4:10021025	SLC2A9	-0.45	-5.32	-0.43	4.65e-7	Bone mineral density;
TGCT	cis	rs1008375	1.000	rs4698635	chr4:17630242	C/A	cg16339924	chr4:17578868	LAP3	0.62	5.11	0.42	1.17e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs11252926	0.599	rs11252213	chr10:454694	C/T	cg18196295	chr10:418757	DIP2C	0.28	4.45	0.37	1.92e-5	Psychosis in Alzheimer's disease;
TGCT	cis	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg02380750	chr20:61661411	NA	0.34	6.02	0.48	1.86e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs916888	0.610	rs199530	chr17:44836653	C/T	cg17911788	chr17:44343683	NA	0.45	5.4	0.44	3.3e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	trans	rs208515	0.518	rs12209790	chr6:66662965	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.87	9.38	0.64	4.06e-16	Exhaled nitric oxide levels;
TGCT	cis	rs28595532	0.920	rs17324821	chr4:119770716	A/G	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs9611565	0.918	rs4820438	chr22:41767135	C/T	cg03806693	chr22:41940476	POLR3H	-1.07	-11.33	-0.71	7.31e-21	Vitiligo;
TGCT	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg17971929	chr21:40555470	PSMG1	0.98	9.51	0.65	1.92e-16	Cognitive function;
TGCT	cis	rs1801251	1.000	rs895430	chr2:233725483	C/A	cg25237894	chr2:233734115	C2orf82	-0.31	-5.52	-0.44	1.89e-7	Coronary artery disease;
TGCT	cis	rs6121246	0.529	rs6058196	chr20:30194714	A/T	cg18721089	chr20:30220636	NA	-0.63	-6.88	-0.53	2.67e-10	Mean corpuscular hemoglobin;
TGCT	cis	rs7552404	0.924	rs1146580	chr1:76209935	T/C	cg10523679	chr1:76189770	ACADM	0.84	9.32	0.64	5.67e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7100689	0.646	rs10749579	chr10:82140959	C/T	cg01528321	chr10:82214614	TSPAN14	0.81	8.21	0.59	2.4e-13	Post bronchodilator FEV1;
TGCT	cis	rs7772486	0.754	rs697053	chr6:145989807	T/C	cg23711669	chr6:146136114	FBXO30	-0.93	-10.56	-0.69	5.5e-19	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7312933	0.558	rs11181466	chr12:42765181	A/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.54	5.14	0.42	1.03e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs13242816	1.000	rs34228114	chr7:116106986	C/T	cg16553024	chr7:116138462	CAV2	-0.43	-4.8	-0.4	4.41e-6	P wave duration;
TGCT	cis	rs2243480	1.000	rs160652	chr7:65538431	A/G	cg20637647	chr7:64974828	NA	0.95	5.8	0.46	5.3e-8	Diabetic kidney disease;
TGCT	cis	rs9357506	1.000	rs12055411	chr6:46306565	A/C	cg21115430	chr6:46460003	NA	-0.26	-5.17	-0.42	9.2e-7	Body mass index;
TGCT	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg11141652	chr22:24348549	GSTTP1	0.34	4.76	0.39	5.37e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs308447	0.516	rs13127908	chr4:123720933	G/C	cg10495464	chr4:123653540	BBS12;LOC729338	0.63	5.77	0.46	5.98e-8	Perceived unattractiveness to mosquitoes;
TGCT	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	16.1	0.82	3.69e-32	Prudent dietary pattern;
TGCT	cis	rs9611565	0.592	rs8779	chr22:42070276	T/C	cg13695892	chr22:41940480	POLR3H	0.89	8.6	0.61	2.92e-14	Vitiligo;
TGCT	cis	rs6671200	0.607	rs3753872	chr1:95699184	T/G	cg06440946	chr1:95699313	RWDD3	-0.62	-5.3	-0.43	5.09e-7	Stearic acid (18:0) levels;
TGCT	cis	rs13191362	0.935	rs34063386	chr6:163041271	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.92	7.24	0.55	4.11e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs523522	0.962	rs603574	chr12:120998443	A/G	cg27279351	chr12:120934652	DYNLL1	0.74	6.46	0.5	2.19e-9	High light scatter reticulocyte count;
TGCT	cis	rs9303401	0.659	rs35828828	chr17:56718205	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.69	6.6	0.51	1.07e-9	Cognitive test performance;
TGCT	cis	rs6988636	0.710	rs17316158	chr8:124157607	A/C	cg27053337	chr8:124217698	FAM83A	0.67	5.12	0.42	1.11e-6	Urinary uromodulin levels;
TGCT	trans	rs629535	0.773	rs489206	chr8:70064883	T/C	cg21567404	chr3:27674614	NA	0.56	8.82	0.62	8.75e-15	Dupuytren's disease;
TGCT	cis	rs9611565	0.506	rs2024566	chr22:41697338	A/G	cg06634786	chr22:41940651	POLR3H	-0.63	-5.66	-0.45	1.01e-7	Vitiligo;
TGCT	cis	rs17767294	0.708	rs72848766	chr6:27908756	T/C	cg08851530	chr6:28072375	NA	1.56	7.22	0.54	4.47e-11	Parkinson's disease;
TGCT	cis	rs6540559	0.673	rs2357230	chr1:210019498	G/A	cg23283495	chr1:209979779	IRF6	0.6	4.5	0.37	1.54e-5	Cleft lip with or without cleft palate;
TGCT	cis	rs9911578	1.000	rs654778	chr17:56736473	A/C	cg12560992	chr17:57184187	TRIM37	0.75	9.21	0.64	1.04e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs3733585	0.806	rs7375599	chr4:9954918	C/T	cg11266682	chr4:10021025	SLC2A9	0.63	8.61	0.61	2.71e-14	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg00149659	chr3:10157352	C3orf10	0.84	5.52	0.44	1.86e-7	Alzheimer's disease;
TGCT	cis	rs1577917	1.000	rs12190604	chr6:86716215	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.54	-0.45	1.73e-7	Response to antipsychotic treatment;
TGCT	cis	rs11098499	0.697	rs11941899	chr4:120382758	C/A	cg09307838	chr4:120376055	NA	0.68	6.53	0.51	1.54e-9	Corneal astigmatism;
TGCT	cis	rs28595532	0.841	rs115852209	chr4:119753465	A/G	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs7681440	0.904	rs7698219	chr4:90771351	C/A	cg14346243	chr4:90757452	SNCA	-0.57	-5.5	-0.44	2.04e-7	Dementia with Lewy bodies;
TGCT	cis	rs9443645	0.901	rs1572584	chr6:79690290	A/G	cg05283184	chr6:79620031	NA	0.2	4.44	0.37	1.96e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg05368731	chr17:41323189	NBR1	1.16	13.7	0.78	1.41e-26	Menopause (age at onset);
TGCT	cis	rs137699	0.959	rs5757633	chr22:39756270	A/G	cg24399712	chr22:39784796	NA	-0.63	-5.54	-0.45	1.73e-7	IgG glycosylation;
TGCT	cis	rs7829975	0.606	rs6601274	chr8:8799059	T/G	cg06636001	chr8:8085503	FLJ10661	-0.79	-6.94	-0.53	1.96e-10	Mood instability;
TGCT	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg17971929	chr21:40555470	PSMG1	0.95	8.67	0.61	2.01e-14	Cognitive function;
TGCT	cis	rs6542838	0.671	rs6752025	chr2:99505699	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.55	-5.2	-0.42	7.88e-7	Fear of minor pain;
TGCT	cis	rs12145833	0.596	rs3926866	chr1:243437632	G/C	cg02356786	chr1:243265016	LOC731275	0.65	4.49	0.37	1.59e-5	Obesity (early onset extreme);
TGCT	cis	rs2742234	0.955	rs2503841	chr10:43675721	C/T	cg02780029	chr10:43622663	RET	-0.26	-4.97	-0.41	2.19e-6	Hirschsprung disease;
TGCT	cis	rs12142240	0.692	rs7529674	chr1:46818508	T/C	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs13217239	0.621	rs12527231	chr6:27001288	G/A	cg05738196	chr6:26577821	NA	0.49	4.75	0.39	5.45e-6	Schizophrenia;
TGCT	cis	rs9921222	0.565	rs10903014	chr16:377623	A/G	cg12437481	chr16:420112	MRPL28	-0.48	-4.63	-0.38	9.17e-6	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs35306767	0.903	rs12761424	chr10:967295	C/T	cg26597838	chr10:835615	NA	0.63	9.0	0.63	3.31e-15	Eosinophil percentage of granulocytes;
TGCT	cis	rs709400	0.663	rs62007687	chr14:103903763	G/T	cg12935359	chr14:103987150	CKB	-0.36	-5.47	-0.44	2.42e-7	Body mass index;
TGCT	cis	rs2439831	1.000	rs689647	chr15:43762196	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.8	5.7	0.46	8.33e-8	Lung cancer in ever smokers;
TGCT	cis	rs9653442	0.564	rs11123809	chr2:100758137	C/T	cg07810366	chr2:100720526	AFF3	-0.35	-5.09	-0.42	1.31e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs7208859	0.524	rs73263982	chr17:28920624	T/C	cg04154034	chr17:28927549	LRRC37B2	0.79	4.8	0.4	4.54e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs12477438	0.871	rs62156364	chr2:99695097	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-6.64	-0.51	8.63e-10	Chronic sinus infection;
TGCT	cis	rs262150	0.579	rs4909110	chr7:158787332	C/T	cg01219135	chr7:158766336	NA	-0.46	-4.82	-0.4	4.09e-6	Facial morphology (factor 20);
TGCT	cis	rs35883536	0.647	rs17411209	chr1:101046734	A/G	cg10298815	chr1:101004474	GPR88	-0.25	-4.5	-0.37	1.54e-5	Monocyte count;
TGCT	cis	rs7226408	0.857	rs72890514	chr18:34588028	A/G	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs2153535	0.541	rs5026687	chr6:8473957	A/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.7	0.46	8.28e-8	Motion sickness;
TGCT	cis	rs9303401	0.659	rs34818467	chr17:56643109	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.65	-6.22	-0.49	7.12e-9	Cognitive test performance;
TGCT	cis	rs10540	1.000	rs78520676	chr11:517173	G/A	cg03934478	chr11:495069	RNH1	0.32	4.82	0.4	4.16e-6	Body mass index;
TGCT	cis	rs7296418	0.699	rs1109559	chr12:123757861	C/T	cg00376283	chr12:123451042	ABCB9	0.66	5.89	0.47	3.37e-8	Platelet count;
TGCT	cis	rs10465746	0.935	rs6692233	chr1:84327214	A/G	cg10977910	chr1:84465055	TTLL7	-0.64	-6.24	-0.49	6.39e-9	Obesity-related traits;
TGCT	cis	rs10876993	0.855	rs1689601	chr12:58049557	G/A	cg15848620	chr12:58087721	OS9	-0.72	-5.82	-0.46	4.71e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg05215272	chr17:6899095	ALOX12	0.56	6.71	0.52	6.18e-10	Tonsillectomy;
TGCT	cis	rs6964587	1.000	rs13239875	chr7:91716104	G/A	cg17063962	chr7:91808500	NA	0.86	9.47	0.65	2.39e-16	Breast cancer;
TGCT	cis	rs200895692	1	rs200895692	chr1:43421956	CGCCTGTAATCCCAG/C	cg09824328	chr1:43425412	SLC2A1	-0.57	-4.9	-0.4	2.91e-6	Monocyte count;
TGCT	cis	rs589249	0.963	rs218985	chr1:37169665	A/G	cg04012535	chr1:37176647	NA	0.33	5.5	0.44	2.07e-7	Neuroticism (multi-trait analysis);Schizophrenia;
TGCT	cis	rs12048904	0.505	rs11166508	chr1:101233511	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.81	-6.96	-0.53	1.78e-10	Multiple sclerosis;
TGCT	trans	rs8073060	0.614	rs72829932	chr17:34055935	A/G	cg19694781	chr19:47549865	TMEM160	0.6	12.13	0.74	8.13e-23	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs4654899	0.865	rs61779120	chr1:21481230	T/C	cg01072550	chr1:21505969	NA	-0.48	-7.21	-0.54	4.91e-11	Superior frontal gyrus grey matter volume;
TGCT	trans	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg27523141	chr10:43048294	ZNF37B	0.73	8.51	0.61	4.68e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs6570726	0.902	rs373321	chr6:145854150	T/A	cg05347473	chr6:146136440	FBXO30	0.49	4.54	0.38	1.29e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7772486	0.790	rs2265917	chr6:146212285	A/G	cg05347473	chr6:146136440	FBXO30	0.52	5.0	0.41	1.89e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7267979	0.565	rs958075	chr20:25595123	C/T	cg03522245	chr20:25566470	NINL	-0.45	-4.66	-0.39	8.06e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2075371	0.966	rs1619682	chr7:133996703	T/G	cg11752832	chr7:134001865	SLC35B4	0.7	6.44	0.5	2.41e-9	Mean platelet volume;
TGCT	cis	rs9902453	0.933	rs7225462	chr17:28321226	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.81	7.61	0.56	5.93e-12	Coffee consumption (cups per day);
TGCT	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.12	0.42	1.15e-6	Prudent dietary pattern;
TGCT	cis	rs9972944	0.902	rs9972883	chr17:63771316	C/A	cg07283582	chr17:63770753	CCDC46	0.28	5.89	0.47	3.34e-8	Total body bone mineral density;
TGCT	cis	rs933688	1.000	rs2059207	chr5:90731931	C/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.07	10.69	0.69	2.68e-19	Smoking behavior;
TGCT	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg10802521	chr3:52805072	NEK4	-0.78	-10.01	-0.67	1.22e-17	Bipolar disorder;
TGCT	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg18402987	chr7:1209562	NA	0.63	6.04	0.48	1.67e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2180341	1.000	rs6904520	chr6:127629802	T/C	cg24812749	chr6:127587940	RNF146	0.98	7.64	0.57	5.06e-12	Breast cancer;
TGCT	cis	rs11098499	0.955	rs56386062	chr4:120155135	T/C	cg24670566	chr4:120433619	PDE5A	0.22	4.44	0.37	1.96e-5	Corneal astigmatism;
TGCT	cis	rs6964587	1.000	rs7785095	chr7:91640773	A/T	cg17063962	chr7:91808500	NA	-0.83	-8.66	-0.61	2.14e-14	Breast cancer;
TGCT	cis	rs4455778	0.580	rs4541847	chr7:49109824	C/G	cg26309511	chr7:48887640	NA	-0.49	-6.17	-0.48	9.08e-9	Lung cancer in never smokers;
TGCT	cis	rs4788570	0.615	rs1423983	chr16:71701248	G/A	cg06353428	chr16:71660113	MARVELD3	1.56	12.54	0.75	8.54e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg03732007	chr1:2071316	PRKCZ	-0.27	-6.37	-0.5	3.37e-9	Height;
TGCT	cis	rs8141529	0.748	rs1318025	chr22:29283757	C/T	cg02153584	chr22:29168773	CCDC117	0.63	4.87	0.4	3.3e-6	Lymphocyte counts;
TGCT	cis	rs73001065	0.818	rs73004966	chr19:19716558	C/T	cg03709012	chr19:19516395	GATAD2A	1.04	5.1	0.42	1.26e-6	LDL cholesterol;
TGCT	cis	rs1163251	0.902	rs511059	chr1:120217081	G/T	cg19096424	chr1:120255104	PHGDH	0.56	5.29	0.43	5.46e-7	Blood metabolite levels;
TGCT	cis	rs10782582	0.593	rs77733234	chr1:76101655	A/T	cg22875332	chr1:76189707	ACADM	-0.52	-6.26	-0.49	5.72e-9	Daytime sleep phenotypes;
TGCT	cis	rs2204008	0.683	rs7305703	chr12:38138381	T/C	cg13010199	chr12:38710504	ALG10B	0.6	4.8	0.4	4.57e-6	Bladder cancer;
TGCT	cis	rs6920965	0.503	rs2475851	chr6:126174215	T/C	cg05901451	chr6:126070800	HEY2	-0.58	-5.12	-0.42	1.12e-6	High light scatter reticulocyte count;
TGCT	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.76	-7.13	-0.54	7.43e-11	Prudent dietary pattern;
TGCT	cis	rs7681440	0.845	rs6843084	chr4:90766230	T/C	cg20003494	chr4:90757398	SNCA	-0.62	-5.93	-0.47	2.74e-8	Dementia with Lewy bodies;
TGCT	cis	rs7224685	0.530	rs36019144	chr17:3987499	T/C	cg09580393	chr17:4869866	SPAG7	-0.39	-4.5	-0.37	1.53e-5	Type 2 diabetes;
TGCT	cis	rs377070	0.873	rs309399	chr4:123614839	C/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.46	5.08	0.42	1.35e-6	Mosquito bite size;
TGCT	cis	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg25427524	chr10:38739819	LOC399744	0.38	7.67	0.57	4.25e-12	Extrinsic epigenetic age acceleration;
TGCT	cis	rs4654899	1.000	rs6426660	chr1:21361640	A/G	cg01072550	chr1:21505969	NA	-0.49	-7.87	-0.58	1.47e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs6598955	0.670	rs4659366	chr1:26542572	G/A	cg01614726	chr1:26633154	UBXN11	0.49	4.67	0.39	7.59e-6	Obesity-related traits;
TGCT	cis	rs8038465	0.624	rs2127015	chr15:73985223	T/C	cg15420318	chr15:73925796	NPTN	0.59	5.62	0.45	1.21e-7	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs28595532	0.920	rs115797971	chr4:119779620	A/G	cg11846333	chr4:119757529	SEC24D	0.92	4.64	0.38	8.74e-6	Cannabis dependence symptom count;
TGCT	cis	rs2204008	0.627	rs10878486	chr12:38148601	T/G	cg26384229	chr12:38710491	ALG10B	0.85	7.47	0.56	1.27e-11	Bladder cancer;
TGCT	cis	rs17108533	0.588	rs12886230	chr14:71301207	A/T	cg23900759	chr14:71108106	TTC9	-1.14	-4.61	-0.38	9.92e-6	Response to antipsychotic treatment in schizophrenia (reasoning);
TGCT	cis	rs7312933	0.558	rs11181507	chr12:42844763	T/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.53	5.02	0.41	1.73e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs35934224	0.891	rs33997573	chr22:19868951	C/T	cg11182965	chr22:19864308	TXNRD2	-0.36	-5.11	-0.42	1.21e-6	Glaucoma (primary open-angle);
TGCT	cis	rs739496	0.527	rs12319165	chr12:112340734	A/G	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs9911578	1.000	rs9902994	chr17:56948722	T/A	cg05425664	chr17:57184151	TRIM37	-0.62	-6.18	-0.49	8.33e-9	Intelligence (multi-trait analysis);
TGCT	trans	rs2727020	0.930	rs1164688	chr11:49290604	C/G	cg03929089	chr4:120376271	NA	0.71	7.73	0.57	3.16e-12	Coronary artery disease;
TGCT	cis	rs5769707	0.967	rs2051626	chr22:50008973	G/A	cg20744362	chr22:50050164	C22orf34	0.29	4.74	0.39	5.83e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg13695892	chr22:41940480	POLR3H	0.9	8.87	0.62	6.78e-15	Vitiligo;
TGCT	cis	rs9549260	0.755	rs1923249	chr13:41143881	C/A	cg21288729	chr13:41239152	FOXO1	0.98	10.08	0.67	8.21e-18	Red blood cell count;
TGCT	cis	rs2439831	0.717	rs9806227	chr15:43680115	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	6.11	0.48	1.19e-8	Lung cancer in ever smokers;
TGCT	cis	rs2639990	1.000	rs609303	chr18:72895242	C/T	cg18449964	chr18:72917101	ZADH2	0.91	6.22	0.49	7e-9	Vascular endothelial growth factor levels;
TGCT	cis	rs12497850	0.931	rs4974079	chr3:48906469	T/G	cg06212747	chr3:49208901	KLHDC8B	0.61	5.62	0.45	1.2e-7	Parkinson's disease;
TGCT	cis	rs11779988	0.545	rs10095395	chr8:17750589	T/A	cg01800426	chr8:17659068	MTUS1	-0.57	-5.13	-0.42	1.09e-6	Breast cancer;
TGCT	trans	rs931812	0.895	rs4734016	chr8:101910071	C/T	cg20993868	chr7:22813445	NA	0.4	8.97	0.63	3.87e-15	Attention deficit hyperactivity disorder and conduct disorder;
TGCT	cis	rs1371867	0.846	rs1788189	chr8:101249762	G/T	cg06002616	chr8:101225028	SPAG1	0.54	6.4	0.5	2.87e-9	Atrioventricular conduction;
TGCT	cis	rs1887596	0.672	rs1854815	chr13:27173485	A/C	cg01312412	chr13:27282625	NA	0.31	5.56	0.45	1.61e-7	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs9611565	0.559	rs132765	chr22:42008068	A/G	cg06481639	chr22:41940642	POLR3H	0.74	6.64	0.51	8.88e-10	Vitiligo;
TGCT	trans	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg21659725	chr3:3221576	CRBN	0.72	8.69	0.62	1.81e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg03188948	chr7:1209495	NA	0.59	4.82	0.4	4.06e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7829975	0.846	rs1879957	chr8:8544808	T/C	cg06636001	chr8:8085503	FLJ10661	-0.6	-5.0	-0.41	1.92e-6	Mood instability;
TGCT	cis	rs7937682	0.961	rs491937	chr11:111494947	A/T	cg09085632	chr11:111637200	PPP2R1B	-1.0	-9.76	-0.66	4.88e-17	Primary sclerosing cholangitis;
TGCT	cis	rs9549367	0.789	rs3794422	chr13:113893729	G/A	cg18105134	chr13:113819100	PROZ	-0.34	-5.49	-0.44	2.14e-7	Platelet distribution width;
TGCT	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg01570182	chr17:44337453	NA	1.07	9.72	0.66	6.04e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs13191362	1.000	rs35449999	chr6:163023465	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7772486	0.790	rs2247206	chr6:146216184	C/T	cg23711669	chr6:146136114	FBXO30	0.87	9.97	0.67	1.48e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg02725872	chr8:58115012	NA	-0.41	-5.38	-0.44	3.5e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2538470	0.869	rs2538475	chr7:148213611	T/C	cg20325032	chr7:149129312	ZNF777	0.24	4.63	0.38	8.98e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs8067545	0.750	rs4267380	chr17:19971564	A/G	cg13482628	chr17:19912719	NA	0.51	4.43	0.37	2.01e-5	Schizophrenia;
TGCT	cis	rs12135062	0.851	rs2651927	chr1:3101762	A/C	cg21609526	chr1:3105151	PRDM16	-0.4	-6.44	-0.5	2.41e-9	Migraine;
TGCT	cis	rs5751150	1	rs5751150	chr22:42153292	T/G	cg06634786	chr22:41940651	POLR3H	0.86	8.01	0.58	7.16e-13	Cannabis dependence symptom count;
TGCT	cis	rs6088580	0.634	rs6058052	chr20:33047084	A/G	cg06115741	chr20:33292138	TP53INP2	0.54	4.71	0.39	6.47e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs9650657	0.504	rs2409724	chr8:11041642	A/T	cg21775007	chr8:11205619	TDH	-0.49	-4.55	-0.38	1.25e-5	Neuroticism;
TGCT	cis	rs6988636	1.000	rs13260798	chr8:124190192	G/A	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs61990749	0.544	rs176962	chr14:78185510	T/C	cg23188588	chr14:78226832	SNW1;C14orf178	0.67	4.73	0.39	6.09e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs12497850	0.931	rs9755490	chr3:48871664	A/C	cg18654377	chr3:49208889	KLHDC8B	-0.42	-5.52	-0.44	1.93e-7	Parkinson's disease;
TGCT	cis	rs2067615	0.542	rs11113120	chr12:107203460	T/C	cg15890332	chr12:107067104	RFX4	0.28	5.57	0.45	1.52e-7	Heart rate;
TGCT	trans	rs1814175	0.646	rs1722010	chr11:49897958	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.58	-0.69	4.9e-19	Height;
TGCT	cis	rs4566357	0.615	rs4350744	chr2:227918146	A/T	cg11843606	chr2:227700838	RHBDD1	-0.54	-5.24	-0.43	6.55e-7	Coronary artery disease;
TGCT	cis	rs4663866	0.901	rs35390666	chr2:239193578	C/T	cg17283117	chr2:239148619	HES6	1.01	4.66	0.39	8.09e-6	Irritable bowel syndrome;
TGCT	cis	rs9942416	0.660	rs66493518	chr5:74990125	G/C	cg19683494	chr5:74908142	NA	0.59	6.26	0.49	5.62e-9	Age-related disease endophenotypes;
TGCT	cis	rs12048904	0.647	rs7528268	chr1:101329295	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.89	8.36	0.6	1.06e-13	Multiple sclerosis;
TGCT	cis	rs28830936	0.510	rs7175346	chr15:42100674	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.19	-5.23	-0.43	7e-7	Diastolic blood pressure;
TGCT	cis	rs7824557	0.836	rs765731	chr8:11121498	T/A	cg21775007	chr8:11205619	TDH	-0.6	-5.88	-0.47	3.63e-8	Retinal vascular caliber;
TGCT	cis	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg22857025	chr5:266934	NA	-0.34	-6.72	-0.52	5.96e-10	Breast cancer;
TGCT	cis	rs12765878	1.000	rs4918067	chr10:105644636	A/C	cg11005552	chr10:105648138	OBFC1	0.45	7.89	0.58	1.36e-12	Coronary artery disease;
TGCT	cis	rs12510870	0.599	rs10020054	chr4:74448638	G/A	cg05868023	chr4:75230803	EREG	-0.54	-4.71	-0.39	6.6e-6	Iris color (b* coordinate);
TGCT	cis	rs1018836	0.851	rs12548741	chr8:91628878	G/A	cg16814680	chr8:91681699	NA	-0.86	-9.19	-0.64	1.12e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg08564027	chr20:61660810	NA	0.37	6.85	0.52	3.1e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs911555	0.519	rs8014069	chr14:104004311	A/C	cg12935359	chr14:103987150	CKB	-0.35	-4.54	-0.38	1.3e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs78487399	0.808	rs7599781	chr2:43678726	T/C	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.72	4.62	0.38	9.53e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs4455778	0.580	rs6974104	chr7:49126777	C/G	cg26309511	chr7:48887640	NA	0.5	6.51	0.5	1.66e-9	Lung cancer in never smokers;
TGCT	cis	rs9611565	0.608	rs202652	chr22:41838792	A/G	cg06634786	chr22:41940651	POLR3H	0.87	8.08	0.59	4.79e-13	Vitiligo;
TGCT	cis	rs28595532	0.920	rs17325192	chr4:119780345	A/G	cg21997857	chr4:120227080	C4orf3	-0.46	-4.55	-0.38	1.25e-5	Cannabis dependence symptom count;
TGCT	cis	rs10992471	0.580	rs12341093	chr9:95234182	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.62	-5.79	-0.46	5.39e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg04944784	chr2:26401820	FAM59B	0.72	5.92	0.47	3e-8	Gut microbiome composition (summer);
TGCT	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg03303774	chr4:1407052	NA	0.35	5.52	0.44	1.94e-7	Obesity-related traits;
TGCT	cis	rs3820928	0.648	rs1997484	chr2:227898962	T/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-4.96	-0.41	2.29e-6	Pulmonary function;
TGCT	cis	rs7523273	0.606	rs1970530	chr1:207924066	G/A	cg22525895	chr1:207977042	MIR29B2	0.51	8.18	0.59	2.87e-13	Schizophrenia;
TGCT	cis	rs9914988	0.943	rs9907178	chr17:27124307	G/C	cg20469991	chr17:27169893	C17orf63	-0.72	-5.04	-0.41	1.58e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs7617773	0.743	rs4632568	chr3:48367819	C/T	cg11946769	chr3:48343235	NME6	0.8	6.91	0.53	2.26e-10	Coronary artery disease;
TGCT	cis	rs4699052	0.963	rs11733615	chr4:104157164	C/T	cg16532752	chr4:104119610	CENPE	-0.56	-5.27	-0.43	5.78e-7	Testicular germ cell tumor;
TGCT	cis	rs6840360	0.571	rs62327277	chr4:152555905	C/T	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.0	-0.58	7.69e-13	Intelligence (multi-trait analysis);
TGCT	trans	rs8073060	0.544	rs225252	chr17:33952401	G/A	cg19694781	chr19:47549865	TMEM160	-0.6	-13.3	-0.77	1.24e-25	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs616402	0.527	rs589151	chr1:10567711	C/T	cg17425144	chr1:10567563	PEX14	0.57	8.21	0.59	2.43e-13	Breast size;
TGCT	cis	rs9611565	0.512	rs9611672	chr22:42209922	A/G	cg13695892	chr22:41940480	POLR3H	-0.87	-8.24	-0.59	2.06e-13	Vitiligo;
TGCT	cis	rs3617	0.539	rs11922975	chr3:52936763	C/T	cg10802521	chr3:52805072	NEK4	0.58	6.45	0.5	2.27e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg13397359	chr6:42928475	GNMT	0.69	6.1	0.48	1.27e-8	Alzheimer's disease in APOE e4+ carriers;
TGCT	trans	rs4332037	0.851	rs34040190	chr7:1920356	G/A	cg25206134	chr2:45395956	NA	1.13	9.57	0.65	1.42e-16	Bipolar disorder;
TGCT	cis	rs66561647	0.634	rs7387606	chr8:128929371	A/G	cg11792826	chr8:129160931	MIR1208	0.22	5.11	0.42	1.21e-6	Hemoglobin concentration;
TGCT	cis	rs9467773	0.620	rs2504599	chr6:26641060	C/T	cg26531700	chr6:26746687	NA	0.51	4.71	0.39	6.4e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	6.09	0.48	1.32e-8	Mean platelet volume;
TGCT	cis	rs2050392	0.517	rs593400	chr10:30762088	A/G	cg18806716	chr10:30721971	MAP3K8	0.45	5.35	0.43	4.02e-7	Inflammatory bowel disease;
TGCT	cis	rs3125734	0.633	rs10761616	chr10:64009076	G/A	cg09941381	chr10:64027924	RTKN2	-0.37	-5.59	-0.45	1.41e-7	Rheumatoid arthritis;
TGCT	cis	rs2933343	0.700	rs789240	chr3:128630635	T/C	cg11901034	chr3:128598214	ACAD9	-0.63	-6.05	-0.48	1.61e-8	IgG glycosylation;
TGCT	cis	rs6733011	0.578	rs1581250	chr2:99500750	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-4.76	-0.39	5.3e-6	Bipolar disorder;
TGCT	cis	rs700590	0.683	rs304152	chr5:88124123	A/C	cg22951263	chr5:87985283	NA	0.56	5.38	0.43	3.64e-7	Educational attainment (years of education);
TGCT	cis	rs892961	0.932	rs9646396	chr17:75416755	G/A	cg05865280	chr17:75406074	SEPT9	0.28	6.42	0.5	2.62e-9	Airflow obstruction;
TGCT	trans	rs1814175	0.502	rs12365889	chr11:49623034	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.42	-8.47	-0.61	6.09e-14	Height;
TGCT	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg22105103	chr4:187893119	NA	0.33	4.62	0.38	9.41e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2594989	0.887	rs2442799	chr3:11488640	A/G	cg26283222	chr3:11613257	VGLL4	-0.21	-4.56	-0.38	1.21e-5	Circulating chemerin levels;
TGCT	cis	rs2302464	1.000	rs73123615	chr4:15728176	G/A	cg18497811	chr4:14860861	NA	-0.49	-4.5	-0.37	1.57e-5	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs13256369	1.000	rs13266699	chr8:8570313	A/T	cg17143192	chr8:8559678	CLDN23	-0.58	-5.56	-0.45	1.56e-7	Obesity-related traits;
TGCT	cis	rs13082711	0.522	rs9310842	chr3:27369765	A/T	cg02860705	chr3:27208620	NA	-0.29	-4.57	-0.38	1.15e-5	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs860295	0.529	rs17381047	chr1:155983648	G/A	cg05700447	chr1:155978627	NA	-0.19	-4.68	-0.39	7.49e-6	Body mass index;
TGCT	cis	rs1059312	0.808	rs11059921	chr12:129289919	C/T	cg09035930	chr12:129282057	SLC15A4	0.55	10.73	0.69	2.06e-19	Systemic lupus erythematosus;
TGCT	cis	rs9787249	0.957	rs41267029	chr1:40214367	A/G	cg19912559	chr1:40204330	PPIE	0.49	5.7	0.46	8.41e-8	Blood protein levels;
TGCT	cis	rs2153535	0.580	rs7742689	chr6:8452433	C/A	cg07606381	chr6:8435919	SLC35B3	0.53	5.02	0.41	1.79e-6	Motion sickness;
TGCT	cis	rs9296092	0.538	rs56199698	chr6:33534505	G/C	cg13560919	chr6:33536144	NA	-0.23	-4.95	-0.41	2.4e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs16958440	0.867	rs75287977	chr18:44686823	G/A	cg17192377	chr18:44677553	HDHD2	0.63	4.7	0.39	6.74e-6	Sitting height ratio;
TGCT	cis	rs137699	1.000	rs5757630	chr22:39754433	G/T	cg11247378	chr22:39784982	NA	-0.45	-4.79	-0.39	4.77e-6	IgG glycosylation;
TGCT	cis	rs4366490	0.687	rs4963249	chr11:62905159	C/G	cg21002970	chr11:62369079	MTA2	0.74	5.2	0.42	7.81e-7	Conotruncal heart defects;
TGCT	cis	rs10832963	1.000	rs10832963	chr11:18664241	T/G	cg20219074	chr11:18656078	SPTY2D1	0.98	9.82	0.66	3.4e-17	Breast cancer;
TGCT	cis	rs9818758	0.607	rs11706189	chr3:49210833	C/A	cg00383909	chr3:49044727	WDR6	1.28	6.68	0.51	7.04e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs11098499	0.779	rs10011097	chr4:120310359	T/G	cg09307838	chr4:120376055	NA	0.65	6.39	0.5	3.02e-9	Corneal astigmatism;
TGCT	cis	rs45509595	0.841	rs200501	chr6:27788942	C/T	cg08798685	chr6:27730294	NA	-0.35	-4.76	-0.39	5.24e-6	Breast cancer;
TGCT	cis	rs854765	0.623	rs9893690	chr17:17753846	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.71	-6.8	-0.52	3.97e-10	Total body bone mineral density;
TGCT	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg22535103	chr8:58192502	C8orf71	0.43	5.26	0.43	6e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7940866	0.801	rs10894288	chr11:130808679	T/C	cg12179176	chr11:130786555	SNX19	0.59	5.89	0.47	3.41e-8	Schizophrenia;
TGCT	cis	rs12478296	1.000	rs66466023	chr2:243046151	T/G	cg06360820	chr2:242988706	NA	-0.61	-4.66	-0.39	8.13e-6	Obesity-related traits;
TGCT	cis	rs3749237	0.615	rs55957735	chr3:49438158	G/A	cg03060546	chr3:49711283	APEH	0.77	8.87	0.62	6.79e-15	Resting heart rate;
TGCT	cis	rs6490294	0.583	rs4767364	chr12:112521448	G/A	cg10833066	chr12:111807467	FAM109A	0.34	5.22	0.42	7.39e-7	Mean platelet volume;
TGCT	cis	rs2153535	0.580	rs2143357	chr6:8497196	A/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg26338869	chr17:61819248	STRADA	-0.53	-4.94	-0.41	2.48e-6	Prudent dietary pattern;
TGCT	cis	rs6545883	0.895	rs796597	chr2:61681060	A/G	cg15711740	chr2:61764176	XPO1	-0.56	-5.1	-0.42	1.23e-6	Tuberculosis;
TGCT	cis	rs8064299	0.967	rs878905	chr17:72769411	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.79	8.01	0.58	7.17e-13	Monocyte count;
TGCT	cis	rs2288073	0.896	rs13404513	chr2:24410780	G/A	cg05570707	chr2:24270316	C2orf44	-0.5	-4.49	-0.37	1.58e-5	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs4700695	1.000	rs3846481	chr5:65417803	T/C	cg21114390	chr5:65439923	SFRS12	-0.58	-4.45	-0.37	1.93e-5	Facial morphology (factor 19);
TGCT	cis	rs7412746	0.658	rs6656535	chr1:150940357	G/T	cg09365446	chr1:150670422	GOLPH3L	0.34	4.72	0.39	6.28e-6	Melanoma;
TGCT	cis	rs523522	0.892	rs4767916	chr12:121024032	T/C	cg27279351	chr12:120934652	DYNLL1	0.74	6.46	0.5	2.19e-9	High light scatter reticulocyte count;
TGCT	cis	rs988712	0.705	rs4923463	chr11:27672500	A/G	cg10635145	chr11:27742435	BDNF	-0.38	-5.25	-0.43	6.38e-7	Obesity;
TGCT	cis	rs2806561	0.704	rs667330	chr1:23515257	A/G	cg12483005	chr1:23474871	LUZP1	0.38	4.73	0.39	5.93e-6	Height;
TGCT	cis	rs12497850	0.897	rs7373778	chr3:48836392	C/G	cg06212747	chr3:49208901	KLHDC8B	0.61	5.62	0.45	1.2e-7	Parkinson's disease;
TGCT	cis	rs9911578	0.900	rs4793593	chr17:56892699	C/G	cg05425664	chr17:57184151	TRIM37	0.63	6.26	0.49	5.86e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg00149659	chr3:10157352	C3orf10	-0.91	-5.89	-0.47	3.32e-8	Alzheimer's disease;
TGCT	cis	rs78487399	0.908	rs17031095	chr2:43819139	A/G	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.66	4.67	0.39	7.66e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs765787	0.530	rs11634794	chr15:45534492	A/C	cg24006582	chr15:45444508	DUOX1	-0.24	-5.28	-0.43	5.51e-7	Uric acid levels;
TGCT	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	11.85	0.73	4.07e-22	Height;
TGCT	cis	rs6500602	0.701	rs4786500	chr16:4525265	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.38	-6.37	-0.5	3.4e-9	Schizophrenia;
TGCT	cis	rs13191362	1.000	rs7764785	chr6:163009967	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7582180	0.627	rs2099611	chr2:101021090	A/G	cg08017756	chr2:100939284	LONRF2	-0.31	-5.02	-0.41	1.72e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs17401966	0.838	rs7553935	chr1:10375179	G/A	cg19773385	chr1:10388646	KIF1B	-0.24	-5.38	-0.44	3.56e-7	Hepatocellular carcinoma;
TGCT	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.5	-6.94	-0.53	1.89e-10	Alzheimer's disease;
TGCT	cis	rs6582630	0.555	rs2090785	chr12:38424342	G/A	cg13010199	chr12:38710504	ALG10B	0.59	4.79	0.4	4.67e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg03396347	chr1:1875803	NA	-0.36	-6.58	-0.51	1.19e-9	Body mass index;
TGCT	cis	rs6831352	0.505	rs11722561	chr4:100088737	T/A	cg12011299	chr4:100065546	ADH4	0.35	5.14	0.42	1.03e-6	Alcohol dependence;
TGCT	cis	rs11690935	0.918	rs11757	chr2:172641045	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.19	-12.83	-0.76	1.7e-24	Schizophrenia;
TGCT	cis	rs9911578	0.967	rs2333410	chr17:57137129	G/A	cg05425664	chr17:57184151	TRIM37	0.68	6.9	0.53	2.4e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs763014	0.966	rs7198877	chr16:661439	A/G	cg07343612	chr16:622815	PIGQ	-0.42	-8.44	-0.6	7.14e-14	Height;
TGCT	cis	rs2458413	0.500	rs2458415	chr8:105351998	A/C	cg04554929	chr8:105342491	NA	0.5	6.07	0.48	1.42e-8	Paget's disease;
TGCT	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg22963979	chr7:1858916	MAD1L1	-0.32	-4.95	-0.41	2.39e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs12615966	0.651	rs72830471	chr2:105407062	A/C	cg16465502	chr2:105461796	NA	0.85	5.6	0.45	1.34e-7	Pancreatic cancer;
TGCT	cis	rs9549367	0.789	rs6577034	chr13:113879900	T/C	cg00898013	chr13:113819073	PROZ	-0.41	-5.21	-0.42	7.7300000000000005e-07	Platelet distribution width;
TGCT	cis	rs78545713	0.892	rs113432940	chr6:26256324	T/A	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.66	-4.77	-0.39	5.17e-6	Iron status biomarkers (total iron binding capacity);
TGCT	cis	rs9467711	0.651	rs34197618	chr6:26083519	T/C	cg16898833	chr6:26189333	HIST1H4D	1.34	6.07	0.48	1.47e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7824557	0.603	rs2246606	chr8:11219334	G/A	cg21775007	chr8:11205619	TDH	0.64	5.92	0.47	2.97e-8	Retinal vascular caliber;
TGCT	cis	rs6785206	0.504	rs34992870	chr3:128503052	A/G	cg25356066	chr3:128598488	ACAD9	-0.78	-4.45	-0.37	1.91e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs2204008	0.775	rs2387809	chr12:38363338	T/A	cg26384229	chr12:38710491	ALG10B	0.83	7.23	0.54	4.44e-11	Bladder cancer;
TGCT	cis	rs9894429	0.646	rs7217415	chr17:79618252	G/A	cg21028142	chr17:79581711	NPLOC4	0.29	5.85	0.46	4.18e-8	Eye color traits;
TGCT	cis	rs7587476	0.531	rs35933323	chr2:215674090	T/G	cg04004882	chr2:215674386	BARD1	-0.65	-5.13	-0.42	1.09e-6	Neuroblastoma;
TGCT	cis	rs35146811	0.695	rs1623264	chr7:99811204	G/C	cg00553149	chr7:99775558	STAG3;GPC2	-0.31	-4.61	-0.38	9.75e-6	Coronary artery disease;
TGCT	cis	rs3087591	0.919	rs2072131	chr17:29559588	G/C	cg24425628	chr17:29625626	OMG;NF1	-0.46	-7.32	-0.55	2.68e-11	Hip circumference;
TGCT	cis	rs10779751	0.734	rs2259886	chr1:11137778	C/T	cg08854313	chr1:11322531	MTOR	0.84	8.3	0.6	1.47e-13	Body mass index;
TGCT	cis	rs17125944	0.505	rs77690283	chr14:53233320	C/G	cg00686598	chr14:53173677	PSMC6	1.08	6.32	0.49	4.37e-9	Alzheimer's disease (late onset);
TGCT	cis	rs610932	0.517	rs670854	chr11:59981769	T/C	cg18570331	chr11:60101691	MS4A6E	0.52	4.84	0.4	3.79e-6	Alzheimer's disease;
TGCT	cis	rs9388451	0.839	rs9401845	chr6:126104118	A/G	cg10911889	chr6:126070802	HEY2	0.51	5.33	0.43	4.47e-7	Brugada syndrome;
TGCT	cis	rs453301	0.686	rs3895823	chr8:8873646	T/C	cg06636001	chr8:8085503	FLJ10661	-0.68	-5.63	-0.45	1.13e-7	Joint mobility (Beighton score);
TGCT	cis	rs595982	0.527	rs73061656	chr19:49372355	G/A	cg21252483	chr19:49399788	TULP2	-0.42	-6.36	-0.5	3.58e-9	Red cell distribution width;
TGCT	cis	rs8179	1.000	rs8179	chr7:92236164	T/C	cg15732164	chr7:92237376	CDK6	0.33	4.9	0.4	2.99e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
TGCT	cis	rs7666738	0.830	rs4699595	chr4:99012827	A/G	cg17366294	chr4:99064904	C4orf37	0.68	7.04	0.53	1.17e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11167764	1.000	rs6887599	chr5:141484349	G/A	cg23435118	chr5:141488016	NDFIP1	-0.3	-5.04	-0.41	1.61e-6	Crohn's disease;
TGCT	cis	rs826838	0.967	rs826856	chr12:39115434	G/A	cg13010199	chr12:38710504	ALG10B	-0.64	-5.07	-0.41	1.39e-6	Heart rate;
TGCT	cis	rs9473924	0.505	rs7738924	chr6:50850600	C/T	cg14470998	chr6:50812995	TFAP2B	1.35	8.39	0.6	9.05e-14	Body mass index;
TGCT	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg19010396	chr19:19431384	KIAA0892;SF4	-0.56	-4.58	-0.38	1.13e-5	Tonsillectomy;
TGCT	cis	rs7246657	0.943	rs10414904	chr19:37830088	G/A	cg18154014	chr19:37997991	ZNF793	0.72	5.19	0.42	8.31e-7	Coronary artery calcification;
TGCT	cis	rs7826238	0.509	rs2948288	chr8:8115304	A/G	cg08975724	chr8:8085496	FLJ10661	0.64	6.07	0.48	1.44e-8	Systolic blood pressure;
TGCT	cis	rs9300255	0.510	rs1790109	chr12:123637752	C/G	cg00376283	chr12:123451042	ABCB9	0.73	5.64	0.45	1.09e-7	Neutrophil percentage of white cells;
TGCT	cis	rs2072499	0.966	rs2984615	chr1:156165317	G/C	cg25208724	chr1:156163844	SLC25A44	1.14	17.15	0.84	1.56e-34	Testicular germ cell tumor;
TGCT	cis	rs1372520	0.935	rs1442152	chr4:90775649	C/A	cg15133208	chr4:90757351	SNCA	-0.5	-5.9	-0.47	3.18e-8	Neuroticism;
TGCT	cis	rs473651	0.935	rs541013	chr2:239336492	G/A	cg08773314	chr2:239334832	ASB1	0.47	7.87	0.58	1.54e-12	Multiple system atrophy;
TGCT	cis	rs3015497	0.616	rs1389650	chr14:51081449	C/T	cg04730355	chr14:51134070	SAV1	-0.64	-6.14	-0.48	1.01e-8	Mean platelet volume;
TGCT	cis	rs7674212	0.556	rs13151569	chr4:103942790	A/G	cg16532752	chr4:104119610	CENPE	-0.56	-4.92	-0.4	2.64e-6	Type 2 diabetes;
TGCT	cis	rs62244186	0.566	rs6766221	chr3:44882784	C/T	cg11003573	chr3:44754125	ZNF502	-0.47	-5.44	-0.44	2.76e-7	Depressive symptoms;
TGCT	cis	rs7949030	0.591	rs12049914	chr11:62369436	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.64	9.48	0.65	2.35e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg02353165	chr6:42928485	GNMT	0.99	10.14	0.67	5.89e-18	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs2708977	0.933	rs2579502	chr2:97198800	A/G	cg01950434	chr2:97203154	ARID5A	-0.7	-6.42	-0.5	2.68e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	trans	rs561341	0.941	rs4795664	chr17:30233467	C/T	cg20587970	chr11:113659929	NA	-0.82	-9.73	-0.66	5.87e-17	Hip circumference adjusted for BMI;
TGCT	cis	rs7119	0.651	rs8025968	chr15:77839616	C/T	cg27398640	chr15:77910606	LINGO1	-0.28	-5.12	-0.42	1.13e-6	Type 2 diabetes;
TGCT	cis	rs2932538	0.922	rs6691917	chr1:113137043	G/C	cg22162597	chr1:113214053	CAPZA1	0.25	5.6	0.45	1.34e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs12477438	0.520	rs13030961	chr2:99799520	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.05	13.31	0.77	1.16e-25	Chronic sinus infection;
TGCT	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg26668828	chr6:292823	DUSP22	0.79	8.26	0.6	1.83e-13	Menopause (age at onset);
TGCT	cis	rs7147624	1.000	rs61987807	chr14:66207050	G/T	cg03016385	chr14:66212404	NA	-0.5	-7.11	-0.54	8.15e-11	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg11062466	chr8:58055876	NA	0.43	4.64	0.38	8.85e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9790314	0.936	rs336572	chr3:161068014	G/A	cg03342759	chr3:160939853	NMD3	-0.47	-4.8	-0.4	4.55e-6	Morning vs. evening chronotype;
TGCT	cis	rs9972944	0.756	rs9894298	chr17:63769225	G/A	cg07283582	chr17:63770753	CCDC46	-0.26	-5.27	-0.43	5.91e-7	Total body bone mineral density;
TGCT	cis	rs8031584	0.678	rs798127	chr15:31117403	T/C	cg08704250	chr15:31115839	NA	0.44	6.43	0.5	2.47e-9	Huntington's disease progression;
TGCT	cis	rs10193935	0.901	rs13375	chr2:42559288	A/G	cg27598129	chr2:42591480	NA	-0.38	-5.22	-0.42	7.42e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs60154123	0.505	rs2206043	chr1:210042983	G/A	cg12034118	chr1:209979487	IRF6	0.65	4.56	0.38	1.2e-5	Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs17027090	chr4:98897923	G/T	cg17366294	chr4:99064904	C4orf37	0.67	6.83	0.52	3.3e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg08975724	chr8:8085496	FLJ10661	0.64	6.07	0.48	1.45e-8	Mood instability;
TGCT	cis	rs17681684	0.541	rs12150176	chr17:9764547	C/T	cg15743799	chr17:9805578	RCVRN	-0.27	-5.8	-0.46	5.29e-8	GIP levels in response to oral glucose tolerance test (fasting);
TGCT	cis	rs9522267	0.737	rs7330902	chr13:112227599	C/T	cg10483660	chr13:112241077	NA	-0.29	-4.7	-0.39	6.81e-6	Hepatitis;
TGCT	cis	rs6964587	0.692	rs4729025	chr7:91847504	C/T	cg17063962	chr7:91808500	NA	0.77	7.17	0.54	6.08e-11	Breast cancer;
TGCT	cis	rs908922	0.676	rs7530609	chr1:152526812	C/A	cg20991723	chr1:152506922	NA	0.45	6.06	0.48	1.55e-8	Hair morphology;
TGCT	cis	rs72634258	0.503	rs697674	chr1:7837878	C/G	cg26816564	chr1:7831052	VAMP3	0.98	7.19	0.54	5.47e-11	Inflammatory bowel disease;
TGCT	cis	rs10927875	0.541	rs1048237	chr1:16341733	T/C	cg21385522	chr1:16154831	NA	0.46	4.85	0.4	3.64e-6	Dilated cardiomyopathy;
TGCT	cis	rs3020736	0.500	rs6519306	chr22:42501217	T/C	cg15557168	chr22:42548783	NA	0.22	5.58	0.45	1.47e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs35883536	0.588	rs12568329	chr1:101104588	A/G	cg06223162	chr1:101003688	GPR88	-0.32	-5.34	-0.43	4.31e-7	Monocyte count;
TGCT	cis	rs1008375	1.000	rs1006722	chr4:17618713	A/G	cg16339924	chr4:17578868	LAP3	-0.61	-5.03	-0.41	1.65e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7246657	0.638	rs7246461	chr19:38196581	C/G	cg18154014	chr19:37997991	ZNF793	-0.63	-4.55	-0.38	1.24e-5	Coronary artery calcification;
TGCT	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg15691649	chr6:25882328	NA	0.43	5.34	0.43	4.27e-7	Blood metabolite levels;
TGCT	cis	rs12765878	1.000	rs4918068	chr10:105644736	T/G	cg11005552	chr10:105648138	OBFC1	0.45	7.89	0.58	1.36e-12	Coronary artery disease;
TGCT	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg17971929	chr21:40555470	PSMG1	0.97	9.4	0.65	3.57e-16	Cognitive function;
TGCT	cis	rs7917772	0.636	rs7911747	chr10:104528890	A/G	cg05855489	chr10:104503620	C10orf26	0.64	5.11	0.42	1.19e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs8014204	0.836	rs7153700	chr14:75268544	C/T	cg06637938	chr14:75390232	RPS6KL1	0.67	6.53	0.51	1.55e-9	Caffeine consumption;
TGCT	cis	rs1403694	0.655	rs3806688	chr3:186434819	T/C	cg12454167	chr3:186435060	KNG1	0.51	8.67	0.61	1.95e-14	Blood protein levels;
TGCT	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-8.64	-0.61	2.39e-14	Platelet count;
TGCT	cis	rs704	0.752	rs6505079	chr17:26718177	T/A	cg10342447	chr17:26645325	TMEM97	-0.51	-4.91	-0.4	2.82e-6	Osteoprotegerin levels;
TGCT	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.45	-5.37	-0.43	3.72e-7	Alzheimer's disease;
TGCT	cis	rs950776	0.722	rs471889	chr15:78870235	T/C	cg06917634	chr15:78832804	PSMA4	-0.66	-5.29	-0.43	5.47e-7	Sudden cardiac arrest;
TGCT	cis	rs11719291	0.667	rs9877542	chr3:48748545	C/T	cg00383909	chr3:49044727	WDR6	0.98	5.67	0.45	9.63e-8	Cognitive function;
TGCT	cis	rs2153535	0.580	rs1577472	chr6:8486215	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs9814567	0.929	rs9855013	chr3:134240414	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.95	-9.55	-0.65	1.56e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs12579753	0.879	rs7971664	chr12:82264101	T/C	cg07988820	chr12:82153109	PPFIA2	-0.52	-5.44	-0.44	2.69e-7	Resting heart rate;
TGCT	cis	rs10426930	0.547	rs2054519	chr19:5059360	T/C	cg09001777	chr19:5851504	FUT3	-0.2	-4.5	-0.37	1.57e-5	Monocyte percentage of white cells;
TGCT	cis	rs11190604	1.000	rs10883492	chr10:102206089	G/A	cg23241863	chr10:102295624	HIF1AN	0.62	4.87	0.4	3.27e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs1532993	0.518	rs6825353	chr4:98604203	G/A	cg05340658	chr4:99064831	C4orf37	-0.37	-4.44	-0.37	1.98e-5	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs4642101	0.561	rs7641959	chr3:12810755	G/C	cg05775895	chr3:12838266	CAND2	0.51	5.11	0.42	1.16e-6	QRS complex (12-leadsum);
TGCT	cis	rs72781680	1.000	rs72796316	chr2:24132272	T/C	cg08917208	chr2:24149416	ATAD2B	0.73	4.51	0.38	1.48e-5	Lymphocyte counts;
TGCT	cis	rs4319547	0.656	rs10161534	chr12:122873864	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.61	-4.74	-0.39	5.7e-6	Body mass index;
TGCT	cis	rs4372836	0.543	rs10204329	chr2:28998077	C/G	cg09522027	chr2:28974177	PPP1CB	-0.75	-7.46	-0.56	1.28e-11	Body mass index;
TGCT	cis	rs11122272	0.735	rs1416916	chr1:231533027	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-6.53	-0.51	1.55e-9	Hemoglobin concentration;
TGCT	cis	rs6912958	0.712	rs4498321	chr6:88339251	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-4.55	-0.38	1.26e-5	Monocyte percentage of white cells;
TGCT	cis	rs67311347	0.544	rs12635762	chr3:40332759	C/T	cg13683864	chr3:40499215	RPL14	0.78	7.24	0.54	4.19e-11	Renal cell carcinoma;
TGCT	cis	rs3087591	0.960	rs10512433	chr17:29600564	T/C	cg24425628	chr17:29625626	OMG;NF1	0.46	7.28	0.55	3.41e-11	Hip circumference;
TGCT	cis	rs7172809	0.643	rs75334741	chr15:77841492	T/C	cg22256960	chr15:77711686	NA	-0.47	-4.62	-0.38	9.37e-6	Glucose homeostasis traits;
TGCT	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg24549020	chr5:56110836	MAP3K1	0.7	5.97	0.47	2.34e-8	Initial pursuit acceleration;
TGCT	cis	rs2404602	0.608	rs17361504	chr15:76601871	A/G	cg26408565	chr15:76604113	ETFA	-0.47	-6.5	-0.5	1.73e-9	Blood metabolite levels;
TGCT	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg12288994	chr5:1860383	NA	0.24	4.52	0.38	1.42e-5	Cardiovascular disease risk factors;
TGCT	cis	rs860295	0.580	rs867549	chr1:155880159	T/C	cg13795986	chr1:155880507	RIT1	0.38	4.59	0.38	1.05e-5	Body mass index;
TGCT	cis	rs7027203	0.828	rs10761288	chr9:96609363	C/T	cg14598338	chr9:96623480	NA	-0.58	-8.53	-0.61	4.27e-14	DNA methylation (variation);
TGCT	cis	rs1129187	0.782	rs9462860	chr6:42947013	G/C	cg13397359	chr6:42928475	GNMT	0.69	6.21	0.49	7.39e-9	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs6815814	0.861	rs17616434	chr4:38812876	T/C	cg02016764	chr4:38805732	TLR1	-0.28	-4.84	-0.4	3.73e-6	Breast cancer;
TGCT	cis	rs2404602	0.608	rs12911035	chr15:76606591	T/C	cg22467129	chr15:76604101	ETFA	-0.61	-7.93	-0.58	1.1e-12	Blood metabolite levels;
TGCT	cis	rs67311347	1.000	rs72861689	chr3:40435890	A/G	cg17264618	chr3:40429014	ENTPD3	0.32	4.65	0.39	8.4e-6	Renal cell carcinoma;
TGCT	cis	rs7267979	1.000	rs7343481	chr20:25300113	C/T	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs5760092	0.755	rs5760096	chr22:24247310	A/G	cg20007245	chr22:24372913	LOC391322	-0.69	-6.27	-0.49	5.45e-9	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs765787	0.556	rs10851422	chr15:45513738	T/C	cg24006582	chr15:45444508	DUOX1	0.25	5.37	0.43	3.76e-7	Uric acid levels;
TGCT	cis	rs57221529	0.709	rs72707023	chr5:667620	G/A	cg09021430	chr5:549028	NA	-0.4	-5.49	-0.44	2.14e-7	Lung disease severity in cystic fibrosis;
TGCT	cis	rs526231	0.543	rs6881225	chr5:102307592	T/C	cg23492399	chr5:102201601	PAM	-0.53	-4.56	-0.38	1.23e-5	Primary biliary cholangitis;
TGCT	cis	rs5417	0.610	rs222843	chr17:7145981	T/C	cg25256661	chr17:7137939	DVL2	0.76	7.17	0.54	5.96e-11	Diastolic blood pressure;
TGCT	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg11494091	chr17:61959527	GH2	0.6	14.51	0.79	1.71e-28	Prudent dietary pattern;
TGCT	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg04267008	chr7:1944627	MAD1L1	-0.35	-4.65	-0.39	8.28e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs924607	1.000	rs2455331	chr5:643593	T/C	cg18765565	chr5:669397	TPPP	0.59	6.33	0.49	4.16e-9	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs6912958	0.535	rs1753154	chr6:88032843	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.72	7.32	0.55	2.77e-11	Monocyte percentage of white cells;
TGCT	cis	rs2288278	0.646	rs10514953	chr17:46589258	C/G	cg25032089	chr17:46643351	HOXB3	-0.41	-4.8	-0.4	4.55e-6	Hand grip strength;
TGCT	cis	rs12468226	1.000	rs77435512	chr2:203198888	G/C	cg26506821	chr2:202639771	ALS2	0.33	4.57	0.38	1.17e-5	Urate levels;
TGCT	cis	rs3125734	0.633	rs1873685	chr10:64032126	C/T	cg05499367	chr10:63213510	TMEM26	-0.33	-4.49	-0.37	1.62e-5	Rheumatoid arthritis;
TGCT	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg24578937	chr1:2090814	PRKCZ	-0.25	-6.39	-0.5	2.97e-9	Height;
TGCT	cis	rs7804356	0.520	rs10255249	chr7:26809963	A/G	cg03456212	chr7:26904342	SKAP2	-0.5	-4.44	-0.37	2e-5	Type 1 diabetes;
TGCT	cis	rs8038465	0.622	rs62004587	chr15:73859016	A/C	cg15420318	chr15:73925796	NPTN	0.63	6.65	0.51	8.32e-10	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9611519	1.000	rs2057070	chr22:41564287	T/C	cg03806693	chr22:41940476	POLR3H	-0.67	-6.19	-0.49	7.94e-9	Neuroticism;
TGCT	cis	rs7904368	0.754	rs7076779	chr10:16852667	C/T	cg23933602	chr10:16859644	RSU1	0.63	4.83	0.4	3.91e-6	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
TGCT	cis	rs9341808	0.667	rs2322632	chr6:80845608	G/A	cg08355045	chr6:80787529	NA	0.31	5.31	0.43	4.96e-7	Sitting height ratio;
TGCT	cis	rs2842992	0.915	rs2758335	chr6:160111011	G/A	cg11366901	chr6:160182831	ACAT2	0.94	6.18	0.49	8.48e-9	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg01585852	chr22:24235823	MIF	-0.21	-4.56	-0.38	1.23e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg11644478	chr21:40555479	PSMG1	1.02	10.93	0.7	6.95e-20	Cognitive function;
TGCT	cis	rs9393692	0.905	rs9358919	chr6:26287862	C/T	cg05868516	chr6:26286170	HIST1H4H	0.56	5.35	0.43	4.11e-7	Educational attainment;
TGCT	cis	rs7926906	1.000	rs10741377	chr11:90539430	T/A	cg26138821	chr11:89956704	CHORDC1	-0.47	-4.95	-0.41	2.36e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs8042680	0.554	rs59902579	chr15:91515489	C/T	cg22570213	chr15:91497863	RCCD1	0.44	4.69	0.39	7.23e-6	Type 2 diabetes;
TGCT	cis	rs7666738	0.830	rs10012271	chr4:99065154	A/C	cg05340658	chr4:99064831	C4orf37	0.52	5.79	0.46	5.32e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3796352	1.000	rs11718752	chr3:53130745	T/C	cg07884673	chr3:53033167	SFMBT1	0.49	5.11	0.42	1.16e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg18876405	chr7:65276391	NA	0.36	5.36	0.43	3.97e-7	Aortic root size;
TGCT	cis	rs8078723	0.714	rs9915252	chr17:38145088	C/G	cg17467752	chr17:38218738	THRA	-0.53	-5.37	-0.43	3.69e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs7267979	0.844	rs6083845	chr20:25388090	G/C	cg03522245	chr20:25566470	NINL	-0.55	-5.55	-0.45	1.68e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11716531	0.574	rs62256311	chr3:27271505	G/A	cg02860705	chr3:27208620	NA	0.45	7.0	0.53	1.45e-10	Diastolic blood pressure;
TGCT	cis	rs17376456	0.877	rs7702521	chr5:93484579	G/T	cg25358565	chr5:93447407	FAM172A	0.98	8.39	0.6	9.21e-14	Diabetic retinopathy;
TGCT	cis	rs78456975	0.568	rs115482599	chr2:1571960	A/G	cg01028140	chr2:1542097	TPO	-0.31	-4.67	-0.39	7.59e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs17197710	0.673	rs3816724	chr11:47312045	C/G	cg13308137	chr11:47528955	CUGBP1	-0.41	-5.82	-0.46	4.71e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9303401	0.614	rs28651036	chr17:57080471	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.63	5.95	0.47	2.59e-8	Cognitive test performance;
TGCT	cis	rs7681440	0.835	rs1899389	chr4:90802998	G/A	cg26578617	chr4:90757533	SNCA	-0.45	-4.63	-0.38	9.12e-6	Dementia with Lewy bodies;
TGCT	cis	rs13191362	1.000	rs34918316	chr6:163005386	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs921968	0.643	rs613539	chr2:219455967	G/T	cg02176678	chr2:219576539	TTLL4	0.38	5.48	0.44	2.31e-7	Mean corpuscular hemoglobin concentration;
TGCT	trans	rs57221529	0.766	rs72706608	chr5:559203	C/T	cg25482853	chr8:67687455	SGK3	1.2	10.16	0.67	5.25e-18	Lung disease severity in cystic fibrosis;
TGCT	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg14820908	chr5:178986412	RUFY1	0.45	4.63	0.38	9.19e-6	Lung cancer;
TGCT	cis	rs1355223	0.583	rs2915178	chr11:34878051	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.77	8.26	0.6	1.87e-13	Systemic lupus erythematosus and Systemic sclerosis;
TGCT	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg08280861	chr8:58055591	NA	-0.52	-5.89	-0.47	3.35e-8	Developmental language disorder (linguistic errors);
TGCT	cis	rs11148252	0.774	rs9596649	chr13:52934610	A/G	cg02158880	chr13:53174818	NA	-0.38	-4.57	-0.38	1.17e-5	Lewy body disease;
TGCT	cis	rs9868809	0.772	rs73078349	chr3:48688114	G/A	cg00383909	chr3:49044727	WDR6	1.29	6.0	0.47	2.04e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs7258465	1.000	rs10164319	chr19:18569833	G/A	cg06462663	chr19:18546047	ISYNA1	0.2	4.51	0.38	1.5e-5	Breast cancer;
TGCT	cis	rs2228479	0.867	rs75110337	chr16:89962635	C/A	cg19635926	chr16:89946313	TCF25	0.29	4.84	0.4	3.84e-6	Skin colour saturation;
TGCT	cis	rs7336332	0.527	rs1475219	chr13:28037415	A/G	cg22138327	chr13:27999177	GTF3A	0.68	5.26	0.43	6.25e-7	Weight;
TGCT	cis	rs17376456	0.825	rs6898842	chr5:93213221	T/C	cg21475434	chr5:93447410	FAM172A	0.7	4.86	0.4	3.51e-6	Diabetic retinopathy;
TGCT	cis	rs739496	0.579	rs12307365	chr12:112290651	G/C	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs36051895	0.659	rs58345215	chr9:5043767	A/T	cg02405213	chr9:5042618	JAK2	-0.72	-9.64	-0.65	9.46e-17	Pediatric autoimmune diseases;
TGCT	cis	rs9560113	0.508	rs2774425	chr13:112235077	A/G	cg10483660	chr13:112241077	NA	-0.32	-5.13	-0.42	1.09e-6	Menarche (age at onset);
TGCT	cis	rs916888	0.779	rs430685	chr17:44859148	T/C	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.7	-4.82	-0.4	4.1e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs4455778	0.580	rs10261034	chr7:49092554	C/A	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs7582180	0.764	rs7425797	chr2:100928337	T/C	cg08017756	chr2:100939284	LONRF2	-0.3	-4.91	-0.4	2.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs909002	1.000	rs1474182	chr1:32136398	C/T	cg11573219	chr1:32083031	HCRTR1	-0.37	-4.71	-0.39	6.42e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7914558	0.966	rs12569617	chr10:104729996	T/C	cg15744005	chr10:104629667	AS3MT	-0.4	-4.93	-0.41	2.55e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs854624	0.892	rs1734959	chr17:34336510	A/G	cg02022384	chr17:34097390	MMP28	0.49	4.55	0.38	1.28e-5	Blood protein levels;
TGCT	cis	rs79349575	0.749	rs8182364	chr17:47018025	A/G	cg07967210	chr17:47022446	SNF8	0.44	6.13	0.48	1.1e-8	Type 2 diabetes;
TGCT	cis	rs12477438	0.765	rs2309520	chr2:99570477	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.53	4.68	0.39	7.41e-6	Chronic sinus infection;
TGCT	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg05552183	chr6:42928497	GNMT	0.57	5.54	0.45	1.72e-7	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs546131	0.642	rs561477	chr11:34852152	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.52	4.55	0.38	1.24e-5	Lung disease severity in cystic fibrosis;
TGCT	cis	rs2073300	1.000	rs79169006	chr20:23443535	A/T	cg09953122	chr20:23471693	CST8	-0.64	-4.56	-0.38	1.19e-5	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg21724239	chr8:58056113	NA	0.42	5.04	0.41	1.59e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs78456975	1.000	rs11899027	chr2:1560414	G/C	cg01028140	chr2:1542097	TPO	-0.33	-4.53	-0.38	1.37e-5	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs2798269	0.544	rs1200030	chr13:22160604	C/T	cg18095732	chr13:22033692	ZDHHC20	-0.5	-4.46	-0.37	1.83e-5	PR segment;
TGCT	cis	rs6840360	0.593	rs4696107	chr4:152606823	G/A	cg17479576	chr4:152424074	FAM160A1	-0.62	-6.23	-0.49	6.69e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg04546413	chr19:29218101	NA	0.7	5.05	0.41	1.54e-6	Methadone dose in opioid dependence;
TGCT	cis	rs6062496	0.631	rs2297436	chr20:62304178	G/C	cg27236539	chr20:62289627	RTEL1	0.69	6.52	0.51	1.59e-9	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg12310025	chr6:25882481	NA	-0.91	-8.67	-0.61	2.01e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs12477438	0.798	rs1530996	chr2:99584079	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-8.79	-0.62	1.04e-14	Chronic sinus infection;
TGCT	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs4906332	0.966	rs17679729	chr14:103924312	A/G	cg26031613	chr14:104095156	KLC1	-0.53	-4.71	-0.39	6.62e-6	Coronary artery disease;
TGCT	cis	rs3806843	1.000	rs9686540	chr5:140174622	G/A	cg19875535	chr5:140030758	IK	0.37	6.34	0.49	3.89e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7267979	0.816	rs390123	chr20:25480105	C/G	cg03522245	chr20:25566470	NINL	0.56	5.79	0.46	5.51e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7926906	0.817	rs7941948	chr11:90527549	C/T	cg22332266	chr11:89956777	CHORDC1	-0.42	-4.6	-0.38	1.03e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs4654899	0.772	rs951805	chr1:21060356	A/G	cg01072550	chr1:21505969	NA	0.47	7.19	0.54	5.38e-11	Superior frontal gyrus grey matter volume;
TGCT	cis	rs9326248	1.000	rs664082	chr11:117071070	C/G	cg16524733	chr11:117070046	TAGLN	0.33	4.9	0.4	2.87e-6	Blood protein levels;
TGCT	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.49	-6.64	-0.51	8.8e-10	Alzheimer's disease;
TGCT	cis	rs9926296	0.632	rs7184315	chr16:89799373	C/G	cg27121462	chr16:89883253	FANCA	-0.54	-5.11	-0.42	1.2e-6	Vitiligo;
TGCT	cis	rs12188164	1.000	rs12188164	chr5:428236	C/A	cg21144161	chr5:423903	AHRR	0.24	4.5	0.37	1.53e-5	Cystic fibrosis severity;
TGCT	cis	rs950169	0.519	rs7237	chr15:85186577	C/T	cg12863693	chr15:85201151	NMB	0.42	5.19	0.42	8.48e-7	Schizophrenia;
TGCT	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg00149659	chr3:10157352	C3orf10	1.17	7.24	0.55	4.13e-11	Alzheimer's disease;
TGCT	cis	rs12711979	0.740	rs6711963	chr2:3820915	A/T	cg17052675	chr2:3827356	NA	-0.4	-7.82	-0.57	2.02e-12	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs709400	0.827	rs2274269	chr14:104029246	G/A	cg26031613	chr14:104095156	KLC1	1.15	14.5	0.79	1.83e-28	Body mass index;
TGCT	cis	rs9611565	0.559	rs5758397	chr22:42019251	C/T	cg06481639	chr22:41940642	POLR3H	0.73	6.47	0.5	2.04e-9	Vitiligo;
TGCT	cis	rs7805747	0.523	rs13239239	chr7:151423196	C/T	cg17611936	chr7:151411526	PRKAG2	-0.39	-4.53	-0.38	1.37e-5	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
TGCT	cis	rs12421382	0.659	rs12417251	chr11:109386273	G/T	cg16359550	chr11:109292809	C11orf87	0.4	4.49	0.37	1.61e-5	Schizophrenia;
TGCT	cis	rs11098499	0.954	rs17005535	chr4:120411562	C/T	cg09307838	chr4:120376055	NA	0.69	6.64	0.51	8.97e-10	Corneal astigmatism;
TGCT	cis	rs4919044	0.808	rs835274	chr10:94796534	A/G	cg05127821	chr10:94822908	CYP26C1	-0.74	-4.83	-0.4	3.95e-6	Coronary artery disease;
TGCT	cis	rs2153535	0.540	rs9378557	chr6:8517381	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.55e-8	Motion sickness;
TGCT	cis	rs903263	1.000	rs12128892	chr1:84624893	G/A	cg09664975	chr1:84543551	PRKACB	0.47	4.5	0.37	1.54e-5	Breast cancer (male);
TGCT	cis	rs10479542	0.806	rs4700836	chr5:178976393	A/G	cg21226059	chr5:178986404	RUFY1	0.44	4.74	0.39	5.79e-6	Lung cancer;
TGCT	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg27454412	chr7:1067447	C7orf50	0.57	4.48	0.37	1.71e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs10501293	0.666	rs7118471	chr11:43005512	T/C	cg03447554	chr11:43094025	NA	0.44	6.28	0.49	5.2e-9	Cognitive performance;
TGCT	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.91	0.4	2.75e-6	Electroencephalogram traits;
TGCT	cis	rs9443645	0.901	rs1960542	chr6:79566643	C/T	cg09184832	chr6:79620586	NA	-0.49	-5.29	-0.43	5.31e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs854765	0.927	rs4925138	chr17:17992793	T/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.63	-5.95	-0.47	2.54e-8	Total body bone mineral density;
TGCT	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg18230493	chr5:56204884	C5orf35	-0.66	-5.65	-0.45	1.05e-7	Initial pursuit acceleration;
TGCT	cis	rs9916302	0.904	rs8081338	chr17:37406139	C/T	cg07936489	chr17:37558343	FBXL20	-0.65	-5.24	-0.43	6.62e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs7647973	1.000	rs3905330	chr3:49550774	A/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.56	-4.76	-0.39	5.24e-6	Menarche (age at onset);
TGCT	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg24060327	chr5:131705240	SLC22A5	-0.58	-6.06	-0.48	1.51e-8	Blood metabolite levels;
TGCT	trans	rs1814175	0.645	rs1874969	chr11:49826700	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.45	-11.09	-0.71	2.8e-20	Height;
TGCT	cis	rs9611519	1.000	rs3818003	chr22:41609690	C/T	cg03806693	chr22:41940476	POLR3H	-0.66	-6.3	-0.49	4.65e-9	Neuroticism;
TGCT	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg10802521	chr3:52805072	NEK4	-0.74	-9.61	-0.65	1.14e-16	Bipolar disorder;
TGCT	cis	rs12549902	1.000	rs12549902	chr8:41509259	C/T	cg21772509	chr8:41503840	NKX6-3	0.87	10.06	0.67	9.27e-18	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
TGCT	cis	rs6674176	0.593	rs3791120	chr1:44431715	T/C	cg12908607	chr1:44402522	ARTN	-0.67	-8.15	-0.59	3.4e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg00149659	chr3:10157352	C3orf10	0.93	6.0	0.47	2.05e-8	Alzheimer's disease;
TGCT	cis	rs290268	1.000	rs290271	chr9:93551619	G/A	cg02608019	chr9:93564028	SYK	0.48	4.82	0.4	4.19e-6	Platelet count;
TGCT	cis	rs7726839	0.540	rs28364691	chr5:664084	G/A	cg16624210	chr5:671434	TPPP	0.42	4.89	0.4	3.06e-6	Obesity-related traits;
TGCT	cis	rs2832191	0.791	rs9983651	chr21:30491227	T/A	cg24692254	chr21:30365293	RNF160	-0.92	-9.97	-0.67	1.45e-17	Dental caries;
TGCT	cis	rs9512730	0.553	rs1007701	chr13:28049143	C/G	cg04070771	chr13:27998621	GTF3A	-0.53	-4.64	-0.38	8.87e-6	Schizophrenia;
TGCT	cis	rs2880765	0.545	rs11631739	chr15:86012578	T/C	cg13263323	chr15:86062960	AKAP13	-0.22	-4.93	-0.41	2.53e-6	Coronary artery disease;
TGCT	cis	rs7119	0.651	rs35577135	chr15:77840074	C/T	cg27398640	chr15:77910606	LINGO1	-0.28	-5.16	-0.42	9.63e-7	Type 2 diabetes;
TGCT	cis	rs4654899	0.772	rs7548269	chr1:21089472	T/C	cg01072550	chr1:21505969	NA	-0.47	-7.01	-0.53	1.32e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs4849845	0.598	rs3933620	chr2:121034936	A/T	cg24070213	chr2:121070622	NA	0.35	4.77	0.39	5.13e-6	Mean platelet volume;
TGCT	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg05890377	chr2:74357713	NA	0.48	6.58	0.51	1.2e-9	Gestational age at birth (maternal effect);
TGCT	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	4.91	0.4	2.78e-6	Menopause (age at onset);
TGCT	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg20573242	chr4:122745356	CCNA2	0.62	5.48	0.44	2.23e-7	Type 2 diabetes;
TGCT	cis	rs1008375	1.000	rs11722037	chr4:17683811	G/A	cg18681998	chr4:17616180	MED28	0.9	10.45	0.68	1e-18	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs752010	0.746	rs10749837	chr1:42089471	T/C	cg06885757	chr1:42089581	HIVEP3	0.25	4.56	0.38	1.23e-5	Lupus nephritis in systemic lupus erythematosus;
TGCT	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg11494091	chr17:61959527	GH2	0.43	7.3	0.55	3.05e-11	Height;
TGCT	cis	rs10206020	0.759	rs11903889	chr2:1576601	C/T	cg01028140	chr2:1542097	TPO	-0.28	-4.51	-0.38	1.47e-5	IgG glycosylation;
TGCT	cis	rs12579753	0.879	rs11615729	chr12:82128318	T/A	cg07988820	chr12:82153109	PPFIA2	-0.68	-7.32	-0.55	2.7e-11	Resting heart rate;
TGCT	cis	rs4849845	0.637	rs62168279	chr2:121026771	T/C	cg24070213	chr2:121070622	NA	0.35	4.64	0.38	8.58e-6	Mean platelet volume;
TGCT	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg08280861	chr8:58055591	NA	0.38	4.81	0.4	4.36e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg02788857	chr8:22132959	PIWIL2	0.28	5.11	0.42	1.2e-6	Hypertriglyceridemia;
TGCT	trans	rs12001652	0.579	rs7025739	chr9:14017640	A/G	cg16456503	chr16:67943052	PSKH1	0.43	6.71	0.52	6.27e-10	Carotid plaque burden;
TGCT	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg03806693	chr22:41940476	POLR3H	-1.13	-13.26	-0.77	1.59e-25	Vitiligo;
TGCT	cis	rs9560113	1.000	rs9560113	chr13:112183348	A/G	cg14154082	chr13:112174009	NA	0.36	4.8	0.4	4.52e-6	Menarche (age at onset);
TGCT	cis	rs1971762	0.563	rs4759284	chr12:54079491	G/A	cg16917193	chr12:54089295	NA	1.37	17.65	0.85	1.25e-35	Height;
TGCT	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg03452623	chr4:187889614	NA	-0.37	-5.7	-0.46	8.2e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11018874	0.597	rs4268468	chr11:89886284	C/T	cg05041596	chr11:89867385	NAALAD2	0.53	5.33	0.43	4.56e-7	White blood cell types;
TGCT	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg20607798	chr8:58055168	NA	0.66	5.58	0.45	1.46e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg03806693	chr22:41940476	POLR3H	-1.14	-12.51	-0.75	9.93e-24	Vitiligo;
TGCT	cis	rs7611238	0.583	rs12630009	chr3:195046618	G/A	cg27323046	chr3:195102265	ACAP2	0.36	4.9	0.4	2.94e-6	Body mass index;
TGCT	cis	rs7772486	0.875	rs56181683	chr6:146286620	A/G	cg05347473	chr6:146136440	FBXO30	-0.54	-5.18	-0.42	8.61e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4711350	1.000	rs943472	chr6:33738442	T/C	cg18005901	chr6:33739558	LEMD2	-0.55	-5.91	-0.47	3.13e-8	Schizophrenia;
TGCT	trans	rs941408	1.000	rs1736184	chr19:2810248	G/A	cg22153745	chr1:153894579	GATAD2B	-0.67	-7.24	-0.55	4.11e-11	Total cholesterol levels;
TGCT	cis	rs1670533	1.000	rs6837145	chr4:1071067	T/C	cg20887711	chr4:1340912	KIAA1530	0.64	5.02	0.41	1.74e-6	Recombination rate (females);
TGCT	cis	rs11098499	0.675	rs11098534	chr4:120556772	T/G	cg09307838	chr4:120376055	NA	0.62	5.86	0.47	3.86e-8	Corneal astigmatism;
TGCT	cis	rs6964587	0.934	rs7793861	chr7:91742728	C/G	cg22709100	chr7:91322751	NA	0.28	4.61	0.38	9.79e-6	Breast cancer;
TGCT	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg03806693	chr22:41940476	POLR3H	-1.13	-13.26	-0.77	1.59e-25	Vitiligo;
TGCT	cis	rs6722750	0.870	rs35899183	chr2:64408776	C/G	cg22352474	chr2:64371530	PELI1	0.58	5.23	0.43	6.84e-7	Neuroticism;
TGCT	cis	rs7666738	0.830	rs7662218	chr4:98983126	T/G	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs514406	0.683	rs10157120	chr1:53210888	A/G	cg08859206	chr1:53392774	SCP2	-0.35	-5.04	-0.41	1.6e-6	Monocyte count;
TGCT	cis	rs4803455	0.565	rs2241713	chr19:41869468	C/G	cg09537434	chr19:41945824	ATP5SL	0.56	5.69	0.45	8.78e-8	Migraine;Coronary artery disease;
TGCT	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg23283495	chr1:209979779	IRF6	0.65	5.53	0.44	1.81e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs9291683	0.552	rs10939656	chr4:10014646	A/C	cg11266682	chr4:10021025	SLC2A9	0.73	10.86	0.7	1.03e-19	Bone mineral density;
TGCT	cis	rs9467773	0.583	rs1021373	chr6:26632457	G/A	cg26531700	chr6:26746687	NA	0.5	4.68	0.39	7.52e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2302045	1.000	rs2270044	chr2:242056924	A/G	cg03756522	chr2:242788804	NA	-0.42	-4.69	-0.39	7.05e-6	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio);
TGCT	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg10802521	chr3:52805072	NEK4	0.79	10.1	0.67	7.29e-18	Bipolar disorder;
TGCT	cis	rs79349575	0.749	rs318093	chr17:46989354	A/G	cg07967210	chr17:47022446	SNF8	0.43	6.04	0.48	1.68e-8	Type 2 diabetes;
TGCT	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg06028808	chr11:68637592	NA	0.54	6.94	0.53	1.93e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs10789491	1.000	rs2083485	chr1:47170091	G/C	cg15501359	chr1:47185051	KIAA0494	0.82	8.26	0.6	1.82e-13	Response to hepatitis C treatment;
TGCT	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg03806693	chr22:41940476	POLR3H	-1.13	-13.26	-0.77	1.59e-25	Vitiligo;
TGCT	cis	rs854765	0.647	rs1008135	chr17:18027143	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.74	7.71	0.57	3.61e-12	Total body bone mineral density;
TGCT	cis	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg08045932	chr20:61659980	NA	0.48	9.16	0.64	1.36e-15	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7584330	0.737	rs1497127	chr2:238369282	A/G	cg08992911	chr2:238395768	MLPH	0.57	4.63	0.38	8.96e-6	Prostate cancer;
TGCT	cis	rs858239	0.670	rs3807452	chr7:23162081	C/T	cg05602783	chr7:23145260	KLHL7	0.56	4.67	0.39	7.66e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs1577917	1.000	rs1911552	chr6:86638024	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.05	-0.41	1.57e-6	Response to antipsychotic treatment;
TGCT	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg11890956	chr21:40555474	PSMG1	-0.76	-7.08	-0.54	9.53e-11	Cognitive function;
TGCT	cis	rs7267979	1.000	rs6115140	chr20:25285507	C/A	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2760061	0.545	rs1636196	chr1:228204030	A/G	cg02753203	chr1:228287806	NA	0.39	7.75	0.57	2.79e-12	Diastolic blood pressure;
TGCT	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg22920501	chr2:26401640	FAM59B	-0.73	-6.12	-0.48	1.12e-8	Gut microbiome composition (summer);
TGCT	cis	rs6138458	1.000	rs227658	chr20:24932028	A/G	cg26195577	chr20:24973756	C20orf3	1.2	12.06	0.73	1.2e-22	Blood protein levels;
TGCT	trans	rs35934224	1.000	rs35934224	chr22:19872645	C/T	cg07537964	chr19:3722604	NA	0.76	6.75	0.52	5.17e-10	Glaucoma (primary open-angle);
TGCT	cis	rs4733781	0.965	rs17285138	chr8:131297696	T/A	cg16277922	chr8:131349729	ASAP1	0.44	5.71	0.46	7.95e-8	Tuberculosis;
TGCT	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs73001065	0.901	rs73004967	chr19:19717056	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	1.01	4.57	0.38	1.18e-5	LDL cholesterol;
TGCT	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg11764359	chr7:65958608	NA	0.58	5.31	0.43	4.91e-7	Aortic root size;
TGCT	cis	rs7681440	0.904	rs12331318	chr4:90770255	A/G	cg01966878	chr4:90757139	SNCA	-0.25	-4.5	-0.37	1.57e-5	Dementia with Lewy bodies;
TGCT	cis	rs9926296	0.586	rs1800359	chr16:89805261	A/G	cg08627397	chr16:89984028	MC1R	-0.32	-5.11	-0.42	1.16e-6	Vitiligo;
TGCT	cis	rs6570726	0.533	rs1832374	chr6:145717752	A/G	cg23711669	chr6:146136114	FBXO30	0.6	5.53	0.44	1.82e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg25036284	chr2:26402008	FAM59B	0.6	4.64	0.38	8.63e-6	Gut microbiome composition (summer);
TGCT	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg07061783	chr6:25882402	NA	-0.67	-6.58	-0.51	1.18e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg17971929	chr21:40555470	PSMG1	0.98	9.61	0.65	1.14e-16	Cognitive function;
TGCT	cis	rs62244186	0.545	rs725866	chr3:44765533	A/G	cg02073558	chr3:44770973	ZNF501	0.73	7.31	0.55	2.81e-11	Depressive symptoms;
TGCT	cis	rs7524258	0.903	rs4908609	chr1:7292910	G/A	cg07173049	chr1:7289937	CAMTA1	0.32	5.31	0.43	4.88e-7	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs2303745	0.589	rs11882562	chr19:17395055	C/G	cg04248312	chr19:17393744	ANKLE1	0.34	5.94	0.47	2.69e-8	Systemic lupus erythematosus;
TGCT	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg03264133	chr6:25882463	NA	-0.53	-5.53	-0.44	1.81e-7	Blood metabolite levels;
TGCT	cis	rs12681287	0.511	rs4129535	chr8:87524094	G/T	cg27223183	chr8:87520930	FAM82B	-0.96	-7.03	-0.53	1.21e-10	Caudate activity during reward;
TGCT	cis	rs9659323	1.000	rs9659323	chr1:119504361	A/G	cg07961512	chr1:119535619	NA	0.44	5.07	0.41	1.4e-6	Body mass index;
TGCT	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg19626725	chr5:178986131	RUFY1	0.55	7.55	0.56	8.39e-12	Lung cancer;
TGCT	cis	rs62380364	0.727	rs797419	chr5:88168955	C/A	cg22951263	chr5:87985283	NA	0.5	5.02	0.41	1.79e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs854765	0.623	rs9893690	chr17:17753846	A/T	cg09796270	chr17:17721594	SREBF1	-0.26	-4.91	-0.4	2.84e-6	Total body bone mineral density;
TGCT	cis	rs9916302	0.861	rs593480	chr17:37453780	A/C	cg07936489	chr17:37558343	FBXL20	0.62	4.91	0.4	2.85e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs11098499	0.566	rs17051356	chr4:120585308	C/T	cg09307838	chr4:120376055	NA	0.59	5.42	0.44	3.01e-7	Corneal astigmatism;
TGCT	cis	rs589448	0.538	rs683790	chr12:69751434	T/G	cg14784868	chr12:69753453	YEATS4	0.66	5.84	0.46	4.33e-8	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs7193541	0.684	rs9923145	chr16:74686166	G/A	cg01733217	chr16:74700730	RFWD3	1.0	13.51	0.77	3.91e-26	Multiple myeloma;
TGCT	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg06481639	chr22:41940642	POLR3H	0.75	6.66	0.51	8.03e-10	Vitiligo;
TGCT	cis	rs12681288	0.748	rs7000148	chr8:1016383	G/C	cg06709756	chr8:1339049	NA	-0.23	-4.57	-0.38	1.17e-5	Schizophrenia;
TGCT	cis	rs1153858	1.000	rs66714503	chr15:45648038	G/C	cg26924012	chr15:45694286	SPATA5L1	1.09	15.16	0.81	5.15e-30	Homoarginine levels;
TGCT	cis	rs77633900	0.614	rs7162982	chr15:76961559	G/A	cg21673338	chr15:77095150	SCAPER	0.52	5.17	0.42	9.04e-7	Non-glioblastoma glioma;Glioma;
TGCT	cis	rs3091242	0.900	rs4649086	chr1:25778967	T/A	cg10117171	chr1:25599238	RHD	-0.3	-4.92	-0.4	2.69e-6	Erythrocyte sedimentation rate;
TGCT	cis	rs801193	0.548	rs6975044	chr7:66227482	C/T	cg11764359	chr7:65958608	NA	0.53	4.64	0.38	8.62e-6	Aortic root size;
TGCT	cis	rs2289681	0.525	rs34637106	chr17:42985772	C/T	cg15193461	chr17:42977049	CCDC103;EFTUD2	-0.72	-6.25	-0.49	5.95e-9	Cognitive function;
TGCT	cis	rs854765	0.583	rs8078138	chr17:17811251	C/T	cg09796270	chr17:17721594	SREBF1	0.27	5.55	0.45	1.69e-7	Total body bone mineral density;
TGCT	cis	rs9921338	0.961	rs4781055	chr16:11369428	C/T	cg00044050	chr16:11439710	C16orf75	-0.9	-6.15	-0.48	9.88e-9	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs5769765	0.773	rs9616378	chr22:50311973	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.23	-12.66	-0.75	4.45e-24	Schizophrenia;
TGCT	cis	rs10892173	0.566	rs111578166	chr11:117666714	G/T	cg07621104	chr11:117668040	DSCAML1	0.69	7.61	0.56	5.84e-12	Myopia;
TGCT	cis	rs711245	0.573	rs7570763	chr2:36800589	A/C	cg10546459	chr2:36825355	FEZ2	-0.6	-5.58	-0.45	1.42e-7	Height;
TGCT	cis	rs3796352	1.000	rs11710707	chr3:52975916	A/G	cg07884673	chr3:53033167	SFMBT1	0.63	5.74	0.46	6.83e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs2299433	0.627	rs62469056	chr7:116336013	G/A	cg18325389	chr7:116450458	NA	-0.2	-4.52	-0.38	1.42e-5	Hematocrit;
TGCT	cis	rs6459788	0.605	rs887628	chr7:157237589	G/A	cg03453431	chr7:157225567	NA	-0.4	-5.8	-0.46	5.3e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs10193935	0.892	rs6744964	chr2:42441088	A/G	cg27598129	chr2:42591480	NA	-0.39	-5.14	-0.42	1.05e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9929218	0.551	rs1886697	chr16:68716179	T/C	cg01251360	chr16:68772225	CDH1	-0.27	-4.92	-0.4	2.75e-6	Colorectal cancer;
TGCT	cis	rs8038465	1.000	rs8038465	chr15:73978337	A/G	cg15420318	chr15:73925796	NPTN	-0.74	-6.98	-0.53	1.55e-10	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6089829	0.925	rs4809270	chr20:61676709	C/A	cg08564027	chr20:61660810	NA	0.37	6.0	0.47	2e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7296418	0.630	rs11057238	chr12:123767971	C/A	cg00376283	chr12:123451042	ABCB9	0.66	5.64	0.45	1.09e-7	Platelet count;
TGCT	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg24060327	chr5:131705240	SLC22A5	-0.73	-7.77	-0.57	2.59e-12	Breast cancer;
TGCT	cis	rs2637266	1.000	rs12260492	chr10:78365242	C/A	cg18941641	chr10:78392320	NA	0.39	4.88	0.4	3.24e-6	Pulmonary function;
TGCT	cis	rs6438424	0.521	rs10934427	chr3:117721983	T/C	cg15509235	chr3:117715573	NA	0.53	5.27	0.43	5.83e-7	Menarche (age at onset);
TGCT	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg07157834	chr1:205819609	PM20D1	0.44	7.12	0.54	7.56e-11	Menarche (age at onset);
TGCT	cis	rs1448094	0.717	rs7298614	chr12:86296513	C/T	cg02569458	chr12:86230093	RASSF9	0.36	4.61	0.38	1e-5	Major depressive disorder;
TGCT	cis	rs28595532	0.748	rs17594978	chr4:119336398	T/C	cg11846333	chr4:119757529	SEC24D	0.72	4.51	0.38	1.48e-5	Cannabis dependence symptom count;
TGCT	cis	rs8179	0.542	rs3731326	chr7:92327026	A/G	cg15732164	chr7:92237376	CDK6	-0.3	-5.17	-0.42	8.94e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
TGCT	trans	rs17685	0.753	rs7788763	chr7:75651665	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.51	-8.53	-0.61	4.32e-14	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs8031584	0.678	rs8028173	chr15:31155749	A/G	cg14829155	chr15:31115871	NA	-0.36	-4.72	-0.39	6.14e-6	Huntington's disease progression;
TGCT	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg03709012	chr19:19516395	GATAD2A	-0.79	-6.75	-0.52	4.97e-10	Tonsillectomy;
TGCT	cis	rs11264213	0.591	rs684594	chr1:36489977	G/A	cg27506609	chr1:36549197	TEKT2	-0.31	-4.47	-0.37	1.77e-5	Schizophrenia;
TGCT	cis	rs74233809	1.000	rs12411886	chr10:104685299	C/A	cg05855489	chr10:104503620	C10orf26	0.75	4.47	0.37	1.72e-5	Birth weight;
TGCT	cis	rs1355223	0.583	rs2941060	chr11:34879154	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.8	8.77	0.62	1.16e-14	Systemic lupus erythematosus and Systemic sclerosis;
TGCT	cis	rs2072499	0.750	rs909269	chr1:156192028	C/T	cg24450063	chr1:156163899	SLC25A44	1.03	9.7	0.66	6.62e-17	Testicular germ cell tumor;
TGCT	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs8050907	0.744	rs7191458	chr16:4511752	T/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.53	4.57	0.38	1.15e-5	Obesity-related traits;
TGCT	cis	rs2153535	0.526	rs9406179	chr6:8538224	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.67	0.45	9.45e-8	Motion sickness;
TGCT	cis	rs7666738	0.606	rs3846446	chr4:99099768	C/A	cg05340658	chr4:99064831	C4orf37	0.42	4.49	0.37	1.62e-5	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs4332037	0.539	rs34809719	chr7:2028968	G/T	cg10840412	chr1:235813424	GNG4	0.93	6.69	0.51	6.97e-10	Bipolar disorder;
TGCT	cis	rs1348850	0.914	rs12616443	chr2:178315751	A/G	cg22681709	chr2:178499509	PDE11A	-0.37	-4.85	-0.4	3.66e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs10028773	0.515	rs9994651	chr4:120587803	C/T	cg09307838	chr4:120376055	NA	0.56	5.33	0.43	4.39e-7	Educational attainment;
TGCT	cis	rs6582630	0.502	rs4309219	chr12:38293584	A/G	cg26384229	chr12:38710491	ALG10B	0.78	7.01	0.53	1.36e-10	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs10876993	0.890	rs810204	chr12:58075733	T/C	cg15848620	chr12:58087721	OS9	-0.72	-5.83	-0.46	4.52e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs6582630	0.537	rs1851124	chr12:38516404	G/A	cg26384229	chr12:38710491	ALG10B	0.84	7.68	0.57	4.16e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs4851254	0.660	rs60697219	chr2:100699507	G/A	cg07810366	chr2:100720526	AFF3	-0.47	-4.92	-0.4	2.66e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs4595586	0.505	rs12826314	chr12:39379435	A/C	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs17376456	0.569	rs10050364	chr5:93064127	T/C	cg25358565	chr5:93447407	FAM172A	0.74	6.42	0.5	2.66e-9	Diabetic retinopathy;
TGCT	cis	rs6570726	0.935	rs368848	chr6:145855281	A/T	cg05347473	chr6:146136440	FBXO30	0.49	4.54	0.38	1.29e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs73001065	0.636	rs8182472	chr19:19539891	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.83	4.59	0.38	1.08e-5	LDL cholesterol;
TGCT	cis	rs7681440	0.775	rs6848181	chr4:90807252	T/C	cg14346243	chr4:90757452	SNCA	-0.5	-4.75	-0.39	5.46e-6	Dementia with Lewy bodies;
TGCT	cis	rs1113500	0.787	rs10881502	chr1:108641819	C/T	cg22161131	chr1:109420278	GPSM2	-0.5	-4.64	-0.38	8.69e-6	Growth-regulated protein alpha levels;
TGCT	cis	rs7017914	0.870	rs3098874	chr8:71934338	G/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-4.97	-0.41	2.16e-6	Bone mineral density;
TGCT	cis	rs7264396	0.690	rs17093156	chr20:34438583	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.04	-0.41	1.58e-6	Total cholesterol levels;
TGCT	cis	rs35306767	0.855	rs61830931	chr10:932497	T/C	cg20503657	chr10:835505	NA	0.8	11.88	0.73	3.41e-22	Eosinophil percentage of granulocytes;
TGCT	cis	rs3096299	0.685	rs3803682	chr16:89544636	C/T	cg08392591	chr16:89556376	ANKRD11	0.55	5.06	0.41	1.49e-6	Multiple myeloma (IgH translocation);
TGCT	cis	rs763121	0.853	rs4821811	chr22:39075145	C/T	cg06022373	chr22:39101656	GTPBP1	0.77	7.47	0.56	1.24e-11	Menopause (age at onset);
TGCT	cis	rs9581857	0.615	rs79793528	chr13:28007823	G/A	cg22138327	chr13:27999177	GTF3A	0.8	5.52	0.44	1.9e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs3796352	0.881	rs11710394	chr3:53015839	A/G	cg15956490	chr3:53032818	SFMBT1	0.61	6.76	0.52	4.92e-10	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg24531977	chr5:56204891	C5orf35	-0.79	-7.18	-0.54	5.77e-11	Initial pursuit acceleration;
TGCT	trans	rs4650994	0.544	rs4652301	chr1:178499799	T/C	cg05059571	chr16:84539110	KIAA1609	-0.54	-11.12	-0.71	2.39e-20	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg18252515	chr7:66147081	NA	-1.14	-6.81	-0.52	3.76e-10	Diabetic kidney disease;
TGCT	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg11494091	chr17:61959527	GH2	0.61	14.48	0.79	2.05e-28	Prudent dietary pattern;
TGCT	cis	rs4788439	0.901	rs11864339	chr16:24993436	T/C	cg07626409	chr16:25250191	ZKSCAN2	0.33	4.6	0.38	1.03e-5	Blood metabolite levels;
TGCT	cis	rs28595532	0.920	rs114165587	chr4:119779525	C/T	cg14228332	chr4:119757509	SEC24D	1.26	7.08	0.54	9.26e-11	Cannabis dependence symptom count;
TGCT	cis	rs12220898	0.749	rs4478905	chr10:50479539	G/A	cg06072769	chr10:50146962	WDFY4	0.35	4.5	0.37	1.56e-5	Inflammatory biomarkers;
TGCT	cis	rs2300747	0.872	rs6677309	chr1:117080166	A/C	cg26677431	chr1:117075710	CD58	-0.22	-4.67	-0.39	7.55e-6	Primary biliary cholangitis;Multiple sclerosis;
TGCT	trans	rs4332037	0.624	rs11766944	chr7:1888051	G/A	cg25206134	chr2:45395956	NA	0.96	8.2	0.59	2.59e-13	Bipolar disorder;
TGCT	cis	rs9653442	0.900	rs6740838	chr2:100813499	T/G	cg22139774	chr2:100720529	AFF3	-0.39	-6.26	-0.49	5.75e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs7119038	0.818	rs1048024	chr11:118618776	A/T	cg19308663	chr11:118741387	NA	0.29	5.39	0.44	3.41e-7	Sjögren's syndrome;
TGCT	cis	rs1348850	0.632	rs13008833	chr2:178514439	G/C	cg22681709	chr2:178499509	PDE11A	-0.51	-6.37	-0.5	3.35e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs950169	0.922	rs6603022	chr15:84830170	T/C	cg11189052	chr15:85197271	WDR73	-0.81	-6.52	-0.51	1.61e-9	Schizophrenia;
TGCT	cis	rs17345786	0.906	rs59359251	chr3:101146362	A/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.84	8.92	0.63	5.05e-15	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs763121	0.813	rs4821807	chr22:39065582	A/G	cg06022373	chr22:39101656	GTPBP1	0.78	7.56	0.56	7.78e-12	Menopause (age at onset);
TGCT	trans	rs1814175	0.692	rs1851873	chr11:49937767	A/G	cg15704280	chr7:45808275	SEPT13	-0.59	-6.82	-0.52	3.54e-10	Height;
TGCT	cis	rs853679	0.546	rs200490	chr6:27796935	G/T	cg10876282	chr6:28092338	ZSCAN16	0.76	4.47	0.37	1.73e-5	Depression;
TGCT	trans	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg17470723	chr8:74884337	TCEB1	0.72	6.94	0.53	1.91e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs514406	0.861	rs35581164	chr1:53271373	C/G	cg01802117	chr1:53393560	SCP2	-0.43	-5.15	-0.42	9.84e-7	Monocyte count;
TGCT	cis	rs9393692	0.645	rs9467703	chr6:26318903	A/G	cg13736514	chr6:26305472	NA	-0.46	-6.7	-0.52	6.47e-10	Educational attainment;
TGCT	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6542838	0.611	rs7423519	chr2:99518319	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.51	-4.65	-0.39	8.34e-6	Fear of minor pain;
TGCT	cis	rs6430585	0.528	rs2278682	chr2:136743143	G/C	cg07169764	chr2:136633963	MCM6	1.2	11.66	0.72	1.18e-21	Corneal structure;
TGCT	cis	rs11711311	0.668	rs11718061	chr3:113341826	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.7	5.81	0.46	4.86e-8	IgG glycosylation;
TGCT	cis	rs2404602	0.692	rs4360890	chr15:77173295	G/A	cg26408565	chr15:76604113	ETFA	-0.36	-4.52	-0.38	1.41e-5	Blood metabolite levels;
TGCT	cis	rs682748	1.000	rs683580	chr5:17155359	G/A	cg23987134	chr5:17158319	LOC285696	-0.23	-5.42	-0.44	2.93e-7	Hippocampal atrophy;
TGCT	cis	rs9303401	0.659	rs2072316	chr17:56604813	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs10791323	0.559	rs10750548	chr11:133729469	A/G	cg15485101	chr11:133734466	NA	0.42	5.26	0.43	6.25e-7	Childhood ear infection;
TGCT	cis	rs7824557	0.527	rs57629785	chr8:11235150	C/A	cg21775007	chr8:11205619	TDH	-0.65	-6.4	-0.5	2.97e-9	Retinal vascular caliber;
TGCT	cis	rs28785552	0.897	rs34244888	chr19:53242228	T/A	cg10871876	chr19:53194124	ZNF83	0.56	7.99	0.58	7.74e-13	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs877282	0.898	rs11253352	chr10:766598	C/A	cg17470449	chr10:769945	NA	0.34	5.24	0.43	6.59e-7	Uric acid levels;
TGCT	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg06481639	chr22:41940642	POLR3H	-0.74	-6.74	-0.52	5.38e-10	Vitiligo;
TGCT	cis	rs8111998	0.826	rs8108776	chr19:22765384	C/T	cg19914732	chr19:22715077	NA	-0.56	-4.51	-0.38	1.46e-5	Corneal structure;
TGCT	cis	rs926938	0.527	rs360670	chr1:115482386	G/A	cg12756093	chr1:115239321	AMPD1	0.34	4.97	0.41	2.19e-6	Autism;
TGCT	cis	rs1372520	0.627	rs2583964	chr4:90727218	A/G	cg14346243	chr4:90757452	SNCA	-0.68	-5.64	-0.45	1.12e-7	Neuroticism;
TGCT	cis	rs9611565	0.512	rs139571	chr22:42214238	G/A	cg06634786	chr22:41940651	POLR3H	-0.86	-8.01	-0.58	7.16e-13	Vitiligo;
TGCT	cis	rs7647973	0.925	rs4955423	chr3:49220448	G/A	cg07690219	chr3:49449608	TCTA;RHOA	-0.57	-4.79	-0.4	4.63e-6	Menarche (age at onset);
TGCT	cis	rs9674544	0.757	rs2289636	chr17:47120776	T/C	cg20966754	chr17:47091339	IGF2BP1	-0.4	-4.45	-0.37	1.89e-5	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
TGCT	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg23758822	chr17:41437982	NA	0.72	6.96	0.53	1.76e-10	Menopause (age at onset);
TGCT	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg13395646	chr4:1353034	KIAA1530	-0.41	-4.6	-0.38	1.01e-5	Longevity;
TGCT	trans	rs10506458	0.834	rs73127067	chr12:63390333	G/T	cg22491629	chr6:157744540	C6orf35	-0.99	-8.5	-0.61	5.08e-14	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs910316	1.000	rs8003506	chr14:75586288	A/C	cg23033748	chr14:75592666	NEK9	-0.26	-4.56	-0.38	1.22e-5	Height;
TGCT	cis	rs72781680	0.799	rs17508218	chr2:23976536	C/T	cg08917208	chr2:24149416	ATAD2B	0.83	5.24	0.43	6.62e-7	Lymphocyte counts;
TGCT	cis	rs6912958	1.000	rs9450701	chr6:88173167	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.6	-5.71	-0.46	8.03e-8	Monocyte percentage of white cells;
TGCT	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg04025307	chr7:1156635	C7orf50	0.22	5.3	0.43	5.13e-7	Longevity;Endometriosis;
TGCT	cis	rs2299587	0.554	rs13253029	chr8:17749622	C/T	cg01800426	chr8:17659068	MTUS1	-0.55	-4.74	-0.39	5.65e-6	Economic and political preferences;
TGCT	cis	rs12477438	0.765	rs10181344	chr2:99692829	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-4.88	-0.4	3.17e-6	Chronic sinus infection;
TGCT	cis	rs6088590	1.000	rs2378256	chr20:33292127	G/C	cg06115741	chr20:33292138	TP53INP2	0.67	5.77	0.46	5.93e-8	Coronary artery disease;
TGCT	cis	rs7095607	0.538	rs2634708	chr10:69920013	C/A	cg18986048	chr10:69913749	MYPN	0.61	5.85	0.46	4.16e-8	Lung function (FVC);
TGCT	cis	rs8180040	0.967	rs807935	chr3:47321669	A/G	cg27129171	chr3:47204927	SETD2	0.7	8.89	0.62	5.88e-15	Colorectal cancer;
TGCT	cis	rs6977955	1.000	rs2893312	chr7:28170403	C/T	cg23620719	chr7:28220237	JAZF1	-0.66	-5.01	-0.41	1.8e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs752010	0.619	rs10736421	chr1:42106230	G/A	cg06885757	chr1:42089581	HIVEP3	0.29	5.02	0.41	1.72e-6	Lupus nephritis in systemic lupus erythematosus;
TGCT	cis	rs17001868	0.568	rs909669	chr22:40742417	C/T	cg07138101	chr22:40742427	ADSL	0.75	5.49	0.44	2.14e-7	Mammographic density (dense area);
TGCT	cis	rs17221829	0.703	rs1962258	chr11:89380687	T/C	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.63	-0.38	9.04e-6	Anxiety in major depressive disorder;
TGCT	cis	rs1215050	0.791	rs1585088	chr4:98675071	C/A	cg05340658	chr4:99064831	C4orf37	-0.43	-5.19	-0.42	8.34e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs13256369	1.000	rs4840352	chr8:8573508	A/G	cg17143192	chr8:8559678	CLDN23	0.62	5.82	0.46	4.82e-8	Obesity-related traits;
TGCT	cis	rs17270561	1.000	rs12200962	chr6:25828986	T/C	cg17691542	chr6:26056736	HIST1H1C	0.78	4.78	0.39	4.87e-6	Iron status biomarkers;
TGCT	cis	rs951366	0.870	rs3747973	chr1:205677148	A/G	cg14893161	chr1:205819251	PM20D1	0.4	4.82	0.4	4.07e-6	Menarche (age at onset);
TGCT	cis	rs586688	0.929	rs678092	chr1:201640266	G/A	cg05779441	chr1:201574716	NA	0.29	4.8	0.4	4.54e-6	Obesity-related traits;
TGCT	cis	rs13326165	0.715	rs11707864	chr3:52392877	G/A	cg27565382	chr3:53032988	SFMBT1	0.36	4.8	0.4	4.54e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs6901004	0.803	rs9387000	chr6:111459941	A/C	cg15721981	chr6:111408429	SLC16A10	-0.53	-4.67	-0.39	7.84e-6	Blood metabolite levels;
TGCT	cis	rs6593803	0.547	rs7528262	chr1:147248817	C/T	cg17941330	chr1:147245494	GJA5	0.34	4.5	0.37	1.52e-5	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
TGCT	cis	rs62103177	0.564	rs7228971	chr18:77738025	C/T	cg07235805	chr18:78004237	PARD6G	-0.51	-4.87	-0.4	3.38e-6	Opioid sensitivity;
TGCT	cis	rs950169	0.541	rs10795	chr15:85177297	G/A	cg12863693	chr15:85201151	NMB	0.46	5.56	0.45	1.6e-7	Schizophrenia;
TGCT	cis	rs4242434	0.927	rs13271626	chr8:22467760	C/G	cg21658235	chr8:22456391	C8orf58	0.43	4.5	0.37	1.54e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs1018836	0.828	rs4735236	chr8:91583909	A/G	cg16814680	chr8:91681699	NA	-0.72	-7.28	-0.55	3.32e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6095298	0.595	rs4810881	chr20:47437212	T/G	cg12307787	chr20:48099359	KCNB1	0.43	4.53	0.38	1.37e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7809950	0.648	rs114452520	chr7:107176780	C/T	cg23024343	chr7:107201750	COG5	-0.35	-5.43	-0.44	2.88e-7	Coronary artery disease;
TGCT	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs6733011	0.508	rs4851173	chr2:99520608	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.57	-5.44	-0.44	2.74e-7	Bipolar disorder;
TGCT	cis	rs7249142	0.549	rs2283623	chr19:19283027	G/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.34	-4.61	-0.38	9.98e-6	IgG glycosylation;
TGCT	cis	rs881375	0.678	rs1014530	chr9:123685092	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	5.19	0.42	8.48e-7	Rheumatoid arthritis;
TGCT	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg00343986	chr7:65444356	GUSB	-0.26	-6.14	-0.48	1.05e-8	Calcium levels;
TGCT	cis	rs6087990	0.769	rs17123658	chr20:31390840	C/A	cg13636640	chr20:31349939	DNMT3B	1.05	14.11	0.78	1.48e-27	Ulcerative colitis;
TGCT	cis	rs9638182	0.623	rs71556715	chr7:72881807	C/T	cg14087351	chr7:73037990	MLXIPL	-0.57	-4.52	-0.38	1.4e-5	Triglycerides;
TGCT	cis	rs7824557	0.843	rs2572418	chr8:11113089	G/A	cg21775007	chr8:11205619	TDH	-0.51	-4.63	-0.38	8.95e-6	Retinal vascular caliber;
TGCT	cis	rs765787	0.530	rs11858988	chr15:45522114	T/C	cg24006582	chr15:45444508	DUOX1	-0.26	-5.64	-0.45	1.12e-7	Uric acid levels;
TGCT	cis	rs13256369	1.000	rs9329166	chr8:8576655	C/T	cg17143192	chr8:8559678	CLDN23	0.59	5.9	0.47	3.27e-8	Obesity-related traits;
TGCT	trans	rs2688608	0.725	rs2633314	chr10:75683590	C/T	cg13918328	chr10:52500089	ASAH2B	0.68	6.93	0.53	1.99e-10	Inflammatory bowel disease;
TGCT	cis	rs7681440	0.904	rs6816305	chr4:90772902	C/G	cg14346243	chr4:90757452	SNCA	-0.57	-5.5	-0.44	2.04e-7	Dementia with Lewy bodies;
TGCT	cis	rs4841097	0.876	rs6601288	chr8:8943430	A/T	cg06636001	chr8:8085503	FLJ10661	0.61	5.03	0.41	1.71e-6	Platelet distribution width;
TGCT	cis	rs35883536	0.967	rs1577509	chr1:101089253	C/T	cg06223162	chr1:101003688	GPR88	0.29	4.56	0.38	1.22e-5	Monocyte count;
TGCT	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg01017244	chr2:74357527	NA	0.5	8.29	0.6	1.58e-13	Gestational age at birth (maternal effect);
TGCT	cis	rs2299587	0.607	rs2237848	chr8:17874604	A/C	cg01800426	chr8:17659068	MTUS1	-0.67	-5.95	-0.47	2.59e-8	Economic and political preferences;
TGCT	cis	rs950169	0.922	rs4338765	chr15:84916836	G/T	cg11189052	chr15:85197271	WDR73	0.83	6.67	0.51	7.71e-10	Schizophrenia;
TGCT	cis	rs832540	0.618	rs41106	chr5:56145057	G/T	cg12311346	chr5:56204834	C5orf35	-0.49	-5.13	-0.42	1.08e-6	Coronary artery disease;
TGCT	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg03709012	chr19:19516395	GATAD2A	0.67	5.75	0.46	6.45e-8	Tonsillectomy;
TGCT	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg01802117	chr1:53393560	SCP2	-0.48	-5.77	-0.46	6.09e-8	Monocyte count;
TGCT	cis	rs9788682	0.948	rs28498264	chr15:78837673	C/T	cg06917634	chr15:78832804	PSMA4	-0.69	-4.71	-0.39	6.49e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs763014	0.865	rs2018789	chr16:632051	T/C	cg07343612	chr16:622815	PIGQ	-0.41	-7.87	-0.58	1.52e-12	Height;
TGCT	cis	rs17826219	0.561	rs11655876	chr17:29017150	G/A	cg13385521	chr17:29058706	SUZ12P	0.74	4.59	0.38	1.07e-5	Body mass index;
TGCT	cis	rs10191773	0.589	rs72833410	chr2:113054119	G/A	cg07905836	chr2:113190072	RGPD8;RGPD5	0.47	5.03	0.41	1.67e-6	Yeast infection;
TGCT	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg00024416	chr22:24240387	NA	-0.27	-5.3	-0.43	5.03e-7	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2072499	0.966	rs2853641	chr1:156181770	A/G	cg06970220	chr1:156163860	SLC25A44	0.66	5.79	0.46	5.4e-8	Testicular germ cell tumor;
TGCT	cis	rs2204008	0.837	rs11495548	chr12:38076756	C/T	cg26384229	chr12:38710491	ALG10B	0.86	7.72	0.57	3.39e-12	Bladder cancer;
TGCT	cis	rs4851254	0.961	rs6713524	chr2:100747357	A/G	cg23118464	chr2:100721844	AFF3	0.71	5.28	0.43	5.62e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs8180040	0.966	rs7651762	chr3:47470484	G/A	cg27129171	chr3:47204927	SETD2	-0.65	-7.56	-0.56	7.97e-12	Colorectal cancer;
TGCT	cis	rs9611565	0.559	rs7290991	chr22:41964361	C/G	cg17554472	chr22:41940697	POLR3H	-0.48	-4.94	-0.41	2.47e-6	Vitiligo;
TGCT	cis	rs5769707	0.749	rs7286706	chr22:50058346	G/C	cg20744362	chr22:50050164	C22orf34	0.29	4.69	0.39	7.19e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs10791097	0.694	rs1893017	chr11:130756253	C/T	cg12179176	chr11:130786555	SNX19	0.83	9.92	0.67	1.94e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs1372520	1.000	rs1372520	chr4:90757505	T/C	cg01966878	chr4:90757139	SNCA	-0.31	-4.74	-0.39	5.73e-6	Neuroticism;
TGCT	cis	rs2997447	0.655	rs12094933	chr1:26374779	T/C	cg19633962	chr1:26362018	EXTL1	-0.66	-4.81	-0.4	4.33e-6	QRS complex (12-leadsum);
TGCT	cis	rs6669919	0.647	rs1578838	chr1:211671118	T/G	cg26515805	chr1:211431828	RCOR3	-0.45	-4.56	-0.38	1.2e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7017914	0.967	rs62508819	chr8:71718106	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.55	-5.1	-0.42	1.24e-6	Bone mineral density;
TGCT	cis	rs853679	0.550	rs34477097	chr6:28197186	C/T	cg12963246	chr6:28129442	ZNF389	0.45	4.44	0.37	1.96e-5	Depression;
TGCT	cis	rs259282	0.583	rs12981373	chr19:33108189	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.59	5.29	0.43	5.27e-7	Schizophrenia;
TGCT	cis	rs7085104	0.700	rs7096183	chr10:104609466	T/C	cg05855489	chr10:104503620	C10orf26	0.51	4.54	0.38	1.34e-5	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs7172809	0.599	rs12324795	chr15:77739786	T/C	cg22256960	chr15:77711686	NA	-0.51	-4.86	-0.4	3.47e-6	Glucose homeostasis traits;
TGCT	cis	rs6671200	0.688	rs4950024	chr1:95713499	A/G	cg26537280	chr1:95699037	RWDD3	-0.51	-4.9	-0.4	2.94e-6	Stearic acid (18:0) levels;
TGCT	cis	rs6674176	0.628	rs4660758	chr1:44424879	A/C	cg12908607	chr1:44402522	ARTN	-0.66	-7.71	-0.57	3.51e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs3806843	0.576	rs246049	chr5:140327590	T/G	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs35306767	0.714	rs17293608	chr10:1056252	C/T	cg20503657	chr10:835505	NA	0.58	6.68	0.51	7.2e-10	Eosinophil percentage of granulocytes;
TGCT	cis	rs1150668	0.830	rs213240	chr6:28315875	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.47	-4.57	-0.38	1.14e-5	Pubertal anthropometrics;
TGCT	cis	rs950776	0.518	rs12906951	chr15:78825562	C/T	cg06917634	chr15:78832804	PSMA4	0.95	9.52	0.65	1.81e-16	Sudden cardiac arrest;
TGCT	cis	rs524281	0.861	rs10750778	chr11:65948648	T/C	cg00563793	chr11:65837595	PACS1	0.57	4.97	0.41	2.13e-6	Electroencephalogram traits;
TGCT	cis	rs11167764	1.000	rs13354528	chr5:141476769	C/T	cg08523384	chr5:141488047	NDFIP1	-0.23	-4.7	-0.39	6.78e-6	Crohn's disease;
TGCT	cis	rs67133203	0.607	rs706801	chr12:51366092	A/G	cg01517968	chr12:52348879	ACVR1B	0.35	4.52	0.38	1.44e-5	Urinary tract infection frequency;
TGCT	cis	rs7829975	0.846	rs6601724	chr8:8544872	C/T	cg06636001	chr8:8085503	FLJ10661	-0.61	-5.26	-0.43	6.15e-7	Mood instability;
TGCT	cis	rs2463822	1.000	rs2463821	chr11:62111662	T/C	cg06239285	chr11:62104954	ASRGL1	0.89	5.91	0.47	3.04e-8	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs3020333	0.703	rs862346	chr6:152016369	A/T	cg22157087	chr6:152012887	ESR1	0.22	5.46	0.44	2.54e-7	Total body bone mineral density;
TGCT	cis	rs9467711	0.606	rs9379873	chr6:26402717	T/C	cg16898833	chr6:26189333	HIST1H4D	1.15	5.55	0.45	1.62e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6809651	0.524	rs1356291	chr3:185824644	C/T	cg00760338	chr3:185826511	ETV5	0.78	6.52	0.51	1.56e-9	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
TGCT	cis	rs13242816	1.000	rs36011826	chr7:116118336	G/A	cg02799643	chr7:116139180	CAV2	-0.49	-5.61	-0.45	1.27e-7	P wave duration;
TGCT	cis	rs7267979	0.780	rs6050679	chr20:25537827	A/T	cg14121845	chr20:25566513	NINL	0.47	4.93	0.4	2.6e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs28735056	0.967	rs498541	chr18:77589655	G/A	cg20368463	chr18:77673604	PQLC1	-0.45	-5.53	-0.44	1.84e-7	Schizophrenia;
TGCT	cis	rs7226408	1.000	rs72883551	chr18:34362836	C/T	cg06757138	chr18:34340585	FHOD3	0.28	4.81	0.4	4.35e-6	Obesity-related traits;
TGCT	cis	rs7208859	0.673	rs2433	chr17:29226228	T/C	cg18442181	chr17:29233375	C17orf42	-0.78	-4.61	-0.38	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs3780378	0.967	rs7039518	chr9:5046881	T/C	cg02405213	chr9:5042618	JAK2	-0.6	-7.68	-0.57	4.04e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg13206674	chr6:150067644	NUP43	0.51	4.47	0.37	1.75e-5	Lung cancer;
TGCT	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg17911788	chr17:44343683	NA	-0.65	-6.93	-0.53	2.02e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	trans	rs629535	0.862	rs598548	chr8:70032438	C/T	cg21567404	chr3:27674614	NA	0.58	9.18	0.64	1.22e-15	Dupuytren's disease;
TGCT	cis	rs8077889	0.672	rs2074143	chr17:41856622	A/G	cg26893861	chr17:41843967	DUSP3	1.14	20.46	0.88	1.46e-41	Triglycerides;
TGCT	cis	rs10540	1.000	rs61876342	chr11:496193	T/G	cg03352830	chr11:487213	PTDSS2	0.26	4.55	0.38	1.27e-5	Body mass index;
TGCT	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.47	0.56	1.28e-11	Prudent dietary pattern;
TGCT	cis	rs6121246	0.821	rs7265413	chr20:30317923	G/A	cg18721089	chr20:30220636	NA	-0.42	-4.65	-0.39	8.2e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs17001868	0.614	rs5995849	chr22:40777072	C/G	cg07138101	chr22:40742427	ADSL	-0.76	-5.91	-0.47	3.07e-8	Mammographic density (dense area);
TGCT	cis	rs2702888	0.512	rs2738153	chr8:6751900	T/G	cg26795848	chr8:6756730	NA	-0.32	-6.55	-0.51	1.41e-9	Blood pressure;
TGCT	cis	rs12681287	0.517	rs34596274	chr8:87517679	C/T	cg27223183	chr8:87520930	FAM82B	-0.96	-7.08	-0.54	9.31e-11	Caudate activity during reward;
TGCT	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg07157834	chr1:205819609	PM20D1	0.45	6.94	0.53	1.96e-10	Menarche (age at onset);
TGCT	cis	rs1372520	0.684	rs1442144	chr4:90736113	T/C	cg20003494	chr4:90757398	SNCA	-0.65	-5.2	-0.42	8.15e-7	Neuroticism;
TGCT	cis	rs2013441	1.000	rs2703821	chr17:20121526	C/T	cg18979559	chr17:20280153	CCDC144C	-0.44	-4.61	-0.38	9.78e-6	Obesity-related traits;
TGCT	cis	rs208520	1.000	rs72884025	chr6:66994185	T/C	cg07460842	chr6:66804631	NA	0.79	6.85	0.52	3.05e-10	Exhaled nitric oxide output;
TGCT	cis	rs9291683	0.588	rs3796842	chr4:9995851	A/T	cg00071950	chr4:10020882	SLC2A9	0.73	8.9	0.62	5.69e-15	Bone mineral density;
TGCT	cis	rs7584330	0.554	rs77956735	chr2:238399130	C/T	cg14458575	chr2:238380390	NA	0.59	5.08	0.42	1.34e-6	Prostate cancer;
TGCT	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.84	7.5	0.56	1.08e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9303542	0.559	rs1042822	chr17:46620095	G/T	cg25032089	chr17:46643351	HOXB3	0.56	5.27	0.43	5.97e-7	Ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs6688613	1.000	rs6699520	chr1:166955405	G/C	cg07049167	chr1:166818506	POGK	0.21	4.52	0.38	1.43e-5	Refractive astigmatism;
TGCT	cis	rs939658	1.000	rs8033963	chr15:79455350	C/T	cg17916960	chr15:79447300	NA	0.54	8.64	0.61	2.42e-14	Refractive error;
TGCT	cis	rs8017423	0.933	rs7150378	chr14:90724566	G/A	cg04374321	chr14:90722782	PSMC1	0.76	7.71	0.57	3.59e-12	Mortality in heart failure;
TGCT	cis	rs7584330	0.868	rs58057291	chr2:238395479	T/A	cg08992911	chr2:238395768	MLPH	0.63	4.61	0.38	9.83e-6	Prostate cancer;
TGCT	cis	rs2050392	0.624	rs303435	chr10:30731491	T/C	cg18806716	chr10:30721971	MAP3K8	-0.69	-9.45	-0.65	2.71e-16	Inflammatory bowel disease;
TGCT	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg18230493	chr5:56204884	C5orf35	-0.72	-4.91	-0.4	2.81e-6	Type 2 diabetes;
TGCT	cis	rs4689388	0.581	rs11727100	chr4:6281458	A/C	cg25554036	chr4:6271136	WFS1	0.56	6.58	0.51	1.21e-9	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs9640161	0.742	rs2159235	chr7:150017228	T/C	cg10018233	chr7:150070692	REPIN1	0.33	4.68	0.39	7.25e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs933688	1.000	rs61612071	chr5:90741470	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.96	8.25	0.6	1.91e-13	Smoking behavior;
TGCT	cis	rs2361718	0.568	rs1042397	chr17:78092063	G/A	cg09238746	chr17:78121135	EIF4A3	-0.66	-5.88	-0.47	3.48e-8	Yeast infection;
TGCT	cis	rs9372498	0.536	rs9489395	chr6:118758884	T/C	cg21191810	chr6:118973309	C6orf204	-0.37	-4.77	-0.39	5.03e-6	Diastolic blood pressure;
TGCT	cis	rs11030122	0.733	rs10835331	chr11:3957365	C/T	cg18678763	chr11:4115507	RRM1	-0.48	-5.99	-0.47	2.15e-8	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs1056107	0.931	rs2274519	chr9:114997288	C/T	cg02332936	chr9:115140584	NA	-0.25	-4.44	-0.37	1.96e-5	Colorectal cancer;
TGCT	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg10295955	chr4:187884368	NA	-0.99	-15.24	-0.81	3.38e-30	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3008870	1.000	rs2985795	chr1:67426223	A/G	cg11518657	chr1:67396239	MIER1	0.54	4.61	0.38	9.72e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs8013055	0.846	rs12893999	chr14:105970842	C/G	cg19700328	chr14:106028568	NA	-0.53	-5.87	-0.47	3.76e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs17102884	0.506	rs10873274	chr14:75407372	G/T	cg08847533	chr14:75593920	NEK9	-0.61	-5.22	-0.42	7.28e-7	Neuroticism;
TGCT	cis	rs7267979	0.934	rs2500399	chr20:25354694	T/G	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10089	0.951	rs56066100	chr5:127460571	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	7.41	0.55	1.72e-11	Ileal carcinoids;
TGCT	cis	rs11578119	0.933	rs1591147	chr1:170445224	T/C	cg09767346	chr1:170501363	GORAB	-0.72	-5.74	-0.46	6.97e-8	Male-pattern baldness;
TGCT	cis	rs904251	0.772	rs756202	chr6:37460350	C/A	cg08126542	chr6:37504118	NA	-0.39	-4.6	-0.38	1.04e-5	Cognitive performance;
TGCT	cis	rs2204008	0.774	rs11616004	chr12:38278822	G/A	cg13010199	chr12:38710504	ALG10B	0.64	4.97	0.41	2.15e-6	Bladder cancer;
TGCT	cis	rs854765	0.562	rs2955381	chr17:17945500	G/C	cg04398451	chr17:18023971	MYO15A	0.34	5.49	0.44	2.21e-7	Total body bone mineral density;
TGCT	cis	rs9467773	1.000	rs9461271	chr6:26554968	G/A	cg15659132	chr6:26577336	NA	0.9	13.19	0.76	2.26e-25	Intelligence (multi-trait analysis);
TGCT	trans	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg21659725	chr3:3221576	CRBN	-0.73	-8.48	-0.61	5.64e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs4372836	0.729	rs11127190	chr2:29043212	G/C	cg09522027	chr2:28974177	PPP1CB	0.66	6.76	0.52	4.88e-10	Body mass index;
TGCT	cis	rs1023500	0.551	rs4822076	chr22:42364057	C/T	cg15557168	chr22:42548783	NA	-0.2	-4.55	-0.38	1.29e-5	Schizophrenia;
TGCT	cis	rs3793683	0.825	rs3793674	chr10:134555773	C/T	cg27286337	chr10:134555280	INPP5A	-0.48	-7.48	-0.56	1.16e-11	Migraine;
TGCT	cis	rs7772486	0.875	rs6930975	chr6:146387111	C/T	cg05347473	chr6:146136440	FBXO30	0.52	4.86	0.4	3.48e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1153858	1.000	rs4395020	chr15:45652889	A/C	cg14582100	chr15:45693742	SPATA5L1	0.51	5.99	0.47	2.12e-8	Homoarginine levels;
TGCT	cis	rs78456975	0.527	rs4073862	chr2:1563433	A/G	cg01028140	chr2:1542097	TPO	-0.33	-5.14	-0.42	1.02e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs4851266	0.833	rs11685491	chr2:100858122	A/G	cg07810366	chr2:100720526	AFF3	-0.36	-5.21	-0.42	7.59e-7	Educational attainment;
TGCT	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg14159672	chr1:205819179	PM20D1	0.61	7.43	0.55	1.57e-11	Menarche (age at onset);
TGCT	cis	rs12136530	0.774	rs12563442	chr1:19786695	T/C	cg18923740	chr1:19971790	NBL1	0.38	4.68	0.39	7.51e-6	Lead levels in blood;
TGCT	cis	rs7567389	0.600	rs72845979	chr2:128095754	C/A	cg09760422	chr2:128146352	NA	0.39	5.18	0.42	8.76e-7	Self-rated health;
TGCT	cis	rs4566357	0.615	rs3769642	chr2:227917323	T/C	cg11843606	chr2:227700838	RHBDD1	-0.54	-5.24	-0.43	6.55e-7	Coronary artery disease;
TGCT	cis	rs6840360	0.509	rs62327273	chr4:152547594	A/G	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.0	-0.58	7.69e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs6456156	0.692	rs9457270	chr6:167512928	A/G	cg07741184	chr6:167504864	NA	0.3	5.95	0.47	2.54e-8	Primary biliary cholangitis;
TGCT	cis	rs1008375	1.000	rs11727312	chr4:17669185	C/T	cg16339924	chr4:17578868	LAP3	0.57	4.75	0.39	5.43e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs992157	0.866	rs2292554	chr2:219146868	T/C	cg00012203	chr2:219082015	ARPC2	-0.79	-7.87	-0.58	1.48e-12	Colorectal cancer;
TGCT	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg18402987	chr7:1209562	NA	0.91	7.67	0.57	4.43e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2295359	1.000	rs4655683	chr1:67611613	C/T	cg03340356	chr1:67600835	NA	0.37	4.6	0.38	1.03e-5	Psoriasis;
TGCT	cis	rs10782582	0.586	rs1856791	chr1:76308942	C/T	cg03433033	chr1:76189801	ACADM	-0.5	-4.98	-0.41	2.11e-6	Daytime sleep phenotypes;
TGCT	cis	rs2458413	0.543	rs2514658	chr8:105337871	G/A	cg23108931	chr8:105342351	NA	-0.35	-6.15	-0.48	9.76e-9	Paget's disease;
TGCT	cis	rs10114408	0.959	rs10761297	chr9:96647433	A/G	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg21862992	chr11:68658383	NA	0.46	6.52	0.51	1.6e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	trans	rs77457752	0.532	rs77481510	chr9:13902347	G/A	cg25510823	chr7:47085976	NA	0.45	6.68	0.51	7.04e-10	Breast cancer;
TGCT	cis	rs9814567	1.000	rs4535272	chr3:134299916	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.91	8.45	0.6	6.55e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs303386	0.501	rs6698436	chr1:99588903	A/G	cg03593336	chr1:99471295	LPPR5	-0.25	-5.06	-0.41	1.49e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors);Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin);
TGCT	cis	rs80282103	0.618	rs11250252	chr10:1124939	G/C	cg08668510	chr10:1095578	IDI1	1.09	5.31	0.43	4.98e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg22764044	chr5:178986830	RUFY1	0.52	6.1	0.48	1.22e-8	Lung cancer;
TGCT	cis	rs1580019	0.539	rs11769109	chr7:32571352	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.57	4.95	0.41	2.34e-6	Cognitive ability;
TGCT	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg04944784	chr2:26401820	FAM59B	-0.68	-6.13	-0.48	1.1e-8	Gut microbiome composition (summer);
TGCT	cis	rs11031096	0.678	rs970329	chr11:4189803	G/T	cg18678763	chr11:4115507	RRM1	-0.46	-6.03	-0.48	1.78e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs8084125	0.832	rs62105178	chr18:74950635	C/T	cg07390210	chr18:74961196	GALR1	0.37	4.51	0.38	1.49e-5	Obesity-related traits;
TGCT	cis	rs75059851	0.756	rs11223656	chr11:133842973	T/A	cg14047540	chr11:133829660	NA	-0.57	-5.69	-0.45	8.72e-8	Schizophrenia;
TGCT	cis	rs2239785	0.958	rs136160	chr22:36657119	C/G	cg15716373	chr22:36655542	APOL1	-0.42	-4.84	-0.4	3.79e-6	Glomerulosclerosis;
TGCT	trans	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg21659725	chr3:3221576	CRBN	0.76	9.35	0.64	4.8e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs10242455	0.702	rs917152	chr7:99004497	T/C	cg13560068	chr7:99070416	ZNF789	1.06	4.5	0.37	1.56e-5	Blood metabolite levels;
TGCT	cis	rs9291683	0.935	rs1860911	chr4:10275057	C/T	cg11266682	chr4:10021025	SLC2A9	0.45	5.41	0.44	3.13e-7	Bone mineral density;
TGCT	cis	rs7552404	0.924	rs114752222	chr1:76180878	C/T	cg22875332	chr1:76189707	ACADM	0.78	9.74	0.66	5.53e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs11098499	0.697	rs28655325	chr4:120372999	A/G	cg09307838	chr4:120376055	NA	0.68	6.53	0.51	1.54e-9	Corneal astigmatism;
TGCT	cis	rs7178572	0.568	rs8030074	chr15:77654232	C/T	cg22256960	chr15:77711686	NA	-0.85	-8.73	-0.62	1.4e-14	Type 2 diabetes;
TGCT	cis	rs13102973	0.965	rs4864244	chr4:135866959	A/G	cg14419869	chr4:135874104	NA	0.27	4.85	0.4	3.62e-6	Subjective well-being;
TGCT	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7824557	0.836	rs1435278	chr8:11123029	G/T	cg21775007	chr8:11205619	TDH	-0.59	-5.7	-0.46	8.28e-8	Retinal vascular caliber;
TGCT	cis	rs7552404	0.924	rs1146581	chr1:76213024	T/G	cg22875332	chr1:76189707	ACADM	0.72	8.9	0.62	5.76e-15	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2013441	1.000	rs3850781	chr17:20181939	T/G	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.63	-0.38	9.19e-6	Obesity-related traits;
TGCT	cis	rs829883	0.664	rs829876	chr12:98842138	A/G	cg25150519	chr12:98850993	NA	0.62	7.36	0.55	2.2e-11	Colorectal adenoma (advanced);
TGCT	cis	rs907683	0.584	rs12991025	chr2:220284779	C/T	cg15015639	chr2:220282977	DES	0.4	5.04	0.41	1.6e-6	Resting heart rate;
TGCT	cis	rs2688608	0.587	rs2894040	chr10:75478159	A/C	cg23231163	chr10:75533350	FUT11	-0.28	-4.68	-0.39	7.4e-6	Inflammatory bowel disease;
TGCT	cis	rs13424612	0.860	rs34277046	chr2:240897331	G/A	cg26363272	chr2:240904871	NDUFA10	0.3	5.13	0.42	1.07e-6	Odorant perception (isobutyraldehyde);
TGCT	cis	rs10782582	0.586	rs12130324	chr1:76370012	A/G	cg03433033	chr1:76189801	ACADM	-0.5	-4.91	-0.4	2.81e-6	Daytime sleep phenotypes;
TGCT	cis	rs11190604	1.000	rs2489047	chr10:102347028	A/G	cg16342193	chr10:102329863	NA	-0.4	-5.12	-0.42	1.12e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs3087591	1.000	rs2905800	chr17:29531980	A/G	cg24425628	chr17:29625626	OMG;NF1	0.48	7.29	0.55	3.25e-11	Hip circumference;
TGCT	cis	rs28595532	0.841	rs116521340	chr4:119757415	C/A	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs35883536	0.647	rs12023028	chr1:101042717	C/T	cg10298815	chr1:101004474	GPR88	-0.25	-4.73	-0.39	6.03e-6	Monocyte count;
TGCT	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg07507251	chr3:52567010	NT5DC2	-0.49	-6.82	-0.52	3.62e-10	Bipolar disorder;
TGCT	cis	rs10876993	0.784	rs10083154	chr12:58020933	G/A	cg15848620	chr12:58087721	OS9	0.71	5.28	0.43	5.5e-7	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs4319547	0.619	rs7973869	chr12:122874284	G/C	cg05707623	chr12:122985044	ZCCHC8	-0.62	-4.87	-0.4	3.32e-6	Body mass index;
TGCT	cis	rs72781680	0.898	rs72796171	chr2:23942667	G/C	cg08917208	chr2:24149416	ATAD2B	0.77	4.71	0.39	6.52e-6	Lymphocyte counts;
TGCT	cis	rs4722166	0.630	rs7808457	chr7:22798265	A/T	cg13104385	chr7:22767384	IL6	-0.19	-4.48	-0.37	1.66e-5	Lung cancer;
TGCT	cis	rs2239547	0.522	rs2710345	chr3:52976075	T/C	cg11645453	chr3:52864694	ITIH4	-0.32	-5.23	-0.42	7.06e-7	Schizophrenia;
TGCT	cis	rs7178572	0.633	rs11855188	chr15:77840714	A/G	cg22256960	chr15:77711686	NA	-0.77	-7.15	-0.54	6.45e-11	Type 2 diabetes;
TGCT	cis	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg07424592	chr7:64974309	NA	1.34	8.08	0.59	4.95e-13	Diabetic kidney disease;
TGCT	trans	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg27523141	chr10:43048294	ZNF37B	0.71	8.26	0.6	1.84e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs11107903	1.000	rs11107896	chr12:95502303	G/A	cg10621809	chr12:95840313	NA	0.7	4.61	0.38	9.89e-6	Coronary artery disease;
TGCT	cis	rs6740322	0.895	rs6760797	chr2:43559612	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.39	-6.58	-0.51	1.17e-9	Coronary artery disease;
TGCT	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg05025164	chr4:1340916	KIAA1530	0.79	6.92	0.53	2.17e-10	Longevity;
TGCT	cis	rs11648796	0.757	rs3809665	chr16:764520	G/C	cg27144592	chr16:783916	NARFL	0.37	5.15	0.42	9.94e-7	Height;
TGCT	cis	rs10490913	1.000	rs7916161	chr10:120145648	A/G	cg23160142	chr10:120154512	NA	-0.3	-4.74	-0.39	5.71e-6	Cancer;
TGCT	cis	rs7731657	0.537	rs7725020	chr5:130285115	C/G	cg08523029	chr5:130500466	HINT1	0.58	4.84	0.4	3.8e-6	Fasting plasma glucose;
TGCT	cis	rs56399783	0.901	rs6964740	chr7:2819656	C/G	cg19731401	chr7:2775893	GNA12	0.36	5.07	0.41	1.41e-6	Childhood ear infection;
TGCT	cis	rs6733011	0.578	rs12468024	chr2:99495980	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.5	-4.79	-0.4	4.63e-6	Bipolar disorder;
TGCT	cis	rs12477438	0.822	rs6727170	chr2:99588042	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-4.93	-0.41	2.53e-6	Chronic sinus infection;
TGCT	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	6.98	0.53	1.55e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2235642	0.826	rs8053605	chr16:1594158	G/A	cg10465839	chr16:1584050	IFT140;TMEM204	-0.31	-5.04	-0.41	1.61e-6	Coronary artery disease;
TGCT	cis	rs28595532	0.920	rs10001115	chr4:119781867	A/C	cg14228332	chr4:119757509	SEC24D	1.19	6.66	0.51	8.07e-10	Cannabis dependence symptom count;
TGCT	cis	rs60843830	1.000	rs55753056	chr2:243929	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.74	7.5	0.56	1.05e-11	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs2637266	0.967	rs7477607	chr10:78358768	G/T	cg18941641	chr10:78392320	NA	0.39	4.87	0.4	3.29e-6	Pulmonary function;
TGCT	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg11211951	chr8:145729740	GPT	0.27	6.56	0.51	1.34e-9	Age at first birth;
TGCT	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9302065	0.565	rs2993586	chr13:95962578	T/C	cg26751094	chr13:95954534	ABCC4	-0.4	-6.74	-0.52	5.33e-10	Blood metabolite levels;
TGCT	cis	rs28595532	0.920	rs56027489	chr4:119780882	A/G	cg14228332	chr4:119757509	SEC24D	1.26	7.08	0.54	9.26e-11	Cannabis dependence symptom count;
TGCT	cis	rs259282	0.605	rs55687317	chr19:33109191	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.6	5.34	0.43	4.25e-7	Schizophrenia;
TGCT	cis	rs67478160	0.643	rs12891175	chr14:104274166	T/C	cg26031613	chr14:104095156	KLC1	-0.64	-6.57	-0.51	1.23e-9	Schizophrenia;
TGCT	cis	rs4383453	0.539	rs12631960	chr3:123097568	A/G	cg04890266	chr3:123102914	ADCY5	-0.5	-8.34	-0.6	1.2e-13	Gestational age at birth (maternal effect);
TGCT	cis	rs7523273	0.546	rs2796261	chr1:207888760	C/T	cg22525895	chr1:207977042	MIR29B2	-0.35	-5.72	-0.46	7.49e-8	Schizophrenia;
TGCT	cis	rs9486719	1.000	rs11152969	chr6:96908712	A/C	cg18709589	chr6:96969512	KIAA0776	-0.68	-5.05	-0.41	1.55e-6	Migraine;Coronary artery disease;
TGCT	trans	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg17830980	chr10:43048298	ZNF37B	-0.83	-10.39	-0.68	1.4e-18	Extrinsic epigenetic age acceleration;
TGCT	trans	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg21659725	chr3:3221576	CRBN	-0.7	-7.98	-0.58	8.35e-13	Body mass index;
TGCT	cis	rs7666738	0.687	rs6839454	chr4:99073914	T/C	cg05340658	chr4:99064831	C4orf37	0.51	5.62	0.45	1.18e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs829883	0.738	rs249854	chr12:98862772	G/A	cg25150519	chr12:98850993	NA	0.63	7.57	0.56	7.21e-12	Colorectal adenoma (advanced);
TGCT	cis	rs12142240	0.659	rs72677591	chr1:46818219	T/G	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs10746514	0.833	rs2356925	chr1:232261769	G/A	cg09506761	chr1:232265262	NA	-0.49	-4.99	-0.41	2.01e-6	Response to statin therapy;
TGCT	cis	rs28595532	0.920	rs114333298	chr4:119765305	C/A	cg21605333	chr4:119757512	SEC24D	1.57	8.38	0.6	9.59e-14	Cannabis dependence symptom count;
TGCT	cis	rs936229	0.690	rs2472299	chr15:75033400	C/T	cg10253484	chr15:75165896	SCAMP2	0.56	4.79	0.4	4.69e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
TGCT	cis	rs1729951	0.575	rs168635	chr3:136699078	A/G	cg12473912	chr3:136751656	NA	0.39	6.18	0.49	8.36e-9	Neuroticism;
TGCT	cis	rs13326165	0.760	rs67834575	chr3:52411929	T/A	cg27565382	chr3:53032988	SFMBT1	0.37	4.9	0.4	2.97e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs514406	0.800	rs4926930	chr1:53217335	A/G	cg08736216	chr1:53307985	ZYG11A	0.25	4.77	0.39	4.98e-6	Monocyte count;
TGCT	cis	rs1729951	0.546	rs12054408	chr3:136677645	T/C	cg12473912	chr3:136751656	NA	0.39	6.18	0.49	8.36e-9	Neuroticism;
TGCT	cis	rs7666738	0.606	rs28481322	chr4:99086638	T/C	cg18180107	chr4:99064573	C4orf37	0.53	4.67	0.39	7.61e-6	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs629535	0.735	rs525610	chr8:70074535	A/G	cg21567404	chr3:27674614	NA	0.57	9.09	0.63	1.94e-15	Dupuytren's disease;
TGCT	cis	rs4654899	0.758	rs3820326	chr1:21277141	G/A	cg01072550	chr1:21505969	NA	-0.56	-9.15	-0.63	1.47e-15	Superior frontal gyrus grey matter volume;
TGCT	cis	rs7647973	0.710	rs11130207	chr3:49611666	T/G	cg03060546	chr3:49711283	APEH	0.63	5.14	0.42	1.03e-6	Menarche (age at onset);
TGCT	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.07	-9.63	-0.65	1.01e-16	Platelet count;
TGCT	cis	rs9467773	1.000	rs9467796	chr6:26568411	A/G	cg05738196	chr6:26577821	NA	0.9	12.48	0.75	1.16e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs1008375	0.900	rs4698625	chr4:17599500	G/T	cg10189774	chr4:17578691	LAP3	0.65	5.28	0.43	5.54e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7666738	0.830	rs1365458	chr4:98950961	C/T	cg05340658	chr4:99064831	C4orf37	0.55	6.13	0.48	1.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9296092	0.500	rs9469504	chr6:33527243	G/A	cg13560919	chr6:33536144	NA	-0.23	-5.06	-0.41	1.49e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg17554472	chr22:41940697	POLR3H	0.48	4.95	0.41	2.39e-6	Vitiligo;
TGCT	cis	rs7216064	1.000	rs4318247	chr17:65882172	A/G	cg12091567	chr17:66097778	LOC651250	-0.83	-6.49	-0.5	1.9e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs6840360	0.593	rs4696287	chr4:152606723	C/T	cg17479576	chr4:152424074	FAM160A1	-0.61	-6.29	-0.49	4.86e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs79349575	0.811	rs60708039	chr17:46999373	C/G	cg07967210	chr17:47022446	SNF8	0.44	6.12	0.48	1.13e-8	Type 2 diabetes;
TGCT	cis	rs17253792	0.822	rs10136155	chr14:56049129	G/A	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs3749237	0.576	rs3877784	chr3:49539417	C/T	cg03060546	chr3:49711283	APEH	0.76	8.69	0.62	1.77e-14	Resting heart rate;
TGCT	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg06238570	chr21:40685208	BRWD1	0.68	6.32	0.49	4.29e-9	Cognitive function;
TGCT	cis	rs28595532	0.920	rs116094766	chr4:119729291	T/C	cg14228332	chr4:119757509	SEC24D	1.32	6.38	0.5	3.2e-9	Cannabis dependence symptom count;
TGCT	cis	rs9329289	0.510	rs35854428	chr10:2554280	T/C	cg07014206	chr10:2547000	NA	-0.28	-4.64	-0.38	8.6e-6	Age-related hearing impairment;
TGCT	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg13342137	chr4:2252803	MXD4	0.17	4.44	0.37	1.94e-5	Obesity-related traits;
TGCT	cis	rs1372520	0.684	rs356188	chr4:90691537	T/C	cg14346243	chr4:90757452	SNCA	0.62	5.29	0.43	5.26e-7	Neuroticism;
TGCT	cis	rs35306767	0.761	rs11253558	chr10:1043983	T/C	cg26597838	chr10:835615	NA	0.6	6.63	0.51	9.45e-10	Eosinophil percentage of granulocytes;
TGCT	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg07061783	chr6:25882402	NA	0.64	6.7	0.52	6.57e-10	Blood metabolite levels;
TGCT	cis	rs9443645	0.869	rs10943585	chr6:79502409	G/C	cg09184832	chr6:79620586	NA	-0.45	-4.82	-0.4	4.16e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2204008	0.774	rs3910796	chr12:38230660	G/T	cg26384229	chr12:38710491	ALG10B	0.85	7.52	0.56	9.65e-12	Bladder cancer;
TGCT	cis	rs2243480	1.000	rs186378	chr7:65582058	A/C	cg18252515	chr7:66147081	NA	-1.24	-8.1	-0.59	4.35e-13	Diabetic kidney disease;
TGCT	cis	rs2885056	0.783	rs12459941	chr19:10666112	A/G	cg04833646	chr19:10679720	CDKN2D	-0.95	-9.26	-0.64	7.75e-16	Red cell distribution width;
TGCT	cis	rs1568889	1.000	rs16917687	chr11:28062614	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	8.86	0.62	7.07e-15	Bipolar disorder;
TGCT	cis	rs10858047	0.883	rs79867	chr1:115165110	A/C	cg12756093	chr1:115239321	AMPD1	-0.48	-4.68	-0.39	7.27e-6	Autism;
TGCT	cis	rs9926296	0.744	rs164748	chr16:89708292	C/G	cg01097406	chr16:89675127	NA	0.35	6.31	0.49	4.55e-9	Vitiligo;
TGCT	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg10802521	chr3:52805072	NEK4	-0.65	-7.82	-0.57	1.98e-12	Electroencephalogram traits;
TGCT	cis	rs453301	0.686	rs28665409	chr8:8869277	G/A	cg06636001	chr8:8085503	FLJ10661	-0.68	-5.62	-0.45	1.21e-7	Joint mobility (Beighton score);
TGCT	cis	rs2905347	0.895	rs2905308	chr7:22648194	G/A	cg26061582	chr7:22766209	IL6	-0.4	-4.53	-0.38	1.38e-5	Major depression and alcohol dependence;
TGCT	cis	rs4727027	0.866	rs12666477	chr7:148812322	A/G	cg23583168	chr7:148888333	NA	-0.72	-9.16	-0.64	1.34e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.72	-5.71	-0.46	7.86e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs854765	0.533	rs2955354	chr17:17948716	G/C	cg04398451	chr17:18023971	MYO15A	0.34	5.49	0.44	2.21e-7	Total body bone mineral density;
TGCT	cis	rs3764400	0.567	rs16953941	chr17:46296204	C/A	cg02340556	chr17:46797764	NA	0.42	4.51	0.38	1.46e-5	Body mass index;
TGCT	cis	rs34245846	0.769	rs12089941	chr1:154827520	T/C	cg06418219	chr1:154948305	SHC1;CKS1B	0.73	5.83	0.46	4.53e-8	Atrial fibrillation;
TGCT	cis	rs7246657	0.722	rs28512414	chr19:38056574	T/A	cg18154014	chr19:37997991	ZNF793	0.69	4.63	0.38	9.25e-6	Coronary artery calcification;
TGCT	cis	rs3096299	0.869	rs748941	chr16:89440754	T/A	cg06640241	chr16:89574553	SPG7	0.64	5.88	0.47	3.55e-8	Multiple myeloma (IgH translocation);
TGCT	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg08280861	chr8:58055591	NA	0.52	5.78	0.46	5.78e-8	Developmental language disorder (linguistic errors);
TGCT	cis	rs12620999	0.555	rs10199274	chr2:238111864	G/C	cg23555395	chr2:238036564	NA	-0.29	-4.94	-0.41	2.43e-6	Systemic lupus erythematosus;
TGCT	cis	rs7949030	0.596	rs11231137	chr11:62315699	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.62	6.25	0.49	5.9e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7226408	0.857	rs59065432	chr18:34419345	T/C	cg06757138	chr18:34340585	FHOD3	0.25	4.83	0.4	4.02e-6	Obesity-related traits;
TGCT	cis	rs9611565	0.722	rs202635	chr22:41809637	C/T	cg17554472	chr22:41940697	POLR3H	0.43	4.79	0.39	4.73e-6	Vitiligo;
TGCT	cis	rs6963495	0.818	rs6977748	chr7:105167462	T/G	cg20976433	chr7:105162600	PUS7	-0.62	-4.45	-0.37	1.88e-5	Bipolar disorder (body mass index interaction);
TGCT	cis	rs11098499	0.820	rs6829903	chr4:120506884	C/T	cg09307838	chr4:120376055	NA	0.69	6.53	0.51	1.49e-9	Corneal astigmatism;
TGCT	cis	rs11098499	0.605	rs6833140	chr4:120266822	G/A	cg09307838	chr4:120376055	NA	0.56	5.49	0.44	2.18e-7	Corneal astigmatism;
TGCT	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg17330251	chr7:94953956	PON1	-0.61	-8.09	-0.59	4.58e-13	Paraoxonase activity;
TGCT	cis	rs7267979	1.000	rs1047171	chr20:25428786	T/C	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg12963246	chr6:28129442	ZNF389	0.51	5.02	0.41	1.73e-6	Depression;
TGCT	cis	rs4455778	0.727	rs10279104	chr7:49071187	A/G	cg26309511	chr7:48887640	NA	0.47	5.33	0.43	4.56e-7	Lung cancer in never smokers;
TGCT	cis	rs12478296	1.000	rs56323081	chr2:243040807	A/G	cg06360820	chr2:242988706	NA	-0.81	-5.39	-0.44	3.36e-7	Obesity-related traits;
TGCT	cis	rs3924048	0.559	rs4075304	chr1:12626803	C/T	cg00291366	chr1:12616550	NA	0.32	5.03	0.41	1.66e-6	Optic cup area;
TGCT	cis	rs568617	0.953	rs658938	chr11:65651830	A/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.57	-5.22	-0.42	7.39e-7	Crohn's disease;
TGCT	cis	rs7752195	0.643	rs75672316	chr6:25250050	A/G	cg16898833	chr6:26189333	HIST1H4D	1.17	5.47	0.44	2.34e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6964587	1.000	rs6974607	chr7:91750116	G/A	cg17063962	chr7:91808500	NA	0.88	9.3	0.64	6.22e-16	Breast cancer;
TGCT	cis	rs7027203	0.576	rs7851269	chr9:96540530	C/T	cg13679303	chr9:96623674	NA	0.53	7.64	0.57	5.06e-12	DNA methylation (variation);
TGCT	cis	rs1018836	0.828	rs12547016	chr8:91563847	T/C	cg16814680	chr8:91681699	NA	-0.75	-7.85	-0.58	1.71e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg11941060	chr3:133502564	NA	-0.31	-6.62	-0.51	9.53e-10	Iron status biomarkers;
TGCT	cis	rs7959452	0.590	rs56054057	chr12:69775972	C/T	cg14784868	chr12:69753453	YEATS4	0.83	8.96	0.63	4.14e-15	Blood protein levels;
TGCT	cis	rs1997103	0.954	rs6593222	chr7:55372932	A/C	cg17469321	chr7:55412551	NA	0.64	6.6	0.51	1.1e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs3796352	1.000	rs11707575	chr3:53113762	G/T	cg15956490	chr3:53032818	SFMBT1	0.48	5.39	0.44	3.4e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs7809950	1.000	rs4730245	chr7:107087294	C/T	cg23024343	chr7:107201750	COG5	-0.35	-5.48	-0.44	2.28e-7	Coronary artery disease;
TGCT	cis	rs2243480	1.000	rs1404147	chr7:65264524	C/T	cg18252515	chr7:66147081	NA	-0.9	-6.4	-0.5	2.83e-9	Diabetic kidney disease;
TGCT	cis	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg07424592	chr7:64974309	NA	1.34	8.08	0.59	4.95e-13	Diabetic kidney disease;
TGCT	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg15242686	chr22:24348715	GSTTP1	-0.5	-7.53	-0.56	9.28e-12	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs3617	0.539	rs4687689	chr3:52948674	A/C	cg05573699	chr3:52720067	GNL3;PBRM1	0.5	4.88	0.4	3.18e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6570726	0.967	rs441364	chr6:145853662	G/C	cg23711669	chr6:146136114	FBXO30	0.7	6.52	0.51	1.63e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11696501	0.688	rs4810461	chr20:44278445	G/A	cg11783356	chr20:44313418	WFDC10B	-0.32	-4.63	-0.38	8.98e-6	Brain structure;
TGCT	cis	rs10883723	0.810	rs7917525	chr10:104246755	C/G	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs798554	0.704	rs798512	chr7:2782592	C/G	cg25467336	chr7:2757616	NA	-0.24	-4.62	-0.38	9.58e-6	Height;
TGCT	cis	rs76419734	0.614	rs72669979	chr4:106523289	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.81	4.47	0.37	1.74e-5	Post bronchodilator FEV1;
TGCT	cis	rs9814567	0.793	rs55940445	chr3:134306064	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.91	8.28	0.6	1.66e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs4478858	0.746	rs10798832	chr1:31688630	C/G	cg00250761	chr1:31883323	NA	0.29	4.78	0.39	4.9e-6	Alcohol dependence;
TGCT	cis	rs7819412	0.595	rs2409712	chr8:10986837	A/C	cg21775007	chr8:11205619	TDH	-0.53	-5.34	-0.43	4.21e-7	Triglycerides;
TGCT	cis	rs11098499	0.697	rs4560394	chr4:120313435	T/G	cg09307838	chr4:120376055	NA	0.65	6.39	0.5	3.02e-9	Corneal astigmatism;
TGCT	cis	rs2115630	0.645	rs1107179	chr15:85198362	A/C	cg11189052	chr15:85197271	WDR73	0.79	7.8	0.57	2.21e-12	P wave terminal force;
TGCT	cis	rs11190604	1.000	rs2495737	chr10:102338344	T/C	cg16342193	chr10:102329863	NA	-0.41	-5.08	-0.41	1.37e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7296418	0.663	rs4553407	chr12:123750748	G/C	cg00376283	chr12:123451042	ABCB9	0.73	6.44	0.5	2.36e-9	Platelet count;
TGCT	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg23131131	chr22:24373011	LOC391322	-0.62	-6.23	-0.49	6.81e-9	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg26116260	chr4:7069785	GRPEL1	1.13	11.1	0.71	2.59e-20	Monocyte percentage of white cells;
TGCT	cis	rs7949030	1.000	rs7949030	chr11:62394881	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.57	6.73	0.52	5.53e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg20637647	chr7:64974828	NA	1.0	5.59	0.45	1.4e-7	Diabetic kidney disease;
TGCT	cis	rs2153535	0.541	rs9405386	chr6:8458067	C/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.3e-6	Motion sickness;
TGCT	cis	rs7523273	0.554	rs2761434	chr1:207917499	C/T	cg22525895	chr1:207977042	MIR29B2	-0.42	-6.09	-0.48	1.32e-8	Schizophrenia;
TGCT	cis	rs78461346	1.000	rs76974730	chr17:80533261	C/T	cg15014069	chr17:80540666	FOXK2	0.4	4.99	0.41	1.97e-6	3-hydroxypropylmercapturic acid levels in smokers;
TGCT	cis	rs9811920	0.965	rs6767441	chr3:99863183	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.41	-4.59	-0.38	1.08e-5	Axial length;
TGCT	cis	rs727563	0.636	rs2187795	chr22:42092225	C/A	cg03806693	chr22:41940476	POLR3H	1.08	11.79	0.73	5.53e-22	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs7552404	1.000	rs211723	chr1:76103030	C/T	cg22875332	chr1:76189707	ACADM	-0.79	-9.61	-0.65	1.12e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg03517284	chr6:25882590	NA	-0.62	-6.45	-0.5	2.24e-9	Blood metabolite levels;
TGCT	cis	rs7246657	0.943	rs10404920	chr19:37881556	T/C	cg18154014	chr19:37997991	ZNF793	1.0	6.69	0.52	6.81e-10	Coronary artery calcification;
TGCT	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg03351412	chr1:154909251	PMVK	0.52	4.92	0.4	2.66e-6	Prostate cancer;
TGCT	cis	rs9303401	0.659	rs35828828	chr17:56718205	C/T	cg25039879	chr17:56429692	SUPT4H1	0.5	4.45	0.37	1.87e-5	Cognitive test performance;
TGCT	cis	rs6725041	0.819	rs939225	chr2:213089002	T/C	cg20637307	chr2:213403960	ERBB4	-0.52	-4.47	-0.37	1.72e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs4478037	0.822	rs9883177	chr3:33123354	T/C	cg19404215	chr3:33155277	CRTAP	0.98	5.13	0.42	1.1e-6	Major depressive disorder;
TGCT	cis	rs933688	1.000	rs1541674	chr5:90660447	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.03	9.42	0.65	3.21e-16	Smoking behavior;
TGCT	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg18876405	chr7:65276391	NA	0.32	4.87	0.4	3.29e-6	Aortic root size;
TGCT	cis	rs36051895	0.632	rs10974987	chr9:5169302	G/T	cg02405213	chr9:5042618	JAK2	-0.75	-9.77	-0.66	4.53e-17	Pediatric autoimmune diseases;
TGCT	cis	rs612683	0.694	rs6688166	chr1:101000717	G/C	cg06223162	chr1:101003688	GPR88	0.34	5.72	0.46	7.52e-8	Breast cancer;
TGCT	cis	rs7267979	0.844	rs8184820	chr20:25250577	C/T	cg03522245	chr20:25566470	NINL	-0.57	-5.67	-0.45	9.54e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9467773	0.596	rs2451751	chr6:26646714	T/C	cg05738196	chr6:26577821	NA	0.88	10.63	0.69	3.68e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs1577917	1.000	rs10455449	chr6:86592226	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.42	-0.44	3.02e-7	Response to antipsychotic treatment;
TGCT	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.49	-6.64	-0.51	8.8e-10	Alzheimer's disease;
TGCT	cis	rs2486288	0.586	rs12909883	chr15:45572054	G/C	cg14582100	chr15:45693742	SPATA5L1	-0.47	-5.38	-0.44	3.57e-7	Glomerular filtration rate;
TGCT	cis	rs523522	0.926	rs10849766	chr12:121025894	G/A	cg12219531	chr12:120966889	COQ5	0.81	7.11	0.54	7.9e-11	High light scatter reticulocyte count;
TGCT	cis	rs4730250	0.654	rs6947857	chr7:106787266	T/G	cg02696742	chr7:106810147	HBP1	0.74	6.15	0.48	9.79e-9	Osteoarthritis;
TGCT	cis	rs4788815	0.533	rs12102548	chr16:71929763	C/G	cg06353428	chr16:71660113	MARVELD3	0.83	7.32	0.55	2.74e-11	Metabolite levels;
TGCT	cis	rs4888262	0.508	rs7193583	chr16:74649589	C/G	cg01733217	chr16:74700730	RFWD3	0.74	7.47	0.56	1.23e-11	Testicular germ cell tumor;
TGCT	cis	rs6427499	0.740	rs7551141	chr1:159892780	A/G	cg15641364	chr1:159892206	TAGLN2	0.3	5.21	0.42	7.49e-7	Platelet distribution width;
TGCT	cis	rs4149423	1.000	rs4149420	chr2:108913090	G/T	cg06795125	chr2:108905320	SULT1C2	-0.46	-6.96	-0.53	1.75e-10	Lobe size;
TGCT	cis	rs4746818	1.000	rs6480385	chr10:70904785	A/T	cg11621586	chr10:70884670	VPS26A	1.23	11.01	0.7	4.3e-20	Left atrial antero-posterior diameter;
TGCT	cis	rs1348850	0.958	rs12471741	chr2:178448196	A/G	cg22681709	chr2:178499509	PDE11A	-0.36	-4.46	-0.37	1.83e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs17331151	0.573	rs13080929	chr3:52885112	A/C	cg07884673	chr3:53033167	SFMBT1	0.49	5.5	0.44	2.12e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs7666738	0.791	rs12233867	chr4:98950233	A/G	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3820068	0.581	rs72645889	chr1:15930251	T/G	cg05660106	chr1:15850417	CASP9	0.82	8.02	0.58	6.63e-13	Systolic blood pressure;
TGCT	cis	rs9291683	0.554	rs7668175	chr4:10125782	T/C	cg00071950	chr4:10020882	SLC2A9	-0.43	-4.7	-0.39	6.69e-6	Bone mineral density;
TGCT	cis	rs8180040	0.932	rs1038394	chr3:47464122	A/G	cg27129171	chr3:47204927	SETD2	0.65	7.74	0.57	2.99e-12	Colorectal cancer;
TGCT	cis	rs11190604	0.806	rs11190510	chr10:102157175	G/A	cg23241863	chr10:102295624	HIF1AN	0.61	4.58	0.38	1.12e-5	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs3733585	0.638	rs7377625	chr4:9953099	T/C	cg11266682	chr4:10021025	SLC2A9	-0.57	-7.6	-0.56	6.21e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs3015497	0.763	rs2934689	chr14:51118327	A/C	cg04730355	chr14:51134070	SAV1	-0.65	-6.29	-0.49	4.85e-9	Mean platelet volume;
TGCT	cis	rs8180040	0.967	rs4858856	chr3:47565424	G/A	cg27129171	chr3:47204927	SETD2	0.61	7.13	0.54	7.45e-11	Colorectal cancer;
TGCT	cis	rs868036	0.681	rs13329567	chr15:68104367	C/T	cg05925327	chr15:68127851	NA	-0.5	-4.85	-0.4	3.57e-6	Restless legs syndrome;
TGCT	cis	rs12042938	0.600	rs823165	chr1:231769446	T/A	cg04892437	chr1:231737901	TSNAX-DISC1	0.48	4.86	0.4	3.4e-6	Neuranatomic and neurocognitive phenotypes;
TGCT	cis	rs7511006	0.798	rs11703673	chr22:50652427	A/G	cg19026356	chr22:50624276	TRABD	0.63	5.61	0.45	1.26e-7	Obesity-related traits;
TGCT	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg11494091	chr17:61959527	GH2	0.61	14.49	0.79	1.92e-28	Prudent dietary pattern;
TGCT	cis	rs3008870	1.000	rs35365746	chr1:67438900	G/A	cg03991309	chr1:68237761	GNG12	-0.27	-4.53	-0.38	1.36e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.36	-4.58	-0.38	1.11e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg18252515	chr7:66147081	NA	1.2	7.83	0.58	1.89e-12	Diabetic kidney disease;
TGCT	cis	rs6484504	0.516	rs1999250	chr11:31287455	C/T	cg14844989	chr11:31128820	NA	-0.23	-4.49	-0.37	1.63e-5	Red blood cell count;
TGCT	cis	rs11696501	0.688	rs6073788	chr20:44213773	C/T	cg11783356	chr20:44313418	WFDC10B	-0.33	-4.79	-0.4	4.67e-6	Brain structure;
TGCT	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg24829409	chr8:58192753	C8orf71	-0.59	-5.18	-0.42	8.54e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg22683308	chr4:1340831	KIAA1530	-0.64	-5.88	-0.47	3.53e-8	Longevity;
TGCT	cis	rs3845702	0.736	rs72960660	chr2:180832482	A/G	cg01881094	chr2:180872142	CWC22	1.04	6.58	0.51	1.21e-9	Schizophrenia;
TGCT	cis	rs754133	0.964	rs894738	chr12:54417525	C/T	cg16264616	chr12:54390824	NA	0.33	4.96	0.41	2.27e-6	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;
TGCT	cis	rs13191362	0.938	rs35760705	chr6:163020637	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.68	5.76	0.46	6.37e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs1443512	0.704	rs4759308	chr12:54329031	A/T	cg17708016	chr12:54321992	NA	0.57	4.67	0.39	7.84e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
TGCT	cis	rs2739330	1.000	rs2739330	chr22:24295286	T/C	cg04234412	chr22:24373322	LOC391322	-0.87	-10.25	-0.68	3.1e-18	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9296661	0.798	rs1326574	chr6:51667219	A/G	cg00593404	chr6:52377740	TRAM2	-0.27	-4.49	-0.37	1.62e-5	Weight loss (gastric bypass surgery);
TGCT	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg08048268	chr3:133502702	NA	-0.53	-7.22	-0.54	4.6e-11	Iron status biomarkers;
TGCT	cis	rs67478160	0.572	rs8016014	chr14:104293798	G/C	cg26031613	chr14:104095156	KLC1	-0.63	-6.37	-0.5	3.33e-9	Schizophrenia;
TGCT	cis	rs4713118	0.597	rs172166	chr6:28020820	C/G	cg12963246	chr6:28129442	ZNF389	0.45	4.55	0.38	1.27e-5	Parkinson's disease;
TGCT	cis	rs6665290	0.904	rs1045290	chr1:227178700	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.01	-20.94	-0.88	1.57e-42	Myeloid white cell count;
TGCT	trans	rs7221878	1.000	rs7220682	chr17:36188471	A/G	cg03614664	chr22:41346948	RBX1	-1.39	-6.64	-0.51	8.97e-10	Macrophage inflammatory protein 1b levels;
TGCT	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.5	-4.76	-0.39	5.41e-6	Prudent dietary pattern;
TGCT	cis	rs12477438	0.765	rs1115757	chr2:99660146	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-4.62	-0.38	9.47e-6	Chronic sinus infection;
TGCT	cis	rs11585357	0.501	rs4262593	chr1:17594263	T/C	cg08277548	chr1:17600880	PADI3	-0.81	-5.64	-0.45	1.08e-7	Hair shape;
TGCT	cis	rs2486012	0.737	rs3791055	chr1:44265655	T/C	cg12908607	chr1:44402522	ARTN	-0.71	-5.54	-0.45	1.75e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs524281	0.861	rs10896091	chr11:65950825	T/C	cg00563793	chr11:65837595	PACS1	0.57	4.91	0.4	2.8e-6	Electroencephalogram traits;
TGCT	cis	rs9457247	0.935	rs1794697	chr6:167395410	C/T	cg23791538	chr6:167370224	RNASET2	-0.5	-4.98	-0.41	2.06e-6	Crohn's disease;
TGCT	cis	rs3096299	0.967	rs11648663	chr16:89466307	C/T	cg02187348	chr16:89574699	SPG7	0.47	4.45	0.37	1.9e-5	Multiple myeloma (IgH translocation);
TGCT	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg27170947	chr2:26402098	FAM59B	-0.41	-4.67	-0.39	7.59e-6	Gut microbiome composition (summer);
TGCT	cis	rs4506170	1.000	rs72712338	chr8:128340537	A/T	cg07795030	chr8:128802207	NA	-0.19	-4.46	-0.37	1.84e-5	Prostate cancer;
TGCT	cis	rs3818285	0.556	rs941864	chr10:111656948	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.3	-5.04	-0.41	1.62e-6	Superior crus of antihelix expression;
TGCT	cis	rs3784262	0.669	rs12909423	chr15:58292433	C/G	cg12031962	chr15:58353849	ALDH1A2	0.43	6.21	0.49	7.49e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs7027203	1.000	rs7027203	chr9:96562563	A/C	cg14598338	chr9:96623480	NA	0.59	8.65	0.61	2.17e-14	DNA methylation (variation);
TGCT	trans	rs8073060	0.586	rs4796100	chr17:33997657	G/T	cg19694781	chr19:47549865	TMEM160	0.6	13.52	0.77	3.75e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs9611565	0.525	rs1883827	chr22:41703579	A/G	cg03806693	chr22:41940476	POLR3H	-0.75	-7.26	-0.55	3.78e-11	Vitiligo;
TGCT	cis	rs7940866	0.838	rs1991898	chr11:130801786	C/G	cg05962950	chr11:130786565	SNX19	-0.74	-7.56	-0.56	7.91e-12	Schizophrenia;
TGCT	cis	rs9638182	0.725	rs17145738	chr7:72982874	C/T	cg14087351	chr7:73037990	MLXIPL	-0.65	-5.18	-0.42	8.75e-7	Triglycerides;
TGCT	cis	rs12497850	0.931	rs9311433	chr3:48863835	T/C	cg05785598	chr3:49045655	WDR6	0.35	4.72	0.39	6.35e-6	Parkinson's disease;
TGCT	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg07061783	chr6:25882402	NA	-0.45	-4.82	-0.4	4.15e-6	Blood metabolite levels;
TGCT	cis	rs8077889	0.917	rs72836545	chr17:41892602	A/G	cg26893861	chr17:41843967	DUSP3	1.07	12.67	0.75	4.21e-24	Triglycerides;
TGCT	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg07870213	chr5:140052090	DND1	-0.62	-7.4	-0.55	1.84e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2469997	1.000	rs1599476	chr8:120351800	C/T	cg00681363	chr8:120844660	TAF2	0.65	4.45	0.37	1.9e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs61990749	0.597	rs2112136	chr14:78248952	T/C	cg23188588	chr14:78226832	SNW1;C14orf178	0.67	4.73	0.39	6.09e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs514406	0.929	rs12145105	chr1:53340564	T/C	cg22166914	chr1:53195759	ZYG11B	0.38	6.46	0.5	2.15e-9	Monocyte count;
TGCT	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg12419862	chr22:24373484	LOC391322	-0.86	-9.98	-0.67	1.4e-17	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9394438	0.593	rs10947679	chr6:37543524	C/G	cg00985040	chr6:37553208	NA	0.24	4.85	0.4	3.63e-6	IgG glycosylation;
TGCT	cis	rs896854	0.573	rs11996455	chr8:95853708	G/A	cg09323728	chr8:95962352	TP53INP1	-0.41	-4.79	-0.39	4.72e-6	Type 2 diabetes;
TGCT	cis	rs12765878	0.557	rs2984133	chr10:105670848	T/A	cg11005552	chr10:105648138	OBFC1	-0.39	-6.12	-0.48	1.15e-8	Coronary artery disease;
TGCT	cis	rs295140	1.000	rs7559005	chr2:201161371	C/T	cg04283868	chr2:201171347	SPATS2L	0.63	6.39	0.5	3.03e-9	QT interval;
TGCT	cis	rs514406	0.505	rs427319	chr1:53178807	T/G	cg25767906	chr1:53392781	SCP2	-0.47	-5.35	-0.43	4.15e-7	Monocyte count;
TGCT	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg04181038	chr4:183730758	NA	0.61	5.76	0.46	6.22e-8	Pediatric autoimmune diseases;
TGCT	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg09365446	chr1:150670422	GOLPH3L	0.3	4.49	0.37	1.63e-5	Tonsillectomy;
TGCT	cis	rs9303401	0.659	rs16943176	chr17:56769887	G/A	cg25039879	chr17:56429692	SUPT4H1	0.52	4.62	0.38	9.48e-6	Cognitive test performance;
TGCT	trans	rs10506458	0.915	rs17763441	chr12:63418335	T/C	cg22491629	chr6:157744540	C6orf35	-0.98	-8.47	-0.61	6.02e-14	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg05368731	chr17:41323189	NBR1	-0.92	-10.85	-0.7	1.07e-19	Menopause (age at onset);
TGCT	cis	rs12477438	0.520	rs11123763	chr2:99750673	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	17.43	0.84	3.73e-35	Chronic sinus infection;
TGCT	cis	rs10751667	0.666	rs10902242	chr11:949700	G/A	cg06064525	chr11:970664	AP2A2	-0.35	-8.22	-0.59	2.29e-13	Alzheimer's disease (late onset);
TGCT	cis	rs17345786	1.000	rs3804778	chr3:101294572	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.45	-9.64	-0.65	9.35e-17	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9611565	0.512	rs5751147	chr22:42139054	G/A	cg06481639	chr22:41940642	POLR3H	0.7	6.1	0.48	1.24e-8	Vitiligo;
TGCT	cis	rs10744422	1.000	rs897386	chr12:123341289	A/C	cg25930673	chr12:123319894	HIP1R	-0.86	-5.09	-0.42	1.29e-6	Schizophrenia;
TGCT	cis	rs9549260	0.564	rs9646110	chr13:41308301	A/T	cg21288729	chr13:41239152	FOXO1	-0.87	-7.87	-0.58	1.5e-12	Red blood cell count;
TGCT	cis	rs7959452	0.640	rs4761154	chr12:69705362	A/G	cg11871910	chr12:69753446	YEATS4	-0.63	-6.37	-0.5	3.34e-9	Blood protein levels;
TGCT	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg10047753	chr17:41438598	NA	0.78	7.25	0.55	3.96e-11	Menopause (age at onset);
TGCT	cis	rs3741404	0.583	rs640999	chr11:63869425	C/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.72	7.32	0.55	2.78e-11	Platelet count;
TGCT	cis	rs2456568	0.695	rs877341	chr11:93689293	C/T	cg26875233	chr11:93583750	C11orf90	0.39	4.76	0.39	5.28e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs2859741	0.967	rs534131	chr1:37484237	T/C	cg09363841	chr1:37513479	NA	-0.21	-4.89	-0.4	3.09e-6	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
TGCT	cis	rs62244186	0.566	rs55901755	chr3:44834707	C/T	cg10108389	chr3:44770937	ZNF501	-0.49	-4.9	-0.4	2.92e-6	Depressive symptoms;
TGCT	cis	rs1843834	0.539	rs10177898	chr2:225437552	C/T	cg22455342	chr2:225449267	CUL3	1.04	10.75	0.69	1.87e-19	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs9916302	0.861	rs632202	chr17:37453294	C/A	cg07936489	chr17:37558343	FBXL20	0.62	4.91	0.4	2.85e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs6952808	0.609	rs4721185	chr7:1951109	T/C	cg22963979	chr7:1858916	MAD1L1	-0.38	-5.63	-0.45	1.15e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs3793683	0.858	rs1571145	chr10:134583672	C/G	cg27286337	chr10:134555280	INPP5A	-0.45	-6.76	-0.52	4.76e-10	Migraine;
TGCT	cis	rs1042058	0.565	rs2480297	chr10:30754512	A/G	cg18806716	chr10:30721971	MAP3K8	-0.57	-6.88	-0.53	2.69e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
TGCT	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.31	-4.82	-0.4	4.12e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg03609598	chr5:56110824	MAP3K1	0.66	4.54	0.38	1.3e-5	Initial pursuit acceleration;
TGCT	cis	rs35306767	0.951	rs12777021	chr10:967270	T/C	cg20503657	chr10:835505	NA	0.71	10.32	0.68	2.12e-18	Eosinophil percentage of granulocytes;
TGCT	trans	rs1814175	0.791	rs10839395	chr11:49846274	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.35	-0.55	2.37e-11	Height;
TGCT	cis	rs1451375	1.000	rs4452748	chr7:50625056	A/C	cg18232548	chr7:50535776	DDC	-0.4	-6.3	-0.49	4.72e-9	Malaria;
TGCT	cis	rs11190604	1.000	rs10883500	chr10:102238324	T/G	cg16342193	chr10:102329863	NA	-0.4	-5.34	-0.43	4.36e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2658782	1.000	rs2605583	chr11:93164957	T/A	cg18152523	chr11:93063302	CCDC67	-0.65	-5.27	-0.43	5.74e-7	Pulmonary function decline;
TGCT	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg24675658	chr1:53192096	ZYG11B	-0.71	-8.23	-0.59	2.14e-13	Monocyte count;
TGCT	cis	rs10992471	0.603	rs968040	chr9:95279985	C/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.6	-5.68	-0.45	9.23e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs4906332	0.901	rs4900575	chr14:103899169	G/C	cg26031613	chr14:104095156	KLC1	-0.52	-4.59	-0.38	1.08e-5	Coronary artery disease;
TGCT	trans	rs3824451	1.000	rs10985839	chr9:101075752	T/C	cg11574975	chr1:112058304	ADORA3	-0.44	-6.71	-0.52	6.34e-10	Schizophrenia;
TGCT	cis	rs595982	0.559	rs73061643	chr19:49368151	A/G	cg17863274	chr19:49399704	TULP2	-0.47	-6.78	-0.52	4.43e-10	Red cell distribution width;
TGCT	cis	rs7829975	0.502	rs7820738	chr8:8702607	C/G	cg15556689	chr8:8085844	FLJ10661	-0.68	-6.41	-0.5	2.79e-9	Mood instability;
TGCT	cis	rs2797160	0.905	rs1418640	chr6:125999866	G/A	cg05901451	chr6:126070800	HEY2	-0.74	-6.48	-0.5	1.96e-9	Endometrial cancer;
TGCT	cis	rs9303401	0.659	rs62083362	chr17:56846464	A/G	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs17376456	0.877	rs10476598	chr5:93367281	C/T	cg25358565	chr5:93447407	FAM172A	-1.0	-8.91	-0.62	5.42e-15	Diabetic retinopathy;
TGCT	cis	rs7236492	0.577	rs7236190	chr18:77198217	T/C	cg15644404	chr18:77186268	NFATC1	-0.27	-4.51	-0.38	1.49e-5	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs1865760	1.000	rs12209482	chr6:25909229	T/G	cg16482183	chr6:26056742	HIST1H1C	0.55	4.97	0.41	2.19e-6	Height;
TGCT	cis	rs10779751	0.734	rs2261317	chr1:11124979	A/G	cg08854313	chr1:11322531	MTOR	0.82	7.04	0.53	1.19e-10	Body mass index;
TGCT	cis	rs7917772	0.582	rs4408249	chr10:104374653	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	5.24	0.43	6.78e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg08280861	chr8:58055591	NA	-0.41	-5.0	-0.41	1.94e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6964587	1.000	rs6964587	chr7:91630620	G/T	cg17063962	chr7:91808500	NA	0.91	9.99	0.67	1.32e-17	Breast cancer;
TGCT	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg11871910	chr12:69753446	YEATS4	0.88	10.21	0.68	3.96e-18	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg06697600	chr4:7070879	GRPEL1	-0.47	-4.94	-0.41	2.42e-6	Monocyte percentage of white cells;
TGCT	cis	rs4750440	0.637	rs2447010	chr10:14032115	T/C	cg05755354	chr10:14372596	FRMD4A	0.3	4.77	0.39	5.1e-6	Adiponectin levels;
TGCT	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg26818010	chr10:134567672	INPP5A	-0.38	-5.39	-0.44	3.37e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs9467711	0.585	rs3884025	chr6:25930088	G/A	cg16898833	chr6:26189333	HIST1H4D	1.32	5.63	0.45	1.16e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6598955	0.724	rs12068388	chr1:26621596	G/A	cg04990556	chr1:26633338	UBXN11	-0.9	-11.73	-0.73	7.95e-22	Obesity-related traits;
TGCT	cis	rs3751972	0.696	rs7220473	chr17:26194116	T/C	cg02948944	chr17:26242737	NA	0.38	5.1	0.42	1.21e-6	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs2836633	0.929	rs11701577	chr21:40028906	C/T	cg05519781	chr21:40033154	ERG	0.69	6.83	0.52	3.34e-10	Coronary artery disease;
TGCT	cis	rs922182	0.557	rs7161764	chr15:64202744	C/T	cg02919090	chr15:64263738	DAPK2	-0.38	-7.0	-0.53	1.4e-10	Blood protein levels;
TGCT	cis	rs7927592	0.513	rs653056	chr11:68203625	T/C	cg16797656	chr11:68205561	LRP5	0.28	5.13	0.42	1.08e-6	Total body bone mineral density;
TGCT	cis	rs12549902	0.933	rs17659428	chr8:41513809	T/C	cg00088007	chr8:41504566	NKX6-3	0.34	5.31	0.43	4.93e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
TGCT	cis	rs611744	0.647	rs10106246	chr8:109268710	T/C	cg21045802	chr8:109455806	TTC35	0.71	7.25	0.55	4.03e-11	Dupuytren's disease;
TGCT	cis	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg13531842	chr10:38383804	ZNF37A	-0.39	-4.64	-0.38	8.78e-6	Extrinsic epigenetic age acceleration;
TGCT	cis	rs1505368	0.781	rs10197836	chr2:213274278	T/C	cg20637307	chr2:213403960	ERBB4	0.47	4.47	0.37	1.71e-5	Symmetrical dimethylarginine levels;
TGCT	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg11764359	chr7:65958608	NA	-0.57	-5.07	-0.41	1.4e-6	Aortic root size;
TGCT	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg19318889	chr4:1322082	MAEA	-0.21	-5.21	-0.42	7.67e-7	Obesity-related traits;
TGCT	trans	rs1814175	0.618	rs1851843	chr11:50021846	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.84	-0.7	1.13e-19	Height;
TGCT	cis	rs9611565	0.649	rs738422	chr22:42123399	C/T	cg03806693	chr22:41940476	POLR3H	0.96	9.91	0.66	2.06e-17	Vitiligo;
TGCT	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg22166914	chr1:53195759	ZYG11B	0.37	5.95	0.47	2.49e-8	Monocyte count;
TGCT	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg08280861	chr8:58055591	NA	0.4	4.56	0.38	1.22e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs1061377	1.000	rs3796511	chr4:39122206	G/A	cg24403649	chr4:39172243	NA	0.18	4.44	0.37	1.99e-5	Uric acid levels;
TGCT	cis	rs17665859	0.925	rs13258819	chr8:479636	G/A	cg17960703	chr8:356704	FBXO25	1.2	4.7	0.39	6.74e-6	Bilirubin levels;
TGCT	cis	rs2933343	0.700	rs876754	chr3:128627753	T/C	cg11901034	chr3:128598214	ACAD9	-0.64	-6.1	-0.48	1.22e-8	IgG glycosylation;
TGCT	cis	rs12681287	0.640	rs10095498	chr8:87425651	C/T	cg27223183	chr8:87520930	FAM82B	0.89	6.36	0.5	3.45e-9	Caudate activity during reward;
TGCT	cis	rs3125734	0.660	rs4979780	chr10:63992740	A/C	cg05499367	chr10:63213510	TMEM26	-0.33	-4.45	-0.37	1.91e-5	Rheumatoid arthritis;
TGCT	cis	rs9393777	0.528	rs9467989	chr6:27064275	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.57	-5.64	-0.45	1.08e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2742417	1.000	rs2742369	chr3:45754487	C/A	cg04837898	chr3:45731254	SACM1L	-0.55	-5.72	-0.46	7.45e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs72945132	0.882	rs72947078	chr11:70197542	G/T	cg00319359	chr11:70116639	PPFIA1	0.97	7.07	0.54	1.01e-10	Coronary artery disease;
TGCT	cis	rs7940866	0.803	rs1865296	chr11:130882944	C/T	cg05962950	chr11:130786565	SNX19	-0.68	-6.77	-0.52	4.64e-10	Schizophrenia;
TGCT	cis	rs13256369	1.000	rs7820159	chr8:8576215	T/C	cg18904891	chr8:8559673	CLDN23	0.63	5.84	0.46	4.38e-8	Obesity-related traits;
TGCT	cis	rs35306767	0.761	rs12770910	chr10:1050318	A/G	cg20503657	chr10:835505	NA	0.61	6.71	0.52	6.11e-10	Eosinophil percentage of granulocytes;
TGCT	cis	rs11577318	0.853	rs2276712	chr1:26627478	T/C	cg12733254	chr1:26682999	NA	-0.2	-4.45	-0.37	1.89e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs35934224	0.783	rs16984299	chr22:19863593	C/T	cg11182965	chr22:19864308	TXNRD2	0.33	4.94	0.41	2.49e-6	Glaucoma (primary open-angle);
TGCT	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg06238570	chr21:40685208	BRWD1	-0.61	-6.34	-0.49	3.97e-9	Menarche (age at onset);
TGCT	cis	rs17376456	0.597	rs10866760	chr5:93338335	G/A	cg25358565	chr5:93447407	FAM172A	-0.63	-5.95	-0.47	2.56e-8	Diabetic retinopathy;
TGCT	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg03264133	chr6:25882463	NA	0.49	4.54	0.38	1.31e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs8016982	0.589	rs4640110	chr14:81692191	A/G	cg01989461	chr14:81687754	GTF2A1	-0.67	-5.33	-0.43	4.54e-7	Schizophrenia;
TGCT	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg15782153	chr7:917662	C7orf20	0.52	6.26	0.49	5.66e-9	Perceived unattractiveness to mosquitoes;
TGCT	cis	rs2439831	1.000	rs2584725	chr15:43793135	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	5.51	0.44	1.95e-7	Lung cancer in ever smokers;
TGCT	trans	rs7824557	0.518	rs11777007	chr8:10801857	C/T	cg15556689	chr8:8085844	FLJ10661	-0.82	-7.42	-0.55	1.62e-11	Retinal vascular caliber;
TGCT	cis	rs968451	1.000	rs12628705	chr22:39693518	C/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.88	7.97	0.58	9.04e-13	Primary biliary cholangitis;
TGCT	cis	rs10501293	0.585	rs4237639	chr11:42969584	A/G	cg03447554	chr11:43094025	NA	-0.43	-6.33	-0.49	4.12e-9	Cognitive performance;
TGCT	cis	rs2032447	0.677	rs199737	chr6:25933538	A/T	cg07061783	chr6:25882402	NA	-0.69	-6.81	-0.52	3.7e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs35306767	0.903	rs12249828	chr10:894838	C/T	cg26597838	chr10:835615	NA	0.74	10.28	0.68	2.64e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg22920501	chr2:26401640	FAM59B	0.81	6.36	0.5	3.52e-9	Gut microbiome composition (summer);
TGCT	cis	rs1997103	1.000	rs6958022	chr7:55397389	G/A	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs3809566	0.676	rs9806544	chr15:63328360	G/A	cg08198488	chr15:63333792	TPM1	-0.34	-5.0	-0.41	1.93e-6	Platelet count;
TGCT	cis	rs2677744	0.719	rs877285	chr15:91452204	A/G	cg23684204	chr15:91497937	RCCD1	0.36	5.17	0.42	9.11e-7	Attention deficit hyperactivity disorder;
TGCT	cis	rs2204008	0.715	rs12815986	chr12:38343869	G/A	cg13010199	chr12:38710504	ALG10B	0.61	4.84	0.4	3.79e-6	Bladder cancer;
TGCT	cis	rs6952808	0.578	rs6949478	chr7:1841342	A/G	cg03103944	chr7:1601985	NA	0.25	4.64	0.38	8.7e-6	Bipolar disorder and schizophrenia;
TGCT	trans	rs4650994	0.525	rs4316329	chr1:178509333	C/T	cg05059571	chr16:84539110	KIAA1609	-0.55	-11.44	-0.72	3.86e-21	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs7246657	0.891	rs7257495	chr19:37823876	C/G	cg18154014	chr19:37997991	ZNF793	0.74	5.08	0.42	1.34e-6	Coronary artery calcification;
TGCT	cis	rs4253772	0.720	rs4253778	chr22:46630634	C/G	cg09491104	chr22:46646882	C22orf40	-0.48	-4.92	-0.4	2.64e-6	LDL cholesterol;Cholesterol, total;
TGCT	trans	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg15556689	chr8:8085844	FLJ10661	0.82	8.18	0.59	2.8e-13	Retinal vascular caliber;
TGCT	cis	rs2933343	0.672	rs1872545	chr3:128645039	G/C	cg11901034	chr3:128598214	ACAD9	-0.65	-6.05	-0.48	1.55e-8	IgG glycosylation;
TGCT	cis	rs3849570	0.925	rs2873054	chr3:81888255	A/C	cg07356753	chr3:81810745	GBE1	-0.72	-6.65	-0.51	8.21e-10	Waist circumference;Body mass index;
TGCT	cis	rs6088580	0.660	rs6059893	chr20:33105897	T/G	cg06115741	chr20:33292138	TP53INP2	0.54	4.63	0.38	9.06e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7312774	0.618	rs2888892	chr12:107328071	C/T	cg16260113	chr12:107380972	MTERFD3	1.03	5.3	0.43	5.07e-7	Severe influenza A (H1N1) infection;
TGCT	cis	rs6964587	0.541	rs6947170	chr7:91451471	A/G	cg17063962	chr7:91808500	NA	0.73	6.69	0.52	6.75e-10	Breast cancer;
TGCT	trans	rs1814175	0.904	rs7924371	chr11:49620595	C/T	cg03929089	chr4:120376271	NA	-0.65	-7.44	-0.56	1.46e-11	Height;
TGCT	cis	rs7635838	0.859	rs9812885	chr3:11508326	G/C	cg00170343	chr3:11313890	ATG7	0.67	6.21	0.49	7.42e-9	HDL cholesterol;
TGCT	cis	rs13082711	0.595	rs7615321	chr3:27368010	A/G	cg02860705	chr3:27208620	NA	0.46	6.65	0.51	8.25e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs2050392	1.000	rs2489864	chr10:30693744	C/G	cg18806716	chr10:30721971	MAP3K8	-0.44	-5.17	-0.42	9.28e-7	Inflammatory bowel disease;
TGCT	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs739496	0.793	rs628825	chr12:111951850	C/T	cg10833066	chr12:111807467	FAM109A	0.37	5.59	0.45	1.4e-7	Platelet count;
TGCT	cis	rs6815814	0.731	rs4504265	chr4:38773865	G/T	cg02016764	chr4:38805732	TLR1	-0.28	-4.79	-0.4	4.63e-6	Breast cancer;
TGCT	cis	rs539096	0.781	rs2970609	chr1:44097514	C/G	cg12908607	chr1:44402522	ARTN	-0.54	-5.68	-0.45	8.9e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9457247	0.602	rs17615336	chr6:167506734	A/G	cg07741184	chr6:167504864	NA	0.28	5.45	0.44	2.64e-7	Crohn's disease;
TGCT	cis	rs7523273	0.597	rs4844619	chr1:207960708	C/T	cg22525895	chr1:207977042	MIR29B2	-0.46	-6.74	-0.52	5.2400000000000005e-10	Schizophrenia;
TGCT	cis	rs7781977	0.554	rs6421315	chr7:50355207	C/G	cg01139861	chr7:50343298	IKZF1	0.49	5.8	0.46	5.19e-8	IgG glycosylation;
TGCT	cis	rs333332	0.504	rs72962889	chr3:124329748	A/G	cg04915618	chr3:124304960	KALRN	0.39	4.57	0.38	1.14e-5	Heschl's gyrus morphology;
TGCT	cis	rs4824093	0.610	rs73443923	chr22:50285348	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.09	-6.31	-0.49	4.6e-9	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg13395646	chr4:1353034	KIAA1530	-0.39	-4.47	-0.37	1.76e-5	Longevity;
TGCT	cis	rs11971779	0.729	rs10464730	chr7:139002227	A/T	cg07862535	chr7:139043722	LUC7L2	0.67	5.29	0.43	5.39e-7	Diisocyanate-induced asthma;
TGCT	cis	rs514406	0.758	rs532242	chr1:53308665	C/G	cg08736216	chr1:53307985	ZYG11A	-0.28	-5.46	-0.44	2.49e-7	Monocyte count;
TGCT	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg16680214	chr1:154839983	KCNN3	-0.36	-7.53	-0.56	9.29e-12	Prostate cancer;
TGCT	cis	rs11578119	0.933	rs12066718	chr1:170385570	C/A	cg09767346	chr1:170501363	GORAB	-0.72	-5.72	-0.46	7.52e-8	Male-pattern baldness;
TGCT	cis	rs6938	0.534	rs8025447	chr15:75192222	T/G	cg09165964	chr15:75287851	SCAMP5	0.56	5.29	0.43	5.31e-7	Breast cancer;
TGCT	cis	rs7267979	0.586	rs6050439	chr20:25192331	T/C	cg16686733	chr20:25566563	NINL	0.53	5.41	0.44	3.06e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9611519	0.894	rs9611486	chr22:41458784	C/G	cg03806693	chr22:41940476	POLR3H	-0.67	-6.05	-0.48	1.57e-8	Neuroticism;
TGCT	cis	rs7524258	0.900	rs2412151	chr1:7303216	G/C	cg07173049	chr1:7289937	CAMTA1	0.28	4.56	0.38	1.21e-5	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs7666738	0.830	rs7679961	chr4:99000202	C/T	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7258465	1.000	rs8109573	chr19:18617151	G/T	cg06462663	chr19:18546047	ISYNA1	0.2	4.67	0.39	7.74e-6	Breast cancer;
TGCT	cis	rs909674	0.775	rs4821896	chr22:39833437	T/C	cg24399712	chr22:39784796	NA	-1.07	-11.12	-0.71	2.43e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs35000415	0.938	rs13236009	chr7:128663173	T/G	cg06242719	chr7:129414860	MIR183;MIR96	-0.31	-4.52	-0.38	1.4e-5	Systemic lupus erythematosus;
TGCT	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	5.15	0.42	9.95e-7	Electroencephalogram traits;
TGCT	cis	rs1153858	1.000	rs66528868	chr15:45668547	A/C	cg14582100	chr15:45693742	SPATA5L1	0.49	5.73	0.46	7.14e-8	Homoarginine levels;
TGCT	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs713587	0.934	rs6728219	chr2:25159172	T/C	cg15423357	chr2:25149977	NA	0.59	5.96	0.47	2.49e-8	Body mass index in non-asthmatics;
TGCT	cis	rs10131894	0.611	rs175002	chr14:75436466	C/G	cg08847533	chr14:75593920	NEK9	0.68	7.05	0.53	1.12e-10	Coronary artery disease;
TGCT	cis	rs9926296	0.656	rs2376881	chr16:89827011	C/G	cg08627397	chr16:89984028	MC1R	-0.29	-4.47	-0.37	1.77e-5	Vitiligo;
TGCT	cis	rs9443645	0.869	rs4706747	chr6:79722639	A/G	cg09184832	chr6:79620586	NA	-0.48	-5.34	-0.43	4.21e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs968451	0.951	rs5750789	chr22:39725280	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.91	8.88	0.62	6.32e-15	Primary biliary cholangitis;
TGCT	cis	rs7666738	0.830	rs34890015	chr4:99023769	A/T	cg05340658	chr4:99064831	C4orf37	0.5	5.64	0.45	1.09e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs78487399	0.808	rs12105786	chr2:43676433	T/G	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.72	4.62	0.38	9.53e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs9311474	0.713	rs352170	chr3:52236077	A/G	cg10802521	chr3:52805072	NEK4	-0.56	-6.08	-0.48	1.35e-8	Electroencephalogram traits;
TGCT	cis	rs116095464	0.510	rs7723883	chr5:270798	T/C	cg22857025	chr5:266934	NA	-0.34	-6.64	-0.51	8.6e-10	Breast cancer;
TGCT	cis	rs4319547	0.737	rs7964138	chr12:122950375	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.64	-5.26	-0.43	6.1e-7	Body mass index;
TGCT	cis	rs3820068	0.871	rs2861484	chr1:15812665	G/T	cg05660106	chr1:15850417	CASP9	1.13	10.99	0.7	4.88e-20	Systolic blood pressure;
TGCT	cis	rs1008375	1.000	rs62295634	chr4:17685346	C/A	cg10189774	chr4:17578691	LAP3	0.54	4.95	0.41	2.37e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2456568	0.564	rs6483270	chr11:93624380	C/T	cg26875233	chr11:93583750	C11orf90	-0.49	-6.13	-0.48	1.07e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs67311347	1.000	rs9968170	chr3:40494274	A/G	cg13683864	chr3:40499215	RPL14	1.03	9.92	0.67	1.95e-17	Renal cell carcinoma;
TGCT	cis	rs13191362	1.000	rs13199223	chr6:163001083	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs910316	0.712	rs175015	chr14:75457075	A/C	cg11812906	chr14:75593930	NEK9	-0.59	-5.59	-0.45	1.37e-7	Height;
TGCT	trans	rs797680	0.822	rs2297707	chr1:93646207	T/C	cg27528825	chr2:159282178	CCDC148	-0.35	-6.89	-0.53	2.53e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs9534288	0.797	rs4142548	chr13:46535350	A/G	cg15192986	chr13:46630673	CPB2	-0.51	-7.21	-0.54	4.75e-11	Blood protein levels;
TGCT	cis	rs6964587	1.000	rs28584017	chr7:91719168	G/A	cg17063962	chr7:91808500	NA	0.86	9.47	0.65	2.39e-16	Breast cancer;
TGCT	cis	rs4389656	0.826	rs395939	chr5:6734245	T/C	cg10857441	chr5:6722123	POLS	-0.22	-4.74	-0.39	5.75e-6	Coronary artery disease;
TGCT	cis	rs2070488	0.775	rs2268762	chr3:38516075	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.77	7.53	0.56	9.03e-12	Electrocardiographic conduction measures;
TGCT	cis	rs7819412	0.594	rs60921132	chr8:10964969	T/A	cg21775007	chr8:11205619	TDH	-0.52	-5.16	-0.42	9.47e-7	Triglycerides;
TGCT	cis	rs8072100	0.713	rs9807106	chr17:45457102	G/T	cg08085267	chr17:45401833	C17orf57	-0.51	-5.58	-0.45	1.47e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs2637266	0.667	rs2395406	chr10:78380519	G/A	cg18941641	chr10:78392320	NA	0.43	5.53	0.44	1.81e-7	Pulmonary function;
TGCT	cis	rs2067615	0.524	rs1922433	chr12:107077172	A/G	cg15890332	chr12:107067104	RFX4	0.29	5.77	0.46	5.9e-8	Heart rate;
TGCT	cis	rs9303401	0.614	rs34900851	chr17:56566399	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.61	6.17	0.48	8.95e-9	Cognitive test performance;
TGCT	cis	rs5769765	1.000	rs1033665	chr22:50252127	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.38	5.77	0.46	5.83e-8	Schizophrenia;
TGCT	cis	rs7264396	0.790	rs6058294	chr20:34259396	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.25	-0.43	6.33e-7	Total cholesterol levels;
TGCT	cis	rs7666738	0.830	rs1426662	chr4:98990319	C/T	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2738048	0.545	rs2738168	chr8:6824577	G/T	cg24860332	chr8:6827800	DEFA10P	-0.46	-6.8	-0.52	3.88e-10	IgA nephropathy;
TGCT	cis	rs2153535	0.580	rs1932284	chr6:8477694	A/T	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg07424592	chr7:64974309	NA	-1.27	-7.84	-0.58	1.8e-12	Diabetic kidney disease;
TGCT	cis	rs6500602	0.701	rs6500614	chr16:4573938	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.28	5.07	0.41	1.43e-6	Schizophrenia;
TGCT	cis	rs1008375	0.966	rs4698636	chr4:17632834	T/C	cg18681998	chr4:17616180	MED28	1.02	11.81	0.73	4.83e-22	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg08280861	chr8:58055591	NA	0.48	5.17	0.42	9.03e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg22105103	chr4:187893119	NA	0.35	4.89	0.4	3.02e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2067615	0.599	rs10778508	chr12:107159405	A/G	cg15890332	chr12:107067104	RFX4	-0.28	-5.64	-0.45	1.11e-7	Heart rate;
TGCT	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg10047753	chr17:41438598	NA	0.6	5.49	0.44	2.13e-7	Menopause (age at onset);
TGCT	cis	rs2797160	1.000	rs1739357	chr6:126019655	T/G	cg05901451	chr6:126070800	HEY2	0.71	6.28	0.49	5.26e-9	Endometrial cancer;
TGCT	cis	rs1577917	0.740	rs7752502	chr6:86410651	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.57	5.26	0.43	6.07e-7	Response to antipsychotic treatment;
TGCT	cis	rs7659604	0.605	rs1396080	chr4:122740454	T/G	cg06713675	chr4:122721982	EXOSC9	-0.63	-8.74	-0.62	1.39e-14	Type 2 diabetes;
TGCT	cis	rs807669	0.524	rs11089258	chr22:19162276	C/T	cg02655711	chr22:19163373	SLC25A1	0.26	5.06	0.41	1.45e-6	Metabolite levels;
TGCT	cis	rs79996792	1.000	rs79996792	chr2:162443934	A/C	cg22496339	chr2:162101262	NA	0.55	4.53	0.38	1.37e-5	Neuroticism;
TGCT	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg07167872	chr1:205819463	PM20D1	0.57	6.98	0.53	1.59e-10	Menarche (age at onset);
TGCT	cis	rs17125944	0.686	rs7141335	chr14:53336934	C/T	cg00686598	chr14:53173677	PSMC6	-0.87	-4.5	-0.37	1.53e-5	Alzheimer's disease (late onset);
TGCT	cis	rs9902453	0.838	rs7217638	chr17:28336772	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.74	-6.59	-0.51	1.12e-9	Coffee consumption (cups per day);
TGCT	cis	rs9913156	0.639	rs72824971	chr17:4604270	A/G	cg00122941	chr17:4613640	ARRB2	0.89	7.59	0.56	6.61e-12	Lymphocyte counts;
TGCT	cis	rs7824557	0.591	rs2572452	chr8:11228254	C/T	cg21775007	chr8:11205619	TDH	-0.72	-7.46	-0.56	1.32e-11	Retinal vascular caliber;
TGCT	cis	rs9296092	0.538	rs115770720	chr6:33517032	A/T	cg13560919	chr6:33536144	NA	-0.21	-4.74	-0.39	5.87e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs7666738	0.830	rs10470951	chr4:99037051	G/A	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs929354	0.772	rs1182444	chr7:157024510	A/G	cg05182265	chr7:156933206	UBE3C	0.4	9.05	0.63	2.54e-15	Body mass index;
TGCT	trans	rs931812	0.825	rs34153562	chr8:101893441	T/C	cg20993868	chr7:22813445	NA	0.42	9.03	0.63	2.75e-15	Attention deficit hyperactivity disorder and conduct disorder;
TGCT	cis	rs7528684	0.872	rs6681271	chr1:157666644	A/G	cg17134153	chr1:157670328	FCRL3	-0.25	-4.68	-0.39	7.31e-6	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;
TGCT	cis	rs2762353	0.574	rs9467574	chr6:25705718	C/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.73	7.52	0.56	9.57e-12	Blood metabolite levels;
TGCT	cis	rs10791323	0.572	rs4353292	chr11:133742656	A/G	cg15485101	chr11:133734466	NA	0.42	6.13	0.48	1.09e-8	Childhood ear infection;
TGCT	cis	rs4268898	0.722	rs12185638	chr2:24382030	C/G	cg02683114	chr2:24398427	C2orf84	0.19	4.57	0.38	1.14e-5	Asthma;
TGCT	cis	rs79349575	0.715	rs9894220	chr17:46989154	C/T	cg26022315	chr17:47021804	SNF8	0.54	5.31	0.43	4.96e-7	Type 2 diabetes;
TGCT	cis	rs72615157	0.645	rs11771660	chr7:99851269	T/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.65	5.01	0.41	1.84e-6	Lung function (FEV1/FVC);
TGCT	cis	rs12497850	0.931	rs4974085	chr3:48924900	C/T	cg06212747	chr3:49208901	KLHDC8B	0.62	5.83	0.46	4.42e-8	Parkinson's disease;
TGCT	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg13395646	chr4:1353034	KIAA1530	-0.38	-4.72	-0.39	6.28e-6	Obesity-related traits;
TGCT	cis	rs10984561	0.881	rs12235956	chr9:122227703	G/A	cg14242995	chr9:122249943	NA	0.73	6.32	0.49	4.34e-9	Pulmonary function decline;
TGCT	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg18402987	chr7:1209562	NA	0.74	6.21	0.49	7.23e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1043515	0.607	rs4795318	chr17:36949053	C/T	cg20826740	chr17:37024042	NA	0.43	4.45	0.37	1.87e-5	Height;
TGCT	cis	rs7586879	0.616	rs12713422	chr2:25134497	A/C	cg01884057	chr2:25150051	NA	0.36	7.1	0.54	8.63e-11	Body mass index;
TGCT	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg11247378	chr22:39784982	NA	-0.73	-9.62	-0.65	1.05e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs9303401	0.614	rs12948536	chr17:56580413	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.71	6.78	0.52	4.45e-10	Cognitive test performance;
TGCT	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg05025164	chr4:1340916	KIAA1530	0.78	6.86	0.52	2.86e-10	Longevity;
TGCT	cis	rs9913156	0.793	rs56020376	chr17:4560909	A/G	cg23387401	chr17:4582204	PELP1	0.31	4.57	0.38	1.14e-5	Lymphocyte counts;
TGCT	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg10411590	chr13:21900810	NA	0.34	4.75	0.39	5.46e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	cis	rs9473924	0.542	rs6901576	chr6:50926064	G/T	cg14470998	chr6:50812995	TFAP2B	-1.26	-7.3	-0.55	3.1e-11	Body mass index;
TGCT	cis	rs137603	0.966	rs137585	chr22:39683444	G/A	cg17798944	chr22:39715225	SNORD43;RPL3	-0.56	-5.14	-0.42	1.05e-6	Primary biliary cholangitis;
TGCT	trans	rs9383153	1.000	rs2073518	chr6:16332730	T/C	cg16722931	chr17:75312494	SEPT9	1.11	6.67	0.51	7.75e-10	Gambling;
TGCT	cis	rs1062177	1.000	rs2964612	chr5:151198750	G/A	cg00977110	chr5:151150581	G3BP1	0.4	4.5	0.38	1.51e-5	Preschool internalizing problems;
TGCT	cis	rs4689388	0.926	rs10937717	chr4:6295087	T/A	cg14416269	chr4:6271139	WFS1	0.39	5.05	0.41	1.56e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs3771570	1.000	rs73018141	chr2:242221570	G/A	cg21155796	chr2:242212141	HDLBP	0.98	6.68	0.51	7.29e-10	Prostate cancer;
TGCT	cis	rs61524473	1	rs61524473	chr15:45646283	T/C	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.62e-8	Metabolite levels (small molecules and protein measures);
TGCT	cis	rs3087591	0.960	rs2952976	chr17:29486152	G/A	cg24425628	chr17:29625626	OMG;NF1	0.48	7.48	0.56	1.16e-11	Hip circumference;
TGCT	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg18876405	chr7:65276391	NA	0.35	5.2	0.42	8.09e-7	Aortic root size;
TGCT	cis	rs7824557	0.564	rs2736302	chr8:11236419	T/C	cg21775007	chr8:11205619	TDH	-0.65	-6.39	-0.5	3.07e-9	Retinal vascular caliber;
TGCT	cis	rs2456568	0.805	rs2032400	chr11:93676937	G/A	cg16099599	chr11:93583650	C11orf90	-0.38	-4.56	-0.38	1.2e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs1552244	0.882	rs9812006	chr3:10022658	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.62	-0.51	9.94e-10	Alzheimer's disease;
TGCT	cis	rs12497850	0.931	rs7621015	chr3:49016056	A/G	cg07636037	chr3:49044803	WDR6	0.96	10.39	0.68	1.45e-18	Parkinson's disease;
TGCT	cis	rs3806843	0.576	rs246009	chr5:140338069	A/G	cg09824255	chr5:140014002	CD14	-0.25	-4.58	-0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs916888	0.821	rs70602	chr17:44859715	T/C	cg01570182	chr17:44337453	NA	-1.01	-9.1	-0.63	1.83e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs12210905	0.688	rs72839479	chr6:27332910	G/A	cg08851530	chr6:28072375	NA	1.25	5.39	0.44	3.38e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs896854	0.684	rs10099059	chr8:95986972	G/C	cg16049864	chr8:95962084	TP53INP1	-0.7	-9.94	-0.67	1.76e-17	Type 2 diabetes;
TGCT	cis	rs7312933	0.533	rs3747557	chr12:42717961	G/T	cg19980929	chr12:42632907	YAF2	-0.41	-5.76	-0.46	6.3e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg20637647	chr7:64974828	NA	0.89	4.95	0.41	2.37e-6	Diabetic kidney disease;
TGCT	cis	rs6163	0.508	rs11191381	chr10:104493444	C/T	cg05855489	chr10:104503620	C10orf26	0.56	4.46	0.37	1.78e-5	Waist circumference;Hip circumference;
TGCT	cis	rs10031466	1.000	rs2279550	chr4:189012728	G/C	cg04086012	chr4:189060900	TRIML1	-0.2	-4.54	-0.38	1.31e-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs28595532	0.920	rs115430947	chr4:119737149	C/A	cg11846333	chr4:119757529	SEC24D	0.93	4.44	0.37	2e-5	Cannabis dependence symptom count;
TGCT	cis	rs78487399	0.808	rs77527404	chr2:43678387	C/T	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.72	4.62	0.38	9.53e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs9928842	0.882	rs1107593	chr16:75261329	G/C	cg09066997	chr16:75300724	BCAR1	0.28	5.01	0.41	1.85e-6	Alcoholic chronic pancreatitis;
TGCT	cis	rs2120019	1.000	rs7175720	chr15:75348962	C/G	cg17294928	chr15:75287854	SCAMP5	0.77	5.82	0.46	4.78e-8	Blood trace element (Zn levels);
TGCT	trans	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg17470723	chr8:74884337	TCEB1	0.75	7.11	0.54	8.2e-11	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7246657	0.722	rs1291	chr19:38229378	G/A	cg03611452	chr19:38183253	ZNF781	-0.6	-5.03	-0.41	1.69e-6	Coronary artery calcification;
TGCT	cis	rs6669919	0.647	rs894985	chr1:211673760	A/G	cg26515805	chr1:211431828	RCOR3	-0.48	-4.87	-0.4	3.27e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7014346	0.736	rs3847136	chr8:128407190	A/G	cg04263511	chr8:128962092	PVT1	-0.38	-4.86	-0.4	3.42e-6	Colorectal cancer;
TGCT	cis	rs11105298	0.891	rs11105302	chr12:89891366	A/G	cg00757033	chr12:89920650	WDR51B	-0.32	-4.97	-0.41	2.17e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg03352830	chr11:487213	PTDSS2	-0.26	-4.65	-0.39	8.4e-6	Body mass index;
TGCT	cis	rs17767294	0.541	rs72845042	chr6:27568734	A/T	cg08851530	chr6:28072375	NA	1.34	6.29	0.49	5.02e-9	Parkinson's disease;
TGCT	cis	rs10992471	0.528	rs10992347	chr9:95220633	C/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.52	-4.91	-0.4	2.8e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs9581857	0.685	rs10467687	chr13:28036516	G/A	cg22138327	chr13:27999177	GTF3A	0.72	5.0	0.41	1.94e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs950776	0.613	rs12915539	chr15:78940795	T/A	cg03762349	chr15:79060523	ADAMTS7	0.28	5.5	0.44	2.11e-7	Sudden cardiac arrest;
TGCT	cis	rs910187	0.678	rs1046659	chr20:45817068	G/A	cg27589058	chr20:45804311	EYA2	-0.32	-6.89	-0.53	2.51e-10	Migraine;
TGCT	cis	rs853679	0.546	rs200989	chr6:27816442	A/G	cg10876282	chr6:28092338	ZSCAN16	0.74	4.44	0.37	1.98e-5	Depression;
TGCT	trans	rs11088226	0.645	rs7281844	chr21:33932435	T/C	cg09050820	chr6:167586206	TCP10L2	0.76	6.79	0.52	4.22e-10	Gastritis;
TGCT	cis	rs72781680	0.752	rs55859418	chr2:23904231	C/A	cg08917208	chr2:24149416	ATAD2B	1.0	5.56	0.45	1.59e-7	Lymphocyte counts;
TGCT	cis	rs3008870	0.536	rs2208576	chr1:67513401	C/G	cg02640540	chr1:67518911	SLC35D1	-0.58	-5.57	-0.45	1.53e-7	Lymphocyte percentage of white cells;
TGCT	cis	rs9303401	0.659	rs34275691	chr17:56736640	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg26039829	chr8:22132926	PIWIL2	-0.26	-5.05	-0.41	1.56e-6	Hypertriglyceridemia;
TGCT	cis	rs11711311	1.000	rs12637066	chr3:113527574	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.76	-7.16	-0.54	6.29e-11	IgG glycosylation;
TGCT	cis	rs9914988	0.832	rs35033748	chr17:27179590	T/C	cg20469991	chr17:27169893	C17orf63	-0.68	-5.0	-0.41	1.92e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	trans	rs11088226	0.681	rs2833899	chr21:33933263	T/C	cg09050820	chr6:167586206	TCP10L2	0.79	7.04	0.53	1.13e-10	Gastritis;
TGCT	cis	rs2228479	0.850	rs117880578	chr16:89910230	C/G	cg06558623	chr16:89946397	TCF25	0.55	4.86	0.4	3.55e-6	Skin colour saturation;
TGCT	cis	rs12477438	0.561	rs2084988	chr2:99655755	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-4.88	-0.4	3.17e-6	Chronic sinus infection;
TGCT	trans	rs2727020	0.587	rs1164658	chr11:49298551	C/A	cg15704280	chr7:45808275	SEPT13	0.72	8.25	0.6	1.92e-13	Coronary artery disease;
TGCT	cis	rs7312933	0.670	rs2406568	chr12:42552297	G/C	cg19980929	chr12:42632907	YAF2	0.47	6.46	0.5	2.13e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs4319547	0.915	rs11058402	chr12:122981053	A/G	cg23029597	chr12:123009494	RSRC2	-0.29	-4.87	-0.4	3.34e-6	Body mass index;
TGCT	cis	rs55794721	0.509	rs2375313	chr1:25748235	G/A	cg09222892	chr1:25734099	RHCE	-0.41	-6.56	-0.51	1.31e-9	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg11941060	chr3:133502564	NA	0.26	5.34	0.43	4.19e-7	Iron status biomarkers;
TGCT	cis	rs3806843	1.000	rs3733707	chr5:140181892	T/C	cg19875535	chr5:140030758	IK	0.36	6.09	0.48	1.33e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs950169	0.922	rs12906983	chr15:84931022	G/A	cg17173187	chr15:85201210	NMB	0.6	6.05	0.48	1.62e-8	Schizophrenia;
TGCT	cis	rs9818758	0.607	rs12185979	chr3:49651970	C/G	cg08550065	chr3:50336684	HYAL3;NAT6	1.15	4.5	0.37	1.53e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs7180079	0.514	rs6494488	chr15:65024204	G/A	cg03791955	chr15:65024147	NA	0.28	5.52	0.44	1.93e-7	Monocyte count;
TGCT	cis	rs10782582	0.593	rs74090712	chr1:76189098	A/G	cg10523679	chr1:76189770	ACADM	-0.65	-6.58	-0.51	1.2e-9	Daytime sleep phenotypes;
TGCT	cis	rs7267979	1.000	rs2258719	chr20:25275843	C/T	cg03522245	chr20:25566470	NINL	0.63	6.79	0.52	4.05e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg11764359	chr7:65958608	NA	0.59	5.28	0.43	5.53e-7	Aortic root size;
TGCT	cis	rs12887734	0.524	rs17791722	chr14:104286210	C/T	cg26031613	chr14:104095156	KLC1	-0.7	-6.04	-0.48	1.67e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9611565	0.918	rs12484074	chr22:41752747	G/A	cg06634786	chr22:41940651	POLR3H	-0.96	-8.69	-0.62	1.83e-14	Vitiligo;
TGCT	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg24549020	chr5:56110836	MAP3K1	0.67	5.89	0.47	3.33e-8	Initial pursuit acceleration;
TGCT	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-6.74	-0.52	5.26e-10	Alzheimer's disease;
TGCT	cis	rs7727544	0.582	rs3805683	chr5:131535125	T/G	cg24060327	chr5:131705240	SLC22A5	-0.44	-4.5	-0.37	1.56e-5	Blood metabolite levels;
TGCT	trans	rs35851103	0.600	rs4841662	chr8:11843758	A/G	cg15556689	chr8:8085844	FLJ10661	-0.81	-8.46	-0.6	6.38e-14	Neuroticism;
TGCT	cis	rs28595532	0.668	rs58467651	chr4:119349011	T/G	cg21605333	chr4:119757512	SEC24D	0.95	5.81	0.46	4.92e-8	Cannabis dependence symptom count;
TGCT	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs3820068	0.608	rs12091750	chr1:16042766	T/C	cg05660106	chr1:15850417	CASP9	0.69	6.45	0.5	2.28e-9	Systolic blood pressure;
TGCT	cis	rs7666738	0.791	rs11729596	chr4:99045461	A/G	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs1814175	0.745	rs7483456	chr11:49774613	C/T	cg15704280	chr7:45808275	SEPT13	-0.69	-8.05	-0.59	5.61e-13	Height;
TGCT	cis	rs16866061	0.517	rs7580488	chr2:225473263	C/T	cg22455342	chr2:225449267	CUL3	0.56	4.88	0.4	3.17e-6	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg03517284	chr6:25882590	NA	-0.72	-6.58	-0.51	1.19e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs12478296	1.000	rs66612947	chr2:243035962	A/T	cg06360820	chr2:242988706	NA	-0.61	-4.75	-0.39	5.52e-6	Obesity-related traits;
TGCT	cis	rs2066819	1.000	rs75754909	chr12:56726349	A/G	cg26714650	chr12:56694279	CS	-1.36	-6.06	-0.48	1.54e-8	Psoriasis vulgaris;
TGCT	cis	rs250677	0.687	rs1422581	chr5:148437386	C/T	cg18129178	chr5:148520854	ABLIM3	0.42	6.16	0.48	9.34e-9	Breast cancer;
TGCT	cis	rs9467711	0.559	rs12176129	chr6:26514940	C/T	cg16898833	chr6:26189333	HIST1H4D	1.04	5.4	0.44	3.34e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg18876405	chr7:65276391	NA	-0.38	-5.88	-0.47	3.53e-8	Aortic root size;
TGCT	cis	rs875971	0.628	rs6974355	chr7:65841981	A/G	cg00343986	chr7:65444356	GUSB	0.22	4.69	0.39	7.21e-6	Aortic root size;
TGCT	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg00343986	chr7:65444356	GUSB	-0.2	-4.51	-0.38	1.51e-5	Aortic root size;
TGCT	cis	rs370915	0.564	rs10027461	chr4:187837608	T/C	cg19519643	chr4:187840862	NA	-0.23	-4.62	-0.38	9.63e-6	Gout;
TGCT	cis	rs11924390	0.749	rs822364	chr3:186452716	A/G	cg12454167	chr3:186435060	KNG1	0.44	6.91	0.53	2.24e-10	Adiponectin levels;
TGCT	cis	rs7666738	0.830	rs1115616	chr4:99006603	A/C	cg17366294	chr4:99064904	C4orf37	0.71	7.3	0.55	3.08e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11651000	0.857	rs57171311	chr17:45826168	A/G	cg06532163	chr17:45867833	NA	0.37	5.23	0.43	6.97e-7	IgG glycosylation;
TGCT	trans	rs2760061	0.659	rs708107	chr1:228189495	C/T	cg16006296	chr10:38738647	LOC399744	-0.31	-6.97	-0.53	1.67e-10	Diastolic blood pressure;
TGCT	cis	rs9457247	0.508	rs6941355	chr6:167506238	A/G	cg07741184	chr6:167504864	NA	0.26	5.12	0.42	1.16e-6	Crohn's disease;
TGCT	cis	rs10782582	0.593	rs4646960	chr1:76211103	C/A	cg03433033	chr1:76189801	ACADM	-0.6	-6.63	-0.51	9.16e-10	Daytime sleep phenotypes;
TGCT	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg03188948	chr7:1209495	NA	0.49	4.68	0.39	7.33e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7582180	0.629	rs11693471	chr2:100948062	G/A	cg08017756	chr2:100939284	LONRF2	-0.29	-4.63	-0.38	9.13e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6933660	0.646	rs6911456	chr6:151778934	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.49	4.68	0.39	7.39e-6	Menarche (age at onset);
TGCT	trans	rs12599106	0.629	rs1391904	chr16:34548934	C/T	cg26668828	chr6:292823	DUSP22	-0.78	-8.15	-0.59	3.38e-13	Menopause (age at onset);
TGCT	cis	rs7914558	1.000	rs6584540	chr10:104927634	A/G	cg05855489	chr10:104503620	C10orf26	0.5	4.47	0.37	1.71e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs6061231	0.597	rs624313	chr20:60927412	G/A	cg06026331	chr20:60912101	LAMA5	-0.26	-4.69	-0.39	7.23e-6	Colorectal cancer;
TGCT	cis	rs7582180	0.591	rs62148360	chr2:101006319	C/T	cg08017756	chr2:100939284	LONRF2	-0.3	-4.73	-0.39	6.06e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs11098499	0.874	rs6826823	chr4:120112098	G/C	cg09307838	chr4:120376055	NA	0.5	4.64	0.38	8.86e-6	Corneal astigmatism;
TGCT	cis	rs597539	0.552	rs10792006	chr11:68722306	T/C	cg21862992	chr11:68658383	NA	-0.34	-5.14	-0.42	1.03e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg11764359	chr7:65958608	NA	-0.55	-5.08	-0.42	1.34e-6	Aortic root size;
TGCT	cis	rs7666738	0.791	rs7660866	chr4:98961335	G/A	cg05340658	chr4:99064831	C4orf37	0.53	5.93	0.47	2.85e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6121246	0.909	rs6119725	chr20:30385557	G/T	cg18721089	chr20:30220636	NA	-0.43	-4.75	-0.39	5.54e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.51	-4.74	-0.39	5.85e-6	Electroencephalogram traits;
TGCT	cis	rs7085104	0.700	rs10883785	chr10:104603588	A/G	cg15744005	chr10:104629667	AS3MT	-0.42	-5.28	-0.43	5.69e-7	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg05368731	chr17:41323189	NBR1	1.1	11.12	0.71	2.38e-20	Menopause (age at onset);
TGCT	cis	rs3617	0.625	rs7612624	chr3:52893426	T/C	cg11645453	chr3:52864694	ITIH4	-0.29	-5.68	-0.45	9.09e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1801251	1.000	rs6746294	chr2:233583050	C/G	cg08000102	chr2:233561755	GIGYF2	-0.57	-5.56	-0.45	1.58e-7	Coronary artery disease;
TGCT	cis	rs858239	0.600	rs10233039	chr7:23143113	G/A	cg05602783	chr7:23145260	KLHL7	-0.66	-5.45	-0.44	2.57e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs10883723	0.810	rs7917525	chr10:104246755	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg04772025	chr11:68637568	NA	0.6	6.78	0.52	4.26e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs1865760	0.964	rs6932113	chr6:25913098	C/T	cg17042849	chr6:26104293	HIST1H4C	-0.52	-4.68	-0.39	7.33e-6	Height;
TGCT	cis	rs651907	0.535	rs34063583	chr3:101509948	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	4.85	0.4	3.68e-6	Colorectal cancer;
TGCT	cis	rs28595532	0.582	rs71608361	chr4:119224081	T/C	cg21605333	chr4:119757512	SEC24D	0.75	4.58	0.38	1.1e-5	Cannabis dependence symptom count;
TGCT	cis	rs2204008	0.744	rs67889662	chr12:38327042	T/A	cg26384229	chr12:38710491	ALG10B	0.83	7.29	0.55	3.15e-11	Bladder cancer;
TGCT	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg27425262	chr2:113953981	PSD4;LOC440839	0.4	5.17	0.42	9.05e-7	Lymphocyte counts;
TGCT	cis	rs9913156	0.793	rs11655166	chr17:4559302	T/A	cg00122941	chr17:4613640	ARRB2	-0.88	-7.44	-0.56	1.46e-11	Lymphocyte counts;
TGCT	cis	rs8050907	0.744	rs12446765	chr16:4569625	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.58	4.74	0.39	5.67e-6	Obesity-related traits;
TGCT	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg00343986	chr7:65444356	GUSB	-0.23	-5.16	-0.42	9.66e-7	Aortic root size;
TGCT	cis	rs778371	0.676	rs7560115	chr2:233709465	T/G	cg08000102	chr2:233561755	GIGYF2	-0.67	-7.64	-0.57	5.21e-12	Schizophrenia;
TGCT	cis	rs698813	0.573	rs6544750	chr2:44490780	T/C	cg00619915	chr2:44497795	NA	-0.24	-5.5	-0.44	2.05e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
TGCT	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg25767906	chr1:53392781	SCP2	0.49	5.77	0.46	5.88e-8	Monocyte count;
TGCT	cis	rs7267979	1.000	rs6050573	chr20:25366065	C/G	cg16686733	chr20:25566563	NINL	0.6	6.07	0.48	1.45e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9372498	0.536	rs9489460	chr6:118925754	C/T	cg21191810	chr6:118973309	C6orf204	-0.38	-4.97	-0.41	2.14e-6	Diastolic blood pressure;
TGCT	cis	rs11578119	0.933	rs12140161	chr1:170444010	A/G	cg09767346	chr1:170501363	GORAB	0.71	5.68	0.45	9.07e-8	Male-pattern baldness;
TGCT	cis	rs4654899	0.965	rs6692081	chr1:21296363	T/C	cg01072550	chr1:21505969	NA	-0.5	-7.94	-0.58	1.04e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.96	-8.31	-0.6	1.43e-13	Platelet count;
TGCT	cis	rs2439831	0.702	rs2788	chr15:44064886	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	5.91	0.47	3.05e-8	Lung cancer in ever smokers;
TGCT	cis	rs682748	0.810	rs6893113	chr5:17112370	A/G	cg23987134	chr5:17158319	LOC285696	-0.21	-4.91	-0.4	2.78e-6	Hippocampal atrophy;
TGCT	cis	rs10782582	0.593	rs12126155	chr1:76131555	C/G	cg22875332	chr1:76189707	ACADM	-0.55	-6.27	-0.49	5.53e-9	Daytime sleep phenotypes;
TGCT	cis	rs986417	1.000	rs1018531	chr14:60970844	C/T	cg27398547	chr14:60952738	C14orf39	1.39	10.61	0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs6880778	0.505	rs13186168	chr5:40376047	T/A	cg01087697	chr5:40835557	RPL37	0.53	4.67	0.39	7.65e-6	Inflammatory bowel disease;
TGCT	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg00786635	chr1:25594202	NA	-0.58	-6.19	-0.49	8.24e-9	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs473651	0.935	rs477041	chr2:239355995	C/G	cg18131467	chr2:239335373	ASB1	-1.03	-15.58	-0.81	5.46e-31	Multiple system atrophy;
TGCT	cis	rs6733011	0.578	rs4851170	chr2:99504323	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.49	4.67	0.39	7.81e-6	Bipolar disorder;
TGCT	cis	rs12477438	0.520	rs6756650	chr2:99801800	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	17.43	0.84	3.73e-35	Chronic sinus infection;
TGCT	cis	rs11874712	1.000	rs9962458	chr18:43678625	G/C	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	5.12	0.42	1.11e-6	Migraine - clinic-based;
TGCT	cis	rs9549260	0.755	rs7328677	chr13:41229905	A/G	cg21288729	chr13:41239152	FOXO1	1.01	10.71	0.69	2.36e-19	Red blood cell count;
TGCT	cis	rs4242434	0.597	rs11985023	chr8:22531463	C/T	cg03733263	chr8:22462867	KIAA1967	-1.03	-14.0	-0.78	2.7e-27	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs5769707	0.967	rs1018812	chr22:50010073	C/T	cg05373962	chr22:49881684	NA	-0.3	-6.1	-0.48	1.22e-8	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.66	-6.41	-0.5	2.71e-9	Menarche (age at onset);
TGCT	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.54	4.47	0.37	1.77e-5	Tonsillectomy;
TGCT	cis	rs9611565	1.000	rs5751086	chr22:41768862	C/T	cg03806693	chr22:41940476	POLR3H	-0.88	-9.56	-0.65	1.5e-16	Vitiligo;
TGCT	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg10802521	chr3:52805072	NEK4	-0.71	-8.79	-0.62	1.04e-14	Bipolar disorder;
TGCT	cis	rs2832191	1.000	rs6516891	chr21:30483070	C/T	cg24692254	chr21:30365293	RNF160	-0.83	-8.72	-0.62	1.56e-14	Dental caries;
TGCT	cis	rs7666738	0.830	rs10000573	chr4:99048785	G/C	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12935418	0.616	rs8045512	chr16:80986307	A/G	cg07676361	chr16:80966860	NA	-0.35	-4.7	-0.39	6.87e-6	Mean corpuscular volume;
TGCT	cis	rs931608	0.585	rs55851405	chr19:22541686	T/C	cg23859931	chr19:22123797	NA	-0.65	-4.81	-0.4	4.37e-6	Dental caries;Response to statins (LDL cholesterol change);
TGCT	cis	rs933688	1.000	rs11950530	chr5:90688740	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.99	8.15	0.59	3.39e-13	Smoking behavior;
TGCT	cis	rs9467711	0.606	rs2072803	chr6:26392515	G/C	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.69	-0.39	7.03e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2439831	1.000	rs689754	chr15:43775895	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	5.26	0.43	6.09e-7	Lung cancer in ever smokers;
TGCT	cis	rs4372836	0.704	rs966250	chr2:28974139	G/T	cg09522027	chr2:28974177	PPP1CB	-0.63	-6.25	-0.49	6.12e-9	Body mass index;
TGCT	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg23758822	chr17:41437982	NA	0.72	6.81	0.52	3.83e-10	Menopause (age at onset);
TGCT	cis	rs539096	0.781	rs2916568	chr1:44091274	A/G	cg12908607	chr1:44402522	ARTN	-0.54	-5.68	-0.45	8.9e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7223966	1.000	rs2854219	chr17:61942682	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	4.62	0.38	9.63e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs6809651	0.524	rs10937240	chr3:185802823	C/T	cg00760338	chr3:185826511	ETV5	-0.79	-6.45	-0.5	2.23e-9	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
TGCT	cis	rs17102884	0.506	rs887746	chr14:75403817	C/T	cg08847533	chr14:75593920	NEK9	-0.61	-5.39	-0.44	3.49e-7	Neuroticism;
TGCT	cis	rs9929218	1.000	rs12921546	chr16:68780069	G/A	cg01251360	chr16:68772225	CDH1	0.29	4.87	0.4	3.27e-6	Colorectal cancer;
TGCT	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg19774624	chr17:42201019	HDAC5	0.88	10.92	0.7	7.5e-20	Total body bone mineral density;
TGCT	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg25703541	chr22:24373054	LOC391322	-0.96	-12.23	-0.74	4.64e-23	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs651907	0.557	rs62284199	chr3:101478531	T/G	cg11279151	chr3:101281821	RG9MTD1	-0.33	-6.83	-0.52	3.35e-10	Colorectal cancer;
TGCT	cis	rs13191362	0.872	rs13215538	chr6:163037975	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.07	8.5	0.61	5.17e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs9467711	0.516	rs548987	chr6:25869371	C/G	cg03517284	chr6:25882590	NA	-0.69	-4.6	-0.38	1.02e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs3820928	0.874	rs10199655	chr2:227892428	T/C	cg11843606	chr2:227700838	RHBDD1	-0.54	-4.96	-0.41	2.29e-6	Pulmonary function;
TGCT	cis	rs9467711	0.606	rs13203358	chr6:26590578	A/T	cg16898833	chr6:26189333	HIST1H4D	1.02	5.25	0.43	6.32e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs11696501	0.739	rs4812933	chr20:44230792	C/A	cg11783356	chr20:44313418	WFDC10B	-0.33	-4.79	-0.4	4.67e-6	Brain structure;
TGCT	cis	rs950169	0.922	rs12911223	chr15:84831671	G/A	cg17173187	chr15:85201210	NMB	-0.54	-5.52	-0.44	1.87e-7	Schizophrenia;
TGCT	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs548987	0.529	rs1165165	chr6:25862466	C/T	cg03264133	chr6:25882463	NA	-0.58	-4.84	-0.4	3.79e-6	Homocysteine levels;
TGCT	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg19318889	chr4:1322082	MAEA	-0.2	-5.12	-0.42	1.13e-6	Obesity-related traits;
TGCT	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg25767906	chr1:53392781	SCP2	0.5	5.85	0.46	4.15e-8	Monocyte count;
TGCT	cis	rs12701220	0.894	rs34712249	chr7:1036634	C/T	cg27454412	chr7:1067447	C7orf50	-0.48	-4.47	-0.37	1.75e-5	Bronchopulmonary dysplasia;
TGCT	cis	rs13102973	0.720	rs67429820	chr4:135888003	G/A	cg14419869	chr4:135874104	NA	0.26	4.67	0.39	7.77e-6	Subjective well-being;
TGCT	cis	rs2013441	1.000	rs2703791	chr17:20163529	A/G	cg18979559	chr17:20280153	CCDC144C	-0.45	-4.67	-0.39	7.61e-6	Obesity-related traits;
TGCT	cis	rs1062177	0.756	rs2915826	chr5:151119963	G/A	cg12924095	chr5:151150029	G3BP1	-0.34	-4.97	-0.41	2.17e-6	Preschool internalizing problems;
TGCT	cis	rs11190604	1.000	rs2489049	chr10:102350732	G/A	cg23241863	chr10:102295624	HIF1AN	0.71	5.36	0.43	3.84e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2204008	0.693	rs12372025	chr12:38202028	G/A	cg13010199	chr12:38710504	ALG10B	0.65	5.14	0.42	1.03e-6	Bladder cancer;
TGCT	cis	rs2236918	0.710	rs2526698	chr1:242029101	T/C	cg04158730	chr1:242011433	EXO1	0.56	5.2	0.42	8.05e-7	Menopause (age at onset);
TGCT	cis	rs8028182	0.636	rs6495182	chr15:75814388	C/T	cg20655648	chr15:75932815	IMP3	0.6	4.66	0.39	7.91e-6	Sudden cardiac arrest;
TGCT	cis	rs950027	0.620	rs1153862	chr15:45631868	A/G	cg14582100	chr15:45693742	SPATA5L1	0.47	6.02	0.48	1.8e-8	Response to fenofibrate (adiponectin levels);
TGCT	trans	rs1814175	0.817	rs10769641	chr11:49960141	A/G	cg03929089	chr4:120376271	NA	-0.72	-8.53	-0.61	4.24e-14	Height;
TGCT	cis	rs950169	0.544	rs12913702	chr15:85153184	G/A	cg17173187	chr15:85201210	NMB	0.53	5.88	0.47	3.53e-8	Schizophrenia;
TGCT	cis	rs1129187	0.782	rs9462860	chr6:42947013	G/C	cg09436375	chr6:42928200	GNMT	-0.42	-5.53	-0.44	1.78e-7	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs6061231	0.546	rs482220	chr20:60927482	G/A	cg06026331	chr20:60912101	LAMA5	-0.26	-4.69	-0.39	7.23e-6	Colorectal cancer;
TGCT	cis	rs6688613	1.000	rs10918606	chr1:166957249	A/G	cg07049167	chr1:166818506	POGK	0.21	4.52	0.38	1.43e-5	Refractive astigmatism;
TGCT	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg03806693	chr22:41940476	POLR3H	0.99	11.15	0.71	2.05e-20	Vitiligo;
TGCT	cis	rs9926296	0.607	rs11076629	chr16:89875259	T/C	cg04287289	chr16:89883240	FANCA	0.72	6.98	0.53	1.61e-10	Vitiligo;
TGCT	cis	rs6558530	0.836	rs7461159	chr8:1716616	A/T	cg09410841	chr8:1729607	CLN8	0.93	10.34	0.68	1.93e-18	Systolic blood pressure;
TGCT	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	5.79	0.46	5.43e-8	Bipolar disorder;
TGCT	cis	rs3820068	0.705	rs4646085	chr1:15825411	A/T	cg05660106	chr1:15850417	CASP9	1.16	14.82	0.8	3.11e-29	Systolic blood pressure;
TGCT	trans	rs2727020	0.615	rs4980435	chr11:49591576	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.36	-7.05	-0.53	1.11e-10	Coronary artery disease;
TGCT	cis	rs17102884	0.506	rs4899541	chr14:75403437	T/G	cg08847533	chr14:75593920	NEK9	-0.62	-5.5	-0.44	2.09e-7	Neuroticism;
TGCT	cis	rs11748684	1.000	rs72754917	chr5:42531009	G/C	cg01169772	chr5:41904236	C5orf51	-0.9	-4.48	-0.37	1.67e-5	Response to taxane treatment (docetaxel);
TGCT	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg16680214	chr1:154839983	KCNN3	0.42	9.26	0.64	7.57e-16	Prostate cancer;
TGCT	cis	rs8033133	0.881	rs4344720	chr15:25324141	C/T	cg14481604	chr15:25334117	SNORD116-22	-0.31	-6.77	-0.52	4.54e-10	Blood osmolality (transformed sodium);
TGCT	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg06238570	chr21:40685208	BRWD1	0.74	6.6	0.51	1.1e-9	Cognitive function;
TGCT	trans	rs1814175	0.527	rs7110797	chr11:49644096	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.42	-8.27	-0.6	1.72e-13	Height;
TGCT	trans	rs7726839	0.561	rs3915384	chr5:573395	G/T	cg25482853	chr8:67687455	SGK3	1.06	9.11	0.63	1.81e-15	Obesity-related traits;
TGCT	cis	rs2735413	0.564	rs79006334	chr16:78124954	A/G	cg09132178	chr16:78079569	NA	0.35	4.47	0.37	1.77e-5	Systolic blood pressure (alcohol consumption interaction);
TGCT	cis	rs3796352	1.000	rs13091844	chr3:53010271	C/T	cg15956490	chr3:53032818	SFMBT1	0.61	6.76	0.52	4.92e-10	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	6.85	0.52	3.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs76954792	0.826	rs4795637	chr17:30027452	T/C	cg18427091	chr17:30115417	NA	-0.36	-4.67	-0.39	7.61e-6	Coronary artery disease;
TGCT	cis	rs12477438	0.520	rs11692699	chr2:99730657	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.82	0.62	8.67e-15	Chronic sinus infection;
TGCT	cis	rs4665630	0.522	rs2551350	chr2:23913985	T/C	cg08063864	chr2:24346004	PFN4;LOC375190	-1.22	-5.82	-0.46	4.81e-8	Hypertension;
TGCT	cis	rs10193935	0.901	rs6752455	chr2:42543577	A/C	cg27598129	chr2:42591480	NA	-0.41	-5.59	-0.45	1.4e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7100689	0.622	rs10749569	chr10:82129892	G/A	cg01528321	chr10:82214614	TSPAN14	0.8	7.76	0.57	2.7e-12	Post bronchodilator FEV1;
TGCT	cis	rs7647973	0.580	rs12637576	chr3:49237334	C/T	cg05785598	chr3:49045655	WDR6	0.36	4.86	0.4	3.51e-6	Menarche (age at onset);
TGCT	cis	rs2562456	0.833	rs62110428	chr19:21613656	C/T	cg25650185	chr19:21324782	ZNF431	-0.56	-4.45	-0.37	1.88e-5	Pain;
TGCT	cis	rs6969780	0.630	rs3735530	chr7:27189982	C/T	cg11410718	chr7:27170412	HOXA4	-0.46	-4.57	-0.38	1.18e-5	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg12419862	chr22:24373484	LOC391322	0.86	9.94	0.67	1.77e-17	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs936229	0.813	rs4886619	chr15:75106138	C/T	cg10253484	chr15:75165896	SCAMP2	-0.66	-5.34	-0.43	4.28e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
TGCT	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.48	-4.47	-0.37	1.71e-5	Bipolar disorder;
TGCT	cis	rs10771431	0.713	rs17794353	chr12:9361783	C/T	cg08997352	chr12:9597637	DDX12	0.27	5.45	0.44	2.59e-7	Breast size;
TGCT	cis	rs7809950	0.954	rs62482543	chr7:107080656	G/A	cg23024343	chr7:107201750	COG5	-0.35	-5.56	-0.45	1.59e-7	Coronary artery disease;
TGCT	cis	rs610932	0.517	rs673996	chr11:59994152	C/A	cg18570331	chr11:60101691	MS4A6E	0.5	4.55	0.38	1.28e-5	Alzheimer's disease;
TGCT	cis	rs950169	0.881	rs4081123	chr15:84956235	A/G	cg12863693	chr15:85201151	NMB	0.45	4.96	0.41	2.28e-6	Schizophrenia;
TGCT	cis	rs11098499	0.738	rs28408407	chr4:120376030	C/G	cg09307838	chr4:120376055	NA	0.71	6.98	0.53	1.57e-10	Corneal astigmatism;
TGCT	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.12	0.42	1.15e-6	Prudent dietary pattern;
TGCT	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg17971929	chr21:40555470	PSMG1	-0.64	-5.81	-0.46	4.88e-8	Cognitive function;
TGCT	cis	rs72627509	0.523	rs9637714	chr4:57731446	C/T	cg26694713	chr4:57773883	REST	-0.53	-5.5	-0.44	2.1e-7	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.62	-5.11	-0.42	1.17e-6	Tonsillectomy;
TGCT	cis	rs6912958	0.781	rs9450712	chr6:88193175	C/T	cg06598631	chr6:88300029	RARS2;ORC3L	-0.53	-4.85	-0.4	3.69e-6	Monocyte percentage of white cells;
TGCT	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10510102	0.872	rs11814703	chr10:123724289	T/G	cg23691251	chr10:123688108	ATE1	-0.59	-4.7	-0.39	6.75e-6	Breast cancer;
TGCT	cis	rs459571	0.920	rs460154	chr9:136909309	C/T	cg13789015	chr9:136890014	NCRNA00094	0.38	6.91	0.53	2.21e-10	Platelet distribution width;
TGCT	cis	rs17102423	0.594	rs8010213	chr14:65552182	C/T	cg11161011	chr14:65562177	MAX	-0.47	-6.42	-0.5	2.57e-9	Obesity-related traits;
TGCT	cis	rs9359856	0.636	rs1980878	chr6:90314749	A/C	cg13799429	chr6:90582589	CASP8AP2	0.45	4.61	0.38	9.8e-6	Bipolar disorder;
TGCT	cis	rs8056742	0.730	rs35993081	chr16:85098003	G/C	cg00229868	chr16:85520891	NA	0.38	4.77	0.39	5.03e-6	Amyotrophic lateral sclerosis;
TGCT	cis	rs3812831	0.635	rs6560937	chr13:114945991	C/G	cg06611532	chr13:114900021	NA	0.35	6.41	0.5	2.76e-9	Schizophrenia;
TGCT	cis	rs7772486	0.875	rs2814869	chr6:146315509	G/A	cg13319975	chr6:146136371	FBXO30	-0.51	-4.55	-0.38	1.28e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs854765	0.603	rs4506967	chr17:17990474	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.68	7.01	0.53	1.33e-10	Total body bone mineral density;
TGCT	cis	rs2439831	0.681	rs3742969	chr15:43621947	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.02	8.69	0.62	1.84e-14	Lung cancer in ever smokers;
TGCT	trans	rs2970818	0.831	rs2970810	chr12:4608103	A/G	cg03807737	chr6:44242160	TMEM151B	0.31	7.24	0.55	4.22e-11	Phosphorus levels;
TGCT	cis	rs4851266	0.966	rs12987662	chr2:100821548	C/A	cg07810366	chr2:100720526	AFF3	-0.41	-5.82	-0.46	4.72e-8	Educational attainment;
TGCT	cis	rs9611565	0.559	rs8139993	chr22:41995335	T/C	cg03806693	chr22:41940476	POLR3H	-1.01	-10.2	-0.68	4.07e-18	Vitiligo;
TGCT	cis	rs12477438	0.834	rs6757019	chr2:99676936	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-8.52	-0.61	4.5e-14	Chronic sinus infection;
TGCT	cis	rs3771570	0.901	rs3821285	chr2:242421314	A/G	cg21155796	chr2:242212141	HDLBP	-0.89	-6.82	-0.52	3.55e-10	Prostate cancer;
TGCT	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg27588902	chr6:42928151	GNMT	-0.5	-5.79	-0.46	5.54e-8	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs7833790	0.553	rs9693128	chr8:82706128	A/G	cg27398817	chr8:82754497	SNX16	-0.71	-6.08	-0.48	1.34e-8	Diastolic blood pressure;
TGCT	cis	rs9733	0.596	rs72702557	chr1:150680130	A/G	cg04414720	chr1:150670196	GOLPH3L	0.37	4.91	0.4	2.76e-6	Tonsillectomy;
TGCT	cis	rs6967414	0.786	rs9639026	chr7:6746736	A/G	cg00387323	chr7:6746715	ZNF12	0.79	4.8	0.4	4.49e-6	Hematocrit;Hemoglobin concentration;
TGCT	cis	rs6684514	1.000	rs2270291	chr1:156244992	G/C	cg20302342	chr1:156215951	PAQR6	0.34	4.6	0.38	1.01e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs16957091	0.647	rs9920182	chr15:43202550	G/A	cg17935677	chr15:44119062	WDR76	0.52	4.71	0.39	6.44e-6	MGMT methylation in smokers;
TGCT	cis	rs6964587	1.000	rs10228334	chr7:91713972	C/T	cg22709100	chr7:91322751	NA	0.29	4.8	0.4	4.45e-6	Breast cancer;
TGCT	cis	rs9527	0.590	rs7920868	chr10:104795409	C/T	cg04362960	chr10:104952993	NT5C2	0.66	5.57	0.45	1.48e-7	Arsenic metabolism;
TGCT	cis	rs600231	0.598	rs2508712	chr11:65232261	C/G	cg17120908	chr11:65337727	SSSCA1	-0.55	-5.11	-0.42	1.17e-6	Bone mineral density;
TGCT	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6570726	0.791	rs6902410	chr6:145905261	G/A	cg05347473	chr6:146136440	FBXO30	0.52	4.95	0.41	2.33e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs12497850	0.931	rs9311430	chr3:48845251	C/T	cg05785598	chr3:49045655	WDR6	0.35	4.72	0.39	6.35e-6	Parkinson's disease;
TGCT	cis	rs2050392	0.624	rs303444	chr10:30729347	C/T	cg18806716	chr10:30721971	MAP3K8	-0.72	-9.67	-0.66	8.12e-17	Inflammatory bowel disease;
TGCT	cis	rs13256369	1.000	rs12545771	chr8:8567977	C/G	cg17143192	chr8:8559678	CLDN23	0.58	5.55	0.45	1.64e-7	Obesity-related traits;
TGCT	cis	rs524281	0.861	rs7943911	chr11:65943054	G/A	cg00563793	chr11:65837595	PACS1	0.57	4.97	0.41	2.13e-6	Electroencephalogram traits;
TGCT	cis	rs7474896	0.583	rs4934898	chr10:37990395	G/C	cg13720705	chr10:37990370	NA	0.35	5.03	0.41	1.71e-6	Obesity (extreme);
TGCT	cis	rs2153535	0.580	rs7767780	chr6:8453462	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.76	0.46	6.39e-8	Motion sickness;
TGCT	cis	rs7772486	0.875	rs6938972	chr6:146410608	G/A	cg13319975	chr6:146136371	FBXO30	-0.51	-4.48	-0.37	1.69e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7267979	0.844	rs6132824	chr20:25238173	T/C	cg14121845	chr20:25566513	NINL	0.49	4.96	0.41	2.24e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs617219	0.765	rs10053349	chr5:78475423	T/C	cg23987322	chr5:78407566	BHMT	0.37	4.97	0.41	2.18e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs7255045	0.742	rs2305796	chr19:12954141	C/T	cg23899408	chr19:12877188	HOOK2	-0.6	-4.83	-0.4	3.96e-6	Mean corpuscular volume;
TGCT	cis	rs2228479	0.681	rs2270461	chr16:89972345	C/T	cg06558623	chr16:89946397	TCF25	-0.39	-4.98	-0.41	2.07e-6	Skin colour saturation;
TGCT	cis	rs6582630	0.519	rs11181526	chr12:38360230	A/G	cg26384229	chr12:38710491	ALG10B	0.79	6.98	0.53	1.61e-10	Drug-induced liver injury (flucloxacillin);
TGCT	trans	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.86	-9.4	-0.65	3.49e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs2742417	0.967	rs9825559	chr3:45740278	T/C	cg04837898	chr3:45731254	SACM1L	-0.55	-5.68	-0.45	9.14e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs1480597	0.518	rs7893447	chr10:45203776	C/T	cg12063947	chr10:45878068	ALOX5	0.26	4.44	0.37	2e-5	Parkinson's disease;
TGCT	cis	rs12220238	0.722	rs6480743	chr10:76398765	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.64	5.19	0.42	8.46e-7	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs12681288	0.550	rs12549204	chr8:959085	G/T	cg04851639	chr8:1020857	NA	-0.27	-4.44	-0.37	1.94e-5	Schizophrenia;
TGCT	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.0	7.42	0.55	1.64e-11	Gut microbiome composition (summer);
TGCT	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg08509172	chr19:19383838	TM6SF2	-0.36	-4.76	-0.39	5.28e-6	Tonsillectomy;
TGCT	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg22920501	chr2:26401640	FAM59B	-0.78	-6.26	-0.49	5.88e-9	Gut microbiome composition (summer);
TGCT	cis	rs7819412	0.505	rs34031674	chr8:10809490	G/C	cg21775007	chr8:11205619	TDH	-0.62	-5.65	-0.45	1.04e-7	Triglycerides;
TGCT	cis	rs9372498	0.572	rs56082110	chr6:118909480	A/G	cg07617317	chr6:118971624	C6orf204	0.48	5.08	0.42	1.32e-6	Diastolic blood pressure;
TGCT	cis	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg22857025	chr5:266934	NA	-0.34	-6.7	-0.52	6.65e-10	Breast cancer;
TGCT	cis	rs2730245	0.645	rs4909282	chr7:158699797	T/C	cg24397884	chr7:158709396	WDR60	0.35	4.48	0.37	1.65e-5	Height;
TGCT	cis	rs9467603	0.800	rs28360585	chr6:25790356	A/T	cg03517284	chr6:25882590	NA	-0.66	-4.5	-0.37	1.53e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7772486	0.654	rs1011597	chr6:146075672	A/C	cg13319975	chr6:146136371	FBXO30	0.52	4.66	0.39	8.02e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs748404	0.660	rs690367	chr15:43748304	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.47	-4.74	-0.39	5.81e-6	Lung cancer;
TGCT	cis	rs17102423	0.755	rs35769504	chr14:65576857	G/A	cg11161011	chr14:65562177	MAX	-0.54	-7.49	-0.56	1.15e-11	Obesity-related traits;
TGCT	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg22618164	chr12:122356400	WDR66	0.69	6.48	0.5	1.93e-9	Mean corpuscular volume;
TGCT	cis	rs7611238	0.560	rs2000051	chr3:194997552	C/G	cg27323046	chr3:195102265	ACAP2	-0.34	-4.51	-0.38	1.46e-5	Body mass index;
TGCT	cis	rs3008870	1.000	rs3008888	chr1:67368965	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.07	11.84	0.73	4.25e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs1371867	0.810	rs2860518	chr8:101238120	G/T	cg00191853	chr8:101177733	SPAG1	0.23	4.73	0.39	5.97e-6	Atrioventricular conduction;
TGCT	cis	rs9916302	0.706	rs1054488	chr17:37687968	A/G	cg07936489	chr17:37558343	FBXL20	-0.85	-6.23	-0.49	6.8e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs7246657	0.722	rs2291002	chr19:38033926	G/A	cg03611452	chr19:38183253	ZNF781	0.58	4.64	0.38	8.62e-6	Coronary artery calcification;
TGCT	trans	rs1864982	0.685	rs13358456	chr5:146209546	C/T	cg07017998	chr4:733617	PCGF3	-0.29	-7.14	-0.54	6.83e-11	Alcohol dependence;
TGCT	cis	rs6570726	0.791	rs9497357	chr6:145912888	G/A	cg05347473	chr6:146136440	FBXO30	0.53	4.91	0.4	2.87e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg13395646	chr4:1353034	KIAA1530	-0.37	-4.63	-0.38	9.18e-6	Obesity-related traits;
TGCT	trans	rs2727020	0.553	rs11040400	chr11:49518296	C/A	cg15704280	chr7:45808275	SEPT13	-0.61	-6.81	-0.52	3.77e-10	Coronary artery disease;
TGCT	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2288884	0.943	rs1433089	chr19:52506985	T/C	cg13540795	chr19:52551618	ZNF432	-0.56	-4.99	-0.41	1.97e-6	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs1008375	0.931	rs2098151	chr4:17577490	T/C	cg10189774	chr4:17578691	LAP3	0.64	5.61	0.45	1.28e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7267979	0.966	rs7270835	chr20:25435067	C/T	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs112591243	0.685	rs80124066	chr21:47912913	A/G	cg10657630	chr21:48055338	PRMT2	1.06	5.21	0.42	7.69e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs7043114	0.525	rs1053441	chr9:95147840	T/A	cg14311495	chr9:95764742	FGD3	-0.22	-4.52	-0.38	1.41e-5	Height;
TGCT	cis	rs10089	1.000	rs2054444	chr5:127493206	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.81	-7.79	-0.57	2.27e-12	Ileal carcinoids;
TGCT	cis	rs2816062	0.775	rs2816048	chr1:18893763	T/C	cg18795169	chr1:18902165	NA	-0.6	-14.18	-0.79	1.04e-27	Urate levels in lean individuals;
TGCT	cis	rs12210905	0.688	rs12215878	chr6:27336844	G/C	cg08851530	chr6:28072375	NA	1.25	5.39	0.44	3.38e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs7258465	0.965	rs271622	chr19:18629277	A/G	cg06462663	chr19:18546047	ISYNA1	0.21	4.96	0.41	2.24e-6	Breast cancer;
TGCT	cis	rs910316	1.000	rs10873275	chr14:75531460	A/T	cg23033748	chr14:75592666	NEK9	0.28	4.68	0.39	7.29e-6	Height;
TGCT	cis	rs651907	0.557	rs11720745	chr3:101441690	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.33	-6.78	-0.52	4.35e-10	Colorectal cancer;
TGCT	cis	rs9457247	0.934	rs2345571	chr6:167403400	T/G	cg23791538	chr6:167370224	RNASET2	-0.47	-4.63	-0.38	9.21e-6	Crohn's disease;
TGCT	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.82	7.64	0.57	5.01e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs72781680	0.799	rs2551332	chr2:23988950	T/C	cg08917208	chr2:24149416	ATAD2B	0.75	4.62	0.38	9.32e-6	Lymphocyte counts;
TGCT	cis	rs644799	0.544	rs1254935	chr11:95631470	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.54	5.15	0.42	9.81e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs797680	0.754	rs4847419	chr1:93845655	T/A	cg17826107	chr1:92977322	EVI5	-0.23	-5.48	-0.44	2.25e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs8180040	0.966	rs1872164	chr3:47415100	G/A	cg27129171	chr3:47204927	SETD2	-0.64	-7.39	-0.55	1.89e-11	Colorectal cancer;
TGCT	cis	rs1997103	0.705	rs56301138	chr7:55396555	G/T	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs17401966	0.838	rs1556917	chr1:10400990	G/T	cg19773385	chr1:10388646	KIF1B	-0.24	-5.58	-0.45	1.46e-7	Hepatocellular carcinoma;
TGCT	cis	rs10504229	0.906	rs2270609	chr8:58194684	G/A	cg21724239	chr8:58056113	NA	0.38	4.7	0.39	6.91e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs12220238	0.841	rs12098284	chr10:76047464	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.82	5.69	0.46	8.63e-8	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs9486719	1.000	rs2472890	chr6:96867646	C/T	cg06623918	chr6:96969491	KIAA0776	1.01	8.86	0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	trans	rs212016	0.636	rs2630189	chr3:59968059	G/T	cg05053403	chr12:133120676	FBRSL1	0.48	6.83	0.52	3.31e-10	Orofacial clefts;
TGCT	cis	rs9393692	0.905	rs2393592	chr6:26285560	A/G	cg13736514	chr6:26305472	NA	-0.41	-5.77	-0.46	6.09e-8	Educational attainment;
TGCT	cis	rs80282103	0.764	rs12247818	chr10:1110464	G/A	cg08668510	chr10:1095578	IDI1	1.07	5.31	0.43	5e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs11711311	0.955	rs10934247	chr3:113534941	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.7	-6.72	-0.52	5.98e-10	IgG glycosylation;
TGCT	cis	rs7937682	0.921	rs10789841	chr11:111469582	T/C	cg09085632	chr11:111637200	PPP2R1B	0.87	7.32	0.55	2.71e-11	Primary sclerosing cholangitis;
TGCT	cis	rs2034088	0.632	rs8067311	chr17:405603	T/G	cg01214346	chr17:406501	NA	-0.36	-5.48	-0.44	2.25e-7	Hip circumference adjusted for BMI;
TGCT	trans	rs10953454	1.000	rs10259925	chr7:104491405	A/T	cg04208666	chr6:19734707	NA	-0.57	-6.89	-0.53	2.52e-10	Obesity;
TGCT	cis	rs548987	0.529	rs651578	chr6:25873883	T/C	cg03264133	chr6:25882463	NA	-0.63	-5.41	-0.44	3.06e-7	Homocysteine levels;
TGCT	cis	rs7044106	0.791	rs4836829	chr9:123482747	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	6.98	0.53	1.59e-10	Hip circumference adjusted for BMI;
TGCT	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg06108461	chr20:60628389	TAF4	-0.7	-10.14	-0.67	5.74e-18	Body mass index;
TGCT	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg05368731	chr17:41323189	NBR1	1.16	13.76	0.78	1.03e-26	Menopause (age at onset);
TGCT	cis	rs265548	0.608	rs265545	chr19:17903465	C/T	cg04517722	chr19:17905589	B3GNT3	0.46	5.88	0.47	3.63e-8	Tumor biomarkers;
TGCT	cis	rs644799	0.735	rs10831432	chr11:95516040	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.28	0.6	1.63e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs4889855	0.530	rs12451459	chr17:78589668	G/A	cg16591659	chr17:78472290	NA	0.28	4.46	0.37	1.84e-5	Fractional excretion of uric acid;
TGCT	cis	rs77633900	0.614	rs279999	chr15:76945466	C/T	cg21673338	chr15:77095150	SCAPER	-0.52	-4.92	-0.4	2.72e-6	Non-glioblastoma glioma;Glioma;
TGCT	cis	rs700651	0.821	rs700666	chr2:198673544	G/A	cg00792783	chr2:198669748	PLCL1	0.56	5.08	0.42	1.35e-6	Intracranial aneurysm;
TGCT	cis	rs7224685	0.569	rs34540447	chr17:3994413	T/C	cg09580393	chr17:4869866	SPAG7	-0.38	-4.48	-0.37	1.64e-5	Type 2 diabetes;
TGCT	cis	rs66573146	1.000	rs56350643	chr4:7017591	G/A	cg01220768	chr4:7056774	TADA2B	0.41	5.11	0.42	1.2e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs7267979	1.000	rs6107046	chr20:25442049	G/A	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs12422267	0.536	rs7976530	chr12:132609140	C/T	cg09764611	chr12:132620959	NA	-0.37	-5.68	-0.45	9e-8	Plasma amyloid beta peptide concentrations (ABx-40);
TGCT	cis	rs12497850	0.931	rs7431710	chr3:48935583	G/A	cg18654377	chr3:49208889	KLHDC8B	-0.41	-5.49	-0.44	2.15e-7	Parkinson's disease;
TGCT	cis	rs12579753	0.917	rs7313521	chr12:82205656	G/A	cg07988820	chr12:82153109	PPFIA2	-0.59	-6.19	-0.49	7.93e-9	Resting heart rate;
TGCT	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg18876405	chr7:65276391	NA	0.37	5.89	0.47	3.34e-8	Aortic root size;
TGCT	cis	rs899997	0.954	rs4887091	chr15:79043580	T/C	cg04896959	chr15:78267971	NA	0.35	5.07	0.41	1.4e-6	Coronary artery disease or large artery stroke;
TGCT	cis	rs36093844	0.948	rs11234451	chr11:85573702	T/A	cg25872744	chr11:85566296	CCDC83	-0.5	-4.61	-0.38	9.71e-6	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
TGCT	cis	rs483180	0.512	rs594400	chr1:120214275	G/T	cg19096424	chr1:120255104	PHGDH	-0.57	-5.43	-0.44	2.79e-7	Macular telangiectasia type 2;
TGCT	cis	rs11719291	0.833	rs11715835	chr3:48770732	C/T	cg00383909	chr3:49044727	WDR6	1.18	6.28	0.49	5.23e-9	Cognitive function;
TGCT	cis	rs7246657	0.891	rs7253114	chr19:37988725	G/A	cg18154014	chr19:37997991	ZNF793	0.71	5.05	0.41	1.51e-6	Coronary artery calcification;
TGCT	cis	rs10883723	0.810	rs2296589	chr10:104248106	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg02353165	chr6:42928485	GNMT	0.97	9.93	0.67	1.83e-17	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs589448	0.538	rs683790	chr12:69751434	T/G	cg19645103	chr12:69753606	YEATS4	-0.63	-5.23	-0.42	7.11e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs2228479	0.850	rs11076624	chr16:89855749	T/C	cg06558623	chr16:89946397	TCF25	0.47	4.58	0.38	1.14e-5	Skin colour saturation;
TGCT	cis	rs7666738	0.830	rs4699584	chr4:98952019	A/G	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs950169	0.881	rs62029596	chr15:84955434	A/G	cg12863693	chr15:85201151	NMB	0.45	4.96	0.41	2.28e-6	Schizophrenia;
TGCT	cis	rs137603	0.644	rs94852	chr22:39712334	T/C	cg17798944	chr22:39715225	SNORD43;RPL3	-0.66	-7.12	-0.54	7.74e-11	Primary biliary cholangitis;
TGCT	cis	rs12477438	0.798	rs7606635	chr2:99644782	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-4.88	-0.4	3.17e-6	Chronic sinus infection;
TGCT	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg23708337	chr7:1209742	NA	0.6	5.57	0.45	1.53e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs12210905	0.687	rs12191649	chr6:27421208	A/T	cg08851530	chr6:28072375	NA	1.34	6.29	0.49	5.02e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs727479	0.502	rs4774583	chr15:51505993	A/G	cg19946085	chr15:51559439	CYP19A1	-0.31	-4.54	-0.38	1.3e-5	Estradiol levels;
TGCT	cis	rs1372520	0.684	rs10008964	chr4:90744721	G/A	cg01966878	chr4:90757139	SNCA	-0.3	-4.69	-0.39	7.05e-6	Neuroticism;
TGCT	cis	rs9650657	0.589	rs12542037	chr8:10758496	G/A	cg27411982	chr8:10470053	RP1L1	0.22	4.72	0.39	6.18e-6	Neuroticism;
TGCT	cis	rs10875746	0.951	rs58865997	chr12:48566873	G/A	cg20731937	chr12:48336164	NA	0.63	4.99	0.41	2.02e-6	Longevity (90 years and older);
TGCT	cis	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg13531842	chr10:38383804	ZNF37A	-0.38	-4.51	-0.38	1.49e-5	Extrinsic epigenetic age acceleration;
TGCT	cis	rs12477438	0.520	rs6756650	chr2:99801800	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.82	0.62	8.67e-15	Chronic sinus infection;
TGCT	cis	rs4886238	0.539	rs4886241	chr13:61157717	T/C	cg23734418	chr13:61221316	NA	-0.25	-4.46	-0.37	1.81e-5	Menopause (age at onset);
TGCT	cis	rs7439150	1.000	rs1800789	chr4:155482743	G/A	cg22130008	chr4:155548532	NA	-0.47	-5.8	-0.46	5.25e-8	Fibrinogen levels;
TGCT	cis	rs8002180	0.959	rs9584288	chr13:95920458	A/G	cg24476569	chr13:95954382	ABCC4	0.39	4.82	0.4	4.04e-6	Blood metabolite levels;
TGCT	cis	rs4455778	0.559	rs6583511	chr7:49122876	G/A	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs854765	0.693	rs8079321	chr17:17760789	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.74	7.65	0.57	4.87e-12	Total body bone mineral density;
TGCT	trans	rs7726839	0.574	rs11134149	chr5:637277	A/G	cg11887960	chr12:57824829	NA	1.05	9.27	0.64	7.22e-16	Obesity-related traits;
TGCT	cis	rs210152	0.531	rs4713634	chr6:33514708	T/C	cg07735790	chr6:34101545	GRM4	-0.52	-4.75	-0.39	5.46e-6	Schizophrenia;
TGCT	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg03388025	chr16:89894329	SPIRE2	0.5	8.67	0.61	2.03e-14	Vitiligo;
TGCT	cis	rs829880	1.000	rs829880	chr12:98845331	G/T	cg25150519	chr12:98850993	NA	0.63	6.32	0.49	4.29e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg04944784	chr2:26401820	FAM59B	0.73	4.68	0.39	7.31e-6	Gut microbiome composition (summer);
TGCT	cis	rs1156327	0.655	rs4238672	chr16:19325519	T/C	cg02978544	chr16:19716338	NA	-0.42	-4.44	-0.37	1.93e-5	Periodontal disease-related phenotypes;
TGCT	cis	rs2130392	1.000	rs2130392	chr4:185639169	A/G	cg14471096	chr4:185570637	CCDC111;CASP3	0.55	5.46	0.44	2.54e-7	Kawasaki disease;
TGCT	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg03517284	chr6:25882590	NA	-0.52	-5.28	-0.43	5.67e-7	Blood metabolite levels;
TGCT	cis	rs4555082	0.834	rs2816623	chr14:105733295	G/A	cg01266790	chr14:105781312	PACS2	0.56	4.6	0.38	1.04e-5	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs1887596	0.624	rs9553856	chr13:27136058	A/G	cg01312412	chr13:27282625	NA	0.27	4.74	0.39	5.72e-6	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs9916302	0.555	rs12940193	chr17:37652178	T/G	cg07936489	chr17:37558343	FBXL20	-0.62	-4.91	-0.4	2.85e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg21724239	chr8:58056113	NA	0.48	5.17	0.42	9.18e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg07424592	chr7:64974309	NA	-1.27	-7.84	-0.58	1.8e-12	Diabetic kidney disease;
TGCT	cis	rs2945232	1	rs2945232	chr8:8098038	T/C	cg15462221	chr8:8086144	FLJ10661	-0.53	-4.85	-0.4	3.61e-6	Schizophrenia;
TGCT	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.52	5.76	0.46	6.2e-8	Lymphocyte counts;
TGCT	cis	rs9291683	0.632	rs10939669	chr4:10045827	A/G	cg00071950	chr4:10020882	SLC2A9	0.68	8.74	0.62	1.38e-14	Bone mineral density;
TGCT	cis	rs9291683	0.566	rs13115776	chr4:10040189	C/G	cg00071950	chr4:10020882	SLC2A9	0.6	6.89	0.53	2.49e-10	Bone mineral density;
TGCT	cis	rs2486288	0.656	rs1719232	chr15:45572072	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.46	-5.17	-0.42	9.1e-7	Glomerular filtration rate;
TGCT	cis	rs926938	0.541	rs360623	chr1:115407268	G/C	cg12756093	chr1:115239321	AMPD1	0.42	6.39	0.5	2.99e-9	Autism;
TGCT	cis	rs9916302	0.904	rs3964723	chr17:37403979	C/T	cg15445000	chr17:37608096	MED1	0.3	4.44	0.37	1.97e-5	Glomerular filtration rate (creatinine);
TGCT	trans	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg27523141	chr10:43048294	ZNF37B	0.7	8.15	0.59	3.36e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg09436375	chr6:42928200	GNMT	-0.42	-5.41	-0.44	3.16e-7	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs6909279	0.933	rs7761420	chr6:151872567	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	0.51	4.47	0.37	1.75e-5	Bone mineral density;
TGCT	cis	rs12681288	0.645	rs35040046	chr8:989973	C/T	cg04851639	chr8:1020857	NA	-0.29	-4.67	-0.39	7.76e-6	Schizophrenia;
TGCT	trans	rs7726839	0.526	rs11960159	chr5:568685	C/T	cg25482853	chr8:67687455	SGK3	1.14	9.45	0.65	2.78e-16	Obesity-related traits;
TGCT	cis	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg22963979	chr7:1858916	MAD1L1	-0.37	-5.58	-0.45	1.42e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs66573146	1.000	rs6812771	chr4:6964048	G/A	cg01220768	chr4:7056774	TADA2B	0.35	4.63	0.38	8.96e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs11578119	0.933	rs1537390	chr1:170473659	C/G	cg09767346	chr1:170501363	GORAB	-0.67	-5.36	-0.43	3.85e-7	Male-pattern baldness;
TGCT	cis	rs4273100	0.512	rs2233072	chr17:19281828	T/G	cg03910582	chr17:19030146	GRAPL	-0.45	-6.21	-0.49	7.38e-9	Schizophrenia;
TGCT	trans	rs7726839	0.540	rs74553517	chr5:665671	C/T	cg25482853	chr8:67687455	SGK3	1.19	10.53	0.69	6.56e-19	Obesity-related traits;
TGCT	cis	rs13256369	0.802	rs12680019	chr8:8561698	A/G	cg17143192	chr8:8559678	CLDN23	0.54	5.03	0.41	1.64e-6	Obesity-related traits;
TGCT	cis	rs9611565	0.512	rs4512	chr22:42206084	G/C	cg17554472	chr22:41940697	POLR3H	-0.46	-4.69	-0.39	7.09e-6	Vitiligo;
TGCT	cis	rs9921222	0.564	rs9923059	chr16:381590	C/A	cg08923669	chr16:420230	MRPL28	-0.54	-5.21	-0.42	7.56e-7	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs524281	0.861	rs10896085	chr11:65913832	A/T	cg00563793	chr11:65837595	PACS1	0.58	4.94	0.41	2.44e-6	Electroencephalogram traits;
TGCT	cis	rs778371	1.000	rs778371	chr2:233743109	A/G	cg08000102	chr2:233561755	GIGYF2	-0.57	-6.12	-0.48	1.12e-8	Schizophrenia;
TGCT	cis	rs2980439	0.818	rs2948300	chr8:8106508	C/T	cg06636001	chr8:8085503	FLJ10661	0.88	8.69	0.62	1.79e-14	Neuroticism;
TGCT	cis	rs394563	0.591	rs237018	chr6:149743930	A/G	cg16235748	chr6:149772707	ZC3H12D	-0.42	-4.89	-0.4	3.06e-6	Dupuytren's disease;
TGCT	cis	rs854765	0.647	rs62073573	chr17:17976354	G/A	cg04398451	chr17:18023971	MYO15A	-0.35	-5.83	-0.46	4.6e-8	Total body bone mineral density;
TGCT	cis	rs3091242	0.933	rs35530120	chr1:25785451	A/G	cg09222892	chr1:25734099	RHCE	0.42	6.95	0.53	1.85e-10	Erythrocyte sedimentation rate;
TGCT	cis	rs6598955	0.671	rs58038522	chr1:26582713	C/T	cg04990556	chr1:26633338	UBXN11	0.62	4.73	0.39	6.12e-6	Obesity-related traits;
TGCT	cis	rs13256369	0.851	rs13255061	chr8:8563834	G/A	cg17143192	chr8:8559678	CLDN23	0.57	5.35	0.43	4.09e-7	Obesity-related traits;
TGCT	cis	rs56104184	0.775	rs56349331	chr19:49403009	T/A	cg21252483	chr19:49399788	TULP2	-0.42	-5.89	-0.47	3.47e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs2013441	1.000	rs2526475	chr17:20136216	T/C	cg18979559	chr17:20280153	CCDC144C	-0.45	-4.67	-0.39	7.61e-6	Obesity-related traits;
TGCT	cis	rs7439150	1.000	rs7439150	chr4:155481541	G/A	cg22130008	chr4:155548532	NA	-0.44	-5.57	-0.45	1.49e-7	Fibrinogen levels;
TGCT	cis	rs12497850	0.931	rs7628719	chr3:48995487	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.42	-5.41	-0.44	3.09e-7	Parkinson's disease;
TGCT	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7822232	0.908	rs6558297	chr8:145143934	C/T	cg14631276	chr8:145163102	KIAA1875	-0.56	-5.05	-0.41	1.55e-6	Blood metabolite levels;
TGCT	cis	rs1023500	0.552	rs5758566	chr22:42454354	G/A	cg15557168	chr22:42548783	NA	-0.21	-5.3	-0.43	5.2e-7	Schizophrenia;
TGCT	cis	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg20637647	chr7:64974828	NA	-0.95	-5.3	-0.43	5.09e-7	Diabetic kidney disease;
TGCT	cis	rs908922	0.523	rs4845786	chr1:152510144	A/G	cg20991723	chr1:152506922	NA	0.45	5.98	0.47	2.27e-8	Hair morphology;
TGCT	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg24690094	chr11:67383802	NA	0.31	4.69	0.39	7.04e-6	Mean corpuscular volume;
TGCT	cis	rs4654899	0.865	rs9426730	chr1:21452255	A/T	cg01072550	chr1:21505969	NA	-0.5	-7.77	-0.57	2.56e-12	Superior frontal gyrus grey matter volume;
TGCT	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg22968622	chr17:43663579	NA	-1.03	-10.02	-0.67	1.12e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs1153858	0.848	rs9806699	chr15:45740392	G/A	cg26924012	chr15:45694286	SPATA5L1	0.97	11.57	0.72	1.92e-21	Homoarginine levels;
TGCT	cis	rs9291683	0.588	rs2240724	chr4:10021290	G/C	cg11266682	chr4:10021025	SLC2A9	0.68	9.96	0.67	1.58e-17	Bone mineral density;
TGCT	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.89	-9.49	-0.65	2.18e-16	Age at first birth;
TGCT	cis	rs2235642	0.750	rs1894649	chr16:1657284	C/G	cg11375102	chr16:1583810	IFT140;TMEM204	-0.27	-4.64	-0.38	8.77e-6	Coronary artery disease;
TGCT	cis	rs10751667	0.643	rs11246362	chr11:969818	C/T	cg06064525	chr11:970664	AP2A2	-0.36	-8.28	-0.6	1.66e-13	Alzheimer's disease (late onset);
TGCT	cis	rs889312	0.500	rs1867731	chr5:56132115	C/G	cg12311346	chr5:56204834	C5orf35	-0.49	-5.44	-0.44	2.77e-7	Breast cancer;Breast cancer (early onset);
TGCT	cis	rs7666738	0.761	rs28758886	chr4:99059704	C/T	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.44e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3740393	0.562	rs1339919	chr10:104534448	A/G	cg05855489	chr10:104503620	C10orf26	0.8	6.47	0.5	2.07e-9	Microalbuminuria;
TGCT	cis	rs9303401	0.659	rs7224276	chr17:56897827	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs9325144	0.647	rs12231313	chr12:39101929	C/T	cg10518543	chr12:38710700	ALG10B	-0.49	-4.55	-0.38	1.25e-5	Morning vs. evening chronotype;
TGCT	cis	rs1044826	0.597	rs6772199	chr3:139178133	C/T	cg00490450	chr3:139108681	COPB2	0.52	4.53	0.38	1.39e-5	Obesity-related traits;
TGCT	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg06221963	chr1:154839813	KCNN3	0.68	11.66	0.72	1.12e-21	Prostate cancer;
TGCT	cis	rs6665290	0.582	rs72764213	chr1:227207391	C/T	cg11404489	chr1:228071452	NA	-0.19	-4.57	-0.38	1.18e-5	Myeloid white cell count;
TGCT	cis	rs711245	0.573	rs11899523	chr2:36800918	T/C	cg15105969	chr2:36825350	FEZ2	0.58	5.27	0.43	5.88e-7	Height;
TGCT	cis	rs7824557	0.592	rs2572371	chr8:11223793	G/T	cg21775007	chr8:11205619	TDH	0.63	5.9	0.47	3.29e-8	Retinal vascular caliber;
TGCT	cis	rs6964587	1.000	rs7455444	chr7:91639313	C/T	cg22709100	chr7:91322751	NA	0.27	4.48	0.37	1.68e-5	Breast cancer;
TGCT	cis	rs1461503	0.838	rs7126962	chr11:122830551	T/C	cg27398637	chr11:122830231	C11orf63	-0.41	-4.77	-0.39	5.14e-6	Menarche (age at onset);
TGCT	cis	rs3885907	0.520	rs4584668	chr13:31319553	A/T	cg22282089	chr13:30686841	NA	-0.22	-4.54	-0.38	1.33e-5	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU);
TGCT	cis	rs734999	0.545	rs41300092	chr1:2537838	C/T	cg18854424	chr1:2615690	NA	0.41	4.58	0.38	1.13e-5	Ulcerative colitis;
TGCT	cis	rs13188771	0.634	rs10043001	chr5:100894557	T/G	cg10455971	chr5:101119566	NA	0.44	4.45	0.37	1.87e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg23574427	chr4:122746245	BBS7;CCNA2	-0.35	-5.72	-0.46	7.66e-8	Type 2 diabetes;
TGCT	cis	rs72945132	0.882	rs7950916	chr11:70210001	T/C	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs2456568	0.548	rs1607402	chr11:93660732	T/G	cg26875233	chr11:93583750	C11orf90	-0.41	-4.9	-0.4	2.96e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	trans	rs10802346	0.545	rs1770003	chr1:246408356	A/G	cg22732515	chr19:44031385	ETHE1	0.84	6.78	0.52	4.34e-10	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg10802521	chr3:52805072	NEK4	-0.71	-8.85	-0.62	7.46e-15	Bipolar disorder;
TGCT	cis	rs1975974	0.511	rs66461325	chr17:21755430	A/G	cg18423549	chr17:21743878	NA	-0.63	-5.67	-0.45	9.38e-8	Psoriasis;
TGCT	cis	rs17433780	0.892	rs72726528	chr1:89455980	C/A	cg09516651	chr1:89888402	LOC400759	0.32	5.89	0.47	3.35e-8	Carotid intima media thickness;
TGCT	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg25036284	chr2:26402008	FAM59B	-0.57	-4.99	-0.41	2e-6	Gut microbiome composition (summer);
TGCT	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg11890956	chr21:40555474	PSMG1	1.11	12.48	0.75	1.21e-23	Cognitive function;
TGCT	cis	rs11874712	1.000	rs9961065	chr18:43653327	C/T	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	5.11	0.42	1.19e-6	Migraine - clinic-based;
TGCT	cis	rs7945705	0.782	rs2742545	chr11:8884308	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.41	-4.5	-0.37	1.56e-5	Hemoglobin concentration;
TGCT	cis	rs9291683	0.552	rs10939655	chr4:10014642	A/T	cg11266682	chr4:10021025	SLC2A9	0.73	11.04	0.7	3.63e-20	Bone mineral density;
TGCT	cis	rs1429606	1.000	rs1881546	chr5:87246567	A/T	cg09451457	chr5:87440246	NA	0.72	4.72	0.39	6.19e-6	Number of children (6+ vs. 0 or 1);
TGCT	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg17747265	chr1:1875780	NA	-0.42	-7.88	-0.58	1.42e-12	Body mass index;
TGCT	cis	rs3772130	0.923	rs13434284	chr3:121482842	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.72	0.39	6.25e-6	Cognitive performance;
TGCT	cis	rs2836633	0.929	rs4143428	chr21:40030582	G/T	cg05519781	chr21:40033154	ERG	0.69	6.83	0.52	3.34e-10	Coronary artery disease;
TGCT	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg23719950	chr11:63933701	MACROD1	-0.71	-5.87	-0.47	3.82e-8	Mean platelet volume;
TGCT	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg07061783	chr6:25882402	NA	-0.5	-5.47	-0.44	2.33e-7	Blood metabolite levels;
TGCT	cis	rs4699052	0.662	rs6828151	chr4:104284756	C/G	cg16532752	chr4:104119610	CENPE	-0.5	-4.75	-0.39	5.48e-6	Testicular germ cell tumor;
TGCT	cis	rs2730260	0.537	rs56260213	chr7:158875921	C/T	cg09066883	chr7:157932951	PTPRN2	0.42	4.66	0.39	8.09e-6	Myopia (pathological);
TGCT	cis	rs904251	0.580	rs62408367	chr6:37444813	G/A	cg01843034	chr6:37503916	NA	-0.46	-5.61	-0.45	1.27e-7	Cognitive performance;
TGCT	cis	rs1008375	0.932	rs4698627	chr4:17605959	T/C	cg10189774	chr4:17578691	LAP3	0.63	5.38	0.43	3.58e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg08280861	chr8:58055591	NA	0.4	4.73	0.39	5.97e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4808199	0.649	rs12983940	chr19:19516431	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.69	4.98	0.41	2.12e-6	Nonalcoholic fatty liver disease;
TGCT	cis	rs6598955	0.543	rs79778574	chr1:26538482	A/G	cg24519413	chr1:26490540	NA	-0.25	-4.61	-0.38	9.99e-6	Obesity-related traits;
TGCT	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg27170947	chr2:26402098	FAM59B	-0.39	-4.46	-0.37	1.8e-5	Gut microbiome composition (summer);
TGCT	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg15691649	chr6:25882328	NA	0.4	4.65	0.39	8.27e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2455799	0.559	rs1900614	chr3:15912127	G/A	cg12172478	chr3:16357591	RFTN1	-0.36	-5.3	-0.43	5.07e-7	Mean platelet volume;
TGCT	cis	rs2898681	0.519	rs76606067	chr4:53728221	G/T	cg00791764	chr4:53727839	RASL11B	0.54	4.58	0.38	1.1e-5	Optic nerve measurement (cup area);
TGCT	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.66	0.39	8.18e-6	Prudent dietary pattern;
TGCT	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg10802521	chr3:52805072	NEK4	-0.78	-9.89	-0.66	2.32e-17	Bipolar disorder;
TGCT	trans	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg17830980	chr10:43048298	ZNF37B	-0.81	-10.13	-0.67	6.19e-18	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2180341	0.924	rs9285459	chr6:127631113	T/C	cg24812749	chr6:127587940	RNF146	0.98	7.64	0.57	5.06e-12	Breast cancer;
TGCT	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg05896524	chr21:47604654	C21orf56	0.43	4.76	0.39	5.35e-6	Testicular germ cell tumor;
TGCT	cis	rs7567389	0.677	rs72848616	chr2:128135097	T/C	cg09760422	chr2:128146352	NA	0.34	4.52	0.38	1.41e-5	Self-rated health;
TGCT	cis	rs12681287	0.752	rs6985427	chr8:87302745	C/T	cg27223183	chr8:87520930	FAM82B	-0.83	-5.97	-0.47	2.36e-8	Caudate activity during reward;
TGCT	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg26338869	chr17:61819248	STRADA	-0.53	-4.9	-0.4	2.95e-6	Prudent dietary pattern;
TGCT	cis	rs9906944	0.933	rs9906710	chr17:47091283	C/A	cg20966754	chr17:47091339	IGF2BP1	-0.43	-4.96	-0.41	2.27e-6	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs62244186	0.659	rs12108134	chr3:44543030	A/G	cg15687855	chr3:44754131	ZNF502	0.44	5.16	0.42	9.48e-7	Depressive symptoms;
TGCT	cis	rs2013441	1.000	rs2058971	chr17:20219508	T/A	cg18979559	chr17:20280153	CCDC144C	-0.45	-4.67	-0.39	7.61e-6	Obesity-related traits;
TGCT	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg02725872	chr8:58115012	NA	-0.38	-4.76	-0.39	5.39e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs12908161	1.000	rs12905057	chr15:85210765	A/G	cg17173187	chr15:85201210	NMB	0.59	6.49	0.5	1.81e-9	Schizophrenia;
TGCT	cis	rs9911578	1.000	rs9911578	chr17:56953147	C/T	cg05425664	chr17:57184151	TRIM37	-0.62	-6.18	-0.49	8.33e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs5769707	0.681	rs4824068	chr22:50024801	G/A	cg05373962	chr22:49881684	NA	-0.31	-5.37	-0.43	3.8e-7	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs2486288	0.656	rs11629858	chr15:45547114	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.7	-6.77	-0.52	4.55e-10	Glomerular filtration rate;
TGCT	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg16049864	chr8:95962084	TP53INP1	-0.75	-10.48	-0.69	8.55e-19	Type 2 diabetes;
TGCT	cis	rs9443645	0.901	rs1567167	chr6:79553827	C/T	cg09184832	chr6:79620586	NA	-0.47	-5.23	-0.43	6.94e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9952991	0.566	rs7241016	chr18:12880206	A/G	cg23598886	chr18:12777645	NA	-0.5	-4.47	-0.37	1.73e-5	Inflammatory skin disease;
TGCT	cis	rs11098499	0.754	rs7672372	chr4:120248406	A/G	cg09307838	chr4:120376055	NA	0.61	5.92	0.47	3e-8	Corneal astigmatism;
TGCT	cis	rs9388451	1.000	rs9388451	chr6:126090377	A/G	cg10911889	chr6:126070802	HEY2	0.52	5.25	0.43	6.27e-7	Brugada syndrome;
TGCT	cis	rs9457247	0.565	rs12178491	chr6:167512474	C/T	cg07741184	chr6:167504864	NA	0.28	5.6	0.45	1.33e-7	Crohn's disease;
TGCT	cis	rs6754311	0.513	rs1438304	chr2:136503157	A/G	cg07169764	chr2:136633963	MCM6	-0.66	-6.11	-0.48	1.2e-8	Mosquito bite size;
TGCT	cis	rs909674	0.690	rs1972280	chr22:39831986	T/A	cg02038168	chr22:39784481	NA	-0.74	-5.67	-0.45	9.63e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs9457247	0.508	rs6918286	chr6:167505829	C/T	cg07741184	chr6:167504864	NA	0.27	5.25	0.43	6.4e-7	Crohn's disease;
TGCT	cis	rs1467026	0.584	rs9865381	chr3:12801685	C/T	cg05775895	chr3:12838266	CAND2	0.7	7.16	0.54	6.26e-11	P wave duration;
TGCT	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg03517284	chr6:25882590	NA	-0.52	-5.27	-0.43	5.77e-7	Blood metabolite levels;
TGCT	cis	rs9388451	0.807	rs1269175	chr6:126040435	A/G	cg10911889	chr6:126070802	HEY2	-0.53	-5.03	-0.41	1.68e-6	Brugada syndrome;
TGCT	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg22166914	chr1:53195759	ZYG11B	-0.39	-6.42	-0.5	2.6e-9	Monocyte count;
TGCT	cis	rs11190604	0.607	rs12220970	chr10:102175269	G/A	cg16342193	chr10:102329863	NA	-0.41	-5.14	-0.42	1.04e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs72945132	0.882	rs12099016	chr11:70195161	C/G	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs11098499	0.863	rs6534141	chr4:120485223	A/T	cg09307838	chr4:120376055	NA	0.74	7.34	0.55	2.49e-11	Corneal astigmatism;
TGCT	cis	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg13531842	chr10:38383804	ZNF37A	0.39	4.58	0.38	1.12e-5	Extrinsic epigenetic age acceleration;
TGCT	cis	rs3806843	0.966	rs7710380	chr5:140156264	T/C	cg19875535	chr5:140030758	IK	0.37	6.23	0.49	6.53e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs910187	0.678	rs6122561	chr20:45813809	A/G	cg27589058	chr20:45804311	EYA2	-0.36	-7.95	-0.58	9.85e-13	Migraine;
TGCT	cis	rs1023500	0.551	rs61665536	chr22:42512613	A/G	cg15557168	chr22:42548783	NA	0.22	5.58	0.45	1.47e-7	Schizophrenia;
TGCT	cis	rs854765	0.583	rs8073001	chr17:17831716	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.74	-7.74	-0.57	2.94e-12	Total body bone mineral density;
TGCT	cis	rs3849570	1.000	rs7638516	chr3:81826249	A/C	cg07356753	chr3:81810745	GBE1	-0.7	-5.94	-0.47	2.67e-8	Waist circumference;Body mass index;
TGCT	cis	rs492146	0.691	rs316138	chr6:52846419	T/C	cg06706454	chr6:52930286	FBXO9	-0.53	-4.95	-0.41	2.36e-6	Epilepsy (remission after treatment);
TGCT	cis	rs3858526	0.676	rs10838752	chr11:5887243	A/G	cg13902645	chr11:5959945	NA	-0.43	-4.61	-0.38	9.96e-6	DNA methylation (variation);
TGCT	cis	rs2639990	0.744	rs640261	chr18:72905808	C/T	cg18449964	chr18:72917101	ZADH2	0.92	6.07	0.48	1.46e-8	Vascular endothelial growth factor levels;
TGCT	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg04632378	chr13:21900426	NA	0.4	4.92	0.4	2.68e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	cis	rs17376456	0.597	rs7708175	chr5:93381182	A/G	cg25358565	chr5:93447407	FAM172A	-0.62	-5.79	-0.46	5.34e-8	Diabetic retinopathy;
TGCT	cis	rs2439831	0.867	rs3809481	chr15:43662829	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	5.92	0.47	3e-8	Lung cancer in ever smokers;
TGCT	cis	rs67311347	1.000	rs34762643	chr3:40475433	C/T	cg17264618	chr3:40429014	ENTPD3	0.32	4.76	0.39	5.36e-6	Renal cell carcinoma;
TGCT	cis	rs4460629	0.521	rs12039316	chr1:155073221	C/T	cg23973274	chr1:155060172	NA	-0.25	-4.5	-0.38	1.51e-5	Serum magnesium levels;
TGCT	cis	rs854765	0.647	rs854790	chr17:18028318	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	7.34	0.55	2.42e-11	Total body bone mineral density;
TGCT	cis	rs7618915	0.798	rs353547	chr3:52268866	A/G	cg07507251	chr3:52567010	NT5DC2	-0.42	-5.74	-0.46	6.75e-8	Bipolar disorder;
TGCT	cis	rs612683	0.602	rs2030048	chr1:101006577	C/T	cg06223162	chr1:101003688	GPR88	-0.34	-6.06	-0.48	1.5e-8	Breast cancer;
TGCT	cis	rs11585357	0.895	rs34324150	chr1:17632464	C/G	cg08277548	chr1:17600880	PADI3	-0.95	-9.6	-0.65	1.15e-16	Hair shape;
TGCT	cis	rs514406	0.505	rs6703127	chr1:53180565	C/T	cg16325326	chr1:53192061	ZYG11B	0.86	12.38	0.74	2.09e-23	Monocyte count;
TGCT	cis	rs317865	0.737	rs73234629	chr4:16169776	G/A	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.78	4.98	0.41	2.08e-6	Kidney disease (early stage) in type 1 diabetes;
TGCT	cis	rs826838	1.000	rs826888	chr12:39104719	C/G	cg26384229	chr12:38710491	ALG10B	-0.88	-8.27	-0.6	1.77e-13	Heart rate;
TGCT	cis	rs7819412	0.805	rs4333549	chr8:10979561	C/G	cg21775007	chr8:11205619	TDH	-0.52	-5.03	-0.41	1.66e-6	Triglycerides;
TGCT	cis	rs317689	0.690	rs595348	chr12:69638610	T/C	cg14784868	chr12:69753453	YEATS4	0.54	4.5	0.37	1.56e-5	Response to diuretic therapy;
TGCT	cis	rs921968	0.643	rs471846	chr2:219432237	C/T	cg02176678	chr2:219576539	TTLL4	0.38	5.48	0.44	2.31e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs12530845	1.000	rs6979391	chr7:135328873	C/T	cg23117316	chr7:135346802	PL-5283	-0.51	-4.83	-0.4	3.98e-6	Red blood cell traits;
TGCT	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg06634786	chr22:41940651	POLR3H	-0.72	-6.61	-0.51	1.02e-9	Vitiligo;
TGCT	cis	rs734999	0.545	rs10910106	chr1:2538886	G/T	cg18854424	chr1:2615690	NA	0.41	4.58	0.38	1.13e-5	Ulcerative colitis;
TGCT	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg26338869	chr17:61819248	STRADA	-0.53	-4.85	-0.4	3.68e-6	Prudent dietary pattern;
TGCT	cis	rs922182	0.579	rs13329518	chr15:64241080	T/C	cg02919090	chr15:64263738	DAPK2	0.37	7.01	0.53	1.33e-10	Blood protein levels;
TGCT	cis	rs939658	0.805	rs11638625	chr15:79434787	T/G	cg17916960	chr15:79447300	NA	-0.49	-7.59	-0.56	6.76e-12	Refractive error;
TGCT	cis	rs350251	0.868	rs350231	chr16:12186376	T/G	cg01574788	chr16:12184133	SNX29	0.4	5.24	0.43	6.58e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg13683864	chr3:40499215	RPL14	-1.18	-13.68	-0.78	1.54e-26	Renal cell carcinoma;
TGCT	cis	rs1062177	0.906	rs2964573	chr5:151160122	A/T	cg00977110	chr5:151150581	G3BP1	0.4	4.57	0.38	1.16e-5	Preschool internalizing problems;
TGCT	trans	rs11088226	0.681	rs2833897	chr21:33931792	T/C	cg09050820	chr6:167586206	TCP10L2	0.78	6.96	0.53	1.71e-10	Gastritis;
TGCT	cis	rs7662987	0.517	rs1154406	chr4:100008494	T/C	cg12011299	chr4:100065546	ADH4	0.42	4.87	0.4	3.38e-6	Smoking initiation;
TGCT	cis	rs763121	0.853	rs138702	chr22:39132601	A/T	cg06022373	chr22:39101656	GTPBP1	-0.81	-7.64	-0.57	5.08e-12	Menopause (age at onset);
TGCT	cis	rs3820068	0.603	rs6696286	chr1:15968770	C/T	cg05660106	chr1:15850417	CASP9	0.83	8.16	0.59	3.25e-13	Systolic blood pressure;
TGCT	cis	rs6426558	0.537	rs7512409	chr1:227484038	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.56	-6.62	-0.51	9.6e-10	Neutrophil percentage of white cells;
TGCT	cis	rs13256369	0.950	rs13248096	chr8:8577476	C/T	cg17143192	chr8:8559678	CLDN23	0.61	5.74	0.46	6.82e-8	Obesity-related traits;
TGCT	cis	rs7726839	0.507	rs56282020	chr5:596701	T/C	cg20362242	chr5:692897	TPPP	0.53	4.62	0.38	9.56e-6	Obesity-related traits;
TGCT	cis	rs9467773	0.620	rs2498351	chr6:26659642	C/T	cg15659132	chr6:26577336	NA	0.87	10.72	0.69	2.19e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs28595532	0.920	rs114584210	chr4:119773363	G/A	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs2180341	0.961	rs910720	chr6:127619070	T/C	cg24812749	chr6:127587940	RNF146	0.99	7.72	0.57	3.33e-12	Breast cancer;
TGCT	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg04234412	chr22:24373322	LOC391322	-0.92	-11.06	-0.7	3.33e-20	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs11190604	0.767	rs10883485	chr10:102174805	G/C	cg16342193	chr10:102329863	NA	-0.4	-5.06	-0.41	1.5e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9611519	0.590	rs4821980	chr22:41415479	C/G	cg13695892	chr22:41940480	POLR3H	-0.54	-5.1	-0.42	1.21e-6	Neuroticism;
TGCT	cis	rs1570884	0.767	rs7996207	chr13:50122681	G/A	cg08779649	chr13:50194554	NA	0.3	4.75	0.39	5.58e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
TGCT	cis	rs2594989	0.943	rs2454504	chr3:11498423	G/A	cg26283222	chr3:11613257	VGLL4	-0.21	-4.6	-0.38	1.01e-5	Circulating chemerin levels;
TGCT	cis	rs7805747	0.961	rs10253736	chr7:151415256	C/T	cg17611936	chr7:151411526	PRKAG2	0.54	6.72	0.52	5.9e-10	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
TGCT	cis	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg04267008	chr7:1944627	MAD1L1	-0.35	-4.44	-0.37	1.95e-5	Bipolar disorder and schizophrenia;
TGCT	cis	rs7586879	0.639	rs6545776	chr2:25099357	A/C	cg15423357	chr2:25149977	NA	0.5	4.75	0.39	5.63e-6	Body mass index;
TGCT	cis	rs10206020	0.885	rs6720923	chr2:1574197	T/C	cg01028140	chr2:1542097	TPO	-0.28	-4.51	-0.38	1.47e-5	IgG glycosylation;
TGCT	cis	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg20637647	chr7:64974828	NA	0.89	4.95	0.41	2.37e-6	Diabetic kidney disease;
TGCT	cis	rs11792861	0.926	rs11788904	chr9:111865052	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.48	4.48	0.37	1.66e-5	Menarche (age at onset);
TGCT	cis	rs924607	1.000	rs4045344	chr5:595870	G/T	cg18765565	chr5:669397	TPPP	-0.58	-6.23	-0.49	6.51e-9	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg16325326	chr1:53192061	ZYG11B	0.6	6.77	0.52	4.62e-10	Monocyte count;
TGCT	cis	rs1018836	0.828	rs9297870	chr8:91570691	C/G	cg16814680	chr8:91681699	NA	-0.8	-8.26	-0.6	1.85e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2760061	0.626	rs672977	chr1:228120288	A/C	cg02753203	chr1:228287806	NA	-0.34	-6.63	-0.51	9.15e-10	Diastolic blood pressure;
TGCT	trans	rs77457752	0.525	rs10121526	chr9:13898615	G/A	cg23609682	chr1:3070786	PRDM16	0.5	6.79	0.52	4.09e-10	Breast cancer;
TGCT	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs986417	1.000	rs10143118	chr14:61066043	G/A	cg27398547	chr14:60952738	C14orf39	1.48	10.51	0.69	7.42e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs3806843	0.612	rs246075	chr5:140300557	T/C	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.42	-5.21	-0.42	7.71e-7	Depressive symptoms (multi-trait analysis);
TGCT	trans	rs4824093	0.610	rs58671506	chr22:50288983	G/A	cg09872104	chr7:134855509	C7orf49	-0.96	-7.87	-0.58	1.49e-12	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg07507251	chr3:52567010	NT5DC2	0.48	6.91	0.53	2.24e-10	Bipolar disorder;
TGCT	cis	rs2439831	0.850	rs8023458	chr15:44080939	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	6.01	0.47	1.91e-8	Lung cancer in ever smokers;
TGCT	cis	rs4631830	0.832	rs1585378	chr10:51523213	A/T	cg10326726	chr10:51549505	MSMB	-0.27	-5.42	-0.44	3.01e-7	Prostate-specific antigen levels;
TGCT	cis	rs2072499	0.750	rs2241109	chr1:156173082	C/T	cg25208724	chr1:156163844	SLC25A44	1.02	9.51	0.65	2e-16	Testicular germ cell tumor;
TGCT	cis	rs1372520	0.684	rs1811442	chr4:90747751	C/T	cg20003494	chr4:90757398	SNCA	-0.63	-5.09	-0.42	1.3e-6	Neuroticism;
TGCT	cis	rs8141529	0.509	rs6005927	chr22:29255884	A/G	cg02153584	chr22:29168773	CCDC117	0.6	4.77	0.39	4.98e-6	Lymphocyte counts;
TGCT	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg08509172	chr19:19383838	TM6SF2	-0.34	-4.48	-0.37	1.71e-5	Tonsillectomy;
TGCT	cis	rs7296418	0.961	rs11613937	chr12:123520071	C/T	cg00376283	chr12:123451042	ABCB9	0.87	8.22	0.59	2.34e-13	Platelet count;
TGCT	cis	rs7772486	0.875	rs9403763	chr6:146357655	A/G	cg05347473	chr6:146136440	FBXO30	0.57	5.51	0.44	2.02e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7666738	0.830	rs28465658	chr4:99035866	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs36051895	0.623	rs11506668	chr9:5252789	C/T	cg02405213	chr9:5042618	JAK2	-0.7	-8.27	-0.6	1.78e-13	Pediatric autoimmune diseases;
TGCT	trans	rs7618501	0.699	rs11130224	chr3:49936910	T/A	cg21659725	chr3:3221576	CRBN	0.77	9.15	0.63	1.42e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs7914558	0.966	rs10883817	chr10:104755431	C/T	cg15744005	chr10:104629667	AS3MT	-0.4	-4.89	-0.4	3.06e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs2880765	0.835	rs900573	chr15:86037993	G/T	cg13263323	chr15:86062960	AKAP13	0.21	4.52	0.38	1.44e-5	Coronary artery disease;
TGCT	cis	rs3924048	0.574	rs12096486	chr1:12616911	T/C	cg00291366	chr1:12616550	NA	0.33	5.14	0.42	1.05e-6	Optic cup area;
TGCT	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg18230493	chr5:56204884	C5orf35	-0.74	-5.18	-0.42	8.84e-7	Initial pursuit acceleration;
TGCT	cis	rs2840044	1.000	rs225251	chr17:33951228	A/C	cg05299278	chr17:33885742	SLFN14	0.22	4.93	0.4	2.63e-6	Response to radiotherapy in cancer (late toxicity);
TGCT	cis	rs4654899	0.582	rs4654729	chr1:21224253	T/C	cg01072550	chr1:21505969	NA	0.55	8.92	0.62	5.21e-15	Superior frontal gyrus grey matter volume;
TGCT	cis	rs6815814	0.861	rs7658651	chr4:38786002	A/C	cg02016764	chr4:38805732	TLR1	-0.27	-4.46	-0.37	1.78e-5	Breast cancer;
TGCT	cis	rs9357506	0.967	rs4714923	chr6:46304002	A/T	cg21115430	chr6:46460003	NA	-0.26	-5.04	-0.41	1.58e-6	Body mass index;
TGCT	cis	rs308403	0.568	rs13120869	chr4:123646152	T/C	cg10495464	chr4:123653540	BBS12;LOC729338	0.7	6.41	0.5	2.8e-9	Blood protein levels;
TGCT	cis	rs9457247	1.000	rs2149085	chr6:167371110	T/C	cg23791538	chr6:167370224	RNASET2	0.51	4.98	0.41	2.06e-6	Crohn's disease;
TGCT	cis	rs13242816	1.000	rs55803834	chr7:116103141	C/T	cg02799643	chr7:116139180	CAV2	-0.45	-5.38	-0.44	3.5e-7	P wave duration;
TGCT	trans	rs208520	0.690	rs4710564	chr6:66823478	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	7.71	0.57	3.49e-12	Exhaled nitric oxide output;
TGCT	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg25036284	chr2:26402008	FAM59B	-0.56	-4.85	-0.4	3.62e-6	Gut microbiome composition (summer);
TGCT	cis	rs7666738	0.546	rs1456207	chr4:98676911	G/A	cg05340658	chr4:99064831	C4orf37	0.49	5.29	0.43	5.45e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.59	-5.89	-0.47	3.47e-8	Bipolar disorder;
TGCT	cis	rs3617	0.652	rs7630552	chr3:52891570	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.49	-4.58	-0.38	1.09e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7726839	0.540	rs56325086	chr5:640728	G/A	cg20362242	chr5:692897	TPPP	0.49	4.45	0.37	1.89e-5	Obesity-related traits;
TGCT	cis	rs362272	0.505	rs10155132	chr4:3369500	A/G	cg22655196	chr4:3374909	RGS12	0.22	4.56	0.38	1.23e-5	Serum sulfate level;
TGCT	cis	rs9467773	1.000	rs10946834	chr6:26533664	G/C	cg26531700	chr6:26746687	NA	0.47	4.57	0.38	1.14e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg16145915	chr7:1198662	ZFAND2A	0.56	7.23	0.54	4.47e-11	Longevity;Endometriosis;
TGCT	cis	rs6570726	0.935	rs390252	chr6:145856896	A/G	cg23711669	chr6:146136114	FBXO30	0.71	7.03	0.53	1.25e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2115630	0.691	rs61322921	chr15:85163638	T/C	cg12501888	chr15:85177176	SCAND2	-0.51	-4.74	-0.39	5.88e-6	P wave terminal force;
TGCT	cis	rs1008375	0.931	rs10008337	chr4:17593849	G/C	cg16339924	chr4:17578868	LAP3	0.81	6.69	0.52	6.75e-10	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2120019	0.786	rs12911421	chr15:75287822	C/A	cg17294928	chr15:75287854	SCAMP5	0.98	9.45	0.65	2.65e-16	Blood trace element (Zn levels);
TGCT	cis	rs2115630	1.000	rs2879828	chr15:85361977	G/T	cg17173187	chr15:85201210	NMB	-0.4	-4.9	-0.4	2.89e-6	P wave terminal force;
TGCT	cis	rs593982	0.920	rs4930298	chr11:65448108	T/A	cg08755490	chr11:65554678	OVOL1	-1.21	-6.67	-0.51	7.71e-10	Atopic dermatitis;
TGCT	cis	rs11690935	0.851	rs9808259	chr2:172648974	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.18	-12.58	-0.75	6.59e-24	Schizophrenia;
TGCT	trans	rs1814175	0.715	rs11040586	chr11:49858432	T/A	cg03929089	chr4:120376271	NA	-0.72	-8.26	-0.6	1.84e-13	Height;
TGCT	trans	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg21659725	chr3:3221576	CRBN	-0.67	-7.53	-0.56	9.05e-12	Body mass index;
TGCT	cis	rs12682352	0.652	rs1567398	chr8:8726804	A/C	cg06636001	chr8:8085503	FLJ10661	-0.7	-6.63	-0.51	9.32e-10	Neuroticism;
TGCT	cis	rs11948739	0.539	rs10045319	chr5:130250710	G/A	cg08523029	chr5:130500466	HINT1	0.57	4.62	0.38	9.66e-6	Pediatric bone mineral content (hip);
TGCT	cis	rs12682352	0.602	rs6988939	chr8:8666916	C/T	cg15556689	chr8:8085844	FLJ10661	0.59	5.03	0.41	1.69e-6	Neuroticism;
TGCT	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg25767906	chr1:53392781	SCP2	0.61	7.44	0.56	1.48e-11	Monocyte count;
TGCT	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	16.05	0.82	4.59e-32	Prudent dietary pattern;
TGCT	cis	rs1635	0.826	rs4711167	chr6:28294888	C/T	cg15743358	chr6:28303923	ZNF323	1.32	6.0	0.47	2.05e-8	Schizophrenia;
TGCT	cis	rs7647973	1.000	rs10865956	chr3:49581559	C/A	cg07636037	chr3:49044803	WDR6	0.65	5.35	0.43	4.01e-7	Menarche (age at onset);
TGCT	cis	rs2637266	0.935	rs6480822	chr10:78354092	A/C	cg18941641	chr10:78392320	NA	0.41	4.86	0.4	3.51e-6	Pulmonary function;
TGCT	cis	rs9296092	0.517	rs3912041	chr6:33521271	T/C	cg13560919	chr6:33536144	NA	-0.21	-4.75	-0.39	5.5e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.68	4.89	0.4	3e-6	Platelet count;
TGCT	cis	rs11098499	0.754	rs10213554	chr4:120260785	A/G	cg09307838	chr4:120376055	NA	-0.61	-5.95	-0.47	2.56e-8	Corneal astigmatism;
TGCT	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg22920501	chr2:26401640	FAM59B	0.8	6.34	0.49	3.84e-9	Gut microbiome composition (summer);
TGCT	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg14820908	chr5:178986412	RUFY1	-0.44	-4.44	-0.37	1.96e-5	Lung cancer;
TGCT	cis	rs6693567	0.545	rs9436009	chr1:150459426	T/A	cg09579323	chr1:150459698	TARS2	0.52	4.58	0.38	1.12e-5	Migraine;
TGCT	cis	rs3026101	0.671	rs1071705	chr17:5290033	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	4.57	0.38	1.16e-5	Body mass index;
TGCT	cis	rs7772486	0.875	rs865913	chr6:146308874	C/T	cg13319975	chr6:146136371	FBXO30	-0.53	-4.68	-0.39	7.44e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11719291	0.504	rs71324924	chr3:48865444	G/A	cg00383909	chr3:49044727	WDR6	1.26	6.52	0.51	1.58e-9	Cognitive function;
TGCT	cis	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg18252515	chr7:66147081	NA	-1.09	-6.4	-0.5	2.88e-9	Diabetic kidney disease;
TGCT	cis	rs42648	0.748	rs10227385	chr7:89890368	C/A	cg25739043	chr7:89950458	NA	-0.63	-6.12	-0.48	1.15e-8	Homocysteine levels;
TGCT	cis	rs7439150	0.954	rs2227424	chr4:155492720	C/G	cg22130008	chr4:155548532	NA	-0.51	-6.87	-0.52	2.79e-10	Fibrinogen levels;
TGCT	cis	rs939574	0.512	rs6730612	chr2:220146196	G/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.78	5.54	0.45	1.71e-7	Platelet distribution width;
TGCT	cis	rs2032447	0.613	rs6456708	chr6:26032847	G/C	cg03264133	chr6:25882463	NA	-0.46	-4.59	-0.38	1.08e-5	Intelligence (multi-trait analysis);
TGCT	trans	rs561341	0.739	rs4795663	chr17:30214542	T/C	cg20587970	chr11:113659929	NA	0.59	8.85	0.62	7.64e-15	Hip circumference adjusted for BMI;
TGCT	cis	rs7698623	0.717	rs4693893	chr4:88797765	A/G	cg27387453	chr4:88533842	DSPP	-0.61	-4.6	-0.38	1.03e-5	Cardiovascular disease risk factors;
TGCT	cis	rs854765	0.693	rs9907246	chr17:17770965	T/C	cg09796270	chr17:17721594	SREBF1	-0.28	-5.62	-0.45	1.17e-7	Total body bone mineral density;
TGCT	cis	rs6582630	0.537	rs1949611	chr12:38373092	C/T	cg26384229	chr12:38710491	ALG10B	-0.77	-6.93	-0.53	2.05e-10	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs9389248	0.500	rs116273677	chr6:135339135	A/C	cg24558204	chr6:135376177	HBS1L	0.48	4.77	0.39	5.14e-6	High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs736408	0.812	rs2071507	chr3:52826707	G/A	cg10802521	chr3:52805072	NEK4	-0.64	-7.42	-0.55	1.65e-11	Bipolar disorder;
TGCT	cis	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg18252515	chr7:66147081	NA	-1.13	-6.81	-0.52	3.7e-10	Diabetic kidney disease;
TGCT	cis	rs6840360	0.904	rs6813516	chr4:152594407	C/G	cg22705602	chr4:152727874	NA	-0.26	-4.46	-0.37	1.81e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg08280861	chr8:58055591	NA	0.36	4.98	0.41	2.08e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9296661	0.832	rs6458787	chr6:51667058	A/G	cg00593404	chr6:52377740	TRAM2	-0.27	-4.49	-0.37	1.62e-5	Weight loss (gastric bypass surgery);
TGCT	cis	rs11648796	0.765	rs2003832	chr16:769538	G/A	cg27144592	chr16:783916	NARFL	0.42	5.76	0.46	6.37e-8	Height;
TGCT	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg26513180	chr16:89883248	FANCA	-1.01	-13.53	-0.77	3.53e-26	Vitiligo;
TGCT	cis	rs2235642	0.893	rs2076439	chr16:1587277	C/T	cg08296037	chr16:1584118	IFT140;TMEM204	-0.31	-5.43	-0.44	2.89e-7	Coronary artery disease;
TGCT	cis	rs7582180	0.663	rs6542944	chr2:100988038	T/C	cg08017756	chr2:100939284	LONRF2	-0.31	-5.14	-0.42	1.06e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7216064	1.000	rs7223813	chr17:65945840	A/G	cg12091567	chr17:66097778	LOC651250	-0.82	-6.2	-0.49	7.54e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs2688608	0.592	rs3849967	chr10:75483366	C/T	cg23231163	chr10:75533350	FUT11	-0.28	-4.68	-0.39	7.4e-6	Inflammatory bowel disease;
TGCT	cis	rs2243480	1.000	rs67536397	chr7:65947917	G/A	cg07424592	chr7:64974309	NA	1.29	8.01	0.58	7.16e-13	Diabetic kidney disease;
TGCT	cis	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg07424592	chr7:64974309	NA	1.38	8.17	0.59	3.04e-13	Diabetic kidney disease;
TGCT	trans	rs2727020	0.724	rs4109837	chr11:49372051	A/T	cg03929089	chr4:120376271	NA	-0.67	-6.99	-0.53	1.52e-10	Coronary artery disease;
TGCT	cis	rs904251	0.864	rs2797801	chr6:37487161	A/G	cg01843034	chr6:37503916	NA	-0.52	-6.28	-0.49	5.17e-9	Cognitive performance;
TGCT	cis	rs7572733	0.555	rs6434953	chr2:198929693	A/G	cg00792783	chr2:198669748	PLCL1	0.58	5.11	0.42	1.21e-6	Dermatomyositis;
TGCT	cis	rs1933488	1.000	rs6927516	chr6:153441831	G/A	cg24028809	chr6:153414101	RGS17	0.2	4.5	0.38	1.51e-5	Prostate cancer;
TGCT	trans	rs7726839	0.540	rs72703087	chr5:598029	C/T	cg11887960	chr12:57824829	NA	1.2	9.56	0.65	1.47e-16	Obesity-related traits;
TGCT	cis	rs17376456	1.000	rs34854140	chr5:93538169	G/A	cg25358565	chr5:93447407	FAM172A	0.93	7.91	0.58	1.22e-12	Diabetic retinopathy;
TGCT	cis	rs2153535	0.580	rs7743418	chr6:8438128	A/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.58	0.45	1.42e-7	Motion sickness;
TGCT	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg23982607	chr1:1823379	GNB1	-0.54	-8.17	-0.59	3.1e-13	Body mass index;
TGCT	cis	rs782590	0.967	rs35504023	chr2:55806503	C/T	cg03859395	chr2:55845619	SMEK2	-0.92	-11.39	-0.72	5.08e-21	Metabolic syndrome;
TGCT	cis	rs9611565	0.512	rs5758450	chr22:42141640	G/A	cg03806693	chr22:41940476	POLR3H	1.02	10.5	0.69	7.8e-19	Vitiligo;
TGCT	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg26118208	chr10:134322334	NA	0.25	4.65	0.39	8.37e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	trans	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg17830980	chr10:43048298	ZNF37B	-0.86	-11.18	-0.71	1.68e-20	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7811142	1.000	rs6972167	chr7:100080013	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.75	5.33	0.43	4.52e-7	Platelet count;
TGCT	cis	rs610932	0.517	rs474123	chr11:59901422	C/A	cg18570331	chr11:60101691	MS4A6E	-0.51	-4.58	-0.38	1.1e-5	Alzheimer's disease;
TGCT	cis	rs7937682	0.632	rs7128862	chr11:111755435	C/T	cg09085632	chr11:111637200	PPP2R1B	0.84	7.27	0.55	3.45e-11	Primary sclerosing cholangitis;
TGCT	cis	rs9467773	0.549	rs9461273	chr6:26584526	A/G	cg05738196	chr6:26577821	NA	-0.86	-10.85	-0.7	1.11e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs68170813	0.641	rs6979368	chr7:107089009	C/G	cg02696742	chr7:106810147	HBP1	-0.65	-5.15	-0.42	1.01e-6	Coronary artery disease;
TGCT	cis	rs7677751	0.806	rs7689569	chr4:55096398	G/A	cg17187183	chr4:55093834	PDGFRA	0.55	7.05	0.54	1.08e-10	Corneal astigmatism;
TGCT	cis	rs9916302	0.706	rs9899069	chr17:37540772	A/G	cg07936489	chr17:37558343	FBXL20	0.87	6.27	0.49	5.47e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs1570884	0.857	rs9535263	chr13:50137363	T/A	cg08779649	chr13:50194554	NA	0.3	4.45	0.37	1.92e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
TGCT	cis	rs9549367	0.713	rs3024769	chr13:113825601	A/C	cg18105134	chr13:113819100	PROZ	0.47	8.34	0.6	1.23e-13	Platelet distribution width;
TGCT	cis	rs2236918	0.710	rs1635510	chr1:242027500	G/T	cg04158730	chr1:242011433	EXO1	0.56	5.2	0.42	8.05e-7	Menopause (age at onset);
TGCT	cis	rs6967414	0.786	rs9639026	chr7:6746736	A/G	cg09896999	chr7:6746977	ZNF12	-0.59	-6.48	-0.5	1.96e-9	Hematocrit;Hemoglobin concentration;
TGCT	cis	rs2921036	0.503	rs7817832	chr8:8380821	T/C	cg06636001	chr8:8085503	FLJ10661	0.82	6.36	0.5	3.49e-9	Neuroticism;
TGCT	cis	rs4654899	0.865	rs6673455	chr1:21361048	T/C	cg01072550	chr1:21505969	NA	-0.47	-7.02	-0.53	1.28e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs4466137	0.794	rs6869296	chr5:83007333	C/G	cg16102102	chr5:83017553	HAPLN1	0.8	8.59	0.61	3.08e-14	Prostate cancer;
TGCT	cis	rs1505368	0.789	rs13419353	chr2:213271459	A/T	cg16329650	chr2:213403929	ERBB4	-0.59	-5.79	-0.46	5.49e-8	Symmetrical dimethylarginine levels;
TGCT	cis	rs4722166	0.630	rs10950916	chr7:22799667	C/T	cg23864514	chr7:22882512	NA	0.21	4.46	0.37	1.83e-5	Lung cancer;
TGCT	cis	rs7845219	0.544	rs10956932	chr8:95948202	C/T	cg09323728	chr8:95962352	TP53INP1	0.39	4.6	0.38	1.02e-5	Type 2 diabetes;
TGCT	cis	rs4294134	0.545	rs11534080	chr7:135247528	C/T	cg08396481	chr7:135194601	CNOT4	-0.58	-4.68	-0.39	7.53e-6	Paget's disease;
TGCT	cis	rs9926296	0.682	rs258328	chr16:89730314	C/T	cg26513180	chr16:89883248	FANCA	-0.67	-6.37	-0.5	3.32e-9	Vitiligo;
TGCT	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg18876405	chr7:65276391	NA	0.31	4.79	0.4	4.58e-6	Aortic root size;
TGCT	cis	rs4746818	0.901	rs4746816	chr10:70874866	G/T	cg11621586	chr10:70884670	VPS26A	1.14	7.94	0.58	1.03e-12	Left atrial antero-posterior diameter;
TGCT	cis	rs7614311	0.681	rs6796317	chr3:63927739	A/G	cg22134162	chr3:63841271	THOC7	-0.49	-6.18	-0.49	8.42e-9	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs7552404	0.731	rs17650138	chr1:76398887	C/T	cg03433033	chr1:76189801	ACADM	-0.84	-7.75	-0.57	2.91e-12	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2115630	0.936	rs11073663	chr15:85260268	A/G	cg12863693	chr15:85201151	NMB	-0.33	-4.52	-0.38	1.41e-5	P wave terminal force;
TGCT	cis	rs2180341	0.920	rs9398836	chr6:127576497	T/G	cg27446573	chr6:127587934	RNF146	1.07	9.73	0.66	5.7e-17	Breast cancer;
TGCT	cis	rs1577917	0.958	rs34622605	chr6:86456519	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.53	-0.44	1.8e-7	Response to antipsychotic treatment;
TGCT	cis	rs10504229	1.000	rs58608483	chr8:58195269	T/G	cg24829409	chr8:58192753	C8orf71	-0.49	-4.58	-0.38	1.11e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7267979	0.966	rs2227890	chr20:25260931	A/G	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs873946	0.564	rs2803991	chr10:134557068	A/G	cg17054783	chr10:134559939	INPP5A	0.23	4.48	0.37	1.66e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs17102423	0.723	rs55658675	chr14:65554638	C/T	cg11161011	chr14:65562177	MAX	-0.55	-7.7	-0.57	3.74e-12	Obesity-related traits;
TGCT	cis	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg15556689	chr8:8085844	FLJ10661	0.72	7.19	0.54	5.32e-11	Mood instability;
TGCT	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg21724239	chr8:58056113	NA	0.39	5.28	0.43	5.67e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-8.64	-0.61	2.39e-14	Platelet count;
TGCT	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	8.39	0.6	9.03e-14	Platelet count;
TGCT	cis	rs3733585	0.699	rs7686538	chr4:9948077	C/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.45	-0.5	2.22e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.51	-4.82	-0.4	4.16e-6	Bipolar disorder;
TGCT	cis	rs1568079	0.516	rs2361382	chr10:125220299	C/G	cg02936953	chr10:124639892	FAM24B;LOC399815	-0.35	-5.29	-0.43	5.31e-7	Body mass index;
TGCT	cis	rs9921222	0.500	rs8046256	chr16:393948	C/T	cg00101154	chr16:420108	MRPL28	-0.52	-5.01	-0.41	1.85e-6	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs7824557	0.579	rs10098322	chr8:11196295	C/G	cg21775007	chr8:11205619	TDH	0.7	6.85	0.52	3.08e-10	Retinal vascular caliber;
TGCT	cis	rs514406	0.505	rs431427	chr1:53179094	C/A	cg24675658	chr1:53192096	ZYG11B	-0.79	-9.71	-0.66	6.32e-17	Monocyte count;
TGCT	trans	rs2727020	0.729	rs6485965	chr11:49166730	C/T	cg03929089	chr4:120376271	NA	0.69	7.69	0.57	3.93e-12	Coronary artery disease;
TGCT	cis	rs11971779	0.793	rs11764426	chr7:139024050	C/G	cg07862535	chr7:139043722	LUC7L2	0.74	5.9	0.47	3.21e-8	Diisocyanate-induced asthma;
TGCT	cis	rs17030434	0.834	rs11734251	chr4:154732218	C/T	cg14289246	chr4:154710475	SFRP2	-0.91	-7.57	-0.56	7.44e-12	Electrocardiographic conduction measures;
TGCT	cis	rs1483890	0.723	rs13061189	chr3:69411453	T/C	cg22125112	chr3:69402811	FRMD4B	0.29	4.74	0.39	5.85e-6	Resting heart rate;
TGCT	cis	rs9814567	1.000	rs62269547	chr3:134214042	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.95	-9.62	-0.65	1.04e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs3796352	1.000	rs61172708	chr3:52996052	T/G	cg07884673	chr3:53033167	SFMBT1	0.6	5.53	0.44	1.82e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs727505	1.000	rs1541418	chr7:124448672	A/G	cg23710748	chr7:124431027	NA	-0.28	-4.9	-0.4	2.92e-6	Lewy body disease;
TGCT	cis	rs6964587	0.626	rs4422709	chr7:91510968	A/G	cg17063962	chr7:91808500	NA	-0.75	-7.02	-0.53	1.25e-10	Breast cancer;
TGCT	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg27170947	chr2:26402098	FAM59B	-0.39	-4.46	-0.37	1.8e-5	Gut microbiome composition (summer);
TGCT	cis	rs6089584	0.927	rs2296081	chr20:60572663	G/T	cg13770153	chr20:60521292	NA	-0.54	-7.57	-0.56	7.23e-12	Body mass index;
TGCT	cis	rs7979473	1	rs7979473	chr12:121420260	A/G	cg02403541	chr12:121454288	C12orf43	-0.52	-4.48	-0.37	1.68e-5	C-reactive protein;
TGCT	cis	rs6540559	0.546	rs735694	chr1:210034029	T/C	cg22029157	chr1:209979665	IRF6	0.79	5.78	0.46	5.6e-8	Cleft lip with or without cleft palate;
TGCT	cis	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg25427524	chr10:38739819	LOC399744	-0.39	-8.04	-0.59	5.95e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs35160687	0.829	rs13017143	chr2:86466549	C/T	cg03171300	chr2:86307199	POLR1A	-0.32	-5.28	-0.43	5.56e-7	Night sleep phenotypes;
TGCT	cis	rs2153535	0.563	rs1796688	chr6:8536423	A/T	cg23788917	chr6:8435910	SLC35B3	0.67	5.94	0.47	2.69e-8	Motion sickness;
TGCT	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg07343612	chr16:622815	PIGQ	-0.42	-8.25	-0.6	2.01e-13	Height;
TGCT	cis	rs8180040	0.620	rs749511	chr3:47035735	A/C	cg27129171	chr3:47204927	SETD2	-0.7	-8.34	-0.6	1.21e-13	Colorectal cancer;
TGCT	cis	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg03213289	chr20:61660250	NA	0.68	9.9	0.66	2.25e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg05785598	chr3:49045655	WDR6	0.36	4.8	0.4	4.48e-6	Parkinson's disease;
TGCT	cis	rs12519773	0.501	rs4321736	chr5:92533363	C/T	cg04854328	chr5:92914828	FLJ42709	-0.3	-4.58	-0.38	1.12e-5	Migraine;
TGCT	cis	rs763121	0.819	rs5757169	chr22:39003495	G/A	cg06022373	chr22:39101656	GTPBP1	0.81	8.26	0.6	1.84e-13	Menopause (age at onset);
TGCT	trans	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg21659725	chr3:3221576	CRBN	-0.73	-8.48	-0.61	5.64e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs554111	0.637	rs604659	chr1:21043913	T/C	cg08890418	chr1:21044141	KIF17	0.51	5.57	0.45	1.51e-7	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs868036	0.681	rs13329582	chr15:68104608	G/C	cg05925327	chr15:68127851	NA	-0.5	-4.85	-0.4	3.57e-6	Restless legs syndrome;
TGCT	cis	rs17376456	0.825	rs34592268	chr5:93232751	G/C	cg25358565	chr5:93447407	FAM172A	1.01	8.13	0.59	3.77e-13	Diabetic retinopathy;
TGCT	cis	rs950169	0.840	rs4842854	chr15:84942339	T/G	cg17173187	chr15:85201210	NMB	0.58	5.93	0.47	2.77e-8	Schizophrenia;
TGCT	cis	rs5750830	0.594	rs5757648	chr22:39775156	G/A	cg02038168	chr22:39784481	NA	-0.64	-5.48	-0.44	2.32e-7	Intelligence (multi-trait analysis);
TGCT	trans	rs561341	1.000	rs535151	chr17:30317405	C/T	cg20587970	chr11:113659929	NA	-0.96	-12.16	-0.74	6.93e-23	Hip circumference adjusted for BMI;
TGCT	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.69	-6.21	-0.49	7.3e-9	Tonsillectomy;
TGCT	cis	rs2880765	0.835	rs7163958	chr15:86045215	G/A	cg13263323	chr15:86062960	AKAP13	-0.23	-4.82	-0.4	4.1e-6	Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs34461023	chr4:99023751	C/T	cg05340658	chr4:99064831	C4orf37	0.5	5.64	0.45	1.09e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs904251	1.000	rs10947673	chr6:37445079	C/T	cg25019722	chr6:37503610	NA	-0.47	-6.26	-0.49	5.69e-9	Cognitive performance;
TGCT	cis	rs2692947	0.795	rs2252697	chr2:96778190	G/C	cg23100626	chr2:96804247	ASTL	-0.39	-4.68	-0.39	7.5e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs7552404	0.727	rs1146653	chr1:76280438	A/G	cg10523679	chr1:76189770	ACADM	0.74	7.2	0.54	5.04e-11	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs3772130	1.000	rs33988592	chr3:121415610	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.54	4.85	0.4	3.66e-6	Cognitive performance;
TGCT	cis	rs617219	0.597	rs10474581	chr5:78578884	G/A	cg23514016	chr5:78407564	BHMT	-0.34	-5.09	-0.42	1.29e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs4919694	0.572	rs12255989	chr10:104867206	C/T	cg04362960	chr10:104952993	NT5C2	0.99	7.01	0.53	1.36e-10	Arsenic metabolism;
TGCT	cis	rs1008375	1.000	rs4698641	chr4:17642630	C/T	cg10189774	chr4:17578691	LAP3	0.55	4.9	0.4	2.96e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6912958	0.535	rs242283	chr6:88030931	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.71	7.21	0.54	4.9e-11	Monocyte percentage of white cells;
TGCT	cis	rs9467773	0.620	rs2101581	chr6:26622769	G/T	cg09904177	chr6:26538194	HMGN4	0.67	6.48	0.5	1.97e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs2842992	0.958	rs2758318	chr6:160069637	C/G	cg11366901	chr6:160182831	ACAT2	0.92	6.27	0.49	5.5e-9	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg02353165	chr6:42928485	GNMT	0.94	9.36	0.64	4.5e-16	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs7639513	0.737	rs13070228	chr3:12706914	G/A	cg23032965	chr3:12705835	RAF1	0.77	8.55	0.61	3.81e-14	Itch intensity from mosquito bite;
TGCT	cis	rs9653442	0.564	rs2309756	chr2:100780269	G/C	cg07810366	chr2:100720526	AFF3	-0.36	-5.26	-0.43	6.14e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs769267	0.965	rs10419245	chr19:19383755	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.61	5.01	0.41	1.86e-6	Tonsillectomy;
TGCT	trans	rs1814175	0.511	rs61905634	chr11:49819736	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.35	-0.55	2.38e-11	Height;
TGCT	cis	rs453301	0.598	rs2921383	chr8:8892221	C/T	cg15556689	chr8:8085844	FLJ10661	0.76	6.87	0.52	2.8e-10	Joint mobility (Beighton score);
TGCT	cis	rs7175404	0.591	rs57685087	chr15:94060306	G/A	cg18324227	chr15:93584571	NA	0.5	4.88	0.4	3.15e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs8177179	0.560	rs8177237	chr3:133476421	C/G	cg08048268	chr3:133502702	NA	-0.44	-5.22	-0.42	7.37e-7	Iron status biomarkers (transferrin levels);
TGCT	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	4.51	0.38	1.48e-5	Menopause (age at onset);
TGCT	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg11301795	chr4:187892539	NA	-0.3	-4.48	-0.37	1.69e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.37	-4.91	-0.4	2.81e-6	Menarche (age at onset);
TGCT	cis	rs7666738	0.830	rs11725652	chr4:98878362	G/A	cg18180107	chr4:99064573	C4orf37	0.54	4.94	0.41	2.42e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9436747	0.641	rs3828039	chr1:66053556	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.53	4.68	0.39	7.45e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg10819733	chr22:24237672	NA	-0.31	-4.95	-0.41	2.37e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs4767364	1.000	rs7979545	chr12:112790648	T/C	cg10833066	chr12:111807467	FAM109A	0.33	5.1	0.42	1.23e-6	Oral cavity and pharyngeal cancer;
TGCT	cis	rs2197308	0.765	rs11182900	chr12:37934009	C/T	cg13010199	chr12:38710504	ALG10B	0.66	5.33	0.43	4.41e-7	Morning vs. evening chronotype;
TGCT	cis	rs11190604	1.000	rs11190578	chr10:102238953	C/T	cg16342193	chr10:102329863	NA	-0.4	-5.34	-0.43	4.36e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	trans	rs62103177	0.673	rs7242867	chr18:77603270	A/T	cg05926928	chr17:57297772	GDPD1	1.05	10.15	0.67	5.52e-18	Opioid sensitivity;
TGCT	trans	rs8073060	0.586	rs72829923	chr17:34045089	T/A	cg19694781	chr19:47549865	TMEM160	0.6	13.37	0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs7647973	0.592	rs6774202	chr3:49687779	T/G	cg03034192	chr3:50606346	HEMK1;C3orf18	0.36	4.75	0.39	5.61e-6	Menarche (age at onset);
TGCT	cis	rs11578119	0.898	rs10919391	chr1:170381360	T/C	cg09767346	chr1:170501363	GORAB	0.71	5.64	0.45	1.07e-7	Male-pattern baldness;
TGCT	cis	rs9911578	0.805	rs1811202	chr17:56454435	T/G	cg12560992	chr17:57184187	TRIM37	-0.71	-7.41	-0.55	1.69e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs6089584	1.000	rs6089587	chr20:60564829	C/T	cg06108461	chr20:60628389	TAF4	-0.53	-7.39	-0.55	1.9e-11	Body mass index;
TGCT	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.45	6.77	0.52	4.52e-10	Schizophrenia;
TGCT	cis	rs8180040	0.739	rs4683320	chr3:47152992	C/T	cg27129171	chr3:47204927	SETD2	0.76	9.9	0.66	2.25e-17	Colorectal cancer;
TGCT	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs231513	0.769	rs537169	chr17:41976740	G/A	cg26893861	chr17:41843967	DUSP3	-0.71	-5.33	-0.43	4.45e-7	Cognitive function;
TGCT	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg05896524	chr21:47604654	C21orf56	0.4	4.53	0.38	1.37e-5	Testicular germ cell tumor;
TGCT	cis	rs9902453	1.000	rs4328498	chr17:28344276	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-6.55	-0.51	1.36e-9	Coffee consumption (cups per day);
TGCT	cis	rs9926296	0.632	rs4785716	chr16:89801127	T/C	cg27121462	chr16:89883253	FANCA	0.55	5.06	0.41	1.45e-6	Vitiligo;
TGCT	cis	rs6750047	0.932	rs11124631	chr2:38274908	A/G	cg07380506	chr2:38303506	CYP1B1	-0.6	-5.31	-0.43	4.92e-7	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg11764359	chr7:65958608	NA	-0.55	-5.08	-0.42	1.34e-6	Aortic root size;
TGCT	cis	rs7666738	0.800	rs10028921	chr4:98962630	G/T	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.83e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg17345569	chr6:42928274	GNMT	-0.48	-4.97	-0.41	2.22e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs1153858	1.000	rs1980288	chr15:45620612	T/C	cg14582100	chr15:45693742	SPATA5L1	0.48	5.65	0.45	1.05e-7	Homoarginine levels;
TGCT	cis	rs6569992	0.500	rs3752383	chr6:135522755	A/G	cg22676075	chr6:135203613	NA	0.77	4.86	0.4	3.51e-6	Red blood cell traits;
TGCT	cis	rs6840360	0.571	rs72728182	chr4:152487027	T/C	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.0	-0.58	7.69e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs4919669	0.668	rs10786700	chr10:104387735	C/T	cg05855489	chr10:104503620	C10orf26	0.73	4.67	0.39	7.6e-6	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs9914988	0.943	rs11656256	chr17:27153553	G/A	cg20469991	chr17:27169893	C17orf63	-0.72	-5.09	-0.42	1.28e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	trans	rs66573146	0.831	rs6851488	chr4:6987412	C/T	cg07817883	chr1:32538562	TMEM39B	1.33	7.25	0.55	4.02e-11	Granulocyte percentage of myeloid white cells;
TGCT	trans	rs11764590	0.585	rs11772463	chr7:2078132	A/C	cg25206134	chr2:45395956	NA	0.97	6.73	0.52	5.68e-10	Neuroticism;
TGCT	cis	rs7267979	1.000	rs6037105	chr20:25374199	C/A	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10751667	0.666	rs10902247	chr11:953686	G/A	cg06064525	chr11:970664	AP2A2	-0.35	-8.22	-0.59	2.29e-13	Alzheimer's disease (late onset);
TGCT	cis	rs6545883	0.929	rs12713436	chr2:61691260	T/C	cg15711740	chr2:61764176	XPO1	-0.6	-5.5	-0.44	2.09e-7	Tuberculosis;
TGCT	cis	rs6545883	0.929	rs12612982	chr2:61747355	G/A	cg15711740	chr2:61764176	XPO1	-0.57	-5.29	-0.43	5.32e-7	Tuberculosis;
TGCT	cis	rs75686122	0.892	rs17806378	chr8:104544502	T/C	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs7833790	0.777	rs1005850	chr8:82692255	G/A	cg06027949	chr8:82754900	SNX16	-0.67	-4.47	-0.37	1.75e-5	Diastolic blood pressure;
TGCT	cis	rs10465746	0.967	rs6576956	chr1:84343885	T/G	cg10977910	chr1:84465055	TTLL7	0.63	6.19	0.49	8.08e-9	Obesity-related traits;
TGCT	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg05872129	chr22:39784769	NA	0.87	9.27	0.64	7.32e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs514406	0.861	rs11206026	chr1:53281708	G/A	cg25767906	chr1:53392781	SCP2	-0.47	-5.31	-0.43	4.84e-7	Monocyte count;
TGCT	cis	rs231513	0.954	rs231479	chr17:41983616	A/G	cg26893861	chr17:41843967	DUSP3	-0.76	-5.44	-0.44	2.67e-7	Cognitive function;
TGCT	cis	rs1801251	0.727	rs6437071	chr2:233568793	G/A	cg08000102	chr2:233561755	GIGYF2	0.62	7.0	0.53	1.43e-10	Coronary artery disease;
TGCT	cis	rs2439831	1.000	rs550239	chr15:43720197	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.8	5.7	0.46	8.33e-8	Lung cancer in ever smokers;
TGCT	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg19318889	chr4:1322082	MAEA	0.27	6.62	0.51	9.72e-10	Longevity;
TGCT	cis	rs62244186	0.566	rs55852922	chr3:44826188	A/G	cg18722847	chr3:44754129	ZNF502	-0.4	-4.49	-0.37	1.59e-5	Depressive symptoms;
TGCT	cis	rs11249608	0.548	rs34054398	chr5:178458371	A/G	cg21905437	chr5:178450457	ZNF879	0.44	4.62	0.38	9.35e-6	Pubertal anthropometrics;
TGCT	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg03188948	chr7:1209495	NA	0.64	5.38	0.43	3.61e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs8070740	0.898	rs4442872	chr17:5324236	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	4.77	0.39	5.14e-6	Menopause (age at onset);
TGCT	cis	rs9467711	0.720	rs1417998	chr6:26162019	T/A	cg16898833	chr6:26189333	HIST1H4D	1.02	5.17	0.42	9.02e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs75686122	0.892	rs12681640	chr8:104669409	C/G	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs208520	0.874	rs208456	chr6:66907942	A/G	cg07460842	chr6:66804631	NA	-0.9	-9.14	-0.63	1.54e-15	Exhaled nitric oxide output;
TGCT	cis	rs73198271	0.960	rs10503392	chr8:8609555	G/C	ch.8.214553F	chr8:8189620	PRAGMIN	-0.27	-4.62	-0.38	9.34e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs13256369	1.000	rs12547721	chr8:8570671	C/T	cg17143192	chr8:8559678	CLDN23	0.58	5.55	0.45	1.64e-7	Obesity-related traits;
TGCT	cis	rs1371867	0.846	rs2439460	chr8:101312665	C/T	cg06636551	chr8:101224915	SPAG1	-0.42	-5.65	-0.45	1.06e-7	Atrioventricular conduction;
TGCT	cis	rs17125944	0.505	rs2295826	chr14:53174923	C/T	cg00686598	chr14:53173677	PSMC6	-1.18	-7.11	-0.54	8.02e-11	Alzheimer's disease (late onset);
TGCT	cis	rs10089	1.000	rs62373701	chr5:127416294	C/T	cg19767477	chr5:127420684	SLC12A2	-0.46	-4.84	-0.4	3.74e-6	Ileal carcinoids;
TGCT	cis	rs1153858	1.000	rs4774578	chr15:45646051	G/A	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.62e-8	Homoarginine levels;
TGCT	cis	rs9430161	0.611	rs34032547	chr1:11034374	C/G	cg27631724	chr1:11040367	C1orf127	0.53	6.05	0.48	1.58e-8	Ewing sarcoma;
TGCT	cis	rs6728642	1.000	rs6728642	chr2:97607071	A/G	cg26665480	chr2:98280029	ACTR1B	-0.92	-5.54	-0.45	1.74e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	cis	rs6121246	0.909	rs6060679	chr20:30270772	C/G	cg13852791	chr20:30311386	BCL2L1	-0.78	-5.8	-0.46	5.15e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs2762353	0.935	rs1892249	chr6:25768992	A/G	cg03264133	chr6:25882463	NA	0.52	5.51	0.44	2.01e-7	Blood metabolite levels;
TGCT	cis	rs8014252	0.803	rs74062726	chr14:70986179	A/G	cg11204974	chr14:71022665	NA	-0.53	-4.46	-0.37	1.79e-5	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
TGCT	cis	rs112217694	1.000	rs78594675	chr4:104642796	C/A	cg24090629	chr4:104641072	TACR3	-0.97	-4.81	-0.4	4.25e-6	Menarche (age at onset);
TGCT	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg13206674	chr6:150067644	NUP43	0.52	4.51	0.38	1.5e-5	Lung cancer;
TGCT	trans	rs564343	0.563	rs574335	chr11:65833266	C/T	cg26701943	chr11:108369231	KDELC2	0.72	6.73	0.52	5.71e-10	Obesity (early onset extreme);
TGCT	cis	rs3087591	0.960	rs1124918	chr17:29492423	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.46	-7.55	-0.56	8.04e-12	Hip circumference;
TGCT	cis	rs4767364	1.000	rs7977534	chr12:112717920	T/C	cg10833066	chr12:111807467	FAM109A	0.33	5.1	0.42	1.23e-6	Oral cavity and pharyngeal cancer;
TGCT	cis	rs225245	0.755	rs7217565	chr17:34024707	C/A	cg05299278	chr17:33885742	SLFN14	0.21	4.5	0.37	1.54e-5	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs9394841	0.692	rs13193235	chr6:41792659	T/C	cg08135965	chr6:41755394	TOMM6	0.55	5.17	0.42	9.29e-7	Mean corpuscular hemoglobin;Red cell distribution width;
TGCT	cis	rs877282	0.898	rs11253346	chr10:765313	A/G	cg17470449	chr10:769945	NA	0.37	5.59	0.45	1.37e-7	Uric acid levels;
TGCT	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg04013166	chr16:89971882	TCF25	0.32	4.76	0.39	5.31e-6	Skin colour saturation;
TGCT	cis	rs10751667	0.666	rs7395182	chr11:927553	A/C	cg06064525	chr11:970664	AP2A2	-0.35	-8.09	-0.59	4.54e-13	Alzheimer's disease (late onset);
TGCT	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg21724239	chr8:58056113	NA	0.39	5.14	0.42	1.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7772486	0.875	rs11155452	chr6:146424631	C/T	cg13319975	chr6:146136371	FBXO30	-0.51	-4.48	-0.37	1.69e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9359856	0.510	rs3736984	chr6:90408589	C/T	cg13799429	chr6:90582589	CASP8AP2	0.45	4.66	0.39	7.9e-6	Bipolar disorder;
TGCT	cis	rs1552244	0.688	rs113940455	chr3:10014165	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	5.55	0.45	1.66e-7	Alzheimer's disease;
TGCT	cis	rs7635838	0.819	rs4684782	chr3:11518755	C/T	cg00170343	chr3:11313890	ATG7	-0.69	-6.67	-0.51	7.44e-10	HDL cholesterol;
TGCT	cis	rs473651	0.777	rs550890	chr2:239332555	G/A	cg08773314	chr2:239334832	ASB1	0.49	7.08	0.54	9.56e-11	Multiple system atrophy;
TGCT	cis	rs67072384	1.000	rs55957377	chr11:72445476	A/G	cg03713592	chr11:72463424	ARAP1	-0.9	-4.63	-0.38	9.26e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs6988636	1.000	rs16898088	chr8:124190501	G/A	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs17270561	0.562	rs74293932	chr6:26014811	C/A	cg16482183	chr6:26056742	HIST1H1C	0.97	7.36	0.55	2.21e-11	Iron status biomarkers;
TGCT	cis	rs7666738	0.830	rs9995386	chr4:98907826	T/C	cg17366294	chr4:99064904	C4orf37	0.67	6.94	0.53	1.91e-10	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs1814175	0.817	rs7924619	chr11:49620632	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.38	-7.79	-0.57	2.3e-12	Height;
TGCT	cis	rs3806843	0.676	rs1583005	chr5:140031537	G/A	cg19875535	chr5:140030758	IK	-0.36	-6.26	-0.49	5.68e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs651907	0.557	rs7629753	chr3:101371922	C/T	cg11279151	chr3:101281821	RG9MTD1	0.33	6.92	0.53	2.1e-10	Colorectal cancer;
TGCT	cis	rs8077889	0.672	rs15359	chr17:41843979	C/G	cg26893861	chr17:41843967	DUSP3	-1.15	-21.87	-0.89	2.21e-44	Triglycerides;
TGCT	cis	rs10782582	0.609	rs112431348	chr1:76275571	A/G	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.52	4.54	0.38	1.31e-5	Daytime sleep phenotypes;
TGCT	cis	rs6901250	0.851	rs339361	chr6:117162515	C/T	cg12892004	chr6:117198278	RFX6	0.58	7.17	0.54	6.08e-11	C-reactive protein levels;
TGCT	cis	rs1865760	0.573	rs7450342	chr6:25919480	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.6	6.38	0.5	3.26e-9	Height;
TGCT	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg10295955	chr4:187884368	NA	-0.97	-14.51	-0.79	1.72e-28	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9534288	0.762	rs9534264	chr13:46541673	T/A	cg15192986	chr13:46630673	CPB2	-0.53	-7.66	-0.57	4.65e-12	Blood protein levels;
TGCT	cis	rs6912958	0.712	rs9444526	chr6:88326402	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-4.55	-0.38	1.26e-5	Monocyte percentage of white cells;
TGCT	cis	rs208520	0.821	rs9363572	chr6:67012231	C/T	cg07460842	chr6:66804631	NA	0.69	5.72	0.46	7.53e-8	Exhaled nitric oxide output;
TGCT	cis	rs910316	1.000	rs3742773	chr14:75579643	A/G	cg11812906	chr14:75593930	NEK9	0.75	7.4	0.55	1.77e-11	Height;
TGCT	cis	rs9467773	0.935	rs11752946	chr6:26560364	C/A	cg02458000	chr6:26745757	NA	0.56	5.47	0.44	2.41e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7582180	0.591	rs62148360	chr2:101006319	C/T	cg14675211	chr2:100938903	LONRF2	0.5	4.77	0.39	5.1e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2458413	1.000	rs2458414	chr8:105355840	A/G	cg04554929	chr8:105342491	NA	0.52	7.14	0.54	6.76e-11	Paget's disease;
TGCT	cis	rs10782582	0.545	rs111927462	chr1:76195422	A/G	cg03433033	chr1:76189801	ACADM	-0.59	-6.57	-0.51	1.24e-9	Daytime sleep phenotypes;
TGCT	cis	rs975752	0.717	rs7916126	chr10:102007373	T/C	cg04750910	chr10:102416409	NA	0.73	4.48	0.37	1.69e-5	Schizophrenia;
TGCT	cis	rs1561288	0.553	rs12988548	chr2:25323083	A/T	cg15423357	chr2:25149977	NA	-0.5	-4.53	-0.38	1.36e-5	Body mass index;
TGCT	cis	rs2288884	1.000	rs72483951	chr19:52573682	G/C	cg13540795	chr19:52551618	ZNF432	-0.59	-5.02	-0.41	1.79e-6	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs28595532	0.920	rs56302493	chr4:119772382	A/T	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs9916302	0.571	rs28799952	chr17:37533056	C/T	cg07936489	chr17:37558343	FBXL20	0.87	6.27	0.49	5.47e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs1580019	0.883	rs6945294	chr7:32472099	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.83	7.82	0.57	1.98e-12	Cognitive ability;
TGCT	cis	rs6750047	0.625	rs59363818	chr2:38261973	A/C	cg07380506	chr2:38303506	CYP1B1	-0.58	-5.2	-0.42	8.09e-7	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs9818758	0.607	rs9837625	chr3:49215966	C/T	cg07636037	chr3:49044803	WDR6	-1.04	-5.15	-0.42	1.01e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg06212747	chr3:49208901	KLHDC8B	0.66	6.19	0.49	7.94e-9	Menarche (age at onset);
TGCT	cis	rs1215050	0.740	rs1214997	chr4:99041533	A/T	cg05340658	chr4:99064831	C4orf37	0.43	5.27	0.43	5.73e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9894429	1.000	rs7503679	chr17:79583843	G/C	cg18240062	chr17:79603768	NPLOC4	0.67	6.84	0.52	3.23e-10	Eye color traits;
TGCT	cis	rs7772486	0.875	rs1331640	chr6:146427250	G/A	cg05347473	chr6:146136440	FBXO30	0.56	5.21	0.42	7.7e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg27436995	chr16:743998	FBXL16	-0.47	-5.13	-0.42	1.07e-6	Height;
TGCT	cis	rs910316	0.687	rs175059	chr14:75490667	T/C	cg08847533	chr14:75593920	NEK9	-0.84	-8.77	-0.62	1.16e-14	Height;
TGCT	cis	rs835154	0.845	rs835156	chr5:14875813	C/A	cg14843632	chr5:14870594	ANKH	0.33	4.6	0.38	1.02e-5	Blood metabolite levels;
TGCT	cis	rs16866061	1.000	rs72974263	chr2:225447371	C/T	cg12698349	chr2:225449008	CUL3	1.01	9.99	0.67	1.31e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	cis	rs7824557	0.547	rs4512344	chr8:11078781	A/C	cg21775007	chr8:11205619	TDH	-0.51	-4.7	-0.39	6.83e-6	Retinal vascular caliber;
TGCT	cis	rs7044106	0.791	rs10985004	chr9:123484937	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.62	6.67	0.51	7.39e-10	Hip circumference adjusted for BMI;
TGCT	cis	rs35146811	0.844	rs12705071	chr7:99682026	T/C	cg13334819	chr7:99746414	C7orf59	-0.78	-6.52	-0.51	1.61e-9	Coronary artery disease;
TGCT	cis	rs734999	0.588	rs876938	chr1:2523212	G/C	cg18854424	chr1:2615690	NA	0.46	5.23	0.43	6.92e-7	Ulcerative colitis;
TGCT	cis	rs1903068	0.719	rs9284955	chr4:56003117	A/G	cg16572876	chr4:56024045	NA	-0.43	-4.59	-0.38	1.05e-5	Endometriosis;
TGCT	cis	rs11148252	0.538	rs9535880	chr13:52706143	G/A	cg00495681	chr13:53174319	NA	0.57	5.87	0.47	3.78e-8	Lewy body disease;
TGCT	cis	rs6087990	0.806	rs6088008	chr20:31382860	A/G	cg13636640	chr20:31349939	DNMT3B	1.06	14.04	0.78	2.21e-27	Ulcerative colitis;
TGCT	cis	rs62103177	0.810	rs62103197	chr18:77632923	G/A	cg12964065	chr18:77638022	KCNG2	0.37	4.76	0.39	5.4e-6	Opioid sensitivity;
TGCT	cis	rs56309584	0.560	rs7223859	chr17:8080853	C/T	cg08322244	chr17:8066669	VAMP2	0.51	4.83	0.4	3.91e-6	Initial pursuit acceleration;
TGCT	cis	rs4478858	0.735	rs12734617	chr1:31823446	G/T	cg07478791	chr1:31886160	SERINC2	-0.47	-4.55	-0.38	1.29e-5	Alcohol dependence;
TGCT	cis	rs12220238	0.908	rs4746179	chr10:75940169	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.78	0.57	2.42e-12	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs4713118	0.616	rs9348789	chr6:28025486	C/T	cg12963246	chr6:28129442	ZNF389	0.45	4.55	0.38	1.27e-5	Parkinson's disease;
TGCT	cis	rs12762955	0.561	rs2620942	chr10:1048398	C/T	cg18964960	chr10:1102726	WDR37	0.67	5.88	0.47	3.53e-8	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs79976124	0.760	rs74295030	chr6:66654441	T/C	cg07460842	chr6:66804631	NA	0.58	5.29	0.43	5.33e-7	Type 2 diabetes;
TGCT	cis	rs2710642	0.886	rs10153716	chr2:63007059	A/G	cg17519650	chr2:63277830	OTX1	-0.64	-5.9	-0.47	3.29e-8	LDL cholesterol levels;LDL cholesterol;
TGCT	cis	rs11748023	0.531	rs155947	chr5:139520556	C/T	cg01081189	chr5:139537190	NA	0.26	4.62	0.38	9.35e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9858542	0.953	rs1873625	chr3:49666964	C/A	cg03060546	chr3:49711283	APEH	-0.64	-5.7	-0.46	8.18e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs7647973	0.961	rs4955417	chr3:49298205	T/C	cg05785598	chr3:49045655	WDR6	0.39	4.61	0.38	9.91e-6	Menarche (age at onset);
TGCT	cis	rs3806843	0.676	rs753280	chr5:140024042	C/T	cg19875535	chr5:140030758	IK	0.35	6.27	0.49	5.41e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2288884	0.943	rs1433089	chr19:52506985	T/C	cg15405931	chr19:52693188	PPP2R1A	-0.75	-5.19	-0.42	8.38e-7	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs12477438	0.871	rs13396584	chr2:99611768	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.64	4.86	0.4	3.42e-6	Chronic sinus infection;
TGCT	cis	rs12477438	0.520	rs13022329	chr2:99731189	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.82	0.62	8.67e-15	Chronic sinus infection;
TGCT	cis	rs17376456	0.877	rs114256265	chr5:93473130	T/A	cg21475434	chr5:93447410	FAM172A	0.61	4.73	0.39	5.98e-6	Diabetic retinopathy;
TGCT	cis	rs9837602	0.507	rs793448	chr3:99532949	G/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.58	6.71	0.52	6.1e-10	Breast cancer;
TGCT	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg24829409	chr8:58192753	C8orf71	-0.57	-5.38	-0.43	3.63e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7705042	0.659	rs11743029	chr5:141509282	G/A	cg07392085	chr5:141489673	NDFIP1	-0.34	-4.54	-0.38	1.34e-5	Asthma;
TGCT	cis	rs7412746	0.658	rs4970988	chr1:150950062	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.39	-4.72	-0.39	6.38e-6	Melanoma;
TGCT	cis	rs11031096	0.754	rs4910886	chr11:4143721	G/T	cg18678763	chr11:4115507	RRM1	-0.46	-5.78	-0.46	5.76e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs903263	0.870	rs955492	chr1:84657539	A/T	cg09664975	chr1:84543551	PRKACB	0.47	4.48	0.37	1.65e-5	Breast cancer (male);
TGCT	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.11	13.91	0.78	4.47e-27	Height;
TGCT	cis	rs9467773	0.620	rs2130657	chr6:26650826	C/T	cg15659132	chr6:26577336	NA	0.87	10.72	0.69	2.19e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs9393777	0.513	rs9348728	chr6:26634436	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.59	-5.33	-0.43	4.44e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs6840360	0.642	rs2709842	chr4:152370637	C/T	cg17479576	chr4:152424074	FAM160A1	0.56	6.0	0.47	2.02e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9902453	0.704	rs2628179	chr17:28071796	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.74	-6.95	-0.53	1.82e-10	Coffee consumption (cups per day);
TGCT	cis	rs9467773	0.620	rs6925087	chr6:26592853	T/A	cg05738196	chr6:26577821	NA	0.88	11.13	0.71	2.26e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs2072499	0.966	rs11587860	chr1:156156951	G/C	cg24450063	chr1:156163899	SLC25A44	1.15	15.99	0.82	6.37e-32	Testicular germ cell tumor;
TGCT	cis	rs10832963	1.000	rs10832962	chr11:18656271	C/T	cg20219074	chr11:18656078	SPTY2D1	0.98	9.9	0.66	2.19e-17	Breast cancer;
TGCT	cis	rs6831352	0.918	rs2851248	chr4:100045974	A/G	cg12011299	chr4:100065546	ADH4	0.39	4.76	0.39	5.29e-6	Alcohol dependence;
TGCT	cis	rs7666738	0.570	rs1869351	chr4:99077286	T/C	cg17366294	chr4:99064904	C4orf37	0.58	5.46	0.44	2.55e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9796	0.835	rs11856848	chr15:41370961	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.47	-6.09	-0.48	1.34e-8	Menopause (age at onset);
TGCT	cis	rs7647973	0.560	rs77473999	chr3:49777660	T/C	cg05785598	chr3:49045655	WDR6	-0.43	-5.13	-0.42	1.07e-6	Menarche (age at onset);
TGCT	cis	rs3849570	0.925	rs6799080	chr3:81905591	G/A	cg07356753	chr3:81810745	GBE1	-0.74	-6.77	-0.52	4.57e-10	Waist circumference;Body mass index;
TGCT	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg21724239	chr8:58056113	NA	0.38	4.76	0.39	5.39e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9611565	0.649	rs5758466	chr22:42176059	G/A	cg03806693	chr22:41940476	POLR3H	0.9	8.76	0.62	1.2e-14	Vitiligo;
TGCT	cis	rs12048904	0.505	rs6577209	chr1:101255080	A/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.8	6.85	0.52	2.99e-10	Multiple sclerosis;
TGCT	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg05665937	chr4:1216051	CTBP1	0.24	4.52	0.38	1.4e-5	Obesity-related traits;
TGCT	cis	rs9291683	0.609	rs7678012	chr4:9993772	T/C	cg00071950	chr4:10020882	SLC2A9	0.71	9.25	0.64	8.04e-16	Bone mineral density;
TGCT	cis	rs7017914	0.967	rs13264669	chr8:71626772	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.55	-5.13	-0.42	1.11e-6	Bone mineral density;
TGCT	cis	rs523522	0.962	rs4766966	chr12:120942911	G/C	cg27279351	chr12:120934652	DYNLL1	0.76	6.59	0.51	1.15e-9	High light scatter reticulocyte count;
TGCT	cis	rs9913156	0.707	rs72835625	chr17:4560274	G/A	cg00122941	chr17:4613640	ARRB2	0.87	7.38	0.55	1.95e-11	Lymphocyte counts;
TGCT	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg22166914	chr1:53195759	ZYG11B	0.35	5.78	0.46	5.7e-8	Monocyte count;
TGCT	cis	rs12367572	0.965	rs7979717	chr12:45242272	A/T	cg04608330	chr12:45269318	NELL2	-0.65	-6.96	-0.53	1.74e-10	Gut microbiome composition (summer);
TGCT	cis	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg22857025	chr5:266934	NA	-0.31	-6.32	-0.49	4.33e-9	Breast cancer;
TGCT	cis	rs929354	0.772	rs1182448	chr7:157021415	G/A	cg05182265	chr7:156933206	UBE3C	0.4	9.05	0.63	2.54e-15	Body mass index;
TGCT	cis	rs2204008	0.837	rs11172728	chr12:38070042	C/A	cg26384229	chr12:38710491	ALG10B	0.85	7.76	0.57	2.71e-12	Bladder cancer;
TGCT	cis	rs734999	0.505	rs10797437	chr1:2539006	T/C	cg18854424	chr1:2615690	NA	0.46	5.36	0.43	4e-7	Ulcerative colitis;
TGCT	cis	rs9303401	0.659	rs7210700	chr17:56668186	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs9467711	0.606	rs34781270	chr6:26593037	A/G	cg16898833	chr6:26189333	HIST1H4D	1.26	5.95	0.47	2.59e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs57994353	0.568	rs3812581	chr9:139311471	C/T	cg13741927	chr9:139327495	INPP5E	-0.24	-5.42	-0.44	2.99e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs10276381	0.685	rs56398224	chr7:28205748	A/AT	cg23620719	chr7:28220237	JAZF1	0.95	5.05	0.41	1.54e-6	Crohn's disease;
TGCT	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg02018176	chr4:1364513	KIAA1530	0.29	4.81	0.4	4.34e-6	Longevity;
TGCT	cis	rs7666738	0.830	rs1534318	chr4:98965058	C/T	cg18180107	chr4:99064573	C4orf37	0.55	5.0	0.41	1.9e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.56	-5.32	-0.43	4.76e-7	Prudent dietary pattern;
TGCT	cis	rs3820928	1.000	rs3820927	chr2:227779191	C/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-4.92	-0.4	2.75e-6	Pulmonary function;
TGCT	cis	rs13064411	0.696	rs13325046	chr3:113104444	C/T	cg10517650	chr3:113235015	CCDC52	-0.35	-4.65	-0.38	8.54e-6	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs514406	0.505	rs856721	chr1:53162156	C/A	cg25767906	chr1:53392781	SCP2	-0.45	-4.85	-0.4	3.64e-6	Monocyte count;
TGCT	cis	rs1580019	0.961	rs4255041	chr7:32496383	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.79	7.42	0.55	1.63e-11	Cognitive ability;
TGCT	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg00024416	chr22:24240387	NA	-0.25	-4.79	-0.39	4.74e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9810089	0.814	rs864437	chr3:136119909	C/G	cg12473912	chr3:136751656	NA	0.36	5.04	0.41	1.58e-6	Gestational age at birth (child effect);
TGCT	cis	rs9818758	0.607	rs113186424	chr3:49272726	T/C	cg07636037	chr3:49044803	WDR6	-1.04	-5.13	-0.42	1.09e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs10986311	0.832	rs10119911	chr9:127127172	A/G	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.21	4.97	0.41	2.13e-6	Vitiligo;
TGCT	cis	rs587847	0.737	rs4924154	chr15:37666384	C/T	cg00216138	chr15:37171175	LOC145845	0.31	4.45	0.37	1.91e-5	Intraocular pressure;
TGCT	cis	rs7666738	0.791	rs13146909	chr4:98934198	C/T	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs16924631	0.518	rs7033570	chr9:6440123	G/A	cg13560576	chr9:5833327	ERMP1	0.78	4.63	0.38	9.23e-6	Periodontal microbiota;
TGCT	cis	rs10984561	0.881	rs7032085	chr9:122253740	G/T	cg14242995	chr9:122249943	NA	0.74	6.01	0.47	1.96e-8	Pulmonary function decline;
TGCT	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg12310025	chr6:25882481	NA	-0.62	-6.42	-0.5	2.62e-9	Blood metabolite levels;
TGCT	cis	rs7772486	0.754	rs9386132	chr6:146140751	T/C	cg13319975	chr6:146136371	FBXO30	-0.57	-5.1	-0.42	1.22e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9527	0.590	rs1926029	chr10:104855670	C/T	cg04362960	chr10:104952993	NT5C2	0.65	5.38	0.43	3.64e-7	Arsenic metabolism;
TGCT	cis	rs11096990	0.593	rs7662880	chr4:39285224	C/T	cg20847110	chr4:39482781	LOC401127	-0.16	-4.51	-0.38	1.46e-5	Cognitive function;
TGCT	cis	rs7666738	0.830	rs3857217	chr4:99034347	T/C	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4455778	0.664	rs12718313	chr7:49024855	G/A	cg26309511	chr7:48887640	NA	-0.43	-5.07	-0.41	1.4e-6	Lung cancer in never smokers;
TGCT	cis	rs2361718	0.500	rs4889818	chr17:78085228	A/G	cg22255288	chr17:78854418	RPTOR	-0.25	-4.55	-0.38	1.27e-5	Yeast infection;
TGCT	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg00343986	chr7:65444356	GUSB	0.24	5.25	0.43	6.3e-7	Aortic root size;
TGCT	cis	rs6089829	0.888	rs4809467	chr20:61671688	A/G	cg03213289	chr20:61660250	NA	0.72	9.45	0.65	2.69e-16	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7647973	0.593	rs9870755	chr3:49809841	A/G	cg03034192	chr3:50606346	HEMK1;C3orf18	0.36	4.8	0.4	4.49e-6	Menarche (age at onset);
TGCT	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg10295955	chr4:187884368	NA	-0.96	-14.31	-0.79	5.02e-28	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2739330	0.964	rs2739338	chr22:24297130	T/C	cg25703541	chr22:24373054	LOC391322	-0.81	-8.7	-0.62	1.68e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.61	-8.65	-0.61	2.24e-14	Longevity;Endometriosis;
TGCT	cis	rs7666738	0.830	rs6831925	chr4:98947401	T/C	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8077577	0.945	rs8069094	chr17:18096528	C/T	cg09161412	chr17:18057145	MYO15A	-0.64	-5.22	-0.42	7.2e-7	Obesity-related traits;
TGCT	trans	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg17830980	chr10:43048298	ZNF37B	-0.86	-11.18	-0.71	1.68e-20	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7772486	0.806	rs2265477	chr6:146212338	T/C	cg23711669	chr6:146136114	FBXO30	0.83	9.16	0.64	1.32e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs13256369	0.826	rs12678414	chr8:8586016	G/T	cg17143192	chr8:8559678	CLDN23	0.58	5.25	0.43	6.26e-7	Obesity-related traits;
TGCT	trans	rs7824557	0.564	rs2572392	chr8:11235605	T/G	cg15556689	chr8:8085844	FLJ10661	-0.74	-6.7	-0.52	6.48e-10	Retinal vascular caliber;
TGCT	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg18135555	chr8:22132992	PIWIL2	0.3	6.14	0.48	1.02e-8	Hypertriglyceridemia;
TGCT	cis	rs7568458	0.846	rs6705971	chr2:85761417	G/T	cg17127132	chr2:85788382	GGCX	-0.55	-5.38	-0.43	3.63e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs12681287	0.547	rs9297921	chr8:87542286	C/T	cg27223183	chr8:87520930	FAM82B	0.94	6.91	0.53	2.24e-10	Caudate activity during reward;
TGCT	cis	rs2932538	0.922	rs61818800	chr1:113148571	A/G	cg22162597	chr1:113214053	CAPZA1	0.23	4.71	0.39	6.44e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	trans	rs797680	0.822	rs1572343	chr1:93616202	T/C	cg27528825	chr2:159282178	CCDC148	-0.35	-6.77	-0.52	4.54e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs9911578	0.817	rs304264	chr17:56749628	A/G	cg05425664	chr17:57184151	TRIM37	-0.62	-6.29	-0.49	5.01e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs2836950	0.520	rs59916147	chr21:40634702	T/G	cg11644478	chr21:40555479	PSMG1	-0.52	-4.79	-0.4	4.64e-6	Menarche (age at onset);
TGCT	cis	rs11190604	1.000	rs2273694	chr10:102256496	G/T	cg23241863	chr10:102295624	HIF1AN	0.69	5.31	0.43	4.99e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7647973	1.000	rs3448	chr3:49396751	T/C	cg06212747	chr3:49208901	KLHDC8B	0.59	4.7	0.39	6.94e-6	Menarche (age at onset);
TGCT	cis	rs4455778	0.539	rs7780870	chr7:49014630	A/G	cg26309511	chr7:48887640	NA	-0.44	-5.68	-0.45	9.03e-8	Lung cancer in never smokers;
TGCT	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs8078723	0.901	rs709591	chr17:38175561	T/A	cg17467752	chr17:38218738	THRA	0.52	4.93	0.41	2.54e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg25767906	chr1:53392781	SCP2	-0.57	-6.81	-0.52	3.8e-10	Monocyte count;
TGCT	cis	rs1865760	0.663	rs9348704	chr6:26000393	A/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.7	6.81	0.52	3.72e-10	Height;
TGCT	cis	rs7666738	0.830	rs28867087	chr4:98880349	T/A	cg05340658	chr4:99064831	C4orf37	0.54	6.13	0.48	1.06e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs13242816	1.000	rs3807995	chr7:116197976	C/T	cg16553024	chr7:116138462	CAV2	-0.44	-5.23	-0.43	7e-7	P wave duration;
TGCT	cis	rs6964587	1.000	rs2299238	chr7:91654517	G/A	cg17063962	chr7:91808500	NA	0.91	9.99	0.67	1.32e-17	Breast cancer;
TGCT	cis	rs7937682	0.883	rs659529	chr11:111436896	T/A	cg09085632	chr11:111637200	PPP2R1B	-0.98	-10.12	-0.67	6.37e-18	Primary sclerosing cholangitis;
TGCT	cis	rs9914544	1.000	rs1634409	chr17:18836177	C/T	cg26378065	chr17:18585709	ZNF286B	0.54	4.85	0.4	3.67e-6	Educational attainment (years of education);
TGCT	cis	rs9467773	0.620	rs2101581	chr6:26622769	G/T	cg26531700	chr6:26746687	NA	0.51	4.77	0.39	5.07e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9486715	1.000	rs6899647	chr6:97065661	A/G	cg06623918	chr6:96969491	KIAA0776	-1.08	-13.52	-0.77	3.67e-26	Headache;
TGCT	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg21862992	chr11:68658383	NA	0.47	6.58	0.51	1.19e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs6866344	0.697	rs62392823	chr5:178126968	T/C	cg03877680	chr5:178157825	ZNF354A	0.73	5.72	0.46	7.46e-8	Neutrophil percentage of white cells;
TGCT	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg19729930	chr2:74357872	NA	0.57	7.78	0.57	2.42e-12	Gestational age at birth (maternal effect);
TGCT	cis	rs6671200	0.607	rs3753872	chr1:95699184	T/G	cg26537280	chr1:95699037	RWDD3	-0.51	-4.9	-0.4	2.94e-6	Stearic acid (18:0) levels;
TGCT	cis	rs34014631	1.000	rs3758557	chr10:103572925	A/G	cg22630918	chr10:102748988	C10orf2	0.43	4.8	0.4	4.57e-6	Coronary artery calcification;
TGCT	cis	rs9894429	1.000	rs9748176	chr17:79584043	C/G	cg18240062	chr17:79603768	NPLOC4	0.7	7.23	0.54	4.45e-11	Eye color traits;
TGCT	cis	rs1062177	0.901	rs1549622	chr5:151266049	A/G	cg12924095	chr5:151150029	G3BP1	0.35	4.81	0.4	4.36e-6	Preschool internalizing problems;
TGCT	cis	rs6121246	0.559	rs6060932	chr20:30350545	A/G	cg13852791	chr20:30311386	BCL2L1	0.82	8.0	0.58	7.65e-13	Mean corpuscular hemoglobin;
TGCT	cis	rs35306767	0.903	rs12244355	chr10:944465	T/C	cg26597838	chr10:835615	NA	0.76	10.69	0.69	2.61e-19	Eosinophil percentage of granulocytes;
TGCT	cis	rs6598955	0.671	rs17257169	chr1:26570009	C/T	cg04990556	chr1:26633338	UBXN11	0.61	5.26	0.43	6.13e-7	Obesity-related traits;
TGCT	cis	rs2486288	0.656	rs12899058	chr15:45547324	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.72	-7.46	-0.56	1.34e-11	Glomerular filtration rate;
TGCT	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg06873352	chr17:61820015	STRADA	0.55	5.69	0.46	8.57e-8	Prudent dietary pattern;
TGCT	cis	rs3749237	0.964	rs34522271	chr3:49808517	A/G	cg03060546	chr3:49711283	APEH	0.72	7.36	0.55	2.17e-11	Resting heart rate;
TGCT	cis	rs2075165	0.901	rs2274226	chr1:156314627	C/T	cg16558208	chr1:156270281	VHLL	-0.27	-4.83	-0.4	3.87e-6	Tonsillectomy;
TGCT	cis	rs9633740	0.945	rs6586030	chr10:82254047	C/T	cg01528321	chr10:82214614	TSPAN14	-0.9	-7.09	-0.54	9.14e-11	Post bronchodilator FEV1;
TGCT	cis	rs4819052	1.000	rs4819052	chr21:46699777	A/G	cg06618935	chr21:46677482	NA	-0.38	-4.98	-0.41	2.08e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.51	-4.97	-0.41	2.18e-6	Prudent dietary pattern;
TGCT	cis	rs2204008	0.594	rs2711545	chr12:38061039	C/T	cg26384229	chr12:38710491	ALG10B	0.58	4.96	0.41	2.24e-6	Bladder cancer;
TGCT	cis	rs7312933	0.669	rs7974476	chr12:42542484	C/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.57	5.24	0.43	6.8e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs2439831	0.681	rs28578454	chr15:43603032	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.94	6.23	0.49	6.7e-9	Lung cancer in ever smokers;
TGCT	cis	rs9611519	0.761	rs35445172	chr22:41660301	G/A	cg13695892	chr22:41940480	POLR3H	-0.64	-6.05	-0.48	1.58e-8	Neuroticism;
TGCT	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg11890956	chr21:40555474	PSMG1	-0.76	-7.39	-0.55	1.87e-11	Cognitive function;
TGCT	cis	rs2836974	0.830	rs2735309	chr21:40715313	C/T	cg11890956	chr21:40555474	PSMG1	0.99	9.11	0.63	1.78e-15	Cognitive function;
TGCT	cis	rs13064411	0.696	rs9839921	chr3:113199093	G/C	cg18753928	chr3:113234510	CCDC52	-0.7	-5.75	-0.46	6.6e-8	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.34	0.43	4.23e-7	Prudent dietary pattern;
TGCT	cis	rs2439831	0.618	rs8023508	chr15:44176103	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.66	-4.64	-0.38	8.61e-6	Lung cancer in ever smokers;
TGCT	cis	rs13191362	1.000	rs36107456	chr6:162997399	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.57	4.94	0.41	2.45e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7843479	0.601	rs2002941	chr8:21834366	A/C	cg17168535	chr8:21777572	XPO7	0.8	8.11	0.59	4.09e-13	Mean corpuscular volume;
TGCT	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg17554472	chr22:41940697	POLR3H	0.48	5.14	0.42	1.05e-6	Vitiligo;
TGCT	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg01577475	chr2:114033581	PAX8;LOC440839	-0.44	-4.75	-0.39	5.42e-6	Lymphocyte counts;
TGCT	trans	rs17685	0.753	rs6465000	chr7:75787417	G/A	cg19862616	chr7:65841803	NCRNA00174	0.52	9.01	0.63	3.02e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg04025307	chr7:1156635	C7orf50	0.24	5.59	0.45	1.39e-7	Longevity;Endometriosis;
TGCT	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg17178900	chr1:205818956	PM20D1	0.66	9.32	0.64	5.66e-16	Menarche (age at onset);
TGCT	cis	rs1801251	1.000	rs283484	chr2:233646505	A/G	cg08000102	chr2:233561755	GIGYF2	0.64	6.52	0.51	1.58e-9	Coronary artery disease;
TGCT	cis	rs75686122	0.655	rs4472479	chr8:104624760	C/T	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg07507251	chr3:52567010	NT5DC2	0.47	6.64	0.51	8.82e-10	Electroencephalogram traits;
TGCT	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg03407747	chr17:6899364	ALOX12	-0.48	-5.37	-0.43	3.8e-7	Tonsillectomy;
TGCT	cis	rs17384381	1.000	rs79695640	chr1:85836073	T/C	cg16011679	chr1:85725395	C1orf52	0.84	6.52	0.51	1.6e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs734999	0.572	rs2985857	chr1:2532624	C/T	cg18854424	chr1:2615690	NA	-0.44	-5.1	-0.42	1.22e-6	Ulcerative colitis;
TGCT	cis	rs6882046	0.513	rs1081158	chr5:88004616	C/T	cg22951263	chr5:87985283	NA	-0.59	-6.28	-0.49	5.21e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs514406	0.505	rs387436	chr1:53179376	C/T	cg25767906	chr1:53392781	SCP2	0.47	5.35	0.43	4.15e-7	Monocyte count;
TGCT	cis	rs11203032	0.831	rs7477966	chr10:90924258	A/G	cg16672925	chr10:90967113	CH25H	0.73	4.5	0.37	1.55e-5	Heart failure;
TGCT	cis	rs12971120	0.891	rs12968731	chr18:72169708	G/T	cg26446133	chr18:72167187	CNDP2	-0.37	-6.33	-0.49	4.13e-9	Refractive error;
TGCT	cis	rs9818758	0.556	rs9814987	chr3:49207849	T/C	cg07636037	chr3:49044803	WDR6	-1.02	-5.13	-0.42	1.09e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs6835098	0.692	rs10520252	chr4:174070959	T/C	cg08422745	chr4:174089978	GALNT7	-0.77	-8.6	-0.61	2.87e-14	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs9419702	0.538	rs9322837	chr10:133539229	G/A	cg23460707	chr10:133558971	NA	0.43	4.85	0.4	3.57e-6	Survival in rectal cancer;
TGCT	cis	rs12579753	0.913	rs12579018	chr12:82231943	T/C	cg07988820	chr12:82153109	PPFIA2	-0.6	-6.48	-0.5	1.91e-9	Resting heart rate;
TGCT	cis	rs928736	0.557	rs2834083	chr21:34436973	A/G	cg00274965	chr21:34405681	NA	0.52	5.93	0.47	2.81e-8	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs10464366	0.746	rs4723821	chr7:39141532	A/G	cg15212455	chr7:39170539	POU6F2	0.26	5.62	0.45	1.19e-7	IgG glycosylation;
TGCT	cis	rs7937682	0.737	rs542275	chr11:111431614	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.79	-8.12	-0.59	4e-13	Primary sclerosing cholangitis;
TGCT	cis	rs6840360	0.571	rs72730104	chr4:152543857	A/G	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.0	-0.58	7.69e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs929354	0.772	rs1182360	chr7:157020550	C/G	cg05182265	chr7:156933206	UBE3C	-0.4	-9.08	-0.63	2.11e-15	Body mass index;
TGCT	cis	rs8017423	0.935	rs7144335	chr14:90732280	A/G	cg04374321	chr14:90722782	PSMC1	-0.79	-7.85	-0.58	1.66e-12	Mortality in heart failure;
TGCT	cis	rs12971120	1.000	rs3829640	chr18:72174980	A/G	cg26446133	chr18:72167187	CNDP2	-0.34	-6.31	-0.49	4.51e-9	Refractive error;
TGCT	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg16049864	chr8:95962084	TP53INP1	-0.76	-11.14	-0.71	2.13e-20	Type 2 diabetes;
TGCT	cis	rs9811920	0.638	rs796977	chr3:99549723	T/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.6	6.82	0.52	3.63e-10	Axial length;
TGCT	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg16680214	chr1:154839983	KCNN3	-0.36	-7.26	-0.55	3.81e-11	Prostate cancer;
TGCT	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg06634786	chr22:41940651	POLR3H	-0.88	-8.54	-0.61	3.98e-14	Vitiligo;
TGCT	cis	rs7208859	0.673	rs60020217	chr17:29185054	G/A	cg14008862	chr17:28927542	LRRC37B2	0.72	4.66	0.39	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7017914	0.967	rs6999739	chr8:71637212	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.03	-0.41	1.69e-6	Bone mineral density;
TGCT	cis	rs929354	0.772	rs2301914	chr7:157000176	T/C	cg05182265	chr7:156933206	UBE3C	-0.39	-8.77	-0.62	1.19e-14	Body mass index;
TGCT	cis	rs7552404	1.000	rs1498315	chr1:76159225	G/A	cg03433033	chr1:76189801	ACADM	0.83	9.91	0.66	2.13e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2070488	0.730	rs2268759	chr3:38514327	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.8	8.08	0.59	4.79e-13	Electrocardiographic conduction measures;
TGCT	cis	rs13202913	0.709	rs11965449	chr6:151830598	C/T	cg03627880	chr6:151815985	C6orf97	0.56	5.88	0.47	3.48e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs35146811	0.700	rs2950520	chr7:99827148	T/C	cg04778012	chr7:99775508	STAG3;GPC2	-0.35	-5.09	-0.42	1.31e-6	Coronary artery disease;
TGCT	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.08	0.48	1.37e-8	Bipolar disorder;
TGCT	cis	rs3008870	1.000	rs58680688	chr1:67443751	C/G	cg11518657	chr1:67396239	MIER1	-0.54	-4.61	-0.38	9.72e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs2718812	0.766	rs12497513	chr3:133388670	C/G	cg16414030	chr3:133502952	NA	0.4	5.32	0.43	4.76e-7	Iron status biomarkers;
TGCT	cis	rs9486715	1.000	rs2273621	chr6:97058553	A/G	cg18709589	chr6:96969512	KIAA0776	-0.78	-7.29	-0.55	3.22e-11	Headache;
TGCT	cis	rs921968	0.541	rs41461846	chr2:219313354	A/G	cg02176678	chr2:219576539	TTLL4	-0.51	-7.35	-0.55	2.31e-11	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs1670533	1.000	rs4690213	chr4:1054868	C/T	cg27284194	chr4:1044797	NA	0.68	5.88	0.47	3.56e-8	Recombination rate (females);
TGCT	cis	rs3809566	0.632	rs9806533	chr15:63328298	A/G	cg08198488	chr15:63333792	TPM1	-0.33	-4.97	-0.41	2.15e-6	Platelet count;
TGCT	cis	rs6460942	1.000	rs6460938	chr7:12406808	T/G	cg06484146	chr7:12443880	VWDE	-0.57	-5.34	-0.43	4.36e-7	Coronary artery disease;
TGCT	cis	rs981844	0.712	rs1037652	chr4:154746565	C/T	cg14289246	chr4:154710475	SFRP2	0.99	9.12	0.63	1.65e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs7552404	0.960	rs12085123	chr1:76149749	G/A	cg03433033	chr1:76189801	ACADM	0.83	9.91	0.66	2.13e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs17253792	0.822	rs74609892	chr14:56053002	G/A	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.53	-6.22	-0.49	7.09e-9	Longevity;Endometriosis;
TGCT	cis	rs2933343	0.729	rs789231	chr3:128602847	A/G	cg11901034	chr3:128598214	ACAD9	-0.68	-6.63	-0.51	9.16e-10	IgG glycosylation;
TGCT	cis	rs7605378	0.528	rs1704190	chr2:200760629	G/A	cg23649088	chr2:200775458	C2orf69	0.47	9.78	0.66	4.27e-17	Osteoporosis;
TGCT	cis	rs11785400	0.793	rs750530	chr8:143744931	G/A	cg10596483	chr8:143751796	JRK	0.55	5.48	0.44	2.29e-7	Schizophrenia;
TGCT	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	8.05	0.59	5.82e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs62244186	0.659	rs7649834	chr3:44503732	C/T	cg21672276	chr3:44754072	ZNF502	-0.41	-4.62	-0.38	9.62e-6	Depressive symptoms;
TGCT	cis	rs80282103	0.618	rs74117850	chr10:1165777	T/C	cg08668510	chr10:1095578	IDI1	1.07	5.04	0.41	1.59e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs9372498	0.572	rs62422230	chr6:118959436	T/C	cg21191810	chr6:118973309	C6orf204	-0.38	-4.98	-0.41	2.04e-6	Diastolic blood pressure;
TGCT	cis	rs739496	0.615	rs4646777	chr12:112230036	G/A	cg10833066	chr12:111807467	FAM109A	0.36	4.67	0.39	7.74e-6	Platelet count;
TGCT	cis	rs8070128	0.534	rs2955350	chr17:17953548	G/A	cg04398451	chr17:18023971	MYO15A	0.34	5.49	0.44	2.21e-7	Total body bone mineral density;
TGCT	trans	rs4332037	0.539	rs55988458	chr7:2059761	G/A	cg10840412	chr1:235813424	GNG4	0.94	6.84	0.52	3.21e-10	Bipolar disorder;
TGCT	cis	rs9467773	0.587	rs9467722	chr6:26352566	T/C	cg05738196	chr6:26577821	NA	-0.62	-6.72	-0.52	5.8e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs9388451	0.772	rs1268064	chr6:126042578	G/A	cg05901451	chr6:126070800	HEY2	0.98	12.62	0.75	5.47e-24	Brugada syndrome;
TGCT	cis	rs9291683	0.609	rs55959894	chr4:10026580	G/A	cg11266682	chr4:10021025	SLC2A9	0.66	9.53	0.65	1.78e-16	Bone mineral density;
TGCT	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg04511125	chr2:88470314	THNSL2	-0.47	-4.44	-0.37	1.96e-5	Response to metformin (IC50);
TGCT	cis	rs631288	0.557	rs4534444	chr1:146679283	T/C	cg25205988	chr1:146714368	CHD1L	1.33	5.42	0.44	2.97e-7	PR interval in Tripanosoma cruzi seropositivity;
TGCT	cis	rs752092	1.000	rs7182945	chr15:101784223	C/T	cg25114630	chr15:101792522	CHSY1	0.57	5.54	0.45	1.71e-7	Corneal structure;
TGCT	trans	rs1908814	0.516	rs4840597	chr8:11796068	A/C	cg15556689	chr8:8085844	FLJ10661	0.75	7.26	0.55	3.66e-11	Neuroticism;
TGCT	cis	rs11208691	0.520	rs4655795	chr1:66159368	G/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.54	4.44	0.37	1.98e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs1868673	0.545	rs10804747	chr3:150094926	A/C	cg24290546	chr3:150134309	TSC22D2	-0.3	-4.75	-0.39	5.42e-6	Waist circumference;
TGCT	cis	rs17030434	0.953	rs6535953	chr4:154728186	G/A	cg14289246	chr4:154710475	SFRP2	-0.89	-7.01	-0.53	1.33e-10	Electrocardiographic conduction measures;
TGCT	cis	rs12711979	0.509	rs1031478	chr2:3827425	G/A	cg17052675	chr2:3827356	NA	-0.56	-13.37	-0.77	8.42e-26	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.5	-6.94	-0.53	1.89e-10	Alzheimer's disease;
TGCT	cis	rs75059851	0.756	rs7122746	chr11:133838808	A/G	cg14047540	chr11:133829660	NA	-0.5	-5.04	-0.41	1.61e-6	Schizophrenia;
TGCT	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg09359103	chr1:154839909	KCNN3	-0.66	-12.15	-0.74	7.27e-23	Prostate cancer;
TGCT	cis	rs739496	0.947	rs55851737	chr12:111936838	T/C	cg10833066	chr12:111807467	FAM109A	0.37	5.16	0.42	9.31e-7	Platelet count;
TGCT	cis	rs7659604	0.521	rs10001697	chr4:122677737	G/T	cg19748678	chr4:122722346	EXOSC9	-0.51	-5.0	-0.41	1.89e-6	Type 2 diabetes;
TGCT	cis	rs12497850	1.000	rs1352420	chr3:48757291	A/G	cg06212747	chr3:49208901	KLHDC8B	0.62	5.72	0.46	7.46e-8	Parkinson's disease;
TGCT	cis	rs9581857	0.547	rs9581877	chr13:28104321	T/A	cg22138327	chr13:27999177	GTF3A	0.72	4.75	0.39	5.45e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs11098499	0.863	rs12502389	chr4:120454191	A/G	cg09307838	chr4:120376055	NA	0.69	6.53	0.51	1.49e-9	Corneal astigmatism;
TGCT	cis	rs1372520	0.684	rs356191	chr4:90688120	G/A	cg20003494	chr4:90757398	SNCA	0.56	4.46	0.37	1.83e-5	Neuroticism;
TGCT	cis	rs2562456	0.958	rs2562508	chr19:21726281	G/A	cg01304269	chr19:21688519	ZNF429	-0.57	-4.77	-0.39	5.02e-6	Pain;
TGCT	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg26338869	chr17:61819248	STRADA	-0.53	-4.87	-0.4	3.29e-6	Prudent dietary pattern;
TGCT	cis	rs72781680	0.716	rs2551326	chr2:23982378	T/C	cg08917208	chr2:24149416	ATAD2B	0.75	5.04	0.41	1.59e-6	Lymphocyte counts;
TGCT	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg09365446	chr1:150670422	GOLPH3L	0.31	4.64	0.38	8.7e-6	Tonsillectomy;
TGCT	cis	rs10791097	0.690	rs12284487	chr11:130729705	T/C	cg12179176	chr11:130786555	SNX19	0.73	8.69	0.62	1.75e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs7772486	0.597	rs1970306	chr6:146154543	A/G	cg13319975	chr6:146136371	FBXO30	-0.67	-6.06	-0.48	1.53e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2404602	0.967	rs12148805	chr15:76800659	G/A	cg26408565	chr15:76604113	ETFA	-0.41	-5.28	-0.43	5.48e-7	Blood metabolite levels;
TGCT	cis	rs12145833	0.596	rs12043646	chr1:243281992	G/A	cg02356786	chr1:243265016	LOC731275	0.52	4.53	0.38	1.36e-5	Obesity (early onset extreme);
TGCT	cis	rs6088580	0.634	rs2378134	chr20:32938085	C/T	cg06115741	chr20:33292138	TP53INP2	-0.56	-4.91	-0.4	2.77e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg00684032	chr4:1343700	KIAA1530	0.23	4.95	0.41	2.36e-6	Obesity-related traits;
TGCT	cis	rs9341808	0.718	rs910266	chr6:80921170	A/T	cg08355045	chr6:80787529	NA	0.32	5.6	0.45	1.29e-7	Sitting height ratio;
TGCT	cis	rs12497850	0.931	rs6446196	chr3:49004723	A/G	cg05785598	chr3:49045655	WDR6	0.37	4.83	0.4	3.94e-6	Parkinson's disease;
TGCT	cis	rs950169	0.526	rs698620	chr15:85177208	G/A	cg17173187	chr15:85201210	NMB	-0.47	-5.88	-0.47	3.59e-8	Schizophrenia;
TGCT	cis	rs9611565	0.607	rs132792	chr22:42062822	C/T	cg13695892	chr22:41940480	POLR3H	0.83	8.01	0.58	7.22e-13	Vitiligo;
TGCT	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg23708337	chr7:1209742	NA	0.6	5.57	0.45	1.53e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs8077889	0.917	rs4793037	chr17:41914826	C/T	cg26893861	chr17:41843967	DUSP3	1.11	13.36	0.77	8.83e-26	Triglycerides;
TGCT	cis	rs807669	0.934	rs762523	chr22:19180589	A/G	cg02655711	chr22:19163373	SLC25A1	0.42	9.94	0.67	1.76e-17	Metabolite levels;
TGCT	cis	rs10501293	0.912	rs4755694	chr11:43088582	A/G	cg03447554	chr11:43094025	NA	-0.47	-6.61	-0.51	1.04e-9	Cognitive performance;
TGCT	cis	rs62244186	0.545	rs7640654	chr3:44763037	A/C	cg15687855	chr3:44754131	ZNF502	-0.52	-6.31	-0.49	4.59e-9	Depressive symptoms;
TGCT	cis	rs9302065	0.565	rs2993584	chr13:95961678	C/A	cg26751094	chr13:95954534	ABCC4	-0.4	-6.74	-0.52	5.33e-10	Blood metabolite levels;
TGCT	cis	rs28735056	0.904	rs72980087	chr18:77632194	G/A	cg20368463	chr18:77673604	PQLC1	-0.45	-5.55	-0.45	1.65e-7	Schizophrenia;
TGCT	cis	rs10949662	0.961	rs75323120	chr7:157529590	C/A	cg14168080	chr7:157504135	PTPRN2	-0.39	-4.6	-0.38	1.05e-5	Intelligence (multi-trait analysis);
TGCT	trans	rs77457752	0.525	rs1923351	chr9:13898902	G/A	cg25510823	chr7:47085976	NA	0.45	6.68	0.51	7.21e-10	Breast cancer;
TGCT	cis	rs9486719	1.000	rs3798296	chr6:97052286	G/A	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.32	-0.6	1.32e-13	Migraine;Coronary artery disease;
TGCT	cis	rs75229567	0.717	rs77874289	chr12:70234203	A/G	cg10114359	chr12:70132523	RAB3IP	1.55	7.66	0.57	4.5e-12	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
TGCT	cis	rs17767294	0.708	rs72848767	chr6:27909287	C/A	cg08851530	chr6:28072375	NA	1.56	7.22	0.54	4.47e-11	Parkinson's disease;
TGCT	cis	rs9902453	0.836	rs62070337	chr17:28466257	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	6.39	0.5	3.03e-9	Coffee consumption (cups per day);
TGCT	cis	rs10193935	1.000	rs10193935	chr2:42419829	C/T	cg27598129	chr2:42591480	NA	-0.4	-5.44	-0.44	2.73e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7714584	1.000	rs11739677	chr5:150294883	A/G	cg22134413	chr5:150180641	NA	1.01	7.24	0.55	4.17e-11	Crohn's disease;
TGCT	cis	rs12477438	0.765	rs2309454	chr2:99595418	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-4.88	-0.4	3.17e-6	Chronic sinus infection;
TGCT	cis	rs79057730	0.639	rs6463933	chr7:793954	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.69	6.59	0.51	1.11e-9	Initial pursuit acceleration;
TGCT	cis	rs7582180	0.629	rs2164847	chr2:100958715	C/T	cg14675211	chr2:100938903	LONRF2	0.5	4.78	0.39	4.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs12510870	0.599	rs28838047	chr4:74410925	C/T	cg05868023	chr4:75230803	EREG	0.56	5.14	0.42	1.06e-6	Iris color (b* coordinate);
TGCT	cis	rs42648	0.869	rs1015403	chr7:89913702	A/G	cg25739043	chr7:89950458	NA	-0.73	-7.31	-0.55	2.87e-11	Homocysteine levels;
TGCT	cis	rs7975161	0.624	rs11111943	chr12:104632418	T/C	cg25273343	chr12:104657179	TXNRD1	-0.35	-4.83	-0.4	3.87e-6	Toenail selenium levels;
TGCT	cis	rs7959452	0.535	rs4761228	chr12:69682327	G/A	cg20891283	chr12:69753455	YEATS4	0.65	6.39	0.5	3.1e-9	Blood protein levels;
TGCT	trans	rs1864729	1.000	rs2567773	chr8:98279182	G/A	cg08679828	chr8:102218111	ZNF706	-1.1	-7.71	-0.57	3.56e-12	Estradiol plasma levels (breast cancer);
TGCT	trans	rs34421088	0.560	rs2248325	chr8:11396874	A/G	cg15556689	chr8:8085844	FLJ10661	-0.75	-7.08	-0.54	9.46e-11	Neuroticism;
TGCT	cis	rs514406	0.584	rs7548832	chr1:53193576	A/T	cg08736216	chr1:53307985	ZYG11A	-0.24	-4.48	-0.37	1.68e-5	Monocyte count;
TGCT	cis	rs6714788	0.565	rs12712063	chr2:100663281	C/T	cg07810366	chr2:100720526	AFF3	-0.37	-5.53	-0.44	1.82e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs711245	0.637	rs6729495	chr2:36834192	T/A	cg10546459	chr2:36825355	FEZ2	0.57	5.39	0.44	3.48e-7	Height;
TGCT	cis	rs6671200	0.607	rs3767315	chr1:95705972	A/G	cg20701556	chr1:95698924	RWDD3	-0.52	-5.34	-0.43	4.26e-7	Stearic acid (18:0) levels;
TGCT	trans	rs11082490	1.000	rs61104666	chr18:43420177	G/A	cg05654096	chr12:106477691	NUAK1	0.55	6.66	0.51	8.03e-10	Response to paliperidone in schizophrenia (positive Marder score);Response to paliperidone in schizophrenia (PANSS score);
TGCT	trans	rs1974653	0.672	rs9606243	chr22:20080927	A/G	cg08822737	chr17:71088851	SLC39A11	-0.93	-7.61	-0.56	5.97e-12	Schizophrenia;
TGCT	cis	rs7945705	0.692	rs11042149	chr11:9010737	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.45	-4.82	-0.4	4.11e-6	Hemoglobin concentration;
TGCT	cis	rs12049351	0.774	rs12024146	chr1:229660891	C/T	cg12130225	chr1:229698885	NA	0.38	4.63	0.38	8.95e-6	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs9300255	0.602	rs1790095	chr12:123681222	G/A	cg00376283	chr12:123451042	ABCB9	0.72	5.61	0.45	1.27e-7	Neutrophil percentage of white cells;
TGCT	cis	rs10836699	0.586	rs2662199	chr11:37200795	A/C	cg18520238	chr11:36422557	PRR5L	0.18	4.52	0.38	1.41e-5	Low high density lipoprotein cholesterol levels;
TGCT	cis	rs9611565	0.546	rs5758426	chr22:42098763	T/G	cg17554472	chr22:41940697	POLR3H	0.47	5.06	0.41	1.46e-6	Vitiligo;
TGCT	cis	rs301043	0.500	rs2596765	chr12:95896810	G/A	cg07805603	chr12:95869602	METAP2	0.41	5.19	0.42	8.35e-7	Immature fraction of reticulocytes;
TGCT	cis	rs12145833	0.538	rs9803701	chr1:243391634	T/C	cg02356786	chr1:243265016	LOC731275	-0.59	-5.11	-0.42	1.18e-6	Obesity (early onset extreme);
TGCT	cis	rs28595532	0.925	rs116785973	chr4:119611350	G/A	cg14228332	chr4:119757509	SEC24D	1.0	5.76	0.46	6.22e-8	Cannabis dependence symptom count;
TGCT	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg09737314	chr17:6899359	ALOX12	-0.44	-4.82	-0.4	4.08e-6	Tonsillectomy;
TGCT	cis	rs2658782	0.547	rs3020064	chr11:93060851	A/G	cg15737290	chr11:93063684	CCDC67	1.04	11.37	0.71	5.74e-21	Pulmonary function decline;
TGCT	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg03303774	chr4:1407052	NA	0.31	4.96	0.41	2.25e-6	Obesity-related traits;
TGCT	cis	rs9814567	0.762	rs13071852	chr3:134223217	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.83	6.53	0.51	1.51e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs4950928	0.823	rs2486065	chr1:203167871	A/G	cg17014757	chr1:203156097	CHI3L1	-0.37	-4.76	-0.39	5.19e-6	YKL-40 levels;
TGCT	cis	rs6570726	0.875	rs12524077	chr6:145866333	G/C	cg05347473	chr6:146136440	FBXO30	0.49	4.54	0.38	1.29e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2439831	0.850	rs11070408	chr15:44034788	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	5.91	0.47	3.05e-8	Lung cancer in ever smokers;
TGCT	cis	rs7552404	0.924	rs1146580	chr1:76209935	T/C	cg03433033	chr1:76189801	ACADM	0.77	9.25	0.64	8.26e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	trans	rs877282	0.842	rs7092986	chr10:756373	G/A	cg22713356	chr15:30763199	NA	1.07	8.27	0.6	1.75e-13	Uric acid levels;
TGCT	cis	rs6589563	0.737	rs73588403	chr11:116628271	C/T	cg01124546	chr11:117515332	DSCAML1	-0.45	-4.85	-0.4	3.69e-6	Eosinophil counts;
TGCT	cis	rs1062177	0.951	rs2915876	chr5:151150745	C/A	cg00977110	chr5:151150581	G3BP1	0.4	4.57	0.38	1.18e-5	Preschool internalizing problems;
TGCT	cis	rs7086627	0.515	rs7078254	chr10:82212193	C/T	cg00277334	chr10:82204260	NA	-0.56	-8.71	-0.62	1.61e-14	Post bronchodilator FEV1;
TGCT	cis	rs478304	0.651	rs11227299	chr11:65549570	C/G	cg17480646	chr11:65405466	SIPA1	-0.55	-6.43	-0.5	2.55e-9	Acne (severe);
TGCT	cis	rs12497850	1.000	rs4858828	chr3:48724811	C/T	cg07636037	chr3:49044803	WDR6	0.92	10.34	0.68	1.91e-18	Parkinson's disease;
TGCT	cis	rs6088590	1.000	rs6087625	chr20:33342477	A/G	cg06115741	chr20:33292138	TP53INP2	-0.68	-5.7	-0.46	8.23e-8	Coronary artery disease;
TGCT	cis	rs7267979	1.000	rs2482940	chr20:25349830	C/T	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3757318	0.540	rs6916386	chr6:151853773	G/C	cg18745416	chr6:152011399	ESR1	0.54	4.89	0.4	3.06e-6	Breast cancer (estrogen-receptor negative, progesterone-receptor negative, and human epidermal growth factor-receptor negative);Breast cancer;
TGCT	cis	rs514406	0.584	rs7548832	chr1:53193576	A/T	cg01802117	chr1:53393560	SCP2	-0.4	-4.63	-0.38	9.22e-6	Monocyte count;
TGCT	cis	rs10992471	0.756	rs2761681	chr9:95186937	A/G	cg14631576	chr9:95140430	CENPP	-0.3	-4.97	-0.41	2.21e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs637571	0.584	rs594689	chr11:65635559	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.63	-6.57	-0.51	1.24e-9	Eosinophil percentage of white cells;
TGCT	cis	rs263156	1.000	rs263157	chr6:142908618	A/G	cg18419694	chr6:143832440	FUCA2	0.4	4.65	0.39	8.22e-6	Ear morphology;Lobe size;Lobe attachment;
TGCT	cis	rs1568889	1.000	rs7949057	chr11:28255053	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.82	8.44	0.6	6.97e-14	Bipolar disorder;
TGCT	cis	rs9296092	0.560	rs9469511	chr6:33530930	T/G	cg13560919	chr6:33536144	NA	-0.22	-4.95	-0.41	2.33e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	trans	rs7726839	0.561	rs11955068	chr5:582324	C/T	cg11887960	chr12:57824829	NA	0.98	7.81	0.57	2.09e-12	Obesity-related traits;
TGCT	cis	rs2836974	0.545	rs8128901	chr21:40710419	G/A	cg17971929	chr21:40555470	PSMG1	0.6	5.52	0.44	1.92e-7	Cognitive function;
TGCT	cis	rs7666738	0.830	rs4292342	chr4:98959870	A/T	cg18180107	chr4:99064573	C4orf37	0.58	5.39	0.44	3.4e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2153535	0.580	rs9406165	chr6:8488837	C/T	cg23788917	chr6:8435910	SLC35B3	0.62	5.64	0.45	1.11e-7	Motion sickness;
TGCT	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	6.95	0.53	1.86e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7769051	1.000	rs12203977	chr6:133122760	A/G	cg07930552	chr6:133119739	C6orf192	0.93	5.0	0.41	1.87e-6	Type 2 diabetes nephropathy;
TGCT	cis	rs6845621	0.716	rs13142105	chr4:18882307	A/T	cg12196642	chr4:18937545	NA	-0.24	-4.49	-0.37	1.62e-5	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
TGCT	cis	rs2456568	0.802	rs10765638	chr11:93636171	A/T	cg17595323	chr11:93583763	C11orf90	-0.47	-6.44	-0.5	2.38e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs4849845	0.637	rs13022486	chr2:121038611	C/T	cg24070213	chr2:121070622	NA	0.35	4.64	0.38	8.58e-6	Mean platelet volume;
TGCT	cis	rs9381040	0.655	rs7738684	chr6:41038552	G/A	cg03526776	chr6:41159608	TREML2	0.27	5.34	0.43	4.21e-7	Alzheimer's disease (late onset);
TGCT	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg19010396	chr19:19431384	KIAA0892;SF4	-0.55	-4.6	-0.38	1.02e-5	Tonsillectomy;
TGCT	cis	rs4148883	0.504	rs28720150	chr4:100132790	T/G	cg12011299	chr4:100065546	ADH4	-0.36	-5.17	-0.42	9.13e-7	Alcohol dependence;
TGCT	cis	rs9611519	0.929	rs73174657	chr22:41434158	G/A	cg13695892	chr22:41940480	POLR3H	-0.53	-4.62	-0.38	9.54e-6	Neuroticism;
TGCT	cis	rs1552244	0.554	rs13081079	chr3:10056348	A/G	cg00149659	chr3:10157352	C3orf10	0.69	4.99	0.41	2.03e-6	Alzheimer's disease;
TGCT	cis	rs4273100	0.790	rs60166680	chr17:19277544	C/G	cg01534423	chr17:18965556	NA	0.9	6.05	0.48	1.62e-8	Schizophrenia;
TGCT	cis	rs546131	0.928	rs546521	chr11:34824773	G/C	cg11058730	chr11:34937778	PDHX;APIP	0.54	4.81	0.4	4.36e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.64	0.51	8.93e-10	Bipolar disorder;
TGCT	cis	rs35000415	0.688	rs13237546	chr7:128720433	G/A	cg06242719	chr7:129414860	MIR183;MIR96	-0.3	-4.58	-0.38	1.1e-5	Systemic lupus erythematosus;
TGCT	cis	rs6095298	0.553	rs112601802	chr20:47453884	T/C	cg12307787	chr20:48099359	KCNB1	0.42	4.51	0.38	1.51e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg12288994	chr5:1860383	NA	0.25	5.02	0.41	1.78e-6	Cardiovascular disease risk factors;
TGCT	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg11890956	chr21:40555474	PSMG1	1.1	12.31	0.74	2.99e-23	Cognitive function;
TGCT	cis	rs367943	1.000	rs348954	chr5:112821716	A/G	cg12552261	chr5:112820674	MCC	-0.24	-4.91	-0.4	2.81e-6	Type 2 diabetes;
TGCT	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg09737314	chr17:6899359	ALOX12	0.47	5.19	0.42	8.17e-7	Tonsillectomy;
TGCT	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2486288	0.656	rs11632419	chr15:45557456	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.75	-7.78	-0.57	2.39e-12	Glomerular filtration rate;
TGCT	cis	rs4851254	0.961	rs13019618	chr2:100753963	G/T	cg23118464	chr2:100721844	AFF3	0.66	5.08	0.42	1.35e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs10049627	chr4:99025272	A/C	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7666738	0.715	rs116787789	chr4:98718720	G/A	cg18180107	chr4:99064573	C4orf37	0.53	4.99	0.41	2.03e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2760061	0.626	rs634106	chr1:228121548	C/T	cg18477163	chr1:228402036	OBSCN	-0.31	-6.24	-0.49	6.26e-9	Diastolic blood pressure;
TGCT	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	5.87	0.47	3.78e-8	Alzheimer's disease;
TGCT	cis	rs877282	0.838	rs11253408	chr10:796374	T/C	cg17470449	chr10:769945	NA	0.3	4.82	0.4	4.14e-6	Uric acid levels;
TGCT	cis	rs3617	0.625	rs2535633	chr3:52859630	C/G	cg05573699	chr3:52720067	GNL3;PBRM1	0.47	4.6	0.38	1.02e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9985766	1.000	rs4356899	chr4:151002618	C/A	cg05926478	chr4:151174724	DCLK2	-0.24	-4.72	-0.39	6.32e-6	Coronary artery disease;Myocardial infarction;
TGCT	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg26354017	chr1:205819088	PM20D1	0.71	9.98	0.67	1.39e-17	Menarche (age at onset);
TGCT	cis	rs367943	1.000	rs348955	chr5:112821643	C/T	cg12552261	chr5:112820674	MCC	-0.24	-5.01	-0.41	1.82e-6	Type 2 diabetes;
TGCT	cis	rs7772486	0.774	rs2748503	chr6:146295042	T/C	cg05347473	chr6:146136440	FBXO30	0.51	4.56	0.38	1.2e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs208520	0.690	rs10455594	chr6:66737894	C/G	cg07460842	chr6:66804631	NA	0.94	9.91	0.66	2.15e-17	Exhaled nitric oxide output;
TGCT	cis	rs7666738	0.887	rs34509663	chr4:98982531	C/T	cg17366294	chr4:99064904	C4orf37	0.77	7.0	0.53	1.4e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2439831	0.867	rs6493085	chr15:43654182	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	8.65	0.61	2.26e-14	Lung cancer in ever smokers;
TGCT	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg08280861	chr8:58055591	NA	0.36	4.58	0.38	1.11e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg05785598	chr3:49045655	WDR6	0.36	4.86	0.4	3.41e-6	Menarche (age at onset);
TGCT	cis	rs4919044	0.808	rs2478238	chr10:94805531	A/G	cg05127821	chr10:94822908	CYP26C1	-0.74	-4.83	-0.4	3.95e-6	Coronary artery disease;
TGCT	trans	rs17685	0.753	rs9691174	chr7:75790405	T/C	cg19862616	chr7:65841803	NCRNA00174	0.51	8.88	0.62	6.28e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.31	-4.76	-0.39	5.36e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs4654899	0.865	rs6426658	chr1:21361176	G/A	cg01072550	chr1:21505969	NA	-0.46	-6.71	-0.52	6.27e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs7119	0.700	rs60701760	chr15:77888152	G/A	cg27398640	chr15:77910606	LINGO1	0.33	6.85	0.52	3.09e-10	Type 2 diabetes;
TGCT	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg22166914	chr1:53195759	ZYG11B	0.35	6.09	0.48	1.32e-8	Monocyte count;
TGCT	cis	rs10186029	0.676	rs10497991	chr2:213968775	G/A	cg08319019	chr2:214017104	IKZF2	0.63	5.79	0.46	5.4e-8	Systemic sclerosis;
TGCT	cis	rs6722750	0.783	rs4671550	chr2:64389314	T/A	cg22352474	chr2:64371530	PELI1	0.67	6.33	0.49	4.07e-9	Neuroticism;
TGCT	cis	rs13631	0.965	rs9411307	chr9:139994947	C/T	cg14289826	chr9:140003911	NA	0.26	6.07	0.48	1.44e-8	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs758747	0.514	rs8054140	chr16:3572694	G/T	cg07396092	chr16:3662230	BTBD12	0.57	4.8	0.4	4.54e-6	Body mass index;
TGCT	cis	rs7255045	0.788	rs2290688	chr19:12958697	T/C	cg11738485	chr19:12877000	HOOK2	-0.57	-4.55	-0.38	1.24e-5	Mean corpuscular volume;
TGCT	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9858542	1.000	rs11718165	chr3:49696797	A/G	cg03060546	chr3:49711283	APEH	-0.67	-6.09	-0.48	1.28e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs2197308	0.703	rs10880251	chr12:37903297	G/A	cg26384229	chr12:38710491	ALG10B	0.89	7.98	0.58	8.43e-13	Morning vs. evening chronotype;
TGCT	cis	rs826838	0.904	rs11612004	chr12:39204282	G/A	cg13010199	chr12:38710504	ALG10B	0.77	6.09	0.48	1.31e-8	Heart rate;
TGCT	cis	rs7010267	0.570	rs7004539	chr8:120040499	C/T	cg17171407	chr8:119960777	TNFRSF11B	0.26	4.59	0.38	1.06e-5	Total body bone mineral density (age 45-60);
TGCT	cis	rs6540559	0.673	rs7550857	chr1:209956542	C/A	cg21951975	chr1:209979733	IRF6	0.71	5.47	0.44	2.43e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs62244186	0.659	rs7649834	chr3:44503732	C/T	cg04389838	chr3:44770851	ZNF501	-0.41	-5.7	-0.46	8.13e-8	Depressive symptoms;
TGCT	cis	rs11696501	0.539	rs6073849	chr20:44299385	A/T	cg11783356	chr20:44313418	WFDC10B	-0.32	-4.63	-0.38	9.25e-6	Brain structure;
TGCT	cis	rs875971	0.660	rs10229345	chr7:65982168	G/C	cg00343986	chr7:65444356	GUSB	0.22	4.71	0.39	6.59e-6	Aortic root size;
TGCT	cis	rs6831352	0.819	rs896992	chr4:100002372	C/T	cg12011299	chr4:100065546	ADH4	0.42	5.76	0.46	6.11e-8	Alcohol dependence;
TGCT	cis	rs2147959	0.941	rs1007686	chr1:228651457	A/G	cg22700015	chr1:228743131	NA	-0.57	-4.48	-0.37	1.66e-5	Adult asthma;
TGCT	cis	rs4642101	1.000	rs4642101	chr3:12842223	T/G	cg05775895	chr3:12838266	CAND2	0.55	5.21	0.42	7.75e-7	QRS complex (12-leadsum);
TGCT	cis	rs72945132	0.882	rs12278125	chr11:70134016	T/C	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs3087591	0.887	rs2905875	chr17:29541339	A/T	cg24425628	chr17:29625626	OMG;NF1	0.47	7.05	0.54	1.08e-10	Hip circumference;
TGCT	cis	rs4555082	0.957	rs2975216	chr14:105713134	T/C	cg01266790	chr14:105781312	PACS2	0.52	4.49	0.37	1.61e-5	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs78461346	1.000	rs76195156	chr17:80488094	C/T	cg15014069	chr17:80540666	FOXK2	0.4	5.04	0.41	1.62e-6	3-hydroxypropylmercapturic acid levels in smokers;
TGCT	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg03806693	chr22:41940476	POLR3H	-1.13	-13.24	-0.77	1.73e-25	Vitiligo;
TGCT	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg12311346	chr5:56204834	C5orf35	-0.67	-6.82	-0.52	3.63e-10	Initial pursuit acceleration;
TGCT	trans	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.86	-9.4	-0.65	3.49e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs909674	0.731	rs4821897	chr22:39835587	A/G	cg24399712	chr22:39784796	NA	-1.08	-11.12	-0.71	2.43e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs7727544	0.606	rs72795121	chr5:131638324	T/A	cg24060327	chr5:131705240	SLC22A5	-0.52	-5.43	-0.44	2.8e-7	Blood metabolite levels;
TGCT	cis	rs9513627	0.512	rs9517759	chr13:100180108	T/G	cg25919922	chr13:100150906	NA	0.84	6.12	0.48	1.13e-8	Obesity-related traits;
TGCT	cis	rs6598955	0.572	rs12089219	chr1:26638751	C/T	cg04990556	chr1:26633338	UBXN11	0.64	4.91	0.4	2.78e-6	Obesity-related traits;
TGCT	cis	rs3739821	1.000	rs3739821	chr9:130702477	A/G	cg17308606	chr9:130706144	FAM102A	0.29	4.82	0.4	4.1e-6	Glaucoma (primary angle closure);
TGCT	cis	rs66731853	0.769	rs477679	chr1:20894618	A/G	cg01468656	chr1:19991678	HTR6	-0.43	-4.49	-0.37	1.61e-5	Mean corpuscular volume;
TGCT	cis	rs806215	0.526	rs3808086	chr7:127539245	G/C	cg11539674	chr7:127291444	SND1	-0.37	-4.74	-0.39	5.81e-6	Type 2 diabetes;
TGCT	cis	rs9926296	0.632	rs72807526	chr16:89775946	A/G	cg27121462	chr16:89883253	FANCA	-0.54	-4.7	-0.39	6.86e-6	Vitiligo;
TGCT	cis	rs6121246	0.567	rs6088796	chr20:30213229	C/T	cg18721089	chr20:30220636	NA	-0.64	-6.86	-0.52	2.84e-10	Mean corpuscular hemoglobin;
TGCT	cis	rs881375	0.678	rs10739581	chr9:123696871	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.44	4.77	0.39	5.11e-6	Rheumatoid arthritis;
TGCT	cis	rs765787	0.505	rs11630884	chr15:45532246	C/T	cg24006582	chr15:45444508	DUOX1	-0.24	-5.28	-0.43	5.51e-7	Uric acid levels;
TGCT	cis	rs9902453	0.934	rs11080120	chr17:28507021	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	6.39	0.5	3.03e-9	Coffee consumption (cups per day);
TGCT	cis	rs981844	0.712	rs4632640	chr4:154742389	G/C	cg14289246	chr4:154710475	SFRP2	-1.0	-9.26	-0.64	7.7e-16	Response to statins (LDL cholesterol change);
TGCT	cis	rs1784581	0.588	rs6455790	chr6:162418447	C/T	cg17173639	chr6:162384350	PARK2	-0.4	-6.6	-0.51	1.08e-9	Itch intensity from mosquito bite;
TGCT	cis	rs3806843	0.576	rs246011	chr5:140336405	G/C	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2404602	0.610	rs28823285	chr15:77050395	T/C	cg23625390	chr15:77176239	SCAPER	-0.38	-4.79	-0.39	4.75e-6	Blood metabolite levels;
TGCT	cis	rs651907	0.557	rs7612283	chr3:101434919	C/T	cg12386194	chr3:101231763	SENP7	0.51	4.9	0.4	2.89e-6	Colorectal cancer;
TGCT	cis	rs2832191	0.791	rs2832198	chr21:30498240	C/T	cg24692254	chr21:30365293	RNF160	0.84	8.58	0.61	3.24e-14	Dental caries;
TGCT	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	5.02	0.41	1.72e-6	Prudent dietary pattern;
TGCT	cis	rs4443100	0.670	rs8139280	chr22:23405957	G/A	cg14186256	chr22:23484241	RTDR1	0.57	4.47	0.37	1.75e-5	Serum parathyroid hormone levels;
TGCT	cis	rs763121	0.888	rs2235229	chr22:39124912	A/G	cg06022373	chr22:39101656	GTPBP1	0.67	6.1	0.48	1.24e-8	Menopause (age at onset);
TGCT	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg24503407	chr1:205819492	PM20D1	-0.53	-7.16	-0.54	6.37e-11	Monocyte percentage of white cells;
TGCT	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg00024416	chr22:24240387	NA	-0.25	-4.74	-0.39	5.74e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2657888	0.529	rs11171863	chr12:56879548	C/T	cg23002907	chr12:56915593	RBMS2	-0.38	-4.77	-0.39	5.13e-6	Adiponectin levels;
TGCT	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg20607798	chr8:58055168	NA	0.5	4.66	0.39	8.04e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs910187	0.678	rs1046667	chr20:45817255	A/C	cg27589058	chr20:45804311	EYA2	-0.35	-7.6	-0.56	6.23e-12	Migraine;
TGCT	cis	rs9362426	1.000	rs6930076	chr6:88088654	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.46	5.19	0.42	8.5e-7	Depressive episodes in bipolar disorder;
TGCT	cis	rs6840360	0.533	rs13119490	chr4:152713412	A/G	cg17479576	chr4:152424074	FAM160A1	0.49	4.94	0.41	2.51e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs67311347	0.911	rs6775936	chr3:40377399	T/G	cg13683864	chr3:40499215	RPL14	-1.03	-10.51	-0.69	7.36e-19	Renal cell carcinoma;
TGCT	cis	rs2455799	0.613	rs4685260	chr3:15832417	C/T	cg16303742	chr3:15540471	COLQ	-0.25	-4.75	-0.39	5.41e-6	Mean platelet volume;
TGCT	trans	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg17470723	chr8:74884337	TCEB1	0.73	7.11	0.54	8.13e-11	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7829975	0.774	rs1703982	chr8:8598388	A/T	cg06636001	chr8:8085503	FLJ10661	-0.61	-5.29	-0.43	5.27e-7	Mood instability;
TGCT	cis	rs12682352	0.652	rs3827806	chr8:8724276	C/T	cg06636001	chr8:8085503	FLJ10661	0.68	6.25	0.49	5.99e-9	Neuroticism;
TGCT	cis	rs9296092	0.517	rs55963187	chr6:33523778	G/C	cg13560919	chr6:33536144	NA	-0.2	-4.64	-0.38	8.68e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	trans	rs7726839	0.794	rs11739663	chr5:594083	A/G	cg11887960	chr12:57824829	NA	0.95	7.43	0.56	1.52e-11	Obesity-related traits;
TGCT	cis	rs9583531	0.891	rs9521906	chr13:111358000	T/G	cg24331049	chr13:111365604	ING1	-0.73	-4.97	-0.41	2.17e-6	Coronary artery disease;
TGCT	cis	rs4580814	0.869	rs4535497	chr5:1107428	G/T	cg13592947	chr5:1111049	SLC12A7	0.3	5.87	0.47	3.74e-8	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs10883723	0.810	rs913025	chr10:104276043	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	8.36	0.6	1.1e-13	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs909674	0.818	rs5757681	chr22:39845547	A/G	cg11247378	chr22:39784982	NA	-0.73	-8.79	-0.62	1.04e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs6598955	0.670	rs7522905	chr1:26609259	C/T	cg04990556	chr1:26633338	UBXN11	-0.9	-11.45	-0.72	3.7e-21	Obesity-related traits;
TGCT	cis	rs9814567	1.000	rs6793487	chr3:134299426	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.91	8.83	0.62	8.17e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs1532993	0.518	rs1508464	chr4:98572205	A/C	cg05340658	chr4:99064831	C4orf37	-0.42	-5.05	-0.41	1.57e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg08280861	chr8:58055591	NA	0.4	4.67	0.39	7.79e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs11105298	0.891	rs10858909	chr12:89935387	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.7	-5.02	-0.41	1.78e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg18188782	chr20:61659543	NA	0.44	5.38	0.43	3.6e-7	Prostate cancer (SNP x SNP interaction);
TGCT	trans	rs1974653	0.672	rs1558495	chr22:20071652	T/G	cg08822737	chr17:71088851	SLC39A11	-0.93	-7.61	-0.56	5.97e-12	Schizophrenia;
TGCT	cis	rs67311347	1.000	rs9841335	chr3:40475858	G/A	cg13683864	chr3:40499215	RPL14	-1.04	-10.79	-0.7	1.54e-19	Renal cell carcinoma;
TGCT	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7264396	0.635	rs7263302	chr20:34545858	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.04	-0.41	1.58e-6	Total cholesterol levels;
TGCT	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg11890956	chr21:40555474	PSMG1	-1.03	-10.04	-0.67	1.03e-17	Cognitive function;
TGCT	cis	rs4072705	0.646	rs4838187	chr9:127242076	G/C	cg13476313	chr9:127244764	NR5A1	0.29	4.75	0.39	5.54e-6	Menarche (age at onset);
TGCT	cis	rs2019216	0.524	rs1518049	chr17:21922055	C/T	cg22648282	chr17:21454238	C17orf51	-0.56	-5.45	-0.44	2.57e-7	Pelvic organ prolapse;
TGCT	trans	rs1814175	0.754	rs10839453	chr11:49955815	A/T	cg15704280	chr7:45808275	SEPT13	-0.74	-8.5	-0.61	5.05e-14	Height;
TGCT	cis	rs9372498	0.536	rs2356501	chr6:118942371	C/A	cg21191810	chr6:118973309	C6orf204	-0.38	-4.97	-0.41	2.14e-6	Diastolic blood pressure;
TGCT	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg11871910	chr12:69753446	YEATS4	0.88	10.21	0.68	3.96e-18	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg23758822	chr17:41437982	NA	0.72	6.81	0.52	3.83e-10	Menopause (age at onset);
TGCT	cis	rs7208859	0.673	rs9889755	chr17:29234505	A/G	cg14008862	chr17:28927542	LRRC37B2	-0.66	-4.46	-0.37	1.79e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs8038465	0.594	rs55816897	chr15:73869767	G/T	cg15420318	chr15:73925796	NPTN	0.66	7.26	0.55	3.69e-11	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs17221829	0.703	rs75183199	chr11:89356987	A/G	cg02982614	chr11:89391479	FOLH1B	-0.28	-4.87	-0.4	3.35e-6	Anxiety in major depressive disorder;
TGCT	cis	rs1801251	0.963	rs283481	chr2:233648091	A/G	cg08000102	chr2:233561755	GIGYF2	0.63	6.35	0.5	3.67e-9	Coronary artery disease;
TGCT	cis	rs10083777	0.551	rs111889995	chr16:81033771	A/C	cg07676361	chr16:80966860	NA	-0.61	-4.87	-0.4	3.27e-6	Metabolite levels (small molecules and protein measures);
TGCT	cis	rs7769051	0.711	rs7758531	chr6:133085302	T/C	cg22852734	chr6:133119734	C6orf192	1.22	6.68	0.51	7.22e-10	Type 2 diabetes nephropathy;
TGCT	cis	rs6582630	0.503	rs4882293	chr12:38388200	G/C	cg26384229	chr12:38710491	ALG10B	-0.52	-4.51	-0.38	1.46e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs7666738	0.830	rs13124127	chr4:98990729	G/A	cg05340658	chr4:99064831	C4orf37	0.49	5.6	0.45	1.31e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9467773	0.534	rs34453863	chr6:26628005	T/C	cg09904177	chr6:26538194	HMGN4	0.63	5.85	0.46	4.16e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2836950	0.545	rs2836956	chr21:40623018	C/G	cg06238570	chr21:40685208	BRWD1	0.6	6.21	0.49	7.28e-9	Menarche (age at onset);
TGCT	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg00343986	chr7:65444356	GUSB	0.22	5.31	0.43	4.99e-7	Calcium levels;
TGCT	cis	rs12776158	0.901	rs61086796	chr10:71216848	T/C	cg12610070	chr10:71211762	TSPAN15	-0.59	-5.17	-0.42	9.16e-7	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs12497850	0.931	rs12493289	chr3:48905161	G/A	cg18654377	chr3:49208889	KLHDC8B	-0.41	-5.49	-0.44	2.15e-7	Parkinson's disease;
TGCT	cis	rs7843479	0.965	rs17616085	chr8:21857267	C/T	cg17168535	chr8:21777572	XPO7	0.64	5.79	0.46	5.31e-8	Mean corpuscular volume;
TGCT	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg05025164	chr4:1340916	KIAA1530	0.79	6.92	0.53	2.17e-10	Longevity;
TGCT	trans	rs4346053	0.702	rs4347471	chr12:33116181	A/C	cg06490627	chr16:50344198	ADCY7	0.44	6.82	0.52	3.61e-10	Body mass index (change over time) in lung cancer;
TGCT	cis	rs7224685	0.569	rs67815988	chr17:3998312	A/C	cg09580393	chr17:4869866	SPAG7	-0.38	-4.48	-0.37	1.64e-5	Type 2 diabetes;
TGCT	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.35	0.83	9.56e-33	Prudent dietary pattern;
TGCT	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg16049864	chr8:95962084	TP53INP1	-0.74	-10.49	-0.69	8.05e-19	Type 2 diabetes;
TGCT	cis	rs12049351	0.719	rs10916492	chr1:229634396	G/T	cg12130225	chr1:229698885	NA	0.39	4.59	0.38	1.06e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs265548	0.608	rs36690	chr19:17910483	C/T	cg16744531	chr19:17905626	B3GNT3	0.43	5.45	0.44	2.61e-7	Tumor biomarkers;
TGCT	cis	rs370915	0.542	rs7687552	chr4:187837862	G/C	cg19519643	chr4:187840862	NA	-0.23	-4.65	-0.39	8.5e-6	Gout;
TGCT	cis	rs35306767	0.761	rs1871621	chr10:1049596	C/T	cg26597838	chr10:835615	NA	0.6	6.63	0.51	9.45e-10	Eosinophil percentage of granulocytes;
TGCT	cis	rs3796352	1.000	rs71301809	chr3:53090312	C/T	cg27565382	chr3:53032988	SFMBT1	0.43	4.6	0.38	1.01e-5	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs9796	0.870	rs10851402	chr15:41263438	C/T	cg18705301	chr15:41695430	NDUFAF1	0.43	5.48	0.44	2.23e-7	Menopause (age at onset);
TGCT	cis	rs28374715	0.617	rs28626792	chr15:41562218	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.65	-8.7	-0.62	1.71e-14	Ulcerative colitis;
TGCT	cis	rs2204008	0.713	rs12366709	chr12:38210179	G/A	cg13010199	chr12:38710504	ALG10B	0.62	4.96	0.41	2.32e-6	Bladder cancer;
TGCT	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg27588902	chr6:42928151	GNMT	-0.57	-7.0	-0.53	1.39e-10	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs12893668	0.543	rs12147645	chr14:104100208	T/A	cg26031613	chr14:104095156	KLC1	-0.59	-5.1	-0.42	1.25e-6	Reticulocyte count;
TGCT	cis	rs7666738	0.830	rs28795113	chr4:98951331	A/G	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs58722170	0.659	rs72659423	chr1:38083472	C/T	cg17933807	chr1:38061675	GNL2	-0.84	-8.42	-0.6	7.9e-14	High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs7267979	1.000	rs6076336	chr20:25319212	C/T	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2188554	0.740	rs6957018	chr7:117210368	C/T	cg09181792	chr7:117119393	CFTR	0.52	4.68	0.39	7.3e-6	Esophageal adenocarcinoma;
TGCT	cis	rs758129	0.501	rs3176202	chr15:89866286	G/A	cg24365117	chr15:89879190	POLG	0.35	4.56	0.38	1.23e-5	Schizophrenia;
TGCT	cis	rs79149102	0.579	rs12592477	chr15:75292699	C/T	cg09165964	chr15:75287851	SCAMP5	-1.07	-5.81	-0.46	4.89e-8	Lung cancer;
TGCT	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg08280861	chr8:58055591	NA	0.48	5.11	0.42	1.21e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs950776	0.678	rs12910237	chr15:78956338	C/T	cg03762349	chr15:79060523	ADAMTS7	0.25	4.87	0.4	3.35e-6	Sudden cardiac arrest;
TGCT	cis	rs6663390	0.510	rs6693798	chr1:208090018	A/G	cg03990033	chr1:208084030	CD34	0.57	4.89	0.4	3.07e-6	Facial morphology (factor 18);
TGCT	cis	rs35000415	0.566	rs34644138	chr7:128720967	A/G	cg06242719	chr7:129414860	MIR183;MIR96	-0.3	-4.58	-0.38	1.1e-5	Systemic lupus erythematosus;
TGCT	cis	rs473651	0.935	rs482775	chr2:239335403	G/C	cg18131467	chr2:239335373	ASB1	1.0	14.33	0.79	4.58e-28	Multiple system atrophy;
TGCT	cis	rs7192750	0.652	rs152828	chr16:72123886	T/C	cg14768367	chr16:72042858	DHODH	0.88	4.57	0.38	1.17e-5	LDL cholesterol levels;Total cholesterol levels;
TGCT	trans	rs7726839	0.561	rs4957048	chr5:583442	G/A	cg25482853	chr8:67687455	SGK3	1.07	8.9	0.62	5.55e-15	Obesity-related traits;
TGCT	cis	rs9467711	0.606	rs68112369	chr6:26365759	T/C	cg10795676	chr6:26370623	BTN3A2	-0.47	-4.82	-0.4	4.1e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs727505	0.954	rs2054586	chr7:124708414	C/T	cg23710748	chr7:124431027	NA	-0.27	-4.7	-0.39	6.77e-6	Lewy body disease;
TGCT	cis	rs61931739	0.500	rs11053177	chr12:34412829	G/A	cg06521331	chr12:34319734	NA	-0.29	-4.49	-0.37	1.59e-5	Morning vs. evening chronotype;
TGCT	cis	rs7267979	0.873	rs6115093	chr20:25210730	C/T	cg03522245	chr20:25566470	NINL	0.61	6.59	0.51	1.13e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2338224	1.000	rs9293307	chr5:71746767	A/C	cg01187920	chr5:71015162	CARTPT	-0.53	-4.57	-0.38	1.15e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Granulocyte count;Myeloid white cell count;
TGCT	cis	rs7095607	0.813	rs7894981	chr10:69927518	T/C	cg18986048	chr10:69913749	MYPN	0.44	5.02	0.41	1.72e-6	Lung function (FVC);
TGCT	cis	rs611744	0.967	rs677330	chr8:109177572	A/G	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs7726839	0.574	rs72705017	chr5:623733	G/A	cg20362242	chr5:692897	TPPP	0.52	4.48	0.37	1.68e-5	Obesity-related traits;
TGCT	cis	rs4713118	0.868	rs35069907	chr6:27746692	T/C	cg20933634	chr6:27740509	NA	0.35	4.82	0.4	4.13e-6	Parkinson's disease;
TGCT	cis	rs7940866	0.774	rs2162059	chr11:130831224	C/T	cg12179176	chr11:130786555	SNX19	0.63	6.15	0.48	9.91e-9	Schizophrenia;
TGCT	cis	rs12681288	0.645	rs2600509	chr8:989022	C/G	cg04851639	chr8:1020857	NA	0.3	4.88	0.4	3.22e-6	Schizophrenia;
TGCT	trans	rs8073060	0.586	rs226084	chr17:34019582	T/A	cg19694781	chr19:47549865	TMEM160	-0.6	-13.37	-0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs3091242	0.781	rs71652378	chr1:25721457	G/C	cg23205692	chr1:25664452	TMEM50A	0.5	5.14	0.42	1.05e-6	Erythrocyte sedimentation rate;
TGCT	cis	rs2012796	0.956	rs56223983	chr14:81814754	G/T	cg02996355	chr14:81879375	NA	0.5	4.82	0.4	4.2e-6	Night sleep phenotypes;
TGCT	cis	rs2455799	0.533	rs924754	chr3:15756215	A/T	cg16303742	chr3:15540471	COLQ	-0.26	-4.84	-0.4	3.75e-6	Mean platelet volume;
TGCT	cis	rs66573146	0.831	rs67702333	chr4:6983040	C/G	cg05069807	chr4:6945702	TBC1D14	0.32	5.01	0.41	1.83e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg00814883	chr7:100076585	TSC22D4	-0.9	-9.56	-0.65	1.5e-16	Platelet count;
TGCT	cis	rs611744	0.647	rs615233	chr8:109254262	C/T	cg21045802	chr8:109455806	TTC35	0.72	7.28	0.55	3.32e-11	Dupuytren's disease;
TGCT	cis	rs3784262	0.654	rs4646568	chr15:58344290	A/G	cg12031962	chr15:58353849	ALDH1A2	0.52	8.25	0.6	1.98e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs9291683	0.935	rs1860910	chr4:10275470	T/G	cg00071950	chr4:10020882	SLC2A9	0.42	4.58	0.38	1.13e-5	Bone mineral density;
TGCT	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg13206674	chr6:150067644	NUP43	0.52	4.51	0.38	1.5e-5	Lung cancer;
TGCT	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg20607798	chr8:58055168	NA	0.53	4.54	0.38	1.3e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs4499344	0.633	rs259246	chr19:33146154	G/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	9.01	0.63	3.11e-15	Mean platelet volume;
TGCT	cis	rs4988958	0.525	rs3771159	chr2:103004958	T/C	cg03938978	chr2:103052716	IL18RAP	0.26	5.22	0.42	7.15e-7	Asthma (childhood onset);
TGCT	trans	rs941408	0.963	rs1640268	chr19:2791469	T/C	cg22153745	chr1:153894579	GATAD2B	-0.65	-7.35	-0.55	2.39e-11	Total cholesterol levels;
TGCT	cis	rs2243480	0.908	rs313822	chr7:65573939	G/A	cg18252515	chr7:66147081	NA	-1.24	-8.1	-0.59	4.35e-13	Diabetic kidney disease;
TGCT	cis	rs611744	0.967	rs662591	chr8:109211358	C/T	cg21045802	chr8:109455806	TTC35	0.52	4.72	0.39	6.21e-6	Dupuytren's disease;
TGCT	cis	rs7666738	0.830	rs2019163	chr4:99022747	C/T	cg17366294	chr4:99064904	C4orf37	0.69	7.06	0.54	1.04e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7618915	0.501	rs55678971	chr3:52717229	T/A	cg07507251	chr3:52567010	NT5DC2	0.46	6.47	0.5	2.04e-9	Bipolar disorder;
TGCT	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg21724239	chr8:58056113	NA	0.4	5.01	0.41	1.8e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs548987	0.507	rs3757132	chr6:25832691	C/T	cg03517284	chr6:25882590	NA	-0.56	-4.56	-0.38	1.22e-5	Homocysteine levels;
TGCT	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.12	0.54	7.78e-11	Prudent dietary pattern;
TGCT	cis	rs476633	0.573	rs2099652	chr15:41528745	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.68	-8.54	-0.61	3.98e-14	Glomerular filtration rate (creatinine);
TGCT	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg11764359	chr7:65958608	NA	-0.57	-5.12	-0.42	1.12e-6	Aortic root size;
TGCT	cis	rs9811920	0.625	rs9290003	chr3:99906993	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.41	-4.83	-0.4	3.89e-6	Axial length;
TGCT	cis	rs12477438	0.765	rs7607578	chr2:99669771	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-4.88	-0.4	3.17e-6	Chronic sinus infection;
TGCT	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg23302884	chr18:44338147	ST8SIA5	-0.4	-4.58	-0.38	1.11e-5	Personality dimensions;
TGCT	trans	rs2469997	1.000	rs2447174	chr8:120358571	G/A	cg01792902	chr3:178864926	PIK3CA	0.83	6.77	0.52	4.49e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs12620999	0.555	rs4663242	chr2:238102905	C/T	cg23555395	chr2:238036564	NA	-0.26	-4.45	-0.37	1.88e-5	Systemic lupus erythematosus;
TGCT	trans	rs804280	0.509	rs12719915	chr8:11786255	A/G	cg15556689	chr8:8085844	FLJ10661	-0.76	-7.27	-0.55	3.59e-11	Myopia (pathological);
TGCT	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg01570182	chr17:44337453	NA	1.01	9.34	0.64	4.88e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7399018	0.739	rs6580811	chr12:51612501	T/C	cg25754956	chr12:51612065	POU6F1	0.94	8.81	0.62	9.47e-15	Cisplatin-induced ototoxicity;
TGCT	cis	rs67311347	0.521	rs2887963	chr3:40243466	C/T	cg13683864	chr3:40499215	RPL14	0.64	5.92	0.47	2.94e-8	Renal cell carcinoma;
TGCT	cis	rs617219	0.698	rs13177470	chr5:78495899	T/C	cg23987322	chr5:78407566	BHMT	0.38	5.07	0.41	1.39e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs4803468	1.000	rs284651	chr19:41928336	T/C	cg09537434	chr19:41945824	ATP5SL	-0.91	-10.16	-0.67	5.26e-18	Height;
TGCT	cis	rs9964724	0.559	rs7243439	chr18:35156196	A/G	cg27332583	chr18:35150602	NA	0.3	4.63	0.38	9.19e-6	Educational attainment (years of education);
TGCT	cis	rs3772130	0.962	rs9883467	chr3:121517833	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.72	0.39	6.25e-6	Cognitive performance;
TGCT	cis	rs7647973	0.626	rs1463728	chr3:49647404	T/A	cg03060546	chr3:49711283	APEH	0.65	5.26	0.43	6.07e-7	Menarche (age at onset);
TGCT	cis	rs2242194	0.844	rs11264295	chr1:154987526	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.55	-5.05	-0.41	1.53e-6	Schizophrenia;
TGCT	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg06713675	chr4:122721982	EXOSC9	-0.68	-9.18	-0.64	1.23e-15	Type 2 diabetes;
TGCT	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg21548813	chr6:291882	DUSP22	-0.72	-7.59	-0.56	6.53e-12	Menopause (age at onset);
TGCT	cis	rs3091242	0.933	rs9438905	chr1:25764177	A/G	cg23205692	chr1:25664452	TMEM50A	0.47	4.88	0.4	3.15e-6	Erythrocyte sedimentation rate;
TGCT	cis	rs9419702	0.568	rs7075233	chr10:133545170	A/G	cg20568497	chr10:133558893	NA	-0.47	-5.36	-0.43	3.87e-7	Survival in rectal cancer;
TGCT	cis	rs1395	0.710	rs11674947	chr2:27471996	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.62	7.72	0.57	3.38e-12	Blood metabolite levels;
TGCT	trans	rs2610739	0.554	rs9353574	chr6:89223576	G/A	cg05764691	chr16:22927585	HS3ST2	0.4	6.62	0.51	9.76e-10	IgG glycosylation;
TGCT	cis	rs7336332	0.891	rs927578	chr13:28075022	G/T	cg22138327	chr13:27999177	GTF3A	0.83	5.89	0.47	3.34e-8	Weight;
TGCT	cis	rs12497850	0.805	rs11130176	chr3:48844077	A/G	cg05785598	chr3:49045655	WDR6	0.35	4.72	0.39	6.35e-6	Parkinson's disease;
TGCT	cis	rs1401999	0.510	rs12634398	chr3:183708405	A/G	cg01324343	chr3:183735012	ABCC5	0.52	5.66	0.45	9.97e-8	Anterior chamber depth;
TGCT	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg06618935	chr21:46677482	NA	-0.37	-5.56	-0.45	1.58e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg08048268	chr3:133502702	NA	-0.53	-7.17	-0.54	5.89e-11	Iron status biomarkers;
TGCT	cis	rs7617773	0.744	rs2125482	chr3:48323133	T/G	cg11946769	chr3:48343235	NME6	0.72	6.12	0.48	1.14e-8	Coronary artery disease;
TGCT	cis	rs6988636	0.710	rs73339621	chr8:124138936	C/T	cg23067535	chr8:124195133	FAM83A	-0.38	-4.8	-0.4	4.53e-6	Urinary uromodulin levels;
TGCT	cis	rs7666738	0.791	rs13149968	chr4:99070262	G/T	cg17366294	chr4:99064904	C4orf37	0.73	7.45	0.56	1.4e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs35306767	0.903	rs12240651	chr10:943656	A/G	cg26597838	chr10:835615	NA	0.76	10.69	0.69	2.61e-19	Eosinophil percentage of granulocytes;
TGCT	cis	rs7246657	0.943	rs9304566	chr19:37845504	T/C	cg18154014	chr19:37997991	ZNF793	0.97	6.49	0.5	1.82e-9	Coronary artery calcification;
TGCT	cis	rs868036	0.609	rs2278076	chr15:68099600	C/T	cg27219399	chr15:67835830	MAP2K5	0.34	4.49	0.37	1.6e-5	Restless legs syndrome;
TGCT	cis	rs11997175	0.599	rs66474258	chr8:33640225	A/T	ch.8.33884649F	chr8:33765107	NA	0.28	4.45	0.37	1.87e-5	Body mass index;
TGCT	cis	rs1008375	0.800	rs62296338	chr4:17613425	G/T	cg18681998	chr4:17616180	MED28	1.05	10.97	0.7	5.56e-20	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	trans	rs561341	1.000	rs8069199	chr17:30281845	A/G	cg20587970	chr11:113659929	NA	-1.03	-10.98	-0.7	5.21e-20	Hip circumference adjusted for BMI;
TGCT	cis	rs9790314	0.871	rs336551	chr3:161109720	T/C	cg03342759	chr3:160939853	NMD3	-0.49	-5.13	-0.42	1.08e-6	Morning vs. evening chronotype;
TGCT	cis	rs1552244	0.832	rs67145301	chr3:10197314	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.55	-6.53	-0.51	1.5e-9	Alzheimer's disease;
TGCT	cis	rs1461503	0.966	rs10892937	chr11:122841904	T/C	cg27398637	chr11:122830231	C11orf63	-0.42	-5.25	-0.43	6.42e-7	Menarche (age at onset);
TGCT	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	6.18	0.49	8.58e-9	Bipolar disorder;
TGCT	cis	rs7267979	1.000	rs6050631	chr20:25431749	C/T	cg14121845	chr20:25566513	NINL	0.51	5.47	0.44	2.35e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6460942	0.915	rs62447639	chr7:12486803	T/C	cg06484146	chr7:12443880	VWDE	-0.61	-5.43	-0.44	2.87e-7	Coronary artery disease;
TGCT	cis	rs4689388	0.890	rs4689398	chr4:6302199	C/T	cg25554036	chr4:6271136	WFS1	0.56	7.96	0.58	9.38e-13	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs7914558	0.966	rs1591915	chr10:104646849	C/T	cg15744005	chr10:104629667	AS3MT	-0.41	-5.09	-0.42	1.29e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs6582630	0.559	rs12318620	chr12:38522340	T/C	cg26384229	chr12:38710491	ALG10B	-0.55	-4.89	-0.4	3.05e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs9357506	0.935	rs11963572	chr6:46302448	T/C	cg21115430	chr6:46460003	NA	-0.25	-5.16	-0.42	9.35e-7	Body mass index;
TGCT	cis	rs2115630	1.000	rs6496441	chr15:85363348	A/G	cg11189052	chr15:85197271	WDR73	-0.61	-5.7	-0.46	8.1e-8	P wave terminal force;
TGCT	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg21016266	chr12:122356598	WDR66	0.43	5.67	0.45	9.63e-8	Mean corpuscular volume;
TGCT	cis	rs2692947	0.537	rs12478605	chr2:96377078	C/T	cg23100626	chr2:96804247	ASTL	0.47	5.57	0.45	1.48e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs9399135	0.904	rs4895438	chr6:135317665	G/T	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.36e-6	Red blood cell count;
TGCT	cis	rs12134133	1.000	rs4844590	chr1:207496129	C/T	cg02152968	chr1:207494213	CD55	0.6	4.47	0.37	1.74e-5	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	trans	rs8073060	0.544	rs225287	chr17:33929487	G/T	cg19694781	chr19:47549865	TMEM160	-0.59	-12.83	-0.76	1.67e-24	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs2637266	1.000	rs10824431	chr10:78356622	C/A	cg18941641	chr10:78392320	NA	0.4	5.01	0.41	1.81e-6	Pulmonary function;
TGCT	cis	rs6433857	0.505	rs7561255	chr2:181369216	A/G	cg23363182	chr2:181467187	NA	-0.33	-4.98	-0.41	2.05e-6	Body mass index;
TGCT	cis	rs7542091	0.637	rs9429826	chr1:210052146	G/A	cg21951975	chr1:209979733	IRF6	0.58	5.87	0.47	3.81e-8	Monobrow;
TGCT	cis	rs6459788	0.693	rs35146559	chr7:157238557	G/A	cg06271696	chr7:157225062	NA	-0.29	-5.13	-0.42	1.07e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs4622507	0.728	rs34585830	chr16:55054891	G/T	cg04853843	chr16:55358461	IRX6	-0.52	-4.71	-0.39	6.42e-6	Social communication problems;
TGCT	cis	rs25422	0.938	rs62421538	chr6:118729703	A/T	cg21191810	chr6:118973309	C6orf204	-0.37	-4.77	-0.39	5.03e-6	Renal cell carcinoma;
TGCT	cis	rs670523	0.596	rs72708239	chr1:155985899	A/G	cg13795986	chr1:155880507	RIT1	0.37	4.48	0.37	1.66e-5	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg24846343	chr22:24311635	DDTL	0.25	6.34	0.49	3.97e-9	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg18252515	chr7:66147081	NA	-1.13	-6.81	-0.52	3.7e-10	Diabetic kidney disease;
TGCT	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg10819733	chr22:24237672	NA	-0.32	-5.59	-0.45	1.39e-7	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6740322	0.901	rs2163228	chr2:43549246	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.35	-5.21	-0.42	7.74e-7	Coronary artery disease;
TGCT	cis	rs6547741	1.000	rs7604798	chr2:27824940	T/C	cg27432699	chr2:27873401	GPN1	0.18	4.65	0.38	8.53e-6	Oral cavity cancer;
TGCT	cis	rs73001065	0.591	rs2285626	chr19:19467545	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.71	4.49	0.37	1.62e-5	LDL cholesterol;
TGCT	cis	rs7714584	1.000	rs6579803	chr5:150255559	C/T	cg22134413	chr5:150180641	NA	0.83	6.53	0.51	1.54e-9	Crohn's disease;
TGCT	cis	rs13064411	0.696	rs11921931	chr3:113015091	G/A	cg18753928	chr3:113234510	CCDC52	-0.7	-5.01	-0.41	1.8e-6	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs240764	0.658	rs35967345	chr6:101187858	T/G	cg09795085	chr6:101329169	ASCC3	-0.51	-4.51	-0.38	1.45e-5	Neuroticism;
TGCT	cis	rs42648	0.869	rs42613	chr7:89950303	C/T	cg25739043	chr7:89950458	NA	-0.73	-7.29	-0.55	3.2e-11	Homocysteine levels;
TGCT	cis	rs6684514	1.000	rs11264467	chr1:156273061	A/G	cg20302342	chr1:156215951	PAQR6	-0.36	-4.73	-0.39	6.11e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs8067545	1.000	rs8065337	chr17:19941879	C/A	cg13482628	chr17:19912719	NA	0.54	4.73	0.39	5.94e-6	Schizophrenia;
TGCT	cis	rs4494114	0.967	rs6696437	chr1:39348165	G/A	cg25970120	chr1:39325951	RRAGC	-0.6	-6.23	-0.49	6.58e-9	Blood protein levels;
TGCT	cis	rs7618915	1.000	rs3852064	chr3:52349412	G/T	cg10802521	chr3:52805072	NEK4	-0.54	-5.74	-0.46	6.9e-8	Bipolar disorder;
TGCT	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg15320075	chr8:145703422	NA	-0.61	-5.66	-0.45	1.01e-7	Age at first birth;
TGCT	cis	rs9300255	0.679	rs10772998	chr12:123721177	T/G	cg00376283	chr12:123451042	ABCB9	0.72	5.59	0.45	1.35e-7	Neutrophil percentage of white cells;
TGCT	cis	rs6964587	0.626	rs2269810	chr7:91508837	T/C	cg17063962	chr7:91808500	NA	-0.75	-7.02	-0.53	1.25e-10	Breast cancer;
TGCT	cis	rs5769765	0.542	rs5769751	chr22:50242733	T/G	cg22709217	chr22:50311962	ALG12;CRELD2	1.07	5.7	0.46	8.46e-8	Schizophrenia;
TGCT	cis	rs80033912	0.626	rs71324982	chr3:49669948	G/A	cg12257692	chr3:49977190	RBM6	0.27	4.8	0.4	4.4e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6121246	0.697	rs6120970	chr20:30232452	C/T	cg18721089	chr20:30220636	NA	-0.53	-5.43	-0.44	2.86e-7	Mean corpuscular hemoglobin;
TGCT	cis	rs28595532	0.920	rs10001115	chr4:119781867	A/C	cg00700008	chr4:120138107	USP53	0.49	4.48	0.37	1.71e-5	Cannabis dependence symptom count;
TGCT	cis	rs977747	0.872	rs10890471	chr1:47676525	C/A	cg03885399	chr1:47691550	TAL1	-0.42	-5.48	-0.44	2.27e-7	Body mass index;
TGCT	cis	rs7513165	0.736	rs4889	chr1:204159787	G/C	cg12731349	chr1:204159619	KISS1	0.49	5.62	0.45	1.19e-7	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
TGCT	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg24829409	chr8:58192753	C8orf71	-0.59	-5.18	-0.42	8.54e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7014346	0.767	rs10956367	chr8:128423544	T/C	cg04263511	chr8:128962092	PVT1	-0.31	-4.55	-0.38	1.25e-5	Colorectal cancer;
TGCT	cis	rs6563842	0.528	rs56340348	chr13:41296371	C/T	cg21288729	chr13:41239152	FOXO1	0.94	9.1	0.63	1.87e-15	Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
TGCT	cis	rs7043114	0.525	rs7045409	chr9:95201540	A/T	cg14631576	chr9:95140430	CENPP	-0.28	-4.67	-0.39	7.71e-6	Height;
TGCT	cis	rs11711311	1.000	rs62268169	chr3:113493860	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.79	-7.38	-0.55	2e-11	IgG glycosylation;
TGCT	trans	rs9388451	0.874	rs9398787	chr6:126090608	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.74	-8.38	-0.6	9.81e-14	Brugada syndrome;
TGCT	cis	rs2274471	0.645	rs12237834	chr9:5093646	C/T	cg03390472	chr9:5043263	JAK2	-0.29	-4.68	-0.39	7.53e-6	Crohn's disease;
TGCT	cis	rs11252926	0.598	rs4881256	chr10:453831	T/A	cg18196295	chr10:418757	DIP2C	0.3	4.78	0.39	4.82e-6	Psychosis in Alzheimer's disease;
TGCT	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg18876405	chr7:65276391	NA	0.31	4.78	0.39	4.81e-6	Aortic root size;
TGCT	trans	rs7726839	0.526	rs11960158	chr5:568665	C/T	cg11887960	chr12:57824829	NA	1.02	7.74	0.57	3.07e-12	Obesity-related traits;
TGCT	cis	rs8017423	0.935	rs4904661	chr14:90729332	T/C	cg04374321	chr14:90722782	PSMC1	0.76	7.46	0.56	1.35e-11	Mortality in heart failure;
TGCT	cis	rs6740322	0.644	rs11690918	chr2:43474112	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.4	-6.01	-0.48	1.87e-8	Coronary artery disease;
TGCT	cis	rs514406	0.698	rs11206043	chr1:53402552	C/T	cg08736216	chr1:53307985	ZYG11A	-0.23	-4.55	-0.38	1.24e-5	Monocyte count;
TGCT	cis	rs9303401	0.659	rs62083525	chr17:56658088	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs9926296	0.593	rs6500456	chr16:89888341	T/C	cg04287289	chr16:89883240	FANCA	0.7	7.06	0.54	1.05e-10	Vitiligo;
TGCT	cis	rs9486719	1.000	rs12205655	chr6:96891733	T/A	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.21	-0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs12682352	0.602	rs4841044	chr8:8664940	A/G	cg06636001	chr8:8085503	FLJ10661	-0.62	-5.42	-0.44	3.03e-7	Neuroticism;
TGCT	cis	rs6665290	0.669	rs3738725	chr1:227174210	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.91	-15.21	-0.81	4.04e-30	Myeloid white cell count;
TGCT	cis	rs9303401	0.614	rs34678056	chr17:57177549	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.58	5.74	0.46	6.76e-8	Cognitive test performance;
TGCT	cis	rs7772486	0.875	rs2814874	chr6:146305895	C/T	cg23711669	chr6:146136114	FBXO30	0.88	9.48	0.65	2.31e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg10152585	chr3:50297680	NA	0.52	4.97	0.41	2.17e-6	Resting heart rate;
TGCT	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg12310025	chr6:25882481	NA	-0.67	-6.09	-0.48	1.32e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs4523957	0.690	rs11078855	chr17:2091308	A/G	cg16513277	chr17:2031491	SMG6	0.2	4.6	0.38	1.05e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs11650494	0.908	rs78208413	chr17:47398282	G/A	cg08112188	chr17:47440006	ZNF652	1.04	5.35	0.43	4.09e-7	Prostate cancer;
TGCT	cis	rs3617	0.539	rs11922975	chr3:52936763	C/T	cg11645453	chr3:52864694	ITIH4	-0.28	-5.37	-0.43	3.77e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7980687	0.628	rs1727332	chr12:123718301	C/T	cg00376283	chr12:123451042	ABCB9	0.75	6.4	0.5	2.89e-9	Height;Educational attainment;Head circumference (infant);
TGCT	cis	rs72781680	0.752	rs72796110	chr2:23905658	T/A	cg08917208	chr2:24149416	ATAD2B	1.0	5.56	0.45	1.59e-7	Lymphocyte counts;
TGCT	cis	rs5769765	0.773	rs58375955	chr22:50312630	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.43	6.08	0.48	1.35e-8	Schizophrenia;
TGCT	cis	rs6061231	0.546	rs482220	chr20:60927482	G/A	cg24112000	chr20:60950667	NA	0.34	4.76	0.39	5.24e-6	Colorectal cancer;
TGCT	cis	rs3784262	0.564	rs12148652	chr15:58198091	A/G	cg12031962	chr15:58353849	ALDH1A2	0.51	6.72	0.52	5.9e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg16414030	chr3:133502952	NA	0.49	6.95	0.53	1.8e-10	Iron status biomarkers;
TGCT	cis	rs1903068	0.719	rs17711225	chr4:55999185	G/A	cg16572876	chr4:56024045	NA	0.44	4.74	0.39	5.7e-6	Endometriosis;
TGCT	cis	rs950776	0.518	rs4887063	chr15:78839715	C/T	cg21242079	chr15:79101063	ADAMTS7	0.27	4.46	0.37	1.79e-5	Sudden cardiac arrest;
TGCT	cis	rs1691799	0.899	rs1168300	chr12:66736467	C/A	cg16791601	chr12:66731901	HELB	-0.28	-6.11	-0.48	1.19e-8	White blood cell count (basophil);
TGCT	cis	rs9467773	0.620	rs2498351	chr6:26659642	C/T	cg26531700	chr6:26746687	NA	0.51	4.61	0.38	9.86e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1158570	0.778	rs7817803	chr8:131319822	A/C	cg16277922	chr8:131349729	ASAP1	0.47	7.12	0.54	7.62e-11	Platelet count;
TGCT	cis	rs4595586	0.545	rs9669705	chr12:39374459	C/T	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs7772486	0.719	rs702307	chr6:145993454	C/G	cg13319975	chr6:146136371	FBXO30	0.56	5.03	0.41	1.7e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6665290	0.566	rs1513617	chr1:227447213	C/T	cg10327440	chr1:227177885	CDC42BPA	0.56	5.83	0.46	4.5e-8	Myeloid white cell count;
TGCT	cis	rs3087591	1.000	rs7214792	chr17:29460673	G/A	cg24425628	chr17:29625626	OMG;NF1	0.47	7.3	0.55	3.03e-11	Hip circumference;
TGCT	cis	rs12791968	0.917	rs11038238	chr11:45002010	A/G	cg11846598	chr11:44996168	LOC221122	-0.35	-6.45	-0.5	2.29e-9	Inhibitory control;
TGCT	trans	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg21659725	chr3:3221576	CRBN	0.73	8.19	0.59	2.76e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	1.000	rs10504229	chr8:58196495	A/G	cg24829409	chr8:58192753	C8orf71	-0.55	-4.74	-0.39	5.83e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1865760	1.000	rs6938233	chr6:25914077	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.65	6.19	0.49	8.16e-9	Height;
TGCT	cis	rs12477438	0.520	rs2516830	chr2:99773702	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	10.3	0.68	2.42e-18	Chronic sinus infection;
TGCT	cis	rs11534004	0.514	rs10500037	chr7:113707787	T/C	cg21852992	chr7:112726869	GPR85	0.36	4.95	0.41	2.33e-6	Schizophrenia;
TGCT	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg13395646	chr4:1353034	KIAA1530	-0.36	-4.62	-0.38	9.52e-6	Obesity-related traits;
TGCT	trans	rs9388451	0.657	rs4895799	chr6:126052729	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.74	-7.27	-0.55	3.49e-11	Brugada syndrome;
TGCT	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg23302884	chr18:44338147	ST8SIA5	-0.41	-4.68	-0.39	7.48e-6	Personality dimensions;
TGCT	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg12963246	chr6:28129442	ZNF389	0.51	4.97	0.41	2.19e-6	Depression;
TGCT	cis	rs67460515	0.892	rs6780536	chr3:161058726	T/C	cg03342759	chr3:160939853	NMD3	-0.53	-5.88	-0.47	3.6e-8	Parkinson's disease;
TGCT	cis	rs4727027	0.933	rs1058059	chr7:148879134	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	4.77	0.39	5.16e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs75686122	0.892	rs12156411	chr8:104716477	C/T	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs2637266	0.967	rs12246605	chr10:78352994	G/A	cg18941641	chr10:78392320	NA	0.4	5.01	0.41	1.81e-6	Pulmonary function;
TGCT	cis	rs9457247	1.000	rs932644	chr6:167404187	A/C	cg23791538	chr6:167370224	RNASET2	-0.49	-4.96	-0.41	2.26e-6	Crohn's disease;
TGCT	cis	rs17221829	0.932	rs10830358	chr11:89452943	T/A	cg02982614	chr11:89391479	FOLH1B	-0.29	-4.97	-0.41	2.16e-6	Anxiety in major depressive disorder;
TGCT	cis	rs7412746	0.658	rs7521719	chr1:150913134	G/A	cg09365446	chr1:150670422	GOLPH3L	0.34	4.71	0.39	6.58e-6	Melanoma;
TGCT	cis	rs7611238	0.560	rs2275519	chr3:195022534	G/T	cg27323046	chr3:195102265	ACAP2	0.35	4.68	0.39	7.5e-6	Body mass index;
TGCT	cis	rs9611565	0.512	rs2050033	chr22:42159229	G/T	cg13695892	chr22:41940480	POLR3H	0.85	8.06	0.59	5.4e-13	Vitiligo;
TGCT	cis	rs9894429	0.646	rs9905639	chr17:79614154	A/G	cg21028142	chr17:79581711	NPLOC4	0.31	6.7	0.52	6.63e-10	Eye color traits;
TGCT	cis	rs8180040	0.966	rs3736177	chr3:47451411	C/T	cg27129171	chr3:47204927	SETD2	-0.64	-7.35	-0.55	2.39e-11	Colorectal cancer;
TGCT	cis	rs4747241	1.000	rs12768834	chr10:74043874	A/G	cg09661010	chr10:73848153	SPOCK2	0.4	4.46	0.37	1.8e-5	Heschl's gyrus morphology;
TGCT	cis	rs6570726	0.738	rs7746330	chr6:145899257	A/C	cg23711669	chr6:146136114	FBXO30	0.89	9.85	0.66	2.95e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2013441	1.000	rs2526464	chr17:20075052	A/G	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.61	-0.38	9.96e-6	Obesity-related traits;
TGCT	cis	rs72627509	0.767	rs6853156	chr4:57774843	C/T	cg26694713	chr4:57773883	REST	0.72	6.46	0.5	2.14e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs6687430	0.543	rs7512495	chr1:10631237	C/T	cg17425144	chr1:10567563	PEX14	0.48	5.2	0.42	7.84e-7	Hand grip strength;
TGCT	cis	rs28595532	0.920	rs116791817	chr4:119763303	C/T	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg11494091	chr17:61959527	GH2	0.61	14.81	0.8	3.37e-29	Prudent dietary pattern;
TGCT	cis	rs115056730	0.520	rs113247402	chr2:98168573	T/C	cg26665480	chr2:98280029	ACTR1B	-0.96	-4.48	-0.37	1.67e-5	Monocyte chemoattractant protein-3 levels;
TGCT	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg11890956	chr21:40555474	PSMG1	1.03	10.71	0.69	2.36e-19	Cognitive function;
TGCT	cis	rs61990749	0.597	rs10142722	chr14:78275549	A/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.65	4.74	0.39	5.79e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs13315871	1.000	rs9869276	chr3:58401076	G/A	cg12435725	chr3:58293450	RPP14	-0.44	-4.5	-0.37	1.57e-5	Cholesterol, total;
TGCT	cis	rs2832191	0.791	rs7282843	chr21:30475226	A/G	cg24692254	chr21:30365293	RNF160	0.94	10.58	0.69	4.82e-19	Dental caries;
TGCT	cis	rs1847202	0.859	rs13090900	chr3:72946560	C/A	cg25664220	chr3:72788482	NA	-0.36	-4.48	-0.37	1.69e-5	Motion sickness;
TGCT	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg10047753	chr17:41438598	NA	0.94	9.23	0.64	9.06e-16	Menopause (age at onset);
TGCT	cis	rs6543140	0.964	rs13390895	chr2:103075499	G/A	cg09003973	chr2:102972529	NA	0.55	4.67	0.39	7.71e-6	Blood protein levels;
TGCT	cis	rs639012	0.503	rs7114401	chr11:85839935	C/T	cg07180834	chr11:85838833	NA	-0.31	-4.57	-0.38	1.17e-5	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg24503407	chr1:205819492	PM20D1	0.43	5.25	0.43	6.31e-7	Menarche (age at onset);
TGCT	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	4.45	0.37	1.91e-5	Height;
TGCT	cis	rs858239	0.699	rs1881200	chr7:23201637	T/C	cg05602783	chr7:23145260	KLHL7	0.68	5.64	0.45	1.1e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs9457247	0.967	rs428805	chr6:167403132	C/A	cg23791538	chr6:167370224	RNASET2	-0.49	-4.96	-0.41	2.26e-6	Crohn's disease;
TGCT	cis	rs9952991	0.608	rs9960807	chr18:12770851	A/G	cg23598886	chr18:12777645	NA	-0.71	-5.52	-0.44	1.86e-7	Inflammatory skin disease;
TGCT	cis	rs56011263	0.687	rs11734460	chr4:705074	C/T	cg20735989	chr4:730612	PCGF3	-0.24	-5.43	-0.44	2.86e-7	White blood cell count;
TGCT	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg23302884	chr18:44338147	ST8SIA5	-0.4	-4.63	-0.38	9.02e-6	Personality dimensions;
TGCT	cis	rs514406	0.505	rs440871	chr1:53173052	C/T	cg22166914	chr1:53195759	ZYG11B	0.44	7.81	0.57	2.06e-12	Monocyte count;
TGCT	cis	rs6570726	0.791	rs13202312	chr6:145913093	T/G	cg23711669	chr6:146136114	FBXO30	0.89	9.62	0.65	1.06e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7312933	0.558	rs11181501	chr12:42822671	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.54	5.14	0.42	1.06e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs7267979	0.903	rs6115109	chr20:25239667	G/A	cg14121845	chr20:25566513	NINL	0.5	5.51	0.44	1.95e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7208859	0.673	rs9899349	chr17:29200122	C/T	cg18442181	chr17:29233375	C17orf42	-0.78	-4.61	-0.38	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg08048268	chr3:133502702	NA	-0.68	-10.61	-0.69	4.08e-19	Iron status biomarkers;
TGCT	cis	rs4711350	0.834	rs9461905	chr6:33721933	T/C	cg18005901	chr6:33739558	LEMD2	-0.46	-5.04	-0.41	1.62e-6	Schizophrenia;
TGCT	trans	rs28735056	0.584	rs11664834	chr18:77644876	G/T	cg05926928	chr17:57297772	GDPD1	0.88	9.52	0.65	1.86e-16	Schizophrenia;
TGCT	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg03264133	chr6:25882463	NA	-0.51	-5.36	-0.43	3.84e-7	Blood metabolite levels;
TGCT	cis	rs733175	0.857	rs3796838	chr4:10011030	C/T	cg11266682	chr4:10021025	SLC2A9	0.52	4.68	0.39	7.48e-6	Psychosis and Alzheimer's disease;
TGCT	cis	rs2742417	0.603	rs7631818	chr3:45775931	A/T	cg04837898	chr3:45731254	SACM1L	-0.67	-7.3	-0.55	3.06e-11	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg25767906	chr1:53392781	SCP2	-0.61	-7.43	-0.56	1.51e-11	Monocyte count;
TGCT	cis	rs6912958	0.516	rs242278	chr6:88047059	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.4	4.71	0.39	6.65e-6	Monocyte percentage of white cells;
TGCT	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg12311346	chr5:56204834	C5orf35	-0.67	-6.82	-0.52	3.63e-10	Initial pursuit acceleration;
TGCT	cis	rs2858942	0.602	rs1211375	chr16:240280	G/T	cg00126636	chr16:237282	NA	0.18	4.57	0.38	1.16e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs79349575	0.811	rs60708039	chr17:46999373	C/G	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.51	-0.38	1.48e-5	Type 2 diabetes;
TGCT	cis	rs6545883	0.894	rs1186703	chr2:61672965	A/C	cg15711740	chr2:61764176	XPO1	-0.57	-5.1	-0.42	1.25e-6	Tuberculosis;
TGCT	cis	rs908922	0.676	rs11205014	chr1:152483634	C/T	cg20991723	chr1:152506922	NA	0.47	6.63	0.51	9.06e-10	Hair morphology;
TGCT	cis	rs7819412	0.522	rs11776603	chr8:11020313	G/T	cg21775007	chr8:11205619	TDH	-0.53	-4.65	-0.39	8.31e-6	Triglycerides;
TGCT	cis	rs4478858	0.735	rs6679393	chr1:31770944	T/C	cg00250761	chr1:31883323	NA	-0.28	-5.01	-0.41	1.86e-6	Alcohol dependence;
TGCT	cis	rs9534288	0.797	rs1319712	chr13:46591707	T/C	cg15192986	chr13:46630673	CPB2	-0.53	-7.62	-0.56	5.82e-12	Blood protein levels;
TGCT	cis	rs3733585	0.725	rs6449201	chr4:9973894	C/T	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.68	-0.57	4.13e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs6426551	1.000	rs6668851	chr1:226545866	C/A	cg18564989	chr1:226411057	MIXL1	-0.48	-4.75	-0.39	5.42e-6	Coronary artery disease;
TGCT	cis	rs826838	0.510	rs17523988	chr12:39222785	A/C	cg13010199	chr12:38710504	ALG10B	0.6	4.7	0.39	6.75e-6	Heart rate;
TGCT	cis	rs7586879	0.638	rs10203482	chr2:25136916	T/C	cg15423357	chr2:25149977	NA	0.5	4.84	0.4	3.71e-6	Body mass index;
TGCT	cis	rs6088590	1.000	rs6119512	chr20:33306904	T/C	cg24642439	chr20:33292090	TP53INP2	0.69	6.17	0.48	8.94e-9	Coronary artery disease;
TGCT	cis	rs11148252	0.553	rs2147692	chr13:53287023	C/G	cg02158880	chr13:53174818	NA	0.43	5.1	0.42	1.26e-6	Lewy body disease;
TGCT	trans	rs17685	0.753	rs1104878	chr7:75685593	G/T	cg19862616	chr7:65841803	NCRNA00174	0.52	8.84	0.62	7.72e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs7582180	0.764	rs11689439	chr2:100925399	T/C	cg08017756	chr2:100939284	LONRF2	-0.32	-5.31	-0.43	4.86e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs8051431	0.806	rs7205297	chr16:72025531	C/T	cg06353428	chr16:71660113	MARVELD3	0.59	4.91	0.4	2.84e-6	LDL cholesterol levels;
TGCT	cis	rs1034435	0.755	rs5767171	chr22:48891881	A/G	cg05992904	chr22:48892994	FAM19A5	-0.33	-4.52	-0.38	1.41e-5	Late-onset Alzheimer's disease;
TGCT	cis	rs7666738	0.830	rs10031292	chr4:99056877	A/G	cg17366294	chr4:99064904	C4orf37	0.72	7.25	0.55	3.95e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs838147	0.508	rs507766	chr19:49208543	T/C	cg04599840	chr19:48886497	KDELR1	0.23	4.74	0.39	5.83e-6	Dietary macronutrient intake;
TGCT	cis	rs67478160	0.609	rs1547604	chr14:104270659	A/T	cg26031613	chr14:104095156	KLC1	-0.64	-6.42	-0.5	2.64e-9	Schizophrenia;
TGCT	cis	rs4727443	0.866	rs12531809	chr7:99620473	G/T	cg13334819	chr7:99746414	C7orf59	0.56	4.71	0.39	6.63e-6	Interstitial lung disease;
TGCT	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg06238570	chr21:40685208	BRWD1	0.69	6.39	0.5	3.07e-9	Cognitive function;
TGCT	cis	rs7727544	0.735	rs272875	chr5:131674888	T/C	cg24060327	chr5:131705240	SLC22A5	-0.56	-6.34	-0.5	3.8e-9	Blood metabolite levels;
TGCT	cis	rs950169	0.959	rs12911210	chr15:84792083	A/C	cg17173187	chr15:85201210	NMB	0.52	5.86	0.47	3.98e-8	Schizophrenia;
TGCT	cis	rs2816958	0.803	rs2821335	chr1:200094786	T/C	cg07971716	chr1:199773294	NA	0.46	4.52	0.38	1.45e-5	Ulcerative colitis;Inflammatory bowel disease;
TGCT	cis	rs2404602	0.655	rs8028294	chr15:77084877	T/C	cg22467129	chr15:76604101	ETFA	-0.45	-5.11	-0.42	1.18e-6	Blood metabolite levels;
TGCT	cis	rs57221529	0.766	rs72706606	chr5:558609	T/C	cg09021430	chr5:549028	NA	-0.4	-5.46	-0.44	2.44e-7	Lung disease severity in cystic fibrosis;
TGCT	cis	rs9467711	0.606	rs9379871	chr6:26375854	C/G	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg02503808	chr4:7069936	GRPEL1	1.05	10.21	0.68	3.94e-18	Monocyte percentage of white cells;
TGCT	cis	rs7412746	0.658	rs1546376	chr1:150937661	A/G	cg09365446	chr1:150670422	GOLPH3L	0.34	4.7	0.39	6.76e-6	Melanoma;
TGCT	cis	rs67311347	0.955	rs12487955	chr3:40412853	T/C	cg13409248	chr3:40428643	ENTPD3	0.55	4.49	0.37	1.61e-5	Renal cell carcinoma;
TGCT	cis	rs7524258	0.868	rs11120885	chr1:7306755	C/G	cg07173049	chr1:7289937	CAMTA1	0.29	4.74	0.39	5.72e-6	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs1865760	0.566	rs2032443	chr6:26046802	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.77	7.31	0.55	2.87e-11	Height;
TGCT	cis	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg20637647	chr7:64974828	NA	1.0	5.59	0.45	1.4e-7	Diabetic kidney disease;
TGCT	cis	rs7727544	0.816	rs274555	chr5:131722951	C/T	cg00255919	chr5:131827918	IRF1	0.2	4.85	0.4	3.7e-6	Blood metabolite levels;
TGCT	cis	rs17345786	0.906	rs72940399	chr3:101122575	A/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.84	8.92	0.63	5.05e-15	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg06418219	chr1:154948305	SHC1;CKS1B	-0.69	-7.19	-0.54	5.48e-11	Prostate cancer;
TGCT	cis	rs25422	0.938	rs62422193	chr6:118912285	G/A	cg07617317	chr6:118971624	C6orf204	0.48	5.08	0.42	1.32e-6	Renal cell carcinoma;
TGCT	cis	rs12479064	0.724	rs28369945	chr2:100080928	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.7	-5.87	-0.47	3.79e-8	Chronic sinus infection;
TGCT	cis	rs1355023	0.547	rs9399943	chr6:106228922	C/T	cg17356964	chr6:106582638	NA	0.26	4.92	0.4	2.7e-6	Age-related macular degeneration;
TGCT	cis	rs2455799	0.559	rs2166761	chr3:15914838	G/A	cg12172478	chr3:16357591	RFTN1	-0.36	-5.3	-0.43	5.07e-7	Mean platelet volume;
TGCT	cis	rs2153535	0.580	rs9405390	chr6:8466209	T/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs35306767	0.714	rs67205460	chr10:1090366	C/T	cg26597838	chr10:835615	NA	0.61	7.09	0.54	8.8e-11	Eosinophil percentage of granulocytes;
TGCT	cis	rs2637266	0.935	rs1907299	chr10:78325316	T/C	cg18941641	chr10:78392320	NA	0.42	5.38	0.43	3.6e-7	Pulmonary function;
TGCT	cis	rs6840360	0.642	rs6843639	chr4:152416015	C/T	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.82e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs4822044	0.560	rs7284839	chr22:42010902	C/T	cg06634786	chr22:41940651	POLR3H	0.89	8.56	0.61	3.56e-14	Cannabis dependence symptom count;
TGCT	cis	rs11122272	0.701	rs743120	chr1:231531232	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-6.35	-0.5	3.66e-9	Hemoglobin concentration;
TGCT	cis	rs73198271	0.729	rs67653033	chr8:8605044	G/C	ch.8.214553F	chr8:8189620	PRAGMIN	-0.28	-4.79	-0.4	4.63e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs2075371	0.611	rs11762920	chr7:134018514	C/T	cg11752832	chr7:134001865	SLC35B4	0.63	5.1	0.42	1.23e-6	Mean platelet volume;
TGCT	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.5	-4.84	-0.4	3.82e-6	Longevity;Endometriosis;
TGCT	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg05985448	chr10:134359359	INPP5A	0.23	4.99	0.41	2.01e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg13393036	chr8:95962371	TP53INP1	-0.63	-8.52	-0.61	4.43e-14	Type 2 diabetes;
TGCT	cis	rs9902453	0.904	rs12939344	chr17:28328819	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.8	-7.56	-0.56	7.78e-12	Coffee consumption (cups per day);
TGCT	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg07507251	chr3:52567010	NT5DC2	0.47	6.63	0.51	9.08e-10	Electroencephalogram traits;
TGCT	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.45	0.56	1.42e-11	Prudent dietary pattern;
TGCT	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg27535305	chr1:53392650	SCP2	-0.26	-4.97	-0.41	2.16e-6	Monocyte count;
TGCT	cis	rs2070488	1.000	rs7433707	chr3:38443180	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	9.66	0.66	8.43e-17	Electrocardiographic conduction measures;
TGCT	cis	rs9329221	0.905	rs13252982	chr8:10255105	C/G	cg21775007	chr8:11205619	TDH	-0.53	-4.8	-0.4	4.5e-6	Neuroticism;
TGCT	cis	rs2463822	1.000	rs951677	chr11:62107249	G/C	cg06239285	chr11:62104954	ASRGL1	0.95	6.56	0.51	1.33e-9	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.47	0.56	1.28e-11	Prudent dietary pattern;
TGCT	cis	rs6545883	0.894	rs6545867	chr2:61651027	C/T	cg15711740	chr2:61764176	XPO1	0.52	4.62	0.38	9.55e-6	Tuberculosis;
TGCT	cis	rs941408	0.963	rs2537855	chr19:2806574	A/G	cg06609049	chr19:2785107	THOP1	0.86	7.27	0.55	3.49e-11	Total cholesterol levels;
TGCT	cis	rs11785400	0.928	rs10100287	chr8:143734836	C/T	cg24634471	chr8:143751801	JRK	0.56	6.12	0.48	1.12e-8	Schizophrenia;
TGCT	cis	rs60843830	1.000	rs9213	chr2:218386	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.69	6.11	0.48	1.17e-8	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg27121462	chr16:89883253	FANCA	0.81	8.95	0.63	4.42e-15	Vitiligo;
TGCT	cis	rs6540559	0.543	rs672819	chr1:210436404	T/A	cg22029157	chr1:209979665	IRF6	0.62	4.45	0.37	1.92e-5	Cleft lip with or without cleft palate;
TGCT	cis	rs7267979	1.000	rs6138572	chr20:25435934	G/C	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6746896	0.959	rs2314398	chr2:97413488	C/G	cg26085987	chr2:97230376	NA	0.19	4.63	0.38	9.18e-6	Bipolar disorder;
TGCT	cis	rs35306767	0.903	rs34270014	chr10:904666	T/C	cg26597838	chr10:835615	NA	0.75	10.61	0.69	4.13e-19	Eosinophil percentage of granulocytes;
TGCT	cis	rs13082711	0.522	rs608374	chr3:27345397	G/A	cg02860705	chr3:27208620	NA	0.34	5.58	0.45	1.43e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs1536827	0.541	rs11592587	chr10:135363653	G/A	cg12448312	chr10:135032219	KNDC1	-0.53	-5.09	-0.42	1.27e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg03264133	chr6:25882463	NA	-0.61	-5.68	-0.45	9.01e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs8013055	0.796	rs4074453	chr14:105998544	T/C	cg19700328	chr14:106028568	NA	-0.49	-5.2	-0.42	8.1e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs1635	0.655	rs73742541	chr6:28310615	T/C	cg15743358	chr6:28303923	ZNF323	-1.29	-6.5	-0.5	1.73e-9	Schizophrenia;
TGCT	cis	rs7267979	1.000	rs6083856	chr20:25407585	C/T	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4767364	1.000	rs2285810	chr12:112699540	T/C	cg10833066	chr12:111807467	FAM109A	0.34	5.17	0.42	8.98e-7	Oral cavity and pharyngeal cancer;
TGCT	cis	rs6693567	0.565	rs3754217	chr1:150480373	G/T	cg09579323	chr1:150459698	TARS2	0.52	4.63	0.38	9.26e-6	Migraine;
TGCT	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg03352830	chr11:487213	PTDSS2	0.26	4.58	0.38	1.12e-5	Body mass index;
TGCT	cis	rs4820539	0.934	rs3788348	chr22:23467946	G/C	cg14186256	chr22:23484241	RTDR1	0.98	11.82	0.73	4.6e-22	Bone mineral density;
TGCT	cis	rs7698623	0.850	rs4147244	chr4:88779168	C/T	cg27387453	chr4:88533842	DSPP	-0.61	-4.6	-0.38	1.03e-5	Cardiovascular disease risk factors;
TGCT	cis	rs7216064	1.000	rs55896768	chr17:65913358	T/C	cg12091567	chr17:66097778	LOC651250	-0.85	-6.33	-0.49	4.03e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs55882075	0.967	rs12656648	chr5:179152106	C/A	cg14593053	chr5:179126677	CANX	0.47	5.04	0.41	1.57e-6	Monocyte percentage of white cells;
TGCT	cis	rs9303401	0.614	rs28651036	chr17:57080471	G/A	cg25039879	chr17:56429692	SUPT4H1	0.54	4.88	0.4	3.25e-6	Cognitive test performance;
TGCT	cis	rs7017914	0.967	rs35115527	chr8:71643009	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.03	-0.41	1.69e-6	Bone mineral density;
TGCT	cis	rs1472147	0.868	rs13227216	chr7:128490553	T/C	cg00260937	chr7:128520193	KCP	0.42	5.96	0.47	2.38e-8	Calcium levels;
TGCT	cis	rs60871478	0.636	rs4721600	chr7:871728	C/T	cg15782153	chr7:917662	C7orf20	0.51	4.69	0.39	7.23e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg21171335	chr12:122356390	WDR66	0.63	7.03	0.53	1.24e-10	Mean corpuscular volume;
TGCT	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg10295955	chr4:187884368	NA	-0.99	-15.24	-0.81	3.38e-30	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs877282	0.945	rs11253397	chr10:789774	A/G	cg22713356	chr15:30763199	NA	1.18	10.55	0.69	5.81e-19	Uric acid levels;
TGCT	cis	rs6964587	1.000	rs10281556	chr7:91660053	C/T	cg17063962	chr7:91808500	NA	-0.91	-10.53	-0.69	6.54e-19	Breast cancer;
TGCT	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg17054783	chr10:134559939	INPP5A	0.24	4.61	0.38	9.88e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs617219	0.710	rs10054122	chr5:78581371	A/T	cg23514016	chr5:78407564	BHMT	-0.33	-5.04	-0.41	1.6e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs6430585	0.583	rs12475516	chr2:136560761	C/G	cg07169764	chr2:136633963	MCM6	1.05	10.03	0.67	1.09e-17	Corneal structure;
TGCT	cis	rs62244186	0.566	rs2135531	chr3:44881158	C/G	cg02073558	chr3:44770973	ZNF501	0.69	6.87	0.52	2.8e-10	Depressive symptoms;
TGCT	cis	rs13191362	0.507	rs1954810	chr6:163061749	C/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.6	-5.74	-0.46	6.71e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg12570787	chr5:219185	SDHA;CCDC127	0.66	4.48	0.37	1.64e-5	Breast cancer;
TGCT	cis	rs1008375	1.000	rs28545485	chr4:17645376	C/T	cg16339924	chr4:17578868	LAP3	0.63	5.33	0.43	4.49e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7178572	0.524	rs12904088	chr15:77399397	C/G	cg22256960	chr15:77711686	NA	-0.85	-8.71	-0.62	1.61e-14	Type 2 diabetes;
TGCT	cis	rs4808199	0.842	rs11085259	chr19:19445856	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.63	4.56	0.38	1.23e-5	Nonalcoholic fatty liver disease;
TGCT	cis	rs9527	0.590	rs11191547	chr10:104843148	C/T	cg15744005	chr10:104629667	AS3MT	-0.43	-4.92	-0.4	2.69e-6	Arsenic metabolism;
TGCT	cis	rs593531	0.571	rs35170680	chr11:74085420	T/G	cg25592907	chr11:73676012	DNAJB13	0.33	4.81	0.4	4.23e-6	Neuroticism;
TGCT	cis	rs9611565	0.592	rs4822040	chr22:41963553	C/G	cg03806693	chr22:41940476	POLR3H	-1.01	-10.42	-0.68	1.19e-18	Vitiligo;
TGCT	cis	rs2295359	0.892	rs72676069	chr1:67658954	T/C	cg12940439	chr1:67600707	NA	0.6	6.2	0.49	7.79e-9	Psoriasis;
TGCT	cis	rs597480	0.510	rs11607789	chr11:85526151	C/T	cg11817631	chr11:85522609	SYTL2	0.52	4.87	0.4	3.31e-6	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);
TGCT	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg24549020	chr5:56110836	MAP3K1	0.7	5.97	0.47	2.34e-8	Initial pursuit acceleration;
TGCT	cis	rs929354	0.739	rs12533082	chr7:157014172	T/A	cg05182265	chr7:156933206	UBE3C	-0.4	-9.08	-0.63	2.11e-15	Body mass index;
TGCT	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg06873352	chr17:61820015	STRADA	0.57	6.22	0.49	6.85e-9	Prudent dietary pattern;
TGCT	cis	rs909674	0.818	rs8137426	chr22:39844350	T/G	cg11247378	chr22:39784982	NA	-0.72	-8.56	-0.61	3.55e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs9467773	0.534	rs34453863	chr6:26628005	T/C	cg26531700	chr6:26746687	NA	0.66	6.56	0.51	1.32e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs17030434	0.654	rs28640133	chr4:154645926	T/A	cg14289246	chr4:154710475	SFRP2	-0.76	-5.72	-0.46	7.51e-8	Electrocardiographic conduction measures;
TGCT	cis	rs9527	0.637	rs11191424	chr10:104625886	G/A	cg04362960	chr10:104952993	NT5C2	0.57	4.9	0.4	2.89e-6	Arsenic metabolism;
TGCT	cis	rs7635838	0.722	rs6773963	chr3:11511975	G/A	cg00170343	chr3:11313890	ATG7	0.69	6.64	0.51	8.86e-10	HDL cholesterol;
TGCT	cis	rs2404602	0.716	rs67204011	chr15:76846555	C/T	cg22467129	chr15:76604101	ETFA	-0.47	-5.4	-0.44	3.21e-7	Blood metabolite levels;
TGCT	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg12963246	chr6:28129442	ZNF389	0.52	5.1	0.42	1.23e-6	Depression;
TGCT	cis	rs1692580	0.807	rs60635488	chr1:2202572	C/T	cg21194808	chr1:2205498	SKI	0.29	5.52	0.44	1.88e-7	Coronary artery disease;
TGCT	cis	rs9467773	1.000	rs2224380	chr6:26553943	G/A	cg05738196	chr6:26577821	NA	0.91	13.14	0.76	2.99e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg03517284	chr6:25882590	NA	-0.77	-8.05	-0.59	5.9e-13	Blood metabolite levels;
TGCT	cis	rs9303401	0.580	rs2013166	chr17:56637630	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs6430585	0.527	rs60966546	chr2:136401843	C/T	cg07169764	chr2:136633963	MCM6	0.98	8.44	0.6	7.04e-14	Corneal structure;
TGCT	cis	rs9972944	0.729	rs7211481	chr17:63766434	A/C	cg07283582	chr17:63770753	CCDC46	-0.26	-5.16	-0.42	9.6e-7	Total body bone mineral density;
TGCT	cis	rs7845219	0.544	rs9643351	chr8:95917290	C/T	cg16049864	chr8:95962084	TP53INP1	-0.48	-5.3	-0.43	5.23e-7	Type 2 diabetes;
TGCT	cis	rs7439150	0.954	rs2059503	chr4:155493419	A/T	cg22130008	chr4:155548532	NA	-0.49	-6.41	-0.5	2.74e-9	Fibrinogen levels;
TGCT	cis	rs7819412	0.560	rs13265553	chr8:10989057	G/A	cg21775007	chr8:11205619	TDH	-0.6	-5.3	-0.43	5.03e-7	Triglycerides;
TGCT	cis	rs782590	1.000	rs782590	chr2:55843413	C/T	cg03859395	chr2:55845619	SMEK2	0.93	11.31	0.71	8.26e-21	Metabolic syndrome;
TGCT	cis	rs17221829	0.549	rs1844196	chr11:89389256	A/G	cg02982614	chr11:89391479	FOLH1B	-0.25	-4.46	-0.37	1.8e-5	Anxiety in major depressive disorder;
TGCT	cis	rs425277	1.000	rs262654	chr1:2089526	G/A	cg03732007	chr1:2071316	PRKCZ	0.26	5.44	0.44	2.77e-7	Height;
TGCT	cis	rs4072705	0.967	rs4838195	chr9:127351217	G/A	cg13476313	chr9:127244764	NR5A1	0.28	4.5	0.37	1.54e-5	Menarche (age at onset);
TGCT	cis	rs35306767	0.903	rs765867	chr10:869901	G/T	cg20503657	chr10:835505	NA	0.7	9.83	0.66	3.22e-17	Eosinophil percentage of granulocytes;
TGCT	cis	rs344364	0.511	rs911392	chr16:1947259	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.45	-5.08	-0.42	1.35e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg12311346	chr5:56204834	C5orf35	-0.66	-6.63	-0.51	9.22e-10	Initial pursuit acceleration;
TGCT	cis	rs514406	0.547	rs377808	chr1:53190359	T/G	cg16325326	chr1:53192061	ZYG11B	0.89	13.01	0.76	6.31e-25	Monocyte count;
TGCT	cis	rs7698623	0.850	rs1982623	chr4:88790777	C/G	cg27387453	chr4:88533842	DSPP	-0.61	-4.6	-0.38	1.03e-5	Cardiovascular disease risk factors;
TGCT	cis	rs67311347	1.000	rs112619360	chr3:40432645	T/G	cg17264618	chr3:40429014	ENTPD3	0.33	4.72	0.39	6.27e-6	Renal cell carcinoma;
TGCT	cis	rs9788682	0.747	rs938682	chr15:78896547	A/G	cg24631222	chr15:78858424	CHRNA5	0.89	7.01	0.53	1.35e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs35883536	0.626	rs7536054	chr1:101047849	A/G	cg06223162	chr1:101003688	GPR88	-0.41	-7.64	-0.57	5.04e-12	Monocyte count;
TGCT	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg13395646	chr4:1353034	KIAA1530	-0.6	-8.06	-0.59	5.55e-13	Obesity-related traits;
TGCT	cis	rs36051895	0.632	rs7022901	chr9:5177680	C/G	cg02405213	chr9:5042618	JAK2	-0.74	-10.54	-0.69	6.17e-19	Pediatric autoimmune diseases;
TGCT	cis	rs7582180	0.715	rs920270	chr2:100917961	T/C	cg08017756	chr2:100939284	LONRF2	-0.32	-5.31	-0.43	4.89e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg16624210	chr5:671434	TPPP	0.44	4.85	0.4	3.68e-6	Obesity-related traits;
TGCT	cis	rs6670062	0.536	rs1778538	chr1:247412899	G/A	cg01868367	chr1:247372405	NA	0.27	4.57	0.38	1.15e-5	Trans fatty acid levels;
TGCT	cis	rs3796352	1.000	rs17052727	chr3:53070914	T/C	cg27565382	chr3:53032988	SFMBT1	0.42	4.56	0.38	1.21e-5	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs1008375	1.000	rs10805357	chr4:17652352	G/A	cg18681998	chr4:17616180	MED28	1.01	11.89	0.73	3.17e-22	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs644799	0.930	rs587123	chr11:95560539	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	10.52	0.69	6.94e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg20999797	chr1:1681921	NA	0.19	4.87	0.4	3.28e-6	Body mass index;
TGCT	cis	rs4720575	1.000	rs1859522	chr7:47096901	G/A	cg00036614	chr7:47093842	NA	-0.21	-5.35	-0.43	4.1e-7	Angiotensin-converting enzyme inhibitor intolerance;
TGCT	cis	rs7552404	0.961	rs1061337	chr1:76227022	A/G	cg03433033	chr1:76189801	ACADM	0.83	9.53	0.65	1.69e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7582180	0.585	rs13031711	chr2:100939433	T/C	cg08017756	chr2:100939284	LONRF2	-0.3	-4.78	-0.39	4.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg04944784	chr2:26401820	FAM59B	-0.76	-6.24	-0.49	6.46e-9	Gut microbiome composition (summer);
TGCT	cis	rs4319547	0.695	rs4758645	chr12:122946487	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.66	-5.33	-0.43	4.48e-7	Body mass index;
TGCT	cis	rs11105298	0.891	rs10858864	chr12:89846230	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.67	-4.74	-0.39	5.67e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs2439831	0.850	rs28578398	chr15:44075046	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	5.91	0.47	3.05e-8	Lung cancer in ever smokers;
TGCT	cis	rs77633900	0.614	rs280012	chr15:76974854	G/T	cg21673338	chr15:77095150	SCAPER	-0.5	-4.92	-0.4	2.68e-6	Non-glioblastoma glioma;Glioma;
TGCT	cis	rs3741404	0.672	rs4980524	chr11:63959259	A/C	cg00022866	chr11:64108440	CCDC88B	0.24	4.55	0.38	1.25e-5	Platelet count;
TGCT	cis	rs7582180	0.629	rs4850926	chr2:100954117	C/T	cg08017756	chr2:100939284	LONRF2	-0.3	-4.87	-0.4	3.27e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9467711	0.559	rs6920256	chr6:26537801	G/A	cg16898833	chr6:26189333	HIST1H4D	1.02	5.22	0.42	7.42e-7	Autism spectrum disorder or schizophrenia;
TGCT	trans	rs7824557	0.689	rs10481454	chr8:11109303	C/G	cg15556689	chr8:8085844	FLJ10661	-0.8	-6.72	-0.52	5.94e-10	Retinal vascular caliber;
TGCT	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg21862992	chr11:68658383	NA	0.46	6.37	0.5	3.37e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9527	0.518	rs12771834	chr10:104655419	G/A	cg15744005	chr10:104629667	AS3MT	-0.61	-4.96	-0.41	2.3e-6	Arsenic metabolism;
TGCT	trans	rs608114	1.000	rs608114	chr6:96376698	A/T	cg04008557	chr11:2826328	KCNQ1	-0.65	-6.82	-0.52	3.51e-10	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
TGCT	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg05665937	chr4:1216051	CTBP1	0.22	4.47	0.37	1.75e-5	Obesity-related traits;
TGCT	trans	rs13064411	0.542	rs1463643	chr3:113215447	A/G	cg00307254	chr3:126706825	PLXNA1	0.34	6.72	0.52	5.79e-10	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs116161686	0.500	rs55871867	chr1:210051029	A/G	cg22029157	chr1:209979665	IRF6	0.74	5.6	0.45	1.31e-7	Coronary artery disease;
TGCT	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg22920501	chr2:26401640	FAM59B	-0.74	-6.4	-0.5	2.86e-9	Gut microbiome composition (summer);
TGCT	cis	rs7264396	0.790	rs6121018	chr20:34249060	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.25	-0.43	6.33e-7	Total cholesterol levels;
TGCT	cis	rs4072705	0.933	rs10760376	chr9:127554070	A/G	cg13476313	chr9:127244764	NR5A1	-0.29	-4.62	-0.38	9.39e-6	Menarche (age at onset);
TGCT	cis	rs11711311	1.000	rs12632983	chr3:113481913	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.72	-6.74	-0.52	5.36e-10	IgG glycosylation;
TGCT	cis	rs11098499	0.954	rs6848389	chr4:120402622	A/G	cg09307838	chr4:120376055	NA	0.73	6.95	0.53	1.84e-10	Corneal astigmatism;
TGCT	cis	rs9399135	0.935	rs987690	chr6:135350379	A/G	cg24558204	chr6:135376177	HBS1L	0.5	5.0	0.41	1.89e-6	Red blood cell count;
TGCT	cis	rs10858047	0.883	rs12040800	chr1:115108577	T/C	cg12756093	chr1:115239321	AMPD1	0.47	4.96	0.41	2.27e-6	Autism;
TGCT	cis	rs6598955	0.724	rs884533	chr1:26585657	G/T	cg04990556	chr1:26633338	UBXN11	-0.91	-11.45	-0.72	3.65e-21	Obesity-related traits;
TGCT	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg11062466	chr8:58055876	NA	0.44	4.68	0.39	7.38e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9443645	0.869	rs6926537	chr6:79554193	T/A	cg09184832	chr6:79620586	NA	-0.48	-5.35	-0.43	4.01e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.08	0.48	1.37e-8	Bipolar disorder;
TGCT	cis	rs9467773	0.620	rs2451737	chr6:26619041	T/C	cg11502198	chr6:26597334	ABT1	0.53	4.9	0.4	2.95e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs877282	1.000	rs12775643	chr10:773242	G/A	cg17470449	chr10:769945	NA	0.31	4.8	0.4	4.44e-6	Uric acid levels;
TGCT	cis	rs11792861	0.781	rs838835	chr9:111758590	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.51	-4.83	-0.4	3.89e-6	Menarche (age at onset);
TGCT	cis	rs11190604	0.767	rs10883490	chr10:102194775	C/T	cg16005271	chr10:102321736	NA	0.47	4.66	0.39	8.14e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs4689388	0.926	rs4308429	chr4:6294001	A/G	cg00701064	chr4:6280414	WFS1	0.37	4.72	0.39	6.3e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs1903068	0.719	rs1350545	chr4:56004454	C/T	cg01777861	chr4:56023843	NA	0.51	5.61	0.45	1.26e-7	Endometriosis;
TGCT	cis	rs1008375	1.000	rs10027755	chr4:17615954	G/C	cg10189774	chr4:17578691	LAP3	0.54	4.78	0.39	4.9100000000000004e-06	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs78456975	0.527	rs7590742	chr2:1575049	A/T	cg01028140	chr2:1542097	TPO	-0.28	-4.51	-0.38	1.47e-5	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs853679	0.546	rs493161	chr6:27850714	A/T	cg08798685	chr6:27730294	NA	-0.36	-5.06	-0.41	1.45e-6	Depression;
TGCT	cis	rs4689388	0.890	rs6446481	chr4:6295583	C/A	cg14416269	chr4:6271139	WFS1	0.39	4.99	0.41	2.01e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs3749237	0.595	rs1568661	chr3:49520958	A/G	cg02487422	chr3:49467188	NICN1	0.58	5.89	0.47	3.43e-8	Resting heart rate;
TGCT	cis	rs2361718	0.521	rs2361724	chr17:78099114	G/A	cg09238746	chr17:78121135	EIF4A3	-1.07	-9.91	-0.66	2.06e-17	Yeast infection;
TGCT	cis	rs3091242	0.933	rs3093584	chr1:25668714	T/C	cg10117171	chr1:25599238	RHD	0.35	5.67	0.45	9.51e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg10047753	chr17:41438598	NA	0.96	9.6	0.65	1.16e-16	Menopause (age at onset);
TGCT	cis	rs9399401	0.667	rs1329707	chr6:142724439	T/C	cg03128060	chr6:142623767	GPR126	0.37	4.47	0.37	1.77e-5	Chronic obstructive pulmonary disease;
TGCT	cis	rs2404602	0.692	rs55864032	chr15:77122548	A/G	cg22467129	chr15:76604101	ETFA	-0.45	-5.04	-0.41	1.63e-6	Blood metabolite levels;
TGCT	cis	rs148734725	1	rs148734725	chr3:49406708	G/A	cg03060546	chr3:49711283	APEH	-0.64	-5.61	-0.45	1.27e-7	Educational attainment (college completion);
TGCT	cis	rs1023500	0.573	rs133381	chr22:42470608	C/G	cg05082376	chr22:42548792	NA	-0.23	-5.38	-0.43	3.61e-7	Schizophrenia;
TGCT	cis	rs6088590	1.000	rs11698977	chr20:33449691	C/T	cg06115741	chr20:33292138	TP53INP2	0.66	5.26	0.43	5.99e-7	Coronary artery disease;
TGCT	cis	rs7246657	0.606	rs2972439	chr19:38212581	T/C	cg03611452	chr19:38183253	ZNF781	-0.56	-4.63	-0.38	8.97e-6	Coronary artery calcification;
TGCT	cis	rs644799	1.000	rs3748256	chr11:95521953	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	11.08	0.71	2.9e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs11711311	0.712	rs2271498	chr3:113334752	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.6	-5.1	-0.42	1.24e-6	IgG glycosylation;
TGCT	cis	rs9911578	1.000	rs999431	chr17:56854441	A/G	cg12560992	chr17:57184187	TRIM37	0.77	9.32	0.64	5.7e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs77633900	0.614	rs2469242	chr15:76876710	A/G	cg21673338	chr15:77095150	SCAPER	-0.51	-4.7	-0.39	6.69e-6	Non-glioblastoma glioma;Glioma;
TGCT	cis	rs1499614	0.522	rs13247442	chr7:66188858	T/C	cg18252515	chr7:66147081	NA	-1.11	-5.89	-0.47	3.32e-8	Gout;
TGCT	cis	rs346785	0.692	rs3803737	chr17:74289500	G/A	cg09812376	chr17:74270190	QRICH2	-0.36	-5.33	-0.43	4.43e-7	White matter hyperintensities in ischemic stroke;
TGCT	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg14159672	chr1:205819179	PM20D1	0.62	7.71	0.57	3.56e-12	Menarche (age at onset);
TGCT	cis	rs17826219	0.706	rs9905827	chr17:29192168	C/A	cg18442181	chr17:29233375	C17orf42	-0.78	-4.6	-0.38	1.03e-5	Body mass index;
TGCT	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg24250549	chr1:154909240	PMVK	-0.6	-6.27	-0.49	5.39e-9	Prostate cancer;
TGCT	cis	rs955333	0.543	rs6557365	chr6:154924457	A/G	cg22719623	chr6:154360732	OPRM1	0.35	4.67	0.39	7.75e-6	Diabetic kidney disease;
TGCT	cis	rs6088590	0.523	rs6058084	chr20:33183804	C/T	cg06115741	chr20:33292138	TP53INP2	0.51	4.47	0.37	1.76e-5	Coronary artery disease;
TGCT	cis	rs941408	1.000	rs1640266	chr19:2787832	T/G	cg06609049	chr19:2785107	THOP1	0.81	7.81	0.57	2.05e-12	Total cholesterol levels;
TGCT	cis	rs7119038	0.509	rs10892256	chr11:118578705	G/A	cg19308663	chr11:118741387	NA	0.24	4.5	0.37	1.54e-5	Sjögren's syndrome;
TGCT	cis	rs10782582	0.609	rs5745331	chr1:76273313	A/G	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.52	4.54	0.38	1.31e-5	Daytime sleep phenotypes;
TGCT	cis	rs2289681	0.525	rs2277617	chr17:42977073	T/G	cg15193461	chr17:42977049	CCDC103;EFTUD2	-0.7	-6.23	-0.49	6.57e-9	Cognitive function;
TGCT	cis	rs7614311	0.636	rs3821902	chr3:63941697	T/G	cg22134162	chr3:63841271	THOC7	-0.46	-5.83	-0.46	4.5e-8	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs17102423	0.929	rs4902363	chr14:65601689	T/G	cg11161011	chr14:65562177	MAX	-0.47	-6.26	-0.49	5.62e-9	Obesity-related traits;
TGCT	cis	rs7959452	0.503	rs7300266	chr12:69654187	A/G	cg20891283	chr12:69753455	YEATS4	0.63	6.09	0.48	1.32e-8	Blood protein levels;
TGCT	cis	rs10838634	1.000	rs7118097	chr11:46820899	A/G	cg18332754	chr11:46939436	LRP4	0.9	4.59	0.38	1.05e-5	Schizophrenia;
TGCT	cis	rs6831352	1.000	rs6837685	chr4:100049145	G/A	cg12011299	chr4:100065546	ADH4	0.41	5.2	0.42	8.11e-7	Alcohol dependence;
TGCT	cis	rs10927875	0.557	rs1572381	chr1:16344494	G/A	cg22431228	chr1:16359049	CLCNKA	-0.29	-5.94	-0.47	2.68e-8	Dilated cardiomyopathy;
TGCT	cis	rs12134133	1.000	rs1429904	chr1:207461884	A/C	cg02152968	chr1:207494213	CD55	0.57	4.47	0.37	1.74e-5	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs11785400	0.793	rs9774627	chr8:143731267	G/A	cg24634471	chr8:143751801	JRK	0.53	5.24	0.43	6.79e-7	Schizophrenia;
TGCT	trans	rs4919669	0.668	rs7094614	chr10:104334874	G/C	cg24066601	chr6:26271455	HIST1H3G	0.66	6.81	0.52	3.7e-10	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs9467773	1.000	rs9467783	chr6:26542894	C/T	cg26531700	chr6:26746687	NA	0.46	4.54	0.38	1.33e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs806215	0.526	rs3808088	chr7:127526038	C/T	cg11539674	chr7:127291444	SND1	-0.36	-4.53	-0.38	1.39e-5	Type 2 diabetes;
TGCT	cis	rs9486719	1.000	rs10457159	chr6:96993139	G/A	cg06623918	chr6:96969491	KIAA0776	-0.99	-7.99	-0.58	7.78e-13	Migraine;Coronary artery disease;
TGCT	cis	rs7226408	0.842	rs1609425	chr18:34345684	A/G	cg06757138	chr18:34340585	FHOD3	-0.3	-5.12	-0.42	1.16e-6	Obesity-related traits;
TGCT	cis	rs424971	0.933	rs8047999	chr16:85947527	G/C	cg04599946	chr16:85936480	IRF8	0.25	4.48	0.37	1.64e-5	Monocyte count;
TGCT	cis	rs12136530	0.593	rs2314145	chr1:19736843	C/G	cg24875000	chr1:19041556	PAX7	-0.26	-4.62	-0.38	9.56e-6	Lead levels in blood;
TGCT	cis	rs904251	0.861	rs2776877	chr6:37487135	G/A	cg25019722	chr6:37503610	NA	-0.51	-7.03	-0.53	1.24e-10	Cognitive performance;
TGCT	cis	rs12136530	0.577	rs12066114	chr1:19792527	A/G	cg00755546	chr1:19971792	NBL1	0.37	4.64	0.38	8.74e-6	Lead levels in blood;
TGCT	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg20203395	chr5:56204925	C5orf35	-0.58	-4.87	-0.4	3.34e-6	Initial pursuit acceleration;
TGCT	cis	rs2406342	0.511	rs472676	chr18:74607924	C/T	cg16472389	chr18:74514291	NA	0.46	4.63	0.38	9.19e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin);
TGCT	cis	rs17384381	0.734	rs12129013	chr1:85891709	A/C	cg16011679	chr1:85725395	C1orf52	0.7	6.32	0.49	4.33e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6570726	0.764	rs9403726	chr6:145901686	G/T	cg05347473	chr6:146136440	FBXO30	0.52	4.93	0.41	2.54e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs12142240	0.698	rs932816	chr1:46859749	G/A	cg14993813	chr1:46806288	NSUN4	-0.59	-4.86	-0.4	3.45e-6	Menopause (age at onset);
TGCT	cis	rs2445762	0.642	rs72729210	chr15:51633629	G/A	cg00184732	chr15:51633821	GLDN	0.53	5.37	0.43	3.72e-7	Hormone measurements;
TGCT	cis	rs2063714	0.658	rs12196864	chr6:157212862	C/T	cg23222435	chr6:157204239	ARID1B	-0.31	-5.12	-0.42	1.11e-6	Sitting height ratio;
TGCT	cis	rs7246657	0.722	rs3101746	chr19:38146400	T/A	cg03611452	chr19:38183253	ZNF781	-0.57	-4.79	-0.39	4.72e-6	Coronary artery calcification;
TGCT	cis	rs2188554	0.740	rs213933	chr7:117211054	A/G	cg09181792	chr7:117119393	CFTR	0.52	4.68	0.39	7.3e-6	Esophageal adenocarcinoma;
TGCT	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg05368731	chr17:41323189	NBR1	1.2	14.48	0.79	1.98e-28	Menopause (age at onset);
TGCT	cis	rs12541335	0.579	rs59283125	chr8:22212311	G/A	cg26039829	chr8:22132926	PIWIL2	0.28	5.23	0.42	7.05e-7	Hypertriglyceridemia;
TGCT	cis	rs1729951	0.546	rs12054218	chr3:136677496	C/G	cg12473912	chr3:136751656	NA	0.39	6.18	0.49	8.36e-9	Neuroticism;
TGCT	cis	rs1801251	1.000	rs13013142	chr2:233600606	A/G	cg25237894	chr2:233734115	C2orf82	0.33	5.95	0.47	2.53e-8	Coronary artery disease;
TGCT	cis	rs2486012	1.000	rs3011221	chr1:44312109	A/G	cg12908607	chr1:44402522	ARTN	-0.69	-5.57	-0.45	1.49e-7	Intelligence (multi-trait analysis);
TGCT	trans	rs2727020	0.930	rs1164686	chr11:49291822	C/T	cg15704280	chr7:45808275	SEPT13	0.72	7.71	0.57	3.47e-12	Coronary artery disease;
TGCT	cis	rs35883536	0.513	rs4907910	chr1:101013277	T/A	cg10298815	chr1:101004474	GPR88	0.24	4.6	0.38	1.01e-5	Monocyte count;
TGCT	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg00024416	chr22:24240387	NA	-0.25	-4.76	-0.39	5.27e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7267979	1.000	rs2257985	chr20:25269743	G/T	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg06618935	chr21:46677482	NA	-0.37	-5.04	-0.41	1.64e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs10465746	0.935	rs11580836	chr1:84333310	C/T	cg10977910	chr1:84465055	TTLL7	0.63	6.19	0.49	8.08e-9	Obesity-related traits;
TGCT	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg13699009	chr12:122356056	WDR66	0.27	5.34	0.43	4.24e-7	Mean corpuscular volume;
TGCT	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg08280861	chr8:58055591	NA	0.41	4.63	0.38	8.93e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1552244	0.832	rs66597916	chr3:10195407	T/C	cg00149659	chr3:10157352	C3orf10	1.05	5.81	0.46	4.95e-8	Alzheimer's disease;
TGCT	cis	rs1018836	0.828	rs4734250	chr8:91591239	C/G	cg16814680	chr8:91681699	NA	0.68	6.72	0.52	5.82e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs13217239	0.646	rs4269366	chr6:27016413	C/T	cg06035815	chr6:26189597	HIST1H4D	-0.44	-4.58	-0.38	1.12e-5	Schizophrenia;
TGCT	cis	rs1865760	0.865	rs1436306	chr6:25948421	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.64	6.31	0.49	4.56e-9	Height;
TGCT	trans	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg23505145	chr19:12996616	KLF1	0.79	8.3	0.6	1.47e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs3741151	1.000	rs112840535	chr11:73066771	G/A	cg17517138	chr11:73019481	ARHGEF17	0.91	4.63	0.38	9e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
TGCT	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	6.75	0.52	5.02e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	trans	rs10802346	0.545	rs10924568	chr1:246385482	C/A	cg13514129	chr1:39547527	MACF1	0.96	8.52	0.61	4.45e-14	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.76	5.5	0.44	2.07e-7	Platelet count;
TGCT	cis	rs4851266	0.898	rs2309812	chr2:100869702	C/T	cg22139774	chr2:100720529	AFF3	-0.32	-4.66	-0.39	7.89e-6	Educational attainment;
TGCT	cis	rs2880765	0.566	rs17553790	chr15:86013665	C/T	cg13263323	chr15:86062960	AKAP13	0.22	5.04	0.41	1.64e-6	Coronary artery disease;
TGCT	cis	rs7666738	0.716	rs6827474	chr4:99089683	T/G	cg05340658	chr4:99064831	C4orf37	0.5	5.51	0.44	2.02e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	5.03	0.41	1.69e-6	Prudent dietary pattern;
TGCT	cis	rs3125734	0.633	rs6479791	chr10:63980341	T/C	cg09941381	chr10:64027924	RTKN2	-0.36	-5.53	-0.44	1.83e-7	Rheumatoid arthritis;
TGCT	cis	rs853679	0.527	rs853683	chr6:28295039	A/G	cg18815343	chr6:28367644	ZSCAN12	-0.46	-4.81	-0.4	4.24e-6	Depression;
TGCT	cis	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg25427524	chr10:38739819	LOC399744	-0.39	-8.05	-0.59	5.9e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs1005277	0.522	rs289650	chr10:37975505	G/T	cg25427524	chr10:38739819	LOC399744	-0.33	-6.54	-0.51	1.47e-9	Extrinsic epigenetic age acceleration;
TGCT	cis	rs12950390	0.548	rs7215477	chr17:45858117	A/C	cg06532163	chr17:45867833	NA	0.26	4.7	0.39	6.7e-6	IgG glycosylation;
TGCT	cis	rs2730245	0.569	rs842692	chr7:158657228	T/C	cg24397884	chr7:158709396	WDR60	0.38	4.88	0.4	3.13e-6	Height;
TGCT	cis	rs7394190	0.748	rs4082339	chr10:75539812	C/T	cg07699608	chr10:75541558	CHCHD1	-0.73	-5.16	-0.42	9.35e-7	Incident atrial fibrillation;
TGCT	cis	rs3733585	0.806	rs11723382	chr4:9954660	T/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-8.02	-0.58	6.93e-13	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs1534166	0.602	rs3817524	chr3:133526403	C/T	cg08048268	chr3:133502702	NA	0.39	4.63	0.38	9e-6	Alcohol consumption (transferrin glycosylation);
TGCT	cis	rs2404602	0.583	rs11072580	chr15:76540231	G/A	cg26408565	chr15:76604113	ETFA	-0.48	-6.75	-0.52	4.94e-10	Blood metabolite levels;
TGCT	cis	rs7590720	0.759	rs6737781	chr2:216914920	A/G	cg12620499	chr2:216877984	MREG	0.79	7.33	0.55	2.61e-11	Alcohol dependence;
TGCT	cis	rs3812831	0.654	rs6560933	chr13:114937294	A/G	cg06611532	chr13:114900021	NA	-0.29	-5.45	-0.44	2.6e-7	Schizophrenia;
TGCT	cis	rs610932	0.517	rs650943	chr11:60006765	G/T	cg18570331	chr11:60101691	MS4A6E	-0.65	-5.34	-0.43	4.31e-7	Alzheimer's disease;
TGCT	cis	rs67073037	0.592	rs4558548	chr2:28985674	C/G	cg09522027	chr2:28974177	PPP1CB	-0.56	-4.67	-0.39	7.57e-6	Breast cancer;Breast cancer (estrogen-receptor negative);
TGCT	cis	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg03213289	chr20:61660250	NA	0.68	9.99	0.67	1.36e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7213347	0.780	rs216224	chr17:2156285	T/C	cg13315690	chr17:1944831	OVCA2;DPH1	0.4	5.11	0.42	1.2e-6	Total body bone mineral density;
TGCT	cis	rs1008375	0.931	rs1860592	chr4:17577028	C/G	cg10189774	chr4:17578691	LAP3	0.64	5.61	0.45	1.28e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1048238	0.506	rs7547314	chr1:16186722	G/A	cg21385522	chr1:16154831	NA	0.61	7.01	0.53	1.34e-10	Systolic blood pressure;
TGCT	cis	rs62103177	0.810	rs62103189	chr18:77627815	G/A	cg12964065	chr18:77638022	KCNG2	0.37	4.76	0.39	5.4e-6	Opioid sensitivity;
TGCT	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg22433210	chr17:43662623	NA	-1.0	-7.13	-0.54	7.26e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2832077	0.527	rs59730679	chr21:30226244	T/C	cg24692254	chr21:30365293	RNF160	-0.59	-5.05	-0.41	1.53e-6	Cognitive test performance;
TGCT	cis	rs6448317	0.863	rs2695228	chr4:24901985	C/T	cg21108841	chr4:24914750	CCDC149	0.68	5.63	0.45	1.13e-7	Heschl's gyrus morphology;
TGCT	cis	rs9611565	0.649	rs139559	chr22:42191636	A/G	cg03806693	chr22:41940476	POLR3H	-0.88	-8.52	-0.61	4.43e-14	Vitiligo;
TGCT	cis	rs6490294	0.904	rs112426410	chr12:112407438	A/G	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Mean platelet volume;
TGCT	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg06873352	chr17:61820015	STRADA	0.56	6.22	0.49	6.93e-9	Prudent dietary pattern;
TGCT	cis	rs3784262	0.740	rs8032572	chr15:58311280	A/G	cg12031962	chr15:58353849	ALDH1A2	0.45	6.69	0.51	6.94e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs66573146	0.808	rs55942328	chr4:6990960	T/G	cg00086871	chr4:6988644	TBC1D14	0.95	4.69	0.39	7.15e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs7666738	0.830	rs28516388	chr4:98987449	A/G	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9399135	0.967	rs4376365	chr6:135307740	T/C	cg24558204	chr6:135376177	HBS1L	0.48	4.75	0.39	5.5e-6	Red blood cell count;
TGCT	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg13395646	chr4:1353034	KIAA1530	-0.38	-4.72	-0.39	6.28e-6	Obesity-related traits;
TGCT	cis	rs1801251	1.000	rs778166	chr2:233664097	A/T	cg08000102	chr2:233561755	GIGYF2	0.64	6.56	0.51	1.28e-9	Coronary artery disease;
TGCT	cis	rs3008870	1.000	rs1925408	chr1:67365034	C/T	cg11518657	chr1:67396239	MIER1	0.53	4.72	0.39	6.16e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs2242116	0.796	rs4587	chr3:46963502	T/C	cg27129171	chr3:47204927	SETD2	0.66	6.34	0.49	3.88e-9	Birth weight;
TGCT	cis	rs11955175	1.000	rs111310950	chr5:40641951	G/T	cg17351974	chr5:40835760	RPL37	0.76	4.75	0.39	5.46e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs9291683	0.597	rs11722989	chr4:10126139	A/G	cg11266682	chr4:10021025	SLC2A9	-0.46	-5.5	-0.44	2.12e-7	Bone mineral density;
TGCT	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg03452623	chr4:187889614	NA	-0.38	-5.67	-0.45	9.41e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3733585	0.673	rs7376505	chr4:9952744	C/A	cg11266682	chr4:10021025	SLC2A9	-0.57	-7.6	-0.56	6.21e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	trans	rs9951602	1.000	rs1903723	chr18:76646571	A/G	cg02800362	chr5:177631904	HNRNPAB	0.98	7.2	0.54	5.03e-11	Obesity-related traits;
TGCT	cis	rs7917772	0.536	rs11191361	chr10:104411958	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	7.97	0.58	8.86e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs10851411	0.908	rs10454039	chr15:42832534	C/T	cg23803468	chr15:43513504	EPB42	-0.23	-4.44	-0.37	1.93e-5	Glucose homeostasis traits;
TGCT	cis	rs2729354	0.909	rs2729374	chr11:57326927	C/T	cg24343310	chr11:57249947	NA	0.29	4.92	0.4	2.73e-6	Blood protein levels;
TGCT	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg18876405	chr7:65276391	NA	0.35	5.2	0.42	7.81e-7	Aortic root size;
TGCT	cis	rs13326165	0.760	rs11711934	chr3:52358117	T/C	cg07884673	chr3:53033167	SFMBT1	0.39	4.69	0.39	7.1e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs1865760	1.000	rs7757666	chr6:25902626	T/C	cg16482183	chr6:26056742	HIST1H1C	0.55	4.97	0.41	2.19e-6	Height;
TGCT	cis	rs6977660	0.652	rs10486362	chr7:19755224	A/G	cg05791153	chr7:19748676	TWISTNB	-1.21	-7.93	-0.58	1.07e-12	Thyroid stimulating hormone;
TGCT	cis	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg07424592	chr7:64974309	NA	1.27	7.84	0.58	1.8e-12	Diabetic kidney disease;
TGCT	cis	rs12530845	1.000	rs12530845	chr7:135329978	T/C	cg23117316	chr7:135346802	PL-5283	-0.51	-4.83	-0.4	3.98e-6	Red blood cell traits;
TGCT	cis	rs9894429	0.546	rs55917554	chr17:79608776	T/C	cg18240062	chr17:79603768	NPLOC4	0.75	7.11	0.54	8.06e-11	Eye color traits;
TGCT	cis	rs9894429	0.789	rs7213849	chr17:79567610	C/T	cg21984481	chr17:79567631	NPLOC4	0.26	4.9	0.4	2.91e-6	Eye color traits;
TGCT	cis	rs826838	0.874	rs11183816	chr12:38834656	T/G	cg26384229	chr12:38710491	ALG10B	1.06	10.68	0.69	2.84e-19	Heart rate;
TGCT	cis	rs11785400	1.000	rs6988393	chr8:143740596	A/G	cg24634471	chr8:143751801	JRK	0.57	6.12	0.48	1.11e-8	Schizophrenia;
TGCT	cis	rs12478296	1.000	rs12469535	chr2:243044147	G/A	cg06360820	chr2:242988706	NA	-0.59	-4.52	-0.38	1.45e-5	Obesity-related traits;
TGCT	cis	rs28595532	0.764	rs55704595	chr4:119780607	G/A	cg11846333	chr4:119757529	SEC24D	0.92	4.64	0.38	8.74e-6	Cannabis dependence symptom count;
TGCT	cis	rs9807989	0.773	rs72823661	chr2:102968716	G/A	cg09003973	chr2:102972529	NA	0.64	5.7	0.46	8.28e-8	Asthma;
TGCT	cis	rs7818382	0.967	rs7812465	chr8:96050557	C/T	cg13393036	chr8:95962371	TP53INP1	0.48	5.95	0.47	2.55e-8	Alzheimer's disease (late onset);
TGCT	cis	rs6484504	0.576	rs11031320	chr11:31242545	C/T	cg14844989	chr11:31128820	NA	-0.23	-4.51	-0.38	1.47e-5	Red blood cell count;
TGCT	cis	rs910187	0.537	rs2154035	chr20:45760083	T/G	cg27589058	chr20:45804311	EYA2	-0.35	-6.72	-0.52	5.88e-10	Migraine;
TGCT	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg06873352	chr17:61820015	STRADA	0.56	6.22	0.49	7.1e-9	Prudent dietary pattern;
TGCT	cis	rs4776059	1.000	rs2288271	chr15:52886466	A/G	cg25063058	chr15:52860530	ARPP19	0.53	4.79	0.4	4.59e-6	Schizophrenia;
TGCT	cis	rs6087990	0.735	rs6087420	chr20:31359391	G/A	cg13636640	chr20:31349939	DNMT3B	0.97	12.92	0.76	1e-24	Ulcerative colitis;
TGCT	cis	rs700651	0.789	rs1147169	chr2:198901395	C/T	cg00792783	chr2:198669748	PLCL1	-0.57	-4.99	-0.41	2.03e-6	Intracranial aneurysm;
TGCT	cis	rs939574	0.929	rs10190834	chr2:220070301	T/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-1.06	-6.52	-0.51	1.6e-9	Platelet distribution width;
TGCT	cis	rs2486012	0.737	rs2906470	chr1:44306559	T/C	cg12908607	chr1:44402522	ARTN	-0.72	-5.68	-0.45	8.89e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg00149659	chr3:10157352	C3orf10	0.77	5.14	0.42	1.03e-6	Alzheimer's disease;
TGCT	cis	rs7666738	0.830	rs13121766	chr4:98935766	A/C	cg05340658	chr4:99064831	C4orf37	0.53	6.02	0.48	1.8e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7267979	0.966	rs6050567	chr20:25354561	C/T	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs910187	0.678	rs3818012	chr20:45816594	G/A	cg27589058	chr20:45804311	EYA2	-0.35	-7.58	-0.56	7.14e-12	Migraine;
TGCT	cis	rs2153535	0.580	rs1335636	chr6:8465047	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs4242434	0.757	rs4872531	chr8:22529695	A/G	cg21658235	chr8:22456391	C8orf58	-0.46	-5.04	-0.41	1.6e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	trans	rs1814175	0.817	rs7946556	chr11:49944874	G/A	cg03929089	chr4:120376271	NA	-0.71	-8.09	-0.59	4.74e-13	Height;
TGCT	cis	rs708547	0.874	rs7674167	chr4:57721477	A/G	cg25525207	chr4:57843836	C4orf14;POLR2B	0.5	4.47	0.37	1.71e-5	Response to bleomycin (chromatid breaks);
TGCT	cis	rs6669919	0.901	rs7527396	chr1:211667857	C/T	cg26515805	chr1:211431828	RCOR3	-0.4	-4.69	-0.39	7.22e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs13242816	1.000	rs34295495	chr7:116068266	C/A	cg16553024	chr7:116138462	CAV2	-0.48	-5.31	-0.43	4.89e-7	P wave duration;
TGCT	cis	rs9916302	0.904	rs9898773	chr17:37532507	C/G	cg15445000	chr17:37608096	MED1	-0.33	-4.71	-0.39	6.46e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs2410601	0.503	rs7843667	chr8:18925228	G/A	cg19414122	chr8:18896631	NA	-0.28	-4.64	-0.38	8.68e-6	Urinary albumin excretion rate in type 1 diabetes;
TGCT	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg11905131	chr22:24372483	LOC391322	-0.71	-7.19	-0.54	5.46e-11	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs12579753	0.879	rs1986537	chr12:82156475	G/C	cg21231944	chr12:82153410	PPFIA2	-0.34	-4.52	-0.38	1.4e-5	Resting heart rate;
TGCT	cis	rs72781680	0.898	rs72798049	chr2:23958002	C/G	cg08917208	chr2:24149416	ATAD2B	0.83	5.24	0.43	6.62e-7	Lymphocyte counts;
TGCT	cis	rs4824093	0.610	rs7410534	chr22:50289925	C/T	cg14114931	chr22:50943910	LMF2	0.37	4.53	0.38	1.35e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg06238570	chr21:40685208	BRWD1	-0.85	-8.62	-0.61	2.68e-14	Cognitive function;
TGCT	cis	rs9796	0.870	rs7181816	chr15:41358720	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.43	-5.62	-0.45	1.22e-7	Menopause (age at onset);
TGCT	cis	rs6424115	0.830	rs2503002	chr1:24196957	C/G	cg15997130	chr1:24165203	NA	0.87	10.12	0.67	6.32e-18	Immature fraction of reticulocytes;
TGCT	cis	rs57602752	1.000	rs1961317	chr10:120654022	A/G	cg18286127	chr10:120070743	C10orf84	0.55	4.48	0.37	1.69e-5	Cannabis dependence;
TGCT	cis	rs13256369	0.802	rs12681925	chr8:8561649	G/A	cg17143192	chr8:8559678	CLDN23	0.54	5.03	0.41	1.64e-6	Obesity-related traits;
TGCT	cis	rs4720575	1.000	rs4720574	chr7:47085597	A/C	cg00036614	chr7:47093842	NA	-0.2	-4.99	-0.41	1.95e-6	Angiotensin-converting enzyme inhibitor intolerance;
TGCT	cis	rs7781977	0.669	rs7791218	chr7:50353627	G/A	cg14216940	chr7:50343131	IKZF1	0.36	4.55	0.38	1.26e-5	IgG glycosylation;
TGCT	cis	rs7772486	0.686	rs857882	chr6:145969716	T/G	cg23711669	chr6:146136114	FBXO30	-0.86	-9.6	-0.65	1.2e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs939574	0.722	rs115402093	chr2:220096128	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.0	4.56	0.38	1.2e-5	Platelet distribution width;
TGCT	cis	rs514406	0.505	rs146750	chr1:53183447	C/G	cg16325326	chr1:53192061	ZYG11B	0.84	12.01	0.73	1.59e-22	Monocyte count;
TGCT	cis	rs2073300	1.000	rs6106655	chr20:23441982	C/G	cg09953122	chr20:23471693	CST8	-0.61	-4.45	-0.37	1.9e-5	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs7552404	0.924	rs1146574	chr1:76202671	A/G	cg22875332	chr1:76189707	ACADM	0.72	8.9	0.62	5.76e-15	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.02	0.53	1.3e-10	Prudent dietary pattern;
TGCT	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg00684032	chr4:1343700	KIAA1530	-0.23	-4.98	-0.41	2.08e-6	Obesity-related traits;
TGCT	cis	rs743757	1.000	rs734767	chr3:50431410	C/G	cg07344955	chr3:50374863	RASSF1	0.79	5.24	0.43	6.66e-7	Diastolic blood pressure;
TGCT	cis	rs3751972	0.748	rs4796172	chr17:26198381	C/T	cg02948944	chr17:26242737	NA	-0.45	-6.38	-0.5	3.26e-9	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs727505	0.954	rs17327014	chr7:124709349	C/T	cg23710748	chr7:124431027	NA	-0.27	-4.7	-0.39	6.77e-6	Lewy body disease;
TGCT	cis	rs40363	1.000	rs37769	chr16:3514580	C/G	cg00484396	chr16:3507460	NAT15	0.44	5.08	0.41	1.36e-6	Tuberculosis;
TGCT	cis	rs6430585	0.528	rs75524146	chr2:136725459	C/T	cg07169764	chr2:136633963	MCM6	1.25	12.67	0.75	4.02e-24	Corneal structure;
TGCT	cis	rs6754311	0.773	rs309130	chr2:136631031	C/A	cg07169764	chr2:136633963	MCM6	-0.65	-6.06	-0.48	1.5e-8	Mosquito bite size;
TGCT	cis	rs6545883	0.929	rs3821222	chr2:61713526	C/G	cg15711740	chr2:61764176	XPO1	-0.56	-5.3	-0.43	5.03e-7	Tuberculosis;
TGCT	cis	rs9486719	0.948	rs2472906	chr6:96875318	G/T	cg06623918	chr6:96969491	KIAA0776	1.01	8.86	0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs3806843	0.966	rs2563255	chr5:140142547	T/C	cg19875535	chr5:140030758	IK	-0.36	-6.17	-0.48	8.74e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2204008	0.837	rs12369089	chr12:38060263	G/A	cg26384229	chr12:38710491	ALG10B	0.86	7.77	0.57	2.55e-12	Bladder cancer;
TGCT	cis	rs5769765	0.874	rs4624	chr22:50281917	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	1.11	11.81	0.73	5.03e-22	Schizophrenia;
TGCT	cis	rs546131	0.642	rs836950	chr11:34852020	C/G	cg06937548	chr11:34938143	PDHX;APIP	-0.52	-4.56	-0.38	1.21e-5	Lung disease severity in cystic fibrosis;
TGCT	cis	rs2228479	0.702	rs17233253	chr16:89828437	A/G	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs12497850	0.931	rs11924597	chr3:48937790	T/C	cg06212747	chr3:49208901	KLHDC8B	0.61	5.62	0.45	1.2e-7	Parkinson's disease;
TGCT	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg08280861	chr8:58055591	NA	0.4	4.73	0.39	5.97e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs12360000	0.864	rs9919410	chr10:1902486	A/G	cg26364871	chr10:1889757	NA	-0.41	-4.6	-0.38	1.04e-5	Metabolite levels (Dihydroxy docosatrienoic acid);
TGCT	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg09323728	chr8:95962352	TP53INP1	-0.53	-6.84	-0.52	3.27e-10	Type 2 diabetes;
TGCT	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg17971929	chr21:40555470	PSMG1	-0.65	-5.71	-0.46	8.04e-8	Cognitive function;
TGCT	cis	rs12477438	0.520	rs6542869	chr2:99783403	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	12.84	0.76	1.57e-24	Chronic sinus infection;
TGCT	cis	rs2594989	0.708	rs2594997	chr3:11365739	A/T	cg00170343	chr3:11313890	ATG7	0.67	5.06	0.41	1.44e-6	Circulating chemerin levels;
TGCT	cis	rs769267	0.501	rs2074295	chr19:19369435	A/G	cg21559469	chr19:19431446	KIAA0892;SF4	0.61	4.52	0.38	1.43e-5	Tonsillectomy;
TGCT	cis	rs4975709	0.959	rs9312959	chr5:1877008	G/A	cg14773178	chr5:1868261	NA	0.37	5.32	0.43	4.58e-7	Cardiovascular disease risk factors;
TGCT	cis	rs7044106	0.791	rs10985008	chr9:123492960	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.49	5.38	0.43	3.65e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs17376456	0.877	rs17083462	chr5:93462401	T/G	cg25358565	chr5:93447407	FAM172A	0.92	8.38	0.6	9.58e-14	Diabetic retinopathy;
TGCT	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs600231	0.706	rs11227221	chr11:65319265	T/C	cg13974409	chr11:65292307	SCYL1	-0.47	-4.46	-0.37	1.84e-5	Bone mineral density;
TGCT	cis	rs6089584	1.000	rs6089584	chr20:60564086	G/C	cg06108461	chr20:60628389	TAF4	-0.53	-7.39	-0.55	1.9e-11	Body mass index;
TGCT	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg04772025	chr11:68637568	NA	-0.6	-6.78	-0.52	4.28e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9443189	0.526	rs9359132	chr6:76289553	G/A	cg01950844	chr6:76311363	SENP6	0.97	6.1	0.48	1.27e-8	Prostate cancer;
TGCT	cis	rs12142240	0.698	rs7525309	chr1:46809025	G/T	cg14993813	chr1:46806288	NSUN4	-0.58	-4.81	-0.4	4.34e-6	Menopause (age at onset);
TGCT	cis	rs7208859	0.573	rs58920731	chr17:29191746	G/T	cg18442181	chr17:29233375	C17orf42	-0.79	-4.78	-0.39	4.95e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg03264133	chr6:25882463	NA	-0.53	-5.65	-0.45	1.06e-7	Height;
TGCT	cis	rs4972806	0.814	rs1446575	chr2:177047801	A/C	cg13092806	chr2:177043255	NA	0.54	4.92	0.4	2.71e-6	IgG glycosylation;
TGCT	cis	rs9297145	0.565	rs941001	chr7:98735185	A/T	cg05967295	chr7:98741636	SMURF1	-0.68	-8.74	-0.62	1.36e-14	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs9896933	0.775	rs79299098	chr17:80830944	G/A	cg20578329	chr17:80767326	TBCD	-0.33	-4.67	-0.39	7.66e-6	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
TGCT	cis	rs921968	0.548	rs13427522	chr2:219438359	C/T	cg02176678	chr2:219576539	TTLL4	0.44	6.33	0.49	4.17e-9	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg05368731	chr17:41323189	NBR1	1.2	14.59	0.79	1.08e-28	Menopause (age at onset);
TGCT	trans	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg17830980	chr10:43048298	ZNF37B	-0.85	-11.24	-0.71	1.2e-20	Extrinsic epigenetic age acceleration;
TGCT	cis	rs9926296	0.687	rs258317	chr16:89732238	C/T	cg27121462	chr16:89883253	FANCA	-0.54	-4.93	-0.4	2.63e-6	Vitiligo;
TGCT	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.36	4.58	0.38	1.12e-5	Total body bone mineral density;
TGCT	cis	rs782590	0.643	rs13009906	chr2:55739434	A/G	cg03859395	chr2:55845619	SMEK2	-0.69	-7.05	-0.53	1.09e-10	Metabolic syndrome;
TGCT	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg18230493	chr5:56204884	C5orf35	-0.8	-6.33	-0.49	4.08e-9	Type 2 diabetes;
TGCT	cis	rs17387100	0.551	rs2531156	chr4:16017531	C/G	cg13480465	chr4:16795757	LDB2	0.41	5.18	0.42	8.53e-7	Suicide attempts in depression or bipolar disorder;
TGCT	cis	rs7246657	0.943	rs4803347	chr19:37848017	G/A	cg03233940	chr19:37894644	NA	-0.36	-4.68	-0.39	7.53e-6	Coronary artery calcification;
TGCT	cis	rs1371867	0.846	rs1660316	chr8:101333049	T/C	cg06002616	chr8:101225028	SPAG1	-0.56	-6.58	-0.51	1.2e-9	Atrioventricular conduction;
TGCT	cis	rs3796352	1.000	rs13072457	chr3:53102389	G/A	cg15956490	chr3:53032818	SFMBT1	0.59	6.64	0.51	8.89e-10	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs11112613	0.713	rs11112590	chr12:105951376	C/G	cg03607813	chr12:105948248	NA	-0.46	-5.56	-0.45	1.59e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	cis	rs4455778	0.580	rs4292637	chr7:49121114	C/T	cg26309511	chr7:48887640	NA	-0.5	-6.51	-0.5	1.66e-9	Lung cancer in never smokers;
TGCT	cis	rs62103177	0.564	rs2115996	chr18:77701007	C/G	cg12964065	chr18:77638022	KCNG2	0.32	4.53	0.38	1.36e-5	Opioid sensitivity;
TGCT	cis	rs62064224	0.748	rs72813015	chr17:30693331	T/C	cg18200150	chr17:30822561	MYO1D	0.54	7.06	0.54	1.05e-10	Schizophrenia;
TGCT	cis	rs9911578	0.805	rs12601867	chr17:56455260	C/G	cg12560992	chr17:57184187	TRIM37	-0.65	-7.32	-0.55	2.77e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs6424115	1.000	rs7515969	chr1:24158398	G/A	cg15997130	chr1:24165203	NA	-0.92	-10.61	-0.69	4.13e-19	Immature fraction of reticulocytes;
TGCT	cis	rs1371867	0.875	rs1660311	chr8:101330579	C/T	cg06002616	chr8:101225028	SPAG1	-0.56	-6.58	-0.51	1.2e-9	Atrioventricular conduction;
TGCT	cis	rs9300255	0.537	rs1619561	chr12:123620268	G/C	cg00376283	chr12:123451042	ABCB9	0.73	5.54	0.45	1.71e-7	Neutrophil percentage of white cells;
TGCT	cis	rs6671200	1.000	rs6678964	chr1:95694268	C/T	cg03123541	chr1:95699097	RWDD3	0.9	6.7	0.52	6.67e-10	Stearic acid (18:0) levels;
TGCT	cis	rs78456975	0.527	rs11885279	chr2:1560633	T/C	cg12573674	chr2:1569213	NA	-0.45	-4.76	-0.39	5.37e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs360798	0.532	rs1553832	chr2:63013515	C/G	cg17519650	chr2:63277830	OTX1	-0.6	-5.24	-0.43	6.64e-7	Coronary artery disease;
TGCT	cis	rs9534288	0.797	rs2896951	chr13:46581185	A/G	cg15192986	chr13:46630673	CPB2	-0.53	-7.62	-0.56	5.82e-12	Blood protein levels;
TGCT	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.06	-9.6	-0.65	1.15e-16	Platelet count;
TGCT	cis	rs137699	0.652	rs2413589	chr22:39755689	C/T	cg01416388	chr22:39784598	NA	0.54	4.88	0.4	3.26e-6	IgG glycosylation;
TGCT	cis	rs4455778	0.659	rs10249340	chr7:49036690	T/C	cg26309511	chr7:48887640	NA	0.44	5.22	0.42	7.26e-7	Lung cancer in never smokers;
TGCT	cis	rs2456568	0.803	rs10831138	chr11:93640468	T/C	cg17595323	chr11:93583763	C11orf90	-0.46	-6.24	-0.49	6.46e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7666738	0.830	rs28456179	chr4:98991439	A/G	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1982963	1.000	rs4901186	chr14:52509484	G/A	cg10843707	chr14:52510701	NID2	-0.43	-6.52	-0.51	1.62e-9	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9916302	0.861	rs644173	chr17:37430519	T/C	cg07936489	chr17:37558343	FBXL20	-0.61	-4.7	-0.39	6.9e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs2708977	0.901	rs3731938	chr2:97166204	A/G	cg01950434	chr2:97203154	ARID5A	-0.69	-6.27	-0.49	5.43e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs9303401	0.659	rs17822908	chr17:56801778	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.67	6.3	0.49	4.7e-9	Cognitive test performance;
TGCT	cis	rs739496	0.895	rs2283357	chr12:111897379	G/C	cg10833066	chr12:111807467	FAM109A	0.37	5.2	0.42	8.01e-7	Platelet count;
TGCT	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg04352962	chr1:209979756	IRF6	0.61	4.67	0.39	7.72e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs1865760	0.613	rs9379805	chr6:25938764	T/A	cg03264133	chr6:25882463	NA	-0.51	-5.27	-0.43	5.81e-7	Height;
TGCT	cis	rs1062177	1.000	rs41494545	chr5:151235094	A/G	cg12924095	chr5:151150029	G3BP1	-0.35	-5.05	-0.41	1.53e-6	Preschool internalizing problems;
TGCT	cis	rs72781680	0.664	rs2712076	chr2:23993366	T/C	cg08917208	chr2:24149416	ATAD2B	0.79	4.94	0.41	2.51e-6	Lymphocyte counts;
TGCT	cis	rs36051895	0.664	rs7857081	chr9:5096728	G/A	cg02405213	chr9:5042618	JAK2	-0.77	-10.92	-0.7	7.16e-20	Pediatric autoimmune diseases;
TGCT	cis	rs6912958	0.754	rs10755484	chr6:88244648	C/T	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.92	-0.4	2.7e-6	Monocyte percentage of white cells;
TGCT	cis	rs79387448	0.745	rs76720903	chr2:103162826	G/A	cg09003973	chr2:102972529	NA	0.92	5.89	0.47	3.39e-8	Gut microbiota (bacterial taxa);
TGCT	cis	rs295137	0.836	rs1217429	chr2:201094151	G/T	cg23649088	chr2:200775458	C2orf69	0.34	5.98	0.47	2.18e-8	Asthma (bronchodilator response);
TGCT	trans	rs1814175	0.817	rs10839401	chr11:49876144	C/T	cg15704280	chr7:45808275	SEPT13	-0.72	-8.14	-0.59	3.61e-13	Height;
TGCT	cis	rs709400	0.593	rs12898029	chr14:103877884	T/C	cg26031613	chr14:104095156	KLC1	-0.82	-8.95	-0.63	4.19e-15	Body mass index;
TGCT	trans	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg27523141	chr10:43048294	ZNF37B	0.73	8.39	0.6	9.23e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg11644478	chr21:40555479	PSMG1	1.03	11.15	0.71	2.01e-20	Cognitive function;
TGCT	cis	rs6540559	0.673	rs17015330	chr1:210012795	T/G	cg21951975	chr1:209979733	IRF6	0.64	4.82	0.4	4.12e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg16325326	chr1:53192061	ZYG11B	0.5	5.56	0.45	1.56e-7	Monocyte count;
TGCT	cis	rs2663905	0.611	rs1509560	chr15:81391713	T/G	cg09236163	chr15:81426669	C15orf26	-0.52	-5.58	-0.45	1.47e-7	QT interval (drug interaction);
TGCT	cis	rs1670533	1.000	rs6821725	chr4:1060360	C/G	cg27284194	chr4:1044797	NA	0.7	6.04	0.48	1.63e-8	Recombination rate (females);
TGCT	cis	rs9467773	0.649	rs2145318	chr6:26496603	T/A	cg02458000	chr6:26745757	NA	0.48	4.49	0.37	1.59e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs10089	0.953	rs1012851	chr5:127360241	T/C	cg19767477	chr5:127420684	SLC12A2	-0.42	-4.46	-0.37	1.85e-5	Ileal carcinoids;
TGCT	cis	rs908922	0.676	rs12059256	chr1:152515431	G/A	cg20991723	chr1:152506922	NA	0.46	6.17	0.48	8.79e-9	Hair morphology;
TGCT	cis	rs8031584	0.678	rs4779496	chr15:31151054	A/G	cg08109568	chr15:31115862	NA	-0.38	-5.03	-0.41	1.67e-6	Huntington's disease progression;
TGCT	cis	rs11690935	1.000	rs12053003	chr2:172537350	A/C	cg13550731	chr2:172543902	DYNC1I2	1.2	12.91	0.76	1.08e-24	Schizophrenia;
TGCT	cis	rs11239930	0.538	rs59064267	chr1:146560693	G/A	cg00044796	chr1:146552390	NA	-0.35	-4.5	-0.37	1.54e-5	AIDS progression;
TGCT	cis	rs13188771	0.690	rs164620	chr5:100873498	C/T	cg18665594	chr5:101119420	NA	0.44	4.46	0.37	1.83e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs2456568	0.802	rs1395386	chr11:93639331	A/G	cg26875233	chr11:93583750	C11orf90	0.48	6.34	0.5	3.8e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7809950	0.678	rs2395869	chr7:106940098	C/A	cg23024343	chr7:107201750	COG5	-0.44	-5.93	-0.47	2.83e-8	Coronary artery disease;
TGCT	cis	rs7568458	0.660	rs55692129	chr2:85792404	A/T	cg17127132	chr2:85788382	GGCX	0.53	4.69	0.39	7.22e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs7568458	0.684	rs3731828	chr2:85806266	C/T	cg02493740	chr2:85810744	VAMP5	-0.29	-5.57	-0.45	1.52e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs75686122	0.772	rs117466837	chr8:104612512	T/C	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs59197085	0.636	rs62479621	chr7:128465246	C/A	cg00260937	chr7:128520193	KCP	0.47	5.01	0.41	1.82e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
TGCT	cis	rs1403694	1.000	rs1656911	chr3:186439373	T/C	cg12454167	chr3:186435060	KNG1	0.42	7.32	0.55	2.77e-11	Blood protein levels;
TGCT	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg05025164	chr4:1340916	KIAA1530	0.75	6.26	0.49	5.69e-9	Longevity;
TGCT	cis	rs1499614	1.000	rs2659913	chr7:66157336	T/A	cg18252515	chr7:66147081	NA	-1.26	-7.95	-0.58	9.71e-13	Gout;
TGCT	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg22920501	chr2:26401640	FAM59B	0.71	5.59	0.45	1.36e-7	Gut microbiome composition (summer);
TGCT	cis	rs909674	0.818	rs5757681	chr22:39845547	A/G	cg02038168	chr22:39784481	NA	-0.71	-5.49	-0.44	2.21e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs694739	0.541	rs61886926	chr11:64133552	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.69	6.71	0.52	6.1e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs11785693	0.862	rs17351027	chr8:4987098	A/G	cg26367366	chr8:4980734	NA	-0.57	-4.49	-0.37	1.61e-5	Neuroticism (multi-trait analysis);Neuroticism;
TGCT	cis	rs9467773	0.935	rs4573	chr6:26546808	A/G	cg26531700	chr6:26746687	NA	0.63	6.59	0.51	1.15e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs904251	0.861	rs1757171	chr6:37487044	T/C	cg01843034	chr6:37503916	NA	-0.51	-6.1	-0.48	1.22e-8	Cognitive performance;
TGCT	cis	rs79057730	0.599	rs34411410	chr7:811721	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.64	5.23	0.43	6.91e-7	Initial pursuit acceleration;
TGCT	cis	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg08045932	chr20:61659980	NA	0.48	9.16	0.64	1.36e-15	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2404602	0.692	rs12913810	chr15:77166675	T/C	cg26408565	chr15:76604113	ETFA	-0.36	-4.52	-0.38	1.41e-5	Blood metabolite levels;
TGCT	cis	rs2115630	0.645	rs3825877	chr15:85174631	G/A	cg11189052	chr15:85197271	WDR73	-0.76	-7.38	-0.55	1.99e-11	P wave terminal force;
TGCT	cis	rs2404602	0.709	rs11072591	chr15:76649562	A/G	cg22467129	chr15:76604101	ETFA	-0.5	-5.41	-0.44	3.15e-7	Blood metabolite levels;
TGCT	cis	rs2458413	0.542	rs2458430	chr8:105367785	C/T	cg04554929	chr8:105342491	NA	-0.49	-5.79	-0.46	5.35e-8	Paget's disease;
TGCT	cis	rs7824557	0.564	rs2572404	chr8:11199584	A/G	cg21775007	chr8:11205619	TDH	0.73	6.81	0.52	3.72e-10	Retinal vascular caliber;
TGCT	cis	rs6456156	0.792	rs7775443	chr6:167513252	A/C	cg07741184	chr6:167504864	NA	-0.22	-4.51	-0.38	1.48e-5	Primary biliary cholangitis;
TGCT	cis	rs11671005	0.616	rs12980907	chr19:58956326	C/T	cg07777224	chr19:58919807	ZNF584	-0.63	-4.47	-0.37	1.77e-5	Mean platelet volume;
TGCT	cis	rs709400	0.628	rs11622356	chr14:103912195	C/T	cg12935359	chr14:103987150	CKB	-0.34	-4.95	-0.41	2.34e-6	Body mass index;
TGCT	cis	rs9952991	0.883	rs11663253	chr18:12789556	A/G	cg24737193	chr18:12778029	NA	-0.51	-5.39	-0.44	3.45e-7	Inflammatory skin disease;
TGCT	cis	rs7940866	0.845	rs2324314	chr11:130834589	A/C	cg05962950	chr11:130786565	SNX19	0.69	7.0	0.53	1.42e-10	Schizophrenia;
TGCT	cis	rs1153858	1.000	rs1618874	chr15:45622786	A/G	cg14582100	chr15:45693742	SPATA5L1	0.47	5.59	0.45	1.39e-7	Homoarginine levels;
TGCT	cis	rs9914544	0.966	rs7210746	chr17:18798593	T/C	cg26306683	chr17:18585705	ZNF286B	0.57	5.08	0.41	1.36e-6	Educational attainment (years of education);
TGCT	cis	rs7226408	0.857	rs72885302	chr18:34453491	G/A	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs2777491	0.872	rs61037359	chr15:41585926	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.75	-10.86	-0.7	9.98e-20	Ulcerative colitis;
TGCT	cis	rs7086627	0.507	rs7077907	chr10:82017082	A/G	cg01528321	chr10:82214614	TSPAN14	0.62	5.68	0.45	9.18e-8	Post bronchodilator FEV1;
TGCT	cis	rs1894292	0.527	rs10938079	chr4:74375473	C/T	cg05868023	chr4:75230803	EREG	0.53	4.67	0.39	7.56e-6	Prostate cancer;
TGCT	cis	rs920590	0.510	rs4922101	chr8:19648895	A/G	cg03894339	chr8:19674705	INTS10	0.82	5.29	0.43	5.28e-7	Acute lymphoblastic leukemia (childhood);
TGCT	cis	rs6912958	0.754	rs2268994	chr6:88185386	A/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-5.08	-0.41	1.36e-6	Monocyte percentage of white cells;
TGCT	cis	rs4076764	1.000	rs7528020	chr1:163426537	G/A	cg24596788	chr1:163392923	NA	-0.17	-4.75	-0.39	5.46e-6	Motion sickness;
TGCT	cis	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg06636001	chr8:8085503	FLJ10661	0.68	5.98	0.47	2.17e-8	Mood instability;
TGCT	cis	rs4253772	0.591	rs6007747	chr22:46657261	A/G	cg09491104	chr22:46646882	C22orf40	-0.63	-6.39	-0.5	3.05e-9	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs3796352	1.000	rs11707575	chr3:53113762	G/T	cg07884673	chr3:53033167	SFMBT1	0.48	4.97	0.41	2.13e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs10782582	0.609	rs5745394	chr1:76311731	G/A	cg10523679	chr1:76189770	ACADM	-0.59	-5.42	-0.44	2.94e-7	Daytime sleep phenotypes;
TGCT	cis	rs4629710	0.568	rs9492883	chr6:131573872	A/T	cg12606694	chr6:131520996	AKAP7	0.41	4.82	0.4	4.09e-6	Multiple myeloma (IgH translocation);
TGCT	cis	rs908922	0.676	rs486283	chr1:152525957	A/G	cg20991723	chr1:152506922	NA	0.45	6.06	0.48	1.55e-8	Hair morphology;
TGCT	cis	rs1371867	0.875	rs1660311	chr8:101330579	C/T	cg06636551	chr8:101224915	SPAG1	-0.48	-6.52	-0.51	1.62e-9	Atrioventricular conduction;
TGCT	cis	rs9357506	0.846	rs2396640	chr6:46309620	A/G	cg21115430	chr6:46460003	NA	-0.26	-5.16	-0.42	9.6e-7	Body mass index;
TGCT	cis	rs12765878	0.580	rs55983834	chr10:105601210	C/T	cg11005552	chr10:105648138	OBFC1	-0.39	-6.05	-0.48	1.6e-8	Coronary artery disease;
TGCT	cis	rs2455799	0.613	rs2455813	chr3:15735051	C/G	cg16303742	chr3:15540471	COLQ	-0.24	-4.51	-0.38	1.47e-5	Mean platelet volume;
TGCT	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg06634786	chr22:41940651	POLR3H	0.7	6.65	0.51	8.51e-10	Vitiligo;
TGCT	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-5.1	-0.42	1.23e-6	Bipolar disorder;
TGCT	cis	rs12136530	0.593	rs12121189	chr1:19740421	G/A	cg24875000	chr1:19041556	PAX7	-0.26	-4.62	-0.38	9.56e-6	Lead levels in blood;
TGCT	cis	rs483180	0.512	rs598685	chr1:120215269	G/A	cg19096424	chr1:120255104	PHGDH	0.56	5.29	0.43	5.46e-7	Macular telangiectasia type 2;
TGCT	cis	rs4242434	0.927	rs3736147	chr8:22471824	A/G	cg03733263	chr8:22462867	KIAA1967	-1.15	-20.1	-0.87	7.99e-41	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg01570182	chr17:44337453	NA	1.08	9.48	0.65	2.25e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs112591243	0.504	rs73381504	chr21:48027668	G/T	cg23283320	chr21:48055893	PRMT2	0.7	4.99	0.41	1.99e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs986417	1.000	rs7160408	chr14:60977471	A/G	cg27398547	chr14:60952738	C14orf39	1.42	9.26	0.64	7.81e-16	Gut microbiota (bacterial taxa);
TGCT	cis	rs6121246	0.697	rs6087716	chr20:30229040	C/T	cg21427119	chr20:30132790	HM13	-0.37	-5.19	-0.42	8.51e-7	Mean corpuscular hemoglobin;
TGCT	cis	rs10992471	0.528	rs10117627	chr9:95203953	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.52	-4.91	-0.4	2.8e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs7666738	0.546	rs13105521	chr4:98734419	C/T	cg18180107	chr4:99064573	C4orf37	0.51	4.55	0.38	1.28e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2730245	0.959	rs2527201	chr7:158738611	G/T	cg11984989	chr7:158649758	WDR60	-0.97	-8.97	-0.63	3.94e-15	Height;
TGCT	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.54	4.88	0.4	3.18e-6	Prudent dietary pattern;
TGCT	cis	rs11190604	0.943	rs11190574	chr10:102234331	T/C	cg23241863	chr10:102295624	HIF1AN	0.64	4.85	0.4	3.56e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7582180	0.629	rs4851308	chr2:100971865	C/A	cg14675211	chr2:100938903	LONRF2	0.5	4.79	0.4	4.66e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6040399	1.000	rs6040398	chr20:11156550	C/T	cg07941953	chr20:10508668	C20orf94	-0.31	-4.58	-0.38	1.13e-5	Response to citalopram treatment;
TGCT	cis	rs2562456	0.837	rs62110205	chr19:21760071	A/G	cg01304269	chr19:21688519	ZNF429	0.58	4.46	0.37	1.84e-5	Pain;
TGCT	cis	rs9928842	0.664	rs9921632	chr16:75220263	C/T	cg09066997	chr16:75300724	BCAR1	0.22	4.44	0.37	1.98e-5	Alcoholic chronic pancreatitis;
TGCT	cis	rs2463822	0.920	rs11828383	chr11:62067818	C/T	cg23876832	chr11:62092739	NA	-0.74	-4.85	-0.4	3.59e-6	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs422249	0.512	rs174546	chr11:61569830	C/T	cg19610905	chr11:61596333	FADS2	-1.09	-11.84	-0.73	4.21e-22	Trans fatty acid levels;
TGCT	cis	rs12497850	0.966	rs6792510	chr3:48723302	G/C	cg18654377	chr3:49208889	KLHDC8B	-0.41	-5.43	-0.44	2.84e-7	Parkinson's disease;
TGCT	cis	rs904251	0.797	rs1757181	chr6:37485728	A/G	cg25019722	chr6:37503610	NA	0.48	6.62	0.51	9.78e-10	Cognitive performance;
TGCT	cis	rs4631830	0.863	rs4486572	chr10:51531805	A/G	cg10326726	chr10:51549505	MSMB	-0.25	-4.9	-0.4	2.88e-6	Prostate-specific antigen levels;
TGCT	trans	rs1814175	0.817	rs11040651	chr11:49938395	G/A	cg15704280	chr7:45808275	SEPT13	-0.71	-8.0	-0.58	7.45e-13	Height;
TGCT	cis	rs302972	0.826	rs9461103	chr6:25099116	C/T	cg18428180	chr6:24646492	KIAA0319	0.98	4.45	0.37	1.91e-5	Creatinine levels in ischemic stroke;
TGCT	cis	rs2180341	0.883	rs9388568	chr6:127690694	C/A	cg27446573	chr6:127587934	RNF146	1.1	10.61	0.69	4.22e-19	Breast cancer;
TGCT	cis	rs9926296	0.682	rs645019	chr16:89716883	C/T	cg04287289	chr16:89883240	FANCA	-0.53	-4.96	-0.41	2.24e-6	Vitiligo;
TGCT	cis	rs2458413	1.000	rs2458413	chr8:105359432	C/T	cg04554929	chr8:105342491	NA	0.52	7.14	0.54	6.76e-11	Paget's disease;
TGCT	cis	rs6163	0.727	rs284854	chr10:104574562	T/G	cg04362960	chr10:104952993	NT5C2	-0.53	-4.66	-0.39	8.04e-6	Waist circumference;Hip circumference;
TGCT	cis	rs597480	0.963	rs589327	chr11:85446226	A/G	cg11817631	chr11:85522609	SYTL2	-0.44	-4.45	-0.37	1.89e-5	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);
TGCT	cis	rs10484885	0.878	rs111664889	chr6:90566427	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.47	-4.58	-0.38	1.11e-5	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs2820315	0.931	rs2644114	chr1:201864830	A/G	cg12730843	chr1:201915899	LMOD1	0.27	4.81	0.4	4.25e-6	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
TGCT	cis	rs7923609	0.967	rs7095571	chr10:65150959	T/G	cg08743896	chr10:65200160	JMJD1C	-0.34	-4.57	-0.38	1.16e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2073300	1.000	rs6137966	chr20:23444359	A/T	cg09953122	chr20:23471693	CST8	-0.64	-4.56	-0.38	1.19e-5	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs155076	1.000	rs598754	chr13:21845010	C/A	cg11317459	chr13:21872234	NA	-1.42	-12.02	-0.73	1.53e-22	White matter hyperintensity burden;
TGCT	cis	rs9611565	0.921	rs6002333	chr22:41719469	C/T	cg06481639	chr22:41940642	POLR3H	-0.6	-5.43	-0.44	2.89e-7	Vitiligo;
TGCT	cis	rs2302045	1.000	rs3815292	chr2:242032762	A/G	cg04553960	chr2:241721320	KIF1A	-0.7	-4.68	-0.39	7.4e-6	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio);
TGCT	cis	rs12908161	0.960	rs17599989	chr15:85285536	A/G	cg12863693	chr15:85201151	NMB	0.43	5.15	0.42	9.84e-7	Schizophrenia;
TGCT	cis	rs2742417	1.000	rs2742452	chr3:45765708	C/T	cg04837898	chr3:45731254	SACM1L	-0.52	-5.28	-0.43	5.58e-7	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs9297145	0.958	rs11975761	chr7:98766688	G/A	cg05967295	chr7:98741636	SMURF1	-1.03	-16.21	-0.82	1.99e-32	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg11764359	chr7:65958608	NA	-0.55	-5.08	-0.42	1.34e-6	Aortic root size;
TGCT	cis	rs9467711	1.000	rs6903015	chr6:26322526	A/G	cg03517284	chr6:25882590	NA	-0.86	-4.67	-0.39	7.69e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs79149102	0.579	rs6495146	chr15:75367630	A/T	cg09165964	chr15:75287851	SCAMP5	-1.03	-5.69	-0.45	8.73e-8	Lung cancer;
TGCT	cis	rs9517313	0.592	rs61969458	chr13:99177633	A/G	cg07423050	chr13:99094983	FARP1	-0.29	-5.49	-0.44	2.22e-7	Neuroticism;
TGCT	cis	rs617219	0.698	rs7379187	chr5:78521354	T/C	cg23987322	chr5:78407566	BHMT	0.37	5.12	0.42	1.14e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs698813	0.604	rs768006	chr2:44487612	C/G	cg00619915	chr2:44497795	NA	-0.25	-5.7	-0.46	8.4e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
TGCT	cis	rs12134133	1.000	rs2782850	chr1:207465437	A/T	cg02152968	chr1:207494213	CD55	0.57	4.47	0.37	1.74e-5	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs11935103	0.569	rs10022988	chr4:187291021	T/C	cg16785698	chr4:186456103	PDLIM3	0.45	4.58	0.38	1.14e-5	Response to citalopram treatment;
TGCT	trans	rs7618501	0.966	rs2246832	chr3:49881134	A/T	cg21659725	chr3:3221576	CRBN	0.98	15.34	0.81	2.02e-30	Intelligence (multi-trait analysis);
TGCT	cis	rs2307449	0.929	rs9788714	chr15:89781855	G/A	cg24365117	chr15:89879190	POLG	0.35	4.46	0.37	1.81e-5	Menopause (age at onset);
TGCT	cis	rs7100689	0.753	rs2185426	chr10:82120887	G/A	cg01528321	chr10:82214614	TSPAN14	0.88	8.48	0.61	5.61e-14	Post bronchodilator FEV1;
TGCT	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg09177884	chr7:1199841	ZFAND2A	-0.51	-4.9	-0.4	2.98e-6	Longevity;Endometriosis;
TGCT	cis	rs12579753	1.000	rs10862372	chr12:82249804	C/T	cg07988820	chr12:82153109	PPFIA2	-0.6	-6.48	-0.5	1.91e-9	Resting heart rate;
TGCT	cis	rs7959452	0.535	rs10878953	chr12:69674187	A/G	cg20891283	chr12:69753455	YEATS4	0.62	5.94	0.47	2.74e-8	Blood protein levels;
TGCT	cis	rs4689388	0.750	rs10001190	chr4:6284633	C/T	cg14416269	chr4:6271139	WFS1	-0.38	-5.12	-0.42	1.13e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg03517284	chr6:25882590	NA	0.82	8.28	0.6	1.68e-13	Blood metabolite levels;
TGCT	cis	rs4820539	1.000	rs885963	chr22:23460939	G/T	cg21100191	chr22:23484243	RTDR1	0.94	11.14	0.71	2.17e-20	Bone mineral density;
TGCT	cis	rs1532993	0.518	rs1545598	chr4:98633592	T/G	cg05340658	chr4:99064831	C4orf37	-0.4	-4.91	-0.4	2.77e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs826838	1.000	rs11168505	chr12:38939057	A/T	cg13010199	chr12:38710504	ALG10B	-0.65	-5.46	-0.44	2.52e-7	Heart rate;
TGCT	cis	rs3733585	0.673	rs6849729	chr4:9958732	T/C	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.67	-0.51	7.44e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg19318889	chr4:1322082	MAEA	0.2	4.58	0.38	1.1e-5	Longevity;
TGCT	cis	rs910316	0.967	rs4899550	chr14:75647666	C/T	cg11812906	chr14:75593930	NEK9	-0.72	-7.1	-0.54	8.47e-11	Height;
TGCT	cis	rs394563	0.591	rs237018	chr6:149743930	A/G	cg11245181	chr6:149772854	ZC3H12D	-0.28	-4.5	-0.37	1.54e-5	Dupuytren's disease;
TGCT	cis	rs4555082	0.874	rs4677	chr14:105717279	T/C	cg01266790	chr14:105781312	PACS2	0.54	4.5	0.37	1.53e-5	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg03351412	chr1:154909251	PMVK	0.52	4.83	0.4	3.96e-6	Prostate cancer;
TGCT	cis	rs7666738	0.791	rs7678564	chr4:99057341	A/G	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.44e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8180040	0.966	rs13075233	chr3:47420627	T/C	cg27129171	chr3:47204927	SETD2	0.65	7.74	0.57	2.99e-12	Colorectal cancer;
TGCT	cis	rs826838	0.900	rs1403523	chr12:39130570	T/A	cg26384229	chr12:38710491	ALG10B	-0.86	-7.7	-0.57	3.65e-12	Heart rate;
TGCT	cis	rs6840360	0.533	rs13119490	chr4:152713412	A/G	cg22705602	chr4:152727874	NA	0.34	5.98	0.47	2.2e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2288073	0.930	rs7604097	chr2:24401805	G/C	cg02683114	chr2:24398427	C2orf84	-0.24	-5.72	-0.46	7.53e-8	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs4975709	0.569	rs2353583	chr5:1858834	G/C	cg15595755	chr5:1867978	NA	0.46	5.21	0.42	7.54e-7	Cardiovascular disease risk factors;
TGCT	cis	rs7918232	1.000	rs6482595	chr10:27380261	A/G	cg15469871	chr10:27541418	LOC387646	-0.51	-4.6	-0.38	1.02e-5	Breast cancer;
TGCT	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg11764359	chr7:65958608	NA	-0.61	-5.35	-0.43	4.05e-7	Aortic root size;
TGCT	cis	rs6831352	0.918	rs17817958	chr4:100061245	A/C	cg12011299	chr4:100065546	ADH4	0.45	5.16	0.42	9.65e-7	Alcohol dependence;
TGCT	cis	rs7937682	0.889	rs521155	chr11:111492563	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.05	-11.36	-0.71	6.21e-21	Primary sclerosing cholangitis;
TGCT	cis	rs208515	0.525	rs10755508	chr6:66675790	T/C	cg07460842	chr6:66804631	NA	0.87	9.16	0.64	1.32e-15	Exhaled nitric oxide levels;
TGCT	cis	rs7945705	0.747	rs2568020	chr11:8994715	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.45	-4.97	-0.41	2.16e-6	Hemoglobin concentration;
TGCT	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg22963979	chr7:1858916	MAD1L1	-0.36	-5.63	-0.45	1.13e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs422249	0.511	rs102274	chr11:61557826	T/C	cg01500311	chr11:61656094	FADS3	-0.34	-5.93	-0.47	2.8e-8	Trans fatty acid levels;
TGCT	cis	rs7552404	0.731	rs931507	chr1:76401577	G/A	cg10523679	chr1:76189770	ACADM	-0.8	-7.4	-0.55	1.79e-11	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs12368653	0.789	rs2270777	chr12:58145156	C/T	cg12615879	chr12:58013172	SLC26A10	0.53	6.58	0.51	1.17e-9	Multiple sclerosis;
TGCT	cis	rs7226408	0.857	rs56364983	chr18:34430275	A/G	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs2842992	0.872	rs9456440	chr6:160074463	G/T	cg11366901	chr6:160182831	ACAT2	1.02	6.71	0.52	6.06e-10	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs9486715	0.867	rs9480700	chr6:96965056	A/G	cg18709589	chr6:96969512	KIAA0776	0.82	8.01	0.58	7.14e-13	Headache;
TGCT	cis	rs28595532	0.920	rs56342843	chr4:119765070	G/A	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs514406	0.584	rs7524702	chr1:53197830	G/A	cg08859206	chr1:53392774	SCP2	0.34	4.83	0.4	4.01e-6	Monocyte count;
TGCT	cis	rs4727027	0.901	rs6943937	chr7:148869915	A/G	cg23583168	chr7:148888333	NA	-0.75	-9.82	-0.66	3.48e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs9436747	0.667	rs4370791	chr1:66052228	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.52	4.82	0.4	4.14e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs10779751	1.000	rs742824	chr1:11274022	G/A	cg08854313	chr1:11322531	MTOR	0.91	9.86	0.66	2.71e-17	Body mass index;
TGCT	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg12310025	chr6:25882481	NA	0.54	5.41	0.44	3.11e-7	Blood metabolite levels;
TGCT	cis	rs7804356	1.000	rs10229837	chr7:26840652	G/A	cg03456212	chr7:26904342	SKAP2	-0.61	-4.7	-0.39	6.82e-6	Type 1 diabetes;
TGCT	cis	rs5758659	0.714	rs5751216	chr22:42508937	G/T	cg15557168	chr22:42548783	NA	0.18	4.63	0.38	9.14e-6	Cognitive function;
TGCT	cis	rs1347297	0.526	rs6757186	chr2:179259719	G/C	cg03991736	chr2:179345203	MIR548N;PLEKHA3	-0.51	-5.01	-0.41	1.86e-6	Alzheimer disease and age of onset;
TGCT	cis	rs62244186	0.659	rs4682745	chr3:44508967	T/C	cg17546649	chr3:44802566	KIF15;KIAA1143	-0.36	-4.44	-0.37	1.99e-5	Depressive symptoms;
TGCT	cis	rs7666738	0.830	rs35644814	chr4:98886111	G/C	cg17366294	chr4:99064904	C4orf37	0.68	6.87	0.53	2.72e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1215050	0.791	rs548892	chr4:98724701	C/T	cg17366294	chr4:99064904	C4orf37	0.52	5.57	0.45	1.54e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9611519	0.580	rs8138349	chr22:41412723	C/T	cg06634786	chr22:41940651	POLR3H	-0.49	-4.54	-0.38	1.33e-5	Neuroticism;
TGCT	cis	rs7819412	0.805	rs4333549	chr8:10979561	C/G	cg27411982	chr8:10470053	RP1L1	-0.21	-4.68	-0.39	7.39e-6	Triglycerides;
TGCT	cis	rs539096	1.000	rs539096	chr1:44072420	C/T	cg12908607	chr1:44402522	ARTN	0.51	5.43	0.44	2.89e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7106204	0.748	rs28656439	chr11:24207653	G/C	ch.11.24196551F	chr11:24239977	NA	0.47	4.45	0.37	1.91e-5	Response to Homoharringtonine (cytotoxicity);
TGCT	trans	rs10506458	1.000	rs1495013	chr12:63428188	C/T	cg22491629	chr6:157744540	C6orf35	-0.97	-8.42	-0.6	7.88e-14	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs7843479	0.965	rs11135763	chr8:21813962	A/G	cg17168535	chr8:21777572	XPO7	0.65	5.99	0.47	2.14e-8	Mean corpuscular volume;
TGCT	cis	rs6534347	0.573	rs9992580	chr4:123526195	T/G	cg10583651	chr4:123538969	IL21	-0.33	-4.9	-0.4	2.99e-6	Type 1 diabetes;
TGCT	cis	rs903263	0.601	rs12132032	chr1:84566589	A/G	cg09664975	chr1:84543551	PRKACB	0.5	4.86	0.4	3.47e-6	Breast cancer (male);
TGCT	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg10047753	chr17:41438598	NA	0.81	7.71	0.57	3.5e-12	Menopause (age at onset);
TGCT	cis	rs7178572	0.568	rs8030074	chr15:77654232	C/T	cg15453836	chr15:77711506	NA	-0.42	-4.79	-0.4	4.68e-6	Type 2 diabetes;
TGCT	cis	rs2120019	0.935	rs8042409	chr15:75350433	G/A	cg09165964	chr15:75287851	SCAMP5	-1.18	-10.44	-0.68	1.07e-18	Blood trace element (Zn levels);
TGCT	cis	rs3087591	0.960	rs2953012	chr17:29496486	A/G	cg24425628	chr17:29625626	OMG;NF1	0.45	7.23	0.54	4.41e-11	Hip circumference;
TGCT	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg13732083	chr21:47605072	C21orf56	0.34	4.52	0.38	1.44e-5	Testicular germ cell tumor;
TGCT	cis	rs9303401	0.659	rs35797125	chr17:56736547	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs611744	0.538	rs59930666	chr8:109262296	T/C	cg21045802	chr8:109455806	TTC35	0.8	8.25	0.6	1.98e-13	Dupuytren's disease;
TGCT	cis	rs2404602	0.647	rs12914196	chr15:76941361	C/T	cg22467129	chr15:76604101	ETFA	0.47	4.61	0.38	9.77e-6	Blood metabolite levels;
TGCT	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg05368731	chr17:41323189	NBR1	1.2	14.2	0.79	8.98e-28	Menopause (age at onset);
TGCT	cis	rs227917	1.000	rs10257096	chr7:23691283	C/G	cg12601843	chr7:23510954	IGF2BP3	0.58	4.66	0.39	8.1e-6	Common carotid intima-media thickness in HIV negative individuals;
TGCT	cis	rs75229567	0.717	rs17107156	chr12:70234066	A/G	cg10114359	chr12:70132523	RAB3IP	-1.55	-7.66	-0.57	4.5e-12	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
TGCT	cis	rs6840360	0.582	rs2709827	chr4:152331252	G/C	cg17479576	chr4:152424074	FAM160A1	-0.56	-5.85	-0.46	4.13e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs4074961	0.509	rs4653300	chr1:38024054	A/G	cg11397548	chr1:38022522	DNALI1	0.41	5.09	0.42	1.28e-6	Axial length;
TGCT	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg04546413	chr19:29218101	NA	0.84	6.82	0.52	3.52e-10	Methadone dose in opioid dependence;
TGCT	cis	rs9913156	0.793	rs11568061	chr17:4546445	G/A	cg23387401	chr17:4582204	PELP1	0.32	4.73	0.39	5.96e-6	Lymphocyte counts;
TGCT	cis	rs6964587	0.934	rs12531561	chr7:91707780	A/G	cg17063962	chr7:91808500	NA	0.88	9.65	0.66	8.73e-17	Breast cancer;
TGCT	cis	rs8062405	0.964	rs11860513	chr16:28825420	C/T	cg09754948	chr16:28834200	ATXN2L	0.63	4.73	0.39	6.03e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs9611565	0.559	rs132768	chr22:42013523	C/A	cg13695892	chr22:41940480	POLR3H	0.88	8.46	0.6	6.38e-14	Vitiligo;
TGCT	cis	rs1949733	0.655	rs2631736	chr4:8478421	C/G	cg11789530	chr4:8429930	ACOX3	-0.57	-5.32	-0.43	4.68e-7	Response to antineoplastic agents;
TGCT	cis	rs12908161	0.960	rs17599989	chr15:85285536	A/G	cg11189052	chr15:85197271	WDR73	0.68	5.65	0.45	1.03e-7	Schizophrenia;
TGCT	cis	rs6088590	1.000	rs6119535	chr20:33442138	A/C	cg06115741	chr20:33292138	TP53INP2	0.62	5.09	0.42	1.28e-6	Coronary artery disease;
TGCT	cis	rs6048205	0.764	rs1203905	chr20:22560689	A/G	cg10773670	chr20:23331356	NXT1	-0.97	-4.66	-0.39	8.05e-6	Fasting blood glucose (BMI interaction);Fasting blood glucose;
TGCT	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg24549020	chr5:56110836	MAP3K1	0.67	5.78	0.46	5.74e-8	Initial pursuit acceleration;
TGCT	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg06418219	chr1:154948305	SHC1;CKS1B	0.64	6.44	0.5	2.41e-9	Prostate cancer;
TGCT	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg11494091	chr17:61959527	GH2	0.6	14.54	0.79	1.46e-28	Prudent dietary pattern;
TGCT	cis	rs4389656	0.857	rs274677	chr5:6754402	T/C	cg10857441	chr5:6722123	POLS	-0.21	-4.6	-0.38	1.03e-5	Coronary artery disease;
TGCT	cis	rs11785400	0.793	rs1137521	chr8:143739162	C/T	cg24634471	chr8:143751801	JRK	0.55	5.51	0.44	1.99e-7	Schizophrenia;
TGCT	cis	rs4924935	1.000	rs4924935	chr17:18753870	C/T	cg26378065	chr17:18585709	ZNF286B	0.57	4.8	0.4	4.44e-6	Pancreatic cancer;
TGCT	cis	rs3784262	0.565	rs12595410	chr15:58293040	A/G	cg12031962	chr15:58353849	ALDH1A2	0.39	5.56	0.45	1.57e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs12510870	0.634	rs2178292	chr4:74384761	T/C	cg05868023	chr4:75230803	EREG	0.55	4.7	0.39	6.84e-6	Iris color (b* coordinate);
TGCT	cis	rs28595532	0.920	rs116405053	chr4:119739352	C/T	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs9660992	0.762	rs1668871	chr1:205237137	T/C	cg00857998	chr1:205179979	DSTYK	0.51	4.71	0.39	6.47e-6	Mean corpuscular volume;Mean platelet volume;
TGCT	cis	rs6688613	0.729	rs10918603	chr1:166936503	T/C	cg07049167	chr1:166818506	POGK	0.27	5.16	0.42	9.39e-7	Refractive astigmatism;
TGCT	cis	rs6723226	0.552	rs62136336	chr2:32804106	G/A	cg02381751	chr2:32503542	YIPF4	0.5	4.53	0.38	1.34e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs765787	0.530	rs16941017	chr15:45543281	T/C	cg24006582	chr15:45444508	DUOX1	-0.25	-5.49	-0.44	2.16e-7	Uric acid levels;
TGCT	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg03404566	chr17:6899310	ALOX12	0.45	5.11	0.42	1.17e-6	Tonsillectomy;
TGCT	cis	rs1865760	0.865	rs9467645	chr6:25955176	G/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.64	6.29	0.49	4.91e-9	Height;
TGCT	cis	rs1691799	0.867	rs1027401	chr12:66760892	C/G	cg16791601	chr12:66731901	HELB	-0.28	-6.03	-0.48	1.74e-8	White blood cell count (basophil);
TGCT	cis	rs11098499	0.687	rs71610270	chr4:120287436	A/G	cg09307838	chr4:120376055	NA	0.54	5.08	0.41	1.37e-6	Corneal astigmatism;
TGCT	cis	rs1555895	0.576	rs10904571	chr10:850762	A/G	cg02193355	chr10:851439	NA	0.22	4.86	0.4	3.54e-6	Survival in rectal cancer;
TGCT	cis	rs3008870	0.536	rs2208576	chr1:67513401	C/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.67	-6.51	-0.5	1.72e-9	Lymphocyte percentage of white cells;
TGCT	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg24549020	chr5:56110836	MAP3K1	0.67	5.78	0.46	5.74e-8	Initial pursuit acceleration;
TGCT	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg06873352	chr17:61820015	STRADA	0.56	6.22	0.49	7.1e-9	Prudent dietary pattern;
TGCT	cis	rs13191362	0.507	rs2846519	chr6:163045463	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.59	-5.79	-0.46	5.55e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs35306767	0.761	rs11253540	chr10:1011958	C/T	cg26597838	chr10:835615	NA	-0.57	-6.62	-0.51	9.89e-10	Eosinophil percentage of granulocytes;
TGCT	cis	rs9811920	0.599	rs1688758	chr3:99539890	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.6	7.02	0.53	1.32e-10	Axial length;
TGCT	cis	rs12210905	0.920	rs858995	chr6:27181701	T/C	cg08851530	chr6:28072375	NA	-0.96	-4.73	-0.39	5.89e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs7614311	0.636	rs73117059	chr3:63916028	A/G	cg22134162	chr3:63841271	THOC7	-0.49	-6.17	-0.48	8.78e-9	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs10464366	0.544	rs4355688	chr7:39158402	C/T	cg18850127	chr7:39170497	POU6F2	0.33	7.16	0.54	6.13e-11	IgG glycosylation;
TGCT	cis	rs2235642	0.821	rs8051895	chr16:1602811	A/G	cg08296037	chr16:1584118	IFT140;TMEM204	-0.31	-5.64	-0.45	1.08e-7	Coronary artery disease;
TGCT	cis	rs9325144	0.560	rs7980635	chr12:38668355	G/T	cg26384229	chr12:38710491	ALG10B	-0.66	-6.0	-0.47	2.06e-8	Morning vs. evening chronotype;
TGCT	cis	rs12048904	0.619	rs10875347	chr1:101333737	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.83	8.07	0.59	5.08e-13	Multiple sclerosis;
TGCT	cis	rs7617773	0.780	rs13067450	chr3:48337206	C/T	cg11946769	chr3:48343235	NME6	0.82	7.06	0.54	1.03e-10	Coronary artery disease;
TGCT	cis	rs6921919	0.515	rs1339898	chr6:28395506	C/T	cg13525197	chr6:28411240	ZSCAN23	-0.47	-4.49	-0.37	1.63e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9894429	0.646	rs7210026	chr17:79612382	T/C	cg21028142	chr17:79581711	NPLOC4	0.28	5.87	0.47	3.73e-8	Eye color traits;
TGCT	cis	rs12210905	0.687	rs72843622	chr6:27161152	C/T	cg08851530	chr6:28072375	NA	1.12	5.43	0.44	2.82e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg12751644	chr20:60527061	NA	-0.52	-7.06	-0.54	1.07e-10	Obesity-related traits;
TGCT	cis	rs612683	0.826	rs7556246	chr1:100828914	A/G	cg06223162	chr1:101003688	GPR88	0.29	4.99	0.41	1.97e-6	Breast cancer;
TGCT	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg22857025	chr5:266934	NA	-0.31	-6.32	-0.49	4.33e-9	Breast cancer;
TGCT	cis	rs6089584	0.606	rs2296082	chr20:60573983	A/G	cg06108461	chr20:60628389	TAF4	-0.4	-4.86	-0.4	3.46e-6	Body mass index;
TGCT	cis	rs7312933	0.558	rs11181483	chr12:42798384	G/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.52	4.97	0.41	2.2e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs7666738	0.830	rs113999196	chr4:99041961	C/T	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg03732007	chr1:2071316	PRKCZ	0.28	6.63	0.51	9.05e-10	Height;
TGCT	cis	rs2075371	0.674	rs11771785	chr7:134013249	A/G	cg11752832	chr7:134001865	SLC35B4	-0.64	-5.22	-0.42	7.36e-7	Mean platelet volume;
TGCT	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg13732083	chr21:47605072	C21orf56	0.35	4.69	0.39	7.17e-6	Testicular germ cell tumor;
TGCT	cis	rs9611565	0.592	rs5758405	chr22:42076381	C/A	cg06481639	chr22:41940642	POLR3H	0.73	6.62	0.51	9.76e-10	Vitiligo;
TGCT	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.68	5.62	0.45	1.18e-7	Tonsillectomy;
TGCT	cis	rs992157	0.932	rs56109829	chr2:219149740	G/A	cg00012203	chr2:219082015	ARPC2	0.8	8.47	0.61	5.95e-14	Colorectal cancer;
TGCT	cis	rs9527	0.590	rs3781281	chr10:104852648	A/G	cg15744005	chr10:104629667	AS3MT	0.42	4.96	0.41	2.27e-6	Arsenic metabolism;
TGCT	cis	rs67311347	1.000	rs73080137	chr3:40516412	A/G	cg13683864	chr3:40499215	RPL14	-1.17	-13.09	-0.76	4.01e-25	Renal cell carcinoma;
TGCT	cis	rs36051895	0.586	rs12342421	chr9:5065750	G/C	cg02405213	chr9:5042618	JAK2	-0.74	-9.76	-0.66	4.79e-17	Pediatric autoimmune diseases;
TGCT	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg01416388	chr22:39784598	NA	-0.74	-7.49	-0.56	1.1e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs9467711	0.790	rs66488313	chr6:26631568	G/T	cg12315302	chr6:26189340	HIST1H4D	0.99	4.44	0.37	1.93e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9611519	1.000	rs6002271	chr22:41566595	C/T	cg03806693	chr22:41940476	POLR3H	-0.67	-6.1	-0.48	1.23e-8	Neuroticism;
TGCT	cis	rs13168506	0.538	rs12521857	chr5:135440364	G/A	cg16684184	chr5:135415129	NA	-0.25	-4.44	-0.37	1.99e-5	Stroke;
TGCT	cis	rs617219	0.698	rs7445125	chr5:78507417	A/G	cg23514016	chr5:78407564	BHMT	0.35	5.34	0.43	4.24e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs12681288	0.782	rs12549337	chr8:1030187	A/G	cg04851639	chr8:1020857	NA	-0.35	-6.24	-0.49	6.21e-9	Schizophrenia;
TGCT	cis	rs12477438	0.700	rs12467679	chr2:99654449	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-6.1	-0.48	1.22e-8	Chronic sinus infection;
TGCT	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg14159672	chr1:205819179	PM20D1	0.63	7.96	0.58	9.34e-13	Menarche (age at onset);
TGCT	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg20607798	chr8:58055168	NA	0.5	4.66	0.39	8.04e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs763121	0.785	rs5750646	chr22:39013830	T/C	cg06022373	chr22:39101656	GTPBP1	0.81	8.37	0.6	9.98e-14	Menopause (age at onset);
TGCT	cis	rs4523957	0.615	rs59207721	chr17:2070479	C/A	cg16513277	chr17:2031491	SMG6	-0.21	-4.69	-0.39	7e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs17826219	0.500	rs61685770	chr17:29085713	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Body mass index;
TGCT	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.0	7.42	0.55	1.64e-11	Gut microbiome composition (summer);
TGCT	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg12310025	chr6:25882481	NA	-0.62	-6.42	-0.5	2.63e-9	Blood metabolite levels;
TGCT	cis	rs78487399	0.808	rs74821293	chr2:43742923	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.39	-4.61	-0.38	9.77e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs12540874	0.529	rs732215	chr7:50544063	A/C	cg18232548	chr7:50535776	DDC	-0.36	-6.28	-0.49	5.26e-9	Systemic sclerosis;
TGCT	cis	rs2204008	0.529	rs1315350	chr12:38164282	C/A	cg26384229	chr12:38710491	ALG10B	-0.58	-5.09	-0.42	1.28e-6	Bladder cancer;
TGCT	cis	rs1865760	0.713	rs9461229	chr6:25992279	G/T	cg16482183	chr6:26056742	HIST1H1C	0.54	4.77	0.39	5.15e-6	Height;
TGCT	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg06618935	chr21:46677482	NA	-0.37	-5.81	-0.46	5.06e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7666738	0.830	rs1426668	chr4:98945585	T/A	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1153858	0.895	rs12593402	chr15:45617392	G/A	cg14582100	chr15:45693742	SPATA5L1	0.48	5.66	0.45	9.96e-8	Homoarginine levels;
TGCT	cis	rs1801251	0.835	rs1446310	chr2:233683245	G/C	cg25237894	chr2:233734115	C2orf82	-0.3	-5.45	-0.44	2.63e-7	Coronary artery disease;
TGCT	cis	rs514406	0.607	rs6696940	chr1:53203427	C/T	cg01802117	chr1:53393560	SCP2	0.44	5.16	0.42	9.62e-7	Monocyte count;
TGCT	cis	rs9611565	0.592	rs12484467	chr22:41957610	T/C	cg13695892	chr22:41940480	POLR3H	-0.83	-7.68	-0.57	4.15e-12	Vitiligo;
TGCT	cis	rs17376456	0.877	rs9314100	chr5:93447394	T/C	cg21475434	chr5:93447410	FAM172A	0.6	4.62	0.38	9.48e-6	Diabetic retinopathy;
TGCT	cis	rs2730245	0.636	rs2657382	chr7:158650941	G/A	cg24397884	chr7:158709396	WDR60	0.35	4.55	0.38	1.26e-5	Height;
TGCT	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.7	0.52	6.47e-10	Bipolar disorder;
TGCT	cis	rs1691799	0.899	rs1168305	chr12:66738714	A/G	cg16791601	chr12:66731901	HELB	-0.28	-6.11	-0.48	1.19e-8	White blood cell count (basophil);
TGCT	cis	rs7267979	0.934	rs4815423	chr20:25387521	A/G	cg03522245	chr20:25566470	NINL	-0.63	-6.78	-0.52	4.39e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9916302	0.706	rs597069	chr17:37458512	G/T	cg07936489	chr17:37558343	FBXL20	0.84	6.16	0.48	9.3e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs9807989	0.507	rs10439410	chr2:102990788	A/C	cg03938978	chr2:103052716	IL18RAP	-0.26	-5.22	-0.42	7.15e-7	Asthma;
TGCT	cis	rs10193935	0.901	rs3755304	chr2:42589921	A/G	cg27598129	chr2:42591480	NA	0.37	5.13	0.42	1.09e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs473651	0.901	rs563282	chr2:239329736	T/C	cg08773314	chr2:239334832	ASB1	0.49	7.84	0.58	1.72e-12	Multiple system atrophy;
TGCT	cis	rs2730260	0.500	rs73169244	chr7:158887293	T/C	cg09066883	chr7:157932951	PTPRN2	0.42	4.66	0.39	8.09e-6	Myopia (pathological);
TGCT	cis	rs6582630	0.555	rs7133706	chr12:38475465	G/A	cg13010199	chr12:38710504	ALG10B	-0.54	-4.44	-0.37	1.95e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs11249608	0.548	rs62393076	chr5:178450646	C/G	cg01312482	chr5:178451176	ZNF879	-0.56	-5.5	-0.44	2.09e-7	Pubertal anthropometrics;
TGCT	trans	rs6089829	0.962	rs57684920	chr20:61662639	G/A	cg13615516	chr5:77269221	NA	-0.67	-8.09	-0.59	4.7e-13	Prostate cancer (SNP x SNP interaction);
TGCT	trans	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg13615516	chr5:77269221	NA	0.69	8.57	0.61	3.51e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs922182	0.556	rs12443020	chr15:64215823	G/T	cg02919090	chr15:64263738	DAPK2	0.37	6.77	0.52	4.69e-10	Blood protein levels;
TGCT	cis	rs1451375	0.698	rs7797131	chr7:50647934	A/G	cg18232548	chr7:50535776	DDC	0.44	6.72	0.52	5.81e-10	Malaria;
TGCT	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg00814883	chr7:100076585	TSC22D4	-0.52	-5.05	-0.41	1.54e-6	Lung function (FEV1/FVC);
TGCT	cis	rs9921338	0.923	rs72771877	chr16:11368616	T/A	cg00044050	chr16:11439710	C16orf75	-0.84	-5.42	-0.44	3.05e-7	Vein graft stenosis in coronary artery bypass grafting;
TGCT	trans	rs1814175	0.817	rs10769598	chr11:49669326	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.38	-7.7	-0.57	3.66e-12	Height;
TGCT	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg07507251	chr3:52567010	NT5DC2	0.47	6.6	0.51	1.05e-9	Bipolar disorder;
TGCT	cis	rs7542091	0.635	rs7550733	chr1:210044968	G/A	cg00989853	chr1:209979345	IRF6	0.43	4.56	0.38	1.21e-5	Monobrow;
TGCT	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg09365446	chr1:150670422	GOLPH3L	0.31	4.64	0.38	8.7e-6	Tonsillectomy;
TGCT	trans	rs62103177	0.810	rs62103197	chr18:77632923	G/A	cg05926928	chr17:57297772	GDPD1	1.22	11.16	0.71	1.85e-20	Opioid sensitivity;
TGCT	cis	rs6964587	1.000	rs10236397	chr7:91691601	C/T	cg17063962	chr7:91808500	NA	0.88	9.65	0.66	8.73e-17	Breast cancer;
TGCT	cis	rs68170813	0.559	rs2894459	chr7:106960166	C/T	cg02696742	chr7:106810147	HBP1	-0.62	-4.47	-0.37	1.71e-5	Coronary artery disease;
TGCT	cis	rs986417	0.901	rs1950310	chr14:60988526	T/A	cg27398547	chr14:60952738	C14orf39	1.38	10.8	0.7	1.4e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs9467773	1.000	rs6925895	chr6:26572165	G/T	cg15659132	chr6:26577336	NA	0.88	12.27	0.74	3.83e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs854765	0.663	rs9915248	chr17:17747514	C/T	cg09796270	chr17:17721594	SREBF1	-0.24	-4.52	-0.38	1.45e-5	Total body bone mineral density;
TGCT	cis	rs9318086	0.712	rs66683041	chr13:24442090	T/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.99	11.2	0.71	1.51e-20	Myopia (pathological);
TGCT	cis	rs2836950	0.501	rs11702505	chr21:40700614	G/T	cg17971929	chr21:40555470	PSMG1	-0.51	-4.48	-0.37	1.7e-5	Menarche (age at onset);
TGCT	cis	rs9457247	0.935	rs1187529	chr6:167376693	T/A	cg23791538	chr6:167370224	RNASET2	0.49	4.63	0.38	8.93e-6	Crohn's disease;
TGCT	cis	rs11648796	0.717	rs10682	chr16:767430	C/G	cg27144592	chr16:783916	NARFL	0.39	5.56	0.45	1.56e-7	Height;
TGCT	cis	rs7552404	1.000	rs1498315	chr1:76159225	G/A	cg10523679	chr1:76189770	ACADM	0.91	9.92	0.67	2.01e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs6582630	0.516	rs12814528	chr12:38296111	G/A	cg26384229	chr12:38710491	ALG10B	-0.54	-4.7	-0.39	6.68e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs4822044	0.617	rs13054514	chr22:42130383	A/G	cg17554472	chr22:41940697	POLR3H	0.43	4.54	0.38	1.31e-5	Cannabis dependence symptom count;
TGCT	cis	rs7552404	1.000	rs12091720	chr1:76186949	G/A	cg22875332	chr1:76189707	ACADM	0.78	9.53	0.65	1.76e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9653442	0.510	rs12712068	chr2:100764439	A/G	cg07810366	chr2:100720526	AFF3	-0.36	-5.29	-0.43	5.46e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	trans	rs2970818	0.831	rs2970810	chr12:4608103	A/G	cg22985033	chr20:36975012	LBP	0.25	7.25	0.55	3.9e-11	Phosphorus levels;
TGCT	cis	rs3733585	0.631	rs4697925	chr4:10124330	G/C	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.07	-0.48	1.43e-8	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs9393777	0.778	rs13219354	chr6:27185664	T/C	cg16898833	chr6:26189333	HIST1H4D	0.94	5.6	0.45	1.33e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs921968	0.541	rs4674314	chr2:219423520	A/G	cg02176678	chr2:219576539	TTLL4	-0.49	-6.93	-0.53	1.99e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs2688608	0.934	rs2675679	chr10:75658581	C/T	cg23231163	chr10:75533350	FUT11	-0.26	-4.69	-0.39	7.01e-6	Inflammatory bowel disease;
TGCT	cis	rs7772486	0.837	rs2474354	chr6:146323795	T/A	cg05347473	chr6:146136440	FBXO30	0.5	4.83	0.4	3.94e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9926296	1.000	rs9926296	chr16:89818089	A/G	cg03388025	chr16:89894329	SPIRE2	0.4	6.27	0.49	5.45e-9	Vitiligo;
TGCT	cis	rs7178572	1.000	rs11633054	chr15:77747276	A/G	cg22256960	chr15:77711686	NA	-0.95	-10.89	-0.7	8.57e-20	Type 2 diabetes;
TGCT	cis	rs3820928	1.000	rs4675120	chr2:227774888	C/T	cg11843606	chr2:227700838	RHBDD1	-0.53	-4.73	-0.39	5.89e-6	Pulmonary function;
TGCT	trans	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg23505145	chr19:12996616	KLF1	0.76	7.75	0.57	2.92e-12	Prostate cancer (SNP x SNP interaction);
TGCT	trans	rs561341	0.883	rs6505274	chr17:30344581	G/T	cg20587970	chr11:113659929	NA	-0.81	-9.74	-0.66	5.46e-17	Hip circumference adjusted for BMI;
TGCT	trans	rs28735056	0.904	rs62103174	chr18:77621048	A/G	cg05926928	chr17:57297772	GDPD1	0.64	6.76	0.52	4.85e-10	Schizophrenia;
TGCT	cis	rs12950390	0.853	rs10445375	chr17:45864314	C/T	cg06532163	chr17:45867833	NA	-0.37	-5.96	-0.47	2.45e-8	IgG glycosylation;
TGCT	cis	rs80264589	1	rs80264589	chr6:26927602	G/A	cg16898833	chr6:26189333	HIST1H4D	1.28	6.15	0.48	9.89e-9	Lung cancer;Intelligence (multi-trait analysis);
TGCT	cis	rs7647973	1.000	rs974495	chr3:49400482	T/C	cg07690219	chr3:49449608	TCTA;RHOA	-0.56	-4.6	-0.38	1.02e-5	Menarche (age at onset);
TGCT	cis	rs61990749	0.544	rs12435761	chr14:78246077	C/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.64	4.5	0.37	1.54e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs9814567	1.000	rs2056603	chr3:134312749	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.91	-8.83	-0.62	8.17e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs3733585	0.578	rs4466042	chr4:9955367	T/C	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.7	-0.52	6.62e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs1005277	0.505	rs200931	chr10:38128434	A/C	cg25427524	chr10:38739819	LOC399744	-0.37	-7.13	-0.54	7.29e-11	Extrinsic epigenetic age acceleration;
TGCT	cis	rs13223928	0.516	rs1872880	chr7:3148389	G/C	cg19214707	chr7:3157722	NA	-0.44	-6.15	-0.48	9.76e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
TGCT	cis	rs2997447	0.761	rs61776585	chr1:26438498	G/C	cg03844060	chr1:26490628	NA	0.28	4.55	0.38	1.27e-5	QRS complex (12-leadsum);
TGCT	cis	rs986417	0.818	rs8014133	chr14:61104738	A/G	cg18240143	chr14:60952599	C14orf39	0.88	4.57	0.38	1.15e-5	Gut microbiota (bacterial taxa);
TGCT	cis	rs7772486	0.536	rs9373467	chr6:145955605	C/T	cg23711669	chr6:146136114	FBXO30	0.72	6.73	0.52	5.71e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs832540	0.669	rs832539	chr5:56199386	A/C	cg20203395	chr5:56204925	C5orf35	-0.6	-5.43	-0.44	2.81e-7	Coronary artery disease;
TGCT	cis	rs9467773	0.620	rs2504565	chr6:26656890	G/A	cg09904177	chr6:26538194	HMGN4	0.67	6.15	0.48	9.93e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs2729354	0.768	rs2848640	chr11:57262680	A/G	cg24343310	chr11:57249947	NA	0.29	4.74	0.39	5.69e-6	Blood protein levels;
TGCT	trans	rs1814175	0.746	rs10839429	chr11:49906845	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.36	-7.05	-0.53	1.13e-10	Height;
TGCT	cis	rs9393692	0.840	rs9358915	chr6:26277268	G/A	cg00631329	chr6:26305371	NA	-0.41	-6.09	-0.48	1.34e-8	Educational attainment;
TGCT	cis	rs6918586	0.658	rs198838	chr6:26113340	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.69	6.43	0.5	2.44e-9	Schizophrenia;
TGCT	cis	rs8072100	0.875	rs7208530	chr17:45544107	C/T	cg08085267	chr17:45401833	C17orf57	-0.43	-4.68	-0.39	7.26e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg06873352	chr17:61820015	STRADA	0.58	6.42	0.5	2.65e-9	Prudent dietary pattern;
TGCT	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.84	7.5	0.56	1.08e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs1372520	0.577	rs1811443	chr4:90747883	G/C	cg20003494	chr4:90757398	SNCA	-0.63	-5.09	-0.42	1.3e-6	Neuroticism;
TGCT	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg18110333	chr6:292329	DUSP22	-0.67	-7.41	-0.55	1.75e-11	Menopause (age at onset);
TGCT	cis	rs4654899	1.000	rs7535895	chr1:21439239	T/A	cg01072550	chr1:21505969	NA	-0.49	-7.88	-0.58	1.41e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg20849893	chr7:64541193	NA	0.49	5.16	0.42	9.32e-7	Calcium levels;
TGCT	cis	rs80282103	0.867	rs13377037	chr10:1068639	C/T	cg08668510	chr10:1095578	IDI1	1.08	5.21	0.42	7.5e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs6840360	0.667	rs2709829	chr4:152355390	C/T	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.83e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs5769765	0.862	rs138870	chr22:50209737	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.36	5.5	0.44	2.1e-7	Schizophrenia;
TGCT	cis	rs4601821	1.000	rs4601821	chr11:113250346	A/G	cg14159747	chr11:113255604	NA	0.39	4.47	0.37	1.78e-5	Alcoholic chronic pancreatitis;
TGCT	cis	rs7103648	1.000	rs2293579	chr11:47440758	G/A	cg20307385	chr11:47447363	PSMC3	1.0	12.43	0.74	1.52e-23	Diastolic blood pressure;Systolic blood pressure;
TGCT	cis	rs11172134	0.508	rs7305179	chr12:57576567	G/C	cg19258868	chr12:57585184	LRP1	-0.31	-5.93	-0.47	2.76e-8	Urate levels in overweight individuals;
TGCT	trans	rs7819412	0.807	rs6991930	chr8:10963288	G/C	cg15556689	chr8:8085844	FLJ10661	-0.73	-6.94	-0.53	1.98e-10	Triglycerides;
TGCT	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg11764359	chr7:65958608	NA	-0.58	-4.99	-0.41	2.01e-6	Aortic root size;
TGCT	cis	rs78487399	0.908	rs77994584	chr2:43817076	C/G	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.66	4.67	0.39	7.66e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs1670533	0.872	rs10017931	chr4:1060747	G/A	cg27284194	chr4:1044797	NA	0.67	5.74	0.46	6.78e-8	Recombination rate (females);
TGCT	cis	rs11190604	1.000	rs2489035	chr10:102319395	C/T	cg23241863	chr10:102295624	HIF1AN	0.69	5.21	0.42	7.75e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	trans	rs10504390	0.527	rs4392943	chr8:66523799	C/A	cg26037026	chr7:1641922	NA	-0.64	-6.84	-0.52	3.29e-10	IgG glycosylation;
TGCT	cis	rs4665809	0.617	rs930263	chr2:26402594	G/C	cg22920501	chr2:26401640	FAM59B	-0.79	-6.28	-0.49	5.21e-9	Gut microbiome composition (summer);
TGCT	cis	rs7819412	0.875	rs11250121	chr8:11060311	A/C	cg27411982	chr8:10470053	RP1L1	-0.2	-4.47	-0.37	1.77e-5	Triglycerides;
TGCT	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg22166914	chr1:53195759	ZYG11B	-0.5	-9.42	-0.65	3.19e-16	Monocyte count;
TGCT	cis	rs74054849	0.717	rs80042126	chr1:15938108	C/A	cg05660106	chr1:15850417	CASP9	0.86	4.47	0.37	1.71e-5	Alcoholic chronic pancreatitis;
TGCT	cis	rs7772486	0.840	rs2814864	chr6:146345046	A/C	cg23711669	chr6:146136114	FBXO30	0.72	6.64	0.51	8.98e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7772486	0.754	rs9497401	chr6:146051271	T/C	cg23711669	chr6:146136114	FBXO30	-0.95	-10.87	-0.7	9.46e-20	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg06481639	chr22:41940642	POLR3H	0.75	6.66	0.51	8.03e-10	Vitiligo;
TGCT	cis	rs2688608	0.592	rs10762563	chr10:75524802	C/A	cg23231163	chr10:75533350	FUT11	-0.28	-4.67	-0.39	7.55e-6	Inflammatory bowel disease;
TGCT	cis	rs752010	0.756	rs6600380	chr1:42054814	C/T	cg06885757	chr1:42089581	HIVEP3	-0.24	-4.48	-0.37	1.68e-5	Lupus nephritis in systemic lupus erythematosus;
TGCT	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.5	-4.81	-0.4	4.26e-6	Bipolar disorder;
TGCT	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg00343986	chr7:65444356	GUSB	-0.24	-5.53	-0.44	1.85e-7	Aortic root size;
TGCT	cis	rs78487399	0.808	rs17039133	chr2:43694570	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-5.45	-0.44	2.63e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg10862848	chr6:42927986	GNMT	-0.38	-4.72	-0.39	6.35e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs1691799	0.899	rs1168306	chr12:66738900	A/G	cg16791601	chr12:66731901	HELB	-0.28	-6.11	-0.48	1.19e-8	White blood cell count (basophil);
TGCT	cis	rs2458413	0.542	rs2514671	chr8:105364256	G/A	cg04554929	chr8:105342491	NA	0.49	5.75	0.46	6.49e-8	Paget's disease;
TGCT	cis	rs7267979	1.000	rs910997	chr20:25267301	G/A	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs12291225	0.585	rs11023197	chr11:14380998	G/A	cg19336497	chr11:14380999	RRAS2	-0.44	-7.14	-0.54	6.96e-11	Sense of smell;
TGCT	cis	rs4733781	1.000	rs2114196	chr8:131225299	G/A	cg16277922	chr8:131349729	ASAP1	0.45	5.65	0.45	1.03e-7	Tuberculosis;
TGCT	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg23758822	chr17:41437982	NA	0.71	6.75	0.52	5.16e-10	Menopause (age at onset);
TGCT	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	5.24	0.43	6.7e-7	Height;
TGCT	cis	rs7394190	0.748	rs2242254	chr10:75585307	G/A	cg07699608	chr10:75541558	CHCHD1	0.8	5.52	0.44	1.86e-7	Incident atrial fibrillation;
TGCT	cis	rs1577917	0.958	rs12193904	chr6:86452703	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.43	-0.44	2.81e-7	Response to antipsychotic treatment;
TGCT	cis	rs939658	0.626	rs11631406	chr15:79445789	C/T	cg17916960	chr15:79447300	NA	-0.41	-5.91	-0.47	3.1e-8	Refractive error;
TGCT	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg23708337	chr7:1209742	NA	0.57	5.13	0.42	1.09e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1577917	0.771	rs2484355	chr6:86394403	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.8	-0.46	5.09e-8	Response to antipsychotic treatment;
TGCT	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg20607798	chr8:58055168	NA	0.5	4.66	0.39	8.04e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg00684032	chr4:1343700	KIAA1530	0.22	4.82	0.4	4.11e-6	Obesity-related traits;
TGCT	cis	rs6426551	1.000	rs7517174	chr1:226540327	A/C	cg18564989	chr1:226411057	MIXL1	-0.5	-5.04	-0.41	1.62e-6	Coronary artery disease;
TGCT	cis	rs4733781	0.509	rs12550365	chr8:131136046	A/T	cg16277922	chr8:131349729	ASAP1	0.45	6.66	0.51	7.99e-10	Tuberculosis;
TGCT	cis	rs7772486	0.875	rs9322045	chr6:146384950	C/G	cg05347473	chr6:146136440	FBXO30	0.55	5.14	0.42	1.05e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9650657	0.645	rs56057779	chr8:10516880	G/C	cg27411982	chr8:10470053	RP1L1	-0.22	-4.79	-0.4	4.62e-6	Neuroticism;
TGCT	cis	rs11190604	0.731	rs10883480	chr10:102163821	G/T	cg16005271	chr10:102321736	NA	-0.43	-4.48	-0.37	1.66e-5	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs10791097	0.694	rs1893018	chr11:130756632	T/C	cg12179176	chr11:130786555	SNX19	0.83	9.92	0.67	1.94e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9467773	1.000	rs9467779	chr6:26536687	A/T	cg05738196	chr6:26577821	NA	-0.85	-11.96	-0.73	2.09e-22	Intelligence (multi-trait analysis);
TGCT	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	8.0	0.58	7.67e-13	Platelet count;
TGCT	cis	rs3820068	0.580	rs34426856	chr1:16006315	C/T	cg05660106	chr1:15850417	CASP9	0.58	5.38	0.43	3.64e-7	Systolic blood pressure;
TGCT	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg01448562	chr3:133502909	NA	-0.26	-4.87	-0.4	3.28e-6	Iron status biomarkers;
TGCT	cis	rs1018836	0.631	rs9987133	chr8:91470730	T/C	cg16814680	chr8:91681699	NA	-0.77	-7.57	-0.56	7.42e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7226408	0.847	rs115623155	chr18:34684712	C/T	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs1150668	0.799	rs1736891	chr6:28187101	C/A	cg13525197	chr6:28411240	ZSCAN23	-0.47	-4.56	-0.38	1.22e-5	Pubertal anthropometrics;
TGCT	cis	rs2370759	1.000	rs11599044	chr10:32615445	A/G	cg01819863	chr10:32635814	EPC1	1.03	9.79	0.66	4.07e-17	Sexual dysfunction (female);
TGCT	cis	rs1692580	0.807	rs4648818	chr1:2178999	C/T	cg24578937	chr1:2090814	PRKCZ	0.2	4.48	0.37	1.7e-5	Coronary artery disease;
TGCT	cis	rs1075232	1.000	rs56396205	chr15:31678385	G/A	cg01030201	chr15:31746330	NA	-1.1	-5.4	-0.44	3.27e-7	Survival in colorectal cancer (non-distant metastatic);
TGCT	cis	rs10206020	0.921	rs72776300	chr2:1571152	A/G	cg01028140	chr2:1542097	TPO	-0.32	-4.99	-0.41	1.97e-6	IgG glycosylation;
TGCT	cis	rs4808199	0.948	rs757000	chr19:19448301	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.63	4.56	0.38	1.23e-5	Nonalcoholic fatty liver disease;
TGCT	cis	rs3849570	1.000	rs9817181	chr3:81827765	A/C	cg07356753	chr3:81810745	GBE1	-0.81	-7.4	-0.55	1.81e-11	Waist circumference;Body mass index;
TGCT	cis	rs12882406	0.602	rs4981470	chr14:23811264	C/G	cg16420801	chr14:23816088	SLC22A17	-0.27	-4.47	-0.37	1.71e-5	Body mass index;
TGCT	cis	rs6901004	0.803	rs354539	chr6:111517829	T/C	cg15721981	chr6:111408429	SLC16A10	-0.51	-4.48	-0.37	1.66e-5	Blood metabolite levels;
TGCT	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg12311346	chr5:56204834	C5orf35	-0.67	-6.82	-0.52	3.63e-10	Initial pursuit acceleration;
TGCT	cis	rs11098499	0.863	rs3822192	chr4:120445720	A/C	cg09307838	chr4:120376055	NA	0.68	6.47	0.5	2.02e-9	Corneal astigmatism;
TGCT	cis	rs2017387	0.572	rs283518	chr19:50492564	C/T	cg19230443	chr19:49950584	PIH1D1	-0.28	-4.62	-0.38	9.5e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
TGCT	cis	rs6088580	0.634	rs6088483	chr20:32984714	T/A	cg06115741	chr20:33292138	TP53INP2	-0.55	-4.81	-0.4	4.28e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg07061783	chr6:25882402	NA	-0.58	-5.57	-0.45	1.48e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2739330	0.964	rs2739338	chr22:24297130	T/C	cg11905131	chr22:24372483	LOC391322	-0.98	-12.41	-0.74	1.79e-23	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	trans	rs5771242	0.769	rs4838865	chr22:50664612	A/G	cg26607758	chr8:91997553	NA	0.78	7.88	0.58	1.42e-12	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
TGCT	cis	rs6076065	0.962	rs2424529	chr20:23369317	A/G	cg11657817	chr20:23433608	CST11	0.28	4.62	0.38	9.4e-6	Facial morphology (factor 15, philtrum width);
TGCT	cis	rs1048238	0.506	rs7552077	chr1:16196759	A/G	cg22431228	chr1:16359049	CLCNKA	-0.22	-4.48	-0.37	1.69e-5	Systolic blood pressure;
TGCT	cis	rs2404602	1.000	rs12594541	chr15:76834368	G/A	cg22467129	chr15:76604101	ETFA	-0.5	-5.63	-0.45	1.12e-7	Blood metabolite levels;
TGCT	cis	rs4851254	0.961	rs13022707	chr2:100734946	C/A	cg07810366	chr2:100720526	AFF3	-0.4	-4.48	-0.37	1.67e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7552404	0.731	rs1689275	chr1:76409655	T/C	cg22875332	chr1:76189707	ACADM	-0.67	-6.89	-0.53	2.5e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2235642	0.893	rs2143285	chr16:1593171	A/G	cg08296037	chr16:1584118	IFT140;TMEM204	-0.31	-5.39	-0.44	3.44e-7	Coronary artery disease;
TGCT	trans	rs9951602	0.512	rs9946123	chr18:76654557	A/G	cg02800362	chr5:177631904	HNRNPAB	1.14	12.55	0.75	7.84e-24	Obesity-related traits;
TGCT	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg10150615	chr22:24372951	LOC391322	0.81	9.1	0.63	1.9e-15	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs66561647	0.634	rs7387606	chr8:128929371	A/G	cg05480350	chr8:128972681	MIR1205;PVT1	0.22	4.54	0.38	1.29e-5	Hemoglobin concentration;
TGCT	cis	rs8050907	0.744	rs9922933	chr16:4572602	T/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.58	4.74	0.39	5.67e-6	Obesity-related traits;
TGCT	cis	rs11585357	0.843	rs12095095	chr1:17625832	C/G	cg08277548	chr1:17600880	PADI3	-0.95	-9.58	-0.65	1.3e-16	Hair shape;
TGCT	cis	rs933688	1.000	rs35712350	chr5:90679519	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	9.32	0.64	5.44e-16	Smoking behavior;
TGCT	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg01448562	chr3:133502909	NA	0.35	7.38	0.55	2e-11	Iron status biomarkers;
TGCT	cis	rs7524258	0.903	rs4908609	chr1:7292910	G/A	cg04342483	chr1:7259290	CAMTA1	-0.31	-4.49	-0.37	1.6e-5	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg25703541	chr22:24373054	LOC391322	-0.82	-8.62	-0.61	2.61e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs4642101	0.824	rs3889515	chr3:12844112	G/C	cg05775895	chr3:12838266	CAND2	0.73	7.24	0.55	4.1e-11	QRS complex (12-leadsum);
TGCT	cis	rs7617773	0.780	rs71323396	chr3:48374734	T/G	cg11946769	chr3:48343235	NME6	0.81	6.96	0.53	1.71e-10	Coronary artery disease;
TGCT	cis	rs2013441	1.000	rs2703799	chr17:20085768	G/T	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.61	-0.38	9.96e-6	Obesity-related traits;
TGCT	cis	rs6964587	0.967	rs10280620	chr7:91582183	C/G	cg22709100	chr7:91322751	NA	-0.27	-4.48	-0.37	1.68e-5	Breast cancer;
TGCT	cis	rs295140	0.933	rs10931900	chr2:201177193	T/C	cg04283868	chr2:201171347	SPATS2L	0.65	6.67	0.51	7.73e-10	QT interval;
TGCT	cis	rs7208859	0.673	rs28588622	chr17:29245699	G/A	cg18442181	chr17:29233375	C17orf42	-0.75	-4.49	-0.37	1.61e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs9467773	0.620	rs1027203	chr6:26639332	G/C	cg15659132	chr6:26577336	NA	0.84	10.39	0.68	1.39e-18	Intelligence (multi-trait analysis);
TGCT	cis	rs28595532	0.920	rs115317002	chr4:119722809	T/C	cg21605333	chr4:119757512	SEC24D	1.72	8.99	0.63	3.52e-15	Cannabis dependence symptom count;
TGCT	cis	rs931127	0.719	rs7949980	chr11:65445950	T/C	cg17480646	chr11:65405466	SIPA1	-0.44	-5.8	-0.46	5.26e-8	Systemic lupus erythematosus;
TGCT	cis	rs1008375	1.000	rs7659718	chr4:17638020	A/C	cg10189774	chr4:17578691	LAP3	0.65	5.64	0.45	1.08e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4808199	0.895	rs8105094	chr19:19374061	C/T	cg03709012	chr19:19516395	GATAD2A	0.8	6.04	0.48	1.66e-8	Nonalcoholic fatty liver disease;
TGCT	cis	rs9549367	0.577	rs3024713	chr13:113813321	G/A	cg18105134	chr13:113819100	PROZ	-0.46	-7.31	-0.55	2.88e-11	Platelet distribution width;
TGCT	cis	rs35306767	0.903	rs17159970	chr10:935601	T/C	cg20503657	chr10:835505	NA	0.74	10.3	0.68	2.41e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg20607798	chr8:58055168	NA	0.6	5.0	0.41	1.9e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg07507251	chr3:52567010	NT5DC2	0.46	6.38	0.5	3.24e-9	Bipolar disorder;
TGCT	cis	rs9302065	1.000	rs2389236	chr13:95971477	G/A	cg24476569	chr13:95954382	ABCC4	-0.44	-6.63	-0.51	9.28e-10	Blood metabolite levels;
TGCT	cis	rs9611565	0.512	rs5996063	chr22:42168767	G/A	cg17554472	chr22:41940697	POLR3H	0.46	4.8	0.4	4.46e-6	Vitiligo;
TGCT	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg06108461	chr20:60628389	TAF4	-0.69	-10.64	-0.69	3.59e-19	Body mass index;
TGCT	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg00343986	chr7:65444356	GUSB	-0.22	-5.01	-0.41	1.84e-6	Aortic root size;
TGCT	cis	rs7617773	0.780	rs11718350	chr3:48360992	T/G	cg11946769	chr3:48343235	NME6	0.82	7.08	0.54	9.69e-11	Coronary artery disease;
TGCT	cis	rs12136530	0.593	rs12125806	chr1:19734781	A/G	cg24875000	chr1:19041556	PAX7	-0.26	-4.62	-0.38	9.56e-6	Lead levels in blood;
TGCT	cis	rs68170813	0.559	rs12538090	chr7:106974647	T/C	cg02696742	chr7:106810147	HBP1	-0.66	-5.68	-0.45	9.27e-8	Coronary artery disease;
TGCT	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg24531977	chr5:56204891	C5orf35	-0.66	-6.92	-0.53	2.12e-10	Initial pursuit acceleration;
TGCT	cis	rs11190604	1.000	rs11190572	chr10:102232879	A/G	cg23241863	chr10:102295624	HIF1AN	0.62	4.87	0.4	3.27e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs4880487	0.505	rs4880778	chr10:1205810	C/G	cg03183215	chr10:1252341	ADARB2	-0.24	-4.73	-0.39	5.99e-6	Migraine;
TGCT	cis	rs3902035	0.964	rs62422258	chr6:119007427	T/G	cg07617317	chr6:118971624	C6orf204	0.43	5.01	0.41	1.79e-6	QT interval;
TGCT	cis	rs2836974	0.799	rs8129303	chr21:40711959	G/A	cg11644478	chr21:40555479	PSMG1	0.9	8.16	0.59	3.16e-13	Cognitive function;
TGCT	cis	rs7917772	0.636	rs1475644	chr10:104491164	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.59	4.83	0.4	3.92e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1843834	0.539	rs2068244	chr2:225440011	A/G	cg22455342	chr2:225449267	CUL3	-1.06	-10.84	-0.7	1.16e-19	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs58235267	0.656	rs13410889	chr2:63087778	T/C	cg17519650	chr2:63277830	OTX1	0.55	5.07	0.41	1.44e-6	Prostate-specific antigen levels (conditioned on lead SNPs);
TGCT	cis	rs3733585	0.673	rs7377578	chr4:9952775	T/C	cg11266682	chr4:10021025	SLC2A9	-0.57	-7.6	-0.56	6.21e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	trans	rs1814175	0.607	rs11493324	chr11:50011304	T/C	cg03929089	chr4:120376271	NA	-0.6	-6.94	-0.53	1.9e-10	Height;
TGCT	cis	rs2153535	0.580	rs9379213	chr6:8474945	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs6880778	0.505	rs11952844	chr5:40384295	G/C	cg01087697	chr5:40835557	RPL37	0.55	4.91	0.4	2.86e-6	Inflammatory bowel disease;
TGCT	cis	rs9549260	0.651	rs9549251	chr13:41228650	A/G	cg21288729	chr13:41239152	FOXO1	0.99	10.42	0.68	1.22e-18	Red blood cell count;
TGCT	cis	rs9473924	0.542	rs67538952	chr6:50894400	T/C	cg14470998	chr6:50812995	TFAP2B	1.35	8.39	0.6	9.05e-14	Body mass index;
TGCT	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	4.63	0.38	9.19e-6	Height;
TGCT	cis	rs7089973	0.604	rs765173	chr10:116601675	C/T	cg03647239	chr10:116582469	FAM160B1	0.61	5.86	0.47	3.87e-8	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs2637266	0.967	rs2579760	chr10:78321768	A/C	cg18941641	chr10:78392320	NA	0.39	4.84	0.4	3.73e-6	Pulmonary function;
TGCT	cis	rs2075371	1.000	rs7486	chr7:133975183	A/G	cg11752832	chr7:134001865	SLC35B4	0.7	6.51	0.5	1.68e-9	Mean platelet volume;
TGCT	cis	rs4796354	0.676	rs12951137	chr17:6695697	A/G	cg04115740	chr17:6690948	FBXO39	0.25	4.54	0.38	1.32e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10089	1.000	rs6595800	chr5:127411647	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	6.93	0.53	2e-10	Ileal carcinoids;
TGCT	cis	rs80282103	0.867	rs7098169	chr10:1078601	G/A	cg18964960	chr10:1102726	WDR37	1.13	4.43	0.37	2.01e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg26039829	chr8:22132926	PIWIL2	0.27	5.13	0.42	1.1e-6	Hypertriglyceridemia;
TGCT	cis	rs6088580	0.567	rs6088520	chr20:33132364	A/G	cg08999081	chr20:33150536	PIGU	-0.27	-5.32	-0.43	4.72e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs7698623	0.702	rs4693884	chr4:88770229	C/T	cg02735620	chr4:88950514	PKD2	0.44	4.81	0.4	4.22e-6	Cardiovascular disease risk factors;
TGCT	cis	rs7727544	0.740	rs419291	chr5:131633355	T/C	cg24060327	chr5:131705240	SLC22A5	-0.56	-6.07	-0.48	1.45e-8	Blood metabolite levels;
TGCT	trans	rs9990220	0.586	rs12106967	chr3:112060758	T/C	cg23646235	chr19:36164513	UPK1A	-0.48	-6.69	-0.51	6.93e-10	Eosinophil percentage of white cells;
TGCT	cis	rs11098499	0.820	rs6534140	chr4:120455311	C/T	cg09307838	chr4:120376055	NA	0.69	6.53	0.51	1.49e-9	Corneal astigmatism;
TGCT	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg04013166	chr16:89971882	TCF25	0.33	4.47	0.37	1.75e-5	Skin colour saturation;
TGCT	cis	rs7617773	0.779	rs9833309	chr3:48327450	C/T	cg11946769	chr3:48343235	NME6	0.74	6.34	0.49	3.97e-9	Coronary artery disease;
TGCT	cis	rs5769765	0.624	rs2285187	chr22:50185432	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.95	-8.54	-0.61	4.11e-14	Schizophrenia;
TGCT	cis	rs2458413	0.586	rs2669453	chr8:105368930	C/A	cg04554929	chr8:105342491	NA	0.51	6.34	0.49	3.86e-9	Paget's disease;
TGCT	cis	rs7659604	0.935	rs73844280	chr4:122664687	G/A	cg19748678	chr4:122722346	EXOSC9	0.57	5.5	0.44	2.07e-7	Type 2 diabetes;
TGCT	cis	rs7926906	0.577	rs1981424	chr11:90516272	C/T	cg26138821	chr11:89956704	CHORDC1	-0.48	-4.85	-0.4	3.61e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9611565	0.592	rs5758427	chr22:42099688	A/G	cg06634786	chr22:41940651	POLR3H	0.89	9.09	0.63	1.96e-15	Vitiligo;
TGCT	cis	rs2692947	0.727	rs1657502	chr2:96795608	A/C	cg23100626	chr2:96804247	ASTL	0.43	5.32	0.43	4.67e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	trans	rs877282	0.945	rs10904555	chr10:787740	C/A	cg22713356	chr15:30763199	NA	1.16	10.26	0.68	3.01e-18	Uric acid levels;
TGCT	cis	rs6089829	0.962	rs6089825	chr20:61668447	C/T	cg02380750	chr20:61661411	NA	0.34	6.02	0.48	1.85e-8	Prostate cancer (SNP x SNP interaction);
TGCT	trans	rs114540395	0.858	rs117998275	chr10:103183891	T/G	cg10198749	chr1:39920707	MACF1	0.52	7.12	0.54	7.77e-11	Schizophrenia;
TGCT	cis	rs6582630	0.537	rs11611326	chr12:38547958	C/A	cg26384229	chr12:38710491	ALG10B	0.85	7.75	0.57	2.91e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs4845570	1.000	rs4845579	chr1:151770138	C/T	cg07092448	chr1:151763213	TDRKH	-1.13	-9.59	-0.65	1.26e-16	Coronary artery disease;
TGCT	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg20607798	chr8:58055168	NA	0.49	5.76	0.46	6.31e-8	Developmental language disorder (linguistic errors);
TGCT	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg18402987	chr7:1209562	NA	0.69	6.05	0.48	1.58e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs12478296	0.901	rs59477854	chr2:243015490	T/C	cg06360820	chr2:242988706	NA	-0.59	-4.83	-0.4	3.89e-6	Obesity-related traits;
TGCT	cis	rs3740393	0.562	rs72845847	chr10:104531606	A/G	cg05855489	chr10:104503620	C10orf26	0.79	6.32	0.49	4.23e-9	Microalbuminuria;
TGCT	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg22963979	chr7:1858916	MAD1L1	-0.38	-5.99	-0.47	2.13e-8	Bipolar disorder and schizophrenia;
TGCT	trans	rs797680	0.856	rs11164876	chr1:93630510	T/C	cg27528825	chr2:159282178	CCDC148	-0.35	-6.78	-0.52	4.27e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs9883204	1.000	rs2124500	chr3:123093530	T/C	cg04890266	chr3:123102914	ADCY5	-0.36	-5.11	-0.42	1.17e-6	Birth weight;
TGCT	cis	rs2549003	0.870	rs61175929	chr5:131821548	C/G	cg21138405	chr5:131827807	IRF1	0.19	4.82	0.4	4.09e-6	Asthma (sex interaction);
TGCT	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg01416388	chr22:39784598	NA	0.72	7.55	0.56	8.25e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.800	rs1559858	chr4:99024075	A/G	cg17366294	chr4:99064904	C4orf37	0.73	7.55	0.56	8.37e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2439831	0.867	rs4583210	chr15:43660925	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	6.61	0.51	1e-9	Lung cancer in ever smokers;
TGCT	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg04234412	chr22:24373322	LOC391322	-0.92	-11.41	-0.72	4.62e-21	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	trans	rs7618501	0.521	rs11712056	chr3:49914397	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.85	8.93	0.63	4.73e-15	Intelligence (multi-trait analysis);
TGCT	trans	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg11887960	chr12:57824829	NA	1.14	9.28	0.64	6.87e-16	Obesity-related traits;
TGCT	cis	rs4819052	0.765	rs2838827	chr21:46656146	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.69	6.07	0.48	1.41e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg03517284	chr6:25882590	NA	-0.66	-5.8	-0.46	5.14e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs6570726	0.818	rs437147	chr6:145875423	A/T	cg13319975	chr6:146136371	FBXO30	-0.51	-4.6	-0.38	1.01e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg17264618	chr3:40429014	ENTPD3	-0.32	-4.45	-0.37	1.9e-5	Renal cell carcinoma;
TGCT	cis	rs7542091	0.669	rs7540534	chr1:210044824	A/T	cg21951975	chr1:209979733	IRF6	0.6	6.1	0.48	1.24e-8	Monobrow;
TGCT	cis	rs4786125	0.665	rs6500857	chr16:6903364	C/T	cg03623568	chr16:6915990	A2BP1	-0.42	-6.03	-0.48	1.72e-8	Heart rate variability traits (SDNN);
TGCT	cis	rs11098499	0.954	rs59394118	chr4:120295551	A/G	cg09307838	chr4:120376055	NA	0.66	6.46	0.5	2.15e-9	Corneal astigmatism;
TGCT	cis	rs1215050	0.782	rs6532693	chr4:98655815	T/C	cg17366294	chr4:99064904	C4orf37	-0.52	-5.51	-0.44	1.97e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2692947	0.644	rs1030864	chr2:96822373	A/G	cg23100626	chr2:96804247	ASTL	0.47	5.57	0.45	1.52e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg11494091	chr17:61959527	GH2	0.61	14.35	0.79	4.1e-28	Prudent dietary pattern;
TGCT	trans	rs2469997	1.000	rs2447171	chr8:120360953	C/T	cg01792902	chr3:178864926	PIK3CA	0.83	6.77	0.52	4.49e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs7267979	1.000	rs2482931	chr20:25334445	G/A	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7714584	1.000	rs1896708	chr5:150245076	A/T	cg22134413	chr5:150180641	NA	0.87	6.75	0.52	4.97e-10	Crohn's disease;
TGCT	cis	rs9611519	0.507	rs12484525	chr22:41443877	G/C	cg03806693	chr22:41940476	POLR3H	-0.59	-5.48	-0.44	2.29e-7	Neuroticism;
TGCT	cis	rs7267979	1.000	rs4815421	chr20:25386509	G/A	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9902453	0.904	rs4994353	chr17:28386280	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-6.56	-0.51	1.3e-9	Coffee consumption (cups per day);
TGCT	cis	rs950169	0.881	rs34117475	chr15:85108443	T/C	cg17173187	chr15:85201210	NMB	0.48	5.02	0.41	1.75e-6	Schizophrenia;
TGCT	cis	rs17376456	0.877	rs9314093	chr5:93333347	G/A	cg25358565	chr5:93447407	FAM172A	0.97	8.5	0.61	5.11e-14	Diabetic retinopathy;
TGCT	cis	rs7666738	0.530	rs2865992	chr4:99067181	A/T	cg05340658	chr4:99064831	C4orf37	0.44	5.3	0.43	5.03e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs739496	0.579	rs9971746	chr12:112337362	A/G	cg10833066	chr12:111807467	FAM109A	-0.38	-5.41	-0.44	3.08e-7	Platelet count;
TGCT	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg18402987	chr7:1209562	NA	0.76	6.6	0.51	1.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs564309	0.681	rs1150918	chr1:228608689	T/C	cg22700015	chr1:228743131	NA	-0.77	-4.57	-0.38	1.16e-5	Hip circumference (psychosocial stress interaction);
TGCT	cis	rs13394619	0.775	rs10200851	chr2:11722082	C/T	cg07314298	chr2:11723111	GREB1	-0.3	-5.05	-0.41	1.54e-6	Endometriosis;
TGCT	cis	rs7666738	0.924	rs13124368	chr4:99039615	T/C	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7772486	0.875	rs6913797	chr6:146413758	A/G	cg23711669	chr6:146136114	FBXO30	0.89	9.47	0.65	2.36e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6882046	0.513	rs2431391	chr5:88046590	C/T	cg22951263	chr5:87985283	NA	-0.55	-5.91	-0.47	3.09e-8	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs1062177	1.000	rs2964576	chr5:151150602	T/G	cg12924095	chr5:151150029	G3BP1	0.35	5.09	0.42	1.31e-6	Preschool internalizing problems;
TGCT	cis	rs12765878	0.580	rs11191840	chr10:105634896	A/T	cg11005552	chr10:105648138	OBFC1	-0.4	-6.28	-0.49	5.19e-9	Coronary artery disease;
TGCT	cis	rs2463822	0.507	rs72919442	chr11:62028707	A/G	cg06239285	chr11:62104954	ASRGL1	-0.91	-5.82	-0.46	4.64e-8	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs7312933	0.567	rs11181399	chr12:42666412	G/A	cg19980929	chr12:42632907	YAF2	0.42	5.87	0.47	3.69e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs6570726	0.791	rs378937	chr6:145834745	C/T	cg13319975	chr6:146136371	FBXO30	-0.5	-4.44	-0.37	2e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg06896619	chr17:61851486	DDX42;CCDC47	-0.48	-4.66	-0.39	8.07e-6	Prudent dietary pattern;
TGCT	cis	rs7439150	1.000	rs1800787	chr4:155484015	C/T	cg22130008	chr4:155548532	NA	-0.47	-5.8	-0.46	5.25e-8	Fibrinogen levels;
TGCT	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	16.05	0.82	4.59e-32	Prudent dietary pattern;
TGCT	cis	rs9393777	0.668	rs3800318	chr6:27263641	A/T	cg11262757	chr6:27280423	POM121L2	0.63	4.69	0.39	7.21e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9400467	0.537	rs12202418	chr6:111451467	A/G	cg15721981	chr6:111408429	SLC16A10	0.71	4.57	0.38	1.15e-5	Blood metabolite levels;Amino acid levels;
TGCT	cis	rs225245	0.755	rs226441	chr17:34033072	C/T	cg05299278	chr17:33885742	SLFN14	0.21	4.53	0.38	1.37e-5	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs7659604	1.000	rs35901586	chr4:122664757	T/A	cg19748678	chr4:122722346	EXOSC9	0.57	5.5	0.44	2.07e-7	Type 2 diabetes;
TGCT	cis	rs56235845	0.694	rs36102285	chr5:176774018	C/T	cg17509989	chr5:176798049	RGS14	0.57	7.78	0.57	2.49e-12	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	4.89	0.4	3e-6	Menopause (age at onset);
TGCT	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg06640241	chr16:89574553	SPG7	0.77	8.86	0.62	7.12e-15	Multiple myeloma (IgH translocation);
TGCT	cis	rs200986	1	rs200986	chr6:27824766	G/C	cg18675097	chr6:28227127	NKAPL	-0.35	-4.57	-0.38	1.18e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7582180	0.629	rs10202326	chr2:100950237	A/G	cg14675211	chr2:100938903	LONRF2	0.53	5.16	0.42	9.36e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg04287289	chr16:89883240	FANCA	0.91	11.7	0.72	9.35e-22	Vitiligo;
TGCT	cis	rs1371867	0.846	rs2919469	chr8:101233896	C/T	cg00191853	chr8:101177733	SPAG1	-0.23	-4.85	-0.4	3.62e-6	Atrioventricular conduction;
TGCT	cis	rs1981331	0.609	rs59121565	chr21:48043023	A/G	cg17243659	chr21:48055224	PRMT2	1.26	6.43	0.5	2.45e-9	Cerebrospinal fluid t-tau:AB1-42 ratio;
TGCT	cis	rs73198271	0.694	rs73201840	chr8:8647067	G/T	cg15556689	chr8:8085844	FLJ10661	-0.6	-4.46	-0.37	1.8e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs77633900	0.614	rs2468120	chr15:76909975	G/A	cg21673338	chr15:77095150	SCAPER	-0.51	-4.82	-0.4	4.09e-6	Non-glioblastoma glioma;Glioma;
TGCT	cis	rs6938	0.618	rs11072514	chr15:75221865	T/A	cg10253484	chr15:75165896	SCAMP2	-0.57	-5.05	-0.41	1.53e-6	Breast cancer;
TGCT	cis	rs11785400	0.793	rs2976400	chr8:143743611	G/A	cg24634471	chr8:143751801	JRK	0.55	5.51	0.44	1.99e-7	Schizophrenia;
TGCT	cis	rs986417	0.818	rs761557	chr14:61077484	C/T	cg07862488	chr14:60977054	SIX6	0.61	5.32	0.43	4.59e-7	Gut microbiota (bacterial taxa);
TGCT	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.5	-6.56	-0.51	1.33e-9	Alzheimer's disease;
TGCT	cis	rs1903068	0.785	rs10013228	chr4:55997340	A/G	cg16572876	chr4:56024045	NA	0.42	4.74	0.39	5.64e-6	Endometriosis;
TGCT	cis	rs7267979	1.000	rs6050602	chr20:25401203	A/G	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2236918	0.622	rs1776177	chr1:242012149	C/T	cg04158730	chr1:242011433	EXO1	0.49	4.5	0.37	1.54e-5	Menopause (age at onset);
TGCT	cis	rs6484504	0.576	rs286653	chr11:31227824	C/T	cg14844989	chr11:31128820	NA	-0.23	-4.46	-0.37	1.83e-5	Red blood cell count;
TGCT	cis	rs4727027	0.933	rs62505074	chr7:148834780	C/T	cg23583168	chr7:148888333	NA	-0.72	-9.18	-0.64	1.18e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs360798	0.857	rs2710636	chr2:63202997	T/C	cg17519650	chr2:63277830	OTX1	0.63	4.54	0.38	1.29e-5	Coronary artery disease;
TGCT	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg03188948	chr7:1209495	NA	0.71	6.04	0.48	1.68e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs10791323	0.604	rs2853116	chr11:133707063	A/G	cg03690763	chr11:133734501	NA	-0.35	-5.38	-0.43	3.58e-7	Childhood ear infection;
TGCT	cis	rs7267979	0.740	rs2259961	chr20:25282626	T/G	cg03522245	chr20:25566470	NINL	0.55	5.55	0.45	1.68e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9916302	0.706	rs8073907	chr17:37424149	C/T	cg07936489	chr17:37558343	FBXL20	-0.84	-6.23	-0.49	6.68e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs55883249	0.957	rs16867083	chr2:9767441	C/T	cg23886495	chr2:9695866	ADAM17	-0.73	-4.94	-0.41	2.52e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs915832	1.000	rs915832	chr21:43275495	C/T	cg14897238	chr21:43198283	NA	0.39	4.53	0.38	1.36e-5	Response to taxane treatment (placlitaxel);
TGCT	cis	rs3749237	0.595	rs17650792	chr3:49390250	A/G	cg02487422	chr3:49467188	NICN1	0.63	6.42	0.5	2.62e-9	Resting heart rate;
TGCT	cis	rs11249608	0.636	rs13359572	chr5:178449276	T/C	cg21905437	chr5:178450457	ZNF879	0.45	4.48	0.37	1.67e-5	Pubertal anthropometrics;
TGCT	cis	rs79419269	0.643	rs73169668	chr7:150930363	C/T	cg03289901	chr7:150933506	CHPF2	0.32	4.45	0.37	1.85e-5	Immunoglobulin light chain (AL) amyloidosis;
TGCT	cis	rs9811920	0.809	rs6806323	chr3:99722564	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.46	5.18	0.42	8.58e-7	Axial length;
TGCT	cis	rs185694	1.000	rs846498	chr13:30900541	A/G	cg07600127	chr13:30881527	KATNAL1	-0.81	-6.53	-0.51	1.53e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
TGCT	cis	rs6978712	0.685	rs7784284	chr7:127155188	G/A	cg02908720	chr7:127292155	SND1	-0.7	-4.47	-0.37	1.71e-5	Medication adherence in chronic diseases;
TGCT	cis	rs2228479	0.850	rs11640188	chr16:89807732	C/T	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs7264396	0.676	rs6060723	chr20:34549947	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.04	-0.41	1.58e-6	Total cholesterol levels;
TGCT	cis	rs7552404	0.731	rs1493367	chr1:76344011	C/A	cg10523679	chr1:76189770	ACADM	-0.83	-7.8	-0.57	2.24e-12	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9325144	0.560	rs11183189	chr12:38683770	T/A	cg26384229	chr12:38710491	ALG10B	0.64	5.77	0.46	5.98e-8	Morning vs. evening chronotype;
TGCT	cis	rs3806843	0.576	rs246064	chr5:140324309	C/G	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9906944	0.933	rs12945020	chr17:47082775	G/A	cg20966754	chr17:47091339	IGF2BP1	-0.43	-4.95	-0.41	2.36e-6	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs7833790	1.000	rs7833790	chr8:82731157	T/C	cg23324259	chr8:82754387	SNX16	-0.65	-4.6	-0.38	1.04e-5	Diastolic blood pressure;
TGCT	cis	rs11105298	0.891	rs10858906	chr12:89934474	C/T	cg00757033	chr12:89920650	WDR51B	0.29	4.6	0.38	1.01e-5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs6815814	0.950	rs114719937	chr4:38808585	G/C	cg02016764	chr4:38805732	TLR1	-0.35	-5.65	-0.45	1.04e-7	Breast cancer;
TGCT	cis	rs796364	1.000	rs281785	chr2:200749566	A/G	cg17644776	chr2:200775616	C2orf69	0.31	4.83	0.4	3.99e-6	Schizophrenia;
TGCT	cis	rs7017914	0.905	rs1908033	chr8:71922799	C/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.55	-5.1	-0.42	1.24e-6	Bone mineral density;
TGCT	cis	rs7027203	0.576	rs4509402	chr9:96543377	C/T	cg13679303	chr9:96623674	NA	0.53	7.61	0.56	6.13e-12	DNA methylation (variation);
TGCT	cis	rs4237845	0.804	rs11172372	chr12:58286273	T/C	cg02175503	chr12:58329896	NA	0.51	5.26	0.43	6.21e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg09359103	chr1:154839909	KCNN3	-0.66	-12.15	-0.74	7.27e-23	Prostate cancer;
TGCT	trans	rs4650994	1.000	rs12138561	chr1:178518784	G/T	cg05059571	chr16:84539110	KIAA1609	-0.4	-7.43	-0.56	1.54e-11	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs71597109	0.957	rs2052445	chr4:102738722	A/G	cg14855874	chr4:102712397	BANK1	0.42	4.43	0.37	2.01e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs4689388	0.853	rs13103357	chr4:6294544	A/G	cg14416269	chr4:6271139	WFS1	0.37	4.9	0.4	2.95e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7552404	0.655	rs1146646	chr1:76265500	G/A	cg03433033	chr1:76189801	ACADM	0.6	6.39	0.5	3.02e-9	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs1008375	0.966	rs2010053	chr4:17583806	A/C	cg18681998	chr4:17616180	MED28	0.94	9.56	0.65	1.44e-16	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs13326165	0.715	rs34908451	chr3:52385115	C/T	cg27565382	chr3:53032988	SFMBT1	0.37	4.9	0.4	2.97e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs208520	0.690	rs207114	chr6:66791703	C/T	cg07460842	chr6:66804631	NA	-0.96	-10.02	-0.67	1.14e-17	Exhaled nitric oxide output;
TGCT	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.61	0.38	9.85e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	trans	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg17470723	chr8:74884337	TCEB1	0.74	6.92	0.53	2.19e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs539096	0.505	rs501861	chr1:44101440	T/A	cg12908607	chr1:44402522	ARTN	-0.56	-5.99	-0.47	2.08e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9733	0.596	rs11586422	chr1:150679358	C/T	cg04414720	chr1:150670196	GOLPH3L	0.37	4.91	0.4	2.76e-6	Tonsillectomy;
TGCT	cis	rs7100689	0.646	rs9804233	chr10:82134667	T/C	cg01528321	chr10:82214614	TSPAN14	0.8	7.72	0.57	3.42e-12	Post bronchodilator FEV1;
TGCT	cis	rs6570726	0.791	rs427128	chr6:145865917	T/C	cg05347473	chr6:146136440	FBXO30	0.54	5.15	0.42	1.01e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9926296	0.581	rs1108064	chr16:89894150	G/C	cg08627397	chr16:89984028	MC1R	-0.3	-4.68	-0.39	7.47e-6	Vitiligo;
TGCT	cis	rs858239	0.570	rs6968242	chr7:23167411	T/G	cg05602783	chr7:23145260	KLHL7	-0.65	-5.48	-0.44	2.32e-7	Cerebrospinal fluid biomarker levels;
TGCT	trans	rs8073060	0.586	rs225303	chr17:33922149	A/G	cg19694781	chr19:47549865	TMEM160	0.59	13.16	0.76	2.77e-25	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg11764359	chr7:65958608	NA	-0.61	-5.36	-0.43	3.96e-7	Aortic root size;
TGCT	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg01238044	chr22:24384105	GSTT1	-0.57	-5.54	-0.45	1.7e-7	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs13326165	0.760	rs13076890	chr3:52407933	T/C	cg07884673	chr3:53033167	SFMBT1	0.39	4.69	0.39	7e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs924607	1.000	rs1697978	chr5:642829	A/G	cg18765565	chr5:669397	TPPP	0.59	6.3	0.49	4.73e-9	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs12142240	0.698	rs1057534	chr1:46815880	A/C	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs6570726	0.791	rs9390336	chr6:145896823	A/T	cg23711669	chr6:146136114	FBXO30	0.86	9.54	0.65	1.64e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2594989	0.565	rs7621843	chr3:11603229	T/G	cg00170343	chr3:11313890	ATG7	-0.66	-5.03	-0.41	1.69e-6	Circulating chemerin levels;
TGCT	cis	rs7772486	0.686	rs6570705	chr6:145961201	C/T	cg23711669	chr6:146136114	FBXO30	0.84	9.16	0.64	1.36e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs12477438	0.520	rs34766932	chr2:99737273	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	12.84	0.76	1.57e-24	Chronic sinus infection;
TGCT	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg08280861	chr8:58055591	NA	0.39	4.56	0.38	1.2e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs682748	0.846	rs12655526	chr5:17128613	A/G	cg23987134	chr5:17158319	LOC285696	-0.21	-5.11	-0.42	1.21e-6	Hippocampal atrophy;
TGCT	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg11890956	chr21:40555474	PSMG1	-0.69	-6.72	-0.52	5.77e-10	Menarche (age at onset);
TGCT	cis	rs6988636	1.000	rs58741168	chr8:124191852	G/A	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs4919669	0.668	rs7086898	chr10:104386152	A/G	cg05855489	chr10:104503620	C10orf26	0.71	4.69	0.39	7.18e-6	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs7208859	0.673	rs9899525	chr17:29120296	T/A	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs797680	0.964	rs1856027	chr1:93544131	T/C	cg17826107	chr1:92977322	EVI5	-0.21	-4.94	-0.41	2.51e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs1949733	0.701	rs940136	chr4:8448992	G/A	cg11789530	chr4:8429930	ACOX3	0.53	4.99	0.41	2e-6	Response to antineoplastic agents;
TGCT	cis	rs9549367	1.000	rs9549367	chr13:113911532	C/G	cg00898013	chr13:113819073	PROZ	-0.38	-4.68	-0.39	7.39e-6	Platelet distribution width;
TGCT	cis	rs478304	0.934	rs474483	chr11:65520060	T/G	cg17480646	chr11:65405466	SIPA1	0.43	5.38	0.43	3.62e-7	Acne (severe);
TGCT	cis	rs4803468	1.000	rs17318666	chr19:41940342	T/G	cg09537434	chr19:41945824	ATP5SL	0.91	10.05	0.67	9.48e-18	Height;
TGCT	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg08439880	chr3:133502540	NA	0.32	6.08	0.48	1.34e-8	Iron status biomarkers;
TGCT	cis	rs3796352	1.000	rs13074524	chr3:52974184	A/G	cg07884673	chr3:53033167	SFMBT1	0.6	5.53	0.44	1.82e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs35160687	0.901	rs34069316	chr2:86529792	T/C	cg12542933	chr2:85804724	VAMP8	0.41	4.9	0.4	2.97e-6	Night sleep phenotypes;
TGCT	cis	rs7647973	0.667	rs11721148	chr3:49646669	G/A	cg03060546	chr3:49711283	APEH	0.63	5.14	0.42	1.03e-6	Menarche (age at onset);
TGCT	cis	rs1403694	0.966	rs1656910	chr3:186438993	A/C	cg12454167	chr3:186435060	KNG1	0.42	7.28	0.55	3.38e-11	Blood protein levels;
TGCT	cis	rs2439831	1.000	rs550239	chr15:43720197	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.01	8.37	0.6	1.02e-13	Lung cancer in ever smokers;
TGCT	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	8.55	0.61	3.84e-14	Platelet count;
TGCT	cis	rs7223966	1.000	rs2854218	chr17:61942940	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	4.62	0.38	9.63e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs7617773	0.817	rs6800492	chr3:48323890	G/A	cg11946769	chr3:48343235	NME6	0.72	6.12	0.48	1.14e-8	Coronary artery disease;
TGCT	cis	rs4455778	0.580	rs4529410	chr7:49125486	C/T	cg26309511	chr7:48887640	NA	0.48	6.25	0.49	6.09e-9	Lung cancer in never smokers;
TGCT	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg16228356	chr17:43848958	NA	-0.26	-4.62	-0.38	9.47e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7666738	0.830	rs11931166	chr4:99054187	A/T	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1451375	1.000	rs1451374	chr7:50622653	G/A	cg18232548	chr7:50535776	DDC	0.43	6.8	0.52	3.98e-10	Malaria;
TGCT	cis	rs7103648	0.695	rs7933019	chr11:47509137	G/C	cg20307385	chr11:47447363	PSMC3	0.87	8.49	0.61	5.4e-14	Diastolic blood pressure;Systolic blood pressure;
TGCT	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg22920501	chr2:26401640	FAM59B	-0.71	-6.41	-0.5	2.81e-9	Gut microbiome composition (summer);
TGCT	cis	rs73058052	0.597	rs11878568	chr19:50095961	T/C	cg09250473	chr19:50168907	IRF3;BCL2L12	0.68	5.93	0.47	2.83e-8	Fibrinogen levels;
TGCT	cis	rs644799	1.000	rs474252	chr11:95619292	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	9.85	0.66	2.9e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs12210905	1.000	rs12209393	chr6:27085073	C/T	cg08851530	chr6:28072375	NA	1.21	5.58	0.45	1.43e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg03452623	chr4:187889614	NA	-0.36	-5.46	-0.44	2.45e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11118844	0.793	rs10218652	chr1:221947406	T/C	cg04222084	chr1:221915650	DUSP10	-0.72	-5.05	-0.41	1.51e-6	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
TGCT	cis	rs78487399	0.908	rs76765584	chr2:43808034	C/A	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.66	4.67	0.39	7.66e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs1577917	0.958	rs16876530	chr6:86595641	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.16	-0.42	9.71e-7	Response to antipsychotic treatment;
TGCT	cis	rs1865760	0.566	rs4529296	chr6:26083135	C/G	cg16482183	chr6:26056742	HIST1H1C	0.58	4.97	0.41	2.13e-6	Height;
TGCT	cis	rs2242116	0.761	rs6780601	chr3:46965856	A/G	cg02527881	chr3:46936655	PTH1R	-0.33	-6.09	-0.48	1.29e-8	Birth weight;
TGCT	cis	rs908922	0.885	rs2181173	chr1:152474866	A/T	cg20991723	chr1:152506922	NA	-0.46	-6.3	-0.49	4.81e-9	Hair morphology;
TGCT	cis	rs1532993	0.518	rs6822846	chr4:98636833	A/G	cg05340658	chr4:99064831	C4orf37	-0.41	-4.92	-0.4	2.72e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs12477438	0.520	rs4588238	chr2:99749350	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.82	0.62	8.67e-15	Chronic sinus infection;
TGCT	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.18	0.49	8.32e-9	Bipolar disorder;
TGCT	cis	rs137699	1.000	rs2049986	chr22:39756854	C/G	cg05872129	chr22:39784769	NA	0.58	5.17	0.42	8.97e-7	IgG glycosylation;
TGCT	cis	rs2933343	0.700	rs6787833	chr3:128656184	A/G	cg11901034	chr3:128598214	ACAD9	-0.65	-6.08	-0.48	1.38e-8	IgG glycosylation;
TGCT	cis	rs13177918	0.677	rs2073472	chr5:149824067	T/C	cg14059543	chr5:149831962	NA	-0.71	-9.34	-0.64	4.91e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs1865760	0.622	rs10946807	chr6:26079638	T/C	cg17042849	chr6:26104293	HIST1H4C	-0.85	-7.46	-0.56	1.29e-11	Height;
TGCT	cis	rs9549260	0.539	rs4943813	chr13:41338134	G/C	cg21288729	chr13:41239152	FOXO1	0.95	9.2	0.64	1.08e-15	Red blood cell count;
TGCT	cis	rs259282	0.605	rs66489063	chr19:33108959	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.6	5.34	0.43	4.25e-7	Schizophrenia;
TGCT	cis	rs709400	0.663	rs10133035	chr14:103979127	C/T	cg12935359	chr14:103987150	CKB	-0.38	-5.7	-0.46	8.3e-8	Body mass index;
TGCT	cis	rs7584330	0.780	rs12474519	chr2:238377012	G/A	cg14458575	chr2:238380390	NA	0.5	8.08	0.59	4.96e-13	Prostate cancer;
TGCT	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg06221963	chr1:154839813	KCNN3	-0.75	-12.65	-0.75	4.66e-24	Prostate cancer;
TGCT	cis	rs7635838	0.819	rs2454481	chr3:11535178	C/T	cg00170343	chr3:11313890	ATG7	0.68	6.36	0.5	3.46e-9	HDL cholesterol;
TGCT	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg13206674	chr6:150067644	NUP43	0.51	4.45	0.37	1.91e-5	Lung cancer;
TGCT	cis	rs68170813	0.559	rs11769527	chr7:106912948	C/T	cg02696742	chr7:106810147	HBP1	-0.69	-5.61	-0.45	1.27e-7	Coronary artery disease;
TGCT	cis	rs79349575	0.783	rs318095	chr17:46974734	T/C	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.47	-0.37	1.72e-5	Type 2 diabetes;
TGCT	cis	rs11118844	0.793	rs12136350	chr1:221943347	C/T	cg04222084	chr1:221915650	DUSP10	-0.89	-5.75	-0.46	6.42e-8	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
TGCT	cis	rs3008870	0.651	rs2815376	chr1:67508531	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.7	6.81	0.52	3.66e-10	Lymphocyte percentage of white cells;
TGCT	cis	rs4722166	0.630	rs12700391	chr7:22777327	C/A	cg26061582	chr7:22766209	IL6	0.57	7.36	0.55	2.27e-11	Lung cancer;
TGCT	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg24829409	chr8:58192753	C8orf71	-0.58	-5.32	-0.43	4.67e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs34034915	1	rs34034915	chr6:27720703	T/TG	cg10876282	chr6:28092338	ZSCAN16	0.5	5.09	0.42	1.29e-6	Hepatitis A;
TGCT	cis	rs5750830	0.594	rs9611166	chr22:39775268	T/C	cg11247378	chr22:39784982	NA	-0.64	-8.48	-0.61	5.71e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg11890956	chr21:40555474	PSMG1	1.11	12.54	0.75	8.57e-24	Cognitive function;
TGCT	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg14008862	chr17:28927542	LRRC37B2	-0.72	-4.61	-0.38	9.83e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs473651	0.716	rs548179	chr2:239320505	G/A	cg18131467	chr2:239335373	ASB1	0.97	12.97	0.76	7.62e-25	Multiple system atrophy;
TGCT	cis	rs2204008	0.774	rs11495520	chr12:38060605	T/G	cg13010199	chr12:38710504	ALG10B	0.65	5.29	0.43	5.47e-7	Bladder cancer;
TGCT	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg18402987	chr7:1209562	NA	0.78	6.54	0.51	1.46e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs12497850	0.931	rs7430198	chr3:48988760	T/C	cg07636037	chr3:49044803	WDR6	0.96	10.52	0.69	6.9e-19	Parkinson's disease;
TGCT	cis	rs6674176	0.660	rs6801	chr1:44396646	C/G	cg13606994	chr1:44402422	ARTN	0.49	5.4	0.44	3.22e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs7615952	0.800	rs13086460	chr3:125646417	C/T	cg05084668	chr3:125655381	ALG1L	-0.75	-6.07	-0.48	1.41e-8	Blood pressure (smoking interaction);
TGCT	cis	rs11190604	1.000	rs7099913	chr10:102314777	T/C	cg16342193	chr10:102329863	NA	-0.39	-4.95	-0.41	2.36e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg06753367	chr22:24256600	NA	-0.25	-4.73	-0.39	5.98e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	8.99	0.63	3.48e-15	Platelet count;
TGCT	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg10053473	chr17:62856997	LRRC37A3	-0.46	-6.76	-0.52	4.77e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs35934224	0.783	rs35554477	chr22:19856561	G/A	cg11182965	chr22:19864308	TXNRD2	-0.36	-4.95	-0.41	2.33e-6	Glaucoma (primary open-angle);
TGCT	cis	rs7267979	1.000	rs4815418	chr20:25382211	T/G	cg03522245	chr20:25566470	NINL	-0.64	-7.05	-0.53	1.12e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs739401	0.611	rs12284275	chr11:3024384	T/C	cg25174290	chr11:3078921	CARS	0.5	4.83	0.4	4.01e-6	Longevity;
TGCT	cis	rs9303401	0.659	rs34556735	chr17:56694447	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	trans	rs62103177	0.636	rs9958792	chr18:77627876	T/C	cg05926928	chr17:57297772	GDPD1	-0.93	-8.77	-0.62	1.15e-14	Opioid sensitivity;
TGCT	cis	rs4851254	0.920	rs4850920	chr2:100757308	C/A	cg23118464	chr2:100721844	AFF3	0.7	5.17	0.42	9.07e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7412746	0.622	rs72704654	chr1:150826410	G/A	cg09365446	chr1:150670422	GOLPH3L	0.35	4.98	0.41	2.11e-6	Melanoma;
TGCT	cis	rs9650657	0.707	rs4841452	chr8:10687121	A/G	cg27411982	chr8:10470053	RP1L1	-0.23	-5.08	-0.42	1.35e-6	Neuroticism;
TGCT	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	5.03	0.41	1.69e-6	Prudent dietary pattern;
TGCT	cis	rs3796352	1.000	rs2564926	chr3:53094730	G/A	cg15956490	chr3:53032818	SFMBT1	-0.58	-6.57	-0.51	1.22e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs295140	0.535	rs6743157	chr2:201230076	C/T	cg04283868	chr2:201171347	SPATS2L	0.52	4.99	0.41	2.02e-6	QT interval;
TGCT	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg13206674	chr6:150067644	NUP43	0.53	4.56	0.38	1.23e-5	Lung cancer;
TGCT	cis	rs1801251	0.778	rs778338	chr2:233740227	A/G	cg25237894	chr2:233734115	C2orf82	-0.29	-5.61	-0.45	1.23e-7	Coronary artery disease;
TGCT	cis	rs12579753	0.789	rs1343933	chr12:82123301	A/C	cg21231944	chr12:82153410	PPFIA2	-0.36	-4.67	-0.39	7.86e-6	Resting heart rate;
TGCT	cis	rs1691799	0.867	rs1027399	chr12:66760942	G/A	cg16791601	chr12:66731901	HELB	-0.29	-6.17	-0.48	8.9e-9	White blood cell count (basophil);
TGCT	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg12311346	chr5:56204834	C5orf35	-0.66	-6.65	-0.51	8.41e-10	Initial pursuit acceleration;
TGCT	cis	rs7647973	0.516	rs4955419	chr3:49200692	T/A	cg02487422	chr3:49467188	NICN1	0.51	4.89	0.4	3.1e-6	Menarche (age at onset);
TGCT	cis	rs9325144	0.647	rs35254764	chr12:39102928	T/C	cg10518543	chr12:38710700	ALG10B	-0.49	-4.55	-0.38	1.25e-5	Morning vs. evening chronotype;
TGCT	cis	rs7681440	0.904	rs35424815	chr4:90767877	C/T	cg14346243	chr4:90757452	SNCA	-0.57	-5.6	-0.45	1.31e-7	Dementia with Lewy bodies;
TGCT	cis	rs67385638	0.962	rs72872549	chr11:5290053	C/T	cg12559170	chr11:5275217	HBG2	0.46	8.25	0.6	1.97e-13	Hemoglobin levels;
TGCT	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.51	-5.85	-0.47	4.02e-8	Longevity;Endometriosis;
TGCT	cis	rs228437	0.526	rs228434	chr6:134896214	A/G	cg09872934	chr6:134495829	SGK1	-0.5	-4.62	-0.38	9.58e-6	Melanoma;
TGCT	cis	rs6815814	0.851	rs11466617	chr4:38780471	T/C	cg02016764	chr4:38805732	TLR1	-0.35	-5.51	-0.44	1.96e-7	Breast cancer;
TGCT	cis	rs225245	0.755	rs8078905	chr17:34009029	T/C	cg05299278	chr17:33885742	SLFN14	0.21	4.5	0.37	1.56e-5	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg13206674	chr6:150067644	NUP43	0.51	4.47	0.37	1.75e-5	Lung cancer;
TGCT	cis	rs9346649	0.802	rs1109191	chr6:168495750	G/A	cg02770688	chr6:168491649	NA	-0.31	-6.01	-0.47	1.94e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
TGCT	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg06221963	chr1:154839813	KCNN3	-0.76	-13.39	-0.77	7.63e-26	Prostate cancer;
TGCT	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	6.78	0.52	4.27e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6570726	0.935	rs366308	chr6:145814532	T/A	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.16e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg21862992	chr11:68658383	NA	0.46	6.24	0.49	6.48e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.74	-8.07	-0.59	5.16e-13	Uric acid levels;
TGCT	cis	rs4906332	1.000	rs10459573	chr14:103925457	A/C	cg26031613	chr14:104095156	KLC1	-0.53	-4.71	-0.39	6.62e-6	Coronary artery disease;
TGCT	cis	rs6591182	0.503	rs11227241	chr11:65389890	G/C	cg27068330	chr11:65405492	SIPA1	-0.81	-8.06	-0.59	5.51e-13	Non-alcoholic fatty liver disease histology (lobular);
TGCT	cis	rs34014631	1.000	rs79515366	chr10:103582573	A/G	cg22630918	chr10:102748988	C10orf2	0.43	4.83	0.4	3.98e-6	Coronary artery calcification;
TGCT	cis	rs79057730	0.599	rs112891948	chr7:816059	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.74	5.64	0.45	1.08e-7	Initial pursuit acceleration;
TGCT	cis	rs13191362	1.000	rs13191362	chr6:163033350	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.93	8.25	0.6	2e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs1023500	0.506	rs6002625	chr22:42517689	A/G	cg05082376	chr22:42548792	NA	0.22	5.42	0.44	2.99e-7	Schizophrenia;
TGCT	cis	rs7552404	0.727	rs12093623	chr1:76256232	T/G	cg22875332	chr1:76189707	ACADM	0.63	6.71	0.52	6.24e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg03709012	chr19:19516395	GATAD2A	0.76	6.42	0.5	2.64e-9	Tonsillectomy;
TGCT	cis	rs9309473	0.687	rs6748040	chr2:73609928	A/G	cg20560298	chr2:73613845	ALMS1	0.43	4.81	0.4	4.38e-6	Metabolite levels;
TGCT	trans	rs9858542	0.953	rs9837341	chr3:49664767	A/G	cg21659725	chr3:3221576	CRBN	-0.69	-6.62	-0.51	9.63e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs2153535	0.580	rs4404802	chr6:8442052	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.58	0.45	1.42e-7	Motion sickness;
TGCT	cis	rs9357506	0.935	rs4481428	chr6:46310647	A/G	cg21115430	chr6:46460003	NA	-0.26	-5.16	-0.42	9.6e-7	Body mass index;
TGCT	trans	rs57221529	0.709	rs72703090	chr5:598314	C/T	cg25482853	chr8:67687455	SGK3	1.27	10.56	0.69	5.48e-19	Lung disease severity in cystic fibrosis;
TGCT	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	5.02	0.41	1.78e-6	Prudent dietary pattern;
TGCT	cis	rs4478858	0.735	rs4949384	chr1:31792141	A/G	cg07478791	chr1:31886160	SERINC2	-0.47	-4.52	-0.38	1.43e-5	Alcohol dependence;
TGCT	trans	rs3780486	0.846	rs10124479	chr9:33136233	T/G	cg20290983	chr6:43655470	MRPS18A	1.2	14.83	0.8	3.07e-29	IgG glycosylation;
TGCT	trans	rs8073060	0.586	rs225280	chr17:33976296	C/T	cg19694781	chr19:47549865	TMEM160	-0.6	-13.37	-0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	trans	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg21659725	chr3:3221576	CRBN	-0.99	-15.57	-0.81	5.76e-31	Intelligence (multi-trait analysis);
TGCT	cis	rs2236918	0.710	rs1776130	chr1:242023362	A/G	cg04158730	chr1:242011433	EXO1	0.56	5.32	0.43	4.59e-7	Menopause (age at onset);
TGCT	cis	rs9300255	0.568	rs1790090	chr12:123633424	G/A	cg00376283	chr12:123451042	ABCB9	0.71	5.54	0.45	1.7e-7	Neutrophil percentage of white cells;
TGCT	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg22963979	chr7:1858916	MAD1L1	0.46	7.4	0.55	1.81e-11	Bipolar disorder and schizophrenia;
TGCT	cis	rs854765	0.647	rs854769	chr17:18019011	A/G	cg04398451	chr17:18023971	MYO15A	0.38	6.77	0.52	4.49e-10	Total body bone mineral density;
TGCT	cis	rs11711311	0.826	rs13077644	chr3:113467777	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.72	-6.74	-0.52	5.36e-10	IgG glycosylation;
TGCT	cis	rs2115630	0.875	rs8039472	chr15:85361644	A/G	cg11189052	chr15:85197271	WDR73	-0.58	-5.18	-0.42	8.84e-7	P wave terminal force;
TGCT	cis	rs588177	0.522	rs34358026	chr11:64015422	T/C	cg04317338	chr11:64019027	PLCB3	0.79	6.73	0.52	5.67e-10	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs2299587	0.500	rs7815785	chr8:17730338	T/C	cg01800426	chr8:17659068	MTUS1	-0.53	-4.79	-0.4	4.62e-6	Economic and political preferences;
TGCT	cis	rs7904368	0.754	rs11254231	chr10:16870246	A/G	cg14835575	chr10:16859367	RSU1	0.58	5.81	0.46	4.9e-8	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
TGCT	cis	rs317865	0.737	rs28516589	chr4:16234111	C/T	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.77	5.08	0.42	1.34e-6	Kidney disease (early stage) in type 1 diabetes;
TGCT	cis	rs4727027	0.704	rs12535115	chr7:148895087	C/T	cg23583168	chr7:148888333	NA	-0.83	-11.12	-0.71	2.36e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg23708337	chr7:1209742	NA	0.64	5.94	0.47	2.63e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1577917	0.917	rs1579886	chr6:86557191	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.29	-0.43	5.34e-7	Response to antipsychotic treatment;
TGCT	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg11644478	chr21:40555479	PSMG1	-0.55	-5.18	-0.42	8.6e-7	Menarche (age at onset);
TGCT	trans	rs877282	0.583	rs11253424	chr10:813426	C/T	cg22713356	chr15:30763199	NA	0.85	7.16	0.54	6.3e-11	Uric acid levels;
TGCT	cis	rs7731657	0.537	rs4705850	chr5:130220358	A/G	cg08523029	chr5:130500466	HINT1	-0.6	-4.96	-0.41	2.23e-6	Fasting plasma glucose;
TGCT	cis	rs3812831	0.599	rs428636	chr13:114927133	T/C	cg15513719	chr13:114904418	NA	0.38	4.69	0.39	7.03e-6	Schizophrenia;
TGCT	cis	rs2688608	0.653	rs12775558	chr10:75570868	G/A	cg04320760	chr10:75533139	FUT11	-0.36	-5.52	-0.44	1.89e-7	Inflammatory bowel disease;
TGCT	cis	rs4654899	0.931	rs7520481	chr1:21140385	T/G	cg01072550	chr1:21505969	NA	0.49	7.71	0.57	3.49e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg05890377	chr2:74357713	NA	0.47	5.99	0.47	2.07e-8	Gestational age at birth (maternal effect);
TGCT	cis	rs7681440	0.935	rs3756059	chr4:90757272	G/A	cg14346243	chr4:90757452	SNCA	-0.59	-5.73	-0.46	7.07e-8	Dementia with Lewy bodies;
TGCT	cis	rs68170813	0.523	rs12154285	chr7:106993573	G/A	cg02696742	chr7:106810147	HBP1	-0.7	-5.7	-0.46	8.16e-8	Coronary artery disease;
TGCT	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg18402987	chr7:1209562	NA	0.7	5.67	0.45	9.66e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	trans	rs11722228	0.522	rs2241468	chr4:10113905	G/A	cg26043149	chr18:55253948	FECH	1.17	12.23	0.74	4.71e-23	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs8014204	0.550	rs7152906	chr14:75125540	T/C	cg06637938	chr14:75390232	RPS6KL1	0.66	5.99	0.47	2.12e-8	Caffeine consumption;
TGCT	cis	rs2228479	0.681	rs62052184	chr16:89967217	T/C	cg06558623	chr16:89946397	TCF25	0.41	4.99	0.41	1.97e-6	Skin colour saturation;
TGCT	cis	rs7635838	0.963	rs7627171	chr3:11413429	G/C	cg00170343	chr3:11313890	ATG7	0.61	5.78	0.46	5.68e-8	HDL cholesterol;
TGCT	cis	rs7513165	0.551	rs12750834	chr1:204140784	G/A	cg12731349	chr1:204159619	KISS1	0.49	4.84	0.4	3.74e-6	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
TGCT	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg17554472	chr22:41940697	POLR3H	0.49	5.06	0.41	1.44e-6	Vitiligo;
TGCT	cis	rs2172802	0.570	rs2133009	chr4:62516026	T/C	cg04118610	chr4:62707027	LPHN3	-0.41	-4.89	-0.4	3.07e-6	Partial epilepsies;
TGCT	cis	rs2933343	0.700	rs1680778	chr3:128614185	A/C	cg11901034	chr3:128598214	ACAD9	-0.64	-6.26	-0.49	5.85e-9	IgG glycosylation;
TGCT	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg24250549	chr1:154909240	PMVK	0.62	6.28	0.49	5.29e-9	Prostate cancer;
TGCT	cis	rs929354	0.772	rs3802123	chr7:156970641	G/A	cg05182265	chr7:156933206	UBE3C	-0.37	-8.2	-0.59	2.57e-13	Body mass index;
TGCT	cis	rs2562456	0.876	rs62110163	chr19:21728822	G/A	cg25650185	chr19:21324782	ZNF431	-0.64	-5.73	-0.46	7.12e-8	Pain;
TGCT	cis	rs4253772	0.591	rs6519994	chr22:46656805	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.55	-4.46	-0.37	1.84e-5	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs1018836	0.851	rs7004287	chr8:91620842	G/C	cg16814680	chr8:91681699	NA	-0.83	-8.71	-0.62	1.56e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4478858	0.735	rs11582342	chr1:31810681	A/G	cg00250761	chr1:31883323	NA	-0.28	-4.96	-0.41	2.32e-6	Alcohol dependence;
TGCT	cis	rs9868809	0.505	rs56735597	chr3:48765168	A/G	cg15315015	chr3:49131774	QRICH1	0.92	4.52	0.38	1.4e-5	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs7178572	0.524	rs2175941	chr15:77584498	T/C	cg15453836	chr15:77711506	NA	-0.42	-4.79	-0.4	4.68e-6	Type 2 diabetes;
TGCT	cis	rs3617	0.625	rs2245647	chr3:52862753	A/G	cg10802521	chr3:52805072	NEK4	-0.6	-6.89	-0.53	2.46e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2439831	0.702	rs7175032	chr15:44060236	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	5.91	0.47	3.05e-8	Lung cancer in ever smokers;
TGCT	cis	rs9297145	1.000	rs10953280	chr7:98763405	A/G	cg05967295	chr7:98741636	SMURF1	-1.03	-16.21	-0.82	1.99e-32	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs904251	0.772	rs2252920	chr6:37418327	A/G	cg25019722	chr6:37503610	NA	-0.44	-4.99	-0.41	2.01e-6	Cognitive performance;
TGCT	cis	rs62064224	0.554	rs9894877	chr17:30679517	T/A	cg18200150	chr17:30822561	MYO1D	0.39	4.7	0.39	6.66e-6	Schizophrenia;
TGCT	cis	rs7044106	0.791	rs10985001	chr9:123484232	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	6.46	0.5	2.12e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs992157	0.687	rs10206984	chr2:219066980	C/T	cg00012203	chr2:219082015	ARPC2	0.81	10.19	0.68	4.34e-18	Colorectal cancer;
TGCT	trans	rs7615952	0.932	rs13321217	chr3:125631771	G/A	cg07211511	chr3:129823064	LOC729375	-0.43	-7.22	-0.54	4.49e-11	Blood pressure (smoking interaction);
TGCT	cis	rs1857353	1.000	rs4949851	chr1:75858519	A/G	cg11838876	chr1:75668600	SLC44A5	-0.46	-4.52	-0.38	1.41e-5	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs2228479	1.000	rs62052180	chr16:89963289	C/G	cg19635926	chr16:89946313	TCF25	0.29	4.84	0.4	3.84e-6	Skin colour saturation;
TGCT	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.01	0.41	1.86e-6	Prudent dietary pattern;
TGCT	cis	rs7542091	0.704	rs9429825	chr1:210052133	C/G	cg23283495	chr1:209979779	IRF6	0.55	5.42	0.44	3.02e-7	Monobrow;
TGCT	cis	rs11249608	0.636	rs13359549	chr5:178449178	T/A	cg01312482	chr5:178451176	ZNF879	-0.58	-5.77	-0.46	5.94e-8	Pubertal anthropometrics;
TGCT	cis	rs2153535	0.580	rs1328862	chr6:8526681	A/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.55e-8	Motion sickness;
TGCT	cis	rs9303401	0.659	rs34468504	chr17:56648277	C/T	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs2549003	1.000	rs17848418	chr5:131821188	C/T	cg02551604	chr5:131831745	NA	-0.89	-11.95	-0.73	2.33e-22	Asthma (sex interaction);
TGCT	cis	rs17741873	0.779	rs17631000	chr10:75602500	C/T	cg07699608	chr10:75541558	CHCHD1	-0.73	-5.05	-0.41	1.51e-6	Paclitaxel disposition in epithelial ovarian cancer;
TGCT	cis	rs2153535	0.580	rs6941670	chr6:8446346	G/A	cg07606381	chr6:8435919	SLC35B3	0.55	5.17	0.42	9.24e-7	Motion sickness;
TGCT	cis	rs3784262	0.869	rs12903792	chr15:58261280	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.5	-7.78	-0.57	2.39e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs9653442	0.545	rs1821826	chr2:100764711	C/T	cg07810366	chr2:100720526	AFF3	-0.37	-5.54	-0.45	1.75e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs1008375	1.000	rs10939744	chr4:17664473	G/T	cg18681998	chr4:17616180	MED28	0.94	11.11	0.71	2.49e-20	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2456568	0.835	rs8181533	chr11:93638614	C/T	cg26875233	chr11:93583750	C11orf90	-0.48	-6.47	-0.5	2.09e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7845219	0.506	rs12548999	chr8:95929843	C/T	cg16049864	chr8:95962084	TP53INP1	-0.47	-5.12	-0.42	1.11e-6	Type 2 diabetes;
TGCT	cis	rs7249142	0.562	rs1050544	chr19:19287901	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.34	-4.73	-0.39	5.96e-6	IgG glycosylation;
TGCT	cis	rs12681287	0.752	rs12677470	chr8:87260559	G/A	cg27223183	chr8:87520930	FAM82B	-0.81	-5.66	-0.45	9.9e-8	Caudate activity during reward;
TGCT	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg20607798	chr8:58055168	NA	0.5	4.66	0.39	8.04e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs36051895	0.659	rs12351277	chr9:5061405	A/C	cg02405213	chr9:5042618	JAK2	-0.73	-9.89	-0.66	2.38e-17	Pediatric autoimmune diseases;
TGCT	cis	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg18252515	chr7:66147081	NA	-1.31	-8.18	-0.59	2.87e-13	Diabetic kidney disease;
TGCT	cis	rs58950470	0.849	rs7122657	chr11:65378028	C/T	cg27068330	chr11:65405492	SIPA1	0.61	5.36	0.43	3.92e-7	Schizophrenia;
TGCT	cis	rs3782455	1.000	rs117139141	chr12:114402939	T/G	cg23502203	chr12:113549970	RASAL1	-0.55	-4.92	-0.4	2.7e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs7044106	0.791	rs7043969	chr9:123493989	A/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.2	4.74	0.39	5.66e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs1949733	1.000	rs2631758	chr4:8495304	G/A	cg13073564	chr4:8508604	NA	0.5	5.52	0.44	1.91e-7	Response to antineoplastic agents;
TGCT	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.71	0.39	6.53e-6	Prudent dietary pattern;
TGCT	cis	rs7772486	0.790	rs4896852	chr6:146284621	T/C	cg23711669	chr6:146136114	FBXO30	-0.88	-10.07	-0.67	8.66e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.58	5.84	0.46	4.25e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg24250549	chr1:154909240	PMVK	0.63	6.25	0.49	6.03e-9	Prostate cancer;
TGCT	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg05368731	chr17:41323189	NBR1	1.08	11.0	0.7	4.76e-20	Menopause (age at onset);
TGCT	cis	rs9527	0.615	rs3897401	chr10:104696379	T/C	cg04362960	chr10:104952993	NT5C2	0.64	5.4	0.44	3.33e-7	Arsenic metabolism;
TGCT	cis	rs7568458	0.870	rs6719046	chr2:85757371	G/A	cg02493740	chr2:85810744	VAMP5	-0.27	-4.81	-0.4	4.25e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs2549003	1.000	rs2070722	chr5:131824486	A/C	cg02551604	chr5:131831745	NA	-0.88	-12.37	-0.74	2.22e-23	Asthma (sex interaction);
TGCT	cis	rs4372836	0.658	rs11127189	chr2:28992020	T/G	cg09522027	chr2:28974177	PPP1CB	-0.68	-6.93	-0.53	2e-10	Body mass index;
TGCT	cis	rs9611565	0.625	rs2076199	chr22:41903743	G/T	cg02107564	chr22:41488750	EP300	-0.55	-4.51	-0.38	1.49e-5	Vitiligo;
TGCT	cis	rs514406	0.698	rs1775540	chr1:53407893	C/A	cg24675658	chr1:53192096	ZYG11B	-0.74	-9.03	-0.63	2.84e-15	Monocyte count;
TGCT	cis	rs7666738	0.830	rs3846445	chr4:99032939	T/A	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs2727020	0.796	rs7131672	chr11:49274421	A/C	cg15704280	chr7:45808275	SEPT13	0.68	7.13	0.54	7.39e-11	Coronary artery disease;
TGCT	cis	rs1215050	0.791	rs2658477	chr4:98850993	G/A	cg05340658	chr4:99064831	C4orf37	-0.47	-5.9	-0.47	3.18e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7255045	0.742	rs10411443	chr19:12950948	C/G	cg23899408	chr19:12877188	HOOK2	0.58	4.7	0.39	6.71e-6	Mean corpuscular volume;
TGCT	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg23172400	chr8:95962367	TP53INP1	-0.4	-6.79	-0.52	4.22e-10	Type 2 diabetes;
TGCT	cis	rs854765	0.663	rs6502618	chr17:17746741	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.7	-6.65	-0.51	8.42e-10	Total body bone mineral density;
TGCT	cis	rs478304	0.654	rs7934036	chr11:65451020	G/T	cg17480646	chr11:65405466	SIPA1	-0.63	-8.24	-0.59	2.09e-13	Acne (severe);
TGCT	cis	rs6933660	0.745	rs6557138	chr6:151732017	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.87	-9.14	-0.63	1.48e-15	Menarche (age at onset);
TGCT	cis	rs9467773	0.620	rs9295701	chr6:26627508	T/C	cg09904177	chr6:26538194	HMGN4	0.67	6.48	0.5	1.94e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7772486	0.720	rs4896837	chr6:146014168	C/T	cg05347473	chr6:146136440	FBXO30	-0.51	-4.8	-0.4	4.44e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs611744	0.647	rs647907	chr8:109251374	T/C	cg21045802	chr8:109455806	TTC35	0.72	7.28	0.55	3.32e-11	Dupuytren's disease;
TGCT	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg03517284	chr6:25882590	NA	-0.58	-6.03	-0.48	1.76e-8	Blood metabolite levels;
TGCT	cis	rs57221529	0.766	rs12519763	chr5:559145	C/T	cg09021430	chr5:549028	NA	-0.4	-5.46	-0.44	2.44e-7	Lung disease severity in cystic fibrosis;
TGCT	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg17971929	chr21:40555470	PSMG1	0.73	7.23	0.54	4.31e-11	Cognitive function;
TGCT	cis	rs17270561	0.887	rs12201170	chr6:25866247	A/G	cg17042849	chr6:26104293	HIST1H4C	-0.89	-5.78	-0.46	5.57e-8	Iron status biomarkers;
TGCT	cis	rs2737273	0.849	rs2249250	chr9:35711806	G/T	cg12717594	chr9:36037454	RECK	0.53	4.49	0.37	1.61e-5	Platelet distribution width;
TGCT	cis	rs4803468	0.967	rs11083619	chr19:41913267	A/C	cg09537434	chr19:41945824	ATP5SL	-0.92	-10.69	-0.69	2.72e-19	Height;
TGCT	cis	rs7072216	0.727	rs3750603	chr10:100175536	A/T	cg26618903	chr10:100175079	PYROXD2	-0.4	-4.49	-0.37	1.64e-5	Metabolite levels;
TGCT	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg26119090	chr2:26468346	HADHA;HADHB	0.95	5.74	0.46	6.74e-8	Gut microbiome composition (summer);
TGCT	cis	rs6429082	0.818	rs291340	chr1:235674379	C/T	cg26050004	chr1:235667680	B3GALNT2	0.59	5.23	0.42	7.08e-7	Adiposity;
TGCT	cis	rs2688608	0.592	rs10824031	chr10:75509273	C/T	cg04320760	chr10:75533139	FUT11	-0.36	-5.66	-0.45	9.83e-8	Inflammatory bowel disease;
TGCT	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.02	0.53	1.3e-10	Prudent dietary pattern;
TGCT	cis	rs9905704	0.647	rs11079367	chr17:57009024	A/G	cg12560992	chr17:57184187	TRIM37	0.58	4.93	0.4	2.57e-6	Testicular germ cell tumor;
TGCT	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg00149659	chr3:10157352	C3orf10	0.73	4.72	0.39	6.17e-6	Alzheimer's disease;
TGCT	cis	rs17376456	0.778	rs10440717	chr5:93424852	C/A	cg25358565	chr5:93447407	FAM172A	0.92	8.38	0.6	9.58e-14	Diabetic retinopathy;
TGCT	cis	rs614226	0.935	rs7956998	chr12:120994932	G/A	cg01236616	chr12:121019343	POP5	1.26	13.2	0.76	2.23e-25	Type 1 diabetes nephropathy;
TGCT	cis	rs909002	0.819	rs2292989	chr1:32135773	A/G	cg11573219	chr1:32083031	HCRTR1	0.38	4.69	0.39	7.04e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9549260	0.577	rs6563841	chr13:41239178	A/C	cg21288729	chr13:41239152	FOXO1	1.01	10.63	0.69	3.76e-19	Red blood cell count;
TGCT	cis	rs9549367	0.713	rs3024764	chr13:113824314	A/G	cg09473364	chr13:112927190	NA	-0.31	-4.74	-0.39	5.81e-6	Platelet distribution width;
TGCT	cis	rs8180040	0.726	rs2061197	chr3:47001350	C/T	cg27129171	chr3:47204927	SETD2	-0.73	-9.52	-0.65	1.86e-16	Colorectal cancer;
TGCT	cis	rs11190604	1.000	rs11190597	chr10:102293676	A/T	cg16342193	chr10:102329863	NA	-0.41	-5.37	-0.43	3.78e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs858239	0.600	rs7341483	chr7:23127657	G/T	cg05602783	chr7:23145260	KLHL7	0.6	4.99	0.41	2.02e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs9303401	0.659	rs714959	chr17:56628601	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs4455778	0.580	rs6583507	chr7:49122261	T/C	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs4906332	1.000	rs12896612	chr14:103877868	A/G	cg26031613	chr14:104095156	KLC1	-0.5	-4.45	-0.37	1.89e-5	Coronary artery disease;
TGCT	cis	rs10751667	0.666	rs7944815	chr11:959776	C/T	cg06064525	chr11:970664	AP2A2	-0.35	-8.23	-0.59	2.17e-13	Alzheimer's disease (late onset);
TGCT	cis	rs1903068	0.819	rs17711320	chr4:56000053	A/C	cg01777861	chr4:56023843	NA	0.54	6.38	0.5	3.2e-9	Endometriosis;
TGCT	cis	rs9733	0.650	rs4970923	chr1:150608300	A/G	cg13175981	chr1:150552382	MCL1	0.51	5.75	0.46	6.61e-8	Tonsillectomy;
TGCT	cis	rs2721195	0.845	rs756627	chr8:145737286	G/A	cg13257436	chr8:145726034	PPP1R16A	-0.32	-4.71	-0.39	6.54e-6	Age at first birth;
TGCT	cis	rs12681288	0.862	rs34510005	chr8:1018943	T/C	cg04851639	chr8:1020857	NA	-0.4	-7.48	-0.56	1.21e-11	Schizophrenia;
TGCT	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg23034840	chr1:205782522	SLC41A1	0.55	5.02	0.41	1.73e-6	Menarche (age at onset);
TGCT	cis	rs7809950	1.000	rs2107713	chr7:107232369	C/T	cg23024343	chr7:107201750	COG5	-0.42	-6.24	-0.49	6.41e-9	Coronary artery disease;
TGCT	cis	rs763014	0.833	rs916415	chr16:632115	G/A	cg00908189	chr16:619842	PIGQ	0.87	10.5	0.69	7.53e-19	Height;
TGCT	cis	rs7552404	0.727	rs2172507	chr1:76331320	A/G	cg22875332	chr1:76189707	ACADM	-0.59	-6.22	-0.49	6.97e-9	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs6121246	0.567	rs6058203	chr20:30198979	C/T	cg13852791	chr20:30311386	BCL2L1	0.7	4.58	0.38	1.1e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.75	5.41	0.44	3.09e-7	Platelet count;
TGCT	cis	rs10894604	1.000	rs10894604	chr11:132641746	A/C	cg16919708	chr11:133023150	OPCML	-0.5	-4.6	-0.38	1.01e-5	Waist-hip ratio;
TGCT	cis	rs56104184	0.775	rs3760785	chr19:49403178	G/T	cg15549821	chr19:49342101	PLEKHA4	-0.73	-9.04	-0.63	2.66e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs7586879	0.796	rs36071142	chr2:25080570	C/T	cg01884057	chr2:25150051	NA	0.26	4.59	0.38	1.08e-5	Body mass index;
TGCT	cis	rs11785400	0.963	rs9771845	chr8:143726577	C/G	cg10596483	chr8:143751796	JRK	0.54	5.84	0.46	4.34e-8	Schizophrenia;
TGCT	cis	rs13242816	1.000	rs36011826	chr7:116118336	G/A	cg16553024	chr7:116138462	CAV2	-0.45	-4.81	-0.4	4.32e-6	P wave duration;
TGCT	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg20203395	chr5:56204925	C5orf35	-0.52	-4.8	-0.4	4.44e-6	Initial pursuit acceleration;
TGCT	cis	rs2153535	0.580	rs9378552	chr6:8463748	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs910316	1.000	rs8017642	chr14:75590822	G/A	cg23033748	chr14:75592666	NEK9	0.29	4.9	0.4	2.95e-6	Height;
TGCT	cis	rs2455799	0.613	rs62241264	chr3:15943471	T/C	cg16303742	chr3:15540471	COLQ	-0.25	-4.59	-0.38	1.09e-5	Mean platelet volume;
TGCT	cis	rs3020333	0.875	rs2982572	chr6:152010561	C/T	cg22157087	chr6:152012887	ESR1	0.19	4.73	0.39	6.06e-6	Total body bone mineral density;
TGCT	cis	rs73198271	0.628	rs11780486	chr8:8589494	C/T	ch.8.214553F	chr8:8189620	PRAGMIN	0.33	5.25	0.43	6.4e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs7267979	0.816	rs404775	chr20:25481117	A/G	cg03522245	chr20:25566470	NINL	0.56	5.79	0.46	5.51e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs35883536	0.647	rs11166485	chr1:101048805	G/C	cg06223162	chr1:101003688	GPR88	-0.41	-7.64	-0.57	5.04e-12	Monocyte count;
TGCT	cis	rs2180341	0.961	rs910720	chr6:127619070	T/C	cg27446573	chr6:127587934	RNF146	1.13	10.12	0.67	6.64e-18	Breast cancer;
TGCT	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg09263875	chr16:632152	PIGQ	0.31	6.91	0.53	2.25e-10	Height;
TGCT	cis	rs7226408	0.948	rs11660227	chr18:34381823	C/T	cg06757138	chr18:34340585	FHOD3	0.26	4.79	0.4	4.62e-6	Obesity-related traits;
TGCT	cis	rs4788570	0.538	rs16973260	chr16:71534853	A/G	cg06353428	chr16:71660113	MARVELD3	1.22	7.91	0.58	1.21e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs78487399	0.808	rs78108161	chr2:43663848	C/T	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.72	4.64	0.38	8.86e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs11741688	0.557	rs10043579	chr5:178330174	C/T	cg09339527	chr5:178322752	ZFP2	-0.29	-4.85	-0.4	3.57e-6	Sleep duration;
TGCT	cis	rs61990749	0.597	rs1549119	chr14:78219812	A/T	cg23188588	chr14:78226832	SNW1;C14orf178	0.65	4.59	0.38	1.06e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs6490294	0.904	rs10850003	chr12:112571169	C/T	cg10833066	chr12:111807467	FAM109A	0.37	5.52	0.44	1.93e-7	Mean platelet volume;
TGCT	cis	rs308403	0.600	rs309367	chr4:123662211	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.73	6.85	0.52	3e-10	Blood protein levels;
TGCT	cis	rs7572733	0.534	rs4550664	chr2:198691405	C/T	cg00792783	chr2:198669748	PLCL1	0.56	5.14	0.42	1.06e-6	Dermatomyositis;
TGCT	cis	rs7180079	0.514	rs7403751	chr15:64979291	G/C	cg03791955	chr15:65024147	NA	0.29	5.58	0.45	1.41e-7	Monocyte count;
TGCT	cis	rs10791097	0.694	rs2236717	chr11:130739887	G/T	cg05962950	chr11:130786565	SNX19	0.92	11.55	0.72	2.13e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs736408	1.000	rs2710331	chr3:52837855	T/C	cg10802521	chr3:52805072	NEK4	-0.68	-7.49	-0.56	1.11e-11	Bipolar disorder;
TGCT	cis	rs713587	0.571	rs475868	chr2:25318059	A/G	cg01884057	chr2:25150051	NA	-0.26	-4.88	-0.4	3.16e-6	Body mass index in non-asthmatics;
TGCT	cis	rs7666738	0.753	rs13120995	chr4:98972762	A/G	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs6840360	0.554	rs58751443	chr4:152709905	A/G	cg22705602	chr4:152727874	NA	-0.33	-5.9	-0.47	3.26e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs1865760	0.566	rs1800702	chr6:26086463	C/G	cg16482183	chr6:26056742	HIST1H1C	0.58	4.97	0.41	2.13e-6	Height;
TGCT	cis	rs6570726	0.791	rs12208812	chr6:145900924	T/G	cg23711669	chr6:146136114	FBXO30	0.89	9.85	0.66	2.95e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4144743	1.000	rs67080286	chr17:45322248	T/G	cg18085866	chr17:45331354	ITGB3	-0.7	-4.67	-0.39	7.69e-6	Body mass index;
TGCT	cis	rs910316	0.904	rs7156089	chr14:75645527	A/G	cg08847533	chr14:75593920	NEK9	-0.93	-10.14	-0.67	5.65e-18	Height;
TGCT	cis	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg20637647	chr7:64974828	NA	0.93	5.2	0.42	8.11e-7	Diabetic kidney disease;
TGCT	cis	rs1538970	0.924	rs6657284	chr1:45879088	T/C	cg05343316	chr1:45956843	TESK2	0.73	5.6	0.45	1.31e-7	Platelet count;
TGCT	cis	rs11711311	1.000	rs2712348	chr3:113460614	C/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.73	-6.83	-0.52	3.45e-10	IgG glycosylation;
TGCT	cis	rs2836950	0.520	rs59916147	chr21:40634702	T/G	cg11890956	chr21:40555474	PSMG1	-0.69	-6.63	-0.51	9.44e-10	Menarche (age at onset);
TGCT	cis	rs514406	0.505	rs436363	chr1:53172163	T/C	cg25767906	chr1:53392781	SCP2	-0.45	-4.98	-0.41	2.1e-6	Monocyte count;
TGCT	cis	rs362272	0.524	rs10937924	chr4:3374898	T/C	cg06533319	chr4:3265114	C4orf44	-0.27	-5.49	-0.44	2.16e-7	Serum sulfate level;
TGCT	cis	rs2762353	0.562	rs1165206	chr6:25867566	G/A	cg07061783	chr6:25882402	NA	-0.45	-4.62	-0.38	9.65e-6	Blood metabolite levels;
TGCT	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg25811766	chr13:21894605	NA	0.28	5.38	0.44	3.53e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	cis	rs7760949	0.963	rs7761500	chr6:13917140	G/A	cg27413430	chr6:13925136	RNF182	0.59	5.65	0.45	1.06e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs68170813	0.617	rs17481842	chr7:107121862	C/T	cg02696742	chr7:106810147	HBP1	-0.68	-5.15	-0.42	9.83e-7	Coronary artery disease;
TGCT	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg23131131	chr22:24373011	LOC391322	-0.81	-8.78	-0.62	1.12e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7590720	1.000	rs7559031	chr2:216902583	A/G	cg12620499	chr2:216877984	MREG	0.85	8.48	0.61	5.57e-14	Alcohol dependence;
TGCT	cis	rs687432	0.774	rs7938062	chr11:57904766	C/T	cg04811534	chr11:57115016	P2RX3	0.18	4.5	0.38	1.51e-5	Parkinson's disease;
TGCT	cis	rs7954584	0.813	rs12827200	chr12:122451278	G/A	cg21016266	chr12:122356598	WDR66	0.43	5.29	0.43	5.32e-7	Mean corpuscular volume;
TGCT	cis	rs3741404	0.868	rs595880	chr11:64006466	T/G	cg01727686	chr11:63997306	NUDT22;DNAJC4	-0.22	-4.6	-0.38	1.01e-5	Platelet count;
TGCT	cis	rs2295359	1.000	rs736197	chr1:67607135	G/T	cg03340356	chr1:67600835	NA	0.37	4.48	0.37	1.66e-5	Psoriasis;
TGCT	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.84	7.5	0.56	1.08e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9807989	0.765	rs6751977	chr2:102967430	T/C	cg09003973	chr2:102972529	NA	0.64	5.7	0.46	8.28e-8	Asthma;
TGCT	cis	rs10791097	0.694	rs4936123	chr11:130740967	G/A	cg14779329	chr11:130786720	SNX19	0.26	4.45	0.37	1.85e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs875971	0.793	rs460678	chr7:65527200	C/G	cg18876405	chr7:65276391	NA	0.32	4.86	0.4	3.49e-6	Aortic root size;
TGCT	cis	rs2180341	0.618	rs12529077	chr6:127634244	G/T	cg24812749	chr6:127587940	RNF146	0.63	5.33	0.43	4.51e-7	Breast cancer;
TGCT	cis	rs2456568	0.548	rs10466335	chr11:93663820	G/C	cg17595323	chr11:93583763	C11orf90	-0.42	-5.28	-0.43	5.63e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs8031584	0.678	rs4779496	chr15:31151054	A/G	cg08704250	chr15:31115839	NA	-0.43	-6.31	-0.49	4.47e-9	Huntington's disease progression;
TGCT	cis	rs10940138	0.774	rs16897196	chr5:67228478	G/C	ch.5.1281357F	chr5:67228439	NA	0.43	5.02	0.41	1.74e-6	Menarche (age at onset);
TGCT	cis	rs28595532	0.920	rs6818519	chr4:119787820	G/T	cg21605333	chr4:119757512	SEC24D	1.44	8.24	0.6	2.03e-13	Cannabis dependence symptom count;
TGCT	cis	rs4689388	0.750	rs10755148	chr4:6295064	A/G	cg14416269	chr4:6271139	WFS1	0.37	4.72	0.39	6.17e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs2739330	0.576	rs2858912	chr22:24297197	A/G	cg02953382	chr22:24373134	LOC391322	-0.75	-7.83	-0.58	1.82e-12	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs12549025	0.559	rs721183	chr8:23385834	A/G	cg00472375	chr8:23315376	ENTPD4	0.61	4.95	0.41	2.32e-6	Reticulocyte fraction of red cells;
TGCT	cis	rs9906944	0.707	rs4794019	chr17:47107290	G/T	cg20966754	chr17:47091339	IGF2BP1	-0.45	-5.28	-0.43	5.55e-7	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg00814883	chr7:100076585	TSC22D4	-0.92	-9.76	-0.66	4.73e-17	Platelet count;
TGCT	cis	rs6076065	0.963	rs6048777	chr20:23373302	C/T	cg11657817	chr20:23433608	CST11	0.28	4.55	0.38	1.25e-5	Facial morphology (factor 15, philtrum width);
TGCT	cis	rs28595532	1.000	rs115706377	chr4:119628481	G/A	cg11846333	chr4:119757529	SEC24D	0.92	5.01	0.41	1.85e-6	Cannabis dependence symptom count;
TGCT	cis	rs10507380	0.709	rs117603945	chr13:27922164	G/A	cg25543773	chr13:27185723	WASF3	0.34	4.83	0.4	3.97e-6	Electrocardiographic traits;
TGCT	cis	rs3820068	0.705	rs72643694	chr1:15860185	C/T	cg05660106	chr1:15850417	CASP9	1.16	14.82	0.8	3.11e-29	Systolic blood pressure;
TGCT	cis	rs67478160	0.679	rs7156834	chr14:104211180	G/A	cg26031613	chr14:104095156	KLC1	-0.63	-6.37	-0.5	3.33e-9	Schizophrenia;
TGCT	cis	rs1953600	0.645	rs2819950	chr10:81935279	G/A	cg00277334	chr10:82204260	NA	0.32	4.52	0.38	1.41e-5	Sarcoidosis;
TGCT	cis	rs6003958	1	rs6003958	chr22:24264089	T/G	cg00024416	chr22:24240387	NA	0.37	6.42	0.5	2.58e-9	S-phenylmercapturic acid levels in smokers;
TGCT	cis	rs7681440	0.804	rs1442135	chr4:90819093	C/T	cg14346243	chr4:90757452	SNCA	0.49	4.95	0.41	2.33e-6	Dementia with Lewy bodies;
TGCT	cis	rs644799	1.000	rs544119	chr11:95538624	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	8.74	0.62	1.39e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs2239547	0.522	rs2581780	chr3:53058960	C/T	cg11645453	chr3:52864694	ITIH4	-0.35	-5.6	-0.45	1.33e-7	Schizophrenia;
TGCT	cis	rs2535633	0.631	rs2581819	chr3:53016552	C/A	cg11645453	chr3:52864694	ITIH4	-0.27	-4.96	-0.41	2.25e-6	Body mass index;
TGCT	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg04414720	chr1:150670196	GOLPH3L	0.39	5.04	0.41	1.59e-6	Urate levels;
TGCT	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6495122	0.699	rs4886410	chr15:75065644	G/C	cg10253484	chr15:75165896	SCAMP2	-0.7	-6.04	-0.48	1.63e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
TGCT	cis	rs6867032	0.527	rs1017924	chr5:1976187	C/T	cg05184729	chr5:1962311	NA	-0.31	-5.25	-0.43	6.53e-7	Gut microbiome composition (winter);
TGCT	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs1008375	0.966	rs3775927	chr4:17599894	G/T	cg16339924	chr4:17578868	LAP3	0.75	6.45	0.5	2.26e-9	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs3796352	1.000	rs3097417	chr3:53088601	C/G	cg07884673	chr3:53033167	SFMBT1	-0.58	-6.29	-0.49	4.94e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs7666738	0.800	rs13106995	chr4:99028790	A/T	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6088590	0.813	rs1884668	chr20:33285514	A/G	cg06115741	chr20:33292138	TP53INP2	0.57	4.86	0.4	3.51e-6	Coronary artery disease;
TGCT	cis	rs6693567	0.545	rs2133129	chr1:150355537	T/C	cg09579323	chr1:150459698	TARS2	0.52	4.67	0.39	7.77e-6	Migraine;
TGCT	cis	rs10858047	0.883	rs6681386	chr1:115183183	G/A	cg12756093	chr1:115239321	AMPD1	-0.45	-4.73	-0.39	6.09e-6	Autism;
TGCT	cis	rs6088580	0.634	rs1205334	chr20:32930369	T/C	cg06115741	chr20:33292138	TP53INP2	-0.55	-4.9	-0.4	2.97e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs12220238	1.000	rs12357530	chr10:75928654	C/A	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.06	0.54	1.05e-10	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs9372498	0.536	rs9481821	chr6:118846022	A/C	cg07617317	chr6:118971624	C6orf204	0.53	5.72	0.46	7.66e-8	Diastolic blood pressure;
TGCT	trans	rs66573146	0.901	rs55659111	chr4:7012338	G/T	cg07817883	chr1:32538562	TMEM39B	1.8	8.36	0.6	1.09e-13	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs7843479	0.601	rs11780532	chr8:21838670	T/A	cg17168535	chr8:21777572	XPO7	0.8	8.02	0.58	6.77e-13	Mean corpuscular volume;
TGCT	cis	rs13191362	1.000	rs13192894	chr6:163052444	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.92	7.24	0.55	4.11e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs6589563	0.737	rs56143464	chr11:116627056	G/A	cg01124546	chr11:117515332	DSCAML1	-0.45	-4.85	-0.4	3.69e-6	Eosinophil counts;
TGCT	cis	rs9611565	0.918	rs9611562	chr22:41760172	T/G	cg06634786	chr22:41940651	POLR3H	-0.91	-8.79	-0.62	1.02e-14	Vitiligo;
TGCT	cis	rs11153730	0.503	rs188181	chr6:118620094	C/T	cg21191810	chr6:118973309	C6orf204	0.27	4.53	0.38	1.36e-5	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
TGCT	cis	rs6840360	0.615	rs7669465	chr4:152609289	C/T	cg17479576	chr4:152424074	FAM160A1	-0.58	-5.88	-0.47	3.63e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs12935418	0.616	rs718954	chr16:80987116	C/G	cg07676361	chr16:80966860	NA	-0.35	-4.7	-0.39	6.87e-6	Mean corpuscular volume;
TGCT	cis	rs3087591	0.919	rs2953011	chr17:29412046	A/G	cg24425628	chr17:29625626	OMG;NF1	0.47	7.01	0.53	1.36e-10	Hip circumference;
TGCT	cis	rs1975974	0.511	rs56935892	chr17:21754089	A/G	cg18423549	chr17:21743878	NA	-0.67	-6.33	-0.49	4.06e-9	Psoriasis;
TGCT	cis	rs3806843	0.608	rs155364	chr5:140346468	T/A	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.11	-0.42	1.17e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs1208285	1.000	rs1208285	chr6:134158800	T/C	cg01805282	chr6:133563764	EYA4	-0.44	-4.83	-0.4	4.02e-6	Infantile hypertrophic pyloric stenosis;
TGCT	trans	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.85	-8.85	-0.62	7.57e-15	Body mass index;
TGCT	cis	rs12693043	0.701	rs3815969	chr2:175432098	G/A	cg11778734	chr2:175439522	WIPF1	-0.37	-4.67	-0.39	7.82e-6	Urate levels (BMI interaction);
TGCT	cis	rs10931896	0.531	rs295118	chr2:201144004	C/T	cg23649088	chr2:200775458	C2orf69	0.38	6.31	0.49	4.4e-9	Systolic blood pressure;
TGCT	cis	rs709400	0.633	rs10141433	chr14:103962559	A/G	cg12935359	chr14:103987150	CKB	-0.36	-5.64	-0.45	1.11e-7	Body mass index;
TGCT	cis	rs4523957	0.583	rs9907384	chr17:2045375	A/C	cg16513277	chr17:2031491	SMG6	-0.2	-4.58	-0.38	1.13e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs1215050	0.716	rs356549	chr4:98699344	A/G	cg17366294	chr4:99064904	C4orf37	0.52	5.61	0.45	1.27e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs17767294	0.708	rs79956881	chr6:28030150	T/C	cg08851530	chr6:28072375	NA	1.56	7.22	0.54	4.47e-11	Parkinson's disease;
TGCT	cis	rs11098499	0.863	rs10013305	chr4:120450424	G/A	cg09307838	chr4:120376055	NA	0.69	6.53	0.51	1.49e-9	Corneal astigmatism;
TGCT	cis	rs2204008	0.505	rs11182550	chr12:38570061	A/T	cg26384229	chr12:38710491	ALG10B	0.55	5.04	0.41	1.58e-6	Bladder cancer;
TGCT	cis	rs67460515	0.892	rs34016896	chr3:160992864	C/T	cg03342759	chr3:160939853	NMD3	-0.51	-5.42	-0.44	2.98e-7	Parkinson's disease;
TGCT	cis	rs739496	0.527	rs12427012	chr12:112343374	G/A	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs1215050	0.740	rs783929	chr4:98972495	T/A	cg05340658	chr4:99064831	C4orf37	-0.43	-5.27	-0.43	5.8e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs4077515	0.935	rs3812565	chr9:139272502	T/C	cg13741927	chr9:139327495	INPP5E	-0.2	-4.51	-0.38	1.48e-5	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs7439150	1.000	rs2227403	chr4:155486646	T/C	cg22130008	chr4:155548532	NA	-0.46	-5.77	-0.46	6.08e-8	Fibrinogen levels;
TGCT	trans	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg23505145	chr19:12996616	KLF1	0.78	8.12	0.59	4.03e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs6977660	0.714	rs10231980	chr7:19789383	C/G	cg07541023	chr7:19748670	TWISTNB	0.85	4.84	0.4	3.74e-6	Thyroid stimulating hormone;
TGCT	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg13683864	chr3:40499215	RPL14	-1.19	-13.2	-0.76	2.17e-25	Renal cell carcinoma;
TGCT	cis	rs9611565	0.512	rs6519289	chr22:42170432	A/C	cg06634786	chr22:41940651	POLR3H	0.85	8.15	0.59	3.41e-13	Vitiligo;
TGCT	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg25036284	chr2:26402008	FAM59B	-0.54	-4.68	-0.39	7.3e-6	Gut microbiome composition (summer);
TGCT	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7565124	1.000	rs67305930	chr2:20258070	G/C	cg00462460	chr2:20212509	MATN3	-0.43	-4.67	-0.39	7.65e-6	Major depressive disorder;
TGCT	cis	rs950169	0.580	rs1061737	chr15:85183790	G/C	cg12863693	chr15:85201151	NMB	0.46	5.56	0.45	1.6e-7	Schizophrenia;
TGCT	cis	rs10507380	0.824	rs74918771	chr13:27921717	T/G	cg25543773	chr13:27185723	WASF3	0.34	4.83	0.4	3.97e-6	Electrocardiographic traits;
TGCT	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg03264133	chr6:25882463	NA	-0.64	-6.02	-0.48	1.86e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs111803315	1.000	rs112819780	chr14:60001564	A/G	cg22995959	chr14:59931024	GPR135	0.66	4.8	0.4	4.39e-6	Schizophrenia;
TGCT	cis	rs8180040	1.000	rs295428	chr3:47359262	G/T	cg27129171	chr3:47204927	SETD2	0.7	8.88	0.62	6.43e-15	Colorectal cancer;
TGCT	cis	rs600231	0.706	rs3782091	chr11:65336483	G/T	cg21890820	chr11:65308645	LTBP3	-0.37	-4.9	-0.4	2.91e-6	Bone mineral density;
TGCT	trans	rs9329221	1.000	rs9329221	chr8:10240202	G/T	cg15556689	chr8:8085844	FLJ10661	0.71	6.69	0.51	6.87e-10	Neuroticism;
TGCT	cis	rs7523050	0.643	rs76218180	chr1:109404131	T/A	cg08274380	chr1:109419600	GPSM2	1.31	6.12	0.48	1.15e-8	Fat distribution (HIV);
TGCT	cis	rs3733585	0.683	rs6449140	chr4:9936437	G/C	cg11266682	chr4:10021025	SLC2A9	-0.59	-7.61	-0.56	5.87e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs10423674	0.526	rs34482977	chr19:18824038	C/G	cg14292368	chr19:18793705	CRTC1	-0.53	-4.89	-0.4	3.1e-6	Menarche (age at onset);
TGCT	cis	rs2832191	0.791	rs2832178	chr21:30479858	T/G	cg24692254	chr21:30365293	RNF160	-0.94	-10.58	-0.69	4.82e-19	Dental caries;
TGCT	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg00431813	chr7:1051703	C7orf50	-0.2	-4.44	-0.37	1.99e-5	Longevity;Endometriosis;
TGCT	cis	rs17534004	1.000	rs17599764	chr13:31469580	G/A	cg13251181	chr13:31481184	C13orf33	0.37	4.6	0.38	1.04e-5	3-hydroxypropylmercapturic acid levels in smokers;
TGCT	cis	rs12711979	0.528	rs1823860	chr2:3867013	A/G	cg17052675	chr2:3827356	NA	-0.27	-4.44	-0.37	1.97e-5	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs4478858	0.746	rs7520468	chr1:31688812	G/A	cg00250761	chr1:31883323	NA	0.29	4.78	0.39	4.9e-6	Alcohol dependence;
TGCT	cis	rs2842992	0.872	rs1570318	chr6:160111473	C/T	cg11366901	chr6:160182831	ACAT2	0.94	6.18	0.49	8.48e-9	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs11190604	0.513	rs2495730	chr10:102361277	T/C	cg16342193	chr10:102329863	NA	-0.46	-5.15	-0.42	1.02e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs11711311	0.911	rs3773681	chr3:113523901	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.76	-7.16	-0.54	6.29e-11	IgG glycosylation;
TGCT	cis	rs67311347	1.000	rs7631893	chr3:40440869	C/T	cg17264618	chr3:40429014	ENTPD3	0.3	4.44	0.37	1.97e-5	Renal cell carcinoma;
TGCT	cis	rs13256369	0.853	rs13256216	chr8:8577883	C/T	cg18904891	chr8:8559673	CLDN23	0.64	5.62	0.45	1.21e-7	Obesity-related traits;
TGCT	cis	rs7267979	0.903	rs6115109	chr20:25239667	G/A	cg03522245	chr20:25566470	NINL	0.6	6.58	0.51	1.21e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs864745	0.902	rs12531540	chr7:28162674	C/T	cg23620719	chr7:28220237	JAZF1	-0.5	-4.47	-0.37	1.77e-5	Crohn's disease;Type 2 diabetes;
TGCT	cis	rs617219	0.737	rs1275103	chr5:78448105	C/G	cg23514016	chr5:78407564	BHMT	0.34	5.26	0.43	6.16e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs1942	0.837	rs12440045	chr15:41782684	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.49	-6.38	-0.5	3.2e-9	Eosinophil percentage of granulocytes;
TGCT	cis	rs1215050	0.755	rs783958	chr4:98893836	A/T	cg17366294	chr4:99064904	C4orf37	-0.53	-5.69	-0.45	8.67e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs17345786	0.861	rs11707689	chr3:101086475	A/G	cg12386194	chr3:101231763	SENP7	0.65	6.39	0.5	3.06e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs669446	0.561	rs628342	chr1:44090736	C/T	cg12908607	chr1:44402522	ARTN	-0.54	-5.68	-0.45	8.9e-8	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.75	5.41	0.44	3.09e-7	Platelet count;
TGCT	cis	rs4699052	0.963	rs4698890	chr4:104181878	T/C	cg16532752	chr4:104119610	CENPE	-0.55	-4.97	-0.41	2.19e-6	Testicular germ cell tumor;
TGCT	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg03188948	chr7:1209495	NA	0.47	6.37	0.5	3.42e-9	Longevity;Endometriosis;
TGCT	cis	rs2549003	0.966	rs2706386	chr5:131832687	C/T	cg00255919	chr5:131827918	IRF1	-0.22	-5.24	-0.43	6.67e-7	Asthma (sex interaction);
TGCT	cis	rs886126	0.950	rs916682	chr12:111699146	A/G	cg10833066	chr12:111807467	FAM109A	0.34	5.8	0.46	5.28e-8	Coronary heart disease;
TGCT	cis	rs7917772	0.636	rs2863718	chr10:104519631	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.57	-4.62	-0.38	9.3e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7193541	0.595	rs4476202	chr16:74709940	T/C	cg01733217	chr16:74700730	RFWD3	0.87	9.66	0.66	8.44e-17	Multiple myeloma;
TGCT	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg13012494	chr21:47604986	C21orf56	-0.39	-4.66	-0.39	7.88e-6	Testicular germ cell tumor;
TGCT	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-5.79	-0.46	5.39e-8	Alzheimer's disease;
TGCT	cis	rs9916302	0.904	rs4795384	chr17:37716771	C/G	cg07936489	chr17:37558343	FBXL20	-0.61	-4.72	-0.39	6.35e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs6725041	0.792	rs4638732	chr2:213090070	A/C	cg16329650	chr2:213403929	ERBB4	-0.53	-4.52	-0.38	1.44e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs79387448	0.626	rs80277428	chr2:103080056	G/A	cg09003973	chr2:102972529	NA	1.36	9.34	0.64	4.94e-16	Gut microbiota (bacterial taxa);
TGCT	cis	rs7027203	0.828	rs10122041	chr9:96615517	A/G	cg14598338	chr9:96623480	NA	-0.61	-9.54	-0.65	1.68e-16	DNA methylation (variation);
TGCT	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg00149659	chr3:10157352	C3orf10	0.91	5.89	0.47	3.32e-8	Alzheimer's disease;
TGCT	cis	rs7949030	0.695	rs11231161	chr11:62378221	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.65	9.85	0.66	2.86e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs3902354	1	rs3902354	chr1:109819296	C/A	cg00908766	chr1:109817496	CELSR2	0.46	4.56	0.38	1.23e-5	Cholesterol, total;
TGCT	trans	rs4332037	0.539	rs11764780	chr7:2020904	G/C	cg25206134	chr2:45395956	NA	0.97	7.33	0.55	2.6e-11	Bipolar disorder;
TGCT	cis	rs6456156	0.846	rs7774396	chr6:167519786	G/A	cg07741184	chr6:167504864	NA	0.22	4.44	0.37	2e-5	Primary biliary cholangitis;
TGCT	cis	rs28595532	0.920	rs115994240	chr4:119744622	C/T	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg20607798	chr8:58055168	NA	0.61	5.06	0.41	1.5e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs17376456	0.877	rs10059230	chr5:93450347	A/G	cg25358565	chr5:93447407	FAM172A	0.92	8.38	0.6	9.58e-14	Diabetic retinopathy;
TGCT	cis	rs10464366	0.544	rs34866559	chr7:39166071	G/A	cg18850127	chr7:39170497	POU6F2	0.33	7.16	0.54	6.13e-11	IgG glycosylation;
TGCT	cis	rs6964587	1.000	rs6944591	chr7:91642714	T/C	cg22709100	chr7:91322751	NA	0.27	4.48	0.37	1.68e-5	Breast cancer;
TGCT	cis	rs12142240	0.698	rs6684274	chr1:46810842	A/G	cg14993813	chr1:46806288	NSUN4	0.58	4.78	0.39	4.79e-6	Menopause (age at onset);
TGCT	cis	rs9467773	0.967	rs9467775	chr6:26513435	G/A	cg26531700	chr6:26746687	NA	0.47	4.57	0.38	1.14e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs6558530	0.666	rs28376731	chr8:1696252	C/A	cg09410841	chr8:1729607	CLN8	0.68	6.01	0.48	1.89e-8	Systolic blood pressure;
TGCT	trans	rs7618501	0.699	rs11130224	chr3:49936910	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.87	9.3	0.64	6.15e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg20203395	chr5:56204925	C5orf35	-0.58	-4.97	-0.41	2.19e-6	Initial pursuit acceleration;
TGCT	cis	rs56235845	0.694	rs11738681	chr5:176761535	A/G	cg17509989	chr5:176798049	RGS14	0.54	7.46	0.56	1.28e-11	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs2153535	0.580	rs969421	chr6:8451949	A/C	cg07606381	chr6:8435919	SLC35B3	0.53	5.02	0.41	1.79e-6	Motion sickness;
TGCT	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg05368731	chr17:41323189	NBR1	1.02	11.43	0.72	4.07e-21	Menopause (age at onset);
TGCT	cis	rs7216064	1.000	rs7221651	chr17:65832390	A/G	cg12091567	chr17:66097778	LOC651250	0.87	6.62	0.51	9.79e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs3803170	0.513	rs4572196	chr12:111831993	A/G	cg10833066	chr12:111807467	FAM109A	0.33	5.17	0.42	9.22e-7	Mean corpuscular hemoglobin;
TGCT	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg22963979	chr7:1858916	MAD1L1	-0.39	-5.94	-0.47	2.68e-8	Bipolar disorder and schizophrenia;
TGCT	cis	rs644799	0.582	rs1727149	chr11:95497171	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.7	-7.7	-0.57	3.71e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs12220238	1.000	rs11000925	chr10:75972601	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.78	0.57	2.42e-12	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs1153858	1.000	rs1145074	chr15:45703824	T/A	cg14582100	chr15:45693742	SPATA5L1	0.49	6.0	0.47	2.04e-8	Homoarginine levels;
TGCT	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg02592271	chr2:27665507	KRTCAP3	-0.4	-4.53	-0.38	1.38e-5	Total body bone mineral density;
TGCT	cis	rs9634489	0.502	rs2011392	chr13:97099975	T/C	cg11411106	chr13:97107445	HS6ST3	-0.25	-4.44	-0.37	1.96e-5	Body mass index;
TGCT	cis	rs12478296	0.792	rs6738361	chr2:243014257	C/T	cg06360820	chr2:242988706	NA	-0.83	-5.68	-0.45	9.2e-8	Obesity-related traits;
TGCT	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg10047753	chr17:41438598	NA	0.94	9.23	0.64	9.06e-16	Menopause (age at onset);
TGCT	cis	rs60843830	0.964	rs17713568	chr2:242132	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.69	6.48	0.5	1.96e-9	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs16958440	0.867	rs76922914	chr18:44688454	T/C	cg17192377	chr18:44677553	HDHD2	0.63	4.7	0.39	6.74e-6	Sitting height ratio;
TGCT	cis	rs7666738	0.830	rs2865979	chr4:99027137	T/C	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4809627	1	rs4809627	chr20:45757655	C/T	cg27589058	chr20:45804311	EYA2	-0.3	-7.08	-0.54	9.38e-11	Type 2 diabetes;
TGCT	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg15691649	chr6:25882328	NA	-0.51	-6.33	-0.49	4.02e-9	Uric acid levels;
TGCT	cis	rs9300255	0.537	rs1727334	chr12:123714236	A/G	cg00376283	chr12:123451042	ABCB9	0.67	5.26	0.43	6.13e-7	Neutrophil percentage of white cells;
TGCT	cis	rs25645	0.830	rs4072639	chr17:38189049	G/A	cg17467752	chr17:38218738	THRA	-0.56	-5.06	-0.41	1.46e-6	Myeloid white cell count;
TGCT	cis	rs17152411	0.895	rs61872120	chr10:126583588	T/G	cg07906193	chr10:126599966	NA	0.41	5.05	0.41	1.52e-6	Height;
TGCT	cis	rs17197710	0.608	rs12573962	chr11:47305660	G/C	cg13308137	chr11:47528955	CUGBP1	0.41	5.82	0.46	4.71e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2072499	0.750	rs55910626	chr1:156159909	C/G	cg24450063	chr1:156163899	SLC25A44	1.11	10.16	0.67	5.03e-18	Testicular germ cell tumor;
TGCT	cis	rs7397814	0.558	rs4764447	chr12:9579109	C/T	cg27502298	chr12:9555721	NA	0.54	8.6	0.61	2.9e-14	IgG glycosylation;
TGCT	cis	rs9916302	0.861	rs632202	chr17:37453294	C/A	cg15445000	chr17:37608096	MED1	-0.31	-4.59	-0.38	1.06e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs644799	1.000	rs1944074	chr11:95511445	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	8.53	0.61	4.41e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs308403	0.568	rs1512975	chr4:123657342	G/A	cg10495464	chr4:123653540	BBS12;LOC729338	0.71	6.62	0.51	9.74e-10	Blood protein levels;
TGCT	cis	rs7020830	0.898	rs308492	chr9:37298020	C/T	cg14294708	chr9:37120828	ZCCHC7	1.18	15.56	0.81	6.32e-31	Schizophrenia;
TGCT	cis	rs9814567	1.000	rs1880377	chr3:134270468	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.96	9.11	0.63	1.79e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs7937682	0.883	rs12366001	chr11:111433916	A/G	cg09085632	chr11:111637200	PPP2R1B	0.99	9.52	0.65	1.82e-16	Primary sclerosing cholangitis;
TGCT	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg24675658	chr1:53192096	ZYG11B	-0.75	-8.92	-0.63	5.02e-15	Monocyte count;
TGCT	cis	rs13191362	0.935	rs73023493	chr6:162952769	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.67	5.16	0.42	9.64e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs10791323	0.569	rs10736608	chr11:133740048	C/T	cg03690763	chr11:133734501	NA	-0.28	-4.78	-0.39	4.96e-6	Childhood ear infection;
TGCT	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg15383120	chr6:291909	DUSP22	-0.68	-7.03	-0.53	1.21e-10	Menopause (age at onset);
TGCT	cis	rs9393692	0.905	rs9358919	chr6:26287862	C/T	cg13736514	chr6:26305472	NA	-0.37	-5.42	-0.44	3.01e-7	Educational attainment;
TGCT	cis	rs1008375	0.966	rs11722132	chr4:17697217	T/C	cg18681998	chr4:17616180	MED28	0.78	7.35	0.55	2.35e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg17971929	chr21:40555470	PSMG1	0.98	9.51	0.65	1.95e-16	Cognitive function;
TGCT	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg25036284	chr2:26402008	FAM59B	-0.69	-4.95	-0.41	2.39e-6	Gut microbiome composition (summer);
TGCT	cis	rs514406	0.584	rs12095247	chr1:53193796	A/C	cg04995860	chr1:53192072	ZYG11B	0.4	4.49	0.37	1.6e-5	Monocyte count;
TGCT	cis	rs12136530	0.714	rs34553579	chr1:19779378	A/C	cg18923740	chr1:19971790	NBL1	0.37	4.53	0.38	1.34e-5	Lead levels in blood;
TGCT	cis	rs921968	0.541	rs12617603	chr2:219369288	A/G	cg02176678	chr2:219576539	TTLL4	-0.48	-6.84	-0.52	3.21e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg25036284	chr2:26402008	FAM59B	-0.56	-4.85	-0.4	3.62e-6	Gut microbiome composition (summer);
TGCT	cis	rs3091242	0.933	rs4649084	chr1:25752617	A/G	cg09222892	chr1:25734099	RHCE	-0.43	-7.11	-0.54	7.99e-11	Erythrocyte sedimentation rate;
TGCT	cis	rs7829975	0.846	rs6601724	chr8:8544872	C/T	cg15556689	chr8:8085844	FLJ10661	-0.68	-6.14	-0.48	1e-8	Mood instability;
TGCT	cis	rs73110464	0.609	rs6580923	chr12:53358352	A/G	cg16329197	chr12:53359506	NA	-0.56	-7.89	-0.58	1.32e-12	Cancer (pleiotropy);
TGCT	cis	rs4285028	0.747	rs9850439	chr3:121393075	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.92	-7.3	-0.55	3.03e-11	Multiple sclerosis;
TGCT	cis	rs875971	0.929	rs4122249	chr7:65920936	T/C	cg18876405	chr7:65276391	NA	0.31	4.67	0.39	7.78e-6	Aortic root size;
TGCT	cis	rs66573146	0.808	rs56268690	chr4:6923887	C/T	cg00135399	chr4:7783873	AFAP1	0.42	4.54	0.38	1.3e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs79349575	0.715	rs62075844	chr17:47002389	G/A	cg26022315	chr17:47021804	SNF8	0.49	4.89	0.4	3.03e-6	Type 2 diabetes;
TGCT	cis	rs7959452	0.570	rs10878964	chr12:69720691	T/G	cg14784868	chr12:69753453	YEATS4	0.67	6.96	0.53	1.77e-10	Blood protein levels;
TGCT	cis	rs694739	0.628	rs11606081	chr11:64137875	T/C	cg23796481	chr11:64053134	BAD;GPR137	0.64	6.62	0.51	9.49e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs8013055	0.846	rs8003942	chr14:105971670	A/G	cg19700328	chr14:106028568	NA	-0.53	-5.91	-0.47	3.03e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs9787249	0.915	rs6664570	chr1:40206298	G/A	cg19912559	chr1:40204330	PPIE	0.49	5.7	0.46	8.41e-8	Blood protein levels;
TGCT	cis	rs67311347	1.000	rs9835219	chr3:40424093	C/T	cg13683864	chr3:40499215	RPL14	-1.11	-11.7	-0.72	9.11e-22	Renal cell carcinoma;
TGCT	cis	rs72945132	0.769	rs3781644	chr11:70190375	G/A	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg17747265	chr1:1875780	NA	-0.43	-8.09	-0.59	4.53e-13	Body mass index;
TGCT	cis	rs40363	0.951	rs250632	chr16:3523047	C/T	cg22508957	chr16:3507546	NAT15	0.56	5.41	0.44	3.11e-7	Tuberculosis;
TGCT	trans	rs1973993	0.669	rs510552	chr1:96891671	A/G	cg10631902	chr5:14652156	NA	0.4	10.92	0.7	7.19e-20	Weight;
TGCT	cis	rs13191362	0.507	rs2849511	chr6:163139050	C/G	cg06582575	chr6:163149167	PACRG;PARK2	-0.6	-5.69	-0.45	8.72e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs5750830	0.620	rs1007337	chr22:39781585	C/T	cg11247378	chr22:39784982	NA	-0.73	-9.73	-0.66	5.72e-17	Intelligence (multi-trait analysis);
TGCT	trans	rs2727020	0.521	rs7107178	chr11:49526668	G/A	cg11707556	chr5:10655725	ANKRD33B	0.42	8.63	0.61	2.5e-14	Coronary artery disease;
TGCT	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.69	-7.19	-0.54	5.48e-11	Prostate cancer;
TGCT	cis	rs7100689	0.599	rs7077847	chr10:82134952	A/G	cg01528321	chr10:82214614	TSPAN14	0.83	7.87	0.58	1.5e-12	Post bronchodilator FEV1;
TGCT	cis	rs2224391	0.628	rs2753230	chr6:5248538	C/G	cg09085698	chr6:5261316	LYRM4;FARS2	0.96	6.05	0.48	1.61e-8	Height;
TGCT	cis	rs12477438	0.765	rs6749059	chr2:99591021	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.67	-5.89	-0.47	3.39e-8	Chronic sinus infection;
TGCT	cis	rs13217239	0.646	rs10946898	chr6:27003884	T/C	cg02458000	chr6:26745757	NA	0.5	4.61	0.38	1e-5	Schizophrenia;
TGCT	cis	rs2235642	0.893	rs2076445	chr16:1592266	A/T	cg00463982	chr16:1583984	IFT140;TMEM204	-0.29	-4.98	-0.41	2.11e-6	Coronary artery disease;
TGCT	cis	rs854765	0.547	rs6502632	chr17:17913057	A/G	cg04398451	chr17:18023971	MYO15A	-0.32	-5.12	-0.42	1.15e-6	Total body bone mineral density;
TGCT	cis	rs2072499	0.898	rs2736609	chr1:156202640	C/T	cg06970220	chr1:156163860	SLC25A44	0.71	5.87	0.47	3.81e-8	Testicular germ cell tumor;
TGCT	cis	rs9916302	0.904	rs620686	chr17:37453617	A/G	cg07936489	chr17:37558343	FBXL20	0.62	4.91	0.4	2.85e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7818688	0.697	rs11783985	chr8:95979886	A/G	cg16049864	chr8:95962084	TP53INP1	0.54	4.64	0.38	8.87e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg20607798	chr8:58055168	NA	0.56	4.7	0.39	6.67e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.01	0.48	1.9e-8	Bipolar disorder;
TGCT	cis	rs4478858	0.684	rs17440445	chr1:31722562	C/T	cg07478791	chr1:31886160	SERINC2	0.47	4.51	0.38	1.47e-5	Alcohol dependence;
TGCT	cis	rs2692947	0.537	rs11685849	chr2:96243804	C/A	cg14612417	chr2:95688557	NA	0.37	4.68	0.39	7.34e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg17971929	chr21:40555470	PSMG1	0.98	9.47	0.65	2.42e-16	Cognitive function;
TGCT	cis	rs9467773	0.620	rs2494716	chr6:26662736	T/C	cg11502198	chr6:26597334	ABT1	0.55	4.89	0.4	3.05e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2204008	0.537	rs28680519	chr12:38502946	C/T	cg26384229	chr12:38710491	ALG10B	0.78	7.47	0.56	1.27e-11	Bladder cancer;
TGCT	cis	rs7226408	0.857	rs55804703	chr18:34452703	A/G	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	trans	rs8073060	0.586	rs188959	chr17:34021307	C/A	cg19694781	chr19:47549865	TMEM160	-0.6	-13.37	-0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg11890956	chr21:40555474	PSMG1	1.06	9.91	0.66	2.1e-17	Cognitive function;
TGCT	cis	rs9796	0.674	rs6492978	chr15:41317702	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.41	-5.33	-0.43	4.57e-7	Menopause (age at onset);
TGCT	cis	rs2692947	0.644	rs2969491	chr2:96794982	C/T	cg23100626	chr2:96804247	ASTL	0.47	5.61	0.45	1.28e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs228437	0.526	rs228435	chr6:134896528	C/T	cg09872934	chr6:134495829	SGK1	0.51	4.62	0.38	9.39e-6	Melanoma;
TGCT	cis	rs2721195	0.816	rs4925826	chr8:145706276	G/A	cg15320075	chr8:145703422	NA	0.73	7.48	0.56	1.18e-11	Age at first birth;
TGCT	cis	rs4319547	1.000	rs6489071	chr12:123025576	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.69	-5.47	-0.44	2.42e-7	Body mass index;
TGCT	cis	rs1008375	1.000	rs3846357	chr4:17635887	A/T	cg18681998	chr4:17616180	MED28	1.01	11.55	0.72	2.15e-21	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10832963	0.594	rs1550869	chr11:18613498	G/T	cg20219074	chr11:18656078	SPTY2D1	0.71	6.33	0.49	4.09e-9	Breast cancer;
TGCT	cis	rs35306767	0.715	rs1250891	chr10:1040159	G/C	cg26597838	chr10:835615	NA	0.62	6.86	0.52	2.84e-10	Eosinophil percentage of granulocytes;
TGCT	cis	rs2742417	0.603	rs2742456	chr3:45767176	C/T	cg04837898	chr3:45731254	SACM1L	-0.66	-6.96	-0.53	1.77e-10	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs916888	0.610	rs142167	chr17:44795234	C/T	cg17911788	chr17:44343683	NA	0.48	5.64	0.45	1.11e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs3749237	0.595	rs4855859	chr3:49526300	C/T	cg02487422	chr3:49467188	NICN1	0.61	6.29	0.49	5.08e-9	Resting heart rate;
TGCT	cis	rs7044106	0.762	rs3903886	chr9:123383646	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.55	-6.06	-0.48	1.49e-8	Hip circumference adjusted for BMI;
TGCT	cis	rs6570726	0.620	rs12201226	chr6:145913419	A/T	cg23711669	chr6:146136114	FBXO30	0.7	6.45	0.5	2.23e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs367615	0.501	rs447849	chr5:108951190	A/C	cg17395555	chr5:108820864	NA	-0.25	-4.74	-0.39	5.86e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs2153535	0.580	rs6929206	chr6:8447961	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.76	0.46	6.39e-8	Motion sickness;
TGCT	cis	rs7647973	1.000	rs11719762	chr3:49409002	G/C	cg05785598	chr3:49045655	WDR6	0.39	4.65	0.39	8.28e-6	Menarche (age at onset);
TGCT	cis	rs6840360	0.870	rs1372978	chr4:152456180	A/G	cg17479576	chr4:152424074	FAM160A1	-0.57	-6.34	-0.49	3.85e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs360798	0.553	rs7562734	chr2:63047973	G/C	cg17519650	chr2:63277830	OTX1	-0.58	-4.83	-0.4	3.93e-6	Coronary artery disease;
TGCT	cis	rs4372836	1.000	rs7598876	chr2:28974466	T/C	cg09522027	chr2:28974177	PPP1CB	-0.59	-5.15	-0.42	1e-6	Body mass index;
TGCT	cis	rs9372253	1.000	rs2235989	chr6:110714584	A/T	cg19196401	chr6:110721138	DDO	-0.49	-7.08	-0.54	9.26e-11	Platelet distribution width;
TGCT	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	4.54	0.38	1.3e-5	Menopause (age at onset);
TGCT	trans	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg11887960	chr12:57824829	NA	1.1	9.44	0.65	2.89e-16	Lung disease severity in cystic fibrosis;
TGCT	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg11764359	chr7:65958608	NA	-0.55	-4.87	-0.4	3.3e-6	Aortic root size;
TGCT	trans	rs4650994	0.623	rs35854525	chr1:178618604	C/T	cg05059571	chr16:84539110	KIAA1609	0.41	7.11	0.54	8.28e-11	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs1215050	0.765	rs471500	chr4:98714820	T/C	cg17366294	chr4:99064904	C4orf37	0.52	5.61	0.45	1.27e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs919433	0.713	rs6719483	chr2:198472886	A/G	cg00792783	chr2:198669748	PLCL1	0.49	4.61	0.38	9.95e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	5.23	0.43	6.92e-7	Menopause (age at onset);
TGCT	cis	rs11203032	0.831	rs9651495	chr10:90932381	G/A	cg16672925	chr10:90967113	CH25H	0.73	4.5	0.37	1.55e-5	Heart failure;
TGCT	cis	rs295140	0.605	rs296818	chr2:201176944	C/T	cg04283868	chr2:201171347	SPATS2L	-0.47	-4.47	-0.37	1.72e-5	QT interval;
TGCT	cis	rs7296418	0.961	rs4148862	chr12:123568619	A/C	cg00376283	chr12:123451042	ABCB9	0.82	7.08	0.54	9.57e-11	Platelet count;
TGCT	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg24829409	chr8:58192753	C8orf71	-0.57	-5.33	-0.43	4.56e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg16680214	chr1:154839983	KCNN3	-0.36	-7.22	-0.54	4.53e-11	Prostate cancer;
TGCT	cis	rs2797160	1.000	rs1739354	chr6:126017808	G/C	cg05901451	chr6:126070800	HEY2	0.73	6.29	0.49	5.01e-9	Endometrial cancer;
TGCT	trans	rs931812	1.000	rs4734494	chr8:101917721	T/C	cg20993868	chr7:22813445	NA	0.36	8.02	0.58	6.78e-13	Attention deficit hyperactivity disorder and conduct disorder;
TGCT	cis	rs174601	0.864	rs174545	chr11:61569306	C/G	cg01500311	chr11:61656094	FADS3	-0.33	-5.6	-0.45	1.3e-7	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
TGCT	cis	rs7937682	0.575	rs10789851	chr11:111750955	G/C	cg09085632	chr11:111637200	PPP2R1B	0.88	8.5	0.61	5.19e-14	Primary sclerosing cholangitis;
TGCT	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs739401	0.611	rs10833048	chr11:3020040	A/G	cg05729581	chr11:3078854	CARS	-0.54	-4.87	-0.4	3.33e-6	Longevity;
TGCT	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg04414720	chr1:150670196	GOLPH3L	0.39	5.04	0.41	1.58e-6	Tonsillectomy;
TGCT	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg13206674	chr6:150067644	NUP43	0.52	4.51	0.38	1.5e-5	Lung cancer;
TGCT	cis	rs7017914	0.935	rs35564237	chr8:71600474	G/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.03	-0.41	1.69e-6	Bone mineral density;
TGCT	cis	rs9914988	0.943	rs4262997	chr17:27129562	A/G	cg20469991	chr17:27169893	C17orf63	-0.72	-5.09	-0.42	1.29e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs185694	0.779	rs628483	chr13:30895462	C/T	cg07600127	chr13:30881527	KATNAL1	-0.75	-6.12	-0.48	1.11e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
TGCT	cis	rs7633770	0.769	rs3796371	chr3:46667224	C/T	cg11219411	chr3:46661640	NA	0.33	4.69	0.39	6.99e-6	Coronary artery disease;
TGCT	cis	rs2688608	0.560	rs10128354	chr10:75470045	T/C	cg15838173	chr10:75533400	FUT11	-0.31	-5.01	-0.41	1.81e-6	Inflammatory bowel disease;
TGCT	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg22920501	chr2:26401640	FAM59B	0.73	6.12	0.48	1.12e-8	Gut microbiome composition (summer);
TGCT	cis	rs77669868	0.929	rs3782007	chr11:114066438	A/G	cg01914181	chr11:114070210	ZBTB16	-0.33	-6.31	-0.49	4.52e-9	Monocyte percentage of white cells;
TGCT	cis	rs6866344	0.697	rs72812613	chr5:178135257	G/A	cg10224037	chr5:178157518	ZNF354A	0.94	8.08	0.59	4.77e-13	Neutrophil percentage of white cells;
TGCT	cis	rs35883536	0.525	rs2647321	chr1:101032006	T/G	cg06223162	chr1:101003688	GPR88	0.42	7.85	0.58	1.67e-12	Monocyte count;
TGCT	cis	rs8141529	0.732	rs6005881	chr22:29183133	A/G	cg02153584	chr22:29168773	CCDC117	0.75	6.44	0.5	2.33e-9	Lymphocyte counts;
TGCT	cis	rs6088590	0.965	rs13040449	chr20:33358901	T/A	cg06115741	chr20:33292138	TP53INP2	0.67	5.6	0.45	1.34e-7	Coronary artery disease;
TGCT	cis	rs7412746	0.658	rs72704682	chr1:150897677	A/T	cg09365446	chr1:150670422	GOLPH3L	0.34	4.71	0.39	6.58e-6	Melanoma;
TGCT	cis	rs617219	0.671	rs2591388	chr5:78557241	A/G	cg05890484	chr5:78407552	BHMT	0.36	4.77	0.39	5.06e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs9457247	0.967	rs1794694	chr6:167404751	T/C	cg23791538	chr6:167370224	RNASET2	-0.49	-4.96	-0.41	2.26e-6	Crohn's disease;
TGCT	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9325144	0.600	rs10880934	chr12:38730455	C/T	cg10518543	chr12:38710700	ALG10B	-0.49	-4.44	-0.37	1.99e-5	Morning vs. evening chronotype;
TGCT	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg10047753	chr17:41438598	NA	0.96	9.65	0.65	9.13e-17	Menopause (age at onset);
TGCT	cis	rs9399135	0.660	rs4646868	chr6:135271946	A/G	cg24558204	chr6:135376177	HBS1L	0.5	5.39	0.44	3.37e-7	Red blood cell count;
TGCT	cis	rs3026101	0.624	rs1058398	chr17:5288760	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	-0.48	-4.76	-0.39	5.33e-6	Body mass index;
TGCT	cis	rs1403694	0.966	rs9869244	chr3:186437554	A/T	cg12454167	chr3:186435060	KNG1	0.43	7.53	0.56	9.3e-12	Blood protein levels;
TGCT	cis	rs2549003	1.000	rs2549002	chr5:131829578	C/A	cg00255919	chr5:131827918	IRF1	-0.2	-4.76	-0.39	5.22e-6	Asthma (sex interaction);
TGCT	cis	rs12682352	0.650	rs13265731	chr8:8673320	T/C	cg15556689	chr8:8085844	FLJ10661	0.59	5.08	0.41	1.35e-6	Neuroticism;
TGCT	cis	rs6840360	1.000	rs6833368	chr4:152603177	C/T	cg17479576	chr4:152424074	FAM160A1	0.51	5.4	0.44	3.24e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	5.11	0.42	1.18e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs3096299	0.933	rs2965934	chr16:89481229	C/G	cg06640241	chr16:89574553	SPG7	0.66	6.47	0.5	2.04e-9	Multiple myeloma (IgH translocation);
TGCT	cis	rs6940638	0.688	rs2022272	chr6:27103580	A/G	cg26531700	chr6:26746687	NA	-0.62	-5.63	-0.45	1.15e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs4273100	0.688	rs4924980	chr17:19204863	T/C	cg01534423	chr17:18965556	NA	-0.79	-7.15	-0.54	6.62e-11	Schizophrenia;
TGCT	cis	rs600231	0.665	rs12790095	chr11:65326086	T/G	cg13974409	chr11:65292307	SCYL1	0.5	4.76	0.39	5.27e-6	Bone mineral density;
TGCT	cis	rs6088580	0.634	rs6059824	chr20:33014543	T/C	cg06115741	chr20:33292138	TP53INP2	0.53	4.67	0.39	7.67e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs9993613	0.841	rs11731563	chr4:73489191	T/C	cg15102770	chr4:73434591	ADAMTS3	0.5	4.62	0.38	9.46e-6	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs8077889	0.871	rs7212648	chr17:41917962	A/C	cg25876840	chr17:41920477	NA	0.24	4.53	0.38	1.36e-5	Triglycerides;
TGCT	cis	rs350251	0.833	rs350272	chr16:12234773	A/C	cg01574788	chr16:12184133	SNX29	-0.36	-4.79	-0.4	4.68e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2485376	0.842	rs11191283	chr10:104163569	G/A	cg26089160	chr10:104170217	PSD	0.51	5.03	0.41	1.68e-6	QT interval;
TGCT	cis	rs611744	0.647	rs2859813	chr8:109263497	G/A	cg21045802	chr8:109455806	TTC35	0.7	7.05	0.54	1.07e-10	Dupuytren's disease;
TGCT	cis	rs60843830	1.000	rs2126129	chr2:212548	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.63	5.28	0.43	5.63e-7	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs9914544	0.564	rs4334348	chr17:18787004	G/T	cg26378065	chr17:18585709	ZNF286B	0.53	4.63	0.38	9.01e-6	Educational attainment (years of education);
TGCT	cis	rs3902035	0.964	rs62423961	chr6:119008401	T/C	cg07617317	chr6:118971624	C6orf204	0.43	5.0	0.41	1.95e-6	QT interval;
TGCT	cis	rs526231	0.819	rs26233	chr5:102596816	G/T	cg05225461	chr5:102596755	C5orf30	0.22	4.49	0.37	1.64e-5	Primary biliary cholangitis;
TGCT	trans	rs208520	1.000	rs12209225	chr6:66996443	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.84	7.59	0.56	6.69e-12	Exhaled nitric oxide output;
TGCT	cis	rs12681287	0.604	rs13279589	chr8:87477723	C/T	cg27223183	chr8:87520930	FAM82B	-0.9	-6.49	-0.5	1.83e-9	Caudate activity during reward;
TGCT	cis	rs3812049	0.737	rs790155	chr5:127498380	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.57	5.18	0.42	8.76e-7	Lymphocyte counts;Red cell distribution width;
TGCT	cis	rs752010	0.523	rs943376	chr1:42122117	A/G	cg06885757	chr1:42089581	HIVEP3	0.28	5.06	0.41	1.47e-6	Lupus nephritis in systemic lupus erythematosus;
TGCT	cis	rs6540559	1.000	rs1044516	chr1:209959614	G/T	cg21951975	chr1:209979733	IRF6	0.68	5.83	0.46	4.59e-8	Cleft lip with or without cleft palate;
TGCT	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg27535305	chr1:53392650	SCP2	-0.24	-4.73	-0.39	5.98e-6	Monocyte count;
TGCT	cis	rs36051895	0.658	rs7030260	chr9:5008070	C/A	cg02405213	chr9:5042618	JAK2	-0.79	-11.27	-0.71	1.03e-20	Pediatric autoimmune diseases;
TGCT	cis	rs7959452	0.868	rs12812860	chr12:69746671	T/C	cg11871910	chr12:69753446	YEATS4	0.76	8.31	0.6	1.44e-13	Blood protein levels;
TGCT	cis	rs12421382	0.507	rs2186673	chr11:109285519	G/A	cg16359550	chr11:109292809	C11orf87	0.75	7.97	0.58	8.93e-13	Schizophrenia;
TGCT	cis	rs2243480	1.000	rs781157	chr7:65478311	G/A	cg18252515	chr7:66147081	NA	-1.31	-8.18	-0.59	2.87e-13	Diabetic kidney disease;
TGCT	cis	rs4455778	0.538	rs67216951	chr7:49088028	C/T	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	16.05	0.82	4.59e-32	Prudent dietary pattern;
TGCT	cis	rs17102423	0.964	rs11623603	chr14:65602287	T/A	cg11161011	chr14:65562177	MAX	-0.47	-6.26	-0.49	5.62e-9	Obesity-related traits;
TGCT	cis	rs76878669	0.561	rs1039594	chr11:66131149	C/T	cg18002602	chr11:66138449	SLC29A2	0.54	6.71	0.52	6.1e-10	Educational attainment (years of education);
TGCT	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg04317338	chr11:64019027	PLCB3	0.75	6.19	0.49	8.06e-9	Attention deficit hyperactivity disorder;
TGCT	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg18305652	chr10:134549665	INPP5A	0.34	5.75	0.46	6.52e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg18252515	chr7:66147081	NA	1.2	7.33	0.55	2.56e-11	Diabetic kidney disease;
TGCT	cis	rs6582630	0.638	rs10880620	chr12:38517467	A/G	cg26384229	chr12:38710491	ALG10B	-0.55	-4.89	-0.4	3.05e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs6088590	0.561	rs6059934	chr20:33178324	G/T	cg06115741	chr20:33292138	TP53INP2	0.54	4.72	0.39	6.32e-6	Coronary artery disease;
TGCT	cis	rs10927875	0.557	rs1572381	chr1:16344494	G/A	cg21385522	chr1:16154831	NA	0.47	4.85	0.4	3.57e-6	Dilated cardiomyopathy;
TGCT	cis	rs9326248	0.813	rs588534	chr11:117068504	A/G	cg16524733	chr11:117070046	TAGLN	0.34	4.5	0.37	1.52e-5	Blood protein levels;
TGCT	cis	rs9527	0.571	rs12219246	chr10:104613355	A/G	cg15744005	chr10:104629667	AS3MT	-0.5	-6.39	-0.5	3.12e-9	Arsenic metabolism;
TGCT	cis	rs10193935	0.901	rs10175378	chr2:42456267	A/C	cg27598129	chr2:42591480	NA	-0.39	-5.13	-0.42	1.07e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs244731	0.959	rs918459	chr5:176669030	C/T	cg16006841	chr5:176797999	RGS14	-0.55	-7.36	-0.55	2.22e-11	Urate levels in lean individuals;
TGCT	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg03303774	chr4:1407052	NA	-0.31	-4.93	-0.4	2.6e-6	Obesity-related traits;
TGCT	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg13395646	chr4:1353034	KIAA1530	-0.46	-5.84	-0.46	4.32e-8	Obesity-related traits;
TGCT	cis	rs2191566	0.639	rs7257749	chr19:44548666	G/A	cg03039196	chr19:44506973	ZNF230	0.53	4.47	0.37	1.78e-5	Acute lymphoblastic leukemia (childhood);
TGCT	cis	rs55692411	0.517	rs13095697	chr3:50136463	G/A	cg14019146	chr3:50243930	SLC38A3	-0.21	-4.58	-0.38	1.11e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs6121246	0.779	rs6060763	chr20:30282223	A/G	cg13852791	chr20:30311386	BCL2L1	0.78	5.8	0.46	5.15e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs7666738	0.861	rs28829607	chr4:98964325	G/C	cg18180107	chr4:99064573	C4orf37	0.57	5.18	0.42	8.63e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg08439880	chr3:133502540	NA	-0.28	-5.13	-0.42	1.11e-6	Iron status biomarkers;
TGCT	cis	rs617219	0.574	rs3930426	chr5:78597535	C/T	cg09550809	chr5:78407562	BHMT	-0.34	-4.58	-0.38	1.11e-5	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs600550	0.889	rs1365247	chr11:60027309	C/T	cg18570331	chr11:60101691	MS4A6E	0.5	4.44	0.37	1.93e-5	Lipoprotein-associated phospholipase A2 activity and mass;
TGCT	cis	rs11792861	0.816	rs2275637	chr9:111696043	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.53	5.0	0.41	1.88e-6	Menarche (age at onset);
TGCT	cis	rs11585357	0.947	rs72646795	chr1:17612120	C/T	cg08277548	chr1:17600880	PADI3	-0.96	-9.72	-0.66	5.97e-17	Hair shape;
TGCT	cis	rs1075232	1.000	rs12439239	chr15:31651718	G/A	cg01030201	chr15:31746330	NA	-1.01	-5.25	-0.43	6.38e-7	Survival in colorectal cancer (non-distant metastatic);
TGCT	cis	rs2387326	1.000	rs12252465	chr10:129932395	G/A	cg03458096	chr10:129105057	DOCK1	-0.3	-4.67	-0.39	7.78e-6	Select biomarker traits;
TGCT	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg20887711	chr4:1340912	KIAA1530	-0.99	-9.17	-0.64	1.27e-15	Longevity;
TGCT	cis	rs7904368	0.806	rs6602161	chr10:16862280	A/G	cg14835575	chr10:16859367	RSU1	0.68	7.26	0.55	3.79e-11	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
TGCT	cis	rs13394619	0.622	rs7571803	chr2:11744573	G/A	cg07314298	chr2:11723111	GREB1	0.28	4.82	0.4	4.04e-6	Endometriosis;
TGCT	cis	rs11578119	1.000	rs66639118	chr1:170510613	G/T	cg09767346	chr1:170501363	GORAB	0.65	5.17	0.42	9.21e-7	Male-pattern baldness;
TGCT	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg20203395	chr5:56204925	C5orf35	-0.58	-4.87	-0.4	3.34e-6	Initial pursuit acceleration;
TGCT	cis	rs1894292	0.527	rs11733262	chr4:74357851	A/G	cg05868023	chr4:75230803	EREG	0.53	4.59	0.38	1.08e-5	Prostate cancer;
TGCT	cis	rs3096299	0.967	rs28689480	chr16:89460093	T/C	cg02187348	chr16:89574699	SPG7	0.48	4.61	0.38	9.87e-6	Multiple myeloma (IgH translocation);
TGCT	cis	rs7043114	0.525	rs10116241	chr9:95240546	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-5.39	-0.44	3.36e-7	Height;
TGCT	cis	rs17221829	0.965	rs10830365	chr11:89459065	G/A	cg02982614	chr11:89391479	FOLH1B	-0.27	-4.75	-0.39	5.63e-6	Anxiety in major depressive disorder;
TGCT	cis	rs6484504	0.576	rs208088	chr11:31192686	T/C	cg26647111	chr11:31128758	NA	-0.34	-4.63	-0.38	9.09e-6	Red blood cell count;
TGCT	cis	rs2288884	1.000	rs56808319	chr19:52577874	A/T	cg13540795	chr19:52551618	ZNF432	-0.59	-5.0	-0.41	1.89e-6	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs9486719	0.857	rs6568392	chr6:96861476	G/T	cg18709589	chr6:96969512	KIAA0776	0.7	6.19	0.49	7.97e-9	Migraine;Coronary artery disease;
TGCT	cis	rs7666738	0.753	rs11097607	chr4:99011640	C/T	cg05340658	chr4:99064831	C4orf37	0.48	5.43	0.44	2.92e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2486288	0.656	rs8039540	chr15:45551842	C/G	cg14582100	chr15:45693742	SPATA5L1	-0.46	-5.59	-0.45	1.38e-7	Glomerular filtration rate;
TGCT	cis	rs10788575	0.805	rs12569998	chr10:89674157	A/C	cg15103050	chr10:90582504	ANKRD22	0.35	4.72	0.39	6.23e-6	Type 2 diabetes;
TGCT	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg23131131	chr22:24373011	LOC391322	-0.8	-8.69	-0.62	1.78e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg11764359	chr7:65958608	NA	0.61	5.53	0.44	1.79e-7	Aortic root size;
TGCT	cis	rs910187	0.596	rs12329631	chr20:45794427	C/T	cg27589058	chr20:45804311	EYA2	-0.36	-6.84	-0.52	3.18e-10	Migraine;
TGCT	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg06112835	chr11:68658793	MRPL21	0.47	8.3	0.6	1.48e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs3791556	1.000	rs2411429	chr2:240113928	A/G	cg03281426	chr2:240109471	HDAC4	0.28	4.46	0.37	1.82e-5	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs67073037	0.955	rs11695230	chr2:29130140	G/C	cg09522027	chr2:28974177	PPP1CB	0.63	4.97	0.41	2.17e-6	Breast cancer;Breast cancer (estrogen-receptor negative);
TGCT	cis	rs1153858	0.848	rs9806699	chr15:45740392	G/A	cg14582100	chr15:45693742	SPATA5L1	0.41	4.69	0.39	7.18e-6	Homoarginine levels;
TGCT	cis	rs7845219	0.555	rs1129152	chr8:95888307	C/T	cg09323728	chr8:95962352	TP53INP1	-0.48	-5.55	-0.45	1.69e-7	Type 2 diabetes;
TGCT	cis	rs78456975	0.574	rs13412980	chr2:1545231	C/A	cg12573674	chr2:1569213	NA	-0.5	-4.89	-0.4	3.04e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs739496	0.579	rs12307192	chr12:112290346	G/T	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs9291683	0.588	rs2240724	chr4:10021290	G/C	cg00071950	chr4:10020882	SLC2A9	0.7	9.52	0.65	1.86e-16	Bone mineral density;
TGCT	cis	rs5769765	0.955	rs6520066	chr22:50294988	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.41	6.2	0.49	7.76e-9	Schizophrenia;
TGCT	cis	rs9527	0.622	rs12779263	chr10:104886533	G/T	cg15744005	chr10:104629667	AS3MT	-0.44	-4.97	-0.41	2.21e-6	Arsenic metabolism;
TGCT	cis	rs2486012	0.850	rs3124746	chr1:44320934	G/C	cg12908607	chr1:44402522	ARTN	-0.72	-5.68	-0.45	8.89e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs6912958	0.712	rs7755167	chr6:88338752	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-4.55	-0.38	1.26e-5	Monocyte percentage of white cells;
TGCT	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg08439880	chr3:133502540	NA	-0.31	-5.91	-0.47	3.08e-8	Iron status biomarkers;
TGCT	cis	rs210138	1.000	rs210137	chr6:33542478	C/T	cg24505687	chr6:33548425	BAK1	0.51	5.72	0.46	7.67e-8	Testicular germ cell tumor;
TGCT	cis	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg07424592	chr7:64974309	NA	1.36	7.93	0.58	1.1e-12	Diabetic kidney disease;
TGCT	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg03264133	chr6:25882463	NA	0.51	4.71	0.39	6.45e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9952991	1.000	rs9952991	chr18:12780464	G/A	cg09945482	chr18:12777974	NA	0.48	4.52	0.38	1.43e-5	Inflammatory skin disease;
TGCT	cis	rs911263	0.961	rs10131490	chr14:68743307	A/G	cg18825221	chr14:68749962	RAD51L1	-0.27	-5.16	-0.42	9.38e-7	Primary biliary cholangitis;
TGCT	cis	rs28595532	0.764	rs116302502	chr4:119748848	T/A	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs7582180	0.764	rs11689439	chr2:100925399	T/C	cg14675211	chr2:100938903	LONRF2	0.49	4.8	0.4	4.49e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs853679	0.546	rs200950	chr6:27835772	A/G	cg10876282	chr6:28092338	ZSCAN16	0.75	4.45	0.37	1.88e-5	Depression;
TGCT	cis	rs77106637	0.929	rs1059000	chr11:72504972	G/C	cg03713592	chr11:72463424	ARAP1	0.95	6.2	0.49	7.69e-9	Type 2 diabetes;
TGCT	cis	rs7819412	0.838	rs4840544	chr8:10960572	C/T	cg03192020	chr8:11204681	TDH	-0.52	-4.69	-0.39	7.18e-6	Triglycerides;
TGCT	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg24675658	chr1:53192096	ZYG11B	0.74	8.68	0.61	1.87e-14	Monocyte count;
TGCT	cis	rs2204008	0.538	rs61931093	chr12:38242911	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-4.7	-0.39	6.68e-6	Bladder cancer;
TGCT	cis	rs10779751	1.000	rs11121711	chr1:11317661	A/T	cg08854313	chr1:11322531	MTOR	0.99	10.58	0.69	4.78e-19	Body mass index;
TGCT	cis	rs739496	0.615	rs12579287	chr12:112090814	A/G	cg10833066	chr12:111807467	FAM109A	0.36	5.22	0.42	7.28e-7	Platelet count;
TGCT	cis	rs138229	0.506	rs9628282	chr22:50534952	G/T	cg08875078	chr22:50639485	SELO	0.56	4.73	0.39	6.03e-6	Behavioural disinhibition (generation interaction);
TGCT	cis	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg07424592	chr7:64974309	NA	-1.31	-7.72	-0.57	3.33e-12	Diabetic kidney disease;
TGCT	cis	rs7027203	0.576	rs4424329	chr9:96560806	G/C	cg13679303	chr9:96623674	NA	0.53	7.61	0.56	6.13e-12	DNA methylation (variation);
TGCT	cis	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg07424592	chr7:64974309	NA	-1.31	-7.72	-0.57	3.33e-12	Diabetic kidney disease;
TGCT	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg01238044	chr22:24384105	GSTT1	-0.51	-4.9	-0.4	2.95e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2115630	0.645	rs2292463	chr15:85175750	A/G	cg12863693	chr15:85201151	NMB	-0.4	-5.23	-0.43	6.91e-7	P wave terminal force;
TGCT	cis	rs2235642	0.717	rs9937922	chr16:1658154	C/G	cg00463982	chr16:1583984	IFT140;TMEM204	-0.27	-4.56	-0.38	1.22e-5	Coronary artery disease;
TGCT	cis	rs3960554	0.709	rs73138006	chr7:75769990	T/C	cg17325771	chr7:75508891	RHBDD2	-0.58	-4.83	-0.4	3.91e-6	Eotaxin levels;
TGCT	cis	rs651907	0.535	rs13084113	chr3:101534039	C/G	cg12386194	chr3:101231763	SENP7	0.45	4.45	0.37	1.87e-5	Colorectal cancer;
TGCT	cis	rs9399135	0.967	rs9399129	chr6:135285148	C/A	cg24558204	chr6:135376177	HBS1L	0.48	4.75	0.39	5.48e-6	Red blood cell count;
TGCT	cis	rs7020830	0.898	rs308495	chr9:37277603	G/T	cg14294708	chr9:37120828	ZCCHC7	1.16	15.74	0.82	2.4e-31	Schizophrenia;
TGCT	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg10295955	chr4:187884368	NA	-1.02	-15.6	-0.81	5.02e-31	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7666738	0.830	rs2114426	chr4:98933130	C/T	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.4	-6.81	-0.52	3.77e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs826838	1.000	rs11168676	chr12:38977304	A/G	cg26384229	chr12:38710491	ALG10B	1.03	10.33	0.68	1.97e-18	Heart rate;
TGCT	cis	rs7666738	0.606	rs28481322	chr4:99086638	T/C	cg05340658	chr4:99064831	C4orf37	0.44	4.8	0.4	4.5e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg07507251	chr3:52567010	NT5DC2	0.47	6.7	0.52	6.47e-10	Bipolar disorder;
TGCT	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg26338869	chr17:61819248	STRADA	-0.55	-5.08	-0.42	1.34e-6	Prudent dietary pattern;
TGCT	cis	rs669446	0.527	rs72883034	chr1:44112379	T/C	cg12908607	chr1:44402522	ARTN	-0.55	-5.9	-0.47	3.25e-8	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs476633	0.691	rs28735224	chr15:41537539	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.57	-7.34	-0.55	2.47e-11	Glomerular filtration rate (creatinine);
TGCT	cis	rs60871478	0.898	rs35928069	chr7:823067	G/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.47	4.58	0.38	1.13e-5	Cerebrospinal P-tau181p levels;
TGCT	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	16.1	0.82	3.69e-32	Prudent dietary pattern;
TGCT	cis	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg03213289	chr20:61660250	NA	0.68	9.99	0.67	1.36e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs6429082	0.689	rs10802803	chr1:235709610	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.54	-4.67	-0.39	7.62e-6	Adiposity;
TGCT	cis	rs250677	0.524	rs250665	chr5:148454394	A/C	cg18129178	chr5:148520854	ABLIM3	-0.36	-5.32	-0.43	4.66e-7	Breast cancer;
TGCT	cis	rs2464469	0.654	rs4646570	chr15:58343146	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.4	-5.88	-0.47	3.57e-8	Barrett's esophagus  or Esophageal adenocarcinoma;
TGCT	cis	rs1552244	0.608	rs9837460	chr3:10049922	G/C	cg00149659	chr3:10157352	C3orf10	0.69	4.99	0.41	2.03e-6	Alzheimer's disease;
TGCT	trans	rs11082438	1.000	rs11082438	chr18:42865210	G/T	cg06374610	chr10:50328992	NA	-0.83	-6.79	-0.52	4.09e-10	Follicular lymphoma;
TGCT	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg05785598	chr3:49045655	WDR6	-0.37	-5.01	-0.41	1.87e-6	Menarche (age at onset);
TGCT	cis	rs9486719	0.857	rs4346856	chr6:96880270	C/T	cg18709589	chr6:96969512	KIAA0776	0.76	6.58	0.51	1.19e-9	Migraine;Coronary artery disease;
TGCT	cis	rs9341808	0.754	rs10733162	chr6:81023389	G/A	cg08355045	chr6:80787529	NA	0.26	4.46	0.37	1.79e-5	Sitting height ratio;
TGCT	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg02353165	chr6:42928485	GNMT	0.97	9.86	0.66	2.8e-17	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs3125734	0.633	rs6479792	chr10:63983264	T/G	cg09941381	chr10:64027924	RTKN2	-0.36	-5.53	-0.44	1.83e-7	Rheumatoid arthritis;
TGCT	cis	rs9902453	0.817	rs55974138	chr17:28215546	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.8	7.07	0.54	9.76e-11	Coffee consumption (cups per day);
TGCT	cis	rs1018836	0.847	rs4735226	chr8:91569238	T/A	cg16814680	chr8:91681699	NA	-0.9	-9.91	-0.66	2.06e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs694419	0.602	rs7226431	chr18:60176204	A/C	cg13506219	chr18:60193840	ZCCHC2	-0.55	-4.93	-0.4	2.58e-6	Serum albumin level;
TGCT	cis	rs7267979	0.833	rs6138556	chr20:25243310	C/T	cg14121845	chr20:25566513	NINL	0.49	5.44	0.44	2.73e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9517302	0.578	rs2274054	chr13:99098470	C/T	cg22223119	chr13:99095684	FARP1	-0.55	-5.99	-0.47	2.16e-8	Obesity-related traits;
TGCT	cis	rs17401966	0.627	rs35859381	chr1:10466040	G/A	cg19773385	chr1:10388646	KIF1B	-0.22	-5.17	-0.42	9.17e-7	Hepatocellular carcinoma;
TGCT	cis	rs5769765	0.955	rs61136468	chr22:50312679	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.39	5.49	0.44	2.16e-7	Schizophrenia;
TGCT	cis	rs4886920	0.563	rs4420498	chr15:78079425	T/C	cg25212270	chr15:78015279	NA	-0.23	-4.87	-0.4	3.36e-6	Neuroticism;
TGCT	cis	rs7572733	0.515	rs1518368	chr2:198839145	G/A	cg00792783	chr2:198669748	PLCL1	0.57	5.1	0.42	1.24e-6	Dermatomyositis;
TGCT	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg16414030	chr3:133502952	NA	-0.65	-10.6	-0.69	4.35e-19	Iron status biomarkers;
TGCT	cis	rs317689	0.581	rs160829	chr12:69769538	G/C	cg14784868	chr12:69753453	YEATS4	0.64	5.72	0.46	7.3900000000000007e-08	Response to diuretic therapy;
TGCT	cis	rs36051895	0.623	rs2146040	chr9:5260039	C/G	cg02405213	chr9:5042618	JAK2	0.72	9.78	0.66	4.22e-17	Pediatric autoimmune diseases;
TGCT	cis	rs59107033	0.643	rs9841543	chr3:123118315	T/C	cg04890266	chr3:123102914	ADCY5	-0.38	-5.96	-0.47	2.4e-8	Lymphocyte counts;
TGCT	trans	rs3780486	0.801	rs56687083	chr9:33132134	A/G	cg20290983	chr6:43655470	MRPS18A	1.19	14.84	0.8	2.81e-29	IgG glycosylation;
TGCT	cis	rs185694	0.947	rs595451	chr13:30896848	T/C	cg07600127	chr13:30881527	KATNAL1	-0.82	-6.64	-0.51	8.92e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
TGCT	cis	rs9486715	0.838	rs4839840	chr6:96941149	T/C	cg18709589	chr6:96969512	KIAA0776	0.82	8.01	0.58	7.14e-13	Headache;
TGCT	cis	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg06697600	chr4:7070879	GRPEL1	-0.44	-4.51	-0.38	1.49e-5	Monocyte percentage of white cells;
TGCT	cis	rs2657888	0.965	rs2694909	chr12:56934928	T/C	cg23932658	chr12:57637574	STAC3	0.48	4.57	0.38	1.18e-5	Adiponectin levels;
TGCT	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	4.93	0.4	2.63e-6	Menopause (age at onset);
TGCT	cis	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg08564027	chr20:61660810	NA	0.37	6.85	0.52	3.1e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9457247	0.905	rs453184	chr6:167387404	A/C	cg25258033	chr6:167368657	RNASET2	0.18	4.49	0.37	1.63e-5	Crohn's disease;
TGCT	cis	rs7208859	0.623	rs77544470	chr17:28934550	C/A	cg13385521	chr17:29058706	SUZ12P	0.81	4.87	0.4	3.39e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs1887596	0.663	rs2776437	chr13:27245466	A/G	cg01312412	chr13:27282625	NA	0.28	5.07	0.41	1.41e-6	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs6430585	0.527	rs76622824	chr2:136411879	A/G	cg07169764	chr2:136633963	MCM6	0.97	8.24	0.59	2.09e-13	Corneal structure;
TGCT	cis	rs7255045	0.742	rs7251196	chr19:12950863	C/T	cg23899408	chr19:12877188	HOOK2	-0.58	-4.73	-0.39	5.98e-6	Mean corpuscular volume;
TGCT	cis	rs425277	0.916	rs414777	chr1:2101687	G/A	cg03732007	chr1:2071316	PRKCZ	0.26	5.29	0.43	5.41e-7	Height;
TGCT	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg15462221	chr8:8086144	FLJ10661	0.56	5.45	0.44	2.66e-7	Schizophrenia;
TGCT	cis	rs1532993	0.518	rs3907814	chr4:98586758	C/A	cg05340658	chr4:99064831	C4orf37	-0.42	-5.02	-0.41	1.75e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg27588902	chr6:42928151	GNMT	-0.56	-6.93	-0.53	2.08e-10	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs3806843	0.576	rs246062	chr5:140324580	T/A	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs6570726	0.599	rs9376951	chr6:145898911	C/T	cg05347473	chr6:146136440	FBXO30	0.62	5.7	0.46	8.22e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4919694	0.901	rs79331374	chr10:104882913	G/A	cg04362960	chr10:104952993	NT5C2	1.08	7.22	0.54	4.53e-11	Arsenic metabolism;
TGCT	cis	rs6429082	0.791	rs61836205	chr1:235638753	C/G	cg26050004	chr1:235667680	B3GALNT2	0.57	4.95	0.41	2.41e-6	Adiposity;
TGCT	cis	rs62064224	0.614	rs4795700	chr17:30763794	A/G	cg18200150	chr17:30822561	MYO1D	0.44	5.28	0.43	5.61e-7	Schizophrenia;
TGCT	cis	rs8056742	0.642	rs11149705	chr16:85026261	T/G	cg00229868	chr16:85520891	NA	0.37	4.67	0.39	7.7e-6	Amyotrophic lateral sclerosis;
TGCT	cis	rs9300255	0.739	rs12824957	chr12:123750228	T/C	cg00376283	chr12:123451042	ABCB9	-0.73	-5.04	-0.41	1.6e-6	Neutrophil percentage of white cells;
TGCT	cis	rs72781680	0.716	rs2712065	chr2:23973603	C/T	cg08917208	chr2:24149416	ATAD2B	-0.79	-4.94	-0.41	2.51e-6	Lymphocyte counts;
TGCT	cis	rs9818758	0.607	rs10049462	chr3:49309684	C/T	cg00383909	chr3:49044727	WDR6	1.28	6.57	0.51	1.23e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs1635	0.826	rs742107	chr6:28290714	A/C	cg15743358	chr6:28303923	ZNF323	-1.27	-6.2	-0.49	7.86e-9	Schizophrenia;
TGCT	cis	rs4242434	0.646	rs6988593	chr8:22527440	A/G	cg03733263	chr8:22462867	KIAA1967	-1.02	-14.95	-0.8	1.55e-29	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg10802521	chr3:52805072	NEK4	-0.73	-9.23	-0.64	9.18e-16	Bipolar disorder;
TGCT	cis	rs28785552	0.536	rs7246050	chr19:53248632	T/C	cg22067481	chr19:53234126	ZNF611	-0.44	-5.92	-0.47	2.99e-8	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs7085104	0.700	rs743572	chr10:104597152	A/G	cg04362960	chr10:104952993	NT5C2	0.57	5.05	0.41	1.54e-6	Immature fraction of reticulocytes;Schizophrenia;
TGCT	trans	rs931812	0.825	rs55818461	chr8:101899229	T/C	cg20993868	chr7:22813445	NA	0.41	8.93	0.63	4.77e-15	Attention deficit hyperactivity disorder and conduct disorder;
TGCT	cis	rs7666738	0.830	rs6855393	chr4:99056534	T/C	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.44e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg05665937	chr4:1216051	CTBP1	0.24	4.63	0.38	8.9e-6	Obesity-related traits;
TGCT	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg11644478	chr21:40555479	PSMG1	0.88	8.03	0.59	6.26e-13	Cognitive function;
TGCT	cis	rs11719291	0.833	rs11709246	chr3:48859498	G/A	cg00383909	chr3:49044727	WDR6	1.26	6.52	0.51	1.58e-9	Cognitive function;
TGCT	cis	rs9467773	1.000	rs9467783	chr6:26542894	C/T	cg09904177	chr6:26538194	HMGN4	0.64	6.48	0.5	1.94e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg24549020	chr5:56110836	MAP3K1	-0.66	-4.97	-0.41	2.2e-6	Initial pursuit acceleration;
TGCT	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.68	5.69	0.46	8.51e-8	Tonsillectomy;
TGCT	trans	rs2688608	0.653	rs12775558	chr10:75570868	G/A	cg13918328	chr10:52500089	ASAH2B	0.7	6.95	0.53	1.83e-10	Inflammatory bowel disease;
TGCT	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg12310025	chr6:25882481	NA	0.9	9.29	0.64	6.69e-16	Blood metabolite levels;
TGCT	cis	rs57994353	0.578	rs10448340	chr9:139320069	A/C	cg13741927	chr9:139327495	INPP5E	-0.24	-6.06	-0.48	1.48e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs9611565	0.921	rs5758297	chr22:41720697	A/G	cg13695892	chr22:41940480	POLR3H	-0.72	-7.33	-0.55	2.61e-11	Vitiligo;
TGCT	cis	rs11264213	0.901	rs72661643	chr1:36451599	A/G	cg27506609	chr1:36549197	TEKT2	0.41	4.61	0.38	9.88e-6	Schizophrenia;
TGCT	cis	rs17197710	0.673	rs12576461	chr11:47320772	T/C	cg13308137	chr11:47528955	CUGBP1	0.41	5.82	0.46	4.71e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs589249	0.963	rs4652925	chr1:37179511	T/C	cg04012535	chr1:37176647	NA	0.35	5.57	0.45	1.52e-7	Neuroticism (multi-trait analysis);Schizophrenia;
TGCT	cis	rs9512730	0.527	rs11619784	chr13:27999643	A/G	cg04070771	chr13:27998621	GTF3A	0.61	5.33	0.43	4.55e-7	Schizophrenia;
TGCT	cis	rs17376456	0.877	rs17374627	chr5:93296306	C/T	cg25358565	chr5:93447407	FAM172A	0.95	8.01	0.58	7.25e-13	Diabetic retinopathy;
TGCT	cis	rs1887596	0.624	rs9581701	chr13:27123670	T/C	cg01312412	chr13:27282625	NA	0.26	4.59	0.38	1.09e-5	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs1429606	1.000	rs9293493	chr5:87198583	C/T	cg09451457	chr5:87440246	NA	-0.69	-4.44	-0.37	2e-5	Number of children (6+ vs. 0 or 1);
TGCT	cis	rs17253792	0.822	rs76205307	chr14:56166038	C/T	cg01858014	chr14:56050164	KTN1	-0.35	-4.45	-0.37	1.9e-5	Putamen volume;
TGCT	cis	rs7312933	0.558	rs4768399	chr12:42742696	G/A	cg19980929	chr12:42632907	YAF2	-0.41	-5.76	-0.46	6.18e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs17030434	0.784	rs11099896	chr4:154664697	T/G	cg14289246	chr4:154710475	SFRP2	-0.87	-7.47	-0.56	1.24e-11	Electrocardiographic conduction measures;
TGCT	cis	rs1801251	1.000	rs6714245	chr2:233580505	T/C	cg08000102	chr2:233561755	GIGYF2	0.63	6.41	0.5	2.8e-9	Coronary artery disease;
TGCT	cis	rs9611519	0.780	rs2235850	chr22:41657626	C/T	cg03806693	chr22:41940476	POLR3H	-0.74	-7.23	-0.54	4.46e-11	Neuroticism;
TGCT	cis	rs28374715	0.662	rs28827035	chr15:41492290	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.81	-11.53	-0.72	2.33e-21	Ulcerative colitis;
TGCT	cis	rs9929218	0.581	rs7203337	chr16:68774800	C/G	cg01251360	chr16:68772225	CDH1	-0.25	-4.55	-0.38	1.25e-5	Colorectal cancer;
TGCT	cis	rs28595532	0.920	rs114796605	chr4:119744472	C/A	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg18252515	chr7:66147081	NA	-1.22	-7.98	-0.58	8.46e-13	Diabetic kidney disease;
TGCT	cis	rs11673344	0.523	rs7248948	chr19:37547219	G/T	cg08039142	chr19:36980659	ZNF566	0.51	4.69	0.39	7.03e-6	Obesity-related traits;
TGCT	cis	rs1372520	0.748	rs1471484	chr4:90754313	C/T	cg20003494	chr4:90757398	SNCA	-0.6	-4.72	-0.39	6.34e-6	Neuroticism;
TGCT	cis	rs732765	0.734	rs10130425	chr14:75185394	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.55	-4.48	-0.37	1.71e-5	Non-small cell lung cancer;
TGCT	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg00343986	chr7:65444356	GUSB	-0.23	-5.16	-0.42	9.66e-7	Aortic root size;
TGCT	cis	rs1801251	0.778	rs2250665	chr2:233752639	A/T	cg25237894	chr2:233734115	C2orf82	-0.31	-5.84	-0.46	4.25e-8	Coronary artery disease;
TGCT	cis	rs7681440	0.967	rs1372517	chr4:90755909	G/A	cg26578617	chr4:90757533	SNCA	-0.48	-4.97	-0.41	2.15e-6	Dementia with Lewy bodies;
TGCT	cis	rs1372520	0.623	rs2583975	chr4:90748488	T/C	cg15133208	chr4:90757351	SNCA	-0.5	-5.81	-0.46	4.96e-8	Neuroticism;
TGCT	cis	rs6901250	0.522	rs693602	chr6:117085784	A/C	cg12892004	chr6:117198278	RFX6	0.37	4.69	0.39	7.12e-6	C-reactive protein levels;
TGCT	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg16325326	chr1:53192061	ZYG11B	0.63	7.34	0.55	2.51e-11	Monocyte count;
TGCT	cis	rs896854	0.738	rs481887	chr8:95967838	A/G	cg13393036	chr8:95962371	TP53INP1	0.56	6.67	0.51	7.41e-10	Type 2 diabetes;
TGCT	cis	rs7666738	0.830	rs11941844	chr4:99042722	A/T	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7715806	0.500	rs3797581	chr5:75002895	G/T	cg19683494	chr5:74908142	NA	0.53	4.63	0.38	9.15e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs4820539	0.902	rs4822359	chr22:23474972	A/G	cg21100191	chr22:23484243	RTDR1	0.89	10.47	0.69	8.92e-19	Bone mineral density;
TGCT	cis	rs2832191	1.000	rs2832190	chr21:30488226	G/A	cg24692254	chr21:30365293	RNF160	-0.83	-8.71	-0.62	1.58e-14	Dental caries;
TGCT	cis	rs990171	1.000	rs1420106	chr2:103035044	C/T	cg04239558	chr2:103089729	SLC9A4	-0.33	-4.57	-0.38	1.16e-5	Lymphocyte counts;
TGCT	cis	rs2859741	0.967	rs494157	chr1:37512995	C/T	cg09363841	chr1:37513479	NA	0.19	4.68	0.39	7.42e-6	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
TGCT	cis	rs751728	1.000	rs2296748	chr6:33745071	C/T	cg13859433	chr6:33739653	LEMD2	-0.39	-7.13	-0.54	7.29e-11	Crohn's disease;
TGCT	cis	rs11514810	1.000	rs9648619	chr7:1427949	G/T	cg24899294	chr7:1481343	MICALL2	-0.46	-6.22	-0.49	7.03e-9	Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder;
TGCT	cis	rs2204008	0.715	rs11514282	chr12:38169056	G/T	cg13010199	chr12:38710504	ALG10B	0.64	5.16	0.42	9.41e-7	Bladder cancer;
TGCT	cis	rs9430161	0.611	rs72644043	chr1:11033051	T/A	cg27631724	chr1:11040367	C1orf127	0.54	6.05	0.48	1.62e-8	Ewing sarcoma;
TGCT	cis	rs2658782	1.000	rs2608216	chr11:93149172	G/A	cg15737290	chr11:93063684	CCDC67	0.82	5.67	0.45	9.52e-8	Pulmonary function decline;
TGCT	cis	rs2153535	0.580	rs9378554	chr6:8488468	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg26338869	chr17:61819248	STRADA	-0.52	-4.73	-0.39	6e-6	Prudent dietary pattern;
TGCT	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg03188948	chr7:1209495	NA	0.5	7.0	0.53	1.44e-10	Longevity;Endometriosis;
TGCT	cis	rs7772486	0.875	rs10457795	chr6:146415665	A/G	cg13319975	chr6:146136371	FBXO30	-0.51	-4.48	-0.37	1.69e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs854765	0.618	rs8068820	chr17:17834119	A/G	cg09796270	chr17:17721594	SREBF1	0.24	4.77	0.39	5.16e-6	Total body bone mineral density;
TGCT	cis	rs13223928	0.651	rs4722426	chr7:3150697	C/T	cg19214707	chr7:3157722	NA	0.49	7.19	0.54	5.38e-11	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
TGCT	cis	rs57920188	0.640	rs10915600	chr1:4082105	T/G	cg20703997	chr1:4087676	NA	0.44	5.4	0.44	3.22e-7	Interleukin-17 levels;
TGCT	cis	rs6964587	0.967	rs34863529	chr7:91644341	C/G	cg17063962	chr7:91808500	NA	0.91	9.88	0.66	2.45e-17	Breast cancer;
TGCT	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs1729951	0.545	rs1097288	chr3:136693721	C/T	cg12473912	chr3:136751656	NA	0.39	6.18	0.49	8.36e-9	Neuroticism;
TGCT	cis	rs1670533	1.000	rs10026482	chr4:1051128	C/G	cg20887711	chr4:1340912	KIAA1530	0.7	5.66	0.45	9.77e-8	Recombination rate (females);
TGCT	cis	rs4730250	0.708	rs74983157	chr7:106823951	A/G	cg02696742	chr7:106810147	HBP1	-0.7	-6.05	-0.48	1.59e-8	Osteoarthritis;
TGCT	cis	rs752010	0.619	rs4393146	chr1:42118766	A/G	cg06885757	chr1:42089581	HIVEP3	0.27	4.73	0.39	5.88e-6	Lupus nephritis in systemic lupus erythematosus;
TGCT	cis	rs3749237	0.595	rs2878298	chr3:49406080	T/C	cg02487422	chr3:49467188	NICN1	0.59	6.0	0.47	2.04e-8	Resting heart rate;
TGCT	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg06221963	chr1:154839813	KCNN3	-0.75	-12.65	-0.75	4.66e-24	Prostate cancer;
TGCT	cis	rs9467711	0.559	rs9348721	chr6:26485573	A/G	cg16898833	chr6:26189333	HIST1H4D	0.94	4.58	0.38	1.12e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6671200	1.000	rs12749053	chr1:95660556	A/G	cg20701556	chr1:95698924	RWDD3	0.65	5.58	0.45	1.43e-7	Stearic acid (18:0) levels;
TGCT	cis	rs28374715	0.681	rs11629979	chr15:41626579	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.87	-13.45	-0.77	5.4e-26	Ulcerative colitis;
TGCT	cis	rs9818758	0.607	rs35108630	chr3:49088356	T/A	cg00383909	chr3:49044727	WDR6	1.3	6.73	0.52	5.74e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	trans	rs9951602	0.512	rs4798995	chr18:76654344	T/G	cg02800362	chr5:177631904	HNRNPAB	1.13	12.84	0.76	1.57e-24	Obesity-related traits;
TGCT	cis	rs2239547	0.562	rs6794389	chr3:53096394	A/G	cg11645453	chr3:52864694	ITIH4	0.31	4.99	0.41	1.98e-6	Schizophrenia;
TGCT	cis	rs3772130	0.564	rs35178434	chr3:121595936	G/A	cg20356878	chr3:121714668	ILDR1	0.38	4.83	0.4	3.93e-6	Cognitive performance;
TGCT	cis	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg18188782	chr20:61659543	NA	0.47	5.68	0.45	9.19e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs8141529	0.673	rs132548	chr22:29317559	C/G	cg02153584	chr22:29168773	CCDC117	-0.58	-4.6	-0.38	1.02e-5	Lymphocyte counts;
TGCT	cis	rs5769707	0.609	rs135861	chr22:49998118	A/G	cg06623630	chr22:50017776	C22orf34	-0.26	-4.44	-0.37	1.97e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs4595586	0.545	rs11615638	chr12:39364766	A/C	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs11577318	0.853	rs4333841	chr1:26631927	T/C	cg12733254	chr1:26682999	NA	-0.2	-4.45	-0.37	1.89e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs2180341	0.924	rs9285459	chr6:127631113	T/C	cg27446573	chr6:127587934	RNF146	1.12	10.11	0.67	6.87e-18	Breast cancer;
TGCT	cis	rs3617	0.573	rs9860296	chr3:52913781	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	4.76	0.39	5.23e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	trans	rs7726839	0.507	rs56282020	chr5:596701	T/C	cg25482853	chr8:67687455	SGK3	1.27	10.62	0.69	4.03e-19	Obesity-related traits;
TGCT	cis	rs7726839	0.540	rs74553517	chr5:665671	C/T	cg16624210	chr5:671434	TPPP	0.42	4.89	0.4	3.06e-6	Obesity-related traits;
TGCT	cis	rs6933660	0.745	rs9322320	chr6:151751908	C/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.5	4.76	0.39	5.36e-6	Menarche (age at onset);
TGCT	cis	rs854765	0.647	rs4426402	chr17:17977926	C/T	cg04398451	chr17:18023971	MYO15A	0.36	6.16	0.48	9.27e-9	Total body bone mineral density;
TGCT	cis	rs6748734	1.000	rs4675863	chr2:241830763	A/T	cg04034577	chr2:241836375	C2orf54	-0.4	-6.32	-0.49	4.22e-9	Urinary metabolites;
TGCT	cis	rs7208859	0.673	rs36056619	chr17:29172284	T/C	cg14008862	chr17:28927542	LRRC37B2	0.72	4.66	0.39	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg07507251	chr3:52567010	NT5DC2	0.49	6.71	0.52	6.33e-10	Bipolar disorder;
TGCT	cis	rs4727027	0.899	rs11768971	chr7:148825826	C/G	cg23583168	chr7:148888333	NA	-0.72	-9.18	-0.64	1.18e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs3806843	0.576	rs246049	chr5:140327590	T/G	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs4664308	0.967	rs7563607	chr2:160910215	C/G	cg03641300	chr2:160917029	PLA2R1	-0.26	-6.53	-0.51	1.49e-9	Idiopathic membranous nephropathy;
TGCT	cis	rs4319547	0.876	rs10846978	chr12:122964708	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.66	-5.32	-0.43	4.71e-7	Body mass index;
TGCT	cis	rs2562456	0.917	rs6511253	chr19:21678798	A/G	cg25650185	chr19:21324782	ZNF431	0.57	5.08	0.42	1.35e-6	Pain;
TGCT	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg22166914	chr1:53195759	ZYG11B	-0.47	-8.65	-0.61	2.18e-14	Monocyte count;
TGCT	cis	rs9611565	0.802	rs132916	chr22:41806768	C/G	cg17554472	chr22:41940697	POLR3H	0.45	5.02	0.41	1.74e-6	Vitiligo;
TGCT	cis	rs4924935	0.851	rs966811	chr17:18830287	G/A	cg26378065	chr17:18585709	ZNF286B	-0.55	-4.52	-0.38	1.44e-5	Pancreatic cancer;
TGCT	cis	rs861020	1.000	rs680923	chr1:209986672	T/C	cg05527609	chr1:210001259	C1orf107	0.91	7.4	0.55	1.84e-11	Orofacial clefts;
TGCT	cis	rs9948	0.655	rs78424221	chr2:97410399	A/G	cg01990225	chr2:97406019	LMAN2L	-1.01	-5.13	-0.42	1.08e-6	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7216064	1.000	rs6504548	chr17:65886048	T/C	cg12091567	chr17:66097778	LOC651250	-0.84	-6.8	-0.52	4.01e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs9649213	0.614	rs9640655	chr7:98017099	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.94	-8.9	-0.62	5.66e-15	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg12288994	chr5:1860383	NA	0.24	4.65	0.39	8.46e-6	Cardiovascular disease risk factors;
TGCT	cis	rs9926296	0.715	rs467035	chr16:89740285	C/G	cg26513180	chr16:89883248	FANCA	0.59	5.64	0.45	1.1e-7	Vitiligo;
TGCT	cis	rs1801251	0.896	rs4973561	chr2:233687337	C/G	cg08000102	chr2:233561755	GIGYF2	-0.53	-5.5	-0.44	2.04e-7	Coronary artery disease;
TGCT	cis	rs7726839	0.540	rs72707016	chr5:665148	A/G	cg20362242	chr5:692897	TPPP	0.51	4.66	0.39	8.11e-6	Obesity-related traits;
TGCT	cis	rs1903068	0.853	rs12331597	chr4:55997914	T/C	cg16572876	chr4:56024045	NA	0.47	5.29	0.43	5.35e-7	Endometriosis;
TGCT	cis	rs3125734	0.633	rs12217669	chr10:63988456	A/G	cg09941381	chr10:64027924	RTKN2	0.38	5.71	0.46	8.06e-8	Rheumatoid arthritis;
TGCT	cis	rs7917772	0.508	rs2252147	chr10:104467774	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	5.76	0.46	6.18e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs981844	0.961	rs62325108	chr4:154679767	G/A	cg14289246	chr4:154710475	SFRP2	1.04	8.89	0.62	6.07e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs9647570	0.582	rs2973656	chr5:167280392	G/A	cg11091196	chr5:167285540	ODZ2	0.32	5.0	0.41	1.88e-6	Menarche (age at onset);
TGCT	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg24250549	chr1:154909240	PMVK	0.56	5.42	0.44	2.92e-7	Prostate cancer;
TGCT	cis	rs2235642	0.826	rs8048410	chr16:1614097	A/G	cg07639376	chr16:1584516	IFT140;TMEM204	-0.34	-5.64	-0.45	1.1e-7	Coronary artery disease;
TGCT	cis	rs7586879	0.551	rs7565460	chr2:25130073	C/T	cg15423357	chr2:25149977	NA	0.5	4.87	0.4	3.29e-6	Body mass index;
TGCT	cis	rs7937612	1.000	rs11217852	chr11:120261187	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.28	-4.54	-0.38	1.32e-5	Intraocular pressure;
TGCT	trans	rs10506458	1.000	rs12425932	chr12:63410497	C/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.48	-7.61	-0.56	5.87e-12	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg18252515	chr7:66147081	NA	-1.2	-7.83	-0.58	1.89e-12	Diabetic kidney disease;
TGCT	cis	rs9814567	1.000	rs7427492	chr3:134261654	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.98	-9.89	-0.66	2.32e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs4589502	0.512	rs7183242	chr15:67096658	A/G	cg12317470	chr15:67143691	NA	0.55	4.93	0.4	2.6e-6	Lung cancer (smoking interaction);
TGCT	cis	rs2067615	0.579	rs7297592	chr12:107223969	G/T	cg15890332	chr12:107067104	RFX4	0.29	5.79	0.46	5.36e-8	Heart rate;
TGCT	trans	rs629535	0.814	rs549643	chr8:70062884	C/T	cg21567404	chr3:27674614	NA	0.52	7.95	0.58	9.59e-13	Dupuytren's disease;
TGCT	cis	rs763014	0.966	rs7198877	chr16:661439	A/G	cg00908189	chr16:619842	PIGQ	0.86	10.25	0.68	3.12e-18	Height;
TGCT	cis	rs317689	0.918	rs581911	chr12:69738293	C/T	cg20891283	chr12:69753455	YEATS4	0.56	4.6	0.38	1.03e-5	Response to diuretic therapy;
TGCT	cis	rs4660261	0.526	rs803680	chr1:44364370	G/C	cg12908607	chr1:44402522	ARTN	-0.67	-8.24	-0.59	2.07e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs9467773	0.935	rs4573	chr6:26546808	A/G	cg09904177	chr6:26538194	HMGN4	0.64	6.32	0.49	4.25e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7611238	0.560	rs7653406	chr3:195040226	G/A	cg27323046	chr3:195102265	ACAP2	0.36	4.9	0.4	2.94e-6	Body mass index;
TGCT	cis	rs7524258	0.868	rs916393	chr1:7272250	T/C	cg07173049	chr1:7289937	CAMTA1	0.29	4.77	0.39	5.07e-6	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs7226408	0.948	rs72885222	chr18:34401184	G/T	cg06757138	chr18:34340585	FHOD3	0.26	4.79	0.4	4.62e-6	Obesity-related traits;
TGCT	cis	rs2050392	0.861	rs1042058	chr10:30728101	T/C	cg18806716	chr10:30721971	MAP3K8	-0.51	-6.0	-0.47	2.04e-8	Inflammatory bowel disease;
TGCT	cis	rs9611565	0.694	rs5758389	chr22:41941749	T/C	cg17554472	chr22:41940697	POLR3H	-0.48	-5.46	-0.44	2.44e-7	Vitiligo;
TGCT	cis	rs28595532	0.920	rs115154776	chr4:119774803	A/G	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs6565180	0.632	rs8050812	chr16:30385837	C/T	cg17640201	chr16:30407289	ZNF48	-0.77	-6.12	-0.48	1.16e-8	Tonsillectomy;
TGCT	cis	rs11030122	0.635	rs10835540	chr11:4071429	T/A	cg08557956	chr11:4115526	RRM1	-0.56	-4.73	-0.39	5.93e-6	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs9951602	0.607	rs3017651	chr18:76668622	T/C	cg00806245	chr18:76673096	NA	-0.3	-4.97	-0.41	2.18e-6	Obesity-related traits;
TGCT	cis	rs244731	0.959	rs3105419	chr5:176551396	G/C	cg16006841	chr5:176797999	RGS14	0.53	6.5	0.5	1.79e-9	Urate levels in lean individuals;
TGCT	cis	rs2074585	0.618	rs2060854	chr15:90917827	C/T	cg22089800	chr15:90895588	ZNF774	0.83	8.94	0.63	4.62e-15	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
TGCT	cis	rs17102423	0.689	rs7158239	chr14:65520616	G/A	cg11161011	chr14:65562177	MAX	-0.47	-6.27	-0.49	5.52e-9	Obesity-related traits;
TGCT	cis	rs7635838	0.617	rs346074	chr3:11294310	T/C	cg00170343	chr3:11313890	ATG7	0.64	6.43	0.5	2.5e-9	HDL cholesterol;
TGCT	cis	rs4700695	0.619	rs37230	chr5:65218264	A/C	cg21114390	chr5:65439923	SFRS12	0.63	4.77	0.39	5.1e-6	Facial morphology (factor 19);
TGCT	cis	rs7647973	0.961	rs6778080	chr3:49317338	C/T	cg05785598	chr3:49045655	WDR6	-0.38	-4.59	-0.38	1.09e-5	Menarche (age at onset);
TGCT	cis	rs1215050	0.791	rs983187	chr4:98816350	A/T	cg05340658	chr4:99064831	C4orf37	0.45	5.78	0.46	5.8e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs6921919	0.515	rs1339898	chr6:28395506	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.49	-4.9	-0.4	2.87e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1034435	0.755	rs5767172	chr22:48892314	A/C	cg05992904	chr22:48892994	FAM19A5	-0.35	-4.77	-0.39	5.03e-6	Late-onset Alzheimer's disease;
TGCT	cis	rs7584330	0.554	rs1343768	chr2:238444881	G/A	cg08992911	chr2:238395768	MLPH	0.64	4.49	0.37	1.63e-5	Prostate cancer;
TGCT	cis	rs7552404	0.696	rs1417405	chr1:76457797	T/C	cg03433033	chr1:76189801	ACADM	0.73	6.36	0.5	3.6e-9	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs10972341	0.900	rs4878605	chr9:35150720	C/T	cg00812861	chr9:35114699	KIAA1539	0.33	4.92	0.4	2.64e-6	Weight;
TGCT	cis	rs9611565	0.592	rs12484254	chr22:41962003	T/A	cg06481639	chr22:41940642	POLR3H	-0.67	-5.71	-0.46	7.87e-8	Vitiligo;
TGCT	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg04267008	chr7:1944627	MAD1L1	-0.4	-5.28	-0.43	5.52e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs61867294	0.794	rs6584633	chr10:106667382	C/T	cg08000847	chr10:105880925	C10orf78	0.56	4.46	0.37	1.82e-5	Schizophrenia;
TGCT	cis	rs2486012	1.000	rs2248305	chr1:44379493	C/T	cg12908607	chr1:44402522	ARTN	0.71	5.86	0.47	3.87e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.817	rs60646469	chr8:58195348	T/C	cg08280861	chr8:58055591	NA	0.37	4.69	0.39	6.96e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg21285383	chr16:89894308	SPIRE2	0.42	6.41	0.5	2.82e-9	Vitiligo;
TGCT	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg12311346	chr5:56204834	C5orf35	-0.67	-6.77	-0.52	4.59e-10	Initial pursuit acceleration;
TGCT	cis	rs1552244	0.554	rs7638846	chr3:10048601	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.65	4.58	0.38	1.09e-5	Alzheimer's disease;
TGCT	cis	rs651907	0.514	rs12636047	chr3:101434449	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	4.73	0.39	5.91e-6	Colorectal cancer;
TGCT	cis	rs902774	0.554	rs4919749	chr12:53358034	C/T	cg25025879	chr12:53359317	NA	-0.46	-5.19	-0.42	8.37e-7	Prostate cancer;
TGCT	cis	rs3862435	0.572	rs2601167	chr15:90912567	G/A	cg14166756	chr15:90894880	ZNF774	-0.31	-4.88	-0.4	3.17e-6	Response to exercise (triglyceride level interaction);
TGCT	cis	rs7909074	0.714	rs10900129	chr10:45398609	G/C	cg04218760	chr10:45406644	TMEM72	-0.25	-4.62	-0.38	9.58e-6	Mean corpuscular volume;
TGCT	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg15921436	chr17:44337874	NA	0.58	8.13	0.59	3.77e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7824557	0.628	rs34237267	chr8:11197301	G/C	cg21775007	chr8:11205619	TDH	0.69	6.81	0.52	3.8e-10	Retinal vascular caliber;
TGCT	cis	rs7772486	0.641	rs960385	chr6:146371074	G/A	cg23711669	chr6:146136114	FBXO30	0.68	6.55	0.51	1.39e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs28595532	0.920	rs114670456	chr4:119771202	A/G	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs6586163	0.872	rs7069841	chr10:90741955	T/C	cg03111039	chr10:90751583	FAS;ACTA2	-0.36	-4.47	-0.37	1.76e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs9467773	1.000	rs6925895	chr6:26572165	G/T	cg05738196	chr6:26577821	NA	0.9	12.48	0.75	1.16e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs6684514	1.000	rs2241106	chr1:156218910	C/G	cg20302342	chr1:156215951	PAQR6	0.37	4.73	0.39	6e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg10802521	chr3:52805072	NEK4	-0.74	-9.02	-0.63	2.87e-15	Bipolar disorder;
TGCT	cis	rs9911578	1.000	rs9892795	chr17:57023054	G/C	cg12560992	chr17:57184187	TRIM37	0.76	9.21	0.64	1.03e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs4733781	0.829	rs4733770	chr8:131152665	G/A	cg16277922	chr8:131349729	ASAP1	0.36	4.47	0.37	1.75e-5	Tuberculosis;
TGCT	cis	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg22857025	chr5:266934	NA	-0.34	-6.7	-0.52	6.65e-10	Breast cancer;
TGCT	cis	rs7552404	0.727	rs7547056	chr1:76279267	C/T	cg03433033	chr1:76189801	ACADM	0.66	6.88	0.53	2.57e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9486719	1.000	rs2499809	chr6:96870110	C/T	cg18709589	chr6:96969512	KIAA0776	0.71	5.21	0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	trans	rs7726839	0.561	rs6555357	chr5:560923	A/G	cg11887960	chr12:57824829	NA	1.03	8.25	0.6	1.96e-13	Obesity-related traits;
TGCT	cis	rs2295359	1.000	rs10889664	chr1:67635475	C/T	cg12940439	chr1:67600707	NA	0.54	5.66	0.45	9.77e-8	Psoriasis;
TGCT	cis	rs1568889	1.000	rs7949704	chr11:28373543	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	7.83	0.58	1.84e-12	Bipolar disorder;
TGCT	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg08280861	chr8:58055591	NA	0.52	5.97	0.47	2.35e-8	Developmental language disorder (linguistic errors);
TGCT	cis	rs35146811	0.657	rs36019559	chr7:99814586	A/G	cg13334819	chr7:99746414	C7orf59	0.74	6.31	0.49	4.4e-9	Coronary artery disease;
TGCT	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg14893161	chr1:205819251	PM20D1	0.53	7.12	0.54	7.78e-11	Menarche (age at onset);
TGCT	cis	rs56235845	0.964	rs11746443	chr5:176798306	G/A	cg17509989	chr5:176798049	RGS14	0.8	12.25	0.74	4.18e-23	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs4563143	0.675	rs56407818	chr19:29279379	G/A	cg12756686	chr19:29218302	NA	0.78	6.69	0.51	6.93e-10	Methadone dose in opioid dependence;
TGCT	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg00814883	chr7:100076585	TSC22D4	-0.92	-9.76	-0.66	4.73e-17	Platelet count;
TGCT	cis	rs10883723	0.810	rs10748823	chr10:104274465	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs6725041	0.819	rs2049180	chr2:213081740	G/A	cg20637307	chr2:213403960	ERBB4	-0.51	-4.48	-0.37	1.68e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs7647973	1.000	rs2312462	chr3:49601255	A/G	cg06212747	chr3:49208901	KLHDC8B	0.55	4.5	0.37	1.55e-5	Menarche (age at onset);
TGCT	cis	rs6977660	0.714	rs2390157	chr7:19786177	G/A	cg05791153	chr7:19748676	TWISTNB	0.84	4.71	0.39	6.52e-6	Thyroid stimulating hormone;
TGCT	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg18230493	chr5:56204884	C5orf35	-0.68	-5.92	-0.47	2.92e-8	Initial pursuit acceleration;
TGCT	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg18402987	chr7:1209562	NA	0.81	6.94	0.53	1.9e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg11644478	chr21:40555479	PSMG1	1.0	10.6	0.69	4.32e-19	Cognitive function;
TGCT	cis	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg20637647	chr7:64974828	NA	0.9	5.29	0.43	5.42e-7	Diabetic kidney disease;
TGCT	cis	rs11098499	0.691	rs9307471	chr4:120261262	G/A	cg09307838	chr4:120376055	NA	0.55	5.36	0.43	3.98e-7	Corneal astigmatism;
TGCT	cis	rs2180341	0.538	rs11154402	chr6:127711932	C/A	cg24812749	chr6:127587940	RNF146	0.61	5.39	0.44	3.45e-7	Breast cancer;
TGCT	cis	rs9309473	0.660	rs62151564	chr2:73615449	A/G	cg07208825	chr2:73871855	ALMS1P	0.25	4.54	0.38	1.33e-5	Metabolite levels;
TGCT	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg10802521	chr3:52805072	NEK4	-0.74	-9.22	-0.64	9.87e-16	Bipolar disorder;
TGCT	cis	rs1156327	0.655	rs179225	chr16:19317985	C/T	cg27311092	chr16:19142612	NA	0.49	4.47	0.37	1.74e-5	Periodontal disease-related phenotypes;
TGCT	cis	rs7666738	0.830	rs4441757	chr4:98927059	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2191566	1.000	rs369106	chr19:44506930	C/T	cg03039196	chr19:44506973	ZNF230	-0.54	-4.76	-0.39	5.23e-6	Acute lymphoblastic leukemia (childhood);
TGCT	cis	rs6088580	0.570	rs6058057	chr20:33065283	G/A	cg06115741	chr20:33292138	TP53INP2	0.52	4.47	0.37	1.75e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs9811920	0.638	rs793503	chr3:99588070	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.58	-6.76	-0.52	4.82e-10	Axial length;
TGCT	cis	rs9633740	1.000	rs7910643	chr10:82251769	G/A	cg01528321	chr10:82214614	TSPAN14	1.0	8.33	0.6	1.25e-13	Post bronchodilator FEV1;
TGCT	cis	rs250677	0.687	rs250674	chr5:148438597	A/G	cg18129178	chr5:148520854	ABLIM3	0.42	6.27	0.49	5.53e-9	Breast cancer;
TGCT	cis	rs10782582	0.593	rs11164042	chr1:76178440	G/A	cg10523679	chr1:76189770	ACADM	-0.69	-7.19	-0.54	5.39e-11	Daytime sleep phenotypes;
TGCT	cis	rs889312	0.500	rs865570	chr5:56161975	C/T	cg12311346	chr5:56204834	C5orf35	-0.46	-5.0	-0.41	1.87e-6	Breast cancer;Breast cancer (early onset);
TGCT	cis	rs2180341	0.751	rs9388553	chr6:127574044	A/G	cg24812749	chr6:127587940	RNF146	0.83	6.69	0.51	6.91e-10	Breast cancer;
TGCT	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.13	9.74	0.66	5.47e-17	Platelet count;
TGCT	cis	rs9914988	0.943	rs9913801	chr17:27132105	G/A	cg20469991	chr17:27169893	C17orf63	-0.72	-5.09	-0.42	1.28e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs2580764	0.566	rs2972075	chr2:55292322	T/G	cg09592903	chr2:55203963	RTN4	0.23	5.06	0.41	1.47e-6	Mean platelet volume;
TGCT	cis	rs12142240	0.698	rs56909107	chr1:46808224	A/C	cg00530320	chr1:46809349	NSUN4	0.29	5.88	0.47	3.63e-8	Menopause (age at onset);
TGCT	cis	rs975752	0.717	rs7082753	chr10:102008483	A/G	cg04750910	chr10:102416409	NA	0.73	4.48	0.37	1.69e-5	Schizophrenia;
TGCT	cis	rs9341808	0.652	rs2505940	chr6:80851191	T/C	cg08355045	chr6:80787529	NA	0.32	5.38	0.43	3.6e-7	Sitting height ratio;
TGCT	cis	rs2241685	0.920	rs59907143	chr2:1934163	T/C	cg21862353	chr2:1801628	MYT1L	-0.53	-4.86	-0.4	3.47e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs2228479	0.850	rs62056069	chr16:89912000	C/T	cg06558623	chr16:89946397	TCF25	0.55	4.86	0.4	3.55e-6	Skin colour saturation;
TGCT	cis	rs7681440	0.647	rs11941110	chr4:90819569	T/C	cg20003494	chr4:90757398	SNCA	-0.51	-4.54	-0.38	1.33e-5	Dementia with Lewy bodies;
TGCT	cis	rs7772486	0.790	rs9403750	chr6:146167762	G/A	cg23711669	chr6:146136114	FBXO30	0.92	10.44	0.68	1.06e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7666738	0.830	rs10001701	chr4:98918871	G/C	cg05340658	chr4:99064831	C4orf37	0.53	6.12	0.48	1.13e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.51	-4.82	-0.4	4.16e-6	Bipolar disorder;
TGCT	cis	rs2862064	0.872	rs6555776	chr5:156403505	C/A	cg12943317	chr5:156479607	HAVCR1	-0.39	-5.15	-0.42	1.01e-6	Platelet count;
TGCT	cis	rs3796352	0.892	rs9756317	chr3:53088815	T/C	cg15956490	chr3:53032818	SFMBT1	-0.54	-6.44	-0.5	2.33e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs933688	0.938	rs10942634	chr5:90658392	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.0	9.41	0.65	3.47e-16	Smoking behavior;
TGCT	cis	rs1801251	0.896	rs2305141	chr2:233684402	A/G	cg08000102	chr2:233561755	GIGYF2	-0.58	-5.97	-0.47	2.3e-8	Coronary artery disease;
TGCT	cis	rs877282	0.898	rs11253349	chr10:765897	C/G	cg17470449	chr10:769945	NA	0.37	5.59	0.45	1.37e-7	Uric acid levels;
TGCT	cis	rs79349575	0.783	rs62075818	chr17:46982327	T/A	cg26022315	chr17:47021804	SNF8	0.48	4.82	0.4	4.06e-6	Type 2 diabetes;
TGCT	cis	rs77372450	0.551	rs3749797	chr5:157078475	C/G	cg12606933	chr5:157078573	SOX30	-0.42	-4.75	-0.39	5.48e-6	Bipolar disorder (body mass index interaction);
TGCT	cis	rs4478858	0.735	rs12563669	chr1:31858067	A/G	cg00250761	chr1:31883323	NA	-0.25	-4.56	-0.38	1.22e-5	Alcohol dependence;
TGCT	cis	rs4788570	0.625	rs2434885	chr16:71583859	C/T	cg06353428	chr16:71660113	MARVELD3	-0.96	-6.91	-0.53	2.2e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs11874712	1.000	rs11082509	chr18:43655010	G/A	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	5.23	0.42	7.11e-7	Migraine - clinic-based;
TGCT	cis	rs35146811	0.735	rs2272345	chr7:99797031	C/G	cg13334819	chr7:99746414	C7orf59	-0.74	-6.31	-0.49	4.4e-9	Coronary artery disease;
TGCT	cis	rs2245008	0.950	rs824400	chr16:83989936	C/G	cg27171569	chr16:83987465	OSGIN1	-0.56	-6.3	-0.49	4.65e-9	Pursuit maintenance gain;
TGCT	trans	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg17830980	chr10:43048298	ZNF37B	-0.81	-10.13	-0.67	6.19e-18	Extrinsic epigenetic age acceleration;
TGCT	cis	rs4149178	1.000	rs4149178	chr6:43272188	A/G	cg08373528	chr6:42672105	PRPH2	0.47	4.59	0.38	1.08e-5	Urate levels;
TGCT	cis	rs114540395	1.000	rs114540395	chr10:103479062	C/T	cg24291461	chr10:102749544	C10orf2	0.35	4.65	0.39	8.4e-6	Schizophrenia;
TGCT	cis	rs3617	0.625	rs2240917	chr3:52851137	T/C	cg10802521	chr3:52805072	NEK4	-0.6	-6.89	-0.53	2.46e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg22963979	chr7:1858916	MAD1L1	0.36	5.56	0.45	1.58e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs11247915	0.600	rs12059495	chr1:26655614	A/G	cg01414934	chr1:26605969	SH3BGRL3	0.21	4.52	0.38	1.4e-5	Obesity-related traits;
TGCT	cis	rs2235642	0.928	rs1057610	chr16:1605537	T/C	cg07639376	chr16:1584516	IFT140;TMEM204	-0.32	-5.75	-0.46	6.52e-8	Coronary artery disease;
TGCT	cis	rs854765	0.856	rs2955382	chr17:17947710	C/T	cg04398451	chr17:18023971	MYO15A	0.29	4.51	0.38	1.48e-5	Total body bone mineral density;
TGCT	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg15691649	chr6:25882328	NA	-0.35	-4.55	-0.38	1.25e-5	Blood metabolite levels;
TGCT	cis	rs7095607	0.630	rs10998012	chr10:69958690	A/G	cg18986048	chr10:69913749	MYPN	0.57	5.92	0.47	2.89e-8	Lung function (FVC);
TGCT	cis	rs7246657	0.722	rs10409605	chr19:38123137	T/G	cg03611452	chr19:38183253	ZNF781	0.59	4.76	0.39	5.34e-6	Coronary artery calcification;
TGCT	cis	rs28595532	0.841	rs115924581	chr4:119786333	T/C	cg21605333	chr4:119757512	SEC24D	1.53	8.87	0.62	6.71e-15	Cannabis dependence symptom count;
TGCT	cis	rs7017914	0.967	rs6472539	chr8:71629810	G/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.03	-0.41	1.69e-6	Bone mineral density;
TGCT	cis	rs637571	0.522	rs493899	chr11:65747952	A/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.65	6.4	0.5	2.96e-9	Eosinophil percentage of white cells;
TGCT	cis	rs9914544	0.966	rs9906795	chr17:18816740	G/A	cg26378065	chr17:18585709	ZNF286B	0.52	4.64	0.38	8.75e-6	Educational attainment (years of education);
TGCT	cis	rs8141529	0.509	rs5762864	chr22:29253364	T/C	cg02153584	chr22:29168773	CCDC117	0.59	4.65	0.39	8.49e-6	Lymphocyte counts;
TGCT	cis	rs7666738	0.830	rs28761309	chr4:98867393	C/T	cg18180107	chr4:99064573	C4orf37	0.55	5.14	0.42	1.03e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2637266	0.703	rs4437973	chr10:78484971	G/A	cg18941641	chr10:78392320	NA	0.41	4.98	0.41	2.11e-6	Pulmonary function;
TGCT	cis	rs447735	0.537	rs7190341	chr16:89917537	T/C	cg27121462	chr16:89883253	FANCA	0.57	4.95	0.41	2.36e-6	Hemoglobin concentration;
TGCT	cis	rs72945132	0.882	rs7929271	chr11:70165749	A/G	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs4722166	0.630	rs13311155	chr7:22789789	A/C	cg26061582	chr7:22766209	IL6	0.57	7.17	0.54	5.91e-11	Lung cancer;
TGCT	cis	rs9527	0.590	rs1541213	chr10:104885330	A/G	cg04362960	chr10:104952993	NT5C2	0.69	5.82	0.46	4.78e-8	Arsenic metabolism;
TGCT	cis	rs17401966	0.838	rs4846206	chr1:10310258	G/C	cg19773385	chr1:10388646	KIF1B	-0.2	-4.5	-0.37	1.54e-5	Hepatocellular carcinoma;
TGCT	cis	rs3091242	0.933	rs10903129	chr1:25768937	A/G	cg10117171	chr1:25599238	RHD	-0.3	-4.95	-0.41	2.37e-6	Erythrocyte sedimentation rate;
TGCT	cis	rs11578119	0.713	rs10800520	chr1:170382131	G/A	cg09767346	chr1:170501363	GORAB	-0.59	-4.92	-0.4	2.72e-6	Male-pattern baldness;
TGCT	cis	rs1018836	0.608	rs12679836	chr8:91465287	A/G	cg16814680	chr8:91681699	NA	-0.73	-7.61	-0.56	5.91e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs17401966	0.838	rs11580854	chr1:10293565	G/A	cg19773385	chr1:10388646	KIF1B	-0.23	-4.99	-0.41	1.97e-6	Hepatocellular carcinoma;
TGCT	cis	rs7618915	1.000	rs34569561	chr3:52287293	T/C	cg07507251	chr3:52567010	NT5DC2	0.43	5.83	0.46	4.46e-8	Bipolar disorder;
TGCT	cis	rs62244186	0.659	rs9311358	chr3:44538748	C/G	cg02073558	chr3:44770973	ZNF501	0.61	5.85	0.47	4.09e-8	Depressive symptoms;
TGCT	cis	rs58688157	0.960	rs10902178	chr11:612843	T/G	cg16486109	chr11:613632	IRF7	0.36	5.26	0.43	6.02e-7	Systemic lupus erythematosus;
TGCT	cis	rs10791097	0.935	rs4601795	chr11:130729430	T/C	cg05962950	chr11:130786565	SNX19	0.74	8.51	0.61	4.71e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs8017423	0.605	rs8181930	chr14:90811289	A/G	cg04374321	chr14:90722782	PSMC1	-0.58	-5.68	-0.45	9.14e-8	Mortality in heart failure;
TGCT	cis	rs2070488	0.761	rs6807940	chr3:38460062	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.73	7.17	0.54	5.95e-11	Electrocardiographic conduction measures;
TGCT	cis	rs854765	0.647	rs7406744	chr17:17981938	C/G	cg04398451	chr17:18023971	MYO15A	-0.36	-6.28	-0.49	5.29e-9	Total body bone mineral density;
TGCT	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg00684032	chr4:1343700	KIAA1530	0.23	4.93	0.41	2.55e-6	Obesity-related traits;
TGCT	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.92	7.33	0.55	2.53e-11	Platelet count;
TGCT	cis	rs13191362	1.000	rs60719662	chr6:163006643	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.68	5.79	0.46	5.33e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs854765	0.964	rs12950562	chr17:17995166	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.63	-5.96	-0.47	2.46e-8	Total body bone mineral density;
TGCT	cis	rs9399135	0.967	rs6923765	chr6:135335176	C/G	cg24558204	chr6:135376177	HBS1L	-0.48	-4.81	-0.4	4.28e-6	Red blood cell count;
TGCT	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg00149659	chr3:10157352	C3orf10	0.91	5.89	0.47	3.32e-8	Alzheimer's disease;
TGCT	cis	rs7552404	0.924	rs1611823	chr1:76221706	T/G	cg22875332	chr1:76189707	ACADM	0.69	8.32	0.6	1.32e-13	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs1451375	0.729	rs6593017	chr7:50644812	G/A	cg18232548	chr7:50535776	DDC	0.44	6.83	0.52	3.36e-10	Malaria;
TGCT	cis	rs7267979	1.000	rs6515651	chr20:25414539	T/G	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1056107	0.931	rs3908938	chr9:114991220	C/G	cg02332936	chr9:115140584	NA	-0.25	-4.45	-0.37	1.89e-5	Colorectal cancer;
TGCT	cis	rs7599312	0.534	rs2128321	chr2:213405276	G/T	cg16329650	chr2:213403929	ERBB4	1.01	15.21	0.81	3.96e-30	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs611744	0.967	rs689256	chr8:109186398	T/A	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs9467773	0.935	rs9461270	chr6:26544110	A/G	cg05738196	chr6:26577821	NA	0.88	12.49	0.75	1.11e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs4713118	0.513	rs156734	chr6:28007357	A/C	cg10876282	chr6:28092338	ZSCAN16	0.51	4.56	0.38	1.19e-5	Parkinson's disease;
TGCT	cis	rs11190604	0.767	rs7076606	chr10:102192267	T/C	cg16005271	chr10:102321736	NA	0.45	4.7	0.39	6.81e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs12776158	0.792	rs12413268	chr10:71205504	G/A	cg12610070	chr10:71211762	TSPAN15	-0.58	-5.04	-0.41	1.64e-6	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs7666738	0.830	rs4699588	chr4:98973789	A/G	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1215050	0.740	rs783963	chr4:98989070	A/G	cg05340658	chr4:99064831	C4orf37	0.41	4.84	0.4	3.81e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9916302	0.904	rs9894500	chr17:37515735	G/C	cg07936489	chr17:37558343	FBXL20	0.64	4.93	0.4	2.62e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg02725872	chr8:58115012	NA	-0.38	-4.99	-0.41	1.98e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs950776	0.613	rs12915539	chr15:78940795	T/A	cg21242079	chr15:79101063	ADAMTS7	-0.31	-4.76	-0.39	5.21e-6	Sudden cardiac arrest;
TGCT	cis	rs12257961	0.579	rs6602837	chr10:15370901	A/G	cg10616319	chr10:15468812	NA	-0.26	-4.72	-0.39	6.16e-6	Selective IgA deficiency;
TGCT	cis	rs1580019	0.922	rs766658	chr7:32499391	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.81	7.7	0.57	3.71e-12	Cognitive ability;
TGCT	cis	rs4938534	0.750	rs1944927	chr11:111287404	C/A	cg01212326	chr11:111250286	POU2AF1	-0.23	-4.83	-0.4	3.94e-6	Primary biliary cholangitis;
TGCT	cis	rs7772486	0.875	rs6570738	chr6:146412695	G/A	cg23711669	chr6:146136114	FBXO30	0.86	9.3	0.64	6.2e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2153535	0.580	rs7745043	chr6:8513507	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.55e-8	Motion sickness;
TGCT	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.52	-4.9	-0.4	2.9e-6	Bipolar disorder;
TGCT	cis	rs11779988	0.545	rs208762	chr8:17806734	G/A	cg01800426	chr8:17659068	MTUS1	-0.64	-4.99	-0.41	2.02e-6	Breast cancer;
TGCT	cis	rs7666738	0.784	rs4699602	chr4:99034903	T/C	cg18180107	chr4:99064573	C4orf37	0.57	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs67073037	0.955	rs12620770	chr2:29144892	C/T	cg09522027	chr2:28974177	PPP1CB	0.57	4.49	0.37	1.59e-5	Breast cancer;Breast cancer (estrogen-receptor negative);
TGCT	cis	rs9787249	1.000	rs9787249	chr1:40212878	G/A	cg20968010	chr1:40505947	CAP1	-0.53	-5.0	-0.41	1.91e-6	Blood protein levels;
TGCT	cis	rs854765	0.822	rs1889014	chr17:17767165	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.64	-6.37	-0.5	3.37e-9	Total body bone mineral density;
TGCT	cis	rs68170813	0.559	rs997311	chr7:106953033	G/A	cg02696742	chr7:106810147	HBP1	-0.69	-5.81	-0.46	4.85e-8	Coronary artery disease;
TGCT	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg00814883	chr7:100076585	TSC22D4	-0.92	-9.76	-0.66	4.73e-17	Platelet count;
TGCT	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg24250549	chr1:154909240	PMVK	0.56	5.42	0.44	2.92e-7	Prostate cancer;
TGCT	cis	rs2204008	0.775	rs11514369	chr12:38305411	C/T	cg26384229	chr12:38710491	ALG10B	0.82	7.18	0.54	5.6e-11	Bladder cancer;
TGCT	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg11494091	chr17:61959527	GH2	0.61	14.4	0.79	3.14e-28	Prudent dietary pattern;
TGCT	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	4.93	0.4	2.63e-6	Menopause (age at onset);
TGCT	cis	rs6121246	0.529	rs6060296	chr20:30198480	T/C	cg18721089	chr20:30220636	NA	-0.57	-6.19	-0.49	7.9e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg06028808	chr11:68637592	NA	0.53	6.91	0.53	2.23e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9894429	0.671	rs6565616	chr17:79612161	C/T	cg18240062	chr17:79603768	NPLOC4	0.56	4.9	0.4	2.95e-6	Eye color traits;
TGCT	cis	rs2734839	0.537	rs1554929	chr11:113278764	C/T	cg14159747	chr11:113255604	NA	0.38	4.97	0.41	2.22e-6	Information processing speed;
TGCT	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg21285383	chr16:89894308	SPIRE2	0.46	7.19	0.54	5.44e-11	Vitiligo;
TGCT	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg12963246	chr6:28129442	ZNF389	0.51	5.02	0.41	1.73e-6	Depression;
TGCT	cis	rs57590327	0.528	rs2229519	chr3:81698130	T/C	cg07356753	chr3:81810745	GBE1	-0.77	-6.97	-0.53	1.63e-10	Extraversion;
TGCT	cis	rs3091242	0.933	rs61775167	chr1:25780893	A/G	cg10117171	chr1:25599238	RHD	0.3	4.92	0.4	2.69e-6	Erythrocyte sedimentation rate;
TGCT	cis	rs372883	0.648	rs15092	chr21:30718201	G/A	cg24692254	chr21:30365293	RNF160	-0.52	-4.7	-0.39	6.8e-6	Pancreatic cancer;
TGCT	cis	rs7119	0.604	rs2682927	chr15:77859168	C/T	cg27398640	chr15:77910606	LINGO1	0.27	4.82	0.4	4.2e-6	Type 2 diabetes;
TGCT	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg05368731	chr17:41323189	NBR1	1.21	14.63	0.8	8.89e-29	Menopause (age at onset);
TGCT	cis	rs10276381	0.892	rs7786444	chr7:28154384	C/T	cg23620719	chr7:28220237	JAZF1	0.81	5.22	0.42	7.21e-7	Crohn's disease;
TGCT	cis	rs11175492	0.528	rs7302505	chr12:65018121	T/G	cg18624581	chr12:65153313	GNS	-0.82	-4.69	-0.39	7.05e-6	Platelet count;
TGCT	trans	rs797680	0.856	rs7547244	chr1:93781768	A/G	cg27528825	chr2:159282178	CCDC148	-0.33	-6.67	-0.51	7.68e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs17221829	0.733	rs10830333	chr11:89399224	T/C	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.44	-0.37	1.93e-5	Anxiety in major depressive disorder;
TGCT	cis	rs67311347	1.000	rs66841330	chr3:40531123	G/A	cg17264618	chr3:40429014	ENTPD3	0.35	4.87	0.4	3.3e-6	Renal cell carcinoma;
TGCT	cis	rs7246657	0.722	rs10402671	chr19:38117086	C/T	cg18154014	chr19:37997991	ZNF793	0.69	4.63	0.38	9.25e-6	Coronary artery calcification;
TGCT	cis	rs7772486	0.754	rs9373475	chr6:146126419	C/T	cg13319975	chr6:146136371	FBXO30	-0.57	-5.13	-0.42	1.07e-6	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs2727020	0.638	rs1164668	chr11:49330627	A/C	cg15704280	chr7:45808275	SEPT13	0.69	7.76	0.57	2.73e-12	Coronary artery disease;
TGCT	cis	rs8141529	0.732	rs6005872	chr22:29172898	T/G	cg02153584	chr22:29168773	CCDC117	0.69	5.96	0.47	2.47e-8	Lymphocyte counts;
TGCT	cis	rs17826219	0.706	rs28469200	chr17:29133572	T/A	cg13385521	chr17:29058706	SUZ12P	0.81	4.92	0.4	2.74e-6	Body mass index;
TGCT	trans	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg13615516	chr5:77269221	NA	0.7	8.83	0.62	8.34e-15	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg18876405	chr7:65276391	NA	-0.36	-5.71	-0.46	7.96e-8	Aortic root size;
TGCT	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg09509183	chr1:209979624	IRF6	0.52	5.12	0.42	1.16e-6	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
TGCT	cis	rs936229	0.871	rs2290574	chr15:75135447	T/C	cg10253484	chr15:75165896	SCAMP2	-0.78	-6.51	-0.5	1.67e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
TGCT	cis	rs936229	1.000	rs936229	chr15:75132319	A/G	cg10253484	chr15:75165896	SCAMP2	-0.79	-6.56	-0.51	1.31e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
TGCT	cis	rs2188554	1.000	rs2188554	chr7:117040117	A/G	cg08576598	chr7:116962626	WNT2	-0.4	-5.07	-0.41	1.4e-6	Esophageal adenocarcinoma;
TGCT	cis	rs4589502	0.925	rs57729347	chr15:67136438	G/A	cg12317470	chr15:67143691	NA	0.66	5.43	0.44	2.9e-7	Lung cancer (smoking interaction);
TGCT	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg11644478	chr21:40555479	PSMG1	-0.62	-5.52	-0.44	1.88e-7	Cognitive function;
TGCT	cis	rs79057730	0.599	rs34411410	chr7:811721	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.65	6.07	0.48	1.41e-8	Initial pursuit acceleration;
TGCT	cis	rs7588654	0.793	rs17608726	chr2:219947002	G/A	cg19394737	chr2:219892361	CCDC108	-0.35	-4.55	-0.38	1.27e-5	Height;
TGCT	cis	rs7833790	0.660	rs67666182	chr8:82772037	A/G	cg23324259	chr8:82754387	SNX16	0.62	4.71	0.39	6.47e-6	Diastolic blood pressure;
TGCT	cis	rs2742417	0.935	rs2248991	chr3:45754749	G/A	cg04837898	chr3:45731254	SACM1L	-0.55	-5.72	-0.46	7.45e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs2688608	0.620	rs7098444	chr10:75580042	C/T	cg15838173	chr10:75533400	FUT11	-0.3	-4.83	-0.4	3.97e-6	Inflammatory bowel disease;
TGCT	cis	rs1218582	0.596	rs906595	chr1:154822907	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.49	-4.67	-0.39	7.72e-6	Prostate cancer;
TGCT	cis	rs7914558	1.000	rs3740387	chr10:104849468	G/A	cg04362960	chr10:104952993	NT5C2	0.62	5.42	0.44	2.99e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs11190604	1.000	rs9420782	chr10:102235015	G/A	cg16342193	chr10:102329863	NA	-0.39	-5.14	-0.42	1.03e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7208859	0.623	rs7220289	chr17:29103762	G/T	cg13385521	chr17:29058706	SUZ12P	0.81	4.84	0.4	3.86e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs2836974	0.563	rs6517522	chr21:40553845	T/C	cg11890956	chr21:40555474	PSMG1	0.88	9.47	0.65	2.49e-16	Cognitive function;
TGCT	cis	rs2692947	0.644	rs1168974	chr2:96814928	G/A	cg23100626	chr2:96804247	ASTL	0.46	5.42	0.44	3.03e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	-0.53	-5.12	-0.42	1.11e-6	Prudent dietary pattern;
TGCT	cis	rs9549367	0.789	rs12584981	chr13:113881185	T/C	cg00898013	chr13:113819073	PROZ	-0.4	-4.88	-0.4	3.18e-6	Platelet distribution width;
TGCT	cis	rs9486715	0.838	rs7452350	chr6:96883326	C/A	cg18709589	chr6:96969512	KIAA0776	0.79	7.77	0.57	2.5e-12	Headache;
TGCT	cis	rs11148252	0.967	rs11618716	chr13:53046836	A/G	cg00495681	chr13:53174319	NA	-0.5	-5.08	-0.42	1.34e-6	Lewy body disease;
TGCT	cis	rs10875595	0.779	rs2338532	chr5:140675264	G/A	cg20560182	chr5:140700478	TAF7	-0.64	-4.91	-0.4	2.76e-6	Pulmonary function decline;
TGCT	trans	rs797680	0.964	rs2152358	chr1:93634009	G/A	cg27528825	chr2:159282178	CCDC148	-0.34	-6.63	-0.51	9.04e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs9818758	0.607	rs9847839	chr3:49289003	T/C	cg07636037	chr3:49044803	WDR6	-1.04	-5.13	-0.42	1.09e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs17102423	0.573	rs7144259	chr14:65537559	T/A	cg11161011	chr14:65562177	MAX	-0.55	-6.8	-0.52	3.84e-10	Obesity-related traits;
TGCT	cis	rs7731657	0.537	rs6867710	chr5:130201260	A/C	cg08523029	chr5:130500466	HINT1	-0.55	-4.57	-0.38	1.15e-5	Fasting plasma glucose;
TGCT	cis	rs4589502	0.925	rs4259997	chr15:67153310	A/G	cg12317470	chr15:67143691	NA	-0.57	-4.88	-0.4	3.2e-6	Lung cancer (smoking interaction);
TGCT	cis	rs12580194	0.593	rs61556775	chr12:55745640	A/C	cg10672482	chr12:55725839	OR6C3	-0.51	-4.43	-0.37	2.01e-5	Cancer;
TGCT	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg04944784	chr2:26401820	FAM59B	-0.68	-6.13	-0.48	1.1e-8	Gut microbiome composition (summer);
TGCT	cis	rs3806843	0.735	rs801185	chr5:140068869	A/G	cg19875535	chr5:140030758	IK	-0.37	-6.23	-0.49	6.51e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs1532993	0.518	rs13138073	chr4:98566397	G/A	cg05340658	chr4:99064831	C4orf37	-0.38	-4.53	-0.38	1.36e-5	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs950027	0.549	rs2899375	chr15:45598335	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.72	-7.46	-0.56	1.32e-11	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs2204008	0.536	rs12368354	chr12:38042798	G/A	cg13010199	chr12:38710504	ALG10B	0.65	5.23	0.42	7.11e-7	Bladder cancer;
TGCT	cis	rs7474896	0.616	rs1985260	chr10:38434090	C/T	cg25427524	chr10:38739819	LOC399744	-0.36	-4.55	-0.38	1.24e-5	Obesity (extreme);
TGCT	cis	rs36051895	0.632	rs10974980	chr9:5140671	C/G	cg02405213	chr9:5042618	JAK2	-0.7	-9.44	-0.65	2.91e-16	Pediatric autoimmune diseases;
TGCT	cis	rs861020	0.771	rs126280	chr1:210019824	A/G	cg05527609	chr1:210001259	C1orf107	1.05	10.03	0.67	1.07e-17	Orofacial clefts;
TGCT	cis	rs2594989	0.943	rs2252601	chr3:11481234	A/G	cg26283222	chr3:11613257	VGLL4	-0.21	-4.45	-0.37	1.92e-5	Circulating chemerin levels;
TGCT	cis	rs6912958	0.525	rs59322	chr6:88020521	C/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.7	6.93	0.53	2.02e-10	Monocyte percentage of white cells;
TGCT	cis	rs7772486	0.869	rs2777473	chr6:146301494	G/A	cg05347473	chr6:146136440	FBXO30	0.54	5.15	0.42	9.88e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg18876405	chr7:65276391	NA	0.32	4.87	0.4	3.29e-6	Aortic root size;
TGCT	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg17911788	chr17:44343683	NA	-0.67	-7.15	-0.54	6.59e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2235642	1.000	rs2076438	chr16:1584618	T/C	cg11375102	chr16:1583810	IFT140;TMEM204	-0.3	-5.35	-0.43	4.01e-7	Coronary artery disease;
TGCT	cis	rs2439831	1.000	rs537115	chr15:43729948	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.8	5.7	0.46	8.33e-8	Lung cancer in ever smokers;
TGCT	cis	rs4319547	0.656	rs3817011	chr12:122819566	C/T	cg08088222	chr12:122070432	ORAI1	0.26	4.69	0.39	6.99e-6	Body mass index;
TGCT	cis	rs7617773	0.780	rs4392440	chr3:48343920	C/T	cg11946769	chr3:48343235	NME6	0.82	7.09	0.54	9.1e-11	Coronary artery disease;
TGCT	cis	rs597539	0.521	rs2060982	chr11:68612927	A/G	cg06112835	chr11:68658793	MRPL21	0.32	5.31	0.43	4.95e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs514475	0.526	rs12199435	chr6:137954339	G/A	cg02673417	chr6:137105249	MAP3K5	0.29	4.45	0.37	1.88e-5	Inflammatory skin disease;
TGCT	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg20119798	chr7:94954144	PON1	-0.28	-4.52	-0.38	1.45e-5	Paraoxonase activity;
TGCT	cis	rs1059312	0.771	rs7974764	chr12:129296588	G/C	cg09035930	chr12:129282057	SLC15A4	0.55	10.73	0.69	2.06e-19	Systemic lupus erythematosus;
TGCT	cis	rs9916302	0.861	rs752314	chr17:37410700	C/T	cg07936489	chr17:37558343	FBXL20	-0.63	-4.99	-0.41	2.03e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs1023500	1.000	rs7293091	chr22:42341308	A/G	cg04692870	chr22:42525206	CYP2D6	-0.33	-5.0	-0.41	1.9e-6	Schizophrenia;
TGCT	cis	rs67614146	1	rs67614146	chr6:87821827	AC/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.65	-6.42	-0.5	2.63e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs796364	0.806	rs79333757	chr2:200915716	T/C	cg17644776	chr2:200775616	C2orf69	-0.33	-5.0	-0.41	1.91e-6	Schizophrenia;
TGCT	cis	rs1865760	0.927	rs6915834	chr6:25935427	A/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.64	6.15	0.48	9.9e-9	Height;
TGCT	cis	rs9611519	1.000	rs9611510	chr22:41569124	T/C	cg03806693	chr22:41940476	POLR3H	-0.67	-6.19	-0.49	7.94e-9	Neuroticism;
TGCT	cis	rs7809950	0.817	rs2204833	chr7:107283069	T/C	cg23024343	chr7:107201750	COG5	0.42	5.9	0.47	3.27e-8	Coronary artery disease;
TGCT	cis	rs2230307	0.536	rs57637634	chr1:100447467	G/A	cg24955406	chr1:100503596	HIAT1	0.72	4.68	0.39	7.51e-6	Carotid intima media thickness;
TGCT	cis	rs3096299	0.685	rs4785676	chr16:89553624	T/C	cg02187348	chr16:89574699	SPG7	0.61	6.52	0.51	1.61e-9	Multiple myeloma (IgH translocation);
TGCT	cis	rs4253772	0.530	rs6008774	chr22:46755298	C/G	cg24881330	chr22:46731750	TRMU	0.94	6.42	0.5	2.64e-9	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs2898681	0.519	rs3811781	chr4:53729166	T/G	cg00791764	chr4:53727839	RASL11B	0.54	4.58	0.38	1.1e-5	Optic nerve measurement (cup area);
TGCT	cis	rs6456156	0.586	rs2285148	chr6:167490999	G/T	cg07741184	chr6:167504864	NA	0.24	4.72	0.39	6.21e-6	Primary biliary cholangitis;
TGCT	cis	rs2242116	0.796	rs4683297	chr3:46973673	T/C	cg02527881	chr3:46936655	PTH1R	0.33	6.23	0.49	6.54e-9	Birth weight;
TGCT	cis	rs2067615	0.542	rs7133161	chr12:107139540	A/G	cg15890332	chr12:107067104	RFX4	0.3	5.93	0.47	2.85e-8	Heart rate;
TGCT	trans	rs7698623	0.850	rs4693192	chr4:88797913	T/C	cg01186725	chr1:53905612	FLJ40434	-0.48	-6.63	-0.51	9.21e-10	Cardiovascular disease risk factors;
TGCT	cis	rs1505368	0.505	rs1394781	chr2:213248822	C/T	cg16329650	chr2:213403929	ERBB4	-0.59	-5.15	-0.42	9.99e-7	Symmetrical dimethylarginine levels;
TGCT	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.95	9.68	0.66	7.34e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.791	rs10010438	chr4:99022177	C/T	cg05340658	chr4:99064831	C4orf37	0.48	5.43	0.44	2.92e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.6	6.44	0.5	2.39e-9	Height;
TGCT	cis	rs7267979	0.934	rs2261115	chr20:25259807	G/A	cg16686733	chr20:25566563	NINL	0.61	6.07	0.48	1.44e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1215050	0.547	rs6822735	chr4:98613915	A/G	cg05340658	chr4:99064831	C4orf37	-0.41	-4.96	-0.41	2.3e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs62244186	0.748	rs6441861	chr3:44652287	A/G	cg04389838	chr3:44770851	ZNF501	-0.42	-5.54	-0.45	1.73e-7	Depressive symptoms;
TGCT	cis	rs40363	1.000	rs37767	chr16:3514962	C/T	cg22508957	chr16:3507546	NAT15	0.57	5.15	0.42	1.01e-6	Tuberculosis;
TGCT	trans	rs208520	0.690	rs12198297	chr6:66714665	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	11.06	0.7	3.28e-20	Exhaled nitric oxide output;
TGCT	cis	rs13217239	0.572	rs9379958	chr6:27066163	A/C	cg06035815	chr6:26189597	HIST1H4D	0.44	4.52	0.38	1.41e-5	Schizophrenia;
TGCT	cis	rs2153535	0.580	rs2184583	chr6:8447808	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.76	0.46	6.39e-8	Motion sickness;
TGCT	trans	rs7819412	0.511	rs7464263	chr8:11434176	A/T	cg15556689	chr8:8085844	FLJ10661	-0.77	-7.2	-0.54	5.08e-11	Triglycerides;
TGCT	cis	rs6831352	0.918	rs4699713	chr4:100060513	C/T	cg12011299	chr4:100065546	ADH4	-0.41	-4.97	-0.41	2.21e-6	Alcohol dependence;
TGCT	cis	rs11785693	0.862	rs11782556	chr8:5002389	C/G	cg26367366	chr8:4980734	NA	0.56	4.44	0.37	1.95e-5	Neuroticism (multi-trait analysis);Neuroticism;
TGCT	cis	rs7666738	0.830	rs13102652	chr4:99006737	T/G	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12477438	0.508	rs2516832	chr2:99771268	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.82	0.62	8.67e-15	Chronic sinus infection;
TGCT	cis	rs798766	1.000	rs798767	chr4:1734281	A/G	cg05874882	chr4:1763078	NA	-0.35	-4.45	-0.37	1.86e-5	Bladder cancer;Urinary bladder cancer;
TGCT	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg27286337	chr10:134555280	INPP5A	0.46	5.5	0.44	2.08e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs9534288	0.742	rs1977395	chr13:46638131	C/T	cg15192986	chr13:46630673	CPB2	-0.54	-6.99	-0.53	1.48e-10	Blood protein levels;
TGCT	cis	rs453301	0.658	rs13271797	chr8:8885954	G/A	cg15556689	chr8:8085844	FLJ10661	-0.66	-5.4	-0.44	3.27e-7	Joint mobility (Beighton score);
TGCT	cis	rs6121246	0.954	rs7266148	chr20:30431070	G/T	cg18721089	chr20:30220636	NA	-0.43	-4.75	-0.39	5.54e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs6901250	0.851	rs2175622	chr6:117149667	T/A	cg12892004	chr6:117198278	RFX6	0.54	6.65	0.51	8.24e-10	C-reactive protein levels;
TGCT	cis	rs6500602	0.647	rs4786514	chr16:4576798	A/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.28	5.16	0.42	9.66e-7	Schizophrenia;
TGCT	cis	rs4372836	0.964	rs4665432	chr2:28952026	G/A	cg09522027	chr2:28974177	PPP1CB	0.59	5.15	0.42	1e-6	Body mass index;
TGCT	trans	rs10506458	0.915	rs17687426	chr12:63397900	G/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.47	-7.58	-0.56	6.97e-12	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg11764359	chr7:65958608	NA	0.59	5.28	0.43	5.53e-7	Aortic root size;
TGCT	cis	rs72945132	0.882	rs11235967	chr11:70191691	T/C	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs17376456	0.877	rs10476601	chr5:93402522	G/A	cg25358565	chr5:93447407	FAM172A	0.92	8.38	0.6	9.58e-14	Diabetic retinopathy;
TGCT	cis	rs12188164	0.965	rs56146525	chr5:442571	A/C	cg26850624	chr5:429559	AHRR	-0.2	-4.84	-0.4	3.78e-6	Cystic fibrosis severity;
TGCT	cis	rs35306767	0.714	rs67696450	chr10:1090684	C/T	cg18964960	chr10:1102726	WDR37	0.68	4.77	0.39	5.02e-6	Eosinophil percentage of granulocytes;
TGCT	cis	rs7772486	0.875	rs2814874	chr6:146305895	C/T	cg13319975	chr6:146136371	FBXO30	-0.52	-4.62	-0.38	9.45e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9467711	0.606	rs2393667	chr6:26421345	T/C	cg16898833	chr6:26189333	HIST1H4D	1.12	5.36	0.43	3.91e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9457247	1.000	rs416131	chr6:167406544	A/C	cg23791538	chr6:167370224	RNASET2	0.47	4.74	0.39	5.81e-6	Crohn's disease;
TGCT	cis	rs1401999	0.546	rs56889301	chr3:183675315	T/C	cg01324343	chr3:183735012	ABCC5	0.75	8.96	0.63	4.06e-15	Anterior chamber depth;
TGCT	cis	rs35160687	0.901	rs10520415	chr2:86498738	C/T	cg12542933	chr2:85804724	VAMP8	-0.4	-4.82	-0.4	4.16e-6	Night sleep phenotypes;
TGCT	cis	rs155076	1.000	rs566364	chr13:21837583	T/C	cg11317459	chr13:21872234	NA	-1.42	-12.02	-0.73	1.53e-22	White matter hyperintensity burden;
TGCT	cis	rs12134133	1.000	rs10494890	chr1:207424386	C/G	cg02152968	chr1:207494213	CD55	-0.62	-4.79	-0.4	4.64e-6	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs7552404	0.924	rs1313071	chr1:76195542	C/G	cg03433033	chr1:76189801	ACADM	0.77	9.31	0.64	5.74e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs28595532	0.841	rs114385163	chr4:119737058	C/T	cg14228332	chr4:119757509	SEC24D	1.31	7.06	0.54	1.06e-10	Cannabis dependence symptom count;
TGCT	cis	rs739496	0.615	rs624716	chr12:112166696	A/G	cg10833066	chr12:111807467	FAM109A	0.36	5.06	0.41	1.46e-6	Platelet count;
TGCT	cis	rs7833790	0.777	rs7815272	chr8:82691809	T/G	cg06027949	chr8:82754900	SNX16	-0.67	-4.47	-0.37	1.75e-5	Diastolic blood pressure;
TGCT	cis	rs2050392	0.590	rs685319	chr10:30719331	G/A	cg13289132	chr10:30722225	MAP3K8	-0.46	-5.57	-0.45	1.47e-7	Inflammatory bowel disease;
TGCT	cis	rs10114408	0.959	rs10821247	chr9:96645864	G/C	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs8180040	0.654	rs11714373	chr3:47214817	G/A	cg27129171	chr3:47204927	SETD2	-0.69	-8.12	-0.59	3.88e-13	Colorectal cancer;
TGCT	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg02953382	chr22:24373134	LOC391322	0.77	7.12	0.54	7.61e-11	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs62244186	0.545	rs7640654	chr3:44763037	A/C	cg02073558	chr3:44770973	ZNF501	0.73	7.31	0.55	2.81e-11	Depressive symptoms;
TGCT	cis	rs806215	0.547	rs1419967	chr7:127474435	G/C	cg11539674	chr7:127291444	SND1	-0.36	-4.6	-0.38	1.02e-5	Type 2 diabetes;
TGCT	cis	rs17102423	0.530	rs4902359	chr14:65542790	G/A	cg11161011	chr14:65562177	MAX	-0.47	-6.4	-0.5	2.92e-9	Obesity-related traits;
TGCT	cis	rs7698623	0.717	rs1463094	chr4:88792584	G/A	cg27387453	chr4:88533842	DSPP	-0.61	-4.6	-0.38	1.03e-5	Cardiovascular disease risk factors;
TGCT	cis	rs151997	0.853	rs3846498	chr5:50253625	A/C	cg06027927	chr5:50259733	NA	-0.59	-6.38	-0.5	3.21e-9	Callous-unemotional behaviour;
TGCT	cis	rs67311347	1.000	rs9849992	chr3:40402140	C/T	cg17264618	chr3:40429014	ENTPD3	0.31	4.59	0.38	1.09e-5	Renal cell carcinoma;
TGCT	cis	rs2243480	0.708	rs35825036	chr7:65986502	T/C	cg18252515	chr7:66147081	NA	-1.22	-8.04	-0.59	6.02e-13	Diabetic kidney disease;
TGCT	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg02038168	chr22:39784481	NA	-0.73	-6.0	-0.47	2.05e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs6951245	0.507	rs10227709	chr7:1180515	T/G	cg03188948	chr7:1209495	NA	0.48	4.65	0.39	8.44e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg07424592	chr7:64974309	NA	1.4	8.42	0.6	7.87e-14	Diabetic kidney disease;
TGCT	cis	rs6424115	0.830	rs2501424	chr1:24199182	T/C	cg15997130	chr1:24165203	NA	0.87	9.53	0.65	1.79e-16	Immature fraction of reticulocytes;
TGCT	cis	rs523522	0.962	rs2235218	chr12:120888619	A/C	cg27279351	chr12:120934652	DYNLL1	0.74	6.4	0.5	2.95e-9	High light scatter reticulocyte count;
TGCT	cis	rs10464366	0.746	rs34792397	chr7:39146331	G/A	cg15212455	chr7:39170539	POU6F2	0.26	5.63	0.45	1.15e-7	IgG glycosylation;
TGCT	cis	rs6840360	0.593	rs6857073	chr4:152689274	A/G	cg22705602	chr4:152727874	NA	0.35	5.89	0.47	3.36e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9969804	0.818	rs10992439	chr9:95495134	T/A	cg13940029	chr9:95239186	CENPP;ASPN	-0.17	-4.51	-0.38	1.47e-5	Height;
TGCT	cis	rs7178572	0.568	rs12910480	chr15:77664212	G/C	cg22256960	chr15:77711686	NA	-0.87	-9.0	-0.63	3.34e-15	Type 2 diabetes;
TGCT	cis	rs79349575	0.691	rs28528789	chr17:46986616	C/T	cg26022315	chr17:47021804	SNF8	-0.54	-5.37	-0.43	3.73e-7	Type 2 diabetes;
TGCT	cis	rs303386	0.501	rs4908303	chr1:99583230	C/T	cg03593336	chr1:99471295	LPPR5	-0.28	-6.01	-0.47	1.91e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors);Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin);
TGCT	cis	rs362272	0.545	rs3135145	chr4:3299504	T/C	cg06533319	chr4:3265114	C4orf44	-0.28	-5.52	-0.44	1.94e-7	Serum sulfate level;
TGCT	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg10802521	chr3:52805072	NEK4	-0.78	-10.0	-0.67	1.26e-17	Bipolar disorder;
TGCT	cis	rs4845570	0.831	rs11588258	chr1:151780728	A/T	cg07092448	chr1:151763213	TDRKH	-1.17	-8.37	-0.6	1e-13	Coronary artery disease;
TGCT	cis	rs9894429	0.646	rs7405870	chr17:79617284	G/A	cg18240062	chr17:79603768	NPLOC4	0.56	4.9	0.4	2.95e-6	Eye color traits;
TGCT	cis	rs4642101	0.511	rs9809596	chr3:12840513	C/G	cg05775895	chr3:12838266	CAND2	0.83	9.36	0.64	4.36e-16	QRS complex (12-leadsum);
TGCT	cis	rs5750830	0.594	rs9611165	chr22:39775250	A/G	cg24399712	chr22:39784796	NA	-0.95	-11.01	-0.7	4.37e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs35146811	0.844	rs13223792	chr7:99675659	T/G	cg13334819	chr7:99746414	C7orf59	-0.79	-6.87	-0.53	2.73e-10	Coronary artery disease;
TGCT	cis	rs35306767	0.904	rs10904584	chr10:983747	A/T	cg26597838	chr10:835615	NA	0.56	7.61	0.56	5.93e-12	Eosinophil percentage of granulocytes;
TGCT	cis	rs7918232	0.943	rs4747584	chr10:27373333	G/A	cg14442939	chr10:27389572	ANKRD26	0.73	5.37	0.43	3.69e-7	Breast cancer;
TGCT	cis	rs9611519	0.780	rs1983631	chr22:41644074	C/T	cg03806693	chr22:41940476	POLR3H	-0.73	-6.79	-0.52	4.19e-10	Neuroticism;
TGCT	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg04944784	chr2:26401820	FAM59B	-0.72	-5.92	-0.47	2.93e-8	Gut microbiome composition (summer);
TGCT	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg17747265	chr1:1875780	NA	-0.39	-7.23	-0.54	4.33e-11	Body mass index;
TGCT	cis	rs7666738	0.888	rs13110683	chr4:98983368	G/C	cg17366294	chr4:99064904	C4orf37	0.77	7.0	0.53	1.4e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7119	0.678	rs12914098	chr15:77823013	C/T	cg27398640	chr15:77910606	LINGO1	-0.26	-4.66	-0.39	7.98e-6	Type 2 diabetes;
TGCT	cis	rs7666738	0.830	rs13119913	chr4:98977983	G/T	cg05340658	chr4:99064831	C4orf37	0.5	5.84	0.46	4.35e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg06481639	chr22:41940642	POLR3H	-0.74	-6.74	-0.52	5.38e-10	Vitiligo;
TGCT	cis	rs7959452	0.535	rs10878953	chr12:69674187	A/G	cg14784868	chr12:69753453	YEATS4	0.69	7.06	0.54	1.04e-10	Blood protein levels;
TGCT	cis	rs910316	1.000	rs2268617	chr14:75608728	G/A	cg08847533	chr14:75593920	NEK9	0.95	10.55	0.69	5.78e-19	Height;
TGCT	cis	rs2115630	0.936	rs6496318	chr15:85215229	C/T	cg11189052	chr15:85197271	WDR73	-0.67	-6.67	-0.51	7.74e-10	P wave terminal force;
TGCT	cis	rs28595532	1.000	rs56000725	chr4:119637675	G/A	cg14228332	chr4:119757509	SEC24D	1.02	5.37	0.43	3.75e-7	Cannabis dependence symptom count;
TGCT	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg04944784	chr2:26401820	FAM59B	-0.76	-6.45	-0.5	2.29e-9	Gut microbiome composition (summer);
TGCT	cis	rs919433	0.713	rs1455653	chr2:198478320	G/A	cg00792783	chr2:198669748	PLCL1	0.5	4.67	0.39	7.84e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	trans	rs7819412	0.745	rs7017567	chr8:10933699	T/A	cg06636001	chr8:8085503	FLJ10661	-0.77	-7.04	-0.53	1.16e-10	Triglycerides;
TGCT	cis	rs9611565	0.572	rs139569	chr22:42211141	A/G	cg06634786	chr22:41940651	POLR3H	-0.78	-7.31	-0.55	2.93e-11	Vitiligo;
TGCT	cis	rs7439150	1.000	rs72681206	chr4:155478278	A/G	cg22130008	chr4:155548532	NA	-0.44	-5.59	-0.45	1.36e-7	Fibrinogen levels;
TGCT	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg03264133	chr6:25882463	NA	-0.62	-5.71	-0.46	7.72e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9948	0.521	rs61750875	chr2:97359364	A/G	cg01990225	chr2:97406019	LMAN2L	-0.94	-5.3	-0.43	5.2e-7	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	8.55	0.61	3.84e-14	Platelet count;
TGCT	cis	rs11779988	0.545	rs439374	chr8:17786818	C/T	cg01800426	chr8:17659068	MTUS1	-0.64	-5.17	-0.42	9.04e-7	Breast cancer;
TGCT	cis	rs2836950	0.762	rs8134638	chr21:40644170	T/C	cg11890956	chr21:40555474	PSMG1	-0.64	-6.02	-0.48	1.81e-8	Menarche (age at onset);
TGCT	cis	rs62244186	0.593	rs9814298	chr3:44871899	T/A	cg09333631	chr3:44802604	KIF15;KIAA1143	-0.42	-4.57	-0.38	1.17e-5	Depressive symptoms;
TGCT	cis	rs60012524	1	rs60012524	chr2:99559117	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-5.45	-0.44	2.57e-7	Chronic sinus infection;
TGCT	cis	rs10479542	0.929	rs7718673	chr5:178980009	C/T	cg09060608	chr5:178986726	RUFY1	-0.48	-5.29	-0.43	5.38e-7	Lung cancer;
TGCT	cis	rs75686122	0.892	rs12676448	chr8:104479217	A/G	cg04852977	chr8:104510831	NA	-0.65	-4.8	-0.4	4.53e-6	Cocaine dependence;
TGCT	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg13607699	chr17:42295918	UBTF	0.6	5.48	0.44	2.29e-7	Total body bone mineral density;
TGCT	cis	rs793571	0.544	rs12912699	chr15:58917021	T/C	cg05156742	chr15:59063176	FAM63B	0.56	5.34	0.43	4.21e-7	Schizophrenia;
TGCT	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg08219700	chr8:58056026	NA	0.38	4.61	0.38	1e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg03709012	chr19:19516395	GATAD2A	-0.66	-5.69	-0.46	8.62e-8	Tonsillectomy;
TGCT	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg07061783	chr6:25882402	NA	-0.63	-6.68	-0.51	7.27e-10	Blood metabolite levels;
TGCT	cis	rs9650657	0.644	rs10091386	chr8:10696620	A/C	cg16664915	chr8:10907788	XKR6	-0.29	-4.71	-0.39	6.47e-6	Neuroticism;
TGCT	cis	rs7829975	0.564	rs2921057	chr8:8318667	C/T	cg15556689	chr8:8085844	FLJ10661	0.65	6.02	0.48	1.87e-8	Mood instability;
TGCT	cis	rs12220238	0.554	rs10824192	chr10:76251573	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.89	5.75	0.46	6.45e-8	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg06896619	chr17:61851486	DDX42;CCDC47	-0.51	-4.96	-0.41	2.24e-6	Prudent dietary pattern;
TGCT	trans	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg23505145	chr19:12996616	KLF1	0.78	8.12	0.59	4.03e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs881375	0.967	rs2109896	chr9:123683106	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.38	4.52	0.38	1.45e-5	Rheumatoid arthritis;
TGCT	cis	rs600550	0.963	rs657928	chr11:59988906	G/A	cg18570331	chr11:60101691	MS4A6E	0.51	4.64	0.38	8.87e-6	Lipoprotein-associated phospholipase A2 activity and mass;
TGCT	cis	rs250677	0.958	rs36068	chr5:148417512	C/T	cg18129178	chr5:148520854	ABLIM3	-0.4	-5.63	-0.45	1.17e-7	Breast cancer;
TGCT	cis	rs6931421	1.000	rs6931421	chr6:80880138	A/C	cg08355045	chr6:80787529	NA	0.3	4.77	0.39	5.09e-6	Sitting height ratio;
TGCT	cis	rs2288884	0.943	rs12611112	chr19:52574939	G/A	cg13540795	chr19:52551618	ZNF432	-0.59	-5.02	-0.41	1.79e-6	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs11190604	1.000	rs9419897	chr10:102246125	T/C	cg23241863	chr10:102295624	HIF1AN	0.64	5.04	0.41	1.59e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs6909279	0.933	rs7753676	chr6:151876815	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	0.51	4.47	0.37	1.75e-5	Bone mineral density;
TGCT	cis	rs11105306	1	rs11105306	chr12:89897388	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.7	-5.02	-0.41	1.79e-6	NT-proBNP levels in acute coronary syndrome;
TGCT	cis	rs7246657	0.722	rs2909100	chr19:38212680	C/T	cg18154014	chr19:37997991	ZNF793	-0.72	-5.06	-0.41	1.48e-6	Coronary artery calcification;
TGCT	cis	rs6754311	0.773	rs309180	chr2:136614255	A/G	cg07169764	chr2:136633963	MCM6	0.63	5.91	0.47	3.13e-8	Mosquito bite size;
TGCT	cis	rs2952156	0.684	rs881844	chr17:37810218	C/G	cg00129232	chr17:37814104	STARD3	-0.22	-4.5	-0.37	1.56e-5	Asthma;
TGCT	trans	rs1814175	0.817	rs28544182	chr11:50049577	G/T	cg15704280	chr7:45808275	SEPT13	-0.72	-8.47	-0.61	6.02e-14	Height;
TGCT	cis	rs425277	0.527	rs3107144	chr1:2045380	C/A	cg24578937	chr1:2090814	PRKCZ	-0.23	-5.54	-0.45	1.73e-7	Height;
TGCT	cis	rs12497850	0.931	rs12493289	chr3:48905161	G/A	cg07636037	chr3:49044803	WDR6	0.95	10.74	0.69	2e-19	Parkinson's disease;
TGCT	cis	rs4824093	0.535	rs73443931	chr22:50291603	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.48	4.93	0.41	2.53e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs61990749	0.597	rs13379065	chr14:78141295	C/A	cg02301378	chr14:78227641	SNW1;C14orf178	-0.63	-4.62	-0.38	9.34e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg12419862	chr22:24373484	LOC391322	0.87	7.67	0.57	4.33e-12	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs78487399	0.808	rs111783562	chr2:43759381	G/A	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.8	4.93	0.41	2.54e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg06634786	chr22:41940651	POLR3H	-0.88	-8.54	-0.61	3.98e-14	Vitiligo;
TGCT	cis	rs7552404	0.924	rs1498317	chr1:76171984	A/C	cg22875332	chr1:76189707	ACADM	0.78	9.74	0.66	5.53e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs185694	0.948	rs200512	chr13:30906446	C/T	cg07600127	chr13:30881527	KATNAL1	-0.81	-6.52	-0.51	1.6e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
TGCT	cis	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg18252515	chr7:66147081	NA	-1.22	-7.33	-0.55	2.53e-11	Diabetic kidney disease;
TGCT	cis	rs56104184	0.775	rs56146968	chr19:49398847	A/G	cg17863274	chr19:49399704	TULP2	-0.54	-7.43	-0.55	1.58e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs1878931	0.597	rs37816	chr16:3456371	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.71	-5.53	-0.44	1.83e-7	Body mass index (adult);
TGCT	trans	rs7726839	0.574	rs11739866	chr5:636299	C/T	cg11887960	chr12:57824829	NA	1.14	9.28	0.64	6.87e-16	Obesity-related traits;
TGCT	cis	rs425277	0.958	rs262687	chr1:2117155	G/A	cg24578937	chr1:2090814	PRKCZ	0.31	7.81	0.57	2.09e-12	Height;
TGCT	cis	rs826838	0.868	rs864324	chr12:39122853	A/G	cg26384229	chr12:38710491	ALG10B	0.82	7.52	0.56	9.37e-12	Heart rate;
TGCT	cis	rs739401	0.572	rs389285	chr11:3062673	G/A	cg05729581	chr11:3078854	CARS	-0.57	-5.34	-0.43	4.35e-7	Longevity;
TGCT	cis	rs11107903	1.000	rs4762172	chr12:95493912	T/C	cg10621809	chr12:95840313	NA	0.68	4.54	0.38	1.3e-5	Coronary artery disease;
TGCT	cis	rs79349575	0.783	rs9747646	chr17:47016882	C/T	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.52	-0.38	1.44e-5	Type 2 diabetes;
TGCT	cis	rs2180341	0.960	rs9401953	chr6:127687574	G/A	cg24812749	chr6:127587940	RNF146	0.92	7.43	0.55	1.55e-11	Breast cancer;
TGCT	trans	rs561341	0.941	rs2428336	chr17:30290577	T/C	cg20587970	chr11:113659929	NA	-1.03	-10.74	-0.69	1.99e-19	Hip circumference adjusted for BMI;
TGCT	cis	rs7208859	0.623	rs8079891	chr17:29058863	G/A	cg14008862	chr17:28927542	LRRC37B2	0.77	4.59	0.38	1.08e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs2249625	0.545	rs55681410	chr6:72877859	G/A	cg08500200	chr6:72892038	RIMS1	0.43	4.61	0.38	1e-5	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
TGCT	cis	rs9467711	0.606	rs9393710	chr6:26367833	A/G	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9807989	0.507	rs4851571	chr2:103019000	C/T	cg03938978	chr2:103052716	IL18RAP	0.27	5.41	0.44	3.17e-7	Asthma;
TGCT	cis	rs3820068	0.608	rs12734937	chr1:16047726	T/C	cg05660106	chr1:15850417	CASP9	0.73	6.78	0.52	4.44e-10	Systolic blood pressure;
TGCT	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg08975724	chr8:8085496	FLJ10661	-0.61	-5.91	-0.47	3.07e-8	Schizophrenia;
TGCT	cis	rs13223928	0.572	rs12538887	chr7:3134821	G/A	cg19214707	chr7:3157722	NA	-0.48	-6.9	-0.53	2.42e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
TGCT	cis	rs854765	0.647	rs854817	chr17:18021882	T/C	cg04398451	chr17:18023971	MYO15A	-0.39	-6.81	-0.52	3.78e-10	Total body bone mineral density;
TGCT	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg00290607	chr11:67383545	NA	0.29	4.76	0.39	5.31e-6	Mean corpuscular volume;
TGCT	cis	rs6089584	0.566	rs55881457	chr20:60608424	G/A	cg13770153	chr20:60521292	NA	-0.39	-4.77	-0.39	5.17e-6	Body mass index;
TGCT	trans	rs28595532	0.702	rs72670256	chr4:119391043	G/A	cg26518628	chr1:97050305	NA	-0.54	-6.79	-0.52	4.14e-10	Cannabis dependence symptom count;
TGCT	cis	rs9894429	0.646	rs6565612	chr17:79602820	C/T	cg18240062	chr17:79603768	NPLOC4	-0.54	-4.7	-0.39	6.71e-6	Eye color traits;
TGCT	cis	rs7772486	0.790	rs2254257	chr6:146203724	C/T	cg05347473	chr6:146136440	FBXO30	0.53	5.08	0.42	1.33e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg22920501	chr2:26401640	FAM59B	0.72	5.27	0.43	5.77e-7	Gut microbiome composition (summer);
TGCT	cis	rs10875595	0.836	rs57396973	chr5:140659106	T/A	cg20560182	chr5:140700478	TAF7	-0.66	-5.06	-0.41	1.49e-6	Pulmonary function decline;
TGCT	cis	rs2239547	0.522	rs9831409	chr3:52985711	A/T	cg11645453	chr3:52864694	ITIH4	-0.32	-5.32	-0.43	4.67e-7	Schizophrenia;
TGCT	cis	rs568617	0.903	rs601863	chr11:65646557	C/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.57	-5.22	-0.42	7.39e-7	Crohn's disease;
TGCT	cis	rs7666738	0.546	rs10461174	chr4:98698293	G/A	cg17366294	chr4:99064904	C4orf37	0.62	5.77	0.46	6.03e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7945705	0.719	rs2012680	chr11:8996059	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.45	-4.97	-0.41	2.16e-6	Hemoglobin concentration;
TGCT	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg17054783	chr10:134559939	INPP5A	0.26	5.3	0.43	5.04e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs603424	0.554	rs10786586	chr10:102087962	A/G	cg22671421	chr10:102507979	PAX2	0.54	4.78	0.39	4.95e-6	Phospholipid levels (plasma);Palmitic acid (16:0) levels;Palmitoleic acid (16:1n-7) levels;Mean platelet volume;Serum metabolite levels;Blood metabolite levels;Vaccenic acid (18:1n-7) levels;Metabolic traits;Coronary artery disease;Blood metabolite ratios;Glycerophospholipid levels;
TGCT	cis	rs12048904	0.619	rs10875347	chr1:101333737	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.67	5.57	0.45	1.52e-7	Multiple sclerosis;
TGCT	cis	rs459571	0.796	rs10993894	chr9:136884511	C/T	cg13789015	chr9:136890014	NCRNA00094	0.4	7.22	0.54	4.48e-11	Platelet distribution width;
TGCT	cis	rs7572733	0.534	rs2060488	chr2:198751637	T/G	cg00792783	chr2:198669748	PLCL1	0.56	5.08	0.42	1.35e-6	Dermatomyositis;
TGCT	cis	rs854765	0.551	rs8070748	chr17:17859421	A/G	cg09796270	chr17:17721594	SREBF1	0.23	4.55	0.38	1.27e-5	Total body bone mineral density;
TGCT	cis	rs7666738	0.830	rs991169	chr4:98928567	C/A	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8056742	0.818	rs870149	chr16:85096556	T/C	cg00229868	chr16:85520891	NA	0.34	4.94	0.41	2.47e-6	Amyotrophic lateral sclerosis;
TGCT	cis	rs1153858	1.000	rs9783731	chr15:45642884	C/T	cg26924012	chr15:45694286	SPATA5L1	-1.07	-14.56	-0.79	1.32e-28	Homoarginine levels;
TGCT	cis	rs4699052	0.662	rs6848593	chr4:104250113	G/T	cg16532752	chr4:104119610	CENPE	-0.49	-4.89	-0.4	3.07e-6	Testicular germ cell tumor;
TGCT	cis	rs72781680	0.898	rs72782137	chr2:24047805	C/T	cg08917208	chr2:24149416	ATAD2B	0.8	4.93	0.4	2.62e-6	Lymphocyte counts;
TGCT	cis	rs8077889	0.956	rs116979403	chr17:41849105	G/A	cg26893861	chr17:41843967	DUSP3	1.08	13.16	0.76	2.76e-25	Triglycerides;
TGCT	cis	rs7666738	0.791	rs10033994	chr4:98969582	C/T	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs782590	0.807	rs782642	chr2:55928444	G/T	cg03859395	chr2:55845619	SMEK2	0.81	8.93	0.63	4.9e-15	Metabolic syndrome;
TGCT	cis	rs1669338	0.588	rs62228620	chr3:3184913	C/T	cg16797762	chr3:3221439	CRBN	-0.83	-5.24	-0.43	6.58e-7	White matter integrity;
TGCT	cis	rs4888262	0.508	rs6564153	chr16:74658723	A/C	cg01733217	chr16:74700730	RFWD3	0.73	6.92	0.53	2.14e-10	Testicular germ cell tumor;
TGCT	cis	rs1797081	0.542	rs2603796	chr10:16871456	C/T	cg23933602	chr10:16859644	RSU1	0.73	7.55	0.56	8.37e-12	Platelet distribution width;
TGCT	cis	rs2239547	0.563	rs6445547	chr3:52908577	T/C	cg10802521	chr3:52805072	NEK4	-0.58	-5.46	-0.44	2.53e-7	Schizophrenia;
TGCT	cis	rs4805272	0.539	rs1075733	chr19:29324460	C/T	cg14983838	chr19:29218262	NA	0.69	4.7	0.39	6.67e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
TGCT	cis	rs6923462	0.735	rs13216391	chr6:7789943	A/G	cg16988958	chr6:7987739	MGC26597	0.24	4.55	0.38	1.28e-5	Lung function (forced vital capacity);
TGCT	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg12042659	chr19:58951599	ZNF132	0.52	4.67	0.39	7.67e-6	Uric acid clearance;
TGCT	cis	rs6540559	0.673	rs7550857	chr1:209956542	C/A	cg04352962	chr1:209979756	IRF6	0.65	4.52	0.38	1.42e-5	Cleft lip with or without cleft palate;
TGCT	cis	rs11642862	1.000	rs11642603	chr16:30886221	C/G	cg02466173	chr16:30829666	NA	-0.4	-4.64	-0.38	8.82e-6	Tonsillectomy;
TGCT	cis	rs2688608	0.618	rs28718766	chr10:75489844	C/A	cg04320760	chr10:75533139	FUT11	-0.39	-6.01	-0.48	1.89e-8	Inflammatory bowel disease;
TGCT	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg06618935	chr21:46677482	NA	-0.34	-5.29	-0.43	5.29e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs12908161	0.959	rs62019472	chr15:85331493	A/G	cg12863693	chr15:85201151	NMB	0.42	4.95	0.41	2.38e-6	Schizophrenia;
TGCT	cis	rs6964587	0.869	rs55811257	chr7:91484799	T/A	cg17063962	chr7:91808500	NA	-0.85	-8.94	-0.63	4.52e-15	Breast cancer;
TGCT	cis	rs17270561	0.666	rs4712976	chr6:25842203	C/T	cg17042849	chr6:26104293	HIST1H4C	-0.59	-4.52	-0.38	1.45e-5	Iron status biomarkers;
TGCT	cis	rs4523957	0.583	rs8067895	chr17:2030234	G/A	cg16513277	chr17:2031491	SMG6	-0.2	-4.57	-0.38	1.17e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs2439831	0.850	rs28707214	chr15:44131623	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.44	0.37	1.99e-5	Lung cancer in ever smokers;
TGCT	cis	rs12142240	0.959	rs12137934	chr1:46728913	A/G	cg00530320	chr1:46809349	NSUN4	0.24	4.63	0.38	9.02e-6	Menopause (age at onset);
TGCT	trans	rs17684571	1.000	rs5024547	chr6:56563093	G/A	cg14229071	chr15:89282588	NA	0.52	6.82	0.52	3.54e-10	Schizophrenia;
TGCT	cis	rs4822044	0.680	rs8138780	chr22:42097462	A/T	cg17554472	chr22:41940697	POLR3H	0.49	5.22	0.42	7.4e-7	Cannabis dependence symptom count;
TGCT	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg04944784	chr2:26401820	FAM59B	-0.7	-5.66	-0.45	9.98e-8	Gut microbiome composition (summer);
TGCT	cis	rs3749237	0.595	rs4855839	chr3:49507847	G/A	cg03060546	chr3:49711283	APEH	0.77	8.86	0.62	6.92e-15	Resting heart rate;
TGCT	cis	rs6964587	1.000	rs7791138	chr7:91686789	A/G	cg17063962	chr7:91808500	NA	0.88	9.63	0.65	9.8e-17	Breast cancer;
TGCT	cis	rs9611519	0.808	rs5751074	chr22:41665722	G/A	cg13695892	chr22:41940480	POLR3H	-0.64	-6.08	-0.48	1.39e-8	Neuroticism;
TGCT	cis	rs6733301	0.529	rs2196792	chr2:25259953	A/G	cg01884057	chr2:25150051	NA	-0.27	-4.62	-0.38	9.61e-6	Height;
TGCT	cis	rs7917772	0.545	rs3934960	chr10:104355275	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-5.46	-0.44	2.51e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs36051895	0.632	rs10974983	chr9:5149657	G/T	cg02405213	chr9:5042618	JAK2	-0.7	-8.84	-0.62	8.02e-15	Pediatric autoimmune diseases;
TGCT	cis	rs6547741	0.935	rs6761095	chr2:27778010	G/T	cg27432699	chr2:27873401	GPN1	0.19	4.7	0.39	6.92e-6	Oral cavity cancer;
TGCT	cis	rs9308731	0.644	rs1837368	chr2:111874508	T/C	cg04202892	chr2:111875749	ACOXL	0.55	6.24	0.49	6.3e-9	Chronic lymphocytic leukemia;
TGCT	cis	rs1215050	0.740	rs2695464	chr4:98980929	T/C	cg17366294	chr4:99064904	C4orf37	-0.55	-5.8	-0.46	5.23e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs644799	0.622	rs1255167	chr11:95500213	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.6	6.23	0.49	6.59e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs10504229	1.000	rs10504229	chr8:58196495	A/G	cg22535103	chr8:58192502	C8orf71	-0.39	-4.55	-0.38	1.24e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7833790	0.654	rs6415652	chr8:82702257	G/A	cg06027949	chr8:82754900	SNX16	-0.65	-4.92	-0.4	2.65e-6	Diastolic blood pressure;
TGCT	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg20203395	chr5:56204925	C5orf35	0.78	6.15	0.48	9.89e-9	Initial pursuit acceleration;
TGCT	trans	rs7864133	1.000	rs11139265	chr9:84073624	T/C	cg23451063	chr7:1059876	C7orf50	0.53	6.71	0.52	6.31e-10	Post bronchodilator FEV1 in COPD;
TGCT	cis	rs6933660	0.760	rs6904364	chr6:151754273	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.83	-8.66	-0.61	2.09e-14	Menarche (age at onset);
TGCT	cis	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg22857025	chr5:266934	NA	-0.34	-6.72	-0.52	5.96e-10	Breast cancer;
TGCT	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs17826219	0.500	rs2449749	chr17:29078298	C/T	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Body mass index;
TGCT	cis	rs1729951	0.575	rs361242	chr3:136698330	C/G	cg21827317	chr3:136751795	NA	0.4	5.6	0.45	1.28e-7	Neuroticism;
TGCT	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg22920501	chr2:26401640	FAM59B	-0.72	-6.22	-0.49	7.14e-9	Gut microbiome composition (summer);
TGCT	cis	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg06636001	chr8:8085503	FLJ10661	0.7	6.68	0.51	7.11e-10	Mood instability;
TGCT	cis	rs7635838	0.684	rs2594968	chr3:11352442	T/C	cg00170343	chr3:11313890	ATG7	0.6	5.86	0.47	3.84e-8	HDL cholesterol;
TGCT	cis	rs74181299	0.927	rs2723064	chr2:65279805	T/C	cg05010058	chr2:65284262	CEP68	0.44	4.93	0.4	2.55e-6	Pulse pressure;
TGCT	cis	rs78487399	0.731	rs6722104	chr2:43752346	A/G	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.78	4.84	0.4	3.8e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs12579753	0.879	rs1922552	chr12:82158093	G/T	cg07988820	chr12:82153109	PPFIA2	-0.67	-7.44	-0.56	1.46e-11	Resting heart rate;
TGCT	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.83	-9.98	-0.67	1.38e-17	Urate levels;
TGCT	cis	rs939658	0.935	rs12903747	chr15:79449627	A/C	cg17916960	chr15:79447300	NA	0.56	8.87	0.62	6.75e-15	Refractive error;
TGCT	cis	rs1008375	1.000	rs10027755	chr4:17615954	G/C	cg16339924	chr4:17578868	LAP3	0.6	4.97	0.41	2.14e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs34526934	0.566	rs1374325	chr2:177043971	G/A	cg14324370	chr2:177042789	NA	-0.91	-8.69	-0.62	1.8e-14	Obstructive sleep apnea trait (apnea hypopnea index);
TGCT	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.12	0.54	7.78e-11	Prudent dietary pattern;
TGCT	cis	rs13217239	0.646	rs10456352	chr6:26990358	A/T	cg02458000	chr6:26745757	NA	0.51	4.72	0.39	6.22e-6	Schizophrenia;
TGCT	cis	rs9389248	0.690	rs6569982	chr6:135256495	C/G	cg22676075	chr6:135203613	NA	0.49	4.81	0.4	4.31e-6	High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs7267979	1.000	rs7267979	chr20:25298087	C/T	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4820539	1.000	rs885963	chr22:23460939	G/T	cg14186256	chr22:23484241	RTDR1	0.97	11.66	0.72	1.16e-21	Bone mineral density;
TGCT	cis	rs4808199	1.000	rs12972397	chr19:19562349	G/A	cg03709012	chr19:19516395	GATAD2A	0.97	7.52	0.56	9.52e-12	Nonalcoholic fatty liver disease;
TGCT	cis	rs7949030	0.590	rs12225213	chr11:62350248	T/A	cg11742103	chr11:62369870	EML3;MTA2	0.61	8.69	0.62	1.79e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs6570726	0.738	rs6925594	chr6:145898454	T/C	cg05347473	chr6:146136440	FBXO30	0.52	4.95	0.41	2.33e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1729951	0.575	rs35289288	chr3:136680568	C/T	cg21827317	chr3:136751795	NA	0.4	5.61	0.45	1.28e-7	Neuroticism;
TGCT	cis	rs7216064	1.000	rs4271626	chr17:65930133	G/A	cg12091567	chr17:66097778	LOC651250	-0.81	-6.15	-0.48	9.71e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs6978712	1.000	rs7789737	chr7:127150683	A/G	cg01017541	chr7:127776461	NA	0.76	4.6	0.38	1.01e-5	Medication adherence in chronic diseases;
TGCT	cis	rs2153535	0.580	rs6905242	chr6:8471799	A/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.73	0.46	7.1e-8	Motion sickness;
TGCT	cis	rs3008870	1.000	rs2985818	chr1:67398916	G/A	cg08660285	chr1:67390436	MIER1;WDR78	1.1	11.97	0.73	2.07e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs919433	0.713	rs6719729	chr2:198480072	G/A	cg00792783	chr2:198669748	PLCL1	0.49	4.56	0.38	1.19e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs2486288	0.656	rs2271438	chr15:45557468	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.45	-5.34	-0.43	4.26e-7	Glomerular filtration rate;
TGCT	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg18230493	chr5:56204884	C5orf35	-0.67	-5.88	-0.47	3.5e-8	Initial pursuit acceleration;
TGCT	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg17971929	chr21:40555470	PSMG1	-0.68	-5.96	-0.47	2.47e-8	Cognitive function;
TGCT	cis	rs6940638	0.956	rs3922717	chr6:27030924	A/G	cg26531700	chr6:26746687	NA	-0.6	-4.63	-0.38	9.25e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10193935	0.901	rs2374429	chr2:42677888	A/G	cg27598129	chr2:42591480	NA	-0.37	-5.14	-0.42	1.04e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9653442	0.545	rs13032454	chr2:100756009	T/C	cg22139774	chr2:100720529	AFF3	-0.36	-5.56	-0.45	1.55e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg23708337	chr7:1209742	NA	0.64	5.94	0.47	2.63e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs6748734	0.739	rs10185785	chr2:241843752	A/G	cg04034577	chr2:241836375	C2orf54	-0.39	-5.64	-0.45	1.09e-7	Urinary metabolites;
TGCT	cis	rs4299518	0.504	rs2673052	chr3:45733827	A/T	cg04837898	chr3:45731254	SACM1L	-0.55	-5.55	-0.45	1.64e-7	Hirschsprung disease;
TGCT	cis	rs6866344	0.601	rs4419608	chr5:178097049	C/T	cg10224037	chr5:178157518	ZNF354A	0.58	5.07	0.41	1.4e-6	Neutrophil percentage of white cells;
TGCT	cis	rs6586111	1.000	rs4933462	chr10:82372612	A/G	cg03086067	chr10:82368399	SH2D4B	-0.26	-5.17	-0.42	9.28e-7	Capecitabine sensitivity;
TGCT	cis	rs7829975	0.807	rs519019	chr8:8595104	A/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-4.72	-0.39	6.16e-6	Mood instability;
TGCT	cis	rs6543140	0.964	rs10193485	chr2:103089573	T/C	cg09003973	chr2:102972529	NA	0.54	4.46	0.37	1.83e-5	Blood protein levels;
TGCT	cis	rs2361718	0.500	rs8068856	chr17:78100731	A/G	cg17882374	chr17:78041429	CCDC40	0.29	4.49	0.37	1.6e-5	Yeast infection;
TGCT	cis	rs12220238	0.659	rs10824208	chr10:76357634	A/T	cg19889307	chr10:75911429	ADK;AP3M1	0.89	5.75	0.46	6.45e-8	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs11992186	0.597	rs77717027	chr8:8591632	T/C	cg06636001	chr8:8085503	FLJ10661	-0.59	-4.9	-0.4	2.91e-6	Neuroticism;
TGCT	cis	rs7666738	0.546	rs17546687	chr4:98769266	T/A	cg18180107	chr4:99064573	C4orf37	0.53	4.62	0.38	9.51e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8049040	0.644	rs16973000	chr16:71493165	T/C	cg06353428	chr16:71660113	MARVELD3	-0.66	-5.24	-0.43	6.71e-7	Blood protein levels;
TGCT	cis	rs1635	0.655	rs58019071	chr6:28304016	T/C	cg15743358	chr6:28303923	ZNF323	-1.28	-6.27	-0.49	5.57e-9	Schizophrenia;
TGCT	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg24531977	chr5:56204891	C5orf35	-0.77	-7.61	-0.56	5.83e-12	Initial pursuit acceleration;
TGCT	cis	rs7091068	0.518	rs913045	chr10:95431535	C/T	cg20715218	chr10:95462985	C10orf4	0.52	5.56	0.45	1.59e-7	Urinary tract infection frequency;
TGCT	cis	rs12544026	0.581	rs519197	chr8:102860675	C/A	cg01952226	chr8:102507382	GRHL2	-0.27	-4.54	-0.38	1.31e-5	Major depression and alcohol dependence;
TGCT	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg22968622	chr17:43663579	NA	1.29	11.02	0.7	4.06e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs10504229	0.679	rs60869047	chr8:58053221	G/A	cg08280861	chr8:58055591	NA	0.35	4.88	0.4	3.2e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9926296	0.744	rs154657	chr16:89708096	A/G	cg01097406	chr16:89675127	NA	-0.35	-6.31	-0.49	4.55e-9	Vitiligo;
TGCT	trans	rs783396	0.584	rs783414	chr6:106966701	A/G	cg09013229	chr1:225332226	DNAH14	-0.53	-6.66	-0.51	8.13e-10	Stroke;
TGCT	cis	rs68170813	0.570	rs7794915	chr7:106849393	C/T	cg02696742	chr7:106810147	HBP1	-0.66	-4.7	-0.39	6.66e-6	Coronary artery disease;
TGCT	cis	rs763014	0.931	rs7191939	chr16:630089	C/T	cg00908189	chr16:619842	PIGQ	0.87	10.5	0.69	7.53e-19	Height;
TGCT	cis	rs2439831	0.764	rs2447193	chr15:43929733	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	4.95	0.41	2.38e-6	Lung cancer in ever smokers;
TGCT	cis	rs911555	0.928	rs911554	chr14:103999371	G/T	cg12935359	chr14:103987150	CKB	0.35	4.94	0.41	2.49e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	8.99	0.63	3.48e-15	Platelet count;
TGCT	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg08509172	chr19:19383838	TM6SF2	-0.35	-4.63	-0.38	9.18e-6	Tonsillectomy;
TGCT	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg07167872	chr1:205819463	PM20D1	0.41	4.77	0.39	5.15e-6	Menarche (age at onset);
TGCT	cis	rs7267979	0.966	rs6083855	chr20:25405118	A/G	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6690583	0.562	rs12024977	chr1:85531051	A/C	cg20280350	chr1:85513789	MCOLN3	-0.74	-4.66	-0.39	7.96e-6	Serum sulfate level;
TGCT	cis	rs7552404	1.000	rs7516226	chr1:76234257	G/A	cg10523679	chr1:76189770	ACADM	0.91	9.53	0.65	1.7e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs8180040	0.966	rs13059519	chr3:47539969	C/T	cg27129171	chr3:47204927	SETD2	0.66	8.01	0.58	7.07e-13	Colorectal cancer;
TGCT	cis	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg06558623	chr16:89946397	TCF25	0.45	4.52	0.38	1.42e-5	Skin colour saturation;
TGCT	cis	rs514406	0.893	rs1242315	chr1:53417181	A/G	cg01802117	chr1:53393560	SCP2	-0.39	-4.7	-0.39	6.93e-6	Monocyte count;
TGCT	cis	rs4409675	0.576	rs7535816	chr1:28234054	A/G	cg23691781	chr1:28212827	C1orf38	0.26	5.51	0.44	2.01e-7	Corneal astigmatism;
TGCT	cis	rs7666738	0.822	rs979946	chr4:98921235	C/A	cg17366294	chr4:99064904	C4orf37	0.73	7.5	0.56	1.09e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2346177	0.605	rs7556828	chr2:46663172	A/G	cg26688816	chr2:46740690	ATP6V1E2	0.43	4.67	0.39	7.59e-6	HDL cholesterol;
TGCT	cis	rs2562456	0.833	rs552800	chr19:21484642	G/A	cg25650185	chr19:21324782	ZNF431	0.54	4.52	0.38	1.41e-5	Pain;
TGCT	cis	rs1563304	1	rs1563304	chr17:44874453	C/T	cg01570182	chr17:44337453	NA	0.72	4.87	0.4	3.37e-6	Neuroticism;
TGCT	cis	rs13088645	0.683	rs9790169	chr3:134151959	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.63	-6.11	-0.48	1.17e-8	Coronary artery disease;
TGCT	cis	rs28735056	0.903	rs56185453	chr18:77638297	A/G	cg20368463	chr18:77673604	PQLC1	-0.44	-5.33	-0.43	4.38e-7	Schizophrenia;
TGCT	cis	rs3824662	0.592	rs263418	chr10:8118191	A/G	cg20314737	chr10:8096579	FLJ45983;GATA3	0.64	4.48	0.37	1.64e-5	Acute lymphoblastic leukemia (B-cell precursor);Acute lymphoblastic leukemia (adolescents and young adults);
TGCT	cis	rs13168506	0.538	rs12515040	chr5:135441559	A/G	cg00308130	chr5:135415190	NA	-0.33	-4.59	-0.38	1.08e-5	Stroke;
TGCT	cis	rs12188164	1.000	rs72717411	chr5:429124	C/G	cg17553881	chr5:443987	EXOC3;C5orf55	-0.4	-4.76	-0.39	5.27e-6	Cystic fibrosis severity;
TGCT	cis	rs2905347	0.895	rs2961283	chr7:22640498	A/G	cg26061582	chr7:22766209	IL6	0.4	4.49	0.37	1.63e-5	Major depression and alcohol dependence;
TGCT	cis	rs2204008	0.639	rs7311462	chr12:38278130	G/A	cg26384229	chr12:38710491	ALG10B	0.86	7.48	0.56	1.17e-11	Bladder cancer;
TGCT	cis	rs4494114	1.000	rs3790442	chr1:39357646	C/A	cg25970120	chr1:39325951	RRAGC	-0.6	-6.17	-0.48	8.89e-9	Blood protein levels;
TGCT	cis	rs5769707	0.967	rs763127	chr22:50006078	C/T	cg05373962	chr22:49881684	NA	-0.31	-6.26	-0.49	5.71e-9	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs174601	0.615	rs174534	chr11:61549458	C/T	cg19610905	chr11:61596333	FADS2	0.8	7.91	0.58	1.19e-12	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
TGCT	trans	rs7698623	0.850	rs3886171	chr4:88800053	A/G	cg01186725	chr1:53905612	FLJ40434	-0.48	-6.61	-0.51	1.01e-9	Cardiovascular disease risk factors;
TGCT	cis	rs7651736	0.835	rs6439679	chr3:136757463	C/T	cg21827317	chr3:136751795	NA	-0.41	-5.85	-0.46	4.17e-8	Neuroticism;
TGCT	cis	rs782590	0.902	rs7582278	chr2:55742924	C/G	cg18811423	chr2:55921094	PNPT1	0.67	7.1	0.54	8.6e-11	Metabolic syndrome;
TGCT	cis	rs548181	0.611	rs562599	chr11:125459951	A/C	cg03464685	chr11:125439445	EI24	1.31	9.21	0.64	1.01e-15	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg08975724	chr8:8085496	FLJ10661	0.56	4.91	0.4	2.85e-6	Mood instability;
TGCT	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg21963583	chr11:68658836	MRPL21	0.37	6.08	0.48	1.39e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs4863687	0.752	rs4863507	chr4:140643322	A/G	cg10136560	chr4:140737518	MAML3	-0.32	-5.01	-0.41	1.82e-6	Chronic mucus hypersecretion;
TGCT	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg25036284	chr2:26402008	FAM59B	-0.65	-5.19	-0.42	8.36e-7	Gut microbiome composition (summer);
TGCT	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.13	14.76	0.8	4.39e-29	Height;
TGCT	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs17376456	0.877	rs10057814	chr5:93399092	C/G	cg21475434	chr5:93447410	FAM172A	0.61	4.85	0.4	3.62e-6	Diabetic retinopathy;
TGCT	cis	rs35306767	0.953	rs7908138	chr10:962978	C/T	cg20503657	chr10:835505	NA	0.68	9.49	0.65	2.12e-16	Eosinophil percentage of granulocytes;
TGCT	cis	rs4242434	0.672	rs6993302	chr8:22527457	T/C	cg03733263	chr8:22462867	KIAA1967	-1.05	-15.55	-0.81	6.67e-31	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.47	0.56	1.28e-11	Prudent dietary pattern;
TGCT	cis	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg17689763	chr4:710664	PCGF3	-0.24	-7.09	-0.54	8.75e-11	White blood cell count;
TGCT	cis	rs2455799	0.573	rs2455834	chr3:15753641	A/G	cg16303742	chr3:15540471	COLQ	-0.25	-4.77	-0.39	5.01e-6	Mean platelet volume;
TGCT	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg00786635	chr1:25594202	NA	0.58	6.04	0.48	1.69e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs6840360	0.593	rs1429559	chr4:152681952	A/G	cg22705602	chr4:152727874	NA	-0.35	-5.94	-0.47	2.63e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg06238570	chr21:40685208	BRWD1	0.68	6.36	0.5	3.5e-9	Cognitive function;
TGCT	cis	rs3091242	0.933	rs34933589	chr1:25788198	T/C	cg23205692	chr1:25664452	TMEM50A	-0.47	-4.93	-0.4	2.63e-6	Erythrocyte sedimentation rate;
TGCT	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg03609598	chr5:56110824	MAP3K1	-0.57	-4.74	-0.39	5.7e-6	Initial pursuit acceleration;
TGCT	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg00149659	chr3:10157352	C3orf10	0.96	6.1	0.48	1.26e-8	Alzheimer's disease;
TGCT	cis	rs7666738	0.645	rs10013290	chr4:99082799	G/A	cg17366294	chr4:99064904	C4orf37	0.71	6.87	0.53	2.73e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs727563	0.638	rs4820443	chr22:42193913	A/G	cg03806693	chr22:41940476	POLR3H	-0.97	-9.87	-0.66	2.66e-17	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs4689388	0.926	rs1801214	chr4:6303022	C/T	cg00701064	chr4:6280414	WFS1	0.38	4.85	0.4	3.61e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs921968	0.541	rs642520	chr2:219423605	A/G	cg02176678	chr2:219576539	TTLL4	-0.47	-6.81	-0.52	3.72e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs7258465	1.000	rs4808804	chr19:18585325	A/G	cg06462663	chr19:18546047	ISYNA1	0.2	4.6	0.38	1.03e-5	Breast cancer;
TGCT	cis	rs2033711	0.755	rs4801587	chr19:58936679	C/A	cg04608855	chr19:58913158	NA	0.57	5.7	0.46	8.22e-8	Uric acid clearance;
TGCT	cis	rs473651	0.935	rs515412	chr2:239345394	A/T	cg08773314	chr2:239334832	ASB1	0.45	7.62	0.56	5.75e-12	Multiple system atrophy;
TGCT	trans	rs2688608	0.725	rs2675666	chr10:75682651	G/T	cg13918328	chr10:52500089	ASAH2B	0.68	6.93	0.53	1.99e-10	Inflammatory bowel disease;
TGCT	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg20203395	chr5:56204925	C5orf35	-0.59	-5.12	-0.42	1.12e-6	Initial pursuit acceleration;
TGCT	trans	rs208520	0.690	rs207118	chr6:66788948	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-10.77	-0.7	1.66e-19	Exhaled nitric oxide output;
TGCT	cis	rs10779751	1.000	rs1064261	chr1:11288758	C/T	cg08854313	chr1:11322531	MTOR	1.0	8.95	0.63	4.4e-15	Body mass index;
TGCT	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg21724239	chr8:58056113	NA	0.42	5.04	0.41	1.59e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7312933	0.670	rs10880269	chr12:42606135	C/T	cg19980929	chr12:42632907	YAF2	0.47	6.46	0.5	2.13e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.64	0.51	8.85e-10	Bipolar disorder;
TGCT	cis	rs10464366	0.614	rs62442213	chr7:39146933	C/T	cg18850127	chr7:39170497	POU6F2	0.33	7.5	0.56	1.05e-11	IgG glycosylation;
TGCT	cis	rs2933343	0.951	rs789218	chr3:128592670	G/A	cg11901034	chr3:128598214	ACAD9	-0.65	-5.12	-0.42	1.15e-6	IgG glycosylation;
TGCT	cis	rs9611519	0.857	rs4820434	chr22:41637119	G/T	cg03806693	chr22:41940476	POLR3H	-0.78	-7.71	-0.57	3.49e-12	Neuroticism;
TGCT	cis	rs7666738	0.830	rs62321564	chr4:98976496	C/G	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg11494091	chr17:61959527	GH2	0.61	14.34	0.79	4.3e-28	Prudent dietary pattern;
TGCT	cis	rs6840360	1.000	rs4696283	chr4:152580516	A/G	cg17479576	chr4:152424074	FAM160A1	-0.46	-4.81	-0.4	4.26e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10464366	0.912	rs7785889	chr7:39106368	G/T	cg18850127	chr7:39170497	POU6F2	0.21	4.5	0.37	1.55e-5	IgG glycosylation;
TGCT	cis	rs910316	0.737	rs175077	chr14:75506875	G/A	cg08847533	chr14:75593920	NEK9	-0.84	-8.43	-0.6	7.53e-14	Height;
TGCT	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	6.75	0.52	5.18e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs10782582	0.593	rs74090712	chr1:76189098	A/G	cg03433033	chr1:76189801	ACADM	-0.61	-6.76	-0.52	4.85e-10	Daytime sleep phenotypes;
TGCT	cis	rs2404602	0.647	rs12904149	chr15:77043652	A/C	cg22467129	chr15:76604101	ETFA	0.47	4.58	0.38	1.13e-5	Blood metabolite levels;
TGCT	cis	rs986417	0.711	rs2224409	chr14:60957216	C/T	cg27398547	chr14:60952738	C14orf39	1.41	9.11	0.63	1.75e-15	Gut microbiota (bacterial taxa);
TGCT	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg08280861	chr8:58055591	NA	0.4	4.73	0.39	5.97e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2721195	0.845	rs3816732	chr8:145724275	T/C	cg13257436	chr8:145726034	PPP1R16A	-0.31	-4.5	-0.37	1.53e-5	Age at first birth;
TGCT	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg06418219	chr1:154948305	SHC1;CKS1B	-0.69	-7.06	-0.54	1.07e-10	Prostate cancer;
TGCT	cis	rs7731657	0.510	rs2569257	chr5:130245468	A/G	cg08523029	chr5:130500466	HINT1	-0.58	-4.75	-0.39	5.41e-6	Fasting plasma glucose;
TGCT	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg21724239	chr8:58056113	NA	0.37	4.95	0.41	2.38e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9911578	1.000	rs8076121	chr17:57041699	G/A	cg05425664	chr17:57184151	TRIM37	-0.62	-6.18	-0.49	8.33e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs1784581	0.588	rs9295179	chr6:162420546	G/A	cg17173639	chr6:162384350	PARK2	0.39	6.5	0.5	1.73e-9	Itch intensity from mosquito bite;
TGCT	cis	rs9457247	0.935	rs1187530	chr6:167376812	C/T	cg25258033	chr6:167368657	RNASET2	-0.18	-4.48	-0.37	1.64e-5	Crohn's disease;
TGCT	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg10802521	chr3:52805072	NEK4	-0.71	-8.79	-0.62	1.04e-14	Bipolar disorder;
TGCT	trans	rs783396	0.584	rs9486400	chr6:107013846	A/C	cg09256880	chr4:2791952	NA	0.49	6.77	0.52	4.5e-10	Stroke;
TGCT	cis	rs548987	0.507	rs3757132	chr6:25832691	C/T	cg03264133	chr6:25882463	NA	-0.54	-4.47	-0.37	1.73e-5	Homocysteine levels;
TGCT	cis	rs1008375	1.000	rs9991307	chr4:17662408	A/G	cg10189774	chr4:17578691	LAP3	0.54	4.97	0.41	2.21e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4664308	1.000	rs6719686	chr2:160908292	T/G	cg03641300	chr2:160917029	PLA2R1	-0.26	-6.53	-0.51	1.49e-9	Idiopathic membranous nephropathy;
TGCT	cis	rs17376456	0.877	rs10476599	chr5:93383423	A/G	cg25358565	chr5:93447407	FAM172A	0.92	8.38	0.6	9.58e-14	Diabetic retinopathy;
TGCT	cis	rs4319547	0.656	rs28730465	chr12:122863864	A/C	cg05707623	chr12:122985044	ZCCHC8	0.62	4.87	0.4	3.32e-6	Body mass index;
TGCT	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg22920501	chr2:26401640	FAM59B	-0.71	-6.2	-0.49	7.53e-9	Gut microbiome composition (summer);
TGCT	cis	rs3617	0.573	rs12492391	chr3:52912296	C/A	cg11645453	chr3:52864694	ITIH4	0.26	5.05	0.41	1.54e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7772486	0.790	rs9403756	chr6:146257761	C/G	cg13319975	chr6:146136371	FBXO30	0.48	4.5	0.37	1.52e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs669446	0.561	rs571862	chr1:44083110	C/T	cg12908607	chr1:44402522	ARTN	-0.55	-5.9	-0.47	3.25e-8	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg27454412	chr7:1067447	C7orf50	0.6	4.7	0.39	6.76e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7216064	1.000	rs62084238	chr17:65856573	T/A	cg12091567	chr17:66097778	LOC651250	-0.83	-6.52	-0.51	1.61e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs2663905	0.706	rs7162859	chr15:81360038	C/T	cg27045999	chr15:81426544	C15orf26	0.63	5.63	0.45	1.15e-7	QT interval (drug interaction);
TGCT	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.64	0.51	8.85e-10	Electroencephalogram traits;
TGCT	cis	rs9581857	0.547	rs76435345	chr13:28107638	G/A	cg22138327	chr13:27999177	GTF3A	0.72	4.75	0.39	5.45e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs7953249	0.618	rs7954039	chr12:121398654	A/C	cg02403541	chr12:121454288	C12orf43	-0.65	-5.5	-0.44	2.07e-7	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs2730245	0.527	rs2527197	chr7:158735260	G/A	cg11984989	chr7:158649758	WDR60	-1.01	-7.88	-0.58	1.4e-12	Height;
TGCT	cis	rs11098499	0.955	rs11944880	chr4:120159334	A/G	cg24670566	chr4:120433619	PDE5A	-0.23	-4.45	-0.37	1.89e-5	Corneal astigmatism;
TGCT	cis	rs11650494	0.908	rs11656535	chr17:47425588	C/T	cg08112188	chr17:47440006	ZNF652	1.04	5.34	0.43	4.3e-7	Prostate cancer;
TGCT	cis	rs66573146	1.000	rs66573146	chr4:6984464	C/G	cg01220768	chr4:7056774	TADA2B	0.39	4.91	0.4	2.77e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs76878669	0.561	rs10791876	chr11:66169646	C/T	cg18002602	chr11:66138449	SLC29A2	-0.53	-6.5	-0.5	1.74e-9	Educational attainment (years of education);
TGCT	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg11905131	chr22:24372483	LOC391322	-0.86	-9.98	-0.67	1.38e-17	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs854765	0.583	rs9890341	chr17:17823175	G/C	cg09796270	chr17:17721594	SREBF1	0.24	4.7	0.39	6.83e-6	Total body bone mineral density;
TGCT	cis	rs826838	0.967	rs4768330	chr12:39129399	T/C	cg26384229	chr12:38710491	ALG10B	-0.87	-7.78	-0.57	2.42e-12	Heart rate;
TGCT	trans	rs8073060	0.544	rs17550716	chr17:33893208	A/G	cg19694781	chr19:47549865	TMEM160	0.59	12.8	0.75	1.95e-24	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs7582180	0.627	rs6542947	chr2:100999647	C/G	cg08017756	chr2:100939284	LONRF2	0.3	5.0	0.41	1.93e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2228479	0.850	rs62056065	chr16:89905115	C/G	cg06558623	chr16:89946397	TCF25	0.55	4.86	0.4	3.55e-6	Skin colour saturation;
TGCT	cis	rs28595532	0.748	rs67928655	chr4:119336525	C/A	cg21605333	chr4:119757512	SEC24D	0.85	5.43	0.44	2.84e-7	Cannabis dependence symptom count;
TGCT	trans	rs2688608	0.592	rs3933085	chr10:75483331	C/T	cg13918328	chr10:52500089	ASAH2B	0.68	6.7	0.52	6.48e-10	Inflammatory bowel disease;
TGCT	cis	rs4888262	0.526	rs8056718	chr16:74612030	G/C	cg01733217	chr16:74700730	RFWD3	0.75	7.54	0.56	8.8e-12	Testicular germ cell tumor;
TGCT	cis	rs2797160	0.967	rs4897151	chr6:125993202	T/G	cg05901451	chr6:126070800	HEY2	-0.74	-6.49	-0.5	1.84e-9	Endometrial cancer;
TGCT	cis	rs174601	0.668	rs174559	chr11:61581656	G/A	cg19610905	chr11:61596333	FADS2	-0.96	-9.3	-0.64	6.26e-16	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
TGCT	cis	rs8050907	0.744	rs28629405	chr16:4525933	G/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.53	4.57	0.38	1.15e-5	Obesity-related traits;
TGCT	cis	rs1982963	0.906	rs2029976	chr14:52505811	C/T	cg10843707	chr14:52510701	NID2	-0.43	-6.6	-0.51	1.09e-9	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg24399712	chr22:39784796	NA	-0.99	-9.19	-0.64	1.15e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs13217239	0.646	rs7747454	chr6:27034253	T/G	cg05738196	chr6:26577821	NA	-0.51	-4.92	-0.4	2.71e-6	Schizophrenia;
TGCT	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.85	-9.09	-0.63	2.04e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs28595532	0.920	rs115214765	chr4:119728167	C/T	cg21605333	chr4:119757512	SEC24D	1.66	8.33	0.6	1.28e-13	Cannabis dependence symptom count;
TGCT	cis	rs712888	0.564	rs712902	chr1:99725473	A/G	cg02083189	chr1:100503813	HIAT1	-0.54	-4.73	-0.39	5.95e-6	Bacterial meningitis;
TGCT	cis	rs17152411	1.000	rs2241541	chr10:126671673	T/C	cg07906193	chr10:126599966	NA	0.41	4.83	0.4	3.97e-6	Height;
TGCT	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg23758822	chr17:41437982	NA	0.67	6.74	0.52	5.2400000000000005e-10	Menopause (age at onset);
TGCT	cis	rs6740322	0.895	rs28456986	chr2:43553321	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.4	-6.72	-0.52	5.98e-10	Coronary artery disease;
TGCT	cis	rs9486715	0.867	rs7451950	chr6:96879974	T/C	cg06623918	chr6:96969491	KIAA0776	1.11	16.62	0.83	2.35e-33	Headache;
TGCT	cis	rs7698623	0.717	rs4147245	chr4:88779237	A/C	cg02735620	chr4:88950514	PKD2	-0.44	-4.81	-0.4	4.22e-6	Cardiovascular disease risk factors;
TGCT	cis	rs1023500	0.573	rs133370	chr22:42465260	T/C	cg05082376	chr22:42548792	NA	-0.22	-5.41	-0.44	3.18e-7	Schizophrenia;
TGCT	cis	rs4919669	0.668	rs77630251	chr10:104338370	C/G	cg05855489	chr10:104503620	C10orf26	0.73	4.71	0.39	6.65e-6	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs1986116	0.773	rs4903538	chr14:77516821	C/T	cg04913803	chr14:77510549	NA	0.39	4.62	0.38	9.48e-6	Sleep quality;
TGCT	cis	rs5769765	0.955	rs8135963	chr22:50301476	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.37	5.21	0.42	7.51e-7	Schizophrenia;
TGCT	cis	rs3772130	0.962	rs9856641	chr3:121566859	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.62	0.38	9.48e-6	Cognitive performance;
TGCT	cis	rs2180341	0.889	rs2000909	chr6:127711173	G/A	cg27446573	chr6:127587934	RNF146	0.92	8.63	0.61	2.47e-14	Breast cancer;
TGCT	cis	rs9650657	0.535	rs7011756	chr8:11019578	C/G	cg21775007	chr8:11205619	TDH	-0.53	-5.0	-0.41	1.88e-6	Neuroticism;
TGCT	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg16423285	chr20:60520624	NA	-0.61	-6.57	-0.51	1.23e-9	Body mass index;
TGCT	cis	rs868036	0.645	rs4492996	chr15:68113240	A/G	cg05925327	chr15:68127851	NA	-0.51	-5.04	-0.41	1.63e-6	Restless legs syndrome;
TGCT	cis	rs7267979	0.966	rs2261795	chr20:25263136	T/C	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9409154	0.816	rs10116195	chr9:118212010	T/C	cg14094498	chr9:119000864	PAPPA	0.23	4.59	0.38	1.05e-5	Visceral adipose tissue adjusted for BMI;
TGCT	cis	rs9926296	0.607	rs11076629	chr16:89875259	T/C	cg26513180	chr16:89883248	FANCA	0.74	7.0	0.53	1.4e-10	Vitiligo;
TGCT	cis	rs6896969	0.510	rs1899982	chr5:40425045	C/T	cg01087697	chr5:40835557	RPL37	0.56	5.03	0.41	1.69e-6	Multiple sclerosis;
TGCT	cis	rs9948	0.708	rs116121826	chr2:97441914	A/G	cg01990225	chr2:97406019	LMAN2L	-0.88	-4.81	-0.4	4.37e-6	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs826838	0.616	rs7977357	chr12:38626008	C/G	cg26384229	chr12:38710491	ALG10B	-0.54	-4.74	-0.39	5.87e-6	Heart rate;
TGCT	cis	rs8111998	0.826	rs4932778	chr19:22766971	G/A	cg19914732	chr19:22715077	NA	-0.56	-4.51	-0.38	1.46e-5	Corneal structure;
TGCT	cis	rs12549902	0.932	rs6981607	chr8:41508168	A/C	cg00088007	chr8:41504566	NKX6-3	0.34	5.47	0.44	2.33e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
TGCT	cis	rs12477438	0.765	rs12468807	chr2:99691994	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-6.1	-0.48	1.22e-8	Chronic sinus infection;
TGCT	cis	rs10256972	0.721	rs10435145	chr7:1065988	C/T	cg00431813	chr7:1051703	C7orf50	-0.22	-4.9	-0.4	2.93e-6	Longevity;Endometriosis;
TGCT	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	5.71	0.46	8.05e-8	Alzheimer's disease;
TGCT	cis	rs478304	0.651	rs11532071	chr11:65500198	C/A	cg27068330	chr11:65405492	SIPA1	-0.95	-9.64	-0.65	9.63e-17	Acne (severe);
TGCT	cis	rs7945705	0.791	rs4579928	chr11:8815704	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.44	4.88	0.4	3.17e-6	Hemoglobin concentration;
TGCT	cis	rs9911578	0.935	rs7218105	chr17:57041119	A/G	cg12560992	chr17:57184187	TRIM37	0.76	9.21	0.64	1.03e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs35883536	0.647	rs17411209	chr1:101046734	A/G	cg06223162	chr1:101003688	GPR88	-0.41	-7.64	-0.57	5.04e-12	Monocyte count;
TGCT	cis	rs600231	0.665	rs1616810	chr11:65220105	A/G	cg17120908	chr11:65337727	SSSCA1	-0.51	-4.6	-0.38	1.02e-5	Bone mineral density;
TGCT	trans	rs28595532	0.660	rs11933762	chr4:119307126	A/G	cg26518628	chr1:97050305	NA	-0.52	-7.66	-0.57	4.58e-12	Cannabis dependence symptom count;
TGCT	cis	rs9467773	0.620	rs2504567	chr6:26662920	C/G	cg11502198	chr6:26597334	ABT1	0.55	4.9	0.4	2.92e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs17030434	0.834	rs28658020	chr4:154759048	C/T	cg14289246	chr4:154710475	SFRP2	-0.91	-7.82	-0.57	1.98e-12	Electrocardiographic conduction measures;
TGCT	cis	rs1448094	0.717	rs60713909	chr12:86294469	C/G	cg00310523	chr12:86230176	RASSF9	0.32	4.62	0.38	9.64e-6	Major depressive disorder;
TGCT	cis	rs12136530	0.577	rs12066114	chr1:19792527	A/G	cg18923740	chr1:19971790	NBL1	0.4	4.9	0.4	2.98e-6	Lead levels in blood;
TGCT	cis	rs2486288	0.656	rs8041702	chr15:45547093	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.8	-7.91	-0.58	1.24e-12	Glomerular filtration rate;
TGCT	cis	rs6582630	0.638	rs61931383	chr12:38513845	G/A	cg26384229	chr12:38710491	ALG10B	-0.54	-4.79	-0.4	4.57e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs4494114	0.967	rs7527128	chr1:39302993	C/T	cg25970120	chr1:39325951	RRAGC	-0.6	-6.28	-0.49	5.09e-9	Blood protein levels;
TGCT	cis	rs4642101	0.793	rs56082700	chr3:12833833	T/C	cg05775895	chr3:12838266	CAND2	0.78	8.75	0.62	1.3e-14	QRS complex (12-leadsum);
TGCT	cis	rs4665630	0.522	rs889866	chr2:23885168	A/G	cg08063864	chr2:24346004	PFN4;LOC375190	-1.13	-5.45	-0.44	2.64e-7	Hypertension;
TGCT	cis	rs711245	0.574	rs1179494	chr2:36809496	C/G	cg01206211	chr2:36825736	FEZ2	-0.32	-4.82	-0.4	4.09e-6	Height;
TGCT	cis	rs3806843	0.735	rs2563333	chr5:140052271	A/G	cg19875535	chr5:140030758	IK	-0.36	-6.17	-0.48	8.95e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs4713118	0.955	rs9380011	chr6:27683924	A/G	cg10876282	chr6:28092338	ZSCAN16	0.5	4.62	0.38	9.35e-6	Parkinson's disease;
TGCT	cis	rs1577917	0.740	rs9344533	chr6:86236188	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.54	4.87	0.4	3.29e-6	Response to antipsychotic treatment;
TGCT	cis	rs1670533	1.000	rs7685541	chr4:1058501	G/A	cg27284194	chr4:1044797	NA	0.67	5.79	0.46	5.37e-8	Recombination rate (females);
TGCT	cis	rs10992471	0.528	rs10514815	chr9:95256695	C/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.5	-4.62	-0.38	9.57e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs11969893	0.737	rs6930051	chr6:101406108	A/G	cg12253828	chr6:101329408	ASCC3	1.36	6.32	0.49	4.33e-9	Economic and political preferences (immigration/crime);
TGCT	cis	rs17826219	0.568	rs2626985	chr17:29077437	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Body mass index;
TGCT	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg02725872	chr8:58115012	NA	-0.38	-5.05	-0.41	1.55e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1878931	0.554	rs3207360	chr16:3498115	G/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.86	7.81	0.57	2.07e-12	Body mass index (adult);
TGCT	cis	rs9611519	0.780	rs9611527	chr22:41644428	G/A	cg03806693	chr22:41940476	POLR3H	-0.77	-7.41	-0.55	1.72e-11	Neuroticism;
TGCT	cis	rs5744897	0.581	rs35235926	chr12:133304126	G/A	cg17341477	chr12:133246679	POLE	0.35	4.65	0.39	8.45e-6	Urate levels in overweight individuals;
TGCT	cis	rs3806933	0.522	rs34962120	chr5:110446091	G/A	cg04022379	chr5:110408740	TSLP	0.6	6.25	0.49	6.08e-9	Eosinophilic esophagitis;
TGCT	cis	rs5769707	0.837	rs1573726	chr22:50032872	G/A	cg05373962	chr22:49881684	NA	-0.28	-5.44	-0.44	2.73e-7	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs4919044	0.733	rs12413378	chr10:94759305	A/G	cg05127821	chr10:94822908	CYP26C1	-0.82	-4.97	-0.41	2.14e-6	Coronary artery disease;
TGCT	trans	rs751984	0.706	rs10792315	chr11:61274790	T/G	cg03305746	chr2:106927199	NA	-0.58	-6.8	-0.52	3.93e-10	Diastolic blood pressure;Systolic blood pressure;Mean arterial pressure;
TGCT	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg05872129	chr22:39784769	NA	-1.01	-11.06	-0.7	3.28e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs9916302	0.800	rs9892675	chr17:37549200	C/T	cg07936489	chr17:37558343	FBXL20	0.89	7.38	0.55	1.99e-11	Glomerular filtration rate (creatinine);
TGCT	cis	rs11098499	0.754	rs9991959	chr4:120253773	C/T	cg09307838	chr4:120376055	NA	-0.61	-5.86	-0.47	3.95e-8	Corneal astigmatism;
TGCT	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg04267008	chr7:1944627	MAD1L1	-0.4	-5.35	-0.43	4.15e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs644799	0.965	rs3789960	chr11:95509037	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	8.46	0.6	6.27e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7267979	1.000	rs422844	chr20:25445591	T/C	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9303542	0.625	rs8066613	chr17:46583520	T/A	cg25032089	chr17:46643351	HOXB3	0.57	5.74	0.46	6.78e-8	Ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs6815814	0.950	rs56408159	chr4:38812116	T/A	cg02016764	chr4:38805732	TLR1	-0.36	-5.67	-0.45	9.33e-8	Breast cancer;
TGCT	cis	rs7246657	0.943	rs3803895	chr19:37898669	A/G	cg18154014	chr19:37997991	ZNF793	0.73	5.38	0.44	3.53e-7	Coronary artery calcification;
TGCT	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg11890956	chr21:40555474	PSMG1	1.11	12.39	0.74	1.95e-23	Cognitive function;
TGCT	cis	rs2458413	0.564	rs2458431	chr8:105367096	T/C	cg04554929	chr8:105342491	NA	0.49	5.79	0.46	5.35e-8	Paget's disease;
TGCT	trans	rs11722228	0.521	rs62288520	chr4:10099674	G/A	cg26043149	chr18:55253948	FECH	1.16	11.2	0.71	1.55e-20	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs7172809	0.897	rs17394448	chr15:77825149	C/A	cg22256960	chr15:77711686	NA	-0.44	-4.48	-0.37	1.67e-5	Glucose homeostasis traits;
TGCT	cis	rs17767294	0.708	rs72846777	chr6:28114810	C/T	cg08851530	chr6:28072375	NA	1.47	6.82	0.52	3.64e-10	Parkinson's disease;
TGCT	cis	rs422249	0.512	rs174562	chr11:61585144	A/G	cg01500311	chr11:61656094	FADS3	-0.3	-5.25	-0.43	6.42e-7	Trans fatty acid levels;
TGCT	cis	rs7095607	0.933	rs12785213	chr10:69964674	G/A	cg18986048	chr10:69913749	MYPN	0.45	4.89	0.4	3.07e-6	Lung function (FVC);
TGCT	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg12564285	chr5:131593104	PDLIM4	0.4	4.78	0.39	4.79e-6	Acylcarnitine levels;
TGCT	cis	rs1466788	1.000	rs1869596	chr1:110624104	G/A	cg11787288	chr1:111506544	C1orf103	0.5	4.48	0.37	1.64e-5	Blood metabolite levels;
TGCT	cis	rs35306767	0.855	rs12774985	chr10:904245	C/T	cg20503657	chr10:835505	NA	0.77	11.34	0.71	6.95e-21	Eosinophil percentage of granulocytes;
TGCT	cis	rs12135062	0.755	rs1553287	chr1:3101277	G/A	cg21609526	chr1:3105151	PRDM16	-0.36	-5.73	-0.46	7.25e-8	Migraine;
TGCT	trans	rs7698623	0.850	rs10011586	chr4:88798921	C/T	cg01186725	chr1:53905612	FLJ40434	-0.48	-6.61	-0.51	1.01e-9	Cardiovascular disease risk factors;
TGCT	cis	rs6087990	0.765	rs6058900	chr20:31400673	T/C	cg09149842	chr20:31351091	DNMT3B	-0.36	-4.89	-0.4	3.05e-6	Ulcerative colitis;
TGCT	cis	rs4689388	0.890	rs1801206	chr4:6302707	C/T	cg25554036	chr4:6271136	WFS1	0.57	8.25	0.6	1.99e-13	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs9303542	0.559	rs56038617	chr17:46612578	C/T	cg25032089	chr17:46643351	HOXB3	0.58	5.47	0.44	2.38e-7	Ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg05368731	chr17:41323189	NBR1	1.19	13.98	0.78	3.03e-27	Menopause (age at onset);
TGCT	cis	rs9916302	0.706	rs597069	chr17:37458512	G/T	cg03321784	chr17:37729644	NA	-0.43	-4.46	-0.37	1.84e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs6546537	1.000	rs6712370	chr2:69855094	C/G	cg10773587	chr2:69614142	GFPT1	0.73	6.34	0.49	3.98e-9	Serum thyroid-stimulating hormone levels;
TGCT	cis	rs2204008	0.555	rs7310307	chr12:38107497	G/T	cg13010199	chr12:38710504	ALG10B	0.65	5.15	0.42	9.75e-7	Bladder cancer;
TGCT	cis	rs16867321	0.618	rs13400340	chr2:181561429	A/G	cg12875548	chr2:181044332	NA	-0.38	-4.75	-0.39	5.44e-6	Obesity;
TGCT	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg06212747	chr3:49208901	KLHDC8B	0.65	6.08	0.48	1.36e-8	Menarche (age at onset);
TGCT	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg03352830	chr11:487213	PTDSS2	0.26	4.44	0.37	1.95e-5	Body mass index;
TGCT	cis	rs7607369	0.500	rs6712856	chr2:219658617	A/T	cg02176678	chr2:219576539	TTLL4	-0.48	-6.34	-0.49	3.89e-9	Red blood cell count;Amyotrophic lateral sclerosis;
TGCT	cis	rs9942416	0.660	rs17649055	chr5:74984269	C/T	cg02573091	chr5:74908125	NA	0.39	4.45	0.37	1.88e-5	Age-related disease endophenotypes;
TGCT	cis	rs1401999	1.000	rs6800217	chr3:183685893	T/C	cg01324343	chr3:183735012	ABCC5	0.82	10.97	0.7	5.41e-20	Anterior chamber depth;
TGCT	cis	rs3782455	1.000	rs16943528	chr12:114403582	A/C	cg10631684	chr12:113795897	PLBD2	-0.7	-4.61	-0.38	1e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg09033563	chr22:24373618	LOC391322	0.51	4.98	0.41	2.11e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg08280861	chr8:58055591	NA	0.54	6.1	0.48	1.22e-8	Developmental language disorder (linguistic errors);
TGCT	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg03517284	chr6:25882590	NA	0.49	5.07	0.41	1.42e-6	Blood metabolite levels;
TGCT	cis	rs78487399	0.808	rs10203174	chr2:43690030	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.99	-0.47	2.13e-8	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs4727027	0.933	rs1044358	chr7:148879951	C/A	cg23583168	chr7:148888333	NA	-0.74	-9.81	-0.66	3.64e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	trans	rs8073060	0.518	rs225285	chr17:33931084	G/C	cg19694781	chr19:47549865	TMEM160	-0.44	-8.53	-0.61	4.24e-14	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs4642101	0.793	rs6799179	chr3:12829095	A/C	cg05775895	chr3:12838266	CAND2	0.78	8.9	0.62	5.77e-15	QRS complex (12-leadsum);
TGCT	cis	rs7833790	0.963	rs1451997	chr8:82774053	A/T	cg23324259	chr8:82754387	SNX16	0.66	4.6	0.38	1.02e-5	Diastolic blood pressure;
TGCT	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg04013166	chr16:89971882	TCF25	0.32	4.46	0.37	1.84e-5	Skin colour saturation;
TGCT	cis	rs9300255	0.568	rs1047158	chr12:123644056	C/A	cg00376283	chr12:123451042	ABCB9	0.73	5.64	0.45	1.09e-7	Neutrophil percentage of white cells;
TGCT	cis	rs9611565	0.559	rs9611619	chr22:41986714	C/T	cg06634786	chr22:41940651	POLR3H	-0.89	-8.16	-0.59	3.16e-13	Vitiligo;
TGCT	cis	rs9549367	0.789	rs57747440	chr13:113894750	C/A	cg18105134	chr13:113819100	PROZ	-0.34	-5.52	-0.44	1.9e-7	Platelet distribution width;
TGCT	cis	rs3741404	0.895	rs2429455	chr11:63995302	C/G	cg19570321	chr11:63258214	HRASLS5	0.44	5.05	0.41	1.57e-6	Platelet count;
TGCT	cis	rs1372520	0.684	rs1442148	chr4:90748846	T/A	cg15133208	chr4:90757351	SNCA	-0.5	-5.86	-0.47	4e-8	Neuroticism;
TGCT	cis	rs854765	0.583	rs66531105	chr17:17809001	C/T	cg09796270	chr17:17721594	SREBF1	0.23	4.68	0.39	7.36e-6	Total body bone mineral density;
TGCT	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg18876405	chr7:65276391	NA	0.35	5.2	0.42	8.09e-7	Aortic root size;
TGCT	cis	rs11190604	0.943	rs3750632	chr10:102279295	G/C	cg16342193	chr10:102329863	NA	-0.42	-5.37	-0.43	3.74e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs1048238	0.506	rs848194	chr1:16285342	G/A	cg21385522	chr1:16154831	NA	-0.57	-6.41	-0.5	2.78e-9	Systolic blood pressure;
TGCT	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg07636037	chr3:49044803	WDR6	0.83	8.06	0.59	5.4e-13	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs80033912	0.640	rs6785832	chr3:49224316	C/T	cg07636037	chr3:49044803	WDR6	0.63	6.15	0.48	9.82e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs911263	0.603	rs2180769	chr14:68799102	A/T	cg18825221	chr14:68749962	RAD51L1	0.23	4.47	0.37	1.73e-5	Primary biliary cholangitis;
TGCT	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg18230493	chr5:56204884	C5orf35	0.69	5.93	0.47	2.75e-8	Initial pursuit acceleration;
TGCT	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg11764359	chr7:65958608	NA	0.55	5.08	0.42	1.34e-6	Aortic root size;
TGCT	cis	rs3774830	0.534	rs7687596	chr4:5472092	C/T	cg26943120	chr4:5472116	STK32B	-0.29	-7.44	-0.56	1.49e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs910187	0.678	rs1046664	chr20:45817223	G/A	cg27589058	chr20:45804311	EYA2	-0.35	-7.6	-0.56	6.23e-12	Migraine;
TGCT	cis	rs8180040	0.764	rs13062022	chr3:47169375	G/A	cg27129171	chr3:47204927	SETD2	0.74	9.88	0.66	2.48e-17	Colorectal cancer;
TGCT	cis	rs9291683	0.620	rs7699512	chr4:10125808	C/T	cg11266682	chr4:10021025	SLC2A9	-0.45	-5.32	-0.43	4.65e-7	Bone mineral density;
TGCT	cis	rs931608	1.000	rs931608	chr19:22614122	A/C	cg23859931	chr19:22123797	NA	0.6	4.66	0.39	7.99e-6	Dental caries;Response to statins (LDL cholesterol change);
TGCT	cis	rs698813	0.604	rs1988663	chr2:44492753	C/T	cg00619915	chr2:44497795	NA	-0.24	-5.5	-0.44	2.05e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
TGCT	cis	rs1023500	0.596	rs5751204	chr22:42433801	C/T	cg15557168	chr22:42548783	NA	-0.19	-4.91	-0.4	2.78e-6	Schizophrenia;
TGCT	cis	rs1215050	0.765	rs783947	chr4:99012943	T/C	cg17366294	chr4:99064904	C4orf37	-0.54	-5.86	-0.47	3.98e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs4252435	0.614	rs28440780	chr7:142596824	G/T	cg09833174	chr7:143059591	FAM131B	-0.96	-4.52	-0.38	1.41e-5	Cancer;
TGCT	cis	rs11785693	0.862	rs62491202	chr8:5001470	C/A	cg26367366	chr8:4980734	NA	0.58	4.59	0.38	1.06e-5	Neuroticism (multi-trait analysis);Neuroticism;
TGCT	cis	rs7568458	0.660	rs6722691	chr2:85758352	C/T	cg17127132	chr2:85788382	GGCX	0.51	4.73	0.39	5.89e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg22920501	chr2:26401640	FAM59B	-0.72	-6.38	-0.5	3.19e-9	Gut microbiome composition (summer);
TGCT	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs611744	0.967	rs594405	chr8:109193607	A/G	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs1670533	1.000	rs935971	chr4:1045265	G/A	cg20887711	chr4:1340912	KIAA1530	0.74	5.57	0.45	1.51e-7	Recombination rate (females);
TGCT	cis	rs7474896	0.537	rs1208591	chr10:38212502	A/T	cg13720705	chr10:37990370	NA	0.35	4.44	0.37	1.97e-5	Obesity (extreme);
TGCT	cis	rs79149102	0.579	rs12591994	chr15:75320306	A/G	cg09165964	chr15:75287851	SCAMP5	-1.04	-5.48	-0.44	2.28e-7	Lung cancer;
TGCT	cis	rs9911578	1.000	rs9901114	chr17:56575208	G/A	cg12560992	chr17:57184187	TRIM37	-0.75	-9.1	-0.63	1.91e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs2836950	0.501	rs4818019	chr21:40694456	T/A	cg17971929	chr21:40555470	PSMG1	-0.51	-4.56	-0.38	1.19e-5	Menarche (age at onset);
TGCT	cis	rs11696845	0.666	rs6073533	chr20:43361082	G/T	cg25301532	chr20:43378953	KCNK15	-0.5	-5.35	-0.43	4.02e-7	Obesity-related traits;
TGCT	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg11062466	chr8:58055876	NA	0.37	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9814567	0.896	rs11915964	chr3:134348930	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.85	7.79	0.57	2.3e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	trans	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg06636001	chr8:8085503	FLJ10661	0.77	7.08	0.54	9.66e-11	Triglycerides;
TGCT	cis	rs8014204	0.905	rs8014289	chr14:75377352	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.74	-6.97	-0.53	1.68e-10	Caffeine consumption;
TGCT	cis	rs422249	0.547	rs174535	chr11:61551356	T/C	cg19610905	chr11:61596333	FADS2	-1.08	-10.94	-0.7	6.47e-20	Trans fatty acid levels;
TGCT	cis	rs9381040	0.610	rs2268191	chr6:41027653	G/C	cg03526776	chr6:41159608	TREML2	0.27	5.27	0.43	5.78e-7	Alzheimer's disease (late onset);
TGCT	cis	rs2439831	0.850	rs28891769	chr15:44072860	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	5.91	0.47	3.05e-8	Lung cancer in ever smokers;
TGCT	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.99	10.88	0.7	8.97e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs483180	0.512	rs612430	chr1:120216025	A/G	cg19096424	chr1:120255104	PHGDH	0.56	5.29	0.43	5.46e-7	Macular telangiectasia type 2;
TGCT	cis	rs79839061	0.667	rs73207777	chr4:836046	A/G	cg07828340	chr4:882639	GAK	0.36	4.75	0.39	5.58e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs13242816	1.000	rs7809755	chr7:116110732	C/T	cg16553024	chr7:116138462	CAV2	-0.45	-4.75	-0.39	5.64e-6	P wave duration;
TGCT	cis	rs9372498	0.536	rs17080302	chr6:118854037	A/G	cg21191810	chr6:118973309	C6orf204	-0.37	-4.79	-0.39	4.73e-6	Diastolic blood pressure;
TGCT	cis	rs6486730	0.508	rs7133440	chr12:129269244	A/C	cg09035930	chr12:129282057	SLC15A4	-0.43	-6.5	-0.5	1.76e-9	Systemic lupus erythematosus;
TGCT	cis	rs2933343	0.729	rs1683780	chr3:128640239	C/T	cg11901034	chr3:128598214	ACAD9	-0.69	-6.57	-0.51	1.24e-9	IgG glycosylation;
TGCT	cis	rs319204	0.851	rs319189	chr5:146270355	A/T	cg25021259	chr5:146258546	PPP2R2B	0.35	4.49	0.37	1.63e-5	Schizophrenia;
TGCT	cis	rs2228479	0.850	rs11641147	chr16:89813589	C/T	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs7726839	0.574	rs72705017	chr5:623733	G/A	cg16624210	chr5:671434	TPPP	0.43	4.68	0.39	7.5e-6	Obesity-related traits;
TGCT	cis	rs35146811	0.624	rs1727134	chr7:99813672	T/C	cg00553149	chr7:99775558	STAG3;GPC2	-0.32	-4.81	-0.4	4.28e-6	Coronary artery disease;
TGCT	cis	rs28493229	0.522	rs2233152	chr19:41281016	C/T	cg11601297	chr19:41224147	ITPKC;ADCK4	0.58	5.1	0.42	1.25e-6	Kawasaki disease;
TGCT	cis	rs2762353	0.574	rs4419666	chr6:25693274	C/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.73	7.49	0.56	1.11e-11	Blood metabolite levels;
TGCT	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg23708337	chr7:1209742	NA	0.64	5.94	0.47	2.63e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs74233809	1.000	rs75970938	chr10:104793648	T/C	cg05855489	chr10:104503620	C10orf26	0.77	4.55	0.38	1.27e-5	Birth weight;
TGCT	trans	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg27523141	chr10:43048294	ZNF37B	0.73	8.58	0.61	3.32e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs797680	0.856	rs535760	chr1:93728758	T/A	cg17826107	chr1:92977322	EVI5	0.24	5.29	0.43	5.47e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg02725872	chr8:58115012	NA	-0.38	-4.73	-0.39	5.94e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1483890	0.723	rs12629224	chr3:69411188	T/C	cg22125112	chr3:69402811	FRMD4B	0.29	4.71	0.39	6.53e-6	Resting heart rate;
TGCT	cis	rs3091242	0.804	rs631133	chr1:25724146	T/C	cg23205692	chr1:25664452	TMEM50A	0.52	5.36	0.43	3.96e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs10465746	0.935	rs12410617	chr1:84379461	G/C	cg10977910	chr1:84465055	TTLL7	0.63	6.16	0.48	9.32e-9	Obesity-related traits;
TGCT	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg00343986	chr7:65444356	GUSB	0.24	5.31	0.43	4.81e-7	Aortic root size;
TGCT	cis	rs10940138	1.000	rs10940138	chr5:67194469	C/T	ch.5.1281357F	chr5:67228439	NA	0.41	4.73	0.39	6.13e-6	Menarche (age at onset);
TGCT	cis	rs9911578	1.000	rs1494977	chr17:56863064	C/T	cg05425664	chr17:57184151	TRIM37	-0.63	-6.26	-0.49	5.86e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs11190604	1.000	rs2495751	chr10:102327260	A/G	cg16342193	chr10:102329863	NA	-0.42	-5.39	-0.44	3.47e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg14004847	chr7:1930337	MAD1L1	-0.27	-4.54	-0.38	1.33e-5	Bipolar disorder and schizophrenia;
TGCT	cis	rs12134133	1.000	rs11582249	chr1:207441608	G/A	cg02152968	chr1:207494213	CD55	0.61	4.66	0.39	7.94e-6	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs57994353	0.897	rs11999532	chr9:139371405	G/C	cg13741927	chr9:139327495	INPP5E	-0.24	-5.42	-0.44	2.93e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs17331151	0.541	rs1139106	chr3:52871101	G/A	cg12962167	chr3:53033115	SFMBT1	0.43	4.9	0.4	2.92e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs6809651	0.524	rs12638263	chr3:185795855	A/C	cg00760338	chr3:185826511	ETV5	-0.63	-4.81	-0.4	4.36e-6	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
TGCT	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg16228356	chr17:43848958	NA	-0.26	-4.53	-0.38	1.37e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7914558	1.000	rs10883826	chr10:104830819	A/G	cg15744005	chr10:104629667	AS3MT	-0.4	-4.85	-0.4	3.58e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs6088580	0.609	rs6059845	chr20:33036500	G/A	cg08999081	chr20:33150536	PIGU	0.29	5.67	0.45	9.68e-8	Glomerular filtration rate (creatinine);
TGCT	cis	rs918629	0.716	rs3756703	chr5:95276063	G/A	cg16656078	chr5:95278638	ELL2	-0.27	-4.67	-0.39	7.55e-6	IgG glycosylation;
TGCT	cis	rs3087591	1.000	rs2905877	chr17:29543269	A/C	cg24425628	chr17:29625626	OMG;NF1	-0.5	-7.33	-0.55	2.63e-11	Hip circumference;
TGCT	trans	rs7615952	0.800	rs13086460	chr3:125646417	C/T	cg07211511	chr3:129823064	LOC729375	-0.48	-8.02	-0.58	6.91e-13	Blood pressure (smoking interaction);
TGCT	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg07870213	chr5:140052090	DND1	0.65	7.75	0.57	2.79e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg13665807	chr20:60559372	TAF4	-0.53	-5.41	-0.44	3.06e-7	Body mass index;
TGCT	cis	rs1499614	1.000	rs34250985	chr7:66161062	A/T	cg18252515	chr7:66147081	NA	-1.15	-6.48	-0.5	2e-9	Gout;
TGCT	cis	rs881375	1.000	rs1609810	chr9:123642351	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	5.47	0.44	2.33e-7	Rheumatoid arthritis;
TGCT	cis	rs2996428	0.709	rs6424052	chr1:3713746	A/G	cg17848003	chr1:3704513	LRRC47	0.17	4.56	0.38	1.22e-5	Red cell distribution width;
TGCT	cis	rs3749237	0.595	rs7643845	chr3:49530711	A/G	cg02487422	chr3:49467188	NICN1	0.61	6.29	0.49	5.08e-9	Resting heart rate;
TGCT	cis	rs1669338	0.588	rs73009149	chr3:3220473	G/C	cg16797762	chr3:3221439	CRBN	-0.87	-5.5	-0.44	2.12e-7	White matter integrity;
TGCT	cis	rs3008870	1.000	rs3008855	chr1:67386204	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.01	-10.62	-0.69	3.91e-19	Lymphocyte percentage of white cells;
TGCT	cis	rs6088580	0.634	rs1205345	chr20:32914699	A/G	cg06115741	chr20:33292138	TP53INP2	-0.53	-4.66	-0.39	7.94e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs2463822	0.583	rs17709552	chr11:62040519	A/G	cg06239285	chr11:62104954	ASRGL1	-0.89	-5.95	-0.47	2.57e-8	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs10875595	0.779	rs2338532	chr5:140675264	G/A	cg24830062	chr5:140700576	TAF7	-0.61	-5.14	-0.42	1.04e-6	Pulmonary function decline;
TGCT	cis	rs1371867	0.846	rs1660345	chr8:101322762	C/A	cg06636551	chr8:101224915	SPAG1	-0.48	-6.52	-0.51	1.62e-9	Atrioventricular conduction;
TGCT	cis	rs2806561	0.765	rs652783	chr1:23514313	G/T	cg12483005	chr1:23474871	LUZP1	0.38	4.73	0.39	5.93e-6	Height;
TGCT	cis	rs548181	0.621	rs2912098	chr11:125528569	C/T	cg03464685	chr11:125439445	EI24	1.27	9.56	0.65	1.46e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs11030122	0.702	rs1452047	chr11:3991648	A/C	cg18678763	chr11:4115507	RRM1	-0.49	-6.13	-0.48	1.08e-8	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs2204008	0.744	rs67889662	chr12:38327042	T/A	cg13010199	chr12:38710504	ALG10B	0.61	4.77	0.39	5.11e-6	Bladder cancer;
TGCT	cis	rs10883723	0.810	rs7069356	chr10:104254359	G/C	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs7923609	0.811	rs4746204	chr10:65328518	C/T	cg08743896	chr10:65200160	JMJD1C	0.32	4.46	0.37	1.82e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg24846343	chr22:24311635	DDTL	0.23	5.7	0.46	8.19e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.48	-0.37	1.66e-5	Bipolar disorder;
TGCT	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-8.64	-0.61	2.39e-14	Platelet count;
TGCT	cis	rs12477438	0.501	rs7349217	chr2:99815146	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	8.83	0.62	8.31e-15	Chronic sinus infection;
TGCT	cis	rs314370	0.570	rs314313	chr7:100423365	C/T	cg10426581	chr7:100472382	SRRT	-0.7	-7.26	-0.55	3.8e-11	Resting heart rate;
TGCT	cis	rs10131894	0.575	rs2159904	chr14:75432179	G/T	cg08847533	chr14:75593920	NEK9	0.68	6.21	0.49	7.44e-9	Coronary artery disease;
TGCT	cis	rs7216064	1.000	rs8074078	chr17:65838743	A/C	cg12091567	chr17:66097778	LOC651250	-0.87	-6.85	-0.52	3.1e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg18305652	chr10:134549665	INPP5A	0.35	5.94	0.47	2.73e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs6754311	0.906	rs4954387	chr2:136784344	A/G	cg07169764	chr2:136633963	MCM6	0.54	5.07	0.41	1.4e-6	Mosquito bite size;
TGCT	cis	rs941408	0.963	rs2537854	chr19:2786726	A/C	cg06609049	chr19:2785107	THOP1	0.79	7.83	0.58	1.84e-12	Total cholesterol levels;
TGCT	cis	rs614226	1.000	rs614226	chr12:120974510	C/T	cg10072921	chr12:121022843	NA	0.44	4.74	0.39	5.78e-6	Type 1 diabetes nephropathy;
TGCT	cis	rs7020830	0.825	rs10973248	chr9:37197768	C/T	cg14294708	chr9:37120828	ZCCHC7	1.19	15.69	0.82	3.1e-31	Schizophrenia;
TGCT	cis	rs4332037	0.539	rs57148375	chr7:2025001	G/C	cg25834613	chr7:1915315	MAD1L1	-0.47	-4.51	-0.38	1.48e-5	Bipolar disorder;
TGCT	cis	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg07424592	chr7:64974309	NA	1.34	8.08	0.59	4.95e-13	Diabetic kidney disease;
TGCT	cis	rs6657613	0.869	rs9435662	chr1:17314942	G/A	cg21692666	chr1:17199302	NA	-0.42	-4.52	-0.38	1.43e-5	Hip circumference adjusted for BMI;
TGCT	cis	rs10751667	0.643	rs7396767	chr11:938808	G/A	cg06064525	chr11:970664	AP2A2	-0.35	-8.09	-0.59	4.54e-13	Alzheimer's disease (late onset);
TGCT	cis	rs908922	0.651	rs11205035	chr1:152532832	A/G	cg20991723	chr1:152506922	NA	0.44	5.91	0.47	3.08e-8	Hair morphology;
TGCT	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs651907	0.557	rs7651721	chr3:101393583	C/A	cg11279151	chr3:101281821	RG9MTD1	-0.35	-7.28	-0.55	3.4e-11	Colorectal cancer;
TGCT	cis	rs9926296	0.609	rs4785714	chr16:89798404	G/T	cg03388025	chr16:89894329	SPIRE2	-0.32	-4.8	-0.4	4.41e-6	Vitiligo;
TGCT	cis	rs2290402	0.536	rs45486093	chr4:875671	T/C	cg23332689	chr4:987652	IDUA;SLC26A1	0.34	5.07	0.41	1.44e-6	Type 2 diabetes;
TGCT	cis	rs936229	0.784	rs12906946	chr15:75153140	A/G	cg10253484	chr15:75165896	SCAMP2	-0.78	-6.49	-0.5	1.9e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
TGCT	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg12311346	chr5:56204834	C5orf35	-0.82	-7.96	-0.58	9.17e-13	Initial pursuit acceleration;
TGCT	cis	rs11673344	0.523	rs36096221	chr19:37551740	G/A	cg08039142	chr19:36980659	ZNF566	0.51	4.69	0.39	6.97e-6	Obesity-related traits;
TGCT	cis	rs698833	0.518	rs7560807	chr2:44557089	C/T	cg23552047	chr2:44669647	C2orf34	0.28	4.49	0.37	1.63e-5	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
TGCT	cis	rs9457247	1.000	rs365189	chr6:167384545	G/A	cg23791538	chr6:167370224	RNASET2	-0.5	-4.98	-0.41	2.08e-6	Crohn's disease;
TGCT	cis	rs12477438	0.520	rs13018891	chr2:99755099	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	13.05	0.76	4.93e-25	Chronic sinus infection;
TGCT	cis	rs2180341	0.513	rs12196828	chr6:127696864	C/T	cg24812749	chr6:127587940	RNF146	0.62	5.38	0.44	3.5e-7	Breast cancer;
TGCT	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg20999797	chr1:1681921	NA	0.18	4.78	0.39	4.93e-6	Body mass index;
TGCT	cis	rs3771570	1.000	rs17386555	chr2:242371825	G/A	cg21155796	chr2:242212141	HDLBP	0.93	6.62	0.51	9.86e-10	Prostate cancer;
TGCT	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	5.03	0.41	1.69e-6	Prudent dietary pattern;
TGCT	cis	rs6912958	0.559	rs173333	chr6:88047754	T/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.4	4.71	0.39	6.65e-6	Monocyte percentage of white cells;
TGCT	cis	rs4820539	1.000	rs4820539	chr22:23477970	C/T	cg14186256	chr22:23484241	RTDR1	-1.01	-13.19	-0.76	2.34e-25	Bone mineral density;
TGCT	cis	rs79149102	0.579	rs76518150	chr15:75292721	C/G	cg09165964	chr15:75287851	SCAMP5	-1.07	-5.81	-0.46	4.89e-8	Lung cancer;
TGCT	cis	rs7086627	0.515	rs11202960	chr10:82209807	G/A	cg01528321	chr10:82214614	TSPAN14	0.65	6.21	0.49	7.21e-9	Post bronchodilator FEV1;
TGCT	cis	rs4888262	0.526	rs7205258	chr16:74642539	C/T	cg01733217	chr16:74700730	RFWD3	0.74	7.47	0.56	1.23e-11	Testicular germ cell tumor;
TGCT	cis	rs3091242	0.809	rs660129	chr1:25727438	C/T	cg23205692	chr1:25664452	TMEM50A	0.53	5.48	0.44	2.32e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs6663390	0.510	rs1932818	chr1:208078257	C/T	cg03990033	chr1:208084030	CD34	0.64	6.05	0.48	1.57e-8	Facial morphology (factor 18);
TGCT	cis	rs4660261	0.526	rs2906466	chr1:44322220	A/G	cg12908607	chr1:44402522	ARTN	-0.64	-7.74	-0.57	3e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs1475911	1.000	rs12482477	chr21:43517233	T/A	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.25	-4.79	-0.4	4.59e-6	IgG glycosylation;
TGCT	cis	rs35306767	0.903	rs13377166	chr10:886259	G/A	cg20503657	chr10:835505	NA	0.7	9.83	0.66	3.22e-17	Eosinophil percentage of granulocytes;
TGCT	cis	rs9467773	1.000	rs6924838	chr6:26571756	C/T	cg26531700	chr6:26746687	NA	0.5	4.85	0.4	3.64e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4663866	1.000	rs4663866	chr2:239150815	A/C	cg17283117	chr2:239148619	HES6	0.98	4.5	0.37	1.55e-5	Irritable bowel syndrome;
TGCT	cis	rs6597981	0.604	rs7945912	chr11:750849	A/T	cg20225915	chr11:805726	LRDD	-0.33	-4.7	-0.39	6.66e-6	Breast cancer;
TGCT	cis	rs10791097	0.694	rs1893018	chr11:130756632	T/C	cg05962950	chr11:130786565	SNX19	0.9	11.06	0.7	3.32e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs782590	0.967	rs4672054	chr2:55773093	C/A	cg18811423	chr2:55921094	PNPT1	0.66	7.14	0.54	7.11e-11	Metabolic syndrome;
TGCT	cis	rs3858526	1.000	rs3858527	chr11:5959848	G/A	cg13902645	chr11:5959945	NA	-0.43	-4.65	-0.39	8.43e-6	DNA methylation (variation);
TGCT	cis	rs782590	0.607	rs2061032	chr2:55679490	T/C	cg03859395	chr2:55845619	SMEK2	0.61	5.3	0.43	5.12e-7	Metabolic syndrome;
TGCT	cis	rs3849570	0.533	rs6785385	chr3:81989850	A/G	cg07356753	chr3:81810745	GBE1	-0.54	-4.51	-0.38	1.49e-5	Waist circumference;Body mass index;
TGCT	cis	rs651907	0.557	rs7612283	chr3:101434919	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.34	-7.02	-0.53	1.27e-10	Colorectal cancer;
TGCT	cis	rs7940866	0.845	rs1433976	chr11:130875123	C/T	cg12179176	chr11:130786555	SNX19	-0.49	-4.9	-0.4	2.99e-6	Schizophrenia;
TGCT	cis	rs9902453	1.000	rs6505152	chr17:28331466	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.74	-6.59	-0.51	1.12e-9	Coffee consumption (cups per day);
TGCT	cis	rs2224391	0.590	rs72815603	chr6:5278701	A/C	cg09085698	chr6:5261316	LYRM4;FARS2	-1.04	-5.28	-0.43	5.56e-7	Height;
TGCT	cis	rs3020736	0.500	rs5996109	chr22:42493098	A/G	cg15557168	chr22:42548783	NA	0.22	5.58	0.45	1.47e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs13064447	0.753	rs9868500	chr3:12747690	A/G	cg20675869	chr3:12750130	NA	0.18	4.46	0.37	1.81e-5	Major depression and alcohol dependence;
TGCT	cis	rs9611519	0.964	rs20551	chr22:41548008	A/G	cg13695892	chr22:41940480	POLR3H	-0.52	-4.76	-0.39	5.23e-6	Neuroticism;
TGCT	cis	rs7945705	0.967	rs10769973	chr11:8928615	C/G	cg21881798	chr11:8931708	C11orf17;ST5	0.46	5.1	0.42	1.24e-6	Hemoglobin concentration;
TGCT	cis	rs6920965	0.507	rs12203025	chr6:126192034	C/T	cg05901451	chr6:126070800	HEY2	-0.66	-6.5	-0.5	1.81e-9	High light scatter reticulocyte count;
TGCT	cis	rs3125734	0.633	rs4561099	chr10:64041163	T/C	cg05499367	chr10:63213510	TMEM26	-0.33	-4.48	-0.37	1.69e-5	Rheumatoid arthritis;
TGCT	trans	rs2624839	0.602	rs2526398	chr3:50187596	G/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.78	7.04	0.53	1.17e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs1406084	0.636	rs7591066	chr2:154718471	G/A	cg25703346	chr2:154729189	GALNT13	0.77	4.6	0.38	1.03e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9611519	1.000	rs6002271	chr22:41566595	C/T	cg13695892	chr22:41940480	POLR3H	-0.5	-4.48	-0.37	1.65e-5	Neuroticism;
TGCT	cis	rs6893300	0.524	rs62404348	chr5:179146026	G/A	cg14593053	chr5:179126677	CANX	0.48	5.4	0.44	3.23e-7	Resting heart rate;
TGCT	cis	rs9911578	1.000	rs1631237	chr17:56734695	A/G	cg12560992	chr17:57184187	TRIM37	0.75	9.21	0.64	1.04e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg11062466	chr8:58055876	NA	0.43	4.52	0.38	1.45e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs78487399	0.908	rs17031092	chr2:43809248	A/C	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.63	4.52	0.38	1.43e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs1532993	0.518	rs28634627	chr4:98561934	C/T	cg05340658	chr4:99064831	C4orf37	-0.38	-4.53	-0.38	1.36e-5	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs2204008	0.743	rs11182052	chr12:38450421	T/C	cg26384229	chr12:38710491	ALG10B	0.84	7.78	0.57	2.41e-12	Bladder cancer;
TGCT	cis	rs713587	0.521	rs35177510	chr2:25089594	C/A	cg01884057	chr2:25150051	NA	0.3	5.65	0.45	1.03e-7	Body mass index in non-asthmatics;
TGCT	cis	rs514406	0.505	rs448788	chr1:53161620	A/G	cg24675658	chr1:53192096	ZYG11B	0.75	8.3	0.6	1.51e-13	Monocyte count;
TGCT	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg10047753	chr17:41438598	NA	-0.62	-6.22	-0.49	6.96e-9	Menopause (age at onset);
TGCT	cis	rs7100689	0.646	rs4601708	chr10:82119583	G/T	cg01528321	chr10:82214614	TSPAN14	0.8	7.76	0.57	2.7e-12	Post bronchodilator FEV1;
TGCT	cis	rs9357506	0.967	rs9381441	chr6:46310411	C/T	cg21115430	chr6:46460003	NA	-0.26	-5.16	-0.42	9.6e-7	Body mass index;
TGCT	cis	rs12477438	0.501	rs11688004	chr2:99735052	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	10.3	0.68	2.42e-18	Chronic sinus infection;
TGCT	cis	rs7552404	0.924	rs2153126	chr1:76199345	C/G	cg03433033	chr1:76189801	ACADM	0.82	9.91	0.66	2.05e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.54	4.47	0.37	1.77e-5	Tonsillectomy;
TGCT	cis	rs524281	0.954	rs549187	chr11:65898631	C/T	cg00563793	chr11:65837595	PACS1	0.5	4.52	0.38	1.45e-5	Electroencephalogram traits;
TGCT	cis	rs7909074	0.831	rs11239271	chr10:45376294	A/G	cg05187965	chr10:45406764	TMEM72	-0.29	-6.04	-0.48	1.67e-8	Mean corpuscular volume;
TGCT	cis	rs35146811	1.000	rs35146811	chr7:99720994	A/C	cg22906224	chr7:99728672	NA	0.55	5.05	0.41	1.52e-6	Coronary artery disease;
TGCT	cis	rs782590	0.902	rs782595	chr2:55845596	C/G	cg03859395	chr2:55845619	SMEK2	0.96	12.0	0.73	1.71e-22	Metabolic syndrome;
TGCT	cis	rs7267979	1.000	rs6115140	chr20:25285507	C/A	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg26513180	chr16:89883248	FANCA	1.06	14.79	0.8	3.77e-29	Vitiligo;
TGCT	cis	rs3936340	1.000	rs2278237	chr19:48527902	G/C	cg03707168	chr19:49379127	PPP1R15A	0.6	4.56	0.38	1.22e-5	Intelligence;
TGCT	cis	rs1865760	0.566	rs1539183	chr6:26075051	G/C	cg16482183	chr6:26056742	HIST1H1C	0.58	4.97	0.41	2.13e-6	Height;
TGCT	cis	rs77741769	0.571	rs989987	chr12:121274062	C/T	cg02419362	chr12:121203948	SPPL3	0.19	4.5	0.37	1.58e-5	Mean corpuscular volume;
TGCT	cis	rs9611565	0.559	rs132771	chr22:42025350	A/G	cg06634786	chr22:41940651	POLR3H	0.88	8.38	0.6	9.48e-14	Vitiligo;
TGCT	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.5	-4.72	-0.39	6.33e-6	Prudent dietary pattern;
TGCT	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6424115	0.830	rs2229585	chr1:24200921	T/C	cg15997130	chr1:24165203	NA	0.85	9.25	0.64	8.02e-16	Immature fraction of reticulocytes;
TGCT	cis	rs7100689	0.646	rs1340382	chr10:82096997	G/C	cg01528321	chr10:82214614	TSPAN14	0.75	7.49	0.56	1.15e-11	Post bronchodilator FEV1;
TGCT	cis	rs826838	0.935	rs11169547	chr12:39185625	C/A	cg13010199	chr12:38710504	ALG10B	0.77	6.09	0.48	1.31e-8	Heart rate;
TGCT	cis	rs10940138	0.830	rs6867554	chr5:67207725	A/G	ch.5.1281357F	chr5:67228439	NA	0.44	4.91	0.4	2.83e-6	Menarche (age at onset);
TGCT	cis	rs877282	1.000	rs112522746	chr10:772288	T/C	cg17470449	chr10:769945	NA	0.31	4.8	0.4	4.44e-6	Uric acid levels;
TGCT	cis	rs72843506	0.586	rs59890010	chr17:19863673	C/T	cg18979559	chr17:20280153	CCDC144C	-0.59	-4.5	-0.37	1.53e-5	Schizophrenia;
TGCT	cis	rs9972944	0.902	rs9972881	chr17:63771334	A/G	cg07283582	chr17:63770753	CCDC46	0.28	5.89	0.47	3.34e-8	Total body bone mineral density;
TGCT	cis	rs12458462	0.859	rs35493271	chr18:77448793	G/T	cg11879182	chr18:77439856	CTDP1	0.7	7.83	0.58	1.88e-12	Monocyte count;
TGCT	cis	rs2230307	0.536	rs834277	chr1:100510855	T/G	cg24955406	chr1:100503596	HIAT1	0.74	4.86	0.4	3.41e-6	Carotid intima media thickness;
TGCT	cis	rs56104184	0.723	rs1058483	chr19:49407660	G/A	cg17863274	chr19:49399704	TULP2	-0.54	-7.43	-0.55	1.58e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg07157834	chr1:205819609	PM20D1	0.34	5.0	0.41	1.89e-6	Menarche (age at onset);
TGCT	cis	rs6570726	0.791	rs401331	chr6:145831408	A/G	cg05347473	chr6:146136440	FBXO30	0.53	4.95	0.41	2.4e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7208859	0.673	rs60020217	chr17:29185054	G/A	cg18442181	chr17:29233375	C17orf42	-0.78	-4.61	-0.38	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs929354	0.772	rs6967764	chr7:156994964	C/T	cg05182265	chr7:156933206	UBE3C	-0.39	-8.79	-0.62	1.03e-14	Body mass index;
TGCT	cis	rs2708977	0.614	rs12477963	chr2:97261593	G/A	cg01950434	chr2:97203154	ARID5A	0.54	4.49	0.37	1.62e-5	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs7769051	1.000	rs9493446	chr6:133125643	C/T	cg07930552	chr6:133119739	C6orf192	0.93	5.0	0.41	1.87e-6	Type 2 diabetes nephropathy;
TGCT	cis	rs7666738	0.830	rs1426672	chr4:98923984	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7432375	0.901	rs35874192	chr3:136470004	G/C	cg12473912	chr3:136751656	NA	-0.36	-5.03	-0.41	1.68e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs11971779	0.793	rs4728464	chr7:139017670	C/T	cg07862535	chr7:139043722	LUC7L2	-0.74	-5.89	-0.47	3.32e-8	Diisocyanate-induced asthma;
TGCT	cis	rs12200560	0.505	rs60879781	chr6:97075466	A/T	cg06623918	chr6:96969491	KIAA0776	0.59	5.06	0.41	1.44e-6	Coronary heart disease;
TGCT	cis	rs9467711	0.606	rs9358935	chr6:26369587	A/G	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.54	4.87	0.4	3.38e-6	Prudent dietary pattern;
TGCT	cis	rs7824557	0.679	rs6601579	chr8:11138098	T/A	cg21775007	chr8:11205619	TDH	-0.6	-5.65	-0.45	1.03e-7	Retinal vascular caliber;
TGCT	cis	rs950169	0.922	rs11630760	chr15:85113337	G/T	cg17173187	chr15:85201210	NMB	0.47	4.93	0.4	2.62e-6	Schizophrenia;
TGCT	cis	rs4750440	0.576	rs2447011	chr10:14032199	C/T	cg25464840	chr10:14372910	FRMD4A	0.33	4.46	0.37	1.82e-5	Adiponectin levels;
TGCT	cis	rs154659	0.961	rs164739	chr16:89667699	C/G	cg01710450	chr16:89662404	CPNE7	-0.4	-7.12	-0.54	7.83e-11	Tanning;
TGCT	cis	rs7246657	0.722	rs2972437	chr19:38210511	G/T	cg18154014	chr19:37997991	ZNF793	0.72	5.06	0.41	1.48e-6	Coronary artery calcification;
TGCT	cis	rs28595532	0.920	rs114390336	chr4:119771452	C/T	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs9443189	0.762	rs1321162	chr6:76456347	C/T	cg01950844	chr6:76311363	SENP6	0.6	4.48	0.37	1.69e-5	Prostate cancer;
TGCT	cis	rs174601	0.861	rs174581	chr11:61606683	G/A	cg19610905	chr11:61596333	FADS2	-0.96	-9.43	-0.65	3.08e-16	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
TGCT	cis	rs76878669	0.561	rs3177514	chr11:66130358	T/G	cg18002602	chr11:66138449	SLC29A2	0.53	6.58	0.51	1.18e-9	Educational attainment (years of education);
TGCT	cis	rs8072100	0.967	rs4580230	chr17:45738861	G/A	cg08085267	chr17:45401833	C17orf57	-0.47	-5.13	-0.42	1.07e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs4888262	0.508	rs4544266	chr16:74660993	C/A	cg01733217	chr16:74700730	RFWD3	0.7	7.02	0.53	1.26e-10	Testicular germ cell tumor;
TGCT	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg25767906	chr1:53392781	SCP2	0.6	7.15	0.54	6.42e-11	Monocyte count;
TGCT	cis	rs28493229	0.582	rs78915350	chr19:41160609	A/G	cg11601297	chr19:41224147	ITPKC;ADCK4	0.57	5.16	0.42	9.45e-7	Kawasaki disease;
TGCT	cis	rs1127311	0.905	rs6702449	chr1:154583210	A/C	cg17218026	chr1:154582156	ADAR	0.31	7.7	0.57	3.72e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs79349575	0.783	rs4255820	chr17:46996583	T/A	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.51	-0.38	1.48e-5	Type 2 diabetes;
TGCT	cis	rs4812048	0.696	rs6070694	chr20:57591126	G/A	cg14073986	chr20:57617431	SLMO2	0.63	4.67	0.39	7.71e-6	Mean platelet volume;
TGCT	cis	rs10207060	0.500	rs7585903	chr2:240682481	A/C	cg07506560	chr2:240697449	NA	0.48	5.27	0.43	5.96e-7	Obesity-related traits;
TGCT	cis	rs4285028	0.948	rs73855480	chr3:121676646	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.77	-6.55	-0.51	1.35e-9	Multiple sclerosis;
TGCT	cis	rs17125944	0.505	rs77433996	chr14:53212263	G/A	cg00686598	chr14:53173677	PSMC6	1.08	6.35	0.5	3.79e-9	Alzheimer's disease (late onset);
TGCT	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg24675658	chr1:53192096	ZYG11B	-0.71	-8.23	-0.59	2.14e-13	Monocyte count;
TGCT	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg20887711	chr4:1340912	KIAA1530	0.85	7.32	0.55	2.75e-11	Longevity;
TGCT	cis	rs2456568	0.571	rs12807496	chr11:93693064	A/G	cg26875233	chr11:93583750	C11orf90	0.43	5.16	0.42	9.71e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg24829409	chr8:58192753	C8orf71	0.6	5.39	0.44	3.4e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs265548	0.608	rs36690	chr19:17910483	C/T	cg21960279	chr19:17905606	B3GNT3	0.5	5.81	0.46	4.94e-8	Tumor biomarkers;
TGCT	cis	rs617219	0.710	rs2591386	chr5:78561373	C/T	cg09550809	chr5:78407562	BHMT	0.38	5.26	0.43	6.2e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs4919044	0.808	rs1750741	chr10:94804530	G/T	cg05127821	chr10:94822908	CYP26C1	-0.75	-4.85	-0.4	3.67e-6	Coronary artery disease;
TGCT	cis	rs7103648	0.932	rs7104036	chr11:47462140	A/G	cg20307385	chr11:47447363	PSMC3	1.07	13.03	0.76	5.56e-25	Diastolic blood pressure;Systolic blood pressure;
TGCT	cis	rs2836974	0.931	rs2776309	chr21:40715791	A/G	cg06238570	chr21:40685208	BRWD1	0.67	5.84	0.46	4.4e-8	Cognitive function;
TGCT	cis	rs4851266	0.865	rs11123818	chr2:100867308	G/A	cg07810366	chr2:100720526	AFF3	-0.36	-5.21	-0.42	7.59e-7	Educational attainment;
TGCT	cis	rs7666738	0.752	rs35436270	chr4:99088280	G/A	cg17366294	chr4:99064904	C4orf37	0.71	5.48	0.44	2.27e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4820539	1.000	rs2267002	chr22:23456702	T/C	cg21100191	chr22:23484243	RTDR1	0.95	11.39	0.72	5.18e-21	Bone mineral density;
TGCT	cis	rs6121246	0.512	rs6058384	chr20:30276409	A/T	cg13852791	chr20:30311386	BCL2L1	0.82	8.0	0.58	7.65e-13	Mean corpuscular hemoglobin;
TGCT	cis	rs975752	0.867	rs2270962	chr10:102016044	C/T	cg04750910	chr10:102416409	NA	0.73	4.48	0.37	1.69e-5	Schizophrenia;
TGCT	cis	rs709400	0.663	rs1803283	chr14:103986255	C/T	cg26031613	chr14:104095156	KLC1	-0.85	-8.91	-0.62	5.43e-15	Body mass index;
TGCT	cis	rs892961	0.932	rs747481	chr17:75412143	A/G	cg05865280	chr17:75406074	SEPT9	0.28	6.86	0.52	2.9e-10	Airflow obstruction;
TGCT	cis	rs736801	0.891	rs10900809	chr5:131826322	G/A	cg02551604	chr5:131831745	NA	0.57	4.71	0.39	6.64e-6	Breast cancer;Mosquito bite size;
TGCT	cis	rs611744	0.625	rs11991891	chr8:109294858	G/A	cg21045802	chr8:109455806	TTC35	0.74	7.77	0.57	2.59e-12	Dupuytren's disease;
TGCT	cis	rs12142240	0.698	rs72677599	chr1:46834251	G/A	cg14993813	chr1:46806288	NSUN4	-0.58	-4.8	-0.4	4.46e-6	Menopause (age at onset);
TGCT	cis	rs7772486	0.875	rs9403765	chr6:146368041	C/T	cg05347473	chr6:146136440	FBXO30	-0.5	-4.71	-0.39	6.52e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4664308	0.810	rs59019419	chr2:161061287	G/A	cg03641300	chr2:160917029	PLA2R1	-0.27	-6.72	-0.52	6e-10	Idiopathic membranous nephropathy;
TGCT	cis	rs1997103	1.000	rs4947504	chr7:55409428	T/C	cg17469321	chr7:55412551	NA	0.64	6.58	0.51	1.18e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs8072100	0.738	rs3736438	chr17:45486651	T/G	cg08085267	chr17:45401833	C17orf57	-0.52	-5.75	-0.46	6.48e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs1062177	1.000	rs12515762	chr5:151209922	G/T	cg12924095	chr5:151150029	G3BP1	0.36	5.18	0.42	8.79e-7	Preschool internalizing problems;
TGCT	cis	rs67311347	1.000	rs11707278	chr3:40487075	A/T	cg13683864	chr3:40499215	RPL14	-1.18	-13.68	-0.78	1.54e-26	Renal cell carcinoma;
TGCT	cis	rs317689	0.876	rs547332	chr12:69743639	C/G	cg19645103	chr12:69753606	YEATS4	-0.56	-4.57	-0.38	1.14e-5	Response to diuretic therapy;
TGCT	cis	rs1797081	0.504	rs2995476	chr10:16871358	C/A	cg23933602	chr10:16859644	RSU1	0.79	8.05	0.59	5.83e-13	Platelet distribution width;
TGCT	cis	rs28595532	0.920	rs17324807	chr4:119770638	G/A	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg04546413	chr19:29218101	NA	0.73	6.61	0.51	1.02e-9	Methadone dose in opioid dependence;
TGCT	cis	rs9303401	0.659	rs17222691	chr17:56771096	C/T	cg25039879	chr17:56429692	SUPT4H1	0.52	4.62	0.38	9.48e-6	Cognitive test performance;
TGCT	cis	rs3096299	0.658	rs12443705	chr16:89547054	C/G	cg08392591	chr16:89556376	ANKRD11	0.55	5.09	0.42	1.32e-6	Multiple myeloma (IgH translocation);
TGCT	cis	rs709400	0.663	rs7152202	chr14:103886757	A/G	cg26031613	chr14:104095156	KLC1	0.84	9.63	0.65	1.02e-16	Body mass index;
TGCT	cis	rs6570726	0.720	rs412623	chr6:145883257	C/A	cg23711669	chr6:146136114	FBXO30	0.83	8.66	0.61	2.09e-14	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7267979	0.789	rs6083820	chr20:25354178	G/A	cg16686733	chr20:25566563	NINL	-0.49	-4.62	-0.38	9.44e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11122272	0.735	rs2749705	chr1:231526696	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-6.3	-0.49	4.72e-9	Hemoglobin concentration;
TGCT	cis	rs4478037	1.000	rs4074418	chr3:33161165	G/T	cg19404215	chr3:33155277	CRTAP	1.28	8.55	0.61	3.75e-14	Major depressive disorder;
TGCT	cis	rs9388451	0.874	rs1159974	chr6:126090277	C/T	cg05901451	chr6:126070800	HEY2	1.02	14.91	0.8	1.92e-29	Brugada syndrome;
TGCT	cis	rs2760061	0.626	rs2313118	chr1:228118084	T/C	cg18477163	chr1:228402036	OBSCN	-0.32	-6.37	-0.5	3.31e-9	Diastolic blood pressure;
TGCT	cis	rs28595532	0.920	rs116821181	chr4:119734892	T/C	cg14228332	chr4:119757509	SEC24D	1.32	6.38	0.5	3.2e-9	Cannabis dependence symptom count;
TGCT	cis	rs763121	0.925	rs5750654	chr22:39051428	T/C	cg06022373	chr22:39101656	GTPBP1	0.78	7.97	0.58	8.82e-13	Menopause (age at onset);
TGCT	cis	rs13191362	0.938	rs13208970	chr6:163006368	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.68	5.79	0.46	5.33e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs9814567	0.712	rs4245905	chr3:134328864	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-6.41	-0.5	2.8e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs9389248	0.690	rs1028314	chr6:135255710	A/C	cg22676075	chr6:135203613	NA	-0.5	-5.04	-0.41	1.59e-6	High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs35883536	0.528	rs1414414	chr1:101028907	T/C	cg06223162	chr1:101003688	GPR88	0.42	8.22	0.59	2.25e-13	Monocyte count;
TGCT	trans	rs8073060	0.516	rs2376177	chr17:33938089	T/G	cg19694781	chr19:47549865	TMEM160	-0.61	-13.7	-0.78	1.39e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs1552244	0.706	rs279545	chr3:9972493	A/G	cg00149659	chr3:10157352	C3orf10	0.59	4.73	0.39	6.04e-6	Alzheimer's disease;
TGCT	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.9	0.53	2.39e-10	Electroencephalogram traits;
TGCT	cis	rs12950390	0.853	rs17700008	chr17:45863591	A/C	cg06532163	chr17:45867833	NA	-0.37	-5.96	-0.47	2.45e-8	IgG glycosylation;
TGCT	cis	rs9653442	0.900	rs1160544	chr2:100832218	A/C	cg22139774	chr2:100720529	AFF3	-0.38	-6.15	-0.48	9.83e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs782590	0.934	rs17369191	chr2:55757885	T/C	cg03859395	chr2:55845619	SMEK2	0.91	11.32	0.71	7.6e-21	Metabolic syndrome;
TGCT	cis	rs7809950	1.000	rs2808	chr7:107260856	A/G	cg23024343	chr7:107201750	COG5	0.36	5.63	0.45	1.15e-7	Coronary artery disease;
TGCT	cis	rs3947	0.951	rs1692817	chr8:11704719	C/A	cg02840367	chr8:11660030	FDFT1	0.89	6.47	0.5	2e-9	Blood protein levels;
TGCT	cis	rs9902453	0.619	rs2617866	chr17:28076217	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.8	-7.91	-0.58	1.19e-12	Coffee consumption (cups per day);
TGCT	trans	rs2727020	0.664	rs4929893	chr11:49196332	C/T	cg15704280	chr7:45808275	SEPT13	-0.7	-7.67	-0.57	4.26e-12	Coronary artery disease;
TGCT	cis	rs7940866	0.834	rs10791108	chr11:130849354	T/A	cg05962950	chr11:130786565	SNX19	0.71	6.96	0.53	1.79e-10	Schizophrenia;
TGCT	cis	rs763014	0.931	rs7192508	chr16:630367	C/T	cg09263875	chr16:632152	PIGQ	0.3	6.4	0.5	2.88e-9	Height;
TGCT	cis	rs9486715	0.830	rs1475748	chr6:97034143	T/C	cg06623918	chr6:96969491	KIAA0776	-1.11	-15.34	-0.81	1.96e-30	Headache;
TGCT	cis	rs637571	0.510	rs10750772	chr11:65577427	C/T	cg04055107	chr11:65626734	MUS81;CFL1	-0.67	-6.01	-0.48	1.9e-8	Eosinophil percentage of white cells;
TGCT	cis	rs6922269	0.859	rs4869954	chr6:151250567	A/G	cg01013955	chr6:150918915	NA	-0.29	-5.04	-0.41	1.59e-6	Coronary heart disease;
TGCT	cis	rs9650657	0.801	rs4841437	chr8:10596795	T/G	cg27411982	chr8:10470053	RP1L1	-0.21	-4.55	-0.38	1.25e-5	Neuroticism;
TGCT	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg12963246	chr6:28129442	ZNF389	0.52	5.1	0.42	1.23e-6	Parkinson's disease;
TGCT	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg17178900	chr1:205818956	PM20D1	0.56	6.87	0.53	2.72e-10	Menarche (age at onset);
TGCT	cis	rs559928	0.593	rs112275221	chr11:63936994	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	4.56	0.38	1.22e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
TGCT	cis	rs11190604	1.000	rs2489046	chr10:102346282	A/C	cg16342193	chr10:102329863	NA	-0.39	-4.92	-0.4	2.72e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9300255	0.679	rs12829456	chr12:123725395	C/T	cg00376283	chr12:123451042	ABCB9	-0.74	-5.03	-0.41	1.66e-6	Neutrophil percentage of white cells;
TGCT	cis	rs72945132	0.619	rs34552378	chr11:70243208	C/T	cg00319359	chr11:70116639	PPFIA1	1.01	7.03	0.53	1.21e-10	Coronary artery disease;
TGCT	cis	rs7100689	0.577	rs10749560	chr10:82092801	G/T	cg01528321	chr10:82214614	TSPAN14	0.75	7.49	0.56	1.15e-11	Post bronchodilator FEV1;
TGCT	cis	rs9611565	0.512	rs9611672	chr22:42209922	A/G	cg03806693	chr22:41940476	POLR3H	-1.04	-10.57	-0.69	5.2e-19	Vitiligo;
TGCT	cis	rs9653442	0.522	rs4851274	chr2:100870862	T/C	cg22139774	chr2:100720529	AFF3	-0.37	-5.81	-0.46	5.05e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs10782582	0.546	rs79652169	chr1:76233882	G/A	cg10523679	chr1:76189770	ACADM	-0.61	-6.13	-0.48	1.09e-8	Daytime sleep phenotypes;
TGCT	trans	rs4650994	0.816	rs2209169	chr1:178601492	C/T	cg05059571	chr16:84539110	KIAA1609	0.42	7.57	0.56	7.21e-12	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs2404602	0.669	rs12595313	chr15:76978370	A/G	cg22467129	chr15:76604101	ETFA	-0.45	-5.11	-0.42	1.2e-6	Blood metabolite levels;
TGCT	cis	rs5750830	0.594	rs9611165	chr22:39775250	A/G	cg05872129	chr22:39784769	NA	-0.84	-8.83	-0.62	8.39e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs5769765	0.542	rs738707	chr22:50250827	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.97	6.35	0.5	3.69e-9	Schizophrenia;
TGCT	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg22920501	chr2:26401640	FAM59B	0.65	5.36	0.43	3.85e-7	Gut microbiome composition (summer);
TGCT	cis	rs7429990	0.932	rs11130155	chr3:48140428	A/C	cg11946769	chr3:48343235	NME6	-0.57	-4.76	-0.39	5.39e-6	Educational attainment (years of education);
TGCT	cis	rs561341	0.700	rs8079471	chr17:30218317	A/G	cg13647721	chr17:30228624	UTP6	0.59	5.21	0.42	7.66e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg24675658	chr1:53192096	ZYG11B	-0.71	-7.87	-0.58	1.5e-12	Monocyte count;
TGCT	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg06238570	chr21:40685208	BRWD1	-0.8	-9.17	-0.64	1.3e-15	Cognitive function;
TGCT	cis	rs9467773	1.000	rs3736781	chr6:26505362	G/A	cg26531700	chr6:26746687	NA	0.47	4.56	0.38	1.19e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs524281	0.814	rs1055615	chr11:65846922	C/G	cg00563793	chr11:65837595	PACS1	0.57	4.84	0.4	3.73e-6	Electroencephalogram traits;
TGCT	trans	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	1.03	13.16	0.76	2.65e-25	Intelligence (multi-trait analysis);
TGCT	trans	rs4332037	0.707	rs62435132	chr7:1891315	C/T	cg25206134	chr2:45395956	NA	0.96	8.1	0.59	4.34e-13	Bipolar disorder;
TGCT	cis	rs2806561	0.765	rs9426692	chr1:23508426	C/T	cg12483005	chr1:23474871	LUZP1	0.37	4.76	0.39	5.23e-6	Height;
TGCT	cis	rs7666738	0.830	rs7657490	chr4:99043973	C/T	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg21659725	chr3:3221576	CRBN	-0.65	-7.16	-0.54	6.39e-11	Body mass index;
TGCT	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg03517284	chr6:25882590	NA	-0.72	-6.6	-0.51	1.09e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7192750	0.538	rs11075911	chr16:71988505	T/C	cg06353428	chr16:71660113	MARVELD3	0.74	6.6	0.51	1.09e-9	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs9581857	0.556	rs9581864	chr13:28041567	T/C	cg22138327	chr13:27999177	GTF3A	0.73	5.7	0.46	8.09e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg27436995	chr16:743998	FBXL16	-0.46	-5.02	-0.41	1.75e-6	Height;
TGCT	cis	rs17125944	0.686	rs4450307	chr14:53334783	G/A	cg00686598	chr14:53173677	PSMC6	-0.86	-4.47	-0.37	1.75e-5	Alzheimer's disease (late onset);
TGCT	cis	rs10791097	0.694	rs1050071	chr11:130747231	C/G	cg05962950	chr11:130786565	SNX19	0.96	11.49	0.72	3.05e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs2224391	0.910	rs7752203	chr6:5260812	C/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.79	-6.05	-0.48	1.61e-8	Height;
TGCT	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg08280861	chr8:58055591	NA	0.38	4.81	0.4	4.36e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs739496	0.579	rs12302040	chr12:112288179	G/A	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs17712049	0.908	rs62447156	chr7:48201198	A/G	cg16849860	chr7:48352531	ABCA13	0.32	5.26	0.43	6.19e-7	Refractive astigmatism;
TGCT	cis	rs9948	0.529	rs2139406	chr2:97366779	A/G	cg01990225	chr2:97406019	LMAN2L	-0.93	-5.29	-0.43	5.38e-7	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs763121	0.853	rs9607566	chr22:39075434	C/G	cg06022373	chr22:39101656	GTPBP1	0.75	7.52	0.56	9.53e-12	Menopause (age at onset);
TGCT	cis	rs6671200	0.920	rs259350	chr1:95724831	G/C	cg03123541	chr1:95699097	RWDD3	-0.91	-6.4	-0.5	2.93e-9	Stearic acid (18:0) levels;
TGCT	cis	rs1887596	0.590	rs9581702	chr13:27131688	C/T	cg01312412	chr13:27282625	NA	0.27	4.76	0.39	5.33e-6	Facial morphology (factor 3, length of philtrum);
TGCT	trans	rs3780486	1.000	rs3780486	chr9:33139453	C/T	cg20290983	chr6:43655470	MRPS18A	1.1	10.62	0.69	3.92e-19	IgG glycosylation;
TGCT	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg13397359	chr6:42928475	GNMT	0.72	6.48	0.5	1.93e-9	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg26338869	chr17:61819248	STRADA	-0.55	-5.03	-0.41	1.65e-6	Prudent dietary pattern;
TGCT	cis	rs7917772	0.503	rs10748825	chr10:104293609	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs3096299	0.934	rs9927904	chr16:89462847	G/A	cg06640241	chr16:89574553	SPG7	0.61	5.76	0.46	6.36e-8	Multiple myeloma (IgH translocation);
TGCT	cis	rs3733585	0.605	rs4697710	chr4:10122649	T/C	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.45	-0.5	2.28e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7737716	0.500	rs17440213	chr5:118239756	A/G	cg21035905	chr5:118964330	FAM170A	0.39	4.56	0.38	1.23e-5	Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;
TGCT	cis	rs4711350	1.000	rs943472	chr6:33738442	T/C	cg00334056	chr6:33755658	LEMD2	-0.29	-4.63	-0.38	9.08e-6	Schizophrenia;
TGCT	cis	rs72720396	0.789	rs10922910	chr1:91199862	G/T	cg13456504	chr1:91191583	NA	0.63	5.43	0.44	2.84e-7	Morning vs. evening chronotype;Chronotype;
TGCT	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.73	-0.39	5.93e-6	Prudent dietary pattern;
TGCT	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg07343612	chr16:622815	PIGQ	-0.42	-8.45	-0.6	6.8e-14	Height;
TGCT	cis	rs425277	1.000	rs74877653	chr1:2065949	C/T	cg24578937	chr1:2090814	PRKCZ	0.33	7.85	0.58	1.71e-12	Height;
TGCT	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg06634786	chr22:41940651	POLR3H	-0.86	-8.34	-0.6	1.18e-13	Vitiligo;
TGCT	cis	rs6558174	0.965	rs2003908	chr8:22491518	T/C	cg03733263	chr8:22462867	KIAA1967	0.67	5.37	0.43	3.72e-7	Breast cancer;
TGCT	cis	rs2663905	0.706	rs2683260	chr15:81385552	A/C	cg09888468	chr15:81410853	NA	-0.73	-5.51	-0.44	1.96e-7	QT interval (drug interaction);
TGCT	cis	rs7119	0.717	rs12902852	chr15:77809016	C/G	cg27398640	chr15:77910606	LINGO1	-0.25	-4.52	-0.38	1.45e-5	Type 2 diabetes;
TGCT	cis	rs2075165	0.901	rs949464	chr1:156272271	C/T	cg20302342	chr1:156215951	PAQR6	0.36	5.38	0.44	3.56e-7	Tonsillectomy;
TGCT	cis	rs3847687	1.000	rs78233646	chr12:131520170	G/T	cg13586425	chr12:131519906	GPR133	-0.33	-5.26	-0.43	6.17e-7	Longevity;
TGCT	cis	rs12422267	0.536	rs11831679	chr12:132609960	C/T	cg09764611	chr12:132620959	NA	-0.37	-5.68	-0.45	9e-8	Plasma amyloid beta peptide concentrations (ABx-40);
TGCT	cis	rs4824093	0.610	rs12106611	chr22:50242686	G/A	cg20569369	chr22:51173646	NA	0.27	4.57	0.38	1.18e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs7727544	0.735	rs272894	chr5:131662460	C/T	cg24060327	chr5:131705240	SLC22A5	-0.56	-6.38	-0.5	3.2e-9	Blood metabolite levels;
TGCT	cis	rs10791323	0.569	rs2298738	chr11:133715153	G/C	cg03690763	chr11:133734501	NA	-0.33	-5.07	-0.41	1.44e-6	Childhood ear infection;
TGCT	cis	rs78487399	0.614	rs77389971	chr2:43718084	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.4	-4.52	-0.38	1.41e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs2652822	0.530	rs12595312	chr15:63494159	T/C	cg12855773	chr15:63363890	TPM1	-0.17	-4.84	-0.4	3.79e-6	Metabolic traits;
TGCT	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg18654377	chr3:49208889	KLHDC8B	-0.42	-5.42	-0.44	3e-7	Parkinson's disease;
TGCT	cis	rs4595586	0.545	rs12828001	chr12:39392208	G/A	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs10255878	0.500	rs73398341	chr7:97046433	G/A	cg01534613	chr7:96337050	SHFM1	0.31	4.7	0.39	6.9e-6	Adverse response to radiation therapy;
TGCT	cis	rs9811920	0.609	rs7638900	chr3:99670773	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.62	7.25	0.55	3.85e-11	Axial length;
TGCT	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg21724239	chr8:58056113	NA	0.33	4.54	0.38	1.31e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs12477438	0.684	rs6756880	chr2:99676991	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-4.88	-0.4	3.17e-6	Chronic sinus infection;
TGCT	cis	rs12908161	1.000	rs35630683	chr15:85349231	T/C	cg11189052	chr15:85197271	WDR73	0.71	5.87	0.47	3.68e-8	Schizophrenia;
TGCT	cis	rs1878931	0.501	rs9302871	chr16:3415512	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.76	7.12	0.54	7.59e-11	Body mass index (adult);
TGCT	cis	rs7103648	1.000	rs7947450	chr11:47429904	G/A	cg20307385	chr11:47447363	PSMC3	1.01	12.36	0.74	2.3e-23	Diastolic blood pressure;Systolic blood pressure;
TGCT	cis	rs56104184	0.779	rs4802513	chr19:49357656	T/A	cg21252483	chr19:49399788	TULP2	-0.36	-4.5	-0.37	1.53e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs6503863	1	rs6503863	chr17:56517034	G/A	cg05425664	chr17:57184151	TRIM37	-0.46	-4.45	-0.37	1.91e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs2468186	0.553	rs2465404	chr8:120090859	G/T	cg02248809	chr8:120845432	TAF2	-0.44	-4.71	-0.39	6.49e-6	Osteoprotegerin levels;
TGCT	cis	rs477895	1.000	rs1047206	chr11:64089216	C/G	cg04317338	chr11:64019027	PLCB3	0.71	5.65	0.45	1.05e-7	Mean platelet volume;
TGCT	cis	rs9467773	0.967	rs9358954	chr6:26531178	A/G	cg09904177	chr6:26538194	HMGN4	0.65	6.53	0.51	1.53e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs739496	0.579	rs73426314	chr12:112345056	T/C	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs703842	0.575	rs701006	chr12:58106836	C/T	cg15848620	chr12:58087721	OS9	0.57	4.75	0.39	5.46e-6	Multiple sclerosis;
TGCT	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg10802521	chr3:52805072	NEK4	-0.73	-9.02	-0.63	2.87e-15	Electroencephalogram traits;
TGCT	cis	rs1059312	0.500	rs10734964	chr12:129286486	C/T	cg09035930	chr12:129282057	SLC15A4	0.51	7.33	0.55	2.63e-11	Systemic lupus erythematosus;
TGCT	cis	rs7772486	0.597	rs7746618	chr6:146281367	T/C	cg23711669	chr6:146136114	FBXO30	-0.73	-6.87	-0.53	2.71e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs73198271	0.960	rs11776546	chr8:8609181	T/G	ch.8.214553F	chr8:8189620	PRAGMIN	-0.27	-4.62	-0.38	9.34e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.55	4.92	0.4	2.74e-6	Prudent dietary pattern;
TGCT	cis	rs7772486	0.701	rs2244308	chr6:146213706	C/T	cg05347473	chr6:146136440	FBXO30	0.5	4.9	0.4	2.96e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1971762	0.527	rs7976398	chr12:54028862	T/C	cg16917193	chr12:54089295	NA	1.06	11.82	0.73	4.57e-22	Height;
TGCT	cis	rs789852	1.000	rs789852	chr3:194327098	T/C	cg18000598	chr3:194342907	TMEM44	-0.81	-5.19	-0.42	8.35e-7	QT interval;
TGCT	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg03264133	chr6:25882463	NA	-0.62	-5.5	-0.44	2.07e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7017914	0.967	rs7842851	chr8:71663805	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.49	-4.55	-0.38	1.28e-5	Bone mineral density;
TGCT	cis	rs910316	0.935	rs175448	chr14:75591071	G/A	cg23033748	chr14:75592666	NEK9	-0.28	-4.84	-0.4	3.71e-6	Height;
TGCT	cis	rs12615966	1.000	rs9941641	chr2:105384179	A/G	cg16465502	chr2:105461796	NA	0.78	5.03	0.41	1.66e-6	Pancreatic cancer;
TGCT	cis	rs1580019	0.961	rs4357201	chr7:32496333	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.79	7.42	0.55	1.63e-11	Cognitive ability;
TGCT	cis	rs12497850	0.864	rs4955410	chr3:49181218	A/G	cg06212747	chr3:49208901	KLHDC8B	0.61	5.55	0.45	1.66e-7	Parkinson's disease;
TGCT	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg01577475	chr2:114033581	PAX8;LOC440839	0.46	4.97	0.41	2.16e-6	Lymphocyte counts;
TGCT	cis	rs1670533	1.000	rs3816474	chr4:1050653	G/A	cg19318889	chr4:1322082	MAEA	0.22	4.57	0.38	1.16e-5	Recombination rate (females);
TGCT	cis	rs2153535	0.580	rs6421948	chr6:8531020	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.55e-8	Motion sickness;
TGCT	cis	rs6088580	0.609	rs2378205	chr20:33110803	C/G	cg06115741	chr20:33292138	TP53INP2	0.54	4.63	0.38	9.06e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs9921192	0.967	rs251737	chr16:4318305	C/T	cg00021532	chr16:4324280	TFAP4	0.84	9.87	0.66	2.57e-17	Prostate-specific antigen levels;
TGCT	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg04772025	chr11:68637568	NA	0.6	6.78	0.52	4.32e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7552404	0.727	rs12093623	chr1:76256232	T/G	cg03433033	chr1:76189801	ACADM	0.65	6.6	0.51	1.06e-9	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg23708337	chr7:1209742	NA	0.51	4.46	0.37	1.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs137699	0.687	rs4821887	chr22:39756985	C/T	cg11247378	chr22:39784982	NA	-0.61	-6.73	-0.52	5.53e-10	IgG glycosylation;
TGCT	cis	rs7552404	0.731	rs1770887	chr1:76401812	A/G	cg22875332	chr1:76189707	ACADM	-0.67	-6.77	-0.52	4.54e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs4851254	0.961	rs11692215	chr2:100746573	C/T	cg23118464	chr2:100721844	AFF3	0.69	5.03	0.41	1.64e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4820539	0.932	rs3788349	chr22:23467950	A/G	cg14186256	chr22:23484241	RTDR1	0.98	11.82	0.73	4.6e-22	Bone mineral density;
TGCT	cis	rs986417	0.818	rs10139251	chr14:60959958	A/C	cg27398547	chr14:60952738	C14orf39	1.39	10.61	0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs71597109	0.681	rs4699261	chr4:102725474	A/G	cg14855874	chr4:102712397	BANK1	-0.4	-4.74	-0.39	5.64e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs6484504	0.576	rs441975	chr11:31233351	C/T	cg14844989	chr11:31128820	NA	-0.23	-4.51	-0.38	1.47e-5	Red blood cell count;
TGCT	cis	rs12579753	0.810	rs1343934	chr12:82123112	G/A	cg21231944	chr12:82153410	PPFIA2	-0.35	-4.64	-0.38	8.74e-6	Resting heart rate;
TGCT	cis	rs12575480	0.637	rs73398080	chr11:2094599	G/A	cg15541987	chr11:2077307	NA	-0.37	-4.47	-0.37	1.71e-5	Pursuit maintenance gain;
TGCT	trans	rs4824093	0.610	rs7410534	chr22:50289925	C/T	cg09872104	chr7:134855509	C7orf49	-1.02	-8.52	-0.61	4.42e-14	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs9902453	0.845	rs3102558	chr17:28023142	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	7.27	0.55	3.55e-11	Coffee consumption (cups per day);
TGCT	cis	rs9357506	1.000	rs4711849	chr6:46305739	C/T	cg21115430	chr6:46460003	NA	0.23	4.67	0.39	7.56e-6	Body mass index;
TGCT	cis	rs3818285	0.610	rs642938	chr10:111633025	A/C	cg00817464	chr10:111662876	XPNPEP1	0.32	5.57	0.45	1.51e-7	Superior crus of antihelix expression;
TGCT	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg04156016	chr5:1868137	NA	0.33	4.63	0.38	9.04e-6	Cardiovascular disease risk factors;
TGCT	cis	rs9436747	0.714	rs1751492	chr1:65992625	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	-0.49	-4.53	-0.38	1.37e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg26818010	chr10:134567672	INPP5A	-0.35	-4.45	-0.37	1.86e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs9916302	0.706	rs439537	chr17:37734482	T/C	cg07936489	chr17:37558343	FBXL20	-0.84	-6.16	-0.48	9.13e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs3749237	0.615	rs6792911	chr3:49429856	C/T	cg03060546	chr3:49711283	APEH	0.75	8.68	0.61	1.86e-14	Resting heart rate;
TGCT	cis	rs7666738	0.606	rs3846447	chr4:99099907	G/A	cg05340658	chr4:99064831	C4orf37	0.43	4.62	0.38	9.29e-6	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs8073060	0.544	rs2626626	chr17:34026717	A/G	cg19694781	chr19:47549865	TMEM160	-0.6	-13.37	-0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs1887596	0.672	rs4297560	chr13:27264991	A/T	cg01312412	chr13:27282625	NA	0.3	5.36	0.43	3.97e-7	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs8077889	0.703	rs231532	chr17:41945769	C/T	cg26893861	chr17:41843967	DUSP3	-1.07	-10.07	-0.67	8.39e-18	Triglycerides;
TGCT	cis	rs7027203	0.576	rs11790754	chr9:96535709	T/G	cg13679303	chr9:96623674	NA	0.52	7.49	0.56	1.11e-11	DNA methylation (variation);
TGCT	cis	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg25427524	chr10:38739819	LOC399744	-0.41	-8.54	-0.61	4.04e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2346177	0.967	rs4953374	chr2:46654401	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.46	-5.18	-0.42	8.67e-7	HDL cholesterol;
TGCT	cis	rs7666738	0.830	rs10007872	chr4:99001904	T/C	cg18180107	chr4:99064573	C4orf37	0.51	4.68	0.39	7.37e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2361718	0.500	rs12451697	chr17:78100690	T/A	cg09238746	chr17:78121135	EIF4A3	-0.91	-8.85	-0.62	7.48e-15	Yeast infection;
TGCT	cis	rs259282	0.628	rs35946544	chr19:33109983	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.6	5.4	0.44	3.31e-7	Schizophrenia;
TGCT	cis	rs7918232	0.782	rs7910168	chr10:27465296	G/A	cg14442939	chr10:27389572	ANKRD26	0.82	5.74	0.46	6.98e-8	Breast cancer;
TGCT	cis	rs9733	0.565	rs7524620	chr1:150616699	C/T	cg09365446	chr1:150670422	GOLPH3L	-0.3	-4.46	-0.37	1.82e-5	Tonsillectomy;
TGCT	cis	rs3008870	1.000	rs12137403	chr1:67437043	C/T	cg03991309	chr1:68237761	GNG12	-0.27	-4.66	-0.39	8.08e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs11085466	1.000	rs4399664	chr19:21778026	C/T	cg01048962	chr19:21646470	NA	-0.59	-4.61	-0.38	9.72e-6	Colorectal or endometrial cancer;
TGCT	cis	rs4851254	0.660	rs17023468	chr2:100694091	A/G	cg07810366	chr2:100720526	AFF3	-0.44	-4.63	-0.38	9.06e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs8013055	0.846	rs12893999	chr14:105970842	C/G	cg23356831	chr14:105996513	TMEM121	0.41	6.39	0.5	3.04e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs1153858	1.000	rs16952714	chr15:45650358	G/A	cg26924012	chr15:45694286	SPATA5L1	1.09	15.16	0.81	5.15e-30	Homoarginine levels;
TGCT	cis	rs7091068	0.518	rs1409337	chr10:95439822	T/C	cg20715218	chr10:95462985	C10orf4	0.52	5.46	0.44	2.46e-7	Urinary tract infection frequency;
TGCT	cis	rs7010267	0.740	rs1905786	chr8:119951692	T/C	cg17171407	chr8:119960777	TNFRSF11B	0.25	4.44	0.37	2e-5	Total body bone mineral density (age 45-60);
TGCT	cis	rs6750047	0.573	rs162328	chr2:38318688	G/A	cg07380506	chr2:38303506	CYP1B1	0.59	5.47	0.44	2.37e-7	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs1670533	1.000	rs10902752	chr4:1056199	C/T	cg20887711	chr4:1340912	KIAA1530	0.71	5.7	0.46	8.33e-8	Recombination rate (females);
TGCT	cis	rs9926296	0.656	rs4522419	chr16:89853307	T/C	cg03388025	chr16:89894329	SPIRE2	0.35	5.2	0.42	7.97e-7	Vitiligo;
TGCT	cis	rs7178424	0.616	rs1346036	chr15:62137876	G/C	cg00456672	chr15:62358751	C2CD4A	-0.31	-4.67	-0.39	7.7e-6	Height;
TGCT	cis	rs4803468	0.967	rs3745290	chr19:41890003	C/T	cg09537434	chr19:41945824	ATP5SL	-0.9	-10.06	-0.67	9.09e-18	Height;
TGCT	cis	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg13531842	chr10:38383804	ZNF37A	-0.4	-4.63	-0.38	8.93e-6	Extrinsic epigenetic age acceleration;
TGCT	cis	rs9814567	0.712	rs9838889	chr3:134332311	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-6.41	-0.5	2.8e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg14983838	chr19:29218262	NA	0.83	6.85	0.52	3.07e-10	Methadone dose in opioid dependence;
TGCT	cis	rs6088580	0.634	rs6058073	chr20:33116483	T/C	cg08999081	chr20:33150536	PIGU	0.29	5.57	0.45	1.54e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs739496	0.527	rs11066079	chr12:112350403	G/T	cg10833066	chr12:111807467	FAM109A	0.36	5.41	0.44	3.18e-7	Platelet count;
TGCT	cis	rs904251	0.523	rs1776455	chr6:37482923	A/T	cg25019722	chr6:37503610	NA	-0.49	-7.47	-0.56	1.28e-11	Cognitive performance;
TGCT	cis	rs7681440	0.647	rs6824979	chr4:90819407	C/G	cg20003494	chr4:90757398	SNCA	0.53	4.73	0.39	6.11e-6	Dementia with Lewy bodies;
TGCT	cis	rs9660992	0.710	rs1668867	chr1:205240251	C/T	cg00857998	chr1:205179979	DSTYK	0.52	4.56	0.38	1.19e-5	Mean corpuscular volume;Mean platelet volume;
TGCT	cis	rs3733585	0.699	rs6449179	chr4:9969117	G/A	cg00071950	chr4:10020882	SLC2A9	-0.57	-6.83	-0.52	3.47e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs79387448	0.935	rs7567133	chr2:103253128	C/A	cg09003973	chr2:102972529	NA	0.9	5.42	0.44	2.98e-7	Gut microbiota (bacterial taxa);
TGCT	cis	rs9916302	0.555	rs12940193	chr17:37652178	T/G	cg15445000	chr17:37608096	MED1	0.31	4.59	0.38	1.06e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs4466137	0.909	rs4466136	chr5:82985576	T/G	cg16102102	chr5:83017553	HAPLN1	-0.95	-11.71	-0.72	8.78e-22	Prostate cancer;
TGCT	cis	rs6087990	0.806	rs992472	chr20:31385269	G/T	cg13636640	chr20:31349939	DNMT3B	1.1	15.62	0.81	4.5e-31	Ulcerative colitis;
TGCT	cis	rs4938534	0.559	rs1944919	chr11:111259876	A/C	cg18316498	chr11:111250196	POU2AF1	0.28	4.86	0.4	3.53e-6	Primary biliary cholangitis;
TGCT	cis	rs826838	1.000	rs1684416	chr12:39130301	G/A	cg13010199	chr12:38710504	ALG10B	-0.63	-5.06	-0.41	1.46e-6	Heart rate;
TGCT	cis	rs3849570	0.961	rs3821548	chr3:81758728	C/G	cg07356753	chr3:81810745	GBE1	-0.84	-8.06	-0.59	5.54e-13	Waist circumference;Body mass index;
TGCT	cis	rs3617	0.625	rs2239548	chr3:52854186	A/C	cg10802521	chr3:52805072	NEK4	-0.6	-6.89	-0.53	2.46e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4727027	0.901	rs1534197	chr7:148771970	T/C	cg23583168	chr7:148888333	NA	-0.69	-8.67	-0.61	2.04e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs9467711	0.606	rs9358932	chr6:26362705	A/G	cg10795676	chr6:26370623	BTN3A2	0.45	4.71	0.39	6.5e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2404602	1.000	rs12594212	chr15:76802014	T/A	cg22467129	chr15:76604101	ETFA	-0.51	-5.89	-0.47	3.45e-8	Blood metabolite levels;
TGCT	trans	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg21659725	chr3:3221576	CRBN	0.76	9.02	0.63	2.92e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs950776	0.518	rs3813571	chr15:78832792	G/T	cg06917634	chr15:78832804	PSMA4	0.96	9.72	0.66	6.01e-17	Sudden cardiac arrest;
TGCT	cis	rs17376456	0.542	rs10476588	chr5:93208330	C/T	cg25358565	chr5:93447407	FAM172A	-0.81	-6.54	-0.51	1.47e-9	Diabetic retinopathy;
TGCT	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg14784868	chr12:69753453	YEATS4	0.9	10.55	0.69	5.67e-19	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs751728	0.597	rs767895	chr6:33791463	C/G	cg13859433	chr6:33739653	LEMD2	-0.35	-5.78	-0.46	5.75e-8	Crohn's disease;
TGCT	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.68	5.62	0.45	1.18e-7	Tonsillectomy;
TGCT	cis	rs4891159	0.548	rs10782013	chr18:74128348	C/T	cg24786174	chr18:74118243	ZNF516	0.67	13.58	0.77	2.65e-26	Longevity;
TGCT	cis	rs11718455	0.960	rs35711021	chr3:44004791	G/A	cg08738300	chr3:44038990	NA	0.85	6.34	0.49	3.94e-9	Coronary artery disease;
TGCT	cis	rs6733011	0.508	rs6542843	chr2:99533729	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.55	-5.28	-0.43	5.71e-7	Bipolar disorder;
TGCT	cis	rs3617	0.573	rs9880978	chr3:52923251	C/G	cg07507251	chr3:52567010	NT5DC2	0.34	4.5	0.37	1.54e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1163251	0.623	rs493427	chr1:120207482	A/T	cg19096424	chr1:120255104	PHGDH	-0.58	-5.79	-0.46	5.48e-8	Blood metabolite levels;
TGCT	cis	rs894734	0.535	rs7301643	chr12:54325796	G/T	cg17708016	chr12:54321992	NA	0.77	6.43	0.5	2.54e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
TGCT	cis	rs10089	0.904	rs3087889	chr5:127524944	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.79	7.5	0.56	1.05e-11	Ileal carcinoids;
TGCT	cis	rs6095298	0.595	rs720727	chr20:47447960	C/T	cg12307787	chr20:48099359	KCNB1	0.44	4.67	0.39	7.75e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs8017423	0.967	rs11627528	chr14:90719697	C/A	cg04374321	chr14:90722782	PSMC1	-0.75	-7.4	-0.55	1.79e-11	Mortality in heart failure;
TGCT	cis	rs2455799	0.613	rs4684261	chr3:15796505	G/A	cg16303742	chr3:15540471	COLQ	-0.25	-4.88	-0.4	3.18e-6	Mean platelet volume;
TGCT	cis	rs10484885	0.887	rs17764308	chr6:90602268	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.43	-4.46	-0.37	1.8e-5	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs9905704	0.647	rs33922512	chr17:57114148	C/G	cg12560992	chr17:57184187	TRIM37	-0.62	-5.52	-0.44	1.9e-7	Testicular germ cell tumor;
TGCT	cis	rs17030434	1.000	rs12646758	chr4:154731625	A/G	cg14289246	chr4:154710475	SFRP2	-0.89	-6.94	-0.53	1.97e-10	Electrocardiographic conduction measures;
TGCT	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.97	10.6	0.69	4.33e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs55883249	0.957	rs17453675	chr2:9754407	A/G	cg23886495	chr2:9695866	ADAM17	0.79	4.66	0.39	8.09e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs7927592	0.763	rs596494	chr11:68251054	T/G	cg16797656	chr11:68205561	LRP5	0.26	4.46	0.37	1.79e-5	Total body bone mineral density;
TGCT	cis	rs7267979	0.932	rs372678	chr20:25465248	G/A	cg16686733	chr20:25566563	NINL	0.56	5.69	0.46	8.49e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7714584	1.000	rs59321715	chr5:150313480	C/A	cg22134413	chr5:150180641	NA	1.13	7.97	0.58	8.75e-13	Crohn's disease;
TGCT	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg22433210	chr17:43662623	NA	-0.86	-7.23	-0.54	4.29e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs12548874	0.607	rs12543492	chr8:95891843	C/A	cg13393036	chr8:95962371	TP53INP1	-0.51	-6.24	-0.49	6.48e-9	Hemoglobin concentration;
TGCT	cis	rs422249	0.512	rs99780	chr11:61596633	C/T	cg20584555	chr11:61717780	BEST1	-0.23	-4.49	-0.37	1.6e-5	Trans fatty acid levels;
TGCT	cis	rs2295359	1.000	rs11209006	chr1:67619259	T/G	cg03340356	chr1:67600835	NA	0.36	4.55	0.38	1.24e-5	Psoriasis;
TGCT	cis	rs6500602	0.702	rs4786493	chr16:4500122	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.28	5.23	0.43	6.91e-7	Schizophrenia;
TGCT	cis	rs13256369	0.760	rs7839473	chr8:8575836	C/T	cg06671706	chr8:8559999	CLDN23	0.35	4.62	0.38	9.35e-6	Obesity-related traits;
TGCT	trans	rs7824557	0.527	rs57629785	chr8:11235150	C/A	cg15556689	chr8:8085844	FLJ10661	-0.74	-6.7	-0.52	6.42e-10	Retinal vascular caliber;
TGCT	cis	rs992157	0.835	rs13031757	chr2:219151926	T/C	cg00012203	chr2:219082015	ARPC2	-0.8	-7.98	-0.58	8.26e-13	Colorectal cancer;
TGCT	cis	rs4888262	0.508	rs4887779	chr16:74647795	A/G	cg01733217	chr16:74700730	RFWD3	-0.74	-7.46	-0.56	1.28e-11	Testicular germ cell tumor;
TGCT	cis	rs4746822	0.539	rs10998646	chr10:70976702	G/T	cg14418922	chr10:70824840	NA	-0.27	-4.58	-0.38	1.1e-5	Glycemic traits (pregnancy);
TGCT	cis	rs7666738	0.830	rs35685312	chr4:98858521	G/A	cg17366294	chr4:99064904	C4orf37	0.7	7.27	0.55	3.62e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7312933	0.645	rs11181404	chr12:42683840	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.57	5.27	0.43	5.87e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg13395646	chr4:1353034	KIAA1530	0.4	4.98	0.41	2.1e-6	Obesity-related traits;
TGCT	cis	rs9303401	0.659	rs7224276	chr17:56897827	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs9291683	0.588	rs35866697	chr4:10018604	C/A	cg00071950	chr4:10020882	SLC2A9	0.75	10.2	0.68	4.17e-18	Bone mineral density;
TGCT	cis	rs7607369	0.580	rs17573724	chr2:219652141	T/A	cg02176678	chr2:219576539	TTLL4	-0.45	-5.86	-0.47	3.89e-8	Red blood cell count;Amyotrophic lateral sclerosis;
TGCT	cis	rs4455778	0.665	rs7804817	chr7:49071509	C/T	cg26309511	chr7:48887640	NA	0.47	5.33	0.43	4.56e-7	Lung cancer in never smokers;
TGCT	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg13695892	chr22:41940480	POLR3H	-0.91	-9.07	-0.63	2.18e-15	Vitiligo;
TGCT	cis	rs3096299	0.967	rs2911255	chr16:89487137	C/T	cg02187348	chr16:89574699	SPG7	0.47	4.56	0.38	1.2e-5	Multiple myeloma (IgH translocation);
TGCT	cis	rs2282802	0.685	rs6580515	chr5:139698110	A/C	cg01081189	chr5:139537190	NA	-0.27	-4.9	-0.4	2.87e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6121246	0.609	rs6060948	chr20:30376393	C/G	cg13852791	chr20:30311386	BCL2L1	0.83	8.16	0.59	3.22e-13	Mean corpuscular hemoglobin;
TGCT	trans	rs877282	0.945	rs71489301	chr10:770191	A/G	cg22713356	chr15:30763199	NA	1.26	10.48	0.69	8.73e-19	Uric acid levels;
TGCT	cis	rs77972916	0.536	rs7562101	chr2:43592756	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.38	-6.02	-0.48	1.8e-8	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg16049864	chr8:95962084	TP53INP1	-0.75	-10.57	-0.69	5.23e-19	Type 2 diabetes;
TGCT	cis	rs151997	0.925	rs27270	chr5:50183712	A/G	cg06027927	chr5:50259733	NA	-0.45	-4.63	-0.38	9.02e-6	Callous-unemotional behaviour;
TGCT	cis	rs4851266	1.000	rs13013169	chr2:100814087	A/C	cg22139774	chr2:100720529	AFF3	-0.38	-5.53	-0.44	1.81e-7	Educational attainment;
TGCT	cis	rs12682352	0.579	rs7006589	chr8:8668486	A/G	cg08975724	chr8:8085496	FLJ10661	0.53	4.74	0.39	5.87e-6	Neuroticism;
TGCT	cis	rs56104184	0.725	rs4347731	chr19:49385154	A/G	cg17863274	chr19:49399704	TULP2	-0.54	-7.2	-0.54	5.19e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs9902453	0.967	rs1042173	chr17:28525011	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	6.39	0.5	3.03e-9	Coffee consumption (cups per day);
TGCT	cis	rs7666738	0.861	rs5010991	chr4:98972179	A/G	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4699052	0.963	rs6849319	chr4:104192742	G/C	cg16532752	chr4:104119610	CENPE	-0.55	-4.97	-0.41	2.19e-6	Testicular germ cell tumor;
TGCT	cis	rs7226408	0.857	rs11081988	chr18:34697833	T/A	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs6570726	0.577	rs399502	chr6:145805874	A/G	cg13319975	chr6:146136371	FBXO30	-0.64	-5.69	-0.46	8.55e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7572733	0.555	rs2341778	chr2:198776546	G/A	cg00792783	chr2:198669748	PLCL1	-0.56	-5.11	-0.42	1.21e-6	Dermatomyositis;
TGCT	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg13397359	chr6:42928475	GNMT	-0.72	-6.48	-0.5	1.93e-9	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs12048904	0.964	rs12027668	chr1:101330984	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.48	4.62	0.38	9.44e-6	Multiple sclerosis;
TGCT	cis	rs7044106	0.791	rs10984998	chr9:123481516	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	7.05	0.53	1.11e-10	Hip circumference adjusted for BMI;
TGCT	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg01171360	chr6:293285	DUSP22	-0.78	-7.87	-0.58	1.47e-12	Menopause (age at onset);
TGCT	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg18538332	chr22:24372958	LOC391322	-1.02	-13.18	-0.76	2.42e-25	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7412746	0.611	rs2280627	chr1:150935872	A/G	cg04414720	chr1:150670196	GOLPH3L	0.38	4.5	0.37	1.52e-5	Melanoma;
TGCT	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg27170947	chr2:26402098	FAM59B	-0.39	-4.46	-0.37	1.8e-5	Gut microbiome composition (summer);
TGCT	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg22166914	chr1:53195759	ZYG11B	-0.4	-6.94	-0.53	1.89e-10	Monocyte count;
TGCT	cis	rs6750795	0.569	rs1667308	chr2:232406344	T/C	cg19187155	chr2:232395269	NMUR1	0.41	4.68	0.39	7.29e-6	Height;
TGCT	cis	rs752010	0.808	rs7529858	chr1:42086606	G/C	cg06885757	chr1:42089581	HIVEP3	0.25	4.56	0.38	1.23e-5	Lupus nephritis in systemic lupus erythematosus;
TGCT	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.46	0.56	1.3e-11	Prudent dietary pattern;
TGCT	cis	rs9916302	0.904	rs7503705	chr17:37669704	A/G	cg07936489	chr17:37558343	FBXL20	-0.62	-4.88	-0.4	3.2e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs2456568	0.771	rs8181530	chr11:93638678	G/A	cg26875233	chr11:93583750	C11orf90	-0.48	-6.47	-0.5	2.09e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs3008870	0.917	rs12044492	chr1:67461667	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-1.1	-11.8	-0.73	5.15e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs6912958	0.754	rs4587143	chr6:88292291	A/G	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.91	-0.4	2.78e-6	Monocyte percentage of white cells;
TGCT	trans	rs7819412	0.806	rs10113808	chr8:10926892	C/A	cg06636001	chr8:8085503	FLJ10661	-0.73	-6.72	-0.52	5.88e-10	Triglycerides;
TGCT	cis	rs35883536	0.588	rs114540631	chr1:101101249	A/G	cg06223162	chr1:101003688	GPR88	0.33	5.4	0.44	3.28e-7	Monocyte count;
TGCT	cis	rs514406	0.621	rs2003250	chr1:53196666	T/C	cg25767906	chr1:53392781	SCP2	0.44	4.79	0.4	4.68e-6	Monocyte count;
TGCT	cis	rs514406	0.607	rs1930305	chr1:53195481	G/T	cg25767906	chr1:53392781	SCP2	0.44	4.79	0.4	4.68e-6	Monocyte count;
TGCT	cis	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg09021430	chr5:549028	NA	-0.37	-5.35	-0.43	4.16e-7	Lung disease severity in cystic fibrosis;
TGCT	cis	rs9733	0.596	rs12072339	chr1:150686099	A/G	cg09365446	chr1:150670422	GOLPH3L	0.3	4.52	0.38	1.4e-5	Tonsillectomy;
TGCT	cis	rs11247915	0.600	rs61775118	chr1:26659692	C/T	cg25392287	chr1:26333318	NA	0.22	4.69	0.39	7.01e-6	Obesity-related traits;
TGCT	cis	rs7086627	0.515	rs10887899	chr10:82210214	G/A	cg00277334	chr10:82204260	NA	-0.54	-8.46	-0.6	6.41e-14	Post bronchodilator FEV1;
TGCT	cis	rs3125734	0.633	rs6479792	chr10:63983264	T/G	cg19640130	chr10:64028056	RTKN2	-0.39	-5.11	-0.42	1.19e-6	Rheumatoid arthritis;
TGCT	cis	rs11642862	1.000	rs113454775	chr16:30809534	A/G	cg02466173	chr16:30829666	NA	-0.39	-4.64	-0.38	8.67e-6	Tonsillectomy;
TGCT	cis	rs904251	0.523	rs2797796	chr6:37480886	T/C	cg08126542	chr6:37504118	NA	-0.44	-6.51	-0.5	1.71e-9	Cognitive performance;
TGCT	cis	rs13242816	1.000	rs17138714	chr7:116114274	C/T	cg16553024	chr7:116138462	CAV2	-0.44	-5.05	-0.41	1.54e-6	P wave duration;
TGCT	cis	rs2404602	0.692	rs3816266	chr15:76993835	T/G	cg22467129	chr15:76604101	ETFA	-0.45	-5.11	-0.42	1.2e-6	Blood metabolite levels;
TGCT	cis	rs7336332	0.598	rs74183666	chr13:28007765	A/T	cg22138327	chr13:27999177	GTF3A	0.83	6.51	0.5	1.67e-9	Weight;
TGCT	cis	rs6912958	0.967	rs6914299	chr6:88149176	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.37	-4.74	-0.39	5.79e-6	Monocyte percentage of white cells;
TGCT	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg27535305	chr1:53392650	SCP2	-0.24	-4.73	-0.39	5.98e-6	Monocyte count;
TGCT	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg11965913	chr1:205819406	PM20D1	0.51	7.19	0.54	5.34e-11	Menarche (age at onset);
TGCT	cis	rs7809950	0.954	rs2712193	chr7:107125885	A/C	cg23024343	chr7:107201750	COG5	-0.34	-5.45	-0.44	2.58e-7	Coronary artery disease;
TGCT	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg08280861	chr8:58055591	NA	0.52	5.97	0.47	2.35e-8	Developmental language disorder (linguistic errors);
TGCT	cis	rs2075371	0.796	rs35440439	chr7:134006094	C/T	cg11752832	chr7:134001865	SLC35B4	0.72	6.55	0.51	1.35e-9	Mean platelet volume;
TGCT	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg03303774	chr4:1407052	NA	0.3	4.74	0.39	5.79e-6	Obesity-related traits;
TGCT	cis	rs1670533	0.818	rs6835141	chr4:1070140	G/T	cg27284194	chr4:1044797	NA	0.7	6.11	0.48	1.17e-8	Recombination rate (females);
TGCT	cis	rs7296418	0.675	rs1879379	chr12:123727443	G/A	cg00376283	chr12:123451042	ABCB9	0.73	6.5	0.5	1.75e-9	Platelet count;
TGCT	cis	rs2468186	0.524	rs2450064	chr8:120097144	A/G	cg02248809	chr8:120845432	TAF2	-0.45	-4.83	-0.4	3.99e-6	Osteoprotegerin levels;
TGCT	cis	rs4595586	0.505	rs76485055	chr12:39358294	A/G	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs6988636	1.000	rs7002021	chr8:124185250	G/A	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs7772486	0.727	rs2235481	chr6:146056848	T/C	cg23711669	chr6:146136114	FBXO30	-0.73	-6.61	-0.51	1.04e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4148883	0.675	rs116265877	chr4:100096896	G/A	cg12011299	chr4:100065546	ADH4	0.39	5.85	0.47	4.03e-8	Alcohol dependence;
TGCT	cis	rs2688608	0.592	rs7909544	chr10:75484004	G/C	cg15838173	chr10:75533400	FUT11	-0.31	-5.02	-0.41	1.73e-6	Inflammatory bowel disease;
TGCT	cis	rs8077889	0.917	rs1859048	chr17:41892039	A/C	cg26893861	chr17:41843967	DUSP3	-1.1	-13.53	-0.77	3.52e-26	Triglycerides;
TGCT	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg27121462	chr16:89883253	FANCA	-0.73	-7.85	-0.58	1.63e-12	Vitiligo;
TGCT	cis	rs2997447	0.706	rs17184898	chr1:26447870	A/T	cg03844060	chr1:26490628	NA	0.28	4.56	0.38	1.19e-5	QRS complex (12-leadsum);
TGCT	cis	rs7945705	0.902	rs10769979	chr11:9010659	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.46	5.15	0.42	9.85e-7	Hemoglobin concentration;
TGCT	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg27170947	chr2:26402098	FAM59B	-0.4	-4.63	-0.38	8.93e-6	Gut microbiome composition (summer);
TGCT	trans	rs797680	0.856	rs2031225	chr1:93786714	A/G	cg27528825	chr2:159282178	CCDC148	0.33	6.67	0.51	7.68e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs8017423	1.000	rs769044	chr14:90671138	A/G	cg04374321	chr14:90722782	PSMC1	0.74	7.7	0.57	3.71e-12	Mortality in heart failure;
TGCT	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg11644478	chr21:40555479	PSMG1	0.98	10.31	0.68	2.21e-18	Cognitive function;
TGCT	trans	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg17830980	chr10:43048298	ZNF37B	-0.86	-11.18	-0.71	1.68e-20	Extrinsic epigenetic age acceleration;
TGCT	trans	rs2688608	0.592	rs10762560	chr10:75495405	T/G	cg13918328	chr10:52500089	ASAH2B	0.68	6.7	0.52	6.48e-10	Inflammatory bowel disease;
TGCT	cis	rs116161686	0.500	rs55871867	chr1:210051029	A/G	cg23283495	chr1:209979779	IRF6	0.61	4.81	0.4	4.3e-6	Coronary artery disease;
TGCT	cis	rs2380220	0.678	rs4308568	chr6:96009525	A/C	cg04719120	chr6:96025338	MANEA	-0.7	-5.35	-0.43	4.16e-7	Behavioural disinhibition (generation interaction);
TGCT	cis	rs9393777	0.513	rs9393739	chr6:26646966	T/G	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.53	-4.88	-0.4	3.19e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs861020	1.000	rs861020	chr1:209977111	A/G	cg05527609	chr1:210001259	C1orf107	0.89	7.18	0.54	5.65e-11	Orofacial clefts;
TGCT	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg12751644	chr20:60527061	NA	0.49	6.32	0.49	4.26e-9	Obesity-related traits;
TGCT	cis	rs4808199	0.948	rs2074301	chr19:19381715	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.69	5.22	0.42	7.2e-7	Nonalcoholic fatty liver disease;
TGCT	cis	rs71636778	0.509	rs17162387	chr1:27293356	T/G	cg23921621	chr1:27994728	IFI6	-0.43	-4.61	-0.38	9.92e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
TGCT	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.93	7.44	0.56	1.44e-11	Platelet count;
TGCT	trans	rs1814175	0.781	rs2866734	chr11:49886338	A/G	cg15704280	chr7:45808275	SEPT13	-0.72	-8.14	-0.59	3.61e-13	Height;
TGCT	cis	rs9814567	0.806	rs9841371	chr3:134320765	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.76	-7.11	-0.54	8.15e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs12188164	0.930	rs72717440	chr5:449701	A/T	cg26850624	chr5:429559	AHRR	-0.2	-4.84	-0.4	3.78e-6	Cystic fibrosis severity;
TGCT	cis	rs9560113	0.960	rs9560101	chr13:112173798	G/A	cg14154082	chr13:112174009	NA	0.34	4.67	0.39	7.79e-6	Menarche (age at onset);
TGCT	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg01577475	chr2:114033581	PAX8;LOC440839	-0.45	-4.93	-0.41	2.54e-6	Lymphocyte counts;
TGCT	cis	rs12216125	0.801	rs56107510	chr6:25987436	C/A	cg17042849	chr6:26104293	HIST1H4C	-0.74	-6.55	-0.51	1.41e-9	Iron status biomarkers;
TGCT	cis	rs9807989	0.507	rs7584093	chr2:102997721	C/T	cg03938978	chr2:103052716	IL18RAP	0.26	5.22	0.42	7.15e-7	Asthma;
TGCT	cis	rs67311347	1.000	rs12630072	chr3:40517190	T/G	cg17264618	chr3:40429014	ENTPD3	0.32	4.45	0.37	1.88e-5	Renal cell carcinoma;
TGCT	cis	rs9659323	1.000	rs56897173	chr1:119515732	G/A	cg07961512	chr1:119535619	NA	0.44	5.07	0.41	1.4e-6	Body mass index;
TGCT	trans	rs9388451	0.559	rs1777210	chr6:126098916	T/G	cg05039488	chr6:79577232	IRAK1BP1	-0.79	-9.13	-0.63	1.57e-15	Brugada syndrome;
TGCT	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg22920501	chr2:26401640	FAM59B	-0.71	-6.23	-0.49	6.65e-9	Gut microbiome composition (summer);
TGCT	cis	rs2201841	0.960	rs114173254	chr1:67709650	G/A	cg25131922	chr1:68698529	GPR177	0.46	4.95	0.41	2.34e-6	Ulcerative colitis;Psoriasis;Crohn's disease;
TGCT	cis	rs7267979	0.933	rs2258728	chr20:25276343	G/A	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg10802521	chr3:52805072	NEK4	-0.71	-8.81	-0.62	9.29e-15	Bipolar disorder;
TGCT	cis	rs2932538	0.885	rs6661642	chr1:113090109	T/C	cg22162597	chr1:113214053	CAPZA1	0.27	5.89	0.47	3.46e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg13695892	chr22:41940480	POLR3H	0.79	7.83	0.58	1.85e-12	Vitiligo;
TGCT	cis	rs25422	0.887	rs9320666	chr6:118989181	C/T	cg21191810	chr6:118973309	C6orf204	-0.34	-4.65	-0.39	8.45e-6	Renal cell carcinoma;
TGCT	cis	rs9486719	1.000	rs67996804	chr6:96884387	C/T	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.21	-0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	trans	rs4332037	0.539	rs11762636	chr7:2061111	C/A	cg10840412	chr1:235813424	GNG4	0.94	6.84	0.52	3.21e-10	Bipolar disorder;
TGCT	cis	rs886126	1.000	rs876027	chr12:111678458	A/T	cg10833066	chr12:111807467	FAM109A	0.32	5.08	0.41	1.37e-6	Coronary heart disease;
TGCT	cis	rs46522	0.585	rs79049364	chr17:47014991	T/A	cg07967210	chr17:47022446	SNF8	0.44	6.13	0.48	1.06e-8	Coronary heart disease;
TGCT	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg00343986	chr7:65444356	GUSB	0.26	6.11	0.48	1.18e-8	Calcium levels;
TGCT	cis	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg18188782	chr20:61659543	NA	0.44	5.37	0.43	3.73e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg24250549	chr1:154909240	PMVK	-0.62	-6.09	-0.48	1.32e-8	Prostate cancer;
TGCT	cis	rs1541995	1.000	rs4984458	chr15:96392021	A/T	cg00882281	chr15:96346592	NA	0.29	4.68	0.39	7.42e-6	Photic sneeze reflex;
TGCT	cis	rs4478037	0.749	rs72856153	chr3:33111182	T/G	cg19404215	chr3:33155277	CRTAP	1.26	7.36	0.55	2.18e-11	Major depressive disorder;
TGCT	cis	rs66573146	1.000	rs55688389	chr4:7030689	C/G	cg01220768	chr4:7056774	TADA2B	0.43	5.04	0.41	1.6e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs9303401	0.614	rs35308719	chr17:57163501	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.58	5.74	0.46	6.76e-8	Cognitive test performance;
TGCT	cis	rs12220238	0.722	rs10740441	chr10:76410225	C/T	cg19889307	chr10:75911429	ADK;AP3M1	-0.58	-4.51	-0.38	1.48e-5	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs3820928	0.605	rs4281898	chr2:227855493	A/C	cg11843606	chr2:227700838	RHBDD1	-0.51	-4.71	-0.39	6.41e-6	Pulmonary function;
TGCT	cis	rs1008375	1.000	rs3815414	chr4:17606659	A/G	cg10189774	chr4:17578691	LAP3	-0.59	-5.27	-0.43	5.81e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs67478160	0.643	rs7147171	chr14:104264857	G/A	cg26031613	chr14:104095156	KLC1	-0.64	-6.58	-0.51	1.2e-9	Schizophrenia;
TGCT	cis	rs9329289	0.510	rs11251283	chr10:2555784	C/G	cg07014206	chr10:2547000	NA	-0.28	-4.64	-0.38	8.72e-6	Age-related hearing impairment;
TGCT	cis	rs12477438	0.798	rs4622780	chr2:99631760	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-8.31	-0.6	1.43e-13	Chronic sinus infection;
TGCT	cis	rs1372520	0.684	rs2737030	chr4:90710099	C/T	cg15133208	chr4:90757351	SNCA	-0.5	-5.92	-0.47	2.9e-8	Neuroticism;
TGCT	cis	rs6977660	0.507	rs72591450	chr7:19775480	A/G	cg07541023	chr7:19748670	TWISTNB	1.01	6.55	0.51	1.39e-9	Thyroid stimulating hormone;
TGCT	trans	rs2727020	0.619	rs1164665	chr11:49295630	T/C	cg03929089	chr4:120376271	NA	0.67	6.89	0.53	2.44e-10	Coronary artery disease;
TGCT	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg03188948	chr7:1209495	NA	0.68	5.8	0.46	5.09e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs4372836	0.543	rs6747852	chr2:29009840	A/T	cg09522027	chr2:28974177	PPP1CB	-0.77	-7.46	-0.56	1.33e-11	Body mass index;
TGCT	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs1205863	0.607	rs9394412	chr6:11931887	A/C	cg07106625	chr6:11870215	NA	0.47	4.77	0.39	5.17e-6	Disc degeneration (lumbar);
TGCT	cis	rs7647973	0.848	rs4955426	chr3:49143438	C/A	cg07636037	chr3:49044803	WDR6	0.81	6.17	0.48	8.81e-9	Menarche (age at onset);
TGCT	cis	rs9379774	0.517	rs72840524	chr6:25651664	T/C	cg11165035	chr6:26601993	NA	0.23	4.5	0.37	1.57e-5	Coronary artery disease;
TGCT	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.49	-4.76	-0.39	5.34e-6	Bipolar disorder;
TGCT	cis	rs6570726	0.791	rs1509213	chr6:145783360	G/A	cg05347473	chr6:146136440	FBXO30	-0.5	-4.67	-0.39	7.56e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg18402987	chr7:1209562	NA	0.67	5.94	0.47	2.72e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs6674176	0.611	rs2486011	chr1:44381246	C/T	cg12908607	chr1:44402522	ARTN	-0.73	-4.61	-0.38	9.87e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg24829409	chr8:58192753	C8orf71	0.6	5.3	0.43	5.2e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7917772	0.507	rs2778036	chr10:104485725	G/A	cg05855489	chr10:104503620	C10orf26	-0.72	-5.92	-0.47	2.94e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs4746059	0.545	rs7081273	chr10:72457038	C/G	cg03087610	chr10:71892362	AIFM2	0.5	4.63	0.38	9.26e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6674970	1.000	rs6656450	chr1:151089602	A/T	cg00003202	chr1:151319512	RFX5	-0.51	-4.46	-0.37	1.84e-5	Childhood ear infection;
TGCT	cis	rs1729951	0.575	rs361242	chr3:136698330	C/G	cg12473912	chr3:136751656	NA	0.39	6.18	0.49	8.62e-9	Neuroticism;
TGCT	cis	rs7819412	0.545	rs11985603	chr8:10918393	G/A	cg21775007	chr8:11205619	TDH	-0.49	-4.87	-0.4	3.35e-6	Triglycerides;
TGCT	trans	rs11088226	0.681	rs1015048	chr21:33949306	T/C	cg09050820	chr6:167586206	TCP10L2	0.76	7.31	0.55	2.88e-11	Gastritis;
TGCT	cis	rs17376456	0.877	rs17083455	chr5:93446380	A/C	cg25358565	chr5:93447407	FAM172A	0.9	8.26	0.6	1.9e-13	Diabetic retinopathy;
TGCT	cis	rs2777491	0.915	rs7178634	chr15:41634587	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.74	-10.4	-0.68	1.37e-18	Ulcerative colitis;
TGCT	cis	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg13531842	chr10:38383804	ZNF37A	-0.39	-4.64	-0.38	8.78e-6	Extrinsic epigenetic age acceleration;
TGCT	cis	rs651907	0.557	rs11712748	chr3:101383562	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.24	0.43	6.66e-7	Colorectal cancer;
TGCT	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg03452623	chr4:187889614	NA	-0.36	-5.19	-0.42	8.19e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9913156	0.789	rs55999196	chr17:4600655	A/G	cg00122941	chr17:4613640	ARRB2	0.88	7.63	0.57	5.46e-12	Lymphocyte counts;
TGCT	trans	rs9929218	0.529	rs8059194	chr16:68749663	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.57	7.25	0.55	3.99e-11	Colorectal cancer;
TGCT	cis	rs10927875	0.615	rs10927886	chr1:16339313	C/G	cg22431228	chr1:16359049	CLCNKA	0.28	5.99	0.47	2.09e-8	Dilated cardiomyopathy;
TGCT	cis	rs6815814	0.950	rs66819621	chr4:38819403	A/G	cg02016764	chr4:38805732	TLR1	-0.34	-5.4	-0.44	3.26e-7	Breast cancer;
TGCT	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.46	4.9	0.4	2.98e-6	Lymphocyte counts;
TGCT	cis	rs10875746	0.768	rs10875724	chr12:48420253	C/A	cg20731937	chr12:48336164	NA	0.72	6.1	0.48	1.23e-8	Longevity (90 years and older);
TGCT	cis	rs7666738	0.830	rs115279324	chr4:99042114	T/C	cg18180107	chr4:99064573	C4orf37	0.56	5.08	0.41	1.37e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2180341	0.960	rs7753913	chr6:127671296	A/G	cg27446573	chr6:127587934	RNF146	1.21	10.87	0.7	9.57e-20	Breast cancer;
TGCT	cis	rs11190604	0.767	rs7078070	chr10:102166415	A/C	cg16342193	chr10:102329863	NA	-0.39	-5.05	-0.41	1.54e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs4851254	0.618	rs13033732	chr2:100644797	A/G	cg07810366	chr2:100720526	AFF3	-0.46	-4.64	-0.38	8.78e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg05025164	chr4:1340916	KIAA1530	0.69	5.63	0.45	1.13e-7	Longevity;
TGCT	cis	rs11031096	0.678	rs11031184	chr11:4186192	C/T	cg18678763	chr11:4115507	RRM1	-0.38	-4.87	-0.4	3.35e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs8038465	0.904	rs12594627	chr15:73986264	G/T	cg15420318	chr15:73925796	NPTN	0.52	4.59	0.38	1.08e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg09021430	chr5:549028	NA	-0.43	-5.77	-0.46	5.99e-8	Obesity-related traits;
TGCT	cis	rs17376456	0.877	rs10062711	chr5:93348659	G/A	cg21475434	chr5:93447410	FAM172A	0.6	4.74	0.39	5.71e-6	Diabetic retinopathy;
TGCT	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg11301795	chr4:187892539	NA	-0.34	-5.02	-0.41	1.74e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10744422	0.925	rs2061098	chr12:123349410	T/C	cg25930673	chr12:123319894	HIP1R	-0.86	-4.86	-0.4	3.47e-6	Schizophrenia;
TGCT	cis	rs7216064	1.000	rs7216064	chr17:65898809	G/A	cg12091567	chr17:66097778	LOC651250	-0.81	-6.15	-0.48	9.71e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs4566357	1.000	rs6705989	chr2:227923320	G/A	cg11843606	chr2:227700838	RHBDD1	-0.58	-5.31	-0.43	4.92e-7	Coronary artery disease;
TGCT	cis	rs8017423	0.605	rs4904676	chr14:90819220	G/A	cg04374321	chr14:90722782	PSMC1	-0.58	-5.75	-0.46	6.5e-8	Mortality in heart failure;
TGCT	cis	rs9291683	0.526	rs7695555	chr4:10001656	T/C	cg11266682	chr4:10021025	SLC2A9	0.62	7.88	0.58	1.41e-12	Bone mineral density;
TGCT	cis	rs10501293	1.000	rs6485394	chr11:43080041	A/C	cg03447554	chr11:43094025	NA	-0.46	-6.6	-0.51	1.06e-9	Cognitive performance;
TGCT	cis	rs9942416	0.617	rs72633979	chr5:74990178	A/T	cg02573091	chr5:74908125	NA	0.41	4.62	0.38	9.62e-6	Age-related disease endophenotypes;
TGCT	cis	rs9807989	0.708	rs6543124	chr2:102987459	T/A	cg09003973	chr2:102972529	NA	0.63	5.48	0.44	2.26e-7	Asthma;
TGCT	cis	rs733175	0.857	rs751092	chr4:10005897	C/T	cg11266682	chr4:10021025	SLC2A9	0.52	4.5	0.37	1.55e-5	Psychosis and Alzheimer's disease;
TGCT	cis	rs4780401	0.609	rs8047190	chr16:11807097	T/C	cg01061890	chr16:11836724	TXNDC11	-0.6	-5.82	-0.46	4.74e-8	Rheumatoid arthritis;
TGCT	cis	rs6088590	0.542	rs6059956	chr20:33220070	A/G	cg08999081	chr20:33150536	PIGU	0.26	5.14	0.42	1.04e-6	Coronary artery disease;
TGCT	trans	rs1814175	0.817	rs28502006	chr11:50049930	T/C	cg15704280	chr7:45808275	SEPT13	-0.72	-8.47	-0.61	6.02e-14	Height;
TGCT	cis	rs763121	0.853	rs2413545	chr22:39092524	C/T	cg06022373	chr22:39101656	GTPBP1	0.78	7.67	0.57	4.44e-12	Menopause (age at onset);
TGCT	cis	rs1215050	0.791	rs6532702	chr4:98766641	C/T	cg05340658	chr4:99064831	C4orf37	0.44	5.51	0.44	2.01e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1395	0.744	rs72817536	chr2:27497548	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.64	6.98	0.53	1.54e-10	Blood metabolite levels;
TGCT	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg00814883	chr7:100076585	TSC22D4	-0.92	-9.76	-0.66	4.73e-17	Platelet count;
TGCT	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg03806693	chr22:41940476	POLR3H	1.15	12.98	0.76	7.24e-25	Vitiligo;
TGCT	cis	rs7044106	0.664	rs7861679	chr9:123375589	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.19	-4.52	-0.38	1.43e-5	Hip circumference adjusted for BMI;
TGCT	cis	rs2963155	0.518	rs1438732	chr5:142756266	G/C	cg17617527	chr5:142782415	NR3C1	0.84	5.51	0.44	1.99e-7	Breast cancer;
TGCT	cis	rs6460942	0.915	rs79232243	chr7:12459494	G/A	cg06484146	chr7:12443880	VWDE	-0.57	-5.54	-0.45	1.71e-7	Coronary artery disease;
TGCT	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg14983838	chr19:29218262	NA	0.79	7.44	0.56	1.48e-11	Methadone dose in opioid dependence;
TGCT	cis	rs2282802	0.685	rs2116790	chr5:139654115	G/A	cg01081189	chr5:139537190	NA	0.28	5.15	0.42	9.75e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs11935078	chr4:99010476	T/A	cg17366294	chr4:99064904	C4orf37	0.68	7.04	0.53	1.17e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7714584	1.000	rs11743488	chr5:150279218	A/G	cg22134413	chr5:150180641	NA	1.14	8.32	0.6	1.33e-13	Crohn's disease;
TGCT	cis	rs5750830	0.594	rs5757648	chr22:39775156	G/A	cg01416388	chr22:39784598	NA	-0.59	-5.8	-0.46	5.09e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2677744	0.688	rs2238340	chr15:91447686	G/A	cg23684204	chr15:91497937	RCCD1	0.33	4.61	0.38	1e-5	Attention deficit hyperactivity disorder;
TGCT	cis	rs7172809	0.573	rs7496431	chr15:77452054	T/C	cg22256960	chr15:77711686	NA	-0.48	-4.63	-0.38	9.17e-6	Glucose homeostasis traits;
TGCT	cis	rs12579753	0.917	rs12822036	chr12:82183009	C/T	cg07988820	chr12:82153109	PPFIA2	-0.59	-6.19	-0.49	7.93e-9	Resting heart rate;
TGCT	cis	rs2334880	0.678	rs66778248	chr16:71451424	A/G	cg06353428	chr16:71660113	MARVELD3	-1.22	-7.81	-0.57	2.05e-12	Malaria;
TGCT	cis	rs2996428	0.709	rs7527973	chr1:3704041	C/T	cg17848003	chr1:3704513	LRRC47	0.16	4.49	0.37	1.59e-5	Red cell distribution width;
TGCT	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg02975922	chr3:195473998	MUC4	-0.24	-5.47	-0.44	2.4e-7	Pancreatic cancer;
TGCT	cis	rs10504229	1.000	rs76270388	chr8:58195605	T/A	cg22535103	chr8:58192502	C8orf71	-0.39	-4.62	-0.38	9.61e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.08	0.48	1.37e-8	Bipolar disorder;
TGCT	cis	rs9527	0.568	rs12772775	chr10:104702999	C/A	cg15744005	chr10:104629667	AS3MT	-0.45	-5.31	-0.43	4.9e-7	Arsenic metabolism;
TGCT	cis	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg07424592	chr7:64974309	NA	1.4	8.42	0.6	7.87e-14	Diabetic kidney disease;
TGCT	cis	rs2730245	0.569	rs1188955	chr7:158690866	A/G	cg24397884	chr7:158709396	WDR60	0.36	4.57	0.38	1.17e-5	Height;
TGCT	cis	rs13242816	1.000	rs34234085	chr7:116114066	G/A	cg16553024	chr7:116138462	CAV2	-0.45	-4.75	-0.39	5.64e-6	P wave duration;
TGCT	cis	rs35146811	0.735	rs1636978	chr7:99813912	G/A	cg13334819	chr7:99746414	C7orf59	0.74	6.41	0.5	2.82e-9	Coronary artery disease;
TGCT	cis	rs13191362	0.935	rs35942036	chr6:163163297	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.14	9.38	0.64	4.1e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.67	6.69	0.51	6.89e-10	Eosinophil percentage of white cells;
TGCT	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg15242686	chr22:24348715	GSTTP1	0.42	5.68	0.45	9.1e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7523273	0.526	rs2952	chr1:208049077	C/T	cg22525895	chr1:207977042	MIR29B2	0.34	5.49	0.44	2.2e-7	Schizophrenia;
TGCT	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg27286337	chr10:134555280	INPP5A	0.39	4.82	0.4	4.1e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs6714710	0.603	rs35255677	chr2:98567820	G/A	cg26665480	chr2:98280029	ACTR1B	0.63	5.99	0.47	2.13e-8	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs1997103	1.000	rs6593237	chr7:55411015	T/C	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs428668	0.523	rs10060607	chr5:150679304	A/C	cg14086364	chr5:150678334	SLC36A3	0.17	4.55	0.38	1.28e-5	Skin aging (microtopography measurement);
TGCT	cis	rs6088590	1.000	rs6119512	chr20:33306904	T/C	cg06115741	chr20:33292138	TP53INP2	0.67	5.61	0.45	1.24e-7	Coronary artery disease;
TGCT	cis	rs1635	0.655	rs59598126	chr6:28303600	A/C	cg15743358	chr6:28303923	ZNF323	-1.28	-6.27	-0.49	5.57e-9	Schizophrenia;
TGCT	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg02953382	chr22:24373134	LOC391322	0.78	6.6	0.51	1.07e-9	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs7916697	0.626	rs3858144	chr10:70011354	A/G	cg25926515	chr10:70321889	TET1	0.35	4.46	0.37	1.84e-5	Optic disc area;
TGCT	cis	rs4820539	1.000	rs4822361	chr22:23482718	A/G	cg21100191	chr22:23484243	RTDR1	-0.89	-10.78	-0.7	1.61e-19	Bone mineral density;
TGCT	cis	rs9894429	0.789	rs6565611	chr17:79598319	T/C	cg21984481	chr17:79567631	NPLOC4	-0.26	-4.9	-0.4	2.91e-6	Eye color traits;
TGCT	cis	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg22121687	chr7:65037720	NA	-0.78	-4.7	-0.39	6.74e-6	Diabetic kidney disease;
TGCT	cis	rs644148	1.000	rs644148	chr19:44970935	T/G	cg15540054	chr19:45004280	ZNF180	-0.59	-5.21	-0.42	7.8e-7	Personality dimensions;
TGCT	cis	rs67311347	1.000	rs977652	chr3:40479169	A/G	cg17264618	chr3:40429014	ENTPD3	0.32	4.76	0.39	5.36e-6	Renal cell carcinoma;
TGCT	trans	rs9951602	0.512	rs12458828	chr18:76648522	C/T	cg02800362	chr5:177631904	HNRNPAB	-1.17	-12.42	-0.74	1.64e-23	Obesity-related traits;
TGCT	cis	rs9611565	0.918	rs28638318	chr22:41753059	G/A	cg06634786	chr22:41940651	POLR3H	-0.87	-8.23	-0.59	2.17e-13	Vitiligo;
TGCT	cis	rs11864453	0.514	rs2269918	chr16:72134831	C/A	cg14768367	chr16:72042858	DHODH	0.52	5.21	0.42	7.61e-7	Fibrinogen levels;
TGCT	cis	rs4563143	0.514	rs112651366	chr19:29299704	A/T	cg14983838	chr19:29218262	NA	0.71	5.18	0.42	8.75e-7	Methadone dose in opioid dependence;
TGCT	cis	rs6570726	0.764	rs367065	chr6:145882309	T/G	cg05347473	chr6:146136440	FBXO30	0.54	5.15	0.42	1.01e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9611565	0.694	rs202641	chr22:41833116	C/T	cg03806693	chr22:41940476	POLR3H	1.11	12.05	0.73	1.3e-22	Vitiligo;
TGCT	cis	rs2013441	1.000	rs34712254	chr17:20049308	C/T	cg23224458	chr17:20280056	CCDC144C	0.38	4.61	0.38	9.96e-6	Obesity-related traits;
TGCT	cis	rs4663866	1.000	rs4663300	chr2:239181491	T/C	cg17283117	chr2:239148619	HES6	1.0	4.6	0.38	1.03e-5	Irritable bowel syndrome;
TGCT	trans	rs8073060	0.586	rs2428464	chr17:34021994	C/G	cg19694781	chr19:47549865	TMEM160	-0.6	-13.37	-0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.0	8.22	0.59	2.32e-13	Platelet count;
TGCT	cis	rs6684514	1.000	rs12027741	chr1:156248148	T/G	cg20302342	chr1:156215951	PAQR6	0.34	4.6	0.38	1.01e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs707040	1.000	rs10202750	chr2:155233823	T/C	cg18104148	chr2:154337490	NA	0.19	4.57	0.38	1.17e-5	Sudden cardiac arrest;
TGCT	cis	rs2228479	0.850	rs74251570	chr16:89910068	C/A	cg06558623	chr16:89946397	TCF25	0.55	4.86	0.4	3.55e-6	Skin colour saturation;
TGCT	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg10047753	chr17:41438598	NA	0.97	9.99	0.67	1.37e-17	Menopause (age at onset);
TGCT	cis	rs7017914	0.967	rs7001162	chr8:71587470	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.03	-0.41	1.69e-6	Bone mineral density;
TGCT	cis	rs56104184	0.723	rs73063515	chr19:49407715	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.73	-9.15	-0.63	1.47e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs11690935	0.959	rs4668412	chr2:172619770	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.18	-12.58	-0.75	6.59e-24	Schizophrenia;
TGCT	cis	rs1372520	0.577	rs748849	chr4:90734961	G/A	cg15133208	chr4:90757351	SNCA	-0.53	-6.29	-0.49	4.94e-9	Neuroticism;
TGCT	cis	rs2354432	0.556	rs4424557	chr1:146871119	A/G	cg25205988	chr1:146714368	CHD1L	1.32	5.88	0.47	3.62e-8	Mitochondrial DNA levels;
TGCT	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg20203395	chr5:56204925	C5orf35	-0.53	-4.92	-0.4	2.67e-6	Initial pursuit acceleration;
TGCT	cis	rs2797160	0.515	rs4897149	chr6:125980018	G/T	cg05901451	chr6:126070800	HEY2	0.63	5.31	0.43	4.85e-7	Endometrial cancer;
TGCT	cis	rs2549003	1.000	rs2070725	chr5:131821788	C/T	cg21138405	chr5:131827807	IRF1	0.19	4.79	0.39	4.76e-6	Asthma (sex interaction);
TGCT	cis	rs2439831	1.000	rs2245908	chr15:43731454	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.8	5.7	0.46	8.33e-8	Lung cancer in ever smokers;
TGCT	cis	rs1461503	0.966	rs10892939	chr11:122841959	T/C	cg27398637	chr11:122830231	C11orf63	-0.42	-5.25	-0.43	6.42e-7	Menarche (age at onset);
TGCT	cis	rs7727544	0.669	rs113823725	chr5:131563501	C/G	cg24060327	chr5:131705240	SLC22A5	-0.55	-5.12	-0.42	1.15e-6	Blood metabolite levels;
TGCT	cis	rs3780378	0.875	rs2031906	chr9:5087495	C/T	cg02405213	chr9:5042618	JAK2	-0.64	-8.72	-0.62	1.51e-14	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs854765	0.693	rs8080061	chr17:17776389	C/T	cg09796270	chr17:17721594	SREBF1	-0.24	-4.78	-0.39	4.77e-6	Total body bone mineral density;
TGCT	cis	rs9527	0.615	rs9733635	chr10:104711940	G/A	cg15744005	chr10:104629667	AS3MT	-0.45	-5.24	-0.43	6.77e-7	Arsenic metabolism;
TGCT	cis	rs9457247	0.967	rs1211447	chr6:167381979	C/T	cg25258033	chr6:167368657	RNASET2	0.18	4.49	0.37	1.63e-5	Crohn's disease;
TGCT	cis	rs1372520	0.684	rs356162	chr4:90697157	T/C	cg01966878	chr4:90757139	SNCA	0.3	4.82	0.4	4.11e-6	Neuroticism;
TGCT	cis	rs2840044	1.000	rs225304	chr17:33921857	G/T	cg05299278	chr17:33885742	SLFN14	0.23	5.05	0.41	1.53e-6	Response to radiotherapy in cancer (late toxicity);
TGCT	cis	rs7926906	0.715	rs7111916	chr11:90525776	C/T	cg26138821	chr11:89956704	CHORDC1	-0.48	-4.91	-0.4	2.76e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1011108	0.561	rs1053807	chr2:26800422	G/A	cg18742855	chr2:26800399	C2orf70	0.29	6.48	0.5	1.99e-9	Periodontal microbiota;
TGCT	cis	rs60843830	1.000	rs62114497	chr2:214837	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.63	5.44	0.44	2.67e-7	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs6138458	1.000	rs227616	chr20:24908811	T/C	cg26195577	chr20:24973756	C20orf3	1.2	12.04	0.73	1.35e-22	Blood protein levels;
TGCT	cis	rs7975161	0.882	rs4406890	chr12:104638773	A/C	cg25273343	chr12:104657179	TXNRD1	-0.31	-4.82	-0.4	4.08e-6	Toenail selenium levels;
TGCT	cis	rs2486288	0.656	rs11854325	chr15:45548959	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.72	-7.46	-0.56	1.34e-11	Glomerular filtration rate;
TGCT	cis	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg20362242	chr5:692897	TPPP	0.5	4.71	0.39	6.66e-6	Lung disease severity in cystic fibrosis;
TGCT	trans	rs2727020	0.658	rs7111215	chr11:49430552	T/C	cg03929089	chr4:120376271	NA	-0.74	-8.58	-0.61	3.35e-14	Coronary artery disease;
TGCT	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.29	-4.56	-0.38	1.19e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7666738	0.962	rs2865985	chr4:99068009	T/C	cg17366294	chr4:99064904	C4orf37	0.73	6.51	0.5	1.72e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs854765	0.964	rs854813	chr17:18003845	C/T	cg04398451	chr17:18023971	MYO15A	0.3	4.79	0.39	4.75e-6	Total body bone mineral density;
TGCT	cis	rs9905704	0.624	rs4932691	chr17:57094617	T/C	cg05425664	chr17:57184151	TRIM37	0.68	5.7	0.46	8.23e-8	Testicular germ cell tumor;
TGCT	cis	rs7926906	0.575	rs1981422	chr11:90517256	G/C	cg26138821	chr11:89956704	CHORDC1	-0.48	-4.96	-0.41	2.22e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs8020441	0.541	rs67026579	chr14:51155207	A/G	cg04730355	chr14:51134070	SAV1	1.23	9.65	0.66	8.78e-17	Cognitive performance;
TGCT	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg23758822	chr17:41437982	NA	0.72	6.96	0.53	1.76e-10	Menopause (age at onset);
TGCT	cis	rs2245008	0.950	rs824400	chr16:83989936	C/G	cg05451527	chr16:83999617	OSGIN1	0.25	4.51	0.38	1.47e-5	Pursuit maintenance gain;
TGCT	cis	rs2932538	0.922	rs7522110	chr1:113072914	A/C	cg22162597	chr1:113214053	CAPZA1	0.27	5.92	0.47	2.95e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs2243480	1.000	rs160643	chr7:65558222	C/T	cg18252515	chr7:66147081	NA	-1.09	-7.55	-0.56	8.39e-12	Diabetic kidney disease;
TGCT	cis	rs7552404	1.000	rs942270	chr1:76177332	G/A	cg10523679	chr1:76189770	ACADM	0.9	9.75	0.66	5.01e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs11785400	1.000	rs3824208	chr8:143743653	C/G	cg24634471	chr8:143751801	JRK	0.57	6.12	0.48	1.11e-8	Schizophrenia;
TGCT	cis	rs7267979	1.000	rs11087521	chr20:25440648	G/A	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9527	0.590	rs7088200	chr10:104793235	G/A	cg15744005	chr10:104629667	AS3MT	-0.41	-4.8	-0.4	4.43e-6	Arsenic metabolism;
TGCT	cis	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg18252515	chr7:66147081	NA	1.2	7.83	0.58	1.89e-12	Diabetic kidney disease;
TGCT	cis	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg18252515	chr7:66147081	NA	-1.31	-8.18	-0.59	2.87e-13	Diabetic kidney disease;
TGCT	cis	rs13256369	0.826	rs7846050	chr8:8575669	A/G	cg17143192	chr8:8559678	CLDN23	0.63	6.01	0.47	1.96e-8	Obesity-related traits;
TGCT	cis	rs2180341	0.855	rs9385422	chr6:127716457	C/T	cg24812749	chr6:127587940	RNF146	0.79	6.49	0.5	1.9e-9	Breast cancer;
TGCT	cis	rs12042938	0.902	rs1094658	chr1:231773397	G/C	cg04892437	chr1:231737901	TSNAX-DISC1	0.45	4.69	0.39	7.15e-6	Neuranatomic and neurocognitive phenotypes;
TGCT	trans	rs208520	0.690	rs9345764	chr6:66820597	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-10.78	-0.7	1.6e-19	Exhaled nitric oxide output;
TGCT	cis	rs1153858	1.000	rs2467858	chr15:45711492	A/G	cg26924012	chr15:45694286	SPATA5L1	0.99	12.38	0.74	2.11e-23	Homoarginine levels;
TGCT	cis	rs7178424	0.616	rs10851703	chr15:62137215	A/G	cg00456672	chr15:62358751	C2CD4A	-0.31	-4.71	-0.39	6.66e-6	Height;
TGCT	cis	rs1538970	0.816	rs868351	chr1:46009818	G/T	cg05343316	chr1:45956843	TESK2	0.66	5.42	0.44	2.98e-7	Platelet count;
TGCT	cis	rs67385638	0.802	rs11036635	chr11:5308896	C/T	cg12559170	chr11:5275217	HBG2	0.41	7.74	0.57	3.03e-12	Hemoglobin levels;
TGCT	cis	rs1048238	0.846	rs945422	chr1:16345619	T/C	cg21385522	chr1:16154831	NA	0.42	4.46	0.37	1.81e-5	Systolic blood pressure;
TGCT	cis	rs7829975	0.628	rs1109618	chr8:8571364	A/T	cg17143192	chr8:8559678	CLDN23	-0.49	-4.86	-0.4	3.49e-6	Mood instability;
TGCT	cis	rs6845621	0.727	rs7676193	chr4:18889088	C/T	cg12196642	chr4:18937545	NA	-0.25	-4.54	-0.38	1.3e-5	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
TGCT	cis	rs11696501	0.738	rs6104294	chr20:44326850	T/C	cg11783356	chr20:44313418	WFDC10B	-0.33	-4.49	-0.37	1.6e-5	Brain structure;
TGCT	cis	rs3087591	1.000	rs2952980	chr17:29473353	G/A	cg24425628	chr17:29625626	OMG;NF1	0.46	7.23	0.54	4.3e-11	Hip circumference;
TGCT	cis	rs514406	0.644	rs928451	chr1:53195800	A/G	cg08859206	chr1:53392774	SCP2	0.34	4.82	0.4	4.1e-6	Monocyte count;
TGCT	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.64	0.51	8.82e-10	Electroencephalogram traits;
TGCT	cis	rs9467711	1.000	rs9467707	chr6:26327905	G/C	cg03517284	chr6:25882590	NA	-0.86	-4.67	-0.39	7.69e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2486012	1.000	rs2485995	chr1:44369600	G/A	cg12908607	chr1:44402522	ARTN	0.71	5.86	0.47	3.87e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2692947	0.537	rs11679899	chr2:96378162	A/G	cg23100626	chr2:96804247	ASTL	0.39	4.55	0.38	1.26e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs1008375	1.000	rs11737138	chr4:17657986	G/A	cg16339924	chr4:17578868	LAP3	0.63	5.33	0.43	4.49e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs11190604	1.000	rs10883507	chr10:102291275	C/T	cg16342193	chr10:102329863	NA	-0.42	-5.37	-0.43	3.74e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs910316	0.737	rs175045	chr14:75475275	A/C	cg08847533	chr14:75593920	NEK9	-0.82	-7.97	-0.58	8.73e-13	Height;
TGCT	cis	rs11098499	0.542	rs7677836	chr4:120310638	T/A	cg09307838	chr4:120376055	NA	0.65	6.39	0.5	3.02e-9	Corneal astigmatism;
TGCT	cis	rs3733585	0.673	rs116046986	chr4:9957794	A/G	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.7	-0.52	6.58e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs11696501	0.688	rs6104291	chr20:44323368	C/G	cg11783356	chr20:44313418	WFDC10B	-0.33	-4.49	-0.37	1.6e-5	Brain structure;
TGCT	cis	rs4478858	0.684	rs2062951	chr1:31762981	T/C	cg07478791	chr1:31886160	SERINC2	-0.52	-5.02	-0.41	1.73e-6	Alcohol dependence;
TGCT	cis	rs12477438	0.501	rs11683107	chr2:99759235	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.75	7.24	0.55	4.04e-11	Chronic sinus infection;
TGCT	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg09263875	chr16:632152	PIGQ	0.32	6.9	0.53	2.34e-10	Height;
TGCT	cis	rs4730250	0.707	rs6960148	chr7:106786142	A/G	cg02696742	chr7:106810147	HBP1	0.74	6.15	0.48	9.79e-9	Osteoarthritis;
TGCT	cis	rs9549367	0.673	rs3024735	chr13:113819513	G/A	cg18105134	chr13:113819100	PROZ	-0.47	-8.12	-0.59	3.97e-13	Platelet distribution width;
TGCT	cis	rs7772486	0.875	rs9399573	chr6:146403255	A/T	cg23711669	chr6:146136114	FBXO30	0.89	9.47	0.65	2.36e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs12142240	0.698	rs7515598	chr1:46818479	C/T	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs651907	0.557	rs17347644	chr3:101547733	C/T	cg12386194	chr3:101231763	SENP7	0.46	4.59	0.38	1.06e-5	Colorectal cancer;
TGCT	cis	rs10028773	0.568	rs6838457	chr4:120267367	A/G	cg09307838	chr4:120376055	NA	0.56	5.5	0.44	2.08e-7	Educational attainment;
TGCT	cis	rs3749237	0.576	rs3877784	chr3:49539417	C/T	cg02487422	chr3:49467188	NICN1	0.61	6.29	0.49	5.08e-9	Resting heart rate;
TGCT	cis	rs514406	0.679	rs11206006	chr1:53218380	A/G	cg25767906	chr1:53392781	SCP2	0.59	6.95	0.53	1.87e-10	Monocyte count;
TGCT	cis	rs9296092	0.538	rs9461881	chr6:33520041	C/T	cg13560919	chr6:33536144	NA	-0.21	-4.75	-0.39	5.5e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs7103648	0.966	rs10838702	chr11:47410888	G/T	cg20307385	chr11:47447363	PSMC3	0.98	11.33	0.71	7.39e-21	Diastolic blood pressure;Systolic blood pressure;
TGCT	cis	rs6490294	0.659	rs7133964	chr12:112198021	C/G	cg10833066	chr12:111807467	FAM109A	0.31	4.85	0.4	3.56e-6	Mean platelet volume;
TGCT	cis	rs9807989	0.507	rs4479442	chr2:103054074	A/T	cg03938978	chr2:103052716	IL18RAP	0.28	5.52	0.44	1.86e-7	Asthma;
TGCT	cis	rs9399135	0.660	rs9376072	chr6:135280519	G/C	cg24558204	chr6:135376177	HBS1L	0.48	5.02	0.41	1.74e-6	Red blood cell count;
TGCT	cis	rs2456568	0.803	rs10831138	chr11:93640468	T/C	cg14065697	chr11:93583672	C11orf90	-0.36	-4.45	-0.37	1.85e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg06238570	chr21:40685208	BRWD1	-0.6	-6.3	-0.49	4.8e-9	Menarche (age at onset);
TGCT	cis	rs12681288	0.676	rs17668031	chr8:1007176	A/G	cg04851639	chr8:1020857	NA	-0.32	-5.22	-0.42	7.23e-7	Schizophrenia;
TGCT	cis	rs7666738	0.924	rs13124368	chr4:99039615	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7542091	0.704	rs4133950	chr1:210044393	C/G	cg22029157	chr1:209979665	IRF6	0.64	6.1	0.48	1.23e-8	Monobrow;
TGCT	cis	rs2172802	0.629	rs1948616	chr4:62487688	A/G	cg04118610	chr4:62707027	LPHN3	-0.47	-4.96	-0.41	2.27e-6	Partial epilepsies;
TGCT	cis	rs4237845	0.586	rs4760174	chr12:58320436	G/A	cg02175503	chr12:58329896	NA	0.67	7.26	0.55	3.64e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs682748	0.810	rs6888760	chr5:17112174	C/T	cg23987134	chr5:17158319	LOC285696	-0.21	-4.96	-0.41	2.31e-6	Hippocampal atrophy;
TGCT	cis	rs1218582	0.596	rs4845676	chr1:154827861	C/G	cg16680214	chr1:154839983	KCNN3	-0.25	-4.8	-0.4	4.55e-6	Prostate cancer;
TGCT	cis	rs447921	0.813	rs34234366	chr17:74398510	C/A	cg09812376	chr17:74270190	QRICH2	-0.46	-4.6	-0.38	1.01e-5	Mitochondrial DNA levels;
TGCT	cis	rs76025697	1	rs76025697	chr5:179184488	G/A	cg14593053	chr5:179126677	CANX	0.48	5.25	0.43	6.37e-7	Granulocyte percentage of myeloid white cells;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Granulocyte count;
TGCT	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg22968622	chr17:43663579	NA	1.0	9.72	0.66	6.16e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs8017423	0.967	rs61989980	chr14:90727635	C/T	cg04374321	chr14:90722782	PSMC1	0.76	7.63	0.57	5.3e-12	Mortality in heart failure;
TGCT	cis	rs2658782	0.654	rs2248531	chr11:93255363	G/T	cg15737290	chr11:93063684	CCDC67	0.64	4.93	0.4	2.59e-6	Pulmonary function decline;
TGCT	cis	rs17601876	0.814	rs7181429	chr15:51559496	G/A	cg19946085	chr15:51559439	CYP19A1	-0.33	-5.06	-0.41	1.45e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs2204008	0.606	rs1581358	chr12:38391582	G/T	cg13010199	chr12:38710504	ALG10B	0.6	4.74	0.39	5.76e-6	Bladder cancer;
TGCT	cis	rs6866344	0.697	rs11742808	chr5:178131658	G/A	cg10224037	chr5:178157518	ZNF354A	0.95	8.47	0.61	6.06e-14	Neutrophil percentage of white cells;
TGCT	cis	rs9300255	0.602	rs1727294	chr12:123616514	A/G	cg00376283	chr12:123451042	ABCB9	0.71	5.58	0.45	1.42e-7	Neutrophil percentage of white cells;
TGCT	cis	rs35146811	0.660	rs3779045	chr7:99779259	T/C	cg22906224	chr7:99728672	NA	0.49	4.45	0.37	1.88e-5	Coronary artery disease;
TGCT	cis	rs2013441	0.965	rs2386485	chr17:20095246	G/A	cg18979559	chr17:20280153	CCDC144C	-0.44	-4.61	-0.38	9.78e-6	Obesity-related traits;
TGCT	cis	rs864745	1.000	rs849142	chr7:28185891	T/C	cg23620719	chr7:28220237	JAZF1	-0.5	-4.55	-0.38	1.24e-5	Crohn's disease;Type 2 diabetes;
TGCT	cis	rs3617	0.573	rs12492391	chr3:52912296	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	5.05	0.41	1.55e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7617773	0.963	rs6766754	chr3:48182589	T/C	cg11946769	chr3:48343235	NME6	-0.59	-5.35	-0.43	4.07e-7	Coronary artery disease;
TGCT	cis	rs7666738	0.791	rs4699329	chr4:99056212	G/A	cg17366294	chr4:99064904	C4orf37	0.73	7.45	0.56	1.4e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs79387448	0.592	rs6728945	chr2:102986471	T/C	cg09003973	chr2:102972529	NA	1.39	11.41	0.72	4.54e-21	Gut microbiota (bacterial taxa);
TGCT	cis	rs7208859	0.623	rs73271842	chr17:29137155	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs921968	0.608	rs658378	chr2:219483881	T/A	cg02176678	chr2:219576539	TTLL4	0.38	5.5	0.44	2.07e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg08280861	chr8:58055591	NA	0.52	5.94	0.47	2.65e-8	Developmental language disorder (linguistic errors);
TGCT	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg24675658	chr1:53192096	ZYG11B	-0.69	-8.17	-0.59	3.05e-13	Monocyte count;
TGCT	cis	rs7267979	1.000	rs2856	chr20:25433536	T/C	cg14121845	chr20:25566513	NINL	0.49	5.23	0.42	7.08e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs79149102	0.579	rs7182286	chr15:75293839	A/G	cg09165964	chr15:75287851	SCAMP5	-1.04	-5.71	-0.46	7.93e-8	Lung cancer;
TGCT	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg03407747	chr17:6899364	ALOX12	-0.51	-5.48	-0.44	2.29e-7	Tonsillectomy;
TGCT	cis	rs9549260	0.755	rs2721045	chr13:41162632	T/A	cg21288729	chr13:41239152	FOXO1	1.0	10.25	0.68	3.06e-18	Red blood cell count;
TGCT	cis	rs9818758	0.607	rs12185979	chr3:49651970	C/G	cg00383909	chr3:49044727	WDR6	1.47	5.86	0.47	3.83e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs3849570	0.643	rs1851928	chr3:81975395	C/T	cg07356753	chr3:81810745	GBE1	-0.64	-5.63	-0.45	1.16e-7	Waist circumference;Body mass index;
TGCT	cis	rs2742417	0.603	rs9826208	chr3:45773991	C/T	cg04837898	chr3:45731254	SACM1L	-0.67	-7.3	-0.55	3.06e-11	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs7772486	0.790	rs3923579	chr6:146230232	C/G	cg23711669	chr6:146136114	FBXO30	-0.89	-10.38	-0.68	1.54e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9952991	0.882	rs2847274	chr18:12777603	T/C	cg09945482	chr18:12777974	NA	0.51	4.86	0.4	3.47e-6	Inflammatory skin disease;
TGCT	cis	rs2836950	0.565	rs7279497	chr21:40531306	A/G	cg11644478	chr21:40555479	PSMG1	0.53	5.04	0.41	1.63e-6	Menarche (age at onset);
TGCT	cis	rs2836950	0.520	rs8133928	chr21:40689963	G/A	cg11890956	chr21:40555474	PSMG1	-0.65	-5.97	-0.47	2.27e-8	Menarche (age at onset);
TGCT	cis	rs7824557	0.564	rs11781637	chr8:11214972	C/T	cg21775007	chr8:11205619	TDH	-0.67	-6.7	-0.52	6.64e-10	Retinal vascular caliber;
TGCT	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg18402987	chr7:1209562	NA	0.72	5.97	0.47	2.31e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7267979	1.000	rs2387884	chr20:25379069	C/T	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs45509595	0.659	rs390764	chr6:27782535	C/T	cg08798685	chr6:27730294	NA	-0.35	-4.76	-0.39	5.24e-6	Breast cancer;
TGCT	cis	rs9383153	1.000	rs7749925	chr6:16340776	C/G	cg14009473	chr6:15502099	JARID2	-0.67	-5.63	-0.45	1.13e-7	Gambling;
TGCT	cis	rs6121246	0.529	rs750144	chr20:30179027	C/T	cg21427119	chr20:30132790	HM13	0.43	6.28	0.49	5.3e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs9913156	0.793	rs4346260	chr17:4567215	A/G	cg23387401	chr17:4582204	PELP1	-0.31	-4.63	-0.38	8.97e-6	Lymphocyte counts;
TGCT	cis	rs9788682	1.000	rs7164594	chr15:78803057	C/T	cg24631222	chr15:78858424	CHRNA5	0.88	7.63	0.57	5.35e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs3862260	0.509	rs3862262	chr1:120161841	G/T	cg16322792	chr1:120165303	ZNF697	0.35	8.4	0.6	8.93e-14	Systemic lupus erythematosus;
TGCT	cis	rs7582180	0.614	rs2241809	chr2:101014363	C/T	cg14675211	chr2:100938903	LONRF2	0.5	4.74	0.39	5.68e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2832191	0.716	rs2249028	chr21:30365322	G/A	cg24692254	chr21:30365293	RNF160	0.96	11.23	0.71	1.29e-20	Dental caries;
TGCT	cis	rs9467773	0.620	rs2451711	chr6:26663110	A/G	cg09904177	chr6:26538194	HMGN4	0.68	6.31	0.49	4.52e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs4654899	0.664	rs10799665	chr1:21152640	C/T	cg01072550	chr1:21505969	NA	-0.46	-6.94	-0.53	1.92e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg07424592	chr7:64974309	NA	1.36	8.15	0.59	3.36e-13	Diabetic kidney disease;
TGCT	cis	rs35160687	1.000	rs35160687	chr2:86472114	C/T	cg04877910	chr2:85804641	VAMP8	0.35	4.6	0.38	1.04e-5	Night sleep phenotypes;
TGCT	cis	rs78487399	0.908	rs12463527	chr2:43815945	A/G	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.66	4.67	0.39	7.66e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs76473307	0.661	rs61558260	chr20:57414867	C/G	cg06163629	chr20:57414884	GNASAS;GNAS	-0.64	-4.5	-0.37	1.54e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg17054783	chr10:134559939	INPP5A	-0.25	-4.8	-0.4	4.56e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs4285028	0.898	rs12491991	chr3:121706021	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.77	6.5	0.5	1.78e-9	Multiple sclerosis;
TGCT	cis	rs4700695	0.614	rs437399	chr5:65208533	A/G	cg21114390	chr5:65439923	SFRS12	0.67	5.02	0.41	1.73e-6	Facial morphology (factor 19);
TGCT	cis	rs7772486	0.846	rs9376976	chr6:146355605	T/C	cg05347473	chr6:146136440	FBXO30	0.57	5.51	0.44	2.02e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.51	5.37	0.43	3.71e-7	Menopause (age at onset);
TGCT	cis	rs4820539	1.000	rs2267003	chr22:23457098	A/G	cg21100191	chr22:23484243	RTDR1	0.95	11.36	0.71	6.23e-21	Bone mineral density;
TGCT	cis	rs79057730	0.599	rs6944167	chr7:826274	G/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.73	5.56	0.45	1.6e-7	Initial pursuit acceleration;
TGCT	cis	rs3617	0.625	rs2239548	chr3:52854186	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	4.59	0.38	1.08e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6964587	0.626	rs12704631	chr7:91523525	T/C	cg17063962	chr7:91808500	NA	-0.76	-7.15	-0.54	6.42e-11	Breast cancer;
TGCT	cis	rs2455799	0.634	rs1345160	chr3:15862026	C/T	cg16303742	chr3:15540471	COLQ	-0.25	-4.82	-0.4	4.06e-6	Mean platelet volume;
TGCT	cis	rs2439831	0.867	rs11856184	chr15:43919162	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	6.61	0.51	1.03e-9	Lung cancer in ever smokers;
TGCT	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg13206674	chr6:150067644	NUP43	0.52	4.51	0.38	1.5e-5	Lung cancer;
TGCT	cis	rs1371867	0.846	rs1788205	chr8:101306546	G/C	cg00191853	chr8:101177733	SPAG1	-0.22	-4.47	-0.37	1.75e-5	Atrioventricular conduction;
TGCT	cis	rs1008375	0.900	rs3822235	chr4:17694916	C/T	cg18681998	chr4:17616180	MED28	-0.72	-6.59	-0.51	1.11e-9	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7043114	0.525	rs1133908	chr9:95068046	C/T	cg14311495	chr9:95764742	FGD3	-0.22	-4.44	-0.37	1.95e-5	Height;
TGCT	cis	rs2278034	0.502	rs3747672	chr3:195612034	T/C	cg16000393	chr3:195602323	TNK2	-0.16	-4.46	-0.37	1.8e-5	Bronchopulmonary dysplasia;
TGCT	cis	rs2439831	0.702	rs495175	chr15:43798684	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.82	5.69	0.45	8.68e-8	Lung cancer in ever smokers;
TGCT	cis	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg20637647	chr7:64974828	NA	-0.94	-5.27	-0.43	5.9e-7	Diabetic kidney disease;
TGCT	cis	rs7917772	0.503	rs7087665	chr10:104282418	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1163251	0.902	rs487081	chr1:120217389	G/A	cg19096424	chr1:120255104	PHGDH	0.56	5.29	0.43	5.46e-7	Blood metabolite levels;
TGCT	cis	rs9634489	0.502	rs7320228	chr13:97085948	A/G	cg11411106	chr13:97107445	HS6ST3	-0.28	-5.13	-0.42	1.09e-6	Body mass index;
TGCT	cis	rs1215050	0.740	rs1648568	chr4:98957619	A/G	cg05340658	chr4:99064831	C4orf37	-0.44	-5.35	-0.43	4.13e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs3749237	1.000	rs1317140	chr3:49878652	G/A	cg03060546	chr3:49711283	APEH	0.7	7.05	0.54	1.08e-10	Resting heart rate;
TGCT	cis	rs804292	0.695	rs804279	chr8:11623889	A/T	cg26752888	chr8:11627280	NEIL2	0.85	8.95	0.63	4.42e-15	Alcohol dependence;Nicotine use;
TGCT	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	8.0	0.58	7.67e-13	Platelet count;
TGCT	cis	rs2302045	1.000	rs2302051	chr2:242062410	C/A	cg04553960	chr2:241721320	KIF1A	-0.69	-4.74	-0.39	5.8e-6	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio);
TGCT	trans	rs62103177	0.714	rs7227962	chr18:77603283	T/G	cg05926928	chr17:57297772	GDPD1	1.05	10.15	0.67	5.52e-18	Opioid sensitivity;
TGCT	cis	rs7666738	0.716	rs1426660	chr4:98876792	T/A	cg18180107	chr4:99064573	C4orf37	0.55	5.14	0.42	1.03e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg16590910	chr6:42928470	GNMT	-0.49	-4.58	-0.38	1.11e-5	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg11965913	chr1:205819406	PM20D1	0.49	6.53	0.51	1.49e-9	Menarche (age at onset);
TGCT	cis	rs79349575	0.783	rs4793991	chr17:47001801	A/G	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.51	-0.38	1.48e-5	Type 2 diabetes;
TGCT	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg08048268	chr3:133502702	NA	-0.65	-9.82	-0.66	3.44e-17	Iron status biomarkers;
TGCT	cis	rs7666738	0.830	rs10010223	chr4:99021758	G/A	cg17366294	chr4:99064904	C4orf37	0.68	7.04	0.53	1.17e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2180341	0.711	rs4371861	chr6:127568447	G/T	cg27446573	chr6:127587934	RNF146	0.7	6.97	0.53	1.66e-10	Breast cancer;
TGCT	cis	rs58722170	0.610	rs61776206	chr1:38073048	C/T	cg17933807	chr1:38061675	GNL2	-0.83	-7.42	-0.55	1.6e-11	High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs6988636	1.000	rs13260626	chr8:124190317	C/T	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs9942416	0.617	rs72633979	chr5:74990178	A/T	cg19683494	chr5:74908142	NA	0.61	6.4	0.5	2.94e-9	Age-related disease endophenotypes;
TGCT	cis	rs3812831	0.695	rs6560936	chr13:114945972	C/T	cg15513719	chr13:114904418	NA	-0.36	-4.46	-0.37	1.78e-5	Schizophrenia;
TGCT	cis	rs72634258	0.554	rs12723500	chr1:7857374	G/C	cg26816564	chr1:7831052	VAMP3	0.88	6.53	0.51	1.52e-9	Inflammatory bowel disease;
TGCT	cis	rs763014	0.898	rs4984897	chr16:632180	G/C	cg00908189	chr16:619842	PIGQ	0.87	10.5	0.69	7.53e-19	Height;
TGCT	cis	rs763121	0.853	rs5750669	chr22:39080638	T/A	cg06022373	chr22:39101656	GTPBP1	0.74	7.29	0.55	3.22e-11	Menopause (age at onset);
TGCT	cis	rs41464348	0.515	rs870858	chr2:33501320	G/C	cg16572410	chr2:33467199	LTBP1	-0.27	-4.49	-0.37	1.64e-5	Height;
TGCT	cis	rs9467773	0.935	rs11752946	chr6:26560364	C/A	cg26531700	chr6:26746687	NA	0.64	6.56	0.51	1.34e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs4506170	1.000	rs34585331	chr8:128323731	T/G	cg07795030	chr8:128802207	NA	-0.21	-4.66	-0.39	7.91e-6	Prostate cancer;
TGCT	cis	rs12477438	0.520	rs2632276	chr2:99779655	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.51	0.61	4.87e-14	Chronic sinus infection;
TGCT	cis	rs1971762	0.527	rs7311902	chr12:54015236	A/G	cg16917193	chr12:54089295	NA	1.05	10.86	0.7	1e-19	Height;
TGCT	cis	rs7666738	0.753	rs1830230	chr4:99026186	G/C	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1697139	0.583	rs1428475	chr5:66543954	G/T	cg11553311	chr5:66541588	NA	0.28	6.02	0.48	1.82e-8	Breast cancer;
TGCT	cis	rs7226408	0.857	rs72885287	chr18:34446659	C/A	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg00684032	chr4:1343700	KIAA1530	0.23	5.01	0.41	1.79e-6	Obesity-related traits;
TGCT	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg07747251	chr5:1868357	NA	0.38	5.46	0.44	2.45e-7	Cardiovascular disease risk factors;
TGCT	cis	rs12142240	0.698	rs72677594	chr1:46824371	A/C	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	trans	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg20587970	chr11:113659929	NA	0.8	9.3	0.64	6.34e-16	Hip circumference adjusted for BMI;
TGCT	cis	rs7819412	0.505	rs17782554	chr8:11022106	C/G	cg21775007	chr8:11205619	TDH	-0.49	-4.49	-0.37	1.59e-5	Triglycerides;
TGCT	cis	rs9787249	0.957	rs11809515	chr1:40205326	C/A	cg19912559	chr1:40204330	PPIE	0.49	5.7	0.46	8.41e-8	Blood protein levels;
TGCT	cis	rs9303542	0.559	rs12938390	chr17:46614722	T/C	cg25032089	chr17:46643351	HOXB3	0.58	5.48	0.44	2.23e-7	Ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs7666738	0.830	rs1967977	chr4:98966141	A/G	cg17366294	chr4:99064904	C4orf37	0.74	7.54	0.56	8.74e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs16866061	0.962	rs3845840	chr2:225359100	G/A	cg12698349	chr2:225449008	CUL3	1.0	9.83	0.66	3.23e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	cis	rs7113874	0.569	rs10444244	chr11:8534603	T/C	cg14521421	chr11:8862019	ST5	0.28	4.48	0.37	1.64e-5	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs858239	0.867	rs10250602	chr7:23303701	T/C	cg05602783	chr7:23145260	KLHL7	-0.69	-5.46	-0.44	2.51e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs13394619	1.000	rs13394619	chr2:11727507	A/G	cg07314298	chr2:11723111	GREB1	0.29	5.26	0.43	6.09e-7	Endometriosis;
TGCT	cis	rs17376456	0.741	rs10036829	chr5:93309897	G/C	cg21475434	chr5:93447410	FAM172A	0.65	4.85	0.4	3.58e-6	Diabetic retinopathy;
TGCT	cis	rs1577917	0.958	rs7747897	chr6:86647349	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.54	-0.45	1.73e-7	Response to antipsychotic treatment;
TGCT	trans	rs12599106	0.679	rs34584967	chr16:34475725	T/G	cg26668828	chr6:292823	DUSP22	-0.76	-8.07	-0.59	5.15e-13	Menopause (age at onset);
TGCT	cis	rs9560113	1.000	rs9560105	chr13:112175363	A/T	cg14154082	chr13:112174009	NA	-0.34	-4.65	-0.39	8.49e-6	Menarche (age at onset);
TGCT	cis	rs2235642	0.893	rs2076439	chr16:1587277	C/T	cg00463982	chr16:1583984	IFT140;TMEM204	-0.29	-4.96	-0.41	2.27e-6	Coronary artery disease;
TGCT	cis	rs6684514	1.000	rs12038481	chr1:156284815	T/C	cg16558208	chr1:156270281	VHLL	0.48	9.6	0.65	1.19e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs7959452	0.590	rs6581889	chr12:69757429	T/C	cg14784868	chr12:69753453	YEATS4	0.83	8.85	0.62	7.59e-15	Blood protein levels;
TGCT	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.36	0.55	2.25e-11	Prudent dietary pattern;
TGCT	cis	rs732765	1.000	rs13391	chr14:75370123	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.65	-5.51	-0.44	1.99e-7	Non-small cell lung cancer;
TGCT	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.44	4.67	0.39	7.7e-6	Menopause (age at onset);
TGCT	cis	rs2980439	0.517	rs17594093	chr8:8106406	G/T	cg08975724	chr8:8085496	FLJ10661	-0.55	-4.75	-0.39	5.6e-6	Neuroticism;
TGCT	cis	rs4911259	0.507	rs8118663	chr20:31398876	A/G	cg13636640	chr20:31349939	DNMT3B	0.9	7.78	0.57	2.41e-12	Inflammatory bowel disease;
TGCT	cis	rs7095607	0.967	rs10998018	chr10:69962954	G/A	cg18986048	chr10:69913749	MYPN	0.45	4.89	0.4	3.07e-6	Lung function (FVC);
TGCT	cis	rs35771425	0.536	rs6656860	chr1:211620805	A/G	cg25617285	chr1:211431773	RCOR3	-0.5	-6.15	-0.48	9.9e-9	Educational attainment (years of education);
TGCT	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg20607798	chr8:58055168	NA	0.45	4.57	0.38	1.15e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2115630	0.936	rs8033459	chr15:85253258	C/T	cg12501888	chr15:85177176	SCAND2	-0.5	-4.83	-0.4	3.89e-6	P wave terminal force;
TGCT	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg24675658	chr1:53192096	ZYG11B	-0.74	-9.02	-0.63	2.95e-15	Monocyte count;
TGCT	cis	rs600231	0.542	rs11227205	chr11:65256164	G/A	cg17120908	chr11:65337727	SSSCA1	-0.6	-4.58	-0.38	1.09e-5	Bone mineral density;
TGCT	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7668190	1.000	rs7668190	chr4:55096270	A/T	cg17187183	chr4:55093834	PDGFRA	0.44	6.04	0.48	1.63e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs586688	0.625	rs602668	chr1:201657709	A/G	cg14168733	chr1:201708718	NAV1	0.52	4.45	0.37	1.86e-5	Obesity-related traits;
TGCT	cis	rs6074578	0.679	rs6086171	chr20:136374	G/A	cg16931068	chr20:139680	DEFB127	0.29	4.94	0.41	2.48e-6	Hirschsprung disease;
TGCT	cis	rs28595532	0.920	rs115688334	chr4:119770805	C/T	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs6969780	0.722	rs983185	chr7:27188607	G/A	cg07317062	chr7:27170388	HOXA4	-0.45	-4.62	-0.38	9.36e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg03806693	chr22:41940476	POLR3H	1.16	13.52	0.77	3.78e-26	Vitiligo;
TGCT	cis	rs6598955	0.614	rs1134584	chr1:26608828	G/A	cg04990556	chr1:26633338	UBXN11	-0.86	-10.22	-0.68	3.7e-18	Obesity-related traits;
TGCT	cis	rs981844	1.000	rs2579917	chr4:154652648	T/G	cg14289246	chr4:154710475	SFRP2	1.01	8.56	0.61	3.55e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg08859206	chr1:53392774	SCP2	-0.42	-6.4	-0.5	2.95e-9	Monocyte count;
TGCT	cis	rs4268898	0.722	rs4665253	chr2:24382546	G/A	cg05570707	chr2:24270316	C2orf44	0.48	4.59	0.38	1.08e-5	Asthma;
TGCT	cis	rs644799	1.000	rs11021319	chr11:95523123	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	8.74	0.62	1.39e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9913156	0.841	rs34230287	chr17:4613630	C/T	cg00122941	chr17:4613640	ARRB2	0.94	8.09	0.59	4.57e-13	Lymphocyte counts;
TGCT	cis	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg20637647	chr7:64974828	NA	1.0	5.59	0.45	1.4e-7	Diabetic kidney disease;
TGCT	cis	rs1801251	0.963	rs13021246	chr2:233623111	T/C	cg25237894	chr2:233734115	C2orf82	0.33	5.95	0.47	2.53e-8	Coronary artery disease;
TGCT	cis	rs11734570	0.581	rs75356782	chr4:38600053	T/G	cg18361445	chr4:38666374	KLF3;FLJ13197	0.69	5.66	0.45	9.9e-8	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs2115630	1.000	rs55646601	chr15:85323568	G/T	cg17173187	chr15:85201210	NMB	-0.39	-4.78	-0.39	4.83e-6	P wave terminal force;
TGCT	cis	rs7224685	0.569	rs8066378	chr17:3996334	T/C	cg09580393	chr17:4869866	SPAG7	-0.38	-4.48	-0.37	1.64e-5	Type 2 diabetes;
TGCT	cis	rs6674176	0.611	rs1636876	chr1:44387228	T/G	cg12908607	chr1:44402522	ARTN	-0.68	-4.45	-0.37	1.89e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.28	0.43	5.68e-7	Prudent dietary pattern;
TGCT	cis	rs62244186	0.748	rs12635624	chr3:44678498	G/A	cg11003573	chr3:44754125	ZNF502	-0.4	-4.44	-0.37	1.96e-5	Depressive symptoms;
TGCT	cis	rs6570726	0.902	rs406979	chr6:145838983	G/T	cg23711669	chr6:146136114	FBXO30	0.7	6.46	0.5	2.12e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs17376456	0.877	rs7736620	chr5:93305762	C/T	cg25358565	chr5:93447407	FAM172A	0.98	8.39	0.6	9.01e-14	Diabetic retinopathy;
TGCT	cis	rs3784262	0.692	rs12907125	chr15:58282621	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.43	-6.05	-0.48	1.56e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg04944784	chr2:26401820	FAM59B	-0.71	-6.27	-0.49	5.4e-9	Gut microbiome composition (summer);
TGCT	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg06618935	chr21:46677482	NA	-0.37	-5.81	-0.46	5.06e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2760061	0.583	rs708113	chr1:228192753	T/A	cg02753203	chr1:228287806	NA	0.33	6.31	0.49	4.41e-9	Diastolic blood pressure;
TGCT	cis	rs62244186	0.627	rs12386385	chr3:44457540	A/G	cg15687855	chr3:44754131	ZNF502	-0.41	-4.91	-0.4	2.77e-6	Depressive symptoms;
TGCT	cis	rs3617	0.625	rs3774364	chr3:52863605	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	4.73	0.39	5.98e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7809950	1.000	rs2712200	chr7:107142435	G/T	cg23024343	chr7:107201750	COG5	-0.35	-5.3	-0.43	5.09e-7	Coronary artery disease;
TGCT	cis	rs10540	1.000	rs67912009	chr11:495057	G/T	cg03352830	chr11:487213	PTDSS2	0.26	4.51	0.38	1.48e-5	Body mass index;
TGCT	cis	rs1215050	0.755	rs6851840	chr4:98776366	A/G	cg17366294	chr4:99064904	C4orf37	0.52	5.59	0.45	1.4e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7926906	1.000	rs12291122	chr11:90531578	A/C	cg26138821	chr11:89956704	CHORDC1	-0.53	-5.6	-0.45	1.34e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs4689388	0.890	rs13130845	chr4:6297646	A/C	cg00701064	chr4:6280414	WFS1	0.38	4.78	0.39	4.96e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs477895	0.838	rs2070765	chr11:64010085	A/G	cg23719950	chr11:63933701	MACROD1	-0.65	-5.36	-0.43	3.92e-7	Mean platelet volume;
TGCT	cis	rs4148883	0.737	rs13148577	chr4:100060836	G/A	cg12011299	chr4:100065546	ADH4	0.39	6.02	0.48	1.83e-8	Alcohol dependence;
TGCT	cis	rs28595532	0.920	rs114547492	chr4:119773078	G/C	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs7178572	0.568	rs12913233	chr15:77543297	C/T	cg15453836	chr15:77711506	NA	-0.41	-4.58	-0.38	1.13e-5	Type 2 diabetes;
TGCT	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg02038168	chr22:39784481	NA	-0.78	-6.68	-0.51	7.08e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs17345786	0.817	rs11720560	chr3:101328484	C/T	cg12386194	chr3:101231763	SENP7	0.61	5.66	0.45	9.91e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7681440	0.874	rs1372523	chr4:90775923	G/A	cg14346243	chr4:90757452	SNCA	-0.56	-5.47	-0.44	2.41e-7	Dementia with Lewy bodies;
TGCT	cis	rs4660261	0.526	rs2906458	chr1:44336389	A/G	cg12908607	chr1:44402522	ARTN	0.66	8.26	0.6	1.85e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs9309473	0.615	rs62149774	chr2:73787652	G/A	cg07208825	chr2:73871855	ALMS1P	0.24	4.68	0.39	7.32e-6	Metabolite levels;
TGCT	cis	rs13191362	0.935	rs13212137	chr6:163010261	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs2468186	0.583	rs1485293	chr8:120091999	C/T	cg02248809	chr8:120845432	TAF2	-0.44	-4.71	-0.39	6.49e-6	Osteoprotegerin levels;
TGCT	cis	rs1153858	1.000	rs12441971	chr15:45671957	A/T	cg26924012	chr15:45694286	SPATA5L1	1.09	15.16	0.81	5.15e-30	Homoarginine levels;
TGCT	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg18402987	chr7:1209562	NA	0.61	5.03	0.41	1.66e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1552244	0.608	rs3732962	chr3:10048951	T/C	cg00149659	chr3:10157352	C3orf10	0.69	4.99	0.41	2.03e-6	Alzheimer's disease;
TGCT	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg08219700	chr8:58056026	NA	0.41	4.98	0.41	2.11e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1372520	0.684	rs2619347	chr4:90745770	G/A	cg01966878	chr4:90757139	SNCA	-0.3	-4.76	-0.39	5.2e-6	Neuroticism;
TGCT	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg16497277	chr3:49208875	KLHDC8B	-0.54	-5.17	-0.42	9.07e-7	Menarche (age at onset);
TGCT	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.05	8.69	0.62	1.83e-14	Platelet count;
TGCT	cis	rs9311474	0.713	rs352169	chr3:52236762	C/T	cg07507251	chr3:52567010	NT5DC2	0.39	5.21	0.42	7.71e-7	Electroencephalogram traits;
TGCT	cis	rs4654899	0.865	rs10493006	chr1:21375904	G/A	cg01072550	chr1:21505969	NA	-0.47	-7.03	-0.53	1.22e-10	Superior frontal gyrus grey matter volume;
TGCT	trans	rs12191082	0.646	rs17470494	chr6:46883834	C/T	cg15621338	chr7:128577916	IRF5	1.26	6.89	0.53	2.44e-10	Mean platelet volume;
TGCT	cis	rs17767294	0.572	rs11965137	chr6:27624749	G/A	cg08851530	chr6:28072375	NA	1.23	5.63	0.45	1.14e-7	Parkinson's disease;
TGCT	cis	rs2153535	0.580	rs1414345	chr6:8471537	T/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs829418	0.582	rs747662	chr1:21947218	C/G	cg09118749	chr1:21952566	RAP1GAP	0.4	5.02	0.41	1.72e-6	Neurocognitive impairment in HIV-1 infection (continuous);
TGCT	trans	rs208520	0.690	rs74707865	chr6:66717352	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	11.06	0.7	3.28e-20	Exhaled nitric oxide output;
TGCT	cis	rs7772486	0.720	rs9403757	chr6:146261271	C/T	cg23711669	chr6:146136114	FBXO30	-0.87	-9.9	-0.66	2.24e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1080500	1.000	rs1080500	chr3:53175017	C/T	cg10802521	chr3:52805072	NEK4	-0.46	-4.51	-0.38	1.48e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs765787	0.530	rs28815867	chr15:45526805	G/C	cg24006582	chr15:45444508	DUOX1	-0.25	-5.54	-0.45	1.75e-7	Uric acid levels;
TGCT	cis	rs9611565	0.649	rs5758466	chr22:42176059	G/A	cg13695892	chr22:41940480	POLR3H	0.8	7.65	0.57	4.87e-12	Vitiligo;
TGCT	cis	rs4689388	0.890	rs4689397	chr4:6299387	G/A	cg14416269	chr4:6271139	WFS1	0.4	5.33	0.43	4.42e-7	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs9906944	0.678	rs56015440	chr17:47136631	C/G	cg07075026	chr17:47091521	IGF2BP1	-0.44	-4.62	-0.38	9.52e-6	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg27286337	chr10:134555280	INPP5A	0.44	5.23	0.42	7.1e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs6424115	0.830	rs6672157	chr1:24198840	C/G	cg15997130	chr1:24165203	NA	0.85	9.26	0.64	7.92e-16	Immature fraction of reticulocytes;
TGCT	cis	rs1218582	0.741	rs705094	chr1:154917314	G/A	cg03351412	chr1:154909251	PMVK	0.5	4.66	0.39	7.92e-6	Prostate cancer;
TGCT	cis	rs6570726	0.791	rs385729	chr6:145855465	T/C	cg13319975	chr6:146136371	FBXO30	-0.51	-4.6	-0.38	1.01e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9325144	0.600	rs6582634	chr12:38748041	G/A	cg13010199	chr12:38710504	ALG10B	0.52	4.53	0.38	1.37e-5	Morning vs. evening chronotype;
TGCT	cis	rs6582630	0.519	rs8186992	chr12:38325848	C/T	cg26384229	chr12:38710491	ALG10B	0.79	6.98	0.53	1.61e-10	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs68170813	0.559	rs2249043	chr7:106960515	C/T	cg02696742	chr7:106810147	HBP1	-0.71	-5.83	-0.46	4.43e-8	Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs17027225	chr4:99028564	C/T	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9467773	0.620	rs2494701	chr6:26634432	C/T	cg26531700	chr6:26746687	NA	0.5	4.68	0.39	7.52e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7412746	0.634	rs72704658	chr1:150833010	T/C	cg09365446	chr1:150670422	GOLPH3L	0.35	5.04	0.41	1.62e-6	Melanoma;
TGCT	cis	rs11971779	0.793	rs11772447	chr7:139033589	T/G	cg07862535	chr7:139043722	LUC7L2	0.75	6.1	0.48	1.26e-8	Diisocyanate-induced asthma;
TGCT	cis	rs36051895	0.623	rs1575283	chr9:5238588	C/T	cg02405213	chr9:5042618	JAK2	-0.73	-9.55	-0.65	1.55e-16	Pediatric autoimmune diseases;
TGCT	cis	rs7937682	0.564	rs1944114	chr11:111366460	T/C	cg09085632	chr11:111637200	PPP2R1B	0.55	4.94	0.41	2.52e-6	Primary sclerosing cholangitis;
TGCT	cis	rs28595532	0.920	rs115354352	chr4:119750358	T/C	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg08219700	chr8:58056026	NA	0.38	4.69	0.39	6.95e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4478858	0.647	rs7524117	chr1:31738416	A/G	cg00250761	chr1:31883323	NA	-0.25	-4.52	-0.38	1.45e-5	Alcohol dependence;
TGCT	cis	rs6912958	0.516	rs242278	chr6:88047059	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.72	7.53	0.56	9.05e-12	Monocyte percentage of white cells;
TGCT	cis	rs877529	0.605	rs139397	chr22:39543371	T/C	cg18708252	chr22:39545030	CBX7	-0.35	-5.18	-0.42	8.84e-7	Multiple myeloma;
TGCT	cis	rs10465746	0.780	rs4907190	chr1:84409168	T/C	cg10977910	chr1:84465055	TTLL7	0.69	7.07	0.54	9.97e-11	Obesity-related traits;
TGCT	cis	rs6424115	0.692	rs573361	chr1:24053674	A/T	cg15997130	chr1:24165203	NA	0.68	6.41	0.5	2.8e-9	Immature fraction of reticulocytes;
TGCT	cis	rs34245846	0.705	rs56382016	chr1:154828683	A/C	cg06418219	chr1:154948305	SHC1;CKS1B	0.76	6.04	0.48	1.7e-8	Atrial fibrillation;
TGCT	cis	rs9811920	0.609	rs6809988	chr3:99656615	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.58	6.65	0.51	8.38e-10	Axial length;
TGCT	trans	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-1.03	-13.16	-0.76	2.65e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs3806843	1.000	rs2337985	chr5:140157861	T/C	cg19875535	chr5:140030758	IK	0.37	6.34	0.49	3.89e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.94	-12.61	-0.75	5.71e-24	Prudent dietary pattern;
TGCT	cis	rs12971120	0.947	rs8083001	chr18:72165058	A/G	cg26446133	chr18:72167187	CNDP2	-0.39	-7.57	-0.56	7.29e-12	Refractive error;
TGCT	cis	rs1801251	1.000	rs895430	chr2:233725483	C/A	cg08000102	chr2:233561755	GIGYF2	-0.64	-6.48	-0.5	1.97e-9	Coronary artery disease;
TGCT	cis	rs9993613	1.000	rs6446849	chr4:73459446	G/A	cg15102770	chr4:73434591	ADAMTS3	-0.5	-4.62	-0.38	9.39e-6	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs2404602	0.669	rs1875885	chr15:76638081	G/A	cg26408565	chr15:76604113	ETFA	-0.41	-5.3	-0.43	5.1e-7	Blood metabolite levels;
TGCT	cis	rs5750830	0.620	rs1007337	chr22:39781585	C/T	cg05872129	chr22:39784769	NA	-0.95	-10.16	-0.67	5.11e-18	Intelligence (multi-trait analysis);
TGCT	cis	rs9611565	0.512	rs5758439	chr22:42131762	C/T	cg06634786	chr22:41940651	POLR3H	0.87	8.12	0.59	3.86e-13	Vitiligo;
TGCT	cis	rs1150668	0.830	rs2531831	chr6:28388765	C/G	cg13525197	chr6:28411240	ZSCAN23	-0.51	-4.98	-0.41	2.1e-6	Pubertal anthropometrics;
TGCT	trans	rs8073060	0.586	rs226087	chr17:34017652	T/C	cg19694781	chr19:47549865	TMEM160	-0.6	-13.37	-0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs1371867	0.846	rs1788203	chr8:101303721	T/C	cg06636551	chr8:101224915	SPAG1	-0.48	-6.52	-0.51	1.62e-9	Atrioventricular conduction;
TGCT	cis	rs9556958	0.588	rs9556964	chr13:99159306	T/C	cg15168958	chr13:99100528	FARP1	0.23	4.69	0.39	7.03e-6	Educational attainment (years of education);
TGCT	cis	rs3749237	0.595	rs7621003	chr3:49411404	T/C	cg03060546	chr3:49711283	APEH	0.77	8.87	0.62	6.79e-15	Resting heart rate;
TGCT	cis	rs7666738	0.830	rs957742	chr4:99029409	C/T	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12711979	0.765	rs6715805	chr2:3821117	T/C	cg17052675	chr2:3827356	NA	-0.4	-7.82	-0.57	2.02e-12	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs10875746	0.859	rs4760622	chr12:48591960	C/A	cg20731937	chr12:48336164	NA	0.63	5.05	0.41	1.51e-6	Longevity (90 years and older);
TGCT	cis	rs11098499	0.909	rs11098530	chr4:120413154	C/T	cg09307838	chr4:120376055	NA	0.69	6.64	0.51	8.97e-10	Corneal astigmatism;
TGCT	cis	rs2014572	0.510	rs8111661	chr19:57752326	C/G	cg24459738	chr19:57751996	ZNF805	0.53	5.08	0.42	1.32e-6	Hyperactive-impulsive symptoms;
TGCT	cis	rs10746514	0.931	rs11582890	chr1:232251218	C/T	cg09506761	chr1:232265262	NA	0.53	5.31	0.43	4.79e-7	Response to statin therapy;
TGCT	cis	rs2153535	0.580	rs6421948	chr6:8531020	T/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.01	0.41	1.86e-6	Motion sickness;
TGCT	cis	rs6988636	0.892	rs58116120	chr8:124191776	T/G	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs9303401	0.659	rs35797125	chr17:56736547	G/A	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs2469997	1.000	rs2470024	chr8:120363181	C/A	cg00681363	chr8:120844660	TAF2	0.69	4.48	0.37	1.64e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs11122272	0.735	rs973252	chr1:231520802	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-7.0	-0.53	1.41e-10	Hemoglobin concentration;
TGCT	cis	rs611744	0.647	rs1609472	chr8:109269232	T/G	cg21045802	chr8:109455806	TTC35	0.71	7.25	0.55	4.03e-11	Dupuytren's disease;
TGCT	cis	rs11687170	0.786	rs10211471	chr2:237081854	C/T	cg19324714	chr2:237145437	ASB18	0.5	4.64	0.38	8.65e-6	Educational attainment;Educational attainment (years of education);
TGCT	cis	rs58950470	0.927	rs1193851	chr11:65386206	C/G	cg27068330	chr11:65405492	SIPA1	0.6	5.37	0.43	3.81e-7	Schizophrenia;
TGCT	trans	rs208520	0.690	rs207091	chr6:66799847	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-10.83	-0.7	1.19e-19	Exhaled nitric oxide output;
TGCT	cis	rs7666738	0.830	rs7662389	chr4:99019892	G/A	cg17366294	chr4:99064904	C4orf37	0.73	7.42	0.55	1.6e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg08736216	chr1:53307985	ZYG11A	0.25	4.93	0.4	2.59e-6	Monocyte count;
TGCT	cis	rs7582180	0.627	rs4149523	chr2:101007039	T/C	cg08017756	chr2:100939284	LONRF2	-0.31	-5.01	-0.41	1.85e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6722750	0.716	rs2422115	chr2:64414815	A/G	cg22352474	chr2:64371530	PELI1	-0.53	-4.46	-0.37	1.83e-5	Neuroticism;
TGCT	cis	rs72781680	0.716	rs2551334	chr2:24000396	G/A	cg08917208	chr2:24149416	ATAD2B	0.79	4.94	0.41	2.51e-6	Lymphocyte counts;
TGCT	cis	rs1062177	1.000	rs2016409	chr5:151126324	G/T	cg00977110	chr5:151150581	G3BP1	-0.41	-4.62	-0.38	9.52e-6	Preschool internalizing problems;
TGCT	cis	rs4742903	0.967	rs2417485	chr9:106867106	A/C	cg21169611	chr9:106856078	SMC2	0.5	4.65	0.39	8.38e-6	High-grade serous ovarian cancer;Breast cancer;
TGCT	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7552404	0.727	rs5745433	chr1:76333163	T/G	cg22875332	chr1:76189707	ACADM	0.58	6.08	0.48	1.36e-8	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs644799	0.544	rs1527450	chr11:95467777	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.56	5.62	0.45	1.18e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs77372450	0.551	rs60235007	chr5:157069349	G/C	cg19063654	chr5:156516798	HAVCR2	-0.37	-4.43	-0.37	2.01e-5	Bipolar disorder (body mass index interaction);
TGCT	trans	rs6762477	0.748	rs2073726	chr3:50223593	T/A	cg21659725	chr3:3221576	CRBN	-0.65	-7.35	-0.55	2.37e-11	Menarche (age at onset);
TGCT	cis	rs7223966	0.883	rs2727317	chr17:61961302	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	5.32	0.43	4.68e-7	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs12210905	0.920	rs72839451	chr6:27265437	G/C	cg08851530	chr6:28072375	NA	1.29	5.45	0.44	2.65e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs13191362	1.000	rs55847707	chr6:163003414	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs727505	0.954	rs7789055	chr7:124677543	G/T	cg23710748	chr7:124431027	NA	-0.26	-4.51	-0.38	1.49e-5	Lewy body disease;
TGCT	cis	rs79349575	0.783	rs903567	chr17:46980318	C/T	cg07967210	chr17:47022446	SNF8	0.43	6.06	0.48	1.54e-8	Type 2 diabetes;
TGCT	cis	rs9517302	0.665	rs3752968	chr13:99097025	C/T	cg22223119	chr13:99095684	FARP1	-0.54	-6.16	-0.48	9.37e-9	Obesity-related traits;
TGCT	cis	rs9916302	0.904	rs8079355	chr17:37473018	G/A	cg07936489	chr17:37558343	FBXL20	0.65	5.08	0.41	1.36e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs921968	0.541	rs4674308	chr2:219310483	A/C	cg02176678	chr2:219576539	TTLL4	0.47	6.72	0.52	5.75e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs6964587	0.967	rs1978061	chr7:91779242	G/A	cg22709100	chr7:91322751	NA	0.29	4.62	0.38	9.33e-6	Breast cancer;
TGCT	trans	rs11088226	0.645	rs78172258	chr21:33936539	T/G	cg09050820	chr6:167586206	TCP10L2	0.79	7.04	0.53	1.13e-10	Gastritis;
TGCT	cis	rs2455799	0.586	rs6805034	chr3:15856929	C/G	cg12172478	chr3:16357591	RFTN1	-0.31	-4.62	-0.38	9.31e-6	Mean platelet volume;
TGCT	cis	rs12477438	0.520	rs1044575	chr2:99812070	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	12.84	0.76	1.57e-24	Chronic sinus infection;
TGCT	trans	rs1005277	0.505	rs10827836	chr10:38215441	A/G	cg17830980	chr10:43048298	ZNF37B	0.73	8.35	0.6	1.13e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.55	-5.58	-0.45	1.47e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2456568	0.802	rs10765639	chr11:93636194	G/A	cg14065697	chr11:93583672	C11orf90	-0.37	-4.63	-0.38	9.11e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7666738	0.830	rs9996098	chr4:98867740	T/C	cg05340658	chr4:99064831	C4orf37	0.52	6.0	0.47	1.98e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2721195	1.000	rs11542372	chr8:145677089	G/A	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.82	-8.64	-0.61	2.39e-14	Age at first birth;
TGCT	cis	rs4253772	0.591	rs6519993	chr22:46656479	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.55	4.46	0.37	1.84e-5	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs3771570	1.000	rs73004382	chr2:242382192	C/T	cg21155796	chr2:242212141	HDLBP	0.93	6.6	0.51	1.08e-9	Prostate cancer;
TGCT	cis	rs4824093	0.545	rs58876234	chr22:50258868	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.48	4.97	0.41	2.17e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs6701037	0.681	rs2285220	chr1:175130773	T/A	cg00321850	chr1:175162397	KIAA0040	-0.42	-5.83	-0.46	4.61e-8	Alcohol dependence;
TGCT	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg00814883	chr7:100076585	TSC22D4	-0.89	-9.26	-0.64	7.79e-16	Platelet count;
TGCT	cis	rs4389656	0.740	rs274706	chr5:6726629	T/C	cg10857441	chr5:6722123	POLS	-0.22	-4.74	-0.39	5.75e-6	Coronary artery disease;
TGCT	cis	rs4810479	0.513	rs3746506	chr20:44586036	G/A	cg23252815	chr20:44420276	WFDC3;DNTTIP1	0.31	5.35	0.43	4.06e-7	Metabolite levels;
TGCT	cis	rs9926296	0.572	rs8046872	chr16:89841552	T/C	cg03388025	chr16:89894329	SPIRE2	0.35	5.13	0.42	1.09e-6	Vitiligo;
TGCT	cis	rs17433780	0.928	rs10922533	chr1:89456659	C/G	cg09516651	chr1:89888402	LOC400759	0.32	5.89	0.47	3.35e-8	Carotid intima media thickness;
TGCT	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg18876405	chr7:65276391	NA	0.31	4.79	0.4	4.58e-6	Aortic root size;
TGCT	cis	rs8017423	0.967	rs4904658	chr14:90721640	C/T	cg04374321	chr14:90722782	PSMC1	0.76	7.71	0.57	3.59e-12	Mortality in heart failure;
TGCT	cis	rs7568458	0.846	rs7605975	chr2:85772548	C/T	cg02493740	chr2:85810744	VAMP5	-0.29	-5.47	-0.44	2.37e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs7818688	0.697	rs11776186	chr8:95971968	A/G	cg16049864	chr8:95962084	TP53INP1	0.54	4.64	0.38	8.87e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs992157	0.932	rs10203039	chr2:219187367	T/C	cg00012203	chr2:219082015	ARPC2	0.69	6.96	0.53	1.78e-10	Colorectal cancer;
TGCT	cis	rs644799	0.710	rs1852535	chr11:95501241	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.26	0.6	1.89e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs10838634	1.000	rs11039015	chr11:46897865	C/T	cg18332754	chr11:46939436	LRP4	-0.89	-4.77	-0.39	5.13e-6	Schizophrenia;
TGCT	cis	rs2032447	0.641	rs442601	chr6:25934524	G/A	cg07061783	chr6:25882402	NA	-0.62	-6.15	-0.48	9.71e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.71	6.36	0.5	3.53e-9	Tonsillectomy;
TGCT	cis	rs514406	0.763	rs6685599	chr1:53213172	G/A	cg16325326	chr1:53192061	ZYG11B	-0.74	-9.11	-0.63	1.79e-15	Monocyte count;
TGCT	cis	rs1153858	1.000	rs12595087	chr15:45655232	A/G	cg26924012	chr15:45694286	SPATA5L1	1.09	15.16	0.81	5.15e-30	Homoarginine levels;
TGCT	cis	rs6089584	0.606	rs6089599	chr20:60576992	A/G	cg13770153	chr20:60521292	NA	0.4	4.99	0.41	2.03e-6	Body mass index;
TGCT	cis	rs739496	0.947	rs10849948	chr12:111875410	A/G	cg10833066	chr12:111807467	FAM109A	0.36	5.51	0.44	2.01e-7	Platelet count;
TGCT	cis	rs34734847	0.933	rs998727	chr12:121149064	T/G	cg21892295	chr12:121157589	UNC119B	-0.22	-5.32	-0.43	4.75e-7	Mean corpuscular volume;
TGCT	cis	rs9457247	0.624	rs2239826	chr6:167504880	T/C	cg07741184	chr6:167504864	NA	0.28	5.56	0.45	1.57e-7	Crohn's disease;
TGCT	cis	rs28595532	0.920	rs115681185	chr4:119757700	G/A	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs4704846	1.000	rs4704737	chr5:156533219	A/G	cg12943317	chr5:156479607	HAVCR1	-0.34	-4.7	-0.39	6.82e-6	Blood protein levels;
TGCT	cis	rs7655441	0.964	rs12647691	chr4:80905990	C/G	cg02241357	chr4:80885279	ANTXR2	-0.24	-4.59	-0.38	1.07e-5	Neutrophil percentage of white cells;
TGCT	cis	rs7267979	1.000	rs2424713	chr20:25418482	C/T	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9467773	0.525	rs1535274	chr6:26520747	A/C	cg09904177	chr6:26538194	HMGN4	0.5	4.76	0.39	5.25e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7824557	0.767	rs3808513	chr8:11157460	G/T	cg21775007	chr8:11205619	TDH	-0.52	-5.07	-0.41	1.39e-6	Retinal vascular caliber;
TGCT	cis	rs11098499	0.909	rs28793658	chr4:120307214	A/C	cg09307838	chr4:120376055	NA	0.65	6.39	0.5	3.02e-9	Corneal astigmatism;
TGCT	cis	rs9914988	0.778	rs4794837	chr17:27110024	T/C	cg20469991	chr17:27169893	C17orf63	-0.72	-5.04	-0.41	1.58e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs9814567	0.778	rs4955546	chr3:134334738	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-6.66	-0.51	7.8e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs9611565	0.573	rs9306355	chr22:42111896	A/T	cg03806693	chr22:41940476	POLR3H	0.96	9.91	0.66	2.06e-17	Vitiligo;
TGCT	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg00343986	chr7:65444356	GUSB	-0.22	-4.71	-0.39	6.63e-6	Aortic root size;
TGCT	cis	rs12615966	1.000	rs9941579	chr2:105384506	C/T	cg16465502	chr2:105461796	NA	0.78	5.01	0.41	1.83e-6	Pancreatic cancer;
TGCT	cis	rs6815814	0.950	rs3924112	chr4:38795810	C/T	cg02016764	chr4:38805732	TLR1	-0.34	-5.4	-0.44	3.2e-7	Breast cancer;
TGCT	cis	rs7666738	0.830	rs10012167	chr4:99048579	T/C	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs514406	0.505	rs447581	chr1:53177098	T/C	cg01802117	chr1:53393560	SCP2	-0.42	-4.88	-0.4	3.24e-6	Monocyte count;
TGCT	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg01802117	chr1:53393560	SCP2	0.41	4.93	0.4	2.56e-6	Monocyte count;
TGCT	cis	rs12142240	0.698	rs17361950	chr1:46864150	C/T	cg00530320	chr1:46809349	NSUN4	0.29	5.72	0.46	7.49e-8	Menopause (age at onset);
TGCT	cis	rs524281	0.861	rs2293121	chr11:65961347	T/G	cg00563793	chr11:65837595	PACS1	0.53	4.67	0.39	7.6e-6	Electroencephalogram traits;
TGCT	cis	rs17125944	0.505	rs10483618	chr14:53203590	T/C	cg00686598	chr14:53173677	PSMC6	1.09	5.66	0.45	1e-7	Alzheimer's disease (late onset);
TGCT	cis	rs6570726	0.846	rs7773939	chr6:145927384	C/T	cg23711669	chr6:146136114	FBXO30	-0.79	-8.46	-0.6	6.26e-14	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10992471	0.603	rs4743873	chr9:95270781	C/T	cg13798575	chr9:95087839	CENPP;NOL8	0.61	5.55	0.45	1.62e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs7677751	1.000	rs7677751	chr4:55124460	C/T	cg17187183	chr4:55093834	PDGFRA	0.49	5.0	0.41	1.94e-6	Corneal astigmatism;
TGCT	cis	rs796364	1.000	rs769950	chr2:200730028	A/G	cg17644776	chr2:200775616	C2orf69	0.31	4.83	0.4	3.99e-6	Schizophrenia;
TGCT	cis	rs11578119	0.836	rs12402306	chr1:170377418	C/T	cg09767346	chr1:170501363	GORAB	0.74	5.94	0.47	2.67e-8	Male-pattern baldness;
TGCT	trans	rs9929218	0.551	rs8051095	chr16:68722049	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.62	8.24	0.59	2.07e-13	Colorectal cancer;
TGCT	cis	rs7772486	0.790	rs6917482	chr6:146243581	C/T	cg23711669	chr6:146136114	FBXO30	-0.87	-9.9	-0.66	2.24e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7647973	0.516	rs12490393	chr3:49196132	C/T	cg05785598	chr3:49045655	WDR6	0.36	4.87	0.4	3.27e-6	Menarche (age at onset);
TGCT	cis	rs2777491	0.915	rs8036498	chr15:41603276	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.77	-10.8	-0.7	1.46e-19	Ulcerative colitis;
TGCT	cis	rs2862064	1.000	rs4407618	chr5:156445875	A/C	cg12943317	chr5:156479607	HAVCR1	-0.38	-5.14	-0.42	1.02e-6	Platelet count;
TGCT	cis	rs644799	1.000	rs651445	chr11:95539122	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	10.57	0.69	5.17e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs12908161	0.960	rs62019463	chr15:85288087	G/A	cg12863693	chr15:85201151	NMB	0.42	4.99	0.41	2.03e-6	Schizophrenia;
TGCT	cis	rs9914988	0.943	rs9908881	chr17:27100924	T/A	cg20469991	chr17:27169893	C17orf63	-0.72	-5.04	-0.41	1.58e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg17054783	chr10:134559939	INPP5A	0.24	4.83	0.4	3.92e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs1355223	0.583	rs2915179	chr11:34871943	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.79	8.68	0.61	1.94e-14	Systemic lupus erythematosus and Systemic sclerosis;
TGCT	cis	rs16854884	0.683	rs920968	chr3:143770698	C/G	cg06585982	chr3:143692056	C3orf58	0.54	4.54	0.38	1.33e-5	Economic and political preferences (feminism/equality);
TGCT	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg02018176	chr4:1364513	KIAA1530	0.29	4.81	0.4	4.22e-6	Longevity;
TGCT	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.5	5.64	0.45	1.11e-7	Lymphocyte counts;
TGCT	cis	rs4654899	1.000	rs10799685	chr1:21465930	A/C	cg01072550	chr1:21505969	NA	0.51	8.3	0.6	1.5e-13	Superior frontal gyrus grey matter volume;
TGCT	cis	rs4478858	0.735	rs68008576	chr1:31805905	T/C	cg00250761	chr1:31883323	NA	-0.28	-4.96	-0.41	2.32e-6	Alcohol dependence;
TGCT	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.07	-9.63	-0.65	1.01e-16	Platelet count;
TGCT	cis	rs11792861	0.555	rs4978767	chr9:111762925	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.65	7.42	0.55	1.59e-11	Menarche (age at onset);
TGCT	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.18	0.49	8.32e-9	Electroencephalogram traits;
TGCT	cis	rs1843834	0.721	rs4674939	chr2:225613552	G/A	cg22455342	chr2:225449267	CUL3	0.65	6.29	0.49	5.01e-9	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs11601602	0.531	rs35031414	chr11:28545563	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.64	4.54	0.38	1.3e-5	Obesity-related traits;
TGCT	cis	rs6964587	1.000	rs4265	chr7:91719608	A/G	cg17063962	chr7:91808500	NA	-0.9	-10.29	-0.68	2.43e-18	Breast cancer;
TGCT	cis	rs3087591	0.664	rs2854308	chr17:29666539	A/G	cg24425628	chr17:29625626	OMG;NF1	0.39	5.56	0.45	1.57e-7	Hip circumference;
TGCT	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg03264133	chr6:25882463	NA	-0.68	-7.58	-0.56	7e-12	Blood metabolite levels;
TGCT	cis	rs6693567	0.565	rs1262432	chr1:150371839	C/A	cg09579323	chr1:150459698	TARS2	0.52	4.64	0.38	8.63e-6	Migraine;
TGCT	cis	rs7100689	0.646	rs7098045	chr10:82123856	G/C	cg01528321	chr10:82214614	TSPAN14	0.8	7.76	0.57	2.7e-12	Post bronchodilator FEV1;
TGCT	cis	rs7539409	0.915	rs1977119	chr1:84275509	A/G	cg10977910	chr1:84465055	TTLL7	0.95	5.28	0.43	5.5e-7	Alzheimer's disease;
TGCT	cis	rs933688	0.938	rs6869048	chr5:90664322	G/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.03	9.42	0.65	3.21e-16	Smoking behavior;
TGCT	cis	rs244731	0.959	rs6556307	chr5:176641434	C/T	cg16006841	chr5:176797999	RGS14	0.54	6.99	0.53	1.51e-10	Urate levels in lean individuals;
TGCT	trans	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg20587970	chr11:113659929	NA	-1.03	-10.98	-0.7	5.21e-20	Hip circumference adjusted for BMI;
TGCT	cis	rs7809950	1.000	rs10267907	chr7:107184466	C/T	cg23024343	chr7:107201750	COG5	-0.35	-5.43	-0.44	2.88e-7	Coronary artery disease;
TGCT	cis	rs9911578	0.967	rs8075786	chr17:56819216	T/C	cg05425664	chr17:57184151	TRIM37	-0.63	-6.26	-0.49	5.86e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg25036284	chr2:26402008	FAM59B	-0.54	-4.7	-0.39	6.93e-6	Gut microbiome composition (summer);
TGCT	cis	rs2235642	0.750	rs2755185	chr16:1645827	A/G	cg11375102	chr16:1583810	IFT140;TMEM204	-0.26	-4.55	-0.38	1.27e-5	Coronary artery disease;
TGCT	cis	rs4664308	1.000	rs6759836	chr2:160912802	C/T	cg03641300	chr2:160917029	PLA2R1	-0.26	-6.53	-0.51	1.49e-9	Idiopathic membranous nephropathy;
TGCT	cis	rs6964587	1.000	rs13231820	chr7:91663529	A/G	cg17063962	chr7:91808500	NA	0.88	9.54	0.65	1.69e-16	Breast cancer;
TGCT	cis	rs4242434	0.672	rs10099266	chr8:22484268	C/G	cg03733263	chr8:22462867	KIAA1967	0.97	13.6	0.77	2.44e-26	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg06238570	chr21:40685208	BRWD1	0.68	6.32	0.49	4.3e-9	Cognitive function;
TGCT	cis	rs9381040	1.000	rs2093396	chr6:41155000	G/A	cg03526776	chr6:41159608	TREML2	0.34	6.97	0.53	1.62e-10	Alzheimer's disease (late onset);
TGCT	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg24531977	chr5:56204891	C5orf35	-0.76	-7.34	-0.55	2.45e-11	Initial pursuit acceleration;
TGCT	cis	rs2361718	0.590	rs4527052	chr17:78140910	A/G	cg21238619	chr17:78079768	GAA	-0.31	-4.57	-0.38	1.16e-5	Yeast infection;
TGCT	cis	rs2354432	0.607	rs7511989	chr1:146720160	A/G	cg25205988	chr1:146714368	CHD1L	-1.34	-6.07	-0.48	1.44e-8	Mitochondrial DNA levels;
TGCT	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	5.23	0.43	6.92e-7	Menopause (age at onset);
TGCT	cis	rs1887596	0.624	rs2150472	chr13:27145012	G/A	cg01312412	chr13:27282625	NA	0.27	4.87	0.4	3.37e-6	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs11677370	0.574	rs12329183	chr2:3866943	G/A	cg17052675	chr2:3827356	NA	-0.43	-6.82	-0.52	3.48e-10	Type 2 diabetes;
TGCT	cis	rs2658782	0.951	rs2608215	chr11:93148817	G/A	cg18152523	chr11:93063302	CCDC67	-0.7	-5.73	-0.46	7.25e-8	Pulmonary function decline;
TGCT	cis	rs9910055	0.530	rs11652651	chr17:42302907	A/G	cg13607699	chr17:42295918	UBTF	-0.96	-10.78	-0.7	1.58e-19	Total body bone mineral density;
TGCT	cis	rs7973719	1.000	rs7973719	chr12:7334813	C/T	cg07052231	chr12:7363540	PEX5	0.34	5.03	0.41	1.7e-6	IgG glycosylation;
TGCT	cis	rs74233809	1.000	rs11191479	chr10:104723620	T/C	cg05855489	chr10:104503620	C10orf26	0.74	4.45	0.37	1.87e-5	Birth weight;
TGCT	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg22683308	chr4:1340831	KIAA1530	-0.64	-5.88	-0.47	3.6e-8	Longevity;
TGCT	cis	rs2933343	1.000	rs789227	chr3:128600585	C/G	cg11901034	chr3:128598214	ACAD9	-0.64	-5.05	-0.41	1.56e-6	IgG glycosylation;
TGCT	cis	rs2153535	0.601	rs7738877	chr6:8542230	A/G	cg23788917	chr6:8435910	SLC35B3	0.6	5.41	0.44	3.1e-7	Motion sickness;
TGCT	cis	rs910316	0.789	rs175444	chr14:75601782	G/C	cg11812906	chr14:75593930	NEK9	-0.63	-5.81	-0.46	4.98e-8	Height;
TGCT	cis	rs992157	0.585	rs62182795	chr2:219100202	C/T	cg00012203	chr2:219082015	ARPC2	-0.81	-9.41	-0.65	3.47e-16	Colorectal cancer;
TGCT	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg10802521	chr3:52805072	NEK4	-0.72	-8.85	-0.62	7.34e-15	Bipolar disorder;
TGCT	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg10876282	chr6:28092338	ZSCAN16	0.49	4.53	0.38	1.37e-5	Parkinson's disease;
TGCT	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg13395646	chr4:1353034	KIAA1530	-0.35	-4.51	-0.38	1.51e-5	Obesity-related traits;
TGCT	cis	rs1153858	1.000	rs1618874	chr15:45622786	A/G	cg26924012	chr15:45694286	SPATA5L1	0.96	11.77	0.73	6.36e-22	Homoarginine levels;
TGCT	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.51	5.37	0.43	3.71e-7	Menopause (age at onset);
TGCT	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg04025307	chr7:1156635	C7orf50	0.23	5.23	0.43	6.91e-7	Longevity;Endometriosis;
TGCT	cis	rs6977660	0.652	rs58559474	chr7:19751569	C/T	cg07541023	chr7:19748670	TWISTNB	1.15	7.28	0.55	3.33e-11	Thyroid stimulating hormone;
TGCT	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg04944784	chr2:26401820	FAM59B	-0.68	-6.07	-0.48	1.45e-8	Gut microbiome composition (summer);
TGCT	cis	rs854765	0.583	rs4925130	chr17:17807858	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.74	7.58	0.56	7.18e-12	Total body bone mineral density;
TGCT	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg22168489	chr12:122356033	WDR66	0.19	4.57	0.38	1.18e-5	Mean corpuscular volume;
TGCT	cis	rs4808199	0.948	rs7259434	chr19:19428805	A/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.69	5.48	0.44	2.24e-7	Nonalcoholic fatty liver disease;
TGCT	cis	rs7226408	0.901	rs56360477	chr18:34456833	G/A	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs700585	0.769	rs244760	chr5:88111209	C/G	cg02265379	chr5:87898506	LOC645323	0.4	4.91	0.4	2.8e-6	Platelet count;
TGCT	trans	rs797680	0.856	rs637646	chr1:93716383	A/C	cg27528825	chr2:159282178	CCDC148	0.35	6.88	0.53	2.65e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs12497850	0.897	rs9884022	chr3:48956862	G/C	cg07636037	chr3:49044803	WDR6	0.94	10.29	0.68	2.43e-18	Parkinson's disease;
TGCT	cis	rs17401966	0.838	rs946502	chr1:10309279	G/C	cg19773385	chr1:10388646	KIF1B	-0.2	-4.5	-0.37	1.54e-5	Hepatocellular carcinoma;
TGCT	cis	rs11247915	0.622	rs34370465	chr1:26670609	C/T	cg23732845	chr1:26663426	AIM1L	-0.37	-4.63	-0.38	8.98e-6	Obesity-related traits;
TGCT	cis	rs7818688	0.697	rs80217195	chr8:95986853	T/C	cg16049864	chr8:95962084	TP53INP1	0.54	4.64	0.38	8.87e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs9467773	1.000	rs10484442	chr6:26555879	A/G	cg05738196	chr6:26577821	NA	0.91	12.79	0.75	2.07e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs4727027	0.901	rs6944781	chr7:148829566	A/G	cg23583168	chr7:148888333	NA	-0.72	-9.18	-0.64	1.18e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs12579753	0.871	rs1922540	chr12:82197496	A/G	cg07988820	chr12:82153109	PPFIA2	-0.65	-6.79	-0.52	4.09e-10	Resting heart rate;
TGCT	cis	rs60733400	0.818	rs10909839	chr1:2708430	G/A	cg18854424	chr1:2615690	NA	0.45	4.99	0.41	1.99e-6	Multiple sclerosis;
TGCT	cis	rs9611565	0.729	rs12165508	chr22:41819960	T/C	cg03806693	chr22:41940476	POLR3H	1.03	11.32	0.71	7.58e-21	Vitiligo;
TGCT	cis	rs67478160	0.575	rs8014294	chr14:104322983	A/G	cg26031613	chr14:104095156	KLC1	-0.65	-6.52	-0.51	1.63e-9	Schizophrenia;
TGCT	cis	rs7584330	0.744	rs58223447	chr2:238378644	G/C	cg14458575	chr2:238380390	NA	0.61	9.25	0.64	8.25e-16	Prostate cancer;
TGCT	cis	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg25427524	chr10:38739819	LOC399744	-0.39	-7.88	-0.58	1.44e-12	Extrinsic epigenetic age acceleration;
TGCT	cis	rs4722166	0.604	rs2390715	chr7:22783878	A/C	cg26061582	chr7:22766209	IL6	0.57	7.31	0.55	2.85e-11	Lung cancer;
TGCT	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg08219700	chr8:58056026	NA	0.3	4.55	0.38	1.27e-5	Developmental language disorder (linguistic errors);
TGCT	trans	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg17830980	chr10:43048298	ZNF37B	-0.87	-11.11	-0.71	2.53e-20	Extrinsic epigenetic age acceleration;
TGCT	trans	rs1814175	0.653	rs10839480	chr11:50034556	C/T	cg15704280	chr7:45808275	SEPT13	-0.72	-8.47	-0.61	6.02e-14	Height;
TGCT	cis	rs3091242	0.836	rs35346083	chr1:25788425	C/A	cg23205692	chr1:25664452	TMEM50A	-0.49	-5.1	-0.42	1.26e-6	Erythrocyte sedimentation rate;
TGCT	cis	rs7432375	0.901	rs9836231	chr3:136414321	C/T	cg12473912	chr3:136751656	NA	-0.36	-5.06	-0.41	1.5e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs858239	0.932	rs1637190	chr7:23269065	A/G	cg05602783	chr7:23145260	KLHL7	-0.63	-5.22	-0.42	7.35e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs7772486	0.754	rs9399567	chr6:146147295	C/T	cg05347473	chr6:146136440	FBXO30	0.53	5.06	0.41	1.46e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3008870	0.959	rs4655658	chr1:67389608	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.1	12.09	0.74	1.01e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg08439880	chr3:133502540	NA	-0.36	-7.05	-0.53	1.1e-10	Iron status biomarkers;
TGCT	cis	rs6977955	1.000	rs2189965	chr7:28172014	C/T	cg23620719	chr7:28220237	JAZF1	0.59	4.63	0.38	9.15e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs2820315	1.000	rs2644122	chr1:201810407	A/G	cg12730843	chr1:201915899	LMOD1	-0.27	-4.76	-0.39	5.2e-6	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
TGCT	cis	rs3806843	0.966	rs2563267	chr5:140136913	C/T	cg19875535	chr5:140030758	IK	-0.37	-6.32	-0.49	4.29e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs4601821	0.789	rs7123797	chr11:113262571	A/G	cg14159747	chr11:113255604	NA	0.4	4.94	0.41	2.46e-6	Alcoholic chronic pancreatitis;
TGCT	cis	rs6088580	0.634	rs6059897	chr20:33113224	A/G	cg08999081	chr20:33150536	PIGU	0.29	5.57	0.45	1.54e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs1215050	0.874	rs2167893	chr4:99048464	A/T	cg17366294	chr4:99064904	C4orf37	0.49	4.93	0.41	2.55e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs3820068	0.532	rs6701009	chr1:15935614	T/C	cg05660106	chr1:15850417	CASP9	0.75	7.3	0.55	3.1e-11	Systolic blood pressure;
TGCT	cis	rs1885364	0.740	rs9608641	chr22:28093712	G/A	cg17187762	chr22:28070120	NA	0.25	4.48	0.37	1.67e-5	Facial morphology (factor 8, orbital inclination due to vertical and horizontal position of exocanthion);
TGCT	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg06481639	chr22:41940642	POLR3H	0.69	5.92	0.47	2.95e-8	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.12	0.54	7.78e-11	Prudent dietary pattern;
TGCT	cis	rs7666738	0.830	rs35685312	chr4:98858521	G/A	cg05340658	chr4:99064831	C4orf37	0.52	6.0	0.47	1.98e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg26338869	chr17:61819248	STRADA	0.56	5.12	0.42	1.13e-6	Prudent dietary pattern;
TGCT	cis	rs2288073	0.965	rs13395596	chr2:24410738	T/C	cg05570707	chr2:24270316	C2orf44	-0.5	-4.49	-0.37	1.58e-5	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs2469997	0.925	rs2470032	chr8:120371299	A/G	cg00681363	chr8:120844660	TAF2	0.69	4.48	0.37	1.64e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg25703541	chr22:24373054	LOC391322	-0.94	-11.32	-0.71	7.74e-21	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs11673344	0.523	rs2562599	chr19:37516374	A/C	cg08039142	chr19:36980659	ZNF566	-0.51	-4.8	-0.4	4.53e-6	Obesity-related traits;
TGCT	cis	rs2180341	0.960	rs9398839	chr6:127665863	G/A	cg24812749	chr6:127587940	RNF146	1.02	7.68	0.57	4.11e-12	Breast cancer;
TGCT	cis	rs8072100	0.811	rs9889709	chr17:45445229	C/T	cg08085267	chr17:45401833	C17orf57	-0.49	-5.6	-0.45	1.33e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs854765	0.506	rs7210400	chr17:17949957	C/T	cg09796270	chr17:17721594	SREBF1	-0.26	-5.16	-0.42	9.37e-7	Total body bone mineral density;
TGCT	cis	rs651907	0.535	rs11711903	chr3:101500748	C/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.82	9.98	0.67	1.4e-17	Colorectal cancer;
TGCT	cis	rs7826238	0.601	rs2979206	chr8:8345581	G/C	cg08975724	chr8:8085496	FLJ10661	0.61	5.93	0.47	2.78e-8	Systolic blood pressure;
TGCT	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg03388025	chr16:89894329	SPIRE2	0.5	8.5	0.61	4.92e-14	Vitiligo;
TGCT	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg23172400	chr8:95962367	TP53INP1	-0.4	-6.79	-0.52	4.23e-10	Type 2 diabetes;
TGCT	cis	rs9858542	0.537	rs35869135	chr3:49359102	A/G	cg00383909	chr3:49044727	WDR6	0.67	4.53	0.38	1.38e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg05754148	chr16:3507555	NAT15	-0.39	-4.59	-0.38	1.06e-5	Tuberculosis;
TGCT	cis	rs9611565	0.546	rs739129	chr22:42118249	G/A	cg13695892	chr22:41940480	POLR3H	0.88	8.63	0.61	2.45e-14	Vitiligo;
TGCT	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg11062466	chr8:58055876	NA	0.38	4.62	0.38	9.5e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg04944784	chr2:26401820	FAM59B	0.67	6.16	0.48	9.54e-9	Gut microbiome composition (summer);
TGCT	cis	rs2836974	0.583	rs9981884	chr21:40585633	G/A	cg17971929	chr21:40555470	PSMG1	0.64	6.01	0.48	1.88e-8	Cognitive function;
TGCT	cis	rs7208859	0.623	rs9916727	chr17:29107472	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs11242417	0.786	rs11746476	chr5:137511540	T/C	ch.5.2533205R	chr5:137273929	FAM13B;PKD2L2	-0.54	-4.64	-0.38	8.86e-6	Immune reponse to smallpox (secreted IL-12p40);
TGCT	cis	rs7959452	0.557	rs899224	chr12:69784774	A/G	cg11871910	chr12:69753446	YEATS4	0.82	8.95	0.63	4.38e-15	Blood protein levels;
TGCT	cis	rs2594989	0.943	rs2244617	chr3:11503097	T/C	cg00170343	chr3:11313890	ATG7	0.69	5.12	0.42	1.16e-6	Circulating chemerin levels;
TGCT	cis	rs394563	0.559	rs7752555	chr6:149671116	A/G	cg11245181	chr6:149772854	ZC3H12D	0.28	4.5	0.37	1.57e-5	Dupuytren's disease;
TGCT	cis	rs2075371	0.897	rs1646743	chr7:134003451	C/A	cg11752832	chr7:134001865	SLC35B4	0.81	7.72	0.57	3.36e-12	Mean platelet volume;
TGCT	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg11871910	chr12:69753446	YEATS4	0.88	10.41	0.68	1.28e-18	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg03806693	chr22:41940476	POLR3H	-1.14	-13.51	-0.77	4e-26	Vitiligo;
TGCT	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg13397359	chr6:42928475	GNMT	0.73	6.51	0.5	1.65e-9	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs3820068	0.603	rs1122387	chr1:15947282	T/C	cg05660106	chr1:15850417	CASP9	0.83	8.16	0.59	3.26e-13	Systolic blood pressure;
TGCT	cis	rs6750047	0.647	rs11124632	chr2:38276412	G/C	cg07380506	chr2:38303506	CYP1B1	0.62	5.7	0.46	8.25e-8	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs155076	0.938	rs9509630	chr13:21844314	G/A	cg14456004	chr13:21872349	NA	-1.32	-10.82	-0.7	1.25e-19	White matter hyperintensity burden;
TGCT	cis	rs11030122	0.702	rs995498	chr11:3967791	A/G	cg18678763	chr11:4115507	RRM1	-0.49	-6.14	-0.48	1.01e-8	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	5.88	0.47	3.64e-8	Alzheimer's disease;
TGCT	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.74	-0.39	5.77e-6	Prudent dietary pattern;
TGCT	cis	rs9796	0.553	rs2925343	chr15:41306493	T/C	cg18705301	chr15:41695430	NDUFAF1	0.52	6.74	0.52	5.41e-10	Menopause (age at onset);
TGCT	cis	rs7681440	0.904	rs2301135	chr4:90758389	G/C	cg14346243	chr4:90757452	SNCA	-0.59	-5.74	-0.46	6.87e-8	Dementia with Lewy bodies;
TGCT	cis	rs11190604	1.000	rs2003284	chr10:102202338	A/G	cg16342193	chr10:102329863	NA	-0.4	-5.31	-0.43	4.85e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs1153858	1.000	rs4775909	chr15:45643042	T/C	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.63e-8	Homoarginine levels;
TGCT	cis	rs10883723	0.703	rs7898410	chr10:104245858	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg27535305	chr1:53392650	SCP2	0.26	5.05	0.41	1.53e-6	Monocyte count;
TGCT	cis	rs7500321	1.000	rs7500321	chr16:28977020	G/A	cg01117621	chr16:28073818	GSG1L	-0.35	-4.47	-0.37	1.76e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs61990749	0.597	rs2364584	chr14:78152286	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	-0.62	-4.59	-0.38	1.09e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs7267979	0.932	rs2260997	chr20:25256266	A/C	cg03522245	chr20:25566470	NINL	-0.63	-7.09	-0.54	8.76e-11	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9914544	0.966	rs1737943	chr17:18841590	A/G	cg26306683	chr17:18585705	ZNF286B	-0.58	-5.2	-0.42	8.01e-7	Educational attainment (years of education);
TGCT	cis	rs651907	0.557	rs3094296	chr3:101400167	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	4.96	0.41	2.26e-6	Colorectal cancer;
TGCT	cis	rs9913156	0.894	rs28365158	chr17:4620928	T/C	cg00122941	chr17:4613640	ARRB2	0.94	8.09	0.59	4.57e-13	Lymphocyte counts;
TGCT	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.67	-4.55	-0.38	1.28e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs3096299	0.874	rs3102342	chr16:89451575	T/C	cg06640241	chr16:89574553	SPG7	0.65	6.32	0.49	4.2e-9	Multiple myeloma (IgH translocation);
TGCT	cis	rs6582630	0.502	rs8186661	chr12:38380781	G/A	cg26384229	chr12:38710491	ALG10B	0.84	7.3	0.55	2.97e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs988712	0.550	rs988748	chr11:27724745	C/G	cg10635145	chr11:27742435	BDNF	0.44	6.3	0.49	4.71e-9	Obesity;
TGCT	cis	rs7552404	1.000	rs4949674	chr1:76213715	C/A	cg03433033	chr1:76189801	ACADM	0.81	9.52	0.65	1.84e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2303745	0.589	rs751599	chr19:17396549	A/G	cg04248312	chr19:17393744	ANKLE1	-0.32	-5.35	-0.43	4.12e-7	Systemic lupus erythematosus;
TGCT	cis	rs79349575	0.594	rs62078375	chr17:47034974	A/G	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.44	-0.37	1.99e-5	Type 2 diabetes;
TGCT	cis	rs4466137	1.000	rs1154888	chr5:82977410	C/A	cg16102102	chr5:83017553	HAPLN1	-0.93	-10.85	-0.7	1.06e-19	Prostate cancer;
TGCT	trans	rs1973993	0.567	rs2800433	chr1:96998126	T/A	cg10631902	chr5:14652156	NA	0.37	9.49	0.65	2.22e-16	Weight;
TGCT	cis	rs11577318	1.000	rs11577318	chr1:26601570	A/G	cg04990556	chr1:26633338	UBXN11	0.66	5.01	0.41	1.85e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs7542091	0.704	rs1883331	chr1:210043483	A/G	cg23283495	chr1:209979779	IRF6	0.55	5.47	0.44	2.34e-7	Monobrow;
TGCT	cis	rs6901250	0.851	rs7740481	chr6:117149307	G/C	cg12892004	chr6:117198278	RFX6	0.54	6.65	0.51	8.24e-10	C-reactive protein levels;
TGCT	cis	rs1552244	0.554	rs34883592	chr3:10046165	C/T	cg00149659	chr3:10157352	C3orf10	0.69	4.99	0.41	2.03e-6	Alzheimer's disease;
TGCT	cis	rs7666738	0.791	rs1830231	chr4:99026185	A/C	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs669446	0.591	rs649504	chr1:44105948	T/C	cg12908607	chr1:44402522	ARTN	-0.55	-5.9	-0.47	3.25e-8	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs79057730	0.599	rs35928068	chr7:805363	G/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.65	5.41	0.44	3.16e-7	Initial pursuit acceleration;
TGCT	trans	rs4332037	0.539	rs57148375	chr7:2025001	G/C	cg25206134	chr2:45395956	NA	0.97	7.33	0.55	2.6e-11	Bipolar disorder;
TGCT	cis	rs514406	0.644	rs928451	chr1:53195800	A/G	cg24675658	chr1:53192096	ZYG11B	0.84	10.45	0.68	1.03e-18	Monocyte count;
TGCT	cis	rs7267979	1.000	rs10966	chr20:25282944	A/G	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7666738	0.830	rs28451001	chr4:98924544	T/A	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7860634	0.872	rs7847312	chr9:139089718	A/C	cg04455058	chr9:139085579	NA	0.47	5.14	0.42	1.04e-6	Thyroid hormone levels;
TGCT	cis	rs35146811	0.735	rs7811662	chr7:99792608	A/G	cg04778012	chr7:99775508	STAG3;GPC2	0.35	4.93	0.41	2.55e-6	Coronary artery disease;
TGCT	cis	rs7824557	0.545	rs2572450	chr8:11229638	C/T	cg21775007	chr8:11205619	TDH	-0.66	-6.47	-0.5	2.01e-9	Retinal vascular caliber;
TGCT	cis	rs763121	0.853	rs2072796	chr22:39064230	A/G	cg06022373	chr22:39101656	GTPBP1	0.77	7.51	0.56	9.98e-12	Menopause (age at onset);
TGCT	cis	rs6570726	0.935	rs414646	chr6:145831685	T/C	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg02380750	chr20:61661411	NA	0.33	5.88	0.47	3.54e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg00864171	chr11:67383662	NA	0.33	5.06	0.41	1.47e-6	Mean corpuscular volume;
TGCT	cis	rs9303401	0.659	rs62083368	chr17:56878062	G/A	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs6912958	0.935	rs6454629	chr6:88165515	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.37	-4.74	-0.39	5.79e-6	Monocyte percentage of white cells;
TGCT	cis	rs8180040	0.966	rs11719877	chr3:47425473	C/T	cg27129171	chr3:47204927	SETD2	0.65	7.74	0.57	2.99e-12	Colorectal cancer;
TGCT	cis	rs2228638	0.816	rs2269088	chr10:33530050	A/G	cg08604594	chr10:33798231	NA	-0.39	-4.82	-0.4	4.2e-6	Tetralogy of Fallot;
TGCT	cis	rs9527	0.590	rs10509766	chr10:104926334	T/C	cg04362960	chr10:104952993	NT5C2	0.67	5.64	0.45	1.07e-7	Arsenic metabolism;
TGCT	cis	rs806215	0.526	rs62481447	chr7:127563189	G/T	cg11539674	chr7:127291444	SND1	-0.36	-4.65	-0.39	8.37e-6	Type 2 diabetes;
TGCT	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.72	5.19	0.42	8.33e-7	Platelet count;
TGCT	cis	rs36051895	0.658	rs72699574	chr9:5020089	G/A	cg02405213	chr9:5042618	JAK2	-0.71	-9.1	-0.63	1.89e-15	Pediatric autoimmune diseases;
TGCT	cis	rs73198271	0.653	rs10087742	chr8:8660474	A/G	cg06636001	chr8:8085503	FLJ10661	-0.6	-4.47	-0.37	1.78e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs7772486	0.790	rs2253768	chr6:146199922	A/G	cg13319975	chr6:146136371	FBXO30	-0.51	-4.43	-0.37	2.01e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10193935	0.818	rs10221927	chr2:42546680	A/C	cg27598129	chr2:42591480	NA	-0.41	-5.59	-0.45	1.4e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10256972	0.514	rs2140578	chr7:1214003	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.62	-8.32	-0.6	1.37e-13	Longevity;Endometriosis;
TGCT	cis	rs782590	0.934	rs17369191	chr2:55757885	T/C	cg18811423	chr2:55921094	PNPT1	0.66	7.14	0.54	7.11e-11	Metabolic syndrome;
TGCT	cis	rs6504950	0.720	rs7216138	chr17:52995664	G/A	cg07707039	chr17:53042137	COX11	0.27	4.66	0.39	8.15e-6	Breast cancer;
TGCT	cis	rs7819412	0.561	rs2001328	chr8:10987199	T/C	cg21775007	chr8:11205619	TDH	-0.55	-5.05	-0.41	1.53e-6	Triglycerides;
TGCT	cis	rs7666738	0.830	rs11727235	chr4:98946331	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9457247	1.000	rs415842	chr6:167406681	G/A	cg23791538	chr6:167370224	RNASET2	-0.49	-4.96	-0.41	2.26e-6	Crohn's disease;
TGCT	cis	rs9611565	0.765	rs132909	chr22:41802031	G/A	cg17554472	chr22:41940697	POLR3H	0.43	4.79	0.39	4.73e-6	Vitiligo;
TGCT	cis	rs6586111	1.000	rs7097564	chr10:82372188	T/C	cg03086067	chr10:82368399	SH2D4B	-0.24	-4.7	-0.39	6.84e-6	Capecitabine sensitivity;
TGCT	cis	rs9902453	0.868	rs7212162	chr17:28321328	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.84	8.01	0.58	7.28e-13	Coffee consumption (cups per day);
TGCT	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.73	7.52	0.56	9.57e-12	Blood metabolite levels;
TGCT	cis	rs7267979	1.000	rs6050602	chr20:25401203	A/G	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs17767294	0.614	rs41269291	chr6:28251539	A/G	cg08851530	chr6:28072375	NA	1.54	6.89	0.53	2.51e-10	Parkinson's disease;
TGCT	cis	rs9916302	0.904	rs57399933	chr17:37551189	A/G	cg07936489	chr17:37558343	FBXL20	0.63	4.84	0.4	3.76e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs2456568	0.548	rs1607402	chr11:93660732	T/G	cg17595323	chr11:93583763	C11orf90	-0.42	-5.14	-0.42	1.03e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs896854	0.608	rs6991067	chr8:95875676	A/G	cg16049864	chr8:95962084	TP53INP1	-0.58	-7.09	-0.54	9.12e-11	Type 2 diabetes;
TGCT	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg07507251	chr3:52567010	NT5DC2	0.46	6.68	0.51	7.37e-10	Bipolar disorder;
TGCT	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg03609598	chr5:56110824	MAP3K1	-0.58	-4.7	-0.39	6.72e-6	Initial pursuit acceleration;
TGCT	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg06618935	chr21:46677482	NA	-0.38	-5.69	-0.45	8.75e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7147624	1.000	rs10083363	chr14:66200768	G/A	cg03016385	chr14:66212404	NA	-0.5	-7.04	-0.53	1.13e-10	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs2456568	0.802	rs8181567	chr11:93637209	C/T	cg26875233	chr11:93583750	C11orf90	-0.48	-6.47	-0.5	2.09e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7833790	0.724	rs10958045	chr8:82722994	T/C	cg23324259	chr8:82754387	SNX16	-0.61	-4.71	-0.39	6.42e-6	Diastolic blood pressure;
TGCT	cis	rs877282	0.786	rs11253392	chr10:788768	G/A	cg17470449	chr10:769945	NA	0.3	4.71	0.39	6.53e-6	Uric acid levels;
TGCT	cis	rs2440129	0.591	rs312466	chr17:6899221	G/A	cg03407747	chr17:6899364	ALOX12	-0.49	-5.55	-0.45	1.61e-7	Tonsillectomy;
TGCT	cis	rs2541522	0.600	rs8057438	chr16:10744907	G/C	cg21839338	chr16:10912331	FAM18A	0.4	4.48	0.37	1.65e-5	Gut microbiome composition (summer);
TGCT	cis	rs68170813	0.559	rs6967638	chr7:106929356	T/G	cg02696742	chr7:106810147	HBP1	-0.68	-5.69	-0.46	8.53e-8	Coronary artery disease;
TGCT	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg11905131	chr22:24372483	LOC391322	0.66	5.2	0.42	7.88e-7	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs6545883	0.718	rs2694624	chr2:61672313	C/A	cg15711740	chr2:61764176	XPO1	-0.54	-4.93	-0.4	2.62e-6	Tuberculosis;
TGCT	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg11764359	chr7:65958608	NA	-0.59	-5.28	-0.43	5.5e-7	Aortic root size;
TGCT	cis	rs11673344	0.523	rs2562607	chr19:37522260	A/G	cg08039142	chr19:36980659	ZNF566	0.5	4.64	0.38	8.58e-6	Obesity-related traits;
TGCT	cis	rs6867032	0.527	rs4246752	chr5:1975575	T/A	cg05184729	chr5:1962311	NA	0.28	4.75	0.39	5.57e-6	Gut microbiome composition (winter);
TGCT	cis	rs1775715	0.705	rs2778651	chr10:32106575	C/T	cg14930904	chr10:32216787	ARHGAP12	0.5	4.85	0.4	3.62e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs7586879	0.828	rs12986610	chr2:25106265	A/G	cg01884057	chr2:25150051	NA	-0.25	-4.51	-0.38	1.5e-5	Body mass index;
TGCT	cis	rs2115630	0.967	rs28595395	chr15:85334952	T/C	cg11189052	chr15:85197271	WDR73	-0.63	-6.08	-0.48	1.34e-8	P wave terminal force;
TGCT	cis	rs2046867	0.908	rs2322610	chr3:72793651	C/A	cg25664220	chr3:72788482	NA	-0.55	-6.95	-0.53	1.83e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs12210905	0.688	rs12213471	chr6:27406063	C/G	cg08851530	chr6:28072375	NA	1.34	6.07	0.48	1.44e-8	Hip circumference adjusted for BMI;
TGCT	cis	rs10504229	1.000	rs67096506	chr8:58195655	G/A	cg22535103	chr8:58192502	C8orf71	-0.39	-4.62	-0.38	9.61e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	9.52	0.65	1.86e-16	Platelet count;
TGCT	trans	rs2727020	0.521	rs11040377	chr11:49474346	T/C	cg15704280	chr7:45808275	SEPT13	-0.64	-7.11	-0.54	8.23e-11	Coronary artery disease;
TGCT	cis	rs1018836	0.923	rs9694450	chr8:91618292	G/A	cg16814680	chr8:91681699	NA	-0.91	-9.64	-0.65	9.57e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs3125734	0.719	rs3852410	chr10:64037563	A/G	cg19640130	chr10:64028056	RTKN2	0.37	4.48	0.37	1.67e-5	Rheumatoid arthritis;
TGCT	cis	rs17376456	0.809	rs12152763	chr5:93405509	T/A	cg21475434	chr5:93447410	FAM172A	0.6	4.62	0.38	9.48e-6	Diabetic retinopathy;
TGCT	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg08439880	chr3:133502540	NA	-0.33	-6.28	-0.49	5.28e-9	Iron status biomarkers;
TGCT	cis	rs1371867	0.875	rs1788184	chr8:101335106	A/G	cg06636551	chr8:101224915	SPAG1	-0.42	-5.65	-0.45	1.06e-7	Atrioventricular conduction;
TGCT	cis	rs2180341	0.538	rs3756993	chr6:127651551	A/C	cg24812749	chr6:127587940	RNF146	0.63	5.32	0.43	4.67e-7	Breast cancer;
TGCT	cis	rs3935685	0.874	rs11072665	chr15:78006256	T/C	cg03457338	chr15:78040120	NA	-0.22	-5.59	-0.45	1.37e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2073300	1.000	rs6048833	chr20:23462185	G/A	cg09953122	chr20:23471693	CST8	-0.59	-4.75	-0.39	5.62e-6	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs6500602	0.627	rs9934267	chr16:4534366	G/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.43	6.28	0.49	5.19e-9	Schizophrenia;
TGCT	cis	rs11785400	0.762	rs7017931	chr8:143726728	A/G	cg24634471	chr8:143751801	JRK	0.53	5.33	0.43	4.41e-7	Schizophrenia;
TGCT	cis	rs2688608	0.620	rs12253408	chr10:75495956	G/T	cg23231163	chr10:75533350	FUT11	-0.28	-4.68	-0.39	7.4e-6	Inflammatory bowel disease;
TGCT	cis	rs2204008	0.720	rs11180923	chr12:38255172	A/T	cg13010199	chr12:38710504	ALG10B	0.61	4.67	0.39	7.69e-6	Bladder cancer;
TGCT	cis	rs13242816	1.000	rs2052105	chr7:116187979	T/C	cg16553024	chr7:116138462	CAV2	-0.45	-5.3	-0.43	5.1e-7	P wave duration;
TGCT	cis	rs17401966	0.838	rs1556916	chr1:10403482	G/A	cg19773385	chr1:10388646	KIF1B	-0.23	-5.38	-0.44	3.57e-7	Hepatocellular carcinoma;
TGCT	cis	rs3892630	0.878	rs2903759	chr19:33195947	A/G	cg22980127	chr19:33182716	NUDT19	0.7	5.18	0.42	8.9e-7	Red blood cell traits;
TGCT	cis	rs7843479	0.930	rs2054713	chr8:21840534	A/G	cg17168535	chr8:21777572	XPO7	0.63	5.73	0.46	7.05e-8	Mean corpuscular volume;
TGCT	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg07636037	chr3:49044803	WDR6	0.85	8.85	0.62	7.4e-15	Menarche (age at onset);
TGCT	cis	rs2153535	0.580	rs763376	chr6:8492776	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs6089584	0.893	rs6089306	chr20:60574868	G/A	cg06108461	chr20:60628389	TAF4	-0.58	-8.21	-0.59	2.37e-13	Body mass index;
TGCT	cis	rs2153535	0.580	rs9378552	chr6:8463748	G/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs1008375	0.966	rs6839660	chr4:17667987	C/T	cg16339924	chr4:17578868	LAP3	0.56	4.91	0.4	2.78e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs11247915	0.644	rs11588739	chr1:26653319	G/A	cg23732845	chr1:26663426	AIM1L	-0.34	-4.44	-0.37	1.95e-5	Obesity-related traits;
TGCT	cis	rs2361710	0.611	rs12451471	chr17:78102517	C/T	cg09238746	chr17:78121135	EIF4A3	-0.59	-4.75	-0.39	5.6e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
TGCT	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg04944784	chr2:26401820	FAM59B	0.76	6.24	0.49	6.46e-9	Gut microbiome composition (summer);
TGCT	cis	rs7772486	0.754	rs1055212	chr6:146058315	A/T	cg05347473	chr6:146136440	FBXO30	-0.51	-4.66	-0.39	8.17e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs62380364	0.602	rs610217	chr5:88065263	G/A	cg22951263	chr5:87985283	NA	-0.6	-6.34	-0.49	3.84e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs6570726	0.791	rs6570693	chr6:145910841	C/T	cg05347473	chr6:146136440	FBXO30	0.51	4.75	0.39	5.42e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4812048	0.602	rs59637156	chr20:57619618	T/C	cg14073986	chr20:57617431	SLMO2	0.54	4.48	0.37	1.66e-5	Mean platelet volume;
TGCT	cis	rs11098499	0.954	rs2306455	chr4:120421969	G/A	cg09307838	chr4:120376055	NA	0.68	6.37	0.5	3.41e-9	Corneal astigmatism;
TGCT	cis	rs612683	0.517	rs3767832	chr1:100943100	A/G	cg06223162	chr1:101003688	GPR88	-0.31	-5.58	-0.45	1.41e-7	Breast cancer;
TGCT	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	5.52	0.44	1.86e-7	Height;
TGCT	cis	rs4733781	0.863	rs6470805	chr8:131161571	A/G	cg16277922	chr8:131349729	ASAP1	0.39	4.87	0.4	3.3e-6	Tuberculosis;
TGCT	cis	rs9894429	0.966	rs6565601	chr17:79580173	C/T	cg18240062	chr17:79603768	NPLOC4	0.67	6.84	0.52	3.23e-10	Eye color traits;
TGCT	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg11366901	chr6:160182831	ACAT2	0.74	5.59	0.45	1.36e-7	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs9549367	0.789	rs71446679	chr13:113894821	C/T	cg18105134	chr13:113819100	PROZ	-0.34	-5.58	-0.45	1.41e-7	Platelet distribution width;
TGCT	cis	rs1878931	0.507	rs34370895	chr16:3396319	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.66	-5.09	-0.42	1.28e-6	Body mass index (adult);
TGCT	cis	rs7945705	0.967	rs56316046	chr11:8876598	G/T	cg21881798	chr11:8931708	C11orf17;ST5	0.44	5.04	0.41	1.59e-6	Hemoglobin concentration;
TGCT	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg11301795	chr4:187892539	NA	-0.34	-4.97	-0.41	2.17e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs595982	0.527	rs17272673	chr19:49362992	C/A	cg21252483	chr19:49399788	TULP2	-0.43	-6.54	-0.51	1.48e-9	Red cell distribution width;
TGCT	cis	rs8180040	0.620	rs4683322	chr3:47093189	T/C	cg27129171	chr3:47204927	SETD2	0.71	8.55	0.61	3.9e-14	Colorectal cancer;
TGCT	cis	rs7172809	0.897	rs74026930	chr15:77825253	G/A	cg22256960	chr15:77711686	NA	-0.44	-4.48	-0.37	1.67e-5	Glucose homeostasis traits;
TGCT	cis	rs6589563	0.609	rs57641217	chr11:116632956	C/T	cg20660624	chr11:117307972	DSCAML1	-0.35	-4.65	-0.39	8.34e-6	Eosinophil counts;
TGCT	cis	rs1362404	0.552	rs2192858	chr16:51992615	C/T	cg03955530	chr16:52681474	NA	0.3	4.81	0.4	4.38e-6	Gut microbiota (bacterial taxa);
TGCT	cis	rs9372498	0.536	rs9481833	chr6:118919631	G/A	cg07617317	chr6:118971624	C6orf204	0.49	5.22	0.42	7.37e-7	Diastolic blood pressure;
TGCT	cis	rs9443645	0.836	rs9352676	chr6:79629999	A/G	cg09184832	chr6:79620586	NA	-0.49	-5.29	-0.43	5.29e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7845219	0.525	rs6471501	chr8:95922491	A/G	cg16049864	chr8:95962084	TP53INP1	-0.51	-5.45	-0.44	2.56e-7	Type 2 diabetes;
TGCT	cis	rs7586879	0.639	rs13407913	chr2:25097644	A/G	cg01884057	chr2:25150051	NA	0.31	5.94	0.47	2.72e-8	Body mass index;
TGCT	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg16423285	chr20:60520624	NA	-0.61	-6.46	-0.5	2.12e-9	Body mass index;
TGCT	cis	rs12541335	0.639	rs4872468	chr8:22179844	G/C	cg02788857	chr8:22132959	PIWIL2	0.28	5.13	0.42	1.1e-6	Hypertriglyceridemia;
TGCT	cis	rs4494114	1.000	rs9439081	chr1:39343012	A/G	cg25970120	chr1:39325951	RRAGC	-0.58	-5.93	-0.47	2.84e-8	Blood protein levels;
TGCT	cis	rs7582180	0.764	rs4635546	chr2:100921125	G/A	cg14675211	chr2:100938903	LONRF2	0.51	4.93	0.4	2.61e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg18252515	chr7:66147081	NA	1.25	7.75	0.57	2.92e-12	Diabetic kidney disease;
TGCT	cis	rs1153858	1.000	rs67744121	chr15:45677237	C/G	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.62e-8	Homoarginine levels;
TGCT	cis	rs62064224	0.638	rs9748130	chr17:30739113	A/G	cg18200150	chr17:30822561	MYO1D	0.41	4.92	0.4	2.72e-6	Schizophrenia;
TGCT	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg11764359	chr7:65958608	NA	-0.55	-5.12	-0.42	1.14e-6	Aortic root size;
TGCT	cis	rs265548	0.608	rs36690	chr19:17910483	C/T	cg04517722	chr19:17905589	B3GNT3	0.49	6.48	0.5	1.93e-9	Tumor biomarkers;
TGCT	cis	rs999943	0.774	rs10947421	chr6:33611278	G/T	cg14003231	chr6:33640908	ITPR3	0.39	4.9	0.4	2.97e-6	Obesity (extreme);
TGCT	cis	rs7208859	0.623	rs28627615	chr17:29145817	G/C	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs644799	1.000	rs488246	chr11:95560473	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	10.52	0.69	6.94e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg08280861	chr8:58055591	NA	0.38	4.81	0.4	4.36e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7104764	0.917	rs1045288	chr11:237087	A/G	cg18336825	chr11:236787	PSMD13;SIRT3	1.07	11.15	0.71	2.05e-20	Menarche (age at onset);
TGCT	cis	rs2637266	1.000	rs2395389	chr10:78357701	C/T	cg18941641	chr10:78392320	NA	0.37	4.5	0.37	1.53e-5	Pulmonary function;
TGCT	cis	rs60843830	1.000	rs55936726	chr2:258210	T/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.71	6.83	0.52	3.39e-10	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg20607798	chr8:58055168	NA	0.61	5.16	0.42	9.38e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6582630	0.519	rs7305570	chr12:38349285	G/A	cg13010199	chr12:38710504	ALG10B	0.58	4.52	0.38	1.41e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg18252515	chr7:66147081	NA	-1.09	-6.4	-0.5	2.88e-9	Diabetic kidney disease;
TGCT	cis	rs763014	0.833	rs916415	chr16:632115	G/A	cg27436995	chr16:743998	FBXL16	-0.45	-4.82	-0.4	4.17e-6	Height;
TGCT	cis	rs4901869	0.966	rs431343	chr14:59345530	C/T	cg02291164	chr14:59296302	NA	0.25	4.82	0.4	4.11e-6	Panic disorder;
TGCT	cis	rs6921919	0.583	rs7764722	chr6:28354533	C/T	cg13525197	chr6:28411240	ZSCAN23	-0.5	-4.52	-0.38	1.42e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs61897795	0.628	rs174597	chr11:61621040	G/C	cg19610905	chr11:61596333	FADS2	-0.62	-4.65	-0.39	8.27e-6	Neutrophil count;Sum basophil neutrophil counts;
TGCT	cis	rs319204	1.000	rs319217	chr5:146253893	T/C	cg13983063	chr5:146258615	PPP2R2B	0.32	4.6	0.38	1.04e-5	Schizophrenia;
TGCT	cis	rs12711979	0.509	rs10187740	chr2:3823965	A/G	cg17052675	chr2:3827356	NA	0.55	12.73	0.75	2.94e-24	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs3845702	0.736	rs12465592	chr2:180862654	C/G	cg01881094	chr2:180872142	CWC22	1.06	6.66	0.51	8.12e-10	Schizophrenia;
TGCT	cis	rs155076	1.000	rs261430	chr13:21865242	C/T	cg14456004	chr13:21872349	NA	-1.23	-9.97	-0.67	1.49e-17	White matter hyperintensity burden;
TGCT	trans	rs1005277	0.522	rs289648	chr10:37971837	T/C	cg17830980	chr10:43048298	ZNF37B	-0.66	-7.47	-0.56	1.22e-11	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2120019	1.000	rs1867146	chr15:75354971	C/G	cg09165964	chr15:75287851	SCAMP5	-1.18	-9.83	-0.66	3.33e-17	Blood trace element (Zn levels);
TGCT	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg24829409	chr8:58192753	C8orf71	-0.54	-5.17	-0.42	9.01e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6089829	0.851	rs6089827	chr20:61668845	C/T	cg08045932	chr20:61659980	NA	0.48	9.09	0.63	2.04e-15	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs8177179	0.967	rs4287912	chr3:133437778	A/G	cg24879335	chr3:133465180	TF	0.36	4.79	0.4	4.67e-6	Iron status biomarkers (transferrin levels);
TGCT	cis	rs6429082	0.818	rs291383	chr1:235643100	G/A	cg26050004	chr1:235667680	B3GALNT2	0.62	5.58	0.45	1.43e-7	Adiposity;
TGCT	trans	rs7824557	0.547	rs6601570	chr8:11079367	G/A	cg15556689	chr8:8085844	FLJ10661	-0.89	-8.62	-0.61	2.69e-14	Retinal vascular caliber;
TGCT	cis	rs10510102	0.872	rs11200292	chr10:123726898	A/G	cg23691251	chr10:123688108	ATE1	-0.59	-4.7	-0.39	6.75e-6	Breast cancer;
TGCT	cis	rs3091242	0.935	rs4233043	chr1:25765483	A/G	cg00786635	chr1:25594202	NA	0.54	5.72	0.46	7.45e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs7944584	0.611	rs10838696	chr11:47363285	A/G	cg20307385	chr11:47447363	PSMC3	-0.82	-8.29	-0.6	1.55e-13	Fasting blood glucose;Fasting blood glucose (BMI interaction);
TGCT	cis	rs9302001	0.920	rs9516479	chr13:95459936	C/T	cg07483244	chr13:95358924	NA	0.37	4.81	0.4	4.22e-6	Panic disorder;
TGCT	cis	rs7845219	0.544	rs9643352	chr8:95918288	C/T	cg13393036	chr8:95962371	TP53INP1	-0.45	-5.18	-0.42	8.66e-7	Type 2 diabetes;
TGCT	cis	rs7523050	0.558	rs35926243	chr1:109407712	T/A	cg08274380	chr1:109419600	GPSM2	1.3	6.39	0.5	2.99e-9	Fat distribution (HIV);
TGCT	cis	rs61990749	0.597	rs1477260	chr14:78256818	G/C	cg23188588	chr14:78226832	SNW1;C14orf178	0.67	4.73	0.39	6.09e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs7511006	0.895	rs5771270	chr22:50682865	G/A	cg08875078	chr22:50639485	SELO	0.51	4.73	0.39	5.99e-6	Obesity-related traits;
TGCT	trans	rs6762477	0.715	rs12631337	chr3:50198537	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.88	-9.49	-0.65	2.16e-16	Menarche (age at onset);
TGCT	cis	rs2688608	0.592	rs10824032	chr10:75528130	G/A	cg19442545	chr10:75533431	FUT11	-0.35	-5.66	-0.45	9.97e-8	Inflammatory bowel disease;
TGCT	cis	rs7100689	0.622	rs4933378	chr10:82147057	T/C	cg01528321	chr10:82214614	TSPAN14	0.79	7.93	0.58	1.11e-12	Post bronchodilator FEV1;
TGCT	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg11644478	chr21:40555479	PSMG1	1.02	11.02	0.7	4.19e-20	Cognitive function;
TGCT	cis	rs362272	0.545	rs2236052	chr4:3318413	C/T	cg22655196	chr4:3374909	RGS12	-0.24	-4.98	-0.41	2.07e-6	Serum sulfate level;
TGCT	cis	rs11578119	0.866	rs12140680	chr1:170353228	C/G	cg09767346	chr1:170501363	GORAB	0.61	4.61	0.38	9.8e-6	Male-pattern baldness;
TGCT	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg07747251	chr5:1868357	NA	0.39	5.66	0.45	9.96e-8	Cardiovascular disease risk factors;
TGCT	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg19318889	chr4:1322082	MAEA	0.27	6.54	0.51	1.45e-9	Longevity;
TGCT	cis	rs9916302	0.653	rs11654954	chr17:37745979	C/T	cg07936489	chr17:37558343	FBXL20	0.68	5.35	0.43	4.11e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs2153535	0.580	rs2327051	chr6:8441150	A/G	cg07606381	chr6:8435919	SLC35B3	-0.51	-4.57	-0.38	1.18e-5	Motion sickness;
TGCT	cis	rs4930103	0.619	rs739905	chr11:1980360	G/C	cg18032502	chr11:1949113	TNNT3	0.25	4.72	0.39	6.27e-6	DNA methylation (parent-of-origin);DNA methylation (variation);
TGCT	cis	rs854765	0.624	rs12952723	chr17:17731651	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.68	-6.35	-0.5	3.78e-9	Total body bone mineral density;
TGCT	cis	rs11249608	0.548	rs13161528	chr5:178452958	C/G	cg21905437	chr5:178450457	ZNF879	0.43	4.5	0.37	1.53e-5	Pubertal anthropometrics;
TGCT	cis	rs7698623	0.850	rs2045834	chr4:88800642	C/T	cg02735620	chr4:88950514	PKD2	-0.44	-4.78	-0.39	4.95e-6	Cardiovascular disease risk factors;
TGCT	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg08219700	chr8:58056026	NA	0.38	4.61	0.38	1e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs682748	0.810	rs62349987	chr5:17108579	T/C	cg23987134	chr5:17158319	LOC285696	-0.2	-4.76	-0.39	5.33e-6	Hippocampal atrophy;
TGCT	cis	rs9814567	0.752	rs7649910	chr3:134241310	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.98	-9.89	-0.66	2.32e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs17384381	0.953	rs12122816	chr1:85792384	C/T	cg16011679	chr1:85725395	C1orf52	0.81	6.34	0.49	3.82e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs903263	0.562	rs35452337	chr1:84534503	C/A	cg09664975	chr1:84543551	PRKACB	0.48	4.75	0.39	5.42e-6	Breast cancer (male);
TGCT	trans	rs4650994	0.525	rs4651000	chr1:178532223	A/G	cg05059571	chr16:84539110	KIAA1609	-0.54	-11.05	-0.7	3.58e-20	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs514406	0.505	rs427319	chr1:53178807	T/G	cg01802117	chr1:53393560	SCP2	-0.4	-4.75	-0.39	5.55e-6	Monocyte count;
TGCT	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg20999797	chr1:1681921	NA	0.18	4.69	0.39	7.02e-6	Body mass index;
TGCT	cis	rs778371	0.697	rs6717048	chr2:233586427	T/C	cg08000102	chr2:233561755	GIGYF2	0.75	9.07	0.63	2.27e-15	Schizophrenia;
TGCT	cis	rs35934224	0.831	rs8141610	chr22:19870147	A/G	cg11182965	chr22:19864308	TXNRD2	0.36	5.08	0.41	1.37e-6	Glaucoma (primary open-angle);
TGCT	cis	rs2486288	0.539	rs2433601	chr15:45716425	T/C	cg14582100	chr15:45693742	SPATA5L1	0.43	5.38	0.44	3.52e-7	Glomerular filtration rate;
TGCT	cis	rs2180341	0.782	rs4897214	chr6:127723625	G/T	cg24812749	chr6:127587940	RNF146	0.65	5.19	0.42	8.37e-7	Breast cancer;
TGCT	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg06112835	chr11:68658793	MRPL21	0.48	8.42	0.6	7.63e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs8141529	0.764	rs5762854	chr22:29246278	T/C	cg02153584	chr22:29168773	CCDC117	0.65	5.49	0.44	2.2e-7	Lymphocyte counts;
TGCT	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg08219700	chr8:58056026	NA	0.38	4.69	0.39	6.95e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6546537	0.550	rs4852272	chr2:69776730	C/T	cg10773587	chr2:69614142	GFPT1	-0.76	-7.08	-0.54	9.55e-11	Serum thyroid-stimulating hormone levels;
TGCT	cis	rs9916302	0.904	rs11078910	chr17:37671269	G/T	cg07936489	chr17:37558343	FBXL20	-0.61	-4.92	-0.4	2.69e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs17376456	0.877	rs10055340	chr5:93317644	T/C	cg25358565	chr5:93447407	FAM172A	0.98	8.39	0.6	9.01e-14	Diabetic retinopathy;
TGCT	cis	rs10504229	0.679	rs12375445	chr8:58040082	A/G	cg08280861	chr8:58055591	NA	0.35	4.92	0.4	2.72e-6	Developmental language disorder (linguistic errors);
TGCT	trans	rs208520	0.690	rs1580430	chr6:66715162	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	11.13	0.71	2.27e-20	Exhaled nitric oxide output;
TGCT	cis	rs7147624	1.000	rs8021889	chr14:66214811	A/G	cg03016385	chr14:66212404	NA	-0.5	-7.11	-0.54	8.15e-11	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs2239815	0.545	rs5762855	chr22:29246605	A/T	cg02153584	chr22:29168773	CCDC117	0.67	4.57	0.38	1.17e-5	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
TGCT	cis	rs832540	1.000	rs252914	chr5:56198150	A/C	cg12311346	chr5:56204834	C5orf35	-0.49	-5.15	-0.42	9.94e-7	Coronary artery disease;
TGCT	cis	rs2180341	1.000	rs6569477	chr6:127589302	T/A	cg24812749	chr6:127587940	RNF146	0.99	7.72	0.57	3.33e-12	Breast cancer;
TGCT	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg00149659	chr3:10157352	C3orf10	1.18	7.44	0.56	1.44e-11	Alzheimer's disease;
TGCT	cis	rs10875595	0.836	rs1363453	chr5:140657864	G/A	cg24830062	chr5:140700576	TAF7	-0.6	-5.07	-0.41	1.42e-6	Pulmonary function decline;
TGCT	cis	rs9814567	1.000	rs13322305	chr3:134310791	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.91	-8.83	-0.62	8.17e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs9902453	0.619	rs2244585	chr17:28072176	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.8	-7.97	-0.58	8.91e-13	Coffee consumption (cups per day);
TGCT	cis	rs7772486	0.624	rs9485018	chr6:146025731	T/C	cg23711669	chr6:146136114	FBXO30	-0.88	-9.77	-0.66	4.64e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10771431	0.967	rs7137443	chr12:9372029	C/T	cg09152401	chr12:9436616	LOC642846	-0.56	-5.68	-0.45	9.1e-8	Breast size;
TGCT	cis	rs7833790	0.963	rs10958046	chr8:82729210	A/G	cg27398817	chr8:82754497	SNX16	-0.84	-5.98	-0.47	2.18e-8	Diastolic blood pressure;
TGCT	cis	rs12510870	0.565	rs10016403	chr4:74399407	C/T	cg05868023	chr4:75230803	EREG	0.56	5.14	0.42	1.06e-6	Iris color (b* coordinate);
TGCT	cis	rs68170813	0.559	rs79778437	chr7:107004972	T/A	cg02696742	chr7:106810147	HBP1	-0.71	-5.96	-0.47	2.38e-8	Coronary artery disease;
TGCT	cis	rs6545883	0.929	rs12617911	chr2:61740825	A/G	cg15711740	chr2:61764176	XPO1	-0.56	-5.17	-0.42	9.02e-7	Tuberculosis;
TGCT	cis	rs35306767	0.855	rs55697724	chr10:885622	T/C	cg26597838	chr10:835615	NA	0.8	12.11	0.74	9.26e-23	Eosinophil percentage of granulocytes;
TGCT	cis	rs6540559	0.673	rs17015218	chr1:209967915	A/G	cg23283495	chr1:209979779	IRF6	0.65	5.04	0.41	1.63e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs7819412	1.000	rs7819412	chr8:11045161	A/G	cg27411982	chr8:10470053	RP1L1	0.21	4.62	0.38	9.61e-6	Triglycerides;
TGCT	cis	rs858239	0.665	rs858306	chr7:23242754	A/T	cg05602783	chr7:23145260	KLHL7	-0.63	-5.21	-0.42	7.52e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs17293817	0.650	rs12778422	chr10:1413776	A/G	cg02408697	chr10:1416920	ADARB2	0.39	4.52	0.38	1.42e-5	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs548987	0.529	rs1165164	chr6:25863481	G/A	cg03264133	chr6:25882463	NA	-0.61	-5.16	-0.42	9.63e-7	Homocysteine levels;
TGCT	cis	rs17331151	0.505	rs71299610	chr3:52641703	T/G	cg15956490	chr3:53032818	SFMBT1	0.7	5.71	0.46	7.8e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs2282802	0.585	rs2189659	chr5:139697220	C/A	cg01081189	chr5:139537190	NA	-0.27	-5.01	-0.41	1.79e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6967414	0.681	rs2881352	chr7:6753511	T/A	cg00387323	chr7:6746715	ZNF12	0.77	4.73	0.39	6.05e-6	Hematocrit;Hemoglobin concentration;
TGCT	trans	rs2727020	0.576	rs10839305	chr11:49598733	T/C	cg15704280	chr7:45808275	SEPT13	-0.75	-8.9	-0.62	5.74e-15	Coronary artery disease;
TGCT	cis	rs12458462	0.812	rs34583578	chr18:77491070	C/T	cg11879182	chr18:77439856	CTDP1	0.7	7.99	0.58	7.93e-13	Monocyte count;
TGCT	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg03351412	chr1:154909251	PMVK	0.53	4.93	0.4	2.6e-6	Prostate cancer;
TGCT	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg12311346	chr5:56204834	C5orf35	-0.63	-6.36	-0.5	3.5e-9	Initial pursuit acceleration;
TGCT	cis	rs17345786	0.511	rs1138818	chr3:101399583	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.03	0.41	1.65e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs36051895	0.695	rs62541532	chr9:5017384	C/A	cg02405213	chr9:5042618	JAK2	-0.71	-9.1	-0.63	1.89e-15	Pediatric autoimmune diseases;
TGCT	cis	rs9325144	0.555	rs6582607	chr12:38717678	T/C	cg26384229	chr12:38710491	ALG10B	-0.63	-5.91	-0.47	3.03e-8	Morning vs. evening chronotype;
TGCT	cis	rs9818758	0.607	rs35060561	chr3:49255503	T/C	cg00383909	chr3:49044727	WDR6	1.28	6.57	0.51	1.23e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg11062466	chr8:58055876	NA	0.38	4.62	0.38	9.5e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg11644478	chr21:40555479	PSMG1	1.0	10.38	0.68	1.5e-18	Cognitive function;
TGCT	cis	rs2677744	0.597	rs16945091	chr15:91499081	A/T	cg23684204	chr15:91497937	RCCD1	0.39	6.08	0.48	1.39e-8	Attention deficit hyperactivity disorder;
TGCT	cis	rs13082711	0.516	rs1492339	chr3:27371526	A/C	cg02860705	chr3:27208620	NA	-0.29	-4.44	-0.37	1.95e-5	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs4720575	0.839	rs10255464	chr7:47097043	A/G	cg00036614	chr7:47093842	NA	-0.21	-5.35	-0.43	4.1e-7	Angiotensin-converting enzyme inhibitor intolerance;
TGCT	cis	rs7772486	0.875	rs10872583	chr6:146396699	G/T	cg05347473	chr6:146136440	FBXO30	-0.54	-4.99	-0.41	2.01e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9611565	0.592	rs12484467	chr22:41957610	T/C	cg06481639	chr22:41940642	POLR3H	-0.63	-5.27	-0.43	5.9e-7	Vitiligo;
TGCT	cis	rs3784262	0.528	rs8027964	chr15:58335272	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.44	-6.47	-0.5	2.08e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs9894429	0.646	rs12948797	chr17:79617384	G/A	cg18240062	chr17:79603768	NPLOC4	0.56	4.89	0.4	3e-6	Eye color traits;
TGCT	cis	rs62380364	0.701	rs304136	chr5:88170066	T/C	cg22951263	chr5:87985283	NA	0.52	5.22	0.42	7.17e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs3733631	1.000	rs11943988	chr4:104654699	A/G	cg24090629	chr4:104641072	TACR3	-0.77	-6.29	-0.49	4.9e-9	Menarche (age at onset);
TGCT	cis	rs7542091	0.704	rs2142907	chr1:210039505	T/C	cg23283495	chr1:209979779	IRF6	0.56	5.59	0.45	1.36e-7	Monobrow;
TGCT	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.31	-4.76	-0.39	5.36e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs12286929	0.639	rs4938180	chr11:115041012	C/T	cg04017736	chr11:115827165	NA	-0.2	-4.46	-0.37	1.78e-5	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs2404602	0.647	rs12904417	chr15:76964152	A/G	cg23625390	chr15:77176239	SCAPER	0.36	4.56	0.38	1.21e-5	Blood metabolite levels;
TGCT	cis	rs7772486	0.754	rs697055	chr6:146003790	C/G	cg23711669	chr6:146136114	FBXO30	0.91	10.65	0.69	3.23e-19	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2235642	0.826	rs8048410	chr16:1614097	A/G	cg10465839	chr16:1584050	IFT140;TMEM204	-0.32	-4.95	-0.41	2.39e-6	Coronary artery disease;
TGCT	cis	rs9467773	1.000	rs9461259	chr6:26504835	C/A	cg26531700	chr6:26746687	NA	0.47	4.56	0.38	1.19e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7824557	0.675	rs2736265	chr8:11186674	A/G	cg21775007	chr8:11205619	TDH	0.7	6.77	0.52	4.48e-10	Retinal vascular caliber;
TGCT	cis	rs7647973	0.588	rs9883000	chr3:49667691	A/G	cg03060546	chr3:49711283	APEH	0.62	5.35	0.43	4.12e-7	Menarche (age at onset);
TGCT	cis	rs7267979	0.966	rs6050532	chr20:25308793	A/T	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9910055	0.659	rs112114764	chr17:42201041	G/T	cg13607699	chr17:42295918	UBTF	-0.59	-5.39	-0.44	3.37e-7	Total body bone mineral density;
TGCT	cis	rs2070488	0.965	rs6599206	chr3:38545349	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.85	-8.67	-0.61	2.01e-14	Electrocardiographic conduction measures;
TGCT	cis	rs7666738	0.546	rs17546687	chr4:98769266	T/A	cg17366294	chr4:99064904	C4orf37	0.61	5.7	0.46	8.38e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg22963979	chr7:1858916	MAD1L1	-0.35	-5.5	-0.44	2.08e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs9894429	0.646	rs12603868	chr17:79618834	G/C	cg21028142	chr17:79581711	NPLOC4	0.29	5.91	0.47	3.09e-8	Eye color traits;
TGCT	cis	rs9910055	0.762	rs2526020	chr17:42216588	G/T	cg13607699	chr17:42295918	UBTF	0.83	7.64	0.57	5.01e-12	Total body bone mineral density;
TGCT	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.84	7.5	0.56	1.08e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7119038	0.779	rs11217045	chr11:118697865	C/A	cg19308663	chr11:118741387	NA	0.3	5.88	0.47	3.49e-8	Sjögren's syndrome;
TGCT	cis	rs155076	1.000	rs2478824	chr13:21844144	G/C	cg14456004	chr13:21872349	NA	-1.32	-10.82	-0.7	1.25e-19	White matter hyperintensity burden;
TGCT	cis	rs9527	0.590	rs11191513	chr10:104772984	T/G	cg15744005	chr10:104629667	AS3MT	-0.42	-4.92	-0.4	2.74e-6	Arsenic metabolism;
TGCT	cis	rs7100689	0.622	rs1417221	chr10:82100428	G/A	cg01528321	chr10:82214614	TSPAN14	0.75	7.49	0.56	1.15e-11	Post bronchodilator FEV1;
TGCT	cis	rs9611565	0.512	rs2050033	chr22:42159229	G/T	cg17554472	chr22:41940697	POLR3H	0.46	4.8	0.4	4.46e-6	Vitiligo;
TGCT	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.08	0.48	1.37e-8	Bipolar disorder;
TGCT	cis	rs41271473	0.706	rs72763990	chr1:228719071	A/T	cg04850211	chr1:228464232	OBSCN	-0.7	-4.46	-0.37	1.79e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs7226408	0.857	rs11662905	chr18:34433270	T/G	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs11098499	0.554	rs2175381	chr4:120265967	T/C	cg09307838	chr4:120376055	NA	0.56	5.49	0.44	2.18e-7	Corneal astigmatism;
TGCT	cis	rs1048238	0.506	rs7552077	chr1:16196759	A/G	cg21385522	chr1:16154831	NA	0.58	6.76	0.52	4.89e-10	Systolic blood pressure;
TGCT	cis	rs7769051	0.711	rs7738071	chr6:133085116	G/A	cg22852734	chr6:133119734	C6orf192	1.26	6.8	0.52	3.97e-10	Type 2 diabetes nephropathy;
TGCT	cis	rs3617	0.573	rs3821873	chr3:52913006	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.5	-4.79	-0.39	4.73e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg16325326	chr1:53192061	ZYG11B	0.63	7.34	0.55	2.51e-11	Monocyte count;
TGCT	cis	rs1475911	0.947	rs67055914	chr21:43510427	T/C	cg19766460	chr21:43528205	UMODL1;C21orf128	0.52	7.1	0.54	8.32e-11	IgG glycosylation;
TGCT	cis	rs11627546	0.571	rs61980575	chr14:70363900	G/T	cg10496350	chr14:71275911	MAP3K9	-0.88	-4.49	-0.37	1.59e-5	Red blood cell traits;
TGCT	cis	rs10876993	0.928	rs2640636	chr12:58077544	A/G	cg15848620	chr12:58087721	OS9	-0.71	-5.77	-0.46	5.92e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.56	4.97	0.41	2.19e-6	Height;
TGCT	cis	rs698833	0.509	rs12987415	chr2:44530423	C/T	cg23552047	chr2:44669647	C2orf34	0.28	4.53	0.38	1.36e-5	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
TGCT	cis	rs2486288	0.656	rs11629859	chr15:45547121	T/G	cg26924012	chr15:45694286	SPATA5L1	-0.7	-6.77	-0.52	4.55e-10	Glomerular filtration rate;
TGCT	cis	rs7178572	0.568	rs11636554	chr15:77608747	C/T	cg22256960	chr15:77711686	NA	-0.87	-9.11	-0.63	1.74e-15	Type 2 diabetes;
TGCT	cis	rs950169	0.922	rs12906983	chr15:84931022	G/A	cg12863693	chr15:85201151	NMB	0.46	4.97	0.41	2.13e-6	Schizophrenia;
TGCT	cis	rs4851266	0.898	rs13026143	chr2:100865406	A/G	cg07810366	chr2:100720526	AFF3	0.35	5.01	0.41	1.87e-6	Educational attainment;
TGCT	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	8.13	0.59	3.82e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7824557	0.679	rs6991074	chr8:11136046	T/C	cg21775007	chr8:11205619	TDH	-0.59	-5.38	-0.44	3.52e-7	Retinal vascular caliber;
TGCT	cis	rs1448094	0.511	rs17345975	chr12:86202318	T/A	cg02569458	chr12:86230093	RASSF9	0.4	5.08	0.42	1.32e-6	Major depressive disorder;
TGCT	cis	rs2404602	0.716	rs17364076	chr15:76760891	C/T	cg26408565	chr15:76604113	ETFA	-0.39	-5.24	-0.43	6.74e-7	Blood metabolite levels;
TGCT	cis	rs4699052	0.893	rs4699058	chr4:104171321	T/A	cg16532752	chr4:104119610	CENPE	-0.52	-4.76	-0.39	5.34e-6	Testicular germ cell tumor;
TGCT	cis	rs11792861	0.962	rs11789624	chr9:111796231	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.48	4.47	0.37	1.77e-5	Menarche (age at onset);
TGCT	cis	rs7666738	0.830	rs9995386	chr4:98907826	T/C	cg18180107	chr4:99064573	C4orf37	0.53	4.88	0.4	3.2e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs634534	0.622	rs1308733	chr11:65720841	T/C	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.22	-4.71	-0.39	6.65e-6	Sum eosinophil basophil counts;Eosinophil counts;
TGCT	cis	rs12134133	1.000	rs55638602	chr1:207428942	C/T	cg02152968	chr1:207494213	CD55	0.61	4.83	0.4	3.92e-6	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs76878669	0.561	rs1784029	chr11:66099987	C/T	cg18002602	chr11:66138449	SLC29A2	0.53	6.5	0.5	1.77e-9	Educational attainment (years of education);
TGCT	cis	rs4237845	0.537	rs10747786	chr12:58260601	G/T	cg23860436	chr12:58378763	NA	0.33	4.61	0.38	1e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs739401	0.611	rs572373	chr11:3055361	T/C	cg05729581	chr11:3078854	CARS	-0.55	-5.15	-0.42	9.85e-7	Longevity;
TGCT	cis	rs67311347	1.000	rs11914297	chr3:40410070	T/C	cg17264618	chr3:40429014	ENTPD3	0.33	4.71	0.39	6.52e-6	Renal cell carcinoma;
TGCT	cis	rs2243480	1.000	rs316331	chr7:65604622	A/G	cg20637647	chr7:64974828	NA	-0.88	-5.21	-0.42	7.77e-7	Diabetic kidney disease;
TGCT	cis	rs7666738	0.515	rs28615369	chr4:98896858	C/T	cg17366294	chr4:99064904	C4orf37	0.63	5.54	0.45	1.72e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9868809	0.505	rs28567949	chr3:48744560	G/A	cg00383909	chr3:49044727	WDR6	1.06	6.28	0.49	5.26e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs9341808	0.690	rs6930534	chr6:80896050	C/T	cg08355045	chr6:80787529	NA	0.32	5.6	0.45	1.29e-7	Sitting height ratio;
TGCT	cis	rs2075371	0.829	rs727202	chr7:133947942	A/G	cg11752832	chr7:134001865	SLC35B4	0.66	5.51	0.44	1.95e-7	Mean platelet volume;
TGCT	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg06634786	chr22:41940651	POLR3H	0.89	8.55	0.61	3.83e-14	Vitiligo;
TGCT	cis	rs17376456	0.877	rs56373208	chr5:93491276	C/A	cg25358565	chr5:93447407	FAM172A	0.97	8.32	0.6	1.34e-13	Diabetic retinopathy;
TGCT	cis	rs9467773	0.595	rs7767847	chr6:26597893	A/T	cg05738196	chr6:26577821	NA	0.88	11.09	0.71	2.86e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs137699	0.652	rs2413589	chr22:39755689	C/T	cg24399712	chr22:39784796	NA	0.65	5.66	0.45	1.01e-7	IgG glycosylation;
TGCT	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg24846343	chr22:24311635	DDTL	0.23	5.79	0.46	5.54e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs4975616	0.869	rs401681	chr5:1322087	C/T	cg00059399	chr5:2008272	NA	-0.27	-4.44	-0.37	2e-5	Lung cancer;
TGCT	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg14773178	chr5:1868261	NA	0.34	5.77	0.46	6.08e-8	Cardiovascular disease risk factors;
TGCT	cis	rs10279301	1	rs10279301	chr7:156261315	C/T	cg02321112	chr7:156810523	NA	-0.38	-4.64	-0.38	8.89e-6	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
TGCT	trans	rs2727020	0.553	rs4980447	chr11:49591662	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.41	-8.21	-0.59	2.4e-13	Coronary artery disease;
TGCT	cis	rs12142240	0.698	rs6703669	chr1:46862555	C/T	cg14993813	chr1:46806288	NSUN4	-0.59	-4.86	-0.4	3.45e-6	Menopause (age at onset);
TGCT	cis	rs9467711	0.790	rs10484439	chr6:26309908	G/A	cg16898833	chr6:26189333	HIST1H4D	1.2	5.52	0.44	1.87e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12762955	0.608	rs7922760	chr10:1156815	G/C	cg18964960	chr10:1102726	WDR37	-0.78	-6.8	-0.52	3.92e-10	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs17152411	0.895	rs66531168	chr10:126586908	T/A	cg07906193	chr10:126599966	NA	0.41	5.05	0.41	1.52e-6	Height;
TGCT	cis	rs7193541	0.965	rs8050262	chr16:74661159	T/C	cg01733217	chr16:74700730	RFWD3	0.78	7.59	0.56	6.64e-12	Multiple myeloma;
TGCT	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	4.93	0.4	2.6e-6	Menopause (age at onset);
TGCT	cis	rs66573146	0.831	rs73088564	chr4:6984553	G/C	cg05069807	chr4:6945702	TBC1D14	0.32	5.01	0.41	1.83e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs9303401	0.538	rs10515155	chr17:56481944	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.58	5.58	0.45	1.43e-7	Cognitive test performance;
TGCT	cis	rs9894429	0.716	rs7405578	chr17:79588306	C/A	cg18240062	chr17:79603768	NPLOC4	0.84	9.67	0.66	8.1e-17	Eye color traits;
TGCT	cis	rs72781680	1.000	rs72798411	chr2:24184343	A/G	cg08917208	chr2:24149416	ATAD2B	0.84	5.13	0.42	1.1e-6	Lymphocyte counts;
TGCT	cis	rs1982963	0.950	rs61973203	chr14:52510567	A/G	cg10843707	chr14:52510701	NID2	0.43	6.57	0.51	1.22e-9	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7845219	0.544	rs9643350	chr8:95917276	C/A	cg13393036	chr8:95962371	TP53INP1	-0.43	-4.95	-0.41	2.33e-6	Type 2 diabetes;
TGCT	cis	rs4886920	0.601	rs12901558	chr15:78076379	G/A	cg25212270	chr15:78015279	NA	-0.23	-4.87	-0.4	3.37e-6	Neuroticism;
TGCT	cis	rs4845570	0.920	rs1521185	chr1:151764049	A/G	cg07092448	chr1:151763213	TDRKH	1.05	9.0	0.63	3.3e-15	Coronary artery disease;
TGCT	cis	rs12579753	0.879	rs7131927	chr12:82166313	T/C	cg21231944	chr12:82153410	PPFIA2	-0.34	-4.62	-0.38	9.52e-6	Resting heart rate;
TGCT	cis	rs9902453	0.679	rs2054847	chr17:28532013	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	5.98	0.47	2.22e-8	Coffee consumption (cups per day);
TGCT	cis	rs6754311	0.597	rs2278544	chr2:136546110	A/G	cg07169764	chr2:136633963	MCM6	-0.71	-6.37	-0.5	3.33e-9	Mosquito bite size;
TGCT	cis	rs9733	0.650	rs11204668	chr1:150543686	G/A	cg13175981	chr1:150552382	MCL1	0.52	5.6	0.45	1.32e-7	Tonsillectomy;
TGCT	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg04944784	chr2:26401820	FAM59B	-0.68	-6.13	-0.48	1.1e-8	Gut microbiome composition (summer);
TGCT	cis	rs10883723	0.810	rs6584504	chr10:104253507	T/C	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	trans	rs1814175	0.791	rs10839468	chr11:49986288	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.36	-7.14	-0.54	6.88e-11	Height;
TGCT	cis	rs36051895	0.658	rs72699568	chr9:5007138	C/T	cg02405213	chr9:5042618	JAK2	-0.8	-11.07	-0.7	3.18e-20	Pediatric autoimmune diseases;
TGCT	cis	rs2663905	0.664	rs2460855	chr15:81361729	G/T	cg18837035	chr15:81426597	C15orf26	-0.57	-4.88	-0.4	3.14e-6	QT interval (drug interaction);
TGCT	cis	rs644799	0.601	rs7902	chr11:95565288	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.6	5.59	0.45	1.36e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs13242816	1.000	rs6979182	chr7:116119345	T/G	cg16553024	chr7:116138462	CAV2	-0.44	-4.59	-0.38	1.06e-5	P wave duration;
TGCT	cis	rs2440129	0.591	rs312466	chr17:6899221	G/A	cg09737314	chr17:6899359	ALOX12	-0.45	-4.86	-0.4	3.49e-6	Tonsillectomy;
TGCT	cis	rs9457247	0.935	rs2757050	chr6:167377165	G/T	cg25258033	chr6:167368657	RNASET2	-0.18	-4.48	-0.37	1.64e-5	Crohn's disease;
TGCT	cis	rs3820928	0.874	rs13393894	chr2:227880543	A/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-4.94	-0.41	2.51e-6	Pulmonary function;
TGCT	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg10150615	chr22:24372951	LOC391322	0.77	8.38	0.6	9.9e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs10791097	0.609	rs3751039	chr11:130773076	A/G	cg05962950	chr11:130786565	SNX19	-0.95	-12.2	-0.74	5.48e-23	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.83	-9.98	-0.67	1.38e-17	Urate levels;
TGCT	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	4.93	0.4	2.63e-6	Menopause (age at onset);
TGCT	trans	rs1814175	0.935	rs11040462	chr11:49683158	G/A	cg15704280	chr7:45808275	SEPT13	-0.61	-6.69	-0.51	6.72e-10	Height;
TGCT	cis	rs9677476	0.542	rs6437009	chr2:232110483	C/T	cg07929768	chr2:232055508	NA	-0.29	-4.49	-0.37	1.61e-5	Food antigen IgG levels;
TGCT	cis	rs1982963	1.000	rs2029975	chr14:52506070	C/T	cg10843707	chr14:52510701	NID2	-0.43	-6.6	-0.51	1.09e-9	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2486288	0.656	rs2413771	chr15:45553140	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.77	-8.01	-0.58	7.01e-13	Glomerular filtration rate;
TGCT	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg17971929	chr21:40555470	PSMG1	-0.71	-6.61	-0.51	1.01e-9	Cognitive function;
TGCT	cis	rs155076	0.938	rs536209	chr13:21847714	C/T	cg11317459	chr13:21872234	NA	-1.42	-12.26	-0.74	4.07e-23	White matter hyperintensity burden;
TGCT	cis	rs3892630	0.824	rs34748593	chr19:33240447	T/C	cg22980127	chr19:33182716	NUDT19	0.7	5.07	0.41	1.44e-6	Red blood cell traits;
TGCT	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg13395646	chr4:1353034	KIAA1530	0.39	4.84	0.4	3.81e-6	Obesity-related traits;
TGCT	cis	rs17197710	0.673	rs61897361	chr11:47346378	G/A	cg13308137	chr11:47528955	CUGBP1	0.41	5.82	0.46	4.71e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs4919694	0.611	rs2271750	chr10:105174869	A/G	cg04362960	chr10:104952993	NT5C2	-0.86	-5.41	-0.44	3.09e-7	Arsenic metabolism;
TGCT	cis	rs2204008	0.677	rs1581356	chr12:38391467	T/C	cg26384229	chr12:38710491	ALG10B	0.81	7.13	0.54	7.19e-11	Bladder cancer;
TGCT	cis	rs561341	0.700	rs79272796	chr17:30226974	T/C	cg13647721	chr17:30228624	UTP6	0.6	5.32	0.43	4.64e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs2239547	0.522	rs6768844	chr3:53004620	A/G	cg10802521	chr3:52805072	NEK4	0.59	5.34	0.43	4.26e-7	Schizophrenia;
TGCT	cis	rs250677	0.641	rs2915807	chr5:148450950	A/G	cg18129178	chr5:148520854	ABLIM3	-0.45	-6.06	-0.48	1.54e-8	Breast cancer;
TGCT	cis	rs698833	0.509	rs4952709	chr2:44519142	A/G	cg23552047	chr2:44669647	C2orf34	0.29	4.64	0.38	8.77e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
TGCT	cis	rs13064447	1.000	rs13064447	chr3:12753131	C/A	cg20675869	chr3:12750130	NA	0.18	4.54	0.38	1.32e-5	Major depression and alcohol dependence;
TGCT	cis	rs2050392	0.760	rs10826797	chr10:30690376	A/C	cg18806716	chr10:30721971	MAP3K8	-0.62	-8.34	-0.6	1.18e-13	Inflammatory bowel disease;
TGCT	cis	rs7103648	0.966	rs896817	chr11:47394305	A/G	cg20307385	chr11:47447363	PSMC3	-0.99	-11.78	-0.73	5.92e-22	Diastolic blood pressure;Systolic blood pressure;
TGCT	cis	rs8014252	0.803	rs60860517	chr14:71029919	A/C	cg11204974	chr14:71022665	NA	-0.53	-4.49	-0.37	1.63e-5	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
TGCT	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg05872129	chr22:39784769	NA	-1.01	-11.09	-0.71	2.82e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs919433	0.713	rs11900232	chr2:198466273	T/C	cg00792783	chr2:198669748	PLCL1	0.48	4.47	0.37	1.75e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs8031584	0.958	rs34909055	chr15:31284170	C/T	cg08704250	chr15:31115839	NA	-0.33	-4.55	-0.38	1.28e-5	Huntington's disease progression;
TGCT	cis	rs7975161	0.753	rs7972034	chr12:104640881	G/T	cg25273343	chr12:104657179	TXNRD1	-0.35	-4.83	-0.4	3.87e-6	Toenail selenium levels;
TGCT	cis	rs4794106	0.792	rs847682	chr17:48208274	C/T	cg13127421	chr17:48202128	SAMD14	-0.25	-6.45	-0.5	2.3e-9	Temporomandibular joint disorder;
TGCT	cis	rs7584330	0.657	rs10190310	chr2:238352282	C/T	cg14458575	chr2:238380390	NA	0.5	7.44	0.56	1.45e-11	Prostate cancer;
TGCT	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg22963979	chr7:1858916	MAD1L1	-0.38	-5.73	-0.46	7.15e-8	Bipolar disorder and schizophrenia;
TGCT	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg03517284	chr6:25882590	NA	0.88	8.68	0.61	1.88e-14	Blood metabolite levels;
TGCT	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg04744514	chr10:134541379	INPP5A	0.25	4.47	0.37	1.73e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg12311346	chr5:56204834	C5orf35	-0.67	-6.77	-0.52	4.59e-10	Initial pursuit acceleration;
TGCT	cis	rs4820539	1.000	rs916585	chr22:23469438	G/A	cg14186256	chr22:23484241	RTDR1	0.99	12.58	0.75	6.81e-24	Bone mineral density;
TGCT	cis	rs514406	0.607	rs6696940	chr1:53203427	C/T	cg24675658	chr1:53192096	ZYG11B	0.83	10.08	0.67	8.25e-18	Monocyte count;
TGCT	cis	rs9291683	0.618	rs13137343	chr4:10043028	C/A	cg00071950	chr4:10020882	SLC2A9	0.68	8.74	0.62	1.38e-14	Bone mineral density;
TGCT	cis	rs9640161	0.750	rs11769348	chr7:150026753	C/T	cg10018233	chr7:150070692	REPIN1	-0.32	-4.59	-0.38	1.08e-5	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg18252515	chr7:66147081	NA	-1.2	-7.83	-0.58	1.89e-12	Diabetic kidney disease;
TGCT	cis	rs904251	0.861	rs2776875	chr6:37486796	G/C	cg01843034	chr6:37503916	NA	-0.52	-6.29	-0.49	4.88e-9	Cognitive performance;
TGCT	cis	rs1878931	0.535	rs55732163	chr16:3411518	A/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.73	-6.0	-0.47	2.01e-8	Body mass index (adult);
TGCT	cis	rs6558530	0.587	rs6986102	chr8:1700640	C/G	cg09410841	chr8:1729607	CLN8	0.72	6.49	0.5	1.87e-9	Systolic blood pressure;
TGCT	cis	rs1505368	0.836	rs10201067	chr2:213284411	A/G	cg16329650	chr2:213403929	ERBB4	-0.65	-6.62	-0.51	9.53e-10	Symmetrical dimethylarginine levels;
TGCT	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg27535305	chr1:53392650	SCP2	0.24	4.76	0.39	5.22e-6	Monocyte count;
TGCT	cis	rs5751150	1	rs5751150	chr22:42153292	T/G	cg06481639	chr22:41940642	POLR3H	0.69	6.02	0.48	1.83e-8	Cannabis dependence symptom count;
TGCT	cis	rs4295623	0.556	rs10903343	chr8:11695872	T/C	cg21775007	chr8:11205619	TDH	0.53	4.69	0.39	6.99e-6	Morning vs. evening chronotype;
TGCT	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg11644478	chr21:40555479	PSMG1	0.64	5.77	0.46	5.84e-8	Cognitive function;
TGCT	cis	rs6570726	0.791	rs1280276	chr6:145892350	A/C	cg05347473	chr6:146136440	FBXO30	0.54	5.11	0.42	1.16e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg13695892	chr22:41940480	POLR3H	-0.91	-8.85	-0.62	7.39e-15	Vitiligo;
TGCT	cis	rs986417	0.818	rs1254325	chr14:60909689	A/G	cg27398547	chr14:60952738	C14orf39	-1.39	-10.61	-0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg11644478	chr21:40555479	PSMG1	-0.52	-4.87	-0.4	3.28e-6	Menarche (age at onset);
TGCT	cis	rs651907	0.557	rs3806653	chr3:101396972	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.03	0.41	1.65e-6	Colorectal cancer;
TGCT	cis	rs42648	0.837	rs12375075	chr7:89940331	G/A	cg25739043	chr7:89950458	NA	-0.74	-7.35	-0.55	2.29e-11	Homocysteine levels;
TGCT	cis	rs9916302	0.861	rs11078896	chr17:37415544	C/T	cg07936489	chr17:37558343	FBXL20	-0.63	-4.99	-0.41	2.03e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs6163	0.727	rs284854	chr10:104574562	T/G	cg05855489	chr10:104503620	C10orf26	-0.64	-6.16	-0.48	9.31e-9	Waist circumference;Hip circumference;
TGCT	cis	rs17376456	0.757	rs10476591	chr5:93333723	G/C	cg25358565	chr5:93447407	FAM172A	0.97	8.43	0.6	7.5e-14	Diabetic retinopathy;
TGCT	cis	rs910316	1.000	rs175512	chr14:75523382	T/C	cg23033748	chr14:75592666	NEK9	-0.27	-4.53	-0.38	1.34e-5	Height;
TGCT	cis	rs9329221	0.905	rs10283145	chr8:10241411	C/T	cg21775007	chr8:11205619	TDH	-0.54	-5.06	-0.41	1.49e-6	Neuroticism;
TGCT	cis	rs2964802	0.505	rs7717266	chr5:10832134	C/G	cg14521931	chr5:10832172	NA	-0.28	-4.65	-0.39	8.37e-6	Major depressive disorder;Recurrent major depressive disorder;
TGCT	cis	rs4906332	1.000	rs2065015	chr14:103904061	G/T	cg26031613	chr14:104095156	KLC1	0.51	4.61	0.38	1e-5	Coronary artery disease;
TGCT	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg17971929	chr21:40555470	PSMG1	0.96	9.05	0.63	2.44e-15	Cognitive function;
TGCT	cis	rs13256369	0.853	rs13256216	chr8:8577883	C/T	cg17143192	chr8:8559678	CLDN23	0.64	5.72	0.46	7.58e-8	Obesity-related traits;
TGCT	cis	rs2506155	1.000	rs2506155	chr10:33503179	C/A	cg25928881	chr10:32632685	EPC1	0.31	4.6	0.38	1.04e-5	Migraine;
TGCT	cis	rs9486719	1.000	rs2472882	chr6:96863474	C/T	cg18709589	chr6:96969512	KIAA0776	0.71	5.21	0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs9486719	0.857	rs11759769	chr6:97065212	G/A	cg18709589	chr6:96969512	KIAA0776	-0.83	-6.46	-0.5	2.16e-9	Migraine;Coronary artery disease;
TGCT	cis	rs7552404	1.000	rs7524467	chr1:76194054	C/G	cg03433033	chr1:76189801	ACADM	0.82	9.66	0.66	8.48e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs62244186	0.683	rs6766334	chr3:44567065	T/C	cg10108389	chr3:44770937	ZNF501	-0.46	-4.57	-0.38	1.16e-5	Depressive symptoms;
TGCT	cis	rs2153535	0.580	rs6937186	chr6:8494493	A/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs12908161	1.000	rs56864281	chr15:85357649	C/A	cg12863693	chr15:85201151	NMB	0.42	5.01	0.41	1.81e-6	Schizophrenia;
TGCT	cis	rs11098499	0.909	rs28714195	chr4:120316950	A/T	cg09307838	chr4:120376055	NA	0.68	6.7	0.52	6.46e-10	Corneal astigmatism;
TGCT	cis	rs1403694	0.515	rs5030058	chr3:186452415	T/G	cg12454167	chr3:186435060	KNG1	0.44	6.91	0.53	2.24e-10	Blood protein levels;
TGCT	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.49	-4.64	-0.38	8.8e-6	Longevity;Endometriosis;
TGCT	cis	rs832540	1.000	rs832540	chr5:56199202	G/A	cg12311346	chr5:56204834	C5orf35	-0.49	-5.31	-0.43	4.89e-7	Coronary artery disease;
TGCT	cis	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg20637647	chr7:64974828	NA	0.92	5.09	0.42	1.26e-6	Diabetic kidney disease;
TGCT	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg04944784	chr2:26401820	FAM59B	0.76	6.24	0.49	6.46e-9	Gut microbiome composition (summer);
TGCT	cis	rs6993244	1	rs6993244	chr8:8863059	C/G	cg15556689	chr8:8085844	FLJ10661	0.75	6.75	0.52	5.16e-10	Mean corpuscular hemoglobin;
TGCT	trans	rs459571	1.000	rs456207	chr9:136911140	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.75	-8.02	-0.58	6.93e-13	Platelet distribution width;
TGCT	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg08439880	chr3:133502540	NA	-0.31	-5.91	-0.47	3.08e-8	Iron status biomarkers;
TGCT	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.74	7.02	0.53	1.3e-10	Prudent dietary pattern;
TGCT	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg10047753	chr17:41438598	NA	0.77	7.29	0.55	3.18e-11	Menopause (age at onset);
TGCT	cis	rs568617	0.953	rs658524	chr11:65647260	A/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.57	-5.22	-0.42	7.39e-7	Crohn's disease;
TGCT	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg02725872	chr8:58115012	NA	-0.38	-5.16	-0.42	9.32e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs11690935	0.527	rs7586556	chr2:172901887	G/C	cg13550731	chr2:172543902	DYNC1I2	0.64	5.83	0.46	4.45e-8	Schizophrenia;
TGCT	cis	rs854765	0.647	rs2955366	chr17:18024013	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	7.57	0.56	7.33e-12	Total body bone mineral density;
TGCT	cis	rs2486288	0.656	rs11637838	chr15:45550657	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.75	-7.78	-0.57	2.39e-12	Glomerular filtration rate;
TGCT	cis	rs892961	0.932	rs55661113	chr17:75408386	A/C	cg05865280	chr17:75406074	SEPT9	0.29	7.02	0.53	1.26e-10	Airflow obstruction;
TGCT	cis	rs6735179	0.565	rs6726887	chr2:1749257	A/G	cg08534653	chr2:1747700	PXDN	0.54	4.45	0.37	1.92e-5	Response to antipsychotic treatment;
TGCT	cis	rs28785552	0.796	rs8112908	chr19:53248041	C/T	cg22067481	chr19:53234126	ZNF611	-0.4	-5.81	-0.46	4.95e-8	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs909674	0.690	rs5750823	chr22:39829973	C/T	cg05872129	chr22:39784769	NA	-0.99	-9.57	-0.65	1.36e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg21226059	chr5:178986404	RUFY1	0.62	7.13	0.54	7.36e-11	Lung cancer;
TGCT	cis	rs6733011	0.508	rs12712041	chr2:99522059	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.57	-5.44	-0.44	2.74e-7	Bipolar disorder;
TGCT	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg21724239	chr8:58056113	NA	0.43	4.44	0.37	1.93e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs13256369	1.000	rs883648	chr8:8569521	A/G	cg18904891	chr8:8559673	CLDN23	0.59	5.54	0.45	1.73e-7	Obesity-related traits;
TGCT	cis	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg03213289	chr20:61660250	NA	0.68	9.99	0.67	1.36e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9467773	1.000	rs4713008	chr6:26538268	T/C	cg26531700	chr6:26746687	NA	0.47	4.57	0.38	1.14e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7524258	0.835	rs2412150	chr1:7303343	A/C	cg07173049	chr1:7289937	CAMTA1	0.29	4.82	0.4	4.2e-6	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs6867032	1.000	rs10462750	chr5:2012963	A/G	cg26168224	chr5:2018326	NA	0.45	8.03	0.58	6.44e-13	Gut microbiome composition (winter);
TGCT	cis	rs2067615	0.579	rs12424114	chr12:107144328	A/G	cg15890332	chr12:107067104	RFX4	0.29	5.63	0.45	1.14e-7	Heart rate;
TGCT	cis	rs1008375	0.897	rs67455495	chr4:17665238	A/T	cg16339924	chr4:17578868	LAP3	-0.62	-5.0	-0.41	1.91e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs12971120	0.838	rs2241510	chr18:72180739	G/A	cg25817165	chr18:72167213	CNDP2	-0.26	-4.58	-0.38	1.12e-5	Refractive error;
TGCT	cis	rs6671200	1.000	rs35179427	chr1:95670888	G/A	cg26537280	chr1:95699037	RWDD3	0.68	5.49	0.44	2.15e-7	Stearic acid (18:0) levels;
TGCT	cis	rs644799	0.932	rs480079	chr11:95643777	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.77	-9.57	-0.65	1.4e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs2777491	1.000	rs1757455	chr15:41761332	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.76	-11.32	-0.71	7.77e-21	Ulcerative colitis;
TGCT	cis	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg13531842	chr10:38383804	ZNF37A	0.39	4.53	0.38	1.39e-5	Extrinsic epigenetic age acceleration;
TGCT	cis	rs28374715	0.510	rs8034073	chr15:41545613	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.69	-8.88	-0.62	6.37e-15	Ulcerative colitis;
TGCT	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg06238570	chr21:40685208	BRWD1	0.7	6.11	0.48	1.2e-8	Cognitive function;
TGCT	cis	rs12765878	1.000	rs11191846	chr10:105649813	A/G	cg11005552	chr10:105648138	OBFC1	0.44	7.7	0.57	3.69e-12	Coronary artery disease;
TGCT	cis	rs713587	0.776	rs1172294	chr2:25169200	A/G	cg15423357	chr2:25149977	NA	0.59	5.98	0.47	2.17e-8	Body mass index in non-asthmatics;
TGCT	cis	rs986417	0.748	rs8019541	chr14:60929145	A/G	cg27398547	chr14:60952738	C14orf39	1.39	10.61	0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs3741151	1.000	rs74346863	chr11:73054772	C/T	cg17517138	chr11:73019481	ARHGEF17	1.06	5.6	0.45	1.3e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
TGCT	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg03236948	chr11:63997492	DNAJC4	0.38	4.71	0.39	6.48e-6	Platelet count;
TGCT	cis	rs1008375	0.932	rs4698626	chr4:17605821	G/C	cg16339924	chr4:17578868	LAP3	0.64	5.22	0.42	7.4e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	trans	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg11887960	chr12:57824829	NA	1.17	9.7	0.66	6.57e-17	Lung disease severity in cystic fibrosis;
TGCT	cis	rs1215050	0.716	rs11940331	chr4:99054041	G/C	cg05340658	chr4:99064831	C4orf37	0.43	5.27	0.43	5.73e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg22920501	chr2:26401640	FAM59B	-0.84	-6.85	-0.52	3.02e-10	Gut microbiome composition (summer);
TGCT	cis	rs10782582	0.609	rs112431348	chr1:76275571	A/G	cg10523679	chr1:76189770	ACADM	-0.58	-5.38	-0.43	3.6e-7	Daytime sleep phenotypes;
TGCT	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg07507251	chr3:52567010	NT5DC2	0.48	6.67	0.51	7.55e-10	Bipolar disorder;
TGCT	cis	rs1691799	0.899	rs903590	chr12:66745777	C/G	cg16791601	chr12:66731901	HELB	-0.27	-5.8	-0.46	5.11e-8	White blood cell count (basophil);
TGCT	cis	rs10484885	0.824	rs72919976	chr6:90526686	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.47	-4.58	-0.38	1.11e-5	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs7829975	0.606	rs6422352	chr8:8794193	A/G	cg06636001	chr8:8085503	FLJ10661	-0.73	-6.47	-0.5	2.01e-9	Mood instability;
TGCT	cis	rs3858526	0.959	rs4758219	chr11:5951846	G/C	cg13902645	chr11:5959945	NA	-0.48	-5.0	-0.41	1.95e-6	DNA methylation (variation);
TGCT	cis	rs7027203	1.000	rs7027203	chr9:96562563	A/C	cg14396892	chr9:96623032	NA	0.24	4.81	0.4	4.27e-6	DNA methylation (variation);
TGCT	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	9.52	0.65	1.86e-16	Platelet count;
TGCT	cis	rs10510102	0.872	rs12248806	chr10:123718153	T/C	cg23691251	chr10:123688108	ATE1	-0.59	-4.7	-0.39	6.75e-6	Breast cancer;
TGCT	cis	rs910187	0.678	rs6122563	chr20:45813885	C/T	cg27589058	chr20:45804311	EYA2	-0.35	-7.74	-0.57	3.01e-12	Migraine;
TGCT	cis	rs7666738	0.830	rs7661264	chr4:98961574	G/A	cg17366294	chr4:99064904	C4orf37	0.74	7.56	0.56	7.89e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7100689	0.725	rs10736340	chr10:82061071	C/T	cg01528321	chr10:82214614	TSPAN14	0.8	7.9	0.58	1.29e-12	Post bronchodilator FEV1;
TGCT	cis	rs17376456	0.877	rs10063045	chr5:93457584	A/T	cg25358565	chr5:93447407	FAM172A	0.91	7.62	0.56	5.75e-12	Diabetic retinopathy;
TGCT	cis	rs7513165	0.551	rs57406581	chr1:204141832	C/T	cg12731349	chr1:204159619	KISS1	0.49	4.84	0.4	3.74e-6	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
TGCT	cis	rs6840360	0.615	rs12641433	chr4:152607548	A/C	cg22705602	chr4:152727874	NA	-0.33	-5.42	-0.44	2.93e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs904251	0.523	rs1776454	chr6:37482099	C/T	cg25019722	chr6:37503610	NA	-0.53	-8.19	-0.59	2.75e-13	Cognitive performance;
TGCT	cis	rs4072705	0.646	rs10120967	chr9:127244134	C/T	cg13476313	chr9:127244764	NR5A1	0.29	4.86	0.4	3.4e-6	Menarche (age at onset);
TGCT	cis	rs7829975	0.511	rs1401390	chr8:8136410	C/T	cg06636001	chr8:8085503	FLJ10661	0.73	6.46	0.5	2.18e-9	Mood instability;
TGCT	cis	rs174479	0.677	rs174456	chr11:61656182	G/T	cg01500311	chr11:61656094	FADS3	0.29	5.19	0.42	8.31e-7	Sphingolipid levels;
TGCT	cis	rs75686122	0.892	rs17806104	chr8:104535511	C/T	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs7829975	0.523	rs9644774	chr8:8559832	G/A	cg06636001	chr8:8085503	FLJ10661	-0.61	-5.18	-0.42	8.67e-7	Mood instability;
TGCT	cis	rs6912958	0.781	rs6940150	chr6:88287114	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-5.06	-0.41	1.45e-6	Monocyte percentage of white cells;
TGCT	cis	rs3806843	0.576	rs155363	chr5:140301543	A/G	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.44	-5.45	-0.44	2.65e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2786098	0.577	rs12043482	chr1:197817740	T/C	cg00114966	chr1:197893920	LHX9	0.38	4.59	0.38	1.05e-5	Asthma;
TGCT	trans	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg21659725	chr3:3221576	CRBN	-0.98	-15.33	-0.81	2.1000000000000002e-30	Intelligence (multi-trait analysis);
TGCT	cis	rs7959452	0.590	rs11177643	chr12:69785712	T/G	cg11871910	chr12:69753446	YEATS4	0.82	8.95	0.63	4.38e-15	Blood protein levels;
TGCT	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg03264133	chr6:25882463	NA	-0.57	-5.28	-0.43	5.51e-7	Intelligence (multi-trait analysis);
TGCT	trans	rs4824093	0.535	rs73443931	chr22:50291603	G/A	cg09872104	chr7:134855509	C7orf49	-0.96	-7.87	-0.58	1.49e-12	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs4839827	1	rs4839827	chr6:96853967	C/T	cg06623918	chr6:96969491	KIAA0776	0.65	6.72	0.52	5.89e-10	Migraine;
TGCT	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg03188948	chr7:1209495	NA	0.53	4.47	0.37	1.72e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs72781680	0.898	rs56216411	chr2:23934533	G/A	cg08917208	chr2:24149416	ATAD2B	0.89	5.41	0.44	3.11e-7	Lymphocyte counts;
TGCT	cis	rs9951602	0.651	rs2959408	chr18:76681702	T/C	cg00806245	chr18:76673096	NA	0.31	4.47	0.37	1.72e-5	Obesity-related traits;
TGCT	cis	rs6964587	1.000	rs2106171	chr7:91750450	A/G	cg17063962	chr7:91808500	NA	0.88	9.42	0.65	3.2e-16	Breast cancer;
TGCT	cis	rs7267979	1.000	rs1888997	chr20:25298988	G/A	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7662987	0.517	rs2602880	chr4:100040653	C/T	cg12011299	chr4:100065546	ADH4	0.39	4.81	0.4	4.36e-6	Smoking initiation;
TGCT	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg18230493	chr5:56204884	C5orf35	-0.83	-6.54	-0.51	1.47e-9	Initial pursuit acceleration;
TGCT	cis	rs3784262	0.669	rs12915821	chr15:58315685	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.43	-6.27	-0.49	5.58e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs7072216	0.763	rs10748730	chr10:100171440	C/T	cg26618903	chr10:100175079	PYROXD2	-0.4	-4.49	-0.37	1.64e-5	Metabolite levels;
TGCT	cis	rs6430585	0.646	rs1057031	chr2:136633962	G/A	cg07169764	chr2:136633963	MCM6	1.26	12.74	0.75	2.78e-24	Corneal structure;
TGCT	cis	rs2242116	0.932	rs4683301	chr3:46931478	A/T	cg23352942	chr3:46931381	PTH1R	0.36	5.86	0.47	3.84e-8	Birth weight;
TGCT	cis	rs6088580	0.634	rs6059829	chr20:33017074	G/A	cg06115741	chr20:33292138	TP53INP2	0.55	4.81	0.4	4.24e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs950027	0.572	rs12910764	chr15:45609360	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.72	-7.44	-0.56	1.48e-11	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs7147624	0.938	rs7147231	chr14:66212371	A/G	cg03016385	chr14:66212404	NA	-0.52	-7.29	-0.55	3.26e-11	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs2404602	0.716	rs7174953	chr15:76906847	A/C	cg22467129	chr15:76604101	ETFA	-0.44	-4.98	-0.41	2.07e-6	Blood metabolite levels;
TGCT	cis	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg25427524	chr10:38739819	LOC399744	-0.39	-8.04	-0.59	5.95e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg02380750	chr20:61661411	NA	0.34	6.09	0.48	1.29e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs6831352	1.000	rs6822348	chr4:100053894	A/T	cg12011299	chr4:100065546	ADH4	0.41	5.16	0.42	9.55e-7	Alcohol dependence;
TGCT	cis	rs7178424	0.875	rs17271193	chr15:62165168	A/G	cg00456672	chr15:62358751	C2CD4A	-0.31	-4.69	-0.39	7.14e-6	Height;
TGCT	cis	rs9790314	0.905	rs1154701	chr3:161008025	T/A	cg03342759	chr3:160939853	NMD3	-0.42	-4.51	-0.38	1.5e-5	Morning vs. evening chronotype;
TGCT	cis	rs10832963	0.961	rs10832954	chr11:18643559	G/A	cg20219074	chr11:18656078	SPTY2D1	0.97	9.61	0.65	1.12e-16	Breast cancer;
TGCT	cis	rs79387448	0.745	rs72995626	chr2:103162580	T/C	cg09003973	chr2:102972529	NA	0.92	5.89	0.47	3.39e-8	Gut microbiota (bacterial taxa);
TGCT	cis	rs7586879	0.638	rs10203482	chr2:25136916	T/C	cg01884057	chr2:25150051	NA	0.34	6.58	0.51	1.16e-9	Body mass index;
TGCT	cis	rs9393777	0.513	rs9379895	chr6:26592707	A/G	cg15659132	chr6:26577336	NA	-0.65	-4.84	-0.4	3.82e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs35883536	0.626	rs80052576	chr1:101039229	A/G	cg06223162	chr1:101003688	GPR88	-0.42	-8.0	-0.58	7.38e-13	Monocyte count;
TGCT	cis	rs7586879	1.000	rs7603153	chr2:25116966	T/C	cg01884057	chr2:25150051	NA	0.28	5.03	0.41	1.69e-6	Body mass index;
TGCT	cis	rs9796	0.689	rs576336	chr15:41452771	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.53	-6.97	-0.53	1.68e-10	Menopause (age at onset);
TGCT	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg22105103	chr4:187893119	NA	0.33	4.54	0.38	1.3e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7666738	0.830	rs7684646	chr4:99071062	C/T	cg18180107	chr4:99064573	C4orf37	0.56	5.08	0.42	1.33e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2749592	0.725	rs9417245	chr10:37826322	C/T	cg25427524	chr10:38739819	LOC399744	0.34	5.01	0.41	1.86e-6	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs12971120	0.891	rs2303463	chr18:72168608	G/A	cg25817165	chr18:72167213	CNDP2	-0.29	-4.98	-0.41	2.05e-6	Refractive error;
TGCT	cis	rs9611565	0.592	rs5758406	chr22:42076641	A/G	cg06481639	chr22:41940642	POLR3H	0.73	6.62	0.51	9.76e-10	Vitiligo;
TGCT	cis	rs10465746	0.935	rs942848	chr1:84427707	G/C	cg10977910	chr1:84465055	TTLL7	0.63	6.25	0.49	5.95e-9	Obesity-related traits;
TGCT	cis	rs7843479	1.000	rs2306641	chr8:21833965	A/G	cg17168535	chr8:21777572	XPO7	-0.68	-6.39	-0.5	3.01e-9	Mean corpuscular volume;
TGCT	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg00149659	chr3:10157352	C3orf10	1.22	7.58	0.56	7.14e-12	Alzheimer's disease;
TGCT	trans	rs4650994	0.524	rs2761465	chr1:178579404	G/T	cg05059571	chr16:84539110	KIAA1609	0.52	10.34	0.68	1.85e-18	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs4073582	1.000	rs4073582	chr11:66050712	G/A	cg16950941	chr11:66035639	RAB1B	0.53	4.44	0.37	1.96e-5	Gout;
TGCT	cis	rs877282	1.000	rs877282	chr10:771532	G/A	cg17470449	chr10:769945	NA	0.31	4.77	0.39	5.04e-6	Uric acid levels;
TGCT	cis	rs908922	0.676	rs7532535	chr1:152517597	T/A	cg20991723	chr1:152506922	NA	0.46	6.17	0.48	8.79e-9	Hair morphology;
TGCT	cis	rs2440129	0.591	rs312466	chr17:6899221	G/A	cg03760483	chr17:6899297	ALOX12	-0.44	-5.2	-0.42	7.81e-7	Tonsillectomy;
TGCT	cis	rs8180040	1.000	rs2302278	chr3:47361082	G/T	cg27129171	chr3:47204927	SETD2	-0.68	-8.58	-0.61	3.19e-14	Colorectal cancer;
TGCT	cis	rs941873	0.869	rs7917610	chr10:81117237	T/C	cg09469691	chr10:81107165	PPIF	0.64	6.53	0.51	1.5e-9	Height;
TGCT	cis	rs151997	0.962	rs152687	chr5:50208563	A/G	cg06027927	chr5:50259733	NA	0.47	4.83	0.4	3.9e-6	Callous-unemotional behaviour;
TGCT	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg07507251	chr3:52567010	NT5DC2	0.46	6.48	0.5	1.95e-9	Bipolar disorder;
TGCT	trans	rs3780486	0.846	rs10124479	chr9:33136233	T/G	cg04842962	chr6:43655489	MRPS18A	1.24	15.76	0.82	2.18e-31	IgG glycosylation;
TGCT	cis	rs1497406	1.000	rs1497406	chr1:16505320	A/G	cg20430773	chr1:16534157	ARHGEF19	0.43	4.74	0.39	5.71e-6	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs903263	0.813	rs10874429	chr1:84591649	T/C	cg09664975	chr1:84543551	PRKACB	0.49	4.55	0.38	1.27e-5	Breast cancer (male);
TGCT	cis	rs62244186	0.748	rs6441861	chr3:44652287	A/G	cg02073558	chr3:44770973	ZNF501	0.61	5.87	0.47	3.78e-8	Depressive symptoms;
TGCT	cis	rs10114408	0.959	rs7852957	chr9:96647881	C/T	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs7267979	0.586	rs1473695	chr20:25186965	A/G	cg16686733	chr20:25566563	NINL	0.53	5.41	0.44	3.06e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11190604	0.943	rs2495744	chr10:102329409	C/T	cg23241863	chr10:102295624	HIF1AN	0.64	4.78	0.39	4.95e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg22535103	chr8:58192502	C8orf71	-0.46	-5.13	-0.42	1.09e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs11190604	0.697	rs12355942	chr10:102201320	T/C	cg23241863	chr10:102295624	HIF1AN	-0.65	-5.05	-0.41	1.53e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs6484504	0.516	rs1999250	chr11:31287455	C/T	cg26647111	chr11:31128758	NA	-0.34	-4.69	-0.39	7.02e-6	Red blood cell count;
TGCT	cis	rs826838	0.935	rs980571	chr12:39127532	C/G	cg26384229	chr12:38710491	ALG10B	-0.87	-7.98	-0.58	8.39e-13	Heart rate;
TGCT	cis	rs868036	0.718	rs28587941	chr15:68122509	T/C	cg05925327	chr15:68127851	NA	-0.51	-5.04	-0.41	1.63e-6	Restless legs syndrome;
TGCT	cis	rs7085104	0.572	rs284860	chr10:104572963	T/C	cg05855489	chr10:104503620	C10orf26	-0.63	-6.21	-0.49	7.3e-9	Immature fraction of reticulocytes;Schizophrenia;
TGCT	trans	rs10435719	0.702	rs77055881	chr8:11790581	T/C	cg15556689	chr8:8085844	FLJ10661	0.76	7.18	0.54	5.62e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs28374715	0.580	rs8030228	chr15:41636867	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.91	-14.89	-0.8	2.14e-29	Ulcerative colitis;
TGCT	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg03060546	chr3:49711283	APEH	0.51	4.91	0.4	2.8e-6	Menarche (age at onset);
TGCT	trans	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.85	8.84	0.62	7.83e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs6893807	0.667	rs7733438	chr5:87986284	T/G	cg24804195	chr5:87968844	LOC645323	0.73	4.9	0.4	2.94e-6	Body mass index;
TGCT	cis	rs6095298	0.595	rs7267607	chr20:47447870	A/C	cg12307787	chr20:48099359	KCNB1	0.44	4.67	0.39	7.75e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7605378	0.752	rs769960	chr2:200710706	G/T	cg17644776	chr2:200775616	C2orf69	-0.34	-7.08	-0.54	9.64e-11	Osteoporosis;
TGCT	cis	rs7666738	0.830	rs7664169	chr4:99037859	C/T	cg17366294	chr4:99064904	C4orf37	-0.71	-7.28	-0.55	3.38e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs644799	0.965	rs534488	chr11:95562327	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	10.52	0.69	6.94e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs62244186	0.545	rs7640654	chr3:44763037	A/C	cg25151919	chr3:44754333	ZNF502	-0.47	-5.45	-0.44	2.56e-7	Depressive symptoms;
TGCT	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs1669338	0.588	rs3804783	chr3:3184442	C/T	cg16797762	chr3:3221439	CRBN	-0.83	-5.24	-0.43	6.58e-7	White matter integrity;
TGCT	cis	rs9796	0.689	rs28409432	chr15:41447454	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.53	-6.83	-0.52	3.38e-10	Menopause (age at onset);
TGCT	cis	rs854765	0.927	rs12943914	chr17:17980671	A/G	cg09796270	chr17:17721594	SREBF1	0.26	5.05	0.41	1.54e-6	Total body bone mineral density;
TGCT	cis	rs453301	0.686	rs28665409	chr8:8869277	G/A	cg15556689	chr8:8085844	FLJ10661	-0.61	-4.98	-0.41	2.09e-6	Joint mobility (Beighton score);
TGCT	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg01448562	chr3:133502909	NA	-0.36	-7.37	-0.55	2.11e-11	Iron status biomarkers;
TGCT	cis	rs727505	1.000	rs7791430	chr7:124429953	G/T	cg23710748	chr7:124431027	NA	-0.26	-4.56	-0.38	1.21e-5	Lewy body disease;
TGCT	cis	rs10193935	0.901	rs13384885	chr2:42536646	G/C	cg27598129	chr2:42591480	NA	-0.4	-5.56	-0.45	1.57e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg27286337	chr10:134555280	INPP5A	-0.38	-5.09	-0.42	1.3e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs11098499	0.909	rs9759478	chr4:120367998	G/A	cg09307838	chr4:120376055	NA	0.68	6.52	0.51	1.59e-9	Corneal astigmatism;
TGCT	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg06873352	chr17:61820015	STRADA	0.55	6.13	0.48	1.09e-8	Prudent dietary pattern;
TGCT	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg17054783	chr10:134559939	INPP5A	0.26	4.92	0.4	2.68e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs4788570	0.615	rs2032918	chr16:71703436	T/G	cg06353428	chr16:71660113	MARVELD3	1.56	12.54	0.75	8.54e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs16854884	0.837	rs6804060	chr3:143804040	C/T	cg06585982	chr3:143692056	C3orf58	0.63	4.72	0.39	6.18e-6	Economic and political preferences (feminism/equality);
TGCT	cis	rs16867321	0.950	rs4667223	chr2:181498302	C/G	cg23363182	chr2:181467187	NA	-0.38	-5.55	-0.45	1.62e-7	Obesity;
TGCT	cis	rs7267979	1.000	rs2500446	chr20:25339664	C/T	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3733585	0.588	rs6449154	chr4:9956404	C/T	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.73	-0.57	3.25e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7681440	0.626	rs1372510	chr4:90817259	G/A	cg20003494	chr4:90757398	SNCA	-0.54	-4.88	-0.4	3.21e-6	Dementia with Lewy bodies;
TGCT	trans	rs11722228	1.000	rs4697695	chr4:9915850	C/T	cg26043149	chr18:55253948	FECH	0.76	7.26	0.55	3.68e-11	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs57994353	0.568	rs1130635	chr9:139317869	A/G	cg13741927	chr9:139327495	INPP5E	-0.24	-5.47	-0.44	2.42e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs3008870	0.755	rs4655661	chr1:67408828	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.79	8.41	0.6	8.39e-14	Lymphocyte percentage of white cells;
TGCT	cis	rs60843830	1.000	rs60843830	chr2:286756	C/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.72	6.54	0.51	1.42e-9	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.12	0.42	1.15e-6	Prudent dietary pattern;
TGCT	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.4	-4.76	-0.39	5.24e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg04234412	chr22:24373322	LOC391322	0.9	10.66	0.69	3.1400000000000002e-19	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs3803170	0.513	rs11065888	chr12:111828663	G/C	cg10833066	chr12:111807467	FAM109A	0.36	5.41	0.44	3.09e-7	Mean corpuscular hemoglobin;
TGCT	cis	rs3771570	1.000	rs16843590	chr2:242298228	G/A	cg21155796	chr2:242212141	HDLBP	0.94	6.69	0.51	6.9e-10	Prostate cancer;
TGCT	cis	rs2836633	0.929	rs62217517	chr21:40033177	T/A	cg05519781	chr21:40033154	ERG	0.7	6.95	0.53	1.86e-10	Coronary artery disease;
TGCT	cis	rs7617773	0.746	rs4130995	chr3:48358255	C/T	cg11946769	chr3:48343235	NME6	0.75	6.94	0.53	1.92e-10	Coronary artery disease;
TGCT	cis	rs9341808	0.718	rs3805922	chr6:80891989	A/G	cg08355045	chr6:80787529	NA	0.32	5.6	0.45	1.29e-7	Sitting height ratio;
TGCT	cis	rs28595532	0.920	rs115090549	chr4:119753554	T/C	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs7772486	0.875	rs2814871	chr6:146312274	G/T	cg23711669	chr6:146136114	FBXO30	0.84	8.85	0.62	7.33e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg03188948	chr7:1209495	NA	0.71	6.04	0.48	1.68e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg24250549	chr1:154909240	PMVK	0.63	6.25	0.49	6.03e-9	Prostate cancer;
TGCT	cis	rs12220238	0.841	rs11000993	chr10:76084111	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.87	6.44	0.5	2.37e-9	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	5.12	0.42	1.11e-6	Alzheimer's disease;
TGCT	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg11494091	chr17:61959527	GH2	0.6	14.54	0.79	1.46e-28	Prudent dietary pattern;
TGCT	cis	rs6500602	0.682	rs3761679	chr16:4457907	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	6.24	0.49	6.25e-9	Schizophrenia;
TGCT	cis	rs13256369	0.851	rs11249890	chr8:8565245	G/T	cg17143192	chr8:8559678	CLDN23	0.57	5.35	0.43	4.09e-7	Obesity-related traits;
TGCT	cis	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg07424592	chr7:64974309	NA	1.31	7.66	0.57	4.63e-12	Diabetic kidney disease;
TGCT	cis	rs73198271	0.628	rs11783457	chr8:8588842	G/C	ch.8.214553F	chr8:8189620	PRAGMIN	-0.32	-5.23	-0.42	7.04e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs11578119	0.898	rs11577004	chr1:170440622	C/T	cg09767346	chr1:170501363	GORAB	0.71	5.68	0.45	9.07e-8	Male-pattern baldness;
TGCT	cis	rs6964587	1.000	rs7811564	chr7:91663364	A/G	cg17063962	chr7:91808500	NA	0.88	9.65	0.66	8.73e-17	Breast cancer;
TGCT	trans	rs7698623	0.702	rs1599722	chr4:88782786	A/G	cg01186725	chr1:53905612	FLJ40434	-0.48	-6.63	-0.51	9.21e-10	Cardiovascular disease risk factors;
TGCT	cis	rs7586879	0.609	rs7608976	chr2:25075281	G/A	cg01884057	chr2:25150051	NA	0.31	5.75	0.46	6.47e-8	Body mass index;
TGCT	cis	rs3008870	0.920	rs2755253	chr1:67470843	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.01	10.3	0.68	2.3e-18	Lymphocyte percentage of white cells;
TGCT	trans	rs459571	0.920	rs433402	chr9:136898627	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.71	-7.72	-0.57	3.39e-12	Platelet distribution width;
TGCT	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs4409675	0.576	rs6679432	chr1:28227665	T/C	cg23691781	chr1:28212827	C1orf38	0.26	5.44	0.44	2.76e-7	Corneal astigmatism;
TGCT	cis	rs6433857	0.536	rs7557023	chr2:181350474	G/A	cg23363182	chr2:181467187	NA	-0.32	-4.85	-0.4	3.59e-6	Body mass index;
TGCT	cis	rs17345786	1.000	rs997739	chr3:101313940	A/G	cg12386194	chr3:101231763	SENP7	0.61	5.75	0.46	6.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs80282103	0.618	rs56004802	chr10:1159187	C/T	cg08668510	chr10:1095578	IDI1	1.08	5.04	0.41	1.64e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs6684514	1.000	rs10908502	chr1:156300082	A/G	cg20302342	chr1:156215951	PAQR6	0.35	4.74	0.39	5.77e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg04944784	chr2:26401820	FAM59B	-0.7	-6.49	-0.5	1.89e-9	Gut microbiome composition (summer);
TGCT	cis	rs6438424	0.502	rs6792076	chr3:117724113	A/G	cg15509235	chr3:117715573	NA	0.54	5.41	0.44	3.16e-7	Menarche (age at onset);
TGCT	cis	rs854765	0.547	rs7212167	chr17:17913504	G/A	cg04398451	chr17:18023971	MYO15A	-0.32	-5.12	-0.42	1.15e-6	Total body bone mineral density;
TGCT	cis	rs12142240	0.698	rs41294476	chr1:46818374	C/A	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs17152411	0.895	rs11245418	chr10:126586319	T/C	cg07906193	chr10:126599966	NA	0.41	5.05	0.41	1.52e-6	Height;
TGCT	cis	rs13242816	1.000	rs55977427	chr7:116110768	C/T	cg02799643	chr7:116139180	CAV2	-0.48	-5.52	-0.44	1.87e-7	P wave duration;
TGCT	cis	rs12530845	1.000	rs56060450	chr7:135331777	C/T	cg23117316	chr7:135346802	PL-5283	-0.51	-4.83	-0.4	3.98e-6	Red blood cell traits;
TGCT	cis	rs4919669	0.668	rs7094614	chr10:104334874	G/C	cg05855489	chr10:104503620	C10orf26	0.71	4.69	0.39	7.18e-6	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs9372253	1.000	rs11153232	chr6:110716252	G/T	cg01119278	chr6:110721349	DDO	0.35	5.68	0.45	9e-8	Platelet distribution width;
TGCT	cis	rs11031096	0.678	rs2044135	chr11:4187233	G/A	cg18678763	chr11:4115507	RRM1	-0.46	-5.95	-0.47	2.5e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs889312	0.500	rs3099460	chr5:56133748	G/C	cg12311346	chr5:56204834	C5orf35	-0.47	-5.03	-0.41	1.7e-6	Breast cancer;Breast cancer (early onset);
TGCT	cis	rs2486288	0.656	rs12910009	chr15:45572408	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.47	-5.38	-0.44	3.57e-7	Glomerular filtration rate;
TGCT	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.61	5.06	0.41	1.5e-6	Tonsillectomy;
TGCT	cis	rs9486719	1.000	rs2142652	chr6:96868504	A/C	cg06623918	chr6:96969491	KIAA0776	1.01	8.86	0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs2762353	0.574	rs4409177	chr6:25694491	T/G	cg12310025	chr6:25882481	NA	0.94	9.45	0.65	2.65e-16	Blood metabolite levels;
TGCT	cis	rs7208859	0.510	rs216402	chr17:28917126	A/T	cg13385521	chr17:29058706	SUZ12P	0.86	5.12	0.42	1.15e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs6570726	0.935	rs447818	chr6:145868996	C/T	cg05347473	chr6:146136440	FBXO30	0.49	4.51	0.38	1.46e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg07343612	chr16:622815	PIGQ	-0.42	-8.4	-0.6	8.58e-14	Height;
TGCT	cis	rs62244186	0.659	rs9835270	chr3:44553722	G/A	cg10263370	chr3:44754102	ZNF502	-0.44	-5.19	-0.42	8.19e-7	Depressive symptoms;
TGCT	trans	rs2832077	0.527	rs11088095	chr21:30223188	A/T	cg14791747	chr16:20752902	THUMPD1	1.09	12.67	0.75	4.09e-24	Cognitive test performance;
TGCT	cis	rs4711350	0.749	rs7752348	chr6:33718252	C/G	cg13859433	chr6:33739653	LEMD2	-0.31	-4.55	-0.38	1.24e-5	Schizophrenia;
TGCT	cis	rs7666738	0.830	rs2865980	chr4:99027422	T/G	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2469997	1.000	rs2447174	chr8:120358571	G/A	cg00681363	chr8:120844660	TAF2	0.69	4.48	0.37	1.64e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs9682041	0.696	rs11917147	chr3:170088448	C/T	cg11886554	chr3:170076028	SKIL	0.6	4.76	0.39	5.35e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs941408	0.515	rs1005556	chr19:2778543	G/T	cg06609049	chr19:2785107	THOP1	1.12	13.05	0.76	5.1e-25	Total cholesterol levels;
TGCT	cis	rs6840360	0.593	rs10013612	chr4:152693622	A/G	cg17479576	chr4:152424074	FAM160A1	-0.53	-5.26	-0.43	5.99e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs929354	0.772	rs3802117	chr7:156987000	C/T	cg05182265	chr7:156933206	UBE3C	-0.39	-8.79	-0.62	1.03e-14	Body mass index;
TGCT	trans	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg23505145	chr19:12996616	KLF1	0.78	8.12	0.59	4.03e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg04944784	chr2:26401820	FAM59B	0.76	6.24	0.49	6.46e-9	Gut microbiome composition (summer);
TGCT	cis	rs7786808	0.588	rs4909078	chr7:158183835	C/G	cg01191920	chr7:158217561	PTPRN2	-0.36	-5.27	-0.43	5.82e-7	Obesity-related traits;
TGCT	cis	rs950169	0.579	rs12913054	chr15:84664456	A/G	cg11189052	chr15:85197271	WDR73	0.65	5.06	0.41	1.45e-6	Schizophrenia;
TGCT	cis	rs7178572	0.625	rs907372	chr15:77844516	G/T	cg22256960	chr15:77711686	NA	-0.79	-9.16	-0.64	1.32e-15	Type 2 diabetes;
TGCT	cis	rs12908161	1.000	rs12899981	chr15:85302373	G/A	cg17173187	chr15:85201210	NMB	0.57	6.41	0.5	2.81e-9	Schizophrenia;
TGCT	cis	rs7833790	1.000	rs1463259	chr8:82737745	A/G	cg27398817	chr8:82754497	SNX16	-0.87	-6.35	-0.5	3.66e-9	Diastolic blood pressure;
TGCT	cis	rs4595586	0.545	rs6580893	chr12:39371885	G/T	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs3849570	0.643	rs6797240	chr3:81971856	T/C	cg07356753	chr3:81810745	GBE1	-0.64	-5.62	-0.45	1.19e-7	Waist circumference;Body mass index;
TGCT	cis	rs9788682	1.000	rs7163730	chr15:78814681	A/G	cg06917634	chr15:78832804	PSMA4	-0.71	-5.22	-0.42	7.38e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs9611565	0.765	rs132905	chr22:41799106	C/A	cg13695892	chr22:41940480	POLR3H	0.8	8.01	0.58	7.2e-13	Vitiligo;
TGCT	cis	rs1990950	0.692	rs7723675	chr5:156830865	A/G	cg25387487	chr5:157003181	ADAM19	0.3	4.66	0.39	7.98e-6	Lung function (FEV1/FVC);
TGCT	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	13.43	0.77	6.22e-26	Height;
TGCT	cis	rs2243480	0.615	rs34363376	chr7:65939536	T/C	cg18252515	chr7:66147081	NA	-1.18	-7.56	-0.56	7.99e-12	Diabetic kidney disease;
TGCT	cis	rs7249142	0.597	rs7250650	chr19:19285989	A/T	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.56	5.55	0.45	1.64e-7	IgG glycosylation;
TGCT	cis	rs7264396	0.747	rs2425158	chr20:34419664	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-4.89	-0.4	3.06e-6	Total cholesterol levels;
TGCT	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg12311346	chr5:56204834	C5orf35	0.55	5.89	0.47	3.44e-8	Initial pursuit acceleration;
TGCT	cis	rs9611565	0.559	rs739136	chr22:42100275	C/T	cg03806693	chr22:41940476	POLR3H	-1.08	-11.99	-0.73	1.84e-22	Vitiligo;
TGCT	cis	rs2191566	0.821	rs59756444	chr19:44513656	C/G	cg03039196	chr19:44506973	ZNF230	0.54	4.67	0.39	7.62e-6	Acute lymphoblastic leukemia (childhood);
TGCT	cis	rs9929218	0.551	rs2296409	chr16:68713730	G/A	cg01251360	chr16:68772225	CDH1	-0.26	-4.69	-0.39	6.99e-6	Colorectal cancer;
TGCT	cis	rs17826219	0.706	rs2322197	chr17:29105805	T/C	cg13385521	chr17:29058706	SUZ12P	0.78	4.72	0.39	6.2e-6	Body mass index;
TGCT	cis	rs7914558	1.000	rs7911789	chr10:104756374	T/C	cg15744005	chr10:104629667	AS3MT	-0.4	-4.89	-0.4	3.06e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs4808199	1.000	rs60321073	chr19:19499598	A/G	cg03709012	chr19:19516395	GATAD2A	0.99	7.7	0.57	3.74e-12	Nonalcoholic fatty liver disease;
TGCT	cis	rs2072499	0.865	rs2758608	chr1:156202860	A/T	cg24450063	chr1:156163899	SLC25A44	1.05	11.04	0.7	3.74e-20	Testicular germ cell tumor;
TGCT	cis	rs7584330	0.554	rs2325838	chr2:238386515	C/A	cg14458575	chr2:238380390	NA	0.58	5.05	0.41	1.53e-6	Prostate cancer;
TGCT	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg16414030	chr3:133502952	NA	-0.61	-9.4	-0.65	3.55e-16	Iron status biomarkers;
TGCT	cis	rs245880	0.740	rs245898	chr7:29194143	G/A	cg17163760	chr7:29186267	CPVL	-0.41	-5.08	-0.42	1.35e-6	Warfarin maintenance dose;
TGCT	cis	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg25427524	chr10:38739819	LOC399744	-0.38	-8.01	-0.58	6.99e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg04287289	chr16:89883240	FANCA	0.93	11.53	0.72	2.36e-21	Vitiligo;
TGCT	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg00684032	chr4:1343700	KIAA1530	0.23	5.01	0.41	1.79e-6	Obesity-related traits;
TGCT	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg00814883	chr7:100076585	TSC22D4	-0.92	-9.76	-0.66	4.73e-17	Platelet count;
TGCT	cis	rs1577917	0.771	rs9362237	chr6:86409064	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.63	5.58	0.45	1.43e-7	Response to antipsychotic treatment;
TGCT	cis	rs155076	1.000	rs195570	chr13:21867580	T/G	cg14456004	chr13:21872349	NA	-1.17	-10.03	-0.67	1.09e-17	White matter hyperintensity burden;
TGCT	cis	rs7044106	0.762	rs10760107	chr9:123383630	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.58	6.37	0.5	3.32e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg20607798	chr8:58055168	NA	0.62	5.19	0.42	8.32e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs941408	0.515	rs1640265	chr19:2784405	C/T	cg06609049	chr19:2785107	THOP1	1.14	13.14	0.76	2.97e-25	Total cholesterol levels;
TGCT	trans	rs2801405	0.584	rs1596652	chr10:100644484	C/G	cg04906546	chr1:208317836	PLXNA2	-0.29	-6.86	-0.52	2.94e-10	Obesity-related traits;
TGCT	cis	rs2204008	0.743	rs2127952	chr12:37995364	G/T	cg26384229	chr12:38710491	ALG10B	0.85	7.77	0.57	2.56e-12	Bladder cancer;
TGCT	cis	rs10510102	0.748	rs4589226	chr10:123710588	A/G	cg23691251	chr10:123688108	ATE1	-0.6	-4.65	-0.39	8.51e-6	Breast cancer;
TGCT	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg17971929	chr21:40555470	PSMG1	0.98	9.6	0.65	1.18e-16	Cognitive function;
TGCT	cis	rs3733585	0.781	rs13103879	chr4:9972879	T/C	cg11266682	chr4:10021025	SLC2A9	-0.62	-8.75	-0.62	1.28e-14	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs1008375	0.966	rs3733581	chr4:17695206	C/G	cg18681998	chr4:17616180	MED28	-0.83	-7.63	-0.57	5.33e-12	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs11024102	1.000	rs11024102	chr11:17008605	T/C	cg15378786	chr11:17036137	PLEKHA7	0.49	4.52	0.38	1.44e-5	Glaucoma (primary angle closure);
TGCT	cis	rs2932538	0.922	rs6537744	chr1:113096746	C/G	cg22162597	chr1:113214053	CAPZA1	0.27	5.89	0.47	3.46e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs3780378	0.875	rs7861599	chr9:5067298	C/T	cg02405213	chr9:5042618	JAK2	-0.64	-8.86	-0.62	7.1e-15	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs2241685	0.540	rs4853827	chr2:1867400	A/C	cg21862353	chr2:1801628	MYT1L	-0.47	-4.71	-0.39	6.64e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs56104184	0.725	rs4347731	chr19:49385154	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.73	-8.89	-0.62	5.96e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs35146811	0.695	rs1618851	chr7:99810643	T/G	cg00553149	chr7:99775558	STAG3;GPC2	-0.31	-4.61	-0.38	9.75e-6	Coronary artery disease;
TGCT	cis	rs921968	0.612	rs573555	chr2:219348888	A/C	cg02176678	chr2:219576539	TTLL4	0.38	5.48	0.44	2.31e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs422249	0.512	rs174566	chr11:61592362	A/G	cg01500311	chr11:61656094	FADS3	-0.3	-5.22	-0.42	7.4e-7	Trans fatty acid levels;
TGCT	cis	rs367615	0.704	rs7705399	chr5:108850351	G/C	cg17395555	chr5:108820864	NA	0.32	6.04	0.48	1.67e-8	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg07424592	chr7:64974309	NA	1.32	8.15	0.59	3.39e-13	Diabetic kidney disease;
TGCT	cis	rs7246657	0.941	rs7259618	chr19:37750719	G/A	cg18154014	chr19:37997991	ZNF793	0.8	5.14	0.42	1.02e-6	Coronary artery calcification;
TGCT	cis	rs3806843	0.576	rs246066	chr5:140323147	T/G	cg07102913	chr5:140593443	PCDHB13	-0.48	-4.81	-0.4	4.26e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs637571	0.522	rs503524	chr11:65751764	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.68	6.72	0.52	5.84e-10	Eosinophil percentage of white cells;
TGCT	cis	rs67311347	1.000	rs11716675	chr3:40485280	G/T	cg17264618	chr3:40429014	ENTPD3	0.32	4.76	0.39	5.36e-6	Renal cell carcinoma;
TGCT	cis	rs5760092	0.755	rs5760096	chr22:24247310	A/G	cg18538332	chr22:24372958	LOC391322	-0.77	-7.27	-0.55	3.57e-11	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs12701220	0.894	rs2141274	chr7:1034717	G/A	cg27454412	chr7:1067447	C7orf50	-0.5	-4.78	-0.39	4.9e-6	Bronchopulmonary dysplasia;
TGCT	cis	rs10779751	0.734	rs2791649	chr1:11132561	A/G	cg08854313	chr1:11322531	MTOR	0.82	7.04	0.53	1.19e-10	Body mass index;
TGCT	cis	rs1334894	0.901	rs56062505	chr6:35521182	G/A	cg24281267	chr6:35479648	TULP1	-0.43	-4.54	-0.38	1.34e-5	Coronary artery disease;
TGCT	cis	rs9486719	1.000	rs12208124	chr6:97027942	C/T	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.0	-0.41	1.9e-6	Migraine;Coronary artery disease;
TGCT	cis	rs7312933	0.566	rs11181454	chr12:42746486	T/C	cg19980929	chr12:42632907	YAF2	-0.41	-5.72	-0.46	7.37e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg21724239	chr8:58056113	NA	0.4	5.01	0.41	1.8e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs5769707	0.967	rs8141807	chr22:50043738	C/G	cg20744362	chr22:50050164	C22orf34	0.27	4.57	0.38	1.18e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg23221052	chr5:179740743	GFPT2	-0.36	-5.72	-0.46	7.59e-8	Height;
TGCT	cis	rs9467773	1.000	rs6456734	chr6:26566965	G/T	cg26531700	chr6:26746687	NA	0.5	4.85	0.4	3.64e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg08859206	chr1:53392774	SCP2	-0.49	-7.71	-0.57	3.61e-12	Monocyte count;
TGCT	cis	rs3806843	0.576	rs246043	chr5:140330924	G/A	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	trans	rs1814175	0.791	rs1722011	chr11:49899340	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.04	-0.53	1.16e-10	Height;
TGCT	cis	rs2439831	0.867	rs2278860	chr15:43659046	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.97	-8.19	-0.59	2.78e-13	Lung cancer in ever smokers;
TGCT	cis	rs950027	0.620	rs1346267	chr15:45690989	A/G	cg14582100	chr15:45693742	SPATA5L1	0.44	5.49	0.44	2.21e-7	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs7980687	0.628	rs2102949	chr12:123676763	G/A	cg00376283	chr12:123451042	ABCB9	0.79	6.75	0.52	5e-10	Height;Educational attainment;Head circumference (infant);
TGCT	cis	rs644799	0.710	rs11021309	chr11:95501898	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.81	9.02	0.63	2.92e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7000551	0.653	rs4872504	chr8:22326717	A/G	cg12081754	chr8:22256438	SLC39A14	0.28	4.64	0.38	8.8e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs7044106	0.791	rs10984997	chr9:123481206	T/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	5.09	0.42	1.31e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs2692947	0.683	rs1813381	chr2:96422939	C/T	cg23100626	chr2:96804247	ASTL	-0.49	-5.92	-0.47	3e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs1729951	0.575	rs835642	chr3:136703365	A/T	cg12473912	chr3:136751656	NA	0.39	6.18	0.49	8.36e-9	Neuroticism;
TGCT	cis	rs7249142	0.562	rs10418053	chr19:19287164	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.34	-4.5	-0.37	1.56e-5	IgG glycosylation;
TGCT	cis	rs9611565	0.512	rs1534932	chr22:42150146	C/T	cg06481639	chr22:41940642	POLR3H	0.69	6.05	0.48	1.59e-8	Vitiligo;
TGCT	cis	rs28493229	0.522	rs17713068	chr19:41270055	A/C	cg11601297	chr19:41224147	ITPKC;ADCK4	0.58	5.1	0.42	1.25e-6	Kawasaki disease;
TGCT	cis	rs35113840	1	rs35113840	chr2:239101656	G/GA	cg17459225	chr2:239074497	NA	0.31	4.59	0.38	1.08e-5	Red cell distribution width;
TGCT	cis	rs3796352	1.000	rs11713290	chr3:52971579	G/A	cg15956490	chr3:53032818	SFMBT1	0.59	6.04	0.48	1.65e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs72781680	0.898	rs10490752	chr2:24025132	C/T	cg08917208	chr2:24149416	ATAD2B	0.81	5.01	0.41	1.8e-6	Lymphocyte counts;
TGCT	cis	rs854765	0.583	rs8065416	chr17:17851162	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.76	7.85	0.58	1.65e-12	Total body bone mineral density;
TGCT	cis	rs6582630	0.519	rs10880629	chr12:38533611	T/G	cg26384229	chr12:38710491	ALG10B	0.86	7.8	0.57	2.22e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.8	6.47	0.5	2.06e-9	Mean platelet volume;
TGCT	cis	rs700651	0.675	rs2033570	chr2:198952637	C/T	cg00792783	chr2:198669748	PLCL1	0.54	4.56	0.38	1.23e-5	Intracranial aneurysm;
TGCT	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg26874164	chr19:58962979	ZNF324B	0.91	8.18	0.59	2.88e-13	Mean platelet volume;
TGCT	cis	rs9814567	1.000	rs13089966	chr3:134279197	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.96	9.11	0.63	1.79e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg05665937	chr4:1216051	CTBP1	0.24	4.61	0.38	1e-5	Obesity-related traits;
TGCT	cis	rs7586879	0.575	rs6706316	chr2:25128351	C/G	cg15423357	chr2:25149977	NA	0.5	4.89	0.4	3.06e-6	Body mass index;
TGCT	cis	rs2637266	0.905	rs2130796	chr10:78329712	C/G	cg18941641	chr10:78392320	NA	0.43	5.48	0.44	2.29e-7	Pulmonary function;
TGCT	cis	rs6938	0.534	rs1130741	chr15:75189930	A/G	cg10253484	chr15:75165896	SCAMP2	-0.55	-5.07	-0.41	1.43e-6	Breast cancer;
TGCT	cis	rs13256369	0.951	rs13260947	chr8:8565883	A/G	cg18904891	chr8:8559673	CLDN23	0.59	5.52	0.44	1.93e-7	Obesity-related traits;
TGCT	cis	rs595982	0.559	rs4802516	chr19:49366170	T/C	cg17863274	chr19:49399704	TULP2	-0.47	-6.78	-0.52	4.43e-10	Red cell distribution width;
TGCT	cis	rs2688608	0.592	rs10762560	chr10:75495405	T/G	cg04320760	chr10:75533139	FUT11	-0.4	-6.25	-0.49	6.11e-9	Inflammatory bowel disease;
TGCT	cis	rs28595532	0.920	rs115354352	chr4:119750358	T/C	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs4906332	1.000	rs8012623	chr14:103937086	G/A	cg26031613	chr14:104095156	KLC1	-0.52	-4.72	-0.39	6.31e-6	Coronary artery disease;
TGCT	cis	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg02503808	chr4:7069936	GRPEL1	0.98	9.23	0.64	9.22e-16	Monocyte percentage of white cells;
TGCT	cis	rs11098499	0.954	rs10017371	chr4:120293776	A/G	cg09307838	chr4:120376055	NA	0.62	5.97	0.47	2.35e-8	Corneal astigmatism;
TGCT	cis	rs12615966	1.000	rs12620555	chr2:105379115	T/C	cg16465502	chr2:105461796	NA	0.78	5.01	0.41	1.83e-6	Pancreatic cancer;
TGCT	cis	rs9952991	0.709	rs755390	chr18:12763706	T/C	cg23598886	chr18:12777645	NA	-0.68	-4.74	-0.39	5.74e-6	Inflammatory skin disease;
TGCT	cis	rs9640161	0.830	rs6722	chr7:150068933	T/C	cg10018233	chr7:150070692	REPIN1	0.42	6.84	0.52	3.24e-10	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs7727544	0.570	rs7701237	chr5:131534381	C/T	cg24060327	chr5:131705240	SLC22A5	-0.44	-4.5	-0.37	1.56e-5	Blood metabolite levels;
TGCT	cis	rs6663390	0.510	rs2300055	chr1:208065380	C/T	cg03990033	chr1:208084030	CD34	0.64	4.46	0.37	1.81e-5	Facial morphology (factor 18);
TGCT	cis	rs12681287	0.547	rs7465511	chr8:87521481	C/T	cg27223183	chr8:87520930	FAM82B	-0.96	-7.03	-0.53	1.21e-10	Caudate activity during reward;
TGCT	cis	rs7909074	0.966	rs879074	chr10:45400053	G/A	cg04218760	chr10:45406644	TMEM72	-0.27	-5.35	-0.43	4.05e-7	Mean corpuscular volume;
TGCT	cis	rs74054849	0.850	rs75348249	chr1:15961264	C/T	cg05660106	chr1:15850417	CASP9	0.86	4.48	0.37	1.68e-5	Alcoholic chronic pancreatitis;
TGCT	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg08439880	chr3:133502540	NA	-0.32	-6.09	-0.48	1.33e-8	Iron status biomarkers;
TGCT	cis	rs9811920	0.660	rs11719468	chr3:99671848	G/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.46	5.45	0.44	2.55e-7	Axial length;
TGCT	cis	rs7523050	0.643	rs36052234	chr1:109402943	C/T	cg08274380	chr1:109419600	GPSM2	1.3	6.39	0.5	2.99e-9	Fat distribution (HIV);
TGCT	cis	rs9814567	1.000	rs9832785	chr3:134213070	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.96	-9.19	-0.64	1.16e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs892961	0.932	rs12453822	chr17:75416792	G/A	cg05865280	chr17:75406074	SEPT9	0.28	6.45	0.5	2.27e-9	Airflow obstruction;
TGCT	cis	rs11264213	0.901	rs584873	chr1:36431806	C/A	cg27506609	chr1:36549197	TEKT2	0.4	4.54	0.38	1.32e-5	Schizophrenia;
TGCT	cis	rs939574	0.720	rs6714820	chr2:220071803	C/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-1.06	-6.52	-0.51	1.6e-9	Platelet distribution width;
TGCT	cis	rs4713675	0.709	rs542441	chr6:33675851	A/C	cg06471254	chr6:33690276	IP6K3	0.24	4.7	0.39	6.71e-6	Plateletcrit;
TGCT	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.72	-6.47	-0.5	2.04e-9	Tonsillectomy;
TGCT	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg06634786	chr22:41940651	POLR3H	-0.88	-8.54	-0.61	3.98e-14	Vitiligo;
TGCT	cis	rs2153535	0.623	rs2327055	chr6:8443145	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.58	0.45	1.42e-7	Motion sickness;
TGCT	cis	rs7829975	0.593	rs2921051	chr8:8320104	C/A	cg15556689	chr8:8085844	FLJ10661	0.67	6.38	0.5	3.15e-9	Mood instability;
TGCT	trans	rs12339966	0.581	rs11794337	chr9:11333155	C/T	cg03488587	chr11:64876988	C11orf2	0.32	7.03	0.53	1.19e-10	Systolic blood pressure;
TGCT	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg12963246	chr6:28129442	ZNF389	0.51	5.02	0.41	1.73e-6	Depression;
TGCT	cis	rs9486715	0.867	rs2499775	chr6:97007340	C/T	cg06623918	chr6:96969491	KIAA0776	-1.1	-14.37	-0.79	3.55e-28	Headache;
TGCT	cis	rs11096990	0.552	rs7655170	chr4:39173604	T/G	cg24403649	chr4:39172243	NA	0.2	4.48	0.37	1.7e-5	Cognitive function;
TGCT	cis	rs1008375	1.000	rs6819132	chr4:17689752	G/T	cg18681998	chr4:17616180	MED28	-0.91	-8.98	-0.63	3.58e-15	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg18305652	chr10:134549665	INPP5A	0.34	5.52	0.44	1.87e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs7615952	0.673	rs7632557	chr3:125634881	G/C	cg05084668	chr3:125655381	ALG1L	-0.63	-4.64	-0.38	8.78e-6	Blood pressure (smoking interaction);
TGCT	cis	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg07424592	chr7:64974309	NA	1.34	8.08	0.59	4.95e-13	Diabetic kidney disease;
TGCT	cis	rs6121246	0.567	rs6087701	chr20:30217708	A/C	cg18721089	chr20:30220636	NA	-0.64	-6.86	-0.52	2.84e-10	Mean corpuscular hemoglobin;
TGCT	cis	rs17102423	0.661	rs4468529	chr14:65611968	C/T	cg11161011	chr14:65562177	MAX	-0.45	-5.79	-0.46	5.53e-8	Obesity-related traits;
TGCT	trans	rs1814175	0.781	rs28681334	chr11:50051177	C/T	cg15704280	chr7:45808275	SEPT13	-0.72	-8.47	-0.61	6.02e-14	Height;
TGCT	cis	rs9400467	0.537	rs1891387	chr6:111462290	A/G	cg15721981	chr6:111408429	SLC16A10	0.68	4.48	0.37	1.69e-5	Blood metabolite levels;Amino acid levels;
TGCT	cis	rs6570726	0.935	rs395948	chr6:145820185	G/A	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10206020	0.921	rs2280127	chr2:1546531	C/T	cg01028140	chr2:1542097	TPO	-0.33	-4.72	-0.39	6.17e-6	IgG glycosylation;
TGCT	cis	rs2075371	0.863	rs12707139	chr7:133954153	A/G	cg11752832	chr7:134001865	SLC35B4	0.66	5.52	0.44	1.93e-7	Mean platelet volume;
TGCT	cis	rs2300747	0.872	rs1034919	chr1:117075505	G/C	cg26677431	chr1:117075710	CD58	-0.23	-4.56	-0.38	1.23e-5	Primary biliary cholangitis;Multiple sclerosis;
TGCT	cis	rs7208859	0.623	rs73271872	chr17:29152228	C/G	cg14008862	chr17:28927542	LRRC37B2	0.75	5.06	0.41	1.5e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs1215050	0.765	rs1588018	chr4:98756324	G/C	cg17366294	chr4:99064904	C4orf37	0.52	5.57	0.45	1.54e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.92	7.33	0.55	2.53e-11	Platelet count;
TGCT	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg18876405	chr7:65276391	NA	0.31	4.79	0.4	4.58e-6	Aortic root size;
TGCT	cis	rs10934753	0.632	rs13070856	chr3:125909415	A/G	cg01346077	chr3:125931526	NA	-0.4	-6.48	-0.5	1.95e-9	Plasma homocysteine levels (post-methionine load test);
TGCT	cis	rs7647973	0.587	rs10452032	chr3:49680973	G/A	cg03060546	chr3:49711283	APEH	0.63	5.63	0.45	1.12e-7	Menarche (age at onset);
TGCT	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg21016266	chr12:122356598	WDR66	0.52	7.48	0.56	1.17e-11	Mean corpuscular volume;
TGCT	cis	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg12570787	chr5:219185	SDHA;CCDC127	0.65	4.46	0.37	1.83e-5	Breast cancer;
TGCT	cis	rs6121246	0.529	rs6060171	chr20:30183269	C/T	cg18721089	chr20:30220636	NA	-0.63	-6.86	-0.52	2.95e-10	Mean corpuscular hemoglobin;
TGCT	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	4.98	0.41	2.09e-6	Prudent dietary pattern;
TGCT	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg18402987	chr7:1209562	NA	0.39	4.99	0.41	1.97e-6	Longevity;Endometriosis;
TGCT	cis	rs933688	0.938	rs12110065	chr5:90718474	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.98	8.36	0.6	1.11e-13	Smoking behavior;
TGCT	cis	rs11190604	1.000	rs10883504	chr10:102280687	G/A	cg23241863	chr10:102295624	HIF1AN	0.67	5.11	0.42	1.21e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2836974	0.604	rs2854727	chr21:40713787	A/G	cg11890956	chr21:40555474	PSMG1	0.75	7.44	0.56	1.47e-11	Cognitive function;
TGCT	trans	rs877282	0.891	rs10904557	chr10:797490	C/T	cg22713356	chr15:30763199	NA	-1.19	-11.51	-0.72	2.73e-21	Uric acid levels;
TGCT	cis	rs7524258	1.000	rs7524258	chr1:7292229	T/C	cg07173049	chr1:7289937	CAMTA1	0.28	4.74	0.39	5.64e-6	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg22166914	chr1:53195759	ZYG11B	-0.38	-6.45	-0.5	2.23e-9	Monocyte count;
TGCT	cis	rs7617773	0.817	rs9819094	chr3:48319558	C/T	cg11946769	chr3:48343235	NME6	0.68	5.94	0.47	2.62e-8	Coronary artery disease;
TGCT	cis	rs4886920	0.519	rs75789686	chr15:78113577	A/G	cg25212270	chr15:78015279	NA	0.36	5.39	0.44	3.38e-7	Neuroticism;
TGCT	cis	rs2806561	0.796	rs1738467	chr1:23506521	C/T	cg12483005	chr1:23474871	LUZP1	0.37	4.76	0.39	5.23e-6	Height;
TGCT	cis	rs10851411	0.862	rs11022	chr15:42824578	T/C	cg23803468	chr15:43513504	EPB42	0.29	5.38	0.43	3.6e-7	Glucose homeostasis traits;
TGCT	trans	rs2727020	0.595	rs10839281	chr11:49483373	A/C	cg03929089	chr4:120376271	NA	-0.78	-9.57	-0.65	1.37e-16	Coronary artery disease;
TGCT	cis	rs3091242	0.933	rs11249250	chr1:25767609	G/A	cg09222892	chr1:25734099	RHCE	-0.43	-7.21	-0.54	4.72e-11	Erythrocyte sedimentation rate;
TGCT	cis	rs7666738	0.753	rs10029372	chr4:98859002	T/C	cg05340658	chr4:99064831	C4orf37	0.52	6.0	0.47	1.98e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12497850	0.764	rs6784111	chr3:49178846	T/C	cg16497277	chr3:49208875	KLHDC8B	-0.5	-4.55	-0.38	1.25e-5	Parkinson's disease;
TGCT	cis	rs62064224	0.589	rs756785	chr17:30812845	T/C	cg18200150	chr17:30822561	MYO1D	0.42	4.96	0.41	2.25e-6	Schizophrenia;
TGCT	cis	rs769267	0.792	rs4808961	chr19:19577215	C/G	cg03709012	chr19:19516395	GATAD2A	0.77	6.44	0.5	2.38e-9	Tonsillectomy;
TGCT	cis	rs2708977	0.899	rs12992413	chr2:97277489	A/G	cg01950434	chr2:97203154	ARID5A	0.63	5.73	0.46	7.35e-8	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs5769707	0.632	rs6009782	chr22:50010812	C/G	cg05373962	chr22:49881684	NA	-0.29	-4.97	-0.41	2.16e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs2742234	1.000	rs2742234	chr10:43612609	A/G	cg02780029	chr10:43622663	RET	0.23	4.69	0.39	7.03e-6	Hirschsprung disease;
TGCT	cis	rs10984561	0.881	rs1331595	chr9:122254605	T/C	cg14242995	chr9:122249943	NA	0.72	5.82	0.46	4.75e-8	Pulmonary function decline;
TGCT	cis	rs8020441	0.541	rs8012745	chr14:51160753	G/A	cg04730355	chr14:51134070	SAV1	1.17	9.45	0.65	2.78e-16	Cognitive performance;
TGCT	cis	rs473651	0.935	rs520765	chr2:239354712	C/T	cg18131467	chr2:239335373	ASB1	1.03	15.56	0.81	6.07e-31	Multiple system atrophy;
TGCT	cis	rs12188164	0.965	rs11743639	chr5:450710	C/T	cg26850624	chr5:429559	AHRR	-0.2	-4.84	-0.4	3.78e-6	Cystic fibrosis severity;
TGCT	cis	rs3796352	0.571	rs11713926	chr3:53155072	C/T	cg27565382	chr3:53032988	SFMBT1	0.44	5.06	0.41	1.48e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg03732007	chr1:2071316	PRKCZ	-0.27	-6.21	-0.49	7.18e-9	Height;
TGCT	cis	rs2404602	0.692	rs35138393	chr15:76977617	G/A	cg22467129	chr15:76604101	ETFA	-0.45	-5.11	-0.42	1.2e-6	Blood metabolite levels;
TGCT	cis	rs4144743	1.000	rs4541130	chr17:45321037	G/A	cg18085866	chr17:45331354	ITGB3	-0.72	-4.85	-0.4	3.61e-6	Body mass index;
TGCT	cis	rs1903068	0.719	rs73236106	chr4:55996712	C/T	cg16572876	chr4:56024045	NA	0.42	4.74	0.39	5.64e-6	Endometriosis;
TGCT	cis	rs12762955	0.561	rs4880744	chr10:1012026	A/G	cg26597838	chr10:835615	NA	-0.46	-6.19	-0.49	7.94e-9	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.7	-0.39	6.79e-6	Prudent dietary pattern;
TGCT	cis	rs561341	0.528	rs11650908	chr17:30195425	T/C	cg13647721	chr17:30228624	UTP6	-0.6	-4.66	-0.39	8.03e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg15782153	chr7:917662	C7orf20	-0.44	-5.35	-0.43	4.07e-7	Perceived unattractiveness to mosquitoes;
TGCT	cis	rs1801251	0.928	rs737028	chr2:233640750	T/C	cg08000102	chr2:233561755	GIGYF2	0.64	6.52	0.51	1.58e-9	Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs6854902	chr4:99033416	T/G	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1205863	1.000	rs1205874	chr6:11945478	C/G	cg07106625	chr6:11870215	NA	0.49	5.04	0.41	1.57e-6	Disc degeneration (lumbar);
TGCT	cis	rs9393777	0.513	rs13210025	chr6:26654817	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.63	-5.75	-0.46	6.58e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs6840360	0.593	rs1877186	chr4:152692418	C/G	cg22705602	chr4:152727874	NA	-0.34	-5.9	-0.47	3.24e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs4073582	1.000	rs524859	chr11:66041079	G/A	cg16950941	chr11:66035639	RAB1B	0.55	4.89	0.4	3.1e-6	Gout;
TGCT	cis	rs4975616	0.710	rs27996	chr5:1345474	A/G	cg26373071	chr5:1325741	CLPTM1L	0.16	4.66	0.39	8.14e-6	Lung cancer;
TGCT	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg03303774	chr4:1407052	NA	0.3	4.74	0.39	5.79e-6	Obesity-related traits;
TGCT	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.93	7.44	0.56	1.44e-11	Platelet count;
TGCT	cis	rs7255045	0.700	rs11085818	chr19:12952271	G/A	cg23899408	chr19:12877188	HOOK2	-0.61	-4.94	-0.41	2.48e-6	Mean corpuscular volume;
TGCT	cis	rs3862260	0.509	rs10754416	chr1:120163531	A/G	cg16322792	chr1:120165303	ZNF697	0.35	8.49	0.61	5.44e-14	Systemic lupus erythematosus;
TGCT	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg23172400	chr8:95962367	TP53INP1	-0.4	-6.56	-0.51	1.33e-9	Type 2 diabetes;
TGCT	cis	rs682748	0.846	rs13175997	chr5:17160258	A/G	cg23987134	chr5:17158319	LOC285696	-0.22	-5.36	-0.43	3.85e-7	Hippocampal atrophy;
TGCT	cis	rs732765	0.734	rs6574189	chr14:75166493	C/T	cg06637938	chr14:75390232	RPS6KL1	0.6	5.14	0.42	1.06e-6	Non-small cell lung cancer;
TGCT	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg23708337	chr7:1209742	NA	0.6	5.57	0.45	1.53e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1018836	0.599	rs9643295	chr8:91492283	T/G	cg16814680	chr8:91681699	NA	-0.68	-6.83	-0.52	3.31e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10949834	0.504	rs150862	chr7:73524207	C/T	cg07137043	chr7:73588983	EIF4H	0.7	5.44	0.44	2.71e-7	Verbal memory performance (residualized delayed recall change);
TGCT	cis	rs10986311	0.802	rs1323761	chr9:127116942	C/T	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.19	4.75	0.39	5.63e-6	Vitiligo;
TGCT	cis	rs76419734	0.510	rs2216515	chr4:106750214	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	-0.7	-4.52	-0.38	1.43e-5	Post bronchodilator FEV1;
TGCT	cis	rs2982552	0.805	rs3020345	chr6:152056368	T/G	cg22157087	chr6:152012887	ESR1	0.21	5.25	0.43	6.29e-7	Bone properties (heel);
TGCT	cis	rs736408	0.608	rs2239547	chr3:52855229	T/C	cg11645453	chr3:52864694	ITIH4	0.31	5.34	0.43	4.24e-7	Bipolar disorder;
TGCT	cis	rs911186	0.730	rs2393911	chr6:27057079	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.57	-5.64	-0.45	1.08e-7	Autism spectrum disorder or schizophrenia;
TGCT	trans	rs4332037	0.539	rs55790766	chr7:2021248	C/T	cg10840412	chr1:235813424	GNG4	0.93	6.69	0.51	6.97e-10	Bipolar disorder;
TGCT	cis	rs9303401	0.614	rs34058624	chr17:57118121	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.56	5.59	0.45	1.4e-7	Cognitive test performance;
TGCT	cis	rs909674	0.690	rs5750823	chr22:39829973	C/T	cg24399712	chr22:39784796	NA	-1.06	-10.99	-0.7	4.84e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs317689	0.918	rs610192	chr12:69739941	T/C	cg20891283	chr12:69753455	YEATS4	0.58	4.72	0.39	6.28e-6	Response to diuretic therapy;
TGCT	cis	rs228437	0.565	rs6569957	chr6:134939559	C/G	cg09872934	chr6:134495829	SGK1	-0.53	-4.54	-0.38	1.32e-5	Melanoma;
TGCT	cis	rs7412746	0.658	rs11589458	chr1:150792616	A/G	cg09365446	chr1:150670422	GOLPH3L	0.37	5.5	0.44	2.12e-7	Melanoma;
TGCT	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.06	-9.6	-0.65	1.15e-16	Platelet count;
TGCT	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	5.22	0.42	7.2e-7	Height;
TGCT	trans	rs225245	0.531	rs321609	chr17:33880676	G/T	cg19694781	chr19:47549865	TMEM160	-0.39	-7.18	-0.54	5.68e-11	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs12477438	0.520	rs2516829	chr2:99773201	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	8.1	0.59	4.42e-13	Chronic sinus infection;
TGCT	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.08	0.48	1.37e-8	Bipolar disorder;
TGCT	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg21963583	chr11:68658836	MRPL21	0.37	6.24	0.49	6.47e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7528684	0.752	rs2873413	chr1:157737504	G/A	cg17134153	chr1:157670328	FCRL3	-0.27	-4.86	-0.4	3.48e-6	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;
TGCT	cis	rs9972944	0.756	rs6504353	chr17:63768013	T/C	cg07283582	chr17:63770753	CCDC46	-0.26	-5.27	-0.43	5.91e-7	Total body bone mineral density;
TGCT	cis	rs7267979	1.000	rs453329	chr20:25440593	G/A	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs595982	0.546	rs12461075	chr19:49399821	G/A	cg11637076	chr19:49575188	KCNA7	-0.44	-5.23	-0.43	6.99e-7	Red cell distribution width;
TGCT	cis	rs9467773	0.620	rs2101581	chr6:26622769	G/T	cg02458000	chr6:26745757	NA	0.53	5.07	0.41	1.41e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4517514	0.509	rs4385851	chr11:89870750	C/T	cg05041596	chr11:89867385	NAALAD2	0.52	4.61	0.38	9.86e-6	Trans fatty acid levels;
TGCT	cis	rs2404618	0.624	rs7012381	chr8:1475357	C/T	cg13402656	chr8:1511478	DLGAP2	-0.34	-5.64	-0.45	1.09e-7	Lung cancer;
TGCT	trans	rs7698623	0.850	rs4693194	chr4:88798005	T/C	cg01186725	chr1:53905612	FLJ40434	-0.48	-6.63	-0.51	9.21e-10	Cardiovascular disease risk factors;
TGCT	cis	rs12681287	0.640	rs12544463	chr8:87481114	A/G	cg27223183	chr8:87520930	FAM82B	-0.89	-6.41	-0.5	2.8e-9	Caudate activity during reward;
TGCT	cis	rs933688	1.000	rs10058025	chr5:90689052	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.02	8.42	0.6	7.91e-14	Smoking behavior;
TGCT	cis	rs881375	0.934	rs2159778	chr9:123678129	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	5.02	0.41	1.74e-6	Rheumatoid arthritis;
TGCT	cis	rs1371867	0.846	rs1788196	chr8:101290088	C/T	cg06636551	chr8:101224915	SPAG1	-0.42	-5.65	-0.45	1.06e-7	Atrioventricular conduction;
TGCT	cis	rs3812831	0.661	rs2987458	chr13:114919835	A/G	cg15513719	chr13:114904418	NA	0.38	4.7	0.39	6.86e-6	Schizophrenia;
TGCT	cis	rs919433	0.519	rs700658	chr2:198655007	A/T	cg00792783	chr2:198669748	PLCL1	0.56	5.08	0.42	1.35e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg01802117	chr1:53393560	SCP2	-0.39	-4.55	-0.38	1.27e-5	Monocyte count;
TGCT	cis	rs377070	0.966	rs309419	chr4:123624001	C/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.46	5.03	0.41	1.67e-6	Mosquito bite size;
TGCT	cis	rs13242816	1.000	rs67982517	chr7:116075363	A/G	cg02799643	chr7:116139180	CAV2	-0.43	-5.08	-0.42	1.33e-6	P wave duration;
TGCT	cis	rs2594989	0.779	rs7647622	chr3:11590871	G/A	cg00170343	chr3:11313890	ATG7	-0.7	-5.24	-0.43	6.66e-7	Circulating chemerin levels;
TGCT	cis	rs6952808	0.636	rs6461005	chr7:1947687	A/G	cg04267008	chr7:1944627	MAD1L1	-0.36	-4.72	-0.39	6.34e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg20637647	chr7:64974828	NA	0.89	4.99	0.41	2.01e-6	Diabetic kidney disease;
TGCT	cis	rs7914558	0.966	rs10748837	chr10:104880236	T/C	cg15744005	chr10:104629667	AS3MT	-0.42	-5.21	-0.42	7.57e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs17376456	0.877	rs10076052	chr5:93317762	C/T	cg21475434	chr5:93447410	FAM172A	0.65	4.85	0.4	3.58e-6	Diabetic retinopathy;
TGCT	cis	rs9611519	0.964	rs5995992	chr22:41487218	T/C	cg03806693	chr22:41940476	POLR3H	-0.67	-6.21	-0.49	7.16e-9	Neuroticism;
TGCT	cis	rs2594989	0.943	rs9877694	chr3:11418873	A/C	cg00170343	chr3:11313890	ATG7	0.64	4.89	0.4	3.04e-6	Circulating chemerin levels;
TGCT	cis	rs10509586	0.826	rs60623262	chr10:91899317	G/A	cg25278353	chr10:91717815	NA	0.49	4.67	0.39	7.77e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
TGCT	cis	rs7523273	0.606	rs2724382	chr1:207928635	G/C	cg22525895	chr1:207977042	MIR29B2	0.51	8.25	0.6	1.98e-13	Schizophrenia;
TGCT	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.51	-4.97	-0.41	2.18e-6	Prudent dietary pattern;
TGCT	cis	rs858239	0.899	rs2268747	chr7:23313462	A/G	cg05602783	chr7:23145260	KLHL7	-0.66	-5.25	-0.43	6.38e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs2204008	0.775	rs3900361	chr12:38238936	A/G	cg26384229	chr12:38710491	ALG10B	-0.83	-7.18	-0.54	5.51e-11	Bladder cancer;
TGCT	cis	rs2292864	0.764	rs1969269	chr17:45335537	C/A	cg17233517	chr17:45285328	MYL4	0.37	4.59	0.38	1.09e-5	Left atrial antero-posterior diameter;
TGCT	cis	rs13064411	0.696	rs869342	chr3:113226330	C/T	cg18753928	chr3:113234510	CCDC52	-0.71	-5.78	-0.46	5.63e-8	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs8031584	0.706	rs798084	chr15:31126935	C/T	cg14829155	chr15:31115871	NA	-0.38	-5.03	-0.41	1.69e-6	Huntington's disease progression;
TGCT	cis	rs372883	0.648	rs382732	chr21:30719010	A/G	cg24692254	chr21:30365293	RNF160	0.53	4.86	0.4	3.53e-6	Pancreatic cancer;
TGCT	cis	rs8078723	1.000	rs4795412	chr17:38150604	C/T	cg17467752	chr17:38218738	THRA	0.55	5.34	0.43	4.37e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs9527	0.637	rs7096169	chr10:104618695	A/G	cg04362960	chr10:104952993	NT5C2	0.56	4.89	0.4	3.06e-6	Arsenic metabolism;
TGCT	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	5.08	0.41	1.37e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg06618935	chr21:46677482	NA	-0.36	-5.39	-0.44	3.4e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	trans	rs7819412	0.511	rs2409797	chr8:11433780	T/C	cg15556689	chr8:8085844	FLJ10661	-0.77	-7.09	-0.54	9.07e-11	Triglycerides;
TGCT	cis	rs9325144	0.723	rs11169519	chr12:39177441	G/A	cg26384229	chr12:38710491	ALG10B	-0.62	-5.85	-0.46	4.15e-8	Morning vs. evening chronotype;
TGCT	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.69	5.32	0.43	4.67e-7	Lung function (FEV1/FVC);
TGCT	cis	rs1986116	0.773	rs12588022	chr14:77518576	G/C	cg04913803	chr14:77510549	NA	0.39	4.51	0.38	1.46e-5	Sleep quality;
TGCT	cis	rs6032067	0.602	rs2741523	chr20:43920446	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.45	-7.0	-0.53	1.41e-10	Blood protein levels;
TGCT	cis	rs7590720	0.731	rs1864253	chr2:216878008	C/G	cg12620499	chr2:216877984	MREG	0.96	13.29	0.77	1.31e-25	Alcohol dependence;
TGCT	cis	rs35306767	0.761	rs12770910	chr10:1050318	A/G	cg26597838	chr10:835615	NA	0.6	6.63	0.51	9.45e-10	Eosinophil percentage of granulocytes;
TGCT	cis	rs9486719	1.000	rs926276	chr6:96868735	C/T	cg18709589	chr6:96969512	KIAA0776	0.67	5.23	0.43	7e-7	Migraine;Coronary artery disease;
TGCT	cis	rs2302045	1.000	rs2302048	chr2:242062117	G/A	cg04553960	chr2:241721320	KIF1A	-0.69	-4.74	-0.39	5.8e-6	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio);
TGCT	cis	rs11585357	0.947	rs11585119	chr1:17605792	C/A	cg08277548	chr1:17600880	PADI3	-0.97	-9.95	-0.67	1.7e-17	Hair shape;
TGCT	cis	rs13191362	0.935	rs67337490	chr6:162953961	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.67	5.16	0.42	9.64e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs231513	0.954	rs231524	chr17:41953212	G/A	cg26893861	chr17:41843967	DUSP3	-0.87	-6.27	-0.49	5.58e-9	Cognitive function;
TGCT	cis	rs3733585	0.673	rs7378340	chr4:9955198	C/T	cg00071950	chr4:10020882	SLC2A9	-0.58	-6.85	-0.52	3.02e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.29	-4.56	-0.38	1.19e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs6725041	0.792	rs1546719	chr2:213088582	G/C	cg16329650	chr2:213403929	ERBB4	-0.53	-4.52	-0.38	1.44e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs8077889	0.645	rs1230393	chr17:41842592	A/G	cg26893861	chr17:41843967	DUSP3	-1.15	-21.87	-0.89	2.21e-44	Triglycerides;
TGCT	cis	rs9303542	0.527	rs8074125	chr17:46610060	G/T	cg25032089	chr17:46643351	HOXB3	0.58	5.47	0.44	2.38e-7	Ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs853679	0.546	rs200490	chr6:27796935	G/T	cg08798685	chr6:27730294	NA	-0.36	-5.0	-0.41	1.91e-6	Depression;
TGCT	cis	rs12477438	0.520	rs4850897	chr2:99768419	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.75	7.25	0.55	3.92e-11	Chronic sinus infection;
TGCT	cis	rs9942416	0.660	rs67054144	chr5:74991443	G/A	cg19683494	chr5:74908142	NA	0.59	6.26	0.49	5.62e-9	Age-related disease endophenotypes;
TGCT	cis	rs9486719	0.947	rs9386648	chr6:97035656	T/C	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.32	-0.6	1.32e-13	Migraine;Coronary artery disease;
TGCT	cis	rs9911578	0.730	rs55759249	chr17:57027135	A/G	cg05425664	chr17:57184151	TRIM37	0.57	4.62	0.38	9.42e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7267979	1.000	rs2259928	chr20:25281834	G/C	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9911578	0.967	rs8072712	chr17:57162464	A/T	cg05425664	chr17:57184151	TRIM37	-0.68	-6.9	-0.53	2.4e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs6570726	1.000	rs444564	chr6:145859795	G/C	cg23711669	chr6:146136114	FBXO30	0.71	6.66	0.51	7.78e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4563143	0.675	rs56407818	chr19:29279379	G/A	cg14983838	chr19:29218262	NA	0.86	7.07	0.54	9.71e-11	Methadone dose in opioid dependence;
TGCT	cis	rs10486607	0.789	rs12700934	chr7:29179168	A/C	cg11251470	chr7:30008931	SCRN1	0.3	4.44	0.37	1.95e-5	Diabetes related insulin traits;
TGCT	cis	rs7923609	0.967	rs7085018	chr10:65286667	T/C	cg08743896	chr10:65200160	JMJD1C	-0.33	-4.48	-0.37	1.69e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7819412	0.527	rs7821914	chr8:10805015	A/G	cg21775007	chr8:11205619	TDH	-0.58	-5.5	-0.44	2.11e-7	Triglycerides;
TGCT	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg06481639	chr22:41940642	POLR3H	-0.74	-6.74	-0.52	5.38e-10	Vitiligo;
TGCT	cis	rs7772486	0.774	rs2748503	chr6:146295042	T/C	cg23711669	chr6:146136114	FBXO30	0.71	6.6	0.51	1.06e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6912958	0.558	rs9444530	chr6:88343318	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.5	4.51	0.38	1.48e-5	Monocyte percentage of white cells;
TGCT	cis	rs7845219	0.525	rs3019175	chr8:95949013	G/A	cg16049864	chr8:95962084	TP53INP1	-0.49	-5.34	-0.43	4.27e-7	Type 2 diabetes;
TGCT	cis	rs904251	0.797	rs1757181	chr6:37485728	A/G	cg08126542	chr6:37504118	NA	0.4	5.4	0.44	3.25e-7	Cognitive performance;
TGCT	trans	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg27523141	chr10:43048294	ZNF37B	-0.74	-7.98	-0.58	8.18e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs854765	0.624	rs12938501	chr17:17737258	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.69	-6.52	-0.5	1.64e-9	Total body bone mineral density;
TGCT	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg11366901	chr6:160182831	ACAT2	1.01	6.74	0.52	5.42e-10	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs6840360	0.571	rs2407069	chr4:152533201	G/A	cg17479576	chr4:152424074	FAM160A1	-0.73	-7.94	-0.58	1.03e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs9916302	0.851	rs4390625	chr17:37620347	A/G	cg15445000	chr17:37608096	MED1	0.31	4.59	0.38	1.06e-5	Glomerular filtration rate (creatinine);
TGCT	trans	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg23505145	chr19:12996616	KLF1	0.78	8.12	0.59	4.03e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	4.92	0.4	2.68e-6	Menopause (age at onset);
TGCT	cis	rs9611565	0.918	rs2281333	chr22:41749630	T/C	cg17554472	chr22:41940697	POLR3H	-0.46	-4.98	-0.41	2.07e-6	Vitiligo;
TGCT	cis	rs7119	0.717	rs62009070	chr15:77817884	G/C	cg27398640	chr15:77910606	LINGO1	-0.25	-4.6	-0.38	1.05e-5	Type 2 diabetes;
TGCT	cis	rs950169	0.840	rs2896002	chr15:84945121	A/G	cg11189052	chr15:85197271	WDR73	0.81	6.22	0.49	6.89e-9	Schizophrenia;
TGCT	cis	rs7666738	0.830	rs4699584	chr4:98952019	A/G	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11764590	0.950	rs55683212	chr7:2078855	G/C	cg25834613	chr7:1915315	MAD1L1	-0.52	-5.11	-0.42	1.2e-6	Neuroticism;
TGCT	cis	rs8072100	0.875	rs4794047	chr17:45763005	A/T	cg08085267	chr17:45401833	C17orf57	0.49	5.19	0.42	8.18e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs9814567	1.000	rs13081177	chr3:134289860	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.95	8.76	0.62	1.21e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs8103278	1.000	rs8109951	chr19:46289503	C/T	cg11657440	chr19:46296263	DMWD	-0.59	-5.72	-0.46	7.41e-8	Coronary artery disease;
TGCT	cis	rs6840360	0.550	rs4696269	chr4:152481704	T/A	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.0	-0.58	7.69e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs17331151	0.573	rs28552648	chr3:52865593	G/A	cg07884673	chr3:53033167	SFMBT1	0.49	5.66	0.45	1.01e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs921968	0.643	rs3932856	chr2:219320207	C/A	cg02176678	chr2:219576539	TTLL4	0.45	6.37	0.5	3.34e-9	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs782590	0.764	rs2586970	chr2:55829967	A/G	cg03859395	chr2:55845619	SMEK2	0.84	10.09	0.67	7.69e-18	Metabolic syndrome;
TGCT	cis	rs2067615	0.507	rs10746064	chr12:107086245	G/T	cg15890332	chr12:107067104	RFX4	0.29	5.77	0.46	5.9e-8	Heart rate;
TGCT	trans	rs3780486	0.813	rs3780488	chr9:33133812	T/C	cg04842962	chr6:43655489	MRPS18A	1.24	15.83	0.82	1.46e-31	IgG glycosylation;
TGCT	cis	rs6598955	0.671	rs12088858	chr1:26643708	C/A	cg04990556	chr1:26633338	UBXN11	0.62	4.6	0.38	1.04e-5	Obesity-related traits;
TGCT	cis	rs651907	0.557	rs34457525	chr3:101435225	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.89	10.45	0.68	1.02e-18	Colorectal cancer;
TGCT	cis	rs7666738	1.000	rs7666738	chr4:98968077	C/T	cg18180107	chr4:99064573	C4orf37	0.56	4.54	0.38	1.34e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10254284	1.000	rs4722756	chr7:28154822	A/G	cg23620719	chr7:28220237	JAZF1	-0.52	-4.58	-0.38	1.1e-5	Lymphocyte percentage of white cells;Systemic lupus erythematosus;
TGCT	cis	rs9308731	0.623	rs11674517	chr2:111903832	C/T	cg04202892	chr2:111875749	ACOXL	0.55	6.36	0.5	3.45e-9	Chronic lymphocytic leukemia;
TGCT	cis	rs7191700	0.601	rs243329	chr16:11352313	A/T	cg00044050	chr16:11439710	C16orf75	0.85	8.8	0.62	9.64e-15	Multiple sclerosis;
TGCT	cis	rs344364	0.511	rs1742460	chr16:1945441	G/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.45	-5.08	-0.42	1.35e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg02503808	chr4:7069936	GRPEL1	0.98	9.23	0.64	9.22e-16	Monocyte percentage of white cells;
TGCT	cis	rs7647973	1.000	rs11928090	chr3:49604904	G/A	cg05785598	chr3:49045655	WDR6	0.37	4.59	0.38	1.05e-5	Menarche (age at onset);
TGCT	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg11062466	chr8:58055876	NA	0.43	4.95	0.41	2.41e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9660992	0.573	rs12125276	chr1:205199440	C/T	cg00857998	chr1:205179979	DSTYK	0.51	4.68	0.39	7.34e-6	Mean corpuscular volume;Mean platelet volume;
TGCT	cis	rs7824557	0.547	rs2736287	chr8:11228006	G/A	cg21775007	chr8:11205619	TDH	-0.75	-7.89	-0.58	1.32e-12	Retinal vascular caliber;
TGCT	cis	rs2153535	0.580	rs6597334	chr6:8504779	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs9921222	0.500	rs12917907	chr16:405866	C/T	cg15001381	chr16:403314	AXIN1	0.31	4.79	0.4	4.66e-6	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs7474896	0.537	rs2472149	chr10:38262196	A/C	cg13720705	chr10:37990370	NA	-0.34	-4.6	-0.38	1.04e-5	Obesity (extreme);
TGCT	cis	rs9468199	0.523	rs9468152	chr6:27492906	A/C	cg21504815	chr6:27791876	HIST1H4J	-0.71	-4.93	-0.4	2.57e-6	Parkinson's disease;
TGCT	cis	rs2224391	0.554	rs2224392	chr6:5261136	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-1.02	-6.38	-0.5	3.19e-9	Height;
TGCT	cis	rs13088645	0.532	rs12695612	chr3:134161824	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.66	6.03	0.48	1.71e-8	Coronary artery disease;
TGCT	cis	rs6754311	0.593	rs313528	chr2:136445869	G/A	cg07169764	chr2:136633963	MCM6	0.69	6.28	0.49	5.13e-9	Mosquito bite size;
TGCT	cis	rs7089973	0.604	rs3758603	chr10:116605368	T/C	cg03647239	chr10:116582469	FAM160B1	0.59	5.74	0.46	6.72e-8	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg14008862	chr17:28927542	LRRC37B2	0.69	4.57	0.38	1.16e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg12140144	chr1:2984275	FLJ42875;PRDM16	-0.32	-4.46	-0.37	1.81e-5	Height;
TGCT	cis	rs7662987	0.517	rs2602866	chr4:100034997	A/G	cg12011299	chr4:100065546	ADH4	0.39	4.81	0.4	4.36e-6	Smoking initiation;
TGCT	cis	rs4930561	1.000	rs4930561	chr11:67931761	C/T	cg04465784	chr11:67976953	SUV420H1	-0.34	-4.44	-0.37	2e-5	Breast cancer in childhood cancer survivors;IgG glycosylation;
TGCT	cis	rs3008870	0.755	rs1925409	chr1:67365089	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.76	-8.12	-0.59	3.89e-13	Lymphocyte percentage of white cells;
TGCT	cis	rs11779988	0.545	rs4124900	chr8:17785266	A/G	cg01800426	chr8:17659068	MTUS1	-0.7	-5.46	-0.44	2.5e-7	Breast cancer;
TGCT	cis	rs921968	0.541	rs10205073	chr2:219412784	C/A	cg02176678	chr2:219576539	TTLL4	-0.49	-6.94	-0.53	1.95e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs12134133	1.000	rs2490261	chr1:207477469	T/C	cg02152968	chr1:207494213	CD55	0.56	4.59	0.38	1.08e-5	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs854765	0.592	rs2955367	chr17:18024266	T/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.7	7.26	0.55	3.74e-11	Total body bone mineral density;
TGCT	cis	rs7714584	1.000	rs34156253	chr5:150226230	A/G	cg22134413	chr5:150180641	NA	0.89	6.96	0.53	1.73e-10	Crohn's disease;
TGCT	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg11366901	chr6:160182831	ACAT2	-0.73	-5.61	-0.45	1.25e-7	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs17423910	1.000	rs17423910	chr1:66689109	C/T	cg04880992	chr1:67434664	MIER1	0.33	4.69	0.39	7.13e-6	Acute lymphoblastic leukemia (childhood);
TGCT	cis	rs10089	0.953	rs758180	chr5:127354423	T/A	cg19767477	chr5:127420684	SLC12A2	-0.42	-4.44	-0.37	2e-5	Ileal carcinoids;
TGCT	cis	rs7089973	0.668	rs7898347	chr10:116644324	G/A	cg03647239	chr10:116582469	FAM160B1	0.58	5.42	0.44	2.94e-7	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs2228479	0.618	rs17233623	chr16:89811209	C/T	cg06558623	chr16:89946397	TCF25	0.45	4.54	0.38	1.31e-5	Skin colour saturation;
TGCT	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg04944784	chr2:26401820	FAM59B	-0.67	-5.98	-0.47	2.23e-8	Gut microbiome composition (summer);
TGCT	cis	rs11671005	0.693	rs11084542	chr19:58932099	T/A	cg13877915	chr19:58951672	ZNF132	0.65	5.08	0.41	1.37e-6	Mean platelet volume;
TGCT	cis	rs2235642	0.893	rs2076440	chr16:1587322	G/A	cg07341220	chr16:1583899	IFT140;TMEM204	-0.3	-4.72	-0.39	6.18e-6	Coronary artery disease;
TGCT	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg00484396	chr16:3507460	NAT15	-0.44	-6.78	-0.52	4.36e-10	Tuberculosis;
TGCT	cis	rs7698623	0.850	rs4693195	chr4:88798211	G/A	cg02735620	chr4:88950514	PKD2	-0.44	-4.77	-0.39	5.18e-6	Cardiovascular disease risk factors;
TGCT	cis	rs2274273	0.743	rs13379159	chr14:55540801	C/T	cg01923255	chr14:55878535	KIAA0831	0.57	4.89	0.4	3.03e-6	Protein biomarker;
TGCT	cis	rs7772486	0.902	rs2748500	chr6:146314852	C/A	cg23711669	chr6:146136114	FBXO30	0.77	7.93	0.58	1.08e-12	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6835098	0.924	rs13138282	chr4:174120906	C/T	cg08422745	chr4:174089978	GALNT7	0.89	10.03	0.67	1.05e-17	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs56235845	0.685	rs35630910	chr5:176757841	A/C	cg06060754	chr5:176797920	RGS14	0.44	6.75	0.52	5.06e-10	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs12477438	0.798	rs6732579	chr2:99560239	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-5.66	-0.45	1e-7	Chronic sinus infection;
TGCT	cis	rs513349	0.964	rs210141	chr6:33546825	T/C	cg24505687	chr6:33548425	BAK1	0.52	6.47	0.5	2.04e-9	Platelet count;
TGCT	cis	rs9303401	0.573	rs62081879	chr17:57181524	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.58	5.74	0.46	6.76e-8	Cognitive test performance;
TGCT	cis	rs7772486	0.754	rs9390356	chr6:146118983	A/T	cg05347473	chr6:146136440	FBXO30	-0.53	-4.99	-0.41	2.02e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6570726	0.791	rs385729	chr6:145855465	T/C	cg23711669	chr6:146136114	FBXO30	0.89	9.93	0.67	1.82e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2050392	0.517	rs602966	chr10:30755853	C/T	cg13289132	chr10:30722225	MAP3K8	-0.39	-4.6	-0.38	1.04e-5	Inflammatory bowel disease;
TGCT	cis	rs2688608	0.901	rs2633312	chr10:75631755	T/A	cg04320760	chr10:75533139	FUT11	-0.32	-4.93	-0.4	2.61e-6	Inflammatory bowel disease;
TGCT	cis	rs10876993	0.821	rs1678522	chr12:58049923	G/A	cg15848620	chr12:58087721	OS9	-0.72	-5.82	-0.46	4.71e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs1215050	0.904	rs9307215	chr4:98813965	A/G	cg17366294	chr4:99064904	C4orf37	0.5	4.99	0.41	1.95e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs3733585	0.604	rs73215003	chr4:10126317	C/G	cg00071950	chr4:10020882	SLC2A9	-0.49	-5.15	-0.42	1.01e-6	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs12477438	0.520	rs2632277	chr2:99778985	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.89	9.3	0.64	6.31e-16	Chronic sinus infection;
TGCT	cis	rs12477438	0.520	rs34766932	chr2:99737273	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	16.87	0.83	6.81e-34	Chronic sinus infection;
TGCT	cis	rs1865760	1.000	rs3799372	chr6:25922311	A/G	cg16482183	chr6:26056742	HIST1H1C	0.51	4.59	0.38	1.06e-5	Height;
TGCT	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg19901468	chr14:105411992	AHNAK2	-0.28	-6.09	-0.48	1.31e-8	Rheumatoid arthritis;
TGCT	cis	rs4824093	0.610	rs4824113	chr22:50284974	C/T	cg14114931	chr22:50943910	LMF2	0.37	4.56	0.38	1.22e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs3924048	0.574	rs12062307	chr1:12611852	C/T	cg00291366	chr1:12616550	NA	0.32	4.87	0.4	3.34e-6	Optic cup area;
TGCT	cis	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg09021430	chr5:549028	NA	-0.39	-5.37	-0.43	3.77e-7	Obesity-related traits;
TGCT	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg03188948	chr7:1209495	NA	0.59	4.82	0.4	4.06e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1008375	0.800	rs62296338	chr4:17613425	G/T	cg16339924	chr4:17578868	LAP3	0.7	5.5	0.44	2.12e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs16957091	0.647	rs28374998	chr15:43289177	C/G	cg17935677	chr15:44119062	WDR76	0.54	4.87	0.4	3.38e-6	MGMT methylation in smokers;
TGCT	cis	rs6840360	0.571	rs10026670	chr4:152539212	C/T	cg17479576	chr4:152424074	FAM160A1	-0.73	-7.94	-0.58	1.03e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs9902453	0.904	rs7218379	chr17:28402737	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.82	-7.84	-0.58	1.8e-12	Coffee consumption (cups per day);
TGCT	cis	rs3733585	0.699	rs12498150	chr4:9950537	C/T	cg00071950	chr4:10020882	SLC2A9	-0.55	-6.43	-0.5	2.49e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs13326165	0.709	rs6796333	chr3:52359678	T/C	cg07884673	chr3:53033167	SFMBT1	0.39	4.69	0.39	7e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs11209185	0.509	rs9436789	chr1:68441456	G/A	cg22082780	chr1:68452167	NA	0.31	4.68	0.39	7.28e-6	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs56235845	0.694	rs6875461	chr5:176754665	C/T	cg17509989	chr5:176798049	RGS14	-0.54	-7.4	-0.55	1.78e-11	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs7439150	0.909	rs2227426	chr4:155493171	A/G	cg22130008	chr4:155548532	NA	0.39	4.84	0.4	3.8e-6	Fibrinogen levels;
TGCT	cis	rs4240897	0.835	rs4845891	chr1:12042506	T/C	cg13216073	chr1:12042593	MFN2	0.19	5.6	0.45	1.34e-7	Tuberculosis;
TGCT	cis	rs9910055	0.529	rs400460	chr17:42182770	A/G	cg13607699	chr17:42295918	UBTF	-0.64	-5.52	-0.44	1.87e-7	Total body bone mineral density;
TGCT	cis	rs854765	0.624	rs11657423	chr17:17728574	T/C	cg09796270	chr17:17721594	SREBF1	-0.27	-5.21	-0.42	7.54e-7	Total body bone mineral density;
TGCT	cis	rs8026198	0.568	rs58712247	chr15:42616288	C/CA	cg23803468	chr15:43513504	EPB42	0.44	5.28	0.43	5.55e-7	Fibrinogen levels;
TGCT	cis	rs78487399	0.908	rs17031088	chr2:43807090	A/G	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.66	4.65	0.39	8.32e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs6545883	0.895	rs2421192	chr2:61643631	T/C	cg15711740	chr2:61764176	XPO1	0.53	4.75	0.39	5.51e-6	Tuberculosis;
TGCT	cis	rs2594989	0.780	rs2454477	chr3:11555842	G/A	cg26283222	chr3:11613257	VGLL4	-0.25	-5.35	-0.43	4.07e-7	Circulating chemerin levels;
TGCT	cis	rs2657888	0.593	rs2638318	chr12:56857422	C/T	cg23002907	chr12:56915593	RBMS2	0.46	6.15	0.48	9.61e-9	Adiponectin levels;
TGCT	cis	rs7904985	0.639	rs12778367	chr10:88116246	A/G	cg02632490	chr10:88024529	MIR346;GRID1	-0.28	-4.54	-0.38	1.31e-5	Barrett's esophagus;
TGCT	cis	rs9467773	1.000	rs1321480	chr6:26532742	A/G	cg26531700	chr6:26746687	NA	0.47	4.56	0.38	1.23e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs1448094	0.512	rs7308229	chr12:86239849	A/T	cg19622623	chr12:86230825	RASSF9	0.23	4.5	0.37	1.52e-5	Major depressive disorder;
TGCT	cis	rs12478296	1.000	rs67535150	chr2:243046099	A/G	cg06360820	chr2:242988706	NA	-0.61	-4.64	-0.38	8.65e-6	Obesity-related traits;
TGCT	cis	rs4699052	0.625	rs6822783	chr4:104284924	T/C	cg16532752	chr4:104119610	CENPE	-0.52	-4.96	-0.41	2.3e-6	Testicular germ cell tumor;
TGCT	cis	rs8180040	0.783	rs11710121	chr3:47351501	T/G	cg27129171	chr3:47204927	SETD2	-0.6	-6.53	-0.51	1.5e-9	Colorectal cancer;
TGCT	cis	rs2164273	0.565	rs2736387	chr8:11157371	A/C	cg27034466	chr8:11760342	NA	0.19	4.45	0.37	1.91e-5	Extraversion;
TGCT	cis	rs1950500	0.565	rs3181248	chr14:24808168	G/A	cg22990158	chr14:24802150	ADCY4	-0.56	-4.98	-0.41	2.07e-6	Height;
TGCT	cis	rs6121246	0.647	rs6088855	chr20:30225792	C/T	cg13852791	chr20:30311386	BCL2L1	0.75	4.76	0.39	5.24e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg20203395	chr5:56204925	C5orf35	0.6	5.25	0.43	6.37e-7	Initial pursuit acceleration;
TGCT	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.84	0.46	4.39e-8	Height;
TGCT	cis	rs1801251	0.929	rs12694917	chr2:233707611	C/T	cg08000102	chr2:233561755	GIGYF2	-0.63	-6.42	-0.5	2.58e-9	Coronary artery disease;
TGCT	cis	rs6430585	0.640	rs58301703	chr2:136532225	G/A	cg07169764	chr2:136633963	MCM6	1.21	11.47	0.72	3.36e-21	Corneal structure;
TGCT	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg04267008	chr7:1944627	MAD1L1	-0.38	-5.01	-0.41	1.84e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg18876405	chr7:65276391	NA	0.37	5.89	0.47	3.33e-8	Aortic root size;
TGCT	cis	rs2486012	1.000	rs1548634	chr1:44399608	T/C	cg12908607	chr1:44402522	ARTN	0.72	5.74	0.46	6.94e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs36051895	0.623	rs17426903	chr9:5203292	A/C	cg02405213	chr9:5042618	JAK2	-0.72	-8.5	-0.61	5.12e-14	Pediatric autoimmune diseases;
TGCT	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg07061783	chr6:25882402	NA	-0.6	-5.59	-0.45	1.35e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9969804	0.782	rs10761169	chr9:95515033	T/C	cg13940029	chr9:95239186	CENPP;ASPN	-0.17	-4.54	-0.38	1.32e-5	Height;
TGCT	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg03303774	chr4:1407052	NA	0.3	4.78	0.39	4.82e-6	Obesity-related traits;
TGCT	cis	rs6429082	0.818	rs291386	chr1:235647050	C/T	cg26050004	chr1:235667680	B3GALNT2	0.6	5.36	0.43	3.88e-7	Adiposity;
TGCT	cis	rs854765	0.693	rs9907246	chr17:17770965	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.76	-7.96	-0.58	9.35e-13	Total body bone mineral density;
TGCT	cis	rs7647973	0.626	rs12715437	chr3:49751856	T/C	cg03060546	chr3:49711283	APEH	0.63	5.63	0.45	1.12e-7	Menarche (age at onset);
TGCT	cis	rs1541995	1.000	rs16975700	chr15:96379923	A/G	cg00882281	chr15:96346592	NA	-0.28	-4.65	-0.39	8.22e-6	Photic sneeze reflex;
TGCT	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg05368731	chr17:41323189	NBR1	1.2	14.48	0.79	1.98e-28	Menopause (age at onset);
TGCT	cis	rs6459788	0.685	rs13226469	chr7:157235777	G/A	cg03453431	chr7:157225567	NA	-0.47	-7.09	-0.54	8.76e-11	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs60843830	1.000	rs17713396	chr2:227201	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.76	7.73	0.57	3.18e-12	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs2228479	0.850	rs62054257	chr16:89900195	G/A	cg06558623	chr16:89946397	TCF25	0.55	4.86	0.4	3.55e-6	Skin colour saturation;
TGCT	cis	rs1538970	0.884	rs61788261	chr1:45899114	G/A	cg05343316	chr1:45956843	TESK2	0.76	6.18	0.49	8.53e-9	Platelet count;
TGCT	cis	rs2692947	0.673	rs3111873	chr2:96781986	G/C	cg05933789	chr2:97190408	NA	-0.16	-4.56	-0.38	1.19e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs7264396	0.570	rs6060717	chr20:34544647	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.04	-0.41	1.58e-6	Total cholesterol levels;
TGCT	cis	rs7635838	0.819	rs6776159	chr3:11519324	A/G	cg00170343	chr3:11313890	ATG7	0.69	6.67	0.51	7.44e-10	HDL cholesterol;
TGCT	cis	rs28595532	1.000	rs28600971	chr4:119712728	G/T	cg21605333	chr4:119757512	SEC24D	1.21	6.77	0.52	4.51e-10	Cannabis dependence symptom count;
TGCT	cis	rs7666738	0.830	rs1834647	chr4:98882915	G/A	cg18180107	chr4:99064573	C4orf37	0.54	4.94	0.41	2.42e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12188164	0.561	rs2251843	chr5:457955	C/T	cg00049323	chr5:472564	LOC25845	-0.25	-4.45	-0.37	1.87e-5	Cystic fibrosis severity;
TGCT	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg15691649	chr6:25882328	NA	0.43	5.34	0.43	4.27e-7	Blood metabolite levels;
TGCT	cis	rs9677476	0.516	rs765458	chr2:231990667	G/A	cg07929768	chr2:232055508	NA	0.34	5.26	0.43	6.11e-7	Food antigen IgG levels;
TGCT	cis	rs6909279	0.522	rs7741872	chr6:151893946	C/G	cg14416726	chr6:151773293	C6orf211;RMND1	0.56	4.67	0.39	7.84e-6	Bone mineral density;
TGCT	cis	rs7666738	0.830	rs13134216	chr4:98919765	C/T	cg18180107	chr4:99064573	C4orf37	0.57	5.23	0.43	6.88e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1005277	0.683	rs7923868	chr10:37989766	T/C	cg25427524	chr10:38739819	LOC399744	-0.33	-5.78	-0.46	5.82e-8	Extrinsic epigenetic age acceleration;
TGCT	cis	rs4972806	0.668	rs2072588	chr2:177042930	G/C	cg14324370	chr2:177042789	NA	0.74	6.83	0.52	3.32e-10	IgG glycosylation;
TGCT	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg11062466	chr8:58055876	NA	0.37	4.53	0.38	1.38e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs73198271	0.729	rs66564323	chr8:8604996	G/A	ch.8.214553F	chr8:8189620	PRAGMIN	-0.28	-4.79	-0.4	4.63e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs2836950	0.585	rs1029004	chr21:40615343	A/G	cg11890956	chr21:40555474	PSMG1	-0.68	-6.67	-0.51	7.4e-10	Menarche (age at onset);
TGCT	cis	rs7819412	0.522	rs3021495	chr8:10994743	C/G	cg21775007	chr8:11205619	TDH	-0.54	-4.87	-0.4	3.33e-6	Triglycerides;
TGCT	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.34	0.55	2.43e-11	Prudent dietary pattern;
TGCT	cis	rs17376456	1.000	rs56046246	chr5:93531545	T/G	cg21475434	chr5:93447410	FAM172A	0.61	4.51	0.38	1.47e-5	Diabetic retinopathy;
TGCT	cis	rs6061231	1.000	rs13043313	chr20:60958269	A/G	cg24112000	chr20:60950667	NA	-0.35	-5.07	-0.41	1.42e-6	Colorectal cancer;
TGCT	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg22166914	chr1:53195759	ZYG11B	0.36	5.96	0.47	2.45e-8	Monocyte count;
TGCT	cis	rs709400	0.597	rs1013650	chr14:103909203	G/A	cg26031613	chr14:104095156	KLC1	0.87	9.75	0.66	5.07e-17	Body mass index;
TGCT	cis	rs7666738	0.830	rs1111541	chr4:99033860	A/G	cg05340658	chr4:99064831	C4orf37	-0.5	-5.55	-0.45	1.64e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2777491	0.915	rs28526381	chr15:41621842	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.75	-10.44	-0.68	1.07e-18	Ulcerative colitis;
TGCT	cis	rs6460942	0.732	rs73677575	chr7:12286532	A/G	cg06484146	chr7:12443880	VWDE	-0.54	-4.82	-0.4	4.13e-6	Coronary artery disease;
TGCT	cis	rs225245	0.791	rs4796103	chr17:34025182	A/G	cg05299278	chr17:33885742	SLFN14	0.21	4.5	0.37	1.54e-5	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs7937682	1.000	rs7128353	chr11:111538875	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.02	-9.84	-0.66	3.17e-17	Primary sclerosing cholangitis;
TGCT	cis	rs9611519	0.602	rs8138520	chr22:41412928	A/G	cg13695892	chr22:41940480	POLR3H	-0.54	-5.1	-0.42	1.21e-6	Neuroticism;
TGCT	cis	rs9393777	0.920	rs66462181	chr6:27091661	T/C	cg16898833	chr6:26189333	HIST1H4D	1.29	5.83	0.46	4.6e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg03517284	chr6:25882590	NA	-0.64	-5.88	-0.47	3.49e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9486715	1.000	rs6905568	chr6:97066382	T/C	cg18709589	chr6:96969512	KIAA0776	-0.77	-7.12	-0.54	7.74e-11	Headache;
TGCT	cis	rs11696501	0.739	rs2281210	chr20:44243172	T/G	cg11783356	chr20:44313418	WFDC10B	-0.32	-4.63	-0.38	9.25e-6	Brain structure;
TGCT	cis	rs7582180	0.739	rs11123822	chr2:100911582	G/T	cg14675211	chr2:100938903	LONRF2	0.45	4.49	0.37	1.63e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.94	7.92	0.58	1.17e-12	Platelet count;
TGCT	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg11764359	chr7:65958608	NA	0.54	5.02	0.41	1.73e-6	Aortic root size;
TGCT	cis	rs10057188	1.000	rs1978629	chr5:77862156	C/T	cg06873401	chr5:77792105	LHFPL2	0.22	4.46	0.37	1.8e-5	Pulse pressure;
TGCT	cis	rs6424115	1.000	rs12116511	chr1:24162662	A/G	cg15997130	chr1:24165203	NA	-0.9	-10.28	-0.68	2.61e-18	Immature fraction of reticulocytes;
TGCT	cis	rs2235642	0.893	rs8051295	chr16:1588087	A/G	cg00463982	chr16:1583984	IFT140;TMEM204	-0.29	-4.84	-0.4	3.84e-6	Coronary artery disease;
TGCT	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg24531977	chr5:56204891	C5orf35	-0.74	-6.99	-0.53	1.51e-10	Initial pursuit acceleration;
TGCT	cis	rs6831352	0.879	rs56222233	chr4:100069627	T/G	cg12011299	chr4:100065546	ADH4	-0.46	-5.22	-0.42	7.38e-7	Alcohol dependence;
TGCT	cis	rs6598955	0.543	rs3795689	chr1:26560366	C/G	cg04990556	chr1:26633338	UBXN11	0.83	8.03	0.59	6.27e-13	Obesity-related traits;
TGCT	cis	rs250677	0.522	rs10045726	chr5:148352990	C/T	cg18129178	chr5:148520854	ABLIM3	0.38	4.88	0.4	3.23e-6	Breast cancer;
TGCT	cis	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg18252515	chr7:66147081	NA	-1.08	-6.32	-0.49	4.33e-9	Diabetic kidney disease;
TGCT	cis	rs2797160	0.904	rs1418637	chr6:125992553	A/G	cg05901451	chr6:126070800	HEY2	-0.78	-6.85	-0.52	3.01e-10	Endometrial cancer;
TGCT	cis	rs11711311	0.955	rs9866806	chr3:113379865	C/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.79	7.03	0.53	1.19e-10	IgG glycosylation;
TGCT	cis	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg00343986	chr7:65444356	GUSB	0.22	4.69	0.39	7.08e-6	Aortic root size;
TGCT	cis	rs7172809	0.573	rs60079927	chr15:77591614	T/C	cg22256960	chr15:77711686	NA	-0.47	-4.61	-0.38	9.99e-6	Glucose homeostasis traits;
TGCT	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg02038168	chr22:39784481	NA	-0.76	-5.64	-0.45	1.12e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs11098499	0.954	rs2389802	chr4:120325732	C/A	cg09307838	chr4:120376055	NA	0.68	6.53	0.51	1.54e-9	Corneal astigmatism;
TGCT	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg03609598	chr5:56110824	MAP3K1	-0.58	-4.66	-0.39	8.11e-6	Initial pursuit acceleration;
TGCT	cis	rs7553864	0.574	rs6576867	chr1:87615796	A/T	cg17420885	chr1:87600446	LOC339524	-0.39	-4.86	-0.4	3.47e-6	Smoking behavior;
TGCT	cis	rs2997447	0.655	rs55820521	chr1:26374286	C/T	cg19759804	chr1:25889155	LDLRAP1	0.33	4.48	0.37	1.65e-5	QRS complex (12-leadsum);
TGCT	cis	rs71335811	1	rs71335811	chr19:49130070	TC/T	cg07996880	chr19:49339085	HSD17B14	-0.29	-5.05	-0.41	1.56e-6	Myeloid white cell count;
TGCT	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg04772025	chr11:68637568	NA	0.62	6.97	0.53	1.69e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	5.43	0.44	2.89e-7	Alzheimer's disease;
TGCT	cis	rs727563	0.562	rs5758458	chr22:42154132	G/A	cg03806693	chr22:41940476	POLR3H	1.04	10.57	0.69	5.2e-19	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs904251	1.000	rs10947673	chr6:37445079	C/T	cg01843034	chr6:37503916	NA	-0.46	-5.44	-0.44	2.72e-7	Cognitive performance;
TGCT	cis	rs9486715	0.838	rs9400034	chr6:96954566	C/T	cg06623918	chr6:96969491	KIAA0776	1.1	15.44	0.81	1.16e-30	Headache;
TGCT	cis	rs3806843	0.576	rs246034	chr5:140332064	A/C	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs10789491	1.000	rs1371834	chr1:47176894	G/A	cg15501359	chr1:47185051	KIAA0494	0.81	8.34	0.6	1.19e-13	Response to hepatitis C treatment;
TGCT	cis	rs7914558	1.000	rs6584540	chr10:104927634	A/G	cg15744005	chr10:104629667	AS3MT	-0.39	-4.75	-0.39	5.53e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs986417	0.818	rs8005621	chr14:61106699	G/A	cg27398547	chr14:60952738	C14orf39	1.45	9.82	0.66	3.5e-17	Gut microbiota (bacterial taxa);
TGCT	cis	rs2075671	0.857	rs11772849	chr7:100308412	G/A	cg20848291	chr7:100343083	ZAN	-0.53	-4.59	-0.38	1.06e-5	Other erythrocyte phenotypes;
TGCT	cis	rs4642101	0.639	rs9870433	chr3:12853566	T/C	cg05775895	chr3:12838266	CAND2	0.6	5.97	0.47	2.33e-8	QRS complex (12-leadsum);
TGCT	cis	rs57920188	0.537	rs4347180	chr1:4074985	C/T	cg20703997	chr1:4087676	NA	0.47	5.84	0.46	4.38e-8	Interleukin-17 levels;
TGCT	cis	rs514406	0.893	rs6588446	chr1:53425260	G/A	cg08859206	chr1:53392774	SCP2	0.4	6.1	0.48	1.22e-8	Monocyte count;
TGCT	cis	rs6088580	0.634	rs6059856	chr20:33057954	G/C	cg08999081	chr20:33150536	PIGU	0.28	5.67	0.45	9.5e-8	Glomerular filtration rate (creatinine);
TGCT	cis	rs2070433	0.800	rs11702190	chr21:47877367	C/T	cg12379764	chr21:47803548	PCNT	0.56	4.79	0.4	4.6e-6	Lymphocyte counts;
TGCT	cis	rs9611565	0.546	rs5758431	chr22:42109917	A/G	cg06481639	chr22:41940642	POLR3H	0.71	6.48	0.5	1.95e-9	Vitiligo;
TGCT	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.67	-6.79	-0.52	4.13e-10	Prostate cancer;
TGCT	cis	rs968451	0.526	rs5757617	chr22:39722714	G/C	cg17798944	chr22:39715225	SNORD43;RPL3	0.84	9.76	0.66	4.82e-17	Primary biliary cholangitis;
TGCT	cis	rs9325144	0.532	rs1352121	chr12:39130696	A/G	cg10518543	chr12:38710700	ALG10B	-0.48	-4.44	-0.37	1.97e-5	Morning vs. evening chronotype;
TGCT	cis	rs62380364	0.602	rs606393	chr5:88058163	T/C	cg24804195	chr5:87968844	LOC645323	-0.55	-5.34	-0.43	4.23e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg02725872	chr8:58115012	NA	-0.39	-4.74	-0.39	5.77e-6	Developmental language disorder (linguistic errors);
TGCT	trans	rs10435719	0.718	rs7813935	chr8:11795636	A/G	cg15556689	chr8:8085844	FLJ10661	0.75	7.27	0.55	3.62e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs9611565	0.512	rs45500192	chr22:42177899	A/G	cg06634786	chr22:41940651	POLR3H	-0.84	-7.83	-0.57	1.91e-12	Vitiligo;
TGCT	cis	rs4073582	0.595	rs474005	chr11:66033301	C/T	cg16950941	chr11:66035639	RAB1B	0.58	5.44	0.44	2.67e-7	Gout;
TGCT	trans	rs2727020	0.553	rs7479975	chr11:49581964	C/G	cg15704280	chr7:45808275	SEPT13	-0.61	-6.72	-0.52	6.04e-10	Coronary artery disease;
TGCT	cis	rs6840360	0.571	rs7692700	chr4:152552797	C/T	cg17479576	chr4:152424074	FAM160A1	-0.71	-7.72	-0.57	3.41e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs9381040	0.655	rs2294695	chr6:41036770	A/G	cg03526776	chr6:41159608	TREML2	0.25	5.05	0.41	1.52e-6	Alzheimer's disease (late onset);
TGCT	cis	rs7542091	0.669	rs11119357	chr1:210042382	C/T	cg21951975	chr1:209979733	IRF6	0.61	6.21	0.49	7.35e-9	Monobrow;
TGCT	cis	rs78456975	1.000	rs11903168	chr2:1560497	C/G	cg01028140	chr2:1542097	TPO	-0.33	-4.53	-0.38	1.37e-5	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs1045714	0.895	rs61729413	chr7:2646796	G/A	cg17215154	chr7:2644645	IQCE	0.28	4.92	0.4	2.75e-6	Urate levels in lean individuals;
TGCT	cis	rs116161686	0.500	rs76610459	chr1:210050756	T/G	cg23283495	chr1:209979779	IRF6	0.61	4.81	0.4	4.3e-6	Coronary artery disease;
TGCT	cis	rs9796	0.621	rs7170049	chr15:41484287	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.53	-7.06	-0.54	1.05e-10	Menopause (age at onset);
TGCT	cis	rs2404602	0.716	rs7164813	chr15:76708066	T/C	cg26408565	chr15:76604113	ETFA	-0.42	-5.43	-0.44	2.8e-7	Blood metabolite levels;
TGCT	cis	rs7829975	0.902	rs777707	chr8:8584344	A/G	cg15556689	chr8:8085844	FLJ10661	0.64	5.74	0.46	6.95e-8	Mood instability;
TGCT	cis	rs6582630	0.539	rs8189604	chr12:38308546	G/T	cg26384229	chr12:38710491	ALG10B	-0.54	-4.72	-0.39	6.38e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs208520	0.874	rs208473	chr6:66917265	G/C	cg07460842	chr6:66804631	NA	-0.9	-9.16	-0.64	1.34e-15	Exhaled nitric oxide output;
TGCT	cis	rs9549260	0.564	rs4941990	chr13:41299857	A/C	cg21288729	chr13:41239152	FOXO1	0.94	9.08	0.63	2.07e-15	Red blood cell count;
TGCT	cis	rs950169	0.881	rs4842852	chr15:84941961	A/G	cg11189052	chr15:85197271	WDR73	0.81	6.22	0.49	6.89e-9	Schizophrenia;
TGCT	trans	rs2760061	0.784	rs1745414	chr1:228212159	T/A	cg16006296	chr10:38738647	LOC399744	-0.31	-7.08	-0.54	9.5e-11	Diastolic blood pressure;
TGCT	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg13393036	chr8:95962371	TP53INP1	-0.63	-8.66	-0.61	2.14e-14	Type 2 diabetes;
TGCT	cis	rs17384381	0.634	rs11801146	chr1:85915374	C/T	cg16011679	chr1:85725395	C1orf52	0.81	6.55	0.51	1.38e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg08859206	chr1:53392774	SCP2	0.4	5.96	0.47	2.46e-8	Monocyte count;
TGCT	cis	rs752010	0.631	rs7515066	chr1:42076915	A/G	cg06885757	chr1:42089581	HIVEP3	-0.3	-5.61	-0.45	1.28e-7	Lupus nephritis in systemic lupus erythematosus;
TGCT	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg24675658	chr1:53192096	ZYG11B	-0.72	-8.08	-0.59	4.93e-13	Monocyte count;
TGCT	cis	rs10057188	0.868	rs35252676	chr5:77916444	C/T	cg07379703	chr5:78279424	ARSB	-0.2	-4.53	-0.38	1.34e-5	Pulse pressure;
TGCT	cis	rs10504229	0.679	rs16921606	chr8:58034477	A/C	cg25986105	chr8:57232688	SDR16C5	0.5	4.48	0.37	1.7e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9486719	0.802	rs2983896	chr6:97029871	G/A	cg06623918	chr6:96969491	KIAA0776	-0.95	-8.68	-0.61	1.88e-14	Migraine;Coronary artery disease;
TGCT	cis	rs7104764	1.000	rs2272563	chr11:236871	T/C	cg18336825	chr11:236787	PSMD13;SIRT3	1.07	11.15	0.71	2.05e-20	Menarche (age at onset);
TGCT	cis	rs7772486	0.790	rs6924159	chr6:146267873	A/G	cg23711669	chr6:146136114	FBXO30	-0.89	-10.38	-0.68	1.54e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs67072384	1.000	rs7128364	chr11:72451941	A/C	cg03713592	chr11:72463424	ARAP1	-0.93	-4.66	-0.39	7.89e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	trans	rs9951602	0.512	rs4798994	chr18:76654327	T/G	cg02800362	chr5:177631904	HNRNPAB	1.13	12.84	0.76	1.57e-24	Obesity-related traits;
TGCT	cis	rs11971779	0.941	rs28395455	chr7:139035986	A/G	cg07862535	chr7:139043722	LUC7L2	0.65	4.64	0.38	8.61e-6	Diisocyanate-induced asthma;
TGCT	trans	rs6740731	0.518	rs16823846	chr2:145299944	C/T	cg19463199	chr3:197401858	MIR922;KIAA0226	0.37	6.77	0.52	4.58e-10	Coronary artery disease;
TGCT	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg20607798	chr8:58055168	NA	0.6	4.9	0.4	2.93e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.74	-0.39	5.77e-6	Prudent dietary pattern;
TGCT	cis	rs523522	0.962	rs651627	chr12:121009198	C/T	cg12219531	chr12:120966889	COQ5	0.82	7.38	0.55	2.05e-11	High light scatter reticulocyte count;
TGCT	cis	rs2230307	0.536	rs575971	chr1:100546591	T/C	cg24955406	chr1:100503596	HIAT1	0.72	4.63	0.38	9.24e-6	Carotid intima media thickness;
TGCT	cis	rs13256369	1.000	rs4840351	chr8:8573148	A/G	cg17143192	chr8:8559678	CLDN23	0.62	5.82	0.46	4.82e-8	Obesity-related traits;
TGCT	cis	rs651907	0.557	rs2288272	chr3:101378476	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.33	-6.58	-0.51	1.19e-9	Colorectal cancer;
TGCT	cis	rs2242116	0.896	rs724449	chr3:46935681	C/T	cg27129171	chr3:47204927	SETD2	0.61	6.22	0.49	7.1e-9	Birth weight;
TGCT	cis	rs739401	0.572	rs404629	chr11:3077025	A/G	cg25174290	chr11:3078921	CARS	0.53	5.06	0.41	1.48e-6	Longevity;
TGCT	cis	rs9611565	0.546	rs132793	chr22:42063681	A/G	cg06481639	chr22:41940642	POLR3H	0.73	6.45	0.5	2.21e-9	Vitiligo;
TGCT	cis	rs2249625	0.523	rs2496554	chr6:72855840	A/T	cg24401219	chr6:72892597	RIMS1	-0.54	-4.74	-0.39	5.75e-6	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
TGCT	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7336332	0.598	rs1885989	chr13:28010117	G/A	cg22138327	chr13:27999177	GTF3A	0.81	6.18	0.49	8.63e-9	Weight;
TGCT	cis	rs8064299	0.597	rs9944506	chr17:72782726	C/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.91	10.35	0.68	1.8e-18	Monocyte count;
TGCT	cis	rs2188554	0.785	rs172507	chr7:117163047	A/T	cg08576598	chr7:116962626	WNT2	0.39	5.23	0.43	7.02e-7	Esophageal adenocarcinoma;
TGCT	cis	rs1797081	1.000	rs780634	chr10:16864327	T/G	cg23933602	chr10:16859644	RSU1	1.07	13.89	0.78	5.05e-27	Platelet distribution width;
TGCT	cis	rs8020441	1.000	rs8020441	chr14:51170879	T/G	cg04730355	chr14:51134070	SAV1	0.71	5.79	0.46	5.51e-8	Cognitive performance;
TGCT	cis	rs2153535	0.580	rs6912193	chr6:8456306	T/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs13040088	1.000	rs910831	chr20:61558775	T/C	cg23096297	chr20:61557774	DIDO1	1.17	9.71	0.66	6.25e-17	Menopause (age at onset);
TGCT	cis	rs73198271	0.653	rs10087742	chr8:8660474	A/G	cg06671706	chr8:8559999	CLDN23	-0.36	-4.61	-0.38	9.98e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs2455799	0.573	rs62243672	chr3:15937200	C/T	cg16303742	chr3:15540471	COLQ	-0.25	-4.61	-0.38	9.69e-6	Mean platelet volume;
TGCT	cis	rs2180341	0.640	rs11154395	chr6:127629138	T/C	cg27446573	chr6:127587934	RNF146	0.66	5.85	0.46	4.12e-8	Breast cancer;
TGCT	cis	rs9611565	0.649	rs4822050	chr22:42177453	C/G	cg06634786	chr22:41940651	POLR3H	-0.77	-7.27	-0.55	3.5e-11	Vitiligo;
TGCT	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg22166914	chr1:53195759	ZYG11B	-0.5	-9.25	-0.64	8.19e-16	Monocyte count;
TGCT	cis	rs7178424	0.616	rs8025282	chr15:62137557	T/C	cg00456672	chr15:62358751	C2CD4A	-0.31	-4.67	-0.39	7.7e-6	Height;
TGCT	cis	rs9914988	0.887	rs11650282	chr17:27090741	C/G	cg20469991	chr17:27169893	C17orf63	-0.72	-5.04	-0.41	1.58e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs12449000	1	rs12449000	chr16:89872970	T/C	cg21285383	chr16:89894308	SPIRE2	0.45	6.83	0.52	3.35e-10	Schizophrenia;
TGCT	cis	rs617219	0.710	rs2607141	chr5:78558635	G/T	cg05890484	chr5:78407552	BHMT	0.34	4.63	0.38	9.24e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs739496	0.843	rs630512	chr12:111952167	C/T	cg10833066	chr12:111807467	FAM109A	0.37	5.59	0.45	1.4e-7	Platelet count;
TGCT	cis	rs9341808	0.718	rs9361584	chr6:80819946	G/C	cg08355045	chr6:80787529	NA	0.32	5.83	0.46	4.48e-8	Sitting height ratio;
TGCT	cis	rs11098499	0.955	rs7685268	chr4:120162188	G/A	cg24670566	chr4:120433619	PDE5A	0.23	4.45	0.37	1.89e-5	Corneal astigmatism;
TGCT	cis	rs2997447	0.655	rs2275949	chr1:26385150	C/G	cg19759804	chr1:25889155	LDLRAP1	0.32	4.52	0.38	1.45e-5	QRS complex (12-leadsum);
TGCT	cis	rs6723226	0.721	rs3769600	chr2:32616879	G/A	cg02381751	chr2:32503542	YIPF4	-0.45	-4.47	-0.37	1.77e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs896854	0.654	rs13281625	chr8:95972738	T/C	cg16049864	chr8:95962084	TP53INP1	-0.75	-10.47	-0.69	9.05e-19	Type 2 diabetes;
TGCT	cis	rs1448094	0.654	rs7133797	chr12:86294184	G/C	cg00310523	chr12:86230176	RASSF9	0.31	4.5	0.37	1.56e-5	Major depressive disorder;
TGCT	cis	rs17001868	0.568	rs9611315	chr22:40736900	A/T	cg07138101	chr22:40742427	ADSL	0.73	5.38	0.44	3.57e-7	Mammographic density (dense area);
TGCT	cis	rs9300255	0.596	rs1727331	chr12:123718879	C/G	cg00376283	chr12:123451042	ABCB9	-0.75	-6.4	-0.5	2.89e-9	Neutrophil percentage of white cells;
TGCT	cis	rs514406	0.505	rs856721	chr1:53162156	C/A	cg22166914	chr1:53195759	ZYG11B	0.44	7.64	0.57	5.13e-12	Monocyte count;
TGCT	cis	rs8180040	0.729	rs11720439	chr3:47347003	T/G	cg27129171	chr3:47204927	SETD2	-0.6	-6.53	-0.51	1.5e-9	Colorectal cancer;
TGCT	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg03303774	chr4:1407052	NA	-0.3	-4.69	-0.39	7.16e-6	Obesity-related traits;
TGCT	cis	rs1670533	0.697	rs658846	chr4:1084723	G/C	cg20887711	chr4:1340912	KIAA1530	0.74	5.62	0.45	1.21e-7	Recombination rate (females);
TGCT	trans	rs9329221	0.741	rs55975067	chr8:9806824	C/G	cg15556689	chr8:8085844	FLJ10661	-0.81	-7.5	-0.56	1.07e-11	Neuroticism;
TGCT	cis	rs2072499	0.966	rs2984615	chr1:156165317	G/C	cg06970220	chr1:156163860	SLC25A44	0.73	6.46	0.5	2.13e-9	Testicular germ cell tumor;
TGCT	cis	rs9916302	0.904	rs2338800	chr17:37498149	C/G	cg15445000	chr17:37608096	MED1	-0.33	-4.88	-0.4	3.25e-6	Glomerular filtration rate (creatinine);
TGCT	trans	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.89	-10.03	-0.67	1.1e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs9486719	0.948	rs11152970	chr6:96909077	A/G	cg18709589	chr6:96969512	KIAA0776	-0.68	-5.05	-0.41	1.55e-6	Migraine;Coronary artery disease;
TGCT	cis	rs7172809	0.897	rs74026933	chr15:77826969	A/C	cg22256960	chr15:77711686	NA	-0.44	-4.48	-0.37	1.67e-5	Glucose homeostasis traits;
TGCT	cis	rs9926296	0.744	rs6860	chr16:89711120	C/T	cg04287289	chr16:89883240	FANCA	-0.54	-4.91	-0.4	2.83e-6	Vitiligo;
TGCT	cis	rs858239	0.601	rs3735228	chr7:23170427	T/G	cg05602783	chr7:23145260	KLHL7	-0.63	-5.28	-0.43	5.64e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs2404602	0.692	rs55729975	chr15:76803226	G/A	cg26408565	chr15:76604113	ETFA	-0.36	-4.65	-0.39	8.27e-6	Blood metabolite levels;
TGCT	cis	rs7216064	1.000	rs2052187	chr17:65834737	T/C	cg12091567	chr17:66097778	LOC651250	-0.87	-6.82	-0.52	3.54e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs7027203	0.759	rs10761282	chr9:96586175	G/A	cg14598338	chr9:96623480	NA	-0.61	-9.21	-0.64	1.03e-15	DNA methylation (variation);
TGCT	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	4.63	0.38	9.19e-6	Height;
TGCT	cis	rs7552404	1.000	rs12123977	chr1:76209754	A/G	cg03433033	chr1:76189801	ACADM	-0.99	-8.26	-0.6	1.87e-13	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9818758	0.607	rs5030795	chr3:49141116	C/T	cg07636037	chr3:49044803	WDR6	-0.94	-5.17	-0.42	9.04e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs7104764	1.000	rs6598066	chr11:243185	A/G	cg18336825	chr11:236787	PSMD13;SIRT3	1.1	10.98	0.7	5.33e-20	Menarche (age at onset);
TGCT	cis	rs11098499	0.865	rs2389809	chr4:120377399	T/C	cg09307838	chr4:120376055	NA	0.71	6.98	0.53	1.57e-10	Corneal astigmatism;
TGCT	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.71	-0.39	6.54e-6	Prudent dietary pattern;
TGCT	cis	rs617219	0.659	rs13182512	chr5:78573790	A/T	cg05890484	chr5:78407552	BHMT	-0.34	-4.63	-0.38	9.24e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs9948	0.786	rs62152775	chr2:97448474	G/T	cg01990225	chr2:97406019	LMAN2L	-0.88	-4.81	-0.4	4.37e-6	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs6450176	0.909	rs6866586	chr5:53295568	A/C	ch.5.1024479R	chr5:53302184	ARL15	-0.53	-5.1	-0.42	1.23e-6	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs7172809	0.573	rs7182221	chr15:77589535	C/T	cg22256960	chr15:77711686	NA	0.47	4.63	0.38	9.08e-6	Glucose homeostasis traits;
TGCT	cis	rs727563	0.555	rs5751136	chr22:42075581	T/A	cg03806693	chr22:41940476	POLR3H	1.08	11.5	0.72	2.85e-21	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg01802117	chr1:53393560	SCP2	-0.42	-4.95	-0.41	2.36e-6	Monocyte count;
TGCT	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg18402987	chr7:1209562	NA	0.61	5.52	0.44	1.88e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9611519	0.964	rs2092563	chr22:41592677	G/A	cg03806693	chr22:41940476	POLR3H	-0.68	-6.28	-0.49	5.17e-9	Neuroticism;
TGCT	cis	rs35934224	0.783	rs58714937	chr22:19856710	C/T	cg11182965	chr22:19864308	TXNRD2	-0.36	-4.95	-0.41	2.33e-6	Glaucoma (primary open-angle);
TGCT	cis	rs3749237	1.000	rs3749237	chr3:49770032	C/T	cg10152585	chr3:50297680	NA	0.5	4.65	0.39	8.38e-6	Resting heart rate;
TGCT	cis	rs593982	0.920	rs618456	chr11:65475620	C/T	cg08755490	chr11:65554678	OVOL1	1.3	7.59	0.56	6.8e-12	Atopic dermatitis;
TGCT	cis	rs3008870	1.000	rs2815361	chr1:67494591	G/T	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.01	0.7	4.47e-20	Lymphocyte percentage of white cells;
TGCT	cis	rs9916302	0.904	rs2338798	chr17:37547269	T/C	cg15445000	chr17:37608096	MED1	-0.33	-4.7	-0.39	6.85e-6	Glomerular filtration rate (creatinine);
TGCT	trans	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.86	-9.4	-0.65	3.49e-16	Intelligence (multi-trait analysis);
TGCT	trans	rs208515	0.525	rs10498841	chr6:66663706	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.9	9.56	0.65	1.46e-16	Exhaled nitric oxide levels;
TGCT	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	5.24	0.43	6.79e-7	Menopause (age at onset);
TGCT	cis	rs752092	1.000	rs752092	chr15:101781934	C/T	cg25114630	chr15:101792522	CHSY1	-0.59	-5.76	-0.46	6.3e-8	Corneal structure;
TGCT	cis	rs12497850	1.000	rs12497850	chr3:48748989	G/T	cg07636037	chr3:49044803	WDR6	0.92	10.34	0.68	1.91e-18	Parkinson's disease;
TGCT	cis	rs4517514	0.509	rs12417652	chr11:89905239	T/G	cg05041596	chr11:89867385	NAALAD2	0.56	5.23	0.43	6.94e-7	Trans fatty acid levels;
TGCT	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg25767906	chr1:53392781	SCP2	-0.59	-7.58	-0.56	7.1e-12	Monocyte count;
TGCT	cis	rs79349575	0.679	rs9894239	chr17:46997959	C/T	cg07967210	chr17:47022446	SNF8	-0.41	-5.44	-0.44	2.69e-7	Type 2 diabetes;
TGCT	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	5.09	0.42	1.29e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	trans	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg13615516	chr5:77269221	NA	0.67	8.36	0.6	1.09e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7584330	0.744	rs10929235	chr2:238380272	A/G	cg14458575	chr2:238380390	NA	0.6	9.0	0.63	3.2e-15	Prostate cancer;
TGCT	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	8.16	0.59	3.1400000000000003e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs79057730	0.684	rs6955004	chr7:790792	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.69	6.62	0.51	9.78e-10	Initial pursuit acceleration;
TGCT	cis	rs7208859	0.623	rs28556733	chr17:29083945	T/G	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg08048268	chr3:133502702	NA	-0.65	-9.84	-0.66	3.1e-17	Iron status biomarkers;
TGCT	cis	rs7666738	0.822	rs17484018	chr4:98988960	G/A	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg22764044	chr5:178986830	RUFY1	0.44	4.75	0.39	5.42e-6	Lung cancer;
TGCT	cis	rs9611565	0.580	rs5758449	chr22:42140160	C/T	cg06481639	chr22:41940642	POLR3H	0.54	4.57	0.38	1.17e-5	Vitiligo;
TGCT	cis	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg06697600	chr4:7070879	GRPEL1	-0.47	-4.94	-0.41	2.42e-6	Monocyte percentage of white cells;
TGCT	trans	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.88	-9.5	-0.65	2.02e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs806215	0.526	rs2402871	chr7:127439519	G/A	cg11539674	chr7:127291444	SND1	-0.37	-4.72	-0.39	6.35e-6	Type 2 diabetes;
TGCT	cis	rs11105298	0.891	rs4842662	chr12:89933446	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.67	-4.85	-0.4	3.63e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs916888	0.610	rs199454	chr17:44800110	G/A	cg16520312	chr17:43971471	MAPT;LOC100128977	0.46	4.52	0.38	1.44e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs12286929	0.933	rs11215381	chr11:115022233	T/C	cg04017736	chr11:115827165	NA	-0.2	-4.71	-0.39	6.44e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg18252515	chr7:66147081	NA	1.25	7.75	0.57	2.92e-12	Diabetic kidney disease;
TGCT	cis	rs72717009	0.825	rs7529425	chr1:161479599	G/A	cg23840854	chr1:161414152	NA	-1.02	-6.12	-0.48	1.12e-8	Rheumatoid arthritis;
TGCT	cis	rs11190604	1.000	rs2495732	chr10:102357780	T/C	cg16342193	chr10:102329863	NA	-0.44	-5.38	-0.44	3.57e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs12220238	0.915	rs75467340	chr10:75907318	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.91	6.77	0.52	4.61e-10	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg23302884	chr18:44338147	ST8SIA5	-0.41	-4.68	-0.39	7.48e-6	Personality dimensions;
TGCT	cis	rs2282802	0.685	rs6870103	chr5:139692515	G/T	cg01081189	chr5:139537190	NA	-0.27	-5.04	-0.41	1.6e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1903068	0.853	rs9312655	chr4:56002665	T/C	cg09978860	chr4:56023921	NA	0.56	6.34	0.49	3.88e-9	Endometriosis;
TGCT	cis	rs12643440	0.538	rs66857912	chr4:17146347	T/C	cg22650099	chr4:17144496	NA	-0.49	-5.03	-0.41	1.66e-6	Metabolite levels (Pyroglutamine);
TGCT	cis	rs1691799	0.867	rs961049	chr12:66762591	A/C	cg16791601	chr12:66731901	HELB	0.27	5.82	0.46	4.7e-8	White blood cell count (basophil);
TGCT	cis	rs4689388	0.926	rs4689394	chr4:6291003	C/G	cg14416269	chr4:6271139	WFS1	-0.38	-5.11	-0.42	1.19e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs9649213	0.614	rs10953254	chr7:97914305	A/G	cg09267113	chr7:98030324	BAIAP2L1	-0.93	-8.7	-0.62	1.72e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs13242816	1.000	rs3807988	chr7:116180735	A/C	cg16553024	chr7:116138462	CAV2	-0.44	-5.26	-0.43	6.11e-7	P wave duration;
TGCT	cis	rs9611565	0.592	rs5996037	chr22:41965292	A/G	cg13695892	chr22:41940480	POLR3H	-0.87	-8.17	-0.59	2.95e-13	Vitiligo;
TGCT	cis	rs2562456	0.876	rs62110163	chr19:21728822	G/A	cg01304269	chr19:21688519	ZNF429	0.57	4.74	0.39	5.86e-6	Pain;
TGCT	cis	rs6674176	1.000	rs6674176	chr1:44379957	G/A	cg12908607	chr1:44402522	ARTN	-0.74	-8.71	-0.62	1.58e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg16414030	chr3:133502952	NA	-0.5	-7.01	-0.53	1.39e-10	Iron status biomarkers;
TGCT	cis	rs11112613	0.762	rs73184078	chr12:105950017	A/G	cg03607813	chr12:105948248	NA	0.52	6.0	0.47	2.03e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	trans	rs1814175	0.534	rs1983448	chr11:49933856	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.42	-9.87	-0.66	2.56e-17	Height;
TGCT	cis	rs7586879	0.616	rs6545813	chr2:25131287	C/T	cg01884057	chr2:25150051	NA	0.36	7.1	0.54	8.43e-11	Body mass index;
TGCT	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg12963246	chr6:28129442	ZNF389	-0.52	-5.1	-0.42	1.23e-6	Depression;
TGCT	cis	rs1008375	1.000	rs10805359	chr4:17684886	A/G	cg18681998	chr4:17616180	MED28	0.92	10.46	0.68	9.72e-19	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs881375	0.678	rs10818488	chr9:123705087	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	5.09	0.42	1.27e-6	Rheumatoid arthritis;
TGCT	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg22963979	chr7:1858916	MAD1L1	-0.36	-5.74	-0.46	6.77e-8	Bipolar disorder and schizophrenia;
TGCT	cis	rs2371030	1.000	rs1019393	chr2:211593081	C/G	cg18417063	chr2:211583084	NA	-0.31	-4.45	-0.37	1.91e-5	Non-small cell lung cancer;
TGCT	cis	rs7772486	0.754	rs702304	chr6:145990797	A/G	cg05347473	chr6:146136440	FBXO30	-0.53	-4.97	-0.41	2.18e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs881375	1.000	rs6478484	chr9:123652380	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.39	4.44	0.37	1.95e-5	Rheumatoid arthritis;
TGCT	cis	rs12220238	0.730	rs11000899	chr10:75913055	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.06	0.54	1.05e-10	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg22535103	chr8:58192502	C8orf71	-0.42	-4.79	-0.4	4.7e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9929218	0.953	rs34909703	chr16:68740097	T/C	cg01251360	chr16:68772225	CDH1	0.29	4.7	0.39	6.75e-6	Colorectal cancer;
TGCT	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg03264133	chr6:25882463	NA	-0.7	-6.47	-0.5	2.03e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.570	rs1921415	chr4:99093804	C/T	cg17366294	chr4:99064904	C4orf37	0.58	5.38	0.43	3.6e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2820315	1.000	rs2644112	chr1:201806106	T/C	cg12730843	chr1:201915899	LMOD1	-0.26	-4.72	-0.39	6.26e-6	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
TGCT	cis	rs2637266	1.000	rs11001830	chr10:78346396	G/A	cg18941641	chr10:78392320	NA	0.4	5.02	0.41	1.77e-6	Pulmonary function;
TGCT	cis	rs4253772	0.550	rs6007779	chr22:46678615	A/C	cg09491104	chr22:46646882	C22orf40	-0.56	-4.52	-0.38	1.44e-5	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs7727544	0.716	rs2089855	chr5:131573529	A/G	cg24060327	chr5:131705240	SLC22A5	-0.6	-5.67	-0.45	9.52e-8	Blood metabolite levels;
TGCT	cis	rs433852	0.718	rs550455	chr19:49136515	A/G	cg07996880	chr19:49339085	HSD17B14	-0.29	-4.88	-0.4	3.16e-6	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs9810089	0.814	rs866758	chr3:136117870	G/C	cg12473912	chr3:136751656	NA	0.36	5.04	0.41	1.58e-6	Gestational age at birth (child effect);
TGCT	cis	rs6700896	0.522	rs6588156	chr1:66160433	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	-0.54	-4.44	-0.37	1.98e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs2243480	1.000	rs13237037	chr7:65997882	T/C	cg18252515	chr7:66147081	NA	-1.22	-8.04	-0.59	6.02e-13	Diabetic kidney disease;
TGCT	cis	rs6087771	0.642	rs6060411	chr20:30222139	T/C	cg13852791	chr20:30311386	BCL2L1	0.77	6.53	0.51	1.51e-9	Subcortical brain region volumes;Putamen volume;
TGCT	cis	rs2730245	0.505	rs2657360	chr7:158673604	A/G	cg11984989	chr7:158649758	WDR60	1.02	9.51	0.65	1.95e-16	Height;
TGCT	cis	rs7552404	0.691	rs1770890	chr1:76401117	A/G	cg22875332	chr1:76189707	ACADM	-0.66	-6.78	-0.52	4.38e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7943191	0.810	rs7942154	chr11:62337163	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.59	7.16	0.54	6.26e-11	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs2742417	1.000	rs2742432	chr3:45737467	G/T	cg04837898	chr3:45731254	SACM1L	-0.55	-5.68	-0.45	9.14e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs116095464	0.558	rs7713524	chr5:276200	C/T	cg22857025	chr5:266934	NA	0.37	6.26	0.49	5.78e-9	Breast cancer;
TGCT	cis	rs858239	0.600	rs7776649	chr7:23119317	C/T	cg05602783	chr7:23145260	KLHL7	-0.64	-5.28	-0.43	5.69e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs9291683	0.632	rs13137074	chr4:10042842	C/T	cg11266682	chr4:10021025	SLC2A9	0.64	8.75	0.62	1.29e-14	Bone mineral density;
TGCT	cis	rs4700695	0.719	rs27046	chr5:65439964	G/C	cg21114390	chr5:65439923	SFRS12	-0.84	-7.36	-0.55	2.26e-11	Facial morphology (factor 19);
TGCT	cis	rs2888674	1.000	rs717658	chr7:150503637	A/T	cg10409299	chr7:150498843	TMEM176B;TMEM176A	0.28	4.76	0.39	5.29e-6	Forced expiratory volume in 1 second (occupational environmental exposures interaction);
TGCT	cis	rs682748	0.810	rs62349989	chr5:17111970	A/T	cg23987134	chr5:17158319	LOC285696	-0.21	-4.96	-0.41	2.31e-6	Hippocampal atrophy;
TGCT	cis	rs2832191	0.791	rs2832181	chr21:30481371	G/T	cg08807101	chr21:30365312	RNF160	-0.66	-6.19	-0.49	8.16e-9	Dental caries;
TGCT	cis	rs138249	0.867	rs715616	chr22:50558505	G/A	cg24864161	chr22:50528282	MOV10L1	0.47	5.02	0.41	1.77e-6	Gestational age at birth in labor-initiated deliveries (child effect);
TGCT	cis	rs7646881	0.504	rs61080878	chr3:158462897	C/T	cg18349298	chr3:158450550	RARRES1	0.42	4.44	0.37	1.97e-5	Tetralogy of Fallot;
TGCT	cis	rs2895526	0.691	rs10752269	chr10:12692902	G/A	cg18283737	chr10:12085149	UPF2	0.48	4.62	0.38	9.47e-6	Headache;
TGCT	cis	rs7208859	0.623	rs7208441	chr17:29143863	C/T	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7191439	0.789	rs4433802	chr16:88784964	A/G	cg27087555	chr16:88793112	FAM38A	-0.55	-5.9	-0.47	3.18e-8	Plateletcrit;
TGCT	trans	rs61931739	0.500	rs7977186	chr12:34431486	C/G	cg26384229	chr12:38710491	ALG10B	0.72	6.8	0.52	4.02e-10	Morning vs. evening chronotype;
TGCT	cis	rs9902453	0.838	rs8064689	chr17:28217053	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.8	7.07	0.54	9.76e-11	Coffee consumption (cups per day);
TGCT	cis	rs308403	0.608	rs309362	chr4:123658154	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.72	6.85	0.52	3.1e-10	Blood protein levels;
TGCT	cis	rs7666738	0.791	rs7377018	chr4:99034962	C/T	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8077889	0.956	rs61608877	chr17:41848713	A/C	cg26893861	chr17:41843967	DUSP3	1.09	13.68	0.78	1.57e-26	Triglycerides;
TGCT	cis	rs185694	0.817	rs1952607	chr13:30888981	A/G	cg07600127	chr13:30881527	KATNAL1	0.61	5.19	0.42	8.26e-7	Antineutrophil cytoplasmic antibody-associated vasculitis;
TGCT	cis	rs6582630	0.555	rs35186318	chr12:38295822	C/T	cg26384229	chr12:38710491	ALG10B	-0.55	-4.75	-0.39	5.58e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs4824093	0.610	rs12106611	chr22:50242686	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.45	4.65	0.39	8.43e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs35306767	0.715	rs1871622	chr10:1049309	T/G	cg18964960	chr10:1102726	WDR37	0.78	5.46	0.44	2.45e-7	Eosinophil percentage of granulocytes;
TGCT	cis	rs886126	0.950	rs2097658	chr12:111690466	C/T	cg10833066	chr12:111807467	FAM109A	0.33	5.64	0.45	1.07e-7	Coronary heart disease;
TGCT	cis	rs2842992	0.872	rs2758330	chr6:160104844	G/T	cg11366901	chr6:160182831	ACAT2	0.94	6.18	0.49	8.48e-9	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs9611565	0.512	rs6519289	chr22:42170432	A/C	cg06481639	chr22:41940642	POLR3H	0.69	6.05	0.48	1.59e-8	Vitiligo;
TGCT	cis	rs11105298	0.685	rs117578503	chr12:89836672	G/C	cg00757033	chr12:89920650	WDR51B	0.34	5.36	0.43	4e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs6121246	0.609	rs6089075	chr20:30392884	A/G	cg13852791	chr20:30311386	BCL2L1	0.81	7.58	0.56	7.06e-12	Mean corpuscular hemoglobin;
TGCT	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.78	-6.92	-0.53	2.16e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs12971120	0.891	rs12608037	chr18:72169395	A/G	cg25817165	chr18:72167213	CNDP2	-0.29	-5.11	-0.42	1.16e-6	Refractive error;
TGCT	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg08439880	chr3:133502540	NA	-0.31	-5.87	-0.47	3.69e-8	Iron status biomarkers;
TGCT	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-8.64	-0.61	2.39e-14	Platelet count;
TGCT	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg25036284	chr2:26402008	FAM59B	-0.66	-5.34	-0.43	4.22e-7	Gut microbiome composition (summer);
TGCT	cis	rs12368653	0.545	rs2277324	chr12:58013175	G/A	cg12615879	chr12:58013172	SLC26A10	0.63	7.5	0.56	1.05e-11	Multiple sclerosis;
TGCT	cis	rs9787249	0.957	rs1046988	chr1:40219065	A/G	cg24920358	chr1:40204285	PPIE	-0.54	-9.82	-0.66	3.37e-17	Blood protein levels;
TGCT	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg24829409	chr8:58192753	C8orf71	-0.57	-5.35	-0.43	4.03e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7833790	0.724	rs6473310	chr8:82707981	A/G	cg23324259	chr8:82754387	SNX16	-0.62	-4.88	-0.4	3.19e-6	Diastolic blood pressure;
TGCT	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg09365446	chr1:150670422	GOLPH3L	0.3	4.52	0.38	1.4e-5	Melanoma;
TGCT	cis	rs3733585	0.699	rs28837683	chr4:9959808	C/T	cg00071950	chr4:10020882	SLC2A9	-0.55	-6.55	-0.51	1.41e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs4285028	0.580	rs2293611	chr3:121643163	G/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.61	-5.22	-0.42	7.38e-7	Multiple sclerosis;
TGCT	cis	rs2404602	0.716	rs12592171	chr15:76755133	G/C	cg22467129	chr15:76604101	ETFA	-0.57	-6.83	-0.52	3.31e-10	Blood metabolite levels;
TGCT	cis	rs10851411	0.779	rs3742997	chr15:42729286	T/A	cg23803468	chr15:43513504	EPB42	0.26	5.08	0.42	1.32e-6	Glucose homeostasis traits;
TGCT	trans	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg17830980	chr10:43048298	ZNF37B	-0.84	-10.46	-0.68	9.38e-19	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2629540	0.889	rs10901815	chr10:126435598	G/A	cg08799069	chr10:126477246	METTL10	-0.3	-4.5	-0.37	1.54e-5	Cocaine dependence;
TGCT	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6074578	0.679	rs12480299	chr20:140171	A/G	cg16931068	chr20:139680	DEFB127	0.27	4.64	0.38	8.57e-6	Hirschsprung disease;
TGCT	cis	rs1483890	0.723	rs12631128	chr3:69411416	G/T	cg22125112	chr3:69402811	FRMD4B	0.29	4.74	0.39	5.85e-6	Resting heart rate;
TGCT	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.43	4.84	0.4	3.75e-6	Lymphocyte counts;
TGCT	cis	rs9443645	0.838	rs946022	chr6:79672133	G/T	cg09184832	chr6:79620586	NA	-0.49	-5.29	-0.43	5.29e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg24399712	chr22:39784796	NA	-1.06	-12.55	-0.75	8.19e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs13401104	0.587	rs62190973	chr2:237145231	T/A	cg26422059	chr2:237146110	ASB18	0.57	4.56	0.38	1.19e-5	Educational attainment;
TGCT	cis	rs12220238	0.915	rs11001003	chr10:76099944	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.88	5.86	0.47	3.87e-8	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs10782582	0.609	rs5745430	chr1:76332994	C/T	cg10523679	chr1:76189770	ACADM	-0.59	-5.42	-0.44	2.94e-7	Daytime sleep phenotypes;
TGCT	cis	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg22857025	chr5:266934	NA	-0.34	-6.7	-0.52	6.65e-10	Breast cancer;
TGCT	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg22618164	chr12:122356400	WDR66	0.59	6.03	0.48	1.71e-8	Mean corpuscular volume;
TGCT	cis	rs2456568	0.778	rs2456563	chr11:93678675	C/T	cg26875233	chr11:93583750	C11orf90	-0.41	-5.18	-0.42	8.79e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs2197308	0.610	rs10880837	chr12:37864924	C/T	cg13010199	chr12:38710504	ALG10B	0.64	5.0	0.41	1.87e-6	Morning vs. evening chronotype;
TGCT	cis	rs1862618	0.641	rs170733	chr5:56249251	A/G	cg12311346	chr5:56204834	C5orf35	0.56	5.93	0.47	2.82e-8	Initial pursuit acceleration;
TGCT	cis	rs7586879	0.520	rs6718511	chr2:25122324	A/G	cg01884057	chr2:25150051	NA	0.35	6.9	0.53	2.39e-10	Body mass index;
TGCT	cis	rs13191362	1.000	rs34725898	chr6:163127302	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.99	8.17	0.59	3.08e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.33	0.43	4.5e-7	Prudent dietary pattern;
TGCT	cis	rs763121	0.706	rs3827356	chr22:39064806	G/T	cg06022373	chr22:39101656	GTPBP1	-0.73	-7.29	-0.55	3.19e-11	Menopause (age at onset);
TGCT	cis	rs7582180	0.629	rs11686799	chr2:100956055	C/G	cg14675211	chr2:100938903	LONRF2	0.5	4.78	0.39	4.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs12134245	0.874	rs35115044	chr1:92021650	A/G	cg25838465	chr1:92012736	NA	-0.34	-5.64	-0.45	1.08e-7	Breast cancer;
TGCT	cis	rs3617	0.625	rs11719137	chr3:52876389	G/T	cg11645453	chr3:52864694	ITIH4	-0.29	-5.71	-0.46	7.84e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6701037	0.566	rs10489326	chr1:175134677	A/G	cg00321850	chr1:175162397	KIAA0040	0.38	5.04	0.41	1.61e-6	Alcohol dependence;
TGCT	cis	rs7666738	0.606	rs6852813	chr4:99084671	G/A	cg17366294	chr4:99064904	C4orf37	0.57	5.34	0.43	4.31e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11785400	0.963	rs4579507	chr8:143733663	C/G	cg10596483	chr8:143751796	JRK	0.55	6.01	0.47	1.93e-8	Schizophrenia;
TGCT	cis	rs2439831	0.867	rs8041132	chr15:43635136	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	8.65	0.61	2.26e-14	Lung cancer in ever smokers;
TGCT	trans	rs1814175	0.746	rs10839429	chr11:49906845	G/A	cg03929089	chr4:120376271	NA	-0.71	-8.09	-0.59	4.74e-13	Height;
TGCT	cis	rs1461503	0.934	rs7113330	chr11:122843358	C/T	cg27398637	chr11:122830231	C11orf63	-0.39	-4.75	-0.39	5.58e-6	Menarche (age at onset);
TGCT	trans	rs1005277	0.505	rs200931	chr10:38128434	A/C	cg17830980	chr10:43048298	ZNF37B	-0.73	-8.06	-0.59	5.35e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7267979	1.000	rs2482943	chr20:25380593	G/A	cg16686733	chr20:25566563	NINL	-0.59	-6.05	-0.48	1.57e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg06238570	chr21:40685208	BRWD1	0.62	6.6	0.51	1.07e-9	Menarche (age at onset);
TGCT	cis	rs7474896	0.583	rs10827818	chr10:38000856	T/C	cg13720705	chr10:37990370	NA	0.34	4.9	0.4	2.9e-6	Obesity (extreme);
TGCT	cis	rs2201728	0.967	rs2173199	chr4:100171379	G/A	cg07219303	chr4:100140905	ADH6	-0.35	-5.2	-0.42	8.15e-7	Cardiac Troponin-T levels;
TGCT	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.07	-9.63	-0.65	1.01e-16	Platelet count;
TGCT	cis	rs910316	1.000	rs28626045	chr14:75589195	G/C	cg08847533	chr14:75593920	NEK9	0.95	10.91	0.7	7.73e-20	Height;
TGCT	cis	rs7267979	0.868	rs6138550	chr20:25223430	C/T	cg14121845	chr20:25566513	NINL	0.5	5.51	0.44	1.95e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6460942	0.915	rs10488158	chr7:12508894	C/T	cg06484146	chr7:12443880	VWDE	-0.6	-5.33	-0.43	4.49e-7	Coronary artery disease;
TGCT	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg03517284	chr6:25882590	NA	0.52	5.14	0.42	1.05e-6	Blood metabolite levels;
TGCT	cis	rs1371867	0.846	rs1788181	chr8:101334068	C/T	cg00191853	chr8:101177733	SPAG1	-0.23	-4.76	-0.39	5.2e-6	Atrioventricular conduction;
TGCT	cis	rs9660180	0.780	rs12038111	chr1:1703849	T/C	cg23982607	chr1:1823379	GNB1	-0.55	-8.56	-0.61	3.69e-14	Body mass index;
TGCT	cis	rs9913156	0.841	rs56239958	chr17:4600280	G/C	cg00122941	chr17:4613640	ARRB2	0.88	7.63	0.57	5.46e-12	Lymphocyte counts;
TGCT	cis	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg02380750	chr20:61661411	NA	0.35	5.76	0.46	6.25e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs6750047	0.719	rs100489	chr2:38266478	T/C	cg07380506	chr2:38303506	CYP1B1	-0.56	-5.04	-0.41	1.62e-6	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs4953076	0.573	rs6738023	chr2:44405931	T/C	cg04920474	chr2:44395004	PPM1B	0.58	5.75	0.46	6.43e-8	Height;
TGCT	cis	rs7829975	0.572	rs28446104	chr8:8795901	C/G	cg06636001	chr8:8085503	FLJ10661	-0.76	-6.67	-0.51	7.48e-10	Mood instability;
TGCT	cis	rs3845702	1.000	rs3845702	chr2:180848488	A/C	cg01881094	chr2:180872142	CWC22	0.65	5.97	0.47	2.31e-8	Schizophrenia;
TGCT	cis	rs7772486	0.846	rs9373482	chr6:146363123	A/C	cg23711669	chr6:146136114	FBXO30	0.89	10.0	0.67	1.25e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg04267008	chr7:1944627	MAD1L1	-0.4	-5.24	-0.43	6.74e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg13683864	chr3:40499215	RPL14	-1.19	-13.2	-0.76	2.17e-25	Renal cell carcinoma;
TGCT	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6598955	0.671	rs7550997	chr1:26596080	G/A	cg04990556	chr1:26633338	UBXN11	0.66	5.0	0.41	1.88e-6	Obesity-related traits;
TGCT	cis	rs6088580	0.634	rs6059905	chr20:33126946	T/C	cg06115741	chr20:33292138	TP53INP2	0.55	4.83	0.4	3.91e-6	Glomerular filtration rate (creatinine);
TGCT	trans	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.83	8.65	0.61	2.29e-14	Body mass index;
TGCT	cis	rs4664308	0.967	rs56293836	chr2:160910958	T/C	cg03641300	chr2:160917029	PLA2R1	-0.26	-6.53	-0.51	1.49e-9	Idiopathic membranous nephropathy;
TGCT	cis	rs9513593	1.000	rs9300540	chr13:100018225	T/A	cg21788972	chr13:99853209	UBAC2	0.56	4.45	0.37	1.92e-5	Psoriasis;
TGCT	cis	rs922182	0.617	rs13329183	chr15:64240809	A/G	cg02919090	chr15:64263738	DAPK2	0.37	7.01	0.53	1.33e-10	Blood protein levels;
TGCT	cis	rs796364	0.865	rs769948	chr2:200728475	C/A	cg17644776	chr2:200775616	C2orf69	0.31	4.83	0.4	3.99e-6	Schizophrenia;
TGCT	cis	rs72627509	0.638	rs73165963	chr4:57740536	A/G	cg26694713	chr4:57773883	REST	0.82	6.68	0.51	7.07e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs826838	0.651	rs12367384	chr12:38618460	G/T	cg26384229	chr12:38710491	ALG10B	0.65	6.07	0.48	1.44e-8	Heart rate;
TGCT	cis	rs12681288	0.862	rs4735981	chr8:1018437	A/C	cg06709756	chr8:1339049	NA	-0.23	-4.47	-0.37	1.75e-5	Schizophrenia;
TGCT	cis	rs8129326	0.934	rs7279041	chr21:35804585	C/T	cg27150370	chr21:34863940	DNAJC28	-0.46	-4.56	-0.38	1.2e-5	Cancer;
TGCT	cis	rs4455778	0.580	rs59806378	chr7:49129934	T/A	cg26309511	chr7:48887640	NA	0.5	6.51	0.5	1.66e-9	Lung cancer in never smokers;
TGCT	cis	rs7666738	0.830	rs17558193	chr4:99049593	A/G	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7666738	0.830	rs4334758	chr4:98971875	A/G	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs514406	0.893	rs1242315	chr1:53417181	A/G	cg16325326	chr1:53192061	ZYG11B	0.59	6.79	0.52	4.22e-10	Monocyte count;
TGCT	cis	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg25427524	chr10:38739819	LOC399744	-0.4	-8.36	-0.6	1.05e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg23758822	chr17:41437982	NA	0.68	6.78	0.52	4.4e-10	Menopause (age at onset);
TGCT	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg08280861	chr8:58055591	NA	0.4	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7267979	1.000	rs4815404	chr20:25301845	T/G	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9929218	0.501	rs12448999	chr16:68815549	T/A	cg01251360	chr16:68772225	CDH1	-0.25	-4.51	-0.38	1.51e-5	Colorectal cancer;
TGCT	cis	rs11642862	1.000	rs11645367	chr16:30770074	C/T	cg02466173	chr16:30829666	NA	-0.39	-4.68	-0.39	7.24e-6	Tonsillectomy;
TGCT	cis	rs2072499	0.778	rs2842868	chr1:156196407	A/C	cg25208724	chr1:156163844	SLC25A44	0.92	8.45	0.6	6.47e-14	Testicular germ cell tumor;
TGCT	cis	rs10782582	0.609	rs5745410	chr1:76314356	C/A	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.52	4.53	0.38	1.37e-5	Daytime sleep phenotypes;
TGCT	cis	rs2760061	0.819	rs1745417	chr1:228204279	C/T	cg02753203	chr1:228287806	NA	0.32	6.14	0.48	1e-8	Diastolic blood pressure;
TGCT	cis	rs1997103	1.000	rs6954474	chr7:55404847	A/G	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg11965913	chr1:205819406	PM20D1	0.6	9.21	0.64	1.03e-15	Menarche (age at onset);
TGCT	cis	rs9322193	0.884	rs11155679	chr6:150080017	T/C	cg13206674	chr6:150067644	NUP43	0.54	4.65	0.39	8.48e-6	Lung cancer;
TGCT	cis	rs6089584	0.821	rs2273990	chr20:60579149	G/T	cg13770153	chr20:60521292	NA	-0.54	-7.29	-0.55	3.23e-11	Body mass index;
TGCT	cis	rs881375	0.967	rs7034653	chr9:123687372	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	5.02	0.41	1.72e-6	Rheumatoid arthritis;
TGCT	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg26338869	chr17:61819248	STRADA	-0.55	-5.08	-0.41	1.37e-6	Prudent dietary pattern;
TGCT	cis	rs514406	0.505	rs425520	chr1:53179805	C/G	cg25767906	chr1:53392781	SCP2	-0.47	-5.35	-0.43	4.15e-7	Monocyte count;
TGCT	cis	rs4383453	0.539	rs4678014	chr3:123100170	A/G	cg04890266	chr3:123102914	ADCY5	-0.5	-8.19	-0.59	2.68e-13	Gestational age at birth (maternal effect);
TGCT	cis	rs7678296	0.649	rs73128366	chr4:37241908	T/C	cg06805348	chr4:37245195	KIAA1239	0.57	4.83	0.4	3.87e-6	3-hydroxypropylmercapturic acid levels in smokers;
TGCT	cis	rs9291683	0.546	rs4529049	chr4:10045389	C/T	cg11266682	chr4:10021025	SLC2A9	0.6	7.52	0.56	9.49e-12	Bone mineral density;
TGCT	cis	rs4523957	0.552	rs923862	chr17:2031382	A/C	cg16513277	chr17:2031491	SMG6	-0.2	-4.58	-0.38	1.13e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs11650494	0.803	rs117801358	chr17:47447950	C/A	cg08112188	chr17:47440006	ZNF652	1.04	5.31	0.43	4.85e-7	Prostate cancer;
TGCT	cis	rs986417	0.901	rs7160405	chr14:60970004	G/C	cg27398547	chr14:60952738	C14orf39	1.39	10.61	0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs3020736	0.500	rs2413669	chr22:42507748	A/C	cg05082376	chr22:42548792	NA	0.23	5.43	0.44	2.83e-7	Autism spectrum disorder or schizophrenia;
TGCT	trans	rs1496653	0.602	rs35975795	chr3:23417996	C/T	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs3008870	0.920	rs3008865	chr1:67402838	T/C	cg03991309	chr1:68237761	GNG12	0.27	4.55	0.38	1.26e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs7178572	0.539	rs16968809	chr15:77672118	C/T	cg15453836	chr15:77711506	NA	0.46	5.09	0.42	1.29e-6	Type 2 diabetes;
TGCT	cis	rs17122693	0.681	rs72679587	chr14:51092686	A/G	cg04730355	chr14:51134070	SAV1	1.24	8.74	0.62	1.38e-14	Cognitive performance;
TGCT	cis	rs910316	1.000	rs910316	chr14:75626042	A/C	cg08847533	chr14:75593920	NEK9	0.94	10.45	0.68	1.01e-18	Height;
TGCT	cis	rs40363	1.000	rs37767	chr16:3514962	C/T	cg00484396	chr16:3507460	NAT15	0.44	5.08	0.41	1.36e-6	Tuberculosis;
TGCT	cis	rs78487399	0.808	rs6544669	chr2:43736171	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-4.84	-0.4	3.79e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs1799949	0.929	rs4792988	chr17:41437547	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.17	0.42	9.27e-7	Menopause (age at onset);
TGCT	cis	rs28374715	0.635	rs28557159	chr15:41657353	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.88	-14.1	-0.78	1.56e-27	Ulcerative colitis;
TGCT	cis	rs7296418	0.885	rs1051434	chr12:123641200	C/T	cg00376283	chr12:123451042	ABCB9	0.84	7.66	0.57	4.68e-12	Platelet count;
TGCT	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg12963246	chr6:28129442	ZNF389	0.52	5.1	0.42	1.23e-6	Depression;
TGCT	cis	rs10929159	0.964	rs3754659	chr2:236950634	C/T	cg16852440	chr2:237570117	NA	-0.29	-4.64	-0.38	8.8e-6	Parkinson's disease;
TGCT	cis	rs1784581	0.802	rs7768986	chr6:162427890	G/C	cg17173639	chr6:162384350	PARK2	0.42	7.38	0.55	2.03e-11	Itch intensity from mosquito bite;
TGCT	cis	rs9894429	0.538	rs9747080	chr17:79606704	A/G	cg18240062	chr17:79603768	NPLOC4	0.75	7.08	0.54	9.3e-11	Eye color traits;
TGCT	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.49	-4.76	-0.39	5.34e-6	Bipolar disorder;
TGCT	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg03709012	chr19:19516395	GATAD2A	0.74	6.22	0.49	7.04e-9	Tonsillectomy;
TGCT	cis	rs9916302	0.718	rs10445306	chr17:37591422	A/G	cg07936489	chr17:37558343	FBXL20	-0.61	-4.81	-0.4	4.27e-6	Glomerular filtration rate (creatinine);
TGCT	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg01341218	chr17:43662625	NA	0.84	7.62	0.56	5.79e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg06558623	chr16:89946397	TCF25	0.53	6.48	0.5	1.99e-9	Skin colour saturation;
TGCT	cis	rs6693567	0.507	rs4970964	chr1:150458029	A/G	cg09579323	chr1:150459698	TARS2	0.52	4.58	0.38	1.12e-5	Migraine;
TGCT	cis	rs12286929	0.637	rs7125361	chr11:115080042	C/G	cg04017736	chr11:115827165	NA	-0.19	-4.64	-0.38	8.84e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs478304	0.593	rs6591188	chr11:65467953	T/C	cg17480646	chr11:65405466	SIPA1	-0.63	-8.43	-0.6	7.5e-14	Acne (severe);
TGCT	cis	rs634534	0.622	rs531612	chr11:65705432	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.22	-4.91	-0.4	2.75e-6	Sum eosinophil basophil counts;Eosinophil counts;
TGCT	cis	rs7973719	0.966	rs7310539	chr12:7329996	C/G	cg07052231	chr12:7363540	PEX5	0.34	5.16	0.42	9.34e-7	IgG glycosylation;
TGCT	cis	rs2458413	0.542	rs2514668	chr8:105362656	A/C	cg04554929	chr8:105342491	NA	-0.49	-5.88	-0.47	3.59e-8	Paget's disease;
TGCT	cis	rs11779988	0.545	rs436506	chr8:17798243	A/G	cg01800426	chr8:17659068	MTUS1	0.68	5.61	0.45	1.28e-7	Breast cancer;
TGCT	cis	rs9677476	0.517	rs60664562	chr2:232060843	T/A	cg07929768	chr2:232055508	NA	0.3	4.83	0.4	4.01e-6	Food antigen IgG levels;
TGCT	cis	rs5769707	0.632	rs135876	chr22:50013573	A/G	cg05373962	chr22:49881684	NA	-0.29	-4.86	-0.4	3.53e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs7954584	0.616	rs10743186	chr12:122356436	C/T	cg10207240	chr12:122356781	WDR66	0.34	4.68	0.39	7.53e-6	Mean corpuscular volume;
TGCT	cis	rs904251	0.504	rs12202664	chr6:37481198	A/G	cg08126542	chr6:37504118	NA	-0.44	-6.39	-0.5	2.99e-9	Cognitive performance;
TGCT	cis	rs1461503	0.900	rs7107502	chr11:122830214	G/A	cg27398637	chr11:122830231	C11orf63	-0.41	-4.77	-0.39	5.14e-6	Menarche (age at onset);
TGCT	cis	rs4242434	0.927	rs34027561	chr8:22465385	T/C	cg03733263	chr8:22462867	KIAA1967	1.14	20.27	0.88	3.6e-41	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs8179	0.645	rs12531820	chr7:92257392	A/G	cg15732164	chr7:92237376	CDK6	-0.27	-4.64	-0.38	8.79e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
TGCT	cis	rs2268241	0.938	rs9808753	chr21:34787312	A/G	cg14850771	chr21:34775459	IFNGR2	0.61	4.9	0.4	2.93e-6	Obesity-related traits;
TGCT	cis	rs7833790	0.777	rs6473301	chr8:82691340	A/G	cg17211192	chr8:82754475	SNX16	-1.04	-8.46	-0.6	6.42e-14	Diastolic blood pressure;
TGCT	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg24399712	chr22:39784796	NA	-1.05	-12.52	-0.75	9.61e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg25811766	chr13:21894605	NA	0.28	5.38	0.44	3.53e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	cis	rs2440129	0.611	rs2292352	chr17:6902887	A/G	cg02493798	chr17:6899577	ALOX12	0.43	4.79	0.39	4.74e-6	Tonsillectomy;
TGCT	cis	rs2229238	0.911	rs12405637	chr1:154501285	C/T	cg13067139	chr1:155221277	FAM189B	0.2	4.51	0.38	1.47e-5	Coronary heart disease;
TGCT	cis	rs7568458	0.905	rs10187424	chr2:85794297	T/C	cg02493740	chr2:85810744	VAMP5	-0.27	-4.86	-0.4	3.53e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg23758822	chr17:41437982	NA	0.72	6.96	0.53	1.79e-10	Menopause (age at onset);
TGCT	cis	rs644799	0.625	rs1255177	chr11:95471495	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.48	4.78	0.39	4.88e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7731657	0.537	rs973900	chr5:130362467	G/T	cg08523029	chr5:130500466	HINT1	-0.61	-5.08	-0.42	1.34e-6	Fasting plasma glucose;
TGCT	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg08439880	chr3:133502540	NA	-0.34	-6.61	-0.51	1e-9	Iron status biomarkers;
TGCT	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg03517284	chr6:25882590	NA	-0.58	-6.03	-0.48	1.76e-8	Blood metabolite levels;
TGCT	cis	rs2871473	0.951	rs1030025	chr2:103105611	A/T	cg09003973	chr2:102972529	NA	0.64	4.52	0.38	1.4e-5	Blood protein levels;
TGCT	cis	rs4788439	0.901	rs72770496	chr16:24972913	G/A	cg07626409	chr16:25250191	ZKSCAN2	0.32	4.45	0.37	1.87e-5	Blood metabolite levels;
TGCT	cis	rs35883536	0.647	rs17402665	chr1:101046940	C/T	cg06223162	chr1:101003688	GPR88	-0.41	-7.64	-0.57	5.04e-12	Monocyte count;
TGCT	cis	rs10858047	0.883	rs11102827	chr1:115181843	C/T	cg12756093	chr1:115239321	AMPD1	-0.45	-4.73	-0.39	6.09e-6	Autism;
TGCT	cis	rs7666738	0.830	rs13113899	chr4:99050422	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.49	0.56	1.11e-11	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg21659725	chr3:3221576	CRBN	-0.73	-8.46	-0.6	6.37e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs453301	0.598	rs1025395	chr8:8836603	G/C	cg06636001	chr8:8085503	FLJ10661	0.83	7.46	0.56	1.33e-11	Joint mobility (Beighton score);
TGCT	cis	rs3749237	0.595	rs7643845	chr3:49530711	A/G	cg03060546	chr3:49711283	APEH	0.76	8.69	0.62	1.77e-14	Resting heart rate;
TGCT	trans	rs2469997	0.748	rs2470019	chr8:120362558	T/C	cg01792902	chr3:178864926	PIK3CA	0.83	6.77	0.52	4.49e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg21963583	chr11:68658836	MRPL21	0.37	6.15	0.48	9.57e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs8064299	0.967	rs878907	chr17:72769694	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.79	8.01	0.58	7.08e-13	Monocyte count;
TGCT	trans	rs17471911	0.708	rs12218280	chr10:100787262	G/C	cg03484267	chr2:207988651	KLF7	-0.52	-6.7	-0.52	6.49e-10	Neuroticism;
TGCT	cis	rs9325144	0.647	rs3759139	chr12:39087609	G/A	cg10518543	chr12:38710700	ALG10B	-0.49	-4.59	-0.38	1.05e-5	Morning vs. evening chronotype;
TGCT	cis	rs7659604	0.521	rs4833232	chr4:122684367	C/T	cg19748678	chr4:122722346	EXOSC9	-0.52	-5.27	-0.43	5.91e-7	Type 2 diabetes;
TGCT	cis	rs7027203	0.964	rs7854075	chr9:96571211	G/A	cg13679303	chr9:96623674	NA	0.67	9.97	0.67	1.47e-17	DNA methylation (variation);
TGCT	cis	rs6964587	1.000	rs13224513	chr7:91601465	G/A	cg22709100	chr7:91322751	NA	0.27	4.48	0.37	1.68e-5	Breast cancer;
TGCT	cis	rs6840360	0.554	rs13108359	chr4:152727852	T/C	cg22705602	chr4:152727874	NA	0.35	6.1	0.48	1.23e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9993613	0.875	rs1818655	chr4:73483204	C/T	cg15102770	chr4:73434591	ADAMTS3	0.52	4.89	0.4	3.12e-6	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs10207060	0.500	rs10177457	chr2:240708067	G/A	cg15726768	chr2:241314588	NA	-0.32	-4.49	-0.37	1.63e-5	Obesity-related traits;
TGCT	cis	rs9443645	0.901	rs2050659	chr6:79734369	A/C	cg09184832	chr6:79620586	NA	-0.48	-5.34	-0.43	4.21e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2228479	0.850	rs11646766	chr16:89838578	A/T	cg06558623	chr16:89946397	TCF25	0.45	4.52	0.38	1.42e-5	Skin colour saturation;
TGCT	cis	rs2204008	0.745	rs12146863	chr12:38502346	G/A	cg13010199	chr12:38710504	ALG10B	0.6	4.88	0.4	3.15e-6	Bladder cancer;
TGCT	cis	rs8070740	0.841	rs4790771	chr17:5324966	G/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.49	4.88	0.4	3.15e-6	Menopause (age at onset);
TGCT	cis	rs6076065	0.748	rs6076055	chr20:23333917	G/C	cg11657817	chr20:23433608	CST11	0.31	5.29	0.43	5.46e-7	Facial morphology (factor 15, philtrum width);
TGCT	cis	rs7089973	0.604	rs7914792	chr10:116591391	T/C	cg03647239	chr10:116582469	FAM160B1	0.59	5.75	0.46	6.46e-8	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs8077577	0.945	rs11871039	chr17:18078904	C/G	cg09161412	chr17:18057145	MYO15A	-0.66	-5.36	-0.43	3.94e-7	Obesity-related traits;
TGCT	cis	rs2594989	0.943	rs2595004	chr3:11406721	C/T	cg00170343	chr3:11313890	ATG7	0.67	5.08	0.42	1.35e-6	Circulating chemerin levels;
TGCT	cis	rs9467773	1.000	rs28558133	chr6:26531433	G/C	cg05738196	chr6:26577821	NA	0.88	12.5	0.75	1.03e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs9419702	0.526	rs9419637	chr10:133548059	T/C	cg20568497	chr10:133558893	NA	0.47	5.18	0.42	8.78e-7	Survival in rectal cancer;
TGCT	cis	rs12540874	0.794	rs1470750	chr7:50576648	C/G	cg18232548	chr7:50535776	DDC	-0.36	-6.11	-0.48	1.17e-8	Systemic sclerosis;
TGCT	cis	rs11690462	0.963	rs12471804	chr2:26559717	C/G	cg04726446	chr2:26624865	C2orf39	0.42	4.58	0.38	1.14e-5	Coronary artery disease;
TGCT	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg25036284	chr2:26402008	FAM59B	0.65	5.19	0.42	8.36e-7	Gut microbiome composition (summer);
TGCT	cis	rs10927875	0.722	rs1763606	chr1:16338282	A/G	cg22431228	chr1:16359049	CLCNKA	-0.26	-4.91	-0.4	2.79e-6	Dilated cardiomyopathy;
TGCT	cis	rs7829975	0.686	rs907180	chr8:8702827	A/G	cg15556689	chr8:8085844	FLJ10661	0.66	6.23	0.49	6.79e-9	Mood instability;
TGCT	cis	rs2180341	1.000	rs3798850	chr6:127613966	C/T	cg24812749	chr6:127587940	RNF146	0.99	7.72	0.57	3.33e-12	Breast cancer;
TGCT	cis	rs67478160	0.608	rs11160760	chr14:104248938	G/T	cg26031613	chr14:104095156	KLC1	-0.64	-6.57	-0.51	1.23e-9	Schizophrenia;
TGCT	cis	rs981844	0.735	rs17371573	chr4:154765216	G/A	cg14289246	chr4:154710475	SFRP2	1.01	8.9	0.62	5.78e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs17221829	0.733	rs12277139	chr11:89389606	G/A	cg02982614	chr11:89391479	FOLH1B	-0.25	-4.46	-0.37	1.8e-5	Anxiety in major depressive disorder;
TGCT	cis	rs904251	0.861	rs914349	chr6:37484715	A/C	cg01843034	chr6:37503916	NA	-0.5	-6.23	-0.49	6.73e-9	Cognitive performance;
TGCT	trans	rs7824557	0.547	rs2409749	chr8:11078949	G/A	cg15556689	chr8:8085844	FLJ10661	-0.85	-8.06	-0.59	5.56e-13	Retinal vascular caliber;
TGCT	trans	rs2727020	0.731	rs10450572	chr11:49281073	T/C	cg03929089	chr4:120376271	NA	0.73	8.48	0.61	5.75e-14	Coronary artery disease;
TGCT	cis	rs7584330	0.554	rs6740722	chr2:238393288	T/C	cg14458575	chr2:238380390	NA	0.58	5.05	0.41	1.53e-6	Prostate cancer;
TGCT	trans	rs877282	0.628	rs11253435	chr10:824169	T/C	cg22713356	chr15:30763199	NA	0.89	6.71	0.52	6.19e-10	Uric acid levels;
TGCT	cis	rs1008375	0.863	rs2058336	chr4:17608299	T/C	cg10189774	chr4:17578691	LAP3	0.57	4.9	0.4	2.93e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10504229	0.679	rs72649114	chr8:58037491	G/T	cg08280861	chr8:58055591	NA	0.35	5.07	0.41	1.43e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.67	-0.39	7.73e-6	Prudent dietary pattern;
TGCT	cis	rs2191566	0.664	rs62115477	chr19:44543027	T/G	cg03039196	chr19:44506973	ZNF230	0.53	4.47	0.37	1.78e-5	Acute lymphoblastic leukemia (childhood);
TGCT	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg21724239	chr8:58056113	NA	0.4	5.01	0.41	1.8e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9467773	1.000	rs1884946	chr6:26545308	C/G	cg15659132	chr6:26577336	NA	0.86	12.17	0.74	6.67e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs9653442	0.593	rs6542920	chr2:100845088	A/G	cg22139774	chr2:100720529	AFF3	-0.3	-4.52	-0.38	1.41e-5	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs9534288	0.699	rs2897028	chr13:46656915	C/T	cg15192986	chr13:46630673	CPB2	-0.53	-6.39	-0.5	3.01e-9	Blood protein levels;
TGCT	cis	rs78487399	0.808	rs12104615	chr2:43676938	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.24	-0.43	6.79e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs35306767	0.633	rs17221491	chr10:1065191	A/G	cg20503657	chr10:835505	NA	0.59	6.61	0.51	1.03e-9	Eosinophil percentage of granulocytes;
TGCT	cis	rs2180341	1.000	rs6569482	chr6:127631371	C/T	cg27446573	chr6:127587934	RNF146	1.12	10.11	0.67	6.87e-18	Breast cancer;
TGCT	cis	rs1729951	0.575	rs1654923	chr3:136692620	A/T	cg21827317	chr3:136751795	NA	0.4	5.61	0.45	1.28e-7	Neuroticism;
TGCT	cis	rs7973719	0.833	rs7970916	chr12:7357746	T/C	cg07052231	chr12:7363540	PEX5	0.37	5.74	0.46	6.97e-8	IgG glycosylation;
TGCT	cis	rs9611565	0.546	rs739132	chr22:42123099	A/T	cg17554472	chr22:41940697	POLR3H	0.47	5.04	0.41	1.63e-6	Vitiligo;
TGCT	cis	rs2227564	0.620	rs11000765	chr10:75512452	G/C	cg04320760	chr10:75533139	FUT11	-0.32	-4.55	-0.38	1.28e-5	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.12	0.54	7.78e-11	Prudent dietary pattern;
TGCT	cis	rs7833790	0.685	rs13255262	chr8:82728024	T/G	cg23324259	chr8:82754387	SNX16	-0.61	-4.71	-0.39	6.42e-6	Diastolic blood pressure;
TGCT	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.07	-13.45	-0.77	5.59e-26	Prudent dietary pattern;
TGCT	cis	rs17001868	0.568	rs2294350	chr22:40784278	C/T	cg07138101	chr22:40742427	ADSL	0.73	5.47	0.44	2.38e-7	Mammographic density (dense area);
TGCT	cis	rs858239	0.539	rs6945510	chr7:23192240	C/T	cg05602783	chr7:23145260	KLHL7	-0.62	-4.95	-0.41	2.37e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs9534288	0.797	rs992631	chr13:46591989	A/G	cg15192986	chr13:46630673	CPB2	0.5	7.16	0.54	6.27e-11	Blood protein levels;
TGCT	cis	rs7666738	0.719	rs35184673	chr4:99050945	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.57	0.38	1.16e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs77633900	0.614	rs280001	chr15:77003566	C/A	cg21673338	chr15:77095150	SCAPER	-0.53	-5.22	-0.42	7.33e-7	Non-glioblastoma glioma;Glioma;
TGCT	cis	rs735396	0.595	rs2258287	chr12:121454313	G/T	cg02403541	chr12:121454288	C12orf43	0.86	9.56	0.65	1.5e-16	N-glycan levels;
TGCT	cis	rs8050907	0.744	rs8055559	chr16:4540227	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.58	4.73	0.39	6.09e-6	Obesity-related traits;
TGCT	cis	rs4919694	1.000	rs17727391	chr10:104836101	C/A	cg04362960	chr10:104952993	NT5C2	1.07	7.2	0.54	5.11e-11	Arsenic metabolism;
TGCT	cis	rs8062405	1.000	rs62037367	chr16:28874547	C/G	cg09754948	chr16:28834200	ATXN2L	0.59	4.45	0.37	1.91e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs11690935	0.959	rs12692974	chr2:172663256	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.19	-12.78	-0.75	2.24e-24	Schizophrenia;
TGCT	cis	rs7833790	0.724	rs6473299	chr8:82676936	A/G	cg27398817	chr8:82754497	SNX16	-0.82	-5.97	-0.47	2.29e-8	Diastolic blood pressure;
TGCT	cis	rs727505	1.000	rs28844358	chr7:124562695	A/C	cg23710748	chr7:124431027	NA	-0.26	-4.49	-0.37	1.6e-5	Lewy body disease;
TGCT	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg02725872	chr8:58115012	NA	-0.38	-5.16	-0.42	9.32e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs3096299	0.509	rs4785691	chr16:89597221	A/G	cg06640241	chr16:89574553	SPG7	0.88	11.32	0.71	7.77e-21	Multiple myeloma (IgH translocation);
TGCT	cis	rs7216064	1.000	rs4791212	chr17:65975385	C/T	cg12091567	chr17:66097778	LOC651250	-0.8	-6.14	-0.48	1.02e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg13695892	chr22:41940480	POLR3H	-0.92	-9.08	-0.63	2.06e-15	Vitiligo;
TGCT	cis	rs11190604	1.000	rs57025426	chr10:102205868	A/G	cg23241863	chr10:102295624	HIF1AN	0.62	4.87	0.4	3.27e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9993613	0.778	rs962191	chr4:73419495	T/C	cg15102770	chr4:73434591	ADAMTS3	0.58	5.29	0.43	5.27e-7	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs2070488	0.775	rs7374458	chr3:38531211	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.76	7.41	0.55	1.72e-11	Electrocardiographic conduction measures;
TGCT	cis	rs3540	0.576	rs1974519	chr15:91036460	A/G	cg22089800	chr15:90895588	ZNF774	0.76	7.77	0.57	2.62e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs72781680	0.848	rs55725028	chr2:23966447	A/G	cg08917208	chr2:24149416	ATAD2B	0.95	6.09	0.48	1.28e-8	Lymphocyte counts;
TGCT	cis	rs72615157	0.595	rs112241539	chr7:99847237	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.69	5.32	0.43	4.67e-7	Lung function (FEV1/FVC);
TGCT	cis	rs2832077	0.506	rs2832088	chr21:30158620	G/A	cg24692254	chr21:30365293	RNF160	-0.61	-5.35	-0.43	4.03e-7	Cognitive test performance;
TGCT	cis	rs2075371	0.829	rs10954442	chr7:134007587	A/G	cg11752832	chr7:134001865	SLC35B4	-0.75	-6.83	-0.52	3.45e-10	Mean platelet volume;
TGCT	cis	rs3733585	0.699	rs4408959	chr4:9948868	C/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.48	-0.5	1.95e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	trans	rs1814175	0.645	rs847630	chr11:49926360	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.51	-0.69	7.2e-19	Height;
TGCT	trans	rs208520	0.690	rs1304672	chr6:66847973	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	9.45	0.65	2.74e-16	Exhaled nitric oxide output;
TGCT	cis	rs9467773	0.620	rs2504600	chr6:26648334	C/A	cg09904177	chr6:26538194	HMGN4	0.68	6.27	0.49	5.41e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs10089	0.904	rs2228112	chr5:127469859	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	7.53	0.56	9.3e-12	Ileal carcinoids;
TGCT	cis	rs887807	0.764	rs200556	chr9:123071678	C/G	cg14457452	chr9:123257038	CDK5RAP2	0.71	5.24	0.43	6.57e-7	Photic sneeze reflex;
TGCT	cis	rs4455778	0.659	rs34031293	chr7:49027864	G/C	cg26309511	chr7:48887640	NA	-0.44	-5.22	-0.42	7.26e-7	Lung cancer in never smokers;
TGCT	trans	rs1814175	0.647	rs10839394	chr11:49844747	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.35	-0.55	2.39e-11	Height;
TGCT	cis	rs7660520	0.524	rs114404677	chr4:183733832	G/A	cg04181038	chr4:183730758	NA	0.65	6.02	0.48	1.86e-8	Pediatric autoimmune diseases;
TGCT	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg07061783	chr6:25882402	NA	-0.56	-5.36	-0.43	3.95e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs314370	0.951	rs17881696	chr7:100493359	G/A	cg10426581	chr7:100472382	SRRT	1.0	10.93	0.7	6.98e-20	Resting heart rate;
TGCT	cis	rs2342371	0.848	rs13092653	chr3:196200188	C/T	cg15048948	chr3:196158458	UBXN7	-0.54	-4.66	-0.39	7.97e-6	Fat distribution (HIV);
TGCT	cis	rs7572733	0.534	rs1464209	chr2:198814396	A/G	cg00792783	chr2:198669748	PLCL1	0.57	5.23	0.43	6.99e-7	Dermatomyositis;
TGCT	cis	rs2075371	1.000	rs2544213	chr7:133982867	G/C	cg11752832	chr7:134001865	SLC35B4	0.69	6.32	0.49	4.19e-9	Mean platelet volume;
TGCT	cis	rs7267979	0.586	rs6050431	chr20:25183908	C/T	cg14121845	chr20:25566513	NINL	0.45	4.88	0.4	3.23e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7772486	0.754	rs6570708	chr6:145989428	C/T	cg13319975	chr6:146136371	FBXO30	0.57	5.2	0.42	8.12e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10791097	0.694	rs1054869	chr11:130742630	G/A	cg05962950	chr11:130786565	SNX19	0.92	11.55	0.72	2.13e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs6978712	0.929	rs56036294	chr7:127152275	C/T	cg01017541	chr7:127776461	NA	0.76	4.6	0.38	1.01e-5	Medication adherence in chronic diseases;
TGCT	cis	rs10851411	0.862	rs8033412	chr15:42822289	C/T	cg23803468	chr15:43513504	EPB42	0.29	5.38	0.43	3.6e-7	Glucose homeostasis traits;
TGCT	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg25036284	chr2:26402008	FAM59B	-0.55	-4.76	-0.39	5.33e-6	Gut microbiome composition (summer);
TGCT	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.61	-0.38	9.96e-6	Prudent dietary pattern;
TGCT	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.65	5.41	0.44	3.16e-7	Initial pursuit acceleration;
TGCT	cis	rs477895	1.000	rs7938380	chr11:64034866	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	5.32	0.43	4.6e-7	Mean platelet volume;
TGCT	cis	rs9902453	0.765	rs2628167	chr17:28064498	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.84	-8.39	-0.6	9.14e-14	Coffee consumption (cups per day);
TGCT	cis	rs1008375	0.966	rs6449313	chr4:17588320	A/G	cg18681998	chr4:17616180	MED28	0.87	8.54	0.61	4.02e-14	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7647973	1.000	rs7648995	chr3:49438803	C/T	cg07636037	chr3:49044803	WDR6	-0.72	-5.79	-0.46	5.35e-8	Menarche (age at onset);
TGCT	cis	rs10779751	0.762	rs3010222	chr1:11326922	T/C	cg08854313	chr1:11322531	MTOR	-0.84	-9.22	-0.64	9.84e-16	Body mass index;
TGCT	cis	rs7120118	0.517	rs3758674	chr11:47278938	T/C	cg13308137	chr11:47528955	CUGBP1	0.33	5.19	0.42	8.16e-7	HDL cholesterol;
TGCT	cis	rs56104184	0.775	rs56317021	chr19:49395960	C/T	cg17863274	chr19:49399704	TULP2	-0.54	-7.43	-0.55	1.58e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs651907	0.557	rs34181125	chr3:101490278	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.89	11.22	0.71	1.34e-20	Colorectal cancer;
TGCT	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg08219700	chr8:58056026	NA	0.3	4.53	0.38	1.35e-5	Developmental language disorder (linguistic errors);
TGCT	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg01341218	chr17:43662625	NA	-0.83	-7.46	-0.56	1.34e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs9818758	0.607	rs11719220	chr3:49245201	A/G	cg07636037	chr3:49044803	WDR6	-1.04	-5.13	-0.42	1.09e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs2404602	0.716	rs56216512	chr15:76686936	T/C	cg22467129	chr15:76604101	ETFA	-0.59	-7.11	-0.54	7.92e-11	Blood metabolite levels;
TGCT	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg12963246	chr6:28129442	ZNF389	0.51	5.02	0.41	1.73e-6	Depression;
TGCT	cis	rs8016982	0.674	rs11159494	chr14:81667611	G/C	cg01989461	chr14:81687754	GTF2A1	0.81	8.45	0.6	6.73e-14	Schizophrenia;
TGCT	cis	rs4523957	0.590	rs9899427	chr17:2063550	A/T	cg16513277	chr17:2031491	SMG6	-0.2	-4.64	-0.38	8.83e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs12477438	0.765	rs10193039	chr2:99692373	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.82	-8.08	-0.59	4.94e-13	Chronic sinus infection;
TGCT	cis	rs10206020	0.885	rs11886082	chr2:1576683	T/C	cg12573674	chr2:1569213	NA	-0.46	-5.28	-0.43	5.66e-7	IgG glycosylation;
TGCT	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg17971929	chr21:40555470	PSMG1	-0.67	-6.0	-0.47	1.99e-8	Cognitive function;
TGCT	cis	rs8078723	0.714	rs8070444	chr17:38151960	A/G	cg17467752	chr17:38218738	THRA	-0.53	-5.37	-0.43	3.8e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs12510870	0.599	rs1919469	chr4:74404245	G/A	cg05868023	chr4:75230803	EREG	0.56	5.14	0.42	1.06e-6	Iris color (b* coordinate);
TGCT	cis	rs921968	0.541	rs17572485	chr2:219296545	C/T	cg02176678	chr2:219576539	TTLL4	-0.46	-6.75	-0.52	5.03e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs2153535	0.580	rs9379222	chr6:8514788	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.55e-8	Motion sickness;
TGCT	cis	rs3784262	0.669	rs4646645	chr15:58245151	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.44	-6.3	-0.49	4.81e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs10984561	0.748	rs116158226	chr9:122248570	G/A	cg14242995	chr9:122249943	NA	0.75	6.12	0.48	1.16e-8	Pulmonary function decline;
TGCT	cis	rs72781680	0.821	rs116583405	chr2:24208221	T/C	cg08917208	chr2:24149416	ATAD2B	0.72	4.5	0.37	1.56e-5	Lymphocyte counts;
TGCT	cis	rs12815613	0.539	rs7300883	chr12:121459440	C/G	cg02403541	chr12:121454288	C12orf43	-0.58	-5.36	-0.43	3.94e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs6582630	0.539	rs4882324	chr12:38499180	T/C	cg26384229	chr12:38710491	ALG10B	-0.55	-4.91	-0.4	2.86e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs2204008	0.774	rs7959048	chr12:37948276	T/A	cg13010199	chr12:38710504	ALG10B	0.63	5.0	0.41	1.93e-6	Bladder cancer;
TGCT	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.64	0.51	8.85e-10	Bipolar disorder;
TGCT	cis	rs3020736	0.500	rs7292241	chr22:42492063	G/A	cg05082376	chr22:42548792	NA	0.23	5.43	0.44	2.85e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs11690935	0.959	rs3770451	chr2:172668715	T/G	cg13550731	chr2:172543902	DYNC1I2	-1.19	-12.78	-0.75	2.24e-24	Schizophrenia;
TGCT	cis	rs10789491	1.000	rs618505	chr1:47144532	T/C	cg15501359	chr1:47185051	KIAA0494	0.81	8.17	0.59	2.99e-13	Response to hepatitis C treatment;
TGCT	cis	rs10871290	0.650	rs3760055	chr16:74490529	G/A	cg01733217	chr16:74700730	RFWD3	0.58	4.46	0.37	1.8e-5	Breast cancer;
TGCT	cis	rs910187	0.572	rs6018325	chr20:45810335	A/G	cg27589058	chr20:45804311	EYA2	-0.38	-8.34	-0.6	1.18e-13	Migraine;
TGCT	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg23262073	chr20:60523788	NA	0.34	5.56	0.45	1.57e-7	Obesity-related traits;
TGCT	cis	rs263156	0.903	rs2077836	chr6:142922061	T/C	cg18419694	chr6:143832440	FUCA2	0.43	4.94	0.41	2.48e-6	Ear morphology;Lobe size;Lobe attachment;
TGCT	cis	rs858239	0.600	rs10235786	chr7:23139940	T/C	cg05602783	chr7:23145260	KLHL7	-0.66	-5.45	-0.44	2.57e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg16049864	chr8:95962084	TP53INP1	-0.75	-10.47	-0.69	9.05e-19	Type 2 diabetes;
TGCT	cis	rs595982	0.546	rs9941490	chr19:49396737	G/A	cg21252483	chr19:49399788	TULP2	-0.3	-5.05	-0.41	1.54e-6	Red cell distribution width;
TGCT	cis	rs933688	1.000	rs6452953	chr5:90723034	T/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.01	9.92	0.67	2e-17	Smoking behavior;
TGCT	cis	rs986417	0.818	rs7153263	chr14:61099261	G/A	cg27398547	chr14:60952738	C14orf39	1.44	10.1	0.67	7.17e-18	Gut microbiota (bacterial taxa);
TGCT	cis	rs1843834	0.898	rs2015099	chr2:225519915	T/C	cg22455342	chr2:225449267	CUL3	0.74	7.25	0.55	3.9e-11	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs739401	0.572	rs7111857	chr11:3068106	A/G	cg05729581	chr11:3078854	CARS	0.58	5.5	0.44	2.11e-7	Longevity;
TGCT	cis	rs2932538	0.922	rs6671645	chr1:113129128	A/G	cg22162597	chr1:113214053	CAPZA1	0.25	5.6	0.45	1.34e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs17376456	0.877	rs13173952	chr5:93307557	A/T	cg21475434	chr5:93447410	FAM172A	0.65	4.85	0.4	3.58e-6	Diabetic retinopathy;
TGCT	cis	rs881375	0.967	rs7046108	chr9:123660339	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.47	-5.18	-0.42	8.9e-7	Rheumatoid arthritis;
TGCT	cis	rs861020	0.563	rs61820640	chr1:210041297	G/T	cg05527609	chr1:210001259	C1orf107	-0.99	-7.56	-0.56	7.95e-12	Orofacial clefts;
TGCT	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg04234412	chr22:24373322	LOC391322	-0.9	-10.36	-0.68	1.73e-18	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9906944	0.933	rs35051752	chr17:47089908	G/A	cg20966754	chr17:47091339	IGF2BP1	-0.43	-4.95	-0.41	2.36e-6	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs4566357	0.615	rs12474622	chr2:227912793	A/G	cg11843606	chr2:227700838	RHBDD1	-0.55	-5.17	-0.42	8.9e-7	Coronary artery disease;
TGCT	cis	rs3820928	0.874	rs7605032	chr2:227847630	T/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-4.59	-0.38	1.05e-5	Pulmonary function;
TGCT	cis	rs7104764	0.879	rs6421986	chr11:221659	A/G	cg18336825	chr11:236787	PSMD13;SIRT3	1.05	10.74	0.69	2e-19	Menarche (age at onset);
TGCT	trans	rs8073060	0.586	rs225296	chr17:33924847	C/G	cg19694781	chr19:47549865	TMEM160	-0.61	-13.7	-0.78	1.39e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs12620999	0.941	rs62183344	chr2:237979165	T/C	cg23555395	chr2:238036564	NA	0.27	4.76	0.39	5.28e-6	Systemic lupus erythematosus;
TGCT	cis	rs523522	0.962	rs12371550	chr12:120987643	C/T	cg27279351	chr12:120934652	DYNLL1	0.76	6.59	0.51	1.15e-9	High light scatter reticulocyte count;
TGCT	cis	rs3820068	0.581	rs16851848	chr1:15927698	G/A	cg05660106	chr1:15850417	CASP9	0.84	8.28	0.6	1.63e-13	Systolic blood pressure;
TGCT	cis	rs36051895	0.632	rs12115301	chr9:5180548	A/G	cg02405213	chr9:5042618	JAK2	0.75	10.09	0.67	7.75e-18	Pediatric autoimmune diseases;
TGCT	cis	rs7829975	0.514	rs2945873	chr8:8260445	C/T	cg08975724	chr8:8085496	FLJ10661	0.58	5.03	0.41	1.65e-6	Mood instability;
TGCT	cis	rs524281	0.814	rs10896093	chr11:65958411	C/G	cg00563793	chr11:65837595	PACS1	0.52	4.5	0.37	1.55e-5	Electroencephalogram traits;
TGCT	cis	rs644799	0.648	rs1255181	chr11:95472148	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.5	4.8	0.4	4.53e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs372883	0.648	rs1153288	chr21:30686091	A/G	cg24692254	chr21:30365293	RNF160	0.53	5.16	0.42	9.57e-7	Pancreatic cancer;
TGCT	cis	rs8072100	0.790	rs6505048	chr17:45674998	G/A	cg10024583	chr17:45772800	TBKBP1	-0.43	-4.47	-0.37	1.76e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs4722166	0.630	rs4722168	chr7:22779002	G/A	cg26061582	chr7:22766209	IL6	0.58	7.41	0.55	1.66e-11	Lung cancer;
TGCT	trans	rs901683	0.702	rs78034568	chr10:46149580	G/C	cg03466342	chr12:52753899	KRT85	-0.58	-7.16	-0.54	6.39e-11	Red blood cell traits;Mean corpuscular volume;
TGCT	cis	rs6060960	0.537	rs75351461	chr20:30458612	C/T	cg06102403	chr20:30458708	TTLL9;DUSP15	0.43	5.12	0.42	1.16e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
TGCT	cis	rs2742417	1.000	rs2742447	chr3:45763977	C/T	cg04837898	chr3:45731254	SACM1L	-0.51	-5.38	-0.43	3.6e-7	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs2997447	0.706	rs55657303	chr1:26421012	A/G	cg03844060	chr1:26490628	NA	0.28	4.57	0.38	1.17e-5	QRS complex (12-leadsum);
TGCT	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg08439880	chr3:133502540	NA	-0.28	-5.15	-0.42	9.73e-7	Iron status biomarkers;
TGCT	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs921968	0.519	rs72966020	chr2:219642620	C/G	cg02176678	chr2:219576539	TTLL4	-0.48	-6.3	-0.49	4.75e-9	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg26338869	chr17:61819248	STRADA	-0.56	-5.11	-0.42	1.17e-6	Prudent dietary pattern;
TGCT	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg08509172	chr19:19383838	TM6SF2	-0.35	-4.6	-0.38	1.02e-5	Tonsillectomy;
TGCT	cis	rs11696501	0.739	rs6073784	chr20:44201931	T/A	cg11783356	chr20:44313418	WFDC10B	-0.33	-4.79	-0.4	4.67e-6	Brain structure;
TGCT	cis	rs7829975	0.511	rs2921028	chr8:8340477	T/C	cg08975724	chr8:8085496	FLJ10661	0.56	5.41	0.44	3.1e-7	Mood instability;
TGCT	cis	rs986417	0.606	rs7156375	chr14:61110627	G/A	cg27398547	chr14:60952738	C14orf39	1.45	9.82	0.66	3.5e-17	Gut microbiota (bacterial taxa);
TGCT	cis	rs7267979	0.816	rs443009	chr20:25499817	A/G	cg16686733	chr20:25566563	NINL	-0.47	-4.65	-0.39	8.28e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs739496	0.615	rs627308	chr12:112146555	A/C	cg10833066	chr12:111807467	FAM109A	-0.36	-5.06	-0.41	1.46e-6	Platelet count;
TGCT	cis	rs1075232	0.826	rs16956738	chr15:31736231	C/T	cg01030201	chr15:31746330	NA	1.0	5.29	0.43	5.44e-7	Survival in colorectal cancer (non-distant metastatic);
TGCT	cis	rs4949448	1.000	rs4949448	chr1:32062066	A/C	cg13919466	chr1:32135498	COL16A1	0.37	5.12	0.42	1.15e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4713118	0.662	rs9468276	chr6:28027688	A/C	cg12963246	chr6:28129442	ZNF389	0.45	4.55	0.38	1.27e-5	Parkinson's disease;
TGCT	cis	rs12220898	0.749	rs4838479	chr10:50476682	C/T	cg06072769	chr10:50146962	WDFY4	0.35	4.5	0.37	1.56e-5	Inflammatory biomarkers;
TGCT	cis	rs13064411	0.542	rs11537650	chr3:113222036	G/A	cg18753928	chr3:113234510	CCDC52	-0.56	-4.72	-0.39	6.3e-6	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg07424592	chr7:64974309	NA	1.27	7.28	0.55	3.29e-11	Diabetic kidney disease;
TGCT	cis	rs367615	0.918	rs10051855	chr5:108859958	G/A	cg17395555	chr5:108820864	NA	0.31	5.01	0.41	1.85e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	trans	rs10435719	0.834	rs11250176	chr8:11792816	A/G	cg15556689	chr8:8085844	FLJ10661	0.75	7.26	0.55	3.66e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs6901250	0.632	rs688961	chr6:117089080	A/T	cg12892004	chr6:117198278	RFX6	0.39	4.64	0.38	8.6e-6	C-reactive protein levels;
TGCT	cis	rs611744	0.870	rs596703	chr8:109160146	A/G	cg21045802	chr8:109455806	TTC35	-0.69	-6.06	-0.48	1.51e-8	Dupuytren's disease;
TGCT	cis	rs7267979	0.873	rs6037062	chr20:25202892	G/A	cg03522245	chr20:25566470	NINL	0.55	5.95	0.47	2.6e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1878931	0.535	rs10852706	chr16:3412582	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.73	6.0	0.47	2.01e-8	Body mass index (adult);
TGCT	cis	rs854765	0.547	rs8069811	chr17:17922280	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.79	8.41	0.6	8.09e-14	Total body bone mineral density;
TGCT	cis	rs7246657	0.943	rs10420754	chr19:37959372	C/G	cg18154014	chr19:37997991	ZNF793	0.73	5.38	0.44	3.53e-7	Coronary artery calcification;
TGCT	cis	rs12477438	0.501	rs12613624	chr2:99732741	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-7.25	-0.55	3.92e-11	Chronic sinus infection;
TGCT	cis	rs7772486	0.875	rs6934467	chr6:146410529	G/T	cg05347473	chr6:146136440	FBXO30	0.54	5.11	0.42	1.18e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs793571	0.669	rs28864995	chr15:58945671	T/G	cg05156742	chr15:59063176	FAM63B	0.51	4.77	0.39	5.04e-6	Schizophrenia;
TGCT	cis	rs7975161	0.630	rs4129598	chr12:104620638	T/C	cg25273343	chr12:104657179	TXNRD1	-0.42	-5.71	-0.46	7.85e-8	Toenail selenium levels;
TGCT	cis	rs17473412	0.784	rs114334621	chr5:122702574	G/T	cg15125798	chr5:122621645	NA	-0.57	-4.83	-0.4	3.88e-6	Total body bone mineral density;
TGCT	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg05896524	chr21:47604654	C21orf56	-0.43	-4.54	-0.38	1.31e-5	Testicular germ cell tumor;
TGCT	cis	rs28595532	1.000	rs114778020	chr4:119662584	C/A	cg14228332	chr4:119757509	SEC24D	1.06	5.75	0.46	6.55e-8	Cannabis dependence symptom count;
TGCT	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg11301795	chr4:187892539	NA	-0.34	-5.03	-0.41	1.68e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1034435	0.692	rs6008739	chr22:48892542	T/C	cg05992904	chr22:48892994	FAM19A5	-0.34	-4.65	-0.39	8.44e-6	Late-onset Alzheimer's disease;
TGCT	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg04772025	chr11:68637568	NA	0.59	6.61	0.51	1.04e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs11648796	0.759	rs12597195	chr16:769026	G/C	cg27144592	chr16:783916	NARFL	0.43	5.83	0.46	4.42e-8	Height;
TGCT	cis	rs35306767	0.903	rs12264711	chr10:929525	T/C	cg26597838	chr10:835615	NA	0.75	10.54	0.69	6.3e-19	Eosinophil percentage of granulocytes;
TGCT	cis	rs3796352	1.000	rs34943350	chr3:53012888	C/T	cg15956490	chr3:53032818	SFMBT1	0.62	6.82	0.52	3.6e-10	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs10927875	0.894	rs10927878	chr1:16319957	C/T	cg22431228	chr1:16359049	CLCNKA	0.23	4.44	0.37	1.94e-5	Dilated cardiomyopathy;
TGCT	cis	rs7617773	0.780	rs13084616	chr3:48339699	A/G	cg11946769	chr3:48343235	NME6	-0.83	-7.23	-0.54	4.25e-11	Coronary artery disease;
TGCT	cis	rs644799	0.965	rs11021305	chr11:95498269	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.82	8.45	0.6	6.69e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs10782582	0.632	rs77099976	chr1:76240524	T/C	cg10523679	chr1:76189770	ACADM	-0.53	-4.98	-0.41	2.04e-6	Daytime sleep phenotypes;
TGCT	trans	rs2688608	0.618	rs28718766	chr10:75489844	C/A	cg13918328	chr10:52500089	ASAH2B	0.68	6.73	0.52	5.68e-10	Inflammatory bowel disease;
TGCT	cis	rs35883536	0.626	rs11799819	chr1:101049382	G/A	cg10298815	chr1:101004474	GPR88	-0.25	-4.57	-0.38	1.17e-5	Monocyte count;
TGCT	cis	rs6964587	0.773	rs2097810	chr7:91977226	G/A	cg17063962	chr7:91808500	NA	0.83	8.18	0.59	2.83e-13	Breast cancer;
TGCT	cis	rs4689388	0.926	rs11725494	chr4:6293855	C/T	cg00701064	chr4:6280414	WFS1	0.44	5.74	0.46	6.95e-8	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs853679	0.546	rs200952	chr6:27836976	C/T	cg08798685	chr6:27730294	NA	-0.34	-4.69	-0.39	7.2e-6	Depression;
TGCT	trans	rs77457752	0.690	rs12335400	chr9:13912195	A/G	cg12973904	chr7:149457885	NA	0.46	7.07	0.54	9.92e-11	Breast cancer;
TGCT	cis	rs9300255	0.568	rs3018098	chr12:123654812	T/C	cg00376283	chr12:123451042	ABCB9	0.72	5.55	0.45	1.65e-7	Neutrophil percentage of white cells;
TGCT	cis	rs4862307	1.000	rs4493587	chr4:185000525	C/T	cg06737308	chr4:185021514	ENPP6	0.44	6.7	0.52	6.5e-10	Serum dimethylarginine levels (asymmetric/symetric ratio);
TGCT	cis	rs12142240	0.698	rs56344958	chr1:46814518	G/A	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs6545883	0.895	rs2256617	chr2:61679924	A/G	cg15711740	chr2:61764176	XPO1	-0.52	-4.74	-0.39	5.8e-6	Tuberculosis;
TGCT	cis	rs394563	0.559	rs7753269	chr6:149671360	G/A	cg16235748	chr6:149772707	ZC3H12D	0.44	5.06	0.41	1.47e-6	Dupuytren's disease;
TGCT	cis	rs10875746	0.556	rs4760619	chr12:48499931	A/T	cg20731937	chr12:48336164	NA	0.68	4.8	0.4	4.4e-6	Longevity (90 years and older);
TGCT	cis	rs12142240	0.698	rs56049453	chr1:46835468	A/G	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg22963979	chr7:1858916	MAD1L1	-0.41	-6.39	-0.5	3.02e-9	Bipolar disorder and schizophrenia;
TGCT	cis	rs1420338	0.933	rs10228731	chr7:34150782	G/T	cg01275685	chr7:34179230	BMPER	-0.27	-4.84	-0.4	3.82e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs67340775	0.541	rs169287	chr6:27854760	C/A	cg26587870	chr6:27730563	NA	-0.34	-4.62	-0.38	9.28e-6	Lung cancer in ever smokers;
TGCT	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.5	5.16	0.42	9.61e-7	Lymphocyte counts;
TGCT	cis	rs4409675	0.527	rs1884469	chr1:28239434	G/A	cg23691781	chr1:28212827	C1orf38	0.28	5.82	0.46	4.74e-8	Corneal astigmatism;
TGCT	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg25767906	chr1:53392781	SCP2	0.48	5.55	0.45	1.62e-7	Monocyte count;
TGCT	cis	rs1008375	0.932	rs964012	chr4:17619184	A/G	cg10189774	chr4:17578691	LAP3	0.64	5.47	0.44	2.42e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7017914	0.935	rs6472551	chr8:71781849	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.51	-4.68	-0.39	7.35e-6	Bone mineral density;
TGCT	cis	rs9467773	1.000	rs3736781	chr6:26505362	G/A	cg05738196	chr6:26577821	NA	0.88	12.49	0.75	1.09e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg00149659	chr3:10157352	C3orf10	0.73	4.72	0.39	6.17e-6	Alzheimer's disease;
TGCT	cis	rs2857078	0.627	rs1476512	chr17:42330122	C/T	cg13607699	chr17:42295918	UBTF	-0.6	-5.55	-0.45	1.68e-7	Red cell distribution width;Reticulocyte count;
TGCT	cis	rs12220898	0.833	rs3996895	chr10:50484365	G/A	cg06072769	chr10:50146962	WDFY4	0.38	5.07	0.41	1.38e-6	Inflammatory biomarkers;
TGCT	trans	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg17470723	chr8:74884337	TCEB1	0.71	6.77	0.52	4.48e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs595982	0.546	rs10401443	chr19:49402059	C/A	cg15549821	chr19:49342101	PLEKHA4	-0.39	-5.29	-0.43	5.24e-7	Red cell distribution width;
TGCT	cis	rs227917	1.000	rs6959005	chr7:23696342	G/C	cg12601843	chr7:23510954	IGF2BP3	0.56	4.49	0.37	1.6e-5	Common carotid intima-media thickness in HIV negative individuals;
TGCT	cis	rs9393692	0.905	rs1125000	chr6:26287256	C/T	cg00631329	chr6:26305371	NA	-0.41	-6.14	-0.48	1.01e-8	Educational attainment;
TGCT	cis	rs17376456	1.000	rs34756085	chr5:93556294	A/G	cg25358565	chr5:93447407	FAM172A	0.94	7.65	0.57	4.72e-12	Diabetic retinopathy;
TGCT	cis	rs2688608	0.836	rs2675668	chr10:75636148	G/A	cg04320760	chr10:75533139	FUT11	-0.31	-4.8	-0.4	4.49e-6	Inflammatory bowel disease;
TGCT	cis	rs751728	0.664	rs2395402	chr6:33753673	G/A	cg13859433	chr6:33739653	LEMD2	-0.32	-5.71	-0.46	7.84e-8	Crohn's disease;
TGCT	cis	rs11239930	1.000	rs11239930	chr1:146560564	C/T	cg00044796	chr1:146552390	NA	-0.32	-4.51	-0.38	1.5e-5	AIDS progression;
TGCT	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg11965913	chr1:205819406	PM20D1	-0.45	-4.44	-0.37	1.96e-5	Menarche (age at onset);
TGCT	trans	rs7824557	0.564	rs2572386	chr8:11236975	A/G	cg15556689	chr8:8085844	FLJ10661	-0.74	-6.68	-0.51	7.12e-10	Retinal vascular caliber;
TGCT	cis	rs7617480	0.648	rs7653408	chr3:48972351	A/C	cg07636037	chr3:49044803	WDR6	0.8	6.66	0.51	8.03e-10	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs10256972	0.642	rs6961424	chr7:1004113	T/C	cg07930192	chr7:1003750	NA	0.3	4.66	0.39	8.07e-6	Longevity;Endometriosis;
TGCT	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg03188948	chr7:1209495	NA	0.59	4.82	0.4	4.06e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7312933	0.703	rs1059360	chr12:42554505	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	5.06	0.41	1.45e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs2046867	0.862	rs67961837	chr3:72840877	T/G	cg25664220	chr3:72788482	NA	-0.56	-7.01	-0.53	1.34e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg13695892	chr22:41940480	POLR3H	-0.9	-9.03	-0.63	2.7e-15	Vitiligo;
TGCT	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg23708337	chr7:1209742	NA	0.51	4.46	0.37	1.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg25036284	chr2:26402008	FAM59B	-0.61	-4.93	-0.4	2.59e-6	Gut microbiome composition (summer);
TGCT	cis	rs2836974	0.583	rs2776306	chr21:40713754	A/G	cg11644478	chr21:40555479	PSMG1	0.64	6.22	0.49	7.07e-9	Cognitive function;
TGCT	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg23574427	chr4:122746245	BBS7;CCNA2	-0.34	-5.26	-0.43	6.07e-7	Type 2 diabetes;
TGCT	cis	rs12368653	0.525	rs1564374	chr12:58010163	C/T	cg00700412	chr12:58011837	NA	0.23	4.57	0.38	1.16e-5	Multiple sclerosis;
TGCT	cis	rs67478160	0.643	rs876002	chr14:104239697	G/A	cg26031613	chr14:104095156	KLC1	-0.63	-6.57	-0.51	1.25e-9	Schizophrenia;
TGCT	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg06634786	chr22:41940651	POLR3H	-0.88	-8.54	-0.61	3.98e-14	Vitiligo;
TGCT	cis	rs9457247	0.534	rs2345568	chr6:167381804	A/G	cg23791538	chr6:167370224	RNASET2	0.65	6.48	0.5	1.96e-9	Crohn's disease;
TGCT	cis	rs6840360	0.642	rs6851814	chr4:152346437	G/A	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.41	-0.5	2.81e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs28728124	chr4:99001116	G/T	cg05340658	chr4:99064831	C4orf37	0.46	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs56104184	0.723	rs73063522	chr19:49408358	C/G	cg15549821	chr19:49342101	PLEKHA4	-0.73	-9.15	-0.63	1.47e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs2769264	1.000	rs6684085	chr1:151357333	C/T	cg18801370	chr1:151430492	POGZ	-0.56	-5.84	-0.46	4.33e-8	Blood trace element (Cu levels);
TGCT	cis	rs9560113	1.000	rs9555807	chr13:112179965	C/T	cg14154082	chr13:112174009	NA	0.37	5.07	0.41	1.42e-6	Menarche (age at onset);
TGCT	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg10862848	chr6:42927986	GNMT	-0.38	-4.67	-0.39	7.65e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg24060327	chr5:131705240	SLC22A5	-0.65	-6.57	-0.51	1.26e-9	Acylcarnitine levels;
TGCT	cis	rs9467711	0.659	rs35304979	chr6:26356347	C/A	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs595982	0.510	rs3826817	chr19:49401444	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.39	-5.29	-0.43	5.24e-7	Red cell distribution width;
TGCT	cis	rs453301	0.658	rs12114954	chr8:8904862	T/G	cg15556689	chr8:8085844	FLJ10661	-0.67	-5.46	-0.44	2.51e-7	Joint mobility (Beighton score);
TGCT	cis	rs1723838	0.826	rs17244671	chr11:73574422	A/C	cg18195628	chr11:73498948	MRPL48	0.94	4.49	0.37	1.6e-5	Obesity-related traits;
TGCT	cis	rs7611238	0.560	rs7616598	chr3:195110186	G/A	cg27323046	chr3:195102265	ACAP2	0.37	4.93	0.4	2.56e-6	Body mass index;
TGCT	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg04155289	chr7:94953770	PON1	-0.37	-6.34	-0.49	3.86e-9	Paraoxonase activity;
TGCT	cis	rs42648	0.869	rs1015404	chr7:89913946	G/C	cg25739043	chr7:89950458	NA	-0.73	-7.31	-0.55	2.87e-11	Homocysteine levels;
TGCT	cis	rs2974760	0.606	rs2858918	chr16:201183	T/C	cg08400316	chr16:204221	HBZ	0.67	6.33	0.49	4.03e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs7044106	0.762	rs1324473	chr9:123404610	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.62	-6.69	-0.52	6.69e-10	Hip circumference adjusted for BMI;
TGCT	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg22920501	chr2:26401640	FAM59B	0.83	5.42	0.44	3.04e-7	Gut microbiome composition (summer);
TGCT	cis	rs782590	0.967	rs782586	chr2:55836165	A/C	cg18811423	chr2:55921094	PNPT1	0.65	6.88	0.53	2.6e-10	Metabolic syndrome;
TGCT	cis	rs79349575	0.783	rs12601955	chr17:47034420	C/T	cg26022315	chr17:47021804	SNF8	0.47	4.61	0.38	9.94e-6	Type 2 diabetes;
TGCT	cis	rs1577917	1.000	rs6940458	chr6:86644992	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.22	-0.42	7.27e-7	Response to antipsychotic treatment;
TGCT	cis	rs4819052	0.851	rs7279182	chr21:46656112	G/A	cg06618935	chr21:46677482	NA	-0.36	-5.48	-0.44	2.23e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.57	-5.67	-0.45	9.59e-8	Electroencephalogram traits;
TGCT	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg20203395	chr5:56204925	C5orf35	-0.59	-5.12	-0.42	1.12e-6	Initial pursuit acceleration;
TGCT	cis	rs2997447	0.761	rs61776575	chr1:26429844	G/A	cg03844060	chr1:26490628	NA	0.28	4.6	0.38	1.02e-5	QRS complex (12-leadsum);
TGCT	cis	rs7010267	0.596	rs7013203	chr8:120017159	C/T	cg17171407	chr8:119960777	TNFRSF11B	-0.26	-4.59	-0.38	1.06e-5	Total body bone mineral density (age 45-60);
TGCT	cis	rs1997103	1.000	rs6593233	chr7:55406200	C/T	cg17469321	chr7:55412551	NA	-0.63	-6.39	-0.5	3.09e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg04944784	chr2:26401820	FAM59B	-0.78	-6.56	-0.51	1.34e-9	Gut microbiome composition (summer);
TGCT	trans	rs10506458	1.000	rs10506458	chr12:63445092	G/A	cg22491629	chr6:157744540	C6orf35	-0.96	-8.34	-0.6	1.21e-13	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs17826219	0.706	rs57698184	chr17:29064918	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	4.87	0.4	3.36e-6	Body mass index;
TGCT	cis	rs9926296	0.682	rs645019	chr16:89716883	C/T	cg01097406	chr16:89675127	NA	0.36	6.24	0.49	6.21e-9	Vitiligo;
TGCT	cis	rs7659604	0.592	rs56077950	chr4:122721412	C/T	cg19748678	chr4:122722346	EXOSC9	0.94	9.89	0.66	2.3e-17	Type 2 diabetes;
TGCT	cis	rs73198271	0.855	rs57301822	chr8:8608642	C/T	cg06671706	chr8:8559999	CLDN23	-0.37	-4.67	-0.39	7.55e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs2832191	0.550	rs66484040	chr21:30511691	G/A	cg24692254	chr21:30365293	RNF160	-0.61	-5.41	-0.44	3.08e-7	Dental caries;
TGCT	cis	rs10992471	0.533	rs331377	chr9:95243549	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.58	-5.76	-0.46	6.34e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1525293	0.659	rs4719054	chr7:70517130	C/T	cg21135135	chr7:70597687	WBSCR17	0.49	4.61	0.38	9.91e-6	Colonoscopy-negative controls vs population controls;Major depressive disorder;
TGCT	cis	rs13191362	0.810	rs13200053	chr6:163011443	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs9900497	0.504	rs2228100	chr17:19642952	C/G	cg22552966	chr17:19620595	SLC47A2	0.2	5.21	0.42	7.56e-7	Response to paliperidone in schizophrenia (CGI-S score);
TGCT	cis	rs10131894	0.575	rs1860935	chr14:75432464	G/A	cg06637938	chr14:75390232	RPS6KL1	0.56	4.9	0.4	2.96e-6	Coronary artery disease;
TGCT	cis	rs651907	0.557	rs1031710	chr3:101463895	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.87	10.21	0.68	3.89e-18	Colorectal cancer;
TGCT	trans	rs4819388	0.915	rs4818892	chr21:45650085	A/G	cg17383793	chr5:52405638	MOCS2	0.67	6.74	0.52	5.21e-10	Celiac disease;
TGCT	cis	rs8070624	0.549	rs60073596	chr17:17870974	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.74	7.28	0.55	3.28e-11	Total body bone mineral density;
TGCT	cis	rs9394841	0.620	rs9462746	chr6:41816279	T/A	cg08135965	chr6:41755394	TOMM6	0.51	4.71	0.39	6.65e-6	Mean corpuscular hemoglobin;Red cell distribution width;
TGCT	cis	rs8032315	0.965	rs7497304	chr15:91429176	G/T	cg03209642	chr15:91427605	FES	0.52	4.96	0.41	2.23e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1005277	0.505	rs200931	chr10:38128434	A/C	cg13531842	chr10:38383804	ZNF37A	-0.39	-4.54	-0.38	1.3e-5	Extrinsic epigenetic age acceleration;
TGCT	trans	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg23505145	chr19:12996616	KLF1	0.79	8.07	0.59	5.16e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.69	-0.39	7e-6	Prudent dietary pattern;
TGCT	cis	rs12039431	0.666	rs215207	chr1:37952524	C/A	cg17933807	chr1:38061675	GNL2	-0.76	-7.21	-0.54	4.81e-11	Epithelial ovarian cancer;
TGCT	cis	rs9911578	1.000	rs1267545	chr17:56646909	A/G	cg12560992	chr17:57184187	TRIM37	0.76	9.34	0.64	4.88e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs174479	0.677	rs174456	chr11:61656182	G/T	cg19610905	chr11:61596333	FADS2	0.55	4.7	0.39	6.94e-6	Sphingolipid levels;
TGCT	cis	rs7666738	0.830	rs2865990	chr4:99067399	C/A	cg05340658	chr4:99064831	C4orf37	0.52	5.79	0.46	5.32e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6912958	0.559	rs499373	chr6:88042062	A/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.7	7.16	0.54	6.1e-11	Monocyte percentage of white cells;
TGCT	cis	rs9486719	1.000	rs12207570	chr6:96987884	A/C	cg06623918	chr6:96969491	KIAA0776	-0.96	-8.5	-0.61	5.01e-14	Migraine;Coronary artery disease;
TGCT	cis	rs7818688	0.697	rs11781757	chr8:95987891	A/T	cg16049864	chr8:95962084	TP53INP1	0.54	4.64	0.38	8.87e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs6456156	0.565	rs6921588	chr6:167494397	G/T	cg07741184	chr6:167504864	NA	0.23	4.66	0.39	7.93e-6	Primary biliary cholangitis;
TGCT	cis	rs4509693	0.943	rs6584395	chr10:102498008	G/C	cg24127310	chr10:102502104	NA	0.7	5.86	0.47	3.84e-8	Alzheimer's disease;
TGCT	cis	rs2060793	0.741	rs7119073	chr11:14690962	G/A	cg00085434	chr11:14927489	NA	0.34	4.67	0.39	7.64e-6	Vitamin D levels;
TGCT	cis	rs1971762	0.730	rs7963016	chr12:54072819	T/A	cg16917193	chr12:54089295	NA	0.6	4.81	0.4	4.22e-6	Height;
TGCT	cis	rs7511006	0.895	rs5771270	chr22:50682865	G/A	cg16473166	chr22:50639996	SELO	0.63	6.17	0.48	8.91e-9	Obesity-related traits;
TGCT	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg03188948	chr7:1209495	NA	0.42	5.5	0.44	2.08e-7	Longevity;Endometriosis;
TGCT	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs1577917	0.958	rs9647601	chr6:86449827	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.4	-0.44	3.28e-7	Response to antipsychotic treatment;
TGCT	cis	rs1941023	0.584	rs2233253	chr11:60157166	C/T	cg08716584	chr11:60157161	MS4A7	-0.35	-5.29	-0.43	5.3e-7	Congenital heart disease (maternal effect);
TGCT	cis	rs3733631	1.000	rs1482582	chr4:104651553	A/C	cg24090629	chr4:104641072	TACR3	-0.77	-6.29	-0.49	4.9e-9	Menarche (age at onset);
TGCT	cis	rs9926296	0.581	rs1108064	chr16:89894150	G/C	cg01719998	chr16:89642051	CPNE7	-0.47	-4.66	-0.39	7.91e-6	Vitiligo;
TGCT	cis	rs62244186	0.659	rs62251383	chr3:44552421	A/G	cg04389838	chr3:44770851	ZNF501	-0.41	-5.58	-0.45	1.42e-7	Depressive symptoms;
TGCT	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg24846343	chr22:24311635	DDTL	-0.23	-5.85	-0.46	4.19e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs854765	0.547	rs4643387	chr17:17972973	C/T	cg04398451	chr17:18023971	MYO15A	-0.31	-4.91	-0.4	2.83e-6	Total body bone mineral density;
TGCT	cis	rs858239	0.600	rs6967419	chr7:23136310	C/T	cg05602783	chr7:23145260	KLHL7	-0.6	-4.99	-0.41	2.02e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs7666738	0.830	rs13110903	chr4:98946373	A/G	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10056811	0.538	rs4703645	chr5:74361140	A/G	cg19683494	chr5:74908142	NA	0.62	5.05	0.41	1.52e-6	Coronary artery disease;
TGCT	cis	rs7917772	0.582	rs7922780	chr10:104401203	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-5.26	-0.43	6.16e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs921968	0.613	rs2303566	chr2:219557738	C/T	cg02176678	chr2:219576539	TTLL4	-0.33	-4.46	-0.37	1.81e-5	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs1783925	1.000	rs1615640	chr11:125308076	C/G	cg03464685	chr11:125439445	EI24	0.64	5.38	0.44	3.5e-7	Formal thought disorder in schizophrenia;
TGCT	trans	rs208515	0.525	rs10755508	chr6:66675790	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.92	10.09	0.67	7.45e-18	Exhaled nitric oxide levels;
TGCT	cis	rs600231	0.665	rs2846861	chr11:65222305	A/G	cg11802864	chr11:65308245	LTBP3	0.45	4.64	0.38	8.62e-6	Bone mineral density;
TGCT	trans	rs1496653	0.557	rs34758087	chr3:23407872	C/T	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs2688608	0.592	rs10762563	chr10:75524802	C/A	cg04320760	chr10:75533139	FUT11	-0.38	-5.99	-0.47	2.06e-8	Inflammatory bowel disease;
TGCT	cis	rs7523273	0.606	rs2796262	chr1:207915180	G/A	cg22525895	chr1:207977042	MIR29B2	0.56	9.36	0.64	4.46e-16	Schizophrenia;
TGCT	cis	rs433598	0.734	rs163276	chr16:20671546	C/T	cg08248577	chr16:19727447	IQCK;C16orf88	-0.22	-5.05	-0.41	1.52e-6	Schizophrenia;
TGCT	cis	rs17601876	0.807	rs10519299	chr15:51551346	C/G	cg19946085	chr15:51559439	CYP19A1	-0.32	-4.81	-0.4	4.33e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg25767906	chr1:53392781	SCP2	0.48	5.55	0.45	1.62e-7	Monocyte count;
TGCT	cis	rs1667284	0.967	rs895888	chr18:29228187	A/G	cg15259973	chr18:29078565	DSG2	0.52	5.0	0.41	1.91e-6	Problematic alcohol use in trauma-exposed individuals;
TGCT	cis	rs11105298	0.891	rs11105309	chr12:89909850	T/C	cg00757033	chr12:89920650	WDR51B	0.34	5.37	0.43	3.75e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs6570726	0.577	rs9497315	chr6:145791967	C/T	cg05347473	chr6:146136440	FBXO30	-0.62	-5.75	-0.46	6.64e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs611744	0.647	rs864166	chr8:109249300	C/G	cg21045802	chr8:109455806	TTC35	0.72	7.28	0.55	3.32e-11	Dupuytren's disease;
TGCT	cis	rs10782582	0.522	rs12125933	chr1:76130920	C/T	cg03433033	chr1:76189801	ACADM	-0.64	-7.32	-0.55	2.78e-11	Daytime sleep phenotypes;
TGCT	cis	rs7647973	0.560	rs7638154	chr3:49299375	C/A	cg05785598	chr3:49045655	WDR6	0.36	4.78	0.39	4.78e-6	Menarche (age at onset);
TGCT	cis	rs2594989	0.790	rs2454491	chr3:11514290	A/G	cg00170343	chr3:11313890	ATG7	0.66	5.16	0.42	9.52e-7	Circulating chemerin levels;
TGCT	cis	rs3091242	1.000	rs3091242	chr1:25674785	C/T	cg23205692	chr1:25664452	TMEM50A	0.53	5.46	0.44	2.5e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs910316	1.000	rs4903275	chr14:75512509	C/T	cg23033748	chr14:75592666	NEK9	0.28	4.68	0.39	7.32e-6	Height;
TGCT	cis	rs7809950	0.817	rs2712195	chr7:107127496	C/T	cg23024343	chr7:107201750	COG5	-0.46	-6.9	-0.53	2.4e-10	Coronary artery disease;
TGCT	cis	rs2762353	0.574	rs4409177	chr6:25694491	T/G	cg03264133	chr6:25882463	NA	0.9	9.01	0.63	3.08e-15	Blood metabolite levels;
TGCT	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg27286337	chr10:134555280	INPP5A	0.41	4.9	0.4	2.97e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs7100689	0.646	rs7092237	chr10:82165640	A/G	cg01528321	chr10:82214614	TSPAN14	0.72	7.8	0.57	2.13e-12	Post bronchodilator FEV1;
TGCT	cis	rs950169	0.541	rs10795	chr15:85177297	G/A	cg11189052	chr15:85197271	WDR73	0.73	6.01	0.47	1.96e-8	Schizophrenia;
TGCT	cis	rs7666738	0.791	rs7678564	chr4:99057341	A/G	cg05340658	chr4:99064831	C4orf37	0.52	5.79	0.46	5.32e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs208520	0.874	rs208512	chr6:66943869	C/G	cg07460842	chr6:66804631	NA	-0.9	-9.15	-0.63	1.45e-15	Exhaled nitric oxide output;
TGCT	cis	rs1042058	0.565	rs2480297	chr10:30754512	A/G	cg13289132	chr10:30722225	MAP3K8	-0.41	-4.86	-0.4	3.54e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
TGCT	cis	rs7647973	0.588	rs62262675	chr3:49673662	A/G	cg05785598	chr3:49045655	WDR6	-0.44	-5.19	-0.42	8.17e-7	Menarche (age at onset);
TGCT	cis	rs9517320	0.515	rs4771307	chr13:99221879	A/G	cg07423050	chr13:99094983	FARP1	-0.23	-4.5	-0.37	1.53e-5	Longevity;
TGCT	cis	rs6835098	0.924	rs13125240	chr4:174151619	T/C	cg08422745	chr4:174089978	GALNT7	0.9	10.24	0.68	3.33e-18	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs2153535	0.580	rs4960412	chr6:8438261	G/C	cg07606381	chr6:8435919	SLC35B3	0.57	5.25	0.43	6.46e-7	Motion sickness;
TGCT	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.44	4.95	0.41	2.33e-6	Lymphocyte counts;
TGCT	cis	rs35306767	0.761	rs11253537	chr10:1010735	G/A	cg26597838	chr10:835615	NA	0.57	6.42	0.5	2.6e-9	Eosinophil percentage of granulocytes;
TGCT	cis	rs9653442	0.545	rs4850921	chr2:100762699	G/T	cg07810366	chr2:100720526	AFF3	-0.38	-5.5	-0.44	2.04e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.99	-7.36	-0.55	2.25e-11	Gut microbiome composition (summer);
TGCT	cis	rs2204008	0.605	rs4608149	chr12:38132057	G/C	cg26384229	chr12:38710491	ALG10B	0.86	7.65	0.57	4.87e-12	Bladder cancer;
TGCT	cis	rs12477438	0.501	rs13033012	chr2:99795149	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.75	7.25	0.55	3.92e-11	Chronic sinus infection;
TGCT	cis	rs796364	0.616	rs7574313	chr2:200681040	C/G	cg17644776	chr2:200775616	C2orf69	0.35	4.96	0.41	2.29e-6	Schizophrenia;
TGCT	cis	rs7412746	0.658	rs6677420	chr1:150946490	G/A	cg04414720	chr1:150670196	GOLPH3L	0.38	4.54	0.38	1.3e-5	Melanoma;
TGCT	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg01802117	chr1:53393560	SCP2	0.44	5.43	0.44	2.87e-7	Monocyte count;
TGCT	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg11890956	chr21:40555474	PSMG1	1.1	12.28	0.74	3.66e-23	Cognitive function;
TGCT	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg21171335	chr12:122356390	WDR66	0.6	6.57	0.51	1.22e-9	Mean corpuscular volume;
TGCT	cis	rs7647973	0.925	rs6808036	chr3:49236439	T/G	cg07636037	chr3:49044803	WDR6	0.63	5.09	0.42	1.27e-6	Menarche (age at onset);
TGCT	cis	rs1971762	0.527	rs6580950	chr12:53926656	T/A	cg16917193	chr12:54089295	NA	1.02	10.39	0.68	1.44e-18	Height;
TGCT	cis	rs13102973	0.932	rs13112935	chr4:135829379	T/C	cg14419869	chr4:135874104	NA	0.24	4.52	0.38	1.4e-5	Subjective well-being;
TGCT	cis	rs6463523	0.898	rs66892628	chr7:759374	T/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.74	10.68	0.69	2.83e-19	Subjective well-being;
TGCT	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg22105103	chr4:187893119	NA	-0.35	-5.03	-0.41	1.66e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6725041	0.547	rs6753945	chr2:213204574	T/C	cg20637307	chr2:213403960	ERBB4	-0.53	-4.5	-0.37	1.52e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs12142240	0.660	rs72885163	chr1:46807117	C/A	cg00530320	chr1:46809349	NSUN4	0.29	5.88	0.47	3.63e-8	Menopause (age at onset);
TGCT	cis	rs6940116	1	rs6940116	chr6:27708732	A/G	cg10876282	chr6:28092338	ZSCAN16	0.65	4.92	0.4	2.71e-6	Intelligence (multi-trait analysis);Autism spectrum disorder or schizophrenia;
TGCT	cis	rs17108533	0.588	rs12886355	chr14:71301165	C/T	cg23900759	chr14:71108106	TTC9	-1.14	-4.61	-0.38	9.92e-6	Response to antipsychotic treatment in schizophrenia (reasoning);
TGCT	cis	rs1153858	1.000	rs11852800	chr15:45639131	A/G	cg26924012	chr15:45694286	SPATA5L1	-1.08	-14.12	-0.79	1.39e-27	Homoarginine levels;
TGCT	cis	rs1372520	0.684	rs2737030	chr4:90710099	C/T	cg14346243	chr4:90757452	SNCA	-0.65	-5.57	-0.45	1.48e-7	Neuroticism;
TGCT	cis	rs12497850	0.931	rs28642807	chr3:48926816	A/G	cg05785598	chr3:49045655	WDR6	0.36	4.75	0.39	5.46e-6	Parkinson's disease;
TGCT	cis	rs7666738	0.830	rs13140676	chr4:98804978	C/T	cg17366294	chr4:99064904	C4orf37	0.65	6.79	0.52	4.13e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4242434	0.597	rs11985023	chr8:22531463	C/T	cg21658235	chr8:22456391	C8orf58	-0.46	-4.81	-0.4	4.37e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs13256369	0.951	rs13270852	chr8:8566853	A/G	cg17143192	chr8:8559678	CLDN23	0.58	5.55	0.45	1.64e-7	Obesity-related traits;
TGCT	cis	rs67072384	1.000	rs2365441	chr11:72450226	T/C	cg03713592	chr11:72463424	ARAP1	-0.93	-4.66	-0.39	7.89e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg20573242	chr4:122745356	CCNA2	0.55	4.94	0.41	2.49e-6	Type 2 diabetes;
TGCT	cis	rs6964587	1.000	rs6960867	chr7:91712698	A/G	cg17063962	chr7:91808500	NA	0.86	9.13	0.63	1.62e-15	Breast cancer;
TGCT	cis	rs1865760	0.713	rs6928951	chr6:25995554	C/T	cg17042849	chr6:26104293	HIST1H4C	-0.55	-4.8	-0.4	4.4e-6	Height;
TGCT	cis	rs6690583	0.623	rs12033900	chr1:85478559	T/C	cg20280350	chr1:85513789	MCOLN3	-0.71	-4.68	-0.39	7.31e-6	Serum sulfate level;
TGCT	cis	rs11754661	1.000	rs11755145	chr6:151207249	G/A	cg01354656	chr6:151411710	MTHFD1L	0.48	4.46	0.37	1.81e-5	Alzheimer's disease (late onset);
TGCT	cis	rs2180341	0.597	rs3798859	chr6:127663116	C/T	cg27446573	chr6:127587934	RNF146	0.66	5.9	0.47	3.23e-8	Breast cancer;
TGCT	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	7.02	0.53	1.29e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs12142240	0.621	rs66828173	chr1:46818166	G/A	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs3935685	0.845	rs7175083	chr15:78006842	T/C	cg25212270	chr15:78015279	NA	0.26	5.45	0.44	2.63e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg06028605	chr16:24865363	SLC5A11	0.41	4.58	0.38	1.13e-5	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg10876282	chr6:28092338	ZSCAN16	0.49	4.53	0.38	1.37e-5	Cardiac Troponin-T levels;
TGCT	cis	rs4455778	0.580	rs7796581	chr7:49124966	C/T	cg26309511	chr7:48887640	NA	0.51	6.62	0.51	9.97e-10	Lung cancer in never smokers;
TGCT	cis	rs7914558	0.966	rs7096269	chr10:104736721	A/G	cg15744005	chr10:104629667	AS3MT	-0.4	-4.97	-0.41	2.21e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs7698623	0.850	rs4693194	chr4:88798005	T/C	cg27387453	chr4:88533842	DSPP	-0.61	-4.6	-0.38	1.03e-5	Cardiovascular disease risk factors;
TGCT	cis	rs9859260	0.555	rs9877493	chr3:195832147	T/C	cg06252355	chr3:195477915	MUC4	-0.2	-4.53	-0.38	1.34e-5	Mean corpuscular volume;
TGCT	cis	rs9467711	0.606	rs9379854	chr6:26362854	T/C	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs3770081	1.000	rs12328085	chr2:86262009	G/A	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.18	-4.81	-0.4	4.33e-6	Facial emotion recognition (sad faces);
TGCT	cis	rs7959452	0.640	rs10878957	chr12:69699638	G/C	cg20891283	chr12:69753455	YEATS4	0.66	6.57	0.51	1.24e-9	Blood protein levels;
TGCT	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.96	-8.31	-0.6	1.43e-13	Platelet count;
TGCT	cis	rs1420338	0.967	rs1014581	chr7:34164677	T/G	cg01275685	chr7:34179230	BMPER	-0.26	-4.87	-0.4	3.28e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg03188948	chr7:1209495	NA	0.55	4.56	0.38	1.2e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs595982	0.527	rs56021835	chr19:49369989	G/A	cg17863274	chr19:49399704	TULP2	-0.47	-6.78	-0.52	4.43e-10	Red cell distribution width;
TGCT	cis	rs651907	0.535	rs11714444	chr3:101513682	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	4.85	0.4	3.68e-6	Colorectal cancer;
TGCT	cis	rs694739	0.536	rs11231740	chr11:64046641	C/T	cg02228329	chr11:64053129	BAD;GPR137	-0.57	-5.11	-0.42	1.2e-6	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs36051895	0.697	rs11788790	chr9:5092263	G/T	cg02405213	chr9:5042618	JAK2	-0.72	-9.52	-0.65	1.85e-16	Pediatric autoimmune diseases;
TGCT	cis	rs3806843	0.551	rs184996	chr5:140323773	T/A	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9913156	0.793	rs72835644	chr17:4573667	G/A	cg23387401	chr17:4582204	PELP1	0.32	4.7	0.39	6.8e-6	Lymphocyte counts;
TGCT	cis	rs9325144	0.671	rs7486919	chr12:38767997	A/G	cg26384229	chr12:38710491	ALG10B	-0.62	-5.77	-0.46	5.9e-8	Morning vs. evening chronotype;
TGCT	cis	rs7681440	0.746	rs6812192	chr4:90817848	A/G	cg20003494	chr4:90757398	SNCA	-0.48	-4.56	-0.38	1.22e-5	Dementia with Lewy bodies;
TGCT	cis	rs79349575	0.783	rs62078370	chr17:47026836	G/C	cg26022315	chr17:47021804	SNF8	0.49	4.9	0.4	2.94e-6	Type 2 diabetes;
TGCT	trans	rs1814175	0.817	rs12295885	chr11:50036762	T/G	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.26	-0.55	3.77e-11	Height;
TGCT	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg00343986	chr7:65444356	GUSB	-0.22	-4.87	-0.4	3.37e-6	Aortic root size;
TGCT	cis	rs7095607	0.606	rs7913133	chr10:69961470	A/G	cg18986048	chr10:69913749	MYPN	0.54	5.52	0.44	1.93e-7	Lung function (FVC);
TGCT	cis	rs13256369	0.851	rs11786125	chr8:8564570	T/G	cg06671706	chr8:8559999	CLDN23	0.34	4.53	0.38	1.38e-5	Obesity-related traits;
TGCT	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.46	-6.7	-0.52	6.44e-10	Alzheimer's disease;
TGCT	trans	rs9295123	0.931	rs13212914	chr6:160570624	C/T	cg22927510	chr22:50968328	TYMP	-0.52	-6.96	-0.53	1.76e-10	Blood protein levels;
TGCT	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg21724239	chr8:58056113	NA	0.48	5.18	0.42	8.86e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg18876405	chr7:65276391	NA	0.35	5.2	0.42	7.81e-7	Aortic root size;
TGCT	cis	rs7474896	0.583	rs12776092	chr10:38015795	G/C	cg25427524	chr10:38739819	LOC399744	-0.34	-5.37	-0.43	3.8e-7	Obesity (extreme);
TGCT	cis	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg15556689	chr8:8085844	FLJ10661	0.66	6.07	0.48	1.47e-8	Mood instability;
TGCT	trans	rs3774749	0.565	rs2188151	chr3:50201924	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.78	-7.58	-0.56	6.84e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs11758351	0.518	rs79922979	chr6:26224975	A/G	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.66	-4.75	-0.39	5.57e-6	Gout;Renal underexcretion gout;
TGCT	cis	rs7246657	0.943	rs28373708	chr19:37976659	C/T	cg18154014	chr19:37997991	ZNF793	0.69	4.74	0.39	5.82e-6	Coronary artery calcification;
TGCT	cis	rs4478858	0.684	rs10753245	chr1:31731208	A/G	cg07478791	chr1:31886160	SERINC2	-0.49	-4.84	-0.4	3.78e-6	Alcohol dependence;
TGCT	cis	rs4700695	0.614	rs446618	chr5:65210062	G/A	cg21114390	chr5:65439923	SFRS12	0.62	4.44	0.37	1.99e-5	Facial morphology (factor 19);
TGCT	cis	rs45509595	0.841	rs2747054	chr6:27783359	A/G	cg08798685	chr6:27730294	NA	-0.35	-4.76	-0.39	5.24e-6	Breast cancer;
TGCT	cis	rs9467773	0.901	rs1407045	chr6:26476155	A/G	cg15659132	chr6:26577336	NA	0.64	7.01	0.53	1.33e-10	Intelligence (multi-trait analysis);
TGCT	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.4	-6.92	-0.53	2.12e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs3008870	1.000	rs3008874	chr1:67431365	A/T	cg08660285	chr1:67390436	MIER1;WDR78	1.1	11.8	0.73	5.15e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs7267979	1.000	rs2482943	chr20:25380593	G/A	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.73e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9660992	0.542	rs17345153	chr1:205179997	A/G	cg00857998	chr1:205179979	DSTYK	0.49	4.58	0.38	1.13e-5	Mean corpuscular volume;Mean platelet volume;
TGCT	cis	rs9811920	0.965	rs9849632	chr3:99867211	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.42	-4.79	-0.4	4.69e-6	Axial length;
TGCT	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg09517075	chr8:22133004	PIWIL2	0.24	4.77	0.39	5.13e-6	Hypertriglyceridemia;
TGCT	cis	rs1801239	1.000	rs77744173	chr10:16938271	T/G	cg00939682	chr10:16933505	CUBN	0.48	4.49	0.37	1.59e-5	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin excretion;
TGCT	cis	rs6750047	0.541	rs162330	chr2:38319496	C/A	cg07380506	chr2:38303506	CYP1B1	0.57	5.34	0.43	4.34e-7	Cutaneous malignant melanoma;Melanoma;
TGCT	trans	rs9929218	0.551	rs2296408	chr16:68713823	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.6	-7.92	-0.58	1.15e-12	Colorectal cancer;
TGCT	cis	rs2067615	0.579	rs6539283	chr12:107222989	C/T	cg15890332	chr12:107067104	RFX4	0.29	5.79	0.46	5.36e-8	Heart rate;
TGCT	cis	rs9859260	0.710	rs34906439	chr3:195779706	A/G	cg22891161	chr3:195456627	MUC20	0.23	4.6	0.38	1.04e-5	Mean corpuscular volume;
TGCT	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg08048268	chr3:133502702	NA	-0.53	-7.17	-0.54	5.89e-11	Iron status biomarkers;
TGCT	cis	rs13217239	0.646	rs6937880	chr6:27000236	C/T	cg05738196	chr6:26577821	NA	0.49	4.75	0.39	5.45e-6	Schizophrenia;
TGCT	cis	rs9300255	0.739	rs6633	chr12:123745809	G/T	cg00376283	chr12:123451042	ABCB9	-0.72	-4.96	-0.41	2.22e-6	Neutrophil percentage of white cells;
TGCT	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg15242686	chr22:24348715	GSTTP1	0.44	5.98	0.47	2.23e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs751728	1.000	rs755496	chr6:33734376	C/G	cg13859433	chr6:33739653	LEMD2	-0.4	-7.63	-0.57	5.49e-12	Crohn's disease;
TGCT	cis	rs1050631	1.000	rs1789504	chr18:33696772	A/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.51	4.95	0.41	2.37e-6	Esophageal squamous cell cancer (length of survival);
TGCT	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg17264618	chr3:40429014	ENTPD3	0.34	4.94	0.41	2.52e-6	Renal cell carcinoma;
TGCT	cis	rs28595532	0.920	rs114051506	chr4:119772893	A/T	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	trans	rs11088226	0.681	rs2833911	chr21:33949629	C/T	cg09050820	chr6:167586206	TCP10L2	-0.76	-7.23	-0.54	4.36e-11	Gastritis;
TGCT	trans	rs6089829	0.962	rs1116450	chr20:61658210	T/C	cg23505145	chr19:12996616	KLF1	0.79	8.3	0.6	1.47e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2637266	0.703	rs4376842	chr10:78456250	C/T	cg18941641	chr10:78392320	NA	0.4	4.94	0.41	2.52e-6	Pulmonary function;
TGCT	cis	rs2243480	0.522	rs431168	chr7:65511604	G/T	cg07424592	chr7:64974309	NA	1.51	8.49	0.61	5.38e-14	Diabetic kidney disease;
TGCT	trans	rs1496653	0.602	rs71322195	chr3:23558386	T/A	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs477895	0.938	rs28395875	chr11:64024048	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	5.32	0.43	4.6e-7	Mean platelet volume;
TGCT	cis	rs9443645	0.901	rs1542977	chr6:79550307	G/T	cg05283184	chr6:79620031	NA	-0.21	-4.77	-0.39	5.1e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9640161	0.789	rs3735174	chr7:150020489	T/C	cg17279839	chr7:150038598	RARRES2	0.44	4.69	0.39	7.22e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs9467773	0.620	rs2504566	chr6:26660488	G/C	cg26531700	chr6:26746687	NA	0.51	4.61	0.38	9.86e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs12530845	0.561	rs73725182	chr7:135291001	C/T	cg23117316	chr7:135346802	PL-5283	-0.6	-5.42	-0.44	2.93e-7	Red blood cell traits;
TGCT	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg12963246	chr6:28129442	ZNF389	0.52	5.1	0.42	1.23e-6	Depression;
TGCT	cis	rs10791097	0.967	rs4366492	chr11:130717256	T/C	cg12179176	chr11:130786555	SNX19	0.63	6.63	0.51	9.22e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs362272	0.545	rs2749782	chr4:3339761	A/G	cg22655196	chr4:3374909	RGS12	0.23	4.69	0.39	7.14e-6	Serum sulfate level;
TGCT	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg07747251	chr5:1868357	NA	0.39	5.78	0.46	5.58e-8	Cardiovascular disease risk factors;
TGCT	cis	rs17270561	0.541	rs17586946	chr6:25939053	C/T	cg17691542	chr6:26056736	HIST1H1C	0.87	5.92	0.47	2.89e-8	Iron status biomarkers;
TGCT	cis	rs2295359	0.643	rs1569922	chr1:67664963	C/T	cg12940439	chr1:67600707	NA	0.44	4.6	0.38	1.03e-5	Psoriasis;
TGCT	cis	rs11190604	1.000	rs10883493	chr10:102208188	A/T	cg23241863	chr10:102295624	HIF1AN	0.62	4.87	0.4	3.27e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7412746	0.658	rs6657388	chr1:150748786	A/G	cg09365446	chr1:150670422	GOLPH3L	0.36	5.19	0.42	8.25e-7	Melanoma;
TGCT	cis	rs66573146	1.000	rs66519732	chr4:6990569	C/G	cg01220768	chr4:7056774	TADA2B	0.39	4.93	0.41	2.54e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs1997103	0.906	rs6593232	chr7:55402916	C/T	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg01802117	chr1:53393560	SCP2	-0.43	-5.2	-0.42	8.03e-7	Monocyte count;
TGCT	cis	rs861020	0.771	rs661849	chr1:210001233	C/T	cg05527609	chr1:210001259	C1orf107	1.03	9.02	0.63	2.96e-15	Orofacial clefts;
TGCT	cis	rs1670533	1.000	rs2290408	chr4:1067267	A/C	cg27284194	chr4:1044797	NA	-0.69	-6.02	-0.48	1.83e-8	Recombination rate (females);
TGCT	cis	rs11971779	0.584	rs6962029	chr7:139034719	T/C	cg07862535	chr7:139043722	LUC7L2	0.56	4.46	0.37	1.82e-5	Diisocyanate-induced asthma;
TGCT	cis	rs2224391	0.955	rs2773322	chr6:5263065	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.75	-5.62	-0.45	1.2e-7	Height;
TGCT	cis	rs9302065	1.000	rs7490267	chr13:95970258	T/C	cg24476569	chr13:95954382	ABCC4	-0.44	-6.46	-0.5	2.15e-9	Blood metabolite levels;
TGCT	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.04	0.53	1.16e-10	Prudent dietary pattern;
TGCT	cis	rs801193	1.000	rs17566701	chr7:66193183	T/C	cg00343986	chr7:65444356	GUSB	0.21	4.58	0.38	1.12e-5	Aortic root size;
TGCT	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg13342137	chr4:2252803	MXD4	0.17	4.59	0.38	1.07e-5	Obesity-related traits;
TGCT	cis	rs1887596	0.624	rs9553858	chr13:27138472	A/G	cg01312412	chr13:27282625	NA	-0.29	-5.19	-0.42	8.24e-7	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs807669	0.903	rs2800974	chr22:19168087	C/T	cg02655711	chr22:19163373	SLC25A1	0.42	10.06	0.67	8.99e-18	Metabolite levels;
TGCT	cis	rs11716531	0.573	rs642570	chr3:27342595	C/G	cg02860705	chr3:27208620	NA	0.33	5.45	0.44	2.62e-7	Diastolic blood pressure;
TGCT	cis	rs739401	0.572	rs12276060	chr11:3015572	A/T	cg25174290	chr11:3078921	CARS	0.5	4.68	0.39	7.28e-6	Longevity;
TGCT	cis	rs2469997	0.925	rs2470015	chr8:120360969	T/C	cg00681363	chr8:120844660	TAF2	0.69	4.48	0.37	1.64e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs7674212	0.507	rs6843738	chr4:103936001	G/A	cg16532752	chr4:104119610	CENPE	-0.59	-5.26	-0.43	6.21e-7	Type 2 diabetes;
TGCT	cis	rs2301573	1.000	rs10934888	chr3:129307191	C/T	cg07730360	chr3:128845626	NA	0.33	4.61	0.38	9.84e-6	Hip circumference;
TGCT	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.57	-5.22	-0.42	7.14e-7	Prudent dietary pattern;
TGCT	cis	rs2463822	0.614	rs117699706	chr11:62161659	T/C	cg06239285	chr11:62104954	ASRGL1	-0.85	-5.54	-0.45	1.76e-7	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	8.55	0.61	3.84e-14	Platelet count;
TGCT	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2777491	0.874	rs28716108	chr15:41655523	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.72	-10.33	-0.68	1.94e-18	Ulcerative colitis;
TGCT	cis	rs7255374	0.566	rs7255904	chr19:41529020	C/T	cg20630647	chr19:41531805	NA	0.37	6.41	0.5	2.73e-9	DDT metabolite (p,p'-DDE levels);
TGCT	cis	rs1150668	0.796	rs9468372	chr6:28379361	T/A	cg19488431	chr6:28601329	NA	0.21	4.61	0.38	9.84e-6	Pubertal anthropometrics;
TGCT	cis	rs7772486	0.534	rs34541797	chr6:146205304	A/G	cg05347473	chr6:146136440	FBXO30	0.64	6.06	0.48	1.48e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2204008	0.660	rs2320745	chr12:38239101	T/C	cg13010199	chr12:38710504	ALG10B	0.59	4.54	0.38	1.29e-5	Bladder cancer;
TGCT	cis	rs6500550	0.605	rs2285813	chr16:3566102	C/A	cg07396092	chr16:3662230	BTBD12	0.53	4.54	0.38	1.31e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;White blood cell count;Neutrophil count;
TGCT	cis	rs11648796	0.765	rs2003832	chr16:769538	G/A	cg00908189	chr16:619842	PIGQ	0.81	6.47	0.5	2.06e-9	Height;
TGCT	cis	rs9926296	0.682	rs258328	chr16:89730314	C/T	cg27121462	chr16:89883253	FANCA	-0.54	-5.01	-0.41	1.83e-6	Vitiligo;
TGCT	cis	rs9611565	0.592	rs6519270	chr22:42078666	A/G	cg17554472	chr22:41940697	POLR3H	0.47	5.06	0.41	1.46e-6	Vitiligo;
TGCT	cis	rs1971762	0.563	rs10747679	chr12:54077750	C/T	cg16917193	chr12:54089295	NA	1.37	17.65	0.85	1.25e-35	Height;
TGCT	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg01802117	chr1:53393560	SCP2	0.42	5.11	0.42	1.2e-6	Monocyte count;
TGCT	cis	rs7949030	0.626	rs7930896	chr11:62325272	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.63	9.2	0.64	1.08e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs11172134	0.508	rs11837145	chr12:57570014	C/A	cg19258868	chr12:57585184	LRP1	-0.31	-5.68	-0.45	9.21e-8	Urate levels in overweight individuals;
TGCT	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg07157834	chr1:205819609	PM20D1	0.34	5.01	0.41	1.81e-6	Menarche (age at onset);
TGCT	cis	rs7843479	0.965	rs1564305	chr8:21803816	A/C	cg17168535	chr8:21777572	XPO7	0.65	5.99	0.47	2.14e-8	Mean corpuscular volume;
TGCT	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg24549020	chr5:56110836	MAP3K1	0.67	5.78	0.46	5.74e-8	Initial pursuit acceleration;
TGCT	cis	rs826838	1.000	rs1095575	chr12:39110284	C/G	cg26384229	chr12:38710491	ALG10B	-0.87	-8.02	-0.58	6.78e-13	Heart rate;
TGCT	cis	rs7635838	0.819	rs4684781	chr3:11516299	G/A	cg00170343	chr3:11313890	ATG7	0.69	6.66	0.51	8.06e-10	HDL cholesterol;
TGCT	cis	rs2842992	0.789	rs9355748	chr6:160194882	G/A	cg11366901	chr6:160182831	ACAT2	1.03	6.92	0.53	2.14e-10	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs9486719	1.000	rs2145535	chr6:97034715	G/A	cg18709589	chr6:96969512	KIAA0776	-0.74	-5.21	-0.42	7.5e-7	Migraine;Coronary artery disease;
TGCT	cis	rs66573146	1.000	rs56074877	chr4:6990374	C/T	cg00086871	chr4:6988644	TBC1D14	0.94	4.62	0.38	9.61e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs7666738	0.791	rs10856934	chr4:99010844	A/G	cg05340658	chr4:99064831	C4orf37	-0.47	-5.02	-0.41	1.77e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.61	5.06	0.41	1.5e-6	Tonsillectomy;
TGCT	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.93	-6.86	-0.52	2.86e-10	Gut microbiome composition (summer);
TGCT	cis	rs644799	0.710	rs56384142	chr11:95502075	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.29	0.6	1.54e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg10802521	chr3:52805072	NEK4	-0.72	-9.11	-0.63	1.82e-15	Bipolar disorder;
TGCT	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs675209	0.525	rs4960296	chr6:7208840	A/T	cg27097018	chr6:6320614	F13A1	0.37	5.35	0.43	4.04e-7	Urate levels;
TGCT	cis	rs6964587	1.000	rs6976122	chr7:91610962	T/C	cg17063962	chr7:91808500	NA	0.91	9.99	0.67	1.32e-17	Breast cancer;
TGCT	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg22683308	chr4:1340831	KIAA1530	-0.66	-6.17	-0.48	8.75e-9	Longevity;
TGCT	cis	rs4372836	0.729	rs10166861	chr2:29061111	A/G	cg09522027	chr2:28974177	PPP1CB	-0.7	-7.28	-0.55	3.39e-11	Body mass index;
TGCT	cis	rs7267979	0.966	rs6050532	chr20:25308793	A/T	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9549367	0.789	rs12866090	chr13:113869410	G/A	cg18105134	chr13:113819100	PROZ	-0.35	-5.68	-0.45	8.89e-8	Platelet distribution width;
TGCT	cis	rs2227564	0.574	rs3849969	chr10:75525999	C/T	cg04320760	chr10:75533139	FUT11	0.33	4.67	0.39	7.82e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs1150668	0.830	rs2023493	chr6:28400162	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.51	-4.93	-0.4	2.6e-6	Pubertal anthropometrics;
TGCT	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg12564285	chr5:131593104	PDLIM4	0.41	4.71	0.39	6.61e-6	Acylcarnitine levels;
TGCT	cis	rs10193935	0.901	rs9789740	chr2:42486799	A/G	cg27598129	chr2:42591480	NA	-0.39	-5.41	-0.44	3.06e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9467773	0.620	rs2451741	chr6:26629404	A/G	cg05738196	chr6:26577821	NA	0.88	11.22	0.71	1.33e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs12220238	0.915	rs11000945	chr10:76030739	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.87	5.85	0.46	4.15e-8	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg12311346	chr5:56204834	C5orf35	0.83	7.78	0.57	2.41e-12	Initial pursuit acceleration;
TGCT	cis	rs4325129	1.000	rs4325129	chr1:159462381	A/G	cg07417683	chr1:159440267	NA	-0.45	-4.63	-0.38	9.16e-6	Obesity-related traits;
TGCT	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg11366901	chr6:160182831	ACAT2	1.06	7.18	0.54	5.54e-11	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs3902035	0.964	rs62422259	chr6:119007732	T/C	cg07617317	chr6:118971624	C6orf204	0.43	5.01	0.41	1.79e-6	QT interval;
TGCT	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg03264133	chr6:25882463	NA	-0.61	-6.51	-0.5	1.68e-9	Blood metabolite levels;
TGCT	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7937682	0.824	rs510866	chr11:111484113	A/C	cg09085632	chr11:111637200	PPP2R1B	-1.06	-11.52	-0.72	2.48e-21	Primary sclerosing cholangitis;
TGCT	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg07332563	chr6:291687	DUSP22	-0.75	-7.62	-0.56	5.67e-12	Menopause (age at onset);
TGCT	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg17054783	chr10:134559939	INPP5A	0.24	4.83	0.4	3.92e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg03303774	chr4:1407052	NA	0.36	5.5	0.44	2.08e-7	Obesity-related traits;
TGCT	cis	rs13217239	0.646	rs10946888	chr6:26951678	A/G	cg26531700	chr6:26746687	NA	0.69	6.92	0.53	2.11e-10	Schizophrenia;
TGCT	cis	rs9467711	0.584	rs34244947	chr6:26761745	T/C	cg16898833	chr6:26189333	HIST1H4D	1.27	6.03	0.48	1.76e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9467773	0.595	rs13207371	chr6:26591074	G/A	cg11502198	chr6:26597334	ABT1	0.52	4.57	0.38	1.17e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs2153535	0.542	rs9378553	chr6:8472632	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg05872129	chr22:39784769	NA	0.99	10.97	0.7	5.41e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs7552404	0.731	rs7523573	chr1:76372020	G/T	cg03433033	chr1:76189801	ACADM	0.74	6.98	0.53	1.58e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9467711	0.606	rs35307327	chr6:26370474	C/T	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs5769765	0.955	rs5770750	chr22:50276828	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	1.11	11.81	0.73	5.03e-22	Schizophrenia;
TGCT	cis	rs7681440	0.874	rs1442151	chr4:90775491	T/A	cg14346243	chr4:90757452	SNCA	-0.56	-5.47	-0.44	2.41e-7	Dementia with Lewy bodies;
TGCT	cis	rs12413816	0.784	rs35537139	chr10:13768894	G/A	cg16485048	chr10:13749193	FRMD4A	0.26	5.36	0.43	3.99e-7	Red cell distribution width;
TGCT	cis	rs8038465	1.000	rs8041523	chr15:73982556	C/T	cg15420318	chr15:73925796	NPTN	0.69	6.4	0.5	2.86e-9	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg16680214	chr1:154839983	KCNN3	-0.41	-8.75	-0.62	1.29e-14	Prostate cancer;
TGCT	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg03806693	chr22:41940476	POLR3H	1.19	13.5	0.77	4.07e-26	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg10802521	chr3:52805072	NEK4	-0.72	-8.9	-0.62	5.64e-15	Bipolar disorder;
TGCT	cis	rs7809950	0.678	rs7788271	chr7:106985873	A/G	cg23024343	chr7:107201750	COG5	-0.43	-5.85	-0.47	4.12e-8	Coronary artery disease;
TGCT	cis	rs734999	0.588	rs2764842	chr1:2529192	A/G	cg18854424	chr1:2615690	NA	-0.46	-5.23	-0.43	6.92e-7	Ulcerative colitis;
TGCT	cis	rs11096990	0.656	rs6531710	chr4:39302278	C/T	cg20847110	chr4:39482781	LOC401127	-0.16	-4.51	-0.38	1.48e-5	Cognitive function;
TGCT	cis	rs2204008	0.687	rs11181339	chr12:38322271	G/T	cg26384229	chr12:38710491	ALG10B	0.77	6.85	0.52	3.04e-10	Bladder cancer;
TGCT	cis	rs912057	0.671	rs1294434	chr6:6745377	G/A	cg06612196	chr6:6737390	NA	0.46	6.71	0.52	6.07e-10	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs7666738	0.830	rs2865951	chr4:99040191	C/T	cg05340658	chr4:99064831	C4orf37	0.55	6.33	0.49	4.12e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs881375	0.967	rs2416806	chr9:123690292	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	4.99	0.41	2.03e-6	Rheumatoid arthritis;
TGCT	cis	rs7584330	0.518	rs74003106	chr2:238447004	A/G	cg14458575	chr2:238380390	NA	0.43	4.51	0.38	1.48e-5	Prostate cancer;
TGCT	cis	rs12188164	0.686	rs72711367	chr5:418494	A/G	cg26850624	chr5:429559	AHRR	-0.21	-4.98	-0.41	2.06e-6	Cystic fibrosis severity;
TGCT	cis	rs6969780	0.722	rs985652	chr7:27198083	A/C	cg04317399	chr7:27170313	HOXA4	-0.43	-4.8	-0.4	4.49e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg16325326	chr1:53192061	ZYG11B	-0.85	-11.97	-0.73	1.98e-22	Monocyte count;
TGCT	cis	rs13256369	1.000	rs13271966	chr8:8575472	T/C	cg06671706	chr8:8559999	CLDN23	0.35	4.62	0.38	9.35e-6	Obesity-related traits;
TGCT	cis	rs8056742	0.908	rs9630655	chr16:85095080	A/G	cg00229868	chr16:85520891	NA	0.33	4.82	0.4	4.04e-6	Amyotrophic lateral sclerosis;
TGCT	cis	rs7917772	0.629	rs1475646	chr10:104522564	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.56	-4.59	-0.38	1.07e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs12497850	0.931	rs1134591	chr3:48972892	C/T	cg05785598	chr3:49045655	WDR6	0.39	4.91	0.4	2.77e-6	Parkinson's disease;
TGCT	trans	rs17471911	0.708	rs7082050	chr10:100757488	C/T	cg03484267	chr2:207988651	KLF7	-0.52	-6.7	-0.52	6.49e-10	Neuroticism;
TGCT	cis	rs2188554	1.000	rs10225824	chr7:117012023	G/A	cg08576598	chr7:116962626	WNT2	-0.38	-4.57	-0.38	1.14e-5	Esophageal adenocarcinoma;
TGCT	cis	rs35883536	0.513	rs6577180	chr1:101016939	G/A	cg06223162	chr1:101003688	GPR88	0.42	8.38	0.6	9.73e-14	Monocyte count;
TGCT	cis	rs250677	0.687	rs2915809	chr5:148452111	A/T	cg18129178	chr5:148520854	ABLIM3	-0.43	-6.29	-0.49	5.05e-9	Breast cancer;
TGCT	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	5.05	0.41	1.51e-6	Menopause (age at onset);
TGCT	cis	rs9906944	0.657	rs4643373	chr17:47123423	T/C	cg07075026	chr17:47091521	IGF2BP1	-0.5	-5.22	-0.42	7.17e-7	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs1008375	0.902	rs12503164	chr4:17656107	C/T	cg10189774	chr4:17578691	LAP3	0.57	5.15	0.42	9.95e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1153858	1.000	rs11070457	chr15:45686943	A/C	cg26924012	chr15:45694286	SPATA5L1	1.09	15.16	0.81	5.15e-30	Homoarginine levels;
TGCT	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg21963583	chr11:68658836	MRPL21	0.36	6.03	0.48	1.74e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs12477438	0.501	rs7349217	chr2:99815146	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.05	13.04	0.76	5.31e-25	Chronic sinus infection;
TGCT	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg08280861	chr8:58055591	NA	0.36	4.77	0.39	5.18e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2153535	0.580	rs1932281	chr6:8473765	A/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs6918586	0.658	rs198843	chr6:26110314	A/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.7	-6.6	-0.51	1.07e-9	Schizophrenia;
TGCT	cis	rs7582180	0.629	rs12617779	chr2:100937707	G/A	cg14675211	chr2:100938903	LONRF2	0.51	4.95	0.41	2.32e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2795502	0.882	rs2744093	chr10:43339243	A/G	cg20628663	chr10:43360327	NA	-0.44	-6.37	-0.5	3.4e-9	Blood protein levels;
TGCT	trans	rs208520	0.690	rs207107	chr6:66794385	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-10.77	-0.7	1.66e-19	Exhaled nitric oxide output;
TGCT	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg27535305	chr1:53392650	SCP2	-0.27	-5.47	-0.44	2.39e-7	Monocyte count;
TGCT	cis	rs7103648	0.669	rs7927445	chr11:47780754	G/T	cg20307385	chr11:47447363	PSMC3	0.77	7.25	0.55	3.99e-11	Diastolic blood pressure;Systolic blood pressure;
TGCT	cis	rs7474896	0.583	rs11011346	chr10:38009483	C/T	cg13720705	chr10:37990370	NA	0.33	4.93	0.41	2.53e-6	Obesity (extreme);
TGCT	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.27	4.81	0.4	4.38e-6	Schizophrenia;
TGCT	cis	rs6009824	1.000	rs6009824	chr22:50086373	C/T	cg27029450	chr22:50098074	NA	0.34	4.44	0.37	1.96e-5	Natriuretic peptide levels;
TGCT	cis	rs568617	0.626	rs78028320	chr11:65582015	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.6	4.82	0.4	4.15e-6	Crohn's disease;
TGCT	cis	rs910316	0.967	rs4903292	chr14:75656245	A/G	cg08847533	chr14:75593920	NEK9	0.93	10.31	0.68	2.18e-18	Height;
TGCT	cis	rs17270561	0.779	rs12209218	chr6:25887776	C/A	cg16482183	chr6:26056742	HIST1H1C	0.9	6.76	0.52	4.9e-10	Iron status biomarkers;
TGCT	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg19774624	chr17:42201019	HDAC5	0.75	9.44	0.65	2.89e-16	Total body bone mineral density;
TGCT	cis	rs62064224	0.593	rs916663	chr17:30835833	A/C	cg18200150	chr17:30822561	MYO1D	-0.52	-6.9	-0.53	2.43e-10	Schizophrenia;
TGCT	cis	rs6669384	0.774	rs61821318	chr1:208033706	C/T	cg22525895	chr1:207977042	MIR29B2	-0.38	-5.35	-0.43	4.04e-7	Immune response to measles vaccine (measles-specific neutralising antibody titre);
TGCT	cis	rs854765	0.547	rs8075189	chr17:17901946	C/G	cg09796270	chr17:17721594	SREBF1	0.25	5.03	0.41	1.71e-6	Total body bone mineral density;
TGCT	cis	rs78366141	0.649	rs78179026	chr4:89657456	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	1.16	5.16	0.42	9.33e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
TGCT	trans	rs2727020	0.638	rs1164668	chr11:49330627	A/C	cg03929089	chr4:120376271	NA	0.7	7.93	0.58	1.1e-12	Coronary artery disease;
TGCT	cis	rs17152411	1.000	rs10901837	chr10:126614618	G/A	cg07906193	chr10:126599966	NA	0.41	5.11	0.42	1.17e-6	Height;
TGCT	cis	rs6570726	0.967	rs374728	chr6:145854598	T/A	cg05347473	chr6:146136440	FBXO30	0.49	4.54	0.38	1.29e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs12477438	0.520	rs11689265	chr2:99799267	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.15	18.32	0.85	4.52e-37	Chronic sinus infection;
TGCT	cis	rs2120019	0.938	rs2120020	chr15:75316845	T/C	cg09165964	chr15:75287851	SCAMP5	-1.14	-10.33	-0.68	2.05e-18	Blood trace element (Zn levels);
TGCT	cis	rs2562456	0.917	rs2681377	chr19:21716520	T/C	cg25650185	chr19:21324782	ZNF431	0.61	5.38	0.43	3.6e-7	Pain;
TGCT	cis	rs1372520	0.935	rs2245801	chr4:90757840	T/C	cg01966878	chr4:90757139	SNCA	-0.31	-4.67	-0.39	7.58e-6	Neuroticism;
TGCT	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg05721485	chr17:44071124	MAPT	0.26	4.58	0.38	1.1e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs225245	0.755	rs6505491	chr17:34026335	A/G	cg05299278	chr17:33885742	SLFN14	0.21	4.5	0.37	1.54e-5	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs9467711	0.606	rs9379863	chr6:26372427	A/G	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg06634786	chr22:41940651	POLR3H	-0.88	-8.72	-0.62	1.55e-14	Vitiligo;
TGCT	cis	rs11098499	0.779	rs80242894	chr4:120375752	G/A	cg09307838	chr4:120376055	NA	0.68	6.53	0.51	1.54e-9	Corneal astigmatism;
TGCT	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.39	-6.63	-0.51	9.28e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg07424592	chr7:64974309	NA	1.4	8.41	0.6	8.17e-14	Diabetic kidney disease;
TGCT	cis	rs7937612	1.000	rs10790380	chr11:120233158	G/A	cg24566217	chr11:120254723	ARHGEF12	-0.29	-4.62	-0.38	9.5e-6	Intraocular pressure;
TGCT	cis	rs568617	1.000	rs656980	chr11:65656282	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.57	5.22	0.42	7.39e-7	Crohn's disease;
TGCT	cis	rs11674184	0.714	rs9789525	chr2:11724580	G/T	cg07314298	chr2:11723111	GREB1	-0.42	-7.73	-0.57	3.21e-12	Endometriosis;
TGCT	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.06	13.15	0.76	2.92e-25	Prudent dietary pattern;
TGCT	cis	rs2980439	0.525	rs2980508	chr8:8171732	C/T	cg06636001	chr8:8085503	FLJ10661	0.6	5.19	0.42	8.29e-7	Neuroticism;
TGCT	cis	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg18252515	chr7:66147081	NA	-1.09	-6.4	-0.5	2.88e-9	Diabetic kidney disease;
TGCT	cis	rs2832191	0.933	rs2832236	chr21:30547602	C/T	cg08807101	chr21:30365312	RNF160	-0.51	-4.72	-0.39	6.16e-6	Dental caries;
TGCT	cis	rs2274273	0.712	rs1002054	chr14:55528913	A/C	cg01923255	chr14:55878535	KIAA0831	0.56	4.76	0.39	5.32e-6	Protein biomarker;
TGCT	cis	rs921968	0.541	rs490483	chr2:219429052	A/T	cg02176678	chr2:219576539	TTLL4	0.48	6.78	0.52	4.32e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs6688613	0.729	rs2072742	chr1:166929673	A/G	cg07049167	chr1:166818506	POGK	0.27	5.16	0.42	9.39e-7	Refractive astigmatism;
TGCT	cis	rs6570726	1.000	rs441477	chr6:145848243	C/T	cg05347473	chr6:146136440	FBXO30	0.49	4.44	0.37	1.96e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4409675	0.576	rs11247705	chr1:28212272	G/A	cg23691781	chr1:28212827	C1orf38	0.25	5.28	0.43	5.66e-7	Corneal astigmatism;
TGCT	cis	rs7666738	0.830	rs28587201	chr4:98991733	C/T	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11148252	0.774	rs9536066	chr13:52983981	A/G	cg00495681	chr13:53174319	NA	0.54	5.39	0.44	3.38e-7	Lewy body disease;
TGCT	cis	rs904251	0.561	rs1757189	chr6:37483727	G/C	cg25019722	chr6:37503610	NA	-0.52	-7.86	-0.58	1.62e-12	Cognitive performance;
TGCT	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg18538332	chr22:24372958	LOC391322	-0.73	-7.63	-0.57	5.45e-12	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs208520	0.690	rs3846808	chr6:66818604	A/G	cg07460842	chr6:66804631	NA	-0.94	-10.0	-0.67	1.23e-17	Exhaled nitric oxide output;
TGCT	cis	rs8072100	0.656	rs2610367	chr17:45569815	A/G	cg08085267	chr17:45401833	C17orf57	-0.44	-4.78	-0.39	4.96e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs9611565	0.500	rs2011053	chr22:42121278	G/A	cg06634786	chr22:41940651	POLR3H	0.82	7.9	0.58	1.3e-12	Vitiligo;
TGCT	cis	rs796364	0.951	rs3098341	chr2:200792498	G/T	cg17644776	chr2:200775616	C2orf69	0.31	4.85	0.4	3.58e-6	Schizophrenia;
TGCT	cis	rs4891159	0.570	rs690132	chr18:74117261	T/C	cg24786174	chr18:74118243	ZNF516	0.71	15.66	0.82	3.6e-31	Longevity;
TGCT	cis	rs7208859	0.673	rs216424	chr17:28943064	T/G	cg04154034	chr17:28927549	LRRC37B2	0.74	4.46	0.37	1.81e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs2795502	0.938	rs3121281	chr10:43400753	A/G	cg20628663	chr10:43360327	NA	0.36	5.45	0.44	2.66e-7	Blood protein levels;
TGCT	cis	rs11577318	0.796	rs4625269	chr1:26626967	C/A	cg12733254	chr1:26682999	NA	-0.2	-4.46	-0.37	1.79e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs9364220	0.662	rs9295044	chr6:168494289	T/G	cg02770688	chr6:168491649	NA	-0.31	-5.72	-0.46	7.6e-8	Attention deficit hyperactivity disorder (inattention symptoms);Attention deficit hyperactivity disorder (combined symptoms);
TGCT	cis	rs2777491	0.872	rs7163649	chr15:41586798	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.74	-10.63	-0.69	3.68e-19	Ulcerative colitis;
TGCT	cis	rs12893668	0.572	rs11540512	chr14:104147377	C/T	cg26031613	chr14:104095156	KLC1	-0.59	-5.08	-0.42	1.34e-6	Reticulocyte count;
TGCT	cis	rs12681288	0.676	rs4565481	chr8:1001944	C/T	cg04851639	chr8:1020857	NA	-0.32	-5.37	-0.43	3.79e-7	Schizophrenia;
TGCT	cis	rs2288884	1.000	rs56808319	chr19:52577874	A/T	cg15405931	chr19:52693188	PPP2R1A	-0.69	-4.47	-0.37	1.74e-5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs2180341	0.804	rs6902233	chr6:127555963	A/G	cg24812749	chr6:127587940	RNF146	0.92	6.46	0.5	2.18e-9	Breast cancer;
TGCT	cis	rs7611238	0.517	rs9814344	chr3:195136047	T/G	cg27323046	chr3:195102265	ACAP2	0.38	5.13	0.42	1.09e-6	Body mass index;
TGCT	cis	rs28735056	1.000	rs56197868	chr18:77636077	C/T	cg20368463	chr18:77673604	PQLC1	-0.44	-5.46	-0.44	2.44e-7	Schizophrenia;
TGCT	cis	rs28595532	0.800	rs111626798	chr4:119352517	C/T	cg11846333	chr4:119757529	SEC24D	0.72	4.51	0.38	1.48e-5	Cannabis dependence symptom count;
TGCT	cis	rs13217239	0.646	rs4269366	chr6:27016413	C/T	cg26531700	chr6:26746687	NA	0.68	6.65	0.51	8.19e-10	Schizophrenia;
TGCT	cis	rs79387448	0.638	rs6759588	chr2:103040159	A/G	cg09003973	chr2:102972529	NA	1.35	9.34	0.64	4.96e-16	Gut microbiota (bacterial taxa);
TGCT	cis	rs6061231	0.631	rs927133	chr20:60972109	C/T	cg24112000	chr20:60950667	NA	-0.35	-4.88	-0.4	3.24e-6	Colorectal cancer;
TGCT	cis	rs11098499	0.738	rs34965784	chr4:120361586	G/C	cg09307838	chr4:120376055	NA	0.68	6.53	0.51	1.54e-9	Corneal astigmatism;
TGCT	cis	rs11785400	0.963	rs4579507	chr8:143733663	C/G	cg24634471	chr8:143751801	JRK	0.56	6.12	0.48	1.13e-8	Schizophrenia;
TGCT	cis	rs514406	0.505	rs431459	chr1:53183230	T/G	cg24675658	chr1:53192096	ZYG11B	-0.79	-9.7	-0.66	6.86e-17	Monocyte count;
TGCT	cis	rs12210905	1.000	rs72843613	chr6:27138467	G/A	cg08851530	chr6:28072375	NA	1.12	5.43	0.44	2.82e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs6840360	0.593	rs10016160	chr4:152693998	A/G	cg22705602	chr4:152727874	NA	-0.34	-5.9	-0.47	3.24e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs56104184	0.830	rs28556985	chr19:49351149	C/T	cg21252483	chr19:49399788	TULP2	-0.43	-5.49	-0.44	2.2e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	trans	rs877282	0.838	rs11253374	chr10:774961	C/T	cg22713356	chr15:30763199	NA	1.17	10.77	0.7	1.7e-19	Uric acid levels;
TGCT	cis	rs2282802	0.685	rs13170475	chr5:139671062	C/T	cg01081189	chr5:139537190	NA	0.29	5.31	0.43	5e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs6840360	0.533	rs1397683	chr4:152715916	T/C	cg22705602	chr4:152727874	NA	0.34	5.95	0.47	2.5e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7568458	0.905	rs6739015	chr2:85755357	A/G	cg17127132	chr2:85788382	GGCX	0.72	6.69	0.51	6.94e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs644799	0.540	rs10831422	chr11:95478968	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.58	5.7	0.46	8.21e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7296418	0.663	rs11057284	chr12:123830692	G/C	cg00376283	chr12:123451042	ABCB9	0.63	5.42	0.44	3.02e-7	Platelet count;
TGCT	trans	rs2688608	0.592	rs11000759	chr10:75493726	G/A	cg13918328	chr10:52500089	ASAH2B	0.68	6.7	0.52	6.48e-10	Inflammatory bowel disease;
TGCT	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	5.8	0.46	5.19e-8	Alzheimer's disease;
TGCT	cis	rs28595532	0.920	rs116405053	chr4:119739352	C/T	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs2204008	0.715	rs3899385	chr12:38169880	C/G	cg13010199	chr12:38710504	ALG10B	0.62	4.89	0.4	3.09e-6	Bladder cancer;
TGCT	cis	rs7666738	0.830	rs60391193	chr4:98933912	T/G	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12257961	0.579	rs4748160	chr10:15360718	T/A	cg10616319	chr10:15468812	NA	-0.25	-4.56	-0.38	1.21e-5	Selective IgA deficiency;
TGCT	cis	rs57590327	0.555	rs3772884	chr3:81802720	G/T	cg07356753	chr3:81810745	GBE1	-0.77	-7.26	-0.55	3.75e-11	Extraversion;
TGCT	cis	rs7959452	0.532	rs2291005	chr12:69764388	A/G	cg11871910	chr12:69753446	YEATS4	0.82	8.82	0.62	8.61e-15	Blood protein levels;
TGCT	cis	rs2456568	0.805	rs2032400	chr11:93676937	G/A	cg26875233	chr11:93583750	C11orf90	-0.44	-5.5	-0.44	2.05e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7552404	0.731	rs12078299	chr1:76365764	T/A	cg22875332	chr1:76189707	ACADM	0.67	6.42	0.5	2.57e-9	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2204008	0.666	rs67792345	chr12:38204698	T/C	cg26384229	chr12:38710491	ALG10B	0.78	6.56	0.51	1.32e-9	Bladder cancer;
TGCT	cis	rs2663905	0.611	rs1509560	chr15:81391713	T/G	cg27045999	chr15:81426544	C15orf26	-0.55	-5.52	-0.44	1.89e-7	QT interval (drug interaction);
TGCT	cis	rs13326165	0.715	rs11718125	chr3:52379420	T/C	cg27565382	chr3:53032988	SFMBT1	0.36	4.8	0.4	4.54e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs1878931	0.559	rs11643501	chr16:3392752	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.76	7.27	0.55	3.55e-11	Body mass index (adult);
TGCT	cis	rs2816062	0.786	rs2816038	chr1:18880525	C/T	cg18795169	chr1:18902165	NA	-0.59	-13.16	-0.76	2.73e-25	Urate levels in lean individuals;
TGCT	cis	rs709400	0.550	rs942865	chr14:104015250	G/A	cg26031613	chr14:104095156	KLC1	0.77	6.32	0.49	4.33e-9	Body mass index;
TGCT	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg06238570	chr21:40685208	BRWD1	0.69	6.41	0.5	2.71e-9	Cognitive function;
TGCT	cis	rs2013441	1.000	rs2243732	chr17:20088589	C/G	cg18979559	chr17:20280153	CCDC144C	-0.44	-4.61	-0.38	9.78e-6	Obesity-related traits;
TGCT	cis	rs17122693	0.748	rs7159861	chr14:51144660	C/T	cg04730355	chr14:51134070	SAV1	-1.23	-10.96	-0.7	5.87e-20	Cognitive performance;
TGCT	cis	rs7267979	1.000	rs4815407	chr20:25341478	G/C	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4919694	0.808	rs77521106	chr10:104980726	G/T	cg04362960	chr10:104952993	NT5C2	1.09	7.26	0.55	3.68e-11	Arsenic metabolism;
TGCT	cis	rs3733585	0.664	rs17185870	chr4:9958214	C/A	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.68	-0.51	7.16e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7845219	0.525	rs7820818	chr8:95919231	G/A	cg09323728	chr8:95962352	TP53INP1	-0.41	-4.57	-0.38	1.17e-5	Type 2 diabetes;
TGCT	cis	rs2239547	0.522	rs9311485	chr3:52987645	T/G	cg11645453	chr3:52864694	ITIH4	-0.32	-5.32	-0.43	4.67e-7	Schizophrenia;
TGCT	cis	rs7412746	0.586	rs2864882	chr1:150883037	C/T	cg04414720	chr1:150670196	GOLPH3L	0.37	4.46	0.37	1.81e-5	Melanoma;
TGCT	cis	rs7582180	0.652	rs11694700	chr2:100936637	C/T	cg08017756	chr2:100939284	LONRF2	-0.3	-4.78	-0.39	4.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs936229	0.768	rs12442901	chr15:75083912	A/G	cg10253484	chr15:75165896	SCAMP2	-0.65	-5.12	-0.42	1.15e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
TGCT	cis	rs9303401	0.580	rs12603808	chr17:56578508	T/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.71	6.78	0.52	4.45e-10	Cognitive test performance;
TGCT	cis	rs9362426	0.639	rs35332886	chr6:88141064	A/G	cg10919329	chr6:88182879	SLC35A1	-0.61	-4.63	-0.38	9.03e-6	Depressive episodes in bipolar disorder;
TGCT	cis	rs9399135	1.000	rs4475342	chr6:135283348	T/C	cg24558204	chr6:135376177	HBS1L	0.48	4.79	0.39	4.75e-6	Red blood cell count;
TGCT	cis	rs9393777	0.513	rs9368450	chr6:26652489	A/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.59	-4.66	-0.39	8.03e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg11845111	chr2:191398756	TMEM194B	0.37	5.65	0.45	1.03e-7	Pulse pressure;
TGCT	cis	rs4788570	0.578	rs4788553	chr16:71780277	T/G	cg06353428	chr16:71660113	MARVELD3	1.56	12.67	0.75	4.05e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs1801251	0.963	rs7591176	chr2:233581803	C/A	cg25237894	chr2:233734115	C2orf82	0.33	6.02	0.48	1.85e-8	Coronary artery disease;
TGCT	cis	rs6882046	0.513	rs587490	chr5:88032522	C/T	cg22951263	chr5:87985283	NA	-0.55	-5.94	-0.47	2.74e-8	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs12791968	0.917	rs11038239	chr11:45002012	A/G	cg11846598	chr11:44996168	LOC221122	-0.35	-6.45	-0.5	2.29e-9	Inhibitory control;
TGCT	cis	rs6088580	0.634	rs6120666	chr20:33090718	A/G	cg06115741	chr20:33292138	TP53INP2	0.54	4.63	0.38	9.06e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs2486012	1.000	rs2428953	chr1:44443459	G/A	cg12908607	chr1:44402522	ARTN	0.67	5.9	0.47	3.17e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs67311347	1.000	rs73080165	chr3:40533062	G/T	cg13683864	chr3:40499215	RPL14	-1.17	-11.19	-0.71	1.56e-20	Renal cell carcinoma;
TGCT	cis	rs1865760	0.613	rs9379805	chr6:25938764	T/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.63	6.65	0.51	8.58e-10	Height;
TGCT	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg08859206	chr1:53392774	SCP2	0.4	5.96	0.47	2.46e-8	Monocyte count;
TGCT	cis	rs17376456	0.877	rs17083462	chr5:93462401	T/G	cg21475434	chr5:93447410	FAM172A	0.59	4.66	0.39	8.09e-6	Diabetic retinopathy;
TGCT	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg13695892	chr22:41940480	POLR3H	-0.91	-8.86	-0.62	6.93e-15	Vitiligo;
TGCT	cis	rs477895	1.000	rs1047206	chr11:64089216	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	5.19	0.42	8.41e-7	Mean platelet volume;
TGCT	cis	rs9527	0.641	rs10786732	chr10:104762535	T/C	cg15744005	chr10:104629667	AS3MT	-0.44	-5.11	-0.42	1.18e-6	Arsenic metabolism;
TGCT	cis	rs6570726	0.870	rs370653	chr6:145823642	G/A	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10504229	0.680	rs11777459	chr8:58044241	A/T	cg21724239	chr8:58056113	NA	0.34	4.44	0.37	1.97e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs1670533	0.932	rs6599276	chr4:1056827	T/C	cg20887711	chr4:1340912	KIAA1530	0.71	5.7	0.46	8.33e-8	Recombination rate (females);
TGCT	cis	rs7647973	0.593	rs55997059	chr3:49858661	A/T	cg03060546	chr3:49711283	APEH	-0.66	-6.02	-0.48	1.86e-8	Menarche (age at onset);
TGCT	cis	rs13326165	0.760	rs56357549	chr3:52374516	T/G	cg07884673	chr3:53033167	SFMBT1	0.39	4.69	0.39	7e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs17401966	0.800	rs2039778	chr1:10354601	A/G	cg19773385	chr1:10388646	KIF1B	-0.21	-4.63	-0.38	9.17e-6	Hepatocellular carcinoma;
TGCT	cis	rs7178572	1.000	rs12910361	chr15:77782335	A/G	cg22256960	chr15:77711686	NA	-0.95	-10.89	-0.7	8.57e-20	Type 2 diabetes;
TGCT	cis	rs9467773	0.967	rs6924865	chr6:26521353	A/G	cg05738196	chr6:26577821	NA	0.88	12.5	0.75	1.03e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs4727027	0.933	rs4727028	chr7:148874666	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	-0.51	-4.76	-0.39	5.36e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs1670533	1.000	rs10007978	chr4:1060984	A/T	cg27284194	chr4:1044797	NA	0.7	6.04	0.48	1.63e-8	Recombination rate (females);
TGCT	cis	rs3862260	0.509	rs10923879	chr1:120163831	A/G	cg11530693	chr1:120165357	ZNF697	0.21	4.75	0.39	5.48e-6	Systemic lupus erythematosus;
TGCT	cis	rs9486719	1.000	rs2472886	chr6:96864876	C/T	cg06623918	chr6:96969491	KIAA0776	1.01	8.86	0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs796364	0.806	rs11688194	chr2:200916239	C/T	cg17644776	chr2:200775616	C2orf69	-0.33	-5.0	-0.41	1.91e-6	Schizophrenia;
TGCT	cis	rs12497850	0.931	rs7636057	chr3:48992582	C/T	cg05785598	chr3:49045655	WDR6	0.37	4.83	0.4	3.98e-6	Parkinson's disease;
TGCT	cis	rs9467773	0.595	rs13207371	chr6:26591074	G/A	cg15659132	chr6:26577336	NA	0.85	10.29	0.68	2.45e-18	Intelligence (multi-trait analysis);
TGCT	cis	rs9296092	0.560	rs7765393	chr6:33525598	A/T	cg13560919	chr6:33536144	NA	-0.23	-5.06	-0.41	1.49e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs7772486	0.701	rs7772717	chr6:145954854	T/C	cg05347473	chr6:146136440	FBXO30	0.53	4.97	0.41	2.2e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7542091	0.635	rs7550733	chr1:210044968	G/A	cg22029157	chr1:209979665	IRF6	0.64	6.12	0.48	1.12e-8	Monobrow;
TGCT	cis	rs55794721	0.543	rs1293260	chr1:25709104	C/G	cg23205692	chr1:25664452	TMEM50A	0.53	5.48	0.44	2.3e-7	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs9906944	0.603	rs10853104	chr17:47092076	C/T	cg07075026	chr17:47091521	IGF2BP1	-0.48	-5.23	-0.43	7e-7	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs7666738	0.546	rs7699578	chr4:98838893	T/C	cg05340658	chr4:99064831	C4orf37	0.58	5.35	0.43	4e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg01802117	chr1:53393560	SCP2	0.51	6.25	0.49	5.91e-9	Monocyte count;
TGCT	cis	rs6901004	0.772	rs191632	chr6:111544882	C/T	cg15721981	chr6:111408429	SLC16A10	-0.52	-4.55	-0.38	1.27e-5	Blood metabolite levels;
TGCT	cis	rs733175	0.855	rs6853437	chr4:10005435	A/G	cg11266682	chr4:10021025	SLC2A9	-0.47	-4.63	-0.38	9.05e-6	Psychosis and Alzheimer's disease;
TGCT	cis	rs881375	0.967	rs1008381	chr9:123681116	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	5.43	0.44	2.89e-7	Rheumatoid arthritis;
TGCT	cis	rs12210905	1.000	rs10946906	chr6:27252780	G/A	cg08851530	chr6:28072375	NA	1.29	5.49	0.44	2.19e-7	Hip circumference adjusted for BMI;
TGCT	trans	rs208520	0.690	rs1563929	chr6:66702108	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	11.26	0.71	1.09e-20	Exhaled nitric oxide output;
TGCT	cis	rs77861329	1.000	rs123681	chr3:52209320	A/G	cg08692210	chr3:52188851	WDR51A	0.94	4.83	0.4	3.91e-6	Macrophage inflammatory protein 1b levels;
TGCT	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg05665937	chr4:1216051	CTBP1	0.24	4.65	0.39	8.32e-6	Obesity-related traits;
TGCT	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg00814883	chr7:100076585	TSC22D4	-0.82	-8.23	-0.59	2.14e-13	Platelet count;
TGCT	cis	rs7191700	0.712	rs7187741	chr16:11433103	C/G	cg00044050	chr16:11439710	C16orf75	-0.88	-10.74	-0.69	2.04e-19	Multiple sclerosis;
TGCT	cis	rs12681287	0.608	rs2953511	chr8:87340870	G/A	cg27223183	chr8:87520930	FAM82B	-0.9	-6.71	-0.52	6.12e-10	Caudate activity during reward;
TGCT	cis	rs7584330	0.518	rs77789507	chr2:238440972	C/T	cg14458575	chr2:238380390	NA	0.43	4.55	0.38	1.25e-5	Prostate cancer;
TGCT	cis	rs7904368	0.806	rs1130684	chr10:16859335	C/G	cg14835575	chr10:16859367	RSU1	0.71	8.0	0.58	7.39e-13	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
TGCT	cis	rs9611565	0.592	rs28750375	chr22:41990644	A/C	cg17554472	chr22:41940697	POLR3H	-0.49	-5.15	-0.42	9.88e-7	Vitiligo;
TGCT	cis	rs2524005	1.000	rs2524005	chr6:29899677	C/T	cg27642588	chr6:29709602	LOC285830	0.41	5.47	0.44	2.42e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs2836950	0.565	rs7279497	chr21:40531306	A/G	cg17971929	chr21:40555470	PSMG1	0.52	4.69	0.39	6.98e-6	Menarche (age at onset);
TGCT	cis	rs60871478	1.000	rs4720917	chr7:806998	C/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.46	4.6	0.38	1.04e-5	Cerebrospinal P-tau181p levels;
TGCT	cis	rs9653442	0.545	rs2009094	chr2:100765077	G/A	cg07810366	chr2:100720526	AFF3	-0.36	-5.31	-0.43	4.95e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs394563	0.619	rs4895787	chr6:149646500	G/A	cg11245181	chr6:149772854	ZC3H12D	0.27	4.44	0.37	1.94e-5	Dupuytren's disease;
TGCT	cis	rs9457247	0.765	rs4710171	chr6:167430186	A/G	cg23791538	chr6:167370224	RNASET2	-0.49	-4.57	-0.38	1.18e-5	Crohn's disease;
TGCT	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg03609598	chr5:56110824	MAP3K1	-0.63	-4.96	-0.41	2.22e-6	Initial pursuit acceleration;
TGCT	cis	rs7582180	0.606	rs4851299	chr2:100954191	C/A	cg14675211	chr2:100938903	LONRF2	0.5	4.78	0.39	4.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1205863	1.000	rs1205881	chr6:11947313	C/T	cg07106625	chr6:11870215	NA	0.51	5.05	0.41	1.51e-6	Disc degeneration (lumbar);
TGCT	cis	rs10464366	0.544	rs34866559	chr7:39166071	G/A	cg15212455	chr7:39170539	POU6F2	0.3	6.63	0.51	9.08e-10	IgG glycosylation;
TGCT	cis	rs433598	0.514	rs75599714	chr16:20677754	T/C	cg08248577	chr16:19727447	IQCK;C16orf88	-0.25	-4.82	-0.4	4.07e-6	Schizophrenia;
TGCT	cis	rs2239547	0.522	rs2581797	chr3:52972468	C/T	cg10802521	chr3:52805072	NEK4	0.65	6.14	0.48	1.02e-8	Schizophrenia;
TGCT	cis	rs2710642	0.925	rs72807578	chr2:63008044	G/A	cg17519650	chr2:63277830	OTX1	-0.59	-4.82	-0.4	4.13e-6	LDL cholesterol levels;LDL cholesterol;
TGCT	cis	rs6087771	0.642	rs6060411	chr20:30222139	T/C	cg10886678	chr20:30946050	ASXL1	-0.57	-4.5	-0.37	1.55e-5	Subcortical brain region volumes;Putamen volume;
TGCT	cis	rs7208859	0.573	rs8078656	chr17:29080971	A/T	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs9291683	0.566	rs13115776	chr4:10040189	C/G	cg11266682	chr4:10021025	SLC2A9	0.61	7.73	0.57	3.25e-12	Bone mineral density;
TGCT	cis	rs3806843	0.576	rs246021	chr5:140334504	C/A	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs12579753	0.957	rs35001833	chr12:82188510	C/G	cg07988820	chr12:82153109	PPFIA2	-0.65	-6.79	-0.52	4.09e-10	Resting heart rate;
TGCT	cis	rs7666738	0.830	rs7664051	chr4:98766970	C/G	cg17366294	chr4:99064904	C4orf37	0.65	6.78	0.52	4.31e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2832191	0.716	rs2692625	chr21:30446360	C/G	cg08807101	chr21:30365312	RNF160	0.65	6.14	0.48	1.03e-8	Dental caries;
TGCT	cis	rs17376456	0.569	rs7702348	chr5:93065683	A/G	cg21475434	chr5:93447410	FAM172A	-0.64	-5.2	-0.42	7.86e-7	Diabetic retinopathy;
TGCT	cis	rs6663390	1.000	rs6663390	chr1:208092269	G/T	cg03990033	chr1:208084030	CD34	0.49	4.98	0.41	2.05e-6	Facial morphology (factor 18);
TGCT	cis	rs4919669	0.668	rs4146429	chr10:104401632	T/C	cg05855489	chr10:104503620	C10orf26	0.76	4.44	0.37	1.98e-5	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg08439880	chr3:133502540	NA	-0.31	-5.91	-0.47	3.08e-8	Iron status biomarkers;
TGCT	cis	rs10946940	0.897	rs6456801	chr6:27625532	T/C	cg10876282	chr6:28092338	ZSCAN16	0.48	4.83	0.4	4e-6	Systemic lupus erythematosus;
TGCT	cis	rs77633900	0.614	rs280033	chr15:77023099	G/A	cg21673338	chr15:77095150	SCAPER	-0.51	-5.12	-0.42	1.11e-6	Non-glioblastoma glioma;Glioma;
TGCT	cis	rs4727027	0.933	rs10277119	chr7:148849942	T/C	cg23583168	chr7:148888333	NA	-0.77	-10.1	-0.67	7.35e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg02953382	chr22:24373134	LOC391322	-0.76	-7.81	-0.57	2.09e-12	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs12477438	1.000	rs12053372	chr2:99810055	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-8.59	-0.61	3.06e-14	Chronic sinus infection;
TGCT	cis	rs4663866	1.000	rs4663867	chr2:239159964	G/C	cg17283117	chr2:239148619	HES6	0.98	4.52	0.38	1.42e-5	Irritable bowel syndrome;
TGCT	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg19774624	chr17:42201019	HDAC5	-0.83	-8.49	-0.61	5.19e-14	Total body bone mineral density;
TGCT	cis	rs7698623	0.850	rs7684659	chr4:88769571	G/A	cg02735620	chr4:88950514	PKD2	-0.44	-4.81	-0.4	4.22e-6	Cardiovascular disease risk factors;
TGCT	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.13	14.46	0.79	2.27e-28	Height;
TGCT	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg22029157	chr1:209979665	IRF6	0.76	6.32	0.49	4.37e-9	Cleft lip with or without cleft palate;
TGCT	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg06753367	chr22:24256600	NA	-0.25	-4.73	-0.39	5.98e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6089584	0.927	rs2296081	chr20:60572663	G/T	cg13665807	chr20:60559372	TAF4	-0.44	-4.93	-0.4	2.59e-6	Body mass index;
TGCT	cis	rs12579753	0.879	rs7958657	chr12:82135067	G/A	cg21231944	chr12:82153410	PPFIA2	-0.36	-4.7	-0.39	6.72e-6	Resting heart rate;
TGCT	cis	rs16957091	0.647	rs28810091	chr15:43156253	G/A	cg17935677	chr15:44119062	WDR76	0.53	4.69	0.39	7.11e-6	MGMT methylation in smokers;
TGCT	cis	rs6543140	0.601	rs78178597	chr2:103023596	G/T	cg09003973	chr2:102972529	NA	0.76	6.19	0.49	8.22e-9	Blood protein levels;
TGCT	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg00684032	chr4:1343700	KIAA1530	0.25	5.09	0.42	1.31e-6	Obesity-related traits;
TGCT	cis	rs8051431	0.840	rs35484594	chr16:72021985	C/A	cg06353428	chr16:71660113	MARVELD3	0.59	4.58	0.38	1.1e-5	LDL cholesterol levels;
TGCT	cis	rs4478037	0.558	rs80167648	chr3:33069317	A/G	cg19404215	chr3:33155277	CRTAP	1.03	4.92	0.4	2.66e-6	Major depressive disorder;
TGCT	cis	rs1018836	0.923	rs4734266	chr8:91628147	C/T	cg16814680	chr8:91681699	NA	-0.86	-9.19	-0.64	1.12e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7772486	0.754	rs2064185	chr6:146066814	G/A	cg13319975	chr6:146136371	FBXO30	0.56	4.93	0.4	2.56e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs13064411	0.696	rs6787026	chr3:113162117	A/G	cg18753928	chr3:113234510	CCDC52	-0.66	-4.53	-0.38	1.39e-5	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs11122272	0.735	rs910822	chr1:231498721	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-6.63	-0.51	9.1e-10	Hemoglobin concentration;
TGCT	cis	rs4372836	0.504	rs13382966	chr2:29068882	T/C	cg09522027	chr2:28974177	PPP1CB	-0.6	-5.91	-0.47	3.15e-8	Body mass index;
TGCT	cis	rs4780355	1.000	rs1111186	chr16:11347048	T/C	cg00044050	chr16:11439710	C16orf75	0.55	4.78	0.39	4.93e-6	Crohn's disease and psoriasis;
TGCT	cis	rs7772486	0.875	rs1412081	chr6:146409733	A/G	cg05347473	chr6:146136440	FBXO30	0.55	5.14	0.42	1.05e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs80282103	0.618	rs2387299	chr10:1163427	A/G	cg18964960	chr10:1102726	WDR37	1.03	4.53	0.38	1.35e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs7043114	0.507	rs10820971	chr9:95161740	G/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-5.6	-0.45	1.32e-7	Height;
TGCT	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg17264618	chr3:40429014	ENTPD3	-0.32	-4.64	-0.38	8.57e-6	Renal cell carcinoma;
TGCT	cis	rs739496	0.843	rs616559	chr12:112003350	C/T	cg10833066	chr12:111807467	FAM109A	-0.34	-4.95	-0.41	2.4e-6	Platelet count;
TGCT	cis	rs7945705	0.967	rs10769968	chr11:8907583	G/C	cg21881798	chr11:8931708	C11orf17;ST5	0.42	4.7	0.39	6.86e-6	Hemoglobin concentration;
TGCT	cis	rs950169	0.887	rs3860265	chr15:84945185	C/T	cg17173187	chr15:85201210	NMB	0.58	5.93	0.47	2.77e-8	Schizophrenia;
TGCT	cis	rs9788721	0.836	rs2009746	chr15:78754102	A/G	cg18825076	chr15:78729989	IREB2	-0.32	-5.02	-0.41	1.76e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
TGCT	cis	rs826838	1.000	rs9795768	chr12:39012479	T/C	cg13010199	chr12:38710504	ALG10B	0.83	6.91	0.53	2.21e-10	Heart rate;
TGCT	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg11494091	chr17:61959527	GH2	0.61	14.8	0.8	3.65e-29	Prudent dietary pattern;
TGCT	cis	rs1964356	0.524	rs7839585	chr8:8854235	C/G	cg15556689	chr8:8085844	FLJ10661	-0.57	-4.69	-0.39	7.16e-6	Mean corpuscular volume;
TGCT	cis	rs62380364	0.602	rs650702	chr5:88055313	G/A	cg24804195	chr5:87968844	LOC645323	-0.57	-5.56	-0.45	1.59e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9858542	0.953	rs9837027	chr3:49597013	C/T	cg03060546	chr3:49711283	APEH	-0.61	-5.37	-0.43	3.78e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs6456156	0.766	rs150112	chr6:167509878	C/T	cg07741184	chr6:167504864	NA	-0.24	-4.74	-0.39	5.7e-6	Primary biliary cholangitis;
TGCT	cis	rs28595532	0.920	rs114639588	chr4:119736176	T/C	cg14228332	chr4:119757509	SEC24D	1.31	7.06	0.54	1.06e-10	Cannabis dependence symptom count;
TGCT	cis	rs17767294	0.708	rs72847383	chr6:27875641	G/A	cg08851530	chr6:28072375	NA	1.57	7.27	0.55	3.59e-11	Parkinson's disease;
TGCT	cis	rs7432375	0.580	rs4678442	chr3:136532971	A/G	cg15507776	chr3:136538369	TMEM22	0.55	5.63	0.45	1.15e-7	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7809950	0.906	rs2253269	chr7:107201114	C/T	cg23024343	chr7:107201750	COG5	-0.34	-5.26	-0.43	6.08e-7	Coronary artery disease;
TGCT	cis	rs2066819	1.000	rs79436528	chr12:56686997	C/T	cg26714650	chr12:56694279	CS	-1.36	-6.06	-0.48	1.54e-8	Psoriasis vulgaris;
TGCT	cis	rs67073037	0.955	rs56289239	chr2:29137309	C/T	cg09522027	chr2:28974177	PPP1CB	0.57	4.49	0.37	1.59e-5	Breast cancer;Breast cancer (estrogen-receptor negative);
TGCT	cis	rs6683273	0.830	rs57342206	chr1:3227501	C/T	cg17435683	chr1:3230609	PRDM16	-0.4	-4.53	-0.38	1.35e-5	QRS duration;
TGCT	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.01	8.32	0.6	1.34e-13	Platelet count;
TGCT	cis	rs981844	0.767	rs6857738	chr4:154689140	A/C	cg14289246	chr4:154710475	SFRP2	-0.91	-8.31	-0.6	1.38e-13	Response to statins (LDL cholesterol change);
TGCT	trans	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg21659725	chr3:3221576	CRBN	-0.7	-7.98	-0.58	8.35e-13	Body mass index;
TGCT	cis	rs12049351	0.774	rs16849844	chr1:229620396	A/G	cg12130225	chr1:229698885	NA	-0.41	-4.79	-0.4	4.64e-6	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs587847	0.737	rs28440992	chr15:37625116	A/G	cg00216138	chr15:37171175	LOC145845	0.31	4.57	0.38	1.15e-5	Intraocular pressure;
TGCT	cis	rs4077515	0.967	rs4567159	chr9:139277059	G/A	cg13741927	chr9:139327495	INPP5E	-0.2	-4.59	-0.38	1.06e-5	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs4900538	0.819	rs72700604	chr14:102882307	G/A	cg18135206	chr14:102964638	TECPR2	-0.2	-4.53	-0.38	1.39e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs10464366	0.912	rs2030960	chr7:39106010	G/A	cg18850127	chr7:39170497	POU6F2	0.21	4.5	0.37	1.55e-5	IgG glycosylation;
TGCT	cis	rs2034088	0.833	rs4968120	chr17:431364	T/G	cg06217071	chr17:408420	NA	0.36	5.35	0.43	4.18e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs17076896	0.786	rs7335968	chr13:19937189	C/A	cg00777926	chr13:20807375	GJB6	-0.41	-4.82	-0.4	4.03e-6	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs3125734	0.633	rs4979773	chr10:63967731	G/C	cg09941381	chr10:64027924	RTKN2	-0.37	-5.7	-0.46	8.15e-8	Rheumatoid arthritis;
TGCT	cis	rs1451375	0.794	rs11238133	chr7:50542914	A/C	cg18232548	chr7:50535776	DDC	-0.44	-6.52	-0.51	1.59e-9	Malaria;
TGCT	cis	rs10791097	0.694	rs10894273	chr11:130742155	G/T	cg12179176	chr11:130786555	SNX19	0.84	10.17	0.67	4.95e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	trans	rs4262150	0.544	rs55802718	chr5:151916541	G/A	cg26032021	chr14:54804413	NA	0.39	6.64	0.51	8.72e-10	Bipolar disorder and schizophrenia;
TGCT	cis	rs903263	0.601	rs12405120	chr1:84556523	C/T	cg09664975	chr1:84543551	PRKACB	-0.49	-4.73	-0.39	6.05e-6	Breast cancer (male);
TGCT	cis	rs790110	1.000	rs790110	chr3:122384020	T/G	cg07366462	chr3:123162899	ADCY5	0.42	4.71	0.39	6.54e-6	Acoustic startle blink response;
TGCT	cis	rs9952991	0.941	rs2542151	chr18:12779947	G/T	cg23598886	chr18:12777645	NA	0.62	5.9	0.47	3.26e-8	Inflammatory skin disease;
TGCT	trans	rs1814175	0.715	rs1722007	chr11:49897319	T/C	cg15704280	chr7:45808275	SEPT13	-0.72	-8.14	-0.59	3.63e-13	Height;
TGCT	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg13206674	chr6:150067644	NUP43	0.52	4.51	0.38	1.5e-5	Lung cancer;
TGCT	cis	rs2742417	1.000	rs2673039	chr3:45748435	A/G	cg04837898	chr3:45731254	SACM1L	-0.51	-5.23	-0.42	7.13e-7	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg27211696	chr2:191398769	TMEM194B	0.29	5.3	0.43	5.19e-7	Pulse pressure;
TGCT	cis	rs709400	0.691	rs12888077	chr14:103872553	G/T	cg12935359	chr14:103987150	CKB	0.34	5.22	0.42	7.18e-7	Body mass index;
TGCT	cis	rs7714584	1.000	rs3900064	chr5:150264414	C/G	cg22134413	chr5:150180641	NA	-0.85	-6.15	-0.48	9.74e-9	Crohn's disease;
TGCT	cis	rs2046867	0.818	rs60228315	chr3:72805034	C/A	cg25664220	chr3:72788482	NA	-0.57	-7.05	-0.53	1.13e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg22508957	chr16:3507546	NAT15	0.5	5.75	0.46	6.64e-8	Tuberculosis;
TGCT	cis	rs2463822	0.583	rs7104825	chr11:62026833	C/T	cg06239285	chr11:62104954	ASRGL1	-0.96	-6.11	-0.48	1.17e-8	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs2197308	0.692	rs1904964	chr12:37933241	T/A	cg13010199	chr12:38710504	ALG10B	0.63	5.04	0.41	1.58e-6	Morning vs. evening chronotype;
TGCT	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.82	7.61	0.56	5.98e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs739496	0.546	rs12426493	chr12:112344756	T/C	cg10833066	chr12:111807467	FAM109A	0.39	5.65	0.45	1.03e-7	Platelet count;
TGCT	cis	rs7833790	0.777	rs7815272	chr8:82691809	T/G	cg17211192	chr8:82754475	SNX16	-1.04	-8.46	-0.6	6.42e-14	Diastolic blood pressure;
TGCT	cis	rs116161686	0.500	rs76610459	chr1:210050756	T/G	cg22029157	chr1:209979665	IRF6	0.74	5.6	0.45	1.31e-7	Coronary artery disease;
TGCT	cis	rs7568458	0.870	rs6719046	chr2:85757371	G/A	cg17127132	chr2:85788382	GGCX	0.72	6.69	0.51	6.94e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.86	-10.09	-0.67	7.49e-18	Prudent dietary pattern;
TGCT	cis	rs7639513	0.520	rs79141906	chr3:12711977	A/C	cg23032965	chr3:12705835	RAF1	0.75	7.85	0.58	1.69e-12	Itch intensity from mosquito bite;
TGCT	cis	rs4237845	0.844	rs4630335	chr12:58302258	A/G	cg23860436	chr12:58378763	NA	0.33	4.9	0.4	2.92e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs36051895	0.559	rs10815172	chr9:5212254	T/A	cg02405213	chr9:5042618	JAK2	-0.67	-8.3	-0.6	1.49e-13	Pediatric autoimmune diseases;
TGCT	cis	rs28595532	0.920	rs114462478	chr4:119752656	T/C	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs9467773	1.000	rs4871	chr6:26545632	G/A	cg26531700	chr6:26746687	NA	0.46	4.46	0.37	1.82e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs3858526	0.959	rs11039699	chr11:5951091	G/A	cg13902645	chr11:5959945	NA	-0.48	-5.0	-0.41	1.95e-6	DNA methylation (variation);
TGCT	cis	rs1008375	1.000	rs2159583	chr4:17658838	T/C	cg16339924	chr4:17578868	LAP3	0.63	5.37	0.43	3.77e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1344694	0.566	rs13029765	chr2:216894976	A/T	cg12620499	chr2:216877984	MREG	0.82	9.34	0.64	4.98e-16	Alcohol dependence;
TGCT	cis	rs7592578	0.766	rs35818159	chr2:191409616	C/G	cg11845111	chr2:191398756	TMEM194B	-0.42	-4.48	-0.37	1.69e-5	Diastolic blood pressure;
TGCT	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg07507251	chr3:52567010	NT5DC2	0.42	5.8	0.46	5.29e-8	Bipolar disorder;
TGCT	cis	rs10992471	0.603	rs987553	chr9:95298694	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.6	-5.68	-0.45	9.01e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs4234284	0.556	rs7650549	chr3:126968288	C/T	cg25436886	chr3:127056972	NA	-0.5	-4.9	-0.4	2.91e-6	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
TGCT	cis	rs7267979	1.000	rs2482911	chr20:25395528	T/C	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10461617	0.512	rs7715746	chr5:56048837	C/T	cg24531977	chr5:56204891	C5orf35	-0.46	-4.52	-0.38	1.45e-5	Type 2 diabetes;
TGCT	cis	rs6543140	0.964	rs4851578	chr2:103028951	T/G	cg09003973	chr2:102972529	NA	0.58	4.83	0.4	3.87e-6	Blood protein levels;
TGCT	cis	rs4268898	0.722	rs11691212	chr2:24404733	A/G	cg02683114	chr2:24398427	C2orf84	0.19	4.76	0.39	5.37e-6	Asthma;
TGCT	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg07507251	chr3:52567010	NT5DC2	0.47	6.6	0.51	1.05e-9	Bipolar disorder;
TGCT	cis	rs881375	0.678	rs9886724	chr9:123665019	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	5.31	0.43	4.92e-7	Rheumatoid arthritis;
TGCT	cis	rs6582630	0.502	rs11181230	chr12:38300085	A/G	cg13010199	chr12:38710504	ALG10B	0.57	4.45	0.37	1.89e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs12410462	0.502	rs75429875	chr1:227957200	A/C	cg23173402	chr1:227635558	NA	0.7	4.81	0.4	4.31e-6	Major depressive disorder;
TGCT	cis	rs9467773	1.000	rs6922824	chr6:26553815	C/G	cg26531700	chr6:26746687	NA	-0.47	-4.55	-0.38	1.25e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7267979	1.000	rs4815405	chr20:25317492	T/C	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2067615	0.579	rs7975576	chr12:107132501	A/G	cg15890332	chr12:107067104	RFX4	0.29	5.84	0.46	4.33e-8	Heart rate;
TGCT	cis	rs10791097	0.694	rs4459316	chr11:130756176	T/C	cg14779329	chr11:130786720	SNX19	0.29	4.94	0.41	2.45e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs2663905	0.706	rs7162859	chr15:81360038	C/T	cg18028999	chr15:81426610	C15orf26	0.73	6.54	0.51	1.44e-9	QT interval (drug interaction);
TGCT	cis	rs9486719	1.000	rs4343922	chr6:96876903	C/T	cg18709589	chr6:96969512	KIAA0776	0.67	5.23	0.43	7e-7	Migraine;Coronary artery disease;
TGCT	cis	rs1150668	0.799	rs2142730	chr6:28266149	T/C	cg11262757	chr6:27280423	POM121L2	0.46	4.62	0.38	9.52e-6	Pubertal anthropometrics;
TGCT	cis	rs7226408	1.000	rs72883555	chr18:34364093	G/A	cg06757138	chr18:34340585	FHOD3	0.28	4.76	0.39	5.23e-6	Obesity-related traits;
TGCT	cis	rs4321325	1.000	rs4321325	chr2:127950997	C/T	cg09760422	chr2:128146352	NA	0.39	4.88	0.4	3.23e-6	Protein C levels;
TGCT	cis	rs4727027	0.899	rs11768971	chr7:148825826	C/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	4.58	0.38	1.13e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	trans	rs17685	0.753	rs1637045	chr7:75703895	T/C	cg19862616	chr7:65841803	NCRNA00174	0.51	8.57	0.61	3.45e-14	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs4862750	0.872	rs10027252	chr4:187873462	T/G	cg10295955	chr4:187884368	NA	-0.93	-12.59	-0.75	6.43e-24	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs60871478	0.588	rs56205589	chr7:910419	G/A	cg15782153	chr7:917662	C7orf20	0.57	5.12	0.42	1.14e-6	Cerebrospinal P-tau181p levels;
TGCT	trans	rs208520	0.690	rs2126120	chr6:66742754	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	10.83	0.7	1.19e-19	Exhaled nitric oxide output;
TGCT	cis	rs9527	0.545	rs7095304	chr10:104954795	G/A	cg15744005	chr10:104629667	AS3MT	-0.41	-4.78	-0.39	4.88e-6	Arsenic metabolism;
TGCT	cis	rs7666738	0.791	rs34437628	chr4:99029232	C/G	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9372498	0.505	rs56406560	chr6:118991787	G/A	cg07617317	chr6:118971624	C6orf204	0.45	4.83	0.4	3.93e-6	Diastolic blood pressure;
TGCT	cis	rs9291683	0.655	rs3822242	chr4:10094904	T/C	cg11266682	chr4:10021025	SLC2A9	-0.51	-6.15	-0.48	9.58e-9	Bone mineral density;
TGCT	cis	rs4862750	0.872	rs10027252	chr4:187873462	T/G	cg11301795	chr4:187892539	NA	-0.34	-5.0	-0.41	1.94e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7914558	1.000	rs12255047	chr10:104760752	G/A	cg04362960	chr10:104952993	NT5C2	0.6	5.42	0.44	2.99e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs6089829	0.962	rs6089825	chr20:61668447	C/T	cg03213289	chr20:61660250	NA	0.7	10.08	0.67	8.18e-18	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs10782582	0.593	rs17585530	chr1:76134990	G/A	cg10523679	chr1:76189770	ACADM	-0.68	-7.1	-0.54	8.65e-11	Daytime sleep phenotypes;
TGCT	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg08859206	chr1:53392774	SCP2	-0.44	-6.62	-0.51	9.74e-10	Monocyte count;
TGCT	cis	rs478304	0.593	rs4645933	chr11:65485120	C/T	cg27068330	chr11:65405492	SIPA1	-1.07	-7.79	-0.57	2.29e-12	Acne (severe);
TGCT	cis	rs7666738	0.611	rs34982650	chr4:98819530	T/A	cg18180107	chr4:99064573	C4orf37	0.55	5.25	0.43	6.31e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs13102973	0.933	rs7656595	chr4:135875693	G/A	cg14419869	chr4:135874104	NA	0.24	4.46	0.37	1.83e-5	Subjective well-being;
TGCT	cis	rs6121246	0.567	rs6060344	chr20:30207316	A/G	cg21427119	chr20:30132790	HM13	-0.43	-6.17	-0.48	8.86e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs7727544	0.582	rs3805683	chr5:131535125	T/G	cg14196790	chr5:131705035	SLC22A5	0.33	4.49	0.37	1.59e-5	Blood metabolite levels;
TGCT	cis	rs2549003	0.966	rs10065633	chr5:131816716	T/C	cg02551604	chr5:131831745	NA	-0.89	-11.77	-0.73	6.36e-22	Asthma (sex interaction);
TGCT	cis	rs2836633	0.929	rs764482	chr21:40033661	C/G	cg05519781	chr21:40033154	ERG	0.69	6.57	0.51	1.27e-9	Coronary artery disease;
TGCT	trans	rs4332037	1.000	rs4332037	chr7:1950809	C/T	cg10840412	chr1:235813424	GNG4	1.06	8.34	0.6	1.21e-13	Bipolar disorder;
TGCT	cis	rs2640806	0.505	rs7818838	chr8:97359279	A/C	cg04026948	chr8:97953330	PGCP	-0.26	-4.64	-0.38	8.63e-6	Obesity-related traits;
TGCT	cis	rs713587	0.713	rs11682135	chr2:25205377	G/A	cg01884057	chr2:25150051	NA	-0.38	-7.81	-0.57	2.04e-12	Body mass index in non-asthmatics;
TGCT	cis	rs2072499	1.000	rs2072499	chr1:156169610	A/G	cg06970220	chr1:156163860	SLC25A44	0.67	5.9	0.47	3.22e-8	Testicular germ cell tumor;
TGCT	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg20607798	chr8:58055168	NA	0.5	4.66	0.39	8.04e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs478304	0.651	rs78412025	chr11:65495696	T/C	cg10518572	chr11:65560635	OVOL1	-0.24	-4.67	-0.39	7.83e-6	Acne (severe);
TGCT	cis	rs79349575	0.783	rs318095	chr17:46974734	T/C	cg07967210	chr17:47022446	SNF8	0.44	6.13	0.48	1.06e-8	Type 2 diabetes;
TGCT	cis	rs9486719	1.000	rs2064947	chr6:97052754	C/T	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.32	-0.6	1.32e-13	Migraine;Coronary artery disease;
TGCT	cis	rs1843834	0.517	rs1908252	chr2:225484736	G/A	cg22455342	chr2:225449267	CUL3	0.62	5.63	0.45	1.12e-7	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs9549260	0.664	rs9532575	chr13:41225361	G/C	cg21288729	chr13:41239152	FOXO1	0.99	10.42	0.68	1.22e-18	Red blood cell count;
TGCT	cis	rs617219	0.710	rs10054122	chr5:78581371	A/T	cg05890484	chr5:78407552	BHMT	-0.36	-4.88	-0.4	3.25e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs7216064	0.953	rs4791046	chr17:65851973	G/A	cg12091567	chr17:66097778	LOC651250	-0.89	-7.11	-0.54	8.05e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs3771570	0.901	rs73006381	chr2:242406654	G/C	cg21155796	chr2:242212141	HDLBP	0.93	6.69	0.52	6.74e-10	Prostate cancer;
TGCT	cis	rs2180341	0.521	rs12203812	chr6:127617816	A/T	cg27446573	chr6:127587934	RNF146	0.64	5.66	0.45	1.01e-7	Breast cancer;
TGCT	cis	rs12579753	0.719	rs10862377	chr12:82270172	C/T	cg07988820	chr12:82153109	PPFIA2	-0.42	-4.44	-0.37	1.97e-5	Resting heart rate;
TGCT	cis	rs1670533	1.000	rs651017	chr4:1091062	A/G	cg20887711	chr4:1340912	KIAA1530	0.6	4.53	0.38	1.38e-5	Recombination rate (females);
TGCT	cis	rs5758659	0.714	rs5758578	chr22:42490292	A/C	cg15557168	chr22:42548783	NA	0.18	4.56	0.38	1.23e-5	Cognitive function;
TGCT	cis	rs2204008	0.624	rs2320449	chr12:38224190	T/C	cg13010199	chr12:38710504	ALG10B	0.63	4.98	0.41	2.09e-6	Bladder cancer;
TGCT	cis	rs7833790	0.724	rs10958045	chr8:82722994	T/C	cg27398817	chr8:82754497	SNX16	-0.67	-5.34	-0.43	4.27e-7	Diastolic blood pressure;
TGCT	cis	rs7772486	0.790	rs6570724	chr6:146151283	T/C	cg23711669	chr6:146136114	FBXO30	0.89	10.12	0.67	6.38e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs8013055	0.846	rs7160747	chr14:105983740	A/G	cg23356831	chr14:105996513	TMEM121	0.33	4.83	0.4	3.86e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs2739330	0.964	rs2739338	chr22:24297130	T/C	cg18538332	chr22:24372958	LOC391322	-0.99	-12.8	-0.75	2e-24	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs968451	0.865	rs5757609	chr22:39707845	G/C	cg17798944	chr22:39715225	SNORD43;RPL3	0.83	8.1	0.59	4.48e-13	Primary biliary cholangitis;
TGCT	cis	rs7666738	0.830	rs28795113	chr4:98951331	A/G	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg02953382	chr22:24373134	LOC391322	0.78	6.56	0.51	1.33e-9	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs478304	0.654	rs7115734	chr11:65458964	G/A	cg17480646	chr11:65405466	SIPA1	-0.61	-8.27	-0.6	1.79e-13	Acne (severe);
TGCT	cis	rs6860806	0.507	rs270615	chr5:131641573	G/C	cg24060327	chr5:131705240	SLC22A5	-0.73	-7.82	-0.57	1.94e-12	Breast cancer;
TGCT	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg09033563	chr22:24373618	LOC391322	-0.47	-4.52	-0.38	1.41e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.96	-8.31	-0.6	1.43e-13	Platelet count;
TGCT	cis	rs7666738	0.830	rs13124127	chr4:98990729	G/A	cg18180107	chr4:99064573	C4orf37	0.51	4.68	0.39	7.37e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg11764359	chr7:65958608	NA	-0.55	-5.0	-0.41	1.94e-6	Aortic root size;
TGCT	cis	rs1580019	0.563	rs13225132	chr7:32800975	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.57	4.83	0.4	3.88e-6	Cognitive ability;
TGCT	cis	rs13242816	1.000	rs34424131	chr7:116119002	G/A	cg16553024	chr7:116138462	CAV2	-0.45	-4.81	-0.4	4.32e-6	P wave duration;
TGCT	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg22963979	chr7:1858916	MAD1L1	-0.41	-6.71	-0.52	6.13e-10	Schizophrenia;
TGCT	cis	rs28595532	0.920	rs116108618	chr4:119763585	C/T	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.46	0.56	1.3e-11	Prudent dietary pattern;
TGCT	cis	rs1865760	0.516	rs9379819	chr6:26049819	A/C	cg16482183	chr6:26056742	HIST1H1C	0.57	5.0	0.41	1.93e-6	Height;
TGCT	cis	rs3735485	0.638	rs10236356	chr7:45138465	C/T	cg16731821	chr7:44153333	AEBP1	-0.25	-4.66	-0.39	8.17e-6	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
TGCT	cis	rs9381040	0.610	rs717883	chr6:41045270	T/C	cg03526776	chr6:41159608	TREML2	0.27	5.34	0.43	4.21e-7	Alzheimer's disease (late onset);
TGCT	trans	rs208520	0.690	rs1885100	chr6:66871047	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-10.43	-0.68	1.13e-18	Exhaled nitric oxide output;
TGCT	cis	rs7169223	0.653	rs12905740	chr15:79082364	C/T	cg03762349	chr15:79060523	ADAMTS7	0.24	4.96	0.41	2.24e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
TGCT	cis	rs9611519	0.780	rs2284079	chr22:41658632	C/T	cg03806693	chr22:41940476	POLR3H	-0.74	-7.15	-0.54	6.65e-11	Neuroticism;
TGCT	cis	rs62380364	0.602	rs591228	chr5:88064809	G/A	cg22951263	chr5:87985283	NA	-0.58	-6.28	-0.49	5.32e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg18876405	chr7:65276391	NA	-0.36	-5.41	-0.44	3.12e-7	Aortic root size;
TGCT	cis	rs8013055	0.846	rs10139300	chr14:105974501	A/G	cg19700328	chr14:106028568	NA	-0.53	-5.91	-0.47	3.03e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs12142240	0.698	rs56358525	chr1:46849520	C/T	cg00530320	chr1:46809349	NSUN4	0.29	5.79	0.46	5.34e-8	Menopause (age at onset);
TGCT	cis	rs941408	0.515	rs1640262	chr19:2779134	C/T	cg06609049	chr19:2785107	THOP1	-1.09	-12.69	-0.75	3.58e-24	Total cholesterol levels;
TGCT	cis	rs854765	0.583	rs4925125	chr17:17794444	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.72	-7.63	-0.57	5.43e-12	Total body bone mineral density;
TGCT	cis	rs4478858	0.647	rs6425720	chr1:31709555	A/G	cg00250761	chr1:31883323	NA	-0.27	-4.9	-0.4	2.89e-6	Alcohol dependence;
TGCT	cis	rs9814567	0.752	rs6779326	chr3:134330027	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-6.41	-0.5	2.8e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs700651	0.789	rs62277902	chr2:198879443	T/A	cg00792783	chr2:198669748	PLCL1	-0.59	-5.27	-0.43	5.92e-7	Intracranial aneurysm;
TGCT	cis	rs11148252	0.595	rs4885325	chr13:53171317	C/T	cg00495681	chr13:53174319	NA	0.62	6.15	0.48	1e-8	Lewy body disease;
TGCT	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg06238570	chr21:40685208	BRWD1	0.67	6.41	0.5	2.8e-9	Cognitive function;
TGCT	cis	rs9807989	0.507	rs4851577	chr2:103028921	T/C	cg03938978	chr2:103052716	IL18RAP	0.27	5.41	0.44	3.18e-7	Asthma;
TGCT	cis	rs9640161	0.830	rs6722	chr7:150068933	T/C	cg21361702	chr7:150065534	REPIN1	0.49	4.56	0.38	1.19e-5	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs2180341	0.960	rs9398842	chr6:127674662	T/C	cg27446573	chr6:127587934	RNF146	1.14	10.91	0.7	7.51e-20	Breast cancer;
TGCT	cis	rs10791323	0.569	rs1119852	chr11:133743022	C/A	cg15485101	chr11:133734466	NA	0.37	5.42	0.44	3e-7	Childhood ear infection;
TGCT	cis	rs4455778	0.580	rs4551289	chr7:49112437	G/T	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs6121246	0.559	rs6058462	chr20:30367674	C/T	cg13852791	chr20:30311386	BCL2L1	0.83	8.16	0.59	3.22e-13	Mean corpuscular hemoglobin;
TGCT	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.46	-5.47	-0.44	2.36e-7	Longevity;Endometriosis;
TGCT	cis	rs1348850	0.915	rs10930798	chr2:178446141	G/A	cg22681709	chr2:178499509	PDE11A	-0.36	-4.47	-0.37	1.75e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs7428	0.847	rs1969260	chr2:85568810	C/T	cg24342717	chr2:85555507	TGOLN2	-0.4	-6.42	-0.5	2.6e-9	Ear protrusion;
TGCT	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg11062466	chr8:58055876	NA	0.42	4.49	0.37	1.61e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs4773330	0.660	rs1557247	chr13:111807648	C/T	cg14154082	chr13:112174009	NA	0.4	4.46	0.37	1.83e-5	Bilirubin levels;
TGCT	cis	rs12510870	0.599	rs10028196	chr4:74389073	A/T	cg05868023	chr4:75230803	EREG	0.55	4.7	0.39	6.84e-6	Iris color (b* coordinate);
TGCT	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg05872129	chr22:39784769	NA	-1.01	-11.09	-0.71	2.82e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs7772486	0.790	rs1832362	chr6:146179955	C/T	cg23711669	chr6:146136114	FBXO30	0.92	10.44	0.68	1.06e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg06028808	chr11:68637592	NA	-0.51	-6.59	-0.51	1.1e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg21862992	chr11:68658383	NA	0.48	6.47	0.5	2.03e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs564309	0.681	rs4581279	chr1:228622347	A/G	cg22700015	chr1:228743131	NA	-0.74	-4.46	-0.37	1.78e-5	Hip circumference (psychosocial stress interaction);
TGCT	cis	rs4372836	0.504	rs10177006	chr2:29088256	A/G	cg09522027	chr2:28974177	PPP1CB	-0.57	-5.63	-0.45	1.14e-7	Body mass index;
TGCT	cis	rs4253772	0.530	rs6008662	chr22:46713917	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.73	5.34	0.43	4.21e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs7786808	0.741	rs62479982	chr7:158227546	A/G	cg01191920	chr7:158217561	PTPRN2	-0.44	-6.66	-0.51	7.85e-10	Obesity-related traits;
TGCT	cis	rs765787	0.530	rs4774542	chr15:45526026	A/C	cg24006582	chr15:45444508	DUOX1	0.26	5.75	0.46	6.64e-8	Uric acid levels;
TGCT	cis	rs909002	0.849	rs6425777	chr1:32105447	G/C	cg11573219	chr1:32083031	HCRTR1	-0.47	-6.09	-0.48	1.29e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs6586111	0.935	rs4933463	chr10:82372866	A/C	cg03086067	chr10:82368399	SH2D4B	-0.24	-4.7	-0.39	6.84e-6	Capecitabine sensitivity;
TGCT	cis	rs9467773	0.967	rs9461267	chr6:26525455	T/G	cg09904177	chr6:26538194	HMGN4	0.65	6.53	0.51	1.53e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg21724239	chr8:58056113	NA	0.42	5.04	0.41	1.59e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7818688	0.674	rs74632106	chr8:95978032	A/G	cg16049864	chr8:95962084	TP53INP1	0.54	4.64	0.38	8.87e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs524023	1.000	rs559946	chr11:64358605	T/C	cg07733098	chr11:64478343	NRXN2	-0.31	-4.67	-0.39	7.59e-6	Urate levels in obese individuals;
TGCT	cis	rs7267979	1.000	rs6107047	chr20:25442097	G/A	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7208859	0.623	rs56812022	chr17:29068733	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	4.87	0.4	3.36e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg01516881	chr6:292596	DUSP22	-0.64	-6.72	-0.52	5.81e-10	Menopause (age at onset);
TGCT	cis	rs7089973	0.872	rs34064819	chr10:116621154	C/A	cg03647239	chr10:116582469	FAM160B1	0.53	4.73	0.39	6.08e-6	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs10992471	0.513	rs710163	chr9:95059804	C/T	cg13798575	chr9:95087839	CENPP;NOL8	0.54	4.98	0.41	2.06e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs13191362	0.688	rs73025321	chr6:162974896	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.63	4.68	0.39	7.32e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs916888	0.647	rs199449	chr17:44808902	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.64	4.91	0.4	2.82e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs3796352	0.568	rs11713376	chr3:52958927	A/G	cg15956490	chr3:53032818	SFMBT1	0.42	4.53	0.38	1.39e-5	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	4.98	0.41	2.08e-6	Prudent dietary pattern;
TGCT	cis	rs473651	0.935	rs474478	chr2:239335473	C/T	cg18131467	chr2:239335373	ASB1	1.01	14.5	0.79	1.78e-28	Multiple system atrophy;
TGCT	cis	rs12110303	1	rs12110303	chr5:90662839	G/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.98	8.99	0.63	3.39e-15	Breast cancer;
TGCT	cis	rs2836950	0.840	rs12482317	chr21:40588241	A/G	cg06238570	chr21:40685208	BRWD1	-0.56	-5.63	-0.45	1.16e-7	Menarche (age at onset);
TGCT	cis	rs3806843	0.966	rs1030163	chr5:140185132	G/A	cg19875535	chr5:140030758	IK	0.35	5.85	0.47	4.01e-8	Depressive symptoms (multi-trait analysis);
TGCT	trans	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg23505145	chr19:12996616	KLF1	0.78	8.12	0.59	4.03e-13	Prostate cancer (SNP x SNP interaction);
TGCT	trans	rs72809171	0.661	rs57817267	chr17:12493228	T/C	cg03074370	chr19:50352995	PTOV1	0.51	6.93	0.53	1.99e-10	Male-pattern baldness;
TGCT	cis	rs10057188	0.786	rs28437030	chr5:77868354	T/C	cg06873401	chr5:77792105	LHFPL2	-0.23	-4.58	-0.38	1.14e-5	Pulse pressure;
TGCT	cis	rs12908161	1.000	rs62021219	chr15:85256159	C/T	cg12863693	chr15:85201151	NMB	0.46	5.51	0.44	1.95e-7	Schizophrenia;
TGCT	cis	rs8141529	0.719	rs132561	chr22:29351179	C/T	cg02153584	chr22:29168773	CCDC117	-0.65	-4.76	-0.39	5.31e-6	Lymphocyte counts;
TGCT	cis	rs7727544	0.618	rs2631367	chr5:131705458	C/G	cg14196790	chr5:131705035	SLC22A5	-0.38	-5.23	-0.43	6.89e-7	Blood metabolite levels;
TGCT	cis	rs3806843	0.576	rs550475	chr5:140273528	G/C	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.52	-0.38	1.42e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg03709012	chr19:19516395	GATAD2A	0.67	5.75	0.46	6.45e-8	Tonsillectomy;
TGCT	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg03351412	chr1:154909251	PMVK	0.51	4.73	0.39	5.9e-6	Prostate cancer;
TGCT	cis	rs9303401	0.659	rs12948133	chr17:56673602	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs7584330	0.554	rs3751109	chr2:238427194	T/C	cg08992911	chr2:238395768	MLPH	0.7	4.72	0.39	6.32e-6	Prostate cancer;
TGCT	cis	rs4727027	0.801	rs12666337	chr7:148796253	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	4.68	0.39	7.53e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs35146811	0.625	rs858514	chr7:99825748	A/G	cg22906224	chr7:99728672	NA	-0.5	-4.51	-0.38	1.48e-5	Coronary artery disease;
TGCT	cis	rs6840360	1.000	rs6840678	chr4:152604331	C/G	cg17479576	chr4:152424074	FAM160A1	0.55	5.87	0.47	3.79e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2594989	1.000	rs2606752	chr3:11360170	A/G	cg00170343	chr3:11313890	ATG7	0.66	4.83	0.4	3.92e-6	Circulating chemerin levels;
TGCT	cis	rs4865875	0.681	rs4242044	chr5:54097130	A/G	cg03861379	chr5:54128677	NA	-0.56	-5.04	-0.41	1.62e-6	Sense of smell;
TGCT	cis	rs7523273	0.526	rs677715	chr1:208047284	A/G	cg22525895	chr1:207977042	MIR29B2	0.32	5.12	0.42	1.14e-6	Schizophrenia;
TGCT	cis	rs6141769	0.542	rs6087976	chr20:31316287	G/A	cg13636640	chr20:31349939	DNMT3B	-0.52	-4.54	-0.38	1.34e-5	Subjective well-being;
TGCT	cis	rs2361718	0.564	rs2304844	chr17:78084507	G/C	cg21238619	chr17:78079768	GAA	-0.34	-4.52	-0.38	1.44e-5	Yeast infection;
TGCT	cis	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg06636001	chr8:8085503	FLJ10661	-0.73	-7.01	-0.53	1.37e-10	Mood instability;
TGCT	cis	rs765787	0.530	rs4514617	chr15:45535439	A/G	cg24006582	chr15:45444508	DUOX1	-0.25	-5.55	-0.45	1.67e-7	Uric acid levels;
TGCT	cis	rs36051895	0.659	rs59668095	chr9:5043688	C/G	cg02405213	chr9:5042618	JAK2	-0.72	-9.64	-0.65	9.46e-17	Pediatric autoimmune diseases;
TGCT	cis	rs7572733	0.534	rs696817	chr2:198722225	A/G	cg00792783	chr2:198669748	PLCL1	0.56	5.08	0.42	1.35e-6	Dermatomyositis;
TGCT	cis	rs11785400	0.762	rs9694556	chr8:143727841	A/G	cg24634471	chr8:143751801	JRK	0.53	5.33	0.43	4.41e-7	Schizophrenia;
TGCT	cis	rs6831352	0.840	rs35073321	chr4:100053276	G/A	cg12011299	chr4:100065546	ADH4	-0.4	-4.88	-0.4	3.26e-6	Alcohol dependence;
TGCT	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg06618935	chr21:46677482	NA	-0.37	-5.56	-0.45	1.58e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg11494091	chr17:61959527	GH2	0.61	14.49	0.79	1.92e-28	Prudent dietary pattern;
TGCT	cis	rs910187	0.605	rs8124918	chr20:45811860	A/G	cg27589058	chr20:45804311	EYA2	-0.36	-7.81	-0.57	2.11e-12	Migraine;
TGCT	cis	rs4722166	0.630	rs6461667	chr7:22796743	A/G	cg13104385	chr7:22767384	IL6	0.22	5.03	0.41	1.65e-6	Lung cancer;
TGCT	cis	rs4845570	0.764	rs12141652	chr1:151716711	A/T	cg07092448	chr1:151763213	TDRKH	-1.03	-7.53	-0.56	8.99e-12	Coronary artery disease;
TGCT	cis	rs1008375	0.966	rs3775927	chr4:17599894	G/T	cg18681998	chr4:17616180	MED28	0.92	9.41	0.65	3.31e-16	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7582180	0.629	rs2309796	chr2:100954385	C/T	cg08017756	chr2:100939284	LONRF2	-0.3	-4.95	-0.41	2.34e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg06238570	chr21:40685208	BRWD1	0.68	6.32	0.49	4.3e-9	Cognitive function;
TGCT	trans	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.88	-9.5	-0.65	2.02e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg04414720	chr1:150670196	GOLPH3L	0.39	5.04	0.41	1.58e-6	Tonsillectomy;
TGCT	cis	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg06636001	chr8:8085503	FLJ10661	0.66	6.04	0.48	1.65e-8	Joint mobility (Beighton score);
TGCT	cis	rs3008870	1.000	rs11208979	chr1:67442275	C/T	cg11518657	chr1:67396239	MIER1	-0.54	-4.61	-0.38	9.72e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs6598955	0.671	rs11247884	chr1:26577338	C/T	cg04990556	chr1:26633338	UBXN11	0.62	4.73	0.39	6.12e-6	Obesity-related traits;
TGCT	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg13683864	chr3:40499215	RPL14	-1.19	-13.2	-0.76	2.17e-25	Renal cell carcinoma;
TGCT	cis	rs3862260	0.509	rs3795663	chr1:120165187	G/A	cg11530693	chr1:120165357	ZNF697	0.21	4.75	0.39	5.48e-6	Systemic lupus erythematosus;
TGCT	cis	rs6964587	0.610	rs7788951	chr7:91468765	A/T	cg17063962	chr7:91808500	NA	0.73	6.7	0.52	6.48e-10	Breast cancer;
TGCT	cis	rs6964587	1.000	rs55745934	chr7:91670998	T/C	cg22709100	chr7:91322751	NA	0.27	4.46	0.37	1.84e-5	Breast cancer;
TGCT	cis	rs9913156	0.841	rs34230287	chr17:4613630	C/T	cg19197139	chr17:4613644	ARRB2	0.86	7.84	0.58	1.73e-12	Lymphocyte counts;
TGCT	cis	rs2201728	0.902	rs12498658	chr4:100237821	G/A	cg07219303	chr4:100140905	ADH6	-0.36	-5.42	-0.44	2.98e-7	Cardiac Troponin-T levels;
TGCT	cis	rs344364	0.511	rs1657144	chr16:1963989	C/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.48	-5.26	-0.43	6.1e-7	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs7647973	0.961	rs11130187	chr3:49307872	T/C	cg07690219	chr3:49449608	TCTA;RHOA	-0.55	-4.48	-0.37	1.68e-5	Menarche (age at onset);
TGCT	cis	rs7568458	0.684	rs1048739	chr2:85764968	T/G	cg17127132	chr2:85788382	GGCX	0.52	4.63	0.38	9.25e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs3820068	0.581	rs61056912	chr1:15926296	A/G	cg05660106	chr1:15850417	CASP9	0.74	7.27	0.55	3.53e-11	Systolic blood pressure;
TGCT	cis	rs3540	0.512	rs3862433	chr15:91076028	G/A	cg22089800	chr15:90895588	ZNF774	-0.76	-7.91	-0.58	1.22e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs8031584	0.781	rs4779498	chr15:31177476	C/T	cg08704250	chr15:31115839	NA	-0.46	-6.73	-0.52	5.7e-10	Huntington's disease progression;
TGCT	cis	rs12477438	0.520	rs13010904	chr2:99754289	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.15	17.85	0.85	4.6e-36	Chronic sinus infection;
TGCT	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg03452623	chr4:187889614	NA	-0.35	-5.28	-0.43	5.49e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1801251	0.963	rs6739638	chr2:233576015	G/A	cg08000102	chr2:233561755	GIGYF2	0.66	6.8	0.52	3.88e-10	Coronary artery disease;
TGCT	cis	rs7027203	0.828	rs4344139	chr9:96600298	T/C	cg14598338	chr9:96623480	NA	-0.61	-9.54	-0.65	1.68e-16	DNA methylation (variation);
TGCT	cis	rs7584330	0.554	rs9646716	chr2:238443784	C/T	cg08992911	chr2:238395768	MLPH	0.64	4.49	0.37	1.63e-5	Prostate cancer;
TGCT	cis	rs8037137	0.915	rs8026714	chr15:91522253	G/A	cg22570213	chr15:91497863	RCCD1	0.49	4.76	0.39	5.37e-6	Platelet count;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
TGCT	cis	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg18252515	chr7:66147081	NA	1.17	7.17	0.54	5.94e-11	Diabetic kidney disease;
TGCT	trans	rs114540395	0.858	rs76114299	chr10:103219315	G/C	cg10198749	chr1:39920707	MACF1	0.55	7.12	0.54	7.73e-11	Schizophrenia;
TGCT	cis	rs1023500	0.573	rs6002592	chr22:42476754	A/C	cg05082376	chr22:42548792	NA	0.23	5.43	0.44	2.83e-7	Schizophrenia;
TGCT	cis	rs11969893	0.737	rs1856131	chr6:101407104	C/G	cg12253828	chr6:101329408	ASCC3	1.36	6.32	0.49	4.33e-9	Economic and political preferences (immigration/crime);
TGCT	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg26338869	chr17:61819248	STRADA	-0.55	-5.08	-0.41	1.37e-6	Prudent dietary pattern;
TGCT	cis	rs72781680	0.846	rs55770503	chr2:24030126	A/T	cg08917208	chr2:24149416	ATAD2B	0.81	4.99	0.41	1.96e-6	Lymphocyte counts;
TGCT	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg17971929	chr21:40555470	PSMG1	0.98	9.57	0.65	1.43e-16	Cognitive function;
TGCT	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg10802521	chr3:52805072	NEK4	-0.71	-8.81	-0.62	9.29e-15	Bipolar disorder;
TGCT	cis	rs2963155	0.518	rs258748	chr5:142656454	C/G	cg17617527	chr5:142782415	NR3C1	0.86	6.49	0.5	1.82e-9	Breast cancer;
TGCT	cis	rs7916852	0.867	rs7923978	chr10:28389499	C/T	cg15286905	chr10:27530250	ACBD5	-0.45	-4.48	-0.37	1.69e-5	Glaucoma (primary open-angle);
TGCT	cis	rs8031584	0.781	rs4779498	chr15:31177476	C/T	cg14829155	chr15:31115871	NA	-0.38	-4.91	-0.4	2.78e-6	Huntington's disease progression;
TGCT	cis	rs28595532	1.000	rs114039398	chr4:119631627	T/C	cg11846333	chr4:119757529	SEC24D	0.92	4.59	0.38	1.07e-5	Cannabis dependence symptom count;
TGCT	cis	rs12477438	0.520	rs2309581	chr2:99784292	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.13	-17.67	-0.85	1.16e-35	Chronic sinus infection;
TGCT	trans	rs62103177	0.713	rs62103186	chr18:77627574	G/C	cg05926928	chr17:57297772	GDPD1	1.22	11.16	0.71	1.85e-20	Opioid sensitivity;
TGCT	cis	rs2439831	0.681	rs1095386	chr15:43609509	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.02	8.69	0.62	1.84e-14	Lung cancer in ever smokers;
TGCT	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.54	-0.38	1.33e-5	Bipolar disorder;
TGCT	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg21724239	chr8:58056113	NA	0.47	5.05	0.41	1.54e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs11247915	1.000	rs11247915	chr1:26650550	G/T	cg12742826	chr1:26365331	SLC30A2	0.23	5.18	0.42	8.78e-7	Obesity-related traits;
TGCT	cis	rs17401966	0.540	rs1467653	chr1:10413123	A/G	cg19773385	chr1:10388646	KIF1B	0.22	5.19	0.42	8.33e-7	Hepatocellular carcinoma;
TGCT	cis	rs1153858	1.000	rs2114501	chr15:45670316	G/A	cg14582100	chr15:45693742	SPATA5L1	0.49	5.73	0.46	7.14e-8	Homoarginine levels;
TGCT	cis	rs950169	0.800	rs4842847	chr15:84931199	G/A	cg12863693	chr15:85201151	NMB	0.45	4.96	0.41	2.28e-6	Schizophrenia;
TGCT	cis	rs10744422	0.640	rs10847751	chr12:123291742	C/T	cg18912006	chr12:123335444	HIP1R	0.56	4.78	0.39	4.84e-6	Schizophrenia;
TGCT	trans	rs2727020	0.523	rs7948958	chr11:49506749	G/A	cg11707556	chr5:10655725	ANKRD33B	0.42	8.54	0.61	4.17e-14	Coronary artery disease;
TGCT	cis	rs11677370	0.603	rs11696104	chr2:3849512	C/G	cg17052675	chr2:3827356	NA	-0.41	-7.0	-0.53	1.39e-10	Type 2 diabetes;
TGCT	cis	rs5769765	0.862	rs9616386	chr22:50313179	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.43	6.08	0.48	1.35e-8	Schizophrenia;
TGCT	cis	rs9467773	0.595	rs7767847	chr6:26597893	A/T	cg26531700	chr6:26746687	NA	0.5	4.64	0.38	8.54e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg08736216	chr1:53307985	ZYG11A	0.25	4.93	0.4	2.59e-6	Monocyte count;
TGCT	cis	rs5769707	0.935	rs1109320	chr22:49989106	G/A	cg10356904	chr22:49881777	NA	-0.23	-4.56	-0.38	1.22e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs12579753	0.869	rs17692407	chr12:82171369	G/C	cg07988820	chr12:82153109	PPFIA2	-0.65	-6.79	-0.52	4.09e-10	Resting heart rate;
TGCT	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	5.53	0.44	1.8e-7	Alzheimer's disease;
TGCT	cis	rs12477438	0.734	rs4851184	chr2:99666434	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-5.87	-0.47	3.74e-8	Chronic sinus infection;
TGCT	cis	rs10883723	0.810	rs10748824	chr10:104274466	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	15.75	0.82	2.24e-31	Prudent dietary pattern;
TGCT	cis	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg16624210	chr5:671434	TPPP	0.4	4.52	0.38	1.44e-5	Obesity-related traits;
TGCT	cis	rs514406	0.505	rs269286	chr1:53169018	C/T	cg25767906	chr1:53392781	SCP2	0.49	5.51	0.44	2.03e-7	Monocyte count;
TGCT	cis	rs9611565	0.592	rs5751139	chr22:42099981	G/C	cg17554472	chr22:41940697	POLR3H	0.47	5.04	0.41	1.63e-6	Vitiligo;
TGCT	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs13424612	0.965	rs34789127	chr2:240952002	C/T	cg26363272	chr2:240904871	NDUFA10	0.28	4.77	0.39	5.18e-6	Odorant perception (isobutyraldehyde);
TGCT	cis	rs9583531	0.600	rs754599	chr13:111354788	C/A	cg24331049	chr13:111365604	ING1	0.82	8.02	0.58	6.64e-13	Coronary artery disease;
TGCT	cis	rs6969780	0.915	rs3801320	chr7:27164364	C/A	cg04321618	chr7:27170880	HOXA4	0.5	4.81	0.4	4.35e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg22535103	chr8:58192502	C8orf71	-0.42	-4.79	-0.4	4.7e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9646954	0.542	rs4149510	chr2:101023635	G/A	cg08017756	chr2:100939284	LONRF2	-0.3	-4.73	-0.39	5.95e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1008375	0.966	rs28441502	chr4:17598384	G/A	cg10189774	chr4:17578691	LAP3	0.62	5.4	0.44	3.28e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7208859	0.623	rs216433	chr17:28921860	T/C	cg14008862	chr17:28927542	LRRC37B2	0.72	4.59	0.38	1.08e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs2050392	0.544	rs598672	chr10:30742388	C/T	cg13289132	chr10:30722225	MAP3K8	-0.38	-4.69	-0.39	7.08e-6	Inflammatory bowel disease;
TGCT	cis	rs34172651	0.517	rs2287783	chr16:24831727	C/T	cg06028605	chr16:24865363	SLC5A11	0.41	4.6	0.38	1.01e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs896854	0.608	rs7004862	chr8:95876963	T/G	cg09323728	chr8:95962352	TP53INP1	-0.42	-4.97	-0.41	2.13e-6	Type 2 diabetes;
TGCT	cis	rs9368481	0.729	rs9379948	chr6:26944783	T/G	cg26531700	chr6:26746687	NA	0.58	5.45	0.44	2.66e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1008375	0.966	rs10006317	chr4:17702525	A/G	cg18681998	chr4:17616180	MED28	0.78	7.37	0.55	2.06e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs28595532	0.920	rs17259284	chr4:119779298	T/C	cg21605333	chr4:119757512	SEC24D	1.53	8.87	0.62	6.71e-15	Cannabis dependence symptom count;
TGCT	cis	rs6879260	0.928	rs11739624	chr5:179727290	T/C	cg23248424	chr5:179741104	GFPT2	-0.35	-6.32	-0.49	4.31e-9	Height;
TGCT	cis	rs7086627	0.515	rs10887903	chr10:82210641	C/T	cg01528321	chr10:82214614	TSPAN14	0.65	6.2	0.49	7.74e-9	Post bronchodilator FEV1;
TGCT	cis	rs1532993	0.518	rs6532688	chr4:98604134	T/C	cg05340658	chr4:99064831	C4orf37	-0.41	-4.96	-0.41	2.3e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs6964587	0.967	rs7781221	chr7:91664645	A/G	cg22709100	chr7:91322751	NA	0.28	4.56	0.38	1.19e-5	Breast cancer;
TGCT	cis	rs9467773	0.967	rs6941022	chr6:26553531	T/C	cg09904177	chr6:26538194	HMGN4	0.66	6.6	0.51	1.05e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs17741873	0.779	rs10458656	chr10:75592662	A/G	cg07699608	chr10:75541558	CHCHD1	0.71	5.02	0.41	1.77e-6	Paclitaxel disposition in epithelial ovarian cancer;
TGCT	cis	rs7561149	0.580	rs36051007	chr2:179545859	C/T	cg12089249	chr2:179345200	MIR548N;PLEKHA3	0.66	5.17	0.42	9.23e-7	QT interval;
TGCT	cis	rs9584850	0.834	rs2031239	chr13:99111560	C/T	cg15168958	chr13:99100528	FARP1	-0.24	-4.75	-0.39	5.48e-6	Neuroticism;
TGCT	cis	rs12497850	0.931	rs11924597	chr3:48937790	T/C	cg18654377	chr3:49208889	KLHDC8B	-0.42	-5.52	-0.44	1.93e-7	Parkinson's disease;
TGCT	cis	rs3806843	0.766	rs2251860	chr5:140048209	T/C	cg19875535	chr5:140030758	IK	-0.35	-5.95	-0.47	2.61e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs682748	0.846	rs12656050	chr5:17142224	C/T	cg23987134	chr5:17158319	LOC285696	-0.21	-5.19	-0.42	8.4e-7	Hippocampal atrophy;
TGCT	cis	rs3091242	0.900	rs4649086	chr1:25778967	T/A	cg00786635	chr1:25594202	NA	0.52	5.56	0.45	1.59e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs7552404	0.727	rs11161626	chr1:76260837	C/T	cg22875332	chr1:76189707	ACADM	0.61	6.4	0.5	2.92e-9	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs1215050	0.791	rs7681599	chr4:98664109	C/T	cg05340658	chr4:99064831	C4orf37	-0.43	-5.4	-0.44	3.2e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1395	0.710	rs11682913	chr2:27473649	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.65	8.48	0.61	5.54e-14	Blood metabolite levels;
TGCT	cis	rs3753275	0.624	rs6577524	chr1:8856972	C/T	cg17029193	chr1:8510607	RERE	-0.31	-4.75	-0.39	5.51e-6	Educational attainment;
TGCT	cis	rs34638657	0.732	rs62045963	chr16:82200661	A/G	cg09439754	chr16:82129088	HSD17B2	-0.24	-4.63	-0.38	9.27e-6	Lung adenocarcinoma;
TGCT	cis	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg25427524	chr10:38739819	LOC399744	-0.39	-8.05	-0.59	5.9e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs6061231	0.793	rs6061512	chr20:60976929	G/A	cg24112000	chr20:60950667	NA	-0.39	-5.06	-0.41	1.48e-6	Colorectal cancer;
TGCT	cis	rs59107033	0.559	rs60088212	chr3:123105548	G/A	cg04890266	chr3:123102914	ADCY5	-0.48	-7.84	-0.58	1.81e-12	Lymphocyte counts;
TGCT	cis	rs9948	0.655	rs76653480	chr2:97375549	C/T	cg01990225	chr2:97406019	LMAN2L	-1.01	-5.13	-0.42	1.08e-6	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs950169	0.959	rs12902070	chr15:84793558	T/C	cg11189052	chr15:85197271	WDR73	0.73	6.13	0.48	1.06e-8	Schizophrenia;
TGCT	cis	rs9443645	0.901	rs9443632	chr6:79664440	T/C	cg05283184	chr6:79620031	NA	-0.21	-4.71	-0.39	6.61e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7000551	0.689	rs6993341	chr8:22310933	T/C	cg12081754	chr8:22256438	SLC39A14	0.31	5.17	0.42	8.96e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs1865760	0.827	rs9461227	chr6:25960815	C/T	cg17042849	chr6:26104293	HIST1H4C	-0.52	-4.78	-0.39	4.88e-6	Height;
TGCT	cis	rs1215050	0.605	rs13140687	chr4:98640565	T/C	cg05340658	chr4:99064831	C4orf37	-0.41	-4.92	-0.4	2.72e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1372520	0.684	rs1837891	chr4:90736131	C/G	cg20003494	chr4:90757398	SNCA	0.63	5.08	0.41	1.37e-6	Neuroticism;
TGCT	cis	rs9486715	1.000	rs6905737	chr6:97066659	A/T	cg18709589	chr6:96969512	KIAA0776	-0.78	-7.14	-0.54	6.99e-11	Headache;
TGCT	cis	rs4727027	0.704	rs7787753	chr7:148901779	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	4.53	0.38	1.35e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	trans	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg17830980	chr10:43048298	ZNF37B	-0.87	-11.3	-0.71	8.5e-21	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7267979	0.966	rs6050567	chr20:25354561	C/T	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg07061783	chr6:25882402	NA	-0.46	-4.88	-0.4	3.2e-6	Blood metabolite levels;
TGCT	cis	rs3806843	0.548	rs246038	chr5:140331699	A/G	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs910316	0.967	rs12147532	chr14:75651858	T/G	cg11812906	chr14:75593930	NEK9	-0.71	-6.76	-0.52	4.84e-10	Height;
TGCT	cis	rs910316	1.000	rs12589876	chr14:75544189	G/A	cg23033748	chr14:75592666	NEK9	0.28	4.76	0.39	5.27e-6	Height;
TGCT	cis	rs17221829	0.733	rs11018715	chr11:89394462	A/T	cg02982614	chr11:89391479	FOLH1B	-0.25	-4.46	-0.37	1.8e-5	Anxiety in major depressive disorder;
TGCT	trans	rs17685	0.712	rs1859794	chr7:75821544	G/A	cg19862616	chr7:65841803	NCRNA00174	0.51	8.78	0.62	1.1e-14	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs7681423	0.951	rs6050	chr4:155507590	C/T	cg20735720	chr4:155535218	FGG	0.38	5.75	0.46	6.59e-8	Fibrinogen;
TGCT	cis	rs4819852	0.752	rs917478	chr22:19972824	T/C	cg07821417	chr22:19972146	ARVCF	0.19	4.56	0.38	1.2e-5	Pulse pressure;
TGCT	cis	rs12477438	0.765	rs4851183	chr2:99629149	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-4.88	-0.4	3.17e-6	Chronic sinus infection;
TGCT	cis	rs651907	0.535	rs12633089	chr3:101528763	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.86	10.47	0.68	9.24e-19	Colorectal cancer;
TGCT	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg07424592	chr7:64974309	NA	-0.64	-6.33	-0.49	4.07e-9	Calcium levels;
TGCT	cis	rs208515	0.525	rs10944859	chr6:66665197	A/G	cg07460842	chr6:66804631	NA	0.85	8.73	0.62	1.41e-14	Exhaled nitric oxide levels;
TGCT	cis	rs1865760	1.000	rs6910174	chr6:25904414	C/T	cg16482183	chr6:26056742	HIST1H1C	0.55	4.97	0.41	2.19e-6	Height;
TGCT	cis	rs35146811	0.735	rs6465766	chr7:99785671	A/G	cg04778012	chr7:99775508	STAG3;GPC2	0.35	4.93	0.41	2.55e-6	Coronary artery disease;
TGCT	cis	rs28437878	1	rs28437878	chr15:78807872	C/T	cg24631222	chr15:78858424	CHRNA5	0.91	7.89	0.58	1.38e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs6964587	0.933	rs6465350	chr7:91768615	G/A	cg17063962	chr7:91808500	NA	0.91	9.84	0.66	3.11e-17	Breast cancer;
TGCT	cis	rs7208859	0.623	rs35916850	chr17:29011173	G/A	cg13385521	chr17:29058706	SUZ12P	0.75	4.51	0.38	1.5e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs11577318	0.579	rs11247934	chr1:26695758	A/T	cg14210634	chr1:25870291	LDLRAP1	0.53	4.61	0.38	9.8e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs6831352	0.918	rs28987097	chr4:100049579	C/T	cg12011299	chr4:100065546	ADH4	-0.41	-4.92	-0.4	2.72e-6	Alcohol dependence;
TGCT	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.39	-4.9	-0.4	2.97e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs3820928	0.904	rs6735069	chr2:227893660	A/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-4.7	-0.39	6.74e-6	Pulmonary function;
TGCT	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg10047753	chr17:41438598	NA	0.95	9.61	0.65	1.12e-16	Menopause (age at onset);
TGCT	cis	rs2544527	0.819	rs2693018	chr2:15921554	A/G	cg26669897	chr2:15909070	NA	0.42	4.98	0.41	2.09e-6	Pulmonary function (smoking interaction);Pulmonary function;
TGCT	cis	rs7824557	0.602	rs1435273	chr8:11209499	T/C	cg21775007	chr8:11205619	TDH	0.73	6.98	0.53	1.6e-10	Retinal vascular caliber;
TGCT	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.04	0.53	1.16e-10	Prudent dietary pattern;
TGCT	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg24531977	chr5:56204891	C5orf35	0.69	7.29	0.55	3.25e-11	Initial pursuit acceleration;
TGCT	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg08280861	chr8:58055591	NA	0.39	4.86	0.4	3.45e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2073300	1.000	rs6132631	chr20:23461848	T/C	cg09953122	chr20:23471693	CST8	-0.59	-4.75	-0.39	5.62e-6	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs2458413	0.563	rs2458422	chr8:105332817	C/T	cg23108931	chr8:105342351	NA	-0.35	-6.15	-0.48	9.76e-9	Paget's disease;
TGCT	cis	rs4642101	0.628	rs1003080	chr3:12811628	C/T	cg05775895	chr3:12838266	CAND2	-0.67	-6.76	-0.52	4.81e-10	QRS complex (12-leadsum);
TGCT	cis	rs3770081	1.000	rs3770090	chr2:86263288	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.18	-4.81	-0.4	4.33e-6	Facial emotion recognition (sad faces);
TGCT	cis	rs6582630	0.555	rs1906260	chr12:38601013	T/G	cg26384229	chr12:38710491	ALG10B	0.9	8.1	0.59	4.36e-13	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs853679	0.567	rs7774981	chr6:28346910	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.52	-4.72	-0.39	6.26e-6	Depression;
TGCT	cis	rs10838634	1.000	rs7106323	chr11:46842841	C/A	cg18332754	chr11:46939436	LRP4	0.89	4.46	0.37	1.82e-5	Schizophrenia;
TGCT	cis	rs797680	0.754	rs12044883	chr1:93820575	G/A	cg17826107	chr1:92977322	EVI5	-0.24	-5.65	-0.45	1.05e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs9926296	0.706	rs2159115	chr16:89831819	A/G	cg04287289	chr16:89883240	FANCA	0.64	6.38	0.5	3.15e-9	Vitiligo;
TGCT	cis	rs2153535	0.580	rs1410766	chr6:8525360	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.55e-8	Motion sickness;
TGCT	cis	rs2832191	0.692	rs2245734	chr21:30359965	C/T	cg08807101	chr21:30365312	RNF160	0.64	6.05	0.48	1.57e-8	Dental caries;
TGCT	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg16680214	chr1:154839983	KCNN3	-0.35	-7.11	-0.54	8.04e-11	Prostate cancer;
TGCT	cis	rs11098499	0.909	rs78332141	chr4:120375782	C/T	cg09307838	chr4:120376055	NA	0.68	6.53	0.51	1.54e-9	Corneal astigmatism;
TGCT	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg06634786	chr22:41940651	POLR3H	0.87	8.2	0.59	2.56e-13	Vitiligo;
TGCT	cis	rs4077515	0.901	rs3812573	chr9:139276680	C/T	cg13741927	chr9:139327495	INPP5E	-0.2	-4.76	-0.39	5.37e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs2115630	0.905	rs1975277	chr15:85329558	C/T	cg17173187	chr15:85201210	NMB	-0.4	-4.93	-0.4	2.56e-6	P wave terminal force;
TGCT	cis	rs3820928	0.874	rs2177594	chr2:227836239	C/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-4.67	-0.39	7.8e-6	Pulmonary function;
TGCT	cis	rs6912958	0.559	rs445434	chr6:88041849	A/G	cg10393598	chr6:87862264	NA	-0.31	-4.51	-0.38	1.5e-5	Monocyte percentage of white cells;
TGCT	cis	rs6714710	0.603	rs6746768	chr2:98466647	C/T	cg26665480	chr2:98280029	ACTR1B	0.64	6.03	0.48	1.71e-8	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs4372836	0.729	rs4611608	chr2:29064536	A/G	cg09522027	chr2:28974177	PPP1CB	0.71	7.46	0.56	1.33e-11	Body mass index;
TGCT	cis	rs12579753	1.000	rs12821073	chr12:82183260	G/T	cg07988820	chr12:82153109	PPFIA2	-0.59	-6.19	-0.49	7.93e-9	Resting heart rate;
TGCT	cis	rs12950390	0.853	rs12450729	chr17:45855363	A/G	cg24803719	chr17:45855879	NA	-0.49	-5.01	-0.41	1.8e-6	IgG glycosylation;
TGCT	cis	rs7119	0.667	rs4886889	chr15:77902347	T/C	cg27398640	chr15:77910606	LINGO1	0.32	6.76	0.52	4.86e-10	Type 2 diabetes;
TGCT	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg08509172	chr19:19383838	TM6SF2	-0.35	-4.49	-0.37	1.62e-5	Tonsillectomy;
TGCT	cis	rs9910055	0.960	rs9911991	chr17:42278916	G/C	cg13607699	chr17:42295918	UBTF	0.88	7.82	0.57	1.96e-12	Total body bone mineral density;
TGCT	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs860554	0.705	rs1779301	chr1:201263330	C/G	cg01022117	chr1:201258280	PKP1	0.34	5.05	0.41	1.54e-6	Panic disorder;
TGCT	cis	rs3008870	1.000	rs3008853	chr1:67385488	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.1	12.09	0.74	1.01e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs12477438	0.501	rs17759607	chr2:99737005	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.75	7.25	0.55	3.92e-11	Chronic sinus infection;
TGCT	cis	rs7043114	0.525	rs6479416	chr9:95053871	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-5.57	-0.45	1.53e-7	Height;
TGCT	cis	rs9814567	0.712	rs4955545	chr3:134332926	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-6.45	-0.5	2.3e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg07424592	chr7:64974309	NA	-1.27	-7.84	-0.58	1.8e-12	Diabetic kidney disease;
TGCT	cis	rs3849570	0.925	rs13091492	chr3:81891476	A/G	cg07356753	chr3:81810745	GBE1	-0.71	-6.2	-0.49	7.85e-9	Waist circumference;Body mass index;
TGCT	cis	rs9296092	0.560	rs62407561	chr6:33528103	T/C	cg13560919	chr6:33536144	NA	-0.23	-5.06	-0.41	1.49e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs28595532	1.000	rs41455648	chr4:119718030	A/G	cg14228332	chr4:119757509	SEC24D	1.08	6.04	0.48	1.65e-8	Cannabis dependence symptom count;
TGCT	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg02018176	chr4:1364513	KIAA1530	0.29	4.81	0.4	4.34e-6	Longevity;
TGCT	cis	rs6840360	0.571	rs17275536	chr4:152498625	C/T	cg17479576	chr4:152424074	FAM160A1	-0.7	-7.47	-0.56	1.28e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs12497850	0.543	rs6446218	chr3:49075513	A/T	cg18654377	chr3:49208889	KLHDC8B	-0.41	-5.3	-0.43	5.13e-7	Parkinson's disease;
TGCT	cis	rs7017914	0.967	rs6472543	chr8:71664408	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.53	-4.9	-0.4	2.87e-6	Bone mineral density;
TGCT	cis	rs2464469	0.526	rs2899612	chr15:58335867	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.44	-6.47	-0.5	2.08e-9	Barrett's esophagus  or Esophageal adenocarcinoma;
TGCT	cis	rs7809950	0.817	rs2701679	chr7:107283908	A/G	cg23024343	chr7:107201750	COG5	0.44	6.2	0.49	7.8e-9	Coronary artery disease;
TGCT	cis	rs4074961	0.585	rs10752600	chr1:38067552	G/T	cg17933807	chr1:38061675	GNL2	1.06	14.95	0.8	1.55e-29	Axial length;
TGCT	cis	rs4638749	0.906	rs34974921	chr2:108860253	A/G	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.69	-0.39	6.95e-6	Blood pressure;
TGCT	cis	rs3617	0.625	rs7620690	chr3:52891707	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	-0.49	-4.58	-0.38	1.09e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg11494091	chr17:61959527	GH2	-0.41	-7.04	-0.53	1.13e-10	Height;
TGCT	trans	rs751984	0.706	rs7931683	chr11:61263581	T/C	cg03305746	chr2:106927199	NA	-0.58	-7.01	-0.53	1.32e-10	Diastolic blood pressure;Systolic blood pressure;Mean arterial pressure;
TGCT	cis	rs36051895	0.659	rs3780366	chr9:5068596	T/C	cg02405213	chr9:5042618	JAK2	-0.77	-10.08	-0.67	8.31e-18	Pediatric autoimmune diseases;
TGCT	cis	rs1775148	1	rs1775148	chr1:205757824	C/T	cg24503407	chr1:205819492	PM20D1	0.37	4.44	0.37	2e-5	Prostate cancer;
TGCT	cis	rs8180040	0.764	rs11130115	chr3:47181661	C/A	cg27129171	chr3:47204927	SETD2	0.75	9.86	0.66	2.82e-17	Colorectal cancer;
TGCT	cis	rs1375194	0.582	rs13391166	chr2:33805314	C/T	cg04131969	chr2:33951647	MYADML	0.56	4.92	0.4	2.7e-6	Response to antidepressants in depression;
TGCT	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.07	-9.63	-0.65	1.01e-16	Platelet count;
TGCT	cis	rs6840360	0.548	rs4254751	chr4:152322571	C/T	cg17479576	chr4:152424074	FAM160A1	-0.63	-6.8	-0.52	3.99e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg26039829	chr8:22132926	PIWIL2	0.28	5.12	0.42	1.13e-6	Hypertriglyceridemia;
TGCT	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg01802117	chr1:53393560	SCP2	-0.45	-5.23	-0.43	7e-7	Monocyte count;
TGCT	trans	rs11082438	1.000	rs11082438	chr18:42865210	G/T	cg13144432	chr15:100513968	ADAMTS17	-0.7	-6.69	-0.51	6.84e-10	Follicular lymphoma;
TGCT	cis	rs6669284	1.000	rs11119355	chr1:206885839	T/G	cg11153969	chr1:207277031	C4BPA	-0.21	-4.47	-0.37	1.76e-5	Blood protein levels;
TGCT	cis	rs3008870	1.000	rs912797	chr1:67413478	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.1	11.91	0.73	2.83e-22	Lymphocyte percentage of white cells;
TGCT	trans	rs11722228	0.964	rs10939614	chr4:9926613	T/C	cg26043149	chr18:55253948	FECH	-0.74	-7.46	-0.56	1.33e-11	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs1371867	0.817	rs1788185	chr8:101335529	T/C	cg00191853	chr8:101177733	SPAG1	-0.22	-4.47	-0.37	1.75e-5	Atrioventricular conduction;
TGCT	cis	rs12142240	0.698	rs966907	chr1:46817125	C/G	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs9611565	0.546	rs5758430	chr22:42109844	G/T	cg03806693	chr22:41940476	POLR3H	1.06	11.92	0.73	2.7e-22	Vitiligo;
TGCT	cis	rs1205863	1.000	rs1205879	chr6:11946831	G/T	cg07106625	chr6:11870215	NA	0.51	5.05	0.41	1.51e-6	Disc degeneration (lumbar);
TGCT	cis	rs2070488	0.775	rs7644530	chr3:38558316	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.71	-6.89	-0.53	2.46e-10	Electrocardiographic conduction measures;
TGCT	cis	rs9372253	0.967	rs1055301	chr6:110713042	A/G	cg01119278	chr6:110721349	DDO	-0.34	-5.45	-0.44	2.55e-7	Platelet distribution width;
TGCT	cis	rs13022357	1.000	rs2288111	chr2:160084534	A/G	cg00168785	chr2:160142643	WDSUB1	0.46	4.6	0.38	1.04e-5	Sudden cardiac arrest;
TGCT	cis	rs1008375	1.000	rs10440301	chr4:17663199	G/A	cg16339924	chr4:17578868	LAP3	0.6	4.98	0.41	2.06e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs981844	0.740	rs6815202	chr4:154682440	A/G	cg14289246	chr4:154710475	SFRP2	-0.89	-8.19	-0.59	2.73e-13	Response to statins (LDL cholesterol change);
TGCT	cis	rs10779751	0.770	rs12097293	chr1:11197467	A/G	cg08854313	chr1:11322531	MTOR	-0.84	-6.81	-0.52	3.82e-10	Body mass index;
TGCT	cis	rs17221829	0.733	rs4753223	chr11:89360653	A/C	cg02982614	chr11:89391479	FOLH1B	-0.28	-4.87	-0.4	3.35e-6	Anxiety in major depressive disorder;
TGCT	cis	rs9921222	0.656	rs12719801	chr16:381141	C/T	cg00101154	chr16:420108	MRPL28	-0.65	-7.45	-0.56	1.36e-11	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs28595532	0.925	rs28627331	chr4:119665345	T/C	cg14228332	chr4:119757509	SEC24D	1.06	5.75	0.46	6.55e-8	Cannabis dependence symptom count;
TGCT	cis	rs4689388	0.856	rs4308430	chr4:6294095	A/G	cg00701064	chr4:6280414	WFS1	0.37	4.72	0.39	6.3e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs2996428	0.667	rs11576900	chr1:3770914	A/G	cg17848003	chr1:3704513	LRRC47	0.18	5.15	0.42	9.99e-7	Red cell distribution width;
TGCT	cis	rs2153535	0.563	rs4428546	chr6:8490376	A/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg26338869	chr17:61819248	STRADA	-0.58	-5.23	-0.43	6.97e-7	Prudent dietary pattern;
TGCT	cis	rs1461503	0.900	rs7110039	chr11:122834001	C/T	cg27398637	chr11:122830231	C11orf63	0.39	4.66	0.39	7.97e-6	Menarche (age at onset);
TGCT	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	trans	rs10768122	0.524	rs7116432	chr11:35244058	C/T	cg26098768	chr20:2187533	NA	0.49	7.32	0.55	2.71e-11	Vitiligo;
TGCT	trans	rs2288327	0.643	rs16866334	chr2:179336672	A/G	cg18634211	chr1:26737262	LIN28	0.89	7.26	0.55	3.68e-11	Atrial fibrillation;
TGCT	cis	rs2050392	0.590	rs694346	chr10:30711929	C/T	cg18806716	chr10:30721971	MAP3K8	-0.71	-9.48	-0.65	2.35e-16	Inflammatory bowel disease;
TGCT	cis	rs9902453	0.740	rs2617867	chr17:28049399	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.84	-8.39	-0.6	9.14e-14	Coffee consumption (cups per day);
TGCT	cis	rs11122272	0.735	rs2808584	chr1:231512925	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.14	-0.54	6.86e-11	Hemoglobin concentration;
TGCT	cis	rs6484504	0.576	rs286649	chr11:31230468	C/T	cg26647111	chr11:31128758	NA	-0.34	-4.73	-0.39	5.88e-6	Red blood cell count;
TGCT	cis	rs10791097	0.694	rs4937583	chr11:130741606	A/G	cg14779329	chr11:130786720	SNX19	0.28	4.82	0.4	4.09e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	trans	rs74910095	0.786	rs73117180	chr5:62939428	A/G	cg02938449	chr2:220419364	OBSL1	0.8	6.75	0.52	4.95e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs4689592	0.587	rs6825954	chr4:7074226	T/C	cg02503808	chr4:7069936	GRPEL1	1.03	9.64	0.65	9.63e-17	Monocyte percentage of white cells;
TGCT	cis	rs2242116	0.727	rs10865943	chr3:46969970	T/C	cg23352942	chr3:46931381	PTH1R	-0.35	-5.26	-0.43	6.05e-7	Birth weight;
TGCT	cis	rs11997175	0.574	rs4733456	chr8:33656359	C/T	ch.8.33884649F	chr8:33765107	NA	0.29	4.69	0.39	6.98e-6	Body mass index;
TGCT	cis	rs7260538	0.808	rs1552219	chr19:41525374	A/G	cg20630647	chr19:41531805	NA	0.3	4.82	0.4	4.18e-6	DDT metabolite (p,p'-DDE levels);
TGCT	cis	rs9549367	0.713	rs4907598	chr13:113861385	C/T	cg00898013	chr13:113819073	PROZ	0.52	6.6	0.51	1.07e-9	Platelet distribution width;
TGCT	cis	rs2762353	0.639	rs566530	chr6:25878361	T/C	cg03264133	chr6:25882463	NA	-0.63	-7.09	-0.54	8.95e-11	Blood metabolite levels;
TGCT	cis	rs10875746	0.768	rs4760609	chr12:48415757	A/C	cg20731937	chr12:48336164	NA	-0.64	-5.7	-0.46	8.29e-8	Longevity (90 years and older);
TGCT	cis	rs453301	0.624	rs2288673	chr8:8860276	G/T	cg15556689	chr8:8085844	FLJ10661	0.79	7.14	0.54	6.99e-11	Joint mobility (Beighton score);
TGCT	cis	rs60871478	1.000	rs67721251	chr7:825114	T/C	cg15782153	chr7:917662	C7orf20	-0.5	-4.51	-0.38	1.48e-5	Cerebrospinal P-tau181p levels;
TGCT	trans	rs10203711	1.000	rs10191070	chr2:239565413	A/G	cg16021909	chr1:248021091	TRIM58	-0.66	-6.62	-0.51	9.76e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs13256369	0.951	rs13270852	chr8:8566853	A/G	cg06671706	chr8:8559999	CLDN23	0.34	4.59	0.38	1.09e-5	Obesity-related traits;
TGCT	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg20203395	chr5:56204925	C5orf35	-0.59	-5.12	-0.42	1.12e-6	Initial pursuit acceleration;
TGCT	cis	rs7552404	0.920	rs1612097	chr1:76218875	C/T	cg22875332	chr1:76189707	ACADM	0.71	8.52	0.61	4.59e-14	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs1215050	0.904	rs2903153	chr4:99057457	C/T	cg17366294	chr4:99064904	C4orf37	0.49	4.89	0.4	3.05e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs950169	0.960	rs35159785	chr15:84804014	G/A	cg11189052	chr15:85197271	WDR73	0.78	6.39	0.5	3.08e-9	Schizophrenia;
TGCT	trans	rs7864133	1.000	rs11139254	chr9:84064100	G/A	cg23451063	chr7:1059876	C7orf50	0.55	6.93	0.53	2.02e-10	Post bronchodilator FEV1 in COPD;
TGCT	cis	rs1372520	0.935	rs1442152	chr4:90775649	C/A	cg20003494	chr4:90757398	SNCA	-0.61	-4.88	-0.4	3.15e-6	Neuroticism;
TGCT	cis	rs6747488	0.515	rs599300	chr2:31811306	G/A	cg02381751	chr2:32503542	YIPF4	0.47	4.54	0.38	1.3e-5	Interleukin-18 levels;
TGCT	cis	rs9383153	1.000	rs9370888	chr6:16335544	A/G	cg10975897	chr6:15504844	JARID2	0.83	5.21	0.42	7.52e-7	Gambling;
TGCT	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.51	5.37	0.43	3.71e-7	Menopause (age at onset);
TGCT	cis	rs9473924	0.505	rs6908879	chr6:50869856	C/T	cg14470998	chr6:50812995	TFAP2B	1.35	8.39	0.6	9.05e-14	Body mass index;
TGCT	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.86	0.4	3.49e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs1395	0.778	rs6709602	chr2:27405497	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.64	9.02	0.63	2.9e-15	Blood metabolite levels;
TGCT	cis	rs7772486	0.790	rs2254257	chr6:146203724	C/T	cg23711669	chr6:146136114	FBXO30	0.91	10.68	0.69	2.77e-19	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1215050	0.904	rs1727285	chr4:98978821	G/A	cg17366294	chr4:99064904	C4orf37	-0.47	-4.67	-0.39	7.61e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs915832	1.000	rs915832	chr21:43275495	C/T	cg20533952	chr21:43198601	NA	0.31	4.78	0.39	4.95e-6	Response to taxane treatment (placlitaxel);
TGCT	cis	rs7647973	0.516	rs4955418	chr3:49200627	A/G	cg02487422	chr3:49467188	NICN1	0.49	4.53	0.38	1.38e-5	Menarche (age at onset);
TGCT	cis	rs1062177	0.694	rs2915816	chr5:151115857	G/A	cg12924095	chr5:151150029	G3BP1	-0.33	-4.73	-0.39	5.96e-6	Preschool internalizing problems;
TGCT	cis	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg24642439	chr20:33292090	TP53INP2	-0.62	-5.66	-0.45	1.01e-7	Coronary artery disease;
TGCT	cis	rs7605378	0.688	rs769961	chr2:200712141	C/A	cg23649088	chr2:200775458	C2orf69	0.44	7.65	0.57	4.82e-12	Osteoporosis;
TGCT	cis	rs3784262	1.000	rs10851630	chr15:58242148	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.48	-7.31	-0.55	2.94e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs7208859	0.573	rs7222803	chr17:29119897	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.31	0.43	4.9e-7	Prudent dietary pattern;
TGCT	cis	rs9311474	0.575	rs4434138	chr3:52556890	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	5.08	0.42	1.35e-6	Electroencephalogram traits;
TGCT	cis	rs2153904	0.793	rs71633563	chr1:205735854	C/T	cg23034840	chr1:205782522	SLC41A1	-0.84	-5.07	-0.41	1.39e-6	Prostate-specific antigen levels;
TGCT	cis	rs6840360	0.615	rs2406973	chr4:152608339	G/T	cg17479576	chr4:152424074	FAM160A1	0.55	5.47	0.44	2.37e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg11494091	chr17:61959527	GH2	0.61	14.8	0.8	3.65e-29	Prudent dietary pattern;
TGCT	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg03517284	chr6:25882590	NA	-0.68	-7.27	-0.55	3.53e-11	Blood metabolite levels;
TGCT	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg09323728	chr8:95962352	TP53INP1	-0.54	-6.89	-0.53	2.54e-10	Type 2 diabetes;
TGCT	cis	rs9910055	0.593	rs58392387	chr17:42297889	A/G	cg19774624	chr17:42201019	HDAC5	-0.72	-6.64	-0.51	8.87e-10	Total body bone mineral density;
TGCT	cis	rs35264875	1.000	rs7110274	chr11:68842704	A/G	cg02660097	chr11:68866761	NA	0.32	4.77	0.39	5e-6	Blond vs. brown hair color;
TGCT	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg13770153	chr20:60521292	NA	-0.54	-6.99	-0.53	1.51e-10	Body mass index;
TGCT	cis	rs67478160	0.584	rs12433009	chr14:104196405	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.19	-4.56	-0.38	1.22e-5	Schizophrenia;
TGCT	cis	rs7666738	0.830	rs11735193	chr4:98761900	C/T	cg18180107	chr4:99064573	C4orf37	0.53	5.07	0.41	1.38e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9653442	0.547	rs1062143	chr2:100659796	A/G	cg07810366	chr2:100720526	AFF3	-0.41	-6.86	-0.52	2.94e-10	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs7119	0.717	rs12899390	chr15:77815238	A/C	cg27398640	chr15:77910606	LINGO1	-0.25	-4.6	-0.38	1.05e-5	Type 2 diabetes;
TGCT	cis	rs1371867	0.817	rs1660314	chr8:101332953	C/T	cg06002616	chr8:101225028	SPAG1	-0.56	-6.58	-0.51	1.2e-9	Atrioventricular conduction;
TGCT	cis	rs7085104	0.572	rs284858	chr10:104573936	T/C	cg05855489	chr10:104503620	C10orf26	-0.63	-6.21	-0.49	7.3e-9	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs1577917	0.958	rs12212480	chr6:86458777	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.53	-0.44	1.8e-7	Response to antipsychotic treatment;
TGCT	cis	rs2933343	0.679	rs1091938	chr3:128637025	T/C	cg11901034	chr3:128598214	ACAD9	-0.66	-6.54	-0.51	1.42e-9	IgG glycosylation;
TGCT	cis	rs7412746	0.658	rs4970982	chr1:150865084	G/C	cg09365446	chr1:150670422	GOLPH3L	0.34	4.71	0.39	6.58e-6	Melanoma;
TGCT	cis	rs9419702	0.526	rs9419637	chr10:133548059	T/C	cg04492858	chr10:133558786	NA	0.56	6.0	0.47	1.98e-8	Survival in rectal cancer;
TGCT	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.64	-5.6	-0.45	1.32e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2692947	0.644	rs1724125	chr2:96831355	G/A	cg23100626	chr2:96804247	ASTL	0.46	5.24	0.43	6.79e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs7781977	0.723	rs11765436	chr7:50344077	T/A	cg01139861	chr7:50343298	IKZF1	0.51	5.37	0.43	3.72e-7	IgG glycosylation;
TGCT	cis	rs10984561	0.881	rs7032141	chr9:122253998	A/G	cg14242995	chr9:122249943	NA	0.76	5.51	0.44	2e-7	Pulmonary function decline;
TGCT	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg05785598	chr3:49045655	WDR6	0.36	4.81	0.4	4.24e-6	Menarche (age at onset);
TGCT	cis	rs35146811	0.695	rs858509	chr7:99821470	A/G	cg04778012	chr7:99775508	STAG3;GPC2	-0.36	-5.1	-0.42	1.22e-6	Coronary artery disease;
TGCT	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg20573242	chr4:122745356	CCNA2	0.64	5.62	0.45	1.22e-7	Type 2 diabetes;
TGCT	cis	rs904251	0.523	rs2776874	chr6:37483197	C/T	cg01843034	chr6:37503916	NA	-0.5	-7.0	-0.53	1.42e-10	Cognitive performance;
TGCT	cis	rs367943	0.901	rs463167	chr5:112799369	C/A	cg12552261	chr5:112820674	MCC	-0.24	-4.91	-0.4	2.81e-6	Type 2 diabetes;
TGCT	cis	rs2180341	1.000	rs9375499	chr6:127618072	T/C	cg24812749	chr6:127587940	RNF146	0.99	7.72	0.57	3.33e-12	Breast cancer;
TGCT	cis	rs6665290	0.904	rs10916075	chr1:227184074	G/A	cg10327440	chr1:227177885	CDC42BPA	-0.98	-19.78	-0.87	3.72e-40	Myeloid white cell count;
TGCT	cis	rs12893668	0.637	rs4525427	chr14:104072793	C/A	cg26031613	chr14:104095156	KLC1	-0.55	-4.64	-0.38	8.81e-6	Reticulocyte count;
TGCT	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg06873352	chr17:61820015	STRADA	0.56	6.22	0.49	7.1e-9	Prudent dietary pattern;
TGCT	cis	rs13256369	1.000	rs7820159	chr8:8576215	T/C	cg06671706	chr8:8559999	CLDN23	0.35	4.69	0.39	7e-6	Obesity-related traits;
TGCT	cis	rs9517320	0.517	rs4772097	chr13:99194652	C/A	cg07423050	chr13:99094983	FARP1	-0.29	-5.54	-0.45	1.69e-7	Longevity;
TGCT	cis	rs9372498	0.908	rs56255677	chr6:118695402	A/G	cg21191810	chr6:118973309	C6orf204	-0.5	-4.61	-0.38	9.92e-6	Diastolic blood pressure;
TGCT	cis	rs79349575	0.783	rs2088139	chr17:47000110	C/T	cg07967210	chr17:47022446	SNF8	0.42	5.86	0.47	3.86e-8	Type 2 diabetes;
TGCT	cis	rs6542838	0.641	rs6724477	chr2:99537074	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.59	5.58	0.45	1.43e-7	Fear of minor pain;
TGCT	cis	rs7845219	0.544	rs2945554	chr8:95939594	C/A	cg13393036	chr8:95962371	TP53INP1	-0.46	-5.34	-0.43	4.29e-7	Type 2 diabetes;
TGCT	cis	rs9393692	0.905	rs9357004	chr6:26303319	A/G	cg05868516	chr6:26286170	HIST1H4H	0.62	5.69	0.46	8.66e-8	Educational attainment;
TGCT	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg03303774	chr4:1407052	NA	0.31	4.93	0.4	2.58e-6	Obesity-related traits;
TGCT	cis	rs12468579	0.503	rs17748980	chr2:191830805	A/C	cg21497043	chr2:191745649	GLS	0.51	4.66	0.39	8.05e-6	JT interval (sulfonylurea treatment interaction);
TGCT	cis	rs7017914	0.967	rs13254908	chr8:71626098	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.55	-5.13	-0.42	1.11e-6	Bone mineral density;
TGCT	cis	rs17473412	0.784	rs114648199	chr5:122702577	A/T	cg15125798	chr5:122621645	NA	-0.57	-4.83	-0.4	3.88e-6	Total body bone mineral density;
TGCT	cis	rs2721195	0.614	rs12719778	chr8:145879883	T/C	cg11211951	chr8:145729740	GPT	0.23	5.11	0.42	1.2e-6	Age at first birth;
TGCT	cis	rs56104184	0.775	rs55737338	chr19:49403141	A/G	cg17863274	chr19:49399704	TULP2	-0.54	-7.43	-0.55	1.58e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs2075371	0.863	rs34231360	chr7:133944988	A/C	cg11752832	chr7:134001865	SLC35B4	0.66	5.51	0.44	1.95e-7	Mean platelet volume;
TGCT	cis	rs9393692	0.905	rs9366649	chr6:26329103	A/T	cg13736514	chr6:26305472	NA	0.38	5.48	0.44	2.26e-7	Educational attainment;
TGCT	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2688608	0.967	rs72814394	chr10:75656325	C/T	cg04320760	chr10:75533139	FUT11	-0.3	-4.58	-0.38	1.1e-5	Inflammatory bowel disease;
TGCT	cis	rs1580019	0.539	rs11769109	chr7:32571352	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.14	15.01	0.8	1.13e-29	Cognitive ability;
TGCT	cis	rs9900497	0.604	rs12949049	chr17:19653310	A/G	cg22552966	chr17:19620595	SLC47A2	0.23	5.52	0.44	1.93e-7	Response to paliperidone in schizophrenia (CGI-S score);
TGCT	cis	rs13217239	0.646	rs10456352	chr6:26990358	A/T	cg26531700	chr6:26746687	NA	0.69	6.94	0.53	1.9e-10	Schizophrenia;
TGCT	cis	rs3008870	1.000	rs2985825	chr1:67412822	T/G	cg11518657	chr1:67396239	MIER1	0.54	4.65	0.39	8.44e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg25767906	chr1:53392781	SCP2	0.5	5.77	0.46	5.99e-8	Monocyte count;
TGCT	cis	rs7714584	0.793	rs35707106	chr5:150225377	G/A	cg22134413	chr5:150180641	NA	0.89	7.04	0.53	1.14e-10	Crohn's disease;
TGCT	cis	rs453301	0.653	rs1562211	chr8:8902424	A/G	cg06636001	chr8:8085503	FLJ10661	-0.86	-7.91	-0.58	1.21e-12	Joint mobility (Beighton score);
TGCT	cis	rs7959452	0.535	rs7135092	chr12:69658330	T/C	cg11871910	chr12:69753446	YEATS4	0.63	6.24	0.49	6.36e-9	Blood protein levels;
TGCT	cis	rs2456568	0.805	rs55649862	chr11:93682888	G/T	cg14065697	chr11:93583672	C11orf90	-0.38	-4.58	-0.38	1.13e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs6456156	0.792	rs9366089	chr6:167512896	A/G	cg07741184	chr6:167504864	NA	0.23	4.58	0.38	1.09e-5	Primary biliary cholangitis;
TGCT	cis	rs6912958	0.703	rs9359748	chr6:88095500	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.4	5.28	0.43	5.56e-7	Monocyte percentage of white cells;
TGCT	cis	rs7119038	0.774	rs11217037	chr11:118677086	G/A	cg19308663	chr11:118741387	NA	0.31	6.43	0.5	2.56e-9	Sjögren's syndrome;
TGCT	cis	rs736408	0.812	rs2071506	chr3:52826276	T/C	cg10802521	chr3:52805072	NEK4	-0.68	-7.79	-0.57	2.28e-12	Bipolar disorder;
TGCT	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	9.52	0.65	1.86e-16	Platelet count;
TGCT	cis	rs12510870	0.634	rs13103378	chr4:74379585	A/T	cg05868023	chr4:75230803	EREG	-0.55	-4.7	-0.39	6.84e-6	Iris color (b* coordinate);
TGCT	cis	rs7027203	0.576	rs11790754	chr9:96535709	T/G	cg14598338	chr9:96623480	NA	0.49	7.07	0.54	9.96e-11	DNA methylation (variation);
TGCT	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.51	-5.0	-0.41	1.92e-6	Bipolar disorder;
TGCT	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg03352830	chr11:487213	PTDSS2	0.26	4.58	0.38	1.12e-5	Body mass index;
TGCT	cis	rs57590327	0.503	rs6800295	chr3:81593011	A/G	cg07356753	chr3:81810745	GBE1	-0.61	-5.1	-0.42	1.24e-6	Extraversion;
TGCT	cis	rs6964587	1.000	rs2269727	chr7:91752690	C/A	cg22709100	chr7:91322751	NA	0.29	4.69	0.39	6.98e-6	Breast cancer;
TGCT	cis	rs4927850	0.666	rs4927853	chr3:195752053	G/C	cg02975922	chr3:195473998	MUC4	-0.24	-4.58	-0.38	1.11e-5	Pancreatic cancer;
TGCT	cis	rs6598955	0.640	rs1577507	chr1:26547179	C/T	cg04990556	chr1:26633338	UBXN11	-0.89	-11.55	-0.72	2.18e-21	Obesity-related traits;
TGCT	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg08509172	chr19:19383838	TM6SF2	0.35	4.6	0.38	1.02e-5	Tonsillectomy;
TGCT	cis	rs4285028	0.696	rs3915060	chr3:121712980	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.76	6.39	0.5	3.09e-9	Multiple sclerosis;
TGCT	cis	rs36051895	0.589	rs2224571	chr9:5196253	A/C	cg02405213	chr9:5042618	JAK2	-0.75	-9.97	-0.67	1.53e-17	Pediatric autoimmune diseases;
TGCT	cis	rs7568458	0.846	rs10179195	chr2:85762761	A/G	cg17127132	chr2:85788382	GGCX	0.63	5.94	0.47	2.65e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs2721195	0.967	rs11777703	chr8:145703508	G/A	cg17328964	chr8:145687451	CYHR1	0.41	5.81	0.46	4.92e-8	Age at first birth;
TGCT	cis	rs9549260	0.709	rs4581585	chr13:41203905	C/T	cg21288729	chr13:41239152	FOXO1	0.97	10.16	0.67	5.23e-18	Red blood cell count;
TGCT	cis	rs2404602	0.692	rs10444858	chr15:76962504	T/C	cg22467129	chr15:76604101	ETFA	-0.45	-5.11	-0.42	1.2e-6	Blood metabolite levels;
TGCT	cis	rs9291683	0.566	rs13144709	chr4:10044182	C/T	cg11266682	chr4:10021025	SLC2A9	0.6	7.52	0.56	9.49e-12	Bone mineral density;
TGCT	cis	rs6500602	0.702	rs11076835	chr16:4549618	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.3	5.65	0.45	1.06e-7	Schizophrenia;
TGCT	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	15.94	0.82	8.5e-32	Prudent dietary pattern;
TGCT	cis	rs829883	0.664	rs829874	chr12:98840615	G/A	cg25150519	chr12:98850993	NA	0.62	7.36	0.55	2.2e-11	Colorectal adenoma (advanced);
TGCT	cis	rs2486288	0.587	rs12899942	chr15:45547280	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.46	-5.59	-0.45	1.38e-7	Glomerular filtration rate;
TGCT	cis	rs9527	0.535	rs4917999	chr10:104963051	C/G	cg15744005	chr10:104629667	AS3MT	0.42	4.72	0.39	6.34e-6	Arsenic metabolism;
TGCT	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	6.13	0.48	1.06e-8	Bipolar disorder;
TGCT	cis	rs9357506	1.000	rs11758843	chr6:46303340	A/G	cg21115430	chr6:46460003	NA	-0.27	-5.47	-0.44	2.43e-7	Body mass index;
TGCT	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg13683864	chr3:40499215	RPL14	-1.19	-13.2	-0.76	2.17e-25	Renal cell carcinoma;
TGCT	cis	rs12540874	0.698	rs12718574	chr7:50573848	G/C	cg18232548	chr7:50535776	DDC	-0.37	-6.43	-0.5	2.46e-9	Systemic sclerosis;
TGCT	cis	rs2932538	0.922	rs6668533	chr1:113064468	C/T	cg22162597	chr1:113214053	CAPZA1	0.27	5.91	0.47	3.05e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs1334894	1.000	rs747411	chr6:35586373	G/A	cg24281267	chr6:35479648	TULP1	-0.43	-4.69	-0.39	7.09e-6	Coronary artery disease;
TGCT	cis	rs7000551	0.751	rs2443505	chr8:22375341	G/A	cg12081754	chr8:22256438	SLC39A14	0.31	5.0	0.41	1.9e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	5.14	0.42	1.03e-6	Height;
TGCT	cis	rs7809950	0.678	rs2237660	chr7:106862963	T/A	cg23024343	chr7:107201750	COG5	-0.44	-5.92	-0.47	2.97e-8	Coronary artery disease;
TGCT	cis	rs6733011	0.578	rs10172158	chr2:99509605	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.51	-4.78	-0.39	4.87e-6	Bipolar disorder;
TGCT	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs9926296	0.542	rs12599531	chr16:89909401	C/T	cg26513180	chr16:89883248	FANCA	-0.7	-6.41	-0.5	2.71e-9	Vitiligo;
TGCT	cis	rs9611565	0.546	rs739129	chr22:42118249	G/A	cg06634786	chr22:41940651	POLR3H	0.89	8.81	0.62	9.46e-15	Vitiligo;
TGCT	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg11764359	chr7:65958608	NA	0.6	5.29	0.43	5.36e-7	Aortic root size;
TGCT	cis	rs12762955	0.561	rs7918118	chr10:1042823	C/A	cg20503657	chr10:835505	NA	-0.4	-5.21	-0.42	7.61e-7	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs9660992	0.626	rs1172113	chr1:205226288	T/C	cg00857998	chr1:205179979	DSTYK	0.48	4.46	0.37	1.85e-5	Mean corpuscular volume;Mean platelet volume;
TGCT	cis	rs2739330	1.000	rs2739330	chr22:24295286	T/C	cg23131131	chr22:24373011	LOC391322	-0.81	-9.09	-0.63	1.99e-15	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9457247	0.905	rs377232	chr6:167409638	C/A	cg23791538	chr6:167370224	RNASET2	-0.49	-4.96	-0.41	2.3e-6	Crohn's disease;
TGCT	cis	rs10089	1.000	rs4836369	chr5:127486462	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	8.19	0.59	2.64e-13	Ileal carcinoids;
TGCT	cis	rs7959452	0.536	rs4761237	chr12:69776461	C/G	cg14784868	chr12:69753453	YEATS4	0.83	8.96	0.63	4.14e-15	Blood protein levels;
TGCT	cis	rs7760949	0.963	rs9475771	chr6:13914869	A/G	cg27413430	chr6:13925136	RNF182	-0.57	-5.5	-0.44	2.09e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs514406	0.763	rs9988539	chr1:53213884	T/C	cg01802117	chr1:53393560	SCP2	0.44	5.26	0.43	6.2e-7	Monocyte count;
TGCT	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg11764359	chr7:65958608	NA	-0.53	-4.68	-0.39	7.26e-6	Aortic root size;
TGCT	cis	rs28595532	0.920	rs17325129	chr4:119778284	T/C	cg14228332	chr4:119757509	SEC24D	1.26	7.08	0.54	9.26e-11	Cannabis dependence symptom count;
TGCT	cis	rs4319547	0.695	rs4758643	chr12:122924819	A/T	cg08088222	chr12:122070432	ORAI1	0.26	4.46	0.37	1.84e-5	Body mass index;
TGCT	cis	rs7666738	0.830	rs4699595	chr4:99012827	A/G	cg18180107	chr4:99064573	C4orf37	0.54	5.03	0.41	1.7e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs854765	0.592	rs2955367	chr17:18024266	T/G	cg04398451	chr17:18023971	MYO15A	-0.39	-6.89	-0.53	2.55e-10	Total body bone mineral density;
TGCT	cis	rs807669	0.802	rs762528	chr22:19166680	A/G	cg02655711	chr22:19163373	SLC25A1	0.42	10.1	0.67	7.26e-18	Metabolite levels;
TGCT	cis	rs1903068	0.719	rs9284955	chr4:56003117	A/G	cg09978860	chr4:56023921	NA	-0.55	-5.76	-0.46	6.21e-8	Endometriosis;
TGCT	cis	rs9311474	0.652	rs411457	chr3:52228150	A/T	cg07507251	chr3:52567010	NT5DC2	-0.37	-4.91	-0.4	2.83e-6	Electroencephalogram traits;
TGCT	cis	rs909674	0.515	rs9611170	chr22:39784845	G/C	cg24399712	chr22:39784796	NA	-1.07	-13.16	-0.76	2.73e-25	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg03609598	chr5:56110824	MAP3K1	-0.59	-4.78	-0.39	4.81e-6	Initial pursuit acceleration;
TGCT	cis	rs6490294	0.904	rs73426401	chr12:112423286	C/T	cg10833066	chr12:111807467	FAM109A	0.35	5.13	0.42	1.09e-6	Mean platelet volume;
TGCT	cis	rs62229266	0.654	rs62230787	chr21:37376480	A/G	cg08632701	chr21:37451849	NA	-0.16	-5.15	-0.42	1e-6	Mitral valve prolapse;
TGCT	cis	rs250677	0.652	rs250670	chr5:148446646	G/T	cg23229984	chr5:148520753	ABLIM3	0.21	4.89	0.4	3.11e-6	Breast cancer;
TGCT	cis	rs7945705	0.902	rs7479407	chr11:9023421	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.46	5.08	0.41	1.38e-6	Hemoglobin concentration;
TGCT	cis	rs7191439	0.789	rs4598894	chr16:88776141	G/A	cg27087555	chr16:88793112	FAM38A	-0.52	-6.0	-0.47	2.05e-8	Plateletcrit;
TGCT	cis	rs12712073	0.512	rs6710355	chr2:100699994	T/C	cg07810366	chr2:100720526	AFF3	-0.38	-5.46	-0.44	2.49e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs78487399	0.808	rs12105399	chr2:43676939	C/G	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.72	4.62	0.38	9.53e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs9430161	0.579	rs6696575	chr1:11037136	G/A	cg02454025	chr1:11042201	C1orf127	0.92	11.24	0.71	1.21e-20	Ewing sarcoma;
TGCT	cis	rs8180040	0.676	rs66564457	chr3:47020072	G/A	cg27129171	chr3:47204927	SETD2	0.73	9.42	0.65	3.15e-16	Colorectal cancer;
TGCT	cis	rs912057	0.671	rs1294428	chr6:6744623	A/G	cg06612196	chr6:6737390	NA	0.47	6.77	0.52	4.57e-10	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs6121246	0.567	rs6060344	chr20:30207316	A/G	cg13852791	chr20:30311386	BCL2L1	0.7	4.58	0.38	1.1e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs17376456	0.877	rs10072592	chr5:93405989	C/G	cg21475434	chr5:93447410	FAM172A	0.6	4.62	0.38	9.48e-6	Diabetic retinopathy;
TGCT	cis	rs4455778	0.580	rs5009336	chr7:49116299	A/G	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs694739	0.796	rs479777	chr11:64107477	A/G	cg02228329	chr11:64053129	BAD;GPR137	0.65	6.11	0.48	1.16e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs208520	1.000	rs12193164	chr6:66978962	C/T	cg07460842	chr6:66804631	NA	0.78	6.82	0.52	3.61e-10	Exhaled nitric oxide output;
TGCT	cis	rs7772486	0.743	rs9403742	chr6:146060193	A/C	cg23711669	chr6:146136114	FBXO30	0.83	8.91	0.62	5.47e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg21724239	chr8:58056113	NA	-0.5	-5.43	-0.44	2.9e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs3125734	0.633	rs4561099	chr10:64041163	T/C	cg19640130	chr10:64028056	RTKN2	-0.38	-4.87	-0.4	3.36e-6	Rheumatoid arthritis;
TGCT	cis	rs7760949	0.889	rs9475816	chr6:13935425	T/C	cg27413430	chr6:13925136	RNF182	0.73	6.79	0.52	4.22e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs10771431	0.967	rs7137443	chr12:9372029	C/T	cg08997352	chr12:9597637	DDX12	-0.27	-5.55	-0.45	1.65e-7	Breast size;
TGCT	cis	rs273218	0.573	rs16882051	chr5:53342979	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.71	-5.67	-0.45	9.67e-8	Migraine;
TGCT	cis	rs1568889	0.938	rs7128045	chr11:28190180	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.81	8.17	0.59	3.04e-13	Bipolar disorder;
TGCT	cis	rs7103648	0.630	rs7934481	chr11:47883337	C/T	cg20307385	chr11:47447363	PSMC3	0.76	7.16	0.54	6.36e-11	Diastolic blood pressure;Systolic blood pressure;
TGCT	cis	rs826838	0.967	rs11183622	chr12:38792849	T/C	cg26384229	chr12:38710491	ALG10B	1.06	10.68	0.69	2.84e-19	Heart rate;
TGCT	cis	rs7666738	0.783	rs10028584	chr4:98962404	C/T	cg17366294	chr4:99064904	C4orf37	0.74	7.56	0.56	7.89e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6940638	0.615	rs9393801	chr6:27242681	A/G	cg15659132	chr6:26577336	NA	-0.59	-5.57	-0.45	1.48e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs6095298	0.553	rs4810882	chr20:47437220	C/A	cg12307787	chr20:48099359	KCNB1	0.43	4.53	0.38	1.37e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs2032447	0.613	rs6456708	chr6:26032847	G/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.75	8.23	0.59	2.21e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs17767294	0.614	rs72849210	chr6:28180459	C/T	cg08851530	chr6:28072375	NA	1.46	6.76	0.52	4.79e-10	Parkinson's disease;
TGCT	cis	rs12908161	0.959	rs34784022	chr15:85231906	T/C	cg12863693	chr15:85201151	NMB	0.46	5.53	0.44	1.79e-7	Schizophrenia;
TGCT	cis	rs10927875	0.541	rs1739843	chr1:16343254	T/C	cg21385522	chr1:16154831	NA	0.46	4.85	0.4	3.64e-6	Dilated cardiomyopathy;
TGCT	cis	rs2153535	0.580	rs6927589	chr6:8456632	A/G	cg07606381	chr6:8435919	SLC35B3	-0.53	-4.94	-0.41	2.47e-6	Motion sickness;
TGCT	cis	rs9486719	1.000	rs13202675	chr6:97028427	C/T	cg06623918	chr6:96969491	KIAA0776	-0.99	-8.05	-0.59	5.65e-13	Migraine;Coronary artery disease;
TGCT	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg27286337	chr10:134555280	INPP5A	0.41	4.9	0.4	2.97e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs3845702	0.736	rs6733426	chr2:180830958	A/G	cg01881094	chr2:180872142	CWC22	-1.05	-6.78	-0.52	4.27e-10	Schizophrenia;
TGCT	cis	rs6430585	0.528	rs309119	chr2:136710372	T/C	cg07169764	chr2:136633963	MCM6	1.2	11.66	0.72	1.18e-21	Corneal structure;
TGCT	cis	rs9914988	0.832	rs12946132	chr17:27157362	T/C	cg20469991	chr17:27169893	C17orf63	-0.72	-5.09	-0.42	1.28e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs6163	0.588	rs10786706	chr10:104500659	C/T	cg05855489	chr10:104503620	C10orf26	1.01	12.87	0.76	1.39e-24	Waist circumference;Hip circumference;
TGCT	cis	rs28735056	0.563	rs55642704	chr18:77688124	C/T	cg20368463	chr18:77673604	PQLC1	-0.44	-5.15	-0.42	9.9e-7	Schizophrenia;
TGCT	cis	rs7843479	0.601	rs1058486	chr8:21862551	A/G	cg17168535	chr8:21777572	XPO7	0.81	8.25	0.6	1.91e-13	Mean corpuscular volume;
TGCT	cis	rs713587	0.967	rs6752378	chr2:25150116	C/A	cg01884057	chr2:25150051	NA	0.4	8.24	0.59	2.05e-13	Body mass index in non-asthmatics;
TGCT	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg10862848	chr6:42927986	GNMT	-0.4	-4.95	-0.41	2.37e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-8.64	-0.61	2.39e-14	Platelet count;
TGCT	trans	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg17830980	chr10:43048298	ZNF37B	-0.81	-10.13	-0.67	6.19e-18	Extrinsic epigenetic age acceleration;
TGCT	cis	rs6582630	0.555	rs8189479	chr12:38308240	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-4.7	-0.39	6.68e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs4366490	0.848	rs7106537	chr11:62905841	G/A	cg21002970	chr11:62369079	MTA2	0.87	4.67	0.39	7.78e-6	Conotruncal heart defects;
TGCT	cis	rs78487399	0.808	rs13416978	chr2:43705265	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.41	5.64	0.45	1.1e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs1903068	0.657	rs73236104	chr4:55990954	G/C	cg01777861	chr4:56023843	NA	0.52	5.58	0.45	1.44e-7	Endometriosis;
TGCT	cis	rs138249	0.934	rs138228	chr22:50557120	A/C	cg24864161	chr22:50528282	MOV10L1	-0.47	-5.02	-0.41	1.77e-6	Gestational age at birth in labor-initiated deliveries (child effect);
TGCT	cis	rs2288884	1.000	rs11669540	chr19:52549739	C/A	cg15405931	chr19:52693188	PPP2R1A	-0.69	-4.5	-0.37	1.56e-5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs11644362	0.903	rs2014726	chr16:12992849	T/C	cg06890432	chr16:12997467	SHISA9	-0.61	-6.77	-0.52	4.49e-10	Positive affect;Subjective well-being;
TGCT	cis	rs2816062	0.813	rs2745321	chr1:18889198	G/C	cg18795169	chr1:18902165	NA	-0.6	-14.18	-0.79	1.04e-27	Urate levels in lean individuals;
TGCT	cis	rs2445762	0.559	rs4774585	chr15:51616480	G/A	cg00184732	chr15:51633821	GLDN	0.52	5.28	0.43	5.54e-7	Hormone measurements;
TGCT	cis	rs11098499	0.754	rs1980025	chr4:120252806	A/G	cg09307838	chr4:120376055	NA	-0.63	-5.86	-0.47	3.84e-8	Corneal astigmatism;
TGCT	cis	rs797680	0.822	rs6541401	chr1:93738948	G/A	cg17826107	chr1:92977322	EVI5	0.23	5.11	0.42	1.2e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs34172651	0.517	rs35560136	chr16:24788915	T/A	cg06028605	chr16:24865363	SLC5A11	0.4	4.45	0.37	1.91e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs13394619	0.533	rs12615856	chr2:11746177	C/T	cg07314298	chr2:11723111	GREB1	0.29	4.93	0.4	2.59e-6	Endometriosis;
TGCT	cis	rs11098499	0.691	rs28396837	chr4:120271541	G/A	cg09307838	chr4:120376055	NA	0.56	5.5	0.44	2.05e-7	Corneal astigmatism;
TGCT	cis	rs9611565	0.681	rs5751094	chr22:41803279	C/T	cg13695892	chr22:41940480	POLR3H	0.8	8.01	0.58	7.2e-13	Vitiligo;
TGCT	cis	rs62103177	0.810	rs62103191	chr18:77628769	C/G	cg12964065	chr18:77638022	KCNG2	0.37	4.76	0.39	5.4e-6	Opioid sensitivity;
TGCT	cis	rs11785400	0.762	rs2280880	chr8:143721929	C/A	cg10596483	chr8:143751796	JRK	0.53	5.03	0.41	1.68e-6	Schizophrenia;
TGCT	cis	rs4631830	0.720	rs113082846	chr10:51502802	G/C	cg10326726	chr10:51549505	MSMB	-0.23	-4.68	-0.39	7.43e-6	Prostate-specific antigen levels;
TGCT	cis	rs9911578	0.835	rs58647683	chr17:56483194	T/C	cg12560992	chr17:57184187	TRIM37	-0.78	-9.12	-0.63	1.72e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg18876405	chr7:65276391	NA	-0.37	-5.88	-0.47	3.63e-8	Calcium levels;
TGCT	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg18876405	chr7:65276391	NA	0.31	4.79	0.4	4.58e-6	Aortic root size;
TGCT	cis	rs3812831	0.654	rs9314900	chr13:114937618	A/C	cg06611532	chr13:114900021	NA	0.29	5.45	0.44	2.6e-7	Schizophrenia;
TGCT	trans	rs1005277	0.522	rs200943	chr10:38148730	A/G	cg17830980	chr10:43048298	ZNF37B	-0.74	-8.59	-0.61	3.11e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7666738	0.830	rs7667796	chr4:99071415	G/T	cg17366294	chr4:99064904	C4orf37	-0.74	-7.39	-0.55	1.93e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12210905	0.541	rs62617138	chr6:27463766	C/A	cg08851530	chr6:28072375	NA	1.34	6.29	0.49	5.02e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs6988636	1.000	rs60827294	chr8:124187842	T/C	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs6669072	0.647	rs814547	chr1:91238821	T/C	cg08895590	chr1:91227319	NA	-0.33	-4.58	-0.38	1.14e-5	Cognitive function;
TGCT	cis	rs1371867	0.775	rs3020183	chr8:101233297	A/T	cg06002616	chr8:101225028	SPAG1	0.52	5.91	0.47	3.1e-8	Atrioventricular conduction;
TGCT	cis	rs2115630	1.000	rs6496452	chr15:85372645	A/T	cg11189052	chr15:85197271	WDR73	-0.66	-6.44	-0.5	2.42e-9	P wave terminal force;
TGCT	cis	rs9467773	0.967	rs1056347	chr6:26527524	G/C	cg26531700	chr6:26746687	NA	0.47	4.57	0.38	1.14e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs3020736	0.500	rs6002601	chr22:42489058	A/T	cg15557168	chr22:42548783	NA	0.22	5.54	0.45	1.73e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs11098499	0.863	rs3822194	chr4:120471648	A/G	cg09307838	chr4:120376055	NA	0.72	6.87	0.52	2.81e-10	Corneal astigmatism;
TGCT	cis	rs9303401	0.614	rs34843288	chr17:57103140	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.63	5.87	0.47	3.77e-8	Cognitive test performance;
TGCT	cis	rs686320	1.000	rs72643572	chr11:65250967	A/G	cg00206168	chr11:65308501	LTBP3	0.76	4.66	0.39	8.07e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs6430585	0.583	rs3769008	chr2:136586183	C/T	cg07169764	chr2:136633963	MCM6	1.18	11.26	0.71	1.09e-20	Corneal structure;
TGCT	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg17971929	chr21:40555470	PSMG1	-0.71	-6.26	-0.49	5.78e-9	Cognitive function;
TGCT	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg08280861	chr8:58055591	NA	0.39	4.86	0.4	3.45e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs78487399	0.710	rs80100685	chr2:43650413	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.46	-5.5	-0.44	2.07e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs5167	0.820	rs204468	chr19:45490636	T/C	cg09555818	chr19:45449301	APOC2	-0.23	-4.77	-0.39	5.01e-6	Blood protein levels;
TGCT	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.72	5.19	0.42	8.33e-7	Platelet count;
TGCT	cis	rs10771431	0.967	rs7137443	chr12:9372029	C/T	cg21349645	chr12:9436242	LOC642846	-0.42	-4.44	-0.37	1.96e-5	Breast size;
TGCT	cis	rs7727544	0.684	rs272889	chr5:131665378	A/G	cg24060327	chr5:131705240	SLC22A5	-0.59	-6.48	-0.5	1.92e-9	Blood metabolite levels;
TGCT	cis	rs11577318	0.626	rs11806568	chr1:26686837	C/A	cg14210634	chr1:25870291	LDLRAP1	0.54	4.73	0.39	6.06e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs7267979	0.868	rs6138553	chr20:25239233	G/A	cg14121845	chr20:25566513	NINL	0.51	5.55	0.45	1.63e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6938	0.534	rs1130741	chr15:75189930	A/G	cg09165964	chr15:75287851	SCAMP5	0.56	5.29	0.43	5.31e-7	Breast cancer;
TGCT	cis	rs7246657	0.722	rs2909093	chr19:38199462	T/C	cg03611452	chr19:38183253	ZNF781	-0.56	-4.63	-0.38	8.97e-6	Coronary artery calcification;
TGCT	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg11301795	chr4:187892539	NA	-0.36	-5.57	-0.45	1.52e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs933688	1.000	rs10058025	chr5:90689052	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.96	8.05	0.59	5.84e-13	Smoking behavior;
TGCT	cis	rs6740322	0.748	rs6732337	chr2:43462822	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.4	6.34	0.49	3.94e-9	Coronary artery disease;
TGCT	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.01	0.48	1.89e-8	Bipolar disorder;
TGCT	cis	rs9818758	0.882	rs74926817	chr3:49378833	C/G	cg08550065	chr3:50336684	HYAL3;NAT6	0.66	4.59	0.38	1.08e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg17554472	chr22:41940697	POLR3H	-0.49	-5.27	-0.43	5.9e-7	Vitiligo;
TGCT	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.11	14.83	0.8	3.1e-29	Height;
TGCT	cis	rs76473307	1.000	rs117547698	chr20:57376104	A/G	cg06163629	chr20:57414884	GNASAS;GNAS	-0.7	-4.61	-0.38	1.01e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs10876993	0.928	rs813854	chr12:58071347	A/G	cg15848620	chr12:58087721	OS9	-0.72	-5.83	-0.46	4.52e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs6495367	0.898	rs1443657	chr15:79386946	C/A	cg17916960	chr15:79447300	NA	0.37	5.28	0.43	5.69e-7	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7772486	0.754	rs9399567	chr6:146147295	C/T	cg13319975	chr6:146136371	FBXO30	-0.51	-4.63	-0.38	9.14e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7208859	0.623	rs9890558	chr17:29110355	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs6089584	0.924	rs6142906	chr20:60552554	G/C	cg13770153	chr20:60521292	NA	-0.46	-5.81	-0.46	4.88e-8	Body mass index;
TGCT	cis	rs4919694	1.000	rs11191525	chr10:104793435	G/C	cg04362960	chr10:104952993	NT5C2	1.06	7.05	0.53	1.09e-10	Arsenic metabolism;
TGCT	cis	rs9393777	0.546	rs9366673	chr6:26893329	C/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.64	-4.82	-0.4	4.11e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs3749237	0.595	rs4855877	chr3:49448527	T/C	cg07636037	chr3:49044803	WDR6	0.63	5.97	0.47	2.36e-8	Resting heart rate;
TGCT	cis	rs6688613	0.649	rs2294195	chr1:166838281	T/C	cg07049167	chr1:166818506	POGK	0.25	5.23	0.43	6.88e-7	Refractive astigmatism;
TGCT	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs57677839	1	rs57677839	chr11:17028189	G/A	cg15378786	chr11:17036137	PLEKHA7	1.03	15.95	0.82	8.09e-32	Coronary artery disease;
TGCT	cis	rs9952991	0.941	rs2847278	chr18:12778715	C/T	cg23598886	chr18:12777645	NA	0.62	5.9	0.47	3.25e-8	Inflammatory skin disease;
TGCT	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg11062466	chr8:58055876	NA	0.46	4.91	0.4	2.8e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7772486	0.790	rs9376970	chr6:146241472	A/C	cg23711669	chr6:146136114	FBXO30	-0.88	-10.27	-0.68	2.84e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3806843	0.576	rs246034	chr5:140332064	A/C	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs3820068	0.705	rs7533125	chr1:15883744	T/C	cg05660106	chr1:15850417	CASP9	1.17	14.8	0.8	3.47e-29	Systolic blood pressure;
TGCT	cis	rs9357506	0.935	rs11965941	chr6:46302727	A/G	cg21115430	chr6:46460003	NA	-0.27	-5.47	-0.44	2.43e-7	Body mass index;
TGCT	cis	rs12477438	0.501	rs6751927	chr2:99740175	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.15	18.22	0.85	7.28e-37	Chronic sinus infection;
TGCT	cis	rs9611519	0.929	rs9611474	chr22:41434858	G/A	cg13695892	chr22:41940480	POLR3H	-0.53	-4.62	-0.38	9.54e-6	Neuroticism;
TGCT	cis	rs6500602	0.826	rs11076831	chr16:4460133	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.43	-6.72	-0.52	5.78e-10	Schizophrenia;
TGCT	cis	rs11190604	0.767	rs11190509	chr10:102156208	G/A	cg16005271	chr10:102321736	NA	0.46	4.72	0.39	6.25e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7833790	0.777	rs6473301	chr8:82691340	A/G	cg27398817	chr8:82754497	SNX16	-0.83	-5.96	-0.47	2.43e-8	Diastolic blood pressure;
TGCT	cis	rs11122272	0.735	rs2474630	chr1:231535335	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-6.64	-0.51	8.59e-10	Hemoglobin concentration;
TGCT	trans	rs7698623	0.850	rs2045834	chr4:88800642	C/T	cg01186725	chr1:53905612	FLJ40434	-0.48	-6.61	-0.51	1.01e-9	Cardiovascular disease risk factors;
TGCT	cis	rs2046867	0.908	rs11927126	chr3:72806622	A/G	cg25664220	chr3:72788482	NA	-0.55	-6.96	-0.53	1.75e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.73	-0.39	5.93e-6	Prudent dietary pattern;
TGCT	cis	rs73110464	0.609	rs4919752	chr12:53359229	G/C	cg14581129	chr12:53358946	NA	-0.63	-6.81	-0.52	3.68e-10	Cancer (pleiotropy);
TGCT	cis	rs116095464	0.558	rs7356535	chr5:284117	G/T	cg22857025	chr5:266934	NA	-0.35	-6.87	-0.53	2.7e-10	Breast cancer;
TGCT	trans	rs804280	0.542	rs35647515	chr8:11791629	C/T	cg15556689	chr8:8085844	FLJ10661	0.75	7.26	0.55	3.66e-11	Myopia (pathological);
TGCT	cis	rs138857	0.515	rs9616375	chr22:50310600	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.22	-7.53	-0.56	9.3e-12	Mean platelet volume;
TGCT	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.87	0.4	3.31e-6	Electroencephalogram traits;
TGCT	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.46	-6.7	-0.52	6.44e-10	Alzheimer's disease;
TGCT	cis	rs1322512	0.876	rs1744372	chr6:152944926	C/G	cg03415253	chr6:152958462	SYNE1	-0.57	-4.99	-0.41	2e-6	Tonometry;
TGCT	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-5.79	-0.46	5.39e-8	Alzheimer's disease;
TGCT	cis	rs6725041	0.819	rs13429136	chr2:213092176	T/C	cg16329650	chr2:213403929	ERBB4	-0.53	-4.52	-0.38	1.44e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs1903068	0.853	rs12498317	chr4:56007093	G/A	cg09978860	chr4:56023921	NA	0.58	6.22	0.49	7.14e-9	Endometriosis;
TGCT	cis	rs1878931	0.580	rs8062722	chr16:3409161	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.92	10.32	0.68	2.14e-18	Body mass index (adult);
TGCT	cis	rs9811920	0.638	rs793471	chr3:99546335	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.6	6.82	0.52	3.63e-10	Axial length;
TGCT	cis	rs11718455	0.960	rs17076254	chr3:44000361	C/T	cg08738300	chr3:44038990	NA	0.81	6.09	0.48	1.31e-8	Coronary artery disease;
TGCT	trans	rs12038357	0.867	rs10914965	chr1:34977219	A/G	cg06277588	chr6:13489246	GFOD1	0.52	7.05	0.53	1.1e-10	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs2996428	0.667	rs72640928	chr1:3768568	T/C	cg13057898	chr1:3703894	LRRC47	0.21	4.64	0.38	8.81e-6	Red cell distribution width;
TGCT	cis	rs6911131	0.614	rs12202625	chr6:143880787	T/G	cg26846959	chr6:143998958	PHACTR2	0.9	4.79	0.4	4.64e-6	Response to paliperidone in schizophrenia (positive Marder score);
TGCT	cis	rs57590327	0.679	rs13061830	chr3:81525696	A/G	cg07356753	chr3:81810745	GBE1	-0.53	-4.44	-0.37	1.97e-5	Extraversion;
TGCT	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg04944784	chr2:26401820	FAM59B	-0.68	-6.13	-0.48	1.1e-8	Gut microbiome composition (summer);
TGCT	cis	rs7647973	0.516	rs4955418	chr3:49200627	A/G	cg05785598	chr3:49045655	WDR6	0.37	4.87	0.4	3.34e-6	Menarche (age at onset);
TGCT	cis	rs7772486	0.790	rs2814879	chr6:146201743	T/C	cg23711669	chr6:146136114	FBXO30	0.93	10.56	0.69	5.35e-19	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9646954	0.542	rs4149505	chr2:101033697	G/A	cg14675211	chr2:100938903	LONRF2	0.49	4.64	0.38	8.65e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2562456	0.724	rs58001930	chr19:21742863	C/T	cg25650185	chr19:21324782	ZNF431	-0.64	-5.73	-0.46	7.09e-8	Pain;
TGCT	cis	rs9467711	0.720	rs3857546	chr6:26157762	C/T	cg16898833	chr6:26189333	HIST1H4D	0.98	4.97	0.41	2.21e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9611519	0.780	rs9611542	chr22:41677317	C/T	cg13695892	chr22:41940480	POLR3H	-0.67	-6.47	-0.5	2.07e-9	Neuroticism;
TGCT	cis	rs34779708	0.931	rs4351760	chr10:35280254	A/G	cg04310649	chr10:35416472	CREM	-0.51	-4.55	-0.38	1.24e-5	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs9302065	0.565	rs2993585	chr13:95961966	G/A	cg26751094	chr13:95954534	ABCC4	-0.4	-6.74	-0.52	5.33e-10	Blood metabolite levels;
TGCT	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg09359103	chr1:154839909	KCNN3	0.7	14.57	0.79	1.23e-28	Prostate cancer;
TGCT	cis	rs9467773	1.000	rs3736782	chr6:26505403	C/A	cg26531700	chr6:26746687	NA	0.47	4.56	0.38	1.19e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg09323728	chr8:95962352	TP53INP1	-0.53	-6.88	-0.53	2.67e-10	Type 2 diabetes;
TGCT	cis	rs116095464	0.558	rs55664502	chr5:270485	T/C	cg22857025	chr5:266934	NA	-0.34	-6.64	-0.51	8.6e-10	Breast cancer;
TGCT	cis	rs910316	0.712	rs175074	chr14:75504454	G/A	cg08847533	chr14:75593920	NEK9	-0.82	-8.66	-0.61	2.07e-14	Height;
TGCT	cis	rs8077577	0.895	rs11658477	chr17:18044893	G/A	cg09161412	chr17:18057145	MYO15A	-0.68	-5.24	-0.43	6.8e-7	Obesity-related traits;
TGCT	cis	rs9660992	0.789	rs1768584	chr1:205240145	A/G	cg00857998	chr1:205179979	DSTYK	0.51	4.71	0.39	6.47e-6	Mean corpuscular volume;Mean platelet volume;
TGCT	cis	rs7666738	0.830	rs7659006	chr4:98934529	T/C	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28595532	0.841	rs115918392	chr4:119610356	T/A	cg11846333	chr4:119757529	SEC24D	0.95	4.68	0.39	7.54e-6	Cannabis dependence symptom count;
TGCT	cis	rs60154123	0.505	rs76426571	chr1:210041634	C/T	cg12034118	chr1:209979487	IRF6	0.65	4.56	0.38	1.2e-5	Coronary artery disease;
TGCT	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg03806693	chr22:41940476	POLR3H	1.16	13.52	0.77	3.78e-26	Vitiligo;
TGCT	cis	rs12753569	0.748	rs1013629	chr1:76513759	A/G	cg00791851	chr1:76518896	NA	0.34	4.58	0.38	1.13e-5	Personality dimensions;
TGCT	cis	rs7666738	0.830	rs10009943	chr4:99021475	G/A	cg05340658	chr4:99064831	C4orf37	0.48	5.43	0.44	2.92e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4237845	0.788	rs1962047	chr12:58292707	G/A	cg02175503	chr12:58329896	NA	0.52	4.86	0.4	3.52e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7833790	0.632	rs6473308	chr8:82707708	G/A	cg23324259	chr8:82754387	SNX16	-0.65	-5.05	-0.41	1.56e-6	Diastolic blood pressure;
TGCT	trans	rs208520	0.526	rs6455072	chr6:66797215	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-16.96	-0.84	4.22e-34	Exhaled nitric oxide output;
TGCT	cis	rs6952809	0.926	rs55970742	chr7:2441337	C/T	cg23289794	chr7:2394357	EIF3B	-0.59	-4.92	-0.4	2.74e-6	Multiple sclerosis;
TGCT	cis	rs9858542	0.953	rs6446264	chr3:49417243	C/A	cg03060546	chr3:49711283	APEH	-0.64	-5.61	-0.45	1.27e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs5769765	0.955	rs2319465	chr22:50265784	A/C	cg22709217	chr22:50311962	ALG12;CRELD2	1.11	11.76	0.73	6.5e-22	Schizophrenia;
TGCT	cis	rs6121246	0.542	rs6059761	chr20:30110522	G/C	cg18721089	chr20:30220636	NA	-0.54	-5.7	-0.46	8.21e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg15320075	chr8:145703422	NA	-0.73	-8.0	-0.58	7.69e-13	Age at first birth;
TGCT	cis	rs4455778	0.580	rs35333419	chr7:49120543	A/C	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs79349575	0.745	rs170319	chr17:46991531	T/C	cg07967210	chr17:47022446	SNF8	0.44	6.12	0.48	1.13e-8	Type 2 diabetes;
TGCT	cis	rs17376456	0.877	rs34673483	chr5:93315079	C/A	cg25358565	chr5:93447407	FAM172A	0.98	8.39	0.6	9.01e-14	Diabetic retinopathy;
TGCT	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	6.11	0.48	1.17e-8	Alzheimer's disease;
TGCT	cis	rs8077889	0.957	rs17742929	chr17:41891437	C/T	cg26893861	chr17:41843967	DUSP3	1.04	11.89	0.73	3.25e-22	Triglycerides;
TGCT	cis	rs6693567	0.565	rs11205355	chr1:150252329	G/A	cg09579323	chr1:150459698	TARS2	-0.55	-5.13	-0.42	1.09e-6	Migraine;
TGCT	cis	rs2066819	1.000	rs75598973	chr12:56746558	C/T	cg26714650	chr12:56694279	CS	-1.36	-5.89	-0.47	3.4e-8	Psoriasis vulgaris;
TGCT	cis	rs4888262	0.526	rs6564145	chr16:74621129	G/A	cg01733217	chr16:74700730	RFWD3	0.74	7.4	0.55	1.83e-11	Testicular germ cell tumor;
TGCT	cis	rs3015497	0.616	rs10131107	chr14:51062455	G/A	cg04730355	chr14:51134070	SAV1	-0.64	-6.14	-0.48	1.01e-8	Mean platelet volume;
TGCT	cis	rs12210905	1.000	rs9348756	chr6:27228259	G/A	cg08851530	chr6:28072375	NA	1.37	5.96	0.47	2.46e-8	Hip circumference adjusted for BMI;
TGCT	cis	rs9787249	0.957	rs3738673	chr1:40204823	C/T	cg20968010	chr1:40505947	CAP1	-0.53	-5.0	-0.41	1.91e-6	Blood protein levels;
TGCT	cis	rs651907	0.557	rs36002990	chr3:101437862	G/A	cg12386194	chr3:101231763	SENP7	0.48	4.63	0.38	9.23e-6	Colorectal cancer;
TGCT	cis	rs7208859	0.623	rs216434	chr17:28922335	G/C	cg14008862	chr17:28927542	LRRC37B2	0.93	5.64	0.45	1.11e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs3784262	0.867	rs8036453	chr15:58371635	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.49	-6.98	-0.53	1.61e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs6912958	0.967	rs9450688	chr6:88159276	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.63	-6.22	-0.49	7.06e-9	Monocyte percentage of white cells;
TGCT	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg02725872	chr8:58115012	NA	-0.39	-4.74	-0.39	5.77e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs954108	0.966	rs9508155	chr13:29372016	C/T	cg11788234	chr13:29393811	NA	0.38	5.01	0.41	1.86e-6	Obesity-related traits;
TGCT	cis	rs2688608	0.592	rs7908825	chr10:75554541	C/G	cg04320760	chr10:75533139	FUT11	0.38	5.89	0.47	3.38e-8	Inflammatory bowel disease;
TGCT	cis	rs2204008	0.550	rs11495600	chr12:38126654	C/T	cg13010199	chr12:38710504	ALG10B	0.64	5.16	0.42	9.41e-7	Bladder cancer;
TGCT	cis	rs4919669	0.720	rs729025	chr10:104342206	C/T	cg05855489	chr10:104503620	C10orf26	0.71	4.69	0.39	7.18e-6	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs826838	1.000	rs10880826	chr12:38672787	G/C	cg26384229	chr12:38710491	ALG10B	1.05	10.25	0.68	3.18e-18	Heart rate;
TGCT	trans	rs3780486	0.834	rs75443249	chr9:33149207	A/G	cg04842962	chr6:43655489	MRPS18A	1.14	10.97	0.7	5.51e-20	IgG glycosylation;
TGCT	cis	rs7914558	0.966	rs12569617	chr10:104729996	T/C	cg04362960	chr10:104952993	NT5C2	0.59	5.3	0.43	5.09e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs3087591	1.000	rs2940183	chr17:29416499	T/C	cg24425628	chr17:29625626	OMG;NF1	0.49	7.33	0.55	2.61e-11	Hip circumference;
TGCT	cis	rs9393692	0.905	rs7450556	chr6:26299900	C/T	cg00631329	chr6:26305371	NA	-0.44	-6.59	-0.51	1.13e-9	Educational attainment;
TGCT	cis	rs9733	0.650	rs61820165	chr1:150555987	C/T	cg13175981	chr1:150552382	MCL1	0.51	5.66	0.45	9.73e-8	Tonsillectomy;
TGCT	cis	rs6121246	0.529	rs56153385	chr20:30187609	C/T	cg21427119	chr20:30132790	HM13	-0.38	-5.63	-0.45	1.14e-7	Mean corpuscular hemoglobin;
TGCT	cis	rs514406	0.929	rs12145105	chr1:53340564	T/C	cg01802117	chr1:53393560	SCP2	-0.41	-4.9	-0.4	2.96e-6	Monocyte count;
TGCT	trans	rs2727020	0.615	rs4980435	chr11:49591576	G/A	cg15704280	chr7:45808275	SEPT13	-0.72	-8.48	-0.61	5.52e-14	Coronary artery disease;
TGCT	cis	rs7647973	0.593	rs4855885	chr3:49690199	G/A	cg05785598	chr3:49045655	WDR6	0.43	5.14	0.42	1.03e-6	Menarche (age at onset);
TGCT	cis	rs2997447	0.846	rs61775431	chr1:26411275	T/G	cg03844060	chr1:26490628	NA	0.28	4.57	0.38	1.17e-5	QRS complex (12-leadsum);
TGCT	cis	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg03388025	chr16:89894329	SPIRE2	-0.38	-5.57	-0.45	1.5e-7	Vitiligo;
TGCT	cis	rs1950626	0.833	rs2400963	chr14:101395706	A/G	cg13660701	chr14:101034812	BEGAIN	-0.45	-4.59	-0.38	1.07e-5	Pelvic organ prolapse (moderate/severe);
TGCT	cis	rs6582630	0.555	rs6582503	chr12:38557886	A/C	cg13010199	chr12:38710504	ALG10B	0.64	5.15	0.42	9.97e-7	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs7666738	0.830	rs6823718	chr4:99063202	C/T	cg17366294	chr4:99064904	C4orf37	0.73	7.45	0.56	1.4e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6121246	0.567	rs6060263	chr20:30193110	T/C	cg21427119	chr20:30132790	HM13	-0.42	-6.17	-0.48	8.75e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs4713118	0.662	rs9468274	chr6:28026077	G/T	cg12963246	chr6:28129442	ZNF389	0.45	4.55	0.38	1.27e-5	Parkinson's disease;
TGCT	cis	rs6570726	0.599	rs4398765	chr6:145935006	C/A	cg23711669	chr6:146136114	FBXO30	0.7	6.45	0.5	2.23e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs611744	0.967	rs603889	chr8:109224232	C/T	cg21045802	chr8:109455806	TTC35	0.52	4.72	0.39	6.21e-6	Dupuytren's disease;
TGCT	trans	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg17470723	chr8:74884337	TCEB1	0.71	6.77	0.52	4.48e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs17712049	0.908	rs61102497	chr7:48198434	T/C	cg16849860	chr7:48352531	ABCA13	0.32	5.26	0.43	6.19e-7	Refractive astigmatism;
TGCT	cis	rs3766606	0.505	rs72633047	chr1:7935440	G/A	cg26816564	chr1:7831052	VAMP3	0.65	4.98	0.41	2.11e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs7017914	0.905	rs2639958	chr8:71922150	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.55	-5.1	-0.42	1.24e-6	Bone mineral density;
TGCT	cis	rs10832963	1.000	rs7943121	chr11:18656062	G/C	cg09201001	chr11:18656081	SPTY2D1	1.04	11.77	0.73	6.2e-22	Breast cancer;
TGCT	cis	rs896854	0.684	rs10099059	chr8:95986972	G/C	cg13393036	chr8:95962371	TP53INP1	-0.58	-7.97	-0.58	8.83e-13	Type 2 diabetes;
TGCT	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	5.71	0.46	8.05e-8	Alzheimer's disease;
TGCT	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg02574844	chr11:5959923	NA	-0.37	-4.51	-0.38	1.48e-5	DNA methylation (variation);
TGCT	cis	rs2688608	0.592	rs10762559	chr10:75486453	G/C	cg23231163	chr10:75533350	FUT11	-0.28	-4.68	-0.39	7.41e-6	Inflammatory bowel disease;
TGCT	trans	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg17830980	chr10:43048298	ZNF37B	0.88	11.37	0.71	5.69e-21	Extrinsic epigenetic age acceleration;
TGCT	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg04234412	chr22:24373322	LOC391322	-0.57	-4.66	-0.39	8.18e-6	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs13256369	0.755	rs11776987	chr8:8559401	C/G	cg18904891	chr8:8559673	CLDN23	0.56	5.0	0.41	1.94e-6	Obesity-related traits;
TGCT	cis	rs7216064	1.000	rs62084240	chr17:65859233	C/A	cg12091567	chr17:66097778	LOC651250	-0.83	-6.49	-0.5	1.9e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs7666738	0.830	rs1593570	chr4:99017058	T/C	cg17366294	chr4:99064904	C4orf37	0.68	7.04	0.53	1.17e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3796352	1.000	rs11707780	chr3:53084326	A/G	cg15956490	chr3:53032818	SFMBT1	-0.52	-6.19	-0.49	7.89e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs2440129	0.611	rs10852889	chr17:6900845	C/T	cg03762994	chr17:6899332	ALOX12	0.38	4.46	0.37	1.84e-5	Tonsillectomy;
TGCT	cis	rs6582630	0.502	rs1915395	chr12:38420726	A/G	cg26384229	chr12:38710491	ALG10B	0.85	7.76	0.57	2.69e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs11779988	0.630	rs7821469	chr8:17894388	G/C	cg01800426	chr8:17659068	MTUS1	-0.53	-4.5	-0.37	1.54e-5	Breast cancer;
TGCT	cis	rs77106637	0.858	rs117819392	chr11:72514503	C/T	cg03713592	chr11:72463424	ARAP1	0.95	6.2	0.49	7.69e-9	Type 2 diabetes;
TGCT	cis	rs9486719	0.857	rs4346856	chr6:96880270	C/T	cg06623918	chr6:96969491	KIAA0776	1.04	11.3	0.71	8.72e-21	Migraine;Coronary artery disease;
TGCT	cis	rs3806843	0.576	rs246032	chr5:140332547	C/A	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg02380750	chr20:61661411	NA	0.34	6.03	0.48	1.72e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.48	-0.37	1.66e-5	Bipolar disorder;
TGCT	cis	rs6770219	0.516	rs55864811	chr3:186140901	G/A	cg20306810	chr3:186501757	SNORD2;EIF4A2	0.73	4.46	0.37	1.81e-5	Cerebrospinal T-tau levels;
TGCT	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg22920501	chr2:26401640	FAM59B	0.81	5.36	0.43	3.89e-7	Gut microbiome composition (summer);
TGCT	cis	rs11122272	0.735	rs2295420	chr1:231485640	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.13	-0.54	7.46e-11	Hemoglobin concentration;
TGCT	cis	rs4378999	0.800	rs7615703	chr3:50732402	A/G	cg09687332	chr3:49977370	RBM6	0.72	4.62	0.38	9.47e-6	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
TGCT	cis	rs3796352	1.000	rs750474	chr3:53085280	A/C	cg15956490	chr3:53032818	SFMBT1	0.52	6.26	0.49	5.79e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs651907	0.557	rs13099674	chr3:101489629	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.89	11.22	0.71	1.34e-20	Colorectal cancer;
TGCT	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg22535103	chr8:58192502	C8orf71	-0.42	-4.79	-0.4	4.7e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs11209002	0.567	rs2224501	chr1:67532526	G/T	cg02640540	chr1:67518911	SLC35D1	0.53	4.45	0.37	1.86e-5	Crohn's disease;
TGCT	cis	rs13096357	0.520	rs17080319	chr3:48732480	T/C	cg00383909	chr3:49044727	WDR6	0.98	5.67	0.45	9.63e-8	Cognitive ability (multi-trait analysis);
TGCT	cis	rs826838	0.967	rs7970069	chr12:38810631	T/C	cg26384229	chr12:38710491	ALG10B	1.06	10.68	0.69	2.84e-19	Heart rate;
TGCT	cis	rs33794	0.836	rs33782	chr3:45290954	G/T	cg18645101	chr3:44551900	NA	0.54	4.74	0.39	5.75e-6	Lung function (forced expiratory volume in 1 second);
TGCT	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.0	7.42	0.55	1.64e-11	Gut microbiome composition (summer);
TGCT	cis	rs6840360	0.571	rs11736116	chr4:152531816	A/G	cg17479576	chr4:152424074	FAM160A1	-0.73	-7.94	-0.58	1.03e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs7584330	0.910	rs66509917	chr2:238395394	T/G	cg16989719	chr2:238392110	NA	-0.27	-4.63	-0.38	8.95e-6	Prostate cancer;
TGCT	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg26338869	chr17:61819248	STRADA	-0.56	-5.11	-0.42	1.17e-6	Prudent dietary pattern;
TGCT	cis	rs11864453	0.826	rs12708928	chr16:72137227	C/A	cg14768367	chr16:72042858	DHODH	0.48	4.44	0.37	1.98e-5	Fibrinogen levels;
TGCT	cis	rs1868673	0.679	rs6778948	chr3:150134304	G/A	cg24290546	chr3:150134309	TSC22D2	-0.25	-4.67	-0.39	7.66e-6	Waist circumference;
TGCT	cis	rs13082711	0.954	rs34348584	chr3:27532704	T/C	cg02860705	chr3:27208620	NA	0.34	4.77	0.39	5.18e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.44	-4.75	-0.39	5.47e-6	Blood metabolite levels;
TGCT	cis	rs2228479	0.867	rs12919804	chr16:89945369	G/A	cg04013166	chr16:89971882	TCF25	0.32	4.46	0.37	1.84e-5	Skin colour saturation;
TGCT	cis	rs17376456	0.597	rs7708175	chr5:93381182	A/G	cg21475434	chr5:93447410	FAM172A	-0.61	-5.66	-0.45	1.01e-7	Diabetic retinopathy;
TGCT	cis	rs7169223	0.653	rs1976007	chr15:79085023	T/C	cg21242079	chr15:79101063	ADAMTS7	0.32	5.28	0.43	5.68e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
TGCT	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg26338869	chr17:61819248	STRADA	-0.53	-4.87	-0.4	3.29e-6	Prudent dietary pattern;
TGCT	cis	rs8084125	0.832	rs62105171	chr18:74945663	G/A	cg05528293	chr18:74961138	GALR1	0.5	4.94	0.41	2.48e-6	Obesity-related traits;
TGCT	cis	rs4713675	0.709	rs626156	chr6:33670482	A/G	cg06471254	chr6:33690276	IP6K3	0.24	4.7	0.39	6.71e-6	Plateletcrit;
TGCT	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs308403	0.640	rs13128246	chr4:123721306	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.66	5.7	0.46	8.18e-8	Blood protein levels;
TGCT	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.33	-5.2	-0.42	7.9e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg17971929	chr21:40555470	PSMG1	0.91	8.16	0.59	3.18e-13	Cognitive function;
TGCT	cis	rs3125734	0.671	rs3852406	chr10:64015162	T/C	cg05499367	chr10:63213510	TMEM26	-0.33	-4.54	-0.38	1.31e-5	Rheumatoid arthritis;
TGCT	cis	rs7044106	0.762	rs4142158	chr9:123410819	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	4.75	0.39	5.55e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs763121	0.853	rs926299	chr22:39095698	C/G	cg06022373	chr22:39101656	GTPBP1	0.78	8.1	0.59	4.34e-13	Menopause (age at onset);
TGCT	cis	rs12908161	1.000	rs35808647	chr15:85377441	G/A	cg11189052	chr15:85197271	WDR73	0.72	5.75	0.46	6.43e-8	Schizophrenia;
TGCT	cis	rs933688	1.000	rs11948075	chr5:90680579	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.99	8.15	0.59	3.39e-13	Smoking behavior;
TGCT	cis	rs11190604	0.767	rs12360395	chr10:102194074	A/T	cg23241863	chr10:102295624	HIF1AN	0.65	4.89	0.4	3e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9818758	0.607	rs11716445	chr3:49406095	C/T	cg00383909	chr3:49044727	WDR6	1.52	6.53	0.51	1.55e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs929596	0.728	rs6744284	chr2:234625297	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.31	-4.89	-0.4	3.1e-6	Total bilirubin levels in HIV-1 infection;
TGCT	cis	rs727505	0.954	rs55768077	chr7:124663216	A/G	cg23710748	chr7:124431027	NA	-0.26	-4.54	-0.38	1.33e-5	Lewy body disease;
TGCT	cis	rs12477438	0.539	rs720228	chr2:99704547	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	8.95	0.63	4.36e-15	Chronic sinus infection;
TGCT	cis	rs13191362	1.000	rs73035012	chr6:162997279	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs2153535	0.580	rs9328484	chr6:8524843	A/T	cg07606381	chr6:8435919	SLC35B3	0.54	5.01	0.41	1.86e-6	Motion sickness;
TGCT	cis	rs9291683	0.546	rs13129453	chr4:10044784	T/C	cg11266682	chr4:10021025	SLC2A9	0.6	7.52	0.56	9.49e-12	Bone mineral density;
TGCT	cis	rs9814567	1.000	rs9863786	chr3:134247203	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.95	-9.55	-0.65	1.56e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs734999	0.549	rs6670198	chr1:2520527	T/C	cg18854424	chr1:2615690	NA	0.49	5.72	0.46	7.65e-8	Ulcerative colitis;
TGCT	cis	rs8177253	0.696	rs4459901	chr3:133465699	T/C	cg08048268	chr3:133502702	NA	-0.53	-6.97	-0.53	1.67e-10	Iron status biomarkers;
TGCT	cis	rs11690935	0.549	rs62183819	chr2:172904520	G/T	cg13550731	chr2:172543902	DYNC1I2	0.64	5.83	0.46	4.45e-8	Schizophrenia;
TGCT	cis	rs6752107	0.901	rs10206299	chr2:234146271	G/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.2	4.87	0.4	3.36e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs11098499	0.618	rs35265692	chr4:120325135	T/C	cg09307838	chr4:120376055	NA	0.7	6.75	0.52	5.18e-10	Corneal astigmatism;
TGCT	cis	rs587847	0.737	rs1520951	chr15:37668534	C/A	cg00216138	chr15:37171175	LOC145845	0.31	4.45	0.37	1.91e-5	Intraocular pressure;
TGCT	cis	rs6598955	0.543	rs4585968	chr1:26535146	G/A	cg04990556	chr1:26633338	UBXN11	0.81	7.32	0.55	2.76e-11	Obesity-related traits;
TGCT	cis	rs10883723	0.962	rs1056739	chr10:104236542	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	7.52	0.56	9.74e-12	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs3784262	0.631	rs12903724	chr15:58310387	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.42	-6.17	-0.48	8.83e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs75059851	0.756	rs11223647	chr11:133839588	G/A	cg14047540	chr11:133829660	NA	-0.57	-5.69	-0.45	8.72e-8	Schizophrenia;
TGCT	cis	rs4711350	0.734	rs9380379	chr6:33766131	A/G	cg18005901	chr6:33739558	LEMD2	-0.55	-6.19	-0.49	8.02e-9	Schizophrenia;
TGCT	cis	rs7772486	0.790	rs2265469	chr6:146219049	T/C	cg23711669	chr6:146136114	FBXO30	0.89	10.16	0.67	5.28e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.71	5.14	0.42	1.02e-6	Platelet count;
TGCT	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg08736216	chr1:53307985	ZYG11A	0.25	4.86	0.4	3.55e-6	Monocyte count;
TGCT	cis	rs10782582	0.593	rs77733234	chr1:76101655	A/T	cg10523679	chr1:76189770	ACADM	-0.68	-7.45	-0.56	1.4e-11	Daytime sleep phenotypes;
TGCT	cis	rs6809651	0.524	rs1356292	chr3:185824903	C/T	cg00760338	chr3:185826511	ETV5	0.78	6.52	0.51	1.56e-9	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
TGCT	cis	rs10489525	0.599	rs34710929	chr1:115606608	G/A	cg12756093	chr1:115239321	AMPD1	-0.4	-5.49	-0.44	2.19e-7	Autism;
TGCT	cis	rs7760949	0.963	rs9396248	chr6:13906360	A/G	cg27413430	chr6:13925136	RNF182	0.52	4.78	0.39	4.9e-6	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs4680	0.701	rs4646317	chr22:19952168	G/A	cg22546130	chr22:19950026	COMT	-0.32	-4.67	-0.39	7.58e-6	Blood metabolite levels;
TGCT	cis	rs6723226	1.000	rs6723226	chr2:32849207	C/T	cg02381751	chr2:32503542	YIPF4	0.49	4.7	0.39	6.86e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs11148252	0.532	rs9536190	chr13:53181044	T/C	cg02158880	chr13:53174818	NA	0.5	5.91	0.47	3.07e-8	Lewy body disease;
TGCT	cis	rs4654899	0.861	rs10916876	chr1:21169996	T/C	cg01072550	chr1:21505969	NA	0.48	7.58	0.56	7.09e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs10242455	0.702	rs75156180	chr7:98964100	G/A	cg13560068	chr7:99070416	ZNF789	1.09	4.66	0.39	8.13e-6	Blood metabolite levels;
TGCT	cis	rs938554	0.571	rs4144	chr4:10016322	T/C	cg00071950	chr4:10020882	SLC2A9	0.55	4.78	0.39	4.88e-6	Blood metabolite levels;
TGCT	cis	rs1857353	1.000	rs17096888	chr1:75903999	G/A	cg11838876	chr1:75668600	SLC44A5	-0.51	-4.81	-0.4	4.23e-6	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs7119038	0.731	rs10892283	chr11:118636980	A/G	cg19308663	chr11:118741387	NA	0.3	5.59	0.45	1.37e-7	Sjögren's syndrome;
TGCT	cis	rs10791097	0.694	rs2155751	chr11:130755240	G/A	cg05962950	chr11:130786565	SNX19	0.91	11.68	0.72	1.01e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg23758822	chr17:41437982	NA	0.74	6.78	0.52	4.27e-10	Menopause (age at onset);
TGCT	cis	rs1372520	0.564	rs2737011	chr4:90746219	T/C	cg15133208	chr4:90757351	SNCA	-0.5	-5.81	-0.46	4.96e-8	Neuroticism;
TGCT	cis	rs4319547	0.626	rs11057882	chr12:122875046	A/G	cg08088222	chr12:122070432	ORAI1	0.25	4.49	0.37	1.58e-5	Body mass index;
TGCT	trans	rs114540395	0.858	rs3730478	chr10:103339142	G/A	cg10198749	chr1:39920707	MACF1	0.55	7.06	0.54	1.06e-10	Schizophrenia;
TGCT	cis	rs6121246	0.909	rs6060812	chr20:30292803	C/T	cg18721089	chr20:30220636	NA	-0.42	-4.65	-0.39	8.2e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs12477438	0.501	rs11683107	chr2:99759235	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	10.28	0.68	2.66e-18	Chronic sinus infection;
TGCT	cis	rs68170813	0.523	rs10253172	chr7:106786474	C/T	cg02696742	chr7:106810147	HBP1	0.74	6.15	0.48	9.79e-9	Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs11735193	chr4:98761900	C/T	cg05340658	chr4:99064831	C4orf37	0.49	5.77	0.46	6.02e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10504229	0.679	rs72649119	chr8:58040301	T/C	cg08280861	chr8:58055591	NA	0.35	4.92	0.4	2.72e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10426930	0.639	rs1136405	chr19:5062814	T/C	cg09001777	chr19:5851504	FUT3	-0.22	-4.77	-0.39	4.98e-6	Monocyte percentage of white cells;
TGCT	cis	rs10488031	0.557	rs74336212	chr7:37082618	A/G	cg06458904	chr7:36312573	EEPD1	0.56	4.7	0.39	6.79e-6	QT interval;
TGCT	trans	rs2469997	1.000	rs2957356	chr8:120373995	T/G	cg01792902	chr3:178864926	PIK3CA	0.83	6.77	0.52	4.49e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs7666738	0.830	rs35235971	chr4:98999833	G/T	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9467711	0.606	rs2076030	chr6:26426856	G/A	cg16898833	chr6:26189333	HIST1H4D	1.12	5.36	0.43	3.91e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg22920501	chr2:26401640	FAM59B	-0.8	-6.34	-0.49	3.84e-9	Gut microbiome composition (summer);
TGCT	cis	rs9733	0.596	rs7418501	chr1:150711896	A/T	cg09365446	chr1:150670422	GOLPH3L	0.29	4.45	0.37	1.86e-5	Tonsillectomy;
TGCT	cis	rs17376456	0.877	rs114256265	chr5:93473130	T/A	cg25358565	chr5:93447407	FAM172A	0.92	8.23	0.59	2.17e-13	Diabetic retinopathy;
TGCT	cis	rs62244186	0.711	rs6778410	chr3:44743993	C/T	cg02073558	chr3:44770973	ZNF501	0.66	6.66	0.51	7.99e-10	Depressive symptoms;
TGCT	cis	rs6429082	0.818	rs834198	chr1:235671987	A/G	cg26050004	chr1:235667680	B3GALNT2	0.58	5.16	0.42	9.46e-7	Adiposity;
TGCT	cis	rs6543140	0.929	rs7602207	chr2:103032366	C/G	cg09003973	chr2:102972529	NA	0.59	4.95	0.41	2.39e-6	Blood protein levels;
TGCT	cis	rs4704846	0.861	rs4704849	chr5:156532928	A/G	cg12943317	chr5:156479607	HAVCR1	-0.34	-4.7	-0.39	6.82e-6	Blood protein levels;
TGCT	cis	rs12725198	0.507	rs41393951	chr1:16053493	C/T	cg02485345	chr1:16061554	SLC25A34	0.39	4.64	0.38	8.66e-6	Cardiac Troponin-T levels;
TGCT	cis	rs9513593	1.000	rs4772181	chr13:99860966	C/G	cg21788972	chr13:99853209	UBAC2	0.61	4.93	0.4	2.59e-6	Psoriasis;
TGCT	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg07507251	chr3:52567010	NT5DC2	0.47	6.64	0.51	8.85e-10	Bipolar disorder;
TGCT	trans	rs9313296	0.661	rs10059799	chr5:165556009	A/G	cg25743221	chr6:152501416	SYNE1	0.84	7.1	0.54	8.6e-11	Weight;Waist circumference;
TGCT	cis	rs11148252	0.875	rs9526913	chr13:52975837	T/C	cg00495681	chr13:53174319	NA	0.48	4.44	0.37	1.94e-5	Lewy body disease;
TGCT	cis	rs36051895	0.658	rs10975029	chr9:5251068	T/C	cg02405213	chr9:5042618	JAK2	-0.7	-8.61	-0.61	2.76e-14	Pediatric autoimmune diseases;
TGCT	cis	rs12762955	0.561	rs7076107	chr10:1043647	T/C	cg18964960	chr10:1102726	WDR37	-0.68	-5.99	-0.47	2.07e-8	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs13177918	0.603	rs13175992	chr5:149830589	G/A	cg14059543	chr5:149831962	NA	-0.68	-9.13	-0.63	1.6e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs514406	0.929	rs12145105	chr1:53340564	T/C	cg25767906	chr1:53392781	SCP2	-0.49	-5.73	-0.46	7.08e-8	Monocyte count;
TGCT	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg13770153	chr20:60521292	NA	-0.54	-7.12	-0.54	7.73e-11	Body mass index;
TGCT	cis	rs2235642	1.000	rs2076438	chr16:1584618	T/C	cg07639376	chr16:1584516	IFT140;TMEM204	-0.32	-5.81	-0.46	5.02e-8	Coronary artery disease;
TGCT	cis	rs7568458	0.905	rs17026396	chr2:85759127	C/T	cg17127132	chr2:85788382	GGCX	-0.72	-6.7	-0.52	6.53e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs72781680	0.821	rs55948613	chr2:24094787	A/G	cg08917208	chr2:24149416	ATAD2B	0.75	4.68	0.39	7.44e-6	Lymphocyte counts;
TGCT	cis	rs8031584	0.958	rs34294266	chr15:31246840	A/G	cg08704250	chr15:31115839	NA	-0.36	-4.97	-0.41	2.2e-6	Huntington's disease progression;
TGCT	cis	rs12510870	0.544	rs34238679	chr4:74387770	T/A	cg05868023	chr4:75230803	EREG	-0.55	-4.7	-0.39	6.84e-6	Iris color (b* coordinate);
TGCT	cis	rs1018836	0.828	rs7008172	chr8:91551613	C/T	cg16814680	chr8:91681699	NA	-0.72	-7.53	-0.56	8.91e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	trans	rs1814175	0.781	rs12286395	chr11:49954062	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.36	-7.14	-0.54	6.88e-11	Height;
TGCT	cis	rs13256369	1.000	rs4840352	chr8:8573508	A/G	cg06671706	chr8:8559999	CLDN23	0.34	4.44	0.37	1.99e-5	Obesity-related traits;
TGCT	cis	rs7312933	0.558	rs4768402	chr12:42755576	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.59	-5.72	-0.46	7.52e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs6840360	0.571	rs718801	chr4:152549247	C/T	cg17479576	chr4:152424074	FAM160A1	-0.72	-7.81	-0.57	2.05e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs1865760	0.516	rs9379818	chr6:26023206	G/T	cg17042849	chr6:26104293	HIST1H4C	-0.66	-5.89	-0.47	3.32e-8	Height;
TGCT	cis	rs1903068	0.657	rs41408948	chr4:55992025	G/A	cg16572876	chr4:56024045	NA	0.42	4.43	0.37	2.01e-5	Endometriosis;
TGCT	cis	rs611744	0.967	rs584555	chr8:109218612	C/G	cg21045802	chr8:109455806	TTC35	0.5	4.56	0.38	1.23e-5	Dupuytren's disease;
TGCT	cis	rs909674	0.818	rs5750830	chr22:39840828	C/A	cg01416388	chr22:39784598	NA	-0.69	-6.27	-0.49	5.6e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg17971929	chr21:40555470	PSMG1	0.97	9.54	0.65	1.67e-16	Cognitive function;
TGCT	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg17775962	chr7:1200435	ZFAND2A	0.27	4.61	0.38	9.85e-6	Longevity;Endometriosis;
TGCT	cis	rs17345786	0.798	rs1609159	chr3:101275902	A/C	cg12386194	chr3:101231763	SENP7	0.57	5.45	0.44	2.62e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7267979	1.000	rs2424700	chr20:25266513	A/G	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs17534004	1.000	rs35646895	chr13:31469604	C/T	cg13251181	chr13:31481184	C13orf33	0.37	4.6	0.38	1.04e-5	3-hydroxypropylmercapturic acid levels in smokers;
TGCT	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg10802521	chr3:52805072	NEK4	-0.73	-9.23	-0.64	9.18e-16	Bipolar disorder;
TGCT	cis	rs7918232	0.941	rs788210	chr10:27476948	T/C	cg14442939	chr10:27389572	ANKRD26	-0.82	-5.75	-0.46	6.69e-8	Breast cancer;
TGCT	cis	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg22857025	chr5:266934	NA	-0.34	-6.7	-0.52	6.65e-10	Breast cancer;
TGCT	cis	rs9790314	0.846	rs7652267	chr3:160998497	A/G	cg03342759	chr3:160939853	NMD3	-0.53	-6.02	-0.48	1.82e-8	Morning vs. evening chronotype;
TGCT	cis	rs9467603	1.000	rs9467607	chr6:25809477	G/A	cg16898833	chr6:26189333	HIST1H4D	1.16	5.51	0.44	2.03e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs908922	0.573	rs7544564	chr1:152527007	A/C	cg20991723	chr1:152506922	NA	0.44	5.96	0.47	2.44e-8	Hair morphology;
TGCT	cis	rs2933343	0.953	rs2933344	chr3:128658715	A/G	cg11901034	chr3:128598214	ACAD9	-0.59	-4.65	-0.39	8.49e-6	IgG glycosylation;
TGCT	trans	rs17684571	0.938	rs4074102	chr6:56562295	C/T	cg14229071	chr15:89282588	NA	0.52	6.82	0.52	3.54e-10	Schizophrenia;
TGCT	cis	rs6700896	0.500	rs72641129	chr1:66075123	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.64	4.95	0.41	2.41e-6	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs4319547	0.915	rs7314638	chr12:122983460	A/G	cg23029597	chr12:123009494	RSRC2	-0.29	-4.87	-0.4	3.34e-6	Body mass index;
TGCT	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg02725872	chr8:58115012	NA	-0.38	-5.16	-0.42	9.32e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg04772025	chr11:68637568	NA	0.62	6.81	0.52	3.77e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs2295359	1.000	rs4655682	chr1:67610967	C/T	cg12940439	chr1:67600707	NA	0.58	6.1	0.48	1.24e-8	Psoriasis;
TGCT	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.18	0.49	8.32e-9	Electroencephalogram traits;
TGCT	cis	rs2243480	0.666	rs1880311	chr7:65276752	G/C	cg18252515	chr7:66147081	NA	1.1	5.88	0.47	3.55e-8	Diabetic kidney disease;
TGCT	cis	rs2153535	0.601	rs4140585	chr6:8503298	T/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs4711350	0.954	rs943464	chr6:33731469	A/G	cg18005901	chr6:33739558	LEMD2	0.57	5.75	0.46	6.52e-8	Schizophrenia;
TGCT	cis	rs853679	0.567	rs13196606	chr6:28370078	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.52	-4.67	-0.39	7.85e-6	Depression;
TGCT	cis	rs13191362	1.000	rs13210412	chr6:163019478	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.57	4.94	0.41	2.45e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs13242816	1.000	rs3779513	chr7:116178992	T/C	cg16553024	chr7:116138462	CAV2	-0.44	-5.26	-0.43	6.11e-7	P wave duration;
TGCT	cis	rs2295359	0.892	rs10889657	chr1:67615487	A/G	cg08029281	chr1:67600428	NA	0.4	4.55	0.38	1.28e-5	Psoriasis;
TGCT	cis	rs2832191	0.935	rs11910475	chr21:30519702	T/C	cg24692254	chr21:30365293	RNF160	-0.77	-7.9	-0.58	1.28e-12	Dental caries;
TGCT	cis	rs9928842	0.771	rs4888363	chr16:75277344	A/T	cg09066997	chr16:75300724	BCAR1	0.25	4.72	0.39	6.17e-6	Alcoholic chronic pancreatitis;
TGCT	cis	rs8031584	0.678	rs8028173	chr15:31155749	A/G	cg08704250	chr15:31115839	NA	-0.43	-6.31	-0.49	4.47e-9	Huntington's disease progression;
TGCT	cis	rs7843479	0.965	rs4636204	chr8:21823206	T/G	cg17168535	chr8:21777572	XPO7	0.64	5.91	0.47	3.12e-8	Mean corpuscular volume;
TGCT	cis	rs7169223	0.653	rs1994017	chr15:79080306	T/C	cg03762349	chr15:79060523	ADAMTS7	-0.24	-5.02	-0.41	1.77e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
TGCT	cis	rs3096299	0.685	rs4785676	chr16:89553624	T/C	cg08392591	chr16:89556376	ANKRD11	0.55	5.1	0.42	1.25e-6	Multiple myeloma (IgH translocation);
TGCT	cis	rs1670533	1.000	rs2045068	chr4:1052212	G/A	cg20887711	chr4:1340912	KIAA1530	0.73	5.74	0.46	6.77e-8	Recombination rate (females);
TGCT	cis	rs12935418	0.616	rs12444054	chr16:80964217	T/G	cg07676361	chr16:80966860	NA	-0.35	-4.64	-0.38	8.56e-6	Mean corpuscular volume;
TGCT	cis	rs4722166	1.000	rs4722166	chr7:22738762	G/T	cg26061582	chr7:22766209	IL6	0.39	4.65	0.39	8.32e-6	Lung cancer;
TGCT	cis	rs9914988	0.778	rs35398767	chr17:27122960	A/T	cg20469991	chr17:27169893	C17orf63	-0.72	-5.04	-0.41	1.58e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs713587	0.691	rs754537	chr2:25176277	A/T	cg15423357	chr2:25149977	NA	-0.46	-4.52	-0.38	1.41e-5	Body mass index in non-asthmatics;
TGCT	cis	rs2153535	0.601	rs330105	chr6:8543981	A/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.63	0.45	1.14e-7	Motion sickness;
TGCT	cis	rs1451375	0.669	rs59086818	chr7:50653830	G/A	cg18232548	chr7:50535776	DDC	0.44	6.72	0.52	5.81e-10	Malaria;
TGCT	cis	rs2046867	0.818	rs6792109	chr3:72867091	C/T	cg25664220	chr3:72788482	NA	-0.54	-7.03	-0.53	1.22e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs651907	0.535	rs13094753	chr3:101525082	A/G	cg12386194	chr3:101231763	SENP7	0.47	4.7	0.39	6.87e-6	Colorectal cancer;
TGCT	cis	rs2721195	0.845	rs2721150	chr8:145724973	C/G	cg11211951	chr8:145729740	GPT	0.27	6.24	0.49	6.37e-9	Age at first birth;
TGCT	cis	rs8038465	1.000	rs8032727	chr15:73977336	A/G	cg15420318	chr15:73925796	NPTN	0.7	6.55	0.51	1.37e-9	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1008375	0.931	rs3775926	chr4:17599837	G/A	cg10189774	chr4:17578691	LAP3	0.69	6.07	0.48	1.47e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	trans	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg27523141	chr10:43048294	ZNF37B	-0.74	-8.46	-0.6	6.33e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7267979	0.966	rs6037097	chr20:25347221	C/T	cg16686733	chr20:25566563	NINL	0.58	5.78	0.46	5.62e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4468007	0.505	rs4837905	chr9:124620796	C/T	cg01549227	chr9:124980074	LHX6	-0.3	-4.55	-0.38	1.24e-5	Educational attainment;
TGCT	cis	rs35146811	0.735	rs858506	chr7:99820050	T/C	cg22906224	chr7:99728672	NA	-0.5	-4.51	-0.38	1.48e-5	Coronary artery disease;
TGCT	cis	rs911555	0.962	rs2765042	chr14:103990745	G/A	cg12935359	chr14:103987150	CKB	0.38	5.37	0.43	3.7e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg06028808	chr11:68637592	NA	0.51	6.66	0.51	7.87e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs11627546	0.615	rs4528503	chr14:70366437	A/G	cg10496350	chr14:71275911	MAP3K9	-0.89	-4.5	-0.37	1.52e-5	Red blood cell traits;
TGCT	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg06873352	chr17:61820015	STRADA	0.58	6.39	0.5	3.01e-9	Prudent dietary pattern;
TGCT	trans	rs2688608	0.725	rs2688623	chr10:75689615	C/T	cg13918328	chr10:52500089	ASAH2B	0.66	6.71	0.52	6.1e-10	Inflammatory bowel disease;
TGCT	cis	rs950776	0.518	rs4887062	chr15:78837801	G/A	cg06917634	chr15:78832804	PSMA4	-0.93	-9.06	-0.63	2.33e-15	Sudden cardiac arrest;
TGCT	cis	rs4601821	1.000	rs877138	chr11:113256508	A/G	cg14159747	chr11:113255604	NA	-0.37	-4.44	-0.37	1.97e-5	Alcoholic chronic pancreatitis;
TGCT	cis	rs929596	0.697	rs17863787	chr2:234611094	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.29	-4.49	-0.37	1.63e-5	Total bilirubin levels in HIV-1 infection;
TGCT	cis	rs5769765	0.908	rs2319464	chr22:50265777	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.41	-6.13	-0.48	1.08e-8	Schizophrenia;
TGCT	cis	rs9302065	0.565	rs2992908	chr13:95960600	G/A	cg24476569	chr13:95954382	ABCC4	-0.54	-8.26	-0.6	1.9e-13	Blood metabolite levels;
TGCT	cis	rs36051895	0.664	rs28378223	chr9:5113087	C/G	cg02405213	chr9:5042618	JAK2	-0.75	-10.29	-0.68	2.5e-18	Pediatric autoimmune diseases;
TGCT	cis	rs10910092	1	rs10910092	chr1:2501516	A/G	cg18854424	chr1:2615690	NA	0.45	5.38	0.43	3.62e-7	Ulcerative colitis;
TGCT	cis	rs910316	1.000	rs4903289	chr14:75623988	C/T	cg11812906	chr14:75593930	NEK9	-0.74	-7.21	-0.54	4.75e-11	Height;
TGCT	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg00343986	chr7:65444356	GUSB	0.23	5.14	0.42	1.06e-6	Aortic root size;
TGCT	cis	rs4654899	1.000	rs6700718	chr1:21299363	A/C	cg01072550	chr1:21505969	NA	0.51	8.15	0.59	3.28e-13	Superior frontal gyrus grey matter volume;
TGCT	cis	rs7216064	1.000	rs55939964	chr17:65869297	G/A	cg12091567	chr17:66097778	LOC651250	-0.83	-6.49	-0.5	1.9e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs7772486	0.790	rs2253880	chr6:146200774	T/C	cg23711669	chr6:146136114	FBXO30	0.93	10.56	0.69	5.35e-19	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2243480	0.614	rs34032527	chr7:65565141	C/G	cg18252515	chr7:66147081	NA	-1.1	-7.18	-0.54	5.77e-11	Diabetic kidney disease;
TGCT	cis	rs6840360	0.615	rs4696290	chr4:152631472	A/G	cg22705602	chr4:152727874	NA	-0.34	-5.83	-0.46	4.4e-8	Intelligence (multi-trait analysis);
TGCT	trans	rs1496653	0.602	rs36021750	chr3:23609741	C/G	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	5.14	0.42	1.03e-6	Height;
TGCT	cis	rs13082711	0.911	rs11717669	chr3:27458484	C/T	cg02860705	chr3:27208620	NA	0.35	4.83	0.4	3.9e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs734999	0.545	rs6698817	chr1:2564183	T/C	cg18854424	chr1:2615690	NA	-0.45	-5.15	-0.42	1e-6	Ulcerative colitis;
TGCT	cis	rs73110464	0.562	rs2363634	chr12:53354683	A/G	cg16329197	chr12:53359506	NA	-0.56	-7.66	-0.57	4.65e-12	Cancer (pleiotropy);
TGCT	cis	rs7568458	0.837	rs3731827	chr2:85806068	T/C	cg17127132	chr2:85788382	GGCX	0.72	6.68	0.51	7.18e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs17068510	0.572	rs11779756	chr8:3883321	C/T	cg25338036	chr8:3047536	CSMD1	-0.44	-4.57	-0.38	1.18e-5	Cerebrospinal fluid clusterin levels;
TGCT	cis	rs9583531	0.714	rs76166228	chr13:111343774	T/C	cg15747390	chr13:111297551	CARS2	0.86	5.84	0.46	4.21e-8	Coronary artery disease;
TGCT	cis	rs36051895	0.632	rs7047795	chr9:5181467	C/T	cg02405213	chr9:5042618	JAK2	-0.74	-10.38	-0.68	1.47e-18	Pediatric autoimmune diseases;
TGCT	cis	rs79349575	0.783	rs62075839	chr17:46996434	G/C	cg07967210	chr17:47022446	SNF8	0.44	6.12	0.48	1.13e-8	Type 2 diabetes;
TGCT	cis	rs62064224	0.902	rs35830939	chr17:30627564	A/C	cg09324608	chr17:30823087	MYO1D	0.21	4.47	0.37	1.73e-5	Schizophrenia;
TGCT	cis	rs2153535	0.580	rs4451187	chr6:8473910	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.7	0.46	8.28e-8	Motion sickness;
TGCT	cis	rs929354	0.772	rs6957939	chr7:156978485	T/C	cg05182265	chr7:156933206	UBE3C	-0.39	-8.79	-0.62	1.03e-14	Body mass index;
TGCT	cis	rs1568889	0.775	rs35243076	chr11:28250618	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.92	10.85	0.7	1.1e-19	Bipolar disorder;
TGCT	cis	rs7772486	0.692	rs2265915	chr6:146194332	A/T	cg13319975	chr6:146136371	FBXO30	-0.54	-4.81	-0.4	4.35e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs72781680	1.000	rs12616899	chr2:24165235	A/G	cg08917208	chr2:24149416	ATAD2B	0.73	4.51	0.38	1.48e-5	Lymphocyte counts;
TGCT	cis	rs1801251	0.964	rs13007783	chr2:233566679	G/A	cg08000102	chr2:233561755	GIGYF2	0.64	6.44	0.5	2.36e-9	Coronary artery disease;
TGCT	cis	rs7829975	0.628	rs1109618	chr8:8571364	A/T	cg06636001	chr8:8085503	FLJ10661	-0.61	-5.26	-0.43	6e-7	Mood instability;
TGCT	cis	rs2692947	0.644	rs772178	chr2:96963684	C/T	cg23100626	chr2:96804247	ASTL	-0.45	-5.64	-0.45	1.08e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs7937682	0.889	rs490199	chr11:111487890	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.1	-11.94	-0.73	2.41e-22	Primary sclerosing cholangitis;
TGCT	cis	rs35146811	0.659	rs863450	chr7:99821685	C/T	cg00553149	chr7:99775558	STAG3;GPC2	-0.32	-4.81	-0.4	4.28e-6	Coronary artery disease;
TGCT	cis	rs3806843	0.576	rs246030	chr5:140333154	C/G	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs992157	0.644	rs6741757	chr2:219182748	T/C	cg00012203	chr2:219082015	ARPC2	0.71	6.71	0.52	6.34e-10	Colorectal cancer;
TGCT	cis	rs858239	0.539	rs4365988	chr7:23190871	T/C	cg05602783	chr7:23145260	KLHL7	-0.63	-4.98	-0.41	2.09e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs7617773	0.817	rs11720622	chr3:48246679	G/A	cg11946769	chr3:48343235	NME6	0.74	7.01	0.53	1.38e-10	Coronary artery disease;
TGCT	cis	rs425277	0.959	rs77665022	chr1:2065958	C/T	cg24578937	chr1:2090814	PRKCZ	0.33	7.85	0.58	1.71e-12	Height;
TGCT	cis	rs7312933	0.558	rs4768411	chr12:42855390	A/G	cg19980929	chr12:42632907	YAF2	-0.4	-5.75	-0.46	6.7e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7959452	0.590	rs10878974	chr12:69781528	C/G	cg14784868	chr12:69753453	YEATS4	0.83	8.96	0.63	4.14e-15	Blood protein levels;
TGCT	cis	rs1865760	0.623	rs12216125	chr6:25997458	C/T	cg16482183	chr6:26056742	HIST1H1C	0.63	5.49	0.44	2.15e-7	Height;
TGCT	cis	rs7666738	0.791	rs13128640	chr4:99003918	A/C	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7246657	1.000	rs6508710	chr19:37749886	A/G	cg18154014	chr19:37997991	ZNF793	0.68	4.69	0.39	6.97e-6	Coronary artery calcification;
TGCT	cis	rs7104764	1.000	rs10400248	chr11:247029	C/T	cg18336825	chr11:236787	PSMD13;SIRT3	1.07	11.19	0.71	1.61e-20	Menarche (age at onset);
TGCT	cis	rs9902453	0.967	rs9900911	chr17:28330280	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.74	-6.59	-0.51	1.12e-9	Coffee consumption (cups per day);
TGCT	cis	rs1865760	0.566	rs2051544	chr6:26071093	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.79	7.55	0.56	8.02e-12	Height;
TGCT	cis	rs72845660	0.550	rs6584499	chr10:104188259	A/C	cg26089160	chr10:104170217	PSD	0.46	4.51	0.38	1.51e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg08280861	chr8:58055591	NA	0.39	4.81	0.4	4.3e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9457247	1.000	rs402749	chr6:167386104	C/T	cg23791538	chr6:167370224	RNASET2	-0.5	-4.98	-0.41	2.08e-6	Crohn's disease;
TGCT	cis	rs710216	0.917	rs900836	chr1:43412727	T/C	cg03128534	chr1:43423976	SLC2A1	-0.56	-4.53	-0.38	1.35e-5	Red cell distribution width;
TGCT	cis	rs7666738	0.830	rs6833312	chr4:98951356	A/T	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7611238	0.560	rs1994880	chr3:195140478	C/T	cg27323046	chr3:195102265	ACAP2	0.38	5.13	0.42	1.09e-6	Body mass index;
TGCT	cis	rs4132509	0.739	rs79367267	chr1:243689543	C/A	cg21452805	chr1:244014465	NA	0.75	4.55	0.38	1.28e-5	RR interval (heart rate);
TGCT	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg23708337	chr7:1209742	NA	0.56	5.08	0.42	1.34e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9921192	0.934	rs233948	chr16:4327174	C/T	cg00021532	chr16:4324280	TFAP4	0.83	9.35	0.64	4.7e-16	Prostate-specific antigen levels;
TGCT	cis	rs4299518	0.516	rs12490293	chr3:45788127	T/C	cg04837898	chr3:45731254	SACM1L	0.48	4.86	0.4	3.41e-6	Hirschsprung disease;
TGCT	cis	rs9814567	0.752	rs4456908	chr3:134340353	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-6.5	-0.5	1.78e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2486288	0.656	rs8039352	chr15:45551790	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.79	-8.16	-0.59	3.27e-13	Glomerular filtration rate;
TGCT	cis	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg05590025	chr7:65112418	INTS4L2	-0.77	-4.5	-0.37	1.52e-5	Diabetic kidney disease;
TGCT	cis	rs13191362	1.000	rs36042757	chr6:163004744	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.68	5.79	0.46	5.33e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs35883536	0.626	rs34752753	chr1:101045193	T/G	cg06223162	chr1:101003688	GPR88	-0.41	-7.64	-0.57	5.04e-12	Monocyte count;
TGCT	cis	rs9486719	1.000	rs12190397	chr6:97036465	G/A	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.32	-0.6	1.32e-13	Migraine;Coronary artery disease;
TGCT	cis	rs208520	0.608	rs3846803	chr6:66805743	C/A	cg07460842	chr6:66804631	NA	-0.94	-9.83	-0.66	3.3e-17	Exhaled nitric oxide output;
TGCT	cis	rs1577917	0.740	rs2758843	chr6:86328431	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.54	-4.87	-0.4	3.28e-6	Response to antipsychotic treatment;
TGCT	cis	rs1008375	0.966	rs6832387	chr4:17697546	G/T	cg18681998	chr4:17616180	MED28	0.78	7.35	0.55	2.35e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7552404	0.960	rs4949877	chr1:76201668	C/G	cg22875332	chr1:76189707	ACADM	0.77	9.42	0.65	3.17e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs112591243	0.685	rs78463142	chr21:47964481	A/G	cg10657630	chr21:48055338	PRMT2	1.03	4.64	0.38	8.57e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs9393692	0.846	rs9366651	chr6:26336696	G/T	cg05868516	chr6:26286170	HIST1H4H	0.56	5.35	0.43	4.08e-7	Educational attainment;
TGCT	cis	rs7178572	0.539	rs12594346	chr15:77671966	A/T	cg22256960	chr15:77711686	NA	0.82	8.1	0.59	4.32e-13	Type 2 diabetes;
TGCT	cis	rs3749237	0.615	rs6792911	chr3:49429856	C/T	cg07636037	chr3:49044803	WDR6	0.64	6.12	0.48	1.11e-8	Resting heart rate;
TGCT	cis	rs4273100	0.790	rs60606605	chr17:19277144	G/A	cg01534423	chr17:18965556	NA	0.95	6.45	0.5	2.28e-9	Schizophrenia;
TGCT	cis	rs12579753	0.879	rs11115007	chr12:82164673	A/T	cg21231944	chr12:82153410	PPFIA2	-0.34	-4.61	-0.38	9.77e-6	Resting heart rate;
TGCT	cis	rs6450176	0.625	rs35027270	chr5:53289068	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.69	-5.58	-0.45	1.45e-7	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs17030434	0.954	rs10000558	chr4:154766835	A/T	cg14289246	chr4:154710475	SFRP2	-0.95	-7.71	-0.57	3.61e-12	Electrocardiographic conduction measures;
TGCT	cis	rs3008870	1.000	rs2815371	chr1:67504313	A/G	cg03991309	chr1:68237761	GNG12	0.27	4.6	0.38	1.02e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs12681288	0.823	rs2600518	chr8:1007214	A/T	cg04851639	chr8:1020857	NA	-0.36	-6.34	-0.49	3.93e-9	Schizophrenia;
TGCT	cis	rs6500602	0.634	rs2270365	chr16:4526758	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.28	5.17	0.42	9.05e-7	Schizophrenia;
TGCT	cis	rs2299587	0.554	rs2283106	chr8:17754330	G/A	cg01800426	chr8:17659068	MTUS1	-0.57	-5.11	-0.42	1.21e-6	Economic and political preferences;
TGCT	cis	rs7582180	0.663	rs2309800	chr2:100992086	C/T	cg08017756	chr2:100939284	LONRF2	-0.31	-4.99	-0.41	2.01e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7312774	0.618	rs4964513	chr12:107375758	T/C	cg16260113	chr12:107380972	MTERFD3	1.04	5.25	0.43	6.37e-7	Severe influenza A (H1N1) infection;
TGCT	cis	rs9372253	0.678	rs6568644	chr6:110707820	C/T	cg19196401	chr6:110721138	DDO	-0.42	-5.67	-0.45	9.33e-8	Platelet distribution width;
TGCT	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg02725872	chr8:58115012	NA	-0.39	-4.74	-0.39	5.77e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7552404	0.883	rs77773255	chr1:76217193	G/A	cg22875332	chr1:76189707	ACADM	0.77	9.42	0.65	3.17e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.51	-4.82	-0.4	4.16e-6	Bipolar disorder;
TGCT	cis	rs9894429	1.000	rs9748176	chr17:79584043	C/G	cg21984481	chr17:79567631	NPLOC4	-0.24	-4.5	-0.37	1.57e-5	Eye color traits;
TGCT	cis	rs735396	0.595	rs1169279	chr12:121455873	C/T	cg15155738	chr12:121454335	C12orf43	0.6	5.47	0.44	2.43e-7	N-glycan levels;
TGCT	cis	rs7552404	1.000	rs11161511	chr1:76210477	A/G	cg22875332	chr1:76189707	ACADM	-0.73	-8.82	-0.62	8.63e-15	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9341808	0.628	rs9294172	chr6:80918561	G/A	cg08355045	chr6:80787529	NA	0.31	5.17	0.42	9e-7	Sitting height ratio;
TGCT	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	7.12	0.54	7.55e-11	Platelet count;
TGCT	cis	rs2204008	0.774	rs9669565	chr12:38294428	C/A	cg26384229	chr12:38710491	ALG10B	0.8	7.04	0.53	1.17e-10	Bladder cancer;
TGCT	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg18402987	chr7:1209562	NA	0.4	5.07	0.41	1.42e-6	Longevity;Endometriosis;
TGCT	cis	rs6032067	0.516	rs991049	chr20:43898139	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	0.37	6.01	0.47	1.92e-8	Blood protein levels;
TGCT	cis	rs6547741	0.844	rs7382	chr2:27873415	G/A	cg27432699	chr2:27873401	GPN1	-0.24	-6.05	-0.48	1.61e-8	Oral cavity cancer;
TGCT	cis	rs77372450	0.551	rs73814843	chr5:157063058	A/C	cg19063654	chr5:156516798	HAVCR2	-0.37	-4.43	-0.37	2.01e-5	Bipolar disorder (body mass index interaction);
TGCT	cis	rs13191362	0.507	rs2849540	chr6:163094522	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.66	-5.88	-0.47	3.61e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs3733585	0.673	rs7375587	chr4:9954758	A/T	cg11266682	chr4:10021025	SLC2A9	0.55	7.09	0.54	8.77e-11	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg06108461	chr20:60628389	TAF4	-0.69	-10.56	-0.69	5.46e-19	Body mass index;
TGCT	cis	rs7267979	1.000	rs6050598	chr20:25397257	C/G	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	4.9	0.4	2.89e-6	Bipolar disorder;
TGCT	cis	rs7731657	0.537	rs10062336	chr5:130193668	T/A	cg08523029	chr5:130500466	HINT1	-0.55	-4.57	-0.38	1.15e-5	Fasting plasma glucose;
TGCT	cis	rs6921919	0.583	rs7749736	chr6:28346031	G/C	cg18815343	chr6:28367644	ZSCAN12	-0.56	-5.33	-0.43	4.48e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1577917	0.771	rs10944133	chr6:86358984	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.58	-0.45	1.43e-7	Response to antipsychotic treatment;
TGCT	cis	rs3764400	0.567	rs12946143	chr17:46154943	C/T	cg02340556	chr17:46797764	NA	0.41	4.47	0.37	1.72e-5	Body mass index;
TGCT	cis	rs17253792	0.822	rs17832365	chr14:56153531	C/G	cg01858014	chr14:56050164	KTN1	-0.37	-4.83	-0.4	4e-6	Putamen volume;
TGCT	cis	rs877282	0.853	rs10904545	chr10:757100	G/A	cg17470449	chr10:769945	NA	0.35	5.06	0.41	1.44e-6	Uric acid levels;
TGCT	cis	rs11105298	0.891	rs4842661	chr12:89930399	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.7	-5.08	-0.42	1.35e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs4891159	0.730	rs7236220	chr18:74099350	A/G	cg24786174	chr18:74118243	ZNF516	-0.59	-9.27	-0.64	7.37e-16	Longevity;
TGCT	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg18876405	chr7:65276391	NA	-0.33	-5.05	-0.41	1.52e-6	Aortic root size;
TGCT	cis	rs9916302	0.904	rs9904334	chr17:37468336	G/A	cg15445000	chr17:37608096	MED1	-0.33	-4.71	-0.39	6.46e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs6088580	0.634	rs9789792	chr20:32957709	G/A	cg08999081	chr20:33150536	PIGU	-0.26	-4.98	-0.41	2.06e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs9303401	0.615	rs7502342	chr17:56922629	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs12048904	1.000	rs12048904	chr1:101331536	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.54	-5.07	-0.41	1.43e-6	Multiple sclerosis;
TGCT	cis	rs10779751	1.000	rs1205592	chr1:11305663	C/T	cg08854313	chr1:11322531	MTOR	1.0	9.28	0.64	7.14e-16	Body mass index;
TGCT	cis	rs7804356	0.651	rs55649724	chr7:26804005	G/A	cg03456212	chr7:26904342	SKAP2	-0.54	-4.6	-0.38	1.04e-5	Type 1 diabetes;
TGCT	cis	rs7267979	1.000	rs6083825	chr20:25366424	T/C	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9790314	0.846	rs4470535	chr3:160974468	G/A	cg03342759	chr3:160939853	NMD3	-0.48	-5.23	-0.43	6.93e-7	Morning vs. evening chronotype;
TGCT	cis	rs1497406	0.744	rs1007887	chr1:16509029	C/T	cg20430773	chr1:16534157	ARHGEF19	0.56	6.28	0.49	5.24e-9	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs10782582	0.593	rs79552201	chr1:76215497	A/T	cg03433033	chr1:76189801	ACADM	-0.6	-6.63	-0.51	9.16e-10	Daytime sleep phenotypes;
TGCT	cis	rs910316	1.000	rs10140851	chr14:75512612	G/A	cg11812906	chr14:75593930	NEK9	0.74	7.25	0.55	3.97e-11	Height;
TGCT	cis	rs3862435	0.572	rs2601183	chr15:90925721	T/G	cg14166756	chr15:90894880	ZNF774	-0.32	-5.12	-0.42	1.14e-6	Response to exercise (triglyceride level interaction);
TGCT	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg08280861	chr8:58055591	NA	-0.37	-4.56	-0.38	1.22e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2440129	0.632	rs15966	chr17:6905643	T/C	cg09737314	chr17:6899359	ALOX12	0.51	5.31	0.43	4.82e-7	Tonsillectomy;
TGCT	cis	rs9393777	0.513	rs3999471	chr6:26650306	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.63	-5.75	-0.46	6.58e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs11779988	0.545	rs411531	chr8:17795934	A/G	cg01800426	chr8:17659068	MTUS1	-0.68	-5.41	-0.44	3.14e-7	Breast cancer;
TGCT	cis	rs6125597	0.805	rs6063382	chr20:47889958	C/T	cg11220565	chr20:47934802	NA	-0.3	-4.61	-0.38	9.8e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs240764	0.658	rs12664626	chr6:101195720	A/G	cg09795085	chr6:101329169	ASCC3	-0.51	-4.51	-0.38	1.45e-5	Neuroticism;
TGCT	cis	rs6087990	0.842	rs4911253	chr20:31352585	A/G	cg13636640	chr20:31349939	DNMT3B	0.99	12.99	0.76	6.87e-25	Ulcerative colitis;
TGCT	cis	rs6484504	0.553	rs7113880	chr11:31279557	A/G	cg26647111	chr11:31128758	NA	-0.35	-4.85	-0.4	3.58e-6	Red blood cell count;
TGCT	trans	rs7615952	0.932	rs7630077	chr3:125649676	T/C	cg07211511	chr3:129823064	LOC729375	-0.47	-7.68	-0.57	4.13e-12	Blood pressure (smoking interaction);
TGCT	cis	rs4319547	0.656	rs10846664	chr12:122823777	C/T	cg05707623	chr12:122985044	ZCCHC8	0.61	4.7	0.39	6.77e-6	Body mass index;
TGCT	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg05368731	chr17:41323189	NBR1	1.17	13.8	0.78	7.84e-27	Menopause (age at onset);
TGCT	cis	rs4072705	0.904	rs721863	chr9:127536267	A/T	cg13476313	chr9:127244764	NR5A1	0.29	4.47	0.37	1.72e-5	Menarche (age at onset);
TGCT	cis	rs3771570	1.000	rs59536819	chr2:242272388	A/G	cg21155796	chr2:242212141	HDLBP	0.98	6.68	0.51	7.29e-10	Prostate cancer;
TGCT	cis	rs9650657	0.707	rs7814757	chr8:10675188	T/C	cg27411982	chr8:10470053	RP1L1	-0.22	-4.69	-0.39	7.17e-6	Neuroticism;
TGCT	cis	rs62244186	0.659	rs62251383	chr3:44552421	A/G	cg10108389	chr3:44770937	ZNF501	-0.49	-5.03	-0.41	1.7e-6	Depressive symptoms;
TGCT	cis	rs10875595	0.836	rs4912747	chr5:140676027	T/A	cg24830062	chr5:140700576	TAF7	-0.61	-5.14	-0.42	1.04e-6	Pulmonary function decline;
TGCT	cis	rs7447593	0.666	rs10866705	chr5:176801131	G/T	cg06060754	chr5:176797920	RGS14	-0.56	-8.3	-0.6	1.46e-13	Urinary electrolytes (magnesium/calcium ratio);
TGCT	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg25767906	chr1:53392781	SCP2	-0.59	-7.49	-0.56	1.12e-11	Monocyte count;
TGCT	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg13395646	chr4:1353034	KIAA1530	-0.38	-4.64	-0.38	8.78e-6	Longevity;
TGCT	cis	rs7524258	0.868	rs4908610	chr1:7311260	C/A	cg04342483	chr1:7259290	CAMTA1	-0.31	-4.59	-0.38	1.06e-5	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	trans	rs561341	0.556	rs2470269	chr17:30406949	T/C	cg20587970	chr11:113659929	NA	-0.99	-8.11	-0.59	4.23e-13	Hip circumference adjusted for BMI;
TGCT	trans	rs1496653	0.602	rs75709953	chr3:23442537	T/C	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs5750830	0.645	rs4821890	chr22:39777523	G/A	cg11247378	chr22:39784982	NA	-0.68	-9.79	-0.66	4.06e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs796364	0.950	rs56155997	chr2:200768491	C/T	cg17644776	chr2:200775616	C2orf69	-0.31	-4.83	-0.4	3.99e-6	Schizophrenia;
TGCT	cis	rs7267979	0.789	rs6083820	chr20:25354178	G/A	cg21995068	chr20:25989032	LOC100134868	0.43	5.19	0.42	8.41e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6032067	0.636	rs6032093	chr20:43912167	A/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.48	-7.2	-0.54	5.02e-11	Blood protein levels;
TGCT	cis	rs7267979	0.745	rs6132845	chr20:25547767	A/G	cg14121845	chr20:25566513	NINL	0.47	5.0	0.41	1.91e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4409675	0.576	rs10794507	chr1:28216072	T/C	cg23691781	chr1:28212827	C1orf38	0.25	5.26	0.43	6.19e-7	Corneal astigmatism;
TGCT	cis	rs28595532	0.841	rs17258907	chr4:119769905	A/G	cg21605333	chr4:119757512	SEC24D	1.55	8.04	0.59	6.15e-13	Cannabis dependence symptom count;
TGCT	cis	rs478304	0.627	rs1073602	chr11:65455386	G/C	cg17480646	chr11:65405466	SIPA1	-0.61	-8.27	-0.6	1.79e-13	Acne (severe);
TGCT	cis	rs12478296	0.792	rs57482298	chr2:243011148	C/A	cg06360820	chr2:242988706	NA	-0.83	-5.68	-0.45	9.26e-8	Obesity-related traits;
TGCT	cis	rs9913156	0.793	rs55682338	chr17:4582183	G/A	cg00122941	chr17:4613640	ARRB2	0.87	7.49	0.56	1.14e-11	Lymphocyte counts;
TGCT	trans	rs2727020	0.612	rs603672	chr11:49234566	T/A	cg03929089	chr4:120376271	NA	0.71	7.84	0.58	1.79e-12	Coronary artery disease;
TGCT	cis	rs7843479	0.562	rs6988010	chr8:21859084	G/A	cg17168535	chr8:21777572	XPO7	0.8	7.93	0.58	1.11e-12	Mean corpuscular volume;
TGCT	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg24250549	chr1:154909240	PMVK	0.63	6.25	0.49	6.03e-9	Prostate cancer;
TGCT	cis	rs8051431	0.840	rs8048292	chr16:72010484	T/C	cg06353428	chr16:71660113	MARVELD3	0.59	5.02	0.41	1.73e-6	LDL cholesterol levels;
TGCT	cis	rs1609391	0.567	rs835633	chr3:136676496	T/C	cg21827317	chr3:136751795	NA	0.4	5.61	0.45	1.28e-7	Neuroticism;
TGCT	cis	rs6733011	0.578	rs1878585	chr2:99501698	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-4.76	-0.39	5.3e-6	Bipolar disorder;
TGCT	cis	rs9443189	0.570	rs659807	chr6:76293435	C/A	cg01950844	chr6:76311363	SENP6	0.97	6.1	0.48	1.27e-8	Prostate cancer;
TGCT	cis	rs6489882	0.548	rs1732773	chr12:113465611	T/G	cg04001726	chr12:112547043	NAA25	-0.45	-4.49	-0.37	1.58e-5	Chronic lymphocytic leukemia;
TGCT	trans	rs7342694	0.965	rs7189106	chr16:81907731	T/C	cg04928372	chr6:27720905	NA	0.69	6.72	0.52	5.86e-10	Coronary artery disease;
TGCT	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	7.86	0.58	1.55e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs2832191	0.720	rs2832194	chr21:30494250	T/C	cg08807101	chr21:30365312	RNF160	-0.62	-5.74	-0.46	6.74e-8	Dental caries;
TGCT	cis	rs2688608	0.933	rs2633307	chr10:75653881	G/A	cg02947784	chr10:75434997	AGAP5	0.17	4.61	0.38	9.79e-6	Inflammatory bowel disease;
TGCT	cis	rs4629710	0.645	rs35561719	chr6:131551244	G/A	cg12606694	chr6:131520996	AKAP7	0.39	4.63	0.38	9.14e-6	Multiple myeloma (IgH translocation);
TGCT	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg04944784	chr2:26401820	FAM59B	-0.69	-6.37	-0.5	3.31e-9	Gut microbiome composition (summer);
TGCT	cis	rs7666738	0.800	rs10028921	chr4:98962630	G/T	cg17366294	chr4:99064904	C4orf37	0.73	7.35	0.55	2.31e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7586879	0.639	rs7580081	chr2:25097072	G/C	cg01884057	chr2:25150051	NA	0.32	6.08	0.48	1.34e-8	Body mass index;
TGCT	trans	rs4650994	0.967	rs4650992	chr1:178515135	A/T	cg05059571	chr16:84539110	KIAA1609	-0.4	-7.43	-0.56	1.52e-11	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs7412746	0.621	rs72704656	chr1:150828307	A/G	cg09365446	chr1:150670422	GOLPH3L	0.35	4.98	0.41	2.11e-6	Melanoma;
TGCT	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9388451	0.839	rs4897155	chr6:126095144	C/A	cg05901451	chr6:126070800	HEY2	-1.02	-15.06	-0.8	8.78e-30	Brugada syndrome;
TGCT	cis	rs2832191	1.000	rs2832185	chr21:30483761	C/G	cg08807101	chr21:30365312	RNF160	-0.49	-4.48	-0.37	1.65e-5	Dental caries;
TGCT	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	5.02	0.41	1.78e-6	Prudent dietary pattern;
TGCT	cis	rs75686122	0.892	rs75775215	chr8:104538884	C/A	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs1348850	0.757	rs2166554	chr2:178455824	A/G	cg22681709	chr2:178499509	PDE11A	-0.39	-4.88	-0.4	3.22e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs9393777	0.720	rs57713596	chr6:27004098	C/T	cg16898833	chr6:26189333	HIST1H4D	0.97	5.95	0.47	2.6e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg13695892	chr22:41940480	POLR3H	-0.77	-7.47	-0.56	1.24e-11	Vitiligo;
TGCT	cis	rs4925386	0.840	rs6143035	chr20:60920700	C/T	cg06026331	chr20:60912101	LAMA5	-0.37	-6.23	-0.49	6.59e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs4689388	0.889	rs13101355	chr4:6293446	T/C	cg00701064	chr4:6280414	WFS1	0.37	4.72	0.39	6.3e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs9399135	0.933	rs7755680	chr6:135294259	A/G	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.36e-6	Red blood cell count;
TGCT	cis	rs7542091	0.506	rs992976	chr1:210066658	A/T	cg23283495	chr1:209979779	IRF6	-0.47	-4.58	-0.38	1.14e-5	Monobrow;
TGCT	cis	rs727505	1.000	rs10281582	chr7:124423688	A/G	cg23710748	chr7:124431027	NA	-0.26	-4.59	-0.38	1.07e-5	Lewy body disease;
TGCT	cis	rs698833	0.509	rs10198291	chr2:44539009	C/T	cg23552047	chr2:44669647	C2orf34	0.29	4.68	0.39	7.32e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
TGCT	cis	rs6089829	0.962	rs2314131	chr20:61665225	A/G	cg18188782	chr20:61659543	NA	0.41	4.45	0.37	1.85e-5	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg11062466	chr8:58055876	NA	0.42	4.49	0.37	1.61e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs13217239	0.585	rs114919438	chr6:26963792	T/C	cg26531700	chr6:26746687	NA	-0.68	-6.65	-0.51	8.39e-10	Schizophrenia;
TGCT	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg13695892	chr22:41940480	POLR3H	-0.91	-9.07	-0.63	2.18e-15	Vitiligo;
TGCT	cis	rs1150668	0.796	rs2247002	chr6:28397951	G/C	cg19488431	chr6:28601329	NA	0.2	4.43	0.37	2.02e-5	Pubertal anthropometrics;
TGCT	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg24578937	chr1:2090814	PRKCZ	-0.22	-5.27	-0.43	5.94e-7	Height;
TGCT	cis	rs11098499	0.731	rs9995026	chr4:120490499	T/A	cg09307838	chr4:120376055	NA	0.69	6.53	0.51	1.49e-9	Corneal astigmatism;
TGCT	cis	rs78487399	0.808	rs6544666	chr2:43732234	C/T	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.74	4.49	0.37	1.59e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg12288994	chr5:1860383	NA	0.24	4.52	0.38	1.42e-5	Cardiovascular disease risk factors;
TGCT	cis	rs4319547	0.620	rs12372756	chr12:122815130	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.59	-4.53	-0.38	1.35e-5	Body mass index;
TGCT	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg18305652	chr10:134549665	INPP5A	0.33	5.67	0.45	9.71e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs2898290	0.592	rs2736342	chr8:11347289	A/C	cg21775007	chr8:11205619	TDH	-0.48	-4.57	-0.38	1.18e-5	Systolic blood pressure;
TGCT	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg17971929	chr21:40555470	PSMG1	0.98	9.57	0.65	1.43e-16	Cognitive function;
TGCT	cis	rs6733011	0.600	rs1356424	chr2:99425838	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.52	-5.19	-0.42	8.42e-7	Bipolar disorder;
TGCT	cis	rs1153858	0.887	rs7171163	chr15:45636395	A/C	cg26924012	chr15:45694286	SPATA5L1	1.07	14.56	0.79	1.32e-28	Homoarginine levels;
TGCT	cis	rs2243480	1.000	rs2533288	chr7:66056711	C/G	cg18252515	chr7:66147081	NA	-1.22	-8.04	-0.59	6.02e-13	Diabetic kidney disease;
TGCT	cis	rs981844	0.754	rs897608	chr4:154754960	C/T	cg14289246	chr4:154710475	SFRP2	0.98	8.88	0.62	6.38e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg23758822	chr17:41437982	NA	0.72	6.89	0.53	2.46e-10	Menopause (age at onset);
TGCT	cis	rs6952808	0.792	rs35582663	chr7:1948756	G/A	cg04267008	chr7:1944627	MAD1L1	-0.4	-5.44	-0.44	2.71e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-5.1	-0.42	1.23e-6	Electroencephalogram traits;
TGCT	cis	rs1982963	0.951	rs2516592	chr14:52503545	A/G	cg10843707	chr14:52510701	NID2	-0.4	-6.41	-0.5	2.76e-9	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2249625	0.523	rs2463702	chr6:72853778	A/G	cg24401219	chr6:72892597	RIMS1	0.55	4.84	0.4	3.74e-6	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
TGCT	cis	rs763014	0.931	rs2071982	chr16:630405	T/G	cg27436995	chr16:743998	FBXL16	-0.45	-4.82	-0.4	4.17e-6	Height;
TGCT	cis	rs514406	0.505	rs269290	chr1:53167027	A/T	cg08859206	chr1:53392774	SCP2	-0.34	-4.74	-0.39	5.65e-6	Monocyte count;
TGCT	cis	rs7666738	0.649	rs28865589	chr4:98954279	C/A	cg05340658	chr4:99064831	C4orf37	0.51	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs617219	0.710	rs10474578	chr5:78542290	T/C	cg23514016	chr5:78407564	BHMT	0.32	4.87	0.4	3.38e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs6460942	1.000	rs6460942	chr7:12420989	T/C	cg06484146	chr7:12443880	VWDE	-0.58	-5.57	-0.45	1.5e-7	Coronary artery disease;
TGCT	cis	rs9902453	0.709	rs6505162	chr17:28444183	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.76	7.53	0.56	9.27e-12	Coffee consumption (cups per day);
TGCT	cis	rs7264396	0.790	rs8125090	chr20:34360015	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.31	-5.49	-0.44	2.17e-7	Total cholesterol levels;
TGCT	cis	rs1008375	0.932	rs10029173	chr4:17659598	C/T	cg10189774	chr4:17578691	LAP3	-0.58	-4.99	-0.41	1.96e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs73001065	0.591	rs57009615	chr19:19613622	A/G	cg03709012	chr19:19516395	GATAD2A	0.9	5.58	0.45	1.46e-7	LDL cholesterol;
TGCT	cis	rs6912958	0.559	rs107689	chr6:88069333	G/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.44	5.68	0.45	8.95e-8	Monocyte percentage of white cells;
TGCT	cis	rs2180341	0.961	rs3798857	chr6:127659473	A/T	cg24812749	chr6:127587940	RNF146	0.98	7.64	0.57	5.06e-12	Breast cancer;
TGCT	cis	rs2456568	0.802	rs7101791	chr11:93638998	A/G	cg16099599	chr11:93583650	C11orf90	-0.4	-5.12	-0.42	1.13e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs1577917	0.916	rs12198730	chr6:86555138	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.42	-0.44	2.99e-7	Response to antipsychotic treatment;
TGCT	cis	rs765787	0.530	rs12909987	chr15:45512207	C/T	cg24006582	chr15:45444508	DUOX1	-0.24	-5.01	-0.41	1.84e-6	Uric acid levels;
TGCT	trans	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg17830980	chr10:43048298	ZNF37B	-0.82	-10.24	-0.68	3.27e-18	Extrinsic epigenetic age acceleration;
TGCT	cis	rs6125597	0.967	rs1079661	chr20:47850614	A/T	cg11220565	chr20:47934802	NA	-0.3	-4.6	-0.38	1.02e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs9902453	0.933	rs1532042	chr17:28504389	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	5.41	0.44	3.13e-7	Coffee consumption (cups per day);
TGCT	cis	rs877282	1.000	rs11253366	chr10:773386	C/T	cg17470449	chr10:769945	NA	0.31	4.88	0.4	3.2e-6	Uric acid levels;
TGCT	trans	rs7618501	1.000	rs11716575	chr3:49744890	A/G	cg21659725	chr3:3221576	CRBN	-0.99	-15.57	-0.81	5.76e-31	Intelligence (multi-trait analysis);
TGCT	cis	rs16837677	0.649	rs16837622	chr1:156695504	C/T	cg17331738	chr1:156647236	NES	-0.68	-4.78	-0.39	4.83e-6	Sjögren's syndrome;
TGCT	cis	rs4455778	0.894	rs4292636	chr7:49078125	C/A	cg26309511	chr7:48887640	NA	0.45	5.23	0.43	6.97e-7	Lung cancer in never smokers;
TGCT	cis	rs950169	0.922	rs62029585	chr15:84951874	C/G	cg11189052	chr15:85197271	WDR73	0.82	6.2	0.49	7.83e-9	Schizophrenia;
TGCT	cis	rs9921338	0.961	rs7199821	chr16:11425011	T/G	cg00044050	chr16:11439710	C16orf75	-0.89	-6.53	-0.51	1.56e-9	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs9926296	0.715	rs2115401	chr16:89740609	A/G	cg26513180	chr16:89883248	FANCA	0.63	6.12	0.48	1.13e-8	Vitiligo;
TGCT	cis	rs826838	0.904	rs10876086	chr12:39188208	C/A	cg26384229	chr12:38710491	ALG10B	0.98	8.78	0.62	1.07e-14	Heart rate;
TGCT	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg24060327	chr5:131705240	SLC22A5	-0.58	-5.92	-0.47	2.93e-8	Breast cancer;
TGCT	cis	rs317689	0.690	rs607797	chr12:69646010	T/C	cg14784868	chr12:69753453	YEATS4	0.54	4.51	0.38	1.48e-5	Response to diuretic therapy;
TGCT	cis	rs12142240	0.692	rs7532149	chr1:46824932	A/C	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	7.06	0.54	1.07e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs12497850	0.897	rs6446252	chr3:48911125	C/T	cg07636037	chr3:49044803	WDR6	0.94	10.39	0.68	1.46e-18	Parkinson's disease;
TGCT	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.55	4.92	0.4	2.74e-6	Prudent dietary pattern;
TGCT	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg22663859	chr13:21900854	NA	0.36	4.99	0.41	1.97e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	cis	rs853679	0.506	rs1150711	chr6:28208535	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.47	-4.84	-0.4	3.71e-6	Depression;
TGCT	cis	rs3806843	0.548	rs246058	chr5:140325134	G/A	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg03303774	chr4:1407052	NA	0.3	4.78	0.39	4.82e-6	Obesity-related traits;
TGCT	cis	rs11931598	0.783	rs28661210	chr4:7050956	C/A	cg26116260	chr4:7069785	GRPEL1	0.54	4.8	0.4	4.54e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs12497850	0.931	rs11920534	chr3:48937761	G/T	cg06212747	chr3:49208901	KLHDC8B	0.61	5.62	0.45	1.2e-7	Parkinson's disease;
TGCT	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg13770153	chr20:60521292	NA	-0.63	-7.95	-0.58	9.71e-13	Body mass index;
TGCT	cis	rs12142240	0.698	rs17361791	chr1:46812519	A/G	cg00530320	chr1:46809349	NSUN4	0.29	5.84	0.46	4.33e-8	Menopause (age at onset);
TGCT	cis	rs6964587	1.000	rs7785971	chr7:91736794	T/A	cg17063962	chr7:91808500	NA	0.88	9.58	0.65	1.33e-16	Breast cancer;
TGCT	cis	rs4478858	0.684	rs3766289	chr1:31760128	G/A	cg00250761	chr1:31883323	NA	-0.25	-4.52	-0.38	1.45e-5	Alcohol dependence;
TGCT	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg23574427	chr4:122746245	BBS7;CCNA2	-0.34	-5.26	-0.43	6.07e-7	Type 2 diabetes;
TGCT	cis	rs17473412	1.000	rs17408604	chr5:122726783	T/C	cg15125798	chr5:122621645	NA	-0.57	-5.13	-0.42	1.08e-6	Total body bone mineral density;
TGCT	cis	rs651907	0.588	rs2860329	chr3:101632426	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.5	4.72	0.39	6.19e-6	Colorectal cancer;
TGCT	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg23758822	chr17:41437982	NA	0.72	6.96	0.53	1.76e-10	Menopause (age at onset);
TGCT	cis	rs1395	0.925	rs1659676	chr2:27399294	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.5	-6.74	-0.52	5.36e-10	Blood metabolite levels;
TGCT	cis	rs826838	0.904	rs1554550	chr12:39208889	G/A	cg13010199	chr12:38710504	ALG10B	0.77	6.09	0.48	1.31e-8	Heart rate;
TGCT	cis	rs13242816	1.000	rs2402079	chr7:116128670	T/A	cg16553024	chr7:116138462	CAV2	-0.45	-5.04	-0.41	1.57e-6	P wave duration;
TGCT	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg05368731	chr17:41323189	NBR1	1.2	14.48	0.79	1.98e-28	Menopause (age at onset);
TGCT	cis	rs28595532	0.841	rs114175487	chr4:119733580	C/G	cg21605333	chr4:119757512	SEC24D	1.66	8.33	0.6	1.28e-13	Cannabis dependence symptom count;
TGCT	cis	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg20362242	chr5:692897	TPPP	0.53	4.62	0.38	9.42e-6	Obesity-related traits;
TGCT	cis	rs4851266	0.833	rs11685491	chr2:100858122	A/G	cg22139774	chr2:100720529	AFF3	-0.32	-4.66	-0.39	7.89e-6	Educational attainment;
TGCT	cis	rs11031096	0.727	rs2268168	chr11:4142069	C/T	cg18678763	chr11:4115507	RRM1	-0.51	-6.59	-0.51	1.14e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg13732083	chr21:47605072	C21orf56	0.34	4.52	0.38	1.44e-5	Testicular germ cell tumor;
TGCT	cis	rs3733585	0.699	rs6449174	chr4:9966422	C/T	cg00071950	chr4:10020882	SLC2A9	-0.57	-6.66	-0.51	7.91e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs35306767	0.953	rs12762973	chr10:960761	C/G	cg20503657	chr10:835505	NA	0.69	9.84	0.66	3.16e-17	Eosinophil percentage of granulocytes;
TGCT	cis	rs6500602	0.647	rs4786514	chr16:4576798	A/C	cg08645402	chr16:4508243	NA	0.22	5.58	0.45	1.43e-7	Schizophrenia;
TGCT	cis	rs9527	0.518	rs4633383	chr10:104795723	T/G	cg15744005	chr10:104629667	AS3MT	-0.56	-4.52	-0.38	1.41e-5	Arsenic metabolism;
TGCT	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.51	-4.82	-0.4	4.16e-6	Bipolar disorder;
TGCT	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg18876405	chr7:65276391	NA	0.36	5.36	0.43	3.97e-7	Aortic root size;
TGCT	cis	rs2439831	0.681	rs825739	chr15:43592428	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	7.99	0.58	7.86e-13	Lung cancer in ever smokers;
TGCT	trans	rs1814175	0.817	rs7481230	chr11:49772235	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.38	-7.76	-0.57	2.75e-12	Height;
TGCT	cis	rs7635838	0.827	rs9848170	chr3:11495983	G/C	cg00170343	chr3:11313890	ATG7	0.62	5.54	0.45	1.72e-7	HDL cholesterol;
TGCT	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg12963246	chr6:28129442	ZNF389	0.52	5.1	0.42	1.23e-6	Depression;
TGCT	cis	rs13242816	1.000	rs34295495	chr7:116068266	C/A	cg02799643	chr7:116139180	CAV2	-0.44	-5.08	-0.42	1.33e-6	P wave duration;
TGCT	cis	rs7611238	0.560	rs9809730	chr3:195075275	T/C	cg27323046	chr3:195102265	ACAP2	0.36	4.85	0.4	3.65e-6	Body mass index;
TGCT	cis	rs832540	0.931	rs702679	chr5:56221328	A/G	cg12311346	chr5:56204834	C5orf35	-0.48	-5.02	-0.41	1.76e-6	Coronary artery disease;
TGCT	cis	rs78456975	0.527	rs7590743	chr2:1575048	A/G	cg12573674	chr2:1569213	NA	-0.46	-5.2	-0.42	7.88e-7	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs2806561	0.704	rs636940	chr1:23522967	A/T	cg12483005	chr1:23474871	LUZP1	0.42	5.41	0.44	3.15e-7	Height;
TGCT	cis	rs1982963	0.901	rs1566131	chr14:52514684	G/A	cg10843707	chr14:52510701	NID2	-0.43	-6.63	-0.51	9.33e-10	Waist-to-hip ratio adjusted for body mass index;
TGCT	trans	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg23505145	chr19:12996616	KLF1	0.78	8.12	0.59	4.03e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs13064411	0.627	rs28710051	chr3:113143531	G/A	cg18753928	chr3:113234510	CCDC52	-0.69	-5.23	-0.43	6.83e-7	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs11715604	1	rs11715604	chr3:136589549	A/T	cg15507776	chr3:136538369	TMEM22	-0.62	-4.58	-0.38	1.13e-5	B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);
TGCT	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg19723775	chr5:179050963	HNRNPH1	0.51	5.18	0.42	8.81e-7	Lung cancer;
TGCT	cis	rs9682041	0.877	rs10755126	chr3:170071694	C/G	cg11886554	chr3:170076028	SKIL	-0.56	-4.56	-0.38	1.19e-5	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs11167764	0.945	rs6878397	chr5:141474012	A/G	cg08523384	chr5:141488047	NDFIP1	-0.24	-4.91	-0.4	2.85e-6	Crohn's disease;
TGCT	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg03188948	chr7:1209495	NA	0.71	6.04	0.48	1.68e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7914558	1.000	rs7067970	chr10:104913870	C/T	cg04362960	chr10:104952993	NT5C2	0.62	5.55	0.45	1.66e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs9300255	0.602	rs1727316	chr12:123618603	C/T	cg00376283	chr12:123451042	ABCB9	0.67	5.27	0.43	5.78e-7	Neutrophil percentage of white cells;
TGCT	cis	rs611744	0.967	rs595266	chr8:109193784	A/G	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs3617	0.591	rs11918800	chr3:52868145	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	0.49	4.77	0.39	5.04e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7666738	0.830	rs4502686	chr4:98765117	T/C	cg05340658	chr4:99064831	C4orf37	0.49	5.77	0.46	6.02e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9611565	0.512	rs5751153	chr22:42156561	T/C	cg17554472	chr22:41940697	POLR3H	0.46	4.69	0.39	7.09e-6	Vitiligo;
TGCT	cis	rs13064447	0.845	rs67698281	chr3:12774921	G/T	cg20675869	chr3:12750130	NA	-0.2	-5.14	-0.42	1.06e-6	Major depression and alcohol dependence;
TGCT	cis	rs17122693	1.000	rs72679560	chr14:51067379	C/T	cg04730355	chr14:51134070	SAV1	1.21	8.51	0.61	4.69e-14	Cognitive performance;
TGCT	cis	rs8014204	0.870	rs3742790	chr14:75308758	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.7	-6.81	-0.52	3.69e-10	Caffeine consumption;
TGCT	cis	rs1215050	0.716	rs11940331	chr4:99054041	G/C	cg17366294	chr4:99064904	C4orf37	0.58	6.17	0.48	8.78e-9	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7119038	0.774	rs11217001	chr11:118607046	G/A	cg19308663	chr11:118741387	NA	0.26	4.86	0.4	3.52e-6	Sjögren's syndrome;
TGCT	cis	rs34014631	1.000	rs80133219	chr10:103584701	T/C	cg22630918	chr10:102748988	C10orf2	0.43	4.83	0.4	3.98e-6	Coronary artery calcification;
TGCT	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg07343612	chr16:622815	PIGQ	-0.42	-8.39	-0.6	9.08e-14	Height;
TGCT	cis	rs78456975	0.527	rs72778003	chr2:1571487	G/A	cg01028140	chr2:1542097	TPO	-0.35	-5.17	-0.42	9.29e-7	Placebo response in major depressive disorder (% change in symptom score);
TGCT	trans	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg21659725	chr3:3221576	CRBN	-0.76	-9.03	-0.63	2.74e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs7568458	0.870	rs6733913	chr2:85757379	T/C	cg02493740	chr2:85810744	VAMP5	-0.27	-4.81	-0.4	4.25e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	4.89	0.4	3e-6	Menopause (age at onset);
TGCT	cis	rs7666738	0.830	rs13136930	chr4:98937933	A/T	cg05340658	chr4:99064831	C4orf37	0.52	5.92	0.47	2.93e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2486288	0.656	rs12440356	chr15:45567529	T/C	cg14582100	chr15:45693742	SPATA5L1	0.43	4.71	0.39	6.43e-6	Glomerular filtration rate;
TGCT	cis	rs9302001	0.920	rs7997616	chr13:95454986	G/A	cg07483244	chr13:95358924	NA	0.37	4.87	0.4	3.39e-6	Panic disorder;
TGCT	cis	rs1992660	0.523	rs7707395	chr5:40343533	G/C	cg01087697	chr5:40835557	RPL37	0.54	4.87	0.4	3.28e-6	Crohn's disease;
TGCT	cis	rs7017914	0.967	rs6987007	chr8:71600942	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.03	-0.41	1.69e-6	Bone mineral density;
TGCT	cis	rs7772486	0.790	rs11760	chr6:146205973	G/T	cg23711669	chr6:146136114	FBXO30	0.89	10.18	0.67	4.61e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg08219700	chr8:58056026	NA	0.3	4.57	0.38	1.14e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7010267	0.542	rs4618726	chr8:120009385	C/A	cg17171407	chr8:119960777	TNFRSF11B	0.27	5.01	0.41	1.82e-6	Total body bone mineral density (age 45-60);
TGCT	trans	rs10953454	1.000	rs10243529	chr7:104494517	G/C	cg04208666	chr6:19734707	NA	-0.57	-6.89	-0.53	2.52e-10	Obesity;
TGCT	cis	rs7010267	0.773	rs13277230	chr8:119922993	C/T	cg17171407	chr8:119960777	TNFRSF11B	-0.28	-4.94	-0.41	2.46e-6	Total body bone mineral density (age 45-60);
TGCT	cis	rs36051895	0.589	rs6476946	chr9:5195275	C/G	cg02405213	chr9:5042618	JAK2	0.75	9.34	0.64	4.9e-16	Pediatric autoimmune diseases;
TGCT	cis	rs6570726	0.791	rs6914203	chr6:145899975	C/A	cg05347473	chr6:146136440	FBXO30	0.52	4.93	0.41	2.54e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10789491	1.000	rs4553120	chr1:47165729	C/T	cg15501359	chr1:47185051	KIAA0494	0.82	8.26	0.6	1.82e-13	Response to hepatitis C treatment;
TGCT	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg24531977	chr5:56204891	C5orf35	-0.77	-7.7	-0.57	3.71e-12	Initial pursuit acceleration;
TGCT	cis	rs854765	0.603	rs854789	chr17:18026566	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	7.57	0.56	7.33e-12	Total body bone mineral density;
TGCT	cis	rs854765	0.547	rs2955378	chr17:17930253	G/A	cg04398451	chr17:18023971	MYO15A	-0.32	-5.15	-0.42	1.01e-6	Total body bone mineral density;
TGCT	cis	rs7103648	0.553	rs12803857	chr11:47890172	G/A	cg20307385	chr11:47447363	PSMC3	0.78	7.19	0.54	5.29e-11	Diastolic blood pressure;Systolic blood pressure;
TGCT	cis	rs6912958	0.874	rs2103764	chr6:88157392	T/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.37	-4.74	-0.39	5.79e-6	Monocyte percentage of white cells;
TGCT	cis	rs6570726	0.791	rs12208019	chr6:145935572	T/C	cg05347473	chr6:146136440	FBXO30	0.53	4.96	0.41	2.29e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9303401	0.659	rs7225896	chr17:56637337	T/C	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg02038168	chr22:39784481	NA	-0.76	-6.66	-0.51	7.82e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs7772486	0.790	rs2250387	chr6:146205233	C/T	cg23711669	chr6:146136114	FBXO30	0.89	10.18	0.67	4.61e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1050631	1.000	rs11873168	chr18:33707581	T/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.49	4.73	0.39	5.92e-6	Esophageal squamous cell cancer (length of survival);
TGCT	cis	rs7267979	0.932	rs367666	chr20:25449818	T/C	cg03522245	chr20:25566470	NINL	0.61	6.54	0.51	1.46e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9393692	0.875	rs12526215	chr6:26262916	T/C	cg13736514	chr6:26305472	NA	-0.41	-5.76	-0.46	6.14e-8	Educational attainment;
TGCT	cis	rs2228479	0.850	rs17227263	chr16:89810598	G/A	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs4713118	0.628	rs12179134	chr6:27675469	A/G	cg20933634	chr6:27740509	NA	0.36	4.67	0.39	7.6e-6	Parkinson's disease;
TGCT	cis	rs9914544	0.966	rs9915346	chr17:18787931	G/A	cg26378065	chr17:18585709	ZNF286B	0.52	4.73	0.39	5.94e-6	Educational attainment (years of education);
TGCT	cis	rs7647973	0.593	rs4855885	chr3:49690199	G/A	cg03060546	chr3:49711283	APEH	0.63	5.33	0.43	4.49e-7	Menarche (age at onset);
TGCT	cis	rs9527	0.545	rs35756290	chr10:104585572	G/A	cg04362960	chr10:104952993	NT5C2	0.63	5.31	0.43	4.84e-7	Arsenic metabolism;
TGCT	cis	rs1801251	1.000	rs6738386	chr2:233602028	T/C	cg25237894	chr2:233734115	C2orf82	0.31	5.62	0.45	1.21e-7	Coronary artery disease;
TGCT	cis	rs2288073	0.965	rs6545335	chr2:24422011	G/A	cg05570707	chr2:24270316	C2orf44	-0.5	-4.47	-0.37	1.72e-5	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs7336332	0.547	rs9581859	chr13:28035147	A/T	cg22138327	chr13:27999177	GTF3A	0.73	5.1	0.42	1.22e-6	Weight;
TGCT	cis	rs2404602	0.692	rs67570291	chr15:77020502	T/C	cg22467129	chr15:76604101	ETFA	-0.45	-5.11	-0.42	1.2e-6	Blood metabolite levels;
TGCT	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg21724239	chr8:58056113	NA	0.42	5.04	0.41	1.59e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg11845111	chr2:191398756	TMEM194B	-0.36	-5.44	-0.44	2.73e-7	Pulse pressure;
TGCT	cis	rs7772486	0.875	rs865913	chr6:146308874	C/T	cg05347473	chr6:146136440	FBXO30	0.54	5.0	0.41	1.91e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs76473307	1.000	rs6026543	chr20:57394025	G/A	cg06163629	chr20:57414884	GNASAS;GNAS	-0.67	-4.53	-0.38	1.34e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg23131131	chr22:24373011	LOC391322	-0.68	-7.1	-0.54	8.42e-11	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	trans	rs77457752	0.525	rs10961293	chr9:13894250	A/G	cg23609682	chr1:3070786	PRDM16	0.53	7.65	0.57	4.85e-12	Breast cancer;
TGCT	cis	rs72945132	1.000	rs72945132	chr11:70113901	G/C	cg00319359	chr11:70116639	PPFIA1	0.96	6.83	0.52	3.35e-10	Coronary artery disease;
TGCT	cis	rs3733585	0.648	rs13103497	chr4:9979262	A/G	cg00071950	chr4:10020882	SLC2A9	0.57	6.68	0.51	7.18e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs6901250	0.788	rs591794	chr6:117089018	G/A	cg12892004	chr6:117198278	RFX6	0.51	6.28	0.49	5.29e-9	C-reactive protein levels;
TGCT	cis	rs5769765	1.000	rs768618	chr22:50286827	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.4	6.02	0.48	1.81e-8	Schizophrenia;
TGCT	cis	rs12908161	0.959	rs11637728	chr15:85203392	A/T	cg11189052	chr15:85197271	WDR73	0.75	6.23	0.49	6.54e-9	Schizophrenia;
TGCT	cis	rs10411936	1.000	rs7256818	chr19:16558766	C/A	cg14704714	chr19:15740395	CYP4F8	-0.26	-4.57	-0.38	1.17e-5	White blood cell count;Multiple sclerosis;
TGCT	cis	rs76419734	0.510	rs17036102	chr4:106603098	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	-0.67	-4.76	-0.39	5.26e-6	Post bronchodilator FEV1;
TGCT	trans	rs9329221	0.741	rs56243511	chr8:9805695	T/C	cg15556689	chr8:8085844	FLJ10661	-0.82	-7.76	-0.57	2.71e-12	Neuroticism;
TGCT	cis	rs42648	0.935	rs42629	chr7:89963324	G/T	cg25739043	chr7:89950458	NA	-0.75	-7.61	-0.56	5.9e-12	Homocysteine levels;
TGCT	cis	rs669446	0.533	rs11210913	chr1:44222597	G/A	cg12908607	chr1:44402522	ARTN	-0.61	-7.12	-0.54	7.51e-11	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg26338869	chr17:61819248	STRADA	-0.53	-4.94	-0.41	2.48e-6	Prudent dietary pattern;
TGCT	cis	rs6988636	0.534	rs62520600	chr8:124095405	G/A	cg27053337	chr8:124217698	FAM83A	0.53	4.45	0.37	1.92e-5	Urinary uromodulin levels;
TGCT	cis	rs9677476	1.000	rs12470450	chr2:232113888	T/A	cg07929768	chr2:232055508	NA	0.3	4.48	0.37	1.71e-5	Food antigen IgG levels;
TGCT	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg25767906	chr1:53392781	SCP2	-0.49	-5.7	-0.46	8.18e-8	Monocyte count;
TGCT	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg04944784	chr2:26401820	FAM59B	-0.75	-6.16	-0.48	9.33e-9	Gut microbiome composition (summer);
TGCT	cis	rs10276381	0.579	rs11520706	chr7:28202748	C/T	cg23620719	chr7:28220237	JAZF1	-0.96	-5.21	-0.42	7.59e-7	Crohn's disease;
TGCT	trans	rs4824093	0.610	rs73441745	chr22:50237606	G/A	cg09872104	chr7:134855509	C7orf49	-0.91	-7.32	-0.55	2.66e-11	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7611238	0.560	rs7639146	chr3:195094971	T/C	cg27323046	chr3:195102265	ACAP2	0.37	4.93	0.4	2.56e-6	Body mass index;
TGCT	cis	rs28595532	0.920	rs115690307	chr4:119768289	C/T	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs11190604	0.767	rs4919458	chr10:102177728	G/A	cg23241863	chr10:102295624	HIF1AN	-0.64	-4.89	-0.4	3.02e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs6582630	0.502	rs1607867	chr12:38385463	C/T	cg13010199	chr12:38710504	ALG10B	0.59	4.64	0.38	8.86e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg12963246	chr6:28129442	ZNF389	0.52	5.1	0.42	1.23e-6	Depression;
TGCT	cis	rs4476553	0.935	rs12696704	chr4:4711210	C/T	cg05554346	chr4:4145468	NA	0.4	4.69	0.39	7.13e-6	Response to amphetamines;
TGCT	cis	rs4819052	0.620	rs421619	chr21:46546115	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.63	4.99	0.41	2.03e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9653442	0.527	rs13003982	chr2:100759078	T/C	cg22139774	chr2:100720529	AFF3	-0.37	-5.7	-0.46	8.36e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs1348850	0.567	rs3770011	chr2:178537890	C/T	cg22681709	chr2:178499509	PDE11A	-0.48	-6.08	-0.48	1.4e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs3087591	1.000	rs2952989	chr17:29516113	G/A	cg24425628	chr17:29625626	OMG;NF1	0.45	7.11	0.54	8.22e-11	Hip circumference;
TGCT	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg06713675	chr4:122721982	EXOSC9	-0.6	-8.25	-0.6	1.95e-13	Type 2 diabetes;
TGCT	cis	rs9677476	0.516	rs1025107	chr2:232034342	C/T	cg07929768	chr2:232055508	NA	0.33	5.24	0.43	6.78e-7	Food antigen IgG levels;
TGCT	cis	rs9303401	0.527	rs7224468	chr17:56749943	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.61	5.41	0.44	3.12e-7	Cognitive test performance;
TGCT	cis	rs854765	0.533	rs2955354	chr17:17948716	G/C	cg09796270	chr17:17721594	SREBF1	-0.24	-4.7	-0.39	6.8e-6	Total body bone mineral density;
TGCT	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg23708337	chr7:1209742	NA	0.51	4.46	0.37	1.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs6831352	0.879	rs2602888	chr4:100041706	C/T	cg12011299	chr4:100065546	ADH4	0.4	4.77	0.39	5.18e-6	Alcohol dependence;
TGCT	cis	rs10791097	0.720	rs6590517	chr11:130733505	C/T	cg14779329	chr11:130786720	SNX19	0.3	5.11	0.42	1.2e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs7095607	0.606	rs4746738	chr10:69959837	C/T	cg18986048	chr10:69913749	MYPN	0.57	5.92	0.47	2.89e-8	Lung function (FVC);
TGCT	cis	rs6570726	0.791	rs365747	chr6:145866784	C/T	cg13319975	chr6:146136371	FBXO30	-0.51	-4.6	-0.38	1.01e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3617	0.539	rs9880619	chr3:52953055	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	0.46	4.49	0.37	1.58e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs11190604	1.000	rs12219158	chr10:102302923	T/C	cg16342193	chr10:102329863	NA	-0.4	-4.89	-0.4	3.08e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs11864453	0.560	rs6499561	chr16:72148404	A/G	cg14768367	chr16:72042858	DHODH	0.51	4.89	0.4	3.11e-6	Fibrinogen levels;
TGCT	cis	rs4820539	0.966	rs5759594	chr22:23470660	G/A	cg21100191	chr22:23484243	RTDR1	0.89	10.61	0.69	4.23e-19	Bone mineral density;
TGCT	cis	rs6121246	0.529	rs6088814	chr20:30218172	C/T	cg13852791	chr20:30311386	BCL2L1	0.7	4.58	0.38	1.1e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs79349575	0.749	rs957557	chr17:47003221	G/T	cg26022315	chr17:47021804	SNF8	0.49	4.89	0.4	3.03e-6	Type 2 diabetes;
TGCT	cis	rs1008375	0.646	rs13145480	chr4:17565143	T/C	cg18681998	chr4:17616180	MED28	-0.74	-6.67	-0.51	7.39e-10	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.2	0.42	8.14e-7	Menopause (age at onset);
TGCT	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg21724239	chr8:58056113	NA	0.49	5.23	0.43	6.92e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs514406	0.505	rs427319	chr1:53178807	T/G	cg22166914	chr1:53195759	ZYG11B	0.45	8.14	0.59	3.47e-13	Monocyte count;
TGCT	cis	rs2066819	1.000	rs77768890	chr12:56725121	A/G	cg26714650	chr12:56694279	CS	-1.36	-6.06	-0.48	1.54e-8	Psoriasis vulgaris;
TGCT	cis	rs3782455	1.000	rs116855053	chr12:114403055	C/T	cg10631684	chr12:113795897	PLBD2	-0.7	-4.61	-0.38	1e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs2066819	1.000	rs871130	chr12:56648777	A/G	cg26714650	chr12:56694279	CS	1.33	6.24	0.49	6.46e-9	Psoriasis vulgaris;
TGCT	cis	rs815815	0.608	rs815808	chr2:47381097	C/T	cg27223769	chr2:47403360	CALM2	0.58	5.31	0.43	4.8e-7	Dialysis-related mortality;
TGCT	cis	rs9796	0.866	rs516156	chr15:41381257	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.47	-6.09	-0.48	1.34e-8	Menopause (age at onset);
TGCT	cis	rs17376456	0.569	rs11135397	chr5:93214975	G/T	cg21475434	chr5:93447410	FAM172A	0.68	5.24	0.43	6.61e-7	Diabetic retinopathy;
TGCT	cis	rs13040088	1.000	rs2295000	chr20:61536938	A/G	cg23096297	chr20:61557774	DIDO1	-1.2	-10.17	-0.67	4.96e-18	Menopause (age at onset);
TGCT	cis	rs1061377	1.000	rs9997089	chr4:39120883	T/C	cg24403649	chr4:39172243	NA	0.18	4.44	0.37	1.99e-5	Uric acid levels;
TGCT	cis	rs734999	0.967	rs10797433	chr1:2502010	T/C	cg18854424	chr1:2615690	NA	0.47	5.86	0.47	3.94e-8	Ulcerative colitis;
TGCT	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.65	-5.44	-0.44	2.74e-7	Tonsillectomy;
TGCT	cis	rs7412746	0.611	rs12085336	chr1:150775780	A/T	cg09365446	chr1:150670422	GOLPH3L	0.36	5.38	0.44	3.58e-7	Melanoma;
TGCT	cis	rs826838	0.967	rs1684413	chr12:39128704	G/A	cg26384229	chr12:38710491	ALG10B	-0.86	-7.7	-0.57	3.65e-12	Heart rate;
TGCT	cis	rs6558174	0.802	rs3758040	chr8:22487087	T/C	cg03733263	chr8:22462867	KIAA1967	0.58	4.62	0.38	9.62e-6	Breast cancer;
TGCT	trans	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg25482853	chr8:67687455	SGK3	1.19	10.3	0.68	2.4e-18	Obesity-related traits;
TGCT	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg02953382	chr22:24373134	LOC391322	-0.81	-9.29	-0.64	6.56e-16	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs74181299	0.892	rs2540945	chr2:65289825	A/G	cg05010058	chr2:65284262	CEP68	0.43	4.72	0.39	6.15e-6	Pulse pressure;
TGCT	cis	rs9399135	0.933	rs41294852	chr6:135376379	T/G	cg24558204	chr6:135376177	HBS1L	0.46	4.55	0.38	1.24e-5	Red blood cell count;
TGCT	cis	rs4555082	0.834	rs2816607	chr14:105718385	A/T	cg01266790	chr14:105781312	PACS2	0.55	4.53	0.38	1.35e-5	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs62380364	0.566	rs1705565	chr5:88048457	C/T	cg24804195	chr5:87968844	LOC645323	-0.58	-5.68	-0.45	9.18e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2439831	0.850	rs7181039	chr15:44179112	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	5.71	0.46	7.85e-8	Lung cancer in ever smokers;
TGCT	cis	rs2224391	0.628	rs2753240	chr6:5254124	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.99	-6.43	-0.5	2.46e-9	Height;
TGCT	cis	rs11105298	0.891	rs6538190	chr12:89885942	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.7	-5.02	-0.41	1.79e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs12477438	0.501	rs13008171	chr2:99743419	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.75	7.25	0.55	3.92e-11	Chronic sinus infection;
TGCT	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg20007245	chr22:24372913	LOC391322	-0.78	-8.31	-0.6	1.43e-13	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs72781680	1.000	rs72796358	chr2:24160132	T/A	cg08917208	chr2:24149416	ATAD2B	0.73	4.5	0.37	1.58e-5	Lymphocyte counts;
TGCT	cis	rs36051895	0.623	rs7870536	chr9:5245493	C/T	cg02405213	chr9:5042618	JAK2	-0.7	-8.94	-0.63	4.42e-15	Pediatric autoimmune diseases;
TGCT	cis	rs7681423	1.000	rs7654093	chr4:155545072	A/T	cg20735720	chr4:155535218	FGG	-0.49	-7.57	-0.56	7.2e-12	Fibrinogen;
TGCT	cis	rs4654899	1.000	rs6426656	chr1:21343245	G/C	cg01072550	chr1:21505969	NA	-0.5	-7.94	-0.58	1.04e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2562456	0.917	rs2562471	chr19:21715819	C/T	cg01304269	chr19:21688519	ZNF429	-0.55	-4.59	-0.38	1.06e-5	Pain;
TGCT	cis	rs1150668	0.796	rs2531825	chr6:28349264	C/T	cg13525197	chr6:28411240	ZSCAN23	-0.52	-5.08	-0.41	1.37e-6	Pubertal anthropometrics;
TGCT	cis	rs137603	0.562	rs470080	chr22:39712368	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	-0.62	-6.47	-0.5	2.04e-9	Primary biliary cholangitis;
TGCT	cis	rs3820928	0.967	rs720501	chr2:227778445	C/T	cg11843606	chr2:227700838	RHBDD1	-0.53	-4.73	-0.39	5.89e-6	Pulmonary function;
TGCT	cis	rs12579753	1.000	rs7956826	chr12:82173365	A/G	cg07988820	chr12:82153109	PPFIA2	-0.65	-6.79	-0.52	4.09e-10	Resting heart rate;
TGCT	cis	rs3806843	0.705	rs2530230	chr5:140088131	G/A	cg19875535	chr5:140030758	IK	-0.38	-6.33	-0.49	4.09e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2204008	0.837	rs4312131	chr12:38181087	G/T	cg13010199	chr12:38710504	ALG10B	0.64	5.16	0.42	9.41e-7	Bladder cancer;
TGCT	cis	rs9467773	0.620	rs2504540	chr6:26641626	A/G	cg11502198	chr6:26597334	ABT1	0.54	4.87	0.4	3.4e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4849845	0.598	rs11690576	chr2:121019800	A/G	cg24070213	chr2:121070622	NA	-0.34	-4.74	-0.39	5.83e-6	Mean platelet volume;
TGCT	cis	rs5167	0.750	rs3786505	chr19:45490570	A/G	cg13119609	chr19:45449297	APOC2	0.23	4.73	0.39	5.98e-6	Blood protein levels;
TGCT	cis	rs7104764	1.000	rs10902110	chr11:237648	T/C	cg18336825	chr11:236787	PSMD13;SIRT3	1.07	11.15	0.71	2.05e-20	Menarche (age at onset);
TGCT	cis	rs911555	0.504	rs8006526	chr14:104075015	T/C	cg26031613	chr14:104095156	KLC1	0.61	5.6	0.45	1.34e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2115630	0.936	rs11073663	chr15:85260268	A/G	cg17173187	chr15:85201210	NMB	-0.4	-5.04	-0.41	1.58e-6	P wave terminal force;
TGCT	cis	rs7666738	0.830	rs13149404	chr4:99070236	A/G	cg05340658	chr4:99064831	C4orf37	0.52	5.79	0.46	5.32e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg09263875	chr16:632152	PIGQ	0.3	6.75	0.52	4.97e-10	Height;
TGCT	cis	rs838147	0.508	rs507711	chr19:49208564	C/T	cg13540341	chr19:49222985	MAMSTR	-0.38	-4.93	-0.41	2.53e-6	Dietary macronutrient intake;
TGCT	cis	rs2562456	0.833	rs2928211	chr19:21541297	A/G	cg01304269	chr19:21688519	ZNF429	-0.54	-4.44	-0.37	1.97e-5	Pain;
TGCT	cis	rs10875746	0.669	rs2279464	chr12:48690409	C/T	cg20731937	chr12:48336164	NA	0.59	4.49	0.37	1.61e-5	Longevity (90 years and older);
TGCT	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	8.28	0.6	1.66e-13	Platelet count;
TGCT	cis	rs12989701	0.778	rs7584040	chr2:127863224	C/T	cg08168897	chr2:127865431	BIN1	0.36	4.49	0.37	1.58e-5	Alzheimer's disease (late onset);
TGCT	cis	rs12579753	1.000	rs17748942	chr12:82170478	G/A	cg07988820	chr12:82153109	PPFIA2	-0.65	-6.79	-0.52	4.09e-10	Resting heart rate;
TGCT	cis	rs758129	0.578	rs1006660	chr15:89883520	T/C	cg24365117	chr15:89879190	POLG	0.34	4.67	0.39	7.84e-6	Schizophrenia;
TGCT	cis	rs12220898	0.679	rs10745257	chr10:50473892	T/C	cg06072769	chr10:50146962	WDFY4	0.36	4.67	0.39	7.64e-6	Inflammatory biomarkers;
TGCT	cis	rs7267979	0.966	rs2145126	chr20:25263648	G/A	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9325144	0.560	rs1843911	chr12:38676585	C/T	cg13010199	chr12:38710504	ALG10B	-0.53	-4.63	-0.38	9.02e-6	Morning vs. evening chronotype;
TGCT	cis	rs10795061	0.576	rs10904074	chr10:3710962	G/A	cg13668419	chr10:3197757	PITRM1	-0.18	-4.87	-0.4	3.31e-6	Subjective well-being;
TGCT	cis	rs28493229	0.708	rs10425069	chr19:41152847	C/T	cg11601297	chr19:41224147	ITPKC;ADCK4	0.57	5.14	0.42	1.03e-6	Kawasaki disease;
TGCT	cis	rs3820928	0.692	rs2396434	chr2:227775223	G/T	cg11843606	chr2:227700838	RHBDD1	-0.57	-5.4	-0.44	3.3e-7	Pulmonary function;
TGCT	cis	rs9549260	0.755	rs7335520	chr13:41196407	C/T	cg21288729	chr13:41239152	FOXO1	1.01	10.05	0.67	9.71e-18	Red blood cell count;
TGCT	cis	rs858239	0.537	rs6955115	chr7:23227144	A/G	cg05602783	chr7:23145260	KLHL7	-0.71	-5.55	-0.45	1.68e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs6964587	1.000	rs10228334	chr7:91713972	C/T	cg17063962	chr7:91808500	NA	0.86	9.47	0.65	2.39e-16	Breast cancer;
TGCT	cis	rs7666738	0.830	rs62321569	chr4:98984250	T/A	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg06636001	chr8:8085503	FLJ10661	0.6	5.43	0.44	2.86e-7	Mood instability;
TGCT	cis	rs74233809	1.000	rs11191502	chr10:104765494	T/G	cg05855489	chr10:104503620	C10orf26	0.74	4.45	0.37	1.87e-5	Birth weight;
TGCT	cis	rs11190604	0.945	rs11190553	chr10:102207959	T/C	cg16342193	chr10:102329863	NA	-0.4	-5.31	-0.43	4.85e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs11644362	0.932	rs34290494	chr16:12987705	A/C	cg06890432	chr16:12997467	SHISA9	-0.6	-6.49	-0.5	1.88e-9	Positive affect;Subjective well-being;
TGCT	cis	rs28595532	0.920	rs55901549	chr4:119770172	T/A	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs3771570	0.901	rs28433352	chr2:242339656	A/G	cg21155796	chr2:242212141	HDLBP	0.84	6.3	0.49	4.66e-9	Prostate cancer;
TGCT	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg00343986	chr7:65444356	GUSB	-0.23	-5.16	-0.42	9.66e-7	Aortic root size;
TGCT	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg11062466	chr8:58055876	NA	0.43	4.64	0.38	8.85e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs751728	0.664	rs747694	chr6:33736490	A/G	cg13859433	chr6:33739653	LEMD2	-0.32	-5.93	-0.47	2.78e-8	Crohn's disease;
TGCT	cis	rs9899728	0.764	rs7219493	chr17:73044188	T/C	cg27626185	chr17:73056755	KCTD2	-0.66	-6.31	-0.49	4.52e-9	Alzheimer's disease or small vessel stroke;
TGCT	cis	rs17376456	0.757	rs6859757	chr5:93206042	C/T	cg21475434	chr5:93447410	FAM172A	0.71	4.92	0.4	2.69e-6	Diabetic retinopathy;
TGCT	cis	rs4851266	0.966	rs12987662	chr2:100821548	C/A	cg22139774	chr2:100720529	AFF3	-0.36	-5.4	-0.44	3.26e-7	Educational attainment;
TGCT	cis	rs2456568	0.709	rs12806128	chr11:93634972	C/T	cg16099599	chr11:93583650	C11orf90	0.39	4.63	0.38	9.05e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs2180341	0.961	rs7775493	chr6:127615000	C/A	cg27446573	chr6:127587934	RNF146	1.13	10.12	0.67	6.64e-18	Breast cancer;
TGCT	cis	rs11098499	0.754	rs12506487	chr4:120271361	T/G	cg09307838	chr4:120376055	NA	0.56	5.5	0.44	2.05e-7	Corneal astigmatism;
TGCT	cis	rs67311347	0.503	rs11719968	chr3:40241600	G/T	cg13683864	chr3:40499215	RPL14	-0.76	-6.95	-0.53	1.85e-10	Renal cell carcinoma;
TGCT	cis	rs3806843	0.576	rs405192	chr5:140324710	T/G	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.11e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9611565	0.512	rs5758464	chr22:42171300	A/G	cg13695892	chr22:41940480	POLR3H	0.99	7.04	0.53	1.16e-10	Vitiligo;
TGCT	cis	rs9906944	0.742	rs4073893	chr17:47118523	A/G	cg20966754	chr17:47091339	IGF2BP1	-0.45	-5.17	-0.42	9.27e-7	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs10746514	1.000	rs1576618	chr1:232244331	A/G	cg09506761	chr1:232265262	NA	-0.46	-4.77	-0.39	5.07e-6	Response to statin therapy;
TGCT	cis	rs7666738	0.791	rs34790496	chr4:98930516	C/T	cg18180107	chr4:99064573	C4orf37	0.55	4.98	0.41	2.05e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7959452	0.868	rs10784774	chr12:69737879	C/T	cg14784868	chr12:69753453	YEATS4	-0.65	-6.87	-0.53	2.76e-10	Blood protein levels;
TGCT	cis	rs7584330	0.955	rs6729659	chr2:238385126	T/C	cg14458575	chr2:238380390	NA	0.5	7.75	0.57	2.9e-12	Prostate cancer;
TGCT	cis	rs9308731	0.583	rs4848406	chr2:111933758	G/A	cg04202892	chr2:111875749	ACOXL	0.44	4.88	0.4	3.2e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg22920501	chr2:26401640	FAM59B	0.74	6.4	0.5	2.86e-9	Gut microbiome composition (summer);
TGCT	cis	rs9381040	0.701	rs6933231	chr6:41163700	T/C	cg03526776	chr6:41159608	TREML2	0.28	6.06	0.48	1.48e-8	Alzheimer's disease (late onset);
TGCT	cis	rs74233809	1.000	rs12413409	chr10:104719096	C/T	cg05855489	chr10:104503620	C10orf26	0.74	4.45	0.37	1.87e-5	Birth weight;
TGCT	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg24531977	chr5:56204891	C5orf35	0.89	7.5	0.56	1.04e-11	Initial pursuit acceleration;
TGCT	cis	rs12497850	0.897	rs6781790	chr3:49044767	C/T	cg07636037	chr3:49044803	WDR6	0.96	10.9	0.7	8.39e-20	Parkinson's disease;
TGCT	trans	rs1496653	0.602	rs35240920	chr3:23318144	T/C	cg02770683	chr12:57597238	LRP1	0.36	6.66	0.51	8.06e-10	Type 2 diabetes;
TGCT	cis	rs3796352	1.000	rs13058817	chr3:53024139	C/T	cg27565382	chr3:53032988	SFMBT1	0.45	4.58	0.38	1.14e-5	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-6.73	-0.52	5.62e-10	Alzheimer's disease;
TGCT	cis	rs17102423	0.594	rs942626	chr14:65550082	C/T	cg11161011	chr14:65562177	MAX	-0.47	-6.42	-0.5	2.57e-9	Obesity-related traits;
TGCT	cis	rs72945132	0.522	rs4367974	chr11:70248900	C/T	cg00319359	chr11:70116639	PPFIA1	0.9	7.21	0.54	4.9e-11	Coronary artery disease;
TGCT	cis	rs6570726	0.791	rs10872577	chr6:145900560	G/T	cg23711669	chr6:146136114	FBXO30	0.86	9.54	0.65	1.64e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9916302	0.861	rs12150493	chr17:37586154	T/C	cg15445000	chr17:37608096	MED1	0.32	4.68	0.39	7.47e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs9467773	0.620	rs2494696	chr6:26620894	A/G	cg15659132	chr6:26577336	NA	0.84	10.91	0.7	7.83e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg00149659	chr3:10157352	C3orf10	0.73	4.72	0.39	6.17e-6	Alzheimer's disease;
TGCT	cis	rs4455778	0.580	rs12718320	chr7:49109447	A/C	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.83e-9	Lung cancer in never smokers;
TGCT	cis	rs457287	0.772	rs412457	chr9:4825277	C/G	cg21184111	chr9:4792285	RCL1	-0.48	-4.8	-0.4	4.55e-6	Platelet count;
TGCT	cis	rs4253772	0.530	rs6008616	chr22:46707954	A/G	cg24881330	chr22:46731750	TRMU	1.04	5.41	0.44	3.12e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs66887589	0.616	rs11098497	chr4:120187068	C/T	cg24670566	chr4:120433619	PDE5A	0.21	4.57	0.38	1.14e-5	Diastolic blood pressure;
TGCT	cis	rs1023500	1.000	rs9620001	chr22:42330229	T/C	cg04692870	chr22:42525206	CYP2D6	-0.35	-5.28	-0.43	5.57e-7	Schizophrenia;
TGCT	cis	rs807669	0.544	rs2040771	chr22:19161935	C/T	cg02655711	chr22:19163373	SLC25A1	0.26	5.07	0.41	1.39e-6	Metabolite levels;
TGCT	cis	rs11785693	0.862	rs6990234	chr8:4996812	A/G	cg26367366	chr8:4980734	NA	0.57	4.53	0.38	1.38e-5	Neuroticism (multi-trait analysis);Neuroticism;
TGCT	cis	rs12484776	0.677	rs8136580	chr22:40530923	T/C	cg07138101	chr22:40742427	ADSL	0.61	4.6	0.38	1.01e-5	Uterine fibroids;
TGCT	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg03188948	chr7:1209495	NA	0.68	5.8	0.46	5.09e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs10946940	0.965	rs4713112	chr6:27516833	G/T	cg10876282	chr6:28092338	ZSCAN16	-0.47	-4.76	-0.39	5.34e-6	Systemic lupus erythematosus;
TGCT	cis	rs7927592	0.513	rs3853616	chr11:68198252	A/G	cg16797656	chr11:68205561	LRP5	0.27	4.93	0.4	2.62e-6	Total body bone mineral density;
TGCT	cis	rs611744	0.967	rs673854	chr8:109191838	G/A	cg21045802	chr8:109455806	TTC35	0.51	4.57	0.38	1.17e-5	Dupuytren's disease;
TGCT	cis	rs2412208	0.509	rs7546792	chr1:7124346	C/T	cg20434152	chr1:7120926	CAMTA1	-0.29	-4.64	-0.38	8.64e-6	Survival in sporadic amyotrophic lateral sclerosis;
TGCT	cis	rs10504229	0.636	rs114725691	chr8:58054292	C/T	cg08280861	chr8:58055591	NA	0.35	4.88	0.4	3.2e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2880765	0.835	rs11638498	chr15:86023018	T/C	cg13263323	chr15:86062960	AKAP13	-0.23	-4.99	-0.41	2e-6	Coronary artery disease;
TGCT	cis	rs1107366	0.505	rs12489314	chr3:125976864	A/G	cg01346077	chr3:125931526	NA	0.28	4.93	0.4	2.58e-6	Metabolite levels;
TGCT	cis	rs3087591	0.960	rs2952998	chr17:29418412	T/C	cg24425628	chr17:29625626	OMG;NF1	0.46	6.9	0.53	2.36e-10	Hip circumference;
TGCT	cis	rs12360000	0.897	rs7921481	chr10:1898756	A/C	cg26364871	chr10:1889757	NA	-0.47	-5.26	-0.43	5.99e-7	Metabolite levels (Dihydroxy docosatrienoic acid);
TGCT	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg08280861	chr8:58055591	NA	0.39	4.86	0.4	3.45e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs3780378	1.000	rs10117591	chr9:5094539	G/A	cg02405213	chr9:5042618	JAK2	-0.6	-7.82	-0.57	1.94e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs3858526	1.000	rs11039787	chr11:5965611	C/T	cg05234568	chr11:5960015	NA	-0.43	-4.47	-0.37	1.74e-5	DNA methylation (variation);
TGCT	cis	rs2227564	0.620	rs3812637	chr10:75568846	C/T	cg19442545	chr10:75533431	FUT11	-0.31	-4.55	-0.38	1.27e-5	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs9443645	0.810	rs9448610	chr6:79739622	G/A	cg09184832	chr6:79620586	NA	-0.45	-4.88	-0.4	3.19e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7917772	0.582	rs10786689	chr10:104356359	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	5.36	0.43	3.84e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7508	0.612	rs10112857	chr8:17917888	A/G	cg01800426	chr8:17659068	MTUS1	-0.52	-4.52	-0.38	1.44e-5	Atrial fibrillation;
TGCT	cis	rs17376456	0.877	rs28539612	chr5:93499099	C/T	cg21475434	chr5:93447410	FAM172A	0.63	4.63	0.38	8.98e-6	Diabetic retinopathy;
TGCT	cis	rs9430161	0.579	rs77578010	chr1:11035758	G/A	cg27631724	chr1:11040367	C1orf127	0.55	6.05	0.48	1.6e-8	Ewing sarcoma;
TGCT	trans	rs1814175	0.935	rs7925863	chr11:49615802	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.34	-6.67	-0.51	7.47e-10	Height;
TGCT	cis	rs7666738	0.830	rs17027102	chr4:98919221	A/G	cg05340658	chr4:99064831	C4orf37	-0.53	-6.06	-0.48	1.49e-8	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.86	-9.4	-0.65	3.49e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs2235642	0.893	rs2076442	chr16:1591112	G/T	cg00463982	chr16:1583984	IFT140;TMEM204	-0.29	-4.94	-0.41	2.45e-6	Coronary artery disease;
TGCT	cis	rs9611565	0.559	rs12483860	chr22:41961916	C/T	cg17554472	chr22:41940697	POLR3H	-0.48	-4.94	-0.41	2.47e-6	Vitiligo;
TGCT	cis	rs60154123	0.505	rs76101197	chr1:210044089	T/C	cg12034118	chr1:209979487	IRF6	0.65	4.56	0.38	1.2e-5	Coronary artery disease;
TGCT	cis	rs936229	0.705	rs936227	chr15:75131959	A/G	cg10253484	chr15:75165896	SCAMP2	-0.51	-4.77	-0.39	5.14e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
TGCT	cis	rs1552244	0.608	rs6764807	chr3:9998803	T/C	cg00149659	chr3:10157352	C3orf10	0.65	4.8	0.4	4.49e-6	Alzheimer's disease;
TGCT	cis	rs28374715	0.681	rs77187862	chr15:41619276	A/T	cg18705301	chr15:41695430	NDUFAF1	-0.87	-12.32	-0.74	2.82e-23	Ulcerative colitis;
TGCT	cis	rs11690935	0.921	rs10200608	chr2:172597929	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.17	-12.41	-0.74	1.75e-23	Schizophrenia;
TGCT	cis	rs5769707	0.521	rs6009805	chr22:50058715	T/C	cg05373962	chr22:49881684	NA	-0.32	-5.46	-0.44	2.46e-7	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs6089584	0.927	rs3787427	chr20:60579789	T/C	cg13770153	chr20:60521292	NA	-0.53	-7.2	-0.54	5.01e-11	Body mass index;
TGCT	cis	rs9467711	0.606	rs1977	chr6:26377546	A/G	cg16898833	chr6:26189333	HIST1H4D	1.04	5.26	0.43	6.22e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7666738	0.830	rs13130923	chr4:99046281	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9811920	0.690	rs7623587	chr3:99906751	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.44	-5.29	-0.43	5.41e-7	Axial length;
TGCT	cis	rs611744	0.608	rs612744	chr8:109245991	G/A	cg21045802	chr8:109455806	TTC35	0.74	7.37	0.55	2.07e-11	Dupuytren's disease;
TGCT	cis	rs4919669	0.719	rs17114803	chr10:104386934	A/G	cg05855489	chr10:104503620	C10orf26	0.71	4.69	0.39	7.18e-6	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	trans	rs10802346	0.545	rs6662672	chr1:246387611	A/C	cg13514129	chr1:39547527	MACF1	0.96	8.52	0.61	4.45e-14	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs13326165	0.760	rs13059674	chr3:52371789	T/G	cg07884673	chr3:53033167	SFMBT1	0.39	4.69	0.39	7e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.5	5.41	0.44	3.18e-7	Lymphocyte counts;
TGCT	cis	rs6909279	0.678	rs11155795	chr6:151851339	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.61	-5.67	-0.45	9.49e-8	Bone mineral density;
TGCT	trans	rs10435719	0.773	rs7842810	chr8:11794163	A/G	cg15556689	chr8:8085844	FLJ10661	0.75	7.26	0.55	3.66e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs11148252	0.538	rs9535885	chr13:52726524	A/G	cg00495681	chr13:53174319	NA	0.57	5.86	0.47	3.85e-8	Lewy body disease;
TGCT	cis	rs10193935	0.901	rs7594010	chr2:42534896	C/T	cg27598129	chr2:42591480	NA	-0.41	-5.65	-0.45	1.04e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9583531	0.628	rs9521914	chr13:111382231	C/A	cg24331049	chr13:111365604	ING1	0.81	8.0	0.58	7.56e-13	Coronary artery disease;
TGCT	cis	rs17253792	0.822	rs10147431	chr14:56091841	G/A	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs1150668	0.799	rs1150705	chr6:28193786	T/G	cg11262757	chr6:27280423	POM121L2	0.45	4.44	0.37	1.94e-5	Pubertal anthropometrics;
TGCT	cis	rs12497850	0.931	rs13315711	chr3:48986399	A/T	cg05785598	chr3:49045655	WDR6	0.37	4.83	0.4	3.98e-6	Parkinson's disease;
TGCT	cis	rs9467773	0.620	rs6925087	chr6:26592853	T/A	cg15659132	chr6:26577336	NA	0.87	11.0	0.7	4.77e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs6570726	0.755	rs2103633	chr6:145894021	C/T	cg05347473	chr6:146136440	FBXO30	0.52	4.95	0.41	2.33e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg11764359	chr7:65958608	NA	-0.61	-5.52	-0.44	1.93e-7	Aortic root size;
TGCT	cis	rs7674212	0.531	rs4699048	chr4:103926727	A/G	cg16532752	chr4:104119610	CENPE	-0.6	-5.29	-0.43	5.33e-7	Type 2 diabetes;
TGCT	cis	rs9527	0.615	rs10883800	chr10:104671212	A/C	cg15744005	chr10:104629667	AS3MT	-0.45	-5.31	-0.43	4.9e-7	Arsenic metabolism;
TGCT	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg06618935	chr21:46677482	NA	-0.36	-5.61	-0.45	1.25e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.5	-4.45	-0.37	1.92e-5	Prudent dietary pattern;
TGCT	cis	rs1865760	0.865	rs1436306	chr6:25948421	A/G	cg17042849	chr6:26104293	HIST1H4C	-0.52	-4.78	-0.39	4.97e-6	Height;
TGCT	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg12310025	chr6:25882481	NA	-0.65	-6.72	-0.52	6.03e-10	Blood metabolite levels;
TGCT	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg13683864	chr3:40499215	RPL14	-1.19	-13.67	-0.78	1.61e-26	Renal cell carcinoma;
TGCT	cis	rs9394841	0.667	rs12661667	chr6:41792545	C/T	cg08135965	chr6:41755394	TOMM6	0.54	5.06	0.41	1.45e-6	Mean corpuscular hemoglobin;Red cell distribution width;
TGCT	cis	rs6430585	0.591	rs75223002	chr2:136525309	G/T	cg07169764	chr2:136633963	MCM6	1.21	11.47	0.72	3.36e-21	Corneal structure;
TGCT	cis	rs6835098	0.961	rs17322893	chr4:174122556	A/G	cg08422745	chr4:174089978	GALNT7	0.89	10.02	0.67	1.11e-17	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs12711979	0.509	rs13021385	chr2:3826387	T/C	cg17052675	chr2:3827356	NA	-0.55	-12.72	-0.75	3.04e-24	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs11792861	0.816	rs2304779	chr9:111670513	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.51	-4.79	-0.4	4.61e-6	Menarche (age at onset);
TGCT	cis	rs1568889	1.000	rs12287732	chr11:28120845	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	8.86	0.62	7.07e-15	Bipolar disorder;
TGCT	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg22920501	chr2:26401640	FAM59B	-0.73	-6.44	-0.5	2.35e-9	Gut microbiome composition (summer);
TGCT	cis	rs7666738	0.791	rs6828752	chr4:99063382	C/T	cg17366294	chr4:99064904	C4orf37	0.73	7.45	0.56	1.4e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2637266	0.739	rs2395404	chr10:78380513	G/T	cg18941641	chr10:78392320	NA	0.4	4.69	0.39	7.01e-6	Pulmonary function;
TGCT	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.72	-6.47	-0.5	2.04e-9	Tonsillectomy;
TGCT	cis	rs35883536	0.647	rs1855630	chr1:101039979	C/G	cg06223162	chr1:101003688	GPR88	-0.43	-8.27	-0.6	1.73e-13	Monocyte count;
TGCT	cis	rs9682041	0.867	rs6444925	chr3:170123358	G/T	cg11886554	chr3:170076028	SKIL	0.93	6.65	0.51	8.31e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs58688157	0.549	rs11246192	chr11:572473	T/C	cg27205902	chr11:1006985	AP2A2	0.27	4.47	0.37	1.76e-5	Systemic lupus erythematosus;
TGCT	cis	rs2404602	0.692	rs1116535	chr15:77009514	C/G	cg22467129	chr15:76604101	ETFA	0.44	4.98	0.41	2.07e-6	Blood metabolite levels;
TGCT	cis	rs7819412	0.522	rs4291231	chr8:10990164	G/A	cg21775007	chr8:11205619	TDH	-0.6	-5.27	-0.43	5.9e-7	Triglycerides;
TGCT	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg13699009	chr12:122356056	WDR66	0.28	6.26	0.49	5.63e-9	Mean corpuscular volume;
TGCT	cis	rs12478296	0.792	rs6740738	chr2:243007368	A/C	cg06360820	chr2:242988706	NA	-0.65	-5.29	-0.43	5.25e-7	Obesity-related traits;
TGCT	cis	rs13326165	0.760	rs61150019	chr3:52354376	G/A	cg27565382	chr3:53032988	SFMBT1	0.38	5.11	0.42	1.18e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs28595532	0.688	rs116173135	chr4:119721949	C/T	cg21605333	chr4:119757512	SEC24D	1.72	8.99	0.63	3.52e-15	Cannabis dependence symptom count;
TGCT	cis	rs10892173	0.566	rs12364667	chr11:117675286	A/C	cg21640587	chr11:117668038	DSCAML1	0.71	8.26	0.6	1.87e-13	Myopia;
TGCT	cis	rs3796352	0.892	rs58515094	chr3:52995575	C/T	cg07884673	chr3:53033167	SFMBT1	0.6	5.53	0.44	1.82e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs78456975	1.000	rs10192959	chr2:1553393	G/T	cg01028140	chr2:1542097	TPO	-0.35	-4.57	-0.38	1.17e-5	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs3780378	0.875	rs7028112	chr9:5048814	G/A	cg02405213	chr9:5042618	JAK2	-0.58	-7.5	-0.56	1.09e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs4689592	0.546	rs907523	chr4:7052777	A/G	cg25660036	chr4:7070649	GRPEL1	-0.65	-5.46	-0.44	2.52e-7	Monocyte percentage of white cells;
TGCT	cis	rs7072216	0.763	rs2274243	chr10:100175267	T/C	cg26618903	chr10:100175079	PYROXD2	-0.4	-4.49	-0.37	1.64e-5	Metabolite levels;
TGCT	cis	rs12368653	0.651	rs2307097	chr12:58195801	T/C	cg12615879	chr12:58013172	SLC26A10	0.51	6.49	0.5	1.87e-9	Multiple sclerosis;
TGCT	cis	rs7703051	0.585	rs918623	chr5:74596682	A/C	cg00601450	chr5:74908170	NA	0.44	4.99	0.41	1.97e-6	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
TGCT	cis	rs1355023	0.547	rs7766562	chr6:106219028	A/G	cg17356964	chr6:106582638	NA	0.25	4.57	0.38	1.18e-5	Age-related macular degeneration;
TGCT	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg07061783	chr6:25882402	NA	-0.47	-5.14	-0.42	1.02e-6	Blood metabolite levels;
TGCT	cis	rs617219	0.710	rs2607141	chr5:78558635	G/T	cg09550809	chr5:78407562	BHMT	0.37	5.24	0.43	6.65e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs1035144	0.505	rs11159479	chr14:81460651	C/T	cg06600135	chr14:81408086	NA	-0.48	-4.51	-0.38	1.48e-5	Male sexual orientation;
TGCT	trans	rs877282	0.533	rs10904565	chr10:819991	G/T	cg22713356	chr15:30763199	NA	0.88	6.61	0.51	1.01e-9	Uric acid levels;
TGCT	cis	rs1215050	0.782	rs6532693	chr4:98655815	T/C	cg05340658	chr4:99064831	C4orf37	-0.43	-5.4	-0.44	3.2e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg12667521	chr19:29218732	NA	0.53	5.64	0.45	1.07e-7	Methadone dose in opioid dependence;
TGCT	cis	rs1008375	1.000	rs2872958	chr4:17665032	A/G	cg16339924	chr4:17578868	LAP3	0.55	4.73	0.39	5.96e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs950169	0.800	rs34302901	chr15:85110943	C/G	cg17173187	chr15:85201210	NMB	0.48	5.02	0.41	1.75e-6	Schizophrenia;
TGCT	cis	rs11190604	1.000	rs75063298	chr10:102213600	C/A	cg23241863	chr10:102295624	HIF1AN	0.62	4.87	0.4	3.27e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg20607798	chr8:58055168	NA	0.49	4.67	0.39	7.56e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs11864453	0.680	rs8047377	chr16:72148339	T/C	cg14768367	chr16:72042858	DHODH	0.51	4.89	0.4	3.11e-6	Fibrinogen levels;
TGCT	cis	rs2180341	1.000	rs9398838	chr6:127635285	C/T	cg27446573	chr6:127587934	RNF146	1.12	10.11	0.67	6.87e-18	Breast cancer;
TGCT	cis	rs9985766	1.000	rs61361070	chr4:151002365	G/A	cg05926478	chr4:151174724	DCLK2	-0.24	-4.72	-0.39	6.32e-6	Coronary artery disease;Myocardial infarction;
TGCT	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg10802521	chr3:52805072	NEK4	-0.8	-9.8	-0.66	3.79e-17	Bipolar disorder;
TGCT	cis	rs6867913	0.709	rs891987	chr5:141467196	A/T	cg01311360	chr5:140792558	PCDHGA4;PCDHGA6;PCDHGA9;PCDHGA1;PCDHGA8;PCDHGA5;PCDHGB1;PCDHGB4;PCDHGA3;PCDHGA10;PCDHGA2;PCDHGB6;PCDHGA7;PCDHGB2;PCDHGB5;PCDHGB3	0.4	4.6	0.38	1.01e-5	Asthma;
TGCT	cis	rs2370759	1.000	rs76467481	chr10:32610740	T/G	cg01819863	chr10:32635814	EPC1	1.03	10.07	0.67	8.33e-18	Sexual dysfunction (female);
TGCT	trans	rs7726839	1.000	rs7726839	chr5:618586	A/G	cg25482853	chr8:67687455	SGK3	0.9	7.22	0.54	4.58e-11	Obesity-related traits;
TGCT	cis	rs12701220	0.817	rs7798459	chr7:1087965	C/T	cg07217954	chr7:1067459	C7orf50	-0.47	-4.6	-0.38	1.03e-5	Bronchopulmonary dysplasia;
TGCT	cis	rs7666738	0.830	rs7661264	chr4:98961574	G/A	cg18180107	chr4:99064573	C4orf37	0.57	5.18	0.42	8.63e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6831352	0.879	rs17218003	chr4:100054723	G/C	cg12011299	chr4:100065546	ADH4	-0.4	-4.88	-0.4	3.26e-6	Alcohol dependence;
TGCT	cis	rs2197308	0.765	rs11182434	chr12:37923968	C/A	cg13010199	chr12:38710504	ALG10B	0.67	5.38	0.44	3.57e-7	Morning vs. evening chronotype;
TGCT	cis	rs7208859	0.623	rs9911784	chr17:29124580	A/C	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg03732007	chr1:2071316	PRKCZ	0.27	6.23	0.49	6.69e-9	Height;
TGCT	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg02609749	chr16:89786786	C16orf7;ZNF276	0.31	4.67	0.39	7.85e-6	Vitiligo;
TGCT	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg06112835	chr11:68658793	MRPL21	0.46	8.12	0.59	3.91e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs2073300	1.000	rs6137960	chr20:23442886	G/A	cg09953122	chr20:23471693	CST8	-0.64	-4.56	-0.38	1.19e-5	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs4906332	1.000	rs7155980	chr14:103922419	C/G	cg26031613	chr14:104095156	KLC1	-0.53	-4.72	-0.39	6.2e-6	Coronary artery disease;
TGCT	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg05368731	chr17:41323189	NBR1	1.08	11.0	0.7	4.76e-20	Menopause (age at onset);
TGCT	cis	rs7769051	0.615	rs12209144	chr6:133191064	A/T	cg22852734	chr6:133119734	C6orf192	1.1	6.06	0.48	1.5e-8	Type 2 diabetes nephropathy;
TGCT	cis	rs2282802	0.685	rs12188849	chr5:139621570	G/A	cg01081189	chr5:139537190	NA	0.29	5.22	0.42	7.43e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9788333	0.788	rs35007728	chr13:21893221	G/C	cg25811766	chr13:21894605	NA	0.27	5.0	0.41	1.91e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg03395511	chr6:291903	DUSP22	-0.7	-7.2	-0.54	4.99e-11	Menopause (age at onset);
TGCT	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg10862848	chr6:42927986	GNMT	-0.38	-4.68	-0.39	7.53e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs7100689	0.646	rs7089003	chr10:82124155	T/C	cg01528321	chr10:82214614	TSPAN14	0.8	7.76	0.57	2.7e-12	Post bronchodilator FEV1;
TGCT	cis	rs1729951	0.575	rs1654925	chr3:136690391	C/T	cg12473912	chr3:136751656	NA	-0.39	-6.18	-0.49	8.36e-9	Neuroticism;
TGCT	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg11062466	chr8:58055876	NA	0.34	4.67	0.39	7.79e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6087990	0.735	rs6119946	chr20:31329704	A/G	cg13636640	chr20:31349939	DNMT3B	-0.96	-13.14	-0.76	3.01e-25	Ulcerative colitis;
TGCT	cis	rs78707713	0.531	rs12411720	chr10:71192471	T/G	cg12610070	chr10:71211762	TSPAN15	-0.57	-6.35	-0.5	3.69e-9	Venous thromboembolism;
TGCT	cis	rs137603	0.644	rs137636	chr22:39722477	C/A	cg17798944	chr22:39715225	SNORD43;RPL3	-0.65	-7.03	-0.53	1.25e-10	Primary biliary cholangitis;
TGCT	cis	rs79149102	0.579	rs3812943	chr15:75312715	C/G	cg09165964	chr15:75287851	SCAMP5	-1.04	-5.48	-0.44	2.28e-7	Lung cancer;
TGCT	cis	rs6840360	0.593	rs4696287	chr4:152606723	C/T	cg22705602	chr4:152727874	NA	-0.33	-5.5	-0.44	2.09e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2153535	0.580	rs2184585	chr6:8474168	G/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs526231	0.575	rs66730942	chr5:102306779	G/C	cg23492399	chr5:102201601	PAM	-0.53	-4.56	-0.38	1.23e-5	Primary biliary cholangitis;
TGCT	cis	rs651907	0.535	rs17412601	chr3:101499275	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.86	10.47	0.68	9.24e-19	Colorectal cancer;
TGCT	cis	rs875971	1.000	rs1183245	chr7:65541185	C/T	cg18876405	chr7:65276391	NA	-0.35	-5.19	-0.42	8.26e-7	Aortic root size;
TGCT	cis	rs10489202	0.683	rs2294817	chr1:168073601	C/A	cg24449463	chr1:168025552	DCAF6	-0.52	-5.52	-0.44	1.9e-7	Schizophrenia;
TGCT	cis	rs9430161	0.579	rs6694011	chr1:11036935	G/A	cg27631724	chr1:11040367	C1orf127	0.54	6.28	0.49	5.3300000000000004e-09	Ewing sarcoma;
TGCT	cis	rs28595532	0.920	rs114928651	chr4:119734194	T/C	cg21605333	chr4:119757512	SEC24D	1.66	8.33	0.6	1.28e-13	Cannabis dependence symptom count;
TGCT	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg10295955	chr4:187884368	NA	-0.98	-15.16	-0.81	5.3e-30	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10465746	0.967	rs28567085	chr1:84428859	G/A	cg10977910	chr1:84465055	TTLL7	0.63	6.2	0.49	7.68e-9	Obesity-related traits;
TGCT	cis	rs4654899	0.897	rs6679753	chr1:21066634	G/C	cg01072550	chr1:21505969	NA	-0.49	-7.85	-0.58	1.67e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs9527	0.571	rs10786715	chr10:104620735	G/C	cg04362960	chr10:104952993	NT5C2	0.55	4.73	0.39	5.91e-6	Arsenic metabolism;
TGCT	cis	rs7666738	0.830	rs7687958	chr4:99014495	T/C	cg17366294	chr4:99064904	C4orf37	0.68	7.04	0.53	1.17e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs950169	0.800	rs4099846	chr15:84956894	C/G	cg17173187	chr15:85201210	NMB	0.58	5.93	0.47	2.77e-8	Schizophrenia;
TGCT	cis	rs7223966	1.000	rs55868506	chr17:61851686	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	4.68	0.39	7.5e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg04267008	chr7:1944627	MAD1L1	-0.36	-4.82	-0.4	4.03e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs4073582	0.595	rs708471	chr11:65931008	A/G	cg16950941	chr11:66035639	RAB1B	0.55	5.42	0.44	2.94e-7	Gout;
TGCT	cis	rs8017423	1.000	rs11622075	chr14:90669894	G/T	cg04374321	chr14:90722782	PSMC1	0.75	7.72	0.57	3.31e-12	Mortality in heart failure;
TGCT	cis	rs7772486	0.790	rs7753092	chr6:146248863	C/T	cg05347473	chr6:146136440	FBXO30	-0.51	-4.95	-0.41	2.42e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4654899	0.865	rs12119348	chr1:21484633	C/T	cg01072550	chr1:21505969	NA	-0.48	-7.14	-0.54	7.03e-11	Superior frontal gyrus grey matter volume;
TGCT	cis	rs854765	0.663	rs3744115	chr17:17749822	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.73	-7.06	-0.54	1.04e-10	Total body bone mineral density;
TGCT	cis	rs909674	0.662	rs2899318	chr22:39837625	A/G	cg01416388	chr22:39784598	NA	-0.72	-6.54	-0.51	1.47e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs208520	0.690	rs12208977	chr6:66725257	G/A	cg07460842	chr6:66804631	NA	0.95	9.67	0.66	7.83e-17	Exhaled nitric oxide output;
TGCT	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg13395646	chr4:1353034	KIAA1530	0.4	4.95	0.41	2.34e-6	Obesity-related traits;
TGCT	cis	rs10791323	0.628	rs2851118	chr11:133705995	A/C	cg15485101	chr11:133734466	NA	0.4	5.08	0.41	1.38e-6	Childhood ear infection;
TGCT	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg20203395	chr5:56204925	C5orf35	-0.57	-5.27	-0.43	5.77e-7	Coronary artery disease;
TGCT	cis	rs12220898	0.749	rs2377975	chr10:50481421	A/G	cg09603381	chr10:49954066	WDFY4	0.39	4.48	0.37	1.68e-5	Inflammatory biomarkers;
TGCT	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg00684032	chr4:1343700	KIAA1530	0.22	4.73	0.39	5.92e-6	Obesity-related traits;
TGCT	cis	rs7192750	0.562	rs9934803	chr16:71981630	T/G	cg06353428	chr16:71660113	MARVELD3	0.75	6.74	0.52	5.43e-10	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg03609598	chr5:56110824	MAP3K1	-0.59	-4.78	-0.39	4.81e-6	Initial pursuit acceleration;
TGCT	cis	rs78456975	0.527	rs11886696	chr2:1567841	A/G	cg01028140	chr2:1542097	TPO	-0.35	-5.35	-0.43	4.04e-7	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs9291683	0.530	rs13115193	chr4:9982191	C/T	cg00071950	chr4:10020882	SLC2A9	0.65	8.23	0.59	2.21e-13	Bone mineral density;
TGCT	cis	rs62244186	0.566	rs3762636	chr3:44854563	A/G	cg15687855	chr3:44754131	ZNF502	-0.53	-6.79	-0.52	4.2e-10	Depressive symptoms;
TGCT	cis	rs7647973	1.000	rs8897	chr3:49460407	A/G	cg06212747	chr3:49208901	KLHDC8B	0.53	4.44	0.37	1.98e-5	Menarche (age at onset);
TGCT	cis	rs2033711	0.936	rs893185	chr19:58989495	A/C	cg04608855	chr19:58913158	NA	0.53	4.83	0.4	3.94e-6	Uric acid clearance;
TGCT	cis	rs6933660	0.720	rs6913515	chr6:151753470	G/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.51	-4.57	-0.38	1.14e-5	Menarche (age at onset);
TGCT	cis	rs1570884	0.857	rs4942848	chr13:50141345	A/G	cg08779649	chr13:50194554	NA	-0.3	-4.74	-0.39	5.87e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
TGCT	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg03806693	chr22:41940476	POLR3H	-1.05	-10.61	-0.69	4.09e-19	Vitiligo;
TGCT	trans	rs877282	0.755	rs1769242	chr10:787896	T/C	cg22713356	chr15:30763199	NA	0.95	8.14	0.59	3.51e-13	Uric acid levels;
TGCT	cis	rs7017914	0.967	rs7013657	chr8:71637559	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.03	-0.41	1.69e-6	Bone mineral density;
TGCT	cis	rs11190604	1.000	rs2495745	chr10:102329075	A/G	cg23241863	chr10:102295624	HIF1AN	0.67	5.1	0.42	1.23e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7824557	0.564	rs2736290	chr8:11234298	C/T	cg21775007	chr8:11205619	TDH	-0.65	-6.39	-0.5	3.09e-9	Retinal vascular caliber;
TGCT	cis	rs1568889	0.938	rs12795971	chr11:28355104	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	8.61	0.61	2.72e-14	Bipolar disorder;
TGCT	trans	rs7726839	0.540	rs55929359	chr5:595956	C/G	cg25482853	chr8:67687455	SGK3	1.24	10.0	0.67	1.29e-17	Obesity-related traits;
TGCT	cis	rs8014252	0.614	rs28612538	chr14:71025206	G/A	cg11204974	chr14:71022665	NA	-0.55	-4.66	-0.39	7.98e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
TGCT	cis	rs899997	1.000	rs7182567	chr15:79045054	A/G	cg00061860	chr15:78953028	NA	-0.27	-4.51	-0.38	1.49e-5	Coronary artery disease or large artery stroke;
TGCT	cis	rs7681440	0.835	rs6839608	chr4:90805493	T/C	cg14346243	chr4:90757452	SNCA	-0.5	-4.75	-0.39	5.46e-6	Dementia with Lewy bodies;
TGCT	cis	rs6430585	0.941	rs10496737	chr2:136540083	A/G	cg07169764	chr2:136633963	MCM6	0.89	7.96	0.58	9.17e-13	Corneal structure;
TGCT	cis	rs4689388	0.853	rs1079216	chr4:6282473	T/C	cg00701064	chr4:6280414	WFS1	0.39	4.79	0.4	4.7e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs909674	0.818	rs7364148	chr22:39842165	T/C	cg24399712	chr22:39784796	NA	-1.03	-10.67	-0.69	2.89e-19	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg07424592	chr7:64974309	NA	1.4	8.42	0.6	7.87e-14	Diabetic kidney disease;
TGCT	cis	rs7267979	1.000	rs2257420	chr20:25275890	C/A	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs28595532	0.920	rs17323877	chr4:119671188	A/G	cg21605333	chr4:119757512	SEC24D	1.33	7.24	0.55	4.06e-11	Cannabis dependence symptom count;
TGCT	cis	rs4713118	0.666	rs4140646	chr6:27738801	G/A	cg20933634	chr6:27740509	NA	0.35	4.83	0.4	3.92e-6	Parkinson's disease;
TGCT	cis	rs1371867	0.846	rs1616833	chr8:101271821	C/T	cg06002616	chr8:101225028	SPAG1	0.53	6.42	0.5	2.67e-9	Atrioventricular conduction;
TGCT	cis	rs4319547	0.955	rs6489159	chr12:123112806	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.64	-4.88	-0.4	3.25e-6	Body mass index;
TGCT	cis	rs9911578	0.967	rs72628392	chr17:56506160	A/G	cg12560992	chr17:57184187	TRIM37	-0.76	-9.26	-0.64	7.61e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg18876405	chr7:65276391	NA	-0.34	-4.98	-0.41	2.04e-6	Aortic root size;
TGCT	cis	rs7617773	0.694	rs13099560	chr3:48204768	C/T	cg11946769	chr3:48343235	NME6	-0.7	-6.55	-0.51	1.36e-9	Coronary artery disease;
TGCT	cis	rs12510870	0.599	rs7665563	chr4:74452994	G/T	cg05868023	chr4:75230803	EREG	-0.55	-4.74	-0.39	5.71e-6	Iris color (b* coordinate);
TGCT	cis	rs1075265	0.875	rs12616212	chr2:54266246	T/C	cg15001959	chr2:54483431	TSPYL6;ACYP2	-0.18	-4.48	-0.37	1.7e-5	Morning vs. evening chronotype;Chronotype;
TGCT	cis	rs7666738	0.830	rs4699597	chr4:99019031	G/A	cg05340658	chr4:99064831	C4orf37	0.48	5.43	0.44	2.92e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs72781680	1.000	rs72796329	chr2:24141912	G/A	cg08917208	chr2:24149416	ATAD2B	0.73	4.51	0.38	1.48e-5	Lymphocyte counts;
TGCT	cis	rs4700695	0.719	rs27086	chr5:65453185	A/G	cg21114390	chr5:65439923	SFRS12	-0.84	-7.33	-0.55	2.58e-11	Facial morphology (factor 19);
TGCT	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg22963979	chr7:1858916	MAD1L1	-0.43	-7.13	-0.54	7.28e-11	Schizophrenia;
TGCT	cis	rs2075371	0.966	rs1901204	chr7:133985896	A/G	cg11752832	chr7:134001865	SLC35B4	0.7	6.44	0.5	2.39e-9	Mean platelet volume;
TGCT	trans	rs10504390	0.656	rs75002270	chr8:66474587	T/C	cg18118147	chr19:51128640	SYT3	-0.77	-6.81	-0.52	3.71e-10	IgG glycosylation;
TGCT	cis	rs889312	0.500	rs832577	chr5:56163787	G/A	cg24531977	chr5:56204891	C5orf35	-0.5	-5.09	-0.42	1.28e-6	Breast cancer;Breast cancer (early onset);
TGCT	cis	rs2956278	0.717	rs2956295	chr12:84677996	G/A	cg25678815	chr12:85673915	ALX1	-0.54	-4.83	-0.4	3.96e-6	Depressive symptoms;Depressive symptoms (multi-trait analysis);
TGCT	cis	rs10489202	0.632	rs275137	chr1:168051266	A/C	cg24449463	chr1:168025552	DCAF6	0.6	7.2	0.54	5.03e-11	Schizophrenia;
TGCT	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg11890956	chr21:40555474	PSMG1	-0.73	-6.6	-0.51	1.1e-9	Cognitive function;
TGCT	cis	rs62244186	0.659	rs12108134	chr3:44543030	A/G	cg10263370	chr3:44754102	ZNF502	0.38	4.43	0.37	2.01e-5	Depressive symptoms;
TGCT	cis	rs896854	0.714	rs6471503	chr8:95990283	G/A	cg09323728	chr8:95962352	TP53INP1	-0.48	-6.22	-0.49	7.08e-9	Type 2 diabetes;
TGCT	cis	rs67478160	0.619	rs8018062	chr14:104281954	C/T	cg26031613	chr14:104095156	KLC1	-0.63	-6.52	-0.51	1.61e-9	Schizophrenia;
TGCT	cis	rs916888	0.779	rs430685	chr17:44859148	T/C	cg17911788	chr17:44343683	NA	0.59	6.13	0.48	1.09e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg21016266	chr12:122356598	WDR66	0.52	6.57	0.51	1.27e-9	Mean corpuscular volume;
TGCT	cis	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg22121687	chr7:65037720	NA	-0.78	-4.7	-0.39	6.74e-6	Diabetic kidney disease;
TGCT	cis	rs916888	0.647	rs199523	chr17:44848517	C/A	cg15921436	chr17:44337874	NA	-0.43	-6.49	-0.5	1.89e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs11577318	0.537	rs12030833	chr1:26689220	A/G	cg14210634	chr1:25870291	LDLRAP1	0.53	4.68	0.39	7.24e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs9926296	0.632	rs7184315	chr16:89799373	C/G	cg08627397	chr16:89984028	MC1R	0.31	4.98	0.41	2.05e-6	Vitiligo;
TGCT	cis	rs6490294	0.718	rs11065976	chr12:112047571	T/C	cg10833066	chr12:111807467	FAM109A	0.35	5.25	0.43	6.5e-7	Mean platelet volume;
TGCT	cis	rs13191362	1.000	rs34177053	chr6:163007772	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.68	5.79	0.46	5.33e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs3808502	0.605	rs11784572	chr8:11174484	C/G	cg21775007	chr8:11205619	TDH	-0.75	-7.62	-0.56	5.57e-12	Neuroticism;
TGCT	cis	rs5760092	0.755	rs11090298	chr22:24262061	G/A	cg20007245	chr22:24372913	LOC391322	0.84	7.26	0.55	3.69e-11	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs9660992	0.710	rs1668873	chr1:205235990	G/A	cg00857998	chr1:205179979	DSTYK	0.52	4.56	0.38	1.19e-5	Mean corpuscular volume;Mean platelet volume;
TGCT	cis	rs6893300	0.542	rs7736300	chr5:179196898	G/A	cg14593053	chr5:179126677	CANX	0.51	5.9	0.47	3.23e-8	Resting heart rate;
TGCT	cis	rs2506155	0.752	rs17504012	chr10:33516355	G/C	cg25928881	chr10:32632685	EPC1	0.31	4.65	0.39	8.31e-6	Migraine;
TGCT	cis	rs3845702	0.736	rs6433821	chr2:180837806	T/A	cg01881094	chr2:180872142	CWC22	-1.07	-6.88	-0.53	2.6e-10	Schizophrenia;
TGCT	cis	rs12579753	1.000	rs12811607	chr12:82233619	T/G	cg07988820	chr12:82153109	PPFIA2	-0.6	-6.48	-0.5	1.91e-9	Resting heart rate;
TGCT	cis	rs6088580	0.602	rs6059834	chr20:33019299	A/G	cg24642439	chr20:33292090	TP53INP2	0.49	4.51	0.38	1.5e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs4808199	1.000	rs12977524	chr19:19568244	A/G	cg03709012	chr19:19516395	GATAD2A	1.0	7.8	0.57	2.23e-12	Nonalcoholic fatty liver disease;
TGCT	cis	rs858239	0.539	rs6461694	chr7:23187779	G/A	cg05602783	chr7:23145260	KLHL7	-0.68	-5.62	-0.45	1.2e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs7923452	0.507	rs215494	chr10:30776589	T/G	cg13289132	chr10:30722225	MAP3K8	-0.44	-5.23	-0.42	7.08e-7	Itch intensity from mosquito bite;
TGCT	cis	rs4285028	0.747	rs9838301	chr3:121375144	G/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.93	-7.37	-0.55	2.07e-11	Multiple sclerosis;
TGCT	cis	rs858239	0.600	rs28499396	chr7:23124098	A/G	cg05602783	chr7:23145260	KLHL7	-0.6	-5.02	-0.41	1.76e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs933688	1.000	rs1363839	chr5:90671274	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.92	8.52	0.61	4.52e-14	Smoking behavior;
TGCT	cis	rs9814567	0.727	rs4435681	chr3:134344435	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-5.93	-0.47	2.86e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs910316	0.934	rs4903278	chr14:75535019	C/A	cg23033748	chr14:75592666	NEK9	0.28	4.7	0.39	6.7e-6	Height;
TGCT	cis	rs7824557	0.737	rs10481445	chr8:11109269	T/C	cg21775007	chr8:11205619	TDH	-0.52	-4.54	-0.38	1.29e-5	Retinal vascular caliber;
TGCT	cis	rs6540559	0.611	rs61747285	chr1:210004332	G/A	cg22029157	chr1:209979665	IRF6	0.71	5.09	0.42	1.3e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg25660036	chr4:7070649	GRPEL1	-0.67	-5.81	-0.46	4.85e-8	Monocyte percentage of white cells;
TGCT	cis	rs3008870	0.755	rs2815381	chr1:67514591	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.81	7.56	0.56	7.97e-12	Lymphocyte percentage of white cells;
TGCT	cis	rs2354432	0.607	rs1890039	chr1:146681951	T/C	cg25205988	chr1:146714368	CHD1L	1.33	6.31	0.49	4.44e-9	Mitochondrial DNA levels;
TGCT	cis	rs2456568	0.802	rs11020586	chr11:93638547	G/A	cg17595323	chr11:93583763	C11orf90	-0.47	-6.52	-0.51	1.58e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs2075371	0.897	rs1643102	chr7:133999983	T/A	cg11752832	chr7:134001865	SLC35B4	0.7	6.44	0.5	2.41e-9	Mean platelet volume;
TGCT	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.12	14.24	0.79	7.22e-28	Height;
TGCT	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.9	7.25	0.55	3.93e-11	Platelet count;
TGCT	cis	rs858239	0.600	rs4628176	chr7:23142566	C/T	cg05602783	chr7:23145260	KLHL7	-0.72	-6.15	-0.48	9.86e-9	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs67311347	0.955	rs4974067	chr3:40374551	C/T	cg17264618	chr3:40429014	ENTPD3	0.31	4.59	0.38	1.09e-5	Renal cell carcinoma;
TGCT	cis	rs7727544	0.606	rs10058074	chr5:131686146	G/A	cg14196790	chr5:131705035	SLC22A5	0.34	4.81	0.4	4.37e-6	Blood metabolite levels;
TGCT	cis	rs11122272	0.735	rs2749707	chr1:231527316	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-6.23	-0.49	6.8e-9	Hemoglobin concentration;
TGCT	cis	rs2663905	0.706	rs7162859	chr15:81360038	C/T	cg09888468	chr15:81410853	NA	0.74	5.64	0.45	1.09e-7	QT interval (drug interaction);
TGCT	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs57590327	0.503	rs7631052	chr3:81866235	C/A	cg07356753	chr3:81810745	GBE1	-0.65	-5.97	-0.47	2.36e-8	Extraversion;
TGCT	cis	rs9818758	0.607	rs66991555	chr3:49228643	A/G	cg00383909	chr3:49044727	WDR6	1.28	6.57	0.51	1.23e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs9517313	0.554	rs3809366	chr13:99230266	C/T	cg07423050	chr13:99094983	FARP1	-0.23	-4.5	-0.37	1.53e-5	Neuroticism;
TGCT	cis	rs11864453	0.647	rs9941346	chr16:72135707	C/G	cg14768367	chr16:72042858	DHODH	0.52	5.27	0.43	5.78e-7	Fibrinogen levels;
TGCT	cis	rs3784262	0.669	rs12148281	chr15:58311061	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.42	-6.17	-0.48	8.83e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs3820068	0.603	rs59475085	chr1:15911131	G/A	cg05660106	chr1:15850417	CASP9	1.04	11.74	0.73	7.33e-22	Systolic blood pressure;
TGCT	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg11644478	chr21:40555479	PSMG1	1.01	10.7	0.69	2.56e-19	Cognitive function;
TGCT	cis	rs603424	0.551	rs646767	chr10:102084897	A/G	cg22671421	chr10:102507979	PAX2	-0.54	-4.55	-0.38	1.26e-5	Phospholipid levels (plasma);Palmitic acid (16:0) levels;Palmitoleic acid (16:1n-7) levels;Mean platelet volume;Serum metabolite levels;Blood metabolite levels;Vaccenic acid (18:1n-7) levels;Metabolic traits;Coronary artery disease;Blood metabolite ratios;Glycerophospholipid levels;
TGCT	cis	rs3027234	0.668	rs75664430	chr17:8064779	C/G	cg08322244	chr17:8066669	VAMP2	-0.52	-4.99	-0.41	2.03e-6	Telomere length;
TGCT	cis	rs7959452	0.527	rs4761157	chr12:69780907	A/G	cg20891283	chr12:69753455	YEATS4	0.83	8.7	0.62	1.68e-14	Blood protein levels;
TGCT	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg08509172	chr19:19383838	TM6SF2	0.36	4.73	0.39	5.97e-6	Tonsillectomy;
TGCT	cis	rs12497850	0.931	rs9311432	chr3:48850443	T/A	cg18654377	chr3:49208889	KLHDC8B	-0.41	-5.49	-0.44	2.15e-7	Parkinson's disease;
TGCT	cis	rs2456568	0.802	rs10765638	chr11:93636171	A/T	cg16099599	chr11:93583650	C11orf90	-0.4	-4.98	-0.41	2.04e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs10464366	0.544	rs953874	chr7:39147916	G/A	cg15212455	chr7:39170539	POU6F2	0.3	6.48	0.5	1.91e-9	IgG glycosylation;
TGCT	cis	rs6450176	1.000	rs10805455	chr5:53302302	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.53	-5.1	-0.42	1.23e-6	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs11690935	0.959	rs1113389	chr2:172635365	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.18	-12.58	-0.75	6.59e-24	Schizophrenia;
TGCT	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg20891558	chr2:74357851	NA	0.52	6.26	0.49	5.69e-9	Gestational age at birth (maternal effect);
TGCT	cis	rs6674970	0.933	rs11204772	chr1:151056305	C/T	cg00003202	chr1:151319512	RFX5	-0.51	-4.46	-0.37	1.84e-5	Childhood ear infection;
TGCT	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg12311346	chr5:56204834	C5orf35	-0.67	-6.82	-0.52	3.63e-10	Initial pursuit acceleration;
TGCT	cis	rs11690462	0.963	rs6731447	chr2:26590118	C/T	cg11525280	chr2:26624667	C2orf39	0.37	4.52	0.38	1.4e-5	Coronary artery disease;
TGCT	cis	rs2280018	0.526	rs2941257	chr16:15166445	T/C	cg07549590	chr16:15018862	NA	-0.3	-4.81	-0.4	4.28e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs13256369	0.851	rs13255061	chr8:8563834	G/A	cg06671706	chr8:8559999	CLDN23	0.34	4.53	0.38	1.38e-5	Obesity-related traits;
TGCT	cis	rs9916302	0.706	rs590051	chr17:37446571	T/C	cg07936489	chr17:37558343	FBXL20	0.84	6.23	0.49	6.68e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs651907	0.557	rs11720745	chr3:101441690	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.87	10.21	0.68	3.89e-18	Colorectal cancer;
TGCT	cis	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg07424592	chr7:64974309	NA	1.4	8.42	0.6	7.87e-14	Diabetic kidney disease;
TGCT	cis	rs4595586	1.000	rs1403521	chr12:39232007	A/G	cg10518543	chr12:38710700	ALG10B	0.52	5.04	0.41	1.6e-6	Morning vs. evening chronotype;
TGCT	cis	rs9457247	1.000	rs430097	chr6:167405073	A/G	cg23791538	chr6:167370224	RNASET2	-0.49	-4.96	-0.41	2.26e-6	Crohn's disease;
TGCT	cis	rs6061231	0.556	rs6121571	chr20:60977323	T/G	cg24112000	chr20:60950667	NA	-0.38	-4.93	-0.4	2.55e-6	Colorectal cancer;
TGCT	cis	rs2456568	0.548	rs6483280	chr11:93661592	T/C	cg17595323	chr11:93583763	C11orf90	-0.44	-5.62	-0.45	1.21e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs921968	0.643	rs3931102	chr2:219520405	C/T	cg02176678	chr2:219576539	TTLL4	0.4	5.85	0.47	4.03e-8	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs2404602	0.598	rs71405204	chr15:76635305	C/G	cg22467129	chr15:76604101	ETFA	0.48	4.83	0.4	3.99e-6	Blood metabolite levels;
TGCT	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.71	5.14	0.42	1.02e-6	Platelet count;
TGCT	cis	rs2455799	0.613	rs9848007	chr3:15852593	T/A	cg16303742	chr3:15540471	COLQ	-0.24	-4.52	-0.38	1.43e-5	Mean platelet volume;
TGCT	trans	rs7726839	0.540	rs28364691	chr5:664084	G/A	cg25482853	chr8:67687455	SGK3	1.19	10.53	0.69	6.56e-19	Obesity-related traits;
TGCT	cis	rs7086627	0.515	rs10887899	chr10:82210214	G/A	cg01528321	chr10:82214614	TSPAN14	0.65	6.2	0.49	7.78e-9	Post bronchodilator FEV1;
TGCT	cis	rs9500256	0.655	rs12208465	chr6:58330881	C/T	cg16251399	chr6:58287822	GUSBL2	0.56	4.74	0.39	5.76e-6	Eosinophilic esophagitis (pediatric);
TGCT	cis	rs7811142	0.945	rs6974282	chr7:100098295	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.1	9.08	0.63	2.06e-15	Platelet count;
TGCT	cis	rs6429082	0.818	rs453315	chr1:235680585	C/T	cg26050004	chr1:235667680	B3GALNT2	0.58	5.07	0.41	1.43e-6	Adiposity;
TGCT	cis	rs10949662	0.961	rs79566608	chr7:157530524	G/A	cg14168080	chr7:157504135	PTPRN2	-0.39	-4.65	-0.39	8.24e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg06873352	chr17:61820015	STRADA	-0.52	-5.97	-0.47	2.31e-8	Prudent dietary pattern;
TGCT	cis	rs617791	0.530	rs735942	chr11:65749337	A/G	cg09783858	chr11:65769428	EIF1AD;BANF1	0.5	4.56	0.38	1.2e-5	Breast cancer;
TGCT	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg22963979	chr7:1858916	MAD1L1	-0.37	-5.79	-0.46	5.33e-8	Bipolar disorder and schizophrenia;
TGCT	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg22920501	chr2:26401640	FAM59B	-0.71	-6.1	-0.48	1.27e-8	Gut microbiome composition (summer);
TGCT	cis	rs2663905	0.611	rs1509560	chr15:81391713	T/G	cg18837035	chr15:81426597	C15orf26	-0.6	-5.42	-0.44	2.98e-7	QT interval (drug interaction);
TGCT	cis	rs826838	0.809	rs11169666	chr12:39211300	T/C	cg26384229	chr12:38710491	ALG10B	0.94	8.31	0.6	1.42e-13	Heart rate;
TGCT	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg06640241	chr16:89574553	SPG7	0.64	6.33	0.49	4.18e-9	Multiple myeloma (IgH translocation);
TGCT	cis	rs9325144	0.602	rs7965838	chr12:38634365	A/T	cg26384229	chr12:38710491	ALG10B	-0.68	-5.99	-0.47	2.07e-8	Morning vs. evening chronotype;
TGCT	cis	rs12188164	0.515	rs17562461	chr5:411361	C/T	cg22025206	chr5:502436	SLC9A3	-0.26	-4.81	-0.4	4.32e-6	Cystic fibrosis severity;
TGCT	cis	rs9534288	0.699	rs4280137	chr13:46664008	G/A	cg15192986	chr13:46630673	CPB2	-0.5	-5.92	-0.47	2.92e-8	Blood protein levels;
TGCT	cis	rs1669338	0.588	rs3931974	chr3:3186894	A/G	cg16797762	chr3:3221439	CRBN	0.97	5.43	0.44	2.9e-7	White matter integrity;
TGCT	cis	rs6831352	0.879	rs29001229	chr4:100046823	A/G	cg12011299	chr4:100065546	ADH4	-0.43	-5.17	-0.42	9.06e-7	Alcohol dependence;
TGCT	cis	rs826838	1.000	rs1393537	chr12:38920961	C/T	cg13010199	chr12:38710504	ALG10B	0.77	6.38	0.5	3.21e-9	Heart rate;
TGCT	cis	rs7975161	0.580	rs4246270	chr12:104728530	G/A	cg25273343	chr12:104657179	TXNRD1	-0.36	-5.0	-0.41	1.9e-6	Toenail selenium levels;
TGCT	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg24503407	chr1:205819492	PM20D1	0.52	6.92	0.53	2.13e-10	Monocyte percentage of white cells;
TGCT	cis	rs2046867	0.818	rs17010215	chr3:72886965	A/G	cg25664220	chr3:72788482	NA	-0.57	-6.33	-0.49	4.08e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2296887	0.841	rs10883720	chr10:104010971	G/C	cg26089160	chr10:104170217	PSD	-0.61	-5.62	-0.45	1.19e-7	Parkinson's disease;
TGCT	cis	rs66573146	1.000	rs7686168	chr4:6986057	C/A	cg05069807	chr4:6945702	TBC1D14	0.35	4.94	0.41	2.51e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs9868809	0.772	rs9877794	chr3:48718388	G/C	cg00383909	chr3:49044727	WDR6	0.96	5.85	0.47	4.04e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs7647973	0.626	rs2131108	chr3:49665390	C/T	cg03034192	chr3:50606346	HEMK1;C3orf18	0.36	4.75	0.39	5.58e-6	Menarche (age at onset);
TGCT	cis	rs6840360	0.582	rs11732918	chr4:152319045	C/T	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.35	-0.5	3.67e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs28595532	0.764	rs55913633	chr4:119747444	C/A	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg20887711	chr4:1340912	KIAA1530	0.56	4.83	0.4	3.91e-6	Longevity;
TGCT	cis	rs2153535	0.580	rs7450817	chr6:8481421	G/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg15242686	chr22:24348715	GSTTP1	0.39	5.24	0.43	6.81e-7	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9952991	0.882	rs2847274	chr18:12777603	T/C	cg24737193	chr18:12778029	NA	0.54	6.03	0.48	1.76e-8	Inflammatory skin disease;
TGCT	cis	rs904251	0.561	rs1757189	chr6:37483727	G/C	cg01843034	chr6:37503916	NA	-0.54	-7.18	-0.54	5.74e-11	Cognitive performance;
TGCT	cis	rs77633900	0.614	rs279997	chr15:76949262	T/C	cg21673338	chr15:77095150	SCAPER	-0.51	-4.83	-0.4	3.96e-6	Non-glioblastoma glioma;Glioma;
TGCT	cis	rs6088580	0.634	rs6059892	chr20:33105766	A/G	cg06115741	chr20:33292138	TP53INP2	0.54	4.63	0.38	9.06e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs6589563	0.609	rs12292921	chr11:116621963	T/G	cg01124546	chr11:117515332	DSCAML1	-0.44	-4.65	-0.39	8.28e-6	Eosinophil counts;
TGCT	cis	rs11577318	0.853	rs7537477	chr1:26618829	C/T	cg04990556	chr1:26633338	UBXN11	-0.6	-5.53	-0.45	1.78e-7	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	5.24	0.43	6.6e-7	Height;
TGCT	cis	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg22857025	chr5:266934	NA	-0.34	-6.7	-0.52	6.65e-10	Breast cancer;
TGCT	cis	rs7949030	0.504	rs2516633	chr11:62371773	A/C	cg13298116	chr11:62369859	EML3;MTA2	-0.59	-7.27	-0.55	3.49e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2153535	0.580	rs9406169	chr6:8509470	A/T	cg07606381	chr6:8435919	SLC35B3	0.48	4.6	0.38	1.01e-5	Motion sickness;
TGCT	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg13395646	chr4:1353034	KIAA1530	-0.41	-5.02	-0.41	1.75e-6	Longevity;
TGCT	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.69	6.01	0.47	1.94e-8	Tonsillectomy;
TGCT	cis	rs2663905	0.611	rs1509559	chr15:81391411	G/A	cg09888468	chr15:81410853	NA	-0.64	-5.49	-0.44	2.16e-7	QT interval (drug interaction);
TGCT	cis	rs4919694	1.000	rs10509760	chr10:104634107	A/G	cg04362960	chr10:104952993	NT5C2	0.98	6.57	0.51	1.22e-9	Arsenic metabolism;
TGCT	cis	rs62244186	0.627	rs3935212	chr3:44460954	G/A	cg21672276	chr3:44754072	ZNF502	-0.41	-4.63	-0.38	9.16e-6	Depressive symptoms;
TGCT	cis	rs12971120	0.891	rs3794953	chr18:72180519	C/T	cg26446133	chr18:72167187	CNDP2	-0.35	-5.88	-0.47	3.53e-8	Refractive error;
TGCT	cis	rs10892173	0.678	rs7122817	chr11:117657679	A/G	cg21640587	chr11:117668038	DSCAML1	0.46	5.1	0.42	1.24e-6	Myopia;
TGCT	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.69	6.05	0.48	1.57e-8	Tonsillectomy;
TGCT	cis	rs2439831	0.867	rs6493082	chr15:43634808	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	6.61	0.51	1e-9	Lung cancer in ever smokers;
TGCT	cis	rs11779988	0.545	rs404186	chr8:17795496	A/G	cg01800426	chr8:17659068	MTUS1	-0.68	-5.41	-0.44	3.14e-7	Breast cancer;
TGCT	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg03517284	chr6:25882590	NA	-0.49	-5.07	-0.41	1.4e-6	Height;
TGCT	cis	rs644799	0.965	rs566877	chr11:95528045	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	8.74	0.62	1.39e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9467711	0.591	rs36109883	chr6:26133070	G/A	cg16898833	chr6:26189333	HIST1H4D	1.41	6.27	0.49	5.53e-9	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs3733585	0.699	rs10017674	chr4:9967053	T/C	cg00071950	chr4:10020882	SLC2A9	-0.57	-6.85	-0.52	3.12e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	trans	rs10174165	1.000	rs10174165	chr2:240441158	G/T	cg04124606	chr8:142095021	NA	0.89	7.06	0.54	1.04e-10	Diisocyanate-induced asthma;
TGCT	cis	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg02380750	chr20:61661411	NA	0.33	5.96	0.47	2.4e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs11098499	0.954	rs56270433	chr4:120406030	C/T	cg09307838	chr4:120376055	NA	0.69	6.64	0.51	8.97e-10	Corneal astigmatism;
TGCT	cis	rs6977660	0.714	rs10252597	chr7:19791171	G/T	cg07541023	chr7:19748670	TWISTNB	-0.85	-4.84	-0.4	3.74e-6	Thyroid stimulating hormone;
TGCT	cis	rs2180341	0.960	rs7766942	chr6:127691323	G/T	cg24812749	chr6:127587940	RNF146	0.92	7.43	0.55	1.55e-11	Breast cancer;
TGCT	cis	rs9902453	0.935	rs9905950	chr17:28431198	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	7.22	0.54	4.5e-11	Coffee consumption (cups per day);
TGCT	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg05368731	chr17:41323189	NBR1	0.91	7.27	0.55	3.51e-11	Menopause (age at onset);
TGCT	cis	rs7772486	0.875	rs6913797	chr6:146413758	A/G	cg05347473	chr6:146136440	FBXO30	0.55	5.14	0.42	1.05e-6	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs9990220	0.586	rs12106673	chr3:112061731	G/A	cg10677372	chr7:154003270	DPP6	-0.39	-6.72	-0.52	5.88e-10	Eosinophil percentage of white cells;
TGCT	cis	rs559928	0.606	rs11231726	chr11:63987339	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.74	4.46	0.37	1.78e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
TGCT	trans	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg23505145	chr19:12996616	KLF1	0.88	9.67	0.66	8.02e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2997447	0.761	rs79778025	chr1:26449337	A/G	cg03844060	chr1:26490628	NA	0.28	4.61	0.38	9.87e-6	QRS complex (12-leadsum);
TGCT	cis	rs6463523	0.864	rs73047957	chr7:759373	A/T	cg14391382	chr7:866102	UNC84A	0.2	4.58	0.38	1.13e-5	Subjective well-being;
TGCT	cis	rs5769765	0.817	rs8142561	chr22:50291750	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.39	5.91	0.47	3.12e-8	Schizophrenia;
TGCT	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg21862992	chr11:68658383	NA	0.46	6.52	0.51	1.62e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs17376456	0.542	rs6556833	chr5:93104707	T/C	cg25358565	chr5:93447407	FAM172A	0.62	5.89	0.47	3.43e-8	Diabetic retinopathy;
TGCT	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg12963246	chr6:28129442	ZNF389	0.51	5.02	0.41	1.73e-6	Depression;
TGCT	cis	rs7980687	0.657	rs10744151	chr12:123723735	G/C	cg00376283	chr12:123451042	ABCB9	0.79	6.66	0.51	7.81e-10	Height;Educational attainment;Head circumference (infant);
TGCT	cis	rs2742417	0.967	rs1609553	chr3:45735142	T/C	cg04837898	chr3:45731254	SACM1L	-0.55	-5.68	-0.45	9.14e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	trans	rs9388451	0.626	rs3734637	chr6:126081319	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.84	-9.81	-0.66	3.58e-17	Brugada syndrome;
TGCT	cis	rs477895	0.838	rs7111278	chr11:64016284	G/A	cg23719950	chr11:63933701	MACROD1	-0.69	-5.74	-0.46	6.94e-8	Mean platelet volume;
TGCT	cis	rs9467773	0.523	rs2498399	chr6:26706544	T/C	cg02458000	chr6:26745757	NA	0.71	6.65	0.51	8.18e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs6598955	0.671	rs11247908	chr1:26638222	G/A	cg04990556	chr1:26633338	UBXN11	0.67	5.44	0.44	2.77e-7	Obesity-related traits;
TGCT	cis	rs4919694	1.000	rs112240253	chr10:104753726	C/T	cg04362960	chr10:104952993	NT5C2	1.06	7.05	0.53	1.09e-10	Arsenic metabolism;
TGCT	cis	rs2637266	0.905	rs34173296	chr10:78343389	C/T	cg18941641	chr10:78392320	NA	0.42	5.45	0.44	2.62e-7	Pulmonary function;
TGCT	cis	rs1129187	0.935	rs9462859	chr6:42946943	G/A	cg13397359	chr6:42928475	GNMT	0.77	7.18	0.54	5.56e-11	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs36051895	0.659	rs7856912	chr9:5184449	G/A	cg02405213	chr9:5042618	JAK2	-0.71	-8.93	-0.63	4.79e-15	Pediatric autoimmune diseases;
TGCT	cis	rs9653442	0.545	rs2009095	chr2:100765081	C/T	cg22139774	chr2:100720529	AFF3	-0.37	-5.78	-0.46	5.57e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs10510102	0.688	rs76573813	chr10:123688470	G/T	cg23691251	chr10:123688108	ATE1	-0.58	-4.58	-0.38	1.11e-5	Breast cancer;
TGCT	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg12756686	chr19:29218302	NA	0.76	6.49	0.5	1.85e-9	Methadone dose in opioid dependence;
TGCT	trans	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg27523141	chr10:43048294	ZNF37B	0.73	8.39	0.6	9.23e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs11098499	0.644	rs17517414	chr4:120262101	G/C	cg09307838	chr4:120376055	NA	0.55	5.36	0.43	3.98e-7	Corneal astigmatism;
TGCT	cis	rs4653767	1.000	rs4653767	chr1:226916078	T/C	cg11238820	chr1:226410871	MIXL1	0.33	4.47	0.37	1.77e-5	Parkinson's disease;
TGCT	cis	rs12908161	0.920	rs35758837	chr15:85311382	C/T	cg12863693	chr15:85201151	NMB	0.43	5.12	0.42	1.15e-6	Schizophrenia;
TGCT	cis	rs344364	0.511	rs911391	chr16:1947016	C/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.45	-5.08	-0.42	1.35e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs9811920	0.638	rs7629426	chr3:99652577	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.6	6.92	0.53	2.1e-10	Axial length;
TGCT	cis	rs4972806	0.849	rs2113561	chr2:177030925	G/A	cg14324370	chr2:177042789	NA	0.73	6.72	0.52	5.79e-10	IgG glycosylation;
TGCT	cis	rs12579753	0.917	rs2401002	chr12:82215870	C/T	cg07988820	chr12:82153109	PPFIA2	-0.58	-6.06	-0.48	1.52e-8	Resting heart rate;
TGCT	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	5.53	0.44	1.8e-7	Alzheimer's disease;
TGCT	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg10047753	chr17:41438598	NA	0.94	9.23	0.64	9.06e-16	Menopause (age at onset);
TGCT	cis	rs3796352	1.000	rs11720191	chr3:53013839	T/C	cg15956490	chr3:53032818	SFMBT1	0.61	6.76	0.52	4.92e-10	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs8062405	0.965	rs62037363	chr16:28865042	T/C	cg09754948	chr16:28834200	ATXN2L	0.59	4.45	0.37	1.91e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg02487422	chr3:49467188	NICN1	0.5	4.75	0.39	5.41e-6	Menarche (age at onset);
TGCT	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg06028605	chr16:24865363	SLC5A11	0.42	4.63	0.38	9.1e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2073300	1.000	rs6137959	chr20:23442640	T/C	cg09953122	chr20:23471693	CST8	-0.64	-4.56	-0.38	1.19e-5	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg06873352	chr17:61820015	STRADA	0.56	6.22	0.49	6.93e-9	Prudent dietary pattern;
TGCT	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg16325326	chr1:53192061	ZYG11B	-0.85	-11.92	-0.73	2.7e-22	Monocyte count;
TGCT	cis	rs9409154	1.000	rs9409156	chr9:118209918	A/G	cg14094498	chr9:119000864	PAPPA	0.23	4.59	0.38	1.05e-5	Visceral adipose tissue adjusted for BMI;
TGCT	cis	rs514406	0.505	rs374662	chr1:53164549	C/A	cg22166914	chr1:53195759	ZYG11B	0.44	7.66	0.57	4.64e-12	Monocyte count;
TGCT	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.36	0.55	2.25e-11	Prudent dietary pattern;
TGCT	cis	rs9611565	0.512	rs132784	chr22:42052363	G/A	cg06481639	chr22:41940642	POLR3H	0.73	6.26	0.49	5.81e-9	Vitiligo;
TGCT	cis	rs8017423	0.935	rs4643251	chr14:90669256	C/T	cg04374321	chr14:90722782	PSMC1	-0.76	-7.76	-0.57	2.65e-12	Mortality in heart failure;
TGCT	cis	rs76419734	0.558	rs11721732	chr4:106521514	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.8	4.65	0.39	8.22e-6	Post bronchodilator FEV1;
TGCT	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg07747251	chr5:1868357	NA	0.38	5.55	0.45	1.63e-7	Cardiovascular disease risk factors;
TGCT	cis	rs1670533	0.932	rs4690214	chr4:1054636	T/C	cg27284194	chr4:1044797	NA	0.67	5.79	0.46	5.37e-8	Recombination rate (females);
TGCT	cis	rs3087591	0.887	rs12150521	chr17:29595108	C/T	cg24425628	chr17:29625626	OMG;NF1	0.49	7.36	0.55	2.24e-11	Hip circumference;
TGCT	cis	rs2836950	0.501	rs2836985	chr21:40701169	A/G	cg06238570	chr21:40685208	BRWD1	-0.64	-6.56	-0.51	1.34e-9	Menarche (age at onset);
TGCT	cis	rs7845219	0.544	rs7001535	chr8:95921090	C/G	cg13393036	chr8:95962371	TP53INP1	-0.44	-5.14	-0.42	1.05e-6	Type 2 diabetes;
TGCT	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg04267008	chr7:1944627	MAD1L1	-0.39	-5.2	-0.42	8.03e-7	Bipolar disorder and schizophrenia;
TGCT	trans	rs1496653	0.602	rs13084870	chr3:23605117	A/G	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg10802521	chr3:52805072	NEK4	-0.65	-7.65	-0.57	4.72e-12	Electroencephalogram traits;
TGCT	cis	rs782590	0.967	rs10496050	chr2:55806313	C/T	cg18811423	chr2:55921094	PNPT1	0.65	6.93	0.53	2.02e-10	Metabolic syndrome;
TGCT	cis	rs9640161	0.830	rs7800196	chr7:150061534	C/G	cg21361702	chr7:150065534	REPIN1	0.54	5.14	0.42	1.04e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs1865760	0.555	rs2051541	chr6:25945211	C/T	cg03517284	chr6:25882590	NA	0.45	4.68	0.39	7.25e-6	Height;
TGCT	trans	rs2243480	1.000	rs13237037	chr7:65997882	T/C	cg07424592	chr7:64974309	NA	1.3	8.23	0.59	2.19e-13	Diabetic kidney disease;
TGCT	cis	rs2180341	1.000	rs3798853	chr6:127636823	C/T	cg27446573	chr6:127587934	RNF146	-1.1	-9.66	-0.66	8.66e-17	Breast cancer;
TGCT	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg11062466	chr8:58055876	NA	0.37	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs892864	0.554	rs3909897	chr5:127675355	C/G	cg01939274	chr5:127874478	FBN2	-0.95	-4.53	-0.38	1.39e-5	Multiple system atrophy;
TGCT	cis	rs7432375	0.523	rs12486911	chr3:136558953	C/G	cg12473912	chr3:136751656	NA	0.33	4.62	0.38	9.59e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7944584	0.563	rs2280231	chr11:47600438	C/T	cg20307385	chr11:47447363	PSMC3	0.9	8.49	0.61	5.41e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
TGCT	cis	rs8177179	0.967	rs4994582	chr3:133437566	G/C	cg24879335	chr3:133465180	TF	0.35	4.73	0.39	5.96e-6	Iron status biomarkers (transferrin levels);
TGCT	cis	rs587847	0.597	rs4924162	chr15:37770365	A/G	cg00216138	chr15:37171175	LOC145845	0.31	4.55	0.38	1.26e-5	Intraocular pressure;
TGCT	cis	rs1570884	0.516	rs9316462	chr13:50176321	A/G	cg03651054	chr13:50194643	NA	0.33	5.28	0.43	5.66e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
TGCT	cis	rs9527	0.590	rs12355120	chr10:104852166	T/G	cg15744005	chr10:104629667	AS3MT	-0.44	-5.12	-0.42	1.11e-6	Arsenic metabolism;
TGCT	cis	rs12615966	1.000	rs17030284	chr2:105380921	A/G	cg16465502	chr2:105461796	NA	-0.77	-4.46	-0.37	1.83e-5	Pancreatic cancer;
TGCT	cis	rs1480597	0.518	rs10736830	chr10:45208165	G/C	cg12063947	chr10:45878068	ALOX5	0.26	4.44	0.37	2e-5	Parkinson's disease;
TGCT	cis	rs10114408	0.918	rs10992943	chr9:96640493	G/A	cg13679303	chr9:96623674	NA	-0.36	-4.69	-0.39	6.98e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs6570726	0.846	rs6570700	chr6:145931552	A/G	cg05347473	chr6:146136440	FBXO30	0.5	4.6	0.38	1.04e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3751972	0.590	rs12951895	chr17:26264497	C/G	cg02948944	chr17:26242737	NA	-0.46	-5.71	-0.46	7.8e-8	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs921968	0.643	rs545779	chr2:219336108	A/G	cg02176678	chr2:219576539	TTLL4	0.44	6.33	0.49	4.17e-9	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg20735989	chr4:730612	PCGF3	-0.25	-5.55	-0.45	1.65e-7	White blood cell count;
TGCT	cis	rs7666738	0.546	rs7699578	chr4:98838893	T/C	cg17366294	chr4:99064904	C4orf37	0.73	5.84	0.46	4.28e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1153858	1.000	rs12594857	chr15:45667178	A/G	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.62e-8	Homoarginine levels;
TGCT	cis	rs112217694	1.000	rs75885777	chr4:104643130	C/T	cg24090629	chr4:104641072	TACR3	-0.97	-4.81	-0.4	4.25e-6	Menarche (age at onset);
TGCT	cis	rs6088590	0.561	rs6087600	chr20:33157217	T/C	cg06115741	chr20:33292138	TP53INP2	0.51	4.47	0.37	1.76e-5	Coronary artery disease;
TGCT	cis	rs4478858	0.735	rs6685728	chr1:31802550	T/C	cg07478791	chr1:31886160	SERINC2	-0.51	-4.95	-0.41	2.33e-6	Alcohol dependence;
TGCT	cis	rs12765878	0.603	rs1570221	chr10:105656874	G/A	cg04788957	chr10:105438008	SH3PXD2A	0.29	4.44	0.37	2e-5	Coronary artery disease;
TGCT	cis	rs6089829	0.643	rs6011545	chr20:61660038	G/A	cg08564027	chr20:61660810	NA	0.29	4.57	0.38	1.17e-5	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs17767294	0.708	rs72849205	chr6:28171529	C/T	cg08851530	chr6:28072375	NA	1.47	6.82	0.52	3.64e-10	Parkinson's disease;
TGCT	cis	rs36051895	0.589	rs4560849	chr9:5203866	C/G	cg02405213	chr9:5042618	JAK2	-0.74	-9.28	-0.64	7.07e-16	Pediatric autoimmune diseases;
TGCT	cis	rs35306767	0.903	rs11253492	chr10:936873	T/C	cg26597838	chr10:835615	NA	0.75	10.54	0.69	6.3e-19	Eosinophil percentage of granulocytes;
TGCT	cis	rs6424115	0.708	rs12755062	chr1:24185025	T/A	cg15997130	chr1:24165203	NA	-0.68	-6.7	-0.52	6.51e-10	Immature fraction of reticulocytes;
TGCT	cis	rs4713118	0.591	rs2056924	chr6:27690174	G/A	cg10876282	chr6:28092338	ZSCAN16	0.5	5.07	0.41	1.41e-6	Parkinson's disease;
TGCT	cis	rs9303401	0.614	rs2333409	chr17:57139134	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.63	5.8	0.46	5.11e-8	Cognitive test performance;
TGCT	cis	rs832540	0.593	rs252912	chr5:56195792	C/T	cg12311346	chr5:56204834	C5orf35	-0.5	-4.79	-0.4	4.59e-6	Coronary artery disease;
TGCT	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg11644478	chr21:40555479	PSMG1	-0.53	-4.57	-0.38	1.17e-5	Cognitive function;
TGCT	cis	rs8051149	0.652	rs9926829	chr16:87883089	A/G	cg01412419	chr16:87856264	NA	-0.38	-4.62	-0.38	9.34e-6	Blood metabolite levels;
TGCT	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	8.92	0.62	5.22e-15	Platelet count;
TGCT	cis	rs7666738	0.830	rs10012167	chr4:99048579	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1034435	0.755	rs5768680	chr22:48892919	T/C	cg05992904	chr22:48892994	FAM19A5	-0.34	-4.65	-0.39	8.37e-6	Late-onset Alzheimer's disease;
TGCT	cis	rs2456568	0.867	rs7114457	chr11:93657817	C/T	cg17595323	chr11:93583763	C11orf90	-0.45	-5.74	-0.46	6.75e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs2688608	1.000	rs2688610	chr10:75654931	A/G	cg19442545	chr10:75533431	FUT11	0.31	4.97	0.41	2.17e-6	Inflammatory bowel disease;
TGCT	cis	rs79976124	0.877	rs79507557	chr6:66640908	C/A	cg07460842	chr6:66804631	NA	0.57	5.09	0.42	1.26e-6	Type 2 diabetes;
TGCT	cis	rs8180040	0.726	rs1869871	chr3:47023948	C/T	cg27129171	chr3:47204927	SETD2	0.72	9.15	0.63	1.44e-15	Colorectal cancer;
TGCT	cis	rs17331151	0.573	rs13080929	chr3:52885112	A/C	cg15956490	chr3:53032818	SFMBT1	0.45	5.39	0.44	3.43e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs55962025	0.883	rs61792530	chr4:3145866	T/C	cg06533319	chr4:3265114	C4orf44	0.22	4.5	0.37	1.54e-5	Parental longevity (mother's age at death);
TGCT	cis	rs11105298	0.891	rs10858896	chr12:89920184	C/T	cg00757033	chr12:89920650	WDR51B	0.32	5.13	0.42	1.11e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs4919694	1.000	rs17787717	chr10:104695699	T/G	cg04362960	chr10:104952993	NT5C2	1.06	7.07	0.54	9.73e-11	Arsenic metabolism;
TGCT	cis	rs2730260	0.537	rs73169233	chr7:158882201	C/T	cg09066883	chr7:157932951	PTPRN2	0.42	4.66	0.39	8.09e-6	Myopia (pathological);
TGCT	cis	rs9818758	0.607	rs4855860	chr3:49526044	A/T	cg00383909	chr3:49044727	WDR6	-1.47	-6.42	-0.5	2.57e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs655601	0.643	rs112702671	chr5:180220930	C/T	cg13724780	chr5:180237085	MGAT1	1.04	6.37	0.5	3.4e-9	Quantitative traits;
TGCT	cis	rs12615966	1.000	rs17030309	chr2:105391328	G/A	cg16465502	chr2:105461796	NA	0.79	5.07	0.41	1.42e-6	Pancreatic cancer;
TGCT	cis	rs11190604	0.767	rs74869390	chr10:102189385	A/G	cg16342193	chr10:102329863	NA	-0.4	-5.02	-0.41	1.74e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs3733631	1.000	rs10010631	chr4:104644543	A/G	cg24090629	chr4:104641072	TACR3	-0.77	-6.29	-0.49	4.9e-9	Menarche (age at onset);
TGCT	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.77	6.05	0.48	1.56e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6754311	0.510	rs1374329	chr2:136421323	A/G	cg07169764	chr2:136633963	MCM6	0.67	5.96	0.47	2.42e-8	Mosquito bite size;
TGCT	cis	rs11190604	0.767	rs11190533	chr10:102190792	T/C	cg23241863	chr10:102295624	HIF1AN	0.62	4.79	0.4	4.69e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs4689388	0.856	rs1046314	chr4:6303955	A/G	cg25554036	chr4:6271136	WFS1	-0.57	-8.07	-0.59	5.2e-13	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs9640161	0.830	rs35635199	chr7:150063342	C/T	cg10018233	chr7:150070692	REPIN1	0.31	4.63	0.38	9.16e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs11785400	1.000	rs9720653	chr8:143731939	T/G	cg10596483	chr8:143751796	JRK	0.54	5.77	0.46	5.95e-8	Schizophrenia;
TGCT	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg10295955	chr4:187884368	NA	-0.96	-13.89	-0.78	5e-27	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10791323	0.572	rs1114367	chr11:133737304	G/T	cg03690763	chr11:133734501	NA	-0.27	-4.53	-0.38	1.39e-5	Childhood ear infection;
TGCT	cis	rs12541335	0.536	rs4266653	chr8:22169087	A/G	cg09517075	chr8:22133004	PIWIL2	0.24	4.72	0.39	6.35e-6	Hypertriglyceridemia;
TGCT	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg13695892	chr22:41940480	POLR3H	-0.92	-9.32	-0.64	5.69e-16	Vitiligo;
TGCT	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg02725872	chr8:58115012	NA	-0.41	-5.38	-0.44	3.5e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7178572	0.568	rs4886856	chr15:77510585	A/G	cg15453836	chr15:77711506	NA	-0.43	-4.82	-0.4	4.12e-6	Type 2 diabetes;
TGCT	cis	rs7819412	0.512	rs1435282	chr8:11251705	G/A	cg21775007	chr8:11205619	TDH	-0.63	-6.66	-0.51	7.77e-10	Triglycerides;
TGCT	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg17054783	chr10:134559939	INPP5A	0.23	4.48	0.37	1.64e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs346785	0.692	rs2279054	chr17:74287594	G/A	cg09812376	chr17:74270190	QRICH2	-0.37	-5.54	-0.45	1.76e-7	White matter hyperintensities in ischemic stroke;
TGCT	cis	rs523522	0.924	rs11065150	chr12:120958875	T/G	cg27279351	chr12:120934652	DYNLL1	0.77	6.58	0.51	1.18e-9	High light scatter reticulocyte count;
TGCT	cis	rs2243480	1.000	rs462853	chr7:65558167	G/C	cg18252515	chr7:66147081	NA	-1.1	-7.18	-0.54	5.77e-11	Diabetic kidney disease;
TGCT	cis	rs1801251	1.000	rs13035829	chr2:233604487	A/T	cg25237894	chr2:233734115	C2orf82	0.31	5.62	0.45	1.21e-7	Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs13121766	chr4:98935766	A/C	cg17366294	chr4:99064904	C4orf37	0.72	7.39	0.55	1.87e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9611565	0.559	rs6002408	chr22:41967870	C/T	cg13695892	chr22:41940480	POLR3H	-0.86	-7.99	-0.58	8.13e-13	Vitiligo;
TGCT	cis	rs6582630	0.502	rs7311700	chr12:38463232	T/A	cg13010199	chr12:38710504	ALG10B	0.64	5.09	0.42	1.27e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs12477438	0.501	rs6542868	chr2:99782848	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	14.89	0.8	2.21e-29	Chronic sinus infection;
TGCT	cis	rs7178572	1.000	rs8024485	chr15:77718368	C/A	cg22256960	chr15:77711686	NA	-0.95	-10.93	-0.7	6.95e-20	Type 2 diabetes;
TGCT	cis	rs933688	1.000	rs11959525	chr5:90703840	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.04	9.08	0.63	2.08e-15	Smoking behavior;
TGCT	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg16405210	chr4:1374714	KIAA1530	-0.24	-4.47	-0.37	1.71e-5	Longevity;
TGCT	cis	rs7666738	0.830	rs35213297	chr4:98984049	T/C	cg05340658	chr4:99064831	C4orf37	0.5	5.84	0.46	4.35e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7095607	0.813	rs10823143	chr10:69924903	T/A	cg18986048	chr10:69913749	MYPN	0.48	5.51	0.44	2.03e-7	Lung function (FVC);
TGCT	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.6	0.51	1.05e-9	Bipolar disorder;
TGCT	cis	rs11105298	0.891	rs11105299	chr12:89877943	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.7	-5.02	-0.41	1.79e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs9902453	0.817	rs2628170	chr17:28056612	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-6.89	-0.53	2.55e-10	Coffee consumption (cups per day);
TGCT	cis	rs6540559	0.546	rs74991018	chr1:210033790	T/G	cg12034118	chr1:209979487	IRF6	0.65	4.56	0.38	1.2e-5	Cleft lip with or without cleft palate;
TGCT	cis	rs2535633	0.631	rs9823697	chr3:53002150	A/G	cg11645453	chr3:52864694	ITIH4	0.27	5.04	0.41	1.64e-6	Body mass index;
TGCT	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs36051895	0.632	rs12349918	chr9:5125250	A/G	cg02405213	chr9:5042618	JAK2	-0.71	-9.55	-0.65	1.57e-16	Pediatric autoimmune diseases;
TGCT	cis	rs36051895	0.664	rs3780372	chr9:5097544	C/T	cg02405213	chr9:5042618	JAK2	-0.76	-10.67	-0.69	3.05e-19	Pediatric autoimmune diseases;
TGCT	cis	rs62064224	0.791	rs17806082	chr17:30705346	G/C	cg18200150	chr17:30822561	MYO1D	0.58	7.69	0.57	3.92e-12	Schizophrenia;
TGCT	cis	rs2235642	1.000	rs2235642	chr16:1584866	T/C	cg07639376	chr16:1584516	IFT140;TMEM204	-0.32	-5.81	-0.46	5.02e-8	Coronary artery disease;
TGCT	cis	rs3772130	0.962	rs9822949	chr3:121541239	T/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.72	0.39	6.25e-6	Cognitive performance;
TGCT	cis	rs6450176	1.000	rs67473746	chr5:53296730	G/C	ch.5.1024479R	chr5:53302184	ARL15	-0.53	-5.12	-0.42	1.15e-6	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs6684514	1.000	rs12027103	chr1:156244856	G/A	cg20302342	chr1:156215951	PAQR6	0.34	4.6	0.38	1.01e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs3096299	0.900	rs2911258	chr16:89480760	A/G	cg02187348	chr16:89574699	SPG7	0.49	4.66	0.39	7.87e-6	Multiple myeloma (IgH translocation);
TGCT	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg05665937	chr4:1216051	CTBP1	0.22	4.47	0.37	1.75e-5	Obesity-related traits;
TGCT	cis	rs259282	0.605	rs3760937	chr19:33106893	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.56	5.12	0.42	1.11e-6	Schizophrenia;
TGCT	cis	rs1775715	0.737	rs2799000	chr10:32124894	C/T	cg14930904	chr10:32216787	ARHGAP12	0.53	5.11	0.42	1.16e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs9611565	0.918	rs9611562	chr22:41760172	T/G	cg03806693	chr22:41940476	POLR3H	-1.15	-13.26	-0.77	1.52e-25	Vitiligo;
TGCT	cis	rs12220898	0.749	rs7911514	chr10:50485523	T/G	cg09603381	chr10:49954066	WDFY4	0.38	4.45	0.37	1.88e-5	Inflammatory biomarkers;
TGCT	cis	rs4919044	0.808	rs55856996	chr10:94808618	T/G	cg05127821	chr10:94822908	CYP26C1	-0.74	-4.83	-0.4	3.95e-6	Coronary artery disease;
TGCT	cis	rs6964587	1.000	rs12333563	chr7:91667326	G/A	cg17063962	chr7:91808500	NA	0.88	9.65	0.66	8.73e-17	Breast cancer;
TGCT	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.66	0.39	8.18e-6	Prudent dietary pattern;
TGCT	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg21016266	chr12:122356598	WDR66	0.53	6.62	0.51	9.84e-10	Mean corpuscular volume;
TGCT	cis	rs6684514	0.922	rs12128785	chr1:156269389	A/G	cg16558208	chr1:156270281	VHLL	0.46	9.38	0.64	3.92e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs478304	0.903	rs546202	chr11:65510024	C/T	cg27068330	chr11:65405492	SIPA1	-0.74	-7.38	-0.55	1.95e-11	Acne (severe);
TGCT	cis	rs6570726	0.791	rs400329	chr6:145879442	A/T	cg05347473	chr6:146136440	FBXO30	0.54	5.15	0.42	1.01e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs36051895	0.664	rs3780369	chr9:5095095	A/C	cg02405213	chr9:5042618	JAK2	-0.72	-9.44	-0.65	2.89e-16	Pediatric autoimmune diseases;
TGCT	cis	rs60843830	1.000	rs7605824	chr2:280819	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	-0.73	-7.29	-0.55	3.18e-11	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs9993613	0.778	rs6821492	chr4:73421616	G/T	cg15102770	chr4:73434591	ADAMTS3	-0.5	-4.65	-0.39	8.51e-6	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs12615966	1.000	rs55805894	chr2:105380420	A/T	cg16465502	chr2:105461796	NA	0.78	5.03	0.41	1.66e-6	Pancreatic cancer;
TGCT	cis	rs3617	0.573	rs6795646	chr3:52922621	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.5	-4.73	-0.39	5.97e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	trans	rs7698623	0.850	rs4693896	chr4:88797897	T/C	cg01186725	chr1:53905612	FLJ40434	-0.48	-6.63	-0.51	9.21e-10	Cardiovascular disease risk factors;
TGCT	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg18876405	chr7:65276391	NA	-0.34	-5.09	-0.42	1.27e-6	Aortic root size;
TGCT	cis	rs7666738	0.830	rs13148363	chr4:98847498	T/C	cg05340658	chr4:99064831	C4orf37	0.52	6.02	0.48	1.79e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2404602	0.583	rs2139190	chr15:76555539	G/C	cg26408565	chr15:76604113	ETFA	-0.46	-6.46	-0.5	2.15e-9	Blood metabolite levels;
TGCT	cis	rs4891159	0.548	rs11150952	chr18:74128188	T/C	cg24786174	chr18:74118243	ZNF516	0.67	12.93	0.76	9.47e-25	Longevity;
TGCT	cis	rs4820539	1.000	rs13054985	chr22:23458577	G/A	cg21100191	chr22:23484243	RTDR1	0.9	10.7	0.69	2.52e-19	Bone mineral density;
TGCT	cis	rs13242816	1.000	rs17138708	chr7:116109062	T/G	cg02799643	chr7:116139180	CAV2	-0.48	-5.45	-0.44	2.56e-7	P wave duration;
TGCT	cis	rs7617773	0.780	rs13090538	chr3:48370769	A/C	cg11946769	chr3:48343235	NME6	0.79	7.02	0.53	1.29e-10	Coronary artery disease;
TGCT	cis	rs3540	0.574	rs8035980	chr15:90974390	C/G	cg22089800	chr15:90895588	ZNF774	0.73	7.79	0.57	2.34e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg27535305	chr1:53392650	SCP2	-0.28	-5.93	-0.47	2.85e-8	Monocyte count;
TGCT	trans	rs2070856	0.655	rs11699628	chr20:23703951	T/G	cg13434034	chr8:135477110	NA	0.78	6.65	0.51	8.27e-10	Blood protein levels;
TGCT	cis	rs75686122	0.892	rs4734076	chr8:104581641	A/G	cg04852977	chr8:104510831	NA	0.59	4.45	0.37	1.92e-5	Cocaine dependence;
TGCT	trans	rs7628219	0.607	rs10511008	chr3:70768256	A/T	cg21160944	chr7:157584549	PTPRN2	0.6	6.82	0.52	3.58e-10	Insomnia (caffeine-induced);
TGCT	cis	rs733175	0.857	rs751092	chr4:10005897	C/T	cg00071950	chr4:10020882	SLC2A9	0.55	4.45	0.37	1.85e-5	Psychosis and Alzheimer's disease;
TGCT	cis	rs6688613	0.685	rs6427047	chr1:166914258	A/G	cg07049167	chr1:166818506	POGK	0.24	5.03	0.41	1.71e-6	Refractive astigmatism;
TGCT	cis	rs9858542	0.953	rs6803222	chr3:49665976	T/G	cg03060546	chr3:49711283	APEH	-0.64	-5.7	-0.46	8.18e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs28595532	1.000	rs115965820	chr4:119586485	G/A	cg11846333	chr4:119757529	SEC24D	0.92	5.05	0.41	1.54e-6	Cannabis dependence symptom count;
TGCT	cis	rs9677476	1.000	rs6724253	chr2:232121998	A/G	cg07929768	chr2:232055508	NA	0.3	4.44	0.37	1.97e-5	Food antigen IgG levels;
TGCT	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg12963246	chr6:28129442	ZNF389	0.52	5.01	0.41	1.85e-6	Depression;
TGCT	cis	rs929354	0.629	rs6950739	chr7:156982450	T/C	cg05182265	chr7:156933206	UBE3C	-0.38	-8.2	-0.59	2.53e-13	Body mass index;
TGCT	cis	rs11190604	1.000	rs10883506	chr10:102289743	C/G	cg16342193	chr10:102329863	NA	-0.42	-5.37	-0.43	3.74e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg06112835	chr11:68658793	MRPL21	0.44	7.43	0.55	1.55e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	trans	rs17685	0.753	rs4732542	chr7:75663203	A/G	cg19862616	chr7:65841803	NCRNA00174	0.51	8.87	0.62	6.67e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs7829975	0.660	rs10093926	chr8:8549020	A/C	cg06636001	chr8:8085503	FLJ10661	-0.6	-5.02	-0.41	1.77e-6	Mood instability;
TGCT	cis	rs17206232	0.534	rs16893787	chr5:64689014	A/G	cg09571848	chr5:64330935	NA	-0.31	-4.59	-0.38	1.05e-5	Schizophrenia;
TGCT	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg13395646	chr4:1353034	KIAA1530	-0.36	-4.57	-0.38	1.17e-5	Obesity-related traits;
TGCT	cis	rs2302045	1.000	rs2074823	chr2:242051503	C/A	cg04553960	chr2:241721320	KIF1A	-0.7	-4.68	-0.39	7.4e-6	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio);
TGCT	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg03264133	chr6:25882463	NA	0.52	4.82	0.4	4.2e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7172809	0.523	rs76675107	chr15:77552944	T/C	cg22256960	chr15:77711686	NA	-0.48	-4.67	-0.39	7.76e-6	Glucose homeostasis traits;
TGCT	cis	rs259282	0.605	rs2302970	chr19:33098632	G/C	cg26639809	chr19:33781782	NA	0.24	4.74	0.39	5.77e-6	Schizophrenia;
TGCT	cis	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg18252515	chr7:66147081	NA	-1.22	-8.04	-0.59	6.02e-13	Diabetic kidney disease;
TGCT	cis	rs2301573	1.000	rs12635414	chr3:129312981	G/A	cg07730360	chr3:128845626	NA	0.5	5.81	0.46	5.04e-8	Hip circumference;
TGCT	cis	rs2439831	0.867	rs2927072	chr15:43922398	T/C	cg19166733	chr15:44192098	FRMD5	-0.24	-4.89	-0.4	3.08e-6	Lung cancer in ever smokers;
TGCT	cis	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg03213289	chr20:61660250	NA	0.68	9.99	0.67	1.36e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1395	1.000	rs1659695	chr2:27406944	T/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.5	-6.75	-0.52	5.06e-10	Blood metabolite levels;
TGCT	cis	rs3125734	0.633	rs1864836	chr10:64028538	C/G	cg05499367	chr10:63213510	TMEM26	-0.33	-4.47	-0.37	1.77e-5	Rheumatoid arthritis;
TGCT	cis	rs636291	0.510	rs1307487	chr1:10506667	G/A	cg17425144	chr1:10567563	PEX14	0.5	7.06	0.54	1.04e-10	Prostate cancer;
TGCT	cis	rs1997103	1.000	rs2177805	chr7:55404381	T/A	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs3772130	1.000	rs11721318	chr3:121429485	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.54	4.85	0.4	3.66e-6	Cognitive performance;
TGCT	cis	rs7208859	0.623	rs216436	chr17:28922900	G/A	cg13385521	chr17:29058706	SUZ12P	0.86	5.14	0.42	1.05e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs2070488	0.804	rs13092164	chr3:38458533	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	7.95	0.58	9.74e-13	Electrocardiographic conduction measures;
TGCT	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg11764359	chr7:65958608	NA	-0.56	-5.04	-0.41	1.61e-6	Aortic root size;
TGCT	cis	rs17428076	0.514	rs3821095	chr2:172684006	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.59	-4.66	-0.39	8.07e-6	Myopia;
TGCT	cis	rs6076065	0.748	rs2180139	chr20:23405281	G/A	cg11657817	chr20:23433608	CST11	0.3	5.13	0.42	1.07e-6	Facial morphology (factor 15, philtrum width);
TGCT	cis	rs9341808	0.628	rs1892475	chr6:80862213	T/C	cg08355045	chr6:80787529	NA	0.31	5.31	0.43	4.96e-7	Sitting height ratio;
TGCT	cis	rs4654899	0.931	rs4654887	chr1:21234923	A/G	cg01072550	chr1:21505969	NA	0.51	8.15	0.59	3.28e-13	Superior frontal gyrus grey matter volume;
TGCT	cis	rs12052801	0.648	rs6734622	chr2:68350891	A/G	cg00095431	chr2:67775781	NA	-0.32	-4.46	-0.37	1.83e-5	Schizophrenia;
TGCT	cis	rs2742417	0.603	rs2742455	chr3:45767116	A/G	cg04837898	chr3:45731254	SACM1L	-0.65	-6.95	-0.53	1.84e-10	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs9611519	0.780	rs2235850	chr22:41657626	C/T	cg13695892	chr22:41940480	POLR3H	-0.64	-6.05	-0.48	1.58e-8	Neuroticism;
TGCT	cis	rs2280018	0.581	rs7404524	chr16:15129158	A/G	cg07549590	chr16:15018862	NA	-0.31	-4.68	-0.39	7.42e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg00149659	chr3:10157352	C3orf10	0.73	4.72	0.39	6.17e-6	Alzheimer's disease;
TGCT	cis	rs62244186	0.593	rs9814298	chr3:44871899	T/A	cg10108389	chr3:44770937	ZNF501	-0.48	-4.74	-0.39	5.68e-6	Depressive symptoms;
TGCT	cis	rs4889855	0.614	rs9898443	chr17:78469357	C/T	cg16591659	chr17:78472290	NA	0.36	5.66	0.45	1.01e-7	Fractional excretion of uric acid;
TGCT	cis	rs10493773	1.000	rs10493774	chr1:86137963	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.36	-4.58	-0.38	1.11e-5	Urate levels in overweight individuals;
TGCT	cis	rs1062177	1.000	rs12515762	chr5:151209922	G/T	cg00977110	chr5:151150581	G3BP1	0.4	4.52	0.38	1.4e-5	Preschool internalizing problems;
TGCT	cis	rs546131	0.928	rs558967	chr11:34827168	T/A	cg11058730	chr11:34937778	PDHX;APIP	0.54	4.78	0.39	4.93e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs1670533	1.000	rs6852558	chr4:1059944	C/T	cg27284194	chr4:1044797	NA	0.69	5.96	0.47	2.44e-8	Recombination rate (females);
TGCT	cis	rs17152411	1.000	rs61873263	chr10:126589202	G/A	cg07906193	chr10:126599966	NA	0.41	5.05	0.41	1.52e-6	Height;
TGCT	cis	rs76419734	0.702	rs72673888	chr4:106808181	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	1.01	4.61	0.38	9.71e-6	Post bronchodilator FEV1;
TGCT	cis	rs7666738	0.830	rs28852677	chr4:99039509	T/G	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.52	5.73	0.46	7.21e-8	Lymphocyte counts;
TGCT	cis	rs8032315	1.000	rs6227	chr15:91425232	C/T	cg05211768	chr15:91427848	FES	0.47	4.52	0.38	1.44e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4788570	0.584	rs8051968	chr16:71761978	C/A	cg06353428	chr16:71660113	MARVELD3	1.42	11.93	0.73	2.54e-22	Intelligence (multi-trait analysis);
TGCT	cis	rs9993613	0.808	rs12645174	chr4:73431464	C/T	cg15102770	chr4:73434591	ADAMTS3	0.51	4.57	0.38	1.16e-5	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs793571	0.614	rs347117	chr15:59000957	C/T	cg05156742	chr15:59063176	FAM63B	0.47	4.45	0.37	1.86e-5	Schizophrenia;
TGCT	cis	rs116095464	0.510	rs73016876	chr5:244475	T/C	cg22857025	chr5:266934	NA	-0.34	-6.72	-0.52	5.92e-10	Breast cancer;
TGCT	cis	rs7119	0.651	rs12904208	chr15:77845911	C/T	cg27398640	chr15:77910606	LINGO1	-0.28	-5.11	-0.42	1.21e-6	Type 2 diabetes;
TGCT	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg12310025	chr6:25882481	NA	-0.55	-5.58	-0.45	1.41e-7	Blood metabolite levels;
TGCT	cis	rs9560113	1.000	rs9555804	chr13:112179751	T/C	cg14154082	chr13:112174009	NA	0.37	5.07	0.41	1.42e-6	Menarche (age at onset);
TGCT	cis	rs17767294	0.708	rs78094982	chr6:27968350	G/A	cg08851530	chr6:28072375	NA	1.56	7.22	0.54	4.47e-11	Parkinson's disease;
TGCT	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9467773	0.620	rs2451737	chr6:26619041	T/C	cg26531700	chr6:26746687	NA	0.52	5.01	0.41	1.8e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs3806843	0.576	rs246028	chr5:140333513	C/T	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9653442	0.564	rs7601892	chr2:100789490	G/A	cg22139774	chr2:100720529	AFF3	-0.35	-5.55	-0.45	1.63e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs7524258	0.903	rs4908608	chr1:7292772	T/C	cg04342483	chr1:7259290	CAMTA1	-0.31	-4.56	-0.38	1.21e-5	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs9650657	0.769	rs2116094	chr8:10598822	C/T	cg27411982	chr8:10470053	RP1L1	-0.22	-4.79	-0.4	4.6e-6	Neuroticism;
TGCT	cis	rs3806843	0.518	rs2569191	chr5:140013903	C/T	cg19875535	chr5:140030758	IK	-0.32	-5.19	-0.42	8.17e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg12963246	chr6:28129442	ZNF389	0.51	5.02	0.41	1.73e-6	Depression;
TGCT	cis	rs669446	0.561	rs585652	chr1:44099910	T/C	cg12908607	chr1:44402522	ARTN	-0.54	-5.68	-0.45	8.9e-8	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs1691799	0.899	rs1168302	chr12:66737518	C/T	cg16791601	chr12:66731901	HELB	-0.29	-6.38	-0.5	3.25e-9	White blood cell count (basophil);
TGCT	cis	rs67072384	1.000	rs12272109	chr11:72453850	G/A	cg03713592	chr11:72463424	ARAP1	-0.93	-4.66	-0.39	7.89e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs854765	0.522	rs63721860	chr17:17829576	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	7.6	0.56	6.32e-12	Total body bone mineral density;
TGCT	cis	rs6460942	0.915	rs17444044	chr7:12458736	A/G	cg06484146	chr7:12443880	VWDE	-0.57	-5.52	-0.44	1.92e-7	Coronary artery disease;
TGCT	cis	rs7412746	0.611	rs11204726	chr1:150743492	T/C	cg04414720	chr1:150670196	GOLPH3L	0.38	4.73	0.39	6.04e-6	Melanoma;
TGCT	cis	rs903263	0.601	rs10493750	chr1:84562265	C/T	cg09664975	chr1:84543551	PRKACB	-0.5	-4.86	-0.4	3.47e-6	Breast cancer (male);
TGCT	cis	rs734999	0.588	rs2260976	chr1:2527678	A/G	cg18854424	chr1:2615690	NA	-0.46	-5.23	-0.43	6.92e-7	Ulcerative colitis;
TGCT	cis	rs7833790	0.724	rs4739627	chr8:82734657	A/G	cg17211192	chr8:82754475	SNX16	-0.95	-8.83	-0.62	8.45e-15	Diastolic blood pressure;
TGCT	cis	rs7208859	0.673	rs11649765	chr17:29233888	T/A	cg14008862	chr17:28927542	LRRC37B2	0.72	4.66	0.39	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs6964587	1.000	rs2282971	chr7:91584356	A/G	cg22709100	chr7:91322751	NA	0.27	4.5	0.37	1.53e-5	Breast cancer;
TGCT	cis	rs933688	1.000	rs10474353	chr5:90732285	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.97	8.61	0.61	2.82e-14	Smoking behavior;
TGCT	cis	rs34779708	0.931	rs4007289	chr10:35269790	G/A	cg04310649	chr10:35416472	CREM	-0.51	-4.49	-0.37	1.6e-5	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs7917772	0.582	rs10786682	chr10:104318322	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.59	-5.73	-0.46	7.1e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9915657	0.595	rs10438697	chr17:70055734	A/G	cg06234051	chr17:70120541	SOX9	0.23	5.07	0.41	1.41e-6	Thyroid hormone levels;
TGCT	cis	rs6500602	0.627	rs863501	chr16:4588394	G/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	-0.36	-5.23	-0.43	6.95e-7	Schizophrenia;
TGCT	cis	rs694739	0.687	rs11231771	chr11:64140642	T/G	cg23796481	chr11:64053134	BAD;GPR137	0.63	6.54	0.51	1.44e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs478304	0.934	rs610037	chr11:65546857	A/C	cg17480646	chr11:65405466	SIPA1	0.4	4.95	0.41	2.42e-6	Acne (severe);
TGCT	cis	rs1865760	0.566	rs3752419	chr6:26027433	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.76	7.33	0.55	2.58e-11	Height;
TGCT	cis	rs892864	0.685	rs10063393	chr5:127745955	A/T	cg01939274	chr5:127874478	FBN2	0.91	4.52	0.38	1.44e-5	Multiple system atrophy;
TGCT	cis	rs67133203	0.632	rs829022	chr12:51374748	G/T	cg01517968	chr12:52348879	ACVR1B	-0.35	-4.52	-0.38	1.44e-5	Urinary tract infection frequency;
TGCT	cis	rs6912958	0.500	rs9342104	chr6:87798512	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.37	-4.54	-0.38	1.33e-5	Monocyte percentage of white cells;
TGCT	cis	rs6840360	0.638	rs6816002	chr4:152589439	C/T	cg22705602	chr4:152727874	NA	-0.32	-5.45	-0.44	2.64e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2180341	0.920	rs6906717	chr6:127596782	C/A	cg27446573	chr6:127587934	RNF146	1.13	10.12	0.67	6.64e-18	Breast cancer;
TGCT	cis	rs12449000	1	rs12449000	chr16:89872970	T/C	cg26513180	chr16:89883248	FANCA	1.05	13.4	0.77	7.36e-26	Schizophrenia;
TGCT	cis	rs7412746	0.634	rs12562939	chr1:150951452	A/C	cg04414720	chr1:150670196	GOLPH3L	0.39	4.68	0.39	7.48e-6	Melanoma;
TGCT	cis	rs2842992	0.747	rs9365095	chr6:160192928	T/G	cg11366901	chr6:160182831	ACAT2	1.03	6.92	0.53	2.14e-10	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs6061231	0.631	rs2427317	chr20:60975725	C/T	cg15674680	chr20:60982522	CABLES2	0.57	5.01	0.41	1.86e-6	Colorectal cancer;
TGCT	cis	rs6674176	0.518	rs917294	chr1:44249485	A/G	cg12908607	chr1:44402522	ARTN	-0.64	-7.09	-0.54	8.92e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs9303401	0.659	rs12946852	chr17:57013337	G/C	cg25039879	chr17:56429692	SUPT4H1	0.52	4.57	0.38	1.15e-5	Cognitive test performance;
TGCT	cis	rs6088590	0.687	rs73106933	chr20:33287425	T/C	cg08999081	chr20:33150536	PIGU	0.27	5.04	0.41	1.61e-6	Coronary artery disease;
TGCT	cis	rs3782455	1.000	rs76258123	chr12:114402449	G/C	cg10631684	chr12:113795897	PLBD2	-0.7	-4.61	-0.38	1e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs3935685	0.874	rs4073356	chr15:78008430	C/T	cg25212270	chr15:78015279	NA	0.25	5.45	0.44	2.66e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs13102973	0.965	rs13106621	chr4:135854975	A/T	cg14419869	chr4:135874104	NA	0.23	4.58	0.38	1.12e-5	Subjective well-being;
TGCT	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg26119090	chr2:26468346	HADHA;HADHB	0.97	7.19	0.54	5.48e-11	Gut microbiome composition (summer);
TGCT	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg00684032	chr4:1343700	KIAA1530	0.22	4.83	0.4	3.99e-6	Obesity-related traits;
TGCT	cis	rs3905510	0.817	rs11750782	chr5:122976743	C/G	cg15125798	chr5:122621645	NA	0.56	5.0	0.41	1.91e-6	Total body bone mineral density;
TGCT	cis	rs7611238	0.560	rs7430205	chr3:195093242	A/T	cg27323046	chr3:195102265	ACAP2	0.39	5.09	0.42	1.29e-6	Body mass index;
TGCT	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.72	-6.52	-0.51	1.57e-9	Tonsillectomy;
TGCT	trans	rs6561151	0.718	rs11842000	chr13:44413467	T/C	cg12856521	chr11:46389249	DGKZ	0.78	7.24	0.55	4.17e-11	Crohn's disease;
TGCT	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg26516362	chr5:178986906	RUFY1	0.44	4.93	0.4	2.57e-6	Lung cancer;
TGCT	cis	rs4727443	0.736	rs4727444	chr7:99614851	T/A	cg13334819	chr7:99746414	C7orf59	0.56	4.71	0.39	6.63e-6	Interstitial lung disease;
TGCT	cis	rs2180341	0.814	rs6940933	chr6:127732740	C/G	cg24812749	chr6:127587940	RNF146	0.77	6.33	0.49	4.14e-9	Breast cancer;
TGCT	cis	rs1348850	0.537	rs3770010	chr2:178537796	T/C	cg22681709	chr2:178499509	PDE11A	-0.49	-6.15	-0.48	9.86e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	6.73	0.52	5.48e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs12711979	0.875	rs11686157	chr2:3855020	C/G	cg17052675	chr2:3827356	NA	-0.32	-5.82	-0.46	4.77e-8	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg10295955	chr4:187884368	NA	-1.02	-15.84	-0.82	1.42e-31	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg16423285	chr20:60520624	NA	-0.6	-6.41	-0.5	2.76e-9	Body mass index;
TGCT	cis	rs9467773	0.869	rs1796520	chr6:26410800	C/T	cg26531700	chr6:26746687	NA	-0.5	-4.81	-0.4	4.36e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs709400	0.628	rs11622356	chr14:103912195	C/T	cg26031613	chr14:104095156	KLC1	0.88	9.75	0.66	5.05e-17	Body mass index;
TGCT	cis	rs9926296	0.632	rs1800286	chr16:89869761	T/C	cg04287289	chr16:89883240	FANCA	0.75	7.35	0.55	2.38e-11	Vitiligo;
TGCT	cis	rs11785400	0.928	rs750529	chr8:143744877	G/C	cg24634471	chr8:143751801	JRK	0.57	6.12	0.48	1.11e-8	Schizophrenia;
TGCT	cis	rs1670533	1.000	rs10902752	chr4:1056199	C/T	cg27284194	chr4:1044797	NA	0.67	5.79	0.46	5.37e-8	Recombination rate (females);
TGCT	cis	rs7666738	0.830	rs6854994	chr4:98977624	C/G	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7043114	0.507	rs7856204	chr9:95173814	G/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.56	-5.61	-0.45	1.27e-7	Height;
TGCT	cis	rs3806843	0.547	rs246054	chr5:140326159	G/A	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs62244186	0.659	rs9850129	chr3:44532047	C/T	cg15687855	chr3:44754131	ZNF502	-0.43	-5.27	-0.43	5.98e-7	Depressive symptoms;
TGCT	cis	rs2153535	0.563	rs1737584	chr6:8536742	C/T	cg07606381	chr6:8435919	SLC35B3	0.55	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs7923609	0.967	rs10761751	chr10:65154885	A/G	cg08743896	chr10:65200160	JMJD1C	-0.34	-4.57	-0.38	1.15e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1061377	0.965	rs7690465	chr4:39148635	G/T	cg24403649	chr4:39172243	NA	0.2	4.55	0.38	1.26e-5	Uric acid levels;
TGCT	cis	rs826838	1.000	rs11168367	chr12:38913397	T/G	cg26384229	chr12:38710491	ALG10B	1.01	9.79	0.66	4.11e-17	Heart rate;
TGCT	cis	rs2295359	1.000	rs11465753	chr1:67631423	T/C	cg12940439	chr1:67600707	NA	0.54	5.62	0.45	1.22e-7	Psoriasis;
TGCT	cis	rs3091242	0.933	rs28633797	chr1:25741629	C/A	cg10117171	chr1:25599238	RHD	-0.35	-5.73	-0.46	7.34e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs6882046	0.513	rs34320	chr5:88021527	T/G	cg24804195	chr5:87968844	LOC645323	-0.57	-5.57	-0.45	1.5e-7	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs78487399	0.808	rs6708735	chr2:43731354	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-4.82	-0.4	4.03e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs11247915	0.600	rs11247917	chr1:26655507	G/T	cg25392287	chr1:26333318	NA	0.22	4.54	0.38	1.34e-5	Obesity-related traits;
TGCT	cis	rs68170813	0.559	rs58319984	chr7:106965794	G/A	cg02696742	chr7:106810147	HBP1	-0.68	-5.64	-0.45	1.09e-7	Coronary artery disease;
TGCT	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	0.49	6.43	0.5	2.46e-9	Lymphocyte counts;
TGCT	cis	rs2749592	0.611	rs2505199	chr10:38392457	G/A	cg25427524	chr10:38739819	LOC399744	-0.4	-6.97	-0.53	1.62e-10	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs12216125	0.549	rs9358905	chr6:26077839	T/A	cg17042849	chr6:26104293	HIST1H4C	-0.66	-5.82	-0.46	4.73e-8	Iron status biomarkers;
TGCT	trans	rs7698623	0.850	rs6532021	chr4:88769661	C/G	cg01186725	chr1:53905612	FLJ40434	-0.48	-6.63	-0.51	9.21e-10	Cardiovascular disease risk factors;
TGCT	cis	rs10540	0.686	rs12421266	chr11:537120	C/T	cg03934478	chr11:495069	RNH1	0.32	4.55	0.38	1.28e-5	Body mass index;
TGCT	cis	rs17761864	0.919	rs12452089	chr17:2135002	A/T	cg02171503	chr17:1588363	PRPF8	-0.49	-4.86	-0.4	3.45e-6	Esophageal cancer (squamous cell);
TGCT	cis	rs763014	0.898	rs8050792	chr16:656033	T/C	cg07343612	chr16:622815	PIGQ	-0.42	-8.44	-0.6	7.14e-14	Height;
TGCT	cis	rs13188771	0.527	rs365366	chr5:100877873	A/T	cg10455971	chr5:101119566	NA	0.44	4.44	0.37	1.95e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs939658	0.805	rs11631590	chr15:79446199	C/T	cg17916960	chr15:79447300	NA	-0.51	-7.75	-0.57	2.89e-12	Refractive error;
TGCT	cis	rs6570726	0.791	rs9373463	chr6:145894762	C/T	cg05347473	chr6:146136440	FBXO30	0.52	4.95	0.41	2.33e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7617773	0.817	rs6794644	chr3:48330037	T/C	cg11946769	chr3:48343235	NME6	0.74	6.34	0.49	3.97e-9	Coronary artery disease;
TGCT	cis	rs116095464	0.558	rs62346506	chr5:201594	T/C	cg22857025	chr5:266934	NA	-0.35	-6.52	-0.51	1.63e-9	Breast cancer;
TGCT	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.54	4.95	0.41	2.35e-6	Prudent dietary pattern;
TGCT	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg04414720	chr1:150670196	GOLPH3L	0.39	5.04	0.41	1.59e-6	Tonsillectomy;
TGCT	cis	rs3733585	0.605	rs4235354	chr4:10122942	C/A	cg00071950	chr4:10020882	SLC2A9	-0.51	-5.29	-0.43	5.33e-7	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg24250549	chr1:154909240	PMVK	0.63	6.25	0.49	5.94e-9	Prostate cancer;
TGCT	cis	rs6665290	0.904	rs1045285	chr1:227179054	G/A	cg10327440	chr1:227177885	CDC42BPA	-0.98	-19.72	-0.87	4.93e-40	Myeloid white cell count;
TGCT	cis	rs11122272	0.735	rs2491412	chr1:231535880	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-6.18	-0.49	8.48e-9	Hemoglobin concentration;
TGCT	cis	rs250677	0.687	rs185155	chr5:148455893	T/C	cg23229984	chr5:148520753	ABLIM3	0.21	4.89	0.4	3.11e-6	Breast cancer;
TGCT	cis	rs7666738	0.830	rs10516426	chr4:99035827	A/G	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6674970	1.000	rs6676190	chr1:151079317	C/T	cg00003202	chr1:151319512	RFX5	-0.51	-4.46	-0.37	1.84e-5	Childhood ear infection;
TGCT	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg24675658	chr1:53192096	ZYG11B	-0.71	-7.87	-0.58	1.5e-12	Monocyte count;
TGCT	cis	rs2688608	0.592	rs12253482	chr10:75496130	G/A	cg23231163	chr10:75533350	FUT11	-0.28	-4.79	-0.4	4.71e-6	Inflammatory bowel disease;
TGCT	cis	rs1461503	0.932	rs56778812	chr11:122840491	C/T	cg27398637	chr11:122830231	C11orf63	-0.42	-5.25	-0.43	6.42e-7	Menarche (age at onset);
TGCT	cis	rs12048904	0.619	rs10783153	chr1:101328230	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.91	8.36	0.6	1.07e-13	Multiple sclerosis;
TGCT	cis	rs7617773	0.780	rs7653336	chr3:48369464	T/A	cg11946769	chr3:48343235	NME6	0.8	6.91	0.53	2.26e-10	Coronary artery disease;
TGCT	cis	rs12477438	1.000	rs57846982	chr2:99921574	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.98	-8.47	-0.61	6.09e-14	Chronic sinus infection;
TGCT	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg09359103	chr1:154839909	KCNN3	-0.64	-11.6	-0.72	1.58e-21	Prostate cancer;
TGCT	cis	rs2637266	1.000	rs7896379	chr10:78366247	C/T	cg18941641	chr10:78392320	NA	0.39	4.88	0.4	3.24e-6	Pulmonary function;
TGCT	cis	rs6582630	0.504	rs4882367	chr12:38330878	A/T	cg26384229	chr12:38710491	ALG10B	-0.52	-4.51	-0.38	1.5e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs7772486	0.754	rs1415747	chr6:146077249	A/G	cg05347473	chr6:146136440	FBXO30	0.53	4.95	0.41	2.41e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs28595532	0.920	rs56364904	chr4:119742504	T/C	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs10992471	0.756	rs10123342	chr9:95087824	T/G	cg14631576	chr9:95140430	CENPP	-0.29	-4.69	-0.39	6.98e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs7267979	1.000	rs2482931	chr20:25334445	G/A	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.43	6.25	0.49	6.11e-9	Schizophrenia;
TGCT	cis	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg20637647	chr7:64974828	NA	0.93	5.2	0.42	8.11e-7	Diabetic kidney disease;
TGCT	cis	rs4319547	1.000	rs6489156	chr12:123100397	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.69	-5.44	-0.44	2.68e-7	Body mass index;
TGCT	cis	rs1008375	0.574	rs7670135	chr4:17566221	G/T	cg16339924	chr4:17578868	LAP3	0.6	5.0	0.41	1.87e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg12923728	chr3:195709715	SDHAP1	-0.37	-7.53	-0.56	8.92e-12	Pancreatic cancer;
TGCT	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg07061783	chr6:25882402	NA	-0.45	-4.82	-0.4	4.15e-6	Blood metabolite levels;
TGCT	cis	rs1670533	1.000	rs652063	chr4:1084137	T/C	cg20887711	chr4:1340912	KIAA1530	0.66	5.33	0.43	4.49e-7	Recombination rate (females);
TGCT	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.53	-4.92	-0.4	2.7e-6	Prudent dietary pattern;
TGCT	trans	rs1814175	0.817	rs4881658	chr11:49941123	G/A	cg15704280	chr7:45808275	SEPT13	-0.7	-7.78	-0.57	2.45e-12	Height;
TGCT	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.58	-5.58	-0.45	1.47e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg06636001	chr8:8085503	FLJ10661	-0.77	-7.05	-0.53	1.09e-10	Joint mobility (Beighton score);
TGCT	cis	rs1475911	0.744	rs12481958	chr21:43517269	A/G	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.25	-5.42	-0.44	2.94e-7	IgG glycosylation;
TGCT	cis	rs7714584	1.000	rs79442859	chr5:150171210	T/C	cg22134413	chr5:150180641	NA	1.11	7.3	0.55	3.05e-11	Crohn's disease;
TGCT	cis	rs1403694	0.695	rs5029975	chr3:186436918	A/G	cg12454167	chr3:186435060	KNG1	-0.51	-8.72	-0.62	1.49e-14	Blood protein levels;
TGCT	cis	rs17401966	0.931	rs2185252	chr1:10415912	T/C	cg19773385	chr1:10388646	KIF1B	-0.24	-5.5	-0.44	2.03e-7	Hepatocellular carcinoma;
TGCT	cis	rs6964587	0.758	rs7798233	chr7:91500083	G/A	cg17063962	chr7:91808500	NA	-0.83	-6.71	-0.52	6.27e-10	Breast cancer;
TGCT	cis	rs2535633	0.631	rs2336670	chr3:52998504	T/G	cg11645453	chr3:52864694	ITIH4	-0.28	-4.94	-0.41	2.44e-6	Body mass index;
TGCT	cis	rs4891159	0.790	rs683306	chr18:74112473	C/G	cg24786174	chr18:74118243	ZNF516	-0.64	-10.12	-0.67	6.55e-18	Longevity;
TGCT	cis	rs2204008	0.749	rs4579984	chr12:38166266	A/G	cg13010199	chr12:38710504	ALG10B	0.6	4.8	0.4	4.57e-6	Bladder cancer;
TGCT	cis	rs7833790	0.700	rs28390260	chr8:82769175	A/T	cg27398817	chr8:82754497	SNX16	0.69	5.52	0.44	1.9e-7	Diastolic blood pressure;
TGCT	cis	rs8180040	0.932	rs12489046	chr3:47527683	T/G	cg27129171	chr3:47204927	SETD2	0.66	8.01	0.58	7.07e-13	Colorectal cancer;
TGCT	cis	rs4653767	1.000	rs10916030	chr1:226919908	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.47	-5.26	-0.43	6.06e-7	Parkinson's disease;
TGCT	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg04546413	chr19:29218101	NA	0.84	6.82	0.52	3.52e-10	Methadone dose in opioid dependence;
TGCT	cis	rs9467773	1.000	rs9461259	chr6:26504835	C/A	cg15659132	chr6:26577336	NA	0.86	12.18	0.74	6.14e-23	Intelligence (multi-trait analysis);
TGCT	trans	rs208520	0.526	rs9363522	chr6:66816642	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-16.44	-0.83	5.98e-33	Exhaled nitric oxide output;
TGCT	cis	rs9436747	0.667	rs7413823	chr1:66023716	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	-0.56	-5.24	-0.43	6.6e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs7666738	0.830	rs17027102	chr4:98919221	A/G	cg17366294	chr4:99064904	C4orf37	-0.72	-7.32	-0.55	2.7e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11105298	0.891	rs12369685	chr12:89928905	A/G	cg00757033	chr12:89920650	WDR51B	0.29	4.46	0.37	1.78e-5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg24503407	chr1:205819492	PM20D1	0.61	8.72	0.62	1.52e-14	Menarche (age at onset);
TGCT	cis	rs7178572	1.000	rs952471	chr15:77776498	C/G	cg22256960	chr15:77711686	NA	-0.95	-10.89	-0.7	8.57e-20	Type 2 diabetes;
TGCT	cis	rs753778	0.628	rs11579	chr8:142205132	G/A	cg18755752	chr8:142205143	DENND3	-0.28	-5.08	-0.41	1.36e-6	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs5751150	1	rs5751150	chr22:42153292	T/G	cg03806693	chr22:41940476	POLR3H	1.04	10.57	0.69	5.2e-19	Cannabis dependence symptom count;
TGCT	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg26338869	chr17:61819248	STRADA	-0.55	-5.08	-0.41	1.37e-6	Prudent dietary pattern;
TGCT	cis	rs367615	0.513	rs11741087	chr5:108807760	G/A	cg17395555	chr5:108820864	NA	0.3	5.68	0.45	9.17e-8	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs1395	0.744	rs11126931	chr2:27474306	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.62	7.72	0.57	3.38e-12	Blood metabolite levels;
TGCT	cis	rs11578119	0.866	rs4623763	chr1:170349715	G/A	cg09767346	chr1:170501363	GORAB	0.61	4.57	0.38	1.16e-5	Male-pattern baldness;
TGCT	trans	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-1.03	-13.16	-0.76	2.65e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs12286929	0.687	rs6589485	chr11:115083875	G/A	cg04017736	chr11:115827165	NA	0.19	4.63	0.38	9.21e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs2115630	0.764	rs11073716	chr15:85335774	C/T	cg11189052	chr15:85197271	WDR73	-0.58	-4.94	-0.41	2.45e-6	P wave terminal force;
TGCT	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg03388025	chr16:89894329	SPIRE2	0.44	7.08	0.54	9.32e-11	Vitiligo;
TGCT	cis	rs9549367	0.664	rs3794419	chr13:113851874	T/C	cg18105134	chr13:113819100	PROZ	-0.45	-7.84	-0.58	1.81e-12	Platelet distribution width;
TGCT	cis	rs4722585	0.533	rs2158359	chr7:26193309	A/C	cg07876897	chr7:26191696	NFE2L3	-0.41	-5.81	-0.46	4.96e-8	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
TGCT	cis	rs422249	0.512	rs174576	chr11:61603510	C/A	cg19610905	chr11:61596333	FADS2	-0.96	-9.66	-0.66	8.51e-17	Trans fatty acid levels;
TGCT	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg23131131	chr22:24373011	LOC391322	-0.81	-8.78	-0.62	1.12e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs739496	0.579	rs7973309	chr12:112382251	T/C	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs10791097	0.592	rs7116068	chr11:130732739	A/C	cg12179176	chr11:130786555	SNX19	-0.82	-10.21	-0.68	3.97e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs936229	0.813	rs8033381	chr15:75080685	G/A	cg10253484	chr15:75165896	SCAMP2	-0.67	-5.38	-0.43	3.64e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
TGCT	cis	rs2455799	0.613	rs2470537	chr3:15716898	C/T	cg16303742	chr3:15540471	COLQ	-0.24	-4.56	-0.38	1.2e-5	Mean platelet volume;
TGCT	cis	rs7412746	0.658	rs6669855	chr1:150861229	C/T	cg04414720	chr1:150670196	GOLPH3L	0.4	4.87	0.4	3.35e-6	Melanoma;
TGCT	cis	rs1048238	0.605	rs1889785	chr1:16348729	G/A	cg22431228	chr1:16359049	CLCNKA	-0.31	-6.72	-0.52	5.96e-10	Systolic blood pressure;
TGCT	cis	rs61990749	0.544	rs12435761	chr14:78246077	C/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.61	4.52	0.38	1.43e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.55	4.92	0.4	2.74e-6	Prudent dietary pattern;
TGCT	cis	rs909674	0.734	rs5757675	chr22:39838892	G/T	cg01416388	chr22:39784598	NA	-0.73	-6.89	-0.53	2.45e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs4499344	0.768	rs10411319	chr19:33102805	C/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.81	8.62	0.61	2.57e-14	Mean platelet volume;
TGCT	cis	rs1355223	0.583	rs2941044	chr11:34867444	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.75	8.24	0.59	2.05e-13	Systemic lupus erythematosus and Systemic sclerosis;
TGCT	cis	rs892961	0.932	rs11650011	chr17:75412334	A/G	cg05865280	chr17:75406074	SEPT9	0.28	6.71	0.52	6.35e-10	Airflow obstruction;
TGCT	cis	rs3540	0.553	rs2158406	chr15:90994499	T/C	cg22089800	chr15:90895588	ZNF774	0.76	8.12	0.59	3.92e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs7726839	0.540	rs58599998	chr5:596087	A/G	cg09021430	chr5:549028	NA	-0.43	-5.77	-0.46	5.99e-8	Obesity-related traits;
TGCT	cis	rs28595532	0.841	rs115080469	chr4:119720501	C/T	cg14228332	chr4:119757509	SEC24D	1.3	6.62	0.51	9.91e-10	Cannabis dependence symptom count;
TGCT	cis	rs1461503	0.900	rs1057704	chr11:122830274	T/C	cg27398637	chr11:122830231	C11orf63	-0.41	-4.77	-0.39	5.14e-6	Menarche (age at onset);
TGCT	cis	rs9913156	0.793	rs11568061	chr17:4546445	G/A	cg19197139	chr17:4613644	ARRB2	0.85	7.91	0.58	1.19e-12	Lymphocyte counts;
TGCT	cis	rs9443645	0.869	rs9443626	chr6:79629564	G/C	cg05283184	chr6:79620031	NA	-0.21	-4.71	-0.39	6.61e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg20607798	chr8:58055168	NA	0.49	4.52	0.38	1.43e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg05368731	chr17:41323189	NBR1	1.1	11.12	0.71	2.38e-20	Menopause (age at onset);
TGCT	cis	rs2486288	0.656	rs12908818	chr15:45571668	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.78	-7.68	-0.57	4.17e-12	Glomerular filtration rate;
TGCT	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.84	7.48	0.56	1.19e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs10875746	0.903	rs989144	chr12:48483973	T/C	cg20731937	chr12:48336164	NA	0.62	4.95	0.41	2.36e-6	Longevity (90 years and older);
TGCT	cis	rs17102423	0.623	rs12100752	chr14:65611546	G/C	cg11161011	chr14:65562177	MAX	-0.4	-5.52	-0.44	1.89e-7	Obesity-related traits;
TGCT	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg25036284	chr2:26402008	FAM59B	-0.61	-4.9	-0.4	2.92e-6	Gut microbiome composition (summer);
TGCT	cis	rs9534288	0.830	rs2897027	chr13:46636235	A/G	cg15192986	chr13:46630673	CPB2	-0.52	-6.41	-0.5	2.82e-9	Blood protein levels;
TGCT	cis	rs10504229	0.861	rs57314710	chr8:58196051	T/C	cg08280861	chr8:58055591	NA	0.36	4.61	0.38	9.98e-6	Developmental language disorder (linguistic errors);
TGCT	trans	rs10953454	1.000	rs10272668	chr7:104494565	A/C	cg04208666	chr6:19734707	NA	-0.57	-6.89	-0.53	2.52e-10	Obesity;
TGCT	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.61	5.06	0.41	1.5e-6	Tonsillectomy;
TGCT	cis	rs12477438	0.501	rs11123770	chr2:99825102	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.68	6.37	0.5	3.39e-9	Chronic sinus infection;
TGCT	cis	rs3796619	1.000	rs1453605	chr4:1075771	C/T	cg27284194	chr4:1044797	NA	0.48	4.62	0.38	9.32e-6	Recombination rate (males);
TGCT	cis	rs9902453	0.765	rs34585141	chr17:28336432	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.81	-7.67	-0.57	4.37e-12	Coffee consumption (cups per day);
TGCT	cis	rs1371867	0.810	rs1618528	chr8:101259134	T/C	cg06002616	chr8:101225028	SPAG1	0.57	6.77	0.52	4.48e-10	Atrioventricular conduction;
TGCT	cis	rs854765	0.547	rs9913277	chr17:17919749	G/T	cg09796270	chr17:17721594	SREBF1	0.25	5.03	0.41	1.71e-6	Total body bone mineral density;
TGCT	cis	rs806215	0.547	rs3824003	chr7:127469624	C/T	cg11539674	chr7:127291444	SND1	-0.35	-4.54	-0.38	1.33e-5	Type 2 diabetes;
TGCT	cis	rs2439831	0.867	rs6493085	chr15:43654182	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	6.61	0.51	1e-9	Lung cancer in ever smokers;
TGCT	cis	rs9372498	0.908	rs56255677	chr6:118695402	A/G	cg18833306	chr6:118973337	C6orf204	-0.61	-4.81	-0.4	4.28e-6	Diastolic blood pressure;
TGCT	cis	rs4642101	0.737	rs6767504	chr3:12826667	C/T	cg05775895	chr3:12838266	CAND2	0.79	9.02	0.63	2.86e-15	QRS complex (12-leadsum);
TGCT	cis	rs4237845	0.773	rs6650218	chr12:58289078	T/A	cg02175503	chr12:58329896	NA	0.52	5.49	0.44	2.17e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9467773	1.000	rs6910899	chr6:26524339	A/G	cg26531700	chr6:26746687	NA	0.47	4.57	0.38	1.14e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg26039829	chr8:22132926	PIWIL2	0.27	5.18	0.42	8.83e-7	Hypertriglyceridemia;
TGCT	cis	rs11018874	0.597	rs4393275	chr11:89886397	C/T	cg05041596	chr11:89867385	NAALAD2	0.51	5.29	0.43	5.4e-7	White blood cell types;
TGCT	cis	rs644799	0.710	rs3748253	chr11:95519506	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.8	9.01	0.63	3.14e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs10019087	chr4:99030211	C/T	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9650657	0.771	rs6601513	chr8:10594843	A/G	cg27411982	chr8:10470053	RP1L1	-0.21	-4.69	-0.39	6.99e-6	Neuroticism;
TGCT	cis	rs1568889	0.877	rs1384903	chr11:28124359	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	6.46	0.5	2.2e-9	Bipolar disorder;
TGCT	cis	rs3617	0.625	rs7617468	chr3:52849549	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	4.5	0.37	1.55e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs367943	1.000	rs348925	chr5:112817533	T/A	cg12552261	chr5:112820674	MCC	-0.24	-4.91	-0.4	2.81e-6	Type 2 diabetes;
TGCT	cis	rs1505368	0.817	rs1283310	chr2:213273891	A/G	cg16329650	chr2:213403929	ERBB4	0.64	6.07	0.48	1.43e-8	Symmetrical dimethylarginine levels;
TGCT	cis	rs6089584	0.606	rs7270666	chr20:60577598	C/T	cg06108461	chr20:60628389	TAF4	-0.41	-5.07	-0.41	1.43e-6	Body mass index;
TGCT	cis	rs7267979	0.966	rs6037083	chr20:25290543	T/C	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs73110464	0.609	rs4919752	chr12:53359229	G/C	cg25025879	chr12:53359317	NA	-0.53	-5.78	-0.46	5.61e-8	Cancer (pleiotropy);
TGCT	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg12310025	chr6:25882481	NA	-0.67	-5.84	-0.46	4.3e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs3796619	1.000	rs4974638	chr4:1099201	G/A	cg27284194	chr4:1044797	NA	0.47	4.57	0.38	1.17e-5	Recombination rate (males);
TGCT	cis	rs11190604	1.000	rs3750719	chr10:102248950	C/G	cg23241863	chr10:102295624	HIF1AN	0.61	4.62	0.38	9.54e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	trans	rs1814175	0.817	rs10839318	chr11:49657511	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.38	-7.79	-0.57	2.3e-12	Height;
TGCT	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg05457628	chr5:178986728	RUFY1	-0.52	-5.96	-0.47	2.42e-8	Lung cancer;
TGCT	cis	rs61990749	0.597	rs759808	chr14:78250845	T/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.61	4.52	0.38	1.43e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs4523957	0.583	rs903159	chr17:2055109	C/T	cg16513277	chr17:2031491	SMG6	-0.2	-4.64	-0.38	8.69e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.45	4.68	0.39	7.24e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs921968	0.643	rs524012	chr2:219433273	T/G	cg02176678	chr2:219576539	TTLL4	0.44	6.33	0.49	4.17e-9	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs3806843	1.000	rs11167600	chr5:140174865	G/C	cg19875535	chr5:140030758	IK	0.36	6.11	0.48	1.21e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs231513	0.556	rs7212487	chr17:42013499	A/T	cg26893861	chr17:41843967	DUSP3	0.58	4.51	0.38	1.5e-5	Cognitive function;
TGCT	cis	rs3617	0.539	rs12629687	chr3:52950659	T/C	cg10802521	chr3:52805072	NEK4	0.58	6.69	0.51	6.85e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs651907	0.557	rs13081846	chr3:101383321	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.35	-7.28	-0.55	3.4e-11	Colorectal cancer;
TGCT	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.18	0.49	8.32e-9	Bipolar disorder;
TGCT	cis	rs2816062	0.786	rs2745317	chr1:18896552	G/A	cg18795169	chr1:18902165	NA	-0.6	-14.18	-0.79	1.04e-27	Urate levels in lean individuals;
TGCT	cis	rs4713118	0.662	rs149900	chr6:28014597	C/T	cg12963246	chr6:28129442	ZNF389	0.49	4.84	0.4	3.82e-6	Parkinson's disease;
TGCT	cis	rs7666738	0.687	rs6830176	chr4:99093955	G/C	cg17366294	chr4:99064904	C4orf37	0.58	5.37	0.43	3.72e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs17376456	0.877	rs17316137	chr5:93456577	C/T	cg21475434	chr5:93447410	FAM172A	0.59	4.66	0.39	8.09e-6	Diabetic retinopathy;
TGCT	cis	rs7044106	0.791	rs12554440	chr9:123485333	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	7.88	0.58	1.4e-12	Hip circumference adjusted for BMI;
TGCT	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.48	0.56	1.19e-11	Prudent dietary pattern;
TGCT	cis	rs2066819	1.000	rs74496027	chr12:56726340	C/T	cg26714650	chr12:56694279	CS	-1.36	-6.06	-0.48	1.54e-8	Psoriasis vulgaris;
TGCT	cis	rs2153535	0.580	rs9505448	chr6:8459804	A/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs6684514	0.922	rs12047994	chr1:156284535	C/A	cg16558208	chr1:156270281	VHLL	0.48	9.6	0.65	1.19e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs2404602	0.647	rs11852395	chr15:77087785	T/C	cg22467129	chr15:76604101	ETFA	0.48	4.75	0.39	5.58e-6	Blood metabolite levels;
TGCT	cis	rs1799949	0.965	rs8071278	chr17:41193910	A/T	cg10047753	chr17:41438598	NA	0.64	5.75	0.46	6.45e-8	Menopause (age at onset);
TGCT	cis	rs9942416	0.660	rs67803720	chr5:74984408	A/T	cg19683494	chr5:74908142	NA	0.59	6.29	0.49	4.99e-9	Age-related disease endophenotypes;
TGCT	cis	rs7439150	1.000	rs10050162	chr4:155478641	T/C	cg22130008	chr4:155548532	NA	-0.4	-5.08	-0.42	1.32e-6	Fibrinogen levels;
TGCT	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg12042659	chr19:58951599	ZNF132	0.93	8.55	0.61	3.75e-14	Mean platelet volume;
TGCT	cis	rs12693043	0.727	rs7562798	chr2:175434640	C/T	cg11778734	chr2:175439522	WIPF1	-0.4	-5.17	-0.42	8.93e-7	Urate levels (BMI interaction);
TGCT	cis	rs1568889	0.838	rs10835299	chr11:28277693	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.9	-10.14	-0.67	5.63e-18	Bipolar disorder;
TGCT	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg27425262	chr2:113953981	PSD4;LOC440839	-0.52	-8.2	-0.59	2.53e-13	Lymphocyte counts;
TGCT	cis	rs151997	0.649	rs152688	chr5:50211776	C/T	cg06027927	chr5:50259733	NA	0.56	5.64	0.45	1.11e-7	Callous-unemotional behaviour;
TGCT	cis	rs910316	0.737	rs175055	chr14:75488946	T/G	cg08847533	chr14:75593920	NEK9	-0.84	-8.77	-0.62	1.16e-14	Height;
TGCT	cis	rs7575217	0.643	rs2309996	chr2:101735838	T/G	cg12737833	chr2:101500543	NPAS2	0.28	4.51	0.38	1.48e-5	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
TGCT	cis	rs7149242	0.922	rs9671394	chr14:101159674	C/T	cg18089426	chr14:101175970	NA	-0.47	-4.92	-0.4	2.68e-6	Platelet count;
TGCT	cis	rs11148252	0.538	rs9535887	chr13:52730761	G/A	cg00495681	chr13:53174319	NA	0.57	5.91	0.47	3.12e-8	Lewy body disease;
TGCT	cis	rs7617773	0.817	rs3731555	chr3:48206102	G/A	cg11946769	chr3:48343235	NME6	0.73	6.33	0.49	4.03e-9	Coronary artery disease;
TGCT	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg25767906	chr1:53392781	SCP2	-0.52	-6.19	-0.49	8.06e-9	Monocyte count;
TGCT	cis	rs11209185	0.509	rs9436356	chr1:68447202	A/G	cg22082780	chr1:68452167	NA	0.31	4.84	0.4	3.86e-6	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs7651736	1.000	rs7651736	chr3:136760598	A/G	cg12473912	chr3:136751656	NA	0.34	5.34	0.43	4.19e-7	Neuroticism;
TGCT	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg03934478	chr11:495069	RNH1	0.35	5.77	0.46	6.03e-8	Body mass index;
TGCT	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg04944784	chr2:26401820	FAM59B	-0.68	-6.13	-0.48	1.1e-8	Gut microbiome composition (summer);
TGCT	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9372498	0.536	rs9489428	chr6:118852935	T/C	cg07617317	chr6:118971624	C6orf204	0.52	5.55	0.45	1.69e-7	Diastolic blood pressure;
TGCT	cis	rs6087990	0.735	rs1855350	chr20:31387525	C/T	cg13636640	chr20:31349939	DNMT3B	0.95	12.3	0.74	3.25e-23	Ulcerative colitis;
TGCT	trans	rs208520	0.526	rs4710310	chr6:66802808	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-15.68	-0.82	3.23e-31	Exhaled nitric oxide output;
TGCT	cis	rs77972916	0.611	rs6709988	chr2:43601317	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.4	-6.2	-0.49	7.52e-9	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs2882877	0.648	rs11694976	chr2:190377894	C/T	cg10752008	chr2:190445175	SLC40A1	0.61	4.5	0.37	1.53e-5	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs12220238	0.915	rs11000948	chr10:76031721	C/T	cg19889307	chr10:75911429	ADK;AP3M1	-0.88	-5.95	-0.47	2.59e-8	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs7226408	0.857	rs72887017	chr18:34464233	C/T	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.45	-5.44	-0.44	2.76e-7	Longevity;Endometriosis;
TGCT	cis	rs12142240	0.698	rs13374893	chr1:46843800	A/G	cg14993813	chr1:46806288	NSUN4	-0.58	-4.79	-0.4	4.69e-6	Menopause (age at onset);
TGCT	cis	rs909002	0.800	rs11589306	chr1:32082822	C/G	cg11573219	chr1:32083031	HCRTR1	-0.44	-5.75	-0.46	6.6e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg06873352	chr17:61820015	STRADA	0.56	6.22	0.49	7.08e-9	Prudent dietary pattern;
TGCT	cis	rs6988636	0.818	rs73339658	chr8:124173007	A/G	cg23067535	chr8:124195133	FAM83A	-0.34	-4.5	-0.37	1.57e-5	Urinary uromodulin levels;
TGCT	cis	rs11190604	0.767	rs10748794	chr10:102175918	G/T	cg16342193	chr10:102329863	NA	0.37	4.81	0.4	4.21e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7639513	0.590	rs3729931	chr3:12626516	A/G	cg23032965	chr3:12705835	RAF1	-0.71	-7.49	-0.56	1.1e-11	Itch intensity from mosquito bite;
TGCT	cis	rs11718455	0.960	rs11920021	chr3:44000856	T/C	cg08738300	chr3:44038990	NA	0.85	6.41	0.5	2.72e-9	Coronary artery disease;
TGCT	cis	rs7267979	0.903	rs6050482	chr20:25226327	C/T	cg03522245	chr20:25566470	NINL	0.58	6.22	0.49	6.92e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg19748678	chr4:122722346	EXOSC9	0.88	8.76	0.62	1.21e-14	Type 2 diabetes;
TGCT	cis	rs6933660	0.800	rs2046371	chr6:151754744	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.91	-9.69	-0.66	7.28e-17	Menarche (age at onset);
TGCT	cis	rs73198271	0.740	rs10094270	chr8:8646633	G/A	cg06671706	chr8:8559999	CLDN23	-0.35	-4.5	-0.37	1.52e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs7666738	0.830	rs10049627	chr4:99025272	A/C	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11191419	1	rs11191419	chr10:104612335	T/A	cg15744005	chr10:104629667	AS3MT	-0.51	-6.51	-0.5	1.7e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs10992471	0.756	rs1121979	chr9:95140218	G/A	cg14631576	chr9:95140430	CENPP	-0.3	-4.97	-0.41	2.21e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs317689	0.788	rs317679	chr12:69693172	A/C	cg14784868	chr12:69753453	YEATS4	0.57	4.9	0.4	2.96e-6	Response to diuretic therapy;
TGCT	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.51	5.71	0.46	7.95e-8	Lymphocyte counts;
TGCT	cis	rs7945705	0.747	rs2568045	chr11:9004060	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.45	-4.95	-0.41	2.4e-6	Hemoglobin concentration;
TGCT	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg25036284	chr2:26402008	FAM59B	-0.66	-5.34	-0.43	4.22e-7	Gut microbiome composition (summer);
TGCT	cis	rs9308731	0.966	rs36018702	chr2:111928373	G/T	cg04202892	chr2:111875749	ACOXL	-0.43	-4.74	-0.39	5.85e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs739496	0.527	rs2269801	chr12:112326123	T/C	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg22857025	chr5:266934	NA	-0.32	-6.58	-0.51	1.18e-9	Breast cancer;
TGCT	cis	rs6998277	1.000	rs4281092	chr8:103647956	A/G	cg10187029	chr8:103597600	NA	-0.47	-6.1	-0.48	1.26e-8	Migraine;
TGCT	cis	rs2295359	0.892	rs10889657	chr1:67615487	A/G	cg12940439	chr1:67600707	NA	0.63	6.53	0.51	1.51e-9	Psoriasis;
TGCT	cis	rs3764563	1.000	rs8107240	chr19:15737392	A/G	cg20725493	chr19:15740067	CYP4F8	-0.43	-4.67	-0.39	7.75e-6	Inflammatory biomarkers;
TGCT	cis	rs4237845	0.837	rs7963992	chr12:58295949	G/C	cg02175503	chr12:58329896	NA	0.53	5.49	0.44	2.21e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs644799	0.511	rs1016030	chr11:95472693	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.66	6.29	0.49	5.03e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg06873352	chr17:61820015	STRADA	0.58	6.42	0.5	2.65e-9	Prudent dietary pattern;
TGCT	cis	rs6545883	0.965	rs6734830	chr2:61731112	G/A	cg15711740	chr2:61764176	XPO1	-0.5	-4.51	-0.38	1.46e-5	Tuberculosis;
TGCT	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg04944784	chr2:26401820	FAM59B	0.7	5.41	0.44	3.15e-7	Gut microbiome composition (summer);
TGCT	cis	rs10193935	0.901	rs222478	chr2:42656919	G/T	cg27598129	chr2:42591480	NA	-0.32	-4.75	-0.39	5.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs172166	0.515	rs2622320	chr6:28115336	T/A	cg13525197	chr6:28411240	ZSCAN23	-0.46	-4.5	-0.37	1.55e-5	Cardiac Troponin-T levels;
TGCT	cis	rs13177918	0.677	rs3857421	chr5:149823147	C/T	cg14059543	chr5:149831962	NA	0.71	10.06	0.67	9.14e-18	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs7267979	0.966	rs4813557	chr20:25292545	C/T	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1215050	0.791	rs1585088	chr4:98675071	C/A	cg17366294	chr4:99064904	C4orf37	-0.5	-5.2	-0.42	7.83e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg27535305	chr1:53392650	SCP2	-0.24	-4.73	-0.39	5.98e-6	Monocyte count;
TGCT	cis	rs2742417	1.000	rs2742385	chr3:45756270	G/A	cg04837898	chr3:45731254	SACM1L	-0.55	-5.72	-0.46	7.58e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs7833790	0.963	rs6473312	chr8:82732515	C/A	cg27398817	chr8:82754497	SNX16	-0.84	-6.06	-0.48	1.52e-8	Diastolic blood pressure;
TGCT	trans	rs7726839	0.540	rs57306627	chr5:597643	T/C	cg25482853	chr8:67687455	SGK3	1.27	10.56	0.69	5.48e-19	Obesity-related traits;
TGCT	cis	rs12753569	0.837	rs1251490	chr1:76518693	T/C	cg00791851	chr1:76518896	NA	-0.34	-4.5	-0.37	1.52e-5	Personality dimensions;
TGCT	cis	rs12497850	0.805	rs6446198	chr3:49007638	T/A	cg18654377	chr3:49208889	KLHDC8B	-0.42	-5.42	-0.44	2.97e-7	Parkinson's disease;
TGCT	cis	rs72615157	0.606	rs941288	chr7:99776808	G/A	cg00814883	chr7:100076585	TSC22D4	-0.5	-4.86	-0.4	3.53e-6	Lung function (FEV1/FVC);
TGCT	cis	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg02380750	chr20:61661411	NA	0.33	5.96	0.47	2.4e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	16.05	0.82	4.59e-32	Prudent dietary pattern;
TGCT	cis	rs7647973	0.559	rs9586	chr3:49213637	C/T	cg07636037	chr3:49044803	WDR6	0.62	4.64	0.38	8.56e-6	Menarche (age at onset);
TGCT	cis	rs6088580	0.634	rs11700221	chr20:32940320	T/C	cg08999081	chr20:33150536	PIGU	-0.27	-5.33	-0.43	4.46e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs4803468	1.000	rs10422956	chr19:41901261	C/T	cg09537434	chr19:41945824	ATP5SL	-0.89	-10.09	-0.67	7.79e-18	Height;
TGCT	cis	rs977747	0.872	rs11211479	chr1:47680978	T/C	cg03885399	chr1:47691550	TAL1	-0.43	-5.58	-0.45	1.42e-7	Body mass index;
TGCT	cis	rs2070488	0.965	rs2300668	chr3:38540541	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.81	-8.45	-0.6	6.55e-14	Electrocardiographic conduction measures;
TGCT	cis	rs7917772	0.503	rs7914389	chr10:104295402	T/C	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs10782582	0.593	rs11578480	chr1:76208989	T/G	cg22875332	chr1:76189707	ACADM	-0.49	-5.39	-0.44	3.35e-7	Daytime sleep phenotypes;
TGCT	cis	rs6087771	0.714	rs6058259	chr20:30235302	A/G	cg13852791	chr20:30311386	BCL2L1	0.8	7.08	0.54	9.22e-11	Subcortical brain region volumes;Putamen volume;
TGCT	cis	rs10207060	0.771	rs4852124	chr2:240680022	C/T	cg07506560	chr2:240697449	NA	0.6	8.04	0.59	6.17e-13	Obesity-related traits;
TGCT	cis	rs7674212	0.512	rs2720462	chr4:104056210	T/G	cg16532752	chr4:104119610	CENPE	-0.61	-5.58	-0.45	1.44e-7	Type 2 diabetes;
TGCT	cis	rs9372498	0.536	rs9489409	chr6:118802721	A/G	cg21191810	chr6:118973309	C6orf204	-0.36	-4.74	-0.39	5.8e-6	Diastolic blood pressure;
TGCT	cis	rs17270561	1.000	rs12200962	chr6:25828986	T/C	cg16482183	chr6:26056742	HIST1H1C	0.79	5.25	0.43	6.49e-7	Iron status biomarkers;
TGCT	cis	rs7698623	0.850	rs1477604	chr4:88771060	C/T	cg27387453	chr4:88533842	DSPP	-0.59	-4.48	-0.37	1.65e-5	Cardiovascular disease risk factors;
TGCT	cis	rs4808199	0.947	rs10404728	chr19:19595014	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.72	5.2	0.42	8.14e-7	Nonalcoholic fatty liver disease;
TGCT	cis	rs7511006	0.893	rs5771104	chr22:50651839	C/T	cg08875078	chr22:50639485	SELO	0.54	5.1	0.42	1.21e-6	Obesity-related traits;
TGCT	cis	rs5760092	0.755	rs5760096	chr22:24247310	A/G	cg10150615	chr22:24372951	LOC391322	-0.78	-7.5	-0.56	1.04e-11	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg18765753	chr7:1198926	ZFAND2A	0.49	5.73	0.46	7.14e-8	Longevity;Endometriosis;
TGCT	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9372498	0.505	rs62422247	chr6:118987559	G/T	cg07617317	chr6:118971624	C6orf204	0.49	5.15	0.42	9.91e-7	Diastolic blood pressure;
TGCT	cis	rs6728642	1.000	rs116171118	chr2:97695036	C/A	cg26665480	chr2:98280029	ACTR1B	-0.96	-5.36	-0.43	3.91e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	cis	rs7267979	1.000	rs2257991	chr20:25270339	C/T	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11711311	1.000	rs4362695	chr3:113534856	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.67	-6.31	-0.49	4.49e-9	IgG glycosylation;
TGCT	cis	rs3741404	0.868	rs595880	chr11:64006466	T/G	cg03236948	chr11:63997492	DNAJC4	-0.36	-4.49	-0.37	1.6e-5	Platelet count;
TGCT	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg13395646	chr4:1353034	KIAA1530	-0.48	-6.09	-0.48	1.34e-8	Obesity-related traits;
TGCT	cis	rs1008375	0.966	rs3775924	chr4:17585984	T/C	cg16339924	chr4:17578868	LAP3	0.8	6.96	0.53	1.73e-10	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7666738	0.830	rs28451101	chr4:99001190	T/C	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1696756	0.759	rs1298563	chr17:77834703	G/A	cg00646381	chr17:77835854	NA	0.48	8.03	0.59	6.32e-13	Glucocorticoid-induced osteonecrosis (age 10 years and older);
TGCT	cis	rs910316	1.000	rs4899544	chr14:75546556	C/T	cg11812906	chr14:75593930	NEK9	0.74	7.25	0.55	3.9e-11	Height;
TGCT	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.71	5.14	0.42	1.02e-6	Platelet count;
TGCT	cis	rs17221829	0.764	rs6483020	chr11:89386384	A/T	cg02982614	chr11:89391479	FOLH1B	-0.25	-4.46	-0.37	1.8e-5	Anxiety in major depressive disorder;
TGCT	cis	rs151997	0.777	rs3846499	chr5:50254200	G/A	cg06027927	chr5:50259733	NA	0.59	6.2	0.49	7.53e-9	Callous-unemotional behaviour;
TGCT	cis	rs7959452	0.590	rs11177643	chr12:69785712	T/G	cg20891283	chr12:69753455	YEATS4	0.83	8.7	0.62	1.68e-14	Blood protein levels;
TGCT	cis	rs7769051	1.000	rs12204027	chr6:133122831	A/G	cg22852734	chr6:133119734	C6orf192	1.22	6.9	0.53	2.34e-10	Type 2 diabetes nephropathy;
TGCT	cis	rs7216064	0.773	rs74541577	chr17:65853651	C/T	cg12091567	chr17:66097778	LOC651250	-0.83	-6.49	-0.5	1.9e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	8.39	0.6	9.03e-14	Platelet count;
TGCT	cis	rs4906332	1.000	rs2065017	chr14:103879579	T/C	cg26031613	chr14:104095156	KLC1	-0.51	-4.63	-0.38	9.17e-6	Coronary artery disease;
TGCT	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg08280861	chr8:58055591	NA	0.4	4.73	0.39	5.97e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg08045932	chr20:61659980	NA	0.48	9.16	0.64	1.36e-15	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs3858526	0.959	rs4559671	chr11:5923419	C/T	cg05234568	chr11:5960015	NA	-0.44	-4.6	-0.38	1.03e-5	DNA methylation (variation);
TGCT	cis	rs2933343	0.700	rs2249514	chr3:128643812	C/T	cg11901034	chr3:128598214	ACAD9	-0.65	-6.05	-0.48	1.55e-8	IgG glycosylation;
TGCT	cis	rs968451	0.813	rs5757619	chr22:39724558	G/A	cg17798944	chr22:39715225	SNORD43;RPL3	0.85	8.61	0.61	2.85e-14	Primary biliary cholangitis;
TGCT	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.63	-0.51	9.04e-10	Alzheimer's disease;
TGCT	cis	rs909674	0.818	rs5757678	chr22:39843409	A/G	cg24399712	chr22:39784796	NA	1.03	11.23	0.71	1.26e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs9473924	0.542	rs56240592	chr6:50815514	T/A	cg14470998	chr6:50812995	TFAP2B	1.36	8.61	0.61	2.74e-14	Body mass index;
TGCT	cis	rs7618915	1.000	rs3852063	chr3:52349204	A/G	cg07507251	chr3:52567010	NT5DC2	0.46	6.07	0.48	1.44e-8	Bipolar disorder;
TGCT	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg10253484	chr15:75165896	SCAMP2	-0.58	-5.33	-0.43	4.48e-7	Breast cancer;
TGCT	cis	rs1215050	0.791	rs165241	chr4:98681112	C/T	cg17366294	chr4:99064904	C4orf37	0.52	5.51	0.44	1.97e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs28595532	0.920	rs56331118	chr4:119767054	G/T	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs58950470	0.887	rs1784223	chr11:65380248	T/C	cg27068330	chr11:65405492	SIPA1	0.59	5.23	0.42	7.07e-7	Schizophrenia;
TGCT	trans	rs10506458	1.000	rs17763435	chr12:63416511	A/G	cg22491629	chr6:157744540	C6orf35	0.98	8.47	0.61	6.02e-14	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs7246657	0.943	rs10406177	chr19:37907947	G/A	cg18154014	chr19:37997991	ZNF793	0.73	5.38	0.44	3.53e-7	Coronary artery calcification;
TGCT	cis	rs8031584	0.678	rs4779497	chr15:31151365	T/A	cg08704250	chr15:31115839	NA	-0.43	-6.31	-0.49	4.47e-9	Huntington's disease progression;
TGCT	cis	rs748404	0.690	rs2467737	chr15:43737188	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	4.75	0.39	5.51e-6	Lung cancer;
TGCT	cis	rs57590327	0.528	rs11707026	chr3:81694044	C/A	cg07356753	chr3:81810745	GBE1	-0.77	-6.91	-0.53	2.23e-10	Extraversion;
TGCT	cis	rs9611519	0.602	rs8138520	chr22:41412928	A/G	cg06634786	chr22:41940651	POLR3H	-0.49	-4.54	-0.38	1.33e-5	Neuroticism;
TGCT	cis	rs2180341	0.843	rs4895821	chr6:127572761	T/A	cg27446573	chr6:127587934	RNF146	1.07	9.73	0.66	5.7e-17	Breast cancer;
TGCT	cis	rs8077889	0.871	rs17675370	chr17:41900030	T/C	cg26893861	chr17:41843967	DUSP3	1.08	12.97	0.76	7.86e-25	Triglycerides;
TGCT	cis	rs77372450	0.515	rs2277948	chr5:157098233	T/C	cg12606933	chr5:157078573	SOX30	-0.41	-4.65	-0.39	8.5e-6	Bipolar disorder (body mass index interaction);
TGCT	cis	rs11674184	0.659	rs11679605	chr2:11722468	G/A	cg07314298	chr2:11723111	GREB1	-0.4	-6.6	-0.51	1.08e-9	Endometriosis;
TGCT	cis	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg15556689	chr8:8085844	FLJ10661	-0.68	-6.44	-0.5	2.37e-9	Mood instability;
TGCT	cis	rs603424	0.509	rs6584362	chr10:102087113	G/T	cg22671421	chr10:102507979	PAX2	-0.54	-4.5	-0.37	1.53e-5	Phospholipid levels (plasma);Palmitic acid (16:0) levels;Palmitoleic acid (16:1n-7) levels;Mean platelet volume;Serum metabolite levels;Blood metabolite levels;Vaccenic acid (18:1n-7) levels;Metabolic traits;Coronary artery disease;Blood metabolite ratios;Glycerophospholipid levels;
TGCT	cis	rs9921338	1.000	rs8049173	chr16:11436882	G/A	cg00044050	chr16:11439710	C16orf75	-0.87	-6.68	-0.51	7.32e-10	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs713587	0.713	rs62143001	chr2:25288675	G/A	cg15423357	chr2:25149977	NA	-0.6	-6.12	-0.48	1.15e-8	Body mass index in non-asthmatics;
TGCT	cis	rs6831352	0.703	rs4235435	chr4:100039578	C/T	cg12011299	chr4:100065546	ADH4	0.39	5.2	0.42	8.04e-7	Alcohol dependence;
TGCT	cis	rs17076896	0.786	rs61956081	chr13:19933518	T/C	cg00777926	chr13:20807375	GJB6	-0.37	-4.53	-0.38	1.36e-5	Coronary artery aneurysm in Kawasaki disease;
TGCT	trans	rs9388451	0.839	rs3757217	chr6:126069636	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.74	-8.29	-0.6	1.61e-13	Brugada syndrome;
TGCT	trans	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg17830980	chr10:43048298	ZNF37B	-0.84	-10.46	-0.68	9.38e-19	Extrinsic epigenetic age acceleration;
TGCT	cis	rs9303401	0.538	rs2240258	chr17:56458183	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.56	5.21	0.42	7.76e-7	Cognitive test performance;
TGCT	cis	rs2334880	0.678	rs34400718	chr16:71455852	G/A	cg06353428	chr16:71660113	MARVELD3	-1.25	-8.07	-0.59	5.27e-13	Malaria;
TGCT	trans	rs208520	0.690	rs12204512	chr6:66710486	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	11.22	0.71	1.34e-20	Exhaled nitric oxide output;
TGCT	cis	rs6582630	0.502	rs10880092	chr12:38262965	A/T	cg26384229	chr12:38710491	ALG10B	0.86	7.48	0.56	1.17e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs514406	0.698	rs11206043	chr1:53402552	C/T	cg16325326	chr1:53192061	ZYG11B	0.5	5.52	0.44	1.87e-7	Monocyte count;
TGCT	cis	rs7119	0.604	rs2271397	chr15:77907775	T/C	cg27398640	chr15:77910606	LINGO1	0.32	6.88	0.53	2.63e-10	Type 2 diabetes;
TGCT	cis	rs12541335	0.639	rs68063696	chr8:22153236	A/G	cg07298985	chr8:22133076	PIWIL2	0.33	5.0	0.41	1.91e-6	Hypertriglyceridemia;
TGCT	cis	rs4776059	1.000	rs34431049	chr15:52940538	G/C	cg25063058	chr15:52860530	ARPP19	0.51	4.57	0.38	1.18e-5	Schizophrenia;
TGCT	cis	rs7568458	0.870	rs1009	chr2:85808737	A/G	cg17127132	chr2:85788382	GGCX	0.67	6.24	0.49	6.43e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs62064224	0.818	rs35677406	chr17:30665005	T/C	cg18200150	chr17:30822561	MYO1D	0.58	7.63	0.57	5.24e-12	Schizophrenia;
TGCT	cis	rs12421382	0.507	rs10890995	chr11:109327622	A/G	cg27471124	chr11:109292789	C11orf87	-0.51	-6.2	-0.49	7.73e-9	Schizophrenia;
TGCT	cis	rs3617	0.591	rs11918800	chr3:52868145	G/A	cg10802521	chr3:52805072	NEK4	0.62	7.17	0.54	6e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg23708337	chr7:1209742	NA	0.44	4.87	0.4	3.27e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs12142240	0.738	rs17361749	chr1:46806480	C/T	cg00530320	chr1:46809349	NSUN4	0.29	5.95	0.47	2.58e-8	Menopause (age at onset);
TGCT	trans	rs1908814	0.516	rs56102998	chr8:11796675	G/A	cg15556689	chr8:8085844	FLJ10661	0.75	7.07	0.54	9.74e-11	Neuroticism;
TGCT	cis	rs916888	0.821	rs199514	chr17:44856881	G/A	cg15921436	chr17:44337874	NA	-0.51	-6.96	-0.53	1.73e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg03517284	chr6:25882590	NA	-0.65	-5.75	-0.46	6.49e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs4700695	0.614	rs37231	chr5:65218662	G/A	cg21114390	chr5:65439923	SFRS12	0.64	4.61	0.38	9.9e-6	Facial morphology (factor 19);
TGCT	cis	rs7572733	0.534	rs770657	chr2:198674184	C/A	cg00792783	chr2:198669748	PLCL1	0.56	5.08	0.42	1.35e-6	Dermatomyositis;
TGCT	cis	rs9341808	0.718	rs35447745	chr6:80816748	T/C	cg08355045	chr6:80787529	NA	0.32	5.83	0.46	4.48e-8	Sitting height ratio;
TGCT	cis	rs1055129	0.682	rs7217432	chr17:73834604	A/G	cg10935138	chr17:73851978	WBP2	0.51	4.46	0.37	1.79e-5	White matter hyperintensity burden;
TGCT	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg20276088	chr3:133502917	NA	-0.26	-5.39	-0.44	3.47e-7	Iron status biomarkers;
TGCT	cis	rs9942416	0.660	rs4704234	chr5:75001432	A/G	cg02573091	chr5:74908125	NA	0.45	5.17	0.42	9.3e-7	Age-related disease endophenotypes;
TGCT	trans	rs1496653	0.602	rs35190363	chr3:23386880	T/C	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs6088580	0.634	rs6059866	chr20:33075810	A/C	cg06115741	chr20:33292138	TP53INP2	0.51	4.5	0.37	1.56e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs986417	0.818	rs1950311	chr14:60989604	A/C	cg27398547	chr14:60952738	C14orf39	1.49	10.78	0.7	1.64e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs7666738	0.830	rs6829567	chr4:99047340	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12497850	0.931	rs6446253	chr3:48911443	C/T	cg07636037	chr3:49044803	WDR6	0.95	10.74	0.69	2e-19	Parkinson's disease;
TGCT	cis	rs8141529	0.702	rs132536	chr22:29302906	A/G	cg02153584	chr22:29168773	CCDC117	-0.63	-4.92	-0.4	2.64e-6	Lymphocyte counts;
TGCT	cis	rs9393777	0.513	rs9348728	chr6:26634436	G/A	cg15659132	chr6:26577336	NA	-0.77	-5.48	-0.44	2.26e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs950169	0.724	rs11632668	chr15:84948687	T/C	cg11189052	chr15:85197271	WDR73	0.81	6.22	0.49	6.89e-9	Schizophrenia;
TGCT	cis	rs78545713	1.000	rs78661760	chr6:26250033	A/T	cg12260798	chr6:26240519	HIST1H4F	-0.54	-4.57	-0.38	1.16e-5	Iron status biomarkers (total iron binding capacity);
TGCT	cis	rs477895	1.000	rs2286614	chr11:64068310	C/T	cg23719950	chr11:63933701	MACROD1	-0.59	-4.63	-0.38	9.27e-6	Mean platelet volume;
TGCT	cis	rs10927875	0.518	rs1763597	chr1:16343297	C/T	cg21385522	chr1:16154831	NA	0.46	4.85	0.4	3.64e-6	Dilated cardiomyopathy;
TGCT	cis	rs7582180	0.845	rs11683088	chr2:100920667	C/T	cg14675211	chr2:100938903	LONRF2	0.46	4.52	0.38	1.43e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs1023500	0.573	rs4822088	chr22:42470589	G/C	cg15557168	chr22:42548783	NA	-0.22	-5.58	-0.45	1.47e-7	Schizophrenia;
TGCT	cis	rs2439831	0.681	rs3742971	chr15:43622916	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.9	-6.84	-0.52	3.25e-10	Lung cancer in ever smokers;
TGCT	cis	rs950027	0.549	rs2899375	chr15:45598335	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.47	-5.86	-0.47	3.98e-8	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs9487051	0.872	rs9487033	chr6:109605388	C/G	cg01475377	chr6:109611718	NA	0.29	4.56	0.38	1.23e-5	Reticulocyte fraction of red cells;
TGCT	cis	rs10791097	0.694	rs4937583	chr11:130741606	A/G	cg12179176	chr11:130786555	SNX19	0.84	10.17	0.67	4.95e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs4888262	0.526	rs7193423	chr16:74626340	A/C	cg01733217	chr16:74700730	RFWD3	0.74	7.22	0.54	4.54e-11	Testicular germ cell tumor;
TGCT	cis	rs2354432	0.607	rs6689243	chr1:146710559	A/T	cg25205988	chr1:146714368	CHD1L	-1.15	-4.8	-0.4	4.49e-6	Mitochondrial DNA levels;
TGCT	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.61	5.06	0.41	1.5e-6	Tonsillectomy;
TGCT	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg18402987	chr7:1209562	NA	0.39	4.48	0.37	1.68e-5	Longevity;Endometriosis;
TGCT	cis	rs4845570	1.000	rs11586946	chr1:151769806	G/A	cg07092448	chr1:151763213	TDRKH	-1.12	-8.71	-0.62	1.64e-14	Coronary artery disease;
TGCT	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg00080972	chr5:178986291	RUFY1	0.46	5.38	0.44	3.5e-7	Lung cancer;
TGCT	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg11890956	chr21:40555474	PSMG1	-0.76	-7.45	-0.56	1.36e-11	Cognitive function;
TGCT	trans	rs1814175	0.817	rs1390676	chr11:50056778	C/T	cg03929089	chr4:120376271	NA	-0.72	-8.55	-0.61	3.8e-14	Height;
TGCT	cis	rs10088262	0.629	rs9918907	chr8:124816862	A/G	cg02993010	chr8:124780839	FAM91A1	-0.6	-4.61	-0.38	9.78e-6	Pancreatic cancer;
TGCT	cis	rs2153535	0.580	rs969422	chr6:8451780	A/T	cg07606381	chr6:8435919	SLC35B3	0.53	5.02	0.41	1.79e-6	Motion sickness;
TGCT	cis	rs7666738	0.830	rs62318471	chr4:98925848	G/A	cg17366294	chr4:99064904	C4orf37	0.72	7.19	0.54	5.3e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2013441	1.000	rs2703802	chr17:20101039	T/C	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.61	-0.38	9.96e-6	Obesity-related traits;
TGCT	cis	rs1865760	0.713	rs2013063	chr6:25994098	C/T	cg17042849	chr6:26104293	HIST1H4C	-0.55	-4.8	-0.4	4.4e-6	Height;
TGCT	cis	rs1371867	0.875	rs1660320	chr8:101337579	A/C	cg06636551	chr8:101224915	SPAG1	-0.45	-6.12	-0.48	1.13e-8	Atrioventricular conduction;
TGCT	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg27286337	chr10:134555280	INPP5A	0.4	4.82	0.4	4.09e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs453301	0.571	rs2929452	chr8:9084465	G/A	cg15556689	chr8:8085844	FLJ10661	-0.64	-6.05	-0.48	1.6e-8	Joint mobility (Beighton score);
TGCT	cis	rs2832191	0.791	rs28633762	chr21:30500070	C/T	cg08807101	chr21:30365312	RNF160	-0.62	-5.8	-0.46	5.14e-8	Dental caries;
TGCT	trans	rs208520	1.000	rs12200490	chr6:66976084	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.86	7.83	0.58	1.88e-12	Exhaled nitric oxide output;
TGCT	cis	rs7107174	0.901	rs990706	chr11:78135704	C/T	cg12700464	chr11:78128424	GAB2	-0.68	-4.54	-0.38	1.33e-5	Testicular germ cell tumor;
TGCT	cis	rs11578119	0.832	rs12131969	chr1:170352101	G/A	cg09767346	chr1:170501363	GORAB	0.61	4.61	0.38	9.8e-6	Male-pattern baldness;
TGCT	cis	rs1887596	0.705	rs2441067	chr13:27268653	A/G	cg01312412	chr13:27282625	NA	0.27	4.83	0.4	3.96e-6	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg24531977	chr5:56204891	C5orf35	-0.76	-7.66	-0.57	4.53e-12	Initial pursuit acceleration;
TGCT	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg12963246	chr6:28129442	ZNF389	0.52	5.01	0.41	1.85e-6	Depression;
TGCT	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg03609598	chr5:56110824	MAP3K1	-0.59	-4.87	-0.4	3.3e-6	Initial pursuit acceleration;
TGCT	cis	rs3087591	1.000	rs7220268	chr17:29451910	T/C	cg24425628	chr17:29625626	OMG;NF1	0.48	7.68	0.57	4.23e-12	Hip circumference;
TGCT	cis	rs2486288	0.554	rs1719235	chr15:45576108	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.79	-8.17	-0.59	2.97e-13	Glomerular filtration rate;
TGCT	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg08280861	chr8:58055591	NA	0.4	4.73	0.39	5.97e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs3741404	0.868	rs595880	chr11:64006466	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.87	-9.49	-0.65	2.14e-16	Platelet count;
TGCT	cis	rs7772486	0.875	rs6914813	chr6:146397798	A/G	cg23711669	chr6:146136114	FBXO30	0.91	9.82	0.66	3.55e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7674212	0.531	rs6816370	chr4:103939433	C/T	cg16532752	chr4:104119610	CENPE	-0.59	-5.29	-0.43	5.43e-7	Type 2 diabetes;
TGCT	cis	rs78487399	0.908	rs6717791	chr2:43822006	A/G	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.66	4.67	0.39	7.66e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs3757318	0.540	rs17838427	chr6:151852039	G/A	cg18745416	chr6:152011399	ESR1	0.52	4.84	0.4	3.82e-6	Breast cancer (estrogen-receptor negative, progesterone-receptor negative, and human epidermal growth factor-receptor negative);Breast cancer;
TGCT	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg21862992	chr11:68658383	NA	0.46	6.64	0.51	8.64e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/A	cg21285383	chr16:89894308	SPIRE2	0.49	7.19	0.54	5.41e-11	Vitiligo;
TGCT	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg02574844	chr11:5959923	NA	0.41	4.54	0.38	1.31e-5	DNA methylation (variation);
TGCT	cis	rs7666738	0.830	rs7662218	chr4:98983126	T/G	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11676348	0.791	rs6726126	chr2:218952233	G/A	cg00012203	chr2:219082015	ARPC2	-0.5	-4.63	-0.38	8.99e-6	Ulcerative colitis;
TGCT	cis	rs1887596	0.705	rs2776435	chr13:27217535	T/C	cg01312412	chr13:27282625	NA	0.28	4.92	0.4	2.69e-6	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs6540559	0.673	rs6540561	chr1:209982255	C/T	cg22029157	chr1:209979665	IRF6	0.74	5.53	0.44	1.84e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs4237845	0.844	rs4628718	chr12:58301600	A/C	cg23860436	chr12:58378763	NA	0.35	4.97	0.41	2.16e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs34526934	0.608	rs13017511	chr2:177035395	A/G	cg23561606	chr2:177418561	NA	-0.44	-4.45	-0.37	1.91e-5	Obstructive sleep apnea trait (apnea hypopnea index);
TGCT	cis	rs131777	0.563	rs5770927	chr22:51028945	C/T	cg25309564	chr22:51001381	C22orf41	0.54	5.04	0.41	1.63e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs9467711	1.000	rs9467708	chr6:26327956	T/C	cg26531700	chr6:26746687	NA	-0.94	-5.09	-0.42	1.28e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7829975	0.517	rs12542733	chr8:8824858	G/T	cg15556689	chr8:8085844	FLJ10661	-0.76	-6.8	-0.52	3.85e-10	Mood instability;
TGCT	cis	rs682748	1.000	rs682285	chr5:17149016	A/C	cg23987134	chr5:17158319	LOC285696	-0.23	-5.42	-0.44	2.93e-7	Hippocampal atrophy;
TGCT	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg17179660	chr6:151773299	C6orf211;RMND1	-0.55	-4.95	-0.41	2.37e-6	Menarche (age at onset);
TGCT	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.65	-6.68	-0.51	7.09e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs7552404	1.000	rs211723	chr1:76103030	C/T	cg03433033	chr1:76189801	ACADM	-0.84	-10.0	-0.67	1.29e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs3091242	0.933	rs10903130	chr1:25769221	A/T	cg00786635	chr1:25594202	NA	0.52	5.56	0.45	1.59e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs67311347	0.544	rs7644643	chr3:40350209	C/T	cg13683864	chr3:40499215	RPL14	0.8	7.48	0.56	1.18e-11	Renal cell carcinoma;
TGCT	cis	rs453301	0.574	rs10081437	chr8:8948979	T/C	cg06636001	chr8:8085503	FLJ10661	-0.61	-4.8	-0.4	4.49e-6	Joint mobility (Beighton score);
TGCT	cis	rs9894429	1.000	rs35435780	chr17:79579602	G/T	cg21028142	chr17:79581711	NPLOC4	0.29	6.81	0.52	3.83e-10	Eye color traits;
TGCT	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg22535103	chr8:58192502	C8orf71	-0.42	-4.79	-0.4	4.7e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1215050	0.765	rs1530905	chr4:98805705	A/G	cg05340658	chr4:99064831	C4orf37	0.44	5.51	0.44	2.01e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs3096299	0.632	rs4399533	chr16:89539382	G/C	cg08392591	chr16:89556376	ANKRD11	0.58	5.47	0.44	2.38e-7	Multiple myeloma (IgH translocation);
TGCT	cis	rs2228479	0.718	rs62054253	chr16:89896932	T/C	cg06558623	chr16:89946397	TCF25	0.55	4.77	0.39	5.13e-6	Skin colour saturation;
TGCT	cis	rs12620999	0.941	rs7593758	chr2:237980920	G/T	cg23555395	chr2:238036564	NA	-0.27	-4.85	-0.4	3.69e-6	Systemic lupus erythematosus;
TGCT	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.38	-4.53	-0.38	1.39e-5	Total body bone mineral density;
TGCT	cis	rs28374715	0.532	rs316604	chr15:41775221	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.94	-17.29	-0.84	7.89e-35	Ulcerative colitis;
TGCT	cis	rs9859260	0.614	rs493661	chr3:195786489	T/A	cg02975922	chr3:195473998	MUC4	0.25	4.92	0.4	2.64e-6	Mean corpuscular volume;
TGCT	cis	rs5769707	0.642	rs135880	chr22:50018654	T/A	cg06623630	chr22:50017776	C22orf34	-0.27	-4.58	-0.38	1.11e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs7192750	0.538	rs8054403	chr16:71990573	G/A	cg06353428	chr16:71660113	MARVELD3	0.74	6.34	0.49	3.84e-9	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs4076764	1.000	rs4076764	chr1:163441286	A/G	cg24596788	chr1:163392923	NA	-0.17	-4.99	-0.41	2.01e-6	Motion sickness;
TGCT	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg23758822	chr17:41437982	NA	0.67	6.8	0.52	3.96e-10	Menopause (age at onset);
TGCT	cis	rs2404602	1.000	rs2896954	chr15:76851692	C/A	cg22467129	chr15:76604101	ETFA	-0.57	-6.54	-0.51	1.45e-9	Blood metabolite levels;
TGCT	cis	rs4919694	1.000	rs77827514	chr10:104822009	C/T	cg04362960	chr10:104952993	NT5C2	1.07	7.09	0.54	8.9e-11	Arsenic metabolism;
TGCT	cis	rs2288884	1.000	rs2043298	chr19:52573067	A/C	cg13540795	chr19:52551618	ZNF432	0.59	5.06	0.41	1.5e-6	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg26338869	chr17:61819248	STRADA	-0.53	-4.85	-0.4	3.68e-6	Prudent dietary pattern;
TGCT	cis	rs7772486	0.875	rs969694	chr6:146394655	A/G	cg23711669	chr6:146136114	FBXO30	0.9	9.83	0.66	3.29e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2797160	0.547	rs1418645	chr6:125946476	T/A	cg05901451	chr6:126070800	HEY2	-0.6	-5.02	-0.41	1.79e-6	Endometrial cancer;
TGCT	cis	rs950169	0.922	rs4842941	chr15:84831312	G/C	cg12863693	chr15:85201151	NMB	-0.41	-4.47	-0.37	1.77e-5	Schizophrenia;
TGCT	cis	rs9419702	0.614	rs9419567	chr10:133535149	C/G	cg20568497	chr10:133558893	NA	0.44	4.87	0.4	3.4e-6	Survival in rectal cancer;
TGCT	trans	rs797680	0.891	rs9432453	chr1:93771629	G/A	cg27528825	chr2:159282178	CCDC148	-0.34	-6.71	-0.52	6.19e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs7914558	0.966	rs11191438	chr10:104637864	C/G	cg05855489	chr10:104503620	C10orf26	0.51	4.6	0.38	1.02e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs114540395	0.925	rs76197608	chr10:103392896	T/C	cg18276125	chr10:102749041	C10orf2	0.41	5.04	0.41	1.58e-6	Schizophrenia;
TGCT	cis	rs57244997	1.000	rs73026573	chr6:162405119	C/T	cg17173639	chr6:162384350	PARK2	-0.46	-5.07	-0.41	1.43e-6	Mosquito bite size;
TGCT	cis	rs2299587	0.554	rs2073566	chr8:17743655	G/A	cg01800426	chr8:17659068	MTUS1	-0.55	-4.96	-0.41	2.25e-6	Economic and political preferences;
TGCT	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg26338869	chr17:61819248	STRADA	-0.55	-5.08	-0.41	1.37e-6	Prudent dietary pattern;
TGCT	cis	rs9611565	0.592	rs5996037	chr22:41965292	A/G	cg06634786	chr22:41940651	POLR3H	-0.88	-8.25	-0.6	1.98e-13	Vitiligo;
TGCT	cis	rs1857353	1.000	rs17096851	chr1:75888748	T/C	cg11838876	chr1:75668600	SLC44A5	-0.51	-4.81	-0.4	4.23e-6	Whole-brain volume (Alzheimer's disease interaction);
TGCT	trans	rs561341	0.943	rs508566	chr17:30289861	G/C	cg20587970	chr11:113659929	NA	-1.02	-10.68	-0.69	2.87e-19	Hip circumference adjusted for BMI;
TGCT	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.52	5.54	0.45	1.73e-7	Lymphocyte counts;
TGCT	cis	rs2463822	1.000	rs2513744	chr11:62077785	C/A	cg06239285	chr11:62104954	ASRGL1	0.88	5.78	0.46	5.64e-8	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs1062177	0.826	rs2053063	chr5:151166764	T/C	cg00977110	chr5:151150581	G3BP1	0.4	4.62	0.38	9.33e-6	Preschool internalizing problems;
TGCT	cis	rs858239	0.509	rs6962213	chr7:23188109	G/A	cg05602783	chr7:23145260	KLHL7	-0.59	-4.74	-0.39	5.69e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs748404	0.534	rs489509	chr15:43586907	T/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	4.78	0.39	4.86e-6	Lung cancer;
TGCT	cis	rs4851266	1.000	rs12990462	chr2:100827216	G/A	cg22139774	chr2:100720529	AFF3	-0.35	-5.19	-0.42	8.51e-7	Educational attainment;
TGCT	cis	rs17741873	0.836	rs17630952	chr10:75601414	T/A	cg07699608	chr10:75541558	CHCHD1	0.69	4.87	0.4	3.27e-6	Paclitaxel disposition in epithelial ovarian cancer;
TGCT	cis	rs7617773	0.539	rs17593974	chr3:48387334	G/T	cg11946769	chr3:48343235	NME6	0.56	4.75	0.39	5.46e-6	Coronary artery disease;
TGCT	cis	rs1153858	1.000	rs1365610	chr15:45694610	C/T	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.62e-8	Homoarginine levels;
TGCT	cis	rs7267979	0.873	rs7453	chr20:25207074	A/G	cg16686733	chr20:25566563	NINL	0.55	5.56	0.45	1.57e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1729951	0.575	rs361245	chr3:136695706	A/G	cg12473912	chr3:136751656	NA	0.38	6.0	0.47	1.99e-8	Neuroticism;
TGCT	cis	rs10875746	0.951	rs10875748	chr12:48526360	A/G	cg20731937	chr12:48336164	NA	0.61	4.82	0.4	4.14e-6	Longevity (90 years and older);
TGCT	cis	rs7589728	0.563	rs78168096	chr2:88473575	G/A	cg04511125	chr2:88470314	THNSL2	0.63	4.98	0.41	2.04e-6	Plasma clusterin levels;
TGCT	cis	rs910316	1.000	rs175443	chr14:75601963	C/T	cg23033748	chr14:75592666	NEK9	-0.28	-4.84	-0.4	3.71e-6	Height;
TGCT	cis	rs2832191	0.791	rs57721945	chr21:30498744	T/C	cg24692254	chr21:30365293	RNF160	-0.86	-9.11	-0.63	1.83e-15	Dental caries;
TGCT	cis	rs7698623	0.850	rs3886171	chr4:88800053	A/G	cg02735620	chr4:88950514	PKD2	-0.44	-4.78	-0.39	4.95e-6	Cardiovascular disease risk factors;
TGCT	cis	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg08975724	chr8:8085496	FLJ10661	0.65	6.31	0.49	4.52e-9	Mood instability;
TGCT	cis	rs1451375	0.698	rs68143668	chr7:50638110	C/T	cg18232548	chr7:50535776	DDC	0.44	6.72	0.52	5.81e-10	Malaria;
TGCT	cis	rs2456568	0.803	rs10765642	chr11:93640355	C/T	cg26875233	chr11:93583750	C11orf90	0.46	6.09	0.48	1.33e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs9467711	0.651	rs7749414	chr6:26074884	G/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.6	-4.67	-0.39	7.83e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs769267	1.000	rs2285627	chr19:19467937	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.68	-5.97	-0.47	2.3e-8	Tonsillectomy;
TGCT	cis	rs72945132	0.825	rs72947052	chr11:70188575	A/G	cg00319359	chr11:70116639	PPFIA1	0.97	7.07	0.54	1.01e-10	Coronary artery disease;
TGCT	cis	rs9611565	0.512	rs139561	chr22:42195410	C/T	cg06481639	chr22:41940642	POLR3H	0.69	6.26	0.49	5.71e-9	Vitiligo;
TGCT	cis	rs6733011	0.518	rs12992214	chr2:99466337	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.5	-4.81	-0.4	4.34e-6	Bipolar disorder;
TGCT	cis	rs295140	0.803	rs4233994	chr2:201129211	G/C	cg04283868	chr2:201171347	SPATS2L	0.52	5.2	0.42	8.14e-7	QT interval;
TGCT	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg20607798	chr8:58055168	NA	0.44	4.45	0.37	1.9e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs11024102	0.925	rs7127818	chr11:17004090	G/C	cg15378786	chr11:17036137	PLEKHA7	0.48	4.44	0.37	1.95e-5	Glaucoma (primary angle closure);
TGCT	cis	rs78487399	0.908	rs73925553	chr2:43810646	T/C	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.66	4.67	0.39	7.66e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg25036284	chr2:26402008	FAM59B	-0.57	-4.99	-0.41	2e-6	Gut microbiome composition (summer);
TGCT	cis	rs3733585	0.654	rs4447863	chr4:9938969	T/C	cg00071950	chr4:10020882	SLC2A9	-0.62	-7.46	-0.56	1.33e-11	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs2439831	0.681	rs528517	chr15:43612925	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	6.63	0.51	9.35e-10	Lung cancer in ever smokers;
TGCT	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg22535103	chr8:58192502	C8orf71	-0.41	-4.81	-0.4	4.27e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9388451	0.807	rs1269175	chr6:126040435	A/G	cg05901451	chr6:126070800	HEY2	1.01	12.34	0.74	2.52e-23	Brugada syndrome;
TGCT	cis	rs7412746	0.634	rs12409208	chr1:150860055	A/G	cg04414720	chr1:150670196	GOLPH3L	0.4	4.82	0.4	4.06e-6	Melanoma;
TGCT	cis	rs739496	0.541	rs593226	chr12:111993886	A/G	cg10833066	chr12:111807467	FAM109A	0.35	5.57	0.45	1.52e-7	Platelet count;
TGCT	cis	rs727563	0.635	rs5751149	chr22:42139501	A/G	cg17554472	chr22:41940697	POLR3H	0.46	4.72	0.39	6.36e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs7666738	0.830	rs7659420	chr4:98878714	G/C	cg18180107	chr4:99064573	C4orf37	0.57	5.19	0.42	8.47e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9611565	0.921	rs5751077	chr22:41720728	G/C	cg06634786	chr22:41940651	POLR3H	-0.62	-5.93	-0.47	2.82e-8	Vitiligo;
TGCT	cis	rs1801251	1.000	rs283475	chr2:233654381	A/C	cg08000102	chr2:233561755	GIGYF2	-0.62	-6.51	-0.5	1.66e-9	Coronary artery disease;
TGCT	cis	rs13102973	0.720	rs7687641	chr4:135885739	C/T	cg14419869	chr4:135874104	NA	0.26	4.6	0.38	1.03e-5	Subjective well-being;
TGCT	cis	rs896854	0.573	rs13271375	chr8:95853907	A/G	cg23172400	chr8:95962367	TP53INP1	-0.29	-4.44	-0.37	1.97e-5	Type 2 diabetes;
TGCT	trans	rs797680	0.856	rs12044657	chr1:93639596	T/C	cg27528825	chr2:159282178	CCDC148	-0.35	-6.83	-0.52	3.31e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs17376456	0.877	rs13169675	chr5:93331284	A/G	cg21475434	chr5:93447410	FAM172A	0.64	4.73	0.39	6.09e-6	Diabetic retinopathy;
TGCT	cis	rs12477438	0.798	rs17708218	chr2:99696284	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.67	-5.99	-0.47	2.11e-8	Chronic sinus infection;
TGCT	cis	rs9291683	0.552	rs10939655	chr4:10014642	A/T	cg00071950	chr4:10020882	SLC2A9	0.76	10.38	0.68	1.55e-18	Bone mineral density;
TGCT	cis	rs4819052	0.765	rs2838868	chr21:46714641	A/G	cg06618935	chr21:46677482	NA	0.37	5.35	0.43	4e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	trans	rs1005277	0.505	rs200937	chr10:38135772	T/C	cg17830980	chr10:43048298	ZNF37B	-0.72	-8.22	-0.59	2.27e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs3741404	0.560	rs17699798	chr11:63898806	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.76	-7.29	-0.55	3.22e-11	Platelet count;
TGCT	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.71	5.14	0.42	1.02e-6	Platelet count;
TGCT	cis	rs12477438	0.765	rs2278895	chr2:99613484	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-4.88	-0.4	3.17e-6	Chronic sinus infection;
TGCT	cis	rs2677744	0.534	rs6496739	chr15:91494430	C/T	cg23684204	chr15:91497937	RCCD1	0.41	6.36	0.5	3.45e-9	Attention deficit hyperactivity disorder;
TGCT	cis	rs854765	0.575	rs2955357	chr17:17946401	T/C	cg04398451	chr17:18023971	MYO15A	0.33	5.44	0.44	2.77e-7	Total body bone mineral density;
TGCT	cis	rs2204008	0.806	rs1589382	chr12:38408565	T/A	cg26384229	chr12:38710491	ALG10B	0.84	7.51	0.56	1e-11	Bladder cancer;
TGCT	cis	rs2742417	0.967	rs2742427	chr3:45736423	C/T	cg04837898	chr3:45731254	SACM1L	0.51	5.07	0.41	1.43e-6	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg13342137	chr4:2252803	MXD4	0.16	4.46	0.37	1.83e-5	Obesity-related traits;
TGCT	cis	rs1997103	0.954	rs56030000	chr7:55405750	A/G	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs13191362	1.000	rs67025553	chr6:163011552	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs523522	0.962	rs4767912	chr12:120981202	A/G	cg12219531	chr12:120966889	COQ5	0.83	7.27	0.55	3.46e-11	High light scatter reticulocyte count;
TGCT	cis	rs5167	0.534	rs56803710	chr19:45481884	C/T	cg09555818	chr19:45449301	APOC2	0.23	4.62	0.38	9.53e-6	Blood protein levels;
TGCT	cis	rs7547997	0.685	rs7521814	chr1:158346996	G/A	cg03528325	chr1:158223921	CD1A	0.33	4.56	0.38	1.22e-5	QRS duration;
TGCT	cis	rs61990749	0.597	rs11624101	chr14:78138059	G/A	cg23188588	chr14:78226832	SNW1;C14orf178	-0.68	-4.76	-0.39	5.29e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs6967414	0.786	rs7782227	chr7:6748594	T/C	cg09896999	chr7:6746977	ZNF12	-0.57	-6.37	-0.5	3.36e-9	Hematocrit;Hemoglobin concentration;
TGCT	cis	rs7666738	0.830	rs6827516	chr4:98971740	T/C	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg03264133	chr6:25882463	NA	-0.57	-6.07	-0.48	1.45e-8	Blood metabolite levels;
TGCT	cis	rs9311474	1.000	rs7629072	chr3:52305633	C/T	cg10802521	chr3:52805072	NEK4	-0.58	-6.36	-0.5	3.52e-9	Electroencephalogram traits;
TGCT	cis	rs1670533	0.932	rs2045067	chr4:1052355	C/T	cg27284194	chr4:1044797	NA	0.68	5.76	0.46	6.38e-8	Recombination rate (females);
TGCT	cis	rs4727443	0.653	rs6465759	chr7:99587980	T/C	cg13334819	chr7:99746414	C7orf59	-0.58	-4.98	-0.41	2.07e-6	Interstitial lung disease;
TGCT	cis	rs986417	0.901	rs7157458	chr14:60999852	C/T	cg27398547	chr14:60952738	C14orf39	1.38	10.8	0.7	1.4e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs5769765	0.671	rs138844	chr22:50184484	T/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.34	4.68	0.39	7.27e-6	Schizophrenia;
TGCT	cis	rs9921222	0.564	rs9923059	chr16:381590	C/A	cg00101154	chr16:420108	MRPL28	-0.67	-7.59	-0.56	6.74e-12	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs11779988	0.545	rs208759	chr8:17807929	G/C	cg01800426	chr8:17659068	MTUS1	-0.64	-4.99	-0.41	2.02e-6	Breast cancer;
TGCT	trans	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg13565492	chr6:43139072	SRF	-0.77	-7.35	-0.55	2.37e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs427394	0.802	rs200841	chr5:6737134	A/G	cg10857441	chr5:6722123	POLS	-0.34	-8.21	-0.59	2.46e-13	Menopause (age at onset);
TGCT	cis	rs1008375	1.000	rs11727312	chr4:17669185	C/T	cg18681998	chr4:17616180	MED28	0.94	10.42	0.68	1.2e-18	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs13191362	1.000	rs7769686	chr6:163199467	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.94	6.76	0.52	4.71e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs10883723	0.962	rs1056738	chr10:104236481	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	7.52	0.56	9.74e-12	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs896854	0.684	rs10099941	chr8:95987008	C/T	cg09323728	chr8:95962352	TP53INP1	-0.48	-6.22	-0.49	7.08e-9	Type 2 diabetes;
TGCT	cis	rs7819412	0.777	rs1057626	chr8:10962800	T/C	cg21775007	chr8:11205619	TDH	-0.52	-5.06	-0.41	1.45e-6	Triglycerides;
TGCT	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg16049864	chr8:95962084	TP53INP1	-0.72	-10.07	-0.67	8.64e-18	Type 2 diabetes;
TGCT	cis	rs7267979	0.844	rs2257649	chr20:25263457	T/G	cg03522245	chr20:25566470	NINL	0.55	5.55	0.45	1.68e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4319547	0.695	rs12314643	chr12:122917423	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.64	-5.09	-0.42	1.27e-6	Body mass index;
TGCT	cis	rs4711336	1.000	rs2296742	chr6:33659793	G/A	cg14003231	chr6:33640908	ITPR3	0.28	4.51	0.38	1.49e-5	Height;
TGCT	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg04352962	chr1:209979756	IRF6	0.61	4.67	0.39	7.72e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs12477438	0.765	rs2167930	chr2:99592551	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-6.25	-0.49	5.98e-9	Chronic sinus infection;
TGCT	cis	rs66573146	0.831	rs68111914	chr4:6986677	C/T	cg00086871	chr4:6988644	TBC1D14	0.94	4.62	0.38	9.61e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg25427524	chr10:38739819	LOC399744	-0.39	-8.05	-0.59	5.9e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs6933660	0.512	rs13198669	chr6:151799924	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	0.74	4.66	0.39	7.97e-6	Menarche (age at onset);
TGCT	cis	rs7216064	1.000	rs7210027	chr17:65977053	C/T	cg12091567	chr17:66097778	LOC651250	0.83	6.38	0.5	3.16e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs8050907	0.744	rs8044698	chr16:4577069	A/G	cg02183435	chr16:5121731	ALG1	0.74	4.46	0.37	1.8e-5	Obesity-related traits;
TGCT	cis	rs3020736	0.500	rs4147638	chr22:42487900	G/A	cg15557168	chr22:42548783	NA	0.22	5.58	0.45	1.47e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs896854	0.516	rs12679044	chr8:95891356	C/A	cg09323728	chr8:95962352	TP53INP1	-0.38	-4.48	-0.37	1.65e-5	Type 2 diabetes;
TGCT	trans	rs1864982	0.685	rs10062859	chr5:146211917	C/T	cg07017998	chr4:733617	PCGF3	0.28	7.12	0.54	7.8e-11	Alcohol dependence;
TGCT	cis	rs1568889	0.838	rs12273631	chr11:28042135	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.94	11.28	0.71	9.55e-21	Bipolar disorder;
TGCT	cis	rs675209	0.559	rs17762454	chr6:7213200	C/T	cg27097018	chr6:6320614	F13A1	0.37	5.39	0.44	3.35e-7	Urate levels;
TGCT	cis	rs66561647	0.719	rs7821928	chr8:128939295	G/A	cg11792826	chr8:129160931	MIR1208	0.22	4.95	0.41	2.37e-6	Hemoglobin concentration;
TGCT	cis	rs748404	0.578	rs4547312	chr15:43632138	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	4.94	0.41	2.51e-6	Lung cancer;
TGCT	cis	rs6542838	0.704	rs13011428	chr2:99528305	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.55	-5.14	-0.42	1.04e-6	Fear of minor pain;
TGCT	cis	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg21775007	chr8:11205619	TDH	-0.55	-5.3	-0.43	5.23e-7	Neuroticism;
TGCT	cis	rs11122272	0.735	rs2247124	chr1:231493687	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-6.82	-0.52	3.61e-10	Hemoglobin concentration;
TGCT	cis	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg12570787	chr5:219185	SDHA;CCDC127	0.68	4.49	0.37	1.59e-5	Breast cancer;
TGCT	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.27	4.9	0.4	2.94e-6	Schizophrenia;
TGCT	cis	rs2380220	0.606	rs7747776	chr6:96005852	C/T	cg04719120	chr6:96025338	MANEA	0.6	4.87	0.4	3.37e-6	Behavioural disinhibition (generation interaction);
TGCT	cis	rs8180040	0.764	rs13061071	chr3:47138708	G/A	cg27129171	chr3:47204927	SETD2	0.73	9.48	0.65	2.25e-16	Colorectal cancer;
TGCT	cis	rs2952156	0.652	rs11869286	chr17:37813856	C/G	cg00129232	chr17:37814104	STARD3	-0.23	-4.8	-0.4	4.43e-6	Asthma;
TGCT	cis	rs514406	0.698	rs1775540	chr1:53407893	C/A	cg27535305	chr1:53392650	SCP2	-0.28	-5.74	-0.46	6.91e-8	Monocyte count;
TGCT	cis	rs6669072	0.528	rs3856226	chr1:91245109	C/T	cg08895590	chr1:91227319	NA	0.36	4.63	0.38	9.27e-6	Cognitive function;
TGCT	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg04234412	chr22:24373322	LOC391322	-0.91	-10.67	-0.69	2.98e-19	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs12497850	0.931	rs9840050	chr3:49133310	A/G	cg06212747	chr3:49208901	KLHDC8B	0.61	5.66	0.45	9.84e-8	Parkinson's disease;
TGCT	trans	rs9388451	0.772	rs1268064	chr6:126042578	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.7	7.4	0.55	1.84e-11	Brugada syndrome;
TGCT	cis	rs2847281	0.764	rs2847276	chr18:12777948	A/C	cg23598886	chr18:12777645	NA	0.36	4.54	0.38	1.3e-5	C-reactive protein levels;Esophageal cancer (squamous cell);
TGCT	cis	rs9467773	0.620	rs2451744	chr6:26633463	G/T	cg02458000	chr6:26745757	NA	0.53	5.02	0.41	1.76e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7937682	0.737	rs682239	chr11:111425105	A/G	cg09085632	chr11:111637200	PPP2R1B	0.81	8.38	0.6	9.75e-14	Primary sclerosing cholangitis;
TGCT	cis	rs7582180	0.681	rs6754176	chr2:100995691	C/T	cg14675211	chr2:100938903	LONRF2	0.47	4.45	0.37	1.89e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7000551	0.751	rs2449340	chr8:22389900	T/G	cg12081754	chr8:22256438	SLC39A14	0.28	4.66	0.39	8.01e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs4888262	0.526	rs6564142	chr16:74590047	T/C	cg01733217	chr16:74700730	RFWD3	0.71	7.11	0.54	7.94e-11	Testicular germ cell tumor;
TGCT	cis	rs12048904	0.595	rs2295280	chr1:101342497	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.71	7.39	0.55	1.92e-11	Multiple sclerosis;
TGCT	cis	rs8072100	0.967	rs8072644	chr17:45653364	A/T	cg08085267	chr17:45401833	C17orf57	0.43	4.77	0.39	5.01e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs13424612	0.965	rs4149544	chr2:240943162	C/T	cg26363272	chr2:240904871	NDUFA10	0.28	4.67	0.39	7.7e-6	Odorant perception (isobutyraldehyde);
TGCT	cis	rs17102423	0.589	rs4899162	chr14:65614126	G/T	cg11161011	chr14:65562177	MAX	-0.41	-5.66	-0.45	9.83e-8	Obesity-related traits;
TGCT	cis	rs10791323	0.559	rs10750548	chr11:133729469	A/G	cg03690763	chr11:133734501	NA	-0.3	-4.53	-0.38	1.38e-5	Childhood ear infection;
TGCT	cis	rs916888	0.821	rs199512	chr17:44857352	T/C	cg16520312	chr17:43971471	MAPT;LOC100128977	0.57	4.86	0.4	3.45e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs9443645	0.901	rs9343843	chr6:79585625	C/T	cg05283184	chr6:79620031	NA	-0.21	-4.71	-0.39	6.61e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs826838	0.935	rs7301104	chr12:39182821	C/T	cg13010199	chr12:38710504	ALG10B	0.77	6.09	0.48	1.31e-8	Heart rate;
TGCT	cis	rs9443645	0.838	rs946022	chr6:79672133	G/T	cg05283184	chr6:79620031	NA	-0.21	-4.71	-0.39	6.61e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7647973	1.000	rs10155014	chr3:49432321	C/T	cg05785598	chr3:49045655	WDR6	0.39	4.66	0.39	8e-6	Menarche (age at onset);
TGCT	cis	rs7677751	0.806	rs7698425	chr4:55090656	C/T	cg17187183	chr4:55093834	PDGFRA	0.53	6.92	0.53	2.19e-10	Corneal astigmatism;
TGCT	cis	rs453301	0.653	rs7005133	chr8:8901222	T/G	cg15556689	chr8:8085844	FLJ10661	0.86	7.99	0.58	7.9e-13	Joint mobility (Beighton score);
TGCT	cis	rs1215050	0.765	rs1588018	chr4:98756324	G/C	cg05340658	chr4:99064831	C4orf37	0.44	5.63	0.45	1.15e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs12983728	0.732	rs34003091	chr19:58662254	T/C	cg07378217	chr19:58662286	ZNF329	-0.9	-5.1	-0.42	1.25e-6	Cholesterol, total;
TGCT	cis	rs116095464	0.558	rs10475136	chr5:232796	A/G	cg22857025	chr5:266934	NA	-0.33	-6.57	-0.51	1.22e-9	Breast cancer;
TGCT	cis	rs7178572	0.568	rs11072653	chr15:77693934	C/T	cg15453836	chr15:77711506	NA	-0.42	-4.78	-0.39	4.92e-6	Type 2 diabetes;
TGCT	cis	rs6933660	0.665	rs6921042	chr6:151732385	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.87	-9.14	-0.63	1.48e-15	Menarche (age at onset);
TGCT	cis	rs6500602	0.701	rs4786500	chr16:4525265	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	-0.45	-6.49	-0.5	1.88e-9	Schizophrenia;
TGCT	cis	rs7959452	0.868	rs10878967	chr12:69740869	T/C	cg14784868	chr12:69753453	YEATS4	0.7	7.22	0.54	4.55e-11	Blood protein levels;
TGCT	cis	rs901683	0.702	rs78757497	chr10:46161918	T/C	cg18240400	chr10:46168597	ANUBL1	0.56	4.61	0.38	9.7e-6	Red blood cell traits;Mean corpuscular volume;
TGCT	cis	rs972578	0.561	rs5759113	chr22:43443952	C/G	cg03373887	chr22:44389424	SAMM50	0.21	4.53	0.38	1.36e-5	Mean platelet volume;
TGCT	cis	rs10949662	0.961	rs77185864	chr7:157529621	G/T	cg14168080	chr7:157504135	PTPRN2	-0.39	-4.6	-0.38	1.05e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs8031584	0.736	rs11635775	chr15:31160640	A/G	cg08704250	chr15:31115839	NA	-0.44	-6.49	-0.5	1.88e-9	Huntington's disease progression;
TGCT	cis	rs838147	0.507	rs692854	chr19:49209464	C/A	cg05248581	chr19:49925731	PTH2	0.42	4.55	0.38	1.26e-5	Dietary macronutrient intake;
TGCT	cis	rs28595532	0.764	rs115011450	chr4:119778171	C/T	cg14228332	chr4:119757509	SEC24D	1.26	7.08	0.54	9.26e-11	Cannabis dependence symptom count;
TGCT	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg17971929	chr21:40555470	PSMG1	-0.54	-4.93	-0.4	2.56e-6	Menarche (age at onset);
TGCT	cis	rs7192750	0.586	rs1981874	chr16:71897244	C/T	cg06353428	chr16:71660113	MARVELD3	-0.91	-7.93	-0.58	1.1e-12	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs8056742	0.643	rs55877407	chr16:85087310	T/A	cg00229868	chr16:85520891	NA	0.36	4.83	0.4	4.03e-6	Amyotrophic lateral sclerosis;
TGCT	cis	rs6484504	0.576	rs158139	chr11:31216076	C/T	cg26647111	chr11:31128758	NA	-0.34	-4.62	-0.38	9.36e-6	Red blood cell count;
TGCT	cis	rs62244186	0.748	rs6441861	chr3:44652287	A/G	cg10108389	chr3:44770937	ZNF501	-0.47	-4.64	-0.38	8.67e-6	Depressive symptoms;
TGCT	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg08219700	chr8:58056026	NA	0.41	4.94	0.41	2.47e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs736408	0.924	rs2535629	chr3:52833219	C/T	cg10802521	chr3:52805072	NEK4	-0.67	-7.4	-0.55	1.85e-11	Bipolar disorder;
TGCT	cis	rs74233809	1.000	rs35125602	chr10:104656039	G/A	cg05855489	chr10:104503620	C10orf26	0.74	4.45	0.37	1.87e-5	Birth weight;
TGCT	cis	rs11105298	0.891	rs11105310	chr12:89918677	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.67	-4.91	-0.4	2.78e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs11958404	0.789	rs72818145	chr5:157476552	G/C	cg05962755	chr5:157440814	NA	0.35	4.48	0.37	1.65e-5	IgG glycosylation;
TGCT	cis	rs2072499	1.000	rs2253809	chr1:156172125	T/C	cg25208724	chr1:156163844	SLC25A44	1.11	16.13	0.82	3.11e-32	Testicular germ cell tumor;
TGCT	cis	rs2019216	0.542	rs1987424	chr17:21874036	G/A	cg22648282	chr17:21454238	C17orf51	-0.56	-5.51	-0.44	1.95e-7	Pelvic organ prolapse;
TGCT	cis	rs1395	1.000	rs1275530	chr2:27432547	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.49	-6.62	-0.51	9.77e-10	Blood metabolite levels;
TGCT	cis	rs950169	0.881	rs72750843	chr15:85135783	C/T	cg11189052	chr15:85197271	WDR73	0.77	6.5	0.5	1.76e-9	Schizophrenia;
TGCT	cis	rs56104184	0.723	rs73063522	chr19:49408358	C/G	cg21252483	chr19:49399788	TULP2	-0.42	-5.89	-0.47	3.47e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg07507251	chr3:52567010	NT5DC2	-0.45	-6.3	-0.49	4.7e-9	Electroencephalogram traits;
TGCT	cis	rs7119	0.636	rs11635606	chr15:77819591	A/G	cg27398640	chr15:77910606	LINGO1	-0.25	-4.55	-0.38	1.27e-5	Type 2 diabetes;
TGCT	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.71	7.06	0.54	1.07e-10	Prudent dietary pattern;
TGCT	cis	rs4595586	0.545	rs1156707	chr12:39372451	G/T	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs7588654	0.793	rs17608726	chr2:219947002	G/A	cg06736663	chr2:219754761	WNT10A	-0.48	-4.79	-0.39	4.72e-6	Height;
TGCT	cis	rs2033711	0.870	rs4801583	chr19:58918405	A/G	cg04608855	chr19:58913158	NA	0.61	6.18	0.49	8.34e-9	Uric acid clearance;
TGCT	cis	rs6952808	0.609	rs10232234	chr7:1948110	G/T	cg04267008	chr7:1944627	MAD1L1	-0.36	-4.72	-0.39	6.34e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs9611519	0.780	rs5751072	chr22:41656509	C/T	cg06634786	chr22:41940651	POLR3H	-0.55	-5.06	-0.41	1.46e-6	Neuroticism;
TGCT	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg18402987	chr7:1209562	NA	0.81	6.94	0.53	1.9e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7666738	0.791	rs1830231	chr4:99026185	A/C	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12049351	0.774	rs34232465	chr1:229631112	C/T	cg12130225	chr1:229698885	NA	0.39	4.58	0.38	1.12e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs524281	0.647	rs2302883	chr11:65824994	T/C	cg00563793	chr11:65837595	PACS1	0.55	4.84	0.4	3.79e-6	Electroencephalogram traits;
TGCT	cis	rs7917772	0.503	rs2031602	chr10:104307955	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	8.6	0.61	2.97e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9457247	1.000	rs2013815	chr6:167373812	T/A	cg25258033	chr6:167368657	RNASET2	-0.18	-4.48	-0.37	1.65e-5	Crohn's disease;
TGCT	cis	rs17376456	0.877	rs10044139	chr5:93407803	T/C	cg21475434	chr5:93447410	FAM172A	0.59	4.66	0.39	8.09e-6	Diabetic retinopathy;
TGCT	cis	rs612683	0.735	rs3754131	chr1:100931073	A/C	cg06223162	chr1:101003688	GPR88	0.31	4.89	0.4	3.09e-6	Breast cancer;
TGCT	cis	rs7586879	0.616	rs12713422	chr2:25134497	A/C	cg15423357	chr2:25149977	NA	0.52	5.04	0.41	1.63e-6	Body mass index;
TGCT	cis	rs12926788	0.689	rs34365165	chr16:24856208	G/A	cg06028605	chr16:24865363	SLC5A11	0.43	4.87	0.4	3.34e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6570726	0.875	rs373313	chr6:145857791	T/C	cg05347473	chr6:146136440	FBXO30	0.49	4.54	0.38	1.29e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs826838	0.967	rs826858	chr12:39116731	A/G	cg26384229	chr12:38710491	ALG10B	-0.86	-7.76	-0.57	2.68e-12	Heart rate;
TGCT	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg10047753	chr17:41438598	NA	0.84	7.61	0.56	5.9e-12	Menopause (age at onset);
TGCT	cis	rs7715806	0.509	rs34349	chr5:74944868	A/G	cg19683494	chr5:74908142	NA	-0.64	-5.87	-0.47	3.74e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs12136530	0.593	rs881248	chr1:19733961	C/T	cg24875000	chr1:19041556	PAX7	0.27	4.82	0.4	4.15e-6	Lead levels in blood;
TGCT	cis	rs9467711	0.606	rs9393711	chr6:26370659	C/T	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs968451	1.000	rs11704615	chr22:39696834	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.87	7.73	0.57	3.17e-12	Primary biliary cholangitis;
TGCT	cis	rs12701220	0.894	rs12539012	chr7:1052133	G/A	cg27454412	chr7:1067447	C7orf50	-0.48	-4.44	-0.37	1.98e-5	Bronchopulmonary dysplasia;
TGCT	cis	rs617219	0.710	rs6874525	chr5:78574237	C/T	cg23514016	chr5:78407564	BHMT	-0.32	-4.87	-0.4	3.38e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs2562456	0.920	rs2650784	chr19:21666597	T/C	cg25650185	chr19:21324782	ZNF431	0.56	4.83	0.4	4.02e-6	Pain;
TGCT	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg16423285	chr20:60520624	NA	-0.7	-7.45	-0.56	1.42e-11	Body mass index;
TGCT	cis	rs67072384	1.000	rs12292781	chr11:72448385	A/C	cg03713592	chr11:72463424	ARAP1	-0.94	-4.8	-0.4	4.41e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs3806843	1.000	rs10072015	chr5:140170655	A/T	cg19875535	chr5:140030758	IK	-0.37	-6.26	-0.49	5.83e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs4700695	0.719	rs1643415	chr5:65447087	T/C	cg21114390	chr5:65439923	SFRS12	-0.84	-7.45	-0.56	1.35e-11	Facial morphology (factor 19);
TGCT	cis	rs797680	0.856	rs4847410	chr1:93802781	G/A	cg17826107	chr1:92977322	EVI5	-0.23	-5.07	-0.41	1.4e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	trans	rs7726839	0.540	rs3749618	chr5:602650	A/G	cg11887960	chr12:57824829	NA	1.17	9.69	0.66	7.25e-17	Obesity-related traits;
TGCT	cis	rs2303745	0.589	rs891018	chr19:17396761	C/T	cg04248312	chr19:17393744	ANKLE1	0.35	6.14	0.48	1.01e-8	Systemic lupus erythematosus;
TGCT	cis	rs6570726	0.755	rs2103633	chr6:145894021	C/T	cg13319975	chr6:146136371	FBXO30	-0.5	-4.51	-0.38	1.48e-5	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs2749592	0.550	rs7917262	chr10:37874602	A/C	cg17830980	chr10:43048298	ZNF37B	0.65	6.85	0.52	2.99e-10	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs909685	0.538	rs5757589	chr22:39668353	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.73	8.29	0.6	1.61e-13	Rheumatoid arthritis;
TGCT	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg18876405	chr7:65276391	NA	0.38	5.89	0.47	3.4e-8	Calcium levels;
TGCT	cis	rs11096990	0.613	rs35391082	chr4:39192653	C/T	cg20847110	chr4:39482781	LOC401127	0.16	4.52	0.38	1.42e-5	Cognitive function;
TGCT	cis	rs56399783	0.901	rs17132594	chr7:2775102	G/A	cg19731401	chr7:2775893	GNA12	0.35	4.98	0.41	2.04e-6	Childhood ear infection;
TGCT	cis	rs1153858	1.000	rs12439274	chr15:45636667	A/G	cg14582100	chr15:45693742	SPATA5L1	0.5	5.77	0.46	6.02e-8	Homoarginine levels;
TGCT	cis	rs317689	0.718	rs645026	chr12:69757931	G/A	cg20891283	chr12:69753455	YEATS4	0.56	4.71	0.39	6.52e-6	Response to diuretic therapy;
TGCT	cis	rs6570726	0.846	rs6570698	chr6:145918635	C/G	cg23711669	chr6:146136114	FBXO30	0.83	8.64	0.61	2.4e-14	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.49	-6.42	-0.5	2.58e-9	Alzheimer's disease;
TGCT	cis	rs2657888	1.000	rs7310284	chr12:56935652	A/G	cg23002907	chr12:56915593	RBMS2	0.48	6.59	0.51	1.14e-9	Adiponectin levels;
TGCT	cis	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg22857025	chr5:266934	NA	-0.34	-6.7	-0.52	6.65e-10	Breast cancer;
TGCT	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg01171360	chr6:293285	DUSP22	-0.77	-7.85	-0.58	1.67e-12	Menopause (age at onset);
TGCT	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg03303774	chr4:1407052	NA	0.28	4.58	0.38	1.12e-5	Obesity-related traits;
TGCT	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg22166914	chr1:53195759	ZYG11B	-0.42	-7.46	-0.56	1.33e-11	Monocyte count;
TGCT	cis	rs4722585	0.605	rs3753098	chr7:26198040	C/T	cg03781084	chr7:26191726	NFE2L3	0.47	4.72	0.39	6.24e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
TGCT	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg05665937	chr4:1216051	CTBP1	0.26	5.12	0.42	1.13e-6	Obesity-related traits;
TGCT	cis	rs35160687	0.901	rs10200186	chr2:86527423	C/T	cg12542933	chr2:85804724	VAMP8	0.41	4.9	0.4	2.97e-6	Night sleep phenotypes;
TGCT	cis	rs9303401	0.614	rs35057477	chr17:57097064	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.63	5.82	0.46	4.8e-8	Cognitive test performance;
TGCT	cis	rs6967414	0.786	rs3757482	chr7:6748927	A/G	cg00387323	chr7:6746715	ZNF12	0.79	4.92	0.4	2.67e-6	Hematocrit;Hemoglobin concentration;
TGCT	cis	rs669446	0.561	rs1143701	chr1:44084739	C/T	cg12908607	chr1:44402522	ARTN	-0.54	-5.68	-0.45	8.9e-8	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs17601876	0.651	rs12908960	chr15:51545860	G/A	cg19946085	chr15:51559439	CYP19A1	-0.34	-4.86	-0.4	3.5e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs926938	0.563	rs360642	chr1:115425429	C/G	cg12756093	chr1:115239321	AMPD1	0.4	6.34	0.49	3.97e-9	Autism;
TGCT	cis	rs75686122	1.000	rs2114249	chr8:104719519	T/A	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs9611565	0.649	rs4822050	chr22:42177453	C/G	cg03806693	chr22:41940476	POLR3H	-0.88	-8.55	-0.61	3.93e-14	Vitiligo;
TGCT	cis	rs4722166	0.645	rs1404006	chr7:22795077	T/C	cg26061582	chr7:22766209	IL6	0.49	6.28	0.49	5.1e-9	Lung cancer;
TGCT	cis	rs9788721	0.836	rs2568494	chr15:78740964	G/A	cg18825076	chr15:78729989	IREB2	-0.33	-5.32	-0.43	4.68e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
TGCT	cis	rs7095607	0.521	rs2673792	chr10:69927959	T/A	cg18986048	chr10:69913749	MYPN	0.6	6.29	0.49	4.96e-9	Lung function (FVC);
TGCT	trans	rs561341	0.505	rs41291021	chr17:30410689	C/A	cg20587970	chr11:113659929	NA	-1.01	-8.24	-0.59	2.09e-13	Hip circumference adjusted for BMI;
TGCT	cis	rs6582630	0.599	rs8189525	chr12:38424982	A/C	cg26384229	chr12:38710491	ALG10B	0.56	5.13	0.42	1.1e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs60871478	0.853	rs62432864	chr7:808405	T/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.45	4.51	0.38	1.46e-5	Cerebrospinal P-tau181p levels;
TGCT	cis	rs6570726	0.905	rs1355146	chr6:145781741	A/C	cg23711669	chr6:146136114	FBXO30	-0.7	-6.5	-0.5	1.78e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs57590327	0.503	rs2372906	chr3:81504673	G/A	cg07356753	chr3:81810745	GBE1	0.58	4.89	0.4	3.06e-6	Extraversion;
TGCT	trans	rs901683	0.702	rs73292848	chr10:46169752	T/C	cg18828137	chr12:52968145	KRT74	-0.61	-6.84	-0.52	3.2e-10	Red blood cell traits;Mean corpuscular volume;
TGCT	cis	rs1150668	0.799	rs2142730	chr6:28266149	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.49	-4.86	-0.4	3.52e-6	Pubertal anthropometrics;
TGCT	cis	rs1903068	0.853	rs28680424	chr4:56009245	T/C	cg01777861	chr4:56023843	NA	0.54	6.11	0.48	1.21e-8	Endometriosis;
TGCT	cis	rs2295359	0.892	rs17375018	chr1:67655147	A/G	cg12940439	chr1:67600707	NA	-0.61	-6.1	-0.48	1.22e-8	Psoriasis;
TGCT	cis	rs4563143	0.592	rs12151001	chr19:29283386	C/G	cg12756686	chr19:29218302	NA	0.78	6.69	0.51	6.93e-10	Methadone dose in opioid dependence;
TGCT	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg08280861	chr8:58055591	NA	0.41	4.63	0.38	8.93e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs8051431	0.840	rs7185272	chr16:72013797	G/C	cg06353428	chr16:71660113	MARVELD3	0.59	5.02	0.41	1.73e-6	LDL cholesterol levels;
TGCT	cis	rs7605378	0.528	rs281787	chr2:200784238	C/T	cg17644776	chr2:200775616	C2orf69	-0.32	-7.16	-0.54	6.12e-11	Osteoporosis;
TGCT	cis	rs9902453	0.900	rs12451122	chr17:28486376	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	5.41	0.44	3.13e-7	Coffee consumption (cups per day);
TGCT	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg00684032	chr4:1343700	KIAA1530	-0.22	-4.73	-0.39	6.06e-6	Obesity-related traits;
TGCT	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg24250549	chr1:154909240	PMVK	0.58	5.76	0.46	6.21e-8	Prostate cancer;
TGCT	cis	rs7208859	0.673	rs11658435	chr17:29228561	A/G	cg14008862	chr17:28927542	LRRC37B2	0.72	4.66	0.39	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs11792861	0.926	rs11787878	chr9:111866749	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.48	4.48	0.37	1.66e-5	Menarche (age at onset);
TGCT	cis	rs78461346	0.908	rs77207724	chr17:80506440	T/C	cg15014069	chr17:80540666	FOXK2	0.4	5.04	0.41	1.62e-6	3-hydroxypropylmercapturic acid levels in smokers;
TGCT	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	4.92	0.4	2.64e-6	Menopause (age at onset);
TGCT	cis	rs7552404	0.731	rs11161836	chr1:76354333	C/T	cg03433033	chr1:76189801	ACADM	0.75	7.34	0.55	2.41e-11	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs853679	0.567	rs7754960	chr6:28346945	G/C	cg18815343	chr6:28367644	ZSCAN12	-0.52	-4.72	-0.39	6.26e-6	Depression;
TGCT	cis	rs4727027	0.704	rs12704083	chr7:148909759	G/A	cg23583168	chr7:148888333	NA	-0.86	-10.99	-0.7	4.87e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs4919694	1.000	rs4917986	chr10:104630181	T/C	cg04362960	chr10:104952993	NT5C2	1.05	7.23	0.54	4.37e-11	Arsenic metabolism;
TGCT	cis	rs67311347	1.000	rs11715214	chr3:40403004	C/A	cg13409248	chr3:40428643	ENTPD3	0.54	4.52	0.38	1.41e-5	Renal cell carcinoma;
TGCT	cis	rs4788570	0.615	rs6499526	chr16:71648299	C/T	cg06353428	chr16:71660113	MARVELD3	1.54	12.75	0.75	2.57e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs7552404	0.696	rs67487205	chr1:76373756	T/C	cg03433033	chr1:76189801	ACADM	0.76	7.2	0.54	5.19e-11	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7666738	0.830	rs11944107	chr4:98931638	G/C	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	6.11	0.48	1.17e-8	Alzheimer's disease;
TGCT	cis	rs11167764	1.000	rs10057309	chr5:141479870	T/C	cg23435118	chr5:141488016	NDFIP1	-0.29	-4.83	-0.4	3.94e-6	Crohn's disease;
TGCT	cis	rs7666738	0.830	rs35531558	chr4:98938217	A/G	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10465746	0.725	rs6694752	chr1:84389960	C/T	cg10977910	chr1:84465055	TTLL7	0.73	7.31	0.55	2.95e-11	Obesity-related traits;
TGCT	cis	rs10876993	0.928	rs1689595	chr12:58056763	C/T	cg15848620	chr12:58087721	OS9	-0.73	-6.07	-0.48	1.44e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs1891275	0.515	rs11186666	chr10:93477919	T/C	cg07889827	chr10:93443413	NA	-0.32	-6.75	-0.52	5.12e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs950169	0.810	rs2879976	chr15:85109578	G/A	cg11189052	chr15:85197271	WDR73	0.77	6.42	0.5	2.68e-9	Schizophrenia;
TGCT	cis	rs11031096	0.811	rs4910599	chr11:4156040	T/A	cg18678763	chr11:4115507	RRM1	-0.46	-5.79	-0.46	5.36e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs478304	0.651	rs4930319	chr11:65555458	G/C	cg27068330	chr11:65405492	SIPA1	-0.95	-9.23	-0.64	8.93e-16	Acne (severe);
TGCT	cis	rs727563	0.594	rs5758408	chr22:42077737	A/C	cg13695892	chr22:41940480	POLR3H	0.89	8.6	0.61	2.92e-14	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs3749237	0.595	rs11130192	chr3:49467206	C/G	cg03060546	chr3:49711283	APEH	0.76	8.69	0.62	1.77e-14	Resting heart rate;
TGCT	cis	rs6815814	0.861	rs6843043	chr4:38843136	A/G	cg02016764	chr4:38805732	TLR1	-0.29	-4.68	-0.39	7.51e-6	Breast cancer;
TGCT	cis	rs7119	0.931	rs7176875	chr15:77832675	A/G	cg27398640	chr15:77910606	LINGO1	0.26	4.89	0.4	3.12e-6	Type 2 diabetes;
TGCT	cis	rs78456975	1.000	rs13400784	chr2:1564473	T/A	cg01028140	chr2:1542097	TPO	-0.32	-4.5	-0.37	1.54e-5	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs9858542	0.953	rs1987628	chr3:49399259	G/A	cg03060546	chr3:49711283	APEH	-0.64	-5.61	-0.45	1.27e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs7582180	0.663	rs6542930	chr2:100944383	T/A	cg14675211	chr2:100938903	LONRF2	0.49	4.89	0.4	3.02e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg22857025	chr5:266934	NA	-0.34	-6.7	-0.52	6.65e-10	Breast cancer;
TGCT	cis	rs151997	0.962	rs32482	chr5:50207118	T/C	cg06027927	chr5:50259733	NA	0.47	4.83	0.4	3.9e-6	Callous-unemotional behaviour;
TGCT	cis	rs1385374	0.800	rs12321679	chr12:129284791	G/A	cg09035930	chr12:129282057	SLC15A4	-0.55	-4.76	-0.39	5.27e-6	Systemic lupus erythematosus;
TGCT	cis	rs7267979	0.753	rs404148	chr20:25447931	A/G	cg16686733	chr20:25566563	NINL	0.49	4.59	0.38	1.06e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg22166914	chr1:53195759	ZYG11B	-0.42	-7.46	-0.56	1.33e-11	Monocyte count;
TGCT	cis	rs60843830	1.000	rs62114544	chr2:269679	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.71	6.79	0.52	4.24e-10	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs10206020	0.921	rs10177509	chr2:1568536	T/C	cg01028140	chr2:1542097	TPO	-0.33	-5.22	-0.42	7.28e-7	IgG glycosylation;
TGCT	cis	rs797680	0.856	rs7535628	chr1:93648728	T/C	cg17826107	chr1:92977322	EVI5	-0.23	-5.03	-0.41	1.67e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs6490294	0.898	rs57646770	chr12:112431212	T/C	cg10833066	chr12:111807467	FAM109A	0.36	5.11	0.42	1.17e-6	Mean platelet volume;
TGCT	cis	rs3812831	0.695	rs6560936	chr13:114945972	C/T	cg06611532	chr13:114900021	NA	-0.37	-6.78	-0.52	4.34e-10	Schizophrenia;
TGCT	cis	rs7542091	0.704	rs2142907	chr1:210039505	T/C	cg00989853	chr1:209979345	IRF6	0.42	4.44	0.37	1.97e-5	Monobrow;
TGCT	cis	rs10193935	0.901	rs2088281	chr2:42672731	A/G	cg27598129	chr2:42591480	NA	0.4	5.56	0.45	1.61e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs36051895	0.632	rs61461940	chr9:5157277	T/C	cg02405213	chr9:5042618	JAK2	-0.76	-10.0	-0.67	1.28e-17	Pediatric autoimmune diseases;
TGCT	cis	rs9911578	0.967	rs9894274	chr17:56977919	G/A	cg12560992	chr17:57184187	TRIM37	0.76	9.21	0.64	1.03e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs13185784	0.625	rs4270655	chr5:179645244	A/G	cg04734276	chr5:178882605	NA	0.29	4.46	0.37	1.81e-5	TRAIL levels;
TGCT	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg11301795	chr4:187892539	NA	0.31	4.69	0.39	6.98e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs28595532	0.920	rs116149978	chr4:119761069	A/C	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs9611565	0.512	rs964899	chr22:42142386	G/A	cg06634786	chr22:41940651	POLR3H	0.84	7.89	0.58	1.32e-12	Vitiligo;
TGCT	cis	rs916888	0.821	rs70600	chr17:44860021	C/T	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.57	-4.86	-0.4	3.45e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	trans	rs2801405	0.623	rs1444803	chr10:100624132	G/A	cg04906546	chr1:208317836	PLXNA2	-0.3	-6.97	-0.53	1.67e-10	Obesity-related traits;
TGCT	cis	rs727563	0.565	rs132774	chr22:42031953	C/G	cg13695892	chr22:41940480	POLR3H	-0.78	-7.4	-0.55	1.76e-11	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs3733585	0.746	rs4318650	chr4:10016868	T/C	cg00071950	chr4:10020882	SLC2A9	0.66	7.75	0.57	2.83e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	trans	rs17685	0.753	rs3757593	chr7:75678735	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.52	-8.84	-0.62	7.72e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs1580019	0.665	rs34147895	chr7:32531796	G/C	cg07520158	chr7:32535189	LSM5;AVL9	0.56	4.6	0.38	1.02e-5	Cognitive ability;
TGCT	trans	rs10506458	0.915	rs17738485	chr12:63394932	T/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.47	-7.58	-0.56	6.97e-12	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs6032067	0.516	rs6017530	chr20:43899731	G/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.38	-5.96	-0.47	2.38e-8	Blood protein levels;
TGCT	cis	rs12200560	0.505	rs12192623	chr6:97081432	A/G	cg06623918	chr6:96969491	KIAA0776	-0.58	-4.89	-0.4	3.09e-6	Coronary heart disease;
TGCT	cis	rs7707921	0.767	rs6894520	chr5:81594748	C/T	cg15871215	chr5:81402204	ATG10	-0.29	-4.61	-0.38	9.95e-6	Breast cancer;
TGCT	cis	rs921968	0.541	rs3755041	chr2:219442499	A/T	cg02176678	chr2:219576539	TTLL4	-0.49	-6.93	-0.53	1.99e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg03709012	chr19:19516395	GATAD2A	0.67	5.75	0.46	6.45e-8	Tonsillectomy;
TGCT	cis	rs7666738	0.830	rs969049	chr4:98988857	C/T	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs637571	0.558	rs10896064	chr11:65641033	G/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.64	-6.7	-0.52	6.64e-10	Eosinophil percentage of white cells;
TGCT	cis	rs1008375	1.000	rs2058339	chr4:17678456	C/T	cg10189774	chr4:17578691	LAP3	0.54	5.06	0.41	1.44e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs59721556	0.655	rs2364582	chr14:78121114	A/G	cg04906283	chr14:77965859	ISM2	0.4	4.5	0.37	1.53e-5	Response to paliperidone in schizophrenia (positive Marder score);Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (CGI-S score);Red cell distribution width;Response to paliperidone in schizophrenia (Multivariate);
TGCT	cis	rs2455799	0.613	rs6795100	chr3:15793798	C/T	cg16303742	chr3:15540471	COLQ	-0.25	-4.88	-0.4	3.18e-6	Mean platelet volume;
TGCT	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg24675658	chr1:53192096	ZYG11B	0.85	10.97	0.7	5.36e-20	Monocyte count;
TGCT	cis	rs6939532	0.517	rs733528	chr6:26374903	A/G	cg05738196	chr6:26577821	NA	-0.51	-4.89	-0.4	3.08e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs616402	0.527	rs604814	chr1:10567122	G/A	cg17425144	chr1:10567563	PEX14	0.56	8.14	0.59	3.58e-13	Breast size;
TGCT	cis	rs6121246	0.559	rs6060952	chr20:30382108	T/G	cg13852791	chr20:30311386	BCL2L1	0.83	8.16	0.59	3.22e-13	Mean corpuscular hemoglobin;
TGCT	cis	rs9302001	0.662	rs34408365	chr13:95469123	T/C	cg07483244	chr13:95358924	NA	0.37	4.84	0.4	3.86e-6	Panic disorder;
TGCT	cis	rs7267979	1.000	rs1077889	chr20:25267893	A/G	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6540559	0.673	rs6540560	chr1:209982073	A/G	cg04352962	chr1:209979756	IRF6	-0.61	-4.87	-0.4	3.37e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs763121	0.853	rs5757232	chr22:39071677	C/T	cg06022373	chr22:39101656	GTPBP1	0.77	7.46	0.56	1.35e-11	Menopause (age at onset);
TGCT	cis	rs3902035	0.964	rs62423970	chr6:119010901	T/C	cg07617317	chr6:118971624	C6orf204	0.43	5.01	0.41	1.79e-6	QT interval;
TGCT	cis	rs514406	0.505	rs146750	chr1:53183447	C/G	cg22166914	chr1:53195759	ZYG11B	0.45	8.18	0.59	2.87e-13	Monocyte count;
TGCT	cis	rs3935685	0.934	rs11630598	chr15:78006095	C/T	cg03457338	chr15:78040120	NA	-0.22	-5.24	-0.43	6.62e-7	Intelligence (multi-trait analysis);
TGCT	trans	rs1814175	0.817	rs2866863	chr11:49953242	C/T	cg15704280	chr7:45808275	SEPT13	-0.73	-8.48	-0.61	5.58e-14	Height;
TGCT	cis	rs12579753	0.879	rs35087297	chr12:82133398	C/T	cg07988820	chr12:82153109	PPFIA2	-0.68	-7.32	-0.55	2.7e-11	Resting heart rate;
TGCT	cis	rs9906944	0.707	rs9916472	chr17:47109998	C/T	cg07075026	chr17:47091521	IGF2BP1	-0.43	-4.6	-0.38	1.03e-5	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs4972806	0.814	rs2113560	chr2:177030986	T/C	cg14324370	chr2:177042789	NA	0.73	6.74	0.52	5.28e-10	IgG glycosylation;
TGCT	cis	rs6684514	1.000	rs11264464	chr1:156250887	T/G	cg16558208	chr1:156270281	VHLL	0.46	9.38	0.64	3.92e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg11301795	chr4:187892539	NA	0.32	4.92	0.4	2.73e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6543140	0.964	rs10196334	chr2:103090041	T/C	cg09003973	chr2:102972529	NA	0.54	4.46	0.37	1.83e-5	Blood protein levels;
TGCT	cis	rs12753569	0.934	rs6676370	chr1:76490185	G/T	cg00791851	chr1:76518896	NA	-0.39	-5.17	-0.42	8.94e-7	Personality dimensions;
TGCT	cis	rs7267979	0.509	rs6115218	chr20:25566485	A/G	cg17729667	chr20:25566382	NINL	0.4	4.49	0.37	1.63e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9858542	0.537	rs67882627	chr3:49380441	A/T	cg08550065	chr3:50336684	HYAL3;NAT6	0.66	4.59	0.38	1.08e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs9393692	0.902	rs6456711	chr6:26302572	A/C	cg00631329	chr6:26305371	NA	-0.46	-6.92	-0.53	2.19e-10	Educational attainment;
TGCT	cis	rs9436747	0.641	rs11208678	chr1:66049691	A/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.53	4.73	0.39	5.97e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs7681440	0.904	rs28750169	chr4:90774303	A/G	cg20003494	chr4:90757398	SNCA	-0.59	-5.52	-0.44	1.9e-7	Dementia with Lewy bodies;
TGCT	cis	rs57590327	0.527	rs9845467	chr3:81614473	G/A	cg07356753	chr3:81810745	GBE1	-0.61	-5.1	-0.42	1.24e-6	Extraversion;
TGCT	cis	rs28595532	0.920	rs114094671	chr4:119753540	G/A	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs2806561	0.765	rs2806556	chr1:23502850	G/A	cg12483005	chr1:23474871	LUZP1	0.37	4.77	0.39	5.03e-6	Height;
TGCT	cis	rs9291683	0.552	rs17187075	chr4:9990328	G/C	cg00071950	chr4:10020882	SLC2A9	0.71	9.35	0.64	4.62e-16	Bone mineral density;
TGCT	cis	rs7769051	1.000	rs12203977	chr6:133122760	A/G	cg22852734	chr6:133119734	C6orf192	1.22	7.01	0.53	1.38e-10	Type 2 diabetes nephropathy;
TGCT	trans	rs2727020	0.757	rs7924526	chr11:49267043	G/A	cg15704280	chr7:45808275	SEPT13	0.73	8.14	0.59	3.47e-13	Coronary artery disease;
TGCT	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg06028808	chr11:68637592	NA	0.52	6.73	0.52	5.58e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs10838634	1.000	rs7115986	chr11:46829174	T/A	cg18332754	chr11:46939436	LRP4	0.9	4.59	0.38	1.05e-5	Schizophrenia;
TGCT	cis	rs9911578	0.933	rs2531725	chr17:56517962	G/A	cg12560992	chr17:57184187	TRIM37	0.76	9.26	0.64	7.61e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs35822567	chr4:98654138	G/A	cg05340658	chr4:99064831	C4orf37	0.46	5.42	0.44	3.01e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9368481	0.761	rs4713062	chr6:26948195	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.46	-5.22	-0.42	7.38e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs614226	0.938	rs7972244	chr12:120994872	A/G	cg10072921	chr12:121022843	NA	-0.44	-4.74	-0.39	5.78e-6	Type 1 diabetes nephropathy;
TGCT	cis	rs16854884	0.739	rs1075113	chr3:143760535	C/T	cg06585982	chr3:143692056	C3orf58	0.54	4.54	0.38	1.33e-5	Economic and political preferences (feminism/equality);
TGCT	cis	rs4733781	0.563	rs7387699	chr8:131339029	T/C	cg16277922	chr8:131349729	ASAP1	-0.59	-10.18	-0.67	4.59e-18	Tuberculosis;
TGCT	cis	rs12931792	0.712	rs4787495	chr16:30165725	C/T	cg17640201	chr16:30407289	ZNF48	-0.61	-5.54	-0.45	1.72e-7	Tonsillectomy;
TGCT	cis	rs739496	0.546	rs11066055	chr12:112313216	A/T	cg10833066	chr12:111807467	FAM109A	0.38	5.42	0.44	2.97e-7	Platelet count;
TGCT	cis	rs929354	0.772	rs3802124	chr7:156970609	G/A	cg05182265	chr7:156933206	UBE3C	-0.39	-8.79	-0.62	1.03e-14	Body mass index;
TGCT	cis	rs6684514	1.000	rs66965793	chr1:156285814	G/A	cg20302342	chr1:156215951	PAQR6	0.35	4.74	0.39	5.77e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg26513180	chr16:89883248	FANCA	-1.04	-13.91	-0.78	4.47e-27	Vitiligo;
TGCT	cis	rs4699052	0.963	rs56144793	chr4:104150653	A/G	cg16532752	chr4:104119610	CENPE	-0.58	-5.46	-0.44	2.43e-7	Testicular germ cell tumor;
TGCT	cis	rs10782582	0.593	rs11801414	chr1:76124517	G/A	cg22875332	chr1:76189707	ACADM	-0.54	-6.36	-0.5	3.61e-9	Daytime sleep phenotypes;
TGCT	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg11905131	chr22:24372483	LOC391322	-0.87	-10.04	-0.67	1.03e-17	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs868036	0.681	rs4776375	chr15:68085555	G/A	cg05925327	chr15:68127851	NA	-0.5	-4.85	-0.4	3.57e-6	Restless legs syndrome;
TGCT	cis	rs7647973	0.626	rs62262672	chr3:49655927	T/A	cg03060546	chr3:49711283	APEH	-0.61	-5.14	-0.42	1.03e-6	Menarche (age at onset);
TGCT	cis	rs6430585	0.584	rs4954276	chr2:136402117	A/G	cg07169764	chr2:136633963	MCM6	0.66	5.8	0.46	5.18e-8	Corneal structure;
TGCT	cis	rs9916302	0.706	rs8075737	chr17:37727316	C/T	cg07936489	chr17:37558343	FBXL20	0.88	7.1	0.54	8.42e-11	Glomerular filtration rate (creatinine);
TGCT	cis	rs13191362	0.507	rs2849524	chr6:163127070	C/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.59	-5.75	-0.46	6.6e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs854765	0.693	rs12941039	chr17:17765655	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.75	-7.92	-0.58	1.12e-12	Total body bone mineral density;
TGCT	cis	rs6684514	0.922	rs12128785	chr1:156269389	A/G	cg20302342	chr1:156215951	PAQR6	0.34	4.6	0.38	1.01e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs4925386	1.000	rs6121990	chr20:60919263	G/A	cg06026331	chr20:60912101	LAMA5	-0.3	-5.5	-0.44	2.12e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs17345786	0.798	rs4257518	chr3:101281709	C/T	cg11279151	chr3:101281821	RG9MTD1	0.45	10.63	0.69	3.76e-19	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9914544	1.000	rs1634411	chr17:18833810	C/T	cg26378065	chr17:18585709	ZNF286B	0.54	4.85	0.4	3.67e-6	Educational attainment (years of education);
TGCT	cis	rs1023500	1.000	rs1023500	chr22:42340844	C/T	cg04692870	chr22:42525206	CYP2D6	0.33	5.0	0.41	1.9e-6	Schizophrenia;
TGCT	cis	rs4566357	0.615	rs2396445	chr2:227917726	C/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-5.09	-0.42	1.28e-6	Coronary artery disease;
TGCT	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg08280861	chr8:58055591	NA	0.4	4.56	0.38	1.22e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9611565	0.681	rs5751094	chr22:41803279	C/T	cg17554472	chr22:41940697	POLR3H	0.43	4.79	0.39	4.73e-6	Vitiligo;
TGCT	cis	rs9467711	0.606	rs9379859	chr6:26369549	C/T	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs13418410	0.539	rs1545399	chr2:33843801	A/G	cg04131969	chr2:33951647	MYADML	-0.78	-7.55	-0.56	8.23e-12	Non-response to antidepressants and depression;
TGCT	cis	rs425277	0.585	rs3128294	chr1:2065343	G/C	cg24578937	chr1:2090814	PRKCZ	-0.26	-6.38	-0.5	3.2e-9	Height;
TGCT	trans	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg13615516	chr5:77269221	NA	0.68	8.54	0.61	3.97e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7726839	0.574	rs11739866	chr5:636299	C/T	cg09021430	chr5:549028	NA	-0.38	-5.11	-0.42	1.21e-6	Obesity-related traits;
TGCT	cis	rs11148252	0.904	rs3892337	chr13:53029485	C/G	cg00495681	chr13:53174319	NA	0.58	6.06	0.48	1.48e-8	Lewy body disease;
TGCT	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg26338869	chr17:61819248	STRADA	-0.53	-4.9	-0.4	2.95e-6	Prudent dietary pattern;
TGCT	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.7	4.98	0.41	2.08e-6	Platelet count;
TGCT	cis	rs11031096	0.655	rs1822289	chr11:4212184	T/C	cg08557956	chr11:4115526	RRM1	-0.49	-4.56	-0.38	1.2e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs7975161	0.638	rs4592489	chr12:104619699	C/T	cg25273343	chr12:104657179	TXNRD1	-0.28	-4.45	-0.37	1.9e-5	Toenail selenium levels;
TGCT	cis	rs12780845	0.540	rs10904903	chr10:17238336	T/A	cg01003015	chr10:17271136	VIM	-0.5	-4.55	-0.38	1.26e-5	Homocysteine levels;
TGCT	cis	rs9354352	1.000	rs9354352	chr6:66696272	T/C	cg07460842	chr6:66804631	NA	0.65	6.68	0.51	7.29e-10	Initial pursuit acceleration in psychotic disorders;
TGCT	cis	rs909674	0.690	rs5750825	chr22:39831278	A/G	cg24399712	chr22:39784796	NA	-1.06	-10.99	-0.7	4.84e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs12643440	0.538	rs56290948	chr4:17138950	C/T	cg22650099	chr4:17144496	NA	-0.46	-4.7	-0.39	6.79e-6	Metabolite levels (Pyroglutamine);
TGCT	cis	rs10992471	0.603	rs10761155	chr9:95153729	C/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.64	-5.91	-0.47	3.03e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs9611565	0.559	rs7290991	chr22:41964361	C/G	cg13695892	chr22:41940480	POLR3H	-0.87	-8.17	-0.59	2.95e-13	Vitiligo;
TGCT	cis	rs4919694	1.000	rs58317752	chr10:104799267	T/A	cg04362960	chr10:104952993	NT5C2	1.06	7.05	0.53	1.09e-10	Arsenic metabolism;
TGCT	cis	rs17345786	0.628	rs11718446	chr3:101552553	C/T	cg12386194	chr3:101231763	SENP7	0.51	5.06	0.41	1.48e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2228479	1.000	rs11642267	chr16:89957635	T/C	cg06558623	chr16:89946397	TCF25	0.57	6.52	0.51	1.62e-9	Skin colour saturation;
TGCT	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg18876405	chr7:65276391	NA	0.33	4.95	0.41	2.39e-6	Aortic root size;
TGCT	cis	rs7772486	0.790	rs9791313	chr6:146266172	T/C	cg23711669	chr6:146136114	FBXO30	-0.85	-9.7	-0.66	6.73e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2762353	0.603	rs12201071	chr6:25778055	C/T	cg03264133	chr6:25882463	NA	0.47	4.75	0.39	5.54e-6	Blood metabolite levels;
TGCT	cis	rs11030122	0.661	rs963998	chr11:4062803	A/G	cg18678763	chr11:4115507	RRM1	-0.46	-5.57	-0.45	1.53e-7	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs7085104	0.632	rs7097872	chr10:104606636	C/T	cg15744005	chr10:104629667	AS3MT	-0.43	-5.37	-0.43	3.77e-7	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs1577917	0.958	rs36035797	chr6:86562880	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.29	-0.43	5.34e-7	Response to antipsychotic treatment;
TGCT	cis	rs9650657	0.644	rs7012206	chr8:10697015	A/G	cg16664915	chr8:10907788	XKR6	-0.28	-4.54	-0.38	1.31e-5	Neuroticism;
TGCT	trans	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg27523141	chr10:43048294	ZNF37B	0.73	8.51	0.61	4.68e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg05665937	chr4:1216051	CTBP1	0.24	4.65	0.39	8.32e-6	Obesity-related traits;
TGCT	cis	rs6076065	0.925	rs6083106	chr20:23368809	A/C	cg11657817	chr20:23433608	CST11	0.28	4.55	0.38	1.25e-5	Facial morphology (factor 15, philtrum width);
TGCT	cis	rs601338	1	rs601338	chr19:49206674	G/A	cg13540341	chr19:49222985	MAMSTR	-0.34	-4.66	-0.39	8.06e-6	Number of common colds;Blood metabolite levels;Blood metabolite ratios;
TGCT	cis	rs7552404	0.924	rs7546641	chr1:76158035	T/C	cg03433033	chr1:76189801	ACADM	0.82	9.89	0.66	2.31e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2580764	0.515	rs4672005	chr2:55246551	C/T	cg09592903	chr2:55203963	RTN4	-0.26	-5.76	-0.46	6.14e-8	Mean platelet volume;
TGCT	cis	rs7208859	0.623	rs11652631	chr17:29060766	A/G	cg14008862	chr17:28927542	LRRC37B2	0.77	4.59	0.38	1.08e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs17345786	1.000	rs58907984	chr3:101305170	T/G	cg11279151	chr3:101281821	RG9MTD1	-0.45	-9.64	-0.65	9.35e-17	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7208859	0.524	rs28760584	chr17:29141017	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs6840360	1.000	rs7671651	chr4:152597202	C/G	cg17479576	chr4:152424074	FAM160A1	-0.49	-5.18	-0.42	8.55e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9326248	1.000	rs664971	chr11:117070857	A/G	cg26566898	chr11:117069891	TAGLN	-0.35	-4.44	-0.37	2e-5	Blood protein levels;
TGCT	cis	rs853679	0.546	rs200952	chr6:27836976	C/T	cg01031101	chr6:28227091	NKAPL	-0.49	-4.66	-0.39	8.09e-6	Depression;
TGCT	cis	rs68170813	0.559	rs76020313	chr7:106877468	A/G	cg02696742	chr7:106810147	HBP1	-0.69	-5.61	-0.45	1.27e-7	Coronary artery disease;
TGCT	cis	rs826838	0.806	rs826873	chr12:39121305	G/A	cg13010199	chr12:38710504	ALG10B	-0.64	-5.07	-0.41	1.39e-6	Heart rate;
TGCT	cis	rs28595532	0.764	rs56309519	chr4:119754158	C/T	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs13256369	1.000	rs13266699	chr8:8570313	A/T	cg18904891	chr8:8559673	CLDN23	-0.59	-5.54	-0.45	1.73e-7	Obesity-related traits;
TGCT	cis	rs10791097	0.720	rs6590516	chr11:130733393	G/T	cg14779329	chr11:130786720	SNX19	0.29	4.97	0.41	2.18e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	trans	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg23505145	chr19:12996616	KLF1	0.79	8.3	0.6	1.47e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9467711	0.790	rs55706012	chr6:26266311	A/C	cg16898833	chr6:26189333	HIST1H4D	1.33	5.93	0.47	2.74e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9549260	0.591	rs9577115	chr13:41276553	T/C	cg21288729	chr13:41239152	FOXO1	0.94	9.32	0.64	5.56e-16	Red blood cell count;
TGCT	cis	rs4689388	0.926	rs4689391	chr4:6280449	G/A	cg00701064	chr4:6280414	WFS1	0.45	6.19	0.49	8e-9	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg11494091	chr17:61959527	GH2	0.61	14.43	0.79	2.59e-28	Prudent dietary pattern;
TGCT	cis	rs7255045	0.742	rs6511841	chr19:12955149	G/T	cg23899408	chr19:12877188	HOOK2	-0.58	-4.78	-0.39	4.85e-6	Mean corpuscular volume;
TGCT	cis	rs78461346	1.000	rs78014296	chr17:80532744	A/G	cg15014069	chr17:80540666	FOXK2	0.4	4.99	0.41	1.97e-6	3-hydroxypropylmercapturic acid levels in smokers;
TGCT	cis	rs73198271	0.729	rs67000451	chr8:8605083	A/G	ch.8.214553F	chr8:8189620	PRAGMIN	-0.28	-4.79	-0.4	4.63e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg06028808	chr11:68637592	NA	0.51	6.67	0.51	7.76e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg13395646	chr4:1353034	KIAA1530	-0.39	-4.97	-0.41	2.2e-6	Obesity-related traits;
TGCT	cis	rs6748734	1.000	rs4311055	chr2:241821017	T/C	cg04034577	chr2:241836375	C2orf54	-0.39	-6.2	-0.49	7.61e-9	Urinary metabolites;
TGCT	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg22166914	chr1:53195759	ZYG11B	0.34	5.71	0.46	7.92e-8	Monocyte count;
TGCT	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg11062466	chr8:58055876	NA	-0.38	-4.62	-0.38	9.5e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7439150	0.954	rs4220	chr4:155491759	G/A	cg22130008	chr4:155548532	NA	-0.48	-5.79	-0.46	5.4e-8	Fibrinogen levels;
TGCT	cis	rs57920188	0.513	rs4290031	chr1:4094701	A/G	cg20703997	chr1:4087676	NA	0.48	5.77	0.46	5.97e-8	Interleukin-17 levels;
TGCT	cis	rs13256369	0.802	rs12681925	chr8:8561649	G/A	cg18904891	chr8:8559673	CLDN23	0.57	5.27	0.43	5.87e-7	Obesity-related traits;
TGCT	cis	rs2197308	0.655	rs1971964	chr12:37870474	C/T	cg26384229	chr12:38710491	ALG10B	0.89	7.94	0.58	1.06e-12	Morning vs. evening chronotype;
TGCT	cis	rs427394	0.743	rs274716	chr5:6722289	T/C	cg10857441	chr5:6722123	POLS	-0.31	-7.2	-0.54	5.08e-11	Menopause (age at onset);
TGCT	cis	rs7104764	1.000	rs6598063	chr11:243672	G/A	cg18336825	chr11:236787	PSMD13;SIRT3	1.07	11.19	0.71	1.61e-20	Menarche (age at onset);
TGCT	cis	rs6951245	0.507	rs10227709	chr7:1180515	T/G	cg18402987	chr7:1209562	NA	0.5	4.69	0.39	7.13e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs11098499	0.954	rs11722872	chr4:120233030	G/C	cg09307838	chr4:120376055	NA	0.63	5.84	0.46	4.34e-8	Corneal astigmatism;
TGCT	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg21285383	chr16:89894308	SPIRE2	0.44	6.89	0.53	2.46e-10	Vitiligo;
TGCT	cis	rs7267979	1.000	rs6050544	chr20:25320228	T/A	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs8032315	0.965	rs1894400	chr15:91428955	C/T	cg03209642	chr15:91427605	FES	0.52	4.98	0.41	2.07e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs763121	0.853	rs5750649	chr22:39036769	T/C	cg06022373	chr22:39101656	GTPBP1	0.8	8.25	0.6	1.95e-13	Menopause (age at onset);
TGCT	cis	rs7267979	0.834	rs6115100	chr20:25225938	C/A	cg14121845	chr20:25566513	NINL	0.5	5.51	0.44	1.95e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7226408	0.857	rs2166294	chr18:34488534	A/G	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs6125597	0.967	rs6067030	chr20:47884403	C/T	cg11220565	chr20:47934802	NA	-0.3	-4.61	-0.38	9.8e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2997447	0.739	rs3008223	chr1:26389633	T/C	cg19633962	chr1:26362018	EXTL1	-0.68	-4.7	-0.39	6.68e-6	QRS complex (12-leadsum);
TGCT	cis	rs6570726	0.791	rs11155435	chr6:145938545	T/C	cg05347473	chr6:146136440	FBXO30	0.53	4.96	0.41	2.29e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs494003	0.951	rs11227283	chr11:65499022	C/T	cg04293602	chr11:65553660	OVOL1	0.36	4.5	0.37	1.52e-5	Systemic lupus erythematosus;
TGCT	cis	rs270601	0.817	rs460089	chr5:131629772	C/G	cg24060327	chr5:131705240	SLC22A5	-0.71	-7.27	-0.55	3.58e-11	Acylcarnitine levels;
TGCT	cis	rs4273100	0.688	rs28582509	chr17:19165179	T/C	cg01534423	chr17:18965556	NA	0.8	7.26	0.55	3.79e-11	Schizophrenia;
TGCT	cis	rs11190604	0.767	rs10883483	chr10:102174244	T/C	cg23241863	chr10:102295624	HIF1AN	0.6	4.57	0.38	1.17e-5	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg12963246	chr6:28129442	ZNF389	0.52	5.01	0.41	1.85e-6	Depression;
TGCT	cis	rs6433895	0.961	rs6746347	chr2:182017374	T/G	cg16904960	chr2:182549928	NA	0.34	4.47	0.37	1.77e-5	Lymphocyte counts;
TGCT	cis	rs12681287	0.605	rs6471296	chr8:87374654	A/G	cg27223183	chr8:87520930	FAM82B	0.68	5.07	0.41	1.44e-6	Caudate activity during reward;
TGCT	cis	rs12510870	0.566	rs16849727	chr4:74460744	A/C	cg05868023	chr4:75230803	EREG	0.56	5.01	0.41	1.83e-6	Iris color (b* coordinate);
TGCT	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg12379764	chr21:47803548	PCNT	0.5	5.13	0.42	1.08e-6	Testicular germ cell tumor;
TGCT	cis	rs7666738	1.000	rs13116475	chr4:99054843	C/T	cg05340658	chr4:99064831	C4orf37	-0.47	-4.65	-0.39	8.52e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2486288	0.656	rs6493143	chr15:45570781	G/T	cg14582100	chr15:45693742	SPATA5L1	-0.43	-4.86	-0.4	3.48e-6	Glomerular filtration rate;
TGCT	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg23758822	chr17:41437982	NA	-0.57	-6.0	-0.47	2.05e-8	Menopause (age at onset);
TGCT	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg19774624	chr17:42201019	HDAC5	-0.87	-10.64	-0.69	3.55e-19	Total body bone mineral density;
TGCT	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg11494091	chr17:61959527	GH2	0.61	14.78	0.8	4.02e-29	Prudent dietary pattern;
TGCT	cis	rs2404602	0.716	rs7179142	chr15:76698268	G/A	cg22467129	chr15:76604101	ETFA	-0.57	-7.0	-0.53	1.39e-10	Blood metabolite levels;
TGCT	cis	rs6460942	0.778	rs76030612	chr7:12462937	C/A	cg06484146	chr7:12443880	VWDE	-0.53	-5.59	-0.45	1.36e-7	Coronary artery disease;
TGCT	cis	rs11077998	0.840	rs9894993	chr17:80481088	T/C	cg10255544	chr17:80519551	FOXK2	0.24	4.79	0.39	4.76e-6	Reticulocyte fraction of red cells;
TGCT	cis	rs904251	0.600	rs4714068	chr6:37455642	A/C	cg08126542	chr6:37504118	NA	-0.41	-5.98	-0.47	2.24e-8	Cognitive performance;
TGCT	cis	rs6969780	0.841	rs10246712	chr7:27198860	C/T	cg04321618	chr7:27170880	HOXA4	0.54	4.93	0.4	2.55e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs4654899	0.680	rs10916885	chr1:21188703	A/T	cg01072550	chr1:21505969	NA	0.55	8.93	0.63	4.85e-15	Superior frontal gyrus grey matter volume;
TGCT	cis	rs11098499	0.909	rs79704848	chr4:120309351	T/A	cg09307838	chr4:120376055	NA	0.65	6.39	0.5	3.02e-9	Corneal astigmatism;
TGCT	cis	rs904251	0.828	rs1757178	chr6:37486310	C/T	cg01843034	chr6:37503916	NA	0.51	6.11	0.48	1.16e-8	Cognitive performance;
TGCT	trans	rs2688608	0.672	rs4065	chr10:75676464	C/T	cg13918328	chr10:52500089	ASAH2B	0.68	6.76	0.52	4.94e-10	Inflammatory bowel disease;
TGCT	cis	rs2816062	0.735	rs2816045	chr1:18892999	A/G	cg18795169	chr1:18902165	NA	-0.58	-13.28	-0.77	1.36e-25	Urate levels in lean individuals;
TGCT	cis	rs12477438	0.765	rs1115756	chr2:99659845	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-7.6	-0.56	6.47e-12	Chronic sinus infection;
TGCT	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg16325326	chr1:53192061	ZYG11B	0.5	5.56	0.45	1.56e-7	Monocyte count;
TGCT	cis	rs8014204	0.804	rs35769520	chr14:75255115	G/A	cg06637938	chr14:75390232	RPS6KL1	0.7	6.77	0.52	4.47e-10	Caffeine consumption;
TGCT	cis	rs6547741	0.816	rs7560847	chr2:27882700	A/G	cg27432699	chr2:27873401	GPN1	-0.24	-6.06	-0.48	1.5e-8	Oral cavity cancer;
TGCT	trans	rs2727020	0.576	rs12293522	chr11:49558425	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.36	-7.12	-0.54	7.81e-11	Coronary artery disease;
TGCT	cis	rs1903068	0.785	rs10013228	chr4:55997340	A/G	cg09978860	chr4:56023921	NA	0.55	6.09	0.48	1.31e-8	Endometriosis;
TGCT	cis	rs1797081	0.811	rs1797076	chr10:16853076	A/G	cg23933602	chr10:16859644	RSU1	0.88	10.22	0.68	3.67e-18	Platelet distribution width;
TGCT	cis	rs6725041	0.846	rs10185271	chr2:213089454	T/G	cg20637307	chr2:213403960	ERBB4	-0.52	-4.47	-0.37	1.72e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs9906944	0.707	rs9916472	chr17:47109998	C/T	cg20966754	chr17:47091339	IGF2BP1	-0.45	-5.17	-0.42	9.27e-7	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs12477438	0.871	rs62156364	chr2:99695097	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.56	-4.45	-0.37	1.9e-5	Chronic sinus infection;
TGCT	cis	rs7267979	0.899	rs2104734	chr20:25526668	A/G	cg14121845	chr20:25566513	NINL	0.49	5.36	0.43	3.83e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9611565	0.649	rs5758466	chr22:42176059	G/A	cg06481639	chr22:41940642	POLR3H	0.53	4.54	0.38	1.29e-5	Vitiligo;
TGCT	cis	rs9872999	1	rs9872999	chr3:133457514	C/T	cg16262614	chr3:133464971	TF	0.34	4.62	0.38	9.28e-6	Iron status biomarkers;
TGCT	cis	rs4906332	1.000	rs4906327	chr14:103929039	C/T	cg26031613	chr14:104095156	KLC1	-0.53	-4.71	-0.39	6.62e-6	Coronary artery disease;
TGCT	cis	rs727505	0.754	rs55723877	chr7:124780899	T/A	cg23710748	chr7:124431027	NA	-0.25	-4.44	-0.37	1.97e-5	Lewy body disease;
TGCT	cis	rs611744	0.967	rs652485	chr8:109202696	G/A	cg21045802	chr8:109455806	TTC35	0.5	4.54	0.38	1.33e-5	Dupuytren's disease;
TGCT	cis	rs3733631	1.000	rs3775971	chr4:104641920	C/T	cg24090629	chr4:104641072	TACR3	0.74	6.05	0.48	1.6e-8	Menarche (age at onset);
TGCT	cis	rs7666738	0.819	rs62318904	chr4:99036101	A/T	cg05340658	chr4:99064831	C4orf37	0.51	5.69	0.45	8.74e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12541335	0.639	rs4872468	chr8:22179844	G/C	cg02463440	chr8:22132932	PIWIL2	0.26	5.17	0.42	9.05e-7	Hypertriglyceridemia;
TGCT	cis	rs61990749	0.597	rs2267759	chr14:78147615	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	-0.66	-4.65	-0.39	8.45e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs75686122	0.892	rs77472944	chr8:104697477	G/T	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg08975724	chr8:8085496	FLJ10661	0.6	5.75	0.46	6.63e-8	Mood instability;
TGCT	cis	rs711245	0.572	rs3821150	chr2:36795233	G/A	cg01206211	chr2:36825736	FEZ2	0.38	5.78	0.46	5.66e-8	Height;
TGCT	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg19318889	chr4:1322082	MAEA	0.19	5.05	0.41	1.54e-6	Longevity;
TGCT	cis	rs74181299	1.000	rs74181299	chr2:65283972	T/C	cg05010058	chr2:65284262	CEP68	0.43	4.82	0.4	4.11e-6	Pulse pressure;
TGCT	cis	rs72949976	0.584	rs13001511	chr2:214025262	G/A	cg08319019	chr2:214017104	IKZF2	0.84	8.38	0.6	9.58e-14	Lung cancer;Squamous cell lung carcinoma;
TGCT	cis	rs12497850	0.931	rs9840684	chr3:48893780	T/C	cg07636037	chr3:49044803	WDR6	0.94	10.39	0.68	1.46e-18	Parkinson's disease;
TGCT	trans	rs2688608	0.836	rs2675668	chr10:75636148	G/A	cg13918328	chr10:52500089	ASAH2B	0.66	6.92	0.53	2.18e-10	Inflammatory bowel disease;
TGCT	cis	rs4690686	0.500	rs7683662	chr4:177272004	A/T	cg17059388	chr4:177262070	NA	0.28	4.51	0.38	1.46e-5	Essential tremor;
TGCT	cis	rs7017914	0.935	rs2732093	chr8:71919079	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.55	-5.1	-0.42	1.24e-6	Bone mineral density;
TGCT	cis	rs858239	0.539	rs4504540	chr7:23186198	C/G	cg05602783	chr7:23145260	KLHL7	-0.62	-5.03	-0.41	1.67e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs7666738	0.830	rs3896704	chr4:99034252	C/T	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11626933	1.000	rs2236402	chr14:90734378	C/G	cg14092571	chr14:90743983	NA	-0.3	-5.77	-0.46	6.02e-8	Gut microbiota (bacterial taxa);
TGCT	cis	rs7772486	0.686	rs857882	chr6:145969716	T/G	cg05347473	chr6:146136440	FBXO30	-0.49	-4.59	-0.38	1.06e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2204008	0.837	rs11168504	chr12:37964922	G/T	cg13010199	chr12:38710504	ALG10B	0.65	5.29	0.43	5.47e-7	Bladder cancer;
TGCT	trans	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg13615516	chr5:77269221	NA	0.67	8.36	0.6	1.09e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs67340775	0.541	rs200965	chr6:27866384	G/A	cg26587870	chr6:27730563	NA	-0.31	-4.47	-0.37	1.77e-5	Lung cancer in ever smokers;
TGCT	cis	rs9303542	0.625	rs8072250	chr17:46569216	C/T	cg25032089	chr17:46643351	HOXB3	0.5	5.5	0.44	2.03e-7	Ovarian cancer;Epithelial ovarian cancer;
TGCT	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg10053473	chr17:62856997	LRRC37A3	0.39	6.72	0.52	5.98e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs4631830	0.863	rs2611508	chr10:51518047	T/A	cg10326726	chr10:51549505	MSMB	-0.26	-5.03	-0.41	1.68e-6	Prostate-specific antigen levels;
TGCT	cis	rs2637266	1.000	rs6480824	chr10:78355705	G/A	cg18941641	chr10:78392320	NA	0.4	5.01	0.41	1.81e-6	Pulmonary function;
TGCT	cis	rs1018836	0.884	rs13279263	chr8:91648780	T/C	cg16814680	chr8:91681699	NA	-0.84	-8.77	-0.62	1.15e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs514406	0.505	rs405208	chr1:53176674	C/T	cg08859206	chr1:53392774	SCP2	-0.36	-5.13	-0.42	1.1e-6	Monocyte count;
TGCT	cis	rs7017914	0.935	rs3110258	chr8:71938532	A/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-4.97	-0.41	2.16e-6	Bone mineral density;
TGCT	cis	rs7246657	0.722	rs8103647	chr19:38100452	C/A	cg03611452	chr19:38183253	ZNF781	0.59	4.72	0.39	6.14e-6	Coronary artery calcification;
TGCT	cis	rs4824093	0.541	rs8142132	chr22:50211294	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.97	-5.07	-0.41	1.42e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg05368731	chr17:41323189	NBR1	1.19	13.98	0.78	2.93e-27	Menopause (age at onset);
TGCT	cis	rs11190604	0.767	rs11190509	chr10:102156208	G/A	cg16342193	chr10:102329863	NA	-0.39	-5.06	-0.41	1.49e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg06618935	chr21:46677482	NA	-0.33	-5.37	-0.43	3.71e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs155076	0.938	rs485361	chr13:21845826	G/T	cg14456004	chr13:21872349	NA	-1.32	-10.82	-0.7	1.25e-19	White matter hyperintensity burden;
TGCT	cis	rs1801251	1.000	rs4973055	chr2:233720283	G/T	cg08000102	chr2:233561755	GIGYF2	-0.64	-6.43	-0.5	2.46e-9	Coronary artery disease;
TGCT	cis	rs644799	0.965	rs566877	chr11:95528045	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	10.57	0.69	5.17e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs4455778	0.659	rs7782271	chr7:49057494	G/A	cg26309511	chr7:48887640	NA	0.44	5.12	0.42	1.13e-6	Lung cancer in never smokers;
TGCT	trans	rs10435719	0.647	rs10092605	chr8:11787395	T/G	cg15556689	chr8:8085844	FLJ10661	0.78	7.32	0.55	2.78e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs13082711	0.554	rs7635958	chr3:27385616	A/C	cg02860705	chr3:27208620	NA	0.43	6.05	0.48	1.6e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs6977660	0.714	rs12700077	chr7:19791607	A/G	cg05791153	chr7:19748676	TWISTNB	-0.8	-4.52	-0.38	1.44e-5	Thyroid stimulating hormone;
TGCT	cis	rs7432375	0.610	rs6793936	chr3:136509793	A/C	cg15507776	chr3:136538369	TMEM22	0.55	5.64	0.45	1.1e-7	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9916302	0.904	rs4795384	chr17:37716771	C/G	cg15445000	chr17:37608096	MED1	0.35	5.1	0.42	1.25e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs10751667	0.666	rs7483273	chr11:951127	T/C	cg06064525	chr11:970664	AP2A2	-0.35	-7.98	-0.58	8.36e-13	Alzheimer's disease (late onset);
TGCT	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg11941060	chr3:133502564	NA	-0.31	-6.56	-0.51	1.32e-9	Iron status biomarkers;
TGCT	trans	rs797680	0.786	rs10874772	chr1:93787770	G/A	cg27528825	chr2:159282178	CCDC148	-0.33	-6.67	-0.51	7.68e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs7681423	1.000	rs7681423	chr4:155542248	C/T	cg20735720	chr4:155535218	FGG	-0.46	-6.8	-0.52	3.99e-10	Fibrinogen;
TGCT	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg21724239	chr8:58056113	NA	0.42	5.04	0.41	1.59e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs12477438	0.520	rs11695751	chr2:99708247	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.15	18.22	0.85	7.28e-37	Chronic sinus infection;
TGCT	cis	rs3008870	0.920	rs12132532	chr1:67457015	G/T	cg03991309	chr1:68237761	GNG12	-0.27	-4.53	-0.38	1.36e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg17054783	chr10:134559939	INPP5A	-0.25	-5.06	-0.41	1.45e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs13191362	1.000	rs35593345	chr6:163174981	G/C	cg21926612	chr6:163149169	PACRG;PARK2	1.11	8.17	0.59	2.98e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs17125944	0.505	rs77949716	chr14:53204234	G/A	cg00686598	chr14:53173677	PSMC6	1.09	5.66	0.45	1e-7	Alzheimer's disease (late onset);
TGCT	cis	rs9911578	0.967	rs11656413	chr17:57082013	A/C	cg12560992	chr17:57184187	TRIM37	-0.78	-9.58	-0.65	1.35e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs17608059	0.504	rs11656981	chr17:13978777	A/G	cg11395062	chr17:14139857	CDRT15	0.47	6.56	0.51	1.3e-9	Temperament;
TGCT	cis	rs782590	0.967	rs4290693	chr2:55799991	C/G	cg18811423	chr2:55921094	PNPT1	0.66	7.0	0.53	1.39e-10	Metabolic syndrome;
TGCT	cis	rs1372520	0.935	rs1372519	chr4:90757309	A/G	cg14346243	chr4:90757452	SNCA	-0.64	-5.24	-0.43	6.59e-7	Neuroticism;
TGCT	cis	rs1801251	1.000	rs4973054	chr2:233710713	G/C	cg08000102	chr2:233561755	GIGYF2	-0.63	-6.46	-0.5	2.2e-9	Coronary artery disease;
TGCT	cis	rs11577318	0.853	rs4450008	chr1:26643860	C/A	cg04990556	chr1:26633338	UBXN11	-0.57	-4.94	-0.41	2.51e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs6684514	0.961	rs12029695	chr1:156299847	C/T	cg16558208	chr1:156270281	VHLL	0.48	9.6	0.65	1.19e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs10479542	0.896	rs10078712	chr5:178978805	C/T	cg21226059	chr5:178986404	RUFY1	-0.47	-4.91	-0.4	2.79e-6	Lung cancer;
TGCT	cis	rs4851313	0.527	rs10183150	chr2:100939117	A/G	cg14675211	chr2:100938903	LONRF2	0.51	5.02	0.41	1.72e-6	Intelligence (multi-trait analysis);
TGCT	trans	rs1415174	0.958	rs1415173	chr1:87850592	C/T	cg23065576	chr20:25207247	ENTPD6	0.27	6.9	0.53	2.33e-10	Breast cancer;
TGCT	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg05368731	chr17:41323189	NBR1	1.16	13.44	0.77	5.72e-26	Menopause (age at onset);
TGCT	cis	rs1577917	0.771	rs2842612	chr6:86303091	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.58	-0.45	1.43e-7	Response to antipsychotic treatment;
TGCT	cis	rs7666738	0.924	rs11097592	chr4:98927532	C/T	cg17366294	chr4:99064904	C4orf37	0.77	7.39	0.55	1.87e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10782582	0.593	rs11163967	chr1:76154185	T/C	cg03433033	chr1:76189801	ACADM	-0.65	-7.41	-0.55	1.67e-11	Daytime sleep phenotypes;
TGCT	cis	rs587847	0.767	rs12148402	chr15:37651465	G/T	cg00216138	chr15:37171175	LOC145845	0.31	4.45	0.37	1.86e-5	Intraocular pressure;
TGCT	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg11235426	chr6:292522	DUSP22	0.66	6.84	0.52	3.2e-10	Menopause (age at onset);
TGCT	cis	rs4252435	0.614	rs4252393	chr7:142628482	C/G	cg21621906	chr7:142494914	NA	0.92	4.45	0.37	1.87e-5	Cancer;
TGCT	cis	rs3812049	0.826	rs17764730	chr5:127357526	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.59	5.34	0.43	4.27e-7	Lymphocyte counts;Red cell distribution width;
TGCT	cis	rs477895	0.838	rs12794145	chr11:64006484	C/T	cg23719950	chr11:63933701	MACROD1	-0.69	-5.78	-0.46	5.66e-8	Mean platelet volume;
TGCT	cis	rs10114408	0.921	rs7020529	chr9:96640224	G/A	cg13679303	chr9:96623674	NA	-0.36	-4.69	-0.39	6.98e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs9646954	0.542	rs4149505	chr2:101033697	G/A	cg08017756	chr2:100939284	LONRF2	-0.29	-4.53	-0.38	1.39e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs9457247	0.935	rs2757046	chr6:167374353	C/T	cg23791538	chr6:167370224	RNASET2	0.5	4.98	0.41	2.05e-6	Crohn's disease;
TGCT	cis	rs6751439	0.765	rs2348537	chr2:154730020	T/C	cg25703346	chr2:154729189	GALNT13	0.77	4.65	0.39	8.25e-6	Forced expiratory volume in 1 second (occupational environmental exposures interaction);
TGCT	cis	rs2299587	0.554	rs3739404	chr8:17739843	C/A	cg01800426	chr8:17659068	MTUS1	-0.56	-4.99	-0.41	1.97e-6	Economic and political preferences;
TGCT	cis	rs782590	0.935	rs782652	chr2:55862775	C/A	cg18811423	chr2:55921094	PNPT1	0.65	6.85	0.52	3.04e-10	Metabolic syndrome;
TGCT	cis	rs2242116	0.796	rs4587	chr3:46963502	T/C	cg02527881	chr3:46936655	PTH1R	-0.33	-6.09	-0.48	1.29e-8	Birth weight;
TGCT	cis	rs9399135	0.967	rs7766189	chr6:135353851	A/C	cg24558204	chr6:135376177	HBS1L	0.48	4.77	0.39	5.14e-6	Red blood cell count;
TGCT	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg22891161	chr3:195456627	MUC20	-0.2	-4.73	-0.39	5.98e-6	Pancreatic cancer;
TGCT	cis	rs6977660	0.652	rs2072187	chr7:19747915	A/G	cg07541023	chr7:19748670	TWISTNB	1.03	6.16	0.48	9.21e-9	Thyroid stimulating hormone;
TGCT	cis	rs9911578	1.000	rs7215808	chr17:56940742	G/C	cg12560992	chr17:57184187	TRIM37	0.76	9.21	0.64	1.03e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs2806561	0.765	rs1738468	chr1:23510850	T/G	cg12483005	chr1:23474871	LUZP1	0.37	4.76	0.39	5.23e-6	Height;
TGCT	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.77	5.62	0.45	1.22e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs208515	0.525	rs12204452	chr6:66680325	C/T	cg07460842	chr6:66804631	NA	0.88	9.35	0.64	4.63e-16	Exhaled nitric oxide levels;
TGCT	cis	rs7178572	0.568	rs4886850	chr15:77404160	G/C	cg22256960	chr15:77711686	NA	-0.86	-8.84	-0.62	8.05e-15	Type 2 diabetes;
TGCT	cis	rs9818758	0.607	rs71324929	chr3:49044713	C/T	cg00383909	chr3:49044727	WDR6	1.33	6.68	0.51	7.32e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs11096990	0.634	rs7659894	chr4:39284435	G/A	cg20847110	chr4:39482781	LOC401127	-0.17	-4.58	-0.38	1.12e-5	Cognitive function;
TGCT	cis	rs9400467	0.500	rs1361425	chr6:111472243	A/T	cg15721981	chr6:111408429	SLC16A10	-0.53	-4.67	-0.39	7.84e-6	Blood metabolite levels;Amino acid levels;
TGCT	cis	rs477895	0.838	rs72922039	chr11:64013116	A/C	cg23719950	chr11:63933701	MACROD1	-0.69	-5.77	-0.46	5.92e-8	Mean platelet volume;
TGCT	cis	rs17761864	0.579	rs12452074	chr17:2051730	G/T	cg02171503	chr17:1588363	PRPF8	-0.48	-4.64	-0.38	8.86e-6	Esophageal cancer (squamous cell);
TGCT	cis	rs35160687	0.814	rs6547673	chr2:86528938	A/G	cg12542933	chr2:85804724	VAMP8	0.38	4.46	0.37	1.79e-5	Night sleep phenotypes;
TGCT	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs12464483	0.524	rs2602772	chr2:30885263	C/A	cg17749961	chr2:30669863	LCLAT1	0.59	4.69	0.39	7.22e-6	Pre-treatment pain in head and neck squamous cell carcinoma;
TGCT	cis	rs6500602	0.893	rs6500598	chr16:4470964	G/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	6.31	0.49	4.45e-9	Schizophrenia;
TGCT	cis	rs7786808	0.579	rs12669482	chr7:158188813	G/A	cg01191920	chr7:158217561	PTPRN2	-0.36	-5.38	-0.43	3.65e-7	Obesity-related traits;
TGCT	cis	rs7945705	0.520	rs1984791	chr11:9035027	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.45	4.99	0.41	1.97e-6	Hemoglobin concentration;
TGCT	cis	rs28374715	0.662	rs1554445	chr15:41503198	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.77	-10.97	-0.7	5.4e-20	Ulcerative colitis;
TGCT	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg21016266	chr12:122356598	WDR66	0.51	6.29	0.49	4.93e-9	Mean corpuscular volume;
TGCT	cis	rs4595586	0.525	rs7968566	chr12:39377200	C/T	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	trans	rs1005277	0.522	rs9418276	chr10:37940116	G/T	cg17830980	chr10:43048298	ZNF37B	-0.67	-7.46	-0.56	1.32e-11	Extrinsic epigenetic age acceleration;
TGCT	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg00684032	chr4:1343700	KIAA1530	0.23	4.8	0.4	4.53e-6	Obesity-related traits;
TGCT	cis	rs1691799	0.899	rs903587	chr12:66746061	C/A	cg16791601	chr12:66731901	HELB	-0.28	-6.18	-0.49	8.52e-9	White blood cell count (basophil);
TGCT	cis	rs2288884	0.945	rs78336183	chr19:52561483	C/T	cg13540795	chr19:52551618	ZNF432	-0.54	-4.83	-0.4	4.02e-6	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs8054556	0.740	rs12716975	chr16:29950829	C/T	cg26859862	chr16:30389551	SEPT1	-0.54	-4.71	-0.39	6.64e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7917772	0.560	rs11595170	chr10:104339851	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-5.46	-0.44	2.51e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs910316	0.763	rs1548807	chr14:75479582	T/G	cg08847533	chr14:75593920	NEK9	0.83	8.89	0.62	5.99e-15	Height;
TGCT	cis	rs9467773	0.620	rs2494700	chr6:26631306	C/T	cg26531700	chr6:26746687	NA	0.5	4.68	0.39	7.52e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4850410	0.581	rs6434900	chr2:197910432	C/A	cg19149314	chr2:197065128	HECW2	0.23	4.57	0.38	1.14e-5	Interferon alpha levels in systemic lupus erythematosus;
TGCT	cis	rs2115630	0.967	rs11073731	chr15:85355113	C/A	cg11189052	chr15:85197271	WDR73	-0.65	-6.29	-0.49	4.99e-9	P wave terminal force;
TGCT	trans	rs11764590	0.950	rs11514731	chr7:2051503	C/G	cg10840412	chr1:235813424	GNG4	0.96	6.93	0.53	1.99e-10	Neuroticism;
TGCT	cis	rs651907	0.557	rs35117343	chr3:101445126	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.87	10.21	0.68	3.89e-18	Colorectal cancer;
TGCT	cis	rs3796352	1.000	rs7645611	chr3:53125297	G/C	cg07884673	chr3:53033167	SFMBT1	0.53	5.68	0.45	8.87e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	trans	rs1496653	0.602	rs35230557	chr3:23386956	G/A	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs2456568	0.570	rs1518579	chr11:93656821	A/G	cg17595323	chr11:93583763	C11orf90	-0.46	-5.77	-0.46	5.83e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs3026101	0.624	rs1058383	chr17:5288203	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	4.63	0.38	9.15e-6	Body mass index;
TGCT	cis	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg07424592	chr7:64974309	NA	1.32	8.0	0.58	7.51e-13	Diabetic kidney disease;
TGCT	cis	rs9486719	0.948	rs2499813	chr6:96875338	T/C	cg06623918	chr6:96969491	KIAA0776	1.01	8.86	0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs904251	0.504	rs9380677	chr6:37480366	A/G	cg01843034	chr6:37503916	NA	-0.56	-7.35	-0.55	2.36e-11	Cognitive performance;
TGCT	cis	rs12908161	1.000	rs35630683	chr15:85349231	T/C	cg12863693	chr15:85201151	NMB	0.42	5.06	0.41	1.5e-6	Schizophrenia;
TGCT	cis	rs7772486	0.764	rs2265468	chr6:146218346	A/C	cg05347473	chr6:146136440	FBXO30	0.51	5.0	0.41	1.95e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs75686122	0.892	rs76748895	chr8:104641510	A/G	cg04852977	chr8:104510831	NA	0.59	4.48	0.37	1.67e-5	Cocaine dependence;
TGCT	cis	rs12210905	1.000	rs12205628	chr6:27225959	C/A	cg08851530	chr6:28072375	NA	1.06	5.05	0.41	1.55e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs7681423	1.000	rs2066864	chr4:155525695	G/A	cg20735720	chr4:155535218	FGG	-0.46	-6.8	-0.52	4e-10	Fibrinogen;
TGCT	cis	rs250677	0.687	rs250666	chr5:148454622	A/G	cg18129178	chr5:148520854	ABLIM3	-0.43	-6.29	-0.49	5.05e-9	Breast cancer;
TGCT	cis	rs377070	0.816	rs309400	chr4:123616189	C/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.42	4.65	0.39	8.39e-6	Mosquito bite size;
TGCT	cis	rs1008375	1.000	rs1008374	chr4:17683219	G/A	cg18681998	chr4:17616180	MED28	0.88	10.22	0.68	3.66e-18	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7119	0.651	rs12904533	chr15:77845928	G/A	cg27398640	chr15:77910606	LINGO1	-0.28	-5.2	-0.42	7.98e-7	Type 2 diabetes;
TGCT	cis	rs2147959	0.766	rs2182200	chr1:228716166	C/A	cg22700015	chr1:228743131	NA	-0.61	-5.15	-0.42	9.77e-7	Adult asthma;
TGCT	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg12756686	chr19:29218302	NA	0.72	6.9	0.53	2.32e-10	Methadone dose in opioid dependence;
TGCT	cis	rs7752195	0.643	rs76266945	chr6:25240510	G/A	cg16898833	chr6:26189333	HIST1H4D	1.17	5.47	0.44	2.34e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7216064	1.000	rs12602655	chr17:65909442	A/G	cg12091567	chr17:66097778	LOC651250	-0.81	-6.06	-0.48	1.53e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs9326248	0.954	rs8521	chr11:117067699	C/T	cg26566898	chr11:117069891	TAGLN	0.36	5.08	0.42	1.33e-6	Blood protein levels;
TGCT	cis	rs981844	0.961	rs17299034	chr4:154671396	A/G	cg14289246	chr4:154710475	SFRP2	1.01	8.67	0.61	2.02e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs886126	0.684	rs3858704	chr12:111705893	A/G	cg10833066	chr12:111807467	FAM109A	0.37	6.58	0.51	1.2e-9	Coronary heart disease;
TGCT	trans	rs11722228	0.522	rs12504600	chr4:10067138	C/A	cg26043149	chr18:55253948	FECH	1.1	10.53	0.69	6.47e-19	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs9326248	1.000	rs664082	chr11:117071070	C/G	cg11861562	chr11:117069780	TAGLN	0.27	4.48	0.37	1.69e-5	Blood protein levels;
TGCT	cis	rs6752107	1.000	rs2241878	chr2:234183718	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.2	4.79	0.39	4.74e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs7178424	0.516	rs2414758	chr15:62327127	T/C	cg00456672	chr15:62358751	C2CD4A	-0.29	-4.46	-0.37	1.84e-5	Height;
TGCT	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg25036284	chr2:26402008	FAM59B	-0.6	-4.84	-0.4	3.83e-6	Gut microbiome composition (summer);
TGCT	cis	rs12681287	0.752	rs34279109	chr8:87247944	G/A	cg27223183	chr8:87520930	FAM82B	-0.83	-5.76	-0.46	6.33e-8	Caudate activity during reward;
TGCT	cis	rs524281	0.861	rs11227409	chr11:65870938	A/G	cg00563793	chr11:65837595	PACS1	0.55	4.62	0.38	9.44e-6	Electroencephalogram traits;
TGCT	cis	rs12681288	0.862	rs34510005	chr8:1018943	T/C	cg21347738	chr8:1310380	NA	-0.22	-4.43	-0.37	2.01e-5	Schizophrenia;
TGCT	cis	rs13217239	0.646	rs7768407	chr6:27016795	G/A	cg05738196	chr6:26577821	NA	0.53	5.22	0.42	7.24e-7	Schizophrenia;
TGCT	trans	rs7618501	0.522	rs73077175	chr3:49774658	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.8	-7.32	-0.55	2.74e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg04267008	chr7:1944627	MAD1L1	-0.36	-4.6	-0.38	1.03e-5	Bipolar disorder and schizophrenia;
TGCT	cis	rs7647973	0.710	rs7629322	chr3:49621994	C/T	cg05785598	chr3:49045655	WDR6	0.4	4.62	0.38	9.42e-6	Menarche (age at onset);
TGCT	cis	rs7216064	0.684	rs7406031	chr17:66021753	C/T	cg12091567	chr17:66097778	LOC651250	1.07	8.8	0.62	9.68e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg05368731	chr17:41323189	NBR1	1.16	13.7	0.78	1.41e-26	Menopause (age at onset);
TGCT	cis	rs651907	0.557	rs34624546	chr3:101374226	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.03	0.41	1.65e-6	Colorectal cancer;
TGCT	cis	rs729982	1	rs729982	chr22:40810946	T/C	cg07138101	chr22:40742427	ADSL	0.78	5.29	0.43	5.4e-7	Number of common colds;
TGCT	cis	rs34467563	1.000	rs34467563	chr8:97416907	C/T	cg15747595	chr8:98289880	TSPYL5	-0.42	-4.57	-0.38	1.15e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9443645	0.810	rs10943613	chr6:79745107	C/T	cg09184832	chr6:79620586	NA	-0.45	-4.88	-0.4	3.19e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7103648	0.897	rs2278890	chr11:47399602	G/A	cg20307385	chr11:47447363	PSMC3	1.05	12.13	0.74	8.16e-23	Diastolic blood pressure;Systolic blood pressure;
TGCT	cis	rs11190604	1.000	rs28522614	chr10:102323141	T/A	cg16342193	chr10:102329863	NA	-0.41	-5.15	-0.42	9.86e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7010267	0.543	rs6469796	chr8:120018042	G/A	cg17171407	chr8:119960777	TNFRSF11B	0.26	4.59	0.38	1.06e-5	Total body bone mineral density (age 45-60);
TGCT	cis	rs79349575	0.783	rs1994970	chr17:47014127	C/T	cg07967210	chr17:47022446	SNF8	-0.39	-5.46	-0.44	2.53e-7	Type 2 diabetes;
TGCT	cis	rs17345786	0.906	rs55710435	chr3:101180330	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.84	8.92	0.63	5.05e-15	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg02546618	chr19:19431379	KIAA0892;SF4	-0.63	-5.13	-0.42	1.07e-6	Tonsillectomy;
TGCT	cis	rs4808199	0.842	rs11085259	chr19:19445856	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.69	5.33	0.43	4.49e-7	Nonalcoholic fatty liver disease;
TGCT	cis	rs9388451	0.872	rs2008027	chr6:126052359	A/G	cg10911889	chr6:126070802	HEY2	0.51	5.14	0.42	1.03e-6	Brugada syndrome;
TGCT	cis	rs8077577	0.895	rs13284	chr17:18112130	C/T	cg09161412	chr17:18057145	MYO15A	-0.64	-5.22	-0.42	7.2e-7	Obesity-related traits;
TGCT	cis	rs4595586	0.545	rs7310463	chr12:39368927	T/C	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs112217694	1.000	rs80123509	chr4:104651589	A/C	cg24090629	chr4:104641072	TACR3	-0.97	-4.81	-0.4	4.25e-6	Menarche (age at onset);
TGCT	cis	rs13188771	0.690	rs350560	chr5:100857718	C/T	cg10455971	chr5:101119566	NA	-0.44	-4.52	-0.38	1.44e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg25427524	chr10:38739819	LOC399744	-0.4	-8.23	-0.59	2.17e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs1887596	0.705	rs9551301	chr13:27237134	G/A	cg01312412	chr13:27282625	NA	0.28	4.91	0.4	2.83e-6	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg02725872	chr8:58115012	NA	-0.38	-5.05	-0.41	1.55e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2239547	0.657	rs2072391	chr3:52862200	C/T	cg11645453	chr3:52864694	ITIH4	0.34	5.67	0.45	9.34e-8	Schizophrenia;
TGCT	cis	rs3008870	0.959	rs56707923	chr1:67388016	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.1	12.09	0.74	1.01e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg03161606	chr19:29218774	NA	0.59	5.71	0.46	7.95e-8	Methadone dose in opioid dependence;
TGCT	cis	rs4901869	0.931	rs12891570	chr14:59334338	T/A	cg02291164	chr14:59296302	NA	0.24	4.58	0.38	1.11e-5	Panic disorder;
TGCT	cis	rs28595532	0.920	rs114057512	chr4:119750179	G/A	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs17268829	1.000	rs17321542	chr7:94103352	A/G	cg06439941	chr7:93550756	GNG11	-0.23	-4.47	-0.37	1.75e-5	Breast cancer;
TGCT	cis	rs7666738	0.830	rs6823718	chr4:99063202	C/T	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.44e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs854765	0.583	rs4413022	chr17:17858280	G/C	cg09796270	chr17:17721594	SREBF1	0.23	4.55	0.38	1.27e-5	Total body bone mineral density;
TGCT	cis	rs6692209	1	rs6692209	chr1:152506444	C/T	cg20991723	chr1:152506922	NA	0.46	6.28	0.49	5.26e-9	Plantar warts;
TGCT	cis	rs2562456	0.833	rs2681388	chr19:21732253	G/C	cg25650185	chr19:21324782	ZNF431	-0.64	-5.73	-0.46	7.12e-8	Pain;
TGCT	cis	rs9527	0.545	rs12784384	chr10:104957594	G/C	cg04362960	chr10:104952993	NT5C2	0.68	5.73	0.46	7.14e-8	Arsenic metabolism;
TGCT	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.05	-0.48	1.57e-8	Gut microbiome composition (summer);
TGCT	cis	rs72781680	1.000	rs72781683	chr2:24247423	T/C	cg08917208	chr2:24149416	ATAD2B	0.82	5.02	0.41	1.75e-6	Lymphocyte counts;
TGCT	cis	rs7412746	0.658	rs10305711	chr1:150802996	T/C	cg04414720	chr1:150670196	GOLPH3L	0.37	4.65	0.39	8.51e-6	Melanoma;
TGCT	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	5.5	0.44	2.05e-7	Alzheimer's disease;
TGCT	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg11941060	chr3:133502564	NA	0.3	6.67	0.51	7.61e-10	Iron status biomarkers;
TGCT	cis	rs5167	0.536	rs1882752	chr19:45461342	G/C	cg13119609	chr19:45449297	APOC2	0.23	4.67	0.39	7.7e-6	Blood protein levels;
TGCT	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg24503407	chr1:205819492	PM20D1	0.58	7.84	0.58	1.72e-12	Menarche (age at onset);
TGCT	cis	rs2153535	0.601	rs9505451	chr6:8469950	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs12477438	0.765	rs6722164	chr2:99561527	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.74	-7.06	-0.54	1.04e-10	Chronic sinus infection;
TGCT	cis	rs2832191	0.703	rs2853827	chr21:30443596	T/C	cg08807101	chr21:30365312	RNF160	0.65	6.14	0.48	1.01e-8	Dental caries;
TGCT	cis	rs2404602	0.716	rs1588961	chr15:76752698	A/G	cg26408565	chr15:76604113	ETFA	-0.4	-5.26	-0.43	6.23e-7	Blood metabolite levels;
TGCT	cis	rs892961	0.806	rs312910	chr17:75413961	A/C	cg05865280	chr17:75406074	SEPT9	0.27	6.52	0.51	1.56e-9	Airflow obstruction;
TGCT	cis	rs9436747	0.567	rs10889565	chr1:66053489	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.53	4.68	0.39	7.45e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs17376456	0.825	rs13165400	chr5:93091427	G/A	cg21475434	chr5:93447410	FAM172A	0.65	4.85	0.4	3.58e-6	Diabetic retinopathy;
TGCT	cis	rs6490294	0.799	rs11066080	chr12:112350404	T/A	cg10833066	chr12:111807467	FAM109A	0.36	5.41	0.44	3.18e-7	Mean platelet volume;
TGCT	cis	rs1348850	0.831	rs1345139	chr2:178449791	G/T	cg22681709	chr2:178499509	PDE11A	-0.38	-4.5	-0.37	1.56e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs8013055	0.846	rs10136015	chr14:105973469	A/C	cg19700328	chr14:106028568	NA	-0.53	-5.91	-0.47	3.03e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs889312	0.500	rs832570	chr5:56156408	G/A	cg24531977	chr5:56204891	C5orf35	-0.51	-5.19	-0.42	8.42e-7	Breast cancer;Breast cancer (early onset);
TGCT	cis	rs992157	0.560	rs4674274	chr2:219089131	A/T	cg00012203	chr2:219082015	ARPC2	-0.81	-9.36	-0.64	4.37e-16	Colorectal cancer;
TGCT	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg26513180	chr16:89883248	FANCA	1.06	14.86	0.8	2.56e-29	Vitiligo;
TGCT	cis	rs1158570	0.564	rs2554372	chr8:131333913	A/G	cg16277922	chr8:131349729	ASAP1	0.46	6.47	0.5	2.02e-9	Platelet count;
TGCT	cis	rs7809950	0.798	rs2701684	chr7:107299527	C/T	cg23024343	chr7:107201750	COG5	0.27	4.49	0.37	1.63e-5	Coronary artery disease;
TGCT	cis	rs13082711	0.954	rs67282221	chr3:27552752	T/A	cg02860705	chr3:27208620	NA	0.33	4.56	0.38	1.21e-5	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg07507251	chr3:52567010	NT5DC2	0.46	6.53	0.51	1.51e-9	Electroencephalogram traits;
TGCT	cis	rs3751972	0.668	rs7224724	chr17:26216090	A/G	cg02948944	chr17:26242737	NA	0.33	4.79	0.4	4.63e-6	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs7552404	1.000	rs441109	chr1:76120430	T/G	cg22875332	chr1:76189707	ACADM	-0.8	-9.79	-0.66	4.2e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs3862435	0.572	rs74480504	chr15:90924025	T/C	cg14166756	chr15:90894880	ZNF774	-0.32	-5.06	-0.41	1.49e-6	Response to exercise (triglyceride level interaction);
TGCT	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg18110333	chr6:292329	DUSP22	-0.72	-7.76	-0.57	2.71e-12	Menopause (age at onset);
TGCT	cis	rs9894429	0.682	rs7406360	chr17:79591545	G/A	cg21984481	chr17:79567631	NPLOC4	-0.26	-4.9	-0.4	2.98e-6	Eye color traits;
TGCT	cis	rs72781680	1.000	rs12616985	chr2:24165511	A/C	cg08917208	chr2:24149416	ATAD2B	0.73	4.51	0.38	1.48e-5	Lymphocyte counts;
TGCT	cis	rs78707713	0.560	rs35060419	chr10:71229539	A/G	cg14388049	chr10:71211838	TSPAN15	-0.39	-4.64	-0.38	8.84e-6	Venous thromboembolism;
TGCT	cis	rs1878931	0.624	rs28089	chr16:3446937	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.68	-5.28	-0.43	5.65e-7	Body mass index (adult);
TGCT	cis	rs1801251	1.000	rs13008942	chr2:233594875	G/A	cg25237894	chr2:233734115	C2orf82	0.33	6.02	0.48	1.82e-8	Coronary artery disease;
TGCT	trans	rs208520	0.742	rs208454	chr6:66907783	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.93	-9.78	-0.66	4.3e-17	Exhaled nitric oxide output;
TGCT	cis	rs2361718	0.501	rs11869566	chr17:78143248	T/C	cg21238619	chr17:78079768	GAA	-0.33	-4.44	-0.37	1.95e-5	Yeast infection;
TGCT	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg00343986	chr7:65444356	GUSB	0.23	5.14	0.42	1.06e-6	Aortic root size;
TGCT	cis	rs7666738	0.830	rs6825211	chr4:98807698	A/T	cg17366294	chr4:99064904	C4orf37	0.65	6.79	0.52	4.13e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11864453	0.713	rs7191127	chr16:72123992	G/T	cg14768367	chr16:72042858	DHODH	0.5	4.8	0.4	4.5e-6	Fibrinogen levels;
TGCT	cis	rs7824557	0.603	rs2250028	chr8:11213589	T/G	cg21775007	chr8:11205619	TDH	0.63	5.89	0.47	3.35e-8	Retinal vascular caliber;
TGCT	cis	rs7086627	0.515	rs6585994	chr10:82191643	A/G	cg01528321	chr10:82214614	TSPAN14	0.56	5.05	0.41	1.54e-6	Post bronchodilator FEV1;
TGCT	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg14893161	chr1:205819251	PM20D1	-0.52	-7.36	-0.55	2.19e-11	Menarche (age at onset);
TGCT	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg02725872	chr8:58115012	NA	-0.38	-5.05	-0.41	1.55e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9993613	0.875	rs4694501	chr4:73476315	C/T	cg15102770	chr4:73434591	ADAMTS3	0.54	4.96	0.41	2.26e-6	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs992157	0.698	rs6746089	chr2:219170377	A/G	cg00012203	chr2:219082015	ARPC2	0.81	8.07	0.59	5.04e-13	Colorectal cancer;
TGCT	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg12311346	chr5:56204834	C5orf35	0.75	6.81	0.52	3.83e-10	Initial pursuit acceleration;
TGCT	cis	rs7089973	0.604	rs35319791	chr10:116602296	C/A	cg03647239	chr10:116582469	FAM160B1	0.59	5.74	0.46	6.72e-8	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs7666738	0.791	rs28858828	chr4:98950442	C/G	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9467773	0.620	rs2101581	chr6:26622769	G/T	cg11502198	chr6:26597334	ABT1	0.54	4.99	0.41	1.99e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2404618	0.593	rs7815979	chr8:1484887	A/G	cg13402656	chr8:1511478	DLGAP2	-0.35	-5.95	-0.47	2.5e-8	Lung cancer;
TGCT	cis	rs826838	0.510	rs17523988	chr12:39222785	A/C	cg26384229	chr12:38710491	ALG10B	0.64	5.18	0.42	8.89e-7	Heart rate;
TGCT	cis	rs26868	0.690	rs26835	chr16:2237549	C/T	cg26873644	chr16:2260806	C16orf79	-0.22	-4.59	-0.38	1.08e-5	Height;
TGCT	cis	rs57221529	0.766	rs72703075	chr5:592819	C/T	cg20362242	chr5:692897	TPPP	0.55	4.79	0.4	4.65e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg06112835	chr11:68658793	MRPL21	0.46	8.12	0.59	3.91e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.58	-4.59	-0.38	1.09e-5	Lung function (FEV1/FVC);
TGCT	cis	rs7772486	0.754	rs697054	chr6:146003770	C/T	cg05347473	chr6:146136440	FBXO30	0.53	5.09	0.42	1.28e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1348850	0.632	rs4470372	chr2:178505857	G/A	cg22681709	chr2:178499509	PDE11A	-0.52	-6.5	-0.5	1.77e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs7647973	0.925	rs6446257	chr3:49253492	A/G	cg07690219	chr3:49449608	TCTA;RHOA	0.54	4.6	0.38	1.03e-5	Menarche (age at onset);
TGCT	cis	rs2836974	0.965	rs8134733	chr21:40683459	C/T	cg11644478	chr21:40555479	PSMG1	1.0	9.54	0.65	1.68e-16	Cognitive function;
TGCT	cis	rs9916302	0.904	rs634365	chr17:37436966	C/T	cg07936489	chr17:37558343	FBXL20	-0.62	-5.12	-0.42	1.14e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs11585357	0.947	rs6666990	chr1:17611520	G/A	cg08277548	chr1:17600880	PADI3	0.97	9.95	0.67	1.7e-17	Hair shape;
TGCT	cis	rs4879913	0.768	rs7036505	chr9:35599066	T/C	cg18130437	chr9:35658183	CCDC107;RMRP	-0.5	-4.92	-0.4	2.74e-6	Electroencephalogram traits;
TGCT	cis	rs7707921	0.541	rs10066167	chr5:81495445	C/T	cg15871215	chr5:81402204	ATG10	0.25	4.97	0.41	2.22e-6	Breast cancer;
TGCT	cis	rs709400	0.663	rs62007681	chr14:103884651	G/A	cg26031613	chr14:104095156	KLC1	0.86	9.43	0.65	2.96e-16	Body mass index;
TGCT	cis	rs6840360	0.615	rs6858483	chr4:152465509	C/T	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.03	-0.58	6.46e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs7178572	0.568	rs12906708	chr15:77681444	A/G	cg22256960	chr15:77711686	NA	-0.88	-9.16	-0.64	1.32e-15	Type 2 diabetes;
TGCT	cis	rs7552404	1.000	rs11161515	chr1:76212559	C/T	cg22875332	chr1:76189707	ACADM	0.76	9.2	0.64	1.1e-15	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs13326165	0.760	rs123602	chr3:52442354	C/G	cg27565382	chr3:53032988	SFMBT1	0.37	4.9	0.4	2.97e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs8050907	0.744	rs13335503	chr16:4529028	T/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.53	4.57	0.38	1.15e-5	Obesity-related traits;
TGCT	cis	rs9916302	0.861	rs8079590	chr17:37426201	T/C	cg15445000	chr17:37608096	MED1	0.32	4.69	0.39	7.11e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs763014	0.931	rs710925	chr16:633354	G/A	cg27436995	chr16:743998	FBXL16	-0.45	-4.82	-0.4	4.17e-6	Height;
TGCT	cis	rs11122272	0.637	rs2808593	chr1:231524228	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-6.94	-0.53	1.98e-10	Hemoglobin concentration;
TGCT	cis	rs826838	0.967	rs2069211	chr12:39128892	C/T	cg13010199	chr12:38710504	ALG10B	-0.63	-5.06	-0.41	1.46e-6	Heart rate;
TGCT	cis	rs9911578	0.741	rs2611776	chr17:56819636	G/T	cg05425664	chr17:57184151	TRIM37	-0.63	-6.26	-0.49	5.86e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs6456156	0.755	rs4710182	chr6:167514061	G/A	cg07741184	chr6:167504864	NA	0.22	4.51	0.38	1.48e-5	Primary biliary cholangitis;
TGCT	trans	rs66573146	1.000	rs67405518	chr4:6965930	C/T	cg07817883	chr1:32538562	TMEM39B	1.56	8.31	0.6	1.45e-13	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs2832191	1.000	rs2832183	chr21:30482150	G/A	cg24692254	chr21:30365293	RNF160	-0.83	-8.72	-0.62	1.56e-14	Dental caries;
TGCT	cis	rs9583531	0.891	rs61969076	chr13:111391568	C/T	cg24331049	chr13:111365604	ING1	-0.75	-5.25	-0.43	6.49e-7	Coronary artery disease;
TGCT	cis	rs4478858	0.735	rs6679360	chr1:31817936	G/T	cg00250761	chr1:31883323	NA	-0.27	-4.9	-0.4	2.92e-6	Alcohol dependence;
TGCT	cis	rs4642101	0.561	rs7638333	chr3:12806142	T/C	cg05775895	chr3:12838266	CAND2	0.51	5.11	0.42	1.16e-6	QRS complex (12-leadsum);
TGCT	cis	rs78487399	0.710	rs7567685	chr2:43668169	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.24	-0.43	6.79e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg17178900	chr1:205818956	PM20D1	0.56	6.97	0.53	1.63e-10	Menarche (age at onset);
TGCT	cis	rs28595532	0.920	rs56227053	chr4:119772460	C/T	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.41	-4.5	-0.37	1.53e-5	Longevity;Endometriosis;
TGCT	trans	rs1814175	0.791	rs1722023	chr11:49908136	G/C	cg15704280	chr7:45808275	SEPT13	-0.71	-8.0	-0.58	7.45e-13	Height;
TGCT	cis	rs12989701	0.877	rs71414738	chr2:127876242	C/T	cg08168897	chr2:127865431	BIN1	0.53	5.77	0.46	6.05e-8	Alzheimer's disease (late onset);
TGCT	cis	rs7085104	0.700	rs6163	chr10:104596924	C/A	cg15744005	chr10:104629667	AS3MT	-0.42	-5.28	-0.43	5.69e-7	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs2692947	0.702	rs7604842	chr2:96777340	C/T	cg22654517	chr2:96458247	NA	-0.22	-4.62	-0.38	9.34e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs8028182	0.501	rs7166281	chr15:75928192	G/T	cg20655648	chr15:75932815	IMP3	-0.59	-5.09	-0.42	1.29e-6	Sudden cardiac arrest;
TGCT	cis	rs11031096	0.678	rs61899754	chr11:4201312	A/T	cg18678763	chr11:4115507	RRM1	-0.46	-6.03	-0.48	1.78e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.66	0.39	8.18e-6	Prudent dietary pattern;
TGCT	cis	rs2933343	0.700	rs883602	chr3:128653952	A/G	cg11901034	chr3:128598214	ACAD9	-0.65	-6.08	-0.48	1.38e-8	IgG glycosylation;
TGCT	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg05368731	chr17:41323189	NBR1	1.16	13.44	0.77	5.72e-26	Menopause (age at onset);
TGCT	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.95	-10.88	-0.7	9.21e-20	Menarche (age at onset);
TGCT	cis	rs11249608	0.548	rs13161528	chr5:178452958	C/G	cg01312482	chr5:178451176	ZNF879	-0.49	-4.76	-0.39	5.2e-6	Pubertal anthropometrics;
TGCT	cis	rs6121246	0.909	rs6119720	chr20:30347568	T/G	cg18721089	chr20:30220636	NA	-0.43	-4.75	-0.39	5.54e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs9972944	0.756	rs6416949	chr17:63767219	A/T	cg07283582	chr17:63770753	CCDC46	-0.26	-5.24	-0.43	6.59e-7	Total body bone mineral density;
TGCT	cis	rs3820928	0.845	rs7570869	chr2:227878818	A/C	cg11843606	chr2:227700838	RHBDD1	-0.52	-4.62	-0.38	9.54e-6	Pulmonary function;
TGCT	cis	rs11112613	0.713	rs12296355	chr12:105953321	C/A	cg03607813	chr12:105948248	NA	0.47	5.72	0.46	7.49e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	cis	rs9443645	0.901	rs9361488	chr6:79782874	T/C	cg09184832	chr6:79620586	NA	-0.48	-5.34	-0.43	4.21e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7523050	0.643	rs7522324	chr1:109399644	T/C	cg08274380	chr1:109419600	GPSM2	1.3	6.39	0.5	2.99e-9	Fat distribution (HIV);
TGCT	cis	rs78487399	0.808	rs7578597	chr2:43732823	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-4.84	-0.4	3.79e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs4478037	0.822	rs4528891	chr3:33121392	G/T	cg19404215	chr3:33155277	CRTAP	1.03	5.37	0.43	3.8e-7	Major depressive disorder;
TGCT	cis	rs651907	0.557	rs59596156	chr3:101394217	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.34	-7.12	-0.54	7.61e-11	Colorectal cancer;
TGCT	trans	rs2760061	0.819	rs1745416	chr1:228204497	G/A	cg16006296	chr10:38738647	LOC399744	-0.31	-7.21	-0.54	4.89e-11	Diastolic blood pressure;
TGCT	cis	rs60871478	0.636	rs56393680	chr7:885696	A/G	cg15782153	chr7:917662	C7orf20	0.54	4.91	0.4	2.86e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs10754283	0.934	rs6661282	chr1:90119992	C/T	cg03145924	chr1:90228473	NA	-0.4	-4.51	-0.38	1.51e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs7523273	1.000	rs34385765	chr1:207993637	A/G	cg22525895	chr1:207977042	MIR29B2	-0.49	-8.55	-0.61	3.78e-14	Schizophrenia;
TGCT	cis	rs950169	0.519	rs7237	chr15:85186577	C/T	cg17173187	chr15:85201210	NMB	0.59	7.05	0.53	1.1e-10	Schizophrenia;
TGCT	cis	rs3825199	0.515	rs2072593	chr12:93970026	T/C	cg18151635	chr12:93972918	NA	-0.19	-4.52	-0.38	1.41e-5	Height;
TGCT	cis	rs185694	1.000	rs846495	chr13:30894250	T/C	cg07600127	chr13:30881527	KATNAL1	-0.82	-6.64	-0.51	8.92e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
TGCT	cis	rs9549367	0.826	rs9549713	chr13:113905308	G/T	cg18105134	chr13:113819100	PROZ	-0.34	-5.58	-0.45	1.41e-7	Platelet distribution width;
TGCT	cis	rs4478858	0.684	rs4949369	chr1:31723845	T/A	cg07478791	chr1:31886160	SERINC2	-0.49	-4.92	-0.4	2.73e-6	Alcohol dependence;
TGCT	cis	rs13191362	1.000	rs13209728	chr6:162997533	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.68	5.79	0.46	5.33e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7107174	1.000	rs11602622	chr11:78010830	A/G	cg12700464	chr11:78128424	GAB2	-0.7	-4.86	-0.4	3.46e-6	Testicular germ cell tumor;
TGCT	trans	rs1864729	0.901	rs1348184	chr8:98276912	C/G	cg08679828	chr8:102218111	ZNF706	-1.09	-7.6	-0.56	6.34e-12	Estradiol plasma levels (breast cancer);
TGCT	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg10150615	chr22:24372951	LOC391322	-1.0	-12.91	-0.76	1.1e-24	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs72781680	0.898	rs72798064	chr2:23982832	T/C	cg08917208	chr2:24149416	ATAD2B	0.83	5.24	0.43	6.62e-7	Lymphocyte counts;
TGCT	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg13395646	chr4:1353034	KIAA1530	0.4	4.98	0.41	2.1e-6	Obesity-related traits;
TGCT	cis	rs727563	0.635	rs5751149	chr22:42139501	A/G	cg13695892	chr22:41940480	POLR3H	0.89	8.43	0.6	7.37e-14	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs2075165	0.901	rs2274226	chr1:156314627	C/T	cg20302342	chr1:156215951	PAQR6	-0.36	-5.38	-0.44	3.56e-7	Tonsillectomy;
TGCT	cis	rs17376456	0.877	rs10059630	chr5:93459807	C/A	cg25358565	chr5:93447407	FAM172A	0.92	8.38	0.6	9.58e-14	Diabetic retinopathy;
TGCT	cis	rs1483890	0.723	rs900670	chr3:69406781	G/A	cg22125112	chr3:69402811	FRMD4B	0.29	4.71	0.39	6.53e-6	Resting heart rate;
TGCT	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg20607798	chr8:58055168	NA	0.5	4.67	0.39	7.65e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6088580	0.634	rs6142159	chr20:32993035	G/A	cg06115741	chr20:33292138	TP53INP2	-0.53	-4.67	-0.39	7.83e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs4237845	0.537	rs9645819	chr12:58270063	T/C	cg23860436	chr12:58378763	NA	0.33	4.56	0.38	1.23e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs12908161	1.000	rs12908161	chr15:85207825	A/G	cg17173187	chr15:85201210	NMB	0.59	6.74	0.52	5.44e-10	Schizophrenia;
TGCT	cis	rs4727027	0.868	rs10952799	chr7:148840772	C/T	cg23583168	chr7:148888333	NA	-0.72	-9.17	-0.64	1.31e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs9682041	0.808	rs9875109	chr3:170064776	A/G	cg01716527	chr3:170072769	NA	-0.26	-4.92	-0.4	2.67e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs9644630	0.897	rs4921654	chr8:19359974	G/T	cg01280390	chr8:19363452	CSGALNACT1	-0.27	-4.78	-0.39	4.89e-6	Oropharynx cancer;
TGCT	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.59	-8.31	-0.6	1.38e-13	Longevity;Endometriosis;
TGCT	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg17971929	chr21:40555470	PSMG1	0.98	9.57	0.65	1.43e-16	Cognitive function;
TGCT	cis	rs7918232	0.830	rs7911024	chr10:27433636	A/C	cg14442939	chr10:27389572	ANKRD26	0.72	5.35	0.43	4.16e-7	Breast cancer;
TGCT	cis	rs250677	0.522	rs2217638	chr5:148364355	A/G	cg18129178	chr5:148520854	ABLIM3	0.36	4.63	0.38	9.23e-6	Breast cancer;
TGCT	cis	rs11792861	0.564	rs3816237	chr9:111718348	T/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.66	7.62	0.56	5.71e-12	Menarche (age at onset);
TGCT	cis	rs35883536	0.528	rs1414414	chr1:101028907	T/C	cg10298815	chr1:101004474	GPR88	0.25	4.7	0.39	6.82e-6	Monocyte count;
TGCT	cis	rs9341808	0.667	rs2490241	chr6:80846342	T/C	cg08355045	chr6:80787529	NA	0.32	5.38	0.43	3.6e-7	Sitting height ratio;
TGCT	cis	rs763014	0.865	rs2018789	chr16:632051	T/C	cg00908189	chr16:619842	PIGQ	0.87	10.5	0.69	7.53e-19	Height;
TGCT	cis	rs7647973	1.000	rs74471041	chr3:49542543	T/G	cg07636037	chr3:49044803	WDR6	-0.7	-5.73	-0.46	7.08e-8	Menarche (age at onset);
TGCT	cis	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg20637647	chr7:64974828	NA	-0.9	-5.31	-0.43	4.87e-7	Diabetic kidney disease;
TGCT	cis	rs6722750	0.901	rs7567728	chr2:64411932	A/C	cg22352474	chr2:64371530	PELI1	-0.55	-4.9	-0.4	2.98e-6	Neuroticism;
TGCT	cis	rs476633	0.573	rs6492995	chr15:41529712	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.68	-8.54	-0.61	3.98e-14	Glomerular filtration rate (creatinine);
TGCT	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg22105103	chr4:187893119	NA	0.31	4.44	0.37	1.98e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2652822	0.662	rs34367270	chr15:63410912	G/A	cg12855773	chr15:63363890	TPM1	-0.16	-4.59	-0.38	1.05e-5	Metabolic traits;
TGCT	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg27454412	chr7:1067447	C7orf50	0.51	4.61	0.38	9.99e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs854765	0.583	rs7207395	chr17:17819335	C/T	cg09796270	chr17:17721594	SREBF1	0.27	5.55	0.45	1.69e-7	Total body bone mineral density;
TGCT	cis	rs539096	0.872	rs573350	chr1:44057950	T/C	cg12908607	chr1:44402522	ARTN	-0.52	-5.36	-0.43	3.99e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs896854	0.608	rs7004862	chr8:95876963	T/G	cg13393036	chr8:95962371	TP53INP1	-0.52	-6.45	-0.5	2.21e-9	Type 2 diabetes;
TGCT	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg08859206	chr1:53392774	SCP2	0.39	5.79	0.46	5.33e-8	Monocyte count;
TGCT	cis	rs7666738	0.747	rs2865955	chr4:99040518	A/C	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6570726	0.935	rs9390329	chr6:145828026	T/C	cg23711669	chr6:146136114	FBXO30	0.7	6.46	0.5	2.12e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9787249	0.915	rs58589165	chr1:40213670	A/T	cg24920358	chr1:40204285	PPIE	0.57	10.56	0.69	5.57e-19	Blood protein levels;
TGCT	cis	rs17376456	0.569	rs6556834	chr5:93123067	C/T	cg25358565	chr5:93447407	FAM172A	-0.76	-6.68	-0.51	7.23e-10	Diabetic retinopathy;
TGCT	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg06873352	chr17:61820015	STRADA	0.56	6.22	0.49	7.1e-9	Prudent dietary pattern;
TGCT	cis	rs11792861	0.962	rs72607161	chr9:111792640	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.48	4.44	0.37	1.99e-5	Menarche (age at onset);
TGCT	cis	rs9911578	0.967	rs11656413	chr17:57082013	A/C	cg05425664	chr17:57184151	TRIM37	0.68	6.89	0.53	2.55e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs11997175	0.846	rs34860600	chr8:33761566	C/A	ch.8.33884649F	chr8:33765107	NA	0.32	4.72	0.39	6.33e-6	Body mass index;
TGCT	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6570726	0.526	rs7755237	chr6:145731852	T/C	cg23711669	chr6:146136114	FBXO30	-0.61	-5.42	-0.44	3e-7	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs10501293	0.746	rs7131154	chr11:43001206	A/G	cg23728189	chr2:10470961	HPCAL1	-0.27	-6.72	-0.52	5.74e-10	Cognitive performance;
TGCT	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg18538332	chr22:24372958	LOC391322	1.02	13.19	0.76	2.24e-25	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg13732083	chr21:47605072	C21orf56	0.34	4.47	0.37	1.74e-5	Testicular germ cell tumor;
TGCT	cis	rs6570726	0.791	rs952406	chr6:145925616	C/A	cg23711669	chr6:146136114	FBXO30	0.84	8.91	0.62	5.38e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs910316	1.000	rs12897094	chr14:75579416	C/T	cg08847533	chr14:75593920	NEK9	0.95	10.61	0.69	4.09e-19	Height;
TGCT	cis	rs459571	0.834	rs379417	chr9:136890704	G/A	cg13789015	chr9:136890014	NCRNA00094	0.39	7.2	0.54	5.17e-11	Platelet distribution width;
TGCT	cis	rs9388451	0.839	rs11154331	chr6:126111429	A/T	cg10911889	chr6:126070802	HEY2	0.48	4.97	0.41	2.18e-6	Brugada syndrome;
TGCT	cis	rs11098499	0.644	rs10012252	chr4:120559139	T/C	cg09307838	chr4:120376055	NA	0.62	5.82	0.46	4.83e-8	Corneal astigmatism;
TGCT	cis	rs7267979	1.000	rs6115168	chr20:25372891	C/A	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7211079	0.879	rs7221505	chr17:78128231	G/A	cg09238746	chr17:78121135	EIF4A3	-0.73	-5.86	-0.47	3.82e-8	Myocardial infarction;
TGCT	cis	rs3540	0.597	rs3539	chr15:91045419	G/T	cg22089800	chr15:90895588	ZNF774	-0.76	-7.77	-0.57	2.55e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs4722585	0.605	rs3753098	chr7:26198040	C/T	cg07876897	chr7:26191696	NFE2L3	-0.38	-5.14	-0.42	1.03e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
TGCT	cis	rs6088580	0.634	rs6088498	chr20:33020446	A/G	cg08999081	chr20:33150536	PIGU	0.28	5.52	0.44	1.91e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs12579753	1.000	rs17749267	chr12:82178308	A/G	cg21231944	chr12:82153410	PPFIA2	0.34	4.5	0.37	1.54e-5	Resting heart rate;
TGCT	cis	rs2535633	0.631	rs2581803	chr3:52994981	G/A	cg11645453	chr3:52864694	ITIH4	-0.29	-5.36	-0.43	3.99e-7	Body mass index;
TGCT	cis	rs9467773	0.967	rs6941022	chr6:26553531	T/C	cg26531700	chr6:26746687	NA	0.48	4.72	0.39	6.37e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs11948739	0.501	rs4254896	chr5:130363499	C/T	cg08523029	chr5:130500466	HINT1	-0.61	-5.08	-0.42	1.34e-6	Pediatric bone mineral content (hip);
TGCT	cis	rs1453308	0.766	rs1470860	chr2:237176943	T/A	cg19324714	chr2:237145437	ASB18	0.59	5.22	0.42	7.18e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs34366173	1	rs34366173	chr15:63998914	CTT/C	cg12036633	chr15:63758958	NA	-0.53	-4.64	-0.38	8.85e-6	Reticulocyte fraction of red cells;
TGCT	cis	rs6582630	0.679	rs7301806	chr12:38596667	G/A	cg26384229	chr12:38710491	ALG10B	0.55	5.0	0.41	1.93e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs1609391	0.567	rs835633	chr3:136676496	T/C	cg12473912	chr3:136751656	NA	0.39	6.18	0.49	8.36e-9	Neuroticism;
TGCT	cis	rs17712049	0.908	rs62447149	chr7:48198747	C/G	cg16849860	chr7:48352531	ABCA13	0.32	5.26	0.43	6.19e-7	Refractive astigmatism;
TGCT	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg06618935	chr21:46677482	NA	-0.37	-5.66	-0.45	9.9e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs3008870	1.000	rs2985794	chr1:67425311	T/G	cg08660285	chr1:67390436	MIER1;WDR78	1.1	11.8	0.73	5.15e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs11785693	0.862	rs7007542	chr8:4996718	G/A	cg26367366	chr8:4980734	NA	0.58	4.45	0.37	1.91e-5	Neuroticism (multi-trait analysis);Neuroticism;
TGCT	cis	rs3733585	0.762	rs6449217	chr4:10009151	T/A	cg11266682	chr4:10021025	SLC2A9	0.67	8.49	0.61	5.35e-14	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7017914	0.934	rs13255886	chr8:71565954	G/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.5	-4.68	-0.39	7.37e-6	Bone mineral density;
TGCT	cis	rs3751972	0.866	rs9646434	chr17:26251158	C/G	cg02948944	chr17:26242737	NA	0.5	6.96	0.53	1.78e-10	Fractional exhaled nitric oxide (childhood);
TGCT	trans	rs1973993	0.691	rs1980684	chr1:96890636	A/G	cg10631902	chr5:14652156	NA	0.4	10.92	0.7	7.4e-20	Weight;
TGCT	trans	rs629535	0.773	rs630235	chr8:70033529	T/G	cg21567404	chr3:27674614	NA	0.58	9.28	0.64	7e-16	Dupuytren's disease;
TGCT	cis	rs6988636	0.710	rs62521797	chr8:124134321	A/T	cg22384356	chr8:124195192	FAM83A	-0.5	-4.79	-0.39	4.71e-6	Urinary uromodulin levels;
TGCT	cis	rs7809950	0.953	rs2520267	chr7:107187497	T/C	cg23024343	chr7:107201750	COG5	-0.35	-5.54	-0.45	1.72e-7	Coronary artery disease;
TGCT	cis	rs11690935	0.549	rs796839	chr2:172916214	A/C	cg13550731	chr2:172543902	DYNC1I2	0.69	6.39	0.5	3.06e-9	Schizophrenia;
TGCT	cis	rs797680	0.964	rs1060622	chr1:93620393	G/A	cg17826107	chr1:92977322	EVI5	-0.24	-5.13	-0.42	1.09e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs910316	1.000	rs7142235	chr14:75559963	T/C	cg11812906	chr14:75593930	NEK9	0.74	7.38	0.55	1.97e-11	Height;
TGCT	cis	rs2010099	0.759	rs116358073	chr3:124299095	G/A	cg17170942	chr3:124452405	UMPS	-0.4	-4.59	-0.38	1.07e-5	Thyroid peroxidase antibody levels;
TGCT	cis	rs12579753	0.810	rs10862355	chr12:82162698	C/T	cg07988820	chr12:82153109	PPFIA2	-0.61	-6.82	-0.52	3.63e-10	Resting heart rate;
TGCT	cis	rs453301	0.719	rs34004903	chr8:8892604	C/T	cg06636001	chr8:8085503	FLJ10661	-0.66	-5.58	-0.45	1.42e-7	Joint mobility (Beighton score);
TGCT	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg14773178	chr5:1868261	NA	0.34	5.62	0.45	1.21e-7	Cardiovascular disease risk factors;
TGCT	cis	rs651907	0.557	rs11925001	chr3:101373966	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.35	-7.28	-0.55	3.4e-11	Colorectal cancer;
TGCT	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg17178900	chr1:205818956	PM20D1	0.7	9.77	0.66	4.54e-17	Menarche (age at onset);
TGCT	cis	rs854765	0.547	rs2955385	chr17:17939247	C/T	cg04398451	chr17:18023971	MYO15A	-0.32	-5.12	-0.42	1.11e-6	Total body bone mineral density;
TGCT	cis	rs9325144	0.647	rs11169258	chr12:39113040	C/T	cg10518543	chr12:38710700	ALG10B	-0.5	-4.69	-0.39	6.99e-6	Morning vs. evening chronotype;
TGCT	cis	rs11690935	0.851	rs6731562	chr2:172798262	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.81	-7.08	-0.54	9.26e-11	Schizophrenia;
TGCT	cis	rs9902453	0.769	rs7210288	chr17:28243473	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.81	7.28	0.55	3.32e-11	Coffee consumption (cups per day);
TGCT	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg07157834	chr1:205819609	PM20D1	0.48	8.44	0.6	6.93e-14	Menarche (age at onset);
TGCT	cis	rs1723838	0.826	rs1531001	chr11:73606963	G/A	cg18195628	chr11:73498948	MRPL48	0.92	4.5	0.38	1.51e-5	Obesity-related traits;
TGCT	cis	rs72945132	0.579	rs61341131	chr11:70246956	C/A	cg00319359	chr11:70116639	PPFIA1	0.9	6.82	0.52	3.52e-10	Coronary artery disease;
TGCT	cis	rs9905704	0.647	rs6503888	chr17:57028126	T/C	cg12560992	chr17:57184187	TRIM37	0.58	5.05	0.41	1.52e-6	Testicular germ cell tumor;
TGCT	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	12.04	0.73	1.36e-22	Height;
TGCT	cis	rs10771431	0.817	rs17202253	chr12:9361850	A/G	cg08997352	chr12:9597637	DDX12	-0.26	-5.24	-0.43	6.71e-7	Breast size;
TGCT	cis	rs9811216	1.000	rs12696304	chr3:169481271	C/G	cg08193579	chr3:169529701	LRRC34	0.28	4.6	0.38	1.03e-5	Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;
TGCT	cis	rs4938534	0.750	rs1944927	chr11:111287404	C/A	cg24049888	chr11:111250129	POU2AF1	-0.26	-4.54	-0.38	1.3e-5	Primary biliary cholangitis;
TGCT	cis	rs4711350	0.723	rs608971	chr6:33702079	C/T	cg00334056	chr6:33755658	LEMD2	0.33	4.46	0.37	1.82e-5	Schizophrenia;
TGCT	cis	rs9467711	1.000	rs9467707	chr6:26327905	G/C	cg02458000	chr6:26745757	NA	-1.05	-5.8	-0.46	5.29e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs539096	0.607	rs3001723	chr1:44037685	G/A	cg12908607	chr1:44402522	ARTN	0.4	4.43	0.37	2.02e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs13216391	0.628	rs55865034	chr6:7776136	T/A	cg16988958	chr6:7987739	MGC26597	0.26	4.52	0.38	1.4e-5	Hip circumference adjusted for BMI;
TGCT	cis	rs10992471	0.651	rs2296669	chr9:95373790	A/G	cg13798575	chr9:95087839	CENPP;NOL8	0.58	5.2	0.42	8.05e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	trans	rs2727020	0.553	rs3907576	chr11:49536639	A/C	cg03929089	chr4:120376271	NA	-0.66	-7.62	-0.56	5.75e-12	Coronary artery disease;
TGCT	cis	rs2235642	0.928	rs1057610	chr16:1605537	T/C	cg10465839	chr16:1584050	IFT140;TMEM204	-0.29	-4.83	-0.4	3.88e-6	Coronary artery disease;
TGCT	cis	rs3008870	1.000	rs6673462	chr1:67461857	A/C	cg11518657	chr1:67396239	MIER1	-0.54	-4.61	-0.38	9.72e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs6089584	0.586	rs4925216	chr20:60599923	G/A	cg06108461	chr20:60628389	TAF4	-0.43	-5.24	-0.43	6.68e-7	Body mass index;
TGCT	cis	rs739401	0.572	rs739399	chr11:3016452	A/G	cg05729581	chr11:3078854	CARS	-0.59	-5.39	-0.44	3.47e-7	Longevity;
TGCT	cis	rs7552404	0.731	rs5745458	chr1:76345429	G/A	cg10523679	chr1:76189770	ACADM	-0.83	-7.8	-0.57	2.24e-12	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs11758351	0.660	rs2143345	chr6:26229148	C/T	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.6	-4.54	-0.38	1.32e-5	Gout;Renal underexcretion gout;
TGCT	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg11764359	chr7:65958608	NA	0.61	5.53	0.44	1.79e-7	Aortic root size;
TGCT	cis	rs12580194	1.000	rs7971451	chr12:55699950	G/A	cg20672549	chr12:56432144	IKZF4	0.26	4.71	0.39	6.51e-6	Cancer;
TGCT	cis	rs3110496	0.819	rs3115097	chr17:27907313	A/G	cg05877788	chr17:27899874	TP53I13	-0.52	-4.75	-0.39	5.47e-6	Height;
TGCT	cis	rs7267979	0.966	rs2227892	chr20:25264814	T/C	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2046867	0.862	rs75638790	chr3:72830502	C/T	cg25664220	chr3:72788482	NA	-0.58	-7.21	-0.54	4.9e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2228479	0.850	rs62054224	chr16:89892071	C/T	cg06558623	chr16:89946397	TCF25	0.55	4.79	0.4	4.69e-6	Skin colour saturation;
TGCT	cis	rs9796	0.727	rs61203391	chr15:41352912	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.49	-6.18	-0.49	8.53e-9	Menopause (age at onset);
TGCT	cis	rs7714584	1.000	rs76548544	chr5:150223515	T/A	cg22134413	chr5:150180641	NA	0.89	6.96	0.53	1.73e-10	Crohn's disease;
TGCT	cis	rs3748682	0.861	rs2291297	chr1:38272660	G/A	cg04496824	chr1:38276835	MTF1	0.21	4.61	0.38	1.01e-5	Hypothyroidism;
TGCT	cis	rs10875746	0.579	rs10875778	chr12:48624655	T/C	cg20731937	chr12:48336164	NA	0.59	4.49	0.37	1.61e-5	Longevity (90 years and older);
TGCT	cis	rs13102973	0.965	rs4280794	chr4:135857174	T/C	cg14419869	chr4:135874104	NA	0.23	4.58	0.38	1.12e-5	Subjective well-being;
TGCT	cis	rs42648	0.869	rs6970376	chr7:89938086	A/G	cg25739043	chr7:89950458	NA	0.71	7.16	0.54	6.18e-11	Homocysteine levels;
TGCT	cis	rs796364	0.951	rs769952	chr2:200734368	C/T	cg17644776	chr2:200775616	C2orf69	0.31	4.83	0.4	3.99e-6	Schizophrenia;
TGCT	cis	rs3960554	0.808	rs13438599	chr7:75768022	G/A	cg17325771	chr7:75508891	RHBDD2	-0.52	-4.44	-0.37	2e-5	Eotaxin levels;
TGCT	cis	rs7226408	0.901	rs17568091	chr18:34739590	T/C	cg06757138	chr18:34340585	FHOD3	0.26	4.92	0.4	2.69e-6	Obesity-related traits;
TGCT	cis	rs9372498	0.536	rs2356501	chr6:118942371	C/A	cg07617317	chr6:118971624	C6orf204	0.48	5.08	0.42	1.32e-6	Diastolic blood pressure;
TGCT	cis	rs12580194	0.957	rs73118932	chr12:55706631	C/T	cg20672549	chr12:56432144	IKZF4	0.28	4.55	0.38	1.26e-5	Cancer;
TGCT	cis	rs12971120	0.783	rs7229256	chr18:72169129	T/A	cg26446133	chr18:72167187	CNDP2	-0.4	-7.77	-0.57	2.58e-12	Refractive error;
TGCT	trans	rs11722228	1.000	rs11722228	chr4:9915741	C/T	cg26043149	chr18:55253948	FECH	0.75	7.76	0.57	2.64e-12	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg03388025	chr16:89894329	SPIRE2	0.5	8.7	0.62	1.73e-14	Vitiligo;
TGCT	cis	rs595982	0.559	rs73061632	chr19:49361663	G/A	cg21252483	chr19:49399788	TULP2	-0.42	-6.46	-0.5	2.11e-9	Red cell distribution width;
TGCT	cis	rs12477438	0.765	rs2309520	chr2:99570477	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.57	4.91	0.4	2.84e-6	Chronic sinus infection;
TGCT	trans	rs1974653	0.672	rs7288396	chr22:20086571	G/T	cg08822737	chr17:71088851	SLC39A11	-0.93	-7.61	-0.56	5.97e-12	Schizophrenia;
TGCT	cis	rs1998418	0.673	rs11245391	chr10:126547439	A/G	cg03585084	chr10:126284563	LHPP	0.33	4.88	0.4	3.22e-6	Mean platelet volume;
TGCT	cis	rs7772486	0.754	rs9373475	chr6:146126419	C/T	cg05347473	chr6:146136440	FBXO30	0.54	5.09	0.42	1.28e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7584330	0.826	rs72620824	chr2:238381083	G/A	cg14458575	chr2:238380390	NA	0.6	9.37	0.64	4.27e-16	Prostate cancer;
TGCT	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg06112835	chr11:68658793	MRPL21	0.48	8.14	0.59	3.49e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs858239	0.600	rs7456915	chr7:23143049	T/C	cg05602783	chr7:23145260	KLHL7	-0.68	-5.75	-0.46	6.69e-8	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs2172802	0.693	rs11131337	chr4:62491495	T/C	cg04118610	chr4:62707027	LPHN3	-0.43	-4.6	-0.38	1.02e-5	Partial epilepsies;
TGCT	cis	rs7432375	0.901	rs4521165	chr3:136369710	T/C	cg12473912	chr3:136751656	NA	-0.36	-5.06	-0.41	1.5e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1385374	0.858	rs12321643	chr12:129302867	A/T	cg09035930	chr12:129282057	SLC15A4	-0.55	-4.76	-0.39	5.27e-6	Systemic lupus erythematosus;
TGCT	cis	rs524023	1.000	rs3825018	chr11:64358809	G/A	cg07733098	chr11:64478343	NRXN2	0.31	4.66	0.39	7.9e-6	Urate levels in obese individuals;
TGCT	cis	rs9788721	0.836	rs17483686	chr15:78733390	A/T	cg18825076	chr15:78729989	IREB2	-0.33	-5.22	-0.42	7.38e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
TGCT	cis	rs2120019	1.000	rs7162900	chr15:75368017	T/C	cg11632617	chr15:75315747	PPCDC	-0.34	-4.82	-0.4	4.18e-6	Blood trace element (Zn levels);
TGCT	cis	rs362272	0.524	rs13150241	chr4:3367281	A/G	cg22655196	chr4:3374909	RGS12	0.22	4.45	0.37	1.86e-5	Serum sulfate level;
TGCT	cis	rs9419702	0.639	rs4367873	chr10:133533485	C/T	cg23460707	chr10:133558971	NA	0.42	4.63	0.38	9.08e-6	Survival in rectal cancer;
TGCT	cis	rs73198271	0.740	rs10098636	chr8:8647324	C/T	cg15556689	chr8:8085844	FLJ10661	-0.6	-4.46	-0.37	1.8e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs910316	0.935	rs175076	chr14:75505486	A/G	cg23033748	chr14:75592666	NEK9	-0.27	-4.65	-0.39	8.3e-6	Height;
TGCT	cis	rs1008375	0.618	rs6842764	chr4:17568420	C/T	cg16339924	chr4:17578868	LAP3	-0.77	-6.37	-0.5	3.33e-9	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs12682352	0.652	rs3827806	chr8:8724276	C/T	cg15556689	chr8:8085844	FLJ10661	0.66	6.06	0.48	1.52e-8	Neuroticism;
TGCT	cis	rs4919694	1.000	rs77969925	chr10:104649357	C/T	cg04362960	chr10:104952993	NT5C2	1.03	6.95	0.53	1.83e-10	Arsenic metabolism;
TGCT	cis	rs2806561	0.704	rs2746560	chr1:23526279	G/A	cg12483005	chr1:23474871	LUZP1	0.42	5.41	0.44	3.15e-7	Height;
TGCT	cis	rs6598955	0.671	rs17163746	chr1:26564230	C/A	cg04990556	chr1:26633338	UBXN11	0.64	5.11	0.42	1.19e-6	Obesity-related traits;
TGCT	cis	rs7582180	0.614	rs4851309	chr2:100975390	C/T	cg14675211	chr2:100938903	LONRF2	0.5	4.79	0.4	4.66e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs617219	0.698	rs10055956	chr5:78479678	G/A	cg09550809	chr5:78407562	BHMT	0.4	5.75	0.46	6.44e-8	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs7246657	0.823	rs4802236	chr19:37919246	A/G	cg18154014	chr19:37997991	ZNF793	0.95	6.55	0.51	1.4e-9	Coronary artery calcification;
TGCT	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.01	8.32	0.6	1.34e-13	Platelet count;
TGCT	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.88	-5.91	-0.47	3.15e-8	Alzheimer's disease;
TGCT	cis	rs8141529	0.871	rs5762877	chr22:29277555	G/A	cg02153584	chr22:29168773	CCDC117	0.7	5.16	0.42	9.38e-7	Lymphocyte counts;
TGCT	cis	rs1061377	1.000	rs3733274	chr4:39122577	A/G	cg24403649	chr4:39172243	NA	0.18	4.44	0.37	1.99e-5	Uric acid levels;
TGCT	cis	rs9302001	0.883	rs7329015	chr13:95453928	C/T	cg07483244	chr13:95358924	NA	0.37	4.62	0.38	9.47e-6	Panic disorder;
TGCT	cis	rs4727027	0.933	rs7788925	chr7:148831621	A/G	cg23583168	chr7:148888333	NA	-0.72	-9.18	-0.64	1.18e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs9814567	1.000	rs7611828	chr3:134250325	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.95	-9.55	-0.65	1.56e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs950169	0.580	rs35516100	chr15:85195430	C/T	cg11189052	chr15:85197271	WDR73	0.76	6.33	0.49	4.04e-9	Schizophrenia;
TGCT	cis	rs4443656	0.711	rs67760158	chr8:21548344	C/T	cg26401870	chr8:21882439	NPM2	-0.47	-4.61	-0.38	9.76e-6	Blood protein levels;
TGCT	cis	rs9646954	0.560	rs4149507	chr2:101032745	C/T	cg14675211	chr2:100938903	LONRF2	0.5	4.67	0.39	7.79e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs11673344	0.504	rs2385375	chr19:37578522	G/C	cg08039142	chr19:36980659	ZNF566	0.5	4.6	0.38	1.02e-5	Obesity-related traits;
TGCT	cis	rs6121246	0.529	rs6058152	chr20:30178107	G/A	cg21427119	chr20:30132790	HM13	-0.43	-6.28	-0.49	5.3e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs9611565	0.546	rs34077262	chr22:42061639	A/G	cg06634786	chr22:41940651	POLR3H	0.83	7.91	0.58	1.22e-12	Vitiligo;
TGCT	cis	rs3213545	0.700	rs10849829	chr12:121470256	A/G	cg02403541	chr12:121454288	C12orf43	-0.7	-8.03	-0.58	6.44e-13	Subjective well-being;Cardiovascular disease risk factors;
TGCT	cis	rs698813	0.555	rs7605771	chr2:44479778	G/A	cg00619915	chr2:44497795	NA	-0.24	-5.62	-0.45	1.19e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
TGCT	cis	rs999943	0.846	rs10947422	chr6:33611351	G/A	cg14003231	chr6:33640908	ITPR3	0.39	4.9	0.4	2.97e-6	Obesity (extreme);
TGCT	cis	rs9677476	0.516	rs1549339	chr2:231982826	G/A	cg27665808	chr2:232055229	NA	0.37	4.59	0.38	1.05e-5	Food antigen IgG levels;
TGCT	cis	rs45430	1.000	rs443099	chr21:42743327	G/T	cg22778903	chr21:42741698	MX2	0.33	5.38	0.43	3.63e-7	Melanoma;
TGCT	cis	rs8141529	0.778	rs7287806	chr22:29213011	G/A	cg02153584	chr22:29168773	CCDC117	0.68	5.9	0.47	3.31e-8	Lymphocyte counts;
TGCT	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg16414030	chr3:133502952	NA	-0.61	-9.84	-0.66	3.15e-17	Iron status biomarkers;
TGCT	cis	rs8072100	0.676	rs9908049	chr17:45502096	G/C	cg08085267	chr17:45401833	C17orf57	-0.51	-5.64	-0.45	1.11e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs7542091	0.704	rs7550330	chr1:210044587	G/A	cg00989853	chr1:209979345	IRF6	0.43	4.58	0.38	1.12e-5	Monobrow;
TGCT	cis	rs2204008	0.837	rs11168334	chr12:37961768	A/G	cg26384229	chr12:38710491	ALG10B	0.81	7.19	0.54	5.25e-11	Bladder cancer;
TGCT	cis	rs2243480	1.000	rs67536397	chr7:65947917	G/A	cg18252515	chr7:66147081	NA	-1.18	-7.56	-0.56	7.99e-12	Diabetic kidney disease;
TGCT	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg04267008	chr7:1944627	MAD1L1	-0.4	-5.37	-0.43	3.81e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs1008375	0.966	rs4235389	chr4:17696280	A/G	cg18681998	chr4:17616180	MED28	0.76	7.55	0.56	8.3e-12	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs11098499	0.780	rs7680914	chr4:120563053	A/G	cg09307838	chr4:120376055	NA	0.7	6.52	0.51	1.6e-9	Corneal astigmatism;
TGCT	cis	rs6088580	0.634	rs1205338	chr20:32925625	C/G	cg08999081	chr20:33150536	PIGU	-0.25	-4.85	-0.4	3.66e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs4776059	0.798	rs7167494	chr15:52928453	C/G	cg25063058	chr15:52860530	ARPP19	-0.58	-4.49	-0.37	1.61e-5	Schizophrenia;
TGCT	cis	rs79349575	0.783	rs12453394	chr17:46994970	G/A	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.51	-0.38	1.48e-5	Type 2 diabetes;
TGCT	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg08736216	chr1:53307985	ZYG11A	0.25	4.93	0.4	2.59e-6	Monocyte count;
TGCT	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg17971929	chr21:40555470	PSMG1	0.97	9.54	0.65	1.67e-16	Cognitive function;
TGCT	cis	rs4285028	0.731	rs2332035	chr3:121715432	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.68	-5.65	-0.45	1.03e-7	Multiple sclerosis;
TGCT	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg11644478	chr21:40555479	PSMG1	0.97	9.14	0.63	1.54e-15	Cognitive function;
TGCT	cis	rs514406	0.570	rs1332776	chr1:53189816	C/T	cg22166914	chr1:53195759	ZYG11B	0.45	8.41	0.6	8.07e-14	Monocyte count;
TGCT	cis	rs9929218	0.861	rs3114409	chr16:68732049	A/C	cg01251360	chr16:68772225	CDH1	0.29	4.76	0.39	5.36e-6	Colorectal cancer;
TGCT	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg07167872	chr1:205819463	PM20D1	0.59	7.65	0.57	4.74e-12	Menarche (age at onset);
TGCT	cis	rs854765	0.547	rs2955370	chr17:17966945	C/T	cg09796270	chr17:17721594	SREBF1	-0.24	-4.69	-0.39	7e-6	Total body bone mineral density;
TGCT	cis	rs651907	0.514	rs11706494	chr3:101509475	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	4.85	0.4	3.68e-6	Colorectal cancer;
TGCT	trans	rs17471911	0.708	rs7919734	chr10:100771294	C/T	cg03484267	chr2:207988651	KLF7	-0.52	-6.7	-0.52	6.49e-10	Neuroticism;
TGCT	cis	rs2338224	1.000	rs12517661	chr5:71745716	C/T	cg01187920	chr5:71015162	CARTPT	-0.53	-4.57	-0.38	1.15e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Granulocyte count;Myeloid white cell count;
TGCT	cis	rs7107174	1.000	rs58565853	chr11:78036707	C/T	cg12700464	chr11:78128424	GAB2	-0.66	-4.71	-0.39	6.53e-6	Testicular germ cell tumor;
TGCT	cis	rs2242116	1.000	rs2242116	chr3:46941116	A/G	cg27129171	chr3:47204927	SETD2	0.64	6.28	0.49	5.31e-9	Birth weight;
TGCT	cis	rs7809950	1.000	rs986994	chr7:107104115	G/T	cg23024343	chr7:107201750	COG5	-0.34	-5.26	-0.43	6.05e-7	Coronary artery disease;
TGCT	cis	rs2153535	0.580	rs1328862	chr6:8526681	A/T	cg07606381	chr6:8435919	SLC35B3	0.54	5.01	0.41	1.86e-6	Motion sickness;
TGCT	cis	rs6089584	0.830	rs4925331	chr20:60580174	T/C	cg06108461	chr20:60628389	TAF4	-0.58	-8.35	-0.6	1.12e-13	Body mass index;
TGCT	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg20007245	chr22:24372913	LOC391322	0.7	6.91	0.53	2.2e-10	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs12815613	0.621	rs11065360	chr12:121386532	A/G	cg02403541	chr12:121454288	C12orf43	-0.55	-5.07	-0.41	1.41e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg18252515	chr7:66147081	NA	-1.31	-8.18	-0.59	2.87e-13	Diabetic kidney disease;
TGCT	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg22920501	chr2:26401640	FAM59B	0.81	6.36	0.5	3.52e-9	Gut microbiome composition (summer);
TGCT	cis	rs7072216	0.763	rs6584202	chr10:100170383	G/A	cg26618903	chr10:100175079	PYROXD2	-0.4	-4.49	-0.37	1.64e-5	Metabolite levels;
TGCT	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg01802117	chr1:53393560	SCP2	0.43	5.12	0.42	1.14e-6	Monocyte count;
TGCT	cis	rs7666738	0.830	rs28456179	chr4:98991439	A/G	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs13126513	0.519	rs959247	chr4:100556984	A/G	cg05468953	chr4:100565104	NA	0.4	5.31	0.43	4.95e-7	Metabolite levels (MHPG);
TGCT	cis	rs12497850	0.931	rs4974085	chr3:48924900	C/T	cg05785598	chr3:49045655	WDR6	0.35	4.72	0.39	6.35e-6	Parkinson's disease;
TGCT	cis	rs11098499	0.697	rs28458294	chr4:120238924	T/C	cg09307838	chr4:120376055	NA	0.63	6.22	0.49	7.01e-9	Corneal astigmatism;
TGCT	cis	rs2840044	1.000	rs11080357	chr17:33898933	G/A	cg05299278	chr17:33885742	SLFN14	-0.23	-5.32	-0.43	4.65e-7	Response to radiotherapy in cancer (late toxicity);
TGCT	cis	rs832540	0.564	rs33329	chr5:56145068	T/C	cg12311346	chr5:56204834	C5orf35	-0.49	-5.13	-0.42	1.08e-6	Coronary artery disease;
TGCT	cis	rs6570726	0.846	rs4896824	chr6:145927048	C/T	cg13319975	chr6:146136371	FBXO30	-0.51	-4.5	-0.37	1.53e-5	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs1814175	0.817	rs11040474	chr11:49708441	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.38	-7.6	-0.56	6.14e-12	Height;
TGCT	cis	rs644799	0.542	rs10831416	chr11:95467220	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.6	5.83	0.46	4.5e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs6671200	1.000	rs6678964	chr1:95694268	C/T	cg20701556	chr1:95698924	RWDD3	0.67	6.03	0.48	1.75e-8	Stearic acid (18:0) levels;
TGCT	cis	rs6728642	1.000	rs11900461	chr2:97615993	C/T	cg26665480	chr2:98280029	ACTR1B	-0.98	-5.36	-0.43	3.94e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	cis	rs55704346	0.935	rs12510672	chr4:25192577	C/T	cg26487582	chr4:25322200	ZCCHC4	0.18	4.44	0.37	1.97e-5	Tonsillectomy;
TGCT	cis	rs713587	0.967	rs713586	chr2:25158008	A/G	cg01884057	chr2:25150051	NA	0.39	8.05	0.59	5.72e-13	Body mass index in non-asthmatics;
TGCT	cis	rs6690583	0.623	rs11588160	chr1:85444226	T/G	cg20280350	chr1:85513789	MCOLN3	-0.67	-4.5	-0.37	1.52e-5	Serum sulfate level;
TGCT	cis	rs60154123	0.730	rs4844987	chr1:210458190	G/T	cg22029157	chr1:209979665	IRF6	0.6	4.46	0.37	1.81e-5	Coronary artery disease;
TGCT	cis	rs7760949	0.852	rs9475800	chr6:13932230	A/G	cg27413430	chr6:13925136	RNF182	0.74	6.83	0.52	3.37e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs11718455	0.961	rs3846068	chr3:44029835	G/A	cg08738300	chr3:44038990	NA	0.81	6.0	0.47	2.02e-8	Coronary artery disease;
TGCT	cis	rs12579753	0.871	rs35801863	chr12:82238818	A/T	cg07988820	chr12:82153109	PPFIA2	-0.6	-6.48	-0.5	1.91e-9	Resting heart rate;
TGCT	cis	rs644799	1.000	rs494829	chr11:95571750	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	8.11	0.59	4.26e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs2288073	0.619	rs6713263	chr2:24375463	A/G	cg06627628	chr2:24431161	ITSN2	-0.16	-4.45	-0.37	1.93e-5	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs7100689	0.646	rs2050824	chr10:82123563	G/A	cg01528321	chr10:82214614	TSPAN14	0.8	7.76	0.57	2.7e-12	Post bronchodilator FEV1;
TGCT	cis	rs7104764	0.957	rs58692051	chr11:207410	C/T	cg18336825	chr11:236787	PSMD13;SIRT3	-0.99	-10.18	-0.67	4.61e-18	Menarche (age at onset);
TGCT	cis	rs904251	0.861	rs1757180	chr6:37486145	T/C	cg01843034	chr6:37503916	NA	-0.51	-6.22	-0.49	7.05e-9	Cognitive performance;
TGCT	cis	rs72700829	0.507	rs11204766	chr1:151018060	G/C	cg00666978	chr1:150947442	LASS2	0.89	4.64	0.38	8.54e-6	Schizophrenia;
TGCT	cis	rs11679640	0.610	rs56383943	chr2:43113641	G/A	cg00484711	chr2:42331922	NA	-0.2	-4.63	-0.38	9.27e-6	White matter hyperintensity burden;
TGCT	cis	rs8028182	0.583	rs9944207	chr15:75912889	A/T	cg20655648	chr15:75932815	IMP3	0.63	4.83	0.4	3.87e-6	Sudden cardiac arrest;
TGCT	cis	rs35883536	0.647	rs12023028	chr1:101042717	C/T	cg06223162	chr1:101003688	GPR88	-0.42	-7.93	-0.58	1.1e-12	Monocyte count;
TGCT	cis	rs651907	0.535	rs13085776	chr3:101505507	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.29	-6.41	-0.5	2.73e-9	Colorectal cancer;
TGCT	cis	rs12210905	1.000	rs72843609	chr6:27125877	G/A	cg08851530	chr6:28072375	NA	1.12	5.43	0.44	2.82e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-6.49	-0.5	1.85e-9	Alzheimer's disease;
TGCT	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg24503407	chr1:205819492	PM20D1	0.59	8.22	0.59	2.3e-13	Menarche (age at onset);
TGCT	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg17971929	chr21:40555470	PSMG1	0.97	9.4	0.65	3.57e-16	Cognitive function;
TGCT	cis	rs10791111	1	rs10791111	chr11:130856099	T/G	cg12179176	chr11:130786555	SNX19	0.6	5.75	0.46	6.67e-8	Autism spectrum disorder or schizophrenia;
TGCT	trans	rs1268083	0.546	rs9398785	chr6:126057748	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.74	-7.15	-0.54	6.58e-11	Migraine;
TGCT	cis	rs11864453	0.713	rs12708927	chr16:72126165	C/T	cg14768367	chr16:72042858	DHODH	0.5	4.8	0.4	4.5e-6	Fibrinogen levels;
TGCT	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg26338869	chr17:61819248	STRADA	-0.55	-5.08	-0.41	1.37e-6	Prudent dietary pattern;
TGCT	cis	rs2456568	0.802	rs7115629	chr11:93635477	G/A	cg14065697	chr11:93583672	C11orf90	-0.37	-4.63	-0.38	9.11e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs6940638	0.531	rs12211984	chr6:26986054	G/C	cg15659132	chr6:26577336	NA	0.55	5.55	0.45	1.62e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2204008	0.805	rs12146846	chr12:37985847	C/T	cg13010199	chr12:38710504	ALG10B	0.65	5.29	0.43	5.47e-7	Bladder cancer;
TGCT	cis	rs2549003	1.000	rs9282761	chr5:131822224	T/C	cg00255919	chr5:131827918	IRF1	0.2	4.65	0.39	8.22e-6	Asthma (sex interaction);
TGCT	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg21862992	chr11:68658383	NA	0.46	6.52	0.51	1.6e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs10206020	0.885	rs11899557	chr2:1576123	G/T	cg12573674	chr2:1569213	NA	-0.46	-5.2	-0.42	7.88e-7	IgG glycosylation;
TGCT	cis	rs12762955	0.519	rs7094331	chr10:1022816	T/C	cg18964960	chr10:1102726	WDR37	-0.59	-5.24	-0.43	6.73e-7	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg03264133	chr6:25882463	NA	-0.65	-6.06	-0.48	1.5e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.91	7.44	0.56	1.45e-11	Platelet count;
TGCT	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg06238570	chr21:40685208	BRWD1	0.73	6.66	0.51	8.12e-10	Cognitive function;
TGCT	cis	rs9921222	1.000	rs10794639	chr16:377367	A/G	cg08923669	chr16:420230	MRPL28	-0.48	-5.07	-0.41	1.43e-6	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs10465746	0.657	rs67045520	chr1:84414998	G/T	cg10977910	chr1:84465055	TTLL7	0.67	6.74	0.52	5.32e-10	Obesity-related traits;
TGCT	cis	rs9325144	0.541	rs7303395	chr12:38664124	C/T	cg26384229	chr12:38710491	ALG10B	-0.66	-6.0	-0.47	2.06e-8	Morning vs. evening chronotype;
TGCT	cis	rs9372498	0.831	rs62421532	chr6:118705454	A/T	cg18833306	chr6:118973337	C6orf204	-0.61	-4.76	-0.39	5.22e-6	Diastolic blood pressure;
TGCT	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg11494091	chr17:61959527	GH2	0.61	14.34	0.79	4.3e-28	Prudent dietary pattern;
TGCT	cis	rs10423674	0.526	rs2023878	chr19:18834124	A/G	cg20185461	chr19:18899082	COMP	0.52	5.02	0.41	1.78e-6	Menarche (age at onset);
TGCT	cis	rs7714584	1.000	rs74955473	chr5:150174558	T/A	cg22134413	chr5:150180641	NA	1.13	8.18	0.59	2.91e-13	Crohn's disease;
TGCT	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg22166914	chr1:53195759	ZYG11B	0.36	5.96	0.47	2.45e-8	Monocyte count;
TGCT	cis	rs736408	0.812	rs2239699	chr3:52827915	C/T	cg10802521	chr3:52805072	NEK4	-0.63	-7.07	-0.54	9.9e-11	Bipolar disorder;
TGCT	cis	rs9534288	0.664	rs1926447	chr13:46629944	C/T	cg15192986	chr13:46630673	CPB2	0.57	7.26	0.55	3.65e-11	Blood protein levels;
TGCT	cis	rs2797160	1.000	rs2747723	chr6:126010790	C/T	cg05901451	chr6:126070800	HEY2	0.73	6.3	0.49	4.83e-9	Endometrial cancer;
TGCT	cis	rs17345786	0.906	rs59359251	chr3:101146362	A/C	cg12386194	chr3:101231763	SENP7	0.65	6.39	0.5	3.06e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8014204	0.836	rs12588415	chr14:75278211	G/A	cg06637938	chr14:75390232	RPS6KL1	0.68	6.49	0.5	1.84e-9	Caffeine consumption;
TGCT	cis	rs7020830	0.894	rs13300951	chr9:37146627	A/G	cg14294708	chr9:37120828	ZCCHC7	1.31	20.34	0.88	2.57e-41	Schizophrenia;
TGCT	cis	rs1580019	0.885	rs4460270	chr7:32496450	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.79	7.42	0.55	1.63e-11	Cognitive ability;
TGCT	cis	rs854765	0.565	rs4072738	chr17:17884547	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.74	7.26	0.55	3.67e-11	Total body bone mineral density;
TGCT	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg27211696	chr2:191398769	TMEM194B	0.29	5.3	0.43	5.19e-7	Pulse pressure;
TGCT	cis	rs477895	1.000	rs2276014	chr11:64081445	G/A	cg23719950	chr11:63933701	MACROD1	-0.59	-4.6	-0.38	1.01e-5	Mean platelet volume;
TGCT	cis	rs8016982	0.632	rs7142641	chr14:81677454	A/G	cg01989461	chr14:81687754	GTF2A1	0.62	4.62	0.38	9.48e-6	Schizophrenia;
TGCT	cis	rs6558530	0.730	rs7341635	chr8:1721643	G/A	cg09410841	chr8:1729607	CLN8	0.83	9.76	0.66	4.92e-17	Systolic blood pressure;
TGCT	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg22920501	chr2:26401640	FAM59B	-0.74	-6.4	-0.5	2.86e-9	Gut microbiome composition (summer);
TGCT	cis	rs6921919	0.583	rs9461456	chr6:28343816	A/G	cg18815343	chr6:28367644	ZSCAN12	-0.56	-5.33	-0.43	4.48e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7635838	0.718	rs2594981	chr3:11380638	C/G	cg00170343	chr3:11313890	ATG7	0.62	6.09	0.48	1.28e-8	HDL cholesterol;
TGCT	cis	rs9814567	1.000	rs11919350	chr3:134235970	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.96	9.11	0.63	1.79e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs2467099	0.504	rs55956362	chr17:73901294	G/T	cg02678768	chr17:74002944	EVPL	0.27	4.44	0.37	1.97e-5	Systolic blood pressure;
TGCT	cis	rs35306767	0.761	rs11253558	chr10:1043983	T/C	cg18964960	chr10:1102726	WDR37	0.78	5.46	0.44	2.45e-7	Eosinophil percentage of granulocytes;
TGCT	cis	rs9549367	0.601	rs558869	chr13:113849932	G/T	cg18105134	chr13:113819100	PROZ	0.46	8.58	0.61	3.25e-14	Platelet distribution width;
TGCT	cis	rs9611565	0.592	rs4822044	chr22:41979668	G/C	cg13695892	chr22:41940480	POLR3H	-0.83	-7.48	-0.56	1.18e-11	Vitiligo;
TGCT	cis	rs11112613	0.762	rs17037308	chr12:105949847	T/G	cg03607813	chr12:105948248	NA	0.52	6.0	0.47	2.03e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	cis	rs4566357	0.576	rs6750845	chr2:227911037	T/G	cg11843606	chr2:227700838	RHBDD1	-0.55	-5.17	-0.42	8.92e-7	Coronary artery disease;
TGCT	cis	rs35000415	0.688	rs13232316	chr7:128715299	A/T	cg06242719	chr7:129414860	MIR183;MIR96	-0.3	-4.58	-0.38	1.1e-5	Systemic lupus erythematosus;
TGCT	cis	rs288326	0.561	rs77426227	chr2:183890678	A/T	cg09997497	chr2:183902928	NCKAP1	1.11	4.95	0.41	2.38e-6	Blood protein levels;
TGCT	cis	rs9733	0.596	rs6669369	chr1:150695892	C/T	cg04414720	chr1:150670196	GOLPH3L	0.37	4.91	0.4	2.76e-6	Tonsillectomy;
TGCT	cis	rs62064224	0.703	rs62065492	chr17:30822607	C/T	cg18200150	chr17:30822561	MYO1D	0.57	8.04	0.59	6.08e-13	Schizophrenia;
TGCT	cis	rs62244186	0.659	rs1806579	chr3:44509281	T/C	cg25151919	chr3:44754333	ZNF502	-0.39	-4.55	-0.38	1.26e-5	Depressive symptoms;
TGCT	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg12311346	chr5:56204834	C5orf35	-0.57	-6.13	-0.48	1.07e-8	Initial pursuit acceleration;
TGCT	cis	rs6121246	0.559	rs1062794	chr20:30381758	G/C	cg13852791	chr20:30311386	BCL2L1	0.82	8.0	0.58	7.65e-13	Mean corpuscular hemoglobin;
TGCT	cis	rs7586879	0.752	rs11683748	chr2:25130434	C/T	cg01884057	chr2:25150051	NA	0.26	4.67	0.39	7.75e-6	Body mass index;
TGCT	cis	rs9611519	0.780	rs2235852	chr22:41661154	G/T	cg03806693	chr22:41940476	POLR3H	-0.76	-5.23	-0.42	7.06e-7	Neuroticism;
TGCT	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	6.81	0.52	3.67e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs1403694	0.695	rs5029970	chr3:186434491	T/C	cg12454167	chr3:186435060	KNG1	0.51	8.67	0.61	1.95e-14	Blood protein levels;
TGCT	cis	rs4478858	0.663	rs11591060	chr1:31780012	G/A	cg07478791	chr1:31886160	SERINC2	-0.48	-4.61	-0.38	1e-5	Alcohol dependence;
TGCT	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg11764359	chr7:65958608	NA	-0.57	-5.25	-0.43	6.43e-7	Aortic root size;
TGCT	cis	rs2594989	0.943	rs346068	chr3:11302933	A/G	cg00170343	chr3:11313890	ATG7	0.69	4.97	0.41	2.21e-6	Circulating chemerin levels;
TGCT	cis	rs9682041	1.000	rs6444920	chr3:170090374	A/G	cg07589077	chr3:170072950	NA	0.31	4.7	0.39	6.94e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs2486288	0.656	rs2413773	chr15:45549442	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.72	-7.46	-0.56	1.34e-11	Glomerular filtration rate;
TGCT	cis	rs651907	0.514	rs34301719	chr3:101417993	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.32	-6.26	-0.49	5.65e-9	Colorectal cancer;
TGCT	cis	rs2235642	0.826	rs8053605	chr16:1594158	G/A	cg11375102	chr16:1583810	IFT140;TMEM204	-0.3	-5.35	-0.43	4.1e-7	Coronary artery disease;
TGCT	cis	rs832540	0.931	rs331499	chr5:56210923	C/T	cg12311346	chr5:56204834	C5orf35	-0.46	-4.79	-0.4	4.58e-6	Coronary artery disease;
TGCT	cis	rs3617	0.625	rs6445541	chr3:52880128	G/T	cg10802521	chr3:52805072	NEK4	-0.59	-6.82	-0.52	3.64e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6500602	0.702	rs4786493	chr16:4500122	C/T	cg08645402	chr16:4508243	NA	0.17	4.65	0.39	8.38e-6	Schizophrenia;
TGCT	cis	rs9467711	0.606	rs9348709	chr6:26360311	G/A	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6570726	0.875	rs373313	chr6:145857791	T/C	cg23711669	chr6:146136114	FBXO30	0.71	7.03	0.53	1.25e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9902453	0.740	rs2617884	chr17:28120430	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.84	-8.19	-0.59	2.73e-13	Coffee consumption (cups per day);
TGCT	cis	rs17712049	0.908	rs58887783	chr7:48198403	C/T	cg16849860	chr7:48352531	ABCA13	0.32	5.26	0.43	6.19e-7	Refractive astigmatism;
TGCT	cis	rs1062177	1.000	rs17741826	chr5:151149262	C/T	cg12924095	chr5:151150029	G3BP1	-0.35	-5.04	-0.41	1.6e-6	Preschool internalizing problems;
TGCT	cis	rs9916302	0.851	rs11868029	chr17:37650304	A/G	cg15445000	chr17:37608096	MED1	0.33	4.93	0.4	2.59e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs9457247	0.508	rs9457268	chr6:167503639	A/T	cg07741184	chr6:167504864	NA	0.27	5.25	0.43	6.4e-7	Crohn's disease;
TGCT	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.4	-4.76	-0.39	5.24e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs13256369	1.000	rs12545771	chr8:8567977	C/G	cg18904891	chr8:8559673	CLDN23	0.59	5.52	0.44	1.93e-7	Obesity-related traits;
TGCT	cis	rs1635	0.655	rs73742539	chr6:28305471	C/T	cg15743358	chr6:28303923	ZNF323	-1.29	-6.5	-0.5	1.73e-9	Schizophrenia;
TGCT	cis	rs2115630	1.000	rs6496441	chr15:85363348	A/G	cg17173187	chr15:85201210	NMB	-0.4	-4.89	-0.4	3.1e-6	P wave terminal force;
TGCT	cis	rs727479	0.543	rs1143704	chr15:51510702	T/A	cg19946085	chr15:51559439	CYP19A1	-0.3	-4.49	-0.37	1.62e-5	Estradiol levels;
TGCT	cis	rs910316	1.000	rs28626045	chr14:75589195	G/C	cg23033748	chr14:75592666	NEK9	0.27	4.71	0.39	6.59e-6	Height;
TGCT	cis	rs617219	0.671	rs13165414	chr5:78548873	C/T	cg23987322	chr5:78407566	BHMT	0.35	4.69	0.39	7.07e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg13395646	chr4:1353034	KIAA1530	-0.4	-4.87	-0.4	3.27e-6	Longevity;
TGCT	cis	rs12477438	0.520	rs6542866	chr2:99764592	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	14.89	0.8	2.21e-29	Chronic sinus infection;
TGCT	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg10802521	chr3:52805072	NEK4	-0.7	-8.75	-0.62	1.28e-14	Bipolar disorder;
TGCT	trans	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg17470723	chr8:74884337	TCEB1	0.72	6.94	0.53	1.91e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs4460629	0.710	rs11264318	chr1:155083717	A/T	cg23973274	chr1:155060172	NA	-0.25	-4.5	-0.37	1.54e-5	Serum magnesium levels;
TGCT	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg22968622	chr17:43663579	NA	1.05	10.19	0.68	4.43e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs308403	0.509	rs7690133	chr4:123673809	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.82	11.9	0.73	2.98e-22	Blood protein levels;
TGCT	trans	rs3774749	0.565	rs6800021	chr3:50190346	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.7	6.81	0.52	3.67e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs7647973	1.000	rs13088309	chr3:49368317	A/G	cg05785598	chr3:49045655	WDR6	0.39	4.62	0.38	9.58e-6	Menarche (age at onset);
TGCT	cis	rs11190604	1.000	rs11190570	chr10:102227702	G/C	cg16342193	chr10:102329863	NA	-0.4	-5.31	-0.43	4.85e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg06221963	chr1:154839813	KCNN3	-0.75	-12.65	-0.75	4.48e-24	Prostate cancer;
TGCT	trans	rs1814175	0.669	rs12364577	chr11:49707361	A/C	cg15704280	chr7:45808275	SEPT13	-0.6	-6.94	-0.53	1.92e-10	Height;
TGCT	cis	rs7666738	0.830	rs13124904	chr4:98856973	T/C	cg05340658	chr4:99064831	C4orf37	0.52	6.0	0.47	1.98e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs62244186	0.659	rs12489887	chr3:44547124	A/T	cg21672276	chr3:44754072	ZNF502	-0.41	-4.66	-0.39	7.99e-6	Depressive symptoms;
TGCT	cis	rs611744	0.647	rs7015240	chr8:109262204	G/A	cg21045802	chr8:109455806	TTC35	0.69	6.92	0.53	2.12e-10	Dupuytren's disease;
TGCT	cis	rs77861329	1.000	rs9816434	chr3:52197513	C/T	cg08692210	chr3:52188851	WDR51A	0.93	4.79	0.4	4.61e-6	Macrophage inflammatory protein 1b levels;
TGCT	cis	rs2013441	1.000	rs34089239	chr17:20057959	G/T	cg18979559	chr17:20280153	CCDC144C	0.44	4.61	0.38	9.78e-6	Obesity-related traits;
TGCT	cis	rs2455799	0.613	rs2470547	chr3:15737610	T/C	cg16303742	chr3:15540471	COLQ	-0.26	-4.87	-0.4	3.26e-6	Mean platelet volume;
TGCT	cis	rs12210905	0.688	rs12196452	chr6:27344415	A/T	cg08851530	chr6:28072375	NA	1.25	5.39	0.44	3.38e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs67311347	1.000	rs17078916	chr3:40445438	C/T	cg17264618	chr3:40429014	ENTPD3	0.32	4.57	0.38	1.18e-5	Renal cell carcinoma;
TGCT	cis	rs921968	0.613	rs2556388	chr2:219541056	T/C	cg02176678	chr2:219576539	TTLL4	-0.33	-4.45	-0.37	1.91e-5	Mean corpuscular hemoglobin concentration;
TGCT	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg22968622	chr17:43663579	NA	1.3	11.87	0.73	3.46e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs1800469	0.928	rs12462166	chr19:41857404	T/C	cg09537434	chr19:41945824	ATP5SL	-0.5	-4.64	-0.38	8.9e-6	Colorectal cancer;
TGCT	cis	rs6460942	0.915	rs17541242	chr7:12459068	A/G	cg06484146	chr7:12443880	VWDE	-0.57	-5.52	-0.44	1.92e-7	Coronary artery disease;
TGCT	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.46	-5.47	-0.44	2.36e-7	Longevity;Endometriosis;
TGCT	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg12667521	chr19:29218732	NA	0.53	5.64	0.45	1.07e-7	Methadone dose in opioid dependence;
TGCT	cis	rs806215	1.000	rs806216	chr7:127237862	C/A	cg25922125	chr7:127225783	GCC1	-0.61	-6.41	-0.5	2.76e-9	Type 2 diabetes;
TGCT	trans	rs941408	1.000	rs1076448	chr19:2792343	G/A	cg19676328	chr12:49525230	TUBA1B	-0.77	-7.88	-0.58	1.43e-12	Total cholesterol levels;
TGCT	cis	rs2066819	1.000	rs117683816	chr12:56638267	T/C	cg26714650	chr12:56694279	CS	-1.32	-6.2	-0.49	7.69e-9	Psoriasis vulgaris;
TGCT	cis	rs5769765	0.819	rs9616379	chr22:50312035	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.24	-12.97	-0.76	7.81e-25	Schizophrenia;
TGCT	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg18402987	chr7:1209562	NA	0.69	5.63	0.45	1.13e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs12048904	0.505	rs11166511	chr1:101240686	G/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.68	-5.36	-0.43	3.96e-7	Multiple sclerosis;
TGCT	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9517313	0.897	rs4772087	chr13:99115041	A/G	cg07423050	chr13:99094983	FARP1	0.31	6.94	0.53	1.95e-10	Neuroticism;
TGCT	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg11890956	chr21:40555474	PSMG1	1.11	12.48	0.75	1.21e-23	Cognitive function;
TGCT	cis	rs7044106	0.791	rs10984995	chr9:123479210	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.61	6.56	0.51	1.3e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg11764359	chr7:65958608	NA	-0.53	-4.68	-0.39	7.26e-6	Aortic root size;
TGCT	cis	rs67072384	0.892	rs72964172	chr11:72436436	G/A	cg03713592	chr11:72463424	ARAP1	-0.94	-4.67	-0.39	7.65e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs2204008	0.665	rs11179830	chr12:38220966	T/C	cg26384229	chr12:38710491	ALG10B	0.83	7.45	0.56	1.35e-11	Bladder cancer;
TGCT	cis	rs6433857	0.536	rs4625864	chr2:181353942	G/C	cg23363182	chr2:181467187	NA	-0.32	-4.83	-0.4	3.98e-6	Body mass index;
TGCT	cis	rs3743266	0.507	rs10162677	chr15:60748568	C/T	cg18480781	chr15:60294291	NA	0.63	5.01	0.41	1.81e-6	Menarche (age at onset);
TGCT	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg22663859	chr13:21900854	NA	0.34	4.93	0.4	2.59e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	cis	rs1997103	1.000	rs2009441	chr7:55405989	A/G	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs6964587	0.692	rs2374550	chr7:91820987	A/G	cg17063962	chr7:91808500	NA	0.77	7.17	0.54	6.08e-11	Breast cancer;
TGCT	cis	rs9527	0.615	rs4919682	chr10:104584330	C/T	cg04362960	chr10:104952993	NT5C2	0.57	4.65	0.39	8.47e-6	Arsenic metabolism;
TGCT	cis	rs4727027	0.933	rs6961605	chr7:148870108	G/A	cg23583168	chr7:148888333	NA	-0.74	-9.61	-0.65	1.1e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs9914544	0.545	rs8071783	chr17:18807939	C/G	cg26378065	chr17:18585709	ZNF286B	0.53	4.65	0.39	8.4e-6	Educational attainment (years of education);
TGCT	cis	rs10782582	0.609	rs2029682	chr1:76341619	T/C	cg03433033	chr1:76189801	ACADM	-0.5	-4.98	-0.41	2.11e-6	Daytime sleep phenotypes;
TGCT	cis	rs9467773	0.967	rs9358954	chr6:26531178	A/G	cg26531700	chr6:26746687	NA	0.47	4.57	0.38	1.14e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs2932538	0.922	rs4838961	chr1:113163967	T/C	cg22162597	chr1:113214053	CAPZA1	-0.27	-5.98	-0.47	2.24e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs6539288	0.513	rs7977247	chr12:107259470	T/C	cg15890332	chr12:107067104	RFX4	0.22	4.54	0.38	1.31e-5	Total body bone mineral density;
TGCT	cis	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg09021430	chr5:549028	NA	-0.37	-5.16	-0.42	9.7e-7	Lung disease severity in cystic fibrosis;
TGCT	cis	rs9303401	0.659	rs34351230	chr17:56782555	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.59	5.99	0.47	2.08e-8	Cognitive test performance;
TGCT	cis	rs57221529	0.600	rs11750269	chr5:666270	G/A	cg09021430	chr5:549028	NA	-0.4	-5.51	-0.44	2.02e-7	Lung disease severity in cystic fibrosis;
TGCT	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.47	0.56	1.28e-11	Prudent dietary pattern;
TGCT	cis	rs1205863	0.831	rs1205889	chr6:11948193	C/T	cg07106625	chr6:11870215	NA	0.51	5.05	0.41	1.51e-6	Disc degeneration (lumbar);
TGCT	cis	rs7772486	0.624	rs6930154	chr6:146025662	C/T	cg13319975	chr6:146136371	FBXO30	0.52	4.74	0.39	5.77e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6998277	0.830	rs6981007	chr8:103598257	G/C	cg10187029	chr8:103597600	NA	0.56	8.83	0.62	8.12e-15	Migraine;
TGCT	cis	rs9611565	0.512	rs5751153	chr22:42156561	T/C	cg06634786	chr22:41940651	POLR3H	0.86	8.01	0.58	7.16e-13	Vitiligo;
TGCT	cis	rs367943	0.965	rs644154	chr5:112799080	G/T	cg12552261	chr5:112820674	MCC	-0.24	-4.91	-0.4	2.81e-6	Type 2 diabetes;
TGCT	cis	rs9486715	1.000	rs6902835	chr6:97063005	C/G	cg18709589	chr6:96969512	KIAA0776	-0.75	-6.75	-0.52	5.11e-10	Headache;
TGCT	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg13397359	chr6:42928475	GNMT	0.73	6.81	0.52	3.7e-10	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs35306767	0.669	rs2101051	chr10:1158791	G/T	cg17861458	chr10:536227	DIP2C	0.23	4.44	0.37	1.99e-5	Eosinophil percentage of granulocytes;
TGCT	cis	rs6912958	0.781	rs9450723	chr6:88226641	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.51	4.91	0.4	2.81e-6	Monocyte percentage of white cells;
TGCT	cis	rs79349575	0.783	rs4255820	chr17:46996583	T/A	cg07967210	chr17:47022446	SNF8	0.44	6.12	0.48	1.13e-8	Type 2 diabetes;
TGCT	cis	rs11096990	0.634	rs11096988	chr4:39265701	G/A	cg20847110	chr4:39482781	LOC401127	0.16	4.53	0.38	1.38e-5	Cognitive function;
TGCT	cis	rs2281636	1.000	rs10786569	chr10:101513585	G/A	cg17885402	chr10:101492224	COX15;CUTC	0.58	4.51	0.38	1.45e-5	Obesity-related traits;
TGCT	cis	rs7666738	0.678	rs7670805	chr4:99008763	A/G	cg18180107	chr4:99064573	C4orf37	0.53	4.86	0.4	3.46e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2806561	0.514	rs7414010	chr1:23543929	T/C	cg19743168	chr1:23544995	NA	0.47	7.78	0.57	2.4e-12	Height;
TGCT	trans	rs7726839	0.540	rs11750321	chr5:599196	C/T	cg11887960	chr12:57824829	NA	1.2	9.56	0.65	1.47e-16	Obesity-related traits;
TGCT	cis	rs9393777	0.513	rs9379905	chr6:26630990	G/A	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.51	-4.68	-0.39	7.36e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs12497850	0.897	rs6781790	chr3:49044767	C/T	cg06212747	chr3:49208901	KLHDC8B	0.61	5.66	0.45	9.84e-8	Parkinson's disease;
TGCT	cis	rs7246657	0.714	rs12972195	chr19:37752505	T/C	cg24025825	chr19:37761650	NA	-0.25	-4.51	-0.38	1.51e-5	Coronary artery calcification;
TGCT	cis	rs2013441	1.000	rs2526467	chr17:20165054	T/A	cg18979559	chr17:20280153	CCDC144C	-0.45	-4.67	-0.39	7.61e-6	Obesity-related traits;
TGCT	cis	rs7666738	0.830	rs10014284	chr4:98681951	G/C	cg18180107	chr4:99064573	C4orf37	0.53	5.07	0.41	1.41e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg02487422	chr3:49467188	NICN1	0.54	5.2	0.42	8.11e-7	Menarche (age at onset);
TGCT	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg08859206	chr1:53392774	SCP2	0.41	5.98	0.47	2.19e-8	Monocyte count;
TGCT	cis	rs1971762	0.583	rs1864448	chr12:54087856	T/G	cg16917193	chr12:54089295	NA	1.35	17.63	0.85	1.39e-35	Height;
TGCT	cis	rs9902453	0.780	rs3115093	chr17:28039755	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.9	9.42	0.65	3.28e-16	Coffee consumption (cups per day);
TGCT	cis	rs896854	0.516	rs12679044	chr8:95891356	C/A	cg16049864	chr8:95962084	TP53INP1	-0.57	-6.85	-0.52	3.02e-10	Type 2 diabetes;
TGCT	cis	rs6906287	0.647	rs13192574	chr6:118875258	C/T	cg21191810	chr6:118973309	C6orf204	0.26	4.5	0.38	1.51e-5	Electrocardiographic conduction measures;
TGCT	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg23758822	chr17:41437982	NA	0.69	6.37	0.5	3.34e-9	Menopause (age at onset);
TGCT	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	8.16	0.59	3.25e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs3733585	0.699	rs4408959	chr4:9948868	C/T	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.43	-0.55	1.56e-11	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs826838	0.935	rs980571	chr12:39127532	C/G	cg13010199	chr12:38710504	ALG10B	-0.64	-5.19	-0.42	8.26e-7	Heart rate;
TGCT	cis	rs12478296	0.786	rs28802397	chr2:243049730	G/A	cg06360820	chr2:242988706	NA	-0.61	-4.66	-0.39	8.13e-6	Obesity-related traits;
TGCT	cis	rs4566357	1.000	rs6436649	chr2:227923952	A/G	cg11843606	chr2:227700838	RHBDD1	-0.58	-5.38	-0.44	3.51e-7	Coronary artery disease;
TGCT	cis	rs77972916	0.518	rs55877805	chr2:43557597	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.39	-4.54	-0.38	1.32e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs17826219	0.706	rs9905827	chr17:29192168	C/A	cg14008862	chr17:28927542	LRRC37B2	0.73	4.7	0.39	6.79e-6	Body mass index;
TGCT	trans	rs804280	0.517	rs7815179	chr8:11792048	C/G	cg15556689	chr8:8085844	FLJ10661	0.75	7.26	0.55	3.66e-11	Myopia (pathological);
TGCT	cis	rs12971120	1.000	rs12971120	chr18:72174023	A/G	cg26446133	chr18:72167187	CNDP2	-0.34	-6.09	-0.48	1.31e-8	Refractive error;
TGCT	cis	rs9581857	0.685	rs78595793	chr13:28031881	C/T	cg22138327	chr13:27999177	GTF3A	0.8	5.58	0.45	1.47e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs7226408	0.857	rs72885291	chr18:34449344	G/A	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	trans	rs8073060	0.586	rs7214742	chr17:33981969	C/A	cg19694781	chr19:47549865	TMEM160	-0.6	-13.37	-0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg27535305	chr1:53392650	SCP2	0.23	4.47	0.37	1.72e-5	Monocyte count;
TGCT	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg03352830	chr11:487213	PTDSS2	0.26	4.46	0.37	1.8e-5	Body mass index;
TGCT	cis	rs4372836	0.658	rs7579321	chr2:28983166	T/C	cg09522027	chr2:28974177	PPP1CB	-0.68	-6.93	-0.53	2e-10	Body mass index;
TGCT	cis	rs57221529	0.608	rs11749927	chr5:668842	C/T	cg16624210	chr5:671434	TPPP	0.39	4.69	0.39	6.99e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs72781680	0.898	rs56413706	chr2:24086961	G/A	cg08917208	chr2:24149416	ATAD2B	0.9	5.5	0.44	2.06e-7	Lymphocyte counts;
TGCT	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg07424592	chr7:64974309	NA	0.62	6.08	0.48	1.37e-8	Calcium levels;
TGCT	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg10876282	chr6:28092338	ZSCAN16	0.49	4.53	0.38	1.37e-5	Cardiac Troponin-T levels;
TGCT	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg19635926	chr16:89946313	TCF25	0.28	4.8	0.4	4.47e-6	Skin colour saturation;
TGCT	cis	rs931608	0.925	rs11085533	chr19:22612880	T/C	cg23859931	chr19:22123797	NA	0.59	4.57	0.38	1.16e-5	Dental caries;Response to statins (LDL cholesterol change);
TGCT	cis	rs77633900	0.614	rs1905694	chr15:76951772	T/C	cg21673338	chr15:77095150	SCAPER	-0.52	-4.94	-0.41	2.43e-6	Non-glioblastoma glioma;Glioma;
TGCT	cis	rs6840360	0.642	rs1596290	chr4:152410540	G/T	cg17479576	chr4:152424074	FAM160A1	-0.57	-6.02	-0.48	1.85e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs3796352	1.000	rs7625448	chr3:53120766	C/A	cg27565382	chr3:53032988	SFMBT1	0.41	4.6	0.38	1.01e-5	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg04267008	chr7:1944627	MAD1L1	-0.35	-4.53	-0.38	1.34e-5	Bipolar disorder and schizophrenia;
TGCT	cis	rs42648	0.720	rs9655741	chr7:89933874	C/G	cg25739043	chr7:89950458	NA	-0.62	-6.03	-0.48	1.73e-8	Homocysteine levels;
TGCT	cis	rs7267979	0.932	rs2260997	chr20:25256266	A/C	cg14121845	chr20:25566513	NINL	-0.51	-5.72	-0.46	7.58e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg26354017	chr1:205819088	PM20D1	0.56	6.81	0.52	3.75e-10	Menarche (age at onset);
TGCT	cis	rs813218	0.523	rs669676	chr3:99448852	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.42	5.13	0.42	1.07e-6	Orofacial clefts;
TGCT	cis	rs7412746	0.503	rs72704639	chr1:150798335	A/C	cg09365446	chr1:150670422	GOLPH3L	0.33	4.62	0.38	9.47e-6	Melanoma;
TGCT	cis	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg13531842	chr10:38383804	ZNF37A	-0.38	-4.51	-0.38	1.49e-5	Extrinsic epigenetic age acceleration;
TGCT	cis	rs1113500	0.541	rs9803640	chr1:108576267	A/C	cg06207961	chr1:108661230	NA	-0.24	-4.7	-0.39	6.83e-6	Growth-regulated protein alpha levels;
TGCT	cis	rs7949030	0.626	rs11231145	chr11:62328854	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.64	9.42	0.65	3.17e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9653442	1.000	rs1160542	chr2:100832155	A/G	cg07810366	chr2:100720526	AFF3	0.44	7.49	0.56	1.11e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs250677	1.000	rs250677	chr5:148433549	T/C	cg18129178	chr5:148520854	ABLIM3	-0.43	-6.21	-0.49	7.22e-9	Breast cancer;
TGCT	cis	rs9807989	0.507	rs1420105	chr2:103035119	A/G	cg03938978	chr2:103052716	IL18RAP	0.27	5.41	0.44	3.17e-7	Asthma;
TGCT	cis	rs11190604	1.000	rs11190613	chr10:102313997	C/T	cg23241863	chr10:102295624	HIF1AN	-0.7	-5.35	-0.43	4.03e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs208520	0.690	rs12202805	chr6:66703903	A/G	cg07460842	chr6:66804631	NA	-0.96	-10.26	-0.68	2.92e-18	Exhaled nitric oxide output;
TGCT	cis	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg15556689	chr8:8085844	FLJ10661	0.71	6.47	0.5	2.08e-9	Mood instability;
TGCT	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.07	-9.63	-0.65	1.01e-16	Platelet count;
TGCT	cis	rs17443541	0.507	rs4675697	chr2:200450808	C/T	cg00055341	chr2:200446845	NA	-0.33	-4.58	-0.38	1.12e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg08564027	chr20:61660810	NA	0.37	6.63	0.51	9.14e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7192750	0.586	rs4788576	chr16:71934105	C/T	cg06353428	chr16:71660113	MARVELD3	0.83	7.32	0.55	2.74e-11	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs4455778	0.580	rs4357241	chr7:49089468	A/G	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs854765	0.583	rs9635697	chr17:17870394	T/A	cg09796270	chr17:17721594	SREBF1	0.23	4.55	0.38	1.27e-5	Total body bone mineral density;
TGCT	cis	rs17001868	0.568	rs74424549	chr22:40736938	A/C	cg07138101	chr22:40742427	ADSL	0.73	5.38	0.44	3.57e-7	Mammographic density (dense area);
TGCT	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg22963979	chr7:1858916	MAD1L1	-0.35	-5.27	-0.43	5.75e-7	Bipolar disorder and schizophrenia;
TGCT	trans	rs10506458	1.000	rs73128779	chr12:63441852	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.47	-7.62	-0.56	5.8e-12	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs986417	0.901	rs10151423	chr14:60996667	A/G	cg27398547	chr14:60952738	C14orf39	1.47	10.91	0.7	7.87e-20	Gut microbiota (bacterial taxa);
TGCT	cis	rs13256369	0.851	rs11786125	chr8:8564570	T/G	cg17143192	chr8:8559678	CLDN23	0.57	5.35	0.43	4.09e-7	Obesity-related traits;
TGCT	cis	rs17001868	0.541	rs2092163	chr22:40810231	C/T	cg07138101	chr22:40742427	ADSL	0.78	5.29	0.43	5.4e-7	Mammographic density (dense area);
TGCT	cis	rs9314614	0.934	rs2980955	chr8:6694434	A/G	cg27319216	chr8:6693540	XKR5	-0.28	-4.72	-0.39	6.37e-6	IgA nephropathy;White blood cell count (basophil);
TGCT	cis	rs6121246	0.529	rs6060142	chr20:30178028	A/G	cg13852791	chr20:30311386	BCL2L1	0.69	4.64	0.38	8.6e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs2228479	0.618	rs62052174	chr16:89950901	G/A	cg06558623	chr16:89946397	TCF25	0.56	6.83	0.52	3.38e-10	Skin colour saturation;
TGCT	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg03303774	chr4:1407052	NA	0.3	4.89	0.4	3.09e-6	Obesity-related traits;
TGCT	cis	rs3020736	0.500	rs4147641	chr22:42482502	C/G	cg15557168	chr22:42548783	NA	0.22	5.58	0.45	1.47e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs3862435	0.572	rs2601186	chr15:90926921	A/G	cg14166756	chr15:90894880	ZNF774	-0.32	-5.12	-0.42	1.14e-6	Response to exercise (triglyceride level interaction);
TGCT	cis	rs9534288	0.956	rs962694	chr13:46619026	T/C	cg15192986	chr13:46630673	CPB2	-0.49	-6.18	-0.49	8.64e-9	Blood protein levels;
TGCT	cis	rs1018836	0.923	rs9643298	chr8:91552502	G/A	cg16814680	chr8:91681699	NA	-0.88	-9.81	-0.66	3.71e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs5769765	0.954	rs1569954	chr22:50244071	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	-0.37	-5.7	-0.46	8.42e-8	Schizophrenia;
TGCT	cis	rs10493773	0.775	rs11161649	chr1:86165446	A/C	cg17807903	chr1:86174739	ZNHIT6	-0.43	-6.18	-0.49	8.29e-9	Urate levels in overweight individuals;
TGCT	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg22535103	chr8:58192502	C8orf71	-0.38	-4.7	-0.39	6.91e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs35160687	0.901	rs12478575	chr2:86535314	C/G	cg04877910	chr2:85804641	VAMP8	0.34	4.51	0.38	1.49e-5	Night sleep phenotypes;
TGCT	cis	rs939658	0.728	rs12904323	chr15:79412583	A/C	cg17916960	chr15:79447300	NA	-0.46	-6.39	-0.5	3.11e-9	Refractive error;
TGCT	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg01448562	chr3:133502909	NA	-0.35	-7.2	-0.54	5.08e-11	Iron status biomarkers;
TGCT	cis	rs9549260	0.755	rs2721067	chr13:41156708	C/T	cg21288729	chr13:41239152	FOXO1	1.0	10.06	0.67	9.29e-18	Red blood cell count;
TGCT	trans	rs77457752	0.690	rs75036580	chr9:13912781	C/T	cg12973904	chr7:149457885	NA	0.46	7.39	0.55	1.88e-11	Breast cancer;
TGCT	cis	rs6495367	1.000	rs4778882	chr15:79382019	A/G	cg17916960	chr15:79447300	NA	0.38	5.46	0.44	2.52e-7	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs7923609	1.000	rs2393969	chr10:65140440	A/C	cg08743896	chr10:65200160	JMJD1C	-0.34	-4.58	-0.38	1.09e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4808199	0.947	rs754255	chr19:19578890	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.72	5.2	0.42	8.14e-7	Nonalcoholic fatty liver disease;
TGCT	cis	rs10114408	0.959	rs10120285	chr9:96652473	C/A	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs4654899	1.000	rs7554770	chr1:21481361	A/T	cg01072550	chr1:21505969	NA	-0.5	-8.08	-0.59	4.94e-13	Superior frontal gyrus grey matter volume;
TGCT	cis	rs4746818	1.000	rs1506769	chr10:70959710	T/C	cg11621586	chr10:70884670	VPS26A	1.2	10.28	0.68	2.63e-18	Left atrial antero-posterior diameter;
TGCT	cis	rs7818688	0.697	rs77055525	chr8:95980583	G/A	cg16049864	chr8:95962084	TP53INP1	0.54	4.64	0.38	8.87e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs12908161	1.000	rs35726233	chr15:85337800	C/T	cg12863693	chr15:85201151	NMB	0.42	5.06	0.41	1.5e-6	Schizophrenia;
TGCT	cis	rs72720396	0.789	rs12022460	chr1:91202257	A/G	cg13456504	chr1:91191583	NA	-0.61	-5.33	-0.43	4.51e-7	Morning vs. evening chronotype;Chronotype;
TGCT	cis	rs57590327	0.503	rs13073613	chr3:81888512	C/A	cg07356753	chr3:81810745	GBE1	-0.67	-6.19	-0.49	7.97e-9	Extraversion;
TGCT	cis	rs11711311	1.000	rs921741	chr3:113444051	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.71	-6.58	-0.51	1.19e-9	IgG glycosylation;
TGCT	cis	rs8062405	0.754	rs3859172	chr16:28566158	G/T	cg09754948	chr16:28834200	ATXN2L	0.63	4.97	0.41	2.16e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs12580194	0.593	rs73326725	chr12:55749222	G/C	cg10672482	chr12:55725839	OR6C3	-0.51	-4.43	-0.37	2.01e-5	Cancer;
TGCT	cis	rs72700829	0.593	rs7526955	chr1:150990913	C/G	cg00666978	chr1:150947442	LASS2	0.83	4.59	0.38	1.05e-5	Schizophrenia;
TGCT	cis	rs8077889	0.917	rs58283314	chr17:41905963	T/G	cg26893861	chr17:41843967	DUSP3	1.09	13.08	0.76	4.26e-25	Triglycerides;
TGCT	cis	rs7296418	0.961	rs11608811	chr12:123529056	A/G	cg00376283	chr12:123451042	ABCB9	0.83	7.72	0.57	3.27e-12	Platelet count;
TGCT	cis	rs1043515	0.607	rs4795318	chr17:36949053	C/T	cg09592244	chr17:37024020	NA	0.5	4.89	0.4	3.08e-6	Height;
TGCT	cis	rs10174077	0.687	rs10172023	chr2:152476028	C/G	cg06191203	chr2:152266755	RIF1	-0.62	-5.8	-0.46	5.06e-8	Squamous cell lung carcinoma;
TGCT	cis	rs2463822	1.000	rs1881534	chr11:62085083	A/G	cg23876832	chr11:62092739	NA	0.65	4.52	0.38	1.42e-5	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs77372450	0.551	rs57823519	chr5:157101500	G/A	cg12606933	chr5:157078573	SOX30	-0.42	-4.68	-0.39	7.47e-6	Bipolar disorder (body mass index interaction);
TGCT	trans	rs34421088	0.560	rs2245250	chr8:11400680	G/A	cg15556689	chr8:8085844	FLJ10661	-0.74	-7.05	-0.53	1.09e-10	Neuroticism;
TGCT	cis	rs7617773	0.817	rs6801801	chr3:48326433	T/C	cg11946769	chr3:48343235	NME6	0.72	6.16	0.48	9.39e-9	Coronary artery disease;
TGCT	cis	rs67311347	1.000	rs897117	chr3:40437294	C/T	cg13683864	chr3:40499215	RPL14	1.02	10.34	0.68	1.93e-18	Renal cell carcinoma;
TGCT	cis	rs10131894	0.575	rs2159904	chr14:75432179	G/T	cg06637938	chr14:75390232	RPS6KL1	0.59	5.07	0.41	1.42e-6	Coronary artery disease;
TGCT	cis	rs4727027	0.870	rs1105261	chr7:148794442	T/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	4.52	0.38	1.43e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs2439831	1.000	rs689826	chr15:43749916	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.8	5.56	0.45	1.56e-7	Lung cancer in ever smokers;
TGCT	cis	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg03213289	chr20:61660250	NA	0.68	9.9	0.66	2.25e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7937682	1.000	rs11213980	chr11:111562692	A/T	cg09085632	chr11:111637200	PPP2R1B	0.92	7.9	0.58	1.31e-12	Primary sclerosing cholangitis;
TGCT	cis	rs9916302	0.808	rs12943928	chr17:37611330	G/A	cg07936489	chr17:37558343	FBXL20	-0.62	-4.91	-0.4	2.85e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7953249	0.594	rs11065384	chr12:121423285	T/C	cg02403541	chr12:121454288	C12orf43	-0.7	-6.33	-0.49	4.11e-9	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs7100689	0.784	rs3802638	chr10:82179689	T/C	cg01528321	chr10:82214614	TSPAN14	0.9	9.37	0.64	4.33e-16	Post bronchodilator FEV1;
TGCT	cis	rs854765	0.552	rs6502624	chr17:17847936	G/A	cg09796270	chr17:17721594	SREBF1	0.24	4.79	0.4	4.7e-6	Total body bone mineral density;
TGCT	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.48	-0.37	1.66e-5	Bipolar disorder;
TGCT	cis	rs9517320	0.534	rs4772090	chr13:99150674	T/C	cg20487152	chr13:99095054	FARP1	-0.24	-4.62	-0.38	9.58e-6	Longevity;
TGCT	cis	rs9467773	1.000	rs6924838	chr6:26571756	C/T	cg15659132	chr6:26577336	NA	0.88	12.27	0.74	3.83e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.98	10.79	0.7	1.55e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg05573699	chr3:52720067	GNL3;PBRM1	0.49	4.64	0.38	8.8e-6	Bipolar disorder;
TGCT	cis	rs7917772	0.503	rs1536308	chr10:104288777	T/G	cg05855489	chr10:104503620	C10orf26	-0.58	-5.06	-0.41	1.47e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs72781680	0.898	rs7569424	chr2:24036222	A/G	cg08917208	chr2:24149416	ATAD2B	0.8	4.93	0.4	2.62e-6	Lymphocyte counts;
TGCT	cis	rs17345786	0.628	rs11718446	chr3:101552553	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.8	8.9	0.62	5.72e-15	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1023500	1.000	rs3752591	chr22:42339516	A/G	cg04692870	chr22:42525206	CYP2D6	-0.34	-5.06	-0.41	1.47e-6	Schizophrenia;
TGCT	cis	rs9611565	0.607	rs132792	chr22:42062822	C/T	cg17554472	chr22:41940697	POLR3H	0.48	5.14	0.42	1.04e-6	Vitiligo;
TGCT	cis	rs7772486	0.686	rs10872579	chr6:145966012	C/G	cg13319975	chr6:146136371	FBXO30	-0.52	-4.68	-0.39	7.39e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3749237	1.000	rs11920900	chr3:49823024	G/C	cg07636037	chr3:49044803	WDR6	0.61	5.32	0.43	4.68e-7	Resting heart rate;
TGCT	trans	rs731174	0.592	rs1010805	chr1:38189142	A/C	cg19725343	chr19:51830960	IGLON5	-0.63	-7.18	-0.54	5.57e-11	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs10769945	0.592	rs1635155	chr11:1972919	G/T	cg06503573	chr11:1949039	TNNT3	-0.26	-4.59	-0.38	1.08e-5	DNA methylation (variation);
TGCT	cis	rs10744422	0.920	rs897393	chr12:123312051	A/G	cg25930673	chr12:123319894	HIP1R	0.84	5.22	0.42	7.45e-7	Schizophrenia;
TGCT	cis	rs7647973	0.925	rs4384984	chr3:49289878	T/G	cg07636037	chr3:49044803	WDR6	0.67	5.41	0.44	3.15e-7	Menarche (age at onset);
TGCT	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg24829409	chr8:58192753	C8orf71	-0.58	-5.51	-0.44	2.03e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs3749237	0.595	rs6784820	chr3:49450864	C/T	cg02487422	chr3:49467188	NICN1	-0.6	-6.31	-0.49	4.42e-9	Resting heart rate;
TGCT	cis	rs1008375	0.931	rs3775926	chr4:17599837	G/A	cg16339924	chr4:17578868	LAP3	0.83	7.1	0.54	8.37e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs3772130	0.564	rs4420917	chr3:121567863	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.59	5.43	0.44	2.8e-7	Cognitive performance;
TGCT	cis	rs2180341	0.960	rs9401952	chr6:127677027	A/C	cg27446573	chr6:127587934	RNF146	1.14	10.91	0.7	7.51e-20	Breast cancer;
TGCT	cis	rs909674	0.909	rs1557541	chr22:39851970	C/A	cg01416388	chr22:39784598	NA	-0.67	-6.0	-0.47	1.99e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	8.16	0.59	3.1400000000000003e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs4891159	0.548	rs690423	chr18:74117984	G/A	cg24786174	chr18:74118243	ZNF516	0.71	15.7	0.82	2.91e-31	Longevity;
TGCT	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg20607798	chr8:58055168	NA	0.5	4.66	0.39	8.04e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs8014204	0.762	rs973879	chr14:75297727	T/C	cg06637938	chr14:75390232	RPS6KL1	0.57	5.07	0.41	1.4e-6	Caffeine consumption;
TGCT	cis	rs116095464	0.558	rs28636067	chr5:199415	G/A	cg12570787	chr5:219185	SDHA;CCDC127	0.74	4.65	0.39	8.43e-6	Breast cancer;
TGCT	cis	rs16866061	0.515	rs114968850	chr2:225352461	C/G	cg12698349	chr2:225449008	CUL3	1.12	15.51	0.81	8.08e-31	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	cis	rs36051895	0.632	rs11788164	chr9:5129395	A/G	cg02405213	chr9:5042618	JAK2	-0.77	-10.84	-0.7	1.15e-19	Pediatric autoimmune diseases;
TGCT	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.72	5.19	0.42	8.33e-7	Platelet count;
TGCT	cis	rs208515	0.518	rs12209790	chr6:66662965	T/C	cg07460842	chr6:66804631	NA	0.83	8.65	0.61	2.18e-14	Exhaled nitric oxide levels;
TGCT	cis	rs8044995	0.563	rs73615919	chr16:68398862	C/T	cg05110241	chr16:68378359	PRMT7	-0.36	-4.48	-0.37	1.66e-5	Schizophrenia;
TGCT	cis	rs8017423	0.608	rs12588149	chr14:90822676	G/A	cg04374321	chr14:90722782	PSMC1	-0.54	-5.44	-0.44	2.71e-7	Mortality in heart failure;
TGCT	cis	rs17331151	0.573	rs79664140	chr3:52866936	A/G	cg15956490	chr3:53032818	SFMBT1	0.46	5.75	0.46	6.57e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs1857353	0.901	rs79110498	chr1:75899763	C/T	cg11838876	chr1:75668600	SLC44A5	-0.51	-4.81	-0.4	4.23e-6	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs477895	0.838	rs11605738	chr11:64013406	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.83	6.93	0.53	2.04e-10	Mean platelet volume;
TGCT	cis	rs2354432	0.607	rs55918563	chr1:146718973	G/C	cg25205988	chr1:146714368	CHD1L	-1.34	-6.07	-0.48	1.44e-8	Mitochondrial DNA levels;
TGCT	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg04944784	chr2:26401820	FAM59B	0.76	6.24	0.49	6.46e-9	Gut microbiome composition (summer);
TGCT	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg27454412	chr7:1067447	C7orf50	0.57	4.46	0.37	1.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs10186029	0.657	rs11689895	chr2:213938553	G/T	cg08319019	chr2:214017104	IKZF2	0.54	5.18	0.42	8.57e-7	Systemic sclerosis;
TGCT	cis	rs9660992	0.710	rs1668869	chr1:205239779	G/C	cg00857998	chr1:205179979	DSTYK	0.52	4.56	0.38	1.19e-5	Mean corpuscular volume;Mean platelet volume;
TGCT	cis	rs3733585	0.725	rs10939636	chr4:9972640	T/G	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.68	-0.57	4.13e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs13188771	0.690	rs352060	chr5:100877204	A/G	cg18665594	chr5:101119420	NA	0.44	4.46	0.37	1.83e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg22963979	chr7:1858916	MAD1L1	-0.39	-5.87	-0.47	3.76e-8	Bipolar disorder and schizophrenia;
TGCT	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg24531977	chr5:56204891	C5orf35	-0.93	-8.51	-0.61	4.85e-14	Initial pursuit acceleration;
TGCT	cis	rs951366	0.677	rs1775140	chr1:205672107	C/A	cg24503407	chr1:205819492	PM20D1	0.59	7.87	0.58	1.48e-12	Menarche (age at onset);
TGCT	cis	rs2299587	0.554	rs2073564	chr8:17743341	G/A	cg04898035	chr8:17640624	MTUS1	-0.2	-4.67	-0.39	7.77e-6	Economic and political preferences;
TGCT	cis	rs875971	0.862	rs1167399	chr7:65561877	G/A	cg11764359	chr7:65958608	NA	-0.56	-4.82	-0.4	4.1e-6	Aortic root size;
TGCT	cis	rs10057188	1.000	rs10074749	chr5:77856454	G/A	cg06873401	chr5:77792105	LHFPL2	-0.23	-4.67	-0.39	7.69e-6	Pulse pressure;
TGCT	cis	rs910316	1.000	rs11845639	chr14:75570293	C/T	cg08847533	chr14:75593920	NEK9	0.95	10.61	0.69	4.09e-19	Height;
TGCT	cis	rs10782582	0.609	rs11161848	chr1:76367722	A/G	cg10523679	chr1:76189770	ACADM	-0.58	-5.26	-0.43	5.99e-7	Daytime sleep phenotypes;
TGCT	cis	rs9394438	0.628	rs10947680	chr6:37543668	T/C	cg00985040	chr6:37553208	NA	-0.25	-4.96	-0.41	2.23e-6	IgG glycosylation;
TGCT	cis	rs6582630	0.638	rs12831496	chr12:38552604	G/A	cg26384229	chr12:38710491	ALG10B	-0.53	-4.77	-0.39	5.12e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs1403694	0.515	rs1648700	chr3:186449916	C/T	cg12454167	chr3:186435060	KNG1	-0.46	-7.23	-0.54	4.46e-11	Blood protein levels;
TGCT	cis	rs9467773	0.596	rs2451750	chr6:26646579	A/T	cg15659132	chr6:26577336	NA	0.87	10.72	0.69	2.19e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs1403694	1.000	rs1403694	chr3:186439998	T/C	cg12454167	chr3:186435060	KNG1	0.42	7.32	0.55	2.77e-11	Blood protein levels;
TGCT	cis	rs8078723	0.802	rs9303283	chr17:38192633	A/G	cg17467752	chr17:38218738	THRA	0.71	7.44	0.56	1.42e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs4803455	0.565	rs1800470	chr19:41858921	G/A	cg09537434	chr19:41945824	ATP5SL	-0.52	-5.04	-0.41	1.63e-6	Migraine;Coronary artery disease;
TGCT	cis	rs9486719	1.000	rs2092096	chr6:96870919	A/G	cg18709589	chr6:96969512	KIAA0776	0.68	5.05	0.41	1.55e-6	Migraine;Coronary artery disease;
TGCT	cis	rs9733	0.596	rs7418501	chr1:150711896	A/T	cg04414720	chr1:150670196	GOLPH3L	0.35	4.66	0.39	8.05e-6	Tonsillectomy;
TGCT	cis	rs208520	1.000	rs9453671	chr6:66991208	A/G	cg07460842	chr6:66804631	NA	0.74	6.46	0.5	2.11e-9	Exhaled nitric oxide output;
TGCT	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg14827481	chr10:134361889	INPP5A	0.3	4.87	0.4	3.27e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs524281	0.861	rs10896087	chr11:65924549	A/G	cg00563793	chr11:65837595	PACS1	0.58	4.92	0.4	2.66e-6	Electroencephalogram traits;
TGCT	cis	rs651907	0.640	rs771575	chr3:101619359	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	5.64	0.45	1.09e-7	Colorectal cancer;
TGCT	cis	rs7312933	0.531	rs2708059	chr12:42851008	C/T	cg19980929	chr12:42632907	YAF2	-0.42	-5.96	-0.47	2.44e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	-0.62	-5.88	-0.47	3.62e-8	Bipolar disorder;
TGCT	cis	rs7980687	0.506	rs1611973	chr12:123622731	C/G	cg05973401	chr12:123451056	ABCB9	0.54	4.47	0.37	1.71e-5	Height;Educational attainment;Head circumference (infant);
TGCT	cis	rs2249625	0.523	rs2496552	chr6:72853042	T/C	cg24401219	chr6:72892597	RIMS1	-0.58	-4.96	-0.41	2.27e-6	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
TGCT	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg20891558	chr2:74357851	NA	0.62	9.13	0.63	1.62e-15	Gestational age at birth (maternal effect);
TGCT	cis	rs9394841	0.692	rs9381097	chr6:41847800	A/G	cg08135965	chr6:41755394	TOMM6	-0.51	-4.57	-0.38	1.14e-5	Mean corpuscular hemoglobin;Red cell distribution width;
TGCT	cis	rs2288884	0.806	rs12460587	chr19:52586919	T/G	cg13540795	chr19:52551618	ZNF432	-0.62	-5.33	-0.43	4.48e-7	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs7267979	1.000	rs2258563	chr20:25273435	C/T	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs8038465	0.550	rs11072431	chr15:73987642	T/A	cg15420318	chr15:73925796	NPTN	0.6	6.03	0.48	1.74e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs950169	0.656	rs748455	chr15:85149575	T/C	cg17173187	chr15:85201210	NMB	0.53	5.88	0.47	3.53e-8	Schizophrenia;
TGCT	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg22920501	chr2:26401640	FAM59B	-0.74	-6.4	-0.5	2.86e-9	Gut microbiome composition (summer);
TGCT	cis	rs7590720	1.000	rs6755934	chr2:216907198	C/A	cg12620499	chr2:216877984	MREG	0.86	8.59	0.61	3.03e-14	Alcohol dependence;
TGCT	cis	rs829880	0.858	rs733180	chr12:98842588	C/T	cg25150519	chr12:98850993	NA	0.63	6.32	0.49	4.29e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4654899	0.758	rs2320826	chr1:21392096	A/C	cg01072550	chr1:21505969	NA	-0.57	-9.35	-0.64	4.68e-16	Superior frontal gyrus grey matter volume;
TGCT	cis	rs1005277	0.505	rs7099777	chr10:38183569	A/C	cg25427524	chr10:38739819	LOC399744	0.37	7.61	0.56	5.93e-12	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7819412	0.595	rs10503416	chr8:10987553	C/T	cg21775007	chr8:11205619	TDH	0.56	5.21	0.42	7.76e-7	Triglycerides;
TGCT	cis	rs1451375	0.657	rs12672526	chr7:50657695	C/T	cg18232548	chr7:50535776	DDC	0.44	6.6	0.51	1.05e-9	Malaria;
TGCT	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg04317338	chr11:64019027	PLCB3	0.78	6.43	0.5	2.53e-9	Mean platelet volume;
TGCT	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg23758822	chr17:41437982	NA	0.72	6.81	0.52	3.73e-10	Menopause (age at onset);
TGCT	cis	rs28374715	0.629	rs2118740	chr15:41577232	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.91	-13.14	-0.76	2.98e-25	Ulcerative colitis;
TGCT	trans	rs7726839	0.540	rs7434	chr5:660804	A/G	cg11887960	chr12:57824829	NA	-1.13	-9.82	-0.66	3.45e-17	Obesity-related traits;
TGCT	cis	rs6088580	0.634	rs2225837	chr20:33005634	C/T	cg24642439	chr20:33292090	TP53INP2	-0.49	-4.49	-0.37	1.59e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg10047753	chr17:41438598	NA	-0.77	-7.34	-0.55	2.46e-11	Menopause (age at onset);
TGCT	cis	rs9660180	0.836	rs12038134	chr1:1703865	T/A	cg23982607	chr1:1823379	GNB1	-0.55	-8.56	-0.61	3.69e-14	Body mass index;
TGCT	cis	rs10031466	1.000	rs10031466	chr4:189015402	G/A	cg14506195	chr4:188913931	NA	-0.25	-4.77	-0.39	5.06e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs9399135	0.967	rs11756988	chr6:135347595	A/G	cg24558204	chr6:135376177	HBS1L	0.5	5.0	0.41	1.89e-6	Red blood cell count;
TGCT	cis	rs71435601	0.657	rs12712940	chr2:21426743	C/A	cg25035485	chr2:21266500	APOB	-0.55	-4.68	-0.39	7.46e-6	Cholesterol, total;
TGCT	cis	rs12681287	0.752	rs2917557	chr8:87314071	C/T	cg27223183	chr8:87520930	FAM82B	-0.83	-6.04	-0.48	1.67e-8	Caudate activity during reward;
TGCT	cis	rs651907	0.535	rs9830943	chr3:101428899	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	4.71	0.39	6.54e-6	Colorectal cancer;
TGCT	cis	rs62244186	0.659	rs9855433	chr3:44468065	C/A	cg10263370	chr3:44754102	ZNF502	-0.39	-4.64	-0.38	8.7e-6	Depressive symptoms;
TGCT	trans	rs6089829	0.962	rs1116450	chr20:61658210	T/C	cg17470723	chr8:74884337	TCEB1	0.72	6.94	0.53	1.91e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1215050	0.904	rs890469	chr4:98923293	T/C	cg05340658	chr4:99064831	C4orf37	-0.46	-5.6	-0.45	1.32e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	trans	rs6089829	0.962	rs3746747	chr20:61667631	T/C	cg23505145	chr19:12996616	KLF1	0.81	8.7	0.62	1.74e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs17401966	0.931	rs912961	chr1:10356848	A/G	cg19773385	chr1:10388646	KIF1B	-0.21	-4.66	-0.39	8.14e-6	Hepatocellular carcinoma;
TGCT	cis	rs3845702	0.668	rs12693215	chr2:180826007	A/C	cg01881094	chr2:180872142	CWC22	-1.05	-6.78	-0.52	4.27e-10	Schizophrenia;
TGCT	cis	rs798766	0.830	rs8389	chr4:1746844	A/T	cg05874882	chr4:1763078	NA	-0.33	-4.56	-0.38	1.2e-5	Bladder cancer;Urinary bladder cancer;
TGCT	cis	rs6714710	0.603	rs12995673	chr2:98409046	G/A	cg26665480	chr2:98280029	ACTR1B	0.69	6.34	0.49	3.96e-9	Posterior cortical atrophy and Alzheimer's disease;
TGCT	trans	rs4576506	0.536	rs13295330	chr9:31503145	T/C	cg11445191	chr5:140227765	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA5;PCDHA9;PCDHA3;PCDHA4;PCDHA8	0.98	6.69	0.51	6.76e-10	Psychosis and Alzheimer's disease;
TGCT	cis	rs7917772	0.636	rs2253709	chr10:104542745	T/A	cg05855489	chr10:104503620	C10orf26	-0.65	-5.1	-0.42	1.26e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs922182	0.763	rs1380841	chr15:64261912	T/C	cg02919090	chr15:64263738	DAPK2	0.34	6.37	0.5	3.33e-9	Blood protein levels;
TGCT	cis	rs1865760	0.566	rs10807006	chr6:26048752	C/A	cg16482183	chr6:26056742	HIST1H1C	0.58	4.98	0.41	2.12e-6	Height;
TGCT	cis	rs2235642	0.691	rs2281235	chr16:1603535	T/C	cg10465839	chr16:1584050	IFT140;TMEM204	-0.31	-5.23	-0.43	7.02e-7	Coronary artery disease;
TGCT	cis	rs8180040	0.903	rs12487736	chr3:47459679	C/T	cg27129171	chr3:47204927	SETD2	0.65	7.61	0.56	6.03e-12	Colorectal cancer;
TGCT	cis	rs904251	0.523	rs914348	chr6:37484729	G/A	cg25019722	chr6:37503610	NA	-0.51	-7.92	-0.58	1.16e-12	Cognitive performance;
TGCT	cis	rs9300255	0.544	rs2049114	chr12:123657338	T/C	cg00376283	chr12:123451042	ABCB9	0.73	5.64	0.45	1.1e-7	Neutrophil percentage of white cells;
TGCT	cis	rs12142240	0.698	rs72885198	chr1:46812888	C/T	cg14993813	chr1:46806288	NSUN4	-0.58	-4.77	-0.39	5.1e-6	Menopause (age at onset);
TGCT	cis	rs12477438	0.520	rs11692699	chr2:99730657	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	17.43	0.84	3.73e-35	Chronic sinus infection;
TGCT	cis	rs903263	0.965	rs12723299	chr1:84590315	A/G	cg09664975	chr1:84543551	PRKACB	-0.49	-4.6	-0.38	1.01e-5	Breast cancer (male);
TGCT	cis	rs9905704	0.647	rs33922512	chr17:57114148	C/G	cg05425664	chr17:57184151	TRIM37	0.68	5.61	0.45	1.25e-7	Testicular germ cell tumor;
TGCT	cis	rs17376456	0.569	rs2045021	chr5:93224222	G/A	cg25358565	chr5:93447407	FAM172A	-0.81	-6.5	-0.5	1.79e-9	Diabetic retinopathy;
TGCT	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg13866156	chr1:1669148	SLC35E2	-0.22	-5.21	-0.42	7.6e-7	Body mass index;
TGCT	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg18402987	chr7:1209562	NA	0.7	5.67	0.45	9.66e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg02380750	chr20:61661411	NA	0.35	6.1	0.48	1.25e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg25767906	chr1:53392781	SCP2	-0.55	-6.64	-0.51	8.87e-10	Monocyte count;
TGCT	trans	rs1814175	0.746	rs10839429	chr11:49906845	G/A	cg15704280	chr7:45808275	SEPT13	-0.71	-8.0	-0.58	7.45e-13	Height;
TGCT	cis	rs1865760	0.593	rs9295678	chr6:25937033	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.63	6.67	0.51	7.58e-10	Height;
TGCT	cis	rs2832191	0.740	rs2832177	chr21:30478353	G/A	cg08807101	chr21:30365312	RNF160	-0.67	-6.13	-0.48	1.08e-8	Dental caries;
TGCT	cis	rs9303401	0.625	rs66508449	chr17:56691034	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs1577917	1.000	rs2166663	chr6:86593896	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-5.15	-0.42	9.91e-7	Response to antipsychotic treatment;
TGCT	cis	rs9914544	0.564	rs11868500	chr17:18770254	A/G	cg26378065	chr17:18585709	ZNF286B	0.52	4.5	0.37	1.56e-5	Educational attainment (years of education);
TGCT	cis	rs9303401	0.659	rs62081315	chr17:56781468	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.67	6.3	0.49	4.7e-9	Cognitive test performance;
TGCT	cis	rs6545883	0.895	rs4430924	chr2:61703856	A/G	cg15711740	chr2:61764176	XPO1	-0.58	-5.23	-0.43	6.96e-7	Tuberculosis;
TGCT	cis	rs17376456	0.877	rs10476596	chr5:93367074	C/T	cg25358565	chr5:93447407	FAM172A	-0.93	-8.37	-0.6	1.04e-13	Diabetic retinopathy;
TGCT	cis	rs9858213	1	rs9858213	chr3:49731861	G/T	cg03060546	chr3:49711283	APEH	-0.67	-6.09	-0.48	1.28e-8	Educational attainment;
TGCT	cis	rs6969780	0.545	rs983184	chr7:27188379	C/T	cg22997113	chr7:27170241	HOXA4	-0.44	-4.6	-0.38	1.05e-5	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs6901250	0.523	rs592669	chr6:117090944	T/C	cg12892004	chr6:117198278	RFX6	0.37	4.77	0.39	5.09e-6	C-reactive protein levels;
TGCT	cis	rs1865760	0.602	rs2157050	chr6:26020431	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.8	7.57	0.56	7.45e-12	Height;
TGCT	cis	rs1949733	0.701	rs4696828	chr4:8455604	G/A	cg13073564	chr4:8508604	NA	0.42	4.61	0.38	9.77e-6	Response to antineoplastic agents;
TGCT	cis	rs1129187	0.755	rs2296804	chr6:42931261	C/G	cg09436375	chr6:42928200	GNMT	-0.41	-5.19	-0.42	8.34e-7	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs9372498	0.505	rs4416700	chr6:118975461	G/C	cg21191810	chr6:118973309	C6orf204	-0.37	-4.71	-0.39	6.4e-6	Diastolic blood pressure;
TGCT	cis	rs7312933	0.558	rs7965743	chr12:42736822	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.59	-5.72	-0.46	7.52e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs4319547	0.910	rs6416298	chr12:123002143	C/T	cg23029597	chr12:123009494	RSRC2	-0.32	-4.94	-0.41	2.45e-6	Body mass index;
TGCT	cis	rs11239930	0.538	rs630630	chr1:146551926	T/C	cg00044796	chr1:146552390	NA	-0.34	-4.46	-0.37	1.84e-5	AIDS progression;
TGCT	cis	rs4234284	0.556	rs13072737	chr3:126948835	C/T	cg25436886	chr3:127056972	NA	-0.47	-4.5	-0.37	1.54e-5	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
TGCT	cis	rs554111	0.660	rs12042978	chr1:21170811	T/C	cg01072550	chr1:21505969	NA	0.33	4.94	0.41	2.43e-6	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs12477438	1.000	rs17760953	chr2:99859863	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-6.39	-0.5	2.97e-9	Chronic sinus infection;
TGCT	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg26818010	chr10:134567672	INPP5A	-0.36	-5.16	-0.42	9.32e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs6665290	0.935	rs1929862	chr1:227199718	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.0	-20.65	-0.88	6.07e-42	Myeloid white cell count;
TGCT	cis	rs916888	0.610	rs199453	chr17:44800946	C/T	cg01570182	chr17:44337453	NA	0.76	7.36	0.55	2.22e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs6546537	0.955	rs1396798	chr2:69887837	G/T	cg10773587	chr2:69614142	GFPT1	-0.75	-6.49	-0.5	1.9e-9	Serum thyroid-stimulating hormone levels;
TGCT	cis	rs208520	1.000	rs12194996	chr6:66973366	G/C	cg07460842	chr6:66804631	NA	0.77	6.82	0.52	3.49e-10	Exhaled nitric oxide output;
TGCT	cis	rs9611565	0.512	rs5996063	chr22:42168767	G/A	cg06481639	chr22:41940642	POLR3H	0.69	6.05	0.48	1.59e-8	Vitiligo;
TGCT	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg07157834	chr1:205819609	PM20D1	0.49	8.61	0.61	2.77e-14	Menarche (age at onset);
TGCT	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg03188948	chr7:1209495	NA	0.71	6.04	0.48	1.68e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs6748734	0.857	rs4675857	chr2:241842326	T/C	cg04034577	chr2:241836375	C2orf54	-0.4	-6.35	-0.5	3.72e-9	Urinary metabolites;
TGCT	cis	rs2115630	0.967	rs8027779	chr15:85255385	T/C	cg12863693	chr15:85201151	NMB	-0.33	-4.51	-0.38	1.48e-5	P wave terminal force;
TGCT	cis	rs6430585	0.527	rs6753232	chr2:136436317	C/T	cg07169764	chr2:136633963	MCM6	-0.99	-8.92	-0.63	4.97e-15	Corneal structure;
TGCT	cis	rs6088580	0.542	rs6059882	chr20:33090167	T/C	cg06115741	chr20:33292138	TP53INP2	0.54	4.63	0.38	9.06e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7044106	0.762	rs4837789	chr9:123426256	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	6.68	0.51	7.09e-10	Hip circumference adjusted for BMI;
TGCT	trans	rs57221529	0.766	rs12522140	chr5:587261	C/A	cg25482853	chr8:67687455	SGK3	1.2	10.12	0.67	6.42e-18	Lung disease severity in cystic fibrosis;
TGCT	cis	rs1215050	0.791	rs6838628	chr4:98809574	A/G	cg05340658	chr4:99064831	C4orf37	0.44	5.61	0.45	1.24e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs11690935	0.959	rs6709156	chr2:172591944	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.18	-12.51	-0.75	9.78e-24	Schizophrenia;
TGCT	cis	rs3008870	0.755	rs2815368	chr1:67500778	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.8	8.48	0.61	5.61e-14	Lymphocyte percentage of white cells;
TGCT	cis	rs9858542	0.537	rs34514189	chr3:49373045	A/G	cg08550065	chr3:50336684	HYAL3;NAT6	0.66	4.57	0.38	1.18e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs11711311	1.000	rs7645473	chr3:113516187	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.7	-6.64	-0.51	8.96e-10	IgG glycosylation;
TGCT	cis	rs4455778	0.580	rs4276634	chr7:49118612	A/G	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs9473924	0.505	rs9463663	chr6:50902266	G/A	cg14470998	chr6:50812995	TFAP2B	1.35	8.39	0.6	9.05e-14	Body mass index;
TGCT	cis	rs9325144	0.534	rs1843887	chr12:38692380	T/C	cg26384229	chr12:38710491	ALG10B	0.66	6.12	0.48	1.11e-8	Morning vs. evening chronotype;
TGCT	cis	rs10782582	0.609	rs1251584	chr1:76424440	C/T	cg05598546	chr1:76251766	SNORD45C;RABGGTB	-0.59	-5.28	-0.43	5.51e-7	Daytime sleep phenotypes;
TGCT	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg03396347	chr1:1875803	NA	-0.36	-6.51	-0.5	1.66e-9	Body mass index;
TGCT	cis	rs3733585	0.673	rs4580649	chr4:9948461	G/A	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.23	-0.54	4.33e-11	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs9837602	0.529	rs1688774	chr3:99521108	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.58	6.71	0.52	6.1e-10	Breast cancer;
TGCT	cis	rs637571	0.546	rs10791827	chr11:65596546	C/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.6	-5.89	-0.47	3.32e-8	Eosinophil percentage of white cells;
TGCT	cis	rs3776081	0.600	rs4432875	chr5:149539527	G/A	cg18424208	chr5:149546337	CDX1	-0.25	-4.48	-0.37	1.66e-5	Blood protein levels;
TGCT	cis	rs17376456	0.597	rs7728825	chr5:93384594	T/C	cg21475434	chr5:93447410	FAM172A	-0.6	-5.65	-0.45	1.05e-7	Diabetic retinopathy;
TGCT	cis	rs10504229	0.679	rs12679920	chr8:58051710	G/T	cg11062466	chr8:58055876	NA	0.34	4.64	0.38	8.58e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2688608	0.967	rs9971040	chr10:75661162	G/C	cg02947784	chr10:75434997	AGAP5	0.16	4.51	0.38	1.46e-5	Inflammatory bowel disease;
TGCT	cis	rs950776	0.518	rs8025429	chr15:78836362	G/A	cg06917634	chr15:78832804	PSMA4	-0.93	-9.08	-0.63	2.07e-15	Sudden cardiac arrest;
TGCT	cis	rs12497850	0.864	rs7431857	chr3:48900347	G/A	cg07636037	chr3:49044803	WDR6	0.95	10.74	0.69	2e-19	Parkinson's disease;
TGCT	cis	rs9650657	0.547	rs11250099	chr8:10818657	C/T	cg21775007	chr8:11205619	TDH	0.5	4.82	0.4	4.13e-6	Neuroticism;
TGCT	cis	rs3733346	0.553	rs10008187	chr4:941017	C/T	cg22718636	chr4:961658	DGKQ	0.46	4.47	0.37	1.77e-5	Sjögren's syndrome;
TGCT	cis	rs9467773	1.000	rs28558133	chr6:26531433	G/C	cg09904177	chr6:26538194	HMGN4	0.65	6.53	0.51	1.53e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs6879260	1.000	rs10903252	chr5:179733934	T/C	cg23221052	chr5:179740743	GFPT2	-0.36	-5.75	-0.46	6.7e-8	Height;
TGCT	cis	rs1448094	0.511	rs11117042	chr12:86207547	G/T	cg02569458	chr12:86230093	RASSF9	0.39	4.75	0.39	5.44e-6	Major depressive disorder;
TGCT	cis	rs17376456	0.569	rs7729807	chr5:93104089	C/T	cg21475434	chr5:93447410	FAM172A	0.61	4.97	0.41	2.17e-6	Diabetic retinopathy;
TGCT	cis	rs992157	1.000	rs6736362	chr2:219115108	C/T	cg00012203	chr2:219082015	ARPC2	0.76	8.17	0.59	3.03e-13	Colorectal cancer;
TGCT	cis	rs72634258	0.554	rs4908705	chr1:7926401	C/T	cg26816564	chr1:7831052	VAMP3	0.64	5.21	0.42	7.71e-7	Inflammatory bowel disease;
TGCT	cis	rs6690583	0.573	rs75119114	chr1:85451385	A/C	cg20280350	chr1:85513789	MCOLN3	-0.74	-5.11	-0.42	1.2e-6	Serum sulfate level;
TGCT	cis	rs9486715	0.830	rs2475023	chr6:96996833	G/A	cg18709589	chr6:96969512	KIAA0776	-0.85	-8.33	-0.6	1.29e-13	Headache;
TGCT	cis	rs72781680	0.898	rs17462558	chr2:24020812	T/C	cg08917208	chr2:24149416	ATAD2B	0.81	5.01	0.41	1.8e-6	Lymphocyte counts;
TGCT	cis	rs2486012	0.678	rs2906460	chr1:44335323	A/G	cg12908607	chr1:44402522	ARTN	-0.69	-5.57	-0.45	1.49e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9517302	0.615	rs3752973	chr13:99097509	G/A	cg22223119	chr13:99095684	FARP1	-0.56	-6.11	-0.48	1.18e-8	Obesity-related traits;
TGCT	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg21724239	chr8:58056113	NA	0.34	4.51	0.38	1.46e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs11696845	0.712	rs6130685	chr20:43366730	T/G	cg25301532	chr20:43378953	KCNK15	0.43	4.6	0.38	1.01e-5	Obesity-related traits;
TGCT	cis	rs28595532	0.920	rs116062544	chr4:119735548	G/C	cg21605333	chr4:119757512	SEC24D	1.66	8.33	0.6	1.28e-13	Cannabis dependence symptom count;
TGCT	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg21724239	chr8:58056113	NA	0.47	5.05	0.41	1.54e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs941873	0.868	rs2181080	chr10:81121960	A/G	cg09469691	chr10:81107165	PPIF	0.68	6.91	0.53	2.23e-10	Height;
TGCT	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg26513180	chr16:89883248	FANCA	1.03	14.05	0.78	2.1e-27	Vitiligo;
TGCT	cis	rs9527	0.830	rs11191440	chr10:104641511	G/A	cg04362960	chr10:104952993	NT5C2	0.62	5.06	0.41	1.46e-6	Arsenic metabolism;
TGCT	cis	rs7714584	1.000	rs11746108	chr5:150264622	C/A	cg22134413	chr5:150180641	NA	0.78	6.12	0.48	1.16e-8	Crohn's disease;
TGCT	cis	rs514406	0.893	rs1242317	chr1:53414766	T/C	cg01802117	chr1:53393560	SCP2	-0.4	-4.86	-0.4	3.44e-6	Monocyte count;
TGCT	cis	rs9549367	0.713	rs9549352	chr13:113833221	A/G	cg00898013	chr13:113819073	PROZ	-0.55	-6.95	-0.53	1.83e-10	Platelet distribution width;
TGCT	cis	rs9425326	0.508	rs3010055	chr1:183817289	A/C	cg15569801	chr1:184197096	NA	0.15	5.25	0.43	6.37e-7	Antipsychotic drug-induced QTc interval change in schizophrenia;
TGCT	cis	rs5167	0.781	rs2075619	chr19:45495682	A/G	cg13119609	chr19:45449297	APOC2	0.23	4.81	0.4	4.29e-6	Blood protein levels;
TGCT	cis	rs3733585	0.699	rs7699609	chr4:9961059	A/G	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.7	-0.57	3.69e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs3774830	0.658	rs171846	chr4:5428077	G/A	cg26943120	chr4:5472116	STK32B	-0.25	-5.78	-0.46	5.6e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs10114408	0.959	rs10821253	chr9:96653063	G/A	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs2071303	0.502	rs9393686	chr6:26106601	C/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.72	6.17	0.48	8.75e-9	Intelligence (multi-trait analysis);
TGCT	trans	rs797680	0.789	rs797671	chr1:93700363	C/A	cg27528825	chr2:159282178	CCDC148	0.35	6.88	0.53	2.65e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs790110	0.702	rs9820197	chr3:122352525	C/G	cg18016254	chr3:122296505	PARP15	-0.44	-4.45	-0.37	1.86e-5	Acoustic startle blink response;
TGCT	cis	rs1865760	0.566	rs2051544	chr6:26071093	C/T	cg16482183	chr6:26056742	HIST1H1C	0.58	4.97	0.41	2.19e-6	Height;
TGCT	cis	rs11030122	0.702	rs10500590	chr11:3964724	T/C	cg18678763	chr11:4115507	RRM1	-0.49	-6.14	-0.48	1.01e-8	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs10883723	0.668	rs12414407	chr10:104387019	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.8	-8.7	-0.62	1.68e-14	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs11648796	0.680	rs11248946	chr16:768597	A/G	cg00908189	chr16:619842	PIGQ	0.79	6.43	0.5	2.54e-9	Height;
TGCT	cis	rs2204008	0.715	rs3899385	chr12:38169880	C/G	cg26384229	chr12:38710491	ALG10B	0.86	7.68	0.57	4.17e-12	Bladder cancer;
TGCT	cis	rs6840360	0.571	rs28454076	chr4:152520083	G/T	cg17479576	chr4:152424074	FAM160A1	-0.73	-7.94	-0.58	1.03e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs61867294	0.574	rs6584647	chr10:106711259	T/A	cg08000847	chr10:105880925	C10orf78	0.48	4.46	0.37	1.81e-5	Schizophrenia;
TGCT	cis	rs9911578	0.967	rs12603238	chr17:57130785	C/T	cg05425664	chr17:57184151	TRIM37	0.68	6.76	0.52	4.78e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs1018836	0.923	rs13254212	chr8:91582355	T/C	cg16814680	chr8:91681699	NA	-0.86	-9.06	-0.63	2.36e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9443645	0.901	rs9352664	chr6:79566162	G/T	cg09184832	chr6:79620586	NA	-0.48	-5.17	-0.42	9.23e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	trans	rs1814175	0.645	rs7928714	chr11:49887622	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.45	-11.09	-0.71	2.8e-20	Height;
TGCT	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	4.93	0.4	2.6e-6	Menopause (age at onset);
TGCT	cis	rs7220711	0.967	rs4793023	chr17:41800656	C/A	cg26893861	chr17:41843967	DUSP3	0.56	5.02	0.41	1.76e-6	Bone mineral density (spine);Bone mineral density (hip);
TGCT	cis	rs7937682	0.889	rs1784787	chr11:111486125	T/A	cg09085632	chr11:111637200	PPP2R1B	-1.05	-11.36	-0.71	6.21e-21	Primary sclerosing cholangitis;
TGCT	cis	rs9640161	0.789	rs60283368	chr7:150023258	G/A	cg17279839	chr7:150038598	RARRES2	0.43	4.6	0.38	1.02e-5	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs11190604	0.767	rs10883478	chr10:102162852	C/T	cg23241863	chr10:102295624	HIF1AN	0.6	4.57	0.38	1.17e-5	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs1045714	0.895	rs73043180	chr7:2645972	C/T	cg17215154	chr7:2644645	IQCE	0.28	4.92	0.4	2.75e-6	Urate levels in lean individuals;
TGCT	cis	rs9640161	0.702	rs11765692	chr7:150026567	C/T	cg17279839	chr7:150038598	RARRES2	0.43	4.66	0.39	8.18e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs8180040	0.726	rs2305638	chr3:47046842	G/C	cg27129171	chr3:47204927	SETD2	0.77	9.85	0.66	2.86e-17	Colorectal cancer;
TGCT	trans	rs696279	0.967	rs697511	chr7:16700648	C/A	cg14841483	chr5:131310671	ACSL6	0.38	6.79	0.52	4.05e-10	Mean platelet volume;
TGCT	cis	rs9911578	0.967	rs3826353	chr17:57075299	C/T	cg12560992	chr17:57184187	TRIM37	0.77	9.56	0.65	1.48e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs11671005	0.779	rs3794971	chr19:58985866	T/C	cg18639983	chr19:58920768	ZNF584	0.34	4.67	0.39	7.6e-6	Mean platelet volume;
TGCT	cis	rs853679	0.657	rs1778483	chr6:28240991	T/G	cg18815343	chr6:28367644	ZSCAN12	-0.51	-5.14	-0.42	1.02e-6	Depression;
TGCT	cis	rs12478296	0.901	rs6731775	chr2:242999443	T/C	cg06360820	chr2:242988706	NA	-0.57	-4.65	-0.39	8.52e-6	Obesity-related traits;
TGCT	cis	rs4383453	0.539	rs55689356	chr3:123098203	T/C	cg04890266	chr3:123102914	ADCY5	-0.5	-8.3	-0.6	1.48e-13	Gestational age at birth (maternal effect);
TGCT	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg26818010	chr10:134567672	INPP5A	-0.39	-5.53	-0.45	1.78e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs7666738	0.830	rs10019087	chr4:99030211	C/T	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs453301	0.658	rs6986044	chr8:8874786	G/C	cg00184457	chr8:8946301	NA	-0.26	-4.71	-0.39	6.52e-6	Joint mobility (Beighton score);
TGCT	cis	rs477895	1.000	rs11600990	chr11:64082807	C/T	cg23719950	chr11:63933701	MACROD1	-0.59	-4.6	-0.38	1.01e-5	Mean platelet volume;
TGCT	cis	rs7617773	0.780	rs4479622	chr3:48338173	C/T	cg11946769	chr3:48343235	NME6	0.82	7.06	0.54	1.03e-10	Coronary artery disease;
TGCT	trans	rs74910095	0.786	rs73761393	chr5:62940990	T/C	cg02938449	chr2:220419364	OBSL1	0.8	6.75	0.52	4.95e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs568617	1.000	rs641018	chr11:65655393	G/C	cg04055107	chr11:65626734	MUS81;CFL1	0.57	5.22	0.42	7.39e-7	Crohn's disease;
TGCT	cis	rs9674544	0.646	rs8069452	chr17:47140999	A/G	cg10950924	chr17:47092072	IGF2BP1	0.33	4.54	0.38	1.3e-5	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
TGCT	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg10802521	chr3:52805072	NEK4	-0.71	-8.79	-0.62	1.04e-14	Bipolar disorder;
TGCT	cis	rs11105298	0.891	rs10777184	chr12:89919568	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.67	-4.91	-0.4	2.78e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs1018836	0.923	rs4495387	chr8:91650997	C/T	cg16814680	chr8:91681699	NA	-0.85	-8.91	-0.62	5.26e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs12142240	0.698	rs17357683	chr1:46815378	C/T	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg04772025	chr11:68637568	NA	0.59	6.69	0.52	6.73e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9892942	1	rs9892942	chr17:27178761	C/T	cg20469991	chr17:27169893	C17orf63	-0.7	-4.68	-0.39	7.4e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs6938	0.534	rs1127796	chr15:75193004	C/T	cg10253484	chr15:75165896	SCAMP2	0.58	5.34	0.43	4.23e-7	Breast cancer;
TGCT	cis	rs986417	0.748	rs1955700	chr14:61046481	A/G	cg27398547	chr14:60952738	C14orf39	1.42	10.64	0.69	3.42e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs9611519	0.828	rs28814423	chr22:41452301	G/A	cg03806693	chr22:41940476	POLR3H	-0.67	-6.03	-0.48	1.73e-8	Neuroticism;
TGCT	cis	rs6969780	0.722	rs3823764	chr7:27187753	C/T	cg06942814	chr7:27170819	HOXA4	-0.39	-4.46	-0.37	1.8e-5	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs2404602	0.647	rs11072636	chr15:77185786	A/G	cg23625390	chr15:77176239	SCAPER	-0.38	-4.89	-0.4	3.05e-6	Blood metabolite levels;
TGCT	cis	rs6912958	0.684	rs4707382	chr6:88320641	T/C	cg06598631	chr6:88300029	RARS2;ORC3L	-0.57	-5.2	-0.42	7.9e-7	Monocyte percentage of white cells;
TGCT	cis	rs6540559	0.673	rs6694552	chr1:209976459	A/C	cg22029157	chr1:209979665	IRF6	0.74	5.53	0.44	1.84e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs2463822	1.000	rs2513071	chr11:62098387	A/C	cg23876832	chr11:62092739	NA	0.67	4.91	0.4	2.82e-6	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs909341	0.537	rs6011098	chr20:62398935	C/T	cg14758556	chr20:62440591	NA	-0.34	-4.77	-0.39	5.13e-6	Atopic dermatitis;
TGCT	cis	rs10883723	0.810	rs2296585	chr10:104245549	C/T	cg05855489	chr10:104503620	C10orf26	-0.58	-5.06	-0.41	1.47e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs6831352	0.765	rs35361391	chr4:100069281	A/T	cg12011299	chr4:100065546	ADH4	-0.46	-5.22	-0.42	7.38e-7	Alcohol dependence;
TGCT	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg05368731	chr17:41323189	NBR1	1.2	14.2	0.79	9.05e-28	Menopause (age at onset);
TGCT	cis	rs7552404	1.000	rs4949872	chr1:76131392	C/G	cg03433033	chr1:76189801	ACADM	0.84	10.12	0.67	6.34e-18	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs854765	0.647	rs2974998	chr17:17995619	A/G	cg04398451	chr17:18023971	MYO15A	-0.38	-6.61	-0.51	1.04e-9	Total body bone mineral density;
TGCT	cis	rs12541335	0.639	rs4872468	chr8:22179844	G/C	cg26039829	chr8:22132926	PIWIL2	0.27	5.18	0.42	8.64e-7	Hypertriglyceridemia;
TGCT	cis	rs9611565	0.625	rs2076199	chr22:41903743	G/T	cg13695892	chr22:41940480	POLR3H	-0.84	-8.44	-0.6	7.04e-14	Vitiligo;
TGCT	trans	rs561341	0.609	rs7209493	chr17:30197323	A/G	cg20587970	chr11:113659929	NA	0.65	8.07	0.59	5.07e-13	Hip circumference adjusted for BMI;
TGCT	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg10047753	chr17:41438598	NA	0.95	9.5	0.65	2.09e-16	Menopause (age at onset);
TGCT	cis	rs2153535	0.542	rs4440510	chr6:8471818	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.73	0.46	7.1e-8	Motion sickness;
TGCT	cis	rs73058052	1.000	rs67546213	chr19:50082587	G/A	cg09250473	chr19:50168907	IRF3;BCL2L12	0.77	5.31	0.43	4.93e-7	Fibrinogen levels;
TGCT	cis	rs3020736	0.500	rs28791586	chr22:42500483	A/G	cg05082376	chr22:42548792	NA	0.23	5.43	0.44	2.83e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12220238	1.000	rs7096553	chr10:75957835	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.78	0.57	2.42e-12	Soluble interleukin-2 receptor subunit alpha;
TGCT	trans	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg11887960	chr12:57824829	NA	1.1	9.44	0.65	2.89e-16	Lung disease severity in cystic fibrosis;
TGCT	cis	rs2439831	0.702	rs8033995	chr15:44013509	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.93	6.33	0.49	4.18e-9	Lung cancer in ever smokers;
TGCT	cis	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg20637647	chr7:64974828	NA	0.9	5.06	0.41	1.45e-6	Diabetic kidney disease;
TGCT	trans	rs11722228	0.549	rs41268389	chr4:10099277	G/A	cg26043149	chr18:55253948	FECH	1.16	11.2	0.71	1.55e-20	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs7192750	0.586	rs2288029	chr16:71917058	G/A	cg06353428	chr16:71660113	MARVELD3	0.83	6.97	0.53	1.65e-10	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs796364	0.664	rs4673660	chr2:200915395	C/T	cg17644776	chr2:200775616	C2orf69	0.28	4.52	0.38	1.41e-5	Schizophrenia;
TGCT	cis	rs9486715	0.830	rs4425602	chr6:96893906	G/A	cg06623918	chr6:96969491	KIAA0776	1.11	16.62	0.83	2.35e-33	Headache;
TGCT	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.18	0.49	8.32e-9	Electroencephalogram traits;
TGCT	cis	rs4478858	0.684	rs4949374	chr1:31754511	G/C	cg07478791	chr1:31886160	SERINC2	-0.49	-4.91	-0.4	2.82e-6	Alcohol dependence;
TGCT	trans	rs1908814	0.516	rs13279577	chr8:11793096	C/G	cg15556689	chr8:8085844	FLJ10661	0.77	7.37	0.55	2.13e-11	Neuroticism;
TGCT	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg25767906	chr1:53392781	SCP2	0.52	5.98	0.47	2.25e-8	Monocyte count;
TGCT	cis	rs35306767	0.714	rs12783621	chr10:1083304	C/T	cg26597838	chr10:835615	NA	0.47	5.38	0.43	3.58e-7	Eosinophil percentage of granulocytes;
TGCT	cis	rs13188771	0.651	rs12523298	chr5:100903067	T/A	cg10455971	chr5:101119566	NA	0.44	4.45	0.37	1.87e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs250677	1.000	rs36080	chr5:148430451	A/G	cg18129178	chr5:148520854	ABLIM3	-0.42	-6.2	-0.49	7.79e-9	Breast cancer;
TGCT	cis	rs901683	0.702	rs73292848	chr10:46169752	T/C	cg09623279	chr10:45395734	NA	-0.49	-5.14	-0.42	1.05e-6	Red blood cell traits;Mean corpuscular volume;
TGCT	cis	rs6088580	0.602	rs6059840	chr20:33030405	G/A	cg24642439	chr20:33292090	TP53INP2	0.49	4.5	0.37	1.55e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs9911578	1.000	rs8071280	chr17:57010225	T/C	cg12560992	chr17:57184187	TRIM37	0.76	9.21	0.64	1.03e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.0	7.42	0.55	1.64e-11	Gut microbiome composition (summer);
TGCT	cis	rs57221529	0.563	rs4957057	chr5:569230	C/G	cg09021430	chr5:549028	NA	-0.42	-5.68	-0.45	9.25e-8	Lung disease severity in cystic fibrosis;
TGCT	cis	rs988712	0.622	rs4922793	chr11:27729505	A/G	cg10635145	chr11:27742435	BDNF	-0.44	-6.37	-0.5	3.35e-9	Obesity;
TGCT	cis	rs13177918	0.559	rs10447224	chr5:149834365	G/A	cg14059543	chr5:149831962	NA	-0.62	-7.86	-0.58	1.63e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs17601876	0.814	rs28520437	chr15:51553277	C/T	cg19946085	chr15:51559439	CYP19A1	-0.31	-4.76	-0.39	5.38e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.7	0.52	6.47e-10	Bipolar disorder;
TGCT	cis	rs752010	0.523	rs10890160	chr1:42120011	A/G	cg06885757	chr1:42089581	HIVEP3	0.26	4.73	0.39	6.1e-6	Lupus nephritis in systemic lupus erythematosus;
TGCT	cis	rs6693567	0.545	rs1313568	chr1:150344180	C/G	cg09579323	chr1:150459698	TARS2	0.54	4.79	0.4	4.59e-6	Migraine;
TGCT	cis	rs7772486	0.875	rs2814873	chr6:146308932	T/C	cg13319975	chr6:146136371	FBXO30	-0.53	-4.68	-0.39	7.44e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9527	0.615	rs11191489	chr10:104740568	C/A	cg15744005	chr10:104629667	AS3MT	-0.46	-5.37	-0.43	3.77e-7	Arsenic metabolism;
TGCT	cis	rs2204008	0.715	rs12815986	chr12:38343869	G/A	cg26384229	chr12:38710491	ALG10B	0.83	7.25	0.55	3.99e-11	Bladder cancer;
TGCT	cis	rs904251	0.522	rs882322	chr6:37484103	A/G	cg08126542	chr6:37504118	NA	-0.44	-6.47	-0.5	2.04e-9	Cognitive performance;
TGCT	trans	rs1496653	0.602	rs34804976	chr3:23474436	T/G	cg02770683	chr12:57597238	LRP1	0.38	6.89	0.53	2.53e-10	Type 2 diabetes;
TGCT	cis	rs3824867	0.920	rs4752836	chr11:47465095	T/C	cg20307385	chr11:47447363	PSMC3	0.7	6.03	0.48	1.71e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg24531977	chr5:56204891	C5orf35	0.75	7.33	0.55	2.57e-11	Initial pursuit acceleration;
TGCT	cis	rs2282802	0.685	rs13359519	chr5:139654664	G/A	cg01081189	chr5:139537190	NA	0.28	5.15	0.42	9.75e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1577917	0.771	rs7742201	chr6:86432930	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-5.31	-0.43	4.97e-7	Response to antipsychotic treatment;
TGCT	trans	rs10506458	0.915	rs1463821	chr12:63402875	C/G	cg22491629	chr6:157744540	C6orf35	0.96	9.02	0.63	2.91e-15	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs12989701	1.000	rs12989701	chr2:127887985	C/A	cg08168897	chr2:127865431	BIN1	0.59	5.76	0.46	6.14e-8	Alzheimer's disease (late onset);
TGCT	cis	rs6964587	0.626	rs6979235	chr7:91511776	T/C	cg17063962	chr7:91808500	NA	-0.76	-7.15	-0.54	6.42e-11	Breast cancer;
TGCT	cis	rs6921919	0.583	rs35560946	chr6:28395437	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.54	-5.19	-0.42	8.49e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6460942	0.908	rs78780802	chr7:12233216	T/C	cg06484146	chr7:12443880	VWDE	-0.52	-4.52	-0.38	1.44e-5	Coronary artery disease;
TGCT	cis	rs4478858	0.735	rs4622114	chr1:31772571	A/G	cg07478791	chr1:31886160	SERINC2	-0.52	-5.03	-0.41	1.67e-6	Alcohol dependence;
TGCT	cis	rs9443189	0.570	rs661229	chr6:76293793	G/A	cg01950844	chr6:76311363	SENP6	0.97	6.1	0.48	1.27e-8	Prostate cancer;
TGCT	cis	rs6912958	0.559	rs183599	chr6:88061024	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.44	5.71	0.46	7.78e-8	Monocyte percentage of white cells;
TGCT	trans	rs324780	0.566	rs3103502	chr12:83911511	C/T	cg27144766	chr5:150604977	CCDC69	0.24	6.63	0.51	9.42e-10	Vertical cup-disc ratio;
TGCT	cis	rs3924048	0.574	rs11121931	chr1:12617009	G/A	cg00291366	chr1:12616550	NA	0.33	5.14	0.42	1.05e-6	Optic cup area;
TGCT	cis	rs113084984	0.771	rs12623299	chr2:11685558	A/G	cg25804072	chr2:10829725	NOL10	0.52	4.48	0.37	1.68e-5	Breast cancer;
TGCT	cis	rs9467773	0.844	rs2393669	chr6:26503873	C/T	cg26531700	chr6:26746687	NA	0.47	4.56	0.38	1.19e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg19729930	chr2:74357872	NA	0.6	9.1	0.63	1.92e-15	Gestational age at birth (maternal effect);
TGCT	cis	rs9303401	0.614	rs34920953	chr17:56589406	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.63	6.47	0.5	2.08e-9	Cognitive test performance;
TGCT	cis	rs3812831	0.695	rs7995986	chr13:114938802	A/G	cg06611532	chr13:114900021	NA	0.33	5.99	0.47	2.15e-8	Schizophrenia;
TGCT	cis	rs1990950	0.933	rs11747685	chr5:156903590	C/T	cg25387487	chr5:157003181	ADAM19	0.32	4.74	0.39	5.79e-6	Lung function (FEV1/FVC);
TGCT	cis	rs2230307	0.536	rs554742	chr1:100512568	G/A	cg24955406	chr1:100503596	HIAT1	0.74	4.86	0.4	3.41e-6	Carotid intima media thickness;
TGCT	cis	rs11098499	0.754	rs1980026	chr4:120251643	C/A	cg09307838	chr4:120376055	NA	0.61	5.91	0.47	3.14e-8	Corneal astigmatism;
TGCT	cis	rs7017914	0.875	rs3110251	chr8:71936974	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-4.97	-0.41	2.16e-6	Bone mineral density;
TGCT	cis	rs3096299	0.933	rs2965934	chr16:89481229	C/G	cg02187348	chr16:89574699	SPG7	0.49	4.71	0.39	6.63e-6	Multiple myeloma (IgH translocation);
TGCT	cis	rs4820539	1.000	rs5751589	chr22:23475762	A/G	cg21100191	chr22:23484243	RTDR1	-0.89	-10.79	-0.7	1.54e-19	Bone mineral density;
TGCT	cis	rs67385638	0.802	rs72872555	chr11:5310169	G/A	cg12559170	chr11:5275217	HBG2	0.44	7.98	0.58	8.2e-13	Hemoglobin levels;
TGCT	cis	rs1205863	1.000	rs1205871	chr6:11945048	T/C	cg07106625	chr6:11870215	NA	0.51	5.05	0.41	1.51e-6	Disc degeneration (lumbar);
TGCT	cis	rs17376456	0.569	rs13186432	chr5:93336940	G/A	cg25358565	chr5:93447407	FAM172A	-0.63	-5.82	-0.46	4.71e-8	Diabetic retinopathy;
TGCT	cis	rs6815814	0.950	rs5743565	chr4:38805983	T/C	cg02016764	chr4:38805732	TLR1	-0.35	-5.65	-0.45	1.04e-7	Breast cancer;
TGCT	cis	rs7917772	0.628	rs4604806	chr10:104373904	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	5.36	0.43	3.84e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs12478296	1.000	rs56102931	chr2:243039936	A/G	cg06360820	chr2:242988706	NA	-0.61	-4.66	-0.39	8.13e-6	Obesity-related traits;
TGCT	cis	rs11711311	1.000	rs10212375	chr3:113471336	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.72	-6.74	-0.52	5.36e-10	IgG glycosylation;
TGCT	cis	rs7809950	0.678	rs62483640	chr7:106900214	T/G	cg23024343	chr7:107201750	COG5	-0.43	-5.81	-0.46	4.86e-8	Coronary artery disease;
TGCT	cis	rs926938	0.505	rs2878573	chr1:115521602	A/G	cg12756093	chr1:115239321	AMPD1	0.34	4.97	0.41	2.19e-6	Autism;
TGCT	cis	rs1577917	0.917	rs12202170	chr6:86590386	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.42	-0.44	3.02e-7	Response to antipsychotic treatment;
TGCT	cis	rs2970818	0.831	rs7304949	chr12:4609625	A/G	cg02722637	chr12:4922070	KCNA6	0.31	5.7	0.46	8.32e-8	Phosphorus levels;
TGCT	cis	rs10431058	0.708	rs537974	chr11:107466572	T/G	cg18204760	chr11:107461044	ELMOD1;LOC643923	0.59	5.04	0.41	1.6e-6	Common traits (Other);
TGCT	cis	rs9818758	0.607	rs9311439	chr3:49310408	A/G	cg07636037	chr3:49044803	WDR6	-1.04	-5.13	-0.42	1.09e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs35146811	0.735	rs1727140	chr7:99815399	T/A	cg00553149	chr7:99775558	STAG3;GPC2	-0.31	-4.61	-0.38	9.75e-6	Coronary artery disease;
TGCT	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg21285383	chr16:89894308	SPIRE2	0.43	6.53	0.51	1.51e-9	Vitiligo;
TGCT	cis	rs7020830	0.867	rs55845273	chr9:37362219	C/T	cg14294708	chr9:37120828	ZCCHC7	1.15	15.73	0.82	2.55e-31	Schizophrenia;
TGCT	cis	rs1395	0.778	rs6749393	chr2:27451000	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.7	9.47	0.65	2.4e-16	Blood metabolite levels;
TGCT	cis	rs185694	0.817	rs9315003	chr13:30896885	T/C	cg07600127	chr13:30881527	KATNAL1	0.65	5.57	0.45	1.48e-7	Antineutrophil cytoplasmic antibody-associated vasculitis;
TGCT	cis	rs7727544	0.581	rs10075801	chr5:131677642	A/G	cg24060327	chr5:131705240	SLC22A5	-0.5	-5.39	-0.44	3.44e-7	Blood metabolite levels;
TGCT	cis	rs6450176	0.909	rs2448	chr5:53302354	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.53	-5.1	-0.42	1.23e-6	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs17376456	0.504	rs6898507	chr5:93082343	C/T	cg21475434	chr5:93447410	FAM172A	0.61	4.95	0.41	2.35e-6	Diabetic retinopathy;
TGCT	cis	rs9435341	0.965	rs12401598	chr1:107580533	C/A	cg09367891	chr1:107599246	PRMT6	0.64	5.71	0.46	7.78e-8	Facial morphology (factor 21, depth of nasal alae);
TGCT	cis	rs9560113	1.000	rs9560106	chr13:112179605	A/G	cg14154082	chr13:112174009	NA	0.36	4.93	0.4	2.58e-6	Menarche (age at onset);
TGCT	cis	rs7172809	0.599	rs74026912	chr15:77730856	G/A	cg22256960	chr15:77711686	NA	-0.51	-4.87	-0.4	3.32e-6	Glucose homeostasis traits;
TGCT	cis	rs12615966	1.000	rs12615966	chr2:105378957	A/G	cg16465502	chr2:105461796	NA	-0.78	-5.01	-0.41	1.83e-6	Pancreatic cancer;
TGCT	cis	rs2663905	0.611	rs1509560	chr15:81391713	T/G	cg18028999	chr15:81426610	C15orf26	-0.54	-5.23	-0.42	7.14e-7	QT interval (drug interaction);
TGCT	cis	rs10751667	0.643	rs11246344	chr11:933783	A/C	cg06064525	chr11:970664	AP2A2	-0.35	-8.09	-0.59	4.54e-13	Alzheimer's disease (late onset);
TGCT	cis	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg20637647	chr7:64974828	NA	-0.95	-5.3	-0.43	5.09e-7	Diabetic kidney disease;
TGCT	cis	rs7772486	0.846	rs2748499	chr6:146315002	T/C	cg23711669	chr6:146136114	FBXO30	0.87	9.39	0.64	3.74e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2816062	0.861	rs2745312	chr1:18904012	T/A	cg18795169	chr1:18902165	NA	-0.55	-11.27	-0.71	1.02e-20	Urate levels in lean individuals;
TGCT	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.15	0.82	2.71e-32	Prudent dietary pattern;
TGCT	cis	rs11971779	0.715	rs10954646	chr7:139061069	C/G	cg07862535	chr7:139043722	LUC7L2	-0.6	-4.89	-0.4	3.03e-6	Diisocyanate-induced asthma;
TGCT	trans	rs1814175	0.765	rs1794141	chr11:49914135	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.36	-7.05	-0.53	1.13e-10	Height;
TGCT	cis	rs137603	0.602	rs137654	chr22:39732413	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	-0.64	-6.96	-0.53	1.77e-10	Primary biliary cholangitis;
TGCT	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg06028605	chr16:24865363	SLC5A11	-0.42	-4.66	-0.39	8.11e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs11578119	0.933	rs4281371	chr1:170427536	A/G	cg09767346	chr1:170501363	GORAB	-0.72	-5.74	-0.46	6.97e-8	Male-pattern baldness;
TGCT	cis	rs2749592	0.531	rs994804	chr10:37900140	A/C	cg25427524	chr10:38739819	LOC399744	0.31	5.65	0.45	1.05e-7	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs11648796	0.721	rs743987	chr16:769566	C/G	cg07343612	chr16:622815	PIGQ	-0.38	-5.24	-0.43	6.6e-7	Height;
TGCT	cis	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg08975724	chr8:8085496	FLJ10661	0.53	4.82	0.4	4.03e-6	Mood instability;
TGCT	cis	rs4730250	0.634	rs257371	chr7:106795043	C/A	cg02696742	chr7:106810147	HBP1	-0.72	-5.89	-0.47	3.44e-8	Osteoarthritis;
TGCT	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg24829409	chr8:58192753	C8orf71	-0.56	-5.29	-0.43	5.34e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9796	0.621	rs11858678	chr15:41467932	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.52	-7.17	-0.54	5.94e-11	Menopause (age at onset);
TGCT	cis	rs4886920	0.666	rs11629621	chr15:78080737	C/G	cg25212270	chr15:78015279	NA	0.23	4.9	0.4	2.88e-6	Neuroticism;
TGCT	cis	rs9372498	0.536	rs9489395	chr6:118758884	T/C	cg07617317	chr6:118971624	C6orf204	0.5	5.39	0.44	3.37e-7	Diastolic blood pressure;
TGCT	cis	rs3008870	1.000	rs2755248	chr1:67492624	A/G	cg11518657	chr1:67396239	MIER1	0.52	4.47	0.37	1.73e-5	Lymphocyte percentage of white cells;
TGCT	trans	rs877282	0.945	rs71491311	chr10:791747	G/A	cg22713356	chr15:30763199	NA	1.18	10.55	0.69	5.81e-19	Uric acid levels;
TGCT	cis	rs9928842	0.765	rs6564223	chr16:75225899	T/C	cg09066997	chr16:75300724	BCAR1	0.27	4.44	0.37	1.93e-5	Alcoholic chronic pancreatitis;
TGCT	cis	rs6740322	0.696	rs10188539	chr2:43484675	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.39	-5.66	-0.45	9.75e-8	Coronary artery disease;
TGCT	cis	rs929596	0.755	rs887829	chr2:234668570	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.33	5.48	0.44	2.31e-7	Total bilirubin levels in HIV-1 infection;
TGCT	cis	rs6840360	0.571	rs62327275	chr4:152548238	G/T	cg17479576	chr4:152424074	FAM160A1	-0.71	-7.72	-0.57	3.41e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs1541995	0.789	rs35544332	chr15:96230473	G/A	cg00882281	chr15:96346592	NA	0.3	4.76	0.39	5.28e-6	Photic sneeze reflex;
TGCT	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg14159672	chr1:205819179	PM20D1	0.57	6.92	0.53	2.1e-10	Menarche (age at onset);
TGCT	cis	rs7666738	0.830	rs1456208	chr4:98678563	C/T	cg17366294	chr4:99064904	C4orf37	0.62	6.4	0.5	2.94e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8177253	0.632	rs6782523	chr3:133438917	C/T	cg01448562	chr3:133502909	NA	-0.26	-4.71	-0.39	6.44e-6	Iron status biomarkers;
TGCT	cis	rs9993613	0.808	rs12648992	chr4:73431560	T/C	cg15102770	chr4:73434591	ADAMTS3	0.51	4.57	0.38	1.16e-5	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs7666738	0.546	rs1813970	chr4:98887167	A/G	cg05340658	chr4:99064831	C4orf37	-0.58	-6.02	-0.48	1.85e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10840270	1.000	rs10840270	chr11:9629553	C/G	cg03787988	chr11:10602522	MRVI1	0.18	4.62	0.38	9.47e-6	Bacteremia;
TGCT	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg17179660	chr6:151773299	C6orf211;RMND1	-0.51	-4.62	-0.38	9.45e-6	Menarche (age at onset);
TGCT	cis	rs28595532	0.920	rs115675321	chr4:119742153	A/T	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs28595532	1.000	rs114682099	chr4:119702004	C/T	cg14228332	chr4:119757509	SEC24D	1.02	5.06	0.41	1.47e-6	Cannabis dependence symptom count;
TGCT	cis	rs2242116	0.796	rs7645278	chr3:46974100	A/C	cg02527881	chr3:46936655	PTH1R	-0.32	-6.03	-0.48	1.77e-8	Birth weight;
TGCT	trans	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg17830980	chr10:43048298	ZNF37B	-0.85	-10.91	-0.7	7.78e-20	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2797780	0.964	rs2797782	chr6:37504036	T/C	cg00985040	chr6:37553208	NA	0.24	4.57	0.38	1.18e-5	Systemic lupus erythematosus;
TGCT	cis	rs73198271	0.628	rs11783707	chr8:8589609	C/T	ch.8.214553F	chr8:8189620	PRAGMIN	-0.33	-5.48	-0.44	2.3e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs708547	0.836	rs1315005	chr4:57858237	C/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.55	-5.03	-0.41	1.71e-6	Response to bleomycin (chromatid breaks);
TGCT	cis	rs7258465	0.897	rs1043327	chr19:18554972	A/G	cg22489759	chr19:18572700	ELL	0.2	4.59	0.38	1.05e-5	Breast cancer;
TGCT	cis	rs9399137	0.507	rs6940878	chr6:135366309	G/A	cg24558204	chr6:135376177	HBS1L	0.46	4.57	0.38	1.15e-5	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
TGCT	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg03303774	chr4:1407052	NA	0.3	4.78	0.39	4.8e-6	Obesity-related traits;
TGCT	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.49	-6.5	-0.5	1.76e-9	Alzheimer's disease;
TGCT	cis	rs112591243	0.570	rs117783236	chr21:47971219	A/T	cg10657630	chr21:48055338	PRMT2	1.05	5.16	0.42	9.69e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs317689	0.680	rs315140	chr12:69790780	A/T	cg14784868	chr12:69753453	YEATS4	0.54	4.58	0.38	1.11e-5	Response to diuretic therapy;
TGCT	cis	rs539096	0.624	rs653953	chr1:44083015	G/A	cg12908607	chr1:44402522	ARTN	-0.45	-4.99	-0.41	1.97e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs669446	0.527	rs667676	chr1:44082216	G/A	cg12908607	chr1:44402522	ARTN	-0.55	-5.9	-0.47	3.25e-8	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs55823223	0.564	rs936391	chr17:73847799	A/G	cg10935138	chr17:73851978	WBP2	-0.78	-7.49	-0.56	1.14e-11	Psoriasis;
TGCT	cis	rs9325144	0.647	rs12424190	chr12:39111206	A/T	cg26384229	chr12:38710491	ALG10B	-0.57	-5.3	-0.43	5.16e-7	Morning vs. evening chronotype;
TGCT	cis	rs4918072	0.876	rs4918069	chr10:105654391	T/G	cg11005552	chr10:105648138	OBFC1	0.41	5.4	0.44	3.29e-7	Coronary artery disease;
TGCT	cis	rs7208859	0.673	rs55904046	chr17:29215391	G/A	cg14008862	chr17:28927542	LRRC37B2	0.72	4.66	0.39	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7208859	0.623	rs9897728	chr17:29108804	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs11122272	0.615	rs1465740	chr1:231495255	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.73	-6.89	-0.53	2.51e-10	Hemoglobin concentration;
TGCT	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg00343986	chr7:65444356	GUSB	0.26	5.95	0.47	2.56e-8	Calcium levels;
TGCT	cis	rs7772486	0.817	rs9322047	chr6:146400394	G/A	cg05347473	chr6:146136440	FBXO30	0.55	5.14	0.42	1.05e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9788682	1.000	rs12441354	chr15:78821016	G/A	cg24631222	chr15:78858424	CHRNA5	0.93	7.96	0.58	9.55e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs7615952	0.932	rs7630077	chr3:125649676	T/C	cg05084668	chr3:125655381	ALG1L	-0.75	-6.07	-0.48	1.43e-8	Blood pressure (smoking interaction);
TGCT	cis	rs6665290	0.904	rs3768425	chr1:227178127	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.01	-20.94	-0.88	1.57e-42	Myeloid white cell count;
TGCT	cis	rs2201728	0.967	rs34397848	chr4:100147247	A/G	cg07219303	chr4:100140905	ADH6	-0.35	-5.22	-0.42	7.29e-7	Cardiac Troponin-T levels;
TGCT	cis	rs7772486	0.875	rs10457792	chr6:146412415	T/C	cg23711669	chr6:146136114	FBXO30	0.89	9.47	0.65	2.36e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs28785552	1.000	rs28785552	chr19:53234161	G/A	cg10871876	chr19:53194124	ZNF83	0.6	8.53	0.61	4.35e-14	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs11190604	1.000	rs10883513	chr10:102316964	A/G	cg23241863	chr10:102295624	HIF1AN	0.68	4.89	0.4	3.08e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7914558	0.966	rs1971589	chr10:104744406	A/G	cg05855489	chr10:104503620	C10orf26	0.51	4.53	0.38	1.39e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs611744	0.631	rs627392	chr8:109254677	C/T	cg21045802	chr8:109455806	TTC35	0.72	7.28	0.55	3.32e-11	Dupuytren's disease;
TGCT	cis	rs12477438	1.000	rs995617	chr2:99857904	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.76	5.79	0.46	5.47e-8	Chronic sinus infection;
TGCT	cis	rs2439831	0.850	rs7168158	chr15:44050376	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	5.91	0.47	3.05e-8	Lung cancer in ever smokers;
TGCT	cis	rs8013055	0.846	rs10139300	chr14:105974501	A/G	cg25008857	chr14:105974488	NA	0.27	4.65	0.39	8.35e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs3008870	1.000	rs3008859	chr1:67390999	G/C	cg03991309	chr1:68237761	GNG12	0.27	4.56	0.38	1.23e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg05665937	chr4:1216051	CTBP1	0.22	4.5	0.37	1.53e-5	Obesity-related traits;
TGCT	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg02038168	chr22:39784481	NA	-0.79	-6.79	-0.52	4.07e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg11062466	chr8:58055876	NA	0.38	4.5	0.37	1.56e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs4253772	0.550	rs6007779	chr22:46678615	A/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.67	4.62	0.38	9.61e-6	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs6570726	0.846	rs6914304	chr6:145921017	T/C	cg23711669	chr6:146136114	FBXO30	0.83	8.64	0.61	2.4e-14	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7312933	0.645	rs12049942	chr12:42587052	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	5.06	0.41	1.45e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs10114408	0.877	rs10739961	chr9:96647692	G/A	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs6840360	0.550	rs12651635	chr4:152557786	C/T	cg17479576	chr4:152424074	FAM160A1	-0.71	-7.72	-0.57	3.41e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg08564027	chr20:61660810	NA	0.38	7.08	0.54	9.36e-11	Prostate cancer (SNP x SNP interaction);
TGCT	trans	rs3857536	0.505	rs208459	chr6:66911055	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.74	-7.75	-0.57	2.85e-12	Blood trace element (Cu levels);
TGCT	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.53	-4.59	-0.38	1.06e-5	Height;
TGCT	cis	rs4808199	0.895	rs8105984	chr19:19374068	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.68	5.14	0.42	1.03e-6	Nonalcoholic fatty liver disease;
TGCT	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs3087591	0.960	rs11868459	chr17:29458197	C/T	cg24425628	chr17:29625626	OMG;NF1	0.46	7.25	0.55	3.92e-11	Hip circumference;
TGCT	cis	rs9650657	0.707	rs10098699	chr8:10676756	C/T	cg27411982	chr8:10470053	RP1L1	-0.23	-5.19	-0.42	8.48e-7	Neuroticism;
TGCT	cis	rs12220238	1.000	rs11000922	chr10:75969305	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.06	0.54	1.05e-10	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg11905131	chr22:24372483	LOC391322	0.69	5.55	0.45	1.68e-7	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg20637647	chr7:64974828	NA	0.89	4.77	0.39	4.98e-6	Diabetic kidney disease;
TGCT	cis	rs6460942	0.915	rs62448593	chr7:12436845	G/C	cg06484146	chr7:12443880	VWDE	-0.57	-5.52	-0.44	1.92e-7	Coronary artery disease;
TGCT	cis	rs981844	0.775	rs1020704	chr4:154736494	C/T	cg14289246	chr4:154710475	SFRP2	1.01	9.01	0.63	3.12e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg11317459	chr13:21872234	NA	1.32	13.31	0.77	1.2e-25	White matter hyperintensity burden;
TGCT	cis	rs10984561	0.881	rs77882033	chr9:122250600	C/T	cg14242995	chr9:122249943	NA	0.73	5.96	0.47	2.46e-8	Pulmonary function decline;
TGCT	cis	rs751728	1.000	rs4713682	chr6:33757047	G/C	cg00334056	chr6:33755658	LEMD2	-0.25	-4.55	-0.38	1.24e-5	Crohn's disease;
TGCT	cis	rs7772486	0.727	rs11155442	chr6:146140725	T/C	cg13319975	chr6:146136371	FBXO30	-0.52	-4.65	-0.39	8.45e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.61	0.38	9.85e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg13206674	chr6:150067644	NUP43	0.52	4.46	0.37	1.78e-5	Lung cancer;
TGCT	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg24675658	chr1:53192096	ZYG11B	-0.73	-8.2	-0.59	2.62e-13	Monocyte count;
TGCT	cis	rs67460515	0.892	rs7648279	chr3:160979646	G/A	cg03342759	chr3:160939853	NMD3	-0.49	-5.3	-0.43	5.16e-7	Parkinson's disease;
TGCT	cis	rs10782582	0.609	rs72979226	chr1:76302222	C/A	cg10523679	chr1:76189770	ACADM	-0.59	-5.42	-0.44	2.94e-7	Daytime sleep phenotypes;
TGCT	cis	rs801193	1.000	rs2055682	chr7:66260289	A/G	cg18876405	chr7:65276391	NA	0.38	5.83	0.46	4.48e-8	Aortic root size;
TGCT	cis	rs9807989	0.507	rs6710034	chr2:103023678	G/A	cg03938978	chr2:103052716	IL18RAP	0.27	5.41	0.44	3.17e-7	Asthma;
TGCT	trans	rs4332037	0.539	rs55773130	chr7:2070554	T/C	cg10840412	chr1:235813424	GNG4	0.95	6.94	0.53	1.97e-10	Bipolar disorder;
TGCT	cis	rs79839061	0.562	rs10516158	chr4:942439	A/G	cg07828340	chr4:882639	GAK	-0.32	-4.62	-0.38	9.63e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1843834	1.000	rs1565072	chr2:225545245	C/T	cg22455342	chr2:225449267	CUL3	-0.75	-7.41	-0.55	1.73e-11	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg22963979	chr7:1858916	MAD1L1	-0.38	-5.96	-0.47	2.38e-8	Bipolar disorder and schizophrenia;
TGCT	trans	rs4824093	0.610	rs4141437	chr22:50243719	C/G	cg09872104	chr7:134855509	C7orf49	0.91	7.33	0.55	2.66e-11	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs11734570	0.581	rs73811715	chr4:38590569	A/C	cg18361445	chr4:38666374	KLF3;FLJ13197	0.63	4.61	0.38	9.67e-6	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs860554	0.672	rs866215	chr1:201264853	T/C	cg01022117	chr1:201258280	PKP1	0.34	5.04	0.41	1.61e-6	Panic disorder;
TGCT	cis	rs854624	0.892	rs1734961	chr17:34335511	C/G	cg02022384	chr17:34097390	MMP28	-0.5	-4.59	-0.38	1.09e-5	Blood protein levels;
TGCT	cis	rs9486719	0.843	rs2499797	chr6:96848669	C/T	cg06623918	chr6:96969491	KIAA0776	0.93	7.08	0.54	9.59e-11	Migraine;Coronary artery disease;
TGCT	cis	rs13242816	1.000	rs34652384	chr7:116157011	T/C	cg02799643	chr7:116139180	CAV2	-0.44	-5.54	-0.45	1.74e-7	P wave duration;
TGCT	cis	rs7959452	0.535	rs2305641	chr12:69646914	C/T	cg11871910	chr12:69753446	YEATS4	0.62	6.22	0.49	6.95e-9	Blood protein levels;
TGCT	cis	rs2718812	0.792	rs1867503	chr3:133410648	G/A	cg16414030	chr3:133502952	NA	0.39	5.22	0.42	7.17e-7	Iron status biomarkers;
TGCT	cis	rs896854	0.517	rs1011795	chr8:95951073	G/A	cg16049864	chr8:95962084	TP53INP1	-0.54	-5.95	-0.47	2.54e-8	Type 2 diabetes;
TGCT	cis	rs9549260	0.755	rs4943797	chr13:41201633	A/G	cg21288729	chr13:41239152	FOXO1	-0.96	-9.96	-0.67	1.56e-17	Red blood cell count;
TGCT	cis	rs1903068	0.853	rs28680424	chr4:56009245	T/C	cg16572876	chr4:56024045	NA	0.44	4.87	0.4	3.29e-6	Endometriosis;
TGCT	cis	rs854765	0.583	rs5002487	chr17:17832460	A/G	cg09796270	chr17:17721594	SREBF1	0.26	5.37	0.43	3.76e-7	Total body bone mineral density;
TGCT	cis	rs7226408	0.857	rs9675466	chr18:34502792	T/C	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs11252926	0.507	rs4881199	chr10:428090	C/G	cg18196295	chr10:418757	DIP2C	0.31	5.21	0.42	7.57e-7	Psychosis in Alzheimer's disease;
TGCT	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg23034840	chr1:205782522	SLC41A1	-0.63	-5.9	-0.47	3.29e-8	Monocyte percentage of white cells;
TGCT	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg03709012	chr19:19516395	GATAD2A	0.75	6.16	0.48	9.21e-9	Tonsillectomy;
TGCT	cis	rs1891275	0.515	rs10786010	chr10:93443773	G/A	cg07889827	chr10:93443413	NA	-0.33	-6.99	-0.53	1.53e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs1129187	0.935	rs9462859	chr6:42946943	G/A	cg17345569	chr6:42928274	GNMT	-0.44	-4.5	-0.37	1.55e-5	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs473651	0.935	rs508483	chr2:239339709	T/C	cg08773314	chr2:239334832	ASB1	0.48	8.13	0.59	3.65e-13	Multiple system atrophy;
TGCT	cis	rs877282	0.629	rs78997110	chr10:764388	A/G	cg17470449	chr10:769945	NA	0.37	5.59	0.45	1.37e-7	Uric acid levels;
TGCT	cis	rs7223966	0.960	rs2854222	chr17:61939015	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	5.17	0.42	9.21e-7	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs17102423	1.000	rs4902364	chr14:65602006	G/A	cg11161011	chr14:65562177	MAX	-0.49	-6.7	-0.52	6.46e-10	Obesity-related traits;
TGCT	cis	rs319204	0.918	rs319169	chr5:146290938	G/C	cg25021259	chr5:146258546	PPP2R2B	0.35	4.48	0.37	1.65e-5	Schizophrenia;
TGCT	cis	rs1005277	0.505	rs10827836	chr10:38215441	A/G	cg25427524	chr10:38739819	LOC399744	0.38	7.67	0.57	4.25e-12	Extrinsic epigenetic age acceleration;
TGCT	cis	rs3752962	0.588	rs903164	chr17:1939502	G/A	cg24156229	chr17:1948635	NA	-0.37	-7.11	-0.54	8.07e-11	Itch intensity from mosquito bite;
TGCT	cis	rs9814567	1.000	rs7433991	chr3:134312292	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.91	-8.83	-0.62	8.17e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg07424592	chr7:64974309	NA	-1.31	-7.72	-0.57	3.33e-12	Diabetic kidney disease;
TGCT	cis	rs17401966	0.931	rs17410217	chr1:10371854	A/G	cg19773385	chr1:10388646	KIF1B	-0.23	-4.8	-0.4	4.51e-6	Hepatocellular carcinoma;
TGCT	cis	rs17253792	0.822	rs75555677	chr14:56096429	G/A	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs7772486	0.727	rs10447449	chr6:146138707	A/G	cg13319975	chr6:146136371	FBXO30	-0.52	-4.7	-0.39	6.68e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9948	0.655	rs2280356	chr2:97366324	C/T	cg01990225	chr2:97406019	LMAN2L	0.94	5.33	0.43	4.44e-7	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9818758	0.607	rs9862483	chr3:49195441	G/A	cg00383909	chr3:49044727	WDR6	1.28	6.57	0.51	1.23e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs3812049	0.784	rs7734927	chr5:127453735	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	6.27	0.49	5.59e-9	Lymphocyte counts;Red cell distribution width;
TGCT	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg06238570	chr21:40685208	BRWD1	-0.79	-8.7	-0.62	1.7e-14	Cognitive function;
TGCT	cis	rs2721195	0.845	rs3757966	chr8:145744618	G/A	cg15857475	chr8:145742913	RECQL4;LRRC14	0.88	9.6	0.65	1.17e-16	Age at first birth;
TGCT	cis	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg02380750	chr20:61661411	NA	0.34	6.02	0.48	1.86e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs8017423	0.935	rs11626869	chr14:90788985	A/G	cg04374321	chr14:90722782	PSMC1	-0.71	-6.76	-0.52	4.87e-10	Mortality in heart failure;
TGCT	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg01171360	chr6:293285	DUSP22	0.71	7.25	0.55	3.87e-11	Menopause (age at onset);
TGCT	cis	rs288326	0.561	rs75139715	chr2:183890660	T/A	cg09997497	chr2:183902928	NCKAP1	1.11	4.95	0.41	2.38e-6	Blood protein levels;
TGCT	cis	rs4654899	0.931	rs10799669	chr1:21172501	T/C	cg01072550	chr1:21505969	NA	0.47	7.4	0.55	1.83e-11	Superior frontal gyrus grey matter volume;
TGCT	cis	rs7208859	0.524	rs73263982	chr17:28920624	T/C	cg19761014	chr17:28927070	LRRC37B2	0.56	4.81	0.4	4.32e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs2580764	0.566	rs2968827	chr2:55297629	C/G	cg09592903	chr2:55203963	RTN4	0.25	5.64	0.45	1.09e-7	Mean platelet volume;
TGCT	cis	rs889312	0.500	rs832552	chr5:56113850	A/C	cg12311346	chr5:56204834	C5orf35	0.44	4.59	0.38	1.09e-5	Breast cancer;Breast cancer (early onset);
TGCT	cis	rs10782582	0.593	rs6673786	chr1:76149637	C/T	cg03433033	chr1:76189801	ACADM	-0.64	-7.35	-0.55	2.29e-11	Daytime sleep phenotypes;
TGCT	cis	rs78487399	0.908	rs10186307	chr2:43839896	G/A	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.64	4.63	0.38	8.92e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs10791097	0.765	rs7943757	chr11:130716157	C/T	cg05962950	chr11:130786565	SNX19	0.71	7.48	0.56	1.2e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9611565	0.694	rs5758324	chr22:41787950	G/T	cg03806693	chr22:41940476	POLR3H	-1.02	-11.06	-0.7	3.33e-20	Vitiligo;
TGCT	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg21280719	chr6:42927975	GNMT	-0.37	-4.61	-0.38	9.86e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs9640161	0.742	rs2108852	chr7:150019628	T/C	cg10018233	chr7:150070692	REPIN1	0.33	4.74	0.39	5.68e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs7666738	0.830	rs7669407	chr4:98750251	G/A	cg18180107	chr4:99064573	C4orf37	0.53	5.07	0.41	1.38e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7772486	0.754	rs9390356	chr6:146118983	A/T	cg13319975	chr6:146136371	FBXO30	0.58	5.24	0.43	6.75e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg00814883	chr7:100076585	TSC22D4	-0.92	-9.76	-0.66	4.73e-17	Platelet count;
TGCT	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg02725872	chr8:58115012	NA	-0.38	-5.16	-0.42	9.32e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs4851254	0.961	rs13022707	chr2:100734946	C/A	cg23118464	chr2:100721844	AFF3	0.67	4.9	0.4	2.93e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9611519	0.780	rs9611546	chr22:41698542	C/G	cg06634786	chr22:41940651	POLR3H	-0.64	-5.99	-0.47	2.08e-8	Neuroticism;
TGCT	cis	rs7178572	0.568	rs12905951	chr15:77649431	G/A	cg15453836	chr15:77711506	NA	-0.42	-4.79	-0.4	4.68e-6	Type 2 diabetes;
TGCT	trans	rs2727020	0.553	rs10839295	chr11:49527345	A/C	cg03929089	chr4:120376271	NA	-0.66	-7.62	-0.56	5.75e-12	Coronary artery disease;
TGCT	cis	rs17433780	0.808	rs12122780	chr1:89508916	T/C	cg09516651	chr1:89888402	LOC400759	0.26	4.94	0.41	2.48e-6	Carotid intima media thickness;
TGCT	cis	rs6430585	0.591	rs1374330	chr2:136420908	A/C	cg07169764	chr2:136633963	MCM6	1.09	9.79	0.66	4.14e-17	Corneal structure;
TGCT	cis	rs9517313	0.591	rs9554480	chr13:99221138	T/A	cg07423050	chr13:99094983	FARP1	-0.23	-4.48	-0.37	1.69e-5	Neuroticism;
TGCT	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg24829409	chr8:58192753	C8orf71	-0.54	-5.17	-0.42	9.01e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs11209002	0.567	rs983110	chr1:67539215	A/T	cg02640540	chr1:67518911	SLC35D1	0.53	4.45	0.37	1.86e-5	Crohn's disease;
TGCT	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg03264133	chr6:25882463	NA	-0.66	-6.11	-0.48	1.19e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs1577917	0.727	rs9351065	chr6:86360428	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.58	-0.45	1.43e-7	Response to antipsychotic treatment;
TGCT	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg11494091	chr17:61959527	GH2	0.61	14.49	0.79	1.92e-28	Prudent dietary pattern;
TGCT	trans	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.88	9.9	0.66	2.18e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs1994135	0.594	rs10772096	chr12:33732869	A/G	cg06521331	chr12:34319734	NA	-0.3	-4.71	-0.39	6.63e-6	Resting heart rate;
TGCT	cis	rs2658782	0.826	rs1975820	chr11:93081815	G/A	cg18152523	chr11:93063302	CCDC67	-0.67	-5.19	-0.42	8.29e-7	Pulmonary function decline;
TGCT	cis	rs2204008	0.567	rs2703685	chr12:38081423	G/C	cg26384229	chr12:38710491	ALG10B	0.58	4.96	0.41	2.24e-6	Bladder cancer;
TGCT	cis	rs68170813	0.559	rs17428126	chr7:106897037	C/T	cg02696742	chr7:106810147	HBP1	-0.69	-5.61	-0.45	1.27e-7	Coronary artery disease;
TGCT	cis	rs6665290	0.935	rs11588904	chr1:227196211	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.99	-20.13	-0.88	6.85e-41	Myeloid white cell count;
TGCT	cis	rs9926296	0.656	rs2376882	chr16:89827002	T/C	cg01719998	chr16:89642051	CPNE7	-0.44	-4.48	-0.37	1.69e-5	Vitiligo;
TGCT	cis	rs9911578	1.000	rs11869828	chr17:56609525	G/A	cg12560992	chr17:57184187	TRIM37	-0.76	-9.34	-0.64	4.88e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs11190604	0.767	rs4919459	chr10:102200371	C/T	cg16005271	chr10:102321736	NA	0.46	4.68	0.39	7.39e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs6840360	1.000	rs4571	chr4:152592191	T/C	cg17479576	chr4:152424074	FAM160A1	-0.48	-5.06	-0.41	1.47e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4252435	0.522	rs4252427	chr7:142623357	C/T	cg09833174	chr7:143059591	FAM131B	0.99	4.92	0.4	2.68e-6	Cancer;
TGCT	cis	rs1971762	0.545	rs3864905	chr12:54058324	C/T	cg16917193	chr12:54089295	NA	1.07	11.12	0.71	2.39e-20	Height;
TGCT	cis	rs6582630	0.555	rs7305352	chr12:38473800	T/C	cg26384229	chr12:38710491	ALG10B	0.88	8.04	0.59	5.98e-13	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs2663905	0.611	rs1509558	chr15:81391244	C/T	cg18028999	chr15:81426610	C15orf26	-0.51	-4.68	-0.39	7.24e-6	QT interval (drug interaction);
TGCT	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg18654377	chr3:49208889	KLHDC8B	-0.45	-5.89	-0.47	3.44e-8	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs9372498	0.505	rs62422247	chr6:118987559	G/T	cg21191810	chr6:118973309	C6orf204	-0.37	-4.71	-0.39	6.4e-6	Diastolic blood pressure;
TGCT	cis	rs4409675	0.576	rs6565	chr1:28213157	T/C	cg23691781	chr1:28212827	C1orf38	0.26	5.32	0.43	4.68e-7	Corneal astigmatism;
TGCT	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	5.23	0.43	6.92e-7	Menopause (age at onset);
TGCT	cis	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg20637647	chr7:64974828	NA	0.92	5.36	0.43	3.87e-7	Diabetic kidney disease;
TGCT	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs9372498	0.536	rs9489409	chr6:118802721	A/G	cg07617317	chr6:118971624	C6orf204	0.51	5.52	0.44	1.92e-7	Diastolic blood pressure;
TGCT	cis	rs9457247	1.000	rs2757042	chr6:167371234	A/T	cg23791538	chr6:167370224	RNASET2	0.53	4.97	0.41	2.14e-6	Crohn's disease;
TGCT	cis	rs17331151	0.573	rs3755801	chr3:52865798	G/A	cg11137980	chr3:52469226	SEMA3G	0.28	5.07	0.41	1.42e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs8072100	0.875	rs12451409	chr17:45544856	A/G	cg08085267	chr17:45401833	C17orf57	-0.43	-4.68	-0.39	7.26e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs9952991	0.656	rs7235964	chr18:12761249	G/A	cg23598886	chr18:12777645	NA	-0.65	-4.66	-0.39	8.08e-6	Inflammatory skin disease;
TGCT	cis	rs9394438	0.628	rs4714078	chr6:37543852	G/A	cg00985040	chr6:37553208	NA	-0.25	-4.97	-0.41	2.19e-6	IgG glycosylation;
TGCT	cis	rs4819052	0.851	rs2838867	chr21:46713092	C/T	cg06618935	chr21:46677482	NA	-0.36	-5.5	-0.44	2.06e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs873917	0.620	rs784595	chr1:40135017	C/T	cg06209491	chr1:40138402	NT5C1A	-0.34	-5.9	-0.47	3.29e-8	Amyotrophic lateral sclerosis;
TGCT	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg25036284	chr2:26402008	FAM59B	0.65	5.19	0.42	8.36e-7	Gut microbiome composition (summer);
TGCT	cis	rs2836974	0.565	rs2836939	chr21:40578546	C/T	cg17971929	chr21:40555470	PSMG1	0.66	4.63	0.38	8.99e-6	Cognitive function;
TGCT	cis	rs526231	0.853	rs2561477	chr5:102608924	G/A	cg05225461	chr5:102596755	C5orf30	0.23	4.65	0.39	8.39e-6	Primary biliary cholangitis;
TGCT	cis	rs10507380	0.824	rs9512638	chr13:27920657	T/C	cg25543773	chr13:27185723	WASF3	0.34	4.83	0.4	3.97e-6	Electrocardiographic traits;
TGCT	cis	rs7246657	0.722	rs4802029	chr19:38055612	A/T	cg03611452	chr19:38183253	ZNF781	0.58	4.64	0.38	8.62e-6	Coronary artery calcification;
TGCT	cis	rs6542838	0.703	rs7593332	chr2:99467991	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.48	-4.67	-0.39	7.71e-6	Fear of minor pain;
TGCT	cis	rs7772486	0.727	rs11155442	chr6:146140725	T/C	cg23711669	chr6:146136114	FBXO30	0.89	9.8	0.66	3.89e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6582630	0.547	rs1589388	chr12:38416025	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-4.64	-0.38	8.67e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs9653442	0.900	rs6754937	chr2:100827720	T/G	cg22139774	chr2:100720529	AFF3	-0.4	-6.34	-0.49	3.95e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs10833905	0.680	rs2433479	chr11:23034703	G/A	cg06387204	chr11:22647648	FANCF	0.51	4.56	0.38	1.19e-5	Sudden cardiac arrest;
TGCT	cis	rs9549367	0.713	rs9549691	chr13:113861606	A/C	cg00898013	chr13:113819073	PROZ	-0.52	-6.6	-0.51	1.06e-9	Platelet distribution width;
TGCT	cis	rs2580764	0.565	rs6760429	chr2:55228499	C/T	cg09592903	chr2:55203963	RTN4	-0.25	-5.45	-0.44	2.58e-7	Mean platelet volume;
TGCT	cis	rs7647973	0.925	rs9834003	chr3:49216472	T/C	cg07690219	chr3:49449608	TCTA;RHOA	-0.57	-4.79	-0.4	4.63e-6	Menarche (age at onset);
TGCT	trans	rs9650657	0.538	rs6984496	chr8:10796093	G/T	cg15556689	chr8:8085844	FLJ10661	-0.79	-6.99	-0.53	1.53e-10	Neuroticism;
TGCT	cis	rs1475911	1.000	rs17114359	chr21:43510437	A/C	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.24	-4.9	-0.4	2.94e-6	IgG glycosylation;
TGCT	cis	rs11681930	0.708	rs10165609	chr2:206090248	A/G	cg11793701	chr2:206547163	NRP2	0.85	4.45	0.37	1.87e-5	Attention deficit hyperactivity disorder (combined symptoms);
TGCT	cis	rs6500602	0.702	rs4786511	chr16:4571645	C/T	cg08645402	chr16:4508243	NA	0.19	5.25	0.43	6.32e-7	Schizophrenia;
TGCT	cis	rs77633900	0.614	rs2629021	chr15:76974083	C/T	cg21673338	chr15:77095150	SCAPER	-0.5	-4.92	-0.4	2.68e-6	Non-glioblastoma glioma;Glioma;
TGCT	cis	rs7666738	0.830	rs10470894	chr4:99039107	G/A	cg18180107	chr4:99064573	C4orf37	0.56	5.08	0.41	1.37e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2153535	0.580	rs5001324	chr6:8451604	A/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.76	0.46	6.39e-8	Motion sickness;
TGCT	cis	rs17739167	0.550	rs6493014	chr15:42225008	A/G	cg20935245	chr15:42234343	EHD4	-0.2	-4.45	-0.37	1.9e-5	Monocyte count;
TGCT	cis	rs79387448	0.638	rs116055209	chr2:103032189	C/T	cg09003973	chr2:102972529	NA	1.27	9.82	0.66	3.37e-17	Gut microbiota (bacterial taxa);
TGCT	cis	rs6534347	0.573	rs6814458	chr4:123520842	G/A	cg10583651	chr4:123538969	IL21	-0.36	-5.27	-0.43	5.97e-7	Type 1 diabetes;
TGCT	cis	rs709400	0.526	rs8017780	chr14:103987305	C/A	cg12935359	chr14:103987150	CKB	-0.48	-6.22	-0.49	6.85e-9	Body mass index;
TGCT	cis	rs8017423	0.904	rs7147212	chr14:90697809	A/C	cg04374321	chr14:90722782	PSMC1	0.77	8.04	0.59	5.94e-13	Mortality in heart failure;
TGCT	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg05368731	chr17:41323189	NBR1	-1.07	-12.19	-0.74	5.97e-23	Menopause (age at onset);
TGCT	trans	rs2727020	0.755	rs652655	chr11:49251293	G/A	cg03929089	chr4:120376271	NA	0.73	8.5	0.61	5.16e-14	Coronary artery disease;
TGCT	cis	rs7208859	0.623	rs9895785	chr17:29107708	C/T	cg14008862	chr17:28927542	LRRC37B2	-0.76	-4.44	-0.37	1.93e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs9831754	0.906	rs2314196	chr3:78411050	C/T	cg06138941	chr3:78371609	NA	-0.44	-5.06	-0.41	1.46e-6	Calcium levels;
TGCT	cis	rs3096299	0.658	rs12443705	chr16:89547054	C/G	cg02187348	chr16:89574699	SPG7	0.63	6.73	0.52	5.51e-10	Multiple myeloma (IgH translocation);
TGCT	cis	rs921968	0.678	rs660432	chr2:219432127	C/T	cg02176678	chr2:219576539	TTLL4	0.38	5.48	0.44	2.31e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs57590327	0.679	rs13082609	chr3:81642131	A/G	cg07356753	chr3:81810745	GBE1	-0.56	-4.64	-0.38	8.77e-6	Extraversion;
TGCT	cis	rs617219	0.698	rs72764983	chr5:78513806	T/C	cg23514016	chr5:78407564	BHMT	0.34	5.2	0.42	7.9e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs921968	0.643	rs62191565	chr2:219482017	C/T	cg02176678	chr2:219576539	TTLL4	0.45	6.5	0.5	1.79e-9	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs6089829	0.888	rs6011559	chr20:61675620	C/T	cg03213289	chr20:61660250	NA	-0.68	-8.39	-0.6	8.97e-14	Prostate cancer (SNP x SNP interaction);
TGCT	trans	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg10840412	chr1:235813424	GNG4	1.04	8.16	0.59	3.22e-13	Bipolar disorder;
TGCT	cis	rs73201462	1.000	rs2811416	chr3:127991938	A/G	cg06138505	chr3:127317209	MCM2	-0.88	-4.56	-0.38	1.2e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs7830933	0.822	rs13249197	chr8:23578404	G/T	cg04349084	chr8:23602677	NA	0.23	4.44	0.37	1.98e-5	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
TGCT	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.02	7.55	0.56	8.3e-12	Platelet count;
TGCT	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg11764359	chr7:65958608	NA	-0.6	-5.32	-0.43	4.63e-7	Aortic root size;
TGCT	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg03161606	chr19:29218774	NA	0.6	5.84	0.46	4.28e-8	Methadone dose in opioid dependence;
TGCT	cis	rs593982	0.920	rs1151500	chr11:65481166	T/C	cg08755490	chr11:65554678	OVOL1	1.35	8.22	0.59	2.34e-13	Atopic dermatitis;
TGCT	trans	rs853410	0.516	rs6939049	chr6:4009723	G/A	cg13911294	chr9:88951310	ZCCHC6	-0.64	-6.66	-0.51	8.02e-10	Night sleep phenotypes;
TGCT	cis	rs73198271	0.523	rs11787172	chr8:8538201	G/A	ch.8.214553F	chr8:8189620	PRAGMIN	-0.32	-5.2	-0.42	7.83e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs8177179	0.666	rs4075352	chr3:133468012	A/G	cg16414030	chr3:133502952	NA	-0.36	-4.86	-0.4	3.5e-6	Iron status biomarkers (transferrin levels);
TGCT	cis	rs4242434	0.927	rs11781149	chr8:22473158	C/T	cg03733263	chr8:22462867	KIAA1967	1.15	20.1	0.87	7.99e-41	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs9467773	0.967	rs9358954	chr6:26531178	A/G	cg05738196	chr6:26577821	NA	0.88	12.5	0.75	1.03e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs68170813	0.559	rs78267892	chr7:106823734	C/T	cg02696742	chr7:106810147	HBP1	-0.72	-6.28	-0.49	5.29e-9	Coronary artery disease;
TGCT	cis	rs2180341	1.000	rs6569480	chr6:127621748	A/G	cg27446573	chr6:127587934	RNF146	1.03	9.89	0.66	2.34e-17	Breast cancer;
TGCT	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg25703541	chr22:24373054	LOC391322	-0.89	-10.3	-0.68	2.39e-18	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs709400	0.628	rs1989565	chr14:103862193	G/A	cg12935359	chr14:103987150	CKB	0.34	5.2	0.42	7.86e-7	Body mass index;
TGCT	cis	rs10892173	0.566	rs2298649	chr11:117672225	A/G	cg04064380	chr11:117688259	NA	-0.5	-4.48	-0.37	1.66e-5	Myopia;
TGCT	cis	rs9910055	0.529	rs228757	chr17:42164885	G/C	cg19774624	chr17:42201019	HDAC5	0.71	6.35	0.5	3.71e-9	Total body bone mineral density;
TGCT	cis	rs7085104	0.632	rs4290163	chr10:104610926	G/T	cg04362960	chr10:104952993	NT5C2	0.56	4.94	0.41	2.49e-6	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs1525293	0.670	rs10269838	chr7:70490427	C/T	cg21135135	chr7:70597687	WBSCR17	-0.48	-4.7	-0.39	6.81e-6	Colonoscopy-negative controls vs population controls;Major depressive disorder;
TGCT	cis	rs72647484	1.000	rs72647484	chr1:22587728	T/C	cg21876283	chr1:22149684	LDLRAD2;HSPG2	0.27	4.49	0.37	1.6e-5	Colorectal cancer;
TGCT	trans	rs7819412	0.668	rs920047	chr8:11087475	C/T	cg15556689	chr8:8085844	FLJ10661	-0.81	-7.89	-0.58	1.38e-12	Triglycerides;
TGCT	trans	rs4650994	1.000	rs10798615	chr1:178513895	T/G	cg05059571	chr16:84539110	KIAA1609	-0.41	-7.67	-0.57	4.33e-12	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs74544699	0.826	rs3756074	chr4:74848065	G/C	cg15398841	chr4:74847761	PF4	0.88	4.87	0.4	3.3e-6	Growth-regulated protein alpha levels;
TGCT	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.12	0.42	1.12e-6	Prudent dietary pattern;
TGCT	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs1008375	1.000	rs28501187	chr4:17643620	G/A	cg16339924	chr4:17578868	LAP3	0.64	5.47	0.44	2.42e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg19774624	chr17:42201019	HDAC5	-0.76	-7.67	-0.57	4.24e-12	Total body bone mineral density;
TGCT	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg07343612	chr16:622815	PIGQ	-0.42	-8.39	-0.6	9.08e-14	Height;
TGCT	trans	rs7864133	1.000	rs11139255	chr9:84064152	A/T	cg23451063	chr7:1059876	C7orf50	0.55	6.93	0.53	2.02e-10	Post bronchodilator FEV1 in COPD;
TGCT	cis	rs2204008	0.577	rs11520050	chr12:38051839	G/A	cg26384229	chr12:38710491	ALG10B	0.86	7.77	0.57	2.55e-12	Bladder cancer;
TGCT	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg24829409	chr8:58192753	C8orf71	-0.59	-4.97	-0.41	2.17e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4919694	1.000	rs17727044	chr10:104821256	A/T	cg04362960	chr10:104952993	NT5C2	1.07	7.09	0.54	8.9e-11	Arsenic metabolism;
TGCT	cis	rs9457247	0.935	rs2757050	chr6:167377165	G/T	cg23791538	chr6:167370224	RNASET2	0.5	4.98	0.41	2.06e-6	Crohn's disease;
TGCT	cis	rs17102423	0.755	rs11158574	chr14:65579467	T/G	cg11161011	chr14:65562177	MAX	-0.55	-7.3	-0.55	3.01e-11	Obesity-related traits;
TGCT	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg03060546	chr3:49711283	APEH	0.5	4.83	0.4	3.89e-6	Menarche (age at onset);
TGCT	cis	rs7246657	0.943	rs4452075	chr19:37879589	A/G	cg18154014	chr19:37997991	ZNF793	0.74	5.33	0.43	4.48e-7	Coronary artery calcification;
TGCT	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg08280861	chr8:58055591	NA	0.4	4.56	0.38	1.22e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs10479542	0.896	rs10078712	chr5:178978805	C/T	cg19626725	chr5:178986131	RUFY1	-0.45	-5.52	-0.44	1.9e-7	Lung cancer;
TGCT	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg12311346	chr5:56204834	C5orf35	-0.67	-6.68	-0.51	7.25e-10	Initial pursuit acceleration;
TGCT	cis	rs7226408	1.000	rs485935	chr18:34370503	C/A	cg06757138	chr18:34340585	FHOD3	0.28	4.76	0.39	5.23e-6	Obesity-related traits;
TGCT	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg12963246	chr6:28129442	ZNF389	0.52	5.01	0.41	1.85e-6	Parkinson's disease;
TGCT	cis	rs10751667	0.666	rs7396677	chr11:958878	C/T	cg06064525	chr11:970664	AP2A2	-0.35	-8.23	-0.59	2.17e-13	Alzheimer's disease (late onset);
TGCT	cis	rs1878931	0.501	rs9302871	chr16:3415512	T/C	cg05754148	chr16:3507555	NAT15	-0.33	-4.46	-0.37	1.82e-5	Body mass index (adult);
TGCT	trans	rs34421088	0.560	rs2248699	chr8:11393764	A/G	cg15556689	chr8:8085844	FLJ10661	-0.78	-7.43	-0.56	1.56e-11	Neuroticism;
TGCT	cis	rs17826219	0.568	rs9903854	chr17:29153998	C/T	cg14008862	chr17:28927542	LRRC37B2	0.75	5.06	0.41	1.5e-6	Body mass index;
TGCT	cis	rs9581857	0.685	rs9581856	chr13:28025615	G/C	cg22138327	chr13:27999177	GTF3A	0.76	5.41	0.44	3.1e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	trans	rs561341	0.941	rs550213	chr17:30317518	C/G	cg20587970	chr11:113659929	NA	-1.05	-12.74	-0.75	2.84e-24	Hip circumference adjusted for BMI;
TGCT	trans	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg21659725	chr3:3221576	CRBN	-0.76	-9.03	-0.63	2.74e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg22963979	chr7:1858916	MAD1L1	-0.38	-5.99	-0.47	2.12e-8	Bipolar disorder and schizophrenia;
TGCT	cis	rs12908161	1.000	rs4643294	chr15:85250253	C/T	cg11189052	chr15:85197271	WDR73	0.75	6.29	0.49	5.02e-9	Schizophrenia;
TGCT	cis	rs9467773	0.595	rs2172007	chr6:26639777	A/C	cg15659132	chr6:26577336	NA	0.84	10.39	0.68	1.39e-18	Intelligence (multi-trait analysis);
TGCT	cis	rs1801251	0.963	rs35362030	chr2:233612845	A/G	cg08000102	chr2:233561755	GIGYF2	0.64	6.52	0.51	1.58e-9	Coronary artery disease;
TGCT	cis	rs12477438	0.501	rs13033012	chr2:99795149	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	10.3	0.68	2.42e-18	Chronic sinus infection;
TGCT	cis	rs16958440	0.867	rs9304342	chr18:44720199	T/G	cg17192377	chr18:44677553	HDHD2	0.63	4.7	0.39	6.74e-6	Sitting height ratio;
TGCT	cis	rs9457247	1.000	rs407515	chr6:167407544	G/C	cg23791538	chr6:167370224	RNASET2	-0.49	-4.96	-0.41	2.31e-6	Crohn's disease;
TGCT	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg23758822	chr17:41437982	NA	0.72	6.96	0.53	1.79e-10	Menopause (age at onset);
TGCT	cis	rs748404	0.631	rs7166812	chr15:43644760	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	4.72	0.39	6.3e-6	Lung cancer;
TGCT	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg21724239	chr8:58056113	NA	0.39	5.29	0.43	5.44e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2288278	0.601	rs11079825	chr17:46596312	C/T	cg25032089	chr17:46643351	HOXB3	-0.42	-5.01	-0.41	1.86e-6	Hand grip strength;
TGCT	cis	rs838147	0.508	rs507766	chr19:49208543	T/C	cg13540341	chr19:49222985	MAMSTR	-0.38	-4.93	-0.4	2.61e-6	Dietary macronutrient intake;
TGCT	cis	rs6906287	0.647	rs12211576	chr6:118872080	G/A	cg21191810	chr6:118973309	C6orf204	0.26	4.5	0.38	1.51e-5	Electrocardiographic conduction measures;
TGCT	cis	rs11098499	0.530	rs114866537	chr4:120258608	A/T	cg09307838	chr4:120376055	NA	0.55	5.29	0.43	5.31e-7	Corneal astigmatism;
TGCT	trans	rs7819412	0.775	rs4545055	chr8:10935366	T/C	cg15556689	chr8:8085844	FLJ10661	-0.84	-8.16	-0.59	3.12e-13	Triglycerides;
TGCT	cis	rs208520	0.739	rs1935894	chr6:66891434	A/G	cg07460842	chr6:66804631	NA	-0.9	-9.33	-0.64	5.29e-16	Exhaled nitric oxide output;
TGCT	cis	rs6912958	0.781	rs6454631	chr6:88225863	G/A	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.99	-0.41	2.03e-6	Monocyte percentage of white cells;
TGCT	cis	rs889312	0.521	rs12651942	chr5:56088484	C/T	cg24531977	chr5:56204891	C5orf35	-0.48	-4.92	-0.4	2.64e-6	Breast cancer;Breast cancer (early onset);
TGCT	cis	rs7772486	0.558	rs702322	chr6:146007166	G/A	cg23711669	chr6:146136114	FBXO30	-0.73	-6.84	-0.52	3.19e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs644799	0.932	rs572015	chr11:95637416	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	9.92	0.67	1.94e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg18402987	chr7:1209562	NA	0.67	5.93	0.47	2.87e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs11679640	0.836	rs17682575	chr2:43152304	C/T	cg18281102	chr2:44065550	ABCG5;ABCG8	-0.26	-4.62	-0.38	9.58e-6	White matter hyperintensity burden;
TGCT	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg06108461	chr20:60628389	TAF4	-0.75	-11.03	-0.7	3.95e-20	Body mass index;
TGCT	cis	rs151997	0.893	rs27607	chr5:50228977	A/G	cg06027927	chr5:50259733	NA	-0.46	-4.6	-0.38	1.03e-5	Callous-unemotional behaviour;
TGCT	cis	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg02380750	chr20:61661411	NA	0.34	6.02	0.48	1.86e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg03709012	chr19:19516395	GATAD2A	0.67	5.75	0.46	6.45e-8	Tonsillectomy;
TGCT	cis	rs8056742	0.730	rs116531971	chr16:85072347	T/C	cg00229868	chr16:85520891	NA	0.4	5.18	0.42	8.9e-7	Amyotrophic lateral sclerosis;
TGCT	cis	rs10501293	0.584	rs7120544	chr11:43040945	T/C	cg03447554	chr11:43094025	NA	0.33	4.5	0.37	1.53e-5	Cognitive performance;
TGCT	cis	rs877282	0.898	rs12356709	chr10:763365	A/G	cg17470449	chr10:769945	NA	0.36	5.17	0.42	9.01e-7	Uric acid levels;
TGCT	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg06618935	chr21:46677482	NA	-0.37	-5.56	-0.45	1.58e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7267979	0.753	rs404148	chr20:25447931	A/G	cg03522245	chr20:25566470	NINL	0.52	5.2	0.42	8.01e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3924048	0.559	rs6541038	chr1:12626210	G/T	cg00291366	chr1:12616550	NA	0.32	5.01	0.41	1.86e-6	Optic cup area;
TGCT	cis	rs6750795	0.870	rs6754952	chr2:232381245	G/T	cg19187155	chr2:232395269	NMUR1	-0.53	-6.3	-0.49	4.78e-9	Height;
TGCT	cis	rs7611238	0.560	rs60100329	chr3:195078662	A/C	cg27323046	chr3:195102265	ACAP2	0.37	4.93	0.4	2.56e-6	Body mass index;
TGCT	cis	rs860554	0.595	rs12025174	chr1:201258309	G/A	cg01022117	chr1:201258280	PKP1	-0.35	-6.85	-0.52	3.1e-10	Panic disorder;
TGCT	cis	rs477895	0.713	rs12575642	chr11:63979643	G/T	cg23719950	chr11:63933701	MACROD1	-0.72	-6.16	-0.48	9.41e-9	Mean platelet volume;
TGCT	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg06238570	chr21:40685208	BRWD1	0.58	5.11	0.42	1.16e-6	Cognitive function;
TGCT	cis	rs9549367	0.713	rs576463	chr13:113846614	C/T	cg09473364	chr13:112927190	NA	0.29	4.64	0.38	8.73e-6	Platelet distribution width;
TGCT	cis	rs12681287	0.640	rs7820234	chr8:87350950	A/C	cg27223183	chr8:87520930	FAM82B	-0.9	-6.71	-0.52	6.12e-10	Caudate activity during reward;
TGCT	cis	rs5821446	1	rs5821446	chr17:65962538	A/AT	cg12091567	chr17:66097778	LOC651250	0.81	6.14	0.48	1.02e-8	Eosinophil percentage of granulocytes;
TGCT	cis	rs11997175	0.574	rs4370495	chr8:33654819	G/A	ch.8.33884649F	chr8:33765107	NA	0.28	4.54	0.38	1.33e-5	Body mass index;
TGCT	cis	rs3020736	0.500	rs6002623	chr22:42513761	G/A	cg15557168	chr22:42548783	NA	0.22	5.58	0.45	1.47e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs977747	0.872	rs6695898	chr1:47681761	G/A	cg03885399	chr1:47691550	TAL1	-0.43	-5.44	-0.44	2.72e-7	Body mass index;
TGCT	cis	rs17221829	0.645	rs12288897	chr11:89388816	C/T	cg02982614	chr11:89391479	FOLH1B	-0.25	-4.46	-0.37	1.8e-5	Anxiety in major depressive disorder;
TGCT	cis	rs4938573	0.526	rs11216973	chr11:118587001	T/C	cg19308663	chr11:118741387	NA	0.25	4.48	0.37	1.66e-5	Follicular lymphoma;
TGCT	cis	rs12967678	1	rs12967678	chr18:12805388	G/A	cg23544223	chr18:12777786	NA	-0.66	-5.33	-0.43	4.42e-7	Selective IgA deficiency;
TGCT	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg23708337	chr7:1209742	NA	0.6	5.57	0.45	1.53e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9467773	0.626	rs6936006	chr6:26350565	A/G	cg05738196	chr6:26577821	NA	-0.63	-6.77	-0.52	4.5e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs7819412	0.642	rs11250117	chr8:10972740	C/A	cg12940923	chr8:10282607	MSRA	-0.19	-4.6	-0.38	1.05e-5	Triglycerides;
TGCT	cis	rs981844	0.712	rs1456397	chr4:154744554	C/G	cg14289246	chr4:154710475	SFRP2	1.0	9.35	0.64	4.84e-16	Response to statins (LDL cholesterol change);
TGCT	cis	rs10751667	0.643	rs12278229	chr11:946985	A/G	cg06064525	chr11:970664	AP2A2	-0.36	-8.24	-0.59	2.11e-13	Alzheimer's disease (late onset);
TGCT	cis	rs7666738	0.830	rs28818218	chr4:98880575	A/C	cg18180107	chr4:99064573	C4orf37	0.57	5.19	0.42	8.47e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs13223928	0.605	rs10951052	chr7:3155301	A/G	cg19214707	chr7:3157722	NA	-0.45	-6.06	-0.48	1.54e-8	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
TGCT	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg07157834	chr1:205819609	PM20D1	0.45	7.32	0.55	2.76e-11	Menarche (age at onset);
TGCT	cis	rs7647973	0.710	rs12637313	chr3:49645458	A/G	cg03060546	chr3:49711283	APEH	0.63	5.14	0.42	1.03e-6	Menarche (age at onset);
TGCT	cis	rs7937682	0.632	rs11214037	chr11:111773296	C/T	cg09085632	chr11:111637200	PPP2R1B	0.84	7.33	0.55	2.55e-11	Primary sclerosing cholangitis;
TGCT	cis	rs1018836	0.798	rs4735295	chr8:91671608	C/A	cg16814680	chr8:91681699	NA	-0.97	-12.22	-0.74	5.02e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs17384381	1.000	rs12132677	chr1:85879613	A/C	cg16011679	chr1:85725395	C1orf52	0.8	6.44	0.5	2.39e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4595586	0.525	rs12809307	chr12:39365927	A/G	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs2180341	0.960	rs7745944	chr6:127709574	A/G	cg27446573	chr6:127587934	RNF146	1.16	10.47	0.68	9.13e-19	Breast cancer;
TGCT	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg07343612	chr16:622815	PIGQ	-0.42	-8.53	-0.61	4.32e-14	Height;
TGCT	cis	rs4523957	0.614	rs7217108	chr17:2059408	G/C	cg16513277	chr17:2031491	SMG6	-0.2	-4.64	-0.38	8.83e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs208520	0.955	rs17644076	chr6:67004973	A/G	cg07460842	chr6:66804631	NA	-0.68	-5.96	-0.47	2.41e-8	Exhaled nitric oxide output;
TGCT	cis	rs2549003	1.000	rs6873426	chr5:131818631	G/T	cg00255919	chr5:131827918	IRF1	0.22	5.15	0.42	1.01e-6	Asthma (sex interaction);
TGCT	cis	rs1218582	0.741	rs11264291	chr1:154914797	C/T	cg24250549	chr1:154909240	PMVK	0.63	6.45	0.5	2.25e-9	Prostate cancer;
TGCT	cis	rs17122693	0.748	rs57198801	chr14:51119456	T/C	cg04730355	chr14:51134070	SAV1	1.35	12.44	0.75	1.47e-23	Cognitive performance;
TGCT	cis	rs17376456	0.877	rs17315943	chr5:93442830	T/C	cg25358565	chr5:93447407	FAM172A	0.92	8.38	0.6	9.58e-14	Diabetic retinopathy;
TGCT	cis	rs7917772	0.582	rs7087984	chr10:104380686	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.56	5.47	0.44	2.35e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs727505	1.000	rs66922607	chr7:124512555	T/A	cg23710748	chr7:124431027	NA	-0.26	-4.49	-0.37	1.6e-5	Lewy body disease;
TGCT	cis	rs10197940	0.710	rs4500942	chr2:152334580	A/G	cg06191203	chr2:152266755	RIF1	-0.8	-7.89	-0.58	1.39e-12	Lung cancer;
TGCT	cis	rs7523050	0.643	rs12729998	chr1:109405505	T/C	cg08274380	chr1:109419600	GPSM2	1.3	6.39	0.5	2.99e-9	Fat distribution (HIV);
TGCT	cis	rs9814567	0.929	rs9838834	chr3:134207077	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.93	-9.27	-0.64	7.51e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs4808199	0.895	rs12981405	chr19:19651577	C/T	cg03709012	chr19:19516395	GATAD2A	0.98	6.87	0.52	2.78e-10	Nonalcoholic fatty liver disease;
TGCT	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg03188948	chr7:1209495	NA	0.5	5.23	0.43	6.99e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs10256972	0.514	rs2140578	chr7:1214003	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.51	-5.57	-0.45	1.5e-7	Longevity;Endometriosis;
TGCT	cis	rs611744	0.967	rs2600615	chr8:109201170	G/A	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs7570971	0.617	rs1869829	chr2:135877562	C/T	cg07169764	chr2:136633963	MCM6	-0.62	-4.86	-0.4	3.41e-6	Blood metabolite levels;Body mass index;Cholesterol, total;
TGCT	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg12963246	chr6:28129442	ZNF389	0.53	5.09	0.42	1.27e-6	Depression;
TGCT	cis	rs6570726	0.791	rs1280275	chr6:145892402	C/T	cg13319975	chr6:146136371	FBXO30	-0.5	-4.51	-0.38	1.48e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7831492	0.564	rs6981979	chr8:41612255	C/T	cg17182837	chr8:41585554	ANK1	-0.17	-4.52	-0.38	1.44e-5	Colorectal cancer;
TGCT	cis	rs71597109	0.568	rs11940244	chr4:102727575	G/T	cg14855874	chr4:102712397	BANK1	0.41	4.72	0.39	6.16e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs3821902	0.547	rs56237630	chr3:64049375	C/A	cg22134162	chr3:63841271	THOC7	-0.33	-4.91	-0.4	2.82e-6	Breast cancer;
TGCT	cis	rs7666738	0.830	rs34892904	chr4:98938097	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9814567	0.712	rs9838119	chr3:134331980	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-6.41	-0.5	2.8e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs4523957	0.583	rs6503302	chr17:2052704	C/T	cg16513277	chr17:2031491	SMG6	-0.2	-4.64	-0.38	8.69e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9372253	1.000	rs9384740	chr6:110716207	G/A	cg01119278	chr6:110721349	DDO	-0.35	-5.68	-0.45	9e-8	Platelet distribution width;
TGCT	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg21724239	chr8:58056113	NA	0.39	5.29	0.43	5.33e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7547997	0.517	rs6687405	chr1:158240757	T/G	cg03528325	chr1:158223921	CD1A	0.34	4.58	0.38	1.11e-5	QRS duration;
TGCT	cis	rs17001868	0.568	rs3788579	chr22:40742989	T/C	cg07138101	chr22:40742427	ADSL	0.72	5.25	0.43	6.46e-7	Mammographic density (dense area);
TGCT	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg08859206	chr1:53392774	SCP2	-0.42	-6.4	-0.5	2.95e-9	Monocyte count;
TGCT	cis	rs10493773	0.609	rs12058974	chr1:86192235	T/A	cg17807903	chr1:86174739	ZNHIT6	-0.52	-8.15	-0.59	3.45e-13	Urate levels in overweight individuals;
TGCT	cis	rs9359856	0.636	rs9294440	chr6:90308666	C/G	cg13799429	chr6:90582589	CASP8AP2	0.45	4.61	0.38	9.8e-6	Bipolar disorder;
TGCT	cis	rs644799	0.601	rs662168	chr11:95586982	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.69	7.18	0.54	5.72e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs12765878	1.000	rs12765878	chr10:105669622	C/T	cg11005552	chr10:105648138	OBFC1	-0.44	-7.7	-0.57	3.69e-12	Coronary artery disease;
TGCT	cis	rs2115630	0.905	rs6496401	chr15:85297793	A/T	cg12501888	chr15:85177176	SCAND2	-0.48	-4.49	-0.37	1.6e-5	P wave terminal force;
TGCT	cis	rs7584330	0.737	rs7568588	chr2:238364342	G/T	cg14458575	chr2:238380390	NA	0.51	8.14	0.59	3.53e-13	Prostate cancer;
TGCT	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.45	-6.02	-0.48	1.8e-8	Alzheimer's disease;
TGCT	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.48	-0.37	1.66e-5	Bipolar disorder;
TGCT	cis	rs617219	0.853	rs57587638	chr5:78513167	C/T	cg09550809	chr5:78407562	BHMT	0.35	4.56	0.38	1.22e-5	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs514406	0.505	rs6688064	chr1:53165609	C/T	cg16325326	chr1:53192061	ZYG11B	0.85	11.53	0.72	2.38e-21	Monocyte count;
TGCT	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg03806693	chr22:41940476	POLR3H	-1.13	-12.67	-0.75	4.12e-24	Vitiligo;
TGCT	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.63	-6.58	-0.51	1.2e-9	Longevity;Endometriosis;
TGCT	cis	rs10501293	1.000	rs12222341	chr11:43126722	T/G	cg03447554	chr11:43094025	NA	-0.49	-6.9	-0.53	2.33e-10	Cognitive performance;
TGCT	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg06108461	chr20:60628389	TAF4	-0.69	-10.77	-0.7	1.71e-19	Body mass index;
TGCT	cis	rs7611238	0.560	rs11718226	chr3:195054345	C/A	cg27323046	chr3:195102265	ACAP2	0.35	4.75	0.39	5.5e-6	Body mass index;
TGCT	cis	rs1691799	0.867	rs1168338	chr12:66759369	T/C	cg16791601	chr12:66731901	HELB	-0.29	-6.18	-0.49	8.39e-9	White blood cell count (basophil);
TGCT	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.63	-6.61	-0.51	1.01e-9	Longevity;Endometriosis;
TGCT	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg25767906	chr1:53392781	SCP2	-0.55	-6.3	-0.49	4.75e-9	Monocyte count;
TGCT	cis	rs797680	0.856	rs1335679	chr1:93645182	C/T	cg17826107	chr1:92977322	EVI5	-0.24	-5.27	-0.43	5.93e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs9653442	0.648	rs6733895	chr2:100666082	C/G	cg07810366	chr2:100720526	AFF3	-0.42	-7.18	-0.54	5.78e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs6964587	0.610	rs6465338	chr7:91450624	T/C	cg17063962	chr7:91808500	NA	0.73	6.69	0.52	6.75e-10	Breast cancer;
TGCT	cis	rs7731657	0.537	rs3981333	chr5:130375045	A/T	cg08523029	chr5:130500466	HINT1	-0.64	-5.33	-0.43	4.38e-7	Fasting plasma glucose;
TGCT	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-5.1	-0.42	1.23e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs877282	0.898	rs11253339	chr10:759640	C/T	cg17470449	chr10:769945	NA	0.36	5.35	0.43	4.04e-7	Uric acid levels;
TGCT	cis	rs9942416	0.660	rs4704234	chr5:75001432	A/G	cg00601450	chr5:74908170	NA	0.38	4.65	0.39	8.34e-6	Age-related disease endophenotypes;
TGCT	cis	rs3087591	0.801	rs2012535	chr17:29561391	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.48	-7.68	-0.57	4.06e-12	Hip circumference;
TGCT	cis	rs36051895	0.623	rs4358852	chr9:5251238	C/T	cg02405213	chr9:5042618	JAK2	-0.73	-9.79	-0.66	4.1e-17	Pediatric autoimmune diseases;
TGCT	cis	rs2692947	0.696	rs2576437	chr2:96800417	T/C	cg22654517	chr2:96458247	NA	0.22	4.83	0.4	4e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg12923728	chr3:195709715	SDHAP1	-0.37	-7.3	-0.55	3.07e-11	Pancreatic cancer;
TGCT	cis	rs4253772	0.513	rs9306512	chr22:46716603	T/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.7	5.14	0.42	1.02e-6	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs1577917	0.710	rs1059306	chr6:86388109	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.63	5.58	0.45	1.43e-7	Response to antipsychotic treatment;
TGCT	cis	rs3806843	0.546	rs246023	chr5:140333990	G/T	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs55823223	0.564	rs9894009	chr17:73850414	C/T	cg08125733	chr17:73851984	WBP2	0.87	8.8	0.62	1e-14	Psoriasis;
TGCT	cis	rs9916302	0.706	rs11657153	chr17:37699729	A/G	cg03321784	chr17:37729644	NA	0.44	4.58	0.38	1.1e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg23156509	chr2:114033830	PAX8;LOC440839	-0.31	-4.83	-0.4	3.92e-6	Lymphocyte counts;
TGCT	cis	rs28595532	0.920	rs116023902	chr4:119725131	A/G	cg14228332	chr4:119757509	SEC24D	1.38	6.93	0.53	2.07e-10	Cannabis dependence symptom count;
TGCT	cis	rs6061231	1.000	rs67941642	chr20:60958108	C/T	cg24112000	chr20:60950667	NA	-0.36	-5.23	-0.42	7.05e-7	Colorectal cancer;
TGCT	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg06238570	chr21:40685208	BRWD1	0.69	6.41	0.5	2.71e-9	Cognitive function;
TGCT	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg26118208	chr10:134322334	NA	0.26	5.0	0.41	1.92e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs763014	0.865	rs8909	chr16:633851	T/C	cg00908189	chr16:619842	PIGQ	0.87	10.5	0.69	7.53e-19	Height;
TGCT	cis	rs28374715	0.578	rs8036026	chr15:41630499	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.9	-14.93	-0.8	1.76e-29	Ulcerative colitis;
TGCT	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg12756686	chr19:29218302	NA	0.76	6.49	0.5	1.85e-9	Methadone dose in opioid dependence;
TGCT	cis	rs17125944	0.556	rs7152229	chr14:53313405	T/C	cg00686598	chr14:53173677	PSMC6	-0.86	-4.71	-0.39	6.42e-6	Alzheimer's disease (late onset);
TGCT	cis	rs7178424	0.806	rs4775453	chr15:62217391	A/C	cg00456672	chr15:62358751	C2CD4A	0.31	4.73	0.39	6.09e-6	Height;
TGCT	cis	rs7666738	0.830	rs34461023	chr4:99023751	C/T	cg17366294	chr4:99064904	C4orf37	0.74	7.62	0.56	5.53e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1691799	0.867	rs2172881	chr12:66766039	C/G	cg16791601	chr12:66731901	HELB	-0.28	-6.01	-0.47	1.94e-8	White blood cell count (basophil);
TGCT	cis	rs2075371	0.527	rs1862046	chr7:134023524	T/C	cg11752832	chr7:134001865	SLC35B4	0.67	5.47	0.44	2.34e-7	Mean platelet volume;
TGCT	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg05665937	chr4:1216051	CTBP1	0.25	4.68	0.39	7.33e-6	Obesity-related traits;
TGCT	cis	rs9467773	0.620	rs2494692	chr6:26615223	G/A	cg26531700	chr6:26746687	NA	0.53	5.04	0.41	1.58e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7611238	0.538	rs13316914	chr3:195153124	C/T	cg27323046	chr3:195102265	ACAP2	0.39	5.14	0.42	1.05e-6	Body mass index;
TGCT	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	5.07	0.41	1.42e-6	Electroencephalogram traits;
TGCT	cis	rs9916302	0.904	rs8076546	chr17:37555403	G/A	cg07936489	chr17:37558343	FBXL20	0.65	4.98	0.41	2.11e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs4886920	0.563	rs8039011	chr15:78078445	A/G	cg03457338	chr15:78040120	NA	0.18	4.51	0.38	1.48e-5	Neuroticism;
TGCT	cis	rs6988636	1.000	rs16898088	chr8:124190501	G/A	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs2857078	1.000	rs2857078	chr17:42330171	A/C	cg19774624	chr17:42201019	HDAC5	0.62	5.7	0.46	8.17e-8	Red cell distribution width;Reticulocyte count;
TGCT	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/A	cg11502198	chr6:26597334	ABT1	0.52	4.64	0.38	8.69e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2239547	0.563	rs4302374	chr3:52905802	T/C	cg10802521	chr3:52805072	NEK4	-0.58	-5.46	-0.44	2.53e-7	Schizophrenia;
TGCT	cis	rs3806843	0.735	rs801167	chr5:140081423	A/G	cg19875535	chr5:140030758	IK	0.36	6.09	0.48	1.31e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7804356	1.000	rs73065517	chr7:26830555	T/C	cg03456212	chr7:26904342	SKAP2	-0.63	-4.88	-0.4	3.19e-6	Type 1 diabetes;
TGCT	cis	rs932287	0.540	rs4910442	chr11:9044337	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.43	4.8	0.4	4.55e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12220238	1.000	rs10762582	chr10:75968316	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.91	7.77	0.57	2.63e-12	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs2836950	0.545	rs2836922	chr21:40516308	C/T	cg17971929	chr21:40555470	PSMG1	-0.54	-4.98	-0.41	2.06e-6	Menarche (age at onset);
TGCT	cis	rs6429082	0.713	rs867363	chr1:235579727	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.57	-5.03	-0.41	1.7e-6	Adiposity;
TGCT	cis	rs9467773	0.620	rs2451738	chr6:26618459	A/T	cg15659132	chr6:26577336	NA	-0.81	-10.32	-0.68	2.15e-18	Intelligence (multi-trait analysis);
TGCT	cis	rs9325144	0.555	rs4882358	chr12:38726640	A/G	cg13010199	chr12:38710504	ALG10B	0.52	4.54	0.38	1.32e-5	Morning vs. evening chronotype;
TGCT	cis	rs6882046	0.513	rs628158	chr5:88041781	G/A	cg22951263	chr5:87985283	NA	-0.55	-5.91	-0.47	3.09e-8	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs28595532	0.841	rs116452272	chr4:119770802	T/C	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs2486288	0.656	rs11854365	chr15:45558083	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.75	-7.78	-0.57	2.39e-12	Glomerular filtration rate;
TGCT	cis	rs1941023	0.503	rs4939350	chr11:60136243	C/G	cg08716584	chr11:60157161	MS4A7	-0.31	-4.56	-0.38	1.21e-5	Congenital heart disease (maternal effect);
TGCT	trans	rs1814175	0.669	rs10839315	chr11:49654406	G/A	cg15704280	chr7:45808275	SEPT13	-0.63	-7.39	-0.55	1.92e-11	Height;
TGCT	cis	rs2688608	0.530	rs71507081	chr10:75493136	G/A	cg15838173	chr10:75533400	FUT11	-0.31	-5.02	-0.41	1.73e-6	Inflammatory bowel disease;
TGCT	trans	rs2727020	0.658	rs10839278	chr11:49450847	G/C	cg15704280	chr7:45808275	SEPT13	-0.77	-8.75	-0.62	1.29e-14	Coronary artery disease;
TGCT	cis	rs7267979	0.934	rs2261753	chr20:25262291	G/A	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2067615	0.524	rs10778498	chr12:107063340	C/A	cg15890332	chr12:107067104	RFX4	0.28	5.56	0.45	1.59e-7	Heart rate;
TGCT	cis	rs877282	1.000	rs34257857	chr10:772993	C/A	cg17470449	chr10:769945	NA	0.31	4.8	0.4	4.44e-6	Uric acid levels;
TGCT	cis	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg25660036	chr4:7070649	GRPEL1	-0.6	-5.17	-0.42	9.07e-7	Monocyte percentage of white cells;
TGCT	trans	rs8073060	0.586	rs7217533	chr17:34015876	A/G	cg19694781	chr19:47549865	TMEM160	-0.6	-13.37	-0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs7246657	0.722	rs4802051	chr19:38072328	C/A	cg03611452	chr19:38183253	ZNF781	0.6	4.83	0.4	3.97e-6	Coronary artery calcification;
TGCT	cis	rs7666738	0.830	rs28785514	chr4:98959135	G/A	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs66573146	0.831	rs56031152	chr4:6973832	C/A	cg07817883	chr1:32538562	TMEM39B	1.42	7.53	0.56	8.92e-12	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg06873352	chr17:61820015	STRADA	0.55	6.13	0.48	1.09e-8	Prudent dietary pattern;
TGCT	cis	rs80282103	0.618	rs1079389	chr10:1161980	A/G	cg18964960	chr10:1102726	WDR37	1.03	4.55	0.38	1.28e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs926938	0.521	rs360649	chr1:115439668	G/C	cg12756093	chr1:115239321	AMPD1	0.4	6.05	0.48	1.58e-8	Autism;
TGCT	cis	rs12049351	0.613	rs12037690	chr1:229642385	G/A	cg12130225	chr1:229698885	NA	0.39	4.6	0.38	1.02e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs861020	0.959	rs658860	chr1:209990549	C/T	cg05527609	chr1:210001259	C1orf107	0.91	7.4	0.55	1.84e-11	Orofacial clefts;
TGCT	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg18402987	chr7:1209562	NA	0.7	5.67	0.45	9.66e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs28374715	0.662	rs13329579	chr15:41467435	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.81	-11.41	-0.72	4.6e-21	Ulcerative colitis;
TGCT	cis	rs854765	0.647	rs7406744	chr17:17981938	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.69	7.2	0.54	5.18e-11	Total body bone mineral density;
TGCT	cis	rs137603	1.000	rs137607	chr22:39695505	G/A	cg17798944	chr22:39715225	SNORD43;RPL3	-0.54	-5.12	-0.42	1.13e-6	Primary biliary cholangitis;
TGCT	cis	rs611744	0.934	rs673356	chr8:109185159	A/T	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg08219700	chr8:58056026	NA	0.37	4.48	0.37	1.71e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs35146811	0.731	rs2257213	chr7:99810113	T/C	cg13334819	chr7:99746414	C7orf59	0.74	6.41	0.5	2.82e-9	Coronary artery disease;
TGCT	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg16423285	chr20:60520624	NA	-0.61	-6.57	-0.51	1.23e-9	Body mass index;
TGCT	cis	rs539096	0.692	rs6686238	chr1:44210253	C/G	cg12908607	chr1:44402522	ARTN	-0.63	-7.43	-0.56	1.52e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs514406	0.929	rs12145105	chr1:53340564	T/C	cg08736216	chr1:53307985	ZYG11A	-0.29	-5.99	-0.47	2.1e-8	Monocyte count;
TGCT	cis	rs916888	0.610	rs199438	chr17:44791643	G/A	cg17911788	chr17:44343683	NA	-0.48	-5.64	-0.45	1.08e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs1059312	0.808	rs4760533	chr12:129297651	A/G	cg09035930	chr12:129282057	SLC15A4	-0.55	-10.97	-0.7	5.38e-20	Systemic lupus erythematosus;
TGCT	cis	rs12681287	0.752	rs10103229	chr8:87248954	C/T	cg27223183	chr8:87520930	FAM82B	0.81	5.64	0.45	1.09e-7	Caudate activity during reward;
TGCT	cis	rs42648	0.642	rs11771963	chr7:89887587	G/T	cg25739043	chr7:89950458	NA	-0.54	-5.04	-0.41	1.62e-6	Homocysteine levels;
TGCT	cis	rs1801251	1.000	rs11679079	chr2:233612656	C/T	cg08000102	chr2:233561755	GIGYF2	0.64	6.56	0.51	1.34e-9	Coronary artery disease;
TGCT	cis	rs2070488	0.804	rs13100195	chr3:38482539	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.78	7.96	0.58	9.56e-13	Electrocardiographic conduction measures;
TGCT	cis	rs9372253	0.678	rs9487392	chr6:110708626	C/T	cg19196401	chr6:110721138	DDO	0.43	5.92	0.47	2.99e-8	Platelet distribution width;
TGCT	cis	rs12950390	0.853	rs10445375	chr17:45864314	C/T	cg24803719	chr17:45855879	NA	0.49	5.03	0.41	1.64e-6	IgG glycosylation;
TGCT	cis	rs28595532	0.764	rs56071514	chr4:119761833	T/C	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs9467711	0.516	rs1324087	chr6:25841408	A/G	cg12310025	chr6:25882481	NA	0.72	4.77	0.39	5.17e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs3806843	0.547	rs246065	chr5:140323638	A/G	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs6558174	0.930	rs12676084	chr8:22493350	C/T	cg03733263	chr8:22462867	KIAA1967	0.65	5.19	0.42	8.19e-7	Breast cancer;
TGCT	cis	rs13191362	0.507	rs2849511	chr6:163139050	C/G	cg21926612	chr6:163149169	PACRG;PARK2	-0.6	-5.42	-0.44	3.04e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs9393692	0.905	rs1124999	chr6:26287043	G/T	cg05868516	chr6:26286170	HIST1H4H	0.63	5.9	0.47	3.18e-8	Educational attainment;
TGCT	cis	rs4299518	1.000	rs4299518	chr3:45809273	C/T	cg04837898	chr3:45731254	SACM1L	0.45	4.59	0.38	1.05e-5	Hirschsprung disease;
TGCT	cis	rs4237845	0.816	rs61935769	chr12:58294344	G/A	cg23860436	chr12:58378763	NA	0.37	5.12	0.42	1.12e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6089584	1.000	rs6089583	chr20:60563624	G/A	cg16423285	chr20:60520624	NA	-0.52	-5.45	-0.44	2.6e-7	Body mass index;
TGCT	cis	rs7666738	0.830	rs28887893	chr4:98963006	G/A	cg18180107	chr4:99064573	C4orf37	0.57	5.18	0.42	8.63e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10791097	0.690	rs12284487	chr11:130729705	T/C	cg05962950	chr11:130786565	SNX19	0.81	9.74	0.66	5.3e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs28595532	1.000	rs56000725	chr4:119637675	G/A	cg11846333	chr4:119757529	SEC24D	0.92	4.59	0.38	1.07e-5	Cannabis dependence symptom count;
TGCT	cis	rs10931896	0.531	rs295117	chr2:201146828	C/T	cg17644776	chr2:200775616	C2orf69	0.26	4.72	0.39	6.19e-6	Systolic blood pressure;
TGCT	cis	rs7666738	0.830	rs6832568	chr4:98994061	G/A	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs61884328	0.733	rs77654484	chr11:47206594	C/A	cg13308137	chr11:47528955	CUGBP1	0.38	4.48	0.37	1.65e-5	Total body bone mineral density (age over 60);
TGCT	cis	rs2070488	0.804	rs13094715	chr3:38504430	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.78	7.85	0.58	1.64e-12	Electrocardiographic conduction measures;
TGCT	cis	rs12497850	0.627	rs4974078	chr3:49009386	C/T	cg06212747	chr3:49208901	KLHDC8B	0.52	5.35	0.43	4.01e-7	Parkinson's disease;
TGCT	cis	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg18188782	chr20:61659543	NA	0.44	5.37	0.43	3.77e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1050631	1.000	rs719147	chr18:33698192	T/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.51	4.98	0.41	2.12e-6	Esophageal squamous cell cancer (length of survival);
TGCT	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg23982607	chr1:1823379	GNB1	-0.55	-8.17	-0.59	2.98e-13	Body mass index;
TGCT	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.56	5.3	0.43	5.22e-7	Menarche (age at onset);
TGCT	cis	rs9818758	0.607	rs34343820	chr3:49309534	C/G	cg07636037	chr3:49044803	WDR6	-1.04	-5.13	-0.42	1.09e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs999943	0.846	rs10947420	chr6:33611061	C/G	cg14003231	chr6:33640908	ITPR3	0.39	4.9	0.4	2.97e-6	Obesity (extreme);
TGCT	trans	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg27523141	chr10:43048294	ZNF37B	0.7	8.15	0.59	3.36e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7192750	0.586	rs8057124	chr16:71972409	T/C	cg06353428	chr16:71660113	MARVELD3	0.77	6.82	0.52	3.61e-10	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs939658	0.805	rs11634903	chr15:79436192	C/T	cg17916960	chr15:79447300	NA	0.53	8.41	0.6	8.3e-14	Refractive error;
TGCT	cis	rs7226408	0.894	rs17652340	chr18:34391103	A/G	cg06757138	chr18:34340585	FHOD3	-0.26	-4.72	-0.39	6.24e-6	Obesity-related traits;
TGCT	cis	rs986417	0.748	rs11158289	chr14:61032390	C/T	cg27398547	chr14:60952738	C14orf39	1.33	10.37	0.68	1.56e-18	Gut microbiota (bacterial taxa);
TGCT	cis	rs12464483	0.524	rs2602772	chr2:30885263	C/A	cg12454169	chr2:30669597	LCLAT1	0.46	5.15	0.42	1.01e-6	Pre-treatment pain in head and neck squamous cell carcinoma;
TGCT	cis	rs7944584	0.610	rs2596407	chr11:47361838	A/G	cg20307385	chr11:47447363	PSMC3	-0.79	-7.99	-0.58	8.1e-13	Fasting blood glucose;Fasting blood glucose (BMI interaction);
TGCT	cis	rs7666738	0.861	rs13139309	chr4:99020916	A/G	cg18180107	chr4:99064573	C4orf37	0.54	5.03	0.41	1.7e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg04772025	chr11:68637568	NA	0.61	6.78	0.52	4.36e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs919433	0.617	rs12619333	chr2:198567638	C/G	cg00792783	chr2:198669748	PLCL1	-0.55	-5.04	-0.41	1.62e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs10057188	1.000	rs34026188	chr5:77855871	C/A	cg06873401	chr5:77792105	LHFPL2	-0.23	-4.62	-0.38	9.39e-6	Pulse pressure;
TGCT	cis	rs61884328	0.777	rs17790342	chr11:47127706	G/A	cg13308137	chr11:47528955	CUGBP1	0.35	4.47	0.37	1.75e-5	Total body bone mineral density (age over 60);
TGCT	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg13409248	chr3:40428643	ENTPD3	0.57	4.57	0.38	1.17e-5	Renal cell carcinoma;
TGCT	cis	rs6570726	0.791	rs408443	chr6:145874643	T/C	cg13319975	chr6:146136371	FBXO30	-0.51	-4.6	-0.38	1.01e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1997103	1.000	rs4590393	chr7:55408990	C/T	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs155076	1.000	rs261406	chr13:21855854	G/A	cg14456004	chr13:21872349	NA	-1.23	-10.21	-0.68	3.9e-18	White matter hyperintensity burden;
TGCT	cis	rs36051895	0.623	rs10975033	chr9:5262567	C/T	cg02405213	chr9:5042618	JAK2	-0.64	-8.14	-0.59	3.49e-13	Pediatric autoimmune diseases;
TGCT	cis	rs1056053	0.514	rs3127334	chr6:166574246	G/A	cg17219086	chr6:166541254	NA	-0.19	-4.5	-0.37	1.55e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs9653442	0.545	rs11123814	chr2:100767082	A/G	cg07810366	chr2:100720526	AFF3	-0.34	-5.13	-0.42	1.1e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs3862260	0.509	rs3795662	chr1:120165135	G/T	cg11530693	chr1:120165357	ZNF697	0.21	4.75	0.39	5.48e-6	Systemic lupus erythematosus;
TGCT	cis	rs7100689	0.622	rs1890890	chr10:82090643	A/T	cg01528321	chr10:82214614	TSPAN14	0.75	7.42	0.55	1.64e-11	Post bronchodilator FEV1;
TGCT	cis	rs9611565	0.592	rs5758405	chr22:42076381	C/A	cg13695892	chr22:41940480	POLR3H	0.9	9.02	0.63	2.89e-15	Vitiligo;
TGCT	cis	rs6088590	1.000	rs12626122	chr20:33425800	A/G	cg06115741	chr20:33292138	TP53INP2	0.65	5.22	0.42	7.25e-7	Coronary artery disease;
TGCT	cis	rs9611565	0.649	rs9623450	chr22:42175231	G/A	cg06634786	chr22:41940651	POLR3H	0.78	7.31	0.55	2.85e-11	Vitiligo;
TGCT	cis	rs319204	0.760	rs319166	chr5:146293197	A/G	cg25021259	chr5:146258546	PPP2R2B	0.36	4.66	0.39	8.15e-6	Schizophrenia;
TGCT	cis	rs8192284	1.000	rs2228145	chr1:154426970	A/C	cg11650704	chr1:154556575	ADAR	0.25	4.49	0.37	1.58e-5	Fibrinogen;C-reactive protein;Fibrinogen levels;
TGCT	cis	rs9467711	1.000	rs9467701	chr6:26312170	G/C	cg26531700	chr6:26746687	NA	-0.94	-5.09	-0.42	1.28e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs262150	1.000	rs262150	chr7:158777934	G/A	cg19418458	chr7:158789849	NA	-0.45	-4.62	-0.38	9.5e-6	Facial morphology (factor 20);
TGCT	cis	rs459571	0.959	rs2520100	chr9:136918137	A/T	cg13789015	chr9:136890014	NCRNA00094	0.4	7.15	0.54	6.64e-11	Platelet distribution width;
TGCT	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg02187348	chr16:89574699	SPG7	0.62	6.72	0.52	5.91e-10	Multiple myeloma (IgH translocation);
TGCT	cis	rs1008375	0.835	rs9760627	chr4:17651508	C/T	cg16339924	chr4:17578868	LAP3	0.67	5.52	0.44	1.89e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs11190604	1.000	rs1417823	chr10:102227886	C/T	cg16342193	chr10:102329863	NA	0.39	5.14	0.42	1.03e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg06221963	chr1:154839813	KCNN3	-0.75	-12.65	-0.75	4.66e-24	Prostate cancer;
TGCT	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg11644478	chr21:40555479	PSMG1	-0.51	-4.77	-0.39	5.15e-6	Menarche (age at onset);
TGCT	cis	rs9611565	0.921	rs5751077	chr22:41720728	G/C	cg13695892	chr22:41940480	POLR3H	-0.72	-7.33	-0.55	2.61e-11	Vitiligo;
TGCT	cis	rs2153535	0.580	rs1115079	chr6:8449615	G/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.76	0.46	6.39e-8	Motion sickness;
TGCT	cis	rs6738485	0.507	rs66569888	chr2:106886967	G/A	cg15412446	chr2:106886593	NA	-0.45	-4.79	-0.39	4.75e-6	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
TGCT	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg07507251	chr3:52567010	NT5DC2	0.46	6.34	0.5	3.8e-9	Bipolar disorder;
TGCT	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg03264133	chr6:25882463	NA	0.52	5.38	0.43	3.59e-7	Blood metabolite levels;
TGCT	cis	rs9435341	0.731	rs4914939	chr1:107558361	A/T	cg09367891	chr1:107599246	PRMT6	0.64	5.42	0.44	2.93e-7	Facial morphology (factor 21, depth of nasal alae);
TGCT	cis	rs9814567	0.806	rs4955526	chr3:134317337	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-6.95	-0.53	1.82e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs7647973	0.516	rs4955418	chr3:49200627	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.55	-5.26	-0.43	6.09e-7	Menarche (age at onset);
TGCT	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg04414720	chr1:150670196	GOLPH3L	0.37	4.81	0.4	4.38e-6	Tonsillectomy;
TGCT	cis	rs11690935	0.595	rs788170	chr2:172919958	T/C	cg13550731	chr2:172543902	DYNC1I2	0.69	6.36	0.5	3.49e-9	Schizophrenia;
TGCT	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg13628971	chr7:2884303	GNA12	0.54	4.64	0.38	8.74e-6	Height;
TGCT	cis	rs13191362	0.935	rs7767254	chr6:162954674	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.67	5.16	0.42	9.64e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs6589563	0.609	rs56225305	chr11:116625362	G/A	cg01124546	chr11:117515332	DSCAML1	-0.44	-4.77	-0.39	5.18e-6	Eosinophil counts;
TGCT	cis	rs7726839	0.540	rs72707016	chr5:665148	A/G	cg16624210	chr5:671434	TPPP	0.42	4.89	0.4	3.06e-6	Obesity-related traits;
TGCT	cis	rs6545883	0.931	rs9807965	chr2:61732159	T/C	cg15711740	chr2:61764176	XPO1	-0.5	-4.51	-0.38	1.46e-5	Tuberculosis;
TGCT	cis	rs11690462	0.514	rs11126465	chr2:26627689	T/C	cg11525280	chr2:26624667	C2orf39	0.4	4.76	0.39	5.32e-6	Coronary artery disease;
TGCT	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg14773178	chr5:1868261	NA	0.34	5.8	0.46	5.29e-8	Cardiovascular disease risk factors;
TGCT	cis	rs2239547	0.562	rs6794389	chr3:53096394	A/G	cg10802521	chr3:52805072	NEK4	-0.57	-5.24	-0.43	6.68e-7	Schizophrenia;
TGCT	cis	rs2956278	0.717	rs1482397	chr12:84689423	T/C	cg25678815	chr12:85673915	ALX1	-0.53	-4.76	-0.39	5.4e-6	Depressive symptoms;Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7698623	0.850	rs716808	chr4:88800136	G/T	cg27387453	chr4:88533842	DSPP	-0.6	-4.53	-0.38	1.35e-5	Cardiovascular disease risk factors;
TGCT	cis	rs7666738	0.830	rs13111977	chr4:98953813	G/A	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs62380364	0.626	rs11749912	chr5:88065628	A/G	cg22951263	chr5:87985283	NA	-0.6	-6.35	-0.5	3.73e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs13082711	0.554	rs73055724	chr3:27380397	T/G	cg02860705	chr3:27208620	NA	0.44	6.17	0.48	9.11e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs3087591	0.659	rs7218930	chr17:29640204	A/G	cg24425628	chr17:29625626	OMG;NF1	0.4	5.63	0.45	1.14e-7	Hip circumference;
TGCT	cis	rs10883723	0.810	rs1409311	chr10:104282160	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	8.36	0.6	1.1e-13	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs751728	0.544	rs2281820	chr6:33768897	A/G	cg00334056	chr6:33755658	LEMD2	-0.26	-4.63	-0.38	9.04e-6	Crohn's disease;
TGCT	cis	rs8056742	0.730	rs35500222	chr16:85098097	C/G	cg00229868	chr16:85520891	NA	0.38	4.77	0.39	5.03e-6	Amyotrophic lateral sclerosis;
TGCT	cis	rs501916	1.000	rs586118	chr15:48049776	C/T	cg16110827	chr15:48056943	SEMA6D	-0.17	-5.33	-0.43	4.5e-7	Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs11578119	0.933	rs10919401	chr1:170410369	T/A	cg09767346	chr1:170501363	GORAB	0.71	5.65	0.45	1.04e-7	Male-pattern baldness;
TGCT	cis	rs7681440	0.904	rs35424815	chr4:90767877	C/T	cg01966878	chr4:90757139	SNCA	-0.25	-4.56	-0.38	1.2e-5	Dementia with Lewy bodies;
TGCT	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg27588902	chr6:42928151	GNMT	-0.49	-5.92	-0.47	3.01e-8	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.67	-5.38	-0.44	3.55e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs6582630	0.593	rs7299329	chr12:38447943	G/C	cg26384229	chr12:38710491	ALG10B	0.83	7.62	0.56	5.64e-12	Drug-induced liver injury (flucloxacillin);
TGCT	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg01341218	chr17:43662625	NA	-1.11	-9.34	-0.64	5.11e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg10047753	chr17:41438598	NA	0.96	9.64	0.65	9.37e-17	Menopause (age at onset);
TGCT	cis	rs9467773	0.901	rs1407045	chr6:26476155	A/G	cg05738196	chr6:26577821	NA	0.73	8.21	0.59	2.44e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs4747241	0.515	rs11000212	chr10:73955652	C/G	cg09661010	chr10:73848153	SPOCK2	-0.42	-5.34	-0.43	4.24e-7	Heschl's gyrus morphology;
TGCT	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg04944784	chr2:26401820	FAM59B	0.72	5.92	0.47	3e-8	Gut microbiome composition (summer);
TGCT	cis	rs2239547	0.522	rs2581801	chr3:52972907	G/T	cg10802521	chr3:52805072	NEK4	0.64	6.17	0.48	8.79e-9	Schizophrenia;
TGCT	cis	rs7523273	0.597	rs4844392	chr1:207991209	C/G	cg22525895	chr1:207977042	MIR29B2	-0.44	-6.34	-0.49	3.93e-9	Schizophrenia;
TGCT	cis	rs7824557	0.564	rs2572399	chr8:11234520	A/G	cg21775007	chr8:11205619	TDH	-0.65	-6.4	-0.5	2.97e-9	Retinal vascular caliber;
TGCT	trans	rs2727020	0.658	rs4980442	chr11:49445016	G/T	cg15704280	chr7:45808275	SEPT13	-0.73	-8.24	-0.59	2.12e-13	Coronary artery disease;
TGCT	cis	rs10791323	0.604	rs2723605	chr11:133711241	C/G	cg03690763	chr11:133734501	NA	-0.31	-4.88	-0.4	3.13e-6	Childhood ear infection;
TGCT	cis	rs17376456	0.825	rs12188163	chr5:93250608	A/G	cg25358565	chr5:93447407	FAM172A	-0.91	-8.1	-0.59	4.46e-13	Diabetic retinopathy;
TGCT	cis	rs1580019	0.547	rs56981934	chr7:32535202	C/G	cg06627557	chr7:32535165	LSM5;AVL9	1.15	14.27	0.79	6.08e-28	Cognitive ability;
TGCT	cis	rs8180040	0.620	rs6442055	chr3:47110722	A/G	cg27129171	chr3:47204927	SETD2	0.71	8.57	0.61	3.49e-14	Colorectal cancer;
TGCT	cis	rs9560113	0.960	rs1163862	chr13:112174319	C/T	cg10483660	chr13:112241077	NA	0.32	4.69	0.39	7.08e-6	Menarche (age at onset);
TGCT	cis	rs114540395	0.925	rs7090062	chr10:103408014	A/G	cg18276125	chr10:102749041	C10orf2	0.41	4.79	0.39	4.73e-6	Schizophrenia;
TGCT	cis	rs7568458	0.684	rs1048740	chr2:85764966	A/T	cg17127132	chr2:85788382	GGCX	0.52	4.63	0.38	9.25e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs3091242	0.902	rs36003018	chr1:25784318	A/G	cg23205692	chr1:25664452	TMEM50A	-0.47	-4.97	-0.41	2.22e-6	Erythrocyte sedimentation rate;
TGCT	cis	rs2549003	1.000	rs13170412	chr5:131823519	A/G	cg02551604	chr5:131831745	NA	-0.86	-10.87	-0.7	9.47e-20	Asthma (sex interaction);
TGCT	cis	rs7246657	0.722	rs10412510	chr19:38075944	A/G	cg03611452	chr19:38183253	ZNF781	0.58	4.64	0.38	8.62e-6	Coronary artery calcification;
TGCT	cis	rs3812831	0.543	rs389108	chr13:114925389	A/G	cg08824895	chr13:115047677	UPF3A	0.49	4.65	0.39	8.45e-6	Schizophrenia;
TGCT	cis	rs933688	1.000	rs6866191	chr5:90746852	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.0	8.47	0.61	6.09e-14	Smoking behavior;
TGCT	cis	rs909002	0.849	rs6664789	chr1:32072406	C/G	cg11573219	chr1:32083031	HCRTR1	-0.5	-6.59	-0.51	1.13e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs9640161	0.750	rs61421252	chr7:150037972	T/C	cg17279839	chr7:150038598	RARRES2	0.44	4.78	0.39	4.82e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs4700695	0.614	rs1862600	chr5:65206940	T/C	cg21114390	chr5:65439923	SFRS12	0.67	4.69	0.39	7.07e-6	Facial morphology (factor 19);
TGCT	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg06634786	chr22:41940651	POLR3H	-0.88	-8.54	-0.61	3.98e-14	Vitiligo;
TGCT	cis	rs8141529	0.732	rs5762784	chr22:29171298	C/T	cg02153584	chr22:29168773	CCDC117	0.74	6.34	0.49	3.85e-9	Lymphocyte counts;
TGCT	cis	rs586688	1.000	rs525492	chr1:201638858	G/A	cg05779441	chr1:201574716	NA	0.29	4.81	0.4	4.25e-6	Obesity-related traits;
TGCT	cis	rs10883723	0.810	rs2296588	chr10:104248087	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs3101457	0.515	rs4658629	chr1:244516754	G/T	cg09033006	chr1:244517177	C1orf100	-0.4	-4.46	-0.37	1.8e-5	Smoking behavior;
TGCT	cis	rs7655441	1.000	rs7655441	chr4:80879803	C/T	cg02241357	chr4:80885279	ANTXR2	-0.23	-4.46	-0.37	1.81e-5	Neutrophil percentage of white cells;
TGCT	cis	rs13394619	0.744	rs10929759	chr2:11722012	C/G	cg07314298	chr2:11723111	GREB1	0.3	5.08	0.41	1.38e-6	Endometriosis;
TGCT	trans	rs459571	0.959	rs456205	chr9:136911146	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.77	-8.29	-0.6	1.58e-13	Platelet distribution width;
TGCT	cis	rs10206020	0.842	rs7590900	chr2:1574902	A/G	cg12573674	chr2:1569213	NA	-0.46	-5.2	-0.42	7.88e-7	IgG glycosylation;
TGCT	cis	rs3733585	0.699	rs12498956	chr4:9950705	G/T	cg00071950	chr4:10020882	SLC2A9	-0.55	-6.41	-0.5	2.8e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs1865760	0.713	rs7766342	chr6:25990674	C/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.72	6.94	0.53	1.97e-10	Height;
TGCT	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg06238570	chr21:40685208	BRWD1	-0.62	-6.34	-0.49	3.9e-9	Menarche (age at onset);
TGCT	cis	rs9810089	0.814	rs834305	chr3:136119354	C/T	cg12473912	chr3:136751656	NA	0.36	5.04	0.41	1.58e-6	Gestational age at birth (child effect);
TGCT	cis	rs7830933	1.000	rs7830933	chr8:23603324	A/G	cg04349084	chr8:23602677	NA	0.25	4.9	0.4	2.96e-6	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
TGCT	cis	rs250677	0.522	rs4562031	chr5:148368451	A/G	cg18129178	chr5:148520854	ABLIM3	0.36	4.69	0.39	7.23e-6	Breast cancer;
TGCT	cis	rs67311347	0.822	rs11709089	chr3:40351484	C/T	cg13683864	chr3:40499215	RPL14	-0.91	-8.88	-0.62	6.23e-15	Renal cell carcinoma;
TGCT	cis	rs6141769	0.542	rs6057632	chr20:31319841	A/G	cg13636640	chr20:31349939	DNMT3B	-0.52	-4.55	-0.38	1.26e-5	Subjective well-being;
TGCT	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg04772025	chr11:68637568	NA	0.6	6.67	0.51	7.4e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9527	0.590	rs1926037	chr10:104878010	A/C	cg15744005	chr10:104629667	AS3MT	-0.43	-4.9	-0.4	2.89e-6	Arsenic metabolism;
TGCT	cis	rs10791097	0.935	rs4601795	chr11:130729430	T/C	cg12179176	chr11:130786555	SNX19	0.63	7.01	0.53	1.36e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs7707921	0.767	rs862245	chr5:81585737	A/C	cg15871215	chr5:81402204	ATG10	-0.3	-4.67	-0.39	7.64e-6	Breast cancer;
TGCT	cis	rs2806561	0.765	rs668234	chr1:23515467	G/A	cg12483005	chr1:23474871	LUZP1	0.38	4.73	0.39	5.93e-6	Height;
TGCT	cis	rs1538970	1.000	rs2050884	chr1:45830824	A/G	cg05343316	chr1:45956843	TESK2	0.64	5.13	0.42	1.08e-6	Platelet count;
TGCT	cis	rs7582180	0.629	rs12612809	chr2:100951616	G/T	cg14675211	chr2:100938903	LONRF2	0.5	4.78	0.39	4.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7917772	0.503	rs11191321	chr10:104293412	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	8.36	0.6	1.1e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7916852	0.867	rs10763642	chr10:28388150	G/A	cg15286905	chr10:27530250	ACBD5	-0.45	-4.46	-0.37	1.78e-5	Glaucoma (primary open-angle);
TGCT	cis	rs12134133	1.000	rs7518565	chr1:207420343	G/A	cg02152968	chr1:207494213	CD55	0.61	4.83	0.4	3.92e-6	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs7043114	0.544	rs7852510	chr9:95316359	T/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.53	-5.25	-0.43	6.26e-7	Height;
TGCT	cis	rs6671200	0.573	rs3820345	chr1:95713175	C/T	cg20701556	chr1:95698924	RWDD3	-0.52	-5.34	-0.43	4.26e-7	Stearic acid (18:0) levels;
TGCT	cis	rs13242816	1.000	rs1049334	chr7:116200380	A/G	cg16553024	chr7:116138462	CAV2	0.44	5.16	0.42	9.48e-7	P wave duration;
TGCT	cis	rs9810089	0.814	rs73226190	chr3:136213310	T/C	cg12473912	chr3:136751656	NA	0.36	4.95	0.41	2.39e-6	Gestational age at birth (child effect);
TGCT	cis	rs7267979	1.000	rs13038834	chr20:25441433	C/T	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs12339966	0.581	rs62529421	chr9:11339611	G/A	cg03488587	chr11:64876988	C11orf2	0.32	7.04	0.53	1.16e-10	Systolic blood pressure;
TGCT	cis	rs2295359	0.892	rs72676067	chr1:67658803	G/A	cg08029281	chr1:67600428	NA	0.4	4.68	0.39	7.36e-6	Psoriasis;
TGCT	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	16.1	0.82	3.69e-32	Prudent dietary pattern;
TGCT	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	4.99	0.41	1.95e-6	Prudent dietary pattern;
TGCT	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg25703541	chr22:24373054	LOC391322	-0.81	-8.47	-0.61	5.88e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9788721	0.836	rs7181486	chr15:78741618	C/T	cg18825076	chr15:78729989	IREB2	0.33	5.23	0.43	6.95e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
TGCT	cis	rs9660992	0.512	rs12142402	chr1:205128215	A/T	cg03948781	chr1:205179583	DSTYK	0.34	4.47	0.37	1.77e-5	Mean corpuscular volume;Mean platelet volume;
TGCT	cis	rs250677	0.522	rs4431331	chr5:148353574	A/C	cg18129178	chr5:148520854	ABLIM3	-0.36	-4.57	-0.38	1.17e-5	Breast cancer;
TGCT	cis	rs1552244	0.554	rs6796411	chr3:10010681	G/A	cg00149659	chr3:10157352	C3orf10	0.64	4.69	0.39	7.12e-6	Alzheimer's disease;
TGCT	cis	rs9311474	0.652	rs411457	chr3:52228150	A/T	cg10802521	chr3:52805072	NEK4	0.57	6.25	0.49	6.06e-9	Electroencephalogram traits;
TGCT	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg17971929	chr21:40555470	PSMG1	-0.92	-9.42	-0.65	3.21e-16	Cognitive function;
TGCT	cis	rs7213347	0.581	rs11657636	chr17:2053920	C/T	cg22033759	chr17:1182267	TUSC5	-0.23	-4.65	-0.39	8.48e-6	Total body bone mineral density;
TGCT	cis	rs2303759	0.918	rs7251704	chr19:49890873	T/G	cg22307029	chr19:49891270	CCDC155	0.54	5.09	0.42	1.29e-6	Multiple sclerosis;
TGCT	cis	rs7904368	0.951	rs7905776	chr10:16853609	C/T	cg23933602	chr10:16859644	RSU1	0.62	4.57	0.38	1.17e-5	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
TGCT	cis	rs11696501	0.688	rs6065859	chr20:44302697	C/T	cg11783356	chr20:44313418	WFDC10B	-0.32	-4.63	-0.38	9.25e-6	Brain structure;
TGCT	cis	rs2692947	0.631	rs2312954	chr2:96772447	C/T	cg23100626	chr2:96804247	ASTL	-0.42	-5.0	-0.41	1.92e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs12893668	0.703	rs35026580	chr14:104042753	A/G	cg26031613	chr14:104095156	KLC1	-0.54	-4.44	-0.37	1.97e-5	Reticulocyte count;
TGCT	cis	rs7223966	0.729	rs2003549	chr17:62008437	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	4.59	0.38	1.09e-5	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg06028808	chr11:68637592	NA	0.54	6.92	0.53	2.19e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg10876282	chr6:28092338	ZSCAN16	0.51	4.63	0.38	9.13e-6	Cardiac Troponin-T levels;
TGCT	cis	rs7918232	0.830	rs7915902	chr10:27410734	T/C	cg14442939	chr10:27389572	ANKRD26	0.72	5.35	0.43	4.16e-7	Breast cancer;
TGCT	cis	rs6977660	0.607	rs10243965	chr7:19797893	G/A	cg07541023	chr7:19748670	TWISTNB	0.93	5.25	0.43	6.27e-7	Thyroid stimulating hormone;
TGCT	cis	rs3015497	0.904	rs3015501	chr14:51108524	C/T	cg04730355	chr14:51134070	SAV1	-0.51	-4.52	-0.38	1.44e-5	Mean platelet volume;
TGCT	cis	rs2742417	1.000	rs2742437	chr3:45743277	G/A	cg04837898	chr3:45731254	SACM1L	-0.51	-5.23	-0.42	7.13e-7	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs1799899	0.826	rs6785596	chr3:133466457	T/A	cg18342939	chr3:134203408	ANAPC13;CEP63	0.48	4.91	0.4	2.85e-6	Alcohol consumption (transferrin glycosylation);
TGCT	cis	rs1129187	0.755	rs2296804	chr6:42931261	C/G	cg13397359	chr6:42928475	GNMT	0.58	4.89	0.4	3.02e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs3125734	0.633	rs4979774	chr10:63967795	A/T	cg05499367	chr10:63213510	TMEM26	-0.33	-4.56	-0.38	1.2e-5	Rheumatoid arthritis;
TGCT	cis	rs9916302	0.851	rs7220650	chr17:37487168	A/G	cg15445000	chr17:37608096	MED1	-0.33	-4.7	-0.39	6.89e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs2880765	0.835	rs4340287	chr15:86043737	A/G	cg13263323	chr15:86062960	AKAP13	-0.23	-4.82	-0.4	4.1e-6	Coronary artery disease;
TGCT	cis	rs10501293	0.746	rs7114320	chr11:43013621	C/G	cg03447554	chr11:43094025	NA	-0.44	-6.35	-0.5	3.67e-9	Cognitive performance;
TGCT	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg18876405	chr7:65276391	NA	-0.34	-5.1	-0.42	1.22e-6	Aortic root size;
TGCT	cis	rs2243480	0.706	rs34466769	chr7:65453292	A/C	cg18252515	chr7:66147081	NA	-0.9	-5.93	-0.47	2.84e-8	Diabetic kidney disease;
TGCT	cis	rs1008375	0.966	rs10006317	chr4:17702525	A/G	cg10189774	chr4:17578691	LAP3	0.52	4.47	0.37	1.73e-5	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	trans	rs7819412	0.775	rs4841490	chr8:10936891	T/C	cg06636001	chr8:8085503	FLJ10661	-0.77	-7.08	-0.54	9.66e-11	Triglycerides;
TGCT	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.03	0.41	1.68e-6	Prudent dietary pattern;
TGCT	cis	rs35306767	0.715	rs11253539	chr10:1011347	G/A	cg26597838	chr10:835615	NA	0.57	6.42	0.5	2.6e-9	Eosinophil percentage of granulocytes;
TGCT	cis	rs28595532	0.841	rs55744948	chr4:119769243	T/C	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs4455778	0.659	rs28522097	chr7:49043054	G/A	cg26309511	chr7:48887640	NA	0.42	4.98	0.41	2.08e-6	Lung cancer in never smokers;
TGCT	cis	rs10882165	0.751	rs11817146	chr10:94911300	C/T	cg15980076	chr10:94822747	CYP26C1	0.42	4.54	0.38	1.34e-5	Refractive error;
TGCT	cis	rs10193935	0.792	rs13430031	chr2:42499968	C/T	cg27598129	chr2:42591480	NA	-0.42	-5.7	-0.46	8.35e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2549003	0.966	rs10065633	chr5:131816716	T/C	cg21138405	chr5:131827807	IRF1	0.2	5.08	0.41	1.36e-6	Asthma (sex interaction);
TGCT	cis	rs2562456	0.917	rs2650805	chr19:21687939	T/G	cg01304269	chr19:21688519	ZNF429	-0.55	-4.59	-0.38	1.06e-5	Pain;
TGCT	trans	rs2727020	0.664	rs4929893	chr11:49196332	C/T	cg03929089	chr4:120376271	NA	-0.71	-7.91	-0.58	1.22e-12	Coronary artery disease;
TGCT	cis	rs12579753	0.917	rs4842410	chr12:82219225	A/T	cg07988820	chr12:82153109	PPFIA2	-0.57	-6.06	-0.48	1.54e-8	Resting heart rate;
TGCT	cis	rs2268241	0.938	rs9978166	chr21:34770516	A/G	cg14850771	chr21:34775459	IFNGR2	0.6	5.31	0.43	4.82e-7	Obesity-related traits;
TGCT	cis	rs11690935	0.959	rs1474074	chr2:172659852	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.19	-12.78	-0.75	2.24e-24	Schizophrenia;
TGCT	cis	rs67981189	0.513	rs2526856	chr14:71412717	A/G	cg15910301	chr14:71632612	NA	0.26	4.62	0.38	9.39e-6	Schizophrenia;
TGCT	trans	rs62103177	0.525	rs10438902	chr18:77745640	A/G	cg05926928	chr17:57297772	GDPD1	-0.75	-6.87	-0.53	2.8e-10	Opioid sensitivity;
TGCT	cis	rs950169	0.810	rs2879976	chr15:85109578	G/A	cg17173187	chr15:85201210	NMB	0.48	5.02	0.41	1.75e-6	Schizophrenia;
TGCT	cis	rs1577917	0.740	rs7771612	chr6:86264374	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.54	4.87	0.4	3.29e-6	Response to antipsychotic treatment;
TGCT	cis	rs7772486	0.875	rs9403770	chr6:146423334	C/T	cg23711669	chr6:146136114	FBXO30	0.91	9.95	0.67	1.67e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7698623	0.850	rs6532019	chr4:88768672	C/T	cg02735620	chr4:88950514	PKD2	-0.44	-4.81	-0.4	4.28e-6	Cardiovascular disease risk factors;
TGCT	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg07636037	chr3:49044803	WDR6	0.96	10.9	0.7	8.39e-20	Parkinson's disease;
TGCT	cis	rs7666738	0.861	rs5014702	chr4:99052102	C/A	cg18180107	chr4:99064573	C4orf37	0.57	5.15	0.42	1.01e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs60733400	0.817	rs4648657	chr1:2560735	A/G	cg18854424	chr1:2615690	NA	-0.45	-5.13	-0.42	1.07e-6	Multiple sclerosis;
TGCT	cis	rs112217694	1.000	rs75027425	chr4:104649311	C/T	cg24090629	chr4:104641072	TACR3	-0.97	-4.81	-0.4	4.25e-6	Menarche (age at onset);
TGCT	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs10254284	0.959	rs10275989	chr7:28159696	A/G	cg23620719	chr7:28220237	JAZF1	0.53	4.81	0.4	4.26e-6	Lymphocyte percentage of white cells;Systemic lupus erythematosus;
TGCT	cis	rs921968	0.643	rs535830	chr2:219372233	C/G	cg02176678	chr2:219576539	TTLL4	0.38	5.48	0.44	2.31e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs362272	0.505	rs13104157	chr4:3366950	T/C	cg06533319	chr4:3265114	C4orf44	-0.26	-5.28	-0.43	5.71e-7	Serum sulfate level;
TGCT	cis	rs12530845	0.945	rs76298187	chr7:135334534	A/G	cg23117316	chr7:135346802	PL-5283	-0.51	-4.83	-0.4	3.98e-6	Red blood cell traits;
TGCT	cis	rs6940638	0.513	rs4424065	chr6:27036456	C/T	cg26531700	chr6:26746687	NA	-0.67	-6.48	-0.5	1.97e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs6912958	0.559	rs183599	chr6:88061024	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.68	6.88	0.53	2.68e-10	Monocyte percentage of white cells;
TGCT	cis	rs1395	0.778	rs56364136	chr2:27451429	T/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.51	6.68	0.51	7.27e-10	Blood metabolite levels;
TGCT	cis	rs6901250	0.851	rs6938235	chr6:117147946	G/T	cg12892004	chr6:117198278	RFX6	0.55	6.8	0.52	3.85e-10	C-reactive protein levels;
TGCT	cis	rs9926296	0.607	rs11076629	chr16:89875259	T/C	cg03388025	chr16:89894329	SPIRE2	0.36	5.12	0.42	1.15e-6	Vitiligo;
TGCT	cis	rs546131	0.928	rs572690	chr11:34833614	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.62	5.56	0.45	1.57e-7	Lung disease severity in cystic fibrosis;
TGCT	cis	rs4676380	0.927	rs1583259	chr2:241644934	G/T	cg21930842	chr2:241631663	AQP12A	0.25	4.65	0.39	8.43e-6	Response to metformin (IC50);
TGCT	cis	rs12220238	0.908	rs73284278	chr10:76011751	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.91	7.36	0.55	2.18e-11	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs250677	1.000	rs190378	chr5:148434275	G/T	cg18129178	chr5:148520854	ABLIM3	-0.44	-6.39	-0.5	3.09e-9	Breast cancer;
TGCT	cis	rs4845570	0.920	rs6694952	chr1:151760131	T/C	cg07092448	chr1:151763213	TDRKH	1.15	9.69	0.66	7.09e-17	Coronary artery disease;
TGCT	cis	rs782590	0.967	rs17798852	chr2:55805172	A/C	cg03859395	chr2:55845619	SMEK2	0.92	11.39	0.72	5.08e-21	Metabolic syndrome;
TGCT	cis	rs1215050	0.846	rs783923	chr4:98968686	C/T	cg05340658	chr4:99064831	C4orf37	-0.46	-5.55	-0.45	1.67e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs11676348	0.714	rs4674254	chr2:218986077	T/C	cg00012203	chr2:219082015	ARPC2	-0.52	-4.98	-0.41	2.08e-6	Ulcerative colitis;
TGCT	cis	rs7568458	0.905	rs6547620	chr2:85755928	C/T	cg02493740	chr2:85810744	VAMP5	-0.27	-4.81	-0.4	4.25e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs4455778	0.543	rs4357242	chr7:49067599	T/C	cg26309511	chr7:48887640	NA	0.51	6.63	0.51	9.47e-10	Lung cancer in never smokers;
TGCT	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg22433210	chr17:43662623	NA	0.98	6.85	0.52	3.13e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs6138458	0.717	rs2179732	chr20:25000446	A/T	cg26195577	chr20:24973756	C20orf3	1.02	9.48	0.65	2.3e-16	Blood protein levels;
TGCT	cis	rs9611565	0.694	rs4822032	chr22:41925535	T/C	cg03806693	chr22:41940476	POLR3H	-0.97	-10.77	-0.7	1.72e-19	Vitiligo;
TGCT	cis	rs1215050	0.791	rs1215049	chr4:98848280	C/T	cg17366294	chr4:99064904	C4orf37	0.54	5.66	0.45	9.77e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7264396	0.790	rs2425096	chr20:34308588	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.3	-5.31	-0.43	4.96e-7	Total cholesterol levels;
TGCT	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg06221963	chr1:154839813	KCNN3	-0.71	-11.68	-0.72	1.06e-21	Prostate cancer;
TGCT	cis	rs3806843	0.576	rs246045	chr5:140329884	C/T	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs6866344	0.561	rs55974982	chr5:178141421	G/A	cg10224037	chr5:178157518	ZNF354A	0.98	9.87	0.66	2.66e-17	Neutrophil percentage of white cells;
TGCT	cis	rs7666738	0.830	rs11097609	chr4:99011707	C/T	cg05340658	chr4:99064831	C4orf37	0.48	5.43	0.44	2.92e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4819052	0.655	rs2330103	chr21:46694514	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.62	6.01	0.47	1.93e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6952809	0.532	rs6956223	chr7:2431331	T/C	cg23289794	chr7:2394357	EIF3B	-0.82	-7.14	-0.54	7.04e-11	Multiple sclerosis;
TGCT	trans	rs4819388	0.751	rs2838531	chr21:45638586	C/T	cg17383793	chr5:52405638	MOCS2	-0.71	-6.73	-0.52	5.65e-10	Celiac disease;
TGCT	cis	rs1891275	0.515	rs6583784	chr10:93491576	A/G	cg07889827	chr10:93443413	NA	0.3	6.29	0.49	4.85e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg04944784	chr2:26401820	FAM59B	-0.86	-6.26	-0.49	5.74e-9	Gut microbiome composition (summer);
TGCT	cis	rs7681440	0.874	rs7687945	chr4:90764699	C/T	cg20003494	chr4:90757398	SNCA	-0.63	-6.09	-0.48	1.3e-8	Dementia with Lewy bodies;
TGCT	cis	rs13242816	1.000	rs13247987	chr7:116113344	A/C	cg16553024	chr7:116138462	CAV2	-0.45	-4.75	-0.39	5.64e-6	P wave duration;
TGCT	cis	rs13191362	0.935	rs13219926	chr6:163004213	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs9926296	0.656	rs2376883	chr16:89826926	A/G	cg26513180	chr16:89883248	FANCA	0.7	6.76	0.52	4.76e-10	Vitiligo;
TGCT	cis	rs603424	0.509	rs598133	chr10:102082245	A/G	cg22671421	chr10:102507979	PAX2	0.56	4.66	0.39	8e-6	Phospholipid levels (plasma);Palmitic acid (16:0) levels;Palmitoleic acid (16:1n-7) levels;Mean platelet volume;Serum metabolite levels;Blood metabolite levels;Vaccenic acid (18:1n-7) levels;Metabolic traits;Coronary artery disease;Blood metabolite ratios;Glycerophospholipid levels;
TGCT	cis	rs73198271	0.740	rs10098636	chr8:8647324	C/T	cg06671706	chr8:8559999	CLDN23	-0.35	-4.5	-0.37	1.52e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg15595755	chr5:1867978	NA	0.45	5.13	0.42	1.08e-6	Cardiovascular disease risk factors;
TGCT	cis	rs1670533	1.000	rs629260	chr4:1086764	A/G	cg27284194	chr4:1044797	NA	0.68	5.95	0.47	2.59e-8	Recombination rate (females);
TGCT	cis	rs12142240	0.660	rs72886903	chr1:46813860	C/T	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs1371867	0.817	rs7846076	chr8:101327629	A/G	cg06002616	chr8:101225028	SPAG1	-0.53	-6.21	-0.49	7.16e-9	Atrioventricular conduction;
TGCT	cis	rs62402013	1	rs62402013	chr6:26915000	A/G	cg02458000	chr6:26745757	NA	0.6	5.33	0.43	4.42e-7	Schizophrenia;
TGCT	cis	rs4499344	0.556	rs259228	chr19:33134635	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.81	8.16	0.59	3.17e-13	Mean platelet volume;
TGCT	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg24503407	chr1:205819492	PM20D1	0.58	8.13	0.59	3.84e-13	Menarche (age at onset);
TGCT	trans	rs1814175	0.645	rs1721996	chr11:49915527	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.51	-0.69	7.2e-19	Height;
TGCT	trans	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.83	-8.71	-0.62	1.65e-14	Body mass index;
TGCT	cis	rs2288884	0.943	rs3752120	chr19:52552021	C/T	cg15405931	chr19:52693188	PPP2R1A	-0.69	-4.5	-0.37	1.56e-5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs11809207	0.501	rs2232654	chr1:26496870	A/G	cg24519413	chr1:26490540	NA	0.22	4.6	0.38	1.02e-5	Height;
TGCT	trans	rs1496653	0.602	rs34882744	chr3:23626018	C/T	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs2718812	0.766	rs1822744	chr3:133366227	A/G	cg16414030	chr3:133502952	NA	-0.4	-5.19	-0.42	8.27e-7	Iron status biomarkers;
TGCT	cis	rs459571	0.959	rs455381	chr9:136905577	C/A	cg13789015	chr9:136890014	NCRNA00094	0.41	7.58	0.56	7.09e-12	Platelet distribution width;
TGCT	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.46	-6.7	-0.52	6.44e-10	Alzheimer's disease;
TGCT	cis	rs17401966	1.000	rs12734068	chr1:10376803	G/A	cg19773385	chr1:10388646	KIF1B	-0.22	-4.58	-0.38	1.12e-5	Hepatocellular carcinoma;
TGCT	cis	rs1008375	1.000	rs11724495	chr4:17621310	G/A	cg16339924	chr4:17578868	LAP3	0.64	5.32	0.43	4.72e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7412746	0.611	rs10788794	chr1:150728676	T/C	cg09365446	chr1:150670422	GOLPH3L	0.33	4.78	0.39	4.8e-6	Melanoma;
TGCT	cis	rs74233809	1.000	rs11191454	chr10:104660004	A/G	cg05855489	chr10:104503620	C10orf26	0.75	4.47	0.37	1.72e-5	Birth weight;
TGCT	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	5.12	0.42	1.11e-6	Alzheimer's disease;
TGCT	cis	rs4727027	0.704	rs4727031	chr7:148908305	T/C	cg23583168	chr7:148888333	NA	-0.86	-11.0	-0.7	4.61e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs9325144	0.555	rs1813392	chr12:38692203	C/T	cg26384229	chr12:38710491	ALG10B	-0.65	-6.23	-0.49	6.73e-9	Morning vs. evening chronotype;
TGCT	cis	rs9291683	0.620	rs717615	chr4:10104670	C/T	cg00071950	chr4:10020882	SLC2A9	0.48	5.25	0.43	6.48e-7	Bone mineral density;
TGCT	cis	rs6088590	0.965	rs6088620	chr20:33412022	A/G	cg24642439	chr20:33292090	TP53INP2	0.68	6.09	0.48	1.32e-8	Coronary artery disease;
TGCT	cis	rs904251	0.600	rs4714068	chr6:37455642	A/C	cg25019722	chr6:37503610	NA	-0.47	-6.95	-0.53	1.87e-10	Cognitive performance;
TGCT	cis	rs7178572	0.789	rs4886869	chr15:77799657	A/G	cg22256960	chr15:77711686	NA	-0.78	-8.06	-0.59	5.4e-13	Type 2 diabetes;
TGCT	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg26531700	chr6:26746687	NA	-0.57	-5.21	-0.42	7.62e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4689388	0.926	rs5018647	chr4:6292799	A/C	cg14416269	chr4:6271139	WFS1	0.37	4.9	0.4	2.95e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	trans	rs9388451	0.513	rs1268069	chr6:126039994	A/C	cg05039488	chr6:79577232	IRAK1BP1	-0.66	-6.78	-0.52	4.43e-10	Brugada syndrome;
TGCT	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.14	0.42	1.06e-6	Prudent dietary pattern;
TGCT	cis	rs7826238	0.653	rs2979202	chr8:8344127	T/C	cg06636001	chr8:8085503	FLJ10661	0.63	5.8	0.46	5.09e-8	Systolic blood pressure;
TGCT	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg20999797	chr1:1681921	NA	0.18	4.78	0.39	4.93e-6	Body mass index;
TGCT	cis	rs3091242	0.933	rs34006994	chr1:25780668	C/T	cg00786635	chr1:25594202	NA	-0.52	-5.56	-0.45	1.59e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs7312933	0.558	rs1051453	chr12:42852217	C/T	cg19980929	chr12:42632907	YAF2	0.43	6.19	0.49	8.26e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg20637647	chr7:64974828	NA	0.89	4.99	0.41	2.01e-6	Diabetic kidney disease;
TGCT	cis	rs1552244	0.608	rs9837460	chr3:10049922	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.33	-4.95	-0.41	2.39e-6	Alzheimer's disease;
TGCT	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.54	4.7	0.39	6.81e-6	Prudent dietary pattern;
TGCT	cis	rs7666738	0.830	rs7682991	chr4:98982595	C/A	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2455799	0.573	rs2470546	chr3:15733897	T/C	cg16303742	chr3:15540471	COLQ	-0.26	-4.8	-0.4	4.49e-6	Mean platelet volume;
TGCT	cis	rs7634476	1	rs7634476	chr3:136398387	A/G	cg12473912	chr3:136751656	NA	-0.34	-4.92	-0.4	2.71e-6	Neuroticism;
TGCT	trans	rs7698623	0.850	rs4693892	chr4:88796983	T/G	cg01186725	chr1:53905612	FLJ40434	-0.48	-6.63	-0.51	9.21e-10	Cardiovascular disease risk factors;
TGCT	cis	rs7552404	0.731	rs10873787	chr1:76367797	G/A	cg03433033	chr1:76189801	ACADM	0.77	7.43	0.56	1.5e-11	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs881375	1.000	rs6478484	chr9:123652380	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	5.38	0.44	3.52e-7	Rheumatoid arthritis;
TGCT	cis	rs66573146	1.000	rs56178503	chr4:6961748	C/T	cg05069807	chr4:6945702	TBC1D14	0.31	4.6	0.38	1.03e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs8014204	0.868	rs2230237	chr14:75359670	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.75	-7.22	-0.54	4.62e-11	Caffeine consumption;
TGCT	cis	rs2224391	0.628	rs2773317	chr6:5254509	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.99	-6.48	-0.5	1.99e-9	Height;
TGCT	cis	rs67366981	0.778	rs3952319	chr14:77684379	A/T	cg22824376	chr14:77648248	TMEM63C	0.73	4.71	0.39	6.61e-6	Obsessive-compulsive symptoms;
TGCT	cis	rs7953508	0.506	rs3782415	chr12:93967755	T/C	cg18151635	chr12:93972918	NA	-0.19	-4.52	-0.38	1.41e-5	Pubertal anthropometrics;
TGCT	cis	rs7213347	0.678	rs11658797	chr17:2088969	T/G	cg13315690	chr17:1944831	OVCA2;DPH1	-0.38	-4.8	-0.4	4.44e-6	Total body bone mineral density;
TGCT	cis	rs7633770	0.805	rs11710264	chr3:46661579	T/C	cg11219411	chr3:46661640	NA	0.36	5.27	0.43	5.86e-7	Coronary artery disease;
TGCT	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg02487422	chr3:49467188	NICN1	0.54	5.26	0.43	6.11e-7	Menarche (age at onset);
TGCT	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg24531977	chr5:56204891	C5orf35	0.68	7.22	0.54	4.69e-11	Initial pursuit acceleration;
TGCT	cis	rs7552404	1.000	rs4949874	chr1:76161889	T/C	cg03433033	chr1:76189801	ACADM	0.83	9.91	0.66	2.13e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7975161	0.938	rs4964271	chr12:104652441	T/C	cg25273343	chr12:104657179	TXNRD1	-0.36	-5.28	-0.43	5.53e-7	Toenail selenium levels;
TGCT	cis	rs3784262	0.631	rs4646566	chr15:58348173	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.42	-6.24	-0.49	6.32e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs2404602	0.684	rs12591622	chr15:76930655	A/T	cg22467129	chr15:76604101	ETFA	0.47	4.61	0.38	9.77e-6	Blood metabolite levels;
TGCT	cis	rs9811920	0.535	rs792837	chr3:99477182	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.39	4.6	0.38	1.04e-5	Axial length;
TGCT	cis	rs6543140	0.964	rs2160200	chr2:103033963	G/T	cg09003973	chr2:102972529	NA	0.59	4.95	0.41	2.39e-6	Blood protein levels;
TGCT	cis	rs7772486	0.875	rs2814877	chr6:146299763	C/G	cg13319975	chr6:146136371	FBXO30	-0.53	-4.71	-0.39	6.53e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs12791968	0.659	rs12808379	chr11:45009273	C/G	cg11846598	chr11:44996168	LOC221122	-0.32	-5.2	-0.42	8.09e-7	Inhibitory control;
TGCT	cis	rs2657888	1.000	rs73118833	chr12:56941734	C/A	cg23002907	chr12:56915593	RBMS2	-0.45	-6.07	-0.48	1.44e-8	Adiponectin levels;
TGCT	cis	rs2204008	0.837	rs11172728	chr12:38070042	C/A	cg13010199	chr12:38710504	ALG10B	0.61	4.91	0.4	2.86e-6	Bladder cancer;
TGCT	cis	rs7677751	0.806	rs7681399	chr4:55090886	T/G	cg17187183	chr4:55093834	PDGFRA	0.53	6.8	0.52	3.9e-10	Corneal astigmatism;
TGCT	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg11494091	chr17:61959527	GH2	0.61	14.81	0.8	3.37e-29	Prudent dietary pattern;
TGCT	cis	rs9611565	0.694	rs11090056	chr22:42095904	A/C	cg03806693	chr22:41940476	POLR3H	0.96	9.69	0.66	7.24e-17	Vitiligo;
TGCT	cis	rs514406	0.679	rs11206006	chr1:53218380	A/G	cg24675658	chr1:53192096	ZYG11B	0.88	11.43	0.72	4.12e-21	Monocyte count;
TGCT	cis	rs904251	0.797	rs1757177	chr6:37486370	C/T	cg25019722	chr6:37503610	NA	-0.52	-6.77	-0.52	4.49e-10	Cognitive performance;
TGCT	cis	rs1059312	1.000	rs9738216	chr12:129281788	C/T	cg09035930	chr12:129282057	SLC15A4	0.55	10.83	0.7	1.22e-19	Systemic lupus erythematosus;
TGCT	cis	rs6922617	0.786	rs57437999	chr6:41345126	A/G	cg07798131	chr6:41471673	NA	0.98	4.85	0.4	3.6e-6	Alzheimer's disease biomarkers;
TGCT	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg22800045	chr5:56110881	MAP3K1	0.53	4.43	0.37	2.01e-5	Initial pursuit acceleration;
TGCT	cis	rs9522267	0.559	rs9522300	chr13:112236668	C/G	cg10483660	chr13:112241077	NA	-0.27	-4.61	-0.38	9.78e-6	Hepatitis;
TGCT	cis	rs8077577	0.895	rs16960996	chr17:18110559	A/G	cg09161412	chr17:18057145	MYO15A	-0.64	-5.22	-0.42	7.2e-7	Obesity-related traits;
TGCT	trans	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg13615516	chr5:77269221	NA	0.73	8.42	0.6	7.74e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs797680	0.786	rs7525248	chr1:93828523	T/A	cg17826107	chr1:92977322	EVI5	-0.24	-5.63	-0.45	1.13e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs2456568	0.867	rs2456569	chr11:93691393	C/A	cg17595323	chr11:93583763	C11orf90	-0.46	-6.13	-0.48	1.07e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs17376456	0.825	rs35426871	chr5:93291613	C/T	cg21475434	chr5:93447410	FAM172A	0.65	4.47	0.37	1.72e-5	Diabetic retinopathy;
TGCT	cis	rs7582180	0.700	rs2309852	chr2:100982527	T/C	cg14675211	chr2:100938903	LONRF2	0.48	4.54	0.38	1.32e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs9911578	0.813	rs8066773	chr17:56601552	A/G	cg12560992	chr17:57184187	TRIM37	0.75	8.23	0.59	2.22e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs2025751	0.666	rs10214606	chr6:51686081	G/A	cg23457901	chr6:52402140	TRAM2	-0.22	-4.52	-0.38	1.43e-5	Intraocular pressure;
TGCT	cis	rs4804368	0.714	rs4804372	chr19:7191712	A/G	cg10148591	chr19:7197021	INSR	0.38	4.61	0.38	9.78e-6	Renal cell carcinoma;
TGCT	cis	rs12134245	0.776	rs6688261	chr1:91987034	C/T	cg25838465	chr1:92012736	NA	-0.4	-6.93	-0.53	2.05e-10	Breast cancer;
TGCT	cis	rs10501293	0.642	rs1489198	chr11:43000335	G/A	cg03447554	chr11:43094025	NA	0.44	6.48	0.5	1.92e-9	Cognitive performance;
TGCT	cis	rs763121	0.815	rs4821799	chr22:39021326	T/G	cg06022373	chr22:39101656	GTPBP1	0.72	7.01	0.53	1.35e-10	Menopause (age at onset);
TGCT	cis	rs986417	0.786	rs7156379	chr14:61110634	G/C	cg27398547	chr14:60952738	C14orf39	1.61	8.49	0.61	5.37e-14	Gut microbiota (bacterial taxa);
TGCT	cis	rs4906332	1.000	rs17617935	chr14:103952886	A/T	cg26031613	chr14:104095156	KLC1	-0.51	-4.51	-0.38	1.48e-5	Coronary artery disease;
TGCT	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg05368731	chr17:41323189	NBR1	-1.02	-11.38	-0.71	5.62e-21	Menopause (age at onset);
TGCT	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg00684032	chr4:1343700	KIAA1530	0.23	4.93	0.4	2.58e-6	Obesity-related traits;
TGCT	cis	rs7959452	0.901	rs1384	chr12:69747834	C/T	cg11871910	chr12:69753446	YEATS4	0.76	8.31	0.6	1.44e-13	Blood protein levels;
TGCT	cis	rs17253792	0.822	rs12100753	chr14:56042870	G/A	cg01858014	chr14:56050164	KTN1	-0.35	-4.5	-0.37	1.53e-5	Putamen volume;
TGCT	cis	rs9443645	0.869	rs9361467	chr6:79621098	A/G	cg09184832	chr6:79620586	NA	-0.49	-5.29	-0.43	5.29e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs12134133	0.962	rs17258843	chr1:207414732	C/T	cg02152968	chr1:207494213	CD55	0.6	4.67	0.39	7.74e-6	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs877282	0.898	rs12358966	chr10:758703	A/G	cg17470449	chr10:769945	NA	0.36	5.32	0.43	4.77e-7	Uric acid levels;
TGCT	cis	rs114540395	0.858	rs117998275	chr10:103183891	T/G	cg18276125	chr10:102749041	C10orf2	0.36	4.44	0.37	1.98e-5	Schizophrenia;
TGCT	cis	rs899997	0.773	rs8032156	chr15:78964498	A/G	cg00061860	chr15:78953028	NA	-0.32	-5.07	-0.41	1.41e-6	Coronary artery disease or large artery stroke;
TGCT	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs7666738	0.800	rs2839836	chr4:98970512	A/G	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6459680	0.583	rs6957217	chr7:156268109	C/T	cg02321112	chr7:156810523	NA	-0.31	-4.64	-0.38	8.79e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs1670533	1.000	rs1010342	chr4:1068819	C/T	cg27284194	chr4:1044797	NA	0.67	5.98	0.47	2.17e-8	Recombination rate (females);
TGCT	cis	rs7249142	0.562	rs10417796	chr19:19287072	A/G	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.45	-4.49	-0.37	1.6e-5	IgG glycosylation;
TGCT	cis	rs8067545	0.750	rs4925072	chr17:19956899	C/T	cg13482628	chr17:19912719	NA	-0.55	-4.93	-0.4	2.57e-6	Schizophrenia;
TGCT	cis	rs11578119	0.689	rs2027020	chr1:170387134	A/G	cg09767346	chr1:170501363	GORAB	0.57	4.74	0.39	5.75e-6	Male-pattern baldness;
TGCT	cis	rs10851411	0.789	rs1900920	chr15:42768198	C/T	cg23803468	chr15:43513504	EPB42	-0.24	-4.67	-0.39	7.77e-6	Glucose homeostasis traits;
TGCT	cis	rs7180079	0.502	rs6494466	chr15:64508763	A/G	cg02848875	chr15:64387786	SNX1	0.38	5.84	0.46	4.24e-8	Monocyte count;
TGCT	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg12756686	chr19:29218302	NA	0.76	6.45	0.5	2.29e-9	Methadone dose in opioid dependence;
TGCT	cis	rs11785400	1.000	rs4327844	chr8:143733540	C/T	cg10596483	chr8:143751796	JRK	-0.52	-5.7	-0.46	8.31e-8	Schizophrenia;
TGCT	trans	rs6561151	0.681	rs17571812	chr13:44472462	G/A	cg12856521	chr11:46389249	DGKZ	0.77	7.12	0.54	7.74e-11	Crohn's disease;
TGCT	cis	rs28595532	0.920	rs114168088	chr4:119772666	G/A	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg09365446	chr1:150670422	GOLPH3L	0.31	4.64	0.38	8.74e-6	Tonsillectomy;
TGCT	cis	rs7818688	0.697	rs77805255	chr8:95983566	G/A	cg16049864	chr8:95962084	TP53INP1	0.54	4.64	0.38	8.87e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs7539409	0.764	rs4001465	chr1:84285304	T/C	cg10977910	chr1:84465055	TTLL7	0.98	5.58	0.45	1.42e-7	Alzheimer's disease;
TGCT	cis	rs7809950	0.817	rs4727679	chr7:107085018	T/C	cg23024343	chr7:107201750	COG5	-0.48	-7.05	-0.54	1.08e-10	Coronary artery disease;
TGCT	trans	rs1496653	0.602	rs34732257	chr3:23386571	T/G	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs2730245	0.569	rs1188955	chr7:158690866	A/G	cg11984989	chr7:158649758	WDR60	1.1	10.21	0.68	3.87e-18	Height;
TGCT	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.11	14.68	0.8	6.95e-29	Height;
TGCT	cis	rs7662987	0.517	rs2851265	chr4:100029684	A/G	cg12011299	chr4:100065546	ADH4	0.42	4.95	0.41	2.37e-6	Smoking initiation;
TGCT	cis	rs2439831	0.867	rs486301	chr15:43836949	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.98	7.46	0.56	1.35e-11	Lung cancer in ever smokers;
TGCT	cis	rs1784581	0.761	rs6455791	chr6:162418533	G/A	cg17173639	chr6:162384350	PARK2	0.44	7.6	0.56	6.3e-12	Itch intensity from mosquito bite;
TGCT	cis	rs11785400	0.762	rs9694556	chr8:143727841	A/G	cg10596483	chr8:143751796	JRK	0.53	5.3	0.43	5.12e-7	Schizophrenia;
TGCT	cis	rs6964587	0.967	rs6465353	chr7:91779971	G/T	cg17063962	chr7:91808500	NA	-0.84	-9.58	-0.65	1.34e-16	Breast cancer;
TGCT	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg23131131	chr22:24373011	LOC391322	-0.84	-9.16	-0.64	1.33e-15	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg20203395	chr5:56204925	C5orf35	-0.59	-5.12	-0.42	1.12e-6	Initial pursuit acceleration;
TGCT	cis	rs75686122	0.892	rs76161982	chr8:104659745	C/T	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs2832077	0.527	rs2705690	chr21:30239245	T/A	cg24692254	chr21:30365293	RNF160	0.59	4.98	0.41	2.04e-6	Cognitive test performance;
TGCT	cis	rs7659604	0.605	rs2071486	chr4:122740162	C/T	cg20573242	chr4:122745356	CCNA2	0.58	5.37	0.43	3.73e-7	Type 2 diabetes;
TGCT	cis	rs2730245	0.636	rs2657382	chr7:158650941	G/A	cg11984989	chr7:158649758	WDR60	1.05	9.79	0.66	4.1e-17	Height;
TGCT	cis	rs1799949	0.929	rs4792988	chr17:41437547	T/C	cg05368731	chr17:41323189	NBR1	1.11	11.95	0.73	2.23e-22	Menopause (age at onset);
TGCT	cis	rs939574	1.000	rs1109866	chr2:220083279	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-1.04	-6.24	-0.49	6.22e-9	Platelet distribution width;
TGCT	cis	rs2224391	0.784	rs59548069	chr6:5276595	T/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.8	-4.92	-0.4	2.64e-6	Height;
TGCT	cis	rs9831754	0.906	rs7621811	chr3:78388816	G/A	cg06138941	chr3:78371609	NA	-0.49	-5.4	-0.44	3.25e-7	Calcium levels;
TGCT	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg11871910	chr12:69753446	YEATS4	0.88	10.41	0.68	1.28e-18	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs10193935	0.901	rs13413617	chr2:42537546	A/G	cg27598129	chr2:42591480	NA	-0.34	-4.79	-0.4	4.65e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6840360	0.582	rs7691601	chr4:152321631	A/G	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.35	-0.5	3.68e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs2303745	0.544	rs12710308	chr19:17395879	T/A	cg04248312	chr19:17393744	ANKLE1	-0.34	-5.7	-0.46	8.29e-8	Systemic lupus erythematosus;
TGCT	cis	rs1568889	0.838	rs11030185	chr11:28041904	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.94	11.28	0.71	9.55e-21	Bipolar disorder;
TGCT	cis	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg18305652	chr10:134549665	INPP5A	0.31	4.94	0.41	2.44e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs1205863	1.000	rs1205867	chr6:11943991	C/T	cg07106625	chr6:11870215	NA	0.51	5.05	0.41	1.51e-6	Disc degeneration (lumbar);
TGCT	cis	rs9911578	0.967	rs302842	chr17:56728102	C/G	cg05425664	chr17:57184151	TRIM37	-0.64	-6.48	-0.5	1.99e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg03396347	chr1:1875803	NA	0.35	5.75	0.46	6.45e-8	Body mass index;
TGCT	cis	rs17253792	0.822	rs75995456	chr14:56073194	A/G	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs709400	0.628	rs3783394	chr14:103858673	G/A	cg26031613	chr14:104095156	KLC1	0.85	9.32	0.64	5.53e-16	Body mass index;
TGCT	cis	rs208520	0.690	rs12201219	chr6:66748862	A/T	cg07460842	chr6:66804631	NA	0.94	9.91	0.66	2.15e-17	Exhaled nitric oxide output;
TGCT	cis	rs16958440	0.867	rs79285649	chr18:44699019	A/T	cg17192377	chr18:44677553	HDHD2	0.63	4.7	0.39	6.74e-6	Sitting height ratio;
TGCT	cis	rs11696501	0.688	rs6065851	chr20:44279034	C/T	cg11783356	chr20:44313418	WFDC10B	-0.32	-4.63	-0.38	9.25e-6	Brain structure;
TGCT	cis	rs7666738	0.830	rs13138051	chr4:99050367	C/T	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs10506458	0.915	rs56321182	chr12:63392023	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.47	-7.58	-0.56	6.97e-12	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs9309473	0.519	rs2421584	chr2:73898852	G/A	cg20560298	chr2:73613845	ALMS1	0.41	4.51	0.38	1.46e-5	Metabolite levels;
TGCT	cis	rs151227923	1	rs151227923	chr7:155106564	C/T	cg14927855	chr7:155151427	NA	0.49	6.82	0.52	3.51e-10	Stem cell growth factor beta levels;
TGCT	cis	rs9611565	0.592	rs5758406	chr22:42076641	A/G	cg17554472	chr22:41940697	POLR3H	0.5	5.36	0.43	3.92e-7	Vitiligo;
TGCT	cis	rs3749237	0.595	rs885592	chr3:49497883	T/G	cg03060546	chr3:49711283	APEH	0.76	8.69	0.62	1.77e-14	Resting heart rate;
TGCT	cis	rs9674544	0.646	rs8069452	chr17:47140999	A/G	cg07075026	chr17:47091521	IGF2BP1	0.41	4.58	0.38	1.13e-5	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
TGCT	cis	rs7043114	0.525	rs7853859	chr9:95151377	A/G	cg14311495	chr9:95764742	FGD3	-0.21	-4.64	-0.38	8.89e-6	Height;
TGCT	cis	rs4455778	0.626	rs10230504	chr7:49052918	G/T	cg26309511	chr7:48887640	NA	0.45	5.25	0.43	6.32e-7	Lung cancer in never smokers;
TGCT	cis	rs7786808	0.586	rs7794256	chr7:158206214	T/G	cg01191920	chr7:158217561	PTPRN2	0.39	5.8	0.46	5.29e-8	Obesity-related traits;
TGCT	cis	rs6121246	0.909	rs6119651	chr20:30259246	G/T	cg13852791	chr20:30311386	BCL2L1	0.79	5.72	0.46	7.61e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg24829409	chr8:58192753	C8orf71	-0.57	-4.72	-0.39	6.14e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs3806843	0.517	rs246031	chr5:140333107	G/A	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs700651	0.789	rs1371663	chr2:198900305	C/T	cg00792783	chr2:198669748	PLCL1	-0.58	-4.96	-0.41	2.25e-6	Intracranial aneurysm;
TGCT	cis	rs7246657	0.722	rs2909100	chr19:38212680	C/T	cg03611452	chr19:38183253	ZNF781	-0.56	-4.63	-0.38	8.97e-6	Coronary artery calcification;
TGCT	cis	rs2956278	0.717	rs10161500	chr12:84685521	A/T	cg25678815	chr12:85673915	ALX1	-0.53	-4.76	-0.39	5.4e-6	Depressive symptoms;Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2859741	0.967	rs507460	chr1:37493206	C/G	cg09363841	chr1:37513479	NA	0.2	4.71	0.39	6.5e-6	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
TGCT	cis	rs2486288	0.656	rs9920290	chr15:45548035	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.72	-7.46	-0.56	1.34e-11	Glomerular filtration rate;
TGCT	cis	rs4808199	0.948	rs8108647	chr19:19427623	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.72	5.58	0.45	1.44e-7	Nonalcoholic fatty liver disease;
TGCT	cis	rs9818758	0.607	rs9855123	chr3:49229457	C/T	cg00383909	chr3:49044727	WDR6	1.28	6.57	0.51	1.23e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs12220238	1.000	rs11000916	chr10:75953909	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.91	7.77	0.57	2.63e-12	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs734999	0.545	rs7368072	chr1:2556125	C/T	cg18854424	chr1:2615690	NA	0.45	5.15	0.42	1e-6	Ulcerative colitis;
TGCT	cis	rs7552404	1.000	rs72686191	chr1:76218319	G/T	cg10523679	chr1:76189770	ACADM	0.92	9.55	0.65	1.53e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	trans	rs877282	0.700	rs816311	chr10:796490	C/A	cg22713356	chr15:30763199	NA	0.97	8.41	0.6	8.08e-14	Uric acid levels;
TGCT	cis	rs2637266	1.000	rs35991266	chr10:78378733	A/G	cg18941641	chr10:78392320	NA	0.4	4.73	0.39	6.03e-6	Pulmonary function;
TGCT	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.54	-0.38	1.33e-5	Bipolar disorder;
TGCT	cis	rs6693567	0.545	rs1260391	chr1:150373077	T/C	cg09579323	chr1:150459698	TARS2	0.52	4.64	0.38	8.63e-6	Migraine;
TGCT	cis	rs6967414	0.786	rs6948965	chr7:6758547	G/A	cg00387323	chr7:6746715	ZNF12	0.76	4.65	0.39	8.23e-6	Hematocrit;Hemoglobin concentration;
TGCT	cis	rs56235845	0.694	rs6875461	chr5:176754665	C/T	cg06060754	chr5:176797920	RGS14	-0.4	-6.25	-0.49	6.15e-9	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs6893807	0.943	rs13166120	chr5:87948883	G/A	cg24804195	chr5:87968844	LOC645323	0.75	5.48	0.44	2.28e-7	Body mass index;
TGCT	cis	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg20637647	chr7:64974828	NA	-0.95	-5.3	-0.43	5.09e-7	Diabetic kidney disease;
TGCT	cis	rs71444571	1	rs71444571	chr12:123771015	G/A	cg00376283	chr12:123451042	ABCB9	-0.67	-4.52	-0.38	1.42e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs910316	1.000	rs4903281	chr14:75554361	G/C	cg23033748	chr14:75592666	NEK9	0.28	4.68	0.39	7.29e-6	Height;
TGCT	cis	rs42648	0.755	rs1557650	chr7:89971556	A/C	cg25739043	chr7:89950458	NA	-0.67	-6.51	-0.5	1.65e-9	Homocysteine levels;
TGCT	cis	rs17401966	0.838	rs4846212	chr1:10370312	T/C	cg19773385	chr1:10388646	KIF1B	-0.22	-4.7	-0.39	6.81e-6	Hepatocellular carcinoma;
TGCT	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg23708337	chr7:1209742	NA	0.63	6.03	0.48	1.78e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7267979	0.739	rs6138555	chr20:25242910	G/A	cg03522245	chr20:25566470	NINL	0.57	5.67	0.45	9.54e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg27523141	chr10:43048294	ZNF37B	0.73	8.4	0.6	8.55e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs12220898	0.749	rs4838486	chr10:50484962	G/A	cg06072769	chr10:50146962	WDFY4	0.38	5.07	0.41	1.38e-6	Inflammatory biomarkers;
TGCT	cis	rs2404602	0.716	rs4886813	chr15:76838221	C/T	cg22467129	chr15:76604101	ETFA	0.42	4.77	0.39	5.1e-6	Blood metabolite levels;
TGCT	cis	rs17253792	0.822	rs7145064	chr14:56088860	C/T	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs12497850	0.931	rs7636057	chr3:48992582	C/T	cg06212747	chr3:49208901	KLHDC8B	0.6	5.43	0.44	2.82e-7	Parkinson's disease;
TGCT	trans	rs117132860	0.661	rs10275574	chr7:17118448	C/G	cg25519926	chr7:130132360	MEST;MESTIT1	0.95	6.72	0.52	5.93e-10	Cutaneous squamous cell carcinoma;
TGCT	cis	rs12220898	0.749	rs7068959	chr10:50468696	A/C	cg09603381	chr10:49954066	WDFY4	0.39	4.49	0.37	1.58e-5	Inflammatory biomarkers;
TGCT	cis	rs9929218	0.748	rs34592833	chr16:68739125	G/A	cg01251360	chr16:68772225	CDH1	0.29	4.68	0.39	7.37e-6	Colorectal cancer;
TGCT	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg00814883	chr7:100076585	TSC22D4	-0.92	-9.76	-0.66	4.73e-17	Platelet count;
TGCT	trans	rs9650657	0.547	rs11250099	chr8:10818657	C/T	cg15556689	chr8:8085844	FLJ10661	0.92	10.0	0.67	1.29e-17	Neuroticism;
TGCT	cis	rs7666738	0.606	rs28481322	chr4:99086638	T/C	cg17366294	chr4:99064904	C4orf37	0.57	5.34	0.43	4.31e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12765878	0.934	rs11191841	chr10:105639611	C/T	cg11005552	chr10:105648138	OBFC1	-0.41	-6.71	-0.52	6.34e-10	Coronary artery disease;
TGCT	cis	rs3902035	0.964	rs62423966	chr6:119010144	A/C	cg07617317	chr6:118971624	C6orf204	0.43	5.01	0.41	1.79e-6	QT interval;
TGCT	cis	rs11785400	0.793	rs4736366	chr8:143742413	C/T	cg10596483	chr8:143751796	JRK	0.55	5.43	0.44	2.82e-7	Schizophrenia;
TGCT	cis	rs6750047	0.605	rs1374191	chr2:38265420	T/G	cg07380506	chr2:38303506	CYP1B1	-0.59	-5.34	-0.43	4.23e-7	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs739496	0.895	rs614591	chr12:111946435	A/G	cg10833066	chr12:111807467	FAM109A	0.37	5.59	0.45	1.4e-7	Platelet count;
TGCT	cis	rs8002180	0.877	rs7325813	chr13:95920679	T/A	cg24476569	chr13:95954382	ABCC4	0.39	4.97	0.41	2.2e-6	Blood metabolite levels;
TGCT	cis	rs896854	0.738	rs1713669	chr8:95958637	C/G	cg13393036	chr8:95962371	TP53INP1	-0.55	-6.79	-0.52	4.12e-10	Type 2 diabetes;
TGCT	cis	rs11690935	0.959	rs7597387	chr2:172577116	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.18	-12.58	-0.75	6.59e-24	Schizophrenia;
TGCT	trans	rs208520	0.874	rs208512	chr6:66943869	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-9.93	-0.67	1.84e-17	Exhaled nitric oxide output;
TGCT	cis	rs909674	0.818	rs5757680	chr22:39844793	C/T	cg02038168	chr22:39784481	NA	0.7	5.42	0.44	3.03e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg27454412	chr7:1067447	C7orf50	0.57	4.46	0.37	1.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg03188948	chr7:1209495	NA	0.44	5.79	0.46	5.49e-8	Longevity;Endometriosis;
TGCT	cis	rs7681440	0.775	rs6848181	chr4:90807252	T/C	cg26578617	chr4:90757533	SNCA	-0.45	-4.63	-0.38	9.12e-6	Dementia with Lewy bodies;
TGCT	cis	rs968567	0.559	rs174548	chr11:61571348	C/G	cg01500311	chr11:61656094	FADS3	-0.28	-4.82	-0.4	4.17e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
TGCT	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg07061783	chr6:25882402	NA	-0.55	-5.18	-0.42	8.75e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs10193935	1.000	rs10173107	chr2:42420302	A/T	cg27598129	chr2:42591480	NA	-0.39	-5.14	-0.42	1.05e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg11905131	chr22:24372483	LOC391322	-0.89	-10.25	-0.68	3.1e-18	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs111803315	1.000	rs111489600	chr14:59993021	G/A	cg22995959	chr14:59931024	GPR135	0.66	4.8	0.4	4.39e-6	Schizophrenia;
TGCT	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg25036284	chr2:26402008	FAM59B	0.65	5.19	0.42	8.36e-7	Gut microbiome composition (summer);
TGCT	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg06558623	chr16:89946397	TCF25	0.5	6.04	0.48	1.68e-8	Skin colour saturation;
TGCT	cis	rs4642101	0.662	rs9840766	chr3:12821870	G/A	cg05775895	chr3:12838266	CAND2	0.89	9.51	0.65	1.94e-16	QRS complex (12-leadsum);
TGCT	cis	rs13202913	0.518	rs13205543	chr6:151813779	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.72	-4.46	-0.37	1.78e-5	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs7226408	0.842	rs11660592	chr18:34333952	A/G	cg06757138	chr18:34340585	FHOD3	0.29	4.95	0.41	2.4e-6	Obesity-related traits;
TGCT	cis	rs3096299	0.728	rs1011749	chr16:89510869	G/C	cg08392591	chr16:89556376	ANKRD11	0.64	6.12	0.48	1.14e-8	Multiple myeloma (IgH translocation);
TGCT	cis	rs2657888	0.965	rs67036743	chr12:56948786	C/A	cg23002907	chr12:56915593	RBMS2	-0.45	-5.77	-0.46	5.87e-8	Adiponectin levels;
TGCT	cis	rs7824557	0.518	rs11250094	chr8:10802001	G/C	cg27411982	chr8:10470053	RP1L1	-0.24	-5.04	-0.41	1.62e-6	Retinal vascular caliber;
TGCT	cis	rs7772486	0.719	rs7753770	chr6:146066161	G/A	cg13319975	chr6:146136371	FBXO30	0.56	4.93	0.4	2.56e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6840360	0.598	rs11944921	chr4:152731109	A/G	cg22705602	chr4:152727874	NA	0.27	4.89	0.4	3.08e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs739401	0.611	rs2301140	chr11:3022629	C/T	cg05729581	chr11:3078854	CARS	-0.53	-5.04	-0.41	1.61e-6	Longevity;
TGCT	cis	rs61990749	0.597	rs1477262	chr14:78226653	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	0.6	4.45	0.37	1.88e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs11249608	0.548	rs35568336	chr5:178451854	A/G	cg01312482	chr5:178451176	ZNF879	-0.56	-5.5	-0.44	2.09e-7	Pubertal anthropometrics;
TGCT	cis	rs67478160	0.634	rs2024669	chr14:104275602	G/C	cg01849466	chr14:104193079	ZFYVE21	-0.17	-4.44	-0.37	2e-5	Schizophrenia;
TGCT	cis	rs7786808	0.536	rs4909210	chr7:158194376	T/C	cg01191920	chr7:158217561	PTPRN2	-0.36	-5.55	-0.45	1.63e-7	Obesity-related traits;
TGCT	cis	rs61935443	0.666	rs11107780	chr12:95299142	G/A	cg21533806	chr12:95267307	NA	0.58	4.85	0.4	3.7e-6	Schizophrenia;
TGCT	cis	rs4727027	0.899	rs7791496	chr7:148863674	C/G	cg23583168	chr7:148888333	NA	-0.76	-10.09	-0.67	7.46e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs909002	0.849	rs6663012	chr1:32091779	T/G	cg13919466	chr1:32135498	COL16A1	-0.32	-4.46	-0.37	1.82e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs1577917	1.000	rs4707239	chr6:86610717	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.05	-0.41	1.57e-6	Response to antipsychotic treatment;
TGCT	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg03264133	chr6:25882463	NA	-0.65	-5.98	-0.47	2.26e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg11764359	chr7:65958608	NA	0.59	5.28	0.43	5.53e-7	Aortic root size;
TGCT	cis	rs2243480	0.522	rs12698511	chr7:65474919	G/T	cg07424592	chr7:64974309	NA	1.51	8.49	0.61	5.38e-14	Diabetic kidney disease;
TGCT	cis	rs7246657	0.525	rs10401417	chr19:37467540	C/T	cg18154014	chr19:37997991	ZNF793	0.73	4.58	0.38	1.11e-5	Coronary artery calcification;
TGCT	cis	rs6901004	0.685	rs354550	chr6:111546484	G/A	cg15721981	chr6:111408429	SLC16A10	-0.53	-4.58	-0.38	1.11e-5	Blood metabolite levels;
TGCT	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg06873352	chr17:61820015	STRADA	0.55	6.13	0.48	1.09e-8	Prudent dietary pattern;
TGCT	cis	rs10782582	0.609	rs79835994	chr1:76287508	G/T	cg10523679	chr1:76189770	ACADM	-0.59	-5.42	-0.44	2.94e-7	Daytime sleep phenotypes;
TGCT	cis	rs7267979	0.966	rs6037103	chr20:25369095	A/G	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6723226	0.732	rs390480	chr2:32510072	A/C	cg02381751	chr2:32503542	YIPF4	-0.51	-5.3	-0.43	5.23e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs554111	0.634	rs12026318	chr1:21316623	T/C	cg01072550	chr1:21505969	NA	0.36	5.43	0.44	2.9e-7	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg20637647	chr7:64974828	NA	1.0	5.59	0.45	1.4e-7	Diabetic kidney disease;
TGCT	cis	rs3733585	0.673	rs7376948	chr4:9954708	G/A	cg00071950	chr4:10020882	SLC2A9	-0.55	-6.48	-0.5	1.93e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7666738	0.830	rs11097605	chr4:98985167	T/C	cg17366294	chr4:99064904	C4orf37	0.68	6.94	0.53	1.95e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg13699009	chr12:122356056	WDR66	0.29	5.64	0.45	1.09e-7	Mean corpuscular volume;
TGCT	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg02187348	chr16:89574699	SPG7	0.64	6.75	0.52	5.08e-10	Multiple myeloma (IgH translocation);
TGCT	cis	rs7772486	0.754	rs6922507	chr6:146250155	A/T	cg23711669	chr6:146136114	FBXO30	-0.89	-10.38	-0.68	1.54e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.56	-5.5	-0.44	2.1e-7	Electroencephalogram traits;
TGCT	cis	rs2455799	0.613	rs1532767	chr3:15733600	A/T	cg16303742	chr3:15540471	COLQ	-0.25	-4.57	-0.38	1.15e-5	Mean platelet volume;
TGCT	cis	rs1784581	0.855	rs1790002	chr6:162384397	G/T	cg17173639	chr6:162384350	PARK2	-0.5	-9.31	-0.64	6.05e-16	Itch intensity from mosquito bite;
TGCT	cis	rs12898370	0.561	rs8028830	chr15:77508046	A/G	cg27398640	chr15:77910606	LINGO1	-0.33	-4.58	-0.38	1.12e-5	Risky sexual behaviors (alcohol dependence interaction);
TGCT	cis	rs9914988	0.559	rs1109024	chr17:27189971	C/T	cg20469991	chr17:27169893	C17orf63	0.69	5.06	0.41	1.5e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs1894292	0.505	rs35233345	chr4:74362387	G/A	cg05868023	chr4:75230803	EREG	0.53	4.52	0.38	1.43e-5	Prostate cancer;
TGCT	cis	rs10089	1.000	rs4835941	chr5:127430905	C/T	cg19767477	chr5:127420684	SLC12A2	-0.43	-4.52	-0.38	1.43e-5	Ileal carcinoids;
TGCT	cis	rs1669338	0.588	rs3846135	chr3:3195574	C/T	cg16797762	chr3:3221439	CRBN	-0.89	-5.74	-0.46	6.95e-8	White matter integrity;
TGCT	trans	rs1908814	0.516	rs7833079	chr8:11792129	A/G	cg15556689	chr8:8085844	FLJ10661	0.75	7.26	0.55	3.66e-11	Neuroticism;
TGCT	cis	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg22857025	chr5:266934	NA	-0.33	-6.6	-0.51	1.1e-9	Breast cancer;
TGCT	cis	rs739496	0.843	rs4766462	chr12:111871141	A/T	cg10833066	chr12:111807467	FAM109A	0.36	5.51	0.44	2.01e-7	Platelet count;
TGCT	cis	rs1538970	0.781	rs10890330	chr1:45920406	G/A	cg05343316	chr1:45956843	TESK2	0.86	6.87	0.53	2.7e-10	Platelet count;
TGCT	trans	rs66573146	1.000	rs56350643	chr4:7017591	G/A	cg07817883	chr1:32538562	TMEM39B	1.69	8.36	0.6	1.1e-13	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg21963583	chr11:68658836	MRPL21	0.34	5.66	0.45	9.96e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	trans	rs17685	0.753	rs2302435	chr7:75676987	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.5	-8.42	-0.6	7.75e-14	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs5769707	0.609	rs2071890	chr22:50001291	G/A	cg05373962	chr22:49881684	NA	-0.31	-5.25	-0.43	6.36e-7	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs36051895	0.695	rs1327494	chr9:4999303	A/G	cg02405213	chr9:5042618	JAK2	-0.73	-9.46	-0.65	2.54e-16	Pediatric autoimmune diseases;
TGCT	cis	rs7917772	0.636	rs10786708	chr10:104526245	C/T	cg05855489	chr10:104503620	C10orf26	-0.65	-5.33	-0.43	4.54e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs709400	1.000	rs56660916	chr14:104126137	G/T	cg26031613	chr14:104095156	KLC1	1.14	17.16	0.84	1.53e-34	Body mass index;
TGCT	cis	rs273218	0.573	rs11742692	chr5:53343576	C/T	ch.5.1024479R	chr5:53302184	ARL15	-0.71	-5.56	-0.45	1.55e-7	Migraine;
TGCT	cis	rs62064224	0.589	rs2344976	chr17:30685935	T/C	cg18200150	chr17:30822561	MYO1D	0.39	4.76	0.39	5.35e-6	Schizophrenia;
TGCT	cis	rs3774830	0.714	rs73212742	chr4:5464915	A/G	cg26943120	chr4:5472116	STK32B	0.22	4.82	0.4	4.15e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7647973	0.667	rs6446286	chr3:49681704	A/G	cg05785598	chr3:49045655	WDR6	0.42	5.24	0.43	6.67e-7	Menarche (age at onset);
TGCT	cis	rs709400	0.628	rs7150317	chr14:103921691	C/G	cg26031613	chr14:104095156	KLC1	0.84	9.43	0.65	2.98e-16	Body mass index;
TGCT	cis	rs6095298	0.595	rs8124687	chr20:47453776	T/C	cg12307787	chr20:48099359	KCNB1	0.42	4.51	0.38	1.51e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7959452	0.570	rs10878964	chr12:69720691	T/G	cg11871910	chr12:69753446	YEATS4	0.63	6.42	0.5	2.57e-9	Blood protein levels;
TGCT	cis	rs9486715	0.867	rs9384602	chr6:96919561	G/A	cg18709589	chr6:96969512	KIAA0776	0.82	8.02	0.58	6.9e-13	Headache;
TGCT	cis	rs2302045	1.000	rs78797111	chr2:242056048	T/C	cg04553960	chr2:241721320	KIF1A	-0.7	-4.68	-0.39	7.4e-6	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio);
TGCT	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg02725872	chr8:58115012	NA	-0.39	-5.25	-0.43	6.44e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg10802521	chr3:52805072	NEK4	-0.72	-8.83	-0.62	8.28e-15	Bipolar disorder;
TGCT	trans	rs10203711	0.966	rs6713626	chr2:239566896	C/T	cg16021909	chr1:248021091	TRIM58	-0.66	-6.66	-0.51	7.94e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11031096	0.542	rs10742200	chr11:3989521	A/T	cg18678763	chr11:4115507	RRM1	-0.42	-5.14	-0.42	1.04e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs6964587	1.000	rs10228800	chr7:91610111	T/G	cg22709100	chr7:91322751	NA	0.27	4.48	0.37	1.68e-5	Breast cancer;
TGCT	cis	rs4730250	0.707	rs257377	chr7:106801088	G/T	cg02696742	chr7:106810147	HBP1	-0.71	-5.89	-0.47	3.42e-8	Osteoarthritis;
TGCT	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg05368731	chr17:41323189	NBR1	1.0	10.83	0.7	1.18e-19	Menopause (age at onset);
TGCT	cis	rs4711350	0.765	rs943476	chr6:33750086	A/G	cg18005901	chr6:33739558	LEMD2	-0.55	-6.02	-0.48	1.85e-8	Schizophrenia;
TGCT	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg13699009	chr12:122356056	WDR66	0.29	5.7	0.46	8.3e-8	Mean corpuscular volume;
TGCT	cis	rs938554	0.657	rs7679724	chr4:9985376	G/T	cg11266682	chr4:10021025	SLC2A9	0.47	4.76	0.39	5.19e-6	Blood metabolite levels;
TGCT	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.51	5.4	0.44	3.28e-7	Lymphocyte counts;
TGCT	cis	rs10876993	0.928	rs1678530	chr12:58054076	A/C	cg15848620	chr12:58087721	OS9	-0.73	-5.94	-0.47	2.74e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs11190604	1.000	rs3750720	chr10:102248884	C/T	cg23241863	chr10:102295624	HIF1AN	0.59	4.45	0.37	1.92e-5	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7412746	0.658	rs4970986	chr1:150907955	A/G	cg09365446	chr1:150670422	GOLPH3L	0.34	4.71	0.39	6.58e-6	Melanoma;
TGCT	cis	rs210152	0.541	rs36003672	chr6:33457816	T/A	cg16739976	chr6:34101401	GRM4	0.58	4.75	0.39	5.47e-6	Schizophrenia;
TGCT	cis	rs6570726	0.935	rs391524	chr6:145823844	A/G	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10057188	0.545	rs10069173	chr5:77929023	A/C	cg17456851	chr5:78090622	ARSB	0.28	4.53	0.38	1.36e-5	Pulse pressure;
TGCT	cis	rs17253792	0.558	rs10083353	chr14:56066370	G/T	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs11785400	0.928	rs750529	chr8:143744877	G/C	cg10596483	chr8:143751796	JRK	0.56	6.05	0.48	1.61e-8	Schizophrenia;
TGCT	cis	rs35146811	0.700	rs7788301	chr7:99782753	C/G	cg13334819	chr7:99746414	C7orf59	-0.74	-6.31	-0.49	4.4e-9	Coronary artery disease;
TGCT	cis	rs1505368	0.543	rs13413590	chr2:213292329	C/T	cg20637307	chr2:213403960	ERBB4	0.53	4.99	0.41	2.02e-6	Symmetrical dimethylarginine levels;
TGCT	cis	rs7607369	0.580	rs7568196	chr2:219652373	G/A	cg02176678	chr2:219576539	TTLL4	-0.44	-5.46	-0.44	2.54e-7	Red blood cell count;Amyotrophic lateral sclerosis;
TGCT	cis	rs56399783	0.901	rs73049380	chr7:2832845	C/T	cg19731401	chr7:2775893	GNA12	0.37	4.89	0.4	3.12e-6	Childhood ear infection;
TGCT	cis	rs4383453	0.539	rs4678020	chr3:123102353	C/T	cg04890266	chr3:123102914	ADCY5	-0.49	-7.91	-0.58	1.23e-12	Gestational age at birth (maternal effect);
TGCT	cis	rs4727027	0.933	rs6955564	chr7:148866173	A/G	cg23583168	chr7:148888333	NA	-0.74	-9.82	-0.66	3.47e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs13168506	0.518	rs6883838	chr5:135543677	A/G	cg07158503	chr5:135415693	NA	-0.42	-4.68	-0.39	7.24e-6	Stroke;
TGCT	cis	rs10791323	0.572	rs10750551	chr11:133737462	G/A	cg15485101	chr11:133734466	NA	0.42	6.12	0.48	1.14e-8	Childhood ear infection;
TGCT	cis	rs11031096	0.678	rs11031220	chr11:4197638	G/A	cg18678763	chr11:4115507	RRM1	-0.46	-6.03	-0.48	1.78e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs782590	0.967	rs10496050	chr2:55806313	C/T	cg03859395	chr2:55845619	SMEK2	0.92	11.39	0.72	5.08e-21	Metabolic syndrome;
TGCT	cis	rs67478160	0.654	rs11628240	chr14:104218135	A/G	cg26031613	chr14:104095156	KLC1	-0.63	-6.53	-0.51	1.56e-9	Schizophrenia;
TGCT	cis	rs7044106	1.000	rs7044106	chr9:123494062	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	4.65	0.39	8.42e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs7909074	1.000	rs4481983	chr10:45400428	G/T	cg05187965	chr10:45406764	TMEM72	-0.24	-5.02	-0.41	1.73e-6	Mean corpuscular volume;
TGCT	cis	rs79976124	0.837	rs10944858	chr6:66646039	G/A	cg07460842	chr6:66804631	NA	0.57	5.22	0.42	7.44e-7	Type 2 diabetes;
TGCT	cis	rs5769765	0.773	rs9616206	chr22:50310847	G/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.44	6.19	0.49	8.22e-9	Schizophrenia;
TGCT	cis	rs929354	0.713	rs6946660	chr7:156948648	T/C	cg05182265	chr7:156933206	UBE3C	-0.39	-8.98	-0.63	3.72e-15	Body mass index;
TGCT	cis	rs7843479	0.506	rs7818430	chr8:21798429	C/T	cg17168535	chr8:21777572	XPO7	0.81	8.33	0.6	1.28e-13	Mean corpuscular volume;
TGCT	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg08048268	chr3:133502702	NA	0.65	9.82	0.66	3.47e-17	Iron status biomarkers;
TGCT	cis	rs7584330	0.910	rs880932	chr2:238396963	A/G	cg14458575	chr2:238380390	NA	0.49	6.96	0.53	1.75e-10	Prostate cancer;
TGCT	cis	rs1355223	0.583	rs1553757	chr11:34867089	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.75	8.13	0.59	3.8e-13	Systemic lupus erythematosus and Systemic sclerosis;
TGCT	cis	rs4148883	0.675	rs11724783	chr4:100099688	C/A	cg12011299	chr4:100065546	ADH4	0.39	5.85	0.47	4.03e-8	Alcohol dependence;
TGCT	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.31	-4.82	-0.4	4.12e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	trans	rs1814175	0.817	rs11040651	chr11:49938395	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.36	-7.05	-0.53	1.13e-10	Height;
TGCT	cis	rs4478858	0.684	rs12135540	chr1:31764693	G/A	cg00250761	chr1:31883323	NA	-0.25	-4.48	-0.37	1.64e-5	Alcohol dependence;
TGCT	cis	rs986417	0.748	rs4899011	chr14:60986698	A/G	cg27398547	chr14:60952738	C14orf39	1.38	10.8	0.7	1.4e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs9467711	0.659	rs35555795	chr6:26509382	C/T	cg16898833	chr6:26189333	HIST1H4D	1.24	5.61	0.45	1.26e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9467711	0.606	rs9379871	chr6:26375854	C/G	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs17102423	0.768	rs8005829	chr14:65576165	C/T	cg11161011	chr14:65562177	MAX	0.43	5.68	0.45	9.04e-8	Obesity-related traits;
TGCT	cis	rs2153535	0.580	rs7769020	chr6:8457724	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs2760061	0.626	rs594916	chr1:228133544	C/A	cg02753203	chr1:228287806	NA	-0.34	-6.56	-0.51	1.33e-9	Diastolic blood pressure;
TGCT	cis	rs6912958	0.781	rs4707379	chr6:88310623	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-4.57	-0.38	1.16e-5	Monocyte percentage of white cells;
TGCT	cis	rs7772486	0.754	rs9399561	chr6:145955687	C/G	cg05347473	chr6:146136440	FBXO30	0.53	4.97	0.41	2.2e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	5.92	0.47	2.92e-8	Alzheimer's disease;
TGCT	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg24675658	chr1:53192096	ZYG11B	0.7	7.98	0.58	8.59e-13	Monocyte count;
TGCT	cis	rs12220898	0.749	rs7911514	chr10:50485523	T/G	cg06072769	chr10:50146962	WDFY4	0.38	5.07	0.41	1.38e-6	Inflammatory biomarkers;
TGCT	cis	rs4730250	0.670	rs9641380	chr7:106868151	C/G	cg02696742	chr7:106810147	HBP1	-0.71	-5.76	-0.46	6.26e-8	Osteoarthritis;
TGCT	cis	rs13217239	0.646	rs4583981	chr6:26992023	G/T	cg05738196	chr6:26577821	NA	0.49	4.78	0.39	4.97e-6	Schizophrenia;
TGCT	cis	rs35883536	0.626	rs7536054	chr1:101047849	A/G	cg10298815	chr1:101004474	GPR88	-0.25	-4.5	-0.37	1.54e-5	Monocyte count;
TGCT	trans	rs2243480	1.000	rs2707844	chr7:66059509	G/A	cg07424592	chr7:64974309	NA	1.3	8.23	0.59	2.19e-13	Diabetic kidney disease;
TGCT	cis	rs6121246	0.567	rs6060297	chr20:30198560	A/G	cg21427119	chr20:30132790	HM13	-0.43	-6.17	-0.48	8.86e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs12530845	0.943	rs78188670	chr7:135335163	T/C	cg23117316	chr7:135346802	PL-5283	-0.51	-4.83	-0.4	3.98e-6	Red blood cell traits;
TGCT	cis	rs1008375	0.966	rs6813375	chr4:17649499	T/G	cg10189774	chr4:17578691	LAP3	0.6	5.29	0.43	5.23e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9399135	0.816	rs4134030	chr6:135354094	G/T	cg24558204	chr6:135376177	HBS1L	0.48	4.77	0.39	5.14e-6	Red blood cell count;
TGCT	cis	rs4642101	0.561	rs7641959	chr3:12810755	G/C	cg04715183	chr3:11886989	C3orf31	-0.17	-4.44	-0.37	2e-5	QRS complex (12-leadsum);
TGCT	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg03452623	chr4:187889614	NA	-0.36	-5.34	-0.43	4.3e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs950169	0.544	rs62021193	chr15:85170583	C/G	cg11189052	chr15:85197271	WDR73	0.75	6.25	0.49	5.98e-9	Schizophrenia;
TGCT	trans	rs10506458	0.915	rs998505	chr12:63400018	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.47	-7.58	-0.56	6.97e-12	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs1153858	0.887	rs7171163	chr15:45636395	A/C	cg14582100	chr15:45693742	SPATA5L1	0.48	5.7	0.46	8.17e-8	Homoarginine levels;
TGCT	cis	rs1371867	0.810	rs2919470	chr8:101233301	C/A	cg06002616	chr8:101225028	SPAG1	0.52	5.91	0.47	3.1e-8	Atrioventricular conduction;
TGCT	cis	rs2742417	1.000	rs2742406	chr3:45760600	C/T	cg04837898	chr3:45731254	SACM1L	-0.51	-5.27	-0.43	5.85e-7	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs3806843	1.000	rs1548699	chr5:140164918	T/C	cg19875535	chr5:140030758	IK	0.37	6.17	0.48	8.88e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2204008	0.713	rs2320522	chr12:38251438	C/T	cg26384229	chr12:38710491	ALG10B	0.86	7.48	0.56	1.17e-11	Bladder cancer;
TGCT	cis	rs17473412	1.000	rs74455127	chr5:122746164	T/A	cg15125798	chr5:122621645	NA	-0.6	-5.38	-0.44	3.52e-7	Total body bone mineral density;
TGCT	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.44	0.44	2.74e-7	Tonsillectomy;
TGCT	cis	rs11690935	1.000	rs6721680	chr2:172543913	G/T	cg13550731	chr2:172543902	DYNC1I2	1.2	12.95	0.76	8.62e-25	Schizophrenia;
TGCT	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg12963246	chr6:28129442	ZNF389	0.51	5.02	0.41	1.73e-6	Depression;
TGCT	cis	rs6912958	0.535	rs1753153	chr6:88032834	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.43	5.57	0.45	1.51e-7	Monocyte percentage of white cells;
TGCT	cis	rs6586111	1.000	rs6586107	chr10:82373516	C/T	cg03086067	chr10:82368399	SH2D4B	0.26	5.23	0.43	6.93e-7	Capecitabine sensitivity;
TGCT	cis	rs1008375	0.966	rs28441502	chr4:17598384	G/A	cg16339924	chr4:17578868	LAP3	0.74	6.32	0.49	4.28e-9	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs55962025	0.804	rs2269499	chr4:3239702	C/T	cg06533319	chr4:3265114	C4orf44	0.24	4.86	0.4	3.48e-6	Parental longevity (mother's age at death);
TGCT	trans	rs1116255	0.725	rs9569158	chr13:55554192	A/G	cg27012908	chr16:22345154	POLR3E	0.52	6.93	0.53	2.05e-10	Post-traumatic stress disorder;
TGCT	cis	rs7809950	0.723	rs62483633	chr7:106876644	T/G	cg23024343	chr7:107201750	COG5	-0.43	-6.11	-0.48	1.19e-8	Coronary artery disease;
TGCT	cis	rs861020	0.771	rs654470	chr1:210014093	A/T	cg05527609	chr1:210001259	C1orf107	1.05	9.38	0.64	4e-16	Orofacial clefts;
TGCT	cis	rs35306767	0.714	rs10508206	chr10:1075777	A/C	cg20503657	chr10:835505	NA	0.51	5.79	0.46	5.46e-8	Eosinophil percentage of granulocytes;
TGCT	cis	rs7000551	0.663	rs11778831	chr8:22335088	C/T	cg12081754	chr8:22256438	SLC39A14	0.3	4.97	0.41	2.14e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs6450176	1.000	rs3776702	chr5:53305419	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.49	-4.6	-0.38	1.03e-5	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs11792861	0.781	rs17729408	chr9:111740860	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.5	-4.72	-0.39	6.2e-6	Menarche (age at onset);
TGCT	cis	rs6500602	0.727	rs55939215	chr16:4541390	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.3	5.52	0.44	1.86e-7	Schizophrenia;
TGCT	cis	rs7208859	0.623	rs9914499	chr17:29107588	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs10501293	0.709	rs10768911	chr11:43028688	G/T	cg03447554	chr11:43094025	NA	0.44	6.28	0.49	5.14e-9	Cognitive performance;
TGCT	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg22535103	chr8:58192502	C8orf71	-0.42	-4.79	-0.4	4.7e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs8013055	0.898	rs8004007	chr14:105971435	G/C	cg25008857	chr14:105974488	NA	0.28	4.65	0.39	8.41e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs12220238	0.915	rs2894235	chr10:76082945	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.9	6.28	0.49	5.18e-9	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg03517284	chr6:25882590	NA	-0.65	-6.72	-0.52	5.87e-10	Blood metabolite levels;
TGCT	cis	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg18252515	chr7:66147081	NA	-1.31	-8.18	-0.59	2.87e-13	Diabetic kidney disease;
TGCT	cis	rs11031096	0.621	rs11031159	chr11:4179695	T/G	cg18678763	chr11:4115507	RRM1	-0.43	-5.51	-0.44	1.99e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.04	0.53	1.16e-10	Prudent dietary pattern;
TGCT	cis	rs651907	0.557	rs3094296	chr3:101400167	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.33	-6.6	-0.51	1.09e-9	Colorectal cancer;
TGCT	cis	rs7674212	0.539	rs6850461	chr4:104120041	C/T	cg16532752	chr4:104119610	CENPE	-0.6	-5.46	-0.44	2.51e-7	Type 2 diabetes;
TGCT	cis	rs10746514	1.000	rs9724948	chr1:232248244	C/T	cg09506761	chr1:232265262	NA	0.5	5.11	0.42	1.17e-6	Response to statin therapy;
TGCT	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg11764359	chr7:65958608	NA	0.59	5.28	0.43	5.53e-7	Aortic root size;
TGCT	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg25703541	chr22:24373054	LOC391322	-0.82	-8.62	-0.61	2.61e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1215050	0.791	rs783959	chr4:98893476	C/T	cg17366294	chr4:99064904	C4orf37	-0.55	-5.92	-0.47	2.97e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs240764	0.658	rs1336244	chr6:101197953	C/T	cg09795085	chr6:101329169	ASCC3	-0.51	-4.51	-0.38	1.45e-5	Neuroticism;
TGCT	cis	rs2463822	1.000	rs115395195	chr11:62100353	G/A	cg23876832	chr11:62092739	NA	-0.65	-4.56	-0.38	1.19e-5	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs7572733	0.515	rs893808	chr2:198860837	C/G	cg00792783	chr2:198669748	PLCL1	0.57	5.1	0.42	1.24e-6	Dermatomyositis;
TGCT	cis	rs9913156	0.793	rs8074545	chr17:4567337	C/G	cg23387401	chr17:4582204	PELP1	-0.31	-4.63	-0.38	8.97e-6	Lymphocyte counts;
TGCT	trans	rs3780486	0.713	rs3780489	chr9:33129844	G/T	cg04842962	chr6:43655489	MRPS18A	1.24	15.83	0.82	1.46e-31	IgG glycosylation;
TGCT	cis	rs9527	0.590	rs7906754	chr10:104782557	T/C	cg04362960	chr10:104952993	NT5C2	0.65	5.54	0.45	1.73e-7	Arsenic metabolism;
TGCT	cis	rs1008375	0.866	rs12233712	chr4:17570063	T/A	cg16339924	chr4:17578868	LAP3	0.75	6.62	0.51	9.69e-10	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs11577318	0.579	rs11583205	chr1:26684141	C/A	cg14210634	chr1:25870291	LDLRAP1	0.53	4.62	0.38	9.59e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs9858542	0.953	rs9853683	chr3:49512588	A/G	cg03060546	chr3:49711283	APEH	-0.61	-5.37	-0.43	3.78e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs4786125	0.920	rs6500852	chr16:6896649	A/G	cg03623568	chr16:6915990	A2BP1	-0.35	-4.76	-0.39	5.25e-6	Heart rate variability traits (SDNN);
TGCT	cis	rs7267979	0.933	rs2387887	chr20:25427081	G/T	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs13064411	0.660	rs3829889	chr3:113015464	G/A	cg18753928	chr3:113234510	CCDC52	-0.71	-5.09	-0.42	1.29e-6	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.71	5.14	0.42	1.02e-6	Platelet count;
TGCT	cis	rs28595532	0.920	rs116634064	chr4:119736514	C/T	cg11846333	chr4:119757529	SEC24D	0.93	4.44	0.37	2e-5	Cannabis dependence symptom count;
TGCT	cis	rs6582630	0.555	rs11181684	chr12:38388000	T/C	cg26384229	chr12:38710491	ALG10B	0.8	6.88	0.53	2.6200000000000003e-10	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs3820068	0.603	rs1980607	chr1:15975237	A/G	cg05660106	chr1:15850417	CASP9	0.82	8.06	0.59	5.53e-13	Systolic blood pressure;
TGCT	cis	rs9467773	0.526	rs12199613	chr6:26367218	C/T	cg15659132	chr6:26577336	NA	-0.5	-5.05	-0.41	1.53e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6901250	0.632	rs1853080	chr6:117196157	T/C	cg12892004	chr6:117198278	RFX6	-0.45	-5.68	-0.45	9e-8	C-reactive protein levels;
TGCT	cis	rs67460515	0.892	rs34896809	chr3:161059804	C/T	cg03342759	chr3:160939853	NMD3	-0.54	-5.9	-0.47	3.25e-8	Parkinson's disease;
TGCT	cis	rs7107174	0.892	rs7115850	chr11:78045071	C/G	cg12700464	chr11:78128424	GAB2	-0.61	-4.48	-0.37	1.67e-5	Testicular germ cell tumor;
TGCT	cis	rs7819412	0.594	rs60921132	chr8:10964969	T/A	cg12940923	chr8:10282607	MSRA	-0.19	-4.61	-0.38	1e-5	Triglycerides;
TGCT	cis	rs2115630	0.645	rs3825878	chr15:85174755	C/T	cg11189052	chr15:85197271	WDR73	-0.76	-7.38	-0.55	1.99e-11	P wave terminal force;
TGCT	cis	rs9916302	0.768	rs62077464	chr17:37656056	C/G	cg07936489	chr17:37558343	FBXL20	-0.62	-4.87	-0.4	3.4e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs57590327	0.679	rs17018967	chr3:81512209	G/A	cg07356753	chr3:81810745	GBE1	-0.53	-4.44	-0.37	1.97e-5	Extraversion;
TGCT	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.61	5.06	0.41	1.5e-6	Tonsillectomy;
TGCT	cis	rs6901004	0.803	rs1150083	chr6:111510767	C/T	cg15721981	chr6:111408429	SLC16A10	-0.53	-4.64	-0.38	8.82e-6	Blood metabolite levels;
TGCT	cis	rs12497850	0.931	rs11920534	chr3:48937761	G/T	cg05785598	chr3:49045655	WDR6	0.36	4.75	0.39	5.46e-6	Parkinson's disease;
TGCT	cis	rs208520	0.955	rs208538	chr6:66964492	C/G	cg07460842	chr6:66804631	NA	-0.82	-7.44	-0.56	1.46e-11	Exhaled nitric oxide output;
TGCT	cis	rs2749592	0.588	rs2504144	chr10:38383525	C/T	cg25427524	chr10:38739819	LOC399744	-0.4	-7.02	-0.53	1.27e-10	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs992157	0.560	rs10932763	chr2:219085863	G/C	cg00012203	chr2:219082015	ARPC2	-0.81	-9.36	-0.64	4.37e-16	Colorectal cancer;
TGCT	cis	rs10838634	1.000	rs11822959	chr11:46806553	C/T	cg18332754	chr11:46939436	LRP4	0.84	4.66	0.39	8.02e-6	Schizophrenia;
TGCT	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg11494091	chr17:61959527	GH2	0.6	14.54	0.79	1.46e-28	Prudent dietary pattern;
TGCT	cis	rs4372836	0.518	rs12472549	chr2:28992004	T/C	cg09522027	chr2:28974177	PPP1CB	-0.73	-7.07	-0.54	9.78e-11	Body mass index;
TGCT	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg27454412	chr7:1067447	C7orf50	0.6	4.7	0.39	6.76e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9291683	0.530	rs6449196	chr4:9973660	C/T	cg11266682	chr4:10021025	SLC2A9	-0.62	-8.62	-0.61	2.56e-14	Bone mineral density;
TGCT	cis	rs617791	0.678	rs551659	chr11:65749645	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.23	4.87	0.4	3.28e-6	Breast cancer;
TGCT	cis	rs763121	0.853	rs2281020	chr22:39064406	A/G	cg06022373	chr22:39101656	GTPBP1	0.77	7.57	0.56	7.47e-12	Menopause (age at onset);
TGCT	cis	rs6815814	0.861	rs1135430	chr4:38789361	T/C	cg02016764	chr4:38805732	TLR1	-0.27	-4.51	-0.38	1.5e-5	Breast cancer;
TGCT	cis	rs9560113	0.764	rs1177401	chr13:112173067	T/C	cg14154082	chr13:112174009	NA	-0.34	-4.47	-0.37	1.73e-5	Menarche (age at onset);
TGCT	cis	rs7267979	1.000	rs2257982	chr20:25269630	A/G	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs36051895	0.589	rs6476948	chr9:5204404	C/T	cg02405213	chr9:5042618	JAK2	-0.74	-9.28	-0.64	7.07e-16	Pediatric autoimmune diseases;
TGCT	cis	rs4372836	1.000	rs6710959	chr2:28958603	C/T	cg09522027	chr2:28974177	PPP1CB	-0.59	-5.15	-0.42	1e-6	Body mass index;
TGCT	cis	rs6684514	1.000	rs12023704	chr1:156294149	C/A	cg20302342	chr1:156215951	PAQR6	0.35	4.74	0.39	5.77e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.71	5.14	0.42	1.02e-6	Platelet count;
TGCT	cis	rs813218	0.584	rs11711935	chr3:99808804	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.44	-4.98	-0.41	2.06e-6	Orofacial clefts;
TGCT	cis	rs9467773	1.000	rs1056667	chr6:26510564	T/C	cg26531700	chr6:26746687	NA	0.47	4.56	0.38	1.19e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs882732	0.576	rs12895360	chr14:95038922	T/C	cg24754598	chr14:95966488	NA	0.24	4.54	0.38	1.31e-5	Blood protein levels;
TGCT	cis	rs910187	1.000	rs6063085	chr20:45840459	A/C	cg27589058	chr20:45804311	EYA2	-0.31	-5.66	-0.45	9.88e-8	Migraine;
TGCT	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg03609598	chr5:56110824	MAP3K1	-0.59	-4.78	-0.39	4.97e-6	Initial pursuit acceleration;
TGCT	cis	rs6722750	0.933	rs4671553	chr2:64408476	A/T	cg22352474	chr2:64371530	PELI1	-0.58	-5.14	-0.42	1.05e-6	Neuroticism;
TGCT	cis	rs6121246	0.529	rs6060171	chr20:30183269	C/T	cg13852791	chr20:30311386	BCL2L1	0.69	4.53	0.38	1.36e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs3093024	0.967	rs1571878	chr6:167540842	C/T	cg07741184	chr6:167504864	NA	-0.24	-4.85	-0.4	3.6e-6	Rheumatoid arthritis;
TGCT	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg01017244	chr2:74357527	NA	0.42	5.82	0.46	4.64e-8	Gestational age at birth (maternal effect);
TGCT	cis	rs4455778	0.802	rs35570114	chr7:49094318	C/T	cg26309511	chr7:48887640	NA	0.49	5.49	0.44	2.21e-7	Lung cancer in never smokers;
TGCT	cis	rs612683	0.599	rs2809823	chr1:101003762	C/A	cg14855972	chr1:101004472	GPR88	0.24	4.76	0.39	5.28e-6	Breast cancer;
TGCT	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg18402987	chr7:1209562	NA	0.7	5.67	0.45	9.66e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7611238	0.560	rs62288367	chr3:195118322	T/C	cg27323046	chr3:195102265	ACAP2	0.39	5.17	0.42	8.93e-7	Body mass index;
TGCT	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg18230493	chr5:56204884	C5orf35	-0.69	-6.01	-0.48	1.9e-8	Initial pursuit acceleration;
TGCT	cis	rs7611238	0.560	rs9817672	chr3:195141827	T/C	cg27323046	chr3:195102265	ACAP2	0.37	4.97	0.41	2.17e-6	Body mass index;
TGCT	cis	rs7582180	0.629	rs6757754	chr2:100951273	C/T	cg14675211	chr2:100938903	LONRF2	-0.53	-5.16	-0.42	9.36e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1205863	1.000	rs1205855	chr6:11942657	A/G	cg07106625	chr6:11870215	NA	0.51	5.05	0.41	1.51e-6	Disc degeneration (lumbar);
TGCT	cis	rs3784262	0.643	rs8030766	chr15:58369209	A/G	cg12031962	chr15:58353849	ALDH1A2	0.39	5.68	0.45	9.05e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg13397359	chr6:42928475	GNMT	0.72	6.48	0.5	1.93e-9	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs826838	0.935	rs1719855	chr12:39127242	C/T	cg13010199	chr12:38710504	ALG10B	-0.63	-5.04	-0.41	1.6e-6	Heart rate;
TGCT	cis	rs6674176	0.597	rs2352990	chr1:44393276	T/A	cg13606994	chr1:44402422	ARTN	-0.51	-5.42	-0.44	2.94e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs7914558	1.000	rs7899084	chr10:104872547	A/T	cg04362960	chr10:104952993	NT5C2	0.63	5.64	0.45	1.07e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs317689	0.918	rs610192	chr12:69739941	T/C	cg11871910	chr12:69753446	YEATS4	0.6	5.08	0.41	1.36e-6	Response to diuretic therapy;
TGCT	cis	rs4727027	0.625	rs75129390	chr7:148846775	T/A	cg23583168	chr7:148888333	NA	-0.74	-9.12	-0.63	1.72e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs7917772	0.503	rs1409310	chr10:104282265	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs8002180	1.000	rs8002180	chr13:95922765	T/C	cg24476569	chr13:95954382	ABCC4	0.41	5.09	0.42	1.31e-6	Blood metabolite levels;
TGCT	cis	rs9914544	0.545	rs9915343	chr17:18766494	A/G	cg26378065	chr17:18585709	ZNF286B	0.52	4.5	0.37	1.56e-5	Educational attainment (years of education);
TGCT	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg12140144	chr1:2984275	FLJ42875;PRDM16	-0.34	-4.85	-0.4	3.66e-6	Height;
TGCT	cis	rs1008375	0.932	rs7677212	chr4:17675932	A/G	cg16339924	chr4:17578868	LAP3	-0.59	-4.82	-0.4	4.05e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9486715	0.867	rs9373887	chr6:96957004	C/T	cg18709589	chr6:96969512	KIAA0776	0.82	8.01	0.58	7.14e-13	Headache;
TGCT	cis	rs3772130	0.540	rs57791671	chr3:121608433	T/A	cg20356878	chr3:121714668	ILDR1	0.39	4.85	0.4	3.64e-6	Cognitive performance;
TGCT	cis	rs1692580	0.774	rs10797416	chr1:2182342	T/C	cg21194808	chr1:2205498	SKI	0.29	5.5	0.44	2.06e-7	Coronary artery disease;
TGCT	cis	rs7586879	0.639	rs6749170	chr2:25110962	A/G	cg01884057	chr2:25150051	NA	0.34	6.5	0.5	1.8e-9	Body mass index;
TGCT	cis	rs61990749	0.544	rs1477259	chr14:78256138	C/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.61	4.52	0.38	1.43e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs6088580	0.634	rs4911421	chr20:32998948	T/C	cg08999081	chr20:33150536	PIGU	-0.29	-5.65	-0.45	1.02e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs2070433	0.615	rs2073379	chr21:47863025	C/T	cg12379764	chr21:47803548	PCNT	0.55	4.6	0.38	1.04e-5	Lymphocyte counts;
TGCT	cis	rs7659604	0.689	rs4283687	chr4:122663460	A/G	cg06713675	chr4:122721982	EXOSC9	-0.45	-5.11	-0.42	1.19e-6	Type 2 diabetes;
TGCT	cis	rs11648796	0.757	rs6600231	chr16:766485	A/G	cg27144592	chr16:783916	NARFL	-0.36	-5.04	-0.41	1.58e-6	Height;
TGCT	cis	rs240764	0.764	rs6910391	chr6:100925774	T/C	cg21058520	chr6:100914733	NA	0.38	4.6	0.38	1.04e-5	Neuroticism;
TGCT	cis	rs6831352	0.879	rs56272995	chr4:100060882	A/G	cg12011299	chr4:100065546	ADH4	-0.41	-4.97	-0.41	2.21e-6	Alcohol dependence;
TGCT	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg24829409	chr8:58192753	C8orf71	-0.54	-4.84	-0.4	3.79e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4280164	0.551	rs2295300	chr14:24805117	C/T	cg07162820	chr14:24837146	NFATC4	0.36	4.6	0.38	1.05e-5	Parent of origin effect on language impairment (paternal);
TGCT	cis	rs595982	0.661	rs606400	chr19:49371498	T/C	cg21252483	chr19:49399788	TULP2	-0.26	-4.5	-0.37	1.53e-5	Red cell distribution width;
TGCT	cis	rs968567	0.705	rs174573	chr11:61600327	G/A	cg19610905	chr11:61596333	FADS2	-0.99	-9.08	-0.63	2.15e-15	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
TGCT	cis	rs4925386	1.000	rs2151512	chr20:60913495	T/C	cg24112000	chr20:60950667	NA	0.33	4.57	0.38	1.17e-5	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs6430585	0.528	rs309172	chr2:136674028	A/G	cg07169764	chr2:136633963	MCM6	1.21	11.7	0.72	9.03e-22	Corneal structure;
TGCT	cis	rs62344088	0.590	rs2115276	chr5:169829	C/G	cg10601043	chr5:1076365	SLC12A7	0.58	4.74	0.39	5.71e-6	Asthma (childhood onset);
TGCT	cis	rs6087990	0.735	rs2065576	chr20:31389009	C/T	cg13636640	chr20:31349939	DNMT3B	0.97	12.84	0.76	1.63e-24	Ulcerative colitis;
TGCT	cis	rs1401999	0.966	rs2313216	chr3:183637251	C/T	cg01324343	chr3:183735012	ABCC5	0.81	11.09	0.71	2.81e-20	Anterior chamber depth;
TGCT	cis	rs9303401	0.659	rs34556735	chr17:56694447	A/C	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs12142240	0.660	rs72885163	chr1:46807117	C/A	cg14993813	chr1:46806288	NSUN4	-0.58	-4.81	-0.4	4.34e-6	Menopause (age at onset);
TGCT	cis	rs10876993	0.928	rs774890	chr12:58068388	C/T	cg15848620	chr12:58087721	OS9	-0.72	-5.91	-0.47	3.12e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg22920501	chr2:26401640	FAM59B	-0.74	-6.4	-0.5	2.86e-9	Gut microbiome composition (summer);
TGCT	cis	rs4253772	0.614	rs11090859	chr22:46687460	T/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.7	5.22	0.42	7.37e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs7312933	0.558	rs1796384	chr12:42780568	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.57	-5.57	-0.45	1.5e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs11711311	1.000	rs9848993	chr3:113497914	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.76	-7.16	-0.54	6.29e-11	IgG glycosylation;
TGCT	cis	rs7945705	0.875	rs2653616	chr11:8885892	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-5.5	-0.44	2.03e-7	Hemoglobin concentration;
TGCT	cis	rs7666738	0.830	rs4699601	chr4:99034429	G/A	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs921968	0.541	rs599973	chr2:219387273	C/G	cg02176678	chr2:219576539	TTLL4	0.48	6.78	0.52	4.32e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs11785400	1.000	rs9720653	chr8:143731939	T/G	cg24634471	chr8:143751801	JRK	0.54	5.85	0.46	4.19e-8	Schizophrenia;
TGCT	cis	rs11122272	0.735	rs2808583	chr1:231512587	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.14	-0.54	6.96e-11	Hemoglobin concentration;
TGCT	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg11062466	chr8:58055876	NA	0.37	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs12477438	0.715	rs7586608	chr2:99558017	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-4.74	-0.39	5.73e-6	Chronic sinus infection;
TGCT	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg03303774	chr4:1407052	NA	0.29	4.81	0.4	4.24e-6	Obesity-related traits;
TGCT	cis	rs1008375	1.000	rs4698199	chr4:17656738	G/C	cg16339924	chr4:17578868	LAP3	0.63	5.33	0.43	4.49e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs796364	0.806	rs11679676	chr2:201040981	C/T	cg17644776	chr2:200775616	C2orf69	-0.34	-4.8	-0.4	4.49e-6	Schizophrenia;
TGCT	cis	rs1865760	0.566	rs2794720	chr6:26087202	G/C	cg17042849	chr6:26104293	HIST1H4C	-0.63	-5.47	-0.44	2.43e-7	Height;
TGCT	cis	rs12579753	0.956	rs35278765	chr12:82173126	T/C	cg07988820	chr12:82153109	PPFIA2	-0.65	-6.79	-0.52	4.09e-10	Resting heart rate;
TGCT	cis	rs6912958	0.559	rs445434	chr6:88041849	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.7	7.16	0.54	6.1e-11	Monocyte percentage of white cells;
TGCT	cis	rs10946940	0.965	rs6915266	chr6:27528643	G/A	cg10876282	chr6:28092338	ZSCAN16	-0.47	-4.74	-0.39	5.81e-6	Systemic lupus erythematosus;
TGCT	cis	rs7666738	0.519	rs13136069	chr4:98819568	C/T	cg05340658	chr4:99064831	C4orf37	0.55	5.96	0.47	2.42e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11122272	0.735	rs2790883	chr1:231532726	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-6.56	-0.51	1.3e-9	Hemoglobin concentration;
TGCT	cis	rs12142240	0.698	rs41293285	chr1:46808426	C/T	cg00530320	chr1:46809349	NSUN4	0.29	5.88	0.47	3.63e-8	Menopause (age at onset);
TGCT	cis	rs11031096	0.678	rs61899666	chr11:4178711	C/A	cg18678763	chr11:4115507	RRM1	-0.44	-5.75	-0.46	6.48e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs11122272	0.735	rs910823	chr1:231498766	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-6.63	-0.51	9.1e-10	Hemoglobin concentration;
TGCT	cis	rs7209700	0.889	rs11079769	chr17:45349731	A/T	cg21624342	chr17:45890973	OSBPL7	0.18	4.99	0.41	1.97e-6	IgG glycosylation;
TGCT	cis	rs7647973	0.516	rs4499638	chr3:49202782	C/G	cg07636037	chr3:49044803	WDR6	0.86	8.75	0.62	1.33e-14	Menarche (age at onset);
TGCT	cis	rs6770219	0.516	rs59017423	chr3:186133885	C/A	cg20306810	chr3:186501757	SNORD2;EIF4A2	0.75	4.6	0.38	1.03e-5	Cerebrospinal T-tau levels;
TGCT	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg03934478	chr11:495069	RNH1	0.36	5.95	0.47	2.54e-8	Body mass index;
TGCT	cis	rs9611565	0.649	rs139559	chr22:42191636	A/G	cg13695892	chr22:41940480	POLR3H	-0.81	-7.83	-0.58	1.87e-12	Vitiligo;
TGCT	cis	rs12541335	0.536	rs4266653	chr8:22169087	A/G	cg07298985	chr8:22133076	PIWIL2	0.32	5.14	0.42	1.03e-6	Hypertriglyceridemia;
TGCT	cis	rs4295623	0.531	rs2898295	chr8:11595969	C/T	cg21775007	chr8:11205619	TDH	-0.52	-4.9	-0.4	2.97e-6	Morning vs. evening chronotype;
TGCT	cis	rs3847687	0.966	rs3847689	chr12:131525534	T/G	cg25772418	chr12:131519998	GPR133	-0.33	-6.1	-0.48	1.26e-8	Longevity;
TGCT	cis	rs10782582	0.586	rs12130324	chr1:76370012	A/G	cg10523679	chr1:76189770	ACADM	-0.58	-5.26	-0.43	5.99e-7	Daytime sleep phenotypes;
TGCT	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg01448562	chr3:133502909	NA	-0.26	-5.01	-0.41	1.83e-6	Iron status biomarkers;
TGCT	cis	rs6964587	1.000	rs1859114	chr7:91682848	T/C	cg17063962	chr7:91808500	NA	0.88	9.65	0.66	8.73e-17	Breast cancer;
TGCT	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs589249	0.963	rs1395455	chr1:37185190	A/G	cg04012535	chr1:37176647	NA	0.35	5.57	0.45	1.52e-7	Neuroticism (multi-trait analysis);Schizophrenia;
TGCT	cis	rs6815814	0.851	rs73236644	chr4:38863193	A/G	cg02016764	chr4:38805732	TLR1	-0.37	-5.49	-0.44	2.19e-7	Breast cancer;
TGCT	cis	rs1403694	0.695	rs13317089	chr3:186436217	G/C	cg12454167	chr3:186435060	KNG1	0.51	8.67	0.61	1.95e-14	Blood protein levels;
TGCT	cis	rs7246657	0.943	rs13345116	chr19:37847098	A/T	cg18154014	chr19:37997991	ZNF793	0.72	5.19	0.42	8.3e-7	Coronary artery calcification;
TGCT	cis	rs6546537	0.869	rs35024605	chr2:69820332	A/G	cg10773587	chr2:69614142	GFPT1	-0.73	-6.92	-0.53	2.1e-10	Serum thyroid-stimulating hormone levels;
TGCT	cis	rs7666738	0.800	rs13107586	chr4:99028788	G/C	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7824557	0.592	rs2736280	chr8:11223022	C/A	cg21775007	chr8:11205619	TDH	0.66	6.19	0.49	8.04e-9	Retinal vascular caliber;
TGCT	cis	rs1153858	1.000	rs12440038	chr15:45706739	A/G	cg14582100	chr15:45693742	SPATA5L1	0.48	5.67	0.45	9.65e-8	Homoarginine levels;
TGCT	cis	rs2486288	0.656	rs11632777	chr15:45551045	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.72	-7.46	-0.56	1.34e-11	Glomerular filtration rate;
TGCT	cis	rs2120019	1.000	rs12901243	chr15:75374233	C/T	cg09165964	chr15:75287851	SCAMP5	-1.07	-8.58	-0.61	3.34e-14	Blood trace element (Zn levels);
TGCT	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg25767906	chr1:53392781	SCP2	0.48	5.56	0.45	1.57e-7	Monocyte count;
TGCT	trans	rs6089829	0.962	rs3746747	chr20:61667631	T/C	cg13615516	chr5:77269221	NA	0.68	8.55	0.61	3.8e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs910316	1.000	rs10140851	chr14:75512612	G/A	cg23033748	chr14:75592666	NEK9	0.28	4.68	0.39	7.32e-6	Height;
TGCT	cis	rs11190604	1.000	rs4919465	chr10:102221703	C/T	cg23241863	chr10:102295624	HIF1AN	0.62	4.87	0.4	3.27e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg00149659	chr3:10157352	C3orf10	0.93	5.98	0.47	2.25e-8	Alzheimer's disease;
TGCT	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	4.62	0.38	9.36e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7772486	0.846	rs2892453	chr6:146377717	C/A	cg23711669	chr6:146136114	FBXO30	0.85	9.11	0.63	1.76e-15	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs1005277	0.522	rs289647	chr10:37968278	A/G	cg17830980	chr10:43048298	ZNF37B	-0.64	-7.29	-0.55	3.11e-11	Extrinsic epigenetic age acceleration;
TGCT	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg22663859	chr13:21900854	NA	0.34	4.93	0.4	2.59e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	cis	rs9814567	1.000	rs6806417	chr3:134211446	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	1.07	9.61	0.65	1.14e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs4372836	0.964	rs4531886	chr2:28917964	T/C	cg09522027	chr2:28974177	PPP1CB	0.57	4.67	0.39	7.61e-6	Body mass index;
TGCT	cis	rs9341808	0.754	rs1015158	chr6:80945745	C/T	cg08355045	chr6:80787529	NA	0.29	5.1	0.42	1.23e-6	Sitting height ratio;
TGCT	cis	rs79349575	0.783	rs12453374	chr17:46994846	G/C	cg07967210	chr17:47022446	SNF8	0.44	6.12	0.48	1.13e-8	Type 2 diabetes;
TGCT	cis	rs7809950	0.773	rs9791733	chr7:107041730	T/C	cg23024343	chr7:107201750	COG5	-0.48	-6.33	-0.49	4.11e-9	Coronary artery disease;
TGCT	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg15242686	chr22:24348715	GSTTP1	-0.41	-4.96	-0.41	2.25e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg08280861	chr8:58055591	NA	0.36	4.98	0.41	2.07e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2742417	0.603	rs2742371	chr3:45782763	G/A	cg04837898	chr3:45731254	SACM1L	-0.67	-7.3	-0.55	3.06e-11	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs7394190	0.748	rs11000771	chr10:75524458	T/G	cg07699608	chr10:75541558	CHCHD1	0.76	4.77	0.39	5.13e-6	Incident atrial fibrillation;
TGCT	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.46	-6.76	-0.52	4.77e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs60154123	0.730	rs10863818	chr1:210458007	C/T	cg22029157	chr1:209979665	IRF6	0.6	4.46	0.37	1.81e-5	Coronary artery disease;
TGCT	cis	rs9467711	0.516	rs1165184	chr6:25836257	C/G	cg03264133	chr6:25882463	NA	-0.66	-4.55	-0.38	1.26e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs28595532	1.000	rs115965820	chr4:119586485	G/A	cg14228332	chr4:119757509	SEC24D	1.0	5.77	0.46	5.96e-8	Cannabis dependence symptom count;
TGCT	cis	rs3858526	1.000	rs10838909	chr11:5960490	G/A	cg05234568	chr11:5960015	NA	-0.45	-4.54	-0.38	1.3e-5	DNA methylation (variation);
TGCT	cis	rs9467773	1.000	rs11756120	chr6:26529808	G/C	cg26531700	chr6:26746687	NA	0.47	4.57	0.38	1.14e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs1949733	0.598	rs55765509	chr4:8532732	T/A	cg13073564	chr4:8508604	NA	0.47	4.56	0.38	1.19e-5	Response to antineoplastic agents;
TGCT	cis	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg25427524	chr10:38739819	LOC399744	0.38	7.87	0.58	1.51e-12	Extrinsic epigenetic age acceleration;
TGCT	cis	rs3809566	0.597	rs9806545	chr15:63328490	C/T	cg08198488	chr15:63333792	TPM1	-0.34	-5.11	-0.42	1.18e-6	Platelet count;
TGCT	cis	rs1008375	1.000	rs12507142	chr4:17656103	A/G	cg18681998	chr4:17616180	MED28	1.02	12.01	0.73	1.65e-22	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6087990	0.735	rs6058891	chr20:31386347	T/C	cg13636640	chr20:31349939	DNMT3B	0.95	12.3	0.74	3.25e-23	Ulcerative colitis;
TGCT	cis	rs6993813	0.805	rs4327884	chr8:120019593	A/G	cg17171407	chr8:119960777	TNFRSF11B	0.25	4.49	0.37	1.59e-5	Bone mineral density (hip);
TGCT	trans	rs34421088	0.560	rs2248316	chr8:11397073	A/C	cg15556689	chr8:8085844	FLJ10661	-0.75	-7.08	-0.54	9.46e-11	Neuroticism;
TGCT	cis	rs3796352	1.000	rs11710707	chr3:52975916	A/G	cg15956490	chr3:53032818	SFMBT1	0.61	6.11	0.48	1.17e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs2235642	0.893	rs8051295	chr16:1588087	A/G	cg08296037	chr16:1584118	IFT140;TMEM204	-0.3	-5.24	-0.43	6.8e-7	Coronary artery disease;
TGCT	cis	rs9486715	1.000	rs7752277	chr6:97065131	C/T	cg06623918	chr6:96969491	KIAA0776	-1.08	-13.59	-0.77	2.61e-26	Headache;
TGCT	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg14416726	chr6:151773293	C6orf211;RMND1	0.9	9.63	0.65	1.01e-16	Menarche (age at onset);
TGCT	cis	rs9581857	0.556	rs1885991	chr13:28040470	G/A	cg22138327	chr13:27999177	GTF3A	0.73	5.7	0.46	8.09e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2228479	0.850	rs1108063	chr16:89893983	A/G	cg06558623	chr16:89946397	TCF25	0.55	4.79	0.4	4.69e-6	Skin colour saturation;
TGCT	cis	rs7552404	1.000	rs11163924	chr1:76132070	A/C	cg03433033	chr1:76189801	ACADM	-0.83	-10.26	-0.68	3.01e-18	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs739401	0.566	rs7931504	chr11:3026712	C/T	cg05729581	chr11:3078854	CARS	-0.53	-4.81	-0.4	4.3e-6	Longevity;
TGCT	cis	rs10883723	0.810	rs7093028	chr10:104259417	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs6424115	0.964	rs2473375	chr1:24136545	C/T	cg15997130	chr1:24165203	NA	0.92	10.78	0.7	1.58e-19	Immature fraction of reticulocytes;
TGCT	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg03709012	chr19:19516395	GATAD2A	0.74	6.12	0.48	1.15e-8	Tonsillectomy;
TGCT	cis	rs1538970	0.847	rs781230	chr1:45880751	C/T	cg05343316	chr1:45956843	TESK2	-0.73	-5.85	-0.47	4.08e-8	Platelet count;
TGCT	cis	rs12220238	1.000	rs9665468	chr10:75938838	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.92	6.98	0.53	1.61e-10	Soluble interleukin-2 receptor subunit alpha;
TGCT	trans	rs2688608	0.592	rs3849967	chr10:75483366	C/T	cg13918328	chr10:52500089	ASAH2B	0.68	6.7	0.52	6.48e-10	Inflammatory bowel disease;
TGCT	cis	rs4654899	0.865	rs12123300	chr1:21323568	T/C	cg01072550	chr1:21505969	NA	-0.46	-6.95	-0.53	1.88e-10	Superior frontal gyrus grey matter volume;
TGCT	trans	rs7819412	0.806	rs17723229	chr8:10930069	A/C	cg06636001	chr8:8085503	FLJ10661	-0.77	-7.06	-0.54	1.04e-10	Triglycerides;
TGCT	cis	rs735396	0.770	rs2464196	chr12:121435427	G/A	cg02403541	chr12:121454288	C12orf43	0.76	7.54	0.56	8.67e-12	N-glycan levels;
TGCT	cis	rs7226408	0.857	rs11081985	chr18:34682970	A/G	cg06757138	chr18:34340585	FHOD3	-0.25	-4.81	-0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs908922	0.582	rs1856121	chr1:152512169	A/T	cg20991723	chr1:152506922	NA	0.46	6.18	0.48	8.66e-9	Hair morphology;
TGCT	cis	rs7944584	0.632	rs11606683	chr11:47302733	C/T	cg20307385	chr11:47447363	PSMC3	0.79	7.89	0.58	1.37e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
TGCT	cis	rs1153858	0.943	rs4774580	chr15:45652086	G/A	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.62e-8	Homoarginine levels;
TGCT	cis	rs7666738	0.962	rs11728816	chr4:98951767	C/T	cg05340658	chr4:99064831	C4orf37	0.51	5.0	0.41	1.88e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7762018	0.760	rs28660085	chr6:170101996	C/G	cg15038512	chr6:170123185	PHF10	0.63	4.76	0.39	5.21e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	cis	rs3806843	1.000	rs11167609	chr5:140200426	T/G	cg19875535	chr5:140030758	IK	0.35	5.86	0.47	3.93e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs782590	0.837	rs782585	chr2:55922930	C/T	cg03859395	chr2:55845619	SMEK2	0.83	9.81	0.66	3.69e-17	Metabolic syndrome;
TGCT	cis	rs9653442	0.545	rs10496344	chr2:100764125	C/T	cg22139774	chr2:100720529	AFF3	0.37	5.82	0.46	4.82e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs2204008	0.549	rs12312109	chr12:38228251	G/T	cg26384229	chr12:38710491	ALG10B	-0.53	-4.52	-0.38	1.44e-5	Bladder cancer;
TGCT	cis	rs992157	0.798	rs2382818	chr2:219155907	A/T	cg00012203	chr2:219082015	ARPC2	-0.77	-7.41	-0.55	1.68e-11	Colorectal cancer;
TGCT	cis	rs896854	0.625	rs4735336	chr8:95973410	A/C	cg13393036	chr8:95962371	TP53INP1	0.58	7.86	0.58	1.58e-12	Type 2 diabetes;
TGCT	cis	rs7193541	0.965	rs7199068	chr16:74698263	C/G	cg05800356	chr16:74706258	MLKL	0.25	4.48	0.37	1.71e-5	Multiple myeloma;
TGCT	cis	rs7584330	0.737	rs1497129	chr2:238369184	C/T	cg14458575	chr2:238380390	NA	0.49	7.88	0.58	1.41e-12	Prostate cancer;
TGCT	cis	rs9926296	0.562	rs4785725	chr16:89893243	A/G	cg04287289	chr16:89883240	FANCA	0.67	6.82	0.52	3.63e-10	Vitiligo;
TGCT	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg21433313	chr16:3507492	NAT15	-0.4	-5.32	-0.43	4.71e-7	Tuberculosis;
TGCT	cis	rs208515	0.556	rs12214562	chr6:66681011	T/A	cg07460842	chr6:66804631	NA	0.88	9.35	0.64	4.63e-16	Exhaled nitric oxide levels;
TGCT	cis	rs17039065	0.920	rs1017431	chr4:109474091	A/C	cg16022748	chr4:109541635	LOC285456;RPL34	0.82	4.93	0.4	2.63e-6	Gut microbiome composition (summer);
TGCT	cis	rs6912958	1.000	rs13214153	chr6:88153983	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.37	-4.69	-0.39	7.08e-6	Monocyte percentage of white cells;
TGCT	cis	rs17221829	0.733	rs10765222	chr11:89372109	T/C	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.63	-0.38	9.04e-6	Anxiety in major depressive disorder;
TGCT	cis	rs6598955	0.671	rs11247880	chr1:26568926	G/A	cg04990556	chr1:26633338	UBXN11	0.64	5.11	0.42	1.19e-6	Obesity-related traits;
TGCT	cis	rs7666738	0.830	rs957742	chr4:99029409	C/T	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7100689	0.646	rs10736348	chr10:82139244	C/A	cg01528321	chr10:82214614	TSPAN14	0.81	8.27	0.6	1.71e-13	Post bronchodilator FEV1;
TGCT	cis	rs1008375	0.932	rs9283698	chr4:17662471	T/C	cg10189774	chr4:17578691	LAP3	0.52	4.55	0.38	1.29e-5	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg14893161	chr1:205819251	PM20D1	0.66	10.45	0.68	1.04e-18	Menarche (age at onset);
TGCT	cis	rs2243480	1.000	rs160644	chr7:65558186	C/T	cg18252515	chr7:66147081	NA	-1.1	-7.18	-0.54	5.77e-11	Diabetic kidney disease;
TGCT	cis	rs6921919	0.583	rs7759191	chr6:28353434	A/C	cg18815343	chr6:28367644	ZSCAN12	-0.56	-5.32	-0.43	4.76e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1372520	0.684	rs2197120	chr4:90729602	A/G	cg15133208	chr4:90757351	SNCA	-0.52	-6.07	-0.48	1.44e-8	Neuroticism;
TGCT	cis	rs3096299	0.606	rs2965960	chr16:89541795	G/A	cg02187348	chr16:89574699	SPG7	0.47	4.51	0.38	1.47e-5	Multiple myeloma (IgH translocation);
TGCT	cis	rs75059851	0.756	rs11223646	chr11:133839560	C/T	cg14047540	chr11:133829660	NA	-0.53	-5.37	-0.43	3.7e-7	Schizophrenia;
TGCT	cis	rs7917772	0.503	rs7899576	chr10:104307504	G/A	cg05855489	chr10:104503620	C10orf26	-0.61	-5.41	-0.44	3.16e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs28595532	0.841	rs114735834	chr4:119772722	G/A	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs7772486	0.754	rs4896841	chr6:146041522	T/C	cg05347473	chr6:146136440	FBXO30	-0.52	-4.85	-0.4	3.61e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs875971	0.929	rs4122249	chr7:65920936	T/C	cg11764359	chr7:65958608	NA	0.6	5.43	0.44	2.85e-7	Aortic root size;
TGCT	cis	rs3780378	1.000	rs3780378	chr9:5112288	C/T	cg02405213	chr9:5042618	JAK2	-0.61	-7.89	-0.58	1.36e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs7043114	0.507	rs10992340	chr9:95209693	T/C	cg14631576	chr9:95140430	CENPP	-0.28	-4.58	-0.38	1.11e-5	Height;
TGCT	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg15556689	chr8:8085844	FLJ10661	0.73	6.5	0.5	1.75e-9	Mood instability;
TGCT	cis	rs1062177	1.000	rs17741826	chr5:151149262	C/T	cg00977110	chr5:151150581	G3BP1	-0.41	-4.62	-0.38	9.52e-6	Preschool internalizing problems;
TGCT	cis	rs651907	0.513	rs34963630	chr3:101504817	C/T	cg12386194	chr3:101231763	SENP7	0.48	4.81	0.4	4.36e-6	Colorectal cancer;
TGCT	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg03806693	chr22:41940476	POLR3H	-1.14	-13.38	-0.77	8.05e-26	Vitiligo;
TGCT	cis	rs6964587	0.869	rs10250641	chr7:91490746	C/T	cg17063962	chr7:91808500	NA	0.82	8.89	0.62	5.87e-15	Breast cancer;
TGCT	cis	rs494003	1.000	rs11227284	chr11:65503224	C/T	cg04293602	chr11:65553660	OVOL1	0.37	4.65	0.39	8.5e-6	Systemic lupus erythematosus;
TGCT	cis	rs7523050	0.730	rs72984614	chr1:109435848	T/C	cg08274380	chr1:109419600	GPSM2	1.35	6.86	0.52	2.89e-10	Fat distribution (HIV);
TGCT	cis	rs8100891	0.665	rs7259259	chr19:32819841	G/C	cg16662424	chr19:32837316	ZNF507	-0.43	-5.24	-0.43	6.57e-7	Neuroticism;
TGCT	cis	rs801193	0.569	rs13226966	chr7:66233623	A/G	cg11764359	chr7:65958608	NA	0.51	4.48	0.37	1.7e-5	Aortic root size;
TGCT	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg03264133	chr6:25882463	NA	-0.61	-6.51	-0.5	1.69e-9	Blood metabolite levels;
TGCT	cis	rs28595532	0.920	rs114390336	chr4:119771452	C/T	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg11890956	chr21:40555474	PSMG1	1.06	10.7	0.69	2.44e-19	Cognitive function;
TGCT	cis	rs782590	0.729	rs706548	chr2:55850106	C/G	cg18811423	chr2:55921094	PNPT1	0.55	5.82	0.46	4.7e-8	Metabolic syndrome;
TGCT	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg14983838	chr19:29218262	NA	0.86	7.0	0.53	1.42e-10	Methadone dose in opioid dependence;
TGCT	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg03709012	chr19:19516395	GATAD2A	-0.75	-6.51	-0.5	1.71e-9	Tonsillectomy;
TGCT	cis	rs11792861	0.926	rs72607173	chr9:111879398	T/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.5	5.01	0.41	1.8e-6	Menarche (age at onset);
TGCT	cis	rs10484885	0.571	rs56019056	chr6:90630623	G/C	cg10278699	chr6:90661155	BACH2	0.32	4.76	0.39	5.2e-6	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg00786635	chr1:25594202	NA	0.61	6.37	0.5	3.32e-9	Erythrocyte sedimentation rate;
TGCT	cis	rs737008	0.922	rs2550475	chr16:11371986	C/T	cg00044050	chr16:11439710	C16orf75	0.73	7.56	0.56	7.92e-12	Obesity-related traits;
TGCT	cis	rs8014252	0.803	rs12586299	chr14:71085215	C/T	cg11204974	chr14:71022665	NA	-0.56	-4.7	-0.39	6.89e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
TGCT	cis	rs7100689	0.555	rs1934146	chr10:82062121	C/A	cg01528321	chr10:82214614	TSPAN14	0.75	7.46	0.56	1.32e-11	Post bronchodilator FEV1;
TGCT	cis	rs2235642	0.821	rs2281234	chr16:1602938	A/G	cg07639376	chr16:1584516	IFT140;TMEM204	-0.33	-5.85	-0.46	4.15e-8	Coronary artery disease;
TGCT	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg03806693	chr22:41940476	POLR3H	0.99	11.15	0.71	2.05e-20	Vitiligo;
TGCT	cis	rs9486715	0.867	rs3860243	chr6:96905303	T/G	cg18709589	chr6:96969512	KIAA0776	0.77	7.64	0.57	4.99e-12	Headache;
TGCT	cis	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg15556689	chr8:8085844	FLJ10661	0.69	6.43	0.5	2.56e-9	Mood instability;
TGCT	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.43	-4.62	-0.38	9.36e-6	Longevity;Endometriosis;
TGCT	cis	rs2688608	0.592	rs7080579	chr10:75504029	T/A	cg15838173	chr10:75533400	FUT11	-0.31	-4.89	-0.4	3.12e-6	Inflammatory bowel disease;
TGCT	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg06238570	chr21:40685208	BRWD1	0.7	6.11	0.48	1.2e-8	Cognitive function;
TGCT	cis	rs1670533	1.000	rs10084849	chr4:1053586	T/C	cg27284194	chr4:1044797	NA	0.66	5.69	0.45	8.85e-8	Recombination rate (females);
TGCT	cis	rs17270561	0.578	rs76182885	chr6:25904085	G/C	cg17691542	chr6:26056736	HIST1H1C	0.89	6.28	0.49	5.19e-9	Iron status biomarkers;
TGCT	cis	rs7216064	1.000	rs62084214	chr17:65843325	C/G	cg12091567	chr17:66097778	LOC651250	-0.83	-6.49	-0.5	1.9e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs7208859	0.673	rs216410	chr17:28903831	C/G	cg04154034	chr17:28927549	LRRC37B2	-0.76	-4.46	-0.37	1.82e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs9549367	0.789	rs12584813	chr13:113895443	C/G	cg00898013	chr13:113819073	PROZ	-0.46	-4.78	-0.39	4.86e-6	Platelet distribution width;
TGCT	cis	rs2832077	0.527	rs2250141	chr21:30241984	A/T	cg24692254	chr21:30365293	RNF160	0.57	4.78	0.39	4.87e-6	Cognitive test performance;
TGCT	cis	rs9372498	0.536	rs72952793	chr6:118892979	T/A	cg21191810	chr6:118973309	C6orf204	-0.39	-5.06	-0.41	1.5e-6	Diastolic blood pressure;
TGCT	cis	rs6121246	0.559	rs10439607	chr20:30258541	G/A	cg13852791	chr20:30311386	BCL2L1	0.84	8.15	0.59	3.38e-13	Mean corpuscular hemoglobin;
TGCT	cis	rs1949733	1.000	rs6837429	chr4:8502374	A/G	cg11789530	chr4:8429930	ACOX3	0.64	5.95	0.47	2.52e-8	Response to antineoplastic agents;
TGCT	cis	rs4654899	0.785	rs9426736	chr1:21505931	T/G	cg01072550	chr1:21505969	NA	-0.57	-9.4	-0.64	3.62e-16	Superior frontal gyrus grey matter volume;
TGCT	cis	rs9611565	0.879	rs4820437	chr22:41761290	T/C	cg06481639	chr22:41940642	POLR3H	-0.58	-5.01	-0.41	1.81e-6	Vitiligo;
TGCT	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg20573242	chr4:122745356	CCNA2	0.64	5.58	0.45	1.43e-7	Type 2 diabetes;
TGCT	cis	rs10992471	0.580	rs724102	chr9:95383290	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.54	-4.59	-0.38	1.07e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs7208859	0.673	rs73271887	chr17:29154935	T/C	cg14008862	chr17:28927542	LRRC37B2	0.75	5.1	0.42	1.26e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs11711311	1.000	rs9828449	chr3:113518602	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.76	-7.16	-0.54	6.29e-11	IgG glycosylation;
TGCT	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg11890956	chr21:40555474	PSMG1	-0.76	-7.43	-0.56	1.54e-11	Cognitive function;
TGCT	cis	rs7223966	0.729	rs7921	chr17:62006259	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	4.57	0.38	1.15e-5	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs3091242	1.000	rs3091242	chr1:25674785	C/T	cg09222892	chr1:25734099	RHCE	-0.42	-6.69	-0.52	6.75e-10	Erythrocyte sedimentation rate;
TGCT	cis	rs9807989	0.801	rs6752482	chr2:102967858	T/C	cg09003973	chr2:102972529	NA	0.64	5.7	0.46	8.28e-8	Asthma;
TGCT	cis	rs4654899	0.802	rs935918	chr1:21145660	C/T	cg01072550	chr1:21505969	NA	-0.45	-6.65	-0.51	8.51e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs1801251	1.000	rs283477	chr2:233649427	A/G	cg25237894	chr2:233734115	C2orf82	0.27	4.66	0.39	8.04e-6	Coronary artery disease;
TGCT	cis	rs1355223	0.583	rs2915238	chr11:34884405	C/A	cg11058730	chr11:34937778	PDHX;APIP	0.8	8.94	0.63	4.53e-15	Systemic lupus erythematosus and Systemic sclerosis;
TGCT	cis	rs4478858	0.735	rs4494186	chr1:31857847	G/A	cg07478791	chr1:31886160	SERINC2	0.47	4.7	0.39	6.79e-6	Alcohol dependence;
TGCT	cis	rs2013441	1.000	rs2703789	chr17:20162923	G/A	cg18979559	chr17:20280153	CCDC144C	-0.45	-4.67	-0.39	7.61e-6	Obesity-related traits;
TGCT	cis	rs231513	0.954	rs231504	chr17:41970906	C/G	cg26893861	chr17:41843967	DUSP3	-0.71	-5.33	-0.43	4.45e-7	Cognitive function;
TGCT	cis	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg12570787	chr5:219185	SDHA;CCDC127	0.66	4.48	0.37	1.64e-5	Breast cancer;
TGCT	cis	rs4911259	0.552	rs13041458	chr20:31467376	G/T	cg13636640	chr20:31349939	DNMT3B	-0.89	-9.83	-0.66	3.33e-17	Inflammatory bowel disease;
TGCT	trans	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg17830980	chr10:43048298	ZNF37B	-0.86	-11.18	-0.71	1.68e-20	Extrinsic epigenetic age acceleration;
TGCT	cis	rs3806843	0.576	rs246008	chr5:140338485	C/T	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs6671200	0.607	rs3753872	chr1:95699184	T/G	cg03123541	chr1:95699097	RWDD3	-0.81	-7.26	-0.55	3.81e-11	Stearic acid (18:0) levels;
TGCT	cis	rs2637266	0.765	rs2395391	chr10:78359932	G/A	cg18941641	chr10:78392320	NA	0.42	5.39	0.44	3.36e-7	Pulmonary function;
TGCT	cis	rs796364	0.616	rs769955	chr2:200692595	C/T	cg17644776	chr2:200775616	C2orf69	0.34	4.84	0.4	3.76e-6	Schizophrenia;
TGCT	cis	rs12220238	0.722	rs4745749	chr10:76393742	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.64	5.19	0.42	8.46e-7	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs854765	0.547	rs2955353	chr17:17948979	T/C	cg09796270	chr17:17721594	SREBF1	-0.24	-4.7	-0.39	6.8e-6	Total body bone mineral density;
TGCT	cis	rs6770219	0.516	rs59725628	chr3:186136635	G/A	cg20306810	chr3:186501757	SNORD2;EIF4A2	0.73	4.45	0.37	1.89e-5	Cerebrospinal T-tau levels;
TGCT	cis	rs453301	0.653	rs7853	chr8:8890814	A/G	cg06636001	chr8:8085503	FLJ10661	0.78	7.14	0.54	6.86e-11	Joint mobility (Beighton score);
TGCT	cis	rs9942416	0.660	rs111937612	chr5:74979631	C/T	cg19683494	chr5:74908142	NA	0.59	6.29	0.49	4.99e-9	Age-related disease endophenotypes;
TGCT	cis	rs4851254	0.660	rs59447631	chr2:100691493	T/C	cg22139774	chr2:100720529	AFF3	-0.45	-4.88	-0.4	3.13e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs68170813	0.559	rs17428071	chr7:106878200	C/G	cg02696742	chr7:106810147	HBP1	-0.69	-5.61	-0.45	1.27e-7	Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs7682991	chr4:98982595	C/A	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs941873	0.868	rs10740497	chr10:81126380	T/C	cg09469691	chr10:81107165	PPIF	0.64	6.53	0.51	1.49e-9	Height;
TGCT	cis	rs2932538	0.961	rs2932529	chr1:113193364	G/A	cg22162597	chr1:113214053	CAPZA1	-0.28	-5.83	-0.46	4.4e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs67073037	0.955	rs3924272	chr2:29167678	C/T	cg09522027	chr2:28974177	PPP1CB	0.57	4.49	0.37	1.59e-5	Breast cancer;Breast cancer (estrogen-receptor negative);
TGCT	cis	rs9311474	0.713	rs352171	chr3:52234203	A/G	cg07507251	chr3:52567010	NT5DC2	0.39	5.12	0.42	1.16e-6	Electroencephalogram traits;
TGCT	cis	rs10811516	0.520	rs4568676	chr9:21184475	C/G	cg23029519	chr9:21187344	IFNA4	0.29	4.59	0.38	1.09e-5	Response to mepolizumab in severe asthma;
TGCT	cis	rs907683	0.584	rs12920	chr2:220285666	C/G	cg15015639	chr2:220282977	DES	0.39	4.83	0.4	3.88e-6	Resting heart rate;
TGCT	cis	rs826838	1.000	rs7975243	chr12:38849220	C/T	cg26384229	chr12:38710491	ALG10B	1.06	10.68	0.69	2.84e-19	Heart rate;
TGCT	cis	rs11122272	0.668	rs1538664	chr1:231555295	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.6	-5.71	-0.46	7.8e-8	Hemoglobin concentration;
TGCT	cis	rs4786125	0.581	rs7194903	chr16:6918194	A/G	cg03623568	chr16:6915990	A2BP1	-0.44	-6.57	-0.51	1.27e-9	Heart rate variability traits (SDNN);
TGCT	cis	rs55794721	0.509	rs6699113	chr1:25777743	C/T	cg09222892	chr1:25734099	RHCE	-0.41	-6.8	-0.52	3.99e-10	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs2361718	1.000	rs2361718	chr17:78103466	C/T	cg09238746	chr17:78121135	EIF4A3	-0.51	-4.57	-0.38	1.16e-5	Yeast infection;
TGCT	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg05665937	chr4:1216051	CTBP1	0.24	4.61	0.38	1e-5	Obesity-related traits;
TGCT	cis	rs453301	0.686	rs28482034	chr8:8869664	G/A	cg15556689	chr8:8085844	FLJ10661	-0.64	-5.29	-0.43	5.37e-7	Joint mobility (Beighton score);
TGCT	cis	rs11578119	0.902	rs2421326	chr1:170512369	T/A	cg09767346	chr1:170501363	GORAB	-0.62	-5.11	-0.42	1.18e-6	Male-pattern baldness;
TGCT	cis	rs7804356	1.000	rs10276471	chr7:26837940	C/G	cg03456212	chr7:26904342	SKAP2	-0.61	-4.7	-0.39	6.82e-6	Type 1 diabetes;
TGCT	cis	rs854765	0.547	rs2955372	chr17:17970229	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.79	-8.28	-0.6	1.68e-13	Total body bone mineral density;
TGCT	cis	rs10465746	0.780	rs2389648	chr1:84403031	C/T	cg10977910	chr1:84465055	TTLL7	0.69	7.07	0.54	9.97e-11	Obesity-related traits;
TGCT	trans	rs1814175	0.817	rs7483795	chr11:49704930	G/A	cg15704280	chr7:45808275	SEPT13	-0.71	-8.23	-0.59	2.14e-13	Height;
TGCT	cis	rs9814567	0.964	rs9833753	chr3:134213665	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.95	-9.62	-0.65	1.04e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs789852	1.000	rs789850	chr3:194325496	T/C	cg18000598	chr3:194342907	TMEM44	-0.81	-5.27	-0.43	5.93e-7	QT interval;
TGCT	cis	rs10114408	0.918	rs4523325	chr9:96661833	G/A	cg13679303	chr9:96623674	NA	-0.36	-4.63	-0.38	9.04e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs11997175	0.784	rs36083407	chr8:33812930	G/T	ch.8.33884649F	chr8:33765107	NA	0.34	5.28	0.43	5.56e-7	Body mass index;
TGCT	cis	rs651907	0.588	rs1378838	chr3:101634543	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.5	4.79	0.4	4.65e-6	Colorectal cancer;
TGCT	cis	rs72781680	0.898	rs55657921	chr2:24008091	C/G	cg08917208	chr2:24149416	ATAD2B	0.81	5.01	0.41	1.8e-6	Lymphocyte counts;
TGCT	cis	rs1775715	0.737	rs2799017	chr10:32203460	A/G	cg14930904	chr10:32216787	ARHGAP12	0.53	5.12	0.42	1.15e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs2115630	1.000	rs1030863	chr15:85282635	C/T	cg12501888	chr15:85177176	SCAND2	-0.48	-4.49	-0.37	1.6e-5	P wave terminal force;
TGCT	cis	rs709400	0.628	rs10141120	chr14:103923008	T/C	cg12935359	chr14:103987150	CKB	-0.35	-5.33	-0.43	4.54e-7	Body mass index;
TGCT	cis	rs9952991	0.941	rs7237497	chr18:12777325	T/C	cg09945482	chr18:12777974	NA	0.51	4.86	0.4	3.47e-6	Inflammatory skin disease;
TGCT	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg10802521	chr3:52805072	NEK4	-0.78	-10.0	-0.67	1.26e-17	Bipolar disorder;
TGCT	cis	rs7681440	0.835	rs7668531	chr4:90791819	G/T	cg20003494	chr4:90757398	SNCA	-0.62	-5.94	-0.47	2.67e-8	Dementia with Lewy bodies;
TGCT	cis	rs9534288	0.797	rs2104515	chr13:46569846	T/C	cg15192986	chr13:46630673	CPB2	-0.53	-7.62	-0.56	5.82e-12	Blood protein levels;
TGCT	cis	rs1577917	1.000	rs12203924	chr6:86776412	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.09	-0.42	1.27e-6	Response to antipsychotic treatment;
TGCT	cis	rs6121246	0.909	rs57726761	chr20:30314046	A/G	cg18721089	chr20:30220636	NA	-0.42	-4.65	-0.39	8.2e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg13395646	chr4:1353034	KIAA1530	-0.55	-7.57	-0.56	7.56e-12	Obesity-related traits;
TGCT	cis	rs10744422	1.000	rs10744434	chr12:123368419	T/A	cg25930673	chr12:123319894	HIP1R	-0.85	-5.03	-0.41	1.69e-6	Schizophrenia;
TGCT	cis	rs1334894	1.000	rs10498734	chr6:35559773	A/C	cg24281267	chr6:35479648	TULP1	-0.44	-4.49	-0.37	1.59e-5	Coronary artery disease;
TGCT	trans	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg21659725	chr3:3221576	CRBN	0.88	12.71	0.75	3.19e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs9467773	0.572	rs62394558	chr6:26604650	G/A	cg02458000	chr6:26745757	NA	0.71	7.0	0.53	1.43e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs78487399	0.808	rs10189235	chr2:43745520	C/G	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.77	4.68	0.39	7.28e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs6138458	1.000	rs6106984	chr20:24977006	T/C	cg26195577	chr20:24973756	C20orf3	1.22	12.1	0.74	9.98e-23	Blood protein levels;
TGCT	cis	rs11122272	0.735	rs2808580	chr1:231509259	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.14	-0.54	6.86e-11	Hemoglobin concentration;
TGCT	cis	rs6733011	0.628	rs4851163	chr2:99466664	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-4.51	-0.38	1.46e-5	Bipolar disorder;
TGCT	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.03	0.41	1.68e-6	Prudent dietary pattern;
TGCT	cis	rs7666738	0.830	rs7657490	chr4:99043973	C/T	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-6.74	-0.52	5.26e-10	Alzheimer's disease;
TGCT	cis	rs66573146	1.000	rs28384174	chr4:6961107	G/T	cg05069807	chr4:6945702	TBC1D14	0.31	4.6	0.38	1.03e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs2304725	0.526	rs1601364	chr3:10830250	C/T	cg15914589	chr3:10206523	IRAK2	-0.47	-4.49	-0.37	1.61e-5	Pulmonary function in asthmatics;
TGCT	cis	rs2013441	0.669	rs62066947	chr17:20351458	G/A	cg23224458	chr17:20280056	CCDC144C	0.39	4.55	0.38	1.25e-5	Obesity-related traits;
TGCT	cis	rs9291683	0.530	rs4697698	chr4:9942577	C/T	cg11266682	chr4:10021025	SLC2A9	0.63	8.46	0.6	6.42e-14	Bone mineral density;
TGCT	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg18188782	chr20:61659543	NA	0.45	5.51	0.44	1.95e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs13064411	0.735	rs9875025	chr3:113147552	T/C	cg10517650	chr3:113235015	CCDC52	-0.35	-4.63	-0.38	9.06e-6	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs9611565	0.605	rs202638	chr22:41855458	A/G	cg06634786	chr22:41940651	POLR3H	0.86	8.15	0.59	3.45e-13	Vitiligo;
TGCT	cis	rs8111998	0.826	rs6511364	chr19:22765808	C/T	cg19914732	chr19:22715077	NA	-0.56	-4.51	-0.38	1.46e-5	Corneal structure;
TGCT	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg13012494	chr21:47604986	C21orf56	-0.37	-4.78	-0.39	4.81e-6	Testicular germ cell tumor;
TGCT	cis	rs7172809	0.643	rs907370	chr15:77844272	G/C	cg22256960	chr15:77711686	NA	-0.48	-4.77	-0.39	5.1e-6	Glucose homeostasis traits;
TGCT	cis	rs11190604	1.000	rs2495747	chr10:102328247	C/T	cg23241863	chr10:102295624	HIF1AN	0.67	5.1	0.42	1.23e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs12210905	0.688	rs72845011	chr6:27500822	T/G	cg08851530	chr6:28072375	NA	1.34	6.29	0.49	5.02e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs6893807	1.000	rs13163173	chr5:87943620	C/A	cg24804195	chr5:87968844	LOC645323	0.74	5.2	0.42	8.09e-7	Body mass index;
TGCT	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg01017244	chr2:74357527	NA	0.5	8.39	0.6	9.34e-14	Gestational age at birth (maternal effect);
TGCT	cis	rs4663866	1.000	rs71426509	chr2:239175334	A/C	cg17283117	chr2:239148619	HES6	0.98	4.52	0.38	1.42e-5	Irritable bowel syndrome;
TGCT	cis	rs2013441	1.000	rs2243732	chr17:20088589	C/G	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.61	-0.38	9.96e-6	Obesity-related traits;
TGCT	cis	rs4494114	0.967	rs1886748	chr1:39333775	C/A	cg25970120	chr1:39325951	RRAGC	-0.6	-6.25	-0.49	5.96e-9	Blood protein levels;
TGCT	cis	rs16957091	0.606	rs2412748	chr15:43227515	G/A	cg17935677	chr15:44119062	WDR76	0.52	4.67	0.39	7.6e-6	MGMT methylation in smokers;
TGCT	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg06618935	chr21:46677482	NA	-0.36	-5.61	-0.45	1.25e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9952991	0.883	rs2542148	chr18:12777573	C/G	cg23544223	chr18:12777786	NA	0.63	6.02	0.48	1.85e-8	Inflammatory skin disease;
TGCT	cis	rs877282	0.898	rs34490091	chr10:765800	A/C	cg17470449	chr10:769945	NA	0.37	5.59	0.45	1.37e-7	Uric acid levels;
TGCT	cis	rs9818758	0.607	rs73084135	chr3:49272218	A/G	cg07636037	chr3:49044803	WDR6	-1.01	-4.93	-0.4	2.63e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs6540559	0.673	rs6694552	chr1:209976459	A/C	cg23283495	chr1:209979779	IRF6	0.65	5.04	0.41	1.63e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs6671200	0.790	rs259357	chr1:95711478	G/T	cg03123541	chr1:95699097	RWDD3	-0.91	-6.4	-0.5	2.93e-9	Stearic acid (18:0) levels;
TGCT	cis	rs9638182	0.945	rs35368205	chr7:73017657	C/T	cg14087351	chr7:73037990	MLXIPL	-0.57	-4.77	-0.39	5.02e-6	Triglycerides;
TGCT	trans	rs986417	0.818	rs761557	chr14:61077484	C/T	cg12876356	chr1:92946825	GFI1	0.71	6.93	0.53	1.98e-10	Gut microbiota (bacterial taxa);
TGCT	cis	rs12477438	0.501	rs11685756	chr2:99766215	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	12.84	0.76	1.57e-24	Chronic sinus infection;
TGCT	cis	rs2010099	0.583	rs112519474	chr3:124315623	G/A	cg17170942	chr3:124452405	UMPS	-0.4	-4.64	-0.38	8.55e-6	Thyroid peroxidase antibody levels;
TGCT	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg09263875	chr16:632152	PIGQ	0.31	6.93	0.53	2.06e-10	Height;
TGCT	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.4	-4.52	-0.38	1.4e-5	Longevity;Endometriosis;
TGCT	cis	rs7552404	0.924	rs2275378	chr1:76198436	T/C	cg03433033	chr1:76189801	ACADM	0.81	9.7	0.66	6.89e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.75	0.52	5.11e-10	Bipolar disorder;
TGCT	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg06238570	chr21:40685208	BRWD1	-0.62	-6.51	-0.5	1.68e-9	Menarche (age at onset);
TGCT	cis	rs13177918	0.626	rs3819332	chr5:149828750	G/C	cg14059543	chr5:149831962	NA	-0.69	-9.27	-0.64	7.32e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg18867708	chr6:26865862	GUSBL1	0.41	5.48	0.44	2.3e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs8180040	0.764	rs11708451	chr3:47198826	G/A	cg27129171	chr3:47204927	SETD2	0.75	9.86	0.66	2.82e-17	Colorectal cancer;
TGCT	trans	rs4948418	0.579	rs10821745	chr10:62136206	T/G	cg03916014	chr16:1722352	CRAMP1L	0.45	6.84	0.52	3.16e-10	Bipolar disorder;
TGCT	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg03264133	chr6:25882463	NA	-0.72	-6.85	-0.52	3.11e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs9372498	0.536	rs9489477	chr6:118946192	T/G	cg21191810	chr6:118973309	C6orf204	-0.38	-4.97	-0.41	2.14e-6	Diastolic blood pressure;
TGCT	cis	rs7937682	0.663	rs35581942	chr11:111756286	C/T	cg09085632	chr11:111637200	PPP2R1B	0.84	7.27	0.55	3.45e-11	Primary sclerosing cholangitis;
TGCT	cis	rs8141529	0.748	rs5762874	chr22:29269658	C/G	cg02153584	chr22:29168773	CCDC117	0.63	4.87	0.4	3.3e-6	Lymphocyte counts;
TGCT	cis	rs7255045	0.789	rs1078264	chr19:12963143	T/C	cg23899408	chr19:12877188	HOOK2	-0.61	-4.99	-0.41	1.97e-6	Mean corpuscular volume;
TGCT	cis	rs7666738	0.791	rs1426674	chr4:98924247	C/A	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2702888	0.503	rs2738143	chr8:6758816	G/A	cg26795848	chr8:6756730	NA	-0.31	-6.46	-0.5	2.11e-9	Blood pressure;
TGCT	cis	rs3784262	0.669	rs4646594	chr15:58302386	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.42	-6.17	-0.48	8.85e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs6831352	0.918	rs13133647	chr4:100058727	C/T	cg12011299	chr4:100065546	ADH4	-0.4	-4.88	-0.4	3.26e-6	Alcohol dependence;
TGCT	cis	rs10779751	0.734	rs2748878	chr1:11129434	T/C	cg08854313	chr1:11322531	MTOR	0.82	7.04	0.53	1.19e-10	Body mass index;
TGCT	cis	rs7833790	0.963	rs2400473	chr8:82703403	C/T	cg27398817	chr8:82754497	SNX16	-0.93	-6.44	-0.5	2.37e-9	Diastolic blood pressure;
TGCT	trans	rs4820792	0.945	rs2017309	chr22:29131426	A/T	cg00373991	chr10:102763563	LZTS2	0.32	6.77	0.52	4.68e-10	Breast size;
TGCT	cis	rs1568889	1.000	rs61236373	chr11:28212720	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.81	8.17	0.59	3.04e-13	Bipolar disorder;
TGCT	cis	rs13256369	1.000	rs12550762	chr8:8576535	T/A	cg17143192	chr8:8559678	CLDN23	0.62	5.87	0.47	3.67e-8	Obesity-related traits;
TGCT	cis	rs7666738	0.830	rs6854994	chr4:98977624	C/G	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg10802521	chr3:52805072	NEK4	-0.78	-10.09	-0.67	7.59e-18	Bipolar disorder;
TGCT	cis	rs9467773	1.000	rs9467787	chr6:26556769	G/T	cg26531700	chr6:26746687	NA	0.49	4.73	0.39	6.06e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs3733585	0.699	rs6449158	chr4:9960459	T/C	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.54	-0.56	8.83e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs1801251	0.711	rs778368	chr2:233745333	G/C	cg25237894	chr2:233734115	C2orf82	-0.31	-5.84	-0.46	4.3e-8	Coronary artery disease;
TGCT	cis	rs7647973	0.710	rs1491983	chr3:49639803	G/T	cg05785598	chr3:49045655	WDR6	0.41	4.66	0.39	8.03e-6	Menarche (age at onset);
TGCT	cis	rs6598955	0.671	rs11247905	chr1:26627907	G/C	cg04990556	chr1:26633338	UBXN11	0.67	5.44	0.44	2.77e-7	Obesity-related traits;
TGCT	cis	rs11673344	0.504	rs6510588	chr19:37597395	G/T	cg08039142	chr19:36980659	ZNF566	-0.51	-4.78	-0.39	4.81e-6	Obesity-related traits;
TGCT	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg21724239	chr8:58056113	NA	0.47	5.14	0.42	1.05e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7119	0.717	rs12917175	chr15:77818193	A/G	cg27398640	chr15:77910606	LINGO1	-0.26	-4.67	-0.39	7.6e-6	Type 2 diabetes;
TGCT	cis	rs9914988	0.943	rs66588554	chr17:27141110	A/G	cg20469991	chr17:27169893	C17orf63	-0.72	-5.09	-0.42	1.28e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg00343986	chr7:65444356	GUSB	0.22	4.8	0.4	4.51e-6	Aortic root size;
TGCT	cis	rs2153535	0.580	rs7742794	chr6:8459723	C/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs589249	0.926	rs4652927	chr1:37188699	G/T	cg04012535	chr1:37176647	NA	0.35	5.57	0.45	1.52e-7	Neuroticism (multi-trait analysis);Schizophrenia;
TGCT	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg16325326	chr1:53192061	ZYG11B	-0.71	-8.61	-0.61	2.81e-14	Monocyte count;
TGCT	cis	rs9788682	0.747	rs2938671	chr15:78732754	A/G	cg24631222	chr15:78858424	CHRNA5	-0.61	-4.55	-0.38	1.25e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs829661	0.947	rs829665	chr2:30724701	T/A	cg12454169	chr2:30669597	LCLAT1	0.73	6.92	0.53	2.1e-10	Midgestational circulating levels of PBDEs (fetal genetic effect);
TGCT	cis	rs1843834	0.505	rs2140508	chr2:225355839	G/T	cg22455342	chr2:225449267	CUL3	1.04	10.81	0.7	1.35e-19	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs67311347	0.910	rs7651204	chr3:40512835	C/T	cg13683864	chr3:40499215	RPL14	1.17	13.19	0.76	2.34e-25	Renal cell carcinoma;
TGCT	cis	rs9457247	1.000	rs376574	chr6:167389956	A/T	cg25258033	chr6:167368657	RNASET2	0.18	4.49	0.37	1.63e-5	Crohn's disease;
TGCT	cis	rs4478858	0.684	rs1532861	chr1:31766491	T/C	cg00250761	chr1:31883323	NA	-0.26	-4.55	-0.38	1.28e-5	Alcohol dependence;
TGCT	cis	rs2191566	0.664	rs4803669	chr19:44539962	C/A	cg03039196	chr19:44506973	ZNF230	0.53	4.47	0.37	1.78e-5	Acute lymphoblastic leukemia (childhood);
TGCT	cis	rs1697139	0.583	rs1428474	chr5:66544015	C/A	cg11553311	chr5:66541588	NA	0.29	6.27	0.49	5.38e-9	Breast cancer;
TGCT	cis	rs9486719	1.000	rs2472895	chr6:96870387	A/T	cg06623918	chr6:96969491	KIAA0776	1.01	8.86	0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs7119	0.717	rs12902925	chr15:77819141	T/C	cg27398640	chr15:77910606	LINGO1	-0.25	-4.61	-0.38	9.81e-6	Type 2 diabetes;
TGCT	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg00343986	chr7:65444356	GUSB	0.24	5.25	0.43	6.3e-7	Aortic root size;
TGCT	cis	rs11785400	0.793	rs1056012	chr8:143740167	A/G	cg24634471	chr8:143751801	JRK	0.55	5.51	0.44	1.99e-7	Schizophrenia;
TGCT	cis	rs7552404	0.961	rs17587071	chr1:76225083	A/C	cg22875332	chr1:76189707	ACADM	0.78	8.96	0.63	4.17e-15	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg05552183	chr6:42928497	GNMT	0.52	4.57	0.38	1.16e-5	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg14004847	chr7:1930337	MAD1L1	0.31	5.46	0.44	2.47e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	6.18	0.49	8.58e-9	Bipolar disorder;
TGCT	trans	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg17830980	chr10:43048298	ZNF37B	-0.84	-10.45	-0.68	1.02e-18	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7940866	0.834	rs10791105	chr11:130839161	A/G	cg12179176	chr11:130786555	SNX19	0.62	5.93	0.47	2.75e-8	Schizophrenia;
TGCT	cis	rs7044106	0.791	rs2416798	chr9:123480603	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	4.98	0.41	2.12e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs11696501	0.739	rs6073821	chr20:44251791	A/G	cg11783356	chr20:44313418	WFDC10B	-0.32	-4.63	-0.38	9.25e-6	Brain structure;
TGCT	cis	rs7772486	0.754	rs9373476	chr6:146139741	C/G	cg13319975	chr6:146136371	FBXO30	-0.52	-4.65	-0.39	8.45e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs5769707	0.846	rs5770610	chr22:50036897	A/C	cg20744362	chr22:50050164	C22orf34	0.27	4.57	0.38	1.18e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs4925386	0.681	rs2427296	chr20:60927475	G/A	cg06026331	chr20:60912101	LAMA5	0.34	5.46	0.44	2.48e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs9357506	1.000	rs9381444	chr6:46316690	C/A	cg21115430	chr6:46460003	NA	-0.25	-4.8	-0.4	4.49e-6	Body mass index;
TGCT	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg03709012	chr19:19516395	GATAD2A	0.75	6.51	0.5	1.71e-9	Tonsillectomy;
TGCT	cis	rs71636778	0.509	rs12741472	chr1:27221609	A/G	cg23921621	chr1:27994728	IFI6	-0.43	-4.61	-0.38	9.95e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
TGCT	cis	rs539096	0.624	rs11210892	chr1:44100084	A/G	cg12908607	chr1:44402522	ARTN	0.43	4.87	0.4	3.37e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2070433	0.500	rs9306156	chr21:47960493	T/C	cg12379764	chr21:47803548	PCNT	0.44	4.58	0.38	1.11e-5	Lymphocyte counts;
TGCT	cis	rs2282802	0.685	rs2053055	chr5:139646776	C/T	cg01081189	chr5:139537190	NA	0.28	5.15	0.42	9.75e-7	Intelligence (multi-trait analysis);
TGCT	trans	rs4332037	0.539	rs56180486	chr7:2050747	C/T	cg25206134	chr2:45395956	NA	0.99	7.46	0.56	1.34e-11	Bipolar disorder;
TGCT	trans	rs4824093	0.541	rs8142132	chr22:50211294	C/T	cg09872104	chr7:134855509	C7orf49	-1.12	-8.69	-0.62	1.84e-14	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs778371	0.649	rs13021823	chr2:233686862	A/G	cg08000102	chr2:233561755	GIGYF2	-0.67	-7.47	-0.56	1.25e-11	Schizophrenia;
TGCT	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg26354017	chr1:205819088	PM20D1	0.57	7.09	0.54	8.8e-11	Menarche (age at onset);
TGCT	cis	rs651907	0.557	rs34181125	chr3:101490278	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	5.02	0.41	1.77e-6	Colorectal cancer;
TGCT	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg03188948	chr7:1209495	NA	0.65	5.39	0.44	3.36e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2562456	0.720	rs6511250	chr19:21656046	C/T	cg01304269	chr19:21688519	ZNF429	-0.55	-4.53	-0.38	1.34e-5	Pain;
TGCT	cis	rs240764	0.658	rs7746947	chr6:101188708	G/A	cg09795085	chr6:101329169	ASCC3	-0.51	-4.51	-0.38	1.45e-5	Neuroticism;
TGCT	cis	rs9926296	0.744	rs164746	chr16:89709019	C/T	cg04287289	chr16:89883240	FANCA	-0.49	-4.7	-0.39	6.94e-6	Vitiligo;
TGCT	cis	rs1670533	1.000	rs11731320	chr4:1057916	T/A	cg20887711	chr4:1340912	KIAA1530	0.71	5.7	0.46	8.33e-8	Recombination rate (females);
TGCT	cis	rs4975616	0.836	rs460073	chr5:1336459	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.28	-6.88	-0.53	2.69e-10	Lung cancer;
TGCT	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg00149659	chr3:10157352	C3orf10	0.79	4.96	0.41	2.27e-6	Alzheimer's disease;
TGCT	cis	rs9814567	0.752	rs9846111	chr3:134335034	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-6.66	-0.51	7.8e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs1008375	1.000	rs10939748	chr4:17691230	T/C	cg18681998	chr4:17616180	MED28	0.79	7.53	0.56	9.23e-12	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs826838	0.754	rs2387920	chr12:38626351	A/G	cg26384229	chr12:38710491	ALG10B	0.9	8.1	0.59	4.36e-13	Heart rate;
TGCT	cis	rs2456568	0.803	rs10765642	chr11:93640355	C/T	cg16099599	chr11:93583650	C11orf90	0.39	4.88	0.4	3.17e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7091068	0.616	rs4322326	chr10:95483382	A/T	cg20715218	chr10:95462985	C10orf4	0.56	5.19	0.42	8.51e-7	Urinary tract infection frequency;
TGCT	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg17775962	chr7:1200435	ZFAND2A	0.28	4.8	0.4	4.57e-6	Longevity;Endometriosis;
TGCT	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg20203395	chr5:56204925	C5orf35	-0.56	-4.8	-0.4	4.39e-6	Initial pursuit acceleration;
TGCT	cis	rs2663905	0.611	rs1509559	chr15:81391411	G/A	cg18028999	chr15:81426610	C15orf26	-0.54	-5.23	-0.42	7.14e-7	QT interval (drug interaction);
TGCT	cis	rs10501293	1.000	rs10501293	chr11:43086094	G/T	cg03447554	chr11:43094025	NA	0.47	6.64	0.51	8.97e-10	Cognitive performance;
TGCT	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg24531977	chr5:56204891	C5orf35	-0.74	-7.1	-0.54	8.53e-11	Initial pursuit acceleration;
TGCT	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg11366901	chr6:160182831	ACAT2	0.79	5.81	0.46	4.92e-8	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs9611565	0.649	rs79005	chr22:41835544	G/A	cg13695892	chr22:41940480	POLR3H	0.89	8.48	0.61	5.62e-14	Vitiligo;
TGCT	cis	rs12360000	0.740	rs55679834	chr10:1910856	T/A	cg26364871	chr10:1889757	NA	0.4	4.58	0.38	1.12e-5	Metabolite levels (Dihydroxy docosatrienoic acid);
TGCT	cis	rs1008375	0.932	rs10009933	chr4:17670107	A/C	cg16339924	chr4:17578868	LAP3	0.54	4.48	0.37	1.67e-5	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg11764359	chr7:65958608	NA	0.58	5.31	0.43	4.91e-7	Aortic root size;
TGCT	cis	rs9611565	0.592	rs5751129	chr22:42015765	C/T	cg06481639	chr22:41940642	POLR3H	0.61	5.32	0.43	4.75e-7	Vitiligo;
TGCT	cis	rs10744422	1.000	rs12255	chr12:123350204	C/T	cg25930673	chr12:123319894	HIP1R	-0.9	-5.06	-0.41	1.49e-6	Schizophrenia;
TGCT	cis	rs904251	0.523	rs2776874	chr6:37483197	C/T	cg08126542	chr6:37504118	NA	-0.38	-5.81	-0.46	4.9e-8	Cognitive performance;
TGCT	cis	rs9911578	1.000	rs12602346	chr17:56901713	T/C	cg05425664	chr17:57184151	TRIM37	-0.62	-6.18	-0.49	8.33e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7209700	0.614	rs7225927	chr17:45323934	A/G	cg21624342	chr17:45890973	OSBPL7	0.16	4.46	0.37	1.8e-5	IgG glycosylation;
TGCT	cis	rs7208859	0.673	rs11655623	chr17:29162173	T/C	cg18442181	chr17:29233375	C17orf42	-0.76	-4.5	-0.38	1.52e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs6912958	0.781	rs9450732	chr6:88249826	G/A	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.91	-0.4	2.78e-6	Monocyte percentage of white cells;
TGCT	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg21724239	chr8:58056113	NA	0.47	5.14	0.42	1.05e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7647973	0.626	rs11130217	chr3:49737323	A/G	cg03060546	chr3:49711283	APEH	0.63	5.63	0.45	1.12e-7	Menarche (age at onset);
TGCT	cis	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg18252515	chr7:66147081	NA	-1.22	-7.33	-0.55	2.53e-11	Diabetic kidney disease;
TGCT	trans	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-1.04	-13.29	-0.77	1.33e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs7302981	0.967	rs35998534	chr12:50556782	A/G	cg23855989	chr12:50355821	AQP5	0.3	4.46	0.37	1.84e-5	Systolic blood pressure;
TGCT	cis	rs11031096	0.655	rs11031252	chr11:4211165	A/G	cg18678763	chr11:4115507	RRM1	-0.45	-5.77	-0.46	6.11e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs7267979	1.000	rs6050562	chr20:25336186	C/G	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	-1.04	-13.29	-0.77	1.33e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs589249	0.926	rs6677366	chr1:37187504	A/G	cg04012535	chr1:37176647	NA	0.35	5.57	0.45	1.52e-7	Neuroticism (multi-trait analysis);Schizophrenia;
TGCT	cis	rs11098499	0.863	rs3775841	chr4:120425777	A/C	cg09307838	chr4:120376055	NA	0.68	6.29	0.49	4.97e-9	Corneal astigmatism;
TGCT	cis	rs933688	0.877	rs1477349	chr5:90707773	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.98	8.03	0.58	6.35e-13	Smoking behavior;
TGCT	cis	rs28374715	0.681	rs59000092	chr15:41626148	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.87	-13.45	-0.77	5.4e-26	Ulcerative colitis;
TGCT	trans	rs2469997	0.925	rs2470001	chr8:120356402	C/T	cg01792902	chr3:178864926	PIK3CA	0.84	6.9	0.53	2.41e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs7017914	0.905	rs4738105	chr8:71958918	A/C	cg23757474	chr8:71581111	LACTB2;XKR9	0.55	5.07	0.41	1.39e-6	Bone mineral density;
TGCT	cis	rs11264213	0.901	rs614235	chr1:36450565	G/A	cg07093915	chr1:36184400	C1orf216	0.65	4.51	0.38	1.46e-5	Schizophrenia;
TGCT	cis	rs910187	0.596	rs6066222	chr20:45801917	G/A	cg27589058	chr20:45804311	EYA2	-0.37	-7.95	-0.58	9.93e-13	Migraine;
TGCT	cis	rs1865760	0.663	rs9467656	chr6:25993559	G/A	cg17042849	chr6:26104293	HIST1H4C	-0.59	-5.43	-0.44	2.91e-7	Height;
TGCT	cis	rs2842992	0.789	rs2475566	chr6:160148741	C/T	cg11366901	chr6:160182831	ACAT2	1.04	6.93	0.53	2.05e-10	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs981844	0.712	rs1012029	chr4:154749233	C/T	cg14289246	chr4:154710475	SFRP2	-0.99	-9.12	-0.63	1.65e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs350251	0.865	rs350271	chr16:12235372	A/G	cg01574788	chr16:12184133	SNX29	0.36	4.71	0.39	6.63e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7727544	0.716	rs2089855	chr5:131573529	A/G	cg22598563	chr5:131563921	P4HA2	-0.31	-4.79	-0.39	4.73e-6	Blood metabolite levels;
TGCT	cis	rs6570726	0.599	rs426371	chr6:145886469	A/G	cg05347473	chr6:146136440	FBXO30	-0.62	-5.76	-0.46	6.15e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1577917	1.000	rs36096931	chr6:86693134	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.54	-0.45	1.73e-7	Response to antipsychotic treatment;
TGCT	cis	rs11096990	0.634	rs1564710	chr4:39292798	G/T	cg20847110	chr4:39482781	LOC401127	-0.16	-4.51	-0.38	1.48e-5	Cognitive function;
TGCT	cis	rs7824557	0.585	rs2572382	chr8:11211302	T/G	cg21775007	chr8:11205619	TDH	0.77	7.4	0.55	1.79e-11	Retinal vascular caliber;
TGCT	cis	rs2594714	0.515	rs10411270	chr19:13940838	A/T	cg18576835	chr19:13944261	NA	-0.41	-5.25	-0.43	6.45e-7	Breast cancer;
TGCT	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg06028605	chr16:24865363	SLC5A11	-0.42	-4.69	-0.39	7.14e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs939574	0.722	rs55951006	chr2:220132151	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.02	4.66	0.39	8.19e-6	Platelet distribution width;
TGCT	cis	rs986417	1.000	rs3931460	chr14:60939101	A/C	cg27398547	chr14:60952738	C14orf39	1.42	8.07	0.59	5.03e-13	Gut microbiota (bacterial taxa);
TGCT	cis	rs7824557	0.767	rs4559208	chr8:11153925	C/G	cg21775007	chr8:11205619	TDH	0.59	5.69	0.45	8.75e-8	Retinal vascular caliber;
TGCT	cis	rs377070	0.934	rs309418	chr4:123623441	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.48	5.27	0.43	5.73e-7	Mosquito bite size;
TGCT	cis	rs3757318	0.540	rs6900089	chr6:151851124	G/T	cg18745416	chr6:152011399	ESR1	0.5	4.77	0.39	5.12e-6	Breast cancer (estrogen-receptor negative, progesterone-receptor negative, and human epidermal growth factor-receptor negative);Breast cancer;
TGCT	cis	rs10876993	0.928	rs2640637	chr12:58077586	G/A	cg15848620	chr12:58087721	OS9	-0.71	-5.77	-0.46	5.92e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs4285028	0.848	rs4118376	chr3:121636450	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.76	-6.49	-0.5	1.89e-9	Multiple sclerosis;
TGCT	cis	rs1215050	0.546	rs7660713	chr4:98621341	T/C	cg05340658	chr4:99064831	C4orf37	-0.41	-4.96	-0.41	2.3e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs6933660	0.720	rs6936936	chr6:151753395	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.64	6.4	0.5	2.87e-9	Menarche (age at onset);
TGCT	cis	rs8192284	0.965	rs4129267	chr1:154426264	C/T	cg11650704	chr1:154556575	ADAR	0.25	4.46	0.37	1.81e-5	Fibrinogen;C-reactive protein;Fibrinogen levels;
TGCT	cis	rs4642101	0.737	rs4447735	chr3:12825513	C/T	cg05775895	chr3:12838266	CAND2	0.79	9.04	0.63	2.61e-15	QRS complex (12-leadsum);
TGCT	cis	rs8180040	0.654	rs6791062	chr3:47174343	T/A	cg27129171	chr3:47204927	SETD2	0.7	8.55	0.61	3.75e-14	Colorectal cancer;
TGCT	cis	rs13242816	1.000	rs12706090	chr7:116104045	A/G	cg16553024	chr7:116138462	CAV2	0.43	4.79	0.39	4.74e-6	P wave duration;
TGCT	cis	rs9309473	0.660	rs10496192	chr2:73679866	T/C	cg07208825	chr2:73871855	ALMS1P	0.25	4.53	0.38	1.34e-5	Metabolite levels;
TGCT	cis	rs7949030	0.626	rs1061093	chr11:62334908	G/C	cg22862634	chr11:62369728	EML3;MTA2	0.71	9.07	0.63	2.23e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7267979	0.933	rs2261109	chr20:25259200	T/C	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs12627970	0.565	rs5757613	chr22:39715262	G/A	cg17798944	chr22:39715225	SNORD43;RPL3	0.86	10.74	0.69	1.98e-19	Inflammatory bowel disease;
TGCT	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg26668828	chr6:292823	DUSP22	-0.77	-8.12	-0.59	3.85e-13	Menopause (age at onset);
TGCT	cis	rs1878931	0.501	rs4785934	chr16:3419934	G/T	cg05754148	chr16:3507555	NAT15	-0.33	-4.46	-0.37	1.82e-5	Body mass index (adult);
TGCT	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg13607699	chr17:42295918	UBTF	-0.84	-7.72	-0.57	3.33e-12	Total body bone mineral density;
TGCT	cis	rs3772130	1.000	rs3732408	chr3:121421179	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.54	4.85	0.4	3.66e-6	Cognitive performance;
TGCT	cis	rs7666738	0.830	rs7680909	chr4:98934604	A/G	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7772486	0.875	rs9376975	chr6:146355581	T/G	cg23711669	chr6:146136114	FBXO30	0.89	10.0	0.67	1.25e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2594989	0.943	rs2442785	chr3:11521828	C/T	cg00170343	chr3:11313890	ATG7	0.7	5.22	0.42	7.17e-7	Circulating chemerin levels;
TGCT	cis	rs931127	0.692	rs7934517	chr11:65445673	C/T	cg27068330	chr11:65405492	SIPA1	-0.63	-6.18	-0.49	8.33e-9	Systemic lupus erythematosus;
TGCT	cis	rs2760061	0.583	rs1636195	chr1:228211589	T/C	cg02753203	chr1:228287806	NA	0.39	8.12	0.59	3.9e-13	Diastolic blood pressure;
TGCT	cis	rs13315871	1.000	rs9869940	chr3:58401523	G/A	cg12435725	chr3:58293450	RPP14	-0.43	-4.47	-0.37	1.71e-5	Cholesterol, total;
TGCT	cis	rs4664308	1.000	rs17831191	chr2:160911332	T/C	cg03641300	chr2:160917029	PLA2R1	-0.26	-6.53	-0.51	1.49e-9	Idiopathic membranous nephropathy;
TGCT	cis	rs7904368	0.754	rs12253908	chr10:16853358	T/C	cg14835575	chr10:16859367	RSU1	0.71	7.25	0.55	3.93e-11	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
TGCT	cis	rs6448317	0.906	rs6448313	chr4:24905088	G/A	cg21108841	chr4:24914750	CCDC149	0.68	5.58	0.45	1.43e-7	Heschl's gyrus morphology;
TGCT	cis	rs9611565	0.559	rs132768	chr22:42013523	C/A	cg06481639	chr22:41940642	POLR3H	0.74	6.64	0.51	8.88e-10	Vitiligo;
TGCT	cis	rs3741151	0.892	rs7105681	chr11:73059341	G/A	cg17517138	chr11:73019481	ARHGEF17	0.97	5.02	0.41	1.73e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
TGCT	cis	rs7772486	0.875	rs1331644	chr6:146398660	T/C	cg05347473	chr6:146136440	FBXO30	0.55	5.14	0.42	1.05e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg16680214	chr1:154839983	KCNN3	-0.37	-7.66	-0.57	4.71e-12	Prostate cancer;
TGCT	cis	rs798766	0.903	rs798726	chr4:1685211	C/T	cg05874882	chr4:1763078	NA	0.36	4.83	0.4	3.87e-6	Bladder cancer;Urinary bladder cancer;
TGCT	cis	rs7119038	0.818	rs2077579	chr11:118619047	T/G	cg19308663	chr11:118741387	NA	0.29	5.39	0.44	3.41e-7	Sjögren's syndrome;
TGCT	cis	rs7949030	0.653	rs2849030	chr11:62366986	G/A	cg11742103	chr11:62369870	EML3;MTA2	-0.6	-8.74	-0.62	1.39e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1971762	0.545	rs7485472	chr12:54044438	T/C	cg16917193	chr12:54089295	NA	1.07	11.4	0.72	4.81e-21	Height;
TGCT	cis	rs7017914	0.905	rs1908035	chr8:71922408	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.55	-5.1	-0.42	1.24e-6	Bone mineral density;
TGCT	trans	rs4332037	0.539	rs11764590	chr7:2032803	C/T	cg10840412	chr1:235813424	GNG4	0.93	6.69	0.51	6.97e-10	Bipolar disorder;
TGCT	cis	rs1150668	0.796	rs213237	chr6:28323938	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.49	-4.68	-0.39	7.38e-6	Pubertal anthropometrics;
TGCT	cis	rs7584330	0.737	rs6431540	chr2:238360966	T/C	cg14458575	chr2:238380390	NA	0.47	7.48	0.56	1.17e-11	Prostate cancer;
TGCT	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg10802521	chr3:52805072	NEK4	-0.78	-10.0	-0.67	1.28e-17	Electroencephalogram traits;
TGCT	cis	rs9467603	0.920	rs34493019	chr6:25714959	A/G	cg16898833	chr6:26189333	HIST1H4D	1.37	6.13	0.48	1.1e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs11096990	0.656	rs2066786	chr4:39302029	T/C	cg20847110	chr4:39482781	LOC401127	0.16	4.65	0.39	8.26e-6	Cognitive function;
TGCT	cis	rs2862064	1.000	rs7706978	chr5:156432566	T/C	cg12943317	chr5:156479607	HAVCR1	-0.45	-5.77	-0.46	5.83e-8	Platelet count;
TGCT	cis	rs9467773	0.620	rs2101582	chr6:26622734	C/T	cg05738196	chr6:26577821	NA	0.87	11.5	0.72	2.82e-21	Intelligence (multi-trait analysis);
TGCT	cis	rs6582630	0.513	rs1596446	chr12:38282160	C/T	cg13010199	chr12:38710504	ALG10B	-0.59	-4.61	-0.38	9.88e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs7267979	0.933	rs2258728	chr20:25276343	G/A	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7264396	0.676	rs6058380	chr20:34552900	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.04	-0.41	1.58e-6	Total cholesterol levels;
TGCT	trans	rs2832077	0.527	rs9980449	chr21:30224889	G/C	cg14791747	chr16:20752902	THUMPD1	1.09	12.67	0.75	4.09e-24	Cognitive test performance;
TGCT	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg20887711	chr4:1340912	KIAA1530	0.77	6.49	0.5	1.89e-9	Longevity;
TGCT	cis	rs78487399	0.808	rs7601039	chr2:43828637	C/A	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.71	5.07	0.41	1.44e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	trans	rs1814175	0.765	rs11493326	chr11:50018063	T/C	cg15704280	chr7:45808275	SEPT13	-0.71	-7.97	-0.58	8.91e-13	Height;
TGCT	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg22968622	chr17:43663579	NA	-0.96	-9.35	-0.64	4.62e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs9467711	0.606	rs66827971	chr6:26365766	T/C	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7659604	1.000	rs6823488	chr4:122664819	A/G	cg19748678	chr4:122722346	EXOSC9	0.56	5.35	0.43	4.14e-7	Type 2 diabetes;
TGCT	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg00101154	chr16:420108	MRPL28	-0.66	-7.69	-0.57	3.97e-12	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs26868	0.742	rs26848	chr16:2263516	A/G	cg10160842	chr16:2261107	C16orf79	-0.28	-4.69	-0.39	7.13e-6	Height;
TGCT	cis	rs889312	0.500	rs866223	chr5:56125353	A/G	cg24531977	chr5:56204891	C5orf35	-0.52	-5.48	-0.44	2.31e-7	Breast cancer;Breast cancer (early onset);
TGCT	cis	rs459571	0.606	rs457420	chr9:136909261	A/G	cg13789015	chr9:136890014	NCRNA00094	-0.39	-6.77	-0.52	4.64e-10	Platelet distribution width;
TGCT	cis	rs877282	1.000	rs12779159	chr10:772143	T/C	cg17470449	chr10:769945	NA	0.3	4.68	0.39	7.39e-6	Uric acid levels;
TGCT	cis	rs72945132	0.882	rs12274436	chr11:70132204	T/C	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs1035144	0.505	rs6574617	chr14:81457615	G/A	cg06600135	chr14:81408086	NA	-0.48	-4.49	-0.37	1.58e-5	Male sexual orientation;
TGCT	cis	rs12210905	0.688	rs12215353	chr6:27407022	C/T	cg08851530	chr6:28072375	NA	1.34	6.07	0.48	1.44e-8	Hip circumference adjusted for BMI;
TGCT	trans	rs17685	0.725	rs4476928	chr7:75642107	C/A	cg19862616	chr7:65841803	NCRNA00174	-0.5	-8.5	-0.61	5.01e-14	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs7044106	0.708	rs10984992	chr9:123473416	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.61	6.35	0.5	3.69e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs7918232	0.941	rs1753415	chr10:27395102	T/C	cg14442939	chr10:27389572	ANKRD26	0.71	5.33	0.43	4.45e-7	Breast cancer;
TGCT	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg26668828	chr6:292823	DUSP22	-0.83	-8.57	-0.61	3.38e-14	Menopause (age at onset);
TGCT	cis	rs7192750	0.538	rs28594331	chr16:71863482	C/T	cg06353428	chr16:71660113	MARVELD3	0.84	7.44	0.56	1.44e-11	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs2235642	0.893	rs2076445	chr16:1592266	A/T	cg07639376	chr16:1584516	IFT140;TMEM204	-0.33	-5.95	-0.47	2.56e-8	Coronary artery disease;
TGCT	cis	rs3733585	0.577	rs5014939	chr4:9953253	T/A	cg11266682	chr4:10021025	SLC2A9	-0.57	-7.41	-0.55	1.69e-11	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs2932538	0.885	rs6693880	chr1:113110261	A/G	cg22162597	chr1:113214053	CAPZA1	0.27	5.98	0.47	2.24e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs72627509	0.904	rs56281640	chr4:57765816	G/A	cg26694713	chr4:57773883	REST	0.71	6.36	0.5	3.58e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs3749237	0.636	rs1568662	chr3:49521263	A/G	cg02487422	chr3:49467188	NICN1	0.61	6.29	0.49	5.08e-9	Resting heart rate;
TGCT	cis	rs4975616	0.869	rs452384	chr5:1330840	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.28	-6.88	-0.53	2.69e-10	Lung cancer;
TGCT	cis	rs7085104	0.727	rs12773892	chr10:104631177	G/A	cg15744005	chr10:104629667	AS3MT	-0.45	-4.52	-0.38	1.45e-5	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg24250549	chr1:154909240	PMVK	0.64	6.26	0.49	5.86e-9	Prostate cancer;
TGCT	cis	rs12477438	0.798	rs4850894	chr2:99629396	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-8.52	-0.61	4.5e-14	Chronic sinus infection;
TGCT	cis	rs9682041	0.696	rs10936627	chr3:170104406	C/T	cg11886554	chr3:170076028	SKIL	0.62	4.82	0.4	4.11e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs67460515	0.852	rs2404341	chr3:161092405	T/C	cg03342759	chr3:160939853	NMD3	-0.52	-5.38	-0.44	3.56e-7	Parkinson's disease;
TGCT	cis	rs57994353	0.600	rs10870163	chr9:139315594	G/A	cg13741927	chr9:139327495	INPP5E	-0.25	-5.59	-0.45	1.35e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs992157	0.735	rs2271541	chr2:219082119	G/T	cg00012203	chr2:219082015	ARPC2	0.81	10.19	0.68	4.34e-18	Colorectal cancer;
TGCT	cis	rs6938	0.534	rs12904897	chr15:75217686	A/G	cg10253484	chr15:75165896	SCAMP2	-0.51	-4.66	-0.39	8.1e-6	Breast cancer;
TGCT	cis	rs2172802	0.924	rs11941524	chr4:62446484	A/G	cg04118610	chr4:62707027	LPHN3	-0.4	-4.64	-0.38	8.56e-6	Partial epilepsies;
TGCT	cis	rs9534288	0.797	rs6561280	chr13:46583691	T/C	cg15192986	chr13:46630673	CPB2	-0.53	-7.62	-0.56	5.82e-12	Blood protein levels;
TGCT	cis	rs9911578	1.000	rs9907499	chr17:56949044	A/G	cg05425664	chr17:57184151	TRIM37	-0.62	-6.18	-0.49	8.33e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs9814567	1.000	rs6439484	chr3:134249899	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.92	-8.81	-0.62	9.26e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs514406	0.505	rs6688064	chr1:53165609	C/T	cg01802117	chr1:53393560	SCP2	-0.42	-4.84	-0.4	3.86e-6	Monocyte count;
TGCT	cis	rs9611565	0.921	rs5758297	chr22:41720697	A/G	cg06634786	chr22:41940651	POLR3H	-0.62	-5.93	-0.47	2.82e-8	Vitiligo;
TGCT	cis	rs2710642	0.927	rs2539980	chr2:63208460	T/C	cg17519650	chr2:63277830	OTX1	0.64	6.07	0.48	1.47e-8	LDL cholesterol levels;LDL cholesterol;
TGCT	cis	rs9560113	1.000	rs9555812	chr13:112181535	A/G	cg14154082	chr13:112174009	NA	0.38	5.01	0.41	1.83e-6	Menarche (age at onset);
TGCT	cis	rs9467711	0.790	rs35400317	chr6:26593275	C/T	cg12315302	chr6:26189340	HIST1H4D	0.99	4.44	0.37	1.93e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9467773	0.549	rs9461273	chr6:26584526	A/G	cg15659132	chr6:26577336	NA	-0.84	-10.59	-0.69	4.57e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs41271951	0.512	rs115968379	chr1:151050087	A/C	cg00666978	chr1:150947442	LASS2	0.89	4.64	0.38	8.54e-6	Blood protein levels;
TGCT	cis	rs881375	0.933	rs10818485	chr9:123667816	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	5.06	0.41	1.49e-6	Rheumatoid arthritis;
TGCT	cis	rs11718455	0.960	rs11921995	chr3:44017301	C/A	cg08738300	chr3:44038990	NA	0.87	6.63	0.51	9.07e-10	Coronary artery disease;
TGCT	cis	rs453301	0.686	rs13252797	chr8:8861430	A/G	cg11995313	chr8:8860691	ERI1	-0.53	-4.5	-0.37	1.55e-5	Joint mobility (Beighton score);
TGCT	cis	rs1451375	1.000	rs2329340	chr7:50620229	C/T	cg18232548	chr7:50535776	DDC	0.44	6.59	0.51	1.11e-9	Malaria;
TGCT	trans	rs2288327	0.643	rs16866334	chr2:179336672	A/G	cg14011486	chr1:26737247	LIN28	1.05	8.23	0.59	2.24e-13	Atrial fibrillation;
TGCT	trans	rs66573146	1.000	rs6838042	chr4:6973049	G/T	cg07817883	chr1:32538562	TMEM39B	1.6	7.9	0.58	1.28e-12	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg17971929	chr21:40555470	PSMG1	0.98	9.49	0.65	2.19e-16	Cognitive function;
TGCT	cis	rs17376456	0.877	rs34184666	chr5:93444584	T/C	cg25358565	chr5:93447407	FAM172A	0.92	8.38	0.6	9.58e-14	Diabetic retinopathy;
TGCT	cis	rs9467603	1.000	rs9467603	chr6:25803712	A/G	cg16898833	chr6:26189333	HIST1H4D	1.16	5.51	0.44	2.03e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs3892630	0.878	rs8108621	chr19:33183291	G/A	cg22980127	chr19:33182716	NUDT19	0.72	5.11	0.42	1.16e-6	Red blood cell traits;
TGCT	cis	rs9894429	0.646	rs7406825	chr17:79619188	C/T	cg18240062	chr17:79603768	NPLOC4	0.56	4.88	0.4	3.15e-6	Eye color traits;
TGCT	cis	rs10782582	0.609	rs112205173	chr1:76310100	C/T	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.52	4.53	0.38	1.37e-5	Daytime sleep phenotypes;
TGCT	cis	rs6700896	0.500	rs4655556	chr1:66080563	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.59	4.56	0.38	1.22e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg06028605	chr16:24865363	SLC5A11	0.41	4.46	0.37	1.82e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs9427116	0.740	rs11264230	chr1:154608418	G/T	cg17218026	chr1:154582156	ADAR	0.28	7.02	0.53	1.3e-10	Blood protein levels;
TGCT	cis	rs4925386	0.959	rs4925385	chr20:60920624	A/G	cg06026331	chr20:60912101	LAMA5	-0.3	-5.5	-0.44	2.12e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs12908161	1.000	rs35726233	chr15:85337800	C/T	cg11189052	chr15:85197271	WDR73	0.71	5.87	0.47	3.68e-8	Schizophrenia;
TGCT	cis	rs6500602	0.682	rs3761679	chr16:4457907	C/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.42	5.17	0.42	9.28e-7	Schizophrenia;
TGCT	cis	rs3008870	1.000	rs3008870	chr1:67418027	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.1	11.91	0.73	2.83e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs67311347	0.524	rs11129869	chr3:40259738	G/A	cg13683864	chr3:40499215	RPL14	-0.79	-7.39	-0.55	1.93e-11	Renal cell carcinoma;
TGCT	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg23708337	chr7:1209742	NA	0.57	5.14	0.42	1.02e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs6840360	0.642	rs12647555	chr4:152401098	A/T	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.82e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs1635	0.826	rs79567170	chr6:28280057	C/T	cg15743358	chr6:28303923	ZNF323	-1.34	-5.96	-0.47	2.44e-8	Schizophrenia;
TGCT	cis	rs4253772	0.550	rs6008729	chr22:46727428	C/G	cg24881330	chr22:46731750	TRMU	-0.75	-5.59	-0.45	1.38e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg22963979	chr7:1858916	MAD1L1	0.35	5.49	0.44	2.2e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs2299587	0.554	rs3853530	chr8:17748420	C/T	cg01800426	chr8:17659068	MTUS1	-0.57	-5.08	-0.42	1.33e-6	Economic and political preferences;
TGCT	cis	rs8067545	0.750	rs9915758	chr17:19964775	A/G	cg13482628	chr17:19912719	NA	0.54	4.64	0.38	8.78e-6	Schizophrenia;
TGCT	cis	rs11148252	0.508	rs1886542	chr13:52706281	A/C	cg00495681	chr13:53174319	NA	0.57	5.87	0.47	3.78e-8	Lewy body disease;
TGCT	cis	rs2742417	0.603	rs1962800	chr3:45779943	C/T	cg04837898	chr3:45731254	SACM1L	-0.66	-7.06	-0.54	1.05e-10	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs35934224	0.891	rs34249993	chr22:19872170	G/T	cg11182965	chr22:19864308	TXNRD2	-0.36	-5.03	-0.41	1.67e-6	Glaucoma (primary open-angle);
TGCT	cis	rs9300255	0.544	rs1727309	chr12:123658258	A/G	cg00376283	chr12:123451042	ABCB9	0.74	5.08	0.42	1.32e-6	Neutrophil percentage of white cells;
TGCT	cis	rs7191439	0.728	rs8043924	chr16:88787704	G/C	cg27087555	chr16:88793112	FAM38A	-0.45	-5.3	-0.43	5.01e-7	Plateletcrit;
TGCT	cis	rs10423674	0.526	rs34482977	chr19:18824038	C/G	cg20185461	chr19:18899082	COMP	-0.53	-5.03	-0.41	1.68e-6	Menarche (age at onset);
TGCT	cis	rs910187	0.641	rs6066232	chr20:45818905	C/T	cg27589058	chr20:45804311	EYA2	-0.35	-7.32	-0.55	2.76e-11	Migraine;
TGCT	cis	rs1008375	0.618	rs6842764	chr4:17568420	C/T	cg10189774	chr4:17578691	LAP3	-0.6	-5.08	-0.42	1.35e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9650657	0.771	rs4240670	chr8:10665848	T/A	cg27411982	chr8:10470053	RP1L1	-0.23	-5.17	-0.42	9.17e-7	Neuroticism;
TGCT	cis	rs3806843	0.576	rs155359	chr5:140315425	G/T	cg07102913	chr5:140593443	PCDHB13	-0.48	-4.77	-0.39	5.15e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs10791323	0.569	rs2257004	chr11:133712473	C/T	cg03690763	chr11:133734501	NA	-0.31	-4.82	-0.4	4.08e-6	Childhood ear infection;
TGCT	cis	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg07424592	chr7:64974309	NA	1.27	7.84	0.58	1.8e-12	Diabetic kidney disease;
TGCT	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg20607798	chr8:58055168	NA	0.54	5.94	0.47	2.65e-8	Developmental language disorder (linguistic errors);
TGCT	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg27535305	chr1:53392650	SCP2	-0.27	-5.47	-0.44	2.39e-7	Monocyte count;
TGCT	cis	rs11031096	0.803	rs6578454	chr11:4173384	A/G	cg18678763	chr11:4115507	RRM1	0.39	5.28	0.43	5.52e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs35883536	0.528	rs1577512	chr1:101030832	G/A	cg10298815	chr1:101004474	GPR88	0.25	4.68	0.39	7.46e-6	Monocyte count;
TGCT	cis	rs10464366	0.746	rs4723822	chr7:39141613	C/T	cg15212455	chr7:39170539	POU6F2	0.26	5.62	0.45	1.19e-7	IgG glycosylation;
TGCT	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg22433210	chr17:43662623	NA	1.04	7.37	0.55	2.07e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2070488	1.000	rs4147024	chr3:38456664	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	9.65	0.65	9.06e-17	Electrocardiographic conduction measures;
TGCT	cis	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg25427524	chr10:38739819	LOC399744	-0.4	-8.32	-0.6	1.33e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs9357506	1.000	rs6910610	chr6:46307337	C/A	cg21115430	chr6:46460003	NA	-0.26	-5.17	-0.42	9.2e-7	Body mass index;
TGCT	cis	rs7819412	0.618	rs10105377	chr8:10975733	A/G	cg21775007	chr8:11205619	TDH	-0.52	-4.97	-0.41	2.13e-6	Triglycerides;
TGCT	cis	rs9790314	1.000	rs336570	chr3:161072054	A/G	cg03342759	chr3:160939853	NMD3	0.43	4.45	0.37	1.89e-5	Morning vs. evening chronotype;
TGCT	cis	rs1215050	0.547	rs9999993	chr4:98562671	T/A	cg05340658	chr4:99064831	C4orf37	-0.38	-4.53	-0.38	1.36e-5	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs8072100	0.790	rs3760371	chr17:45695914	T/C	cg10024583	chr17:45772800	TBKBP1	-0.43	-4.47	-0.37	1.76e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg00149659	chr3:10157352	C3orf10	1.0	6.43	0.5	2.45e-9	Alzheimer's disease;
TGCT	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg06634786	chr22:41940651	POLR3H	-0.85	-7.8	-0.57	2.16e-12	Vitiligo;
TGCT	cis	rs7666738	0.830	rs13149779	chr4:99010145	G/T	cg17366294	chr4:99064904	C4orf37	0.72	7.37	0.55	2.13e-11	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs62103177	0.584	rs9956207	chr18:77968392	A/G	cg05926928	chr17:57297772	GDPD1	-0.76	-6.88	-0.53	2.61e-10	Opioid sensitivity;
TGCT	cis	rs556990	0.570	rs5960	chr13:113801737	C/T	cg18105134	chr13:113819100	PROZ	0.45	7.35	0.55	2.35e-11	Blood protein levels;
TGCT	cis	rs2594989	0.943	rs6442251	chr3:11417477	A/G	cg00170343	chr3:11313890	ATG7	0.64	4.89	0.4	3.04e-6	Circulating chemerin levels;
TGCT	cis	rs308403	0.600	rs376131	chr4:123629225	G/A	cg10495464	chr4:123653540	BBS12;LOC729338	0.59	5.8	0.46	5.1e-8	Blood protein levels;
TGCT	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg13695892	chr22:41940480	POLR3H	-0.91	-9.07	-0.63	2.18e-15	Vitiligo;
TGCT	cis	rs2276314	1.000	rs62101367	chr18:33550884	C/T	cg05985134	chr18:33552581	C18orf21	0.55	4.84	0.4	3.76e-6	Endometriosis;Drug-induced torsades de pointes;
TGCT	cis	rs9921338	0.924	rs7193645	chr16:11381036	A/G	cg00044050	chr16:11439710	C16orf75	-0.87	-6.25	-0.49	5.97e-9	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs6882046	0.513	rs679232	chr5:88054763	A/C	cg22951263	chr5:87985283	NA	0.59	6.4	0.5	2.87e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs6570726	0.935	rs585292	chr6:145862228	T/C	cg23711669	chr6:146136114	FBXO30	0.71	7.03	0.53	1.25e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7666738	0.830	rs10017201	chr4:98983561	G/A	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg03806693	chr22:41940476	POLR3H	-1.13	-13.24	-0.77	1.73e-25	Vitiligo;
TGCT	cis	rs11673344	0.523	rs6510584	chr19:37549601	G/C	cg08039142	chr19:36980659	ZNF566	0.5	4.64	0.38	8.58e-6	Obesity-related traits;
TGCT	cis	rs992157	0.710	rs12612347	chr2:219057338	C/T	cg00012203	chr2:219082015	ARPC2	-0.82	-10.43	-0.68	1.14e-18	Colorectal cancer;
TGCT	cis	rs7715806	0.500	rs17649248	chr5:74998426	C/T	cg19683494	chr5:74908142	NA	0.53	4.85	0.4	3.67e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs986417	1.000	rs7159212	chr14:61068725	T/C	cg27398547	chr14:60952738	C14orf39	1.41	8.43	0.6	7.41e-14	Gut microbiota (bacterial taxa);
TGCT	cis	rs7917772	0.604	rs7908249	chr10:104373300	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	5.36	0.43	3.84e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs13217239	0.585	rs114919438	chr6:26963792	T/C	cg15659132	chr6:26577336	NA	-0.61	-6.24	-0.49	6.24e-9	Schizophrenia;
TGCT	cis	rs1577917	0.655	rs9359658	chr6:86305769	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.53	4.91	0.4	2.84e-6	Response to antipsychotic treatment;
TGCT	cis	rs9916302	0.706	rs2879259	chr17:37410892	C/G	cg07936489	chr17:37558343	FBXL20	-0.84	-6.16	-0.48	9.13e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs10504229	0.679	rs2317991	chr8:58035080	C/T	cg08280861	chr8:58055591	NA	-0.34	-4.94	-0.41	2.5e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7104764	1.000	rs1533825	chr11:214163	G/A	cg18336825	chr11:236787	PSMD13;SIRT3	-1.02	-10.54	-0.69	6.26e-19	Menarche (age at onset);
TGCT	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	8.13	0.59	3.82e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs10493773	0.609	rs2389972	chr1:86190666	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.5	-7.73	-0.57	3.23e-12	Urate levels in overweight individuals;
TGCT	cis	rs9467773	1.000	rs10946835	chr6:26533757	C/T	cg09904177	chr6:26538194	HMGN4	0.65	6.53	0.51	1.53e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs67311347	1.000	rs56291770	chr3:40515370	T/C	cg13683864	chr3:40499215	RPL14	-1.2	-13.3	-0.77	1.27e-25	Renal cell carcinoma;
TGCT	cis	rs6964587	1.000	rs6465347	chr7:91693837	A/G	cg17063962	chr7:91808500	NA	0.88	9.65	0.66	8.73e-17	Breast cancer;
TGCT	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg16680214	chr1:154839983	KCNN3	-0.43	-9.34	-0.64	4.93e-16	Prostate cancer;
TGCT	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg06634786	chr22:41940651	POLR3H	0.73	6.81	0.52	3.84e-10	Vitiligo;
TGCT	cis	rs4891159	0.790	rs1056714	chr18:74149526	A/G	cg24786174	chr18:74118243	ZNF516	-0.54	-7.2	-0.54	5.09e-11	Longevity;
TGCT	cis	rs12621445	1	rs12621445	chr2:24154964	C/T	cg08917208	chr2:24149416	ATAD2B	0.85	5.28	0.43	5.53e-7	Immature fraction of reticulocytes;
TGCT	cis	rs5769765	0.862	rs138856	chr22:50199378	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.07	-10.91	-0.7	7.73e-20	Schizophrenia;
TGCT	trans	rs1814175	0.645	rs1851869	chr11:49960552	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.67	-0.69	2.92e-19	Height;
TGCT	cis	rs2235642	0.821	rs2281234	chr16:1602938	A/G	cg10465839	chr16:1584050	IFT140;TMEM204	-0.31	-5.23	-0.43	7.02e-7	Coronary artery disease;
TGCT	cis	rs6921919	0.583	rs1124131	chr6:28380248	A/C	cg18815343	chr6:28367644	ZSCAN12	-0.54	-5.25	-0.43	6.29e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1903068	0.925	rs1551645	chr4:55994314	T/G	cg01777861	chr4:56023843	NA	0.56	6.43	0.5	2.54e-9	Endometriosis;
TGCT	cis	rs926938	0.584	rs1286561	chr1:115375428	T/C	cg12756093	chr1:115239321	AMPD1	-0.41	-6.02	-0.48	1.84e-8	Autism;
TGCT	cis	rs6866344	0.697	rs11739893	chr5:178127837	G/A	cg10224037	chr5:178157518	ZNF354A	0.93	7.9	0.58	1.26e-12	Neutrophil percentage of white cells;
TGCT	cis	rs938554	0.513	rs1014290	chr4:10001861	G/A	cg02734326	chr4:10020555	SLC2A9	0.46	4.69	0.39	6.98e-6	Blood metabolite levels;
TGCT	trans	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg21659725	chr3:3221576	CRBN	-0.76	-9.03	-0.63	2.74e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs909002	0.925	rs7524405	chr1:32108579	A/C	cg13919466	chr1:32135498	COL16A1	0.33	4.7	0.39	6.76e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9790314	0.601	rs1450519	chr3:161094930	A/G	cg03342759	chr3:160939853	NMD3	-0.39	-4.51	-0.38	1.48e-5	Morning vs. evening chronotype;
TGCT	cis	rs11203032	0.831	rs12219735	chr10:90922890	C/T	cg16672925	chr10:90967113	CH25H	0.73	4.5	0.37	1.55e-5	Heart failure;
TGCT	cis	rs8017423	0.904	rs12433417	chr14:90804028	A/G	cg04374321	chr14:90722782	PSMC1	-0.74	-7.13	-0.54	7.15e-11	Mortality in heart failure;
TGCT	cis	rs6424115	0.790	rs72874118	chr1:24177800	A/G	cg15997130	chr1:24165203	NA	-0.89	-10.18	-0.67	4.6e-18	Immature fraction of reticulocytes;
TGCT	cis	rs853679	0.546	rs200952	chr6:27836976	C/T	cg10876282	chr6:28092338	ZSCAN16	0.75	4.45	0.37	1.88e-5	Depression;
TGCT	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg24549020	chr5:56110836	MAP3K1	0.7	5.97	0.47	2.34e-8	Initial pursuit acceleration;
TGCT	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg22166914	chr1:53195759	ZYG11B	0.39	6.39	0.5	3.1e-9	Monocyte count;
TGCT	trans	rs9329221	0.592	rs7832708	chr8:10190040	C/T	cg15556689	chr8:8085844	FLJ10661	0.72	6.75	0.52	5.17e-10	Neuroticism;
TGCT	cis	rs10779751	0.762	rs6671083	chr1:11325910	A/G	cg08854313	chr1:11322531	MTOR	-0.84	-9.56	-0.65	1.46e-16	Body mass index;
TGCT	cis	rs2204008	0.653	rs11182569	chr12:38572452	G/A	cg13010199	chr12:38710504	ALG10B	0.65	5.18	0.42	8.83e-7	Bladder cancer;
TGCT	cis	rs1005224	0.927	rs8007792	chr14:76175666	C/A	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.61	-4.91	-0.4	2.79e-6	Large artery stroke;
TGCT	cis	rs7822232	0.908	rs1127096	chr8:145140472	A/G	cg26272248	chr8:145163034	KIAA1875	-0.49	-4.81	-0.4	4.24e-6	Blood metabolite levels;
TGCT	cis	rs854765	0.506	rs7210400	chr17:17949957	C/T	cg04398451	chr17:18023971	MYO15A	0.33	5.37	0.43	3.76e-7	Total body bone mineral density;
TGCT	cis	rs9640161	0.742	rs2159236	chr7:150017214	A/G	cg10018233	chr7:150070692	REPIN1	0.33	4.78	0.39	4.89e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.46	4.86	0.4	3.51e-6	Lymphocyte counts;
TGCT	cis	rs5417	0.761	rs6503010	chr17:7180435	C/T	cg25256661	chr17:7137939	DVL2	-0.7	-6.99	-0.53	1.52e-10	Diastolic blood pressure;
TGCT	cis	rs7246657	0.722	rs954504	chr19:38045394	A/G	cg03611452	chr19:38183253	ZNF781	0.58	4.64	0.38	8.62e-6	Coronary artery calcification;
TGCT	cis	rs651907	0.513	rs34963630	chr3:101504817	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.86	10.4	0.68	1.35e-18	Colorectal cancer;
TGCT	cis	rs4699052	0.927	rs1870888	chr4:104169326	G/C	cg16532752	chr4:104119610	CENPE	-0.6	-5.61	-0.45	1.28e-7	Testicular germ cell tumor;
TGCT	cis	rs9486715	0.867	rs9384628	chr6:96960232	T/C	cg06623918	chr6:96969491	KIAA0776	1.1	15.44	0.81	1.17e-30	Headache;
TGCT	cis	rs9436747	0.803	rs1751485	chr1:66020219	C/A	cg14976592	chr1:65886160	LEPROT;LEPR	-0.5	-4.71	-0.39	6.48e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs1552244	0.765	rs17050675	chr3:10027686	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.44	-6.38	-0.5	3.16e-9	Alzheimer's disease;
TGCT	cis	rs2305707	0.867	rs34258629	chr15:51555500	T/C	cg19946085	chr15:51559439	CYP19A1	0.48	5.05	0.41	1.53e-6	Height;
TGCT	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg18876405	chr7:65276391	NA	0.35	5.2	0.42	7.81e-7	Aortic root size;
TGCT	cis	rs12983728	0.831	rs35081008	chr19:58662235	C/T	cg07378217	chr19:58662286	ZNF329	-0.9	-5.1	-0.42	1.25e-6	Cholesterol, total;
TGCT	cis	rs61935443	0.832	rs11107771	chr12:95276844	A/G	cg21533806	chr12:95267307	NA	0.52	4.54	0.38	1.31e-5	Schizophrenia;
TGCT	cis	rs17376456	0.877	rs10514380	chr5:93409370	C/T	cg21475434	chr5:93447410	FAM172A	0.59	4.66	0.39	8.09e-6	Diabetic retinopathy;
TGCT	trans	rs4650994	0.525	rs11806608	chr1:178511375	T/C	cg05059571	chr16:84539110	KIAA1609	-0.55	-11.51	-0.72	2.72e-21	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.7	6.24	0.49	6.33e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs10193935	0.901	rs2118889	chr2:42451683	G/T	cg27598129	chr2:42591480	NA	-0.36	-4.78	-0.39	4.78e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs56399783	0.614	rs73047368	chr7:2766396	G/T	cg19731401	chr7:2775893	GNA12	0.38	5.36	0.43	3.93e-7	Childhood ear infection;
TGCT	cis	rs2046867	0.862	rs62251653	chr3:72811827	C/T	cg25664220	chr3:72788482	NA	-0.57	-7.06	-0.54	1.06e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs11719291	0.833	rs34037363	chr3:48821036	C/T	cg07636037	chr3:49044803	WDR6	-1.0	-4.98	-0.41	2.11e-6	Cognitive function;
TGCT	cis	rs644799	1.000	rs1784135	chr11:95531748	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	10.57	0.69	5.17e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs3111414	1.000	rs3111414	chr2:8443859	C/G	cg10367409	chr2:8711177	NA	-0.2	-4.58	-0.38	1.11e-5	Itch intensity from mosquito bite;
TGCT	cis	rs8033133	0.602	rs4906699	chr15:25321029	A/G	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	0.24	4.65	0.39	8.33e-6	Blood osmolality (transformed sodium);
TGCT	cis	rs9303401	0.614	rs62084384	chr17:57126842	G/A	cg25039879	chr17:56429692	SUPT4H1	0.54	4.84	0.4	3.85e-6	Cognitive test performance;
TGCT	cis	rs854765	0.583	rs8080823	chr17:17864048	T/C	cg09796270	chr17:17721594	SREBF1	0.26	5.31	0.43	4.88e-7	Total body bone mineral density;
TGCT	cis	rs7647973	0.559	rs9586	chr3:49213637	C/T	cg05785598	chr3:49045655	WDR6	0.44	5.12	0.42	1.15e-6	Menarche (age at onset);
TGCT	cis	rs651907	0.557	rs56291106	chr3:101377474	C/T	cg12386194	chr3:101231763	SENP7	0.53	5.13	0.42	1.08e-6	Colorectal cancer;
TGCT	cis	rs7772486	0.790	rs9390365	chr6:146235626	A/G	cg23711669	chr6:146136114	FBXO30	-0.89	-10.38	-0.68	1.54e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4746818	1.000	rs9299502	chr10:70876934	C/T	cg04149295	chr10:70884716	VPS26A	0.76	5.33	0.43	4.49e-7	Left atrial antero-posterior diameter;
TGCT	cis	rs72781680	1.000	rs72796326	chr2:24137047	G/A	cg08917208	chr2:24149416	ATAD2B	0.73	4.51	0.38	1.48e-5	Lymphocyte counts;
TGCT	cis	rs763014	0.931	rs1981483	chr16:630665	G/A	cg09263875	chr16:632152	PIGQ	0.3	6.4	0.5	2.88e-9	Height;
TGCT	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg10047753	chr17:41438598	NA	-0.93	-9.16	-0.64	1.35e-15	Menopause (age at onset);
TGCT	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.49	-6.63	-0.51	9.16e-10	Alzheimer's disease;
TGCT	cis	rs696279	0.869	rs697509	chr7:16700495	G/A	cg16702815	chr7:16920271	AGR3	0.27	4.51	0.38	1.47e-5	Mean platelet volume;
TGCT	cis	rs875971	0.964	rs160635	chr7:65528918	T/C	cg18876405	chr7:65276391	NA	0.32	4.86	0.4	3.49e-6	Aortic root size;
TGCT	cis	rs4478037	0.822	rs77355992	chr3:33107518	T/C	cg19404215	chr3:33155277	CRTAP	1.24	5.97	0.47	2.36e-8	Major depressive disorder;
TGCT	cis	rs916888	0.821	rs199513	chr17:44856932	A/G	cg15921436	chr17:44337874	NA	-0.42	-5.88	-0.47	3.48e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg21963583	chr11:68658836	MRPL21	0.35	5.8	0.46	5.09e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs12477438	0.748	rs10200974	chr2:99675227	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-4.62	-0.38	9.47e-6	Chronic sinus infection;
TGCT	cis	rs9473924	0.542	rs9463665	chr6:50928520	G/T	cg14470998	chr6:50812995	TFAP2B	1.26	7.3	0.55	3.1e-11	Body mass index;
TGCT	cis	rs377070	0.934	rs309397	chr4:123614323	A/C	cg10495464	chr4:123653540	BBS12;LOC729338	0.46	5.1	0.42	1.25e-6	Mosquito bite size;
TGCT	cis	rs9926296	0.715	rs2115401	chr16:89740609	A/G	cg01097406	chr16:89675127	NA	-0.31	-5.49	-0.44	2.2e-7	Vitiligo;
TGCT	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg24549020	chr5:56110836	MAP3K1	-0.67	-5.78	-0.46	5.74e-8	Initial pursuit acceleration;
TGCT	cis	rs2847297	1.000	rs6505765	chr18:12782849	C/G	cg23598886	chr18:12777645	NA	-0.41	-4.81	-0.4	4.28e-6	Rheumatoid arthritis;
TGCT	cis	rs3858526	1.000	rs3858526	chr11:5959757	A/C	cg05234568	chr11:5960015	NA	-0.44	-4.49	-0.37	1.61e-5	DNA methylation (variation);
TGCT	cis	rs2439831	0.850	rs7183809	chr15:44120868	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.9	6.3	0.49	4.62e-9	Lung cancer in ever smokers;
TGCT	cis	rs4919694	0.611	rs76695159	chr10:105070837	C/T	cg04362960	chr10:104952993	NT5C2	0.91	6.05	0.48	1.59e-8	Arsenic metabolism;
TGCT	cis	rs2115630	0.936	rs6496318	chr15:85215229	C/T	cg12863693	chr15:85201151	NMB	-0.34	-4.73	-0.39	5.96e-6	P wave terminal force;
TGCT	cis	rs3824867	0.920	rs9919526	chr11:47451623	C/T	cg20307385	chr11:47447363	PSMC3	-0.69	-5.86	-0.47	3.99e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs8038465	0.662	rs7497012	chr15:73968719	G/A	cg15420318	chr15:73925796	NPTN	0.7	7.49	0.56	1.15e-11	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs910187	0.605	rs6063080	chr20:45805091	G/A	cg27589058	chr20:45804311	EYA2	-0.4	-8.9	-0.62	5.75e-15	Migraine;
TGCT	trans	rs4650994	0.935	rs12039531	chr1:178515612	G/A	cg05059571	chr16:84539110	KIAA1609	-0.41	-7.67	-0.57	4.33e-12	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs921968	0.541	rs514356	chr2:219375018	C/T	cg02176678	chr2:219576539	TTLL4	0.48	6.78	0.52	4.32e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs9311474	0.652	rs352158	chr3:52217704	C/T	cg10802521	chr3:52805072	NEK4	-0.6	-6.64	-0.51	8.67e-10	Electroencephalogram traits;
TGCT	cis	rs2204008	0.623	rs1607878	chr12:38376000	A/G	cg26384229	chr12:38710491	ALG10B	0.76	6.89	0.53	2.46e-10	Bladder cancer;
TGCT	cis	rs244731	0.959	rs11740250	chr5:176721272	G/C	cg06060754	chr5:176797920	RGS14	0.46	6.42	0.5	2.66e-9	Urate levels in lean individuals;
TGCT	cis	rs798766	1.000	rs1665364	chr4:1727206	A/G	cg05874882	chr4:1763078	NA	0.36	4.87	0.4	3.27e-6	Bladder cancer;Urinary bladder cancer;
TGCT	cis	rs4975616	0.804	rs381949	chr5:1322468	G/A	cg07493874	chr5:1342172	CLPTM1L	-0.27	-6.69	-0.51	6.91e-10	Lung cancer;
TGCT	cis	rs12541335	0.639	rs68063696	chr8:22153236	A/G	cg09517075	chr8:22133004	PIWIL2	0.24	4.57	0.38	1.17e-5	Hypertriglyceridemia;
TGCT	cis	rs9467773	0.620	rs2504600	chr6:26648334	C/A	cg11502198	chr6:26597334	ABT1	0.55	4.89	0.4	3.05e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7786808	0.778	rs34212455	chr7:158224490	C/T	cg01191920	chr7:158217561	PTPRN2	-0.39	-5.89	-0.47	3.32e-8	Obesity-related traits;
TGCT	cis	rs12620999	0.941	rs4663240	chr2:238036632	G/T	cg23555395	chr2:238036564	NA	-0.31	-5.51	-0.44	2.02e-7	Systemic lupus erythematosus;
TGCT	cis	rs10992471	0.603	rs4744141	chr9:95352140	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.6	-5.71	-0.46	7.82e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs17221829	0.528	rs4561217	chr11:89375265	T/C	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.63	-0.38	9.04e-6	Anxiety in major depressive disorder;
TGCT	cis	rs11671005	0.735	rs56290606	chr19:58919320	A/G	cg13877915	chr19:58951672	ZNF132	0.63	4.99	0.41	1.99e-6	Mean platelet volume;
TGCT	cis	rs5758265	1	rs5758265	chr22:41617897	G/A	cg03806693	chr22:41940476	POLR3H	-0.65	-6.22	-0.49	6.86e-9	Depressive symptoms (multi-trait analysis);
TGCT	trans	rs1814175	0.817	rs4881648	chr11:49812901	A/G	cg03929089	chr4:120376271	NA	-0.72	-8.26	-0.6	1.84e-13	Height;
TGCT	cis	rs2762353	0.574	rs9467574	chr6:25705718	C/G	cg12310025	chr6:25882481	NA	0.9	8.89	0.62	5.87e-15	Blood metabolite levels;
TGCT	trans	rs2727020	0.688	rs2734002	chr11:49234162	A/G	cg03929089	chr4:120376271	NA	0.71	7.84	0.58	1.79e-12	Coronary artery disease;
TGCT	cis	rs1997103	0.871	rs6956733	chr7:55393032	A/C	cg17469321	chr7:55412551	NA	0.58	5.18	0.42	8.69e-7	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg10862848	chr6:42927986	GNMT	-0.39	-4.7	-0.39	6.86e-6	Plasma homocysteine levels (post-methionine load test);
TGCT	cis	rs7727544	0.788	rs270613	chr5:131640583	A/G	cg24060327	chr5:131705240	SLC22A5	-0.57	-6.15	-0.48	9.79e-9	Blood metabolite levels;
TGCT	cis	rs7147624	1.000	rs7150233	chr14:66200816	A/G	cg03016385	chr14:66212404	NA	-0.5	-7.04	-0.53	1.13e-10	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs8111998	0.826	rs10421335	chr19:22768105	G/A	cg19914732	chr19:22715077	NA	-0.56	-4.51	-0.38	1.46e-5	Corneal structure;
TGCT	trans	rs1499614	1.000	rs2659913	chr7:66157336	T/A	cg07424592	chr7:64974309	NA	1.35	8.11	0.59	4.14e-13	Gout;
TGCT	cis	rs11690462	0.963	rs11674089	chr2:26587076	G/A	cg04726446	chr2:26624865	C2orf39	0.43	4.64	0.38	8.58e-6	Coronary artery disease;
TGCT	cis	rs10791097	0.694	rs61910787	chr11:130744473	G/A	cg14779329	chr11:130786720	SNX19	0.28	4.82	0.4	4.09e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs10791323	0.569	rs10750542	chr11:133713436	T/C	cg15485101	chr11:133734466	NA	0.39	5.18	0.42	8.85e-7	Childhood ear infection;
TGCT	cis	rs1775715	0.707	rs2808081	chr10:32162342	C/T	cg14930904	chr10:32216787	ARHGAP12	-0.5	-4.73	-0.39	6.06e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs1801251	0.896	rs6719061	chr2:233695885	C/T	cg25237894	chr2:233734115	C2orf82	-0.29	-5.41	-0.44	3.14e-7	Coronary artery disease;
TGCT	cis	rs3087591	0.960	rs2905787	chr17:29482381	G/A	cg24425628	chr17:29625626	OMG;NF1	0.43	6.39	0.5	3.07e-9	Hip circumference;
TGCT	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	14.32	0.79	4.83e-28	Prudent dietary pattern;
TGCT	cis	rs6589563	0.609	rs56225305	chr11:116625362	G/A	cg20660624	chr11:117307972	DSCAML1	-0.38	-4.99	-0.41	2.02e-6	Eosinophil counts;
TGCT	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.53	-5.12	-0.42	1.13e-6	Menarche (age at onset);
TGCT	cis	rs9902453	0.933	rs9908901	chr17:28469713	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	5.41	0.44	3.13e-7	Coffee consumption (cups per day);
TGCT	cis	rs1555895	0.543	rs1555898	chr10:853783	T/C	cg02193355	chr10:851439	NA	0.2	4.54	0.38	1.3e-5	Survival in rectal cancer;
TGCT	trans	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-1.03	-13.16	-0.76	2.65e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs4285028	0.747	rs6791882	chr3:121373058	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.92	-7.33	-0.55	2.54e-11	Multiple sclerosis;
TGCT	cis	rs3796619	1.000	rs3796619	chr4:1095281	A/G	cg27284194	chr4:1044797	NA	0.47	4.57	0.38	1.17e-5	Recombination rate (males);
TGCT	cis	rs6089584	0.526	rs6089316	chr20:60627552	C/T	cg06108461	chr20:60628389	TAF4	-0.42	-5.1	-0.42	1.24e-6	Body mass index;
TGCT	cis	rs6087990	0.735	rs2064350	chr20:31390533	T/C	cg13636640	chr20:31349939	DNMT3B	0.95	12.3	0.74	3.25e-23	Ulcerative colitis;
TGCT	cis	rs1008375	0.966	rs4698619	chr4:17580955	G/A	cg18681998	chr4:17616180	MED28	0.94	9.56	0.65	1.44e-16	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9513593	1.000	rs9585019	chr13:99850487	T/C	cg21788972	chr13:99853209	UBAC2	0.61	4.96	0.41	2.24e-6	Psoriasis;
TGCT	cis	rs17767294	0.614	rs72849222	chr6:28202354	G/T	cg08851530	chr6:28072375	NA	1.46	6.76	0.52	4.79e-10	Parkinson's disease;
TGCT	cis	rs12477438	0.765	rs10193039	chr2:99692373	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.59	-5.03	-0.41	1.71e-6	Chronic sinus infection;
TGCT	cis	rs12971120	0.947	rs4891559	chr18:72170397	C/T	cg25817165	chr18:72167213	CNDP2	-0.29	-5.51	-0.44	1.98e-7	Refractive error;
TGCT	cis	rs6740322	0.895	rs11684601	chr2:43574242	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.38	-5.93	-0.47	2.87e-8	Coronary artery disease;
TGCT	cis	rs4824093	0.610	rs77128035	chr22:50241024	C/T	cg14114931	chr22:50943910	LMF2	0.37	4.61	0.38	9.67e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs12477438	0.798	rs2045057	chr2:99684929	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-6.1	-0.48	1.22e-8	Chronic sinus infection;
TGCT	cis	rs7605378	0.528	rs281791	chr2:200850402	A/G	cg19045956	chr2:200819837	C2orf60;C2orf47	-0.54	-5.88	-0.47	3.6e-8	Osteoporosis;
TGCT	cis	rs2404602	0.716	rs12902174	chr15:76863540	T/C	cg22467129	chr15:76604101	ETFA	-0.44	-5.05	-0.41	1.51e-6	Blood metabolite levels;
TGCT	cis	rs1420338	0.967	rs9655014	chr7:34148632	T/C	cg01275685	chr7:34179230	BMPER	-0.27	-4.84	-0.4	3.82e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs9303401	0.592	rs66583824	chr17:56639853	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs7937612	1.000	rs12417256	chr11:120337519	A/C	cg24566217	chr11:120254723	ARHGEF12	-0.29	-4.59	-0.38	1.07e-5	Intraocular pressure;
TGCT	cis	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg25427524	chr10:38739819	LOC399744	-0.4	-8.2	-0.59	2.5e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs4845570	0.834	rs7007	chr1:151735576	T/C	cg07092448	chr1:151763213	TDRKH	-1.05	-7.65	-0.57	4.72e-12	Coronary artery disease;
TGCT	cis	rs208520	0.779	rs208446	chr6:66903515	T/C	cg07460842	chr6:66804631	NA	-0.9	-9.14	-0.63	1.54e-15	Exhaled nitric oxide output;
TGCT	cis	rs9902453	0.904	rs11080115	chr17:28408070	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.84	-7.98	-0.58	8.19e-13	Coffee consumption (cups per day);
TGCT	cis	rs6540559	0.673	rs6694552	chr1:209976459	A/C	cg04352962	chr1:209979756	IRF6	0.65	4.6	0.38	1.05e-5	Cleft lip with or without cleft palate;
TGCT	cis	rs6582630	0.555	rs6582503	chr12:38557886	A/C	cg26384229	chr12:38710491	ALG10B	0.89	8.14	0.59	3.55e-13	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs12765878	0.580	rs4918058	chr10:105596641	G/C	cg11005552	chr10:105648138	OBFC1	-0.39	-6.05	-0.48	1.58e-8	Coronary artery disease;
TGCT	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg04317338	chr11:64019027	PLCB3	0.79	6.5	0.5	1.77e-9	Mean platelet volume;
TGCT	cis	rs6121246	0.529	rs58757492	chr20:30181425	G/A	cg21427119	chr20:30132790	HM13	-0.43	-6.28	-0.49	5.3e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs1857353	1.000	rs111226767	chr1:75853959	C/A	cg11838876	chr1:75668600	SLC44A5	-0.47	-4.54	-0.38	1.32e-5	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs11785693	0.862	rs11786657	chr8:5001792	T/C	cg26367366	chr8:4980734	NA	0.56	4.44	0.37	1.95e-5	Neuroticism (multi-trait analysis);Neuroticism;
TGCT	cis	rs7666738	0.830	rs13138051	chr4:99050367	C/T	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs896854	0.654	rs896846	chr8:95972453	G/A	cg13393036	chr8:95962371	TP53INP1	-0.63	-8.52	-0.61	4.51e-14	Type 2 diabetes;
TGCT	cis	rs908922	0.847	rs499697	chr1:152493154	A/G	cg20991723	chr1:152506922	NA	-0.42	-5.38	-0.43	3.62e-7	Hair morphology;
TGCT	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.6	-5.05	-0.41	1.54e-6	Lung function (FEV1/FVC);
TGCT	cis	rs72781680	0.948	rs72796319	chr2:24133027	T/C	cg08917208	chr2:24149416	ATAD2B	0.73	4.51	0.38	1.48e-5	Lymphocyte counts;
TGCT	cis	rs6912958	0.712	rs7755167	chr6:88338752	T/C	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.98	-0.41	2.06e-6	Monocyte percentage of white cells;
TGCT	cis	rs78487399	0.614	rs7600657	chr2:43710444	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.41	-5.26	-0.43	6.23e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg12751644	chr20:60527061	NA	0.5	6.64	0.51	9.01e-10	Obesity-related traits;
TGCT	cis	rs8013055	0.706	rs8003957	chr14:105971702	A/G	cg23356831	chr14:105996513	TMEM121	0.41	6.22	0.49	6.83e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs7617773	0.539	rs11130165	chr3:48384721	G/T	cg11946769	chr3:48343235	NME6	0.57	4.83	0.4	4.01e-6	Coronary artery disease;
TGCT	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6725041	0.547	rs6753945	chr2:213204574	T/C	cg16329650	chr2:213403929	ERBB4	-0.67	-5.85	-0.47	4.03e-8	QT interval (ambient particulate matter interaction);
TGCT	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg11764359	chr7:65958608	NA	0.61	5.53	0.44	1.84e-7	Aortic root size;
TGCT	cis	rs10992471	0.603	rs10761155	chr9:95153729	C/G	cg14631576	chr9:95140430	CENPP	-0.33	-4.96	-0.41	2.23e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs3862260	0.905	rs3850870	chr1:120161037	C/T	cg16322792	chr1:120165303	ZNF697	0.27	5.71	0.46	7.73e-8	Systemic lupus erythematosus;
TGCT	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg02725872	chr8:58115012	NA	-0.41	-4.95	-0.41	2.37e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs568617	1.000	rs568617	chr11:65653242	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.57	5.22	0.42	7.39e-7	Crohn's disease;
TGCT	cis	rs8103278	0.507	rs10422883	chr19:46247641	A/G	cg11657440	chr19:46296263	DMWD	0.75	7.74	0.57	3.02e-12	Coronary artery disease;
TGCT	cis	rs9914544	0.524	rs8071147	chr17:18790678	A/G	cg26378065	chr17:18585709	ZNF286B	0.53	4.63	0.38	9.01e-6	Educational attainment (years of education);
TGCT	cis	rs7681440	0.626	rs2289515	chr4:90816790	T/A	cg20003494	chr4:90757398	SNCA	-0.54	-4.88	-0.4	3.21e-6	Dementia with Lewy bodies;
TGCT	cis	rs2486012	0.737	rs246773	chr1:44300249	A/G	cg12908607	chr1:44402522	ARTN	-0.72	-5.68	-0.45	8.89e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2549003	0.811	rs10072700	chr5:131816903	A/C	cg02551604	chr5:131831745	NA	-0.76	-7.42	-0.55	1.65e-11	Asthma (sex interaction);
TGCT	trans	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg27523141	chr10:43048294	ZNF37B	0.73	8.58	0.61	3.32e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs11098499	0.863	rs17050695	chr4:120489527	G/T	cg09307838	chr4:120376055	NA	0.7	7.03	0.53	1.23e-10	Corneal astigmatism;
TGCT	cis	rs2795502	0.554	rs1620395	chr10:43341185	G/A	cg20628663	chr10:43360327	NA	-0.35	-6.05	-0.48	1.57e-8	Blood protein levels;
TGCT	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.34	0.43	4.23e-7	Prudent dietary pattern;
TGCT	cis	rs7267979	0.966	rs2482948	chr20:25296499	T/C	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1729951	0.575	rs835641	chr3:136703474	G/T	cg21827317	chr3:136751795	NA	0.4	5.61	0.45	1.24e-7	Neuroticism;
TGCT	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg10802521	chr3:52805072	NEK4	-0.74	-9.02	-0.63	2.87e-15	Bipolar disorder;
TGCT	cis	rs7954584	0.531	rs6486781	chr12:122318985	A/C	cg22618164	chr12:122356400	WDR66	0.53	5.26	0.43	6.24e-7	Mean corpuscular volume;
TGCT	cis	rs1215050	0.776	rs1627946	chr4:98844416	G/A	cg05340658	chr4:99064831	C4orf37	-0.47	-5.9	-0.47	3.22e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9858542	0.953	rs6766131	chr3:49538932	T/C	cg03060546	chr3:49711283	APEH	-0.61	-5.37	-0.43	3.78e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs854765	0.547	rs7223696	chr17:17915791	G/T	cg09796270	chr17:17721594	SREBF1	0.25	5.03	0.41	1.71e-6	Total body bone mineral density;
TGCT	cis	rs3125734	0.534	rs10821973	chr10:64052337	G/A	cg19640130	chr10:64028056	RTKN2	-0.38	-4.79	-0.39	4.73e-6	Rheumatoid arthritis;
TGCT	cis	rs2072499	0.778	rs41265025	chr1:156163906	C/T	cg24450063	chr1:156163899	SLC25A44	1.1	10.15	0.67	5.42e-18	Testicular germ cell tumor;
TGCT	cis	rs6840360	0.642	rs1443088	chr4:152450126	G/A	cg17479576	chr4:152424074	FAM160A1	-0.57	-6.02	-0.48	1.85e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7829975	0.514	rs2979151	chr8:8258019	A/G	cg15462221	chr8:8086144	FLJ10661	0.49	4.49	0.37	1.63e-5	Mood instability;
TGCT	cis	rs7552404	0.924	rs1146588	chr1:76229787	C/G	cg03433033	chr1:76189801	ACADM	0.75	8.76	0.62	1.19e-14	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg03188948	chr7:1209495	NA	0.67	5.62	0.45	1.18e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2242116	0.796	rs4683296	chr3:46973820	G/C	cg02527881	chr3:46936655	PTH1R	0.32	6.0	0.47	1.99e-8	Birth weight;
TGCT	cis	rs7246657	0.722	rs12979640	chr19:38179156	T/C	cg03611452	chr19:38183253	ZNF781	-0.62	-5.08	-0.41	1.37e-6	Coronary artery calcification;
TGCT	trans	rs797680	0.856	rs11164902	chr1:93778794	A/G	cg27528825	chr2:159282178	CCDC148	-0.33	-6.67	-0.51	7.68e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs7551222	0.683	rs898386	chr1:204579697	A/G	cg09150239	chr1:204347429	NA	0.49	4.93	0.41	2.55e-6	Schizophrenia;
TGCT	cis	rs9916302	0.904	rs620686	chr17:37453617	A/G	cg15445000	chr17:37608096	MED1	-0.31	-4.59	-0.38	1.06e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs9311474	1.000	rs7614727	chr3:52295895	C/T	cg10802521	chr3:52805072	NEK4	-0.57	-6.19	-0.49	8.19e-9	Electroencephalogram traits;
TGCT	cis	rs6163	0.727	rs284862	chr10:104572081	C/T	cg05855489	chr10:104503620	C10orf26	-0.66	-6.23	-0.49	6.63e-9	Waist circumference;Hip circumference;
TGCT	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg13732083	chr21:47605072	C21orf56	0.37	4.69	0.39	7.07e-6	Testicular germ cell tumor;
TGCT	cis	rs6964587	0.626	rs68009402	chr7:91516226	G/A	cg17063962	chr7:91808500	NA	-0.76	-7.15	-0.54	6.42e-11	Breast cancer;
TGCT	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg24549020	chr5:56110836	MAP3K1	0.7	5.97	0.47	2.34e-8	Initial pursuit acceleration;
TGCT	cis	rs1997103	1.000	rs6950311	chr7:55400990	G/A	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs7193541	0.646	rs7188880	chr16:74664810	A/T	cg01733217	chr16:74700730	RFWD3	0.96	13.17	0.76	2.62e-25	Multiple myeloma;
TGCT	cis	rs2688608	0.934	rs2675679	chr10:75658581	C/T	cg02947784	chr10:75434997	AGAP5	0.16	4.47	0.37	1.74e-5	Inflammatory bowel disease;
TGCT	cis	rs9911578	0.835	rs9788975	chr17:56460800	G/A	cg12560992	chr17:57184187	TRIM37	-0.73	-8.17	-0.59	3.05e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs950169	0.881	rs150965	chr15:85080527	T/G	cg12863693	chr15:85201151	NMB	0.41	4.49	0.37	1.63e-5	Schizophrenia;
TGCT	cis	rs72945132	0.882	rs60917762	chr11:70211384	C/T	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs12580194	0.593	rs7976828	chr12:55726450	A/T	cg10672482	chr12:55725839	OR6C3	-0.56	-4.89	-0.4	3.1e-6	Cancer;
TGCT	cis	rs6088590	0.523	rs6088536	chr20:33189106	T/C	cg08999081	chr20:33150536	PIGU	0.25	4.99	0.41	1.97e-6	Coronary artery disease;
TGCT	cis	rs10736390	0.640	rs10888858	chr1:55108978	A/G	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.52	-10.89	-0.7	8.84e-20	Survival in pancreatic cancer;
TGCT	cis	rs61990749	0.544	rs2544567	chr14:78181739	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	0.63	4.62	0.38	9.34e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs314370	0.818	rs12705091	chr7:100472380	C/T	cg10426581	chr7:100472382	SRRT	0.97	9.07	0.63	2.26e-15	Resting heart rate;
TGCT	cis	rs7949030	0.626	rs11231154	chr11:62362293	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.64	9.48	0.65	2.35e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7089973	0.604	rs55759483	chr10:116573423	T/C	cg03647239	chr10:116582469	FAM160B1	0.6	5.48	0.44	2.33e-7	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs11264213	0.591	rs558120	chr1:36537640	T/C	cg27506609	chr1:36549197	TEKT2	-0.32	-4.6	-0.38	1.02e-5	Schizophrenia;
TGCT	cis	rs10791323	0.569	rs10750553	chr11:133740251	T/C	cg03690763	chr11:133734501	NA	-0.3	-5.16	-0.42	9.36e-7	Childhood ear infection;
TGCT	cis	rs12135062	1.000	rs12135062	chr1:3103312	A/C	cg00254258	chr1:3105189	PRDM16	0.34	5.66	0.45	9.74e-8	Migraine;
TGCT	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.69	-0.39	7e-6	Prudent dietary pattern;
TGCT	cis	rs6665290	0.836	rs12593	chr1:227172290	A/G	cg10327440	chr1:227177885	CDC42BPA	0.96	17.72	0.85	8.7e-36	Myeloid white cell count;
TGCT	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg05872129	chr22:39784769	NA	-1.02	-11.25	-0.71	1.17e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs10744422	0.925	rs3825143	chr12:123352179	C/T	cg25930673	chr12:123319894	HIP1R	-0.88	-5.28	-0.43	5.59e-7	Schizophrenia;
TGCT	cis	rs8180040	0.764	rs11718795	chr3:47218727	G/A	cg27129171	chr3:47204927	SETD2	0.75	9.86	0.66	2.82e-17	Colorectal cancer;
TGCT	cis	rs681343	1.000	rs516246	chr19:49206172	C/T	cg13540341	chr19:49222985	MAMSTR	-0.33	-4.48	-0.37	1.69e-5	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
TGCT	cis	rs763121	0.889	rs9610971	chr22:38910810	C/T	cg06022373	chr22:39101656	GTPBP1	0.75	7.37	0.55	2.1e-11	Menopause (age at onset);
TGCT	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg11965913	chr1:205819406	PM20D1	0.51	7.19	0.54	5.34e-11	Menarche (age at onset);
TGCT	cis	rs6598955	0.724	rs10902737	chr1:26635716	G/A	cg04990556	chr1:26633338	UBXN11	-0.92	-12.18	-0.74	6.18e-23	Obesity-related traits;
TGCT	cis	rs477895	1.000	rs11600990	chr11:64082807	C/T	cg04317338	chr11:64019027	PLCB3	0.71	5.65	0.45	1.05e-7	Mean platelet volume;
TGCT	cis	rs9467773	0.620	rs2494700	chr6:26631306	C/T	cg09904177	chr6:26538194	HMGN4	0.67	6.48	0.5	1.94e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs228437	0.586	rs9494011	chr6:134964580	T/A	cg09872934	chr6:134495829	SGK1	-0.58	-4.74	-0.39	5.66e-6	Melanoma;
TGCT	cis	rs778371	0.676	rs4973563	chr2:233716421	C/T	cg08000102	chr2:233561755	GIGYF2	-0.69	-7.7	-0.57	3.75e-12	Schizophrenia;
TGCT	cis	rs7296418	0.699	rs11057219	chr12:123750073	T/C	cg00376283	chr12:123451042	ABCB9	0.73	6.44	0.5	2.36e-9	Platelet count;
TGCT	cis	rs6690583	0.623	rs74761855	chr1:85432947	A/C	cg20280350	chr1:85513789	MCOLN3	-0.68	-4.49	-0.37	1.6e-5	Serum sulfate level;
TGCT	cis	rs7017914	0.967	rs17760497	chr8:71617045	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.55	-5.13	-0.42	1.11e-6	Bone mineral density;
TGCT	cis	rs929354	0.772	rs10230895	chr7:157007038	T/C	cg05182265	chr7:156933206	UBE3C	-0.39	-8.95	-0.63	4.3e-15	Body mass index;
TGCT	cis	rs7666738	0.752	rs62318905	chr4:99036103	T/G	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg10047753	chr17:41438598	NA	0.96	9.64	0.65	9.37e-17	Menopause (age at onset);
TGCT	cis	rs244731	0.959	rs918459	chr5:176669030	C/T	cg06060754	chr5:176797920	RGS14	-0.44	-6.3	-0.49	4.81e-9	Urate levels in lean individuals;
TGCT	cis	rs11651000	0.625	rs58067360	chr17:45819587	G/C	cg06532163	chr17:45867833	NA	0.32	4.83	0.4	3.87e-6	IgG glycosylation;
TGCT	cis	rs12477438	0.520	rs13035311	chr2:99717322	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	16.87	0.83	6.81e-34	Chronic sinus infection;
TGCT	cis	rs9868809	0.881	rs13324142	chr3:48669447	C/T	cg00383909	chr3:49044727	WDR6	0.99	5.63	0.45	1.13e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg13732083	chr21:47605072	C21orf56	0.35	4.69	0.39	7.17e-6	Testicular germ cell tumor;
TGCT	cis	rs4523957	0.690	rs11867782	chr17:2090507	T/G	cg16513277	chr17:2031491	SMG6	-0.2	-4.52	-0.38	1.42e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	6.18	0.48	8.67e-9	Alzheimer's disease;
TGCT	cis	rs12464483	0.591	rs4952171	chr2:30886903	G/A	cg17749961	chr2:30669863	LCLAT1	0.67	5.05	0.41	1.56e-6	Pre-treatment pain in head and neck squamous cell carcinoma;
TGCT	cis	rs9291683	0.546	rs7442336	chr4:10045783	G/A	cg11266682	chr4:10021025	SLC2A9	0.6	7.52	0.56	9.49e-12	Bone mineral density;
TGCT	cis	rs12701220	0.894	rs12539012	chr7:1052133	G/A	cg07217954	chr7:1067459	C7orf50	-0.49	-4.76	-0.39	5.27e-6	Bronchopulmonary dysplasia;
TGCT	cis	rs9534288	0.797	rs994351	chr13:46588194	A/G	cg15192986	chr13:46630673	CPB2	-0.53	-7.62	-0.56	5.82e-12	Blood protein levels;
TGCT	cis	rs10751667	0.643	rs7394524	chr11:933865	T/C	cg06064525	chr11:970664	AP2A2	-0.35	-8.09	-0.59	4.54e-13	Alzheimer's disease (late onset);
TGCT	cis	rs910316	0.737	rs175510	chr14:75524839	G/A	cg11812906	chr14:75593930	NEK9	-0.61	-5.68	-0.45	9e-8	Height;
TGCT	cis	rs7010267	0.602	rs1485307	chr8:120007395	T/C	cg17171407	chr8:119960777	TNFRSF11B	0.25	4.46	0.37	1.85e-5	Total body bone mineral density (age 45-60);
TGCT	cis	rs2562456	0.917	rs2681377	chr19:21716520	T/C	cg01304269	chr19:21688519	ZNF429	-0.55	-4.59	-0.38	1.06e-5	Pain;
TGCT	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg07424592	chr7:64974309	NA	-0.61	-5.81	-0.46	5.06e-8	Calcium levels;
TGCT	cis	rs739496	0.542	rs7316698	chr12:111790511	C/T	cg10833066	chr12:111807467	FAM109A	0.44	7.52	0.56	9.58e-12	Platelet count;
TGCT	cis	rs3784262	0.740	rs4646582	chr15:58307381	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.43	-6.26	-0.49	5.67e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs13256369	1.000	rs7843488	chr8:8576217	C/T	cg17143192	chr8:8559678	CLDN23	0.62	5.8	0.46	5.1e-8	Obesity-related traits;
TGCT	cis	rs7666738	0.791	rs10017624	chr4:98984009	G/T	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12950390	0.776	rs4793646	chr17:45853966	A/C	cg24803719	chr17:45855879	NA	-0.5	-5.05	-0.41	1.51e-6	IgG glycosylation;
TGCT	trans	rs1814175	0.817	rs7483795	chr11:49704930	G/A	cg03929089	chr4:120376271	NA	-0.71	-8.36	-0.6	1.09e-13	Height;
TGCT	cis	rs58722170	0.659	rs55852308	chr1:38078630	A/T	cg17933807	chr1:38061675	GNL2	-0.86	-8.69	-0.62	1.83e-14	High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs1580019	0.563	rs896137	chr7:32579345	G/T	cg07520158	chr7:32535189	LSM5;AVL9	0.6	4.95	0.41	2.39e-6	Cognitive ability;
TGCT	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.71	5.14	0.42	1.02e-6	Platelet count;
TGCT	cis	rs12367572	0.504	rs1903937	chr12:45521487	C/T	cg04608330	chr12:45269318	NELL2	-0.49	-4.55	-0.38	1.26e-5	Gut microbiome composition (summer);
TGCT	cis	rs149026780	1	rs149026780	chr2:97881612	A/C	cg26665480	chr2:98280029	ACTR1B	-0.97	-4.85	-0.4	3.69e-6	Monocyte chemoattractant protein-3 levels;
TGCT	cis	rs6570726	0.791	rs6902404	chr6:145905254	G/A	cg23711669	chr6:146136114	FBXO30	0.84	8.89	0.62	6.14e-15	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs9951602	0.512	rs12455591	chr18:76656028	A/G	cg02800362	chr5:177631904	HNRNPAB	1.13	12.71	0.75	3.32e-24	Obesity-related traits;
TGCT	cis	rs12188164	1.000	rs12188678	chr5:428231	T/C	cg21144161	chr5:423903	AHRR	0.24	4.5	0.37	1.53e-5	Cystic fibrosis severity;
TGCT	cis	rs13217239	0.646	rs6456767	chr6:27070543	C/T	cg06035815	chr6:26189597	HIST1H4D	0.44	4.52	0.38	1.41e-5	Schizophrenia;
TGCT	cis	rs4273100	0.564	rs10445411	chr17:19265797	C/T	cg01534423	chr17:18965556	NA	-0.78	-7.57	-0.56	7.37e-12	Schizophrenia;
TGCT	cis	rs3820068	0.608	rs12091750	chr1:16042766	T/C	cg17385448	chr1:15911702	AGMAT	0.36	4.92	0.4	2.67e-6	Systolic blood pressure;
TGCT	cis	rs8051431	0.806	rs12927205	chr16:72025077	G/A	cg06353428	chr16:71660113	MARVELD3	0.61	5.06	0.41	1.47e-6	LDL cholesterol levels;
TGCT	cis	rs11674184	0.564	rs746579	chr2:11744694	C/T	cg07314298	chr2:11723111	GREB1	-0.39	-6.59	-0.51	1.13e-9	Endometriosis;
TGCT	cis	rs7312933	0.558	rs1796381	chr12:42842475	C/T	cg19980929	chr12:42632907	YAF2	0.39	5.59	0.45	1.36e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs4957048	0.891	rs11960196	chr5:568857	C/A	cg09021430	chr5:549028	NA	-0.42	-5.68	-0.45	9.25e-8	Ulcerative colitis;
TGCT	cis	rs12579753	0.956	rs34146892	chr12:82188581	T/G	cg07988820	chr12:82153109	PPFIA2	-0.65	-6.79	-0.52	4.09e-10	Resting heart rate;
TGCT	cis	rs66573146	0.901	rs7668802	chr4:6986236	T/A	cg01220768	chr4:7056774	TADA2B	0.41	4.86	0.4	3.49e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs10927875	0.894	rs34957618	chr1:16320499	G/C	cg22431228	chr1:16359049	CLCNKA	0.23	4.44	0.37	1.94e-5	Dilated cardiomyopathy;
TGCT	cis	rs185694	0.901	rs668301	chr13:30904082	T/G	cg07600127	chr13:30881527	KATNAL1	-0.54	-4.7	-0.39	6.94e-6	Antineutrophil cytoplasmic antibody-associated vasculitis;
TGCT	cis	rs7731657	0.537	rs973901	chr5:130362623	G/T	cg08523029	chr5:130500466	HINT1	-0.61	-5.08	-0.42	1.34e-6	Fasting plasma glucose;
TGCT	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg11941060	chr3:133502564	NA	-0.29	-6.11	-0.48	1.2e-8	Iron status biomarkers;
TGCT	cis	rs67072384	1.000	rs72964185	chr11:72443177	G/A	cg03713592	chr11:72463424	ARAP1	-0.92	-4.61	-0.38	9.81e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs2153535	0.580	rs1414342	chr6:8462552	A/G	cg07606381	chr6:8435919	SLC35B3	0.52	4.81	0.4	4.34e-6	Motion sickness;
TGCT	cis	rs425277	0.958	rs262687	chr1:2117155	G/A	cg03732007	chr1:2071316	PRKCZ	0.25	5.3	0.43	5.15e-7	Height;
TGCT	cis	rs12681288	0.676	rs34282191	chr8:991290	G/A	cg04851639	chr8:1020857	NA	-0.29	-4.8	-0.4	4.49e-6	Schizophrenia;
TGCT	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg04632378	chr13:21900426	NA	0.4	4.78	0.39	4.94e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	trans	rs1814175	0.817	rs7481230	chr11:49772235	G/A	cg03929089	chr4:120376271	NA	-0.69	-8.17	-0.59	3.03e-13	Height;
TGCT	cis	rs6725041	0.792	rs1521643	chr2:213091417	A/G	cg20637307	chr2:213403960	ERBB4	-0.52	-4.6	-0.38	1.02e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs9467773	0.565	rs4343916	chr6:26522675	A/T	cg15659132	chr6:26577336	NA	0.73	9.04	0.63	2.64e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs4319547	0.615	rs2341439	chr12:122848096	C/G	cg08088222	chr12:122070432	ORAI1	0.26	4.79	0.4	4.58e-6	Body mass index;
TGCT	cis	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg22963979	chr7:1858916	MAD1L1	-0.37	-5.58	-0.45	1.42e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs2816062	0.813	rs2816051	chr1:18895460	A/G	cg18795169	chr1:18902165	NA	-0.6	-14.18	-0.79	1.04e-27	Urate levels in lean individuals;
TGCT	cis	rs617219	0.737	rs2166343	chr5:78484060	A/G	cg23514016	chr5:78407564	BHMT	0.36	5.69	0.46	8.67e-8	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs1475911	1.000	rs2839467	chr21:43513200	A/G	cg24372256	chr21:43528868	UMODL1;C21orf128	0.28	5.17	0.42	9.1e-7	IgG glycosylation;
TGCT	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs4654899	0.802	rs12137203	chr1:21109088	T/A	cg01072550	chr1:21505969	NA	-0.49	-7.89	-0.58	1.37e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg19010396	chr19:19431384	KIAA0892;SF4	-0.54	-4.54	-0.38	1.3e-5	Tonsillectomy;
TGCT	cis	rs11718455	0.767	rs11130019	chr3:43989348	C/A	cg08738300	chr3:44038990	NA	0.75	5.71	0.46	7.9e-8	Coronary artery disease;
TGCT	cis	rs9467773	1.000	rs6926629	chr6:26499903	T/C	cg26531700	chr6:26746687	NA	0.46	4.55	0.38	1.27e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.679	rs4738574	chr8:58033771	T/C	cg08280861	chr8:58055591	NA	0.35	5.07	0.41	1.43e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1474256	0.708	rs74485555	chr15:79454077	C/T	cg17916960	chr15:79447300	NA	0.39	5.43	0.44	2.79e-7	Bronchopulmonary dysplasia;
TGCT	cis	rs9611565	0.592	rs5751129	chr22:42015765	C/T	cg03806693	chr22:41940476	POLR3H	0.97	9.92	0.67	2.01e-17	Vitiligo;
TGCT	cis	rs79976124	0.800	rs12194767	chr6:66639599	A/G	cg07460842	chr6:66804631	NA	0.59	5.0	0.41	1.89e-6	Type 2 diabetes;
TGCT	cis	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg03213289	chr20:61660250	NA	0.68	9.9	0.66	2.25e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs711245	1.000	rs848602	chr2:36778372	G/A	cg01206211	chr2:36825736	FEZ2	0.3	4.52	0.38	1.42e-5	Height;
TGCT	cis	rs7940866	0.874	rs10791113	chr11:130873165	A/G	cg12179176	chr11:130786555	SNX19	0.56	5.4	0.44	3.34e-7	Schizophrenia;
TGCT	cis	rs2046867	0.661	rs7637050	chr3:72910790	A/C	cg25664220	chr3:72788482	NA	-0.44	-5.75	-0.46	6.52e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs4776059	0.550	rs8032394	chr15:52868032	G/A	cg25063058	chr15:52860530	ARPP19	0.65	5.01	0.41	1.83e-6	Schizophrenia;
TGCT	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg08219700	chr8:58056026	NA	0.3	4.53	0.38	1.35e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7772486	0.817	rs9386145	chr6:146363519	A/T	cg05347473	chr6:146136440	FBXO30	0.56	5.42	0.44	2.96e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7428	0.527	rs4459734	chr2:85547429	G/T	cg24342717	chr2:85555507	TGOLN2	-0.49	-7.81	-0.57	2.04e-12	Ear protrusion;
TGCT	cis	rs798554	0.704	rs709282	chr7:2769921	G/A	cg25467336	chr7:2757616	NA	-0.24	-4.61	-0.38	9.99e-6	Height;
TGCT	trans	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg25482853	chr8:67687455	SGK3	1.16	10.5	0.69	7.91e-19	Lung disease severity in cystic fibrosis;
TGCT	cis	rs36051895	0.603	rs10974972	chr9:5130146	G/A	cg02405213	chr9:5042618	JAK2	-0.76	-10.6	-0.69	4.38e-19	Pediatric autoimmune diseases;
TGCT	cis	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg18252515	chr7:66147081	NA	-1.22	-7.98	-0.58	8.46e-13	Diabetic kidney disease;
TGCT	cis	rs4319547	0.915	rs10773208	chr12:122970156	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.66	-5.32	-0.43	4.71e-7	Body mass index;
TGCT	cis	rs72700829	0.518	rs56133109	chr1:150251915	G/A	cg18798344	chr1:149336151	NA	0.56	4.5	0.37	1.52e-5	Schizophrenia;
TGCT	cis	rs644799	1.000	rs487609	chr11:95588102	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	10.76	0.7	1.74e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7507204	0.723	rs12979645	chr19:3414688	A/T	cg08380311	chr19:3435252	NFIC	0.98	8.25	0.6	2e-13	Height;
TGCT	trans	rs17471911	0.708	rs11189944	chr10:100785720	G/A	cg03484267	chr2:207988651	KLF7	-0.52	-6.7	-0.52	6.49e-10	Neuroticism;
TGCT	cis	rs950776	0.593	rs680244	chr15:78871288	T/C	cg06917634	chr15:78832804	PSMA4	-0.65	-5.32	-0.43	4.65e-7	Sudden cardiac arrest;
TGCT	cis	rs2204008	0.745	rs12146863	chr12:38502346	G/A	cg26384229	chr12:38710491	ALG10B	0.85	7.86	0.58	1.55e-12	Bladder cancer;
TGCT	cis	rs9581857	0.547	rs927579	chr13:28075079	A/G	cg22138327	chr13:27999177	GTF3A	0.73	4.45	0.37	1.87e-5	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs651907	0.557	rs17411983	chr3:101399126	A/G	cg12386194	chr3:101231763	SENP7	-0.53	-5.13	-0.42	1.08e-6	Colorectal cancer;
TGCT	cis	rs7044106	0.762	rs7024046	chr9:123419178	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	4.56	0.38	1.21e-5	Hip circumference adjusted for BMI;
TGCT	cis	rs981844	0.583	rs62323859	chr4:154629690	G/A	cg14289246	chr4:154710475	SFRP2	1.02	7.85	0.58	1.69e-12	Response to statins (LDL cholesterol change);
TGCT	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg22920501	chr2:26401640	FAM59B	-0.81	-6.42	-0.5	2.63e-9	Gut microbiome composition (summer);
TGCT	trans	rs561341	0.883	rs1034627	chr17:30219569	C/T	cg20587970	chr11:113659929	NA	-0.69	-8.2	-0.59	2.6e-13	Hip circumference adjusted for BMI;
TGCT	cis	rs36051895	0.632	rs9657576	chr9:5183028	T/G	cg02405213	chr9:5042618	JAK2	-0.77	-10.84	-0.7	1.13e-19	Pediatric autoimmune diseases;
TGCT	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg25036284	chr2:26402008	FAM59B	-0.56	-4.88	-0.4	3.2e-6	Gut microbiome composition (summer);
TGCT	cis	rs42648	0.869	rs6973816	chr7:89921072	C/T	cg25739043	chr7:89950458	NA	-0.75	-7.35	-0.55	2.31e-11	Homocysteine levels;
TGCT	cis	rs17221829	0.537	rs7933470	chr11:89376963	T/C	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.61	-0.38	9.9e-6	Anxiety in major depressive disorder;
TGCT	cis	rs9796	0.611	rs691672	chr15:41444438	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.53	-6.86	-0.52	2.97e-10	Menopause (age at onset);
TGCT	cis	rs2456568	0.778	rs7944194	chr11:93682413	C/G	cg17595323	chr11:93583763	C11orf90	0.39	4.86	0.4	3.43e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7772486	0.790	rs6570723	chr6:146151230	A/T	cg05347473	chr6:146136440	FBXO30	0.5	4.72	0.39	6.31e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs614226	0.938	rs7963543	chr12:120923948	C/A	cg01236616	chr12:121019343	POP5	1.19	12.38	0.74	2.07e-23	Type 1 diabetes nephropathy;
TGCT	cis	rs7681440	0.967	rs6532191	chr4:90745930	C/T	cg20003494	chr4:90757398	SNCA	-0.54	-5.05	-0.41	1.56e-6	Dementia with Lewy bodies;
TGCT	cis	rs2836633	0.929	rs62217517	chr21:40033177	T/A	cg12884169	chr21:40033163	ERG	0.43	4.69	0.39	7.03e-6	Coronary artery disease;
TGCT	cis	rs9633740	1.000	rs1902660	chr10:82263683	G/C	cg01528321	chr10:82214614	TSPAN14	1.03	8.42	0.6	7.78e-14	Post bronchodilator FEV1;
TGCT	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg03351412	chr1:154909251	PMVK	0.52	4.92	0.4	2.66e-6	Prostate cancer;
TGCT	cis	rs889312	0.500	rs252905	chr5:56118875	C/T	cg12311346	chr5:56204834	C5orf35	-0.46	-4.99	-0.41	1.97e-6	Breast cancer;Breast cancer (early onset);
TGCT	cis	rs4566357	0.615	rs1800517	chr2:227915832	G/A	cg11843606	chr2:227700838	RHBDD1	-0.55	-5.17	-0.42	8.92e-7	Coronary artery disease;
TGCT	cis	rs7507204	0.906	rs1860323	chr19:3424799	G/C	cg08380311	chr19:3435252	NFIC	0.94	7.99	0.58	7.76e-13	Height;
TGCT	cis	rs138249	1.000	rs138249	chr22:50569790	C/T	cg24864161	chr22:50528282	MOV10L1	0.47	4.78	0.39	4.9100000000000004e-06	Gestational age at birth in labor-initiated deliveries (child effect);
TGCT	cis	rs9527	0.590	rs1926037	chr10:104878010	A/C	cg04362960	chr10:104952993	NT5C2	0.7	5.88	0.47	3.57e-8	Arsenic metabolism;
TGCT	cis	rs4746818	1.000	rs1506770	chr10:70964357	G/A	cg11621586	chr10:70884670	VPS26A	1.23	10.93	0.7	6.87e-20	Left atrial antero-posterior diameter;
TGCT	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg08280861	chr8:58055591	NA	0.39	4.86	0.4	3.45e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs896854	0.608	rs6991067	chr8:95875676	A/G	cg23172400	chr8:95962367	TP53INP1	-0.29	-4.55	-0.38	1.25e-5	Type 2 diabetes;
TGCT	cis	rs981844	1.000	rs1371161	chr4:154655171	T/C	cg14289246	chr4:154710475	SFRP2	1.05	8.74	0.62	1.39e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs77633900	0.614	rs280024	chr15:77034518	A/C	cg21673338	chr15:77095150	SCAPER	-0.51	-5.12	-0.42	1.11e-6	Non-glioblastoma glioma;Glioma;
TGCT	cis	rs2201728	0.967	rs17584051	chr4:100193652	C/T	cg07219303	chr4:100140905	ADH6	-0.34	-5.08	-0.42	1.32e-6	Cardiac Troponin-T levels;
TGCT	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg08280861	chr8:58055591	NA	0.49	5.38	0.43	3.64e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs17331151	0.505	rs13086936	chr3:52659079	T/C	cg15956490	chr3:53032818	SFMBT1	0.7	5.71	0.46	7.8e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg07636037	chr3:49044803	WDR6	0.88	9.05	0.63	2.49e-15	Menarche (age at onset);
TGCT	cis	rs4791641	0.713	rs9908765	chr17:8214427	G/A	cg18829560	chr17:7298064	PLSCR3	-0.5	-4.61	-0.38	9.85e-6	LDL cholesterol levels;Hematocrit;Hemoglobin concentration;Red blood cell count;LDL cholesterol;
TGCT	cis	rs981844	0.890	rs56184506	chr4:154685889	G/T	cg14289246	chr4:154710475	SFRP2	1.05	9.32	0.64	5.44e-16	Response to statins (LDL cholesterol change);
TGCT	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg11644478	chr21:40555479	PSMG1	-0.61	-5.68	-0.45	8.9e-8	Cognitive function;
TGCT	cis	rs939658	0.683	rs1560895	chr15:79468082	A/G	cg17916960	chr15:79447300	NA	-0.44	-6.95	-0.53	1.81e-10	Refractive error;
TGCT	cis	rs1023500	0.551	rs133355	chr22:42440285	G/A	cg05082376	chr22:42548792	NA	-0.23	-5.42	-0.44	2.92e-7	Schizophrenia;
TGCT	cis	rs55823223	0.646	rs74410877	chr17:73832384	C/T	cg06969265	chr17:73775802	H3F3B	0.76	5.45	0.44	2.62e-7	Psoriasis;
TGCT	cis	rs933688	1.000	rs10073935	chr5:90742188	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	9.69	0.66	7.22e-17	Smoking behavior;
TGCT	cis	rs1532993	0.518	rs3913987	chr4:98606177	A/C	cg05340658	chr4:99064831	C4orf37	-0.41	-4.96	-0.41	2.3e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg11301795	chr4:187892539	NA	-0.33	-4.82	-0.4	4.14e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7255045	0.742	rs6511842	chr19:12955178	C/T	cg23899408	chr19:12877188	HOOK2	-0.58	-4.78	-0.39	4.85e-6	Mean corpuscular volume;
TGCT	cis	rs10791323	0.569	rs2282601	chr11:133712594	C/G	cg15485101	chr11:133734466	NA	0.4	5.27	0.43	5.83e-7	Childhood ear infection;
TGCT	cis	rs9486719	0.947	rs12210834	chr6:96890407	A/T	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.21	-0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs1005224	0.782	rs34882722	chr14:76153896	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.62	-5.75	-0.46	6.6e-8	Large artery stroke;
TGCT	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg07061783	chr6:25882402	NA	-0.59	-5.5	-0.44	2.03e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs858239	0.601	rs4599714	chr7:23168801	C/T	cg05602783	chr7:23145260	KLHL7	-0.65	-5.48	-0.44	2.32e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs66573146	1.000	rs6852613	chr4:7035637	G/A	cg01220768	chr4:7056774	TADA2B	0.36	4.51	0.38	1.48e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs3087591	0.960	rs2953000	chr17:29509791	C/T	cg24425628	chr17:29625626	OMG;NF1	0.46	6.82	0.52	3.5e-10	Hip circumference;
TGCT	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg11494091	chr17:61959527	GH2	0.41	6.99	0.53	1.52e-10	Height;
TGCT	cis	rs933688	1.000	rs889213	chr5:90682151	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.99	8.15	0.59	3.39e-13	Smoking behavior;
TGCT	cis	rs7226408	0.857	rs72888997	chr18:34580216	A/G	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs1475911	0.656	rs9980065	chr21:43528072	G/A	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.29	-5.03	-0.41	1.68e-6	IgG glycosylation;
TGCT	cis	rs651907	0.557	rs7651406	chr3:101393296	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.91	11.43	0.72	4.08e-21	Colorectal cancer;
TGCT	trans	rs208520	0.545	rs10944874	chr6:66752080	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.04	-14.69	-0.8	6.25e-29	Exhaled nitric oxide output;
TGCT	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg04772025	chr11:68637568	NA	0.61	6.82	0.52	3.64e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs2070488	0.775	rs2300669	chr3:38541318	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.73	-6.78	-0.52	4.39e-10	Electrocardiographic conduction measures;
TGCT	cis	rs7829975	0.777	rs560544	chr8:8637429	G/A	cg06636001	chr8:8085503	FLJ10661	-0.67	-5.74	-0.46	6.9e-8	Mood instability;
TGCT	cis	rs9486715	0.867	rs9486181	chr6:96868132	G/A	cg18709589	chr6:96969512	KIAA0776	0.79	7.77	0.57	2.5e-12	Headache;
TGCT	cis	rs10769945	0.679	rs217213	chr11:1979118	C/G	cg02850416	chr11:1986266	NA	-0.26	-4.57	-0.38	1.16e-5	DNA methylation (variation);
TGCT	cis	rs6876348	0.598	rs1898550	chr5:128285661	C/T	cg25555059	chr5:128301488	SLC27A6	-0.29	-4.83	-0.4	4e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs79149102	0.579	rs74023935	chr15:75359184	T/C	cg09165964	chr15:75287851	SCAMP5	-1.15	-6.31	-0.49	4.4e-9	Lung cancer;
TGCT	cis	rs12950390	0.853	rs17773010	chr17:45858297	C/T	cg03474202	chr17:45855739	NA	-0.44	-4.51	-0.38	1.5e-5	IgG glycosylation;
TGCT	cis	rs9677476	0.516	rs6727962	chr2:232045268	G/A	cg07929768	chr2:232055508	NA	0.33	5.18	0.42	8.63e-7	Food antigen IgG levels;
TGCT	cis	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg26818010	chr10:134567672	INPP5A	-0.34	-4.45	-0.37	1.86e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	trans	rs2727020	0.521	rs937430	chr11:49542457	A/G	cg11707556	chr5:10655725	ANKRD33B	0.42	8.63	0.61	2.5e-14	Coronary artery disease;
TGCT	cis	rs35883536	0.647	rs10875314	chr1:101043207	G/C	cg14855972	chr1:101004472	GPR88	-0.24	-4.49	-0.37	1.64e-5	Monocyte count;
TGCT	cis	rs2120019	0.935	rs8042409	chr15:75350433	G/A	cg17294928	chr15:75287854	SCAMP5	-0.81	-6.21	-0.49	7.41e-9	Blood trace element (Zn levels);
TGCT	cis	rs7714584	1.000	rs10041072	chr5:150259642	A/G	cg22134413	chr5:150180641	NA	0.78	6.12	0.48	1.16e-8	Crohn's disease;
TGCT	cis	rs7635838	0.892	rs4684775	chr3:11436413	A/G	cg00170343	chr3:11313890	ATG7	0.65	6.23	0.49	6.56e-9	HDL cholesterol;
TGCT	cis	rs12510870	0.599	rs16849651	chr4:74450308	T/C	cg05868023	chr4:75230803	EREG	-0.54	-4.76	-0.39	5.33e-6	Iris color (b* coordinate);
TGCT	cis	rs854765	0.624	rs4925119	chr17:17742904	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.69	-6.42	-0.5	2.66e-9	Total body bone mineral density;
TGCT	cis	rs6752107	0.936	rs10178603	chr2:234206610	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.21	4.71	0.39	6.47e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs28595532	0.920	rs17323877	chr4:119671188	A/G	cg11846333	chr4:119757529	SEC24D	0.9	4.54	0.38	1.34e-5	Cannabis dependence symptom count;
TGCT	trans	rs2243480	0.708	rs35825036	chr7:65986502	T/C	cg07424592	chr7:64974309	NA	1.3	8.23	0.59	2.19e-13	Diabetic kidney disease;
TGCT	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg11494091	chr17:61959527	GH2	0.42	7.37	0.55	2.06e-11	Height;
TGCT	trans	rs17011478	0.744	rs17011523	chr2:75830612	T/C	cg17835207	chr20:48524531	SPATA2	-0.75	-6.91	-0.53	2.2e-10	Obesity-related traits;
TGCT	cis	rs9527	0.590	rs12414232	chr10:104914491	A/T	cg04362960	chr10:104952993	NT5C2	0.67	5.64	0.45	1.09e-7	Arsenic metabolism;
TGCT	cis	rs10426930	0.607	rs2613755	chr19:5059941	A/G	cg09001777	chr19:5851504	FUT3	-0.22	-4.83	-0.4	3.88e-6	Monocyte percentage of white cells;
TGCT	cis	rs17076896	0.708	rs2992950	chr13:19928251	A/C	cg00777926	chr13:20807375	GJB6	0.36	4.65	0.39	8.4e-6	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs2742417	1.000	rs2245705	chr3:45749722	A/G	cg04837898	chr3:45731254	SACM1L	-0.55	-5.88	-0.47	3.63e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2050392	0.624	rs303449	chr10:30726845	G/A	cg18806716	chr10:30721971	MAP3K8	-0.7	-9.39	-0.64	3.84e-16	Inflammatory bowel disease;
TGCT	cis	rs6933660	0.683	rs8180642	chr6:151756612	A/G	cg17179660	chr6:151773299	C6orf211;RMND1	-0.55	-4.95	-0.41	2.34e-6	Menarche (age at onset);
TGCT	cis	rs6570726	0.791	rs407887	chr6:145843759	C/T	cg23711669	chr6:146136114	FBXO30	0.88	9.55	0.65	1.54e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs854765	0.624	rs12952723	chr17:17731651	T/C	cg09796270	chr17:17721594	SREBF1	-0.25	-4.74	-0.39	5.78e-6	Total body bone mineral density;
TGCT	cis	rs6831352	0.879	rs29001212	chr4:100051877	T/C	cg12011299	chr4:100065546	ADH4	-0.41	-4.92	-0.4	2.72e-6	Alcohol dependence;
TGCT	cis	rs921968	0.643	rs523396	chr2:219338789	T/G	cg02176678	chr2:219576539	TTLL4	0.44	6.33	0.49	4.17e-9	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs16867321	0.588	rs2368175	chr2:181493763	G/C	cg23363182	chr2:181467187	NA	-0.41	-6.15	-0.48	9.7e-9	Obesity;
TGCT	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg11764359	chr7:65958608	NA	0.54	4.85	0.4	3.67e-6	Aortic root size;
TGCT	cis	rs78487399	0.808	rs6746058	chr2:43687542	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.24	-0.43	6.79e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs9926296	0.572	rs2079671	chr16:89884981	T/C	cg04287289	chr16:89883240	FANCA	0.71	7.24	0.54	4.21e-11	Vitiligo;
TGCT	cis	rs208520	1.000	rs12200490	chr6:66976084	G/A	cg07460842	chr6:66804631	NA	0.81	7.17	0.54	6.08e-11	Exhaled nitric oxide output;
TGCT	cis	rs6496044	0.547	rs1564719	chr15:86054266	C/T	cg13263323	chr15:86062960	AKAP13	-0.24	-5.24	-0.43	6.59e-7	Interstitial lung disease;
TGCT	cis	rs9796	0.835	rs3100807	chr15:41292206	G/A	cg18705301	chr15:41695430	NDUFAF1	0.41	5.3	0.43	5.07e-7	Menopause (age at onset);
TGCT	cis	rs3784262	0.565	rs4646607	chr15:58285388	A/C	cg12031962	chr15:58353849	ALDH1A2	-0.39	-5.5	-0.44	2.04e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs422249	0.512	rs1535	chr11:61597972	A/G	cg01500311	chr11:61656094	FADS3	-0.3	-5.25	-0.43	6.49e-7	Trans fatty acid levels;
TGCT	cis	rs9916302	0.821	rs1966915	chr17:37425262	A/C	cg15445000	chr17:37608096	MED1	0.32	4.69	0.39	7.11e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs6558530	0.730	rs6991773	chr8:1723177	A/G	cg09410841	chr8:1729607	CLN8	0.83	9.76	0.66	4.92e-17	Systolic blood pressure;
TGCT	cis	rs9325144	0.560	rs2013804	chr12:38631079	C/T	cg26384229	chr12:38710491	ALG10B	-0.65	-6.12	-0.48	1.13e-8	Morning vs. evening chronotype;
TGCT	cis	rs67311347	1.000	rs73076046	chr3:40447724	C/T	cg13409248	chr3:40428643	ENTPD3	0.57	4.53	0.38	1.37e-5	Renal cell carcinoma;
TGCT	cis	rs6540559	0.673	rs6540560	chr1:209982073	A/G	cg22029157	chr1:209979665	IRF6	-0.67	-5.63	-0.45	1.12e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs1153858	0.621	rs1706824	chr15:45579948	C/T	cg14582100	chr15:45693742	SPATA5L1	0.47	5.2	0.42	8.07e-7	Homoarginine levels;
TGCT	cis	rs3091242	0.933	rs4649084	chr1:25752617	A/G	cg10117171	chr1:25599238	RHD	-0.34	-5.48	-0.44	2.23e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs9611519	0.603	rs9607764	chr22:41411804	G/C	cg13695892	chr22:41940480	POLR3H	-0.54	-5.11	-0.42	1.19e-6	Neuroticism;
TGCT	cis	rs79349575	0.756	rs4793605	chr17:47035869	T/C	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.48	-0.37	1.67e-5	Type 2 diabetes;
TGCT	cis	rs4919694	1.000	rs12245779	chr10:104645944	C/A	cg04362960	chr10:104952993	NT5C2	1.06	7.07	0.54	9.73e-11	Arsenic metabolism;
TGCT	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg23205692	chr1:25664452	TMEM50A	0.54	5.48	0.44	2.22e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg04944784	chr2:26401820	FAM59B	-0.67	-6.16	-0.48	9.54e-9	Gut microbiome composition (summer);
TGCT	cis	rs17601876	0.778	rs4774584	chr15:51562007	G/A	cg19946085	chr15:51559439	CYP19A1	-0.33	-5.06	-0.41	1.45e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs73198271	0.960	rs11778970	chr8:8609334	G/C	ch.8.214553F	chr8:8189620	PRAGMIN	-0.27	-4.62	-0.38	9.34e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs12477438	0.798	rs10198293	chr2:99602929	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-8.52	-0.61	4.5e-14	Chronic sinus infection;
TGCT	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.98	-13.03	-0.76	5.71e-25	Prudent dietary pattern;
TGCT	cis	rs826838	0.967	rs11183577	chr12:38781887	A/G	cg13010199	chr12:38710504	ALG10B	0.82	6.86	0.52	2.91e-10	Heart rate;
TGCT	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg10802521	chr3:52805072	NEK4	-0.71	-8.79	-0.62	1.04e-14	Bipolar disorder;
TGCT	cis	rs2180341	0.814	rs6914131	chr6:127737489	T/C	cg24812749	chr6:127587940	RNF146	0.76	6.22	0.49	7.07e-9	Breast cancer;
TGCT	cis	rs9527	0.590	rs2148200	chr10:104879847	C/A	cg15744005	chr10:104629667	AS3MT	-0.43	-4.9	-0.4	2.89e-6	Arsenic metabolism;
TGCT	cis	rs6138458	0.961	rs227625	chr20:24911618	T/C	cg26195577	chr20:24973756	C20orf3	1.2	12.04	0.73	1.35e-22	Blood protein levels;
TGCT	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.55	5.21	0.42	7.61e-7	Menarche (age at onset);
TGCT	cis	rs11578119	0.933	rs72709774	chr1:170470628	A/C	cg09767346	chr1:170501363	GORAB	0.66	5.29	0.43	5.27e-7	Male-pattern baldness;
TGCT	cis	rs12477438	0.520	rs13031919	chr2:99848932	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.69	6.2	0.49	7.74e-9	Chronic sinus infection;
TGCT	cis	rs12549025	0.530	rs28656888	chr8:23266209	C/T	cg00472375	chr8:23315376	ENTPD4	0.61	5.38	0.43	3.61e-7	Reticulocyte fraction of red cells;
TGCT	cis	rs6921919	0.583	rs6908137	chr6:28370393	A/C	cg18815343	chr6:28367644	ZSCAN12	-0.55	-5.24	-0.43	6.72e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs35306767	0.953	rs11253521	chr10:976416	G/C	cg26597838	chr10:835615	NA	0.57	8.13	0.59	3.79e-13	Eosinophil percentage of granulocytes;
TGCT	cis	rs9913156	0.517	rs12452404	chr17:4587355	C/T	cg19197139	chr17:4613644	ARRB2	-0.6	-5.74	-0.46	6.88e-8	Lymphocyte counts;
TGCT	cis	rs12950390	0.853	rs11079791	chr17:45859099	C/T	cg24803719	chr17:45855879	NA	-0.49	-5.03	-0.41	1.64e-6	IgG glycosylation;
TGCT	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg01416388	chr22:39784598	NA	-0.7	-6.92	-0.53	2.11e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.0	8.22	0.59	2.32e-13	Platelet count;
TGCT	cis	rs7772486	0.846	rs7755440	chr6:146375906	T/C	cg13319975	chr6:146136371	FBXO30	-0.51	-4.48	-0.37	1.69e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7267979	1.000	rs2258884	chr20:25279539	C/T	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg23758822	chr17:41437982	NA	0.69	6.37	0.5	3.34e-9	Menopause (age at onset);
TGCT	cis	rs6582630	0.638	rs12231073	chr12:38526901	T/G	cg26384229	chr12:38710491	ALG10B	-0.55	-4.89	-0.4	3.05e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs2235642	0.859	rs9927529	chr16:1619488	C/T	cg08296037	chr16:1584118	IFT140;TMEM204	-0.31	-5.07	-0.41	1.4e-6	Coronary artery disease;
TGCT	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg03609598	chr5:56110824	MAP3K1	-0.6	-4.86	-0.4	3.55e-6	Initial pursuit acceleration;
TGCT	cis	rs28595532	0.702	rs116320061	chr4:119384600	C/T	cg21605333	chr4:119757512	SEC24D	0.81	5.35	0.43	4.16e-7	Cannabis dependence symptom count;
TGCT	trans	rs11082438	0.786	rs11660485	chr18:42866471	A/C	cg20111269	chr12:107972364	BTBD11	-0.88	-7.09	-0.54	8.76e-11	Follicular lymphoma;
TGCT	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg03732007	chr1:2071316	PRKCZ	-0.28	-6.66	-0.51	8.15e-10	Height;
TGCT	cis	rs7940866	0.804	rs6590540	chr11:130805444	T/C	cg12179176	chr11:130786555	SNX19	0.59	5.81	0.46	4.88e-8	Schizophrenia;
TGCT	cis	rs11252926	0.502	rs7072510	chr10:455596	C/T	cg20256804	chr10:444983	DIP2C	-0.21	-4.52	-0.38	1.41e-5	Psychosis in Alzheimer's disease;
TGCT	cis	rs7568458	0.846	rs2028900	chr2:85767735	A/G	cg02493740	chr2:85810744	VAMP5	0.27	5.0	0.41	1.87e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs2404618	0.534	rs2214861	chr8:1490604	A/G	cg13402656	chr8:1511478	DLGAP2	-0.35	-6.33	-0.49	4.12e-9	Lung cancer;
TGCT	cis	rs5757676	0.858	rs6001585	chr22:39812986	G/T	cg24399712	chr22:39784796	NA	-0.98	-8.59	-0.61	3.16e-14	IgG glycosylation;
TGCT	cis	rs10791097	0.739	rs4936120	chr11:130723452	G/A	cg14779329	chr11:130786720	SNX19	0.27	4.59	0.38	1.06e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg16680214	chr1:154839983	KCNN3	-0.36	-7.26	-0.55	3.81e-11	Prostate cancer;
TGCT	cis	rs7666738	0.893	rs11729640	chr4:99052699	C/T	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg03388025	chr16:89894329	SPIRE2	0.48	8.07	0.59	5.2e-13	Vitiligo;
TGCT	cis	rs7829975	0.577	rs79495969	chr8:8545250	G/A	cg08975724	chr8:8085496	FLJ10661	-0.51	-4.44	-0.37	1.96e-5	Mood instability;
TGCT	cis	rs986417	1.000	rs10130267	chr14:60944527	A/G	cg27398547	chr14:60952738	C14orf39	1.42	8.68	0.61	1.89e-14	Gut microbiota (bacterial taxa);
TGCT	cis	rs9549367	0.756	rs3861723	chr13:113910926	A/G	cg00898013	chr13:113819073	PROZ	-0.38	-4.99	-0.41	2.01e-6	Platelet distribution width;
TGCT	cis	rs28595532	0.841	rs112953035	chr4:119752450	T/C	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs17052344	0.543	rs2342183	chr17:21738349	G/T	cg18423549	chr17:21743878	NA	-0.61	-5.99	-0.47	2.14e-8	Cutaneous psoriasis;
TGCT	cis	rs1150668	0.764	rs9368565	chr6:28345210	C/T	cg13525197	chr6:28411240	ZSCAN23	0.5	4.89	0.4	3.1e-6	Pubertal anthropometrics;
TGCT	cis	rs10789491	1.000	rs1890473	chr1:47149794	C/T	cg15501359	chr1:47185051	KIAA0494	0.78	7.43	0.55	1.55e-11	Response to hepatitis C treatment;
TGCT	cis	rs1801251	1.000	rs283469	chr2:233656997	G/T	cg25237894	chr2:233734115	C2orf82	0.31	5.41	0.44	3.17e-7	Coronary artery disease;
TGCT	cis	rs9913156	0.793	rs9916135	chr17:4568115	A/C	cg19197139	chr17:4613644	ARRB2	-0.87	-8.05	-0.59	5.79e-13	Lymphocyte counts;
TGCT	cis	rs2932538	0.922	rs34531155	chr1:113141550	C/T	cg22162597	chr1:113214053	CAPZA1	0.28	5.83	0.46	4.4e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs2224391	0.628	rs9392666	chr6:5249888	C/A	cg09085698	chr6:5261316	LYRM4;FARS2	-1.04	-6.69	-0.51	6.87e-10	Height;
TGCT	cis	rs1729951	0.575	rs10935214	chr3:136693485	G/A	cg21827317	chr3:136751795	NA	0.4	5.61	0.45	1.28e-7	Neuroticism;
TGCT	cis	rs9604529	0.557	rs74841821	chr13:114742213	G/A	cg13259177	chr13:114761607	RASA3	-0.27	-4.54	-0.38	1.32e-5	Response to tocilizumab in rheumatoid arthritis;
TGCT	cis	rs1865760	0.566	rs2032443	chr6:26046802	A/G	cg16482183	chr6:26056742	HIST1H1C	0.57	4.97	0.41	2.21e-6	Height;
TGCT	cis	rs881375	0.678	rs10760129	chr9:123700183	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	4.93	0.4	2.56e-6	Rheumatoid arthritis;
TGCT	cis	rs1784581	0.674	rs1789990	chr6:162406957	G/T	cg17173639	chr6:162384350	PARK2	-0.39	-6.79	-0.52	4.1e-10	Itch intensity from mosquito bite;
TGCT	cis	rs11112613	0.713	rs17037317	chr12:105952058	T/C	cg03607813	chr12:105948248	NA	0.47	5.72	0.46	7.49e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg16414030	chr3:133502952	NA	-0.49	-6.92	-0.53	2.13e-10	Iron status biomarkers;
TGCT	trans	rs629535	0.814	rs604254	chr8:70059164	A/G	cg21567404	chr3:27674614	NA	0.56	8.83	0.62	8.17e-15	Dupuytren's disease;
TGCT	cis	rs637571	0.544	rs617791	chr11:65702523	C/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.56	5.33	0.43	4.42e-7	Eosinophil percentage of white cells;
TGCT	cis	rs929354	1.000	rs1182389	chr7:157038803	C/T	cg05182265	chr7:156933206	UBE3C	-0.3	-6.43	-0.5	2.5e-9	Body mass index;
TGCT	cis	rs10986311	0.889	rs3780204	chr9:127092887	C/G	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.2	4.58	0.38	1.13e-5	Vitiligo;
TGCT	cis	rs71435601	0.600	rs573314	chr2:21385161	C/G	cg25035485	chr2:21266500	APOB	0.51	4.48	0.37	1.64e-5	Cholesterol, total;
TGCT	cis	rs2120019	0.935	rs34835684	chr15:75331805	T/G	cg09165964	chr15:75287851	SCAMP5	-1.14	-10.22	-0.68	3.76e-18	Blood trace element (Zn levels);
TGCT	cis	rs826838	1.000	rs11183469	chr12:38752311	G/A	cg26384229	chr12:38710491	ALG10B	1.08	10.86	0.7	1.01e-19	Heart rate;
TGCT	cis	rs6964587	1.000	rs56072181	chr7:91690457	A/G	cg22709100	chr7:91322751	NA	0.28	4.56	0.38	1.19e-5	Breast cancer;
TGCT	cis	rs138249	0.934	rs138234	chr22:50560372	C/T	cg24864161	chr22:50528282	MOV10L1	0.47	5.02	0.41	1.77e-6	Gestational age at birth in labor-initiated deliveries (child effect);
TGCT	cis	rs11098499	0.863	rs13149407	chr4:120437825	A/G	cg09307838	chr4:120376055	NA	0.69	6.53	0.51	1.49e-9	Corneal astigmatism;
TGCT	cis	rs2535633	0.594	rs2581789	chr3:53096230	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	0.51	4.92	0.4	2.73e-6	Body mass index;
TGCT	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg07507251	chr3:52567010	NT5DC2	-0.46	-6.41	-0.5	2.74e-9	Electroencephalogram traits;
TGCT	cis	rs9682041	0.932	rs7631221	chr3:170069893	A/G	cg07589077	chr3:170072950	NA	0.37	5.29	0.43	5.42e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs3806843	0.900	rs2531341	chr5:140130894	C/T	cg19875535	chr5:140030758	IK	-0.35	-5.97	-0.47	2.27e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2178146	0.535	rs4843945	chr16:86444032	A/C	cg11165158	chr16:86613094	FOXL1	-0.35	-4.47	-0.37	1.73e-5	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Esophageal adenocarcinoma;
TGCT	cis	rs7267979	0.816	rs390123	chr20:25480105	C/G	cg16686733	chr20:25566563	NINL	0.52	5.05	0.41	1.52e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg24060327	chr5:131705240	SLC22A5	-0.75	-8.27	-0.6	1.8e-13	Breast cancer;
TGCT	cis	rs4688759	0.719	rs73079018	chr3:49875327	T/C	cg07636037	chr3:49044803	WDR6	-0.99	-4.74	-0.39	5.85e-6	Blood protein levels;
TGCT	cis	rs6570726	0.875	rs1883407	chr6:145823432	T/C	cg23711669	chr6:146136114	FBXO30	0.69	6.22	0.49	6.89e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs478304	0.593	rs4645927	chr11:65482827	C/T	cg27068330	chr11:65405492	SIPA1	-0.98	-9.26	-0.64	7.7e-16	Acne (severe);
TGCT	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg25036284	chr2:26402008	FAM59B	0.65	5.19	0.42	8.36e-7	Gut microbiome composition (summer);
TGCT	cis	rs514406	0.698	rs1775540	chr1:53407893	C/A	cg01802117	chr1:53393560	SCP2	-0.44	-5.45	-0.44	2.6e-7	Monocyte count;
TGCT	cis	rs7666738	0.791	rs1559860	chr4:99024422	C/T	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8072100	0.713	rs2292346	chr17:45455473	G/A	cg08085267	chr17:45401833	C17orf57	-0.5	-5.47	-0.44	2.38e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs933688	1.000	rs6452951	chr5:90653868	T/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.08	10.13	0.67	6.16e-18	Smoking behavior;
TGCT	cis	rs13082711	0.522	rs3103745	chr3:27342927	T/C	cg02860705	chr3:27208620	NA	0.33	5.45	0.44	2.62e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs2617583	0.509	rs748209	chr5:1457554	A/C	cg13982541	chr5:1466431	LPCAT1	0.2	4.77	0.39	5.07e-6	Breast cancer;
TGCT	cis	rs2224391	0.628	rs2753243	chr6:5256261	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-1.02	-6.25	-0.49	6.07e-9	Height;
TGCT	cis	rs922182	0.904	rs9972469	chr15:64283793	C/A	cg02919090	chr15:64263738	DAPK2	0.31	5.83	0.46	4.58e-8	Blood protein levels;
TGCT	cis	rs2239815	0.515	rs5762829	chr22:29228130	A/G	cg02153584	chr22:29168773	CCDC117	0.78	5.37	0.43	3.81e-7	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
TGCT	cis	rs950880	0.560	rs59247511	chr2:102954190	T/C	cg09003973	chr2:102972529	NA	-0.53	-4.59	-0.38	1.06e-5	Serum protein levels (sST2);
TGCT	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.15	0.82	2.71e-32	Prudent dietary pattern;
TGCT	cis	rs7666738	0.830	rs7662114	chr4:99019985	A/G	cg05340658	chr4:99064831	C4orf37	0.48	5.43	0.44	2.92e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs17376456	0.825	rs12153021	chr5:93073913	A/G	cg25358565	chr5:93447407	FAM172A	0.89	7.39	0.55	1.89e-11	Diabetic retinopathy;
TGCT	cis	rs2228479	0.850	rs11644526	chr16:89898660	C/T	cg06558623	chr16:89946397	TCF25	0.55	4.86	0.4	3.55e-6	Skin colour saturation;
TGCT	cis	rs1008375	0.646	rs13103430	chr4:17567355	A/C	cg18681998	chr4:17616180	MED28	-0.65	-5.55	-0.45	1.68e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4919694	1.000	rs11191439	chr10:104638723	C/T	cg24592962	chr10:104629151	AS3MT	0.83	4.55	0.38	1.27e-5	Arsenic metabolism;
TGCT	cis	rs79976124	0.837	rs12194087	chr6:66644399	T/A	cg07460842	chr6:66804631	NA	0.57	5.22	0.42	7.44e-7	Type 2 diabetes;
TGCT	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-5.09	-0.42	1.29e-6	Electroencephalogram traits;
TGCT	cis	rs7945705	0.791	rs12421789	chr11:8813956	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.42	-4.63	-0.38	9.11e-6	Hemoglobin concentration;
TGCT	cis	rs9549260	0.564	rs8000965	chr13:41279488	C/T	cg21288729	chr13:41239152	FOXO1	0.94	8.95	0.63	4.28e-15	Red blood cell count;
TGCT	cis	rs709400	0.628	rs4906321	chr14:103878882	C/T	cg12935359	chr14:103987150	CKB	-0.29	-4.57	-0.38	1.15e-5	Body mass index;
TGCT	cis	rs7772486	0.651	rs1292338	chr6:145967471	A/C	cg13319975	chr6:146136371	FBXO30	0.5	4.6	0.38	1.01e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs78487399	0.808	rs74365854	chr2:43661482	T/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.45	-5.35	-0.43	4.03e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs1322512	1.000	rs7765586	chr6:152949109	C/T	cg03415253	chr6:152958462	SYNE1	0.57	4.99	0.41	2e-6	Tonometry;
TGCT	cis	rs2932538	0.883	rs6696991	chr1:113095661	C/T	cg22162597	chr1:113214053	CAPZA1	0.25	5.5	0.44	2.06e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs644799	1.000	rs563653	chr11:95561488	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.82	8.63	0.61	2.52e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs79349575	0.783	rs4793998	chr17:47019899	C/T	cg26022315	chr17:47021804	SNF8	0.49	4.9	0.4	2.94e-6	Type 2 diabetes;
TGCT	trans	rs10435719	0.902	rs11250179	chr8:11800332	C/T	cg15556689	chr8:8085844	FLJ10661	0.78	7.35	0.55	2.32e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg02353165	chr6:42928485	GNMT	0.99	10.14	0.67	5.89e-18	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs35771425	0.626	rs11119744	chr1:211644575	C/T	cg10512769	chr1:211675356	NA	-0.28	-4.96	-0.41	2.29e-6	Educational attainment (years of education);
TGCT	cis	rs9916302	0.847	rs7218670	chr17:37500424	G/A	cg07936489	chr17:37558343	FBXL20	0.65	5.08	0.41	1.36e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs2274273	0.682	rs10145268	chr14:55504514	T/C	cg01923255	chr14:55878535	KIAA0831	0.56	4.94	0.41	2.51e-6	Protein biomarker;
TGCT	cis	rs6882046	0.513	rs616391	chr5:88038845	C/T	cg24804195	chr5:87968844	LOC645323	-0.57	-5.68	-0.45	9.26e-8	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs988712	0.705	rs10501087	chr11:27670108	C/T	cg10635145	chr11:27742435	BDNF	0.38	5.25	0.43	6.38e-7	Obesity;
TGCT	trans	rs11785693	0.909	rs62489556	chr8:4968149	G/A	cg21607066	chr6:79787807	PHIP	0.91	6.8	0.52	3.93e-10	Neuroticism (multi-trait analysis);Neuroticism;
TGCT	cis	rs13323323	0.696	rs66922431	chr3:44474551	C/T	cg04389838	chr3:44770851	ZNF501	-0.43	-4.74	-0.39	5.76e-6	IgG glycosylation;
TGCT	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg16049864	chr8:95962084	TP53INP1	-0.77	-11.21	-0.71	1.44e-20	Type 2 diabetes;
TGCT	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.01	8.32	0.6	1.34e-13	Platelet count;
TGCT	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg23302884	chr18:44338147	ST8SIA5	-0.4	-4.58	-0.38	1.11e-5	Personality dimensions;
TGCT	cis	rs11190604	1.000	rs12358187	chr10:102284449	C/G	cg16342193	chr10:102329863	NA	-0.42	-5.37	-0.43	3.74e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2204008	0.683	rs11522927	chr12:38137537	C/T	cg26384229	chr12:38710491	ALG10B	0.89	7.92	0.58	1.14e-12	Bladder cancer;
TGCT	cis	rs12900413	0.603	rs12907030	chr15:90301439	C/T	cg24249390	chr15:90295951	MESP1	-0.3	-5.2	-0.42	8.04e-7	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs7681440	0.904	rs28777703	chr4:90769924	A/G	cg26578617	chr4:90757533	SNCA	0.46	4.74	0.39	5.65e-6	Dementia with Lewy bodies;
TGCT	cis	rs35146811	0.700	rs2950520	chr7:99827148	T/C	cg13334819	chr7:99746414	C7orf59	0.74	6.42	0.5	2.64e-9	Coronary artery disease;
TGCT	trans	rs2727020	0.521	rs11040408	chr11:49534880	A/T	cg11707556	chr5:10655725	ANKRD33B	0.39	8.0	0.58	7.44e-13	Coronary artery disease;
TGCT	cis	rs17001868	0.568	rs9607701	chr22:40739116	A/G	cg07138101	chr22:40742427	ADSL	0.73	5.38	0.44	3.57e-7	Mammographic density (dense area);
TGCT	cis	rs9926296	0.712	rs258332	chr16:89727683	G/A	cg01097406	chr16:89675127	NA	0.36	6.25	0.49	6.05e-9	Vitiligo;
TGCT	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg22920501	chr2:26401640	FAM59B	-0.73	-6.44	-0.5	2.35e-9	Gut microbiome composition (summer);
TGCT	cis	rs4242434	0.672	rs4615566	chr8:22520682	T/C	cg21658235	chr8:22456391	C8orf58	-0.42	-4.46	-0.37	1.84e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs28595532	0.702	rs56217716	chr4:119338490	T/G	cg21605333	chr4:119757512	SEC24D	0.87	5.49	0.44	2.14e-7	Cannabis dependence symptom count;
TGCT	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg21862992	chr11:68658383	NA	-0.36	-4.75	-0.39	5.42e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9611565	0.729	rs137831	chr22:41903813	A/C	cg06634786	chr22:41940651	POLR3H	-0.79	-7.51	-0.56	1.01e-11	Vitiligo;
TGCT	cis	rs2050392	0.767	rs2183175	chr10:30699336	A/G	cg13289132	chr10:30722225	MAP3K8	0.44	5.42	0.44	2.96e-7	Inflammatory bowel disease;
TGCT	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg13342137	chr4:2252803	MXD4	0.17	4.65	0.39	8.28e-6	Obesity-related traits;
TGCT	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg11890956	chr21:40555474	PSMG1	1.1	12.36	0.74	2.27e-23	Cognitive function;
TGCT	cis	rs2749592	0.588	rs2505192	chr10:38395023	G/A	cg25427524	chr10:38739819	LOC399744	-0.4	-6.97	-0.53	1.62e-10	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs634534	0.561	rs14157	chr11:65769780	T/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.65	6.42	0.5	2.59e-9	Sum eosinophil basophil counts;Eosinophil counts;
TGCT	cis	rs6840360	0.615	rs28659854	chr4:152607442	T/C	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.15	-0.48	9.82e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	16.1	0.82	3.69e-32	Prudent dietary pattern;
TGCT	cis	rs7027203	0.790	rs10123836	chr9:96584109	G/T	cg14598338	chr9:96623480	NA	-0.61	-9.56	-0.65	1.43e-16	DNA methylation (variation);
TGCT	cis	rs7027203	0.557	rs9299411	chr9:96523104	C/A	cg14598338	chr9:96623480	NA	-0.49	-7.04	-0.53	1.18e-10	DNA methylation (variation);
TGCT	cis	rs56176327	0.583	rs7613603	chr3:49812866	C/T	cg05785598	chr3:49045655	WDR6	-0.42	-5.24	-0.43	6.67e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs11252926	0.537	rs4554800	chr10:458477	G/T	cg13477178	chr10:375248	DIP2C	0.24	4.73	0.39	5.9e-6	Psychosis in Alzheimer's disease;
TGCT	cis	rs6840360	0.593	rs1429558	chr4:152685406	A/T	cg22705602	chr4:152727874	NA	-0.35	-5.94	-0.47	2.63e-8	Intelligence (multi-trait analysis);
TGCT	trans	rs10506458	0.915	rs12426017	chr12:63396272	T/G	cg22491629	chr6:157744540	C6orf35	-0.99	-8.55	-0.61	3.94e-14	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs7267979	0.932	rs1541061	chr20:25521057	G/A	cg03522245	chr20:25566470	NINL	0.6	6.46	0.5	2.14e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11105298	0.891	rs11105318	chr12:89926658	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.73	-5.59	-0.45	1.39e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	trans	rs7615952	0.932	rs3811679	chr3:125648283	A/G	cg07211511	chr3:129823064	LOC729375	-0.47	-7.55	-0.56	8.34e-12	Blood pressure (smoking interaction);
TGCT	cis	rs6964587	1.000	rs416	chr7:91580571	A/G	cg17063962	chr7:91808500	NA	-0.91	-9.99	-0.67	1.32e-17	Breast cancer;
TGCT	cis	rs17270561	0.723	rs12192635	chr6:25880907	A/T	cg17042849	chr6:26104293	HIST1H4C	-0.8	-5.87	-0.47	3.66e-8	Iron status biomarkers;
TGCT	cis	rs7833790	0.724	rs6473309	chr8:82707880	A/G	cg17211192	chr8:82754475	SNX16	-0.95	-8.78	-0.62	1.09e-14	Diastolic blood pressure;
TGCT	cis	rs28595532	1.000	rs115004746	chr4:119642137	C/T	cg11846333	chr4:119757529	SEC24D	0.92	4.6	0.38	1.02e-5	Cannabis dependence symptom count;
TGCT	cis	rs11235843	0.602	rs7106773	chr11:73383174	C/G	cg18195628	chr11:73498948	MRPL48	-0.64	-4.52	-0.38	1.42e-5	Hand grip strength;
TGCT	cis	rs6500602	0.964	rs13335685	chr16:4469284	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.31	5.17	0.42	9.12e-7	Schizophrenia;
TGCT	cis	rs950169	1.000	rs1911155	chr15:84787635	A/G	cg17173187	chr15:85201210	NMB	0.51	5.6	0.45	1.3e-7	Schizophrenia;
TGCT	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg23758822	chr17:41437982	NA	0.69	6.37	0.5	3.34e-9	Menopause (age at onset);
TGCT	cis	rs4144743	0.941	rs10438782	chr17:45323892	G/A	cg18085866	chr17:45331354	ITGB3	-0.72	-4.8	-0.4	4.39e-6	Body mass index;
TGCT	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.71	0.39	6.53e-6	Prudent dietary pattern;
TGCT	cis	rs72634258	0.554	rs12092614	chr1:7865710	C/T	cg26816564	chr1:7831052	VAMP3	0.87	6.44	0.5	2.34e-9	Inflammatory bowel disease;
TGCT	cis	rs6089584	0.546	rs6061978	chr20:60615604	C/T	cg13770153	chr20:60521292	NA	-0.4	-4.95	-0.41	2.38e-6	Body mass index;
TGCT	cis	rs9467711	0.516	rs1177441	chr6:25859413	A/G	cg03264133	chr6:25882463	NA	-0.67	-4.47	-0.37	1.76e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg10802521	chr3:52805072	NEK4	-0.71	-8.79	-0.62	1.04e-14	Bipolar disorder;
TGCT	cis	rs12478296	1.000	rs55777943	chr2:243040686	T/C	cg06360820	chr2:242988706	NA	-0.81	-5.39	-0.44	3.36e-7	Obesity-related traits;
TGCT	cis	rs896854	0.846	rs13254283	chr8:95914103	G/T	cg09323728	chr8:95962352	TP53INP1	-0.49	-6.33	-0.49	4.07e-9	Type 2 diabetes;
TGCT	cis	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg08045932	chr20:61659980	NA	0.48	9.16	0.64	1.36e-15	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs977747	0.872	rs4926725	chr1:47679366	A/T	cg03885399	chr1:47691550	TAL1	-0.4	-5.15	-0.42	1e-6	Body mass index;
TGCT	cis	rs933688	1.000	rs6866191	chr5:90746852	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.04	8.8	0.62	9.68e-15	Smoking behavior;
TGCT	cis	rs10949834	0.838	rs1091811	chr7:73491212	A/G	cg07137043	chr7:73588983	EIF4H	0.63	4.61	0.38	1e-5	Verbal memory performance (residualized delayed recall change);
TGCT	cis	rs12188164	1.000	rs55842567	chr5:437586	G/A	cg21144161	chr5:423903	AHRR	0.26	4.94	0.41	2.49e-6	Cystic fibrosis severity;
TGCT	cis	rs1018836	0.632	rs2879361	chr8:91481909	C/T	cg16814680	chr8:91681699	NA	0.79	8.31	0.6	1.43e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg01341218	chr17:43662625	NA	1.09	9.23	0.64	9.27e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs78487399	0.908	rs72868625	chr2:43831186	G/C	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.66	4.67	0.39	7.66e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs892961	0.932	rs67719929	chr17:75412605	G/A	cg05865280	chr17:75406074	SEPT9	0.28	6.86	0.52	2.9e-10	Airflow obstruction;
TGCT	cis	rs832540	1.000	rs832540	chr5:56199202	G/A	cg24531977	chr5:56204891	C5orf35	-0.54	-5.57	-0.45	1.53e-7	Coronary artery disease;
TGCT	cis	rs6500602	0.727	rs1477123	chr16:4560627	T/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.42	6.15	0.48	9.72e-9	Schizophrenia;
TGCT	cis	rs12497850	0.865	rs13072911	chr3:48962128	T/G	cg07636037	chr3:49044803	WDR6	0.94	10.39	0.68	1.46e-18	Parkinson's disease;
TGCT	cis	rs6582630	0.502	rs7312212	chr12:38274760	T/G	cg26384229	chr12:38710491	ALG10B	0.84	7.29	0.55	3.2e-11	Drug-induced liver injury (flucloxacillin);
TGCT	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg22433210	chr17:43662623	NA	-1.0	-7.13	-0.54	7.26e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs9638182	0.725	rs35695283	chr7:72893403	A/G	cg14087351	chr7:73037990	MLXIPL	-0.61	-4.81	-0.4	4.34e-6	Triglycerides;
TGCT	cis	rs9457247	1.000	rs400063	chr6:167386592	C/T	cg23791538	chr6:167370224	RNASET2	-0.5	-4.98	-0.41	2.08e-6	Crohn's disease;
TGCT	cis	rs968451	1.000	rs11703434	chr22:39698915	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.87	7.8	0.57	2.23e-12	Primary biliary cholangitis;
TGCT	cis	rs3862260	0.509	rs12076924	chr1:120165826	C/T	cg16322792	chr1:120165303	ZNF697	0.36	8.35	0.6	1.15e-13	Systemic lupus erythematosus;
TGCT	cis	rs854765	0.693	rs35451946	chr17:17764061	C/G	cg09796270	chr17:17721594	SREBF1	-0.24	-4.78	-0.39	4.77e-6	Total body bone mineral density;
TGCT	cis	rs9486715	0.867	rs9384585	chr6:96875664	C/T	cg18709589	chr6:96969512	KIAA0776	0.79	7.77	0.57	2.5e-12	Headache;
TGCT	cis	rs6545883	0.894	rs6760075	chr2:61612881	C/A	cg15711740	chr2:61764176	XPO1	0.55	4.94	0.41	2.52e-6	Tuberculosis;
TGCT	cis	rs3008870	0.959	rs2985816	chr1:67387750	G/T	cg11518657	chr1:67396239	MIER1	0.52	4.53	0.38	1.39e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs7647973	1.000	rs3870341	chr3:49584745	A/G	cg07636037	chr3:49044803	WDR6	0.61	5.0	0.41	1.95e-6	Menarche (age at onset);
TGCT	cis	rs7772486	0.558	rs2142978	chr6:146012061	T/C	cg05347473	chr6:146136440	FBXO30	-0.65	-6.11	-0.48	1.17e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3858526	0.796	rs9645652	chr11:5944264	C/T	cg13902645	chr11:5959945	NA	-0.44	-4.61	-0.38	9.67e-6	DNA methylation (variation);
TGCT	cis	rs4366490	0.687	rs1939751	chr11:62910269	C/T	cg21002970	chr11:62369079	MTA2	0.71	5.03	0.41	1.66e-6	Conotruncal heart defects;
TGCT	cis	rs2932538	0.846	rs7546203	chr1:113154529	C/A	cg22162597	chr1:113214053	CAPZA1	0.27	5.98	0.47	2.24e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs1158570	0.564	rs2791343	chr8:131316030	C/T	cg16277922	chr8:131349729	ASAP1	-0.47	-6.61	-0.51	1.04e-9	Platelet count;
TGCT	cis	rs9443645	0.901	rs2050660	chr6:79734726	C/T	cg09184832	chr6:79620586	NA	-0.48	-5.34	-0.43	4.21e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg27121462	chr16:89883253	FANCA	0.83	9.13	0.63	1.57e-15	Vitiligo;
TGCT	cis	rs7829975	1.000	rs7829975	chr8:8548117	T/A	cg15556689	chr8:8085844	FLJ10661	-0.73	-6.5	-0.5	1.73e-9	Mood instability;
TGCT	cis	rs12220238	1.000	rs10824114	chr10:75970503	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.78	0.57	2.42e-12	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs7098414	0.511	rs4934134	chr10:82160582	C/T	cg00277334	chr10:82204260	NA	-0.38	-4.98	-0.41	2.08e-6	Post bronchodilator FEV1;
TGCT	cis	rs10504229	1.000	rs73591706	chr8:58195633	C/T	cg22535103	chr8:58192502	C8orf71	-0.39	-4.62	-0.38	9.61e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6582630	0.615	rs11182380	chr12:38511735	G/T	cg26384229	chr12:38710491	ALG10B	-0.54	-4.79	-0.4	4.57e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs7666738	0.830	rs10034330	chr4:99064849	G/A	cg17366294	chr4:99064904	C4orf37	0.73	7.45	0.56	1.37e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10028773	0.600	rs4001390	chr4:120265783	G/C	cg09307838	chr4:120376055	NA	0.56	5.5	0.44	2.08e-7	Educational attainment;
TGCT	cis	rs80282103	0.867	rs7075830	chr10:1091650	G/C	cg08668510	chr10:1095578	IDI1	1.17	4.75	0.39	5.44e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7637230	0.541	rs2449493	chr3:101454514	A/T	cg12932813	chr3:101280753	RG9MTD1	1.26	7.51	0.56	9.95e-12	Psoriasis vulgaris;Psoriasis;
TGCT	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg06634786	chr22:41940651	POLR3H	0.89	8.4	0.6	8.56e-14	Vitiligo;
TGCT	cis	rs733175	0.857	rs3796838	chr4:10011030	C/T	cg00071950	chr4:10020882	SLC2A9	0.54	4.54	0.38	1.3e-5	Psychosis and Alzheimer's disease;
TGCT	cis	rs9911578	0.967	rs7222789	chr17:56819853	C/G	cg05425664	chr17:57184151	TRIM37	-0.63	-6.26	-0.49	5.86e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs9952991	0.622	rs547268	chr18:12823056	G/T	cg23544223	chr18:12777786	NA	0.53	4.68	0.39	7.25e-6	Inflammatory skin disease;
TGCT	cis	rs4253772	0.550	rs6008613	chr22:46707924	G/T	cg24881330	chr22:46731750	TRMU	1.04	5.41	0.44	3.12e-7	LDL cholesterol;Cholesterol, total;
TGCT	trans	rs531864	0.570	rs486153	chr2:169682966	T/C	cg16341836	chr10:90641389	STAMBPL1	-0.29	-7.15	-0.54	6.5e-11	Mitochondrial DNA levels;
TGCT	cis	rs4285028	0.747	rs1463736	chr3:121400725	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.92	-7.3	-0.55	3.03e-11	Multiple sclerosis;
TGCT	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg03303774	chr4:1407052	NA	0.29	4.77	0.39	4.98e-6	Obesity-related traits;
TGCT	cis	rs4975616	0.869	rs421284	chr5:1325590	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.3	-4.6	-0.38	1.04e-5	Lung cancer;
TGCT	cis	rs12422267	0.536	rs12423631	chr12:132606886	C/T	cg09764611	chr12:132620959	NA	-0.38	-5.52	-0.44	1.9e-7	Plasma amyloid beta peptide concentrations (ABx-40);
TGCT	cis	rs68170813	0.559	rs1548523	chr7:106944408	G/A	cg02696742	chr7:106810147	HBP1	-0.69	-5.81	-0.46	4.85e-8	Coronary artery disease;
TGCT	cis	rs911555	0.723	rs11160751	chr14:103925740	T/C	cg12935359	chr14:103987150	CKB	-0.32	-4.47	-0.37	1.73e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg05872129	chr22:39784769	NA	-0.96	-10.82	-0.7	1.29e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs7617480	0.648	rs6806356	chr3:48727636	G/A	cg07636037	chr3:49044803	WDR6	0.77	6.32	0.49	4.38e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.7	7.16	0.54	6.11e-11	Menarche (age at onset);
TGCT	cis	rs372883	0.648	rs2832296	chr21:30741454	C/T	cg24692254	chr21:30365293	RNF160	-0.49	-4.49	-0.37	1.58e-5	Pancreatic cancer;
TGCT	cis	rs433598	0.765	rs163265	chr16:20661809	A/G	cg08248577	chr16:19727447	IQCK;C16orf88	-0.22	-5.07	-0.41	1.42e-6	Schizophrenia;
TGCT	cis	rs7255045	0.752	rs2418568	chr19:12987881	A/G	cg06537894	chr19:12978706	MAST1	-0.49	-4.47	-0.37	1.73e-5	Mean corpuscular volume;
TGCT	cis	rs9549367	0.713	rs3024756	chr13:113822950	G/C	cg18105134	chr13:113819100	PROZ	-0.48	-8.35	-0.6	1.13e-13	Platelet distribution width;
TGCT	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg08280861	chr8:58055591	NA	0.39	4.76	0.39	5.35e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9341808	0.754	rs3812126	chr6:80952701	A/G	cg08355045	chr6:80787529	NA	-0.29	-5.03	-0.41	1.71e-6	Sitting height ratio;
TGCT	cis	rs3617	0.559	rs11915546	chr3:52866845	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.48	-4.53	-0.38	1.35e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1023500	0.551	rs133371	chr22:42465574	G/A	cg05082376	chr22:42548792	NA	-0.22	-5.41	-0.44	3.18e-7	Schizophrenia;
TGCT	cis	rs9325144	0.505	rs901635	chr12:38646572	A/C	cg26384229	chr12:38710491	ALG10B	-0.72	-7.04	-0.53	1.19e-10	Morning vs. evening chronotype;
TGCT	cis	rs877282	0.853	rs11593836	chr10:756715	G/A	cg17470449	chr10:769945	NA	0.32	4.91	0.4	2.76e-6	Uric acid levels;
TGCT	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	8.55	0.61	3.84e-14	Platelet count;
TGCT	cis	rs13242816	1.000	rs35538349	chr7:116117896	C/T	cg16553024	chr7:116138462	CAV2	-0.45	-4.81	-0.4	4.32e-6	P wave duration;
TGCT	cis	rs7829975	0.501	rs74345345	chr8:8578435	C/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-4.49	-0.37	1.62e-5	Mood instability;
TGCT	cis	rs7904368	0.901	rs7923189	chr10:16850214	C/T	cg23933602	chr10:16859644	RSU1	0.64	4.88	0.4	3.24e-6	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
TGCT	cis	rs4319547	0.656	rs7975747	chr12:122816995	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.59	-4.5	-0.37	1.57e-5	Body mass index;
TGCT	cis	rs9389248	0.708	rs7750574	chr6:135350932	G/C	cg24558204	chr6:135376177	HBS1L	0.48	4.97	0.41	2.22e-6	High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg11494091	chr17:61959527	GH2	0.61	14.43	0.79	2.59e-28	Prudent dietary pattern;
TGCT	cis	rs9325144	0.624	rs10506126	chr12:39123244	G/A	cg13010199	chr12:38710504	ALG10B	-0.52	-4.68	-0.39	7.48e-6	Morning vs. evening chronotype;
TGCT	cis	rs2066819	1.000	rs116849218	chr12:56683975	C/T	cg26714650	chr12:56694279	CS	-1.36	-6.06	-0.48	1.54e-8	Psoriasis vulgaris;
TGCT	cis	rs17376456	0.825	rs10038828	chr5:93124056	C/T	cg21475434	chr5:93447410	FAM172A	0.63	4.77	0.39	5.03e-6	Diabetic retinopathy;
TGCT	trans	rs17471911	0.529	rs79483496	chr10:100782911	C/T	cg03484267	chr2:207988651	KLF7	-0.52	-6.7	-0.52	6.49e-10	Neuroticism;
TGCT	cis	rs4455778	0.659	rs2364009	chr7:49030673	T/G	cg26309511	chr7:48887640	NA	0.44	5.22	0.42	7.26e-7	Lung cancer in never smokers;
TGCT	cis	rs7973719	0.833	rs7962563	chr12:7353514	G/A	cg07052231	chr12:7363540	PEX5	0.36	5.6	0.45	1.31e-7	IgG glycosylation;
TGCT	cis	rs11190604	1.000	rs9420785	chr10:102240451	C/G	cg16342193	chr10:102329863	NA	-0.39	-5.17	-0.42	9.29e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9357506	0.967	rs9395176	chr6:46318000	T/C	cg21115430	chr6:46460003	NA	-0.23	-4.52	-0.38	1.4e-5	Body mass index;
TGCT	cis	rs3784262	0.669	rs2197092	chr15:58247781	C/T	cg12031962	chr15:58353849	ALDH1A2	0.44	6.32	0.49	4.39e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs1008375	0.646	rs13145480	chr4:17565143	T/C	cg10189774	chr4:17578691	LAP3	-0.58	-4.94	-0.41	2.52e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs826838	1.000	rs11610522	chr12:38687575	C/T	cg26384229	chr12:38710491	ALG10B	1.12	11.32	0.71	7.88e-21	Heart rate;
TGCT	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg04546413	chr19:29218101	NA	0.84	6.82	0.52	3.52e-10	Methadone dose in opioid dependence;
TGCT	cis	rs7819412	0.608	rs28417109	chr8:10975081	T/A	cg03192020	chr8:11204681	TDH	-0.51	-4.6	-0.38	1.02e-5	Triglycerides;
TGCT	cis	rs9534288	0.797	rs4942467	chr13:46599817	A/C	cg15192986	chr13:46630673	CPB2	-0.52	-7.53	-0.56	9.22e-12	Blood protein levels;
TGCT	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	7.24	0.55	4.17e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.06	6.75	0.52	5.03e-10	Gut microbiome composition (summer);
TGCT	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg02725872	chr8:58115012	NA	-0.39	-4.83	-0.4	3.9e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg08736216	chr1:53307985	ZYG11A	0.25	4.93	0.41	2.55e-6	Monocyte count;
TGCT	cis	rs1801251	0.778	rs709934	chr2:233733352	A/G	cg08000102	chr2:233561755	GIGYF2	-0.44	-4.53	-0.38	1.39e-5	Coronary artery disease;
TGCT	cis	rs4319547	0.656	rs7294559	chr12:122837564	C/A	cg05707623	chr12:122985044	ZCCHC8	-0.62	-4.89	-0.4	3.06e-6	Body mass index;
TGCT	cis	rs7772486	0.692	rs1577916	chr6:146069789	G/A	cg13319975	chr6:146136371	FBXO30	0.56	4.93	0.4	2.56e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9926296	0.581	rs2108838	chr16:89904426	A/G	cg03388025	chr16:89894329	SPIRE2	0.35	5.21	0.42	7.63e-7	Vitiligo;
TGCT	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	5.45	0.44	2.66e-7	Height;
TGCT	cis	rs4566357	0.615	rs10190621	chr2:227914484	A/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-5.09	-0.42	1.28e-6	Coronary artery disease;
TGCT	cis	rs1568889	0.838	rs10458896	chr11:28057957	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.92	11.35	0.71	6.62e-21	Bipolar disorder;
TGCT	cis	rs10779751	1.000	rs7544489	chr1:11299511	A/G	cg08854313	chr1:11322531	MTOR	-0.94	-10.5	-0.69	7.65e-19	Body mass index;
TGCT	cis	rs7746199	0.668	rs7749305	chr6:27446566	T/C	cg10876282	chr6:28092338	ZSCAN16	0.88	4.52	0.38	1.44e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9990333	0.562	rs75681503	chr3:195822285	G/A	cg14488913	chr3:195402182	SDHAP2	-0.36	-4.6	-0.38	1.03e-5	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);
TGCT	cis	rs1865760	1.000	rs1865760	chr6:25916979	C/T	cg16482183	chr6:26056742	HIST1H1C	0.52	4.6	0.38	1.04e-5	Height;
TGCT	cis	rs12681287	0.547	rs9942823	chr8:87509177	A/G	cg19078186	chr8:87526527	CPNE3	-0.37	-4.57	-0.38	1.15e-5	Caudate activity during reward;
TGCT	cis	rs3806843	0.735	rs801168	chr5:140080298	A/G	cg19875535	chr5:140030758	IK	-0.36	-6.14	-0.48	1.04e-8	Depressive symptoms (multi-trait analysis);
TGCT	trans	rs62103177	0.733	rs62103232	chr18:77635553	G/A	cg05926928	chr17:57297772	GDPD1	1.26	11.72	0.72	8.33e-22	Opioid sensitivity;
TGCT	cis	rs854765	0.547	rs4459604	chr17:17888549	A/G	cg09796270	chr17:17721594	SREBF1	0.26	5.09	0.42	1.3e-6	Total body bone mineral density;
TGCT	cis	rs7614311	0.731	rs3774727	chr3:63977875	A/G	cg22134162	chr3:63841271	THOC7	-0.43	-5.68	-0.45	9.12e-8	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs12142240	0.698	rs1057533	chr1:46815836	C/T	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs7226408	0.843	rs10153358	chr18:34334556	C/T	cg06757138	chr18:34340585	FHOD3	0.3	5.46	0.44	2.52e-7	Obesity-related traits;
TGCT	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg23302884	chr18:44338147	ST8SIA5	-0.4	-4.58	-0.38	1.11e-5	Personality dimensions;
TGCT	cis	rs4499344	0.730	rs2868150	chr19:33098875	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	8.81	0.62	9.52e-15	Mean platelet volume;
TGCT	cis	rs7752195	0.643	rs78252389	chr6:25257530	C/T	cg16898833	chr6:26189333	HIST1H4D	1.17	5.47	0.44	2.34e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs861020	1.000	rs630984	chr1:209982293	C/T	cg05527609	chr1:210001259	C1orf107	0.94	7.82	0.57	1.95e-12	Orofacial clefts;
TGCT	cis	rs7439150	1.000	rs72681208	chr4:155478389	A/T	cg22130008	chr4:155548532	NA	-0.44	-5.59	-0.45	1.36e-7	Fibrinogen levels;
TGCT	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg04414720	chr1:150670196	GOLPH3L	0.39	5.04	0.41	1.58e-6	Tonsillectomy;
TGCT	cis	rs36051895	0.589	rs10491651	chr9:5200060	A/G	cg02405213	chr9:5042618	JAK2	-0.75	-9.84	-0.66	3.08e-17	Pediatric autoimmune diseases;
TGCT	cis	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg18188782	chr20:61659543	NA	0.45	4.94	0.41	2.51e-6	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg25427524	chr10:38739819	LOC399744	-0.39	-8.05	-0.59	5.9e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs4919044	0.808	rs9419763	chr10:94788965	G/A	cg05127821	chr10:94822908	CYP26C1	-0.74	-4.83	-0.4	3.95e-6	Coronary artery disease;
TGCT	cis	rs2997447	0.846	rs3008226	chr1:26394997	A/C	cg19633962	chr1:26362018	EXTL1	-0.68	-4.62	-0.38	9.47e-6	QRS complex (12-leadsum);
TGCT	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg22963979	chr7:1858916	MAD1L1	-0.36	-5.63	-0.45	1.13e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs992157	1.000	rs4791	chr2:219138940	C/T	cg00012203	chr2:219082015	ARPC2	0.77	8.2	0.59	2.56e-13	Colorectal cancer;
TGCT	cis	rs68170813	0.559	rs6951639	chr7:106817639	A/G	cg02696742	chr7:106810147	HBP1	-0.7	-6.05	-0.48	1.59e-8	Coronary artery disease;
TGCT	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg23708337	chr7:1209742	NA	0.45	5.04	0.41	1.62e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg25427524	chr10:38739819	LOC399744	-0.4	-8.23	-0.59	2.17e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs4689388	0.926	rs10937720	chr4:6295451	A/G	cg25554036	chr4:6271136	WFS1	0.53	7.33	0.55	2.58e-11	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs7027203	0.828	rs4743934	chr9:96581893	A/G	cg14598338	chr9:96623480	NA	-0.61	-9.56	-0.65	1.43e-16	DNA methylation (variation);
TGCT	cis	rs736408	0.500	rs2878762	chr3:52919002	T/C	cg11645453	chr3:52864694	ITIH4	0.33	5.71	0.46	7.78e-8	Bipolar disorder;
TGCT	cis	rs6061231	0.544	rs2427314	chr20:60973666	C/T	cg24112000	chr20:60950667	NA	-0.38	-5.09	-0.42	1.27e-6	Colorectal cancer;
TGCT	cis	rs35146811	0.586	rs10267231	chr7:99595480	T/C	cg13334819	chr7:99746414	C7orf59	-0.74	-6.4	-0.5	2.92e-9	Coronary artery disease;
TGCT	cis	rs2839186	0.967	rs9637172	chr21:47685787	T/C	cg13732083	chr21:47605072	C21orf56	0.36	4.57	0.38	1.14e-5	Testicular germ cell tumor;
TGCT	cis	rs7772486	0.875	rs7761033	chr6:146356106	C/T	cg23711669	chr6:146136114	FBXO30	0.89	10.0	0.67	1.25e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7809950	0.862	rs58391518	chr7:107030787	T/C	cg23024343	chr7:107201750	COG5	-0.31	-4.75	-0.39	5.55e-6	Coronary artery disease;
TGCT	cis	rs9859260	0.744	rs3933	chr3:195784997	C/T	cg02975922	chr3:195473998	MUC4	0.26	5.21	0.42	7.57e-7	Mean corpuscular volume;
TGCT	cis	rs8056742	0.818	rs13330480	chr16:85091864	C/G	cg00229868	chr16:85520891	NA	-0.36	-5.18	-0.42	8.52e-7	Amyotrophic lateral sclerosis;
TGCT	cis	rs11148252	0.500	rs342768	chr13:53208882	C/T	cg00495681	chr13:53174319	NA	0.57	5.59	0.45	1.4e-7	Lewy body disease;
TGCT	cis	rs7809950	0.906	rs62483723	chr7:107186358	A/C	cg23024343	chr7:107201750	COG5	-0.35	-5.54	-0.45	1.72e-7	Coronary artery disease;
TGCT	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg13397359	chr6:42928475	GNMT	0.66	5.88	0.47	3.54e-8	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg03351412	chr1:154909251	PMVK	-0.47	-4.59	-0.38	1.09e-5	Prostate cancer;
TGCT	cis	rs1580019	0.844	rs1901202	chr7:32503724	A/T	cg06627557	chr7:32535165	LSM5;AVL9	0.87	8.48	0.61	5.56e-14	Cognitive ability;
TGCT	cis	rs7975161	0.535	rs6539138	chr12:104735928	G/A	cg25273343	chr12:104657179	TXNRD1	-0.34	-4.82	-0.4	4.16e-6	Toenail selenium levels;
TGCT	cis	rs10876993	0.928	rs1678540	chr12:58065002	A/G	cg15848620	chr12:58087721	OS9	-0.72	-5.91	-0.47	3.12e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg20007245	chr22:24372913	LOC391322	0.8	8.81	0.62	9.16e-15	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs11118844	0.744	rs10863656	chr1:221952703	T/A	cg04222084	chr1:221915650	DUSP10	-0.78	-4.66	-0.39	8.03e-6	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
TGCT	cis	rs2594989	0.943	rs9822446	chr3:11420780	C/G	cg00170343	chr3:11313890	ATG7	0.64	4.89	0.4	3.04e-6	Circulating chemerin levels;
TGCT	cis	rs10992471	0.756	rs10992303	chr9:95082804	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.62	-6.31	-0.49	4.5e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs35883536	0.647	rs7535762	chr1:101047534	A/G	cg06223162	chr1:101003688	GPR88	-0.41	-7.64	-0.57	5.04e-12	Monocyte count;
TGCT	trans	rs4957048	0.891	rs11960196	chr5:568857	C/A	cg25482853	chr8:67687455	SGK3	1.1	8.74	0.62	1.34e-14	Ulcerative colitis;
TGCT	cis	rs7027203	0.828	rs4744291	chr9:96598297	A/G	cg14598338	chr9:96623480	NA	-0.61	-9.54	-0.65	1.68e-16	DNA methylation (variation);
TGCT	cis	rs67073037	0.955	rs12620330	chr2:29133688	C/T	cg09522027	chr2:28974177	PPP1CB	0.57	4.49	0.37	1.59e-5	Breast cancer;Breast cancer (estrogen-receptor negative);
TGCT	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg07507251	chr3:52567010	NT5DC2	0.48	6.65	0.51	8.49e-10	Bipolar disorder;
TGCT	cis	rs7172809	0.548	rs11853625	chr15:77505206	C/T	cg22256960	chr15:77711686	NA	-0.48	-4.63	-0.38	9.17e-6	Glucose homeostasis traits;
TGCT	cis	rs7959452	0.535	rs10784771	chr12:69621264	A/G	cg11871910	chr12:69753446	YEATS4	0.62	5.98	0.47	2.24e-8	Blood protein levels;
TGCT	cis	rs826838	1.000	rs11183214	chr12:38692938	C/T	cg13010199	chr12:38710504	ALG10B	0.82	6.65	0.51	8.46e-10	Heart rate;
TGCT	cis	rs3916	1.000	rs1799958	chr12:121176083	G/A	cg21892295	chr12:121157589	UNC119B	-0.23	-4.55	-0.38	1.27e-5	Urinary metabolites (H-NMR features);
TGCT	cis	rs4689388	0.609	rs4688988	chr4:6287456	C/T	cg14416269	chr4:6271139	WFS1	0.49	5.83	0.46	4.55e-8	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs12291225	0.679	rs11023170	chr11:14294909	A/G	cg19336497	chr11:14380999	RRAS2	-0.38	-5.9	-0.47	3.23e-8	Sense of smell;
TGCT	cis	rs7412746	0.611	rs4509581	chr1:150774465	A/G	cg09365446	chr1:150670422	GOLPH3L	0.36	5.19	0.42	8.25e-7	Melanoma;
TGCT	cis	rs3796619	1.000	rs28620427	chr4:1086247	T/G	cg27284194	chr4:1044797	NA	0.46	4.53	0.38	1.36e-5	Recombination rate (males);
TGCT	cis	rs12681288	0.723	rs11784252	chr8:1027964	T/C	cg04851639	chr8:1020857	NA	-0.3	-4.9	-0.4	2.97e-6	Schizophrenia;
TGCT	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg13385521	chr17:29058706	SUZ12P	-0.7	-4.48	-0.37	1.69e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs2486288	0.656	rs11637920	chr15:45550905	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.72	-7.46	-0.56	1.34e-11	Glomerular filtration rate;
TGCT	cis	rs71435601	0.628	rs312985	chr2:21378805	A/G	cg25035485	chr2:21266500	APOB	0.51	4.48	0.37	1.66e-5	Cholesterol, total;
TGCT	cis	rs807669	0.903	rs1780637	chr22:19178250	A/G	cg02655711	chr22:19163373	SLC25A1	0.42	9.92	0.67	1.94e-17	Metabolite levels;
TGCT	cis	rs10851411	0.817	rs1060265	chr15:42824582	T/C	cg23803468	chr15:43513504	EPB42	0.29	5.38	0.44	3.52e-7	Glucose homeostasis traits;
TGCT	cis	rs975752	0.867	rs11817486	chr10:102001771	C/T	cg04750910	chr10:102416409	NA	0.73	4.48	0.37	1.69e-5	Schizophrenia;
TGCT	cis	rs9914988	0.887	rs11080072	chr17:27081160	G/T	cg20469991	chr17:27169893	C17orf63	-0.66	-5.03	-0.41	1.65e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs362296	0.661	rs3121420	chr4:3264210	T/C	cg06533319	chr4:3265114	C4orf44	0.23	4.46	0.37	1.82e-5	Parental longevity (mother's age at death);
TGCT	cis	rs59698941	0.527	rs11742089	chr5:132178930	G/A	cg21474247	chr5:131268130	NA	0.32	5.12	0.42	1.15e-6	Apolipoprotein A-IV levels;
TGCT	cis	rs9300255	0.602	rs941305	chr12:123715266	T/C	cg00376283	chr12:123451042	ABCB9	0.67	5.26	0.43	6.13e-7	Neutrophil percentage of white cells;
TGCT	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg21280719	chr6:42927975	GNMT	-0.38	-4.63	-0.38	9.09e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs9467603	0.592	rs1184498	chr6:25864882	G/C	cg12310025	chr6:25882481	NA	-0.71	-4.56	-0.38	1.19e-5	Intelligence (multi-trait analysis);
TGCT	trans	rs12339966	0.653	rs1489175	chr9:11278380	G/T	cg07173112	chr1:1114698	TTLL10	-0.33	-6.69	-0.51	6.89e-10	Systolic blood pressure;
TGCT	cis	rs9341808	0.718	rs2143887	chr6:80917287	T/C	cg08355045	chr6:80787529	NA	0.32	5.6	0.45	1.29e-7	Sitting height ratio;
TGCT	cis	rs13191362	0.938	rs35211042	chr6:162998703	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.57	4.94	0.41	2.45e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs17221829	0.733	rs10501708	chr11:89394435	T/C	cg02982614	chr11:89391479	FOLH1B	-0.27	-4.66	-0.39	7.89e-6	Anxiety in major depressive disorder;
TGCT	trans	rs1415174	0.916	rs12116920	chr1:87839207	T/C	cg23065576	chr20:25207247	ENTPD6	-0.27	-6.64	-0.51	8.97e-10	Breast cancer;
TGCT	cis	rs9467773	0.869	rs742090	chr6:26415637	A/C	cg24010402	chr6:26660753	ZNF322A	0.23	4.46	0.37	1.84e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs17253792	0.822	rs75897560	chr14:56090965	C/T	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs3806843	0.576	rs246021	chr5:140334504	C/A	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9473924	0.542	rs9473922	chr6:50831792	C/T	cg14470998	chr6:50812995	TFAP2B	1.35	8.39	0.6	9.05e-14	Body mass index;
TGCT	cis	rs713587	0.563	rs2033655	chr2:25101092	C/T	cg01884057	chr2:25150051	NA	0.28	5.19	0.42	8.44e-7	Body mass index in non-asthmatics;
TGCT	cis	rs1056107	0.572	rs10817334	chr9:115164057	G/C	cg02332936	chr9:115140584	NA	-0.26	-4.5	-0.37	1.55e-5	Colorectal cancer;
TGCT	cis	rs10992471	0.528	rs4744133	chr9:95226702	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.51	-4.62	-0.38	9.42e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs868036	0.681	rs4776976	chr15:68103291	C/T	cg05925327	chr15:68127851	NA	-0.5	-4.85	-0.4	3.57e-6	Restless legs syndrome;
TGCT	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	6.11	0.48	1.17e-8	Alzheimer's disease;
TGCT	cis	rs8014204	0.533	rs12889955	chr14:75172999	G/A	cg06637938	chr14:75390232	RPS6KL1	0.61	5.51	0.44	1.98e-7	Caffeine consumption;
TGCT	cis	rs67311347	1.000	rs11914297	chr3:40410070	T/C	cg13409248	chr3:40428643	ENTPD3	0.55	4.49	0.37	1.61e-5	Renal cell carcinoma;
TGCT	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg11890956	chr21:40555474	PSMG1	-0.73	-6.98	-0.53	1.59e-10	Menarche (age at onset);
TGCT	cis	rs1570884	0.516	rs9526580	chr13:50164023	C/G	cg03651054	chr13:50194643	NA	-0.35	-5.72	-0.46	7.45e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
TGCT	cis	rs7666738	0.546	rs11097591	chr4:98910173	G/A	cg05340658	chr4:99064831	C4orf37	0.6	6.62	0.51	9.9e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1371867	0.875	rs1962901	chr8:101326428	A/G	cg06636551	chr8:101224915	SPAG1	-0.42	-5.65	-0.45	1.06e-7	Atrioventricular conduction;
TGCT	cis	rs611744	0.967	rs536860	chr8:109230722	A/C	cg21045802	chr8:109455806	TTC35	0.52	4.72	0.39	6.21e-6	Dupuytren's disease;
TGCT	cis	rs17826219	0.636	rs4055314	chr17:29079769	T/C	cg13385521	chr17:29058706	SUZ12P	0.79	4.8	0.4	4.47e-6	Body mass index;
TGCT	cis	rs61931739	0.500	rs12829125	chr12:34314789	A/G	cg06521331	chr12:34319734	NA	-0.3	-4.45	-0.37	1.87e-5	Morning vs. evening chronotype;
TGCT	cis	rs28595532	0.841	rs115851302	chr4:119776504	C/T	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs8016982	0.674	rs28890880	chr14:81708031	A/G	cg01989461	chr14:81687754	GTF2A1	0.77	7.19	0.54	5.35e-11	Schizophrenia;
TGCT	cis	rs28714278	0.609	rs34513107	chr15:40302425	G/A	cg21830797	chr15:40226279	EIF2AK4	-0.54	-4.88	-0.4	3.19e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs12971120	0.891	rs2278159	chr18:72178161	T/C	cg25817165	chr18:72167213	CNDP2	-0.27	-4.65	-0.39	8.37e-6	Refractive error;
TGCT	cis	rs6909279	0.933	rs9479072	chr6:151890789	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	0.52	4.49	0.37	1.59e-5	Bone mineral density;
TGCT	cis	rs3780378	0.902	rs2381195	chr9:5145887	T/C	cg02405213	chr9:5042618	JAK2	-0.59	-7.64	-0.57	5.06e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg06618935	chr21:46677482	NA	-0.36	-5.71	-0.46	7.76e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs4699052	0.625	rs7695593	chr4:104263783	A/T	cg16532752	chr4:104119610	CENPE	-0.5	-4.92	-0.4	2.71e-6	Testicular germ cell tumor;
TGCT	cis	rs35785195	0.633	rs1035774	chr12:114230856	G/C	cg11070030	chr12:114232702	NA	0.26	4.46	0.37	1.79e-5	Daytime sleep phenotypes;
TGCT	cis	rs6570726	0.764	rs9322028	chr6:145895797	G/T	cg23711669	chr6:146136114	FBXO30	0.86	9.54	0.65	1.64e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs892961	0.932	rs11658267	chr17:75411884	C/T	cg05865280	chr17:75406074	SEPT9	-0.28	-6.76	-0.52	4.82e-10	Airflow obstruction;
TGCT	cis	rs9611565	0.592	rs9611613	chr22:41961831	T/C	cg06481639	chr22:41940642	POLR3H	-0.67	-5.71	-0.46	7.87e-8	Vitiligo;
TGCT	cis	rs9341808	0.718	rs9343971	chr6:80882056	C/T	cg08355045	chr6:80787529	NA	0.32	5.64	0.45	1.11e-7	Sitting height ratio;
TGCT	cis	rs35306767	0.807	rs61831436	chr10:837882	G/A	cg26597838	chr10:835615	NA	0.8	11.79	0.73	5.55e-22	Eosinophil percentage of granulocytes;
TGCT	cis	rs727563	0.638	rs5996058	chr22:42141452	A/G	cg06634786	chr22:41940651	POLR3H	0.88	8.54	0.61	4.05e-14	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg06481639	chr22:41940642	POLR3H	-0.74	-6.74	-0.52	5.38e-10	Vitiligo;
TGCT	cis	rs4366490	0.687	rs1944040	chr11:62902984	C/T	cg21002970	chr11:62369079	MTA2	0.74	5.2	0.42	7.81e-7	Conotruncal heart defects;
TGCT	cis	rs838147	0.505	rs1688264	chr19:49209560	T/G	cg05248581	chr19:49925731	PTH2	0.41	4.51	0.38	1.5e-5	Dietary macronutrient intake;
TGCT	cis	rs7727544	0.735	rs273914	chr5:131660431	A/T	cg24060327	chr5:131705240	SLC22A5	-0.56	-6.38	-0.5	3.2e-9	Blood metabolite levels;
TGCT	cis	rs2204008	0.527	rs8189480	chr12:38345648	C/T	cg26384229	chr12:38710491	ALG10B	-0.51	-4.48	-0.37	1.68e-5	Bladder cancer;
TGCT	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg20607798	chr8:58055168	NA	0.62	5.19	0.42	8.32e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6121246	0.697	rs7269866	chr20:30232504	G/A	cg18721089	chr20:30220636	NA	-0.53	-5.43	-0.44	2.86e-7	Mean corpuscular hemoglobin;
TGCT	cis	rs986417	0.901	rs10782440	chr14:61031648	G/C	cg27398547	chr14:60952738	C14orf39	1.38	10.8	0.7	1.4e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.5	-6.61	-0.51	1.02e-9	Alzheimer's disease;
TGCT	trans	rs208520	0.690	rs7764570	chr6:66827600	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.91	-9.02	-0.63	2.89e-15	Exhaled nitric oxide output;
TGCT	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg06108461	chr20:60628389	TAF4	-0.69	-10.56	-0.69	5.46e-19	Body mass index;
TGCT	cis	rs7819412	0.618	rs34772085	chr8:10964906	C/T	cg21775007	chr8:11205619	TDH	-0.54	-5.29	-0.43	5.43e-7	Triglycerides;
TGCT	cis	rs2797160	1.000	rs2211420	chr6:125995549	A/G	cg05901451	chr6:126070800	HEY2	-0.74	-6.49	-0.5	1.84e-9	Endometrial cancer;
TGCT	cis	rs36051895	0.530	rs6476951	chr9:5221614	A/G	cg02405213	chr9:5042618	JAK2	-0.69	-8.89	-0.62	5.91e-15	Pediatric autoimmune diseases;
TGCT	cis	rs694739	0.930	rs574087	chr11:64102948	A/G	cg23796481	chr11:64053134	BAD;GPR137	0.7	7.4	0.55	1.76e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg09365446	chr1:150670422	GOLPH3L	0.31	4.64	0.38	8.7e-6	Tonsillectomy;
TGCT	cis	rs8076336	1	rs8076336	chr17:18212614	A/C	cg26763362	chr17:18266135	SHMT1	0.33	4.69	0.39	7.19e-6	Parental longevity (combined parental age at death);
TGCT	cis	rs1538970	0.816	rs11211123	chr1:45957609	G/A	cg05343316	chr1:45956843	TESK2	0.81	6.64	0.51	8.93e-10	Platelet count;
TGCT	cis	rs2239547	0.522	rs2336669	chr3:52994138	C/T	cg11645453	chr3:52864694	ITIH4	-0.32	-5.27	-0.43	5.93e-7	Schizophrenia;
TGCT	cis	rs7829975	0.514	rs2945873	chr8:8260445	C/T	cg06636001	chr8:8085503	FLJ10661	0.71	6.11	0.48	1.16e-8	Mood instability;
TGCT	cis	rs7267979	0.932	rs2387891	chr20:25470328	C/G	cg03522245	chr20:25566470	NINL	0.6	6.46	0.5	2.14e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4953076	0.533	rs1551315	chr2:44407618	G/A	cg00619915	chr2:44497795	NA	-0.22	-5.02	-0.41	1.72e-6	Height;
TGCT	cis	rs5769765	0.955	rs9616367	chr22:50303515	A/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.41	5.84	0.46	4.39e-8	Schizophrenia;
TGCT	cis	rs2224391	1.000	rs9504369	chr6:5261575	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.8	-6.12	-0.48	1.13e-8	Height;
TGCT	cis	rs3820068	0.705	rs41486146	chr1:15900517	A/G	cg05660106	chr1:15850417	CASP9	-1.13	-13.14	-0.76	3.06e-25	Systolic blood pressure;
TGCT	cis	rs2180341	0.960	rs1964130	chr6:127677391	C/G	cg27446573	chr6:127587934	RNF146	1.08	8.81	0.62	9.1e-15	Breast cancer;
TGCT	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg23708337	chr7:1209742	NA	0.44	4.97	0.41	2.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg03934478	chr11:495069	RNH1	0.35	5.82	0.46	4.66e-8	Body mass index;
TGCT	cis	rs4455778	0.580	rs4598208	chr7:49084584	G/A	cg26309511	chr7:48887640	NA	0.5	6.47	0.5	2.03e-9	Lung cancer in never smokers;
TGCT	cis	rs2243480	0.908	rs313822	chr7:65573939	G/A	cg20637647	chr7:64974828	NA	0.84	4.85	0.4	3.63e-6	Diabetic kidney disease;
TGCT	cis	rs3008870	1.000	rs11208979	chr1:67442275	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.1	-11.8	-0.73	5.15e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs6089829	0.962	rs2314131	chr20:61665225	A/G	cg08045932	chr20:61659980	NA	0.37	5.66	0.45	9.97e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1975974	0.748	rs67473406	chr17:21726745	G/A	cg18423549	chr17:21743878	NA	-0.55	-5.0	-0.41	1.93e-6	Psoriasis;
TGCT	cis	rs11190604	0.666	rs7084768	chr10:102200497	T/C	cg16342193	chr10:102329863	NA	0.4	5.05	0.41	1.56e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	7.12	0.54	7.55e-11	Platelet count;
TGCT	cis	rs6570726	0.791	rs398408	chr6:145801020	G/A	cg05347473	chr6:146136440	FBXO30	0.51	4.72	0.39	6.14e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9467711	0.606	rs9379854	chr6:26362854	T/C	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	trans	rs561341	0.710	rs9900031	chr17:30199537	T/C	cg20587970	chr11:113659929	NA	0.83	8.7	0.62	1.71e-14	Hip circumference adjusted for BMI;
TGCT	cis	rs9911578	0.967	rs6503893	chr17:57149695	G/A	cg12560992	chr17:57184187	TRIM37	0.79	9.71	0.66	6.56e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs79349575	0.783	rs12603969	chr17:47034419	A/G	cg27201301	chr17:47039149	GIP	0.25	4.47	0.37	1.72e-5	Type 2 diabetes;
TGCT	cis	rs11718455	0.960	rs6781618	chr3:44001933	C/T	cg08738300	chr3:44038990	NA	0.85	6.41	0.5	2.72e-9	Coronary artery disease;
TGCT	cis	rs11711311	1.000	rs12636577	chr3:113497507	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.76	-7.16	-0.54	6.29e-11	IgG glycosylation;
TGCT	cis	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg25660036	chr4:7070649	GRPEL1	-0.67	-5.81	-0.46	4.85e-8	Monocyte percentage of white cells;
TGCT	cis	rs8067545	1.000	rs4925065	chr17:19914546	C/T	cg13482628	chr17:19912719	NA	0.55	4.79	0.4	4.69e-6	Schizophrenia;
TGCT	cis	rs17473412	1.000	rs17407759	chr5:122697295	C/G	cg15125798	chr5:122621645	NA	-0.57	-5.13	-0.42	1.08e-6	Total body bone mineral density;
TGCT	cis	rs3784262	0.528	rs8027188	chr15:58334799	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.44	-6.48	-0.5	1.99e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs4906332	0.966	rs2065016	chr14:103879656	T/A	cg26031613	chr14:104095156	KLC1	-0.51	-4.63	-0.38	9.17e-6	Coronary artery disease;
TGCT	cis	rs4803468	1.000	rs3816037	chr19:41918009	C/T	cg09537434	chr19:41945824	ATP5SL	-0.91	-10.9	-0.7	8.11e-20	Height;
TGCT	cis	rs2147959	1.000	rs2147959	chr1:228644232	A/T	cg22700015	chr1:228743131	NA	-0.57	-4.5	-0.37	1.55e-5	Adult asthma;
TGCT	cis	rs10170846	0.800	rs10180462	chr2:223526385	C/T	cg25565276	chr2:223520875	FARSB	0.55	4.58	0.38	1.11e-5	Schizophrenia (inflammation and infection response interaction);
TGCT	cis	rs4953076	0.573	rs920519	chr2:44452344	T/C	cg00619915	chr2:44497795	NA	-0.23	-5.08	-0.41	1.36e-6	Height;
TGCT	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.84	7.5	0.56	1.08e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6840360	0.615	rs12641438	chr4:152607586	A/G	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.13	-0.48	1.1e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg12379764	chr21:47803548	PCNT	-0.48	-4.64	-0.38	8.75e-6	Testicular germ cell tumor;
TGCT	cis	rs62244186	0.535	rs59726036	chr3:44850074	G/T	cg02073558	chr3:44770973	ZNF501	0.72	7.07	0.54	1.02e-10	Depressive symptoms;
TGCT	cis	rs3733585	0.631	rs4697925	chr4:10124330	G/C	cg00071950	chr4:10020882	SLC2A9	-0.49	-5.05	-0.41	1.53e-6	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs35306767	0.903	rs12249634	chr10:872744	G/A	cg26597838	chr10:835615	NA	0.71	10.12	0.67	6.47e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs4076764	1.000	rs7540279	chr1:163429970	A/T	cg24596788	chr1:163392923	NA	-0.17	-4.75	-0.39	5.46e-6	Motion sickness;
TGCT	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg08219700	chr8:58056026	NA	0.38	4.69	0.39	6.95e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7647973	0.807	rs4955416	chr3:49108428	T/C	cg05785598	chr3:49045655	WDR6	0.39	4.5	0.37	1.56e-5	Menarche (age at onset);
TGCT	cis	rs889312	0.500	rs832585	chr5:56125904	T/C	cg24531977	chr5:56204891	C5orf35	-0.52	-5.39	-0.44	3.44e-7	Breast cancer;Breast cancer (early onset);
TGCT	trans	rs4650994	0.544	rs2811311	chr1:178617337	A/G	cg05059571	chr16:84539110	KIAA1609	0.51	9.84	0.66	3.04e-17	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs7017914	0.902	rs10504481	chr8:71699517	T/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-4.94	-0.41	2.52e-6	Bone mineral density;
TGCT	cis	rs7439150	0.954	rs60309797	chr4:155477548	G/A	cg22130008	chr4:155548532	NA	-0.43	-5.43	-0.44	2.87e-7	Fibrinogen levels;
TGCT	cis	rs6424115	1.000	rs7519554	chr1:24154566	T/A	cg15997130	chr1:24165203	NA	-0.92	-10.57	-0.69	5.26e-19	Immature fraction of reticulocytes;
TGCT	cis	rs10779751	0.734	rs910660	chr1:11130643	C/T	cg08854313	chr1:11322531	MTOR	-0.82	-7.04	-0.53	1.19e-10	Body mass index;
TGCT	cis	rs4319547	0.614	rs10846764	chr12:122874297	T/C	cg08088222	chr12:122070432	ORAI1	-0.25	-4.49	-0.37	1.58e-5	Body mass index;
TGCT	cis	rs7582180	0.606	rs12618908	chr2:100947026	A/T	cg08017756	chr2:100939284	LONRF2	-0.3	-4.87	-0.4	3.27e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6695640	0.854	rs2800699	chr1:17733136	C/T	cg25979543	chr1:17888104	ARHGEF10L	-0.25	-4.5	-0.37	1.54e-5	Mean platelet volume;
TGCT	cis	rs4911259	0.552	rs6057663	chr20:31463071	G/T	cg13636640	chr20:31349939	DNMT3B	-0.89	-9.83	-0.66	3.33e-17	Inflammatory bowel disease;
TGCT	cis	rs42648	0.837	rs7786771	chr7:89924767	G/A	cg25739043	chr7:89950458	NA	-0.71	-7.17	-0.54	5.81e-11	Homocysteine levels;
TGCT	cis	rs9443645	0.901	rs9352666	chr6:79572184	C/G	cg05283184	chr6:79620031	NA	-0.22	-4.98	-0.41	2.11e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4523957	0.651	rs9894613	chr17:2071058	C/T	cg16513277	chr17:2031491	SMG6	-0.2	-4.64	-0.38	8.83e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs2797780	0.704	rs16889902	chr6:37516378	C/T	cg00985040	chr6:37553208	NA	0.27	4.63	0.38	9.07e-6	Systemic lupus erythematosus;
TGCT	cis	rs7586879	0.598	rs6545806	chr2:25124348	G/A	cg01884057	chr2:25150051	NA	0.35	6.9	0.53	2.39e-10	Body mass index;
TGCT	cis	rs7104764	1.000	rs2272565	chr11:244414	C/T	cg18336825	chr11:236787	PSMD13;SIRT3	1.07	11.19	0.71	1.61e-20	Menarche (age at onset);
TGCT	cis	rs3820068	0.603	rs72645887	chr1:15929905	G/C	cg05660106	chr1:15850417	CASP9	0.82	8.02	0.58	6.63e-13	Systolic blood pressure;
TGCT	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg20203395	chr5:56204925	C5orf35	-0.61	-5.25	-0.43	6.32e-7	Type 2 diabetes;
TGCT	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg07217954	chr7:1067459	C7orf50	0.48	4.81	0.4	4.26e-6	Bronchopulmonary dysplasia;
TGCT	cis	rs11098499	0.865	rs3956464	chr4:120256764	T/C	cg09307838	chr4:120376055	NA	0.63	6.07	0.48	1.44e-8	Corneal astigmatism;
TGCT	cis	rs1497406	0.744	rs6677710	chr1:16507618	A/G	cg20430773	chr1:16534157	ARHGEF19	0.51	5.86	0.47	3.93e-8	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6543140	0.865	rs6760275	chr2:103079607	C/T	cg09003973	chr2:102972529	NA	0.55	4.56	0.38	1.2e-5	Blood protein levels;
TGCT	cis	rs7635838	0.586	rs347617	chr3:11278211	C/T	cg00170343	chr3:11313890	ATG7	0.62	6.09	0.48	1.28e-8	HDL cholesterol;
TGCT	cis	rs6988636	1.000	rs16898084	chr8:124190377	A/T	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs9467711	1.000	rs34569761	chr6:26334306	A/G	cg02458000	chr6:26745757	NA	-1.1	-6.09	-0.48	1.29e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs319204	1.000	rs167635	chr5:146260896	T/C	cg13983063	chr5:146258615	PPP2R2B	0.33	4.77	0.39	5.05e-6	Schizophrenia;
TGCT	cis	rs9291683	0.588	rs13133766	chr4:10019732	C/T	cg11266682	chr4:10021025	SLC2A9	0.73	10.98	0.7	5.33e-20	Bone mineral density;
TGCT	cis	rs4727027	0.727	rs3801980	chr7:148878620	T/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.13	0.42	1.09e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.46	0.56	1.3e-11	Prudent dietary pattern;
TGCT	cis	rs4713118	0.824	rs9468223	chr6:27740666	C/T	cg02458000	chr6:26745757	NA	-0.57	-4.97	-0.41	2.18e-6	Parkinson's disease;
TGCT	cis	rs4242434	0.672	rs900267	chr8:22485258	T/C	cg03733263	chr8:22462867	KIAA1967	0.98	13.14	0.76	2.97e-25	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs137699	0.695	rs137653	chr22:39732171	A/G	cg05872129	chr22:39784769	NA	0.58	4.88	0.4	3.25e-6	IgG glycosylation;
TGCT	cis	rs10791097	0.694	rs7107595	chr11:130758556	C/T	cg05962950	chr11:130786565	SNX19	0.91	11.83	0.73	4.55e-22	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs66573146	1.000	rs55913461	chr4:7017509	C/T	cg05069807	chr4:6945702	TBC1D14	0.37	5.2	0.42	8.07e-7	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs1129187	0.935	rs9462859	chr6:42946943	G/A	cg05552183	chr6:42928497	GNMT	0.54	4.68	0.39	7.25e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs7086627	0.515	rs10887901	chr10:82210581	G/A	cg01528321	chr10:82214614	TSPAN14	0.65	6.21	0.49	7.21e-9	Post bronchodilator FEV1;
TGCT	cis	rs7937682	0.921	rs11213945	chr11:111461003	A/G	cg09085632	chr11:111637200	PPP2R1B	0.88	7.27	0.55	3.56e-11	Primary sclerosing cholangitis;
TGCT	cis	rs782590	0.522	rs12329050	chr2:55894428	G/A	cg03859395	chr2:55845619	SMEK2	-0.66	-6.39	-0.5	3.05e-9	Metabolic syndrome;
TGCT	cis	rs6088580	0.634	rs4911420	chr20:32998654	A/G	cg08999081	chr20:33150536	PIGU	-0.28	-5.58	-0.45	1.47e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs546131	0.890	rs496558	chr11:34826425	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.66	5.95	0.47	2.59e-8	Lung disease severity in cystic fibrosis;
TGCT	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	5.73	0.46	7.29e-8	Height;
TGCT	cis	rs13191362	1.000	rs35583420	chr6:163214327	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.76	4.78	0.39	4.85e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs6906287	0.647	rs11153752	chr6:118834771	A/T	cg21191810	chr6:118973309	C6orf204	0.26	4.49	0.37	1.58e-5	Electrocardiographic conduction measures;
TGCT	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7926906	1.000	rs2177680	chr11:90532256	A/T	cg26138821	chr11:89956704	CHORDC1	-0.5	-5.33	-0.43	4.44e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2235642	0.859	rs9927529	chr16:1619488	C/T	cg07639376	chr16:1584516	IFT140;TMEM204	-0.33	-5.53	-0.44	1.84e-7	Coronary artery disease;
TGCT	cis	rs12049351	0.774	rs6670553	chr1:229635867	A/G	cg12130225	chr1:229698885	NA	0.39	4.59	0.38	1.06e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs601339	1.000	rs509548	chr12:123181855	T/A	cg11919336	chr12:123188078	GPR109A	0.64	7.82	0.57	2.01e-12	Adiponectin levels;
TGCT	cis	rs6674176	0.597	rs4660262	chr1:44382524	G/A	cg13606994	chr1:44402422	ARTN	-0.51	-5.52	-0.44	1.91e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs651907	0.541	rs2925325	chr3:101630668	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.5	4.86	0.4	3.54e-6	Colorectal cancer;
TGCT	trans	rs9951602	0.573	rs8098953	chr18:76648734	A/G	cg02800362	chr5:177631904	HNRNPAB	1.15	13.03	0.76	5.64e-25	Obesity-related traits;
TGCT	cis	rs3766606	0.505	rs67002863	chr1:7923478	G/A	cg26816564	chr1:7831052	VAMP3	0.68	5.22	0.42	7.18e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg17971929	chr21:40555470	PSMG1	0.96	9.01	0.63	3.05e-15	Cognitive function;
TGCT	cis	rs6964587	1.000	rs9784993	chr7:91672403	G/A	cg22709100	chr7:91322751	NA	0.28	4.56	0.38	1.19e-5	Breast cancer;
TGCT	cis	rs7119	0.634	rs2682922	chr15:77865006	A/C	cg27398640	chr15:77910606	LINGO1	0.25	4.63	0.38	9.12e-6	Type 2 diabetes;
TGCT	trans	rs11722228	0.508	rs3796826	chr4:10092728	G/A	cg26043149	chr18:55253948	FECH	1.16	11.23	0.71	1.26e-20	Gout;Urate levels;Serum uric acid levels;
TGCT	trans	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg21659725	chr3:3221576	CRBN	-0.76	-9.03	-0.63	2.74e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs748404	0.660	rs689767	chr15:43722077	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	4.75	0.39	5.51e-6	Lung cancer;
TGCT	cis	rs7258465	1.000	rs4808133	chr19:18608518	C/A	cg06462663	chr19:18546047	ISYNA1	0.2	4.67	0.39	7.74e-6	Breast cancer;
TGCT	cis	rs2274459	0.500	rs12206173	chr6:33601671	G/C	cg11783815	chr6:33558433	C6orf227	0.33	4.63	0.38	8.95e-6	Obesity (extreme);
TGCT	cis	rs7178572	0.568	rs7175674	chr15:77670910	C/T	cg15453836	chr15:77711506	NA	-0.42	-4.78	-0.39	4.92e-6	Type 2 diabetes;
TGCT	cis	rs4253772	0.550	rs9615949	chr22:46722531	C/T	cg24881330	chr22:46731750	TRMU	0.99	5.45	0.44	2.64e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs7666738	0.830	rs13138438	chr4:99050545	C/A	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2797160	1.000	rs1739375	chr6:126012013	T/C	cg05901451	chr6:126070800	HEY2	0.72	5.91	0.47	3.15e-8	Endometrial cancer;
TGCT	cis	rs7474896	0.583	rs34185758	chr10:37990854	T/C	cg13720705	chr10:37990370	NA	0.4	5.69	0.46	8.61e-8	Obesity (extreme);
TGCT	cis	rs7567389	0.626	rs11683344	chr2:127956252	A/C	cg09760422	chr2:128146352	NA	0.36	4.63	0.38	8.95e-6	Self-rated health;
TGCT	cis	rs12681287	0.608	rs1135451	chr8:87483608	T/C	cg27223183	chr8:87520930	FAM82B	-0.89	-6.41	-0.5	2.8e-9	Caudate activity during reward;
TGCT	cis	rs7043114	0.525	rs2025388	chr9:95128740	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-5.56	-0.45	1.58e-7	Height;
TGCT	cis	rs9916302	0.904	rs588193	chr17:37440439	A/C	cg07936489	chr17:37558343	FBXL20	0.62	4.91	0.4	2.85e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs6545883	0.783	rs7579651	chr2:61800279	C/G	cg15711740	chr2:61764176	XPO1	-0.59	-5.7	-0.46	8.42e-8	Tuberculosis;
TGCT	cis	rs854765	0.583	rs11078404	chr17:17820487	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.74	7.69	0.57	3.91e-12	Total body bone mineral density;
TGCT	cis	rs4523957	0.651	rs9908373	chr17:2086534	G/A	cg16513277	chr17:2031491	SMG6	-0.21	-4.62	-0.38	9.43e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs7267979	0.966	rs6083855	chr20:25405118	A/G	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11167764	0.895	rs13189044	chr5:141471431	A/C	cg23435118	chr5:141488016	NDFIP1	-0.28	-4.63	-0.38	9.14e-6	Crohn's disease;
TGCT	cis	rs6693567	0.545	rs2012751	chr1:150438266	T/C	cg09579323	chr1:150459698	TARS2	0.52	4.62	0.38	9.55e-6	Migraine;
TGCT	cis	rs79387448	0.655	rs76930359	chr2:102924684	G/A	cg09003973	chr2:102972529	NA	1.34	8.26	0.6	1.89e-13	Gut microbiota (bacterial taxa);
TGCT	cis	rs7635838	0.684	rs2606750	chr3:11372151	T/C	cg00170343	chr3:11313890	ATG7	0.6	5.86	0.47	3.86e-8	HDL cholesterol;
TGCT	cis	rs4808199	0.947	rs10404728	chr19:19595014	C/T	cg03709012	chr19:19516395	GATAD2A	0.97	7.53	0.56	9.28e-12	Nonalcoholic fatty liver disease;
TGCT	cis	rs4689388	0.926	rs4416547	chr4:6293967	G/A	cg00701064	chr4:6280414	WFS1	0.37	4.72	0.39	6.3e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs7017914	0.905	rs3098881	chr8:71939690	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-4.97	-0.41	2.16e-6	Bone mineral density;
TGCT	cis	rs12791968	1.000	rs11038240	chr11:45002878	A/G	cg11846598	chr11:44996168	LOC221122	0.35	6.83	0.52	3.43e-10	Inhibitory control;
TGCT	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.6	-8.51	-0.61	4.69e-14	Longevity;Endometriosis;
TGCT	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg04267008	chr7:1944627	MAD1L1	-0.37	-4.85	-0.4	3.56e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs6089829	0.926	rs73921625	chr20:61660891	C/T	cg08045932	chr20:61659980	NA	-0.31	-4.47	-0.37	1.76e-5	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2153535	0.580	rs7748455	chr6:8453625	C/T	cg07606381	chr6:8435919	SLC35B3	0.53	5.02	0.41	1.79e-6	Motion sickness;
TGCT	cis	rs137699	1.000	rs5757632	chr22:39756097	A/C	cg24399712	chr22:39784796	NA	-0.67	-5.99	-0.47	2.08e-8	IgG glycosylation;
TGCT	cis	rs1153858	1.000	rs61365925	chr15:45650311	T/C	cg26924012	chr15:45694286	SPATA5L1	1.09	15.16	0.81	5.15e-30	Homoarginine levels;
TGCT	cis	rs56036086	0.887	rs11912419	chr22:50627188	C/T	cg01548456	chr22:50352384	NA	0.36	5.15	0.42	9.84e-7	Platelet count;Plateletcrit;
TGCT	cis	rs7412746	0.658	rs7521719	chr1:150913134	G/A	cg04414720	chr1:150670196	GOLPH3L	0.37	4.46	0.37	1.81e-5	Melanoma;
TGCT	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg06481639	chr22:41940642	POLR3H	-0.75	-6.8	-0.52	3.92e-10	Vitiligo;
TGCT	cis	rs17253792	0.822	rs75049893	chr14:56089158	A/G	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs7119038	0.818	rs73003215	chr11:118649512	G/A	cg19308663	chr11:118741387	NA	0.27	5.51	0.44	2.02e-7	Sjögren's syndrome;
TGCT	cis	rs3096299	0.781	rs2965819	chr16:89501030	G/T	cg06640241	chr16:89574553	SPG7	-0.72	-7.89	-0.58	1.36e-12	Multiple myeloma (IgH translocation);
TGCT	cis	rs4727027	0.769	rs10952797	chr7:148816722	A/T	cg23583168	chr7:148888333	NA	-0.72	-9.17	-0.64	1.3e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs2302464	1.000	rs16892276	chr4:15728237	T/G	cg18497811	chr4:14860861	NA	-0.49	-4.5	-0.37	1.57e-5	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs6088580	0.619	rs1205335	chr20:32927507	C/T	cg08999081	chr20:33150536	PIGU	-0.25	-4.85	-0.4	3.66e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs478304	0.654	rs12289836	chr11:65436888	C/T	cg27068330	chr11:65405492	SIPA1	1.02	11.5	0.72	2.89e-21	Acne (severe);
TGCT	cis	rs7959452	0.590	rs6581889	chr12:69757429	T/C	cg20891283	chr12:69753455	YEATS4	0.83	8.61	0.61	2.8e-14	Blood protein levels;
TGCT	cis	rs2456568	0.771	rs2102333	chr11:93634749	G/A	cg16099599	chr11:93583650	C11orf90	-0.4	-4.98	-0.41	2.04e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs4499344	0.633	rs259229	chr19:33134425	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.84	-9.18	-0.64	1.2e-15	Mean platelet volume;
TGCT	cis	rs7804356	0.705	rs10250223	chr7:26821320	C/A	cg03456212	chr7:26904342	SKAP2	-0.54	-4.46	-0.37	1.82e-5	Type 1 diabetes;
TGCT	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg02953382	chr22:24373134	LOC391322	-0.78	-8.12	-0.59	4.06e-13	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7211079	0.879	rs66693363	chr17:78128935	G/A	cg09238746	chr17:78121135	EIF4A3	-0.72	-5.9	-0.47	3.18e-8	Myocardial infarction;
TGCT	cis	rs67073037	0.955	rs4389288	chr2:29140711	G/A	cg09522027	chr2:28974177	PPP1CB	0.57	4.49	0.37	1.59e-5	Breast cancer;Breast cancer (estrogen-receptor negative);
TGCT	cis	rs1670533	1.000	rs6821725	chr4:1060360	C/G	cg20887711	chr4:1340912	KIAA1530	0.65	5.07	0.41	1.38e-6	Recombination rate (females);
TGCT	cis	rs4285028	0.948	rs13089878	chr3:121703895	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.77	-6.5	-0.5	1.78e-9	Multiple sclerosis;
TGCT	cis	rs11190604	1.000	rs10883500	chr10:102238324	T/G	cg23241863	chr10:102295624	HIF1AN	0.63	4.95	0.41	2.41e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg13695892	chr22:41940480	POLR3H	-0.9	-9.01	-0.63	3.17e-15	Vitiligo;
TGCT	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs67311347	1.000	rs56992941	chr3:40472434	A/T	cg13683864	chr3:40499215	RPL14	-1.04	-10.79	-0.7	1.54e-19	Renal cell carcinoma;
TGCT	cis	rs2019216	0.500	rs1877497	chr17:21940171	C/T	cg22648282	chr17:21454238	C17orf51	-0.58	-4.95	-0.41	2.37e-6	Pelvic organ prolapse;
TGCT	cis	rs78707713	0.560	rs12784882	chr10:71230334	C/G	cg12610070	chr10:71211762	TSPAN15	-0.62	-7.31	-0.55	2.83e-11	Venous thromboembolism;
TGCT	cis	rs4689592	0.587	rs6825954	chr4:7074226	T/C	cg25660036	chr4:7070649	GRPEL1	-0.64	-5.44	-0.44	2.77e-7	Monocyte percentage of white cells;
TGCT	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg25767906	chr1:53392781	SCP2	-0.57	-6.81	-0.52	3.8e-10	Monocyte count;
TGCT	cis	rs7937682	0.575	rs12808601	chr11:111776066	G/A	cg09085632	chr11:111637200	PPP2R1B	0.97	10.03	0.67	1.06e-17	Primary sclerosing cholangitis;
TGCT	cis	rs9913156	0.793	rs55884013	chr17:4579301	G/A	cg19197139	chr17:4613644	ARRB2	0.87	7.5	0.56	1.09e-11	Lymphocyte counts;
TGCT	cis	rs4076764	0.958	rs12022261	chr1:163398422	A/G	cg24596788	chr1:163392923	NA	-0.17	-4.74	-0.39	5.85e-6	Motion sickness;
TGCT	cis	rs11190604	1.000	rs4919469	chr10:102298855	C/A	cg23241863	chr10:102295624	HIF1AN	0.69	5.1	0.42	1.24e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs854765	0.583	rs12603148	chr17:17865257	C/T	cg09796270	chr17:17721594	SREBF1	0.23	4.56	0.38	1.22e-5	Total body bone mineral density;
TGCT	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg26338869	chr17:61819248	STRADA	0.53	4.94	0.41	2.48e-6	Prudent dietary pattern;
TGCT	cis	rs2120019	0.935	rs34913788	chr15:75372617	A/C	cg09165964	chr15:75287851	SCAMP5	-1.07	-8.58	-0.61	3.34e-14	Blood trace element (Zn levels);
TGCT	trans	rs7726839	0.574	rs72705017	chr5:623733	G/A	cg11887960	chr12:57824829	NA	1.19	9.29	0.64	6.45e-16	Obesity-related traits;
TGCT	cis	rs4072705	0.614	rs1570581	chr9:127234059	A/G	cg13476313	chr9:127244764	NR5A1	0.29	4.47	0.37	1.72e-5	Menarche (age at onset);
TGCT	cis	rs13256369	0.802	rs13281933	chr8:8562665	C/A	cg17143192	chr8:8559678	CLDN23	0.56	5.31	0.43	4.9e-7	Obesity-related traits;
TGCT	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg24503407	chr1:205819492	PM20D1	0.59	8.22	0.59	2.3e-13	Menarche (age at onset);
TGCT	trans	rs7819412	0.811	rs2409691	chr8:10943276	C/T	cg15556689	chr8:8085844	FLJ10661	-0.77	-7.44	-0.56	1.45e-11	Triglycerides;
TGCT	cis	rs13217239	0.646	rs62401067	chr6:27018101	T/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.41	4.57	0.38	1.14e-5	Schizophrenia;
TGCT	cis	rs17826219	0.636	rs2449770	chr17:29101064	G/T	cg13385521	chr17:29058706	SUZ12P	0.82	4.86	0.4	3.52e-6	Body mass index;
TGCT	cis	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg20362242	chr5:692897	TPPP	0.5	4.57	0.38	1.17e-5	Obesity-related traits;
TGCT	cis	rs12497850	0.764	rs6784111	chr3:49178846	T/C	cg18654377	chr3:49208889	KLHDC8B	-0.38	-4.81	-0.4	4.25e-6	Parkinson's disease;
TGCT	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg20887711	chr4:1340912	KIAA1530	0.92	8.35	0.6	1.13e-13	Longevity;
TGCT	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg07747251	chr5:1868357	NA	0.39	5.75	0.46	6.7e-8	Cardiovascular disease risk factors;
TGCT	cis	rs7666738	0.791	rs34088022	chr4:99001508	G/T	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg13206674	chr6:150067644	NUP43	0.51	4.45	0.37	1.91e-5	Lung cancer;
TGCT	cis	rs4808199	0.895	rs10403731	chr19:19469296	G/A	cg03709012	chr19:19516395	GATAD2A	0.84	6.72	0.52	5.97e-10	Nonalcoholic fatty liver disease;
TGCT	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg08859206	chr1:53392774	SCP2	0.34	4.82	0.4	4.1e-6	Monocyte count;
TGCT	cis	rs8036030	0.604	rs11856835	chr15:74716174	G/A	cg10253484	chr15:75165896	SCAMP2	-0.59	-5.3	-0.43	5.18e-7	Airflow obstruction;
TGCT	trans	rs10953454	1.000	rs17777379	chr7:104491000	G/A	cg04208666	chr6:19734707	NA	-0.57	-6.89	-0.53	2.52e-10	Obesity;
TGCT	cis	rs858239	0.601	rs11984129	chr7:23152677	A/G	cg05602783	chr7:23145260	KLHL7	-0.62	-5.24	-0.43	6.55e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs17253792	0.822	rs10133962	chr14:56066088	G/A	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs5769765	0.954	rs5769762	chr22:50264042	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	1.11	11.76	0.73	6.5e-22	Schizophrenia;
TGCT	cis	rs2692947	0.644	rs1168968	chr2:96825363	C/T	cg22654517	chr2:96458247	NA	0.24	5.08	0.41	1.36e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs4499344	0.730	rs369859	chr19:33104305	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	8.81	0.62	9.52e-15	Mean platelet volume;
TGCT	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg08280861	chr8:58055591	NA	0.55	6.12	0.48	1.13e-8	Developmental language disorder (linguistic errors);
TGCT	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg12963246	chr6:28129442	ZNF389	0.52	5.04	0.41	1.61e-6	Depression;
TGCT	cis	rs7940866	0.801	rs10894296	chr11:130840433	T/G	cg12179176	chr11:130786555	SNX19	0.62	5.93	0.47	2.75e-8	Schizophrenia;
TGCT	cis	rs2243480	1.000	rs160655	chr7:65533214	T/C	cg20637647	chr7:64974828	NA	0.95	5.8	0.46	5.3e-8	Diabetic kidney disease;
TGCT	cis	rs35160687	0.865	rs10189492	chr2:86478902	G/A	cg04877910	chr2:85804641	VAMP8	0.34	4.48	0.37	1.67e-5	Night sleep phenotypes;
TGCT	cis	rs4285028	0.948	rs34543553	chr3:121675637	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.77	-6.55	-0.51	1.35e-9	Multiple sclerosis;
TGCT	cis	rs2180341	0.521	rs12203812	chr6:127617816	A/T	cg24812749	chr6:127587940	RNF146	0.61	5.16	0.42	9.54e-7	Breast cancer;
TGCT	cis	rs7833790	0.724	rs6473311	chr8:82726682	G/A	cg27398817	chr8:82754497	SNX16	-0.67	-5.34	-0.43	4.27e-7	Diastolic blood pressure;
TGCT	cis	rs9549367	0.577	rs3024711	chr13:113813268	A/G	cg18105134	chr13:113819100	PROZ	-0.46	-7.31	-0.55	2.85e-11	Platelet distribution width;
TGCT	cis	rs2153535	0.580	rs9505458	chr6:8479215	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs2066819	1.000	rs41363748	chr12:56696056	C/T	cg26714650	chr12:56694279	CS	1.36	6.06	0.48	1.54e-8	Psoriasis vulgaris;
TGCT	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg21724239	chr8:58056113	NA	0.39	5.25	0.43	6.46e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs1801251	0.656	rs10211596	chr2:233699415	C/T	cg08000102	chr2:233561755	GIGYF2	-0.59	-6.75	-0.52	5.08e-10	Coronary artery disease;
TGCT	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs4148883	0.689	rs2851275	chr4:100024883	A/G	cg12011299	chr4:100065546	ADH4	0.37	5.69	0.45	8.77e-8	Alcohol dependence;
TGCT	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg06618935	chr21:46677482	NA	-0.37	-5.56	-0.45	1.58e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs57994353	0.600	rs10870172	chr9:139319469	G/A	cg13741927	chr9:139327495	INPP5E	-0.26	-5.73	-0.46	7.13e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs7027203	0.797	rs57882762	chr9:96580825	T/G	cg13679303	chr9:96623674	NA	-0.66	-10.49	-0.69	8e-19	DNA methylation (variation);
TGCT	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg03188948	chr7:1209495	NA	0.71	6.04	0.48	1.68e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs10089	0.953	rs1432614	chr5:127416919	A/G	cg19767477	chr5:127420684	SLC12A2	-0.46	-4.74	-0.39	5.77e-6	Ileal carcinoids;
TGCT	cis	rs9527	0.614	rs2153774	chr10:104881035	T/C	cg04362960	chr10:104952993	NT5C2	0.7	5.88	0.47	3.57e-8	Arsenic metabolism;
TGCT	cis	rs7267979	1.000	rs6050561	chr20:25334855	C/T	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9611519	0.780	rs5751072	chr22:41656509	C/T	cg13695892	chr22:41940480	POLR3H	-0.65	-6.22	-0.49	7.03e-9	Neuroticism;
TGCT	cis	rs2075371	0.966	rs722657	chr7:133994956	T/C	cg11752832	chr7:134001865	SLC35B4	0.7	6.44	0.5	2.41e-9	Mean platelet volume;
TGCT	cis	rs10465746	0.935	rs6687372	chr1:84447634	C/T	cg10977910	chr1:84465055	TTLL7	0.63	6.23	0.49	6.49e-9	Obesity-related traits;
TGCT	cis	rs6988636	0.710	rs73339626	chr8:124142757	A/G	cg23067535	chr8:124195133	FAM83A	-0.38	-4.8	-0.4	4.53e-6	Urinary uromodulin levels;
TGCT	trans	rs66573146	0.831	rs66645969	chr4:6985614	G/A	cg07817883	chr1:32538562	TMEM39B	1.42	7.53	0.56	8.92e-12	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.61	0.38	9.85e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs651907	0.557	rs2318090	chr3:101474933	A/G	cg12386194	chr3:101231763	SENP7	0.49	4.69	0.39	7.17e-6	Colorectal cancer;
TGCT	cis	rs2887571	0.505	rs34085684	chr12:1637686	C/T	cg01940102	chr12:1095972	NA	0.26	4.78	0.39	4.92e-6	Bone mineral density;
TGCT	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg13395646	chr4:1353034	KIAA1530	-0.4	-5.0	-0.41	1.93e-6	Obesity-related traits;
TGCT	cis	rs904251	0.523	rs2797799	chr6:37483620	T/G	cg08126542	chr6:37504118	NA	-0.42	-6.17	-0.48	8.77e-9	Cognitive performance;
TGCT	cis	rs6835098	0.500	rs13112928	chr4:174158132	A/G	cg08422745	chr4:174089978	GALNT7	0.59	5.57	0.45	1.47e-7	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs954108	0.809	rs947248	chr13:29369553	G/T	cg11788234	chr13:29393811	NA	-0.37	-4.48	-0.37	1.68e-5	Obesity-related traits;
TGCT	cis	rs60871478	0.588	rs56205589	chr7:910419	G/A	cg00475322	chr7:917719	C7orf20	0.52	5.04	0.41	1.58e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs763121	0.776	rs4820346	chr22:39125074	C/G	cg06022373	chr22:39101656	GTPBP1	-0.61	-5.61	-0.45	1.26e-7	Menopause (age at onset);
TGCT	cis	rs651907	0.557	rs2318090	chr3:101474933	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.33	-6.69	-0.51	7.01e-10	Colorectal cancer;
TGCT	cis	rs35306767	0.761	rs11253557	chr10:1043667	C/T	cg20503657	chr10:835505	NA	0.61	6.78	0.52	4.27e-10	Eosinophil percentage of granulocytes;
TGCT	cis	rs7772486	0.777	rs1546966	chr6:146386018	G/T	cg23711669	chr6:146136114	FBXO30	0.66	5.96	0.47	2.46e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7666738	0.830	rs6833822	chr4:98951354	G/A	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9868809	0.505	rs11706203	chr3:48746239	T/A	cg00383909	chr3:49044727	WDR6	1.06	6.28	0.49	5.26e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs7542091	0.704	rs2142907	chr1:210039505	T/C	cg21951975	chr1:209979733	IRF6	0.61	6.19	0.49	8.21e-9	Monobrow;
TGCT	cis	rs9894429	0.966	rs6565604	chr17:79589242	G/A	cg21028142	chr17:79581711	NPLOC4	0.29	6.83	0.52	3.44e-10	Eye color traits;
TGCT	cis	rs2120019	1.000	rs60425110	chr15:75333000	T/A	cg17294928	chr15:75287854	SCAMP5	-0.78	-6.12	-0.48	1.14e-8	Blood trace element (Zn levels);
TGCT	cis	rs4563143	0.675	rs55849754	chr19:29279665	G/A	cg04546413	chr19:29218101	NA	0.86	7.0	0.53	1.45e-10	Methadone dose in opioid dependence;
TGCT	cis	rs10197940	0.710	rs4500942	chr2:152334580	A/G	cg19508488	chr2:152266495	RIF1	0.7	6.53	0.51	1.49e-9	Lung cancer;
TGCT	cis	rs7208859	0.673	rs9899943	chr17:29223925	G/A	cg18442181	chr17:29233375	C17orf42	-0.78	-4.61	-0.38	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg24675658	chr1:53192096	ZYG11B	-0.74	-8.18	-0.59	2.88e-13	Monocyte count;
TGCT	cis	rs7945705	0.905	rs2568054	chr11:8876029	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-5.62	-0.45	1.21e-7	Hemoglobin concentration;
TGCT	cis	rs10791097	0.694	rs3190331	chr11:130748131	C/T	cg12179176	chr11:130786555	SNX19	-0.82	-10.0	-0.67	1.29e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs7614311	0.636	rs17344090	chr3:64004101	T/C	cg22134162	chr3:63841271	THOC7	-0.43	-5.53	-0.44	1.79e-7	Lung function (FVC);Lung function (FEV1);
TGCT	trans	rs12038357	1.000	rs6664636	chr1:34966194	A/G	cg06277588	chr6:13489246	GFOD1	0.54	7.06	0.54	1.02e-10	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg03709012	chr19:19516395	GATAD2A	0.75	6.16	0.48	9.21e-9	Tonsillectomy;
TGCT	cis	rs806215	0.950	rs3735644	chr7:127222157	G/A	cg25922125	chr7:127225783	GCC1	-0.61	-6.3	-0.49	4.71e-9	Type 2 diabetes;
TGCT	cis	rs1008375	1.000	rs11737138	chr4:17657986	G/A	cg10189774	chr4:17578691	LAP3	0.57	5.15	0.42	9.95e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1757171	0.542	rs1757186	chr6:37484111	A/G	cg08126542	chr6:37504118	NA	-0.44	-6.47	-0.5	2.04e-9	Cognitive performance;
TGCT	cis	rs7845219	0.544	rs7015841	chr8:95920193	A/C	cg13393036	chr8:95962371	TP53INP1	-0.44	-5.14	-0.42	1.05e-6	Type 2 diabetes;
TGCT	cis	rs9467711	1.000	rs6939978	chr6:26328462	G/C	cg03517284	chr6:25882590	NA	-0.86	-4.67	-0.39	7.69e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs78456975	0.550	rs11904276	chr2:1524006	T/C	cg01028140	chr2:1542097	TPO	-0.33	-4.77	-0.39	5.01e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs7959452	0.535	rs2305641	chr12:69646914	C/T	cg14784868	chr12:69753453	YEATS4	0.69	7.13	0.54	7.26e-11	Blood protein levels;
TGCT	cis	rs778371	0.958	rs2675968	chr2:233736244	A/G	cg08000102	chr2:233561755	GIGYF2	0.59	6.56	0.51	1.29e-9	Schizophrenia;
TGCT	cis	rs4808199	0.901	rs11669516	chr19:19532682	G/A	cg03709012	chr19:19516395	GATAD2A	0.98	7.76	0.57	2.68e-12	Nonalcoholic fatty liver disease;
TGCT	cis	rs12477438	0.520	rs2632283	chr2:99776000	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.75	7.25	0.55	3.92e-11	Chronic sinus infection;
TGCT	cis	rs1420338	0.967	rs10807873	chr7:34171276	C/T	cg01275685	chr7:34179230	BMPER	-0.26	-4.64	-0.38	8.75e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs2204008	0.639	rs7311462	chr12:38278130	G/A	cg13010199	chr12:38710504	ALG10B	0.64	4.97	0.41	2.15e-6	Bladder cancer;
TGCT	cis	rs7246657	0.722	rs958305	chr19:38189440	A/G	cg03611452	chr19:38183253	ZNF781	-0.66	-5.65	-0.45	1.02e-7	Coronary artery calcification;
TGCT	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg22920501	chr2:26401640	FAM59B	-0.73	-6.44	-0.5	2.35e-9	Gut microbiome composition (summer);
TGCT	cis	rs3806843	0.549	rs246012	chr5:140336277	C/T	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs17102423	0.623	rs2093989	chr14:65553939	C/T	cg11161011	chr14:65562177	MAX	-0.5	-6.94	-0.53	1.91e-10	Obesity-related traits;
TGCT	cis	rs7572733	0.515	rs1836234	chr2:198882873	T/G	cg00792783	chr2:198669748	PLCL1	0.59	5.34	0.43	4.33e-7	Dermatomyositis;
TGCT	cis	rs7523273	0.925	rs10863593	chr1:208018074	C/T	cg22525895	chr1:207977042	MIR29B2	0.54	6.5	0.5	1.77e-9	Schizophrenia;
TGCT	cis	rs6678914	1.000	rs12028423	chr1:202187960	C/T	cg08883485	chr1:201619787	NAV1	-0.39	-4.54	-0.38	1.3e-5	Breast cancer (estrogen-receptor negative);Breast cancer;
TGCT	cis	rs6831352	1.000	rs1126670	chr4:100052733	C/A	cg12011299	chr4:100065546	ADH4	0.41	5.2	0.42	8.11e-7	Alcohol dependence;
TGCT	cis	rs8017423	0.967	rs8009493	chr14:90690083	G/C	cg04374321	chr14:90722782	PSMC1	0.77	8.02	0.58	6.73e-13	Mortality in heart failure;
TGCT	cis	rs9381040	0.610	rs9394758	chr6:41017821	C/T	cg03526776	chr6:41159608	TREML2	0.26	5.14	0.42	1.05e-6	Alzheimer's disease (late onset);
TGCT	cis	rs6964587	0.605	rs6956022	chr7:91553199	A/G	cg17063962	chr7:91808500	NA	-0.76	-7.25	-0.55	3.94e-11	Breast cancer;
TGCT	cis	rs7428	0.520	rs7605890	chr2:85559525	A/C	cg24342717	chr2:85555507	TGOLN2	-0.49	-8.34	-0.6	1.23e-13	Ear protrusion;
TGCT	cis	rs6671200	0.915	rs259334	chr1:95739701	C/T	cg20701556	chr1:95698924	RWDD3	-0.69	-5.28	-0.43	5.53e-7	Stearic acid (18:0) levels;
TGCT	cis	rs875971	0.830	rs12673450	chr7:66009220	G/A	cg11764359	chr7:65958608	NA	0.58	5.31	0.43	4.88e-7	Aortic root size;
TGCT	cis	rs2066819	1.000	rs79718165	chr12:56644251	C/T	cg26714650	chr12:56694279	CS	-1.33	-6.24	-0.49	6.46e-9	Psoriasis vulgaris;
TGCT	cis	rs617219	0.726	rs1275105	chr5:78444148	T/C	cg05890484	chr5:78407552	BHMT	0.36	4.94	0.41	2.47e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs829883	0.616	rs249832	chr12:98832387	C/T	cg25150519	chr12:98850993	NA	0.62	7.36	0.55	2.2e-11	Colorectal adenoma (advanced);
TGCT	cis	rs372883	0.600	rs2832295	chr21:30739843	C/T	cg24692254	chr21:30365293	RNF160	0.51	4.6	0.38	1.02e-5	Pancreatic cancer;
TGCT	cis	rs4319547	0.915	rs10734924	chr12:123018894	T/G	cg05707623	chr12:122985044	ZCCHC8	-0.68	-5.34	-0.43	4.19e-7	Body mass index;
TGCT	cis	rs9914988	0.619	rs12451955	chr17:27314224	A/G	cg16968985	chr17:27313254	SEZ6	-0.36	-4.5	-0.37	1.56e-5	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs9381040	0.655	rs9381032	chr6:41044986	A/T	cg03526776	chr6:41159608	TREML2	0.27	5.34	0.43	4.21e-7	Alzheimer's disease (late onset);
TGCT	cis	rs12950390	0.893	rs72831644	chr17:45824391	T/C	cg06532163	chr17:45867833	NA	0.34	5.28	0.43	5.67e-7	IgG glycosylation;
TGCT	cis	rs1577917	0.917	rs1414201	chr6:86500316	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-5.53	-0.44	1.82e-7	Response to antipsychotic treatment;
TGCT	cis	rs7772486	0.790	rs4314514	chr6:146260010	A/G	cg23711669	chr6:146136114	FBXO30	-0.87	-9.9	-0.66	2.24e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs34734847	1.000	rs55730005	chr12:121157536	C/A	cg21892295	chr12:121157589	UNC119B	-0.24	-5.71	-0.46	7.99e-8	Mean corpuscular volume;
TGCT	trans	rs62103177	0.564	rs11874805	chr18:77697110	T/C	cg05926928	chr17:57297772	GDPD1	0.96	8.96	0.63	3.97e-15	Opioid sensitivity;
TGCT	cis	rs4746818	0.711	rs2491024	chr10:70847084	T/C	cg11621586	chr10:70884670	VPS26A	0.9	7.97	0.58	8.66e-13	Left atrial antero-posterior diameter;
TGCT	cis	rs7582180	0.613	rs12988464	chr2:100946285	A/G	cg14675211	chr2:100938903	LONRF2	0.47	4.57	0.38	1.16e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs2895526	0.715	rs7101243	chr10:12691273	C/G	cg18283737	chr10:12085149	UPF2	-0.46	-4.54	-0.38	1.31e-5	Headache;
TGCT	cis	rs10779751	0.734	rs2039840	chr1:11125866	G/A	cg08854313	chr1:11322531	MTOR	0.82	7.04	0.53	1.19e-10	Body mass index;
TGCT	cis	rs10838634	1.000	rs56311746	chr11:46818043	A/T	cg18332754	chr11:46939436	LRP4	0.9	4.59	0.38	1.05e-5	Schizophrenia;
TGCT	cis	rs2739330	0.964	rs2739338	chr22:24297130	T/C	cg10150615	chr22:24372951	LOC391322	-0.97	-12.67	-0.75	4.14e-24	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9653442	0.510	rs12712068	chr2:100764439	A/G	cg22139774	chr2:100720529	AFF3	-0.36	-5.69	-0.45	8.85e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs2840044	1.000	rs9913003	chr17:33893904	C/A	cg05299278	chr17:33885742	SLFN14	-0.23	-5.28	-0.43	5.7e-7	Response to radiotherapy in cancer (late toxicity);
TGCT	cis	rs1783925	1.000	rs640364	chr11:125300766	G/A	cg03464685	chr11:125439445	EI24	-0.55	-4.48	-0.37	1.67e-5	Formal thought disorder in schizophrenia;
TGCT	cis	rs2115630	1.000	rs2879828	chr15:85361977	G/T	cg12501888	chr15:85177176	SCAND2	-0.49	-4.56	-0.38	1.22e-5	P wave terminal force;
TGCT	cis	rs35306767	0.903	rs11253504	chr10:956046	A/G	cg26597838	chr10:835615	NA	0.75	10.39	0.68	1.43e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs9611565	0.694	rs5758411	chr22:42079734	G/A	cg06634786	chr22:41940651	POLR3H	0.82	7.82	0.57	1.92e-12	Vitiligo;
TGCT	cis	rs907683	0.584	rs12621188	chr2:220287892	C/G	cg15015639	chr2:220282977	DES	0.4	5.11	0.42	1.18e-6	Resting heart rate;
TGCT	cis	rs2797160	0.967	rs1954360	chr6:126001064	A/G	cg05901451	chr6:126070800	HEY2	-0.75	-6.51	-0.5	1.69e-9	Endometrial cancer;
TGCT	cis	rs763121	0.651	rs738249	chr22:39037979	T/C	cg06022373	chr22:39101656	GTPBP1	0.77	7.46	0.56	1.35e-11	Menopause (age at onset);
TGCT	cis	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg16624210	chr5:671434	TPPP	-0.4	-4.52	-0.38	1.44e-5	Obesity-related traits;
TGCT	cis	rs6089829	0.962	rs57684920	chr20:61662639	G/A	cg08564027	chr20:61660810	NA	-0.36	-6.44	-0.5	2.42e-9	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg22166914	chr1:53195759	ZYG11B	0.37	5.98	0.47	2.27e-8	Monocyte count;
TGCT	cis	rs904251	0.861	rs2776875	chr6:37486796	G/C	cg25019722	chr6:37503610	NA	-0.5	-6.92	-0.53	2.17e-10	Cognitive performance;
TGCT	trans	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-1.03	-13.16	-0.76	2.65e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs9372498	0.536	rs9489467	chr6:118935206	C/T	cg21191810	chr6:118973309	C6orf204	-0.38	-4.97	-0.41	2.14e-6	Diastolic blood pressure;
TGCT	cis	rs514406	0.584	rs7548832	chr1:53193576	A/T	cg22166914	chr1:53195759	ZYG11B	0.5	9.39	0.64	3.72e-16	Monocyte count;
TGCT	cis	rs9650657	0.644	rs3808603	chr8:10698218	T/C	cg16664915	chr8:10907788	XKR6	-0.28	-4.54	-0.38	1.3e-5	Neuroticism;
TGCT	cis	rs11031096	0.563	rs12281849	chr11:4224832	C/T	cg18678763	chr11:4115507	RRM1	-0.39	-4.91	-0.4	2.82e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs1056107	0.931	rs7048773	chr9:114988668	C/T	cg02332936	chr9:115140584	NA	-0.27	-4.7	-0.39	6.68e-6	Colorectal cancer;
TGCT	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7524258	0.903	rs4908449	chr1:7292700	T/C	cg07173049	chr1:7289937	CAMTA1	0.32	5.31	0.43	4.88e-7	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs17152411	0.895	rs7080475	chr10:126585767	A/G	cg07906193	chr10:126599966	NA	0.41	5.05	0.41	1.52e-6	Height;
TGCT	cis	rs7772486	0.624	rs6930154	chr6:146025662	C/T	cg23711669	chr6:146136114	FBXO30	-0.92	-10.55	-0.69	5.88e-19	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4242434	0.646	rs6988593	chr8:22527440	A/G	cg21658235	chr8:22456391	C8orf58	-0.44	-4.76	-0.39	5.24e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs9325144	0.600	rs7965877	chr12:38743697	G/T	cg26384229	chr12:38710491	ALG10B	0.61	5.61	0.45	1.28e-7	Morning vs. evening chronotype;
TGCT	cis	rs2075371	1.000	rs2598297	chr7:133993001	T/G	cg11752832	chr7:134001865	SLC35B4	0.69	6.26	0.49	5.87e-9	Mean platelet volume;
TGCT	cis	rs853679	0.546	rs200996	chr6:27811828	G/A	cg08798685	chr6:27730294	NA	-0.34	-4.77	-0.39	5.13e-6	Depression;
TGCT	cis	rs2204008	0.720	rs11181343	chr12:38323616	G/T	cg26384229	chr12:38710491	ALG10B	0.83	7.26	0.55	3.76e-11	Bladder cancer;
TGCT	cis	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg22857025	chr5:266934	NA	-0.34	-6.7	-0.52	6.65e-10	Breast cancer;
TGCT	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg04772025	chr11:68637568	NA	0.61	6.75	0.52	4.94e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg04772025	chr11:68637568	NA	0.6	6.78	0.52	4.32e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs28595532	0.765	rs114082534	chr4:119734184	G/A	cg14228332	chr4:119757509	SEC24D	1.32	5.99	0.47	2.14e-8	Cannabis dependence symptom count;
TGCT	cis	rs3733585	0.753	rs1122141	chr4:9947278	T/C	cg11266682	chr4:10021025	SLC2A9	-0.63	-8.66	-0.61	2.16e-14	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs1018836	0.923	rs13259842	chr8:91550819	A/G	cg16814680	chr8:91681699	NA	-0.88	-9.81	-0.66	3.71e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9952991	0.941	rs34920518	chr18:12783086	A/G	cg23544223	chr18:12777786	NA	-0.6	-5.51	-0.44	1.99e-7	Inflammatory skin disease;
TGCT	cis	rs651907	0.535	rs1460097	chr3:101497569	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.86	10.47	0.68	9.24e-19	Colorectal cancer;
TGCT	cis	rs9993613	0.841	rs16848467	chr4:73529442	A/C	cg15102770	chr4:73434591	ADAMTS3	0.5	4.57	0.38	1.18e-5	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs244731	1.000	rs244730	chr5:176539212	A/G	cg06060754	chr5:176797920	RGS14	-0.39	-5.52	-0.44	1.86e-7	Urate levels in lean individuals;
TGCT	cis	rs1008375	1.000	rs56974987	chr4:17627856	G/A	cg16339924	chr4:17578868	LAP3	0.62	5.11	0.42	1.17e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9399137	0.507	rs6904897	chr6:135382980	T/G	cg24558204	chr6:135376177	HBS1L	0.47	4.73	0.39	5.98e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
TGCT	cis	rs3008870	0.727	rs2755270	chr1:67474503	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.81	8.43	0.6	7.53e-14	Lymphocyte percentage of white cells;
TGCT	cis	rs7769051	1.000	rs9493443	chr6:133121349	C/T	cg07930552	chr6:133119739	C6orf192	0.93	5.0	0.41	1.87e-6	Type 2 diabetes nephropathy;
TGCT	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg06481639	chr22:41940642	POLR3H	0.74	6.35	0.5	3.62e-9	Vitiligo;
TGCT	cis	rs453301	0.686	rs10217044	chr8:8894752	A/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-5.57	-0.45	1.49e-7	Joint mobility (Beighton score);
TGCT	cis	rs425277	1.000	rs262670	chr1:2082458	C/T	cg03732007	chr1:2071316	PRKCZ	0.26	5.44	0.44	2.77e-7	Height;
TGCT	cis	rs910187	0.605	rs6018317	chr20:45803236	A/G	cg27589058	chr20:45804311	EYA2	-0.4	-8.92	-0.63	5.1e-15	Migraine;
TGCT	cis	rs10510102	0.872	rs11200293	chr10:123728710	C/T	cg23691251	chr10:123688108	ATE1	-0.59	-4.7	-0.39	6.75e-6	Breast cancer;
TGCT	cis	rs1044826	0.642	rs432387	chr3:139231853	T/G	cg00490450	chr3:139108681	COPB2	-0.51	-4.48	-0.37	1.67e-5	Obesity-related traits;
TGCT	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	5.04	0.41	1.63e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2180341	0.782	rs6912196	chr6:127722732	C/G	cg24812749	chr6:127587940	RNF146	0.65	5.19	0.42	8.37e-7	Breast cancer;
TGCT	cis	rs28595532	0.841	rs114123875	chr4:119733408	A/G	cg14228332	chr4:119757509	SEC24D	1.32	6.38	0.5	3.2e-9	Cannabis dependence symptom count;
TGCT	cis	rs7412746	0.658	rs4970982	chr1:150865084	G/C	cg04414720	chr1:150670196	GOLPH3L	0.37	4.46	0.37	1.81e-5	Melanoma;
TGCT	cis	rs11718455	0.883	rs6795366	chr3:44005735	C/T	cg08738300	chr3:44038990	NA	0.84	6.27	0.49	5.39e-9	Coronary artery disease;
TGCT	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.5	-4.71	-0.39	6.66e-6	Bipolar disorder;
TGCT	cis	rs68170813	0.641	rs75639044	chr7:107092631	A/C	cg02696742	chr7:106810147	HBP1	-0.65	-5.15	-0.42	1.01e-6	Coronary artery disease;
TGCT	cis	rs12118280	0.921	rs61799378	chr1:108742130	T/C	cg11967332	chr1:108735228	SLC25A24	0.39	5.44	0.44	2.74e-7	Myeloid white cell count;
TGCT	cis	rs9303542	0.694	rs4793854	chr17:46572133	A/G	cg25032089	chr17:46643351	HOXB3	-0.52	-5.88	-0.47	3.51e-8	Ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs11025559	0.796	rs11603462	chr11:20412180	C/A	cg19653624	chr11:20408972	PRMT3	-0.64	-5.07	-0.41	1.43e-6	Pursuit maintenance gain;
TGCT	cis	rs6582630	0.560	rs12315134	chr12:38419857	T/A	cg26384229	chr12:38710491	ALG10B	-0.54	-4.81	-0.4	4.32e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs1215050	0.791	rs7434393	chr4:98768576	T/C	cg17366294	chr4:99064904	C4orf37	0.52	5.59	0.45	1.4e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg05368731	chr17:41323189	NBR1	1.2	14.48	0.79	1.98e-28	Menopause (age at onset);
TGCT	cis	rs3096299	0.632	rs8051537	chr16:89544384	T/A	cg02187348	chr16:89574699	SPG7	0.61	6.67	0.51	7.56e-10	Multiple myeloma (IgH translocation);
TGCT	cis	rs9393777	0.778	rs35608615	chr6:27040402	G/C	cg16898833	chr6:26189333	HIST1H4D	1.0	5.74	0.46	6.81e-8	Intelligence (multi-trait analysis);
TGCT	trans	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.88	9.92	0.67	1.95e-17	Intelligence (multi-trait analysis);
TGCT	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg22433210	chr17:43662623	NA	0.99	7.14	0.54	7.1e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs10031466	0.967	rs12647135	chr4:189011174	A/C	cg14506195	chr4:188913931	NA	0.27	5.11	0.42	1.18e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs250677	1.000	rs36079	chr5:148430504	G/A	cg18129178	chr5:148520854	ABLIM3	-0.42	-6.46	-0.5	2.15e-9	Breast cancer;
TGCT	cis	rs9807841	0.643	rs4435370	chr19:10774623	G/A	cg17848348	chr19:10766748	ILF3	-0.4	-4.58	-0.38	1.12e-5	Inflammatory skin disease;
TGCT	cis	rs7474896	0.583	rs4934898	chr10:37990395	G/C	cg25427524	chr10:38739819	LOC399744	-0.3	-4.53	-0.38	1.36e-5	Obesity (extreme);
TGCT	cis	rs2153535	0.542	rs6912740	chr6:8439959	A/G	cg07606381	chr6:8435919	SLC35B3	0.57	5.25	0.43	6.46e-7	Motion sickness;
TGCT	cis	rs7829975	0.623	rs10087493	chr8:8373557	A/G	cg15556689	chr8:8085844	FLJ10661	-0.73	-7.14	-0.54	6.83e-11	Mood instability;
TGCT	cis	rs921968	0.643	rs520095	chr2:219329485	C/T	cg02176678	chr2:219576539	TTLL4	0.37	5.45	0.44	2.58e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs2439831	0.850	rs3097773	chr15:43893072	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.8	-5.17	-0.42	8.98e-7	Lung cancer in ever smokers;
TGCT	cis	rs35146811	0.735	rs1636975	chr7:99812089	A/G	cg13334819	chr7:99746414	C7orf59	0.74	6.31	0.49	4.4e-9	Coronary artery disease;
TGCT	cis	rs17443541	0.507	rs13020883	chr2:200447031	C/A	cg00055341	chr2:200446845	NA	0.38	4.6	0.38	1.02e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs9972944	0.756	rs6504343	chr17:63755458	C/T	cg07283582	chr17:63770753	CCDC46	-0.26	-5.07	-0.41	1.39e-6	Total body bone mineral density;
TGCT	cis	rs2882877	0.648	rs11680808	chr2:190376493	A/G	cg10752008	chr2:190445175	SLC40A1	0.61	4.48	0.37	1.68e-5	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs2880765	0.835	rs4344688	chr15:86043007	A/C	cg13263323	chr15:86062960	AKAP13	-0.23	-4.82	-0.4	4.1e-6	Coronary artery disease;
TGCT	cis	rs939574	0.790	rs72955447	chr2:220098287	G/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.04	4.8	0.4	4.54e-6	Platelet distribution width;
TGCT	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg17345569	chr6:42928274	GNMT	-0.47	-4.85	-0.4	3.69e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs12681288	0.862	rs2600493	chr8:1024970	A/G	cg08872321	chr8:1308229	NA	-0.25	-4.64	-0.38	8.71e-6	Schizophrenia;
TGCT	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg08859206	chr1:53392774	SCP2	0.47	7.42	0.55	1.58e-11	Monocyte count;
TGCT	cis	rs6754311	0.731	rs13404551	chr2:136721995	T/C	cg07169764	chr2:136633963	MCM6	0.63	5.88	0.47	3.57e-8	Mosquito bite size;
TGCT	cis	rs2948294	0.524	rs13270062	chr8:8112650	C/A	cg15462221	chr8:8086144	FLJ10661	-0.6	-5.1	-0.42	1.23e-6	Red cell distribution width;
TGCT	cis	rs6582630	0.593	rs7134006	chr12:38596245	A/C	cg13010199	chr12:38710504	ALG10B	0.65	5.07	0.41	1.41e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs13256369	0.851	rs12541477	chr8:8563895	G/A	cg06671706	chr8:8559999	CLDN23	0.34	4.53	0.38	1.38e-5	Obesity-related traits;
TGCT	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.89	9.88	0.66	2.53e-17	Platelet count;
TGCT	cis	rs7208859	0.573	rs8064686	chr17:29134839	C/T	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs2456568	0.933	rs1518577	chr11:93674907	C/T	cg17595323	chr11:93583763	C11orf90	-0.46	-5.86	-0.47	3.92e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7714584	1.000	rs7732945	chr5:150261601	A/G	cg22134413	chr5:150180641	NA	0.78	6.12	0.48	1.16e-8	Crohn's disease;
TGCT	cis	rs910316	1.000	rs7156105	chr14:75541954	C/A	cg08847533	chr14:75593920	NEK9	0.97	10.82	0.7	1.3e-19	Height;
TGCT	cis	rs11123694	1.000	rs11123694	chr2:109064563	C/T	cg02082929	chr2:109068933	GCC2	0.26	6.34	0.49	3.96e-9	Mean platelet volume;
TGCT	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs28595532	0.841	rs114363775	chr4:119765587	G/A	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs9300255	0.569	rs1716170	chr12:123716513	C/T	cg00376283	chr12:123451042	ABCB9	0.67	5.26	0.43	6.13e-7	Neutrophil percentage of white cells;
TGCT	cis	rs7772486	0.558	rs62435775	chr6:146136415	G/C	cg05347473	chr6:146136440	FBXO30	0.66	6.2	0.49	7.78e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6558174	0.714	rs12541601	chr8:22524141	G/A	cg03733263	chr8:22462867	KIAA1967	-0.61	-4.76	-0.39	5.19e-6	Breast cancer;
TGCT	cis	rs7572733	0.534	rs700683	chr2:198712332	G/A	cg00792783	chr2:198669748	PLCL1	0.56	5.08	0.42	1.35e-6	Dermatomyositis;
TGCT	cis	rs9611565	0.649	rs79005	chr22:41835544	G/A	cg17554472	chr22:41940697	POLR3H	0.46	4.71	0.39	6.63e-6	Vitiligo;
TGCT	cis	rs826838	0.620	rs11614695	chr12:39331847	C/T	cg13010199	chr12:38710504	ALG10B	0.64	4.91	0.4	2.79e-6	Heart rate;
TGCT	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg04287289	chr16:89883240	FANCA	0.93	11.83	0.73	4.42e-22	Vitiligo;
TGCT	cis	rs2721195	0.577	rs4532636	chr8:145904423	A/C	cg11211951	chr8:145729740	GPT	-0.23	-4.97	-0.41	2.14e-6	Age at first birth;
TGCT	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg11764359	chr7:65958608	NA	0.61	5.53	0.44	1.79e-7	Aortic root size;
TGCT	cis	rs4851254	0.660	rs9784000	chr2:100697201	G/C	cg07810366	chr2:100720526	AFF3	-0.45	-4.7	-0.39	6.91e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1008375	0.932	rs11938710	chr4:17670664	G/C	cg18681998	chr4:17616180	MED28	-0.87	-8.78	-0.62	1.07e-14	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg18876405	chr7:65276391	NA	0.34	5.28	0.43	5.69e-7	Aortic root size;
TGCT	cis	rs9381040	0.610	rs4140580	chr6:41041742	C/T	cg03526776	chr6:41159608	TREML2	0.27	5.34	0.43	4.21e-7	Alzheimer's disease (late onset);
TGCT	cis	rs7666738	0.830	rs1834647	chr4:98882915	G/A	cg05340658	chr4:99064831	C4orf37	0.53	6.1	0.48	1.22e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9388451	0.626	rs7748729	chr6:126077381	C/T	cg05901451	chr6:126070800	HEY2	-0.98	-12.15	-0.74	7.57e-23	Brugada syndrome;
TGCT	cis	rs9911578	0.692	rs412000	chr17:56709058	G/C	cg12560992	chr17:57184187	TRIM37	0.55	5.96	0.47	2.38e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs11190604	0.767	rs10509743	chr10:102190406	C/T	cg16005271	chr10:102321736	NA	0.46	4.67	0.39	7.62e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs3125734	0.719	rs4529854	chr10:64043975	C/T	cg09941381	chr10:64027924	RTKN2	-0.31	-4.5	-0.37	1.55e-5	Rheumatoid arthritis;
TGCT	cis	rs9300255	0.510	rs1727322	chr12:123699520	A/G	cg00376283	chr12:123451042	ABCB9	0.73	5.1	0.42	1.26e-6	Neutrophil percentage of white cells;
TGCT	cis	rs6570726	0.764	rs9403733	chr6:145912311	A/C	cg05347473	chr6:146136440	FBXO30	0.53	4.92	0.4	2.74e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11031096	0.587	rs2920145	chr11:4070552	G/T	cg18678763	chr11:4115507	RRM1	0.36	4.56	0.38	1.2e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs7568458	0.704	rs10176176	chr2:85762048	A/T	cg02493740	chr2:85810744	VAMP5	-0.28	-5.23	-0.42	7.12e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs10782582	0.593	rs6675212	chr1:76230829	C/A	cg10523679	chr1:76189770	ACADM	-0.61	-6.16	-0.48	9.21e-9	Daytime sleep phenotypes;
TGCT	cis	rs6840360	0.571	rs55808836	chr4:152554991	C/T	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.0	-0.58	7.69e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs4523957	0.620	rs9900587	chr17:2071097	G/A	cg16513277	chr17:2031491	SMG6	-0.2	-4.46	-0.37	1.8e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs2456568	0.695	rs7942055	chr11:93691063	A/C	cg26875233	chr11:93583750	C11orf90	0.4	4.79	0.4	4.6e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs447921	0.861	rs12950218	chr17:74409547	G/A	cg09812376	chr17:74270190	QRICH2	-0.46	-4.6	-0.38	1.01e-5	Mitochondrial DNA levels;
TGCT	cis	rs35306767	0.807	rs34982663	chr10:852521	C/G	cg20503657	chr10:835505	NA	0.77	11.14	0.71	2.13e-20	Eosinophil percentage of granulocytes;
TGCT	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg13393036	chr8:95962371	TP53INP1	-0.63	-8.52	-0.61	4.43e-14	Type 2 diabetes;
TGCT	cis	rs12369635	1.000	rs73159540	chr12:129559421	C/T	cg01909103	chr12:129572610	TMEM132D	-0.64	-4.47	-0.37	1.73e-5	Schizophrenia (inflammation and infection response interaction);
TGCT	cis	rs826838	0.904	rs7973992	chr12:39168233	T/C	cg13010199	chr12:38710504	ALG10B	0.78	6.16	0.48	9.26e-9	Heart rate;
TGCT	cis	rs595982	0.527	rs17272673	chr19:49362992	C/A	cg17863274	chr19:49399704	TULP2	-0.47	-6.71	-0.52	6.17e-10	Red cell distribution width;
TGCT	cis	rs3821902	0.646	rs66672237	chr3:64012172	C/A	cg22134162	chr3:63841271	THOC7	-0.33	-4.96	-0.41	2.22e-6	Breast cancer;
TGCT	cis	rs6430585	0.528	rs114760827	chr2:136661110	G/A	cg07169764	chr2:136633963	MCM6	1.25	12.39	0.74	1.91e-23	Corneal structure;
TGCT	cis	rs17376456	0.569	rs7732578	chr5:93410244	C/T	cg21475434	chr5:93447410	FAM172A	-0.61	-5.8	-0.46	5.24e-8	Diabetic retinopathy;
TGCT	cis	rs6430585	0.528	rs309120	chr2:136708787	G/C	cg07169764	chr2:136633963	MCM6	1.21	11.87	0.73	3.62e-22	Corneal structure;
TGCT	cis	rs2404602	0.735	rs2461871	chr15:76822418	C/G	cg06069100	chr15:77574588	SGK269	0.26	4.67	0.39	7.65e-6	Blood metabolite levels;
TGCT	cis	rs6546537	0.550	rs12617329	chr2:69781530	C/A	cg10773587	chr2:69614142	GFPT1	-0.65	-5.94	-0.47	2.7e-8	Serum thyroid-stimulating hormone levels;
TGCT	cis	rs2153535	0.580	rs915351	chr6:8442793	C/T	cg07606381	chr6:8435919	SLC35B3	0.57	5.25	0.43	6.46e-7	Motion sickness;
TGCT	cis	rs708547	0.836	rs1713997	chr4:57843863	G/C	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.54	-5.11	-0.42	1.16e-6	Response to bleomycin (chromatid breaks);
TGCT	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg02038168	chr22:39784481	NA	-0.76	-6.36	-0.5	3.47e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs36051895	0.559	rs7850228	chr9:5210671	C/G	cg02405213	chr9:5042618	JAK2	0.67	8.47	0.61	5.81e-14	Pediatric autoimmune diseases;
TGCT	trans	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg17830980	chr10:43048298	ZNF37B	-0.84	-10.46	-0.68	9.38e-19	Extrinsic epigenetic age acceleration;
TGCT	cis	rs9467773	1.000	rs4713006	chr6:26519872	A/G	cg26531700	chr6:26746687	NA	0.47	4.57	0.38	1.14e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs17102423	0.723	rs8181937	chr14:65555707	A/C	cg11161011	chr14:65562177	MAX	-0.55	-7.67	-0.57	4.42e-12	Obesity-related traits;
TGCT	cis	rs1784581	0.569	rs9364629	chr6:162416831	T/G	cg17173639	chr6:162384350	PARK2	0.4	6.6	0.51	1.07e-9	Itch intensity from mosquito bite;
TGCT	cis	rs2404602	0.647	rs12905181	chr15:77098431	A/G	cg23625390	chr15:77176239	SCAPER	-0.38	-4.77	-0.39	5.13e-6	Blood metabolite levels;
TGCT	cis	rs9814567	1.000	rs7630874	chr3:134293291	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.95	8.76	0.62	1.21e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs10791097	0.702	rs10894267	chr11:130714861	C/T	cg05962950	chr11:130786565	SNX19	-0.7	-7.38	-0.55	1.97e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs11112613	0.713	rs12580741	chr12:105941328	A/G	cg03607813	chr12:105948248	NA	-0.41	-4.66	-0.39	7.91e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	cis	rs57590327	0.528	rs3821552	chr3:81702139	A/G	cg07356753	chr3:81810745	GBE1	-0.77	-6.91	-0.53	2.24e-10	Extraversion;
TGCT	cis	rs2463822	0.514	rs10750972	chr11:62053687	A/G	cg23876832	chr11:62092739	NA	0.69	5.9	0.47	3.17e-8	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs610932	0.517	rs612738	chr11:59990591	G/T	cg18570331	chr11:60101691	MS4A6E	0.51	4.64	0.38	8.88e-6	Alzheimer's disease;
TGCT	cis	rs9296092	0.538	rs9461887	chr6:33526827	C/T	cg13560919	chr6:33536144	NA	-0.22	-4.95	-0.41	2.33e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs7027203	0.576	rs7865043	chr9:96549004	G/T	cg14396892	chr9:96623032	NA	0.22	4.5	0.37	1.54e-5	DNA methylation (variation);
TGCT	cis	rs12368653	0.525	rs1564374	chr12:58010163	C/T	cg12615879	chr12:58013172	SLC26A10	0.54	6.5	0.5	1.77e-9	Multiple sclerosis;
TGCT	cis	rs6665290	0.836	rs56029302	chr1:227203390	G/A	cg11404489	chr1:228071452	NA	-0.19	-4.6	-0.38	1.02e-5	Myeloid white cell count;
TGCT	cis	rs9467773	0.620	rs9467810	chr6:26608261	A/C	cg26531700	chr6:26746687	NA	0.5	4.62	0.38	9.55e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg22920501	chr2:26401640	FAM59B	0.66	6.24	0.49	6.48e-9	Gut microbiome composition (summer);
TGCT	cis	rs8009147	1	rs8009147	chr14:104264662	A/G	cg26031613	chr14:104095156	KLC1	-0.64	-6.58	-0.51	1.2e-9	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs17331151	0.573	rs11718060	chr3:52875546	G/A	cg12962167	chr3:53033115	SFMBT1	0.43	4.71	0.39	6.6e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg22907277	chr7:1156413	C7orf50	0.21	4.8	0.4	4.48e-6	Longevity;Endometriosis;
TGCT	cis	rs6570726	0.791	rs13202312	chr6:145913093	T/G	cg05347473	chr6:146136440	FBXO30	0.53	4.92	0.4	2.74e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2204008	0.624	rs2320449	chr12:38224190	T/C	cg26384229	chr12:38710491	ALG10B	0.83	7.34	0.55	2.44e-11	Bladder cancer;
TGCT	cis	rs763014	0.898	rs1981484	chr16:630710	A/G	cg00908189	chr16:619842	PIGQ	0.87	10.5	0.69	7.53e-19	Height;
TGCT	cis	rs2180341	0.751	rs9388553	chr6:127574044	A/G	cg27446573	chr6:127587934	RNF146	0.98	8.94	0.63	4.63e-15	Breast cancer;
TGCT	cis	rs6121246	0.609	rs6060627	chr20:30262159	C/T	cg18721089	chr20:30220636	NA	-0.35	-4.49	-0.37	1.6e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg07424592	chr7:64974309	NA	1.27	7.84	0.58	1.8e-12	Diabetic kidney disease;
TGCT	cis	rs7027203	0.538	rs10125195	chr9:96523224	T/C	cg14598338	chr9:96623480	NA	-0.49	-7.04	-0.53	1.18e-10	DNA methylation (variation);
TGCT	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg00343986	chr7:65444356	GUSB	0.24	5.25	0.43	6.3e-7	Aortic root size;
TGCT	trans	rs6762477	0.748	rs11717349	chr3:50223977	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.78	-8.11	-0.59	4.24e-13	Menarche (age at onset);
TGCT	cis	rs12478296	0.901	rs67423532	chr2:243004719	A/G	cg06360820	chr2:242988706	NA	-0.64	-5.35	-0.43	4.15e-7	Obesity-related traits;
TGCT	cis	rs9486719	1.000	rs2971608	chr6:97039757	T/C	cg06623918	chr6:96969491	KIAA0776	-1.04	-10.25	-0.68	3.11e-18	Migraine;Coronary artery disease;
TGCT	cis	rs10411936	0.888	rs2034892	chr19:16491549	G/A	cg19006008	chr19:16999768	F2RL3	0.26	4.58	0.38	1.13e-5	White blood cell count;Multiple sclerosis;
TGCT	cis	rs9926296	0.593	rs6500456	chr16:89888341	T/C	cg08627397	chr16:89984028	MC1R	-0.31	-4.92	-0.4	2.67e-6	Vitiligo;
TGCT	trans	rs629535	0.547	rs72654095	chr8:70120770	A/G	cg21567404	chr3:27674614	NA	-0.52	-8.05	-0.59	5.78e-13	Dupuytren's disease;
TGCT	cis	rs75686122	0.892	rs17233499	chr8:104610414	C/G	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	trans	rs1814175	0.817	rs11518158	chr11:49985633	G/T	cg15704280	chr7:45808275	SEPT13	-0.73	-8.48	-0.61	5.59e-14	Height;
TGCT	cis	rs10465746	0.935	rs4907189	chr1:84374982	G/T	cg10977910	chr1:84465055	TTLL7	0.63	6.19	0.49	8.08e-9	Obesity-related traits;
TGCT	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg22764044	chr5:178986830	RUFY1	0.47	5.27	0.43	5.74e-7	Lung cancer;
TGCT	cis	rs7914558	1.000	rs11191577	chr10:104902165	A/G	cg15744005	chr10:104629667	AS3MT	-0.42	-5.24	-0.43	6.69e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs548987	0.529	rs651578	chr6:25873883	T/C	cg12310025	chr6:25882481	NA	-0.66	-5.62	-0.45	1.22e-7	Homocysteine levels;
TGCT	cis	rs651907	0.557	rs2318090	chr3:101474933	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.9	10.87	0.7	9.43e-20	Colorectal cancer;
TGCT	cis	rs858239	0.600	rs10256359	chr7:23123877	C/T	cg05602783	chr7:23145260	KLHL7	-0.6	-4.98	-0.41	2.11e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs4803468	1.000	rs13344563	chr19:41945904	G/C	cg09537434	chr19:41945824	ATP5SL	0.92	10.44	0.68	1.1e-18	Height;
TGCT	cis	rs7822232	0.908	rs4977164	chr8:145144912	T/G	cg26272248	chr8:145163034	KIAA1875	-0.49	-4.81	-0.4	4.24e-6	Blood metabolite levels;
TGCT	cis	rs3026101	0.671	rs739767	chr17:5290681	A/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	4.57	0.38	1.16e-5	Body mass index;
TGCT	cis	rs78487399	0.634	rs6751035	chr2:43752407	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.45	-5.11	-0.42	1.18e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs7635838	0.617	rs13071193	chr3:11284226	G/T	cg00170343	chr3:11313890	ATG7	-0.64	-6.28	-0.49	5.27e-9	HDL cholesterol;
TGCT	cis	rs7618915	0.798	rs353547	chr3:52268866	A/G	cg10802521	chr3:52805072	NEK4	0.47	4.93	0.41	2.53e-6	Bipolar disorder;
TGCT	cis	rs8020441	0.945	rs61410944	chr14:51166736	A/G	cg04730355	chr14:51134070	SAV1	0.71	5.77	0.46	5.92e-8	Cognitive performance;
TGCT	cis	rs2440129	0.611	rs1042357	chr17:6905061	T/G	cg03407747	chr17:6899364	ALOX12	0.54	5.85	0.47	4.06e-8	Tonsillectomy;
TGCT	trans	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg11887960	chr12:57824829	NA	1.1	9.44	0.65	2.89e-16	Lung disease severity in cystic fibrosis;
TGCT	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg09436375	chr6:42928200	GNMT	-0.35	-4.54	-0.38	1.33e-5	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg26354017	chr1:205819088	PM20D1	0.56	6.86	0.52	2.9e-10	Menarche (age at onset);
TGCT	cis	rs78487399	0.731	rs6747229	chr2:43712610	T/A	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.71	4.55	0.38	1.26e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs908922	0.676	rs4845788	chr1:152519496	T/C	cg20991723	chr1:152506922	NA	0.44	5.78	0.46	5.77e-8	Hair morphology;
TGCT	cis	rs62380364	0.558	rs34319	chr5:88023349	A/T	cg24804195	chr5:87968844	LOC645323	-0.59	-5.87	-0.47	3.67e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs4455778	0.580	rs4543492	chr7:49097005	C/T	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs2067615	0.599	rs1579808	chr12:107239947	A/G	cg15890332	chr12:107067104	RFX4	-0.28	-5.54	-0.45	1.72e-7	Heart rate;
TGCT	cis	rs77741769	0.571	rs989986	chr12:121274178	A/C	cg02419362	chr12:121203948	SPPL3	0.19	4.5	0.37	1.58e-5	Mean corpuscular volume;
TGCT	cis	rs59197085	0.636	rs2307036	chr7:128454537	C/A	cg00260937	chr7:128520193	KCP	0.47	4.98	0.41	2.1e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
TGCT	cis	rs7666738	0.830	rs10017557	chr4:98983969	G/A	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs5769765	0.862	rs9616381	chr22:50312382	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.24	-12.97	-0.76	7.81e-25	Schizophrenia;
TGCT	cis	rs45509595	0.841	rs401754	chr6:27782538	T/A	cg10876282	chr6:28092338	ZSCAN16	0.78	4.57	0.38	1.17e-5	Breast cancer;
TGCT	cis	rs7769051	1.000	rs10484629	chr6:133117870	A/C	cg22852734	chr6:133119734	C6orf192	1.22	6.9	0.53	2.34e-10	Type 2 diabetes nephropathy;
TGCT	cis	rs4700695	0.719	rs27082	chr5:65436152	A/C	cg21114390	chr5:65439923	SFRS12	-0.82	-7.51	-0.56	9.94e-12	Facial morphology (factor 19);
TGCT	cis	rs6074578	0.679	rs6086226	chr20:137310	C/A	cg16931068	chr20:139680	DEFB127	0.27	4.8	0.4	4.52e-6	Hirschsprung disease;
TGCT	cis	rs9926296	0.682	rs645019	chr16:89716883	C/T	cg27121462	chr16:89883253	FANCA	-0.53	-4.88	-0.4	3.22e-6	Vitiligo;
TGCT	cis	rs422249	0.512	rs174566	chr11:61592362	A/G	cg19610905	chr11:61596333	FADS2	-1.08	-12.29	-0.74	3.45e-23	Trans fatty acid levels;
TGCT	cis	rs2797160	1.000	rs6904069	chr6:125995134	C/T	cg05901451	chr6:126070800	HEY2	-0.74	-6.68	-0.51	7.16e-10	Endometrial cancer;
TGCT	cis	rs67311347	1.000	rs954589	chr3:40444545	C/T	cg17264618	chr3:40429014	ENTPD3	0.32	4.57	0.38	1.18e-5	Renal cell carcinoma;
TGCT	trans	rs8073060	0.544	rs7210966	chr17:33986334	G/C	cg19694781	chr19:47549865	TMEM160	-0.62	-14.07	-0.78	1.86e-27	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs2486288	0.656	rs7167146	chr15:45571386	A/G	cg14582100	chr15:45693742	SPATA5L1	0.45	5.37	0.43	3.72e-7	Glomerular filtration rate;
TGCT	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.48	-0.37	1.66e-5	Bipolar disorder;
TGCT	cis	rs12477438	0.501	rs2516833	chr2:99777405	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	10.3	0.68	2.42e-18	Chronic sinus infection;
TGCT	cis	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg07424592	chr7:64974309	NA	1.36	8.08	0.59	4.97e-13	Diabetic kidney disease;
TGCT	cis	rs2652822	0.509	rs4774478	chr15:63434763	A/G	cg12855773	chr15:63363890	TPM1	-0.2	-5.3	-0.43	5.04e-7	Metabolic traits;
TGCT	cis	rs8014204	0.604	rs2159906	chr14:75390912	G/T	cg06637938	chr14:75390232	RPS6KL1	0.96	10.93	0.7	6.98e-20	Caffeine consumption;
TGCT	cis	rs11031096	0.711	rs4910890	chr11:4153407	C/T	cg18678763	chr11:4115507	RRM1	-0.52	-6.66	-0.51	7.83e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs6988636	1.000	rs4377946	chr8:124185887	T/C	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs78487399	0.634	rs77881454	chr2:43757293	A/T	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.75	4.63	0.38	9.1e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs6089584	1.000	rs6089585	chr20:60564395	G/A	cg16423285	chr20:60520624	NA	-0.52	-5.62	-0.45	1.18e-7	Body mass index;
TGCT	cis	rs9549367	0.569	rs3024738	chr13:113819921	T/A	cg00898013	chr13:113819073	PROZ	0.5	6.19	0.49	8.12e-9	Platelet distribution width;
TGCT	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg04234412	chr22:24373322	LOC391322	0.96	10.26	0.68	2.96e-18	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg13395646	chr4:1353034	KIAA1530	-0.4	-5.0	-0.41	1.93e-6	Obesity-related traits;
TGCT	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg09436375	chr6:42928200	GNMT	-0.38	-4.88	-0.4	3.2e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs11785400	1.000	rs3824208	chr8:143743653	C/G	cg10596483	chr8:143751796	JRK	0.56	6.05	0.48	1.61e-8	Schizophrenia;
TGCT	cis	rs7772486	0.790	rs2253880	chr6:146200774	T/C	cg05347473	chr6:146136440	FBXO30	0.52	4.88	0.4	3.15e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2549003	1.000	rs7701588	chr5:131819970	T/C	cg02551604	chr5:131831745	NA	-0.89	-11.95	-0.73	2.33e-22	Asthma (sex interaction);
TGCT	cis	rs72949976	0.864	rs62186566	chr2:214024421	G/A	cg08319019	chr2:214017104	IKZF2	-0.8	-7.47	-0.56	1.22e-11	Lung cancer;Squamous cell lung carcinoma;
TGCT	cis	rs13064447	0.817	rs73022939	chr3:12762264	G/A	cg20675869	chr3:12750130	NA	-0.2	-4.99	-0.41	2.03e-6	Major depression and alcohol dependence;
TGCT	cis	rs8103278	0.507	rs62111759	chr19:46296230	A/T	cg11657440	chr19:46296263	DMWD	0.79	8.7	0.62	1.7e-14	Coronary artery disease;
TGCT	cis	rs2663905	0.611	rs1509558	chr15:81391244	C/T	cg09236163	chr15:81426669	C15orf26	-0.46	-4.63	-0.38	9.26e-6	QT interval (drug interaction);
TGCT	cis	rs12497850	0.543	rs6446218	chr3:49075513	A/T	cg07636037	chr3:49044803	WDR6	0.98	10.81	0.7	1.33e-19	Parkinson's disease;
TGCT	cis	rs11098499	0.909	rs28581362	chr4:120283548	T/A	cg09307838	chr4:120376055	NA	0.58	5.76	0.46	6.16e-8	Corneal astigmatism;
TGCT	cis	rs11514810	1.000	rs4385385	chr7:1431125	T/C	cg24899294	chr7:1481343	MICALL2	-0.47	-5.84	-0.46	4.24e-8	Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder;
TGCT	cis	rs17253792	0.731	rs79483151	chr14:56048851	C/T	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg05665937	chr4:1216051	CTBP1	0.23	4.58	0.38	1.13e-5	Obesity-related traits;
TGCT	cis	rs2191566	0.664	rs6509138	chr19:44570393	C/A	cg03039196	chr19:44506973	ZNF230	0.53	4.46	0.37	1.82e-5	Acute lymphoblastic leukemia (childhood);
TGCT	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.94	-10.66	-0.69	3.07e-19	Menarche (age at onset);
TGCT	trans	rs11088226	0.681	rs1134747	chr21:33939011	T/A	cg09050820	chr6:167586206	TCP10L2	0.79	7.04	0.53	1.13e-10	Gastritis;
TGCT	cis	rs72949976	0.584	rs12471471	chr2:214023052	C/T	cg08319019	chr2:214017104	IKZF2	-0.84	-8.38	-0.6	9.58e-14	Lung cancer;Squamous cell lung carcinoma;
TGCT	cis	rs4919694	1.000	rs12268849	chr10:104737682	G/A	cg04362960	chr10:104952993	NT5C2	1.04	6.92	0.53	2.1e-10	Arsenic metabolism;
TGCT	cis	rs7829975	0.871	rs777709	chr8:8583872	T/C	cg08975724	chr8:8085496	FLJ10661	-0.52	-4.53	-0.38	1.39e-5	Mood instability;
TGCT	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	16.1	0.82	3.69e-32	Prudent dietary pattern;
TGCT	cis	rs533581	0.866	rs488251	chr16:88972554	G/A	cg16701003	chr16:89028210	CBFA2T3	0.38	4.86	0.4	3.45e-6	Social autistic-like traits;
TGCT	cis	rs4664308	0.905	rs62175518	chr2:160915149	C/T	cg03641300	chr2:160917029	PLA2R1	-0.26	-6.55	-0.51	1.36e-9	Idiopathic membranous nephropathy;
TGCT	cis	rs1609391	0.561	rs6439675	chr3:136625436	G/A	cg15507776	chr3:136538369	TMEM22	0.66	6.84	0.52	3.27e-10	Neuroticism;
TGCT	cis	rs739496	0.579	rs10849983	chr12:112340409	G/T	cg10833066	chr12:111807467	FAM109A	0.38	5.61	0.45	1.24e-7	Platelet count;
TGCT	cis	rs394563	0.591	rs237029	chr6:149717425	A/G	cg03678062	chr6:149772716	ZC3H12D	-0.38	-4.74	-0.39	5.87e-6	Dupuytren's disease;
TGCT	cis	rs3617	0.625	rs2245647	chr3:52862753	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	4.59	0.38	1.08e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2404602	0.692	rs2117369	chr15:76748861	A/T	cg22467129	chr15:76604101	ETFA	-0.57	-6.83	-0.52	3.31e-10	Blood metabolite levels;
TGCT	cis	rs11626933	1.000	rs11626933	chr14:90754311	A/G	cg14092571	chr14:90743983	NA	-0.29	-6.02	-0.48	1.86e-8	Gut microbiota (bacterial taxa);
TGCT	trans	rs9951602	0.512	rs4799247	chr18:76653449	G/A	cg02800362	chr5:177631904	HNRNPAB	1.13	12.84	0.76	1.57e-24	Obesity-related traits;
TGCT	cis	rs7246657	0.678	rs4802024	chr19:38052193	T/C	cg03611452	chr19:38183253	ZNF781	0.58	4.64	0.38	8.62e-6	Coronary artery calcification;
TGCT	cis	rs8072100	0.701	rs10163469	chr17:45687767	G/A	cg08085267	chr17:45401833	C17orf57	0.43	4.63	0.38	9.02e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs473651	0.935	rs10170056	chr2:239339291	G/C	cg08773314	chr2:239334832	ASB1	0.45	6.39	0.5	3.05e-9	Multiple system atrophy;
TGCT	cis	rs7824557	0.545	rs2572380	chr8:11237477	A/G	cg21775007	chr8:11205619	TDH	-0.65	-6.39	-0.5	3.07e-9	Retinal vascular caliber;
TGCT	cis	rs9394438	0.628	rs804843	chr6:37545923	A/G	cg00985040	chr6:37553208	NA	-0.25	-4.94	-0.41	2.51e-6	IgG glycosylation;
TGCT	cis	rs10782582	0.593	rs12129523	chr1:76129223	C/A	cg03433033	chr1:76189801	ACADM	-0.63	-7.25	-0.55	3.83e-11	Daytime sleep phenotypes;
TGCT	cis	rs7264396	0.635	rs6060696	chr20:34522060	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.04	-0.41	1.58e-6	Total cholesterol levels;
TGCT	cis	rs1023500	0.573	rs133381	chr22:42470608	C/G	cg15557168	chr22:42548783	NA	-0.22	-5.42	-0.44	2.99e-7	Schizophrenia;
TGCT	cis	rs5750830	0.594	rs9611165	chr22:39775250	A/G	cg11247378	chr22:39784982	NA	-0.64	-8.48	-0.61	5.71e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs11690935	0.959	rs10206062	chr2:172577276	A/T	cg13550731	chr2:172543902	DYNC1I2	-1.18	-12.58	-0.75	6.59e-24	Schizophrenia;
TGCT	cis	rs2239547	0.603	rs59989280	chr3:53098875	T/C	cg10802521	chr3:52805072	NEK4	-0.58	-5.31	-0.43	4.87e-7	Schizophrenia;
TGCT	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg02038168	chr22:39784481	NA	-0.76	-6.36	-0.5	3.47e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs308403	0.530	rs13135766	chr4:123664427	C/G	cg10495464	chr4:123653540	BBS12;LOC729338	-0.67	-6.4	-0.5	2.94e-9	Blood protein levels;
TGCT	cis	rs9467773	1.000	rs1535277	chr6:26567802	G/T	cg09904177	chr6:26538194	HMGN4	0.69	6.84	0.52	3.23e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg22963979	chr7:1858916	MAD1L1	-0.35	-5.4	-0.44	3.3e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs782590	0.967	rs1823893	chr2:55788921	T/C	cg18811423	chr2:55921094	PNPT1	0.67	7.1	0.54	8.63e-11	Metabolic syndrome;
TGCT	cis	rs877282	0.797	rs11253329	chr10:753200	A/T	cg17470449	chr10:769945	NA	0.32	4.91	0.4	2.76e-6	Uric acid levels;
TGCT	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	5.24	0.43	6.79e-7	Menopause (age at onset);
TGCT	cis	rs4689388	0.890	rs4688991	chr4:6302220	C/G	cg00701064	chr4:6280414	WFS1	0.44	5.85	0.47	4.08e-8	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs9467711	1.000	rs6903015	chr6:26322526	A/G	cg16898833	chr6:26189333	HIST1H4D	1.04	5.51	0.44	1.97e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg10802521	chr3:52805072	NEK4	-0.78	-10.0	-0.67	1.26e-17	Electroencephalogram traits;
TGCT	cis	rs7000551	0.715	rs2443502	chr8:22340499	G/A	cg12081754	chr8:22256438	SLC39A14	0.27	4.54	0.38	1.29e-5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs10744422	1.000	rs7972447	chr12:123354545	C/G	cg25930673	chr12:123319894	HIP1R	-0.85	-5.09	-0.42	1.29e-6	Schizophrenia;
TGCT	cis	rs473651	0.935	rs482775	chr2:239335403	G/C	cg21699342	chr2:239360505	ASB1	0.18	4.9	0.4	2.93e-6	Multiple system atrophy;
TGCT	cis	rs921968	0.643	rs4674321	chr2:219511368	G/A	cg02176678	chr2:219576539	TTLL4	0.44	6.16	0.48	9.35e-9	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs832540	0.656	rs6862118	chr5:56106474	G/A	cg12311346	chr5:56204834	C5orf35	-0.47	-4.86	-0.4	3.42e-6	Coronary artery disease;
TGCT	cis	rs7246657	0.943	rs1373991	chr19:37838911	T/C	cg18154014	chr19:37997991	ZNF793	0.72	5.19	0.42	8.3e-7	Coronary artery calcification;
TGCT	cis	rs9532580	0.778	rs34373380	chr13:41244217	T/A	cg21288729	chr13:41239152	FOXO1	1.01	10.56	0.69	5.52e-19	Mean corpuscular hemoglobin;
TGCT	trans	rs6089829	0.888	rs4809268	chr20:61675249	C/G	cg13615516	chr5:77269221	NA	0.73	8.39	0.6	9.12e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7666738	0.830	rs11941961	chr4:99065654	G/T	cg17366294	chr4:99064904	C4orf37	0.72	7.39	0.55	1.9e-11	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg17470723	chr8:74884337	TCEB1	0.71	6.72	0.52	5.96e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs60154123	0.505	rs115881613	chr1:210040369	C/T	cg22029157	chr1:209979665	IRF6	0.79	5.78	0.46	5.6e-8	Coronary artery disease;
TGCT	cis	rs2996428	0.667	rs11578070	chr1:3769871	G/C	cg17848003	chr1:3704513	LRRC47	0.18	5.15	0.42	9.99e-7	Red cell distribution width;
TGCT	cis	rs4919044	0.641	rs11187232	chr10:94737477	A/G	cg05127821	chr10:94822908	CYP26C1	-0.73	-4.47	-0.37	1.74e-5	Coronary artery disease;
TGCT	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg13770153	chr20:60521292	NA	-0.54	-6.99	-0.53	1.51e-10	Body mass index;
TGCT	cis	rs4808199	0.948	rs8108647	chr19:19427623	A/G	cg03709012	chr19:19516395	GATAD2A	0.8	6.24	0.49	6.43e-9	Nonalcoholic fatty liver disease;
TGCT	cis	rs7666738	0.680	rs11726233	chr4:99079773	G/A	cg18180107	chr4:99064573	C4orf37	0.58	5.15	0.42	9.95e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs907683	0.546	rs1058261	chr2:220285309	C/T	cg15015639	chr2:220282977	DES	-0.39	-4.83	-0.4	3.88e-6	Resting heart rate;
TGCT	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg14893161	chr1:205819251	PM20D1	0.55	7.8	0.57	2.23e-12	Menarche (age at onset);
TGCT	cis	rs704	0.628	rs2239908	chr17:26725265	G/A	cg10342447	chr17:26645325	TMEM97	-0.47	-4.69	-0.39	7.22e-6	Osteoprotegerin levels;
TGCT	cis	rs4851254	0.660	rs59447631	chr2:100691493	T/C	cg07810366	chr2:100720526	AFF3	-0.49	-5.15	-0.42	1e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6684514	1.000	rs3806407	chr1:156251742	T/C	cg16558208	chr1:156270281	VHLL	0.46	9.38	0.64	3.92e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs793571	0.568	rs6494029	chr15:58923206	T/C	cg05156742	chr15:59063176	FAM63B	0.56	5.33	0.43	4.43e-7	Schizophrenia;
TGCT	cis	rs2762353	0.562	rs1165206	chr6:25867566	G/A	cg12310025	chr6:25882481	NA	-0.59	-5.91	-0.47	3.03e-8	Blood metabolite levels;
TGCT	cis	rs7558911	0.801	rs3769827	chr2:202102685	A/G	cg24599065	chr2:202093848	CASP10	0.21	4.63	0.38	8.94e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs950027	0.620	rs1153860	chr15:45636584	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.48	-6.04	-0.48	1.67e-8	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg25036284	chr2:26402008	FAM59B	-0.65	-5.18	-0.42	8.59e-7	Gut microbiome composition (summer);
TGCT	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg18876405	chr7:65276391	NA	0.32	4.89	0.4	3.11e-6	Aortic root size;
TGCT	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.01	0.48	1.9e-8	Bipolar disorder;
TGCT	cis	rs73058052	1.000	rs73057994	chr19:50091273	C/A	cg09250473	chr19:50168907	IRF3;BCL2L12	0.87	6.6	0.51	1.06e-9	Fibrinogen levels;
TGCT	cis	rs2204008	0.754	rs11181643	chr12:38380553	G/A	cg26384229	chr12:38710491	ALG10B	0.83	7.26	0.55	3.72e-11	Bladder cancer;
TGCT	cis	rs9467773	0.626	rs9379860	chr6:26370605	T/C	cg05738196	chr6:26577821	NA	-0.63	-6.8	-0.52	3.97e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs7020830	0.898	rs13290794	chr9:37183628	C/T	cg14294708	chr9:37120828	ZCCHC7	1.24	17.13	0.84	1.79e-34	Schizophrenia;
TGCT	cis	rs3763267	0.649	rs73038057	chr6:169569765	C/T	cg02129017	chr6:168983500	SMOC2	-0.42	-4.45	-0.37	1.86e-5	Blood protein levels;
TGCT	cis	rs1401999	0.659	rs7622660	chr3:183753337	C/T	cg20387954	chr3:183756860	HTR3D	0.23	4.95	0.41	2.35e-6	Anterior chamber depth;
TGCT	cis	rs909002	0.849	rs4949449	chr1:32088534	T/G	cg11573219	chr1:32083031	HCRTR1	-0.49	-6.41	-0.5	2.78e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs112217694	1.000	rs79743141	chr4:104642724	G/A	cg24090629	chr4:104641072	TACR3	-0.97	-4.81	-0.4	4.25e-6	Menarche (age at onset);
TGCT	cis	rs8179	0.761	rs42035	chr7:92239531	A/G	cg15732164	chr7:92237376	CDK6	-0.3	-5.34	-0.43	4.37e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
TGCT	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg25036284	chr2:26402008	FAM59B	0.65	5.19	0.42	8.36e-7	Gut microbiome composition (summer);
TGCT	cis	rs2729354	0.953	rs2649650	chr11:57327567	C/T	cg24343310	chr11:57249947	NA	0.29	4.92	0.4	2.73e-6	Blood protein levels;
TGCT	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	5.12	0.42	1.11e-6	Alzheimer's disease;
TGCT	cis	rs854765	0.647	rs1008136	chr17:18027142	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	7.6	0.56	6.35e-12	Total body bone mineral density;
TGCT	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg26338869	chr17:61819248	STRADA	-0.53	-4.87	-0.4	3.29e-6	Prudent dietary pattern;
TGCT	cis	rs854765	0.964	rs12943202	chr17:17994332	T/A	cg04398451	chr17:18023971	MYO15A	0.3	4.67	0.39	7.62e-6	Total body bone mineral density;
TGCT	cis	rs75686122	1.000	rs75686122	chr8:104573789	C/A	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs3820068	0.581	rs59684759	chr1:15919893	A/G	cg05660106	chr1:15850417	CASP9	0.84	8.27	0.6	1.8e-13	Systolic blood pressure;
TGCT	cis	rs1355223	0.583	rs2941044	chr11:34867444	A/C	cg24088639	chr11:34937564	PDHX;APIP	-0.51	-4.64	-0.38	8.76e-6	Systemic lupus erythematosus and Systemic sclerosis;
TGCT	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg07507251	chr3:52567010	NT5DC2	0.47	6.7	0.52	6.47e-10	Bipolar disorder;
TGCT	cis	rs10489202	0.608	rs10800334	chr1:168075613	T/C	cg24449463	chr1:168025552	DCAF6	-0.52	-5.41	-0.44	3.13e-7	Schizophrenia;
TGCT	trans	rs9765602	1	rs9765602	chr5:35426631	A/G	cg10378735	chr7:142558305	EPHB6	0.87	6.79	0.52	4.14e-10	Post bronchodilator FEV1 in COPD;
TGCT	cis	rs3902035	0.964	rs62423999	chr6:119013532	A/G	cg07617317	chr6:118971624	C6orf204	0.43	5.01	0.41	1.79e-6	QT interval;
TGCT	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg06713675	chr4:122721982	EXOSC9	-0.68	-9.22	-0.64	9.56e-16	Type 2 diabetes;
TGCT	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg24675658	chr1:53192096	ZYG11B	0.89	11.76	0.73	6.48e-22	Monocyte count;
TGCT	cis	rs4132509	0.793	rs7538011	chr1:243703344	A/G	cg21452805	chr1:244014465	NA	0.75	4.55	0.38	1.28e-5	RR interval (heart rate);
TGCT	cis	rs13188771	0.525	rs10477735	chr5:100918100	T/C	cg10455971	chr5:101119566	NA	0.46	4.6	0.38	1.02e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs7772486	0.790	rs6926076	chr6:146232804	C/T	cg05347473	chr6:146136440	FBXO30	-0.51	-4.95	-0.41	2.32e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg24675658	chr1:53192096	ZYG11B	-0.71	-7.89	-0.58	1.32e-12	Monocyte count;
TGCT	cis	rs6074578	0.679	rs2298108	chr20:138125	G/T	cg16931068	chr20:139680	DEFB127	0.27	4.71	0.39	6.51e-6	Hirschsprung disease;
TGCT	cis	rs7091068	1.000	rs7091068	chr10:95420385	G/T	cg20715218	chr10:95462985	C10orf4	0.5	4.56	0.38	1.21e-5	Urinary tract infection frequency;
TGCT	cis	rs72781680	1.000	rs72781658	chr2:24220141	A/G	cg08917208	chr2:24149416	ATAD2B	0.84	5.12	0.42	1.12e-6	Lymphocyte counts;
TGCT	cis	rs9393692	0.578	rs806795	chr6:26205293	G/A	cg00631329	chr6:26305371	NA	-0.31	-4.55	-0.38	1.26e-5	Educational attainment;
TGCT	cis	rs7552404	0.920	rs1612097	chr1:76218875	C/T	cg10523679	chr1:76189770	ACADM	0.84	9.05	0.63	2.44e-15	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs6459788	0.720	rs11768765	chr7:157253133	C/T	cg06271696	chr7:157225062	NA	-0.27	-4.91	-0.4	2.85e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs7914558	1.000	rs12255047	chr10:104760752	G/A	cg15744005	chr10:104629667	AS3MT	-0.41	-5.08	-0.42	1.33e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs10984561	0.881	rs73540254	chr9:122255448	C/G	cg14242995	chr9:122249943	NA	0.72	5.82	0.46	4.75e-8	Pulmonary function decline;
TGCT	cis	rs7547997	0.615	rs35752748	chr1:158321565	A/C	cg07950803	chr1:158223934	CD1A	0.31	4.66	0.39	8.18e-6	QRS duration;
TGCT	cis	rs2594989	0.779	rs2437685	chr3:11593013	A/G	cg00170343	chr3:11313890	ATG7	0.67	5.09	0.42	1.28e-6	Circulating chemerin levels;
TGCT	cis	rs7830933	0.780	rs6983481	chr8:23609009	G/T	cg04349084	chr8:23602677	NA	0.26	5.13	0.42	1.09e-6	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
TGCT	cis	rs2439831	0.867	rs2260160	chr15:43895643	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.97	7.11	0.54	8.02e-11	Lung cancer in ever smokers;
TGCT	cis	rs7635838	0.617	rs2594971	chr3:11313910	G/A	cg00170343	chr3:11313890	ATG7	0.61	5.98	0.47	2.16e-8	HDL cholesterol;
TGCT	cis	rs2439831	0.867	rs3213991	chr15:43670280	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	8.65	0.61	2.26e-14	Lung cancer in ever smokers;
TGCT	cis	rs68170813	0.522	rs12535814	chr7:107038432	A/T	cg02696742	chr7:106810147	HBP1	-0.7	-5.68	-0.45	8.91e-8	Coronary artery disease;
TGCT	cis	rs682748	0.846	rs6893755	chr5:17140421	A/T	cg23987134	chr5:17158319	LOC285696	-0.21	-5.19	-0.42	8.4e-7	Hippocampal atrophy;
TGCT	cis	rs6840360	0.837	rs13137669	chr4:152710943	A/G	cg22705602	chr4:152727874	NA	-0.24	-4.45	-0.37	1.86e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg13636640	chr20:31349939	DNMT3B	0.99	12.23	0.74	4.84e-23	Ulcerative colitis;
TGCT	cis	rs9926296	0.609	rs4785710	chr16:89796756	C/T	cg03388025	chr16:89894329	SPIRE2	-0.32	-4.84	-0.4	3.86e-6	Vitiligo;
TGCT	cis	rs1348850	0.519	rs1527406	chr2:178525655	C/T	cg22681709	chr2:178499509	PDE11A	-0.48	-6.08	-0.48	1.36e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg27170947	chr2:26402098	FAM59B	-0.39	-4.46	-0.37	1.8e-5	Gut microbiome composition (summer);
TGCT	cis	rs921968	0.509	rs655441	chr2:219357545	C/T	cg02176678	chr2:219576539	TTLL4	0.48	6.78	0.52	4.32e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg03213289	chr20:61660250	NA	0.68	9.9	0.66	2.25e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs250677	0.687	rs10040624	chr5:148437579	A/G	cg18129178	chr5:148520854	ABLIM3	-0.43	-6.29	-0.49	5.05e-9	Breast cancer;
TGCT	cis	rs939658	0.935	rs954292	chr15:79449237	C/T	cg17916960	chr15:79447300	NA	0.55	8.85	0.62	7.63e-15	Refractive error;
TGCT	cis	rs12142240	0.698	rs1135459	chr1:46815930	C/T	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.09	0.54	8.96e-11	Prudent dietary pattern;
TGCT	cis	rs926938	0.520	rs6660624	chr1:115272163	G/A	cg12756093	chr1:115239321	AMPD1	-0.41	-4.93	-0.4	2.62e-6	Autism;
TGCT	cis	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg07424592	chr7:64974309	NA	-1.31	-7.72	-0.57	3.33e-12	Diabetic kidney disease;
TGCT	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg06753367	chr22:24256600	NA	-0.24	-4.66	-0.39	7.89e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	trans	rs1814175	0.645	rs28436748	chr11:50046422	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.84	-0.7	1.13e-19	Height;
TGCT	cis	rs2180341	0.920	rs7756880	chr6:127683999	A/T	cg24812749	chr6:127587940	RNF146	1.01	7.62	0.56	5.59e-12	Breast cancer;
TGCT	cis	rs6671200	0.607	rs3767315	chr1:95705972	A/G	cg06440946	chr1:95699313	RWDD3	-0.62	-5.3	-0.43	5.09e-7	Stearic acid (18:0) levels;
TGCT	cis	rs9517320	0.534	rs9554477	chr13:99160379	C/T	cg07423050	chr13:99094983	FARP1	-0.29	-5.8	-0.46	5.2e-8	Longevity;
TGCT	cis	rs4919694	1.000	rs75691516	chr10:104652045	C/T	cg04362960	chr10:104952993	NT5C2	1.03	6.95	0.53	1.83e-10	Arsenic metabolism;
TGCT	cis	rs8072100	0.713	rs2136750	chr17:45456100	A/G	cg08085267	chr17:45401833	C17orf57	-0.51	-5.6	-0.45	1.3e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs1577917	0.958	rs12208227	chr6:86670944	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.24	-0.43	6.64e-7	Response to antipsychotic treatment;
TGCT	cis	rs9611565	0.512	rs4820444	chr22:42202606	A/G	cg13695892	chr22:41940480	POLR3H	0.87	8.24	0.59	2.06e-13	Vitiligo;
TGCT	cis	rs12643440	0.538	rs4435747	chr4:17139645	C/T	cg22650099	chr4:17144496	NA	-0.46	-4.7	-0.39	6.79e-6	Metabolite levels (Pyroglutamine);
TGCT	cis	rs2439831	1.000	rs2467426	chr15:43989518	A/G	cg19166733	chr15:44192098	FRMD5	-0.25	-4.56	-0.38	1.21e-5	Lung cancer in ever smokers;
TGCT	cis	rs7208859	0.673	rs73263776	chr17:29211331	G/C	cg14008862	chr17:28927542	LRRC37B2	0.72	4.66	0.39	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7923609	0.967	rs2393966	chr10:65134814	T/G	cg08743896	chr10:65200160	JMJD1C	-0.34	-4.57	-0.38	1.15e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2688608	0.967	rs2633299	chr10:75656754	T/G	cg23231163	chr10:75533350	FUT11	-0.25	-4.45	-0.37	1.89e-5	Inflammatory bowel disease;
TGCT	cis	rs7119038	0.818	rs4936444	chr11:118743338	A/G	cg19308663	chr11:118741387	NA	-0.33	-6.63	-0.51	9.3e-10	Sjögren's syndrome;
TGCT	cis	rs2229238	0.911	rs4390168	chr1:154509096	A/G	cg13067139	chr1:155221277	FAM189B	0.2	4.51	0.38	1.47e-5	Coronary heart disease;
TGCT	trans	rs9593057	0.892	rs720506	chr13:35619734	T/C	cg02044145	chr5:176520341	FGFR4	0.42	6.62	0.51	9.8e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6121246	0.559	rs6087771	chr20:30306724	A/G	cg13852791	chr20:30311386	BCL2L1	0.84	7.74	0.57	3.08e-12	Mean corpuscular hemoglobin;
TGCT	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.51	5.51	0.44	2.02e-7	Lymphocyte counts;
TGCT	cis	rs3213545	0.659	rs2259693	chr12:121457995	G/A	cg02403541	chr12:121454288	C12orf43	0.7	7.9	0.58	1.3e-12	Subjective well-being;Cardiovascular disease risk factors;
TGCT	cis	rs8105265	1	rs8105265	chr19:2920705	A/G	cg08634464	chr19:2901147	ZNF57	1.37	7.75	0.57	2.79e-12	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs13191362	0.935	rs35049401	chr6:162968464	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.64	4.8	0.4	4.48e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg04944784	chr2:26401820	FAM59B	0.76	6.24	0.49	6.46e-9	Gut microbiome composition (summer);
TGCT	cis	rs4631830	0.863	rs6481329	chr10:51529746	G/A	cg10326726	chr10:51549505	MSMB	-0.26	-5.3	-0.43	5.17e-7	Prostate-specific antigen levels;
TGCT	cis	rs3733585	0.673	rs9994937	chr4:9964799	G/T	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.56	-0.56	7.77e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs28595532	0.702	rs56217716	chr4:119338490	T/G	cg11846333	chr4:119757529	SEC24D	0.72	4.51	0.38	1.48e-5	Cannabis dependence symptom count;
TGCT	cis	rs12643440	0.538	rs12650732	chr4:17141641	A/T	cg22650099	chr4:17144496	NA	-0.46	-4.7	-0.39	6.79e-6	Metabolite levels (Pyroglutamine);
TGCT	cis	rs12477438	0.798	rs896886	chr2:99652713	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.71	6.27	0.49	5.34e-9	Chronic sinus infection;
TGCT	cis	rs1552244	0.554	rs2272119	chr3:10049352	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.33	-4.95	-0.41	2.39e-6	Alzheimer's disease;
TGCT	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	16.1	0.82	3.69e-32	Prudent dietary pattern;
TGCT	cis	rs7100689	0.784	rs10749562	chr10:82108253	G/T	cg01528321	chr10:82214614	TSPAN14	0.8	8.0	0.58	7.5e-13	Post bronchodilator FEV1;
TGCT	cis	rs12477438	0.798	rs4324365	chr2:99623845	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-8.52	-0.61	4.5e-14	Chronic sinus infection;
TGCT	cis	rs2153535	0.580	rs4140586	chr6:8503192	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs308403	0.509	rs10016979	chr4:123673192	G/A	cg10495464	chr4:123653540	BBS12;LOC729338	0.82	11.84	0.73	4.22e-22	Blood protein levels;
TGCT	cis	rs2153535	0.580	rs1335628	chr6:8491742	A/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs9486719	0.843	rs2103539	chr6:96844342	T/A	cg06623918	chr6:96969491	KIAA0776	0.93	7.08	0.54	9.59e-11	Migraine;Coronary artery disease;
TGCT	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg08280861	chr8:58055591	NA	0.41	4.63	0.38	8.93e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6840360	0.642	rs2709834	chr4:152375424	T/G	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.83e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs1941023	0.584	rs7935082	chr11:60155000	T/C	cg08716584	chr11:60157161	MS4A7	-0.35	-5.29	-0.43	5.3e-7	Congenital heart disease (maternal effect);
TGCT	cis	rs2404602	1.000	rs2404741	chr15:76851735	C/T	cg26408565	chr15:76604113	ETFA	-0.45	-5.75	-0.46	6.55e-8	Blood metabolite levels;
TGCT	cis	rs8072100	0.790	rs7222225	chr17:45693497	A/G	cg10024583	chr17:45772800	TBKBP1	-0.43	-4.47	-0.37	1.76e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs28595532	0.702	rs72670238	chr4:119322751	C/T	cg21605333	chr4:119757512	SEC24D	0.79	4.99	0.41	1.96e-6	Cannabis dependence symptom count;
TGCT	cis	rs1005224	0.927	rs1981899	chr14:76175594	G/A	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.71	-5.88	-0.47	3.58e-8	Large artery stroke;
TGCT	cis	rs941873	0.868	rs4980063	chr10:81105844	A/T	cg09469691	chr10:81107165	PPIF	0.57	5.61	0.45	1.23e-7	Height;
TGCT	cis	rs57590327	0.679	rs17019088	chr3:81611535	A/T	cg07356753	chr3:81810745	GBE1	-0.6	-5.29	-0.43	5.38e-7	Extraversion;
TGCT	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs826838	1.000	rs7953227	chr12:38946193	G/A	cg26384229	chr12:38710491	ALG10B	0.99	9.96	0.67	1.54e-17	Heart rate;
TGCT	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg24675658	chr1:53192096	ZYG11B	-0.74	-9.02	-0.63	2.95e-15	Monocyte count;
TGCT	cis	rs7223966	0.961	rs112709843	chr17:61836936	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	4.68	0.39	7.54e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs8070740	1.000	rs8080400	chr17:5328633	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	4.55	0.38	1.27e-5	Menopause (age at onset);
TGCT	cis	rs9942416	0.660	rs166183	chr5:74977845	T/C	cg19683494	chr5:74908142	NA	-0.59	-6.29	-0.49	4.99e-9	Age-related disease endophenotypes;
TGCT	cis	rs78456975	0.550	rs11904276	chr2:1524006	T/C	cg12573674	chr2:1569213	NA	-0.46	-4.63	-0.38	9.04e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg20637647	chr7:64974828	NA	0.92	5.35	0.43	4.12e-7	Diabetic kidney disease;
TGCT	cis	rs2075165	0.870	rs9943105	chr1:156245245	T/C	cg20302342	chr1:156215951	PAQR6	0.36	5.38	0.44	3.56e-7	Tonsillectomy;
TGCT	cis	rs7615952	1.000	rs7616044	chr3:125649354	G/C	cg05084668	chr3:125655381	ALG1L	-0.75	-6.14	-0.48	1.03e-8	Blood pressure (smoking interaction);
TGCT	cis	rs7647973	0.566	rs57630346	chr3:49086215	T/C	cg05785598	chr3:49045655	WDR6	0.39	4.52	0.38	1.42e-5	Menarche (age at onset);
TGCT	cis	rs2486288	0.656	rs8040185	chr15:45552081	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.72	-7.46	-0.56	1.34e-11	Glomerular filtration rate;
TGCT	cis	rs66887589	0.616	rs6822808	chr4:120217365	C/A	cg24670566	chr4:120433619	PDE5A	0.21	4.57	0.38	1.17e-5	Diastolic blood pressure;
TGCT	cis	rs7917772	0.503	rs7100753	chr10:104300979	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs8180040	0.934	rs12630641	chr3:47534836	G/T	cg27129171	chr3:47204927	SETD2	0.66	7.91	0.58	1.22e-12	Colorectal cancer;
TGCT	cis	rs7772486	0.875	rs9403763	chr6:146357655	A/G	cg23711669	chr6:146136114	FBXO30	0.89	10.0	0.67	1.25e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9611565	0.559	rs5758397	chr22:42019251	C/T	cg13695892	chr22:41940480	POLR3H	0.86	8.2	0.59	2.63e-13	Vitiligo;
TGCT	cis	rs4478858	0.684	rs7549245	chr1:31752187	A/G	cg00250761	chr1:31883323	NA	-0.25	-4.52	-0.38	1.45e-5	Alcohol dependence;
TGCT	cis	rs666930	0.519	rs532303	chr1:120265444	A/G	cg19096424	chr1:120255104	PHGDH	0.64	5.86	0.47	3.83e-8	Breast cancer;
TGCT	cis	rs2297441	0.550	rs6011097	chr20:62398825	G/A	cg14758556	chr20:62440591	NA	-0.34	-4.77	-0.39	5.13e-6	Ulcerative colitis;
TGCT	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg20607798	chr8:58055168	NA	0.61	5.16	0.42	9.38e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs473651	0.935	rs508483	chr2:239339709	T/C	cg18131467	chr2:239335373	ASB1	1.02	15.01	0.8	1.18e-29	Multiple system atrophy;
TGCT	cis	rs13631	0.965	rs7853589	chr9:140003844	A/G	cg14289826	chr9:140003911	NA	-0.28	-6.64	-0.51	8.94e-10	Cerebrospinal fluid biomarker levels;
TGCT	trans	rs17685	0.672	rs1639623	chr7:75707951	A/G	cg19862616	chr7:65841803	NCRNA00174	0.52	9.04	0.63	2.65e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg24060327	chr5:131705240	SLC22A5	-0.61	-6.37	-0.5	3.32e-9	Acylcarnitine levels;
TGCT	cis	rs72781680	1.000	rs61739076	chr2:24149439	G/A	cg08917208	chr2:24149416	ATAD2B	0.85	5.28	0.43	5.53e-7	Lymphocyte counts;
TGCT	cis	rs6500602	0.627	rs3848372	chr16:4587875	C/A	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.25	4.65	0.38	8.54e-6	Schizophrenia;
TGCT	trans	rs12339966	0.615	rs1387295	chr9:11284569	C/T	cg07173112	chr1:1114698	TTLL10	-0.34	-6.68	-0.51	7.34e-10	Systolic blood pressure;
TGCT	cis	rs4988958	0.565	rs885088	chr2:103039044	A/G	cg03938978	chr2:103052716	IL18RAP	0.26	5.26	0.43	6.01e-7	Asthma (childhood onset);
TGCT	cis	rs6500602	0.627	rs841231	chr16:4583147	C/T	cg08645402	chr16:4508243	NA	-0.21	-5.49	-0.44	2.15e-7	Schizophrenia;
TGCT	cis	rs1322512	0.958	rs74608294	chr6:152944818	T/C	cg03415253	chr6:152958462	SYNE1	-0.57	-4.99	-0.41	2e-6	Tonometry;
TGCT	cis	rs62244186	0.566	rs55901755	chr3:44834707	C/T	cg10263370	chr3:44754102	ZNF502	-0.47	-5.67	-0.45	9.48e-8	Depressive symptoms;
TGCT	cis	rs6940638	0.688	rs9348750	chr6:27057945	T/G	cg26531700	chr6:26746687	NA	-0.56	-4.88	-0.4	3.25e-6	Intelligence (multi-trait analysis);
TGCT	trans	rs61931739	0.500	rs11053197	chr12:34441949	C/T	cg26384229	chr12:38710491	ALG10B	0.73	6.93	0.53	2e-10	Morning vs. evening chronotype;
TGCT	cis	rs6752107	0.935	rs10199278	chr2:234160669	C/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.2	4.86	0.4	3.46e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs6438424	0.521	rs10934426	chr3:117717570	T/G	cg15509235	chr3:117715573	NA	0.52	5.11	0.42	1.17e-6	Menarche (age at onset);
TGCT	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg06618935	chr21:46677482	NA	-0.36	-5.61	-0.45	1.25e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7216064	0.532	rs8065296	chr17:66018562	T/A	cg12091567	chr17:66097778	LOC651250	1.06	8.62	0.61	2.69e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs9486719	0.843	rs3849198	chr6:97036539	C/A	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.32	-0.6	1.32e-13	Migraine;Coronary artery disease;
TGCT	cis	rs9303542	0.527	rs62066689	chr17:46609092	T/C	cg25032089	chr17:46643351	HOXB3	0.58	5.47	0.44	2.38e-7	Ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs1372520	0.684	rs3113355	chr4:90745345	A/T	cg01966878	chr4:90757139	SNCA	-0.3	-4.69	-0.39	7.05e-6	Neuroticism;
TGCT	cis	rs9650657	0.771	rs12542888	chr8:10662555	A/C	cg27411982	chr8:10470053	RP1L1	-0.23	-5.04	-0.41	1.59e-6	Neuroticism;
TGCT	cis	rs317689	0.513	rs529268	chr12:69687051	G/A	cg11871910	chr12:69753446	YEATS4	0.63	6.11	0.48	1.18e-8	Response to diuretic therapy;
TGCT	cis	rs2404602	0.669	rs12441484	chr15:77109875	G/A	cg22467129	chr15:76604101	ETFA	-0.46	-5.22	-0.42	7.3e-7	Blood metabolite levels;
TGCT	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg22433210	chr17:43662623	NA	-1.01	-7.25	-0.55	3.83e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs854765	0.647	rs854769	chr17:18019011	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-6.95	-0.53	1.87e-10	Total body bone mineral density;
TGCT	cis	rs11690935	0.959	rs66835971	chr2:172677459	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.16	-12.07	-0.74	1.15e-22	Schizophrenia;
TGCT	cis	rs9527	0.830	rs12249194	chr10:104643698	T/C	cg15744005	chr10:104629667	AS3MT	-0.51	-6.04	-0.48	1.63e-8	Arsenic metabolism;
TGCT	cis	rs9560113	1.000	rs11069895	chr13:112178824	C/T	cg14154082	chr13:112174009	NA	0.37	5.07	0.41	1.42e-6	Menarche (age at onset);
TGCT	cis	rs3806843	0.576	rs246041	chr5:140331128	C/G	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs10992471	0.639	rs10125587	chr9:95499882	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.58	-5.48	-0.44	2.27e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs78487399	0.808	rs6705351	chr2:43843137	A/C	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.65	4.53	0.38	1.39e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs1696756	0.816	rs2650242	chr17:77827360	A/T	cg00646381	chr17:77835854	NA	0.43	6.11	0.48	1.21e-8	Glucocorticoid-induced osteonecrosis (age 10 years and older);
TGCT	cis	rs12477438	0.501	rs6727749	chr2:99793590	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	14.89	0.8	2.21e-29	Chronic sinus infection;
TGCT	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg16405210	chr4:1374714	KIAA1530	-0.25	-4.5	-0.37	1.54e-5	Longevity;
TGCT	cis	rs7178572	0.568	rs12443386	chr15:77491389	C/T	cg22256960	chr15:77711686	NA	0.89	8.92	0.63	4.95e-15	Type 2 diabetes;
TGCT	cis	rs9914988	0.832	rs34267753	chr17:27157586	T/C	cg20469991	chr17:27169893	C17orf63	-0.72	-5.09	-0.42	1.28e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg23708337	chr7:1209742	NA	0.6	5.57	0.45	1.53e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2255336	0.938	rs2126888	chr12:10546388	A/G	cg16084090	chr12:10586130	KLRC2	0.28	4.46	0.37	1.81e-5	Blood protein levels;
TGCT	cis	rs2013441	1.000	rs2703791	chr17:20163529	A/G	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.63	-0.38	9.19e-6	Obesity-related traits;
TGCT	cis	rs8062405	1.000	rs2008514	chr16:28825605	A/G	cg09754948	chr16:28834200	ATXN2L	-0.62	-4.69	-0.39	7.18e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs2204008	0.837	rs11612125	chr12:38213212	C/T	cg26384229	chr12:38710491	ALG10B	0.84	7.43	0.56	1.51e-11	Bladder cancer;
TGCT	cis	rs62244186	0.715	rs13321717	chr3:44667455	C/A	cg04389838	chr3:44770851	ZNF501	-0.4	-5.36	-0.43	3.87e-7	Depressive symptoms;
TGCT	cis	rs919433	0.647	rs13404366	chr2:198522632	A/G	cg00792783	chr2:198669748	PLCL1	0.56	4.85	0.4	3.64e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs7937682	0.575	rs34888817	chr11:111756455	C/T	cg09085632	chr11:111637200	PPP2R1B	0.92	8.7	0.62	1.7e-14	Primary sclerosing cholangitis;
TGCT	cis	rs7845219	0.544	rs4735330	chr8:95917770	A/C	cg16049864	chr8:95962084	TP53INP1	-0.48	-5.3	-0.43	5.23e-7	Type 2 diabetes;
TGCT	cis	rs2997447	0.655	rs1317709	chr1:26384690	A/C	cg19633962	chr1:26362018	EXTL1	-0.62	-4.55	-0.38	1.28e-5	QRS complex (12-leadsum);
TGCT	cis	rs67311347	1.000	rs13324109	chr3:40460767	T/C	cg13683864	chr3:40499215	RPL14	-1.04	-10.79	-0.7	1.54e-19	Renal cell carcinoma;
TGCT	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg21724239	chr8:58056113	NA	0.47	5.14	0.42	1.05e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9291683	0.530	rs882223	chr4:9981625	A/C	cg00071950	chr4:10020882	SLC2A9	0.65	8.23	0.59	2.21e-13	Bone mineral density;
TGCT	cis	rs7914558	0.966	rs4917997	chr10:104945213	A/G	cg05855489	chr10:104503620	C10orf26	0.51	4.48	0.37	1.65e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs8031584	0.578	rs1088473	chr15:31139298	A/G	cg08109568	chr15:31115862	NA	0.38	5.03	0.41	1.67e-6	Huntington's disease progression;
TGCT	cis	rs6669072	0.647	rs1335727	chr1:91238652	C/T	cg08895590	chr1:91227319	NA	-0.32	-4.45	-0.37	1.86e-5	Cognitive function;
TGCT	cis	rs9868809	0.881	rs7631574	chr3:48663046	A/G	cg00383909	chr3:49044727	WDR6	-0.84	-4.7	-0.39	6.72e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs12620999	1.000	rs4377286	chr2:238069686	C/T	cg23555395	chr2:238036564	NA	-0.3	-5.16	-0.42	9.38e-7	Systemic lupus erythematosus;
TGCT	trans	rs3780486	0.801	rs28517717	chr9:33179451	C/T	cg04842962	chr6:43655489	MRPS18A	1.12	12.06	0.73	1.25e-22	IgG glycosylation;
TGCT	cis	rs8084125	0.832	rs62105174	chr18:74948324	G/A	cg05528293	chr18:74961138	GALR1	0.52	5.2	0.42	8.04e-7	Obesity-related traits;
TGCT	cis	rs11779988	0.545	rs454692	chr8:17789298	T/C	cg01800426	chr8:17659068	MTUS1	-0.7	-5.46	-0.44	2.5e-7	Breast cancer;
TGCT	cis	rs35306767	0.668	rs12356612	chr10:1055055	C/T	cg20503657	chr10:835505	NA	0.57	6.65	0.51	8.47e-10	Eosinophil percentage of granulocytes;
TGCT	cis	rs6484504	0.576	rs158140	chr11:31212971	T/C	cg26647111	chr11:31128758	NA	-0.34	-4.62	-0.38	9.36e-6	Red blood cell count;
TGCT	trans	rs1814175	0.765	rs1722003	chr11:49895896	G/A	cg15704280	chr7:45808275	SEPT13	-0.72	-8.15	-0.59	3.33e-13	Height;
TGCT	trans	rs117132860	0.661	rs28826706	chr7:17121097	T/G	cg25519926	chr7:130132360	MEST;MESTIT1	0.95	6.71	0.52	6.21e-10	Cutaneous squamous cell carcinoma;
TGCT	cis	rs60871478	0.588	rs6952577	chr7:872100	C/T	cg00475322	chr7:917719	C7orf20	-0.49	-4.79	-0.39	4.72e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs2637266	0.967	rs4608018	chr10:78376110	T/C	cg18941641	chr10:78392320	NA	0.4	4.73	0.39	6.03e-6	Pulmonary function;
TGCT	cis	rs694739	1.000	rs11231757	chr11:64106317	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.68	7.03	0.53	1.25e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs7617773	0.539	rs13087050	chr3:48392800	C/T	cg11946769	chr3:48343235	NME6	0.6	5.01	0.41	1.82e-6	Coronary artery disease;
TGCT	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg02725872	chr8:58115012	NA	-0.39	-4.83	-0.4	3.99e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs12479064	0.724	rs737094	chr2:100089078	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.69	-5.83	-0.46	4.53e-8	Chronic sinus infection;
TGCT	cis	rs709400	0.663	rs62007718	chr14:103940436	G/A	cg26031613	chr14:104095156	KLC1	0.86	9.73	0.66	5.62e-17	Body mass index;
TGCT	cis	rs7582180	0.629	rs36103184	chr2:100942634	G/A	cg14675211	chr2:100938903	LONRF2	0.5	4.78	0.39	4.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs617219	0.710	rs2166344	chr5:78534134	T/G	cg23987322	chr5:78407566	BHMT	0.35	4.69	0.39	7.07e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs1670533	1.000	rs6837145	chr4:1071067	T/C	cg27284194	chr4:1044797	NA	0.68	5.85	0.47	4.09e-8	Recombination rate (females);
TGCT	cis	rs11190604	0.767	rs10883490	chr10:102194775	C/T	cg16342193	chr10:102329863	NA	-0.42	-5.26	-0.43	6.02e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs4566357	0.595	rs10206912	chr2:227921095	A/T	cg11843606	chr2:227700838	RHBDD1	-0.53	-4.83	-0.4	3.92e-6	Coronary artery disease;
TGCT	cis	rs896854	0.517	rs2013597	chr8:95951807	G/A	cg16049864	chr8:95962084	TP53INP1	-0.54	-5.95	-0.47	2.54e-8	Type 2 diabetes;
TGCT	cis	rs1153858	1.000	rs7169818	chr15:45640191	G/A	cg14582100	chr15:45693742	SPATA5L1	0.47	5.65	0.45	1.05e-7	Homoarginine levels;
TGCT	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg11890956	chr21:40555474	PSMG1	1.04	10.93	0.7	6.96e-20	Cognitive function;
TGCT	cis	rs909674	0.818	rs5757678	chr22:39843409	A/G	cg05872129	chr22:39784769	NA	0.96	9.61	0.65	1.09e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs7937612	1.000	rs6589812	chr11:120278359	T/C	cg24566217	chr11:120254723	ARHGEF12	-0.28	-4.44	-0.37	1.96e-5	Intraocular pressure;
TGCT	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg13770153	chr20:60521292	NA	-0.54	-7.11	-0.54	7.9e-11	Body mass index;
TGCT	cis	rs1801251	1.000	rs2675974	chr2:233727071	A/G	cg25237894	chr2:233734115	C2orf82	0.31	5.47	0.44	2.36e-7	Coronary artery disease;
TGCT	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg25036284	chr2:26402008	FAM59B	0.65	5.19	0.42	8.36e-7	Gut microbiome composition (summer);
TGCT	cis	rs669446	0.622	rs623965	chr1:44111187	A/G	cg12908607	chr1:44402522	ARTN	-0.55	-5.9	-0.47	3.25e-8	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs910316	0.934	rs8006587	chr14:75664939	A/G	cg08847533	chr14:75593920	NEK9	0.95	9.85	0.66	2.89e-17	Height;
TGCT	cis	rs9814567	0.537	rs9879993	chr3:134162559	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	7.4	0.55	1.82e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs60871478	1.000	rs62432252	chr7:802886	C/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.45	4.56	0.38	1.21e-5	Cerebrospinal P-tau181p levels;
TGCT	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.61	-4.49	-0.37	1.6e-5	Tuberculosis;
TGCT	cis	rs4665630	0.522	rs747622	chr2:23881466	G/C	cg08063864	chr2:24346004	PFN4;LOC375190	-1.28	-5.96	-0.47	2.43e-8	Hypertension;
TGCT	cis	rs6964587	0.626	rs10225241	chr7:91524940	A/G	cg17063962	chr7:91808500	NA	-0.76	-7.15	-0.54	6.42e-11	Breast cancer;
TGCT	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg20607798	chr8:58055168	NA	0.44	4.53	0.38	1.36e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs13102973	0.645	rs11734870	chr4:135885118	T/A	cg14419869	chr4:135874104	NA	0.26	4.55	0.38	1.28e-5	Subjective well-being;
TGCT	cis	rs7552404	0.655	rs5745336	chr1:76273519	G/A	cg03433033	chr1:76189801	ACADM	0.66	6.88	0.53	2.57e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7659604	0.967	rs34949254	chr4:122664344	G/A	cg19748678	chr4:122722346	EXOSC9	0.57	5.54	0.45	1.69e-7	Type 2 diabetes;
TGCT	trans	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg17470723	chr8:74884337	TCEB1	0.71	6.77	0.52	4.48e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs514406	0.505	rs856721	chr1:53162156	C/A	cg01802117	chr1:53393560	SCP2	-0.42	-4.86	-0.4	3.51e-6	Monocyte count;
TGCT	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg06028808	chr11:68637592	NA	0.51	6.54	0.51	1.48e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs2204008	0.774	rs3910796	chr12:38230660	G/T	cg13010199	chr12:38710504	ALG10B	0.62	4.91	0.4	2.81e-6	Bladder cancer;
TGCT	cis	rs6987853	0.865	rs2923445	chr8:42400743	C/A	cg20539142	chr8:42623718	CHRNA6	-0.19	-4.58	-0.38	1.11e-5	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs114540395	0.925	rs78646802	chr10:103392029	A/G	cg03300883	chr10:102748874	C10orf2	0.42	4.63	0.38	9.24e-6	Schizophrenia;
TGCT	cis	rs3806843	1.000	rs12717860	chr5:140171442	C/T	cg19875535	chr5:140030758	IK	0.37	6.34	0.49	3.89e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9467773	1.000	rs6922824	chr6:26553815	C/G	cg05738196	chr6:26577821	NA	-0.9	-13.24	-0.77	1.71e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs2970818	0.831	rs4238020	chr12:4616642	C/T	cg02722637	chr12:4922070	KCNA6	-0.32	-4.58	-0.38	1.11e-5	Phosphorus levels;
TGCT	cis	rs12477438	0.501	rs11123770	chr2:99825102	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.98	12.5	0.75	1.03e-23	Chronic sinus infection;
TGCT	trans	rs4650994	0.816	rs2811303	chr1:178595646	G/T	cg05059571	chr16:84539110	KIAA1609	0.4	7.44	0.56	1.49e-11	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg09359103	chr1:154839909	KCNN3	0.63	11.15	0.71	1.98e-20	Prostate cancer;
TGCT	cis	rs826838	0.967	rs4768329	chr12:39129394	T/C	cg13010199	chr12:38710504	ALG10B	-0.64	-5.11	-0.42	1.19e-6	Heart rate;
TGCT	cis	rs12135062	0.687	rs6685614	chr1:3108517	C/T	cg25382214	chr1:3105252	PRDM16	0.28	4.87	0.4	3.27e-6	Migraine;
TGCT	trans	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg25482853	chr8:67687455	SGK3	1.22	10.31	0.68	2.2e-18	Obesity-related traits;
TGCT	cis	rs2406342	0.528	rs75536638	chr18:74499060	G/T	cg16472389	chr18:74514291	NA	0.52	5.27	0.43	5.81e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin);
TGCT	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg25036284	chr2:26402008	FAM59B	-0.65	-5.19	-0.42	8.36e-7	Gut microbiome composition (summer);
TGCT	cis	rs4788570	0.667	rs4788557	chr16:71804802	C/T	cg06353428	chr16:71660113	MARVELD3	1.53	12.59	0.75	6.48e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs2816062	0.813	rs2816040	chr1:18889536	C/T	cg18795169	chr1:18902165	NA	0.6	14.18	0.79	1.04e-27	Urate levels in lean individuals;
TGCT	cis	rs10789491	1.000	rs10789491	chr1:47179310	A/G	cg15501359	chr1:47185051	KIAA0494	0.81	8.34	0.6	1.19e-13	Response to hepatitis C treatment;
TGCT	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.0	7.42	0.55	1.64e-11	Gut microbiome composition (summer);
TGCT	cis	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg22857025	chr5:266934	NA	-0.34	-6.7	-0.52	6.65e-10	Breast cancer;
TGCT	cis	rs12220898	0.679	rs4582889	chr10:50475014	A/C	cg06072769	chr10:50146962	WDFY4	0.36	4.67	0.39	7.64e-6	Inflammatory biomarkers;
TGCT	cis	rs62244186	0.715	rs11130032	chr3:44704083	G/A	cg10263370	chr3:44754102	ZNF502	-0.41	-4.79	-0.39	4.73e-6	Depressive symptoms;
TGCT	cis	rs1008375	0.898	rs7670500	chr4:17586957	A/G	cg10189774	chr4:17578691	LAP3	0.64	5.61	0.45	1.28e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg20887711	chr4:1340912	KIAA1530	0.91	7.94	0.58	1.06e-12	Longevity;
TGCT	cis	rs7296418	0.517	rs73231928	chr12:123724325	T/C	cg00376283	chr12:123451042	ABCB9	0.73	6.5	0.5	1.75e-9	Platelet count;
TGCT	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.91	-10.66	-0.69	3.08e-19	Menarche (age at onset);
TGCT	cis	rs7954584	0.813	rs1523261	chr12:122462877	C/A	cg22168489	chr12:122356033	WDR66	0.2	4.72	0.39	6.21e-6	Mean corpuscular volume;
TGCT	cis	rs7582180	0.638	rs6734316	chr2:100976210	A/G	cg14675211	chr2:100938903	LONRF2	0.47	4.55	0.38	1.27e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs8103278	0.507	rs4802275	chr19:46260375	C/T	cg14061069	chr19:46274453	DMPK	0.63	11.0	0.7	4.62e-20	Coronary artery disease;
TGCT	cis	rs710216	0.843	rs2297972	chr1:43418026	C/T	cg03128534	chr1:43423976	SLC2A1	-0.61	-5.02	-0.41	1.79e-6	Red cell distribution width;
TGCT	cis	rs9811920	0.683	rs793439	chr3:99637783	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.45	-5.33	-0.43	4.52e-7	Axial length;
TGCT	cis	rs3008870	0.792	rs72673729	chr1:67441673	T/TG	cg03991309	chr1:68237761	GNG12	-0.27	-4.51	-0.38	1.48e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.42	-5.41	-0.44	3.15e-7	Parkinson's disease;
TGCT	cis	rs3753275	0.624	rs6664000	chr1:8858532	C/T	cg17029193	chr1:8510607	RERE	-0.31	-4.46	-0.37	1.8e-5	Educational attainment;
TGCT	cis	rs3820928	0.874	rs6728239	chr2:227856552	A/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-4.63	-0.38	9.03e-6	Pulmonary function;
TGCT	cis	rs1949733	1.000	rs2631758	chr4:8495304	G/A	cg11789530	chr4:8429930	ACOX3	-0.59	-5.43	-0.44	2.83e-7	Response to antineoplastic agents;
TGCT	trans	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.86	9.4	0.65	3.49e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs7633770	0.805	rs12330414	chr3:46662428	T/C	cg11219411	chr3:46661640	NA	0.35	5.07	0.41	1.43e-6	Coronary artery disease;
TGCT	trans	rs1814175	0.791	rs10839468	chr11:49986288	A/G	cg03929089	chr4:120376271	NA	-0.72	-8.53	-0.61	4.24e-14	Height;
TGCT	cis	rs9400467	0.537	rs17606481	chr6:111542388	A/G	cg15721981	chr6:111408429	SLC16A10	0.73	4.79	0.4	4.71e-6	Blood metabolite levels;Amino acid levels;
TGCT	cis	rs7659604	0.540	rs10012775	chr4:122676878	T/C	cg19748678	chr4:122722346	EXOSC9	-0.51	-5.0	-0.41	1.89e-6	Type 2 diabetes;
TGCT	trans	rs877282	1.000	rs12779159	chr10:772143	T/C	cg22713356	chr15:30763199	NA	1.16	9.82	0.66	3.37e-17	Uric acid levels;
TGCT	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg00343986	chr7:65444356	GUSB	-0.24	-5.29	-0.43	5.43e-7	Aortic root size;
TGCT	cis	rs709400	1.000	rs861538	chr14:104166733	C/T	cg26031613	chr14:104095156	KLC1	1.13	16.84	0.83	7.59e-34	Body mass index;
TGCT	cis	rs1570884	1.000	rs1570884	chr13:50121511	A/G	cg08779649	chr13:50194554	NA	0.34	5.39	0.44	3.46e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
TGCT	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.0	8.22	0.59	2.32e-13	Platelet count;
TGCT	cis	rs4689388	0.853	rs11729672	chr4:6293838	A/G	cg25554036	chr4:6271136	WFS1	0.54	7.37	0.55	2.11e-11	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs7010267	0.570	rs7009768	chr8:120041303	G/A	cg17171407	chr8:119960777	TNFRSF11B	0.26	4.59	0.38	1.06e-5	Total body bone mineral density (age 45-60);
TGCT	cis	rs17221829	0.733	rs12365125	chr11:89359929	C/T	cg02982614	chr11:89391479	FOLH1B	-0.28	-4.87	-0.4	3.35e-6	Anxiety in major depressive disorder;
TGCT	cis	rs2153535	0.525	rs1335644	chr6:8488041	A/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs7412746	0.658	rs12067685	chr1:150952917	T/C	cg09365446	chr1:150670422	GOLPH3L	0.35	4.88	0.4	3.17e-6	Melanoma;
TGCT	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg04287289	chr16:89883240	FANCA	0.94	11.87	0.73	3.65e-22	Vitiligo;
TGCT	cis	rs6815814	0.731	rs11734342	chr4:38773109	A/G	cg02016764	chr4:38805732	TLR1	-0.28	-4.79	-0.4	4.63e-6	Breast cancer;
TGCT	cis	rs9303401	0.527	rs34835800	chr17:56764990	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.61	5.41	0.44	3.12e-7	Cognitive test performance;
TGCT	cis	rs9858542	1.000	rs9858542	chr3:49701983	A/G	cg03060546	chr3:49711283	APEH	0.67	6.09	0.48	1.28e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs1670533	1.000	rs935970	chr4:1045323	C/G	cg27284194	chr4:1044797	NA	-0.67	-5.68	-0.45	9.03e-8	Recombination rate (females);
TGCT	cis	rs36051895	0.632	rs10118789	chr9:5141178	G/A	cg02405213	chr9:5042618	JAK2	-0.7	-9.44	-0.65	2.91e-16	Pediatric autoimmune diseases;
TGCT	cis	rs66573146	1.000	rs73088528	chr4:6967747	G/C	cg01220768	chr4:7056774	TADA2B	0.35	4.63	0.38	8.96e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs16910800	0.731	rs56067480	chr11:23190184	C/T	cg20040320	chr11:23191996	NA	-0.51	-4.47	-0.37	1.71e-5	Cancer;
TGCT	cis	rs1153858	1.000	rs12591058	chr15:45640172	T/C	cg14582100	chr15:45693742	SPATA5L1	0.48	5.7	0.46	8.17e-8	Homoarginine levels;
TGCT	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg11644478	chr21:40555479	PSMG1	0.64	5.93	0.47	2.86e-8	Cognitive function;
TGCT	cis	rs3812831	0.662	rs407531	chr13:114929218	G/A	cg06611532	chr13:114900021	NA	0.36	6.4	0.5	2.95e-9	Schizophrenia;
TGCT	cis	rs6840360	0.550	rs4696288	chr4:152621150	A/C	cg17479576	chr4:152424074	FAM160A1	-0.67	-6.69	-0.52	6.7e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs941408	0.515	rs1005556	chr19:2778543	G/T	cg26465405	chr19:3039745	TLE2	-0.22	-4.52	-0.38	1.41e-5	Total cholesterol levels;
TGCT	cis	rs3771570	0.642	rs56241013	chr2:242185311	T/C	cg21155796	chr2:242212141	HDLBP	0.89	5.45	0.44	2.64e-7	Prostate cancer;
TGCT	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg10560079	chr2:191398806	TMEM194B	-0.35	-4.97	-0.41	2.21e-6	Pulse pressure;
TGCT	cis	rs9303542	0.559	rs12939811	chr17:46607958	A/T	cg25032089	chr17:46643351	HOXB3	0.59	5.6	0.45	1.31e-7	Ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs7617773	0.514	rs11130166	chr3:48388056	A/G	cg11946769	chr3:48343235	NME6	0.56	4.75	0.39	5.46e-6	Coronary artery disease;
TGCT	cis	rs7513165	0.935	rs7538055	chr1:204161069	A/G	cg04791601	chr1:204159016	NA	0.26	5.21	0.42	7.68e-7	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
TGCT	cis	rs9818758	0.607	rs13077498	chr3:49313978	C/T	cg07636037	chr3:49044803	WDR6	-1.04	-5.13	-0.42	1.09e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs7698623	0.850	rs6821260	chr4:88787439	T/C	cg27387453	chr4:88533842	DSPP	-0.62	-4.64	-0.38	8.66e-6	Cardiovascular disease risk factors;
TGCT	cis	rs10186029	0.676	rs10932464	chr2:213968315	T/A	cg08319019	chr2:214017104	IKZF2	0.63	5.79	0.46	5.4e-8	Systemic sclerosis;
TGCT	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg14159672	chr1:205819179	PM20D1	0.58	7.07	0.54	9.96e-11	Menarche (age at onset);
TGCT	cis	rs6430585	0.527	rs961360	chr2:136393658	A/G	cg07169764	chr2:136633963	MCM6	0.98	8.33	0.6	1.3e-13	Corneal structure;
TGCT	cis	rs727563	0.593	rs132770	chr22:42017264	A/G	cg13695892	chr22:41940480	POLR3H	0.85	8.03	0.58	6.49e-13	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs2439831	0.867	rs2264876	chr15:43757419	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.81	5.66	0.45	9.81e-8	Lung cancer in ever smokers;
TGCT	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg07507251	chr3:52567010	NT5DC2	0.45	6.3	0.49	4.7e-9	Electroencephalogram traits;
TGCT	cis	rs6977660	0.714	rs12666488	chr7:19788403	G/A	cg05791153	chr7:19748676	TWISTNB	0.84	4.86	0.4	3.49e-6	Thyroid stimulating hormone;
TGCT	trans	rs1973993	0.967	rs11165643	chr1:96924097	C/T	cg10631902	chr5:14652156	NA	0.32	7.41	0.55	1.75e-11	Weight;
TGCT	cis	rs3096299	0.933	rs28608022	chr16:89454292	C/T	cg02187348	chr16:89574699	SPG7	0.49	4.7	0.39	6.79e-6	Multiple myeloma (IgH translocation);
TGCT	cis	rs909341	0.909	rs1295810	chr20:62330484	G/A	cg14758556	chr20:62440591	NA	0.29	4.45	0.37	1.92e-5	Atopic dermatitis;
TGCT	cis	rs9430161	0.598	rs34350247	chr1:11034460	A/G	cg27631724	chr1:11040367	C1orf127	0.52	5.95	0.47	2.57e-8	Ewing sarcoma;
TGCT	trans	rs7726839	0.794	rs11739663	chr5:594083	A/G	cg25482853	chr8:67687455	SGK3	0.97	7.68	0.57	4.21e-12	Obesity-related traits;
TGCT	cis	rs7267979	0.966	rs2261785	chr20:25262403	C/T	cg14121845	chr20:25566513	NINL	0.51	5.5	0.44	2.04e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2013441	1.000	rs1373147	chr17:20206645	T/A	cg23224458	chr17:20280056	CCDC144C	-0.41	-4.88	-0.4	3.25e-6	Obesity-related traits;
TGCT	cis	rs1903068	0.853	rs12331471	chr4:56001509	T/C	cg01777861	chr4:56023843	NA	0.54	6.38	0.5	3.2e-9	Endometriosis;
TGCT	cis	rs7100689	0.646	rs1953971	chr10:82145647	G/C	cg01528321	chr10:82214614	TSPAN14	0.78	7.86	0.58	1.56e-12	Post bronchodilator FEV1;
TGCT	cis	rs9303401	0.659	rs8074016	chr17:56840587	A/G	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs7552404	1.000	rs437298	chr1:76113770	T/C	cg10523679	chr1:76189770	ACADM	-0.92	-10.05	-0.67	9.78e-18	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs17376456	0.877	rs35075119	chr5:93385457	T/C	cg21475434	chr5:93447410	FAM172A	0.59	4.66	0.39	8.09e-6	Diabetic retinopathy;
TGCT	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs68170813	0.559	rs7798223	chr7:106829223	T/C	cg02696742	chr7:106810147	HBP1	-0.69	-5.73	-0.46	7.17e-8	Coronary artery disease;
TGCT	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.84	7.5	0.56	1.08e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2637266	1.000	rs1873461	chr10:78338966	A/C	cg18941641	chr10:78392320	NA	-0.38	-4.73	-0.39	6.01e-6	Pulmonary function;
TGCT	cis	rs9650657	0.770	rs6601529	chr8:10670550	A/G	cg27411982	chr8:10470053	RP1L1	-0.23	-5.28	-0.43	5.51e-7	Neuroticism;
TGCT	trans	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg20587970	chr11:113659929	NA	-1.03	-10.98	-0.7	5.21e-20	Hip circumference adjusted for BMI;
TGCT	cis	rs7308134	0.766	rs73036228	chr12:1991782	G/A	cg09189752	chr12:2113749	DCP1B	-0.57	-4.44	-0.37	1.93e-5	QRS duration in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10754283	0.967	rs6428559	chr1:90099036	C/T	cg03145924	chr1:90228473	NA	-0.4	-4.47	-0.37	1.75e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs4700695	0.545	rs29441	chr5:65509116	G/T	cg21114390	chr5:65439923	SFRS12	-0.79	-7.22	-0.54	4.7e-11	Facial morphology (factor 19);
TGCT	trans	rs10506458	0.915	rs1463821	chr12:63402875	C/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	0.44	7.53	0.56	8.98e-12	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs62244186	0.535	rs59726036	chr3:44850074	G/T	cg11003573	chr3:44754125	ZNF502	-0.48	-5.42	-0.44	2.96e-7	Depressive symptoms;
TGCT	cis	rs478222	1.000	rs551573	chr2:25305504	A/G	cg01884057	chr2:25150051	NA	0.27	4.95	0.41	2.35e-6	Type 1 diabetes;
TGCT	cis	rs9303401	0.659	rs12952325	chr17:56899371	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.69	6.4	0.5	2.86e-9	Cognitive test performance;
TGCT	cis	rs4746818	0.643	rs2855020	chr10:70856510	C/T	cg11621586	chr10:70884670	VPS26A	1.14	7.64	0.57	5.15e-12	Left atrial antero-posterior diameter;
TGCT	cis	rs1577917	1.000	rs2816815	chr6:86691656	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.1	-0.42	1.22e-6	Response to antipsychotic treatment;
TGCT	cis	rs6921919	0.583	rs7764722	chr6:28354533	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.54	-5.3	-0.43	5.14e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg10047753	chr17:41438598	NA	0.84	7.61	0.56	5.9e-12	Menopause (age at onset);
TGCT	cis	rs950776	0.642	rs12905641	chr15:78964362	A/G	cg03762349	chr15:79060523	ADAMTS7	-0.28	-5.59	-0.45	1.38e-7	Sudden cardiac arrest;
TGCT	cis	rs950027	0.787	rs1153845	chr15:45724729	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.38	-4.81	-0.4	4.32e-6	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs2742417	1.000	rs2673036	chr3:45752471	C/T	cg04837898	chr3:45731254	SACM1L	-0.55	-5.72	-0.46	7.45e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs9640161	0.783	rs35435439	chr7:150063534	C/T	cg21361702	chr7:150065534	REPIN1	0.51	4.52	0.38	1.43e-5	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs9611565	0.694	rs5758411	chr22:42079734	G/A	cg13695892	chr22:41940480	POLR3H	0.84	8.14	0.59	3.45e-13	Vitiligo;
TGCT	cis	rs3733585	0.673	rs4312757	chr4:9956145	T/A	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.7	-0.52	6.62e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs9649213	0.586	rs11768599	chr7:97974555	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.93	-8.73	-0.62	1.45e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg12310025	chr6:25882481	NA	-0.62	-6.42	-0.5	2.63e-9	Blood metabolite levels;
TGCT	cis	rs76878669	0.917	rs3116068	chr11:66104993	C/T	cg18002602	chr11:66138449	SLC29A2	-0.46	-4.82	-0.4	4.19e-6	Educational attainment (years of education);
TGCT	cis	rs10927875	0.619	rs7537101	chr1:16150384	T/C	cg21385522	chr1:16154831	NA	-0.76	-9.68	-0.66	7.71e-17	Dilated cardiomyopathy;
TGCT	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg20607798	chr8:58055168	NA	0.6	4.9	0.4	2.93e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg03060546	chr3:49711283	APEH	0.51	4.91	0.4	2.84e-6	Menarche (age at onset);
TGCT	cis	rs35306767	0.903	rs12264711	chr10:929525	T/C	cg20503657	chr10:835505	NA	0.74	10.3	0.68	2.41e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg06481639	chr22:41940642	POLR3H	0.74	6.58	0.51	1.2e-9	Vitiligo;
TGCT	cis	rs739496	0.527	rs2097701	chr12:112316774	T/G	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs2486288	0.656	rs12899058	chr15:45547324	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.46	-5.59	-0.45	1.38e-7	Glomerular filtration rate;
TGCT	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg03388025	chr16:89894329	SPIRE2	0.48	7.85	0.58	1.7e-12	Vitiligo;
TGCT	cis	rs3784262	0.669	rs1063666	chr15:58246602	A/C	cg12031962	chr15:58353849	ALDH1A2	-0.43	-6.28	-0.49	5.28e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs3821902	0.646	rs17344723	chr3:64019808	G/A	cg22134162	chr3:63841271	THOC7	-0.32	-4.77	-0.39	5.15e-6	Breast cancer;
TGCT	cis	rs6952808	0.792	rs34269264	chr7:1948712	C/T	cg22963979	chr7:1858916	MAD1L1	-0.35	-5.43	-0.44	2.9e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs5760092	0.755	rs3884794	chr22:24251766	C/A	cg07154950	chr22:24370586	NA	-0.21	-4.69	-0.39	6.96e-6	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs4654899	0.802	rs10916903	chr1:21247944	T/C	cg01072550	chr1:21505969	NA	-0.47	-7.06	-0.54	1.03e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs8180040	0.726	rs11130110	chr3:47000606	T/C	cg27129171	chr3:47204927	SETD2	0.73	9.4	0.64	3.62e-16	Colorectal cancer;
TGCT	cis	rs6939532	0.522	rs2073528	chr6:26375143	G/C	cg05738196	chr6:26577821	NA	-0.52	-4.99	-0.41	2.03e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs10504229	0.593	rs2317990	chr8:58024168	G/T	cg08280861	chr8:58055591	NA	0.36	5.16	0.42	9.31e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7617773	0.817	rs17647717	chr3:48305456	C/T	cg11946769	chr3:48343235	NME6	0.76	6.64	0.51	8.76e-10	Coronary artery disease;
TGCT	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	5.71	0.46	8.05e-8	Alzheimer's disease;
TGCT	cis	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg07424592	chr7:64974309	NA	1.4	8.42	0.6	7.87e-14	Diabetic kidney disease;
TGCT	cis	rs7666738	0.830	rs1967977	chr4:98966141	A/G	cg18180107	chr4:99064573	C4orf37	0.57	5.19	0.42	8.47e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2832191	0.716	rs1888439	chr21:30454457	A/G	cg24692254	chr21:30365293	RNF160	0.95	11.91	0.73	2.84e-22	Dental caries;
TGCT	cis	rs514406	0.584	rs12095247	chr1:53193796	A/C	cg16325326	chr1:53192061	ZYG11B	-0.9	-13.25	-0.77	1.67e-25	Monocyte count;
TGCT	cis	rs12541335	0.639	rs4565458	chr8:22154133	T/C	cg26039829	chr8:22132926	PIWIL2	0.26	4.74	0.39	5.84e-6	Hypertriglyceridemia;
TGCT	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg15595755	chr5:1867978	NA	0.47	5.52	0.44	1.94e-7	Cardiovascular disease risk factors;
TGCT	cis	rs6424115	0.729	rs1737362	chr1:24054800	T/C	cg15997130	chr1:24165203	NA	0.69	6.6	0.51	1.05e-9	Immature fraction of reticulocytes;
TGCT	cis	rs7647973	0.925	rs6808036	chr3:49236439	T/G	cg05785598	chr3:49045655	WDR6	0.38	4.68	0.39	7.48e-6	Menarche (age at onset);
TGCT	cis	rs4319547	0.695	rs12314643	chr12:122917423	C/T	cg08088222	chr12:122070432	ORAI1	0.26	4.59	0.38	1.08e-5	Body mass index;
TGCT	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg11890956	chr21:40555474	PSMG1	1.04	11.07	0.7	3.18e-20	Cognitive function;
TGCT	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.72	-6.47	-0.5	2.04e-9	Tonsillectomy;
TGCT	cis	rs4711350	1.000	rs2395401	chr6:33759471	T/C	cg00334056	chr6:33755658	LEMD2	-0.29	-4.56	-0.38	1.22e-5	Schizophrenia;
TGCT	cis	rs7833790	0.926	rs72686467	chr8:82758929	T/G	cg27398817	chr8:82754497	SNX16	0.84	5.98	0.47	2.18e-8	Diastolic blood pressure;
TGCT	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg16325326	chr1:53192061	ZYG11B	0.6	5.1	0.42	1.25e-6	Monocyte count;
TGCT	cis	rs8016982	1.000	rs8016982	chr14:81707057	C/T	cg01989461	chr14:81687754	GTF2A1	0.59	4.89	0.4	3.09e-6	Schizophrenia;
TGCT	cis	rs72717009	0.825	rs9427398	chr1:161476205	A/G	cg23840854	chr1:161414152	NA	-0.98	-5.86	-0.47	3.95e-8	Rheumatoid arthritis;
TGCT	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.85	8.69	0.62	1.79e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs7714584	0.826	rs34005003	chr5:150225199	C/T	cg22134413	chr5:150180641	NA	0.89	6.96	0.53	1.73e-10	Crohn's disease;
TGCT	cis	rs57920188	0.535	rs58051771	chr1:4092146	T/C	cg20703997	chr1:4087676	NA	0.49	5.79	0.46	5.39e-8	Interleukin-17 levels;
TGCT	cis	rs2486288	0.656	rs11639420	chr15:45559268	A/C	cg26924012	chr15:45694286	SPATA5L1	-0.72	-7.49	-0.56	1.11e-11	Glomerular filtration rate;
TGCT	cis	rs2153535	0.601	rs1855768	chr6:8472969	T/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	trans	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg13615516	chr5:77269221	NA	0.67	8.36	0.6	1.09e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1670533	1.000	rs935972	chr4:1045171	A/G	cg27284194	chr4:1044797	NA	0.73	5.74	0.46	6.91e-8	Recombination rate (females);
TGCT	cis	rs478304	0.900	rs502468	chr11:65525119	T/G	cg17480646	chr11:65405466	SIPA1	0.43	5.38	0.43	3.62e-7	Acne (severe);
TGCT	cis	rs7226408	0.857	rs17652483	chr18:34482270	G/A	cg06757138	chr18:34340585	FHOD3	0.25	4.77	0.39	5.08e-6	Obesity-related traits;
TGCT	cis	rs7552404	0.590	rs1565717	chr1:76320441	T/C	cg03433033	chr1:76189801	ACADM	-0.59	-6.06	-0.48	1.51e-8	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7647973	1.000	rs13088309	chr3:49368317	A/G	cg06212747	chr3:49208901	KLHDC8B	0.59	4.72	0.39	6.22e-6	Menarche (age at onset);
TGCT	cis	rs751728	0.965	rs2296743	chr6:33740025	C/T	cg13859433	chr6:33739653	LEMD2	-0.4	-7.28	-0.55	3.43e-11	Crohn's disease;
TGCT	cis	rs67073037	0.955	rs6721781	chr2:29120030	G/A	cg09522027	chr2:28974177	PPP1CB	0.57	4.49	0.37	1.59e-5	Breast cancer;Breast cancer (estrogen-receptor negative);
TGCT	cis	rs7552404	0.960	rs61797339	chr1:76189946	G/T	cg22875332	chr1:76189707	ACADM	0.79	9.77	0.66	4.68e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9611565	0.681	rs5751094	chr22:41803279	C/T	cg03806693	chr22:41940476	POLR3H	1.01	11.44	0.72	3.94e-21	Vitiligo;
TGCT	cis	rs9611565	0.525	rs1883827	chr22:41703579	A/G	cg06634786	chr22:41940651	POLR3H	-0.58	-5.28	-0.43	5.62e-7	Vitiligo;
TGCT	cis	rs7072216	0.763	rs6584201	chr10:100170209	T/C	cg26618903	chr10:100175079	PYROXD2	-0.4	-4.49	-0.37	1.64e-5	Metabolite levels;
TGCT	cis	rs7072216	0.763	rs3814140	chr10:100170762	C/T	cg26618903	chr10:100175079	PYROXD2	-0.4	-4.49	-0.37	1.64e-5	Metabolite levels;
TGCT	cis	rs6882046	0.513	rs254780	chr5:88019747	G/C	cg22951263	chr5:87985283	NA	-0.58	-6.18	-0.49	8.49e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg18402987	chr7:1209562	NA	0.78	6.64	0.51	8.96e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs6500602	0.627	rs863501	chr16:4588394	G/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	-0.26	-4.68	-0.39	7.28e-6	Schizophrenia;
TGCT	cis	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg15556689	chr8:8085844	FLJ10661	0.69	6.17	0.48	8.84e-9	Mood instability;
TGCT	cis	rs7216064	1.000	rs2365468	chr17:65841318	C/T	cg12091567	chr17:66097778	LOC651250	-0.84	-6.8	-0.52	4.01e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs7666738	0.830	rs10014986	chr4:99000687	A/C	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7617773	0.709	rs4404473	chr3:48353626	A/G	cg11946769	chr3:48343235	NME6	0.83	7.12	0.54	7.56e-11	Coronary artery disease;
TGCT	cis	rs11874712	0.527	rs7359798	chr18:43648999	A/C	cg20479805	chr18:43684716	ATP5A1;HAUS1	-0.44	-4.47	-0.37	1.73e-5	Migraine - clinic-based;
TGCT	cis	rs3020736	0.500	rs6002597	chr22:42488160	C/A	cg05082376	chr22:42548792	NA	0.23	5.43	0.44	2.85e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg07424592	chr7:64974309	NA	1.38	8.17	0.59	3.04e-13	Diabetic kidney disease;
TGCT	cis	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg15556689	chr8:8085844	FLJ10661	0.69	6.59	0.51	1.11e-9	Mood instability;
TGCT	cis	rs13191362	1.000	rs35044651	chr6:163004142	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.39	6.83	0.52	3.32e-10	Schizophrenia;
TGCT	cis	rs72781680	0.848	rs6748727	chr2:24041058	G/A	cg08917208	chr2:24149416	ATAD2B	0.8	4.93	0.4	2.62e-6	Lymphocyte counts;
TGCT	cis	rs2066819	1.000	rs2371494	chr12:56728000	G/A	cg26714650	chr12:56694279	CS	-1.53	-8.28	-0.6	1.67e-13	Psoriasis vulgaris;
TGCT	cis	rs8072100	0.790	rs34200664	chr17:45744652	C/T	cg08085267	chr17:45401833	C17orf57	0.46	5.0	0.41	1.91e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs7681440	0.904	rs28777703	chr4:90769924	A/G	cg14346243	chr4:90757452	SNCA	0.53	5.14	0.42	1.03e-6	Dementia with Lewy bodies;
TGCT	cis	rs36051895	0.632	rs7038813	chr9:5177685	A/G	cg02405213	chr9:5042618	JAK2	-0.77	-10.92	-0.7	7.2e-20	Pediatric autoimmune diseases;
TGCT	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg07507251	chr3:52567010	NT5DC2	0.45	6.33	0.49	4.06e-9	Bipolar disorder;
TGCT	cis	rs35160687	0.814	rs4392258	chr2:86552577	T/C	cg03171300	chr2:86307199	POLR1A	-0.27	-4.73	-0.39	6.08e-6	Night sleep phenotypes;
TGCT	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	5.11	0.42	1.18e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6906287	0.647	rs2077162	chr6:118687469	G/A	cg21191810	chr6:118973309	C6orf204	0.26	4.46	0.37	1.85e-5	Electrocardiographic conduction measures;
TGCT	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg13397359	chr6:42928475	GNMT	0.73	6.82	0.52	3.63e-10	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.79	-8.66	-0.61	2.13e-14	Age at first birth;
TGCT	cis	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg18252515	chr7:66147081	NA	-1.17	-7.49	-0.56	1.13e-11	Diabetic kidney disease;
TGCT	cis	rs79349575	0.783	rs17708633	chr17:47011620	C/G	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.52	-0.38	1.44e-5	Type 2 diabetes;
TGCT	cis	rs7666738	0.830	rs732299	chr4:98995389	C/T	cg18180107	chr4:99064573	C4orf37	0.51	4.68	0.39	7.37e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs797680	0.856	rs7540025	chr1:93759228	C/T	cg17826107	chr1:92977322	EVI5	0.23	5.1	0.42	1.24e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg18252515	chr7:66147081	NA	-1.1	-6.4	-0.5	2.85e-9	Diabetic kidney disease;
TGCT	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg17971929	chr21:40555470	PSMG1	0.95	9.18	0.64	1.22e-15	Cognitive function;
TGCT	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg04317338	chr11:64019027	PLCB3	0.78	6.46	0.5	2.17e-9	Mean platelet volume;
TGCT	cis	rs2239547	0.657	rs6445539	chr3:52874296	G/A	cg11645453	chr3:52864694	ITIH4	0.35	5.88	0.47	3.57e-8	Schizophrenia;
TGCT	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg20607798	chr8:58055168	NA	0.49	4.67	0.39	7.56e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs909674	0.865	rs5757684	chr22:39851584	G/A	cg11247378	chr22:39784982	NA	-0.71	-8.5	-0.61	5.02e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg23758822	chr17:41437982	NA	0.7	6.6	0.51	1.1e-9	Menopause (age at onset);
TGCT	cis	rs6754311	0.593	rs313523	chr2:136432103	G/A	cg07169764	chr2:136633963	MCM6	0.65	5.79	0.46	5.38e-8	Mosquito bite size;
TGCT	cis	rs7246657	0.765	rs10402455	chr19:37728707	G/A	cg18154014	chr19:37997991	ZNF793	0.91	5.6	0.45	1.33e-7	Coronary artery calcification;
TGCT	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg12963246	chr6:28129442	ZNF389	0.51	5.02	0.41	1.73e-6	Depression;
TGCT	cis	rs1513670	1.000	rs1534402	chr17:41809847	C/T	cg10758466	chr17:41974087	MPP2	0.27	4.44	0.37	2e-5	Bone mineral density (hip);
TGCT	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg06238570	chr21:40685208	BRWD1	-0.84	-9.31	-0.64	6.01e-16	Cognitive function;
TGCT	cis	rs922182	0.748	rs1380839	chr15:64312164	A/G	cg02919090	chr15:64263738	DAPK2	0.25	4.54	0.38	1.29e-5	Blood protein levels;
TGCT	cis	rs1865760	0.713	rs2013063	chr6:25994098	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.72	6.94	0.53	1.97e-10	Height;
TGCT	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg22963979	chr7:1858916	MAD1L1	-0.34	-5.25	-0.43	6.44e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs6570726	0.693	rs450921	chr6:145864260	C/T	cg23711669	chr6:146136114	FBXO30	0.89	9.93	0.67	1.82e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6964587	0.967	rs10248102	chr7:91699779	G/A	cg17063962	chr7:91808500	NA	0.88	9.65	0.66	8.73e-17	Breast cancer;
TGCT	cis	rs9389248	0.690	rs2294321	chr6:135253048	T/G	cg24558204	chr6:135376177	HBS1L	-0.47	-4.81	-0.4	4.35e-6	High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs909341	0.716	rs71325463	chr20:62362834	G/A	cg14758556	chr20:62440591	NA	0.3	4.53	0.38	1.38e-5	Atopic dermatitis;
TGCT	cis	rs73001065	0.818	rs16996185	chr19:19720788	G/T	cg03709012	chr19:19516395	GATAD2A	-1.05	-5.47	-0.44	2.33e-7	LDL cholesterol;
TGCT	cis	rs4129767	0.647	rs1976703	chr17:76401328	C/T	cg05887092	chr17:76393375	PGS1	0.22	4.64	0.38	8.75e-6	HDL cholesterol;
TGCT	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg10047753	chr17:41438598	NA	0.84	7.61	0.56	5.9e-12	Menopause (age at onset);
TGCT	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg03609598	chr5:56110824	MAP3K1	-0.59	-4.72	-0.39	6.18e-6	Initial pursuit acceleration;
TGCT	cis	rs9325144	0.560	rs6582561	chr12:38666821	G/A	cg26384229	chr12:38710491	ALG10B	-0.66	-6.0	-0.47	2.06e-8	Morning vs. evening chronotype;
TGCT	cis	rs2338224	1.000	rs6888856	chr5:71740716	T/C	cg01187920	chr5:71015162	CARTPT	-0.53	-4.57	-0.38	1.15e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Granulocyte count;Myeloid white cell count;
TGCT	cis	rs6964587	1.000	rs12530646	chr7:91588036	A/G	cg22709100	chr7:91322751	NA	-0.28	-4.72	-0.39	6.31e-6	Breast cancer;
TGCT	cis	rs854765	0.583	rs6502625	chr17:17848286	G/C	cg09796270	chr17:17721594	SREBF1	0.26	5.32	0.43	4.72e-7	Total body bone mineral density;
TGCT	trans	rs7726839	0.507	rs60068988	chr5:597668	T/C	cg25482853	chr8:67687455	SGK3	1.27	10.56	0.69	5.48e-19	Obesity-related traits;
TGCT	cis	rs9653442	0.593	rs6542920	chr2:100845088	A/G	cg07810366	chr2:100720526	AFF3	-0.32	-4.51	-0.38	1.46e-5	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg22857025	chr5:266934	NA	-0.31	-6.32	-0.49	4.33e-9	Breast cancer;
TGCT	cis	rs7666738	0.830	rs1405767	chr4:98965295	T/C	cg05340658	chr4:99064831	C4orf37	0.53	5.93	0.47	2.85e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs16867321	0.671	rs10190767	chr2:181475701	G/A	cg23363182	chr2:181467187	NA	-0.47	-4.93	-0.4	2.56e-6	Obesity;
TGCT	cis	rs9527	0.590	rs1807298	chr10:104870218	G/A	cg04362960	chr10:104952993	NT5C2	0.7	5.88	0.47	3.57e-8	Arsenic metabolism;
TGCT	cis	rs12134245	0.776	rs6688261	chr1:91987034	C/T	cg07090678	chr1:91966139	CDC7	0.31	4.5	0.37	1.54e-5	Breast cancer;
TGCT	cis	rs62244186	0.748	rs13319803	chr3:44635461	G/A	cg10263370	chr3:44754102	ZNF502	-0.42	-5.02	-0.41	1.74e-6	Depressive symptoms;
TGCT	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg02725872	chr8:58115012	NA	-0.39	-4.83	-0.4	3.9e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs17155006	0.676	rs4730287	chr7:107770624	C/T	cg12651599	chr7:107428290	SLC26A3	0.21	4.62	0.38	9.36e-6	Pneumococcal bacteremia;
TGCT	cis	rs1971762	0.545	rs4759280	chr12:54064958	C/A	cg16917193	chr12:54089295	NA	1.09	11.22	0.71	1.37e-20	Height;
TGCT	cis	rs9393777	0.513	rs9379893	chr6:26584668	A/G	cg15659132	chr6:26577336	NA	0.73	5.32	0.43	4.62e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1843834	0.539	rs6713629	chr2:225410973	A/T	cg22455342	chr2:225449267	CUL3	1.04	10.75	0.69	1.87e-19	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs478304	0.651	rs11227281	chr11:65496558	T/C	cg27068330	chr11:65405492	SIPA1	-0.94	-9.4	-0.65	3.49e-16	Acne (severe);
TGCT	cis	rs7666738	0.830	rs10011009	chr4:98981749	G/A	cg17366294	chr4:99064904	C4orf37	0.68	6.94	0.53	1.95e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11031096	0.711	rs10767882	chr11:4205841	G/A	cg18678763	chr11:4115507	RRM1	-0.45	-5.84	-0.46	4.31e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs7819412	0.838	rs3021494	chr8:10983534	A/G	cg21775007	chr8:11205619	TDH	-0.53	-5.2	-0.42	8.06e-7	Triglycerides;
TGCT	cis	rs7819412	0.511	rs2898290	chr8:11433909	T/C	cg21775007	chr8:11205619	TDH	-0.54	-5.07	-0.41	1.41e-6	Triglycerides;
TGCT	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2404602	0.716	rs284895	chr15:76751225	C/G	cg22467129	chr15:76604101	ETFA	0.53	6.44	0.5	2.39e-9	Blood metabolite levels;
TGCT	cis	rs6598955	0.543	rs3795687	chr1:26560745	G/A	cg04990556	chr1:26633338	UBXN11	0.83	8.03	0.59	6.27e-13	Obesity-related traits;
TGCT	cis	rs6912958	0.728	rs7773906	chr6:88251869	T/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-5.06	-0.41	1.45e-6	Monocyte percentage of white cells;
TGCT	cis	rs3755132	0.633	rs16862856	chr2:15794281	C/G	cg12888861	chr2:15731646	DDX1	0.37	4.55	0.38	1.24e-5	Wilms tumor;
TGCT	cis	rs1008375	0.932	rs10009933	chr4:17670107	A/C	cg10189774	chr4:17578691	LAP3	0.51	4.5	0.37	1.54e-5	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9399137	0.507	rs6569986	chr6:135311641	T/C	cg24558204	chr6:135376177	HBS1L	0.47	4.78	0.39	4.95e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
TGCT	cis	rs7000551	0.689	rs12545909	chr8:22310052	A/G	cg12081754	chr8:22256438	SLC39A14	-0.28	-4.54	-0.38	1.33e-5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs1372520	0.748	rs990085	chr4:90754771	A/G	cg01966878	chr4:90757139	SNCA	-0.3	-4.76	-0.39	5.2e-6	Neuroticism;
TGCT	cis	rs250677	1.000	rs40525	chr5:148432932	G/T	cg23229984	chr5:148520753	ABLIM3	-0.21	-4.72	-0.39	6.38e-6	Breast cancer;
TGCT	cis	rs2204008	0.658	rs11495742	chr12:38395688	C/A	cg13010199	chr12:38710504	ALG10B	0.62	4.79	0.4	4.7e-6	Bladder cancer;
TGCT	cis	rs9911578	0.935	rs420878	chr17:56709077	A/G	cg05425664	chr17:57184151	TRIM37	-0.64	-6.48	-0.5	1.99e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs9911578	0.967	rs8182277	chr17:57144367	C/T	cg12560992	chr17:57184187	TRIM37	0.79	9.71	0.66	6.56e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs986417	0.901	rs2351172	chr14:61008687	A/G	cg27398547	chr14:60952738	C14orf39	1.42	8.85	0.62	7.44e-15	Gut microbiota (bacterial taxa);
TGCT	cis	rs9388451	0.839	rs3799711	chr6:126075313	C/T	cg10911889	chr6:126070802	HEY2	-0.51	-5.43	-0.44	2.83e-7	Brugada syndrome;
TGCT	cis	rs727505	0.954	rs989177	chr7:124412886	A/G	cg23710748	chr7:124431027	NA	-0.27	-4.71	-0.39	6.45e-6	Lewy body disease;
TGCT	cis	rs7113874	0.610	rs1446462	chr11:8566343	C/T	cg14521421	chr11:8862019	ST5	0.29	4.68	0.39	7.52e-6	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs7772486	0.875	rs1331645	chr6:146398407	C/G	cg23711669	chr6:146136114	FBXO30	0.88	9.18	0.64	1.19e-15	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs561341	0.739	rs1978116	chr17:30220978	A/C	cg20587970	chr11:113659929	NA	-0.65	-9.08	-0.63	2.05e-15	Hip circumference adjusted for BMI;
TGCT	cis	rs9581857	0.547	rs75085794	chr13:28095944	A/C	cg22138327	chr13:27999177	GTF3A	0.72	4.75	0.39	5.45e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs7674212	0.539	rs2866635	chr4:104121576	G/A	cg16532752	chr4:104119610	CENPE	-0.6	-5.46	-0.44	2.51e-7	Type 2 diabetes;
TGCT	cis	rs739496	0.793	rs607316	chr12:111969448	C/T	cg10833066	chr12:111807467	FAM109A	0.37	5.38	0.44	3.53e-7	Platelet count;
TGCT	cis	rs763121	0.819	rs5757237	chr22:39073835	G/C	cg06022373	chr22:39101656	GTPBP1	0.76	7.43	0.56	1.52e-11	Menopause (age at onset);
TGCT	cis	rs7091068	0.532	rs1018634	chr10:95401292	G/A	cg20715218	chr10:95462985	C10orf4	-0.48	-5.81	-0.46	4.88e-8	Urinary tract infection frequency;
TGCT	cis	rs12220238	0.818	rs10824082	chr10:75904080	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.91	7.98	0.58	8.43e-13	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs7829975	0.633	rs2979181	chr8:8323088	A/T	cg06636001	chr8:8085503	FLJ10661	0.79	7.76	0.57	2.65e-12	Mood instability;
TGCT	cis	rs2404602	0.716	rs3866543	chr15:76629609	T/G	cg26408565	chr15:76604113	ETFA	-0.45	-6.09	-0.48	1.28e-8	Blood metabolite levels;
TGCT	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg15691649	chr6:25882328	NA	-0.5	-5.61	-0.45	1.24e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7809950	1.000	rs2520271	chr7:107194949	C/T	cg23024343	chr7:107201750	COG5	-0.34	-5.26	-0.43	6.08e-7	Coronary artery disease;
TGCT	cis	rs7715806	0.500	rs77544433	chr5:75001025	C/A	cg19683494	chr5:74908142	NA	0.53	4.63	0.38	9.15e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg03609598	chr5:56110824	MAP3K1	-0.59	-4.78	-0.39	4.81e-6	Initial pursuit acceleration;
TGCT	trans	rs1814175	0.645	rs1608632	chr11:49967148	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.67	-0.69	2.92e-19	Height;
TGCT	cis	rs7192750	0.562	rs8063403	chr16:71931032	C/T	cg06353428	chr16:71660113	MARVELD3	0.8	7.2	0.54	5.05e-11	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs3806933	0.522	rs12522383	chr5:110455266	C/T	cg04022379	chr5:110408740	TSLP	0.55	5.88	0.47	3.51e-8	Eosinophilic esophagitis;
TGCT	cis	rs5760092	0.842	rs5751763	chr22:24247793	T/C	cg10150615	chr22:24372951	LOC391322	-0.76	-6.21	-0.49	7.18e-9	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs10507380	0.824	rs117542137	chr13:27904586	T/G	cg25543773	chr13:27185723	WASF3	0.31	4.49	0.37	1.6e-5	Electrocardiographic traits;
TGCT	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg00149659	chr3:10157352	C3orf10	0.73	4.72	0.39	6.17e-6	Alzheimer's disease;
TGCT	cis	rs4622507	0.773	rs12925215	chr16:55049850	T/A	cg04853843	chr16:55358461	IRX6	-0.57	-4.94	-0.41	2.45e-6	Social communication problems;
TGCT	cis	rs4383453	0.539	rs4677887	chr3:123100223	A/C	cg04890266	chr3:123102914	ADCY5	-0.49	-8.4	-0.6	8.88e-14	Gestational age at birth (maternal effect);
TGCT	cis	rs11958404	0.789	rs7736318	chr5:157477593	A/G	cg05962755	chr5:157440814	NA	0.35	4.48	0.37	1.65e-5	IgG glycosylation;
TGCT	cis	rs7914558	1.000	rs7077097	chr10:104945463	G/A	cg05855489	chr10:104503620	C10orf26	0.51	4.48	0.37	1.65e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs7772486	0.754	rs4566902	chr6:146244128	A/G	cg23711669	chr6:146136114	FBXO30	-0.87	-9.9	-0.66	2.24e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9443645	0.901	rs9448590	chr6:79606429	C/G	cg09184832	chr6:79620586	NA	-0.49	-5.29	-0.43	5.29e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs597539	0.552	rs10792006	chr11:68722306	T/C	cg06112835	chr11:68658793	MRPL21	-0.34	-6.11	-0.48	1.18e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg06753367	chr22:24256600	NA	-0.24	-4.51	-0.38	1.5e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs13256369	0.590	rs10113115	chr8:8559588	A/G	cg18904891	chr8:8559673	CLDN23	0.54	4.8	0.4	4.46e-6	Obesity-related traits;
TGCT	cis	rs12908161	0.960	rs34452033	chr15:85221993	A/G	cg17173187	chr15:85201210	NMB	0.59	6.74	0.52	5.44e-10	Schizophrenia;
TGCT	cis	rs56104184	0.775	rs73063505	chr19:49402765	T/C	cg21252483	chr19:49399788	TULP2	-0.42	-5.89	-0.47	3.47e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg07507251	chr3:52567010	NT5DC2	0.49	7.06	0.54	1.03e-10	Cognitive function;
TGCT	cis	rs11696501	0.688	rs6104295	chr20:44326917	C/T	cg11783356	chr20:44313418	WFDC10B	-0.33	-4.49	-0.37	1.6e-5	Brain structure;
TGCT	cis	rs858239	0.600	rs59073109	chr7:23133226	C/A	cg05602783	chr7:23145260	KLHL7	-0.58	-4.85	-0.4	3.68e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	5.11	0.42	1.18e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs3096299	0.874	rs3102342	chr16:89451575	T/C	cg02187348	chr16:89574699	SPG7	0.5	4.84	0.4	3.86e-6	Multiple myeloma (IgH translocation);
TGCT	cis	rs1903068	0.853	rs28838369	chr4:56007249	A/G	cg16572876	chr4:56024045	NA	0.46	5.03	0.41	1.65e-6	Endometriosis;
TGCT	cis	rs6714710	0.603	rs12104810	chr2:98443658	C/T	cg26665480	chr2:98280029	ACTR1B	0.66	6.24	0.49	6.33e-9	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs7582180	0.627	rs6542947	chr2:100999647	C/G	cg14675211	chr2:100938903	LONRF2	-0.47	-4.57	-0.38	1.16e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs6582630	0.638	rs12424222	chr12:38548273	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-4.77	-0.39	5.12e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs2153535	0.580	rs7745043	chr6:8513507	T/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.01	0.41	1.86e-6	Motion sickness;
TGCT	cis	rs7226408	0.857	rs55811995	chr18:34622341	T/G	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg23758822	chr17:41437982	NA	0.72	6.91	0.53	2.23e-10	Menopause (age at onset);
TGCT	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg06238570	chr21:40685208	BRWD1	-0.62	-6.17	-0.48	8.82e-9	Menarche (age at onset);
TGCT	cis	rs9325144	0.647	rs10875953	chr12:39050536	G/C	cg10518543	chr12:38710700	ALG10B	-0.48	-4.49	-0.37	1.58e-5	Morning vs. evening chronotype;
TGCT	cis	rs9858542	0.953	rs7646366	chr3:49470668	G/A	cg03060546	chr3:49711283	APEH	-0.61	-5.37	-0.43	3.78e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs2692947	0.673	rs2692894	chr2:96784934	T/G	cg22654517	chr2:96458247	NA	-0.22	-4.72	-0.39	6.17e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs13008689	0.875	rs55776708	chr2:8520167	A/C	cg26785157	chr2:7987059	NA	-0.21	-4.5	-0.37	1.56e-5	Longevity;
TGCT	cis	rs6815814	0.950	rs9306967	chr4:38807911	G/C	cg02016764	chr4:38805732	TLR1	-0.31	-5.15	-0.42	9.95e-7	Breast cancer;
TGCT	cis	rs17122693	0.551	rs2934681	chr14:51061491	C/T	cg04730355	chr14:51134070	SAV1	1.19	12.02	0.73	1.56e-22	Cognitive performance;
TGCT	cis	rs7178572	0.633	rs11857860	chr15:77839761	T/C	cg22256960	chr15:77711686	NA	-0.81	-7.57	-0.56	7.27e-12	Type 2 diabetes;
TGCT	cis	rs7772486	0.686	rs9399564	chr6:146078907	C/T	cg13319975	chr6:146136371	FBXO30	0.5	4.51	0.38	1.46e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs5750830	0.645	rs4821890	chr22:39777523	G/A	cg24399712	chr22:39784796	NA	-0.98	-12.63	-0.75	5.18e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.04	0.53	1.16e-10	Prudent dietary pattern;
TGCT	cis	rs80033912	0.626	rs71324982	chr3:49669948	G/A	cg03060546	chr3:49711283	APEH	0.71	6.72	0.52	5.8e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs2797160	1.000	rs6933471	chr6:126017029	T/G	cg05901451	chr6:126070800	HEY2	0.73	6.29	0.49	5.01e-9	Endometrial cancer;
TGCT	cis	rs6867032	0.958	rs4246754	chr5:2014776	A/C	cg26168224	chr5:2018326	NA	0.46	8.31	0.6	1.44e-13	Gut microbiome composition (winter);
TGCT	cis	rs2235642	0.928	rs1057610	chr16:1605537	T/C	cg00463982	chr16:1583984	IFT140;TMEM204	-0.28	-4.74	-0.39	5.81e-6	Coronary artery disease;
TGCT	cis	rs739496	0.652	rs10849974	chr12:112264158	C/T	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs6693567	0.565	rs11205370	chr1:150397567	A/G	cg09579323	chr1:150459698	TARS2	0.52	4.64	0.38	8.63e-6	Migraine;
TGCT	cis	rs7095607	0.813	rs10823148	chr10:69926334	C/G	cg18986048	chr10:69913749	MYPN	0.45	5.25	0.43	6.44e-7	Lung function (FVC);
TGCT	cis	rs6714788	0.565	rs7599083	chr2:100658077	G/A	cg07810366	chr2:100720526	AFF3	-0.35	-5.04	-0.41	1.59e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2458413	0.563	rs2458419	chr8:105337141	G/C	cg23108931	chr8:105342351	NA	-0.35	-6.15	-0.48	9.76e-9	Paget's disease;
TGCT	cis	rs9640161	0.783	rs35435439	chr7:150063534	C/T	cg10018233	chr7:150070692	REPIN1	0.34	4.92	0.4	2.7e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg22857025	chr5:266934	NA	-0.34	-6.7	-0.52	6.65e-10	Breast cancer;
TGCT	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg03609598	chr5:56110824	MAP3K1	-0.58	-4.7	-0.39	6.72e-6	Initial pursuit acceleration;
TGCT	cis	rs7635838	0.620	rs1666988	chr3:11284950	A/G	cg00170343	chr3:11313890	ATG7	0.68	6.48	0.5	1.97e-9	HDL cholesterol;
TGCT	cis	rs12220238	0.722	rs6480748	chr10:76421529	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.61	4.76	0.39	5.23e-6	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg10802521	chr3:52805072	NEK4	-0.73	-8.95	-0.63	4.39e-15	Electroencephalogram traits;
TGCT	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg05368731	chr17:41323189	NBR1	1.2	14.2	0.79	8.98e-28	Menopause (age at onset);
TGCT	cis	rs9393692	0.846	rs7771202	chr6:26279907	A/G	cg00631329	chr6:26305371	NA	-0.44	-6.59	-0.51	1.14e-9	Educational attainment;
TGCT	cis	rs7582180	0.607	rs1530029	chr2:100968205	C/T	cg14675211	chr2:100938903	LONRF2	0.5	4.76	0.39	5.35e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6922617	0.786	rs4141937	chr6:41341253	G/T	cg07798131	chr6:41471673	NA	0.98	4.85	0.4	3.6e-6	Alzheimer's disease biomarkers;
TGCT	cis	rs11190604	1.000	rs2495734	chr10:102338686	G/A	cg16342193	chr10:102329863	NA	-0.43	-5.39	-0.44	3.43e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	trans	rs561341	0.709	rs11542477	chr17:30185892	A/G	cg20587970	chr11:113659929	NA	0.85	8.5	0.61	5.13e-14	Hip circumference adjusted for BMI;
TGCT	cis	rs3008870	1.000	rs2815370	chr1:67503727	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.02	-10.78	-0.7	1.65e-19	Lymphocyte percentage of white cells;
TGCT	cis	rs17102423	0.685	rs4899161	chr14:65540901	G/A	cg11161011	chr14:65562177	MAX	-0.51	-7.28	-0.55	3.3e-11	Obesity-related traits;
TGCT	cis	rs2692947	0.702	rs7604842	chr2:96777340	C/T	cg23100626	chr2:96804247	ASTL	-0.4	-4.63	-0.38	9.19e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs10883723	0.810	rs2296588	chr10:104248087	T/C	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs4081724	0.565	rs59527310	chr19:33798393	C/T	cg18823272	chr19:34111733	CHST8	0.41	4.8	0.4	4.56e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs6681544	0.721	rs9438719	chr1:82425063	A/G	cg04226724	chr1:82268649	LPHN2	-0.48	-4.95	-0.41	2.42e-6	Metabolite levels  (X-11787);
TGCT	cis	rs483180	0.531	rs662243	chr1:120209564	A/C	cg19096424	chr1:120255104	PHGDH	0.57	5.33	0.43	4.39e-7	Macular telangiectasia type 2;
TGCT	cis	rs9399135	0.660	rs4267967	chr6:135272477	T/G	cg24558204	chr6:135376177	HBS1L	0.51	5.41	0.44	3.13e-7	Red blood cell count;
TGCT	cis	rs10876993	0.928	rs7136269	chr12:58075937	G/A	cg15848620	chr12:58087721	OS9	-0.72	-5.83	-0.46	4.52e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg01802117	chr1:53393560	SCP2	0.41	4.84	0.4	3.79e-6	Monocyte count;
TGCT	cis	rs11783469	0.522	rs13281304	chr8:23266922	T/C	cg00472375	chr8:23315376	ENTPD4	0.67	5.31	0.43	4.94e-7	Reticulocyte count;
TGCT	cis	rs12477438	0.520	rs6712704	chr2:99719687	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	17.43	0.84	3.73e-35	Chronic sinus infection;
TGCT	cis	rs1801251	0.711	rs2592117	chr2:233735693	C/T	cg08000102	chr2:233561755	GIGYF2	-0.44	-4.45	-0.37	1.87e-5	Coronary artery disease;
TGCT	cis	rs4372836	0.664	rs4233729	chr2:29092679	T/C	cg09522027	chr2:28974177	PPP1CB	0.68	7.1	0.54	8.73e-11	Body mass index;
TGCT	cis	rs9303401	0.659	rs9303399	chr17:56672309	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.59	5.84	0.46	4.39e-8	Cognitive test performance;
TGCT	cis	rs1062177	0.756	rs2964587	chr5:151119972	C/T	cg00977110	chr5:151150581	G3BP1	-0.4	-4.67	-0.39	7.7e-6	Preschool internalizing problems;
TGCT	cis	rs9341808	0.718	rs1324123	chr6:80932894	G/A	cg08355045	chr6:80787529	NA	0.31	5.4	0.44	3.2e-7	Sitting height ratio;
TGCT	cis	rs1475911	1.000	rs17114359	chr21:43510437	A/C	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.25	-4.74	-0.39	5.69e-6	IgG glycosylation;
TGCT	cis	rs7659604	0.540	rs28672860	chr4:122705051	G/A	cg19748678	chr4:122722346	EXOSC9	-0.58	-5.55	-0.45	1.64e-7	Type 2 diabetes;
TGCT	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg11494091	chr17:61959527	GH2	0.43	7.51	0.56	9.88e-12	Height;
TGCT	cis	rs13242816	1.000	rs62471184	chr7:116090300	G/A	cg16553024	chr7:116138462	CAV2	-0.46	-5.18	-0.42	8.58e-7	P wave duration;
TGCT	trans	rs8073060	0.586	rs225278	chr17:33974170	C/T	cg19694781	chr19:47549865	TMEM160	-0.6	-13.37	-0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs992157	0.764	rs10932774	chr2:219191569	A/G	cg00012203	chr2:219082015	ARPC2	0.71	6.54	0.51	1.44e-9	Colorectal cancer;
TGCT	cis	rs2842992	0.830	rs2273819	chr6:160183325	G/C	cg11366901	chr6:160182831	ACAT2	1.03	6.92	0.53	2.14e-10	Age-related macular degeneration (geographic atrophy);
TGCT	trans	rs66573146	1.000	rs66712119	chr4:6965428	A/T	cg07817883	chr1:32538562	TMEM39B	1.56	8.31	0.6	1.45e-13	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs10514758	0.744	rs1949122	chr3:114923069	A/G	cg05943254	chr3:114009756	NA	-0.76	-4.53	-0.38	1.39e-5	Urate levels in obese individuals;
TGCT	cis	rs2658782	0.901	rs7116173	chr11:93222311	C/T	cg18152523	chr11:93063302	CCDC67	0.69	5.63	0.45	1.17e-7	Pulmonary function decline;
TGCT	cis	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg08975724	chr8:8085496	FLJ10661	0.58	5.18	0.42	8.76e-7	Mood instability;
TGCT	cis	rs13242816	1.000	rs62471202	chr7:116112562	G/A	cg16553024	chr7:116138462	CAV2	-0.45	-4.75	-0.39	5.64e-6	P wave duration;
TGCT	cis	rs6964587	1.000	rs926192	chr7:91671853	C/A	cg17063962	chr7:91808500	NA	0.88	9.63	0.65	9.8e-17	Breast cancer;
TGCT	cis	rs617219	0.726	rs72764969	chr5:78451409	A/G	cg23987322	chr5:78407566	BHMT	0.36	4.67	0.39	7.58e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	trans	rs4332037	0.586	rs62442944	chr7:2015047	T/G	cg10840412	chr1:235813424	GNG4	0.93	6.69	0.51	6.97e-10	Bipolar disorder;
TGCT	cis	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg20637647	chr7:64974828	NA	-0.9	-5.31	-0.43	4.87e-7	Diabetic kidney disease;
TGCT	cis	rs68170813	0.617	rs117884147	chr7:107177593	T/C	cg02696742	chr7:106810147	HBP1	-0.58	-4.47	-0.37	1.74e-5	Coronary artery disease;
TGCT	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.32	-5.13	-0.42	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs17345786	0.511	rs1138818	chr3:101399583	C/G	cg12386194	chr3:101231763	SENP7	0.53	5.13	0.42	1.08e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11971779	0.715	rs7787398	chr7:139061846	A/G	cg07862535	chr7:139043722	LUC7L2	0.71	5.55	0.45	1.63e-7	Diisocyanate-induced asthma;
TGCT	cis	rs11098499	0.820	rs2389885	chr4:120533931	C/T	cg09307838	chr4:120376055	NA	0.67	6.32	0.49	4.29e-9	Corneal astigmatism;
TGCT	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg11764359	chr7:65958608	NA	0.61	5.53	0.44	1.79e-7	Aortic root size;
TGCT	cis	rs9682041	0.877	rs9682908	chr3:170072010	C/T	cg07589077	chr3:170072950	NA	0.29	5.15	0.42	1e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs7552404	0.883	rs11161493	chr1:76206254	T/A	cg03433033	chr1:76189801	ACADM	0.82	9.91	0.66	2.05e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg07424592	chr7:64974309	NA	1.36	8.15	0.59	3.36e-13	Diabetic kidney disease;
TGCT	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg06418219	chr1:154948305	SHC1;CKS1B	-0.69	-6.95	-0.53	1.82e-10	Prostate cancer;
TGCT	cis	rs13326165	0.671	rs6794675	chr3:52374889	T/A	cg07884673	chr3:53033167	SFMBT1	0.39	4.8	0.4	4.54e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs12477438	0.520	rs13030961	chr2:99799520	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.9	9.33	0.64	5.15e-16	Chronic sinus infection;
TGCT	cis	rs9311474	0.575	rs4434138	chr3:52556890	A/G	cg07507251	chr3:52567010	NT5DC2	0.47	6.56	0.51	1.29e-9	Electroencephalogram traits;
TGCT	cis	rs911263	0.581	rs12890110	chr14:68781595	C/T	cg18825221	chr14:68749962	RAD51L1	0.22	4.46	0.37	1.82e-5	Primary biliary cholangitis;
TGCT	cis	rs10986311	0.832	rs10123514	chr9:127142878	T/C	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.21	-5.07	-0.41	1.38e-6	Vitiligo;
TGCT	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.02	0.53	1.3e-10	Prudent dietary pattern;
TGCT	cis	rs13191362	1.000	rs35103567	chr6:163183400	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.19	0.59	2.72e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg06896619	chr17:61851486	DDX42;CCDC47	-0.51	-4.97	-0.41	2.18e-6	Prudent dietary pattern;
TGCT	cis	rs6570726	0.846	rs371186	chr6:145886971	T/C	cg23711669	chr6:146136114	FBXO30	0.84	8.89	0.62	6.14e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2072499	0.868	rs2758600	chr1:156195205	C/T	cg06970220	chr1:156163860	SLC25A44	0.74	5.98	0.47	2.22e-8	Testicular germ cell tumor;
TGCT	cis	rs10056811	0.538	rs2035191	chr5:74413713	T/C	cg19683494	chr5:74908142	NA	0.68	5.65	0.45	1.05e-7	Coronary artery disease;
TGCT	cis	rs61990749	0.597	rs2032781	chr14:78214875	A/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.67	4.73	0.39	6.09e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs7552404	0.556	rs12124417	chr1:76353294	T/C	cg22875332	chr1:76189707	ACADM	0.57	5.8	0.46	5.09e-8	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs6671200	1.000	rs76064624	chr1:95661033	A/G	cg20701556	chr1:95698924	RWDD3	0.65	5.58	0.45	1.43e-7	Stearic acid (18:0) levels;
TGCT	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	5.11	0.42	1.18e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs709400	0.663	rs11628213	chr14:103952453	A/C	cg12935359	chr14:103987150	CKB	-0.38	-5.78	-0.46	5.69e-8	Body mass index;
TGCT	cis	rs6424115	0.618	rs10917420	chr1:24062987	C/T	cg15997130	chr1:24165203	NA	0.64	6.92	0.53	2.16e-10	Immature fraction of reticulocytes;
TGCT	cis	rs10193935	0.901	rs997288	chr2:42525582	C/G	cg27598129	chr2:42591480	NA	-0.39	-5.31	-0.43	4.84e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1865760	1.000	rs12209482	chr6:25909229	T/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.65	6.24	0.49	6.27e-9	Height;
TGCT	cis	rs17331151	0.512	rs9637477	chr3:52891426	G/C	cg27565382	chr3:53032988	SFMBT1	-0.45	-5.76	-0.46	6.25e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs59107033	0.511	rs62262394	chr3:123105428	C/T	cg04890266	chr3:123102914	ADCY5	-0.49	-7.87	-0.58	1.48e-12	Lymphocyte counts;
TGCT	cis	rs2730260	0.537	rs73169246	chr7:158890593	C/T	cg02078164	chr7:157982224	PTPRN2	0.41	4.58	0.38	1.11e-5	Myopia (pathological);
TGCT	cis	rs1949733	1.000	rs1880023	chr4:8480831	C/T	cg11789530	chr4:8429930	ACOX3	-0.65	-6.04	-0.48	1.68e-8	Response to antineoplastic agents;
TGCT	cis	rs7666738	0.830	rs880472	chr4:98922595	C/A	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs992157	0.661	rs17653757	chr2:219109364	G/C	cg00012203	chr2:219082015	ARPC2	0.81	9.98	0.67	1.41e-17	Colorectal cancer;
TGCT	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg19318889	chr4:1322082	MAEA	0.27	6.62	0.51	9.72e-10	Longevity;
TGCT	cis	rs10936602	0.527	rs6793160	chr3:169535266	A/C	cg08193579	chr3:169529701	LRRC34	-0.29	-5.43	-0.44	2.79e-7	Renal cell carcinoma;
TGCT	cis	rs12950390	0.853	rs28589850	chr17:45855713	A/G	cg06532163	chr17:45867833	NA	0.34	5.42	0.44	2.94e-7	IgG glycosylation;
TGCT	cis	rs61867294	0.794	rs2007698	chr10:106661383	G/A	cg08000847	chr10:105880925	C10orf78	0.56	4.46	0.37	1.82e-5	Schizophrenia;
TGCT	trans	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.87	-9.37	-0.64	4.14e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs28595532	0.920	rs116094766	chr4:119729291	T/C	cg21605333	chr4:119757512	SEC24D	1.66	8.33	0.6	1.28e-13	Cannabis dependence symptom count;
TGCT	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg00343986	chr7:65444356	GUSB	-0.24	-5.29	-0.43	5.43e-7	Aortic root size;
TGCT	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.43	-6.34	-0.49	3.94e-9	Alzheimer's disease;
TGCT	cis	rs709400	0.663	rs7158822	chr14:103887868	C/T	cg12935359	chr14:103987150	CKB	-0.35	-5.33	-0.43	4.54e-7	Body mass index;
TGCT	cis	rs1008375	1.000	rs2109522	chr4:17658645	T/A	cg16339924	chr4:17578868	LAP3	0.63	5.33	0.43	4.49e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs3015497	0.616	rs3825571	chr14:51052118	A/G	cg04730355	chr14:51134070	SAV1	-0.61	-6.01	-0.48	1.88e-8	Mean platelet volume;
TGCT	cis	rs938554	0.612	rs4385059	chr4:9989233	A/G	cg11266682	chr4:10021025	SLC2A9	-0.57	-5.06	-0.41	1.47e-6	Blood metabolite levels;
TGCT	cis	rs1075232	1.000	rs12438318	chr15:31680445	G/A	cg01030201	chr15:31746330	NA	-1.1	-5.4	-0.44	3.27e-7	Survival in colorectal cancer (non-distant metastatic);
TGCT	cis	rs12971120	0.891	rs4891558	chr18:72170359	A/G	cg25817165	chr18:72167213	CNDP2	-0.29	-5.07	-0.41	1.44e-6	Refractive error;
TGCT	cis	rs4700695	0.719	rs27079	chr5:65443966	C/T	cg21114390	chr5:65439923	SFRS12	-0.84	-7.45	-0.56	1.35e-11	Facial morphology (factor 19);
TGCT	trans	rs9951602	0.512	rs7237214	chr18:76657394	C/G	cg02800362	chr5:177631904	HNRNPAB	1.13	12.44	0.75	1.51e-23	Obesity-related traits;
TGCT	cis	rs7312933	0.576	rs11181364	chr12:42567800	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	5.06	0.41	1.45e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs7267979	0.528	rs2387976	chr20:25599560	C/T	cg14121845	chr20:25566513	NINL	-0.41	-4.48	-0.37	1.7e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs1814175	0.781	rs1851872	chr11:50009770	A/G	cg15704280	chr7:45808275	SEPT13	-0.72	-8.47	-0.61	6.02e-14	Height;
TGCT	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.78	6.29	0.49	5.05e-9	Mean platelet volume;
TGCT	cis	rs7959452	0.535	rs10878953	chr12:69674187	A/G	cg11871910	chr12:69753446	YEATS4	0.62	6.14	0.48	1.03e-8	Blood protein levels;
TGCT	trans	rs1075232	0.677	rs72714666	chr15:31492226	T/C	cg17079325	chr7:130131480	MEST;MESTIT1	0.96	6.67	0.51	7.57e-10	Survival in colorectal cancer (non-distant metastatic);
TGCT	trans	rs629535	0.814	rs62513381	chr8:70110991	T/C	cg21567404	chr3:27674614	NA	-0.55	-8.64	-0.61	2.37e-14	Dupuytren's disease;
TGCT	cis	rs8017423	0.967	rs8015510	chr14:90729984	C/T	cg04374321	chr14:90722782	PSMC1	0.78	7.86	0.58	1.59e-12	Mortality in heart failure;
TGCT	cis	rs6671200	1.000	rs933107	chr1:95672229	C/T	cg20701556	chr1:95698924	RWDD3	-0.65	-5.58	-0.45	1.43e-7	Stearic acid (18:0) levels;
TGCT	cis	rs78456975	1.000	rs13429866	chr2:1555211	C/A	cg01028140	chr2:1542097	TPO	-0.35	-4.57	-0.38	1.17e-5	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs12900413	0.603	rs2118848	chr15:90302503	T/C	cg24249390	chr15:90295951	MESP1	-0.3	-5.2	-0.42	8.04e-7	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs12681287	0.547	rs9942793	chr8:87509091	C/T	cg19078186	chr8:87526527	CPNE3	-0.37	-4.57	-0.38	1.15e-5	Caudate activity during reward;
TGCT	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.63	0.38	9.2e-6	Prudent dietary pattern;
TGCT	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg05368731	chr17:41323189	NBR1	0.96	9.32	0.64	5.61e-16	Menopause (age at onset);
TGCT	cis	rs6988636	1.000	rs4377946	chr8:124185887	T/C	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs68190844	1	rs68190844	chr17:4568953	CTA/C	cg00122941	chr17:4613640	ARRB2	-0.89	-7.56	-0.56	7.65e-12	Eosinophil percentage of white cells;
TGCT	cis	rs12134133	0.927	rs4844589	chr1:207432630	C/A	cg02152968	chr1:207494213	CD55	0.61	4.66	0.39	7.94e-6	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	trans	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg17830980	chr10:43048298	ZNF37B	-0.86	-11.18	-0.71	1.68e-20	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7772486	0.875	rs10872583	chr6:146396699	G/T	cg13319975	chr6:146136371	FBXO30	0.52	4.61	0.38	9.71e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs155076	0.938	rs536209	chr13:21847714	C/T	cg14456004	chr13:21872349	NA	-1.34	-11.21	-0.71	1.42e-20	White matter hyperintensity burden;
TGCT	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.43	-4.78	-0.39	4.82e-6	Longevity;Endometriosis;
TGCT	cis	rs12477438	0.520	rs1453563	chr2:99720267	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.75	7.25	0.55	3.92e-11	Chronic sinus infection;
TGCT	trans	rs7819412	1.000	rs7819412	chr8:11045161	A/G	cg06636001	chr8:8085503	FLJ10661	0.72	6.74	0.52	5.28e-10	Triglycerides;
TGCT	cis	rs514406	0.505	rs431459	chr1:53183230	T/G	cg16325326	chr1:53192061	ZYG11B	0.84	12.01	0.73	1.59e-22	Monocyte count;
TGCT	cis	rs9972944	0.729	rs10083875	chr17:63773303	T/C	cg07283582	chr17:63770753	CCDC46	0.26	5.05	0.41	1.53e-6	Total body bone mineral density;
TGCT	cis	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg18252515	chr7:66147081	NA	-1.25	-7.75	-0.57	2.92e-12	Diabetic kidney disease;
TGCT	cis	rs909674	0.865	rs5757684	chr22:39851584	G/A	cg05872129	chr22:39784769	NA	-0.98	-9.64	-0.65	9.22e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg25703541	chr22:24373054	LOC391322	-0.82	-8.48	-0.61	5.5e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1018836	0.828	rs7014967	chr8:91557843	G/T	cg16814680	chr8:91681699	NA	-0.75	-7.83	-0.58	1.82e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10276381	0.579	rs9648026	chr7:28161983	A/G	cg23620719	chr7:28220237	JAZF1	-0.76	-4.67	-0.39	7.73e-6	Crohn's disease;
TGCT	cis	rs55823223	0.564	rs58363746	chr17:73850819	C/T	cg10935138	chr17:73851978	WBP2	0.82	7.59	0.56	6.81e-12	Psoriasis;
TGCT	cis	rs6840360	0.615	rs12647462	chr4:152607278	C/T	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.15	-0.48	9.82e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs6840360	0.593	rs2089811	chr4:152685171	C/T	cg17479576	chr4:152424074	FAM160A1	0.52	5.19	0.42	8.44e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2404602	0.583	rs12908334	chr15:76581592	C/T	cg26408565	chr15:76604113	ETFA	-0.46	-6.46	-0.5	2.15e-9	Blood metabolite levels;
TGCT	cis	rs1018836	0.663	rs56784954	chr8:91505094	C/T	cg16814680	chr8:91681699	NA	-0.84	-8.45	-0.6	6.52e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs8031584	0.958	rs11293	chr15:31234981	G/A	cg08704250	chr15:31115839	NA	-0.36	-4.96	-0.41	2.28e-6	Huntington's disease progression;
TGCT	cis	rs7833790	0.553	rs9693128	chr8:82706128	A/G	cg17211192	chr8:82754475	SNX16	-0.9	-8.84	-0.62	8.03e-15	Diastolic blood pressure;
TGCT	cis	rs1982963	0.951	rs56834750	chr14:52509483	T/C	cg10843707	chr14:52510701	NID2	-0.42	-6.42	-0.5	2.69e-9	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs6570726	0.791	rs6923074	chr6:145893332	T/C	cg13319975	chr6:146136371	FBXO30	-0.5	-4.51	-0.38	1.48e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6854137	0.967	rs10033898	chr4:169734457	A/G	cg20607169	chr4:169750834	PALLD	-0.23	-5.0	-0.41	1.89e-6	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs11864453	0.713	rs6680	chr16:72146570	T/C	cg14768367	chr16:72042858	DHODH	0.51	4.89	0.4	3.11e-6	Fibrinogen levels;
TGCT	cis	rs1348850	0.651	rs4893821	chr2:178229352	A/G	cg22681709	chr2:178499509	PDE11A	0.35	4.47	0.37	1.75e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg07507251	chr3:52567010	NT5DC2	0.44	6.06	0.48	1.5e-8	Bipolar disorder;
TGCT	cis	rs7666738	0.830	rs6854703	chr4:98977586	A/T	cg17366294	chr4:99064904	C4orf37	0.68	6.94	0.53	1.95e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9926296	0.581	rs1108064	chr16:89894150	G/C	cg27121462	chr16:89883253	FANCA	0.56	5.18	0.42	8.83e-7	Vitiligo;
TGCT	cis	rs74233809	0.901	rs1004467	chr10:104594507	A/G	cg05855489	chr10:104503620	C10orf26	0.81	4.71	0.39	6.44e-6	Birth weight;
TGCT	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7027203	0.828	rs10761287	chr9:96609150	A/G	cg14396892	chr9:96623032	NA	-0.26	-5.46	-0.44	2.51e-7	DNA methylation (variation);
TGCT	cis	rs9788682	0.895	rs3813570	chr15:78832832	T/C	cg06917634	chr15:78832804	PSMA4	-0.7	-4.86	-0.4	3.47e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs74417235	0.684	rs12655636	chr5:154057618	T/C	cg08754654	chr5:154026448	NA	0.58	5.53	0.44	1.84e-7	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
TGCT	cis	rs6500602	0.702	rs11076835	chr16:4549618	G/A	cg08645402	chr16:4508243	NA	0.18	5.19	0.42	8.41e-7	Schizophrenia;
TGCT	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg16031515	chr1:205743344	RAB7L1	-0.27	-4.56	-0.38	1.2e-5	Menarche (age at onset);
TGCT	cis	rs9527	0.545	rs10218853	chr10:104796787	A/C	cg15744005	chr10:104629667	AS3MT	-0.41	-4.78	-0.39	4.88e-6	Arsenic metabolism;
TGCT	cis	rs8032315	0.965	rs12906125	chr15:91427612	G/A	cg05211768	chr15:91427848	FES	0.49	4.93	0.4	2.57e-6	Autism spectrum disorder or schizophrenia;
TGCT	trans	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.88	-9.5	-0.65	2.02e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs5769765	0.819	rs9616377	chr22:50310880	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.24	-12.97	-0.76	7.81e-25	Schizophrenia;
TGCT	cis	rs3806843	0.676	rs2245643	chr5:140029780	C/T	cg19875535	chr5:140030758	IK	-0.37	-6.44	-0.5	2.4e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs56309584	0.560	rs56346215	chr17:8076917	A/C	cg08322244	chr17:8066669	VAMP2	-0.52	-4.89	-0.4	3.04e-6	Initial pursuit acceleration;
TGCT	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg11494091	chr17:61959527	GH2	0.6	16.09	0.82	3.89e-32	Prudent dietary pattern;
TGCT	cis	rs2153535	0.580	rs2327058	chr6:8447018	C/T	cg07606381	chr6:8435919	SLC35B3	0.53	5.02	0.41	1.79e-6	Motion sickness;
TGCT	cis	rs9858542	0.537	rs9873994	chr3:49359943	T/C	cg08550065	chr3:50336684	HYAL3;NAT6	0.65	4.53	0.38	1.37e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs4319547	0.695	rs7969429	chr12:122875606	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.62	-4.87	-0.4	3.32e-6	Body mass index;
TGCT	cis	rs9790314	1.000	rs9850455	chr3:161017192	G/A	cg03342759	chr3:160939853	NMD3	-0.43	-4.55	-0.38	1.25e-5	Morning vs. evening chronotype;
TGCT	cis	rs6570726	0.791	rs378937	chr6:145834745	C/T	cg05347473	chr6:146136440	FBXO30	0.5	4.63	0.38	9.18e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs17108533	0.588	rs35594700	chr14:71302415	G/T	cg23900759	chr14:71108106	TTC9	-1.14	-4.61	-0.38	9.92e-6	Response to antipsychotic treatment in schizophrenia (reasoning);
TGCT	cis	rs2120019	1.000	rs12903201	chr15:75370776	A/C	cg17294928	chr15:75287854	SCAMP5	-0.86	-6.62	-0.51	9.55e-10	Blood trace element (Zn levels);
TGCT	cis	rs892961	0.932	rs3987885	chr17:75414990	A/G	cg05865280	chr17:75406074	SEPT9	0.29	6.98	0.53	1.61e-10	Airflow obstruction;
TGCT	cis	rs7208859	0.673	rs11651802	chr17:29159660	T/C	cg14008862	chr17:28927542	LRRC37B2	0.72	4.66	0.39	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7086627	0.515	rs4933390	chr10:82213081	A/C	cg01528321	chr10:82214614	TSPAN14	0.69	6.51	0.5	1.71e-9	Post bronchodilator FEV1;
TGCT	cis	rs59197085	0.636	rs3807132	chr7:128469484	T/C	cg00260937	chr7:128520193	KCP	0.46	4.82	0.4	4.15e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
TGCT	cis	rs4713118	0.662	rs9468277	chr6:28028390	C/A	cg12963246	chr6:28129442	ZNF389	0.45	4.55	0.38	1.27e-5	Parkinson's disease;
TGCT	cis	rs12200560	0.505	rs211167	chr6:97069087	T/A	cg06623918	chr6:96969491	KIAA0776	0.57	4.82	0.4	4.04e-6	Coronary heart disease;
TGCT	cis	rs6141769	0.542	rs6057628	chr20:31308684	C/T	cg13636640	chr20:31349939	DNMT3B	-0.51	-4.86	-0.4	3.45e-6	Subjective well-being;
TGCT	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	5.06	0.41	1.46e-6	Menopause (age at onset);
TGCT	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg20276088	chr3:133502917	NA	-0.28	-5.9	-0.47	3.28e-8	Iron status biomarkers;
TGCT	cis	rs1371867	0.846	rs1660332	chr8:101309490	A/G	cg06636551	chr8:101224915	SPAG1	0.42	5.65	0.45	1.06e-7	Atrioventricular conduction;
TGCT	cis	rs1541995	0.824	rs12899483	chr15:96241595	A/G	cg00882281	chr15:96346592	NA	0.3	4.85	0.4	3.7e-6	Photic sneeze reflex;
TGCT	cis	rs2562456	0.917	rs2562468	chr19:21714850	G/A	cg01304269	chr19:21688519	ZNF429	-0.55	-4.59	-0.38	1.06e-5	Pain;
TGCT	cis	rs9733	0.596	rs17658705	chr1:150678071	A/C	cg04414720	chr1:150670196	GOLPH3L	-0.39	-5.04	-0.41	1.58e-6	Tonsillectomy;
TGCT	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg21724239	chr8:58056113	NA	0.5	5.78	0.46	5.71e-8	Developmental language disorder (linguistic errors);
TGCT	cis	rs12477438	0.520	rs6542870	chr2:99796638	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	17.43	0.84	3.73e-35	Chronic sinus infection;
TGCT	cis	rs9486719	0.857	rs9285393	chr6:97020917	C/A	cg06623918	chr6:96969491	KIAA0776	-1.01	-9.38	-0.64	4.08e-16	Migraine;Coronary artery disease;
TGCT	trans	rs877282	0.945	rs10904556	chr10:789429	A/G	cg22713356	chr15:30763199	NA	1.16	10.26	0.68	3.01e-18	Uric acid levels;
TGCT	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg06634786	chr22:41940651	POLR3H	0.73	6.81	0.52	3.84e-10	Vitiligo;
TGCT	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg18654377	chr3:49208889	KLHDC8B	-0.38	-5.03	-0.41	1.69e-6	Menarche (age at onset);
TGCT	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg15921436	chr17:44337874	NA	0.56	8.16	0.59	3.13e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2153535	0.580	rs6597318	chr6:8437289	G/A	cg07606381	chr6:8435919	SLC35B3	0.57	5.24	0.43	6.68e-7	Motion sickness;
TGCT	cis	rs8072100	0.905	rs8077106	chr17:45653291	T/G	cg08085267	chr17:45401833	C17orf57	0.47	5.13	0.42	1.07e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs28595532	0.920	rs28837152	chr4:119782868	G/A	cg00700008	chr4:120138107	USP53	0.49	4.48	0.37	1.71e-5	Cannabis dependence symptom count;
TGCT	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg22105103	chr4:187893119	NA	0.33	4.56	0.38	1.22e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs13217239	0.646	rs12527111	chr6:27006475	C/T	cg02458000	chr6:26745757	NA	0.5	4.61	0.38	1e-5	Schizophrenia;
TGCT	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg10802521	chr3:52805072	NEK4	-0.71	-8.79	-0.62	1.04e-14	Bipolar disorder;
TGCT	cis	rs1198872	0.503	rs1627163	chr2:10954844	A/G	cg15705551	chr2:10952987	PDIA6	0.53	5.04	0.41	1.64e-6	Cardiac Troponin-T levels;
TGCT	cis	rs2739330	0.615	rs2858911	chr22:24297195	G/T	cg15242686	chr22:24348715	GSTTP1	0.43	5.95	0.47	2.54e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9906944	0.707	rs8068981	chr17:47122525	T/C	cg07075026	chr17:47091521	IGF2BP1	-0.43	-4.6	-0.38	1.03e-5	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs17345786	1.000	rs55641278	chr3:101290577	G/A	cg12386194	chr3:101231763	SENP7	0.59	5.45	0.44	2.65e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7584330	0.657	rs10211024	chr2:238353776	A/T	cg14458575	chr2:238380390	NA	0.46	7.08	0.54	9.6e-11	Prostate cancer;
TGCT	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg00149659	chr3:10157352	C3orf10	0.91	5.89	0.47	3.32e-8	Alzheimer's disease;
TGCT	cis	rs9341808	0.621	rs2322627	chr6:80806341	T/A	cg08355045	chr6:80787529	NA	0.36	6.41	0.5	2.79e-9	Sitting height ratio;
TGCT	cis	rs11122272	0.766	rs2790867	chr1:231548059	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.71	6.89	0.53	2.5e-10	Hemoglobin concentration;
TGCT	cis	rs7428	0.545	rs2366404	chr2:85551779	G/A	cg03728395	chr2:85555865	TGOLN2	-0.29	-4.97	-0.41	2.16e-6	Ear protrusion;
TGCT	cis	rs7681440	0.904	rs17192189	chr4:90774928	A/C	cg14346243	chr4:90757452	SNCA	0.5	4.7	0.39	6.86e-6	Dementia with Lewy bodies;
TGCT	cis	rs3733631	1.000	rs7667662	chr4:104590704	A/G	cg24090629	chr4:104641072	TACR3	-0.73	-5.72	-0.46	7.65e-8	Menarche (age at onset);
TGCT	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg01585852	chr22:24235823	MIF	0.22	4.82	0.4	4.16e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7824557	0.544	rs1865521	chr8:11231249	T/C	cg21775007	chr8:11205619	TDH	0.65	6.65	0.51	8.38e-10	Retinal vascular caliber;
TGCT	cis	rs7772486	0.686	rs2092263	chr6:146029687	G/A	cg23711669	chr6:146136114	FBXO30	-0.88	-9.77	-0.66	4.64e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2153535	0.580	rs1115078	chr6:8449638	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.76	0.46	6.39e-8	Motion sickness;
TGCT	cis	rs875971	0.830	rs1167406	chr7:65556936	G/C	cg11764359	chr7:65958608	NA	-0.56	-4.82	-0.4	4.1e-6	Aortic root size;
TGCT	cis	rs6815814	0.851	rs5743551	chr4:38807654	T/C	cg06935464	chr4:38784597	TLR10	0.29	4.59	0.38	1.08e-5	Breast cancer;
TGCT	cis	rs6570726	0.935	rs387965	chr6:145869366	A/G	cg05347473	chr6:146136440	FBXO30	0.5	4.57	0.38	1.17e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs909341	0.537	rs11696871	chr20:62387417	C/T	cg14758556	chr20:62440591	NA	0.4	5.74	0.46	6.9e-8	Atopic dermatitis;
TGCT	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg11941060	chr3:133502564	NA	-0.29	-6.13	-0.48	1.09e-8	Iron status biomarkers;
TGCT	cis	rs2629540	0.765	rs4962687	chr10:126404141	G/A	cg08799069	chr10:126477246	METTL10	-0.29	-4.8	-0.4	4.53e-6	Cocaine dependence;
TGCT	cis	rs9733	0.596	rs12089989	chr1:150715782	G/A	cg04414720	chr1:150670196	GOLPH3L	0.36	4.56	0.38	1.21e-5	Tonsillectomy;
TGCT	cis	rs7258465	1.000	rs76194	chr19:18630580	T/G	cg06462663	chr19:18546047	ISYNA1	0.22	5.16	0.42	9.61e-7	Breast cancer;
TGCT	cis	rs72945132	0.882	rs6592537	chr11:70172975	C/T	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs9549367	0.737	rs11619691	chr13:113904636	T/C	cg18105134	chr13:113819100	PROZ	-0.34	-5.58	-0.45	1.41e-7	Platelet distribution width;
TGCT	cis	rs35306767	0.668	rs35657988	chr10:1103590	A/G	cg26597838	chr10:835615	NA	0.46	5.08	0.41	1.37e-6	Eosinophil percentage of granulocytes;
TGCT	cis	rs6991838	0.593	rs7011464	chr8:66635287	A/T	cg19143639	chr8:66472813	NA	-0.36	-4.45	-0.37	1.87e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg11494091	chr17:61959527	GH2	0.6	14.54	0.79	1.46e-28	Prudent dietary pattern;
TGCT	cis	rs904251	0.523	rs2776871	chr6:37481759	A/G	cg25019722	chr6:37503610	NA	-0.53	-8.19	-0.59	2.75e-13	Cognitive performance;
TGCT	cis	rs6788895	0.661	rs73010956	chr3:150492724	A/G	cg07663535	chr3:150480033	SIAH2	0.96	4.49	0.37	1.6e-5	Breast cancer;
TGCT	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9503598	0.778	rs1328688	chr6:3468508	G/A	cg00476032	chr6:3446245	SLC22A23	0.17	4.99	0.41	2.03e-6	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
TGCT	cis	rs9527	0.590	rs1475642	chr10:104546183	C/T	cg15744005	chr10:104629667	AS3MT	0.5	5.6	0.45	1.34e-7	Arsenic metabolism;
TGCT	trans	rs78661745	0.764	rs77416036	chr3:163924516	G/A	cg25373553	chr5:151328029	NA	0.47	6.64	0.51	8.64e-10	Bulimia nervosa;
TGCT	cis	rs4237845	0.715	rs4760340	chr12:58275176	A/T	cg16577509	chr12:58013651	SLC26A10	-0.43	-4.67	-0.39	7.72e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1878931	0.582	rs27225	chr16:3428060	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.76	-6.41	-0.5	2.7e-9	Body mass index (adult);
TGCT	cis	rs7666738	0.830	rs4699600	chr4:99019429	C/G	cg05340658	chr4:99064831	C4orf37	0.48	5.43	0.44	2.92e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1857353	1.000	rs17096865	chr1:75894676	T/G	cg11838876	chr1:75668600	SLC44A5	-0.51	-4.81	-0.4	4.23e-6	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs56309584	0.560	rs11655996	chr17:8094753	A/C	cg08322244	chr17:8066669	VAMP2	-0.56	-5.42	-0.44	3e-7	Initial pursuit acceleration;
TGCT	cis	rs861020	1.000	rs632746	chr1:209982515	C/T	cg05527609	chr1:210001259	C1orf107	0.91	7.4	0.55	1.84e-11	Orofacial clefts;
TGCT	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10465746	0.905	rs12738214	chr1:84359050	C/A	cg10977910	chr1:84465055	TTLL7	0.63	6.19	0.49	8.08e-9	Obesity-related traits;
TGCT	cis	rs739496	0.602	rs79209359	chr12:111967161	A/T	cg10833066	chr12:111807467	FAM109A	0.37	5.16	0.42	9.31e-7	Platelet count;
TGCT	cis	rs8077889	0.917	rs72836553	chr17:41909851	A/G	cg26893861	chr17:41843967	DUSP3	1.08	12.97	0.76	7.86e-25	Triglycerides;
TGCT	trans	rs10504390	0.656	rs74776773	chr8:66544150	G/A	cg18118147	chr19:51128640	SYT3	-0.77	-6.85	-0.52	2.99e-10	IgG glycosylation;
TGCT	cis	rs11098499	0.754	rs10212775	chr4:120239244	G/C	cg09307838	chr4:120376055	NA	0.61	5.91	0.47	3.14e-8	Corneal astigmatism;
TGCT	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg19748678	chr4:122722346	EXOSC9	0.9	9.34	0.64	4.9e-16	Type 2 diabetes;
TGCT	cis	rs10131894	0.611	rs175001	chr14:75436452	A/C	cg08847533	chr14:75593920	NEK9	0.63	5.73	0.46	7.2e-8	Coronary artery disease;
TGCT	cis	rs60843830	1.000	rs17713729	chr2:249092	A/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.76	7.7	0.57	3.68e-12	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs13256369	0.802	rs35382339	chr8:8559255	G/A	cg18904891	chr8:8559673	CLDN23	0.57	5.04	0.41	1.6e-6	Obesity-related traits;
TGCT	cis	rs7829975	0.774	rs57312668	chr8:8680477	G/A	cg15556689	chr8:8085844	FLJ10661	0.69	6.17	0.48	8.84e-9	Mood instability;
TGCT	cis	rs4862750	0.519	rs10049830	chr4:187861593	T/C	cg10295955	chr4:187884368	NA	0.55	5.54	0.45	1.72e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6542838	0.554	rs4311103	chr2:99538362	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.57	-5.32	-0.43	4.74e-7	Fear of minor pain;
TGCT	cis	rs9677476	0.909	rs13428369	chr2:232125632	T/C	cg07929768	chr2:232055508	NA	0.3	4.48	0.37	1.71e-5	Food antigen IgG levels;
TGCT	cis	rs709400	0.663	rs11624367	chr14:103892818	T/A	cg12935359	chr14:103987150	CKB	-0.34	-4.9	-0.4	2.95e-6	Body mass index;
TGCT	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg08736216	chr1:53307985	ZYG11A	-0.25	-4.68	-0.39	7.33e-6	Monocyte count;
TGCT	cis	rs4780401	0.609	rs4781141	chr16:11808769	A/C	cg01061890	chr16:11836724	TXNDC11	-0.6	-5.82	-0.46	4.74e-8	Rheumatoid arthritis;
TGCT	cis	rs17376456	1.000	rs10514382	chr5:93566534	G/A	cg25358565	chr5:93447407	FAM172A	0.93	6.39	0.5	3.1e-9	Diabetic retinopathy;
TGCT	cis	rs6964587	0.967	rs55801687	chr7:91762629	C/A	cg17063962	chr7:91808500	NA	0.89	9.51	0.65	1.9e-16	Breast cancer;
TGCT	cis	rs11690935	0.959	rs10194102	chr2:172626143	G/C	cg13550731	chr2:172543902	DYNC1I2	-1.19	-12.78	-0.75	2.24e-24	Schizophrenia;
TGCT	trans	rs61931739	0.500	rs7489270	chr12:34432062	C/T	cg26384229	chr12:38710491	ALG10B	0.73	6.93	0.53	2.06e-10	Morning vs. evening chronotype;
TGCT	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg07061783	chr6:25882402	NA	-0.58	-5.47	-0.44	2.41e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg03609598	chr5:56110824	MAP3K1	-0.57	-4.57	-0.38	1.15e-5	Initial pursuit acceleration;
TGCT	cis	rs4820539	0.934	rs3788351	chr22:23469181	T/C	cg21100191	chr22:23484243	RTDR1	0.84	9.39	0.64	3.73e-16	Bone mineral density;
TGCT	cis	rs9911578	1.000	rs7342903	chr17:56914588	C/G	cg05425664	chr17:57184151	TRIM37	-0.62	-6.18	-0.49	8.33e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs28887893	chr4:98963006	G/A	cg17366294	chr4:99064904	C4orf37	0.74	7.56	0.56	7.89e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg15691649	chr6:25882328	NA	-0.35	-4.55	-0.38	1.25e-5	Blood metabolite levels;
TGCT	cis	rs7523273	0.597	rs2724374	chr1:207941191	G/T	cg22525895	chr1:207977042	MIR29B2	0.46	6.74	0.52	5.2400000000000005e-10	Schizophrenia;
TGCT	cis	rs80282103	0.618	rs11818314	chr10:1148157	G/C	cg18964960	chr10:1102726	WDR37	0.98	4.57	0.38	1.15e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg24060327	chr5:131705240	SLC22A5	-0.59	-5.9	-0.47	3.16e-8	Breast cancer;
TGCT	trans	rs8073060	0.586	rs8074800	chr17:33979148	A/G	cg19694781	chr19:47549865	TMEM160	0.55	12.98	0.76	7.31e-25	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg24549020	chr5:56110836	MAP3K1	0.66	5.79	0.46	5.56e-8	Initial pursuit acceleration;
TGCT	cis	rs9921338	0.961	rs8043692	chr16:11426957	C/T	cg00044050	chr16:11439710	C16orf75	-0.91	-7.07	-0.54	1.01e-10	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg26338869	chr17:61819248	STRADA	-0.55	-4.99	-0.41	1.98e-6	Prudent dietary pattern;
TGCT	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg15691649	chr6:25882328	NA	-0.4	-4.65	-0.39	8.35e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1577917	1.000	rs884841	chr6:86680300	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.12	-0.42	1.11e-6	Response to antipsychotic treatment;
TGCT	cis	rs3008870	0.755	rs2815365	chr1:67499628	C/T	cg11518657	chr1:67396239	MIER1	0.47	4.61	0.38	9.68e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs6840360	0.541	rs4696251	chr4:152266326	T/C	cg17479576	chr4:152424074	FAM160A1	-0.45	-4.77	-0.39	5.1e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs17376456	0.825	rs56108532	chr5:93276342	C/T	cg25358565	chr5:93447407	FAM172A	0.98	7.89	0.58	1.35e-12	Diabetic retinopathy;
TGCT	cis	rs13326165	0.715	rs66462821	chr3:52390555	C/T	cg07884673	chr3:53033167	SFMBT1	0.39	4.8	0.4	4.54e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs7772486	0.875	rs2328712	chr6:146344563	T/C	cg05347473	chr6:146136440	FBXO30	0.5	4.73	0.39	6.03e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7312933	0.567	rs11181399	chr12:42666412	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.53	5.1	0.42	1.26e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs9811920	0.609	rs6765027	chr3:99687730	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.59	6.56	0.51	1.34e-9	Axial length;
TGCT	trans	rs66573146	1.000	rs59683609	chr4:6964910	C/G	cg07817883	chr1:32538562	TMEM39B	1.56	8.31	0.6	1.45e-13	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs13256369	1.000	rs873064	chr8:8572380	G/A	cg17143192	chr8:8559678	CLDN23	0.62	5.83	0.46	4.57e-8	Obesity-related traits;
TGCT	cis	rs7267979	1.000	rs7268053	chr20:25328286	A/T	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9788682	0.747	rs7183604	chr15:78899213	T/C	cg24631222	chr15:78858424	CHRNA5	-0.88	-6.66	-0.51	7.79e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs7010267	0.773	rs4876869	chr8:119941277	A/G	cg17171407	chr8:119960777	TNFRSF11B	-0.28	-4.97	-0.41	2.17e-6	Total body bone mineral density (age 45-60);
TGCT	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg07507251	chr3:52567010	NT5DC2	-0.48	-6.71	-0.52	6.19e-10	Bipolar disorder;
TGCT	trans	rs4650994	0.525	rs2493848	chr1:178547838	T/A	cg05059571	chr16:84539110	KIAA1609	0.53	10.64	0.69	3.57e-19	HDL cholesterol levels;HDL cholesterol;
TGCT	trans	rs7864133	1.000	rs11139252	chr9:84063562	T/C	cg23451063	chr7:1059876	C7orf50	0.55	6.93	0.53	2.02e-10	Post bronchodilator FEV1 in COPD;
TGCT	cis	rs28595532	0.920	rs56331118	chr4:119767054	G/T	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg19536664	chr17:6899085	ALOX12	-0.36	-5.83	-0.46	4.47e-8	Tonsillectomy;
TGCT	cis	rs2710642	0.678	rs11125946	chr2:63298150	C/T	cg17519650	chr2:63277830	OTX1	-0.61	-5.62	-0.45	1.22e-7	LDL cholesterol levels;LDL cholesterol;
TGCT	cis	rs1784581	0.588	rs1789986	chr6:162409978	C/T	cg17173639	chr6:162384350	PARK2	-0.39	-6.58	-0.51	1.19e-9	Itch intensity from mosquito bite;
TGCT	trans	rs1828853	1.000	rs4343046	chr11:82106739	G/T	cg22704057	chr2:74425085	MTHFD2	0.55	6.68	0.51	7.27e-10	Curve progression in adolescent idiopathic scoliosis;
TGCT	cis	rs807669	0.903	rs762527	chr22:19183470	A/G	cg02655711	chr22:19163373	SLC25A1	0.42	9.92	0.67	1.94e-17	Metabolite levels;
TGCT	cis	rs12682352	0.602	rs6993494	chr8:8667444	C/T	cg15556689	chr8:8085844	FLJ10661	0.59	5.03	0.41	1.69e-6	Neuroticism;
TGCT	cis	rs35146811	0.695	rs1623264	chr7:99811204	G/C	cg04778012	chr7:99775508	STAG3;GPC2	-0.35	-4.93	-0.41	2.55e-6	Coronary artery disease;
TGCT	cis	rs5760092	0.842	rs5760103	chr22:24248781	A/G	cg02953382	chr22:24373134	LOC391322	-0.76	-6.15	-0.48	9.88e-9	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs539096	0.831	rs10789436	chr1:44040966	T/G	cg12908607	chr1:44402522	ARTN	-0.51	-5.32	-0.43	4.61e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs4499344	0.576	rs259280	chr19:33161452	C/T	cg26639809	chr19:33781782	NA	0.22	4.46	0.37	1.8e-5	Mean platelet volume;
TGCT	cis	rs9486719	1.000	rs2499816	chr6:96878206	C/T	cg18709589	chr6:96969512	KIAA0776	0.71	5.21	0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs6542838	0.641	rs12712042	chr2:99534401	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.56	-5.32	-0.43	4.61e-7	Fear of minor pain;
TGCT	cis	rs13242816	1.000	rs35515812	chr7:116156032	C/G	cg02799643	chr7:116139180	CAV2	-0.44	-5.54	-0.45	1.74e-7	P wave duration;
TGCT	cis	rs453301	0.686	rs2409120	chr8:8882571	G/C	cg00184457	chr8:8946301	NA	-0.26	-4.83	-0.4	3.98e-6	Joint mobility (Beighton score);
TGCT	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg13695892	chr22:41940480	POLR3H	-0.92	-9.33	-0.64	5.22e-16	Vitiligo;
TGCT	cis	rs78456975	1.000	rs11884854	chr2:1566154	A/G	cg01028140	chr2:1542097	TPO	-0.33	-4.54	-0.38	1.29e-5	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.57	-7.2	-0.54	5.16e-11	Longevity;Endometriosis;
TGCT	cis	rs12765878	0.580	rs67764572	chr10:105596007	T/C	cg11005552	chr10:105648138	OBFC1	-0.39	-6.05	-0.48	1.58e-8	Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs62321570	chr4:98984276	G/A	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs734999	0.566	rs10752747	chr1:2524915	G/T	cg18854424	chr1:2615690	NA	0.46	5.23	0.43	6.92e-7	Ulcerative colitis;
TGCT	cis	rs7424096	0.613	rs72873859	chr2:37246738	T/G	cg14987922	chr2:37194071	STRN	0.53	4.81	0.4	4.29e-6	High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs11098499	0.644	rs2389880	chr4:120559870	T/A	cg09307838	chr4:120376055	NA	0.63	5.79	0.46	5.56e-8	Corneal astigmatism;
TGCT	cis	rs3091242	0.933	rs34006994	chr1:25780668	C/T	cg10117171	chr1:25599238	RHD	0.3	4.92	0.4	2.69e-6	Erythrocyte sedimentation rate;
TGCT	cis	rs1670533	0.929	rs6599280	chr4:1063818	A/G	cg27284194	chr4:1044797	NA	0.69	5.99	0.47	2.14e-8	Recombination rate (females);
TGCT	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg12963246	chr6:28129442	ZNF389	0.52	5.1	0.42	1.23e-6	Parkinson's disease;
TGCT	cis	rs10871290	0.650	rs28484753	chr16:74489395	G/C	cg01733217	chr16:74700730	RFWD3	0.56	4.68	0.39	7.37e-6	Breast cancer;
TGCT	cis	rs2204008	0.744	rs11514358	chr12:38255526	G/A	cg26384229	chr12:38710491	ALG10B	0.86	7.48	0.56	1.17e-11	Bladder cancer;
TGCT	cis	rs13242816	1.000	rs3801993	chr7:116190382	C/G	cg16553024	chr7:116138462	CAV2	-0.45	-5.3	-0.43	5.1e-7	P wave duration;
TGCT	cis	rs4319547	0.695	rs10773152	chr12:122910180	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.65	-5.07	-0.41	1.39e-6	Body mass index;
TGCT	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg24846343	chr22:24311635	DDTL	0.23	5.88	0.47	3.59e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs13315871	1.000	rs11706420	chr3:58392411	C/T	cg12435725	chr3:58293450	RPP14	0.43	4.47	0.37	1.71e-5	Cholesterol, total;
TGCT	cis	rs3008870	0.959	rs2815359	chr1:67494374	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.07	11.4	0.72	5.07e-21	Lymphocyte percentage of white cells;
TGCT	cis	rs11642862	1.000	rs74483355	chr16:30836430	C/T	cg02466173	chr16:30829666	NA	-0.38	-4.48	-0.37	1.69e-5	Tonsillectomy;
TGCT	cis	rs7635838	0.859	rs6779840	chr3:11425423	A/G	cg00170343	chr3:11313890	ATG7	0.63	5.93	0.47	2.82e-8	HDL cholesterol;
TGCT	cis	rs12477438	0.520	rs11123762	chr2:99727789	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	13.05	0.76	4.93e-25	Chronic sinus infection;
TGCT	cis	rs35306767	0.668	rs12784928	chr10:1083617	A/C	cg20503657	chr10:835505	NA	0.44	4.99	0.41	1.96e-6	Eosinophil percentage of granulocytes;
TGCT	cis	rs2197308	0.765	rs11182992	chr12:37935572	G/C	cg26384229	chr12:38710491	ALG10B	0.87	7.83	0.58	1.85e-12	Morning vs. evening chronotype;
TGCT	cis	rs28602288	1	rs28602288	chr19:41388740	C/T	cg17435250	chr19:41386441	CYP2A7	-0.51	-5.01	-0.41	1.82e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
TGCT	cis	rs2153535	0.580	rs1119688	chr6:8460850	T/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs12681287	0.640	rs7816275	chr8:87373404	A/G	cg27223183	chr8:87520930	FAM82B	0.9	6.71	0.52	6.12e-10	Caudate activity during reward;
TGCT	cis	rs9952991	0.943	rs9952753	chr18:12780463	A/C	cg23598886	chr18:12777645	NA	0.62	5.78	0.46	5.63e-8	Inflammatory skin disease;
TGCT	cis	rs6570726	0.846	rs453834	chr6:145886261	T/C	cg05347473	chr6:146136440	FBXO30	0.51	4.78	0.39	4.8e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6988636	1.000	rs16898088	chr8:124190501	G/A	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs76935404	0.868	rs73034462	chr19:41418134	G/A	cg19493303	chr19:41414353	NA	0.42	5.05	0.41	1.53e-6	nicotine metabolite ratio in current smokers;
TGCT	cis	rs9733	0.525	rs11584184	chr1:150695689	A/T	cg09365446	chr1:150670422	GOLPH3L	0.3	4.52	0.38	1.4e-5	Tonsillectomy;
TGCT	cis	rs9325144	0.647	rs12822023	chr12:39097964	T/C	cg26384229	chr12:38710491	ALG10B	-0.55	-5.16	-0.42	9.52e-7	Morning vs. evening chronotype;
TGCT	cis	rs7524258	0.868	rs1304712	chr1:7270538	C/T	cg07173049	chr1:7289937	CAMTA1	0.3	4.99	0.41	1.97e-6	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs7666738	0.716	rs13108535	chr4:99046324	A/G	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs59197085	0.636	rs61012549	chr7:128442897	G/A	cg00260937	chr7:128520193	KCP	0.49	5.06	0.41	1.46e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
TGCT	cis	rs624899	1.000	rs624899	chr19:11612498	C/T	cg01045132	chr19:11649571	CNN1	0.47	4.63	0.38	9.12e-6	Presence of antiphospholipid antibodies;
TGCT	cis	rs4654899	0.758	rs6668370	chr1:21369568	C/T	cg01072550	chr1:21505969	NA	-0.57	-9.34	-0.64	4.93e-16	Superior frontal gyrus grey matter volume;
TGCT	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg17345569	chr6:42928274	GNMT	-0.48	-4.97	-0.41	2.22e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs10114408	0.959	rs10124041	chr9:96652394	T/G	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs13191362	1.000	rs34655790	chr6:163202739	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.94	6.76	0.52	4.71e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs9486719	1.000	rs4077932	chr6:96905144	C/T	cg18709589	chr6:96969512	KIAA0776	-0.68	-5.05	-0.41	1.55e-6	Migraine;Coronary artery disease;
TGCT	cis	rs7095607	0.813	rs7895717	chr10:69924100	A/G	cg18986048	chr10:69913749	MYPN	0.49	5.79	0.46	5.36e-8	Lung function (FVC);
TGCT	cis	rs17376456	0.825	rs36042718	chr5:93180997	C/T	cg25358565	chr5:93447407	FAM172A	0.98	7.67	0.57	4.38e-12	Diabetic retinopathy;
TGCT	cis	rs4455778	0.659	rs13226394	chr7:49026826	T/C	cg26309511	chr7:48887640	NA	-0.45	-5.27	-0.43	5.77e-7	Lung cancer in never smokers;
TGCT	cis	rs35934224	0.783	rs12159647	chr22:19860575	C/T	cg11182965	chr22:19864308	TXNRD2	-0.38	-5.3	-0.43	5.04e-7	Glaucoma (primary open-angle);
TGCT	cis	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg07424592	chr7:64974309	NA	1.27	7.84	0.58	1.8e-12	Diabetic kidney disease;
TGCT	cis	rs727563	0.520	rs132773	chr22:42031768	T/A	cg13695892	chr22:41940480	POLR3H	0.86	8.2	0.59	2.63e-13	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs1403694	0.669	rs10440056	chr3:186433822	C/T	cg12454167	chr3:186435060	KNG1	0.51	8.67	0.61	1.95e-14	Blood protein levels;
TGCT	cis	rs7611238	0.560	rs7650623	chr3:195088672	C/T	cg27323046	chr3:195102265	ACAP2	0.37	5.01	0.41	1.86e-6	Body mass index;
TGCT	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg06618935	chr21:46677482	NA	-0.37	-5.64	-0.45	1.1e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg26338869	chr17:61819248	STRADA	-0.53	-4.83	-0.4	3.91e-6	Prudent dietary pattern;
TGCT	cis	rs13064411	0.542	rs2087130	chr3:113226983	T/A	cg18753928	chr3:113234510	CCDC52	-0.56	-4.72	-0.39	6.3e-6	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs902774	0.597	rs7299694	chr12:53352572	A/C	cg16329197	chr12:53359506	NA	-0.5	-7.06	-0.54	1.04e-10	Prostate cancer;
TGCT	cis	rs595982	0.527	rs12151238	chr19:49368613	T/C	cg17863274	chr19:49399704	TULP2	-0.47	-6.78	-0.52	4.43e-10	Red cell distribution width;
TGCT	cis	rs4654899	0.802	rs9651021	chr1:21222770	A/C	cg01072550	chr1:21505969	NA	-0.47	-7.06	-0.54	1.03e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-8.64	-0.61	2.39e-14	Platelet count;
TGCT	cis	rs2050392	0.767	rs2183175	chr10:30699336	A/G	cg18806716	chr10:30721971	MAP3K8	0.66	8.87	0.62	6.6e-15	Inflammatory bowel disease;
TGCT	cis	rs2795502	0.873	rs3121327	chr10:43388285	G/A	cg20628663	chr10:43360327	NA	0.36	5.51	0.44	1.96e-7	Blood protein levels;
TGCT	cis	rs4786125	0.587	rs6500861	chr16:6923966	A/G	cg03623568	chr16:6915990	A2BP1	-0.45	-6.77	-0.52	4.65e-10	Heart rate variability traits (SDNN);
TGCT	cis	rs17741873	0.779	rs10824037	chr10:75588878	G/A	cg07699608	chr10:75541558	CHCHD1	0.73	5.14	0.42	1.03e-6	Paclitaxel disposition in epithelial ovarian cancer;
TGCT	cis	rs904251	0.523	rs2776872	chr6:37482787	C/G	cg08126542	chr6:37504118	NA	-0.43	-6.28	-0.49	5.34e-9	Cognitive performance;
TGCT	cis	rs2153535	0.580	rs1932280	chr6:8473654	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs12711979	0.765	rs7559345	chr2:3818523	G/A	cg17052675	chr2:3827356	NA	-0.4	-7.89	-0.58	1.34e-12	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs1008375	1.000	rs917665	chr4:17668504	A/C	cg18681998	chr4:17616180	MED28	-0.88	-9.73	-0.66	5.62e-17	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2242116	0.932	rs4683301	chr3:46931478	A/T	cg27129171	chr3:47204927	SETD2	-0.59	-6.16	-0.48	9.25e-9	Birth weight;
TGCT	cis	rs909674	0.775	rs8138462	chr22:39839670	G/C	cg24399712	chr22:39784796	NA	-1.05	-11.41	-0.72	4.79e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg04156016	chr5:1868137	NA	0.34	5.08	0.41	1.36e-6	Cardiovascular disease risk factors;
TGCT	cis	rs7818688	0.697	rs17665714	chr8:95982542	T/C	cg16049864	chr8:95962084	TP53INP1	0.54	4.64	0.38	8.87e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg11644478	chr21:40555479	PSMG1	1.03	11.02	0.7	4.14e-20	Cognitive function;
TGCT	cis	rs4319547	0.774	rs7295105	chr12:123124225	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.65	-5.52	-0.44	1.89e-7	Body mass index;
TGCT	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg24846343	chr22:24311635	DDTL	-0.23	-5.85	-0.46	4.17e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs10804591	1.000	rs2811437	chr3:129339045	A/C	cg07730360	chr3:128845626	NA	0.2	4.62	0.38	9.34e-6	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Hip circumference adjusted for BMI;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs208520	0.690	rs3843513	chr6:66836797	A/G	cg07460842	chr6:66804631	NA	-0.92	-9.58	-0.65	1.29e-16	Exhaled nitric oxide output;
TGCT	cis	rs2456568	0.805	rs55649862	chr11:93682888	G/T	cg16099599	chr11:93583650	C11orf90	-0.39	-4.69	-0.39	7.11e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7085104	0.514	rs284855	chr10:104574422	A/G	cg05855489	chr10:104503620	C10orf26	-0.63	-6.21	-0.49	7.3e-9	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs8014204	0.604	rs7156590	chr14:75388183	C/T	cg06637938	chr14:75390232	RPS6KL1	0.89	9.2	0.64	1.09e-15	Caffeine consumption;
TGCT	cis	rs1372520	0.935	rs1372519	chr4:90757309	A/G	cg20003494	chr4:90757398	SNCA	-0.65	-5.17	-0.42	9.26e-7	Neuroticism;
TGCT	cis	rs7017914	0.967	rs6472538	chr8:71586971	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.03	-0.41	1.69e-6	Bone mineral density;
TGCT	cis	rs2046867	0.818	rs7620212	chr3:72778610	C/T	cg25664220	chr3:72788482	NA	-0.56	-7.03	-0.53	1.25e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7666738	0.579	rs7672718	chr4:98645122	A/G	cg17366294	chr4:99064904	C4orf37	0.58	5.4	0.44	3.31e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11105298	0.891	rs6538190	chr12:89885942	T/C	cg00757033	chr12:89920650	WDR51B	0.34	5.37	0.43	3.75e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs6988636	1.000	rs17323510	chr8:124186089	A/G	cg23067535	chr8:124195133	FAM83A	0.35	5.37	0.43	3.79e-7	Urinary uromodulin levels;
TGCT	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg22166914	chr1:53195759	ZYG11B	0.3	4.85	0.4	3.62e-6	Monocyte count;
TGCT	cis	rs2050392	0.894	rs303430	chr10:30706235	C/A	cg18806716	chr10:30721971	MAP3K8	-0.47	-5.53	-0.44	1.82e-7	Inflammatory bowel disease;
TGCT	cis	rs73815153	0.744	rs77736838	chr5:180463764	A/G	cg00299286	chr5:180478185	BTNL9	0.86	4.95	0.41	2.36e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
TGCT	cis	rs1008375	1.000	rs1974624	chr4:17650281	A/G	cg18681998	chr4:17616180	MED28	1.02	12.01	0.73	1.65e-22	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1538970	0.781	rs11211139	chr1:46015751	G/T	cg05343316	chr1:45956843	TESK2	0.7	5.34	0.43	4.26e-7	Platelet count;
TGCT	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg11764359	chr7:65958608	NA	-0.57	-5.25	-0.43	6.27e-7	Aortic root size;
TGCT	cis	rs3015497	0.616	rs34061700	chr14:51084860	G/A	cg04730355	chr14:51134070	SAV1	-0.64	-6.33	-0.49	4.12e-9	Mean platelet volume;
TGCT	cis	rs832540	0.898	rs252888	chr5:56227326	T/A	cg12311346	chr5:56204834	C5orf35	-0.41	-4.45	-0.37	1.87e-5	Coronary artery disease;
TGCT	cis	rs858239	0.600	rs4321896	chr7:23128056	G/A	cg05602783	chr7:23145260	KLHL7	-0.58	-4.85	-0.4	3.68e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs9811920	0.683	rs1718235	chr3:99583484	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.42	4.9	0.4	2.98e-6	Axial length;
TGCT	cis	rs12681287	0.752	rs12548328	chr8:87311219	G/A	cg27223183	chr8:87520930	FAM82B	-0.85	-6.4	-0.5	2.9e-9	Caudate activity during reward;
TGCT	cis	rs7216064	1.000	rs3935969	chr17:65881959	A/G	cg12091567	chr17:66097778	LOC651250	-0.87	-6.85	-0.52	3.1e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs11098499	0.754	rs10518300	chr4:120249499	G/T	cg09307838	chr4:120376055	NA	-0.62	-5.58	-0.45	1.43e-7	Corneal astigmatism;
TGCT	cis	rs9640161	0.830	rs3735165	chr7:150068371	T/C	cg10018233	chr7:150070692	REPIN1	0.42	6.94	0.53	1.97e-10	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs9611565	0.512	rs6519289	chr22:42170432	A/C	cg13695892	chr22:41940480	POLR3H	0.85	8.06	0.59	5.4e-13	Vitiligo;
TGCT	cis	rs7081476	0.826	rs73596338	chr10:27259964	G/C	cg15469871	chr10:27541418	LOC387646	-0.97	-4.57	-0.38	1.14e-5	Age-related diseases and mortality;Age-related diseases, mortality and associated endophenotypes;
TGCT	trans	rs9951602	0.541	rs56882694	chr18:76647010	C/T	cg02800362	chr5:177631904	HNRNPAB	1.13	12.98	0.76	7.25e-25	Obesity-related traits;
TGCT	cis	rs67478160	0.644	rs7159810	chr14:104294117	T/G	cg26031613	chr14:104095156	KLC1	-0.63	-6.53	-0.51	1.56e-9	Schizophrenia;
TGCT	cis	rs3008870	1.000	rs7511948	chr1:67430427	A/G	cg11518657	chr1:67396239	MIER1	0.54	4.61	0.38	9.72e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs6657613	0.903	rs2076605	chr1:17313157	G/A	cg21692666	chr1:17199302	NA	-0.42	-4.52	-0.38	1.43e-5	Hip circumference adjusted for BMI;
TGCT	cis	rs73001065	0.792	rs17216525	chr19:19662220	C/T	cg03709012	chr19:19516395	GATAD2A	1.0	4.66	0.39	8.05e-6	LDL cholesterol;
TGCT	cis	rs694739	0.541	rs61886926	chr11:64133552	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.63	6.54	0.51	1.44e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs1362153	1.000	rs1362153	chr1:44469031	T/C	cg12908607	chr1:44402522	ARTN	0.71	4.73	0.39	5.96e-6	Alcohol dependence (age at onset);
TGCT	cis	rs360798	0.512	rs4671050	chr2:62988169	G/T	cg17519650	chr2:63277830	OTX1	-0.6	-5.15	-0.42	1.01e-6	Coronary artery disease;
TGCT	cis	rs2721195	0.845	rs756627	chr8:145737286	G/A	cg11211951	chr8:145729740	GPT	0.27	6.34	0.49	3.93e-9	Age at first birth;
TGCT	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg23758822	chr17:41437982	NA	0.71	6.83	0.52	3.46e-10	Menopause (age at onset);
TGCT	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg25703541	chr22:24373054	LOC391322	0.96	12.14	0.74	7.85e-23	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2404602	0.716	rs284895	chr15:76751225	C/G	cg26408565	chr15:76604113	ETFA	0.39	5.13	0.42	1.08e-6	Blood metabolite levels;
TGCT	cis	rs7666738	0.830	rs7664305	chr4:99037691	G/A	cg17366294	chr4:99064904	C4orf37	0.74	7.64	0.57	5.19e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7552404	0.731	rs5745491	chr1:76350159	T/G	cg10523679	chr1:76189770	ACADM	-0.82	-7.56	-0.56	7.75e-12	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs6882076	0.961	rs55776147	chr5:156400808	A/G	cg12943317	chr5:156479607	HAVCR1	-0.31	-5.82	-0.46	4.71e-8	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
TGCT	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs10832963	1.000	rs10128711	chr11:18632984	A/G	cg20219074	chr11:18656078	SPTY2D1	0.97	9.5	0.65	2.02e-16	Breast cancer;
TGCT	cis	rs11809207	0.903	rs17257148	chr1:26526348	G/C	cg03844060	chr1:26490628	NA	0.26	4.67	0.39	7.63e-6	Height;
TGCT	cis	rs1008375	0.966	rs2302393	chr4:17654341	G/A	cg16339924	chr4:17578868	LAP3	0.63	5.39	0.44	3.48e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg06112835	chr11:68658793	MRPL21	0.45	7.64	0.57	5.19e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs6693567	0.565	rs6684939	chr1:150440563	G/A	cg09579323	chr1:150459698	TARS2	-0.52	-4.62	-0.38	9.55e-6	Migraine;
TGCT	cis	rs55823223	0.646	rs74410877	chr17:73832384	C/T	cg23806715	chr17:73775811	H3F3B	0.85	5.77	0.46	5.93e-8	Psoriasis;
TGCT	cis	rs12210905	0.688	rs72843151	chr6:27359268	A/C	cg08851530	chr6:28072375	NA	1.32	5.79	0.46	5.48e-8	Hip circumference adjusted for BMI;
TGCT	cis	rs4766566	0.651	rs933306	chr12:111737985	A/T	cg10833066	chr12:111807467	FAM109A	0.4	7.56	0.56	7.74e-12	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
TGCT	cis	rs2970818	0.831	rs2970808	chr12:4640362	C/T	cg02722637	chr12:4922070	KCNA6	0.34	4.73	0.39	6.1e-6	Phosphorus levels;
TGCT	cis	rs36051895	0.659	rs10283730	chr9:5073289	G/A	cg02405213	chr9:5042618	JAK2	-0.79	-10.23	-0.68	3.48e-18	Pediatric autoimmune diseases;
TGCT	cis	rs7267979	1.000	rs2482937	chr20:25340786	A/G	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1053338	0.529	rs17069316	chr3:63713969	C/T	cg22134162	chr3:63841271	THOC7	0.31	4.72	0.39	6.36e-6	Breast cancer;
TGCT	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg09165964	chr15:75287851	SCAMP5	0.52	4.7	0.39	6.92e-6	Breast cancer;
TGCT	cis	rs9381040	0.655	rs2268188	chr6:41042590	T/G	cg03526776	chr6:41159608	TREML2	0.27	5.34	0.43	4.21e-7	Alzheimer's disease (late onset);
TGCT	cis	rs709400	0.663	rs10141388	chr14:103939679	A/G	cg26031613	chr14:104095156	KLC1	0.85	9.75	0.66	5.13e-17	Body mass index;
TGCT	cis	rs11644362	1.000	rs4505301	chr16:12989467	A/G	cg06890432	chr16:12997467	SHISA9	-0.61	-6.7	-0.52	6.46e-10	Positive affect;Subjective well-being;
TGCT	cis	rs7546094	0.509	rs7415988	chr1:113159730	G/T	cg22162597	chr1:113214053	CAPZA1	-0.28	-5.83	-0.46	4.4e-8	Platelet distribution width;
TGCT	cis	rs35306767	0.761	rs12771539	chr10:1050653	A/G	cg20503657	chr10:835505	NA	0.61	6.71	0.52	6.11e-10	Eosinophil percentage of granulocytes;
TGCT	cis	rs12681287	0.640	rs6471314	chr8:87400459	G/A	cg27223183	chr8:87520930	FAM82B	0.87	6.39	0.5	3e-9	Caudate activity during reward;
TGCT	cis	rs35883536	1.000	rs6663612	chr1:101085835	A/G	cg06223162	chr1:101003688	GPR88	0.31	4.93	0.4	2.63e-6	Monocyte count;
TGCT	cis	rs1372520	0.684	rs2197120	chr4:90729602	A/G	cg26578617	chr4:90757533	SNCA	-0.52	-4.44	-0.37	1.99e-5	Neuroticism;
TGCT	cis	rs877282	0.898	rs11253353	chr10:766862	C/A	cg17470449	chr10:769945	NA	0.36	5.36	0.43	3.85e-7	Uric acid levels;
TGCT	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	8.0	0.58	7.67e-13	Platelet count;
TGCT	cis	rs12478296	1.000	rs59036157	chr2:243040228	C/A	cg06360820	chr2:242988706	NA	-0.81	-5.39	-0.44	3.36e-7	Obesity-related traits;
TGCT	cis	rs7714584	1.000	rs3906528	chr5:150266718	G/A	cg22134413	chr5:150180641	NA	0.78	6.12	0.48	1.16e-8	Crohn's disease;
TGCT	cis	rs6490294	0.659	rs608848	chr12:112146964	C/T	cg10833066	chr12:111807467	FAM109A	0.3	4.71	0.39	6.54e-6	Mean platelet volume;
TGCT	cis	rs6570726	0.791	rs6902410	chr6:145905261	G/A	cg13319975	chr6:146136371	FBXO30	-0.5	-4.51	-0.38	1.48e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg20607798	chr8:58055168	NA	0.49	4.52	0.38	1.43e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7666738	0.753	rs34164013	chr4:98976333	A/G	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7681440	0.904	rs28403500	chr4:90769729	T/G	cg26578617	chr4:90757533	SNCA	-0.46	-4.83	-0.4	3.96e-6	Dementia with Lewy bodies;
TGCT	cis	rs2933343	1.000	rs876755	chr3:128627933	C/T	cg11901034	chr3:128598214	ACAD9	-0.63	-5.13	-0.42	1.08e-6	IgG glycosylation;
TGCT	cis	rs28595532	0.920	rs56027489	chr4:119780882	A/G	cg21605333	chr4:119757512	SEC24D	1.53	8.87	0.62	6.71e-15	Cannabis dependence symptom count;
TGCT	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9902453	1.000	rs9902453	chr17:28349095	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.74	-6.61	-0.51	1.03e-9	Coffee consumption (cups per day);
TGCT	cis	rs7095607	0.777	rs2101483	chr10:69922987	G/A	cg18986048	chr10:69913749	MYPN	0.48	5.57	0.45	1.54e-7	Lung function (FVC);
TGCT	cis	rs10782582	0.593	rs114421765	chr1:76141802	C/T	cg03433033	chr1:76189801	ACADM	-0.64	-7.25	-0.55	3.84e-11	Daytime sleep phenotypes;
TGCT	cis	rs9581857	1.000	rs9581857	chr13:28027714	A/C	cg22138327	chr13:27999177	GTF3A	0.76	5.41	0.44	3.1e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs2688608	0.967	rs9971038	chr10:75661149	C/T	cg23231163	chr10:75533350	FUT11	-0.27	-4.74	-0.39	5.8e-6	Inflammatory bowel disease;
TGCT	cis	rs4851266	1.000	rs11695383	chr2:100826098	G/T	cg07810366	chr2:100720526	AFF3	-0.38	-5.44	-0.44	2.7e-7	Educational attainment;
TGCT	cis	rs9733	0.596	rs1415148	chr1:150705755	G/A	cg04414720	chr1:150670196	GOLPH3L	0.37	4.91	0.4	2.76e-6	Tonsillectomy;
TGCT	cis	rs3749237	1.000	rs11717256	chr3:49868520	C/T	cg03060546	chr3:49711283	APEH	0.69	7.12	0.54	7.8e-11	Resting heart rate;
TGCT	cis	rs433598	0.514	rs56073015	chr16:20679391	A/G	cg08248577	chr16:19727447	IQCK;C16orf88	-0.25	-4.82	-0.4	4.13e-6	Schizophrenia;
TGCT	cis	rs17433780	0.666	rs2624	chr1:89518623	C/T	cg09516651	chr1:89888402	LOC400759	-0.25	-4.86	-0.4	3.42e-6	Carotid intima media thickness;
TGCT	cis	rs4512344	0.510	rs35181953	chr8:11435049	G/A	cg21775007	chr8:11205619	TDH	-0.53	-5.01	-0.41	1.85e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs3806843	1.000	rs13157397	chr5:140184442	G/A	cg19875535	chr5:140030758	IK	0.37	6.15	0.48	9.73e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs3096299	0.503	rs4785677	chr16:89555101	A/G	cg06640241	chr16:89574553	SPG7	0.74	8.16	0.59	3.13e-13	Multiple myeloma (IgH translocation);
TGCT	cis	rs11711311	1.000	rs9809850	chr3:113429010	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.76	-6.76	-0.52	4.88e-10	IgG glycosylation;
TGCT	cis	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg07424592	chr7:64974309	NA	1.27	7.86	0.58	1.61e-12	Diabetic kidney disease;
TGCT	cis	rs2439831	1.000	rs2444250	chr15:43785051	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.01	8.19	0.59	2.67e-13	Lung cancer in ever smokers;
TGCT	cis	rs1129187	0.782	rs9462860	chr6:42947013	G/C	cg17345569	chr6:42928274	GNMT	-0.47	-4.92	-0.4	2.75e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg00149659	chr3:10157352	C3orf10	0.78	4.99	0.41	2.04e-6	Alzheimer's disease;
TGCT	cis	rs4443656	0.711	rs7826330	chr8:21548665	G/A	cg26401870	chr8:21882439	NPM2	-0.47	-4.61	-0.38	9.76e-6	Blood protein levels;
TGCT	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg04744514	chr10:134541379	INPP5A	0.25	4.47	0.37	1.73e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs2228479	0.850	rs12598276	chr16:89829196	G/C	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg22857025	chr5:266934	NA	-0.34	-6.83	-0.52	3.42e-10	Breast cancer;
TGCT	cis	rs1784581	0.588	rs6455789	chr6:162417948	C/T	cg17173639	chr6:162384350	PARK2	0.4	6.6	0.51	1.07e-9	Itch intensity from mosquito bite;
TGCT	cis	rs9677476	0.516	rs6706191	chr2:232040047	T/G	cg27665808	chr2:232055229	NA	0.35	4.43	0.37	2.01e-5	Food antigen IgG levels;
TGCT	cis	rs8180040	1.000	rs1076394	chr3:47322781	G/A	cg27129171	chr3:47204927	SETD2	-0.7	-8.64	-0.61	2.35e-14	Colorectal cancer;
TGCT	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-5.1	-0.42	1.23e-6	Electroencephalogram traits;
TGCT	cis	rs6840360	0.593	rs1877185	chr4:152690348	C/T	cg22705602	chr4:152727874	NA	-0.35	-5.78	-0.46	5.68e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs16867321	0.618	rs17455242	chr2:181476558	G/A	cg23363182	chr2:181467187	NA	-0.42	-4.54	-0.38	1.3e-5	Obesity;
TGCT	cis	rs3820928	0.874	rs4675130	chr2:227827740	G/T	cg11843606	chr2:227700838	RHBDD1	-0.52	-4.61	-0.38	9.73e-6	Pulmonary function;
TGCT	cis	rs7267979	1.000	rs447722	chr20:25443510	C/T	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3796352	1.000	rs34340609	chr3:53077276	A/G	cg27565382	chr3:53032988	SFMBT1	0.41	4.47	0.37	1.73e-5	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs11249608	0.548	rs10516150	chr5:178459169	G/C	cg21905437	chr5:178450457	ZNF879	0.45	4.65	0.39	8.3e-6	Pubertal anthropometrics;
TGCT	cis	rs4727027	0.866	rs7778766	chr7:148806729	A/G	cg23583168	chr7:148888333	NA	-0.72	-9.16	-0.64	1.34e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs6840360	0.615	rs12647616	chr4:152607662	G/A	cg22705602	chr4:152727874	NA	-0.32	-5.43	-0.44	2.85e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs556990	0.570	rs5960	chr13:113801737	C/T	cg00898013	chr13:113819073	PROZ	0.56	6.99	0.53	1.48e-10	Blood protein levels;
TGCT	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg18305652	chr10:134549665	INPP5A	-0.33	-5.27	-0.43	5.96e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs17376456	0.825	rs28412976	chr5:93248377	T/C	cg21475434	chr5:93447410	FAM172A	0.7	4.62	0.38	9.34e-6	Diabetic retinopathy;
TGCT	cis	rs8031584	0.678	rs35098644	chr15:31145440	A/G	cg14829155	chr15:31115871	NA	-0.35	-4.51	-0.38	1.46e-5	Huntington's disease progression;
TGCT	cis	rs4862307	0.836	rs13107384	chr4:185004073	C/T	cg06737308	chr4:185021514	ENPP6	-0.35	-5.03	-0.41	1.7e-6	Serum dimethylarginine levels (asymmetric/symetric ratio);
TGCT	cis	rs7714584	0.826	rs12655654	chr5:150174295	A/C	cg22134413	chr5:150180641	NA	1.13	8.18	0.59	2.91e-13	Crohn's disease;
TGCT	cis	rs56104184	0.775	rs55981795	chr19:49401952	A/C	cg21252483	chr19:49399788	TULP2	-0.42	-5.89	-0.47	3.47e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs2486288	0.539	rs2433601	chr15:45716425	T/C	cg26924012	chr15:45694286	SPATA5L1	0.8	9.1	0.63	1.83e-15	Glomerular filtration rate;
TGCT	cis	rs904251	1.000	rs904251	chr6:37451696	G/T	cg25019722	chr6:37503610	NA	-0.47	-6.26	-0.49	5.69e-9	Cognitive performance;
TGCT	cis	rs1008375	0.966	rs2191504	chr4:17675592	C/G	cg16339924	chr4:17578868	LAP3	0.55	4.76	0.39	5.3e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6424115	0.931	rs2982390	chr1:24147830	G/C	cg15997130	chr1:24165203	NA	0.92	10.57	0.69	5.26e-19	Immature fraction of reticulocytes;
TGCT	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg03452623	chr4:187889614	NA	0.33	5.04	0.41	1.59e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11690935	0.632	rs12987931	chr2:172900948	C/T	cg13550731	chr2:172543902	DYNC1I2	0.74	6.73	0.52	5.53e-10	Schizophrenia;
TGCT	cis	rs7681440	0.904	rs28403500	chr4:90769729	T/G	cg14346243	chr4:90757452	SNCA	-0.55	-5.4	-0.44	3.34e-7	Dementia with Lewy bodies;
TGCT	cis	rs2479724	0.901	rs2185798	chr6:41773576	G/C	cg08135965	chr6:41755394	TOMM6	-0.49	-4.77	-0.39	5.1e-6	Menarche (age at onset);
TGCT	cis	rs10875746	0.551	rs10875799	chr12:48740879	C/A	cg20731937	chr12:48336164	NA	0.57	4.47	0.37	1.75e-5	Longevity (90 years and older);
TGCT	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg18230493	chr5:56204884	C5orf35	-0.67	-5.88	-0.47	3.5e-8	Initial pursuit acceleration;
TGCT	cis	rs2013441	1.000	rs2526467	chr17:20165054	T/A	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.63	-0.38	9.19e-6	Obesity-related traits;
TGCT	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg06634786	chr22:41940651	POLR3H	-0.88	-8.54	-0.61	3.98e-14	Vitiligo;
TGCT	cis	rs6840360	0.642	rs7682837	chr4:152427686	C/T	cg17479576	chr4:152424074	FAM160A1	-0.57	-6.02	-0.48	1.85e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs17030434	0.784	rs67664355	chr4:154660229	A/G	cg14289246	chr4:154710475	SFRP2	-0.88	-7.57	-0.56	7.4e-12	Electrocardiographic conduction measures;
TGCT	cis	rs3008870	0.755	rs2755251	chr1:67496425	G/T	cg11518657	chr1:67396239	MIER1	0.48	4.74	0.39	5.69e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs9297145	0.916	rs6969140	chr7:98753900	G/A	cg05967295	chr7:98741636	SMURF1	-1.04	-16.25	-0.82	1.66e-32	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs7824557	0.806	rs10503418	chr8:11118983	C/T	cg21775007	chr8:11205619	TDH	-0.56	-5.66	-0.45	1e-7	Retinal vascular caliber;
TGCT	cis	rs6582630	0.621	rs10880656	chr12:38571220	A/C	cg26384229	chr12:38710491	ALG10B	-0.54	-4.79	-0.4	4.57e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs75059851	1.000	rs73036064	chr11:133829442	G/A	cg14047540	chr11:133829660	NA	-0.53	-5.25	-0.43	6.44e-7	Schizophrenia;
TGCT	cis	rs7255045	0.788	rs7250751	chr19:12962648	A/G	cg23899408	chr19:12877188	HOOK2	-0.61	-4.99	-0.41	1.97e-6	Mean corpuscular volume;
TGCT	cis	rs7727544	1.000	rs10076701	chr5:131596419	A/G	cg00255919	chr5:131827918	IRF1	-0.21	-4.71	-0.39	6.65e-6	Blood metabolite levels;
TGCT	cis	rs986417	0.748	rs2179971	chr14:61055466	T/C	cg27398547	chr14:60952738	C14orf39	1.33	9.93	0.67	1.82e-17	Gut microbiota (bacterial taxa);
TGCT	cis	rs13424612	1.000	rs1465880	chr2:240932326	G/A	cg26363272	chr2:240904871	NDUFA10	0.28	4.66	0.39	7.96e-6	Odorant perception (isobutyraldehyde);
TGCT	cis	rs9549367	0.789	rs9549701	chr13:113881752	G/C	cg18105134	chr13:113819100	PROZ	-0.34	-5.45	-0.44	2.63e-7	Platelet distribution width;
TGCT	cis	rs7681440	0.874	rs10028246	chr4:90766704	G/A	cg26578617	chr4:90757533	SNCA	-0.47	-4.87	-0.4	3.34e-6	Dementia with Lewy bodies;
TGCT	cis	rs735396	0.595	rs2258287	chr12:121454313	G/T	cg15155738	chr12:121454335	C12orf43	0.57	5.25	0.43	6.33e-7	N-glycan levels;
TGCT	cis	rs9913156	0.748	rs72835619	chr17:4557285	G/A	cg00122941	chr17:4613640	ARRB2	0.87	7.38	0.55	1.95e-11	Lymphocyte counts;
TGCT	cis	rs3008870	0.958	rs12143044	chr1:67460054	A/T	cg03991309	chr1:68237761	GNG12	-0.27	-4.53	-0.38	1.36e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs9796	0.689	rs72737758	chr15:41449778	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.51	-6.42	-0.5	2.56e-9	Menopause (age at onset);
TGCT	cis	rs3796352	0.892	rs3821872	chr3:53080555	C/G	cg07884673	chr3:53033167	SFMBT1	-0.56	-6.17	-0.48	8.87e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs5769765	0.954	rs6009900	chr22:50236610	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.37	5.56	0.45	1.59e-7	Schizophrenia;
TGCT	cis	rs2243480	0.901	rs778732	chr7:65822360	C/T	cg20637647	chr7:64974828	NA	0.9	5.0	0.41	1.93e-6	Diabetic kidney disease;
TGCT	cis	rs7909074	1.000	rs4948925	chr10:45392455	C/T	cg04218760	chr10:45406644	TMEM72	-0.28	-5.63	-0.45	1.14e-7	Mean corpuscular volume;
TGCT	cis	rs7208859	0.623	rs7223209	chr17:29107220	C/A	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs709400	0.832	rs55864158	chr14:104068579	G/A	cg26031613	chr14:104095156	KLC1	1.15	16.05	0.82	4.72e-32	Body mass index;
TGCT	cis	rs9486719	0.895	rs12195315	chr6:96905711	T/G	cg18709589	chr6:96969512	KIAA0776	-0.68	-5.05	-0.41	1.55e-6	Migraine;Coronary artery disease;
TGCT	cis	rs1045714	0.895	rs4721860	chr7:2639994	C/T	cg17215154	chr7:2644645	IQCE	0.28	4.97	0.41	2.2e-6	Urate levels in lean individuals;
TGCT	cis	rs7258465	1.000	rs34256197	chr19:18606472	G/A	cg06462663	chr19:18546047	ISYNA1	0.2	4.67	0.39	7.74e-6	Breast cancer;
TGCT	cis	rs910316	0.737	rs108622	chr14:75481908	A/G	cg08847533	chr14:75593920	NEK9	-0.84	-8.92	-0.63	5.19e-15	Height;
TGCT	cis	rs3784262	0.528	rs10518961	chr15:58334345	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.43	-6.39	-0.5	3.11e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg18305652	chr10:134549665	INPP5A	0.35	5.94	0.47	2.73e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs2742234	0.910	rs2505513	chr10:43633537	C/G	cg02780029	chr10:43622663	RET	-0.26	-5.03	-0.41	1.67e-6	Hirschsprung disease;
TGCT	cis	rs1215050	0.716	rs356549	chr4:98699344	A/G	cg05340658	chr4:99064831	C4orf37	0.44	5.52	0.44	1.85e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2688608	0.592	rs11814282	chr10:75490217	T/C	cg15838173	chr10:75533400	FUT11	-0.31	-5.02	-0.41	1.73e-6	Inflammatory bowel disease;
TGCT	cis	rs2739330	0.615	rs2858911	chr22:24297195	G/T	cg02953382	chr22:24373134	LOC391322	-0.75	-7.83	-0.58	1.82e-12	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs425277	0.520	rs10910030	chr1:2035684	C/T	cg24578937	chr1:2090814	PRKCZ	-0.24	-5.34	-0.43	4.22e-7	Height;
TGCT	cis	rs910316	1.000	rs10143132	chr14:75525850	G/A	cg23033748	chr14:75592666	NEK9	0.28	4.68	0.39	7.29e-6	Height;
TGCT	cis	rs9325144	0.560	rs11182930	chr12:38633693	A/T	cg26384229	chr12:38710491	ALG10B	-0.66	-5.98	-0.47	2.23e-8	Morning vs. evening chronotype;
TGCT	cis	rs7255045	0.752	rs10404876	chr19:12987605	T/C	cg06537894	chr19:12978706	MAST1	-0.49	-4.47	-0.37	1.73e-5	Mean corpuscular volume;
TGCT	cis	rs838147	0.563	rs2638282	chr19:49213833	G/A	cg05248581	chr19:49925731	PTH2	0.42	4.44	0.37	1.94e-5	Dietary macronutrient intake;
TGCT	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg22963979	chr7:1858916	MAD1L1	-0.42	-6.67	-0.51	7.72e-10	Schizophrenia;
TGCT	cis	rs208520	0.909	rs58958359	chr6:67021381	A/C	cg07460842	chr6:66804631	NA	0.69	5.72	0.46	7.53e-8	Exhaled nitric oxide output;
TGCT	cis	rs208520	0.690	rs2797693	chr6:66868985	T/C	cg07460842	chr6:66804631	NA	-0.92	-9.58	-0.65	1.29e-16	Exhaled nitric oxide output;
TGCT	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg08280861	chr8:58055591	NA	0.51	5.56	0.45	1.58e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs67311347	0.911	rs6773917	chr3:40469254	G/T	cg17264618	chr3:40429014	ENTPD3	0.32	4.76	0.39	5.36e-6	Renal cell carcinoma;
TGCT	cis	rs12477438	0.798	rs1993230	chr2:99686079	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-6.1	-0.48	1.22e-8	Chronic sinus infection;
TGCT	cis	rs9394841	0.778	rs9349204	chr6:41914378	A/G	cg08135965	chr6:41755394	TOMM6	0.54	5.1	0.42	1.24e-6	Mean corpuscular hemoglobin;Red cell distribution width;
TGCT	cis	rs6088590	0.523	rs6059913	chr20:33143288	G/A	cg08999081	chr20:33150536	PIGU	0.28	5.41	0.44	3.11e-7	Coronary artery disease;
TGCT	cis	rs60843830	1.000	rs56321614	chr2:268191	G/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.71	6.78	0.52	4.33e-10	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs881375	0.967	rs2270231	chr9:123650982	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	5.5	0.44	2.03e-7	Rheumatoid arthritis;
TGCT	cis	rs8017423	0.967	rs11628881	chr14:90713833	C/T	cg04374321	chr14:90722782	PSMC1	0.75	7.76	0.57	2.67e-12	Mortality in heart failure;
TGCT	cis	rs8014204	0.657	rs2884668	chr14:75281576	T/A	cg06637938	chr14:75390232	RPS6KL1	0.55	4.91	0.4	2.81e-6	Caffeine consumption;
TGCT	cis	rs9393777	0.513	rs9393737	chr6:26617306	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.55	5.08	0.42	1.35e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9914544	0.545	rs9912713	chr17:18771145	G/A	cg26378065	chr17:18585709	ZNF286B	0.52	4.5	0.37	1.56e-5	Educational attainment (years of education);
TGCT	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	5.38	0.44	3.58e-7	Alzheimer's disease;
TGCT	cis	rs4629710	0.592	rs11758994	chr6:131582022	A/C	cg12606694	chr6:131520996	AKAP7	0.38	4.53	0.38	1.35e-5	Multiple myeloma (IgH translocation);
TGCT	cis	rs17076896	0.786	rs58325432	chr13:19938351	A/G	cg00777926	chr13:20807375	GJB6	-0.41	-4.82	-0.4	4.03e-6	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs17384381	0.953	rs12138621	chr1:85783970	T/C	cg16011679	chr1:85725395	C1orf52	0.87	6.73	0.52	5.65e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg03264133	chr6:25882463	NA	0.49	4.55	0.38	1.24e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg16031515	chr1:205743344	RAB7L1	-0.27	-4.56	-0.38	1.2e-5	Menarche (age at onset);
TGCT	cis	rs3008870	0.585	rs2815382	chr1:67515228	G/A	cg02640540	chr1:67518911	SLC35D1	0.64	6.06	0.48	1.51e-8	Lymphocyte percentage of white cells;
TGCT	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg07507251	chr3:52567010	NT5DC2	0.48	6.95	0.53	1.82e-10	Bipolar disorder;
TGCT	cis	rs7044106	0.762	rs1547267	chr9:123408736	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.62	6.6	0.51	1.08e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs1577917	0.917	rs2197651	chr6:86495442	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.46	-0.44	2.47e-7	Response to antipsychotic treatment;
TGCT	cis	rs9788721	1.000	rs8031948	chr15:78816057	G/T	cg18825076	chr15:78729989	IREB2	-0.31	-4.65	-0.39	8.24e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
TGCT	cis	rs981844	1.000	rs62325083	chr4:154661775	T/C	cg14289246	chr4:154710475	SFRP2	1.01	8.46	0.6	6.31e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs12900413	0.603	rs12909833	chr15:90301518	G/A	cg24249390	chr15:90295951	MESP1	-0.3	-5.2	-0.42	8.04e-7	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs7267979	0.934	rs2261115	chr20:25259807	G/A	cg14121845	chr20:25566513	NINL	0.51	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs739496	0.579	rs7976557	chr12:112300780	T/C	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	7.4	0.55	1.78e-11	Schizophrenia;
TGCT	cis	rs1043515	0.748	rs11657530	chr17:36942814	T/C	cg09592244	chr17:37024020	NA	0.49	4.69	0.39	7.22e-6	Height;
TGCT	cis	rs9549367	0.713	rs3024746	chr13:113821777	G/A	cg00898013	chr13:113819073	PROZ	-0.53	-6.74	-0.52	5.25e-10	Platelet distribution width;
TGCT	cis	rs2439831	0.717	rs690170	chr15:43810422	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.94	5.77	0.46	5.9e-8	Lung cancer in ever smokers;
TGCT	cis	rs7674212	0.531	rs10006474	chr4:103928047	A/G	cg16532752	chr4:104119610	CENPE	-0.54	-4.64	-0.38	8.77e-6	Type 2 diabetes;
TGCT	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg08219700	chr8:58056026	NA	0.38	5.0	0.41	1.93e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg02380750	chr20:61661411	NA	0.33	5.96	0.47	2.4e-8	Prostate cancer (SNP x SNP interaction);
TGCT	trans	rs10435719	0.867	rs34465618	chr8:11791356	C/T	cg15556689	chr8:8085844	FLJ10661	0.75	7.26	0.55	3.66e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs7943203	0.524	rs373759	chr11:108220657	C/T	cg04873221	chr11:107992290	ACAT1	-0.6	-5.24	-0.43	6.68e-7	Red blood cell count;Mean corpuscular volume;
TGCT	cis	rs9303401	0.659	rs34878689	chr17:56694330	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs17253792	0.822	rs77182097	chr14:56136695	G/A	cg01858014	chr14:56050164	KTN1	-0.35	-4.65	-0.39	8.23e-6	Putamen volume;
TGCT	cis	rs7507204	1.000	rs7507204	chr19:3428834	G/C	cg08380311	chr19:3435252	NFIC	0.94	8.14	0.59	3.48e-13	Height;
TGCT	cis	rs2239547	0.563	rs2581820	chr3:53020544	A/G	cg11645453	chr3:52864694	ITIH4	-0.34	-5.63	-0.45	1.12e-7	Schizophrenia;
TGCT	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg20203395	chr5:56204925	C5orf35	-0.59	-5.12	-0.42	1.12e-6	Initial pursuit acceleration;
TGCT	trans	rs12191082	0.646	rs35965624	chr6:46880137	G/T	cg15621338	chr7:128577916	IRF5	-1.26	-6.89	-0.53	2.44e-10	Mean platelet volume;
TGCT	cis	rs4072705	0.967	rs10818979	chr9:127336913	G/A	cg13476313	chr9:127244764	NR5A1	0.28	4.5	0.38	1.51e-5	Menarche (age at onset);
TGCT	cis	rs11098499	0.863	rs11736416	chr4:120431661	C/T	cg09307838	chr4:120376055	NA	0.68	6.45	0.5	2.28e-9	Corneal astigmatism;
TGCT	cis	rs6599388	0.803	rs11248057	chr4:906131	C/G	cg17500754	chr4:1581635	NA	0.38	5.07	0.41	1.42e-6	Parkinson's disease;
TGCT	cis	rs36051895	0.564	rs7874624	chr9:5179865	A/G	cg02405213	chr9:5042618	JAK2	-0.76	-10.76	-0.69	1.8e-19	Pediatric autoimmune diseases;
TGCT	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg02725872	chr8:58115012	NA	-0.38	-5.16	-0.42	9.32e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs568617	1.000	rs687672	chr11:65649984	T/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.54	-4.69	-0.39	7.03e-6	Crohn's disease;
TGCT	cis	rs1348850	0.872	rs4893824	chr2:178298104	G/A	cg22681709	chr2:178499509	PDE11A	-0.38	-4.73	-0.39	6.12e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs367943	1.000	rs168366	chr5:112818587	C/T	cg12552261	chr5:112820674	MCC	0.24	4.91	0.4	2.81e-6	Type 2 diabetes;
TGCT	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.68	4.84	0.4	3.86e-6	Platelet count;
TGCT	cis	rs6430585	0.528	rs309158	chr2:136680534	A/G	cg07169764	chr2:136633963	MCM6	1.2	11.66	0.72	1.12e-21	Corneal structure;
TGCT	cis	rs11098499	0.908	rs7696649	chr4:120322177	G/A	cg09307838	chr4:120376055	NA	0.68	6.45	0.5	2.25e-9	Corneal astigmatism;
TGCT	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg24675658	chr1:53192096	ZYG11B	0.87	11.26	0.71	1.08e-20	Monocyte count;
TGCT	cis	rs9926296	0.535	rs36022917	chr16:89893238	A/G	cg27121462	chr16:89883253	FANCA	0.53	4.94	0.41	2.48e-6	Vitiligo;
TGCT	cis	rs587847	0.737	rs4923744	chr15:37665412	T/C	cg00216138	chr15:37171175	LOC145845	0.31	4.45	0.37	1.91e-5	Intraocular pressure;
TGCT	cis	rs13242816	1.000	rs34678019	chr7:116189490	A/G	cg02799643	chr7:116139180	CAV2	-0.43	-5.29	-0.43	5.24e-7	P wave duration;
TGCT	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg18765753	chr7:1198926	ZFAND2A	-0.41	-4.53	-0.38	1.39e-5	Longevity;Endometriosis;
TGCT	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg22920501	chr2:26401640	FAM59B	0.81	6.36	0.5	3.52e-9	Gut microbiome composition (summer);
TGCT	cis	rs709400	0.663	rs62007719	chr14:103943130	G/T	cg26031613	chr14:104095156	KLC1	0.86	9.73	0.66	5.62e-17	Body mass index;
TGCT	cis	rs1448094	0.773	rs11117100	chr12:86310392	A/G	cg00310523	chr12:86230176	RASSF9	0.33	4.54	0.38	1.32e-5	Major depressive disorder;
TGCT	trans	rs7819412	0.806	rs2898256	chr8:10932695	G/C	cg15556689	chr8:8085844	FLJ10661	-0.81	-7.77	-0.57	2.51e-12	Triglycerides;
TGCT	cis	rs2692947	0.702	rs2312955	chr2:96777168	T/G	cg05933789	chr2:97190408	NA	-0.16	-4.74	-0.39	5.75e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs7647973	0.580	rs12637576	chr3:49237334	C/T	cg02487422	chr3:49467188	NICN1	0.52	4.91	0.4	2.84e-6	Menarche (age at onset);
TGCT	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg26513180	chr16:89883248	FANCA	1.07	14.67	0.8	7.16e-29	Vitiligo;
TGCT	cis	rs4727027	0.870	rs62507509	chr7:148795522	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	4.68	0.39	7.53e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs6500602	0.673	rs1861652	chr16:4505331	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.35	6.09	0.48	1.32e-8	Schizophrenia;
TGCT	cis	rs2404602	1.000	rs12898430	chr15:76874923	G/A	cg22467129	chr15:76604101	ETFA	-0.44	-4.86	-0.4	3.41e-6	Blood metabolite levels;
TGCT	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg11366901	chr6:160182831	ACAT2	1.02	6.82	0.52	3.57e-10	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs6076065	0.609	rs3746736	chr20:23424613	T/C	cg11657817	chr20:23433608	CST11	0.34	6.34	0.49	3.87e-9	Facial morphology (factor 15, philtrum width);
TGCT	cis	rs7666738	0.830	rs17558193	chr4:99049593	A/G	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs17094222	0.504	rs4917904	chr10:102447292	G/A	cg26540559	chr10:102447443	NA	0.35	4.73	0.39	5.89e-6	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs2153535	0.580	rs9392224	chr6:8472614	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs7666738	0.546	rs28444809	chr4:98916934	C/T	cg18180107	chr4:99064573	C4orf37	0.53	4.5	0.37	1.55e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg13342137	chr4:2252803	MXD4	0.16	4.46	0.37	1.83e-5	Obesity-related traits;
TGCT	trans	rs208520	0.608	rs3846803	chr6:66805743	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-10.77	-0.7	1.66e-19	Exhaled nitric oxide output;
TGCT	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.57	-5.42	-0.44	2.99e-7	Menarche (age at onset);
TGCT	cis	rs28595532	0.920	rs56212415	chr4:119737731	C/T	cg14228332	chr4:119757509	SEC24D	1.31	7.06	0.54	1.06e-10	Cannabis dependence symptom count;
TGCT	cis	rs9611519	0.558	rs8137906	chr22:41442566	A/G	cg03806693	chr22:41940476	POLR3H	-0.59	-5.42	-0.44	2.97e-7	Neuroticism;
TGCT	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg08392591	chr16:89556376	ANKRD11	0.6	5.76	0.46	6.28e-8	Multiple myeloma (IgH translocation);
TGCT	trans	rs4919669	0.546	rs2902544	chr10:104261359	C/T	cg19053889	chr7:1098703	C7orf50;GPR146	0.51	6.77	0.52	4.63e-10	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.64	-5.6	-0.45	1.32e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs9796	0.621	rs2918462	chr15:41481254	A/G	cg18705301	chr15:41695430	NDUFAF1	0.52	7.18	0.54	5.68e-11	Menopause (age at onset);
TGCT	cis	rs12681287	0.517	rs13249753	chr8:87513216	A/G	cg19078186	chr8:87526527	CPNE3	-0.38	-4.73	-0.39	6.04e-6	Caudate activity during reward;
TGCT	cis	rs9393777	0.513	rs34388707	chr6:27050396	A/G	cg16898833	chr6:26189333	HIST1H4D	0.8	4.85	0.4	3.57e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10779751	0.960	rs1883964	chr1:11294942	T/A	cg08854313	chr1:11322531	MTOR	0.98	9.12	0.63	1.65e-15	Body mass index;
TGCT	cis	rs6540559	0.546	rs57315825	chr1:210030197	C/T	cg04352962	chr1:209979756	IRF6	0.74	5.21	0.42	7.7e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.95	-12.8	-0.75	2e-24	Prudent dietary pattern;
TGCT	cis	rs763014	0.931	rs7191939	chr16:630089	C/T	cg27436995	chr16:743998	FBXL16	-0.45	-4.82	-0.4	4.17e-6	Height;
TGCT	cis	rs3796352	1.000	rs35163227	chr3:53127876	A/G	cg15956490	chr3:53032818	SFMBT1	0.5	5.38	0.43	3.65e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs10504229	0.593	rs12216730	chr8:58003894	C/T	cg08280861	chr8:58055591	NA	0.34	4.79	0.39	4.75e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg26531700	chr6:26746687	NA	0.52	4.71	0.39	6.66e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2188554	0.785	rs7789741	chr7:117206941	T/G	cg09181792	chr7:117119393	CFTR	0.52	4.68	0.39	7.3e-6	Esophageal adenocarcinoma;
TGCT	cis	rs7246657	1.000	rs35398388	chr19:37740358	A/G	cg18154014	chr19:37997991	ZNF793	0.84	5.58	0.45	1.46e-7	Coronary artery calcification;
TGCT	cis	rs4919694	0.808	rs80020194	chr10:105035954	A/G	cg04362960	chr10:104952993	NT5C2	1.02	6.5	0.5	1.73e-9	Arsenic metabolism;
TGCT	cis	rs1697139	0.583	rs17289614	chr5:66541592	G/A	cg11553311	chr5:66541588	NA	0.27	5.82	0.46	4.78e-8	Breast cancer;
TGCT	cis	rs2070433	0.660	rs11701034	chr21:47793235	A/G	cg12379764	chr21:47803548	PCNT	0.61	4.9	0.4	2.95e-6	Lymphocyte counts;
TGCT	cis	rs2469997	0.858	rs2470007	chr8:120358833	T/G	cg00681363	chr8:120844660	TAF2	0.69	4.48	0.37	1.64e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs4689388	0.926	rs4308429	chr4:6294001	A/G	cg14416269	chr4:6271139	WFS1	0.37	4.9	0.4	2.95e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs10791097	0.678	rs10894272	chr11:130731081	A/G	cg05962950	chr11:130786565	SNX19	0.84	10.27	0.68	2.87e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.36	0.55	2.25e-11	Prudent dietary pattern;
TGCT	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg07507251	chr3:52567010	NT5DC2	0.47	6.6	0.51	1.05e-9	Bipolar disorder;
TGCT	cis	rs10751667	0.666	rs10902255	chr11:967268	T/C	cg06064525	chr11:970664	AP2A2	-0.36	-8.28	-0.6	1.66e-13	Alzheimer's disease (late onset);
TGCT	cis	rs12497850	0.897	rs6795025	chr3:49081247	T/C	cg05785598	chr3:49045655	WDR6	0.36	4.8	0.4	4.48e-6	Parkinson's disease;
TGCT	cis	rs12451471	0.637	rs7567	chr17:78093549	G/T	cg06718696	chr17:78121285	EIF4A3	0.75	6.24	0.49	6.38e-9	Plateletcrit;Mean corpuscular hemoglobin concentration;
TGCT	cis	rs17270561	0.779	rs78589800	chr6:25883500	C/G	cg17042849	chr6:26104293	HIST1H4C	-0.78	-5.52	-0.44	1.92e-7	Iron status biomarkers;
TGCT	cis	rs6496667	0.779	rs8039719	chr15:90958584	C/G	cg20927724	chr15:90209326	PLIN1	0.34	4.76	0.39	5.26e-6	Rheumatoid arthritis;
TGCT	cis	rs4727027	0.901	rs7794500	chr7:148819519	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	-0.51	-4.64	-0.38	8.88e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs12682352	0.652	rs3789843	chr8:8724257	C/T	cg17143192	chr8:8559678	CLDN23	0.46	4.66	0.39	7.92e-6	Neuroticism;
TGCT	cis	rs7949030	0.653	rs17773169	chr11:62318530	G/T	cg11742103	chr11:62369870	EML3;MTA2	0.62	8.97	0.63	3.88e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9291683	0.595	rs13150928	chr4:10052961	G/T	cg00071950	chr4:10020882	SLC2A9	0.67	8.42	0.6	7.8500000000000006e-14	Bone mineral density;
TGCT	cis	rs11105298	0.838	rs10858862	chr12:89842053	T/C	cg00757033	chr12:89920650	WDR51B	0.34	5.36	0.43	4e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs4253772	0.744	rs1134224	chr22:46633371	A/T	cg09491104	chr22:46646882	C22orf40	-0.48	-4.84	-0.4	3.71e-6	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.61	5.06	0.41	1.5e-6	Tonsillectomy;
TGCT	cis	rs3741151	1.000	rs79794992	chr11:73049352	A/G	cg17517138	chr11:73019481	ARHGEF17	1.21	6.34	0.49	3.83e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
TGCT	trans	rs208520	1.000	rs12191403	chr6:66978137	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.83	7.46	0.56	1.31e-11	Exhaled nitric oxide output;
TGCT	cis	rs10791323	0.569	rs2156680	chr11:133742292	T/G	cg03690763	chr11:133734501	NA	-0.3	-5.16	-0.42	9.36e-7	Childhood ear infection;
TGCT	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg18876405	chr7:65276391	NA	-0.36	-5.41	-0.44	3.12e-7	Aortic root size;
TGCT	cis	rs12210905	0.688	rs72845031	chr6:27535404	C/T	cg08851530	chr6:28072375	NA	1.34	6.29	0.49	5.02e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs686320	1.000	rs1787666	chr11:65249089	A/C	cg21890820	chr11:65308645	LTBP3	0.59	4.71	0.39	6.49e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs17376456	0.825	rs72786702	chr5:93254656	A/C	cg21475434	chr5:93447410	FAM172A	0.65	4.5	0.37	1.57e-5	Diabetic retinopathy;
TGCT	cis	rs114540395	0.925	rs17696674	chr10:103415063	A/T	cg18276125	chr10:102749041	C10orf2	0.41	4.79	0.39	4.73e-6	Schizophrenia;
TGCT	cis	rs7209700	0.963	rs1000232	chr17:45356561	T/C	cg17185639	chr17:45330862	ITGB3	0.18	4.52	0.38	1.4e-5	IgG glycosylation;
TGCT	cis	rs2562456	0.917	rs2650804	chr19:21680184	A/G	cg25650185	chr19:21324782	ZNF431	-0.61	-5.28	-0.43	5.64e-7	Pain;
TGCT	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg20999797	chr1:1681921	NA	0.18	4.61	0.38	1.01e-5	Body mass index;
TGCT	cis	rs2742417	0.603	rs6807438	chr3:45778623	G/A	cg04837898	chr3:45731254	SACM1L	-0.67	-7.3	-0.55	3.06e-11	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs9467711	0.606	rs9393710	chr6:26367833	A/G	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9653442	0.835	rs11694875	chr2:100732845	A/G	cg07810366	chr2:100720526	AFF3	0.47	7.99	0.58	7.99e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs6725041	0.757	rs9973677	chr2:213080994	C/T	cg16329650	chr2:213403929	ERBB4	-0.54	-4.61	-0.38	9.88e-6	QT interval (ambient particulate matter interaction);
TGCT	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg17911788	chr17:44343683	NA	-0.66	-6.85	-0.52	3.03e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	trans	rs77457752	0.525	rs10961293	chr9:13894250	A/G	cg05148404	chr5:132700446	FSTL4	0.61	7.02	0.53	1.3e-10	Breast cancer;
TGCT	cis	rs2050392	0.590	rs303433	chr10:30714963	A/T	cg18806716	chr10:30721971	MAP3K8	-0.7	-9.36	-0.64	4.55e-16	Inflammatory bowel disease;
TGCT	cis	rs739496	0.527	rs7136469	chr12:112348191	T/C	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs6540559	0.546	rs735693	chr1:210033988	A/C	cg12034118	chr1:209979487	IRF6	0.69	4.9	0.4	2.93e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs72945132	0.882	rs55738915	chr11:70190019	C/T	cg00319359	chr11:70116639	PPFIA1	0.98	7.24	0.55	4.12e-11	Coronary artery disease;
TGCT	cis	rs2243480	1.000	rs313824	chr7:65581207	C/T	cg07424592	chr7:64974309	NA	1.22	7.36	0.55	2.2e-11	Diabetic kidney disease;
TGCT	cis	rs12893668	0.572	rs35011804	chr14:104151400	C/T	cg26031613	chr14:104095156	KLC1	-0.59	-5.05	-0.41	1.53e-6	Reticulocyte count;
TGCT	cis	rs2342371	0.805	rs55997345	chr3:196218353	T/C	cg15048948	chr3:196158458	UBXN7	0.53	4.49	0.37	1.6e-5	Fat distribution (HIV);
TGCT	cis	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg25427524	chr10:38739819	LOC399744	-0.39	-8.04	-0.59	5.95e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs11249608	0.548	rs13156530	chr5:178475017	C/T	cg23951258	chr5:178450506	ZNF879	0.44	4.5	0.37	1.57e-5	Pubertal anthropometrics;
TGCT	cis	rs10986311	0.832	rs10818952	chr9:127137803	T/C	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.2	-4.8	-0.4	4.54e-6	Vitiligo;
TGCT	cis	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg18252515	chr7:66147081	NA	-1.22	-7.33	-0.55	2.53e-11	Diabetic kidney disease;
TGCT	cis	rs858239	0.600	rs10241208	chr7:23144914	G/C	cg05602783	chr7:23145260	KLHL7	-0.73	-6.3	-0.49	4.74e-9	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs6545883	0.929	rs6545877	chr2:61741947	T/C	cg15711740	chr2:61764176	XPO1	-0.57	-5.23	-0.42	7.06e-7	Tuberculosis;
TGCT	cis	rs735396	1.000	rs2259816	chr12:121435587	A/C	cg02403541	chr12:121454288	C12orf43	-0.66	-6.42	-0.5	2.59e-9	N-glycan levels;
TGCT	cis	rs114540395	0.777	rs117932321	chr10:103149531	G/A	cg18276125	chr10:102749041	C10orf2	0.38	4.6	0.38	1.05e-5	Schizophrenia;
TGCT	cis	rs6582630	0.524	rs10785494	chr12:38532431	C/G	cg26384229	chr12:38710491	ALG10B	-0.53	-4.78	-0.39	4.9100000000000004e-06	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs66573146	0.831	rs1048009	chr4:6988677	G/A	cg05069807	chr4:6945702	TBC1D14	0.3	4.86	0.4	3.53e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs7666738	0.830	rs13149346	chr4:99009933	C/T	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6582630	0.519	rs4405392	chr12:38293661	A/C	cg26384229	chr12:38710491	ALG10B	0.82	7.23	0.54	4.32e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs9394841	0.692	rs9394837	chr6:41848088	G/A	cg08135965	chr6:41755394	TOMM6	0.54	4.87	0.4	3.36e-6	Mean corpuscular hemoglobin;Red cell distribution width;
TGCT	cis	rs1048238	0.545	rs848199	chr1:16292742	C/T	cg21385522	chr1:16154831	NA	-0.61	-6.83	-0.52	3.34e-10	Systolic blood pressure;
TGCT	cis	rs9911578	0.935	rs2302189	chr17:56584205	A/C	cg12560992	chr17:57184187	TRIM37	-0.74	-9.0	-0.63	3.27e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs694739	1.000	rs646153	chr11:64089588	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.69	7.12	0.54	7.69e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg06481639	chr22:41940642	POLR3H	-0.75	-6.67	-0.51	7.59e-10	Vitiligo;
TGCT	cis	rs651907	0.535	rs34743741	chr3:101532448	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.86	10.43	0.68	1.13e-18	Colorectal cancer;
TGCT	cis	rs78707713	0.560	rs17569412	chr10:71237536	C/A	cg12610070	chr10:71211762	TSPAN15	-0.62	-7.31	-0.55	2.83e-11	Venous thromboembolism;
TGCT	cis	rs3806843	0.838	rs2262567	chr5:140132134	T/A	cg19875535	chr5:140030758	IK	-0.35	-5.97	-0.47	2.27e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs6967414	0.786	rs6972017	chr7:6754034	A/G	cg00387323	chr7:6746715	ZNF12	0.74	4.54	0.38	1.29e-5	Hematocrit;Hemoglobin concentration;
TGCT	cis	rs7666738	0.830	rs13112037	chr4:98976986	A/T	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs546131	0.928	rs499183	chr11:34836678	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.52	4.58	0.38	1.13e-5	Lung disease severity in cystic fibrosis;
TGCT	cis	rs17102423	0.559	rs3783720	chr14:65475411	A/G	cg11161011	chr14:65562177	MAX	-0.46	-5.38	-0.44	3.53e-7	Obesity-related traits;
TGCT	cis	rs79911532	0.515	rs76760929	chr7:75625968	T/G	cg24069840	chr7:75623858	TMEM120A	0.83	4.54	0.38	1.32e-5	Mononucleosis;
TGCT	cis	rs7914558	0.966	rs10786724	chr10:104668942	A/G	cg04362960	chr10:104952993	NT5C2	0.58	5.15	0.42	9.77e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs9902453	0.791	rs28492945	chr17:28223982	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.91	8.82	0.62	8.68e-15	Coffee consumption (cups per day);
TGCT	cis	rs4242434	0.927	rs11778693	chr8:22462852	T/C	cg03733263	chr8:22462867	KIAA1967	1.14	20.27	0.88	3.6e-41	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg07507251	chr3:52567010	NT5DC2	0.47	6.7	0.52	6.47e-10	Bipolar disorder;
TGCT	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.47	-0.37	1.75e-5	Electroencephalogram traits;
TGCT	cis	rs11719291	0.504	rs71324924	chr3:48865444	G/A	cg07636037	chr3:49044803	WDR6	-1.0	-4.98	-0.41	2.11e-6	Cognitive function;
TGCT	cis	rs3617	0.625	rs2240917	chr3:52851137	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	4.59	0.38	1.08e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs68170813	0.641	rs12532953	chr7:106865920	C/T	cg02696742	chr7:106810147	HBP1	-0.69	-5.61	-0.45	1.27e-7	Coronary artery disease;
TGCT	cis	rs67311347	0.866	rs56331709	chr3:40356558	A/C	cg13683864	chr3:40499215	RPL14	-0.92	-8.87	-0.62	6.51e-15	Renal cell carcinoma;
TGCT	cis	rs3806843	0.576	rs246063	chr5:140324492	T/A	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs6840360	0.593	rs1429559	chr4:152681952	A/G	cg17479576	chr4:152424074	FAM160A1	-0.52	-5.16	-0.42	9.49e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2288073	0.965	rs10173173	chr2:24415461	G/T	cg05570707	chr2:24270316	C2orf44	0.5	4.47	0.37	1.72e-5	Venous thromboembolism (SNP x SNP interaction);
TGCT	trans	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg27523141	chr10:43048294	ZNF37B	0.74	8.6	0.61	2.88e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.72	-6.47	-0.5	2.04e-9	Tonsillectomy;
TGCT	cis	rs700590	0.723	rs244761	chr5:88117027	A/T	cg22951263	chr5:87985283	NA	0.55	5.33	0.43	4.45e-7	Educational attainment (years of education);
TGCT	trans	rs4650994	0.507	rs2811312	chr1:178617603	A/G	cg05059571	chr16:84539110	KIAA1609	0.51	9.76	0.66	4.88e-17	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs6912958	0.781	rs1051148	chr6:88221892	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-5.06	-0.41	1.45e-6	Monocyte percentage of white cells;
TGCT	cis	rs6089584	0.627	rs13045575	chr20:60565596	G/A	cg06108461	chr20:60628389	TAF4	-0.37	-4.46	-0.37	1.81e-5	Body mass index;
TGCT	cis	rs7615952	0.800	rs2062773	chr3:125639648	T/C	cg05084668	chr3:125655381	ALG1L	-0.7	-5.74	-0.46	6.93e-8	Blood pressure (smoking interaction);
TGCT	cis	rs9914544	0.564	rs11548434	chr17:18761508	G/A	cg26378065	chr17:18585709	ZNF286B	0.52	4.5	0.37	1.56e-5	Educational attainment (years of education);
TGCT	cis	rs11247915	0.600	rs12059495	chr1:26655614	A/G	cg25392287	chr1:26333318	NA	0.22	4.55	0.38	1.28e-5	Obesity-related traits;
TGCT	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg13695892	chr22:41940480	POLR3H	0.79	7.83	0.58	1.85e-12	Vitiligo;
TGCT	cis	rs7666738	0.606	rs4699611	chr4:99097492	T/G	cg05340658	chr4:99064831	C4orf37	0.42	4.49	0.37	1.62e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs941408	0.963	rs1640267	chr19:2789337	T/C	cg06609049	chr19:2785107	THOP1	0.78	6.56	0.51	1.33e-9	Total cholesterol levels;
TGCT	cis	rs4319547	0.695	rs10846746	chr12:122868696	C/T	cg08088222	chr12:122070432	ORAI1	-0.25	-4.49	-0.37	1.58e-5	Body mass index;
TGCT	cis	rs2307449	0.729	rs2529930	chr15:89881990	T/A	cg24365117	chr15:89879190	POLG	0.33	4.75	0.39	5.58e-6	Menopause (age at onset);
TGCT	cis	rs17376456	0.825	rs6865441	chr5:93284746	G/A	cg25358565	chr5:93447407	FAM172A	1.03	8.1	0.59	4.5e-13	Diabetic retinopathy;
TGCT	cis	rs3806843	0.576	rs246006	chr5:140339228	G/A	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs36051895	0.695	rs10974921	chr9:5024427	T/A	cg02405213	chr9:5042618	JAK2	-0.75	-10.0	-0.67	1.23e-17	Pediatric autoimmune diseases;
TGCT	cis	rs6589563	0.737	rs12274192	chr11:116652351	A/G	cg20660624	chr11:117307972	DSCAML1	-0.38	-4.98	-0.41	2.09e-6	Eosinophil counts;
TGCT	cis	rs10510102	0.872	rs12240308	chr10:123722922	C/A	cg23691251	chr10:123688108	ATE1	-0.59	-4.7	-0.39	6.75e-6	Breast cancer;
TGCT	cis	rs7666738	0.830	rs13102369	chr4:99045912	A/G	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs1703755	0.527	rs12594633	chr15:42705464	A/C	cg19009305	chr15:89181732	ISG20	0.53	6.89	0.53	2.5e-10	Fibrinogen levels;
TGCT	cis	rs1062177	0.950	rs892005	chr5:151180621	A/G	cg12924095	chr5:151150029	G3BP1	0.35	5.05	0.41	1.53e-6	Preschool internalizing problems;
TGCT	cis	rs1801251	0.893	rs6733151	chr2:233592341	A/C	cg08000102	chr2:233561755	GIGYF2	0.63	6.53	0.51	1.51e-9	Coronary artery disease;
TGCT	cis	rs9443645	0.901	rs9448584	chr6:79572799	G/T	cg09184832	chr6:79620586	NA	-0.48	-5.34	-0.43	4.21e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg06873352	chr17:61820015	STRADA	0.55	6.13	0.48	1.09e-8	Prudent dietary pattern;
TGCT	cis	rs6570726	0.791	rs405206	chr6:145836873	C/A	cg05347473	chr6:146136440	FBXO30	0.53	4.95	0.41	2.4e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2997447	0.655	rs2275947	chr1:26383875	A/G	cg19633962	chr1:26362018	EXTL1	-0.65	-4.84	-0.4	3.71e-6	QRS complex (12-leadsum);
TGCT	cis	rs79149102	0.579	rs58645417	chr15:75325858	T/G	cg09165964	chr15:75287851	SCAMP5	-1.07	-5.81	-0.46	4.93e-8	Lung cancer;
TGCT	cis	rs17253792	0.555	rs17683626	chr14:56041112	G/T	cg01858014	chr14:56050164	KTN1	-0.36	-4.57	-0.38	1.15e-5	Putamen volume;
TGCT	cis	rs12946454	0.668	rs4792867	chr17:43249444	C/T	cg10701640	chr17:43249399	NA	0.53	7.19	0.54	5.48e-11	Systolic blood pressure;
TGCT	cis	rs6977660	0.714	rs4721824	chr7:19785898	A/G	cg07541023	chr7:19748670	TWISTNB	0.81	4.46	0.37	1.81e-5	Thyroid stimulating hormone;
TGCT	cis	rs3796352	1.000	rs6445557	chr3:53083969	C/T	cg07884673	chr3:53033167	SFMBT1	-0.56	-6.15	-0.48	9.89e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs3824867	0.920	rs7126210	chr11:47460306	A/G	cg20307385	chr11:47447363	PSMC3	0.7	6.03	0.48	1.71e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs73198271	0.740	rs964771	chr8:8650939	A/G	cg06636001	chr8:8085503	FLJ10661	0.63	4.69	0.39	7.23e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs9638182	0.720	rs13235543	chr7:73013901	C/T	cg14087351	chr7:73037990	MLXIPL	-0.65	-5.07	-0.41	1.43e-6	Triglycerides;
TGCT	cis	rs12971120	0.947	rs3764509	chr18:72167124	C/G	cg25817165	chr18:72167213	CNDP2	-0.29	-5.54	-0.45	1.71e-7	Refractive error;
TGCT	cis	rs11673344	0.542	rs2562585	chr19:37509223	G/A	cg08039142	chr19:36980659	ZNF566	0.52	4.92	0.4	2.68e-6	Obesity-related traits;
TGCT	cis	rs9611519	0.567	rs8141730	chr22:41473061	A/G	cg03806693	chr22:41940476	POLR3H	-0.51	-4.57	-0.38	1.14e-5	Neuroticism;
TGCT	cis	rs561655	0.629	rs10751134	chr11:85858887	G/A	cg07180834	chr11:85838833	NA	-0.32	-4.69	-0.39	7.19e-6	Alzheimer's disease (late onset);
TGCT	cis	rs7819412	0.783	rs28722721	chr8:10948968	G/A	cg27411982	chr8:10470053	RP1L1	-0.21	-4.56	-0.38	1.21e-5	Triglycerides;
TGCT	cis	rs736408	0.608	rs2239547	chr3:52855229	T/C	cg10802521	chr3:52805072	NEK4	-0.64	-6.51	-0.5	1.69e-9	Bipolar disorder;
TGCT	cis	rs9952991	0.941	rs2542149	chr18:12779018	G/A	cg23544223	chr18:12777786	NA	0.64	6.12	0.48	1.15e-8	Inflammatory skin disease;
TGCT	cis	rs9303401	0.659	rs11495824	chr17:56918882	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs909674	0.662	rs2899318	chr22:39837625	A/G	cg11247378	chr22:39784982	NA	-0.72	-8.42	-0.6	7.79e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs7647973	0.580	rs12637576	chr3:49237334	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.55	-5.25	-0.43	6.4e-7	Menarche (age at onset);
TGCT	trans	rs17685	0.697	rs28689051	chr7:75763624	G/A	cg19862616	chr7:65841803	NCRNA00174	0.51	8.35	0.6	1.11e-13	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs308403	0.533	rs309377	chr4:123676353	G/A	cg10495464	chr4:123653540	BBS12;LOC729338	0.83	12.14	0.74	7.98e-23	Blood protein levels;
TGCT	cis	rs12458462	0.859	rs34242155	chr18:77425192	G/A	cg11879182	chr18:77439856	CTDP1	0.68	7.74	0.57	3.03e-12	Monocyte count;
TGCT	cis	rs28830936	0.535	rs28657602	chr15:41869162	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.19	-4.61	-0.38	9.9e-6	Diastolic blood pressure;
TGCT	cis	rs17376456	0.825	rs13161885	chr5:93071242	A/C	cg25358565	chr5:93447407	FAM172A	0.9	7.6	0.56	6.43e-12	Diabetic retinopathy;
TGCT	cis	rs1008375	1.000	rs56974987	chr4:17627856	G/A	cg10189774	chr4:17578691	LAP3	0.59	5.13	0.42	1.06e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg12923728	chr3:195709715	SDHAP1	-0.36	-7.49	-0.56	1.13e-11	Pancreatic cancer;
TGCT	cis	rs2153535	0.580	rs9406143	chr6:8444583	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.58	0.45	1.42e-7	Motion sickness;
TGCT	cis	rs3540	0.921	rs8034050	chr15:91000206	C/T	cg22089800	chr15:90895588	ZNF774	0.75	6.94	0.53	1.92e-10	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs9653442	0.527	rs11690905	chr2:100761473	C/T	cg22139774	chr2:100720529	AFF3	0.36	5.72	0.46	7.68e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs3008870	0.920	rs975452	chr1:67480190	A/T	cg08660285	chr1:67390436	MIER1;WDR78	1.08	11.47	0.72	3.32e-21	Lymphocyte percentage of white cells;
TGCT	cis	rs539096	0.872	rs631248	chr1:44071221	C/T	cg12908607	chr1:44402522	ARTN	-0.51	-5.36	-0.43	3.83e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7552404	0.920	rs2788654	chr1:76219569	C/T	cg22875332	chr1:76189707	ACADM	0.69	8.32	0.6	1.32e-13	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg07424592	chr7:64974309	NA	1.31	8.14	0.59	3.55e-13	Diabetic kidney disease;
TGCT	cis	rs7845219	0.544	rs2123647	chr8:95931782	A/G	cg13393036	chr8:95962371	TP53INP1	0.43	5.03	0.41	1.67e-6	Type 2 diabetes;
TGCT	cis	rs7291412	0.579	rs11090867	chr22:46454792	T/C	cg05468064	chr22:46423449	NA	0.41	4.49	0.37	1.58e-5	Dupuytren's disease;Subjective well-being;
TGCT	trans	rs208520	0.802	rs208496	chr6:66930786	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.95	-9.95	-0.67	1.64e-17	Exhaled nitric oxide output;
TGCT	cis	rs2204008	0.522	rs12370263	chr12:38113311	A/G	cg26384229	chr12:38710491	ALG10B	0.84	7.61	0.56	6.06e-12	Bladder cancer;
TGCT	cis	rs17270561	0.562	rs12199626	chr6:26013604	G/A	cg17042849	chr6:26104293	HIST1H4C	-0.83	-5.82	-0.46	4.74e-8	Iron status biomarkers;
TGCT	cis	rs35306767	0.715	rs12772979	chr10:1034412	C/T	cg20503657	chr10:835505	NA	0.63	6.97	0.53	1.64e-10	Eosinophil percentage of granulocytes;
TGCT	cis	rs2880765	0.835	rs7180213	chr15:86021187	G/A	cg13263323	chr15:86062960	AKAP13	-0.23	-4.97	-0.41	2.13e-6	Coronary artery disease;
TGCT	cis	rs28595532	0.920	rs17325017	chr4:119774607	A/G	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs7267979	0.604	rs242130	chr20:25594020	C/A	cg14121845	chr20:25566513	NINL	-0.44	-4.57	-0.38	1.19e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11679640	1.000	rs73923006	chr2:43132224	G/C	cg18281102	chr2:44065550	ABCG5;ABCG8	-0.27	-4.52	-0.38	1.45e-5	White matter hyperintensity burden;
TGCT	cis	rs17221829	0.673	rs10765226	chr11:89385013	A/C	cg02982614	chr11:89391479	FOLH1B	-0.27	-4.66	-0.39	7.89e-6	Anxiety in major depressive disorder;
TGCT	cis	rs2637266	0.678	rs35278870	chr10:78471394	G/A	cg18941641	chr10:78392320	NA	0.4	4.83	0.4	4e-6	Pulmonary function;
TGCT	cis	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg26116260	chr4:7069785	GRPEL1	1.13	11.1	0.71	2.59e-20	Monocyte percentage of white cells;
TGCT	cis	rs9467711	0.591	rs6913795	chr6:25848025	T/C	cg16898833	chr6:26189333	HIST1H4D	1.16	5.51	0.44	2.03e-7	Autism spectrum disorder or schizophrenia;
TGCT	trans	rs4332037	1.000	rs62442899	chr7:1948454	C/T	cg10840412	chr1:235813424	GNG4	1.05	8.28	0.6	1.71e-13	Bipolar disorder;
TGCT	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg22535103	chr8:58192502	C8orf71	-0.42	-4.72	-0.39	6.22e-6	Developmental language disorder (linguistic errors);
TGCT	trans	rs208520	0.874	rs208485	chr6:66925654	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.97	-10.05	-0.67	9.41e-18	Exhaled nitric oxide output;
TGCT	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs6089829	0.962	rs6089826	chr20:61668595	G/A	cg18188782	chr20:61659543	NA	0.47	5.63	0.45	1.15e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs807669	0.527	rs11089259	chr22:19190143	C/T	cg02655711	chr22:19163373	SLC25A1	0.32	6.44	0.5	2.38e-9	Metabolite levels;
TGCT	cis	rs2249625	0.545	rs2496505	chr6:72891063	C/G	cg08500200	chr6:72892038	RIMS1	-0.42	-4.55	-0.38	1.27e-5	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
TGCT	cis	rs478304	0.654	rs10896029	chr11:65452952	C/T	cg17480646	chr11:65405466	SIPA1	-0.63	-8.47	-0.61	6.08e-14	Acne (severe);
TGCT	cis	rs3796352	1.000	rs4478072	chr3:53106125	G/T	cg27565382	chr3:53032988	SFMBT1	0.44	4.82	0.4	4.11e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs6429082	0.702	rs2131922	chr1:235705001	G/T	cg26050004	chr1:235667680	B3GALNT2	-0.62	-5.68	-0.45	9.27e-8	Adiposity;
TGCT	cis	rs2239547	0.522	rs9844736	chr3:52931971	T/G	cg11645453	chr3:52864694	ITIH4	-0.38	-6.28	-0.49	5.25e-9	Schizophrenia;
TGCT	cis	rs2075371	0.933	rs1868784	chr7:133945932	A/G	cg11752832	chr7:134001865	SLC35B4	0.7	6.0	0.47	2.04e-8	Mean platelet volume;
TGCT	cis	rs425277	0.583	rs3107151	chr1:2051513	T/G	cg24578937	chr1:2090814	PRKCZ	-0.25	-5.94	-0.47	2.68e-8	Height;
TGCT	cis	rs826838	0.967	rs73096706	chr12:38860563	G/A	cg26384229	chr12:38710491	ALG10B	1.06	10.68	0.69	2.84e-19	Heart rate;
TGCT	cis	rs17253792	0.822	rs77544029	chr14:56087917	T/C	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg11845111	chr2:191398756	TMEM194B	-0.36	-5.45	-0.44	2.59e-7	Pulse pressure;
TGCT	cis	rs250677	0.958	rs10056942	chr5:148416114	C/A	cg23229984	chr5:148520753	ABLIM3	0.21	4.81	0.4	4.35e-6	Breast cancer;
TGCT	cis	rs7552404	0.924	rs1498317	chr1:76171984	A/C	cg10523679	chr1:76189770	ACADM	0.9	9.92	0.67	2e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2404602	0.608	rs12911035	chr15:76606591	T/C	cg26408565	chr15:76604113	ETFA	-0.46	-6.46	-0.5	2.15e-9	Blood metabolite levels;
TGCT	cis	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg06558623	chr16:89946397	TCF25	0.45	4.52	0.38	1.42e-5	Skin colour saturation;
TGCT	cis	rs7552404	0.590	rs1565717	chr1:76320441	T/C	cg22875332	chr1:76189707	ACADM	-0.58	-6.24	-0.49	6.18e-9	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs208520	0.545	rs6899712	chr6:66749670	T/C	cg07460842	chr6:66804631	NA	1.02	13.51	0.77	3.89e-26	Exhaled nitric oxide output;
TGCT	cis	rs7147624	0.882	rs7141367	chr14:65938641	C/T	cg03016385	chr14:66212404	NA	-0.5	-7.18	-0.54	5.64e-11	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg12963246	chr6:28129442	ZNF389	0.52	5.1	0.42	1.23e-6	Depression;
TGCT	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg06634786	chr22:41940651	POLR3H	0.73	6.81	0.52	3.84e-10	Vitiligo;
TGCT	cis	rs40363	0.523	rs757270	chr16:3534451	C/T	cg22508957	chr16:3507546	NAT15	-0.4	-4.51	-0.38	1.49e-5	Tuberculosis;
TGCT	cis	rs2245368	0.523	rs67814714	chr7:76517422	T/C	cg15770687	chr7:76625569	PMS2L11	0.35	4.53	0.38	1.36e-5	Body mass index in physically inactive individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);
TGCT	trans	rs7819412	0.511	rs2409798	chr8:11435564	C/T	cg06636001	chr8:8085503	FLJ10661	-0.76	-6.96	-0.53	1.71e-10	Triglycerides;
TGCT	cis	rs933688	1.000	rs10041402	chr5:90738948	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.96	8.43	0.6	7.52e-14	Smoking behavior;
TGCT	cis	rs6570726	0.764	rs76635693	chr6:145834070	T/C	cg05347473	chr6:146136440	FBXO30	0.53	4.95	0.41	2.4e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7267979	1.000	rs2500448	chr20:25404027	A/C	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs858239	0.601	rs6962526	chr7:23158233	G/A	cg05602783	chr7:23145260	KLHL7	-0.65	-5.52	-0.44	1.93e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs1577917	1.000	rs34581302	chr6:86705948	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.54	-0.45	1.73e-7	Response to antipsychotic treatment;
TGCT	cis	rs7191700	0.511	rs243330	chr16:11350991	C/T	cg00044050	chr16:11439710	C16orf75	0.82	8.3	0.6	1.46e-13	Multiple sclerosis;
TGCT	cis	rs10875595	0.836	rs12187725	chr5:140662912	A/G	cg20560182	chr5:140700478	TAF7	-0.67	-4.88	-0.4	3.15e-6	Pulmonary function decline;
TGCT	cis	rs2303759	0.914	rs2288481	chr19:49878196	G/A	cg22307029	chr19:49891270	CCDC155	0.54	5.03	0.41	1.7e-6	Multiple sclerosis;
TGCT	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.92	7.33	0.55	2.53e-11	Platelet count;
TGCT	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg22963979	chr7:1858916	MAD1L1	-0.34	-5.22	-0.42	7.3e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs11030122	0.569	rs11030781	chr11:4083258	T/C	cg18678763	chr11:4115507	RRM1	-0.46	-5.67	-0.45	9.61e-8	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs11190604	0.767	rs3829162	chr10:102172752	T/G	cg16342193	chr10:102329863	NA	-0.4	-5.06	-0.41	1.5e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9486719	1.000	rs2472884	chr6:96863965	C/T	cg06623918	chr6:96969491	KIAA0776	1.01	8.86	0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs9818758	0.607	rs13068038	chr3:49294250	C/A	cg00383909	chr3:49044727	WDR6	1.28	6.57	0.51	1.23e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs4711336	1.000	rs3818523	chr6:33660371	G/A	cg14003231	chr6:33640908	ITPR3	0.28	4.51	0.38	1.49e-5	Height;
TGCT	cis	rs6964587	1.000	rs7805077	chr7:91644553	A/G	cg22709100	chr7:91322751	NA	0.27	4.48	0.37	1.68e-5	Breast cancer;
TGCT	cis	rs62103177	0.733	rs62096748	chr18:77619699	T/C	cg12964065	chr18:77638022	KCNG2	0.37	4.76	0.39	5.4e-6	Opioid sensitivity;
TGCT	cis	rs7208859	0.573	rs79505916	chr17:29062326	C/T	cg14008862	chr17:28927542	LRRC37B2	0.75	4.48	0.37	1.7e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs981844	0.848	rs17279789	chr4:154643245	T/C	cg14289246	chr4:154710475	SFRP2	1.01	8.07	0.59	5.09e-13	Response to statins (LDL cholesterol change);
TGCT	cis	rs6450176	1.000	rs9687611	chr5:53300288	C/T	ch.5.1024479R	chr5:53302184	ARL15	-0.53	-5.1	-0.42	1.23e-6	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs7582180	0.627	rs4149523	chr2:101007039	T/C	cg14675211	chr2:100938903	LONRF2	0.47	4.56	0.38	1.22e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs6570726	0.846	rs372904	chr6:145887425	T/C	cg23711669	chr6:146136114	FBXO30	0.85	9.24	0.64	8.9e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4713118	0.662	rs13218430	chr6:28029837	T/C	cg12963246	chr6:28129442	ZNF389	0.45	4.55	0.38	1.27e-5	Parkinson's disease;
TGCT	cis	rs3020736	0.500	rs8143153	chr22:42515637	G/C	cg05082376	chr22:42548792	NA	0.23	5.43	0.44	2.83e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12477438	0.765	rs2309520	chr2:99570477	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.75	7.54	0.56	8.63e-12	Chronic sinus infection;
TGCT	cis	rs319204	0.798	rs640653	chr5:146287125	G/A	cg25021259	chr5:146258546	PPP2R2B	0.36	4.5	0.37	1.57e-5	Schizophrenia;
TGCT	cis	rs509477	0.811	rs12964519	chr18:32583580	T/G	cg23791764	chr18:32556832	MAPRE2	0.55	4.56	0.38	1.19e-5	Cerebrospinal fluid AB1-42 levels;
TGCT	cis	rs7666738	0.830	rs921521	chr4:98838339	A/G	cg18180107	chr4:99064573	C4orf37	0.57	5.34	0.43	4.23e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9443645	0.901	rs6912683	chr6:79543492	C/A	cg05283184	chr6:79620031	NA	-0.2	-4.51	-0.38	1.49e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs514406	0.505	rs12726160	chr1:53175099	A/G	cg25767906	chr1:53392781	SCP2	-0.49	-5.52	-0.44	1.88e-7	Monocyte count;
TGCT	trans	rs2727020	0.734	rs1164664	chr11:49295542	T/G	cg15704280	chr7:45808275	SEPT13	0.67	6.8	0.52	4.02e-10	Coronary artery disease;
TGCT	cis	rs6964587	1.000	rs6961928	chr7:91669808	C/T	cg17063962	chr7:91808500	NA	0.89	9.7	0.66	6.83e-17	Breast cancer;
TGCT	cis	rs12497850	0.931	rs7628719	chr3:48995487	C/T	cg07636037	chr3:49044803	WDR6	0.96	10.39	0.68	1.45e-18	Parkinson's disease;
TGCT	cis	rs2404602	0.735	rs1607017	chr15:76726465	G/T	cg26408565	chr15:76604113	ETFA	0.38	4.5	0.37	1.56e-5	Blood metabolite levels;
TGCT	cis	rs7085104	0.700	rs3740397	chr10:104592675	G/C	cg04362960	chr10:104952993	NT5C2	0.58	5.12	0.42	1.12e-6	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs6570726	0.791	rs6570695	chr6:145911286	C/A	cg13319975	chr6:146136371	FBXO30	-0.52	-4.68	-0.39	7.45e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7524258	0.903	rs6577424	chr1:7292417	C/T	cg07173049	chr1:7289937	CAMTA1	-0.32	-5.31	-0.43	4.88e-7	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs9389248	0.690	rs6939543	chr6:135255143	A/G	cg24558204	chr6:135376177	HBS1L	-0.47	-4.87	-0.4	3.3e-6	High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs3749237	0.595	rs3870337	chr3:49557095	G/T	cg02487422	chr3:49467188	NICN1	0.57	5.84	0.46	4.26e-8	Resting heart rate;
TGCT	cis	rs7647973	1.000	rs62259944	chr3:49430883	G/A	cg07636037	chr3:49044803	WDR6	-0.71	-5.69	-0.46	8.57e-8	Menarche (age at onset);
TGCT	cis	rs854624	0.711	rs1608205	chr17:34336767	T/A	cg02022384	chr17:34097390	MMP28	0.49	4.55	0.38	1.28e-5	Blood protein levels;
TGCT	cis	rs9467773	0.534	rs34453863	chr6:26628005	T/C	cg05738196	chr6:26577821	NA	0.86	10.52	0.69	6.75e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs3812831	0.695	rs10467349	chr13:114939441	A/G	cg06611532	chr13:114900021	NA	0.35	6.41	0.5	2.77e-9	Schizophrenia;
TGCT	cis	rs7914558	0.869	rs10883842	chr10:104941589	C/T	cg04362960	chr10:104952993	NT5C2	0.61	5.45	0.44	2.6e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs634534	0.622	rs593525	chr11:65727799	T/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.54	5.18	0.42	8.63e-7	Sum eosinophil basophil counts;Eosinophil counts;
TGCT	cis	rs5760092	0.842	rs5751763	chr22:24247793	T/C	cg02953382	chr22:24373134	LOC391322	-0.76	-6.17	-0.48	9.04e-9	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs231513	0.906	rs1642611	chr17:41997712	T/C	cg26893861	chr17:41843967	DUSP3	-0.71	-5.03	-0.41	1.67e-6	Cognitive function;
TGCT	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	7.12	0.54	7.55e-11	Platelet count;
TGCT	cis	rs244731	0.959	rs3105419	chr5:176551396	G/C	cg06060754	chr5:176797920	RGS14	0.44	5.88	0.47	3.5e-8	Urate levels in lean individuals;
TGCT	cis	rs1153858	0.621	rs1706824	chr15:45579948	C/T	cg26924012	chr15:45694286	SPATA5L1	1.0	10.91	0.7	7.59e-20	Homoarginine levels;
TGCT	cis	rs6952809	0.532	rs10227362	chr7:2456799	A/G	cg23289794	chr7:2394357	EIF3B	-0.84	-7.26	-0.55	3.79e-11	Multiple sclerosis;
TGCT	cis	rs2282802	0.685	rs67813630	chr5:139623592	C/A	cg01081189	chr5:139537190	NA	0.28	5.08	0.41	1.36e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg18252515	chr7:66147081	NA	1.2	7.83	0.58	1.89e-12	Diabetic kidney disease;
TGCT	cis	rs10751667	0.560	rs7924794	chr11:962745	A/T	cg06064525	chr11:970664	AP2A2	-0.34	-7.86	-0.58	1.63e-12	Alzheimer's disease (late onset);
TGCT	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs4742903	1.000	rs7854630	chr9:106875277	A/C	cg21169611	chr9:106856078	SMC2	-0.49	-4.49	-0.37	1.61e-5	High-grade serous ovarian cancer;Breast cancer;
TGCT	cis	rs7666738	0.830	rs10031292	chr4:99056877	A/G	cg18180107	chr4:99064573	C4orf37	0.57	5.2	0.42	7.83e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7769051	0.522	rs3736725	chr6:133095172	A/G	cg22852734	chr6:133119734	C6orf192	1.16	4.48	0.37	1.67e-5	Type 2 diabetes nephropathy;
TGCT	cis	rs36051895	0.589	rs12682672	chr9:5187941	T/C	cg02405213	chr9:5042618	JAK2	-0.74	-9.56	-0.65	1.48e-16	Pediatric autoimmune diseases;
TGCT	cis	rs2456568	0.802	rs1395387	chr11:93639307	A/T	cg14065697	chr11:93583672	C11orf90	-0.37	-4.55	-0.38	1.25e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg11764359	chr7:65958608	NA	-0.52	-4.84	-0.4	3.86e-6	Aortic root size;
TGCT	cis	rs425277	1.000	rs55826501	chr1:2059143	G/A	cg24578937	chr1:2090814	PRKCZ	0.32	7.65	0.57	4.86e-12	Height;
TGCT	cis	rs36051895	0.632	rs12352285	chr9:5141476	C/G	cg02405213	chr9:5042618	JAK2	-0.74	-10.39	-0.68	1.4e-18	Pediatric autoimmune diseases;
TGCT	cis	rs6003958	1	rs6003958	chr22:24264089	T/G	cg04234412	chr22:24373322	LOC391322	0.92	8.61	0.61	2.85e-14	S-phenylmercapturic acid levels in smokers;
TGCT	cis	rs73198271	0.628	rs11783944	chr8:8597801	A/G	ch.8.214553F	chr8:8189620	PRAGMIN	-0.32	-5.21	-0.42	7.61e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs7584330	0.868	rs7569197	chr2:238383073	A/G	cg16989719	chr2:238392110	NA	-0.26	-4.48	-0.37	1.7e-5	Prostate cancer;
TGCT	cis	rs7428	0.527	rs7608892	chr2:85542718	G/A	cg24342717	chr2:85555507	TGOLN2	-0.49	-8.1	-0.59	4.49e-13	Ear protrusion;
TGCT	cis	rs10501293	0.828	rs17497596	chr11:43102898	A/G	cg03447554	chr11:43094025	NA	0.44	5.84	0.46	4.27e-8	Cognitive performance;
TGCT	cis	rs909674	0.818	rs5757680	chr22:39844793	C/T	cg05872129	chr22:39784769	NA	0.97	9.64	0.65	9.27e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs9291683	0.530	rs998675	chr4:9948829	A/G	cg00071950	chr4:10020882	SLC2A9	0.68	8.47	0.61	6.04e-14	Bone mineral density;
TGCT	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-8.64	-0.61	2.39e-14	Platelet count;
TGCT	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg12310025	chr6:25882481	NA	-0.73	-6.73	-0.52	5.7e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs422249	0.512	rs174574	chr11:61600342	A/C	cg20584555	chr11:61717780	BEST1	0.23	4.47	0.37	1.74e-5	Trans fatty acid levels;
TGCT	cis	rs77972916	0.561	rs17406174	chr2:43557484	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.39	-4.46	-0.37	1.78e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs7582180	0.652	rs11687864	chr2:100946993	T/A	cg14675211	chr2:100938903	LONRF2	0.52	4.94	0.41	2.5e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs3793917	1.000	rs3793917	chr10:124219275	C/G	cg09507567	chr10:124027408	NA	0.39	4.65	0.39	8.42e-6	Age-related macular degeneration;
TGCT	cis	rs6728642	1.000	rs57035274	chr2:97608124	C/A	cg26665480	chr2:98280029	ACTR1B	-0.91	-5.37	-0.43	3.77e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	cis	rs8032315	1.000	rs8032315	chr15:91418297	A/T	cg05211768	chr15:91427848	FES	0.46	4.97	0.41	2.19e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6088580	0.634	rs1890000	chr20:32968312	G/T	cg24642439	chr20:33292090	TP53INP2	-0.49	-4.49	-0.37	1.59e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs13326165	0.760	rs11706001	chr3:52372128	T/A	cg07884673	chr3:53033167	SFMBT1	0.39	4.67	0.39	7.85e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.51	5.37	0.43	3.71e-7	Menopause (age at onset);
TGCT	cis	rs4788815	1.000	rs4788815	chr16:71634811	A/T	cg06353428	chr16:71660113	MARVELD3	0.58	5.1	0.42	1.25e-6	Metabolite levels;
TGCT	cis	rs910316	0.967	rs175502	chr14:75533679	A/G	cg23033748	chr14:75592666	NEK9	-0.28	-4.7	-0.39	6.67e-6	Height;
TGCT	trans	rs7618501	1.000	rs3811696	chr3:49761605	C/T	cg21659725	chr3:3221576	CRBN	-0.98	-15.33	-0.81	2.1000000000000002e-30	Intelligence (multi-trait analysis);
TGCT	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg10047753	chr17:41438598	NA	0.96	9.6	0.65	1.16e-16	Menopause (age at onset);
TGCT	cis	rs72781680	0.898	rs72796158	chr2:23935727	T/C	cg08917208	chr2:24149416	ATAD2B	0.89	5.41	0.44	3.11e-7	Lymphocyte counts;
TGCT	cis	rs72634258	0.503	rs2794666	chr1:7822009	A/G	cg26816564	chr1:7831052	VAMP3	0.94	6.65	0.51	8.5e-10	Inflammatory bowel disease;
TGCT	cis	rs6964587	1.000	rs7784248	chr7:91758111	A/G	cg22709100	chr7:91322751	NA	0.28	4.51	0.38	1.51e-5	Breast cancer;
TGCT	cis	rs10225163	0.500	rs763746	chr7:27922780	A/G	cg05786569	chr7:27702416	HIBADH	0.72	5.23	0.43	6.99e-7	Gout;
TGCT	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg12756686	chr19:29218302	NA	0.77	6.61	0.51	1.01e-9	Methadone dose in opioid dependence;
TGCT	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg22920501	chr2:26401640	FAM59B	-0.73	-6.28	-0.49	5.18e-9	Gut microbiome composition (summer);
TGCT	cis	rs1975974	0.872	rs17052352	chr17:21721972	A/G	cg18423549	chr17:21743878	NA	-0.53	-5.13	-0.42	1.1e-6	Psoriasis;
TGCT	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg22920501	chr2:26401640	FAM59B	0.8	6.34	0.49	3.84e-9	Gut microbiome composition (summer);
TGCT	cis	rs12510870	0.634	rs6446941	chr4:74390516	C/T	cg05868023	chr4:75230803	EREG	0.55	4.7	0.39	6.84e-6	Iris color (b* coordinate);
TGCT	cis	rs7412746	0.611	rs1889741	chr1:150869045	T/C	cg09365446	chr1:150670422	GOLPH3L	0.34	4.71	0.39	6.58e-6	Melanoma;
TGCT	cis	rs9300255	0.679	rs12817892	chr12:123728702	G/A	cg00376283	chr12:123451042	ABCB9	-0.75	-5.13	-0.42	1.07e-6	Neutrophil percentage of white cells;
TGCT	cis	rs7586879	0.616	rs876186	chr2:25125585	C/T	cg01884057	chr2:25150051	NA	0.35	6.9	0.53	2.39e-10	Body mass index;
TGCT	cis	rs16837677	0.826	rs76114442	chr1:156699977	G/A	cg17331738	chr1:156647236	NES	0.75	4.91	0.4	2.77e-6	Sjögren's syndrome;
TGCT	trans	rs459571	0.629	rs441233	chr9:136876021	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	0.89	10.67	0.69	2.92e-19	Platelet distribution width;
TGCT	cis	rs7208859	0.623	rs9914242	chr17:29216245	G/T	cg18442181	chr17:29233375	C17orf42	-0.8	-4.78	-0.39	4.86e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs6987853	0.966	rs2974338	chr8:42391945	A/G	cg20539142	chr8:42623718	CHRNA6	-0.21	-5.03	-0.41	1.69e-6	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs7666738	0.791	rs6833691	chr4:98951508	A/G	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8017423	0.967	rs59980414	chr14:90687738	G/C	cg04374321	chr14:90722782	PSMC1	0.76	7.85	0.58	1.67e-12	Mortality in heart failure;
TGCT	cis	rs6964587	1.000	rs10234290	chr7:91716951	T/C	cg22709100	chr7:91322751	NA	0.29	4.8	0.4	4.45e-6	Breast cancer;
TGCT	cis	rs7258465	0.931	rs1560119	chr19:18573675	A/G	cg06462663	chr19:18546047	ISYNA1	0.2	4.63	0.38	9.01e-6	Breast cancer;
TGCT	cis	rs13040088	1.000	rs12480117	chr20:61558274	G/A	cg23096297	chr20:61557774	DIDO1	1.15	9.35	0.64	4.71e-16	Menopause (age at onset);
TGCT	cis	rs3796352	1.000	rs60942590	chr3:53016421	G/A	cg15956490	chr3:53032818	SFMBT1	0.61	6.76	0.52	4.92e-10	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs1461503	1.000	rs1461499	chr11:122843987	C/A	cg27398637	chr11:122830231	C11orf63	-0.39	-4.75	-0.39	5.58e-6	Menarche (age at onset);
TGCT	cis	rs62244186	0.566	rs55901755	chr3:44834707	C/T	cg25151919	chr3:44754333	ZNF502	-0.47	-5.44	-0.44	2.78e-7	Depressive symptoms;
TGCT	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg22433210	chr17:43662623	NA	1.06	7.29	0.55	3.2e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg07424592	chr7:64974309	NA	-1.33	-7.99	-0.58	7.81e-13	Diabetic kidney disease;
TGCT	cis	rs5769765	0.837	rs8142737	chr22:50291889	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.09	-11.73	-0.73	7.59e-22	Schizophrenia;
TGCT	cis	rs10114408	0.959	rs7856998	chr9:96642245	G/A	cg13679303	chr9:96623674	NA	-0.35	-4.45	-0.37	1.85e-5	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs6542838	0.553	rs6739503	chr2:99537295	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.57	-5.44	-0.44	2.74e-7	Fear of minor pain;
TGCT	cis	rs28595532	1.000	rs115965820	chr4:119586485	G/A	cg21605333	chr4:119757512	SEC24D	1.33	7.98	0.58	8.3e-13	Cannabis dependence symptom count;
TGCT	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.5	-4.7	-0.39	6.7e-6	Electroencephalogram traits;
TGCT	trans	rs7824557	0.569	rs2409718	chr8:11012977	C/T	cg06636001	chr8:8085503	FLJ10661	-0.8	-7.49	-0.56	1.13e-11	Retinal vascular caliber;
TGCT	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg22920501	chr2:26401640	FAM59B	0.81	6.36	0.5	3.52e-9	Gut microbiome composition (summer);
TGCT	cis	rs9733	0.519	rs7521898	chr1:150707596	G/A	cg04414720	chr1:150670196	GOLPH3L	0.37	4.91	0.4	2.76e-6	Tonsillectomy;
TGCT	cis	rs11785400	0.793	rs4467920	chr8:143736846	C/T	cg24634471	chr8:143751801	JRK	0.55	5.51	0.44	1.95e-7	Schizophrenia;
TGCT	cis	rs9467773	1.000	rs6922824	chr6:26553815	C/G	cg15659132	chr6:26577336	NA	-0.88	-12.88	-0.76	1.29e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs2228479	0.850	rs62054601	chr16:89811751	C/G	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs62244186	0.683	rs6766334	chr3:44567065	T/C	cg10263370	chr3:44754102	ZNF502	-0.43	-5.19	-0.42	8.5e-7	Depressive symptoms;
TGCT	cis	rs12510870	0.599	rs10021827	chr4:74451734	T/A	cg05868023	chr4:75230803	EREG	-0.55	-4.74	-0.39	5.71e-6	Iris color (b* coordinate);
TGCT	cis	rs797680	0.786	rs4847412	chr1:93829248	C/G	cg17826107	chr1:92977322	EVI5	-0.24	-5.63	-0.45	1.13e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs10782582	0.632	rs11810154	chr1:76239973	C/G	cg10523679	chr1:76189770	ACADM	-0.53	-4.99	-0.41	1.98e-6	Daytime sleep phenotypes;
TGCT	cis	rs9894429	0.646	rs12603868	chr17:79618834	G/C	cg18240062	chr17:79603768	NPLOC4	0.56	4.88	0.4	3.15e-6	Eye color traits;
TGCT	cis	rs10464366	0.544	rs4540324	chr7:39185299	G/C	cg15212455	chr7:39170539	POU6F2	0.3	6.73	0.52	5.66e-10	IgG glycosylation;
TGCT	cis	rs12477438	0.520	rs6739579	chr2:99731552	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	17.43	0.84	3.73e-35	Chronic sinus infection;
TGCT	trans	rs2078543	0.616	rs62404669	chr6:22035821	T/C	cg07692489	chr16:8960972	CARHSP1	-0.39	-6.64	-0.51	8.88e-10	Pulmonary function (smoking interaction);
TGCT	cis	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg08045932	chr20:61659980	NA	0.48	9.47	0.65	2.46e-16	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs860554	0.546	rs1543805	chr1:201292794	A/G	cg01022117	chr1:201258280	PKP1	-0.27	-4.93	-0.4	2.57e-6	Panic disorder;
TGCT	cis	rs11122272	0.735	rs2790893	chr1:231508976	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.14	-0.54	6.87e-11	Hemoglobin concentration;
TGCT	cis	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg25427524	chr10:38739819	LOC399744	-0.39	-8.05	-0.59	5.9e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs9341808	0.718	rs9294171	chr6:80839815	C/T	cg08355045	chr6:80787529	NA	0.32	5.87	0.47	3.78e-8	Sitting height ratio;
TGCT	cis	rs453301	0.686	rs3989373	chr8:8911308	G/T	cg08975724	chr8:8085496	FLJ10661	-0.54	-4.55	-0.38	1.25e-5	Joint mobility (Beighton score);
TGCT	cis	rs3849570	0.922	rs3772895	chr3:81769493	A/G	cg07356753	chr3:81810745	GBE1	-0.85	-8.17	-0.59	3.06e-13	Waist circumference;Body mass index;
TGCT	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg23758822	chr17:41437982	NA	0.66	6.68	0.51	7.12e-10	Menopause (age at onset);
TGCT	cis	rs4700695	1.000	rs153389	chr5:65422729	C/T	cg21114390	chr5:65439923	SFRS12	-0.65	-5.06	-0.41	1.47e-6	Facial morphology (factor 19);
TGCT	cis	rs3087591	0.960	rs12945157	chr17:29603631	G/A	cg24425628	chr17:29625626	OMG;NF1	0.47	7.39	0.55	1.94e-11	Hip circumference;
TGCT	cis	rs4072705	0.646	rs2416933	chr9:127245529	C/T	cg13476313	chr9:127244764	NR5A1	-0.3	-5.01	-0.41	1.81e-6	Menarche (age at onset);
TGCT	cis	rs7681440	0.647	rs4522832	chr4:90819391	A/C	cg20003494	chr4:90757398	SNCA	-0.53	-4.7	-0.39	6.75e-6	Dementia with Lewy bodies;
TGCT	cis	rs319204	0.918	rs2436401	chr5:146287183	C/T	cg25021259	chr5:146258546	PPP2R2B	0.36	4.5	0.37	1.57e-5	Schizophrenia;
TGCT	cis	rs4478858	0.746	rs10798831	chr1:31688385	A/C	cg00250761	chr1:31883323	NA	0.29	4.78	0.39	4.9e-6	Alcohol dependence;
TGCT	trans	rs2727020	1.000	rs2727020	chr11:49111407	C/G	cg15704280	chr7:45808275	SEPT13	0.7	7.57	0.56	7.56e-12	Coronary artery disease;
TGCT	cis	rs7917772	0.582	rs729024	chr10:104341975	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	5.36	0.43	3.84e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg10802521	chr3:52805072	NEK4	-0.78	-10.01	-0.67	1.22e-17	Bipolar disorder;
TGCT	cis	rs9733	0.596	rs2275236	chr1:150669952	A/G	cg09365446	chr1:150670422	GOLPH3L	-0.31	-4.64	-0.38	8.7e-6	Tonsillectomy;
TGCT	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs3820928	0.904	rs59135978	chr2:227857763	T/C	cg11843606	chr2:227700838	RHBDD1	-0.52	-4.63	-0.38	9.03e-6	Pulmonary function;
TGCT	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg16497277	chr3:49208875	KLHDC8B	0.53	4.92	0.4	2.71e-6	Menarche (age at onset);
TGCT	cis	rs2228479	0.541	rs12918575	chr16:89811151	A/G	cg04287289	chr16:89883240	FANCA	0.74	4.44	0.37	1.99e-5	Skin colour saturation;
TGCT	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.18	0.49	8.32e-9	Bipolar disorder;
TGCT	cis	rs911555	0.539	rs4374097	chr14:104072766	A/C	cg26031613	chr14:104095156	KLC1	0.61	5.6	0.45	1.34e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2204008	0.694	rs11179394	chr12:38210389	A/G	cg26384229	chr12:38710491	ALG10B	-0.59	-5.19	-0.42	8.23e-7	Bladder cancer;
TGCT	cis	rs2880765	0.835	rs2170735	chr15:86043485	G/A	cg13263323	chr15:86062960	AKAP13	-0.23	-4.82	-0.4	4.1e-6	Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs13138063	chr4:99050438	A/C	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6088580	0.609	rs6059845	chr20:33036500	G/A	cg24642439	chr20:33292090	TP53INP2	0.49	4.5	0.37	1.55e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs2404602	0.716	rs4079681	chr15:76695230	G/A	cg26408565	chr15:76604113	ETFA	-0.42	-5.44	-0.44	2.76e-7	Blood metabolite levels;
TGCT	trans	rs1814175	0.817	rs7109440	chr11:49966296	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.36	-7.14	-0.54	6.88e-11	Height;
TGCT	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg27535305	chr1:53392650	SCP2	-0.28	-5.93	-0.47	2.85e-8	Monocyte count;
TGCT	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	5.49	0.44	2.17e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	5.84	0.46	4.3e-8	Bipolar disorder;
TGCT	cis	rs208520	0.690	rs12192851	chr6:66705862	G/C	cg07460842	chr6:66804631	NA	0.96	10.26	0.68	2.92e-18	Exhaled nitric oxide output;
TGCT	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg18876405	chr7:65276391	NA	-0.33	-5.02	-0.41	1.72e-6	Aortic root size;
TGCT	cis	rs9611565	0.592	rs4822040	chr22:41963553	C/G	cg13695892	chr22:41940480	POLR3H	-0.83	-7.8	-0.57	2.16e-12	Vitiligo;
TGCT	cis	rs9914544	0.545	rs35911764	chr17:18782582	C/T	cg26378065	chr17:18585709	ZNF286B	0.53	4.63	0.38	9.06e-6	Educational attainment (years of education);
TGCT	cis	rs10089	0.953	rs758179	chr5:127354424	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.71	6.22	0.49	6.97e-9	Ileal carcinoids;
TGCT	cis	rs9549260	0.564	rs9577110	chr13:41271878	T/G	cg21288729	chr13:41239152	FOXO1	0.87	8.2	0.59	2.57e-13	Red blood cell count;
TGCT	cis	rs9611565	0.546	rs739134	chr22:42089623	T/C	cg13695892	chr22:41940480	POLR3H	0.9	9.02	0.63	2.89e-15	Vitiligo;
TGCT	cis	rs6558530	0.897	rs10481354	chr8:1704030	A/G	cg09410841	chr8:1729607	CLN8	-0.86	-9.75	-0.66	5.24e-17	Systolic blood pressure;
TGCT	cis	rs3733585	0.699	rs4515163	chr4:9959603	C/T	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.7	-0.57	3.69e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs6087990	0.806	rs4911257	chr20:31359574	T/C	cg13636640	chr20:31349939	DNMT3B	1.02	12.15	0.74	7.56e-23	Ulcerative colitis;
TGCT	cis	rs9527	0.501	rs12244388	chr10:104640052	G/A	cg15744005	chr10:104629667	AS3MT	-0.46	-5.77	-0.46	5.89e-8	Arsenic metabolism;
TGCT	cis	rs763121	0.853	rs5757181	chr22:39013522	G/A	cg06022373	chr22:39101656	GTPBP1	0.78	7.66	0.57	4.56e-12	Menopause (age at onset);
TGCT	cis	rs74233809	1.000	rs74444347	chr10:104769275	A/C	cg05855489	chr10:104503620	C10orf26	0.74	4.45	0.37	1.87e-5	Birth weight;
TGCT	cis	rs644148	0.730	rs2571044	chr19:44985573	G/A	cg15540054	chr19:45004280	ZNF180	-0.59	-4.5	-0.37	1.53e-5	Personality dimensions;
TGCT	cis	rs3818285	0.556	rs2084607	chr10:111681411	C/T	cg00817464	chr10:111662876	XPNPEP1	0.3	5.41	0.44	3.15e-7	Superior crus of antihelix expression;
TGCT	cis	rs1903068	0.719	rs17711225	chr4:55999185	G/A	cg01777861	chr4:56023843	NA	0.54	6.0	0.47	2.02e-8	Endometriosis;
TGCT	cis	rs2236918	0.710	rs2797602	chr1:242029206	G/T	cg04158730	chr1:242011433	EXO1	0.56	5.2	0.42	8.05e-7	Menopause (age at onset);
TGCT	trans	rs1814175	0.817	rs10839358	chr11:49770972	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.38	-7.76	-0.57	2.75e-12	Height;
TGCT	cis	rs6918586	0.658	rs198822	chr6:26123539	G/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.69	-6.49	-0.5	1.87e-9	Schizophrenia;
TGCT	cis	rs9926296	0.632	rs2011925	chr16:89814064	T/G	cg04287289	chr16:89883240	FANCA	0.67	6.53	0.51	1.51e-9	Vitiligo;
TGCT	cis	rs11578119	0.933	rs12724601	chr1:170427510	C/G	cg09767346	chr1:170501363	GORAB	0.71	5.68	0.45	9.07e-8	Male-pattern baldness;
TGCT	cis	rs7216064	1.000	rs11079707	chr17:65835617	A/G	cg12091567	chr17:66097778	LOC651250	0.82	6.39	0.5	3.04e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs78487399	0.808	rs17030998	chr2:43758199	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.07	-0.41	1.41e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs1008375	0.646	rs4235387	chr4:17569327	T/G	cg18681998	chr4:17616180	MED28	0.83	7.55	0.56	8.11e-12	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6088590	0.502	rs6059861	chr20:33068563	A/T	cg06115741	chr20:33292138	TP53INP2	0.52	4.47	0.37	1.75e-5	Coronary artery disease;
TGCT	cis	rs12497850	0.897	rs9850134	chr3:48957147	A/G	cg07636037	chr3:49044803	WDR6	0.94	10.39	0.68	1.46e-18	Parkinson's disease;
TGCT	cis	rs9467711	0.790	rs34158769	chr6:26336572	G/A	cg16898833	chr6:26189333	HIST1H4D	1.2	5.52	0.44	1.87e-7	Autism spectrum disorder or schizophrenia;
TGCT	trans	rs7698623	0.717	rs1463094	chr4:88792584	G/A	cg01186725	chr1:53905612	FLJ40434	-0.48	-6.63	-0.51	9.21e-10	Cardiovascular disease risk factors;
TGCT	cis	rs2191566	0.960	rs6509133	chr19:44522913	A/G	cg03039196	chr19:44506973	ZNF230	-0.52	-4.45	-0.37	1.87e-5	Acute lymphoblastic leukemia (childhood);
TGCT	cis	rs7829975	0.514	rs2976929	chr8:8258712	T/C	cg06636001	chr8:8085503	FLJ10661	0.69	6.02	0.48	1.81e-8	Mood instability;
TGCT	cis	rs2652822	0.504	rs4619348	chr15:63359564	A/C	cg12855773	chr15:63363890	TPM1	-0.17	-4.85	-0.4	3.62e-6	Metabolic traits;
TGCT	cis	rs72945132	0.882	rs7121012	chr11:70214421	A/T	cg00319359	chr11:70116639	PPFIA1	0.99	7.39	0.55	1.94e-11	Coronary artery disease;
TGCT	cis	rs7088591	0.702	rs10491208	chr10:59703352	C/G	cg00579859	chr10:60026291	IPMK	0.89	4.95	0.41	2.4e-6	Blood pressure;
TGCT	trans	rs4332037	0.624	rs11766944	chr7:1888051	G/A	cg10840412	chr1:235813424	GNG4	0.86	6.76	0.52	4.92e-10	Bipolar disorder;
TGCT	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg13770153	chr20:60521292	NA	-0.54	-6.99	-0.53	1.51e-10	Body mass index;
TGCT	cis	rs7674212	0.539	rs6533056	chr4:104120997	T/C	cg16532752	chr4:104119610	CENPE	-0.6	-5.46	-0.44	2.51e-7	Type 2 diabetes;
TGCT	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg20203395	chr5:56204925	C5orf35	-0.57	-5.28	-0.43	5.6e-7	Initial pursuit acceleration;
TGCT	cis	rs2439831	0.850	rs7183809	chr15:44120868	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.44	0.37	1.99e-5	Lung cancer in ever smokers;
TGCT	cis	rs11690935	0.959	rs7355594	chr2:172639448	G/T	cg13550731	chr2:172543902	DYNC1I2	-1.18	-12.58	-0.75	6.59e-24	Schizophrenia;
TGCT	cis	rs61935443	0.720	rs10859783	chr12:95285339	A/G	cg21533806	chr12:95267307	NA	0.54	4.65	0.39	8.26e-6	Schizophrenia;
TGCT	cis	rs910316	0.737	rs398896	chr14:75482827	C/A	cg11812906	chr14:75593930	NEK9	-0.61	-5.66	-0.45	9.87e-8	Height;
TGCT	cis	rs908922	0.676	rs4845789	chr1:152528100	A/G	cg20991723	chr1:152506922	NA	0.45	6.06	0.48	1.55e-8	Hair morphology;
TGCT	cis	rs67478160	0.595	rs1475007	chr14:104297147	A/G	cg26031613	chr14:104095156	KLC1	-0.63	-6.53	-0.51	1.56e-9	Schizophrenia;
TGCT	cis	rs11673344	0.503	rs7246720	chr19:37564628	C/T	cg08039142	chr19:36980659	ZNF566	0.5	4.6	0.38	1.01e-5	Obesity-related traits;
TGCT	cis	rs6582630	0.555	rs34145279	chr12:38405588	T/C	cg26384229	chr12:38710491	ALG10B	0.84	7.42	0.55	1.62e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs4319547	0.794	rs61954972	chr12:123074167	T/G	cg05707623	chr12:122985044	ZCCHC8	-0.68	-5.38	-0.44	3.5e-7	Body mass index;
TGCT	cis	rs1218582	0.596	rs906595	chr1:154822907	C/T	cg06221963	chr1:154839813	KCNN3	-0.55	-7.64	-0.57	5.13e-12	Prostate cancer;
TGCT	cis	rs35306767	0.715	rs1871622	chr10:1049309	T/G	cg20503657	chr10:835505	NA	0.61	6.71	0.52	6.11e-10	Eosinophil percentage of granulocytes;
TGCT	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg23758822	chr17:41437982	NA	0.72	6.85	0.52	3.09e-10	Menopause (age at onset);
TGCT	cis	rs478304	0.651	rs10896038	chr11:65505528	G/C	cg27068330	chr11:65405492	SIPA1	-0.95	-9.64	-0.65	9.63e-17	Acne (severe);
TGCT	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.93	7.44	0.56	1.44e-11	Platelet count;
TGCT	cis	rs4919687	0.550	rs17784294	chr10:104479385	G/T	cg05855489	chr10:104503620	C10orf26	0.55	4.48	0.37	1.67e-5	Colorectal cancer;
TGCT	cis	rs8180040	0.701	rs7617689	chr3:46996442	C/T	cg27129171	chr3:47204927	SETD2	-0.71	-9.05	-0.63	2.45e-15	Colorectal cancer;
TGCT	cis	rs7666738	0.791	rs7684521	chr4:99071219	A/G	cg05340658	chr4:99064831	C4orf37	0.53	5.87	0.47	3.68e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg18876405	chr7:65276391	NA	0.31	4.78	0.39	4.81e-6	Aortic root size;
TGCT	cis	rs10992471	0.535	rs10117041	chr9:95282331	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.6	-5.63	-0.45	1.13e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs3008870	0.959	rs2985816	chr1:67387750	G/T	cg08660285	chr1:67390436	MIER1;WDR78	1.1	12.09	0.74	1.01e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs2760061	0.545	rs1636196	chr1:228204030	A/G	cg18477163	chr1:228402036	OBSCN	0.36	7.16	0.54	6.22e-11	Diastolic blood pressure;
TGCT	cis	rs9916302	0.706	rs7503377	chr17:37708841	A/G	cg03321784	chr17:37729644	NA	0.4	4.5	0.37	1.57e-5	Glomerular filtration rate (creatinine);
TGCT	trans	rs6089829	0.888	rs4809465	chr20:61671156	G/C	cg23505145	chr19:12996616	KLF1	0.96	9.99	0.67	1.36e-17	Prostate cancer (SNP x SNP interaction);
TGCT	trans	rs208520	0.690	rs176289	chr6:66766522	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-11.29	-0.71	9.4e-21	Exhaled nitric oxide output;
TGCT	cis	rs13064411	0.518	rs2399480	chr3:113228599	T/C	cg18753928	chr3:113234510	CCDC52	-0.56	-4.72	-0.39	6.3e-6	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs7829975	0.511	rs2976902	chr8:8341105	T/G	cg06636001	chr8:8085503	FLJ10661	0.61	5.69	0.46	8.54e-8	Mood instability;
TGCT	cis	rs2404602	0.735	rs11632222	chr15:76712927	C/G	cg22467129	chr15:76604101	ETFA	0.52	5.5	0.44	2.05e-7	Blood metabolite levels;
TGCT	cis	rs6840360	0.571	rs7695866	chr4:152488110	G/A	cg17479576	chr4:152424074	FAM160A1	-0.73	-7.94	-0.58	1.03e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs7572733	0.534	rs4850813	chr2:198775982	C/T	cg00792783	chr2:198669748	PLCL1	-0.56	-5.11	-0.42	1.21e-6	Dermatomyositis;
TGCT	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg03188948	chr7:1209495	NA	0.43	5.65	0.45	1.06e-7	Longevity;Endometriosis;
TGCT	cis	rs11696501	0.688	rs6073848	chr20:44298550	G/A	cg11783356	chr20:44313418	WFDC10B	-0.32	-4.63	-0.38	9.25e-6	Brain structure;
TGCT	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-8.71	-0.62	1.58e-14	Platelet count;
TGCT	cis	rs7666738	0.791	rs13120773	chr4:98972589	C/T	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs208520	0.802	rs851600	chr6:66893754	T/C	cg07460842	chr6:66804631	NA	-0.9	-9.37	-0.64	4.18e-16	Exhaled nitric oxide output;
TGCT	cis	rs7208859	0.623	rs216446	chr17:28933718	T/G	cg14008862	chr17:28927542	LRRC37B2	0.88	5.32	0.43	4.75e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs55823223	0.564	rs936396	chr17:73846829	C/G	cg08125733	chr17:73851984	WBP2	0.88	8.95	0.63	4.39e-15	Psoriasis;
TGCT	cis	rs3771570	1.000	rs60209440	chr2:242260340	G/C	cg21155796	chr2:242212141	HDLBP	0.98	6.68	0.51	7.29e-10	Prostate cancer;
TGCT	cis	rs1008375	0.966	rs2191504	chr4:17675592	C/G	cg10189774	chr4:17578691	LAP3	0.53	4.99	0.41	2e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.4	0.44	3.25e-7	Tonsillectomy;
TGCT	cis	rs10484885	0.878	rs55750696	chr6:90552336	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.47	-4.58	-0.38	1.11e-5	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs6681544	0.537	rs12074133	chr1:82385309	A/T	cg04226724	chr1:82268649	LPHN2	0.47	4.95	0.41	2.33e-6	Metabolite levels  (X-11787);
TGCT	cis	rs3796352	1.000	rs13092352	chr3:52969697	C/T	cg15956490	chr3:53032818	SFMBT1	0.59	6.04	0.48	1.65e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg10047753	chr17:41438598	NA	0.84	7.61	0.56	5.9e-12	Menopause (age at onset);
TGCT	cis	rs73001065	1.000	rs56255430	chr19:19477877	A/C	cg03709012	chr19:19516395	GATAD2A	1.03	4.96	0.41	2.23e-6	LDL cholesterol;
TGCT	cis	rs7020830	0.861	rs13295981	chr9:37330067	C/T	cg14294708	chr9:37120828	ZCCHC7	1.29	18.62	0.86	9.89e-38	Schizophrenia;
TGCT	cis	rs6500602	0.701	rs1362626	chr16:4549226	C/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.42	6.26	0.49	5.85e-9	Schizophrenia;
TGCT	cis	rs9611565	0.592	rs5758406	chr22:42076641	A/G	cg03806693	chr22:41940476	POLR3H	1.06	11.74	0.73	7.15e-22	Vitiligo;
TGCT	cis	rs11096990	0.634	rs11947159	chr4:39288520	T/C	cg20847110	chr4:39482781	LOC401127	-0.16	-4.51	-0.38	1.48e-5	Cognitive function;
TGCT	cis	rs11031096	0.503	rs10835604	chr11:4109709	A/T	cg18678763	chr11:4115507	RRM1	-0.47	-5.63	-0.45	1.17e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs10875746	0.768	rs12305182	chr12:48421407	G/T	cg20731937	chr12:48336164	NA	0.69	5.83	0.46	4.46e-8	Longevity (90 years and older);
TGCT	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs72945132	0.607	rs67767222	chr11:70121610	T/A	cg00319359	chr11:70116639	PPFIA1	0.99	7.24	0.55	4.12e-11	Coronary artery disease;
TGCT	cis	rs7027203	0.828	rs4344139	chr9:96600298	T/C	cg14396892	chr9:96623032	NA	-0.26	-5.46	-0.44	2.51e-7	DNA methylation (variation);
TGCT	cis	rs1865760	0.566	rs1539183	chr6:26075051	G/C	cg17042849	chr6:26104293	HIST1H4C	-0.63	-5.47	-0.44	2.43e-7	Height;
TGCT	trans	rs2727020	0.681	rs1976901	chr11:49378697	T/C	cg03929089	chr4:120376271	NA	-0.74	-8.61	-0.61	2.73e-14	Coronary artery disease;
TGCT	cis	rs12580194	0.593	rs61957937	chr12:55746850	G/C	cg10672482	chr12:55725839	OR6C3	-0.51	-4.43	-0.37	2.01e-5	Cancer;
TGCT	cis	rs9911578	0.835	rs1990008	chr17:56459408	C/G	cg05425664	chr17:57184151	TRIM37	0.6	5.56	0.45	1.57e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs17376456	0.825	rs17314797	chr5:93234845	T/A	cg21475434	chr5:93447410	FAM172A	0.7	4.9	0.4	2.96e-6	Diabetic retinopathy;
TGCT	cis	rs7572733	0.555	rs7600269	chr2:198923468	C/G	cg00792783	chr2:198669748	PLCL1	0.59	5.15	0.42	1.01e-6	Dermatomyositis;
TGCT	cis	rs2046867	0.862	rs62251656	chr3:72827393	T/C	cg25664220	chr3:72788482	NA	-0.54	-6.72	-0.52	5.82e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9733	0.525	rs11584184	chr1:150695689	A/T	cg04414720	chr1:150670196	GOLPH3L	0.37	4.91	0.4	2.76e-6	Tonsillectomy;
TGCT	cis	rs2180341	0.883	rs9388568	chr6:127690694	C/A	cg24812749	chr6:127587940	RNF146	0.92	7.43	0.55	1.55e-11	Breast cancer;
TGCT	cis	rs7914558	1.000	rs8139	chr10:104848123	G/A	cg15744005	chr10:104629667	AS3MT	-0.37	-4.55	-0.38	1.28e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs707040	0.921	rs2037660	chr2:155232409	A/G	cg18104148	chr2:154337490	NA	-0.19	-4.63	-0.38	9.05e-6	Sudden cardiac arrest;
TGCT	cis	rs7208859	0.623	rs73271869	chr17:29152221	G/A	cg14008862	chr17:28927542	LRRC37B2	0.75	5.06	0.41	1.5e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs9926296	0.581	rs2108838	chr16:89904426	A/G	cg27121462	chr16:89883253	FANCA	0.64	6.14	0.48	1.05e-8	Vitiligo;
TGCT	cis	rs7568458	0.837	rs35215812	chr2:85792384	G/A	cg02493740	chr2:85810744	VAMP5	-0.27	-4.86	-0.4	3.53e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs8141529	0.702	rs5762870	chr22:29261159	C/T	cg02153584	chr22:29168773	CCDC117	0.62	5.29	0.43	5.39e-7	Lymphocyte counts;
TGCT	cis	rs6570726	0.935	rs369214	chr6:145856709	G/A	cg23711669	chr6:146136114	FBXO30	0.71	7.03	0.53	1.25e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3796352	0.568	rs11713376	chr3:52958927	A/G	cg07884673	chr3:53033167	SFMBT1	0.47	4.81	0.4	4.32e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs2228479	0.717	rs2074904	chr16:89811546	A/G	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs7552404	0.924	rs1611823	chr1:76221706	T/G	cg03433033	chr1:76189801	ACADM	0.75	8.76	0.62	1.19e-14	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs151997	1.000	rs26063	chr5:50216718	G/A	cg06027927	chr5:50259733	NA	0.47	4.83	0.4	3.9e-6	Callous-unemotional behaviour;
TGCT	trans	rs9859260	0.744	rs557527	chr3:195780709	G/A	cg17074656	chr11:63784126	MACROD1	0.53	6.75	0.52	4.98e-10	Mean corpuscular volume;
TGCT	cis	rs6460942	0.778	rs17444259	chr7:12462428	C/T	cg06484146	chr7:12443880	VWDE	-0.52	-5.56	-0.45	1.55e-7	Coronary artery disease;
TGCT	trans	rs4650994	0.905	rs12753251	chr1:178529898	G/A	cg05059571	chr16:84539110	KIAA1609	-0.41	-7.67	-0.57	4.37e-12	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg27454412	chr7:1067447	C7orf50	0.6	4.7	0.39	6.76e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs6840360	0.615	rs4696095	chr4:152467243	A/G	cg17479576	chr4:152424074	FAM160A1	-0.71	-7.74	-0.57	2.95e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg18765753	chr7:1198926	ZFAND2A	-0.5	-5.96	-0.47	2.45e-8	Longevity;Endometriosis;
TGCT	cis	rs554111	0.613	rs6699704	chr1:21241432	G/C	cg01072550	chr1:21505969	NA	0.35	5.33	0.43	4.38e-7	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs637571	0.780	rs677029	chr11:65683531	A/G	cg26695010	chr11:65641043	EFEMP2	-0.46	-4.48	-0.37	1.65e-5	Eosinophil percentage of white cells;
TGCT	cis	rs6840360	0.571	rs4696273	chr4:152528477	G/A	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.0	-0.58	7.69e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs9646954	0.542	rs3828193	chr2:101031561	A/C	cg14675211	chr2:100938903	LONRF2	-0.49	-4.64	-0.38	8.65e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9902453	0.817	rs9909128	chr17:28161482	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.83	7.95	0.58	9.99e-13	Coffee consumption (cups per day);
TGCT	cis	rs11971779	0.680	rs11764236	chr7:139118514	C/T	cg07862535	chr7:139043722	LUC7L2	0.66	5.07	0.41	1.42e-6	Diisocyanate-induced asthma;
TGCT	trans	rs17685	0.712	rs7785025	chr7:75628101	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.5	-8.54	-0.61	4.11e-14	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs6933660	0.800	rs9383900	chr6:151782816	A/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.7	7.12	0.54	7.84e-11	Menarche (age at onset);
TGCT	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg08280861	chr8:58055591	NA	0.4	4.73	0.39	5.97e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1215050	0.755	rs2952911	chr4:98850666	T/C	cg05340658	chr4:99064831	C4orf37	-0.47	-5.9	-0.47	3.18e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7267979	0.549	rs6138537	chr20:25184466	A/G	cg03522245	chr20:25566470	NINL	0.45	4.54	0.38	1.3e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11122272	0.735	rs2739507	chr1:231527329	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-6.23	-0.49	6.8e-9	Hemoglobin concentration;
TGCT	cis	rs9473924	0.505	rs7746581	chr6:50853479	T/C	cg14470998	chr6:50812995	TFAP2B	1.35	8.39	0.6	9.05e-14	Body mass index;
TGCT	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg03452623	chr4:187889614	NA	-0.36	-5.34	-0.43	4.32e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	16.07	0.82	4.16e-32	Prudent dietary pattern;
TGCT	cis	rs986417	0.748	rs1955691	chr14:61004128	G/A	cg27398547	chr14:60952738	C14orf39	1.49	10.43	0.68	1.12e-18	Gut microbiota (bacterial taxa);
TGCT	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.72	5.19	0.42	8.33e-7	Platelet count;
TGCT	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg25767906	chr1:53392781	SCP2	-0.53	-6.21	-0.49	7.34e-9	Monocyte count;
TGCT	cis	rs2456568	0.802	rs7115629	chr11:93635477	G/A	cg17595323	chr11:93583763	C11orf90	-0.47	-6.44	-0.5	2.38e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs17401966	0.931	rs17034821	chr1:10414645	A/G	cg19773385	chr1:10388646	KIF1B	-0.24	-5.5	-0.44	2.03e-7	Hepatocellular carcinoma;
TGCT	cis	rs9894429	0.700	rs113915083	chr17:79552696	G/C	cg18240062	chr17:79603768	NPLOC4	-0.85	-10.0	-0.67	1.28e-17	Eye color traits;
TGCT	cis	rs7647973	1.000	rs13096474	chr3:49443081	C/T	cg07690219	chr3:49449608	TCTA;RHOA	0.57	4.76	0.39	5.25e-6	Menarche (age at onset);
TGCT	cis	rs8103278	0.740	rs2341097	chr19:46268902	C/T	cg14061069	chr19:46274453	DMPK	-0.43	-6.32	-0.49	4.29e-9	Coronary artery disease;
TGCT	cis	rs254781	0.505	rs190438	chr5:88026902	C/T	cg22951263	chr5:87985283	NA	-0.57	-5.59	-0.45	1.4e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9611565	0.649	rs139559	chr22:42191636	A/G	cg06634786	chr22:41940651	POLR3H	-0.76	-7.15	-0.54	6.74e-11	Vitiligo;
TGCT	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	8.3	0.6	1.46e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs2295359	0.892	rs10889657	chr1:67615487	A/G	cg03340356	chr1:67600835	NA	0.39	4.65	0.39	8.4e-6	Psoriasis;
TGCT	cis	rs7100689	0.599	rs946892	chr10:82127551	C/T	cg01528321	chr10:82214614	TSPAN14	0.8	7.76	0.57	2.7e-12	Post bronchodilator FEV1;
TGCT	cis	rs7909670	0.716	rs7073882	chr10:12928571	C/G	cg23097415	chr10:13391488	SEPHS1	0.49	4.62	0.38	9.32e-6	Height;
TGCT	cis	rs9457247	1.000	rs406095	chr6:167409087	C/T	cg23791538	chr6:167370224	RNASET2	-0.49	-4.96	-0.41	2.31e-6	Crohn's disease;
TGCT	cis	rs1005277	0.522	rs9418276	chr10:37940116	G/T	cg25427524	chr10:38739819	LOC399744	-0.35	-7.04	-0.53	1.18e-10	Extrinsic epigenetic age acceleration;
TGCT	cis	rs4851266	0.898	rs12994592	chr2:100857984	T/C	cg22139774	chr2:100720529	AFF3	-0.32	-4.66	-0.39	7.89e-6	Educational attainment;
TGCT	cis	rs3008870	1.000	rs2815352	chr1:67482104	A/G	cg03991309	chr1:68237761	GNG12	0.27	4.49	0.37	1.6e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs7666738	0.830	rs7662199	chr4:99019766	G/A	cg18180107	chr4:99064573	C4orf37	0.54	5.03	0.41	1.65e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9611565	0.592	rs4822046	chr22:41987543	G/A	cg13695892	chr22:41940480	POLR3H	-0.87	-8.01	-0.58	6.94e-13	Vitiligo;
TGCT	cis	rs3858526	0.959	rs10838797	chr11:5920977	A/G	cg13902645	chr11:5959945	NA	-0.44	-4.82	-0.4	4.19e-6	DNA methylation (variation);
TGCT	cis	rs7829975	0.755	rs3789849	chr8:8687054	G/C	cg08975724	chr8:8085496	FLJ10661	0.53	4.76	0.39	5.28e-6	Mood instability;
TGCT	cis	rs78366141	0.649	rs76884708	chr4:89692043	G/C	cg01026744	chr4:89619053	NAP1L5;HERC3	1.26	5.58	0.45	1.43e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
TGCT	cis	rs2836950	0.762	rs8134638	chr21:40644170	T/C	cg06238570	chr21:40685208	BRWD1	-0.56	-5.59	-0.45	1.35e-7	Menarche (age at onset);
TGCT	cis	rs6879260	0.928	rs11739624	chr5:179727290	T/C	cg13944838	chr5:179740914	GFPT2	-0.38	-5.87	-0.47	3.7e-8	Height;
TGCT	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9399135	0.935	rs2150680	chr6:135347131	G/C	cg24558204	chr6:135376177	HBS1L	0.5	5.0	0.41	1.89e-6	Red blood cell count;
TGCT	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg01585852	chr22:24235823	MIF	-0.22	-4.69	-0.39	7.08e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6570726	0.791	rs1935612	chr6:145906090	T/A	cg05347473	chr6:146136440	FBXO30	0.52	4.93	0.41	2.54e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2242194	0.844	rs11264295	chr1:154987526	C/T	cg16680214	chr1:154839983	KCNN3	-0.3	-5.53	-0.44	1.81e-7	Schizophrenia;
TGCT	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg05985448	chr10:134359359	INPP5A	0.23	4.99	0.41	2.01e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg08280861	chr8:58055591	NA	0.4	4.73	0.39	5.97e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg11845111	chr2:191398756	TMEM194B	0.37	5.65	0.45	1.03e-7	Pulse pressure;
TGCT	cis	rs13217239	0.646	rs12201393	chr6:26975690	C/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.4	4.47	0.37	1.76e-5	Schizophrenia;
TGCT	cis	rs9653442	0.564	rs7593261	chr2:100789907	A/G	cg07810366	chr2:100720526	AFF3	-0.35	-5.05	-0.41	1.51e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs13326165	0.760	rs34523877	chr3:52375711	T/C	cg07884673	chr3:53033167	SFMBT1	0.39	4.69	0.39	7e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg08048268	chr3:133502702	NA	-0.54	-7.2	-0.54	5.06e-11	Iron status biomarkers;
TGCT	cis	rs9443645	0.869	rs9343848	chr6:79621101	C/T	cg09184832	chr6:79620586	NA	-0.49	-5.29	-0.43	5.29e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs56804039	0.524	rs4256595	chr8:8402264	A/T	cg14215082	chr8:9055850	NA	-0.48	-4.78	-0.39	4.86e-6	Cervical cancer;
TGCT	cis	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg04013166	chr16:89971882	TCF25	0.33	4.66	0.39	8.16e-6	Skin colour saturation;
TGCT	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs1371867	0.846	rs1660349	chr8:101319326	G/A	cg00191853	chr8:101177733	SPAG1	-0.22	-4.47	-0.37	1.75e-5	Atrioventricular conduction;
TGCT	cis	rs6450176	0.909	rs6884936	chr5:53293198	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.49	-4.59	-0.38	1.08e-5	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs3087591	0.708	rs2525563	chr17:29647908	T/G	cg24425628	chr17:29625626	OMG;NF1	0.39	5.74	0.46	6.74e-8	Hip circumference;
TGCT	cis	rs2120019	0.505	rs77456790	chr15:75330095	G/T	cg09165964	chr15:75287851	SCAMP5	-1.05	-5.56	-0.45	1.59e-7	Blood trace element (Zn levels);
TGCT	cis	rs9650657	0.615	rs2271355	chr8:10692158	C/T	cg16664915	chr8:10907788	XKR6	-0.31	-4.87	-0.4	3.31e-6	Neuroticism;
TGCT	cis	rs9929218	0.953	rs16260	chr16:68771034	C/A	cg01251360	chr16:68772225	CDH1	0.29	4.95	0.41	2.34e-6	Colorectal cancer;
TGCT	cis	rs7306456	0.623	rs10902513	chr12:132693487	A/G	cg02410480	chr12:132819930	GALNT9	-0.31	-4.63	-0.38	8.94e-6	Anti-saccade response;
TGCT	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg06896619	chr17:61851486	DDX42;CCDC47	-0.5	-4.9	-0.4	2.97e-6	Prudent dietary pattern;
TGCT	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs17155006	0.676	rs424866	chr7:107722869	T/C	cg05962710	chr7:107745446	LAMB4	-0.19	-4.72	-0.39	6.19e-6	Pneumococcal bacteremia;
TGCT	cis	rs611744	0.934	rs1989388	chr8:109220269	A/T	cg21045802	chr8:109455806	TTC35	0.51	4.72	0.39	6.23e-6	Dupuytren's disease;
TGCT	cis	rs61935443	0.614	rs11107787	chr12:95311669	C/T	cg21533806	chr12:95267307	NA	0.57	4.75	0.39	5.43e-6	Schizophrenia;
TGCT	cis	rs9894429	0.646	rs7405937	chr17:79597811	G/A	cg21028142	chr17:79581711	NPLOC4	0.28	5.75	0.46	6.54e-8	Eye color traits;
TGCT	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg06618935	chr21:46677482	NA	-0.35	-5.39	-0.44	3.43e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2242116	0.932	rs7646906	chr3:46949379	G/A	cg27129171	chr3:47204927	SETD2	0.63	6.19	0.49	8.22e-9	Birth weight;
TGCT	cis	rs17001868	0.568	rs9611316	chr22:40737027	A/G	cg07138101	chr22:40742427	ADSL	0.73	5.38	0.44	3.57e-7	Mammographic density (dense area);
TGCT	cis	rs9486719	0.656	rs6924957	chr6:96853579	G/T	cg06623918	chr6:96969491	KIAA0776	0.94	7.74	0.57	2.98e-12	Migraine;Coronary artery disease;
TGCT	cis	rs13256369	0.951	rs10503394	chr8:8565775	A/G	cg17143192	chr8:8559678	CLDN23	0.58	5.5	0.44	2.09e-7	Obesity-related traits;
TGCT	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg09365446	chr1:150670422	GOLPH3L	0.31	4.64	0.38	8.74e-6	Tonsillectomy;
TGCT	cis	rs7568458	0.905	rs10198569	chr2:85794415	C/T	cg02493740	chr2:85810744	VAMP5	0.28	4.74	0.39	5.73e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	5.24	0.43	6.79e-7	Menopause (age at onset);
TGCT	cis	rs7267979	0.903	rs1118963	chr20:25247449	G/A	cg03522245	chr20:25566470	NINL	0.6	6.58	0.51	1.21e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs908922	0.676	rs578382	chr1:152514054	A/G	cg20991723	chr1:152506922	NA	-0.46	-6.43	-0.5	2.56e-9	Hair morphology;
TGCT	cis	rs4566357	0.930	rs13398295	chr2:227926873	A/G	cg11843606	chr2:227700838	RHBDD1	-0.5	-4.49	-0.37	1.59e-5	Coronary artery disease;
TGCT	cis	rs4906332	1.000	rs35126287	chr14:103959432	A/G	cg26031613	chr14:104095156	KLC1	-0.51	-4.51	-0.38	1.48e-5	Coronary artery disease;
TGCT	cis	rs2637266	1.000	rs12774835	chr10:78352226	C/G	cg18941641	chr10:78392320	NA	0.4	5.01	0.41	1.81e-6	Pulmonary function;
TGCT	cis	rs6430585	0.591	rs724326	chr2:136485971	T/C	cg07169764	chr2:136633963	MCM6	0.91	8.33	0.6	1.28e-13	Corneal structure;
TGCT	cis	rs17221829	0.669	rs7128681	chr11:89383644	G/A	cg02982614	chr11:89391479	FOLH1B	-0.25	-4.44	-0.37	1.96e-5	Anxiety in major depressive disorder;
TGCT	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg12311346	chr5:56204834	C5orf35	-0.67	-6.82	-0.52	3.63e-10	Initial pursuit acceleration;
TGCT	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg03264133	chr6:25882463	NA	-0.97	-11.19	-0.71	1.6e-20	Uric acid levels;
TGCT	cis	rs975739	0.695	rs1537067	chr13:78581501	A/G	cg07847733	chr13:78271382	SLAIN1	0.49	4.45	0.37	1.88e-5	Hair color;
TGCT	cis	rs11252926	0.527	rs10904093	chr10:436848	A/G	cg13477178	chr10:375248	DIP2C	0.24	4.77	0.39	5.07e-6	Psychosis in Alzheimer's disease;
TGCT	cis	rs9611565	0.512	rs7291736	chr22:42124874	C/A	cg06481639	chr22:41940642	POLR3H	0.71	6.43	0.5	2.56e-9	Vitiligo;
TGCT	cis	rs7772486	0.658	rs6570706	chr6:145962922	T/C	cg13319975	chr6:146136371	FBXO30	-0.5	-4.49	-0.37	1.63e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7119	0.623	rs12905318	chr15:77845873	T/C	cg27398640	chr15:77910606	LINGO1	-0.28	-5.11	-0.42	1.21e-6	Type 2 diabetes;
TGCT	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg24549020	chr5:56110836	MAP3K1	0.67	5.67	0.45	9.57e-8	Initial pursuit acceleration;
TGCT	trans	rs10504390	0.656	rs79932695	chr8:66547075	T/C	cg18118147	chr19:51128640	SYT3	-0.77	-6.85	-0.52	2.99e-10	IgG glycosylation;
TGCT	cis	rs17767294	0.614	rs11546572	chr6:28292662	T/C	cg08851530	chr6:28072375	NA	1.61	6.99	0.53	1.5e-10	Parkinson's disease;
TGCT	cis	rs9291683	0.609	rs13141233	chr4:10028729	T/C	cg11266682	chr4:10021025	SLC2A9	0.66	9.54	0.65	1.61e-16	Bone mineral density;
TGCT	trans	rs3107575	0.572	rs73169365	chr3:165319778	T/C	cg15894581	chr15:63889406	FBXL22	0.88	6.83	0.52	3.32e-10	Morning vs. evening chronotype;
TGCT	cis	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg07424592	chr7:64974309	NA	-1.31	-7.72	-0.57	3.33e-12	Diabetic kidney disease;
TGCT	cis	rs2535633	0.602	rs6801235	chr3:53009595	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.54	-5.2	-0.42	8.09e-7	Body mass index;
TGCT	cis	rs12681287	0.752	rs4427148	chr8:87250668	G/A	cg27223183	chr8:87520930	FAM82B	-0.8	-5.67	-0.45	9.58e-8	Caudate activity during reward;
TGCT	cis	rs9916302	0.706	rs9909304	chr17:37500508	G/T	cg07936489	chr17:37558343	FBXL20	0.87	6.27	0.49	5.47e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs66573146	1.000	rs67405518	chr4:6965930	C/T	cg01220768	chr4:7056774	TADA2B	0.35	4.63	0.38	8.96e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs1371867	0.846	rs1788204	chr8:101303936	C/T	cg00191853	chr8:101177733	SPAG1	-0.22	-4.47	-0.37	1.75e-5	Atrioventricular conduction;
TGCT	cis	rs9647570	0.640	rs36098019	chr5:167269875	T/C	cg11091196	chr5:167285540	ODZ2	-0.31	-4.62	-0.38	9.5e-6	Menarche (age at onset);
TGCT	cis	rs7781977	0.960	rs4917017	chr7:50335232	A/G	cg01139861	chr7:50343298	IKZF1	-0.55	-6.21	-0.49	7.48e-9	IgG glycosylation;
TGCT	cis	rs7208859	0.623	rs8075163	chr17:29106310	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs739496	0.527	rs10849981	chr12:112335217	A/T	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs7312933	0.618	rs6582390	chr12:42634586	C/T	cg19980929	chr12:42632907	YAF2	0.42	6.04	0.48	1.66e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs854765	0.583	rs8065416	chr17:17851162	C/T	cg09796270	chr17:17721594	SREBF1	0.23	4.45	0.37	1.92e-5	Total body bone mineral density;
TGCT	cis	rs2115630	0.967	rs8027779	chr15:85255385	T/C	cg24513567	chr15:85260248	SEC11A	-0.34	-4.47	-0.37	1.76e-5	P wave terminal force;
TGCT	cis	rs11627546	0.615	rs77201600	chr14:70366874	A/G	cg10496350	chr14:71275911	MAP3K9	-0.89	-4.5	-0.37	1.52e-5	Red blood cell traits;
TGCT	cis	rs17401966	0.540	rs7546368	chr1:10418826	G/A	cg19773385	chr1:10388646	KIF1B	-0.22	-5.05	-0.41	1.56e-6	Hepatocellular carcinoma;
TGCT	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg17971929	chr21:40555470	PSMG1	-0.7	-6.56	-0.51	1.29e-9	Cognitive function;
TGCT	cis	rs6693567	0.565	rs834235	chr1:150362154	C/T	cg09579323	chr1:150459698	TARS2	0.52	4.64	0.38	8.63e-6	Migraine;
TGCT	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg10802521	chr3:52805072	NEK4	-0.71	-8.79	-0.62	1.04e-14	Bipolar disorder;
TGCT	cis	rs9611565	0.765	rs727563	chr22:41867377	C/T	cg03806693	chr22:41940476	POLR3H	1.02	11.05	0.7	3.59e-20	Vitiligo;
TGCT	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.54	-7.02	-0.53	1.27e-10	Longevity;Endometriosis;
TGCT	cis	rs12681287	0.517	rs68008113	chr8:87520894	C/A	cg19078186	chr8:87526527	CPNE3	-0.36	-4.49	-0.37	1.59e-5	Caudate activity during reward;
TGCT	cis	rs7095607	0.704	rs34869044	chr10:69953763	C/T	cg18986048	chr10:69913749	MYPN	0.58	6.79	0.52	4.14e-10	Lung function (FVC);
TGCT	cis	rs561341	0.800	rs7209766	chr17:30234848	T/A	cg13647721	chr17:30228624	UTP6	0.61	4.73	0.39	5.89e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs7772486	0.754	rs697053	chr6:145989807	T/C	cg05347473	chr6:146136440	FBXO30	-0.53	-4.97	-0.41	2.18e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs12497850	0.866	rs6791234	chr3:48996137	A/G	cg06212747	chr3:49208901	KLHDC8B	0.61	5.5	0.44	2.06e-7	Parkinson's disease;
TGCT	cis	rs7659604	1.000	rs35249024	chr4:122664538	C/A	cg19748678	chr4:122722346	EXOSC9	0.57	5.54	0.45	1.69e-7	Type 2 diabetes;
TGCT	cis	rs992157	0.764	rs2891079	chr2:219184691	A/G	cg00012203	chr2:219082015	ARPC2	0.7	6.58	0.51	1.16e-9	Colorectal cancer;
TGCT	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	5.38	0.44	3.58e-7	Alzheimer's disease;
TGCT	cis	rs7681423	0.951	rs13130318	chr4:155538470	T/G	cg20735720	chr4:155535218	FGG	-0.44	-6.19	-0.49	8.27e-9	Fibrinogen;
TGCT	cis	rs10927875	0.864	rs12744578	chr1:16173110	A/T	cg21385522	chr1:16154831	NA	-0.88	-10.64	-0.69	3.55e-19	Dilated cardiomyopathy;
TGCT	cis	rs78487399	0.808	rs6752964	chr2:43754655	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.07	-0.41	1.41e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs9611519	0.566	rs4821981	chr22:41415644	A/C	cg06634786	chr22:41940651	POLR3H	0.49	4.54	0.38	1.33e-5	Neuroticism;
TGCT	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg21548813	chr6:291882	DUSP22	-0.65	-6.9	-0.53	2.41e-10	Menopause (age at onset);
TGCT	cis	rs112998813	1.000	rs112998813	chr13:115059729	T/C	cg24704211	chr13:115000206	CDC16	-0.98	-4.53	-0.38	1.36e-5	Nodular sclerosis Hodgkin lymphoma;
TGCT	cis	rs4711336	0.935	rs3818525	chr6:33660779	A/G	cg14003231	chr6:33640908	ITPR3	0.28	4.53	0.38	1.38e-5	Height;
TGCT	cis	rs477895	0.568	rs34838337	chr11:63870892	T/C	cg23719950	chr11:63933701	MACROD1	-0.62	-5.33	-0.43	4.4e-7	Mean platelet volume;
TGCT	cis	rs6089829	0.692	rs6122349	chr20:61664096	T/C	cg08045932	chr20:61659980	NA	0.35	5.38	0.44	3.56e-7	Prostate cancer (SNP x SNP interaction);
TGCT	trans	rs9650657	0.515	rs7820860	chr8:10950396	C/G	cg15556689	chr8:8085844	FLJ10661	-0.85	-8.35	-0.6	1.14e-13	Neuroticism;
TGCT	cis	rs1008375	0.931	rs10019482	chr4:17578079	G/A	cg16339924	chr4:17578868	LAP3	0.8	6.96	0.53	1.73e-10	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg08564027	chr20:61660810	NA	0.37	6.85	0.52	3.1e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg18538332	chr22:24372958	LOC391322	-1.01	-12.94	-0.76	9.13e-25	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs644799	0.542	rs10831417	chr11:95467262	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	-0.59	-6.01	-0.47	1.92e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7617773	0.817	rs3731513	chr3:48219537	A/G	cg11946769	chr3:48343235	NME6	0.76	6.67	0.51	7.6e-10	Coronary artery disease;
TGCT	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg22920501	chr2:26401640	FAM59B	-0.73	-6.44	-0.5	2.36e-9	Gut microbiome composition (summer);
TGCT	cis	rs12530845	1.000	rs12537555	chr7:135334061	G/A	cg23117316	chr7:135346802	PL-5283	-0.51	-4.83	-0.4	3.98e-6	Red blood cell traits;
TGCT	cis	rs950776	0.695	rs1878399	chr15:78912003	G/C	cg06917634	chr15:78832804	PSMA4	-0.68	-5.41	-0.44	3.09e-7	Sudden cardiac arrest;
TGCT	cis	rs2016266	0.859	rs4759061	chr12:53738214	C/T	cg16917193	chr12:54089295	NA	-0.7	-4.68	-0.39	7.49e-6	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs10791323	0.569	rs10750552	chr11:133740141	A/C	cg15485101	chr11:133734466	NA	-0.38	-5.46	-0.44	2.52e-7	Childhood ear infection;
TGCT	cis	rs7223966	0.921	rs34699959	chr17:61960720	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	5.32	0.43	4.68e-7	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs72945132	0.882	rs113472486	chr11:70194945	C/G	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs4566357	1.000	rs4296417	chr2:227921941	G/A	cg11843606	chr2:227700838	RHBDD1	-0.58	-5.31	-0.43	4.92e-7	Coronary artery disease;
TGCT	cis	rs713587	0.967	rs10865320	chr2:25159780	A/G	cg01884057	chr2:25150051	NA	0.39	7.96	0.58	9.32e-13	Body mass index in non-asthmatics;
TGCT	cis	rs9660992	0.573	rs12140703	chr1:205182865	G/C	cg00857998	chr1:205179979	DSTYK	0.51	4.68	0.39	7.34e-6	Mean corpuscular volume;Mean platelet volume;
TGCT	cis	rs28595532	0.841	rs56046449	chr4:119769302	T/C	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs2762353	0.574	rs4409177	chr6:25694491	T/G	cg07061783	chr6:25882402	NA	0.75	7.46	0.56	1.3e-11	Blood metabolite levels;
TGCT	trans	rs10506458	0.915	rs12424908	chr12:63402364	G/A	cg22491629	chr6:157744540	C6orf35	-0.99	-8.55	-0.61	3.94e-14	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs13242816	0.881	rs35062002	chr7:116142458	G/A	cg02799643	chr7:116139180	CAV2	-0.42	-5.46	-0.44	2.45e-7	P wave duration;
TGCT	cis	rs523522	0.962	rs11065145	chr12:120947419	A/G	cg12219531	chr12:120966889	COQ5	0.83	7.27	0.55	3.46e-11	High light scatter reticulocyte count;
TGCT	cis	rs12286929	0.687	rs6589487	chr11:115089927	T/C	cg04017736	chr11:115827165	NA	0.18	4.47	0.37	1.78e-5	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg01802117	chr1:53393560	SCP2	0.48	5.78	0.46	5.62e-8	Monocyte count;
TGCT	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg04772025	chr11:68637568	NA	-0.57	-6.38	-0.5	3.16e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs13191362	0.938	rs28360532	chr6:162997477	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7020830	0.931	rs7034554	chr9:37081301	A/G	cg14294708	chr9:37120828	ZCCHC7	1.29	20.57	0.88	8.69e-42	Schizophrenia;
TGCT	cis	rs7312933	0.645	rs11181404	chr12:42683840	T/C	cg19980929	chr12:42632907	YAF2	0.42	5.71	0.46	8.01e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs7582180	0.614	rs9973737	chr2:100942296	T/C	cg14675211	chr2:100938903	LONRF2	0.47	4.57	0.38	1.16e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs1401999	1.000	rs7632670	chr3:183713877	A/G	cg01324343	chr3:183735012	ABCC5	0.83	11.23	0.71	1.3e-20	Anterior chamber depth;
TGCT	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg04414720	chr1:150670196	GOLPH3L	0.39	5.04	0.41	1.58e-6	Tonsillectomy;
TGCT	cis	rs12477438	0.798	rs13412764	chr2:99583733	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-8.65	-0.61	2.22e-14	Chronic sinus infection;
TGCT	cis	rs473651	0.935	rs559579	chr2:239339501	G/C	cg18131467	chr2:239335373	ASB1	0.95	9.87	0.66	2.62e-17	Multiple system atrophy;
TGCT	cis	rs6964587	1.000	rs10270598	chr7:91700827	T/C	cg22709100	chr7:91322751	NA	0.28	4.56	0.38	1.19e-5	Breast cancer;
TGCT	cis	rs59107033	0.607	rs17295346	chr3:123126972	C/G	cg04890266	chr3:123102914	ADCY5	-0.37	-5.36	-0.43	3.89e-7	Lymphocyte counts;
TGCT	cis	rs16866061	1.000	rs12470077	chr2:225334971	T/C	cg12698349	chr2:225449008	CUL3	0.96	9.57	0.65	1.4e-16	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	cis	rs2288073	0.965	rs6545340	chr2:24422269	C/G	cg02683114	chr2:24398427	C2orf84	-0.25	-5.67	-0.45	9.72e-8	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs6121246	0.559	rs6087771	chr20:30306724	A/G	cg18721089	chr20:30220636	NA	-0.36	-4.46	-0.37	1.83e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs10782582	0.593	rs74968421	chr1:76233496	T/C	cg10523679	chr1:76189770	ACADM	-0.61	-6.17	-0.48	8.87e-9	Daytime sleep phenotypes;
TGCT	cis	rs1568889	0.838	rs7121937	chr11:28359858	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.92	10.85	0.7	1.1e-19	Bipolar disorder;
TGCT	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.52	-5.85	-0.47	4.02e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs11741688	0.557	rs2004503	chr5:178337122	C/T	cg09339527	chr5:178322752	ZFP2	-0.29	-4.96	-0.41	2.29e-6	Sleep duration;
TGCT	cis	rs12477438	0.520	rs13031919	chr2:99848932	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	8.65	0.61	2.21e-14	Chronic sinus infection;
TGCT	cis	rs7917772	0.503	rs1409310	chr10:104282265	T/C	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg23758822	chr17:41437982	NA	0.69	6.41	0.5	2.75e-9	Menopause (age at onset);
TGCT	cis	rs611744	0.647	rs633901	chr8:109242981	G/T	cg21045802	chr8:109455806	TTC35	0.72	7.28	0.55	3.44e-11	Dupuytren's disease;
TGCT	cis	rs1110701	0.525	rs11764792	chr7:50496841	C/T	cg18232548	chr7:50535776	DDC	-0.38	-6.55	-0.51	1.37e-9	Acute lymphoblastic leukemia (childhood);
TGCT	cis	rs3806843	0.548	rs246055	chr5:140325662	C/T	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs60843830	1.000	rs59937473	chr2:271797	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.73	7.29	0.55	3.23e-11	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs6938	0.534	rs1127796	chr15:75193004	C/T	cg09165964	chr15:75287851	SCAMP5	-0.55	-5.11	-0.42	1.16e-6	Breast cancer;
TGCT	cis	rs896854	0.517	rs896851	chr8:95950251	T/C	cg13393036	chr8:95962371	TP53INP1	-0.49	-5.65	-0.45	1.04e-7	Type 2 diabetes;
TGCT	cis	rs892961	0.899	rs66749226	chr17:75412826	G/A	cg05865280	chr17:75406074	SEPT9	0.29	6.93	0.53	1.99e-10	Airflow obstruction;
TGCT	cis	rs9814567	1.000	rs13071551	chr3:134310867	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.95	8.76	0.62	1.21e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg06640241	chr16:89574553	SPG7	-0.76	-8.63	-0.61	2.45e-14	Multiple myeloma (IgH translocation);
TGCT	cis	rs9894429	1.000	rs11651264	chr17:79576394	A/G	cg18240062	chr17:79603768	NPLOC4	-0.67	-6.84	-0.52	3.23e-10	Eye color traits;
TGCT	cis	rs904251	0.772	rs756202	chr6:37460350	C/A	cg25019722	chr6:37503610	NA	-0.44	-5.1	-0.42	1.21e-6	Cognitive performance;
TGCT	cis	rs10931896	0.531	rs296801	chr2:201142812	C/T	cg23649088	chr2:200775458	C2orf69	0.39	6.43	0.5	2.48e-9	Systolic blood pressure;
TGCT	cis	rs2115630	0.645	rs3825877	chr15:85174631	G/A	cg12863693	chr15:85201151	NMB	-0.39	-5.11	-0.42	1.19e-6	P wave terminal force;
TGCT	cis	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg07424592	chr7:64974309	NA	1.34	8.08	0.59	4.95e-13	Diabetic kidney disease;
TGCT	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg12310025	chr6:25882481	NA	-0.53	-5.45	-0.44	2.63e-7	Blood metabolite levels;
TGCT	cis	rs8062405	0.895	rs56186137	chr16:28825953	A/G	cg09754948	chr16:28834200	ATXN2L	0.62	4.69	0.39	6.95e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs1865760	0.516	rs9393684	chr6:26075531	G/C	cg17042849	chr6:26104293	HIST1H4C	-0.66	-5.82	-0.46	4.73e-8	Height;
TGCT	cis	rs10791097	0.694	rs6590520	chr11:130747386	C/G	cg05962950	chr11:130786565	SNX19	0.92	11.5	0.72	2.77e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs7829975	0.846	rs11779061	chr8:8549432	G/A	cg15556689	chr8:8085844	FLJ10661	-0.71	-6.28	-0.49	5.27e-9	Mood instability;
TGCT	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	5.11	0.42	1.18e-6	Height;
TGCT	cis	rs7586879	0.639	rs3903070	chr2:25123463	C/G	cg15423357	chr2:25149977	NA	0.5	4.89	0.4	3.06e-6	Body mass index;
TGCT	cis	rs10927875	0.632	rs6677321	chr1:16149301	A/C	cg21385522	chr1:16154831	NA	-1.0	-17.61	-0.85	1.57e-35	Dilated cardiomyopathy;
TGCT	cis	rs2361718	0.564	rs2304844	chr17:78084507	G/C	cg22255288	chr17:78854418	RPTOR	-0.25	-4.63	-0.38	9.09e-6	Yeast infection;
TGCT	cis	rs3806843	0.966	rs10060640	chr5:140211226	G/A	cg19875535	chr5:140030758	IK	0.35	5.51	0.44	1.94e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs10464366	0.519	rs6974609	chr7:39219149	C/T	cg15212455	chr7:39170539	POU6F2	0.29	6.08	0.48	1.4e-8	IgG glycosylation;
TGCT	cis	rs34779708	0.931	rs11597483	chr10:35285117	A/G	cg04310649	chr10:35416472	CREM	-0.51	-4.55	-0.38	1.24e-5	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs72945132	0.882	rs12278741	chr11:70135742	A/G	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg23719950	chr11:63933701	MACROD1	-0.72	-5.68	-0.45	9.11e-8	Mean platelet volume;
TGCT	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.06	-9.57	-0.65	1.41e-16	Platelet count;
TGCT	cis	rs3008870	0.959	rs1886686	chr1:67390468	C/G	cg03991309	chr1:68237761	GNG12	0.27	4.56	0.38	1.23e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs7192750	0.586	rs28697038	chr16:71952354	G/C	cg06353428	chr16:71660113	MARVELD3	0.8	7.26	0.55	3.65e-11	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs7772486	0.875	rs1331645	chr6:146398407	C/G	cg05347473	chr6:146136440	FBXO30	0.54	4.9	0.4	2.92e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7769051	1.000	rs9493444	chr6:133125320	C/G	cg22852734	chr6:133119734	C6orf192	1.22	6.9	0.53	2.34e-10	Type 2 diabetes nephropathy;
TGCT	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.35	-4.46	-0.37	1.84e-5	Menopause (age at onset);
TGCT	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg24531977	chr5:56204891	C5orf35	-0.76	-7.34	-0.55	2.45e-11	Initial pursuit acceleration;
TGCT	cis	rs7267979	0.745	rs6132845	chr20:25547767	A/G	cg03522245	chr20:25566470	NINL	0.58	6.07	0.48	1.47e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg04772025	chr11:68637568	NA	0.59	6.66	0.51	8.15e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs2153535	0.580	rs9378551	chr6:8463744	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs877282	1.000	rs12773872	chr10:771939	T/C	cg17470449	chr10:769945	NA	0.31	4.89	0.4	3.03e-6	Uric acid levels;
TGCT	cis	rs2836633	0.929	rs4143428	chr21:40030582	G/T	cg12884169	chr21:40033163	ERG	0.42	4.54	0.38	1.34e-5	Coronary artery disease;
TGCT	cis	rs9733	0.519	rs7529194	chr1:150622620	A/T	cg09365446	chr1:150670422	GOLPH3L	0.31	4.55	0.38	1.26e-5	Tonsillectomy;
TGCT	cis	rs2153535	0.584	rs9502723	chr6:8541504	G/A	cg07606381	chr6:8435919	SLC35B3	0.56	5.16	0.42	9.46e-7	Motion sickness;
TGCT	cis	rs17401966	0.838	rs7553228	chr1:10350438	G/C	cg19773385	chr1:10388646	KIF1B	-0.21	-4.57	-0.38	1.17e-5	Hepatocellular carcinoma;
TGCT	cis	rs7949030	0.626	rs11231141	chr11:62326265	T/C	cg13298116	chr11:62369859	EML3;MTA2	0.64	9.45	0.65	2.73e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs854765	0.693	rs9915776	chr17:17749056	A/G	cg09796270	chr17:17721594	SREBF1	-0.28	-5.44	-0.44	2.73e-7	Total body bone mineral density;
TGCT	cis	rs709400	0.658	rs72708874	chr14:103899251	T/G	cg12935359	chr14:103987150	CKB	-0.36	-5.41	-0.44	3.09e-7	Body mass index;
TGCT	cis	rs1577917	0.958	rs12202188	chr6:86562700	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.29	-0.43	5.34e-7	Response to antipsychotic treatment;
TGCT	cis	rs7917772	0.636	rs2249845	chr10:104512095	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.59	-4.86	-0.4	3.41e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs4072705	0.900	rs4836993	chr9:127558370	G/C	cg13476313	chr9:127244764	NR5A1	0.29	4.94	0.41	2.5e-6	Menarche (age at onset);
TGCT	cis	rs6988636	1.000	rs57322232	chr8:124193532	A/G	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs1008375	0.932	rs13127157	chr4:17618049	A/G	cg18681998	chr4:17616180	MED28	-0.98	-9.85	-0.66	2.99e-17	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4662750	0.527	rs10164978	chr2:128385224	C/G	cg01966334	chr2:128378434	MYO7B	0.2	4.62	0.38	9.66e-6	Renal cell carcinoma;
TGCT	cis	rs12510870	0.729	rs11935001	chr4:74362091	G/T	cg05868023	chr4:75230803	EREG	0.53	4.52	0.38	1.43e-5	Iris color (b* coordinate);
TGCT	cis	rs644148	0.836	rs2571112	chr19:45000319	T/A	cg15540054	chr19:45004280	ZNF180	-0.66	-5.36	-0.43	3.83e-7	Personality dimensions;
TGCT	trans	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg20587970	chr11:113659929	NA	-0.97	-11.47	-0.72	3.31e-21	Hip circumference adjusted for BMI;
TGCT	cis	rs1580019	0.961	rs766660	chr7:32499077	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.81	7.7	0.57	3.71e-12	Cognitive ability;
TGCT	cis	rs13242816	1.000	rs3807993	chr7:116197572	T/A	cg02799643	chr7:116139180	CAV2	-0.41	-5.21	-0.42	7.65e-7	P wave duration;
TGCT	cis	rs858239	0.539	rs2390757	chr7:23191492	A/G	cg05602783	chr7:23145260	KLHL7	-0.68	-5.53	-0.44	1.79e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs79839061	0.610	rs3775130	chr4:875144	G/A	cg07828340	chr4:882639	GAK	0.34	4.58	0.38	1.1e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs2677744	0.962	rs1266486	chr15:91460284	T/C	cg22288577	chr15:91498497	RCCD1	0.49	5.23	0.42	7.11e-7	Attention deficit hyperactivity disorder;
TGCT	cis	rs12477438	0.520	rs8179690	chr2:99795300	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.14	-17.24	-0.84	1.02e-34	Chronic sinus infection;
TGCT	cis	rs76878669	0.917	rs10444359	chr11:66102807	G/A	cg18002602	chr11:66138449	SLC29A2	-0.51	-5.71	-0.46	7.78e-8	Educational attainment (years of education);
TGCT	cis	rs3008870	1.000	rs12740884	chr1:67459855	C/A	cg08660285	chr1:67390436	MIER1;WDR78	-1.1	-11.8	-0.73	5.15e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs7581919	0.614	rs2287269	chr2:15650380	C/T	cg19911430	chr2:16430654	NA	-0.55	-4.58	-0.38	1.14e-5	Conduct disorder;
TGCT	cis	rs13631	0.697	rs1018330	chr9:139980385	A/C	cg03717367	chr9:139980219	LOC100289341;MAN1B1	0.25	4.52	0.38	1.45e-5	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs7772486	0.875	rs7761033	chr6:146356106	C/T	cg05347473	chr6:146136440	FBXO30	0.57	5.51	0.44	2.02e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg21862992	chr11:68658383	NA	0.49	6.65	0.51	8.54e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs1371867	0.846	rs1788204	chr8:101303936	C/T	cg06636551	chr8:101224915	SPAG1	-0.48	-6.52	-0.51	1.62e-9	Atrioventricular conduction;
TGCT	cis	rs9644630	0.897	rs13266857	chr8:19364515	C/T	cg01280390	chr8:19363452	CSGALNACT1	-0.26	-4.63	-0.38	9.11e-6	Oropharynx cancer;
TGCT	cis	rs1865760	0.588	rs9467658	chr6:26010881	T/G	cg17042849	chr6:26104293	HIST1H4C	-0.65	-5.78	-0.46	5.77e-8	Height;
TGCT	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg24675658	chr1:53192096	ZYG11B	0.7	7.98	0.58	8.59e-13	Monocyte count;
TGCT	trans	rs3790455	0.610	rs1171554	chr1:156474119	G/A	cg16443977	chr5:115884994	SEMA6A	0.4	6.97	0.53	1.66e-10	Migraine;
TGCT	cis	rs9457247	0.508	rs9459874	chr6:167504127	A/G	cg07741184	chr6:167504864	NA	-0.27	-5.26	-0.43	6.17e-7	Crohn's disease;
TGCT	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg13397359	chr6:42928475	GNMT	-0.7	-6.52	-0.51	1.63e-9	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg12756686	chr19:29218302	NA	0.77	6.61	0.51	1.01e-9	Methadone dose in opioid dependence;
TGCT	cis	rs2404602	0.692	rs4383105	chr15:77055510	T/C	cg22467129	chr15:76604101	ETFA	-0.45	-5.11	-0.42	1.18e-6	Blood metabolite levels;
TGCT	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg05985448	chr10:134359359	INPP5A	0.2	4.49	0.37	1.61e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs9581857	0.547	rs9581869	chr13:28082498	G/A	cg22138327	chr13:27999177	GTF3A	0.73	4.54	0.38	1.34e-5	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs1577917	0.958	rs1337843	chr6:86675545	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.05	-0.41	1.57e-6	Response to antipsychotic treatment;
TGCT	trans	rs66573146	1.000	rs6852613	chr4:7035637	G/A	cg07817883	chr1:32538562	TMEM39B	1.63	8.26	0.6	1.86e-13	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs11098499	0.754	rs10212714	chr4:120254302	T/C	cg09307838	chr4:120376055	NA	0.62	5.95	0.47	2.5e-8	Corneal astigmatism;
TGCT	cis	rs17122693	1.000	rs72679592	chr14:51094047	T/C	cg04730355	chr14:51134070	SAV1	1.31	9.73	0.66	5.63e-17	Cognitive performance;
TGCT	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg12419862	chr22:24373484	LOC391322	-0.84	-9.35	-0.64	4.79e-16	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9858542	0.953	rs6779524	chr3:49450449	C/T	cg03060546	chr3:49711283	APEH	-0.63	-5.49	-0.44	2.18e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs11112613	0.713	rs12307351	chr12:105955634	T/A	cg03607813	chr12:105948248	NA	0.47	5.74	0.46	6.71e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	cis	rs797680	0.856	rs6703310	chr1:93788740	A/C	cg17826107	chr1:92977322	EVI5	-0.22	-5.09	-0.42	1.32e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs12477438	0.520	rs13023744	chr2:99738224	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.06	13.26	0.77	1.59e-25	Chronic sinus infection;
TGCT	cis	rs778371	0.723	rs1022329	chr2:233591239	T/C	cg08000102	chr2:233561755	GIGYF2	0.74	8.91	0.62	5.41e-15	Schizophrenia;
TGCT	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg04267008	chr7:1944627	MAD1L1	-0.37	-4.97	-0.41	2.21e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs248381	0.537	rs478651	chr5:78290682	A/G	cg04677158	chr5:78279841	ARSB	0.28	5.4	0.44	3.32e-7	Toenail selenium levels;
TGCT	cis	rs6750047	0.546	rs10192788	chr2:38272672	C/T	cg07380506	chr2:38303506	CYP1B1	0.59	5.36	0.43	3.84e-7	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs7223966	1.000	rs9912201	chr17:61763208	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	4.51	0.38	1.49e-5	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg13695892	chr22:41940480	POLR3H	0.94	8.92	0.63	5.1e-15	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs2239547	0.657	rs13072536	chr3:52861211	A/T	cg11645453	chr3:52864694	ITIH4	0.34	5.67	0.45	9.34e-8	Schizophrenia;
TGCT	cis	rs6424115	1.000	rs34477640	chr1:24154067	T/C	cg15997130	chr1:24165203	NA	-0.92	-10.57	-0.69	5.26e-19	Immature fraction of reticulocytes;
TGCT	cis	rs3820928	0.874	rs13385711	chr2:227830414	G/T	cg11843606	chr2:227700838	RHBDD1	-0.52	-4.58	-0.38	1.1e-5	Pulmonary function;
TGCT	cis	rs6815814	0.851	rs17582893	chr4:38886420	G/A	cg02016764	chr4:38805732	TLR1	-0.34	-5.16	-0.42	9.63e-7	Breast cancer;
TGCT	cis	rs11190604	1.000	rs7099913	chr10:102314777	T/C	cg23241863	chr10:102295624	HIF1AN	0.71	5.4	0.44	3.26e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9902453	0.845	rs3102559	chr17:28029723	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	7.27	0.55	3.55e-11	Coffee consumption (cups per day);
TGCT	cis	rs12188164	0.965	rs72717415	chr5:430059	G/A	cg26850624	chr5:429559	AHRR	-0.2	-4.81	-0.4	4.22e-6	Cystic fibrosis severity;
TGCT	cis	rs55794721	0.509	rs4649085	chr1:25778832	G/A	cg09222892	chr1:25734099	RHCE	-0.41	-6.8	-0.52	3.99e-10	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs4319547	0.656	rs10773075	chr12:122814236	G/A	cg08088222	chr12:122070432	ORAI1	0.26	4.69	0.39	6.99e-6	Body mass index;
TGCT	cis	rs950169	0.919	rs12915589	chr15:84734464	T/C	cg17173187	chr15:85201210	NMB	0.47	5.23	0.42	7.11e-7	Schizophrenia;
TGCT	cis	rs1865760	0.713	rs6928951	chr6:25995554	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.72	6.94	0.53	1.97e-10	Height;
TGCT	cis	rs711245	0.670	rs7560321	chr2:36822318	C/G	cg10546459	chr2:36825355	FEZ2	-0.56	-5.4	-0.44	3.34e-7	Height;
TGCT	cis	rs13190036	0.901	rs28715668	chr5:176699268	T/C	cg18465082	chr5:176734745	MXD3	-0.35	-4.54	-0.38	1.3e-5	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
TGCT	cis	rs1215050	0.791	rs13107606	chr4:98823187	C/A	cg05340658	chr4:99064831	C4orf37	0.45	5.78	0.46	5.8e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs34779708	0.931	rs9663401	chr10:35278849	G/T	cg04310649	chr10:35416472	CREM	-0.51	-4.55	-0.38	1.24e-5	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs7172809	0.573	rs75180243	chr15:77649707	G/A	cg22256960	chr15:77711686	NA	-0.51	-4.81	-0.4	4.29e-6	Glucose homeostasis traits;
TGCT	cis	rs367615	0.918	rs17161895	chr5:108855831	T/G	cg17395555	chr5:108820864	NA	0.3	4.99	0.41	1.96e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs7552404	0.731	rs11161845	chr1:76367559	T/C	cg22875332	chr1:76189707	ACADM	0.7	6.84	0.52	3.26e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs651907	0.535	rs34743741	chr3:101532448	C/T	cg12386194	chr3:101231763	SENP7	0.45	4.45	0.37	1.87e-5	Colorectal cancer;
TGCT	cis	rs929354	0.772	rs6459739	chr7:156998863	A/T	cg05182265	chr7:156933206	UBE3C	-0.39	-8.79	-0.62	1.03e-14	Body mass index;
TGCT	cis	rs7267979	1.000	rs2500418	chr20:25382268	C/T	cg03522245	chr20:25566470	NINL	-0.64	-7.05	-0.53	1.12e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4252435	0.520	rs7810229	chr7:142641087	A/G	cg21621906	chr7:142494914	NA	1.08	4.53	0.38	1.36e-5	Cancer;
TGCT	cis	rs6918586	0.658	rs198809	chr6:26128766	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.65	-6.2	-0.49	7.67e-9	Schizophrenia;
TGCT	cis	rs12134133	1.000	rs2782840	chr1:207484183	C/T	cg02152968	chr1:207494213	CD55	0.61	4.82	0.4	4.18e-6	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs62064224	0.597	rs7207268	chr17:30725155	T/G	cg18200150	chr17:30822561	MYO1D	0.39	4.7	0.39	6.77e-6	Schizophrenia;
TGCT	cis	rs9372498	0.536	rs9481833	chr6:118919631	G/A	cg21191810	chr6:118973309	C6orf204	-0.39	-5.13	-0.42	1.07e-6	Diastolic blood pressure;
TGCT	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg08219700	chr8:58056026	NA	0.38	4.61	0.38	1e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs67073037	0.868	rs11127193	chr2:29133121	G/T	cg09522027	chr2:28974177	PPP1CB	0.57	4.49	0.37	1.59e-5	Breast cancer;Breast cancer (estrogen-receptor negative);
TGCT	cis	rs12549902	0.966	rs6990613	chr8:41515130	A/G	cg00088007	chr8:41504566	NKX6-3	0.36	5.56	0.45	1.6e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
TGCT	cis	rs7647973	0.588	rs4855848	chr3:49653457	C/T	cg05785598	chr3:49045655	WDR6	0.42	5.24	0.43	6.67e-7	Menarche (age at onset);
TGCT	cis	rs3862030	0.839	rs2281880	chr10:104269217	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.53	-5.15	-0.42	9.99e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
TGCT	cis	rs77741769	0.569	rs10774572	chr12:121309561	A/G	cg02419362	chr12:121203948	SPPL3	0.19	4.49	0.37	1.63e-5	Mean corpuscular volume;
TGCT	trans	rs6089829	0.888	rs6011559	chr20:61675620	C/T	cg23505145	chr19:12996616	KLF1	-0.97	-9.99	-0.67	1.36e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7428	0.527	rs6547612	chr2:85551184	C/T	cg24342717	chr2:85555507	TGOLN2	-0.49	-7.91	-0.58	1.21e-12	Ear protrusion;
TGCT	cis	rs12541335	0.639	rs4565458	chr8:22154133	T/C	cg07298985	chr8:22133076	PIWIL2	0.32	4.83	0.4	3.94e-6	Hypertriglyceridemia;
TGCT	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg20999797	chr1:1681921	NA	-0.2	-5.04	-0.41	1.61e-6	Body mass index;
TGCT	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg04944784	chr2:26401820	FAM59B	0.72	5.92	0.47	2.93e-8	Gut microbiome composition (summer);
TGCT	cis	rs10489525	0.560	rs10858062	chr1:115602563	A/G	cg12756093	chr1:115239321	AMPD1	-0.4	-5.49	-0.44	2.19e-7	Autism;
TGCT	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.71	5.14	0.42	1.02e-6	Platelet count;
TGCT	cis	rs826838	1.000	rs11168217	chr12:38884278	T/C	cg26384229	chr12:38710491	ALG10B	1.04	10.43	0.68	1.11e-18	Heart rate;
TGCT	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg11890956	chr21:40555474	PSMG1	1.12	12.59	0.75	6.25e-24	Cognitive function;
TGCT	cis	rs9814567	0.752	rs4955468	chr3:134340850	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-6.5	-0.5	1.78e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs9297145	0.585	rs10953281	chr7:98772131	C/T	cg05967295	chr7:98741636	SMURF1	-0.67	-8.42	-0.6	8e-14	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs1975974	0.511	rs56047890	chr17:21733405	G/A	cg18423549	chr17:21743878	NA	-0.65	-6.44	-0.5	2.36e-9	Psoriasis;
TGCT	cis	rs13217239	0.646	rs10456351	chr6:26986792	C/T	cg02458000	chr6:26745757	NA	0.5	4.61	0.38	9.84e-6	Schizophrenia;
TGCT	cis	rs7119038	0.774	rs874621	chr11:118655645	G/A	cg19308663	chr11:118741387	NA	0.31	6.13	0.48	1.06e-8	Sjögren's syndrome;
TGCT	cis	rs734999	0.588	rs3748819	chr1:2524966	C/T	cg18854424	chr1:2615690	NA	0.47	5.23	0.43	6.99e-7	Ulcerative colitis;
TGCT	cis	rs9911578	1.000	rs12453459	chr17:56624291	C/T	cg12560992	chr17:57184187	TRIM37	-0.76	-9.34	-0.64	4.88e-16	Intelligence (multi-trait analysis);
TGCT	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg01341218	chr17:43662625	NA	1.11	9.15	0.63	1.43e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	trans	rs2469997	0.858	rs2470031	chr8:120370390	T/A	cg01792902	chr3:178864926	PIK3CA	0.83	6.77	0.52	4.49e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs3820068	0.705	rs6656907	chr1:15896984	A/G	cg05660106	chr1:15850417	CASP9	1.17	14.8	0.8	3.47e-29	Systolic blood pressure;
TGCT	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6490294	0.659	rs601663	chr12:112123284	A/G	cg10833066	chr12:111807467	FAM109A	0.31	4.84	0.4	3.82e-6	Mean platelet volume;
TGCT	cis	rs2795502	1.000	rs2744090	chr10:43339614	G/C	cg20628663	chr10:43360327	NA	-0.44	-6.37	-0.5	3.4e-9	Blood protein levels;
TGCT	cis	rs7246657	0.943	rs10405325	chr19:37883477	G/C	cg18154014	chr19:37997991	ZNF793	1.0	6.69	0.52	6.81e-10	Coronary artery calcification;
TGCT	cis	rs2033711	0.783	rs11671113	chr19:58958087	C/T	cg04608855	chr19:58913158	NA	0.54	5.16	0.42	9.58e-7	Uric acid clearance;
TGCT	cis	rs7772486	0.720	rs702320	chr6:146006654	G/A	cg23711669	chr6:146136114	FBXO30	-0.93	-10.83	-0.7	1.24e-19	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7635838	0.687	rs7625495	chr3:11377918	G/T	cg00170343	chr3:11313890	ATG7	0.62	6.09	0.48	1.28e-8	HDL cholesterol;
TGCT	cis	rs838147	0.537	rs632111	chr19:49208978	A/G	cg13540341	chr19:49222985	MAMSTR	-0.38	-5.06	-0.41	1.5e-6	Dietary macronutrient intake;
TGCT	cis	rs9788682	1.000	rs7181447	chr15:78814567	A/G	cg06917634	chr15:78832804	PSMA4	-0.71	-5.22	-0.42	7.38e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg12963246	chr6:28129442	ZNF389	0.52	5.1	0.42	1.23e-6	Depression;
TGCT	cis	rs10791097	0.967	rs4366492	chr11:130717256	T/C	cg05962950	chr11:130786565	SNX19	0.73	7.89	0.58	1.32e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs2880765	0.835	rs4281668	chr15:86047286	C/T	cg13263323	chr15:86062960	AKAP13	-0.21	-4.49	-0.37	1.63e-5	Coronary artery disease;
TGCT	cis	rs7811142	0.945	rs6978739	chr7:100098680	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	7.77	0.57	2.61e-12	Platelet count;
TGCT	cis	rs7772486	0.719	rs2206141	chr6:146086192	A/G	cg05347473	chr6:146136440	FBXO30	-0.53	-5.01	-0.41	1.84e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs72945132	0.660	rs12292191	chr11:70122426	T/C	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs7267979	0.753	rs400357	chr20:25479058	A/G	cg14121845	chr20:25566513	NINL	0.45	4.6	0.38	1.02e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs637571	0.584	rs659824	chr11:65636509	A/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.63	-6.77	-0.52	4.65e-10	Eosinophil percentage of white cells;
TGCT	cis	rs3733585	0.673	rs7377578	chr4:9952775	T/C	cg00071950	chr4:10020882	SLC2A9	-0.55	-6.58	-0.51	1.21e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs6121246	0.567	rs6087701	chr20:30217708	A/C	cg21427119	chr20:30132790	HM13	-0.43	-6.17	-0.48	8.86e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs4951018	0.821	rs7529037	chr1:205637501	C/G	cg24503407	chr1:205819492	PM20D1	-0.36	-4.68	-0.39	7.53e-6	Prostate-specific antigen levels;
TGCT	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg20007245	chr22:24372913	LOC391322	0.74	6.69	0.52	6.72e-10	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs709400	0.663	rs62007719	chr14:103943130	G/T	cg12935359	chr14:103987150	CKB	-0.37	-5.69	-0.46	8.55e-8	Body mass index;
TGCT	cis	rs1800469	1.000	rs2241712	chr19:41869756	C/T	cg09537434	chr19:41945824	ATP5SL	-0.58	-5.23	-0.43	6.94e-7	Colorectal cancer;
TGCT	cis	rs2354432	0.607	rs6685775	chr1:146744294	A/G	cg25205988	chr1:146714368	CHD1L	-1.34	-6.07	-0.48	1.44e-8	Mitochondrial DNA levels;
TGCT	cis	rs10883723	0.668	rs12414407	chr10:104387019	A/G	cg05855489	chr10:104503620	C10orf26	0.51	4.53	0.38	1.35e-5	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs9467773	0.620	rs3800303	chr6:26598188	A/G	cg11502198	chr6:26597334	ABT1	0.54	4.96	0.41	2.31e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg22963979	chr7:1858916	MAD1L1	-0.39	-6.41	-0.5	2.79e-9	Bipolar disorder and schizophrenia;
TGCT	cis	rs17376456	0.569	rs11135394	chr5:93187135	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.53	-4.55	-0.38	1.24e-5	Diabetic retinopathy;
TGCT	cis	rs67072384	1.000	rs61489692	chr11:72445314	T/C	cg03713592	chr11:72463424	ARAP1	-0.9	-4.63	-0.38	9.26e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs17376456	0.569	rs12653528	chr5:93212833	T/C	cg21475434	chr5:93447410	FAM172A	-0.68	-5.22	-0.42	7.16e-7	Diabetic retinopathy;
TGCT	cis	rs2120019	1.000	rs2120019	chr15:75334184	T/C	cg11632617	chr15:75315747	PPCDC	-0.3	-4.47	-0.37	1.71e-5	Blood trace element (Zn levels);
TGCT	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg22535103	chr8:58192502	C8orf71	-0.42	-4.79	-0.4	4.7e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2070488	0.804	rs13092539	chr3:38458725	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	7.95	0.58	9.74e-13	Electrocardiographic conduction measures;
TGCT	cis	rs10489202	0.608	rs10918826	chr1:168075316	C/T	cg24449463	chr1:168025552	DCAF6	-0.53	-5.49	-0.44	2.16e-7	Schizophrenia;
TGCT	cis	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg22857025	chr5:266934	NA	-0.32	-6.58	-0.51	1.18e-9	Breast cancer;
TGCT	cis	rs9467773	1.000	rs9986382	chr6:26550619	T/C	cg05738196	chr6:26577821	NA	0.91	13.11	0.76	3.53e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs3617	0.573	rs4687682	chr3:52916939	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	0.49	4.83	0.4	3.91e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs916888	0.610	rs199454	chr17:44800110	G/A	cg01570182	chr17:44337453	NA	-0.77	-7.45	-0.56	1.38e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs13082711	0.554	rs1494423	chr3:27375345	A/G	cg02860705	chr3:27208620	NA	-0.35	-5.05	-0.41	1.56e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs7809950	0.678	rs2107317	chr7:106899685	T/C	cg23024343	chr7:107201750	COG5	-0.43	-5.81	-0.46	4.86e-8	Coronary artery disease;
TGCT	cis	rs7267979	1.000	rs34645895	chr20:25368373	A/G	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7091068	0.522	rs10882322	chr10:95483273	C/G	cg20715218	chr10:95462985	C10orf4	0.5	4.86	0.4	3.49e-6	Urinary tract infection frequency;
TGCT	cis	rs9611565	0.921	rs2281332	chr22:41746212	T/C	cg17554472	chr22:41940697	POLR3H	-0.4	-4.58	-0.38	1.11e-5	Vitiligo;
TGCT	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg05368731	chr17:41323189	NBR1	1.16	13.44	0.77	5.72e-26	Menopause (age at onset);
TGCT	trans	rs561341	0.709	rs8068049	chr17:30183857	T/C	cg20587970	chr11:113659929	NA	0.88	8.79	0.62	1.05e-14	Hip circumference adjusted for BMI;
TGCT	cis	rs6750047	0.649	rs4670231	chr2:38267836	T/G	cg07380506	chr2:38303506	CYP1B1	0.56	5.01	0.41	1.82e-6	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg26354017	chr1:205819088	PM20D1	0.53	6.28	0.49	5.15e-9	Menarche (age at onset);
TGCT	cis	rs10504229	0.679	rs73681882	chr8:58030038	A/G	cg08280861	chr8:58055591	NA	0.35	5.01	0.41	1.85e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg03303774	chr4:1407052	NA	0.34	5.44	0.44	2.75e-7	Obesity-related traits;
TGCT	cis	rs1933488	0.898	rs9479505	chr6:153415651	G/C	cg24028809	chr6:153414101	RGS17	0.21	4.67	0.39	7.69e-6	Prostate cancer;
TGCT	cis	rs4268898	0.722	rs12185638	chr2:24382030	C/G	cg05570707	chr2:24270316	C2orf44	0.48	4.59	0.38	1.08e-5	Asthma;
TGCT	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg18876405	chr7:65276391	NA	-0.32	-4.93	-0.4	2.63e-6	Aortic root size;
TGCT	trans	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg13615516	chr5:77269221	NA	0.67	8.36	0.6	1.09e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2637266	1.000	rs10824425	chr10:78340310	C/G	cg18941641	chr10:78392320	NA	0.39	4.86	0.4	3.46e-6	Pulmonary function;
TGCT	cis	rs733175	0.855	rs10016075	chr4:10006663	G/T	cg11266682	chr4:10021025	SLC2A9	0.47	4.48	0.37	1.66e-5	Psychosis and Alzheimer's disease;
TGCT	cis	rs2115630	1.000	rs55646601	chr15:85323568	G/T	cg11189052	chr15:85197271	WDR73	-0.61	-5.89	-0.47	3.35e-8	P wave terminal force;
TGCT	cis	rs2455799	0.559	rs4685267	chr3:15922992	C/T	cg12172478	chr3:16357591	RFTN1	-0.34	-5.1	-0.42	1.23e-6	Mean platelet volume;
TGCT	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg08219700	chr8:58056026	NA	0.37	4.48	0.37	1.71e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs4820792	0.725	rs2347443	chr22:29119220	G/C	cg03733026	chr22:29445468	ZNRF3	0.25	4.89	0.4	3.01e-6	Breast size;
TGCT	cis	rs9902453	0.808	rs62068617	chr17:28144728	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	7.18	0.54	5.76e-11	Coffee consumption (cups per day);
TGCT	cis	rs7659604	0.540	rs10020581	chr4:122676559	A/C	cg19748678	chr4:122722346	EXOSC9	-0.51	-5.0	-0.41	1.89e-6	Type 2 diabetes;
TGCT	cis	rs9911578	1.000	rs304270	chr17:56802141	A/G	cg05425664	chr17:57184151	TRIM37	0.64	6.51	0.5	1.66e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg11871910	chr12:69753446	YEATS4	0.87	10.07	0.67	8.72e-18	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs4700695	0.841	rs153367	chr5:65419170	G/A	cg21114390	chr5:65439923	SFRS12	-0.59	-4.7	-0.39	6.79e-6	Facial morphology (factor 19);
TGCT	cis	rs858239	0.669	rs6461688	chr7:23116615	G/A	cg05407003	chr7:23246146	NA	-0.31	-5.05	-0.41	1.54e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs9914544	0.545	rs9912568	chr17:18792719	G/A	cg26378065	chr17:18585709	ZNF286B	0.53	4.63	0.38	9.01e-6	Educational attainment (years of education);
TGCT	cis	rs2836950	0.545	rs11700449	chr21:40522419	A/T	cg11644478	chr21:40555479	PSMG1	-0.57	-5.47	-0.44	2.41e-7	Menarche (age at onset);
TGCT	cis	rs7666738	0.830	rs11731478	chr4:99001686	A/G	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6570726	0.791	rs427128	chr6:145865917	T/C	cg23711669	chr6:146136114	FBXO30	0.89	9.93	0.67	1.82e-17	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs629535	0.773	rs568159	chr8:70032908	C/G	cg21567404	chr3:27674614	NA	0.58	9.18	0.64	1.22e-15	Dupuytren's disease;
TGCT	cis	rs7666738	0.546	rs10010088	chr4:98655945	C/T	cg18180107	chr4:99064573	C4orf37	0.54	4.73	0.39	5.89e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg07061783	chr6:25882402	NA	0.66	6.75	0.52	4.99e-10	Blood metabolite levels;
TGCT	cis	rs539096	0.715	rs6665014	chr1:44226004	G/T	cg15962314	chr1:44399869	ARTN	-0.32	-4.67	-0.39	7.78e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg10295955	chr4:187884368	NA	-1.02	-15.6	-0.81	5.02e-31	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9443645	0.901	rs1538233	chr6:79743735	G/T	cg09184832	chr6:79620586	NA	-0.48	-5.34	-0.43	4.21e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs13242816	1.000	rs7801950	chr7:116154783	C/T	cg02799643	chr7:116139180	CAV2	-0.44	-5.54	-0.45	1.74e-7	P wave duration;
TGCT	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.12	0.54	7.78e-11	Prudent dietary pattern;
TGCT	cis	rs9921338	0.961	rs4356497	chr16:11414196	C/G	cg00044050	chr16:11439710	C16orf75	0.95	7.39	0.55	1.92e-11	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	4.99	0.41	1.98e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg03806693	chr22:41940476	POLR3H	-1.13	-13.26	-0.77	1.59e-25	Vitiligo;
TGCT	cis	rs644799	1.000	rs627568	chr11:95569253	A/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.88	9.67	0.66	8.05e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs11785400	1.000	rs11776301	chr8:143737142	A/G	cg24634471	chr8:143751801	JRK	0.6	6.5	0.5	1.75e-9	Schizophrenia;
TGCT	cis	rs933688	1.000	rs186717	chr5:90780467	T/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.06	10.57	0.69	5.07e-19	Smoking behavior;
TGCT	cis	rs2404602	0.716	rs8025134	chr15:76781729	C/T	cg22467129	chr15:76604101	ETFA	-0.55	-6.71	-0.52	6.16e-10	Blood metabolite levels;
TGCT	cis	rs6785206	0.527	rs60684891	chr3:128638959	A/G	cg25356066	chr3:128598488	ACAD9	-0.71	-4.45	-0.37	1.85e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg17775962	chr7:1200435	ZFAND2A	0.28	4.51	0.38	1.51e-5	Longevity;Endometriosis;
TGCT	cis	rs2073300	1.000	rs6137980	chr20:23466726	G/T	cg09953122	chr20:23471693	CST8	-0.68	-4.7	-0.39	6.92e-6	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs7582180	0.614	rs6737217	chr2:101006267	T/G	cg08017756	chr2:100939284	LONRF2	-0.31	-5.07	-0.41	1.4e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7772486	0.597	rs1970306	chr6:146154543	A/G	cg05347473	chr6:146136440	FBXO30	0.66	6.2	0.49	7.84e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6429082	0.818	rs61836206	chr1:235638754	C/G	cg26050004	chr1:235667680	B3GALNT2	0.57	4.95	0.41	2.41e-6	Adiposity;
TGCT	cis	rs4460629	0.804	rs56112907	chr1:155070862	C/A	cg23973274	chr1:155060172	NA	-0.25	-4.64	-0.38	8.88e-6	Serum magnesium levels;
TGCT	cis	rs11190604	1.000	rs2295774	chr10:102265847	A/C	cg16342193	chr10:102329863	NA	-0.41	-5.18	-0.42	8.61e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs11690935	0.959	rs4667694	chr2:172605399	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.19	-12.78	-0.75	2.24e-24	Schizophrenia;
TGCT	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	8.55	0.61	3.84e-14	Platelet count;
TGCT	cis	rs9807989	0.507	rs3755266	chr2:103042712	G/A	cg03938978	chr2:103052716	IL18RAP	0.27	5.41	0.44	3.17e-7	Asthma;
TGCT	cis	rs10791097	0.694	rs10894275	chr11:130756251	C/T	cg12179176	chr11:130786555	SNX19	0.83	9.92	0.67	1.94e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs12449000	1	rs12449000	chr16:89872970	T/C	cg03388025	chr16:89894329	SPIRE2	0.5	8.11	0.59	4.19e-13	Schizophrenia;
TGCT	cis	rs12989701	1.000	rs6710467	chr2:127889932	C/T	cg08168897	chr2:127865431	BIN1	0.61	6.51	0.5	1.68e-9	Alzheimer's disease (late onset);
TGCT	cis	rs2760061	0.583	rs1636195	chr1:228211589	T/C	cg18477163	chr1:228402036	OBSCN	0.34	7.02	0.53	1.27e-10	Diastolic blood pressure;
TGCT	cis	rs986417	0.901	rs10134736	chr14:60998540	A/T	cg27398547	chr14:60952738	C14orf39	1.49	8.69	0.62	1.81e-14	Gut microbiota (bacterial taxa);
TGCT	cis	rs7225537	0.559	rs4985721	chr17:16992544	C/A	cg26176665	chr17:16994978	MPRIP	0.24	5.81	0.46	4.88e-8	Mean platelet volume;
TGCT	cis	rs8020441	0.588	rs67977855	chr14:51184662	G/T	cg04730355	chr14:51134070	SAV1	1.01	7.33	0.55	2.58e-11	Cognitive performance;
TGCT	cis	rs2688608	0.933	rs2688614	chr10:75652876	G/A	cg19442545	chr10:75533431	FUT11	-0.29	-4.63	-0.38	8.99e-6	Inflammatory bowel disease;
TGCT	cis	rs12753569	0.748	rs1340689	chr1:76506409	T/A	cg00791851	chr1:76518896	NA	0.34	4.46	0.37	1.8e-5	Personality dimensions;
TGCT	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.7	-0.39	6.79e-6	Prudent dietary pattern;
TGCT	cis	rs9985766	1.000	rs28439804	chr4:151007375	G/A	cg05926478	chr4:151174724	DCLK2	-0.26	-5.19	-0.42	8.26e-7	Coronary artery disease;Myocardial infarction;
TGCT	cis	rs208520	0.526	rs7776413	chr6:66783241	A/G	cg07460842	chr6:66804631	NA	-1.08	-15.95	-0.82	8.03e-32	Exhaled nitric oxide output;
TGCT	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg09359103	chr1:154839909	KCNN3	-0.71	-15.31	-0.81	2.37e-30	Prostate cancer;
TGCT	cis	rs7224685	0.569	rs68060817	chr17:3995188	T/C	cg09580393	chr17:4869866	SPAG7	-0.39	-4.49	-0.37	1.62e-5	Type 2 diabetes;
TGCT	cis	rs9653442	0.545	rs11123813	chr2:100765692	C/T	cg07810366	chr2:100720526	AFF3	-0.35	-5.24	-0.43	6.82e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs12220238	1.000	rs4745740	chr10:75942469	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.78	0.57	2.42e-12	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs35883536	0.528	rs1855800	chr1:101030641	G/A	cg10298815	chr1:101004474	GPR88	0.25	4.68	0.39	7.46e-6	Monocyte count;
TGCT	cis	rs67311347	1.000	rs9865348	chr3:40397658	A/C	cg13409248	chr3:40428643	ENTPD3	0.54	4.52	0.38	1.41e-5	Renal cell carcinoma;
TGCT	cis	rs9368481	0.761	rs4358615	chr6:26998567	A/G	cg18867708	chr6:26865862	GUSBL1	0.38	5.21	0.42	7.7300000000000005e-07	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-6.74	-0.52	5.26e-10	Alzheimer's disease;
TGCT	cis	rs116095464	0.558	rs9312956	chr5:201812	T/C	cg22857025	chr5:266934	NA	-0.35	-6.52	-0.51	1.63e-9	Breast cancer;
TGCT	cis	rs2404602	0.735	rs12906143	chr15:76709523	T/A	cg22467129	chr15:76604101	ETFA	0.52	5.5	0.44	2.05e-7	Blood metabolite levels;
TGCT	cis	rs854765	0.647	rs854809	chr17:18006539	C/T	cg04398451	chr17:18023971	MYO15A	-0.38	-6.48	-0.5	1.91e-9	Total body bone mineral density;
TGCT	cis	rs7772486	0.875	rs7739371	chr6:146424353	C/G	cg13319975	chr6:146136371	FBXO30	-0.51	-4.48	-0.37	1.69e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs909002	0.789	rs3817398	chr1:32119431	C/T	cg11573219	chr1:32083031	HCRTR1	0.43	5.56	0.45	1.59e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9372498	0.536	rs1319987	chr6:118782236	A/G	cg21191810	chr6:118973309	C6orf204	-0.37	-4.77	-0.39	5.03e-6	Diastolic blood pressure;
TGCT	cis	rs916888	0.610	rs199438	chr17:44791643	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.58	4.46	0.37	1.79e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs17473412	1.000	rs10519723	chr5:122711641	T/C	cg15125798	chr5:122621645	NA	-0.6	-5.38	-0.43	3.61e-7	Total body bone mineral density;
TGCT	cis	rs2580764	0.565	rs2919129	chr2:55216545	G/T	cg09592903	chr2:55203963	RTN4	0.25	5.63	0.45	1.15e-7	Mean platelet volume;
TGCT	cis	rs10892173	0.846	rs7943887	chr11:117670282	C/G	cg07621104	chr11:117668040	DSCAML1	0.51	5.55	0.45	1.66e-7	Myopia;
TGCT	cis	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg07424592	chr7:64974309	NA	1.27	7.84	0.58	1.8e-12	Diabetic kidney disease;
TGCT	cis	rs868036	0.609	rs28742003	chr15:68127769	C/T	cg05925327	chr15:68127851	NA	-0.48	-4.6	-0.38	1.05e-5	Restless legs syndrome;
TGCT	cis	rs4478858	0.684	rs4949373	chr1:31741577	G/A	cg00250761	chr1:31883323	NA	-0.25	-4.52	-0.38	1.45e-5	Alcohol dependence;
TGCT	cis	rs9400467	0.506	rs73530915	chr6:111457448	A/G	cg15721981	chr6:111408429	SLC16A10	0.71	4.59	0.38	1.05e-5	Blood metabolite levels;Amino acid levels;
TGCT	cis	rs36051895	0.625	rs12340344	chr9:5176281	C/A	cg02405213	chr9:5042618	JAK2	-0.76	-10.62	-0.69	3.91e-19	Pediatric autoimmune diseases;
TGCT	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs346785	0.692	rs7225131	chr17:74290097	T/A	cg09812376	chr17:74270190	QRICH2	-0.36	-5.33	-0.43	4.43e-7	White matter hyperintensities in ischemic stroke;
TGCT	cis	rs12989701	0.935	rs12994284	chr2:127874020	T/C	cg08168897	chr2:127865431	BIN1	0.5	5.34	0.43	4.28e-7	Alzheimer's disease (late onset);
TGCT	cis	rs2046867	0.908	rs62251648	chr3:72806083	A/G	cg25664220	chr3:72788482	NA	-0.56	-7.15	-0.54	6.59e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7937682	0.575	rs7930208	chr11:111741463	T/C	cg09085632	chr11:111637200	PPP2R1B	0.88	8.47	0.61	5.93e-14	Primary sclerosing cholangitis;
TGCT	cis	rs2288278	0.601	rs2325948	chr17:46574491	C/T	cg25032089	chr17:46643351	HOXB3	-0.4	-4.87	-0.4	3.36e-6	Hand grip strength;
TGCT	cis	rs12681287	0.546	rs12546802	chr8:87499335	T/A	cg27223183	chr8:87520930	FAM82B	-0.92	-6.79	-0.52	4.12e-10	Caudate activity during reward;
TGCT	cis	rs62244186	0.683	rs6766334	chr3:44567065	T/C	cg04389838	chr3:44770851	ZNF501	-0.42	-5.67	-0.45	9.66e-8	Depressive symptoms;
TGCT	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg22105103	chr4:187893119	NA	-0.33	-4.78	-0.39	4.94e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs35146811	0.538	rs3823642	chr7:99796072	T/C	cg13334819	chr7:99746414	C7orf59	-0.74	-6.31	-0.49	4.4e-9	Coronary artery disease;
TGCT	cis	rs6121246	0.529	rs2889528	chr20:30210021	C/T	cg13852791	chr20:30311386	BCL2L1	0.7	4.58	0.38	1.1e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs889312	0.500	rs832580	chr5:56172646	T/C	cg12311346	chr5:56204834	C5orf35	-0.46	-5.0	-0.41	1.87e-6	Breast cancer;Breast cancer (early onset);
TGCT	cis	rs526231	0.819	rs2561476	chr5:102608834	T/C	cg05225461	chr5:102596755	C5orf30	0.23	4.65	0.39	8.39e-6	Primary biliary cholangitis;
TGCT	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs78487399	0.808	rs7559842	chr2:43673442	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-5.09	-0.42	1.3e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs9457247	0.967	rs424185	chr6:167410907	C/T	cg23791538	chr6:167370224	RNASET2	-0.49	-4.96	-0.41	2.31e-6	Crohn's disease;
TGCT	trans	rs7618501	0.501	rs7627864	chr3:49926613	C/G	cg21659725	chr3:3221576	CRBN	0.68	7.77	0.57	2.53e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs4252435	0.520	rs76184304	chr7:142633490	C/G	cg21621906	chr7:142494914	NA	-1.09	-4.56	-0.38	1.22e-5	Cancer;
TGCT	cis	rs7312933	0.703	rs10880259	chr12:42558003	T/C	cg19980929	chr12:42632907	YAF2	0.47	6.46	0.5	2.13e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs8072100	0.967	rs4793842	chr17:45671506	G/A	cg08085267	chr17:45401833	C17orf57	0.43	4.63	0.38	9.02e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs10992471	0.756	rs10115222	chr9:95128149	C/T	cg13798575	chr9:95087839	CENPP;NOL8	0.61	6.26	0.49	5.73e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs6964587	1.000	rs6969536	chr7:91689351	C/G	cg17063962	chr7:91808500	NA	0.88	9.65	0.66	8.73e-17	Breast cancer;
TGCT	cis	rs1056107	0.866	rs12351043	chr9:115003292	G/A	cg02332936	chr9:115140584	NA	-0.25	-4.44	-0.37	1.96e-5	Colorectal cancer;
TGCT	cis	rs9399137	0.507	rs7754722	chr6:135260303	T/C	cg24558204	chr6:135376177	HBS1L	-0.52	-5.24	-0.43	6.6e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
TGCT	trans	rs28595532	0.702	rs55981733	chr4:119306600	G/A	cg26518628	chr1:97050305	NA	-0.61	-7.35	-0.55	2.35e-11	Cannabis dependence symptom count;
TGCT	cis	rs7959452	0.557	rs7980883	chr12:69778914	C/T	cg20891283	chr12:69753455	YEATS4	0.83	8.7	0.62	1.68e-14	Blood protein levels;
TGCT	cis	rs9926296	0.656	rs7191144	chr16:89823393	C/T	cg04287289	chr16:89883240	FANCA	0.63	6.24	0.49	6.2e-9	Vitiligo;
TGCT	cis	rs6484504	0.553	rs2183484	chr11:31259370	G/A	cg14844989	chr11:31128820	NA	-0.25	-4.84	-0.4	3.76e-6	Red blood cell count;
TGCT	cis	rs8077889	0.917	rs58080788	chr17:41902909	A/G	cg26893861	chr17:41843967	DUSP3	1.09	13.08	0.76	4.26e-25	Triglycerides;
TGCT	cis	rs910316	0.967	rs12890371	chr14:75593839	T/C	cg23033748	chr14:75592666	NEK9	0.28	4.79	0.39	4.73e-6	Height;
TGCT	cis	rs8050907	0.744	rs55810554	chr16:4524392	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.53	4.57	0.38	1.15e-5	Obesity-related traits;
TGCT	cis	rs11785400	0.793	rs4587307	chr8:143738529	G/A	cg24634471	chr8:143751801	JRK	0.55	5.51	0.44	1.99e-7	Schizophrenia;
TGCT	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg12311346	chr5:56204834	C5orf35	0.85	7.78	0.57	2.42e-12	Initial pursuit acceleration;
TGCT	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg13732083	chr21:47605072	C21orf56	-0.36	-4.68	-0.39	7.39e-6	Testicular germ cell tumor;
TGCT	cis	rs67311347	0.955	rs11717036	chr3:40379578	G/T	cg13683864	chr3:40499215	RPL14	1.0	10.45	0.68	1.05e-18	Renal cell carcinoma;
TGCT	cis	rs2180341	1.000	rs6569480	chr6:127621748	A/G	cg24812749	chr6:127587940	RNF146	0.87	7.21	0.54	4.85e-11	Breast cancer;
TGCT	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg01516881	chr6:292596	DUSP22	0.75	8.01	0.58	7.08e-13	Menopause (age at onset);
TGCT	cis	rs6570726	0.764	rs4263604	chr6:145916697	A/G	cg23711669	chr6:146136114	FBXO30	0.88	9.32	0.64	5.56e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9527	0.590	rs2148198	chr10:104915310	A/G	cg04362960	chr10:104952993	NT5C2	-0.68	-5.81	-0.46	4.96e-8	Arsenic metabolism;
TGCT	cis	rs7474896	0.583	rs11011346	chr10:38009483	C/T	cg25427524	chr10:38739819	LOC399744	-0.32	-5.1	-0.42	1.23e-6	Obesity (extreme);
TGCT	cis	rs1534166	1.000	rs1534166	chr3:133537067	C/T	cg08048268	chr3:133502702	NA	-0.41	-4.47	-0.37	1.73e-5	Alcohol consumption (transferrin glycosylation);
TGCT	cis	rs6840360	0.571	rs11932059	chr4:152524496	G/A	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.0	-0.58	7.69e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs1046896	0.520	rs9895409	chr17:80902719	C/T	cg03160526	chr17:80928410	B3GNTL1	0.34	4.76	0.39	5.38e-6	Glycated hemoglobin levels;
TGCT	cis	rs7267979	1.000	rs12428	chr20:25433821	G/T	cg16686733	chr20:25566563	NINL	-0.54	-5.49	-0.44	2.13e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11696501	0.739	rs6104252	chr20:44254323	G/A	cg11783356	chr20:44313418	WFDC10B	-0.32	-4.63	-0.38	9.25e-6	Brain structure;
TGCT	cis	rs10789491	1.000	rs12794	chr1:47141718	T/C	cg15501359	chr1:47185051	KIAA0494	0.81	8.17	0.59	2.99e-13	Response to hepatitis C treatment;
TGCT	cis	rs5760092	0.755	rs11090298	chr22:24262061	G/A	cg10150615	chr22:24372951	LOC391322	0.87	7.63	0.57	5.29e-12	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs9926296	0.632	rs4785716	chr16:89801127	T/C	cg04287289	chr16:89883240	FANCA	0.67	6.64	0.51	8.68e-10	Vitiligo;
TGCT	cis	rs7582180	0.629	rs12617779	chr2:100937707	G/A	cg08017756	chr2:100939284	LONRF2	-0.3	-4.78	-0.39	4.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2997447	0.761	rs17184891	chr1:26447557	A/T	cg03844060	chr1:26490628	NA	0.28	4.55	0.38	1.27e-5	QRS complex (12-leadsum);
TGCT	cis	rs4319547	0.620	rs12372756	chr12:122815130	A/G	cg08088222	chr12:122070432	ORAI1	0.26	4.69	0.39	7.14e-6	Body mass index;
TGCT	trans	rs12339966	0.581	rs17788370	chr9:11338859	T/G	cg03488587	chr11:64876988	C11orf2	0.32	7.04	0.53	1.16e-10	Systolic blood pressure;
TGCT	cis	rs1865760	0.515	rs2003208	chr6:25940719	G/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.63	6.65	0.51	8.58e-10	Height;
TGCT	cis	rs7119038	0.580	rs7123726	chr11:118694547	T/C	cg19308663	chr11:118741387	NA	0.27	5.67	0.45	9.63e-8	Sjögren's syndrome;
TGCT	cis	rs4595586	0.545	rs7967931	chr12:39375162	A/C	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs6912958	0.781	rs6454632	chr6:88231824	A/C	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.91	-0.4	2.78e-6	Monocyte percentage of white cells;
TGCT	cis	rs7582180	0.638	rs9973536	chr2:100942243	C/T	cg08017756	chr2:100939284	LONRF2	-0.3	-4.92	-0.4	2.7e-6	Intelligence (multi-trait analysis);
TGCT	trans	rs7615952	0.866	rs13063119	chr3:125643847	G/A	cg07211511	chr3:129823064	LOC729375	-0.48	-8.0	-0.58	7.7e-13	Blood pressure (smoking interaction);
TGCT	cis	rs910316	1.000	rs12589876	chr14:75544189	G/A	cg11812906	chr14:75593930	NEK9	0.74	7.18	0.54	5.58e-11	Height;
TGCT	cis	rs7804356	1.000	rs73065504	chr7:26825984	A/G	cg03456212	chr7:26904342	SKAP2	-0.63	-4.84	-0.4	3.71e-6	Type 1 diabetes;
TGCT	cis	rs826838	0.838	rs11183646	chr12:38799846	A/T	cg26384229	chr12:38710491	ALG10B	1.06	10.68	0.69	2.84e-19	Heart rate;
TGCT	trans	rs1496653	0.602	rs13092830	chr3:23363858	C/G	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs4843747	0.671	rs13334603	chr16:88116016	T/C	cg06915872	chr16:87998081	BANP	-0.3	-4.57	-0.38	1.14e-5	Menopause (age at onset);
TGCT	cis	rs861020	0.606	rs657844	chr1:210006873	T/G	cg05527609	chr1:210001259	C1orf107	0.86	7.54	0.56	8.69e-12	Orofacial clefts;
TGCT	cis	rs9341808	0.683	rs9359409	chr6:80826897	C/G	cg08355045	chr6:80787529	NA	0.32	5.83	0.46	4.48e-8	Sitting height ratio;
TGCT	cis	rs250677	0.958	rs36068	chr5:148417512	C/T	cg23229984	chr5:148520753	ABLIM3	0.21	4.81	0.4	4.35e-6	Breast cancer;
TGCT	cis	rs9653442	0.545	rs4851257	chr2:100775297	C/T	cg22139774	chr2:100720529	AFF3	-0.36	-5.69	-0.46	8.67e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs6674176	0.628	rs2301993	chr1:44426025	G/A	cg12908607	chr1:44402522	ARTN	-0.67	-8.15	-0.59	3.4e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs2836950	0.545	rs11700449	chr21:40522419	A/T	cg11890956	chr21:40555474	PSMG1	-0.72	-7.12	-0.54	7.51e-11	Menarche (age at onset);
TGCT	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg12963246	chr6:28129442	ZNF389	0.51	5.02	0.41	1.73e-6	Depression;
TGCT	cis	rs739496	0.843	rs10774631	chr12:112023001	A/G	cg10833066	chr12:111807467	FAM109A	-0.39	-5.38	-0.43	3.6e-7	Platelet count;
TGCT	cis	rs11677370	0.574	rs10190477	chr2:3862738	A/G	cg17052675	chr2:3827356	NA	0.43	6.82	0.52	3.48e-10	Type 2 diabetes;
TGCT	cis	rs7647973	0.710	rs1532204	chr3:49609477	C/G	cg05785598	chr3:49045655	WDR6	0.41	4.66	0.39	8.03e-6	Menarche (age at onset);
TGCT	cis	rs7010267	0.570	rs6469794	chr8:120016099	C/T	cg17171407	chr8:119960777	TNFRSF11B	0.26	4.59	0.38	1.06e-5	Total body bone mineral density (age 45-60);
TGCT	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg24846343	chr22:24311635	DDTL	0.21	5.34	0.43	4.21e-7	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2204008	0.627	rs10878488	chr12:38148666	G/A	cg26384229	chr12:38710491	ALG10B	0.85	7.47	0.56	1.27e-11	Bladder cancer;
TGCT	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	5.12	0.42	1.11e-6	Alzheimer's disease;
TGCT	cis	rs7666738	0.830	rs11097606	chr4:99011486	C/T	cg17366294	chr4:99064904	C4orf37	0.66	6.55	0.51	1.35e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4654899	0.758	rs6698462	chr1:21341293	G/C	cg01072550	chr1:21505969	NA	-0.55	-8.93	-0.63	4.73e-15	Superior frontal gyrus grey matter volume;
TGCT	cis	rs13217239	0.646	rs10946888	chr6:26951678	A/G	cg02458000	chr6:26745757	NA	0.49	4.53	0.38	1.38e-5	Schizophrenia;
TGCT	cis	rs7584330	0.955	rs58643200	chr2:238389855	A/G	cg08992911	chr2:238395768	MLPH	0.67	5.44	0.44	2.69e-7	Prostate cancer;
TGCT	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg21724239	chr8:58056113	NA	0.44	4.72	0.39	6.3e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9457247	1.000	rs393727	chr6:167398632	T/A	cg23791538	chr6:167370224	RNASET2	-0.49	-4.96	-0.41	2.26e-6	Crohn's disease;
TGCT	cis	rs2762353	0.574	rs4419666	chr6:25693274	C/T	cg03517284	chr6:25882590	NA	0.9	8.79	0.62	1.04e-14	Blood metabolite levels;
TGCT	cis	rs10501293	0.667	rs1844277	chr11:42982685	G/A	cg03447554	chr11:43094025	NA	0.44	6.43	0.5	2.5e-9	Cognitive performance;
TGCT	cis	rs35146811	0.625	rs2906645	chr7:99817859	A/G	cg13334819	chr7:99746414	C7orf59	0.74	6.41	0.5	2.82e-9	Coronary artery disease;
TGCT	cis	rs78707713	0.560	rs55668536	chr10:71242655	A/G	cg14388049	chr10:71211838	TSPAN15	-0.39	-4.64	-0.38	8.88e-6	Venous thromboembolism;
TGCT	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9388451	0.839	rs980014	chr6:126068001	T/G	cg05901451	chr6:126070800	HEY2	-1.04	-15.8	-0.82	1.76e-31	Brugada syndrome;
TGCT	cis	rs7917772	0.503	rs10883732	chr10:104293461	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9399135	0.967	rs9389254	chr6:135330709	C/T	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.36e-6	Red blood cell count;
TGCT	cis	rs523522	0.892	rs4767916	chr12:121024032	T/C	cg12219531	chr12:120966889	COQ5	0.82	7.38	0.55	2.05e-11	High light scatter reticulocyte count;
TGCT	cis	rs62244186	0.566	rs2135531	chr3:44881158	C/G	cg25151919	chr3:44754333	ZNF502	-0.46	-5.39	-0.44	3.47e-7	Depressive symptoms;
TGCT	cis	rs7772486	0.790	rs6923545	chr6:146244743	A/G	cg05347473	chr6:146136440	FBXO30	-0.52	-5.03	-0.41	1.67e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2797160	1.000	rs2747714	chr6:126007620	A/G	cg05901451	chr6:126070800	HEY2	0.74	6.3	0.49	4.62e-9	Endometrial cancer;
TGCT	cis	rs11098499	0.708	rs11732686	chr4:120252330	C/A	cg09307838	chr4:120376055	NA	0.61	5.91	0.47	3.14e-8	Corneal astigmatism;
TGCT	cis	rs992157	0.835	rs12987180	chr2:219144089	G/A	cg00012203	chr2:219082015	ARPC2	-0.79	-7.87	-0.58	1.48e-12	Colorectal cancer;
TGCT	cis	rs11671005	0.735	rs34188294	chr19:58919557	G/A	cg13877915	chr19:58951672	ZNF132	0.62	4.68	0.39	7.3e-6	Mean platelet volume;
TGCT	cis	rs72945132	0.882	rs12289915	chr11:70131956	G/C	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs7572733	0.534	rs7604700	chr2:198718630	A/G	cg00792783	chr2:198669748	PLCL1	0.56	5.08	0.42	1.35e-6	Dermatomyositis;
TGCT	cis	rs2305707	0.867	rs16964228	chr15:51554955	C/T	cg19946085	chr15:51559439	CYP19A1	0.49	5.2	0.42	8.08e-7	Height;
TGCT	cis	rs933688	1.000	rs2052553	chr5:90729906	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.08	9.6	0.65	1.2e-16	Smoking behavior;
TGCT	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg13395646	chr4:1353034	KIAA1530	-0.41	-4.72	-0.39	6.24e-6	Longevity;
TGCT	cis	rs6088580	0.634	rs6059851	chr20:33047945	G/A	cg08999081	chr20:33150536	PIGU	0.29	5.6	0.45	1.31e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs2688608	0.967	rs2688609	chr10:75658181	A/G	cg04320760	chr10:75533139	FUT11	0.29	4.44	0.37	2e-5	Inflammatory bowel disease;
TGCT	cis	rs7582180	0.739	rs11123822	chr2:100911582	G/T	cg08017756	chr2:100939284	LONRF2	-0.28	-4.82	-0.4	4.18e-6	Intelligence (multi-trait analysis);
TGCT	trans	rs2727020	0.729	rs7924782	chr11:49267249	A/G	cg15704280	chr7:45808275	SEPT13	-0.78	-9.13	-0.63	1.58e-15	Coronary artery disease;
TGCT	cis	rs79349575	0.783	rs62078372	chr17:47028989	T/C	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.52	-0.38	1.44e-5	Type 2 diabetes;
TGCT	cis	rs12142240	0.698	rs56909107	chr1:46808224	A/C	cg14993813	chr1:46806288	NSUN4	-0.58	-4.81	-0.4	4.34e-6	Menopause (age at onset);
TGCT	cis	rs4689388	0.581	rs1801212	chr4:6302519	C/T	cg25554036	chr4:6271136	WFS1	0.53	6.36	0.5	3.56e-9	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs67311347	0.955	rs6773383	chr3:40377412	A/T	cg13683864	chr3:40499215	RPL14	-0.96	-9.72	-0.66	6.04e-17	Renal cell carcinoma;
TGCT	cis	rs7607369	0.648	rs7559490	chr2:219656867	A/T	cg02176678	chr2:219576539	TTLL4	-0.47	-6.0	-0.47	1.98e-8	Red blood cell count;Amyotrophic lateral sclerosis;
TGCT	cis	rs854765	0.663	rs2236513	chr17:17747366	A/C	cg04398451	chr17:18023971	MYO15A	0.31	4.65	0.39	8.49e-6	Total body bone mineral density;
TGCT	cis	rs66561647	0.634	rs10097497	chr8:128932363	A/G	cg11792826	chr8:129160931	MIR1208	0.21	4.83	0.4	3.95e-6	Hemoglobin concentration;
TGCT	cis	rs7223966	0.960	rs7212379	chr17:61706122	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	4.84	0.4	3.71e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs3749237	0.595	rs17595772	chr3:49409704	G/A	cg02487422	chr3:49467188	NICN1	0.59	6.01	0.47	1.92e-8	Resting heart rate;
TGCT	trans	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg17470723	chr8:74884337	TCEB1	0.72	6.94	0.53	1.91e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs28595532	0.920	rs116697254	chr4:119733603	T/C	cg14228332	chr4:119757509	SEC24D	1.32	6.38	0.5	3.2e-9	Cannabis dependence symptom count;
TGCT	cis	rs2692947	0.732	rs56847058	chr2:96406893	C/T	cg23100626	chr2:96804247	ASTL	0.37	4.49	0.37	1.62e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs7605378	0.528	rs812760	chr2:200724372	C/T	cg23649088	chr2:200775458	C2orf69	0.47	9.82	0.66	3.39e-17	Osteoporosis;
TGCT	cis	rs8068544	0.818	rs78333491	chr17:40163138	A/G	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.07	-5.1	-0.42	1.26e-6	Reticulocyte fraction of red cells;Reticulocyte count;
TGCT	cis	rs2797160	1.000	rs1777225	chr6:126018270	T/C	cg05901451	chr6:126070800	HEY2	0.73	6.29	0.49	5.01e-9	Endometrial cancer;
TGCT	cis	rs57221529	0.825	rs72703051	chr5:582997	G/A	cg16624210	chr5:671434	TPPP	0.42	4.48	0.37	1.67e-5	Lung disease severity in cystic fibrosis;
TGCT	cis	rs7617773	0.746	rs4371540	chr3:48353543	G/A	cg11946769	chr3:48343235	NME6	0.82	7.08	0.54	9.51e-11	Coronary artery disease;
TGCT	cis	rs523522	0.962	rs9040	chr12:120900274	C/T	cg27279351	chr12:120934652	DYNLL1	0.74	6.44	0.5	2.42e-9	High light scatter reticulocyte count;
TGCT	cis	rs9309473	0.583	rs35885918	chr2:73612234	T/C	cg20560298	chr2:73613845	ALMS1	-0.48	-5.37	-0.43	3.68e-7	Metabolite levels;
TGCT	cis	rs210138	1.000	rs210144	chr6:33547430	G/A	cg07679836	chr6:33548423	BAK1	0.4	5.57	0.45	1.52e-7	Testicular germ cell tumor;
TGCT	cis	rs3733585	0.624	rs58130873	chr4:9972081	T/C	cg00071950	chr4:10020882	SLC2A9	-0.57	-6.83	-0.52	3.41e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg01802117	chr1:53393560	SCP2	-0.44	-5.52	-0.44	1.86e-7	Monocyte count;
TGCT	cis	rs6725041	0.532	rs12623803	chr2:213201642	G/C	cg16329650	chr2:213403929	ERBB4	-0.67	-5.86	-0.47	3.89e-8	QT interval (ambient particulate matter interaction);
TGCT	cis	rs9905704	0.647	rs9898048	chr17:57108543	C/T	cg12560992	chr17:57184187	TRIM37	0.62	5.52	0.44	1.9e-7	Testicular germ cell tumor;
TGCT	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg08736216	chr1:53307985	ZYG11A	-0.24	-4.74	-0.39	5.75e-6	Monocyte count;
TGCT	cis	rs3091242	0.933	rs932372	chr1:25755014	G/A	cg23205692	chr1:25664452	TMEM50A	0.5	5.19	0.42	8.24e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs8072100	0.576	rs12948299	chr17:45403057	T/C	cg08085267	chr17:45401833	C17orf57	-0.67	-7.26	-0.55	3.74e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg13531842	chr10:38383804	ZNF37A	-0.38	-4.51	-0.38	1.49e-5	Extrinsic epigenetic age acceleration;
TGCT	cis	rs1059312	1.000	rs7970815	chr12:129288366	G/A	cg09035930	chr12:129282057	SLC15A4	0.58	11.32	0.71	7.78e-21	Systemic lupus erythematosus;
TGCT	cis	rs4654899	1.000	rs10799686	chr1:21486445	A/T	cg01072550	chr1:21505969	NA	0.51	8.26	0.6	1.91e-13	Superior frontal gyrus grey matter volume;
TGCT	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	4.93	0.4	2.63e-6	Menopause (age at onset);
TGCT	cis	rs1059312	1.000	rs7135854	chr12:129279988	G/C	cg09035930	chr12:129282057	SLC15A4	0.6	12.05	0.73	1.31e-22	Systemic lupus erythematosus;
TGCT	cis	rs17102423	0.760	rs2781375	chr14:65569597	A/G	cg11161011	chr14:65562177	MAX	-0.43	-5.85	-0.46	4.19e-8	Obesity-related traits;
TGCT	cis	rs2300747	0.872	rs10754445	chr1:117077459	A/T	cg26677431	chr1:117075710	CD58	-0.23	-4.56	-0.38	1.23e-5	Primary biliary cholangitis;Multiple sclerosis;
TGCT	trans	rs1814175	0.645	rs2140602	chr11:50022800	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.84	-0.7	1.13e-19	Height;
TGCT	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.81	0.46	4.88e-8	Alzheimer's disease;
TGCT	cis	rs55794721	0.509	rs6699113	chr1:25777743	C/T	cg23205692	chr1:25664452	TMEM50A	0.48	5.07	0.41	1.42e-6	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs3784262	0.565	rs12914603	chr15:58350896	C/G	cg12031962	chr15:58353849	ALDH1A2	-0.38	-5.57	-0.45	1.53e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs9660992	0.573	rs12140422	chr1:205187981	G/A	cg00857998	chr1:205179979	DSTYK	0.51	4.68	0.39	7.34e-6	Mean corpuscular volume;Mean platelet volume;
TGCT	cis	rs9393777	0.778	rs13219354	chr6:27185664	T/C	cg10876282	chr6:28092338	ZSCAN16	0.71	4.62	0.38	9.6e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2455799	0.517	rs1345158	chr3:15931704	G/T	cg12172478	chr3:16357591	RFTN1	-0.32	-4.66	-0.39	8.01e-6	Mean platelet volume;
TGCT	cis	rs7542091	0.635	rs7550733	chr1:210044968	G/A	cg23283495	chr1:209979779	IRF6	0.55	5.5	0.44	2.12e-7	Monobrow;
TGCT	cis	rs7044106	0.762	rs10760112	chr9:123467570	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.59	6.16	0.48	9.29e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs9291683	0.507	rs6845554	chr4:10013173	T/G	cg00071950	chr4:10020882	SLC2A9	0.66	7.82	0.57	1.96e-12	Bone mineral density;
TGCT	cis	rs9859260	0.555	rs9877493	chr3:195832147	T/C	cg02975922	chr3:195473998	MUC4	-0.24	-4.68	-0.39	7.34e-6	Mean corpuscular volume;
TGCT	cis	rs2295359	0.637	rs12044149	chr1:67600686	G/T	cg03340356	chr1:67600835	NA	0.46	5.4	0.44	3.21e-7	Psoriasis;
TGCT	cis	rs9300255	0.596	rs10734901	chr12:123743447	G/A	cg00376283	chr12:123451042	ABCB9	0.79	6.68	0.51	7.08e-10	Neutrophil percentage of white cells;
TGCT	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-8.64	-0.61	2.39e-14	Platelet count;
TGCT	cis	rs4953076	0.573	rs6726680	chr2:44406686	C/G	cg04920474	chr2:44395004	PPM1B	0.59	5.65	0.45	1.02e-7	Height;
TGCT	cis	rs10744422	1.000	rs936083	chr12:123338964	A/G	cg25930673	chr12:123319894	HIP1R	-0.86	-5.02	-0.41	1.72e-6	Schizophrenia;
TGCT	cis	rs6669919	0.933	rs10863899	chr1:211666218	A/G	cg26515805	chr1:211431828	RCOR3	-0.41	-4.72	-0.39	6.34e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6665290	0.935	rs12409755	chr1:227196949	A/T	cg10327440	chr1:227177885	CDC42BPA	-0.99	-20.13	-0.88	6.85e-41	Myeloid white cell count;
TGCT	cis	rs17376456	0.825	rs17374166	chr5:93238655	T/C	cg21475434	chr5:93447410	FAM172A	0.7	4.9	0.4	2.96e-6	Diabetic retinopathy;
TGCT	cis	rs696279	1.000	rs696279	chr7:16700798	A/G	cg08595592	chr7:16780162	NA	-0.24	-4.7	-0.39	6.86e-6	Mean platelet volume;
TGCT	cis	rs2239547	0.522	rs9842974	chr3:53011050	C/A	cg11645453	chr3:52864694	ITIH4	0.34	5.51	0.44	2.02e-7	Schizophrenia;
TGCT	cis	rs80282103	0.867	rs74117668	chr10:1076620	C/T	cg08668510	chr10:1095578	IDI1	1.18	5.51	0.44	2.02e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs2228479	0.702	rs62056100	chr16:89939753	C/T	cg06558623	chr16:89946397	TCF25	0.62	6.98	0.53	1.61e-10	Skin colour saturation;
TGCT	cis	rs1784581	0.588	rs10945792	chr6:162423484	C/T	cg17173639	chr6:162384350	PARK2	0.4	6.6	0.51	1.08e-9	Itch intensity from mosquito bite;
TGCT	cis	rs6546537	0.955	rs7590422	chr2:69883715	T/C	cg10773587	chr2:69614142	GFPT1	-0.68	-5.99	-0.47	2.13e-8	Serum thyroid-stimulating hormone levels;
TGCT	cis	rs1205863	1.000	rs1205873	chr6:11945345	C/T	cg07106625	chr6:11870215	NA	0.51	5.05	0.41	1.51e-6	Disc degeneration (lumbar);
TGCT	cis	rs6547741	1.000	rs10165098	chr2:27796526	C/T	cg27432699	chr2:27873401	GPN1	0.18	4.66	0.39	8.09e-6	Oral cavity cancer;
TGCT	cis	rs9921222	0.565	rs10903014	chr16:377623	A/G	cg10349874	chr16:420996	TMEM8A;MRPL28	-0.28	-5.01	-0.41	1.84e-6	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs17401966	0.931	rs12130563	chr1:10428452	G/A	cg19773385	chr1:10388646	KIF1B	-0.24	-5.5	-0.44	2.03e-7	Hepatocellular carcinoma;
TGCT	cis	rs778371	0.874	rs1083522	chr2:233745521	C/T	cg08000102	chr2:233561755	GIGYF2	-0.6	-6.42	-0.5	2.62e-9	Schizophrenia;
TGCT	cis	rs752092	1.000	rs11636578	chr15:101787969	T/C	cg25114630	chr15:101792522	CHSY1	0.56	5.42	0.44	2.95e-7	Corneal structure;
TGCT	cis	rs3771570	1.000	rs56222556	chr2:242364119	G/A	cg21155796	chr2:242212141	HDLBP	0.94	6.69	0.51	6.97e-10	Prostate cancer;
TGCT	cis	rs35306767	0.761	rs12773961	chr10:1013215	C/G	cg26597838	chr10:835615	NA	0.58	6.43	0.5	2.46e-9	Eosinophil percentage of granulocytes;
TGCT	cis	rs7542091	0.704	rs1883331	chr1:210043483	A/G	cg00989853	chr1:209979345	IRF6	0.43	4.58	0.38	1.12e-5	Monobrow;
TGCT	cis	rs7095607	0.560	rs2255381	chr10:69923535	C/T	cg18986048	chr10:69913749	MYPN	0.53	5.54	0.45	1.7e-7	Lung function (FVC);
TGCT	cis	rs17601876	0.814	rs8039089	chr15:51561328	T/G	cg19946085	chr15:51559439	CYP19A1	-0.33	-5.06	-0.41	1.45e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs6964587	1.000	rs6465347	chr7:91693837	A/G	cg22709100	chr7:91322751	NA	0.28	4.56	0.38	1.19e-5	Breast cancer;
TGCT	cis	rs9787249	0.957	rs10888958	chr1:40211737	T/C	cg20968010	chr1:40505947	CAP1	-0.53	-5.0	-0.41	1.91e-6	Blood protein levels;
TGCT	cis	rs1018836	0.892	rs4735210	chr8:91549399	G/T	cg16814680	chr8:91681699	NA	-0.78	-8.29	-0.6	1.62e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1729951	0.546	rs361246	chr3:136695667	G/A	cg12473912	chr3:136751656	NA	0.39	6.18	0.49	8.62e-9	Neuroticism;
TGCT	cis	rs9611519	1.000	rs4820433	chr22:41607065	C/G	cg03806693	chr22:41940476	POLR3H	-0.66	-6.3	-0.49	4.65e-9	Neuroticism;
TGCT	cis	rs7216064	0.953	rs12450907	chr17:65870644	T/G	cg12091567	chr17:66097778	LOC651250	-0.83	-6.49	-0.5	1.9e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs7091068	0.518	rs1543580	chr10:95446811	C/T	cg20715218	chr10:95462985	C10orf4	0.52	5.46	0.44	2.46e-7	Urinary tract infection frequency;
TGCT	cis	rs6964587	0.967	rs410	chr7:91557425	C/G	cg17063962	chr7:91808500	NA	-0.88	-9.29	-0.64	6.5e-16	Breast cancer;
TGCT	cis	rs79349575	0.783	rs12453374	chr17:46994846	G/C	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.51	-0.38	1.48e-5	Type 2 diabetes;
TGCT	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg00149659	chr3:10157352	C3orf10	1.11	7.56	0.56	7.81e-12	Alzheimer's disease;
TGCT	cis	rs6964587	0.967	rs10953065	chr7:91808915	A/G	cg17063962	chr7:91808500	NA	-0.92	-9.84	-0.66	3.11e-17	Breast cancer;
TGCT	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg23806715	chr17:73775811	H3F3B	0.55	4.55	0.38	1.26e-5	Psoriasis;
TGCT	cis	rs13326165	0.760	rs9861879	chr3:52424001	A/G	cg07884673	chr3:53033167	SFMBT1	0.4	4.86	0.4	3.45e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	trans	rs629535	0.748	rs689410	chr8:70037558	G/A	cg21567404	chr3:27674614	NA	0.58	9.18	0.64	1.22e-15	Dupuytren's disease;
TGCT	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg23708337	chr7:1209742	NA	0.54	4.79	0.4	4.62e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs11098499	0.874	rs7661020	chr4:120106982	T/C	cg09307838	chr4:120376055	NA	0.5	4.64	0.38	8.86e-6	Corneal astigmatism;
TGCT	cis	rs6912958	0.559	rs1201409	chr6:88055264	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.44	5.82	0.46	4.73e-8	Monocyte percentage of white cells;
TGCT	cis	rs7666738	0.830	rs72882693	chr4:98960804	T/A	cg05340658	chr4:99064831	C4orf37	0.53	5.93	0.47	2.85e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs240768	0.511	rs61289570	chr6:101403098	C/T	cg12253828	chr6:101329408	ASCC3	1.36	6.32	0.49	4.33e-9	Economic and political preferences (immigration/crime);
TGCT	cis	rs17253792	0.822	rs79291233	chr14:56065302	G/C	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs13217239	0.646	rs7451149	chr6:27057518	A/G	cg02458000	chr6:26745757	NA	-0.53	-4.88	-0.4	3.17e-6	Schizophrenia;
TGCT	cis	rs928736	0.599	rs1000005	chr21:34433051	C/G	cg10915739	chr21:34405733	NA	0.41	5.13	0.42	1.09e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs7539409	0.831	rs10874417	chr1:84220731	C/T	cg10977910	chr1:84465055	TTLL7	-0.79	-4.81	-0.4	4.32e-6	Alzheimer's disease;
TGCT	trans	rs1499614	1.000	rs2659911	chr7:66158420	G/A	cg07424592	chr7:64974309	NA	1.35	8.11	0.59	4.14e-13	Gout;
TGCT	cis	rs889312	0.500	rs252903	chr5:56117952	A/G	cg12311346	chr5:56204834	C5orf35	-0.49	-5.44	-0.44	2.77e-7	Breast cancer;Breast cancer (early onset);
TGCT	cis	rs6815814	0.898	rs1873195	chr4:38891173	C/T	cg02016764	chr4:38805732	TLR1	-0.34	-5.02	-0.41	1.79e-6	Breast cancer;
TGCT	trans	rs208520	0.754	rs851594	chr6:66876695	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-10.31	-0.68	2.29e-18	Exhaled nitric oxide output;
TGCT	cis	rs10464366	0.746	rs34792397	chr7:39146331	G/A	cg18850127	chr7:39170497	POU6F2	0.28	5.93	0.47	2.76e-8	IgG glycosylation;
TGCT	cis	rs6964587	1.000	rs11981461	chr7:91692662	A/G	cg22709100	chr7:91322751	NA	0.28	4.56	0.38	1.19e-5	Breast cancer;
TGCT	cis	rs9549260	0.755	rs4429172	chr13:41189143	C/A	cg21288729	chr13:41239152	FOXO1	1.02	10.32	0.68	2.17e-18	Red blood cell count;
TGCT	cis	rs4319547	0.915	rs3803005	chr12:123110654	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.69	-5.47	-0.44	2.39e-7	Body mass index;
TGCT	cis	rs2980439	0.525	rs1850511	chr8:8170329	T/A	cg08975724	chr8:8085496	FLJ10661	0.55	4.69	0.39	7.06e-6	Neuroticism;
TGCT	cis	rs344364	0.511	rs2982446	chr16:1947153	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.45	-5.08	-0.42	1.35e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs9682041	1.000	rs4955588	chr3:170072864	C/A	cg07589077	chr3:170072950	NA	0.32	5.24	0.43	6.78e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs2153535	0.580	rs2327064	chr6:8454052	C/T	cg07606381	chr6:8435919	SLC35B3	0.52	4.9	0.4	2.92e-6	Motion sickness;
TGCT	cis	rs6714710	0.603	rs35424768	chr2:98395653	A/C	cg26665480	chr2:98280029	ACTR1B	0.66	6.24	0.49	6.33e-9	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs1881797	0.872	rs12408686	chr1:247691141	C/T	cg14830002	chr1:247616686	OR2B11	0.39	4.46	0.37	1.81e-5	Acute lymphoblastic leukemia (childhood);
TGCT	cis	rs10883723	0.579	rs1967815	chr10:104287051	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.7	6.15	0.48	9.9e-9	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs6121246	0.567	rs7361893	chr20:30200751	C/T	cg13852791	chr20:30311386	BCL2L1	0.7	4.68	0.39	7.29e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.11	14.36	0.79	3.89e-28	Height;
TGCT	cis	rs6570726	1.000	rs373778	chr6:145873252	C/T	cg05347473	chr6:146136440	FBXO30	0.5	4.46	0.37	1.82e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg25036284	chr2:26402008	FAM59B	-0.57	-4.99	-0.41	1.99e-6	Gut microbiome composition (summer);
TGCT	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg09263875	chr16:632152	PIGQ	0.31	6.88	0.53	2.65e-10	Height;
TGCT	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg04944784	chr2:26401820	FAM59B	0.76	6.24	0.49	6.46e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs28735056	0.904	rs12953738	chr18:77627877	A/G	cg20368463	chr18:77673604	PQLC1	0.4	4.89	0.4	3.09e-6	Schizophrenia;
TGCT	cis	rs7264396	0.524	rs3790136	chr20:34143278	A/T	cg23834711	chr20:33872785	EIF6	0.75	4.59	0.38	1.05e-5	Total cholesterol levels;
TGCT	cis	rs7772486	0.875	rs854146	chr6:146341033	A/G	cg13319975	chr6:146136371	FBXO30	-0.53	-4.8	-0.4	4.46e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4727027	0.933	rs13225884	chr7:148857795	A/G	cg23583168	chr7:148888333	NA	-0.69	-8.86	-0.62	6.94e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg22920501	chr2:26401640	FAM59B	-0.73	-6.44	-0.5	2.35e-9	Gut microbiome composition (summer);
TGCT	trans	rs77457752	0.690	rs12335400	chr9:13912195	A/G	cg23609682	chr1:3070786	PRDM16	0.51	7.14	0.54	6.89e-11	Breast cancer;
TGCT	cis	rs858239	0.601	rs6461702	chr7:23249273	C/G	cg05602783	chr7:23145260	KLHL7	-0.72	-5.65	-0.45	1.04e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs62244186	0.545	rs9284880	chr3:44759389	C/T	cg15687855	chr3:44754131	ZNF502	-0.52	-6.31	-0.49	4.58e-9	Depressive symptoms;
TGCT	cis	rs16958440	0.867	rs77348110	chr18:44674167	T/C	cg17192377	chr18:44677553	HDHD2	0.61	4.85	0.4	3.65e-6	Sitting height ratio;
TGCT	cis	rs7267979	1.000	rs6115140	chr20:25285507	C/A	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs8050907	0.744	rs17137053	chr16:4524155	C/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.53	4.57	0.38	1.15e-5	Obesity-related traits;
TGCT	cis	rs9527	0.615	rs7080462	chr10:104736699	T/C	cg04362960	chr10:104952993	NT5C2	0.66	5.55	0.45	1.66e-7	Arsenic metabolism;
TGCT	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg05985448	chr10:134359359	INPP5A	0.23	5.03	0.41	1.68e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs7917772	0.503	rs11191326	chr10:104302959	C/T	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs4499344	0.622	rs10401677	chr19:33061120	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.6	4.97	0.41	2.2e-6	Mean platelet volume;
TGCT	cis	rs9467773	0.572	rs62394558	chr6:26604650	G/A	cg05738196	chr6:26577821	NA	0.87	10.31	0.68	2.25e-18	Intelligence (multi-trait analysis);
TGCT	cis	rs3806933	0.522	rs12515367	chr5:110447853	A/G	cg04022379	chr5:110408740	TSLP	0.6	6.25	0.49	6.08e-9	Eosinophilic esophagitis;
TGCT	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs17401966	0.838	rs4475756	chr1:10387788	A/G	cg19773385	chr1:10388646	KIF1B	-0.23	-5.53	-0.44	1.79e-7	Hepatocellular carcinoma;
TGCT	cis	rs6121246	0.529	rs6060118	chr20:30171209	T/C	cg13852791	chr20:30311386	BCL2L1	0.72	4.96	0.41	2.27e-6	Mean corpuscular hemoglobin;
TGCT	trans	rs2288327	0.557	rs7588593	chr2:179352450	T/C	cg18634211	chr1:26737262	LIN28	0.91	6.86	0.52	2.86e-10	Atrial fibrillation;
TGCT	cis	rs6759518	0.655	rs4665374	chr2:27413096	A/G	cg26210250	chr2:26863503	CIB4	-0.81	-4.48	-0.37	1.66e-5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
TGCT	cis	rs734999	0.545	rs10797441	chr1:2551660	T/G	cg18854424	chr1:2615690	NA	0.45	5.15	0.42	1e-6	Ulcerative colitis;
TGCT	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6674176	0.660	rs6680421	chr1:44408969	A/C	cg12908607	chr1:44402522	ARTN	0.72	9.1	0.63	1.86e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs2806561	0.765	rs1997866	chr1:23512524	A/G	cg12483005	chr1:23474871	LUZP1	0.38	4.74	0.39	5.77e-6	Height;
TGCT	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg11301795	chr4:187892539	NA	0.3	4.55	0.38	1.24e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs727505	1.000	rs2286175	chr7:124431032	G/A	cg23710748	chr7:124431027	NA	-0.26	-4.57	-0.38	1.16e-5	Lewy body disease;
TGCT	cis	rs1552244	0.608	rs7615408	chr3:10000186	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.62	4.57	0.38	1.15e-5	Alzheimer's disease;
TGCT	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg18876405	chr7:65276391	NA	0.31	4.8	0.4	4.53e-6	Aortic root size;
TGCT	cis	rs2288278	0.601	rs11079826	chr17:46597048	C/T	cg25032089	chr17:46643351	HOXB3	-0.43	-5.07	-0.41	1.43e-6	Hand grip strength;
TGCT	cis	rs7572733	0.534	rs1401095	chr2:198779867	C/T	cg00792783	chr2:198669748	PLCL1	-0.56	-5.11	-0.42	1.21e-6	Dermatomyositis;
TGCT	cis	rs1552244	0.882	rs9812006	chr3:10022658	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	5.46	0.44	2.47e-7	Alzheimer's disease;
TGCT	cis	rs2072499	0.750	rs55910626	chr1:156159909	C/G	cg25208724	chr1:156163844	SLC25A44	1.01	9.25	0.64	8.38e-16	Testicular germ cell tumor;
TGCT	cis	rs4699052	0.590	rs1356293	chr4:104288200	A/C	cg16532752	chr4:104119610	CENPE	-0.5	-4.75	-0.39	5.48e-6	Testicular germ cell tumor;
TGCT	cis	rs2439831	0.618	rs8023508	chr15:44176103	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.73	-5.46	-0.44	2.47e-7	Lung cancer in ever smokers;
TGCT	cis	rs12643440	0.538	rs62296685	chr4:17137580	T/C	cg22650099	chr4:17144496	NA	-0.45	-4.61	-0.38	9.97e-6	Metabolite levels (Pyroglutamine);
TGCT	cis	rs9467711	0.606	rs9348712	chr6:26366511	T/A	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9300255	0.739	rs2337934	chr12:123745359	A/G	cg00376283	chr12:123451042	ABCB9	0.72	5.54	0.45	1.76e-7	Neutrophil percentage of white cells;
TGCT	cis	rs12681287	0.640	rs4587306	chr8:87385511	T/C	cg27223183	chr8:87520930	FAM82B	0.89	6.61	0.51	1.04e-9	Caudate activity during reward;
TGCT	cis	rs6582630	0.519	rs12582285	chr12:38298753	C/T	cg13010199	chr12:38710504	ALG10B	0.57	4.45	0.37	1.89e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs6504340	0.793	rs56128659	chr17:46621828	T/A	cg25032089	chr17:46643351	HOXB3	0.56	5.23	0.43	6.86e-7	Primary tooth development (number of teeth);
TGCT	cis	rs2299587	0.554	rs2073562	chr8:17742929	A/G	cg01800426	chr8:17659068	MTUS1	-0.55	-4.96	-0.41	2.25e-6	Economic and political preferences;
TGCT	cis	rs858239	0.600	rs7799422	chr7:23128413	G/A	cg05602783	chr7:23145260	KLHL7	-0.6	-4.99	-0.41	2.02e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs2760061	0.583	rs3094911	chr1:228210179	A/G	cg18477163	chr1:228402036	OBSCN	0.35	7.23	0.54	4.44e-11	Diastolic blood pressure;
TGCT	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.39	5.19	0.42	8.48e-7	Lymphocyte counts;
TGCT	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg09359103	chr1:154839909	KCNN3	-0.64	-12.0	-0.73	1.72e-22	Prostate cancer;
TGCT	cis	rs7666738	0.927	rs11736876	chr4:98987206	A/G	cg18180107	chr4:99064573	C4orf37	0.56	4.54	0.38	1.3e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9372498	0.536	rs55899435	chr6:118812099	C/T	cg21191810	chr6:118973309	C6orf204	-0.35	-4.72	-0.39	6.2e-6	Diastolic blood pressure;
TGCT	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg15242686	chr22:24348715	GSTTP1	0.47	6.61	0.51	1.04e-9	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2562456	0.876	rs11668606	chr19:21737420	T/G	cg25650185	chr19:21324782	ZNF431	-0.64	-5.73	-0.46	7.12e-8	Pain;
TGCT	cis	rs7666738	0.830	rs11097608	chr4:99011693	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.83	0.46	4.6e-8	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs4332037	0.552	rs11773627	chr7:2002733	A/G	cg25206134	chr2:45395956	NA	0.89	7.1	0.54	8.38e-11	Bipolar disorder;
TGCT	cis	rs1215050	0.904	rs1727285	chr4:98978821	G/A	cg05340658	chr4:99064831	C4orf37	-0.46	-5.55	-0.45	1.67e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	trans	rs12655019	0.920	rs1466010	chr5:56213156	A/G	cg25190722	chr1:3801660	DFFB	0.63	7.15	0.54	6.66e-11	Breast cancer (early onset);
TGCT	cis	rs11585357	0.895	rs2977305	chr1:17613737	A/T	cg08277548	chr1:17600880	PADI3	0.96	9.72	0.66	5.97e-17	Hair shape;
TGCT	cis	rs2120019	0.935	rs34913788	chr15:75372617	A/C	cg11632617	chr15:75315747	PPCDC	-0.33	-4.78	-0.39	4.82e-6	Blood trace element (Zn levels);
TGCT	cis	rs4253772	0.637	rs8139035	chr22:46651367	A/G	cg09491104	chr22:46646882	C22orf40	-0.62	-6.49	-0.5	1.87e-9	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs6598955	0.950	rs6700455	chr1:26545864	T/C	cg04990556	chr1:26633338	UBXN11	0.87	10.34	0.68	1.87e-18	Obesity-related traits;
TGCT	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg10253484	chr15:75165896	SCAMP2	-0.57	-5.23	-0.43	6.92e-7	Breast cancer;
TGCT	cis	rs782590	0.967	rs782588	chr2:55841640	T/C	cg18811423	chr2:55921094	PNPT1	0.65	6.88	0.53	2.6e-10	Metabolic syndrome;
TGCT	cis	rs9486719	1.000	rs9486719	chr6:97060124	G/A	cg18709589	chr6:96969512	KIAA0776	-0.79	-6.08	-0.48	1.4e-8	Migraine;Coronary artery disease;
TGCT	cis	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg25427524	chr10:38739819	LOC399744	-0.39	-8.22	-0.59	2.35e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs35306767	0.903	rs11815185	chr10:923617	T/A	cg26597838	chr10:835615	NA	0.75	10.54	0.69	6.3e-19	Eosinophil percentage of granulocytes;
TGCT	cis	rs8064299	0.597	rs2053748	chr17:72775911	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	-0.91	-10.03	-0.67	1.04e-17	Monocyte count;
TGCT	cis	rs6688613	0.679	rs12116418	chr1:166944273	T/A	cg07049167	chr1:166818506	POGK	0.22	4.53	0.38	1.39e-5	Refractive astigmatism;
TGCT	cis	rs1801251	1.000	rs56777991	chr2:233635388	A/C	cg25237894	chr2:233734115	C2orf82	0.31	5.62	0.45	1.21e-7	Coronary artery disease;
TGCT	cis	rs6570726	0.791	rs9376953	chr6:145912226	G/T	cg05347473	chr6:146136440	FBXO30	0.53	4.92	0.4	2.74e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3935685	0.874	rs12911718	chr15:78004325	G/A	cg25212270	chr15:78015279	NA	0.26	5.63	0.45	1.12e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2115630	1.000	rs58581703	chr15:85276935	C/T	cg11189052	chr15:85197271	WDR73	-0.62	-6.0	-0.47	2e-8	P wave terminal force;
TGCT	cis	rs4900538	0.855	rs1210074	chr14:102889098	G/A	cg18135206	chr14:102964638	TECPR2	-0.2	-4.53	-0.38	1.39e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs2242116	0.734	rs4683294	chr3:46979013	C/G	cg02527881	chr3:46936655	PTH1R	0.3	5.65	0.45	1.02e-7	Birth weight;
TGCT	cis	rs6754311	0.597	rs2082729	chr2:136550109	C/T	cg07169764	chr2:136633963	MCM6	-0.66	-6.11	-0.48	1.2e-8	Mosquito bite size;
TGCT	cis	rs910316	0.967	rs4899549	chr14:75647494	G/A	cg11812906	chr14:75593930	NEK9	-0.72	-7.1	-0.54	8.47e-11	Height;
TGCT	cis	rs61931739	0.517	rs7313663	chr12:34417058	T/C	cg06521331	chr12:34319734	NA	-0.29	-4.59	-0.38	1.06e-5	Morning vs. evening chronotype;
TGCT	cis	rs7666738	0.830	rs17027090	chr4:98897923	G/T	cg18180107	chr4:99064573	C4orf37	0.53	4.81	0.4	4.23e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg06112835	chr11:68658793	MRPL21	0.47	8.07	0.59	5.3e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg03264133	chr6:25882463	NA	-0.78	-8.14	-0.59	3.58e-13	Blood metabolite levels;
TGCT	cis	rs1538970	0.781	rs12049503	chr1:46021556	G/T	cg05343316	chr1:45956843	TESK2	0.67	5.2	0.42	7.96e-7	Platelet count;
TGCT	cis	rs7727544	0.582	rs2278398	chr5:131530441	C/T	cg14196790	chr5:131705035	SLC22A5	-0.33	-4.45	-0.37	1.89e-5	Blood metabolite levels;
TGCT	cis	rs9926296	0.609	rs4785709	chr16:89796665	G/A	cg03388025	chr16:89894329	SPIRE2	-0.33	-4.79	-0.4	4.58e-6	Vitiligo;
TGCT	cis	rs7666738	0.830	rs1534319	chr4:98964804	T/C	cg18180107	chr4:99064573	C4orf37	0.57	5.18	0.42	8.63e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11650494	0.908	rs73340399	chr17:47372743	G/C	cg08112188	chr17:47440006	ZNF652	1.04	5.35	0.43	4.09e-7	Prostate cancer;
TGCT	cis	rs11679640	0.610	rs4494803	chr2:43109042	G/T	cg00484711	chr2:42331922	NA	-0.2	-4.53	-0.38	1.39e-5	White matter hyperintensity burden;
TGCT	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg07507251	chr3:52567010	NT5DC2	0.46	6.62	0.51	9.64e-10	Bipolar disorder;
TGCT	cis	rs9291683	0.620	rs11722946	chr4:10125990	A/G	cg00071950	chr4:10020882	SLC2A9	-0.43	-4.73	-0.39	6.01e-6	Bone mineral density;
TGCT	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg24250549	chr1:154909240	PMVK	0.47	4.49	0.37	1.58e-5	Prostate cancer;
TGCT	cis	rs6918586	0.658	rs198856	chr6:26102708	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.7	-6.6	-0.51	1.09e-9	Schizophrenia;
TGCT	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg13393036	chr8:95962371	TP53INP1	-0.63	-8.72	-0.62	1.53e-14	Type 2 diabetes;
TGCT	cis	rs826838	1.000	rs2129627	chr12:38653036	C/T	cg13010199	chr12:38710504	ALG10B	0.77	6.31	0.49	4.59e-9	Heart rate;
TGCT	cis	rs727505	1.000	rs7806680	chr7:124433079	G/A	cg23710748	chr7:124431027	NA	-0.26	-4.6	-0.38	1.03e-5	Lewy body disease;
TGCT	trans	rs10504390	0.656	rs79616747	chr8:66546593	C/A	cg18118147	chr19:51128640	SYT3	-0.77	-6.85	-0.52	2.99e-10	IgG glycosylation;
TGCT	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg07332563	chr6:291687	DUSP22	-0.66	-6.76	-0.52	4.86e-10	Menopause (age at onset);
TGCT	cis	rs854765	0.603	rs4506967	chr17:17990474	A/C	cg04398451	chr17:18023971	MYO15A	-0.37	-6.51	-0.5	1.71e-9	Total body bone mineral density;
TGCT	cis	rs986417	0.688	rs965454	chr14:60960251	T/C	cg27398547	chr14:60952738	C14orf39	1.39	10.61	0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	trans	rs28595532	0.557	rs13435618	chr4:119308814	C/T	cg26518628	chr1:97050305	NA	-0.52	-7.8	-0.57	2.17e-12	Cannabis dependence symptom count;
TGCT	cis	rs7822232	0.908	rs7821112	chr8:145147169	G/A	cg06239191	chr8:145163136	KIAA1875	0.88	6.45	0.5	2.26e-9	Blood metabolite levels;
TGCT	cis	rs68170813	0.559	rs80017637	chr7:107050660	T/C	cg02696742	chr7:106810147	HBP1	-0.68	-5.44	-0.44	2.69e-7	Coronary artery disease;
TGCT	cis	rs8038465	0.615	rs4075802	chr15:73963239	A/G	cg15420318	chr15:73925796	NPTN	0.74	8.25	0.6	1.95e-13	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg03161606	chr19:29218774	NA	0.54	5.79	0.46	5.31e-8	Methadone dose in opioid dependence;
TGCT	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg06896619	chr17:61851486	DDX42;CCDC47	-0.5	-4.9	-0.4	2.97e-6	Prudent dietary pattern;
TGCT	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7647973	0.516	rs12490393	chr3:49196132	C/T	cg07636037	chr3:49044803	WDR6	0.84	8.59	0.61	3.04e-14	Menarche (age at onset);
TGCT	cis	rs17767294	0.708	rs62620226	chr6:28121278	A/G	cg08851530	chr6:28072375	NA	1.47	6.82	0.52	3.64e-10	Parkinson's disease;
TGCT	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg16414030	chr3:133502952	NA	-0.61	-9.65	-0.66	8.74e-17	Iron status biomarkers;
TGCT	cis	rs7523050	0.730	rs72984612	chr1:109434826	T/C	cg08274380	chr1:109419600	GPSM2	1.35	6.86	0.52	2.89e-10	Fat distribution (HIV);
TGCT	trans	rs1033284	0.666	rs11694579	chr2:141928874	T/G	cg17884674	chr19:1967198	CSNK1G2	-0.32	-6.65	-0.51	8.5e-10	Blood pressure (smoking interaction);
TGCT	cis	rs9388451	0.869	rs7764016	chr6:126070789	T/G	cg10911889	chr6:126070802	HEY2	0.56	5.82	0.46	4.69e-8	Brugada syndrome;
TGCT	cis	rs2692947	0.770	rs11689832	chr2:96554851	A/C	cg23100626	chr2:96804247	ASTL	0.37	4.49	0.37	1.62e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs6032067	0.543	rs13045693	chr20:43911817	T/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.38	-6.0	-0.47	2.04e-8	Blood protein levels;
TGCT	cis	rs644799	1.000	rs564675	chr11:95561873	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	10.52	0.69	6.94e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs3020333	0.875	rs2941742	chr6:152012988	A/G	cg22157087	chr6:152012887	ESR1	0.19	4.65	0.39	8.27e-6	Total body bone mineral density;
TGCT	cis	rs68170813	0.559	rs113211438	chr7:106969198	G/A	cg02696742	chr7:106810147	HBP1	-0.68	-5.64	-0.45	1.09e-7	Coronary artery disease;
TGCT	cis	rs6964587	1.000	rs1859113	chr7:91679887	T/C	cg22709100	chr7:91322751	NA	0.28	4.56	0.38	1.19e-5	Breast cancer;
TGCT	cis	rs6504950	0.720	rs9913784	chr17:52989071	A/T	cg07707039	chr17:53042137	COX11	0.27	4.63	0.38	8.98e-6	Breast cancer;
TGCT	cis	rs2677744	0.719	rs12902422	chr15:91469846	T/C	cg23684204	chr15:91497937	RCCD1	0.33	4.71	0.39	6.4e-6	Attention deficit hyperactivity disorder;
TGCT	trans	rs2840044	0.554	rs225267	chr17:33964228	T/C	cg19694781	chr19:47549865	TMEM160	-0.6	-13.37	-0.77	8.63e-26	Response to radiotherapy in cancer (late toxicity);
TGCT	cis	rs13177918	0.603	rs10447222	chr5:149832667	A/G	cg14059543	chr5:149831962	NA	-0.68	-9.02	-0.63	2.93e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs806215	1.000	rs2106187	chr7:127241353	C/T	cg25922125	chr7:127225783	GCC1	0.59	5.98	0.47	2.17e-8	Type 2 diabetes;
TGCT	cis	rs12950390	0.853	rs11655112	chr17:45856563	T/C	cg06532163	chr17:45867833	NA	0.37	5.89	0.47	3.46e-8	IgG glycosylation;
TGCT	cis	rs13064411	0.696	rs36054418	chr3:113204762	G/T	cg18753928	chr3:113234510	CCDC52	-0.7	-5.75	-0.46	6.6e-8	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs12367572	0.930	rs11615964	chr12:45261564	C/T	cg04608330	chr12:45269318	NELL2	-0.64	-6.3	-0.49	4.64e-9	Gut microbiome composition (summer);
TGCT	cis	rs1541995	1.000	rs11073450	chr15:96346544	A/T	cg00882281	chr15:96346592	NA	0.29	4.8	0.4	4.46e-6	Photic sneeze reflex;
TGCT	cis	rs9513593	1.000	rs747848	chr13:100036182	C/T	cg21788972	chr13:99853209	UBAC2	0.56	4.68	0.39	7.51e-6	Psoriasis;
TGCT	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.5	-4.81	-0.4	4.26e-6	Bipolar disorder;
TGCT	cis	rs2019216	0.500	rs12938673	chr17:21941987	C/G	cg22648282	chr17:21454238	C17orf51	-0.58	-4.95	-0.41	2.37e-6	Pelvic organ prolapse;
TGCT	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg06481639	chr22:41940642	POLR3H	-0.74	-6.74	-0.52	5.38e-10	Vitiligo;
TGCT	cis	rs7236492	0.688	rs73494217	chr18:77186200	G/A	cg15644404	chr18:77186268	NFATC1	-0.35	-4.67	-0.39	7.83e-6	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs910187	0.678	rs6018330	chr20:45813216	C/T	cg27589058	chr20:45804311	EYA2	-0.36	-7.88	-0.58	1.44e-12	Migraine;
TGCT	cis	rs3820928	0.605	rs2228555	chr2:227872995	C/T	cg11843606	chr2:227700838	RHBDD1	0.51	4.71	0.39	6.47e-6	Pulmonary function;
TGCT	cis	rs1552244	0.554	rs2272120	chr3:10046703	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.33	-4.95	-0.41	2.39e-6	Alzheimer's disease;
TGCT	cis	rs861020	0.677	rs12723578	chr1:210032392	G/A	cg05527609	chr1:210001259	C1orf107	-0.93	-7.93	-0.58	1.09e-12	Orofacial clefts;
TGCT	cis	rs6671200	1.000	rs933107	chr1:95672229	C/T	cg26537280	chr1:95699037	RWDD3	-0.68	-5.49	-0.44	2.15e-7	Stearic acid (18:0) levels;
TGCT	cis	rs775227	0.574	rs35274817	chr3:113266391	A/G	cg18753928	chr3:113234510	CCDC52	-0.66	-4.45	-0.37	1.88e-5	Dental caries;
TGCT	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.99	-7.28	-0.55	3.39e-11	Gut microbiome composition (summer);
TGCT	cis	rs950169	0.959	rs66801143	chr15:84736657	C/T	cg17173187	chr15:85201210	NMB	0.47	5.23	0.42	7.11e-7	Schizophrenia;
TGCT	cis	rs12935418	0.616	rs62054238	chr16:80999650	T/C	cg07676361	chr16:80966860	NA	-0.35	-4.56	-0.38	1.19e-5	Mean corpuscular volume;
TGCT	cis	rs7937682	0.960	rs480293	chr11:111469132	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.99	-10.02	-0.67	1.16e-17	Primary sclerosing cholangitis;
TGCT	trans	rs77457752	0.690	rs75036580	chr9:13912781	C/T	cg18948646	chr4:83674694	SCD5;MIR575	0.54	6.62	0.51	9.53e-10	Breast cancer;
TGCT	cis	rs28785552	0.589	rs11669056	chr19:53244443	G/A	cg10871876	chr19:53194124	ZNF83	0.46	5.9	0.47	3.2e-8	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs3806843	0.547	rs183679	chr5:140271017	C/T	cg09824255	chr5:140014002	CD14	-0.27	-4.74	-0.39	5.73e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9611565	0.512	rs1534932	chr22:42150146	C/T	cg06634786	chr22:41940651	POLR3H	0.85	8.15	0.59	3.41e-13	Vitiligo;
TGCT	cis	rs10804591	1.000	rs6785282	chr3:129339500	C/G	cg07730360	chr3:128845626	NA	-0.19	-4.44	-0.37	1.99e-5	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Hip circumference adjusted for BMI;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs5769707	0.967	rs2187891	chr22:49994094	C/T	cg10356904	chr22:49881777	NA	-0.23	-4.76	-0.39	5.4e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs9467773	0.620	rs2504599	chr6:26641060	C/T	cg11502198	chr6:26597334	ABT1	0.54	4.87	0.4	3.4e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg13770153	chr20:60521292	NA	-0.54	-7.13	-0.54	7.45e-11	Body mass index;
TGCT	cis	rs35883536	0.609	rs2647327	chr1:101041766	C/T	cg10298815	chr1:101004474	GPR88	0.25	4.7	0.39	6.67e-6	Monocyte count;
TGCT	cis	rs11690462	0.963	rs34918214	chr2:26628100	C/T	cg04726446	chr2:26624865	C2orf39	0.42	4.52	0.38	1.45e-5	Coronary artery disease;
TGCT	cis	rs3087591	0.708	rs7502834	chr17:29689430	G/A	cg24425628	chr17:29625626	OMG;NF1	0.39	5.64	0.45	1.08e-7	Hip circumference;
TGCT	cis	rs709400	0.627	rs62007686	chr14:103899344	A/G	cg12935359	chr14:103987150	CKB	-0.36	-5.41	-0.44	3.09e-7	Body mass index;
TGCT	cis	rs6540559	0.673	rs2357230	chr1:210019498	G/A	cg22029157	chr1:209979665	IRF6	0.71	5.09	0.42	1.3e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs7296418	0.599	rs2277343	chr12:123794450	A/T	cg00376283	chr12:123451042	ABCB9	0.62	5.32	0.43	4.7e-7	Platelet count;
TGCT	cis	rs933688	1.000	rs332544	chr5:90778848	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.87	8.34	0.6	1.21e-13	Smoking behavior;
TGCT	cis	rs13191362	1.000	rs67646369	chr6:163003233	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs79387448	0.745	rs17027496	chr2:103178223	T/A	cg09003973	chr2:102972529	NA	0.97	6.24	0.49	6.29e-9	Gut microbiota (bacterial taxa);
TGCT	cis	rs56104184	0.830	rs73061617	chr19:49350984	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.81	-9.48	-0.65	2.33e-16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs2637266	0.905	rs2395395	chr10:78360770	A/G	cg18941641	chr10:78392320	NA	0.45	5.7	0.46	8.11e-8	Pulmonary function;
TGCT	cis	rs11098499	0.863	rs7657849	chr4:120455494	T/C	cg09307838	chr4:120376055	NA	0.69	6.53	0.51	1.49e-9	Corneal astigmatism;
TGCT	cis	rs6500602	0.727	rs10451135	chr16:4580214	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.32	5.97	0.47	2.35e-8	Schizophrenia;
TGCT	cis	rs11785400	1.000	rs11776301	chr8:143737142	A/G	cg10596483	chr8:143751796	JRK	0.59	6.38	0.5	3.27e-9	Schizophrenia;
TGCT	cis	rs362272	0.524	rs10937924	chr4:3374898	T/C	cg18352616	chr4:3374830	RGS12	0.25	4.97	0.41	2.16e-6	Serum sulfate level;
TGCT	cis	rs2456568	0.803	rs10765642	chr11:93640355	C/T	cg17595323	chr11:93583763	C11orf90	0.45	6.08	0.48	1.38e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs796364	0.806	rs11679658	chr2:200923081	A/G	cg17644776	chr2:200775616	C2orf69	-0.33	-5.0	-0.41	1.91e-6	Schizophrenia;
TGCT	cis	rs1538970	0.924	rs11211117	chr1:45930246	C/T	cg05343316	chr1:45956843	TESK2	0.75	6.27	0.49	5.48e-9	Platelet count;
TGCT	cis	rs57590327	0.504	rs11712243	chr3:81840674	T/G	cg07356753	chr3:81810745	GBE1	-0.73	-6.73	-0.52	5.57e-10	Extraversion;
TGCT	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg06873352	chr17:61820015	STRADA	0.53	5.89	0.47	3.39e-8	Prudent dietary pattern;
TGCT	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg10047753	chr17:41438598	NA	0.95	9.61	0.65	1.12e-16	Menopause (age at onset);
TGCT	cis	rs6964587	1.000	rs10243241	chr7:91705696	A/G	cg22709100	chr7:91322751	NA	0.28	4.56	0.38	1.19e-5	Breast cancer;
TGCT	cis	rs11077998	1.000	rs11077998	chr17:80483946	C/G	cg10255544	chr17:80519551	FOXK2	-0.24	-4.83	-0.4	3.92e-6	Reticulocyte fraction of red cells;
TGCT	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.71	6.36	0.5	3.53e-9	Tonsillectomy;
TGCT	cis	rs2153535	0.580	rs1335637	chr6:8465101	A/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg24531977	chr5:56204891	C5orf35	-0.77	-7.61	-0.56	5.83e-12	Initial pursuit acceleration;
TGCT	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg26338869	chr17:61819248	STRADA	-0.53	-4.94	-0.41	2.48e-6	Prudent dietary pattern;
TGCT	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg11764359	chr7:65958608	NA	0.61	5.56	0.45	1.55e-7	Aortic root size;
TGCT	cis	rs9790314	0.905	rs7613358	chr3:160949296	T/C	cg03342759	chr3:160939853	NMD3	-0.48	-5.23	-0.43	6.93e-7	Morning vs. evening chronotype;
TGCT	cis	rs6089829	0.888	rs6011559	chr20:61675620	C/T	cg08564027	chr20:61660810	NA	-0.35	-5.53	-0.45	1.77e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7260538	0.808	rs2086785	chr19:41527085	T/C	cg27089200	chr19:41531976	NA	0.43	5.39	0.44	3.39e-7	DDT metabolite (p,p'-DDE levels);
TGCT	cis	rs295140	0.710	rs1729421	chr2:201080113	G/C	cg04283868	chr2:201171347	SPATS2L	-0.53	-5.19	-0.42	8.21e-7	QT interval;
TGCT	cis	rs8179	0.645	rs56201652	chr7:92278116	G/A	cg15732164	chr7:92237376	CDK6	-0.28	-4.8	-0.4	4.4e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
TGCT	cis	rs10992471	0.603	rs7872610	chr9:95299137	G/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.6	-5.68	-0.45	9.01e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs9467773	0.620	rs4368798	chr6:26593471	A/G	cg11502198	chr6:26597334	ABT1	0.54	4.95	0.41	2.42e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1008375	0.800	rs35463363	chr4:17613423	G/T	cg10189774	chr4:17578691	LAP3	0.66	5.47	0.44	2.36e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2074585	0.647	rs2601188	chr15:90929563	A/G	cg22089800	chr15:90895588	ZNF774	-0.83	-9.17	-0.64	1.27e-15	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
TGCT	cis	rs35306767	0.633	rs17221491	chr10:1065191	A/G	cg18964960	chr10:1102726	WDR37	0.75	5.29	0.43	5.41e-7	Eosinophil percentage of granulocytes;
TGCT	cis	rs4767364	0.569	rs1468253	chr12:112776042	C/T	cg10833066	chr12:111807467	FAM109A	-0.38	-5.61	-0.45	1.23e-7	Oral cavity and pharyngeal cancer;
TGCT	cis	rs611744	0.870	rs685358	chr8:109161413	T/C	cg21045802	chr8:109455806	TTC35	0.69	6.06	0.48	1.51e-8	Dupuytren's disease;
TGCT	cis	rs2718812	0.719	rs1867505	chr3:133411052	T/C	cg16414030	chr3:133502952	NA	0.4	5.23	0.43	6.91e-7	Iron status biomarkers;
TGCT	cis	rs11264213	0.901	rs74879824	chr1:36413117	T/A	cg27506609	chr1:36549197	TEKT2	0.42	4.72	0.39	6.2e-6	Schizophrenia;
TGCT	cis	rs7267979	0.932	rs6107052	chr20:25530838	G/A	cg16686733	chr20:25566563	NINL	0.56	5.69	0.46	8.49e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2842992	0.789	rs2277072	chr6:160182845	A/G	cg11366901	chr6:160182831	ACAT2	1.03	6.92	0.53	2.14e-10	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs7119038	0.865	rs11217046	chr11:118698907	G/A	cg19308663	chr11:118741387	NA	0.3	5.88	0.47	3.49e-8	Sjögren's syndrome;
TGCT	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg11247378	chr22:39784982	NA	-0.73	-9.59	-0.65	1.22e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs9534288	0.700	rs57192057	chr13:46592327	C/G	cg15192986	chr13:46630673	CPB2	-0.53	-7.62	-0.56	5.82e-12	Blood protein levels;
TGCT	cis	rs2880765	0.835	rs1872074	chr15:86033184	T/G	cg13263323	chr15:86062960	AKAP13	-0.22	-4.79	-0.4	4.68e-6	Coronary artery disease;
TGCT	cis	rs76473307	0.661	rs78350375	chr20:57382520	A/G	cg06163629	chr20:57414884	GNASAS;GNAS	-0.66	-4.53	-0.38	1.39e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg11247378	chr22:39784982	NA	0.68	9.02	0.63	2.97e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs7586879	0.681	rs6756609	chr2:25121125	C/A	cg15423357	chr2:25149977	NA	0.5	4.89	0.4	3.06e-6	Body mass index;
TGCT	cis	rs929354	0.772	rs3802120	chr7:156977794	C/T	cg05182265	chr7:156933206	UBE3C	-0.39	-8.79	-0.62	1.03e-14	Body mass index;
TGCT	cis	rs4455778	0.659	rs6972383	chr7:49022094	G/A	cg26309511	chr7:48887640	NA	-0.43	-5.07	-0.41	1.4e-6	Lung cancer in never smokers;
TGCT	cis	rs7552404	0.731	rs1770885	chr1:76402212	C/T	cg10523679	chr1:76189770	ACADM	-0.84	-7.83	-0.58	1.9e-12	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs1635	0.826	rs1233710	chr6:28215446	C/T	cg15743358	chr6:28303923	ZNF323	-1.15	-4.78	-0.39	4.78e-6	Schizophrenia;
TGCT	cis	rs10461617	0.592	rs6450403	chr5:56062737	A/C	cg24531977	chr5:56204891	C5orf35	-0.52	-5.2	-0.42	8.14e-7	Type 2 diabetes;
TGCT	cis	rs2721195	1.000	rs6599530	chr8:145677418	C/G	cg17328964	chr8:145687451	CYHR1	0.48	6.96	0.53	1.71e-10	Age at first birth;
TGCT	cis	rs2439831	1.000	rs565007	chr15:43716641	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.01	8.37	0.6	1.02e-13	Lung cancer in ever smokers;
TGCT	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg06873352	chr17:61820015	STRADA	0.56	6.22	0.49	7.1e-9	Prudent dietary pattern;
TGCT	cis	rs12579753	1.000	rs17749267	chr12:82178308	A/G	cg07988820	chr12:82153109	PPFIA2	0.62	6.54	0.51	1.43e-9	Resting heart rate;
TGCT	cis	rs727563	0.552	rs4822045	chr22:41985958	C/A	cg06634786	chr22:41940651	POLR3H	-0.89	-8.16	-0.59	3.16e-13	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs7178572	1.000	rs952471	chr15:77776498	C/G	cg15453836	chr15:77711506	NA	-0.4	-4.59	-0.38	1.07e-5	Type 2 diabetes;
TGCT	cis	rs7213347	0.707	rs4790323	chr17:2181658	A/G	cg20777128	chr17:1945076	DPH1;OVCA2	-0.53	-4.79	-0.39	4.74e-6	Total body bone mineral density;
TGCT	cis	rs10193935	1.000	rs13421289	chr2:42412808	T/C	cg27598129	chr2:42591480	NA	-0.39	-5.14	-0.42	1.05e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs950027	0.620	rs2467862	chr15:45643843	T/G	cg26924012	chr15:45694286	SPATA5L1	0.79	8.86	0.62	6.92e-15	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs10465746	0.780	rs1871924	chr1:84398466	T/A	cg10977910	chr1:84465055	TTLL7	0.69	7.07	0.54	9.97e-11	Obesity-related traits;
TGCT	cis	rs1018836	0.923	rs7826178	chr8:91649592	C/A	cg16814680	chr8:91681699	NA	-0.85	-8.82	-0.62	8.85e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2692947	0.770	rs72492163	chr2:96417816	G/A	cg23100626	chr2:96804247	ASTL	0.37	4.49	0.37	1.62e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg10819733	chr22:24237672	NA	-0.28	-4.58	-0.38	1.14e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs3733585	0.699	rs6449202	chr4:9974043	T/C	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.62	-0.56	5.57e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7659604	0.840	rs6821305	chr4:122713863	A/C	cg20573242	chr4:122745356	CCNA2	0.53	4.96	0.41	2.32e-6	Type 2 diabetes;
TGCT	cis	rs17376456	0.825	rs28645862	chr5:93233128	G/C	cg21475434	chr5:93447410	FAM172A	0.7	4.9	0.4	2.96e-6	Diabetic retinopathy;
TGCT	cis	rs289997	1.000	rs981903	chr7:25574197	T/C	cg14064488	chr7:26331273	SNX10	-0.33	-4.8	-0.4	4.47e-6	Breast cancer;
TGCT	cis	rs12142240	0.698	rs28578741	chr1:46825176	T/C	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg05368731	chr17:41323189	NBR1	1.2	14.2	0.79	8.98e-28	Menopause (age at onset);
TGCT	cis	rs9583531	0.657	rs7318291	chr13:111352460	C/T	cg24331049	chr13:111365604	ING1	-0.9	-8.5	-0.61	5.17e-14	Coronary artery disease;
TGCT	cis	rs4455778	0.538	rs6958308	chr7:49123900	C/T	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs2760061	0.846	rs3094912	chr1:228209815	T/A	cg02753203	chr1:228287806	NA	0.32	6.26	0.49	5.64e-9	Diastolic blood pressure;
TGCT	cis	rs7647973	0.961	rs4955417	chr3:49298205	T/C	cg07636037	chr3:49044803	WDR6	0.67	5.41	0.44	3.15e-7	Menarche (age at onset);
TGCT	cis	rs4699052	1.000	rs6533060	chr4:104139996	T/C	cg16532752	chr4:104119610	CENPE	-0.59	-5.63	-0.45	1.14e-7	Testicular germ cell tumor;
TGCT	cis	rs7809950	0.678	rs12670688	chr7:106821016	A/G	cg23024343	chr7:107201750	COG5	0.44	5.79	0.46	5.35e-8	Coronary artery disease;
TGCT	cis	rs35146811	0.538	rs3823642	chr7:99796072	T/C	cg04778012	chr7:99775508	STAG3;GPC2	0.35	4.93	0.41	2.55e-6	Coronary artery disease;
TGCT	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.81	7.65	0.57	4.75e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg06873352	chr17:61820015	STRADA	0.55	6.1	0.48	1.26e-8	Prudent dietary pattern;
TGCT	cis	rs11673344	0.523	rs2891766	chr19:37527959	C/A	cg08039142	chr19:36980659	ZNF566	0.51	4.69	0.39	6.99e-6	Obesity-related traits;
TGCT	cis	rs7192750	0.586	rs7204708	chr16:71986946	C/T	cg06353428	chr16:71660113	MARVELD3	-0.74	-6.57	-0.51	1.25e-9	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs68170813	0.559	rs75313693	chr7:106863170	T/C	cg02696742	chr7:106810147	HBP1	-0.69	-5.61	-0.45	1.27e-7	Coronary artery disease;
TGCT	cis	rs72634258	0.554	rs12741937	chr1:7897622	A/T	cg26816564	chr1:7831052	VAMP3	0.88	6.53	0.51	1.52e-9	Inflammatory bowel disease;
TGCT	cis	rs3091242	0.933	rs9438904	chr1:25756860	T/C	cg00786635	chr1:25594202	NA	0.57	5.97	0.47	2.38e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs910316	1.000	rs10138183	chr14:75615227	T/C	cg11812906	chr14:75593930	NEK9	0.75	7.41	0.55	1.73e-11	Height;
TGCT	cis	rs6964587	0.626	rs2106745	chr7:91506635	C/T	cg17063962	chr7:91808500	NA	-0.76	-7.15	-0.54	6.42e-11	Breast cancer;
TGCT	cis	rs6061231	0.556	rs6121571	chr20:60977323	T/G	cg15674680	chr20:60982522	CABLES2	0.68	5.56	0.45	1.61e-7	Colorectal cancer;
TGCT	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg25036284	chr2:26402008	FAM59B	-0.64	-5.13	-0.42	1.06e-6	Gut microbiome composition (summer);
TGCT	cis	rs6089829	0.962	rs6089826	chr20:61668595	G/A	cg08564027	chr20:61660810	NA	0.36	6.47	0.5	2.07e-9	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs3924048	0.574	rs34494202	chr1:12612868	G/A	cg00291366	chr1:12616550	NA	0.35	5.38	0.44	3.55e-7	Optic cup area;
TGCT	cis	rs3020736	0.500	rs11090076	chr22:42514190	T/C	cg15557168	chr22:42548783	NA	0.22	5.58	0.45	1.47e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg21724239	chr8:58056113	NA	0.48	5.12	0.42	1.11e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7020830	0.830	rs13296413	chr9:37258105	C/T	cg14294708	chr9:37120828	ZCCHC7	1.18	15.6	0.81	4.97e-31	Schizophrenia;
TGCT	cis	rs6740322	0.643	rs13390381	chr2:43534414	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.4	-5.86	-0.47	3.94e-8	Coronary artery disease;
TGCT	cis	rs6450176	1.000	rs3776717	chr5:53298762	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.53	-5.1	-0.42	1.23e-6	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs2456568	0.548	rs4402256	chr11:93660803	T/C	cg17595323	chr11:93583763	C11orf90	-0.44	-5.58	-0.45	1.42e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs6840360	1.000	rs6845944	chr4:152604520	C/T	cg17479576	chr4:152424074	FAM160A1	-0.46	-4.74	-0.39	5.8e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs62103177	0.525	rs10438902	chr18:77745640	A/G	cg20368463	chr18:77673604	PQLC1	-0.43	-4.5	-0.37	1.56e-5	Opioid sensitivity;
TGCT	cis	rs2836974	0.565	rs2836939	chr21:40578546	C/T	cg11890956	chr21:40555474	PSMG1	0.89	6.88	0.53	2.59e-10	Cognitive function;
TGCT	cis	rs1008375	1.000	rs10939740	chr4:17617490	T/C	cg18681998	chr4:17616180	MED28	0.97	10.54	0.69	6.29e-19	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7655441	1.000	rs13118694	chr4:80873106	G/C	cg02241357	chr4:80885279	ANTXR2	-0.23	-4.46	-0.37	1.81e-5	Neutrophil percentage of white cells;
TGCT	cis	rs11112613	0.713	rs68053161	chr12:105950035	G/C	cg03607813	chr12:105948248	NA	0.52	6.0	0.47	2.03e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	cis	rs9926296	0.682	rs467357	chr16:89717397	A/G	cg04287289	chr16:89883240	FANCA	-0.55	-5.06	-0.41	1.48e-6	Vitiligo;
TGCT	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs8014204	0.836	rs11159099	chr14:75235397	A/G	cg06637938	chr14:75390232	RPS6KL1	0.7	6.75	0.52	5.06e-10	Caffeine consumption;
TGCT	cis	rs8141529	0.748	rs1318026	chr22:29283518	A/G	cg02153584	chr22:29168773	CCDC117	0.63	4.87	0.4	3.3e-6	Lymphocyte counts;
TGCT	cis	rs8017423	0.967	rs7147952	chr14:90720831	G/A	cg04374321	chr14:90722782	PSMC1	0.77	7.82	0.57	2.02e-12	Mortality in heart failure;
TGCT	cis	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg20637647	chr7:64974828	NA	0.9	5.29	0.43	5.42e-7	Diabetic kidney disease;
TGCT	cis	rs11098499	0.954	rs10006706	chr4:120409152	A/G	cg09307838	chr4:120376055	NA	0.7	6.6	0.51	1.07e-9	Corneal astigmatism;
TGCT	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg14773178	chr5:1868261	NA	0.34	5.77	0.46	6.08e-8	Cardiovascular disease risk factors;
TGCT	cis	rs4919694	1.000	rs12245343	chr10:104774050	A/G	cg04362960	chr10:104952993	NT5C2	1.06	7.05	0.53	1.09e-10	Arsenic metabolism;
TGCT	cis	rs225245	0.782	rs225272	chr17:33969911	T/C	cg05299278	chr17:33885742	SLFN14	0.21	4.5	0.37	1.53e-5	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg13395646	chr4:1353034	KIAA1530	-0.36	-4.62	-0.38	9.52e-6	Obesity-related traits;
TGCT	cis	rs854765	0.618	rs8068820	chr17:17834119	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.74	7.73	0.57	3.18e-12	Total body bone mineral density;
TGCT	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg11494091	chr17:61959527	GH2	0.6	14.54	0.79	1.46e-28	Prudent dietary pattern;
TGCT	cis	rs4332037	0.539	rs55988458	chr7:2059761	G/A	cg25834613	chr7:1915315	MAD1L1	-0.51	-4.99	-0.41	1.95e-6	Bipolar disorder;
TGCT	cis	rs1008375	0.932	rs10029173	chr4:17659598	C/T	cg18681998	chr4:17616180	MED28	-1.05	-12.0	-0.73	1.69e-22	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs514406	0.763	rs9988539	chr1:53213884	T/C	cg24675658	chr1:53192096	ZYG11B	0.71	7.96	0.58	9.48e-13	Monocyte count;
TGCT	cis	rs11673344	0.562	rs7250507	chr19:37586674	A/T	cg08039142	chr19:36980659	ZNF566	0.5	4.68	0.39	7.49e-6	Obesity-related traits;
TGCT	cis	rs2033711	0.503	rs7254299	chr19:58884965	A/G	cg13691442	chr19:58878570	NA	-0.2	-5.1	-0.42	1.24e-6	Uric acid clearance;
TGCT	cis	rs7635838	0.619	rs347614	chr3:11276399	T/C	cg00170343	chr3:11313890	ATG7	0.66	6.26	0.49	5.88e-9	HDL cholesterol;
TGCT	cis	rs908922	0.676	rs3753451	chr1:152485227	T/G	cg20991723	chr1:152506922	NA	0.47	6.65	0.51	8.33e-10	Hair morphology;
TGCT	cis	rs4746818	1.000	rs10762259	chr10:70890929	C/T	cg11621586	chr10:70884670	VPS26A	1.21	10.66	0.69	3.17e-19	Left atrial antero-posterior diameter;
TGCT	cis	rs938554	0.513	rs4529048	chr4:9997112	G/T	cg00071950	chr4:10020882	SLC2A9	0.68	5.11	0.42	1.19e-6	Blood metabolite levels;
TGCT	cis	rs1403694	0.695	rs1851664	chr3:186436503	T/A	cg12454167	chr3:186435060	KNG1	0.51	8.67	0.61	1.95e-14	Blood protein levels;
TGCT	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg22166914	chr1:53195759	ZYG11B	-0.42	-7.41	-0.55	1.7e-11	Monocyte count;
TGCT	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg22920501	chr2:26401640	FAM59B	-0.74	-6.53	-0.51	1.55e-9	Gut microbiome composition (summer);
TGCT	cis	rs7511006	0.859	rs7292228	chr22:50649560	C/G	cg16473166	chr22:50639996	SELO	0.65	6.47	0.5	2e-9	Obesity-related traits;
TGCT	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg22963979	chr7:1858916	MAD1L1	-0.41	-6.6	-0.51	1.08e-9	Schizophrenia;
TGCT	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg26338869	chr17:61819248	STRADA	-0.53	-4.83	-0.4	3.91e-6	Prudent dietary pattern;
TGCT	cis	rs6815814	0.950	rs67719080	chr4:38787252	A/G	cg02016764	chr4:38805732	TLR1	-0.31	-4.78	-0.39	4.9e-6	Breast cancer;
TGCT	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg03388025	chr16:89894329	SPIRE2	0.51	8.89	0.62	5.95e-15	Vitiligo;
TGCT	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg08509172	chr19:19383838	TM6SF2	-0.35	-4.51	-0.38	1.46e-5	Tonsillectomy;
TGCT	cis	rs2014572	1.000	rs3746231	chr19:57760057	G/A	cg24459738	chr19:57751996	ZNF805	-0.57	-5.63	-0.45	1.17e-7	Hyperactive-impulsive symptoms;
TGCT	cis	rs9419702	0.538	rs4074772	chr10:133540006	A/T	cg20568497	chr10:133558893	NA	0.44	4.71	0.39	6.43e-6	Survival in rectal cancer;
TGCT	cis	rs7552404	1.000	rs7524467	chr1:76194054	C/G	cg22875332	chr1:76189707	ACADM	0.78	9.41	0.65	3.42e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9807989	0.801	rs7558339	chr2:102970243	T/G	cg09003973	chr2:102972529	NA	0.64	5.7	0.46	8.28e-8	Asthma;
TGCT	cis	rs3771570	1.000	rs4346380	chr2:242263223	G/A	cg21155796	chr2:242212141	HDLBP	1.01	6.91	0.53	2.22e-10	Prostate cancer;
TGCT	cis	rs8180040	0.676	rs7636252	chr3:47013542	T/G	cg27129171	chr3:47204927	SETD2	0.73	9.42	0.65	3.15e-16	Colorectal cancer;
TGCT	cis	rs9534288	0.797	rs7338189	chr13:46571035	T/C	cg15192986	chr13:46630673	CPB2	-0.53	-7.62	-0.56	5.82e-12	Blood protein levels;
TGCT	cis	rs2070488	0.965	rs3749386	chr3:38496065	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.95	10.55	0.69	5.82e-19	Electrocardiographic conduction measures;
TGCT	cis	rs17221829	0.764	rs7930024	chr11:89386038	G/C	cg02982614	chr11:89391479	FOLH1B	-0.25	-4.46	-0.37	1.8e-5	Anxiety in major depressive disorder;
TGCT	cis	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg20637647	chr7:64974828	NA	0.97	5.6	0.45	1.29e-7	Diabetic kidney disease;
TGCT	cis	rs3809566	0.963	rs3809565	chr15:63333619	A/G	cg00520135	chr15:63333846	TPM1	-0.44	-5.44	-0.44	2.67e-7	Platelet count;
TGCT	cis	rs4654899	0.629	rs2320590	chr1:21155195	C/T	cg01072550	chr1:21505969	NA	0.53	8.47	0.61	5.83e-14	Superior frontal gyrus grey matter volume;
TGCT	cis	rs2760061	0.626	rs2527615	chr1:228119283	A/G	cg02753203	chr1:228287806	NA	-0.34	-6.63	-0.51	9.15e-10	Diastolic blood pressure;
TGCT	cis	rs861020	0.710	rs7516902	chr1:210022179	A/G	cg05527609	chr1:210001259	C1orf107	1.03	9.06	0.63	2.29e-15	Orofacial clefts;
TGCT	cis	rs4077468	0.927	rs1342063	chr1:205912859	C/T	cg07157834	chr1:205819609	PM20D1	-0.31	-4.46	-0.37	1.83e-5	Cystic fibrosis-related diabetes;
TGCT	cis	rs9682041	0.800	rs7643085	chr3:170070371	A/G	cg07589077	chr3:170072950	NA	0.3	4.87	0.4	3.33e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs12134245	0.776	rs12124682	chr1:91995542	A/G	cg07090678	chr1:91966139	CDC7	0.35	4.75	0.39	5.58e-6	Breast cancer;
TGCT	cis	rs6728642	1.000	rs80303184	chr2:98024633	G/A	cg26665480	chr2:98280029	ACTR1B	-1.02	-5.02	-0.41	1.74e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg22968622	chr17:43663579	NA	1.3	11.75	0.73	6.8e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7172809	0.573	rs55881066	chr15:77507674	T/C	cg22256960	chr15:77711686	NA	-0.48	-4.63	-0.38	9.17e-6	Glucose homeostasis traits;
TGCT	cis	rs7267979	0.844	rs6083824	chr20:25363057	G/A	cg14121845	chr20:25566513	NINL	-0.45	-4.6	-0.38	1.02e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6867032	1.000	rs4975794	chr5:2015330	A/G	cg26168224	chr5:2018326	NA	-0.42	-7.44	-0.56	1.46e-11	Gut microbiome composition (winter);
TGCT	cis	rs938554	0.578	rs7663032	chr4:9993838	C/T	cg00071950	chr4:10020882	SLC2A9	0.55	5.22	0.42	7.29e-7	Blood metabolite levels;
TGCT	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.04	0.53	1.16e-10	Prudent dietary pattern;
TGCT	cis	rs9921338	0.961	rs8060767	chr16:11370598	C/G	cg00044050	chr16:11439710	C16orf75	-0.91	-6.23	-0.49	6.61e-9	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs2832191	0.967	rs3787660	chr21:30520907	C/T	cg24692254	chr21:30365293	RNF160	0.77	8.0	0.58	7.4e-13	Dental caries;
TGCT	trans	rs1415174	0.916	rs2184835	chr1:87856243	G/T	cg23065576	chr20:25207247	ENTPD6	-0.26	-6.83	-0.52	3.36e-10	Breast cancer;
TGCT	cis	rs4788570	0.584	rs6499529	chr16:71715378	C/T	cg06353428	chr16:71660113	MARVELD3	1.56	12.54	0.75	8.54e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs651907	1.000	rs662792	chr3:101599608	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.46	4.76	0.39	5.3e-6	Colorectal cancer;
TGCT	cis	rs36051895	0.664	rs3780371	chr9:5095191	T/A	cg02405213	chr9:5042618	JAK2	-0.72	-9.4	-0.65	3.59e-16	Pediatric autoimmune diseases;
TGCT	cis	rs7843479	0.601	rs10453141	chr8:21847235	T/C	cg17168535	chr8:21777572	XPO7	0.8	7.93	0.58	1.11e-12	Mean corpuscular volume;
TGCT	cis	rs117785887	0.536	rs12203355	chr6:146384475	T/C	cg06708562	chr6:146285465	SHPRH	-0.85	-5.1	-0.42	1.25e-6	Interleukin-17 levels;
TGCT	cis	rs10114408	0.959	rs10761302	chr9:96651133	T/C	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs12522290	0.947	rs76262184	chr5:152795311	A/T	cg26893743	chr5:153749478	GALNT10	0.19	4.47	0.37	1.77e-5	Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs3796352	0.667	rs34288509	chr3:52849493	G/C	cg07884673	chr3:53033167	SFMBT1	0.58	4.83	0.4	3.95e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs3806843	0.576	rs246072	chr5:140320426	C/T	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.11e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9807989	0.507	rs3213732	chr2:102998279	A/G	cg03938978	chr2:103052716	IL18RAP	0.26	5.22	0.42	7.15e-7	Asthma;
TGCT	cis	rs9611565	0.512	rs139571	chr22:42214238	G/A	cg13695892	chr22:41940480	POLR3H	-0.87	-8.24	-0.59	2.06e-13	Vitiligo;
TGCT	cis	rs1997103	1.000	rs4948011	chr7:55403859	A/G	cg17469321	chr7:55412551	NA	0.63	6.28	0.49	5.22e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg03188948	chr7:1209495	NA	0.55	4.56	0.38	1.2e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9467773	0.838	rs3734540	chr6:26463321	A/C	cg15659132	chr6:26577336	NA	0.61	6.75	0.52	5.09e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs13202913	0.837	rs3734800	chr6:151766552	G/A	cg03627880	chr6:151815985	C6orf97	-0.73	-5.42	-0.44	2.92e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg10117171	chr1:25599238	RHD	-0.35	-5.76	-0.46	6.35e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs2980439	0.783	rs2948305	chr8:8098577	G/A	cg15462221	chr8:8086144	FLJ10661	-0.58	-5.37	-0.43	3.66e-7	Neuroticism;
TGCT	cis	rs427394	0.664	rs274722	chr5:6718668	C/T	cg10857441	chr5:6722123	POLS	-0.28	-7.07	-0.54	1e-10	Menopause (age at onset);
TGCT	cis	rs4073582	0.595	rs801734	chr11:65931216	T/C	cg16950941	chr11:66035639	RAB1B	0.55	5.42	0.44	2.94e-7	Gout;
TGCT	cis	rs6088580	0.634	rs3736762	chr20:33037336	C/T	cg06115741	chr20:33292138	TP53INP2	0.55	4.82	0.4	4.15e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs2235642	0.928	rs56289115	chr16:1608934	A/G	cg10465839	chr16:1584050	IFT140;TMEM204	-0.28	-4.66	-0.39	8.12e-6	Coronary artery disease;
TGCT	cis	rs7095607	0.785	rs10823142	chr10:69921335	T/A	cg18986048	chr10:69913749	MYPN	0.45	5.16	0.42	9.71e-7	Lung function (FVC);
TGCT	cis	rs17221829	0.965	rs12276507	chr11:89457053	T/C	cg02982614	chr11:89391479	FOLH1B	-0.27	-4.88	-0.4	3.23e-6	Anxiety in major depressive disorder;
TGCT	cis	rs1801251	0.893	rs11687128	chr2:233608901	T/C	cg25237894	chr2:233734115	C2orf82	0.33	5.95	0.47	2.53e-8	Coronary artery disease;
TGCT	cis	rs78487399	0.908	rs6715003	chr2:43808659	G/C	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.66	4.67	0.39	7.66e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs62064224	0.765	rs11650584	chr17:30679330	T/G	cg18200150	chr17:30822561	MYO1D	0.58	7.59	0.56	6.63e-12	Schizophrenia;
TGCT	cis	rs10788264	0.621	rs7907952	chr10:124056774	C/T	cg09507567	chr10:124027408	NA	-0.4	-5.62	-0.45	1.19e-7	Total body bone mineral density;
TGCT	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg11644478	chr21:40555479	PSMG1	1.02	10.63	0.69	3.73e-19	Cognitive function;
TGCT	cis	rs7959452	0.684	rs11177615	chr12:69754189	G/A	cg14784868	chr12:69753453	YEATS4	0.83	8.8	0.62	9.86e-15	Blood protein levels;
TGCT	cis	rs7772486	0.790	rs80050589	chr6:146230454	T/C	cg23711669	chr6:146136114	FBXO30	-0.89	-10.38	-0.68	1.54e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9796	0.689	rs7180494	chr15:41451841	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.5	-6.32	-0.49	4.26e-9	Menopause (age at onset);
TGCT	cis	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg20637647	chr7:64974828	NA	0.89	4.99	0.41	2.01e-6	Diabetic kidney disease;
TGCT	cis	rs4969178	0.600	rs4969184	chr17:76393413	G/A	cg05887092	chr17:76393375	PGS1	0.22	4.66	0.39	8.18e-6	HDL cholesterol levels;
TGCT	cis	rs11711311	0.712	rs6795099	chr3:113338782	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.69	-5.95	-0.47	2.58e-8	IgG glycosylation;
TGCT	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg09365446	chr1:150670422	GOLPH3L	0.31	4.64	0.38	8.7e-6	Tonsillectomy;
TGCT	cis	rs2153535	0.580	rs6926759	chr6:8456176	G/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs10811516	0.501	rs10283707	chr9:21159810	G/A	cg23029519	chr9:21187344	IFNA4	-0.28	-4.46	-0.37	1.83e-5	Response to mepolizumab in severe asthma;
TGCT	cis	rs9486719	1.000	rs2472887	chr6:96865437	A/G	cg18709589	chr6:96969512	KIAA0776	0.71	5.21	0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg26338869	chr17:61819248	STRADA	-0.53	-4.85	-0.4	3.68e-6	Prudent dietary pattern;
TGCT	cis	rs3796352	1.000	rs35507120	chr3:53053924	C/T	cg15956490	chr3:53032818	SFMBT1	0.62	6.82	0.52	3.6e-10	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs7949030	0.653	rs2849030	chr11:62366986	G/A	cg22862634	chr11:62369728	EML3;MTA2	-0.68	-8.7	-0.62	1.69e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs763014	0.898	rs1045277	chr16:633125	T/C	cg09263875	chr16:632152	PIGQ	0.3	6.4	0.5	2.88e-9	Height;
TGCT	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg03188948	chr7:1209495	NA	0.71	6.04	0.48	1.68e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs6987853	0.966	rs2923439	chr8:42429122	A/G	cg20539142	chr8:42623718	CHRNA6	-0.21	-5.16	-0.42	9.45e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg26513180	chr16:89883248	FANCA	-0.71	-7.02	-0.53	1.29e-10	Vitiligo;
TGCT	cis	rs7666738	0.830	rs6532724	chr4:99060993	C/T	cg05340658	chr4:99064831	C4orf37	0.52	5.79	0.46	5.32e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs208520	0.690	rs4386800	chr6:66755242	A/G	cg07460842	chr6:66804631	NA	0.94	9.91	0.66	2.15e-17	Exhaled nitric oxide output;
TGCT	cis	rs35146811	0.700	rs4729579	chr7:99780282	C/G	cg22906224	chr7:99728672	NA	0.49	4.45	0.37	1.88e-5	Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs10009943	chr4:99021475	G/A	cg18180107	chr4:99064573	C4orf37	0.54	5.03	0.41	1.7e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6988636	1.000	rs58189203	chr8:124184739	G/T	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs6490294	0.904	rs11066099	chr12:112392036	C/G	cg10833066	chr12:111807467	FAM109A	0.38	5.67	0.45	9.69e-8	Mean platelet volume;
TGCT	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg11062466	chr8:58055876	NA	0.38	4.5	0.37	1.56e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9814567	0.752	rs7633868	chr3:134331048	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-6.41	-0.5	2.8e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg01448562	chr3:133502909	NA	-0.34	-6.91	-0.53	2.2e-10	Iron status biomarkers;
TGCT	cis	rs1975974	0.511	rs8078505	chr17:21755889	A/G	cg18423549	chr17:21743878	NA	-0.61	-5.45	-0.44	2.56e-7	Psoriasis;
TGCT	cis	rs6964587	0.967	rs2040499	chr7:91809657	C/G	cg17063962	chr7:91808500	NA	-0.96	-11.12	-0.71	2.36e-20	Breast cancer;
TGCT	cis	rs6969780	0.915	rs2107063	chr7:27167346	G/A	cg04317399	chr7:27170313	HOXA4	-0.43	-4.62	-0.38	9.54e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs6815814	0.808	rs11721824	chr4:38767749	G/A	cg02016764	chr4:38805732	TLR1	-0.33	-5.25	-0.43	6.27e-7	Breast cancer;
TGCT	cis	rs61612642	0.537	rs73434275	chr6:42156239	G/A	cg01092361	chr6:42185687	MRPS10	0.93	6.53	0.51	1.56e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
TGCT	cis	rs2980439	0.607	rs2980419	chr8:8114141	A/T	cg08975724	chr8:8085496	FLJ10661	0.66	6.05	0.48	1.61e-8	Neuroticism;
TGCT	cis	rs7914558	0.966	rs12766205	chr10:104893568	A/G	cg04362960	chr10:104952993	NT5C2	0.62	5.55	0.45	1.66e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg08048268	chr3:133502702	NA	-0.65	-9.83	-0.66	3.21e-17	Iron status biomarkers;
TGCT	cis	rs10490913	0.932	rs12246334	chr10:120150985	G/A	cg23160142	chr10:120154512	NA	0.29	4.47	0.37	1.72e-5	Cancer;
TGCT	cis	rs6463523	0.898	rs66892628	chr7:759374	T/A	cg14391382	chr7:866102	UNC84A	0.2	4.58	0.38	1.13e-5	Subjective well-being;
TGCT	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.56	4.97	0.41	2.19e-6	Height;
TGCT	cis	rs2836950	0.520	rs59916147	chr21:40634702	T/G	cg06238570	chr21:40685208	BRWD1	-0.62	-6.34	-0.49	3.91e-9	Menarche (age at onset);
TGCT	cis	rs7959452	0.557	rs7980883	chr12:69778914	C/T	cg11871910	chr12:69753446	YEATS4	0.82	8.95	0.63	4.38e-15	Blood protein levels;
TGCT	cis	rs12458462	0.859	rs2242177	chr18:77477379	G/A	cg11879182	chr18:77439856	CTDP1	0.69	7.74	0.57	3.03e-12	Monocyte count;
TGCT	cis	rs7959452	0.535	rs11177577	chr12:69671791	C/T	cg20891283	chr12:69753455	YEATS4	0.66	6.37	0.5	3.41e-9	Blood protein levels;
TGCT	cis	rs7267979	1.000	rs2500448	chr20:25404027	A/C	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs916888	0.821	rs199505	chr17:44859410	A/G	cg01570182	chr17:44337453	NA	-1.01	-9.1	-0.63	1.83e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs17102423	0.594	rs7159443	chr14:65550816	T/A	cg11161011	chr14:65562177	MAX	-0.47	-6.42	-0.5	2.57e-9	Obesity-related traits;
TGCT	cis	rs3771570	0.681	rs12151655	chr2:242281438	T/A	cg21155796	chr2:242212141	HDLBP	0.98	6.68	0.51	7.29e-10	Prostate cancer;
TGCT	cis	rs67311347	0.868	rs10865895	chr3:40378677	C/T	cg13683864	chr3:40499215	RPL14	-1.1	-11.59	-0.72	1.72e-21	Renal cell carcinoma;
TGCT	cis	rs6087771	0.682	rs2038397	chr20:30217759	A/G	cg13852791	chr20:30311386	BCL2L1	0.8	6.93	0.53	2.06e-10	Subcortical brain region volumes;Putamen volume;
TGCT	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg13695892	chr22:41940480	POLR3H	0.78	7.62	0.56	5.73e-12	Vitiligo;
TGCT	cis	rs6988636	1.000	rs59834873	chr8:124188824	G/T	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs12497850	0.864	rs4955410	chr3:49181218	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.49	-4.47	-0.37	1.72e-5	Parkinson's disease;
TGCT	cis	rs9443645	0.810	rs7767711	chr6:79810700	G/A	cg09184832	chr6:79620586	NA	-0.45	-4.72	-0.39	6.23e-6	Intelligence (multi-trait analysis);
TGCT	trans	rs9951602	0.512	rs1599633	chr18:76643526	T/C	cg02800362	chr5:177631904	HNRNPAB	1.13	12.94	0.76	9.39e-25	Obesity-related traits;
TGCT	cis	rs1534166	0.647	rs9876158	chr3:133508300	T/C	cg16414030	chr3:133502952	NA	0.45	5.81	0.46	4.92e-8	Alcohol consumption (transferrin glycosylation);
TGCT	cis	rs1371867	0.846	rs1660327	chr8:101292206	A/C	cg00191853	chr8:101177733	SPAG1	-0.22	-4.47	-0.37	1.75e-5	Atrioventricular conduction;
TGCT	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg21951975	chr1:209979733	IRF6	0.77	9.63	0.65	1.02e-16	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
TGCT	cis	rs6570726	0.837	rs636894	chr6:145864122	T/C	cg23711669	chr6:146136114	FBXO30	0.7	6.78	0.52	4.39e-10	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs208520	0.770	rs2224422	chr6:66883993	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-10.21	-0.68	4.02e-18	Exhaled nitric oxide output;
TGCT	cis	rs7904368	0.806	rs45495501	chr10:16861476	G/A	cg14835575	chr10:16859367	RSU1	0.68	7.26	0.55	3.83e-11	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
TGCT	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg22920501	chr2:26401640	FAM59B	-0.91	-6.42	-0.5	2.67e-9	Gut microbiome composition (summer);
TGCT	cis	rs5769707	0.681	rs8137111	chr22:50043750	G/A	cg06623630	chr22:50017776	C22orf34	-0.27	-4.67	-0.39	7.81e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs62244186	0.748	rs12635624	chr3:44678498	G/A	cg15687855	chr3:44754131	ZNF502	-0.44	-5.28	-0.43	5.72e-7	Depressive symptoms;
TGCT	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg11062466	chr8:58055876	NA	0.44	4.6	0.38	1.03e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs78487399	0.808	rs12104615	chr2:43676938	A/T	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.72	4.62	0.38	9.53e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs9644630	0.897	rs17128525	chr8:19364006	C/T	cg01280390	chr8:19363452	CSGALNACT1	-0.26	-4.67	-0.39	7.56e-6	Oropharynx cancer;
TGCT	cis	rs2439831	0.681	rs956391	chr15:43617493	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.93	-7.07	-0.54	1e-10	Lung cancer in ever smokers;
TGCT	cis	rs3087591	1.000	rs6505234	chr17:29688299	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.47	-7.12	-0.54	7.88e-11	Hip circumference;
TGCT	trans	rs2688608	0.620	rs11000767	chr10:75516626	G/T	cg13918328	chr10:52500089	ASAH2B	0.67	6.83	0.52	3.39e-10	Inflammatory bowel disease;
TGCT	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.49	-4.48	-0.37	1.66e-5	Parkinson's disease;
TGCT	cis	rs8050907	0.744	rs1345430	chr16:4527961	G/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.53	4.57	0.38	1.15e-5	Obesity-related traits;
TGCT	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg03609598	chr5:56110824	MAP3K1	-0.58	-4.7	-0.39	6.72e-6	Initial pursuit acceleration;
TGCT	cis	rs6570726	0.738	rs6917199	chr6:145918320	G/A	cg05347473	chr6:146136440	FBXO30	0.53	4.92	0.4	2.74e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2762353	0.603	rs10946798	chr6:25781853	T/G	cg12310025	chr6:25882481	NA	0.5	4.87	0.4	3.28e-6	Blood metabolite levels;
TGCT	cis	rs6681544	0.544	rs1342128	chr1:82391756	A/G	cg04226724	chr1:82268649	LPHN2	0.47	4.95	0.41	2.33e-6	Metabolite levels  (X-11787);
TGCT	cis	rs4566357	0.615	rs12621808	chr2:227909522	A/C	cg11843606	chr2:227700838	RHBDD1	-0.54	-5.24	-0.43	6.55e-7	Coronary artery disease;
TGCT	trans	rs7819412	0.668	rs2409694	chr8:10946861	T/G	cg06636001	chr8:8085503	FLJ10661	-0.81	-7.14	-0.54	7.1e-11	Triglycerides;
TGCT	cis	rs6570726	0.791	rs2096201	chr6:145934273	C/T	cg05347473	chr6:146136440	FBXO30	0.53	4.96	0.41	2.29e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2982552	0.903	rs2982555	chr6:152057656	A/C	cg22157087	chr6:152012887	ESR1	0.2	4.88	0.4	3.21e-6	Bone properties (heel);
TGCT	cis	rs2997447	0.706	rs17184877	chr1:26443908	A/T	cg03844060	chr1:26490628	NA	0.28	4.55	0.38	1.27e-5	QRS complex (12-leadsum);
TGCT	cis	rs9611565	0.559	rs5758397	chr22:42019251	C/T	cg06634786	chr22:41940651	POLR3H	0.88	8.38	0.6	9.48e-14	Vitiligo;
TGCT	cis	rs137699	1.000	rs137703	chr22:39750241	A/G	cg05872129	chr22:39784769	NA	-0.56	-4.65	-0.39	8.39e-6	IgG glycosylation;
TGCT	cis	rs3784262	0.740	rs4646600	chr15:58295616	T/A	cg12031962	chr15:58353849	ALDH1A2	-0.43	-6.3	-0.49	4.77e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs7959452	0.640	rs11177599	chr12:69721970	G/A	cg20891283	chr12:69753455	YEATS4	0.66	6.62	0.51	9.6e-10	Blood protein levels;
TGCT	trans	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg13565492	chr6:43139072	SRF	-0.82	-7.72	-0.57	3.43e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1568889	1.000	rs12800354	chr11:28047723	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.85	9.04	0.63	2.64e-15	Bipolar disorder;
TGCT	cis	rs3806843	0.966	rs3806842	chr5:140212676	C/T	cg19875535	chr5:140030758	IK	0.36	6.0	0.47	2.01e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	5.05	0.41	1.51e-6	Menopause (age at onset);
TGCT	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg13206674	chr6:150067644	NUP43	0.53	4.65	0.39	8.33e-6	Lung cancer;
TGCT	cis	rs9868809	0.772	rs9836462	chr3:48712791	C/T	cg00383909	chr3:49044727	WDR6	-0.89	-5.52	-0.44	1.86e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	trans	rs208520	0.837	rs208489	chr6:66927584	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.97	-10.05	-0.67	9.41e-18	Exhaled nitric oxide output;
TGCT	cis	rs9300255	0.602	rs10744147	chr12:123643729	A/G	cg00376283	chr12:123451042	ABCB9	0.72	4.96	0.41	2.29e-6	Neutrophil percentage of white cells;
TGCT	cis	rs587847	0.737	rs1520952	chr15:37668842	T/C	cg00216138	chr15:37171175	LOC145845	0.31	4.45	0.37	1.91e-5	Intraocular pressure;
TGCT	cis	rs7586879	0.639	rs7567997	chr2:25096952	A/G	cg01884057	chr2:25150051	NA	0.31	5.97	0.47	2.28e-8	Body mass index;
TGCT	trans	rs288326	0.704	rs79576701	chr2:183704659	T/C	cg06580014	chr4:25931115	C4orf52	0.68	6.8	0.52	3.96e-10	Blood protein levels;
TGCT	cis	rs1878931	0.531	rs9635548	chr16:3417156	G/A	cg05754148	chr16:3507555	NAT15	-0.33	-4.46	-0.37	1.82e-5	Body mass index (adult);
TGCT	cis	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg20637647	chr7:64974828	NA	0.93	5.2	0.42	8.11e-7	Diabetic kidney disease;
TGCT	cis	rs12477438	0.520	rs6717723	chr2:99756930	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.15	18.47	0.86	2.08e-37	Chronic sinus infection;
TGCT	cis	rs3849570	0.925	rs6765917	chr3:81891116	C/T	cg07356753	chr3:81810745	GBE1	-0.72	-6.65	-0.51	8.21e-10	Waist circumference;Body mass index;
TGCT	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	9.52	0.65	1.86e-16	Platelet count;
TGCT	cis	rs10782582	0.609	rs10873797	chr1:76377191	G/T	cg10523679	chr1:76189770	ACADM	-0.58	-5.24	-0.43	6.73e-7	Daytime sleep phenotypes;
TGCT	cis	rs6088580	0.609	rs2378205	chr20:33110803	C/G	cg08999081	chr20:33150536	PIGU	0.29	5.57	0.45	1.54e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs2836950	0.501	rs35994303	chr21:40686020	C/T	cg11890956	chr21:40555474	PSMG1	-0.66	-6.17	-0.48	8.85e-9	Menarche (age at onset);
TGCT	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg12311346	chr5:56204834	C5orf35	0.83	7.78	0.57	2.41e-12	Initial pursuit acceleration;
TGCT	cis	rs7937612	1.000	rs11600703	chr11:120249287	C/T	cg24566217	chr11:120254723	ARHGEF12	-0.28	-4.53	-0.38	1.37e-5	Intraocular pressure;
TGCT	cis	rs2880765	0.835	rs7180923	chr15:86050890	A/T	cg13263323	chr15:86062960	AKAP13	-0.22	-4.79	-0.4	4.61e-6	Coronary artery disease;
TGCT	cis	rs453301	0.631	rs28572014	chr8:8793607	C/T	cg06636001	chr8:8085503	FLJ10661	-0.69	-5.92	-0.47	2.97e-8	Joint mobility (Beighton score);
TGCT	cis	rs10507380	0.824	rs9512630	chr13:27918639	A/C	cg25543773	chr13:27185723	WASF3	0.34	4.83	0.4	3.97e-6	Electrocardiographic traits;
TGCT	cis	rs9868809	0.881	rs7620853	chr3:48666503	G/A	cg00383909	chr3:49044727	WDR6	0.97	5.08	0.42	1.34e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg11764359	chr7:65958608	NA	-0.53	-4.68	-0.39	7.26e-6	Aortic root size;
TGCT	trans	rs1814175	0.645	rs1851853	chr11:49953434	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.67	-0.69	2.92e-19	Height;
TGCT	cis	rs7647973	0.516	rs4955418	chr3:49200627	A/G	cg06212747	chr3:49208901	KLHDC8B	0.66	6.18	0.49	8.29e-9	Menarche (age at onset);
TGCT	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.06	-9.52	-0.65	1.81e-16	Platelet count;
TGCT	cis	rs28595532	0.920	rs115046587	chr4:119779604	T/C	cg14228332	chr4:119757509	SEC24D	1.26	7.08	0.54	9.26e-11	Cannabis dependence symptom count;
TGCT	cis	rs17221829	0.733	rs12797439	chr11:89376199	T/C	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.63	-0.38	9.04e-6	Anxiety in major depressive disorder;
TGCT	cis	rs4478858	0.746	rs10914328	chr1:31688406	A/G	cg00250761	chr1:31883323	NA	0.28	4.76	0.39	5.19e-6	Alcohol dependence;
TGCT	cis	rs1018836	0.608	rs6998106	chr8:91479755	G/T	cg16814680	chr8:91681699	NA	-0.71	-7.13	-0.54	7.28e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2797160	1.000	rs1739362	chr6:126020703	A/T	cg05901451	chr6:126070800	HEY2	0.75	6.7	0.52	6.65e-10	Endometrial cancer;
TGCT	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg00814883	chr7:100076585	TSC22D4	-0.85	-8.62	-0.61	2.62e-14	Platelet count;
TGCT	cis	rs3008870	1.000	rs912797	chr1:67413478	A/G	cg11518657	chr1:67396239	MIER1	0.54	4.65	0.39	8.44e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg03351412	chr1:154909251	PMVK	0.52	4.92	0.4	2.66e-6	Prostate cancer;
TGCT	cis	rs1635	0.655	rs73742544	chr6:28317536	T/A	cg24848467	chr6:28134517	ZNF389	-0.58	-4.7	-0.39	6.75e-6	Schizophrenia;
TGCT	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg11905131	chr22:24372483	LOC391322	-0.95	-11.1	-0.71	2.66e-20	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs12484776	0.786	rs11089973	chr22:40535657	A/G	cg07138101	chr22:40742427	ADSL	0.61	4.6	0.38	1.01e-5	Uterine fibroids;
TGCT	cis	rs9883204	1.000	rs9883204	chr3:123096820	T/C	cg04890266	chr3:123102914	ADCY5	-0.37	-5.2	-0.42	7.84e-7	Birth weight;
TGCT	cis	rs8016982	0.633	rs72695758	chr14:81720146	T/C	cg01989461	chr14:81687754	GTF2A1	0.78	7.69	0.57	3.9e-12	Schizophrenia;
TGCT	cis	rs28374715	0.662	rs72737793	chr15:41516823	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.78	-10.91	-0.7	7.59e-20	Ulcerative colitis;
TGCT	cis	rs4237845	0.844	rs4628718	chr12:58301600	A/C	cg02175503	chr12:58329896	NA	0.56	5.44	0.44	2.67e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs17601876	0.814	rs11632903	chr15:51564341	C/T	cg19946085	chr15:51559439	CYP19A1	-0.34	-5.04	-0.41	1.59e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs68170813	0.559	rs59782202	chr7:107032766	G/T	cg02696742	chr7:106810147	HBP1	-0.7	-5.68	-0.45	8.91e-8	Coronary artery disease;
TGCT	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg24531977	chr5:56204891	C5orf35	-0.75	-7.39	-0.55	1.87e-11	Initial pursuit acceleration;
TGCT	cis	rs11874712	0.527	rs6507664	chr18:43693615	T/G	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.49	4.86	0.4	3.47e-6	Migraine - clinic-based;
TGCT	cis	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg08564027	chr20:61660810	NA	-0.36	-6.38	-0.5	3.22e-9	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2239547	0.603	rs6789219	chr3:53098938	C/G	cg10802521	chr3:52805072	NEK4	-0.58	-5.36	-0.43	3.87e-7	Schizophrenia;
TGCT	cis	rs9303401	0.659	rs11495824	chr17:56918882	C/A	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs7953249	0.807	rs2393791	chr12:121423956	A/G	cg02403541	chr12:121454288	C12orf43	0.52	4.61	0.38	9.94e-6	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg19635926	chr16:89946313	TCF25	0.28	4.82	0.4	4.06e-6	Skin colour saturation;
TGCT	cis	rs7666738	0.830	rs13129503	chr4:98987892	T/C	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9916302	0.784	rs34473775	chr17:37396201	G/T	cg07936489	chr17:37558343	FBXL20	-0.64	-5.17	-0.42	9.21e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs2013441	1.000	rs2263175	chr17:20128029	C/G	cg18979559	chr17:20280153	CCDC144C	-0.44	-4.61	-0.38	9.78e-6	Obesity-related traits;
TGCT	cis	rs12478296	0.892	rs60042638	chr2:243038707	G/A	cg06360820	chr2:242988706	NA	-0.61	-4.75	-0.39	5.52e-6	Obesity-related traits;
TGCT	trans	rs77457752	0.690	rs12352669	chr9:13911919	A/T	cg12973904	chr7:149457885	NA	-0.43	-6.86	-0.52	2.96e-10	Breast cancer;
TGCT	cis	rs670523	0.532	rs6427297	chr1:155975493	C/T	cg05700447	chr1:155978627	NA	0.24	5.26	0.43	5.99e-7	Inflammatory bowel disease;Crohn's disease;
TGCT	trans	rs7628219	0.566	rs1344819	chr3:70757099	C/T	cg00765653	chr20:57415144	GNASAS;GNAS	0.71	6.63	0.51	9.41e-10	Insomnia (caffeine-induced);
TGCT	cis	rs60154123	0.541	rs76216762	chr1:210345621	A/G	cg22029157	chr1:209979665	IRF6	0.73	4.51	0.38	1.48e-5	Coronary artery disease;
TGCT	cis	rs1514658	0.903	rs2175971	chr4:119276829	C/G	cg21605333	chr4:119757512	SEC24D	-0.51	-4.51	-0.38	1.49e-5	Congenital heart disease (maternal effect);
TGCT	cis	rs61990749	0.597	rs176980	chr14:78198449	C/G	cg23188588	chr14:78226832	SNW1;C14orf178	-0.65	-4.59	-0.38	1.06e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs7267979	0.789	rs6083820	chr20:25354178	G/A	cg03522245	chr20:25566470	NINL	-0.52	-5.23	-0.43	6.85e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7647973	1.000	rs6785045	chr3:49435243	G/C	cg07636037	chr3:49044803	WDR6	-0.72	-5.79	-0.46	5.35e-8	Menarche (age at onset);
TGCT	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg26818010	chr10:134567672	INPP5A	-0.36	-4.76	-0.39	5.33e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	trans	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg21659725	chr3:3221576	CRBN	-0.99	-15.57	-0.81	5.76e-31	Intelligence (multi-trait analysis);
TGCT	cis	rs8017423	0.967	rs8016385	chr14:90721946	G/A	cg04374321	chr14:90722782	PSMC1	0.76	7.71	0.57	3.59e-12	Mortality in heart failure;
TGCT	cis	rs1421811	0.606	rs62369523	chr5:32713365	T/G	cg16267343	chr5:32710456	NPR3	0.83	7.19	0.54	5.25e-11	Blood pressure;
TGCT	cis	rs9858542	0.953	rs9841110	chr3:49492481	C/G	cg03060546	chr3:49711283	APEH	-0.61	-5.37	-0.43	3.78e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg13397359	chr6:42928475	GNMT	0.73	6.54	0.51	1.45e-9	Plasma homocysteine levels (post-methionine load test);
TGCT	cis	rs1385374	0.642	rs10847691	chr12:129287449	G/A	cg09035930	chr12:129282057	SLC15A4	-0.55	-4.69	-0.39	6.99e-6	Systemic lupus erythematosus;
TGCT	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg26818010	chr10:134567672	INPP5A	-0.36	-5.09	-0.42	1.31e-6	Migraine;
TGCT	trans	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg13615516	chr5:77269221	NA	0.68	8.54	0.61	3.97e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs425277	1.000	rs262672	chr1:2080813	G/T	cg24578937	chr1:2090814	PRKCZ	0.32	8.03	0.58	6.41e-13	Height;
TGCT	cis	rs12360000	0.797	rs11250853	chr10:1909770	A/G	cg26364871	chr10:1889757	NA	0.41	4.63	0.38	9.26e-6	Metabolite levels (Dihydroxy docosatrienoic acid);
TGCT	cis	rs8014204	0.604	rs12147862	chr14:75384471	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.9	-9.23	-0.64	9.17e-16	Caffeine consumption;
TGCT	cis	rs7089973	0.604	rs11196947	chr10:116601372	G/A	cg03647239	chr10:116582469	FAM160B1	0.59	5.74	0.46	6.72e-8	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs9811920	0.665	rs1872609	chr3:99906579	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.39	4.69	0.39	6.98e-6	Axial length;
TGCT	cis	rs62283056	0.512	rs752854	chr4:6281961	C/T	cg14416269	chr4:6271139	WFS1	0.39	4.97	0.41	2.18e-6	Cisplatin-induced ototoxicity;
TGCT	cis	rs2019216	0.521	rs12449447	chr17:21888786	C/T	cg22648282	chr17:21454238	C17orf51	-0.55	-5.42	-0.44	2.97e-7	Pelvic organ prolapse;
TGCT	cis	rs4240897	0.935	rs1474868	chr1:12044164	A/G	cg13216073	chr1:12042593	MFN2	-0.2	-5.93	-0.47	2.82e-8	Tuberculosis;
TGCT	cis	rs7819412	0.668	rs2409721	chr8:11038244	A/T	cg21775007	chr8:11205619	TDH	-0.51	-4.64	-0.38	8.59e-6	Triglycerides;
TGCT	cis	rs155076	1.000	rs261407	chr13:21855213	C/A	cg11317459	chr13:21872234	NA	-1.33	-11.41	-0.72	4.71e-21	White matter hyperintensity burden;
TGCT	cis	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg15556689	chr8:8085844	FLJ10661	0.64	5.93	0.47	2.74e-8	Mood instability;
TGCT	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg22166914	chr1:53195759	ZYG11B	0.35	5.78	0.46	5.7e-8	Monocyte count;
TGCT	cis	rs2070433	0.706	rs55696586	chr21:47733918	T/C	cg12379764	chr21:47803548	PCNT	0.59	5.11	0.42	1.2e-6	Lymphocyte counts;
TGCT	cis	rs8032315	0.965	rs35346340	chr15:91427872	G/C	cg05211768	chr15:91427848	FES	0.49	4.93	0.41	2.54e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg22508957	chr16:3507546	NAT15	0.51	5.92	0.47	2.89e-8	Tuberculosis;
TGCT	trans	rs17684571	0.938	rs35668437	chr6:56565856	C/A	cg14229071	chr15:89282588	NA	0.52	6.82	0.52	3.54e-10	Schizophrenia;
TGCT	cis	rs2070488	0.965	rs3762791	chr3:38568828	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.83	-8.45	-0.6	6.78e-14	Electrocardiographic conduction measures;
TGCT	cis	rs10504229	0.680	rs16921675	chr8:58052082	A/G	cg08280861	chr8:58055591	NA	0.35	5.03	0.41	1.67e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9788682	0.747	rs2568488	chr15:78736593	T/A	cg24631222	chr15:78858424	CHRNA5	-0.61	-4.55	-0.38	1.25e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs34734847	0.871	rs2239760	chr12:121163518	C/A	cg21892295	chr12:121157589	UNC119B	-0.24	-5.65	-0.45	1.02e-7	Mean corpuscular volume;
TGCT	trans	rs35783704	1.000	rs35783704	chr8:105966258	G/A	cg04212021	chr5:180231084	MGAT1	-0.55	-6.64	-0.51	8.79e-10	Systolic blood pressure;
TGCT	cis	rs11754661	1.000	rs17349687	chr6:151207718	C/T	cg01354656	chr6:151411710	MTHFD1L	0.46	4.8	0.4	4.42e-6	Alzheimer's disease (late onset);
TGCT	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.51	-6.24	-0.49	6.39e-9	Longevity;Endometriosis;
TGCT	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.94	9.46	0.65	2.58e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs12497850	0.931	rs9876848	chr3:48844059	G/A	cg05785598	chr3:49045655	WDR6	0.36	4.75	0.39	5.46e-6	Parkinson's disease;
TGCT	trans	rs3780486	0.801	rs28517717	chr9:33179451	C/T	cg20290983	chr6:43655470	MRPS18A	1.08	11.36	0.71	6.12e-21	IgG glycosylation;
TGCT	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	5.71	0.46	8.05e-8	Alzheimer's disease;
TGCT	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg24250549	chr1:154909240	PMVK	0.62	6.28	0.49	5.29e-9	Prostate cancer;
TGCT	cis	rs854765	0.693	rs12936037	chr17:17777245	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.75	-7.92	-0.58	1.12e-12	Total body bone mineral density;
TGCT	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg07636037	chr3:49044803	WDR6	0.85	8.82	0.62	8.86e-15	Menarche (age at onset);
TGCT	cis	rs77633900	0.614	rs280014	chr15:76986890	A/G	cg21673338	chr15:77095150	SCAPER	-0.5	-4.92	-0.4	2.68e-6	Non-glioblastoma glioma;Glioma;
TGCT	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg03303774	chr4:1407052	NA	0.3	4.74	0.39	5.79e-6	Obesity-related traits;
TGCT	cis	rs992157	0.798	rs7557709	chr2:219167529	G/A	cg00012203	chr2:219082015	ARPC2	0.79	7.99	0.58	8.08e-13	Colorectal cancer;
TGCT	cis	rs7264396	0.790	rs10211771	chr20:34219994	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.3	-5.27	-0.43	5.92e-7	Total cholesterol levels;
TGCT	cis	rs6121246	0.821	rs6058448	chr20:30332396	C/T	cg18721089	chr20:30220636	NA	-0.43	-4.75	-0.39	5.54e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg20607798	chr8:58055168	NA	0.68	5.66	0.45	1e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs10892173	0.678	rs7122817	chr11:117657679	A/G	cg07621104	chr11:117668040	DSCAML1	0.51	5.47	0.44	2.36e-7	Myopia;
TGCT	cis	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg22857025	chr5:266934	NA	-0.34	-6.7	-0.52	6.65e-10	Breast cancer;
TGCT	trans	rs208520	0.690	rs207119	chr6:66786408	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-10.77	-0.7	1.66e-19	Exhaled nitric oxide output;
TGCT	cis	rs67385638	0.802	rs7119142	chr11:5309078	A/G	cg12559170	chr11:5275217	HBG2	0.42	7.62	0.56	5.69e-12	Hemoglobin levels;
TGCT	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.12	0.54	7.84e-11	Prudent dietary pattern;
TGCT	cis	rs9952991	0.566	rs484020	chr18:12855440	G/A	cg23544223	chr18:12777786	NA	0.54	4.71	0.39	6.43e-6	Inflammatory skin disease;
TGCT	cis	rs950169	0.580	rs36126054	chr15:85177723	T/G	cg11189052	chr15:85197271	WDR73	0.73	6.01	0.47	1.96e-8	Schizophrenia;
TGCT	cis	rs9796	0.866	rs1678750	chr15:41410705	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.47	-6.1	-0.48	1.24e-8	Menopause (age at onset);
TGCT	cis	rs17681684	0.565	rs62066045	chr17:9765023	T/C	cg15743799	chr17:9805578	RCVRN	-0.28	-5.84	-0.46	4.37e-8	GIP levels in response to oral glucose tolerance test (fasting);
TGCT	cis	rs2074585	0.806	rs8033813	chr15:90999715	A/T	cg22089800	chr15:90895588	ZNF774	0.76	8.12	0.59	3.92e-13	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
TGCT	cis	rs9303401	0.538	rs2240259	chr17:56458129	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.74	6.76	0.52	4.71e-10	Cognitive test performance;
TGCT	cis	rs910316	0.737	rs28687415	chr14:75495482	T/C	cg11812906	chr14:75593930	NEK9	0.59	5.59	0.45	1.38e-7	Height;
TGCT	cis	rs7635838	0.751	rs9811658	chr3:11395833	A/G	cg00170343	chr3:11313890	ATG7	0.64	6.21	0.49	7.42e-9	HDL cholesterol;
TGCT	cis	rs9372253	0.967	rs9400379	chr6:110713783	A/G	cg00083206	chr6:110721305	DDO	-0.4	-5.94	-0.47	2.72e-8	Platelet distribution width;
TGCT	cis	rs651907	0.535	rs13059470	chr3:101424800	A/G	cg12386194	chr3:101231763	SENP7	-0.51	-5.0	-0.41	1.9e-6	Colorectal cancer;
TGCT	cis	rs6543140	0.964	rs6543136	chr2:103065547	G/A	cg09003973	chr2:102972529	NA	0.56	4.67	0.39	7.86e-6	Blood protein levels;
TGCT	cis	rs4273100	0.541	rs7501702	chr17:19293727	C/T	cg01534423	chr17:18965556	NA	-0.75	-7.83	-0.58	1.83e-12	Schizophrenia;
TGCT	cis	rs72949976	0.898	rs6732233	chr2:214022834	C/T	cg08319019	chr2:214017104	IKZF2	-0.72	-6.91	-0.53	2.27e-10	Lung cancer;Squamous cell lung carcinoma;
TGCT	cis	rs66569888	0.507	rs11673736	chr2:106886935	T/C	cg16099169	chr2:106886729	NA	-0.47	-6.17	-0.48	9e-9	Facial morphology (factor 23);
TGCT	cis	rs877282	0.853	rs11595510	chr10:756757	C/G	cg17470449	chr10:769945	NA	0.29	4.77	0.39	4.98e-6	Uric acid levels;
TGCT	cis	rs11190604	1.000	rs2495743	chr10:102329739	G/C	cg16342193	chr10:102329863	NA	-0.43	-5.39	-0.44	3.43e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2075371	0.966	rs2544214	chr7:133985736	G/A	cg11752832	chr7:134001865	SLC35B4	0.69	6.32	0.49	4.19e-9	Mean platelet volume;
TGCT	cis	rs78487399	0.808	rs113373412	chr2:43762987	C/G	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.79	4.82	0.4	4.14e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs75059851	0.756	rs7106806	chr11:133838837	G/C	cg14047540	chr11:133829660	NA	-0.58	-5.85	-0.46	4.17e-8	Schizophrenia;
TGCT	cis	rs7017914	0.967	rs13272523	chr8:71641472	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.03	-0.41	1.69e-6	Bone mineral density;
TGCT	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg02975922	chr3:195473998	MUC4	-0.23	-5.08	-0.42	1.35e-6	Pancreatic cancer;
TGCT	cis	rs6977660	0.507	rs72591448	chr7:19775298	C/T	cg05791153	chr7:19748676	TWISTNB	0.97	6.34	0.49	3.9e-9	Thyroid stimulating hormone;
TGCT	cis	rs11190604	1.000	rs2489036	chr10:102319581	A/G	cg23241863	chr10:102295624	HIF1AN	0.69	5.21	0.42	7.75e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs322458	0.568	rs470931	chr3:120626429	T/C	cg21456320	chr3:121264201	POLQ	-0.32	-4.52	-0.38	1.43e-5	Aging (facial);
TGCT	cis	rs68170813	0.652	rs6976759	chr7:107158506	A/G	cg02696742	chr7:106810147	HBP1	-0.58	-4.47	-0.37	1.74e-5	Coronary artery disease;
TGCT	cis	rs12422267	0.536	rs11246933	chr12:132610314	G/A	cg09764611	chr12:132620959	NA	-0.38	-5.71	-0.46	7.88e-8	Plasma amyloid beta peptide concentrations (ABx-40);
TGCT	cis	rs6903823	0.508	rs1150721	chr6:28255040	G/C	cg18815343	chr6:28367644	ZSCAN12	-0.44	-4.65	-0.39	8.28e-6	Pulmonary function;
TGCT	cis	rs950027	0.596	rs2467853	chr15:45698793	T/G	cg14582100	chr15:45693742	SPATA5L1	0.43	5.38	0.44	3.52e-7	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg07424592	chr7:64974309	NA	1.4	8.42	0.6	7.87e-14	Diabetic kidney disease;
TGCT	cis	rs9467773	0.620	rs6925087	chr6:26592853	T/A	cg02458000	chr6:26745757	NA	0.51	4.77	0.39	5.08e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6840360	0.967	rs6823423	chr4:152604723	T/C	cg17479576	chr4:152424074	FAM160A1	-0.46	-4.8	-0.4	4.53e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs763121	0.853	rs2205802	chr22:39046327	T/C	cg06022373	chr22:39101656	GTPBP1	0.77	7.46	0.56	1.35e-11	Menopause (age at onset);
TGCT	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg16680214	chr1:154839983	KCNN3	-0.35	-7.05	-0.53	1.13e-10	Prostate cancer;
TGCT	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	8.0	0.58	7.67e-13	Platelet count;
TGCT	cis	rs9902453	0.765	rs2729440	chr17:28106874	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.84	-8.19	-0.59	2.73e-13	Coffee consumption (cups per day);
TGCT	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg01802117	chr1:53393560	SCP2	-0.45	-5.42	-0.44	2.98e-7	Monocyte count;
TGCT	trans	rs877282	0.945	rs34367686	chr10:791868	G/C	cg22713356	chr15:30763199	NA	1.18	10.55	0.69	5.81e-19	Uric acid levels;
TGCT	cis	rs7465272	0.500	rs7463655	chr8:143731034	G/C	cg10596483	chr8:143751796	JRK	0.53	5.21	0.42	7.5e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs3796352	1.000	rs11718538	chr3:52975987	C/G	cg15956490	chr3:53032818	SFMBT1	0.59	6.04	0.48	1.65e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg00343986	chr7:65444356	GUSB	-0.26	-6.14	-0.48	1.05e-8	Calcium levels;
TGCT	cis	rs9611565	0.512	rs5758436	chr22:42124265	C/T	cg06634786	chr22:41940651	POLR3H	0.89	8.81	0.62	9.46e-15	Vitiligo;
TGCT	cis	rs7236492	0.683	rs79747802	chr18:77198964	C/T	cg15644404	chr18:77186268	NFATC1	-0.35	-4.76	-0.39	5.22e-6	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs6542838	0.611	rs1878589	chr2:99517979	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.51	-4.66	-0.39	8.02e-6	Fear of minor pain;
TGCT	cis	rs7772486	0.764	rs2265468	chr6:146218346	A/C	cg23711669	chr6:146136114	FBXO30	0.9	10.54	0.69	6.03e-19	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6733011	0.559	rs6711022	chr2:99449536	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-4.95	-0.41	2.37e-6	Bipolar disorder;
TGCT	cis	rs929354	0.707	rs1182445	chr7:157024428	C/G	cg05182265	chr7:156933206	UBE3C	0.4	9.05	0.63	2.54e-15	Body mass index;
TGCT	cis	rs11098499	0.697	rs10016448	chr4:120298845	A/G	cg09307838	chr4:120376055	NA	0.65	6.39	0.5	3.02e-9	Corneal astigmatism;
TGCT	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	6.87	0.52	2.82e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6714710	0.603	rs956039	chr2:98416848	C/A	cg26665480	chr2:98280029	ACTR1B	0.7	6.61	0.51	1.05e-9	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg07061783	chr6:25882402	NA	-0.68	-6.69	-0.52	6.73e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs3858526	0.959	rs11039723	chr11:5956002	G/C	cg13902645	chr11:5959945	NA	-0.44	-4.73	-0.39	6.06e-6	DNA methylation (variation);
TGCT	cis	rs35306767	0.855	rs61830932	chr10:934183	T/C	cg20503657	chr10:835505	NA	0.74	10.3	0.68	2.41e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs2594989	0.887	rs2616535	chr3:11595167	A/G	cg00170343	chr3:11313890	ATG7	0.66	4.6	0.38	1.03e-5	Circulating chemerin levels;
TGCT	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg22920501	chr2:26401640	FAM59B	-0.73	-6.44	-0.5	2.35e-9	Gut microbiome composition (summer);
TGCT	cis	rs734999	0.545	rs3890745	chr1:2553624	C/T	cg18854424	chr1:2615690	NA	-0.45	-5.02	-0.41	1.77e-6	Ulcerative colitis;
TGCT	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.59	5.46	0.44	2.51e-7	Prudent dietary pattern;
TGCT	cis	rs72945132	0.714	rs57320340	chr11:70160010	G/C	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg08509172	chr19:19383838	TM6SF2	-0.35	-4.63	-0.38	9.18e-6	Tonsillectomy;
TGCT	cis	rs2224391	0.590	rs72813697	chr6:5274266	T/A	cg09085698	chr6:5261316	LYRM4;FARS2	-1.0	-5.18	-0.42	8.9e-7	Height;
TGCT	cis	rs16867321	0.570	rs73025489	chr2:181548425	A/G	cg19218067	chr2:181235115	NA	-0.42	-4.54	-0.38	1.34e-5	Obesity;
TGCT	cis	rs2299587	0.698	rs2283113	chr8:17880243	C/A	cg04898035	chr8:17640624	MTUS1	-0.21	-4.77	-0.39	5.09e-6	Economic and political preferences;
TGCT	cis	rs3849570	1.000	rs13088000	chr3:81839404	T/C	cg07356753	chr3:81810745	GBE1	-0.79	-7.16	-0.54	6.31e-11	Waist circumference;Body mass index;
TGCT	cis	rs7267979	1.000	rs401166	chr20:25446308	C/G	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs651907	0.535	rs2290859	chr3:101525625	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.87	10.26	0.68	2.9e-18	Colorectal cancer;
TGCT	cis	rs17253792	0.731	rs74823888	chr14:56049800	T/C	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs9911578	0.692	rs411988	chr17:56709034	G/A	cg12560992	chr17:57184187	TRIM37	0.55	5.96	0.47	2.38e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9383153	0.590	rs2072736	chr6:16328068	T/C	cg06493612	chr6:15502050	JARID2	0.63	4.88	0.4	3.15e-6	Gambling;
TGCT	cis	rs9436747	0.641	rs12042877	chr1:66053148	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.56	5.04	0.41	1.59e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs12477438	0.798	rs1530996	chr2:99584079	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-6.33	-0.49	4.13e-9	Chronic sinus infection;
TGCT	cis	rs9467773	0.869	rs1796520	chr6:26410800	C/T	cg09904177	chr6:26538194	HMGN4	-0.5	-4.62	-0.38	9.41e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg20607798	chr8:58055168	NA	0.44	4.52	0.38	1.44e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg11494091	chr17:61959527	GH2	0.42	7.28	0.55	3.36e-11	Height;
TGCT	cis	rs858239	0.536	rs6956974	chr7:23252318	C/G	cg05602783	chr7:23145260	KLHL7	0.67	5.77	0.46	5.83e-8	Cerebrospinal fluid biomarker levels;
TGCT	trans	rs1814175	0.669	rs11040455	chr11:49669829	G/C	cg03929089	chr4:120376271	NA	-0.6	-6.88	-0.53	2.6e-10	Height;
TGCT	cis	rs7811142	0.945	rs6974282	chr7:100098295	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.04	8.56	0.61	3.72e-14	Platelet count;
TGCT	cis	rs587847	0.708	rs34972991	chr15:37609380	G/A	cg00216138	chr15:37171175	LOC145845	0.31	4.5	0.37	1.56e-5	Intraocular pressure;
TGCT	cis	rs12142240	0.698	rs57267378	chr1:46816644	A/G	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs1971256	0.500	rs1971255	chr6:151816094	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	0.77	4.74	0.39	5.88e-6	Endometriosis;
TGCT	cis	rs669446	0.591	rs636547	chr1:44106516	C/A	cg12908607	chr1:44402522	ARTN	-0.55	-5.9	-0.47	3.25e-8	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs12579753	0.879	rs12579544	chr12:82164043	A/C	cg07988820	chr12:82153109	PPFIA2	-0.69	-7.77	-0.57	2.56e-12	Resting heart rate;
TGCT	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg07061783	chr6:25882402	NA	-0.58	-5.6	-0.45	1.34e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs858239	0.601	rs1034963	chr7:23148473	T/C	cg05602783	chr7:23145260	KLHL7	-0.66	-5.62	-0.45	1.2e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs7666738	0.830	rs10007872	chr4:99001904	T/C	cg05340658	chr4:99064831	C4orf37	0.49	5.6	0.45	1.31e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10088262	0.629	rs12541177	chr8:124800273	G/T	cg20713898	chr8:124780851	FAM91A1	-0.84	-7.19	-0.54	5.3e-11	Pancreatic cancer;
TGCT	cis	rs11190604	0.767	rs10883477	chr10:102161396	A/G	cg16342193	chr10:102329863	NA	-0.39	-5.02	-0.41	1.78e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7605378	0.658	rs4673507	chr2:200710167	G/C	cg23649088	chr2:200775458	C2orf69	0.45	8.18	0.59	2.92e-13	Osteoporosis;
TGCT	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg00343986	chr7:65444356	GUSB	-0.2	-4.51	-0.38	1.51e-5	Aortic root size;
TGCT	cis	rs1153858	1.000	rs10444821	chr15:45647236	C/T	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.62e-8	Homoarginine levels;
TGCT	cis	rs7428	0.527	rs1554110	chr2:85547963	C/T	cg03728395	chr2:85555865	TGOLN2	-0.31	-5.17	-0.42	9.27e-7	Ear protrusion;
TGCT	cis	rs78707713	0.512	rs12412776	chr10:71179502	G/A	cg12610070	chr10:71211762	TSPAN15	-0.57	-6.41	-0.5	2.71e-9	Venous thromboembolism;
TGCT	cis	rs9814567	1.000	rs9856693	chr3:134306913	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.91	-8.83	-0.62	8.17e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs875971	1.000	rs2220626	chr7:65546062	C/T	cg11764359	chr7:65958608	NA	-0.58	-4.99	-0.41	2.01e-6	Aortic root size;
TGCT	cis	rs13242816	1.000	rs55977427	chr7:116110768	C/T	cg16553024	chr7:116138462	CAV2	-0.45	-4.75	-0.39	5.64e-6	P wave duration;
TGCT	cis	rs11030122	0.702	rs12223176	chr11:3982537	T/G	cg18678763	chr11:4115507	RRM1	-0.49	-6.13	-0.48	1.08e-8	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs826838	0.510	rs10506129	chr12:39224242	A/T	cg26384229	chr12:38710491	ALG10B	0.64	5.18	0.42	8.89e-7	Heart rate;
TGCT	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg25036284	chr2:26402008	FAM59B	-0.62	-4.94	-0.41	2.44e-6	Gut microbiome composition (summer);
TGCT	cis	rs12580194	1.000	rs60206376	chr12:55703375	C/A	cg20672549	chr12:56432144	IKZF4	0.27	4.45	0.37	1.92e-5	Cancer;
TGCT	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg10802521	chr3:52805072	NEK4	-0.66	-7.84	-0.58	1.74e-12	Bipolar disorder;
TGCT	cis	rs922182	0.595	rs7176387	chr15:64219108	A/G	cg02919090	chr15:64263738	DAPK2	-0.36	-6.43	-0.5	2.44e-9	Blood protein levels;
TGCT	cis	rs10507380	0.824	rs75594604	chr13:27911116	G/A	cg25543773	chr13:27185723	WASF3	0.34	4.89	0.4	3.02e-6	Electrocardiographic traits;
TGCT	cis	rs7169223	0.653	rs1564499	chr15:79084808	C/T	cg21242079	chr15:79101063	ADAMTS7	-0.29	-4.92	-0.4	2.71e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
TGCT	cis	rs9291683	0.595	rs11722930	chr4:10035454	G/A	cg11266682	chr4:10021025	SLC2A9	0.64	8.92	0.63	5e-15	Bone mineral density;
TGCT	cis	rs1153858	0.943	rs11070454	chr15:45680252	C/T	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.62e-8	Homoarginine levels;
TGCT	cis	rs7833790	0.700	rs7825180	chr8:82723991	T/A	cg06027949	chr8:82754900	SNX16	-0.65	-5.03	-0.41	1.69e-6	Diastolic blood pressure;
TGCT	cis	rs60843830	1.000	rs9213	chr2:218386	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.75	7.05	0.53	1.11e-10	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs35883536	0.566	rs12566440	chr1:101095202	A/G	cg06223162	chr1:101003688	GPR88	0.32	5.34	0.43	4.31e-7	Monocyte count;
TGCT	cis	rs7666738	0.791	rs10005118	chr4:99038196	A/C	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28785552	0.536	rs10401689	chr19:53248430	T/G	cg10871876	chr19:53194124	ZNF83	0.44	5.26	0.43	6.13e-7	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs7614311	0.689	rs73120898	chr3:63828780	G/A	cg22134162	chr3:63841271	THOC7	-0.38	-4.48	-0.37	1.64e-5	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs6723226	0.767	rs10172308	chr2:32555760	G/A	cg02381751	chr2:32503542	YIPF4	-0.57	-5.12	-0.42	1.15e-6	Intelligence (multi-trait analysis);
TGCT	trans	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg11887960	chr12:57824829	NA	1.14	9.1	0.63	1.93e-15	Obesity-related traits;
TGCT	cis	rs35883536	0.647	rs12023028	chr1:101042717	C/T	cg14855972	chr1:101004472	GPR88	-0.24	-4.49	-0.37	1.64e-5	Monocyte count;
TGCT	cis	rs2549003	0.870	rs10053046	chr5:131821558	A/G	cg00255919	chr5:131827918	IRF1	0.2	4.7	0.39	6.92e-6	Asthma (sex interaction);
TGCT	cis	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg20637647	chr7:64974828	NA	0.9	5.31	0.43	4.87e-7	Diabetic kidney disease;
TGCT	cis	rs10514758	0.744	rs78984868	chr3:114853930	C/T	cg05943254	chr3:114009756	NA	-0.85	-5.06	-0.41	1.48e-6	Urate levels in obese individuals;
TGCT	cis	rs7528684	0.816	rs2210918	chr1:157692985	A/G	cg17134153	chr1:157670328	FCRL3	-0.26	-4.69	-0.39	7e-6	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;
TGCT	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg09323728	chr8:95962352	TP53INP1	-0.55	-7.07	-0.54	9.72e-11	Type 2 diabetes;
TGCT	cis	rs6733011	0.582	rs6757099	chr2:99415235	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.52	-5.17	-0.42	9.04e-7	Bipolar disorder;
TGCT	cis	rs4566357	0.615	rs12328876	chr2:227918899	G/T	cg11843606	chr2:227700838	RHBDD1	-0.55	-5.26	-0.43	6.22e-7	Coronary artery disease;
TGCT	cis	rs477895	0.838	rs12798333	chr11:64012784	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.83	6.93	0.53	2.04e-10	Mean platelet volume;
TGCT	cis	rs2242194	0.816	rs2242193	chr1:154995503	A/G	cg12436631	chr1:155007014	DCST1;DCST2	-0.27	-7.62	-0.56	5.57e-12	Schizophrenia;
TGCT	cis	rs9733	0.519	rs7521898	chr1:150707596	G/A	cg09365446	chr1:150670422	GOLPH3L	0.3	4.52	0.38	1.4e-5	Tonsillectomy;
TGCT	cis	rs10493773	0.609	rs10873716	chr1:86178347	G/T	cg17807903	chr1:86174739	ZNHIT6	-0.52	-8.15	-0.59	3.45e-13	Urate levels in overweight individuals;
TGCT	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.71	5.14	0.42	1.02e-6	Platelet count;
TGCT	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg10560079	chr2:191398806	TMEM194B	-0.36	-5.07	-0.41	1.4e-6	Pulse pressure;
TGCT	cis	rs17767294	0.614	rs72850298	chr6:28222556	G/A	cg08851530	chr6:28072375	NA	1.54	6.89	0.53	2.51e-10	Parkinson's disease;
TGCT	cis	rs3806843	0.521	rs246061	chr5:140324656	C/A	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs1008375	0.835	rs13122181	chr4:17708815	C/A	cg18681998	chr4:17616180	MED28	-0.84	-8.54	-0.61	4.13e-14	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2228479	0.557	rs62054639	chr16:89821489	C/T	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs2073300	0.793	rs75758241	chr20:23434696	A/G	cg09953122	chr20:23471693	CST8	-0.61	-4.52	-0.38	1.4e-5	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs651907	0.535	rs11716558	chr3:101528481	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.31	-6.52	-0.51	1.56e-9	Colorectal cancer;
TGCT	trans	rs629535	0.954	rs559245	chr8:70009238	T/A	cg21567404	chr3:27674614	NA	-0.56	-8.41	-0.6	8.26e-14	Dupuytren's disease;
TGCT	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg05754148	chr16:3507555	NAT15	0.43	5.17	0.42	9.15e-7	Tuberculosis;
TGCT	cis	rs4700695	0.719	rs27078	chr5:65445331	G/C	cg21114390	chr5:65439923	SFRS12	-0.84	-7.45	-0.56	1.35e-11	Facial morphology (factor 19);
TGCT	cis	rs344364	0.511	rs2982433	chr16:1954508	A/G	cg26617929	chr16:1858877	NA	-0.24	-4.61	-0.38	9.87e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs9911578	0.967	rs72628392	chr17:56506160	A/G	cg05425664	chr17:57184151	TRIM37	0.62	6.16	0.48	9.42e-9	Intelligence (multi-trait analysis);
TGCT	trans	rs10203711	1.000	rs4994753	chr2:239567253	T/C	cg16021909	chr1:248021091	TRIM58	-0.66	-6.66	-0.51	7.94e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg25036284	chr2:26402008	FAM59B	-0.57	-4.97	-0.41	2.15e-6	Gut microbiome composition (summer);
TGCT	cis	rs6714710	0.535	rs3192177	chr2:98354511	G/A	cg26665480	chr2:98280029	ACTR1B	0.63	5.63	0.45	1.14e-7	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs6671200	0.607	rs7528790	chr1:95709074	A/G	cg26537280	chr1:95699037	RWDD3	-0.51	-4.9	-0.4	2.94e-6	Stearic acid (18:0) levels;
TGCT	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg20276088	chr3:133502917	NA	0.26	5.43	0.44	2.82e-7	Iron status biomarkers;
TGCT	cis	rs11118844	0.744	rs4623704	chr1:221953846	G/A	cg04222084	chr1:221915650	DUSP10	-0.8	-4.83	-0.4	3.89e-6	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
TGCT	cis	rs2066819	1.000	rs77853814	chr12:56687572	G/T	cg26714650	chr12:56694279	CS	-1.36	-6.06	-0.48	1.54e-8	Psoriasis vulgaris;
TGCT	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg18867708	chr6:26865862	GUSBL1	-0.39	-5.16	-0.42	9.66e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs11098499	0.863	rs3775847	chr4:120447642	A/C	cg09307838	chr4:120376055	NA	0.69	6.53	0.51	1.49e-9	Corneal astigmatism;
TGCT	cis	rs910316	0.763	rs12588981	chr14:75460561	A/G	cg11812906	chr14:75593930	NEK9	0.58	5.56	0.45	1.6e-7	Height;
TGCT	cis	rs2050392	0.799	rs2907	chr10:30728250	A/G	cg13289132	chr10:30722225	MAP3K8	-0.41	-4.97	-0.41	2.15e-6	Inflammatory bowel disease;
TGCT	trans	rs459571	0.920	rs460154	chr9:136909309	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.69	-7.36	-0.55	2.2e-11	Platelet distribution width;
TGCT	cis	rs36051895	0.632	rs12340617	chr9:5164492	G/C	cg02405213	chr9:5042618	JAK2	-0.72	-9.27	-0.64	7.51e-16	Pediatric autoimmune diseases;
TGCT	cis	rs17376456	0.597	rs1031423	chr5:93276883	A/G	cg25358565	chr5:93447407	FAM172A	-0.62	-5.85	-0.47	4.08e-8	Diabetic retinopathy;
TGCT	cis	rs7914558	1.000	rs7896547	chr10:104866958	A/G	cg04362960	chr10:104952993	NT5C2	0.63	5.64	0.45	1.07e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs624899	0.522	rs645584	chr19:11612466	A/G	cg04328562	chr19:11649701	CNN1	0.44	4.6	0.38	1.02e-5	Presence of antiphospholipid antibodies;
TGCT	cis	rs514406	0.505	rs6688064	chr1:53165609	C/T	cg24675658	chr1:53192096	ZYG11B	-0.74	-8.3	-0.6	1.52e-13	Monocyte count;
TGCT	cis	rs2147959	0.714	rs6659690	chr1:228628170	A/G	cg22700015	chr1:228743131	NA	-0.57	-4.53	-0.38	1.35e-5	Adult asthma;
TGCT	cis	rs9611565	0.649	rs5758434	chr22:42116163	G/A	cg06481639	chr22:41940642	POLR3H	0.56	4.87	0.4	3.39e-6	Vitiligo;
TGCT	cis	rs2739330	1.000	rs2739330	chr22:24295286	T/C	cg18538332	chr22:24372958	LOC391322	-0.99	-12.78	-0.75	2.24e-24	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg18876405	chr7:65276391	NA	-0.32	-4.92	-0.4	2.72e-6	Aortic root size;
TGCT	cis	rs6669072	0.669	rs814545	chr1:91240551	C/G	cg08895590	chr1:91227319	NA	-0.34	-4.5	-0.37	1.57e-5	Cognitive function;
TGCT	cis	rs10883723	0.810	rs7074343	chr10:104283165	G/A	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs7949030	0.626	rs61296092	chr11:62320838	T/C	cg11742103	chr11:62369870	EML3;MTA2	0.61	8.75	0.62	1.31e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2549003	1.000	rs7735073	chr5:131815357	G/A	cg02551604	chr5:131831745	NA	-0.89	-11.77	-0.73	6.36e-22	Asthma (sex interaction);
TGCT	cis	rs7226408	0.857	rs8099118	chr18:34593699	A/G	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs2688608	0.592	rs7909802	chr10:75484186	G/C	cg19442545	chr10:75533431	FUT11	-0.37	-5.77	-0.46	5.89e-8	Inflammatory bowel disease;
TGCT	cis	rs12142240	0.698	rs6683192	chr1:46830257	C/T	cg14993813	chr1:46806288	NSUN4	-0.58	-4.8	-0.4	4.46e-6	Menopause (age at onset);
TGCT	cis	rs7027203	0.828	rs4744291	chr9:96598297	A/G	cg14396892	chr9:96623032	NA	-0.26	-5.46	-0.44	2.51e-7	DNA methylation (variation);
TGCT	cis	rs74181299	0.964	rs2540949	chr2:65284231	A/T	cg05010058	chr2:65284262	CEP68	0.43	4.85	0.4	3.61e-6	Pulse pressure;
TGCT	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg06634786	chr22:41940651	POLR3H	0.88	8.73	0.62	1.44e-14	Vitiligo;
TGCT	cis	rs12410462	0.502	rs115241368	chr1:227795465	A/G	cg23173402	chr1:227635558	NA	0.67	4.58	0.38	1.11e-5	Major depressive disorder;
TGCT	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg13342137	chr4:2252803	MXD4	0.17	4.59	0.38	1.07e-5	Obesity-related traits;
TGCT	cis	rs7809950	0.822	rs2712228	chr7:107300340	A/C	cg23024343	chr7:107201750	COG5	0.29	4.78	0.39	4.94e-6	Coronary artery disease;
TGCT	cis	rs12935418	0.524	rs9933697	chr16:80973534	A/G	cg07676361	chr16:80966860	NA	-0.32	-4.57	-0.38	1.18e-5	Mean corpuscular volume;
TGCT	cis	rs9653442	0.545	rs4851252	chr2:100757280	C/T	cg07810366	chr2:100720526	AFF3	-0.39	-5.63	-0.45	1.17e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs42648	0.777	rs4728878	chr7:89924232	T/G	cg25739043	chr7:89950458	NA	-0.73	-7.32	-0.55	2.79e-11	Homocysteine levels;
TGCT	cis	rs9297145	0.916	rs4236540	chr7:98769025	A/C	cg05967295	chr7:98741636	SMURF1	1.03	16.21	0.82	1.99e-32	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs6570726	0.818	rs437147	chr6:145875423	A/T	cg23711669	chr6:146136114	FBXO30	0.89	9.93	0.67	1.82e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9303401	0.659	rs7216648	chr17:56790858	C/T	cg25039879	chr17:56429692	SUPT4H1	0.52	4.62	0.38	9.48e-6	Cognitive test performance;
TGCT	cis	rs1008375	0.966	rs11737844	chr4:17697421	A/C	cg18681998	chr4:17616180	MED28	0.78	7.35	0.55	2.35e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9929218	0.551	rs2296406	chr16:68721340	G/A	cg01251360	chr16:68772225	CDH1	-0.25	-4.63	-0.38	8.9e-6	Colorectal cancer;
TGCT	cis	rs12682352	0.602	rs6993494	chr8:8667444	C/T	cg06636001	chr8:8085503	FLJ10661	0.61	5.1	0.42	1.26e-6	Neuroticism;
TGCT	cis	rs933688	1.000	rs6452953	chr5:90723034	T/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.88	8.23	0.59	2.24e-13	Smoking behavior;
TGCT	cis	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg06697600	chr4:7070879	GRPEL1	-0.47	-4.94	-0.41	2.42e-6	Monocyte percentage of white cells;
TGCT	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg00343986	chr7:65444356	GUSB	0.24	5.26	0.43	6.15e-7	Aortic root size;
TGCT	cis	rs9549367	0.789	rs71446679	chr13:113894821	C/T	cg00898013	chr13:113819073	PROZ	-0.4	-5.03	-0.41	1.64e-6	Platelet distribution width;
TGCT	cis	rs12579753	0.672	rs4509857	chr12:82268017	C/T	cg07988820	chr12:82153109	PPFIA2	-0.42	-4.44	-0.37	1.97e-5	Resting heart rate;
TGCT	cis	rs7178572	0.568	rs4886856	chr15:77510585	A/G	cg22256960	chr15:77711686	NA	-0.87	-8.87	-0.62	6.78e-15	Type 2 diabetes;
TGCT	cis	rs28735056	0.596	rs3744879	chr18:77679006	G/C	cg16244155	chr18:77905565	LOC100130522	-0.39	-4.53	-0.38	1.39e-5	Schizophrenia;
TGCT	cis	rs909674	0.865	rs5757682	chr22:39848259	T/G	cg05872129	chr22:39784769	NA	-0.99	-9.89	-0.66	2.4e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg22764044	chr5:178986830	RUFY1	-0.52	-5.98	-0.47	2.21e-8	Lung cancer;
TGCT	cis	rs28785552	0.931	rs8113078	chr19:53239084	T/G	cg04754360	chr19:53238445	ZNF611	-0.66	-5.32	-0.43	4.67e-7	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs3617	0.572	rs2256332	chr3:52855865	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	-0.5	-4.76	-0.39	5.23e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs600231	0.706	rs10896016	chr11:65335705	C/T	cg13974409	chr11:65292307	SCYL1	-0.45	-4.53	-0.38	1.35e-5	Bone mineral density;
TGCT	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg05025164	chr4:1340916	KIAA1530	0.68	5.64	0.45	1.11e-7	Longevity;
TGCT	cis	rs12643440	0.574	rs62296689	chr4:17139096	G/C	cg22650099	chr4:17144496	NA	-0.46	-4.7	-0.39	6.79e-6	Metabolite levels (Pyroglutamine);
TGCT	cis	rs6964587	1.000	rs6946356	chr7:91727385	G/A	cg17063962	chr7:91808500	NA	0.86	9.47	0.65	2.39e-16	Breast cancer;
TGCT	cis	rs6489785	0.509	rs3213570	chr12:121222411	C/G	cg02419362	chr12:121203948	SPPL3	0.19	4.47	0.37	1.74e-5	Longevity;Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs7017914	0.967	rs62530792	chr8:71618767	T/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.55	-5.13	-0.42	1.11e-6	Bone mineral density;
TGCT	cis	rs6988636	1.000	rs28542077	chr8:124190896	T/C	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs12900413	0.603	rs2351493	chr15:90299536	A/G	cg24249390	chr15:90295951	MESP1	-0.29	-5.03	-0.41	1.7e-6	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs4072705	0.614	rs35929043	chr9:127234356	T/C	cg13476313	chr9:127244764	NR5A1	0.29	4.49	0.37	1.64e-5	Menarche (age at onset);
TGCT	cis	rs7100689	0.753	rs4934125	chr10:82147466	T/C	cg01528321	chr10:82214614	TSPAN14	0.86	8.47	0.61	5.9e-14	Post bronchodilator FEV1;
TGCT	cis	rs6582630	0.502	rs11614397	chr12:38328163	C/T	cg26384229	chr12:38710491	ALG10B	0.83	7.27	0.55	3.51e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg04944784	chr2:26401820	FAM59B	0.7	5.71	0.46	7.94e-8	Gut microbiome composition (summer);
TGCT	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.94	10.0	0.67	1.29e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs4253772	0.513	rs9615345	chr22:46713631	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.74	5.37	0.43	3.66e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs71435601	0.600	rs312981	chr2:21378151	G/A	cg25035485	chr2:21266500	APOB	0.51	4.48	0.37	1.66e-5	Cholesterol, total;
TGCT	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg04267008	chr7:1944627	MAD1L1	-0.38	-4.93	-0.4	2.55e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg11890956	chr21:40555474	PSMG1	0.81	7.98	0.58	8.45e-13	Cognitive function;
TGCT	trans	rs10504390	0.656	rs17302765	chr8:66474459	A/G	cg18118147	chr19:51128640	SYT3	-0.77	-6.81	-0.52	3.71e-10	IgG glycosylation;
TGCT	cis	rs4839827	1	rs4839827	chr6:96853967	C/T	cg18709589	chr6:96969512	KIAA0776	0.52	4.84	0.4	3.72e-6	Migraine;
TGCT	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	5.8	0.46	5.19e-8	Alzheimer's disease;
TGCT	cis	rs9796	0.870	rs2925346	chr15:41315695	G/A	cg18705301	chr15:41695430	NDUFAF1	0.41	5.33	0.43	4.57e-7	Menopause (age at onset);
TGCT	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg06221963	chr1:154839813	KCNN3	-0.75	-12.65	-0.75	4.66e-24	Prostate cancer;
TGCT	cis	rs709400	0.597	rs1013650	chr14:103909203	G/A	cg12935359	chr14:103987150	CKB	-0.33	-4.84	-0.4	3.86e-6	Body mass index;
TGCT	trans	rs6762477	0.748	rs9831967	chr3:50217234	C/T	cg21659725	chr3:3221576	CRBN	-0.7	-7.99	-0.58	7.75e-13	Menarche (age at onset);
TGCT	cis	rs4700695	0.719	rs36922	chr5:65464856	C/T	cg21114390	chr5:65439923	SFRS12	-0.82	-6.8	-0.52	4.03e-10	Facial morphology (factor 19);
TGCT	cis	rs13256369	0.851	rs13267036	chr8:8566685	G/A	cg17143192	chr8:8559678	CLDN23	0.58	5.41	0.44	3.15e-7	Obesity-related traits;
TGCT	cis	rs7439150	0.954	rs2227395	chr4:155484511	G/A	cg22130008	chr4:155548532	NA	-0.47	-5.8	-0.46	5.25e-8	Fibrinogen levels;
TGCT	cis	rs13217239	0.646	rs4403259	chr6:26997617	C/T	cg15659132	chr6:26577336	NA	0.54	5.44	0.44	2.78e-7	Schizophrenia;
TGCT	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg21856205	chr7:94953877	PON1	-0.73	-8.46	-0.61	6.15e-14	Paraoxonase activity;
TGCT	cis	rs7666738	0.830	rs2903154	chr4:99048151	A/G	cg05340658	chr4:99064831	C4orf37	0.52	5.94	0.47	2.68e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9291683	0.530	rs4235346	chr4:9945296	C/T	cg11266682	chr4:10021025	SLC2A9	-0.62	-8.01	-0.58	7.07e-13	Bone mineral density;
TGCT	cis	rs7020830	0.789	rs17408112	chr9:37114065	A/G	cg14294708	chr9:37120828	ZCCHC7	1.31	20.37	0.88	2.24e-41	Schizophrenia;
TGCT	cis	rs9952991	0.941	rs1893217	chr18:12809340	A/G	cg23544223	chr18:12777786	NA	-0.59	-5.3	-0.43	5.14e-7	Inflammatory skin disease;
TGCT	cis	rs854765	0.583	rs7214536	chr17:17852446	G/A	cg09796270	chr17:17721594	SREBF1	0.23	4.55	0.38	1.27e-5	Total body bone mineral density;
TGCT	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.16	0.54	6.32e-11	Prudent dietary pattern;
TGCT	cis	rs67311347	0.955	rs4974068	chr3:40376929	T/C	cg13683864	chr3:40499215	RPL14	-1.08	-11.45	-0.72	3.78e-21	Renal cell carcinoma;
TGCT	cis	rs950169	0.881	rs62029596	chr15:84955434	A/G	cg11189052	chr15:85197271	WDR73	0.81	6.22	0.49	6.89e-9	Schizophrenia;
TGCT	cis	rs2180341	0.883	rs7760748	chr6:127690062	C/T	cg27446573	chr6:127587934	RNF146	1.1	10.61	0.69	4.22e-19	Breast cancer;
TGCT	cis	rs67478160	0.584	rs2295148	chr14:104195610	T/C	cg26031613	chr14:104095156	KLC1	-0.77	-7.66	-0.57	4.63e-12	Schizophrenia;
TGCT	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-5.1	-0.42	1.23e-6	Bipolar disorder;
TGCT	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.49	-4.76	-0.39	5.34e-6	Bipolar disorder;
TGCT	cis	rs9640161	0.659	rs7781827	chr7:150008858	T/C	cg10018233	chr7:150070692	REPIN1	0.31	4.44	0.37	1.96e-5	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs72945132	0.709	rs28634008	chr11:70225719	A/C	cg00319359	chr11:70116639	PPFIA1	1.02	7.54	0.56	8.61e-12	Coronary artery disease;
TGCT	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg12140144	chr1:2984275	FLJ42875;PRDM16	-0.37	-5.2	-0.42	8.04e-7	Height;
TGCT	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.46	0.56	1.3e-11	Prudent dietary pattern;
TGCT	cis	rs1371867	0.817	rs1788208	chr8:101312515	T/C	cg06002616	chr8:101225028	SPAG1	-0.56	-6.58	-0.51	1.2e-9	Atrioventricular conduction;
TGCT	cis	rs62244186	0.659	rs4682745	chr3:44508967	T/C	cg25151919	chr3:44754333	ZNF502	-0.39	-4.57	-0.38	1.15e-5	Depressive symptoms;
TGCT	cis	rs8141529	0.644	rs5752795	chr22:29178820	T/C	cg02153584	chr22:29168773	CCDC117	0.74	6.25	0.49	5.89e-9	Lymphocyte counts;
TGCT	cis	rs4901869	0.966	rs9972208	chr14:59336116	C/T	cg02291164	chr14:59296302	NA	0.24	4.69	0.39	7.18e-6	Panic disorder;
TGCT	cis	rs11264213	0.901	rs72661631	chr1:36417453	A/G	cg27506609	chr1:36549197	TEKT2	0.42	4.72	0.39	6.2e-6	Schizophrenia;
TGCT	cis	rs62244186	0.659	rs4682745	chr3:44508967	T/C	cg21672276	chr3:44754072	ZNF502	-0.41	-4.62	-0.38	9.62e-6	Depressive symptoms;
TGCT	cis	rs2120019	1.000	rs7173833	chr15:75369618	C/T	cg11632617	chr15:75315747	PPCDC	-0.33	-4.64	-0.38	8.77e-6	Blood trace element (Zn levels);
TGCT	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg03709012	chr19:19516395	GATAD2A	0.75	6.51	0.5	1.71e-9	Tonsillectomy;
TGCT	cis	rs2153535	0.580	rs7747306	chr6:8453663	C/G	cg07606381	chr6:8435919	SLC35B3	-0.53	-5.04	-0.41	1.64e-6	Motion sickness;
TGCT	cis	rs36051895	0.632	rs12684720	chr9:5150800	T/C	cg02405213	chr9:5042618	JAK2	-0.75	-9.81	-0.66	3.66e-17	Pediatric autoimmune diseases;
TGCT	cis	rs9486719	0.947	rs2499801	chr6:96854594	G/A	cg18709589	chr6:96969512	KIAA0776	0.68	4.93	0.4	2.63e-6	Migraine;Coronary artery disease;
TGCT	cis	rs208520	0.690	rs12197578	chr6:66725905	C/T	cg07460842	chr6:66804631	NA	0.95	10.11	0.67	6.77e-18	Exhaled nitric oxide output;
TGCT	cis	rs631288	0.557	rs894467	chr1:146662018	C/T	cg25205988	chr1:146714368	CHD1L	1.34	5.37	0.43	3.79e-7	PR interval in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2227564	0.620	rs4746148	chr10:75534488	C/T	cg19442545	chr10:75533431	FUT11	-0.3	-4.47	-0.37	1.77e-5	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs6882046	0.513	rs651666	chr5:88048767	A/G	cg24804195	chr5:87968844	LOC645323	-0.58	-5.68	-0.45	9.18e-8	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs7666738	0.830	rs7696568	chr4:99005333	A/T	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs950169	0.922	rs67804993	chr15:85104030	T/G	cg17173187	chr15:85201210	NMB	0.53	5.53	0.44	1.83e-7	Schizophrenia;
TGCT	cis	rs4665809	0.617	rs930263	chr2:26402594	G/C	cg25036284	chr2:26402008	FAM59B	-0.6	-4.81	-0.4	4.25e-6	Gut microbiome composition (summer);
TGCT	cis	rs7567389	0.534	rs72845982	chr2:128098570	G/A	cg09760422	chr2:128146352	NA	0.39	5.18	0.42	8.76e-7	Self-rated health;
TGCT	cis	rs2439831	0.867	rs16957632	chr15:43642897	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	6.61	0.51	1e-9	Lung cancer in ever smokers;
TGCT	cis	rs7772486	0.754	rs702318	chr6:146005873	G/T	cg23711669	chr6:146136114	FBXO30	-0.93	-10.83	-0.7	1.24e-19	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6988636	0.536	rs16898043	chr8:124155886	A/G	cg22384356	chr8:124195192	FAM83A	-0.42	-4.84	-0.4	3.73e-6	Urinary uromodulin levels;
TGCT	cis	rs78456975	0.739	rs13405352	chr2:1518726	C/T	cg01028140	chr2:1542097	TPO	-0.35	-4.71	-0.39	6.58e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs7772486	0.719	rs4391282	chr6:146276780	A/T	cg05347473	chr6:146136440	FBXO30	-0.52	-5.1	-0.42	1.26e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4073582	0.595	rs528842	chr11:66032390	G/A	cg16950941	chr11:66035639	RAB1B	0.58	5.44	0.44	2.67e-7	Gout;
TGCT	cis	rs11203032	0.831	rs2902445	chr10:90934154	A/G	cg16672925	chr10:90967113	CH25H	0.73	4.5	0.37	1.55e-5	Heart failure;
TGCT	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg22029157	chr1:209979665	IRF6	0.77	6.36	0.5	3.47e-9	Cleft lip with or without cleft palate;
TGCT	cis	rs2549003	1.000	rs17848418	chr5:131821188	C/T	cg21138405	chr5:131827807	IRF1	0.19	4.79	0.4	4.64e-6	Asthma (sex interaction);
TGCT	cis	rs7524258	0.835	rs75096060	chr1:7270248	G/C	cg07173049	chr1:7289937	CAMTA1	0.29	4.89	0.4	3.01e-6	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs7833790	0.777	rs7815272	chr8:82691809	T/G	cg27398817	chr8:82754497	SNX16	-0.83	-5.96	-0.47	2.43e-8	Diastolic blood pressure;
TGCT	cis	rs1982963	0.950	rs1566132	chr14:52511836	C/T	cg10843707	chr14:52510701	NID2	-0.44	-6.81	-0.52	3.72e-10	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs17155006	0.655	rs424978	chr7:107724747	C/G	cg05962710	chr7:107745446	LAMB4	-0.19	-4.68	-0.39	7.52e-6	Pneumococcal bacteremia;
TGCT	cis	rs17401966	0.838	rs35759975	chr1:10474430	A/T	cg19773385	chr1:10388646	KIF1B	-0.22	-5.17	-0.42	9.17e-7	Hepatocellular carcinoma;
TGCT	cis	rs12477438	0.798	rs10198293	chr2:99602929	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-6.1	-0.48	1.22e-8	Chronic sinus infection;
TGCT	cis	rs7267979	0.903	rs2474769	chr20:25248725	C/T	cg16686733	chr20:25566563	NINL	0.59	6.06	0.48	1.53e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs76473307	1.000	rs74395447	chr20:57413187	T/C	cg06163629	chr20:57414884	GNASAS;GNAS	-0.64	-4.5	-0.37	1.54e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs10431058	1.000	rs35005608	chr11:107478873	G/T	cg18204760	chr11:107461044	ELMOD1;LOC643923	0.68	6.37	0.5	3.36e-9	Common traits (Other);
TGCT	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg01448562	chr3:133502909	NA	0.35	7.16	0.54	6.23e-11	Iron status biomarkers;
TGCT	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg00024416	chr22:24240387	NA	-0.24	-4.55	-0.38	1.28e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2996428	0.667	rs61768932	chr1:3765671	G/C	cg17848003	chr1:3704513	LRRC47	0.19	5.21	0.42	7.56e-7	Red cell distribution width;
TGCT	cis	rs7552404	0.765	rs1251078	chr1:76189488	C/G	cg22875332	chr1:76189707	ACADM	-0.82	-12.27	-0.74	3.78e-23	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs10833905	0.715	rs7117292	chr11:23038771	G/A	cg06387204	chr11:22647648	FANCF	0.52	4.77	0.39	5.01e-6	Sudden cardiac arrest;
TGCT	cis	rs7772486	0.742	rs4896851	chr6:146278959	T/C	cg05347473	chr6:146136440	FBXO30	-0.51	-4.75	-0.39	5.63e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9394841	0.667	rs71558769	chr6:41782107	T/C	cg08135965	chr6:41755394	TOMM6	0.55	5.15	0.42	9.77e-7	Mean corpuscular hemoglobin;Red cell distribution width;
TGCT	cis	rs611744	0.967	rs650401	chr8:109196854	C/T	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs1215050	0.874	rs17545594	chr4:98652689	A/G	cg05340658	chr4:99064831	C4orf37	-0.44	-5.17	-0.42	9.1e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2070488	0.965	rs2366123	chr3:38493153	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	9.67	0.66	7.99e-17	Electrocardiographic conduction measures;
TGCT	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	5.38	0.44	3.58e-7	Alzheimer's disease;
TGCT	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg04267008	chr7:1944627	MAD1L1	-0.38	-4.86	-0.4	3.54e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs6725041	0.547	rs59096325	chr2:213203853	C/T	cg16329650	chr2:213403929	ERBB4	-0.67	-5.85	-0.47	4.03e-8	QT interval (ambient particulate matter interaction);
TGCT	cis	rs9388451	0.626	rs1343116	chr6:126069702	C/A	cg05901451	chr6:126070800	HEY2	-1.04	-13.0	-0.76	6.65e-25	Brugada syndrome;
TGCT	cis	rs3858526	0.839	rs10466484	chr11:5943696	A/G	cg05234568	chr11:5960015	NA	-0.45	-4.46	-0.37	1.84e-5	DNA methylation (variation);
TGCT	cis	rs2729354	1.000	rs2511983	chr11:57346874	A/G	cg24343310	chr11:57249947	NA	0.28	4.8	0.4	4.5e-6	Blood protein levels;
TGCT	cis	rs1843834	0.505	rs7585047	chr2:225373897	C/T	cg22455342	chr2:225449267	CUL3	1.04	10.75	0.69	1.87e-19	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs9952991	0.941	rs2847280	chr18:12779342	A/G	cg23598886	chr18:12777645	NA	0.62	5.9	0.47	3.25e-8	Inflammatory skin disease;
TGCT	cis	rs8077577	0.789	rs11078411	chr17:18088094	C/T	cg09161412	chr17:18057145	MYO15A	-0.64	-5.22	-0.42	7.2e-7	Obesity-related traits;
TGCT	cis	rs2180341	0.842	rs6569476	chr6:127553539	G/A	cg27446573	chr6:127587934	RNF146	1.06	8.23	0.59	2.16e-13	Breast cancer;
TGCT	cis	rs9796	0.621	rs537244	chr15:41469313	G/T	cg18705301	chr15:41695430	NDUFAF1	0.52	7.17	0.54	5.94e-11	Menopause (age at onset);
TGCT	cis	rs6681544	0.760	rs2182600	chr1:82396766	A/G	cg04226724	chr1:82268649	LPHN2	0.48	4.93	0.41	2.54e-6	Metabolite levels  (X-11787);
TGCT	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg16325326	chr1:53192061	ZYG11B	0.54	6.09	0.48	1.32e-8	Monocyte count;
TGCT	cis	rs651907	0.535	rs13094753	chr3:101525082	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.86	10.47	0.68	9.24e-19	Colorectal cancer;
TGCT	cis	rs12477438	0.539	rs12999417	chr2:99865548	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.84	-8.5	-0.61	4.95e-14	Chronic sinus infection;
TGCT	trans	rs4650994	0.544	rs6682815	chr1:178501109	T/C	cg05059571	chr16:84539110	KIAA1609	-0.55	-11.43	-0.72	4.08e-21	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs6500602	0.727	rs4786516	chr16:4578641	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.32	5.95	0.47	2.54e-8	Schizophrenia;
TGCT	cis	rs10174077	0.874	rs6750342	chr2:152485754	A/G	cg19508488	chr2:152266495	RIF1	0.7	6.63	0.51	9.16e-10	Squamous cell lung carcinoma;
TGCT	trans	rs1814175	0.817	rs80244685	chr11:49763292	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.45	-11.14	-0.71	2.17e-20	Height;
TGCT	cis	rs6714710	0.580	rs17489915	chr2:98420431	T/C	cg26665480	chr2:98280029	ACTR1B	0.66	6.24	0.49	6.33e-9	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs6964587	1.000	rs415	chr7:91580490	A/G	cg22709100	chr7:91322751	NA	-0.27	-4.48	-0.37	1.68e-5	Breast cancer;
TGCT	cis	rs524281	1.000	rs565198	chr11:65913508	A/T	cg00563793	chr11:65837595	PACS1	-0.52	-4.73	-0.39	6.01e-6	Electroencephalogram traits;
TGCT	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg13395646	chr4:1353034	KIAA1530	0.49	7.42	0.55	1.64e-11	Obesity-related traits;
TGCT	cis	rs1670533	1.000	rs62879260	chr4:1050850	T/C	cg27284194	chr4:1044797	NA	0.68	5.87	0.47	3.76e-8	Recombination rate (females);
TGCT	cis	rs7246657	0.638	rs7246461	chr19:38196581	C/G	cg03611452	chr19:38183253	ZNF781	-0.58	-5.13	-0.42	1.08e-6	Coronary artery calcification;
TGCT	cis	rs3741151	1.000	rs7122825	chr11:73061324	C/T	cg17517138	chr11:73019481	ARHGEF17	0.93	4.66	0.39	7.9e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
TGCT	cis	rs4455778	0.536	rs10266289	chr7:48941456	C/T	cg26309511	chr7:48887640	NA	-0.44	-5.24	-0.43	6.67e-7	Lung cancer in never smokers;
TGCT	cis	rs10782582	0.593	rs11578480	chr1:76208989	T/G	cg03433033	chr1:76189801	ACADM	-0.6	-6.63	-0.51	9.16e-10	Daytime sleep phenotypes;
TGCT	cis	rs67072384	1.000	rs7120700	chr11:72444676	A/G	cg03713592	chr11:72463424	ARAP1	-0.89	-4.6	-0.38	1.02e-5	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.71	0.39	6.53e-6	Prudent dietary pattern;
TGCT	cis	rs7091068	0.532	rs559590	chr10:95398886	C/T	cg20715218	chr10:95462985	C10orf4	-0.49	-6.0	-0.47	2.02e-8	Urinary tract infection frequency;
TGCT	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.71	6.36	0.5	3.53e-9	Tonsillectomy;
TGCT	cis	rs9807989	0.524	rs4851576	chr2:103028895	C/T	cg03938978	chr2:103052716	IL18RAP	0.27	5.41	0.44	3.18e-7	Asthma;
TGCT	cis	rs7666738	0.830	rs13125432	chr4:98961253	G/A	cg18180107	chr4:99064573	C4orf37	0.57	5.18	0.42	8.63e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs61990749	0.597	rs176946	chr14:78178439	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.61	4.61	0.38	1e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs10992471	0.651	rs13296623	chr9:95301627	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.53	-5.25	-0.43	6.26e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs72634258	0.554	rs4562654	chr1:7934423	A/T	cg26816564	chr1:7831052	VAMP3	0.65	4.98	0.41	2.11e-6	Inflammatory bowel disease;
TGCT	cis	rs921968	0.541	rs526897	chr2:219433597	C/T	cg02176678	chr2:219576539	TTLL4	0.45	6.63	0.51	9.33e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg22800045	chr5:56110881	MAP3K1	0.53	4.48	0.37	1.67e-5	Initial pursuit acceleration;
TGCT	cis	rs12681287	0.517	rs34367154	chr8:87508749	A/T	cg27223183	chr8:87520930	FAM82B	-0.95	-6.95	-0.53	1.81e-10	Caudate activity during reward;
TGCT	cis	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg20637647	chr7:64974828	NA	0.88	5.12	0.42	1.13e-6	Diabetic kidney disease;
TGCT	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg05368731	chr17:41323189	NBR1	1.16	13.44	0.77	5.72e-26	Menopause (age at onset);
TGCT	cis	rs6062788	0.504	rs8124644	chr20:61699728	C/T	cg04845185	chr20:61696220	NA	-0.31	-4.88	-0.4	3.21e-6	Body mass index;
TGCT	cis	rs67478160	0.634	rs2368559	chr14:104230535	C/T	cg26031613	chr14:104095156	KLC1	-0.63	-6.38	-0.5	3.18e-9	Schizophrenia;
TGCT	cis	rs9549367	0.789	rs2287248	chr13:113889226	T/C	cg18105134	chr13:113819100	PROZ	-0.34	-5.49	-0.44	2.18e-7	Platelet distribution width;
TGCT	cis	rs13392177	0.672	rs1877715	chr2:219052546	C/T	cg00012203	chr2:219082015	ARPC2	0.72	7.48	0.56	1.16e-11	Pyoderma gangrenosum in inflammatory bowel disease;
TGCT	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg12310025	chr6:25882481	NA	-0.67	-5.96	-0.47	2.41e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	5.02	0.41	1.78e-6	Prudent dietary pattern;
TGCT	trans	rs1814175	0.669	rs10839315	chr11:49654406	G/A	cg03929089	chr4:120376271	NA	-0.62	-7.33	-0.55	2.56e-11	Height;
TGCT	cis	rs6504663	0.558	rs7627	chr17:48552154	G/C	cg03168497	chr17:48586147	MYCBPAP	0.49	5.27	0.43	5.98e-7	Visceral fat;
TGCT	cis	rs1670533	0.746	rs688008	chr4:1082829	T/C	cg20887711	chr4:1340912	KIAA1530	0.68	5.33	0.43	4.53e-7	Recombination rate (females);
TGCT	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10791323	0.569	rs2187450	chr11:133743792	A/G	cg15485101	chr11:133734466	NA	0.37	5.42	0.44	3e-7	Childhood ear infection;
TGCT	cis	rs10883723	1.000	rs10883723	chr10:104225832	T/C	cg05855489	chr10:104503620	C10orf26	-0.53	-4.56	-0.38	1.19e-5	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg21171335	chr12:122356390	WDR66	0.69	6.98	0.53	1.56e-10	Mean corpuscular volume;
TGCT	cis	rs977747	1.000	rs7534271	chr1:47693981	C/G	cg03885399	chr1:47691550	TAL1	0.39	4.55	0.38	1.25e-5	Body mass index;
TGCT	cis	rs10794720	0.748	rs11250274	chr10:1171354	T/C	cg08668510	chr10:1095578	IDI1	1.12	4.72	0.39	6.35e-6	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;
TGCT	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg18876405	chr7:65276391	NA	0.31	4.79	0.4	4.58e-6	Aortic root size;
TGCT	cis	rs7727544	0.735	rs272881	chr5:131669264	G/A	cg24060327	chr5:131705240	SLC22A5	-0.56	-6.31	-0.49	4.43e-9	Blood metabolite levels;
TGCT	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg12419862	chr22:24373484	LOC391322	-0.75	-7.61	-0.56	5.89e-12	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs17076896	0.786	rs61956062	chr13:19928282	T/C	cg00777926	chr13:20807375	GJB6	-0.37	-4.51	-0.38	1.5e-5	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs4478858	0.684	rs16865957	chr1:31753353	G/A	cg07478791	chr1:31886160	SERINC2	-0.52	-5.02	-0.41	1.73e-6	Alcohol dependence;
TGCT	cis	rs17376456	0.877	rs12716460	chr5:93416733	A/G	cg21475434	chr5:93447410	FAM172A	0.59	4.58	0.38	1.11e-5	Diabetic retinopathy;
TGCT	cis	rs425277	1.000	rs427811	chr1:2075560	T/G	cg12140144	chr1:2984275	FLJ42875;PRDM16	-0.37	-4.7	-0.39	6.72e-6	Height;
TGCT	cis	rs941408	1.000	rs2741990	chr19:2796644	C/T	cg06609049	chr19:2785107	THOP1	0.8	7.95	0.58	9.66e-13	Total cholesterol levels;
TGCT	cis	rs59197085	0.636	rs4731515	chr7:128450592	A/G	cg00260937	chr7:128520193	KCP	0.47	4.86	0.4	3.49e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
TGCT	cis	rs9611565	0.765	rs132906	chr22:41799767	G/C	cg03806693	chr22:41940476	POLR3H	0.92	10.04	0.67	9.93e-18	Vitiligo;
TGCT	cis	rs11077998	0.967	rs4789782	chr17:80489323	G/T	cg10255544	chr17:80519551	FOXK2	-0.24	-4.67	-0.39	7.86e-6	Reticulocyte fraction of red cells;
TGCT	cis	rs10791323	0.575	rs4489760	chr11:133732265	A/T	cg15485101	chr11:133734466	NA	0.37	5.0	0.41	1.94e-6	Childhood ear infection;
TGCT	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg13342137	chr4:2252803	MXD4	0.17	4.56	0.38	1.23e-5	Obesity-related traits;
TGCT	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg06112835	chr11:68658793	MRPL21	0.47	8.3	0.6	1.48e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.88	9.59	0.65	1.28e-16	Platelet count;
TGCT	cis	rs2228479	0.850	rs11647174	chr16:89958538	G/A	cg06558623	chr16:89946397	TCF25	0.57	6.52	0.51	1.62e-9	Skin colour saturation;
TGCT	cis	rs6088580	0.608	rs2105109	chr20:32971932	A/G	cg06115741	chr20:33292138	TP53INP2	-0.55	-4.81	-0.4	4.28e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs35849525	0.633	rs62263602	chr3:50152491	C/T	cg14019146	chr3:50243930	SLC38A3	-0.21	-4.58	-0.38	1.11e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7843479	1.000	rs13276082	chr8:21823184	A/G	cg17168535	chr8:21777572	XPO7	0.64	5.91	0.47	3.12e-8	Mean corpuscular volume;
TGCT	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg10047753	chr17:41438598	NA	-0.87	-8.58	-0.61	3.31e-14	Menopause (age at onset);
TGCT	cis	rs7428	0.527	rs1061782	chr2:85546615	A/G	cg03728395	chr2:85555865	TGOLN2	0.32	5.74	0.46	6.8e-8	Ear protrusion;
TGCT	cis	rs881375	0.933	rs7021206	chr9:123684157	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.45	-5.02	-0.41	1.72e-6	Rheumatoid arthritis;
TGCT	cis	rs9443189	0.570	rs569731	chr6:76357593	G/A	cg01950844	chr6:76311363	SENP6	1.0	6.24	0.49	6.35e-9	Prostate cancer;
TGCT	cis	rs7954584	0.616	rs10743186	chr12:122356436	C/T	cg21016266	chr12:122356598	WDR66	0.43	5.65	0.45	1.03e-7	Mean corpuscular volume;
TGCT	cis	rs9910055	0.529	rs190144	chr17:42164584	A/G	cg13607699	chr17:42295918	UBTF	-0.63	-5.05	-0.41	1.56e-6	Total body bone mineral density;
TGCT	cis	rs12048904	0.619	rs12239082	chr1:101330077	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.87	-8.56	-0.61	3.68e-14	Multiple sclerosis;
TGCT	cis	rs72945132	0.638	rs11236127	chr11:70241536	G/C	cg00319359	chr11:70116639	PPFIA1	1.0	7.12	0.54	7.76e-11	Coronary artery disease;
TGCT	cis	rs2303745	0.589	rs1965717	chr19:17398559	C/T	cg04248312	chr19:17393744	ANKLE1	-0.34	-5.57	-0.45	1.54e-7	Systemic lupus erythematosus;
TGCT	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.28	-0.43	5.51e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7772486	0.597	rs7746618	chr6:146281367	T/C	cg13319975	chr6:146136371	FBXO30	0.63	5.64	0.45	1.09e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10892173	0.545	rs115865940	chr11:117666711	C/T	cg21014159	chr11:117668035	DSCAML1	0.61	6.05	0.48	1.61e-8	Myopia;
TGCT	cis	rs8060598	0.745	rs8045009	chr16:50735941	C/T	cg05261686	chr16:50743296	NOD2	0.23	4.5	0.37	1.56e-5	Leprosy;
TGCT	cis	rs1891275	0.515	rs1080496	chr10:93444262	C/T	cg07889827	chr10:93443413	NA	0.31	6.22	0.49	6.87e-9	Intelligence (multi-trait analysis);
TGCT	trans	rs1814175	0.791	rs7395713	chr11:49877887	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.38	-7.42	-0.55	1.65e-11	Height;
TGCT	cis	rs71435601	0.574	rs547179	chr2:21384662	A/G	cg25035485	chr2:21266500	APOB	0.51	4.48	0.37	1.64e-5	Cholesterol, total;
TGCT	cis	rs3784262	0.679	rs8031578	chr15:58369145	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.41	-5.86	-0.47	3.82e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs8031584	0.678	rs798086	chr15:31129211	C/G	cg14829155	chr15:31115871	NA	0.37	4.92	0.4	2.75e-6	Huntington's disease progression;
TGCT	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.65	0.39	8.4e-6	Prudent dietary pattern;
TGCT	cis	rs7172809	0.897	rs74026931	chr15:77825474	A/C	cg22256960	chr15:77711686	NA	-0.44	-4.48	-0.37	1.67e-5	Glucose homeostasis traits;
TGCT	cis	rs748404	0.578	rs510108	chr15:43605439	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	4.75	0.39	5.46e-6	Lung cancer;
TGCT	trans	rs324780	0.567	rs3103477	chr12:83908280	A/G	cg27144766	chr5:150604977	CCDC69	0.24	6.63	0.51	9.42e-10	Vertical cup-disc ratio;
TGCT	cis	rs6088580	0.634	rs6119497	chr20:33012529	T/A	cg08999081	chr20:33150536	PIGU	0.29	5.67	0.45	9.68e-8	Glomerular filtration rate (creatinine);
TGCT	cis	rs2730245	1.000	rs2252502	chr7:158738634	G/C	cg11984989	chr7:158649758	WDR60	-0.97	-8.97	-0.63	3.94e-15	Height;
TGCT	cis	rs2458413	0.521	rs2458427	chr8:105339594	G/T	cg13045555	chr8:105342365	NA	-0.41	-6.85	-0.52	3.05e-10	Paget's disease;
TGCT	cis	rs751728	0.717	rs3763260	chr6:33774070	C/T	cg00334056	chr6:33755658	LEMD2	-0.26	-4.75	-0.39	5.41e-6	Crohn's disease;
TGCT	cis	rs1568889	1.000	rs16917689	chr11:28064466	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	8.86	0.62	7.07e-15	Bipolar disorder;
TGCT	cis	rs4711336	1.000	rs764752	chr6:33658066	G/C	cg14003231	chr6:33640908	ITPR3	0.28	4.5	0.37	1.54e-5	Height;
TGCT	trans	rs208520	0.789	rs9351549	chr6:66871851	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-10.31	-0.68	2.29e-18	Exhaled nitric oxide output;
TGCT	cis	rs2075371	1.000	rs2241336	chr7:133979578	A/G	cg11752832	chr7:134001865	SLC35B4	0.69	6.32	0.49	4.36e-9	Mean platelet volume;
TGCT	cis	rs2657888	0.930	rs7312441	chr12:56941146	C/A	cg23932658	chr12:57637574	STAC3	-0.51	-4.73	-0.39	5.9e-6	Adiponectin levels;
TGCT	cis	rs6906287	0.625	rs7764272	chr6:118692498	A/C	cg21191810	chr6:118973309	C6orf204	0.28	4.68	0.39	7.38e-6	Electrocardiographic conduction measures;
TGCT	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg20999797	chr1:1681921	NA	0.18	4.51	0.38	1.51e-5	Body mass index;
TGCT	trans	rs1974653	0.672	rs9606252	chr22:20092996	A/G	cg08822737	chr17:71088851	SLC39A11	0.88	7.33	0.55	2.61e-11	Schizophrenia;
TGCT	cis	rs12579753	0.917	rs7972839	chr12:82178920	C/T	cg07988820	chr12:82153109	PPFIA2	-0.59	-6.16	-0.48	9.4e-9	Resting heart rate;
TGCT	cis	rs6964587	1.000	rs7811873	chr7:91751120	G/A	cg17063962	chr7:91808500	NA	0.89	9.51	0.65	1.95e-16	Breast cancer;
TGCT	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg27436995	chr16:743998	FBXL16	-0.47	-5.12	-0.42	1.12e-6	Height;
TGCT	cis	rs2242116	0.727	rs4683298	chr3:46966387	C/G	cg27129171	chr3:47204927	SETD2	0.63	6.18	0.49	8.32e-9	Birth weight;
TGCT	cis	rs12477438	0.501	rs2632284	chr2:99775865	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.15	18.32	0.85	4.52e-37	Chronic sinus infection;
TGCT	cis	rs9611565	0.512	rs139571	chr22:42214238	G/A	cg03806693	chr22:41940476	POLR3H	-1.04	-10.57	-0.69	5.2e-19	Vitiligo;
TGCT	cis	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg08045932	chr20:61659980	NA	0.48	9.16	0.64	1.36e-15	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2997447	0.894	rs55722280	chr1:26412684	T/C	cg03844060	chr1:26490628	NA	0.28	4.57	0.38	1.16e-5	QRS complex (12-leadsum);
TGCT	trans	rs1908814	0.516	rs13252854	chr8:11792978	T/A	cg15556689	chr8:8085844	FLJ10661	0.77	7.37	0.55	2.13e-11	Neuroticism;
TGCT	cis	rs9913156	0.670	rs9894225	chr17:4546559	A/G	cg00122941	chr17:4613640	ARRB2	-0.83	-7.38	-0.55	2e-11	Lymphocyte counts;
TGCT	cis	rs8013055	0.846	rs10139744	chr14:105974696	G/A	cg23356831	chr14:105996513	TMEM121	0.37	5.62	0.45	1.19e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs9985766	0.958	rs62339909	chr4:151009714	C/T	cg05926478	chr4:151174724	DCLK2	-0.25	-4.91	-0.4	2.82e-6	Coronary artery disease;Myocardial infarction;
TGCT	trans	rs17685	0.753	rs10952840	chr7:75772878	C/T	cg19862616	chr7:65841803	NCRNA00174	0.52	9.01	0.63	3.02e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs12134245	0.776	rs12125947	chr1:91990487	T/C	cg02896835	chr1:92012615	NA	-0.27	-4.62	-0.38	9.32e-6	Breast cancer;
TGCT	cis	rs317689	0.613	rs315112	chr12:69785926	T/A	cg14784868	chr12:69753453	YEATS4	0.63	5.64	0.45	1.09e-7	Response to diuretic therapy;
TGCT	cis	rs8180040	1.000	rs553989	chr3:47400328	A/G	cg27129171	chr3:47204927	SETD2	-0.71	-8.76	-0.62	1.21e-14	Colorectal cancer;
TGCT	cis	rs1008375	0.931	rs6449326	chr4:17699790	G/T	cg18681998	chr4:17616180	MED28	0.77	7.31	0.55	2.88e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7666738	0.791	rs10856933	chr4:98958542	C/A	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11785400	1.000	rs754957	chr8:143746416	A/G	cg10596483	chr8:143751796	JRK	0.55	5.82	0.46	4.69e-8	Schizophrenia;
TGCT	cis	rs9916302	0.706	rs584377	chr17:37460128	G/A	cg07936489	chr17:37558343	FBXL20	0.87	6.27	0.49	5.47e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs916888	0.821	rs199514	chr17:44856881	G/A	cg16520312	chr17:43971471	MAPT;LOC100128977	0.59	5.1	0.42	1.21e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs6500602	0.627	rs934929	chr16:4587789	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	-0.39	-5.7	-0.46	8.2e-8	Schizophrenia;
TGCT	cis	rs67311347	0.955	rs2085114	chr3:40497437	T/A	cg17264618	chr3:40429014	ENTPD3	0.32	4.45	0.37	1.88e-5	Renal cell carcinoma;
TGCT	cis	rs7412746	0.611	rs2280627	chr1:150935872	A/G	cg09365446	chr1:150670422	GOLPH3L	0.34	4.7	0.39	6.76e-6	Melanoma;
TGCT	cis	rs2594989	0.943	rs2606733	chr3:11412319	C/T	cg00170343	chr3:11313890	ATG7	0.65	5.02	0.41	1.74e-6	Circulating chemerin levels;
TGCT	cis	rs1046896	0.521	rs3848403	chr17:80693899	C/T	cg00960700	chr17:80709150	TBCD	0.51	5.04	0.41	1.58e-6	Glycated hemoglobin levels;
TGCT	cis	rs9486719	1.000	rs3798296	chr6:97052286	G/A	cg18709589	chr6:96969512	KIAA0776	-0.74	-5.21	-0.42	7.5e-7	Migraine;Coronary artery disease;
TGCT	cis	rs6964587	1.000	rs10263309	chr7:91645265	A/G	cg22709100	chr7:91322751	NA	0.27	4.48	0.37	1.68e-5	Breast cancer;
TGCT	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg12963246	chr6:28129442	ZNF389	0.52	5.1	0.42	1.23e-6	Depression;
TGCT	cis	rs2243480	1.000	rs160655	chr7:65533214	T/C	cg07424592	chr7:64974309	NA	1.33	8.82	0.62	8.94e-15	Diabetic kidney disease;
TGCT	cis	rs3806843	1.000	rs10038174	chr5:140210616	G/A	cg19875535	chr5:140030758	IK	0.35	5.86	0.47	3.93e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg06481639	chr22:41940642	POLR3H	-0.74	-6.74	-0.52	5.38e-10	Vitiligo;
TGCT	cis	rs453301	0.682	rs2929308	chr8:9084121	T/A	cg06636001	chr8:8085503	FLJ10661	-0.66	-6.04	-0.48	1.65e-8	Joint mobility (Beighton score);
TGCT	trans	rs208520	0.674	rs207103	chr6:66795568	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-10.77	-0.7	1.66e-19	Exhaled nitric oxide output;
TGCT	cis	rs4566357	0.595	rs2272203	chr2:227914655	C/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-5.24	-0.43	6.55e-7	Coronary artery disease;
TGCT	cis	rs7824557	0.527	rs4631425	chr8:11239054	C/T	cg21775007	chr8:11205619	TDH	-0.68	-6.6	-0.51	1.08e-9	Retinal vascular caliber;
TGCT	cis	rs1520333	0.915	rs7463761	chr8:79370919	G/A	cg16589705	chr8:80226364	NA	-0.32	-4.51	-0.38	1.48e-5	Multiple sclerosis;
TGCT	cis	rs10782582	0.593	rs11589276	chr1:76105545	G/A	cg03433033	chr1:76189801	ACADM	-0.61	-7.24	-0.55	4.07e-11	Daytime sleep phenotypes;
TGCT	cis	rs909002	0.800	rs3134718	chr1:32089839	C/T	cg11573219	chr1:32083031	HCRTR1	-0.45	-5.86	-0.47	3.82e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs12477438	0.520	rs11123766	chr2:99780915	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	17.43	0.84	3.73e-35	Chronic sinus infection;
TGCT	cis	rs11098499	1.000	rs58601355	chr4:120186367	T/C	cg09307838	chr4:120376055	NA	0.52	4.69	0.39	6.97e-6	Corneal astigmatism;
TGCT	cis	rs10791097	0.582	rs2282578	chr11:130735691	A/T	cg05962950	chr11:130786565	SNX19	0.9	11.39	0.72	5.2e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs62103177	0.525	rs4799117	chr18:77756604	G/A	cg20368463	chr18:77673604	PQLC1	-0.43	-4.46	-0.37	1.83e-5	Opioid sensitivity;
TGCT	cis	rs67460515	0.892	rs34771618	chr3:161059795	A/C	cg03342759	chr3:160939853	NMD3	-0.54	-5.9	-0.47	3.25e-8	Parkinson's disease;
TGCT	cis	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg05590025	chr7:65112418	INTS4L2	-0.77	-4.5	-0.37	1.52e-5	Diabetic kidney disease;
TGCT	cis	rs9788682	0.747	rs2915695	chr15:78739471	T/C	cg24631222	chr15:78858424	CHRNA5	-0.61	-4.55	-0.38	1.25e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs7666738	0.830	rs6532724	chr4:99060993	C/T	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.44e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4919694	1.000	rs58700372	chr10:104800205	T/C	cg04362960	chr10:104952993	NT5C2	1.06	7.05	0.53	1.09e-10	Arsenic metabolism;
TGCT	cis	rs17376456	0.877	rs10055741	chr5:93297187	C/T	cg25358565	chr5:93447407	FAM172A	0.98	8.56	0.61	3.63e-14	Diabetic retinopathy;
TGCT	cis	rs2439831	1.000	rs2444032	chr15:43755346	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.8	5.6	0.45	1.33e-7	Lung cancer in ever smokers;
TGCT	cis	rs6912958	0.559	rs242280	chr6:88048714	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.47	6.29	0.49	5.04e-9	Monocyte percentage of white cells;
TGCT	cis	rs12681287	0.640	rs67123356	chr8:87453992	A/C	cg27223183	chr8:87520930	FAM82B	-0.89	-6.43	-0.5	2.54e-9	Caudate activity during reward;
TGCT	trans	rs1974653	0.672	rs2008701	chr22:20104235	C/T	cg08822737	chr17:71088851	SLC39A11	-0.93	-7.65	-0.57	4.76e-12	Schizophrenia;
TGCT	cis	rs10114408	0.959	rs10992962	chr9:96657124	C/G	cg13679303	chr9:96623674	NA	-0.36	-4.65	-0.39	8.3e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs17384381	1.000	rs1608536	chr1:85885836	C/T	cg16011679	chr1:85725395	C1orf52	0.78	6.1	0.48	1.27e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2456568	0.802	rs7115629	chr11:93635477	G/A	cg16099599	chr11:93583650	C11orf90	-0.4	-4.98	-0.41	2.04e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs6671200	0.607	rs6671408	chr1:95697091	T/C	cg20701556	chr1:95698924	RWDD3	-0.52	-5.27	-0.43	5.76e-7	Stearic acid (18:0) levels;
TGCT	cis	rs11578119	0.689	rs1591149	chr1:170386716	T/C	cg09767346	chr1:170501363	GORAB	-0.6	-4.97	-0.41	2.2e-6	Male-pattern baldness;
TGCT	cis	rs7772486	0.754	rs6906258	chr6:146089356	A/G	cg23711669	chr6:146136114	FBXO30	-0.92	-10.41	-0.68	1.3e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs208520	0.837	rs208509	chr6:66941706	A/G	cg07460842	chr6:66804631	NA	-0.91	-9.1	-0.63	1.87e-15	Exhaled nitric oxide output;
TGCT	cis	rs7647973	0.961	rs7619016	chr3:49272589	C/T	cg06212747	chr3:49208901	KLHDC8B	0.59	4.72	0.39	6.28e-6	Menarche (age at onset);
TGCT	cis	rs10754283	0.901	rs10922684	chr1:90117934	T/C	cg03145924	chr1:90228473	NA	-0.4	-4.52	-0.38	1.4e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs617219	0.726	rs2364596	chr5:78434291	C/T	cg23514016	chr5:78407564	BHMT	0.34	5.09	0.42	1.28e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs4076764	0.846	rs10753616	chr1:163415855	G/T	cg24596788	chr1:163392923	NA	0.16	4.69	0.39	7.08e-6	Motion sickness;
TGCT	cis	rs7599312	0.534	rs10180824	chr2:213407975	G/A	cg16329650	chr2:213403929	ERBB4	1.08	16.09	0.82	3.86e-32	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7772486	0.641	rs9390370	chr6:146357569	C/T	cg13319975	chr6:146136371	FBXO30	-0.65	-6.11	-0.48	1.2e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9517320	0.534	rs9554478	chr13:99187792	G/A	cg20487152	chr13:99095054	FARP1	-0.24	-4.44	-0.37	1.93e-5	Longevity;
TGCT	cis	rs7412746	0.658	rs3768015	chr1:150812954	C/T	cg04414720	chr1:150670196	GOLPH3L	0.41	5.14	0.42	1.06e-6	Melanoma;
TGCT	cis	rs185694	0.779	rs609919	chr13:30895904	C/G	cg07600127	chr13:30881527	KATNAL1	-0.74	-6.11	-0.48	1.18e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
TGCT	cis	rs12765878	1.000	rs3850671	chr10:105659387	T/C	cg11005552	chr10:105648138	OBFC1	0.45	7.91	0.58	1.21e-12	Coronary artery disease;
TGCT	cis	rs4642101	0.737	rs4299468	chr3:12825559	G/A	cg05775895	chr3:12838266	CAND2	0.79	9.04	0.63	2.61e-15	QRS complex (12-leadsum);
TGCT	cis	rs9905704	0.647	rs11652713	chr17:57079742	C/T	cg05425664	chr17:57184151	TRIM37	-0.63	-5.54	-0.45	1.74e-7	Testicular germ cell tumor;
TGCT	cis	rs1163251	0.837	rs660073	chr1:120245173	T/C	cg19096424	chr1:120255104	PHGDH	0.6	5.93	0.47	2.76e-8	Blood metabolite levels;
TGCT	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	7.06	0.54	1.07e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg07507251	chr3:52567010	NT5DC2	0.48	6.95	0.53	1.82e-10	Bipolar disorder;
TGCT	trans	rs561341	0.739	rs9906455	chr17:30215669	G/A	cg20587970	chr11:113659929	NA	0.65	8.95	0.63	4.33e-15	Hip circumference adjusted for BMI;
TGCT	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg11062466	chr8:58055876	NA	0.42	4.49	0.37	1.61e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg11301795	chr4:187892539	NA	-0.33	-4.82	-0.4	4.14e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9326248	0.581	rs7106437	chr11:116992076	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.61	5.58	0.45	1.43e-7	Blood protein levels;
TGCT	cis	rs17221829	0.965	rs3871189	chr11:89451250	G/A	cg02982614	chr11:89391479	FOLH1B	-0.29	-5.09	-0.42	1.3e-6	Anxiety in major depressive disorder;
TGCT	cis	rs514406	0.505	rs856721	chr1:53162156	C/A	cg16325326	chr1:53192061	ZYG11B	0.85	11.54	0.72	2.24e-21	Monocyte count;
TGCT	cis	rs17376456	1.000	rs9968691	chr5:93509756	C/G	cg21475434	chr5:93447410	FAM172A	0.62	4.5	0.37	1.54e-5	Diabetic retinopathy;
TGCT	cis	rs57590327	0.503	rs7618973	chr3:81619588	C/T	cg07356753	chr3:81810745	GBE1	0.61	5.1	0.42	1.24e-6	Extraversion;
TGCT	cis	rs4944092	0.960	rs10400322	chr11:75910913	C/T	cg04588336	chr11:75916460	WNT11	0.43	6.08	0.48	1.35e-8	PR interval;
TGCT	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg18876405	chr7:65276391	NA	0.39	5.94	0.47	2.65e-8	Aortic root size;
TGCT	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.76	5.05	0.41	1.51e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg11764359	chr7:65958608	NA	0.61	5.53	0.44	1.84e-7	Aortic root size;
TGCT	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg06896619	chr17:61851486	DDX42;CCDC47	0.53	5.33	0.43	4.46e-7	Prudent dietary pattern;
TGCT	cis	rs12477438	0.520	rs7604557	chr2:99747829	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.06	13.28	0.77	1.43e-25	Chronic sinus infection;
TGCT	cis	rs10832169	0.967	rs7102483	chr11:14065883	A/G	cg04547675	chr11:13986162	SPON1	0.51	4.51	0.38	1.49e-5	Blood protein levels;
TGCT	cis	rs8017423	0.935	rs8012303	chr14:90715829	G/A	cg04374321	chr14:90722782	PSMC1	0.72	7.54	0.56	8.86e-12	Mortality in heart failure;
TGCT	cis	rs7940866	0.801	rs2113928	chr11:130835975	A/G	cg12179176	chr11:130786555	SNX19	0.64	6.05	0.48	1.57e-8	Schizophrenia;
TGCT	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg10802521	chr3:52805072	NEK4	0.74	9.21	0.64	1.02e-15	Electroencephalogram traits;
TGCT	cis	rs17270561	0.541	rs12192932	chr6:25911502	A/G	cg17691542	chr6:26056736	HIST1H1C	0.89	6.28	0.49	5.19e-9	Iron status biomarkers;
TGCT	cis	rs4455778	0.659	rs11185621	chr7:49027065	C/T	cg26309511	chr7:48887640	NA	-0.44	-5.22	-0.42	7.26e-7	Lung cancer in never smokers;
TGCT	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.33	-5.2	-0.42	7.9e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg04944784	chr2:26401820	FAM59B	0.76	6.24	0.49	6.46e-9	Gut microbiome composition (summer);
TGCT	cis	rs478304	0.530	rs11568300	chr11:65425167	C/G	cg27068330	chr11:65405492	SIPA1	-0.99	-10.62	-0.69	3.92e-19	Acne (severe);
TGCT	cis	rs7819412	0.560	rs3021497	chr8:10996089	A/G	cg21775007	chr8:11205619	TDH	-0.51	-4.48	-0.37	1.67e-5	Triglycerides;
TGCT	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg06112835	chr11:68658793	MRPL21	0.47	8.03	0.59	6.25e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg20607798	chr8:58055168	NA	0.5	4.66	0.39	8.04e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs72781680	0.848	rs2339926	chr2:24045734	C/G	cg08917208	chr2:24149416	ATAD2B	0.8	4.93	0.4	2.62e-6	Lymphocyte counts;
TGCT	trans	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg17830980	chr10:43048298	ZNF37B	-0.85	-10.57	-0.69	5.07e-19	Extrinsic epigenetic age acceleration;
TGCT	cis	rs79349575	0.749	rs1057902	chr17:47005588	C/T	cg26022315	chr17:47021804	SNF8	0.5	4.89	0.4	3.11e-6	Type 2 diabetes;
TGCT	cis	rs12681287	0.640	rs7461413	chr8:87470978	C/G	cg27223183	chr8:87520930	FAM82B	-0.89	-6.43	-0.5	2.54e-9	Caudate activity during reward;
TGCT	cis	rs2467099	0.504	rs2666005	chr17:73944596	T/G	cg02678768	chr17:74002944	EVPL	0.28	4.82	0.4	4.14e-6	Systolic blood pressure;
TGCT	cis	rs9807989	0.507	rs6543133	chr2:103040177	A/T	cg03938978	chr2:103052716	IL18RAP	0.27	5.41	0.44	3.17e-7	Asthma;
TGCT	cis	rs2228479	0.850	rs17233455	chr16:89816407	A/G	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs559928	0.606	rs76653616	chr11:63936139	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	4.61	0.38	9.89e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
TGCT	cis	rs9993613	0.846	rs16848337	chr4:73493078	C/G	cg15102770	chr4:73434591	ADAMTS3	0.52	4.87	0.4	3.28e-6	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs231513	0.911	rs124720	chr17:41960141	A/G	cg26893861	chr17:41843967	DUSP3	-0.76	-5.45	-0.44	2.62e-7	Cognitive function;
TGCT	cis	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg05590025	chr7:65112418	INTS4L2	-0.77	-4.5	-0.37	1.52e-5	Diabetic kidney disease;
TGCT	cis	rs9467773	0.595	rs13207371	chr6:26591074	G/A	cg26531700	chr6:26746687	NA	0.61	5.75	0.46	6.7e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs4077468	1.000	rs4077469	chr1:205914885	C/T	cg07157834	chr1:205819609	PM20D1	-0.31	-4.43	-0.37	2.01e-5	Cystic fibrosis-related diabetes;
TGCT	cis	rs546131	0.600	rs502857	chr11:34854662	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.52	4.54	0.38	1.32e-5	Lung disease severity in cystic fibrosis;
TGCT	cis	rs72781680	0.898	rs72786277	chr2:24062818	T/G	cg08917208	chr2:24149416	ATAD2B	0.78	4.79	0.4	4.69e-6	Lymphocyte counts;
TGCT	cis	rs13256369	0.802	rs1060106	chr8:8561452	A/G	cg18904891	chr8:8559673	CLDN23	0.57	5.27	0.43	5.87e-7	Obesity-related traits;
TGCT	cis	rs6964587	0.967	rs6465353	chr7:91779971	G/T	cg22709100	chr7:91322751	NA	-0.28	-4.86	-0.4	3.53e-6	Breast cancer;
TGCT	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg25036284	chr2:26402008	FAM59B	-0.57	-4.97	-0.41	2.15e-6	Gut microbiome composition (summer);
TGCT	cis	rs9921222	0.565	rs10903014	chr16:377623	A/G	cg00101154	chr16:420108	MRPL28	-0.57	-6.07	-0.48	1.43e-8	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg12140144	chr1:2984275	FLJ42875;PRDM16	-0.36	-5.13	-0.42	1.1e-6	Height;
TGCT	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg22168489	chr12:122356033	WDR66	0.22	4.76	0.39	5.26e-6	Mean corpuscular volume;
TGCT	cis	rs11676348	0.783	rs13035513	chr2:218960680	C/T	cg00012203	chr2:219082015	ARPC2	-0.53	-4.89	-0.4	3.04e-6	Ulcerative colitis;
TGCT	cis	rs2303759	0.958	rs1465697	chr19:49837246	C/T	cg22307029	chr19:49891270	CCDC155	0.56	5.28	0.43	5.57e-7	Multiple sclerosis;
TGCT	cis	rs208520	0.526	rs1385219	chr6:66754476	C/T	cg07460842	chr6:66804631	NA	1.03	13.88	0.78	5.09e-27	Exhaled nitric oxide output;
TGCT	cis	rs7914558	0.869	rs10883842	chr10:104941589	C/T	cg05855489	chr10:104503620	C10orf26	0.5	4.47	0.37	1.71e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs7267979	1.000	rs6107033	chr20:25363591	A/G	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9357506	1.000	rs74869372	chr6:46314617	T/A	cg21115430	chr6:46460003	NA	-0.26	-5.06	-0.41	1.49e-6	Body mass index;
TGCT	cis	rs2072499	1.000	rs2241108	chr1:156181007	C/G	cg25208724	chr1:156163844	SLC25A44	1.11	15.91	0.82	9.79e-32	Testicular germ cell tumor;
TGCT	cis	rs11190604	0.943	rs113791644	chr10:102324330	T/G	cg23241863	chr10:102295624	HIF1AN	0.74	5.42	0.44	3.05e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs78487399	0.808	rs78191305	chr2:43673978	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-5.09	-0.42	1.3e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs9467773	0.967	rs1056347	chr6:26527524	G/C	cg09904177	chr6:26538194	HMGN4	0.65	6.53	0.51	1.53e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs1997103	0.954	rs7811098	chr7:55413012	A/G	cg17469321	chr7:55412551	NA	0.65	6.75	0.52	5.08e-10	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs28595532	0.702	rs116320061	chr4:119384600	C/T	cg11846333	chr4:119757529	SEC24D	0.7	4.59	0.38	1.08e-5	Cannabis dependence symptom count;
TGCT	cis	rs639012	0.636	rs7110631	chr11:85856187	C/G	cg07180834	chr11:85838833	NA	-0.33	-4.91	-0.4	2.84e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs6424115	1.000	rs58035855	chr1:24165248	G/C	cg15997130	chr1:24165203	NA	-0.9	-10.3	-0.68	2.37e-18	Immature fraction of reticulocytes;
TGCT	cis	rs10489202	0.535	rs12736786	chr1:167988283	C/G	cg24449463	chr1:168025552	DCAF6	-0.57	-6.67	-0.51	7.63e-10	Schizophrenia;
TGCT	cis	rs10744422	0.843	rs3896870	chr12:123333611	T/C	cg25930673	chr12:123319894	HIP1R	-0.84	-4.87	-0.4	3.26e-6	Schizophrenia;
TGCT	cis	rs11098499	0.954	rs878373	chr4:120237484	A/T	cg09307838	chr4:120376055	NA	0.63	5.89	0.47	3.41e-8	Corneal astigmatism;
TGCT	cis	rs782590	0.935	rs782568	chr2:55881538	T/C	cg03859395	chr2:55845619	SMEK2	0.9	10.52	0.69	6.93e-19	Metabolic syndrome;
TGCT	cis	rs9527	0.590	rs12414232	chr10:104914491	A/T	cg15744005	chr10:104629667	AS3MT	-0.41	-4.73	-0.39	6.06e-6	Arsenic metabolism;
TGCT	cis	rs7552404	0.889	rs2211080	chr1:76243438	G/A	cg03433033	chr1:76189801	ACADM	0.67	7.0	0.53	1.41e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs12134133	1.000	rs2782842	chr1:207483576	C/T	cg02152968	chr1:207494213	CD55	0.7	4.59	0.38	1.05e-5	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs7674212	0.541	rs2045746	chr4:104083578	A/C	cg16532752	chr4:104119610	CENPE	0.52	4.81	0.4	4.37e-6	Type 2 diabetes;
TGCT	cis	rs231513	0.954	rs231514	chr17:41964516	C/T	cg26893861	chr17:41843967	DUSP3	-0.75	-5.3	-0.43	5.18e-7	Cognitive function;
TGCT	cis	rs3087591	0.922	rs2905788	chr17:29480295	C/T	cg24425628	chr17:29625626	OMG;NF1	0.46	7.23	0.54	4.3e-11	Hip circumference;
TGCT	cis	rs1580019	1.000	rs1580019	chr7:32493169	A/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.73	-6.89	-0.53	2.52e-10	Cognitive ability;
TGCT	cis	rs12477438	0.798	rs2045057	chr2:99684929	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-5.87	-0.47	3.74e-8	Chronic sinus infection;
TGCT	cis	rs3733585	0.773	rs13107466	chr4:10019390	G/A	cg00071950	chr4:10020882	SLC2A9	0.75	10.33	0.68	2.04e-18	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs11605924	0.934	rs7945689	chr11:45879006	C/T	ch.11.939596F	chr11:45881766	CRY2	-0.38	-4.67	-0.39	7.8e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
TGCT	cis	rs4319547	0.956	rs9988963	chr12:122991478	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.66	-5.1	-0.42	1.22e-6	Body mass index;
TGCT	cis	rs10782582	0.593	rs11576534	chr1:76112751	C/T	cg10523679	chr1:76189770	ACADM	-0.66	-6.97	-0.53	1.69e-10	Daytime sleep phenotypes;
TGCT	cis	rs17376456	0.877	rs17083460	chr5:93462354	A/G	cg21475434	chr5:93447410	FAM172A	0.59	4.66	0.39	8.09e-6	Diabetic retinopathy;
TGCT	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg06481639	chr22:41940642	POLR3H	0.69	5.92	0.47	2.95e-8	Cannabis dependence symptom count;
TGCT	cis	rs7714584	0.590	rs115823027	chr5:150265951	G/A	cg22134413	chr5:150180641	NA	0.78	6.12	0.48	1.16e-8	Crohn's disease;
TGCT	cis	rs12780845	0.540	rs2356829	chr10:17223625	C/T	cg01003015	chr10:17271136	VIM	0.58	4.61	0.38	9.67e-6	Homocysteine levels;
TGCT	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg20203395	chr5:56204925	C5orf35	-0.59	-5.12	-0.42	1.12e-6	Initial pursuit acceleration;
TGCT	cis	rs896854	0.654	rs13248607	chr8:95986637	T/G	cg09323728	chr8:95962352	TP53INP1	-0.49	-6.32	-0.49	4.22e-9	Type 2 diabetes;
TGCT	cis	rs11122272	0.735	rs2486734	chr1:231531392	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-6.35	-0.5	3.66e-9	Hemoglobin concentration;
TGCT	cis	rs12777	0.571	rs6868463	chr5:131856053	T/G	cg16609957	chr5:132161867	SHROOM1	-0.35	-4.68	-0.39	7.43e-6	Fibrinogen levels;
TGCT	cis	rs6840360	0.615	rs12647462	chr4:152607278	C/T	cg22705602	chr4:152727874	NA	-0.32	-5.44	-0.44	2.76e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9814567	1.000	rs9884031	chr3:134256500	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.95	-9.49	-0.65	2.15e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	trans	rs8073060	0.963	rs4795082	chr17:33873501	C/T	cg19694781	chr19:47549865	TMEM160	0.42	7.77	0.57	2.52e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs2997447	0.761	rs61776586	chr1:26438933	T/C	cg03844060	chr1:26490628	NA	0.28	4.55	0.38	1.27e-5	QRS complex (12-leadsum);
TGCT	cis	rs60843830	0.661	rs62116682	chr2:104618	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.62	5.52	0.44	1.92e-7	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs250677	0.687	rs36046	chr5:148441257	A/C	cg23229984	chr5:148520753	ABLIM3	0.21	4.89	0.4	3.11e-6	Breast cancer;
TGCT	cis	rs2456568	0.803	rs10831138	chr11:93640468	T/C	cg16099599	chr11:93583650	C11orf90	-0.39	-4.78	-0.39	4.97e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	trans	rs1814175	0.591	rs11040589	chr11:49862449	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.45	-11.09	-0.71	2.8e-20	Height;
TGCT	cis	rs9911578	1.000	rs6503866	chr17:56619581	C/T	cg12560992	chr17:57184187	TRIM37	-0.76	-9.34	-0.64	4.88e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs939658	0.805	rs36068099	chr15:79438598	G/C	cg17916960	chr15:79447300	NA	-0.49	-7.41	-0.55	1.73e-11	Refractive error;
TGCT	cis	rs9443645	0.869	rs9361467	chr6:79621098	A/G	cg05283184	chr6:79620031	NA	-0.21	-4.71	-0.39	6.61e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1775715	0.677	rs2808074	chr10:32179184	A/C	cg14930904	chr10:32216787	ARHGAP12	0.52	5.07	0.41	1.39e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs3796352	0.764	rs34872575	chr3:52986277	G/A	cg15956490	chr3:53032818	SFMBT1	0.61	6.11	0.48	1.17e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs72781680	0.898	rs113522526	chr2:24018476	C/T	cg08917208	chr2:24149416	ATAD2B	0.81	4.99	0.41	2.01e-6	Lymphocyte counts;
TGCT	cis	rs9807989	0.507	rs2058659	chr2:103054556	A/G	cg03938978	chr2:103052716	IL18RAP	-0.25	-5.06	-0.41	1.47e-6	Asthma;
TGCT	cis	rs12497850	0.897	rs7432989	chr3:49105136	A/G	cg06212747	chr3:49208901	KLHDC8B	0.61	5.51	0.44	2e-7	Parkinson's disease;
TGCT	cis	rs4563143	0.514	rs73029079	chr19:29294903	A/G	cg04546413	chr19:29218101	NA	0.73	5.38	0.43	3.65e-7	Methadone dose in opioid dependence;
TGCT	cis	rs40363	0.729	rs6501176	chr16:3522197	A/G	cg05754148	chr16:3507555	NAT15	-0.44	-5.57	-0.45	1.54e-7	Tuberculosis;
TGCT	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg06873352	chr17:61820015	STRADA	0.58	6.37	0.5	3.32e-9	Prudent dietary pattern;
TGCT	cis	rs4294134	0.608	rs13237671	chr7:135244604	T/C	cg08396481	chr7:135194601	CNOT4	-0.62	-4.81	-0.4	4.25e-6	Paget's disease;
TGCT	cis	rs45509595	0.841	rs370155	chr6:27782031	T/G	cg10876282	chr6:28092338	ZSCAN16	0.78	4.57	0.38	1.17e-5	Breast cancer;
TGCT	cis	rs17401966	0.931	rs3748579	chr1:10420937	C/T	cg19773385	chr1:10388646	KIF1B	-0.24	-5.5	-0.44	2.03e-7	Hepatocellular carcinoma;
TGCT	cis	rs17152411	0.895	rs61872121	chr10:126586795	T/C	cg07906193	chr10:126599966	NA	0.41	5.05	0.41	1.52e-6	Height;
TGCT	cis	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg15556689	chr8:8085844	FLJ10661	0.69	6.17	0.48	8.84e-9	Mood instability;
TGCT	cis	rs4851254	0.660	rs13430705	chr2:100690616	G/A	cg07810366	chr2:100720526	AFF3	-0.49	-5.22	-0.42	7.36e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1532993	0.518	rs1911790	chr4:98586222	T/C	cg05340658	chr4:99064831	C4orf37	-0.4	-4.76	-0.39	5.31e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs3026101	0.624	rs7426	chr17:5288983	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.5	4.89	0.4	3.11e-6	Body mass index;
TGCT	cis	rs362272	0.524	rs7435601	chr4:3369645	A/G	cg18352616	chr4:3374830	RGS12	0.25	5.12	0.42	1.15e-6	Serum sulfate level;
TGCT	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg05890377	chr2:74357713	NA	0.53	7.11	0.54	8.05e-11	Gestational age at birth (maternal effect);
TGCT	cis	rs360798	0.512	rs12989754	chr2:63020970	A/G	cg17519650	chr2:63277830	OTX1	-0.6	-5.23	-0.43	7.02e-7	Coronary artery disease;
TGCT	cis	rs12681287	0.547	rs9942792	chr8:87509046	C/T	cg27223183	chr8:87520930	FAM82B	-0.95	-6.95	-0.53	1.81e-10	Caudate activity during reward;
TGCT	cis	rs28735056	0.904	rs11520415	chr18:77620620	C/T	cg20368463	chr18:77673604	PQLC1	0.38	4.6	0.38	1.04e-5	Schizophrenia;
TGCT	cis	rs651907	0.535	rs12633089	chr3:101528763	C/T	cg12386194	chr3:101231763	SENP7	0.47	4.7	0.39	6.87e-6	Colorectal cancer;
TGCT	cis	rs2243480	1.000	rs160639	chr7:65579987	C/G	cg07424592	chr7:64974309	NA	1.22	7.36	0.55	2.2e-11	Diabetic kidney disease;
TGCT	cis	rs950027	0.620	rs1145080	chr15:45681338	C/T	cg26924012	chr15:45694286	SPATA5L1	0.79	8.86	0.62	6.92e-15	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs55883249	1.000	rs10495573	chr2:9712160	T/G	cg23886495	chr2:9695866	ADAM17	0.82	4.8	0.4	4.47e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs6671200	0.748	rs79375907	chr1:95539561	C/T	cg03123541	chr1:95699097	RWDD3	0.65	4.49	0.37	1.6e-5	Stearic acid (18:0) levels;
TGCT	cis	rs9467773	0.620	rs4368798	chr6:26593471	A/G	cg26531700	chr6:26746687	NA	0.5	4.65	0.39	8.29e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9796	0.649	rs8035828	chr15:41467287	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.52	-7.3	-0.55	3.07e-11	Menopause (age at onset);
TGCT	cis	rs908922	0.676	rs569032	chr1:152508615	C/T	cg20991723	chr1:152506922	NA	0.46	6.18	0.48	8.66e-9	Hair morphology;
TGCT	cis	rs601339	1.000	rs4759361	chr12:123178280	T/A	cg11919336	chr12:123188078	GPR109A	0.64	7.86	0.58	1.61e-12	Adiponectin levels;
TGCT	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg18876405	chr7:65276391	NA	-0.36	-5.41	-0.44	3.12e-7	Aortic root size;
TGCT	cis	rs7192750	0.562	rs4788573	chr16:71921946	A/C	cg06353428	chr16:71660113	MARVELD3	0.82	7.26	0.55	3.82e-11	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs59104589	0.920	rs59916403	chr2:242370751	G/T	cg21155796	chr2:242212141	HDLBP	0.58	4.98	0.41	2.06e-6	Fibrinogen levels;
TGCT	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg06112835	chr11:68658793	MRPL21	0.47	8.14	0.59	3.57e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg03188948	chr7:1209495	NA	0.68	5.72	0.46	7.53e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2880765	0.835	rs4842887	chr15:86035810	T/C	cg13263323	chr15:86062960	AKAP13	-0.22	-4.84	-0.4	3.84e-6	Coronary artery disease;
TGCT	cis	rs7267979	0.753	rs400357	chr20:25479058	A/G	cg16686733	chr20:25566563	NINL	0.52	4.93	0.4	2.61e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4808199	0.895	rs10403731	chr19:19469296	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.71	5.56	0.45	1.59e-7	Nonalcoholic fatty liver disease;
TGCT	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg03609598	chr5:56110824	MAP3K1	-0.56	-4.57	-0.38	1.14e-5	Initial pursuit acceleration;
TGCT	cis	rs77633900	0.614	rs2585730	chr15:76989344	A/G	cg21673338	chr15:77095150	SCAPER	-0.51	-4.89	-0.4	3.08e-6	Non-glioblastoma glioma;Glioma;
TGCT	cis	rs1008375	1.000	rs4698635	chr4:17630242	C/A	cg10189774	chr4:17578691	LAP3	0.59	5.13	0.42	1.06e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9611565	0.921	rs4822021	chr22:41726053	G/A	cg03806693	chr22:41940476	POLR3H	-0.97	-10.25	-0.68	3.06e-18	Vitiligo;
TGCT	cis	rs910316	0.737	rs175048	chr14:75479894	A/T	cg11812906	chr14:75593930	NEK9	-0.56	-5.28	-0.43	5.48e-7	Height;
TGCT	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg08280861	chr8:58055591	NA	0.39	4.86	0.4	3.45e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg17554472	chr22:41940697	POLR3H	0.48	5.08	0.42	1.34e-6	Vitiligo;
TGCT	trans	rs66573146	1.000	rs55833486	chr4:6978729	C/A	cg07817883	chr1:32538562	TMEM39B	1.42	7.53	0.56	8.92e-12	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs12791968	1.000	rs1552301	chr11:45002551	A/G	cg11846598	chr11:44996168	LOC221122	-0.36	-6.79	-0.52	4.04e-10	Inhibitory control;
TGCT	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg04944784	chr2:26401820	FAM59B	-0.68	-6.04	-0.48	1.7e-8	Gut microbiome composition (summer);
TGCT	cis	rs735396	1.000	rs1169311	chr12:121440731	C/T	cg02403541	chr12:121454288	C12orf43	0.66	6.27	0.49	5.35e-9	N-glycan levels;
TGCT	cis	rs9486719	1.000	rs2499804	chr6:96861216	A/G	cg18709589	chr6:96969512	KIAA0776	0.71	5.21	0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs7647973	1.000	rs3870341	chr3:49584745	A/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.57	-4.85	-0.4	3.57e-6	Menarche (age at onset);
TGCT	cis	rs7666738	0.830	rs1813972	chr4:98886828	C/A	cg17366294	chr4:99064904	C4orf37	0.68	6.87	0.53	2.72e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs80282103	0.618	rs10794720	chr10:1156165	A/G	cg08668510	chr10:1095578	IDI1	-0.92	-5.0	-0.41	1.88e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs1580019	0.885	rs4580942	chr7:32496435	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.8	7.36	0.55	2.19e-11	Cognitive ability;
TGCT	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg03709012	chr19:19516395	GATAD2A	-0.69	-5.76	-0.46	6.23e-8	Tonsillectomy;
TGCT	cis	rs453301	0.658	rs12114954	chr8:8904862	T/G	cg06636001	chr8:8085503	FLJ10661	-0.69	-5.59	-0.45	1.37e-7	Joint mobility (Beighton score);
TGCT	cis	rs4072705	0.967	rs4838209	chr9:127528842	C/T	cg13476313	chr9:127244764	NR5A1	0.28	4.57	0.38	1.18e-5	Menarche (age at onset);
TGCT	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.05	0.41	1.54e-6	Prudent dietary pattern;
TGCT	cis	rs7264396	0.561	rs6060753	chr20:34598430	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-4.9	-0.4	2.97e-6	Total cholesterol levels;
TGCT	cis	rs7666738	0.830	rs13145011	chr4:98993410	G/A	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12134245	0.776	rs6688261	chr1:91987034	C/T	cg02896835	chr1:92012615	NA	-0.26	-4.68	-0.39	7.37e-6	Breast cancer;
TGCT	cis	rs4689592	0.503	rs66885632	chr4:7053738	T/C	cg02503808	chr4:7069936	GRPEL1	-0.92	-7.34	-0.55	2.4e-11	Monocyte percentage of white cells;
TGCT	cis	rs3862260	0.967	rs3862261	chr1:120160822	G/A	cg16322792	chr1:120165303	ZNF697	0.27	5.71	0.46	7.73e-8	Systemic lupus erythematosus;
TGCT	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg05368731	chr17:41323189	NBR1	1.15	13.28	0.77	1.44e-25	Menopause (age at onset);
TGCT	cis	rs9443645	0.901	rs9352669	chr6:79584141	T/G	cg09184832	chr6:79620586	NA	-0.48	-5.17	-0.42	9.23e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs67311347	1.000	rs2085115	chr3:40497540	G/T	cg17264618	chr3:40429014	ENTPD3	0.32	4.45	0.37	1.88e-5	Renal cell carcinoma;
TGCT	cis	rs748404	0.631	rs2412781	chr15:43667900	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.46	-4.72	-0.39	6.3e-6	Lung cancer;
TGCT	cis	rs17102423	0.755	rs11625045	chr14:65549089	C/T	cg11161011	chr14:65562177	MAX	-0.55	-7.77	-0.57	2.5e-12	Obesity-related traits;
TGCT	cis	rs155076	1.000	rs658244	chr13:21850976	T/C	cg14456004	chr13:21872349	NA	-1.34	-11.21	-0.71	1.42e-20	White matter hyperintensity burden;
TGCT	trans	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg13565492	chr6:43139072	SRF	-0.82	-7.72	-0.57	3.43e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs10876993	0.855	rs1689585	chr12:58080140	A/G	cg15848620	chr12:58087721	OS9	0.7	5.81	0.46	4.92e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs11030122	0.660	rs10835250	chr11:3911198	G/T	cg18678763	chr11:4115507	RRM1	-0.35	-4.45	-0.37	1.85e-5	Mean platelet volume;Platelet distribution width;
TGCT	trans	rs9929218	0.551	rs3785133	chr16:68728611	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	7.67	0.57	4.25e-12	Colorectal cancer;
TGCT	cis	rs2404602	0.716	rs8039545	chr15:76707247	A/G	cg22467129	chr15:76604101	ETFA	-0.59	-7.13	-0.54	7.33e-11	Blood metabolite levels;
TGCT	cis	rs8051431	0.840	rs4788595	chr16:72025759	A/C	cg06353428	chr16:71660113	MARVELD3	0.61	5.06	0.41	1.47e-6	LDL cholesterol levels;
TGCT	cis	rs933688	0.938	rs7720235	chr5:90659329	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.03	9.27	0.64	7.28e-16	Smoking behavior;
TGCT	cis	rs3617	0.573	rs9880978	chr3:52923251	C/G	cg11645453	chr3:52864694	ITIH4	0.29	5.46	0.44	2.49e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4319547	0.695	rs7301515	chr12:122949673	T/C	cg23029597	chr12:123009494	RSRC2	-0.3	-4.9	-0.4	2.88e-6	Body mass index;
TGCT	cis	rs782590	0.934	rs62165184	chr2:55788253	G/C	cg18811423	chr2:55921094	PNPT1	0.67	7.1	0.54	8.63e-11	Metabolic syndrome;
TGCT	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg06634786	chr22:41940651	POLR3H	-0.89	-8.44	-0.6	6.85e-14	Vitiligo;
TGCT	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.58	-4.61	-0.38	9.85e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg27588902	chr6:42928151	GNMT	-0.5	-5.97	-0.47	2.37e-8	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg02380750	chr20:61661411	NA	0.33	5.96	0.47	2.4e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.51	5.5	0.44	2.06e-7	Lymphocyte counts;
TGCT	cis	rs854765	0.624	rs12450799	chr17:17730201	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.6	-5.62	-0.45	1.19e-7	Total body bone mineral density;
TGCT	cis	rs10509586	0.826	rs77506020	chr10:91898943	T/C	cg25278353	chr10:91717815	NA	0.49	4.67	0.39	7.77e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
TGCT	cis	rs797680	0.856	rs1535699	chr1:93804952	G/A	cg17826107	chr1:92977322	EVI5	-0.23	-5.07	-0.41	1.4e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs7727544	0.716	rs72793278	chr5:131561372	C/A	cg21474247	chr5:131268130	NA	0.32	4.54	0.38	1.32e-5	Blood metabolite levels;
TGCT	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg12140144	chr1:2984275	FLJ42875;PRDM16	-0.32	-4.46	-0.37	1.81e-5	Height;
TGCT	cis	rs35146811	0.700	rs2950520	chr7:99827148	T/C	cg00553149	chr7:99775558	STAG3;GPC2	-0.32	-4.78	-0.39	4.88e-6	Coronary artery disease;
TGCT	cis	rs6831352	0.918	rs34071486	chr4:100051087	A/G	cg12011299	chr4:100065546	ADH4	-0.41	-4.92	-0.4	2.72e-6	Alcohol dependence;
TGCT	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.52	5.52	0.44	1.92e-7	Lymphocyte counts;
TGCT	cis	rs1406084	0.636	rs7420387	chr2:154718142	C/T	cg25703346	chr2:154729189	GALNT13	0.77	4.6	0.38	1.03e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.94	7.92	0.58	1.17e-12	Platelet count;
TGCT	cis	rs2832191	0.716	rs7509628	chr21:30454252	C/T	cg24692254	chr21:30365293	RNF160	0.98	11.36	0.71	6.16e-21	Dental caries;
TGCT	trans	rs10506458	0.834	rs12426860	chr12:63387948	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.47	-7.54	-0.56	8.62e-12	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs35934224	0.783	rs56291622	chr22:19858734	C/T	cg11182965	chr22:19864308	TXNRD2	-0.38	-5.22	-0.42	7.16e-7	Glaucoma (primary open-angle);
TGCT	cis	rs6543140	0.929	rs6742530	chr2:103082280	G/A	cg09003973	chr2:102972529	NA	0.55	4.56	0.38	1.2e-5	Blood protein levels;
TGCT	cis	rs4711350	0.765	rs2182658	chr6:33748831	G/T	cg13859433	chr6:33739653	LEMD2	0.32	4.82	0.4	4.08e-6	Schizophrenia;
TGCT	cis	rs9611565	0.503	rs5996062	chr22:42167464	C/G	cg06481639	chr22:41940642	POLR3H	0.69	6.05	0.48	1.59e-8	Vitiligo;
TGCT	cis	rs9650657	0.535	rs7011756	chr8:11019578	C/G	cg27411982	chr8:10470053	RP1L1	-0.21	-4.68	-0.39	7.54e-6	Neuroticism;
TGCT	cis	rs2180341	1.000	rs9321073	chr6:127609691	C/T	cg27446573	chr6:127587934	RNF146	1.13	10.12	0.67	6.64e-18	Breast cancer;
TGCT	cis	rs9926296	0.712	rs2434872	chr16:89716915	C/G	cg03388025	chr16:89894329	SPIRE2	-0.35	-5.05	-0.41	1.53e-6	Vitiligo;
TGCT	trans	rs62103177	0.759	rs9956512	chr18:77607517	G/A	cg05926928	chr17:57297772	GDPD1	1.22	11.62	0.72	1.41e-21	Opioid sensitivity;
TGCT	cis	rs911555	0.504	rs4444269	chr14:104072724	G/C	cg26031613	chr14:104095156	KLC1	0.61	5.6	0.45	1.34e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs12210905	1.000	rs12196084	chr6:27198204	A/C	cg08851530	chr6:28072375	NA	0.98	4.79	0.4	4.57e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs7607369	0.527	rs72966038	chr2:219656190	G/A	cg02176678	chr2:219576539	TTLL4	-0.47	-6.01	-0.47	1.96e-8	Red blood cell count;Amyotrophic lateral sclerosis;
TGCT	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg13395646	chr4:1353034	KIAA1530	-0.4	-4.95	-0.41	2.4e-6	Obesity-related traits;
TGCT	cis	rs11696501	0.694	rs4812943	chr20:44260966	G/C	cg11783356	chr20:44313418	WFDC10B	-0.32	-4.58	-0.38	1.14e-5	Brain structure;
TGCT	cis	rs7949030	0.765	rs11553576	chr11:62378801	T/C	cg11742103	chr11:62369870	EML3;MTA2	0.62	9.17	0.64	1.27e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs12615966	0.932	rs17030324	chr2:105403251	A/C	cg16465502	chr2:105461796	NA	0.81	5.21	0.42	7.61e-7	Pancreatic cancer;
TGCT	cis	rs2242116	0.761	rs6780601	chr3:46965856	A/G	cg23352942	chr3:46931381	PTH1R	-0.32	-4.53	-0.38	1.36e-5	Birth weight;
TGCT	cis	rs3791556	0.898	rs3828222	chr2:240109568	A/G	cg03281426	chr2:240109471	HDAC4	-0.28	-4.62	-0.38	9.66e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs7617773	0.780	rs7653152	chr3:48362097	G/C	cg11946769	chr3:48343235	NME6	0.82	7.11	0.54	8.07e-11	Coronary artery disease;
TGCT	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg18230493	chr5:56204884	C5orf35	-0.68	-5.92	-0.47	2.92e-8	Initial pursuit acceleration;
TGCT	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	7.12	0.54	7.55e-11	Platelet count;
TGCT	cis	rs9329221	0.772	rs7824675	chr8:10243418	G/T	cg27411982	chr8:10470053	RP1L1	-0.21	-4.83	-0.4	3.98e-6	Neuroticism;
TGCT	cis	rs9300255	0.722	rs10846515	chr12:123801672	T/G	cg00376283	chr12:123451042	ABCB9	0.65	4.57	0.38	1.17e-5	Neutrophil percentage of white cells;
TGCT	cis	rs4665630	0.522	rs2712054	chr2:23956123	C/T	cg08063864	chr2:24346004	PFN4;LOC375190	1.21	6.41	0.5	2.81e-9	Hypertension;
TGCT	cis	rs4319547	0.698	rs10744217	chr12:122942070	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.61	-4.94	-0.41	2.43e-6	Body mass index;
TGCT	cis	rs6121246	0.909	rs1994249	chr20:30287593	C/T	cg18721089	chr20:30220636	NA	-0.42	-4.65	-0.39	8.2e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs2463822	0.858	rs2513037	chr11:62084822	A/T	cg06239285	chr11:62104954	ASRGL1	-0.91	-6.55	-0.51	1.36e-9	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs9296092	0.560	rs3846854	chr6:33528466	T/C	cg13560919	chr6:33536144	NA	-0.23	-5.06	-0.41	1.49e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.91	-6.69	-0.52	6.82e-10	Gut microbiome composition (summer);
TGCT	cis	rs2153535	0.601	rs2143353	chr6:8530111	T/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.55e-8	Motion sickness;
TGCT	cis	rs941408	1.000	rs1736179	chr19:2795516	T/A	cg06609049	chr19:2785107	THOP1	0.79	7.79	0.57	2.36e-12	Total cholesterol levels;
TGCT	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg10047753	chr17:41438598	NA	0.97	9.99	0.67	1.37e-17	Menopause (age at onset);
TGCT	cis	rs6921919	0.583	rs6899603	chr6:28381305	A/G	cg18815343	chr6:28367644	ZSCAN12	-0.54	-5.25	-0.43	6.29e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	5.87	0.47	3.65e-8	Bipolar disorder;
TGCT	cis	rs778371	0.697	rs4973564	chr2:233718440	A/G	cg08000102	chr2:233561755	GIGYF2	-0.72	-8.51	-0.61	4.67e-14	Schizophrenia;
TGCT	cis	rs6565180	0.889	rs8051096	chr16:30347731	A/G	cg17640201	chr16:30407289	ZNF48	-0.87	-8.77	-0.62	1.15e-14	Tonsillectomy;
TGCT	cis	rs3782455	0.590	rs16943539	chr12:114404337	T/G	cg23502203	chr12:113549970	RASAL1	-0.55	-4.92	-0.4	2.7e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs7267979	0.966	rs2261784	chr20:25262396	G/C	cg03522245	chr20:25566470	NINL	0.62	6.61	0.51	1.04e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1903068	0.785	rs12331538	chr4:55998086	A/C	cg16572876	chr4:56024045	NA	0.44	4.94	0.41	2.47e-6	Endometriosis;
TGCT	cis	rs9611519	0.780	rs1983631	chr22:41644074	C/T	cg13695892	chr22:41940480	POLR3H	-0.59	-5.4	-0.44	3.26e-7	Neuroticism;
TGCT	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg17178900	chr1:205818956	PM20D1	0.59	7.49	0.56	1.14e-11	Menarche (age at onset);
TGCT	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg05872129	chr22:39784769	NA	-1.02	-11.72	-0.73	8.03e-22	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.546	rs62320963	chr4:98839297	A/G	cg18180107	chr4:99064573	C4orf37	0.55	4.76	0.39	5.33e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4294134	0.608	rs11767351	chr7:135243837	A/G	cg08396481	chr7:135194601	CNOT4	-0.62	-4.81	-0.4	4.25e-6	Paget's disease;
TGCT	cis	rs9640161	0.658	rs60467296	chr7:150015471	G/A	cg10018233	chr7:150070692	REPIN1	0.32	4.46	0.37	1.84e-5	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs6920965	0.507	rs9401853	chr6:126215197	A/T	cg05901451	chr6:126070800	HEY2	-0.66	-6.56	-0.51	1.3e-9	High light scatter reticulocyte count;
TGCT	cis	rs8020441	1.000	rs68157165	chr14:51169220	A/G	cg04730355	chr14:51134070	SAV1	0.73	6.02	0.48	1.84e-8	Cognitive performance;
TGCT	cis	rs1215050	0.740	rs783924	chr4:98969234	C/T	cg17366294	chr4:99064904	C4orf37	-0.55	-5.8	-0.46	5.23e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg25427524	chr10:38739819	LOC399744	-0.39	-7.84	-0.58	1.74e-12	Extrinsic epigenetic age acceleration;
TGCT	cis	rs8072100	0.790	rs1962307	chr17:45707871	A/G	cg08085267	chr17:45401833	C17orf57	-0.46	-4.96	-0.41	2.26e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs3026101	0.624	rs1806255	chr17:5314263	G/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.47	4.51	0.38	1.46e-5	Body mass index;
TGCT	cis	rs17030434	0.906	rs5020754	chr4:154670444	T/C	cg14289246	chr4:154710475	SFRP2	-0.88	-7.18	-0.54	5.68e-11	Electrocardiographic conduction measures;
TGCT	cis	rs9914544	0.545	rs12942794	chr17:18767217	A/C	cg26378065	chr17:18585709	ZNF286B	0.52	4.5	0.37	1.56e-5	Educational attainment (years of education);
TGCT	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg02953382	chr22:24373134	LOC391322	-0.72	-6.82	-0.52	3.55e-10	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7296418	0.961	rs4148863	chr12:123569375	A/G	cg00376283	chr12:123451042	ABCB9	0.82	7.46	0.56	1.33e-11	Platelet count;
TGCT	cis	rs3816788	0.774	rs11784816	chr8:21773500	C/T	cg17168535	chr8:21777572	XPO7	-0.78	-7.41	-0.55	1.71e-11	Lung cancer in ever smokers;
TGCT	cis	rs4665809	0.617	rs930263	chr2:26402594	G/C	cg04944784	chr2:26401820	FAM59B	-0.76	-6.32	-0.49	4.35e-9	Gut microbiome composition (summer);
TGCT	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg01802117	chr1:53393560	SCP2	0.44	5.11	0.42	1.18e-6	Monocyte count;
TGCT	cis	rs2204008	0.502	rs2387275	chr12:38142836	G/A	cg26384229	chr12:38710491	ALG10B	0.92	8.1	0.59	4.38e-13	Bladder cancer;
TGCT	cis	rs8103278	0.507	rs4802275	chr19:46260375	C/T	cg11657440	chr19:46296263	DMWD	0.75	7.86	0.58	1.62e-12	Coronary artery disease;
TGCT	cis	rs111803315	1.000	rs111237243	chr14:59991030	G/T	cg22995959	chr14:59931024	GPR135	0.66	4.8	0.4	4.39e-6	Schizophrenia;
TGCT	cis	rs611744	0.647	rs689275	chr8:109241822	T/C	cg21045802	chr8:109455806	TTC35	0.72	7.28	0.55	3.44e-11	Dupuytren's disease;
TGCT	cis	rs8017423	0.967	rs1005788	chr14:90692747	C/T	cg04374321	chr14:90722782	PSMC1	0.77	8.03	0.58	6.42e-13	Mortality in heart failure;
TGCT	cis	rs10197940	0.578	rs2432946	chr2:152306897	G/T	cg06191203	chr2:152266755	RIF1	0.57	4.74	0.39	5.78e-6	Lung cancer;
TGCT	cis	rs2073300	1.000	rs34449811	chr20:23443771	T/C	cg09953122	chr20:23471693	CST8	-0.64	-4.56	-0.38	1.19e-5	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	trans	rs7698623	0.850	rs6532019	chr4:88768672	C/T	cg01186725	chr1:53905612	FLJ40434	-0.48	-6.62	-0.51	9.94e-10	Cardiovascular disease risk factors;
TGCT	cis	rs7772486	0.875	rs10457792	chr6:146412415	T/C	cg05347473	chr6:146136440	FBXO30	0.55	5.14	0.42	1.05e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1420338	0.967	rs10272282	chr7:34172073	C/T	cg01275685	chr7:34179230	BMPER	-0.28	-5.08	-0.41	1.36e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs3796352	0.881	rs35384050	chr3:53008769	G/T	cg07884673	chr3:53033167	SFMBT1	0.62	6.19	0.49	8.26e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs611744	0.967	rs684904	chr8:109199417	G/A	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg11965913	chr1:205819406	PM20D1	0.46	6.32	0.49	4.26e-9	Monocyte percentage of white cells;
TGCT	cis	rs8017423	0.967	rs11626011	chr14:90693572	A/G	cg04374321	chr14:90722782	PSMC1	0.76	7.83	0.58	1.9e-12	Mortality in heart failure;
TGCT	trans	rs561341	0.700	rs2074101	chr17:30228656	G/A	cg20587970	chr11:113659929	NA	-0.6	-9.12	-0.63	1.65e-15	Hip circumference adjusted for BMI;
TGCT	cis	rs28595532	0.920	rs114037572	chr4:119735609	T/G	cg14228332	chr4:119757509	SEC24D	1.32	6.38	0.5	3.2e-9	Cannabis dependence symptom count;
TGCT	cis	rs7937682	0.883	rs12804962	chr11:111442683	A/T	cg09085632	chr11:111637200	PPP2R1B	1.0	9.68	0.66	7.65e-17	Primary sclerosing cholangitis;
TGCT	cis	rs7216064	1.000	rs1976053	chr17:65833002	C/G	cg12091567	chr17:66097778	LOC651250	-0.84	-6.75	-0.52	5.15e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs7590720	1.000	rs1991533	chr2:216908910	T/C	cg12620499	chr2:216877984	MREG	0.87	8.73	0.62	1.48e-14	Alcohol dependence;
TGCT	cis	rs7412746	0.611	rs3768018	chr1:150723747	T/C	cg09365446	chr1:150670422	GOLPH3L	0.32	4.58	0.38	1.1e-5	Melanoma;
TGCT	cis	rs2230307	0.536	rs580611	chr1:100622925	G/A	cg24955406	chr1:100503596	HIAT1	-0.74	-5.01	-0.41	1.8e-6	Carotid intima media thickness;
TGCT	cis	rs1670533	0.932	rs4690347	chr4:1057328	A/G	cg20887711	chr4:1340912	KIAA1530	0.71	5.7	0.46	8.33e-8	Recombination rate (females);
TGCT	cis	rs9560113	0.806	rs9560112	chr13:112183320	A/G	cg14154082	chr13:112174009	NA	0.36	4.8	0.4	4.52e-6	Menarche (age at onset);
TGCT	cis	rs79387448	0.745	rs6709719	chr2:103144953	G/A	cg09003973	chr2:102972529	NA	0.97	6.32	0.49	4.33e-9	Gut microbiota (bacterial taxa);
TGCT	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.0	0.41	1.89e-6	Menopause (age at onset);
TGCT	cis	rs12360000	0.770	rs12573442	chr10:1910626	T/C	cg26364871	chr10:1889757	NA	0.41	4.63	0.38	9.26e-6	Metabolite levels (Dihydroxy docosatrienoic acid);
TGCT	cis	rs9650657	0.683	rs7830431	chr8:10700317	A/G	cg27411982	chr8:10470053	RP1L1	-0.22	-4.67	-0.39	7.63e-6	Neuroticism;
TGCT	cis	rs1008375	1.000	rs1860597	chr4:17657650	C/T	cg18681998	chr4:17616180	MED28	1.01	11.89	0.73	3.17e-22	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg12310025	chr6:25882481	NA	-0.53	-5.45	-0.44	2.58e-7	Blood metabolite levels;
TGCT	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.46	0.56	1.3e-11	Prudent dietary pattern;
TGCT	cis	rs7208859	0.673	rs1347359	chr17:28914529	T/C	cg19761014	chr17:28927070	LRRC37B2	0.54	4.67	0.39	7.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs4689592	0.503	rs59640165	chr4:7051661	G/A	cg02503808	chr4:7069936	GRPEL1	-0.94	-7.49	-0.56	1.14e-11	Monocyte percentage of white cells;
TGCT	cis	rs7666738	0.830	rs7696686	chr4:98938445	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7208859	0.614	rs28758251	chr17:29223312	A/T	cg14008862	chr17:28927542	LRRC37B2	0.72	4.66	0.39	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs295140	0.564	rs296790	chr2:201232862	C/G	cg04283868	chr2:201171347	SPATS2L	-0.54	-5.22	-0.42	7.46e-7	QT interval;
TGCT	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg00343986	chr7:65444356	GUSB	0.23	5.02	0.41	1.79e-6	Aortic root size;
TGCT	cis	rs975752	0.867	rs11190443	chr10:102023738	C/T	cg04750910	chr10:102416409	NA	0.73	4.48	0.37	1.69e-5	Schizophrenia;
TGCT	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg25767906	chr1:53392781	SCP2	-0.51	-5.77	-0.46	6.07e-8	Monocyte count;
TGCT	cis	rs7666738	1.000	rs13124102	chr4:98990696	G/A	cg17366294	chr4:99064904	C4orf37	0.69	6.39	0.5	3.1e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2677744	0.688	rs2239293	chr15:91450350	G/A	cg23684204	chr15:91497937	RCCD1	0.34	4.84	0.4	3.74e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs7586879	0.765	rs11683429	chr2:25120733	T/A	cg01884057	chr2:25150051	NA	0.27	4.81	0.4	4.36e-6	Body mass index;
TGCT	cis	rs3806843	1.000	rs6870764	chr5:140171790	C/T	cg19875535	chr5:140030758	IK	0.37	6.34	0.49	3.89e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9291683	0.588	rs35099040	chr4:10018839	T/C	cg11266682	chr4:10021025	SLC2A9	0.73	10.8	0.7	1.4e-19	Bone mineral density;
TGCT	cis	rs7666738	0.753	rs17483788	chr4:98985623	G/A	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3820068	0.705	rs16851727	chr1:15857918	C/T	cg05660106	chr1:15850417	CASP9	1.15	13.74	0.78	1.14e-26	Systolic blood pressure;
TGCT	cis	rs79057730	0.684	rs6955004	chr7:790792	A/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.66	5.45	0.44	2.62e-7	Initial pursuit acceleration;
TGCT	cis	rs2414095	0.527	rs8041967	chr15:51544324	G/A	cg19946085	chr15:51559439	CYP19A1	-0.33	-4.68	-0.39	7.54e-6	Follicule stimulating hormone;Hormone measurements;Total body bone mineral density;
TGCT	cis	rs35306767	0.903	rs11812523	chr10:915638	C/T	cg20503657	chr10:835505	NA	0.74	10.3	0.68	2.41e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs2147959	0.724	rs10753452	chr1:228724604	G/C	cg22700015	chr1:228743131	NA	-0.54	-4.59	-0.38	1.06e-5	Adult asthma;
TGCT	cis	rs2439831	0.681	rs7168940	chr15:43633334	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	6.87	0.52	2.81e-10	Lung cancer in ever smokers;
TGCT	cis	rs7100689	0.577	rs1143694	chr10:82040052	C/T	cg01528321	chr10:82214614	TSPAN14	-0.7	-6.78	-0.52	4.43e-10	Post bronchodilator FEV1;
TGCT	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg01416388	chr22:39784598	NA	-0.73	-7.59	-0.56	6.65e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs7826238	0.564	rs2921053	chr8:8319963	G/C	cg06636001	chr8:8085503	FLJ10661	0.75	7.05	0.53	1.1e-10	Systolic blood pressure;
TGCT	trans	rs2469997	1.000	rs2447176	chr8:120356892	G/A	cg01792902	chr3:178864926	PIK3CA	0.84	6.81	0.52	3.74e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs3862260	1.000	rs3862260	chr1:120160789	G/A	cg16322792	chr1:120165303	ZNF697	0.27	5.71	0.46	7.73e-8	Systemic lupus erythematosus;
TGCT	cis	rs1018836	0.631	rs2205157	chr8:91472384	C/T	cg16814680	chr8:91681699	NA	-0.76	-7.45	-0.56	1.37e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2463822	1.000	rs12279819	chr11:62137245	G/A	cg06239285	chr11:62104954	ASRGL1	-0.94	-6.61	-0.51	1.03e-9	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs9467711	0.606	rs2072806	chr6:26385093	C/G	cg16898833	chr6:26189333	HIST1H4D	1.15	5.5	0.44	2.1e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs10484885	0.763	rs56401039	chr6:90522486	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.46	-4.52	-0.38	1.43e-5	QRS interval (sulfonylurea treatment interaction);
TGCT	trans	rs2727020	0.595	rs10839286	chr11:49497063	C/A	cg03929089	chr4:120376271	NA	-0.76	-9.15	-0.63	1.43e-15	Coronary artery disease;
TGCT	cis	rs1062177	0.826	rs2915879	chr5:151147442	A/G	cg00977110	chr5:151150581	G3BP1	0.4	4.67	0.39	7.61e-6	Preschool internalizing problems;
TGCT	cis	rs6570726	0.791	rs952406	chr6:145925616	C/A	cg05347473	chr6:146136440	FBXO30	0.5	4.61	0.38	9.98e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg21171335	chr12:122356390	WDR66	0.61	6.66	0.51	7.92e-10	Mean corpuscular volume;
TGCT	cis	rs694739	0.687	rs11231771	chr11:64140642	T/G	cg02228329	chr11:64053129	BAD;GPR137	0.7	6.8	0.52	4.02e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs735396	0.627	rs2264778	chr12:121450354	C/A	cg02403541	chr12:121454288	C12orf43	0.86	9.16	0.64	1.35e-15	N-glycan levels;
TGCT	cis	rs611744	0.967	rs653081	chr8:109230383	G/T	cg21045802	chr8:109455806	TTC35	0.52	4.72	0.39	6.21e-6	Dupuytren's disease;
TGCT	cis	rs2288884	1.000	rs11669385	chr19:52571952	G/C	cg13540795	chr19:52551618	ZNF432	-0.59	-4.98	-0.41	2.09e-6	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs3858526	0.959	rs11039699	chr11:5951091	G/A	cg05234568	chr11:5960015	NA	-0.48	-4.77	-0.39	5.08e-6	DNA methylation (variation);
TGCT	cis	rs2692947	0.644	rs1168970	chr2:96816606	C/T	cg22654517	chr2:96458247	NA	0.23	4.86	0.4	3.42e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs2535633	0.631	rs2581803	chr3:52994981	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	0.55	5.31	0.43	4.87e-7	Body mass index;
TGCT	cis	rs11085466	1.000	rs75211977	chr19:21760201	G/A	cg23026602	chr19:21646605	NA	-0.57	-4.59	-0.38	1.07e-5	Colorectal or endometrial cancer;
TGCT	cis	rs2153535	0.542	rs6905925	chr6:8440030	C/T	cg07606381	chr6:8435919	SLC35B3	0.57	5.25	0.43	6.46e-7	Motion sickness;
TGCT	cis	rs12477438	0.501	rs11688004	chr2:99735052	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	14.89	0.8	2.21e-29	Chronic sinus infection;
TGCT	cis	rs231779	0.628	rs12464033	chr2:204796094	G/A	cg14577373	chr2:204102500	CYP20A1	-0.26	-4.45	-0.37	1.9e-5	Hypothyroidism;Tonsillectomy;
TGCT	cis	rs9611565	0.694	rs11090056	chr22:42095904	A/C	cg06634786	chr22:41940651	POLR3H	0.82	7.76	0.57	2.71e-12	Vitiligo;
TGCT	cis	rs986417	0.901	rs1955693	chr14:61012331	T/C	cg27398547	chr14:60952738	C14orf39	1.42	8.85	0.62	7.44e-15	Gut microbiota (bacterial taxa);
TGCT	cis	rs2832191	0.655	rs2247110	chr21:30323888	G/A	cg08807101	chr21:30365312	RNF160	-0.65	-6.08	-0.48	1.35e-8	Dental caries;
TGCT	cis	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg06636001	chr8:8085503	FLJ10661	0.61	5.46	0.44	2.47e-7	Mood instability;
TGCT	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg16414030	chr3:133502952	NA	-0.52	-7.29	-0.55	3.17e-11	Iron status biomarkers;
TGCT	cis	rs854765	0.693	rs9907246	chr17:17770965	T/C	cg04398451	chr17:18023971	MYO15A	0.29	4.55	0.38	1.26e-5	Total body bone mineral density;
TGCT	cis	rs7937682	0.889	rs484013	chr11:111495779	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.05	-11.36	-0.71	6.21e-21	Primary sclerosing cholangitis;
TGCT	cis	rs263156	0.934	rs187810	chr6:142885758	A/G	cg18419694	chr6:143832440	FUCA2	-0.38	-4.46	-0.37	1.79e-5	Ear morphology;Lobe size;Lobe attachment;
TGCT	cis	rs2305707	0.867	rs4614671	chr15:51556594	C/T	cg19946085	chr15:51559439	CYP19A1	0.49	5.2	0.42	8.08e-7	Height;
TGCT	cis	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg18252515	chr7:66147081	NA	-1.1	-6.4	-0.5	2.85e-9	Diabetic kidney disease;
TGCT	cis	rs60871478	0.838	rs7789321	chr7:800977	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.47	4.56	0.38	1.19e-5	Cerebrospinal P-tau181p levels;
TGCT	cis	rs35883536	0.647	rs12046413	chr1:101047430	T/C	cg10298815	chr1:101004474	GPR88	-0.25	-4.5	-0.37	1.54e-5	Monocyte count;
TGCT	cis	rs7213347	0.780	rs9892016	chr17:2146422	A/G	cg13315690	chr17:1944831	OVCA2;DPH1	-0.35	-4.52	-0.38	1.45e-5	Total body bone mineral density;
TGCT	cis	rs6088580	0.634	rs6059896	chr20:33111783	T/C	cg06115741	chr20:33292138	TP53INP2	0.53	4.65	0.39	8.41e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg18252515	chr7:66147081	NA	-1.13	-6.81	-0.52	3.7e-10	Diabetic kidney disease;
TGCT	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.12	0.54	7.78e-11	Prudent dietary pattern;
TGCT	cis	rs6728642	0.908	rs56786766	chr2:98024901	T/C	cg26665480	chr2:98280029	ACTR1B	-0.93	-4.71	-0.39	6.65e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.36	0.55	2.25e-11	Prudent dietary pattern;
TGCT	cis	rs7666738	0.539	rs13150465	chr4:99094892	C/T	cg17366294	chr4:99064904	C4orf37	-0.73	-4.74	-0.39	5.81e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7666738	0.606	rs3846447	chr4:99099907	G/A	cg17366294	chr4:99064904	C4orf37	0.55	5.09	0.42	1.29e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7666738	0.761	rs1456210	chr4:98645932	T/G	cg18180107	chr4:99064573	C4orf37	0.52	5.05	0.41	1.53e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6693567	0.565	rs1776275	chr1:150269437	G/T	cg09579323	chr1:150459698	TARS2	-0.52	-4.73	-0.39	6.09e-6	Migraine;
TGCT	trans	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg27523141	chr10:43048294	ZNF37B	0.7	8.15	0.59	3.36e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.71	7.58	0.56	6.92e-12	Blood metabolite levels;
TGCT	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg04944784	chr2:26401820	FAM59B	-0.71	-6.31	-0.49	4.61e-9	Gut microbiome composition (summer);
TGCT	cis	rs763014	0.931	rs710925	chr16:633354	G/A	cg07343612	chr16:622815	PIGQ	-0.41	-7.87	-0.58	1.52e-12	Height;
TGCT	cis	rs9325144	0.681	rs7957376	chr12:39096518	C/T	cg13010199	chr12:38710504	ALG10B	0.64	4.79	0.39	4.76e-6	Morning vs. evening chronotype;
TGCT	cis	rs7095607	0.813	rs4518986	chr10:69932878	T/G	cg18986048	chr10:69913749	MYPN	0.44	5.02	0.41	1.72e-6	Lung function (FVC);
TGCT	cis	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg18252515	chr7:66147081	NA	-1.19	-7.67	-0.57	4.29e-12	Diabetic kidney disease;
TGCT	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg23758822	chr17:41437982	NA	0.67	6.72	0.52	5.83e-10	Menopause (age at onset);
TGCT	trans	rs1814175	0.817	rs6486046	chr11:49997017	T/C	cg03929089	chr4:120376271	NA	-0.72	-8.53	-0.61	4.24e-14	Height;
TGCT	cis	rs950776	0.518	rs4887063	chr15:78839715	C/T	cg06917634	chr15:78832804	PSMA4	-0.77	-6.74	-0.52	5.25e-10	Sudden cardiac arrest;
TGCT	cis	rs698833	0.548	rs6544760	chr2:44553014	C/T	cg23552047	chr2:44669647	C2orf34	0.3	4.77	0.39	5.16e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
TGCT	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg06675538	chr2:114033490	PAX8;LOC440839	-0.44	-4.88	-0.4	3.18e-6	Lymphocyte counts;
TGCT	cis	rs6500602	0.647	rs1641868	chr16:4594503	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.3	5.55	0.45	1.62e-7	Schizophrenia;
TGCT	cis	rs2017387	0.515	rs157550	chr19:50539371	G/A	cg19230443	chr19:49950584	PIH1D1	-0.29	-4.69	-0.39	7.22e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
TGCT	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg21724239	chr8:58056113	NA	0.42	5.04	0.41	1.59e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg12963246	chr6:28129442	ZNF389	0.52	5.1	0.42	1.23e-6	Depression;
TGCT	cis	rs8077577	0.895	rs11655797	chr17:18107850	C/T	cg09161412	chr17:18057145	MYO15A	-0.65	-5.25	-0.43	6.29e-7	Obesity-related traits;
TGCT	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg12311346	chr5:56204834	C5orf35	-0.66	-6.37	-0.5	3.3e-9	Initial pursuit acceleration;
TGCT	cis	rs4972806	0.849	rs2857535	chr2:177036211	G/A	cg03152288	chr2:177042942	NA	0.63	5.5	0.44	2.08e-7	IgG glycosylation;
TGCT	cis	rs9325144	0.505	rs901635	chr12:38646572	A/C	cg13010199	chr12:38710504	ALG10B	-0.56	-4.94	-0.41	2.52e-6	Morning vs. evening chronotype;
TGCT	cis	rs12497850	0.931	rs7626445	chr3:49114544	C/T	cg05785598	chr3:49045655	WDR6	0.36	4.77	0.39	5.17e-6	Parkinson's disease;
TGCT	cis	rs73058052	0.597	rs56873913	chr19:50091199	T/G	cg09250473	chr19:50168907	IRF3;BCL2L12	0.6	4.6	0.38	1.01e-5	Fibrinogen levels;
TGCT	cis	rs11676348	0.776	rs11690316	chr2:219017462	A/G	cg00012203	chr2:219082015	ARPC2	-0.52	-5.0	-0.41	1.92e-6	Ulcerative colitis;
TGCT	cis	rs17376456	0.877	rs10061080	chr5:93420559	A/G	cg21475434	chr5:93447410	FAM172A	0.62	4.78	0.39	4.78e-6	Diabetic retinopathy;
TGCT	cis	rs7635838	0.751	rs6442260	chr3:11590751	C/T	cg00170343	chr3:11313890	ATG7	-0.71	-6.28	-0.49	5.26e-9	HDL cholesterol;
TGCT	cis	rs8070128	0.601	rs8080602	chr17:17954728	G/C	cg04398451	chr17:18023971	MYO15A	0.34	5.49	0.44	2.21e-7	Total body bone mineral density;
TGCT	cis	rs9902453	0.967	rs60176674	chr17:28479854	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	6.51	0.5	1.66e-9	Coffee consumption (cups per day);
TGCT	cis	rs5769765	0.773	rs6520065	chr22:50294470	A/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.4	6.02	0.48	1.81e-8	Schizophrenia;
TGCT	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg23172400	chr8:95962367	TP53INP1	-0.35	-5.7	-0.46	8.33e-8	Type 2 diabetes;
TGCT	cis	rs6987853	1.000	rs6987853	chr8:42457450	T/C	cg20539142	chr8:42623718	CHRNA6	-0.2	-4.92	-0.4	2.67e-6	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg04944784	chr2:26401820	FAM59B	-0.68	-6.13	-0.48	1.1e-8	Gut microbiome composition (summer);
TGCT	cis	rs3772130	1.000	rs2070180	chr3:121351338	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.54	-4.95	-0.41	2.41e-6	Cognitive performance;
TGCT	cis	rs3808502	0.527	rs56177149	chr8:11247298	G/A	cg21775007	chr8:11205619	TDH	0.6	5.82	0.46	4.67e-8	Neuroticism;
TGCT	cis	rs7085104	0.632	rs3781287	chr10:104595420	A/C	cg04362960	chr10:104952993	NT5C2	0.54	4.79	0.39	4.72e-6	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs11119608	0.846	rs7553708	chr1:210978485	C/T	cg24524366	chr1:211689016	NA	0.5	4.51	0.38	1.46e-5	Cancer;
TGCT	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg03609598	chr5:56110824	MAP3K1	-0.58	-4.7	-0.39	6.72e-6	Initial pursuit acceleration;
TGCT	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg13206674	chr6:150067644	NUP43	0.52	4.51	0.38	1.5e-5	Lung cancer;
TGCT	cis	rs854765	0.647	rs62073573	chr17:17976354	G/A	cg09796270	chr17:17721594	SREBF1	0.24	4.87	0.4	3.39e-6	Total body bone mineral density;
TGCT	cis	rs10782582	0.593	rs12131493	chr1:76139172	G/A	cg03433033	chr1:76189801	ACADM	-0.64	-7.28	-0.55	3.39e-11	Daytime sleep phenotypes;
TGCT	cis	rs3741404	0.609	rs641378	chr11:63869493	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.72	7.32	0.55	2.78e-11	Platelet count;
TGCT	cis	rs700590	0.723	rs304153	chr5:88121188	A/T	cg22951263	chr5:87985283	NA	-0.55	-5.18	-0.42	8.87e-7	Educational attainment (years of education);
TGCT	cis	rs11031096	0.746	rs7949663	chr11:4170123	A/G	cg18678763	chr11:4115507	RRM1	-0.48	-6.23	-0.49	6.52e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs939658	0.805	rs2010524	chr15:79435825	G/T	cg17916960	chr15:79447300	NA	-0.49	-7.59	-0.56	6.76e-12	Refractive error;
TGCT	cis	rs7726839	0.540	rs11739847	chr5:609661	G/A	cg16624210	chr5:671434	TPPP	0.44	4.75	0.39	5.46e-6	Obesity-related traits;
TGCT	cis	rs17030434	1.000	rs17030434	chr4:154703596	A/G	cg14289246	chr4:154710475	SFRP2	-1.04	-8.24	-0.59	2.04e-13	Electrocardiographic conduction measures;
TGCT	cis	rs7666738	0.830	rs13129479	chr4:98987860	T/C	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7617773	0.817	rs9830016	chr3:48282494	A/G	cg11946769	chr3:48343235	NME6	0.74	6.39	0.5	3.01e-9	Coronary artery disease;
TGCT	cis	rs10760123	1	rs10760123	chr9:123650534	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	5.5	0.44	2.03e-7	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs12701220	0.520	rs7803208	chr7:1162084	C/T	cg20824189	chr7:1704082	NA	-0.44	-4.55	-0.38	1.25e-5	Bronchopulmonary dysplasia;
TGCT	cis	rs727563	0.555	rs5751136	chr22:42075581	T/A	cg06634786	chr22:41940651	POLR3H	0.89	8.47	0.61	5.95e-14	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs12477438	0.798	rs6705583	chr2:99602625	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-6.18	-0.49	8.51e-9	Chronic sinus infection;
TGCT	cis	rs60843830	1.000	rs55946380	chr2:268293	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.73	7.41	0.55	1.74e-11	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs2594989	1.000	rs2595002	chr3:11373700	G/A	cg00170343	chr3:11313890	ATG7	0.62	4.78	0.39	4.86e-6	Circulating chemerin levels;
TGCT	cis	rs34526934	0.566	rs1374325	chr2:177043971	G/A	cg00278547	chr2:177037212	HOXD3	-0.36	-4.45	-0.37	1.85e-5	Obstructive sleep apnea trait (apnea hypopnea index);
TGCT	cis	rs11718455	0.960	rs13083325	chr3:44005333	T/C	cg08738300	chr3:44038990	NA	0.85	6.34	0.49	3.94e-9	Coronary artery disease;
TGCT	cis	rs739496	0.542	rs7312913	chr12:111793552	A/G	cg10833066	chr12:111807467	FAM109A	0.44	7.52	0.56	9.58e-12	Platelet count;
TGCT	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg10047753	chr17:41438598	NA	0.97	10.04	0.67	1.04e-17	Menopause (age at onset);
TGCT	cis	rs709400	0.663	rs11623869	chr14:103883633	G/T	cg26031613	chr14:104095156	KLC1	0.84	9.43	0.65	2.98e-16	Body mass index;
TGCT	cis	rs3008870	1.000	rs1137656	chr1:67451602	A/C	cg03991309	chr1:68237761	GNG12	-0.27	-4.53	-0.38	1.36e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg18252515	chr7:66147081	NA	-1.22	-7.98	-0.58	8.46e-13	Diabetic kidney disease;
TGCT	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg03188948	chr7:1209495	NA	0.52	5.4	0.44	3.29e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2440129	0.611	rs10852889	chr17:6900845	C/T	cg03404566	chr17:6899310	ALOX12	0.45	5.29	0.43	5.4e-7	Tonsillectomy;
TGCT	cis	rs5769707	0.967	rs17182154	chr22:49990470	A/G	cg05373962	chr22:49881684	NA	-0.29	-6.03	-0.48	1.71e-8	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs73198271	0.960	rs73198286	chr8:8612022	C/T	ch.8.214553F	chr8:8189620	PRAGMIN	-0.27	-4.65	-0.39	8.24e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs12497850	0.931	rs7623023	chr3:48914238	G/A	cg05785598	chr3:49045655	WDR6	0.35	4.72	0.39	6.35e-6	Parkinson's disease;
TGCT	cis	rs4819852	0.958	rs12628032	chr22:19967980	C/T	cg07821417	chr22:19972146	ARVCF	0.21	5.37	0.43	3.81e-7	Pulse pressure;
TGCT	trans	rs877282	0.945	rs10904554	chr10:786768	T/C	cg22713356	chr15:30763199	NA	1.16	10.26	0.68	3.01e-18	Uric acid levels;
TGCT	cis	rs6714788	0.503	rs1370356	chr2:100675241	G/C	cg22139774	chr2:100720529	AFF3	-0.41	-6.39	-0.5	2.99e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.5	4.79	0.4	4.66e-6	Menarche (age at onset);
TGCT	cis	rs6089584	0.888	rs6142927	chr20:60605848	A/G	cg16423285	chr20:60520624	NA	-0.57	-5.93	-0.47	2.83e-8	Body mass index;
TGCT	cis	rs2016266	0.819	rs7397757	chr12:53652684	A/G	cg16917193	chr12:54089295	NA	-0.62	-4.56	-0.38	1.19e-5	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs8008002	0.965	rs8007789	chr14:75865404	G/A	cg20011974	chr14:75469661	EIF2B2	-0.5	-4.48	-0.37	1.65e-5	Response to paliperidone in schizophrenia (positive Marder score);
TGCT	cis	rs6121246	0.609	rs6088997	chr20:30289824	A/G	cg10886678	chr20:30946050	ASXL1	0.55	4.49	0.37	1.64e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs7226408	0.857	rs72888916	chr18:34521336	C/T	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg09323728	chr8:95962352	TP53INP1	-0.52	-6.68	-0.51	7.06e-10	Type 2 diabetes;
TGCT	cis	rs1215050	0.791	rs7681599	chr4:98664109	C/T	cg17366294	chr4:99064904	C4orf37	-0.52	-5.51	-0.44	1.97e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1867631	0.958	rs7520226	chr1:67080995	T/G	cg13052034	chr1:66999238	SGIP1	0.6	5.17	0.42	9.19e-7	Menopause (age at onset);
TGCT	cis	rs8068544	0.748	rs75881902	chr17:40156612	C/A	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.07	-5.1	-0.42	1.26e-6	Reticulocyte fraction of red cells;Reticulocyte count;
TGCT	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg25767906	chr1:53392781	SCP2	-0.56	-6.45	-0.5	2.25e-9	Monocyte count;
TGCT	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg11062466	chr8:58055876	NA	0.42	4.49	0.37	1.61e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9911578	0.900	rs8067264	chr17:57182793	G/C	cg05425664	chr17:57184151	TRIM37	-0.68	-6.9	-0.53	2.4e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs17027225	chr4:99028564	C/T	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs72627509	0.857	rs781658	chr4:57779567	G/A	cg26694713	chr4:57773883	REST	0.73	6.53	0.51	1.5e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs9393777	0.513	rs11967852	chr6:26612870	G/T	cg15659132	chr6:26577336	NA	-0.79	-5.55	-0.45	1.66e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs10876993	0.890	rs2619441	chr12:58083015	C/A	cg15848620	chr12:58087721	OS9	-0.72	-5.98	-0.47	2.25e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs9467773	0.511	rs11755443	chr6:26891603	T/C	cg15659132	chr6:26577336	NA	0.71	7.0	0.53	1.42e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg17747265	chr1:1875780	NA	-0.42	-7.78	-0.57	2.48e-12	Body mass index;
TGCT	cis	rs79349575	0.783	rs4793992	chr17:47008207	A/G	cg27201301	chr17:47039149	GIP	0.25	4.49	0.37	1.58e-5	Type 2 diabetes;
TGCT	trans	rs1814175	0.803	rs11040451	chr11:49650639	C/T	cg15704280	chr7:45808275	SEPT13	-0.61	-6.8	-0.52	4.02e-10	Height;
TGCT	cis	rs2404602	0.692	rs4886503	chr15:77108874	C/T	cg22467129	chr15:76604101	ETFA	0.43	4.89	0.4	3.04e-6	Blood metabolite levels;
TGCT	cis	rs4689388	0.816	rs13147655	chr4:6293474	A/G	cg00701064	chr4:6280414	WFS1	0.39	4.91	0.4	2.86e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs9372498	0.536	rs9489399	chr6:118767147	C/A	cg07617317	chr6:118971624	C6orf204	0.5	5.39	0.44	3.37e-7	Diastolic blood pressure;
TGCT	cis	rs58688157	0.705	rs12272434	chr11:615011	A/T	cg16486109	chr11:613632	IRF7	0.36	5.26	0.43	6.02e-7	Systemic lupus erythematosus;
TGCT	cis	rs1865760	0.786	rs2164487	chr6:25950800	A/C	cg17042849	chr6:26104293	HIST1H4C	-0.52	-4.78	-0.39	4.97e-6	Height;
TGCT	cis	rs10782582	0.546	rs79652169	chr1:76233882	G/A	cg22875332	chr1:76189707	ACADM	-0.45	-4.93	-0.4	2.55e-6	Daytime sleep phenotypes;
TGCT	cis	rs66573146	1.000	rs73088528	chr4:6967747	G/C	cg05069807	chr4:6945702	TBC1D14	0.31	4.6	0.38	1.03e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs7617480	0.648	rs6801211	chr3:48774420	C/G	cg07636037	chr3:49044803	WDR6	0.76	6.36	0.5	3.6e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs12477438	0.520	rs13798	chr2:99813614	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.05	13.04	0.76	5.31e-25	Chronic sinus infection;
TGCT	cis	rs7267979	1.000	rs2257432	chr20:25271086	T/C	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9486719	0.895	rs3734238	chr6:96996228	A/T	cg18709589	chr6:96969512	KIAA0776	-0.76	-5.32	-0.43	4.63e-7	Migraine;Coronary artery disease;
TGCT	cis	rs8051149	0.688	rs55776570	chr16:87869516	C/G	cg01412419	chr16:87856264	NA	0.5	5.72	0.46	7.68e-8	Blood metabolite levels;
TGCT	cis	rs10908458	0.584	rs10908454	chr1:155066416	C/T	cg23973274	chr1:155060172	NA	-0.27	-5.12	-0.42	1.15e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7428	0.527	rs4459734	chr2:85547429	G/T	cg03728395	chr2:85555865	TGOLN2	-0.31	-5.17	-0.42	9.27e-7	Ear protrusion;
TGCT	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg06618935	chr21:46677482	NA	-0.36	-5.61	-0.45	1.25e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs12477438	0.520	rs2309581	chr2:99784292	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.86	-8.6	-0.61	2.97e-14	Chronic sinus infection;
TGCT	cis	rs2439831	0.717	rs2447198	chr15:43895118	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.85	5.36	0.43	4e-7	Lung cancer in ever smokers;
TGCT	cis	rs7927771	0.832	rs56030824	chr11:47397353	G/A	cg10139015	chr11:47448256	PSMC3	0.52	4.5	0.37	1.54e-5	Subjective well-being;
TGCT	cis	rs2153535	0.601	rs9505474	chr6:8539794	C/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.67	0.45	9.45e-8	Motion sickness;
TGCT	cis	rs2455799	0.552	rs2470519	chr3:15762847	G/A	cg16303742	chr3:15540471	COLQ	-0.26	-4.96	-0.41	2.26e-6	Mean platelet volume;
TGCT	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.5	5.41	0.44	3.18e-7	Lymphocyte counts;
TGCT	cis	rs12776158	0.685	rs60677596	chr10:71216880	A/G	cg12610070	chr10:71211762	TSPAN15	-0.59	-5.17	-0.42	9.16e-7	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs7267979	1.000	rs6115182	chr20:25410259	G/A	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg21862992	chr11:68658383	NA	0.45	6.2	0.49	7.55e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg22433210	chr17:43662623	NA	-0.9	-7.78	-0.57	2.37e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs17665859	0.687	rs117278497	chr8:495397	C/T	cg17960703	chr8:356704	FBXO25	1.21	4.88	0.4	3.25e-6	Bilirubin levels;
TGCT	cis	rs1371867	0.875	rs1788169	chr8:101326314	C/T	cg00191853	chr8:101177733	SPAG1	-0.22	-4.47	-0.37	1.75e-5	Atrioventricular conduction;
TGCT	cis	rs6087771	0.642	rs6060403	chr20:30221104	C/A	cg13852791	chr20:30311386	BCL2L1	0.77	6.53	0.51	1.51e-9	Subcortical brain region volumes;Putamen volume;
TGCT	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.12	0.42	1.15e-6	Prudent dietary pattern;
TGCT	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg18538332	chr22:24372958	LOC391322	-0.96	-11.29	-0.71	9.39e-21	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg06873352	chr17:61820015	STRADA	0.58	6.39	0.5	3.01e-9	Prudent dietary pattern;
TGCT	cis	rs8070740	0.786	rs12761	chr17:5326145	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.49	4.88	0.4	3.15e-6	Menopause (age at onset);
TGCT	cis	rs9467773	0.620	rs2504540	chr6:26641626	A/G	cg02458000	chr6:26745757	NA	0.52	4.86	0.4	3.41e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7267979	0.966	rs2500417	chr20:25383287	A/G	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs1814175	0.817	rs7109440	chr11:49966296	C/T	cg15704280	chr7:45808275	SEPT13	-0.73	-8.48	-0.61	5.58e-14	Height;
TGCT	cis	rs7172809	0.573	rs74025104	chr15:77552587	G/A	cg22256960	chr15:77711686	NA	-0.48	-4.67	-0.39	7.76e-6	Glucose homeostasis traits;
TGCT	cis	rs13064411	0.696	rs2087129	chr3:113142769	T/A	cg18753928	chr3:113234510	CCDC52	-0.67	-5.12	-0.42	1.14e-6	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs3617	0.625	rs7617468	chr3:52849549	T/C	cg10802521	chr3:52805072	NEK4	-0.6	-6.97	-0.53	1.63e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7223966	1.000	rs16947042	chr17:61766457	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	5.17	0.42	8.94e-7	Hip circumference adjusted for BMI;Body mass index;
TGCT	trans	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg17470723	chr8:74884337	TCEB1	0.72	6.94	0.53	1.91e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs6582630	0.555	rs7301250	chr12:38596244	G/T	cg13010199	chr12:38710504	ALG10B	0.65	5.07	0.41	1.41e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs1903068	0.853	rs28411232	chr4:56000009	A/T	cg16572876	chr4:56024045	NA	0.43	4.94	0.41	2.43e-6	Endometriosis;
TGCT	cis	rs11958404	0.719	rs72818153	chr5:157487035	T/C	cg05962755	chr5:157440814	NA	0.35	4.55	0.38	1.27e-5	IgG glycosylation;
TGCT	cis	rs2404602	0.536	rs17364330	chr15:76765385	A/T	cg26408565	chr15:76604113	ETFA	-0.38	-5.26	-0.43	6.01e-7	Blood metabolite levels;
TGCT	cis	rs17376456	0.877	rs17083455	chr5:93446380	A/C	cg21475434	chr5:93447410	FAM172A	0.58	4.57	0.38	1.16e-5	Diabetic retinopathy;
TGCT	trans	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg21659725	chr3:3221576	CRBN	-0.7	-7.95	-0.58	9.9e-13	Body mass index;
TGCT	cis	rs4689388	0.926	rs11725494	chr4:6293855	C/T	cg25554036	chr4:6271136	WFS1	0.56	7.96	0.58	9.12e-13	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg19774624	chr17:42201019	HDAC5	0.84	8.44	0.6	7.03e-14	Total body bone mineral density;
TGCT	cis	rs6546537	0.955	rs2312215	chr2:69839825	T/A	cg10773587	chr2:69614142	GFPT1	-0.72	-6.27	-0.49	5.41e-9	Serum thyroid-stimulating hormone levels;
TGCT	cis	rs700651	0.821	rs770661	chr2:198725444	A/G	cg00792783	chr2:198669748	PLCL1	0.56	5.08	0.42	1.35e-6	Intracranial aneurysm;
TGCT	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg04944784	chr2:26401820	FAM59B	0.65	5.37	0.43	3.74e-7	Gut microbiome composition (summer);
TGCT	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg21862992	chr11:68658383	NA	0.46	6.25	0.49	5.91e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs2235642	0.859	rs9927529	chr16:1619488	C/T	cg00463982	chr16:1583984	IFT140;TMEM204	-0.3	-4.86	-0.4	3.47e-6	Coronary artery disease;
TGCT	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg24675658	chr1:53192096	ZYG11B	0.75	8.72	0.62	1.48e-14	Monocyte count;
TGCT	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs11648796	0.718	rs62032512	chr16:764826	C/T	cg00908189	chr16:619842	PIGQ	0.72	5.76	0.46	6.31e-8	Height;
TGCT	cis	rs6426558	0.537	rs6692080	chr1:227390162	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.6	-7.06	-0.54	1.04e-10	Neutrophil percentage of white cells;
TGCT	cis	rs7095607	1.000	rs7095607	chr10:69957350	G/A	cg18986048	chr10:69913749	MYPN	0.45	4.83	0.4	3.87e-6	Lung function (FVC);
TGCT	cis	rs754133	1.000	rs754133	chr12:54418920	C/T	cg16264616	chr12:54390824	NA	0.3	4.64	0.38	8.68e-6	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;
TGCT	cis	rs7017914	0.934	rs2639904	chr8:71917130	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.57	-5.31	-0.43	4.8e-7	Bone mineral density;
TGCT	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg03806693	chr22:41940476	POLR3H	-1.14	-13.38	-0.77	8.05e-26	Vitiligo;
TGCT	cis	rs6977955	1.000	rs4722760	chr7:28172183	C/T	cg23620719	chr7:28220237	JAZF1	-0.58	-4.55	-0.38	1.24e-5	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs4975616	0.869	rs370348	chr5:1331219	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.28	-6.88	-0.53	2.69e-10	Lung cancer;
TGCT	cis	rs12579753	0.913	rs17749243	chr12:82178079	A/C	cg07988820	chr12:82153109	PPFIA2	-0.65	-6.79	-0.52	4.09e-10	Resting heart rate;
TGCT	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg27454412	chr7:1067447	C7orf50	0.56	4.65	0.39	8.33e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg17971929	chr21:40555470	PSMG1	0.98	9.65	0.65	9.11e-17	Cognitive function;
TGCT	cis	rs4803468	0.935	rs284660	chr19:41932084	G/T	cg09537434	chr19:41945824	ATP5SL	-0.93	-10.44	-0.68	1.11e-18	Height;
TGCT	cis	rs6121246	0.559	rs6060915	chr20:30330306	A/G	cg13852791	chr20:30311386	BCL2L1	0.81	7.92	0.58	1.17e-12	Mean corpuscular hemoglobin;
TGCT	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg13206674	chr6:150067644	NUP43	0.52	4.51	0.38	1.5e-5	Lung cancer;
TGCT	cis	rs2153535	0.580	rs1889715	chr6:8443475	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.58	0.45	1.42e-7	Motion sickness;
TGCT	cis	rs3820928	0.709	rs2894627	chr2:227910171	A/G	cg11843606	chr2:227700838	RHBDD1	-0.51	-4.66	-0.39	8.18e-6	Pulmonary function;
TGCT	cis	rs3803170	0.513	rs10774623	chr12:111833589	C/T	cg10833066	chr12:111807467	FAM109A	-0.38	-5.67	-0.45	9.43e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs7267979	0.844	rs6107027	chr20:25288632	A/G	cg03522245	chr20:25566470	NINL	0.54	5.58	0.45	1.46e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.08	0.48	1.37e-8	Bipolar disorder;
TGCT	cis	rs7715806	0.500	rs72633982	chr5:75001321	C/T	cg19683494	chr5:74908142	NA	0.57	5.02	0.41	1.76e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs13191362	1.000	rs2156257	chr6:163100710	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.99	8.09	0.59	4.62e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs9894429	1.000	rs9747349	chr17:79584297	C/T	cg21028142	chr17:79581711	NPLOC4	0.29	6.81	0.52	3.83e-10	Eye color traits;
TGCT	cis	rs950169	0.922	rs11630507	chr15:85095725	A/G	cg11189052	chr15:85197271	WDR73	0.8	6.64	0.51	8.83e-10	Schizophrenia;
TGCT	cis	rs903263	1.000	rs903263	chr1:84622513	G/T	cg09664975	chr1:84543551	PRKACB	0.47	4.48	0.37	1.65e-5	Breast cancer (male);
TGCT	cis	rs939574	1.000	rs1024131	chr2:220117458	G/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.05	6.46	0.5	2.12e-9	Platelet distribution width;
TGCT	cis	rs2228479	0.718	rs11645376	chr16:89912281	G/C	cg06558623	chr16:89946397	TCF25	0.55	4.86	0.4	3.55e-6	Skin colour saturation;
TGCT	cis	rs1691799	0.899	rs1060724	chr12:66740444	T/C	cg16791601	chr12:66731901	HELB	-0.29	-6.31	-0.49	4.41e-9	White blood cell count (basophil);
TGCT	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg06221963	chr1:154839813	KCNN3	-0.79	-15.15	-0.81	5.4e-30	Prostate cancer;
TGCT	cis	rs7432375	0.901	rs1681817	chr3:136473728	C/T	cg12473912	chr3:136751656	NA	-0.36	-5.21	-0.42	7.55e-7	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7568458	0.516	rs62166769	chr2:85812784	T/A	cg02493740	chr2:85810744	VAMP5	-0.27	-4.61	-0.38	9.88e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs3617	0.625	rs56019197	chr3:52874753	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	0.49	4.76	0.39	5.32e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs533581	0.873	rs579740	chr16:88973937	A/G	cg05579598	chr16:88989069	CBFA2T3	-0.34	-4.49	-0.37	1.6e-5	Social autistic-like traits;
TGCT	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg00786635	chr1:25594202	NA	0.62	6.51	0.5	1.67e-9	Erythrocyte sedimentation rate;
TGCT	cis	rs8062405	1.000	rs80275162	chr16:28863517	T/A	cg09754948	chr16:28834200	ATXN2L	0.59	4.46	0.37	1.84e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs6589563	0.737	rs61905088	chr11:116619867	C/A	cg20660624	chr11:117307972	DSCAML1	-0.35	-4.56	-0.38	1.19e-5	Eosinophil counts;
TGCT	cis	rs11785400	0.793	rs4403386	chr8:143736770	C/G	cg24634471	chr8:143751801	JRK	0.55	5.51	0.44	1.95e-7	Schizophrenia;
TGCT	cis	rs2836974	0.931	rs2776309	chr21:40715791	A/G	cg11890956	chr21:40555474	PSMG1	0.99	9.11	0.63	1.78e-15	Cognitive function;
TGCT	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.94	10.77	0.7	1.71e-19	Platelet count;
TGCT	cis	rs981844	0.714	rs2405204	chr4:154705248	A/G	cg14289246	chr4:154710475	SFRP2	-0.92	-8.41	-0.6	8.38e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs4713118	0.513	rs149897	chr6:28006650	A/G	cg10876282	chr6:28092338	ZSCAN16	0.51	4.56	0.38	1.19e-5	Parkinson's disease;
TGCT	trans	rs6762477	0.748	rs11714799	chr3:50217899	T/G	cg21659725	chr3:3221576	CRBN	-0.67	-7.57	-0.56	7.57e-12	Menarche (age at onset);
TGCT	cis	rs28595532	0.920	rs55649377	chr4:119752745	T/A	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs79387448	0.638	rs13405222	chr2:102981891	T/C	cg09003973	chr2:102972529	NA	1.47	10.36	0.68	1.69e-18	Gut microbiota (bacterial taxa);
TGCT	cis	rs11599315	0.507	rs12217329	chr10:1341897	A/G	cg27336068	chr10:1336103	ADARB2	-0.34	-5.47	-0.44	2.41e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	cis	rs7666738	0.830	rs3896704	chr4:99034252	C/T	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2153535	0.504	rs9328472	chr6:8470848	G/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs67311347	1.000	rs9882171	chr3:40518821	G/A	cg17264618	chr3:40429014	ENTPD3	0.33	4.85	0.4	3.66e-6	Renal cell carcinoma;
TGCT	cis	rs10791323	0.604	rs10791324	chr11:133704065	T/C	cg15485101	chr11:133734466	NA	0.41	5.11	0.42	1.16e-6	Childhood ear infection;
TGCT	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg04414720	chr1:150670196	GOLPH3L	0.39	5.04	0.41	1.58e-6	Tonsillectomy;
TGCT	cis	rs6882046	0.513	rs628158	chr5:88041781	G/A	cg24804195	chr5:87968844	LOC645323	-0.6	-6.06	-0.48	1.48e-8	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs7819412	0.522	rs10088853	chr8:10987967	G/A	cg21775007	chr8:11205619	TDH	-0.6	-5.34	-0.43	4.3e-7	Triglycerides;
TGCT	cis	rs13064411	0.696	rs869343	chr3:113226705	C/T	cg18753928	chr3:113234510	CCDC52	-0.71	-5.78	-0.46	5.63e-8	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs7829975	0.658	rs907181	chr8:8702875	T/C	cg08975724	chr8:8085496	FLJ10661	0.49	4.48	0.37	1.65e-5	Mood instability;
TGCT	cis	rs7267979	1.000	rs1888998	chr20:25291826	A/G	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs17114671	1.000	rs8008440	chr14:21156448	A/G	cg19983597	chr14:21852154	SUPT16H	-0.87	-4.57	-0.38	1.18e-5	Blood protein levels;
TGCT	cis	rs7201929	0.801	rs9933198	chr16:28888409	C/T	cg09754948	chr16:28834200	ATXN2L	-0.64	-5.08	-0.42	1.35e-6	QT interval;
TGCT	cis	rs589249	0.963	rs636521	chr1:37158071	A/C	cg04012535	chr1:37176647	NA	-0.3	-4.86	-0.4	3.47e-6	Neuroticism (multi-trait analysis);Schizophrenia;
TGCT	cis	rs9993613	1.000	rs4694502	chr4:73496157	G/A	cg15102770	chr4:73434591	ADAMTS3	-0.5	-4.59	-0.38	1.07e-5	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs58106596	0.527	rs1866599	chr2:232726300	C/T	cg26500773	chr2:232646331	PDE6D	-0.64	-4.75	-0.39	5.44e-6	White blood cell count;Lymphocyte counts;
TGCT	cis	rs832540	0.618	rs2548663	chr5:56172778	G/A	cg24531977	chr5:56204891	C5orf35	-0.52	-5.02	-0.41	1.73e-6	Coronary artery disease;
TGCT	cis	rs9902453	0.967	rs7222685	chr17:28496430	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	6.39	0.5	3.03e-9	Coffee consumption (cups per day);
TGCT	cis	rs11239930	0.538	rs719969	chr1:146555660	G/A	cg00044796	chr1:146552390	NA	-0.35	-4.5	-0.37	1.54e-5	AIDS progression;
TGCT	cis	rs7582180	0.629	rs4851294	chr2:100941109	C/T	cg14675211	chr2:100938903	LONRF2	0.54	5.33	0.43	4.39e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.723	rs35327100	chr4:98977788	C/A	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg03188948	chr7:1209495	NA	0.59	4.82	0.4	4.06e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs17376456	0.877	rs10040648	chr5:93490301	G/C	cg25358565	chr5:93447407	FAM172A	0.97	8.3	0.6	1.46e-13	Diabetic retinopathy;
TGCT	cis	rs371025208	1	rs371025208	chr20:43928602	TGGGTGTGTGTGTGTAGGG/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.45	-6.93	-0.53	2.04e-10	Parental longevity (mother's age at death);
TGCT	cis	rs7809950	1.000	rs10276604	chr7:107216738	C/T	cg23024343	chr7:107201750	COG5	0.32	4.85	0.4	3.66e-6	Coronary artery disease;
TGCT	cis	rs2070488	0.745	rs9838792	chr3:38546726	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.71	-6.4	-0.5	2.93e-9	Electrocardiographic conduction measures;
TGCT	cis	rs13217239	0.646	rs35691005	chr6:26972070	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.4	4.47	0.37	1.76e-5	Schizophrenia;
TGCT	cis	rs9303401	0.538	rs3785493	chr17:56472119	G/T	cg25039879	chr17:56429692	SUPT4H1	-0.57	-4.79	-0.4	4.67e-6	Cognitive test performance;
TGCT	cis	rs9611565	0.559	rs5758412	chr22:42080803	T/A	cg03806693	chr22:41940476	POLR3H	1.08	11.79	0.73	5.53e-22	Vitiligo;
TGCT	cis	rs6570726	0.967	rs374728	chr6:145854598	T/A	cg23711669	chr6:146136114	FBXO30	0.71	7.03	0.53	1.25e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2486288	0.656	rs1719232	chr15:45572072	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.83	-8.38	-0.6	9.8e-14	Glomerular filtration rate;
TGCT	cis	rs61990749	0.597	rs8016416	chr14:78213100	T/A	cg23188588	chr14:78226832	SNW1;C14orf178	0.67	4.73	0.39	6.09e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs7666738	0.830	rs2865990	chr4:99067399	C/A	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.44e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6770219	0.516	rs73182263	chr3:186135138	T/G	cg20306810	chr3:186501757	SNORD2;EIF4A2	0.73	4.45	0.37	1.89e-5	Cerebrospinal T-tau levels;
TGCT	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg16423285	chr20:60520624	NA	-0.7	-7.43	-0.55	1.56e-11	Body mass index;
TGCT	cis	rs7666738	0.830	rs13148913	chr4:99009732	C/T	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8072100	1.000	rs8072100	chr17:45674687	A/T	cg08085267	chr17:45401833	C17orf57	0.47	5.13	0.42	1.07e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg04944784	chr2:26401820	FAM59B	-0.71	-6.59	-0.51	1.11e-9	Gut microbiome composition (summer);
TGCT	cis	rs2486288	0.656	rs8041702	chr15:45547093	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.44	-4.98	-0.41	2.1e-6	Glomerular filtration rate;
TGCT	cis	rs9660180	0.780	rs12038111	chr1:1703849	T/C	cg20999797	chr1:1681921	NA	0.18	4.77	0.39	5e-6	Body mass index;
TGCT	cis	rs10992471	0.533	rs331381	chr9:95249859	A/G	cg13798575	chr9:95087839	CENPP;NOL8	0.55	5.31	0.43	4.9e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs2075165	0.901	rs1804999	chr1:156219450	A/G	cg20302342	chr1:156215951	PAQR6	0.39	5.64	0.45	1.12e-7	Tonsillectomy;
TGCT	cis	rs9560113	1.000	rs9555809	chr13:112181401	T/C	cg14154082	chr13:112174009	NA	0.38	5.01	0.41	1.83e-6	Menarche (age at onset);
TGCT	cis	rs7666738	0.570	rs11097612	chr4:99079772	T/C	cg05340658	chr4:99064831	C4orf37	0.44	4.8	0.4	4.5e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs826838	0.967	rs11169169	chr12:39093153	A/C	cg26384229	chr12:38710491	ALG10B	1.06	10.4	0.68	1.35e-18	Heart rate;
TGCT	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg11764359	chr7:65958608	NA	-0.59	-5.2	-0.42	8.12e-7	Aortic root size;
TGCT	cis	rs6540559	0.673	rs17015309	chr1:210007218	C/T	cg21951975	chr1:209979733	IRF6	0.64	4.82	0.4	4.12e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg04234412	chr22:24373322	LOC391322	0.94	12.53	0.75	9.02e-24	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs17376456	0.757	rs10476591	chr5:93333723	G/C	cg21475434	chr5:93447410	FAM172A	0.63	4.75	0.39	5.58e-6	Diabetic retinopathy;
TGCT	cis	rs17384381	1.000	rs12140935	chr1:85855716	G/A	cg16011679	chr1:85725395	C1orf52	0.8	6.45	0.5	2.21e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs250677	0.687	rs40522	chr5:148442295	G/A	cg23229984	chr5:148520753	ABLIM3	0.21	4.89	0.4	3.11e-6	Breast cancer;
TGCT	cis	rs7666738	0.830	rs2114425	chr4:99023967	T/C	cg05340658	chr4:99064831	C4orf37	0.5	5.64	0.45	1.09e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3784262	0.740	rs4646598	chr15:58300328	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.42	-6.28	-0.49	5.12e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs4689592	0.523	rs4256224	chr4:7074583	T/C	cg25660036	chr4:7070649	GRPEL1	-0.66	-5.79	-0.46	5.38e-8	Monocyte percentage of white cells;
TGCT	cis	rs1372520	0.748	rs2737002	chr4:90753180	A/G	cg15133208	chr4:90757351	SNCA	-0.5	-5.86	-0.47	4e-8	Neuroticism;
TGCT	cis	rs2404618	0.506	rs12156177	chr8:1493684	C/T	cg13402656	chr8:1511478	DLGAP2	-0.31	-5.51	-0.44	2e-7	Lung cancer;
TGCT	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	4.96	0.41	2.27e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg07870213	chr5:140052090	DND1	0.61	7.51	0.56	9.93e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2816062	0.813	rs725389	chr1:18881980	G/A	cg18795169	chr1:18902165	NA	-0.59	-13.16	-0.76	2.73e-25	Urate levels in lean individuals;
TGCT	cis	rs2404602	0.669	rs17464903	chr15:77195486	A/G	cg26408565	chr15:76604113	ETFA	-0.36	-4.54	-0.38	1.31e-5	Blood metabolite levels;
TGCT	cis	rs478304	0.627	rs11227254	chr11:65454000	A/G	cg17480646	chr11:65405466	SIPA1	-0.63	-8.47	-0.61	6.08e-14	Acne (severe);
TGCT	cis	rs12477438	0.765	rs28648058	chr2:99696417	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.58	-5.07	-0.41	1.4e-6	Chronic sinus infection;
TGCT	cis	rs2204008	0.627	rs10878488	chr12:38148666	G/A	cg13010199	chr12:38710504	ALG10B	0.65	5.15	0.42	1.01e-6	Bladder cancer;
TGCT	cis	rs2204008	0.627	rs1851117	chr12:38398987	G/T	cg13010199	chr12:38710504	ALG10B	0.59	4.68	0.39	7.35e-6	Bladder cancer;
TGCT	cis	rs36051895	0.559	rs7874495	chr9:5209804	A/G	cg02405213	chr9:5042618	JAK2	-0.65	-8.46	-0.61	6.13e-14	Pediatric autoimmune diseases;
TGCT	cis	rs10114408	0.918	rs2153065	chr9:96644415	G/A	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg26119090	chr2:26468346	HADHA;HADHB	1.0	7.42	0.55	1.64e-11	Mean corpuscular hemoglobin;
TGCT	cis	rs7614311	0.681	rs73117042	chr3:63896543	T/C	cg22134162	chr3:63841271	THOC7	-0.4	-5.16	-0.42	9.41e-7	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs1580019	0.534	rs13237495	chr7:32560687	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.57	4.86	0.4	3.43e-6	Cognitive ability;
TGCT	cis	rs1018836	0.505	rs7015030	chr8:91460331	T/C	cg16814680	chr8:91681699	NA	-0.64	-6.19	-0.49	7.91e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9409154	1.000	rs9409154	chr9:118202716	T/C	cg14094498	chr9:119000864	PAPPA	0.21	4.48	0.37	1.67e-5	Visceral adipose tissue adjusted for BMI;
TGCT	cis	rs9611565	0.512	rs1983576	chr22:42166486	G/A	cg06481639	chr22:41940642	POLR3H	0.69	6.05	0.48	1.59e-8	Vitiligo;
TGCT	cis	rs3733585	0.563	rs881971	chr4:9930962	A/G	cg11266682	chr4:10021025	SLC2A9	-0.51	-6.32	-0.49	4.35e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs1371867	0.846	rs1660345	chr8:101322762	C/A	cg00191853	chr8:101177733	SPAG1	-0.22	-4.47	-0.37	1.75e-5	Atrioventricular conduction;
TGCT	cis	rs826838	1.000	rs11183196	chr12:38685915	G/T	cg26384229	chr12:38710491	ALG10B	1.12	11.32	0.71	7.88e-21	Heart rate;
TGCT	cis	rs1153858	1.000	rs11070457	chr15:45686943	A/C	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.62e-8	Homoarginine levels;
TGCT	cis	rs13256369	0.802	rs2280560	chr8:8560602	C/T	cg18904891	chr8:8559673	CLDN23	0.57	5.04	0.41	1.6e-6	Obesity-related traits;
TGCT	cis	rs9899728	0.539	rs11077772	chr17:73035698	C/T	cg27626185	chr17:73056755	KCTD2	-0.99	-7.93	-0.58	1.07e-12	Alzheimer's disease or small vessel stroke;
TGCT	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg05025164	chr4:1340916	KIAA1530	0.8	6.69	0.51	7.02e-10	Longevity;
TGCT	cis	rs34517613	0.589	rs12937920	chr17:26590657	C/T	cg03094083	chr17:26864469	FOXN1	0.31	4.84	0.4	3.74e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs17376456	0.569	rs2045020	chr5:93224466	T/C	cg21475434	chr5:93447410	FAM172A	-0.69	-5.2	-0.42	7.83e-7	Diabetic retinopathy;
TGCT	cis	rs4268898	0.722	rs10445893	chr2:24407128	A/G	cg02683114	chr2:24398427	C2orf84	0.19	4.76	0.39	5.37e-6	Asthma;
TGCT	cis	rs782590	0.774	rs2627773	chr2:55900459	A/G	cg03859395	chr2:55845619	SMEK2	0.85	9.64	0.65	9.63e-17	Metabolic syndrome;
TGCT	cis	rs9467711	1.000	rs6939799	chr6:26328366	G/A	cg03264133	chr6:25882463	NA	-0.82	-4.48	-0.37	1.65e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6840360	0.555	rs4554052	chr4:152726610	T/C	cg17479576	chr4:152424074	FAM160A1	0.46	4.83	0.4	3.88e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6570726	0.791	rs443628	chr6:145883484	T/C	cg05347473	chr6:146136440	FBXO30	0.54	5.04	0.41	1.6e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs17030434	0.906	rs12641631	chr4:154665279	A/G	cg14289246	chr4:154710475	SFRP2	-0.88	-7.18	-0.54	5.68e-11	Electrocardiographic conduction measures;
TGCT	cis	rs1215050	0.791	rs783950	chr4:98878395	C/T	cg17366294	chr4:99064904	C4orf37	-0.57	-6.08	-0.48	1.38e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs4851254	0.618	rs35730185	chr2:100648085	G/A	cg22139774	chr2:100720529	AFF3	-0.45	-4.9	-0.4	2.94e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9790314	0.846	rs4290817	chr3:160967354	G/A	cg03342759	chr3:160939853	NMD3	-0.51	-5.66	-0.45	9.96e-8	Morning vs. evening chronotype;
TGCT	cis	rs12989701	1.000	rs13009551	chr2:127889118	C/T	cg08168897	chr2:127865431	BIN1	0.59	5.76	0.46	6.14e-8	Alzheimer's disease (late onset);
TGCT	cis	rs1577917	1.000	rs12207305	chr6:86723502	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.22	-0.42	7.27e-7	Response to antipsychotic treatment;
TGCT	cis	rs17384381	0.859	rs28529751	chr1:85910951	G/A	cg16011679	chr1:85725395	C1orf52	0.83	6.79	0.52	4.16e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11031096	0.782	rs2165728	chr11:4147004	T/C	cg18678763	chr11:4115507	RRM1	-0.47	-6.01	-0.47	1.91e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg25767906	chr1:53392781	SCP2	0.47	5.26	0.43	6.03e-7	Monocyte count;
TGCT	cis	rs9419702	0.568	rs7093241	chr10:133556596	G/A	cg23460707	chr10:133558971	NA	0.42	4.68	0.39	7.48e-6	Survival in rectal cancer;
TGCT	cis	rs9894429	0.608	rs7406382	chr17:79597786	T/C	cg21028142	chr17:79581711	NPLOC4	0.28	5.75	0.46	6.54e-8	Eye color traits;
TGCT	cis	rs10089	0.953	rs17164427	chr5:127361736	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.74	-6.93	-0.53	2e-10	Ileal carcinoids;
TGCT	cis	rs1801251	1.000	rs35085837	chr2:233624363	A/G	cg08000102	chr2:233561755	GIGYF2	0.64	6.56	0.51	1.34e-9	Coronary artery disease;
TGCT	cis	rs459571	0.916	rs467303	chr9:136904835	C/T	cg14405625	chr9:136855902	VAV2	-0.3	-4.55	-0.38	1.28e-5	Platelet distribution width;
TGCT	cis	rs733175	0.855	rs9291641	chr4:10007259	C/T	cg00071950	chr4:10020882	SLC2A9	0.51	4.53	0.38	1.35e-5	Psychosis and Alzheimer's disease;
TGCT	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg13393036	chr8:95962371	TP53INP1	-0.63	-8.66	-0.61	2.14e-14	Type 2 diabetes;
TGCT	cis	rs4808199	0.947	rs751858	chr19:19602821	G/C	cg03709012	chr19:19516395	GATAD2A	0.97	7.45	0.56	1.35e-11	Nonalcoholic fatty liver disease;
TGCT	cis	rs9303401	0.614	rs17175663	chr17:57108437	G/C	cg25039879	chr17:56429692	SUPT4H1	0.54	4.84	0.4	3.85e-6	Cognitive test performance;
TGCT	cis	rs12497850	0.931	rs9682444	chr3:48852639	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.42	-5.52	-0.44	1.93e-7	Parkinson's disease;
TGCT	cis	rs7647973	1.000	rs6783003	chr3:49524778	G/C	cg06212747	chr3:49208901	KLHDC8B	-0.59	-4.67	-0.39	7.6e-6	Menarche (age at onset);
TGCT	cis	rs4642101	0.765	rs9870269	chr3:12853450	T/G	cg05775895	chr3:12838266	CAND2	0.6	5.97	0.47	2.33e-8	QRS complex (12-leadsum);
TGCT	cis	rs1865760	1.000	rs2071298	chr6:25914901	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.65	6.18	0.49	8.59e-9	Height;
TGCT	cis	rs7772486	0.806	rs4075696	chr6:146250947	T/C	cg05347473	chr6:146136440	FBXO30	-0.52	-5.16	-0.42	9.33e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9311474	0.713	rs352167	chr3:52238656	C/T	cg10802521	chr3:52805072	NEK4	0.57	6.16	0.48	9.22e-9	Electroencephalogram traits;
TGCT	cis	rs79349575	0.745	rs170319	chr17:46991531	T/C	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.51	-0.38	1.48e-5	Type 2 diabetes;
TGCT	cis	rs4629710	0.592	rs35017713	chr6:131581212	G/A	cg12606694	chr6:131520996	AKAP7	0.39	4.57	0.38	1.15e-5	Multiple myeloma (IgH translocation);
TGCT	cis	rs61990749	0.597	rs2267761	chr14:78147849	G/C	cg23188588	chr14:78226832	SNW1;C14orf178	-0.66	-4.69	-0.39	7.04e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs1008375	1.000	rs4698199	chr4:17656738	G/C	cg10189774	chr4:17578691	LAP3	0.57	5.15	0.42	9.95e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7666738	0.791	rs13111960	chr4:98976851	C/T	cg18180107	chr4:99064573	C4orf37	0.53	4.89	0.4	3.01e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9611565	0.525	rs9611549	chr22:41705909	C/G	cg06634786	chr22:41940651	POLR3H	-0.61	-5.53	-0.44	1.8e-7	Vitiligo;
TGCT	cis	rs17384381	1.000	rs12135333	chr1:85890494	C/A	cg16011679	chr1:85725395	C1orf52	0.79	6.37	0.5	3.32e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7681440	0.874	rs7687945	chr4:90764699	C/T	cg14346243	chr4:90757452	SNCA	-0.59	-5.74	-0.46	6.82e-8	Dementia with Lewy bodies;
TGCT	trans	rs4332037	0.950	rs10267593	chr7:1937261	G/A	cg10840412	chr1:235813424	GNG4	0.92	7.25	0.55	3.83e-11	Bipolar disorder;
TGCT	cis	rs7178572	0.568	rs7167794	chr15:77635875	T/C	cg22256960	chr15:77711686	NA	-0.85	-8.73	-0.62	1.4e-14	Type 2 diabetes;
TGCT	cis	rs1534166	0.602	rs3817524	chr3:133526403	C/T	cg16414030	chr3:133502952	NA	0.41	5.15	0.42	1e-6	Alcohol consumption (transferrin glycosylation);
TGCT	cis	rs10751667	0.621	rs7394681	chr11:952111	C/T	cg06064525	chr11:970664	AP2A2	-0.35	-8.22	-0.59	2.29e-13	Alzheimer's disease (late onset);
TGCT	cis	rs67311347	0.955	rs6599100	chr3:40447362	C/T	cg13683864	chr3:40499215	RPL14	-1.04	-10.79	-0.7	1.54e-19	Renal cell carcinoma;
TGCT	trans	rs4650994	0.525	rs2493860	chr1:178541492	A/G	cg05059571	chr16:84539110	KIAA1609	-0.54	-11.16	-0.71	1.91e-20	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs5769765	1.000	rs8184990	chr22:50273174	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.41	-6.13	-0.48	1.08e-8	Schizophrenia;
TGCT	cis	rs73198271	0.740	rs28402110	chr8:8647249	C/A	cg06671706	chr8:8559999	CLDN23	-0.35	-4.5	-0.37	1.52e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs12220238	1.000	rs10824098	chr10:75943579	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.78	0.57	2.42e-12	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs1865760	1.000	rs9467636	chr6:25919549	A/C	cg16482183	chr6:26056742	HIST1H1C	0.51	4.59	0.38	1.06e-5	Height;
TGCT	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg18402987	chr7:1209562	NA	0.48	4.74	0.39	5.7e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs78366141	0.649	rs61737091	chr4:89671721	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	1.15	5.23	0.43	6.86e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
TGCT	cis	rs13392177	0.684	rs6720449	chr2:219080978	G/A	cg00012203	chr2:219082015	ARPC2	-0.79	-8.02	-0.58	6.73e-13	Pyoderma gangrenosum in inflammatory bowel disease;
TGCT	cis	rs2050392	0.624	rs303447	chr10:30728464	T/C	cg13289132	chr10:30722225	MAP3K8	-0.46	-5.57	-0.45	1.47e-7	Inflammatory bowel disease;
TGCT	cis	rs11053548	0.602	rs12819440	chr12:10174884	A/C	cg24820250	chr12:10084936	CLEC2A	0.26	4.65	0.39	8.33e-6	Systolic blood pressure in sickle cell anemia;
TGCT	cis	rs7666738	0.515	rs11733968	chr4:98906448	A/C	cg05340658	chr4:99064831	C4orf37	-0.57	-6.32	-0.49	4.36e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9393777	0.513	rs9348728	chr6:26634436	G/A	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.51	-4.68	-0.39	7.36e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg08736216	chr1:53307985	ZYG11A	0.25	4.93	0.4	2.59e-6	Monocyte count;
TGCT	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg13206674	chr6:150067644	NUP43	0.52	4.46	0.37	1.78e-5	Lung cancer;
TGCT	cis	rs2050392	1.000	rs2480280	chr10:30696092	A/G	cg18806716	chr10:30721971	MAP3K8	-0.44	-5.18	-0.42	8.82e-7	Inflammatory bowel disease;
TGCT	cis	rs10056811	0.538	rs3923323	chr5:74372141	C/T	cg19683494	chr5:74908142	NA	-0.6	-4.74	-0.39	5.68e-6	Coronary artery disease;
TGCT	cis	rs13256369	0.802	rs34762800	chr8:8559294	G/A	cg18904891	chr8:8559673	CLDN23	0.57	5.04	0.41	1.6e-6	Obesity-related traits;
TGCT	cis	rs174479	0.677	rs174463	chr11:61657838	G/A	cg01500311	chr11:61656094	FADS3	0.28	5.03	0.41	1.68e-6	Sphingolipid levels;
TGCT	cis	rs2440129	0.611	rs2292352	chr17:6902887	A/G	cg21237687	chr17:6899380	ALOX12	0.51	5.47	0.44	2.39e-7	Tonsillectomy;
TGCT	cis	rs7552404	0.727	rs7547508	chr1:76327958	A/G	cg03433033	chr1:76189801	ACADM	-0.59	-5.97	-0.47	2.34e-8	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs3733585	0.699	rs7663097	chr4:9966791	T/C	cg11266682	chr4:10021025	SLC2A9	-0.59	-7.87	-0.58	1.53e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs12049351	0.774	rs10799533	chr1:229656562	C/T	cg12130225	chr1:229698885	NA	0.35	4.46	0.37	1.85e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs1372520	0.684	rs2583979	chr4:90750588	A/T	cg15133208	chr4:90757351	SNCA	-0.5	-5.86	-0.47	4e-8	Neuroticism;
TGCT	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg24531977	chr5:56204891	C5orf35	-0.68	-7.22	-0.54	4.69e-11	Initial pursuit acceleration;
TGCT	cis	rs5750830	0.594	rs9611166	chr22:39775268	T/C	cg01416388	chr22:39784598	NA	-0.59	-5.8	-0.46	5.09e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9916302	0.808	rs6503515	chr17:37606433	G/T	cg15445000	chr17:37608096	MED1	0.31	4.59	0.38	1.06e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs4455778	0.600	rs56070219	chr7:49128237	A/T	cg26309511	chr7:48887640	NA	0.5	6.51	0.5	1.66e-9	Lung cancer in never smokers;
TGCT	cis	rs9611565	0.559	rs132765	chr22:42008068	A/G	cg03806693	chr22:41940476	POLR3H	1.07	11.4	0.72	4.95e-21	Vitiligo;
TGCT	cis	rs4862307	0.688	rs6552741	chr4:184990335	A/G	cg06737308	chr4:185021514	ENPP6	-0.38	-5.42	-0.44	2.95e-7	Serum dimethylarginine levels (asymmetric/symetric ratio);
TGCT	cis	rs6684514	1.000	rs12134983	chr1:156290409	T/C	cg20302342	chr1:156215951	PAQR6	0.35	4.74	0.39	5.77e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs6121246	0.529	rs73235789	chr20:30196148	T/C	cg13852791	chr20:30311386	BCL2L1	0.7	4.68	0.39	7.29e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs7552404	0.855	rs385897	chr1:76106962	T/C	cg10523679	chr1:76189770	ACADM	-0.92	-10.1	-0.67	7.29e-18	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs1215050	0.791	rs2865943	chr4:98778449	C/T	cg17366294	chr4:99064904	C4orf37	0.52	5.59	0.45	1.4e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1046896	0.521	rs3859206	chr17:80693128	G/A	cg00960700	chr17:80709150	TBCD	0.49	4.7	0.39	6.78e-6	Glycated hemoglobin levels;
TGCT	cis	rs1511802	0.666	rs28698123	chr4:187123189	C/T	cg19358738	chr4:186734530	SORBS2	0.18	4.57	0.38	1.16e-5	Blood protein levels;
TGCT	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg06481639	chr22:41940642	POLR3H	-0.73	-6.56	-0.51	1.32e-9	Vitiligo;
TGCT	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg22338127	chr1:209979572	IRF6	0.61	5.9	0.47	3.22e-8	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
TGCT	cis	rs2033711	0.870	rs1051500	chr19:58944402	A/G	cg12042659	chr19:58951599	ZNF132	0.51	4.64	0.38	8.67e-6	Uric acid clearance;
TGCT	cis	rs2299587	0.554	rs3853530	chr8:17748420	C/T	cg04898035	chr8:17640624	MTUS1	-0.2	-4.63	-0.38	9.19e-6	Economic and political preferences;
TGCT	trans	rs9388451	0.626	rs1739384	chr6:126099246	C/A	cg05039488	chr6:79577232	IRAK1BP1	-0.8	-9.31	-0.64	5.94e-16	Brugada syndrome;
TGCT	cis	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg20637647	chr7:64974828	NA	0.9	5.31	0.43	4.87e-7	Diabetic kidney disease;
TGCT	cis	rs71435601	0.689	rs34002646	chr2:21425323	A/G	cg25035485	chr2:21266500	APOB	-0.55	-4.68	-0.39	7.46e-6	Cholesterol, total;
TGCT	cis	rs7191439	0.858	rs2290902	chr16:88782676	A/G	cg27087555	chr16:88793112	FAM38A	-0.45	-5.0	-0.41	1.91e-6	Plateletcrit;
TGCT	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	5.23	0.43	6.92e-7	Menopause (age at onset);
TGCT	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg22535103	chr8:58192502	C8orf71	-0.42	-4.77	-0.39	5.18e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2836974	0.549	rs34160989	chr21:40554118	C/G	cg11644478	chr21:40555479	PSMG1	0.83	6.1	0.48	1.23e-8	Cognitive function;
TGCT	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg23758822	chr17:41437982	NA	-0.68	-6.79	-0.52	4.2e-10	Menopause (age at onset);
TGCT	cis	rs2456568	0.835	rs8181533	chr11:93638614	C/T	cg14065697	chr11:93583672	C11orf90	-0.38	-4.74	-0.39	5.65e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs860295	0.557	rs6696019	chr1:155864977	T/C	cg13795986	chr1:155880507	RIT1	0.38	4.61	0.38	9.9e-6	Body mass index;
TGCT	cis	rs2288278	0.601	rs925284	chr17:46585890	A/G	cg25032089	chr17:46643351	HOXB3	-0.42	-5.03	-0.41	1.68e-6	Hand grip strength;
TGCT	cis	rs7666738	0.546	rs28590002	chr4:98722642	C/T	cg17366294	chr4:99064904	C4orf37	0.61	5.68	0.45	9.02e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs77741769	0.571	rs12371178	chr12:121309129	T/C	cg02419362	chr12:121203948	SPPL3	0.19	4.49	0.37	1.63e-5	Mean corpuscular volume;
TGCT	cis	rs4253772	0.637	rs7284687	chr22:46690321	T/C	cg24881330	chr22:46731750	TRMU	1.03	5.67	0.45	9.45e-8	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs12989701	0.877	rs34745987	chr2:127875384	C/T	cg08168897	chr2:127865431	BIN1	0.53	5.77	0.46	6.05e-8	Alzheimer's disease (late onset);
TGCT	cis	rs7267979	0.718	rs2983489	chr20:25244120	C/A	cg14121845	chr20:25566513	NINL	0.45	4.8	0.4	4.44e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9534288	0.699	rs2146885	chr13:46659853	A/G	cg15192986	chr13:46630673	CPB2	-0.53	-6.39	-0.5	3.01e-9	Blood protein levels;
TGCT	cis	rs10875746	0.669	rs11168496	chr12:48650855	G/A	cg20731937	chr12:48336164	NA	0.59	4.52	0.38	1.45e-5	Longevity (90 years and older);
TGCT	cis	rs4366490	0.665	rs2105623	chr11:62904168	A/C	cg21002970	chr11:62369079	MTA2	0.87	4.67	0.39	7.78e-6	Conotruncal heart defects;
TGCT	cis	rs6921919	0.583	rs12697938	chr6:28341099	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.56	-5.37	-0.43	3.8e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg13409248	chr3:40428643	ENTPD3	0.57	4.53	0.38	1.37e-5	Renal cell carcinoma;
TGCT	cis	rs7255045	0.664	rs4614850	chr19:12974636	G/T	cg23899408	chr19:12877188	HOOK2	-0.61	-4.99	-0.41	1.97e-6	Mean corpuscular volume;
TGCT	cis	rs3785574	0.650	rs2070776	chr17:62007498	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-1.0	-11.14	-0.71	2.13e-20	Height;
TGCT	cis	rs9581857	0.556	rs1885990	chr13:28040502	C/T	cg22138327	chr13:27999177	GTF3A	0.71	5.65	0.45	1.05e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg07061783	chr6:25882402	NA	-0.45	-4.82	-0.4	4.15e-6	Blood metabolite levels;
TGCT	cis	rs763014	0.932	rs7204439	chr16:661335	T/C	cg00908189	chr16:619842	PIGQ	0.85	10.29	0.68	2.43e-18	Height;
TGCT	cis	rs7647973	0.626	rs1996664	chr3:49878395	A/G	cg03060546	chr3:49711283	APEH	-0.62	-5.56	-0.45	1.59e-7	Menarche (age at onset);
TGCT	cis	rs12472274	0.817	rs34791859	chr2:239070919	G/C	cg17459225	chr2:239074497	NA	0.32	4.79	0.4	4.65e-6	Phospholipid levels (plasma);
TGCT	cis	rs7937682	0.564	rs4938723	chr11:111382565	T/C	cg09085632	chr11:111637200	PPP2R1B	0.56	4.95	0.41	2.42e-6	Primary sclerosing cholangitis;
TGCT	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg11644478	chr21:40555479	PSMG1	-0.51	-4.68	-0.39	7.41e-6	Menarche (age at onset);
TGCT	cis	rs478304	0.654	rs1074156	chr11:65458169	G/T	cg27068330	chr11:65405492	SIPA1	-1.04	-10.95	-0.7	6.22e-20	Acne (severe);
TGCT	cis	rs2797160	1.000	rs1739373	chr6:126011509	A/G	cg05901451	chr6:126070800	HEY2	0.75	6.33	0.49	4.14e-9	Endometrial cancer;
TGCT	cis	rs10056811	0.538	rs4632781	chr5:74376658	G/C	cg19683494	chr5:74908142	NA	0.63	5.06	0.41	1.49e-6	Coronary artery disease;
TGCT	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg08439880	chr3:133502540	NA	-0.31	-5.87	-0.47	3.69e-8	Iron status biomarkers;
TGCT	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg04414720	chr1:150670196	GOLPH3L	0.38	4.99	0.41	2e-6	Tonsillectomy;
TGCT	cis	rs6121246	0.512	rs6060938	chr20:30363645	T/C	cg13852791	chr20:30311386	BCL2L1	0.82	8.0	0.58	7.65e-13	Mean corpuscular hemoglobin;
TGCT	cis	rs7208859	0.623	rs7220999	chr17:29149298	C/T	cg14008862	chr17:28927542	LRRC37B2	0.8	4.73	0.39	6.11e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	trans	rs783396	0.642	rs9486402	chr6:107014250	C/G	cg09256880	chr4:2791952	NA	0.49	6.77	0.52	4.5e-10	Stroke;
TGCT	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	6.11	0.48	1.17e-8	Alzheimer's disease;
TGCT	cis	rs2204008	0.542	rs34770471	chr12:38009613	C/T	cg26384229	chr12:38710491	ALG10B	0.86	7.77	0.57	2.55e-12	Bladder cancer;
TGCT	cis	rs35306767	0.903	rs12769431	chr10:922633	T/C	cg26597838	chr10:835615	NA	0.75	10.54	0.69	6.3e-19	Eosinophil percentage of granulocytes;
TGCT	cis	rs2996428	0.667	rs7511793	chr1:3744249	A/G	cg17848003	chr1:3704513	LRRC47	0.19	5.21	0.42	7.56e-7	Red cell distribution width;
TGCT	cis	rs9611565	0.573	rs9306355	chr22:42111896	A/T	cg06634786	chr22:41940651	POLR3H	0.82	7.9	0.58	1.3e-12	Vitiligo;
TGCT	cis	rs9807989	0.765	rs9807962	chr2:102971664	A/G	cg09003973	chr2:102972529	NA	0.64	5.7	0.46	8.28e-8	Asthma;
TGCT	cis	rs9372253	1.000	rs9372253	chr6:110716136	C/T	cg13266496	chr6:110720918	DDO	-0.46	-5.68	-0.45	8.89e-8	Platelet distribution width;
TGCT	cis	rs10986311	0.681	rs10818937	chr9:127015440	C/T	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.2	-4.65	-0.39	8.32e-6	Vitiligo;
TGCT	cis	rs4901869	0.932	rs12878445	chr14:59339361	A/G	cg02291164	chr14:59296302	NA	0.24	4.7	0.39	6.86e-6	Panic disorder;
TGCT	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg12311346	chr5:56204834	C5orf35	-0.63	-6.36	-0.5	3.5e-9	Initial pursuit acceleration;
TGCT	cis	rs1784581	0.608	rs1784603	chr6:162370272	G/A	cg17173639	chr6:162384350	PARK2	-0.42	-7.3	-0.55	3.07e-11	Itch intensity from mosquito bite;
TGCT	cis	rs425277	1.000	rs262670	chr1:2082458	C/T	cg24578937	chr1:2090814	PRKCZ	0.32	8.03	0.58	6.41e-13	Height;
TGCT	cis	rs2072499	0.900	rs2248080	chr1:156195971	T/A	cg24450063	chr1:156163899	SLC25A44	1.18	13.63	0.77	1.99e-26	Testicular germ cell tumor;
TGCT	cis	rs61867294	0.761	rs7085496	chr10:106699212	A/G	cg08000847	chr10:105880925	C10orf78	-0.54	-4.46	-0.37	1.81e-5	Schizophrenia;
TGCT	cis	rs10858047	0.883	rs7555301	chr1:115199930	G/A	cg12756093	chr1:115239321	AMPD1	-0.47	-4.96	-0.41	2.27e-6	Autism;
TGCT	cis	rs7843479	0.582	rs11779655	chr8:21794041	A/G	cg17168535	chr8:21777572	XPO7	-0.81	-8.33	-0.6	1.25e-13	Mean corpuscular volume;
TGCT	cis	rs10936602	0.527	rs9882101	chr3:169548655	G/A	cg08193579	chr3:169529701	LRRC34	0.28	5.07	0.41	1.39e-6	Renal cell carcinoma;
TGCT	cis	rs7547997	0.685	rs7521814	chr1:158346996	G/A	cg07950803	chr1:158223934	CD1A	0.32	4.78	0.39	4.95e-6	QRS duration;
TGCT	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg02953382	chr22:24373134	LOC391322	-0.78	-8.12	-0.59	4.06e-13	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs644799	1.000	rs1784135	chr11:95531748	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	8.74	0.62	1.39e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg22920501	chr2:26401640	FAM59B	-0.72	-6.38	-0.5	3.19e-9	Gut microbiome composition (summer);
TGCT	cis	rs2730245	0.592	rs2657385	chr7:158649373	A/G	cg11984989	chr7:158649758	WDR60	1.06	9.85	0.66	2.94e-17	Height;
TGCT	cis	rs7267979	0.789	rs6050472	chr20:25219852	A/G	cg03522245	chr20:25566470	NINL	0.53	5.26	0.43	6.04e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7804356	0.651	rs55959127	chr7:26810146	C/T	cg03456212	chr7:26904342	SKAP2	-0.54	-4.6	-0.38	1.04e-5	Type 1 diabetes;
TGCT	cis	rs611744	0.967	rs651814	chr8:109196571	A/G	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs1541995	0.789	rs71396825	chr15:96236915	G/C	cg00882281	chr15:96346592	NA	0.3	4.63	0.38	9.12e-6	Photic sneeze reflex;
TGCT	cis	rs6424115	0.830	rs1106	chr1:24200772	C/G	cg15997130	chr1:24165203	NA	0.85	9.25	0.64	8.02e-16	Immature fraction of reticulocytes;
TGCT	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg10295955	chr4:187884368	NA	1.01	13.56	0.77	3.07e-26	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6426558	0.621	rs7521639	chr1:227223736	T/C	cg10327440	chr1:227177885	CDC42BPA	0.68	8.74	0.62	1.38e-14	Neutrophil percentage of white cells;
TGCT	cis	rs3806843	0.898	rs3756335	chr5:140213510	A/T	cg19875535	chr5:140030758	IK	0.37	6.06	0.48	1.54e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9308731	0.787	rs13388990	chr2:111862303	T/C	cg04202892	chr2:111875749	ACOXL	0.44	4.46	0.37	1.79e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs9399137	0.507	rs4580893	chr6:135297662	G/A	cg24558204	chr6:135376177	HBS1L	0.47	4.78	0.39	4.95e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
TGCT	cis	rs76878669	0.561	rs7115577	chr11:66172258	G/T	cg18002602	chr11:66138449	SLC29A2	-0.52	-6.31	-0.49	4.48e-9	Educational attainment (years of education);
TGCT	cis	rs6840360	0.571	rs7678080	chr4:152557350	A/G	cg17479576	chr4:152424074	FAM160A1	-0.73	-7.94	-0.58	1.03e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs6484504	0.576	rs208067	chr11:31153578	C/T	cg26647111	chr11:31128758	NA	-0.33	-4.55	-0.38	1.27e-5	Red blood cell count;
TGCT	cis	rs11098499	0.644	rs34835603	chr4:120553428	C/T	cg09307838	chr4:120376055	NA	0.62	5.86	0.47	3.86e-8	Corneal astigmatism;
TGCT	cis	rs28595532	0.920	rs17259284	chr4:119779298	T/C	cg11846333	chr4:119757529	SEC24D	0.92	4.64	0.38	8.74e-6	Cannabis dependence symptom count;
TGCT	cis	rs72781680	0.821	rs111571980	chr2:24201695	C/G	cg08917208	chr2:24149416	ATAD2B	0.72	4.5	0.37	1.56e-5	Lymphocyte counts;
TGCT	cis	rs877282	0.945	rs10904556	chr10:789429	A/G	cg17470449	chr10:769945	NA	0.3	4.71	0.39	6.53e-6	Uric acid levels;
TGCT	cis	rs9473924	0.505	rs4111288	chr6:50908094	G/A	cg14470998	chr6:50812995	TFAP2B	1.35	8.39	0.6	9.05e-14	Body mass index;
TGCT	cis	rs9522267	0.535	rs4644738	chr13:112235995	G/A	cg10483660	chr13:112241077	NA	-0.27	-4.61	-0.38	9.78e-6	Hepatitis;
TGCT	cis	rs12908161	0.960	rs34452033	chr15:85221993	A/G	cg12863693	chr15:85201151	NMB	0.46	5.53	0.44	1.79e-7	Schizophrenia;
TGCT	cis	rs12908161	1.000	rs11632465	chr15:85282045	A/T	cg12863693	chr15:85201151	NMB	0.42	4.99	0.41	2.03e-6	Schizophrenia;
TGCT	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg08859206	chr1:53392774	SCP2	0.4	5.97	0.47	2.38e-8	Monocyte count;
TGCT	cis	rs12971120	0.891	rs12605820	chr18:72167802	G/A	cg26446133	chr18:72167187	CNDP2	-0.36	-6.11	-0.48	1.2e-8	Refractive error;
TGCT	cis	rs11696501	0.739	rs6017637	chr20:44264190	G/A	cg11783356	chr20:44313418	WFDC10B	-0.32	-4.58	-0.38	1.14e-5	Brain structure;
TGCT	cis	rs11690935	0.571	rs13020884	chr2:172901699	T/G	cg13550731	chr2:172543902	DYNC1I2	0.64	5.83	0.46	4.45e-8	Schizophrenia;
TGCT	cis	rs9926296	0.682	rs258328	chr16:89730314	C/T	cg21285383	chr16:89894308	SPIRE2	-0.32	-4.52	-0.38	1.42e-5	Vitiligo;
TGCT	cis	rs7172809	0.643	rs4886874	chr15:77838086	A/C	cg22256960	chr15:77711686	NA	0.49	5.0	0.41	1.91e-6	Glucose homeostasis traits;
TGCT	cis	rs7474896	0.583	rs12783272	chr10:38024885	T/G	cg13720705	chr10:37990370	NA	0.39	5.53	0.44	1.83e-7	Obesity (extreme);
TGCT	cis	rs2239547	0.563	rs6797399	chr3:52905917	G/A	cg11645453	chr3:52864694	ITIH4	0.34	5.72	0.46	7.68e-8	Schizophrenia;
TGCT	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg00684032	chr4:1343700	KIAA1530	-0.22	-4.71	-0.39	6.65e-6	Obesity-related traits;
TGCT	cis	rs11578119	0.933	rs12116910	chr1:170465981	A/T	cg09767346	chr1:170501363	GORAB	0.66	5.29	0.43	5.27e-7	Male-pattern baldness;
TGCT	cis	rs11122272	0.735	rs2808604	chr1:231538916	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-6.28	-0.49	5.32e-9	Hemoglobin concentration;
TGCT	cis	rs244731	0.919	rs12652509	chr5:176626441	A/G	cg17509989	chr5:176798049	RGS14	-0.6	-7.32	-0.55	2.69e-11	Urate levels in lean individuals;
TGCT	cis	rs11098499	0.913	rs11098496	chr4:120167466	C/G	cg24670566	chr4:120433619	PDE5A	0.23	4.58	0.38	1.13e-5	Corneal astigmatism;
TGCT	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg11644478	chr21:40555479	PSMG1	-0.58	-5.1	-0.42	1.23e-6	Cognitive function;
TGCT	cis	rs6088590	1.000	rs1998028	chr20:33344595	A/T	cg06115741	chr20:33292138	TP53INP2	0.67	5.61	0.45	1.24e-7	Coronary artery disease;
TGCT	cis	rs11614913	0.551	rs1867297	chr12:54396971	A/G	cg03037150	chr12:54402717	HOXC8	-0.59	-5.03	-0.41	1.69e-6	Waist circumference adjusted for body mass index;
TGCT	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.06	-9.57	-0.65	1.41e-16	Platelet count;
TGCT	cis	rs10949834	0.504	rs77541100	chr7:73555605	C/T	cg07137043	chr7:73588983	EIF4H	-0.68	-4.71	-0.39	6.54e-6	Verbal memory performance (residualized delayed recall change);
TGCT	cis	rs45509595	0.841	rs9368531	chr6:27781872	G/C	cg10876282	chr6:28092338	ZSCAN16	0.78	4.57	0.38	1.17e-5	Breast cancer;
TGCT	cis	rs910316	0.935	rs175422	chr14:75627319	T/A	cg11812906	chr14:75593930	NEK9	-0.73	-7.21	-0.54	4.87e-11	Height;
TGCT	cis	rs478304	0.651	rs4930313	chr11:65500428	C/T	cg27068330	chr11:65405492	SIPA1	-0.94	-9.4	-0.65	3.49e-16	Acne (severe);
TGCT	cis	rs172166	0.585	rs149963	chr6:28017132	G/A	cg13525197	chr6:28411240	ZSCAN23	-0.46	-4.49	-0.37	1.58e-5	Cardiac Troponin-T levels;
TGCT	cis	rs35306767	0.669	rs2101051	chr10:1158791	G/T	cg20503657	chr10:835505	NA	0.54	5.77	0.46	6.01e-8	Eosinophil percentage of granulocytes;
TGCT	cis	rs11112613	0.713	rs12316204	chr12:105944244	G/A	cg03607813	chr12:105948248	NA	0.48	5.5	0.44	2.04e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	cis	rs9633740	0.947	rs7096909	chr10:82284512	A/T	cg01528321	chr10:82214614	TSPAN14	-0.98	-7.99	-0.58	7.94e-13	Post bronchodilator FEV1;
TGCT	cis	rs2153535	0.505	rs1737583	chr6:8536812	G/A	cg07606381	chr6:8435919	SLC35B3	0.55	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs79349575	0.783	rs58591767	chr17:47026076	G/A	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.52	-0.38	1.44e-5	Type 2 diabetes;
TGCT	cis	rs10754283	0.871	rs72712569	chr1:90125657	G/C	cg03145924	chr1:90228473	NA	0.37	4.46	0.37	1.85e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs6912958	0.559	rs242281	chr6:88048916	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.4	4.71	0.39	6.65e-6	Monocyte percentage of white cells;
TGCT	cis	rs8032315	0.965	rs1894400	chr15:91428955	C/T	cg06330618	chr15:91428456	FES	0.19	4.8	0.4	4.4e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7394190	0.748	rs2306327	chr10:75573778	A/T	cg07699608	chr10:75541558	CHCHD1	0.81	5.6	0.45	1.33e-7	Incident atrial fibrillation;
TGCT	cis	rs11031096	0.754	rs10835611	chr11:4117730	G/C	cg18678763	chr11:4115507	RRM1	-0.43	-5.48	-0.44	2.31e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs7772486	0.686	rs1292336	chr6:145967818	T/C	cg23711669	chr6:146136114	FBXO30	-0.81	-8.79	-0.62	1.03e-14	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9677476	0.657	rs13418346	chr2:232132374	A/G	cg07929768	chr2:232055508	NA	-0.32	-5.06	-0.41	1.45e-6	Food antigen IgG levels;
TGCT	cis	rs9419702	0.614	rs9419567	chr10:133535149	C/G	cg04492858	chr10:133558786	NA	0.53	5.74	0.46	6.85e-8	Survival in rectal cancer;
TGCT	cis	rs11098499	0.866	rs6824111	chr4:120285968	T/A	cg09307838	chr4:120376055	NA	0.58	5.76	0.46	6.16e-8	Corneal astigmatism;
TGCT	cis	rs7666738	0.830	rs1349757	chr4:99058763	C/G	cg18180107	chr4:99064573	C4orf37	0.56	5.08	0.41	1.37e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg03264133	chr6:25882463	NA	-0.71	-6.7	-0.52	6.62e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs13191362	1.000	rs66534429	chr6:163003322	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.68	5.79	0.46	5.33e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7027203	0.828	rs10761288	chr9:96609363	C/T	cg13679303	chr9:96623674	NA	-0.63	-9.61	-0.65	1.11e-16	DNA methylation (variation);
TGCT	cis	rs4722166	0.695	rs4722177	chr7:22798531	T/C	cg26061582	chr7:22766209	IL6	0.48	6.25	0.49	6.15e-9	Lung cancer;
TGCT	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg00024416	chr22:24240387	NA	-0.32	-5.56	-0.45	1.6e-7	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs12478296	1.000	rs60533128	chr2:243028088	A/G	cg06360820	chr2:242988706	NA	-0.85	-5.6	-0.45	1.3e-7	Obesity-related traits;
TGCT	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg20203395	chr5:56204925	C5orf35	-0.56	-4.8	-0.4	4.39e-6	Initial pursuit acceleration;
TGCT	cis	rs8033133	0.958	rs6420956	chr15:25309559	T/C	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	-0.26	-4.73	-0.39	6.13e-6	Blood osmolality (transformed sodium);
TGCT	cis	rs2652822	0.509	rs6494394	chr15:63440938	A/G	cg12855773	chr15:63363890	TPM1	-0.19	-5.01	-0.41	1.85e-6	Metabolic traits;
TGCT	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.12	0.42	1.15e-6	Prudent dietary pattern;
TGCT	cis	rs1018836	0.669	rs6471243	chr8:91656967	C/T	cg16814680	chr8:91681699	NA	0.96	13.2	0.76	2.18e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs968451	0.789	rs11089939	chr22:39680957	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.81	7.97	0.58	8.95e-13	Primary biliary cholangitis;
TGCT	cis	rs8064299	0.597	rs4789097	chr17:72781208	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	-0.9	-10.32	-0.68	2.06e-18	Monocyte count;
TGCT	cis	rs10435719	0.902	rs7014580	chr8:11803262	C/G	cg02840367	chr8:11660030	FDFT1	-0.52	-4.48	-0.37	1.7e-5	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.04	0.53	1.16e-10	Prudent dietary pattern;
TGCT	cis	rs13424612	1.000	rs66534347	chr2:240899346	G/A	cg26363272	chr2:240904871	NDUFA10	0.31	5.19	0.42	8.3e-7	Odorant perception (isobutyraldehyde);
TGCT	cis	rs9427116	0.875	rs11264233	chr1:154625632	C/T	cg17218026	chr1:154582156	ADAR	0.26	6.24	0.49	6.39e-9	Blood protein levels;
TGCT	cis	rs2180341	0.782	rs6912552	chr6:127722946	C/G	cg27446573	chr6:127587934	RNF146	-0.78	-6.82	-0.52	3.47e-10	Breast cancer;
TGCT	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg07167872	chr1:205819463	PM20D1	-0.53	-6.88	-0.53	2.6e-10	Monocyte percentage of white cells;
TGCT	cis	rs12220898	0.679	rs10776555	chr10:50484995	A/G	cg09603381	chr10:49954066	WDFY4	0.38	4.45	0.37	1.88e-5	Inflammatory biomarkers;
TGCT	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg23103009	chr10:134564232	INPP5A	0.28	4.44	0.37	1.94e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs7336332	0.598	rs1885988	chr13:28010262	C/T	cg22138327	chr13:27999177	GTF3A	-0.77	-6.2	-0.49	7.87e-9	Weight;
TGCT	cis	rs6582630	0.519	rs11514372	chr12:38308613	T/G	cg13010199	chr12:38710504	ALG10B	0.57	4.49	0.37	1.62e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs4704846	1.000	rs1036199	chr5:156531736	C/A	cg12943317	chr5:156479607	HAVCR1	-0.34	-4.75	-0.39	5.43e-6	Blood protein levels;
TGCT	cis	rs12579753	0.871	rs4255611	chr12:82215969	C/A	cg07988820	chr12:82153109	PPFIA2	-0.58	-6.06	-0.48	1.52e-8	Resting heart rate;
TGCT	cis	rs2549003	1.000	rs2706384	chr5:131826880	G/T	cg02551604	chr5:131831745	NA	0.9	11.87	0.73	3.59e-22	Asthma (sex interaction);
TGCT	cis	rs11098499	0.863	rs6858592	chr4:120458692	G/A	cg09307838	chr4:120376055	NA	0.71	6.96	0.53	1.71e-10	Corneal astigmatism;
TGCT	cis	rs611744	0.647	rs676654	chr8:109242303	A/G	cg21045802	chr8:109455806	TTC35	0.72	7.28	0.55	3.44e-11	Dupuytren's disease;
TGCT	cis	rs10791323	0.575	rs4489760	chr11:133732265	A/T	cg03690763	chr11:133734501	NA	-0.28	-4.44	-0.37	1.96e-5	Childhood ear infection;
TGCT	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg23708337	chr7:1209742	NA	0.6	5.57	0.45	1.53e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg08280861	chr8:58055591	NA	0.39	5.61	0.45	1.28e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2594989	0.831	rs2443703	chr3:11564191	C/T	cg00170343	chr3:11313890	ATG7	-0.72	-5.09	-0.42	1.27e-6	Circulating chemerin levels;
TGCT	cis	rs244731	0.959	rs4976677	chr5:176629546	G/A	cg17509989	chr5:176798049	RGS14	-0.6	-7.32	-0.55	2.69e-11	Urate levels in lean individuals;
TGCT	cis	rs8016982	0.611	rs8008870	chr14:81709374	C/T	cg01989461	chr14:81687754	GTF2A1	0.78	7.8	0.57	2.21e-12	Schizophrenia;
TGCT	cis	rs4499344	0.633	rs259262	chr19:33153951	G/A	cg26639809	chr19:33781782	NA	0.22	4.47	0.37	1.75e-5	Mean platelet volume;
TGCT	cis	rs4389656	0.767	rs274704	chr5:6728340	A/G	cg10857441	chr5:6722123	POLS	-0.22	-4.74	-0.39	5.75e-6	Coronary artery disease;
TGCT	cis	rs7666738	0.606	rs7663216	chr4:99088385	A/C	cg05340658	chr4:99064831	C4orf37	0.44	4.72	0.39	6.23e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg10295955	chr4:187884368	NA	-0.93	-12.52	-0.75	9.29e-24	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs8013055	0.846	rs10151805	chr14:105974781	T/C	cg19700328	chr14:106028568	NA	-0.53	-5.91	-0.47	3.03e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs12142240	0.845	rs4313342	chr1:46801904	T/C	cg14993813	chr1:46806288	NSUN4	-0.54	-4.51	-0.38	1.46e-5	Menopause (age at onset);
TGCT	cis	rs1453308	1.000	rs6713580	chr2:237184230	T/C	cg19324714	chr2:237145437	ASB18	0.58	5.13	0.42	1.11e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs8067545	1.000	rs3909258	chr17:19945819	C/G	cg13482628	chr17:19912719	NA	0.53	4.48	0.37	1.66e-5	Schizophrenia;
TGCT	cis	rs797680	0.856	rs602204	chr1:93727579	A/G	cg17826107	chr1:92977322	EVI5	0.24	5.29	0.43	5.47e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg18402987	chr7:1209562	NA	0.48	4.79	0.39	4.72e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	trans	rs1814175	0.511	rs61905634	chr11:49819736	G/A	cg15704280	chr7:45808275	SEPT13	-0.72	-8.14	-0.59	3.61e-13	Height;
TGCT	cis	rs4820539	1.000	rs2267002	chr22:23456702	T/C	cg14186256	chr22:23484241	RTDR1	0.99	12.18	0.74	6.44e-23	Bone mineral density;
TGCT	cis	rs1801251	0.778	rs2675957	chr2:233754364	C/T	cg25237894	chr2:233734115	C2orf82	-0.3	-5.75	-0.46	6.52e-8	Coronary artery disease;
TGCT	cis	rs10838634	0.901	rs12281784	chr11:46908250	C/T	cg18332754	chr11:46939436	LRP4	0.87	4.48	0.37	1.68e-5	Schizophrenia;
TGCT	cis	rs2455799	0.613	rs1345157	chr3:15895581	C/G	cg16303742	chr3:15540471	COLQ	-0.24	-4.64	-0.38	8.63e-6	Mean platelet volume;
TGCT	cis	rs10509586	1.000	rs17504192	chr10:91783041	C/A	cg25278353	chr10:91717815	NA	0.48	4.53	0.38	1.34e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
TGCT	cis	rs35146811	0.731	rs2257213	chr7:99810113	T/C	cg04778012	chr7:99775508	STAG3;GPC2	-0.36	-5.1	-0.42	1.22e-6	Coronary artery disease;
TGCT	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg11764359	chr7:65958608	NA	0.54	4.66	0.39	7.88e-6	Aortic root size;
TGCT	cis	rs10779751	0.734	rs2791648	chr1:11132638	G/T	cg08854313	chr1:11322531	MTOR	0.82	7.04	0.53	1.19e-10	Body mass index;
TGCT	cis	rs941873	0.772	rs1316312	chr10:81110417	G/C	cg09469691	chr10:81107165	PPIF	0.51	5.03	0.41	1.69e-6	Height;
TGCT	cis	rs7772486	0.875	rs6938972	chr6:146410608	G/A	cg05347473	chr6:146136440	FBXO30	0.56	5.22	0.42	7.31e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1215050	0.791	rs1605259	chr4:98799732	T/C	cg17366294	chr4:99064904	C4orf37	0.52	5.59	0.45	1.4e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs5769765	0.908	rs138880	chr22:50218611	A/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.37	5.66	0.45	9.92e-8	Schizophrenia;
TGCT	cis	rs1371867	0.875	rs1788173	chr8:101330939	A/G	cg00191853	chr8:101177733	SPAG1	0.22	4.71	0.39	6.63e-6	Atrioventricular conduction;
TGCT	cis	rs7666738	0.830	rs10470951	chr4:99037051	G/A	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9916302	0.904	rs8079560	chr17:37497661	C/T	cg15445000	chr17:37608096	MED1	-0.33	-4.71	-0.39	6.46e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs4372836	0.729	rs12475612	chr2:29030006	T/G	cg09522027	chr2:28974177	PPP1CB	0.65	6.65	0.51	8.32e-10	Body mass index;
TGCT	cis	rs7647973	1.000	rs11928090	chr3:49604904	G/A	cg07636037	chr3:49044803	WDR6	0.6	4.96	0.41	2.22e-6	Menarche (age at onset);
TGCT	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg23719950	chr11:63933701	MACROD1	-0.72	-5.92	-0.47	2.99e-8	Mean platelet volume;
TGCT	cis	rs17030434	0.654	rs1530105	chr4:154646994	C/T	cg14289246	chr4:154710475	SFRP2	0.74	5.53	0.44	1.84e-7	Electrocardiographic conduction measures;
TGCT	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg27535305	chr1:53392650	SCP2	-0.27	-5.45	-0.44	2.58e-7	Monocyte count;
TGCT	cis	rs13102973	0.682	rs13107817	chr4:135885535	C/T	cg14419869	chr4:135874104	NA	0.26	4.55	0.38	1.28e-5	Subjective well-being;
TGCT	cis	rs6460942	0.908	rs77894875	chr7:12248257	T/C	cg06484146	chr7:12443880	VWDE	-0.58	-4.81	-0.4	4.32e-6	Coronary artery disease;
TGCT	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	5.8	0.46	5.19e-8	Alzheimer's disease;
TGCT	cis	rs2439831	0.867	rs2927072	chr15:43922398	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	6.61	0.51	1.03e-9	Lung cancer in ever smokers;
TGCT	cis	rs6459788	0.692	rs10807645	chr7:157258979	T/C	cg06271696	chr7:157225062	NA	0.27	5.02	0.41	1.77e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs7208859	0.623	rs9898084	chr17:29082334	C/G	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7917772	0.636	rs4919676	chr10:104524352	C/T	cg05855489	chr10:104503620	C10orf26	0.67	5.32	0.43	4.77e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg16049864	chr8:95962084	TP53INP1	-0.77	-11.3	-0.71	8.62e-21	Type 2 diabetes;
TGCT	cis	rs1215050	0.791	rs260899	chr4:98707046	G/A	cg17366294	chr4:99064904	C4orf37	0.52	5.61	0.45	1.27e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs977747	0.836	rs4926521	chr1:47674769	G/A	cg03885399	chr1:47691550	TAL1	-0.42	-5.48	-0.44	2.26e-7	Body mass index;
TGCT	cis	rs78245978	0.744	rs7080622	chr10:2637022	A/C	cg17670436	chr10:3374199	NA	0.55	4.95	0.41	2.4e-6	Major depressive disorder;
TGCT	cis	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg18252515	chr7:66147081	NA	-1.13	-6.81	-0.52	3.7e-10	Diabetic kidney disease;
TGCT	cis	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg18188782	chr20:61659543	NA	0.44	5.38	0.43	3.6e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs11098499	0.874	rs28452522	chr4:120110784	A/G	cg09307838	chr4:120376055	NA	0.5	4.61	0.38	1e-5	Corneal astigmatism;
TGCT	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg02487422	chr3:49467188	NICN1	-0.53	-5.15	-0.42	9.76e-7	Menarche (age at onset);
TGCT	cis	rs6089584	1.000	rs6089580	chr20:60558976	G/A	cg13770153	chr20:60521292	NA	-0.44	-5.62	-0.45	1.21e-7	Body mass index;
TGCT	cis	rs9902453	1.000	rs60967688	chr17:28437052	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	6.09	0.48	1.28e-8	Coffee consumption (cups per day);
TGCT	cis	rs7582180	0.663	rs4850929	chr2:100990707	A/C	cg14675211	chr2:100938903	LONRF2	0.48	4.6	0.38	1.01e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg03709012	chr19:19516395	GATAD2A	0.74	6.04	0.48	1.65e-8	Tonsillectomy;
TGCT	cis	rs854765	0.583	rs4077198	chr17:17834563	T/C	cg09796270	chr17:17721594	SREBF1	0.24	4.77	0.39	5.16e-6	Total body bone mineral density;
TGCT	cis	rs12510870	0.599	rs2141470	chr4:74385090	T/C	cg05868023	chr4:75230803	EREG	0.56	5.07	0.41	1.42e-6	Iris color (b* coordinate);
TGCT	cis	rs3806843	0.801	rs801170	chr5:140115343	C/T	cg19875535	chr5:140030758	IK	-0.35	-5.94	-0.47	2.63e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs832540	0.902	rs194059	chr5:56197416	G/A	cg24531977	chr5:56204891	C5orf35	-0.52	-5.23	-0.43	6.85e-7	Coronary artery disease;
TGCT	cis	rs67311347	1.000	rs9874499	chr3:40441908	C/T	cg13683864	chr3:40499215	RPL14	-1.12	-11.8	-0.73	5.17e-22	Renal cell carcinoma;
TGCT	cis	rs1153858	1.000	rs59889118	chr15:45618730	G/A	cg14582100	chr15:45693742	SPATA5L1	0.52	6.13	0.48	1.09e-8	Homoarginine levels;
TGCT	cis	rs7208859	0.673	rs2269915	chr17:29233344	C/T	cg14008862	chr17:28927542	LRRC37B2	0.72	4.66	0.39	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	trans	rs6762477	0.748	rs3755831	chr3:50228767	G/T	cg21659725	chr3:3221576	CRBN	-0.68	-7.49	-0.56	1.12e-11	Menarche (age at onset);
TGCT	trans	rs4332037	0.950	rs7807014	chr7:1939021	T/C	cg10840412	chr1:235813424	GNG4	1.04	8.16	0.59	3.22e-13	Bipolar disorder;
TGCT	cis	rs4733781	1.000	rs876575	chr8:131210851	A/G	cg16277922	chr8:131349729	ASAP1	0.44	5.73	0.46	7.33e-8	Tuberculosis;
TGCT	cis	rs9894429	0.608	rs7406219	chr17:79609410	G/T	cg21028142	chr17:79581711	NPLOC4	0.29	5.95	0.47	2.56e-8	Eye color traits;
TGCT	cis	rs13191362	1.000	rs34443622	chr6:163208214	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.09	7.16	0.54	6.36e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs10779751	0.734	rs2791653	chr1:11129848	A/G	cg08854313	chr1:11322531	MTOR	0.85	6.96	0.53	1.74e-10	Body mass index;
TGCT	cis	rs35306767	0.855	rs12771179	chr10:872347	A/G	cg26597838	chr10:835615	NA	0.8	12.11	0.74	9.26e-23	Eosinophil percentage of granulocytes;
TGCT	cis	rs7666738	0.716	rs11097615	chr4:99092773	T/C	cg18180107	chr4:99064573	C4orf37	0.57	5.04	0.41	1.58e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10170846	0.861	rs7571732	chr2:223538316	A/C	cg25565276	chr2:223520875	FARSB	-0.55	-4.58	-0.38	1.1e-5	Schizophrenia (inflammation and infection response interaction);
TGCT	cis	rs7302981	0.967	rs7136570	chr12:50529936	A/G	cg23855989	chr12:50355821	AQP5	-0.3	-4.44	-0.37	2e-5	Systolic blood pressure;
TGCT	cis	rs6879260	0.928	rs11739624	chr5:179727290	T/C	cg23221052	chr5:179740743	GFPT2	-0.33	-5.09	-0.42	1.27e-6	Height;
TGCT	cis	rs889312	0.500	rs252903	chr5:56117952	A/G	cg24531977	chr5:56204891	C5orf35	-0.53	-5.5	-0.44	2.07e-7	Breast cancer;Breast cancer (early onset);
TGCT	cis	rs11190604	1.000	rs2495750	chr10:102327708	A/G	cg16342193	chr10:102329863	NA	-0.42	-5.39	-0.44	3.47e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs1691799	0.899	rs1168301	chr12:66736771	C/T	cg16791601	chr12:66731901	HELB	-0.27	-5.99	-0.47	2.14e-8	White blood cell count (basophil);
TGCT	cis	rs17511627	0.799	rs2900999	chr13:26732244	C/T	cg20241335	chr13:25876335	NUPL1	0.7	4.54	0.38	1.33e-5	Alzheimer's disease;
TGCT	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.39	-4.61	-0.38	1e-5	Longevity;Endometriosis;
TGCT	trans	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.89	-9.57	-0.65	1.42e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs274567	0.602	rs272853	chr5:131688561	A/G	cg18758796	chr5:131593413	PDLIM4	0.43	4.77	0.39	5.02e-6	Blood metabolite levels;
TGCT	cis	rs9341808	0.727	rs9361599	chr6:81025242	C/G	cg08355045	chr6:80787529	NA	0.28	4.74	0.39	5.73e-6	Sitting height ratio;
TGCT	cis	rs7674212	0.537	rs2623060	chr4:104047504	G/A	cg16532752	chr4:104119610	CENPE	-0.64	-5.86	-0.47	3.95e-8	Type 2 diabetes;
TGCT	cis	rs17767294	0.614	rs72850302	chr6:28241398	A/G	cg08851530	chr6:28072375	NA	1.54	6.89	0.53	2.51e-10	Parkinson's disease;
TGCT	cis	rs910187	0.605	rs2281367	chr20:45808960	T/C	cg27589058	chr20:45804311	EYA2	-0.4	-9.01	-0.63	3.13e-15	Migraine;
TGCT	cis	rs7824557	0.679	rs13279067	chr8:11135828	A/G	cg21775007	chr8:11205619	TDH	-0.59	-5.45	-0.44	2.6e-7	Retinal vascular caliber;
TGCT	cis	rs1729951	0.575	rs361243	chr3:136697786	C/T	cg12473912	chr3:136751656	NA	0.39	6.18	0.49	8.62e-9	Neuroticism;
TGCT	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg10047753	chr17:41438598	NA	0.96	9.86	0.66	2.71e-17	Menopause (age at onset);
TGCT	cis	rs2486288	0.554	rs1719235	chr15:45576108	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.45	-5.36	-0.43	3.89e-7	Glomerular filtration rate;
TGCT	cis	rs72781680	1.000	rs72788286	chr2:24098321	A/C	cg08917208	chr2:24149416	ATAD2B	0.73	4.51	0.38	1.48e-5	Lymphocyte counts;
TGCT	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg06873352	chr17:61820015	STRADA	0.56	6.22	0.49	6.93e-9	Prudent dietary pattern;
TGCT	cis	rs6087990	0.899	rs4911110	chr20:31392366	C/T	cg13636640	chr20:31349939	DNMT3B	-1.01	-14.85	-0.8	2.7e-29	Ulcerative colitis;
TGCT	cis	rs7937682	0.663	rs3867466	chr11:111668256	A/C	cg09085632	chr11:111637200	PPP2R1B	0.79	6.54	0.51	1.45e-9	Primary sclerosing cholangitis;
TGCT	cis	rs7666738	0.830	rs13116691	chr4:98929771	A/C	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg13206674	chr6:150067644	NUP43	0.51	4.47	0.37	1.76e-5	Lung cancer;
TGCT	cis	rs8102476	0.846	rs11083450	chr19:38754239	T/C	cg14131526	chr19:38747285	PPP1R14A	-0.53	-4.63	-0.38	8.98e-6	Prostate cancer;Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7954584	0.813	rs11043288	chr12:122451187	C/T	cg21016266	chr12:122356598	WDR66	-0.41	-5.12	-0.42	1.13e-6	Mean corpuscular volume;
TGCT	cis	rs9302001	0.920	rs4773819	chr13:95456973	T/C	cg07483244	chr13:95358924	NA	0.37	4.8	0.4	4.42e-6	Panic disorder;
TGCT	cis	rs698813	0.604	rs11676798	chr2:44479982	G/C	cg00619915	chr2:44497795	NA	-0.24	-5.62	-0.45	1.19e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
TGCT	cis	rs362296	0.698	rs362279	chr4:3260072	G/A	cg06533319	chr4:3265114	C4orf44	0.24	4.52	0.38	1.4e-5	Parental longevity (mother's age at death);
TGCT	cis	rs7666738	0.830	rs4502686	chr4:98765117	T/C	cg17366294	chr4:99064904	C4orf37	0.65	6.78	0.52	4.31e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7917772	0.636	rs2249850	chr10:104512006	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.66	5.42	0.44	2.94e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7666738	0.830	rs13139024	chr4:99020700	C/T	cg18180107	chr4:99064573	C4orf37	0.54	5.03	0.41	1.7e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg21724239	chr8:58056113	NA	0.4	4.91	0.4	2.75e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs72781680	0.752	rs72796138	chr2:23926233	C/T	cg08917208	chr2:24149416	ATAD2B	1.0	5.79	0.46	5.41e-8	Lymphocyte counts;
TGCT	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg24578937	chr1:2090814	PRKCZ	0.24	5.81	0.46	4.87e-8	Height;
TGCT	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg01802117	chr1:53393560	SCP2	0.43	5.13	0.42	1.1e-6	Monocyte count;
TGCT	cis	rs2439831	1.000	rs690316	chr15:43737880	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.02	8.42	0.6	7.81e-14	Lung cancer in ever smokers;
TGCT	cis	rs7772486	0.754	rs6932863	chr6:146021255	A/T	cg05347473	chr6:146136440	FBXO30	-0.51	-4.8	-0.4	4.44e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg23758822	chr17:41437982	NA	0.68	6.26	0.49	5.76e-9	Menopause (age at onset);
TGCT	cis	rs2562456	0.617	rs34203148	chr19:21773545	T/A	cg13978929	chr19:21580086	ZNF493	-0.55	-4.69	-0.39	7.04e-6	Pain;
TGCT	cis	rs7208859	0.524	rs59923796	chr17:29064919	G/A	cg14008862	chr17:28927542	LRRC37B2	0.76	4.52	0.38	1.42e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg13395646	chr4:1353034	KIAA1530	-0.41	-5.26	-0.43	6.02e-7	Obesity-related traits;
TGCT	cis	rs12188164	0.965	rs72717438	chr5:448663	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.4	-4.71	-0.39	6.42e-6	Cystic fibrosis severity;
TGCT	cis	rs36051895	0.625	rs11792531	chr9:5152203	T/C	cg02405213	chr9:5042618	JAK2	-0.7	-8.84	-0.62	8.02e-15	Pediatric autoimmune diseases;
TGCT	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg22166914	chr1:53195759	ZYG11B	0.33	5.33	0.43	4.4e-7	Monocyte count;
TGCT	cis	rs7940866	0.838	rs10750455	chr11:130800330	C/T	cg05962950	chr11:130786565	SNX19	0.72	7.38	0.55	2.04e-11	Schizophrenia;
TGCT	cis	rs57994353	0.861	rs34936112	chr9:139327062	G/A	cg13741927	chr9:139327495	INPP5E	-0.27	-6.13	-0.48	1.06e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs4953076	0.573	rs6734443	chr2:44408282	G/C	cg00619915	chr2:44497795	NA	-0.23	-5.1	-0.42	1.22e-6	Height;
TGCT	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg20203395	chr5:56204925	C5orf35	-0.59	-5.12	-0.42	1.12e-6	Initial pursuit acceleration;
TGCT	cis	rs1801251	1.000	rs6724117	chr2:233593660	T/G	cg08000102	chr2:233561755	GIGYF2	0.63	6.53	0.51	1.51e-9	Coronary artery disease;
TGCT	cis	rs7312933	0.737	rs10880261	chr12:42573822	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	4.99	0.41	1.99e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs7089973	0.624	rs61867965	chr10:116574794	A/T	cg03647239	chr10:116582469	FAM160B1	0.58	5.31	0.43	4.95e-7	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs72781680	0.898	rs12614616	chr2:23996501	T/G	cg08917208	chr2:24149416	ATAD2B	0.81	5.01	0.41	1.8e-6	Lymphocyte counts;
TGCT	cis	rs1153858	1.000	rs2461702	chr15:45647427	A/G	cg26924012	chr15:45694286	SPATA5L1	0.99	12.23	0.74	4.74e-23	Homoarginine levels;
TGCT	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg11764359	chr7:65958608	NA	-0.55	-5.08	-0.42	1.34e-6	Aortic root size;
TGCT	cis	rs2933343	0.951	rs789251	chr3:128576770	G/A	cg11901034	chr3:128598214	ACAD9	-0.63	-5.14	-0.42	1.05e-6	IgG glycosylation;
TGCT	cis	rs11031096	0.542	rs1155146	chr11:3971020	G/A	cg18678763	chr11:4115507	RRM1	-0.42	-5.14	-0.42	1.05e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs9611565	0.512	rs9607841	chr22:42186838	G/A	cg17554472	chr22:41940697	POLR3H	-0.46	-4.79	-0.39	4.71e-6	Vitiligo;
TGCT	cis	rs13323323	0.842	rs56377787	chr3:44293513	A/G	cg04389838	chr3:44770851	ZNF501	-0.42	-4.57	-0.38	1.15e-5	IgG glycosylation;
TGCT	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	6.72	0.52	5.82e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg01802117	chr1:53393560	SCP2	0.46	5.51	0.44	1.95e-7	Monocyte count;
TGCT	cis	rs2688608	1.000	rs2688608	chr10:75658349	G/T	cg02947784	chr10:75434997	AGAP5	0.16	4.45	0.37	1.86e-5	Inflammatory bowel disease;
TGCT	cis	rs6671200	0.541	rs7555339	chr1:95691579	G/A	cg03123541	chr1:95699097	RWDD3	-0.81	-7.26	-0.55	3.74e-11	Stearic acid (18:0) levels;
TGCT	cis	rs10779751	0.610	rs2486921	chr1:11124943	G/A	cg08854313	chr1:11322531	MTOR	0.82	7.04	0.53	1.19e-10	Body mass index;
TGCT	cis	rs7208859	0.614	rs73265646	chr17:29244023	C/T	cg14008862	chr17:28927542	LRRC37B2	0.73	4.8	0.4	4.43e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	trans	rs629535	0.551	rs62513429	chr8:70149995	A/C	cg21567404	chr3:27674614	NA	-0.51	-7.55	-0.56	8.15e-12	Dupuytren's disease;
TGCT	cis	rs9916302	0.605	rs2879258	chr17:37399379	G/T	cg03321784	chr17:37729644	NA	0.44	4.47	0.37	1.77e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs9818758	0.505	rs11716159	chr3:49631585	G/A	cg00383909	chr3:49044727	WDR6	1.31	6.63	0.51	9.3e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg00684032	chr4:1343700	KIAA1530	0.22	4.9	0.4	2.93e-6	Obesity-related traits;
TGCT	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg21724239	chr8:58056113	NA	0.39	5.28	0.43	5.67e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2025751	0.512	rs6935608	chr6:51687277	A/C	cg23457901	chr6:52402140	TRAM2	-0.22	-4.5	-0.37	1.57e-5	Intraocular pressure;
TGCT	cis	rs1008375	0.966	rs4698636	chr4:17632834	T/C	cg16339924	chr4:17578868	LAP3	0.64	5.33	0.43	4.52e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.12	0.42	1.15e-6	Prudent dietary pattern;
TGCT	cis	rs9807989	0.507	rs6706002	chr2:103006104	A/G	cg03938978	chr2:103052716	IL18RAP	0.26	5.22	0.42	7.15e-7	Asthma;
TGCT	cis	rs9443645	0.869	rs9343827	chr6:79501036	A/G	cg09184832	chr6:79620586	NA	-0.45	-4.84	-0.4	3.76e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs13191362	1.000	rs34594856	chr6:163051845	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.92	7.24	0.55	4.11e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg22891161	chr3:195456627	MUC20	-0.23	-5.35	-0.43	4.08e-7	Pancreatic cancer;
TGCT	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg02725872	chr8:58115012	NA	-0.36	-4.51	-0.38	1.51e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs4689388	0.856	rs4308430	chr4:6294095	A/G	cg25554036	chr4:6271136	WFS1	0.54	7.37	0.55	2.11e-11	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs3820928	0.560	rs55635053	chr2:227952154	G/A	cg11843606	chr2:227700838	RHBDD1	-0.49	-4.56	-0.38	1.21e-5	Pulmonary function;
TGCT	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg03351412	chr1:154909251	PMVK	0.52	4.8	0.4	4.51e-6	Prostate cancer;
TGCT	cis	rs9549367	0.577	rs3024713	chr13:113813321	G/A	cg00898013	chr13:113819073	PROZ	-0.55	-6.52	-0.51	1.62e-9	Platelet distribution width;
TGCT	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-8.64	-0.61	2.39e-14	Platelet count;
TGCT	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg03303774	chr4:1407052	NA	-0.32	-4.92	-0.4	2.7e-6	Obesity-related traits;
TGCT	cis	rs9549260	0.755	rs2721071	chr13:41144507	G/A	cg21288729	chr13:41239152	FOXO1	0.99	10.25	0.68	3.18e-18	Red blood cell count;
TGCT	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	5.68	0.45	9.24e-8	Height;
TGCT	cis	rs6558174	0.965	rs4872524	chr8:22489537	A/G	cg03733263	chr8:22462867	KIAA1967	0.68	5.47	0.44	2.42e-7	Breast cancer;
TGCT	cis	rs1008375	1.000	rs917665	chr4:17668504	A/C	cg16339924	chr4:17578868	LAP3	-0.55	-4.74	-0.39	5.85e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9486719	1.000	rs6921291	chr6:97066242	C/T	cg18709589	chr6:96969512	KIAA0776	-0.75	-5.36	-0.43	4e-7	Migraine;Coronary artery disease;
TGCT	cis	rs13177918	0.629	rs2070842	chr5:149824223	T/C	cg14059543	chr5:149831962	NA	-0.71	-9.45	-0.65	2.77e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.29	-4.6	-0.38	1.03e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	trans	rs9388451	0.626	rs1343116	chr6:126069702	C/A	cg05039488	chr6:79577232	IRAK1BP1	-0.87	-9.71	-0.66	6.39e-17	Brugada syndrome;
TGCT	cis	rs72945132	0.882	rs6592552	chr11:70223831	A/T	cg00319359	chr11:70116639	PPFIA1	0.96	7.04	0.53	1.13e-10	Coronary artery disease;
TGCT	cis	rs838147	0.507	rs1704773	chr19:49209566	A/G	cg13540341	chr19:49222985	MAMSTR	-0.37	-4.98	-0.41	2.08e-6	Dietary macronutrient intake;
TGCT	cis	rs17376456	0.877	rs13185660	chr5:93336500	G/A	cg25358565	chr5:93447407	FAM172A	0.97	8.5	0.61	5.11e-14	Diabetic retinopathy;
TGCT	cis	rs10789491	1.000	rs601060	chr1:47139580	C/G	cg15501359	chr1:47185051	KIAA0494	-0.81	-8.17	-0.59	2.99e-13	Response to hepatitis C treatment;
TGCT	cis	rs5769765	0.819	rs9616379	chr22:50312035	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.43	6.08	0.48	1.35e-8	Schizophrenia;
TGCT	cis	rs1775715	0.870	rs1755084	chr10:32253709	C/T	cg14930904	chr10:32216787	ARHGAP12	0.48	4.51	0.38	1.49e-5	Bipolar disorder with mood-incongruent psychosis;
TGCT	trans	rs1974653	0.672	rs1558497	chr22:20071899	C/T	cg08822737	chr17:71088851	SLC39A11	-0.93	-7.61	-0.56	5.97e-12	Schizophrenia;
TGCT	cis	rs36051895	0.559	rs6476949	chr9:5208048	G/A	cg02405213	chr9:5042618	JAK2	-0.68	-8.65	-0.61	2.23e-14	Pediatric autoimmune diseases;
TGCT	trans	rs629535	0.814	rs614050	chr8:70065642	G/A	cg21567404	chr3:27674614	NA	0.57	9.11	0.63	1.82e-15	Dupuytren's disease;
TGCT	cis	rs6733011	0.500	rs10182043	chr2:99417433	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.48	-4.53	-0.38	1.36e-5	Bipolar disorder;
TGCT	cis	rs7582180	0.629	rs12621892	chr2:100947124	G/C	cg14675211	chr2:100938903	LONRF2	0.5	4.79	0.39	4.74e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7715806	0.500	rs2307115	chr5:74990348	T/C	cg19683494	chr5:74908142	NA	0.57	4.92	0.4	2.71e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg20607798	chr8:58055168	NA	0.45	4.66	0.39	7.88e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs11098499	0.863	rs58452170	chr4:120459674	A/T	cg09307838	chr4:120376055	NA	0.71	6.72	0.52	5.79e-10	Corneal astigmatism;
TGCT	cis	rs12477438	0.501	rs11683188	chr2:99724512	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	14.89	0.8	2.21e-29	Chronic sinus infection;
TGCT	trans	rs1814175	0.615	rs11040654	chr11:49939485	T/G	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.51	-0.69	7.2e-19	Height;
TGCT	cis	rs2956278	0.717	rs2929749	chr12:84681345	G/A	cg25678815	chr12:85673915	ALX1	-0.54	-4.83	-0.4	3.96e-6	Depressive symptoms;Depressive symptoms (multi-trait analysis);
TGCT	cis	rs796364	1.000	rs281788	chr2:200783705	A/T	cg17644776	chr2:200775616	C2orf69	0.31	4.85	0.4	3.58e-6	Schizophrenia;
TGCT	cis	rs11098499	0.954	rs6849561	chr4:120409694	C/G	cg09307838	chr4:120376055	NA	-0.71	-6.7	-0.52	6.42e-10	Corneal astigmatism;
TGCT	cis	rs556990	0.574	rs473598	chr13:113801189	C/T	cg00898013	chr13:113819073	PROZ	-0.56	-7.28	-0.55	3.39e-11	Blood protein levels;
TGCT	cis	rs9611565	0.921	rs2235846	chr22:41741042	G/C	cg03806693	chr22:41940476	POLR3H	-0.87	-9.3	-0.64	6.07e-16	Vitiligo;
TGCT	cis	rs17253792	0.822	rs78824140	chr14:56042715	G/T	cg01858014	chr14:56050164	KTN1	-0.35	-4.5	-0.37	1.53e-5	Putamen volume;
TGCT	cis	rs62380364	0.602	rs589544	chr5:88064462	T/C	cg22951263	chr5:87985283	NA	-0.59	-6.27	-0.49	5.5e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7914558	1.000	rs2275271	chr10:104814162	T/C	cg04362960	chr10:104952993	NT5C2	0.61	5.46	0.44	2.44e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs9942416	0.660	rs1817869	chr5:74989037	T/C	cg19683494	chr5:74908142	NA	0.59	6.26	0.49	5.62e-9	Age-related disease endophenotypes;
TGCT	cis	rs79349575	0.749	rs12601672	chr17:47006493	T/C	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.52	-0.38	1.44e-5	Type 2 diabetes;
TGCT	cis	rs986417	1.000	rs1072328	chr14:60876439	C/G	cg27398547	chr14:60952738	C14orf39	-1.41	-9.11	-0.63	1.75e-15	Gut microbiota (bacterial taxa);
TGCT	cis	rs7267979	0.932	rs431579	chr20:25470056	T/C	cg16686733	chr20:25566563	NINL	0.56	5.69	0.46	8.49e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9677476	0.516	rs2032953	chr2:232035793	C/T	cg27665808	chr2:232055229	NA	0.35	4.43	0.37	2.01e-5	Food antigen IgG levels;
TGCT	cis	rs317689	0.819	rs317683	chr12:69713630	T/G	cg11871910	chr12:69753446	YEATS4	0.52	4.49	0.37	1.59e-5	Response to diuretic therapy;
TGCT	cis	rs9346649	0.777	rs9346522	chr6:168490164	T/A	cg02770688	chr6:168491649	NA	-0.33	-6.18	-0.49	8.28e-9	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
TGCT	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs55823223	0.646	rs55868394	chr17:73851113	C/A	cg08125733	chr17:73851984	WBP2	0.96	6.42	0.5	2.59e-9	Psoriasis;
TGCT	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg24399712	chr22:39784796	NA	-1.07	-13.42	-0.77	6.63e-26	Intelligence (multi-trait analysis);
TGCT	cis	rs7208859	0.623	rs7212991	chr17:29143749	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg00814883	chr7:100076585	TSC22D4	-0.82	-8.23	-0.59	2.14e-13	Platelet count;
TGCT	cis	rs11107903	1.000	rs11107909	chr12:95521370	A/G	cg10621809	chr12:95840313	NA	-0.68	-5.04	-0.41	1.57e-6	Coronary artery disease;
TGCT	trans	rs10435719	0.902	rs7014580	chr8:11803262	C/G	cg15556689	chr8:8085844	FLJ10661	0.77	7.31	0.55	2.93e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs950776	0.545	rs28444683	chr15:78984507	C/A	cg21242079	chr15:79101063	ADAMTS7	-0.3	-4.94	-0.41	2.44e-6	Sudden cardiac arrest;
TGCT	cis	rs9611565	0.559	rs7290991	chr22:41964361	C/G	cg06481639	chr22:41940642	POLR3H	-0.67	-5.71	-0.46	7.87e-8	Vitiligo;
TGCT	cis	rs6582630	0.519	rs4406888	chr12:38293312	A/C	cg26384229	chr12:38710491	ALG10B	0.8	7.08	0.54	9.28e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs617219	0.737	rs1275103	chr5:78448105	C/G	cg05890484	chr5:78407552	BHMT	0.37	5.03	0.41	1.7e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs13424612	1.000	rs34849118	chr2:240919912	T/C	cg26363272	chr2:240904871	NDUFA10	0.28	4.67	0.39	7.7e-6	Odorant perception (isobutyraldehyde);
TGCT	cis	rs7945705	0.902	rs2568059	chr11:8884161	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-5.5	-0.44	2.03e-7	Hemoglobin concentration;
TGCT	cis	rs7027203	0.828	rs10122041	chr9:96615517	A/G	cg13679303	chr9:96623674	NA	-0.66	-10.78	-0.7	1.64e-19	DNA methylation (variation);
TGCT	cis	rs13191362	0.935	rs67084568	chr6:162988548	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.68	5.32	0.43	4.73e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs4076764	0.958	rs11590567	chr1:163396438	A/G	cg24596788	chr1:163392923	NA	-0.17	-4.74	-0.39	5.85e-6	Motion sickness;
TGCT	cis	rs2288073	0.965	rs10173949	chr2:24410256	A/C	cg02683114	chr2:24398427	C2orf84	-0.24	-5.72	-0.46	7.53e-8	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs3008870	1.000	rs3008856	chr1:67387901	T/C	cg11518657	chr1:67396239	MIER1	0.52	4.53	0.38	1.39e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs9916302	0.861	rs8079590	chr17:37426201	T/C	cg07936489	chr17:37558343	FBXL20	-0.62	-4.91	-0.4	2.77e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs2997447	0.846	rs61775427	chr1:26408768	G/A	cg03844060	chr1:26490628	NA	0.27	4.46	0.37	1.82e-5	QRS complex (12-leadsum);
TGCT	cis	rs1568889	0.641	rs34857148	chr11:28481976	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.68	5.25	0.43	6.39e-7	Bipolar disorder;
TGCT	cis	rs2637266	1.000	rs7073355	chr10:78354419	G/A	cg18941641	chr10:78392320	NA	0.4	5.01	0.41	1.81e-6	Pulmonary function;
TGCT	cis	rs7726839	0.540	rs72705097	chr5:655067	G/A	cg20362242	chr5:692897	TPPP	0.51	4.49	0.37	1.61e-5	Obesity-related traits;
TGCT	cis	rs2932538	0.885	rs3762335	chr1:113100548	C/T	cg22162597	chr1:113214053	CAPZA1	0.27	5.89	0.47	3.46e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs5167	0.750	rs3786505	chr19:45490570	A/G	cg09555818	chr19:45449301	APOC2	0.23	5.02	0.41	1.78e-6	Blood protein levels;
TGCT	cis	rs10986311	0.816	rs912355	chr9:127090966	T/C	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.19	4.48	0.37	1.66e-5	Vitiligo;
TGCT	cis	rs2721195	0.845	rs3757966	chr8:145744618	G/A	cg17328964	chr8:145687451	CYHR1	-0.44	-6.25	-0.49	6.15e-9	Age at first birth;
TGCT	cis	rs3008870	0.583	rs11208978	chr1:67442210	C/T	cg11518657	chr1:67396239	MIER1	-0.6	-4.76	-0.39	5.32e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs908922	0.676	rs1572533	chr1:152509742	T/C	cg20991723	chr1:152506922	NA	0.46	6.18	0.48	8.66e-9	Hair morphology;
TGCT	trans	rs10506458	0.915	rs12423078	chr12:63397529	C/T	cg22491629	chr6:157744540	C6orf35	-0.99	-8.55	-0.61	3.94e-14	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg20999797	chr1:1681921	NA	0.18	4.69	0.39	7.02e-6	Body mass index;
TGCT	cis	rs611744	0.967	rs637358	chr8:109197454	C/T	cg21045802	chr8:109455806	TTC35	0.5	4.5	0.37	1.53e-5	Dupuytren's disease;
TGCT	cis	rs4076764	0.958	rs11584957	chr1:163392937	C/T	cg24596788	chr1:163392923	NA	-0.16	-4.68	-0.39	7.43e-6	Motion sickness;
TGCT	cis	rs12118280	0.921	rs72693452	chr1:108740482	G/A	cg11967332	chr1:108735228	SLC25A24	0.39	5.44	0.44	2.74e-7	Myeloid white cell count;
TGCT	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg04944784	chr2:26401820	FAM59B	-0.68	-6.13	-0.48	1.1e-8	Gut microbiome composition (summer);
TGCT	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6570726	0.791	rs401561	chr6:145835917	G/T	cg23711669	chr6:146136114	FBXO30	0.89	9.72	0.66	6.02e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1797081	0.934	rs1797077	chr10:16853252	C/T	cg23933602	chr10:16859644	RSU1	0.97	11.35	0.71	6.47e-21	Platelet distribution width;
TGCT	cis	rs6087990	0.899	rs6087999	chr20:31363774	A/G	cg13636640	chr20:31349939	DNMT3B	1.11	14.99	0.8	1.29e-29	Ulcerative colitis;
TGCT	cis	rs6570726	0.818	rs412350	chr6:145852409	T/C	cg23711669	chr6:146136114	FBXO30	0.86	9.53	0.65	1.77e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4700695	0.614	rs371246	chr5:65209126	G/A	cg21114390	chr5:65439923	SFRS12	0.67	4.69	0.39	7.07e-6	Facial morphology (factor 19);
TGCT	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg24675658	chr1:53192096	ZYG11B	0.7	7.98	0.58	8.42e-13	Monocyte count;
TGCT	cis	rs7726839	0.540	rs72705097	chr5:655067	G/A	cg09021430	chr5:549028	NA	-0.45	-6.27	-0.49	5.56e-9	Obesity-related traits;
TGCT	cis	rs514406	0.758	rs532242	chr1:53308665	C/G	cg25767906	chr1:53392781	SCP2	-0.51	-5.78	-0.46	5.71e-8	Monocyte count;
TGCT	cis	rs1865760	1.000	rs3799372	chr6:25922311	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.65	6.21	0.49	7.42e-9	Height;
TGCT	cis	rs7923452	0.938	rs34560372	chr10:30773831	G/A	cg18806716	chr10:30721971	MAP3K8	0.7	6.23	0.49	6.55e-9	Itch intensity from mosquito bite;
TGCT	cis	rs28595532	0.920	rs115797971	chr4:119779620	A/G	cg14228332	chr4:119757509	SEC24D	1.26	7.08	0.54	9.26e-11	Cannabis dependence symptom count;
TGCT	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg04414720	chr1:150670196	GOLPH3L	0.39	5.04	0.41	1.58e-6	Tonsillectomy;
TGCT	cis	rs12643440	0.503	rs34795372	chr4:17142116	T/C	cg22650099	chr4:17144496	NA	-0.46	-4.7	-0.39	6.79e-6	Metabolite levels (Pyroglutamine);
TGCT	cis	rs9486715	0.867	rs9372106	chr6:96875058	T/C	cg06623918	chr6:96969491	KIAA0776	1.09	15.47	0.81	1.02e-30	Headache;
TGCT	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg18876405	chr7:65276391	NA	-0.34	-5.09	-0.42	1.27e-6	Aortic root size;
TGCT	cis	rs9535307	0.615	rs3736830	chr13:50306221	G/C	cg03651054	chr13:50194643	NA	0.37	4.49	0.37	1.61e-5	Obesity-related traits;
TGCT	cis	rs6815814	0.898	rs1106956	chr4:38889811	A/G	cg02016764	chr4:38805732	TLR1	-0.35	-5.31	-0.43	4.95e-7	Breast cancer;
TGCT	cis	rs13064411	0.542	rs9877649	chr3:113226874	C/T	cg18753928	chr3:113234510	CCDC52	-0.56	-4.72	-0.39	6.3e-6	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs1163251	0.902	rs639761	chr1:120217558	G/A	cg19096424	chr1:120255104	PHGDH	0.56	5.29	0.43	5.46e-7	Blood metabolite levels;
TGCT	cis	rs7829975	0.617	rs4841071	chr8:8791144	G/T	cg06636001	chr8:8085503	FLJ10661	0.69	6.55	0.51	1.35e-9	Mood instability;
TGCT	cis	rs16958440	0.867	rs12386092	chr18:44672058	C/T	cg17192377	chr18:44677553	HDHD2	0.63	4.7	0.39	6.74e-6	Sitting height ratio;
TGCT	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg15383120	chr6:291909	DUSP22	-0.67	-6.91	-0.53	2.3e-10	Menopause (age at onset);
TGCT	cis	rs7715806	0.500	rs72633984	chr5:75005899	A/G	cg19683494	chr5:74908142	NA	0.57	5.02	0.41	1.76e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs3015497	0.967	rs3015483	chr14:51137474	C/G	cg04730355	chr14:51134070	SAV1	-0.53	-4.64	-0.38	8.78e-6	Mean platelet volume;
TGCT	cis	rs7829975	0.577	rs17684466	chr8:8545233	G/A	cg15556689	chr8:8085844	FLJ10661	-0.53	-4.5	-0.37	1.53e-5	Mood instability;
TGCT	cis	rs72945132	0.882	rs11235755	chr11:70136323	A/G	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs10746514	1.000	rs10864715	chr1:232243817	G/A	cg09506761	chr1:232265262	NA	0.54	5.49	0.44	2.13e-7	Response to statin therapy;
TGCT	cis	rs11673344	0.504	rs2595555	chr19:37491121	C/T	cg08039142	chr19:36980659	ZNF566	0.59	5.58	0.45	1.41e-7	Obesity-related traits;
TGCT	cis	rs9677476	0.516	rs6746156	chr2:231967210	A/G	cg27665808	chr2:232055229	NA	0.37	4.68	0.39	7.25e-6	Food antigen IgG levels;
TGCT	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.04	0.53	1.16e-10	Prudent dietary pattern;
TGCT	cis	rs10510102	0.748	rs11200297	chr10:123732431	A/G	cg23691251	chr10:123688108	ATE1	-0.72	-5.21	-0.42	7.69e-7	Breast cancer;
TGCT	cis	rs2242116	0.592	rs2290545	chr3:46967040	C/T	cg27129171	chr3:47204927	SETD2	0.58	4.96	0.41	2.26e-6	Birth weight;
TGCT	cis	rs6912958	0.559	rs242279	chr6:88048191	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.47	6.29	0.49	5.04e-9	Monocyte percentage of white cells;
TGCT	cis	rs1056107	0.541	rs2150258	chr9:115174608	T/C	cg02332936	chr9:115140584	NA	-0.27	-4.59	-0.38	1.09e-5	Colorectal cancer;
TGCT	cis	rs986417	0.901	rs11158292	chr14:61043183	G/T	cg18240143	chr14:60952599	C14orf39	0.88	4.78	0.39	4.84e-6	Gut microbiota (bacterial taxa);
TGCT	cis	rs12048904	0.505	rs6577209	chr1:101255080	A/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.68	5.42	0.44	2.99e-7	Multiple sclerosis;
TGCT	cis	rs6088580	0.634	rs6059892	chr20:33105766	A/G	cg08999081	chr20:33150536	PIGU	0.29	5.57	0.45	1.54e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg07424592	chr7:64974309	NA	1.35	7.66	0.57	4.49e-12	Diabetic kidney disease;
TGCT	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg17554472	chr22:41940697	POLR3H	-0.48	-5.1	-0.42	1.26e-6	Vitiligo;
TGCT	cis	rs11098499	0.863	rs2306456	chr4:120472422	C/G	cg09307838	chr4:120376055	NA	0.72	6.9	0.53	2.41e-10	Corneal astigmatism;
TGCT	cis	rs2657888	0.965	rs67036743	chr12:56948786	C/A	cg23932658	chr12:57637574	STAC3	-0.53	-4.71	-0.39	6.4e-6	Adiponectin levels;
TGCT	cis	rs7772486	0.686	rs1569540	chr6:146069112	A/G	cg05347473	chr6:146136440	FBXO30	-0.49	-4.52	-0.38	1.42e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7666738	0.546	rs1456207	chr4:98676911	G/A	cg17366294	chr4:99064904	C4orf37	0.58	5.36	0.43	3.87e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3008870	0.816	rs1118392	chr1:67366549	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.83	-9.16	-0.64	1.32e-15	Lymphocyte percentage of white cells;
TGCT	cis	rs7923452	0.507	rs215494	chr10:30776589	T/G	cg18806716	chr10:30721971	MAP3K8	-0.61	-7.41	-0.55	1.69e-11	Itch intensity from mosquito bite;
TGCT	cis	rs9653442	0.648	rs6733895	chr2:100666082	C/G	cg22139774	chr2:100720529	AFF3	-0.42	-7.51	-0.56	9.98e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs7927592	0.513	rs689075	chr11:68194432	A/C	cg16797656	chr11:68205561	LRP5	0.29	5.19	0.42	8.33e-7	Total body bone mineral density;
TGCT	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg14827481	chr10:134361889	INPP5A	0.29	4.67	0.39	7.64e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs4906332	1.000	rs55731474	chr14:103878481	G/A	cg26031613	chr14:104095156	KLC1	-0.5	-4.45	-0.37	1.86e-5	Coronary artery disease;
TGCT	cis	rs57221529	0.766	rs72704799	chr5:551457	C/G	cg09021430	chr5:549028	NA	-0.4	-5.14	-0.42	1.02e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs7635838	0.565	rs347592	chr3:11248656	T/C	cg00170343	chr3:11313890	ATG7	0.6	5.62	0.45	1.18e-7	HDL cholesterol;
TGCT	cis	rs7582180	0.591	rs2241810	chr2:101011877	T/C	cg08017756	chr2:100939284	LONRF2	-0.3	-4.73	-0.39	6.02e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs8068544	0.818	rs78333491	chr17:40163138	A/G	cg13092355	chr17:39992602	KLHL10;NT5C3L	-0.95	-4.55	-0.38	1.24e-5	Reticulocyte fraction of red cells;Reticulocyte count;
TGCT	cis	rs13217239	0.646	rs10946897	chr6:26995251	A/C	cg05738196	chr6:26577821	NA	0.49	4.75	0.39	5.45e-6	Schizophrenia;
TGCT	cis	rs7113874	0.569	rs10769916	chr11:8598214	G/A	cg14521421	chr11:8862019	ST5	0.28	4.44	0.37	1.96e-5	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg11494091	chr17:61959527	GH2	-0.6	-15.93	-0.82	8.72e-32	Prudent dietary pattern;
TGCT	cis	rs13242816	1.000	rs36004201	chr7:116126310	C/A	cg02799643	chr7:116139180	CAV2	-0.45	-5.46	-0.44	2.49e-7	P wave duration;
TGCT	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg06558623	chr16:89946397	TCF25	-0.45	-4.5	-0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs1564271	0.528	rs2209350	chr10:26987779	A/G	cg24343755	chr10:26987087	PDSS1	-0.52	-4.58	-0.38	1.12e-5	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
TGCT	cis	rs12765878	0.557	rs10883928	chr10:105615074	C/T	cg11005552	chr10:105648138	OBFC1	-0.39	-6.06	-0.48	1.54e-8	Coronary artery disease;
TGCT	cis	rs941873	0.835	rs4246944	chr10:81105684	C/T	cg09469691	chr10:81107165	PPIF	0.56	5.54	0.45	1.71e-7	Height;
TGCT	cis	rs3733585	0.648	rs7378305	chr4:9954893	C/T	cg00071950	chr4:10020882	SLC2A9	-0.57	-6.75	-0.52	5.09e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg04608855	chr19:58913158	NA	0.58	5.76	0.46	6.36e-8	Uric acid clearance;
TGCT	cis	rs9926296	0.715	rs467035	chr16:89740285	C/G	cg04287289	chr16:89883240	FANCA	0.47	4.46	0.37	1.8e-5	Vitiligo;
TGCT	cis	rs453301	0.657	rs36056437	chr8:8792865	T/G	cg06636001	chr8:8085503	FLJ10661	-0.64	-5.33	-0.43	4.51e-7	Joint mobility (Beighton score);
TGCT	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg11941060	chr3:133502564	NA	-0.29	-6.15	-0.48	9.6e-9	Iron status biomarkers;
TGCT	cis	rs10782582	0.593	rs115291524	chr1:76141811	A/G	cg03433033	chr1:76189801	ACADM	-0.64	-7.25	-0.55	3.84e-11	Daytime sleep phenotypes;
TGCT	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg09365446	chr1:150670422	GOLPH3L	0.31	4.64	0.38	8.7e-6	Tonsillectomy;
TGCT	cis	rs6964587	0.904	rs2023785	chr7:91547369	C/A	cg17063962	chr7:91808500	NA	-0.86	-9.28	-0.64	6.82e-16	Breast cancer;
TGCT	cis	rs3806843	0.576	rs246003	chr5:140340865	C/G	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs40363	0.857	rs55989968	chr16:3530658	C/G	cg22508957	chr16:3507546	NAT15	0.54	5.04	0.41	1.59e-6	Tuberculosis;
TGCT	cis	rs1150668	0.796	rs213237	chr6:28323938	T/C	cg19488431	chr6:28601329	NA	0.2	4.44	0.37	1.99e-5	Pubertal anthropometrics;
TGCT	trans	rs7726839	0.540	rs72703083	chr5:595365	C/T	cg25482853	chr8:67687455	SGK3	1.27	10.56	0.69	5.48e-19	Obesity-related traits;
TGCT	cis	rs317689	0.690	rs595348	chr12:69638610	T/C	cg11871910	chr12:69753446	YEATS4	0.53	4.47	0.37	1.77e-5	Response to diuretic therapy;
TGCT	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg17054783	chr10:134559939	INPP5A	0.26	5.0	0.41	1.94e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs1205863	1.000	rs1205884	chr6:11947933	A/G	cg07106625	chr6:11870215	NA	-0.51	-5.05	-0.41	1.51e-6	Disc degeneration (lumbar);
TGCT	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg03732007	chr1:2071316	PRKCZ	0.28	6.76	0.52	4.87e-10	Height;
TGCT	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg23758822	chr17:41437982	NA	0.72	6.81	0.52	3.83e-10	Menopause (age at onset);
TGCT	cis	rs2836950	0.520	rs8133927	chr21:40689961	G/T	cg06238570	chr21:40685208	BRWD1	-0.63	-6.31	-0.49	4.41e-9	Menarche (age at onset);
TGCT	cis	rs7267979	0.966	rs8123949	chr20:25388133	C/T	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3812831	0.695	rs7983872	chr13:114944781	T/G	cg15513719	chr13:114904418	NA	0.37	4.64	0.38	8.77e-6	Schizophrenia;
TGCT	cis	rs3784262	1.000	rs10851631	chr15:58242193	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.47	-7.12	-0.54	7.85e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs35306767	0.761	rs34480046	chr10:1027440	A/G	cg20503657	chr10:835505	NA	0.59	6.67	0.51	7.75e-10	Eosinophil percentage of granulocytes;
TGCT	cis	rs7666738	0.712	rs34043080	chr4:99008748	G/C	cg17366294	chr4:99064904	C4orf37	0.68	6.92	0.53	2.11e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs875971	0.965	rs697968	chr7:65535033	G/A	cg18876405	chr7:65276391	NA	-0.35	-5.19	-0.42	8.26e-7	Aortic root size;
TGCT	cis	rs35306767	0.761	rs12770173	chr10:1027108	A/C	cg18964960	chr10:1102726	WDR37	0.74	5.31	0.43	4.97e-7	Eosinophil percentage of granulocytes;
TGCT	cis	rs986417	1.000	rs1033733	chr14:60932438	G/T	cg27398547	chr14:60952738	C14orf39	1.49	10.81	0.7	1.38e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs9486719	0.895	rs34051754	chr6:97007754	A/T	cg18709589	chr6:96969512	KIAA0776	-0.74	-5.21	-0.42	7.5e-7	Migraine;Coronary artery disease;
TGCT	cis	rs2486288	0.656	rs1060896	chr15:45554267	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.76	-7.83	-0.58	1.85e-12	Glomerular filtration rate;
TGCT	cis	rs7523050	0.643	rs7519293	chr1:109399543	A/G	cg08274380	chr1:109419600	GPSM2	1.3	6.39	0.5	2.99e-9	Fat distribution (HIV);
TGCT	cis	rs2249625	0.523	rs2496501	chr6:72885364	A/G	cg08500200	chr6:72892038	RIMS1	-0.42	-4.54	-0.38	1.33e-5	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
TGCT	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg21963583	chr11:68658836	MRPL21	0.36	6.04	0.48	1.64e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs11148252	0.538	rs3368	chr13:52707240	C/G	cg00495681	chr13:53174319	NA	0.57	5.86	0.47	3.84e-8	Lewy body disease;
TGCT	cis	rs1018836	0.923	rs13267989	chr8:91581648	C/T	cg16814680	chr8:91681699	NA	-0.86	-9.06	-0.63	2.36e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7104764	1.000	rs76552490	chr11:212015	G/A	cg18336825	chr11:236787	PSMD13;SIRT3	-1.02	-10.54	-0.69	6.26e-19	Menarche (age at onset);
TGCT	cis	rs344364	0.511	rs337284	chr16:1954799	A/C	cg26617929	chr16:1858877	NA	-0.25	-4.48	-0.37	1.69e-5	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs7226408	0.857	rs72888992	chr18:34572381	C/T	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs12220238	1.000	rs11000900	chr10:75918440	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.88	7.24	0.55	4.04e-11	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs3796352	1.000	rs35720014	chr3:52982110	A/C	cg15956490	chr3:53032818	SFMBT1	0.61	6.11	0.48	1.17e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs1801251	1.000	rs6437074	chr2:233712296	C/T	cg25237894	chr2:233734115	C2orf82	-0.33	-5.88	-0.47	3.63e-8	Coronary artery disease;
TGCT	cis	rs11642862	0.901	rs76345698	chr16:30946165	G/A	cg01031475	chr16:30004376	HIRIP3	0.23	4.54	0.38	1.34e-5	Tonsillectomy;
TGCT	cis	rs17741873	0.943	rs11000802	chr10:75654167	C/G	cg07699608	chr10:75541558	CHCHD1	0.76	5.73	0.46	7.07e-8	Paclitaxel disposition in epithelial ovarian cancer;
TGCT	cis	rs78487399	0.634	rs6751035	chr2:43752407	G/A	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.78	4.8	0.4	4.5e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs111326718	1	rs111326718	chr10:104771211	A/AAAAAT	cg15744005	chr10:104629667	AS3MT	-0.4	-4.97	-0.41	2.21e-6	Reticulocyte count;
TGCT	cis	rs9308731	0.623	rs2241844	chr2:111879364	C/T	cg04202892	chr2:111875749	ACOXL	0.54	6.25	0.49	6.1e-9	Chronic lymphocytic leukemia;
TGCT	cis	rs245880	0.740	rs245887	chr7:29190408	G/A	cg17163760	chr7:29186267	CPVL	-0.44	-5.54	-0.45	1.73e-7	Warfarin maintenance dose;
TGCT	cis	rs10186029	0.676	rs12614406	chr2:213955803	A/G	cg08319019	chr2:214017104	IKZF2	-0.62	-5.8	-0.46	5.14e-8	Systemic sclerosis;
TGCT	cis	rs1670533	1.000	rs651017	chr4:1091062	A/G	cg27284194	chr4:1044797	NA	0.63	5.18	0.42	8.8e-7	Recombination rate (females);
TGCT	cis	rs2302464	0.661	rs6822515	chr4:15743194	C/A	cg16359663	chr4:15503662	CC2D2A	-0.37	-4.95	-0.41	2.41e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs7208859	0.623	rs11652533	chr17:29060601	A/C	cg14008862	chr17:28927542	LRRC37B2	0.77	4.59	0.38	1.08e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7249142	0.562	rs10854009	chr19:19284705	A/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.33	-4.51	-0.38	1.48e-5	IgG glycosylation;
TGCT	cis	rs4888262	0.526	rs7193508	chr16:74628630	G/T	cg01733217	chr16:74700730	RFWD3	0.74	7.42	0.55	1.6e-11	Testicular germ cell tumor;
TGCT	cis	rs7103648	0.669	rs7114011	chr11:47811309	A/C	cg20307385	chr11:47447363	PSMC3	0.78	7.51	0.56	1.02e-11	Diastolic blood pressure;Systolic blood pressure;
TGCT	cis	rs1493935	0.667	rs3133581	chr8:119826164	G/T	cg17171407	chr8:119960777	TNFRSF11B	-0.24	-4.46	-0.37	1.82e-5	Eosinophil percentage of white cells;
TGCT	cis	rs600231	0.708	rs1784860	chr11:65240712	C/A	cg17120908	chr11:65337727	SSSCA1	-0.55	-5.14	-0.42	1.03e-6	Bone mineral density;
TGCT	trans	rs1814175	0.935	rs7479914	chr11:49661351	T/C	cg15704280	chr7:45808275	SEPT13	-0.61	-6.78	-0.52	4.28e-10	Height;
TGCT	cis	rs1215050	0.791	rs2695472	chr4:98855127	T/C	cg17366294	chr4:99064904	C4orf37	-0.57	-6.12	-0.48	1.13e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7666738	0.830	rs13112131	chr4:98976784	G/A	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg04287289	chr16:89883240	FANCA	0.94	11.7	0.72	9.44e-22	Vitiligo;
TGCT	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg09359103	chr1:154839909	KCNN3	-0.69	-12.94	-0.76	9.12e-25	Prostate cancer;
TGCT	cis	rs908922	0.676	rs1123567	chr1:152516023	G/A	cg20991723	chr1:152506922	NA	0.47	6.34	0.49	3.9e-9	Hair morphology;
TGCT	cis	rs12701220	0.520	rs7803208	chr7:1162084	C/T	cg04025307	chr7:1156635	C7orf50	0.23	4.57	0.38	1.16e-5	Bronchopulmonary dysplasia;
TGCT	cis	rs73198271	0.737	rs535094	chr8:8633928	A/G	cg06636001	chr8:8085503	FLJ10661	-0.6	-4.45	-0.37	1.92e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs2456568	0.802	rs1395386	chr11:93639331	A/G	cg16099599	chr11:93583650	C11orf90	0.39	4.86	0.4	3.53e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg22535103	chr8:58192502	C8orf71	-0.42	-4.85	-0.4	3.69e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1891275	0.515	rs2421694	chr10:93516104	A/G	cg07889827	chr10:93443413	NA	-0.32	-6.8	-0.52	3.95e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs3820068	0.705	rs16851731	chr1:15860240	A/G	cg05660106	chr1:15850417	CASP9	1.16	14.71	0.8	5.81e-29	Systolic blood pressure;
TGCT	cis	rs9527	1.000	rs4919690	chr10:104616500	C/T	cg15744005	chr10:104629667	AS3MT	0.52	6.38	0.5	3.19e-9	Arsenic metabolism;
TGCT	cis	rs778371	0.671	rs13008436	chr2:233719948	C/T	cg08000102	chr2:233561755	GIGYF2	-0.67	-7.37	-0.55	2.13e-11	Schizophrenia;
TGCT	cis	rs9828933	0.577	rs704374	chr3:63865947	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.75	4.52	0.38	1.41e-5	Type 2 diabetes;
TGCT	cis	rs6424115	0.830	rs6680132	chr1:24198804	T/C	cg15997130	chr1:24165203	NA	0.85	9.26	0.64	7.92e-16	Immature fraction of reticulocytes;
TGCT	cis	rs611744	0.967	rs677842	chr8:109212468	A/G	cg21045802	chr8:109455806	TTC35	0.52	4.72	0.39	6.21e-6	Dupuytren's disease;
TGCT	cis	rs28927680	0.655	rs11820589	chr11:116633862	G/A	cg20660624	chr11:117307972	DSCAML1	-0.36	-4.62	-0.38	9.31e-6	Lipid traits;Triglycerides;
TGCT	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg17054783	chr10:134559939	INPP5A	0.25	5.02	0.41	1.75e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	trans	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg21659725	chr3:3221576	CRBN	0.76	9.35	0.64	4.85e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs4805272	0.539	rs1075733	chr19:29324460	C/T	cg04546413	chr19:29218101	NA	0.72	4.97	0.41	2.16e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
TGCT	cis	rs12620999	0.878	rs7593514	chr2:237980691	A/G	cg23555395	chr2:238036564	NA	0.26	4.72	0.39	6.19e-6	Systemic lupus erythematosus;
TGCT	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	16.07	0.82	4.16e-32	Prudent dietary pattern;
TGCT	cis	rs17534004	1.000	rs17534109	chr13:31470937	C/G	cg13251181	chr13:31481184	C13orf33	-0.34	-4.48	-0.37	1.65e-5	3-hydroxypropylmercapturic acid levels in smokers;
TGCT	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9926296	0.656	rs2376883	chr16:89826926	A/G	cg08627397	chr16:89984028	MC1R	-0.29	-4.55	-0.38	1.26e-5	Vitiligo;
TGCT	cis	rs6866344	0.697	rs17184302	chr5:178127676	C/T	cg03877680	chr5:178157825	ZNF354A	0.72	5.61	0.45	1.27e-7	Neutrophil percentage of white cells;
TGCT	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg06873352	chr17:61820015	STRADA	0.49	5.47	0.44	2.33e-7	Prudent dietary pattern;
TGCT	cis	rs9467711	0.651	rs72834677	chr6:26106604	C/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.57	-4.54	-0.38	1.33e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7769051	0.522	rs60631157	chr6:133094817	G/A	cg07930552	chr6:133119739	C6orf192	1.21	4.81	0.4	4.24e-6	Type 2 diabetes nephropathy;
TGCT	cis	rs7666738	0.830	rs11097598	chr4:98946057	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg08859206	chr1:53392774	SCP2	-0.44	-6.52	-0.51	1.63e-9	Monocyte count;
TGCT	cis	rs2762353	0.574	rs9467570	chr6:25699283	C/A	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.75	7.79	0.57	2.32e-12	Blood metabolite levels;
TGCT	cis	rs17384381	0.953	rs12130145	chr1:85828970	G/C	cg16011679	chr1:85725395	C1orf52	0.86	6.57	0.51	1.25e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7599312	0.534	rs10182996	chr2:213404834	T/C	cg16329650	chr2:213403929	ERBB4	1.06	16.47	0.83	5.13e-33	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs17376456	0.825	rs13171131	chr5:93223028	C/T	cg21475434	chr5:93447410	FAM172A	0.7	4.86	0.4	3.51e-6	Diabetic retinopathy;
TGCT	cis	rs6547741	0.935	rs4666004	chr2:27855052	T/A	cg27432699	chr2:27873401	GPN1	0.19	4.55	0.38	1.28e-5	Oral cavity cancer;
TGCT	trans	rs7819412	0.511	rs2409799	chr8:11435927	G/C	cg15556689	chr8:8085844	FLJ10661	-0.77	-7.17	-0.54	6.04e-11	Triglycerides;
TGCT	cis	rs12893668	0.703	rs2274267	chr14:104029449	G/A	cg26031613	chr14:104095156	KLC1	-0.53	-4.43	-0.37	2.01e-5	Reticulocyte count;
TGCT	cis	rs2797160	0.967	rs926854	chr6:126021780	A/G	cg05901451	chr6:126070800	HEY2	0.74	6.21	0.49	7.18e-9	Endometrial cancer;
TGCT	cis	rs13064411	0.627	rs9872168	chr3:113233132	A/C	cg18753928	chr3:113234510	CCDC52	-0.7	-5.68	-0.45	9.16e-8	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs17473412	0.609	rs6595457	chr5:122867333	T/C	cg15125798	chr5:122621645	NA	-0.53	-4.9	-0.4	2.93e-6	Total body bone mineral density;
TGCT	cis	rs9807841	0.670	rs2738042	chr19:10790143	C/G	cg17848348	chr19:10766748	ILF3	-0.4	-4.58	-0.38	1.12e-5	Inflammatory skin disease;
TGCT	cis	rs13242816	1.000	rs35800921	chr7:116124041	G/A	cg16553024	chr7:116138462	CAV2	-0.44	-4.59	-0.38	1.05e-5	P wave duration;
TGCT	cis	rs12484776	0.786	rs17323591	chr22:40534211	T/A	cg07138101	chr22:40742427	ADSL	0.61	4.6	0.38	1.01e-5	Uterine fibroids;
TGCT	cis	rs61990749	0.597	rs10142722	chr14:78275549	A/T	cg23188588	chr14:78226832	SNW1;C14orf178	0.7	4.86	0.4	3.53e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs1505368	0.837	rs10167244	chr2:213281310	A/G	cg20637307	chr2:213403960	ERBB4	0.5	4.97	0.41	2.15e-6	Symmetrical dimethylarginine levels;
TGCT	cis	rs7809950	1.000	rs2712215	chr7:107188207	A/G	cg23024343	chr7:107201750	COG5	-0.35	-5.4	-0.44	3.21e-7	Coronary artery disease;
TGCT	cis	rs422249	0.512	rs174583	chr11:61609750	A/G	cg01500311	chr11:61656094	FADS3	0.29	4.91	0.4	2.78e-6	Trans fatty acid levels;
TGCT	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg11764359	chr7:65958608	NA	0.61	5.53	0.44	1.79e-7	Aortic root size;
TGCT	cis	rs9952991	0.941	rs2847278	chr18:12778715	C/T	cg24737193	chr18:12778029	NA	0.54	6.03	0.48	1.76e-8	Inflammatory skin disease;
TGCT	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg04772025	chr11:68637568	NA	0.61	6.7	0.52	6.38e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9894429	1.000	rs9674872	chr17:79581931	T/A	cg18240062	chr17:79603768	NPLOC4	0.67	6.84	0.52	3.23e-10	Eye color traits;
TGCT	cis	rs910316	1.000	rs175449	chr14:75590846	A/T	cg08847533	chr14:75593920	NEK9	-0.94	-10.33	-0.68	2.03e-18	Height;
TGCT	cis	rs9914544	0.564	rs9906799	chr17:18795317	A/G	cg26378065	chr17:18585709	ZNF286B	0.53	4.63	0.38	9.01e-6	Educational attainment (years of education);
TGCT	cis	rs56104184	0.725	rs1466896	chr19:49385253	C/G	cg17863274	chr19:49399704	TULP2	-0.54	-7.43	-0.55	1.58e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs7193541	1.000	rs7193541	chr16:74664743	C/T	cg01733217	chr16:74700730	RFWD3	-0.71	-7.18	-0.54	5.58e-11	Multiple myeloma;
TGCT	cis	rs12765878	1.000	rs3814220	chr10:105647300	A/G	cg11005552	chr10:105648138	OBFC1	0.44	7.69	0.57	4.01e-12	Coronary artery disease;
TGCT	cis	rs4803468	1.000	rs284649	chr19:41926838	C/T	cg09537434	chr19:41945824	ATP5SL	-0.92	-10.57	-0.69	5.19e-19	Height;
TGCT	cis	rs8177253	0.511	rs9830001	chr3:133433470	A/G	cg08048268	chr3:133502702	NA	0.47	6.04	0.48	1.7e-8	Iron status biomarkers;
TGCT	cis	rs6893807	0.778	rs7703782	chr5:87938557	A/T	cg24804195	chr5:87968844	LOC645323	0.8	4.7	0.39	6.85e-6	Body mass index;
TGCT	cis	rs6570726	0.738	rs4495284	chr6:145916617	T/A	cg23711669	chr6:146136114	FBXO30	0.88	9.32	0.64	5.56e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7178424	0.840	rs4774427	chr15:62217444	T/C	cg00456672	chr15:62358751	C2CD4A	0.32	4.73	0.39	5.96e-6	Height;
TGCT	cis	rs7824557	0.602	rs11784544	chr8:11204503	G/C	cg21775007	chr8:11205619	TDH	0.72	7.02	0.53	1.27e-10	Retinal vascular caliber;
TGCT	cis	rs11627546	0.528	rs61980574	chr14:70363324	T/C	cg10496350	chr14:71275911	MAP3K9	-0.98	-4.89	-0.4	3.03e-6	Red blood cell traits;
TGCT	cis	rs7267979	1.000	rs422844	chr20:25445591	T/C	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2404602	0.735	rs62028423	chr15:76754514	G/A	cg22467129	chr15:76604101	ETFA	0.49	5.1	0.42	1.24e-6	Blood metabolite levels;
TGCT	cis	rs2458413	0.933	rs2669450	chr8:105371752	C/T	cg04554929	chr8:105342491	NA	0.56	8.06	0.59	5.53e-13	Paget's disease;
TGCT	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg18876405	chr7:65276391	NA	0.33	4.95	0.41	2.39e-6	Aortic root size;
TGCT	cis	rs611744	0.967	rs584716	chr8:109178634	A/T	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs2887571	0.738	rs11613149	chr12:1637676	G/A	cg01940102	chr12:1095972	NA	0.26	4.78	0.39	4.92e-6	Bone mineral density;
TGCT	cis	rs10746514	0.804	rs1854822	chr1:232262270	G/C	cg09506761	chr1:232265262	NA	-0.49	-4.99	-0.41	2.01e-6	Response to statin therapy;
TGCT	cis	rs7681440	0.647	rs11941110	chr4:90819569	T/C	cg10208370	chr4:90758469	SNCA	-0.57	-5.4	-0.44	3.23e-7	Dementia with Lewy bodies;
TGCT	cis	rs36051895	0.695	rs7043489	chr9:5023604	A/C	cg02405213	chr9:5042618	JAK2	-0.81	-11.27	-0.71	1.03e-20	Pediatric autoimmune diseases;
TGCT	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg07870213	chr5:140052090	DND1	-0.62	-7.4	-0.55	1.84e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs17345786	1.000	rs7641261	chr3:101279006	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.85	8.66	0.61	2.16e-14	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs36051895	0.632	rs966871	chr9:5121070	A/T	cg02405213	chr9:5042618	JAK2	-0.76	-10.67	-0.69	2.98e-19	Pediatric autoimmune diseases;
TGCT	cis	rs11828289	0.660	rs17306426	chr11:23222079	G/T	cg20040320	chr11:23191996	NA	0.54	4.51	0.38	1.46e-5	Cancer;
TGCT	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.63	0.38	9.2e-6	Prudent dietary pattern;
TGCT	cis	rs908922	0.676	rs1001834	chr1:152495940	C/A	cg20991723	chr1:152506922	NA	0.46	6.26	0.49	5.7e-9	Hair morphology;
TGCT	cis	rs17169807	1.000	rs17170178	chr7:33349225	T/A	cg06206957	chr7:33080615	NT5C3	0.32	4.44	0.37	1.97e-5	Smooth-surface caries;
TGCT	cis	rs11718455	1.000	rs4682928	chr3:44037192	T/C	cg08738300	chr3:44038990	NA	0.86	6.57	0.51	1.23e-9	Coronary artery disease;
TGCT	cis	rs2153535	0.580	rs986060	chr6:8465428	T/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs9467711	1.000	rs6923139	chr6:26313348	C/T	cg26531700	chr6:26746687	NA	-0.94	-5.09	-0.42	1.28e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs71597109	0.639	rs66638185	chr4:102729417	T/C	cg14855874	chr4:102712397	BANK1	0.42	4.72	0.39	6.29e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg13866156	chr1:1669148	SLC35E2	-0.23	-5.53	-0.44	1.8e-7	Body mass index;
TGCT	cis	rs12148488	0.763	rs12900072	chr15:75307148	G/A	cg10253484	chr15:75165896	SCAMP2	-0.6	-5.23	-0.43	6.95e-7	Caffeine consumption;
TGCT	cis	rs2439831	1.000	rs2467743	chr15:43750346	T/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.81	5.66	0.45	9.81e-8	Lung cancer in ever smokers;
TGCT	cis	rs79149102	0.579	rs73436579	chr15:75294514	C/T	cg09165964	chr15:75287851	SCAMP5	-1.04	-5.71	-0.46	7.93e-8	Lung cancer;
TGCT	cis	rs17376456	0.877	rs10055741	chr5:93297187	C/T	cg21475434	chr5:93447410	FAM172A	0.65	4.87	0.4	3.26e-6	Diabetic retinopathy;
TGCT	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg05368731	chr17:41323189	NBR1	1.2	14.59	0.79	1.08e-28	Menopause (age at onset);
TGCT	cis	rs7552404	1.000	rs4949875	chr1:76173080	G/A	cg10523679	chr1:76189770	ACADM	0.91	9.92	0.67	2.01e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9796	0.866	rs2928148	chr15:41401550	G/A	cg18705301	chr15:41695430	NDUFAF1	0.47	6.09	0.48	1.34e-8	Menopause (age at onset);
TGCT	cis	rs17102423	0.826	rs12887607	chr14:65596887	G/A	cg11161011	chr14:65562177	MAX	-0.57	-7.71	-0.57	3.46e-12	Obesity-related traits;
TGCT	cis	rs921968	0.643	rs532475	chr2:219434208	C/T	cg02176678	chr2:219576539	TTLL4	0.44	6.33	0.49	4.17e-9	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs72627509	0.680	rs66790703	chr4:57773908	G/A	cg26694713	chr4:57773883	REST	0.72	6.46	0.5	2.14e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg11764359	chr7:65958608	NA	0.55	5.08	0.42	1.34e-6	Aortic root size;
TGCT	cis	rs6701037	0.748	rs11583687	chr1:175132049	A/C	cg08873628	chr1:175162347	KIAA0040	0.45	4.47	0.37	1.75e-5	Alcohol dependence;
TGCT	cis	rs12762955	0.677	rs11250267	chr10:1156487	A/G	cg20503657	chr10:835505	NA	0.46	5.04	0.41	1.63e-6	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs514406	0.861	rs35581164	chr1:53271373	C/G	cg25767906	chr1:53392781	SCP2	-0.47	-5.39	-0.44	3.38e-7	Monocyte count;
TGCT	cis	rs921968	0.541	rs667251	chr2:219384384	C/G	cg02176678	chr2:219576539	TTLL4	0.48	6.78	0.52	4.32e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg17264618	chr3:40429014	ENTPD3	0.32	4.57	0.38	1.18e-5	Renal cell carcinoma;
TGCT	cis	rs12931792	0.712	rs2887799	chr16:30163833	G/A	cg17640201	chr16:30407289	ZNF48	0.58	5.1	0.42	1.24e-6	Tonsillectomy;
TGCT	cis	rs3806843	0.576	rs246037	chr5:140331846	C/T	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs4927850	0.752	rs7618864	chr3:195749561	G/A	cg12923728	chr3:195709715	SDHAP1	-0.37	-7.65	-0.57	4.91e-12	Pancreatic cancer;
TGCT	cis	rs4919694	1.000	rs12254254	chr10:104765605	C/T	cg04362960	chr10:104952993	NT5C2	1.06	7.05	0.53	1.09e-10	Arsenic metabolism;
TGCT	cis	rs10032931	0.962	rs7686970	chr4:96457107	G/A	cg03008707	chr4:96468962	UNC5C	-0.4	-5.26	-0.43	6.24e-7	Optic nerve measurement (cup-to-disc ratio);
TGCT	cis	rs10206020	0.921	rs72778009	chr2:1573322	G/T	cg01028140	chr2:1542097	TPO	-0.32	-4.99	-0.41	1.97e-6	IgG glycosylation;
TGCT	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg03517284	chr6:25882590	NA	-0.53	-5.43	-0.44	2.88e-7	Blood metabolite levels;
TGCT	cis	rs12510870	0.599	rs16849659	chr4:74450500	A/G	cg05868023	chr4:75230803	EREG	-0.54	-4.76	-0.39	5.33e-6	Iris color (b* coordinate);
TGCT	cis	rs35883536	0.647	rs2783703	chr1:101040794	T/C	cg06223162	chr1:101003688	GPR88	0.42	8.0	0.58	7.5e-13	Monocyte count;
TGCT	cis	rs1580019	0.961	rs1580021	chr7:32497702	T/G	cg06627557	chr7:32535165	LSM5;AVL9	0.81	7.61	0.56	5.93e-12	Cognitive ability;
TGCT	cis	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg13531842	chr10:38383804	ZNF37A	0.39	4.58	0.38	1.13e-5	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2932538	0.961	rs2932534	chr1:113200797	A/G	cg22162597	chr1:113214053	CAPZA1	0.26	5.87	0.47	3.81e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs700590	0.723	rs244753	chr5:88144520	A/G	cg22951263	chr5:87985283	NA	0.54	5.06	0.41	1.48e-6	Educational attainment (years of education);
TGCT	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg06238570	chr21:40685208	BRWD1	-0.8	-8.22	-0.59	2.31e-13	Cognitive function;
TGCT	cis	rs7819412	0.783	rs28722721	chr8:10948968	G/A	cg21775007	chr8:11205619	TDH	-0.52	-4.86	-0.4	3.52e-6	Triglycerides;
TGCT	cis	rs3779635	0.840	rs2322718	chr8:27257787	A/C	cg17482963	chr8:27591911	CCDC25	-0.22	-4.57	-0.38	1.15e-5	Neuroticism;
TGCT	cis	rs13177918	0.677	rs2070841	chr5:149824471	A/G	cg14059543	chr5:149831962	NA	-0.71	-9.45	-0.65	2.77e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs12477438	0.520	rs11678456	chr2:99708237	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	12.84	0.76	1.57e-24	Chronic sinus infection;
TGCT	cis	rs25422	0.938	rs62422193	chr6:118912285	G/A	cg21191810	chr6:118973309	C6orf204	-0.39	-5.14	-0.42	1.02e-6	Renal cell carcinoma;
TGCT	cis	rs12210905	0.688	rs115030474	chr6:27512220	C/T	cg08851530	chr6:28072375	NA	1.34	6.29	0.49	5.02e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs11122272	0.735	rs2790897	chr1:231491712	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-6.83	-0.52	3.46e-10	Hemoglobin concentration;
TGCT	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.04	0.53	1.16e-10	Prudent dietary pattern;
TGCT	cis	rs6032067	0.636	rs6104093	chr20:43908297	T/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.47	-7.24	-0.54	4.21e-11	Blood protein levels;
TGCT	cis	rs11971779	1.000	rs75919582	chr7:139054919	G/A	cg07862535	chr7:139043722	LUC7L2	0.81	5.85	0.47	4.03e-8	Diisocyanate-induced asthma;
TGCT	cis	rs1775715	0.966	rs1639132	chr10:32301260	G/A	cg14930904	chr10:32216787	ARHGAP12	-0.52	-4.88	-0.4	3.24e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs6463523	0.864	rs73047957	chr7:759373	A/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.94	11.59	0.72	1.71e-21	Subjective well-being;
TGCT	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg00814883	chr7:100076585	TSC22D4	-0.9	-9.56	-0.65	1.5e-16	Platelet count;
TGCT	cis	rs7017914	0.934	rs7814274	chr8:71570411	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	0.52	4.85	0.4	3.6e-6	Bone mineral density;
TGCT	cis	rs8056742	0.730	rs34949898	chr16:85069049	G/C	cg00229868	chr16:85520891	NA	0.42	5.17	0.42	9.14e-7	Amyotrophic lateral sclerosis;
TGCT	cis	rs9325144	0.647	rs12831609	chr12:39051576	C/A	cg10518543	chr12:38710700	ALG10B	-0.48	-4.47	-0.37	1.77e-5	Morning vs. evening chronotype;
TGCT	cis	rs28595532	0.920	rs115982145	chr4:119605707	A/G	cg14228332	chr4:119757509	SEC24D	1.04	5.37	0.43	3.66e-7	Cannabis dependence symptom count;
TGCT	cis	rs1042445	1.000	rs7625980	chr3:186393547	T/C	cg13908232	chr3:186371902	NA	0.46	5.2	0.42	7.95e-7	Blood protein levels;
TGCT	cis	rs78487399	0.808	rs116451849	chr2:43662911	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.45	-5.35	-0.43	4.03e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs514406	0.505	rs12726160	chr1:53175099	A/G	cg16325326	chr1:53192061	ZYG11B	0.85	11.87	0.73	3.53e-22	Monocyte count;
TGCT	cis	rs28595532	0.841	rs114735834	chr4:119772722	G/A	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs4642101	0.765	rs4321514	chr3:12825901	C/T	cg05775895	chr3:12838266	CAND2	0.79	9.04	0.63	2.61e-15	QRS complex (12-leadsum);
TGCT	cis	rs2692947	0.644	rs1168968	chr2:96825363	C/T	cg23100626	chr2:96804247	ASTL	0.47	5.55	0.45	1.67e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs9302001	0.883	rs7988127	chr13:95456386	C/T	cg07483244	chr13:95358924	NA	0.35	4.47	0.37	1.72e-5	Panic disorder;
TGCT	cis	rs35306767	0.903	rs61830933	chr10:934195	G/A	cg26597838	chr10:835615	NA	0.81	12.42	0.74	1.61e-23	Eosinophil percentage of granulocytes;
TGCT	cis	rs62103177	0.810	rs62103178	chr18:77624555	C/G	cg12964065	chr18:77638022	KCNG2	0.37	4.76	0.39	5.4e-6	Opioid sensitivity;
TGCT	cis	rs6840360	0.617	rs2724564	chr4:152349962	G/T	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.83e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7226408	0.749	rs72892525	chr18:34670741	G/C	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs3540	0.557	rs11634314	chr15:91042066	A/C	cg22089800	chr15:90895588	ZNF774	-0.75	-7.58	-0.56	6.96e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs7208859	0.673	rs9895684	chr17:29242600	G/A	cg18442181	chr17:29233375	C17orf42	-0.79	-4.68	-0.39	7.44e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs4149178	0.722	rs9472031	chr6:43293101	C/T	cg12269535	chr6:43142014	SRF	-0.58	-4.84	-0.4	3.72e-6	Urate levels;
TGCT	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg05368731	chr17:41323189	NBR1	1.21	14.63	0.8	8.89e-29	Menopause (age at onset);
TGCT	cis	rs425277	0.606	rs2460001	chr1:2111030	T/C	cg24578937	chr1:2090814	PRKCZ	0.27	7.01	0.53	1.38e-10	Height;
TGCT	cis	rs7923609	1.000	rs4310508	chr10:65138573	A/G	cg08743896	chr10:65200160	JMJD1C	-0.34	-4.57	-0.38	1.15e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7769051	0.522	rs7759524	chr6:133109574	A/G	cg22852734	chr6:133119734	C6orf192	1.22	4.65	0.39	8.32e-6	Type 2 diabetes nephropathy;
TGCT	cis	rs6912958	0.559	rs499373	chr6:88042062	A/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.45	5.88	0.47	3.49e-8	Monocyte percentage of white cells;
TGCT	cis	rs7267979	0.903	rs2500400	chr20:25354705	A/G	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1541995	0.789	rs17584220	chr15:96227411	G/A	cg00882281	chr15:96346592	NA	0.3	4.76	0.39	5.28e-6	Photic sneeze reflex;
TGCT	cis	rs6032067	0.526	rs2743347	chr20:43920493	T/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.45	-7.0	-0.53	1.41e-10	Blood protein levels;
TGCT	cis	rs3845702	0.736	rs3843323	chr2:180856459	T/C	cg01881094	chr2:180872142	CWC22	-1.07	-6.79	-0.52	4.2e-10	Schizophrenia;
TGCT	cis	rs7611238	0.560	rs13317705	chr3:195086609	G/A	cg27323046	chr3:195102265	ACAP2	0.39	5.17	0.42	9.08e-7	Body mass index;
TGCT	cis	rs11577318	0.579	rs58034207	chr1:26683575	C/T	cg14210634	chr1:25870291	LDLRAP1	0.53	4.62	0.38	9.33e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs4595586	1.000	rs4768388	chr12:39223924	G/A	cg10518543	chr12:38710700	ALG10B	-0.49	-4.77	-0.39	5.05e-6	Morning vs. evening chronotype;
TGCT	cis	rs735396	0.770	rs1169315	chr12:121443753	T/G	cg02403541	chr12:121454288	C12orf43	0.76	7.42	0.55	1.58e-11	N-glycan levels;
TGCT	cis	rs7539409	0.915	rs761404	chr1:84226766	G/T	cg10977910	chr1:84465055	TTLL7	-0.83	-4.61	-0.38	9.68e-6	Alzheimer's disease;
TGCT	cis	rs919433	0.679	rs13394214	chr2:198527371	C/T	cg00792783	chr2:198669748	PLCL1	0.55	4.88	0.4	3.24e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs6722750	0.905	rs10170666	chr2:64379672	G/A	cg22352474	chr2:64371530	PELI1	0.77	7.07	0.54	1.01e-10	Neuroticism;
TGCT	cis	rs1395	0.778	rs2078616	chr2:27441904	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.68	9.32	0.64	5.51e-16	Blood metabolite levels;
TGCT	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg06634786	chr22:41940651	POLR3H	-0.82	-7.7	-0.57	3.71e-12	Vitiligo;
TGCT	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg17971929	chr21:40555470	PSMG1	0.98	9.57	0.65	1.43e-16	Cognitive function;
TGCT	cis	rs2299587	0.650	rs12548412	chr8:17796970	G/T	cg01800426	chr8:17659068	MTUS1	-0.65	-5.66	-0.45	9.98e-8	Economic and political preferences;
TGCT	cis	rs8062405	0.721	rs151181	chr16:28490517	A/G	cg09754948	chr16:28834200	ATXN2L	0.61	4.8	0.4	4.54e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs933688	1.000	rs6869717	chr5:90694797	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.99	8.15	0.59	3.39e-13	Smoking behavior;
TGCT	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg23758822	chr17:41437982	NA	0.7	6.6	0.51	1.1e-9	Menopause (age at onset);
TGCT	cis	rs4727027	0.835	rs6959224	chr7:148784495	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	4.73	0.39	6.03e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs6912958	0.703	rs9353483	chr6:88097180	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.63	6.17	0.48	8.96e-9	Monocyte percentage of white cells;
TGCT	trans	rs2832077	0.527	rs2142375	chr21:30223742	G/A	cg14791747	chr16:20752902	THUMPD1	1.09	12.67	0.75	4.09e-24	Cognitive test performance;
TGCT	cis	rs11098499	0.826	rs4472123	chr4:120236630	T/A	cg09307838	chr4:120376055	NA	0.58	5.49	0.44	2.15e-7	Corneal astigmatism;
TGCT	cis	rs8014204	0.901	rs6574200	chr14:75364451	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.73	-6.94	-0.53	1.95e-10	Caffeine consumption;
TGCT	cis	rs6754311	0.731	rs745500	chr2:136583192	G/A	cg07169764	chr2:136633963	MCM6	-0.61	-5.61	-0.45	1.25e-7	Mosquito bite size;
TGCT	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg22963979	chr7:1858916	MAD1L1	-0.4	-6.28	-0.49	5.31e-9	Bipolar disorder and schizophrenia;
TGCT	trans	rs7819412	0.875	rs11250121	chr8:11060311	A/C	cg15556689	chr8:8085844	FLJ10661	-0.75	-7.37	-0.55	2.08e-11	Triglycerides;
TGCT	cis	rs68170813	0.641	rs4730228	chr7:106904077	T/C	cg02696742	chr7:106810147	HBP1	-0.69	-5.61	-0.45	1.27e-7	Coronary artery disease;
TGCT	cis	rs9534288	0.797	rs2182483	chr13:46582600	C/T	cg15192986	chr13:46630673	CPB2	-0.51	-7.18	-0.54	5.61e-11	Blood protein levels;
TGCT	trans	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg21659725	chr3:3221576	CRBN	0.76	9.03	0.63	2.74e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs77861329	1.000	rs893056	chr3:52109564	G/A	cg08692210	chr3:52188851	WDR51A	0.86	4.44	0.37	1.98e-5	Macrophage inflammatory protein 1b levels;
TGCT	cis	rs77216612	0.835	rs10845621	chr12:12887977	C/T	cg09462578	chr12:12878428	APOLD1	-1.0	-8.3	-0.6	1.5e-13	Lymphocyte counts;
TGCT	cis	rs73198271	0.563	rs74556999	chr8:8548459	C/T	cg06636001	chr8:8085503	FLJ10661	-0.72	-4.69	-0.39	7.09e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs9534288	0.664	rs1926446	chr13:46629995	A/C	cg15192986	chr13:46630673	CPB2	0.49	6.89	0.53	2.45e-10	Blood protein levels;
TGCT	cis	rs7666738	0.830	rs6532723	chr4:99052147	A/T	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10782582	0.593	rs4646960	chr1:76211103	C/A	cg22875332	chr1:76189707	ACADM	-0.49	-5.39	-0.44	3.35e-7	Daytime sleep phenotypes;
TGCT	cis	rs4727027	0.866	rs1405124	chr7:148779618	C/T	cg23583168	chr7:148888333	NA	-0.69	-8.75	-0.62	1.29e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs16854884	0.739	rs1898265	chr3:143776096	A/G	cg06585982	chr3:143692056	C3orf58	-0.63	-5.1	-0.42	1.23e-6	Economic and political preferences (feminism/equality);
TGCT	cis	rs797680	0.930	rs12124771	chr1:93799239	A/G	cg17826107	chr1:92977322	EVI5	-0.23	-5.19	-0.42	8.35e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs67311347	0.594	rs12629111	chr3:40285351	T/C	cg13683864	chr3:40499215	RPL14	-0.74	-6.81	-0.52	3.71e-10	Renal cell carcinoma;
TGCT	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg22963979	chr7:1858916	MAD1L1	-0.43	-6.94	-0.53	1.96e-10	Bipolar disorder and schizophrenia;
TGCT	cis	rs7267979	0.903	rs2474769	chr20:25248725	C/T	cg14121845	chr20:25566513	NINL	0.5	5.51	0.44	1.95e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1865760	1.000	rs7739966	chr6:25906040	T/C	cg16482183	chr6:26056742	HIST1H1C	0.55	4.97	0.41	2.19e-6	Height;
TGCT	cis	rs4664308	0.875	rs7593593	chr2:160933811	C/T	cg03641300	chr2:160917029	PLA2R1	-0.28	-6.83	-0.52	3.43e-10	Idiopathic membranous nephropathy;
TGCT	cis	rs477895	0.838	rs35090903	chr11:64000598	C/T	cg04317338	chr11:64019027	PLCB3	0.81	6.93	0.53	2.07e-10	Mean platelet volume;
TGCT	cis	rs2273156	1.000	rs2273156	chr14:35438799	T/C	cg24764865	chr14:36295508	BRMS1L	-0.6	-4.58	-0.38	1.12e-5	Immunoglobulin light chain (AL) amyloidosis;
TGCT	cis	rs9581857	0.512	rs9581874	chr13:28086956	A/G	cg22138327	chr13:27999177	GTF3A	0.73	4.54	0.38	1.34e-5	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs7786808	0.552	rs896762	chr7:158182029	A/G	cg01191920	chr7:158217561	PTPRN2	0.33	4.86	0.4	3.5e-6	Obesity-related traits;
TGCT	cis	rs791888	0.929	rs791887	chr10:89411554	A/G	cg13926569	chr10:89418898	PAPSS2	-0.35	-4.61	-0.38	9.95e-6	Magnesium levels;
TGCT	cis	rs17270561	1.000	rs17270561	chr6:25820439	A/C	cg15022984	chr6:26056706	HIST1H1C	0.71	4.63	0.38	9.03e-6	Iron status biomarkers;
TGCT	cis	rs1008375	1.000	rs10939742	chr4:17659936	G/T	cg10189774	chr4:17578691	LAP3	0.57	5.16	0.42	9.6e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2742417	1.000	rs2742392	chr3:45757282	T/C	cg04837898	chr3:45731254	SACM1L	-0.5	-5.13	-0.42	1.07e-6	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs7582180	0.764	rs13006224	chr2:100917109	C/T	cg08017756	chr2:100939284	LONRF2	-0.3	-4.85	-0.4	3.55e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs35306767	0.855	rs55697724	chr10:885622	T/C	cg20503657	chr10:835505	NA	0.77	11.34	0.71	6.95e-21	Eosinophil percentage of granulocytes;
TGCT	cis	rs853679	0.546	rs200990	chr6:27815823	T/G	cg08798685	chr6:27730294	NA	-0.34	-4.77	-0.39	5.13e-6	Depression;
TGCT	cis	rs7666738	0.716	rs35195511	chr4:98859660	G/A	cg05340658	chr4:99064831	C4orf37	0.52	6.0	0.47	1.98e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg20891283	chr12:69753455	YEATS4	0.91	10.33	0.68	1.96e-18	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs7666738	0.680	rs11097613	chr4:99079991	G/T	cg05340658	chr4:99064831	C4orf37	0.49	5.37	0.43	3.81e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs826838	1.000	rs826886	chr12:39095797	A/G	cg26384229	chr12:38710491	ALG10B	0.84	7.87	0.58	1.5e-12	Heart rate;
TGCT	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg20607798	chr8:58055168	NA	0.61	5.16	0.42	9.38e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs295140	0.632	rs4673905	chr2:201163783	A/G	cg04283868	chr2:201171347	SPATS2L	0.55	4.97	0.41	2.21e-6	QT interval;
TGCT	cis	rs734999	0.549	rs3828154	chr1:2524943	G/A	cg18854424	chr1:2615690	NA	0.5	5.78	0.46	5.64e-8	Ulcerative colitis;
TGCT	cis	rs5750830	0.645	rs756640	chr22:39779300	G/A	cg02038168	chr22:39784481	NA	-0.72	-6.24	-0.49	6.33e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs9381040	0.655	rs2268193	chr6:41024625	A/G	cg03526776	chr6:41159608	TREML2	0.27	5.29	0.43	5.37e-7	Alzheimer's disease (late onset);
TGCT	cis	rs2832191	1.000	rs2832189	chr21:30487414	C/T	cg08807101	chr21:30365312	RNF160	-0.49	-4.48	-0.37	1.65e-5	Dental caries;
TGCT	cis	rs6570726	0.905	rs375692	chr6:145840368	A/G	cg23711669	chr6:146136114	FBXO30	0.69	6.22	0.49	6.89e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6088590	0.561	rs6087605	chr20:33180624	G/T	cg08999081	chr20:33150536	PIGU	0.25	4.99	0.41	1.97e-6	Coronary artery disease;
TGCT	cis	rs2153535	0.580	rs9379215	chr6:8481225	G/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs17253792	0.822	rs28513551	chr14:56094993	G/A	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs1048238	0.525	rs848214	chr1:16265422	A/G	cg21385522	chr1:16154831	NA	-0.61	-6.8	-0.52	3.89e-10	Systolic blood pressure;
TGCT	cis	rs9443645	0.901	rs3805747	chr6:79672522	A/G	cg09184832	chr6:79620586	NA	-0.49	-5.29	-0.43	5.29e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	5.04	0.41	1.58e-6	Menopause (age at onset);
TGCT	cis	rs6671200	0.748	rs34254763	chr1:95540961	T/C	cg03123541	chr1:95699097	RWDD3	0.65	4.49	0.37	1.6e-5	Stearic acid (18:0) levels;
TGCT	cis	rs74233809	1.000	rs78821730	chr10:104684544	G/A	cg05855489	chr10:104503620	C10orf26	0.74	4.45	0.37	1.87e-5	Birth weight;
TGCT	cis	rs7208859	0.673	rs12103759	chr17:29235687	G/A	cg18442181	chr17:29233375	C17orf42	-0.78	-4.61	-0.38	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	trans	rs2688608	1.000	rs2688610	chr10:75654931	A/G	cg13918328	chr10:52500089	ASAH2B	-0.67	-6.88	-0.53	2.56e-10	Inflammatory bowel disease;
TGCT	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg00684032	chr4:1343700	KIAA1530	0.23	4.91	0.4	2.76e-6	Obesity-related traits;
TGCT	cis	rs367943	0.966	rs348932	chr5:112812457	G/A	cg12552261	chr5:112820674	MCC	-0.24	-4.91	-0.4	2.81e-6	Type 2 diabetes;
TGCT	cis	rs11098499	0.863	rs11947234	chr4:120474859	A/G	cg09307838	chr4:120376055	NA	0.72	6.9	0.53	2.41e-10	Corneal astigmatism;
TGCT	cis	rs2070488	0.930	rs928813	chr3:38528537	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.88	8.99	0.63	3.5e-15	Electrocardiographic conduction measures;
TGCT	cis	rs11690935	0.959	rs6433314	chr2:172660971	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.19	-12.78	-0.75	2.24e-24	Schizophrenia;
TGCT	cis	rs2235642	1.000	rs2076438	chr16:1584618	T/C	cg00463982	chr16:1583984	IFT140;TMEM204	-0.28	-4.82	-0.4	4.09e-6	Coronary artery disease;
TGCT	cis	rs17152411	0.817	rs4478950	chr10:126596425	T/C	cg07906193	chr10:126599966	NA	0.43	5.31	0.43	4.92e-7	Height;
TGCT	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.63	5.11	0.42	1.19e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	trans	rs208520	1.000	rs12190316	chr6:66973365	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.82	7.48	0.56	1.21e-11	Exhaled nitric oxide output;
TGCT	cis	rs2933343	0.951	rs796862	chr3:128593040	G/A	cg11901034	chr3:128598214	ACAD9	-0.65	-5.12	-0.42	1.15e-6	IgG glycosylation;
TGCT	cis	rs250677	0.522	rs7702695	chr5:148402550	T/A	cg18129178	chr5:148520854	ABLIM3	-0.35	-4.58	-0.38	1.12e-5	Breast cancer;
TGCT	cis	rs11748023	0.605	rs249616	chr5:139529656	C/T	cg01081189	chr5:139537190	NA	0.26	4.48	0.37	1.69e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs8017423	0.935	rs17260827	chr14:90732703	G/A	cg04374321	chr14:90722782	PSMC1	-0.79	-7.91	-0.58	1.24e-12	Mortality in heart failure;
TGCT	cis	rs74181299	0.571	rs7559813	chr2:65278023	A/G	cg05010058	chr2:65284262	CEP68	-0.48	-4.95	-0.41	2.36e-6	Pulse pressure;
TGCT	cis	rs7226408	0.948	rs11660414	chr18:34376565	C/T	cg06757138	chr18:34340585	FHOD3	0.25	4.56	0.38	1.2e-5	Obesity-related traits;
TGCT	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9640161	0.789	rs4554381	chr7:150025567	G/A	cg17279839	chr7:150038598	RARRES2	0.43	4.6	0.38	1.02e-5	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs2204008	0.837	rs11612397	chr12:38357455	T/C	cg13010199	chr12:38710504	ALG10B	0.58	4.55	0.38	1.26e-5	Bladder cancer;
TGCT	cis	rs7267979	1.000	rs2424704	chr20:25273929	A/G	cg16686733	chr20:25566563	NINL	0.58	5.75	0.46	6.46e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7666738	0.830	rs62318906	chr4:99037110	C/T	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.95	7.54	0.56	8.47e-12	Platelet count;
TGCT	cis	rs17826219	0.500	rs117560728	chr17:29070938	A/C	cg13385521	chr17:29058706	SUZ12P	0.93	5.21	0.42	7.63e-7	Body mass index;
TGCT	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg10150615	chr22:24372951	LOC391322	0.82	7.12	0.54	7.87e-11	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs67478160	0.634	rs2024669	chr14:104275602	G/C	cg26031613	chr14:104095156	KLC1	-0.64	-6.42	-0.5	2.68e-9	Schizophrenia;
TGCT	cis	rs4478858	0.735	rs12408524	chr1:31835853	A/G	cg07478791	chr1:31886160	SERINC2	-0.47	-4.52	-0.38	1.43e-5	Alcohol dependence;
TGCT	cis	rs40363	0.951	rs72778117	chr16:3531827	T/C	cg00484396	chr16:3507460	NAT15	0.42	5.03	0.41	1.64e-6	Tuberculosis;
TGCT	cis	rs10791323	0.569	rs10750553	chr11:133740251	T/C	cg15485101	chr11:133734466	NA	0.37	5.42	0.44	3e-7	Childhood ear infection;
TGCT	cis	rs478304	0.903	rs12293022	chr11:65531698	C/T	cg17480646	chr11:65405466	SIPA1	0.43	5.35	0.43	4.01e-7	Acne (severe);
TGCT	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg21280719	chr6:42927975	GNMT	-0.37	-4.59	-0.38	1.07e-5	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs6754311	0.628	rs309811	chr2:136625602	A/G	cg07169764	chr2:136633963	MCM6	-0.63	-5.88	-0.47	3.51e-8	Mosquito bite size;
TGCT	cis	rs12893668	0.644	rs12890820	chr14:104034849	T/C	cg26031613	chr14:104095156	KLC1	-0.54	-4.45	-0.37	1.88e-5	Reticulocyte count;
TGCT	cis	rs4938534	0.559	rs1944919	chr11:111259876	A/C	cg01212326	chr11:111250286	POU2AF1	0.27	5.3	0.43	5.18e-7	Primary biliary cholangitis;
TGCT	cis	rs4851254	0.626	rs13001783	chr2:100689652	A/T	cg07810366	chr2:100720526	AFF3	-0.49	-5.22	-0.42	7.36e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2455799	0.593	rs13085352	chr3:15914845	T/C	cg16303742	chr3:15540471	COLQ	-0.24	-4.64	-0.38	8.68e-6	Mean platelet volume;
TGCT	cis	rs11167764	1.000	rs7722567	chr5:141483178	C/T	cg23435118	chr5:141488016	NDFIP1	-0.31	-5.09	-0.42	1.27e-6	Crohn's disease;
TGCT	cis	rs1008375	1.000	rs60178264	chr4:17685308	G/T	cg10189774	chr4:17578691	LAP3	0.52	4.74	0.39	5.82e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10946940	0.632	rs9366698	chr6:27672035	C/G	cg10876282	chr6:28092338	ZSCAN16	0.52	4.77	0.39	5.02e-6	Systemic lupus erythematosus;
TGCT	cis	rs7666738	0.791	rs60028147	chr4:99046618	G/A	cg18180107	chr4:99064573	C4orf37	0.56	5.08	0.41	1.37e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11105298	0.838	rs4842488	chr12:89881564	C/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.7	-5.02	-0.41	1.79e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs614226	1.000	rs1167725	chr12:120968559	A/T	cg01236616	chr12:121019343	POP5	1.26	13.2	0.76	2.23e-25	Type 1 diabetes nephropathy;
TGCT	trans	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg21659725	chr3:3221576	CRBN	-0.76	-9.03	-0.63	2.74e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs9399137	0.507	rs7768278	chr6:135274957	T/C	cg24558204	chr6:135376177	HBS1L	0.49	4.96	0.41	2.24e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
TGCT	cis	rs9291683	0.609	rs13149985	chr4:10028390	G/A	cg00071950	chr4:10020882	SLC2A9	0.7	9.43	0.65	3.06e-16	Bone mineral density;
TGCT	cis	rs12911832	1.000	rs4774310	chr15:58985164	T/G	cg05156742	chr15:59063176	FAM63B	0.49	4.66	0.39	8.05e-6	Schizophrenia;
TGCT	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg08859206	chr1:53392774	SCP2	0.34	4.93	0.4	2.63e-6	Monocyte count;
TGCT	cis	rs11030122	0.635	rs10835540	chr11:4071429	T/A	cg18678763	chr11:4115507	RRM1	-0.48	-5.61	-0.45	1.27e-7	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs1949733	1.000	rs2631745	chr4:8490530	T/C	cg11789530	chr4:8429930	ACOX3	-0.6	-5.5	-0.44	2.12e-7	Response to antineoplastic agents;
TGCT	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg04317338	chr11:64019027	PLCB3	0.78	6.43	0.5	2.53e-9	Mean platelet volume;
TGCT	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg08509172	chr19:19383838	TM6SF2	-0.35	-4.6	-0.38	1.02e-5	Tonsillectomy;
TGCT	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg20999797	chr1:1681921	NA	0.18	4.67	0.39	7.67e-6	Body mass index;
TGCT	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9913156	0.793	rs72835633	chr17:4562643	C/T	cg19197139	chr17:4613644	ARRB2	0.86	7.9	0.58	1.32e-12	Lymphocyte counts;
TGCT	cis	rs950169	1.000	rs79318564	chr15:84786150	G/A	cg12863693	chr15:85201151	NMB	0.39	4.65	0.38	8.54e-6	Schizophrenia;
TGCT	cis	rs2180341	0.824	rs9321076	chr6:127655614	G/A	cg27446573	chr6:127587934	RNF146	1.12	10.11	0.67	6.87e-18	Breast cancer;
TGCT	cis	rs1153858	0.832	rs1145078	chr15:45682277	C/T	cg26924012	chr15:45694286	SPATA5L1	0.99	12.19	0.74	5.99e-23	Homoarginine levels;
TGCT	cis	rs9427116	0.840	rs9427114	chr1:154626705	T/C	cg17218026	chr1:154582156	ADAR	0.25	6.08	0.48	1.37e-8	Blood protein levels;
TGCT	cis	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg00343986	chr7:65444356	GUSB	0.23	5.18	0.42	8.86e-7	Aortic root size;
TGCT	cis	rs2721811	0.738	rs2521758	chr7:24762292	G/T	cg17569154	chr7:24781545	DFNA5	0.21	4.6	0.38	1.01e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs10984561	1.000	rs10984561	chr9:122258577	C/T	cg14242995	chr9:122249943	NA	0.59	5.53	0.44	1.84e-7	Pulmonary function decline;
TGCT	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs617219	0.737	rs13158309	chr5:78463395	C/T	cg09550809	chr5:78407562	BHMT	-0.39	-5.49	-0.44	2.17e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs7772486	0.754	rs4896841	chr6:146041522	T/C	cg13319975	chr6:146136371	FBXO30	0.53	4.8	0.4	4.49e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg22963979	chr7:1858916	MAD1L1	-0.44	-6.93	-0.53	2.01e-10	Bipolar disorder and schizophrenia;
TGCT	cis	rs941408	1.000	rs1640272	chr19:2800192	A/T	cg06609049	chr19:2785107	THOP1	0.8	7.76	0.57	2.69e-12	Total cholesterol levels;
TGCT	cis	rs6831352	0.725	rs2602846	chr4:100025151	T/A	cg12011299	chr4:100065546	ADH4	0.4	4.82	0.4	4.07e-6	Alcohol dependence;
TGCT	cis	rs7611238	0.560	rs6788868	chr3:195150694	G/A	cg27323046	chr3:195102265	ACAP2	0.39	5.14	0.42	1.05e-6	Body mass index;
TGCT	cis	rs9910055	0.529	rs228766	chr17:42186813	A/G	cg19774624	chr17:42201019	HDAC5	0.71	6.57	0.51	1.23e-9	Total body bone mineral density;
TGCT	cis	rs9868809	0.881	rs2276850	chr3:48669648	G/A	cg00383909	chr3:49044727	WDR6	0.97	5.08	0.42	1.34e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs9393692	0.905	rs34916901	chr6:26286149	G/T	cg13736514	chr6:26305472	NA	-0.41	-5.76	-0.46	6.12e-8	Educational attainment;
TGCT	cis	rs2046867	0.954	rs6802796	chr3:72782740	T/A	cg25664220	chr3:72788482	NA	-0.55	-6.83	-0.52	3.42e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs72945132	0.882	rs67927691	chr11:70128786	C/A	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs826838	1.000	rs10875991	chr12:39108886	G/C	cg13010199	chr12:38710504	ALG10B	0.82	6.78	0.52	4.27e-10	Heart rate;
TGCT	cis	rs9911578	0.692	rs412000	chr17:56709058	G/C	cg05425664	chr17:57184151	TRIM37	-0.49	-4.67	-0.39	7.63e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9929218	0.906	rs33965787	chr16:68828173	G/A	cg03880890	chr16:69439245	NA	-0.22	-4.48	-0.37	1.68e-5	Colorectal cancer;
TGCT	cis	rs7829975	0.500	rs7841082	chr8:8168987	C/T	cg15556689	chr8:8085844	FLJ10661	-0.63	-5.73	-0.46	7.04e-8	Mood instability;
TGCT	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg13695892	chr22:41940480	POLR3H	0.93	9.17	0.64	1.31e-15	Vitiligo;
TGCT	cis	rs73198271	0.765	rs534103	chr8:8634069	A/G	cg06636001	chr8:8085503	FLJ10661	-0.6	-4.45	-0.37	1.92e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.9	-6.56	-0.51	1.3e-9	Gut microbiome composition (summer);
TGCT	cis	rs9309473	0.606	rs62149804	chr2:73837006	T/A	cg07208825	chr2:73871855	ALMS1P	0.26	4.86	0.4	3.41e-6	Metabolite levels;
TGCT	cis	rs651907	0.535	rs11707250	chr3:101509371	A/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.86	-10.47	-0.68	9.24e-19	Colorectal cancer;
TGCT	cis	rs7172809	0.573	rs17470529	chr15:77673359	A/G	cg22256960	chr15:77711686	NA	-0.51	-4.79	-0.4	4.65e-6	Glucose homeostasis traits;
TGCT	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg09060608	chr5:178986726	RUFY1	0.48	5.63	0.45	1.13e-7	Lung cancer;
TGCT	cis	rs523522	0.962	rs3213565	chr12:120992401	C/T	cg27279351	chr12:120934652	DYNLL1	0.76	6.59	0.51	1.15e-9	High light scatter reticulocyte count;
TGCT	cis	rs7666738	0.830	rs7672901	chr4:98938781	C/T	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg04772025	chr11:68637568	NA	0.6	6.66	0.51	7.88e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	trans	rs208520	0.690	rs851468	chr6:66825875	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-10.72	-0.69	2.28e-19	Exhaled nitric oxide output;
TGCT	cis	rs7818382	0.967	rs7812465	chr8:96050557	C/T	cg16049864	chr8:95962084	TP53INP1	0.6	7.4	0.55	1.84e-11	Alzheimer's disease (late onset);
TGCT	cis	rs6089829	0.962	rs57684920	chr20:61662639	G/A	cg02380750	chr20:61661411	NA	-0.31	-5.22	-0.42	7.4e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9926296	0.712	rs258332	chr16:89727683	G/A	cg26513180	chr16:89883248	FANCA	-0.67	-6.28	-0.49	5.19e-9	Vitiligo;
TGCT	cis	rs9788682	1.000	rs12438181	chr15:78812098	G/A	cg06917634	chr15:78832804	PSMA4	-0.68	-4.96	-0.41	2.27e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs12682352	0.715	rs332039	chr8:8723651	C/G	cg06636001	chr8:8085503	FLJ10661	0.63	5.84	0.46	4.26e-8	Neuroticism;
TGCT	cis	rs10501293	0.675	rs7949021	chr11:43004134	A/G	cg03447554	chr11:43094025	NA	0.44	6.39	0.5	3.03e-9	Cognitive performance;
TGCT	cis	rs6570726	0.791	rs11155426	chr6:145817130	T/C	cg05347473	chr6:146136440	FBXO30	0.53	4.95	0.41	2.4e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs151997	0.925	rs27624	chr5:50167662	C/T	cg06027927	chr5:50259733	NA	0.47	4.77	0.39	5e-6	Callous-unemotional behaviour;
TGCT	cis	rs1865760	0.622	rs9295685	chr6:26071725	G/C	cg17042849	chr6:26104293	HIST1H4C	-0.62	-5.33	-0.43	4.56e-7	Height;
TGCT	cis	rs3733585	0.699	rs6449179	chr4:9969117	G/A	cg11266682	chr4:10021025	SLC2A9	-0.59	-7.85	-0.58	1.7e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs4664308	0.870	rs55959207	chr2:161016981	A/C	cg03641300	chr2:160917029	PLA2R1	-0.27	-6.89	-0.53	2.48e-10	Idiopathic membranous nephropathy;
TGCT	cis	rs7547997	0.615	rs114657189	chr1:158318340	G/C	cg03528325	chr1:158223921	CD1A	0.33	4.81	0.4	4.38e-6	QRS duration;
TGCT	cis	rs13191362	1.000	rs67042566	chr6:163006541	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs12681287	0.640	rs13253261	chr8:87458500	T/C	cg27223183	chr8:87520930	FAM82B	-0.89	-6.43	-0.5	2.54e-9	Caudate activity during reward;
TGCT	cis	rs4072705	0.615	rs4838189	chr9:127248926	C/A	cg13476313	chr9:127244764	NR5A1	0.3	4.98	0.41	2.05e-6	Menarche (age at onset);
TGCT	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg12419862	chr22:24373484	LOC391322	0.84	7.99	0.58	7.84e-13	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs4689388	0.926	rs4343789	chr4:6285228	C/G	cg25554036	chr4:6271136	WFS1	0.56	8.15	0.59	3.3e-13	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs12477438	0.520	rs11677247	chr2:99756358	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	17.43	0.84	3.73e-35	Chronic sinus infection;
TGCT	cis	rs546131	1.000	rs546131	chr11:34851760	G/C	cg06937548	chr11:34938143	PDHX;APIP	0.63	5.61	0.45	1.27e-7	Lung disease severity in cystic fibrosis;
TGCT	cis	rs610932	0.517	rs588084	chr11:59973059	C/T	cg18570331	chr11:60101691	MS4A6E	0.52	4.79	0.4	4.6e-6	Alzheimer's disease;
TGCT	cis	rs2692947	0.673	rs2229169	chr2:96780716	T/G	cg23100626	chr2:96804247	ASTL	-0.44	-5.21	-0.42	7.78e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg14820908	chr5:178986412	RUFY1	-0.59	-6.36	-0.5	3.51e-9	Lung cancer;
TGCT	cis	rs2404602	0.647	rs7165053	chr15:76978918	A/G	cg23625390	chr15:77176239	SCAPER	-0.39	-4.93	-0.41	2.53e-6	Blood metabolite levels;
TGCT	cis	rs3096299	0.586	rs4572400	chr16:89533516	T/A	cg06640241	chr16:89574553	SPG7	0.72	7.31	0.55	2.94e-11	Multiple myeloma (IgH translocation);
TGCT	cis	rs887829	0.569	rs4663967	chr2:234653184	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.26	-4.61	-0.38	9.83e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
TGCT	cis	rs10751667	1.000	rs10794357	chr11:973374	T/C	cg06064525	chr11:970664	AP2A2	-0.31	-6.25	-0.49	5.89e-9	Alzheimer's disease (late onset);
TGCT	cis	rs1729951	0.575	rs361241	chr3:136699561	C/A	cg12473912	chr3:136751656	NA	0.39	6.18	0.49	8.36e-9	Neuroticism;
TGCT	cis	rs1372520	0.935	rs2245801	chr4:90757840	T/C	cg14346243	chr4:90757452	SNCA	-0.58	-4.51	-0.38	1.48e-5	Neuroticism;
TGCT	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg21963583	chr11:68658836	MRPL21	0.39	6.41	0.5	2.78e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg15921436	chr17:44337874	NA	0.56	7.75	0.57	2.88e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs71597109	0.639	rs35194352	chr4:102726594	T/C	cg14855874	chr4:102712397	BANK1	0.41	4.72	0.39	6.16e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs12497850	0.864	rs7431857	chr3:48900347	G/A	cg18654377	chr3:49208889	KLHDC8B	-0.41	-5.49	-0.44	2.15e-7	Parkinson's disease;
TGCT	cis	rs68170813	0.523	rs75999022	chr7:107017135	C/T	cg02696742	chr7:106810147	HBP1	-0.7	-5.7	-0.46	8.16e-8	Coronary artery disease;
TGCT	cis	rs1670533	1.000	rs2045065	chr4:1052488	A/G	cg20887711	chr4:1340912	KIAA1530	0.67	5.2	0.42	7.86e-7	Recombination rate (females);
TGCT	cis	rs875971	0.862	rs57866200	chr7:65565392	A/G	cg11764359	chr7:65958608	NA	-0.56	-4.82	-0.4	4.1e-6	Aortic root size;
TGCT	cis	rs908922	0.676	rs2146120	chr1:152504200	A/T	cg20991723	chr1:152506922	NA	0.44	5.94	0.47	2.66e-8	Hair morphology;
TGCT	cis	rs986417	0.901	rs4901987	chr14:60987529	C/T	cg27398547	chr14:60952738	C14orf39	1.42	8.85	0.62	7.44e-15	Gut microbiota (bacterial taxa);
TGCT	cis	rs2204008	0.714	rs11520135	chr12:38114863	C/T	cg26384229	chr12:38710491	ALG10B	0.86	7.56	0.56	7.76e-12	Bladder cancer;
TGCT	cis	rs2228479	0.850	rs2238525	chr16:89809902	T/C	cg26513180	chr16:89883248	FANCA	0.78	4.5	0.37	1.56e-5	Skin colour saturation;
TGCT	cis	rs9457247	1.000	rs422094	chr6:167397033	C/G	cg23791538	chr6:167370224	RNASET2	-0.49	-4.88	-0.4	3.17e-6	Crohn's disease;
TGCT	cis	rs9926296	0.572	rs2079671	chr16:89884981	T/C	cg27121462	chr16:89883253	FANCA	0.61	5.81	0.46	4.86e-8	Vitiligo;
TGCT	cis	rs12135894	0.648	rs4648423	chr1:3765678	C/T	cg10555106	chr1:3691387	LOC388588	-0.3	-4.59	-0.38	1.07e-5	Mean corpuscular volume;
TGCT	cis	rs826838	0.935	rs1486357	chr12:39073675	A/G	cg26384229	chr12:38710491	ALG10B	1.06	10.35	0.68	1.74e-18	Heart rate;
TGCT	cis	rs9814567	1.000	rs9289471	chr3:134230811	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.95	-9.62	-0.65	1.04e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs3809566	1.000	rs4774471	chr15:63332645	A/T	cg05507819	chr15:63340323	TPM1	-0.5	-4.64	-0.38	8.7e-6	Platelet count;
TGCT	cis	rs4523957	0.583	rs7503141	chr17:2044645	T/C	cg16513277	chr17:2031491	SMG6	-0.2	-4.58	-0.38	1.13e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs1552244	0.608	rs7615408	chr3:10000186	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.32	-4.86	-0.4	3.55e-6	Alzheimer's disease;
TGCT	cis	rs3733585	0.605	rs4697708	chr4:10121189	A/G	cg00071950	chr4:10020882	SLC2A9	-0.51	-5.29	-0.43	5.41e-7	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs910316	1.000	rs1047418	chr14:75605792	A/G	cg11812906	chr14:75593930	NEK9	0.73	7.23	0.54	4.34e-11	Height;
TGCT	cis	rs3540	0.960	rs7167704	chr15:90956801	G/T	cg22089800	chr15:90895588	ZNF774	0.79	7.77	0.57	2.59e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs7119	0.637	rs12913005	chr15:77856571	T/A	cg27398640	chr15:77910606	LINGO1	-0.27	-4.92	-0.4	2.66e-6	Type 2 diabetes;
TGCT	cis	rs734999	0.566	rs6424092	chr1:2532899	C/A	cg18854424	chr1:2615690	NA	-0.44	-5.1	-0.42	1.22e-6	Ulcerative colitis;
TGCT	cis	rs732765	0.734	rs12323528	chr14:75152068	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.57	-4.82	-0.4	4.15e-6	Non-small cell lung cancer;
TGCT	cis	rs6500602	0.727	rs4786510	chr16:4571247	A/G	cg08645402	chr16:4508243	NA	0.19	5.3	0.43	5.14e-7	Schizophrenia;
TGCT	cis	rs2075671	0.903	rs4727459	chr7:100276821	T/C	cg20848291	chr7:100343083	ZAN	-0.52	-4.56	-0.38	1.21e-5	Other erythrocyte phenotypes;
TGCT	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg22105103	chr4:187893119	NA	0.35	4.89	0.4	3.02e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs61990749	0.597	rs176952	chr14:78180736	T/C	cg23188588	chr14:78226832	SNW1;C14orf178	0.66	4.65	0.39	8.45e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.51	-4.89	-0.4	3.06e-6	Longevity;Endometriosis;
TGCT	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg12419862	chr22:24373484	LOC391322	0.89	7.86	0.58	1.55e-12	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs4660261	0.526	rs2485996	chr1:44354661	C/T	cg13606994	chr1:44402422	ARTN	-0.41	-4.46	-0.37	1.82e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs694739	0.628	rs10897487	chr11:64140704	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.63	6.54	0.51	1.44e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs1865760	0.865	rs6929805	chr6:25950834	T/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.64	6.31	0.49	4.56e-9	Height;
TGCT	cis	rs881375	0.967	rs1930780	chr9:123686219	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	5.47	0.44	2.35e-7	Rheumatoid arthritis;
TGCT	cis	rs2361718	0.521	rs2361724	chr17:78099114	G/A	cg02096758	chr17:77394895	HRNBP3	0.24	4.64	0.38	8.9e-6	Yeast infection;
TGCT	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.75	5.41	0.44	3.09e-7	Platelet count;
TGCT	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg08392591	chr16:89556376	ANKRD11	0.57	5.4	0.44	3.2e-7	Multiple myeloma (IgH translocation);
TGCT	cis	rs7914558	1.000	rs10748838	chr10:104943986	T/A	cg05855489	chr10:104503620	C10orf26	0.51	4.48	0.37	1.65e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs896854	0.517	rs1011796	chr8:95951273	A/G	cg16049864	chr8:95962084	TP53INP1	0.55	6.13	0.48	1.07e-8	Type 2 diabetes;
TGCT	cis	rs709400	0.663	rs55723020	chr14:103991401	G/A	cg26031613	chr14:104095156	KLC1	0.88	9.39	0.64	3.88e-16	Body mass index;
TGCT	cis	rs782590	0.967	rs6545506	chr2:55798108	A/G	cg18811423	chr2:55921094	PNPT1	-0.64	-6.9	-0.53	2.39e-10	Metabolic syndrome;
TGCT	cis	rs4242434	0.672	rs10110443	chr8:22484296	C/G	cg03733263	chr8:22462867	KIAA1967	0.97	13.6	0.77	2.44e-26	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg11494091	chr17:61959527	GH2	0.61	14.46	0.79	2.18e-28	Prudent dietary pattern;
TGCT	cis	rs62103177	0.810	rs62103175	chr18:77622467	C/T	cg12964065	chr18:77638022	KCNG2	0.37	4.76	0.39	5.4e-6	Opioid sensitivity;
TGCT	cis	rs3087591	0.708	rs2854319	chr17:29694054	G/C	cg24425628	chr17:29625626	OMG;NF1	0.39	5.65	0.45	1.03e-7	Hip circumference;
TGCT	cis	rs9972944	0.729	rs1895035	chr17:63777711	G/A	cg07283582	chr17:63770753	CCDC46	0.26	5.05	0.41	1.53e-6	Total body bone mineral density;
TGCT	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg16590910	chr6:42928470	GNMT	-0.49	-4.52	-0.38	1.41e-5	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs12477438	0.748	rs10200974	chr2:99675227	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-7.6	-0.56	6.47e-12	Chronic sinus infection;
TGCT	cis	rs60154123	0.505	rs2206043	chr1:210042983	G/A	cg23283495	chr1:209979779	IRF6	0.67	4.99	0.41	1.96e-6	Coronary artery disease;
TGCT	cis	rs2013441	1.000	rs2526472	chr17:20137888	G/A	cg18979559	chr17:20280153	CCDC144C	-0.45	-4.67	-0.39	7.61e-6	Obesity-related traits;
TGCT	cis	rs7917772	0.582	rs7075269	chr10:104365724	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	5.36	0.43	3.84e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs763014	0.931	rs1981483	chr16:630665	G/A	cg07343612	chr16:622815	PIGQ	-0.41	-7.87	-0.58	1.52e-12	Height;
TGCT	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg04944784	chr2:26401820	FAM59B	-0.76	-6.34	-0.49	3.94e-9	Gut microbiome composition (summer);
TGCT	trans	rs2970818	0.831	rs7304949	chr12:4609625	A/G	cg03807737	chr6:44242160	TMEM151B	0.31	7.54	0.56	8.47e-12	Phosphorus levels;
TGCT	cis	rs892961	0.836	rs8071497	chr17:75414358	T/C	cg05865280	chr17:75406074	SEPT9	0.28	6.71	0.52	6.16e-10	Airflow obstruction;
TGCT	cis	rs9921192	1.000	rs251734	chr16:4321441	A/G	cg00021532	chr16:4324280	TFAP4	0.84	9.73	0.66	5.68e-17	Prostate-specific antigen levels;
TGCT	cis	rs3812831	0.662	rs418027	chr13:114929344	A/C	cg06611532	chr13:114900021	NA	0.35	6.28	0.49	5.16e-9	Schizophrenia;
TGCT	cis	rs2576037	0.583	rs9960463	chr18:44522808	T/A	cg23302884	chr18:44338147	ST8SIA5	-0.41	-4.71	-0.39	6.41e-6	Personality dimensions;
TGCT	cis	rs9309473	0.500	rs2421582	chr2:73898420	A/G	cg20560298	chr2:73613845	ALMS1	0.41	4.51	0.38	1.46e-5	Metabolite levels;
TGCT	cis	rs7772486	0.658	rs9403737	chr6:145962193	G/T	cg05347473	chr6:146136440	FBXO30	0.5	4.71	0.39	6.65e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7666738	0.822	rs9992360	chr4:98937123	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9902453	1.000	rs9897206	chr17:28406108	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.76	-6.77	-0.52	4.47e-10	Coffee consumption (cups per day);
TGCT	cis	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg22857025	chr5:266934	NA	-0.31	-6.32	-0.49	4.33e-9	Breast cancer;
TGCT	cis	rs9549367	0.774	rs2287246	chr13:113889127	A/G	cg00898013	chr13:113819073	PROZ	-0.4	-4.92	-0.4	2.7e-6	Platelet distribution width;
TGCT	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg10047753	chr17:41438598	NA	0.96	9.6	0.65	1.16e-16	Menopause (age at onset);
TGCT	cis	rs9788682	0.747	rs7177514	chr15:78907406	C/G	cg24631222	chr15:78858424	CHRNA5	0.78	5.71	0.46	8.03e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs713587	0.571	rs546217	chr2:25311537	A/C	cg01884057	chr2:25150051	NA	-0.25	-4.81	-0.4	4.36e-6	Body mass index in non-asthmatics;
TGCT	cis	rs933688	1.000	rs12651840	chr5:90729592	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	8.86	0.62	7.17e-15	Smoking behavior;
TGCT	cis	rs7786808	0.579	rs4045391	chr7:158181826	T/C	cg01191920	chr7:158217561	PTPRN2	-0.34	-5.06	-0.41	1.45e-6	Obesity-related traits;
TGCT	cis	rs9303542	0.559	rs35621842	chr17:46606222	C/T	cg25032089	chr17:46643351	HOXB3	0.57	5.58	0.45	1.46e-7	Ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg03161606	chr19:29218774	NA	0.56	6.1	0.48	1.26e-8	Methadone dose in opioid dependence;
TGCT	trans	rs877282	0.898	rs12358966	chr10:758703	A/G	cg22713356	chr15:30763199	NA	1.12	8.42	0.6	7.78e-14	Uric acid levels;
TGCT	cis	rs1008375	0.900	rs6851783	chr4:17578469	A/G	cg16339924	chr4:17578868	LAP3	0.83	7.06	0.54	1.04e-10	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2718798	1	rs2718798	chr3:133492088	A/C	cg08048268	chr3:133502702	NA	-0.45	-5.89	-0.47	3.33e-8	Ankle injury;
TGCT	cis	rs6952808	0.636	rs73048162	chr7:1949328	T/C	cg04267008	chr7:1944627	MAD1L1	-0.36	-4.72	-0.39	6.34e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs9383153	1.000	rs2073518	chr6:16332730	T/C	cg06493612	chr6:15502050	JARID2	0.65	5.38	0.44	3.51e-7	Gambling;
TGCT	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg20607798	chr8:58055168	NA	0.65	5.43	0.44	2.86e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7818688	0.697	rs11780130	chr8:95976083	A/G	cg16049864	chr8:95962084	TP53INP1	0.54	4.64	0.38	8.87e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs854765	0.647	rs6502637	chr17:17986098	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.68	7.01	0.53	1.33e-10	Total body bone mineral density;
TGCT	cis	rs13191362	0.935	rs13215748	chr6:163010710	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg20637647	chr7:64974828	NA	0.9	5.31	0.43	4.87e-7	Diabetic kidney disease;
TGCT	cis	rs9894429	0.752	rs6565610	chr17:79592652	A/G	cg21028142	chr17:79581711	NPLOC4	0.3	7.03	0.53	1.2e-10	Eye color traits;
TGCT	cis	rs1784581	0.588	rs7453474	chr6:162421736	C/T	cg17173639	chr6:162384350	PARK2	0.4	6.6	0.51	1.08e-9	Itch intensity from mosquito bite;
TGCT	cis	rs6598955	0.671	rs12085416	chr1:26627835	T/C	cg04990556	chr1:26633338	UBXN11	0.67	5.44	0.44	2.77e-7	Obesity-related traits;
TGCT	trans	rs9388451	0.807	rs1269175	chr6:126040435	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.74	7.56	0.56	7.71e-12	Brugada syndrome;
TGCT	cis	rs929354	0.772	rs1182442	chr7:157026633	G/A	cg05182265	chr7:156933206	UBE3C	0.4	9.0	0.63	3.25e-15	Body mass index;
TGCT	cis	rs7010267	0.570	rs6469798	chr8:120018291	C/T	cg17171407	chr8:119960777	TNFRSF11B	0.26	4.59	0.38	1.06e-5	Total body bone mineral density (age 45-60);
TGCT	cis	rs10782582	0.617	rs1846233	chr1:76159354	C/T	cg03433033	chr1:76189801	ACADM	-0.65	-7.41	-0.55	1.67e-11	Daytime sleep phenotypes;
TGCT	cis	rs11190604	1.000	rs2489043	chr10:102334327	T/C	cg16342193	chr10:102329863	NA	-0.4	-5.08	-0.42	1.32e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs595982	0.527	rs73061658	chr19:49372376	G/C	cg21252483	chr19:49399788	TULP2	-0.42	-6.36	-0.5	3.58e-9	Red cell distribution width;
TGCT	cis	rs595982	0.527	rs73061656	chr19:49372355	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.69	-9.16	-0.64	1.35e-15	Red cell distribution width;
TGCT	cis	rs1153858	1.000	rs12593230	chr15:45646968	A/T	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.62e-8	Homoarginine levels;
TGCT	cis	rs473651	0.935	rs483166	chr2:239346641	C/T	cg21699342	chr2:239360505	ASB1	-0.17	-4.78	-0.39	4.78e-6	Multiple system atrophy;
TGCT	cis	rs57994353	0.802	rs12002854	chr9:139377499	G/A	cg13741927	chr9:139327495	INPP5E	-0.23	-5.16	-0.42	9.54e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs17270561	0.723	rs12192635	chr6:25880907	A/T	cg16482183	chr6:26056742	HIST1H1C	0.86	6.55	0.51	1.4e-9	Iron status biomarkers;
TGCT	cis	rs200810	0.656	rs17752324	chr6:98025365	C/T	cg16511841	chr6:97730490	C6orf167;MIR548H3	-0.65	-4.47	-0.37	1.71e-5	Body mass index;
TGCT	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg23758822	chr17:41437982	NA	0.72	6.9	0.53	2.33e-10	Menopause (age at onset);
TGCT	cis	rs3733631	1.000	rs10014175	chr4:104659515	T/A	cg24090629	chr4:104641072	TACR3	-0.73	-6.03	-0.48	1.76e-8	Menarche (age at onset);
TGCT	cis	rs1865760	0.929	rs12195653	chr6:25958621	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.65	6.25	0.49	6.04e-9	Height;
TGCT	cis	rs7726839	0.574	rs11134149	chr5:637277	A/G	cg09021430	chr5:549028	NA	-0.34	-4.99	-0.41	1.99e-6	Obesity-related traits;
TGCT	cis	rs7937682	0.961	rs1784784	chr11:111483185	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.99	-9.76	-0.66	4.76e-17	Primary sclerosing cholangitis;
TGCT	cis	rs7044106	0.791	rs4836829	chr9:123482747	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	4.95	0.41	2.37e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs1372520	0.684	rs2619368	chr4:90729747	T/G	cg20003494	chr4:90757398	SNCA	-0.66	-5.21	-0.42	7.59e-7	Neuroticism;
TGCT	cis	rs4730250	0.707	rs257372	chr7:106796977	T/G	cg02696742	chr7:106810147	HBP1	-0.72	-5.89	-0.47	3.44e-8	Osteoarthritis;
TGCT	trans	rs9951602	0.512	rs9958376	chr18:76655167	G/T	cg02800362	chr5:177631904	HNRNPAB	1.13	12.84	0.76	1.57e-24	Obesity-related traits;
TGCT	cis	rs2458413	0.563	rs2458422	chr8:105332817	C/T	cg04554929	chr8:105342491	NA	-0.61	-9.81	-0.66	3.55e-17	Paget's disease;
TGCT	cis	rs524023	0.915	rs531763	chr11:64352063	A/G	cg07733098	chr11:64478343	NRXN2	-0.31	-4.63	-0.38	9.14e-6	Urate levels in obese individuals;
TGCT	cis	rs1568889	0.838	rs4572130	chr11:28371794	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.91	10.24	0.68	3.31e-18	Bipolar disorder;
TGCT	cis	rs8180040	0.932	rs12490058	chr3:47529063	T/C	cg27129171	chr3:47204927	SETD2	0.66	8.01	0.58	7.07e-13	Colorectal cancer;
TGCT	cis	rs916888	0.821	rs199505	chr17:44859410	A/G	cg15921436	chr17:44337874	NA	-0.51	-6.96	-0.53	1.77e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs13102973	0.931	rs13134190	chr4:135854932	T/C	cg14419869	chr4:135874104	NA	0.23	4.58	0.38	1.12e-5	Subjective well-being;
TGCT	cis	rs9560113	0.959	rs4773385	chr13:112178452	C/T	cg14154082	chr13:112174009	NA	0.37	5.07	0.41	1.42e-6	Menarche (age at onset);
TGCT	trans	rs4650994	0.524	rs2476558	chr1:178580953	C/T	cg05059571	chr16:84539110	KIAA1609	0.52	10.34	0.68	1.85e-18	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs12142240	0.667	rs12062	chr1:46830447	G/T	cg14993813	chr1:46806288	NSUN4	0.57	4.8	0.4	4.54e-6	Menopause (age at onset);
TGCT	cis	rs8077889	0.645	rs1230396	chr17:41843029	A/C	cg26893861	chr17:41843967	DUSP3	-1.15	-21.87	-0.89	2.21e-44	Triglycerides;
TGCT	cis	rs7829975	0.774	rs35039922	chr8:8675325	A/T	cg08975724	chr8:8085496	FLJ10661	0.54	4.79	0.4	4.63e-6	Mood instability;
TGCT	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg16325326	chr1:53192061	ZYG11B	-0.58	-6.41	-0.5	2.75e-9	Monocyte count;
TGCT	cis	rs9640161	0.750	rs11765644	chr7:150026339	C/G	cg10018233	chr7:150070692	REPIN1	0.32	4.61	0.38	9.67e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg07507251	chr3:52567010	NT5DC2	0.48	6.76	0.52	4.9e-10	Bipolar disorder;
TGCT	cis	rs7772486	0.875	rs1331637	chr6:146337087	T/C	cg23711669	chr6:146136114	FBXO30	0.88	9.67	0.66	7.78e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg12311346	chr5:56204834	C5orf35	0.57	6.13	0.48	1.07e-8	Initial pursuit acceleration;
TGCT	cis	rs9611565	0.592	rs57102627	chr22:41987627	T/C	cg13695892	chr22:41940480	POLR3H	-0.83	-7.82	-0.57	1.94e-12	Vitiligo;
TGCT	cis	rs4803468	0.967	rs2304243	chr19:41942708	C/G	cg09537434	chr19:41945824	ATP5SL	0.91	10.21	0.68	3.82e-18	Height;
TGCT	cis	rs67311347	1.000	rs2276871	chr3:40499273	C/T	cg17264618	chr3:40429014	ENTPD3	0.31	4.48	0.37	1.7e-5	Renal cell carcinoma;
TGCT	cis	rs35146811	0.659	rs863450	chr7:99821685	C/T	cg04778012	chr7:99775508	STAG3;GPC2	-0.36	-5.1	-0.42	1.22e-6	Coronary artery disease;
TGCT	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg01585852	chr22:24235823	MIF	-0.22	-4.7	-0.39	6.78e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9389248	0.690	rs728030	chr6:135246294	G/T	cg22676075	chr6:135203613	NA	-0.48	-4.82	-0.4	4.1e-6	High light scatter reticulocyte percentage of red cells;
TGCT	trans	rs561341	1.000	rs1557731	chr17:30321567	T/G	cg20587970	chr11:113659929	NA	-1.05	-13.02	-0.76	5.98e-25	Hip circumference adjusted for BMI;
TGCT	cis	rs7666738	0.830	rs1869082	chr4:98841254	T/A	cg17366294	chr4:99064904	C4orf37	0.72	7.5	0.56	1.07e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1801251	0.778	rs2592115	chr2:233736349	C/T	cg08000102	chr2:233561755	GIGYF2	-0.44	-4.45	-0.37	1.87e-5	Coronary artery disease;
TGCT	cis	rs4711350	1.000	rs4711350	chr6:33741716	A/G	cg18005901	chr6:33739558	LEMD2	-0.55	-5.87	-0.47	3.73e-8	Schizophrenia;
TGCT	cis	rs8002180	0.959	rs1970477	chr13:95921204	C/T	cg24476569	chr13:95954382	ABCC4	0.39	4.97	0.41	2.2e-6	Blood metabolite levels;
TGCT	cis	rs7121446	0.512	rs7111523	chr11:121897397	A/G	cg22813542	chr11:121986974	LOC399959;BLID	-0.48	-4.59	-0.38	1.08e-5	Cardiovascular risk factors (age interaction);
TGCT	cis	rs6684514	0.922	rs12037778	chr1:156284864	A/G	cg16558208	chr1:156270281	VHLL	0.48	9.6	0.65	1.19e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs35160687	0.865	rs10189492	chr2:86478902	G/A	cg12542933	chr2:85804724	VAMP8	0.4	4.82	0.4	4.16e-6	Night sleep phenotypes;
TGCT	cis	rs12220898	0.749	rs2377976	chr10:50479493	A/G	cg06072769	chr10:50146962	WDFY4	0.37	4.89	0.4	3.03e-6	Inflammatory biomarkers;
TGCT	cis	rs2243480	1.000	rs316331	chr7:65604622	A/G	cg07424592	chr7:64974309	NA	-1.27	-7.96	-0.58	9.33e-13	Diabetic kidney disease;
TGCT	cis	rs8141529	0.687	rs6005867	chr22:29165120	T/C	cg02153584	chr22:29168773	CCDC117	0.71	6.18	0.49	8.58e-9	Lymphocyte counts;
TGCT	cis	rs10992471	0.627	rs4744138	chr9:95291909	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.6	-5.36	-0.43	3.99e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs2033711	0.783	rs8113810	chr19:58932106	A/G	cg13877915	chr19:58951672	ZNF132	0.88	11.09	0.71	2.83e-20	Uric acid clearance;
TGCT	cis	rs1975974	1.000	rs7210944	chr17:21727476	C/T	cg18423549	chr17:21743878	NA	-0.56	-5.12	-0.42	1.11e-6	Psoriasis;
TGCT	cis	rs9549367	0.756	rs9603814	chr13:113900782	C/T	cg18105134	chr13:113819100	PROZ	0.34	5.76	0.46	6.38e-8	Platelet distribution width;
TGCT	cis	rs826838	1.000	rs10875717	chr12:38911174	T/C	cg26384229	chr12:38710491	ALG10B	1.01	9.84	0.66	3.01e-17	Heart rate;
TGCT	cis	rs12971120	0.947	rs7241558	chr18:72169267	A/T	cg25817165	chr18:72167213	CNDP2	-0.3	-5.61	-0.45	1.28e-7	Refractive error;
TGCT	trans	rs72772090	1.000	rs56116814	chr5:96048714	G/A	cg17670890	chr5:176011783	PCDH24	0.37	6.62	0.51	9.8e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs7588654	1.000	rs72613757	chr2:219968869	G/A	cg19394737	chr2:219892361	CCDC108	-0.35	-4.55	-0.38	1.27e-5	Height;
TGCT	cis	rs3027009	0.881	rs3026955	chr1:159144034	C/A	cg24432768	chr1:158149974	CD1D	-0.55	-4.76	-0.39	5.41e-6	Lean body mass and age at menarche (combined);
TGCT	cis	rs2439831	1.000	rs565007	chr15:43716641	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.8	5.7	0.46	8.33e-8	Lung cancer in ever smokers;
TGCT	cis	rs9911578	1.000	rs3744108	chr17:56585872	G/C	cg12560992	chr17:57184187	TRIM37	-0.76	-9.26	-0.64	7.9e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs1153858	1.000	rs4627277	chr15:45652768	C/A	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.62e-8	Homoarginine levels;
TGCT	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.49	5.14	0.42	1.02e-6	Lymphocyte counts;
TGCT	cis	rs4711350	0.765	rs943473	chr6:33743651	G/C	cg18005901	chr6:33739558	LEMD2	-0.59	-6.72	-0.52	5.99e-10	Schizophrenia;
TGCT	cis	rs9318086	0.648	rs7330140	chr13:24473074	A/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.82	8.98	0.63	3.58e-15	Myopia (pathological);
TGCT	cis	rs3020333	0.755	rs1293935	chr6:152017958	C/G	cg22157087	chr6:152012887	ESR1	0.24	6.18	0.49	8.44e-9	Total body bone mineral density;
TGCT	cis	rs8179	0.645	rs6954221	chr7:92283262	A/G	cg15732164	chr7:92237376	CDK6	0.29	5.05	0.41	1.57e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
TGCT	cis	rs412000	0.560	rs4793583	chr17:56451407	A/C	cg12560992	chr17:57184187	TRIM37	-0.71	-7.5	-0.56	1.05e-11	Primary tooth development (time to first tooth eruption);
TGCT	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg11644478	chr21:40555479	PSMG1	1.04	10.72	0.69	2.25e-19	Cognitive function;
TGCT	cis	rs1964356	0.967	rs2953802	chr8:8851881	G/A	cg15556689	chr8:8085844	FLJ10661	0.73	6.57	0.51	1.27e-9	Mean corpuscular volume;
TGCT	cis	rs10908458	0.584	rs10908455	chr1:155067283	C/T	cg23973274	chr1:155060172	NA	0.27	5.11	0.42	1.21e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs5769707	0.632	rs5770601	chr22:50021903	A/G	cg06623630	chr22:50017776	C22orf34	-0.29	-4.86	-0.4	3.48e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs137699	1.000	rs5757630	chr22:39754433	G/T	cg24399712	chr22:39784796	NA	-0.65	-5.64	-0.45	1.11e-7	IgG glycosylation;
TGCT	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg16414030	chr3:133502952	NA	0.66	11.1	0.71	2.65e-20	Iron status biomarkers;
TGCT	cis	rs2836974	0.545	rs8128901	chr21:40710419	G/A	cg11890956	chr21:40555474	PSMG1	0.78	7.81	0.57	2.02e-12	Cognitive function;
TGCT	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg22535103	chr8:58192502	C8orf71	-0.4	-5.06	-0.41	1.44e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg22800045	chr5:56110881	MAP3K1	0.53	4.43	0.37	2.01e-5	Initial pursuit acceleration;
TGCT	cis	rs6076065	0.630	rs2424558	chr20:23429344	A/G	cg11657817	chr20:23433608	CST11	0.34	6.11	0.48	1.2e-8	Facial morphology (factor 15, philtrum width);
TGCT	cis	rs57590327	0.503	rs1461611	chr3:81512061	C/A	cg07356753	chr3:81810745	GBE1	0.58	4.89	0.4	3.06e-6	Extraversion;
TGCT	cis	rs9467773	0.620	rs2451732	chr6:26622904	A/T	cg15659132	chr6:26577336	NA	-0.88	-10.64	-0.69	3.47e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs1371867	0.810	rs2919470	chr8:101233301	C/A	cg06636551	chr8:101224915	SPAG1	0.53	7.24	0.54	4.19e-11	Atrioventricular conduction;
TGCT	cis	rs7617773	0.747	rs34076262	chr3:48370416	C/T	cg11946769	chr3:48343235	NME6	0.8	6.91	0.53	2.26e-10	Coronary artery disease;
TGCT	cis	rs986417	0.818	rs761557	chr14:61077484	C/T	cg24736989	chr14:60973904	NA	0.68	4.44	0.37	2e-5	Gut microbiota (bacterial taxa);
TGCT	cis	rs9952991	0.566	rs657555	chr18:12847136	C/T	cg23598886	chr18:12777645	NA	0.58	5.16	0.42	9.54e-7	Inflammatory skin disease;
TGCT	cis	rs7089973	0.604	rs8181444	chr10:116588981	C/T	cg03647239	chr10:116582469	FAM160B1	0.59	5.75	0.46	6.46e-8	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs3764563	1.000	rs2283603	chr19:15731128	T/C	cg20725493	chr19:15740067	CYP4F8	-0.43	-4.68	-0.39	7.26e-6	Inflammatory biomarkers;
TGCT	cis	rs9527	0.668	rs7092815	chr10:104736345	G/T	cg15744005	chr10:104629667	AS3MT	-0.44	-5.02	-0.41	1.79e-6	Arsenic metabolism;
TGCT	cis	rs17102423	0.964	rs11627859	chr14:65602384	G/A	cg11161011	chr14:65562177	MAX	-0.49	-6.7	-0.52	6.46e-10	Obesity-related traits;
TGCT	trans	rs6740731	0.518	rs16823846	chr2:145299944	C/T	cg03855592	chr7:113034122	NA	0.41	6.71	0.52	6.33e-10	Coronary artery disease;
TGCT	cis	rs9486719	1.000	rs28623445	chr6:96899116	G/T	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.21	-0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg22963979	chr7:1858916	MAD1L1	-0.32	-4.8	-0.4	4.57e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg22166914	chr1:53195759	ZYG11B	-0.36	-5.93	-0.47	2.78e-8	Monocyte count;
TGCT	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg27535305	chr1:53392650	SCP2	-0.23	-4.62	-0.38	9.41e-6	Monocyte count;
TGCT	cis	rs10779751	0.770	rs11581010	chr1:11212458	A/G	cg08854313	chr1:11322531	MTOR	-0.83	-6.46	-0.5	2.16e-9	Body mass index;
TGCT	cis	rs1801251	1.000	rs11676216	chr2:233706368	C/T	cg25237894	chr2:233734115	C2orf82	-0.33	-5.94	-0.47	2.71e-8	Coronary artery disease;
TGCT	cis	rs7208859	0.623	rs56378576	chr17:29010120	C/T	cg13385521	chr17:29058706	SUZ12P	0.75	4.51	0.38	1.5e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs6121246	0.697	rs6060912	chr20:30325755	C/A	cg18721089	chr20:30220636	NA	-0.43	-4.75	-0.39	5.54e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs2228479	0.557	rs11641726	chr16:89891619	G/A	cg06558623	chr16:89946397	TCF25	0.55	4.79	0.4	4.69e-6	Skin colour saturation;
TGCT	cis	rs4148883	0.603	rs1893883	chr4:100124716	C/G	cg12011299	chr4:100065546	ADH4	0.37	5.47	0.44	2.36e-7	Alcohol dependence;
TGCT	cis	rs7666738	0.830	rs28416660	chr4:98899525	C/G	cg05340658	chr4:99064831	C4orf37	0.51	5.93	0.47	2.84e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1355223	0.583	rs2941057	chr11:34882220	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.8	8.94	0.63	4.49e-15	Systemic lupus erythematosus and Systemic sclerosis;
TGCT	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg17747265	chr1:1875780	NA	-0.37	-7.04	-0.53	1.14e-10	Body mass index;
TGCT	cis	rs4455778	0.860	rs6973983	chr7:49069524	T/A	cg26309511	chr7:48887640	NA	0.45	5.32	0.43	4.78e-7	Lung cancer in never smokers;
TGCT	trans	rs12339966	0.653	rs11795038	chr9:11285121	T/G	cg03488587	chr11:64876988	C11orf2	0.3	6.7	0.52	6.5e-10	Systolic blood pressure;
TGCT	trans	rs1415174	0.916	rs7537916	chr1:87852384	A/T	cg23065576	chr20:25207247	ENTPD6	-0.25	-6.66	-0.51	8.09e-10	Breast cancer;
TGCT	cis	rs826838	0.967	rs826870	chr12:39120250	G/A	cg13010199	chr12:38710504	ALG10B	-0.64	-5.07	-0.41	1.39e-6	Heart rate;
TGCT	cis	rs7809950	1.000	rs10274041	chr7:107261556	C/T	cg23024343	chr7:107201750	COG5	0.36	5.63	0.45	1.15e-7	Coronary artery disease;
TGCT	cis	rs427394	1.000	rs427394	chr5:6745875	A/G	cg10857441	chr5:6722123	POLS	-0.29	-6.93	-0.53	2.07e-10	Menopause (age at onset);
TGCT	cis	rs295140	0.535	rs35417285	chr2:201233040	T/C	cg04283868	chr2:201171347	SPATS2L	0.52	4.99	0.41	2.02e-6	QT interval;
TGCT	cis	rs7927592	0.546	rs497261	chr11:68192244	T/C	cg16797656	chr11:68205561	LRP5	0.29	4.97	0.41	2.16e-6	Total body bone mineral density;
TGCT	cis	rs7246657	0.943	rs4969487	chr19:37831039	C/T	cg18154014	chr19:37997991	ZNF793	0.97	6.49	0.5	1.82e-9	Coronary artery calcification;
TGCT	cis	rs1994135	0.669	rs11052747	chr12:33697913	C/G	cg06521331	chr12:34319734	NA	-0.31	-4.81	-0.4	4.32e-6	Resting heart rate;
TGCT	cis	rs56104184	0.775	rs73061689	chr19:49397214	C/T	cg21252483	chr19:49399788	TULP2	-0.42	-5.89	-0.47	3.47e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs7833790	0.724	rs12676336	chr8:82771008	C/T	cg27398817	chr8:82754497	SNX16	0.69	5.52	0.44	1.9e-7	Diastolic blood pressure;
TGCT	cis	rs12210905	1.000	rs72843629	chr6:27175215	G/T	cg08851530	chr6:28072375	NA	1.12	5.43	0.44	2.82e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs61990749	0.597	rs12887606	chr14:78200620	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	0.62	4.58	0.38	1.13e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs4499344	0.730	rs421607	chr19:33104951	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	8.76	0.62	1.23e-14	Mean platelet volume;
TGCT	trans	rs11088226	0.645	rs2833917	chr21:33957544	C/T	cg09050820	chr6:167586206	TCP10L2	0.74	6.96	0.53	1.71e-10	Gastritis;
TGCT	cis	rs7611238	0.560	rs7611090	chr3:195025180	T/G	cg27323046	chr3:195102265	ACAP2	0.37	4.89	0.4	3.12e-6	Body mass index;
TGCT	trans	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.85	8.84	0.62	7.83e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs72843506	0.722	rs78477504	chr17:20138347	C/T	cg18979559	chr17:20280153	CCDC144C	-0.65	-4.88	-0.4	3.2e-6	Schizophrenia;
TGCT	cis	rs9549367	0.713	rs3024743	chr13:113821430	C/T	cg09473364	chr13:112927190	NA	-0.3	-4.47	-0.37	1.71e-5	Platelet distribution width;
TGCT	cis	rs896854	0.738	rs481887	chr8:95967838	A/G	cg09323728	chr8:95962352	TP53INP1	0.45	5.08	0.42	1.33e-6	Type 2 diabetes;
TGCT	cis	rs11711311	0.911	rs9817327	chr3:113478500	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.79	-7.32	-0.55	2.75e-11	IgG glycosylation;
TGCT	cis	rs7219021	0.705	rs11079842	chr17:47002762	G/A	cg26022315	chr17:47021804	SNF8	-0.54	-4.65	-0.39	8.2e-6	Schizophrenia or bipolar disorder;
TGCT	cis	rs28595532	0.920	rs115994609	chr4:119777273	G/A	cg14228332	chr4:119757509	SEC24D	1.26	7.08	0.54	9.26e-11	Cannabis dependence symptom count;
TGCT	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg06112835	chr11:68658793	MRPL21	0.45	7.43	0.56	1.54e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs13082711	0.522	rs543882	chr3:27331854	T/C	cg02860705	chr3:27208620	NA	0.34	5.7	0.46	8.16e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs539096	0.624	rs499257	chr1:44078384	T/C	cg12908607	chr1:44402522	ARTN	-0.44	-4.86	-0.4	3.55e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs60154123	0.505	rs77990373	chr1:210041111	T/C	cg12034118	chr1:209979487	IRF6	0.65	4.56	0.38	1.2e-5	Coronary artery disease;
TGCT	cis	rs546131	0.928	rs547504	chr11:34847225	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.58	5.17	0.42	8.99e-7	Lung disease severity in cystic fibrosis;
TGCT	cis	rs6876348	0.520	rs10037758	chr5:128288397	G/A	cg25555059	chr5:128301488	SLC27A6	-0.28	-4.76	-0.39	5.24e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6754311	0.731	rs6719488	chr2:136575199	G/T	cg07169764	chr2:136633963	MCM6	-0.61	-5.61	-0.45	1.25e-7	Mosquito bite size;
TGCT	cis	rs7582180	0.606	rs10174145	chr2:100932488	T/C	cg08017756	chr2:100939284	LONRF2	-0.3	-4.98	-0.41	2.11e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg04944784	chr2:26401820	FAM59B	0.76	6.24	0.49	6.46e-9	Gut microbiome composition (summer);
TGCT	cis	rs9486719	1.000	rs12190508	chr6:96898269	T/C	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.21	-0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs7208859	0.614	rs216477	chr17:28866744	A/C	cg13385521	chr17:29058706	SUZ12P	-0.69	-4.56	-0.38	1.19e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg05665937	chr4:1216051	CTBP1	0.25	4.75	0.39	5.64e-6	Obesity-related traits;
TGCT	cis	rs1372520	0.873	rs983361	chr4:90761944	T/G	cg14346243	chr4:90757452	SNCA	-0.62	-5.42	-0.44	2.92e-7	Neuroticism;
TGCT	cis	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg06558623	chr16:89946397	TCF25	0.53	6.59	0.51	1.14e-9	Skin colour saturation;
TGCT	cis	rs9985766	0.958	rs62339878	chr4:150987708	G/T	cg05926478	chr4:151174724	DCLK2	-0.24	-4.64	-0.38	8.63e-6	Coronary artery disease;Myocardial infarction;
TGCT	cis	rs6665290	0.904	rs2297415	chr1:227172903	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.0	-19.08	-0.86	1.06e-38	Myeloid white cell count;
TGCT	cis	rs514406	0.505	rs405208	chr1:53176674	C/T	cg25767906	chr1:53392781	SCP2	-0.47	-5.22	-0.42	7.39e-7	Monocyte count;
TGCT	cis	rs7975161	0.521	rs4630362	chr12:104727744	G/C	cg25273343	chr12:104657179	TXNRD1	-0.47	-6.04	-0.48	1.7e-8	Toenail selenium levels;
TGCT	cis	rs3091242	0.933	rs4649084	chr1:25752617	A/G	cg23205692	chr1:25664452	TMEM50A	0.5	5.21	0.42	7.8e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs700590	0.723	rs165945	chr5:88110338	A/G	cg22951263	chr5:87985283	NA	0.56	5.4	0.44	3.24e-7	Educational attainment (years of education);
TGCT	cis	rs8077577	0.895	rs16960986	chr17:18108562	A/G	cg09161412	chr17:18057145	MYO15A	0.66	5.4	0.44	3.29e-7	Obesity-related traits;
TGCT	cis	rs42648	0.869	rs6948139	chr7:89937781	T/A	cg25739043	chr7:89950458	NA	-0.71	-7.18	-0.54	5.5e-11	Homocysteine levels;
TGCT	cis	rs3617	0.591	rs2276823	chr3:52869263	C/A	cg11645453	chr3:52864694	ITIH4	-0.29	-5.64	-0.45	1.11e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	trans	rs28735056	0.875	rs62103176	chr18:77623611	G/C	cg05926928	chr17:57297772	GDPD1	0.64	6.76	0.52	4.85e-10	Schizophrenia;
TGCT	cis	rs3733585	0.699	rs11724510	chr4:9958583	C/T	cg00071950	chr4:10020882	SLC2A9	-0.55	-6.55	-0.51	1.41e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	trans	rs11175194	0.546	rs73122698	chr12:64210942	C/T	cg15233734	chr6:37450823	C6orf129	0.55	6.71	0.52	6.25e-10	Epithelial ovarian cancer;
TGCT	cis	rs72634258	0.517	rs35982383	chr1:7949148	A/G	cg26816564	chr1:7831052	VAMP3	0.63	4.55	0.38	1.28e-5	Inflammatory bowel disease;
TGCT	cis	rs4563143	0.675	rs55849754	chr19:29279665	G/A	cg12667521	chr19:29218732	NA	0.55	5.9	0.47	3.29e-8	Methadone dose in opioid dependence;
TGCT	cis	rs7819412	0.668	rs4841507	chr8:11046394	C/G	cg21775007	chr8:11205619	TDH	-0.54	-5.01	-0.41	1.82e-6	Triglycerides;
TGCT	cis	rs4499344	0.633	rs259256	chr19:33151802	C/T	cg26639809	chr19:33781782	NA	0.22	4.47	0.37	1.75e-5	Mean platelet volume;
TGCT	cis	rs10411936	0.785	rs2363120	chr19:16519871	C/A	cg14704714	chr19:15740395	CYP4F8	-0.26	-4.57	-0.38	1.16e-5	White blood cell count;Multiple sclerosis;
TGCT	cis	rs7236492	0.748	rs78531995	chr18:77198370	C/T	cg15644404	chr18:77186268	NFATC1	-0.35	-4.76	-0.39	5.22e-6	Inflammatory bowel disease;Crohn's disease;
TGCT	trans	rs629535	0.911	rs627382	chr8:70014081	C/T	cg21567404	chr3:27674614	NA	-0.59	-9.15	-0.63	1.43e-15	Dupuytren's disease;
TGCT	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.15	0.82	2.71e-32	Prudent dietary pattern;
TGCT	cis	rs6570726	0.935	rs406343	chr6:145874388	A/G	cg23711669	chr6:146136114	FBXO30	0.71	7.03	0.53	1.25e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4925386	0.840	rs6143024	chr20:60914229	A/G	cg24112000	chr20:60950667	NA	-0.39	-4.65	-0.39	8.33e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs79724016	1.000	rs1105414	chr1:42144764	C/T	cg14093106	chr1:42503579	NA	-0.66	-4.96	-0.41	2.29e-6	Breast cancer;
TGCT	cis	rs6964587	1.000	rs60147309	chr7:91736098	C/G	cg22709100	chr7:91322751	NA	0.28	4.61	0.38	9.79e-6	Breast cancer;
TGCT	cis	rs4516970	0.826	rs59246098	chr6:160149462	C/CA	cg06131755	chr6:160182447	ACAT2	0.61	6.2	0.49	7.52e-9	Iron status biomarkers;
TGCT	cis	rs9457247	0.902	rs34560498	chr6:167395862	A/G	cg25258033	chr6:167368657	RNASET2	0.19	4.77	0.39	5.05e-6	Crohn's disease;
TGCT	cis	rs79976124	0.879	rs12213669	chr6:66627704	G/A	cg07460842	chr6:66804631	NA	0.58	5.32	0.43	4.77e-7	Type 2 diabetes;
TGCT	cis	rs77861329	1.000	rs164638	chr3:52207886	T/G	cg08692210	chr3:52188851	WDR51A	0.93	4.77	0.39	5.04e-6	Macrophage inflammatory protein 1b levels;
TGCT	cis	rs9325144	0.560	rs10785586	chr12:38676197	G/A	cg26384229	chr12:38710491	ALG10B	-0.66	-5.9	-0.47	3.21e-8	Morning vs. evening chronotype;
TGCT	cis	rs1371867	0.846	rs1788206	chr8:101306966	A/G	cg06636551	chr8:101224915	SPAG1	-0.48	-6.52	-0.51	1.62e-9	Atrioventricular conduction;
TGCT	cis	rs514406	0.893	rs6588446	chr1:53425260	G/A	cg27535305	chr1:53392650	SCP2	0.25	4.95	0.41	2.41e-6	Monocyte count;
TGCT	cis	rs6430585	0.528	rs6711493	chr2:136692553	A/G	cg07169764	chr2:136633963	MCM6	1.2	11.66	0.72	1.12e-21	Corneal structure;
TGCT	cis	rs9902453	0.904	rs8071742	chr17:28361669	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-6.56	-0.51	1.3e-9	Coffee consumption (cups per day);
TGCT	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg10047753	chr17:41438598	NA	0.95	9.61	0.65	1.12e-16	Menopause (age at onset);
TGCT	cis	rs1555895	0.611	rs3763722	chr10:859270	C/T	cg02193355	chr10:851439	NA	0.22	5.24	0.43	6.69e-7	Survival in rectal cancer;
TGCT	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	8.16	0.59	3.1400000000000003e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs3847687	1.000	rs34853396	chr12:131519265	G/T	cg13586425	chr12:131519906	GPR133	-0.35	-5.6	-0.45	1.32e-7	Longevity;
TGCT	cis	rs9549367	0.826	rs9549710	chr13:113898064	A/C	cg18105134	chr13:113819100	PROZ	-0.34	-5.58	-0.45	1.41e-7	Platelet distribution width;
TGCT	cis	rs9467711	0.606	rs9357006	chr6:26364628	A/C	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	trans	rs208520	0.690	rs12208977	chr6:66725257	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.99	10.55	0.69	5.8e-19	Exhaled nitric oxide output;
TGCT	cis	rs7312933	0.501	rs7296357	chr12:42729891	T/G	cg19980929	chr12:42632907	YAF2	-0.41	-5.76	-0.46	6.3e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs7267979	1.000	rs6050573	chr20:25366065	C/G	cg14121845	chr20:25566513	NINL	0.5	5.41	0.44	3.12e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9814567	1.000	rs9289478	chr3:134268619	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.92	-9.2	-0.64	1.11e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs35146811	0.735	rs11767968	chr7:99790971	G/A	cg22906224	chr7:99728672	NA	0.49	4.45	0.37	1.88e-5	Coronary artery disease;
TGCT	cis	rs9295536	0.651	rs6900792	chr6:22136938	T/C	cg25792714	chr6:21666554	FLJ22536	-0.52	-4.73	-0.39	6.03e-6	Neuroblastoma;
TGCT	cis	rs11190604	1.000	rs3750633	chr10:102308214	C/T	cg16342193	chr10:102329863	NA	-0.41	-5.13	-0.42	1.1e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs16957091	0.647	rs28581361	chr15:43396604	C/T	cg17935677	chr15:44119062	WDR76	0.53	4.58	0.38	1.11e-5	MGMT methylation in smokers;
TGCT	cis	rs6714710	0.580	rs11680018	chr2:98479581	C/A	cg26665480	chr2:98280029	ACTR1B	0.64	6.09	0.48	1.29e-8	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs12477438	0.765	rs7571390	chr2:99626593	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-7.12	-0.54	7.76e-11	Chronic sinus infection;
TGCT	cis	rs7552404	1.000	rs7533888	chr1:76160449	A/C	cg03433033	chr1:76189801	ACADM	0.83	9.91	0.66	2.13e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs3096299	0.582	rs12935119	chr16:89542874	A/T	cg06640241	chr16:89574553	SPG7	0.59	5.69	0.45	8.77e-8	Multiple myeloma (IgH translocation);
TGCT	cis	rs6964587	1.000	rs28410528	chr7:91647390	A/G	cg17063962	chr7:91808500	NA	0.91	9.99	0.67	1.32e-17	Breast cancer;
TGCT	cis	rs67311347	1.000	rs7612015	chr3:40399974	A/C	cg13683864	chr3:40499215	RPL14	-1.02	-10.8	-0.7	1.43e-19	Renal cell carcinoma;
TGCT	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg24531977	chr5:56204891	C5orf35	-0.94	-9.1	-0.63	1.9e-15	Initial pursuit acceleration;
TGCT	cis	rs7267979	1.000	rs1046073	chr20:25281333	G/A	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9394169	0.875	rs1547670	chr6:33775868	G/A	cg00334056	chr6:33755658	LEMD2	-0.24	-4.55	-0.38	1.28e-5	Essential tremor;
TGCT	cis	rs11190604	1.000	rs10883502	chr10:102238343	T/G	cg23241863	chr10:102295624	HIF1AN	0.63	4.95	0.41	2.41e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs12188164	0.931	rs115554641	chr5:443236	C/G	cg26850624	chr5:429559	AHRR	-0.2	-4.84	-0.4	3.78e-6	Cystic fibrosis severity;
TGCT	cis	rs9359856	0.623	rs1179906	chr6:90323624	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.43	-4.69	-0.39	7.15e-6	Bipolar disorder;
TGCT	trans	rs10022799	1.000	rs6850485	chr4:168150023	T/C	cg08507725	chr4:8239220	SH3TC1	0.3	6.66	0.51	8e-10	Cognitive function;
TGCT	cis	rs9818758	0.556	rs9880309	chr3:49304329	G/C	cg00383909	chr3:49044727	WDR6	1.28	6.57	0.51	1.23e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs17741873	0.722	rs10824045	chr10:75656543	A/G	cg07699608	chr10:75541558	CHCHD1	0.6	4.72	0.39	6.35e-6	Paclitaxel disposition in epithelial ovarian cancer;
TGCT	cis	rs4822044	0.617	rs13054514	chr22:42130383	A/G	cg06634786	chr22:41940651	POLR3H	0.79	7.29	0.55	3.13e-11	Cannabis dependence symptom count;
TGCT	cis	rs12220898	0.526	rs4838505	chr10:50556797	T/C	cg07746882	chr10:49866792	NA	0.32	4.47	0.37	1.77e-5	Inflammatory biomarkers;
TGCT	cis	rs3096299	0.728	rs1011749	chr16:89510869	G/C	cg02187348	chr16:89574699	SPG7	0.62	6.7	0.52	6.56e-10	Multiple myeloma (IgH translocation);
TGCT	cis	rs2637266	1.000	rs12783273	chr10:78353221	T/C	cg18941641	chr10:78392320	NA	0.4	5.01	0.41	1.81e-6	Pulmonary function;
TGCT	trans	rs10435719	0.902	rs7006538	chr8:11804982	A/G	cg15556689	chr8:8085844	FLJ10661	0.76	7.28	0.55	3.36e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	trans	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg17830980	chr10:43048298	ZNF37B	-0.82	-10.2	-0.68	4.02e-18	Extrinsic epigenetic age acceleration;
TGCT	cis	rs4699052	0.625	rs2138592	chr4:104255718	A/G	cg16532752	chr4:104119610	CENPE	-0.51	-5.01	-0.41	1.8e-6	Testicular germ cell tumor;
TGCT	cis	rs9325144	0.554	rs1906264	chr12:38739490	A/G	cg26384229	chr12:38710491	ALG10B	0.61	5.62	0.45	1.22e-7	Morning vs. evening chronotype;
TGCT	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg03806693	chr22:41940476	POLR3H	1.13	12.99	0.76	6.98e-25	Vitiligo;
TGCT	cis	rs10791097	0.739	rs12279359	chr11:130730544	G/A	cg05962950	chr11:130786565	SNX19	0.8	9.66	0.66	8.34e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs16866061	1.000	rs3768886	chr2:225450161	G/C	cg12698349	chr2:225449008	CUL3	1.02	9.8	0.66	3.83e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg02725872	chr8:58115012	NA	-0.39	-4.79	-0.4	4.7e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9858542	0.953	rs35115732	chr3:49475155	T/C	cg03060546	chr3:49711283	APEH	-0.61	-5.37	-0.43	3.78e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs2013441	1.000	rs9325894	chr17:20197101	T/C	cg23224458	chr17:20280056	CCDC144C	-0.42	-4.91	-0.4	2.82e-6	Obesity-related traits;
TGCT	cis	rs763121	0.853	rs6519124	chr22:39045099	T/C	cg06022373	chr22:39101656	GTPBP1	0.8	8.25	0.6	1.95e-13	Menopause (age at onset);
TGCT	cis	rs4803468	1.000	rs3213861	chr19:41919944	A/C	cg09537434	chr19:41945824	ATP5SL	-0.9	-10.59	-0.69	4.65e-19	Height;
TGCT	cis	rs16958440	0.867	rs61689863	chr18:44669157	A/T	cg17192377	chr18:44677553	HDHD2	0.63	4.7	0.39	6.74e-6	Sitting height ratio;
TGCT	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.76	0.46	6.35e-8	Height;
TGCT	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg13683864	chr3:40499215	RPL14	-1.18	-12.96	-0.76	8.39e-25	Renal cell carcinoma;
TGCT	cis	rs9911578	1.000	rs12940681	chr17:56933622	T/C	cg05425664	chr17:57184151	TRIM37	-0.63	-6.25	-0.49	6.03e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs9467711	0.606	rs9393708	chr6:26362643	C/T	cg16898833	chr6:26189333	HIST1H4D	-1.09	-5.35	-0.43	4.15e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs174601	0.861	rs174550	chr11:61571478	T/C	cg01500311	chr11:61656094	FADS3	-0.3	-5.25	-0.43	6.42e-7	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
TGCT	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg13607699	chr17:42295918	UBTF	-0.59	-5.39	-0.44	3.37e-7	Total body bone mineral density;
TGCT	cis	rs11642862	1.000	rs11642862	chr16:30785824	A/G	cg02466173	chr16:30829666	NA	0.36	4.68	0.39	7.31e-6	Tonsillectomy;
TGCT	cis	rs9467773	1.000	rs9393732	chr6:26530898	G/A	cg15659132	chr6:26577336	NA	0.86	12.21	0.74	5.3e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs9291683	0.546	rs6820188	chr4:10051655	C/T	cg00071950	chr4:10020882	SLC2A9	0.55	6.22	0.49	6.92e-9	Bone mineral density;
TGCT	cis	rs1971762	0.545	rs6580949	chr12:53924293	T/C	cg16917193	chr12:54089295	NA	1.01	10.33	0.68	1.96e-18	Height;
TGCT	trans	rs9388451	0.839	rs1811852	chr6:126071575	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.74	-8.29	-0.6	1.61e-13	Brugada syndrome;
TGCT	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg21724239	chr8:58056113	NA	0.39	5.24	0.43	6.73e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs806215	0.526	rs3808078	chr7:127581677	G/A	cg11539674	chr7:127291444	SND1	-0.36	-4.65	-0.39	8.37e-6	Type 2 diabetes;
TGCT	cis	rs2075371	1.000	rs432487	chr7:133990114	T/G	cg11752832	chr7:134001865	SLC35B4	0.69	6.32	0.49	4.19e-9	Mean platelet volume;
TGCT	cis	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg18252515	chr7:66147081	NA	-1.1	-6.4	-0.5	2.85e-9	Diabetic kidney disease;
TGCT	cis	rs881375	0.715	rs10760119	chr9:123646060	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	5.31	0.43	4.79e-7	Rheumatoid arthritis;
TGCT	trans	rs8073060	0.586	rs7214250	chr17:33981704	C/G	cg19694781	chr19:47549865	TMEM160	-0.6	-13.37	-0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs854765	0.547	rs2955356	chr17:17964717	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.8	-8.45	-0.6	6.61e-14	Total body bone mineral density;
TGCT	trans	rs561341	0.739	rs8070554	chr17:30216868	A/T	cg20587970	chr11:113659929	NA	0.65	8.95	0.63	4.33e-15	Hip circumference adjusted for BMI;
TGCT	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	6.06	0.48	1.54e-8	Alzheimer's disease;
TGCT	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg23758822	chr17:41437982	NA	0.72	6.96	0.53	1.76e-10	Menopause (age at onset);
TGCT	cis	rs554111	0.560	rs592060	chr1:21050958	A/G	cg08890418	chr1:21044141	KIF17	-0.77	-7.47	-0.56	1.27e-11	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	trans	rs459571	0.959	rs2520100	chr9:136918137	A/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.77	-8.29	-0.6	1.58e-13	Platelet distribution width;
TGCT	cis	rs362272	0.524	rs6819202	chr4:3368264	G/A	cg22655196	chr4:3374909	RGS12	0.23	4.76	0.39	5.27e-6	Serum sulfate level;
TGCT	cis	rs9535307	0.615	rs3736830	chr13:50306221	G/C	cg08779649	chr13:50194554	NA	0.41	4.81	0.4	4.35e-6	Obesity-related traits;
TGCT	cis	rs9291683	0.609	rs4622999	chr4:10003395	C/G	cg11266682	chr4:10021025	SLC2A9	0.67	9.42	0.65	3.21e-16	Bone mineral density;
TGCT	cis	rs68092024	0.704	rs793487	chr3:99495422	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.53	6.33	0.49	4.06e-9	Cleft lip with or without cleft palate;
TGCT	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg06481639	chr22:41940642	POLR3H	-0.74	-6.74	-0.52	5.38e-10	Vitiligo;
TGCT	cis	rs10197940	0.545	rs2444267	chr2:152308611	T/G	cg06191203	chr2:152266755	RIF1	-0.57	-4.83	-0.4	4.02e-6	Lung cancer;
TGCT	cis	rs1048238	0.935	rs761760	chr1:16342419	A/G	cg21385522	chr1:16154831	NA	0.46	4.85	0.4	3.64e-6	Systolic blood pressure;
TGCT	cis	rs910316	1.000	rs175442	chr14:75603564	T/C	cg11812906	chr14:75593930	NEK9	-0.73	-7.13	-0.54	7.35e-11	Height;
TGCT	cis	rs4455778	0.561	rs6975663	chr7:49122743	G/C	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs7216064	1.000	rs7223930	chr17:65842186	G/A	cg12091567	chr17:66097778	LOC651250	-0.87	-6.85	-0.52	3.1e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs6490294	0.851	rs56814171	chr12:112402950	G/T	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Mean platelet volume;
TGCT	cis	rs2019216	0.500	rs7210996	chr17:21917331	G/A	cg22648282	chr17:21454238	C17orf51	-0.6	-5.54	-0.45	1.75e-7	Pelvic organ prolapse;
TGCT	cis	rs10791097	1.000	rs10791098	chr11:130718711	T/G	cg05962950	chr11:130786565	SNX19	0.75	8.14	0.59	3.64e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs1135314	0.580	rs10870116	chr9:139287674	G/A	cg13741927	chr9:139327495	INPP5E	-0.23	-4.68	-0.39	7.24e-6	Acute insulin response;
TGCT	cis	rs7647973	0.626	rs12715437	chr3:49751856	T/C	cg03034192	chr3:50606346	HEMK1;C3orf18	0.36	4.75	0.39	5.61e-6	Menarche (age at onset);
TGCT	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg06618935	chr21:46677482	NA	-0.32	-4.9	-0.4	2.95e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs950776	0.714	rs3743073	chr15:78909539	G/T	cg06917634	chr15:78832804	PSMA4	-0.62	-4.95	-0.41	2.39e-6	Sudden cardiac arrest;
TGCT	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg26354017	chr1:205819088	PM20D1	0.68	9.58	0.65	1.31e-16	Menarche (age at onset);
TGCT	cis	rs66716358	0.800	rs10838255	chr11:44320172	C/T	cg02785814	chr11:44338707	NA	-0.47	-4.53	-0.38	1.35e-5	Monobrow;
TGCT	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9534288	0.912	rs9534297	chr13:46624630	T/C	cg15192986	chr13:46630673	CPB2	-0.49	-6.18	-0.49	8.64e-9	Blood protein levels;
TGCT	cis	rs6752107	0.936	rs10187822	chr2:234206474	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.21	4.71	0.39	6.47e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs5760092	0.842	rs5760103	chr22:24248781	A/G	cg07154950	chr22:24370586	NA	-0.21	-4.55	-0.38	1.27e-5	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs889312	0.500	rs832570	chr5:56156408	G/A	cg12311346	chr5:56204834	C5orf35	-0.48	-5.26	-0.43	6.05e-7	Breast cancer;Breast cancer (early onset);
TGCT	cis	rs4727027	0.933	rs1468369	chr7:148839840	G/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	4.58	0.38	1.13e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs11955175	1.000	rs77394428	chr5:40743517	A/G	cg17351974	chr5:40835760	RPL37	0.84	5.34	0.43	4.23e-7	Bipolar disorder and schizophrenia;
TGCT	trans	rs1814175	0.565	rs4881721	chr11:49761851	G/A	cg03929089	chr4:120376271	NA	-0.57	-6.61	-0.51	1e-9	Height;
TGCT	cis	rs7267979	0.933	rs6138571	chr20:25435388	A/G	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3617	0.598	rs56214994	chr3:52878600	G/C	cg05573699	chr3:52720067	GNL3;PBRM1	0.49	4.77	0.39	5.04e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1448094	0.717	rs60713909	chr12:86294469	C/G	cg02569458	chr12:86230093	RASSF9	0.36	4.71	0.39	6.44e-6	Major depressive disorder;
TGCT	cis	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg16624210	chr5:671434	TPPP	0.41	4.74	0.39	5.82e-6	Obesity-related traits;
TGCT	cis	rs1163251	0.837	rs611365	chr1:120242571	C/T	cg19096424	chr1:120255104	PHGDH	0.6	5.94	0.47	2.66e-8	Blood metabolite levels;
TGCT	cis	rs10504229	0.679	rs72649131	chr8:58054288	G/T	cg08280861	chr8:58055591	NA	0.35	4.88	0.4	3.2e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6088590	1.000	rs11698977	chr20:33449691	C/T	cg24642439	chr20:33292090	TP53INP2	0.73	6.41	0.5	2.7e-9	Coronary artery disease;
TGCT	cis	rs7208859	0.573	rs73267829	chr17:29003939	G/A	cg13385521	chr17:29058706	SUZ12P	0.77	4.61	0.38	9.67e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.45	0.56	1.42e-11	Prudent dietary pattern;
TGCT	cis	rs9527	0.830	rs3740392	chr10:104636855	T/C	cg04362960	chr10:104952993	NT5C2	0.66	5.27	0.43	5.93e-7	Arsenic metabolism;
TGCT	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg03264133	chr6:25882463	NA	-0.66	-5.96	-0.47	2.4e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2050392	0.767	rs10763787	chr10:30700753	G/A	cg13289132	chr10:30722225	MAP3K8	0.44	5.46	0.44	2.49e-7	Inflammatory bowel disease;
TGCT	cis	rs4494114	0.967	rs3748563	chr1:39311998	G/A	cg25970120	chr1:39325951	RRAGC	-0.6	-6.43	-0.5	2.52e-9	Blood protein levels;
TGCT	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg01802117	chr1:53393560	SCP2	-0.39	-4.55	-0.38	1.27e-5	Monocyte count;
TGCT	cis	rs2073300	0.793	rs36165478	chr20:23457261	C/T	cg09953122	chr20:23471693	CST8	-0.59	-4.71	-0.39	6.5e-6	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg10047753	chr17:41438598	NA	0.68	6.16	0.48	9.22e-9	Menopause (age at onset);
TGCT	cis	rs7666738	0.830	rs35213297	chr4:98984049	T/C	cg18180107	chr4:99064573	C4orf37	0.53	4.89	0.4	3.01e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28735056	0.933	rs499472	chr18:77589759	C/T	cg20368463	chr18:77673604	PQLC1	-0.45	-5.53	-0.44	1.84e-7	Schizophrenia;
TGCT	cis	rs854765	0.547	rs2955372	chr17:17970229	T/C	cg09796270	chr17:17721594	SREBF1	-0.24	-4.69	-0.39	7e-6	Total body bone mineral density;
TGCT	cis	rs617219	0.698	rs10055956	chr5:78479678	G/A	cg23514016	chr5:78407564	BHMT	0.35	5.53	0.44	1.82e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs422249	0.819	rs174605	chr11:61626921	G/T	cg01500311	chr11:61656094	FADS3	-0.3	-5.12	-0.42	1.11e-6	Trans fatty acid levels;
TGCT	cis	rs12142240	0.698	rs12385697	chr1:46818898	T/C	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs13088645	0.532	rs9835166	chr3:134166224	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	6.29	0.49	4.88e-9	Coronary artery disease;
TGCT	cis	rs7582180	0.663	rs1114595	chr2:100960072	T/A	cg08017756	chr2:100939284	LONRF2	-0.3	-5.0	-0.41	1.93e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs3806843	0.576	rs246074	chr5:140307969	C/G	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.09e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	7.12	0.54	7.55e-11	Platelet count;
TGCT	cis	rs9399135	0.935	rs11759999	chr6:135370495	G/T	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.28e-6	Red blood cell count;
TGCT	cis	rs7772486	0.686	rs9497395	chr6:146013592	A/G	cg23711669	chr6:146136114	FBXO30	-0.84	-9.19	-0.64	1.15e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1008375	1.000	rs7659718	chr4:17638020	A/C	cg16339924	chr4:17578868	LAP3	0.71	5.75	0.46	6.46e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs12142240	0.698	rs1057535	chr1:46815898	T/C	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs250677	0.652	rs168751	chr5:148438264	C/T	cg23229984	chr5:148520753	ABLIM3	0.22	4.98	0.41	2.05e-6	Breast cancer;
TGCT	cis	rs992157	0.767	rs2382822	chr2:219173327	T/C	cg00012203	chr2:219082015	ARPC2	-0.82	-8.13	-0.59	3.76e-13	Colorectal cancer;
TGCT	cis	rs4975709	0.838	rs4975752	chr5:1880588	A/C	cg14773178	chr5:1868261	NA	0.33	4.87	0.4	3.31e-6	Cardiovascular disease risk factors;
TGCT	cis	rs2224391	1.000	rs2753248	chr6:5262154	G/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.79	-6.05	-0.48	1.61e-8	Height;
TGCT	cis	rs12477438	0.798	rs2123686	chr2:99690135	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-4.88	-0.4	3.17e-6	Chronic sinus infection;
TGCT	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg20607798	chr8:58055168	NA	0.49	4.63	0.38	9.07e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10823500	0.674	rs7089860	chr10:71992848	C/G	cg04118878	chr10:71993077	PPA1	0.58	5.31	0.43	4.9e-7	Blood protein levels;
TGCT	cis	rs3008870	1.000	rs1925411	chr1:67370292	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.07	11.84	0.73	4.25e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs826838	0.967	rs11169169	chr12:39093153	A/C	cg13010199	chr12:38710504	ALG10B	0.82	6.85	0.52	3.1e-10	Heart rate;
TGCT	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg05368731	chr17:41323189	NBR1	1.01	11.17	0.71	1.78e-20	Menopause (age at onset);
TGCT	cis	rs7246657	0.943	rs1559229	chr19:37876197	T/C	cg18154014	chr19:37997991	ZNF793	0.74	5.33	0.43	4.48e-7	Coronary artery calcification;
TGCT	cis	rs3087591	0.659	rs757376	chr17:29717909	A/G	cg24425628	chr17:29625626	OMG;NF1	0.4	5.87	0.47	3.67e-8	Hip circumference;
TGCT	cis	rs2013441	1.000	rs11654025	chr17:20198160	A/T	cg23224458	chr17:20280056	CCDC144C	-0.37	-4.6	-0.38	1.05e-5	Obesity-related traits;
TGCT	cis	rs11586313	1.000	rs11586313	chr1:152890470	C/T	cg07796016	chr1:152779584	LCE1C	-0.51	-5.97	-0.47	2.3e-8	Vitamin D levels;
TGCT	cis	rs9372253	0.934	rs9320327	chr6:110715194	T/A	cg00083206	chr6:110721305	DDO	-0.43	-6.44	-0.5	2.33e-9	Platelet distribution width;
TGCT	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg24503407	chr1:205819492	PM20D1	0.6	8.53	0.61	4.21e-14	Menarche (age at onset);
TGCT	cis	rs4808199	0.894	rs9304960	chr19:19465529	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.63	4.56	0.38	1.23e-5	Nonalcoholic fatty liver disease;
TGCT	cis	rs6671200	0.541	rs3738170	chr1:95699604	G/C	cg03123541	chr1:95699097	RWDD3	-0.8	-7.03	-0.53	1.24e-10	Stearic acid (18:0) levels;
TGCT	cis	rs1215050	0.740	rs6854802	chr4:99065480	A/C	cg05340658	chr4:99064831	C4orf37	0.44	5.3	0.43	5.03e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.53	4.55	0.38	1.26e-5	Urate levels;
TGCT	cis	rs9894429	0.682	rs7406360	chr17:79591545	G/A	cg21028142	chr17:79581711	NPLOC4	0.3	7.03	0.53	1.22e-10	Eye color traits;
TGCT	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg09365446	chr1:150670422	GOLPH3L	0.31	4.64	0.38	8.7e-6	Tonsillectomy;
TGCT	cis	rs8067545	0.603	rs10083830	chr17:19965883	G/A	cg18979559	chr17:20280153	CCDC144C	0.45	4.69	0.39	7.15e-6	Schizophrenia;
TGCT	cis	rs3008870	1.000	rs2755246	chr1:67488984	A/G	cg03991309	chr1:68237761	GNG12	0.27	4.46	0.37	1.81e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs6570726	0.846	rs7762536	chr6:145923145	T/C	cg23711669	chr6:146136114	FBXO30	0.84	8.91	0.62	5.38e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs939658	0.728	rs11637459	chr15:79413554	A/G	cg17916960	chr15:79447300	NA	-0.46	-6.39	-0.5	3.11e-9	Refractive error;
TGCT	cis	rs7772486	0.875	rs12194437	chr6:146411440	A/G	cg05347473	chr6:146136440	FBXO30	0.56	5.22	0.42	7.31e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1372520	0.684	rs356191	chr4:90688120	G/A	cg14346243	chr4:90757452	SNCA	0.62	5.29	0.43	5.26e-7	Neuroticism;
TGCT	cis	rs9291683	0.588	rs2240722	chr4:10020757	A/G	cg00071950	chr4:10020882	SLC2A9	0.72	9.86	0.66	2.78e-17	Bone mineral density;
TGCT	cis	rs17076896	0.786	rs61956076	chr13:19932216	A/G	cg00777926	chr13:20807375	GJB6	-0.37	-4.53	-0.38	1.36e-5	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs7095607	1.000	rs10998009	chr10:69953416	A/G	cg18986048	chr10:69913749	MYPN	0.46	5.08	0.41	1.37e-6	Lung function (FVC);
TGCT	cis	rs854765	0.663	rs3183702	chr17:17747289	A/G	cg04398451	chr17:18023971	MYO15A	0.31	4.65	0.39	8.49e-6	Total body bone mineral density;
TGCT	trans	rs1814175	0.538	rs1684260	chr11:49224231	G/A	cg15704280	chr7:45808275	SEPT13	0.71	7.66	0.57	4.55e-12	Height;
TGCT	cis	rs6569992	0.636	rs7757054	chr6:135487614	C/T	cg22676075	chr6:135203613	NA	-0.74	-5.03	-0.41	1.69e-6	Red blood cell traits;
TGCT	cis	rs735396	1.000	rs1169310	chr12:121439433	G/A	cg02403541	chr12:121454288	C12orf43	0.66	6.27	0.49	5.35e-9	N-glycan levels;
TGCT	cis	rs17376456	1.000	rs6867042	chr5:93555761	C/T	cg21475434	chr5:93447410	FAM172A	0.65	4.66	0.39	7.92e-6	Diabetic retinopathy;
TGCT	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs6684514	1.000	rs12022194	chr1:156312331	T/A	cg16558208	chr1:156270281	VHLL	0.48	9.61	0.65	1.13e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.47	-0.37	1.72e-5	Bipolar disorder;
TGCT	cis	rs4936891	0.563	rs78294880	chr11:123890006	C/T	cg22125253	chr11:123886957	OR10G4	0.21	4.74	0.39	5.66e-6	Male fertility;
TGCT	cis	rs7833790	0.724	rs12676336	chr8:82771008	C/T	cg17211192	chr8:82754475	SNX16	0.97	9.09	0.63	2.04e-15	Diastolic blood pressure;
TGCT	cis	rs2066819	0.892	rs77415512	chr12:56627300	A/G	cg26714650	chr12:56694279	CS	-1.42	-5.7	-0.46	8.43e-8	Psoriasis vulgaris;
TGCT	cis	rs9303401	0.659	rs12952325	chr17:56899371	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.11	0.48	1.17e-8	Cognitive test performance;
TGCT	cis	rs4595586	0.545	rs12823487	chr12:39391286	A/G	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs9810089	0.843	rs838202	chr3:136035217	G/A	cg12473912	chr3:136751656	NA	0.35	4.96	0.41	2.28e-6	Gestational age at birth (child effect);
TGCT	cis	rs9929218	0.529	rs11075694	chr16:68730366	C/T	cg01251360	chr16:68772225	CDH1	-0.25	-4.67	-0.39	7.62e-6	Colorectal cancer;
TGCT	cis	rs910187	0.605	rs62201430	chr20:45808227	A/T	cg27589058	chr20:45804311	EYA2	-0.4	-9.0	-0.63	3.33e-15	Migraine;
TGCT	cis	rs2180341	0.960	rs9401953	chr6:127687574	G/A	cg27446573	chr6:127587934	RNF146	1.1	10.61	0.69	4.22e-19	Breast cancer;
TGCT	cis	rs2562456	0.917	rs2681392	chr19:21695987	T/G	cg01304269	chr19:21688519	ZNF429	-0.55	-4.59	-0.38	1.06e-5	Pain;
TGCT	cis	rs2033711	0.837	rs3764535	chr19:58929052	G/A	cg12042659	chr19:58951599	ZNF132	0.51	4.6	0.38	1.05e-5	Uric acid clearance;
TGCT	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	4.67	0.39	7.7e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7666738	0.716	rs1426660	chr4:98876792	T/A	cg17366294	chr4:99064904	C4orf37	0.7	7.27	0.55	3.62e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7698623	0.541	rs7682273	chr4:88781772	C/T	cg02735620	chr4:88950514	PKD2	-0.45	-4.79	-0.39	4.73e-6	Cardiovascular disease risk factors;
TGCT	cis	rs4862307	0.836	rs4507404	chr4:185003767	C/T	cg06737308	chr4:185021514	ENPP6	-0.35	-5.03	-0.41	1.65e-6	Serum dimethylarginine levels (asymmetric/symetric ratio);
TGCT	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.0	0.41	1.89e-6	Menopause (age at onset);
TGCT	trans	rs8073060	0.963	rs35614987	chr17:33869466	A/C	cg19694781	chr19:47549865	TMEM160	0.42	7.72	0.57	3.37e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs35883536	0.647	rs10875312	chr1:101042320	G/C	cg14855972	chr1:101004472	GPR88	-0.24	-4.49	-0.37	1.64e-5	Monocyte count;
TGCT	cis	rs9818758	0.607	rs9837237	chr3:49215583	G/T	cg00383909	chr3:49044727	WDR6	1.29	6.62	0.51	9.88e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg11644478	chr21:40555479	PSMG1	1.01	10.47	0.69	8.99e-19	Cognitive function;
TGCT	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.48	-0.37	1.66e-5	Bipolar disorder;
TGCT	cis	rs4242434	0.927	rs34027561	chr8:22465385	T/C	cg21658235	chr8:22456391	C8orf58	0.43	4.53	0.38	1.36e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg15242686	chr22:24348715	GSTTP1	-0.46	-5.24	-0.43	6.6e-7	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs968451	0.789	rs5757603	chr22:39677128	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.76	7.44	0.56	1.47e-11	Primary biliary cholangitis;
TGCT	cis	rs6500602	0.702	rs2304634	chr16:4500544	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.26	4.84	0.4	3.83e-6	Schizophrenia;
TGCT	cis	rs7666738	0.830	rs7678557	chr4:99057329	A/G	cg05340658	chr4:99064831	C4orf37	0.52	5.79	0.46	5.32e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10746514	1.000	rs12129814	chr1:232251730	C/A	cg09506761	chr1:232265262	NA	0.53	5.31	0.43	4.79e-7	Response to statin therapy;
TGCT	cis	rs2456568	0.900	rs2000960	chr11:93682348	C/T	cg26875233	chr11:93583750	C11orf90	-0.45	-5.65	-0.45	1.04e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs2836950	0.565	rs2836945	chr21:40596757	C/T	cg17971929	chr21:40555470	PSMG1	-0.51	-4.64	-0.38	8.88e-6	Menarche (age at onset);
TGCT	cis	rs3784262	0.669	rs4646555	chr15:58355345	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.42	-6.24	-0.49	6.32e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs6540559	0.546	rs57315825	chr1:210030197	C/T	cg23283495	chr1:209979779	IRF6	0.71	5.51	0.44	2.01e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs9811920	0.609	rs2452320	chr3:99645216	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.59	-6.77	-0.52	4.51e-10	Axial length;
TGCT	cis	rs4891159	0.548	rs690082	chr18:74116668	C/T	cg24786174	chr18:74118243	ZNF516	0.71	15.66	0.82	3.6e-31	Longevity;
TGCT	cis	rs1008375	1.000	rs1008375	chr4:17682834	T/C	cg18681998	chr4:17616180	MED28	0.89	10.41	0.68	1.25e-18	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	trans	rs208520	0.690	rs12201156	chr6:66720874	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	11.06	0.7	3.28e-20	Exhaled nitric oxide output;
TGCT	cis	rs9527	0.615	rs2152915	chr10:104691732	A/T	cg04362960	chr10:104952993	NT5C2	0.64	5.4	0.44	3.33e-7	Arsenic metabolism;
TGCT	cis	rs1843834	0.721	rs1601730	chr2:225590153	G/A	cg22455342	chr2:225449267	CUL3	0.69	6.58	0.51	1.2e-9	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs3026101	0.624	rs17635627	chr17:5296059	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.47	4.53	0.38	1.38e-5	Body mass index;
TGCT	cis	rs17376456	0.825	rs10064368	chr5:93266396	C/A	cg25358565	chr5:93447407	FAM172A	1.02	8.11	0.59	4.23e-13	Diabetic retinopathy;
TGCT	cis	rs6121246	0.738	rs6121242	chr20:30410877	T/C	cg18721089	chr20:30220636	NA	-0.43	-4.75	-0.39	5.54e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs17764205	0.777	rs113305163	chr19:3252194	G/C	cg18738857	chr19:3606974	TBXA2R	-0.73	-4.53	-0.38	1.35e-5	Bipolar disorder and schizophrenia;
TGCT	cis	rs6121246	0.529	rs6060359	chr20:30209740	A/G	cg13852791	chr20:30311386	BCL2L1	0.7	4.58	0.38	1.1e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs40363	0.723	rs2736	chr16:3536872	G/A	cg22508957	chr16:3507546	NAT15	-0.51	-4.54	-0.38	1.29e-5	Tuberculosis;
TGCT	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg22963979	chr7:1858916	MAD1L1	-0.43	-6.77	-0.52	4.65e-10	Bipolar disorder and schizophrenia;
TGCT	cis	rs9818758	0.607	rs9990153	chr3:49291883	C/T	cg07636037	chr3:49044803	WDR6	-1.04	-5.13	-0.42	1.09e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs208520	1.000	rs28773210	chr6:66993566	C/T	cg07460842	chr6:66804631	NA	0.79	6.85	0.52	3.05e-10	Exhaled nitric oxide output;
TGCT	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg08280861	chr8:58055591	NA	0.4	4.56	0.38	1.22e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2288884	1.000	rs76368799	chr19:52561507	A/G	cg13540795	chr19:52551618	ZNF432	-0.59	-5.02	-0.41	1.79e-6	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs9818758	0.607	rs11706052	chr3:49064110	A/G	cg07636037	chr3:49044803	WDR6	-1.04	-5.16	-0.42	9.65e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs7666738	0.830	rs35433756	chr4:99070555	C/T	cg05340658	chr4:99064831	C4orf37	0.52	5.79	0.46	5.32e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs116095464	0.558	rs9687621	chr5:229194	C/T	cg22857025	chr5:266934	NA	-0.35	-6.87	-0.53	2.73e-10	Breast cancer;
TGCT	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg07507251	chr3:52567010	NT5DC2	0.47	6.64	0.51	8.82e-10	Electroencephalogram traits;
TGCT	cis	rs10908458	0.743	rs7367207	chr1:155079477	C/T	cg23973274	chr1:155060172	NA	-0.25	-4.51	-0.38	1.51e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs3743266	0.507	rs3759910	chr15:60768469	C/T	cg18480781	chr15:60294291	NA	0.7	5.28	0.43	5.65e-7	Menarche (age at onset);
TGCT	cis	rs12780845	0.558	rs7090965	chr10:17216803	A/G	cg01003015	chr10:17271136	VIM	0.56	4.87	0.4	3.36e-6	Homocysteine levels;
TGCT	cis	rs4372836	0.729	rs11684695	chr2:29088450	G/T	cg09522027	chr2:28974177	PPP1CB	0.67	7.01	0.53	1.38e-10	Body mass index;
TGCT	cis	rs476633	0.691	rs2164996	chr15:41536624	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.52	-7.07	-0.54	1.01e-10	Glomerular filtration rate (creatinine);
TGCT	cis	rs9467773	1.000	rs1078679	chr6:26568741	C/T	cg05738196	chr6:26577821	NA	0.9	12.48	0.75	1.16e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs9467773	0.525	rs1535274	chr6:26520747	A/C	cg15659132	chr6:26577336	NA	0.73	9.04	0.63	2.64e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs6674176	0.542	rs803679	chr1:44349405	G/A	cg12908607	chr1:44402522	ARTN	-0.7	-7.96	-0.58	9.2e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs10791097	0.667	rs1893019	chr11:130756664	C/G	cg05962950	chr11:130786565	SNX19	0.9	11.06	0.7	3.32e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9467773	0.584	rs1021372	chr6:26632444	T/C	cg09904177	chr6:26538194	HMGN4	0.67	6.48	0.5	1.94e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs9906944	0.707	rs3816272	chr17:47120467	A/G	cg20966754	chr17:47091339	IGF2BP1	-0.45	-5.17	-0.42	9.27e-7	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs11690935	0.877	rs13024846	chr2:172835803	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.18	-11.94	-0.73	2.37e-22	Schizophrenia;
TGCT	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.62	-5.11	-0.42	1.17e-6	Tonsillectomy;
TGCT	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.43	-4.66	-0.39	8.09e-6	Longevity;Endometriosis;
TGCT	cis	rs9952991	0.941	rs9952749	chr18:12780456	A/G	cg23598886	chr18:12777645	NA	0.62	5.78	0.46	5.63e-8	Inflammatory skin disease;
TGCT	cis	rs1997103	0.871	rs1997101	chr7:55399652	A/T	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs7635838	0.684	rs384989	chr3:11320120	C/T	cg00170343	chr3:11313890	ATG7	0.63	6.22	0.49	7.07e-9	HDL cholesterol;
TGCT	cis	rs7914558	0.966	rs12571568	chr10:104891396	C/G	cg15744005	chr10:104629667	AS3MT	-0.42	-5.24	-0.43	6.69e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs2762353	0.574	rs4409177	chr6:25694491	T/G	cg03517284	chr6:25882590	NA	0.92	9.18	0.64	1.19e-15	Blood metabolite levels;
TGCT	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg12963246	chr6:28129442	ZNF389	0.52	5.01	0.41	1.85e-6	Parkinson's disease;
TGCT	cis	rs3749237	0.537	rs4459909	chr3:49469217	T/C	cg07636037	chr3:49044803	WDR6	0.63	5.98	0.47	2.26e-8	Resting heart rate;
TGCT	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg11764359	chr7:65958608	NA	0.55	4.99	0.41	1.98e-6	Aortic root size;
TGCT	cis	rs11748684	0.524	rs13162596	chr5:42576257	A/G	cg01169772	chr5:41904236	C5orf51	-0.93	-4.52	-0.38	1.41e-5	Response to taxane treatment (docetaxel);
TGCT	cis	rs896854	0.654	rs2011566	chr8:95971921	G/A	cg16049864	chr8:95962084	TP53INP1	-0.72	-10.17	-0.67	4.8e-18	Type 2 diabetes;
TGCT	cis	rs5760092	0.842	rs5760103	chr22:24248781	A/G	cg25703541	chr22:24373054	LOC391322	-0.8	-6.48	-0.5	1.97e-9	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs7552404	1.000	rs1498312	chr1:76177849	C/T	cg03433033	chr1:76189801	ACADM	0.83	9.91	0.66	2.13e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	trans	rs7618501	0.902	rs7645061	chr3:49868842	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	1.03	13.16	0.76	2.65e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs1008375	1.000	rs10939746	chr4:17684951	A/G	cg16339924	chr4:17578868	LAP3	-0.55	-4.52	-0.38	1.42e-5	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs713587	0.691	rs754537	chr2:25176277	A/T	cg01884057	chr2:25150051	NA	-0.31	-5.93	-0.47	2.79e-8	Body mass index in non-asthmatics;
TGCT	cis	rs2243480	1.000	rs160652	chr7:65538431	A/G	cg07424592	chr7:64974309	NA	1.33	8.82	0.62	8.94e-15	Diabetic kidney disease;
TGCT	trans	rs17684571	0.872	rs13191164	chr6:56566630	G/A	cg14229071	chr15:89282588	NA	0.51	6.68	0.51	7.14e-10	Schizophrenia;
TGCT	cis	rs7582180	0.715	rs7571306	chr2:100906084	G/C	cg08017756	chr2:100939284	LONRF2	-0.28	-4.76	-0.39	5.37e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg08859206	chr1:53392774	SCP2	-0.48	-7.58	-0.56	7.09e-12	Monocyte count;
TGCT	cis	rs7584330	0.910	rs7606177	chr2:238394913	G/C	cg16989719	chr2:238392110	NA	-0.27	-4.72	-0.39	6.24e-6	Prostate cancer;
TGCT	cis	rs7760949	0.889	rs9382688	chr6:13926746	A/T	cg27413430	chr6:13925136	RNF182	0.73	6.79	0.52	4.22e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs2153535	0.580	rs1034273	chr6:8468145	A/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs4988958	0.527	rs6756161	chr2:103048417	C/A	cg03938978	chr2:103052716	IL18RAP	0.27	5.41	0.44	3.17e-7	Asthma (childhood onset);
TGCT	cis	rs860554	0.640	rs2300293	chr1:201264902	C/T	cg01022117	chr1:201258280	PKP1	-0.35	-6.96	-0.53	1.77e-10	Panic disorder;
TGCT	cis	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg22857025	chr5:266934	NA	-0.34	-6.7	-0.52	6.65e-10	Breast cancer;
TGCT	cis	rs10791097	0.694	rs2155750	chr11:130751261	A/C	cg12179176	chr11:130786555	SNX19	0.82	10.15	0.67	5.45e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs1372520	0.684	rs2572318	chr4:90718719	C/T	cg01966878	chr4:90757139	SNCA	-0.33	-4.52	-0.38	1.42e-5	Neuroticism;
TGCT	cis	rs2549003	1.000	rs2070731	chr5:131819798	T/C	cg00255919	chr5:131827918	IRF1	0.19	4.61	0.38	9.78e-6	Asthma (sex interaction);
TGCT	cis	rs3806843	0.576	rs246043	chr5:140330924	G/A	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs3733631	0.948	rs28438896	chr4:104625753	C/T	cg24090629	chr4:104641072	TACR3	-0.73	-5.81	-0.46	4.96e-8	Menarche (age at onset);
TGCT	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.91	7.51	0.56	9.9e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs3008870	0.583	rs2147838	chr1:67399466	T/C	cg11518657	chr1:67396239	MIER1	0.6	4.78	0.39	4.79e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs12142240	0.698	rs67487250	chr1:46811333	T/C	cg00530320	chr1:46809349	NSUN4	0.29	5.88	0.47	3.63e-8	Menopause (age at onset);
TGCT	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg06028808	chr11:68637592	NA	0.51	6.56	0.51	1.32e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs13202913	0.943	rs9383572	chr6:151795210	C/A	cg03627880	chr6:151815985	C6orf97	-0.7	-5.02	-0.41	1.75e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs11190604	1.000	rs10883513	chr10:102316964	A/G	cg16342193	chr10:102329863	NA	-0.44	-5.38	-0.44	3.52e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7666738	0.927	rs11736876	chr4:98987206	A/G	cg17366294	chr4:99064904	C4orf37	0.77	7.0	0.53	1.4e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11690462	0.963	rs17529423	chr2:26583506	A/C	cg04726446	chr2:26624865	C2orf39	0.42	4.63	0.38	9.08e-6	Coronary artery disease;
TGCT	cis	rs1865760	0.865	rs9467650	chr6:25958235	A/G	cg16482183	chr6:26056742	HIST1H1C	0.52	4.84	0.4	3.78e-6	Height;
TGCT	cis	rs789859	0.794	rs1037929	chr3:194375000	G/A	cg21106136	chr3:194405973	FAM43A	-0.39	-5.15	-0.42	9.92e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
TGCT	cis	rs1497406	0.744	rs6656611	chr1:16515805	T/C	cg20430773	chr1:16534157	ARHGEF19	0.52	6.25	0.49	6.18e-9	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs4253772	0.550	rs6007779	chr22:46678615	A/C	cg24881330	chr22:46731750	TRMU	0.88	5.3	0.43	5.07e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs433598	0.704	rs163267	chr16:20660957	T/A	cg16616769	chr16:19727142	IQCK;C16orf88	-0.21	-4.6	-0.38	1.01e-5	Schizophrenia;
TGCT	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.67	-0.39	7.73e-6	Prudent dietary pattern;
TGCT	cis	rs9611565	0.918	rs12484074	chr22:41752747	G/A	cg13695892	chr22:41940480	POLR3H	-0.95	-8.65	-0.61	2.21e-14	Vitiligo;
TGCT	trans	rs783396	0.901	rs1676010	chr6:106999658	A/T	cg09013229	chr1:225332226	DNAH14	-0.58	-6.83	-0.52	3.35e-10	Stroke;
TGCT	cis	rs10972341	1.000	rs10972342	chr9:35144722	T/C	cg00812861	chr9:35114699	KIAA1539	0.33	5.0	0.41	1.88e-6	Weight;
TGCT	cis	rs4073582	0.516	rs1151539	chr11:66031660	C/T	cg16950941	chr11:66035639	RAB1B	0.58	5.44	0.44	2.67e-7	Gout;
TGCT	cis	rs7833790	0.660	rs67666182	chr8:82772037	A/G	cg17211192	chr8:82754475	SNX16	0.97	9.09	0.63	2.04e-15	Diastolic blood pressure;
TGCT	cis	rs9902453	0.933	rs7216487	chr17:28502642	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	5.41	0.44	3.13e-7	Coffee consumption (cups per day);
TGCT	cis	rs13326165	0.760	rs11714402	chr3:52391735	G/T	cg27565382	chr3:53032988	SFMBT1	-0.33	-4.66	-0.39	8.03e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs7833790	0.660	rs7839178	chr8:82763479	A/G	cg06027949	chr8:82754900	SNX16	0.67	5.14	0.42	1.06e-6	Diastolic blood pressure;
TGCT	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg21724239	chr8:58056113	NA	0.47	4.99	0.41	1.96e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7547997	0.685	rs12029228	chr1:158346963	C/T	cg07950803	chr1:158223934	CD1A	0.31	4.6	0.38	1.01e-5	QRS duration;
TGCT	cis	rs4689388	0.824	rs6446482	chr4:6295693	C/G	cg14416269	chr4:6271139	WFS1	0.4	5.24	0.43	6.66e-7	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs6121246	0.697	rs6120970	chr20:30232452	C/T	cg13852791	chr20:30311386	BCL2L1	0.74	4.84	0.4	3.77e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs713587	0.520	rs487617	chr2:25309756	C/G	cg01884057	chr2:25150051	NA	-0.26	-4.87	-0.4	3.36e-6	Body mass index in non-asthmatics;
TGCT	cis	rs35306767	0.714	rs7072554	chr10:1090988	C/T	cg26597838	chr10:835615	NA	0.51	5.71	0.46	7.72e-8	Eosinophil percentage of granulocytes;
TGCT	cis	rs6921919	0.583	rs3734563	chr6:28349725	A/G	cg18815343	chr6:28367644	ZSCAN12	-0.56	-5.3	-0.43	5.13e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs10465746	0.780	rs12139191	chr1:84387871	A/C	cg10977910	chr1:84465055	TTLL7	0.71	7.15	0.54	6.64e-11	Obesity-related traits;
TGCT	cis	rs7223966	1.000	rs61360320	chr17:61800392	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	4.7	0.39	6.69e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs7714584	1.000	rs58717741	chr5:150284936	A/G	cg22134413	chr5:150180641	NA	1.02	7.39	0.55	1.89e-11	Crohn's disease;
TGCT	cis	rs9527	0.590	rs12785223	chr10:104844011	C/T	cg04362960	chr10:104952993	NT5C2	-0.67	-5.62	-0.45	1.22e-7	Arsenic metabolism;
TGCT	cis	rs1153858	1.000	rs7163720	chr15:45639374	G/A	cg14582100	chr15:45693742	SPATA5L1	0.48	5.7	0.46	8.17e-8	Homoarginine levels;
TGCT	cis	rs986417	1.000	rs1254291	chr14:60863570	A/T	cg27398547	chr14:60952738	C14orf39	-1.49	-10.81	-0.7	1.38e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs7714584	1.000	rs2217266	chr5:150272621	C/A	cg22134413	chr5:150180641	NA	0.78	6.12	0.48	1.16e-8	Crohn's disease;
TGCT	cis	rs2932538	0.922	rs7527076	chr1:113150481	G/A	cg22162597	chr1:113214053	CAPZA1	0.27	5.98	0.47	2.24e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg13395646	chr4:1353034	KIAA1530	0.4	4.98	0.41	2.1e-6	Obesity-related traits;
TGCT	cis	rs778371	0.647	rs974321	chr2:233638351	G/A	cg08000102	chr2:233561755	GIGYF2	0.69	7.77	0.57	2.62e-12	Schizophrenia;
TGCT	cis	rs7255045	0.788	rs10424001	chr19:12948462	A/G	cg23899408	chr19:12877188	HOOK2	-0.58	-4.66	-0.39	7.88e-6	Mean corpuscular volume;
TGCT	cis	rs2153535	0.601	rs7775274	chr6:8530303	A/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.01	0.41	1.86e-6	Motion sickness;
TGCT	cis	rs7511006	0.893	rs760743	chr22:50647375	C/T	cg19026356	chr22:50624276	TRABD	-0.5	-4.61	-0.38	1e-5	Obesity-related traits;
TGCT	cis	rs7192750	0.586	rs11075908	chr16:71928850	C/T	cg06353428	chr16:71660113	MARVELD3	-0.82	-7.56	-0.56	7.85e-12	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs6835098	0.509	rs2332655	chr4:174093002	A/G	cg08422745	chr4:174089978	GALNT7	0.66	6.39	0.5	3.02e-9	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg06634786	chr22:41940651	POLR3H	0.9	8.62	0.61	2.67e-14	Vitiligo;
TGCT	cis	rs9788682	0.947	rs12439240	chr15:78829091	T/C	cg24631222	chr15:78858424	CHRNA5	0.92	7.54	0.56	8.79e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs763121	0.819	rs8137829	chr22:39061030	G/A	cg06022373	chr22:39101656	GTPBP1	0.77	7.51	0.56	9.9e-12	Menopause (age at onset);
TGCT	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg08280861	chr8:58055591	NA	0.49	5.38	0.43	3.64e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7267979	0.903	rs1118963	chr20:25247449	G/A	cg16686733	chr20:25566563	NINL	0.59	6.06	0.48	1.53e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs380904	1.000	rs380904	chr8:144565905	A/G	cg22012530	chr8:144635309	GSDMD	0.44	4.56	0.38	1.22e-5	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs936229	0.626	rs3765066	chr15:75140854	G/A	cg10253484	chr15:75165896	SCAMP2	-0.83	-7.48	-0.56	1.2e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
TGCT	cis	rs7772486	0.790	rs4314514	chr6:146260010	A/G	cg05347473	chr6:146136440	FBXO30	-0.51	-4.95	-0.41	2.32e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg04944784	chr2:26401820	FAM59B	-0.67	-6.05	-0.48	1.62e-8	Gut microbiome composition (summer);
TGCT	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg11764359	chr7:65958608	NA	-0.58	-4.99	-0.41	2.01e-6	Aortic root size;
TGCT	cis	rs753778	0.602	rs9792	chr8:142205237	C/T	cg18755752	chr8:142205143	DENND3	0.28	5.14	0.42	1.04e-6	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs7267979	1.000	rs6050609	chr20:25411751	A/G	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs459571	0.876	rs2520095	chr9:136919568	A/G	cg14405625	chr9:136855902	VAV2	-0.32	-4.79	-0.39	4.71e-6	Platelet distribution width;
TGCT	cis	rs903263	0.965	rs2174186	chr1:84662664	A/G	cg09664975	chr1:84543551	PRKACB	0.48	4.6	0.38	1.01e-5	Breast cancer (male);
TGCT	cis	rs7226408	0.857	rs56133445	chr18:34491392	G/A	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg15556689	chr8:8085844	FLJ10661	0.73	6.67	0.51	7.41e-10	Mood instability;
TGCT	trans	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg21659725	chr3:3221576	CRBN	0.76	9.35	0.64	4.6e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs1670533	0.932	rs10902753	chr4:1056223	G/A	cg20887711	chr4:1340912	KIAA1530	0.69	5.48	0.44	2.32e-7	Recombination rate (females);
TGCT	cis	rs8014204	0.748	rs12889277	chr14:75229376	A/T	cg06637938	chr14:75390232	RPS6KL1	0.73	6.97	0.53	1.62e-10	Caffeine consumption;
TGCT	cis	rs477895	1.000	rs41294396	chr11:64078581	G/A	cg04317338	chr11:64019027	PLCB3	0.71	5.65	0.45	1.05e-7	Mean platelet volume;
TGCT	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg00814883	chr7:100076585	TSC22D4	-0.85	-8.62	-0.61	2.62e-14	Platelet count;
TGCT	cis	rs11719291	0.915	rs11557629	chr3:48732223	G/A	cg00383909	chr3:49044727	WDR6	0.98	5.67	0.45	9.63e-8	Cognitive function;
TGCT	cis	rs7659604	0.702	rs61217486	chr4:122693973	T/C	cg23574427	chr4:122746245	BBS7;CCNA2	-0.32	-5.22	-0.42	7.34e-7	Type 2 diabetes;
TGCT	cis	rs9611565	0.592	rs1811113	chr22:42073134	C/T	cg17554472	chr22:41940697	POLR3H	0.49	5.22	0.42	7.4e-7	Vitiligo;
TGCT	cis	rs4824093	0.535	rs73443931	chr22:50291603	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.11	-6.76	-0.52	4.86e-10	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs7772486	0.790	rs4896852	chr6:146284621	T/C	cg05347473	chr6:146136440	FBXO30	-0.54	-5.22	-0.42	7.44e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs854765	0.547	rs9897761	chr17:17912011	A/T	cg04398451	chr17:18023971	MYO15A	-0.32	-5.07	-0.41	1.44e-6	Total body bone mineral density;
TGCT	cis	rs227917	1.000	rs10240211	chr7:23687039	C/G	cg12601843	chr7:23510954	IGF2BP3	0.63	4.86	0.4	3.41e-6	Common carotid intima-media thickness in HIV negative individuals;
TGCT	cis	rs763121	0.889	rs1043402	chr22:38879688	G/A	cg06022373	chr22:39101656	GTPBP1	0.73	6.92	0.53	2.18e-10	Menopause (age at onset);
TGCT	cis	rs9677476	0.516	rs7607338	chr2:231987955	C/A	cg07929768	chr2:232055508	NA	0.34	5.23	0.43	6.91e-7	Food antigen IgG levels;
TGCT	cis	rs8077889	0.672	rs3785810	chr17:41850689	C/G	cg26893861	chr17:41843967	DUSP3	1.14	21.11	0.88	7.06e-43	Triglycerides;
TGCT	cis	rs3741151	1.000	rs75004180	chr11:73024739	A/G	cg17517138	chr11:73019481	ARHGEF17	1.16	5.48	0.44	2.31e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
TGCT	cis	rs9400467	0.537	rs9647629	chr6:111501484	C/T	cg15721981	chr6:111408429	SLC16A10	0.71	4.6	0.38	1.04e-5	Blood metabolite levels;Amino acid levels;
TGCT	cis	rs4631830	0.863	rs7081532	chr10:51526093	A/G	cg10326726	chr10:51549505	MSMB	-0.24	-4.85	-0.4	3.68e-6	Prostate-specific antigen levels;
TGCT	cis	rs6121246	0.909	rs6089070	chr20:30377773	A/G	cg13852791	chr20:30311386	BCL2L1	-0.7	-4.86	-0.4	3.53e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs2070488	0.965	rs2366119	chr3:38484453	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	9.66	0.66	8.59e-17	Electrocardiographic conduction measures;
TGCT	cis	rs10779751	1.000	rs2016559	chr1:11269917	G/T	cg08854313	chr1:11322531	MTOR	0.96	8.97	0.63	3.85e-15	Body mass index;
TGCT	cis	rs2456568	0.867	rs10501810	chr11:93666589	C/G	cg14065697	chr11:93583672	C11orf90	-0.38	-4.57	-0.38	1.14e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7830933	0.955	rs13261166	chr8:23594733	A/G	cg04349084	chr8:23602677	NA	0.23	4.59	0.38	1.08e-5	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
TGCT	cis	rs617219	0.698	rs7445125	chr5:78507417	A/G	cg05890484	chr5:78407552	BHMT	0.4	5.46	0.44	2.48e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs7943191	0.810	rs7942991	chr11:62337203	A/G	cg22862634	chr11:62369728	EML3;MTA2	-0.57	-5.76	-0.46	6.39e-8	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs61935443	0.832	rs11107773	chr12:95282000	C/T	cg21533806	chr12:95267307	NA	0.53	4.55	0.38	1.28e-5	Schizophrenia;
TGCT	trans	rs561341	1.000	rs15654	chr17:30326360	A/C	cg20587970	chr11:113659929	NA	-1.04	-12.57	-0.75	6.97e-24	Hip circumference adjusted for BMI;
TGCT	cis	rs4888262	0.545	rs58136167	chr16:74700628	G/A	cg01733217	chr16:74700730	RFWD3	0.76	7.64	0.57	5.24e-12	Testicular germ cell tumor;
TGCT	cis	rs7659604	0.502	rs13106764	chr4:122699630	C/G	cg19748678	chr4:122722346	EXOSC9	-0.59	-5.82	-0.46	4.81e-8	Type 2 diabetes;
TGCT	cis	rs240764	0.658	rs60658003	chr6:101201191	C/A	cg09795085	chr6:101329169	ASCC3	-0.51	-4.51	-0.38	1.45e-5	Neuroticism;
TGCT	cis	rs10779751	0.770	rs12041740	chr1:11236524	G/A	cg08854313	chr1:11322531	MTOR	0.84	8.09	0.59	4.52e-13	Body mass index;
TGCT	cis	rs8180040	0.966	rs13064843	chr3:47415467	C/T	cg27129171	chr3:47204927	SETD2	0.65	7.74	0.57	2.99e-12	Colorectal cancer;
TGCT	cis	rs62244186	0.659	rs9850129	chr3:44532047	C/T	cg04389838	chr3:44770851	ZNF501	-0.42	-5.72	-0.46	7.66e-8	Depressive symptoms;
TGCT	cis	rs9916302	0.821	rs12938268	chr17:37572139	G/A	cg15445000	chr17:37608096	MED1	0.35	5.05	0.41	1.53e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs950776	0.518	rs2869544	chr15:78839400	G/A	cg06917634	chr15:78832804	PSMA4	-0.92	-8.93	-0.63	4.82e-15	Sudden cardiac arrest;
TGCT	cis	rs861020	0.604	rs3766612	chr1:210020013	G/T	cg05527609	chr1:210001259	C1orf107	-1.02	-9.26	-0.64	7.82e-16	Orofacial clefts;
TGCT	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.5	-4.81	-0.4	4.26e-6	Bipolar disorder;
TGCT	cis	rs12497850	0.931	rs11705888	chr3:48817289	T/C	cg05785598	chr3:49045655	WDR6	0.35	4.72	0.39	6.35e-6	Parkinson's disease;
TGCT	cis	rs12477438	0.520	rs4402818	chr2:99717608	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.52	0.61	4.53e-14	Chronic sinus infection;
TGCT	trans	rs11167764	0.623	rs62384602	chr5:141477685	T/G	cg18543871	chr19:46281018	DMPK	0.33	6.77	0.52	4.64e-10	Crohn's disease;
TGCT	cis	rs9318086	0.712	rs9318099	chr13:24442462	C/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.77	-8.46	-0.61	6.15e-14	Myopia (pathological);
TGCT	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg03709012	chr19:19516395	GATAD2A	0.67	5.74	0.46	6.83e-8	Tonsillectomy;
TGCT	cis	rs2309757	1	rs2309757	chr2:100807725	T/C	cg07810366	chr2:100720526	AFF3	-0.39	-5.69	-0.46	8.49e-8	Educational attainment (college completion);
TGCT	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg00431813	chr7:1051703	C7orf50	-0.22	-4.7	-0.39	6.93e-6	Longevity;Endometriosis;
TGCT	cis	rs7208859	0.623	rs9911173	chr17:29154750	C/T	cg14008862	chr17:28927542	LRRC37B2	0.75	5.1	0.42	1.26e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs9972944	0.692	rs6504346	chr17:63757175	C/A	cg07283582	chr17:63770753	CCDC46	-0.26	-5.09	-0.42	1.27e-6	Total body bone mineral density;
TGCT	cis	rs8180040	0.764	rs12630534	chr3:47001043	T/C	cg27129171	chr3:47204927	SETD2	0.72	9.42	0.65	3.2e-16	Colorectal cancer;
TGCT	cis	rs6684514	1.000	rs11264462	chr1:156241728	G/A	cg20302342	chr1:156215951	PAQR6	0.36	4.75	0.39	5.6e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	8.99	0.63	3.48e-15	Platelet count;
TGCT	cis	rs4711350	1.000	rs751727	chr6:33764158	A/G	cg18005901	chr6:33739558	LEMD2	-0.55	-5.89	-0.47	3.38e-8	Schizophrenia;
TGCT	cis	rs2153535	0.580	rs2152348	chr6:8474301	C/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs2288278	0.601	rs7501529	chr17:46598139	G/T	cg25032089	chr17:46643351	HOXB3	-0.42	-5.01	-0.41	1.86e-6	Hand grip strength;
TGCT	cis	rs910316	1.000	rs876403	chr14:75602834	A/T	cg08847533	chr14:75593920	NEK9	0.95	10.3	0.68	2.33e-18	Height;
TGCT	cis	rs9341808	0.655	rs9350846	chr6:80865481	T/A	cg08355045	chr6:80787529	NA	0.31	5.53	0.44	1.79e-7	Sitting height ratio;
TGCT	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg13012494	chr21:47604986	C21orf56	0.35	4.49	0.37	1.61e-5	Testicular germ cell tumor;
TGCT	cis	rs250677	0.687	rs250664	chr5:148453823	C/T	cg18129178	chr5:148520854	ABLIM3	-0.43	-6.29	-0.49	5.05e-9	Breast cancer;
TGCT	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg08564027	chr20:61660810	NA	0.37	6.0	0.47	2e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs78487399	0.808	rs77852659	chr2:43761652	C/T	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.79	4.82	0.4	4.14e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs2692947	0.770	rs62153678	chr2:96558346	C/T	cg13655245	chr2:97463316	CNNM4	0.15	4.51	0.38	1.51e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs9611565	0.644	rs2413652	chr22:42097238	C/T	cg17554472	chr22:41940697	POLR3H	0.47	5.02	0.41	1.72e-6	Vitiligo;
TGCT	cis	rs6121246	0.567	rs6058203	chr20:30198979	C/T	cg18721089	chr20:30220636	NA	-0.64	-6.86	-0.52	2.84e-10	Mean corpuscular hemoglobin;
TGCT	cis	rs3096299	0.900	rs3114867	chr16:89428967	A/C	cg06640241	chr16:89574553	SPG7	0.6	6.04	0.48	1.68e-8	Multiple myeloma (IgH translocation);
TGCT	trans	rs2760061	0.717	rs708117	chr1:228199902	G/A	cg16006296	chr10:38738647	LOC399744	-0.31	-7.21	-0.54	4.89e-11	Diastolic blood pressure;
TGCT	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg15921436	chr17:44337874	NA	0.56	7.75	0.57	2.88e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs34638657	0.732	rs12102917	chr16:82196808	G/A	cg09439754	chr16:82129088	HSD17B2	-0.24	-4.51	-0.38	1.5e-5	Lung adenocarcinoma;
TGCT	cis	rs1008375	1.000	rs10939742	chr4:17659936	G/T	cg16339924	chr4:17578868	LAP3	0.63	5.34	0.43	4.26e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	trans	rs3780486	0.801	rs10971424	chr9:33138775	T/C	cg20290983	chr6:43655470	MRPS18A	1.2	14.83	0.8	3.07e-29	IgG glycosylation;
TGCT	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg06753367	chr22:24256600	NA	-0.24	-4.64	-0.38	8.75e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7191439	0.728	rs4238687	chr16:88788903	T/G	cg27087555	chr16:88793112	FAM38A	-0.44	-5.03	-0.41	1.66e-6	Plateletcrit;
TGCT	cis	rs9894429	0.869	rs9748184	chr17:79596280	A/G	cg21028142	chr17:79581711	NPLOC4	0.29	6.86	0.52	2.94e-10	Eye color traits;
TGCT	cis	rs921968	0.643	rs4674324	chr2:219523433	T/G	cg02176678	chr2:219576539	TTLL4	0.38	5.47	0.44	2.34e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg27588902	chr6:42928151	GNMT	-0.5	-6.05	-0.48	1.55e-8	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg18538332	chr22:24372958	LOC391322	-1.02	-13.19	-0.76	2.24e-25	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7208859	0.623	rs73269923	chr17:29102571	C/T	cg13385521	chr17:29058706	SUZ12P	0.81	4.84	0.4	3.83e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs992157	0.775	rs1877714	chr2:219134928	A/G	cg00012203	chr2:219082015	ARPC2	-0.76	-7.33	-0.55	2.64e-11	Colorectal cancer;
TGCT	cis	rs12477438	0.765	rs10181422	chr2:99558970	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-4.74	-0.39	5.78e-6	Chronic sinus infection;
TGCT	cis	rs9393777	0.513	rs13215020	chr6:26656073	G/A	cg15659132	chr6:26577336	NA	-0.75	-5.25	-0.43	6.33e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs4851254	0.961	rs13011181	chr2:100732446	T/C	cg23118464	chr2:100721844	AFF3	0.66	4.84	0.4	3.74e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg12963246	chr6:28129442	ZNF389	0.51	5.02	0.41	1.73e-6	Depression;
TGCT	cis	rs7258465	1.000	rs7258465	chr19:18533642	A/G	cg06462663	chr19:18546047	ISYNA1	0.2	4.46	0.37	1.8e-5	Breast cancer;
TGCT	cis	rs7678296	0.649	rs60691639	chr4:37239925	T/C	cg06805348	chr4:37245195	KIAA1239	0.57	4.8	0.4	4.49e-6	3-hydroxypropylmercapturic acid levels in smokers;
TGCT	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg25703541	chr22:24373054	LOC391322	-0.83	-8.57	-0.61	3.53e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1538970	0.781	rs713358	chr1:45988267	C/G	cg05343316	chr1:45956843	TESK2	0.72	5.61	0.45	1.25e-7	Platelet count;
TGCT	cis	rs2797160	1.000	rs61299898	chr6:126007651	G/C	cg05901451	chr6:126070800	HEY2	0.74	6.3	0.49	4.62e-9	Endometrial cancer;
TGCT	cis	rs9457247	0.967	rs382009	chr6:167403121	G/C	cg23791538	chr6:167370224	RNASET2	-0.49	-4.96	-0.41	2.26e-6	Crohn's disease;
TGCT	cis	rs4808199	0.948	rs2301671	chr19:19466269	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.69	5.48	0.44	2.24e-7	Nonalcoholic fatty liver disease;
TGCT	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg08736216	chr1:53307985	ZYG11A	0.25	4.93	0.4	2.59e-6	Monocyte count;
TGCT	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg13409248	chr3:40428643	ENTPD3	0.57	4.53	0.38	1.37e-5	Renal cell carcinoma;
TGCT	cis	rs3935685	0.934	rs11072664	chr15:77999859	C/G	cg25212270	chr15:78015279	NA	0.3	6.06	0.48	1.48e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs28595532	0.920	rs114924396	chr4:119755621	A/G	cg14228332	chr4:119757509	SEC24D	1.32	5.99	0.47	2.14e-8	Cannabis dependence symptom count;
TGCT	cis	rs208520	0.690	rs851464	chr6:66839802	C/T	cg07460842	chr6:66804631	NA	-0.92	-9.58	-0.65	1.29e-16	Exhaled nitric oxide output;
TGCT	cis	rs7572733	0.534	rs4369854	chr2:198800630	T/C	cg00792783	chr2:198669748	PLCL1	0.57	5.23	0.43	6.99e-7	Dermatomyositis;
TGCT	cis	rs112217694	1.000	rs78970556	chr4:104655040	C/A	cg24090629	chr4:104641072	TACR3	-0.97	-4.81	-0.4	4.25e-6	Menarche (age at onset);
TGCT	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg23719950	chr11:63933701	MACROD1	-0.71	-5.93	-0.47	2.77e-8	Mean platelet volume;
TGCT	cis	rs727563	0.648	rs6002406	chr22:41965237	A/T	cg17554472	chr22:41940697	POLR3H	-0.51	-5.26	-0.43	6.08e-7	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs9430161	0.579	rs10864486	chr1:11040979	A/G	cg02454025	chr1:11042201	C1orf127	0.93	11.7	0.72	9.01e-22	Ewing sarcoma;
TGCT	cis	rs3947	0.951	rs1692819	chr8:11705448	G/A	cg02840367	chr8:11660030	FDFT1	0.87	6.58	0.51	1.19e-9	Blood protein levels;
TGCT	cis	rs17384381	0.863	rs12140272	chr1:85789757	G/A	cg16011679	chr1:85725395	C1orf52	0.89	6.94	0.53	1.89e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2302045	0.655	rs1056916	chr2:242053526	G/A	cg04553960	chr2:241721320	KIF1A	-0.7	-4.68	-0.39	7.4e-6	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio);
TGCT	cis	rs1005277	0.505	rs200939	chr10:38139483	T/C	cg25427524	chr10:38739819	LOC399744	-0.37	-7.41	-0.55	1.74e-11	Extrinsic epigenetic age acceleration;
TGCT	cis	rs10836699	0.562	rs7106759	chr11:37199677	A/G	cg18520238	chr11:36422557	PRR5L	0.18	4.52	0.38	1.41e-5	Low high density lipoprotein cholesterol levels;
TGCT	cis	rs36093844	0.898	rs12363602	chr11:85596401	T/A	cg25872744	chr11:85566296	CCDC83	-0.52	-4.66	-0.39	7.93e-6	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
TGCT	cis	rs11122272	0.735	rs2790891	chr1:231513190	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.14	-0.54	6.86e-11	Hemoglobin concentration;
TGCT	cis	rs950169	0.545	rs4354897	chr15:84644971	T/C	cg11189052	chr15:85197271	WDR73	0.63	4.9	0.4	2.94e-6	Schizophrenia;
TGCT	cis	rs7324557	0.684	rs9507165	chr13:24384430	A/C	cg16602799	chr13:25254742	ATP12A	0.57	4.45	0.37	1.93e-5	Visceral adipose tissue adjusted for BMI;
TGCT	cis	rs12908161	0.959	rs34028043	chr15:85231585	G/A	cg12863693	chr15:85201151	NMB	0.46	5.53	0.44	1.79e-7	Schizophrenia;
TGCT	cis	rs854765	0.583	rs8073001	chr17:17831716	A/C	cg09796270	chr17:17721594	SREBF1	-0.24	-4.77	-0.39	5.01e-6	Total body bone mineral density;
TGCT	cis	rs2404602	0.716	rs4079681	chr15:76695230	G/A	cg22467129	chr15:76604101	ETFA	-0.59	-7.13	-0.54	7.47e-11	Blood metabolite levels;
TGCT	cis	rs2290416	0.584	rs3816477	chr8:144685271	T/C	cg08017634	chr8:144659831	NAPRT1	-0.48	-4.68	-0.39	7.51e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg18876405	chr7:65276391	NA	0.32	4.71	0.39	6.42e-6	Aortic root size;
TGCT	cis	rs1475911	0.656	rs9980065	chr21:43528072	G/A	cg19766460	chr21:43528205	UMODL1;C21orf128	0.84	12.25	0.74	4.22e-23	IgG glycosylation;
TGCT	cis	rs1971762	0.527	rs6580953	chr12:54021138	T/C	cg16917193	chr12:54089295	NA	1.07	11.66	0.72	1.17e-21	Height;
TGCT	cis	rs11690935	0.959	rs10204502	chr2:172588866	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.18	-12.51	-0.75	9.78e-24	Schizophrenia;
TGCT	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg13409248	chr3:40428643	ENTPD3	0.57	4.53	0.38	1.37e-5	Renal cell carcinoma;
TGCT	cis	rs6725041	0.792	rs10048750	chr2:213090883	C/T	cg20637307	chr2:213403960	ERBB4	-0.52	-4.6	-0.38	1.02e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg08280861	chr8:58055591	NA	0.37	5.0	0.41	1.89e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6977660	0.507	rs28402966	chr7:19774469	A/C	cg05791153	chr7:19748676	TWISTNB	1.01	6.63	0.51	9.26e-10	Thyroid stimulating hormone;
TGCT	cis	rs9296092	0.560	rs9469500	chr6:33526196	C/T	cg13560919	chr6:33536144	NA	-0.22	-4.95	-0.41	2.33e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs9653442	0.712	rs6749757	chr2:100730111	A/C	cg07810366	chr2:100720526	AFF3	0.41	6.71	0.52	6.19e-10	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs7635838	0.619	rs347616	chr3:11277927	G/A	cg00170343	chr3:11313890	ATG7	0.66	6.26	0.49	5.67e-9	HDL cholesterol;
TGCT	cis	rs9788721	0.630	rs77681598	chr15:78906103	C/A	cg06917634	chr15:78832804	PSMA4	-0.65	-5.35	-0.43	4.02e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
TGCT	cis	rs877282	0.891	rs10904557	chr10:797490	C/T	cg17470449	chr10:769945	NA	-0.3	-4.98	-0.41	2.06e-6	Uric acid levels;
TGCT	cis	rs12510870	0.566	rs7696502	chr4:74453404	T/C	cg05868023	chr4:75230803	EREG	-0.55	-4.74	-0.39	5.71e-6	Iris color (b* coordinate);
TGCT	cis	rs6121246	0.529	rs750144	chr20:30179027	C/T	cg18721089	chr20:30220636	NA	0.63	6.86	0.52	2.95e-10	Mean corpuscular hemoglobin;
TGCT	cis	rs644799	0.544	rs1727165	chr11:95521648	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.57	6.21	0.49	7.25e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7829975	0.545	rs13261926	chr8:8551610	T/C	cg06636001	chr8:8085503	FLJ10661	-0.62	-5.28	-0.43	5.56e-7	Mood instability;
TGCT	cis	rs59698941	0.527	rs11742089	chr5:132178930	G/A	cg27099455	chr5:132201840	GDF9;UQCRQ	0.28	4.76	0.39	5.3e-6	Apolipoprotein A-IV levels;
TGCT	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg06212747	chr3:49208901	KLHDC8B	0.61	5.66	0.45	9.84e-8	Parkinson's disease;
TGCT	cis	rs908922	0.676	rs6687126	chr1:152530894	T/G	cg20991723	chr1:152506922	NA	0.45	6.05	0.48	1.6e-8	Hair morphology;
TGCT	cis	rs1577917	1.000	rs1962716	chr6:86648436	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-4.9	-0.4	2.93e-6	Response to antipsychotic treatment;
TGCT	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg22920501	chr2:26401640	FAM59B	0.81	6.36	0.5	3.52e-9	Gut microbiome composition (summer);
TGCT	cis	rs709400	0.663	rs28444993	chr14:103930564	T/C	cg26031613	chr14:104095156	KLC1	0.84	9.53	0.65	1.78e-16	Body mass index;
TGCT	cis	rs2120019	1.000	rs67544533	chr15:75361539	A/G	cg11632617	chr15:75315747	PPCDC	-0.33	-4.69	-0.39	7.14e-6	Blood trace element (Zn levels);
TGCT	cis	rs17376456	1.000	rs66978370	chr5:93553633	G/A	cg25358565	chr5:93447407	FAM172A	0.94	7.65	0.57	4.72e-12	Diabetic retinopathy;
TGCT	cis	rs6977955	1.000	rs740122	chr7:28166442	G/A	cg23620719	chr7:28220237	JAZF1	0.65	4.96	0.41	2.23e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	8.0	0.58	7.67e-13	Platelet count;
TGCT	cis	rs344364	0.511	rs1657134	chr16:1953127	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.46	-5.31	-0.43	4.97e-7	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs7552404	1.000	rs7516226	chr1:76234257	G/A	cg03433033	chr1:76189801	ACADM	0.82	9.46	0.65	2.61e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7914558	0.966	rs1890185	chr10:104748718	A/G	cg15744005	chr10:104629667	AS3MT	-0.41	-5.08	-0.42	1.33e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs3008870	1.000	rs4620509	chr1:67449941	A/G	cg03991309	chr1:68237761	GNG12	-0.27	-4.53	-0.38	1.36e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs7824557	0.767	rs17797443	chr8:11164012	T/C	cg21775007	chr8:11205619	TDH	0.58	5.46	0.44	2.46e-7	Retinal vascular caliber;
TGCT	cis	rs12216125	0.801	rs56107510	chr6:25987436	C/A	cg16482183	chr6:26056742	HIST1H1C	0.64	5.52	0.44	1.9e-7	Iron status biomarkers;
TGCT	cis	rs1997103	1.000	rs6966183	chr7:55407546	A/C	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs16866061	0.517	rs7594223	chr2:225472985	T/C	cg22455342	chr2:225449267	CUL3	0.58	4.87	0.4	3.37e-6	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg24846343	chr22:24311635	DDTL	-0.22	-5.9	-0.47	3.29e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg04944784	chr2:26401820	FAM59B	-0.67	-6.09	-0.48	1.32e-8	Gut microbiome composition (summer);
TGCT	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg01416388	chr22:39784598	NA	-0.72	-7.12	-0.54	7.66e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs2932538	0.883	rs7549547	chr1:113086717	A/T	cg22162597	chr1:113214053	CAPZA1	0.27	5.89	0.47	3.46e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs2486012	1.000	rs2906597	chr1:44406725	A/G	cg12908607	chr1:44402522	ARTN	0.78	6.04	0.48	1.68e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7568458	0.684	rs7579147	chr2:85805654	G/A	cg17127132	chr2:85788382	GGCX	0.51	4.57	0.38	1.15e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs12701220	0.803	rs12701432	chr7:1052453	C/T	cg27454412	chr7:1067447	C7orf50	-0.5	-4.75	-0.39	5.51e-6	Bronchopulmonary dysplasia;
TGCT	cis	rs2692947	0.631	rs2312954	chr2:96772447	C/T	cg22654517	chr2:96458247	NA	-0.21	-4.58	-0.38	1.11e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs7666738	0.830	rs13125930	chr4:98654695	G/A	cg17366294	chr4:99064904	C4orf37	0.62	6.4	0.5	2.94e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4078252	0.720	rs3922585	chr5:112455254	A/C	cg04226363	chr5:112043716	APC	0.51	4.6	0.38	1.02e-5	Response to cytadine analogues (cytosine arabinoside);
TGCT	cis	rs295140	1.000	rs10931897	chr2:201162520	T/C	cg04283868	chr2:201171347	SPATS2L	0.63	6.39	0.5	3.03e-9	QT interval;
TGCT	cis	rs7599312	0.586	rs7571561	chr2:213386267	T/C	cg16329650	chr2:213403929	ERBB4	0.55	4.62	0.38	9.45e-6	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7786808	0.741	rs11769149	chr7:158227127	A/G	cg01191920	chr7:158217561	PTPRN2	0.43	6.56	0.51	1.28e-9	Obesity-related traits;
TGCT	cis	rs9653442	1.000	rs11676922	chr2:100806940	T/A	cg07810366	chr2:100720526	AFF3	-0.45	-7.79	-0.57	2.34e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	trans	rs66573146	1.000	rs66573146	chr4:6984464	C/G	cg07817883	chr1:32538562	TMEM39B	1.66	8.29	0.6	1.56e-13	Granulocyte percentage of myeloid white cells;
TGCT	trans	rs3780486	0.713	rs3780489	chr9:33129844	G/T	cg20290983	chr6:43655470	MRPS18A	1.19	14.84	0.8	2.81e-29	IgG glycosylation;
TGCT	cis	rs10501293	1.000	rs4755698	chr11:43123536	G/T	cg03447554	chr11:43094025	NA	-0.49	-6.73	-0.52	5.72e-10	Cognitive performance;
TGCT	cis	rs7582180	0.715	rs11123823	chr2:100916315	A/G	cg14675211	chr2:100938903	LONRF2	0.47	4.55	0.38	1.24e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs13082711	0.554	rs34066402	chr3:27387987	G/A	cg02860705	chr3:27208620	NA	0.43	6.0	0.47	2.03e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs4975616	0.686	rs37008	chr5:1351538	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.24	-5.13	-0.42	1.07e-6	Lung cancer;
TGCT	cis	rs17108533	0.588	rs12887301	chr14:71301688	C/T	cg23900759	chr14:71108106	TTC9	-1.14	-4.44	-0.37	2e-5	Response to antipsychotic treatment in schizophrenia (reasoning);
TGCT	cis	rs2486012	0.737	rs1502907	chr1:44258040	A/G	cg12908607	chr1:44402522	ARTN	-0.71	-5.54	-0.45	1.75e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs6570726	0.935	rs428659	chr6:145827039	T/C	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg20637647	chr7:64974828	NA	1.0	5.59	0.45	1.4e-7	Diabetic kidney disease;
TGCT	cis	rs459571	0.959	rs455381	chr9:136905577	C/A	cg14405625	chr9:136855902	VAV2	-0.3	-4.55	-0.38	1.28e-5	Platelet distribution width;
TGCT	cis	rs6964587	0.967	rs55801687	chr7:91762629	C/A	cg22709100	chr7:91322751	NA	0.29	4.7	0.39	6.9e-6	Breast cancer;
TGCT	cis	rs73198271	0.628	rs75693229	chr8:8590926	G/A	ch.8.214553F	chr8:8189620	PRAGMIN	-0.32	-5.22	-0.42	7.19e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs1018836	0.608	rs6986165	chr8:91477062	C/G	cg16814680	chr8:91681699	NA	-0.73	-7.41	-0.55	1.69e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs492146	0.935	rs316137	chr6:52846680	C/A	cg06706454	chr6:52930286	FBXO9	-0.47	-4.54	-0.38	1.29e-5	Epilepsy (remission after treatment);
TGCT	cis	rs9990333	0.544	rs112577972	chr3:195825149	T/G	cg14488913	chr3:195402182	SDHAP2	-0.36	-4.6	-0.38	1.04e-5	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);
TGCT	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg03264133	chr6:25882463	NA	-0.62	-6.62	-0.51	9.81e-10	Blood metabolite levels;
TGCT	cis	rs17125944	0.686	rs7143400	chr14:53324891	A/C	cg00686598	chr14:53173677	PSMC6	-0.89	-4.62	-0.38	9.56e-6	Alzheimer's disease (late onset);
TGCT	cis	rs3806843	0.576	rs251370	chr5:140246287	C/T	cg07102913	chr5:140593443	PCDHB13	0.5	4.76	0.39	5.3e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9325144	0.560	rs7971313	chr12:38653413	A/G	cg26384229	chr12:38710491	ALG10B	-0.63	-5.92	-0.47	2.9e-8	Morning vs. evening chronotype;
TGCT	cis	rs8051431	0.876	rs1559401	chr16:72011181	G/T	cg06353428	chr16:71660113	MARVELD3	0.59	5.02	0.41	1.73e-6	LDL cholesterol levels;
TGCT	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg04546413	chr19:29218101	NA	0.83	6.68	0.51	7.35e-10	Methadone dose in opioid dependence;
TGCT	cis	rs7474896	0.583	rs10764144	chr10:37975732	G/C	cg13720705	chr10:37990370	NA	0.33	4.78	0.39	4.82e-6	Obesity (extreme);
TGCT	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg04944784	chr2:26401820	FAM59B	-0.68	-6.07	-0.48	1.45e-8	Gut microbiome composition (summer);
TGCT	cis	rs6728642	1.000	rs11890407	chr2:97621647	G/C	cg26665480	chr2:98280029	ACTR1B	-0.88	-5.22	-0.42	7.31e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg06238570	chr21:40685208	BRWD1	0.69	6.41	0.5	2.71e-9	Cognitive function;
TGCT	cis	rs6500602	0.647	rs1684600	chr16:4594671	C/T	cg08645402	chr16:4508243	NA	-0.18	-5.09	-0.42	1.27e-6	Schizophrenia;
TGCT	trans	rs114540395	0.720	rs79528180	chr10:103218179	C/T	cg10198749	chr1:39920707	MACF1	0.55	7.11	0.54	8.11e-11	Schizophrenia;
TGCT	cis	rs155076	0.666	rs4638420	chr13:21872348	A/G	cg11317459	chr13:21872234	NA	1.44	13.07	0.76	4.54e-25	White matter hyperintensity burden;
TGCT	cis	rs2033711	0.783	rs11671113	chr19:58958087	C/T	cg12042659	chr19:58951599	ZNF132	0.51	4.57	0.38	1.18e-5	Uric acid clearance;
TGCT	cis	rs2013441	0.932	rs2526479	chr17:20130221	T/G	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.61	-0.38	9.96e-6	Obesity-related traits;
TGCT	cis	rs9291683	0.597	rs11723016	chr4:10126189	A/G	cg00071950	chr4:10020882	SLC2A9	-0.44	-4.84	-0.4	3.73e-6	Bone mineral density;
TGCT	cis	rs79349575	0.811	rs80032154	chr17:47014992	C/A	cg27201301	chr17:47039149	GIP	0.26	4.58	0.38	1.12e-5	Type 2 diabetes;
TGCT	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg04317338	chr11:64019027	PLCB3	0.75	6.19	0.49	8.06e-9	Mean platelet volume;
TGCT	cis	rs9653442	0.805	rs7608424	chr2:100796543	G/T	cg07810366	chr2:100720526	AFF3	-0.47	-7.88	-0.58	1.45e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs308447	0.516	rs6853540	chr4:123679848	G/A	cg10495464	chr4:123653540	BBS12;LOC729338	0.66	6.42	0.5	2.63e-9	Perceived unattractiveness to mosquitoes;
TGCT	cis	rs4845570	1.000	rs4845356	chr1:151759223	T/A	cg07092448	chr1:151763213	TDRKH	1.17	9.52	0.65	1.85e-16	Coronary artery disease;
TGCT	cis	rs78456975	0.527	rs11885279	chr2:1560633	T/C	cg01028140	chr2:1542097	TPO	-0.33	-5.12	-0.42	1.14e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs7647973	1.000	rs3866330	chr3:49582994	T/C	cg07690219	chr3:49449608	TCTA;RHOA	-0.56	-4.76	-0.39	5.24e-6	Menarche (age at onset);
TGCT	cis	rs3125734	0.633	rs7088891	chr10:64034019	G/T	cg19640130	chr10:64028056	RTKN2	-0.4	-5.18	-0.42	8.53e-7	Rheumatoid arthritis;
TGCT	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg27454412	chr7:1067447	C7orf50	0.55	4.7	0.39	6.89e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs427394	0.802	rs274694	chr5:6734079	A/G	cg10857441	chr5:6722123	POLS	-0.32	-7.93	-0.58	1.08e-12	Menopause (age at onset);
TGCT	cis	rs13040088	0.935	rs3787513	chr20:61573736	G/A	cg23096297	chr20:61557774	DIDO1	1.18	9.71	0.66	6.5e-17	Menopause (age at onset);
TGCT	cis	rs2836633	0.895	rs61085980	chr21:40032140	C/T	cg12884169	chr21:40033163	ERG	0.42	4.47	0.37	1.75e-5	Coronary artery disease;
TGCT	cis	rs539096	0.500	rs2906457	chr1:44338575	A/C	cg12908607	chr1:44402522	ARTN	-0.7	-8.79	-0.62	1.01e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs67478160	0.608	rs34066659	chr14:104263427	A/C	cg26031613	chr14:104095156	KLC1	-0.64	-6.58	-0.51	1.2e-9	Schizophrenia;
TGCT	cis	rs9653442	0.545	rs4850921	chr2:100762699	G/T	cg22139774	chr2:100720529	AFF3	-0.39	-6.13	-0.48	1.08e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs1048238	0.506	rs848210	chr1:16259813	A/G	cg21385522	chr1:16154831	NA	-0.55	-5.88	-0.47	3.64e-8	Systolic blood pressure;
TGCT	cis	rs3096299	0.719	rs12934708	chr16:89523790	C/T	cg02187348	chr16:89574699	SPG7	0.6	6.39	0.5	2.98e-9	Multiple myeloma (IgH translocation);
TGCT	cis	rs2120019	1.000	rs34237279	chr15:75361121	A/G	cg11632617	chr15:75315747	PPCDC	-0.33	-4.63	-0.38	9.1e-6	Blood trace element (Zn levels);
TGCT	cis	rs9894429	0.646	rs7220310	chr17:79606056	C/A	cg21028142	chr17:79581711	NPLOC4	0.29	5.95	0.47	2.56e-8	Eye color traits;
TGCT	cis	rs208520	0.690	rs207118	chr6:66788948	T/A	cg07460842	chr6:66804631	NA	-0.94	-9.86	-0.66	2.74e-17	Exhaled nitric oxide output;
TGCT	cis	rs3760982	0.565	rs3786956	chr19:44286829	C/T	cg12072164	chr19:44306565	LYPD5	0.4	5.68	0.45	8.91e-8	Breast cancer (estrogen-receptor negative);Breast cancer;
TGCT	cis	rs9527	0.590	rs2066322	chr10:104909339	T/G	cg15744005	chr10:104629667	AS3MT	-0.4	-4.63	-0.38	9.04e-6	Arsenic metabolism;
TGCT	cis	rs6750047	0.719	rs1583171	chr2:38270107	G/A	cg07380506	chr2:38303506	CYP1B1	0.59	5.25	0.43	6.35e-7	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs860295	0.529	rs11577179	chr1:155983710	A/G	cg05700447	chr1:155978627	NA	-0.19	-4.64	-0.38	8.75e-6	Body mass index;
TGCT	cis	rs1448094	0.506	rs61930640	chr12:86173333	T/C	cg02569458	chr12:86230093	RASSF9	0.38	4.45	0.37	1.89e-5	Major depressive disorder;
TGCT	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg17747265	chr1:1875780	NA	-0.41	-7.74	-0.57	2.95e-12	Body mass index;
TGCT	cis	rs9908158	1	rs9908158	chr17:33890083	T/C	cg05299278	chr17:33885742	SLFN14	-0.23	-5.15	-0.42	9.78e-7	Platelet count;Platelet distribution width;
TGCT	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.45	-5.37	-0.43	3.72e-7	Alzheimer's disease;
TGCT	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg10047753	chr17:41438598	NA	0.72	6.46	0.5	2.18e-9	Menopause (age at onset);
TGCT	cis	rs9467603	1.000	rs13200921	chr6:25790378	T/C	cg16898833	chr6:26189333	HIST1H4D	1.16	5.51	0.44	2.03e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs6840360	0.901	rs6826799	chr4:152455700	G/A	cg17479576	chr4:152424074	FAM160A1	-0.57	-6.34	-0.49	3.85e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs231513	0.911	rs231525	chr17:41951283	C/T	cg26893861	chr17:41843967	DUSP3	-0.87	-6.27	-0.49	5.58e-9	Cognitive function;
TGCT	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg11764359	chr7:65958608	NA	0.56	4.81	0.4	4.32e-6	Aortic root size;
TGCT	cis	rs11779988	0.545	rs409217	chr8:17816597	C/G	cg01800426	chr8:17659068	MTUS1	-0.61	-4.73	-0.39	5.99e-6	Breast cancer;
TGCT	cis	rs12291225	0.535	rs10832248	chr11:14413087	G/A	cg19336497	chr11:14380999	RRAS2	-0.3	-4.63	-0.38	9.21e-6	Sense of smell;
TGCT	cis	rs11690935	0.549	rs2129475	chr2:172916772	A/G	cg13550731	chr2:172543902	DYNC1I2	0.69	6.39	0.5	3.06e-9	Schizophrenia;
TGCT	cis	rs909674	0.662	rs2899318	chr22:39837625	A/G	cg02038168	chr22:39784481	NA	-0.71	-5.35	-0.43	4.03e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg26338869	chr17:61819248	STRADA	-0.55	-5.08	-0.42	1.34e-6	Prudent dietary pattern;
TGCT	cis	rs7216064	0.953	rs11079705	chr17:65835452	A/T	cg12091567	chr17:66097778	LOC651250	-0.83	-6.49	-0.5	1.9e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs9457247	1.000	rs448060	chr6:167382622	A/G	cg23791538	chr6:167370224	RNASET2	-0.5	-4.98	-0.41	2.08e-6	Crohn's disease;
TGCT	cis	rs11792861	0.816	rs11791845	chr9:111683898	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.54	5.13	0.42	1.07e-6	Menarche (age at onset);
TGCT	cis	rs7666738	0.830	rs10021044	chr4:99002488	A/T	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9915657	0.773	rs9896360	chr17:70099469	C/G	cg06234051	chr17:70120541	SOX9	-0.27	-5.65	-0.45	1.05e-7	Thyroid hormone levels;
TGCT	cis	rs7809950	0.954	rs12673675	chr7:107113220	T/C	cg23024343	chr7:107201750	COG5	-0.34	-5.43	-0.44	2.89e-7	Coronary artery disease;
TGCT	cis	rs10883723	0.962	rs10883726	chr10:104236276	C/T	cg05855489	chr10:104503620	C10orf26	-0.55	-4.68	-0.39	7.42e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg11941060	chr3:133502564	NA	0.29	6.19	0.49	7.94e-9	Iron status biomarkers;
TGCT	trans	rs2727020	0.595	rs7924311	chr11:49507573	G/A	cg15704280	chr7:45808275	SEPT13	-0.74	-8.49	-0.61	5.28e-14	Coronary artery disease;
TGCT	cis	rs9902453	0.935	rs9909093	chr17:28271207	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.87	8.26	0.6	1.9e-13	Coffee consumption (cups per day);
TGCT	cis	rs2153535	0.580	rs2225765	chr6:8481785	A/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg26818010	chr10:134567672	INPP5A	-0.38	-5.37	-0.43	3.66e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	trans	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg21659725	chr3:3221576	CRBN	-0.7	-7.98	-0.58	8.35e-13	Body mass index;
TGCT	cis	rs479844	0.617	rs12146493	chr11:65547333	G/A	cg26683025	chr11:65560420	OVOL1	0.24	4.83	0.4	3.91e-6	Allergic disease (asthma, hay fever or eczema);Atopic march;Atopic dermatitis;
TGCT	cis	rs4849845	0.637	rs2028147	chr2:121058412	C/T	cg24070213	chr2:121070622	NA	-0.35	-4.64	-0.38	8.58e-6	Mean platelet volume;
TGCT	cis	rs67311347	1.000	rs28871903	chr3:40511094	T/G	cg13683864	chr3:40499215	RPL14	-1.2	-13.3	-0.77	1.27e-25	Renal cell carcinoma;
TGCT	trans	rs2469997	0.925	rs2470010	chr8:120359532	T/C	cg01792902	chr3:178864926	PIK3CA	0.83	6.77	0.52	4.49e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs9814567	1.000	rs1814336	chr3:134200823	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.99	-10.02	-0.67	1.12e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs12776158	0.901	rs12414678	chr10:71214669	C/T	cg12610070	chr10:71211762	TSPAN15	-0.59	-5.17	-0.42	9.16e-7	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs7662987	0.540	rs2851257	chr4:100039499	G/C	cg12011299	chr4:100065546	ADH4	0.39	4.81	0.4	4.36e-6	Smoking initiation;
TGCT	cis	rs68170813	0.559	rs1548524	chr7:106944563	G/T	cg02696742	chr7:106810147	HBP1	0.69	5.87	0.47	3.69e-8	Coronary artery disease;
TGCT	cis	rs11252926	0.550	rs10795122	chr10:466830	C/T	cg20256804	chr10:444983	DIP2C	-0.21	-4.44	-0.37	1.99e-5	Psychosis in Alzheimer's disease;
TGCT	cis	rs12780845	0.540	rs10490962	chr10:17200363	A/G	cg01003015	chr10:17271136	VIM	-0.52	-4.71	-0.39	6.42e-6	Homocysteine levels;
TGCT	cis	rs7918232	0.941	rs4749230	chr10:27441218	C/T	cg14442939	chr10:27389572	ANKRD26	0.8	5.42	0.44	2.94e-7	Breast cancer;
TGCT	cis	rs7726839	0.507	rs60068988	chr5:597668	T/C	cg20362242	chr5:692897	TPPP	0.53	4.56	0.38	1.22e-5	Obesity-related traits;
TGCT	cis	rs7940866	0.809	rs11222410	chr11:130833994	A/G	cg12179176	chr11:130786555	SNX19	0.57	5.5	0.44	2.05e-7	Schizophrenia;
TGCT	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg20849893	chr7:64541193	NA	-0.45	-4.6	-0.38	1.02e-5	Calcium levels;
TGCT	cis	rs4766566	0.694	rs1362006	chr12:111742222	A/G	cg10833066	chr12:111807467	FAM109A	0.38	7.32	0.55	2.77e-11	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
TGCT	cis	rs9383153	1.000	rs2237223	chr6:16329741	G/A	cg06493612	chr6:15502050	JARID2	0.63	4.88	0.4	3.15e-6	Gambling;
TGCT	cis	rs9467773	0.967	rs6932865	chr6:26540166	C/A	cg15659132	chr6:26577336	NA	0.86	12.21	0.74	5.3e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs4689388	0.824	rs4467645	chr4:6294305	C/T	cg00701064	chr4:6280414	WFS1	0.37	4.72	0.39	6.3e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs9534288	0.797	rs9534277	chr13:46578349	T/C	cg15192986	chr13:46630673	CPB2	-0.53	-7.62	-0.56	5.82e-12	Blood protein levels;
TGCT	cis	rs6906287	0.647	rs3752581	chr6:118869730	G/A	cg21191810	chr6:118973309	C6orf204	0.26	4.5	0.38	1.51e-5	Electrocardiographic conduction measures;
TGCT	cis	rs459571	0.920	rs455073	chr9:136909141	G/C	cg13789015	chr9:136890014	NCRNA00094	0.41	7.66	0.57	4.51e-12	Platelet distribution width;
TGCT	cis	rs2050392	1.000	rs2253585	chr10:30696503	C/T	cg18806716	chr10:30721971	MAP3K8	-0.44	-5.18	-0.42	8.82e-7	Inflammatory bowel disease;
TGCT	cis	rs4642101	0.765	rs9872103	chr3:12827452	G/T	cg05775895	chr3:12838266	CAND2	0.79	9.0	0.63	3.36e-15	QRS complex (12-leadsum);
TGCT	cis	rs9914988	0.943	rs12453504	chr17:27119524	C/A	cg20469991	chr17:27169893	C17orf63	-0.72	-5.04	-0.41	1.58e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg11764359	chr7:65958608	NA	0.53	4.62	0.38	9.5e-6	Aortic root size;
TGCT	cis	rs7914558	0.966	rs7908280	chr10:104816947	C/G	cg15744005	chr10:104629667	AS3MT	-0.38	-4.62	-0.38	9.61e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs4808199	0.948	rs2301671	chr19:19466269	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.64	4.75	0.39	5.58e-6	Nonalcoholic fatty liver disease;
TGCT	cis	rs4699052	0.963	rs11097804	chr4:104215137	A/T	cg16532752	chr4:104119610	CENPE	-0.56	-5.05	-0.41	1.57e-6	Testicular germ cell tumor;
TGCT	cis	rs10114408	0.959	rs10739965	chr9:96651479	A/G	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs7703051	0.513	rs59014134	chr5:74589385	C/T	cg07671805	chr5:74907694	NA	0.54	4.74	0.39	5.79e-6	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
TGCT	cis	rs7647973	0.593	rs59684465	chr3:49874246	C/T	cg05785598	chr3:49045655	WDR6	-0.42	-5.23	-0.42	7.1e-7	Menarche (age at onset);
TGCT	cis	rs4499344	0.524	rs259242	chr19:33144248	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.81	7.96	0.58	9.26e-13	Mean platelet volume;
TGCT	cis	rs6456156	0.792	rs4710179	chr6:167513692	G/T	cg07741184	chr6:167504864	NA	0.22	4.51	0.38	1.48e-5	Primary biliary cholangitis;
TGCT	cis	rs3091242	0.933	rs932372	chr1:25755014	G/A	cg09222892	chr1:25734099	RHCE	-0.43	-6.92	-0.53	2.11e-10	Erythrocyte sedimentation rate;
TGCT	cis	rs9810089	0.843	rs681783	chr3:136035303	C/T	cg12473912	chr3:136751656	NA	0.35	4.96	0.41	2.28e-6	Gestational age at birth (child effect);
TGCT	cis	rs4595586	0.545	rs3858554	chr12:39381460	C/T	cg10518543	chr12:38710700	ALG10B	0.54	4.56	0.38	1.21e-5	Morning vs. evening chronotype;
TGCT	cis	rs2730245	0.959	rs2527201	chr7:158738611	G/T	cg24397884	chr7:158709396	WDR60	-0.38	-5.08	-0.42	1.33e-6	Height;
TGCT	cis	rs651907	0.535	rs34161138	chr3:101510388	T/C	cg12386194	chr3:101231763	SENP7	0.48	4.81	0.4	4.36e-6	Colorectal cancer;
TGCT	cis	rs709400	0.628	rs7155014	chr14:103863970	C/G	cg12935359	chr14:103987150	CKB	-0.35	-5.26	-0.43	6.08e-7	Body mass index;
TGCT	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg13695892	chr22:41940480	POLR3H	0.8	8.01	0.58	7.2e-13	Vitiligo;
TGCT	cis	rs1008375	1.000	rs60178264	chr4:17685308	G/T	cg18681998	chr4:17616180	MED28	0.92	10.51	0.69	7.15e-19	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg06618935	chr21:46677482	NA	-0.37	-5.81	-0.46	5.06e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7513165	0.935	rs7538038	chr1:204161026	C/T	cg12731349	chr1:204159619	KISS1	-0.5	-5.6	-0.45	1.32e-7	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
TGCT	cis	rs7523273	1.000	rs7541230	chr1:207957555	T/C	cg22525895	chr1:207977042	MIR29B2	-0.48	-8.34	-0.6	1.19e-13	Schizophrenia;
TGCT	cis	rs4975616	0.773	rs414965	chr5:1324121	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.3	-4.66	-0.39	8.15e-6	Lung cancer;
TGCT	trans	rs7698623	0.850	rs6813016	chr4:88768808	T/C	cg01186725	chr1:53905612	FLJ40434	-0.48	-6.62	-0.51	9.94e-10	Cardiovascular disease risk factors;
TGCT	cis	rs12477438	0.765	rs2309521	chr2:99592069	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-7.6	-0.56	6.47e-12	Chronic sinus infection;
TGCT	cis	rs7614311	0.636	rs66818634	chr3:63913222	G/A	cg22134162	chr3:63841271	THOC7	-0.48	-6.11	-0.48	1.2e-8	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs12681287	0.640	rs7846090	chr8:87467724	A/T	cg27223183	chr8:87520930	FAM82B	-0.89	-6.43	-0.5	2.54e-9	Caudate activity during reward;
TGCT	cis	rs483180	0.531	rs539708	chr1:120208503	G/T	cg19096424	chr1:120255104	PHGDH	-0.57	-5.45	-0.44	2.62e-7	Macular telangiectasia type 2;
TGCT	cis	rs7568458	0.709	rs2043675	chr2:85769975	C/T	cg17127132	chr2:85788382	GGCX	-0.53	-4.69	-0.39	7.05e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs9291683	0.527	rs3822241	chr4:10094931	G/A	cg11266682	chr4:10021025	SLC2A9	-0.57	-6.84	-0.52	3.15e-10	Bone mineral density;
TGCT	cis	rs4969178	0.641	rs4969141	chr17:76391653	C/T	cg05887092	chr17:76393375	PGS1	0.22	4.66	0.39	8.19e-6	HDL cholesterol levels;
TGCT	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2072499	0.966	rs2842882	chr1:156165342	T/G	cg25208724	chr1:156163844	SLC25A44	1.14	17.15	0.84	1.56e-34	Testicular germ cell tumor;
TGCT	cis	rs2249625	0.935	rs1852702	chr6:72908366	T/C	cg24401219	chr6:72892597	RIMS1	-0.54	-4.52	-0.38	1.43e-5	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
TGCT	cis	rs3096299	0.719	rs2965818	chr16:89510494	A/G	cg02187348	chr16:89574699	SPG7	0.62	6.65	0.51	8.36e-10	Multiple myeloma (IgH translocation);
TGCT	cis	rs7666738	0.800	rs13107586	chr4:99028788	G/C	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3845702	0.935	rs3845695	chr2:180796989	A/G	cg01881094	chr2:180872142	CWC22	-0.66	-5.88	-0.47	3.55e-8	Schizophrenia;
TGCT	cis	rs1448094	0.511	rs61930074	chr12:86218759	G/C	cg02569458	chr12:86230093	RASSF9	0.36	4.53	0.38	1.36e-5	Major depressive disorder;
TGCT	cis	rs7507204	0.767	rs62125962	chr19:3410852	A/G	cg08380311	chr19:3435252	NFIC	0.97	8.14	0.59	3.51e-13	Height;
TGCT	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7010267	0.570	rs4495458	chr8:120042780	G/T	cg17171407	chr8:119960777	TNFRSF11B	0.25	4.49	0.37	1.59e-5	Total body bone mineral density (age 45-60);
TGCT	cis	rs9486715	1.000	rs9386670	chr6:97060688	C/A	cg18709589	chr6:96969512	KIAA0776	-0.82	-7.32	-0.55	2.76e-11	Headache;
TGCT	cis	rs7826238	0.524	rs2921055	chr8:8319342	C/A	cg15556689	chr8:8085844	FLJ10661	0.7	6.4	0.5	2.85e-9	Systolic blood pressure;
TGCT	cis	rs12477438	0.520	rs11685759	chr2:99766217	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.15	18.47	0.86	2.08e-37	Chronic sinus infection;
TGCT	cis	rs62244186	0.714	rs2293600	chr3:44599103	G/T	cg25151919	chr3:44754333	ZNF502	0.42	4.92	0.4	2.67e-6	Depressive symptoms;
TGCT	cis	rs58235267	0.543	rs2539990	chr2:63170185	C/T	cg17519650	chr2:63277830	OTX1	0.7	6.94	0.53	1.9e-10	Prostate-specific antigen levels (conditioned on lead SNPs);
TGCT	cis	rs17376456	0.569	rs896729	chr5:93222178	A/G	cg21475434	chr5:93447410	FAM172A	-0.69	-5.27	-0.43	5.81e-7	Diabetic retinopathy;
TGCT	cis	rs12497850	0.931	rs9835307	chr3:48857805	T/C	cg18654377	chr3:49208889	KLHDC8B	-0.42	-5.52	-0.44	1.93e-7	Parkinson's disease;
TGCT	cis	rs66573146	1.000	rs55672215	chr4:6970529	T/C	cg05069807	chr4:6945702	TBC1D14	0.29	4.74	0.39	5.73e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs9393777	0.623	rs13211166	chr6:27265940	T/A	cg11262757	chr6:27280423	POM121L2	0.62	4.56	0.38	1.19e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7818688	0.697	rs11783878	chr8:95979261	C/T	cg16049864	chr8:95962084	TP53INP1	-0.54	-4.64	-0.38	8.87e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg06112835	chr11:68658793	MRPL21	0.45	7.64	0.57	5.19e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg02725872	chr8:58115012	NA	0.36	5.05	0.41	1.53e-6	Developmental language disorder (linguistic errors);
TGCT	trans	rs7618501	1.000	rs35261599	chr3:49773236	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-1.03	-13.16	-0.76	2.65e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs10779751	0.734	rs12569242	chr1:11127511	A/C	cg08854313	chr1:11322531	MTOR	0.81	6.85	0.52	3.09e-10	Body mass index;
TGCT	cis	rs6882046	0.513	rs681446	chr5:88054292	C/T	cg24804195	chr5:87968844	LOC645323	0.58	5.57	0.45	1.5e-7	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg27211696	chr2:191398769	TMEM194B	0.29	5.3	0.43	5.19e-7	Pulse pressure;
TGCT	cis	rs910316	0.737	rs175510	chr14:75524839	G/A	cg08847533	chr14:75593920	NEK9	-0.83	-8.38	-0.6	9.93e-14	Height;
TGCT	cis	rs1008375	1.000	rs4698200	chr4:17657051	G/A	cg18681998	chr4:17616180	MED28	1.0	11.88	0.73	3.32e-22	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs826838	0.967	rs826879	chr12:39088999	A/C	cg13010199	chr12:38710504	ALG10B	-0.61	-4.98	-0.41	2.06e-6	Heart rate;
TGCT	cis	rs739496	0.579	rs7975437	chr12:112376949	A/G	cg10833066	chr12:111807467	FAM109A	0.38	5.36	0.43	3.98e-7	Platelet count;
TGCT	cis	rs611744	0.523	rs13253581	chr8:109343105	A/G	cg18478394	chr8:109455254	TTC35	0.44	4.45	0.37	1.85e-5	Dupuytren's disease;
TGCT	cis	rs2180341	0.960	rs1964130	chr6:127677391	C/G	cg24812749	chr6:127587940	RNF146	0.82	5.73	0.46	7.1e-8	Breast cancer;
TGCT	cis	rs2153535	0.541	rs6908504	chr6:8456778	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs9500256	0.711	rs6588685	chr6:58319653	A/G	cg16251399	chr6:58287822	GUSBL2	0.56	4.74	0.39	5.76e-6	Eosinophilic esophagitis (pediatric);
TGCT	cis	rs4478858	0.735	rs4622114	chr1:31772571	A/G	cg00250761	chr1:31883323	NA	-0.28	-5.01	-0.41	1.86e-6	Alcohol dependence;
TGCT	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg22968622	chr17:43663579	NA	1.3	11.87	0.73	3.46e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs6138458	1.000	rs227630	chr20:24913584	A/G	cg26195577	chr20:24973756	C20orf3	1.2	12.04	0.73	1.35e-22	Blood protein levels;
TGCT	cis	rs67072384	0.892	rs72966136	chr11:72456710	G/C	cg03713592	chr11:72463424	ARAP1	-0.96	-4.77	-0.39	5.1e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg22920501	chr2:26401640	FAM59B	-0.72	-6.38	-0.5	3.19e-9	Gut microbiome composition (summer);
TGCT	cis	rs28735056	0.967	rs61090726	chr18:77631219	A/G	cg20368463	chr18:77673604	PQLC1	-0.45	-5.55	-0.45	1.65e-7	Schizophrenia;
TGCT	cis	rs1992660	0.523	rs10045016	chr5:40328325	T/A	cg01087697	chr5:40835557	RPL37	0.52	4.7	0.39	6.83e-6	Crohn's disease;
TGCT	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg23758822	chr17:41437982	NA	0.69	6.76	0.52	4.79e-10	Menopause (age at onset);
TGCT	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.5	-4.81	-0.4	4.26e-6	Bipolar disorder;
TGCT	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg13397359	chr6:42928475	GNMT	0.73	6.81	0.52	3.7e-10	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg03213289	chr20:61660250	NA	0.7	10.11	0.67	6.94e-18	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9916302	0.904	rs4794813	chr17:37670994	A/T	cg07936489	chr17:37558343	FBXL20	-0.6	-4.75	-0.39	5.45e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.01	0.41	1.86e-6	Prudent dietary pattern;
TGCT	cis	rs1365505	0.587	rs4238382	chr15:50484746	T/A	cg26188685	chr15:50540269	HDC	-0.4	-6.62	-0.51	9.8e-10	Blood metabolite ratios;
TGCT	cis	rs6840360	0.571	rs875667	chr4:152525477	G/A	cg17479576	chr4:152424074	FAM160A1	-0.71	-7.72	-0.57	3.41e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg18252515	chr7:66147081	NA	-1.09	-6.4	-0.5	2.88e-9	Diabetic kidney disease;
TGCT	cis	rs11711311	1.000	rs2305546	chr3:113503354	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.7	-6.64	-0.51	8.96e-10	IgG glycosylation;
TGCT	cis	rs2153535	0.580	rs9378554	chr6:8488468	C/T	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs62103177	0.513	rs9945153	chr18:77598450	C/T	cg12964065	chr18:77638022	KCNG2	0.41	5.48	0.44	2.31e-7	Opioid sensitivity;
TGCT	cis	rs992157	0.710	rs12694432	chr2:219082330	A/G	cg00012203	chr2:219082015	ARPC2	0.81	10.19	0.68	4.34e-18	Colorectal cancer;
TGCT	trans	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg27523141	chr10:43048294	ZNF37B	0.7	8.15	0.59	3.36e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs10771431	1.000	rs10771431	chr12:9380859	C/T	cg09152401	chr12:9436616	LOC642846	-0.5	-5.18	-0.42	8.57e-7	Breast size;
TGCT	cis	rs57994353	0.600	rs1130640	chr9:139317979	C/T	cg13741927	chr9:139327495	INPP5E	-0.25	-5.59	-0.45	1.35e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs2224391	0.628	rs2773313	chr6:5252213	C/G	cg09085698	chr6:5261316	LYRM4;FARS2	-1.04	-6.69	-0.51	6.87e-10	Height;
TGCT	cis	rs2013441	0.901	rs2526474	chr17:20137134	C/T	cg18979559	chr17:20280153	CCDC144C	-0.45	-4.67	-0.39	7.61e-6	Obesity-related traits;
TGCT	cis	rs600231	0.665	rs1626021	chr11:65226187	A/G	cg17120908	chr11:65337727	SSSCA1	-0.51	-4.71	-0.39	6.51e-6	Bone mineral density;
TGCT	cis	rs9527	0.571	rs7904113	chr10:104633114	G/T	cg15744005	chr10:104629667	AS3MT	-0.46	-5.81	-0.46	4.91e-8	Arsenic metabolism;
TGCT	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg18876405	chr7:65276391	NA	-0.35	-5.58	-0.45	1.44e-7	Aortic root size;
TGCT	cis	rs13392177	0.543	rs12623716	chr2:219073018	C/T	cg00012203	chr2:219082015	ARPC2	-0.78	-7.79	-0.57	2.32e-12	Pyoderma gangrenosum in inflammatory bowel disease;
TGCT	cis	rs10479542	0.701	rs10479541	chr5:178981003	G/C	cg05712903	chr5:178977398	RUFY1	0.49	4.64	0.38	8.7e-6	Lung cancer;
TGCT	cis	rs7568458	0.660	rs6547623	chr2:85801964	T/A	cg02493740	chr2:85810744	VAMP5	-0.31	-6.11	-0.48	1.19e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg00684032	chr4:1343700	KIAA1530	0.22	4.82	0.4	4.11e-6	Obesity-related traits;
TGCT	cis	rs2204008	0.754	rs11514074	chr12:38401128	C/T	cg26384229	chr12:38710491	ALG10B	0.84	7.42	0.55	1.62e-11	Bladder cancer;
TGCT	cis	rs35146811	0.659	rs863450	chr7:99821685	C/T	cg13334819	chr7:99746414	C7orf59	0.74	6.41	0.5	2.82e-9	Coronary artery disease;
TGCT	cis	rs826838	0.904	rs10880981	chr12:38763911	G/A	cg13010199	chr12:38710504	ALG10B	0.82	6.86	0.52	2.91e-10	Heart rate;
TGCT	cis	rs17826219	0.706	rs8075107	chr17:29106649	C/A	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Body mass index;
TGCT	cis	rs6906287	0.647	rs28655926	chr6:118688962	A/G	cg21191810	chr6:118973309	C6orf204	0.26	4.46	0.37	1.85e-5	Electrocardiographic conduction measures;
TGCT	cis	rs2153535	0.580	rs7341382	chr6:8470549	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs40363	0.951	rs250632	chr16:3523047	C/T	cg00484396	chr16:3507460	NAT15	0.42	5.18	0.42	8.85e-7	Tuberculosis;
TGCT	cis	rs17376456	0.597	rs11135401	chr5:93365716	G/A	cg21475434	chr5:93447410	FAM172A	-0.64	-5.99	-0.47	2.14e-8	Diabetic retinopathy;
TGCT	cis	rs12950390	0.853	rs56137679	chr17:45862112	C/G	cg24803719	chr17:45855879	NA	-0.49	-5.03	-0.41	1.64e-6	IgG glycosylation;
TGCT	cis	rs6840360	0.593	rs3805356	chr4:152680701	C/T	cg17479576	chr4:152424074	FAM160A1	0.52	5.2	0.42	7.86e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9467711	0.606	rs35076545	chr6:26603924	C/A	cg16898833	chr6:26189333	HIST1H4D	1.26	5.95	0.47	2.59e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs950169	0.887	rs12903946	chr15:84954430	T/C	cg17173187	chr15:85201210	NMB	0.58	5.93	0.47	2.77e-8	Schizophrenia;
TGCT	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg08859206	chr1:53392774	SCP2	-0.46	-7.42	-0.55	1.64e-11	Monocyte count;
TGCT	cis	rs10744422	1.000	rs4759387	chr12:123377569	C/T	cg25930673	chr12:123319894	HIP1R	-0.85	-5.09	-0.42	1.29e-6	Schizophrenia;
TGCT	cis	rs9611565	0.512	rs2899347	chr22:42158204	T/C	cg06634786	chr22:41940651	POLR3H	0.86	8.01	0.58	7.16e-13	Vitiligo;
TGCT	cis	rs10832169	0.967	rs11023063	chr11:14068571	T/C	cg04547675	chr11:13986162	SPON1	0.54	4.73	0.39	6.08e-6	Blood protein levels;
TGCT	cis	rs2153535	0.580	rs6905242	chr6:8471799	A/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.07	0.41	1.43e-6	Motion sickness;
TGCT	cis	rs7937682	0.883	rs510388	chr11:111451869	G/T	cg09085632	chr11:111637200	PPP2R1B	0.97	10.05	0.67	9.82e-18	Primary sclerosing cholangitis;
TGCT	cis	rs12477438	0.501	rs11688004	chr2:99735052	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.75	7.25	0.55	3.92e-11	Chronic sinus infection;
TGCT	cis	rs4664308	1.000	rs925410	chr2:160912652	C/T	cg03641300	chr2:160917029	PLA2R1	0.26	6.53	0.51	1.49e-9	Idiopathic membranous nephropathy;
TGCT	cis	rs55823223	0.702	rs3785437	chr17:73906222	G/T	cg08125733	chr17:73851984	WBP2	1.0	6.33	0.49	4.16e-9	Psoriasis;
TGCT	trans	rs1496653	0.602	rs13100499	chr3:23491444	T/C	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs367943	0.965	rs458044	chr5:112797779	A/G	cg12552261	chr5:112820674	MCC	-0.24	-4.92	-0.4	2.7e-6	Type 2 diabetes;
TGCT	cis	rs6543140	0.601	rs7558013	chr2:102992806	G/T	cg09003973	chr2:102972529	NA	0.75	6.15	0.48	1e-8	Blood protein levels;
TGCT	cis	rs6121246	0.529	rs2889528	chr20:30210021	C/T	cg18721089	chr20:30220636	NA	-0.64	-6.86	-0.52	2.84e-10	Mean corpuscular hemoglobin;
TGCT	cis	rs2933343	0.661	rs2630259	chr3:128606322	C/T	cg11901034	chr3:128598214	ACAD9	-0.68	-6.63	-0.51	9.16e-10	IgG glycosylation;
TGCT	cis	rs2012796	0.665	rs72703728	chr14:81834523	G/A	cg02996355	chr14:81879375	NA	0.55	5.55	0.45	1.69e-7	Night sleep phenotypes;
TGCT	cis	rs9916302	0.861	rs11658219	chr17:37709782	G/A	cg07936489	chr17:37558343	FBXL20	-0.57	-4.49	-0.37	1.59e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs453301	0.564	rs28649568	chr8:8959671	T/G	cg15556689	chr8:8085844	FLJ10661	-0.72	-5.99	-0.47	2.16e-8	Joint mobility (Beighton score);
TGCT	cis	rs13108904	0.517	rs7671242	chr4:1339875	G/A	cg13395646	chr4:1353034	KIAA1530	-0.56	-7.34	-0.55	2.41e-11	Obesity-related traits;
TGCT	cis	rs514406	0.893	rs6588445	chr1:53424928	T/C	cg22166914	chr1:53195759	ZYG11B	-0.37	-6.37	-0.5	3.34e-9	Monocyte count;
TGCT	cis	rs35306767	0.953	rs12354639	chr10:963681	G/A	cg26597838	chr10:835615	NA	0.63	9.1	0.63	1.93e-15	Eosinophil percentage of granulocytes;
TGCT	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg24675658	chr1:53192096	ZYG11B	0.7	7.98	0.58	8.59e-13	Monocyte count;
TGCT	cis	rs8062405	1.000	rs62036621	chr16:28833299	C/A	cg09754948	chr16:28834200	ATXN2L	0.61	4.54	0.38	1.34e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg25703541	chr22:24373054	LOC391322	0.95	12.0	0.73	1.7e-22	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg01802117	chr1:53393560	SCP2	-0.42	-5.25	-0.43	6.33e-7	Monocyte count;
TGCT	cis	rs13256369	1.000	rs7820159	chr8:8576215	T/C	cg17143192	chr8:8559678	CLDN23	0.62	5.8	0.46	5.1e-8	Obesity-related traits;
TGCT	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg17971929	chr21:40555470	PSMG1	0.93	8.97	0.63	3.91e-15	Cognitive function;
TGCT	cis	rs3812049	0.784	rs2250127	chr5:127388844	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.59	-5.41	-0.44	3.14e-7	Lymphocyte counts;Red cell distribution width;
TGCT	cis	rs727563	0.520	rs132773	chr22:42031768	T/A	cg03806693	chr22:41940476	POLR3H	1.06	11.19	0.71	1.58e-20	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg06221963	chr1:154839813	KCNN3	-0.71	-11.67	-0.72	1.1e-21	Prostate cancer;
TGCT	cis	rs2046867	0.862	rs62251646	chr3:72805787	T/C	cg25664220	chr3:72788482	NA	-0.57	-7.16	-0.54	6.2e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs854765	0.547	rs8075189	chr17:17901946	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.79	8.41	0.6	8.09e-14	Total body bone mineral density;
TGCT	cis	rs6831352	0.734	rs3018046	chr4:100030388	C/T	cg12011299	chr4:100065546	ADH4	0.39	5.2	0.42	8.04e-7	Alcohol dependence;
TGCT	cis	rs5769765	1.000	rs8184990	chr22:50273174	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	1.11	11.76	0.73	6.5e-22	Schizophrenia;
TGCT	cis	rs6938	0.534	rs8025447	chr15:75192222	T/G	cg10253484	chr15:75165896	SCAMP2	-0.55	-5.07	-0.41	1.43e-6	Breast cancer;
TGCT	cis	rs4378999	0.660	rs7627266	chr3:50962368	C/T	ch.3.1075622R	chr3:50010873	RBM6	0.37	4.62	0.38	9.62e-6	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
TGCT	cis	rs1843834	0.505	rs4674911	chr2:225345254	A/G	cg12698349	chr2:225449008	CUL3	0.76	6.26	0.49	5.79e-9	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg00684032	chr4:1343700	KIAA1530	0.23	4.93	0.41	2.55e-6	Obesity-related traits;
TGCT	cis	rs67311347	0.869	rs7646899	chr3:40366982	A/G	cg13683864	chr3:40499215	RPL14	-1.05	-10.95	-0.7	6.12e-20	Renal cell carcinoma;
TGCT	trans	rs9929218	0.551	rs9888942	chr16:68727572	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	7.75	0.57	2.78e-12	Colorectal cancer;
TGCT	trans	rs877282	0.755	rs2790388	chr10:786084	T/C	cg22713356	chr15:30763199	NA	0.94	8.1	0.59	4.33e-13	Uric acid levels;
TGCT	cis	rs1868673	0.708	rs13066779	chr3:150169379	G/C	cg24290546	chr3:150134309	TSC22D2	-0.24	-4.6	-0.38	1.03e-5	Waist circumference;
TGCT	cis	rs2235642	0.717	rs9937922	chr16:1658154	C/G	cg10465839	chr16:1584050	IFT140;TMEM204	-0.28	-4.65	-0.39	8.32e-6	Coronary artery disease;
TGCT	cis	rs478304	0.934	rs1193692	chr11:65504069	A/C	cg27068330	chr11:65405492	SIPA1	0.74	7.3	0.55	3.07e-11	Acne (severe);
TGCT	cis	rs655029	0.645	rs633323	chr2:31463044	A/T	cg14018959	chr2:31480232	EHD3	-0.32	-4.45	-0.37	1.92e-5	Mean platelet volume;Platelet distribution width;Platelet count;Plateletcrit;
TGCT	cis	rs6901250	0.655	rs1398403	chr6:117122646	T/C	cg12892004	chr6:117198278	RFX6	0.46	5.59	0.45	1.37e-7	C-reactive protein levels;
TGCT	cis	rs7246657	0.943	rs1015849	chr19:37946180	G/A	cg18154014	chr19:37997991	ZNF793	0.95	6.52	0.51	1.58e-9	Coronary artery calcification;
TGCT	cis	rs9457247	1.000	rs439237	chr6:167391392	A/G	cg25258033	chr6:167368657	RNASET2	0.18	4.49	0.37	1.63e-5	Crohn's disease;
TGCT	cis	rs854765	0.583	rs7222480	chr17:17818817	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	7.91	0.58	1.2e-12	Total body bone mineral density;
TGCT	cis	rs1008375	0.931	rs2098151	chr4:17577490	T/C	cg18681998	chr4:17616180	MED28	0.94	9.56	0.65	1.44e-16	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6840360	0.593	rs10013612	chr4:152693622	A/G	cg22705602	chr4:152727874	NA	-0.34	-5.9	-0.47	3.24e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs929596	0.793	rs2741044	chr2:234579368	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.29	-4.48	-0.37	1.66e-5	Total bilirubin levels in HIV-1 infection;
TGCT	trans	rs9951602	0.512	rs8084836	chr18:76647841	A/G	cg02800362	chr5:177631904	HNRNPAB	1.11	12.65	0.75	4.66e-24	Obesity-related traits;
TGCT	cis	rs7552404	0.690	rs2029681	chr1:76333846	G/A	cg10523679	chr1:76189770	ACADM	-0.67	-6.27	-0.49	5.47e-9	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg00343986	chr7:65444356	GUSB	0.26	5.96	0.47	2.4e-8	Aortic root size;
TGCT	cis	rs1577917	0.958	rs6900436	chr6:86506288	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-5.53	-0.44	1.82e-7	Response to antipsychotic treatment;
TGCT	cis	rs2549003	1.000	rs2549002	chr5:131829578	C/A	cg02551604	chr5:131831745	NA	0.9	12.39	0.74	2e-23	Asthma (sex interaction);
TGCT	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg13397359	chr6:42928475	GNMT	0.74	6.83	0.52	3.33e-10	Alzheimer's disease in APOE e4+ carriers;
TGCT	trans	rs7726839	0.561	rs72703058	chr5:584519	G/A	cg25482853	chr8:67687455	SGK3	1.07	8.9	0.62	5.55e-15	Obesity-related traits;
TGCT	cis	rs8180040	0.967	rs17411375	chr3:47395135	C/T	cg27129171	chr3:47204927	SETD2	-0.7	-8.63	-0.61	2.53e-14	Colorectal cancer;
TGCT	cis	rs7914558	0.869	rs10883842	chr10:104941589	C/T	cg15744005	chr10:104629667	AS3MT	-0.39	-4.75	-0.39	5.53e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs4253772	0.550	rs11703564	chr22:46722194	G/A	cg24881330	chr22:46731750	TRMU	1.04	5.38	0.44	3.54e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs4568518	0.530	rs11764965	chr7:17998750	A/T	cg03009463	chr7:17980271	SNX13	0.57	4.51	0.38	1.47e-5	Measles;
TGCT	cis	rs4919694	0.808	rs4918001	chr10:105013147	G/T	cg04362960	chr10:104952993	NT5C2	-1.02	-6.91	-0.53	2.3e-10	Arsenic metabolism;
TGCT	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg13607699	chr17:42295918	UBTF	0.84	7.76	0.57	2.72e-12	Total body bone mineral density;
TGCT	cis	rs1784581	0.894	rs1784594	chr6:162382734	A/G	cg17173639	chr6:162384350	PARK2	-0.5	-9.26	-0.64	7.99e-16	Itch intensity from mosquito bite;
TGCT	cis	rs4788570	0.616	rs11075901	chr16:71790812	A/C	cg06353428	chr16:71660113	MARVELD3	1.53	12.17	0.74	6.57e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg22963979	chr7:1858916	MAD1L1	0.43	7.32	0.55	2.8e-11	Bipolar disorder and schizophrenia;
TGCT	cis	rs9902453	0.845	rs3102556	chr17:28042542	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	7.27	0.55	3.55e-11	Coffee consumption (cups per day);
TGCT	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	5.14	0.42	1.03e-6	Height;
TGCT	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg01341218	chr17:43662625	NA	-1.11	-9.42	-0.65	3.27e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs6831352	0.959	rs1139490	chr4:100045141	C/T	cg12011299	chr4:100065546	ADH4	0.41	5.09	0.42	1.3e-6	Alcohol dependence;
TGCT	cis	rs3749237	0.557	rs7631908	chr3:49425707	T/G	cg02487422	chr3:49467188	NICN1	0.59	6.01	0.47	1.92e-8	Resting heart rate;
TGCT	cis	rs10992471	0.729	rs6479418	chr9:95064762	G/A	cg14631576	chr9:95140430	CENPP	-0.29	-4.77	-0.39	5.06e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs9902453	0.765	rs2467334	chr17:28135508	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.83	-7.95	-0.58	9.99e-13	Coffee consumption (cups per day);
TGCT	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg26338869	chr17:61819248	STRADA	-0.53	-4.94	-0.41	2.48e-6	Prudent dietary pattern;
TGCT	cis	rs6684514	0.961	rs11264469	chr1:156276746	A/G	cg20302342	chr1:156215951	PAQR6	0.34	4.43	0.37	2.01e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs7044106	0.664	rs7861679	chr9:123375589	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.6	-6.61	-0.51	1.01e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs7727544	0.684	rs272893	chr5:131663062	T/C	cg24060327	chr5:131705240	SLC22A5	-0.57	-6.22	-0.49	6.92e-9	Blood metabolite levels;
TGCT	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg00149659	chr3:10157352	C3orf10	0.95	6.09	0.48	1.3e-8	Alzheimer's disease;
TGCT	cis	rs3782455	1.000	rs79831570	chr12:114401608	T/C	cg23502203	chr12:113549970	RASAL1	-0.55	-4.92	-0.4	2.7e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs1729951	0.575	rs361237	chr3:136702414	A/G	cg12473912	chr3:136751656	NA	0.38	6.23	0.49	6.63e-9	Neuroticism;
TGCT	cis	rs3849570	1.000	rs3772882	chr3:81808602	C/A	cg07356753	chr3:81810745	GBE1	-0.7	-6.08	-0.48	1.4e-8	Waist circumference;Body mass index;
TGCT	cis	rs6429082	0.714	rs184108	chr1:235646160	A/G	cg26050004	chr1:235667680	B3GALNT2	0.62	5.58	0.45	1.43e-7	Adiposity;
TGCT	cis	rs6750047	0.771	rs1056837	chr2:38298150	A/G	cg07380506	chr2:38303506	CYP1B1	0.66	5.99	0.47	2.14e-8	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs2050392	0.687	rs608693	chr10:30734971	G/A	cg13289132	chr10:30722225	MAP3K8	-0.43	-5.06	-0.41	1.46e-6	Inflammatory bowel disease;
TGCT	cis	rs763121	0.853	rs5995610	chr22:39064681	C/T	cg06022373	chr22:39101656	GTPBP1	0.77	7.57	0.56	7.47e-12	Menopause (age at onset);
TGCT	cis	rs9859260	0.744	rs492288	chr3:195784210	C/T	cg02975922	chr3:195473998	MUC4	0.25	5.1	0.42	1.24e-6	Mean corpuscular volume;
TGCT	cis	rs807669	0.586	rs5746671	chr22:19160899	A/G	cg02655711	chr22:19163373	SLC25A1	0.27	5.35	0.43	4.14e-7	Metabolite levels;
TGCT	cis	rs2836950	0.520	rs8133927	chr21:40689961	G/T	cg11890956	chr21:40555474	PSMG1	-0.65	-5.97	-0.47	2.27e-8	Menarche (age at onset);
TGCT	cis	rs2862064	0.932	rs1393208	chr5:156477725	G/A	cg12943317	chr5:156479607	HAVCR1	-0.46	-5.59	-0.45	1.35e-7	Platelet count;
TGCT	cis	rs4654899	0.865	rs6691824	chr1:21417577	T/G	cg01072550	chr1:21505969	NA	-0.47	-7.03	-0.53	1.22e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs561341	0.700	rs2074101	chr17:30228656	G/A	cg13647721	chr17:30228624	UTP6	0.6	5.33	0.43	4.5e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs909674	0.865	rs5757682	chr22:39848259	T/G	cg02038168	chr22:39784481	NA	-0.72	-5.54	-0.45	1.75e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs6076065	0.748	rs4815198	chr20:23343491	T/C	cg11657817	chr20:23433608	CST11	0.31	5.42	0.44	3.02e-7	Facial morphology (factor 15, philtrum width);
TGCT	cis	rs7937612	1.000	rs10892566	chr11:120241923	T/C	cg24566217	chr11:120254723	ARHGEF12	-0.29	-4.62	-0.38	9.34e-6	Intraocular pressure;
TGCT	cis	rs3733585	0.673	rs4407505	chr4:9953367	T/G	cg00071950	chr4:10020882	SLC2A9	-0.55	-6.58	-0.51	1.21e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.18	0.49	8.32e-9	Electroencephalogram traits;
TGCT	cis	rs938554	0.513	rs10939650	chr4:9998440	C/T	cg00071950	chr4:10020882	SLC2A9	0.57	5.32	0.43	4.76e-7	Blood metabolite levels;
TGCT	cis	rs2933343	0.729	rs1680785	chr3:128644816	C/T	cg11901034	chr3:128598214	ACAD9	-0.65	-6.05	-0.48	1.55e-8	IgG glycosylation;
TGCT	cis	rs9858542	0.951	rs1800668	chr3:49395757	G/A	cg03060546	chr3:49711283	APEH	-0.64	-5.61	-0.45	1.27e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg23283495	chr1:209979779	IRF6	0.65	5.53	0.44	1.81e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs6840360	0.642	rs2724574	chr4:152381800	A/T	cg17479576	chr4:152424074	FAM160A1	0.6	6.19	0.49	8.23e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs901683	0.702	rs78757497	chr10:46161918	T/C	cg09623279	chr10:45395734	NA	-0.49	-5.18	-0.42	8.87e-7	Red blood cell traits;Mean corpuscular volume;
TGCT	cis	rs2836950	0.545	rs2836952	chr21:40616651	G/C	cg06238570	chr21:40685208	BRWD1	-0.61	-6.29	-0.49	5.07e-9	Menarche (age at onset);
TGCT	cis	rs12477438	0.765	rs1115757	chr2:99660146	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-4.88	-0.4	3.17e-6	Chronic sinus infection;
TGCT	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg14784868	chr12:69753453	YEATS4	0.9	10.55	0.69	5.67e-19	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs9467773	0.626	rs9379860	chr6:26370605	T/C	cg15659132	chr6:26577336	NA	-0.53	-5.47	-0.44	2.37e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9372253	0.818	rs2207360	chr6:110706337	G/C	cg19196401	chr6:110721138	DDO	-0.42	-5.81	-0.46	4.95e-8	Platelet distribution width;
TGCT	cis	rs2549003	1.000	rs3846732	chr5:131816087	T/C	cg21138405	chr5:131827807	IRF1	0.2	5.08	0.41	1.36e-6	Asthma (sex interaction);
TGCT	cis	rs975752	0.717	rs2281949	chr10:102006402	C/T	cg04750910	chr10:102416409	NA	0.73	4.48	0.37	1.69e-5	Schizophrenia;
TGCT	cis	rs854765	0.624	rs12952723	chr17:17731651	T/C	cg04398451	chr17:18023971	MYO15A	0.31	4.72	0.39	6.19e-6	Total body bone mineral density;
TGCT	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg24060327	chr5:131705240	SLC22A5	-0.61	-6.37	-0.5	3.32e-9	Acylcarnitine levels;
TGCT	trans	rs1814175	0.817	rs3974439	chr11:50022607	G/A	cg15704280	chr7:45808275	SEPT13	-0.72	-8.47	-0.61	6.02e-14	Height;
TGCT	cis	rs13064411	0.696	rs6783965	chr3:113198722	C/T	cg18753928	chr3:113234510	CCDC52	-0.69	-5.57	-0.45	1.47e-7	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs782590	0.608	rs10207590	chr2:55921782	G/C	cg18811423	chr2:55921094	PNPT1	-0.69	-7.52	-0.56	9.44e-12	Metabolic syndrome;
TGCT	cis	rs2153535	0.580	rs1360054	chr6:8520377	C/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.01	0.41	1.86e-6	Motion sickness;
TGCT	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg25703541	chr22:24373054	LOC391322	-0.81	-8.83	-0.62	8.31e-15	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9916302	0.904	rs8076546	chr17:37555403	G/A	cg15445000	chr17:37608096	MED1	-0.34	-4.8	-0.4	4.43e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7727544	0.716	rs72793283	chr5:131566941	G/A	cg24060327	chr5:131705240	SLC22A5	-0.57	-5.23	-0.43	6.84e-7	Blood metabolite levels;
TGCT	cis	rs17345786	1.000	rs3762729	chr3:101308874	C/T	cg12386194	chr3:101231763	SENP7	0.6	5.58	0.45	1.44e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2486288	0.656	rs11854325	chr15:45548959	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.46	-5.59	-0.45	1.38e-7	Glomerular filtration rate;
TGCT	cis	rs2016266	0.820	rs11170496	chr12:53666195	G/A	cg16917193	chr12:54089295	NA	0.64	5.26	0.43	6.11e-7	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs477895	0.568	rs12418035	chr11:63871558	G/A	cg04317338	chr11:64019027	PLCB3	0.73	6.33	0.49	4.15e-9	Mean platelet volume;
TGCT	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg01802117	chr1:53393560	SCP2	-0.41	-4.74	-0.39	5.73e-6	Monocyte count;
TGCT	cis	rs610932	0.517	rs673141	chr11:59975710	C/T	cg18570331	chr11:60101691	MS4A6E	0.52	4.84	0.4	3.79e-6	Alzheimer's disease;
TGCT	cis	rs9517313	0.615	rs4772079	chr13:99090837	C/G	cg20487152	chr13:99095054	FARP1	-0.25	-4.76	-0.39	5.29e-6	Neuroticism;
TGCT	cis	rs6450176	0.909	rs10940353	chr5:53299959	A/C	ch.5.1024479R	chr5:53302184	ARL15	-0.53	-5.1	-0.42	1.23e-6	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs6969780	0.915	rs3801320	chr7:27164364	C/A	cg04317399	chr7:27170313	HOXA4	0.44	4.87	0.4	3.3e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	trans	rs1814175	0.817	rs1794164	chr11:49899610	T/C	cg15704280	chr7:45808275	SEPT13	-0.71	-8.02	-0.58	6.85e-13	Height;
TGCT	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.57	-5.41	-0.44	3.08e-7	Menarche (age at onset);
TGCT	cis	rs9911578	0.967	rs9894274	chr17:56977919	G/A	cg05425664	chr17:57184151	TRIM37	-0.62	-6.18	-0.49	8.33e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs67311347	1.000	rs72861689	chr3:40435890	A/G	cg13683864	chr3:40499215	RPL14	-1.12	-12.12	-0.74	8.6e-23	Renal cell carcinoma;
TGCT	cis	rs9921222	0.564	rs9923059	chr16:381590	C/A	cg12437481	chr16:420112	MRPL28	-0.54	-5.32	-0.43	4.72e-7	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs4689388	0.926	rs10010131	chr4:6292915	A/G	cg14416269	chr4:6271139	WFS1	0.37	4.9	0.4	2.95e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs916888	0.821	rs199509	chr17:44858728	G/A	cg17911788	chr17:44343683	NA	0.59	6.13	0.48	1.09e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs835154	0.817	rs835157	chr5:14874533	T/C	cg14843632	chr5:14870594	ANKH	0.33	4.57	0.38	1.16e-5	Blood metabolite levels;
TGCT	cis	rs909341	0.537	rs13041528	chr20:62385446	C/G	cg14758556	chr20:62440591	NA	-0.37	-5.68	-0.45	9.25e-8	Atopic dermatitis;
TGCT	cis	rs35146811	0.735	rs11767968	chr7:99790971	G/A	cg00553149	chr7:99775558	STAG3;GPC2	0.31	4.61	0.38	9.75e-6	Coronary artery disease;
TGCT	cis	rs7772486	0.622	rs1292333	chr6:145982344	C/T	cg23711669	chr6:146136114	FBXO30	-0.85	-9.48	-0.65	2.24e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7044106	0.734	rs10491784	chr9:123432289	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.61	6.47	0.5	2.01e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs6681544	0.760	rs3790889	chr1:82412600	C/T	cg04226724	chr1:82268649	LPHN2	0.46	4.74	0.39	5.8e-6	Metabolite levels  (X-11787);
TGCT	cis	rs7191700	0.674	rs12597893	chr16:11426331	A/G	cg00044050	chr16:11439710	C16orf75	0.9	10.96	0.7	5.73e-20	Multiple sclerosis;
TGCT	cis	rs981844	0.753	rs62325149	chr4:154728006	G/C	cg14289246	chr4:154710475	SFRP2	1.04	9.67	0.66	8.17e-17	Response to statins (LDL cholesterol change);
TGCT	cis	rs904251	0.523	rs10807184	chr6:37483713	C/T	cg08126542	chr6:37504118	NA	-0.43	-6.2	-0.49	7.72e-9	Cognitive performance;
TGCT	cis	rs36051895	0.695	rs7045000	chr9:5015143	G/A	cg02405213	chr9:5042618	JAK2	-0.76	-10.18	-0.67	4.62e-18	Pediatric autoimmune diseases;
TGCT	cis	rs4478037	1.000	rs4076086	chr3:33161898	C/T	cg19404215	chr3:33155277	CRTAP	1.33	8.79	0.62	1.04e-14	Major depressive disorder;
TGCT	cis	rs57590327	0.679	rs7639135	chr3:81608976	C/T	cg07356753	chr3:81810745	GBE1	-0.55	-4.54	-0.38	1.3e-5	Extraversion;
TGCT	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg25036284	chr2:26402008	FAM59B	-0.56	-4.85	-0.4	3.62e-6	Gut microbiome composition (summer);
TGCT	cis	rs42648	0.837	rs10262603	chr7:89909442	G/A	cg25739043	chr7:89950458	NA	-0.73	-7.29	-0.55	3.15e-11	Homocysteine levels;
TGCT	cis	rs6912958	0.684	rs6931069	chr6:88367082	C/T	cg06598631	chr6:88300029	RARS2;ORC3L	-0.52	-4.8	-0.4	4.57e-6	Monocyte percentage of white cells;
TGCT	cis	rs3791556	1.000	rs13031713	chr2:240118868	C/T	cg03281426	chr2:240109471	HDAC4	0.28	4.46	0.37	1.82e-5	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg23302884	chr18:44338147	ST8SIA5	-0.41	-4.78	-0.39	4.94e-6	Personality dimensions;
TGCT	cis	rs6964587	0.967	rs2040499	chr7:91809657	C/G	cg22709100	chr7:91322751	NA	-0.29	-4.68	-0.39	7.51e-6	Breast cancer;
TGCT	cis	rs10927875	0.632	rs10927864	chr1:16165661	C/G	cg14742211	chr1:16348397	CLCNKA	-0.19	-4.58	-0.38	1.1e-5	Dilated cardiomyopathy;
TGCT	cis	rs6088580	0.634	rs6142164	chr20:33006597	C/T	cg06115741	chr20:33292138	TP53INP2	-0.53	-4.67	-0.39	7.83e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs3820928	0.874	rs2272198	chr2:227893017	A/G	cg11843606	chr2:227700838	RHBDD1	0.56	5.22	0.42	7.24e-7	Pulmonary function;
TGCT	cis	rs13256369	1.000	rs885000	chr8:8568875	G/T	cg17143192	chr8:8559678	CLDN23	0.58	5.56	0.45	1.56e-7	Obesity-related traits;
TGCT	cis	rs9926296	0.572	rs2079671	chr16:89884981	T/C	cg26513180	chr16:89883248	FANCA	0.76	7.61	0.56	5.85e-12	Vitiligo;
TGCT	cis	rs2458413	0.586	rs2669453	chr8:105368930	C/A	cg13045555	chr8:105342365	NA	0.34	4.71	0.39	6.47e-6	Paget's disease;
TGCT	cis	rs6570726	0.791	rs370654	chr6:145879005	C/G	cg05347473	chr6:146136440	FBXO30	0.54	5.15	0.42	1.01e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs8180040	0.874	rs11130123	chr3:47285912	A/G	cg27129171	chr3:47204927	SETD2	0.69	8.59	0.61	3.04e-14	Colorectal cancer;
TGCT	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg17178900	chr1:205818956	PM20D1	-0.54	-6.85	-0.52	3.1e-10	Menarche (age at onset);
TGCT	cis	rs3892630	0.824	rs35700505	chr19:33325006	C/T	cg22980127	chr19:33182716	NUDT19	0.72	5.22	0.42	7.45e-7	Red blood cell traits;
TGCT	cis	rs9859260	0.614	rs493661	chr3:195786489	T/A	cg22891161	chr3:195456627	MUC20	0.23	4.62	0.38	9.28e-6	Mean corpuscular volume;
TGCT	cis	rs10782582	0.564	rs17647711	chr1:76241710	C/G	cg03433033	chr1:76189801	ACADM	-0.45	-4.6	-0.38	1.02e-5	Daytime sleep phenotypes;
TGCT	cis	rs651907	0.535	rs11717638	chr3:101505468	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.86	10.4	0.68	1.35e-18	Colorectal cancer;
TGCT	cis	rs3096299	0.642	rs12934829	chr16:89523349	T/A	cg02187348	chr16:89574699	SPG7	0.63	6.77	0.52	4.54e-10	Multiple myeloma (IgH translocation);
TGCT	cis	rs7666738	0.830	rs11723283	chr4:99001617	C/T	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10984561	0.881	rs12238498	chr9:122249067	T/C	cg14242995	chr9:122249943	NA	0.75	6.12	0.48	1.16e-8	Pulmonary function decline;
TGCT	cis	rs2404602	0.716	rs56351018	chr15:76824591	T/C	cg26408565	chr15:76604113	ETFA	-0.4	-5.24	-0.43	6.54e-7	Blood metabolite levels;
TGCT	cis	rs1568889	1.000	rs78140392	chr11:28203231	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.82	8.31	0.6	1.42e-13	Bipolar disorder;
TGCT	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg16325326	chr1:53192061	ZYG11B	0.52	5.84	0.46	4.24e-8	Monocyte count;
TGCT	cis	rs910316	0.737	rs28687415	chr14:75495482	T/C	cg08847533	chr14:75593920	NEK9	0.83	8.74	0.62	1.4e-14	Height;
TGCT	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg03934478	chr11:495069	RNH1	0.35	5.89	0.47	3.34e-8	Body mass index;
TGCT	cis	rs7570971	0.792	rs56369224	chr2:136328890	A/T	cg07169764	chr2:136633963	MCM6	0.53	4.81	0.4	4.22e-6	Blood metabolite levels;Body mass index;Cholesterol, total;
TGCT	cis	rs6074578	0.679	rs11087791	chr20:140506	A/G	cg16931068	chr20:139680	DEFB127	0.27	4.64	0.38	8.57e-6	Hirschsprung disease;
TGCT	cis	rs1488864	1.000	rs4758408	chr11:6348639	T/C	cg12755421	chr11:6342214	PRKCDBP	-0.56	-4.48	-0.37	1.7e-5	Smooth-surface caries;
TGCT	cis	rs4824093	0.610	rs13340054	chr22:50311726	G/A	cg20569369	chr22:51173646	NA	0.29	4.56	0.38	1.19e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs6433895	1.000	rs12999974	chr2:182019537	G/A	cg16904960	chr2:182549928	NA	0.34	4.47	0.37	1.78e-5	Lymphocyte counts;
TGCT	cis	rs8017423	0.647	rs4904680	chr14:90822075	C/T	cg04374321	chr14:90722782	PSMC1	-0.54	-5.2	-0.42	7.91e-7	Mortality in heart failure;
TGCT	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.57	-5.67	-0.45	9.64e-8	Electroencephalogram traits;
TGCT	cis	rs40363	1.000	rs1690441	chr16:3517635	C/G	cg00484396	chr16:3507460	NAT15	0.43	5.05	0.41	1.51e-6	Tuberculosis;
TGCT	cis	rs12615966	0.932	rs1947308	chr2:105391930	G/A	cg16465502	chr2:105461796	NA	0.78	5.01	0.41	1.83e-6	Pancreatic cancer;
TGCT	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg22920501	chr2:26401640	FAM59B	0.81	6.36	0.5	3.52e-9	Gut microbiome composition (summer);
TGCT	cis	rs2760061	0.583	rs708118	chr1:228201801	A/G	cg02753203	chr1:228287806	NA	-0.34	-6.94	-0.53	1.92e-10	Diastolic blood pressure;
TGCT	cis	rs1008375	0.933	rs6847966	chr4:17634255	G/A	cg16339924	chr4:17578868	LAP3	0.71	5.75	0.46	6.46e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs11785400	0.793	rs11543967	chr8:143739435	A/G	cg24634471	chr8:143751801	JRK	-0.55	-5.51	-0.44	1.99e-7	Schizophrenia;
TGCT	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg06028808	chr11:68637592	NA	0.55	6.88	0.53	2.61e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs1062177	0.826	rs2915822	chr5:151130901	G/T	cg00977110	chr5:151150581	G3BP1	-0.41	-4.74	-0.39	5.73e-6	Preschool internalizing problems;
TGCT	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg00149659	chr3:10157352	C3orf10	0.9	6.34	0.49	3.96e-9	Alzheimer's disease;
TGCT	cis	rs67311347	1.000	rs7642552	chr3:40424816	T/C	cg17264618	chr3:40429014	ENTPD3	0.32	4.65	0.39	8.52e-6	Renal cell carcinoma;
TGCT	cis	rs7617773	0.539	rs13094496	chr3:48387050	G/C	cg11946769	chr3:48343235	NME6	0.57	4.83	0.4	3.9e-6	Coronary artery disease;
TGCT	cis	rs3820068	0.603	rs2236215	chr1:15892415	A/C	cg05660106	chr1:15850417	CASP9	1.1	13.34	0.77	9.88e-26	Systolic blood pressure;
TGCT	cis	rs11809207	0.855	rs17257155	chr1:26526439	C/T	cg03844060	chr1:26490628	NA	-0.26	-4.81	-0.4	4.28e-6	Height;
TGCT	cis	rs6570726	0.791	rs10872577	chr6:145900560	G/T	cg05347473	chr6:146136440	FBXO30	0.52	4.95	0.41	2.33e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2404602	1.000	rs1117367	chr15:76872330	A/C	cg22467129	chr15:76604101	ETFA	-0.44	-4.94	-0.41	2.5e-6	Blood metabolite levels;
TGCT	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.68	4.89	0.4	3e-6	Platelet count;
TGCT	cis	rs904251	0.797	rs1757177	chr6:37486370	C/T	cg01843034	chr6:37503916	NA	-0.54	-6.29	-0.49	4.93e-9	Cognitive performance;
TGCT	cis	rs2066819	1.000	rs78495928	chr12:56635080	G/C	cg26714650	chr12:56694279	CS	-1.32	-6.2	-0.49	7.69e-9	Psoriasis vulgaris;
TGCT	cis	rs854765	1.000	rs854765	chr17:18012730	T/C	cg00306284	chr17:18855313	SLC5A10	-0.24	-4.48	-0.37	1.68e-5	Total body bone mineral density;
TGCT	cis	rs7914558	1.000	rs10786733	chr10:104794947	G/A	cg15744005	chr10:104629667	AS3MT	-0.37	-4.48	-0.37	1.64e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs4891159	0.790	rs7241485	chr18:74122325	C/T	cg24786174	chr18:74118243	ZNF516	-0.61	-9.12	-0.63	1.68e-15	Longevity;
TGCT	cis	rs9611565	0.500	rs10775759	chr22:42088158	T/C	cg17554472	chr22:41940697	POLR3H	0.5	5.36	0.43	3.92e-7	Vitiligo;
TGCT	cis	rs137699	0.652	rs137707	chr22:39751401	T/C	cg11247378	chr22:39784982	NA	-0.6	-5.94	-0.47	2.68e-8	IgG glycosylation;
TGCT	trans	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg20587970	chr11:113659929	NA	-1.04	-12.68	-0.75	3.82e-24	Hip circumference adjusted for BMI;
TGCT	cis	rs7312933	0.501	rs7296357	chr12:42729891	T/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.59	-5.7	-0.46	8.16e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs9393777	0.582	rs6936561	chr6:26640895	C/T	cg15659132	chr6:26577336	NA	-0.77	-5.48	-0.44	2.26e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs4568518	0.502	rs4543441	chr7:17983297	C/T	cg03009463	chr7:17980271	SNX13	0.54	4.53	0.38	1.38e-5	Measles;
TGCT	cis	rs7547997	0.615	rs114657189	chr1:158318340	G/C	cg07950803	chr1:158223934	CD1A	0.32	5.08	0.42	1.35e-6	QRS duration;
TGCT	cis	rs17221829	0.549	rs7114659	chr11:89383424	A/G	cg02982614	chr11:89391479	FOLH1B	-0.28	-4.99	-0.41	1.95e-6	Anxiety in major depressive disorder;
TGCT	cis	rs739496	0.542	rs10219736	chr12:111788402	C/T	cg10833066	chr12:111807467	FAM109A	0.44	7.47	0.56	1.24e-11	Platelet count;
TGCT	cis	rs1153858	1.000	rs1049508	chr15:45653592	A/G	cg26924012	chr15:45694286	SPATA5L1	0.99	12.23	0.74	4.74e-23	Homoarginine levels;
TGCT	cis	rs7975161	0.630	rs7978101	chr12:104630510	A/G	cg25273343	chr12:104657179	TXNRD1	-0.36	-5.16	-0.42	9.71e-7	Toenail selenium levels;
TGCT	cis	rs763121	0.853	rs3827357	chr22:39079413	A/G	cg06022373	chr22:39101656	GTPBP1	0.74	7.31	0.55	2.94e-11	Menopause (age at onset);
TGCT	cis	rs7267979	0.966	rs2424715	chr20:25420077	A/G	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7635838	0.718	rs2594979	chr3:11381910	T/G	cg00170343	chr3:11313890	ATG7	0.62	6.09	0.48	1.28e-8	HDL cholesterol;
TGCT	cis	rs2702888	0.503	rs2741714	chr8:6759967	C/A	cg26795848	chr8:6756730	NA	-0.32	-6.67	-0.51	7.62e-10	Blood pressure;
TGCT	cis	rs6433857	0.657	rs2368177	chr2:181501242	T/C	cg23363182	chr2:181467187	NA	-0.33	-5.08	-0.42	1.33e-6	Body mass index;
TGCT	cis	rs9398235	1.000	rs9398235	chr6:110732116	A/G	cg19196401	chr6:110721138	DDO	-0.5	-4.92	-0.4	2.64e-6	Systemic lupus erythematosus;
TGCT	cis	rs6547741	0.844	rs9678851	chr2:27887034	C/A	cg27432699	chr2:27873401	GPN1	-0.24	-6.06	-0.48	1.5e-8	Oral cavity cancer;
TGCT	cis	rs546131	0.600	rs525202	chr11:34821948	A/C	cg06937548	chr11:34938143	PDHX;APIP	0.56	4.91	0.4	2.79e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs7267979	0.933	rs11699203	chr20:25435169	G/C	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7043114	0.525	rs7023004	chr9:95098712	A/G	cg14631576	chr9:95140430	CENPP	-0.28	-4.75	-0.39	5.47e-6	Height;
TGCT	cis	rs6089584	1.000	rs6089591	chr20:60570548	A/C	cg06108461	chr20:60628389	TAF4	-0.54	-7.59	-0.56	6.66e-12	Body mass index;
TGCT	cis	rs959260	0.557	rs55762977	chr17:73309338	A/G	cg14668889	chr17:73230827	NUP85	0.21	4.57	0.38	1.14e-5	Systemic lupus erythematosus;
TGCT	cis	rs2075165	0.901	rs2025577	chr1:156314104	T/C	cg20302342	chr1:156215951	PAQR6	0.37	5.49	0.44	2.19e-7	Tonsillectomy;
TGCT	cis	rs72945132	0.562	rs7951959	chr11:70234272	A/G	cg00319359	chr11:70116639	PPFIA1	0.98	7.02	0.53	1.28e-10	Coronary artery disease;
TGCT	cis	rs2859741	1.000	rs2795009	chr1:37509494	C/T	cg09363841	chr1:37513479	NA	-0.2	-4.54	-0.38	1.33e-5	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
TGCT	cis	rs7727544	0.571	rs12521097	chr5:131575338	G/A	cg22598563	chr5:131563921	P4HA2	-0.29	-4.57	-0.38	1.15e-5	Blood metabolite levels;
TGCT	cis	rs975752	0.867	rs7924284	chr10:102018089	A/G	cg04750910	chr10:102416409	NA	-0.73	-4.48	-0.37	1.69e-5	Schizophrenia;
TGCT	cis	rs13242816	1.000	rs13243017	chr7:116189371	G/A	cg16553024	chr7:116138462	CAV2	-0.44	-5.26	-0.43	6.11e-7	P wave duration;
TGCT	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.31	-4.76	-0.39	5.36e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg00149659	chr3:10157352	C3orf10	-0.91	-6.1	-0.48	1.27e-8	Alzheimer's disease;
TGCT	trans	rs3780486	0.505	rs10758188	chr9:33123386	C/T	cg04842962	chr6:43655489	MRPS18A	-0.8	-8.43	-0.6	7.22e-14	IgG glycosylation;
TGCT	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg12000995	chr2:27665139	KRTCAP3	-0.38	-4.53	-0.38	1.39e-5	Total body bone mineral density;
TGCT	cis	rs2574985	0.530	rs7071603	chr10:52272007	C/T	cg12753529	chr10:51525504	NA	0.23	4.61	0.38	9.69e-6	Subjective well-being;
TGCT	cis	rs11264213	0.591	rs399393	chr1:36553673	A/G	cg27506609	chr1:36549197	TEKT2	-0.5	-5.7	-0.46	8.17e-8	Schizophrenia;
TGCT	cis	rs9388451	0.807	rs1268065	chr6:126042783	G/A	cg05901451	chr6:126070800	HEY2	0.98	12.62	0.75	5.47e-24	Brugada syndrome;
TGCT	cis	rs13191362	1.000	rs73008453	chr6:163013384	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs3096299	0.504	rs4785574	chr16:89568875	A/G	cg08392591	chr16:89556376	ANKRD11	0.53	4.93	0.41	2.53e-6	Multiple myeloma (IgH translocation);
TGCT	cis	rs4919694	1.000	rs11191439	chr10:104638723	C/T	cg04362960	chr10:104952993	NT5C2	-1.03	-6.19	-0.49	7.93e-9	Arsenic metabolism;
TGCT	cis	rs492146	0.902	rs316136	chr6:52846769	T/C	cg06706454	chr6:52930286	FBXO9	-0.47	-4.54	-0.38	1.29e-5	Epilepsy (remission after treatment);
TGCT	cis	rs7647973	1.000	rs73088137	chr3:49448423	G/A	cg07636037	chr3:49044803	WDR6	-0.72	-5.72	-0.46	7.47e-8	Menarche (age at onset);
TGCT	cis	rs860554	0.511	rs1772828	chr1:201290217	C/T	cg01022117	chr1:201258280	PKP1	-0.27	-4.91	-0.4	2.77e-6	Panic disorder;
TGCT	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	8.05	0.59	5.7e-13	Platelet count;
TGCT	cis	rs3008870	1.000	rs2755246	chr1:67488984	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.02	10.0	0.67	1.26e-17	Lymphocyte percentage of white cells;
TGCT	cis	rs4506170	1.000	rs72712335	chr8:128338258	G/A	cg07795030	chr8:128802207	NA	-0.21	-4.61	-0.38	9.7e-6	Prostate cancer;
TGCT	cis	rs6121246	0.909	rs8126355	chr20:30332660	C/T	cg13852791	chr20:30311386	BCL2L1	0.8	6.12	0.48	1.15e-8	Mean corpuscular hemoglobin;
TGCT	trans	rs1499614	0.831	rs3800822	chr7:66147149	A/G	cg07424592	chr7:64974309	NA	-1.35	-8.11	-0.59	4.14e-13	Gout;
TGCT	cis	rs1629083	0.967	rs1715449	chr11:118128455	G/A	cg16594165	chr11:118135105	MPZL2	-0.33	-4.62	-0.38	9.51e-6	Lung cancer;
TGCT	cis	rs3774830	0.649	rs41268643	chr4:5469916	G/A	cg26943120	chr4:5472116	STK32B	0.28	6.34	0.49	3.97e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7208859	0.673	rs11654914	chr17:29229424	C/G	cg18442181	chr17:29233375	C17orf42	-0.79	-4.78	-0.39	4.95e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7267979	1.000	rs6115182	chr20:25410259	G/A	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.83	-8.69	-0.62	1.76e-14	Body mass index;
TGCT	cis	rs7223966	0.691	rs9893518	chr17:62006997	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	4.8	0.4	4.48e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs28595532	0.764	rs115916994	chr4:119688758	A/G	cg14228332	chr4:119757509	SEC24D	1.02	5.06	0.41	1.47e-6	Cannabis dependence symptom count;
TGCT	trans	rs1496653	0.544	rs71322201	chr3:23623769	C/T	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs4253772	0.530	rs9627387	chr22:46684678	A/G	cg24881330	chr22:46731750	TRMU	0.96	6.38	0.5	3.18e-9	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs7565124	0.955	rs11674278	chr2:20266381	C/T	cg00462460	chr2:20212509	MATN3	-0.43	-4.66	-0.39	8.1e-6	Major depressive disorder;
TGCT	cis	rs7144547	0.950	rs8004137	chr14:81884857	A/G	cg02996355	chr14:81879375	NA	-0.72	-7.7	-0.57	3.81e-12	Prudent dietary pattern;
TGCT	cis	rs9952991	0.883	rs11663253	chr18:12789556	A/G	cg23598886	chr18:12777645	NA	-0.62	-5.5	-0.44	2.11e-7	Inflammatory skin disease;
TGCT	cis	rs698761	0.505	rs7609180	chr2:44538484	A/G	cg23552047	chr2:44669647	C2orf34	0.29	4.68	0.39	7.33e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
TGCT	cis	rs939658	0.683	rs1474256	chr15:79463847	C/T	cg17916960	chr15:79447300	NA	0.42	6.67	0.51	7.59e-10	Refractive error;
TGCT	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg16325326	chr1:53192061	ZYG11B	-0.71	-8.81	-0.62	9.22e-15	Monocyte count;
TGCT	cis	rs35374984	0.920	rs16930800	chr10:30234268	A/C	cg22629853	chr10:30638455	MTPAP	0.59	5.43	0.44	2.87e-7	Emphysema distribution in smoking;
TGCT	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.91	7.44	0.56	1.45e-11	Platelet count;
TGCT	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg11764359	chr7:65958608	NA	0.59	5.28	0.43	5.64e-7	Aortic root size;
TGCT	cis	rs7917772	0.565	rs61869210	chr10:104437175	A/C	cg05855489	chr10:104503620	C10orf26	-0.68	-5.56	-0.45	1.61e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs6964587	0.967	rs10953063	chr7:91576958	A/G	cg22709100	chr7:91322751	NA	-0.27	-4.48	-0.37	1.68e-5	Breast cancer;
TGCT	cis	rs6088580	0.634	rs6087577	chr20:32955423	C/T	cg08999081	chr20:33150536	PIGU	0.26	5.21	0.42	7.67e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg05025164	chr4:1340916	KIAA1530	-0.84	-7.26	-0.55	3.66e-11	Longevity;
TGCT	cis	rs9929218	0.906	rs4783565	chr16:68750190	G/A	cg01251360	chr16:68772225	CDH1	0.3	5.0	0.41	1.88e-6	Colorectal cancer;
TGCT	cis	rs986417	0.892	rs57925468	chr14:60816129	G/A	cg27398547	chr14:60952738	C14orf39	-1.5	-8.03	-0.58	6.38e-13	Gut microbiota (bacterial taxa);
TGCT	cis	rs651907	0.535	rs36060163	chr3:101360963	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.01	0.41	1.8e-6	Colorectal cancer;
TGCT	cis	rs7651736	0.835	rs6439679	chr3:136757463	C/T	cg12473912	chr3:136751656	NA	-0.37	-5.76	-0.46	6.22e-8	Neuroticism;
TGCT	cis	rs2742417	1.000	rs938363	chr3:45746364	T/G	cg04837898	chr3:45731254	SACM1L	-0.55	-5.68	-0.45	9.22e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs807669	1.000	rs807670	chr22:19154608	A/C	cg02655711	chr22:19163373	SLC25A1	0.31	6.88	0.53	2.57e-10	Metabolite levels;
TGCT	cis	rs35160687	1.000	rs35160687	chr2:86472114	C/T	cg03171300	chr2:86307199	POLR1A	0.33	5.61	0.45	1.25e-7	Night sleep phenotypes;
TGCT	cis	rs4253772	0.591	rs6008384	chr22:46655948	T/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.56	4.52	0.38	1.44e-5	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg25427524	chr10:38739819	LOC399744	-0.39	-8.05	-0.59	5.9e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs9653442	1.000	rs6712515	chr2:100806514	T/C	cg07810366	chr2:100720526	AFF3	-0.52	-8.96	-0.63	4.09e-15	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs3091242	0.933	rs3093584	chr1:25668714	T/C	cg00786635	chr1:25594202	NA	-0.55	-5.64	-0.45	1.07e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.94	7.92	0.58	1.17e-12	Platelet count;
TGCT	cis	rs71435601	0.628	rs312944	chr2:21325188	A/T	cg25035485	chr2:21266500	APOB	0.52	4.48	0.37	1.7e-5	Cholesterol, total;
TGCT	cis	rs317689	0.690	rs604168	chr12:69671158	C/T	cg14784868	chr12:69753453	YEATS4	0.53	4.51	0.38	1.5e-5	Response to diuretic therapy;
TGCT	cis	rs7829975	0.514	rs2920991	chr8:8259117	T/A	cg06636001	chr8:8085503	FLJ10661	0.69	6.02	0.48	1.81e-8	Mood instability;
TGCT	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.06	-9.57	-0.65	1.41e-16	Platelet count;
TGCT	cis	rs7819412	0.745	rs4841498	chr8:10985432	C/T	cg21775007	chr8:11205619	TDH	-0.51	-4.83	-0.4	3.87e-6	Triglycerides;
TGCT	cis	rs7586879	0.681	rs6752483	chr2:25120086	C/T	cg01884057	chr2:25150051	NA	0.35	6.74	0.52	5.27e-10	Body mass index;
TGCT	cis	rs9393692	0.875	rs9358917	chr6:26284417	T/C	cg13736514	chr6:26305472	NA	-0.37	-5.42	-0.44	3.01e-7	Educational attainment;
TGCT	cis	rs12497850	0.931	rs9311434	chr3:48884147	T/C	cg05785598	chr3:49045655	WDR6	0.35	4.72	0.39	6.35e-6	Parkinson's disease;
TGCT	cis	rs9467711	0.606	rs9366656	chr6:26434630	T/C	cg10795676	chr6:26370623	BTN3A2	-0.45	-4.56	-0.38	1.23e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs8141529	0.719	rs6005916	chr22:29233342	T/C	cg02153584	chr22:29168773	CCDC117	0.63	5.35	0.43	4.06e-7	Lymphocyte counts;
TGCT	cis	rs11690935	0.686	rs10165126	chr2:172820315	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.63	-5.29	-0.43	5.3e-7	Schizophrenia;
TGCT	cis	rs6815814	0.731	rs10776483	chr4:38775040	A/G	cg02016764	chr4:38805732	TLR1	-0.28	-4.79	-0.4	4.63e-6	Breast cancer;
TGCT	cis	rs9522267	0.535	rs56330641	chr13:112233538	C/T	cg10483660	chr13:112241077	NA	-0.27	-4.61	-0.38	9.78e-6	Hepatitis;
TGCT	cis	rs1018836	0.798	rs28568272	chr8:91652958	A/G	cg16814680	chr8:91681699	NA	-0.94	-11.83	-0.73	4.43e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs78487399	0.710	rs57381820	chr2:43626668	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-4.87	-0.4	3.39e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs12681288	0.862	rs2701899	chr8:1019581	G/A	cg21347738	chr8:1310380	NA	-0.22	-4.54	-0.38	1.3e-5	Schizophrenia;
TGCT	cis	rs367615	0.879	rs56689485	chr5:108879828	A/T	cg17395555	chr5:108820864	NA	0.31	5.01	0.41	1.85e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg08564027	chr20:61660810	NA	0.38	7.08	0.54	9.36e-11	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1371867	0.846	rs1692007	chr8:101268343	T/C	cg06002616	chr8:101225028	SPAG1	0.53	6.42	0.5	2.67e-9	Atrioventricular conduction;
TGCT	cis	rs10791323	0.628	rs2853117	chr11:133705266	T/G	cg03690763	chr11:133734501	NA	-0.35	-5.44	-0.44	2.78e-7	Childhood ear infection;
TGCT	cis	rs11105298	0.786	rs3803128	chr12:89860319	C/A	cg00757033	chr12:89920650	WDR51B	0.34	5.37	0.43	3.75e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs8014252	0.711	rs59044667	chr14:71043704	A/G	cg11204974	chr14:71022665	NA	-0.54	-4.44	-0.37	2e-5	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
TGCT	cis	rs10779751	0.770	rs2261434	chr1:11170131	A/C	cg08854313	chr1:11322531	MTOR	0.83	8.02	0.58	6.7e-13	Body mass index;
TGCT	cis	rs28595532	0.920	rs17257945	chr4:119666465	T/A	cg21605333	chr4:119757512	SEC24D	1.4	7.94	0.58	1.04e-12	Cannabis dependence symptom count;
TGCT	cis	rs7572733	0.534	rs1518363	chr2:198810131	C/T	cg00792783	chr2:198669748	PLCL1	0.57	5.23	0.43	6.99e-7	Dermatomyositis;
TGCT	cis	rs9527	0.590	rs11191578	chr10:104902337	A/T	cg04362960	chr10:104952993	NT5C2	0.68	5.76	0.46	6.3e-8	Arsenic metabolism;
TGCT	cis	rs7819412	0.511	rs2409797	chr8:11433780	T/C	cg21775007	chr8:11205619	TDH	-0.52	-4.79	-0.4	4.63e-6	Triglycerides;
TGCT	cis	rs4285028	0.747	rs11916169	chr3:121403211	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.92	-7.33	-0.55	2.54e-11	Multiple sclerosis;
TGCT	cis	rs1008375	0.544	rs7685265	chr4:17568510	C/T	cg18681998	chr4:17616180	MED28	0.77	6.79	0.52	4.06e-10	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs28595532	0.925	rs56200441	chr4:119497440	T/G	cg11846333	chr4:119757529	SEC24D	0.93	5.08	0.42	1.32e-6	Cannabis dependence symptom count;
TGCT	cis	rs9291683	0.692	rs1558489	chr4:10325489	T/A	cg00071950	chr4:10020882	SLC2A9	-0.43	-4.48	-0.37	1.66e-5	Bone mineral density;
TGCT	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg25036284	chr2:26402008	FAM59B	-0.54	-4.7	-0.39	6.93e-6	Gut microbiome composition (summer);
TGCT	cis	rs9814567	0.929	rs13088413	chr3:134309977	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.95	9.14	0.63	1.54e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs9527	0.569	rs10786730	chr10:104724200	G/A	cg04362960	chr10:104952993	NT5C2	0.66	5.55	0.45	1.66e-7	Arsenic metabolism;
TGCT	cis	rs912057	1.000	rs1294410	chr6:6738752	C/T	cg06612196	chr6:6737390	NA	-0.39	-4.89	-0.4	3.11e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs9560113	0.919	rs11069896	chr13:112178887	C/T	cg14154082	chr13:112174009	NA	0.37	5.07	0.41	1.42e-6	Menarche (age at onset);
TGCT	cis	rs6657613	0.869	rs761421	chr1:17313654	C/T	cg21692666	chr1:17199302	NA	-0.42	-4.52	-0.38	1.43e-5	Hip circumference adjusted for BMI;
TGCT	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg13732083	chr21:47605072	C21orf56	0.37	4.81	0.4	4.36e-6	Testicular germ cell tumor;
TGCT	cis	rs8016982	0.611	rs11159493	chr14:81639159	A/T	cg01989461	chr14:81687754	GTF2A1	0.78	7.47	0.56	1.26e-11	Schizophrenia;
TGCT	cis	rs9611565	0.592	rs5758427	chr22:42099688	A/G	cg13695892	chr22:41940480	POLR3H	0.89	9.04	0.63	2.55e-15	Vitiligo;
TGCT	cis	rs16921914	0.559	rs2985140	chr11:31315886	C/T	cg14844989	chr11:31128820	NA	0.23	4.56	0.38	1.23e-5	Bone mineral density (spine);
TGCT	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-5.1	-0.42	1.23e-6	Electroencephalogram traits;
TGCT	cis	rs2456568	0.867	rs10501810	chr11:93666589	C/G	cg26875233	chr11:93583750	C11orf90	-0.44	-5.49	-0.44	2.18e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs6951245	0.542	rs28460147	chr7:1217192	G/A	cg23708337	chr7:1209742	NA	0.63	5.87	0.47	3.79e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2836633	0.929	rs62217518	chr21:40033189	T/G	cg05519781	chr21:40033154	ERG	0.7	6.95	0.53	1.86e-10	Coronary artery disease;
TGCT	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg26119090	chr2:26468346	HADHA;HADHB	1.0	7.42	0.55	1.64e-11	Gut microbiome composition (summer);
TGCT	cis	rs6988636	1.000	rs28600861	chr8:124189063	C/T	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	trans	rs8073060	0.505	rs225270	chr17:33968871	A/T	cg19694781	chr19:47549865	TMEM160	-0.6	-13.37	-0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg03188948	chr7:1209495	NA	0.68	5.8	0.46	5.09e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs12210905	1.000	rs12209800	chr6:27189517	C/T	cg08851530	chr6:28072375	NA	-1.04	-5.0	-0.41	1.88e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs734999	0.869	rs61054170	chr1:2498052	C/T	cg18854424	chr1:2615690	NA	0.47	5.75	0.46	6.57e-8	Ulcerative colitis;
TGCT	cis	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg22857025	chr5:266934	NA	-0.32	-6.58	-0.51	1.18e-9	Breast cancer;
TGCT	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg17264618	chr3:40429014	ENTPD3	0.32	4.57	0.38	1.18e-5	Renal cell carcinoma;
TGCT	trans	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg21659725	chr3:3221576	CRBN	0.69	7.57	0.56	7.35e-12	Body mass index;
TGCT	cis	rs7208859	0.673	rs9891413	chr17:29208209	G/C	cg18442181	chr17:29233375	C17orf42	-0.78	-4.61	-0.38	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs1552244	0.554	rs3732963	chr3:10048885	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.33	-4.95	-0.41	2.39e-6	Alzheimer's disease;
TGCT	cis	rs9682041	0.867	rs6444925	chr3:170123358	G/T	cg07589077	chr3:170072950	NA	0.33	4.7	0.39	6.82e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	trans	rs208520	1.000	rs9453663	chr6:66976077	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.82	7.48	0.56	1.21e-11	Exhaled nitric oxide output;
TGCT	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg24531977	chr5:56204891	C5orf35	-0.74	-6.99	-0.53	1.51e-10	Initial pursuit acceleration;
TGCT	trans	rs12599106	0.629	rs1391904	chr16:34548934	C/T	cg07332563	chr6:291687	DUSP22	-0.67	-6.76	-0.52	4.77e-10	Menopause (age at onset);
TGCT	cis	rs3857536	0.505	rs208459	chr6:66911055	C/T	cg07460842	chr6:66804631	NA	-0.68	-6.73	-0.52	5.5e-10	Blood trace element (Cu levels);
TGCT	cis	rs12478296	0.901	rs67951957	chr2:243004901	A/G	cg06360820	chr2:242988706	NA	-0.64	-5.35	-0.43	4.15e-7	Obesity-related traits;
TGCT	cis	rs7917772	0.536	rs4919667	chr10:104426011	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.83	-8.36	-0.6	1.07e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg03732007	chr1:2071316	PRKCZ	0.28	6.76	0.52	4.87e-10	Height;
TGCT	cis	rs6912958	0.781	rs6454632	chr6:88231824	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-5.06	-0.41	1.45e-6	Monocyte percentage of white cells;
TGCT	cis	rs3806843	0.576	rs246074	chr5:140307969	C/G	cg07102913	chr5:140593443	PCDHB13	-0.46	-4.59	-0.38	1.08e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs17376456	1.000	rs58734583	chr5:93532155	C/T	cg25358565	chr5:93447407	FAM172A	0.93	7.91	0.58	1.22e-12	Diabetic retinopathy;
TGCT	cis	rs4654899	1.000	rs6426669	chr1:21430584	C/A	cg01072550	chr1:21505969	NA	-0.51	-8.1	-0.59	4.46e-13	Superior frontal gyrus grey matter volume;
TGCT	cis	rs1023500	0.505	rs134891	chr22:42675882	T/C	cg15557168	chr22:42548783	NA	-0.21	-4.94	-0.41	2.47e-6	Schizophrenia;
TGCT	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	5.12	0.42	1.11e-6	Alzheimer's disease;
TGCT	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.63	6.3	0.49	4.63e-9	Menarche (age at onset);
TGCT	trans	rs17780086	0.527	rs17182651	chr17:30547537	G/A	cg20587970	chr11:113659929	NA	-0.89	-7.15	-0.54	6.46e-11	Height;
TGCT	cis	rs4642101	0.824	rs9835677	chr3:12845158	G/A	cg05775895	chr3:12838266	CAND2	0.73	7.24	0.55	4.1e-11	QRS complex (12-leadsum);
TGCT	cis	rs9388451	0.874	rs9398787	chr6:126090608	A/G	cg10911889	chr6:126070802	HEY2	0.54	5.64	0.45	1.08e-7	Brugada syndrome;
TGCT	cis	rs4266144	0.558	rs4680339	chr3:156835419	G/T	cg05091238	chr3:157813609	NA	-0.48	-5.17	-0.42	9.23e-7	Coronary artery disease;
TGCT	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg02353165	chr6:42928485	GNMT	0.95	9.72	0.66	5.91e-17	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs12257961	0.549	rs11259612	chr10:15382469	C/T	cg10616319	chr10:15468812	NA	-0.26	-4.86	-0.4	3.44e-6	Selective IgA deficiency;
TGCT	cis	rs9928842	0.765	rs6564220	chr16:75224194	T/C	cg09066997	chr16:75300724	BCAR1	0.26	4.61	0.38	9.91e-6	Alcoholic chronic pancreatitis;
TGCT	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.85	-9.0	-0.63	3.25e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs9581857	0.547	rs75800999	chr13:28055293	A/G	cg22138327	chr13:27999177	GTF3A	0.74	4.84	0.4	3.81e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs7618915	0.501	rs55678971	chr3:52717229	T/A	cg10802521	chr3:52805072	NEK4	-0.74	-9.17	-0.64	1.27e-15	Bipolar disorder;
TGCT	cis	rs2692947	0.702	rs7604842	chr2:96777340	C/T	cg05933789	chr2:97190408	NA	-0.17	-5.13	-0.42	1.07e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs853679	0.599	rs188015	chr6:27877446	T/A	cg10876282	chr6:28092338	ZSCAN16	0.77	4.74	0.39	5.85e-6	Depression;
TGCT	cis	rs4654899	0.571	rs6692677	chr1:21251717	C/T	cg01072550	chr1:21505969	NA	-0.54	-8.8	-0.62	9.96e-15	Superior frontal gyrus grey matter volume;
TGCT	trans	rs6762477	0.748	rs34877766	chr3:50234126	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.78	7.81	0.57	2.12e-12	Menarche (age at onset);
TGCT	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg27454412	chr7:1067447	C7orf50	0.55	4.7	0.39	6.89e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7267979	1.000	rs6037105	chr20:25374199	C/A	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1395	0.744	rs62130709	chr2:27505782	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.62	8.02	0.58	6.76e-13	Blood metabolite levels;
TGCT	cis	rs561341	0.602	rs114562703	chr17:30233899	G/T	cg13647721	chr17:30228624	UTP6	0.61	4.71	0.39	6.65e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs2692947	0.666	rs10183151	chr2:96774786	T/G	cg22654517	chr2:96458247	NA	-0.22	-4.81	-0.4	4.27e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs796364	0.662	rs11687313	chr2:201146399	G/A	cg19045956	chr2:200819837	C2orf60;C2orf47	-0.67	-4.68	-0.39	7.3e-6	Schizophrenia;
TGCT	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg18654377	chr3:49208889	KLHDC8B	-0.37	-4.91	-0.4	2.78e-6	Menarche (age at onset);
TGCT	cis	rs6701037	0.512	rs2285216	chr1:175133012	C/T	cg00321850	chr1:175162397	KIAA0040	0.38	5.04	0.41	1.61e-6	Alcohol dependence;
TGCT	cis	rs12497850	1.000	rs12493578	chr3:48730116	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.63	-5.95	-0.47	2.51e-8	Parkinson's disease;
TGCT	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.68	-5.94	-0.47	2.62e-8	Tonsillectomy;
TGCT	cis	rs7786808	0.608	rs9692003	chr7:158204696	G/A	cg01191920	chr7:158217561	PTPRN2	0.39	5.79	0.46	5.52e-8	Obesity-related traits;
TGCT	cis	rs8013055	0.898	rs8014913	chr14:105977313	T/C	cg19700328	chr14:106028568	NA	-0.53	-5.91	-0.47	3.03e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs501916	0.833	rs11855134	chr15:48047676	A/G	cg16110827	chr15:48056943	SEMA6D	-0.16	-4.45	-0.37	1.91e-5	Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs13242816	1.000	rs3801994	chr7:116190469	G/A	cg16553024	chr7:116138462	CAV2	-0.45	-5.3	-0.43	5.1e-7	P wave duration;
TGCT	cis	rs1018836	0.632	rs7017630	chr8:91482604	A/G	cg16814680	chr8:91681699	NA	-0.77	-7.9	-0.58	1.3e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6427419	0.934	rs3768538	chr1:158066042	A/G	cg07184316	chr1:157669111	FCRL3	0.26	4.75	0.39	5.42e-6	Obesity-related traits;
TGCT	cis	rs3617	0.532	rs9836499	chr3:52904524	G/T	cg10802521	chr3:52805072	NEK4	0.57	6.62	0.51	9.79e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg18735214	chr6:43276756	CRIP3	-0.56	-4.89	-0.4	3.05e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs1949733	0.675	rs2688235	chr4:8450546	T/C	cg13073564	chr4:8508604	NA	-0.41	-4.56	-0.38	1.19e-5	Response to antineoplastic agents;
TGCT	cis	rs394563	0.726	rs6942381	chr6:149662991	G/C	cg03678062	chr6:149772716	ZC3H12D	0.41	5.31	0.43	4.84e-7	Dupuytren's disease;
TGCT	cis	rs2455799	0.573	rs2455812	chr3:15734096	C/G	cg16303742	chr3:15540471	COLQ	-0.25	-4.75	-0.39	5.41e-6	Mean platelet volume;
TGCT	trans	rs561341	0.824	rs1978115	chr17:30220776	A/C	cg20587970	chr11:113659929	NA	-0.79	-9.27	-0.64	7.44e-16	Hip circumference adjusted for BMI;
TGCT	cis	rs4455778	0.659	rs10233118	chr7:49058781	C/T	cg26309511	chr7:48887640	NA	0.43	5.27	0.43	5.74e-7	Lung cancer in never smokers;
TGCT	cis	rs6500602	0.701	rs4785968	chr16:4535307	T/A	cg08645402	chr16:4508243	NA	0.2	4.98	0.41	2.09e-6	Schizophrenia;
TGCT	trans	rs7965364	0.651	rs7307747	chr12:25498629	C/T	cg03116648	chr22:50192934	BRD1	-0.46	-6.64	-0.51	8.93e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6582630	0.622	rs11831595	chr12:38511489	C/A	cg26384229	chr12:38710491	ALG10B	-0.54	-4.79	-0.4	4.57e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs7681440	0.904	rs1822217	chr4:90765052	C/T	cg14346243	chr4:90757452	SNCA	-0.57	-5.6	-0.45	1.31e-7	Dementia with Lewy bodies;
TGCT	trans	rs7726839	0.540	rs11738281	chr5:662547	T/C	cg11887960	chr12:57824829	NA	1.14	9.54	0.65	1.65e-16	Obesity-related traits;
TGCT	cis	rs7681440	0.835	rs7668531	chr4:90791819	G/T	cg14346243	chr4:90757452	SNCA	-0.5	-4.75	-0.39	5.44e-6	Dementia with Lewy bodies;
TGCT	cis	rs17345786	0.798	rs4257518	chr3:101281709	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.63	-6.03	-0.48	1.71e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs514406	0.683	rs6588440	chr1:53209587	C/T	cg22166914	chr1:53195759	ZYG11B	-0.5	-9.17	-0.64	1.29e-15	Monocyte count;
TGCT	cis	rs2242116	0.896	rs724449	chr3:46935681	C/T	cg02527881	chr3:46936655	PTH1R	-0.29	-5.66	-0.45	1.02e-7	Birth weight;
TGCT	cis	rs2361718	0.631	rs12601637	chr17:78142455	T/C	cg09238746	chr17:78121135	EIF4A3	-0.77	-7.39	-0.55	1.88e-11	Yeast infection;
TGCT	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg26338869	chr17:61819248	STRADA	-0.53	-4.94	-0.41	2.48e-6	Prudent dietary pattern;
TGCT	cis	rs4851254	0.660	rs34714421	chr2:100692175	T/C	cg07810366	chr2:100720526	AFF3	-0.49	-5.15	-0.42	1e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2948294	0.588	rs12544596	chr8:8116346	A/T	cg15462221	chr8:8086144	FLJ10661	-0.59	-5.0	-0.41	1.94e-6	Red cell distribution width;
TGCT	cis	rs7178572	0.524	rs11853287	chr15:77399371	A/G	cg15453836	chr15:77711506	NA	-0.4	-4.54	-0.38	1.31e-5	Type 2 diabetes;
TGCT	trans	rs3780486	0.846	rs3824458	chr9:33144809	C/T	cg20290983	chr6:43655470	MRPS18A	1.17	14.36	0.79	3.87e-28	IgG glycosylation;
TGCT	cis	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg20637647	chr7:64974828	NA	-1.0	-5.59	-0.45	1.4e-7	Diabetic kidney disease;
TGCT	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg11764359	chr7:65958608	NA	0.52	4.6	0.38	1.04e-5	Aortic root size;
TGCT	cis	rs11651000	0.857	rs11658383	chr17:45842354	A/C	cg06532163	chr17:45867833	NA	0.36	5.24	0.43	6.81e-7	IgG glycosylation;
TGCT	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg25767906	chr1:53392781	SCP2	0.48	5.55	0.45	1.62e-7	Monocyte count;
TGCT	cis	rs62244186	0.748	rs2888410	chr3:44655476	A/C	cg25151919	chr3:44754333	ZNF502	-0.43	-4.98	-0.41	2.05e-6	Depressive symptoms;
TGCT	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg12963246	chr6:28129442	ZNF389	0.52	5.1	0.42	1.23e-6	Depression;
TGCT	cis	rs2721195	0.967	rs11777703	chr8:145703508	G/A	cg11211951	chr8:145729740	GPT	-0.23	-5.41	-0.44	3.17e-7	Age at first birth;
TGCT	cis	rs2688608	0.967	rs1815076	chr10:75659886	C/T	cg23231163	chr10:75533350	FUT11	-0.27	-4.82	-0.4	4.04e-6	Inflammatory bowel disease;
TGCT	cis	rs7647973	0.626	rs6809879	chr3:49834571	A/G	cg03034192	chr3:50606346	HEMK1;C3orf18	-0.36	-4.75	-0.39	5.61e-6	Menarche (age at onset);
TGCT	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.8	9.07	0.63	2.27e-15	Menarche (age at onset);
TGCT	cis	rs523522	0.962	rs4767904	chr12:120930798	T/G	cg12219531	chr12:120966889	COQ5	0.83	7.27	0.55	3.46e-11	High light scatter reticulocyte count;
TGCT	cis	rs9549367	0.577	rs3024711	chr13:113813268	A/G	cg00898013	chr13:113819073	PROZ	-0.55	-6.6	-0.51	1.05e-9	Platelet distribution width;
TGCT	cis	rs7666738	0.830	rs3852122	chr4:98697400	T/C	cg18180107	chr4:99064573	C4orf37	0.53	5.07	0.41	1.38e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs778371	0.915	rs938569	chr2:233759695	C/G	cg08000102	chr2:233561755	GIGYF2	0.59	6.33	0.49	4.09e-9	Schizophrenia;
TGCT	cis	rs7923609	0.967	rs7920058	chr10:65293924	T/G	cg08743896	chr10:65200160	JMJD1C	-0.33	-4.48	-0.37	1.71e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6582630	0.502	rs4559747	chr12:38436235	G/A	cg13010199	chr12:38710504	ALG10B	0.55	4.46	0.37	1.84e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs4733781	1.000	rs72722365	chr8:131190914	G/A	cg16277922	chr8:131349729	ASAP1	0.44	5.64	0.45	1.11e-7	Tuberculosis;
TGCT	cis	rs3821902	0.502	rs17031765	chr3:64036167	A/G	cg22134162	chr3:63841271	THOC7	-0.33	-4.46	-0.37	1.82e-5	Breast cancer;
TGCT	cis	rs9952991	0.883	rs2847260	chr18:12775591	C/T	cg23598886	chr18:12777645	NA	0.62	5.78	0.46	5.63e-8	Inflammatory skin disease;
TGCT	trans	rs7819412	0.618	rs34772085	chr8:10964906	C/T	cg15556689	chr8:8085844	FLJ10661	-0.74	-7.08	-0.54	9.64e-11	Triglycerides;
TGCT	trans	rs9650657	0.537	rs11250092	chr8:10786543	A/G	cg15556689	chr8:8085844	FLJ10661	0.75	6.67	0.51	7.63e-10	Neuroticism;
TGCT	cis	rs6750047	0.546	rs1367696	chr2:38286914	C/T	cg07380506	chr2:38303506	CYP1B1	0.68	6.34	0.49	3.89e-9	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs56334439	0.831	rs67221972	chr3:60100560	T/C	cg17894779	chr3:60066405	FHIT	-0.35	-4.81	-0.4	4.3e-6	Myringotomy;
TGCT	cis	rs28735056	0.904	rs62103183	chr18:77626564	A/G	cg20368463	chr18:77673604	PQLC1	0.4	4.89	0.4	3.09e-6	Schizophrenia;
TGCT	cis	rs10504229	0.679	rs16921623	chr8:58039473	G/C	cg08280861	chr8:58055591	NA	0.35	4.94	0.41	2.49e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1577917	0.958	rs11755864	chr6:86691791	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.48	-0.44	2.23e-7	Response to antipsychotic treatment;
TGCT	cis	rs2204008	0.614	rs4578492	chr12:38036350	T/C	cg26384229	chr12:38710491	ALG10B	0.85	7.63	0.57	5.5e-12	Bladder cancer;
TGCT	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg10802521	chr3:52805072	NEK4	-0.72	-9.11	-0.63	1.82e-15	Bipolar disorder;
TGCT	cis	rs4285028	0.699	rs12637968	chr3:121599976	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.78	-6.72	-0.52	5.95e-10	Multiple sclerosis;
TGCT	cis	rs6545883	0.868	rs28749199	chr2:61827052	A/G	cg15711740	chr2:61764176	XPO1	-0.6	-5.67	-0.45	9.56e-8	Tuberculosis;
TGCT	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg03264133	chr6:25882463	NA	-0.57	-6.07	-0.48	1.45e-8	Blood metabolite levels;
TGCT	cis	rs1371867	0.817	rs1788185	chr8:101335529	T/C	cg06636551	chr8:101224915	SPAG1	-0.48	-6.52	-0.51	1.62e-9	Atrioventricular conduction;
TGCT	cis	rs6952809	0.590	rs1468337	chr7:2432211	C/T	cg23289794	chr7:2394357	EIF3B	-0.83	-7.09	-0.54	8.92e-11	Multiple sclerosis;
TGCT	cis	rs67478160	0.584	rs12433009	chr14:104196405	C/G	cg26031613	chr14:104095156	KLC1	-0.77	-7.67	-0.57	4.27e-12	Schizophrenia;
TGCT	cis	rs7833790	1.000	rs7460277	chr8:82709777	T/C	cg17211192	chr8:82754475	SNX16	-1.05	-8.4	-0.6	8.8e-14	Diastolic blood pressure;
TGCT	cis	rs6570726	0.791	rs398408	chr6:145801020	G/A	cg23711669	chr6:146136114	FBXO30	0.89	9.83	0.66	3.33e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg11301795	chr4:187892539	NA	-0.35	-5.28	-0.43	5.6e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs35306767	0.714	rs66797613	chr10:1090469	C/T	cg26597838	chr10:835615	NA	0.61	7.09	0.54	8.8e-11	Eosinophil percentage of granulocytes;
TGCT	cis	rs2637266	0.739	rs2579737	chr10:78422546	G/T	cg18941641	chr10:78392320	NA	0.38	4.57	0.38	1.15e-5	Pulmonary function;
TGCT	cis	rs6964587	0.869	rs2023784	chr7:91524677	A/G	cg17063962	chr7:91808500	NA	-0.86	-9.28	-0.64	6.82e-16	Breast cancer;
TGCT	cis	rs7599312	0.534	rs2371615	chr2:213405660	G/T	cg20637307	chr2:213403960	ERBB4	0.91	11.8	0.73	5.12e-22	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs763121	0.853	rs5757193	chr22:39034867	A/G	cg06022373	chr22:39101656	GTPBP1	-0.79	-7.74	-0.57	3.07e-12	Menopause (age at onset);
TGCT	cis	rs9810089	0.814	rs10804640	chr3:136165695	G/A	cg12473912	chr3:136751656	NA	0.37	5.13	0.42	1.1e-6	Gestational age at birth (child effect);
TGCT	cis	rs727563	0.635	rs2899348	chr22:42164516	C/G	cg13695892	chr22:41940480	POLR3H	0.85	8.06	0.59	5.4e-13	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs12477438	0.520	rs1133978	chr2:99741964	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.75	7.25	0.55	3.92e-11	Chronic sinus infection;
TGCT	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg20276088	chr3:133502917	NA	-0.24	-4.96	-0.41	2.28e-6	Iron status biomarkers;
TGCT	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.01	0.41	1.86e-6	Prudent dietary pattern;
TGCT	cis	rs9952991	0.566	rs7234029	chr18:12877060	C/T	cg23598886	chr18:12777645	NA	0.55	4.92	0.4	2.71e-6	Inflammatory skin disease;
TGCT	cis	rs68170813	0.559	rs79705824	chr7:106848325	T/C	cg02696742	chr7:106810147	HBP1	-0.69	-5.61	-0.45	1.27e-7	Coronary artery disease;
TGCT	cis	rs57506017	0.585	rs12699338	chr7:12285140	C/T	cg07541786	chr7:12610355	SCIN	0.47	4.73	0.39	6.02e-6	Neuroticism;
TGCT	cis	rs6977660	0.714	rs12666488	chr7:19788403	G/A	cg07541023	chr7:19748670	TWISTNB	0.83	4.69	0.39	7.01e-6	Thyroid stimulating hormone;
TGCT	cis	rs56036086	0.536	rs73187263	chr22:50651785	C/T	cg19890858	chr22:50624742	TRABD	1.05	5.1	0.42	1.23e-6	Platelet count;Plateletcrit;
TGCT	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg19635926	chr16:89946313	TCF25	0.28	5.1	0.42	1.23e-6	Skin colour saturation;
TGCT	cis	rs748404	0.518	rs2927085	chr15:43989530	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	4.59	0.38	1.07e-5	Lung cancer;
TGCT	cis	rs826838	1.000	rs11168218	chr12:38884466	A/G	cg26384229	chr12:38710491	ALG10B	1.04	10.43	0.68	1.11e-18	Heart rate;
TGCT	trans	rs8073060	0.559	rs72829925	chr17:34049778	C/A	cg19694781	chr19:47549865	TMEM160	0.6	13.37	0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg04267008	chr7:1944627	MAD1L1	-0.39	-5.3	-0.43	5.04e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs6582630	0.519	rs4294627	chr12:38293982	C/T	cg26384229	chr12:38710491	ALG10B	0.82	7.18	0.54	5.6e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs877282	0.947	rs7475589	chr10:767479	C/G	cg17470449	chr10:769945	NA	0.34	5.12	0.42	1.15e-6	Uric acid levels;
TGCT	cis	rs908922	0.627	rs11590073	chr1:152500810	C/T	cg20991723	chr1:152506922	NA	0.46	6.28	0.49	5.26e-9	Hair morphology;
TGCT	cis	rs7552404	0.924	rs2173378	chr1:76201992	G/T	cg10523679	chr1:76189770	ACADM	0.84	9.32	0.64	5.67e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs360798	0.532	rs12713468	chr2:62983213	G/A	cg17519650	chr2:63277830	OTX1	-0.58	-5.06	-0.41	1.48e-6	Coronary artery disease;
TGCT	cis	rs2760061	0.819	rs3094914	chr1:228206934	C/T	cg18477163	chr1:228402036	OBSCN	0.34	7.24	0.55	4.1e-11	Diastolic blood pressure;
TGCT	cis	rs11252926	0.624	rs7085214	chr10:468133	A/G	cg20256804	chr10:444983	DIP2C	-0.22	-5.1	-0.42	1.22e-6	Psychosis in Alzheimer's disease;
TGCT	cis	rs73001065	0.818	rs12610185	chr19:19721722	G/A	cg03709012	chr19:19516395	GATAD2A	1.04	5.1	0.42	1.26e-6	LDL cholesterol;
TGCT	cis	rs78366141	0.536	rs76806573	chr4:89682729	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	1.17	5.22	0.42	7.28e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
TGCT	cis	rs9325144	0.600	rs12297194	chr12:38735803	A/G	cg26384229	chr12:38710491	ALG10B	-0.61	-5.81	-0.46	5.03e-8	Morning vs. evening chronotype;
TGCT	cis	rs1156327	0.826	rs4617844	chr16:19325091	A/G	cg02978544	chr16:19716338	NA	-0.42	-4.46	-0.37	1.82e-5	Periodontal disease-related phenotypes;
TGCT	cis	rs2346177	0.580	rs1530628	chr2:46670941	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.45	-5.06	-0.41	1.45e-6	HDL cholesterol;
TGCT	cis	rs11098499	0.863	rs6858777	chr4:120475966	A/G	cg09307838	chr4:120376055	NA	0.72	6.9	0.53	2.41e-10	Corneal astigmatism;
TGCT	cis	rs7666738	0.800	rs1559858	chr4:99024075	A/G	cg18180107	chr4:99064573	C4orf37	0.55	5.06	0.41	1.48e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7659604	0.605	rs2071486	chr4:122740162	C/T	cg06713675	chr4:122721982	EXOSC9	-0.63	-8.74	-0.62	1.39e-14	Type 2 diabetes;
TGCT	cis	rs7833790	0.724	rs6473311	chr8:82726682	G/A	cg06027949	chr8:82754900	SNX16	-0.65	-5.03	-0.41	1.69e-6	Diastolic blood pressure;
TGCT	cis	rs8028182	0.636	rs28783769	chr15:75849009	C/A	cg20655648	chr15:75932815	IMP3	0.58	4.61	0.38	1e-5	Sudden cardiac arrest;
TGCT	cis	rs2456568	0.570	rs1518579	chr11:93656821	A/G	cg16099599	chr11:93583650	C11orf90	-0.41	-4.83	-0.4	4.02e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs9467773	1.000	rs1078679	chr6:26568741	C/T	cg09904177	chr6:26538194	HMGN4	0.69	6.84	0.52	3.23e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs35146811	0.586	rs10267212	chr7:99595422	T/C	cg13334819	chr7:99746414	C7orf59	-0.74	-6.4	-0.5	2.92e-9	Coronary artery disease;
TGCT	cis	rs3125734	0.534	rs10821973	chr10:64052337	G/A	cg09941381	chr10:64027924	RTKN2	-0.33	-4.9	-0.4	2.94e-6	Rheumatoid arthritis;
TGCT	cis	rs2073300	1.000	rs6048834	chr20:23462213	C/T	cg09953122	chr20:23471693	CST8	-0.59	-4.75	-0.39	5.62e-6	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs13242816	1.000	rs62471184	chr7:116090300	G/A	cg02799643	chr7:116139180	CAV2	-0.44	-5.22	-0.42	7.16e-7	P wave duration;
TGCT	cis	rs854765	0.693	rs4924823	chr17:17764502	A/G	cg04398451	chr17:18023971	MYO15A	0.29	4.57	0.38	1.15e-5	Total body bone mineral density;
TGCT	cis	rs2016266	0.855	rs1379610	chr12:53681683	A/G	cg16917193	chr12:54089295	NA	-0.67	-4.94	-0.41	2.52e-6	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs9527	0.640	rs35195396	chr10:104928770	T/A	cg04362960	chr10:104952993	NT5C2	0.67	5.64	0.45	1.07e-7	Arsenic metabolism;
TGCT	cis	rs1008375	0.966	rs1860599	chr4:17638900	T/C	cg18681998	chr4:17616180	MED28	1.01	11.55	0.72	2.15e-21	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7267979	1.000	rs6037095	chr20:25335687	A/G	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg17747265	chr1:1875780	NA	0.37	6.51	0.5	1.71e-9	Body mass index;
TGCT	cis	rs6840360	1.000	rs6810860	chr4:152603164	C/T	cg17479576	chr4:152424074	FAM160A1	0.49	5.17	0.42	9.2e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs4319547	0.695	rs11057797	chr12:122860732	G/A	cg05707623	chr12:122985044	ZCCHC8	0.62	4.87	0.4	3.32e-6	Body mass index;
TGCT	cis	rs2235642	0.717	rs2236269	chr16:1652614	T/A	cg08296037	chr16:1584118	IFT140;TMEM204	-0.29	-5.03	-0.41	1.68e-6	Coronary artery disease;
TGCT	cis	rs7617773	0.743	rs7621785	chr3:48343708	T/C	cg11946769	chr3:48343235	NME6	0.82	7.09	0.54	9.1e-11	Coronary artery disease;
TGCT	cis	rs7208859	0.673	rs73277986	chr17:29196197	C/T	cg18442181	chr17:29233375	C17orf42	-0.79	-4.78	-0.39	4.95e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs4689388	0.889	rs13128674	chr4:6294517	C/T	cg25554036	chr4:6271136	WFS1	0.54	7.37	0.55	2.11e-11	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs709400	0.663	rs7145113	chr14:103945414	A/G	cg12935359	chr14:103987150	CKB	-0.36	-5.56	-0.45	1.61e-7	Body mass index;
TGCT	cis	rs589448	0.538	rs622656	chr12:69753595	C/T	cg19645103	chr12:69753606	YEATS4	-0.62	-5.14	-0.42	1.04e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs225245	0.817	rs225273	chr17:33970935	A/T	cg05299278	chr17:33885742	SLFN14	0.21	4.5	0.37	1.53e-5	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs11190604	1.000	rs2295773	chr10:102265815	A/G	cg23241863	chr10:102295624	HIF1AN	0.67	5.13	0.42	1.1e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	trans	rs7618501	1.000	rs7374183	chr3:49785133	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-1.03	-13.16	-0.76	2.65e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs6121246	0.529	rs58757492	chr20:30181425	G/A	cg13852791	chr20:30311386	BCL2L1	0.69	4.53	0.38	1.36e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs16866061	1.000	rs72974203	chr2:225408430	G/A	cg12698349	chr2:225449008	CUL3	1.0	9.83	0.66	3.23e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	cis	rs6752107	0.967	rs56227616	chr2:234157741	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.21	5.0	0.41	1.87e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs7666738	0.822	rs13110418	chr4:99046963	G/A	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7714584	1.000	rs11167526	chr5:150332481	G/A	cg22134413	chr5:150180641	NA	1.0	4.79	0.4	4.64e-6	Crohn's disease;
TGCT	cis	rs73198271	0.773	rs66618176	chr8:8646974	G/C	cg15556689	chr8:8085844	FLJ10661	-0.6	-4.46	-0.37	1.8e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs9902453	0.726	rs3110494	chr17:27976597	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.86	8.52	0.61	4.53e-14	Coffee consumption (cups per day);
TGCT	cis	rs11096990	0.634	rs1057807	chr4:39289473	A/G	cg20847110	chr4:39482781	LOC401127	-0.16	-4.51	-0.38	1.48e-5	Cognitive function;
TGCT	cis	rs2486012	0.850	rs2906462	chr1:44332084	G/A	cg12908607	chr1:44402522	ARTN	-0.69	-5.57	-0.45	1.49e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7647973	0.677	rs11130211	chr3:49645209	C/T	cg05785598	chr3:49045655	WDR6	0.41	4.66	0.39	8.03e-6	Menarche (age at onset);
TGCT	cis	rs208520	0.802	rs4710315	chr6:66887594	A/G	cg07460842	chr6:66804631	NA	-0.9	-9.36	-0.64	4.37e-16	Exhaled nitric oxide output;
TGCT	cis	rs7772486	0.701	rs697056	chr6:146003897	C/T	cg05347473	chr6:146136440	FBXO30	-0.51	-4.8	-0.4	4.44e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs422249	0.896	rs174449	chr11:61640379	A/G	cg19610905	chr11:61596333	FADS2	-0.6	-5.25	-0.43	6.45e-7	Trans fatty acid levels;
TGCT	cis	rs7843479	0.601	rs10866837	chr8:21861663	G/C	cg17168535	chr8:21777572	XPO7	0.8	8.16	0.59	3.19e-13	Mean corpuscular volume;
TGCT	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg27121462	chr16:89883253	FANCA	0.78	8.53	0.61	4.29e-14	Vitiligo;
TGCT	cis	rs2288073	1.000	rs2288073	chr2:24413298	C/T	cg05570707	chr2:24270316	C2orf44	0.52	4.63	0.38	9.16e-6	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.2	0.42	8.14e-7	Menopause (age at onset);
TGCT	cis	rs3749237	0.595	rs1464566	chr3:49459376	T/C	cg07636037	chr3:49044803	WDR6	0.63	5.98	0.47	2.26e-8	Resting heart rate;
TGCT	cis	rs9910055	0.529	rs228748	chr17:42174390	G/A	cg19774624	chr17:42201019	HDAC5	0.7	6.71	0.52	6.31e-10	Total body bone mineral density;
TGCT	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-5.79	-0.46	5.39e-8	Alzheimer's disease;
TGCT	cis	rs4409675	0.576	rs12070659	chr1:28227175	G/A	cg23691781	chr1:28212827	C1orf38	0.25	5.38	0.43	3.59e-7	Corneal astigmatism;
TGCT	cis	rs10504229	0.679	rs10504217	chr8:58037522	A/G	cg08280861	chr8:58055591	NA	0.35	5.07	0.41	1.43e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10193935	1.000	rs13411405	chr2:42413811	C/A	cg27598129	chr2:42591480	NA	-0.39	-5.14	-0.42	1.05e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs933688	0.532	rs28637141	chr5:90538743	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.54	-4.82	-0.4	4.09e-6	Smoking behavior;
TGCT	cis	rs17473412	0.895	rs58039148	chr5:122746941	C/A	cg15125798	chr5:122621645	NA	-0.55	-5.03	-0.41	1.69e-6	Total body bone mineral density;
TGCT	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg06238570	chr21:40685208	BRWD1	-0.61	-6.34	-0.49	3.83e-9	Menarche (age at onset);
TGCT	cis	rs4886920	0.563	rs12915515	chr15:78075555	A/T	cg03457338	chr15:78040120	NA	0.18	4.51	0.38	1.48e-5	Neuroticism;
TGCT	cis	rs9549367	0.713	rs3024743	chr13:113821430	C/T	cg18105134	chr13:113819100	PROZ	-0.47	-8.19	-0.59	2.73e-13	Platelet distribution width;
TGCT	cis	rs7193541	0.585	rs7978	chr16:74486189	T/C	cg01733217	chr16:74700730	RFWD3	-0.82	-9.42	-0.65	3.25e-16	Multiple myeloma;
TGCT	cis	rs26868	0.742	rs26848	chr16:2263516	A/G	cg07105046	chr16:2261082	C16orf79	-0.28	-4.77	-0.39	5.06e-6	Height;
TGCT	cis	rs6121246	0.529	rs6060174	chr20:30183538	G/A	cg21427119	chr20:30132790	HM13	-0.42	-6.17	-0.48	8.75e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs6121246	0.567	rs2889488	chr20:30185758	G/A	cg18721089	chr20:30220636	NA	-0.57	-6.22	-0.49	6.83e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg01802117	chr1:53393560	SCP2	-0.39	-4.55	-0.38	1.27e-5	Monocyte count;
TGCT	cis	rs7714584	1.000	rs10052606	chr5:150272217	T/G	cg22134413	chr5:150180641	NA	0.78	6.12	0.48	1.16e-8	Crohn's disease;
TGCT	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs929354	0.557	rs62491947	chr7:156960813	G/A	cg05182265	chr7:156933206	UBE3C	-0.39	-8.79	-0.62	1.03e-14	Body mass index;
TGCT	cis	rs7681440	0.804	rs1442140	chr4:90816023	A/G	cg14346243	chr4:90757452	SNCA	-0.5	-4.93	-0.4	2.61e-6	Dementia with Lewy bodies;
TGCT	cis	rs13326165	0.585	rs35860312	chr3:52387078	T/C	cg07884673	chr3:53033167	SFMBT1	0.4	4.86	0.4	3.45e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs7188861	0.626	rs7193871	chr16:11455606	C/G	cg00044050	chr16:11439710	C16orf75	0.69	6.55	0.51	1.39e-9	HDL cholesterol;
TGCT	cis	rs1865760	0.532	rs2006736	chr6:26086017	C/T	cg16482183	chr6:26056742	HIST1H1C	0.58	4.97	0.41	2.13e-6	Height;
TGCT	cis	rs9914988	0.887	rs8078402	chr17:27145124	T/A	cg20469991	chr17:27169893	C17orf63	-0.72	-5.09	-0.42	1.28e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs2075165	0.901	rs2025577	chr1:156314104	T/C	cg16558208	chr1:156270281	VHLL	0.27	4.85	0.4	3.68e-6	Tonsillectomy;
TGCT	cis	rs1008375	0.931	rs6449328	chr4:17700474	C/T	cg18681998	chr4:17616180	MED28	0.78	7.37	0.55	2.06e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs611744	0.647	rs7015513	chr8:109262570	A/C	cg21045802	chr8:109455806	TTC35	0.69	6.92	0.53	2.12e-10	Dupuytren's disease;
TGCT	cis	rs9796	0.870	rs2412572	chr15:41264426	G/C	cg18705301	chr15:41695430	NDUFAF1	0.43	5.59	0.45	1.39e-7	Menopause (age at onset);
TGCT	cis	rs3803170	0.513	rs10849941	chr12:111818487	A/T	cg10833066	chr12:111807467	FAM109A	0.35	5.4	0.44	3.26e-7	Mean corpuscular hemoglobin;
TGCT	cis	rs13242816	1.000	rs73206052	chr7:116117056	G/T	cg16553024	chr7:116138462	CAV2	-0.56	-5.54	-0.45	1.74e-7	P wave duration;
TGCT	trans	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg25482853	chr8:67687455	SGK3	1.25	10.34	0.68	1.86e-18	Lung disease severity in cystic fibrosis;
TGCT	cis	rs3892630	0.878	rs11878394	chr19:33205844	G/C	cg22980127	chr19:33182716	NUDT19	0.71	5.22	0.42	7.46e-7	Red blood cell traits;
TGCT	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg12311346	chr5:56204834	C5orf35	-0.57	-6.13	-0.48	1.07e-8	Initial pursuit acceleration;
TGCT	cis	rs9436747	0.641	rs4655680	chr1:66041469	G/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.54	5.11	0.42	1.17e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs9467773	1.000	rs1078679	chr6:26568741	C/T	cg15659132	chr6:26577336	NA	0.88	12.27	0.74	3.83e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs7267979	0.966	rs2424715	chr20:25420077	A/G	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs67478160	0.634	rs941473	chr14:104201869	C/G	cg26031613	chr14:104095156	KLC1	-0.6	-5.97	-0.47	2.27e-8	Schizophrenia;
TGCT	cis	rs10751667	0.961	rs6597971	chr11:928598	T/A	cg06064525	chr11:970664	AP2A2	-0.31	-6.11	-0.48	1.19e-8	Alzheimer's disease (late onset);
TGCT	cis	rs877282	0.853	rs7079299	chr10:756455	A/G	cg17470449	chr10:769945	NA	0.32	4.91	0.4	2.76e-6	Uric acid levels;
TGCT	cis	rs2033711	0.905	rs1077420	chr19:58968875	A/C	cg04608855	chr19:58913158	NA	0.55	5.29	0.43	5.23e-7	Uric acid clearance;
TGCT	cis	rs6728642	1.000	rs59178801	chr2:97604455	C/T	cg26665480	chr2:98280029	ACTR1B	-0.92	-5.6	-0.45	1.34e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	cis	rs2439831	0.867	rs4075674	chr15:43650230	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	6.61	0.51	1e-9	Lung cancer in ever smokers;
TGCT	cis	rs3091242	0.806	rs35189848	chr1:25788422	A/G	cg00786635	chr1:25594202	NA	-0.55	-5.67	-0.45	9.46e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs2197308	0.667	rs11181073	chr12:37898543	A/G	cg13010199	chr12:38710504	ALG10B	0.61	4.93	0.4	2.57e-6	Morning vs. evening chronotype;
TGCT	cis	rs13202913	0.837	rs6906678	chr6:151772395	A/T	cg03627880	chr6:151815985	C6orf97	-0.62	-4.64	-0.38	8.66e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs1215050	0.846	rs1839903	chr4:98791414	C/T	cg17366294	chr4:99064904	C4orf37	0.48	4.83	0.4	3.94e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg16325326	chr1:53192061	ZYG11B	0.6	6.77	0.52	4.62e-10	Monocyte count;
TGCT	cis	rs1218582	0.741	rs11264291	chr1:154914797	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.67	-6.88	-0.53	2.57e-10	Prostate cancer;
TGCT	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg06634786	chr22:41940651	POLR3H	-0.88	-8.54	-0.61	3.98e-14	Vitiligo;
TGCT	cis	rs1577917	1.000	rs12190598	chr6:86686074	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.41	-0.44	3.05e-7	Response to antipsychotic treatment;
TGCT	cis	rs7552404	0.690	rs11161620	chr1:76255228	A/G	cg03433033	chr1:76189801	ACADM	-0.64	-6.64	-0.51	8.75e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg16680214	chr1:154839983	KCNN3	-0.35	-7.15	-0.54	6.42e-11	Prostate cancer;
TGCT	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.69	-7.06	-0.54	1.07e-10	Prostate cancer;
TGCT	cis	rs250677	0.687	rs384979	chr5:148459267	C/T	cg23229984	chr5:148520753	ABLIM3	-0.2	-4.57	-0.38	1.14e-5	Breast cancer;
TGCT	cis	rs28595532	0.920	rs17324884	chr4:119771477	C/T	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs2692947	0.644	rs3821051	chr2:96912787	A/G	cg23100626	chr2:96804247	ASTL	-0.45	-5.86	-0.47	3.84e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs11105298	0.891	rs4842664	chr12:89938030	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.75	-5.31	-0.43	4.89e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs3008870	0.755	rs12562761	chr1:67396739	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.79	8.42	0.6	7.66e-14	Lymphocyte percentage of white cells;
TGCT	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.05	0.53	1.1e-10	Prudent dietary pattern;
TGCT	cis	rs6964587	0.692	rs4727268	chr7:91840724	T/C	cg17063962	chr7:91808500	NA	0.77	7.17	0.54	6.08e-11	Breast cancer;
TGCT	cis	rs1018836	0.828	rs2105968	chr8:91591825	A/G	cg16814680	chr8:91681699	NA	-0.69	-6.84	-0.52	3.21e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6700896	0.500	rs7540268	chr1:66085236	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.59	4.56	0.38	1.22e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs7412746	0.611	rs10888398	chr1:150886782	A/G	cg09365446	chr1:150670422	GOLPH3L	-0.34	-4.71	-0.39	6.58e-6	Melanoma;
TGCT	cis	rs4750440	0.576	rs2447011	chr10:14032199	C/T	cg05755354	chr10:14372596	FRMD4A	0.3	4.77	0.39	5.1e-6	Adiponectin levels;
TGCT	cis	rs28374715	0.662	rs522063	chr15:41476209	A/G	cg18705301	chr15:41695430	NDUFAF1	0.72	10.65	0.69	3.35e-19	Ulcerative colitis;
TGCT	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg10802521	chr3:52805072	NEK4	-0.72	-9.1	-0.63	1.91e-15	Bipolar disorder;
TGCT	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg13206674	chr6:150067644	NUP43	0.51	4.47	0.37	1.75e-5	Lung cancer;
TGCT	cis	rs74233809	1.000	rs78260931	chr10:104721962	G/C	cg05855489	chr10:104503620	C10orf26	0.74	4.45	0.37	1.87e-5	Birth weight;
TGCT	cis	rs11673344	0.523	rs7246739	chr19:37531731	G/C	cg08039142	chr19:36980659	ZNF566	0.5	4.64	0.38	8.58e-6	Obesity-related traits;
TGCT	cis	rs9303401	0.614	rs2333409	chr17:57139134	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.58	5.82	0.46	4.8e-8	Cognitive test performance;
TGCT	cis	rs7772486	0.790	rs3924499	chr6:146232978	A/T	cg05347473	chr6:146136440	FBXO30	-0.5	-4.85	-0.4	3.55e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1577917	1.000	rs11759855	chr6:86610841	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.54	-0.45	1.73e-7	Response to antipsychotic treatment;
TGCT	cis	rs4722166	0.630	rs7808457	chr7:22798265	A/T	cg23864514	chr7:22882512	NA	-0.21	-4.47	-0.37	1.76e-5	Lung cancer;
TGCT	cis	rs7584330	0.554	rs880931	chr2:238396741	G/A	cg14458575	chr2:238380390	NA	0.58	5.05	0.41	1.53e-6	Prostate cancer;
TGCT	cis	rs12681287	0.547	rs4961197	chr8:87512436	T/C	cg19078186	chr8:87526527	CPNE3	-0.37	-4.57	-0.38	1.15e-5	Caudate activity during reward;
TGCT	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.5	-4.81	-0.4	4.26e-6	Bipolar disorder;
TGCT	cis	rs62380364	0.565	rs40504	chr5:88011139	G/C	cg24804195	chr5:87968844	LOC645323	-0.61	-6.09	-0.48	1.31e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs10465746	0.746	rs6663949	chr1:84452853	T/C	cg10977910	chr1:84465055	TTLL7	0.67	6.69	0.52	6.72e-10	Obesity-related traits;
TGCT	cis	rs7810240	1.000	rs4725889	chr7:150092684	A/G	cg24650120	chr7:150096722	NA	-0.71	-9.66	-0.66	8.6e-17	Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
TGCT	cis	rs1448094	0.654	rs7133797	chr12:86294184	G/C	cg02569458	chr12:86230093	RASSF9	0.35	4.53	0.38	1.38e-5	Major depressive disorder;
TGCT	cis	rs3806843	0.966	rs2563263	chr5:140137644	A/G	cg19875535	chr5:140030758	IK	0.36	5.96	0.47	2.48e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7267979	1.000	rs4815424	chr20:25390284	T/C	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6089584	0.566	rs6061963	chr20:60607480	C/G	cg06108461	chr20:60628389	TAF4	-0.45	-5.65	-0.45	1.04e-7	Body mass index;
TGCT	cis	rs3125734	0.633	rs10761616	chr10:64009076	G/A	cg05499367	chr10:63213510	TMEM26	-0.33	-4.44	-0.37	1.96e-5	Rheumatoid arthritis;
TGCT	cis	rs1050631	0.960	rs1789516	chr18:33691688	T/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.51	4.98	0.41	2.07e-6	Esophageal squamous cell cancer (length of survival);
TGCT	cis	rs508618	0.731	rs12033229	chr1:231545703	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.6	4.92	0.4	2.64e-6	Red blood cell count;
TGCT	cis	rs11673344	0.542	rs826327	chr19:37495299	A/G	cg08039142	chr19:36980659	ZNF566	0.52	4.85	0.4	3.69e-6	Obesity-related traits;
TGCT	cis	rs9894429	0.789	rs7502346	chr17:79603741	T/C	cg21984481	chr17:79567631	NPLOC4	-0.26	-4.9	-0.4	2.91e-6	Eye color traits;
TGCT	trans	rs2727020	0.857	rs1917324	chr11:49371759	G/C	cg03929089	chr4:120376271	NA	-0.67	-6.99	-0.53	1.52e-10	Coronary artery disease;
TGCT	cis	rs60843830	1.000	rs7595075	chr2:264019	C/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.76	7.69	0.57	3.87e-12	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs9787249	0.957	rs10888958	chr1:40211737	T/C	cg19912559	chr1:40204330	PPIE	0.49	5.7	0.46	8.41e-8	Blood protein levels;
TGCT	cis	rs9611565	0.546	rs739132	chr22:42123099	A/T	cg13695892	chr22:41940480	POLR3H	0.88	8.63	0.61	2.45e-14	Vitiligo;
TGCT	cis	rs34638657	0.732	rs11645372	chr16:82202136	C/T	cg09439754	chr16:82129088	HSD17B2	-0.24	-4.53	-0.38	1.37e-5	Lung adenocarcinoma;
TGCT	cis	rs950169	0.887	rs12903946	chr15:84954430	T/C	cg11189052	chr15:85197271	WDR73	0.81	6.22	0.49	6.89e-9	Schizophrenia;
TGCT	cis	rs7833790	0.654	rs6415652	chr8:82702257	G/A	cg17211192	chr8:82754475	SNX16	-0.88	-7.68	-0.57	4.16e-12	Diastolic blood pressure;
TGCT	cis	rs7226408	0.842	rs11660045	chr18:34381159	C/G	cg06757138	chr18:34340585	FHOD3	0.26	4.79	0.4	4.62e-6	Obesity-related traits;
TGCT	cis	rs9611565	0.592	rs6519270	chr22:42078666	A/G	cg06634786	chr22:41940651	POLR3H	0.84	8.08	0.59	4.86e-13	Vitiligo;
TGCT	cis	rs1865760	0.588	rs9467658	chr6:26010881	T/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.76	7.21	0.54	4.86e-11	Height;
TGCT	cis	rs78456975	0.550	rs10197874	chr2:1545310	A/G	cg12573674	chr2:1569213	NA	-0.47	-4.72	-0.39	6.26e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs4563143	0.514	rs73029081	chr19:29295583	C/G	cg12756686	chr19:29218302	NA	0.67	5.16	0.42	9.34e-7	Methadone dose in opioid dependence;
TGCT	cis	rs4906332	1.000	rs34347076	chr14:103955069	G/A	cg26031613	chr14:104095156	KLC1	-0.51	-4.51	-0.38	1.48e-5	Coronary artery disease;
TGCT	cis	rs7582180	0.715	rs764828	chr2:100908634	A/C	cg08017756	chr2:100939284	LONRF2	-0.28	-4.56	-0.38	1.19e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs2688608	0.592	rs10824031	chr10:75509273	C/T	cg15838173	chr10:75533400	FUT11	-0.3	-5.02	-0.41	1.76e-6	Inflammatory bowel disease;
TGCT	trans	rs877282	0.842	rs35117541	chr10:764683	C/T	cg22713356	chr15:30763199	NA	1.2	9.39	0.64	3.76e-16	Uric acid levels;
TGCT	cis	rs9330316	0.632	rs2043462	chr2:110364811	C/T	cg25199208	chr2:109402912	CCDC138	-0.41	-4.44	-0.37	1.99e-5	Schizophrenia;
TGCT	cis	rs9787249	0.957	rs10888958	chr1:40211737	T/C	cg24920358	chr1:40204285	PPIE	0.57	10.56	0.69	5.57e-19	Blood protein levels;
TGCT	cis	rs67311347	1.000	rs2276868	chr3:40498845	C/T	cg13683864	chr3:40499215	RPL14	1.03	10.28	0.68	2.62e-18	Renal cell carcinoma;
TGCT	cis	rs7954584	0.520	rs1169096	chr12:122465836	G/C	cg22168489	chr12:122356033	WDR66	-0.19	-4.52	-0.38	1.42e-5	Mean corpuscular volume;
TGCT	cis	rs78487399	0.908	rs6731636	chr2:43843046	G/T	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.65	4.53	0.38	1.39e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs3099143	1.000	rs2629034	chr15:77042240	G/A	cg21673338	chr15:77095150	SCAPER	-0.51	-5.12	-0.42	1.11e-6	Recalcitrant atopic dermatitis;
TGCT	cis	rs3015497	0.789	rs3015502	chr14:51108427	T/C	cg04730355	chr14:51134070	SAV1	-0.65	-6.29	-0.49	5.07e-9	Mean platelet volume;
TGCT	cis	rs62103177	0.525	rs4283293	chr18:77759582	A/G	cg20368463	chr18:77673604	PQLC1	-0.43	-4.46	-0.37	1.83e-5	Opioid sensitivity;
TGCT	cis	rs6750795	0.569	rs1667305	chr2:232403829	A/G	cg19187155	chr2:232395269	NMUR1	0.41	4.72	0.39	6.29e-6	Height;
TGCT	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg27454412	chr7:1067447	C7orf50	0.6	4.72	0.39	6.32e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9467773	0.620	rs2494696	chr6:26620894	A/G	cg26531700	chr6:26746687	NA	0.52	5.01	0.41	1.8e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs67385638	1.000	rs72872548	chr11:5289139	C/A	cg12559170	chr11:5275217	HBG2	0.47	8.38	0.6	9.96e-14	Hemoglobin levels;
TGCT	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.18	0.49	8.32e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs826838	0.967	rs1719852	chr12:39128531	A/G	cg26384229	chr12:38710491	ALG10B	-0.83	-7.31	-0.55	2.88e-11	Heart rate;
TGCT	cis	rs11122272	0.735	rs2437150	chr1:231488524	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.73	6.95	0.53	1.83e-10	Hemoglobin concentration;
TGCT	cis	rs11190604	0.767	rs10883491	chr10:102196071	G/T	cg16342193	chr10:102329863	NA	-0.41	-5.22	-0.42	7.22e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7945705	0.869	rs11042154	chr11:9029700	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.45	-5.19	-0.42	8.41e-7	Hemoglobin concentration;
TGCT	cis	rs9733	0.596	rs72702556	chr1:150680115	C/T	cg04414720	chr1:150670196	GOLPH3L	0.37	4.91	0.4	2.76e-6	Tonsillectomy;
TGCT	cis	rs4449834	0.961	rs4738832	chr8:61760521	A/G	cg12485212	chr8:61565947	NA	-0.61	-4.5	-0.37	1.53e-5	Sum eosinophil basophil counts;
TGCT	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg04267008	chr7:1944627	MAD1L1	0.34	4.62	0.38	9.66e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs922182	0.663	rs7180057	chr15:64263795	G/A	cg02919090	chr15:64263738	DAPK2	0.38	7.06	0.54	1.03e-10	Blood protein levels;
TGCT	cis	rs2439831	0.850	rs3759790	chr15:44121030	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.9	6.3	0.49	4.62e-9	Lung cancer in ever smokers;
TGCT	trans	rs2970818	0.831	rs7304949	chr12:4609625	A/G	cg23273947	chr15:68267131	NA	0.28	7.64	0.57	5.02e-12	Phosphorus levels;
TGCT	cis	rs7824557	0.767	rs6991606	chr8:11176159	G/A	cg21775007	chr8:11205619	TDH	0.54	5.21	0.42	7.76e-7	Retinal vascular caliber;
TGCT	cis	rs36051895	0.575	rs7035251	chr9:5133665	T/A	cg02405213	chr9:5042618	JAK2	-0.75	-10.52	-0.69	6.97e-19	Pediatric autoimmune diseases;
TGCT	cis	rs1018836	0.923	rs7013893	chr8:91563137	G/A	cg16814680	chr8:91681699	NA	-0.9	-9.91	-0.66	2.06e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6088580	0.634	rs6120669	chr20:33105028	T/C	cg06115741	chr20:33292138	TP53INP2	0.54	4.63	0.38	9.06e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7727544	0.660	rs272886	chr5:131665840	T/C	cg24060327	chr5:131705240	SLC22A5	-0.57	-6.43	-0.5	2.53e-9	Blood metabolite levels;
TGCT	cis	rs7647973	0.516	rs4955419	chr3:49200692	T/A	cg06212747	chr3:49208901	KLHDC8B	0.66	6.35	0.5	3.77e-9	Menarche (age at onset);
TGCT	trans	rs1814175	0.817	rs7946556	chr11:49944874	G/A	cg15704280	chr7:45808275	SEPT13	-0.71	-8.0	-0.58	7.45e-13	Height;
TGCT	cis	rs8031584	0.918	rs1425292	chr15:31285422	G/A	cg08704250	chr15:31115839	NA	-0.36	-4.93	-0.4	2.59e-6	Huntington's disease progression;
TGCT	cis	rs7666738	0.830	rs13115356	chr4:98933171	T/C	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12791968	1.000	rs1552300	chr11:45002594	G/A	cg11846598	chr11:44996168	LOC221122	-0.36	-6.79	-0.52	4.04e-10	Inhibitory control;
TGCT	cis	rs4746818	1.000	rs7918066	chr10:70913116	C/T	cg04149295	chr10:70884716	VPS26A	0.79	5.44	0.44	2.79e-7	Left atrial antero-posterior diameter;
TGCT	cis	rs7666738	0.830	rs11726604	chr4:99000969	T/C	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7731657	0.509	rs6595984	chr5:130335884	A/G	cg08523029	chr5:130500466	HINT1	0.57	4.73	0.39	5.93e-6	Fasting plasma glucose;
TGCT	cis	rs904251	0.965	rs1317563	chr6:37451854	G/T	cg01843034	chr6:37503916	NA	-0.42	-4.86	-0.4	3.45e-6	Cognitive performance;
TGCT	cis	rs1385374	0.858	rs11059928	chr12:129296103	A/T	cg09035930	chr12:129282057	SLC15A4	-0.55	-4.76	-0.39	5.27e-6	Systemic lupus erythematosus;
TGCT	cis	rs295137	0.836	rs1217456	chr2:201092279	C/T	cg17644776	chr2:200775616	C2orf69	0.23	4.53	0.38	1.38e-5	Asthma (bronchodilator response);
TGCT	cis	rs6424115	0.733	rs2502996	chr1:24199041	T/C	cg15997130	chr1:24165203	NA	0.85	9.26	0.64	7.92e-16	Immature fraction of reticulocytes;
TGCT	cis	rs1008375	1.000	rs3815413	chr4:17654648	T/C	cg16339924	chr4:17578868	LAP3	0.67	5.55	0.45	1.68e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2233152	0.656	rs2287691	chr19:41286163	C/G	cg23743927	chr19:41304969	EGLN2	-0.7	-4.69	-0.39	7.06e-6	Kawasaki disease;
TGCT	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg04267008	chr7:1944627	MAD1L1	-0.36	-4.84	-0.4	3.83e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs1129187	0.755	rs2296804	chr6:42931261	C/G	cg17345569	chr6:42928274	GNMT	-0.49	-5.05	-0.41	1.55e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs2762353	0.904	rs13197514	chr6:25785991	C/T	cg03517284	chr6:25882590	NA	0.51	5.33	0.43	4.47e-7	Blood metabolite levels;
TGCT	cis	rs59197085	0.636	rs62479620	chr7:128463971	C/T	cg00260937	chr7:128520193	KCP	0.47	4.98	0.41	2.1e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
TGCT	cis	rs9611565	0.512	rs5758465	chr22:42175314	T/C	cg06634786	chr22:41940651	POLR3H	0.85	8.15	0.59	3.41e-13	Vitiligo;
TGCT	cis	rs28595532	0.800	rs114321375	chr4:119341663	G/A	cg21605333	chr4:119757512	SEC24D	0.87	5.49	0.44	2.14e-7	Cannabis dependence symptom count;
TGCT	trans	rs4332037	0.906	rs62442903	chr7:1953416	G/A	cg10840412	chr1:235813424	GNG4	1.01	8.11	0.59	4.2e-13	Bipolar disorder;
TGCT	cis	rs2180341	0.782	rs6912006	chr6:127722631	C/T	cg27446573	chr6:127587934	RNF146	0.75	7.02	0.53	1.3e-10	Breast cancer;
TGCT	cis	rs2952156	0.920	rs2934951	chr17:37833328	A/G	cg20243544	chr17:37824526	PNMT	0.56	4.81	0.4	4.25e-6	Asthma;
TGCT	cis	rs10875595	0.836	rs3749780	chr5:140682757	C/T	cg20560182	chr5:140700478	TAF7	-0.63	-4.73	-0.39	5.92e-6	Pulmonary function decline;
TGCT	cis	rs8180040	0.966	rs11710322	chr3:47331136	C/T	cg27129171	chr3:47204927	SETD2	-0.7	-8.45	-0.6	6.65e-14	Colorectal cancer;
TGCT	cis	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg25427524	chr10:38739819	LOC399744	-0.4	-8.36	-0.6	1.05e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs4466137	0.553	rs16898	chr5:82986149	T/C	cg16102102	chr5:83017553	HAPLN1	-0.71	-8.11	-0.59	4.1e-13	Prostate cancer;
TGCT	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg03188948	chr7:1209495	NA	0.68	5.69	0.45	8.84e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs6570726	0.577	rs867056	chr6:145784805	A/C	cg05347473	chr6:146136440	FBXO30	-0.67	-6.34	-0.49	3.85e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6988636	0.901	rs62521825	chr8:124185786	C/A	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs62380364	0.566	rs1705565	chr5:88048457	C/T	cg22951263	chr5:87985283	NA	-0.58	-6.12	-0.48	1.12e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7428	0.527	rs6547612	chr2:85551184	C/T	cg03728395	chr2:85555865	TGOLN2	-0.3	-5.0	-0.41	1.89e-6	Ear protrusion;
TGCT	cis	rs7829975	0.582	rs6983150	chr8:8792426	A/G	cg15556689	chr8:8085844	FLJ10661	-0.67	-6.1	-0.48	1.26e-8	Mood instability;
TGCT	cis	rs9291683	0.595	rs13145442	chr4:10037261	C/A	cg11266682	chr4:10021025	SLC2A9	0.64	8.91	0.62	5.31e-15	Bone mineral density;
TGCT	cis	rs981844	1.000	rs2606337	chr4:154656845	C/T	cg14289246	chr4:154710475	SFRP2	1.01	8.46	0.6	6.31e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg06112835	chr11:68658793	MRPL21	0.47	8.18	0.59	2.86e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs8072100	0.701	rs2013383	chr17:45791123	T/G	cg08085267	chr17:45401833	C17orf57	-0.42	-4.74	-0.39	5.78e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs2242194	0.816	rs2242193	chr1:154995503	A/G	cg16680214	chr1:154839983	KCNN3	0.3	5.54	0.45	1.75e-7	Schizophrenia;
TGCT	cis	rs12134245	0.776	rs12122066	chr1:92005140	C/T	cg07090678	chr1:91966139	CDC7	0.35	4.87	0.4	3.28e-6	Breast cancer;
TGCT	cis	rs2301573	0.915	rs2285373	chr3:129308209	G/A	cg07730360	chr3:128845626	NA	0.33	4.61	0.38	9.84e-6	Hip circumference;
TGCT	cis	rs6087771	0.642	rs6060411	chr20:30222139	T/C	cg21427119	chr20:30132790	HM13	-0.3	-5.05	-0.41	1.53e-6	Subcortical brain region volumes;Putamen volume;
TGCT	cis	rs35306767	0.623	rs72760941	chr10:1141244	A/G	cg26597838	chr10:835615	NA	0.47	4.95	0.41	2.37e-6	Eosinophil percentage of granulocytes;
TGCT	cis	rs539096	0.872	rs10890261	chr1:44052377	G/T	cg12908607	chr1:44402522	ARTN	0.52	5.43	0.44	2.8e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs6582630	0.598	rs11182207	chr12:38477514	T/C	cg26384229	chr12:38710491	ALG10B	-0.54	-4.79	-0.4	4.57e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs57221529	0.766	rs56278696	chr5:582669	A/G	cg09021430	chr5:549028	NA	-0.37	-4.98	-0.41	2.07e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs2153535	0.580	rs2152347	chr6:8474281	A/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs644799	1.000	rs10831431	chr11:95510089	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	8.53	0.61	4.41e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs2282802	0.685	rs13177186	chr5:139640476	A/G	cg01081189	chr5:139537190	NA	0.29	5.24	0.43	6.57e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1865760	0.713	rs7766342	chr6:25990674	C/A	cg17042849	chr6:26104293	HIST1H4C	-0.55	-4.8	-0.4	4.4e-6	Height;
TGCT	cis	rs79149102	0.579	rs78664321	chr15:75339575	G/A	cg09165964	chr15:75287851	SCAMP5	-1.05	-5.56	-0.45	1.59e-7	Lung cancer;
TGCT	cis	rs3796352	1.000	rs71301814	chr3:53117663	G/A	cg27565382	chr3:53032988	SFMBT1	0.44	4.71	0.39	6.52e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs11190604	0.767	rs77838250	chr10:102180090	T/G	cg16005271	chr10:102321736	NA	0.46	4.67	0.39	7.62e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs644799	1.000	rs509720	chr11:95562771	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	10.52	0.69	6.94e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs6546537	0.550	rs2312202	chr2:69775104	A/C	cg10773587	chr2:69614142	GFPT1	0.56	5.28	0.43	5.71e-7	Serum thyroid-stimulating hormone levels;
TGCT	cis	rs9659323	1.000	rs11584380	chr1:119517420	C/T	cg07961512	chr1:119535619	NA	0.44	5.07	0.41	1.4e-6	Body mass index;
TGCT	cis	rs4824093	0.535	rs73441802	chr22:50273916	G/A	cg14114931	chr22:50943910	LMF2	0.37	4.59	0.38	1.09e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs56104184	0.830	rs73061622	chr19:49358111	C/T	cg17863274	chr19:49399704	TULP2	-0.45	-5.44	-0.44	2.69e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs7804356	1.000	rs3801850	chr7:26820577	T/C	cg03456212	chr7:26904342	SKAP2	-0.64	-4.88	-0.4	3.16e-6	Type 1 diabetes;
TGCT	cis	rs1949733	0.656	rs2688224	chr4:8404700	C/G	cg13073564	chr4:8508604	NA	-0.43	-4.78	-0.39	4.95e-6	Response to antineoplastic agents;
TGCT	cis	rs614226	0.935	rs588132	chr12:121024066	A/G	cg01236616	chr12:121019343	POP5	1.31	13.71	0.78	1.34e-26	Type 1 diabetes nephropathy;
TGCT	cis	rs17826219	0.636	rs8080829	chr17:29058730	C/T	cg14008862	chr17:28927542	LRRC37B2	0.77	4.59	0.38	1.08e-5	Body mass index;
TGCT	cis	rs28595532	0.920	rs114751999	chr4:119759651	G/A	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg11211951	chr8:145729740	GPT	0.23	5.44	0.44	2.76e-7	Age at first birth;
TGCT	cis	rs4944092	0.793	rs94111	chr11:75915139	A/G	cg04588336	chr11:75916460	WNT11	-0.47	-6.76	-0.52	4.78e-10	PR interval;
TGCT	cis	rs6061231	0.837	rs6121558	chr20:60961365	A/G	cg24112000	chr20:60950667	NA	-0.37	-4.92	-0.4	2.74e-6	Colorectal cancer;
TGCT	cis	rs9902453	0.817	rs2729449	chr17:28089751	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-6.84	-0.52	3.22e-10	Coffee consumption (cups per day);
TGCT	cis	rs4812048	0.793	rs6070693	chr20:57589516	C/T	cg24457521	chr20:57607420	ATP5E	-0.7	-4.61	-0.38	9.66e-6	Mean platelet volume;
TGCT	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg10802521	chr3:52805072	NEK4	-0.72	-9.1	-0.63	1.91e-15	Bipolar disorder;
TGCT	cis	rs9611565	0.649	rs738422	chr22:42123399	C/T	cg06481639	chr22:41940642	POLR3H	0.56	4.87	0.4	3.39e-6	Vitiligo;
TGCT	cis	rs12681287	0.640	rs13261901	chr8:87478717	G/C	cg27223183	chr8:87520930	FAM82B	-0.89	-6.41	-0.5	2.8e-9	Caudate activity during reward;
TGCT	cis	rs4820539	1.000	rs4822361	chr22:23482718	A/G	cg14186256	chr22:23484241	RTDR1	-0.98	-12.77	-0.75	2.31e-24	Bone mineral density;
TGCT	cis	rs950169	0.922	rs12910334	chr15:84958318	G/A	cg12863693	chr15:85201151	NMB	0.45	4.96	0.41	2.28e-6	Schizophrenia;
TGCT	cis	rs7429990	0.932	rs6442101	chr3:48130893	C/T	cg11946769	chr3:48343235	NME6	-0.56	-4.59	-0.38	1.07e-5	Educational attainment (years of education);
TGCT	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg23172400	chr8:95962367	TP53INP1	-0.39	-6.52	-0.51	1.59e-9	Type 2 diabetes;
TGCT	cis	rs968451	0.547	rs11704319	chr22:39722886	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	-0.81	-9.21	-0.64	1.03e-15	Primary biliary cholangitis;
TGCT	cis	rs7945705	0.747	rs2653605	chr11:8993309	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.46	-5.01	-0.41	1.84e-6	Hemoglobin concentration;
TGCT	cis	rs9549260	0.755	rs2755219	chr13:41169625	A/G	cg21288729	chr13:41239152	FOXO1	0.99	10.12	0.67	6.41e-18	Red blood cell count;
TGCT	cis	rs7945705	0.935	rs2568062	chr11:8887945	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-5.63	-0.45	1.13e-7	Hemoglobin concentration;
TGCT	cis	rs6543140	0.964	rs4851593	chr2:103089227	C/T	cg09003973	chr2:102972529	NA	-0.55	-4.52	-0.38	1.45e-5	Blood protein levels;
TGCT	cis	rs6088590	0.523	rs6058084	chr20:33183804	C/T	cg08999081	chr20:33150536	PIGU	0.25	4.99	0.41	1.97e-6	Coronary artery disease;
TGCT	cis	rs9467773	0.587	rs12214031	chr6:26376628	T/C	cg05738196	chr6:26577821	NA	-0.62	-6.56	-0.51	1.29e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs1451375	1.000	rs2329341	chr7:50620275	A/C	cg18232548	chr7:50535776	DDC	0.44	6.59	0.51	1.11e-9	Malaria;
TGCT	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg10819733	chr22:24237672	NA	-0.27	-4.47	-0.37	1.77e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6909279	0.933	rs4391273	chr6:151893073	A/C	cg14416726	chr6:151773293	C6orf211;RMND1	0.53	4.47	0.37	1.77e-5	Bone mineral density;
TGCT	cis	rs9486719	1.000	rs6921291	chr6:97066242	C/T	cg06623918	chr6:96969491	KIAA0776	-1.02	-8.51	-0.61	4.91e-14	Migraine;Coronary artery disease;
TGCT	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg08219700	chr8:58056026	NA	0.37	4.48	0.37	1.71e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs6952808	0.636	rs60605830	chr7:1949198	A/G	cg04267008	chr7:1944627	MAD1L1	-0.36	-4.72	-0.39	6.34e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs860295	0.517	rs1111102	chr1:155993456	G/T	cg05700447	chr1:155978627	NA	-0.22	-4.93	-0.4	2.57e-6	Body mass index;
TGCT	cis	rs7119	0.717	rs12916822	chr15:77818548	G/T	cg27398640	chr15:77910606	LINGO1	-0.25	-4.61	-0.38	9.81e-6	Type 2 diabetes;
TGCT	cis	rs13217239	0.646	rs10946891	chr6:26973215	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.4	4.47	0.37	1.76e-5	Schizophrenia;
TGCT	cis	rs2404602	0.735	rs2280306	chr15:76652258	C/G	cg22467129	chr15:76604101	ETFA	0.47	4.88	0.4	3.19e-6	Blood metabolite levels;
TGCT	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg05985448	chr10:134359359	INPP5A	0.24	5.13	0.42	1.1e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs7267979	0.789	rs6083841	chr20:25384564	C/T	cg13486641	chr20:25479848	NINL	0.16	4.55	0.38	1.26e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7927771	0.689	rs10734557	chr11:47380061	A/C	cg21462715	chr11:47870315	NUP160	-0.55	-4.44	-0.37	1.96e-5	Subjective well-being;
TGCT	cis	rs7590720	1.000	rs7592663	chr2:216894978	T/C	cg12620499	chr2:216877984	MREG	0.87	9.2	0.64	1.11e-15	Alcohol dependence;
TGCT	cis	rs595982	0.702	rs609985	chr19:49370648	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.37	-5.02	-0.41	1.74e-6	Red cell distribution width;
TGCT	cis	rs1062177	1.000	rs6890099	chr5:151151962	A/G	cg00977110	chr5:151150581	G3BP1	0.4	4.57	0.38	1.16e-5	Preschool internalizing problems;
TGCT	cis	rs10751667	0.961	rs7482484	chr11:927020	C/T	cg06064525	chr11:970664	AP2A2	-0.31	-6.11	-0.48	1.19e-8	Alzheimer's disease (late onset);
TGCT	cis	rs617791	0.508	rs2276132	chr11:65770545	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	0.49	4.49	0.37	1.64e-5	Breast cancer;
TGCT	cis	rs3820068	0.734	rs6669156	chr1:15905206	T/A	cg05660106	chr1:15850417	CASP9	1.16	14.38	0.79	3.49e-28	Systolic blood pressure;
TGCT	cis	rs11148252	0.633	rs9535888	chr13:52733206	C/G	cg00495681	chr13:53174319	NA	0.52	4.79	0.4	4.64e-6	Lewy body disease;
TGCT	cis	rs2239547	0.603	rs2276825	chr3:52886605	T/C	cg10802521	chr3:52805072	NEK4	-0.65	-6.14	-0.48	1.02e-8	Schizophrenia;
TGCT	cis	rs9818758	0.607	rs11552724	chr3:49156473	C/G	cg07636037	chr3:49044803	WDR6	-1.04	-5.17	-0.42	9.28e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs763121	0.853	rs5757141	chr22:38957483	G/A	cg06022373	chr22:39101656	GTPBP1	0.82	8.1	0.59	4.32e-13	Menopause (age at onset);
TGCT	cis	rs4975616	0.686	rs37011	chr5:1348798	A/T	cg26373071	chr5:1325741	CLPTM1L	0.16	4.59	0.38	1.08e-5	Lung cancer;
TGCT	cis	rs55794721	0.509	rs11249248	chr1:25753051	T/C	cg10117171	chr1:25599238	RHD	-0.34	-5.48	-0.44	2.31e-7	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs6665290	0.904	rs11578103	chr1:227189642	C/A	cg10327440	chr1:227177885	CDC42BPA	-1.0	-20.53	-0.88	1.06e-41	Myeloid white cell count;
TGCT	cis	rs7760949	0.889	rs9396262	chr6:13927418	C/T	cg27413430	chr6:13925136	RNF182	0.73	6.79	0.52	4.22e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs1395	0.710	rs72817533	chr2:27482612	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.65	8.48	0.61	5.54e-14	Blood metabolite levels;
TGCT	cis	rs739401	0.611	rs7394974	chr11:3038868	C/T	cg05729581	chr11:3078854	CARS	-0.54	-5.13	-0.42	1.07e-6	Longevity;
TGCT	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg03609598	chr5:56110824	MAP3K1	-0.63	-4.96	-0.41	2.22e-6	Initial pursuit acceleration;
TGCT	cis	rs1865760	0.566	rs4529296	chr6:26083135	C/G	cg17042849	chr6:26104293	HIST1H4C	-0.63	-5.47	-0.44	2.43e-7	Height;
TGCT	cis	rs9814567	1.000	rs4423809	chr3:134300107	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.92	8.42	0.6	7.71e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs651907	0.613	rs1707618	chr3:101631207	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.5	4.86	0.4	3.54e-6	Colorectal cancer;
TGCT	cis	rs7647973	0.626	rs1463728	chr3:49647404	T/A	cg05785598	chr3:49045655	WDR6	0.41	4.63	0.38	9.16e-6	Menarche (age at onset);
TGCT	cis	rs9905704	0.647	rs10221208	chr17:57047885	T/C	cg05425664	chr17:57184151	TRIM37	-0.57	-4.58	-0.38	1.1e-5	Testicular germ cell tumor;
TGCT	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg18876405	chr7:65276391	NA	0.37	5.85	0.47	4.02e-8	Calcium levels;
TGCT	cis	rs3617	0.539	rs12629687	chr3:52950659	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	0.5	4.95	0.41	2.38e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg06221963	chr1:154839813	KCNN3	-0.73	-12.24	-0.74	4.41e-23	Prostate cancer;
TGCT	cis	rs12497850	0.864	rs4955410	chr3:49181218	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.38	-4.79	-0.4	4.61e-6	Parkinson's disease;
TGCT	cis	rs4953076	0.573	rs7602070	chr2:44388614	G/A	cg00619915	chr2:44497795	NA	-0.23	-5.07	-0.41	1.41e-6	Height;
TGCT	cis	rs912057	0.841	rs1294423	chr6:6743795	C/T	cg06612196	chr6:6737390	NA	0.37	4.88	0.4	3.17e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.8	5.52	0.44	1.89e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7264396	0.561	rs6058387	chr20:34568092	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-4.85	-0.4	3.6e-6	Total cholesterol levels;
TGCT	cis	rs2019872	1.000	rs2019872	chr17:2010318	C/T	cg24156229	chr17:1948635	NA	-0.37	-4.59	-0.38	1.06e-5	Schizophrenia;
TGCT	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg09165964	chr15:75287851	SCAMP5	0.52	4.87	0.4	3.4e-6	Breast cancer;
TGCT	cis	rs7582180	0.606	rs12618908	chr2:100947026	A/T	cg14675211	chr2:100938903	LONRF2	0.5	4.78	0.39	4.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs921968	0.643	rs483172	chr2:219428299	A/G	cg02176678	chr2:219576539	TTLL4	0.37	5.34	0.43	4.2e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs7584330	0.518	rs74003109	chr2:238448150	C/T	cg14458575	chr2:238380390	NA	0.43	4.55	0.38	1.25e-5	Prostate cancer;
TGCT	cis	rs933688	0.938	rs7720235	chr5:90659329	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.05	9.14	0.63	1.5e-15	Smoking behavior;
TGCT	cis	rs11098499	0.821	rs10032151	chr4:120391628	C/T	cg09307838	chr4:120376055	NA	0.69	6.56	0.51	1.31e-9	Corneal astigmatism;
TGCT	cis	rs2302045	1.000	rs16843267	chr2:242039589	A/C	cg04553960	chr2:241721320	KIF1A	-0.7	-4.68	-0.39	7.4e-6	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio);
TGCT	cis	rs4372836	0.754	rs6709674	chr2:28989667	A/G	cg09522027	chr2:28974177	PPP1CB	-0.68	-6.95	-0.53	1.87e-10	Body mass index;
TGCT	cis	rs7666738	0.830	rs6532719	chr4:99043691	A/G	cg18180107	chr4:99064573	C4orf37	0.56	5.08	0.41	1.37e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg21862992	chr11:68658383	NA	0.46	6.52	0.51	1.6e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7568458	0.905	rs6739015	chr2:85755357	A/G	cg02493740	chr2:85810744	VAMP5	-0.27	-4.81	-0.4	4.25e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs4824093	0.610	rs3761496	chr22:50246466	T/C	cg14114931	chr22:50943910	LMF2	0.37	4.58	0.38	1.11e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs1580019	0.563	rs10486509	chr7:32585443	C/G	cg06627557	chr7:32535165	LSM5;AVL9	-1.1	-13.86	-0.78	5.72e-27	Cognitive ability;
TGCT	cis	rs3829109	0.564	rs11789379	chr9:139285260	T/C	cg13741927	chr9:139327495	INPP5E	-0.23	-4.97	-0.41	2.14e-6	Peak insulin response;Acute insulin response;
TGCT	cis	rs9911578	1.000	rs6503866	chr17:56619581	C/T	cg05425664	chr17:57184151	TRIM37	0.63	6.26	0.49	5.86e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7772486	0.641	rs2748489	chr6:146331287	T/G	cg05347473	chr6:146136440	FBXO30	0.56	5.22	0.42	7.2e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9611565	0.921	rs3927	chr22:41722864	A/G	cg13695892	chr22:41940480	POLR3H	-0.82	-8.43	-0.6	7.34e-14	Vitiligo;
TGCT	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg26119090	chr2:26468346	HADHA;HADHB	1.0	7.42	0.55	1.64e-11	Gut microbiome composition (summer);
TGCT	cis	rs1348850	0.768	rs57681892	chr2:178357645	G/C	cg22681709	chr2:178499509	PDE11A	-0.35	-4.53	-0.38	1.39e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs4517514	0.509	rs10830417	chr11:89871940	A/G	cg05041596	chr11:89867385	NAALAD2	0.52	4.61	0.38	9.86e-6	Trans fatty acid levels;
TGCT	cis	rs2730260	0.537	rs56023468	chr7:158875329	T/C	cg09066883	chr7:157932951	PTPRN2	0.42	4.66	0.39	8.09e-6	Myopia (pathological);
TGCT	cis	rs7769051	0.522	rs3736725	chr6:133095172	A/G	cg07930552	chr6:133119739	C6orf192	1.21	4.81	0.4	4.24e-6	Type 2 diabetes nephropathy;
TGCT	trans	rs9929218	0.551	rs4783663	chr16:68720271	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.62	7.92	0.58	1.13e-12	Colorectal cancer;
TGCT	cis	rs17473412	1.000	rs1047484	chr5:122680667	T/G	cg15125798	chr5:122621645	NA	-0.58	-5.2	-0.42	7.87e-7	Total body bone mineral density;
TGCT	cis	rs9560113	0.959	rs9555802	chr13:112179504	T/C	cg14154082	chr13:112174009	NA	0.37	5.07	0.41	1.42e-6	Menarche (age at onset);
TGCT	cis	rs9394169	0.875	rs1547669	chr6:33775641	A/G	cg13859433	chr6:33739653	LEMD2	-0.33	-5.85	-0.47	4.02e-8	Essential tremor;
TGCT	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg03188948	chr7:1209495	NA	0.64	5.38	0.43	3.61e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs185694	1.000	rs1099860	chr13:30883168	C/T	cg07600127	chr13:30881527	KATNAL1	-0.87	-6.77	-0.52	4.55e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
TGCT	cis	rs6684514	1.000	rs2273833	chr1:156233189	C/T	cg20302342	chr1:156215951	PAQR6	0.35	4.57	0.38	1.17e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs7666738	0.830	rs7686456	chr4:99019695	T/C	cg17366294	chr4:99064904	C4orf37	0.68	7.04	0.53	1.17e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8017423	0.935	rs8012299	chr14:90715822	G/T	cg04374321	chr14:90722782	PSMC1	0.72	7.54	0.56	8.86e-12	Mortality in heart failure;
TGCT	cis	rs739496	0.615	rs9300319	chr12:112064897	T/C	cg10833066	chr12:111807467	FAM109A	0.36	5.22	0.42	7.28e-7	Platelet count;
TGCT	cis	rs6840360	0.642	rs7676059	chr4:152393267	T/C	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.82e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs36051895	0.695	rs2225125	chr9:4998639	A/G	cg02405213	chr9:5042618	JAK2	-0.73	-9.46	-0.65	2.54e-16	Pediatric autoimmune diseases;
TGCT	cis	rs9914544	1.000	rs9914544	chr17:18787828	A/C	cg26378065	chr17:18585709	ZNF286B	0.52	4.73	0.39	5.94e-6	Educational attainment (years of education);
TGCT	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg09365446	chr1:150670422	GOLPH3L	0.31	4.64	0.38	8.7e-6	Tonsillectomy;
TGCT	cis	rs8070740	0.898	rs8078914	chr17:5323924	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	4.77	0.39	5.1e-6	Menopause (age at onset);
TGCT	trans	rs17685	0.712	rs1639620	chr7:75704090	A/G	cg19862616	chr7:65841803	NCRNA00174	0.52	9.01	0.63	3.02e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs936229	0.861	rs7180484	chr15:75115416	G/T	cg10253484	chr15:75165896	SCAMP2	0.66	5.34	0.43	4.28e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
TGCT	cis	rs10838634	1.000	rs12273360	chr11:46889719	T/C	cg18332754	chr11:46939436	LRP4	0.89	4.77	0.39	5.13e-6	Schizophrenia;
TGCT	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg11366901	chr6:160182831	ACAT2	0.74	5.59	0.45	1.36e-7	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs1865760	1.000	rs9467636	chr6:25919549	A/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.65	6.21	0.49	7.42e-9	Height;
TGCT	cis	rs9807989	0.507	rs1592459	chr2:103031569	A/G	cg03938978	chr2:103052716	IL18RAP	0.27	5.41	0.44	3.17e-7	Asthma;
TGCT	cis	rs7267979	1.000	rs4815417	chr20:25379526	C/T	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3540	0.960	rs8030390	chr15:90943471	C/T	cg22089800	chr15:90895588	ZNF774	0.79	4.63	0.38	8.98e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs7432375	0.799	rs4038578	chr3:136426822	A/T	cg12473912	chr3:136751656	NA	-0.34	-4.53	-0.38	1.35e-5	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9457247	1.000	rs364283	chr6:167383750	C/T	cg25258033	chr6:167368657	RNASET2	0.18	4.49	0.37	1.63e-5	Crohn's disease;
TGCT	cis	rs7017914	0.905	rs4078067	chr8:71956471	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	0.55	5.11	0.42	1.17e-6	Bone mineral density;
TGCT	cis	rs7617480	0.617	rs7610519	chr3:48746427	C/G	cg07636037	chr3:49044803	WDR6	0.77	6.37	0.5	3.33e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs9916302	0.861	rs4795376	chr17:37669043	T/C	cg15445000	chr17:37608096	MED1	0.32	4.66	0.39	8.18e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs5771242	0.776	rs6010198	chr22:50610628	A/G	cg08875078	chr22:50639485	SELO	-0.51	-4.49	-0.37	1.63e-5	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
TGCT	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg06212747	chr3:49208901	KLHDC8B	0.67	6.36	0.5	3.57e-9	Menarche (age at onset);
TGCT	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	5.74	0.46	6.73e-8	Alzheimer's disease;
TGCT	cis	rs72945132	0.941	rs66803755	chr11:70117473	G/A	cg00319359	chr11:70116639	PPFIA1	0.99	7.32	0.55	2.78e-11	Coronary artery disease;
TGCT	cis	rs7675861	0.891	rs11945849	chr4:5850343	C/T	cg14241509	chr4:6196512	JAKMIP1	-0.27	-5.07	-0.41	1.44e-6	Dysphagia;
TGCT	cis	rs12220238	1.000	rs10824130	chr10:76008931	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.95	7.37	0.55	2.07e-11	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs7017914	0.967	rs2732091	chr8:71918423	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	0.54	5.08	0.41	1.37e-6	Bone mineral density;
TGCT	cis	rs7647973	0.626	rs11709734	chr3:49745235	G/A	cg03034192	chr3:50606346	HEMK1;C3orf18	0.36	4.75	0.39	5.61e-6	Menarche (age at onset);
TGCT	cis	rs4700695	0.764	rs251278	chr5:65381826	G/A	cg21114390	chr5:65439923	SFRS12	-0.58	-4.52	-0.38	1.43e-5	Facial morphology (factor 19);
TGCT	cis	rs832540	0.656	rs702689	chr5:56177443	G/A	cg24531977	chr5:56204891	C5orf35	-0.53	-5.12	-0.42	1.12e-6	Coronary artery disease;
TGCT	trans	rs35851103	0.627	rs58602899	chr8:11848833	G/T	cg06636001	chr8:8085503	FLJ10661	0.76	7.14	0.54	7.04e-11	Neuroticism;
TGCT	cis	rs899997	1.000	rs7182567	chr15:79045054	A/G	cg04896959	chr15:78267971	NA	0.33	4.66	0.39	8.03e-6	Coronary artery disease or large artery stroke;
TGCT	cis	rs9911578	0.967	rs6503883	chr17:56917543	C/T	cg12560992	chr17:57184187	TRIM37	0.76	9.21	0.64	1.03e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs3820068	0.637	rs4646080	chr1:15826627	A/T	cg05660106	chr1:15850417	CASP9	1.16	14.82	0.8	3.11e-29	Systolic blood pressure;
TGCT	cis	rs10875595	0.732	rs62378370	chr5:140679460	T/C	cg24830062	chr5:140700576	TAF7	-0.63	-5.29	-0.43	5.35e-7	Pulmonary function decline;
TGCT	cis	rs4389656	0.767	rs369769	chr5:6720712	T/C	cg10857441	chr5:6722123	POLS	-0.22	-4.86	-0.4	3.44e-6	Coronary artery disease;
TGCT	cis	rs9611565	1.000	rs1109151	chr22:41752944	A/G	cg17554472	chr22:41940697	POLR3H	-0.46	-5.12	-0.42	1.13e-6	Vitiligo;
TGCT	cis	rs11098499	0.863	rs34868248	chr4:120442430	A/G	cg09307838	chr4:120376055	NA	0.69	6.53	0.51	1.49e-9	Corneal astigmatism;
TGCT	cis	rs427394	0.582	rs274667	chr5:6710771	A/G	cg10857441	chr5:6722123	POLS	0.28	6.07	0.48	1.45e-8	Menopause (age at onset);
TGCT	cis	rs62244186	0.659	rs56234157	chr3:44516221	G/A	cg21672276	chr3:44754072	ZNF502	-0.41	-4.67	-0.39	7.86e-6	Depressive symptoms;
TGCT	cis	rs2404602	1.000	rs12148786	chr15:76800362	A/G	cg22467129	chr15:76604101	ETFA	-0.47	-5.23	-0.43	6.85e-7	Blood metabolite levels;
TGCT	cis	rs6988636	1.000	rs13261100	chr8:124190312	G/A	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs1048238	0.506	rs12039892	chr1:16167974	A/G	cg21385522	chr1:16154831	NA	0.58	6.61	0.51	1.03e-9	Systolic blood pressure;
TGCT	cis	rs2439831	1.000	rs2444029	chr15:43737484	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.8	5.7	0.46	8.33e-8	Lung cancer in ever smokers;
TGCT	trans	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg17830980	chr10:43048298	ZNF37B	-0.81	-10.13	-0.67	6.19e-18	Extrinsic epigenetic age acceleration;
TGCT	cis	rs6964587	1.000	rs36021614	chr7:91717490	C/G	cg22709100	chr7:91322751	NA	0.29	4.8	0.4	4.45e-6	Breast cancer;
TGCT	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg08280861	chr8:58055591	NA	0.4	4.73	0.39	5.97e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs67311347	1.000	rs4973997	chr3:40460145	G/A	cg17264618	chr3:40429014	ENTPD3	0.32	4.76	0.39	5.36e-6	Renal cell carcinoma;
TGCT	cis	rs4776059	1.000	rs8026800	chr15:52933548	C/G	cg25063058	chr15:52860530	ARPP19	0.51	4.64	0.38	8.56e-6	Schizophrenia;
TGCT	cis	rs6969780	0.630	rs10238095	chr7:27196643	A/G	cg17457637	chr7:27170717	HOXA4	-0.44	-4.61	-0.38	9.74e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg26338869	chr17:61819248	STRADA	-0.53	-4.9	-0.4	2.95e-6	Prudent dietary pattern;
TGCT	cis	rs66573146	0.831	rs6851488	chr4:6987412	C/T	cg00086871	chr4:6988644	TBC1D14	0.96	4.89	0.4	3.1e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg12756686	chr19:29218302	NA	0.68	6.47	0.5	2e-9	Methadone dose in opioid dependence;
TGCT	cis	rs6598955	0.671	rs8564	chr1:26605069	T/C	cg04990556	chr1:26633338	UBXN11	0.66	5.0	0.41	1.88e-6	Obesity-related traits;
TGCT	cis	rs7552404	1.000	rs12126607	chr1:76217097	G/A	cg03433033	chr1:76189801	ACADM	0.81	9.52	0.65	1.84e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs17221829	0.733	rs7942295	chr11:89372341	T/G	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.63	-0.38	9.04e-6	Anxiety in major depressive disorder;
TGCT	cis	rs7267979	1.000	rs2482919	chr20:25299756	T/C	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7043114	0.525	rs10820964	chr9:95041636	G/A	cg14311495	chr9:95764742	FGD3	-0.22	-4.44	-0.37	1.95e-5	Height;
TGCT	cis	rs2014572	0.870	rs10426580	chr19:57756221	G/A	cg24459738	chr19:57751996	ZNF805	-0.54	-5.4	-0.44	3.21e-7	Hyperactive-impulsive symptoms;
TGCT	cis	rs2204008	0.577	rs11520050	chr12:38051839	G/A	cg13010199	chr12:38710504	ALG10B	0.65	5.29	0.43	5.47e-7	Bladder cancer;
TGCT	cis	rs6867032	1.000	rs61177713	chr5:2017255	G/A	cg26168224	chr5:2018326	NA	0.44	8.03	0.59	6.26e-13	Gut microbiome composition (winter);
TGCT	trans	rs208520	0.690	rs207094	chr6:66799009	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-10.83	-0.7	1.19e-19	Exhaled nitric oxide output;
TGCT	cis	rs1577917	0.958	rs2324840	chr6:86557620	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.29	-0.43	5.34e-7	Response to antipsychotic treatment;
TGCT	cis	rs12220777	1.000	rs11201660	chr10:81854531	A/G	cg07370745	chr10:80921785	ZMIZ1	-0.29	-4.5	-0.37	1.56e-5	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs1670533	0.932	rs2248083	chr4:1052166	A/C	cg27284194	chr4:1044797	NA	0.7	5.91	0.47	3.12e-8	Recombination rate (females);
TGCT	cis	rs7760949	0.888	rs6939712	chr6:13897246	T/C	cg27413430	chr6:13925136	RNF182	0.54	4.94	0.41	2.44e-6	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs988712	0.705	rs16917204	chr11:27668355	G/C	cg10635145	chr11:27742435	BDNF	-0.38	-5.25	-0.43	6.38e-7	Obesity;
TGCT	cis	rs9486715	0.838	rs9320127	chr6:96865358	G/A	cg06623918	chr6:96969491	KIAA0776	1.11	16.62	0.83	2.35e-33	Headache;
TGCT	cis	rs1153858	1.000	rs28679834	chr15:45616206	C/T	cg14582100	chr15:45693742	SPATA5L1	0.45	5.06	0.41	1.48e-6	Homoarginine levels;
TGCT	cis	rs2760061	0.626	rs596208	chr1:228117982	G/C	cg18477163	chr1:228402036	OBSCN	-0.32	-6.37	-0.5	3.37e-9	Diastolic blood pressure;
TGCT	cis	rs2235642	0.821	rs8051895	chr16:1602811	A/G	cg10465839	chr16:1584050	IFT140;TMEM204	-0.31	-5.23	-0.43	7.02e-7	Coronary artery disease;
TGCT	cis	rs3892630	0.588	rs2112917	chr19:33317543	C/T	cg22980127	chr19:33182716	NUDT19	0.75	6.02	0.48	1.81e-8	Red blood cell traits;
TGCT	cis	rs9359856	0.510	rs17293240	chr6:90396370	C/T	cg13799429	chr6:90582589	CASP8AP2	0.45	4.66	0.39	7.9e-6	Bipolar disorder;
TGCT	cis	rs4891159	0.790	rs17059379	chr18:74160316	A/T	cg24786174	chr18:74118243	ZNF516	0.53	7.34	0.55	2.46e-11	Longevity;
TGCT	cis	rs7772486	0.875	rs2224121	chr6:146343214	G/A	cg05347473	chr6:146136440	FBXO30	0.55	5.21	0.42	7.57e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs42648	0.596	rs6465251	chr7:89847881	C/G	cg25739043	chr7:89950458	NA	-0.49	-4.69	-0.39	7.02e-6	Homocysteine levels;
TGCT	cis	rs7666738	0.830	rs28761309	chr4:98867393	C/T	cg17366294	chr4:99064904	C4orf37	0.7	7.27	0.55	3.62e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2046867	0.583	rs13316962	chr3:72911994	T/C	cg25664220	chr3:72788482	NA	-0.41	-5.43	-0.44	2.86e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs1577917	1.000	rs117907570	chr6:86601283	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.16	-0.42	9.71e-7	Response to antipsychotic treatment;
TGCT	cis	rs3796352	1.000	rs36090694	chr3:53010742	T/C	cg27565382	chr3:53032988	SFMBT1	0.45	4.58	0.38	1.14e-5	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs2456568	0.900	rs2511399	chr11:93682156	C/T	cg26875233	chr11:93583750	C11orf90	0.42	5.4	0.44	3.3e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs10751667	0.643	rs11246348	chr11:939476	G/C	cg06064525	chr11:970664	AP2A2	-0.35	-8.09	-0.59	4.54e-13	Alzheimer's disease (late onset);
TGCT	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg03303774	chr4:1407052	NA	0.38	6.07	0.48	1.45e-8	Obesity-related traits;
TGCT	cis	rs11122272	0.735	rs2808585	chr1:231514218	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.14	-0.54	6.86e-11	Hemoglobin concentration;
TGCT	cis	rs67460515	0.665	rs28384382	chr3:160939141	C/T	cg03342759	chr3:160939853	NMD3	-0.47	-4.87	-0.4	3.28e-6	Parkinson's disease;
TGCT	cis	rs422249	0.819	rs174611	chr11:61627881	T/C	cg01500311	chr11:61656094	FADS3	-0.33	-5.41	-0.44	3.14e-7	Trans fatty acid levels;
TGCT	cis	rs2721195	0.549	rs2620666	chr8:145703413	T/C	cg15320075	chr8:145703422	NA	0.74	8.18	0.59	2.87e-13	Age at first birth;
TGCT	cis	rs6992820	0.967	rs4737418	chr8:56711267	A/G	cg06880721	chr8:56792545	LYN	-0.55	-4.74	-0.39	5.71e-6	Mean platelet volume;
TGCT	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.57	-4.64	-0.38	8.62e-6	Tonsillectomy;
TGCT	cis	rs9399135	0.967	rs4637662	chr6:135298158	T/C	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.36e-6	Red blood cell count;
TGCT	cis	rs682748	0.810	rs1482345	chr5:17114704	G/A	cg23987134	chr5:17158319	LOC285696	-0.21	-4.9	-0.4	2.87e-6	Hippocampal atrophy;
TGCT	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg00814883	chr7:100076585	TSC22D4	-0.9	-9.56	-0.65	1.5e-16	Platelet count;
TGCT	cis	rs561341	0.609	rs7209493	chr17:30197323	A/G	cg13647721	chr17:30228624	UTP6	-0.63	-4.61	-0.38	9.72e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs9653442	0.564	rs7565895	chr2:100774773	G/A	cg07810366	chr2:100720526	AFF3	-0.34	-5.13	-0.42	1.1e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg16049864	chr8:95962084	TP53INP1	-0.77	-10.92	-0.7	7.16e-20	Type 2 diabetes;
TGCT	cis	rs7226408	0.857	rs7234586	chr18:34434634	G/C	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs7727544	0.606	rs10060615	chr5:131708877	T/C	cg24060327	chr5:131705240	SLC22A5	-0.51	-5.43	-0.44	2.85e-7	Blood metabolite levels;
TGCT	cis	rs939574	0.512	rs908197	chr2:220144410	G/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.74	4.89	0.4	3.07e-6	Platelet distribution width;
TGCT	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg06713675	chr4:122721982	EXOSC9	-0.69	-9.7	-0.66	6.92e-17	Type 2 diabetes;
TGCT	cis	rs5769707	0.967	rs9616333	chr22:50050847	G/A	cg20744362	chr22:50050164	C22orf34	0.28	4.59	0.38	1.06e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs603446	0.967	rs180346	chr11:116612659	A/C	cg20608306	chr11:116969690	SIK3	0.41	4.54	0.38	1.3e-5	Triglycerides;
TGCT	cis	rs6087771	0.821	rs6058444	chr20:30315137	A/G	cg18721089	chr20:30220636	NA	-0.36	-4.46	-0.37	1.82e-5	Subcortical brain region volumes;Putamen volume;
TGCT	cis	rs9914544	0.545	rs68046274	chr17:18785126	G/A	cg26378065	chr17:18585709	ZNF286B	0.53	4.63	0.38	9.01e-6	Educational attainment (years of education);
TGCT	cis	rs66573146	0.831	rs67602077	chr4:7024244	A/G	cg01220768	chr4:7056774	TADA2B	0.41	5.07	0.41	1.43e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs6540559	0.673	rs926346	chr1:209962204	A/T	cg22029157	chr1:209979665	IRF6	0.75	5.58	0.45	1.45e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs2820315	0.867	rs2820322	chr1:201880300	T/C	cg12730843	chr1:201915899	LMOD1	-0.26	-4.9	-0.4	2.91e-6	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
TGCT	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg02725872	chr8:58115012	NA	-0.38	-4.69	-0.39	6.95e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7772486	0.817	rs12198065	chr6:146385286	G/C	cg05347473	chr6:146136440	FBXO30	0.56	5.22	0.42	7.31e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1372520	0.745	rs2736994	chr4:90784528	A/G	cg20003494	chr4:90757398	SNCA	-0.6	-4.65	-0.39	8.35e-6	Neuroticism;
TGCT	cis	rs56104184	0.830	rs17272658	chr19:49355405	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.84	-10.28	-0.68	2.68e-18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs11025559	0.716	rs1596376	chr11:20454229	T/C	cg19653624	chr11:20408972	PRMT3	-0.64	-5.07	-0.41	1.43e-6	Pursuit maintenance gain;
TGCT	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg18230493	chr5:56204884	C5orf35	-0.68	-5.92	-0.47	2.92e-8	Initial pursuit acceleration;
TGCT	cis	rs11167764	1.000	rs11167764	chr5:141479065	A/C	cg08523384	chr5:141488047	NDFIP1	-0.23	-4.54	-0.38	1.31e-5	Crohn's disease;
TGCT	cis	rs2242116	0.727	rs10865943	chr3:46969970	T/C	cg02527881	chr3:46936655	PTH1R	-0.28	-5.21	-0.42	7.75e-7	Birth weight;
TGCT	cis	rs2456568	0.802	rs8181578	chr11:93637442	G/A	cg14065697	chr11:93583672	C11orf90	-0.38	-4.74	-0.39	5.65e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs2251381	0.750	rs2251186	chr21:30528880	G/A	cg24692254	chr21:30365293	RNF160	0.74	6.96	0.53	1.76e-10	Selective IgA deficiency;
TGCT	cis	rs2239547	0.562	rs35380116	chr3:52979178	A/G	cg10802521	chr3:52805072	NEK4	0.64	6.1	0.48	1.26e-8	Schizophrenia;
TGCT	cis	rs6138458	1.000	rs227632	chr20:24913729	G/A	cg26195577	chr20:24973756	C20orf3	1.2	12.06	0.73	1.2e-22	Blood protein levels;
TGCT	cis	rs950169	0.922	rs12906983	chr15:84931022	G/A	cg11189052	chr15:85197271	WDR73	0.81	6.12	0.48	1.12e-8	Schizophrenia;
TGCT	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg06873352	chr17:61820015	STRADA	0.58	6.38	0.5	3.2e-9	Prudent dietary pattern;
TGCT	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg05665937	chr4:1216051	CTBP1	0.24	4.53	0.38	1.37e-5	Obesity-related traits;
TGCT	cis	rs2153535	0.580	rs1414349	chr6:8472290	A/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs35934224	0.783	rs13053818	chr22:19859652	G/A	cg11182965	chr22:19864308	TXNRD2	-0.39	-5.13	-0.42	1.1e-6	Glaucoma (primary open-angle);
TGCT	cis	rs9914988	0.943	rs9891925	chr17:27104540	A/T	cg20469991	chr17:27169893	C17orf63	-0.72	-5.04	-0.41	1.58e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs877282	0.945	rs17293517	chr10:778770	C/T	cg17470449	chr10:769945	NA	0.3	4.71	0.39	6.53e-6	Uric acid levels;
TGCT	cis	rs1055129	0.584	rs9895947	chr17:73908566	A/C	cg08125733	chr17:73851984	WBP2	0.6	5.46	0.44	2.55e-7	White matter hyperintensity burden;
TGCT	trans	rs4662986	0.579	rs72858968	chr2:130475906	G/T	cg16461102	chr3:14508078	SLC6A6	0.41	6.92	0.53	2.1e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs2468186	0.583	rs2450068	chr8:120095859	C/G	cg02248809	chr8:120845432	TAF2	-0.45	-4.83	-0.4	3.99e-6	Osteoprotegerin levels;
TGCT	cis	rs7914558	0.966	rs10786725	chr10:104682357	T/C	cg04362960	chr10:104952993	NT5C2	0.58	5.15	0.42	9.77e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs6450176	1.000	rs60652351	chr5:53306140	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.49	-4.6	-0.38	1.03e-5	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg05665937	chr4:1216051	CTBP1	0.24	4.65	0.39	8.32e-6	Obesity-related traits;
TGCT	cis	rs9443645	0.901	rs4415132	chr6:79554107	T/C	cg09184832	chr6:79620586	NA	-0.48	-5.35	-0.43	4.01e-7	Intelligence (multi-trait analysis);
TGCT	trans	rs34816374	1	rs34816374	chr6:26949672	A/G	cg20516262	chr7:155325649	CNPY1	0.63	7.11	0.54	7.99e-11	Lung cancer in ever smokers;
TGCT	trans	rs208520	0.690	rs1318604	chr6:66825278	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-10.72	-0.69	2.28e-19	Exhaled nitric oxide output;
TGCT	trans	rs3780486	0.846	rs7873903	chr9:33142728	G/A	cg20290983	chr6:43655470	MRPS18A	1.19	14.23	0.79	7.61e-28	IgG glycosylation;
TGCT	cis	rs9368481	0.645	rs10456350	chr6:26975581	A/C	cg18867708	chr6:26865862	GUSBL1	0.38	4.94	0.41	2.45e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs72615157	0.606	rs941288	chr7:99776808	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.62	4.87	0.4	3.34e-6	Lung function (FEV1/FVC);
TGCT	cis	rs854765	0.647	rs854808	chr17:18006634	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	7.52	0.56	9.79e-12	Total body bone mineral density;
TGCT	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg16423285	chr20:60520624	NA	-0.74	-9.17	-0.64	1.28e-15	Obesity-related traits;
TGCT	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg17178900	chr1:205818956	PM20D1	0.41	4.56	0.38	1.19e-5	Menarche (age at onset);
TGCT	cis	rs2204008	0.537	rs28680519	chr12:38502946	C/T	cg13010199	chr12:38710504	ALG10B	0.55	4.71	0.39	6.6e-6	Bladder cancer;
TGCT	cis	rs910316	0.935	rs11159119	chr14:75636967	C/T	cg08847533	chr14:75593920	NEK9	-0.94	-10.45	-0.68	1.01e-18	Height;
TGCT	cis	rs3026101	0.671	rs2407	chr17:5289028	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.49	4.88	0.4	3.23e-6	Body mass index;
TGCT	cis	rs2404602	0.716	rs17362383	chr15:76650702	A/G	cg26408565	chr15:76604113	ETFA	-0.4	-5.27	-0.43	5.85e-7	Blood metabolite levels;
TGCT	cis	rs6840360	1.000	rs751012	chr4:152602247	A/C	cg17479576	chr4:152424074	FAM160A1	-0.52	-5.66	-0.45	9.86e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs13424612	1.000	rs10193610	chr2:240940618	A/G	cg26363272	chr2:240904871	NDUFA10	0.3	5.06	0.41	1.46e-6	Odorant perception (isobutyraldehyde);
TGCT	cis	rs6089584	0.586	rs1079755	chr20:60615262	G/A	cg06108461	chr20:60628389	TAF4	-0.42	-5.27	-0.43	5.89e-7	Body mass index;
TGCT	cis	rs2637266	0.703	rs846643	chr10:78516889	T/G	cg18941641	chr10:78392320	NA	0.4	4.79	0.4	4.63e-6	Pulmonary function;
TGCT	cis	rs28785552	0.966	rs7247272	chr19:53236331	C/T	cg10871876	chr19:53194124	ZNF83	-0.58	-8.76	-0.62	1.22e-14	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg24549020	chr5:56110836	MAP3K1	0.7	5.97	0.47	2.34e-8	Initial pursuit acceleration;
TGCT	cis	rs10193935	0.901	rs6733914	chr2:42674741	A/G	cg27598129	chr2:42591480	NA	0.4	5.56	0.45	1.61e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7524258	0.900	rs2412151	chr1:7303216	G/C	cg04342483	chr1:7259290	CAMTA1	-0.3	-4.48	-0.37	1.69e-5	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs7191700	0.578	rs243324	chr16:11354970	A/G	cg00044050	chr16:11439710	C16orf75	0.84	8.69	0.62	1.79e-14	Multiple sclerosis;
TGCT	cis	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg08045932	chr20:61659980	NA	0.48	9.16	0.64	1.36e-15	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7772486	0.754	rs6910790	chr6:146255330	G/A	cg05347473	chr6:146136440	FBXO30	-0.51	-4.95	-0.41	2.32e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs59698941	0.550	rs12652469	chr5:132182765	A/G	cg27099455	chr5:132201840	GDF9;UQCRQ	0.29	4.94	0.41	2.52e-6	Apolipoprotein A-IV levels;
TGCT	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg11644478	chr21:40555479	PSMG1	1.02	10.63	0.69	3.73e-19	Cognitive function;
TGCT	cis	rs6546537	1.000	rs4852867	chr2:69831449	G/A	cg10773587	chr2:69614142	GFPT1	-0.65	-5.82	-0.46	4.67e-8	Serum thyroid-stimulating hormone levels;
TGCT	cis	rs933688	1.000	rs2367353	chr5:90686568	G/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.89	8.17	0.59	2.94e-13	Smoking behavior;
TGCT	cis	rs8016982	0.657	rs8021125	chr14:81704787	C/T	cg02996355	chr14:81879375	NA	-0.44	-4.5	-0.37	1.56e-5	Schizophrenia;
TGCT	cis	rs514406	0.505	rs269290	chr1:53167027	A/T	cg22166914	chr1:53195759	ZYG11B	0.44	7.66	0.57	4.64e-12	Monocyte count;
TGCT	cis	rs231513	0.911	rs231511	chr17:41966335	T/C	cg26893861	chr17:41843967	DUSP3	-0.75	-5.3	-0.43	5.18e-7	Cognitive function;
TGCT	cis	rs7582180	0.630	rs13021801	chr2:100935129	C/A	cg14675211	chr2:100938903	LONRF2	0.51	4.98	0.41	2.11e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs60871478	0.636	rs4719520	chr7:875216	C/G	cg00475322	chr7:917719	C7orf20	0.49	4.79	0.39	4.72e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs6964587	0.869	rs34791781	chr7:91532720	C/T	cg17063962	chr7:91808500	NA	-0.86	-9.28	-0.64	6.82e-16	Breast cancer;
TGCT	cis	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg07424592	chr7:64974309	NA	1.4	8.42	0.6	7.87e-14	Diabetic kidney disease;
TGCT	cis	rs10779751	0.734	rs2791658	chr1:11127871	A/G	cg08854313	chr1:11322531	MTOR	0.82	7.04	0.53	1.19e-10	Body mass index;
TGCT	cis	rs7147624	0.532	rs72716459	chr14:66260654	C/T	cg03016385	chr14:66212404	NA	0.52	6.0	0.47	2.03e-8	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.34	0.55	2.43e-11	Prudent dietary pattern;
TGCT	trans	rs2469997	1.000	rs2447179	chr8:120355775	A/G	cg01792902	chr3:178864926	PIK3CA	0.78	6.66	0.51	7.93e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs6912958	0.582	rs242285	chr6:88070743	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.7	7.33	0.55	2.64e-11	Monocyte percentage of white cells;
TGCT	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg23708337	chr7:1209742	NA	0.5	4.44	0.37	1.98e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs8017423	0.904	rs11848894	chr14:90723660	C/A	cg04374321	chr14:90722782	PSMC1	0.76	7.71	0.57	3.59e-12	Mortality in heart failure;
TGCT	cis	rs6570726	0.935	rs408768	chr6:145871735	A/G	cg05347473	chr6:146136440	FBXO30	0.49	4.54	0.38	1.29e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3617	0.652	rs60332615	chr3:52867595	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	-0.48	-4.53	-0.38	1.35e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9788682	0.747	rs11637630	chr15:78899719	G/A	cg24631222	chr15:78858424	CHRNA5	-0.88	-6.66	-0.51	7.79e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	trans	rs877282	0.853	rs11593836	chr10:756715	G/A	cg22713356	chr15:30763199	NA	1.07	8.27	0.6	1.75e-13	Uric acid levels;
TGCT	cis	rs727505	0.721	rs56069273	chr7:124768604	G/A	cg23710748	chr7:124431027	NA	-0.25	-4.63	-0.38	9.13e-6	Lewy body disease;
TGCT	cis	rs6700896	0.500	rs7549647	chr1:66088184	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.59	4.56	0.38	1.22e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.51	-4.96	-0.41	2.24e-6	Prudent dietary pattern;
TGCT	cis	rs12681287	0.547	rs11992656	chr8:87534869	T/A	cg27223183	chr8:87520930	FAM82B	0.94	6.91	0.53	2.24e-10	Caudate activity during reward;
TGCT	trans	rs4332037	0.539	rs55773130	chr7:2070554	T/C	cg25206134	chr2:45395956	NA	0.97	7.42	0.55	1.6e-11	Bipolar disorder;
TGCT	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg12311346	chr5:56204834	C5orf35	0.66	6.81	0.52	3.82e-10	Initial pursuit acceleration;
TGCT	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg22764044	chr5:178986830	RUFY1	0.42	4.53	0.38	1.38e-5	Lung cancer;
TGCT	cis	rs3806843	0.966	rs2337516	chr5:140140853	A/G	cg19875535	chr5:140030758	IK	-0.37	-6.21	-0.49	7.38e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs4788570	0.585	rs7499576	chr16:71789553	T/G	cg06353428	chr16:71660113	MARVELD3	1.52	11.66	0.72	1.15e-21	Intelligence (multi-trait analysis);
TGCT	cis	rs7552404	1.000	rs7533888	chr1:76160449	A/C	cg22875332	chr1:76189707	ACADM	0.79	9.77	0.66	4.68e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2204008	0.777	rs11179774	chr12:38219559	A/C	cg13010199	chr12:38710504	ALG10B	0.62	4.96	0.41	2.32e-6	Bladder cancer;
TGCT	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg27588902	chr6:42928151	GNMT	-0.56	-6.66	-0.51	7.89e-10	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs9549367	0.673	rs3751413	chr13:113854715	C/T	cg00898013	chr13:113819073	PROZ	0.49	6.46	0.5	2.19e-9	Platelet distribution width;
TGCT	cis	rs7027203	0.828	rs10761288	chr9:96609363	C/T	cg14396892	chr9:96623032	NA	-0.25	-4.91	-0.4	2.78e-6	DNA methylation (variation);
TGCT	cis	rs992157	0.932	rs1473901	chr2:219188838	C/T	cg00012203	chr2:219082015	ARPC2	0.69	6.89	0.53	2.46e-10	Colorectal cancer;
TGCT	cis	rs7216064	0.700	rs4791295	chr17:65997317	G/A	cg12091567	chr17:66097778	LOC651250	-0.97	-7.46	-0.56	1.29e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs9393777	0.513	rs13210025	chr6:26654817	A/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.59	-4.66	-0.39	8.03e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9787249	0.915	rs58589165	chr1:40213670	A/T	cg19912559	chr1:40204330	PPIE	0.49	5.7	0.46	8.41e-8	Blood protein levels;
TGCT	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg05872129	chr22:39784769	NA	-1.01	-11.59	-0.72	1.71e-21	Intelligence (multi-trait analysis);
TGCT	cis	rs4879913	0.801	rs7849006	chr9:35592324	C/A	cg18130437	chr9:35658183	CCDC107;RMRP	-0.5	-4.95	-0.41	2.38e-6	Electroencephalogram traits;
TGCT	cis	rs877426	0.555	rs7988568	chr13:114826751	C/T	cg16820615	chr13:114884918	RASA3	0.33	5.2	0.42	8.08e-7	Facial morphology (factor 14, intercanthal width);
TGCT	cis	rs4919669	0.668	rs10883763	chr10:104427825	C/T	cg05855489	chr10:104503620	C10orf26	0.86	4.63	0.38	9.05e-6	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs797680	0.856	rs2765545	chr1:93677269	G/A	cg17826107	chr1:92977322	EVI5	-0.24	-5.29	-0.43	5.47e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs7772486	0.754	rs6932863	chr6:146021255	A/T	cg13319975	chr6:146136371	FBXO30	0.52	4.68	0.39	7.31e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg03351412	chr1:154909251	PMVK	0.53	4.93	0.4	2.6e-6	Prostate cancer;
TGCT	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg10047753	chr17:41438598	NA	0.96	9.64	0.65	9.37e-17	Menopause (age at onset);
TGCT	cis	rs9942416	0.660	rs4704231	chr5:74986576	G/A	cg19683494	chr5:74908142	NA	0.59	6.26	0.49	5.62e-9	Age-related disease endophenotypes;
TGCT	cis	rs6964587	0.967	rs10231496	chr7:91741132	T/C	cg17063962	chr7:91808500	NA	0.88	9.58	0.65	1.33e-16	Breast cancer;
TGCT	cis	rs2832191	0.636	rs8131283	chr21:30516796	A/G	cg24692254	chr21:30365293	RNF160	-0.61	-5.38	-0.43	3.62e-7	Dental caries;
TGCT	cis	rs1801251	1.000	rs35085837	chr2:233624363	A/G	cg25237894	chr2:233734115	C2orf82	0.33	5.95	0.47	2.53e-8	Coronary artery disease;
TGCT	trans	rs9650657	0.504	rs10093053	chr8:11037187	T/C	cg15556689	chr8:8085844	FLJ10661	-0.85	-8.36	-0.6	1.06e-13	Neuroticism;
TGCT	cis	rs13217239	0.646	rs6456767	chr6:27070543	C/T	cg26531700	chr6:26746687	NA	-0.7	-6.84	-0.52	3.25e-10	Schizophrenia;
TGCT	cis	rs7267979	0.966	rs2227892	chr20:25264814	T/C	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9291683	0.530	rs4235346	chr4:9945296	C/T	cg00071950	chr4:10020882	SLC2A9	-0.64	-7.56	-0.56	7.82e-12	Bone mineral density;
TGCT	cis	rs2243480	1.000	rs160643	chr7:65558222	C/T	cg20637647	chr7:64974828	NA	0.8	4.99	0.41	2.01e-6	Diabetic kidney disease;
TGCT	cis	rs4727027	0.635	rs12111923	chr7:148885877	G/A	cg23583168	chr7:148888333	NA	-0.69	-7.75	-0.57	2.82e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs3809863	0.646	rs9899121	chr17:45395144	C/T	cg25173405	chr17:45401733	C17orf57	-0.43	-4.71	-0.39	6.52e-6	Glaucoma (primary open-angle);
TGCT	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg22891161	chr3:195456627	MUC20	-0.23	-5.38	-0.44	3.53e-7	Pancreatic cancer;
TGCT	cis	rs2832191	0.791	rs2832186	chr21:30484151	A/C	cg24692254	chr21:30365293	RNF160	-0.92	-10.25	-0.68	3.21e-18	Dental caries;
TGCT	cis	rs6840360	0.532	rs4235221	chr4:152511193	C/T	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.0	-0.58	7.69e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.753	rs1830230	chr4:99026186	G/C	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg14983838	chr19:29218262	NA	0.83	6.81	0.52	3.8e-10	Methadone dose in opioid dependence;
TGCT	cis	rs2439831	0.557	rs13329084	chr15:44151063	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.8	-5.64	-0.45	1.1e-7	Lung cancer in ever smokers;
TGCT	cis	rs58688157	0.705	rs12290989	chr11:615010	G/T	cg16486109	chr11:613632	IRF7	0.36	5.26	0.43	6.02e-7	Systemic lupus erythematosus;
TGCT	cis	rs6964587	1.000	rs10264666	chr7:91578639	G/A	cg17063962	chr7:91808500	NA	-0.91	-9.88	-0.66	2.45e-17	Breast cancer;
TGCT	cis	rs7010267	0.805	rs2062375	chr8:119977792	G/C	cg17171407	chr8:119960777	TNFRSF11B	0.33	6.37	0.5	3.28e-9	Total body bone mineral density (age 45-60);
TGCT	cis	rs174479	0.677	rs174463	chr11:61657838	G/A	cg19610905	chr11:61596333	FADS2	0.58	5.05	0.41	1.56e-6	Sphingolipid levels;
TGCT	cis	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg22857025	chr5:266934	NA	-0.33	-6.34	-0.49	3.98e-9	Breast cancer;
TGCT	cis	rs7824557	0.564	rs12547100	chr8:11242632	G/A	cg21775007	chr8:11205619	TDH	-0.71	-6.97	-0.53	1.7e-10	Retinal vascular caliber;
TGCT	cis	rs593982	1.000	rs470360	chr11:65500530	T/C	cg08755490	chr11:65554678	OVOL1	1.42	12.09	0.74	1.03e-22	Atopic dermatitis;
TGCT	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg02493798	chr17:6899577	ALOX12	-0.43	-4.82	-0.4	4.17e-6	Tonsillectomy;
TGCT	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg22920501	chr2:26401640	FAM59B	-0.81	-6.36	-0.5	3.52e-9	Gut microbiome composition (summer);
TGCT	cis	rs736408	0.500	rs2878762	chr3:52919002	T/C	cg10802521	chr3:52805072	NEK4	-0.62	-6.2	-0.49	7.62e-9	Bipolar disorder;
TGCT	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg06400119	chr7:158046222	PTPRN2	0.37	5.87	0.47	3.82e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2299587	0.775	rs10113677	chr8:17767684	T/A	cg01800426	chr8:17659068	MTUS1	-0.62	-5.24	-0.43	6.56e-7	Economic and political preferences;
TGCT	cis	rs28595532	0.920	rs114684527	chr4:119749252	G/T	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9527	0.568	rs1926036	chr10:104883812	C/T	cg15744005	chr10:104629667	AS3MT	-0.43	-4.9	-0.4	2.89e-6	Arsenic metabolism;
TGCT	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg11644478	chr21:40555479	PSMG1	0.94	9.36	0.64	4.43e-16	Cognitive function;
TGCT	cis	rs832540	0.556	rs4146565	chr5:56093825	T/C	cg24531977	chr5:56204891	C5orf35	-0.54	-5.34	-0.43	4.33e-7	Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs1593572	chr4:98979322	A/G	cg18180107	chr4:99064573	C4orf37	-0.52	-4.85	-0.4	3.58e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs896854	0.684	rs10099941	chr8:95987008	C/T	cg23172400	chr8:95962367	TP53INP1	-0.36	-6.07	-0.48	1.44e-8	Type 2 diabetes;
TGCT	cis	rs6840360	0.606	rs2709813	chr4:152357444	T/C	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.83e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7927771	0.725	rs11570094	chr11:47359706	A/C	cg14716172	chr11:46724544	ZNF408	-0.17	-4.54	-0.38	1.32e-5	Subjective well-being;
TGCT	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg20203395	chr5:56204925	C5orf35	-0.59	-5.12	-0.42	1.12e-6	Initial pursuit acceleration;
TGCT	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg03709012	chr19:19516395	GATAD2A	0.74	6.07	0.48	1.44e-8	Tonsillectomy;
TGCT	cis	rs7027203	0.828	rs4744291	chr9:96598297	A/G	cg13679303	chr9:96623674	NA	-0.66	-10.78	-0.7	1.64e-19	DNA methylation (variation);
TGCT	cis	rs1878931	0.697	rs1044390	chr16:3432594	T/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.97	11.89	0.73	3.25e-22	Body mass index (adult);
TGCT	cis	rs77372450	0.551	rs61663448	chr5:157077191	T/C	cg12606933	chr5:157078573	SOX30	-0.42	-4.75	-0.39	5.48e-6	Bipolar disorder (body mass index interaction);
TGCT	cis	rs12497850	0.931	rs7621015	chr3:49016056	A/G	cg06212747	chr3:49208901	KLHDC8B	0.6	5.43	0.44	2.82e-7	Parkinson's disease;
TGCT	cis	rs72781680	0.768	rs112139157	chr2:24150783	A/C	cg08917208	chr2:24149416	ATAD2B	0.74	4.66	0.39	7.9e-6	Lymphocyte counts;
TGCT	cis	rs72627509	0.904	rs781663	chr4:57781754	A/G	cg26694713	chr4:57773883	REST	0.73	6.57	0.51	1.26e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs7909074	1.000	rs10751361	chr10:45398186	C/A	cg04218760	chr10:45406644	TMEM72	-0.27	-5.38	-0.44	3.57e-7	Mean corpuscular volume;
TGCT	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg23262073	chr20:60523788	NA	0.31	4.98	0.41	2.08e-6	Obesity-related traits;
TGCT	cis	rs4819052	0.959	rs9976074	chr21:46655638	G/T	cg06618935	chr21:46677482	NA	-0.33	-4.55	-0.38	1.27e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6460942	0.915	rs7803002	chr7:12306738	C/T	cg06484146	chr7:12443880	VWDE	-0.45	-4.68	-0.39	7.41e-6	Coronary artery disease;
TGCT	cis	rs5769765	0.908	rs4058453	chr22:50250297	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.97	6.32	0.49	4.22e-9	Schizophrenia;
TGCT	cis	rs921968	0.541	rs593888	chr2:219427597	A/G	cg02176678	chr2:219576539	TTLL4	0.48	6.78	0.52	4.32e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs2702888	0.563	rs2741064	chr8:6760152	C/T	cg26795848	chr8:6756730	NA	0.28	5.63	0.45	1.15e-7	Blood pressure;
TGCT	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg11062466	chr8:58055876	NA	0.34	4.64	0.38	8.58e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg00343986	chr7:65444356	GUSB	-0.23	-5.14	-0.42	1.06e-6	Aortic root size;
TGCT	cis	rs6665290	0.904	rs7541033	chr1:227188371	C/A	cg10327440	chr1:227177885	CDC42BPA	-0.98	-19.78	-0.87	3.72e-40	Myeloid white cell count;
TGCT	cis	rs2276314	1.000	rs56050783	chr18:33553791	A/G	cg19628046	chr18:33552617	C18orf21	0.52	4.46	0.37	1.8e-5	Endometriosis;Drug-induced torsades de pointes;
TGCT	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg22168489	chr12:122356033	WDR66	0.22	4.78	0.39	4.96e-6	Mean corpuscular volume;
TGCT	cis	rs6840360	0.615	rs28659854	chr4:152607442	T/C	cg22705602	chr4:152727874	NA	-0.32	-5.44	-0.44	2.76e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs797680	0.964	rs4000699	chr1:93779805	C/T	cg17826107	chr1:92977322	EVI5	-0.23	-5.13	-0.42	1.1e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs9814567	1.000	rs7374325	chr3:134275601	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.96	-9.11	-0.63	1.79e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs1215050	0.791	rs6532702	chr4:98766641	C/T	cg17366294	chr4:99064904	C4orf37	0.52	5.59	0.45	1.4e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9291683	0.609	rs36084205	chr4:10028678	A/C	cg00071950	chr4:10020882	SLC2A9	0.7	9.43	0.65	3.06e-16	Bone mineral density;
TGCT	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.64	5.04	0.41	1.63e-6	Lung function (FEV1/FVC);
TGCT	cis	rs1691799	0.836	rs1168334	chr12:66760972	A/G	cg16791601	chr12:66731901	HELB	-0.28	-6.03	-0.48	1.74e-8	White blood cell count (basophil);
TGCT	cis	rs9394841	0.536	rs6899876	chr6:41796970	A/G	cg08135965	chr6:41755394	TOMM6	0.48	4.66	0.39	8.1e-6	Mean corpuscular hemoglobin;Red cell distribution width;
TGCT	cis	rs5750830	0.594	rs9611166	chr22:39775268	T/C	cg24399712	chr22:39784796	NA	-0.95	-11.01	-0.7	4.37e-20	Intelligence (multi-trait analysis);
TGCT	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg10053473	chr17:62856997	LRRC37A3	-0.46	-6.76	-0.52	4.77e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs6940638	0.956	rs72838268	chr6:27021173	A/G	cg16898833	chr6:26189333	HIST1H4D	0.78	5.81	0.46	5.05e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9653442	0.593	rs6737502	chr2:100862903	C/T	cg07810366	chr2:100720526	AFF3	-0.41	-6.26	-0.49	5.76e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs908922	0.676	rs7529136	chr1:152516389	T/C	cg20991723	chr1:152506922	NA	0.45	6.11	0.48	1.18e-8	Hair morphology;
TGCT	cis	rs2777491	0.540	rs7164684	chr15:41705008	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.93	-16.85	-0.83	7.39e-34	Ulcerative colitis;
TGCT	cis	rs1375194	0.606	rs2044644	chr2:33817559	A/G	cg04131969	chr2:33951647	MYADML	-0.56	-4.86	-0.4	3.51e-6	Response to antidepressants in depression;
TGCT	cis	rs7586879	0.789	rs11688754	chr2:25133885	C/T	cg01884057	chr2:25150051	NA	0.27	4.57	0.38	1.17e-5	Body mass index;
TGCT	cis	rs17376456	0.741	rs12374432	chr5:93481348	C/A	cg25358565	chr5:93447407	FAM172A	0.97	8.35	0.6	1.11e-13	Diabetic retinopathy;
TGCT	cis	rs611744	0.967	rs635219	chr8:109229243	C/T	cg21045802	chr8:109455806	TTC35	0.52	4.72	0.39	6.21e-6	Dupuytren's disease;
TGCT	cis	rs950776	0.642	rs922691	chr15:78963994	A/G	cg21242079	chr15:79101063	ADAMTS7	-0.32	-4.99	-0.41	1.99e-6	Sudden cardiac arrest;
TGCT	trans	rs77457752	0.525	rs10961293	chr9:13894250	A/G	cg18722840	chr3:134321018	KY	0.38	6.68	0.51	7.25e-10	Breast cancer;
TGCT	cis	rs12681288	0.523	rs73176528	chr8:961962	G/A	cg04851639	chr8:1020857	NA	-0.3	-5.08	-0.41	1.36e-6	Schizophrenia;
TGCT	cis	rs10791323	0.604	rs10791324	chr11:133704065	T/C	cg03690763	chr11:133734501	NA	-0.35	-5.39	-0.44	3.46e-7	Childhood ear infection;
TGCT	cis	rs7666738	0.822	rs17484018	chr4:98988960	G/A	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4455778	0.561	rs10243463	chr7:49081185	T/G	cg26309511	chr7:48887640	NA	0.5	6.47	0.5	2.03e-9	Lung cancer in never smokers;
TGCT	cis	rs1865760	0.516	rs9358903	chr6:26061949	A/C	cg17042849	chr6:26104293	HIST1H4C	-0.66	-5.85	-0.47	4.02e-8	Height;
TGCT	cis	rs713587	1.000	rs2384054	chr2:25156773	T/C	cg15423357	chr2:25149977	NA	0.63	6.43	0.5	2.55e-9	Body mass index in non-asthmatics;
TGCT	cis	rs10992471	0.603	rs11794346	chr9:95247288	C/T	cg14631576	chr9:95140430	CENPP	-0.3	-4.54	-0.38	1.3e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs4824093	0.610	rs77128035	chr22:50241024	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.45	4.65	0.39	8.43e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg08280861	chr8:58055591	NA	0.34	4.67	0.39	7.83e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6750047	0.605	rs2121260	chr2:38268763	T/G	cg07380506	chr2:38303506	CYP1B1	0.59	5.34	0.43	4.23e-7	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs3806843	0.576	rs246047	chr5:140328337	C/T	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs12142240	0.698	rs932816	chr1:46859749	G/A	cg00530320	chr1:46809349	NSUN4	0.29	5.79	0.46	5.34e-8	Menopause (age at onset);
TGCT	cis	rs9467773	1.000	rs9295695	chr6:26528250	C/T	cg09904177	chr6:26538194	HMGN4	-0.68	-6.89	-0.53	2.52e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.63	0.38	9.2e-6	Prudent dietary pattern;
TGCT	cis	rs9296092	0.517	rs7743064	chr6:33470529	C/T	cg13560919	chr6:33536144	NA	-0.22	-4.49	-0.37	1.6e-5	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	trans	rs1974653	0.672	rs11703058	chr22:20075048	G/A	cg08822737	chr17:71088851	SLC39A11	-0.93	-7.61	-0.56	5.97e-12	Schizophrenia;
TGCT	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	5.8	0.46	5.19e-8	Alzheimer's disease;
TGCT	cis	rs9611565	0.512	rs5751145	chr22:42133552	C/T	cg06481639	chr22:41940642	POLR3H	0.7	6.1	0.48	1.24e-8	Vitiligo;
TGCT	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg22800045	chr5:56110881	MAP3K1	0.54	4.49	0.37	1.58e-5	Initial pursuit acceleration;
TGCT	cis	rs36051895	0.589	rs7038763	chr9:5076399	T/C	cg02405213	chr9:5042618	JAK2	-0.85	-12.57	-0.75	7.24e-24	Pediatric autoimmune diseases;
TGCT	cis	rs12497850	0.931	rs9311434	chr3:48884147	T/C	cg06212747	chr3:49208901	KLHDC8B	0.62	5.83	0.46	4.42e-8	Parkinson's disease;
TGCT	cis	rs9902453	0.765	rs2729448	chr17:28091953	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.83	-8.18	-0.59	2.86e-13	Coffee consumption (cups per day);
TGCT	cis	rs7223966	1.000	rs8075273	chr17:61728881	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	4.57	0.38	1.16e-5	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg00786635	chr1:25594202	NA	-0.54	-5.68	-0.45	8.94e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs7552404	0.920	rs2788654	chr1:76219569	C/T	cg03433033	chr1:76189801	ACADM	0.75	8.76	0.62	1.19e-14	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs10782582	0.609	rs5745547	chr1:76378275	G/C	cg10523679	chr1:76189770	ACADM	-0.58	-5.24	-0.43	6.73e-7	Daytime sleep phenotypes;
TGCT	cis	rs796364	1.000	rs281794	chr2:200846666	C/T	cg17644776	chr2:200775616	C2orf69	0.31	4.87	0.4	3.37e-6	Schizophrenia;
TGCT	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg05368731	chr17:41323189	NBR1	-0.98	-11.0	-0.7	4.67e-20	Menopause (age at onset);
TGCT	cis	rs11190604	1.000	rs2495759	chr10:102320363	C/T	cg16342193	chr10:102329863	NA	-0.41	-5.35	-0.43	4.04e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs174479	0.743	rs174464	chr11:61657926	A/G	cg19610905	chr11:61596333	FADS2	0.58	5.05	0.41	1.56e-6	Sphingolipid levels;
TGCT	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg25767906	chr1:53392781	SCP2	0.6	7.27	0.55	3.5e-11	Monocyte count;
TGCT	cis	rs9653442	0.622	rs11685341	chr2:100636757	A/G	cg22139774	chr2:100720529	AFF3	0.4	7.07	0.54	9.96e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg07157834	chr1:205819609	PM20D1	0.43	6.75	0.52	4.97e-10	Menarche (age at onset);
TGCT	cis	rs11148252	0.904	rs7321964	chr13:53040822	A/G	cg00495681	chr13:53174319	NA	0.61	6.3	0.49	4.83e-9	Lewy body disease;
TGCT	cis	rs9640161	0.830	rs17173682	chr7:150059602	A/G	cg10018233	chr7:150070692	REPIN1	0.31	4.62	0.38	9.57e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg19626725	chr5:178986131	RUFY1	0.47	5.83	0.46	4.6e-8	Lung cancer;
TGCT	cis	rs7975161	0.630	rs6539128	chr12:104618454	A/G	cg25273343	chr12:104657179	TXNRD1	-0.42	-5.75	-0.46	6.64e-8	Toenail selenium levels;
TGCT	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.92	0.4	2.75e-6	Electroencephalogram traits;
TGCT	cis	rs2013441	1.000	rs2703772	chr17:20131453	C/A	cg18979559	chr17:20280153	CCDC144C	-0.44	-4.61	-0.38	9.78e-6	Obesity-related traits;
TGCT	cis	rs7267979	0.586	rs1007707	chr20:25190598	A/G	cg16686733	chr20:25566563	NINL	0.53	5.41	0.44	3.06e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs600231	0.665	rs1784859	chr11:65220749	A/G	cg17120908	chr11:65337727	SSSCA1	0.51	4.52	0.38	1.45e-5	Bone mineral density;
TGCT	cis	rs711245	0.573	rs7570763	chr2:36800589	A/C	cg01206211	chr2:36825736	FEZ2	-0.31	-4.91	-0.4	2.78e-6	Height;
TGCT	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg11905131	chr22:24372483	LOC391322	0.68	5.41	0.44	3.15e-7	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs1215050	0.904	rs9307215	chr4:98813965	A/G	cg05340658	chr4:99064831	C4orf37	0.46	5.57	0.45	1.49e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.5	-6.65	-0.51	8.34e-10	Lymphocyte counts;
TGCT	cis	rs61990749	0.597	rs8003691	chr14:78211225	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.62	4.58	0.38	1.13e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs1865760	0.566	rs9358902	chr6:26058570	C/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.78	7.49	0.56	1.1e-11	Height;
TGCT	cis	rs2549003	1.000	rs10068129	chr5:131821246	A/G	cg02551604	chr5:131831745	NA	0.92	12.4	0.74	1.83e-23	Asthma (sex interaction);
TGCT	cis	rs11105298	0.891	rs11105314	chr12:89924559	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.67	-4.91	-0.4	2.78e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.38	-4.66	-0.39	8.15e-6	Total body bone mineral density;
TGCT	cis	rs3820068	0.603	rs6429768	chr1:15963531	G/A	cg05660106	chr1:15850417	CASP9	0.83	8.19	0.59	2.78e-13	Systolic blood pressure;
TGCT	cis	rs7666738	0.546	rs9993299	chr4:98815976	G/A	cg17366294	chr4:99064904	C4orf37	0.65	6.1	0.48	1.27e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs77372450	0.551	rs11134891	chr5:157103373	G/A	cg12606933	chr5:157078573	SOX30	-0.42	-4.75	-0.39	5.51e-6	Bipolar disorder (body mass index interaction);
TGCT	cis	rs1371867	0.775	rs3020183	chr8:101233297	A/T	cg00191853	chr8:101177733	SPAG1	0.25	4.96	0.41	2.24e-6	Atrioventricular conduction;
TGCT	cis	rs2996428	0.709	rs12127399	chr1:3721609	G/A	cg17848003	chr1:3704513	LRRC47	0.17	4.57	0.38	1.14e-5	Red cell distribution width;
TGCT	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg14416726	chr6:151773293	C6orf211;RMND1	-1.05	-14.4	-0.79	3.16e-28	Menarche (age at onset);
TGCT	cis	rs4149178	0.656	rs11753396	chr6:43290742	A/C	cg07522644	chr6:43142093	SRF	0.7	4.99	0.41	1.96e-6	Urate levels;
TGCT	cis	rs17108533	0.588	rs12893741	chr14:71302862	A/G	cg23900759	chr14:71108106	TTC9	1.15	4.79	0.39	4.73e-6	Response to antipsychotic treatment in schizophrenia (reasoning);
TGCT	cis	rs7147624	0.572	rs72714470	chr14:65979173	G/A	cg03016385	chr14:66212404	NA	0.6	6.75	0.52	4.98e-10	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs910316	1.000	rs10146482	chr14:75574087	C/T	cg08847533	chr14:75593920	NEK9	0.97	11.14	0.71	2.07e-20	Height;
TGCT	cis	rs12291225	0.546	rs12795545	chr11:14355564	G/A	cg19336497	chr11:14380999	RRAS2	-0.45	-7.25	-0.55	3.87e-11	Sense of smell;
TGCT	cis	rs10883723	0.810	rs7079810	chr10:104243883	C/T	cg05855489	chr10:104503620	C10orf26	-0.58	-5.06	-0.41	1.47e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs35306767	0.903	rs7067865	chr10:908387	C/T	cg26597838	chr10:835615	NA	0.75	10.61	0.69	4.13e-19	Eosinophil percentage of granulocytes;
TGCT	cis	rs763014	0.931	rs2071981	chr16:630025	C/G	cg00908189	chr16:619842	PIGQ	0.87	10.5	0.69	7.53e-19	Height;
TGCT	cis	rs7043114	0.507	rs10761154	chr9:95144086	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-5.59	-0.45	1.36e-7	Height;
TGCT	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.84	7.5	0.56	1.08e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs8028182	0.636	rs4886712	chr15:75812888	C/T	cg20655648	chr15:75932815	IMP3	0.59	4.62	0.38	9.55e-6	Sudden cardiac arrest;
TGCT	cis	rs2236918	0.710	rs2526700	chr1:242019999	C/A	cg04158730	chr1:242011433	EXO1	0.58	5.48	0.44	2.29e-7	Menopause (age at onset);
TGCT	cis	rs2455799	0.573	rs2654650	chr3:15779214	C/T	cg16303742	chr3:15540471	COLQ	-0.25	-4.88	-0.4	3.18e-6	Mean platelet volume;
TGCT	cis	rs6089584	0.566	rs6061964	chr20:60607536	G/A	cg13770153	chr20:60521292	NA	-0.39	-4.77	-0.39	5.17e-6	Body mass index;
TGCT	cis	rs10782582	0.609	rs78556436	chr1:76352875	G/A	cg10523679	chr1:76189770	ACADM	-0.58	-5.38	-0.43	3.6e-7	Daytime sleep phenotypes;
TGCT	cis	rs933688	1.000	rs4382199	chr5:90744228	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.03	8.7	0.62	1.68e-14	Smoking behavior;
TGCT	cis	rs8077889	0.672	rs1230397	chr17:41844689	A/G	cg26893861	chr17:41843967	DUSP3	1.15	21.87	0.89	2.21e-44	Triglycerides;
TGCT	cis	rs12477438	0.834	rs1563106	chr2:99701381	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-6.12	-0.48	1.13e-8	Chronic sinus infection;
TGCT	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg08280861	chr8:58055591	NA	0.38	4.46	0.37	1.81e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs72781680	0.821	rs17046004	chr2:24144873	A/G	cg08917208	chr2:24149416	ATAD2B	0.74	4.66	0.39	7.9e-6	Lymphocyte counts;
TGCT	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg04546413	chr19:29218101	NA	0.74	6.54	0.51	1.46e-9	Methadone dose in opioid dependence;
TGCT	cis	rs10875746	0.551	rs1471997	chr12:48723595	G/A	cg20731937	chr12:48336164	NA	0.57	4.5	0.37	1.52e-5	Longevity (90 years and older);
TGCT	cis	rs1799949	0.929	rs4792988	chr17:41437547	T/C	cg10047753	chr17:41438598	NA	0.85	7.86	0.58	1.56e-12	Menopause (age at onset);
TGCT	cis	rs3820928	0.874	rs4144328	chr2:227790187	A/C	cg11843606	chr2:227700838	RHBDD1	-0.53	-4.77	-0.39	5.13e-6	Pulmonary function;
TGCT	cis	rs3096299	0.933	rs2965824	chr16:89455306	A/G	cg06640241	chr16:89574553	SPG7	0.66	6.5	0.5	1.76e-9	Multiple myeloma (IgH translocation);
TGCT	cis	rs6752107	0.936	rs10192702	chr2:234206750	A/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.21	4.71	0.39	6.47e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs7010267	0.642	rs9969672	chr8:120006080	T/A	cg17171407	chr8:119960777	TNFRSF11B	0.32	6.05	0.48	1.62e-8	Total body bone mineral density (age 45-60);
TGCT	cis	rs7572733	0.534	rs10211202	chr2:198771941	A/G	cg00792783	chr2:198669748	PLCL1	0.56	5.11	0.42	1.21e-6	Dermatomyositis;
TGCT	cis	rs4631830	0.863	rs2611507	chr10:51518673	T/C	cg10326726	chr10:51549505	MSMB	-0.27	-5.3	-0.43	5.18e-7	Prostate-specific antigen levels;
TGCT	cis	rs931127	0.547	rs3886859	chr11:65458310	C/T	cg27068330	chr11:65405492	SIPA1	-0.63	-6.32	-0.49	4.26e-9	Systemic lupus erythematosus;
TGCT	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	4.87	0.4	3.32e-6	Menopause (age at onset);
TGCT	trans	rs941408	0.963	rs1640267	chr19:2789337	T/C	cg19676328	chr12:49525230	TUBA1B	-0.84	-7.6	-0.56	6.46e-12	Total cholesterol levels;
TGCT	cis	rs7929679	0.846	rs11032858	chr11:34794889	G/A	cg18414381	chr11:34642885	EHF	-0.23	-4.6	-0.38	1.03e-5	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
TGCT	cis	rs7226408	0.857	rs11664211	chr18:34461496	C/T	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.68	5.73	0.46	7.3e-8	Tonsillectomy;
TGCT	cis	rs9952991	0.566	rs482160	chr18:12855646	A/G	cg23598886	chr18:12777645	NA	0.55	4.77	0.39	5.06e-6	Inflammatory skin disease;
TGCT	cis	rs6964587	0.647	rs38801	chr7:92046327	G/T	cg17063962	chr7:91808500	NA	-0.59	-4.99	-0.41	2.03e-6	Breast cancer;
TGCT	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg03609598	chr5:56110824	MAP3K1	-0.61	-4.45	-0.37	1.9e-5	Initial pursuit acceleration;
TGCT	cis	rs950169	0.580	rs11636189	chr15:85193554	G/A	cg17173187	chr15:85201210	NMB	0.59	6.75	0.52	5.05e-10	Schizophrenia;
TGCT	cis	rs2228479	0.850	rs3785281	chr16:89824263	G/C	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs7647973	1.000	rs2312462	chr3:49601255	A/G	cg07636037	chr3:49044803	WDR6	0.62	5.14	0.42	1.06e-6	Menarche (age at onset);
TGCT	cis	rs7614311	0.731	rs56126667	chr3:63866286	A/G	cg22134162	chr3:63841271	THOC7	-0.39	-5.12	-0.42	1.14e-6	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	5.53	0.44	1.8e-7	Alzheimer's disease;
TGCT	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg22920501	chr2:26401640	FAM59B	0.72	5.76	0.46	6.28e-8	Gut microbiome composition (summer);
TGCT	cis	rs7818688	0.697	rs74633621	chr8:95981037	A/G	cg16049864	chr8:95962084	TP53INP1	0.54	4.64	0.38	8.87e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs782590	0.764	rs2054728	chr2:55818419	C/T	cg03859395	chr2:55845619	SMEK2	0.83	9.78	0.66	4.33e-17	Metabolic syndrome;
TGCT	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg18230493	chr5:56204884	C5orf35	-0.69	-5.98	-0.47	2.21e-8	Initial pursuit acceleration;
TGCT	cis	rs10254284	0.959	rs10275989	chr7:28159696	A/G	cg24719020	chr7:27187943	HOXA6	-0.32	-4.56	-0.38	1.22e-5	Lymphocyte percentage of white cells;Systemic lupus erythematosus;
TGCT	cis	rs875971	0.862	rs1167408	chr7:65556108	G/A	cg11764359	chr7:65958608	NA	-0.56	-4.82	-0.4	4.1e-6	Aortic root size;
TGCT	cis	rs13326165	0.715	rs11718125	chr3:52379420	T/C	cg07884673	chr3:53033167	SFMBT1	0.38	4.65	0.39	8.36e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs1371867	0.846	rs1660346	chr8:101312497	A/G	cg06002616	chr8:101225028	SPAG1	-0.56	-6.58	-0.51	1.2e-9	Atrioventricular conduction;
TGCT	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg10047753	chr17:41438598	NA	0.96	9.49	0.65	2.15e-16	Menopause (age at onset);
TGCT	cis	rs6089584	1.000	rs6089591	chr20:60570548	A/C	cg13770153	chr20:60521292	NA	-0.47	-6.05	-0.48	1.61e-8	Body mass index;
TGCT	cis	rs2046867	0.908	rs6779684	chr3:72787586	G/A	cg25664220	chr3:72788482	NA	-0.56	-7.03	-0.53	1.25e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9527	0.590	rs12415199	chr10:104895536	T/C	cg15744005	chr10:104629667	AS3MT	-0.43	-4.94	-0.41	2.45e-6	Arsenic metabolism;
TGCT	cis	rs6896969	0.510	rs10042027	chr5:40428811	G/A	cg01087697	chr5:40835557	RPL37	0.57	5.11	0.42	1.2e-6	Multiple sclerosis;
TGCT	cis	rs10779751	0.887	rs2300095	chr1:11265717	A/G	cg08854313	chr1:11322531	MTOR	0.99	9.21	0.64	1.04e-15	Body mass index;
TGCT	cis	rs10894604	0.558	rs11223204	chr11:132652554	A/G	cg16639665	chr11:133402497	OPCML	0.44	4.46	0.37	1.79e-5	Waist-hip ratio;
TGCT	trans	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg17470723	chr8:74884337	TCEB1	0.72	6.94	0.53	1.91e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg03351412	chr1:154909251	PMVK	0.52	4.87	0.4	3.31e-6	Prostate cancer;
TGCT	cis	rs62103177	0.810	rs62096745	chr18:77619135	A/G	cg12964065	chr18:77638022	KCNG2	0.37	4.76	0.39	5.4e-6	Opioid sensitivity;
TGCT	cis	rs9868809	0.772	rs2302295	chr3:48690110	T/C	cg15315015	chr3:49131774	QRICH1	0.8	4.58	0.38	1.1e-5	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs60154123	0.505	rs115881613	chr1:210040369	C/T	cg21951975	chr1:209979733	IRF6	0.69	5.18	0.42	8.74e-7	Coronary artery disease;
TGCT	cis	rs174601	0.861	rs174550	chr11:61571478	T/C	cg19610905	chr11:61596333	FADS2	-1.07	-12.03	-0.73	1.43e-22	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
TGCT	cis	rs12188164	0.686	rs72711370	chr5:421057	A/C	cg26850624	chr5:429559	AHRR	-0.21	-4.96	-0.41	2.23e-6	Cystic fibrosis severity;
TGCT	cis	rs9906944	0.707	rs12942084	chr17:47114392	A/G	cg20966754	chr17:47091339	IGF2BP1	-0.45	-5.17	-0.42	9.27e-7	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg17264618	chr3:40429014	ENTPD3	0.32	4.61	0.38	9.76e-6	Renal cell carcinoma;
TGCT	cis	rs2229238	0.911	rs60368585	chr1:154509340	T/C	cg13067139	chr1:155221277	FAM189B	0.2	4.51	0.38	1.47e-5	Coronary heart disease;
TGCT	cis	rs4455778	0.580	rs10259971	chr7:49085752	A/G	cg26309511	chr7:48887640	NA	0.5	6.47	0.5	2.03e-9	Lung cancer in never smokers;
TGCT	cis	rs4389656	0.743	rs34681760	chr5:6712834	T/C	cg10857441	chr5:6722123	POLS	-0.22	-4.87	-0.4	3.27e-6	Coronary artery disease;
TGCT	cis	rs7000551	0.527	rs11783730	chr8:22244897	C/T	cg12081754	chr8:22256438	SLC39A14	0.34	4.93	0.4	2.58e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs8032315	0.965	rs4932373	chr15:91429287	A/C	cg04510874	chr15:91427884	FES	0.52	5.76	0.46	6.28e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2880765	0.566	rs11630381	chr15:86012503	A/G	cg13263323	chr15:86062960	AKAP13	-0.21	-4.66	-0.39	8e-6	Coronary artery disease;
TGCT	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg18867708	chr6:26865862	GUSBL1	-0.38	-5.03	-0.41	1.65e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs303386	0.581	rs4000190	chr1:99592566	C/T	cg03593336	chr1:99471295	LPPR5	0.22	4.75	0.39	5.51e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors);Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin);
TGCT	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2456568	0.564	rs4608039	chr11:93624799	C/G	cg17595323	chr11:93583763	C11orf90	0.46	6.34	0.49	3.82e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs9467711	0.745	rs9467714	chr6:26340785	C/T	cg16898833	chr6:26189333	HIST1H4D	0.97	4.61	0.38	9.98e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7216064	0.684	rs8182243	chr17:66018505	T/C	cg12091567	chr17:66097778	LOC651250	1.07	8.8	0.62	9.68e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs11711311	0.712	rs6764048	chr3:113332859	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.6	4.88	0.4	3.15e-6	IgG glycosylation;
TGCT	cis	rs4319547	0.774	rs7954006	chr12:123131824	A/C	cg23029597	chr12:123009494	RSRC2	0.28	4.83	0.4	4e-6	Body mass index;
TGCT	cis	rs2180341	0.532	rs6933893	chr6:127707250	A/G	cg24812749	chr6:127587940	RNF146	0.62	5.38	0.44	3.5e-7	Breast cancer;
TGCT	cis	rs9318086	0.712	rs9510917	chr13:24442846	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.77	8.16	0.59	3.26e-13	Myopia (pathological);
TGCT	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs17152411	1.000	rs12573033	chr10:126607803	T/G	cg07906193	chr10:126599966	NA	0.42	5.28	0.43	5.6e-7	Height;
TGCT	cis	rs6882046	0.513	rs681446	chr5:88054292	C/T	cg22951263	chr5:87985283	NA	0.62	6.64	0.51	8.81e-10	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg22508957	chr16:3507546	NAT15	-0.49	-5.5	-0.44	2.08e-7	Tuberculosis;
TGCT	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg09704166	chr2:114031854	PAX8;LOC440839	-0.32	-4.82	-0.4	4.04e-6	Lymphocyte counts;
TGCT	cis	rs10197940	0.624	rs10497081	chr2:152353395	T/G	cg06191203	chr2:152266755	RIF1	-0.76	-7.11	-0.54	8.05e-11	Lung cancer;
TGCT	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg26818010	chr10:134567672	INPP5A	-0.35	-4.52	-0.38	1.42e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs17376456	0.825	rs67328989	chr5:93243133	T/A	cg21475434	chr5:93447410	FAM172A	0.71	4.91	0.4	2.86e-6	Diabetic retinopathy;
TGCT	cis	rs9430161	0.579	rs11576658	chr1:11037736	C/T	cg02454025	chr1:11042201	C1orf127	0.95	10.77	0.7	1.73e-19	Ewing sarcoma;
TGCT	cis	rs7666738	0.830	rs921523	chr4:98841659	C/T	cg17366294	chr4:99064904	C4orf37	0.66	6.56	0.51	1.34e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7666738	0.830	rs7691433	chr4:98968118	A/T	cg05340658	chr4:99064831	C4orf37	0.44	4.68	0.39	7.36e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9913156	0.793	rs55782417	chr17:4562845	G/A	cg00122941	chr17:4613640	ARRB2	0.87	7.38	0.55	1.95e-11	Lymphocyte counts;
TGCT	cis	rs6426558	0.537	rs4351610	chr1:227325245	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.58	-6.91	-0.53	2.21e-10	Neutrophil percentage of white cells;
TGCT	cis	rs4851266	1.000	rs11691409	chr2:100826165	T/A	cg07810366	chr2:100720526	AFF3	-0.38	-5.44	-0.44	2.7e-7	Educational attainment;
TGCT	cis	rs2236918	1.000	rs1635509	chr1:242028027	C/T	cg04158730	chr1:242011433	EXO1	0.52	4.59	0.38	1.07e-5	Menopause (age at onset);
TGCT	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg04944784	chr2:26401820	FAM59B	-0.67	-6.04	-0.48	1.63e-8	Gut microbiome composition (summer);
TGCT	cis	rs12477438	0.798	rs10167015	chr2:99570707	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-5.62	-0.45	1.19e-7	Chronic sinus infection;
TGCT	cis	rs35306767	0.903	rs12249828	chr10:894838	C/T	cg20503657	chr10:835505	NA	0.71	9.59	0.65	1.25e-16	Eosinophil percentage of granulocytes;
TGCT	cis	rs8038465	1.000	rs8041181	chr15:73982336	C/T	cg15420318	chr15:73925796	NPTN	0.69	6.42	0.5	2.6e-9	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs11677416	1.000	rs2071375	chr2:113535438	C/T	cg27083787	chr2:113543245	IL1A	0.17	4.46	0.37	1.85e-5	Response to antipsychotic treatment in schizophrenia (working memory);
TGCT	cis	rs75686122	0.881	rs116856209	chr8:104719961	T/A	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs10992471	0.580	rs4744143	chr9:95438627	A/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-4.59	-0.38	1.07e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs12142240	0.698	rs17361812	chr1:46814008	C/T	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	trans	rs1814175	0.791	rs11040513	chr11:49778153	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.38	-7.76	-0.57	2.75e-12	Height;
TGCT	cis	rs910316	1.000	rs3742778	chr14:75538217	A/C	cg11812906	chr14:75593930	NEK9	-0.74	-7.31	-0.55	2.84e-11	Height;
TGCT	cis	rs6519955	0.866	rs9626920	chr22:46428993	A/G	cg11242978	chr22:46423387	NA	-0.5	-4.54	-0.38	1.33e-5	Dupuytren's disease;
TGCT	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	0.7	7.04	0.53	1.14e-10	Prostate cancer;
TGCT	cis	rs62244186	0.659	rs56234157	chr3:44516221	G/A	cg04389838	chr3:44770851	ZNF501	-0.41	-5.69	-0.46	8.61e-8	Depressive symptoms;
TGCT	cis	rs28785552	0.769	rs11669363	chr19:53232321	C/A	cg10871876	chr19:53194124	ZNF83	0.49	6.66	0.51	7.95e-10	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs986417	0.818	rs7144656	chr14:61032909	A/G	cg27398547	chr14:60952738	C14orf39	1.49	10.43	0.68	1.12e-18	Gut microbiota (bacterial taxa);
TGCT	cis	rs78487399	0.908	rs6726404	chr2:43834163	C/T	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	-0.65	-4.56	-0.38	1.2e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs6450176	0.909	rs255755	chr5:53307772	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.5	-4.64	-0.38	8.56e-6	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg21963583	chr11:68658836	MRPL21	0.36	6.0	0.47	1.99e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs6687430	0.526	rs7555790	chr1:10613167	A/G	cg17425144	chr1:10567563	PEX14	-0.51	-5.89	-0.47	3.35e-8	Hand grip strength;
TGCT	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg14893161	chr1:205819251	PM20D1	0.65	10.64	0.69	3.58e-19	Menarche (age at onset);
TGCT	cis	rs3091242	0.967	rs3093614	chr1:25677844	T/A	cg23205692	chr1:25664452	TMEM50A	-0.5	-5.19	-0.42	8.32e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs9894429	0.546	rs55917554	chr17:79608776	T/C	cg21028142	chr17:79581711	NPLOC4	0.29	6.02	0.48	1.85e-8	Eye color traits;
TGCT	cis	rs9549367	0.713	rs2476319	chr13:113836519	C/T	cg00898013	chr13:113819073	PROZ	0.53	7.2	0.54	5.17e-11	Platelet distribution width;
TGCT	cis	rs2153535	0.580	rs4960421	chr6:8459292	C/T	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs17253792	0.731	rs3736876	chr14:56120178	T/C	cg01858014	chr14:56050164	KTN1	-0.35	-4.65	-0.39	8.23e-6	Putamen volume;
TGCT	cis	rs263156	0.967	rs263103	chr6:142875692	C/G	cg18419694	chr6:143832440	FUCA2	-0.38	-4.53	-0.38	1.36e-5	Ear morphology;Lobe size;Lobe attachment;
TGCT	trans	rs629535	0.821	rs497398	chr8:70037434	A/T	cg21567404	chr3:27674614	NA	0.58	9.18	0.64	1.22e-15	Dupuytren's disease;
TGCT	cis	rs4319547	0.956	rs10847179	chr12:123040985	T/C	cg23029597	chr12:123009494	RSRC2	-0.31	-5.09	-0.42	1.32e-6	Body mass index;
TGCT	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg17971929	chr21:40555470	PSMG1	-0.7	-6.32	-0.49	4.38e-9	Cognitive function;
TGCT	cis	rs939658	0.805	rs11630571	chr15:79432992	C/A	cg17916960	chr15:79447300	NA	-0.49	-7.59	-0.56	6.76e-12	Refractive error;
TGCT	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg12000995	chr2:27665139	KRTCAP3	-0.37	-4.58	-0.38	1.11e-5	Menopause (age at onset);
TGCT	cis	rs36051895	0.672	rs12353218	chr9:5162828	T/C	cg02405213	chr9:5042618	JAK2	-0.75	-9.83	-0.66	3.25e-17	Pediatric autoimmune diseases;
TGCT	cis	rs10465746	0.747	rs34155960	chr1:84447539	T/G	cg10977910	chr1:84465055	TTLL7	0.69	7.04	0.53	1.14e-10	Obesity-related traits;
TGCT	cis	rs9372498	0.536	rs28605789	chr6:118889952	G/A	cg21191810	chr6:118973309	C6orf204	-0.39	-5.04	-0.41	1.59e-6	Diastolic blood pressure;
TGCT	cis	rs6558530	0.965	rs730377	chr8:1707951	G/A	cg09410841	chr8:1729607	CLN8	0.91	10.31	0.68	2.23e-18	Systolic blood pressure;
TGCT	cis	rs8177253	0.665	rs12493887	chr3:133440737	T/C	cg08439880	chr3:133502540	NA	-0.29	-5.42	-0.44	2.93e-7	Iron status biomarkers;
TGCT	cis	rs28595532	0.920	rs17258050	chr4:119672019	G/A	cg11846333	chr4:119757529	SEC24D	0.9	4.54	0.38	1.34e-5	Cannabis dependence symptom count;
TGCT	cis	rs933688	1.000	rs11950530	chr5:90688740	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.96	8.05	0.59	5.84e-13	Smoking behavior;
TGCT	cis	rs8037137	0.915	rs79548680	chr15:91505779	G/C	cg22570213	chr15:91497863	RCCD1	0.52	4.84	0.4	3.85e-6	Platelet count;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
TGCT	cis	rs7267979	1.000	rs2258884	chr20:25279539	C/T	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7772486	0.686	rs857875	chr6:145980033	T/G	cg13319975	chr6:146136371	FBXO30	0.53	4.9	0.4	2.91e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3540	0.960	rs10083661	chr15:91022339	G/A	cg22089800	chr15:90895588	ZNF774	0.74	6.91	0.53	2.27e-10	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs6840360	0.642	rs2034061	chr4:152420756	C/T	cg17479576	chr4:152424074	FAM160A1	-0.57	-6.02	-0.48	1.85e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs35306767	0.903	rs11253504	chr10:956046	A/G	cg20503657	chr10:835505	NA	0.74	10.28	0.68	2.58e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs478304	0.651	rs11537193	chr11:65500003	A/C	cg10518572	chr11:65560635	OVOL1	-0.24	-4.68	-0.39	7.53e-6	Acne (severe);
TGCT	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg24578937	chr1:2090814	PRKCZ	0.25	6.22	0.49	7.12e-9	Height;
TGCT	cis	rs7681440	0.967	rs1372517	chr4:90755909	G/A	cg20003494	chr4:90757398	SNCA	-0.56	-5.33	-0.43	4.56e-7	Dementia with Lewy bodies;
TGCT	cis	rs2237234	0.848	rs2237235	chr6:26391395	A/G	cg16898833	chr6:26189333	HIST1H4D	0.77	5.2	0.42	7.97e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2549003	1.000	rs6873426	chr5:131818631	G/T	cg21138405	chr5:131827807	IRF1	0.2	5.08	0.41	1.36e-6	Asthma (sex interaction);
TGCT	cis	rs7772486	0.566	rs735536	chr6:146036832	A/C	cg05347473	chr6:146136440	FBXO30	-0.49	-4.62	-0.38	9.3e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1008375	1.000	rs11947857	chr4:17691047	T/C	cg18681998	chr4:17616180	MED28	-0.88	-8.45	-0.6	6.46e-14	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1075265	0.870	rs6724389	chr2:54212835	G/A	cg15001959	chr2:54483431	TSPYL6;ACYP2	-0.18	-4.63	-0.38	9.12e-6	Morning vs. evening chronotype;Chronotype;
TGCT	cis	rs10493773	0.674	rs414618	chr1:86220418	G/A	cg17807903	chr1:86174739	ZNHIT6	0.4	5.64	0.45	1.09e-7	Urate levels in overweight individuals;
TGCT	cis	rs7172809	0.573	rs4886864	chr15:77674022	C/T	cg22256960	chr15:77711686	NA	-0.51	-4.79	-0.4	4.65e-6	Glucose homeostasis traits;
TGCT	cis	rs6500602	0.702	rs4786511	chr16:4571645	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.32	5.95	0.47	2.54e-8	Schizophrenia;
TGCT	cis	rs9952991	0.943	rs9952753	chr18:12780463	A/C	cg23544223	chr18:12777786	NA	0.63	6.02	0.48	1.85e-8	Inflammatory skin disease;
TGCT	cis	rs36051895	0.695	rs10974916	chr9:5017350	G/A	cg02405213	chr9:5042618	JAK2	-0.75	-9.96	-0.67	1.62e-17	Pediatric autoimmune diseases;
TGCT	cis	rs2288884	0.748	rs10424368	chr19:52600350	G/A	cg13540795	chr19:52551618	ZNF432	-0.7	-6.03	-0.48	1.78e-8	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs2180341	0.618	rs11154396	chr6:127638911	C/T	cg24812749	chr6:127587940	RNF146	0.63	5.33	0.43	4.51e-7	Breast cancer;
TGCT	cis	rs9303401	0.659	rs62083368	chr17:56878062	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg06896619	chr17:61851486	DDX42;CCDC47	0.49	5.03	0.41	1.68e-6	Prudent dietary pattern;
TGCT	cis	rs7267979	1.000	rs6083862	chr20:25411086	A/T	cg16686733	chr20:25566563	NINL	-0.57	-5.89	-0.47	3.34e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg06713675	chr4:122721982	EXOSC9	-0.62	-8.39	-0.6	9.07e-14	Type 2 diabetes;
TGCT	cis	rs9811920	0.609	rs9817005	chr3:99682692	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.62	6.98	0.53	1.6e-10	Axial length;
TGCT	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg18230493	chr5:56204884	C5orf35	-0.68	-5.85	-0.46	4.13e-8	Initial pursuit acceleration;
TGCT	cis	rs763014	0.865	rs4006748	chr16:632225	T/C	cg07343612	chr16:622815	PIGQ	-0.41	-7.87	-0.58	1.52e-12	Height;
TGCT	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg06753367	chr22:24256600	NA	-0.24	-4.6	-0.38	1.04e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2303759	0.881	rs10412811	chr19:49884495	G/A	cg22307029	chr19:49891270	CCDC155	0.54	5.06	0.41	1.49e-6	Multiple sclerosis;
TGCT	cis	rs1371867	0.726	rs1660333	chr8:101309989	A/G	cg06636551	chr8:101224915	SPAG1	-0.48	-6.5	-0.5	1.74e-9	Atrioventricular conduction;
TGCT	cis	rs372883	0.648	rs2832297	chr21:30742996	A/C	cg24692254	chr21:30365293	RNF160	0.49	4.44	0.37	1.95e-5	Pancreatic cancer;
TGCT	cis	rs9926296	0.542	rs12599531	chr16:89909401	C/T	cg27121462	chr16:89883253	FANCA	-0.56	-4.93	-0.4	2.56e-6	Vitiligo;
TGCT	cis	rs12902680	0.739	rs1402117	chr15:46391419	A/G	cg13605988	chr15:45421612	DUOX1;DUOXA1	0.32	4.5	0.37	1.56e-5	Neuroticism;
TGCT	cis	rs950169	0.840	rs35522895	chr15:84928049	G/A	cg11189052	chr15:85197271	WDR73	0.81	6.46	0.5	2.14e-9	Schizophrenia;
TGCT	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg22433210	chr17:43662623	NA	1.06	7.26	0.55	3.82e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7819412	0.775	rs11773990	chr8:10935082	T/C	cg21775007	chr8:11205619	TDH	-0.5	-4.61	-0.38	9.74e-6	Triglycerides;
TGCT	cis	rs2439831	1.000	rs2439841	chr15:43734749	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.01	8.37	0.6	1.02e-13	Lung cancer in ever smokers;
TGCT	cis	rs56399783	0.614	rs116929101	chr7:2760325	G/A	cg19731401	chr7:2775893	GNA12	0.39	5.36	0.43	3.88e-7	Childhood ear infection;
TGCT	cis	rs73198271	0.710	rs7837843	chr8:8656485	A/G	cg06671706	chr8:8559999	CLDN23	-0.36	-4.52	-0.38	1.42e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs66561647	0.853	rs66824612	chr8:128967819	C/T	cg11792826	chr8:129160931	MIR1208	0.23	5.07	0.41	1.41e-6	Hemoglobin concentration;
TGCT	cis	rs7572733	0.534	rs7557203	chr2:198795650	A/G	cg00792783	chr2:198669748	PLCL1	0.57	5.14	0.42	1.03e-6	Dermatomyositis;
TGCT	cis	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg07424592	chr7:64974309	NA	-1.26	-7.3	-0.55	2.99e-11	Diabetic kidney disease;
TGCT	cis	rs7000551	0.715	rs1879793	chr8:22313986	G/A	cg12081754	chr8:22256438	SLC39A14	0.32	5.31	0.43	4.96e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs6011674	1.000	rs6011674	chr20:61854452	A/G	cg06763829	chr20:61885236	FLJ16779;NKAIN4	-0.79	-4.44	-0.37	1.99e-5	Response to cytadine analogues (cytosine arabinoside);
TGCT	cis	rs9611565	0.559	rs13056262	chr22:42081921	A/G	cg13695892	chr22:41940480	POLR3H	0.89	8.6	0.61	2.92e-14	Vitiligo;
TGCT	cis	rs6500602	0.702	rs3761680	chr16:4524060	C/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.29	5.36	0.43	3.83e-7	Schizophrenia;
TGCT	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.66	6.52	0.51	1.58e-9	Bipolar disorder;
TGCT	cis	rs28595532	0.920	rs115994609	chr4:119777273	G/A	cg21605333	chr4:119757512	SEC24D	1.53	8.87	0.62	6.71e-15	Cannabis dependence symptom count;
TGCT	cis	rs4746818	1.000	rs10762263	chr10:70970178	A/G	cg11621586	chr10:70884670	VPS26A	1.22	10.53	0.69	6.48e-19	Left atrial antero-posterior diameter;
TGCT	cis	rs11249608	0.548	rs6601007	chr5:178455796	G/C	cg23951258	chr5:178450506	ZNF879	0.44	4.54	0.38	1.32e-5	Pubertal anthropometrics;
TGCT	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg00786635	chr1:25594202	NA	0.59	6.07	0.48	1.46e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs6671200	0.607	rs1927043	chr1:95667251	G/A	cg03123541	chr1:95699097	RWDD3	-0.82	-7.07	-0.54	1.01e-10	Stearic acid (18:0) levels;
TGCT	cis	rs67311347	1.000	rs28707772	chr3:40504666	G/A	cg17264618	chr3:40429014	ENTPD3	0.32	4.45	0.37	1.88e-5	Renal cell carcinoma;
TGCT	cis	rs208520	0.690	rs6929762	chr6:66709277	C/T	cg07460842	chr6:66804631	NA	0.96	10.26	0.68	2.92e-18	Exhaled nitric oxide output;
TGCT	cis	rs9513593	1.000	rs9585040	chr13:100015539	T/C	cg21788972	chr13:99853209	UBAC2	0.59	4.54	0.38	1.3e-5	Psoriasis;
TGCT	trans	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg17470723	chr8:74884337	TCEB1	0.72	6.94	0.53	1.91e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs6570726	0.935	rs399169	chr6:145836353	C/A	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7614311	0.636	rs73117041	chr3:63896266	A/T	cg22134162	chr3:63841271	THOC7	-0.4	-5.16	-0.42	9.41e-7	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs7552404	0.727	rs2172507	chr1:76331320	A/G	cg10523679	chr1:76189770	ACADM	-0.68	-6.25	-0.49	6.17e-9	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs1670533	0.818	rs643484	chr4:1085826	A/G	cg27284194	chr4:1044797	NA	0.68	5.95	0.47	2.59e-8	Recombination rate (females);
TGCT	cis	rs793571	0.500	rs2555356	chr15:59016431	T/G	cg05156742	chr15:59063176	FAM63B	0.47	4.46	0.37	1.78e-5	Schizophrenia;
TGCT	cis	rs1371867	0.875	rs7830342	chr8:101327738	T/A	cg00191853	chr8:101177733	SPAG1	-0.23	-4.76	-0.39	5.2e-6	Atrioventricular conduction;
TGCT	cis	rs7647973	0.626	rs1586827	chr3:49671224	T/C	cg03060546	chr3:49711283	APEH	0.63	5.63	0.45	1.12e-7	Menarche (age at onset);
TGCT	cis	rs6463523	0.933	rs6974151	chr7:758269	T/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.74	10.63	0.69	3.74e-19	Subjective well-being;
TGCT	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	8.39	0.6	9.03e-14	Platelet count;
TGCT	cis	rs9549367	0.577	rs513479	chr13:113815200	C/T	cg00898013	chr13:113819073	PROZ	-0.56	-6.86	-0.52	2.88e-10	Platelet distribution width;
TGCT	cis	rs6088590	0.965	rs6087619	chr20:33288511	C/G	cg08999081	chr20:33150536	PIGU	0.27	4.82	0.4	4.18e-6	Coronary artery disease;
TGCT	cis	rs968451	0.526	rs5757617	chr22:39722714	G/C	cg01093212	chr22:39715156	SNORD43;RPL3	0.5	4.66	0.39	8.12e-6	Primary biliary cholangitis;
TGCT	cis	rs8014204	0.819	rs2003490	chr14:75377555	C/A	cg06637938	chr14:75390232	RPS6KL1	0.81	7.79	0.57	2.31e-12	Caffeine consumption;
TGCT	cis	rs2795502	0.935	rs2744060	chr10:43262616	C/G	cg20628663	chr10:43360327	NA	-0.41	-4.84	-0.4	3.8e-6	Blood protein levels;
TGCT	cis	rs892961	0.932	rs7222170	chr17:75413096	G/A	cg05865280	chr17:75406074	SEPT9	0.28	6.86	0.52	2.9e-10	Airflow obstruction;
TGCT	cis	rs10992471	0.598	rs1175788	chr9:95117798	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.63	-6.09	-0.48	1.29e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg11764359	chr7:65958608	NA	0.61	5.54	0.45	1.76e-7	Aortic root size;
TGCT	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg00343986	chr7:65444356	GUSB	0.26	6.14	0.48	1.02e-8	Calcium levels;
TGCT	cis	rs13191362	0.808	rs13217502	chr6:163231414	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.66	4.63	0.38	9.26e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs10028773	0.506	rs12374346	chr4:120281705	G/A	cg09307838	chr4:120376055	NA	0.58	5.76	0.46	6.16e-8	Educational attainment;
TGCT	cis	rs36051895	0.664	rs4593605	chr9:5107278	C/A	cg02405213	chr9:5042618	JAK2	-0.71	-9.43	-0.65	3.07e-16	Pediatric autoimmune diseases;
TGCT	cis	rs6912958	0.500	rs9342104	chr6:87798512	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.73	-7.35	-0.55	2.37e-11	Monocyte percentage of white cells;
TGCT	cis	rs559406	0.623	rs2852151	chr18:12841176	G/A	cg23598886	chr18:12777645	NA	0.38	4.54	0.38	1.32e-5	Psoriasis;
TGCT	cis	rs9916302	0.904	rs6503503	chr17:37514373	G/A	cg07936489	chr17:37558343	FBXL20	0.63	4.91	0.4	2.83e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs854765	0.520	rs9899355	chr17:17898243	C/T	cg04398451	chr17:18023971	MYO15A	-0.3	-4.61	-0.38	1e-5	Total body bone mineral density;
TGCT	trans	rs11088226	0.681	rs11702499	chr21:33938565	C/T	cg09050820	chr6:167586206	TCP10L2	0.79	7.04	0.53	1.13e-10	Gastritis;
TGCT	trans	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg20587970	chr11:113659929	NA	-0.97	-11.61	-0.72	1.49e-21	Hip circumference adjusted for BMI;
TGCT	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg26338869	chr17:61819248	STRADA	-0.53	-4.94	-0.41	2.48e-6	Prudent dietary pattern;
TGCT	cis	rs8077577	0.945	rs62073608	chr17:18071448	T/C	cg09161412	chr17:18057145	MYO15A	-0.67	-5.44	-0.44	2.69e-7	Obesity-related traits;
TGCT	cis	rs2430307	0.518	rs67763033	chr7:76517677	A/G	cg15770687	chr7:76625569	PMS2L11	0.34	4.53	0.38	1.37e-5	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
TGCT	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg23156509	chr2:114033830	PAX8;LOC440839	-0.3	-4.61	-0.38	9.92e-6	Lymphocyte counts;
TGCT	cis	rs9859260	0.744	rs406271	chr3:195776976	T/C	cg22891161	chr3:195456627	MUC20	0.23	4.6	0.38	1.04e-5	Mean corpuscular volume;
TGCT	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.98	8.11	0.59	4.13e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs624899	0.522	rs645584	chr19:11612466	A/G	cg12854483	chr19:11649671	CNN1	0.52	5.7	0.46	8.4e-8	Presence of antiphospholipid antibodies;
TGCT	cis	rs9659323	1.000	rs9658899	chr1:119504543	G/A	cg07961512	chr1:119535619	NA	0.44	5.07	0.41	1.4e-6	Body mass index;
TGCT	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg02725872	chr8:58115012	NA	-0.41	-5.42	-0.44	3.01e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs12477438	0.520	rs36071868	chr2:99737120	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.15	18.22	0.85	7.28e-37	Chronic sinus infection;
TGCT	cis	rs57994353	0.600	rs11145974	chr9:139316744	A/G	cg13741927	chr9:139327495	INPP5E	0.25	5.74	0.46	7.02e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs2594989	0.677	rs7631716	chr3:11576689	T/C	cg00170343	chr3:11313890	ATG7	-0.67	-5.24	-0.43	6.68e-7	Circulating chemerin levels;
TGCT	cis	rs9291683	0.527	rs3822241	chr4:10094931	G/A	cg00071950	chr4:10020882	SLC2A9	-0.54	-5.74	-0.46	6.75e-8	Bone mineral density;
TGCT	cis	rs55794721	0.509	rs909834	chr1:25757996	A/G	cg00786635	chr1:25594202	NA	0.59	6.28	0.49	5.23e-9	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs921968	0.643	rs2178019	chr2:219316303	G/A	cg02176678	chr2:219576539	TTLL4	0.37	5.45	0.44	2.58e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs7226408	0.857	rs8098708	chr18:34563373	A/G	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs3751972	0.911	rs2079714	chr17:26222520	C/T	cg02948944	chr17:26242737	NA	0.49	7.07	0.54	1.02e-10	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs1697139	0.583	rs11739603	chr5:66540687	C/T	cg11553311	chr5:66541588	NA	0.28	6.02	0.48	1.82e-8	Breast cancer;
TGCT	cis	rs7666738	0.830	rs11097609	chr4:99011707	C/T	cg18180107	chr4:99064573	C4orf37	0.54	5.03	0.41	1.7e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2456568	0.606	rs11020616	chr11:93691594	C/T	cg26875233	chr11:93583750	C11orf90	0.43	5.18	0.42	8.54e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg24503407	chr1:205819492	PM20D1	0.6	8.49	0.61	5.35e-14	Menarche (age at onset);
TGCT	cis	rs9611565	0.649	rs126092	chr22:42178441	A/G	cg06634786	chr22:41940651	POLR3H	0.83	7.61	0.56	6.08e-12	Vitiligo;
TGCT	cis	rs7524258	0.900	rs7514988	chr1:7271651	C/T	cg07173049	chr1:7289937	CAMTA1	0.29	4.68	0.39	7.35e-6	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs6840360	0.967	rs6832562	chr4:152602798	A/G	cg17479576	chr4:152424074	FAM160A1	-0.52	-5.65	-0.45	1.03e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs892961	1.000	rs11077909	chr17:75403480	T/C	cg05865280	chr17:75406074	SEPT9	0.27	6.67	0.51	7.74e-10	Airflow obstruction;
TGCT	cis	rs902774	0.554	rs4919749	chr12:53358034	C/T	cg05393297	chr12:53359155	NA	-0.75	-8.54	-0.61	3.99e-14	Prostate cancer;
TGCT	cis	rs4808199	0.895	rs10419672	chr19:19471241	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.73	5.84	0.46	4.35e-8	Nonalcoholic fatty liver disease;
TGCT	cis	rs8014204	0.533	rs12434646	chr14:75178693	C/T	cg06637938	chr14:75390232	RPS6KL1	0.61	5.51	0.44	1.98e-7	Caffeine consumption;
TGCT	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg22920501	chr2:26401640	FAM59B	-0.72	-6.38	-0.5	3.19e-9	Gut microbiome composition (summer);
TGCT	trans	rs10506458	0.915	rs998506	chr12:63400017	C/T	cg22491629	chr6:157744540	C6orf35	-0.99	-8.55	-0.61	3.94e-14	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs9902453	1.000	rs12600855	chr17:28279591	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.76	6.61	0.51	1.01e-9	Coffee consumption (cups per day);
TGCT	cis	rs2816062	0.786	rs2745320	chr1:18893592	G/A	cg18795169	chr1:18902165	NA	-0.6	-14.18	-0.79	1.04e-27	Urate levels in lean individuals;
TGCT	cis	rs2997447	0.761	rs74384164	chr1:26430379	C/T	cg03844060	chr1:26490628	NA	0.28	4.6	0.38	1.04e-5	QRS complex (12-leadsum);
TGCT	cis	rs709400	0.663	rs72710714	chr14:103981849	T/G	cg12935359	chr14:103987150	CKB	-0.39	-5.76	-0.46	6.29e-8	Body mass index;
TGCT	cis	rs968567	0.539	rs174556	chr11:61580635	C/T	cg01500311	chr11:61656094	FADS3	-0.29	-4.98	-0.41	2.1e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
TGCT	cis	rs10883723	0.773	rs1326193	chr10:104271674	G/T	cg05855489	chr10:104503620	C10orf26	-0.58	-5.06	-0.41	1.47e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs6545883	0.965	rs3771261	chr2:61762161	A/G	cg15711740	chr2:61764176	XPO1	-0.57	-5.29	-0.43	5.32e-7	Tuberculosis;
TGCT	cis	rs13191362	1.000	rs13209100	chr6:163159350	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.84	7.84	0.58	1.75e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg26513180	chr16:89883248	FANCA	1.07	14.76	0.8	4.4e-29	Vitiligo;
TGCT	cis	rs7267979	0.604	rs242130	chr20:25594020	C/A	cg16686733	chr20:25566563	NINL	-0.51	-4.92	-0.4	2.66e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7552404	1.000	rs211723	chr1:76103030	C/T	cg10523679	chr1:76189770	ACADM	-0.93	-10.08	-0.67	8.31e-18	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs17293817	0.650	rs12778422	chr10:1413776	A/G	cg27336261	chr10:1975562	NA	0.35	4.91	0.4	2.84e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4919694	1.000	rs11191473	chr10:104710710	C/G	cg04362960	chr10:104952993	NT5C2	1.07	7.15	0.54	6.49e-11	Arsenic metabolism;
TGCT	cis	rs1215050	0.527	rs1214998	chr4:99042878	T/G	cg05340658	chr4:99064831	C4orf37	0.44	5.35	0.43	4.12e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2594989	0.836	rs347609	chr3:11269999	G/C	cg00170343	chr3:11313890	ATG7	0.66	4.56	0.38	1.2e-5	Circulating chemerin levels;
TGCT	cis	rs11214589	0.774	rs10891544	chr11:113256152	A/C	cg14159747	chr11:113255604	NA	-0.4	-4.93	-0.41	2.54e-6	Neuroticism;
TGCT	cis	rs6964587	0.967	rs2299235	chr7:91627500	C/T	cg17063962	chr7:91808500	NA	0.91	9.99	0.67	1.32e-17	Breast cancer;
TGCT	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg27170947	chr2:26402098	FAM59B	-0.4	-4.63	-0.38	8.93e-6	Gut microbiome composition (summer);
TGCT	cis	rs2070488	0.662	rs6599202	chr3:38480651	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.72	5.94	0.47	2.7e-8	Electrocardiographic conduction measures;
TGCT	cis	rs3771570	1.000	rs56383420	chr2:242219281	A/G	cg21155796	chr2:242212141	HDLBP	0.98	6.68	0.51	7.29e-10	Prostate cancer;
TGCT	cis	rs35306767	0.951	rs12777021	chr10:967270	T/C	cg26597838	chr10:835615	NA	0.71	10.24	0.68	3.36e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs1577917	1.000	rs10944170	chr6:86685469	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.54	-0.45	1.73e-7	Response to antipsychotic treatment;
TGCT	cis	rs2281845	0.965	rs3738262	chr1:201083343	A/G	cg22815214	chr1:201083145	CACNA1S	0.25	4.66	0.39	7.93e-6	Permanent tooth development;
TGCT	cis	rs968451	0.951	rs12627838	chr22:39733521	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.92	8.97	0.63	3.87e-15	Primary biliary cholangitis;
TGCT	cis	rs2456568	0.803	rs10831141	chr11:93640728	C/T	cg14065697	chr11:93583672	C11orf90	-0.37	-4.46	-0.37	1.84e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7226408	0.901	rs17652953	chr18:34761705	T/C	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg08219700	chr8:58056026	NA	0.3	4.53	0.38	1.35e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.55	5.23	0.43	6.98e-7	Menarche (age at onset);
TGCT	cis	rs8017423	0.740	rs8003095	chr14:90680643	A/T	cg04374321	chr14:90722782	PSMC1	0.77	7.94	0.58	1.06e-12	Mortality in heart failure;
TGCT	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	6.13	0.48	1.06e-8	Bipolar disorder;
TGCT	cis	rs2299587	0.642	rs2073570	chr8:17782627	C/G	cg01800426	chr8:17659068	MTUS1	-0.64	-5.55	-0.45	1.66e-7	Economic and political preferences;
TGCT	cis	rs4455778	0.580	rs7803736	chr7:49125011	A/G	cg26309511	chr7:48887640	NA	0.51	6.62	0.51	9.97e-10	Lung cancer in never smokers;
TGCT	cis	rs35934224	0.771	rs34820460	chr22:19869210	G/A	cg11182965	chr22:19864308	TXNRD2	-0.38	-5.3	-0.43	5.03e-7	Glaucoma (primary open-angle);
TGCT	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg13409248	chr3:40428643	ENTPD3	0.57	4.53	0.38	1.37e-5	Renal cell carcinoma;
TGCT	cis	rs2120019	0.567	rs12385940	chr15:75168162	C/T	cg09165964	chr15:75287851	SCAMP5	-0.84	-6.58	-0.51	1.19e-9	Blood trace element (Zn levels);
TGCT	trans	rs4332037	0.713	rs56093134	chr7:1973970	C/T	cg25206134	chr2:45395956	NA	0.99	7.94	0.58	1.06e-12	Bipolar disorder;
TGCT	cis	rs8030485	0.536	rs4778918	chr15:79434040	T/C	cg17916960	chr15:79447300	NA	0.39	5.87	0.47	3.66e-8	Left ventricle wall thickness;
TGCT	cis	rs737008	0.922	rs2070923	chr16:11369855	G/T	cg00044050	chr16:11439710	C16orf75	0.72	7.35	0.55	2.29e-11	Obesity-related traits;
TGCT	cis	rs7666738	0.830	rs10001702	chr4:99065160	T/G	cg17366294	chr4:99064904	C4orf37	0.73	7.45	0.56	1.4e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7666738	0.830	rs4323111	chr4:98952276	A/G	cg18180107	chr4:99064573	C4orf37	0.55	4.98	0.41	2.05e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9902453	0.904	rs10853136	chr17:28406018	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.82	-7.84	-0.58	1.77e-12	Coffee consumption (cups per day);
TGCT	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg00814883	chr7:100076585	TSC22D4	-0.85	-8.62	-0.61	2.62e-14	Platelet count;
TGCT	cis	rs651907	0.557	rs34376498	chr3:101480156	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	4.7	0.39	6.87e-6	Colorectal cancer;
TGCT	cis	rs3733585	0.631	rs7699671	chr4:10125874	C/T	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.17	-0.48	8.79e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs986417	0.818	rs12880313	chr14:60935504	T/C	cg27398547	chr14:60952738	C14orf39	1.42	8.68	0.61	1.89e-14	Gut microbiota (bacterial taxa);
TGCT	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg05665937	chr4:1216051	CTBP1	0.24	4.69	0.39	7.09e-6	Obesity-related traits;
TGCT	cis	rs1903068	0.785	rs10020668	chr4:55996903	C/T	cg16572876	chr4:56024045	NA	0.42	4.78	0.39	4.89e-6	Endometriosis;
TGCT	cis	rs1670533	1.000	rs1670534	chr4:1087265	T/C	cg20887711	chr4:1340912	KIAA1530	0.66	5.33	0.43	4.49e-7	Recombination rate (females);
TGCT	cis	rs2204008	0.715	rs12368462	chr12:38336116	C/G	cg13010199	chr12:38710504	ALG10B	0.58	4.55	0.38	1.26e-5	Bladder cancer;
TGCT	cis	rs936229	0.798	rs1869959	chr15:75147332	A/C	cg10253484	chr15:75165896	SCAMP2	-0.79	-6.98	-0.53	1.57e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
TGCT	cis	rs2153535	0.553	rs2984099	chr6:8637274	C/T	cg07606381	chr6:8435919	SLC35B3	-0.75	-5.91	-0.47	3.09e-8	Motion sickness;
TGCT	cis	rs7264396	0.690	rs2425175	chr20:34445563	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.04	-0.41	1.58e-6	Total cholesterol levels;
TGCT	cis	rs9381040	0.655	rs2268192	chr6:41024626	T/C	cg03526776	chr6:41159608	TREML2	0.27	5.29	0.43	5.37e-7	Alzheimer's disease (late onset);
TGCT	cis	rs6831352	0.703	rs3133152	chr4:100031721	C/G	cg12011299	chr4:100065546	ADH4	0.39	5.2	0.42	8.04e-7	Alcohol dependence;
TGCT	cis	rs210138	1.000	rs210137	chr6:33542478	C/T	cg07679836	chr6:33548423	BAK1	0.39	5.34	0.43	4.28e-7	Testicular germ cell tumor;
TGCT	cis	rs8042680	0.554	rs2301826	chr15:91525197	A/G	cg22570213	chr15:91497863	RCCD1	-0.42	-4.44	-0.37	1.94e-5	Type 2 diabetes;
TGCT	cis	rs533581	0.866	rs561795	chr16:88970818	A/G	cg16701003	chr16:89028210	CBFA2T3	0.38	5.12	0.42	1.15e-6	Social autistic-like traits;
TGCT	cis	rs748404	0.660	rs548704	chr15:43791706	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	4.71	0.39	6.47e-6	Lung cancer;
TGCT	cis	rs9611519	0.531	rs1967708	chr22:41444444	G/C	cg13695892	chr22:41940480	POLR3H	-0.58	-5.57	-0.45	1.48e-7	Neuroticism;
TGCT	cis	rs17102423	0.594	rs2781374	chr14:65568563	C/T	cg11161011	chr14:65562177	MAX	-0.47	-6.44	-0.5	2.41e-9	Obesity-related traits;
TGCT	cis	rs6163	0.588	rs12763284	chr10:104508202	C/T	cg05855489	chr10:104503620	C10orf26	-1.0	-12.58	-0.75	6.74e-24	Waist circumference;Hip circumference;
TGCT	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg03303774	chr4:1407052	NA	0.28	4.57	0.38	1.16e-5	Obesity-related traits;
TGCT	cis	rs9394841	0.667	rs9394831	chr6:41753084	C/T	cg08135965	chr6:41755394	TOMM6	0.55	5.15	0.42	9.77e-7	Mean corpuscular hemoglobin;Red cell distribution width;
TGCT	cis	rs7267979	0.764	rs2474767	chr20:25246733	T/C	cg16686733	chr20:25566563	NINL	0.51	5.1	0.42	1.22e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2172802	1.000	rs10866123	chr4:62455828	A/G	cg04118610	chr4:62707027	LPHN3	-0.42	-4.9	-0.4	2.9e-6	Partial epilepsies;
TGCT	cis	rs1577917	0.958	rs11754330	chr6:86455070	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.43	-0.44	2.81e-7	Response to antipsychotic treatment;
TGCT	cis	rs9796	0.553	rs7171437	chr15:41315168	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.52	-6.72	-0.52	5.97e-10	Menopause (age at onset);
TGCT	cis	rs1018836	0.773	rs7837109	chr8:91639178	C/T	cg16814680	chr8:91681699	NA	-0.81	-8.71	-0.62	1.59e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs908922	0.676	rs498184	chr1:152501423	G/C	cg20991723	chr1:152506922	NA	0.46	6.24	0.49	6.32e-9	Hair morphology;
TGCT	cis	rs9302001	0.883	rs1407893	chr13:95457203	A/G	cg07483244	chr13:95358924	NA	0.35	4.45	0.37	1.92e-5	Panic disorder;
TGCT	cis	rs1018836	0.892	rs2187981	chr8:91549629	T/C	cg16814680	chr8:91681699	NA	-0.77	-8.15	-0.59	3.43e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7666738	0.830	rs13129503	chr4:98987892	T/C	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2692947	0.644	rs1168976	chr2:96813480	G/A	cg22654517	chr2:96458247	NA	0.23	4.86	0.4	3.42e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs7412746	0.611	rs10888398	chr1:150886782	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.37	-4.46	-0.37	1.81e-5	Melanoma;
TGCT	cis	rs17345786	0.906	rs72944107	chr3:101197190	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.84	8.92	0.63	5.05e-15	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg22618164	chr12:122356400	WDR66	0.68	6.47	0.5	2.09e-9	Mean corpuscular volume;
TGCT	cis	rs2303759	0.918	rs2288480	chr19:49867016	C/G	cg22307029	chr19:49891270	CCDC155	0.56	5.28	0.43	5.56e-7	Multiple sclerosis;
TGCT	cis	rs60843830	0.623	rs55932737	chr2:107543	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.62	5.47	0.44	2.43e-7	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs7917772	0.503	rs11191325	chr10:104302933	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	8.36	0.6	1.1e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2354432	0.505	rs72691009	chr1:146708397	C/T	cg25205988	chr1:146714368	CHD1L	-1.15	-4.8	-0.4	4.49e-6	Mitochondrial DNA levels;
TGCT	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg19536664	chr17:6899085	ALOX12	0.38	6.04	0.48	1.68e-8	Tonsillectomy;
TGCT	cis	rs6728642	1.000	rs75297860	chr2:97600078	G/A	cg26665480	chr2:98280029	ACTR1B	-0.97	-5.3	-0.43	5.13e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	cis	rs33794	0.901	rs33778	chr3:45287918	A/G	cg18645101	chr3:44551900	NA	0.55	4.82	0.4	4.08e-6	Lung function (forced expiratory volume in 1 second);
TGCT	cis	rs7100689	0.577	rs9285726	chr10:82035150	A/T	cg01528321	chr10:82214614	TSPAN14	0.7	6.78	0.52	4.43e-10	Post bronchodilator FEV1;
TGCT	cis	rs8072100	0.576	rs7216112	chr17:45406345	C/T	cg08085267	chr17:45401833	C17orf57	0.53	5.58	0.45	1.45e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs72945132	0.825	rs58532402	chr11:70189491	C/T	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	trans	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg17830980	chr10:43048298	ZNF37B	-0.87	-11.3	-0.71	8.5e-21	Extrinsic epigenetic age acceleration;
TGCT	cis	rs13217239	0.646	rs9393789	chr6:27067028	G/T	cg26531700	chr6:26746687	NA	-0.7	-6.84	-0.52	3.25e-10	Schizophrenia;
TGCT	cis	rs17401966	0.894	rs12141201	chr1:10454714	G/A	cg19773385	chr1:10388646	KIF1B	-0.23	-5.42	-0.44	2.97e-7	Hepatocellular carcinoma;
TGCT	cis	rs4319547	0.695	rs4758648	chr12:122900460	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.63	-5.01	-0.41	1.87e-6	Body mass index;
TGCT	cis	rs12950390	0.853	rs12451815	chr17:45855956	A/G	cg24803719	chr17:45855879	NA	-0.44	-4.48	-0.37	1.7e-5	IgG glycosylation;
TGCT	cis	rs3761847	0.651	rs1323472	chr9:123826335	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.43	4.52	0.38	1.42e-5	Rheumatoid arthritis;
TGCT	cis	rs79349575	0.811	rs80032154	chr17:47014992	C/A	cg26022315	chr17:47021804	SNF8	0.52	5.17	0.42	9.24e-7	Type 2 diabetes;
TGCT	trans	rs1499614	1.000	rs1267818	chr7:66107024	C/T	cg07424592	chr7:64974309	NA	1.31	7.65	0.57	4.73e-12	Gout;
TGCT	cis	rs1062177	1.000	rs62377945	chr5:151208004	C/G	cg00977110	chr5:151150581	G3BP1	0.4	4.52	0.38	1.4e-5	Preschool internalizing problems;
TGCT	cis	rs7773004	0.905	rs994379	chr6:26305407	C/G	cg13569146	chr6:26330589	NA	0.48	4.57	0.38	1.17e-5	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
TGCT	cis	rs12541335	0.639	rs3923439	chr8:22170079	G/A	cg07298985	chr8:22133076	PIWIL2	0.33	5.25	0.43	6.3e-7	Hypertriglyceridemia;
TGCT	cis	rs9611565	0.568	rs2413656	chr22:42129357	G/T	cg03806693	chr22:41940476	POLR3H	0.94	9.16	0.64	1.35e-15	Vitiligo;
TGCT	cis	rs9303401	0.659	rs12946852	chr17:57013337	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.61	6.16	0.48	9.11e-9	Cognitive test performance;
TGCT	cis	rs228437	0.586	rs12663941	chr6:134916963	A/G	cg09872934	chr6:134495829	SGK1	0.53	4.55	0.38	1.24e-5	Melanoma;
TGCT	cis	rs904251	0.504	rs9380677	chr6:37480366	A/G	cg08126542	chr6:37504118	NA	-0.46	-6.69	-0.51	6.9e-10	Cognitive performance;
TGCT	cis	rs8014204	0.804	rs2287403	chr14:75259140	C/T	cg06637938	chr14:75390232	RPS6KL1	0.7	6.77	0.52	4.47e-10	Caffeine consumption;
TGCT	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg25767906	chr1:53392781	SCP2	-0.5	-5.97	-0.47	2.29e-8	Monocyte count;
TGCT	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg22029157	chr1:209979665	IRF6	0.76	6.32	0.49	4.37e-9	Cleft lip with or without cleft palate;
TGCT	cis	rs9372498	0.536	rs9489452	chr6:118910868	G/C	cg07617317	chr6:118971624	C6orf204	0.49	5.22	0.42	7.37e-7	Diastolic blood pressure;
TGCT	cis	rs11677416	0.961	rs3783557	chr2:113530712	C/T	cg27083787	chr2:113543245	IL1A	0.18	4.46	0.37	1.84e-5	Response to antipsychotic treatment in schizophrenia (working memory);
TGCT	cis	rs904251	0.861	rs2776875	chr6:37486796	G/C	cg08126542	chr6:37504118	NA	-0.44	-5.92	-0.47	2.96e-8	Cognitive performance;
TGCT	cis	rs7223966	1.000	rs9893348	chr17:61676534	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	4.69	0.39	7.19e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg03452623	chr4:187889614	NA	-0.36	-5.3	-0.43	5.01e-7	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs629535	0.725	rs639127	chr8:70073251	A/G	cg21567404	chr3:27674614	NA	0.57	9.09	0.63	1.94e-15	Dupuytren's disease;
TGCT	cis	rs4689388	0.853	rs13114527	chr4:6294655	T/G	cg14416269	chr4:6271139	WFS1	0.37	4.9	0.4	2.95e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs9814567	0.806	rs4955525	chr3:134317008	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-7.13	-0.54	7.12e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs6542838	0.611	rs17758170	chr2:99531842	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.54	-4.88	-0.4	3.18e-6	Fear of minor pain;
TGCT	cis	rs4713118	0.911	rs2394000	chr6:27686991	A/G	cg10876282	chr6:28092338	ZSCAN16	0.5	4.62	0.38	9.35e-6	Parkinson's disease;
TGCT	cis	rs6582630	0.555	rs10880612	chr12:38509427	A/G	cg13010199	chr12:38710504	ALG10B	0.6	4.88	0.4	3.15e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs10788264	0.590	rs4237538	chr10:124063140	A/G	cg09507567	chr10:124027408	NA	0.39	5.46	0.44	2.5e-7	Total body bone mineral density;
TGCT	cis	rs2354432	0.607	rs12404113	chr1:146750343	C/A	cg25205988	chr1:146714368	CHD1L	-1.34	-6.07	-0.48	1.44e-8	Mitochondrial DNA levels;
TGCT	cis	rs9894429	0.646	rs12948797	chr17:79617384	G/A	cg21028142	chr17:79581711	NPLOC4	0.29	5.93	0.47	2.76e-8	Eye color traits;
TGCT	cis	rs6964587	1.000	rs11971885	chr7:91674807	T/C	cg17063962	chr7:91808500	NA	0.88	9.65	0.65	8.91e-17	Breast cancer;
TGCT	cis	rs16910800	0.689	rs4491218	chr11:23163977	G/A	cg20040320	chr11:23191996	NA	-0.52	-4.44	-0.37	1.96e-5	Cancer;
TGCT	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg03709012	chr19:19516395	GATAD2A	0.75	6.2	0.49	7.59e-9	Tonsillectomy;
TGCT	cis	rs362296	0.511	rs2051558	chr4:3324886	G/A	cg06533319	chr4:3265114	C4orf44	-0.22	-4.9	-0.4	2.99e-6	Parental longevity (mother's age at death);
TGCT	cis	rs34526934	0.524	rs1124052	chr2:177040084	G/A	cg26754761	chr2:177040938	NA	-0.3	-5.6	-0.45	1.33e-7	Obstructive sleep apnea trait (apnea hypopnea index);
TGCT	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg00684032	chr4:1343700	KIAA1530	0.23	4.95	0.41	2.36e-6	Obesity-related traits;
TGCT	cis	rs7772486	0.817	rs9322047	chr6:146400394	G/A	cg23711669	chr6:146136114	FBXO30	0.89	9.47	0.65	2.36e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs35146811	0.735	rs858506	chr7:99820050	T/C	cg13334819	chr7:99746414	C7orf59	0.74	6.41	0.5	2.82e-9	Coronary artery disease;
TGCT	cis	rs2239547	0.657	rs2071040	chr3:52864860	A/G	cg11645453	chr3:52864694	ITIH4	0.34	5.59	0.45	1.39e-7	Schizophrenia;
TGCT	cis	rs7178572	0.568	rs12910480	chr15:77664212	G/C	cg15453836	chr15:77711506	NA	-0.42	-4.79	-0.4	4.58e-6	Type 2 diabetes;
TGCT	cis	rs2115630	0.967	rs11073702	chr15:85310071	G/A	cg11189052	chr15:85197271	WDR73	-0.63	-6.04	-0.48	1.67e-8	P wave terminal force;
TGCT	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	9.52	0.65	1.86e-16	Platelet count;
TGCT	cis	rs7226408	0.948	rs17652351	chr18:34393672	C/G	cg06757138	chr18:34340585	FHOD3	0.26	4.7	0.39	6.74e-6	Obesity-related traits;
TGCT	cis	rs910316	0.935	rs2268620	chr14:75640403	G/A	cg11812906	chr14:75593930	NEK9	-0.74	-7.3	-0.55	3.1e-11	Height;
TGCT	trans	rs114540395	0.858	rs117416511	chr10:103351588	G/A	cg10198749	chr1:39920707	MACF1	0.55	7.03	0.53	1.2e-10	Schizophrenia;
TGCT	cis	rs12497850	0.931	rs7431710	chr3:48935583	G/A	cg07636037	chr3:49044803	WDR6	0.95	10.74	0.69	2e-19	Parkinson's disease;
TGCT	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.69	-0.39	7e-6	Prudent dietary pattern;
TGCT	cis	rs478222	1.000	rs2577277	chr2:25310247	T/C	cg01884057	chr2:25150051	NA	-0.26	-4.96	-0.41	2.26e-6	Type 1 diabetes;
TGCT	cis	rs992157	0.835	rs12987219	chr2:219144149	G/A	cg00012203	chr2:219082015	ARPC2	-0.79	-7.87	-0.58	1.48e-12	Colorectal cancer;
TGCT	cis	rs6671200	1.000	rs34396223	chr1:95697828	C/T	cg26537280	chr1:95699037	RWDD3	0.7	5.55	0.45	1.62e-7	Stearic acid (18:0) levels;
TGCT	cis	rs7769051	0.711	rs9493435	chr6:133088205	A/G	cg07930552	chr6:133119739	C6orf192	0.89	5.02	0.41	1.77e-6	Type 2 diabetes nephropathy;
TGCT	cis	rs12479064	0.724	rs3087403	chr2:100058870	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.71	-6.49	-0.5	1.82e-9	Chronic sinus infection;
TGCT	cis	rs826838	0.967	rs1719854	chr12:39127707	G/A	cg26384229	chr12:38710491	ALG10B	-0.86	-7.7	-0.57	3.65e-12	Heart rate;
TGCT	cis	rs7647973	0.554	rs13096480	chr3:49658084	A/G	cg03034192	chr3:50606346	HEMK1;C3orf18	0.36	4.75	0.39	5.61e-6	Menarche (age at onset);
TGCT	cis	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg18188782	chr20:61659543	NA	0.46	5.55	0.45	1.61e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs12210905	0.688	rs115309746	chr6:27491562	G/A	cg08851530	chr6:28072375	NA	1.34	6.29	0.49	5.02e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.46	-6.7	-0.52	6.44e-10	Alzheimer's disease;
TGCT	cis	rs10510102	0.872	rs7906462	chr10:123707613	C/T	cg23691251	chr10:123688108	ATE1	-0.61	-4.71	-0.39	6.41e-6	Breast cancer;
TGCT	cis	rs7666738	0.546	rs2098935	chr4:98914376	A/G	cg05340658	chr4:99064831	C4orf37	0.59	6.52	0.51	1.62e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3740393	0.562	rs60459635	chr10:104500988	T/G	cg05855489	chr10:104503620	C10orf26	0.74	6.05	0.48	1.57e-8	Microalbuminuria;
TGCT	cis	rs3764563	1.000	rs1022413	chr19:15741984	G/A	cg20725493	chr19:15740067	CYP4F8	-0.43	-4.67	-0.39	7.75e-6	Inflammatory biomarkers;
TGCT	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.63	5.3	0.43	5.01e-7	Tonsillectomy;
TGCT	cis	rs6882046	0.513	rs34320	chr5:88021527	T/G	cg22951263	chr5:87985283	NA	-0.58	-6.18	-0.49	8.49e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	trans	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg25482853	chr8:67687455	SGK3	1.16	10.5	0.69	7.91e-19	Lung disease severity in cystic fibrosis;
TGCT	cis	rs6582630	0.555	rs11182422	chr12:38522833	A/G	cg26384229	chr12:38710491	ALG10B	0.83	7.75	0.57	2.85e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs7267979	0.932	rs2260997	chr20:25256266	A/C	cg16686733	chr20:25566563	NINL	-0.58	-6.12	-0.48	1.14e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6500602	0.727	rs4238849	chr16:4538114	G/A	cg08645402	chr16:4508243	NA	0.18	5.05	0.41	1.55e-6	Schizophrenia;
TGCT	cis	rs1475911	1.000	rs2839465	chr21:43511232	C/T	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.25	-4.71	-0.39	6.46e-6	IgG glycosylation;
TGCT	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg15691649	chr6:25882328	NA	-0.35	-4.55	-0.38	1.25e-5	Blood metabolite levels;
TGCT	trans	rs1814175	0.817	rs28525029	chr11:50045815	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.26	-0.55	3.77e-11	Height;
TGCT	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg19010396	chr19:19431384	KIAA0892;SF4	-0.56	-4.58	-0.38	1.13e-5	Tonsillectomy;
TGCT	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg00343986	chr7:65444356	GUSB	-0.23	-5.13	-0.42	1.07e-6	Aortic root size;
TGCT	cis	rs4727027	0.835	rs11767810	chr7:148774433	T/A	cg23583168	chr7:148888333	NA	-0.69	-8.67	-0.61	2.04e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs10791097	0.765	rs10894269	chr11:130722789	C/T	cg12179176	chr11:130786555	SNX19	0.75	8.62	0.61	2.66e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs3809566	0.636	rs4775604	chr15:63323880	A/C	cg00520135	chr15:63333846	TPM1	-0.4	-4.72	-0.39	6.34e-6	Platelet count;
TGCT	cis	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg22857025	chr5:266934	NA	0.31	6.2	0.49	7.82e-9	Breast cancer;
TGCT	cis	rs9640161	0.750	rs55974958	chr7:150037927	C/T	cg17279839	chr7:150038598	RARRES2	0.44	4.78	0.39	4.82e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs11935103	0.673	rs9997142	chr4:187297025	T/C	cg16785698	chr4:186456103	PDLIM3	0.44	4.47	0.37	1.74e-5	Response to citalopram treatment;
TGCT	cis	rs259282	0.605	rs35728696	chr19:33108096	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.52	4.8	0.4	4.39e-6	Schizophrenia;
TGCT	cis	rs7945705	0.837	rs10769981	chr11:9024460	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.46	5.05	0.41	1.56e-6	Hemoglobin concentration;
TGCT	cis	rs2842992	0.915	rs2842958	chr6:160108425	A/G	cg11366901	chr6:160182831	ACAT2	0.94	6.18	0.49	8.48e-9	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs6003958	1	rs6003958	chr22:24264089	T/G	cg12419862	chr22:24373484	LOC391322	0.87	7.7	0.57	3.63e-12	S-phenylmercapturic acid levels in smokers;
TGCT	cis	rs17253792	0.822	rs75936910	chr14:56149351	T/C	cg01858014	chr14:56050164	KTN1	-0.35	-4.62	-0.38	9.37e-6	Putamen volume;
TGCT	trans	rs8073060	1.000	rs8073060	chr17:33875262	T/A	cg19694781	chr19:47549865	TMEM160	0.41	7.48	0.56	1.18e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs1127311	1.000	rs1127311	chr1:154556663	G/A	cg17218026	chr1:154582156	ADAR	0.29	7.29	0.55	3.13e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs55692411	0.537	rs13071931	chr3:50062878	G/A	cg14019146	chr3:50243930	SLC38A3	-0.21	-4.44	-0.37	1.98e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs17331151	0.541	rs1139106	chr3:52871101	G/A	cg11137980	chr3:52469226	SEMA3G	0.28	4.94	0.41	2.51e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs8017423	0.647	rs12895269	chr14:90822430	T/C	cg04374321	chr14:90722782	PSMC1	-0.54	-5.41	-0.44	3.13e-7	Mortality in heart failure;
TGCT	cis	rs17401966	0.518	rs10864453	chr1:10407169	T/G	cg19773385	chr1:10388646	KIF1B	-0.22	-5.27	-0.43	5.96e-7	Hepatocellular carcinoma;
TGCT	cis	rs6570726	0.791	rs9376953	chr6:145912226	G/T	cg13319975	chr6:146136371	FBXO30	-0.54	-4.77	-0.39	5.1e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11190604	0.767	rs10883478	chr10:102162852	C/T	cg16342193	chr10:102329863	NA	-0.39	-5.05	-0.41	1.54e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7729723	0.545	rs3910201	chr5:137812934	A/G	cg19169342	chr5:137827400	NA	0.33	4.71	0.39	6.52e-6	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);
TGCT	cis	rs6089829	0.962	rs3746747	chr20:61667631	T/C	cg02380750	chr20:61661411	NA	0.33	5.82	0.46	4.76e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9948	0.521	rs59073958	chr2:97352693	C/T	cg01990225	chr2:97406019	LMAN2L	-0.94	-4.74	-0.39	5.71e-6	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg25427524	chr10:38739819	LOC399744	-0.39	-8.04	-0.59	5.95e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2224391	0.628	rs2773309	chr6:5248916	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.98	-6.21	-0.49	7.43e-9	Height;
TGCT	cis	rs4786125	0.665	rs6500858	chr16:6906111	T/C	cg03623568	chr16:6915990	A2BP1	-0.42	-6.19	-0.49	7.91e-9	Heart rate variability traits (SDNN);
TGCT	cis	rs55962025	1.000	rs4690071	chr4:3086753	A/T	cg06533319	chr4:3265114	C4orf44	0.23	4.75	0.39	5.53e-6	Parental longevity (mother's age at death);
TGCT	cis	rs9534288	0.797	rs9526127	chr13:46571744	A/G	cg15192986	chr13:46630673	CPB2	-0.53	-7.62	-0.56	5.82e-12	Blood protein levels;
TGCT	trans	rs2898290	0.694	rs2248909	chr8:11392093	A/C	cg15556689	chr8:8085844	FLJ10661	-0.76	-7.1	-0.54	8.56e-11	Systolic blood pressure;
TGCT	cis	rs9359856	0.510	rs2768940	chr6:90436319	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.45	-4.66	-0.39	7.9e-6	Bipolar disorder;
TGCT	cis	rs1524927	1.000	rs12704875	chr7:96341385	G/A	cg03808172	chr7:96339361	SHFM1	0.49	5.06	0.41	1.45e-6	Total body bone mineral density;
TGCT	cis	rs4916646	0.592	rs10030756	chr4:11517076	C/T	cg16957523	chr4:11431359	HS3ST1	-0.47	-4.66	-0.39	8.08e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs797680	0.856	rs531358	chr1:93676011	C/T	cg17826107	chr1:92977322	EVI5	-0.24	-5.29	-0.43	5.47e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs11190604	0.943	rs11190588	chr10:102273565	C/T	cg16342193	chr10:102329863	NA	-0.44	-5.5	-0.44	2.04e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs1005277	0.540	rs1987431	chr10:37988887	T/C	cg25427524	chr10:38739819	LOC399744	-0.33	-6.58	-0.51	1.16e-9	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7572733	0.534	rs700684	chr2:198713099	C/T	cg00792783	chr2:198669748	PLCL1	0.56	5.08	0.42	1.35e-6	Dermatomyositis;
TGCT	cis	rs2067615	0.579	rs10778502	chr12:107090201	T/C	cg15890332	chr12:107067104	RFX4	0.31	6.21	0.49	7.19e-9	Heart rate;
TGCT	cis	rs3733585	0.534	rs7375642	chr4:9955236	A/G	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.7	-0.52	6.62e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs270601	0.837	rs367805	chr5:131701279	T/C	cg24060327	chr5:131705240	SLC22A5	-0.77	-8.49	-0.61	5.36e-14	Acylcarnitine levels;
TGCT	cis	rs6125597	0.967	rs6122779	chr20:47893014	T/C	cg11220565	chr20:47934802	NA	-0.3	-4.61	-0.38	9.8e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9788721	0.836	rs1504550	chr15:78766250	A/G	cg18825076	chr15:78729989	IREB2	-0.34	-5.12	-0.42	1.13e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
TGCT	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg21171335	chr12:122356390	WDR66	0.63	7.03	0.53	1.24e-10	Mean corpuscular volume;
TGCT	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg11644478	chr21:40555479	PSMG1	1.03	11.02	0.7	4.14e-20	Cognitive function;
TGCT	cis	rs9467773	0.620	rs2494692	chr6:26615223	G/A	cg09904177	chr6:26538194	HMGN4	0.66	6.3	0.49	4.64e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs36051895	0.623	rs12349113	chr9:5254224	T/A	cg02405213	chr9:5042618	JAK2	-0.75	-9.51	-0.65	1.9e-16	Pediatric autoimmune diseases;
TGCT	cis	rs2153535	0.541	rs7774752	chr6:8468978	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs62244186	0.659	rs56234157	chr3:44516221	G/A	cg10263370	chr3:44754102	ZNF502	-0.4	-4.8	-0.4	4.47e-6	Depressive symptoms;
TGCT	cis	rs13256369	0.851	rs13266562	chr8:8564065	T/C	cg18904891	chr8:8559673	CLDN23	0.59	5.46	0.44	2.54e-7	Obesity-related traits;
TGCT	cis	rs6599388	0.803	rs11248057	chr4:906131	C/G	cg27636047	chr4:1581088	NA	0.42	4.63	0.38	8.94e-6	Parkinson's disease;
TGCT	cis	rs854624	0.892	rs1734958	chr17:34336561	G/A	cg02022384	chr17:34097390	MMP28	0.46	4.63	0.38	9.18e-6	Blood protein levels;
TGCT	cis	rs10411936	0.785	rs2363120	chr19:16519871	C/A	cg19006008	chr19:16999768	F2RL3	-0.27	-4.73	-0.39	5.95e-6	White blood cell count;Multiple sclerosis;
TGCT	cis	rs7772486	0.682	rs1337840	chr6:146042558	T/C	cg05347473	chr6:146136440	FBXO30	-0.5	-4.75	-0.39	5.58e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9357506	0.818	rs1345057	chr6:46306835	C/T	cg21115430	chr6:46460003	NA	-0.26	-5.17	-0.42	9.2e-7	Body mass index;
TGCT	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.36	0.55	2.25e-11	Prudent dietary pattern;
TGCT	cis	rs3892630	0.757	rs8109823	chr19:33183316	A/G	cg22980127	chr19:33182716	NUDT19	0.72	5.21	0.42	7.77e-7	Red blood cell traits;
TGCT	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs3820068	0.581	rs34453754	chr1:15993208	G/C	cg05660106	chr1:15850417	CASP9	0.68	6.52	0.51	1.59e-9	Systolic blood pressure;
TGCT	cis	rs11190604	1.000	rs10883509	chr10:102296461	C/T	cg23241863	chr10:102295624	HIF1AN	0.71	5.37	0.43	3.67e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs1008375	0.966	rs1860599	chr4:17638900	T/C	cg10189774	chr4:17578691	LAP3	0.62	5.5	0.44	2.08e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs806215	0.950	rs3735642	chr7:127224286	A/G	cg25922125	chr7:127225783	GCC1	-0.61	-6.29	-0.49	5.07e-9	Type 2 diabetes;
TGCT	cis	rs8050907	0.744	rs8063956	chr16:4531761	T/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.53	4.57	0.38	1.15e-5	Obesity-related traits;
TGCT	cis	rs916888	0.610	rs199446	chr17:44813169	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.58	-4.51	-0.38	1.51e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs4253772	0.575	rs9615956	chr22:46749634	C/T	cg24881330	chr22:46731750	TRMU	0.94	4.45	0.37	1.86e-5	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs3806843	0.548	rs246057	chr5:140325583	A/G	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs12911832	0.727	rs2604454	chr15:59098732	C/A	cg05156742	chr15:59063176	FAM63B	0.56	5.5	0.44	2.08e-7	Schizophrenia;
TGCT	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg22963979	chr7:1858916	MAD1L1	-0.45	-7.41	-0.55	1.73e-11	Autism spectrum disorder or schizophrenia;
TGCT	trans	rs3848445	1.000	rs7214411	chr17:14288990	C/T	cg24575275	chr7:1094737	C7orf50	-0.71	-6.72	-0.52	6.03e-10	Protein quantitative trait loci;
TGCT	trans	rs9329221	0.682	rs11786677	chr8:10264260	A/G	cg15556689	chr8:8085844	FLJ10661	0.74	6.71	0.52	6.28e-10	Neuroticism;
TGCT	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg03709012	chr19:19516395	GATAD2A	0.75	6.16	0.48	9.21e-9	Tonsillectomy;
TGCT	cis	rs1401999	1.000	rs4148579	chr3:183685249	T/C	cg01324343	chr3:183735012	ABCC5	0.82	10.97	0.7	5.41e-20	Anterior chamber depth;
TGCT	cis	rs2932538	0.961	rs2932529	chr1:113193364	G/A	cg10983938	chr1:113465962	AFARP1;SLC16A1	-0.21	-4.44	-0.37	1.99e-5	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.54	-5.1	-0.42	1.22e-6	Electroencephalogram traits;
TGCT	cis	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg08564027	chr20:61660810	NA	0.37	6.84	0.52	3.22e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2354432	0.607	rs57078845	chr1:146722222	G/A	cg25205988	chr1:146714368	CHD1L	-1.34	-6.07	-0.48	1.44e-8	Mitochondrial DNA levels;
TGCT	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9831754	0.906	rs6782626	chr3:78406178	T/C	cg06138941	chr3:78371609	NA	-0.48	-5.2	-0.42	7.84e-7	Calcium levels;
TGCT	trans	rs62103177	0.810	rs62103178	chr18:77624555	C/G	cg05926928	chr17:57297772	GDPD1	1.22	11.16	0.71	1.85e-20	Opioid sensitivity;
TGCT	cis	rs614226	1.000	rs1167726	chr12:120967364	A/C	cg01236616	chr12:121019343	POP5	-1.24	-12.65	-0.75	4.55e-24	Type 1 diabetes nephropathy;
TGCT	cis	rs7666738	0.546	rs6827131	chr4:98744810	C/G	cg17366294	chr4:99064904	C4orf37	0.62	5.77	0.46	6.03e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg10802521	chr3:52805072	NEK4	-0.78	-10.01	-0.67	1.22e-17	Bipolar disorder;
TGCT	cis	rs7975161	0.640	rs10778323	chr12:104746075	A/G	cg25273343	chr12:104657179	TXNRD1	0.32	4.64	0.38	8.79e-6	Toenail selenium levels;
TGCT	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg08683831	chr4:1404607	NA	-0.47	-4.67	-0.39	7.72e-6	Obesity-related traits;
TGCT	cis	rs12971120	0.891	rs4891557	chr18:72170299	C/T	cg26446133	chr18:72167187	CNDP2	-0.37	-6.33	-0.49	4.13e-9	Refractive error;
TGCT	cis	rs926938	0.527	rs7526844	chr1:115543759	T/C	cg12756093	chr1:115239321	AMPD1	0.35	5.09	0.42	1.3e-6	Autism;
TGCT	cis	rs921968	0.643	rs563268	chr2:219372912	T/G	cg02176678	chr2:219576539	TTLL4	0.38	5.48	0.44	2.31e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs8056742	0.555	rs16975088	chr16:85017951	A/C	cg00229868	chr16:85520891	NA	-0.43	-5.19	-0.42	8.51e-7	Amyotrophic lateral sclerosis;
TGCT	cis	rs367943	1.000	rs460079	chr5:112800525	G/A	cg12552261	chr5:112820674	MCC	-0.23	-4.78	-0.39	4.94e-6	Type 2 diabetes;
TGCT	cis	rs4919694	1.000	rs7100592	chr10:104769098	T/G	cg04362960	chr10:104952993	NT5C2	1.06	7.05	0.53	1.09e-10	Arsenic metabolism;
TGCT	cis	rs1048238	0.818	rs2017577	chr1:16350123	C/G	cg22431228	chr1:16359049	CLCNKA	-0.3	-6.35	-0.5	3.64e-9	Systolic blood pressure;
TGCT	cis	rs908922	0.676	rs6587686	chr1:152528948	C/T	cg20991723	chr1:152506922	NA	0.45	6.06	0.48	1.55e-8	Hair morphology;
TGCT	cis	rs2836950	0.501	rs2836983	chr21:40689336	G/A	cg06238570	chr21:40685208	BRWD1	-0.63	-6.44	-0.5	2.42e-9	Menarche (age at onset);
TGCT	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg24250549	chr1:154909240	PMVK	0.64	6.47	0.5	2.05e-9	Prostate cancer;
TGCT	cis	rs72949976	0.934	rs10197392	chr2:214038178	G/A	cg08319019	chr2:214017104	IKZF2	-0.81	-7.41	-0.55	1.74e-11	Lung cancer;Squamous cell lung carcinoma;
TGCT	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg22535103	chr8:58192502	C8orf71	0.43	4.84	0.4	3.72e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg20637647	chr7:64974828	NA	0.9	5.29	0.43	5.42e-7	Diabetic kidney disease;
TGCT	cis	rs68170813	0.559	rs9641378	chr7:106868003	T/C	cg02696742	chr7:106810147	HBP1	-0.71	-5.76	-0.46	6.26e-8	Coronary artery disease;
TGCT	cis	rs7647973	0.925	rs11130183	chr3:49228946	A/G	cg07636037	chr3:49044803	WDR6	0.63	5.09	0.42	1.27e-6	Menarche (age at onset);
TGCT	cis	rs4664308	1.000	rs10929966	chr2:160908341	C/T	cg03641300	chr2:160917029	PLA2R1	-0.26	-6.53	-0.51	1.49e-9	Idiopathic membranous nephropathy;
TGCT	cis	rs2235642	0.821	rs2281234	chr16:1602938	A/G	cg08296037	chr16:1584118	IFT140;TMEM204	-0.31	-5.64	-0.45	1.08e-7	Coronary artery disease;
TGCT	trans	rs4650994	1.000	rs35810840	chr1:178522642	G/A	cg05059571	chr16:84539110	KIAA1609	-0.41	-7.67	-0.57	4.37e-12	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs7727544	0.816	rs274555	chr5:131722951	C/T	cg24060327	chr5:131705240	SLC22A5	0.53	5.78	0.46	5.61e-8	Blood metabolite levels;
TGCT	cis	rs6570726	0.791	rs9403734	chr6:145931459	C/G	cg13319975	chr6:146136371	FBXO30	-0.53	-4.68	-0.39	7.51e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7258465	0.931	rs76195	chr19:18629830	A/G	cg06462663	chr19:18546047	ISYNA1	0.2	4.89	0.4	3.03e-6	Breast cancer;
TGCT	cis	rs7666738	0.753	rs28390295	chr4:99028497	C/A	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1468333	0.694	rs7719684	chr5:137614085	C/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.46	4.46	0.37	1.79e-5	Resting heart rate;
TGCT	cis	rs9948	0.655	rs2314399	chr2:97442390	G/A	cg01990225	chr2:97406019	LMAN2L	-1.02	-5.19	-0.42	8.43e-7	Erectile dysfunction and prostate cancer treatment;
TGCT	trans	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.8	-8.32	-0.6	1.31e-13	Body mass index;
TGCT	cis	rs2806561	0.734	rs2235548	chr1:23394062	G/A	cg12483005	chr1:23474871	LUZP1	0.38	4.77	0.39	5e-6	Height;
TGCT	cis	rs8072100	0.713	rs9899859	chr17:45513049	A/G	cg08085267	chr17:45401833	C17orf57	-0.52	-5.75	-0.46	6.48e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs71636778	0.509	rs34667713	chr1:27292678	T/A	cg23921621	chr1:27994728	IFI6	-0.43	-4.61	-0.38	9.92e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
TGCT	cis	rs9549367	0.713	rs2476319	chr13:113836519	C/T	cg09473364	chr13:112927190	NA	0.29	4.64	0.38	8.73e-6	Platelet distribution width;
TGCT	cis	rs6964587	0.585	rs10266481	chr7:91554338	T/C	cg17063962	chr7:91808500	NA	-0.76	-7.25	-0.55	3.94e-11	Breast cancer;
TGCT	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg19748678	chr4:122722346	EXOSC9	0.9	9.35	0.64	4.81e-16	Type 2 diabetes;
TGCT	cis	rs6582630	0.537	rs6582500	chr12:38534206	G/A	cg26384229	chr12:38710491	ALG10B	0.89	8.13	0.59	3.76e-13	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs10992471	0.580	rs7869521	chr9:95411059	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-4.57	-0.38	1.15e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs3892630	0.588	rs7245709	chr19:33242755	C/T	cg22980127	chr19:33182716	NUDT19	0.74	6.09	0.48	1.3e-8	Red blood cell traits;
TGCT	cis	rs13382811	0.722	rs62169223	chr2:145251445	C/T	cg21296320	chr2:145248607	ZEB2	0.36	4.55	0.38	1.27e-5	Myopia (severe);
TGCT	cis	rs919433	0.653	rs700651	chr2:198631714	G/A	cg00792783	chr2:198669748	PLCL1	0.55	4.92	0.4	2.66e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs10779751	0.770	rs1417131	chr1:11191922	T/C	cg08854313	chr1:11322531	MTOR	-0.84	-6.81	-0.52	3.82e-10	Body mass index;
TGCT	cis	rs4788570	0.584	rs6499530	chr16:71723089	C/G	cg06353428	chr16:71660113	MARVELD3	1.56	12.9	0.76	1.15e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs500492	0.542	rs400354	chr16:1074526	T/G	cg01366354	chr16:1075121	NA	0.36	5.23	0.43	6.99e-7	Polycystic ovary syndrome;
TGCT	cis	rs929596	0.793	rs13009407	chr2:234652347	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.34	-4.83	-0.4	3.95e-6	Total bilirubin levels in HIV-1 infection;
TGCT	cis	rs6969780	0.915	rs4722659	chr7:27166750	C/T	cg04317399	chr7:27170313	HOXA4	-0.44	-4.87	-0.4	3.3e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs7582180	0.764	rs12615466	chr2:100924065	C/A	cg14675211	chr2:100938903	LONRF2	0.49	4.8	0.4	4.49e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7953249	0.773	rs7979478	chr12:121420263	A/G	cg02403541	chr12:121454288	C12orf43	-0.52	-4.48	-0.37	1.68e-5	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs2836950	0.520	rs8133928	chr21:40689963	G/A	cg06238570	chr21:40685208	BRWD1	-0.63	-6.31	-0.49	4.41e-9	Menarche (age at onset);
TGCT	cis	rs4845570	0.749	rs11576810	chr1:151712201	C/G	cg07092448	chr1:151763213	TDRKH	-1.03	-7.53	-0.56	8.99e-12	Coronary artery disease;
TGCT	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg13012494	chr21:47604986	C21orf56	0.39	4.66	0.39	8.18e-6	Testicular germ cell tumor;
TGCT	cis	rs17433780	0.504	rs4142706	chr1:89475230	A/C	cg09516651	chr1:89888402	LOC400759	0.26	4.44	0.37	1.93e-5	Carotid intima media thickness;
TGCT	cis	rs11577318	0.853	rs4471263	chr1:26622700	C/T	cg12733254	chr1:26682999	NA	-0.2	-4.59	-0.38	1.06e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs7727544	0.735	rs2569266	chr5:131706791	T/C	cg24060327	chr5:131705240	SLC22A5	0.59	6.59	0.51	1.12e-9	Blood metabolite levels;
TGCT	cis	rs9916302	0.904	rs8079560	chr17:37497661	C/T	cg07936489	chr17:37558343	FBXL20	0.65	5.08	0.41	1.36e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs6582630	0.555	rs10880611	chr12:38509316	C/G	cg26384229	chr12:38710491	ALG10B	0.85	7.86	0.58	1.55e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs9467711	0.790	rs67777156	chr6:26633711	T/A	cg16898833	chr6:26189333	HIST1H4D	1.37	6.2	0.49	7.83e-9	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7809950	1.000	rs6976607	chr7:107223401	A/C	cg23024343	chr7:107201750	COG5	0.33	5.13	0.42	1.09e-6	Coronary artery disease;
TGCT	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg08219700	chr8:58056026	NA	0.38	4.69	0.39	6.95e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7208859	0.623	rs9890855	chr17:29111707	G/C	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg01416388	chr22:39784598	NA	-0.69	-7.12	-0.54	7.63e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs9309473	0.718	rs6546829	chr2:73613789	C/G	cg20560298	chr2:73613845	ALMS1	-0.48	-5.39	-0.44	3.36e-7	Metabolite levels;
TGCT	cis	rs1062177	1.000	rs12654573	chr5:151207473	T/G	cg12924095	chr5:151150029	G3BP1	0.37	5.4	0.44	3.33e-7	Preschool internalizing problems;
TGCT	cis	rs9814567	0.502	rs12634127	chr3:134256159	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-6.84	-0.52	3.18e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs10838634	1.000	rs7129622	chr11:46828895	A/G	cg18332754	chr11:46939436	LRP4	0.9	4.59	0.38	1.05e-5	Schizophrenia;
TGCT	cis	rs9372498	0.505	rs9481789	chr6:118734320	A/C	cg21191810	chr6:118973309	C6orf204	-0.37	-4.77	-0.39	5.03e-6	Diastolic blood pressure;
TGCT	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2404602	1.000	rs2120107	chr15:76869789	A/G	cg22467129	chr15:76604101	ETFA	-0.46	-5.33	-0.43	4.49e-7	Blood metabolite levels;
TGCT	cis	rs6088580	0.634	rs2225837	chr20:33005634	C/T	cg06115741	chr20:33292138	TP53INP2	-0.55	-4.81	-0.4	4.28e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs56104184	0.775	rs55756106	chr19:49403055	A/G	cg21252483	chr19:49399788	TULP2	-0.42	-5.89	-0.47	3.47e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs7267979	1.000	rs1046073	chr20:25281333	G/A	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg09263875	chr16:632152	PIGQ	0.31	6.93	0.53	2.06e-10	Height;
TGCT	cis	rs250677	0.687	rs40522	chr5:148442295	G/A	cg18129178	chr5:148520854	ABLIM3	-0.43	-6.29	-0.49	5.05e-9	Breast cancer;
TGCT	cis	rs7523050	0.643	rs67567504	chr1:109402580	C/A	cg08274380	chr1:109419600	GPSM2	1.3	6.39	0.5	2.99e-9	Fat distribution (HIV);
TGCT	trans	rs9393777	0.920	rs13212562	chr6:27300310	A/G	cg00059246	chr12:54337929	HOXC13	0.62	7.5	0.56	1.06e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs931608	0.789	rs903937	chr19:22609988	G/C	cg23859931	chr19:22123797	NA	0.6	4.51	0.38	1.45e-5	Dental caries;Response to statins (LDL cholesterol change);
TGCT	cis	rs476633	0.708	rs8030657	chr15:41444979	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.66	-8.77	-0.62	1.18e-14	Glomerular filtration rate (creatinine);
TGCT	cis	rs4820539	0.966	rs5996470	chr22:23483255	G/A	cg14186256	chr22:23484241	RTDR1	1.02	13.96	0.78	3.44e-27	Bone mineral density;
TGCT	cis	rs7666738	0.716	rs11721453	chr4:99045485	G/T	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg11941060	chr3:133502564	NA	-0.26	-5.24	-0.43	6.58e-7	Iron status biomarkers;
TGCT	cis	rs1577917	0.958	rs12191340	chr6:86521400	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-5.53	-0.44	1.82e-7	Response to antipsychotic treatment;
TGCT	cis	rs7635838	0.819	rs2443709	chr3:11541814	C/T	cg00170343	chr3:11313890	ATG7	0.67	6.26	0.49	5.88e-9	HDL cholesterol;
TGCT	cis	rs3617	0.572	rs2245538	chr3:52852060	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.6	-0.38	1.02e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9394169	0.875	rs1547669	chr6:33775641	A/G	cg00334056	chr6:33755658	LEMD2	-0.24	-4.55	-0.38	1.28e-5	Essential tremor;
TGCT	cis	rs705471	0.762	rs555978	chr10:3662558	G/A	cg14308648	chr10:3568949	NA	0.25	4.44	0.37	1.95e-5	Capecitabine sensitivity;
TGCT	trans	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg11887960	chr12:57824829	NA	1.1	8.86	0.62	7.14e-15	Obesity-related traits;
TGCT	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.52	-5.85	-0.47	4.02e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs200810	0.634	rs35172302	chr6:97991869	G/A	cg16511841	chr6:97730490	C6orf167;MIR548H3	-0.68	-4.62	-0.38	9.38e-6	Body mass index;
TGCT	cis	rs2688608	0.901	rs2664282	chr10:75620757	T/C	cg04320760	chr10:75533139	FUT11	-0.3	-4.66	-0.39	7.88e-6	Inflammatory bowel disease;
TGCT	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg23708337	chr7:1209742	NA	0.51	4.46	0.37	1.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs6121246	0.559	rs6058462	chr20:30367674	C/T	cg10886678	chr20:30946050	ASXL1	-0.53	-4.5	-0.37	1.55e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs2075371	0.734	rs13225086	chr7:134011411	C/T	cg11752832	chr7:134001865	SLC35B4	0.64	5.38	0.43	3.64e-7	Mean platelet volume;
TGCT	cis	rs644799	0.735	rs10831432	chr11:95516040	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.8	9.01	0.63	3.14e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs6964587	1.000	rs9690778	chr7:91735299	A/G	cg17063962	chr7:91808500	NA	0.88	9.59	0.65	1.22e-16	Breast cancer;
TGCT	cis	rs858239	0.600	rs10256524	chr7:23144947	T/C	cg05602783	chr7:23145260	KLHL7	-0.67	-5.68	-0.45	9.25e-8	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs9916302	0.904	rs6503507	chr17:37525274	C/T	cg07936489	chr17:37558343	FBXL20	0.65	5.08	0.41	1.36e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7973719	0.868	rs2053887	chr12:7346530	G/A	cg07052231	chr12:7363540	PEX5	0.36	5.59	0.45	1.36e-7	IgG glycosylation;
TGCT	cis	rs7819412	0.807	rs6991930	chr8:10963288	G/C	cg27411982	chr8:10470053	RP1L1	-0.21	-4.54	-0.38	1.29e-5	Triglycerides;
TGCT	cis	rs713587	0.967	rs6749422	chr2:25150011	C/G	cg01884057	chr2:25150051	NA	0.4	8.24	0.59	2.05e-13	Body mass index in non-asthmatics;
TGCT	cis	rs6866344	0.570	rs4266420	chr5:178137161	C/G	cg03877680	chr5:178157825	ZNF354A	0.74	6.56	0.51	1.28e-9	Neutrophil percentage of white cells;
TGCT	cis	rs10782582	0.532	rs78106188	chr1:76137836	A/G	cg03433033	chr1:76189801	ACADM	-0.64	-7.35	-0.55	2.29e-11	Daytime sleep phenotypes;
TGCT	trans	rs77457752	0.690	rs12349345	chr9:13912075	T/C	cg12973904	chr7:149457885	NA	0.46	7.07	0.54	9.92e-11	Breast cancer;
TGCT	cis	rs2050392	0.737	rs7898978	chr10:30699800	T/C	cg18806716	chr10:30721971	MAP3K8	0.69	9.2	0.64	1.09e-15	Inflammatory bowel disease;
TGCT	cis	rs4975709	0.569	rs4975742	chr5:1858612	T/C	cg15595755	chr5:1867978	NA	0.46	5.11	0.42	1.18e-6	Cardiovascular disease risk factors;
TGCT	cis	rs7772486	0.720	rs6931553	chr6:146112348	T/C	cg05347473	chr6:146136440	FBXO30	-0.53	-4.99	-0.41	2.02e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7715806	0.500	rs2307112	chr5:75003413	A/C	cg19683494	chr5:74908142	NA	0.57	5.02	0.41	1.76e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs2354432	0.556	rs11239964	chr1:146753902	G/C	cg25205988	chr1:146714368	CHD1L	-1.34	-6.07	-0.48	1.44e-8	Mitochondrial DNA levels;
TGCT	cis	rs6831352	0.918	rs17218073	chr4:100055739	G/A	cg12011299	chr4:100065546	ADH4	-0.4	-4.88	-0.4	3.26e-6	Alcohol dependence;
TGCT	trans	rs2469997	0.623	rs2470023	chr8:120362995	T/A	cg01792902	chr3:178864926	PIK3CA	0.83	6.66	0.51	7.86e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs12188164	1.000	rs56042615	chr5:437667	G/A	cg26850624	chr5:429559	AHRR	-0.2	-4.82	-0.4	4.05e-6	Cystic fibrosis severity;
TGCT	cis	rs35883536	0.609	rs10783142	chr1:101043902	C/G	cg14855972	chr1:101004472	GPR88	-0.23	-4.44	-0.37	1.97e-5	Monocyte count;
TGCT	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.75	5.41	0.44	3.09e-7	Platelet count;
TGCT	cis	rs1801251	1.000	rs2674839	chr2:233669040	G/C	cg08000102	chr2:233561755	GIGYF2	0.64	6.56	0.51	1.34e-9	Coronary artery disease;
TGCT	cis	rs12477438	0.539	rs720228	chr2:99704547	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	17.53	0.84	2.35e-35	Chronic sinus infection;
TGCT	cis	rs7769051	1.000	rs9493444	chr6:133125320	C/G	cg07930552	chr6:133119739	C6orf192	0.94	5.04	0.41	1.6e-6	Type 2 diabetes nephropathy;
TGCT	trans	rs17685	0.712	rs9800948	chr7:75810473	A/G	cg19862616	chr7:65841803	NCRNA00174	0.47	8.5	0.61	4.97e-14	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs3849570	1.000	rs11915016	chr3:81833966	G/A	cg07356753	chr3:81810745	GBE1	-0.82	-7.62	-0.56	5.6e-12	Waist circumference;Body mass index;
TGCT	cis	rs9527	0.568	rs1926036	chr10:104883812	C/T	cg04362960	chr10:104952993	NT5C2	0.7	5.88	0.47	3.57e-8	Arsenic metabolism;
TGCT	cis	rs6121246	0.529	rs73235789	chr20:30196148	T/C	cg21427119	chr20:30132790	HM13	-0.39	-5.61	-0.45	1.25e-7	Mean corpuscular hemoglobin;
TGCT	cis	rs7605378	0.528	rs1704191	chr2:200816393	C/A	cg17644776	chr2:200775616	C2orf69	0.32	6.87	0.52	2.82e-10	Osteoporosis;
TGCT	cis	rs2456568	0.867	rs7935801	chr11:93658000	G/A	cg17595323	chr11:93583763	C11orf90	-0.47	-5.96	-0.47	2.49e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs12762955	0.608	rs7922760	chr10:1156815	G/C	cg20503657	chr10:835505	NA	-0.42	-5.24	-0.43	6.69e-7	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs7772486	0.727	rs10223508	chr6:146285205	C/T	cg05347473	chr6:146136440	FBXO30	-0.52	-5.1	-0.42	1.25e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs78487399	0.808	rs10180005	chr2:43737465	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.07	-0.41	1.41e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs13102973	0.965	rs11730310	chr4:135861925	A/G	cg14419869	chr4:135874104	NA	0.24	4.46	0.37	1.83e-5	Subjective well-being;
TGCT	cis	rs9921338	0.961	rs7206749	chr16:11376922	T/C	cg00044050	chr16:11439710	C16orf75	-0.85	-6.04	-0.48	1.64e-8	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs617219	0.710	rs2591386	chr5:78561373	C/T	cg05890484	chr5:78407552	BHMT	0.34	4.61	0.38	9.69e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg09323728	chr8:95962352	TP53INP1	-0.52	-6.6	-0.51	1.05e-9	Type 2 diabetes;
TGCT	cis	rs8028182	0.636	rs4322627	chr15:75810659	C/T	cg20655648	chr15:75932815	IMP3	0.59	4.62	0.38	9.55e-6	Sudden cardiac arrest;
TGCT	cis	rs7937682	0.855	rs527078	chr11:111479713	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.97	-9.71	-0.66	6.56e-17	Primary sclerosing cholangitis;
TGCT	cis	rs916888	0.821	rs199506	chr17:44859031	A/G	cg17911788	chr17:44343683	NA	0.59	6.13	0.48	1.09e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg26354017	chr1:205819088	PM20D1	0.59	7.3	0.55	3.07e-11	Menarche (age at onset);
TGCT	cis	rs7191439	0.522	rs8060640	chr16:88744430	G/C	cg27087555	chr16:88793112	FAM38A	-0.47	-4.74	-0.39	5.75e-6	Plateletcrit;
TGCT	cis	rs7552404	0.960	rs4949877	chr1:76201668	C/G	cg03433033	chr1:76189801	ACADM	0.82	9.74	0.66	5.46e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9303401	0.614	rs3803753	chr17:56540110	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.61	6.17	0.48	8.95e-9	Cognitive test performance;
TGCT	cis	rs7914558	0.966	rs10748836	chr10:104693917	G/A	cg04362960	chr10:104952993	NT5C2	0.58	5.15	0.42	9.77e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs13082711	0.513	rs66472045	chr3:27242887	G/A	cg02860705	chr3:27208620	NA	0.44	6.78	0.52	4.43e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs17376456	0.825	rs10054790	chr5:93272520	A/G	cg25358565	chr5:93447407	FAM172A	1.03	8.1	0.59	4.5e-13	Diabetic retinopathy;
TGCT	cis	rs3796352	1.000	rs11718538	chr3:52975987	C/G	cg07884673	chr3:53033167	SFMBT1	0.6	5.53	0.44	1.82e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs6840360	0.806	rs13149588	chr4:152717757	C/T	cg22705602	chr4:152727874	NA	0.25	4.61	0.38	1.01e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs12615966	0.651	rs72830472	chr2:105407426	C/T	cg16465502	chr2:105461796	NA	0.85	5.6	0.45	1.34e-7	Pancreatic cancer;
TGCT	cis	rs67460515	0.892	rs73026976	chr3:160964271	G/A	cg03342759	chr3:160939853	NMD3	-0.49	-5.3	-0.43	5.16e-7	Parkinson's disease;
TGCT	cis	rs8014204	0.566	rs7145575	chr14:75145528	T/A	cg06637938	chr14:75390232	RPS6KL1	0.61	5.51	0.44	1.97e-7	Caffeine consumption;
TGCT	cis	rs6586111	1.000	rs7086576	chr10:82372145	C/G	cg03086067	chr10:82368399	SH2D4B	-0.24	-4.7	-0.39	6.84e-6	Capecitabine sensitivity;
TGCT	cis	rs17345786	1.000	rs3804775	chr3:101306507	C/T	cg12386194	chr3:101231763	SENP7	0.59	5.39	0.44	3.43e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11105298	0.891	rs11105299	chr12:89877943	A/G	cg00757033	chr12:89920650	WDR51B	0.34	5.37	0.43	3.75e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs931127	0.617	rs10896027	chr11:65420760	C/G	cg27068330	chr11:65405492	SIPA1	0.56	4.94	0.41	2.47e-6	Systemic lupus erythematosus;
TGCT	cis	rs921968	0.643	rs645796	chr2:219389236	A/G	cg02176678	chr2:219576539	TTLL4	0.44	6.33	0.49	4.17e-9	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs9913156	0.789	rs56003988	chr17:4600764	G/A	cg23387401	chr17:4582204	PELP1	0.31	4.68	0.39	7.44e-6	Lymphocyte counts;
TGCT	cis	rs72627509	0.680	rs79641006	chr4:57847443	T/G	cg26694713	chr4:57773883	REST	0.64	4.83	0.4	3.94e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs6964587	0.967	rs2282969	chr7:91583772	T/C	cg22709100	chr7:91322751	NA	-0.27	-4.48	-0.37	1.68e-5	Breast cancer;
TGCT	cis	rs950169	0.595	rs11631921	chr15:85143277	G/A	cg17173187	chr15:85201210	NMB	0.51	5.43	0.44	2.9e-7	Schizophrenia;
TGCT	cis	rs6840360	0.593	rs1877185	chr4:152690348	C/T	cg17479576	chr4:152424074	FAM160A1	-0.57	-5.47	-0.44	2.35e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs10501293	0.703	rs7937104	chr11:43008528	A/G	cg03447554	chr11:43094025	NA	0.5	5.81	0.46	5.06e-8	Cognitive performance;
TGCT	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg13732083	chr21:47605072	C21orf56	0.37	4.85	0.4	3.62e-6	Testicular germ cell tumor;
TGCT	cis	rs2456568	0.900	rs877340	chr11:93689292	A/T	cg16099599	chr11:93583650	C11orf90	-0.39	-4.71	-0.39	6.41e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg18188782	chr20:61659543	NA	0.44	5.37	0.43	3.73e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs11626933	0.959	rs2149649	chr14:90774974	A/G	cg14092571	chr14:90743983	NA	0.31	6.27	0.49	5.59e-9	Gut microbiota (bacterial taxa);
TGCT	cis	rs4851251	1.000	rs4851251	chr2:100753490	C/T	cg07810366	chr2:100720526	AFF3	0.41	5.27	0.43	5.8e-7	Educational attainment (years of education);
TGCT	cis	rs4478037	0.732	rs12490111	chr3:33103007	G/A	cg19404215	chr3:33155277	CRTAP	1.24	5.97	0.47	2.36e-8	Major depressive disorder;
TGCT	cis	rs7091068	0.616	rs10748611	chr10:95482761	A/C	cg20715218	chr10:95462985	C10orf4	0.56	5.29	0.43	5.36e-7	Urinary tract infection frequency;
TGCT	cis	rs4148883	0.545	rs17595102	chr4:99986316	C/G	cg12011299	chr4:100065546	ADH4	0.39	5.67	0.45	9.5e-8	Alcohol dependence;
TGCT	cis	rs2115630	0.805	rs8042926	chr15:85205454	T/A	cg17173187	chr15:85201210	NMB	-0.36	-4.46	-0.37	1.84e-5	P wave terminal force;
TGCT	cis	rs7666738	0.830	rs1869082	chr4:98841254	T/A	cg05340658	chr4:99064831	C4orf37	0.53	6.17	0.48	8.71e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg03351412	chr1:154909251	PMVK	0.53	4.93	0.4	2.6e-6	Prostate cancer;
TGCT	cis	rs6921919	0.583	rs9468368	chr6:28364949	G/A	cg18815343	chr6:28367644	ZSCAN12	-0.56	-5.27	-0.43	5.78e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7772486	0.790	rs2265474	chr6:146182092	G/A	cg05347473	chr6:146136440	FBXO30	0.53	4.99	0.41	2e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs617219	0.671	rs12189188	chr5:78552312	C/T	cg05890484	chr5:78407552	BHMT	0.38	5.17	0.42	9.01e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg06028808	chr11:68637592	NA	0.51	6.54	0.51	1.48e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg22618164	chr12:122356400	WDR66	0.62	6.43	0.5	2.53e-9	Mean corpuscular volume;
TGCT	cis	rs12497850	0.931	rs7623023	chr3:48914238	G/A	cg18654377	chr3:49208889	KLHDC8B	-0.41	-5.49	-0.44	2.15e-7	Parkinson's disease;
TGCT	cis	rs11098499	0.909	rs17046118	chr4:120387496	T/G	cg09307838	chr4:120376055	NA	0.68	6.53	0.51	1.54e-9	Corneal astigmatism;
TGCT	cis	rs9527	0.571	rs4917985	chr10:104624072	C/T	cg15744005	chr10:104629667	AS3MT	-0.49	-6.13	-0.48	1.07e-8	Arsenic metabolism;
TGCT	cis	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg19635926	chr16:89946313	TCF25	0.27	4.58	0.38	1.11e-5	Skin colour saturation;
TGCT	cis	rs7107356	1	rs7107356	chr11:47676170	A/G	cg20307385	chr11:47447363	PSMC3	0.51	4.65	0.39	8.33e-6	Neuroticism;Neuroticism (multi-trait analysis);
TGCT	cis	rs2777491	1.000	rs66538814	chr15:41685917	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.73	-10.41	-0.68	1.24e-18	Ulcerative colitis;
TGCT	cis	rs473651	0.967	rs483042	chr2:239335320	A/G	cg18131467	chr2:239335373	ASB1	0.99	14.15	0.79	1.2100000000000001e-27	Multiple system atrophy;
TGCT	cis	rs6867032	1.000	rs7729761	chr5:2015783	G/T	cg26168224	chr5:2018326	NA	0.43	7.96	0.58	9.31e-13	Gut microbiome composition (winter);
TGCT	cis	rs7552404	0.824	rs1251077	chr1:76189745	C/G	cg22875332	chr1:76189707	ACADM	-0.82	-12.71	-0.75	3.22e-24	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs12643440	0.538	rs16894418	chr4:17141112	T/C	cg22650099	chr4:17144496	NA	-0.46	-4.7	-0.39	6.79e-6	Metabolite levels (Pyroglutamine);
TGCT	cis	rs28493229	0.881	rs59459325	chr19:41175390	C/T	cg11601297	chr19:41224147	ITPKC;ADCK4	0.59	5.69	0.46	8.61e-8	Kawasaki disease;
TGCT	cis	rs2688608	0.967	rs2633299	chr10:75656754	T/G	cg02947784	chr10:75434997	AGAP5	0.16	4.56	0.38	1.21e-5	Inflammatory bowel disease;
TGCT	cis	rs61897795	0.657	rs174589	chr11:61615803	C/G	cg19610905	chr11:61596333	FADS2	0.76	5.97	0.47	2.37e-8	Neutrophil count;Sum basophil neutrophil counts;
TGCT	cis	rs6088580	0.634	rs1890000	chr20:32968312	G/T	cg06115741	chr20:33292138	TP53INP2	-0.55	-4.81	-0.4	4.28e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs3858526	0.959	rs61876224	chr11:5952859	G/A	cg13902645	chr11:5959945	NA	-0.44	-4.78	-0.39	4.77e-6	DNA methylation (variation);
TGCT	cis	rs9467711	0.606	rs1978	chr6:26377573	A/T	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs80282103	0.618	rs74117831	chr10:1145707	A/C	cg08668510	chr10:1095578	IDI1	1.05	5.31	0.43	4.8e-7	Glomerular filtration rate (creatinine);
TGCT	trans	rs62103177	0.564	rs7228971	chr18:77738025	C/T	cg05926928	chr17:57297772	GDPD1	-0.79	-6.84	-0.52	3.26e-10	Opioid sensitivity;
TGCT	cis	rs9894429	0.624	rs9910935	chr17:79613949	T/C	cg18240062	chr17:79603768	NPLOC4	0.84	9.37	0.64	4.28e-16	Eye color traits;
TGCT	trans	rs877282	0.898	rs11253344	chr10:765162	C/T	cg22713356	chr15:30763199	NA	1.2	9.39	0.64	3.76e-16	Uric acid levels;
TGCT	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.81	9.15	0.63	1.44e-15	Menarche (age at onset);
TGCT	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	5.84	0.46	4.3e-8	Bipolar disorder;
TGCT	cis	rs7208859	0.673	rs9914271	chr17:29232625	G/A	cg18442181	chr17:29233375	C17orf42	-0.79	-4.78	-0.39	4.95e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs2204008	0.774	rs4534658	chr12:38246783	G/A	cg26384229	chr12:38710491	ALG10B	0.86	7.43	0.55	1.57e-11	Bladder cancer;
TGCT	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg25767906	chr1:53392781	SCP2	-0.53	-6.21	-0.49	7.34e-9	Monocyte count;
TGCT	cis	rs910316	1.000	rs10136948	chr14:75511075	C/T	cg08847533	chr14:75593920	NEK9	0.96	10.89	0.7	8.43e-20	Height;
TGCT	cis	rs4975709	0.569	rs931509	chr5:1858821	A/T	cg07747251	chr5:1868357	NA	0.38	5.31	0.43	4.95e-7	Cardiovascular disease risk factors;
TGCT	cis	rs73001065	0.901	rs8107974	chr19:19388500	A/T	cg03709012	chr19:19516395	GATAD2A	1.02	4.87	0.4	3.32e-6	LDL cholesterol;
TGCT	cis	rs79387448	0.745	rs7583683	chr2:103113763	C/T	cg09003973	chr2:102972529	NA	-0.84	-5.66	-0.45	9.87e-8	Gut microbiota (bacterial taxa);
TGCT	cis	rs8177253	0.632	rs6782523	chr3:133438917	C/T	cg08048268	chr3:133502702	NA	-0.54	-7.03	-0.53	1.21e-10	Iron status biomarkers;
TGCT	cis	rs9942416	0.660	rs60423072	chr5:75006113	T/A	cg02573091	chr5:74908125	NA	0.43	4.88	0.4	3.24e-6	Age-related disease endophenotypes;
TGCT	cis	rs9394169	0.514	rs1886355	chr6:33776877	C/T	cg13859433	chr6:33739653	LEMD2	-0.33	-5.85	-0.47	4.02e-8	Essential tremor;
TGCT	cis	rs9911578	0.935	rs302873	chr17:56769481	C/G	cg12560992	chr17:57184187	TRIM37	0.76	9.34	0.64	4.88e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs2239547	0.522	rs2564947	chr3:53046216	C/T	cg10802521	chr3:52805072	NEK4	0.6	5.58	0.45	1.43e-7	Schizophrenia;
TGCT	cis	rs11191270	0.554	rs11191253	chr10:104066507	A/T	cg15320455	chr10:103880129	LDB1	0.82	5.13	0.42	1.11e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs3125734	0.633	rs1873685	chr10:64032126	C/T	cg09941381	chr10:64027924	RTKN2	-0.37	-5.63	-0.45	1.14e-7	Rheumatoid arthritis;
TGCT	cis	rs910316	0.737	rs2098251	chr14:75492696	G/A	cg08847533	chr14:75593920	NEK9	0.84	8.77	0.62	1.16e-14	Height;
TGCT	cis	rs7909074	0.966	rs4268464	chr10:45401081	T/A	cg04218760	chr10:45406644	TMEM72	-0.27	-5.35	-0.43	4.05e-7	Mean corpuscular volume;
TGCT	cis	rs7412746	0.611	rs7556661	chr1:150892009	C/T	cg04414720	chr1:150670196	GOLPH3L	0.37	4.46	0.37	1.81e-5	Melanoma;
TGCT	cis	rs4699052	0.625	rs4481237	chr4:104254009	G/A	cg16532752	chr4:104119610	CENPE	-0.5	-4.92	-0.4	2.71e-6	Testicular germ cell tumor;
TGCT	cis	rs6570726	1.000	rs455109	chr6:145872665	C/T	cg05347473	chr6:146136440	FBXO30	0.5	4.46	0.37	1.82e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9560113	1.000	rs2104790	chr13:112177412	C/T	cg14154082	chr13:112174009	NA	0.37	5.07	0.41	1.42e-6	Menarche (age at onset);
TGCT	cis	rs11098499	0.954	rs10008392	chr4:120318839	G/A	cg09307838	chr4:120376055	NA	0.65	6.18	0.49	8.36e-9	Corneal astigmatism;
TGCT	cis	rs4689388	0.926	rs4416547	chr4:6293967	G/A	cg25554036	chr4:6271136	WFS1	0.54	7.37	0.55	2.11e-11	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs2239547	0.603	rs6789219	chr3:53098938	C/G	cg11645453	chr3:52864694	ITIH4	0.31	4.93	0.4	2.61e-6	Schizophrenia;
TGCT	cis	rs478607	0.831	rs61884374	chr11:64388929	A/G	cg19395706	chr11:64412079	NRXN2	0.48	4.84	0.4	3.8e-6	Urate levels;
TGCT	cis	rs11785400	0.793	rs9297970	chr8:143723386	C/T	cg10596483	chr8:143751796	JRK	0.53	5.3	0.43	5.12e-7	Schizophrenia;
TGCT	cis	rs9581857	0.547	rs9581870	chr13:28083957	T/G	cg22138327	chr13:27999177	GTF3A	0.72	4.51	0.38	1.46e-5	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg02725872	chr8:58115012	NA	-0.38	-4.76	-0.39	5.39e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1008375	0.932	rs6835077	chr4:17653285	A/T	cg18681998	chr4:17616180	MED28	0.98	10.79	0.7	1.49e-19	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs904251	0.504	rs9380677	chr6:37480366	A/G	cg25019722	chr6:37503610	NA	-0.54	-8.18	-0.59	2.84e-13	Cognitive performance;
TGCT	cis	rs11190604	1.000	rs4244338	chr10:102272802	A/G	cg16342193	chr10:102329863	NA	-0.41	-5.2	-0.42	7.99e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7772486	0.714	rs1883365	chr6:146076749	C/T	cg05347473	chr6:146136440	FBXO30	-0.49	-4.52	-0.38	1.42e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs868036	0.681	rs2241423	chr15:68086838	G/A	cg05925327	chr15:68127851	NA	-0.5	-4.85	-0.4	3.57e-6	Restless legs syndrome;
TGCT	cis	rs1371867	0.875	rs962451	chr8:101331010	C/T	cg06002616	chr8:101225028	SPAG1	-0.56	-6.58	-0.51	1.2e-9	Atrioventricular conduction;
TGCT	cis	rs6952808	0.609	rs34967784	chr7:1949507	T/G	cg04267008	chr7:1944627	MAD1L1	-0.37	-4.81	-0.4	4.23e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs9399135	0.967	rs10872427	chr6:135353452	T/C	cg24558204	chr6:135376177	HBS1L	0.48	4.77	0.39	5.14e-6	Red blood cell count;
TGCT	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg06108461	chr20:60628389	TAF4	0.64	9.5	0.65	2.08e-16	Body mass index;
TGCT	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg20203395	chr5:56204925	C5orf35	-0.57	-4.82	-0.4	4.15e-6	Initial pursuit acceleration;
TGCT	cis	rs7159131	0.711	rs10141466	chr14:36995776	T/G	cg07345734	chr14:36986363	NKX2-1	-0.49	-4.61	-0.38	1e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg10802521	chr3:52805072	NEK4	-0.81	-10.05	-0.67	9.7e-18	Bipolar disorder;
TGCT	cis	rs7914558	0.966	rs3977751	chr10:104920232	A/G	cg05855489	chr10:104503620	C10orf26	0.52	4.53	0.38	1.35e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs3820068	0.608	rs12092485	chr1:16048038	A/G	cg05660106	chr1:15850417	CASP9	0.75	6.85	0.52	3.06e-10	Systolic blood pressure;
TGCT	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg16414030	chr3:133502952	NA	-0.6	-9.07	-0.63	2.25e-15	Iron status biomarkers;
TGCT	cis	rs56399783	0.901	rs7803944	chr7:2809087	G/A	cg19731401	chr7:2775893	GNA12	0.35	5.09	0.42	1.28e-6	Childhood ear infection;
TGCT	cis	rs10791323	0.569	rs11223609	chr11:133741766	C/T	cg15485101	chr11:133734466	NA	0.37	5.42	0.44	3e-7	Childhood ear infection;
TGCT	cis	rs7572733	0.534	rs6434943	chr2:198762192	T/G	cg00792783	chr2:198669748	PLCL1	0.56	5.11	0.42	1.21e-6	Dermatomyositis;
TGCT	cis	rs7267979	0.932	rs6138588	chr20:25487523	C/T	cg16686733	chr20:25566563	NINL	0.56	5.69	0.46	8.49e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7772486	0.754	rs2064185	chr6:146066814	G/A	cg23711669	chr6:146136114	FBXO30	-0.97	-11.03	-0.7	4.03e-20	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg22963979	chr7:1858916	MAD1L1	-0.41	-6.48	-0.5	1.98e-9	Bipolar disorder and schizophrenia;
TGCT	cis	rs6684514	1.000	rs12132794	chr1:156281020	C/G	cg16558208	chr1:156270281	VHLL	-0.48	-9.6	-0.65	1.19e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs6674176	0.593	rs3791120	chr1:44431715	T/C	cg13606994	chr1:44402422	ARTN	-0.46	-4.95	-0.41	2.36e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9325144	0.671	rs12818797	chr12:39019409	A/G	cg13010199	chr12:38710504	ALG10B	-0.51	-4.58	-0.38	1.13e-5	Morning vs. evening chronotype;
TGCT	cis	rs4700695	0.764	rs251593	chr5:65313889	G/A	cg21114390	chr5:65439923	SFRS12	0.61	4.56	0.38	1.19e-5	Facial morphology (factor 19);
TGCT	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg23574427	chr4:122746245	BBS7;CCNA2	-0.35	-5.71	-0.46	7.8e-8	Type 2 diabetes;
TGCT	cis	rs826838	0.967	rs826879	chr12:39088999	A/C	cg26384229	chr12:38710491	ALG10B	-0.88	-8.19	-0.59	2.72e-13	Heart rate;
TGCT	cis	rs6998277	0.830	rs12543008	chr8:103603747	C/T	cg10187029	chr8:103597600	NA	0.56	8.83	0.62	8.12e-15	Migraine;
TGCT	cis	rs2072499	0.838	rs2758619	chr1:156162559	A/G	cg06970220	chr1:156163860	SLC25A44	0.72	6.3	0.49	4.62e-9	Testicular germ cell tumor;
TGCT	cis	rs7772486	0.875	rs9373483	chr6:146364194	A/G	cg05347473	chr6:146136440	FBXO30	0.56	5.42	0.44	2.96e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6088580	0.634	rs6579165	chr20:32994715	A/G	cg24642439	chr20:33292090	TP53INP2	-0.49	-4.49	-0.37	1.59e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs17387100	1.000	rs73230286	chr4:15993149	A/C	cg14577840	chr4:16257979	FLJ39653	0.47	4.51	0.38	1.5e-5	Suicide attempts in depression or bipolar disorder;
TGCT	cis	rs1568889	0.887	rs7102237	chr11:28344296	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.93	10.99	0.7	4.8e-20	Bipolar disorder;
TGCT	cis	rs11648796	0.757	rs66649828	chr16:766078	A/G	cg07343612	chr16:622815	PIGQ	-0.34	-5.01	-0.41	1.85e-6	Height;
TGCT	cis	rs2862064	0.932	rs1553317	chr5:156479424	A/C	cg12943317	chr5:156479607	HAVCR1	-0.45	-5.83	-0.46	4.42e-8	Platelet count;
TGCT	cis	rs4499344	0.657	rs402862	chr19:33111102	C/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.72	7.38	0.55	1.99e-11	Mean platelet volume;
TGCT	cis	rs2688608	0.592	rs7923045	chr10:75487498	A/T	cg04320760	chr10:75533139	FUT11	-0.41	-6.53	-0.51	1.49e-9	Inflammatory bowel disease;
TGCT	cis	rs12464483	0.591	rs72800120	chr2:30897122	G/A	cg17749961	chr2:30669863	LCLAT1	0.7	5.27	0.43	5.97e-7	Pre-treatment pain in head and neck squamous cell carcinoma;
TGCT	cis	rs1018836	0.923	rs6999898	chr8:91650549	G/A	cg16814680	chr8:91681699	NA	-0.85	-8.84	-0.62	7.95e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs12220238	1.000	rs7897778	chr10:75916105	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.88	7.24	0.55	4.04e-11	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs10114408	0.959	rs7847426	chr9:96642908	A/T	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	trans	rs2727020	0.731	rs10450572	chr11:49281073	T/C	cg15704280	chr7:45808275	SEPT13	0.73	8.33	0.6	1.27e-13	Coronary artery disease;
TGCT	cis	rs2486288	0.656	rs8037583	chr15:45546378	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.44	-5.39	-0.44	3.35e-7	Glomerular filtration rate;
TGCT	cis	rs3858526	0.959	rs10838795	chr11:5920721	A/G	cg05234568	chr11:5960015	NA	0.43	4.52	0.38	1.4e-5	DNA methylation (variation);
TGCT	cis	rs8031584	0.752	rs1852035	chr15:31184803	C/G	cg14829155	chr15:31115871	NA	-0.34	-4.57	-0.38	1.17e-5	Huntington's disease progression;
TGCT	cis	rs12711979	1.000	rs12711979	chr2:3869559	A/G	cg17052675	chr2:3827356	NA	-0.32	-5.85	-0.46	4.12e-8	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs7914558	0.752	rs7896519	chr10:104866863	C/T	cg15744005	chr10:104629667	AS3MT	-0.45	-5.55	-0.45	1.65e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs1113500	0.787	rs10881501	chr1:108641745	C/T	cg22161131	chr1:109420278	GPSM2	0.5	4.6	0.38	1.02e-5	Growth-regulated protein alpha levels;
TGCT	cis	rs734999	0.550	rs2985855	chr1:2531372	A/C	cg18854424	chr1:2615690	NA	-0.46	-5.36	-0.43	3.84e-7	Ulcerative colitis;
TGCT	cis	rs2046867	0.818	rs62249861	chr3:72867779	A/G	cg25664220	chr3:72788482	NA	-0.56	-7.04	-0.53	1.16e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg18252515	chr7:66147081	NA	-1.2	-7.83	-0.58	1.89e-12	Diabetic kidney disease;
TGCT	cis	rs3845702	0.736	rs72958863	chr2:180808144	C/T	cg01881094	chr2:180872142	CWC22	1.04	6.58	0.51	1.16e-9	Schizophrenia;
TGCT	cis	rs4757319	0.656	rs4334003	chr11:15345573	G/T	cg26427818	chr11:15093613	NA	-0.39	-4.76	-0.39	5.38e-6	Breast cancer;
TGCT	cis	rs28735056	0.967	rs623546	chr18:77595228	C/T	cg20368463	chr18:77673604	PQLC1	-0.45	-5.53	-0.44	1.84e-7	Schizophrenia;
TGCT	cis	rs6582630	0.519	rs8186881	chr12:38310285	A/G	cg13010199	chr12:38710504	ALG10B	0.57	4.49	0.37	1.62e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs17376456	0.569	rs7721668	chr5:93290995	G/A	cg25358565	chr5:93447407	FAM172A	-0.62	-5.97	-0.47	2.33e-8	Diabetic retinopathy;
TGCT	cis	rs9467711	0.651	rs71557316	chr6:26072981	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.6	-4.67	-0.39	7.83e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2013441	1.000	rs1373147	chr17:20206645	T/A	cg18979559	chr17:20280153	CCDC144C	-0.49	-4.99	-0.41	1.97e-6	Obesity-related traits;
TGCT	cis	rs5760092	0.755	rs3884794	chr22:24251766	C/A	cg02953382	chr22:24373134	LOC391322	-0.81	-7.23	-0.54	4.31e-11	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg27211696	chr2:191398769	TMEM194B	0.29	5.3	0.43	5.19e-7	Pulse pressure;
TGCT	cis	rs8031584	0.678	rs8035703	chr15:31168472	T/C	cg08109568	chr15:31115862	NA	-0.38	-5.03	-0.41	1.67e-6	Huntington's disease progression;
TGCT	cis	rs11190604	0.943	rs7900678	chr10:102229016	T/C	cg23241863	chr10:102295624	HIF1AN	0.62	4.87	0.4	3.27e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs12681287	0.604	rs7017716	chr8:87429001	A/C	cg27223183	chr8:87520930	FAM82B	-0.81	-6.15	-0.48	9.62e-9	Caudate activity during reward;
TGCT	cis	rs950169	0.881	rs150965	chr15:85080527	T/G	cg17173187	chr15:85201210	NMB	0.54	5.51	0.44	2.01e-7	Schizophrenia;
TGCT	cis	rs11190604	1.000	rs7088512	chr10:102303498	G/T	cg16342193	chr10:102329863	NA	-0.4	-4.89	-0.4	3e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2862064	1.000	rs1501910	chr5:156418790	A/G	cg12943317	chr5:156479607	HAVCR1	-0.41	-5.41	-0.44	3.17e-7	Platelet count;
TGCT	cis	rs4654899	0.627	rs637990	chr1:21047616	A/G	cg01072550	chr1:21505969	NA	0.39	5.91	0.47	3.05e-8	Superior frontal gyrus grey matter volume;
TGCT	trans	rs11722228	0.522	rs73212808	chr4:10055439	G/C	cg26043149	chr18:55253948	FECH	1.15	11.94	0.73	2.46e-22	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs7975161	0.640	rs10735394	chr12:104687142	C/A	cg25273343	chr12:104657179	TXNRD1	-0.32	-4.52	-0.38	1.42e-5	Toenail selenium levels;
TGCT	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg11494091	chr17:61959527	GH2	0.61	14.8	0.8	3.65e-29	Prudent dietary pattern;
TGCT	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg12311346	chr5:56204834	C5orf35	0.55	5.89	0.47	3.44e-8	Initial pursuit acceleration;
TGCT	cis	rs11673344	0.504	rs8110796	chr19:37623584	C/T	cg08039142	chr19:36980659	ZNF566	0.51	4.68	0.39	7.31e-6	Obesity-related traits;
TGCT	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg12288994	chr5:1860383	NA	0.25	4.81	0.4	4.25e-6	Cardiovascular disease risk factors;
TGCT	cis	rs4819052	0.808	rs2838825	chr21:46655651	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.68	6.05	0.48	1.58e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2730245	0.510	rs2788471	chr7:158649786	G/T	cg11984989	chr7:158649758	WDR60	1.05	9.85	0.66	2.94e-17	Height;
TGCT	cis	rs7249142	0.549	rs62135499	chr19:19294237	T/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.54	5.36	0.43	3.9e-7	IgG glycosylation;
TGCT	cis	rs9291683	0.588	rs3796829	chr4:10019138	C/G	cg00071950	chr4:10020882	SLC2A9	0.75	10.33	0.68	2.04e-18	Bone mineral density;
TGCT	cis	rs9611565	0.649	rs6002480	chr22:42176917	A/T	cg17554472	chr22:41940697	POLR3H	-0.43	-4.58	-0.38	1.13e-5	Vitiligo;
TGCT	cis	rs4906332	1.000	rs13987	chr14:103969909	A/G	cg26031613	chr14:104095156	KLC1	-0.51	-4.51	-0.38	1.48e-5	Coronary artery disease;
TGCT	cis	rs3733631	1.000	rs1905172	chr4:104636034	C/T	cg24090629	chr4:104641072	TACR3	-0.74	-5.81	-0.46	5.02e-8	Menarche (age at onset);
TGCT	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg10802521	chr3:52805072	NEK4	0.74	9.07	0.63	2.26e-15	Bipolar disorder;
TGCT	cis	rs6922617	1.000	rs6922617	chr6:41336101	C/T	cg07798131	chr6:41471673	NA	0.81	4.46	0.37	1.8e-5	Alzheimer's disease biomarkers;
TGCT	cis	rs6076065	0.548	rs1112818	chr20:23323936	G/A	cg11657817	chr20:23433608	CST11	0.28	5.0	0.41	1.95e-6	Facial morphology (factor 15, philtrum width);
TGCT	cis	rs7666738	0.753	rs2903143	chr4:99040480	C/T	cg17366294	chr4:99064904	C4orf37	0.73	7.49	0.56	1.11e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10206020	0.921	rs9678719	chr2:1549628	A/G	cg01028140	chr2:1542097	TPO	-0.32	-4.65	-0.39	8.2e-6	IgG glycosylation;
TGCT	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.54	4.47	0.37	1.77e-5	Tonsillectomy;
TGCT	cis	rs826838	0.935	rs4583043	chr12:38645147	T/G	cg13010199	chr12:38710504	ALG10B	0.74	5.94	0.47	2.67e-8	Heart rate;
TGCT	cis	rs2692947	0.673	rs4907279	chr2:96399968	G/C	cg23100626	chr2:96804247	ASTL	0.38	4.5	0.37	1.55e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs11096990	0.613	rs12505690	chr4:39169045	G/A	cg24403649	chr4:39172243	NA	0.2	4.48	0.37	1.7e-5	Cognitive function;
TGCT	cis	rs4820792	0.725	rs1884817	chr22:29106945	G/C	cg03733026	chr22:29445468	ZNRF3	0.25	4.85	0.4	3.67e-6	Breast size;
TGCT	cis	rs2153535	0.580	rs7742794	chr6:8459723	C/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs2354432	1.000	rs7514864	chr1:146690102	T/C	cg25205988	chr1:146714368	CHD1L	1.24	7.08	0.54	9.53e-11	Mitochondrial DNA levels;
TGCT	cis	rs7772486	0.686	rs9390347	chr6:146044747	G/T	cg23711669	chr6:146136114	FBXO30	-0.88	-9.77	-0.66	4.64e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg21433313	chr16:3507492	NAT15	-0.37	-4.71	-0.39	6.45e-6	Tuberculosis;
TGCT	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg01802117	chr1:53393560	SCP2	-0.46	-5.94	-0.47	2.74e-8	Monocyte count;
TGCT	cis	rs17376456	0.877	rs13165147	chr5:93422214	G/A	cg21475434	chr5:93447410	FAM172A	0.59	4.66	0.39	8.09e-6	Diabetic retinopathy;
TGCT	cis	rs6570726	0.577	rs403345	chr6:145845171	T/C	cg13319975	chr6:146136371	FBXO30	-0.7	-6.36	-0.5	3.5e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7267979	1.000	rs6050566	chr20:25351071	G/A	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs651907	0.557	rs34376498	chr3:101480156	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.87	10.55	0.69	5.84e-19	Colorectal cancer;
TGCT	cis	rs849210	0.580	rs4675513	chr2:206179222	A/T	cg11793701	chr2:206547163	NRP2	-0.54	-4.49	-0.37	1.62e-5	Tonsillectomy;
TGCT	cis	rs7172809	0.599	rs3784788	chr15:77759896	C/T	cg22256960	chr15:77711686	NA	-0.5	-4.69	-0.39	7.07e-6	Glucose homeostasis traits;
TGCT	cis	rs12497850	0.966	rs6792510	chr3:48723302	G/C	cg07636037	chr3:49044803	WDR6	0.9	9.43	0.65	2.99e-16	Parkinson's disease;
TGCT	cis	rs12477438	0.520	rs4851188	chr2:99745898	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	10.3	0.68	2.42e-18	Chronic sinus infection;
TGCT	cis	rs3008870	0.959	rs2985808	chr1:67367741	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.07	11.84	0.73	4.25e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs2153535	0.580	rs7743686	chr6:8526111	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.55e-8	Motion sickness;
TGCT	cis	rs6964587	0.967	rs34574955	chr7:91847550	A/C	cg22709100	chr7:91322751	NA	0.28	4.51	0.38	1.49e-5	Breast cancer;
TGCT	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg10411590	chr13:21900810	NA	0.38	5.06	0.41	1.48e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	cis	rs12210905	0.688	rs60888769	chr6:27490922	A/G	cg08851530	chr6:28072375	NA	1.34	6.29	0.49	5.02e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs6988636	1.000	rs7002332	chr8:124185442	G/C	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs782590	0.935	rs10460508	chr2:55882565	A/C	cg03859395	chr2:55845619	SMEK2	0.89	10.46	0.68	9.87e-19	Metabolic syndrome;
TGCT	cis	rs35883536	0.626	rs10783140	chr1:101042083	A/G	cg06223162	chr1:101003688	GPR88	-0.42	-7.93	-0.58	1.1e-12	Monocyte count;
TGCT	cis	rs7178424	0.516	rs7163326	chr15:62338559	A/G	cg00456672	chr15:62358751	C2CD4A	-0.29	-4.45	-0.37	1.88e-5	Height;
TGCT	cis	rs2066819	1.000	rs41423244	chr12:56693520	A/C	cg26714650	chr12:56694279	CS	1.36	6.06	0.48	1.54e-8	Psoriasis vulgaris;
TGCT	cis	rs2235642	0.787	rs2235646	chr16:1601287	A/G	cg10465839	chr16:1584050	IFT140;TMEM204	-0.33	-5.58	-0.45	1.43e-7	Coronary artery disease;
TGCT	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg10802521	chr3:52805072	NEK4	-0.71	-8.79	-0.62	1.04e-14	Bipolar disorder;
TGCT	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	14.88	0.8	2.36e-29	Height;
TGCT	cis	rs12216125	0.537	rs12207059	chr6:25922385	C/T	cg17042849	chr6:26104293	HIST1H4C	-0.78	-5.66	-0.45	9.93e-8	Iron status biomarkers;
TGCT	cis	rs4919694	1.000	rs79254677	chr10:104691567	A/G	cg04362960	chr10:104952993	NT5C2	1.06	7.07	0.54	9.92e-11	Arsenic metabolism;
TGCT	cis	rs2115630	0.818	rs7176522	chr15:85215383	C/G	cg11189052	chr15:85197271	WDR73	-0.7	-7.04	-0.53	1.18e-10	P wave terminal force;
TGCT	cis	rs950169	0.512	rs4374136	chr15:84645007	C/G	cg11189052	chr15:85197271	WDR73	0.67	4.79	0.4	4.68e-6	Schizophrenia;
TGCT	cis	rs77633900	0.614	rs113557153	chr15:76994445	A/G	cg21673338	chr15:77095150	SCAPER	-0.49	-4.7	-0.39	6.76e-6	Non-glioblastoma glioma;Glioma;
TGCT	cis	rs17376456	0.778	rs72786662	chr5:93137630	C/T	cg21475434	chr5:93447410	FAM172A	0.62	4.67	0.39	7.58e-6	Diabetic retinopathy;
TGCT	cis	rs9325144	0.560	rs1825802	chr12:38650341	C/T	cg26384229	chr12:38710491	ALG10B	-0.63	-5.92	-0.47	2.9e-8	Morning vs. evening chronotype;
TGCT	cis	rs9303401	0.538	rs10515155	chr17:56481944	A/G	cg25039879	chr17:56429692	SUPT4H1	0.58	5.04	0.41	1.63e-6	Cognitive test performance;
TGCT	cis	rs2033711	0.902	rs4801589	chr19:58953398	C/G	cg04608855	chr19:58913158	NA	0.53	5.09	0.42	1.31e-6	Uric acid clearance;
TGCT	cis	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg08564027	chr20:61660810	NA	0.38	7.08	0.54	9.36e-11	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs6688613	0.685	rs2235184	chr1:166870528	A/G	cg07049167	chr1:166818506	POGK	-0.27	-5.64	-0.45	1.07e-7	Refractive astigmatism;
TGCT	cis	rs7833790	0.700	rs28390260	chr8:82769175	A/T	cg17211192	chr8:82754475	SNX16	0.97	9.09	0.63	2.04e-15	Diastolic blood pressure;
TGCT	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg06028808	chr11:68637592	NA	0.51	6.55	0.51	1.38e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg05025164	chr4:1340916	KIAA1530	0.68	5.65	0.45	1.07e-7	Longevity;
TGCT	cis	rs7635838	0.826	rs9867963	chr3:11469126	C/T	cg00170343	chr3:11313890	ATG7	0.68	6.55	0.51	1.41e-9	HDL cholesterol;
TGCT	cis	rs2073300	1.000	rs6114135	chr20:23456746	C/A	cg09953122	chr20:23471693	CST8	-0.59	-4.7	-0.39	6.74e-6	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs12477438	0.520	rs6717723	chr2:99756930	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.89	9.05	0.63	2.42e-15	Chronic sinus infection;
TGCT	cis	rs1997103	1.000	rs6977292	chr7:55396335	T/C	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs12477438	0.784	rs13407840	chr2:99569928	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-7.6	-0.56	6.47e-12	Chronic sinus infection;
TGCT	cis	rs727563	0.635	rs5758444	chr22:42133921	T/A	cg13695892	chr22:41940480	POLR3H	0.89	8.43	0.6	7.37e-14	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs7666738	0.512	rs1648536	chr4:99019881	G/T	cg17366294	chr4:99064904	C4orf37	-0.54	-5.86	-0.47	3.98e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7772486	0.654	rs1011597	chr6:146075672	A/C	cg23711669	chr6:146136114	FBXO30	-0.9	-10.02	-0.67	1.11e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7615952	0.611	rs7632305	chr3:125634767	C/T	cg05084668	chr3:125655381	ALG1L	-0.69	-4.49	-0.37	1.62e-5	Blood pressure (smoking interaction);
TGCT	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7659604	0.521	rs4240263	chr4:122683623	C/T	cg19748678	chr4:122722346	EXOSC9	-0.51	-5.17	-0.42	8.96e-7	Type 2 diabetes;
TGCT	cis	rs2762353	0.562	rs1165206	chr6:25867566	G/A	cg03264133	chr6:25882463	NA	-0.58	-5.89	-0.47	3.44e-8	Blood metabolite levels;
TGCT	cis	rs1570884	0.516	rs2146144	chr13:50170245	C/T	cg08779649	chr13:50194554	NA	0.37	5.82	0.46	4.74e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
TGCT	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg07157834	chr1:205819609	PM20D1	-0.36	-5.62	-0.45	1.19e-7	Monocyte percentage of white cells;
TGCT	cis	rs2153535	0.580	rs1577471	chr6:8485905	T/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg01341218	chr17:43662625	NA	-1.12	-9.65	-0.65	8.83e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs13242816	1.000	rs13233553	chr7:116182232	C/G	cg16553024	chr7:116138462	CAV2	-0.44	-5.26	-0.43	6.11e-7	P wave duration;
TGCT	cis	rs797680	0.856	rs627779	chr1:93684089	T/C	cg17826107	chr1:92977322	EVI5	0.24	5.29	0.43	5.47e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs11031096	0.727	rs7940013	chr11:4138304	C/T	cg18678763	chr11:4115507	RRM1	-0.47	-5.86	-0.47	4e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs9611565	0.559	rs7290990	chr22:41964357	C/A	cg03806693	chr22:41940476	POLR3H	-1.08	-11.36	-0.71	6.34e-21	Vitiligo;
TGCT	cis	rs4727027	0.651	rs12704068	chr7:148856153	T/C	cg15662616	chr7:148823355	ZNF425;ZNF398	0.55	4.52	0.38	1.42e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg06600287	chr1:53387719	ECHDC2	-0.21	-4.57	-0.38	1.17e-5	Monocyte count;
TGCT	cis	rs2797160	0.967	rs1739368	chr6:126011079	C/T	cg05901451	chr6:126070800	HEY2	0.75	6.33	0.49	4.14e-9	Endometrial cancer;
TGCT	cis	rs9549367	0.713	rs2476319	chr13:113836519	C/T	cg18105134	chr13:113819100	PROZ	0.46	8.58	0.61	3.25e-14	Platelet distribution width;
TGCT	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg27170947	chr2:26402098	FAM59B	-0.39	-4.46	-0.37	1.8e-5	Gut microbiome composition (summer);
TGCT	cis	rs7552404	0.655	rs5745336	chr1:76273519	G/A	cg10523679	chr1:76189770	ACADM	0.75	7.21	0.54	4.89e-11	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs1218582	0.596	rs4845676	chr1:154827861	C/G	cg09359103	chr1:154839909	KCNN3	-0.51	-7.92	-0.58	1.15e-12	Prostate cancer;
TGCT	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg25767906	chr1:53392781	SCP2	0.6	7.21	0.54	4.89e-11	Monocyte count;
TGCT	cis	rs8103278	1.000	rs9807819	chr19:46239598	C/T	cg14061069	chr19:46274453	DMPK	-0.42	-6.06	-0.48	1.48e-8	Coronary artery disease;
TGCT	cis	rs1045714	0.895	rs4719594	chr7:2639790	G/A	cg17215154	chr7:2644645	IQCE	0.28	4.97	0.41	2.2e-6	Urate levels in lean individuals;
TGCT	cis	rs11577318	0.538	rs10902745	chr1:26687070	G/C	cg14210634	chr1:25870291	LDLRAP1	0.53	4.68	0.39	7.24e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs57920188	0.640	rs4311852	chr1:4085353	C/A	cg20703997	chr1:4087676	NA	0.42	4.88	0.4	3.16e-6	Interleukin-17 levels;
TGCT	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg26818010	chr10:134567672	INPP5A	0.36	5.09	0.42	1.31e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs6933660	0.665	rs6921042	chr6:151732385	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.5	4.62	0.38	9.63e-6	Menarche (age at onset);
TGCT	cis	rs4253772	0.591	rs12167567	chr22:46659942	G/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.57	4.48	0.37	1.69e-5	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs1372520	0.684	rs2737010	chr4:90746466	G/A	cg20003494	chr4:90757398	SNCA	-0.63	-5.09	-0.42	1.3e-6	Neuroticism;
TGCT	cis	rs2229238	0.915	rs7514452	chr1:154438084	C/T	cg13067139	chr1:155221277	FAM189B	-0.2	-4.75	-0.39	5.6e-6	Coronary heart disease;
TGCT	cis	rs16958440	0.867	rs16949275	chr18:44700703	A/G	cg17192377	chr18:44677553	HDHD2	0.63	4.7	0.39	6.74e-6	Sitting height ratio;
TGCT	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg17971929	chr21:40555470	PSMG1	0.97	9.6	0.65	1.18e-16	Cognitive function;
TGCT	cis	rs752092	0.855	rs7171515	chr15:101769618	C/T	cg19997662	chr15:101784653	CHSY1	-0.27	-4.85	-0.4	3.69e-6	Corneal structure;
TGCT	cis	rs12048904	0.619	rs10783153	chr1:101328230	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.69	5.64	0.45	1.1e-7	Multiple sclerosis;
TGCT	cis	rs12950390	0.548	rs62076098	chr17:45860584	C/T	cg06532163	chr17:45867833	NA	0.27	4.81	0.4	4.31e-6	IgG glycosylation;
TGCT	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg20573242	chr4:122745356	CCNA2	0.64	5.6	0.45	1.29e-7	Type 2 diabetes;
TGCT	cis	rs2932538	0.614	rs6537741	chr1:113085175	A/C	cg22162597	chr1:113214053	CAPZA1	-0.22	-4.54	-0.38	1.32e-5	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg08280861	chr8:58055591	NA	0.4	4.67	0.39	7.79e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs11031096	0.678	rs1442727	chr11:4188188	G/T	cg18678763	chr11:4115507	RRM1	0.46	6.02	0.48	1.81e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs1348850	0.750	rs13031008	chr2:178477114	G/A	cg22681709	chr2:178499509	PDE11A	-0.48	-5.77	-0.46	6.03e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg06634786	chr22:41940651	POLR3H	0.87	8.08	0.59	4.79e-13	Vitiligo;
TGCT	cis	rs9473924	0.505	rs2223869	chr6:50904239	C/T	cg14470998	chr6:50812995	TFAP2B	1.35	8.39	0.6	9.05e-14	Body mass index;
TGCT	trans	rs4512344	0.510	rs35181953	chr8:11435049	G/A	cg06636001	chr8:8085503	FLJ10661	-0.75	-6.9	-0.53	2.33e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs9952991	0.622	rs547268	chr18:12823056	G/T	cg23598886	chr18:12777645	NA	0.54	4.74	0.39	5.88e-6	Inflammatory skin disease;
TGCT	cis	rs67478160	0.643	rs2887282	chr14:104280734	A/G	cg26031613	chr14:104095156	KLC1	-0.6	-6.06	-0.48	1.52e-8	Schizophrenia;
TGCT	cis	rs2239547	0.522	rs6771610	chr3:53026104	T/C	cg10802521	chr3:52805072	NEK4	-0.58	-5.31	-0.43	4.8e-7	Schizophrenia;
TGCT	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg08280861	chr8:58055591	NA	0.54	5.98	0.47	2.17e-8	Developmental language disorder (linguistic errors);
TGCT	cis	rs6484504	0.532	rs12788257	chr11:31255045	T/C	cg26647111	chr11:31128758	NA	-0.35	-4.86	-0.4	3.44e-6	Red blood cell count;
TGCT	cis	rs8026198	0.517	rs8024113	chr15:42686838	G/C	cg23803468	chr15:43513504	EPB42	0.3	4.51	0.38	1.5e-5	Fibrinogen levels;
TGCT	cis	rs2562456	0.724	rs58001930	chr19:21742863	C/T	cg01304269	chr19:21688519	ZNF429	0.56	4.69	0.39	6.99e-6	Pain;
TGCT	cis	rs12477438	0.520	rs11692699	chr2:99730657	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	13.05	0.76	4.93e-25	Chronic sinus infection;
TGCT	cis	rs4700695	0.614	rs42321	chr5:65220342	G/A	cg21114390	chr5:65439923	SFRS12	0.64	4.61	0.38	9.9e-6	Facial morphology (factor 19);
TGCT	cis	rs5769765	1.000	rs761879	chr22:50241210	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	1.11	12.19	0.74	5.93e-23	Schizophrenia;
TGCT	cis	rs6089584	0.893	rs6089306	chr20:60574868	G/A	cg13770153	chr20:60521292	NA	-0.53	-6.98	-0.53	1.58e-10	Body mass index;
TGCT	cis	rs854765	0.647	rs9303144	chr17:17977355	T/C	cg04398451	chr17:18023971	MYO15A	-0.37	-6.18	-0.49	8.32e-9	Total body bone mineral density;
TGCT	cis	rs7949030	0.591	rs35156678	chr11:62369881	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.61	8.75	0.62	1.29e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs3733585	0.673	rs6814664	chr4:9956228	C/T	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.73	-0.57	3.25e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs9325144	0.671	rs35817541	chr12:38975001	T/C	cg10518543	chr12:38710700	ALG10B	-0.49	-4.68	-0.39	7.26e-6	Morning vs. evening chronotype;
TGCT	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.71	7.58	0.56	6.92e-12	Blood metabolite levels;
TGCT	cis	rs7513165	1.000	rs7513165	chr1:204147186	C/T	cg04791601	chr1:204159016	NA	-0.27	-5.51	-0.44	1.96e-7	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
TGCT	trans	rs4512344	0.510	rs35181953	chr8:11435049	G/A	cg15556689	chr8:8085844	FLJ10661	-0.77	-7.22	-0.54	4.68e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs453301	0.686	rs6987107	chr8:8893581	A/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-5.58	-0.45	1.42e-7	Joint mobility (Beighton score);
TGCT	cis	rs587847	0.708	rs1568449	chr15:37631589	C/T	cg00216138	chr15:37171175	LOC145845	0.31	4.66	0.39	7.96e-6	Intraocular pressure;
TGCT	cis	rs35883536	0.647	rs10875314	chr1:101043207	G/C	cg06223162	chr1:101003688	GPR88	-0.42	-7.93	-0.58	1.1e-12	Monocyte count;
TGCT	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg10047753	chr17:41438598	NA	0.95	9.0	0.63	3.2e-15	Menopause (age at onset);
TGCT	cis	rs9926296	0.744	rs164747	chr16:89708680	T/G	cg03388025	chr16:89894329	SPIRE2	-0.34	-5.17	-0.42	9.17e-7	Vitiligo;
TGCT	cis	rs1878931	0.501	rs9921169	chr16:3421261	A/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.76	7.12	0.54	7.59e-11	Body mass index (adult);
TGCT	cis	rs7432375	0.610	rs56163507	chr3:136516056	C/T	cg15507776	chr3:136538369	TMEM22	0.55	5.64	0.45	1.1e-7	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs79349575	0.783	rs4294857	chr17:46983391	G/A	cg07967210	chr17:47022446	SNF8	0.43	6.06	0.48	1.54e-8	Type 2 diabetes;
TGCT	cis	rs11785693	0.862	rs62491196	chr8:4995690	C/T	cg26367366	chr8:4980734	NA	0.58	4.45	0.37	1.91e-5	Neuroticism (multi-trait analysis);Neuroticism;
TGCT	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg02953382	chr22:24373134	LOC391322	-0.74	-7.56	-0.56	7.77e-12	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs11122272	0.735	rs910824	chr1:231498773	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-6.63	-0.51	9.1e-10	Hemoglobin concentration;
TGCT	cis	rs3924048	0.574	rs11121930	chr1:12616956	C/A	cg00291366	chr1:12616550	NA	0.33	5.14	0.42	1.05e-6	Optic cup area;
TGCT	cis	rs7959452	0.535	rs4761228	chr12:69682327	G/A	cg14784868	chr12:69753453	YEATS4	0.68	6.95	0.53	1.87e-10	Blood protein levels;
TGCT	cis	rs1784581	0.588	rs9346894	chr6:162430763	T/C	cg17173639	chr6:162384350	PARK2	0.4	6.68	0.51	7.34e-10	Itch intensity from mosquito bite;
TGCT	cis	rs2637266	1.000	rs7914880	chr10:78363693	A/G	cg18941641	chr10:78392320	NA	0.4	4.73	0.39	6.03e-6	Pulmonary function;
TGCT	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg08280861	chr8:58055591	NA	0.36	4.98	0.41	2.08e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg19774624	chr17:42201019	HDAC5	-0.85	-10.09	-0.67	7.79e-18	Total body bone mineral density;
TGCT	cis	rs7726839	0.561	rs72703050	chr5:582917	A/C	cg09021430	chr5:549028	NA	-0.37	-5.23	-0.42	7.12e-7	Obesity-related traits;
TGCT	cis	rs4812048	1.000	rs6070697	chr20:57599402	G/A	cg24457521	chr20:57607420	ATP5E	-0.67	-4.59	-0.38	1.05e-5	Mean platelet volume;
TGCT	cis	rs9894429	0.608	rs8477	chr17:79618059	C/T	cg21028142	chr17:79581711	NPLOC4	0.28	5.83	0.46	4.52e-8	Eye color traits;
TGCT	cis	rs67311347	1.000	rs9332450	chr3:40458041	C/T	cg17264618	chr3:40429014	ENTPD3	-0.32	-4.76	-0.39	5.36e-6	Renal cell carcinoma;
TGCT	cis	rs6964587	0.967	rs10279943	chr7:91587477	G/C	cg17063962	chr7:91808500	NA	0.91	9.99	0.67	1.32e-17	Breast cancer;
TGCT	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg11965913	chr1:205819406	PM20D1	0.6	9.43	0.65	3.09e-16	Menarche (age at onset);
TGCT	cis	rs1609391	0.543	rs7651085	chr3:136625339	C/G	cg15507776	chr3:136538369	TMEM22	0.66	6.84	0.52	3.27e-10	Neuroticism;
TGCT	cis	rs4654899	0.931	rs4654726	chr1:21203898	A/C	cg01072550	chr1:21505969	NA	0.49	7.75	0.57	2.82e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs4512344	0.514	rs13255193	chr8:11309192	T/C	cg21775007	chr8:11205619	TDH	-0.5	-4.85	-0.4	3.61e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg08045932	chr20:61659980	NA	-0.44	-7.89	-0.58	1.39e-12	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1992660	0.510	rs6889125	chr5:40412590	A/T	cg01087697	chr5:40835557	RPL37	0.55	4.96	0.41	2.25e-6	Crohn's disease;
TGCT	cis	rs1371867	0.846	rs1660324	chr8:101281271	C/T	cg06002616	chr8:101225028	SPAG1	-0.57	-6.77	-0.52	4.48e-10	Atrioventricular conduction;
TGCT	cis	rs10746514	0.841	rs9725652	chr1:232245997	T/A	cg09506761	chr1:232265262	NA	0.46	4.71	0.39	6.41e-6	Response to statin therapy;
TGCT	cis	rs986417	0.901	rs1950313	chr14:60997782	A/G	cg27398547	chr14:60952738	C14orf39	1.51	10.28	0.68	2.67e-18	Gut microbiota (bacterial taxa);
TGCT	cis	rs2594989	0.780	rs2454477	chr3:11555842	G/A	cg00170343	chr3:11313890	ATG7	0.63	4.47	0.37	1.77e-5	Circulating chemerin levels;
TGCT	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg23283495	chr1:209979779	IRF6	0.67	5.7	0.46	8.12e-8	Cleft lip with or without cleft palate;
TGCT	cis	rs6500602	0.627	rs709632	chr16:4587811	C/G	cg08645402	chr16:4508243	NA	-0.21	-5.51	-0.44	2e-7	Schizophrenia;
TGCT	cis	rs9467773	1.000	rs6940188	chr6:26562029	G/C	cg26531700	chr6:26746687	NA	0.49	4.73	0.39	6.06e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg12310025	chr6:25882481	NA	0.7	6.44	0.5	2.4e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs992157	0.710	rs10167446	chr2:219056866	A/G	cg00012203	chr2:219082015	ARPC2	0.84	10.71	0.69	2.41e-19	Colorectal cancer;
TGCT	cis	rs7552404	0.691	rs1770890	chr1:76401117	A/G	cg03433033	chr1:76189801	ACADM	-0.74	-7.49	-0.56	1.14e-11	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7666738	0.830	rs7682991	chr4:98982595	C/A	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs17221829	0.733	rs72971009	chr11:89358840	A/G	cg02982614	chr11:89391479	FOLH1B	-0.28	-4.87	-0.4	3.35e-6	Anxiety in major depressive disorder;
TGCT	cis	rs2456568	0.802	rs10765638	chr11:93636171	A/T	cg14065697	chr11:93583672	C11orf90	-0.37	-4.63	-0.38	9.11e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs2734839	0.537	rs6277	chr11:113283459	G/A	cg14159747	chr11:113255604	NA	0.38	4.8	0.4	4.51e-6	Information processing speed;
TGCT	cis	rs11190604	1.000	rs10883503	chr10:102275504	C/A	cg23241863	chr10:102295624	HIF1AN	0.71	5.36	0.43	3.87e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs1153858	1.000	rs2056493	chr15:45648272	A/G	cg14582100	chr15:45693742	SPATA5L1	0.47	5.65	0.45	1.04e-7	Homoarginine levels;
TGCT	cis	rs2153535	0.580	rs1335637	chr6:8465101	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs1865760	0.820	rs9348697	chr6:25890834	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.62	5.75	0.46	6.49e-8	Height;
TGCT	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg21285383	chr16:89894308	SPIRE2	0.47	7.4	0.55	1.83e-11	Vitiligo;
TGCT	cis	rs6570726	0.764	rs448258	chr6:145869145	C/A	cg05347473	chr6:146136440	FBXO30	0.54	5.15	0.42	1.01e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6570726	0.791	rs9399558	chr6:145911730	T/C	cg05347473	chr6:146136440	FBXO30	0.53	4.92	0.4	2.74e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1395	0.778	rs2580759	chr2:27432500	G/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.64	-8.71	-0.62	1.61e-14	Blood metabolite levels;
TGCT	cis	rs12142240	0.698	rs1057533	chr1:46815836	C/T	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs1008375	0.966	rs1860599	chr4:17638900	T/C	cg16339924	chr4:17578868	LAP3	0.66	5.49	0.44	2.22e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4478858	0.647	rs4949380	chr1:31764160	A/G	cg00250761	chr1:31883323	NA	-0.26	-4.55	-0.38	1.28e-5	Alcohol dependence;
TGCT	cis	rs12681288	0.550	rs6989880	chr8:957209	A/G	cg04851639	chr8:1020857	NA	-0.27	-4.45	-0.37	1.85e-5	Schizophrenia;
TGCT	cis	rs10255878	0.568	rs77330846	chr7:97041183	T/C	cg01534613	chr7:96337050	SHFM1	0.29	4.53	0.38	1.39e-5	Adverse response to radiation therapy;
TGCT	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9682041	0.932	rs9841852	chr3:170067049	C/G	cg07589077	chr3:170072950	NA	0.34	5.14	0.42	1.03e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs4700695	0.841	rs152933	chr5:65359530	A/G	cg21114390	chr5:65439923	SFRS12	-0.61	-4.55	-0.38	1.24e-5	Facial morphology (factor 19);
TGCT	cis	rs587847	0.737	rs17443613	chr15:37665895	C/T	cg00216138	chr15:37171175	LOC145845	0.31	4.53	0.38	1.38e-5	Intraocular pressure;
TGCT	cis	rs9611565	0.506	rs2024566	chr22:41697338	A/G	cg03806693	chr22:41940476	POLR3H	-0.82	-7.85	-0.58	1.7e-12	Vitiligo;
TGCT	cis	rs807669	0.525	rs9605955	chr22:19181557	C/T	cg02655711	chr22:19163373	SLC25A1	0.25	4.61	0.38	9.87e-6	Metabolite levels;
TGCT	cis	rs9611565	0.512	rs5758464	chr22:42171300	A/G	cg06481639	chr22:41940642	POLR3H	0.79	5.3	0.43	5.16e-7	Vitiligo;
TGCT	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg01448562	chr3:133502909	NA	-0.35	-7.23	-0.54	4.43e-11	Iron status biomarkers;
TGCT	cis	rs7584330	0.780	rs7582828	chr2:238378476	A/C	cg14458575	chr2:238380390	NA	-0.5	-7.96	-0.58	9.28e-13	Prostate cancer;
TGCT	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg11366901	chr6:160182831	ACAT2	1.06	7.18	0.54	5.54e-11	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs7089973	0.525	rs11196945	chr10:116600424	G/A	cg03647239	chr10:116582469	FAM160B1	0.59	5.74	0.46	6.72e-8	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs477895	0.838	rs1058735	chr11:64000410	C/G	cg23719950	chr11:63933701	MACROD1	-0.68	-5.65	-0.45	1.07e-7	Mean platelet volume;
TGCT	cis	rs6121246	0.909	rs6119720	chr20:30347568	T/G	cg13852791	chr20:30311386	BCL2L1	0.8	6.12	0.48	1.15e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs910316	0.934	rs4903278	chr14:75535019	C/A	cg11812906	chr14:75593930	NEK9	0.73	7.08	0.54	9.58e-11	Height;
TGCT	cis	rs28595532	0.841	rs115209862	chr4:119742225	G/A	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs2439831	0.681	rs524527	chr15:43599116	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.91	-6.54	-0.51	1.43e-9	Lung cancer in ever smokers;
TGCT	cis	rs9318086	0.648	rs9507184	chr13:24473642	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.82	8.98	0.63	3.58e-15	Myopia (pathological);
TGCT	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-5.1	-0.42	1.23e-6	Electroencephalogram traits;
TGCT	cis	rs7017914	0.905	rs2639957	chr8:71923202	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.56	-5.11	-0.42	1.2e-6	Bone mineral density;
TGCT	cis	rs2506889	0.553	rs17035189	chr1:10597024	A/G	cg17425144	chr1:10567563	PEX14	0.53	7.58	0.56	6.96e-12	Breast cancer;
TGCT	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg15921436	chr17:44337874	NA	0.55	7.61	0.56	5.9e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs4253772	0.614	rs11090859	chr22:46687460	T/G	cg24881330	chr22:46731750	TRMU	0.95	6.23	0.49	6.65e-9	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs6920965	0.545	rs2326242	chr6:126174859	A/C	cg05901451	chr6:126070800	HEY2	-0.58	-5.11	-0.42	1.16e-6	High light scatter reticulocyte count;
TGCT	cis	rs17345786	1.000	rs3804778	chr3:101294572	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	4.69	0.39	7.21e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs17767294	0.708	rs76223516	chr6:27939475	C/T	cg08851530	chr6:28072375	NA	1.56	7.22	0.54	4.47e-11	Parkinson's disease;
TGCT	cis	rs3806843	0.547	rs246033	chr5:140332115	A/C	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs13418410	0.539	rs11695597	chr2:33840024	A/G	cg04131969	chr2:33951647	MYADML	0.78	7.67	0.57	4.47e-12	Non-response to antidepressants and depression;
TGCT	cis	rs6087990	0.735	rs2424907	chr20:31359819	C/T	cg13636640	chr20:31349939	DNMT3B	0.92	11.89	0.73	3.16e-22	Ulcerative colitis;
TGCT	cis	rs10484885	0.824	rs11967579	chr6:90540008	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.47	-4.58	-0.38	1.11e-5	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs6964587	1.000	rs9784993	chr7:91672403	G/A	cg17063962	chr7:91808500	NA	0.88	9.65	0.66	8.73e-17	Breast cancer;
TGCT	cis	rs763121	0.962	rs909564	chr22:39126508	A/G	cg06022373	chr22:39101656	GTPBP1	0.69	6.58	0.51	1.21e-9	Menopause (age at onset);
TGCT	cis	rs12220238	1.000	rs12256105	chr10:75909634	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.91	7.98	0.58	8.43e-13	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs8180040	0.620	rs56217494	chr3:47048452	T/G	cg27129171	chr3:47204927	SETD2	-0.7	-8.36	-0.6	1.09e-13	Colorectal cancer;
TGCT	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.2	0.42	8.14e-7	Menopause (age at onset);
TGCT	cis	rs7582180	0.629	rs12620139	chr2:100943446	A/G	cg08017756	chr2:100939284	LONRF2	-0.3	-4.78	-0.39	4.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg06221963	chr1:154839813	KCNN3	-0.75	-12.65	-0.75	4.66e-24	Prostate cancer;
TGCT	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.53	-6.65	-0.51	8.22e-10	Longevity;Endometriosis;
TGCT	cis	rs17221829	0.673	rs12364712	chr11:89373847	T/C	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.63	-0.38	9.04e-6	Anxiety in major depressive disorder;
TGCT	cis	rs4733781	0.509	rs7008182	chr8:131344745	T/A	cg16277922	chr8:131349729	ASAP1	-0.53	-8.77	-0.62	1.14e-14	Tuberculosis;
TGCT	cis	rs6922617	0.685	rs56902797	chr6:41349029	G/A	cg07798131	chr6:41471673	NA	0.89	4.46	0.37	1.82e-5	Alzheimer's disease biomarkers;
TGCT	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg11941060	chr3:133502564	NA	0.28	6.07	0.48	1.42e-8	Iron status biomarkers;
TGCT	cis	rs9811216	1.000	rs6793295	chr3:169518455	T/C	cg08193579	chr3:169529701	LRRC34	0.3	4.59	0.38	1.05e-5	Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;
TGCT	cis	rs12220238	1.000	rs11000931	chr10:75984800	A/C	cg19889307	chr10:75911429	ADK;AP3M1	-1.06	-8.04	-0.59	6.03e-13	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs1371867	0.875	rs962451	chr8:101331010	C/T	cg06636551	chr8:101224915	SPAG1	-0.48	-6.52	-0.51	1.62e-9	Atrioventricular conduction;
TGCT	cis	rs6450176	0.859	rs3776719	chr5:53298684	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.53	-5.1	-0.42	1.23e-6	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs2075371	1.000	rs8134	chr7:133974519	A/G	cg11752832	chr7:134001865	SLC35B4	0.7	6.51	0.5	1.68e-9	Mean platelet volume;
TGCT	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg08280861	chr8:58055591	NA	0.4	4.73	0.39	5.97e-6	Developmental language disorder (linguistic errors);
TGCT	trans	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg11887960	chr12:57824829	NA	1.16	9.59	0.65	1.25e-16	Lung disease severity in cystic fibrosis;
TGCT	cis	rs12530845	1.000	rs4291211	chr7:135335373	C/T	cg23117316	chr7:135346802	PL-5283	-0.51	-4.83	-0.4	3.98e-6	Red blood cell traits;
TGCT	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg24503407	chr1:205819492	PM20D1	0.67	10.31	0.68	2.24e-18	Menarche (age at onset);
TGCT	cis	rs7824557	0.628	rs6601580	chr8:11193736	T/G	cg21775007	chr8:11205619	TDH	0.7	6.86	0.52	2.93e-10	Retinal vascular caliber;
TGCT	cis	rs11122272	0.735	rs2491410	chr1:231532287	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.74	-7.35	-0.55	2.3e-11	Hemoglobin concentration;
TGCT	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.29	-4.49	-0.37	1.64e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg09704166	chr2:114031854	PAX8;LOC440839	-0.32	-4.82	-0.4	4.04e-6	Lymphocyte counts;
TGCT	cis	rs981844	0.890	rs55850399	chr4:154684906	C/T	cg14289246	chr4:154710475	SFRP2	1.05	9.32	0.64	5.44e-16	Response to statins (LDL cholesterol change);
TGCT	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg12311346	chr5:56204834	C5orf35	-0.67	-6.82	-0.52	3.63e-10	Initial pursuit acceleration;
TGCT	cis	rs7666738	0.830	rs6532715	chr4:99016792	G/A	cg17366294	chr4:99064904	C4orf37	0.68	7.04	0.53	1.17e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3087591	0.960	rs8080679	chr17:29602610	A/G	cg24425628	chr17:29625626	OMG;NF1	0.47	7.21	0.54	4.8e-11	Hip circumference;
TGCT	cis	rs9467773	1.000	rs6924838	chr6:26571756	C/T	cg09904177	chr6:26538194	HMGN4	0.69	6.84	0.52	3.23e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs2956278	0.717	rs2947129	chr12:84690270	T/A	cg25678815	chr12:85673915	ALX1	-0.53	-4.76	-0.39	5.4e-6	Depressive symptoms;Depressive symptoms (multi-trait analysis);
TGCT	cis	rs3806933	0.522	rs11241095	chr5:110439509	A/G	cg04022379	chr5:110408740	TSLP	0.6	6.19	0.49	8.19e-9	Eosinophilic esophagitis;
TGCT	cis	rs709400	0.627	rs55859054	chr14:103953666	T/A	cg12935359	chr14:103987150	CKB	-0.37	-5.53	-0.44	1.81e-7	Body mass index;
TGCT	cis	rs12510870	0.599	rs56384466	chr4:74388990	T/C	cg05868023	chr4:75230803	EREG	-0.55	-4.7	-0.39	6.84e-6	Iris color (b* coordinate);
TGCT	cis	rs7119	0.689	rs12907630	chr15:77812906	G/T	cg27398640	chr15:77910606	LINGO1	-0.25	-4.55	-0.38	1.26e-5	Type 2 diabetes;
TGCT	cis	rs11822910	0.911	rs11828218	chr11:57196223	C/G	cg00522883	chr11:57194120	SLC43A3	0.31	4.54	0.38	1.3e-5	Platelet distribution width;
TGCT	trans	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg27523141	chr10:43048294	ZNF37B	0.73	8.58	0.61	3.32e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs6076065	1.000	rs2405231	chr20:23342239	A/C	cg11657817	chr20:23433608	CST11	0.28	4.55	0.38	1.25e-5	Facial morphology (factor 15, philtrum width);
TGCT	cis	rs7119	0.717	rs12910594	chr15:77817103	G/A	cg27398640	chr15:77910606	LINGO1	-0.25	-4.6	-0.38	1.05e-5	Type 2 diabetes;
TGCT	cis	rs3749237	0.595	rs3870337	chr3:49557095	G/T	cg07636037	chr3:49044803	WDR6	0.62	5.83	0.46	4.59e-8	Resting heart rate;
TGCT	cis	rs2816062	0.786	rs2745316	chr1:18896830	G/A	cg18795169	chr1:18902165	NA	-0.61	-14.28	-0.79	6.04e-28	Urate levels in lean individuals;
TGCT	cis	rs3733585	0.673	rs9993410	chr4:9951264	C/T	cg00071950	chr4:10020882	SLC2A9	-0.55	-6.46	-0.5	2.14e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs4699052	0.507	rs10005997	chr4:104301711	C/G	cg16532752	chr4:104119610	CENPE	-0.74	-6.22	-0.49	6.95e-9	Testicular germ cell tumor;
TGCT	cis	rs67073037	0.915	rs12622793	chr2:29111106	C/T	cg09522027	chr2:28974177	PPP1CB	0.58	4.48	0.37	1.69e-5	Breast cancer;Breast cancer (estrogen-receptor negative);
TGCT	cis	rs6882046	0.513	rs639725	chr5:88001969	A/G	cg22951263	chr5:87985283	NA	-0.61	-6.53	-0.51	1.49e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs36051895	0.664	rs7852755	chr9:5100862	C/T	cg02405213	chr9:5042618	JAK2	-0.76	-10.67	-0.69	3.05e-19	Pediatric autoimmune diseases;
TGCT	cis	rs1568889	0.838	rs716366	chr11:28121536	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.9	10.84	0.7	1.12e-19	Bipolar disorder;
TGCT	cis	rs9796	0.840	rs1009913	chr15:41331050	C/T	cg18705301	chr15:41695430	NDUFAF1	0.41	5.17	0.42	9.27e-7	Menopause (age at onset);
TGCT	cis	rs4911259	0.552	rs6058925	chr20:31465374	G/A	cg13636640	chr20:31349939	DNMT3B	-0.89	-9.83	-0.66	3.33e-17	Inflammatory bowel disease;
TGCT	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg26354017	chr1:205819088	PM20D1	0.67	8.86	0.62	7.19e-15	Menarche (age at onset);
TGCT	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg22920501	chr2:26401640	FAM59B	-0.81	-6.42	-0.5	2.63e-9	Gut microbiome composition (summer);
TGCT	cis	rs2274459	0.841	rs12203688	chr6:33693624	G/T	cg00898486	chr6:34006557	GRM4	-0.29	-4.64	-0.38	8.74e-6	Obesity (extreme);
TGCT	cis	rs6728642	0.572	rs13403225	chr2:97600827	A/G	cg26665480	chr2:98280029	ACTR1B	-0.91	-7.03	-0.53	1.2e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	cis	rs3751972	0.911	rs11657613	chr17:26252856	T/C	cg02948944	chr17:26242737	NA	0.5	6.86	0.52	2.9e-10	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs4851266	0.898	rs12053126	chr2:100864646	A/T	cg22139774	chr2:100720529	AFF3	-0.35	-5.51	-0.44	1.99e-7	Educational attainment;
TGCT	cis	rs854765	0.583	rs11078404	chr17:17820487	A/T	cg09796270	chr17:17721594	SREBF1	0.24	4.7	0.39	6.83e-6	Total body bone mineral density;
TGCT	cis	rs7845219	0.544	rs34208552	chr8:95908067	C/G	cg13393036	chr8:95962371	TP53INP1	-0.45	-5.16	-0.42	9.7e-7	Type 2 diabetes;
TGCT	cis	rs12477438	0.520	rs12621007	chr2:99791946	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.15	18.32	0.85	4.52e-37	Chronic sinus infection;
TGCT	cis	rs2760061	0.598	rs658238	chr1:228121291	A/G	cg02753203	chr1:228287806	NA	-0.34	-6.63	-0.51	9.15e-10	Diastolic blood pressure;
TGCT	cis	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg03213289	chr20:61660250	NA	0.73	9.58	0.65	1.31e-16	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9948	0.655	rs6758151	chr2:97388884	A/G	cg01990225	chr2:97406019	LMAN2L	-0.94	-5.33	-0.43	4.44e-7	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs57244997	0.872	rs11759694	chr6:162405705	C/G	cg17173639	chr6:162384350	PARK2	0.44	4.78	0.39	4.79e-6	Mosquito bite size;
TGCT	cis	rs9583531	1.000	rs9583531	chr13:111385161	T/G	cg24331049	chr13:111365604	ING1	-0.77	-5.5	-0.44	2.1e-7	Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs10025174	chr4:98914172	A/G	cg17366294	chr4:99064904	C4orf37	0.69	7.2	0.54	5.03e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1215050	0.791	rs783960	chr4:98893437	A/G	cg17366294	chr4:99064904	C4orf37	-0.53	-5.69	-0.45	8.67e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	trans	rs17685	0.712	rs6464994	chr7:75784668	C/T	cg19862616	chr7:65841803	NCRNA00174	0.53	9.19	0.64	1.13e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs6840360	0.571	rs62327268	chr4:152522326	T/A	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.0	-0.58	7.69e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs2766547	0.647	rs2766542	chr6:35707690	A/G	cg01618151	chr6:35707957	C6orf81	-0.27	-4.52	-0.38	1.42e-5	Eosinophil percentage of granulocytes;
TGCT	trans	rs7615952	1.000	rs7615952	chr3:125649403	A/C	cg07211511	chr3:129823064	LOC729375	0.46	7.6	0.56	6.4e-12	Blood pressure (smoking interaction);
TGCT	cis	rs112217694	1.000	rs17249126	chr4:104653263	A/G	cg24090629	chr4:104641072	TACR3	0.97	4.81	0.4	4.25e-6	Menarche (age at onset);
TGCT	cis	rs72949976	0.678	rs7573232	chr2:214040425	C/T	cg08319019	chr2:214017104	IKZF2	-0.72	-5.98	-0.47	2.17e-8	Lung cancer;Squamous cell lung carcinoma;
TGCT	cis	rs611744	0.935	rs661036	chr8:109213088	C/T	cg21045802	chr8:109455806	TTC35	0.52	4.72	0.39	6.21e-6	Dupuytren's disease;
TGCT	cis	rs2456568	0.709	rs7942444	chr11:93637160	G/A	cg17595323	chr11:93583763	C11orf90	0.46	5.96	0.47	2.39e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs3087591	0.821	rs1034705	chr17:29536133	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.46	-7.13	-0.54	7.14e-11	Hip circumference;
TGCT	cis	rs2180341	0.513	rs12196828	chr6:127696864	C/T	cg27446573	chr6:127587934	RNF146	0.67	6.07	0.48	1.41e-8	Breast cancer;
TGCT	cis	rs7098414	0.511	rs4934134	chr10:82160582	C/T	cg01528321	chr10:82214614	TSPAN14	0.56	4.98	0.41	2.07e-6	Post bronchodilator FEV1;
TGCT	cis	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg20637647	chr7:64974828	NA	0.9	5.31	0.43	4.87e-7	Diabetic kidney disease;
TGCT	cis	rs4077515	0.874	rs4498662	chr9:139290251	C/G	cg13741927	chr9:139327495	INPP5E	-0.19	-4.63	-0.38	9.06e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs7267979	0.868	rs6107019	chr20:25233985	C/T	cg14121845	chr20:25566513	NINL	0.5	5.51	0.44	1.95e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg24675658	chr1:53192096	ZYG11B	0.85	10.97	0.7	5.36e-20	Monocyte count;
TGCT	cis	rs796364	0.625	rs4673837	chr2:201131159	A/G	cg23649088	chr2:200775458	C2orf69	0.33	4.44	0.37	1.99e-5	Schizophrenia;
TGCT	cis	rs3087591	0.639	rs2342053	chr17:29722196	A/G	cg24425628	chr17:29625626	OMG;NF1	0.4	5.85	0.47	4.05e-8	Hip circumference;
TGCT	cis	rs62225284	1.000	rs62225284	chr22:47572322	T/C	cg18621123	chr22:47569642	TBC1D22A	0.26	5.21	0.42	7.65e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	trans	rs2727020	0.553	rs11040400	chr11:49518296	C/A	cg03929089	chr4:120376271	NA	-0.66	-7.62	-0.56	5.75e-12	Coronary artery disease;
TGCT	cis	rs78487399	0.808	rs13395290	chr2:43706319	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.39	-4.96	-0.41	2.24e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs56235845	0.685	rs35630910	chr5:176757841	A/C	cg16006841	chr5:176797999	RGS14	0.54	7.87	0.58	1.53e-12	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg18876405	chr7:65276391	NA	-0.32	-4.92	-0.4	2.72e-6	Aortic root size;
TGCT	cis	rs910316	1.000	rs11845639	chr14:75570293	C/T	cg11812906	chr14:75593930	NEK9	0.75	7.4	0.55	1.77e-11	Height;
TGCT	cis	rs12908161	1.000	rs36033486	chr15:85319692	A/G	cg12863693	chr15:85201151	NMB	0.43	5.12	0.42	1.15e-6	Schizophrenia;
TGCT	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg03806693	chr22:41940476	POLR3H	1.15	13.16	0.76	2.69e-25	Vitiligo;
TGCT	cis	rs11098499	0.954	rs11935596	chr4:120412457	G/C	cg09307838	chr4:120376055	NA	0.69	6.64	0.51	8.97e-10	Corneal astigmatism;
TGCT	cis	rs10838634	1.000	rs7108147	chr11:46830847	G/A	cg18332754	chr11:46939436	LRP4	0.9	4.59	0.38	1.05e-5	Schizophrenia;
TGCT	cis	rs17152411	0.895	rs3940439	chr10:126584531	C/G	cg07906193	chr10:126599966	NA	0.41	5.05	0.41	1.52e-6	Height;
TGCT	cis	rs7267979	0.932	rs928121	chr20:25534818	A/G	cg14121845	chr20:25566513	NINL	0.49	5.36	0.43	3.83e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg01416388	chr22:39784598	NA	-0.72	-7.05	-0.53	1.1e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg22963979	chr7:1858916	MAD1L1	-0.45	-7.41	-0.55	1.74e-11	Bipolar disorder and schizophrenia;
TGCT	cis	rs2439831	0.850	rs7169322	chr15:44131014	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.9	6.3	0.49	4.62e-9	Lung cancer in ever smokers;
TGCT	cis	rs2485376	0.842	rs11597439	chr10:104184953	C/G	cg26089160	chr10:104170217	PSD	0.51	5.04	0.41	1.62e-6	QT interval;
TGCT	cis	rs2404602	0.692	rs12913810	chr15:77166675	T/C	cg22467129	chr15:76604101	ETFA	-0.47	-5.39	-0.44	3.44e-7	Blood metabolite levels;
TGCT	cis	rs2862064	1.000	rs9313405	chr5:156447750	T/C	cg12943317	chr5:156479607	HAVCR1	-0.36	-4.99	-0.41	1.97e-6	Platelet count;
TGCT	cis	rs997781	0.611	rs8080863	chr17:67169500	A/G	cg21660392	chr17:66950545	ABCA8	-0.29	-4.45	-0.37	1.91e-5	MGMT methylation in smokers;
TGCT	cis	rs11098499	0.863	rs1010739	chr4:120463471	C/T	cg09307838	chr4:120376055	NA	0.6	5.22	0.42	7.16e-7	Corneal astigmatism;
TGCT	cis	rs698813	0.572	rs12613771	chr2:44490660	C/A	cg00619915	chr2:44497795	NA	-0.24	-5.54	-0.45	1.75e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
TGCT	cis	rs5769707	0.777	rs739243	chr22:50057211	C/T	cg20744362	chr22:50050164	C22orf34	0.29	4.68	0.39	7.3e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs11650494	0.908	rs11658111	chr17:47383994	C/T	cg08112188	chr17:47440006	ZNF652	1.04	5.31	0.43	4.88e-7	Prostate cancer;
TGCT	cis	rs7666738	0.791	rs10033211	chr4:98995624	T/A	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg16414030	chr3:133502952	NA	-0.5	-7.03	-0.53	1.2e-10	Iron status biomarkers;
TGCT	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg03388025	chr16:89894329	SPIRE2	-0.49	-8.61	-0.61	2.79e-14	Vitiligo;
TGCT	cis	rs7474896	0.609	rs11011336	chr10:37985316	A/G	cg13720705	chr10:37990370	NA	0.34	5.03	0.41	1.71e-6	Obesity (extreme);
TGCT	cis	rs10936602	0.527	rs9814802	chr3:169532377	A/G	cg08193579	chr3:169529701	LRRC34	0.29	5.33	0.43	4.38e-7	Renal cell carcinoma;
TGCT	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg21433313	chr16:3507492	NAT15	0.37	4.83	0.4	3.95e-6	Tuberculosis;
TGCT	cis	rs6582630	0.519	rs1851130	chr12:38507819	C/T	cg13010199	chr12:38710504	ALG10B	0.59	4.83	0.4	4.02e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg21724239	chr8:58056113	NA	0.5	5.43	0.44	2.83e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs73198271	0.694	rs113694763	chr8:8647076	C/T	cg06671706	chr8:8559999	CLDN23	-0.35	-4.5	-0.37	1.52e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs7805747	0.961	rs10254101	chr7:151415536	C/T	cg17611936	chr7:151411526	PRKAG2	0.54	6.72	0.52	5.9e-10	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
TGCT	cis	rs1891275	0.550	rs4933694	chr10:93499213	C/T	cg07889827	chr10:93443413	NA	-0.33	-6.94	-0.53	1.97e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs8026198	0.929	rs2407707	chr15:42659350	G/A	cg20699549	chr15:42567973	GANC	0.23	4.44	0.37	1.98e-5	Fibrinogen levels;
TGCT	cis	rs539096	0.749	rs12076635	chr1:44026656	G/C	cg12908607	chr1:44402522	ARTN	-0.52	-5.4	-0.44	3.3e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9303401	0.659	rs12602808	chr17:56698420	A/G	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs9611565	0.592	rs12484467	chr22:41957610	T/C	cg03806693	chr22:41940476	POLR3H	-1.07	-11.31	-0.71	8.12e-21	Vitiligo;
TGCT	cis	rs7635838	0.822	rs9861633	chr3:11473437	C/G	cg00170343	chr3:11313890	ATG7	0.66	6.34	0.49	3.87e-9	HDL cholesterol;
TGCT	cis	rs2305707	0.605	rs76084537	chr15:51553278	G/A	cg19946085	chr15:51559439	CYP19A1	0.49	5.15	0.42	9.79e-7	Height;
TGCT	cis	rs2204008	0.740	rs1283308	chr12:38154565	C/T	cg26384229	chr12:38710491	ALG10B	-0.57	-4.9	-0.4	2.99e-6	Bladder cancer;
TGCT	trans	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg27523141	chr10:43048294	ZNF37B	0.71	8.26	0.6	1.84e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs6988636	1.000	rs11992152	chr8:124189455	T/A	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs9329221	0.870	rs11777976	chr8:10255402	A/G	cg21775007	chr8:11205619	TDH	-0.53	-4.8	-0.4	4.5e-6	Neuroticism;
TGCT	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg20607798	chr8:58055168	NA	0.49	4.78	0.39	4.9e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs514406	0.861	rs11206026	chr1:53281708	G/A	cg01802117	chr1:53393560	SCP2	-0.4	-4.83	-0.4	3.92e-6	Monocyte count;
TGCT	cis	rs1903068	0.719	rs17711225	chr4:55999185	G/A	cg09978860	chr4:56023921	NA	0.56	5.89	0.47	3.34e-8	Endometriosis;
TGCT	cis	rs858239	0.601	rs6969733	chr7:23168377	T/C	cg05602783	chr7:23145260	KLHL7	-0.62	-5.18	-0.42	8.52e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs2354432	0.607	rs59606861	chr1:146761478	G/A	cg25205988	chr1:146714368	CHD1L	-1.35	-5.85	-0.46	4.18e-8	Mitochondrial DNA levels;
TGCT	cis	rs1670533	1.000	rs62294756	chr4:1097676	G/A	cg27284194	chr4:1044797	NA	-0.69	-6.07	-0.48	1.45e-8	Recombination rate (females);
TGCT	trans	rs1814175	0.588	rs1794144	chr11:49918233	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.51	-0.69	7.2e-19	Height;
TGCT	cis	rs2013441	0.965	rs8071665	chr17:20209943	T/C	cg23224458	chr17:20280056	CCDC144C	-0.41	-4.88	-0.4	3.25e-6	Obesity-related traits;
TGCT	cis	rs910316	0.737	rs108622	chr14:75481908	A/G	cg11812906	chr14:75593930	NEK9	-0.59	-5.59	-0.45	1.38e-7	Height;
TGCT	cis	rs3749237	0.595	rs17595772	chr3:49409704	G/A	cg07636037	chr3:49044803	WDR6	0.64	6.04	0.48	1.63e-8	Resting heart rate;
TGCT	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.78	5.34	0.43	4.36e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs1395	0.778	rs11126918	chr2:27438710	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.7	9.37	0.64	4.22e-16	Blood metabolite levels;
TGCT	cis	rs6582630	0.519	rs7294300	chr12:38277359	C/A	cg26384229	chr12:38710491	ALG10B	0.86	7.48	0.56	1.17e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.21	4.45	0.37	1.88e-5	Eosinophil percentage of white cells;
TGCT	cis	rs10791323	0.592	rs2851115	chr11:133705381	C/A	cg03690763	chr11:133734501	NA	-0.35	-5.34	-0.43	4.31e-7	Childhood ear infection;
TGCT	cis	rs1670533	1.000	rs652063	chr4:1084137	T/C	cg27284194	chr4:1044797	NA	0.68	5.95	0.47	2.59e-8	Recombination rate (females);
TGCT	cis	rs6430585	0.528	rs16832417	chr2:136744678	C/T	cg07169764	chr2:136633963	MCM6	1.25	12.67	0.75	4.02e-24	Corneal structure;
TGCT	cis	rs9549367	0.713	rs2476328	chr13:113829350	C/T	cg00898013	chr13:113819073	PROZ	0.52	6.61	0.51	1.03e-9	Platelet distribution width;
TGCT	cis	rs7010267	0.935	rs11573824	chr8:119959925	A/T	cg17171407	chr8:119960777	TNFRSF11B	0.33	6.18	0.49	8.29e-9	Total body bone mineral density (age 45-60);
TGCT	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs11711311	0.955	rs10934241	chr3:113394705	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.78	-6.81	-0.52	3.79e-10	IgG glycosylation;
TGCT	cis	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg18252515	chr7:66147081	NA	-1.22	-7.16	-0.54	6.34e-11	Diabetic kidney disease;
TGCT	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg12288994	chr5:1860383	NA	0.24	4.72	0.39	6.2e-6	Cardiovascular disease risk factors;
TGCT	cis	rs9916302	0.706	rs594794	chr17:37453485	T/C	cg07936489	chr17:37558343	FBXL20	0.84	6.23	0.49	6.68e-9	Glomerular filtration rate (creatinine);
TGCT	trans	rs3774749	0.565	rs2518796	chr3:50207075	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.81	7.96	0.58	9.46e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs9640161	0.750	rs1047575	chr7:150035500	C/G	cg10018233	chr7:150070692	REPIN1	0.31	4.45	0.37	1.88e-5	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs981844	0.775	rs62324020	chr4:154763851	G/A	cg14289246	chr4:154710475	SFRP2	1.01	8.89	0.62	5.85e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs7937840	0.581	rs4963286	chr11:61887232	C/A	cg05871569	chr11:61891931	INCENP	0.69	6.4	0.5	2.91e-9	Breast cancer;
TGCT	cis	rs35264875	0.950	rs35337391	chr11:68854012	A/G	cg02660097	chr11:68866761	NA	0.32	4.96	0.41	2.3e-6	Blond vs. brown hair color;
TGCT	cis	rs35771425	0.642	rs11586974	chr1:211464115	A/G	cg26515805	chr1:211431828	RCOR3	0.42	4.53	0.38	1.39e-5	Educational attainment (years of education);
TGCT	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg00814883	chr7:100076585	TSC22D4	-0.82	-8.37	-0.6	1.03e-13	Platelet count;
TGCT	cis	rs9302065	0.866	rs75006318	chr13:95968259	T/G	cg26751094	chr13:95954534	ABCC4	-0.32	-5.3	-0.43	5.01e-7	Blood metabolite levels;
TGCT	cis	rs877282	0.898	rs11253340	chr10:764786	G/T	cg17470449	chr10:769945	NA	0.37	5.59	0.45	1.37e-7	Uric acid levels;
TGCT	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg27121462	chr16:89883253	FANCA	0.78	8.31	0.6	1.45e-13	Vitiligo;
TGCT	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg04156016	chr5:1868137	NA	0.33	4.63	0.38	9.04e-6	Cardiovascular disease risk factors;
TGCT	cis	rs2742234	0.614	rs3026750	chr10:43607756	G/A	cg02780029	chr10:43622663	RET	-0.25	-4.96	-0.41	2.31e-6	Hirschsprung disease;
TGCT	cis	rs7666738	0.830	rs28687737	chr4:99009226	G/A	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7524258	0.868	rs4908448	chr1:7269283	A/G	cg07173049	chr1:7289937	CAMTA1	-0.28	-4.61	-0.38	9.88e-6	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg08509172	chr19:19383838	TM6SF2	-0.34	-4.48	-0.37	1.71e-5	Tonsillectomy;
TGCT	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg10047753	chr17:41438598	NA	0.96	9.54	0.65	1.61e-16	Menopause (age at onset);
TGCT	cis	rs711830	1.000	rs1318778	chr2:177037831	C/G	cg13092806	chr2:177043255	NA	0.77	5.92	0.47	2.92e-8	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
TGCT	cis	rs11096990	0.600	rs6835337	chr4:39282809	T/A	cg20847110	chr4:39482781	LOC401127	-0.16	-4.53	-0.38	1.39e-5	Cognitive function;
TGCT	cis	rs7666738	0.830	rs6827516	chr4:98971740	T/C	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1865760	0.566	rs3752420	chr6:26027135	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.77	7.44	0.56	1.47e-11	Height;
TGCT	cis	rs2243480	1.000	rs410128	chr7:65603173	C/T	cg20637647	chr7:64974828	NA	0.9	5.15	0.42	9.9e-7	Diabetic kidney disease;
TGCT	cis	rs7666738	0.830	rs6854594	chr4:99065312	A/T	cg05340658	chr4:99064831	C4orf37	0.52	5.79	0.46	5.32e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs314370	0.951	rs12705092	chr7:100473550	G/A	cg10426581	chr7:100472382	SRRT	1.0	10.93	0.7	6.98e-20	Resting heart rate;
TGCT	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg13409248	chr3:40428643	ENTPD3	0.57	4.53	0.38	1.37e-5	Renal cell carcinoma;
TGCT	cis	rs35771425	0.619	rs6689078	chr1:211476423	C/G	cg26515805	chr1:211431828	RCOR3	-0.46	-5.04	-0.41	1.6e-6	Educational attainment (years of education);
TGCT	cis	rs3784262	0.692	rs3784256	chr15:58263046	T/A	cg12031962	chr15:58353849	ALDH1A2	-0.41	-5.82	-0.46	4.7e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs7169223	0.653	rs2904228	chr15:79086099	G/A	cg21242079	chr15:79101063	ADAMTS7	-0.37	-5.93	-0.47	2.78e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
TGCT	cis	rs28595532	0.841	rs55744948	chr4:119769243	T/C	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs3540	0.554	rs12443252	chr15:91064690	C/T	cg22089800	chr15:90895588	ZNF774	-0.76	-8.06	-0.59	5.32e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs17253792	0.822	rs78386830	chr14:56069224	G/A	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs9653442	0.545	rs12712067	chr2:100763900	A/C	cg22139774	chr2:100720529	AFF3	0.37	5.85	0.47	4.03e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs2153535	0.601	rs2015281	chr6:8539673	G/A	cg07606381	chr6:8435919	SLC35B3	0.55	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs6684514	0.922	rs12047994	chr1:156284535	C/A	cg20302342	chr1:156215951	PAQR6	0.35	4.74	0.39	5.77e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs926938	0.543	rs360600	chr1:115388116	T/C	cg12756093	chr1:115239321	AMPD1	0.44	6.36	0.5	3.48e-9	Autism;
TGCT	cis	rs595982	0.527	rs17206707	chr19:49361441	A/C	cg21252483	chr19:49399788	TULP2	-0.43	-6.28	-0.49	5.27e-9	Red cell distribution width;
TGCT	cis	rs7772486	0.875	rs13204280	chr6:146415368	T/C	cg05347473	chr6:146136440	FBXO30	0.55	5.14	0.42	1.05e-6	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs57221529	0.563	rs4957057	chr5:569230	C/G	cg25482853	chr8:67687455	SGK3	1.1	8.74	0.62	1.34e-14	Lung disease severity in cystic fibrosis;
TGCT	cis	rs7659604	0.643	rs6839375	chr4:122663610	G/C	cg19748678	chr4:122722346	EXOSC9	0.56	4.86	0.4	3.43e-6	Type 2 diabetes;
TGCT	cis	rs7226408	1.000	rs72883547	chr18:34361227	C/T	cg06757138	chr18:34340585	FHOD3	0.28	4.76	0.39	5.23e-6	Obesity-related traits;
TGCT	cis	rs929354	0.685	rs7807856	chr7:156934498	T/C	cg05182265	chr7:156933206	UBE3C	-0.39	-8.98	-0.63	3.72e-15	Body mass index;
TGCT	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg16497277	chr3:49208875	KLHDC8B	-0.55	-5.25	-0.43	6.31e-7	Menarche (age at onset);
TGCT	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg17971929	chr21:40555470	PSMG1	-0.71	-6.76	-0.52	4.82e-10	Cognitive function;
TGCT	cis	rs7091068	0.671	rs517785	chr10:95403973	G/A	cg20715218	chr10:95462985	C10orf4	-0.54	-5.15	-0.42	9.95e-7	Urinary tract infection frequency;
TGCT	cis	rs636291	0.500	rs655271	chr1:10536635	G/A	cg17425144	chr1:10567563	PEX14	0.53	7.34	0.55	2.52e-11	Prostate cancer;
TGCT	cis	rs682748	0.846	rs7704060	chr5:17124559	C/T	cg23987134	chr5:17158319	LOC285696	-0.21	-5.14	-0.42	1.03e-6	Hippocampal atrophy;
TGCT	cis	rs4700695	1.000	rs111339	chr5:65420347	T/A	cg21114390	chr5:65439923	SFRS12	-0.65	-5.02	-0.41	1.76e-6	Facial morphology (factor 19);
TGCT	cis	rs17030434	0.784	rs6835960	chr4:154650460	G/A	cg14289246	chr4:154710475	SFRP2	-0.85	-7.14	-0.54	6.81e-11	Electrocardiographic conduction measures;
TGCT	cis	rs11711311	1.000	rs2566970	chr3:113462123	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.72	7.05	0.54	1.08e-10	IgG glycosylation;
TGCT	cis	rs10479542	0.806	rs4700836	chr5:178976393	A/G	cg00080972	chr5:178986291	RUFY1	0.44	5.06	0.41	1.45e-6	Lung cancer;
TGCT	cis	rs2797160	1.000	rs1418642	chr6:125999768	G/A	cg05901451	chr6:126070800	HEY2	-0.74	-6.48	-0.5	1.96e-9	Endometrial cancer;
TGCT	cis	rs3749237	0.595	rs17595772	chr3:49409704	G/A	cg03060546	chr3:49711283	APEH	0.77	8.87	0.62	6.79e-15	Resting heart rate;
TGCT	cis	rs254781	0.505	rs190438	chr5:88026902	C/T	cg24804195	chr5:87968844	LOC645323	-0.52	-4.64	-0.38	8.62e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10782582	0.593	rs12126155	chr1:76131555	C/G	cg10523679	chr1:76189770	ACADM	-0.68	-7.1	-0.54	8.65e-11	Daytime sleep phenotypes;
TGCT	cis	rs3087591	1.000	rs7226006	chr17:29650656	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.48	-7.01	-0.53	1.38e-10	Hip circumference;
TGCT	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg06238570	chr21:40685208	BRWD1	-0.69	-6.35	-0.5	3.68e-9	Cognitive function;
TGCT	cis	rs208520	1.000	rs12191598	chr6:66983962	T/C	cg07460842	chr6:66804631	NA	0.78	6.82	0.52	3.61e-10	Exhaled nitric oxide output;
TGCT	cis	rs2204008	0.840	rs7136347	chr12:38453531	G/A	cg26384229	chr12:38710491	ALG10B	0.88	8.04	0.59	5.98e-13	Bladder cancer;
TGCT	cis	rs644799	1.000	rs586498	chr11:95537828	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	10.57	0.69	5.17e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg16325326	chr1:53192061	ZYG11B	-0.7	-8.66	-0.61	2.13e-14	Monocyte count;
TGCT	cis	rs62244186	0.593	rs9814298	chr3:44871899	T/A	cg11003573	chr3:44754125	ZNF502	-0.47	-5.38	-0.43	3.65e-7	Depressive symptoms;
TGCT	cis	rs6693567	0.565	rs698914	chr1:150298750	A/G	cg09579323	chr1:150459698	TARS2	0.54	4.79	0.4	4.59e-6	Migraine;
TGCT	cis	rs308403	0.509	rs309379	chr4:123671456	C/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.83	12.16	0.74	6.83e-23	Blood protein levels;
TGCT	cis	rs6598955	0.670	rs7531518	chr1:26539749	T/C	cg01614726	chr1:26633154	UBXN11	0.49	4.69	0.39	7.09e-6	Obesity-related traits;
TGCT	cis	rs492146	0.783	rs613764	chr6:52840235	C/T	cg06706454	chr6:52930286	FBXO9	-0.53	-4.98	-0.41	2.05e-6	Epilepsy (remission after treatment);
TGCT	cis	rs12135062	0.851	rs2651926	chr1:3101820	C/T	cg21609526	chr1:3105151	PRDM16	-0.4	-6.52	-0.51	1.58e-9	Migraine;
TGCT	cis	rs12791968	0.765	rs11038250	chr11:45009114	A/G	cg11846598	chr11:44996168	LOC221122	-0.31	-5.0	-0.41	1.88e-6	Inhibitory control;
TGCT	cis	rs9916302	0.904	rs11655531	chr17:37697959	T/C	cg07936489	chr17:37558343	FBXL20	-0.61	-4.87	-0.4	3.29e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs9527	0.521	rs12259163	chr10:104961477	A/G	cg04362960	chr10:104952993	NT5C2	0.67	5.7	0.46	8.1e-8	Arsenic metabolism;
TGCT	cis	rs6582630	0.576	rs2387837	chr12:38403164	G/T	cg26384229	chr12:38710491	ALG10B	-0.52	-4.52	-0.38	1.43e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs35146811	0.624	rs1727134	chr7:99813672	T/C	cg22906224	chr7:99728672	NA	-0.5	-4.51	-0.38	1.48e-5	Coronary artery disease;
TGCT	cis	rs7552404	0.731	rs1770885	chr1:76402212	C/T	cg03433033	chr1:76189801	ACADM	-0.76	-7.81	-0.57	2.07e-12	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7192750	0.586	rs9934812	chr16:71981652	T/G	cg06353428	chr16:71660113	MARVELD3	0.75	6.74	0.52	5.43e-10	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg07061783	chr6:25882402	NA	-0.47	-4.95	-0.41	2.37e-6	Blood metabolite levels;
TGCT	cis	rs909674	0.690	rs1972280	chr22:39831986	T/A	cg05872129	chr22:39784769	NA	-0.99	-9.57	-0.65	1.36e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs1801251	1.000	rs10933412	chr2:233707226	G/C	cg25237894	chr2:233734115	C2orf82	-0.33	-5.94	-0.47	2.71e-8	Coronary artery disease;
TGCT	cis	rs7552404	0.727	rs6678348	chr1:76332463	C/T	cg10523679	chr1:76189770	ACADM	0.68	6.27	0.49	5.37e-9	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7611238	0.583	rs9821765	chr3:195148051	T/C	cg27323046	chr3:195102265	ACAP2	0.37	4.97	0.41	2.17e-6	Body mass index;
TGCT	cis	rs6867032	1.000	rs4975802	chr5:2019750	T/C	cg26168224	chr5:2018326	NA	0.44	7.95	0.58	1.01e-12	Gut microbiome composition (winter);
TGCT	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs6430585	0.528	rs721765	chr2:136748779	C/A	cg07169764	chr2:136633963	MCM6	1.25	12.67	0.75	4.02e-24	Corneal structure;
TGCT	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg16414030	chr3:133502952	NA	-0.62	-9.83	-0.66	3.36e-17	Iron status biomarkers;
TGCT	cis	rs2013441	0.965	rs1544421	chr17:20114217	T/C	cg18979559	chr17:20280153	CCDC144C	-0.44	-4.61	-0.38	9.78e-6	Obesity-related traits;
TGCT	cis	rs6964587	1.000	rs6968870	chr7:91661111	G/C	cg17063962	chr7:91808500	NA	0.86	9.25	0.64	8.11e-16	Breast cancer;
TGCT	cis	rs4820539	1.000	rs6003518	chr22:23471533	C/T	cg21100191	chr22:23484243	RTDR1	0.89	10.61	0.69	4.23e-19	Bone mineral density;
TGCT	cis	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg08564027	chr20:61660810	NA	0.38	7.08	0.54	9.36e-11	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2120019	0.938	rs2289582	chr15:75310394	T/C	cg17294928	chr15:75287854	SCAMP5	-0.86	-6.7	-0.52	6.39e-10	Blood trace element (Zn levels);
TGCT	cis	rs1371867	0.875	rs1660320	chr8:101337579	A/C	cg06002616	chr8:101225028	SPAG1	-0.54	-6.29	-0.49	4.88e-9	Atrioventricular conduction;
TGCT	cis	rs7226408	0.901	rs1503359	chr18:34742415	G/A	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs11190604	1.000	rs2489047	chr10:102347028	A/G	cg23241863	chr10:102295624	HIF1AN	0.71	5.36	0.43	3.84e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs933688	1.000	rs985434	chr5:90744509	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.04	8.8	0.62	9.68e-15	Smoking behavior;
TGCT	cis	rs4851266	1.000	rs13034176	chr2:100833913	G/A	cg07810366	chr2:100720526	AFF3	-0.39	-5.73	-0.46	7.19e-8	Educational attainment;
TGCT	cis	rs7582180	0.629	rs6736576	chr2:100950854	C/T	cg14675211	chr2:100938903	LONRF2	0.53	5.16	0.42	9.36e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg06028808	chr11:68637592	NA	0.55	6.91	0.53	2.2e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7914558	0.966	rs10786721	chr10:104654383	C/A	cg15744005	chr10:104629667	AS3MT	-0.41	-5.09	-0.42	1.29e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs56235845	0.694	rs9313758	chr5:176773091	T/G	cg16006841	chr5:176797999	RGS14	0.52	7.83	0.58	1.9e-12	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs10984561	0.881	rs10984552	chr9:122247196	A/G	cg14242995	chr9:122249943	NA	0.75	6.41	0.5	2.7e-9	Pulmonary function decline;
TGCT	cis	rs112217694	1.000	rs77525704	chr4:104655769	C/T	cg24090629	chr4:104641072	TACR3	-1.07	-4.84	-0.4	3.75e-6	Menarche (age at onset);
TGCT	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg18402987	chr7:1209562	NA	0.81	6.94	0.53	1.9e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg06873352	chr17:61820015	STRADA	0.58	6.39	0.5	3.01e-9	Prudent dietary pattern;
TGCT	cis	rs854765	0.647	rs7212447	chr17:17987067	G/A	cg04398451	chr17:18023971	MYO15A	-0.37	-6.51	-0.5	1.71e-9	Total body bone mineral density;
TGCT	cis	rs6840360	0.593	rs1366907	chr4:152682749	T/C	cg22705602	chr4:152727874	NA	-0.35	-5.94	-0.47	2.63e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs3776081	0.600	rs13171150	chr5:149523176	C/T	cg18424208	chr5:149546337	CDX1	-0.26	-4.75	-0.39	5.5e-6	Blood protein levels;
TGCT	cis	rs7017914	0.967	rs2639903	chr8:71917444	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.57	-5.31	-0.43	4.8e-7	Bone mineral density;
TGCT	cis	rs7312933	0.558	rs11181463	chr12:42763636	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	5.22	0.42	7.3e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs4455778	0.727	rs28719863	chr7:49069668	C/G	cg26309511	chr7:48887640	NA	0.47	5.33	0.43	4.56e-7	Lung cancer in never smokers;
TGCT	cis	rs2463822	0.764	rs7125402	chr11:62097259	C/T	cg06239285	chr11:62104954	ASRGL1	0.93	6.71	0.52	6.27e-10	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs950169	0.723	rs17589320	chr15:84919996	C/A	cg17173187	chr15:85201210	NMB	0.54	5.55	0.45	1.67e-7	Schizophrenia;
TGCT	cis	rs360798	0.512	rs2710640	chr2:63144305	A/G	cg17519650	chr2:63277830	OTX1	0.59	5.42	0.44	2.99e-7	Coronary artery disease;
TGCT	cis	rs6988636	1.000	rs13260626	chr8:124190317	C/T	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg05368731	chr17:41323189	NBR1	1.16	13.44	0.77	5.72e-26	Menopause (age at onset);
TGCT	cis	rs1062177	1.000	rs2915880	chr5:151147334	G/A	cg00977110	chr5:151150581	G3BP1	0.4	4.62	0.38	9.43e-6	Preschool internalizing problems;
TGCT	cis	rs877282	0.853	rs7083589	chr10:754494	G/A	cg17470449	chr10:769945	NA	0.32	4.91	0.4	2.76e-6	Uric acid levels;
TGCT	cis	rs881375	0.933	rs1548784	chr9:123685280	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	5.12	0.42	1.14e-6	Rheumatoid arthritis;
TGCT	cis	rs727479	0.543	rs6493488	chr15:51513922	G/C	cg19946085	chr15:51559439	CYP19A1	-0.31	-4.48	-0.37	1.67e-5	Estradiol levels;
TGCT	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs36051895	0.659	rs1159782	chr9:5078117	T/C	cg02405213	chr9:5042618	JAK2	-0.75	-9.83	-0.66	3.19e-17	Pediatric autoimmune diseases;
TGCT	cis	rs1555895	0.576	rs7080989	chr10:851455	C/G	cg02193355	chr10:851439	NA	0.25	5.6	0.45	1.3e-7	Survival in rectal cancer;
TGCT	cis	rs7264396	0.790	rs12480622	chr20:34234620	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.28	-4.74	-0.39	5.75e-6	Total cholesterol levels;
TGCT	cis	rs6964587	0.869	rs7812219	chr7:91545727	C/T	cg17063962	chr7:91808500	NA	-0.84	-8.83	-0.62	8.49e-15	Breast cancer;
TGCT	cis	rs6088580	0.634	rs6058041	chr20:33018008	A/G	cg06115741	chr20:33292138	TP53INP2	0.53	4.67	0.39	7.67e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg11644478	chr21:40555479	PSMG1	1.02	10.86	0.7	1.05e-19	Cognitive function;
TGCT	cis	rs2730245	0.527	rs2730237	chr7:158706166	A/G	cg11984989	chr7:158649758	WDR60	1.01	7.85	0.58	1.65e-12	Height;
TGCT	cis	rs1635	0.655	rs77986494	chr6:28261497	A/G	cg15743358	chr6:28303923	ZNF323	-1.34	-5.96	-0.47	2.44e-8	Schizophrenia;
TGCT	cis	rs2851682	0.706	rs2727270	chr11:61603237	C/T	cg19610905	chr11:61596333	FADS2	-0.96	-5.22	-0.42	7.37e-7	Gestational age at birth (child effect);Trans fatty acid levels;
TGCT	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	-0.55	-4.98	-0.41	2.11e-6	Prudent dietary pattern;
TGCT	cis	rs7193541	0.691	rs3851728	chr16:74480660	C/T	cg01733217	chr16:74700730	RFWD3	0.64	5.91	0.47	3.02e-8	Multiple myeloma;
TGCT	cis	rs7216064	1.000	rs12451511	chr17:65874861	T/G	cg12091567	chr17:66097778	LOC651250	-0.83	-6.49	-0.5	1.9e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs10193935	0.901	rs222483	chr2:42652184	T/G	cg27598129	chr2:42591480	NA	-0.38	-5.43	-0.44	2.85e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs78487399	0.808	rs79955955	chr2:43686985	A/T	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.74	4.77	0.39	5.17e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs7336332	0.598	rs9581852	chr13:28013748	A/G	cg22138327	chr13:27999177	GTF3A	0.79	6.12	0.48	1.15e-8	Weight;
TGCT	cis	rs1215050	0.740	rs804051	chr4:98935935	A/T	cg05340658	chr4:99064831	C4orf37	-0.44	-5.35	-0.43	4.13e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs3125734	0.607	rs7923556	chr10:64024648	A/G	cg05499367	chr10:63213510	TMEM26	-0.33	-4.47	-0.37	1.77e-5	Rheumatoid arthritis;
TGCT	cis	rs523522	0.962	rs10849758	chr12:120971149	C/T	cg27279351	chr12:120934652	DYNLL1	0.76	6.59	0.51	1.15e-9	High light scatter reticulocyte count;
TGCT	cis	rs4654899	0.758	rs6702331	chr1:21516107	A/T	cg01072550	chr1:21505969	NA	-0.56	-9.32	-0.64	5.53e-16	Superior frontal gyrus grey matter volume;
TGCT	cis	rs6426558	0.502	rs6697665	chr1:227474665	T/C	cg10327440	chr1:227177885	CDC42BPA	0.57	6.65	0.51	8.55e-10	Neutrophil percentage of white cells;
TGCT	cis	rs924607	1.000	rs12523022	chr5:598643	C/T	cg04476341	chr5:669733	TPPP	-0.25	-4.55	-0.38	1.25e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs7677751	0.806	rs4864860	chr4:55090021	T/C	cg17187183	chr4:55093834	PDGFRA	0.53	6.87	0.52	2.83e-10	Corneal astigmatism;
TGCT	cis	rs2562456	0.917	rs2681376	chr19:21715525	T/G	cg01304269	chr19:21688519	ZNF429	-0.55	-4.59	-0.38	1.06e-5	Pain;
TGCT	cis	rs9649213	0.533	rs62478235	chr7:98030349	G/C	cg09267113	chr7:98030324	BAIAP2L1	-0.94	-8.74	-0.62	1.38e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs56309584	0.673	rs56256903	chr17:8123128	T/G	cg08322244	chr17:8066669	VAMP2	-0.57	-5.26	-0.43	6.21e-7	Initial pursuit acceleration;
TGCT	cis	rs2749592	0.531	rs1208559	chr10:38221370	T/C	cg13531842	chr10:38383804	ZNF37A	0.43	5.07	0.41	1.43e-6	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs17445774	1.000	rs17445774	chr2:200859249	A/G	cg23649088	chr2:200775458	C2orf69	-0.49	-7.43	-0.56	1.52e-11	LDL cholesterol to HDL cholesterol ratio;
TGCT	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg18305652	chr10:134549665	INPP5A	0.31	5.19	0.42	8.46e-7	Migraine;
TGCT	cis	rs2013441	1.000	rs3850781	chr17:20181939	T/G	cg18979559	chr17:20280153	CCDC144C	-0.45	-4.67	-0.39	7.61e-6	Obesity-related traits;
TGCT	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg14893161	chr1:205819251	PM20D1	0.55	7.75	0.57	2.78e-12	Menarche (age at onset);
TGCT	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.04	0.53	1.16e-10	Prudent dietary pattern;
TGCT	cis	rs13256369	0.802	rs12153	chr8:8560909	G/C	cg17143192	chr8:8559678	CLDN23	0.54	5.03	0.41	1.64e-6	Obesity-related traits;
TGCT	cis	rs75686122	0.541	rs12681238	chr8:104656185	A/T	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs922182	0.547	rs12907026	chr15:64271604	A/C	cg02919090	chr15:64263738	DAPK2	-0.27	-4.84	-0.4	3.74e-6	Blood protein levels;
TGCT	cis	rs7267979	0.966	rs6050611	chr20:25414419	A/G	cg03522245	chr20:25566470	NINL	0.61	6.52	0.51	1.57e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs35934224	0.783	rs7287073	chr22:19864335	G/A	cg11182965	chr22:19864308	TXNRD2	-0.38	-5.2	-0.42	7.82e-7	Glaucoma (primary open-angle);
TGCT	cis	rs2067615	0.524	rs10467029	chr12:107078448	C/T	cg15890332	chr12:107067104	RFX4	0.29	5.69	0.45	8.83e-8	Heart rate;
TGCT	cis	rs5771242	0.518	rs5771258	chr22:50675648	C/A	cg16473166	chr22:50639996	SELO	0.65	5.52	0.44	1.91e-7	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
TGCT	cis	rs11190604	1.000	rs2489043	chr10:102334327	T/C	cg23241863	chr10:102295624	HIF1AN	0.71	5.39	0.44	3.39e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs16867321	0.950	rs12472841	chr2:181491840	C/A	cg23363182	chr2:181467187	NA	-0.39	-5.65	-0.45	1.02e-7	Obesity;
TGCT	cis	rs2997447	0.846	rs61775428	chr1:26409126	G/C	cg03844060	chr1:26490628	NA	0.28	4.57	0.38	1.17e-5	QRS complex (12-leadsum);
TGCT	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg23758822	chr17:41437982	NA	0.71	6.77	0.52	4.56e-10	Menopause (age at onset);
TGCT	cis	rs7528684	0.872	rs7522061	chr1:157668390	A/G	cg17134153	chr1:157670328	FCRL3	-0.25	-4.7	-0.39	6.78e-6	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;
TGCT	cis	rs8051431	0.915	rs7191900	chr16:72014866	G/A	cg06353428	chr16:71660113	MARVELD3	0.58	4.96	0.41	2.28e-6	LDL cholesterol levels;
TGCT	trans	rs1814175	0.817	rs10839401	chr11:49876144	C/T	cg03929089	chr4:120376271	NA	-0.72	-8.26	-0.6	1.84e-13	Height;
TGCT	cis	rs1801251	0.685	rs1515961	chr2:233623763	C/A	cg25237894	chr2:233734115	C2orf82	0.26	4.83	0.4	3.9e-6	Coronary artery disease;
TGCT	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.5	-4.79	-0.4	4.67e-6	Bipolar disorder;
TGCT	cis	rs9807989	0.839	rs10204137	chr2:102968212	A/G	cg09003973	chr2:102972529	NA	0.64	5.7	0.46	8.28e-8	Asthma;
TGCT	trans	rs877282	0.898	rs11253346	chr10:765313	A/G	cg22713356	chr15:30763199	NA	1.2	9.39	0.64	3.76e-16	Uric acid levels;
TGCT	cis	rs3020333	0.875	rs2982570	chr6:152013748	C/T	cg22157087	chr6:152012887	ESR1	0.19	4.51	0.38	1.5e-5	Total body bone mineral density;
TGCT	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	trans	rs28735056	0.596	rs3744879	chr18:77679006	G/C	cg05926928	chr17:57297772	GDPD1	-0.69	-6.72	-0.52	5.9e-10	Schizophrenia;
TGCT	cis	rs7714584	1.000	rs2880791	chr5:150267376	C/A	cg22134413	chr5:150180641	NA	0.78	6.12	0.48	1.16e-8	Crohn's disease;
TGCT	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg17054783	chr10:134559939	INPP5A	0.26	5.0	0.41	1.94e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg17105886	chr17:28927953	LRRC37B2	-0.75	-4.56	-0.38	1.23e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs922182	0.617	rs4776264	chr15:64227124	A/G	cg02919090	chr15:64263738	DAPK2	0.33	6.16	0.48	9.51e-9	Blood protein levels;
TGCT	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg13395646	chr4:1353034	KIAA1530	-0.36	-4.61	-0.38	9.75e-6	Obesity-related traits;
TGCT	cis	rs1865760	0.566	rs10807006	chr6:26048752	C/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.78	7.49	0.56	1.1e-11	Height;
TGCT	cis	rs769267	0.864	rs7245983	chr19:19657632	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.64	5.25	0.43	6.53e-7	Tonsillectomy;
TGCT	cis	rs6582630	0.502	rs11514371	chr12:38306306	G/C	cg26384229	chr12:38710491	ALG10B	0.82	7.18	0.54	5.6e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs6988636	0.710	rs59229243	chr8:124155673	G/A	cg23067535	chr8:124195133	FAM83A	-0.37	-4.59	-0.38	1.07e-5	Urinary uromodulin levels;
TGCT	cis	rs904251	0.523	rs2797799	chr6:37483620	T/G	cg01843034	chr6:37503916	NA	-0.54	-7.3	-0.55	3.04e-11	Cognitive performance;
TGCT	trans	rs1814175	0.587	rs7948538	chr11:50021353	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.84	-0.7	1.13e-19	Height;
TGCT	cis	rs13217239	0.646	rs10946891	chr6:26973215	T/C	cg05738196	chr6:26577821	NA	0.49	4.77	0.39	4.98e-6	Schizophrenia;
TGCT	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg24549020	chr5:56110836	MAP3K1	-0.67	-5.79	-0.46	5.54e-8	Initial pursuit acceleration;
TGCT	cis	rs3796352	1.000	rs7625448	chr3:53120766	C/A	cg15956490	chr3:53032818	SFMBT1	0.53	6.39	0.5	2.97e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg08509172	chr19:19383838	TM6SF2	-0.34	-4.48	-0.37	1.71e-5	Tonsillectomy;
TGCT	cis	rs8135665	0.625	rs8142185	chr22:38451080	A/C	cg13116946	chr22:38479732	SLC16A8	0.28	5.54	0.45	1.72e-7	Advanced age-related macular degeneration;Age-related macular degeneration;
TGCT	cis	rs17401966	1.000	rs17410793	chr1:10391886	A/G	cg19773385	chr1:10388646	KIF1B	-0.21	-4.5	-0.37	1.57e-5	Hepatocellular carcinoma;
TGCT	cis	rs62209	0.800	rs17149174	chr10:11002510	A/G	cg26901096	chr10:10994189	LOC254312	0.34	5.63	0.45	1.14e-7	Alzheimer's disease (late onset);
TGCT	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg03303774	chr4:1407052	NA	0.31	4.93	0.4	2.58e-6	Obesity-related traits;
TGCT	cis	rs2075371	0.863	rs9641966	chr7:133961205	G/A	cg11752832	chr7:134001865	SLC35B4	0.66	5.5	0.44	2.09e-7	Mean platelet volume;
TGCT	cis	rs13082711	0.522	rs646577	chr3:27352225	A/G	cg02860705	chr3:27208620	NA	0.33	5.37	0.43	3.67e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs6545883	0.859	rs13004855	chr2:61505072	C/T	cg15711740	chr2:61764176	XPO1	0.56	4.78	0.39	4.81e-6	Tuberculosis;
TGCT	cis	rs7120118	0.517	rs17726390	chr11:47319706	C/T	cg13308137	chr11:47528955	CUGBP1	0.33	5.19	0.42	8.26e-7	HDL cholesterol;
TGCT	cis	rs12681366	0.762	rs3019148	chr8:95429635	T/C	cg27091703	chr8:95487428	RAD54B	-0.54	-4.52	-0.38	1.4e-5	Nonsyndromic cleft lip with cleft palate;
TGCT	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg10047753	chr17:41438598	NA	0.74	7.0	0.53	1.46e-10	Menopause (age at onset);
TGCT	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg18876405	chr7:65276391	NA	-0.37	-5.6	-0.45	1.33e-7	Aortic root size;
TGCT	cis	rs9473924	0.505	rs2817416	chr6:50809777	T/C	cg14470998	chr6:50812995	TFAP2B	1.36	8.61	0.61	2.74e-14	Body mass index;
TGCT	cis	rs7772486	0.846	rs2144478	chr6:146381445	A/G	cg23711669	chr6:146136114	FBXO30	0.89	9.59	0.65	1.22e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs909341	0.909	rs6122159	chr20:62370732	G/T	cg14758556	chr20:62440591	NA	0.31	4.61	0.38	9.85e-6	Atopic dermatitis;
TGCT	cis	rs10769945	0.500	rs217203	chr11:1972456	G/C	cg18032502	chr11:1949113	TNNT3	-0.25	-4.82	-0.4	4.06e-6	DNA methylation (variation);
TGCT	cis	rs1048238	0.935	rs761760	chr1:16342419	A/G	cg22431228	chr1:16359049	CLCNKA	-0.29	-6.07	-0.48	1.42e-8	Systolic blood pressure;
TGCT	cis	rs514406	0.893	rs6588446	chr1:53425260	G/A	cg25767906	chr1:53392781	SCP2	0.53	6.23	0.49	6.49e-9	Monocyte count;
TGCT	cis	rs950169	0.580	rs2271431	chr15:85189464	A/C	cg11189052	chr15:85197271	WDR73	0.77	6.47	0.5	2.05e-9	Schizophrenia;
TGCT	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	5.01	0.41	1.81e-6	Menopause (age at onset);
TGCT	cis	rs826838	1.000	rs826838	chr12:39106731	C/T	cg26384229	chr12:38710491	ALG10B	-0.8	-7.35	-0.55	2.29e-11	Heart rate;
TGCT	cis	rs12134245	0.747	rs35654098	chr1:92001452	T/A	cg02896835	chr1:92012615	NA	-0.27	-4.59	-0.38	1.08e-5	Breast cancer;
TGCT	cis	rs2153535	0.580	rs1335643	chr6:8488021	T/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs2204008	0.580	rs11520047	chr12:38051778	T/A	cg26384229	chr12:38710491	ALG10B	0.86	7.77	0.57	2.55e-12	Bladder cancer;
TGCT	cis	rs200810	0.694	rs55839714	chr6:98019876	C/T	cg16511841	chr6:97730490	C6orf167;MIR548H3	-0.64	-4.45	-0.37	1.91e-5	Body mass index;
TGCT	cis	rs2456568	0.571	rs1105114	chr11:93693511	C/T	cg17595323	chr11:93583763	C11orf90	0.38	4.62	0.38	9.46e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7412746	0.611	rs2271076	chr1:150916657	C/T	cg04414720	chr1:150670196	GOLPH3L	0.37	4.46	0.37	1.81e-5	Melanoma;
TGCT	trans	rs9650657	0.513	rs4314618	chr8:10816772	A/G	cg06636001	chr8:8085503	FLJ10661	-0.85	-8.39	-0.6	9.04e-14	Neuroticism;
TGCT	cis	rs1205863	1.000	rs209815	chr6:11951314	C/G	cg07106625	chr6:11870215	NA	0.51	5.05	0.41	1.51e-6	Disc degeneration (lumbar);
TGCT	cis	rs9318086	0.904	rs9580769	chr13:24439724	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.68	-6.81	-0.52	3.69e-10	Myopia (pathological);
TGCT	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.1	-15.96	-0.82	7.48e-32	Prudent dietary pattern;
TGCT	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg03264133	chr6:25882463	NA	-0.67	-6.04	-0.48	1.67e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs11249608	0.590	rs36051170	chr5:178447971	T/C	cg21905437	chr5:178450457	ZNF879	0.44	4.45	0.37	1.92e-5	Pubertal anthropometrics;
TGCT	cis	rs1420338	0.933	rs12540602	chr7:34174056	G/A	cg01275685	chr7:34179230	BMPER	-0.28	-5.05	-0.41	1.53e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs11148252	0.774	rs6561666	chr13:52930045	A/G	cg02158880	chr13:53174818	NA	0.39	4.69	0.39	6.96e-6	Lewy body disease;
TGCT	cis	rs13242816	1.000	rs66985071	chr7:116130433	C/T	cg02799643	chr7:116139180	CAV2	-0.46	-5.53	-0.44	1.78e-7	P wave duration;
TGCT	cis	rs977747	0.815	rs6692253	chr1:47680527	G/A	cg03885399	chr1:47691550	TAL1	-0.42	-5.48	-0.44	2.32e-7	Body mass index;
TGCT	cis	rs6754311	0.773	rs309179	chr2:136613780	G/A	cg07169764	chr2:136633963	MCM6	-0.62	-5.74	-0.46	7e-8	Mosquito bite size;
TGCT	cis	rs17376456	0.877	rs28418572	chr5:93144161	A/C	cg25358565	chr5:93447407	FAM172A	0.89	7.62	0.56	5.67e-12	Diabetic retinopathy;
TGCT	cis	rs2204008	0.539	rs1283295	chr12:38146014	A/C	cg26384229	chr12:38710491	ALG10B	-0.58	-5.09	-0.42	1.28e-6	Bladder cancer;
TGCT	cis	rs7949030	0.596	rs71490394	chr11:62370155	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.7	8.89	0.62	5.98e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9611565	0.512	rs132784	chr22:42052363	G/A	cg17554472	chr22:41940697	POLR3H	0.52	5.37	0.43	3.68e-7	Vitiligo;
TGCT	cis	rs4970988	0.787	rs1532770	chr1:150725335	G/T	cg04414720	chr1:150670196	GOLPH3L	0.38	4.67	0.39	7.73e-6	Urate levels;
TGCT	cis	rs931608	1.000	rs11085534	chr19:22613229	A/G	cg23859931	chr19:22123797	NA	0.53	4.49	0.37	1.61e-5	Dental caries;Response to statins (LDL cholesterol change);
TGCT	cis	rs2404602	0.716	rs67888330	chr15:76752483	A/G	cg26408565	chr15:76604113	ETFA	-0.4	-5.26	-0.43	6.23e-7	Blood metabolite levels;
TGCT	cis	rs4566357	0.557	rs2272201	chr2:227912551	T/A	cg11843606	chr2:227700838	RHBDD1	-0.55	-5.17	-0.42	8.9e-7	Coronary artery disease;
TGCT	cis	rs8180040	0.871	rs11716661	chr3:47517773	G/T	cg27129171	chr3:47204927	SETD2	-0.65	-7.68	-0.57	4.2e-12	Colorectal cancer;
TGCT	cis	rs11096990	0.593	rs35552004	chr4:39172534	C/T	cg24403649	chr4:39172243	NA	0.2	4.48	0.37	1.7e-5	Cognitive function;
TGCT	cis	rs7119	0.679	rs12914932	chr15:77839051	G/A	cg27398640	chr15:77910606	LINGO1	-0.27	-5.1	-0.42	1.22e-6	Type 2 diabetes;
TGCT	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.06	-9.57	-0.65	1.41e-16	Platelet count;
TGCT	cis	rs12477438	0.520	rs4851188	chr2:99745898	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.75	7.25	0.55	3.92e-11	Chronic sinus infection;
TGCT	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg23205692	chr1:25664452	TMEM50A	0.53	5.47	0.44	2.33e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs7296418	0.630	rs28419092	chr12:123812629	G/C	cg00376283	chr12:123451042	ABCB9	0.62	5.29	0.43	5.46e-7	Platelet count;
TGCT	cis	rs986417	0.636	rs8020587	chr14:60952612	A/G	cg27398547	chr14:60952738	C14orf39	1.39	10.61	0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg00684032	chr4:1343700	KIAA1530	0.22	4.73	0.39	5.89e-6	Obesity-related traits;
TGCT	cis	rs3091242	0.933	rs34933589	chr1:25788198	T/C	cg10117171	chr1:25599238	RHD	0.3	4.79	0.4	4.67e-6	Erythrocyte sedimentation rate;
TGCT	cis	rs2243480	0.522	rs778717	chr7:65848151	G/C	cg18252515	chr7:66147081	NA	-1.08	-6.17	-0.48	9.09e-9	Diabetic kidney disease;
TGCT	cis	rs7613051	0.945	rs13080709	chr3:33053282	C/T	cg19000631	chr3:33138515	GLB1;TMPPE	0.67	4.9	0.4	2.92e-6	Atopic dermatitis;
TGCT	cis	rs7975161	0.572	rs7957725	chr12:104574749	A/T	cg25273343	chr12:104657179	TXNRD1	-0.33	-4.92	-0.4	2.68e-6	Toenail selenium levels;
TGCT	cis	rs79149102	0.579	rs8040961	chr15:75291864	G/A	cg09165964	chr15:75287851	SCAMP5	-1.06	-5.82	-0.46	4.83e-8	Lung cancer;
TGCT	cis	rs9926296	0.687	rs258317	chr16:89732238	C/T	cg26513180	chr16:89883248	FANCA	-0.67	-6.31	-0.49	4.58e-9	Vitiligo;
TGCT	cis	rs9303401	0.614	rs62084387	chr17:57148027	C/T	cg25039879	chr17:56429692	SUPT4H1	0.54	4.8	0.4	4.49e-6	Cognitive test performance;
TGCT	cis	rs228769	0.543	rs170634	chr17:42175821	C/A	cg13607699	chr17:42295918	UBTF	-0.63	-5.26	-0.43	6.1e-7	Bone mineral density (hip);Bone mineral density (spine);
TGCT	cis	rs67311347	1.000	rs6599102	chr3:40468406	G/A	cg17264618	chr3:40429014	ENTPD3	0.32	4.76	0.39	5.36e-6	Renal cell carcinoma;
TGCT	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.62	5.25	0.43	6.3e-7	Tonsillectomy;
TGCT	cis	rs1395	0.744	rs11686131	chr2:27508710	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.62	8.02	0.58	6.76e-13	Blood metabolite levels;
TGCT	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg07507251	chr3:52567010	NT5DC2	0.47	6.6	0.51	1.05e-9	Bipolar disorder;
TGCT	cis	rs500492	0.542	rs449295	chr16:1074443	G/A	cg01366354	chr16:1075121	NA	0.36	5.23	0.43	6.99e-7	Polycystic ovary syndrome;
TGCT	cis	rs12497850	0.931	rs9846123	chr3:49088112	C/T	cg07636037	chr3:49044803	WDR6	-0.96	-10.9	-0.7	8.39e-20	Parkinson's disease;
TGCT	cis	rs61776719	0.738	rs7555461	chr1:38444749	T/C	cg26398791	chr1:38455867	SF3A3	0.6	5.87	0.47	3.73e-8	Coronary artery disease;
TGCT	cis	rs7246657	0.722	rs2972458	chr19:38135403	T/C	cg03611452	chr19:38183253	ZNF781	-0.57	-4.79	-0.39	4.72e-6	Coronary artery calcification;
TGCT	cis	rs2033711	0.870	rs6510152	chr19:58953319	C/T	cg12042659	chr19:58951599	ZNF132	0.52	4.59	0.38	1.07e-5	Uric acid clearance;
TGCT	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.99	-7.31	-0.55	2.9100000000000002e-11	Gut microbiome composition (summer);
TGCT	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg03188948	chr7:1209495	NA	0.68	5.8	0.46	5.09e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1903068	0.597	rs10013070	chr4:55997201	A/G	cg01777861	chr4:56023843	NA	0.53	5.81	0.46	4.92e-8	Endometriosis;
TGCT	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg24578937	chr1:2090814	PRKCZ	-0.23	-5.36	-0.43	3.88e-7	Height;
TGCT	cis	rs4252435	0.614	rs6961869	chr7:142597508	C/T	cg09833174	chr7:143059591	FAM131B	-0.96	-4.52	-0.38	1.41e-5	Cancer;
TGCT	cis	rs6748734	1.000	rs6724662	chr2:241831560	A/G	cg04034577	chr2:241836375	C2orf54	-0.4	-6.32	-0.49	4.22e-9	Urinary metabolites;
TGCT	cis	rs7727544	0.716	rs7701414	chr5:131585958	A/G	cg22598563	chr5:131563921	P4HA2	-0.28	-4.55	-0.38	1.27e-5	Blood metabolite levels;
TGCT	cis	rs2073300	1.000	rs6036423	chr20:23459810	A/C	cg09953122	chr20:23471693	CST8	-0.59	-4.75	-0.39	5.62e-6	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs7772486	0.641	rs960385	chr6:146371074	G/A	cg05347473	chr6:146136440	FBXO30	0.57	5.38	0.44	3.56e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9972944	0.756	rs2873818	chr17:63762867	A/T	cg07283582	chr17:63770753	CCDC46	-0.26	-5.24	-0.43	6.6e-7	Total body bone mineral density;
TGCT	cis	rs910316	0.935	rs3742771	chr14:75599647	A/G	cg11812906	chr14:75593930	NEK9	0.73	7.18	0.54	5.79e-11	Height;
TGCT	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg13695892	chr22:41940480	POLR3H	0.9	8.73	0.62	1.46e-14	Vitiligo;
TGCT	cis	rs12615966	0.932	rs17020857	chr2:105401306	A/G	cg16465502	chr2:105461796	NA	-0.78	-5.01	-0.41	1.83e-6	Pancreatic cancer;
TGCT	cis	rs1532993	0.518	rs6847710	chr4:98615493	A/G	cg05340658	chr4:99064831	C4orf37	-0.37	-4.44	-0.37	1.98e-5	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs6450176	0.951	rs5013866	chr5:53300947	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.53	-5.1	-0.42	1.23e-6	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs9527	0.571	rs12219246	chr10:104613355	A/G	cg04362960	chr10:104952993	NT5C2	0.55	4.73	0.39	5.91e-6	Arsenic metabolism;
TGCT	cis	rs3733585	0.605	rs4697710	chr4:10122649	T/C	cg00071950	chr4:10020882	SLC2A9	-0.51	-5.29	-0.43	5.33e-7	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs4389656	0.826	rs192443	chr5:6733664	G/T	cg10857441	chr5:6722123	POLS	-0.22	-4.78	-0.39	4.8e-6	Coronary artery disease;
TGCT	cis	rs1555895	0.576	rs748112	chr10:862889	C/T	cg02193355	chr10:851439	NA	0.2	4.64	0.38	8.55e-6	Survival in rectal cancer;
TGCT	cis	rs9910055	0.529	rs228765	chr17:42186422	C/T	cg13607699	chr17:42295918	UBTF	-0.62	-4.97	-0.41	2.18e-6	Total body bone mineral density;
TGCT	cis	rs907683	0.583	rs10932803	chr2:220292739	A/T	cg15015639	chr2:220282977	DES	0.4	5.11	0.42	1.18e-6	Resting heart rate;
TGCT	cis	rs6733011	0.530	rs7608889	chr2:99481350	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.47	-4.55	-0.38	1.24e-5	Bipolar disorder;
TGCT	cis	rs9467711	1.000	rs6939799	chr6:26328366	G/A	cg03517284	chr6:25882590	NA	-0.86	-4.67	-0.39	7.69e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2239547	0.522	rs2581801	chr3:52972907	G/T	cg11645453	chr3:52864694	ITIH4	-0.32	-5.3	-0.43	5.13e-7	Schizophrenia;
TGCT	cis	rs6728302	0.557	rs2741321	chr2:233280239	A/G	cg06555452	chr2:233241558	NA	-0.33	-5.0	-0.41	1.9e-6	Height;
TGCT	cis	rs826838	0.967	rs10875979	chr12:39095149	G/A	cg26384229	chr12:38710491	ALG10B	0.98	9.38	0.64	3.92e-16	Heart rate;
TGCT	cis	rs793571	0.544	rs383902	chr15:59034174	C/T	cg05156742	chr15:59063176	FAM63B	0.5	4.6	0.38	1.05e-5	Schizophrenia;
TGCT	cis	rs6570726	0.935	rs409725	chr6:145840340	G/A	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3824867	0.920	rs10742805	chr11:47454701	A/G	cg20307385	chr11:47447363	PSMC3	0.7	6.03	0.48	1.71e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs2721195	0.816	rs4251689	chr8:145741130	C/T	cg11211951	chr8:145729740	GPT	0.27	6.58	0.51	1.17e-9	Age at first birth;
TGCT	cis	rs7666738	0.830	rs6834014	chr4:98951431	G/A	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2832191	0.626	rs2254796	chr21:30341891	A/G	cg08807101	chr21:30365312	RNF160	-0.63	-6.01	-0.48	1.9e-8	Dental caries;
TGCT	cis	rs7267979	1.000	rs6050561	chr20:25334855	C/T	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7511006	0.859	rs7292228	chr22:50649560	C/G	cg19026356	chr22:50624276	TRABD	-0.49	-4.57	-0.38	1.17e-5	Obesity-related traits;
TGCT	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg20276088	chr3:133502917	NA	-0.24	-5.13	-0.42	1.06e-6	Iron status biomarkers;
TGCT	cis	rs9818758	0.607	rs11716445	chr3:49406095	C/T	cg08550065	chr3:50336684	HYAL3;NAT6	1.18	4.89	0.4	3.03e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs7572733	0.534	rs7572123	chr2:198769637	A/G	cg00792783	chr2:198669748	PLCL1	0.56	5.11	0.42	1.21e-6	Dermatomyositis;
TGCT	trans	rs3780486	0.505	rs10758194	chr9:33157419	G/T	cg04842962	chr6:43655489	MRPS18A	0.8	8.67	0.61	2.02e-14	IgG glycosylation;
TGCT	cis	rs72843506	0.722	rs12051550	chr17:20129546	A/G	cg18979559	chr17:20280153	CCDC144C	-0.65	-4.89	-0.4	3.07e-6	Schizophrenia;
TGCT	cis	rs10883723	0.962	rs1056741	chr10:104236640	A/C	cg05855489	chr10:104503620	C10orf26	-0.55	-4.68	-0.39	7.42e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs12142240	0.660	rs6679080	chr1:46819779	A/T	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs3749237	0.595	rs17650792	chr3:49390250	A/G	cg07636037	chr3:49044803	WDR6	0.64	6.03	0.48	1.72e-8	Resting heart rate;
TGCT	cis	rs3213545	0.676	rs1179998	chr12:121483653	G/A	cg02403541	chr12:121454288	C12orf43	0.66	6.05	0.48	1.6e-8	Subjective well-being;Cardiovascular disease risk factors;
TGCT	cis	rs7666738	0.830	rs36047842	chr4:99004902	C/A	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9291683	0.595	rs3733585	chr4:10036339	A/G	cg00071950	chr4:10020882	SLC2A9	0.68	8.84	0.62	7.71e-15	Bone mineral density;
TGCT	cis	rs9527	1.000	rs12416687	chr10:104629011	T/C	cg04362960	chr10:104952993	NT5C2	0.66	5.42	0.44	3.04e-7	Arsenic metabolism;
TGCT	cis	rs7829975	0.501	rs4840353	chr8:8580570	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-4.62	-0.38	9.47e-6	Mood instability;
TGCT	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	5.06	0.41	1.46e-6	Menopause (age at onset);
TGCT	cis	rs10089	1.000	rs883074	chr5:127445823	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.77	-5.99	-0.47	2.07e-8	Ileal carcinoids;
TGCT	cis	rs7020830	0.522	rs10814509	chr9:37111057	A/G	cg14294708	chr9:37120828	ZCCHC7	0.81	8.61	0.61	2.73e-14	Schizophrenia;
TGCT	cis	rs12681288	0.963	rs7822955	chr8:1029090	C/T	cg04851639	chr8:1020857	NA	0.39	6.82	0.52	3.55e-10	Schizophrenia;
TGCT	cis	rs6430585	0.528	rs895285	chr2:136710554	A/G	cg07169764	chr2:136633963	MCM6	1.25	12.67	0.75	4.02e-24	Corneal structure;
TGCT	cis	rs7819412	0.502	rs4841499	chr8:10988138	A/C	cg21775007	chr8:11205619	TDH	-0.53	-4.86	-0.4	3.4e-6	Triglycerides;
TGCT	cis	rs7085104	0.513	rs192569	chr10:104577915	T/C	cg04362960	chr10:104952993	NT5C2	-0.5	-4.46	-0.37	1.79e-5	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs11247915	0.600	rs11247917	chr1:26655507	G/T	cg01414934	chr1:26605969	SH3BGRL3	0.22	4.65	0.39	8.26e-6	Obesity-related traits;
TGCT	cis	rs2456568	0.543	rs4144616	chr11:93621900	A/G	cg26875233	chr11:93583750	C11orf90	-0.47	-6.03	-0.48	1.71e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs17253792	0.822	rs76264681	chr14:56060447	T/C	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs3617	0.625	rs7620690	chr3:52891707	A/G	cg11645453	chr3:52864694	ITIH4	-0.29	-5.68	-0.45	9.09e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7727544	0.904	rs58835386	chr5:131600559	A/G	cg24060327	chr5:131705240	SLC22A5	-0.6	-6.4	-0.5	2.92e-9	Blood metabolite levels;
TGCT	cis	rs3125734	0.633	rs7100297	chr10:63985100	T/C	cg19640130	chr10:64028056	RTKN2	-0.39	-5.11	-0.42	1.19e-6	Rheumatoid arthritis;
TGCT	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg07507251	chr3:52567010	NT5DC2	0.47	6.64	0.51	8.85e-10	Bipolar disorder;
TGCT	cis	rs1801251	0.727	rs13029336	chr2:233569935	A/G	cg08000102	chr2:233561755	GIGYF2	-0.59	-6.66	-0.51	7.81e-10	Coronary artery disease;
TGCT	cis	rs8177179	0.967	rs4994582	chr3:133437566	G/C	cg16262614	chr3:133464971	TF	0.34	4.52	0.38	1.44e-5	Iron status biomarkers (transferrin levels);
TGCT	cis	rs10744422	0.925	rs897391	chr12:123326374	G/A	cg25930673	chr12:123319894	HIP1R	-0.85	-5.01	-0.41	1.86e-6	Schizophrenia;
TGCT	cis	rs9325144	0.581	rs2653758	chr12:38946233	G/T	cg13010199	chr12:38710504	ALG10B	-0.51	-4.83	-0.4	4.03e-6	Morning vs. evening chronotype;
TGCT	cis	rs4901869	1.000	rs4901869	chr14:59334128	A/G	cg02291164	chr14:59296302	NA	0.24	4.77	0.39	5.17e-6	Panic disorder;
TGCT	cis	rs35146811	0.555	rs2525539	chr7:99545309	A/G	cg13334819	chr7:99746414	C7orf59	0.6	5.09	0.42	1.28e-6	Coronary artery disease;
TGCT	cis	rs7523273	0.606	rs1830764	chr1:207917052	G/A	cg22525895	chr1:207977042	MIR29B2	0.54	8.77	0.62	1.16e-14	Schizophrenia;
TGCT	cis	rs9972944	0.729	rs62065062	chr17:63777383	G/A	cg07283582	chr17:63770753	CCDC46	0.26	5.05	0.41	1.53e-6	Total body bone mineral density;
TGCT	cis	rs2239547	0.522	rs9865094	chr3:52985319	G/C	cg11645453	chr3:52864694	ITIH4	-0.32	-5.28	-0.43	5.48e-7	Schizophrenia;
TGCT	cis	rs2742417	0.565	rs2673031	chr3:45756986	A/G	cg04837898	chr3:45731254	SACM1L	-0.66	-7.02	-0.53	1.27e-10	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs6450176	0.680	rs255756	chr5:53309364	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.83	-6.14	-0.48	1.04e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs2439831	1.000	rs537115	chr15:43729948	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.01	8.37	0.6	1.02e-13	Lung cancer in ever smokers;
TGCT	cis	rs9902453	0.845	rs2628165	chr17:28121166	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.76	7.04	0.53	1.17e-10	Coffee consumption (cups per day);
TGCT	cis	rs983545	0.607	rs9846524	chr3:16922923	C/G	cg21767191	chr3:17082105	PLCL2	0.22	4.5	0.37	1.52e-5	Blood protein levels;
TGCT	cis	rs2742417	1.000	rs2742368	chr3:45752293	C/A	cg04837898	chr3:45731254	SACM1L	-0.55	-5.72	-0.46	7.45e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs6723226	0.765	rs12612824	chr2:32579759	C/T	cg02381751	chr2:32503542	YIPF4	-0.6	-5.54	-0.45	1.75e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg11890956	chr21:40555474	PSMG1	1.03	10.49	0.69	7.98e-19	Cognitive function;
TGCT	cis	rs208520	0.661	rs207090	chr6:66783963	T/A	cg07460842	chr6:66804631	NA	-0.94	-9.84	-0.66	3.12e-17	Exhaled nitric oxide output;
TGCT	cis	rs1153858	1.000	rs1820518	chr15:45694579	C/T	cg26924012	chr15:45694286	SPATA5L1	1.09	15.16	0.81	5.15e-30	Homoarginine levels;
TGCT	cis	rs7524258	0.868	rs4908451	chr1:7299618	C/G	cg07173049	chr1:7289937	CAMTA1	-0.29	-4.93	-0.4	2.62e-6	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs11658309	1	rs11658309	chr17:17762247	T/G	cg04398451	chr17:18023971	MYO15A	0.28	4.51	0.38	1.49e-5	Strep throat;
TGCT	cis	rs12579753	1.000	rs10862373	chr12:82250657	A/G	cg07988820	chr12:82153109	PPFIA2	-0.6	-6.61	-0.51	1.02e-9	Resting heart rate;
TGCT	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg23034840	chr1:205782522	SLC41A1	0.7	6.09	0.48	1.28e-8	Prostate-specific antigen levels;
TGCT	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg06896619	chr17:61851486	DDX42;CCDC47	-0.51	-4.96	-0.41	2.24e-6	Prudent dietary pattern;
TGCT	cis	rs4786125	0.920	rs7194057	chr16:6895960	T/C	cg03623568	chr16:6915990	A2BP1	-0.38	-5.14	-0.42	1.02e-6	Heart rate variability traits (SDNN);
TGCT	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg21963583	chr11:68658836	MRPL21	0.36	6.07	0.48	1.43e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs763121	0.819	rs6001205	chr22:39100264	T/A	cg06022373	chr22:39101656	GTPBP1	0.74	7.31	0.55	2.94e-11	Menopause (age at onset);
TGCT	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.01	8.32	0.6	1.34e-13	Platelet count;
TGCT	cis	rs7804356	1.000	rs1327988	chr7:26828965	C/G	cg03456212	chr7:26904342	SKAP2	0.62	4.71	0.39	6.65e-6	Type 1 diabetes;
TGCT	cis	rs4824093	0.610	rs9627799	chr22:50317989	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.15	-4.45	-0.37	1.86e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs6060960	0.537	rs6089119	chr20:30514161	T/G	cg06102403	chr20:30458708	TTLL9;DUSP15	0.4	4.57	0.38	1.16e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
TGCT	trans	rs75565482	0.546	rs12090359	chr1:168458546	G/A	cg24696473	chr17:17683032	SMCR5;RAI1	0.48	6.73	0.52	5.5e-10	Emphysema imaging phenotypes;
TGCT	cis	rs4919694	0.572	rs12261294	chr10:104934952	C/T	cg04362960	chr10:104952993	NT5C2	0.97	6.81	0.52	3.82e-10	Arsenic metabolism;
TGCT	cis	rs1580019	0.587	rs7806941	chr7:32553319	G/T	cg07520158	chr7:32535189	LSM5;AVL9	0.57	4.98	0.41	2.05e-6	Cognitive ability;
TGCT	cis	rs13088645	0.621	rs7611834	chr3:134146088	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.54	5.02	0.41	1.78e-6	Coronary artery disease;
TGCT	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg03806693	chr22:41940476	POLR3H	-1.14	-13.41	-0.77	6.99e-26	Vitiligo;
TGCT	cis	rs12188164	0.930	rs72717440	chr5:449701	A/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.4	-4.71	-0.39	6.42e-6	Cystic fibrosis severity;
TGCT	cis	rs3820068	0.608	rs7519899	chr1:16045579	A/G	cg05660106	chr1:15850417	CASP9	0.73	6.75	0.52	5.18e-10	Systolic blood pressure;
TGCT	cis	rs2013441	1.000	rs2158473	chr17:20139090	T/C	cg18979559	chr17:20280153	CCDC144C	-0.45	-4.67	-0.39	7.61e-6	Obesity-related traits;
TGCT	cis	rs78487399	0.614	rs13422551	chr2:43724682	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-4.82	-0.4	4.03e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs6089584	0.927	rs1886007	chr20:60581049	G/A	cg16423285	chr20:60520624	NA	-0.62	-6.89	-0.53	2.48e-10	Body mass index;
TGCT	cis	rs17221829	0.733	rs10830327	chr11:89389122	G/A	cg02982614	chr11:89391479	FOLH1B	-0.25	-4.46	-0.37	1.8e-5	Anxiety in major depressive disorder;
TGCT	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg10819733	chr22:24237672	NA	-0.33	-5.44	-0.44	2.7e-7	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs10893109	0.967	rs2045071	chr11:123797007	G/A	cg14126608	chr11:122846540	NA	-0.28	-4.45	-0.37	1.87e-5	Facial morphology (factor 13, vertical position of alar curvature relative to upper lip);
TGCT	cis	rs10464366	1.000	rs10464366	chr7:39121500	A/T	cg08835956	chr7:39171034	POU6F2	-0.23	-4.59	-0.38	1.08e-5	IgG glycosylation;
TGCT	cis	rs2180341	1.000	rs6569483	chr6:127658855	G/A	cg27446573	chr6:127587934	RNF146	1.12	10.11	0.67	6.87e-18	Breast cancer;
TGCT	cis	rs7513165	0.660	rs12040249	chr1:204158228	C/T	cg24450653	chr1:205060293	RBBP5	0.21	4.5	0.37	1.57e-5	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
TGCT	cis	rs8031584	0.678	rs798086	chr15:31129211	C/G	cg08109568	chr15:31115862	NA	0.4	5.24	0.43	6.73e-7	Huntington's disease progression;
TGCT	cis	rs910316	0.967	rs7146523	chr14:75659880	T/C	cg11812906	chr14:75593930	NEK9	-0.72	-6.87	-0.53	2.72e-10	Height;
TGCT	cis	rs2046867	0.908	rs1106310	chr3:72818902	A/T	cg25664220	chr3:72788482	NA	0.56	7.18	0.54	5.54e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6582630	0.502	rs2387603	chr12:38353389	A/C	cg26384229	chr12:38710491	ALG10B	0.78	6.94	0.53	1.91e-10	Drug-induced liver injury (flucloxacillin);
TGCT	trans	rs10506458	0.834	rs73125186	chr12:63373400	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.46	-7.24	-0.55	4.04e-11	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs798766	1.000	rs798754	chr4:1720757	A/G	cg05874882	chr4:1763078	NA	-0.37	-4.93	-0.4	2.6e-6	Bladder cancer;Urinary bladder cancer;
TGCT	cis	rs6460942	0.643	rs7780093	chr7:12233661	C/G	cg06484146	chr7:12443880	VWDE	-0.54	-4.76	-0.39	5.21e-6	Coronary artery disease;
TGCT	cis	rs9549367	0.789	rs3861720	chr13:113906097	A/G	cg18105134	chr13:113819100	PROZ	-0.34	-5.58	-0.45	1.41e-7	Platelet distribution width;
TGCT	cis	rs4728071	0.568	rs10232298	chr7:127219417	A/G	cg22282131	chr7:127439670	SND1	0.21	4.46	0.37	1.82e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs854765	0.663	rs4925120	chr17:17754633	C/T	cg09796270	chr17:17721594	SREBF1	-0.26	-4.93	-0.4	2.59e-6	Total body bone mineral density;
TGCT	cis	rs7666738	0.716	rs6827474	chr4:99089683	T/G	cg18180107	chr4:99064573	C4orf37	0.55	4.94	0.41	2.45e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6912958	0.712	rs9444526	chr6:88326402	A/G	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.98	-0.41	2.06e-6	Monocyte percentage of white cells;
TGCT	trans	rs9991510	0.586	rs2903246	chr4:12141834	A/T	cg04834502	chr16:48644360	N4BP1	-0.95	-6.86	-0.52	2.85e-10	Photic sneeze reflex;
TGCT	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.15	0.82	2.71e-32	Prudent dietary pattern;
TGCT	trans	rs1814175	0.817	rs10769641	chr11:49960141	A/G	cg15704280	chr7:45808275	SEPT13	-0.73	-8.48	-0.61	5.58e-14	Height;
TGCT	cis	rs6690583	0.573	rs7547317	chr1:85456961	T/G	cg20280350	chr1:85513789	MCOLN3	-0.79	-5.27	-0.43	5.77e-7	Serum sulfate level;
TGCT	cis	rs2455799	0.593	rs2470544	chr3:15727234	A/G	cg16303742	chr3:15540471	COLQ	-0.25	-4.74	-0.39	5.65e-6	Mean platelet volume;
TGCT	trans	rs208520	0.837	rs208471	chr6:66916749	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.95	-9.95	-0.67	1.64e-17	Exhaled nitric oxide output;
TGCT	cis	rs17345786	0.906	rs11710016	chr3:101120030	A/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.84	-8.92	-0.63	5.05e-15	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs524281	0.817	rs10896097	chr11:65967953	A/C	cg00563793	chr11:65837595	PACS1	0.54	4.71	0.39	6.4e-6	Electroencephalogram traits;
TGCT	cis	rs9811216	0.958	rs9827710	chr3:169522387	G/C	cg08193579	chr3:169529701	LRRC34	0.3	4.59	0.38	1.05e-5	Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;
TGCT	cis	rs2228479	0.681	rs10153196	chr16:89967397	A/C	cg06558623	chr16:89946397	TCF25	0.41	4.99	0.41	1.97e-6	Skin colour saturation;
TGCT	cis	rs4455778	0.580	rs7780178	chr7:49085140	A/G	cg26309511	chr7:48887640	NA	0.5	6.47	0.5	2.03e-9	Lung cancer in never smokers;
TGCT	cis	rs13188771	0.614	rs66592082	chr5:100914515	T/C	cg10455971	chr5:101119566	NA	0.45	4.64	0.38	8.85e-6	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs3020736	0.500	rs1801311	chr22:42486723	G/A	cg05082376	chr22:42548792	NA	0.23	5.43	0.44	2.83e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7772486	0.875	rs6909827	chr6:146365738	A/G	cg23711669	chr6:146136114	FBXO30	0.85	9.44	0.65	2.92e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg24675658	chr1:53192096	ZYG11B	0.74	8.69	0.62	1.75e-14	Monocyte count;
TGCT	cis	rs12472274	0.941	rs2880131	chr2:239089151	A/C	cg17459225	chr2:239074497	NA	0.34	5.02	0.41	1.78e-6	Phospholipid levels (plasma);
TGCT	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.41	-4.88	-0.4	3.13e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs854765	0.856	rs2955382	chr17:17947710	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-6.46	-0.5	2.13e-9	Total body bone mineral density;
TGCT	cis	rs9634489	0.502	rs732103	chr13:97099614	A/G	cg11411106	chr13:97107445	HS6ST3	-0.25	-4.46	-0.37	1.82e-5	Body mass index;
TGCT	cis	rs7474896	0.515	rs675628	chr10:38305331	C/G	cg13720705	chr10:37990370	NA	-0.37	-4.68	-0.39	7.35e-6	Obesity (extreme);
TGCT	cis	rs17345786	0.954	rs17508319	chr3:101318903	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.56	4.81	0.4	4.21e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3821902	0.691	rs73120936	chr3:64050945	T/C	cg22134162	chr3:63841271	THOC7	-0.34	-4.97	-0.41	2.19e-6	Breast cancer;
TGCT	cis	rs6964587	0.869	rs405	chr7:91546327	G/C	cg17063962	chr7:91808500	NA	-0.86	-9.19	-0.64	1.16e-15	Breast cancer;
TGCT	cis	rs9858542	1.000	rs11709525	chr3:49690496	C/T	cg03060546	chr3:49711283	APEH	-0.67	-6.0	-0.47	2.06e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs2963155	0.518	rs853184	chr5:142640901	C/T	cg17617527	chr5:142782415	NR3C1	0.85	6.34	0.49	3.85e-9	Breast cancer;
TGCT	cis	rs7296418	0.816	rs1790096	chr12:123710364	C/T	cg00376283	chr12:123451042	ABCB9	0.84	7.67	0.57	4.4e-12	Platelet count;
TGCT	cis	rs4517514	0.509	rs10830417	chr11:89871940	A/G	cg14505434	chr11:89522851	NA	0.45	4.45	0.37	1.87e-5	Trans fatty acid levels;
TGCT	cis	rs79387448	0.745	rs17027413	chr2:103153667	A/G	cg09003973	chr2:102972529	NA	-0.96	-5.92	-0.47	2.95e-8	Gut microbiota (bacterial taxa);
TGCT	cis	rs4654899	0.965	rs7512116	chr1:21501095	C/A	cg01072550	chr1:21505969	NA	-0.5	-8.08	-0.59	4.94e-13	Superior frontal gyrus grey matter volume;
TGCT	cis	rs1568889	0.838	rs10835276	chr11:28167147	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.92	11.03	0.7	4.03e-20	Bipolar disorder;
TGCT	cis	rs9818758	0.505	rs67286839	chr3:49265744	C/T	cg00383909	chr3:49044727	WDR6	1.28	6.57	0.51	1.23e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs9296092	0.538	rs9469488	chr6:33517117	G/T	cg13560919	chr6:33536144	NA	-0.2	-4.63	-0.38	9.25e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs9486715	0.867	rs4839842	chr6:96955387	A/T	cg06623918	chr6:96969491	KIAA0776	1.1	15.44	0.81	1.17e-30	Headache;
TGCT	cis	rs6964587	0.967	rs6970743	chr7:91744311	C/G	cg22709100	chr7:91322751	NA	0.29	4.75	0.39	5.61e-6	Breast cancer;
TGCT	trans	rs1814175	0.647	rs61306292	chr11:49856040	G/C	cg15704280	chr7:45808275	SEPT13	-0.71	-7.92	-0.58	1.18e-12	Height;
TGCT	cis	rs6964587	1.000	rs10280927	chr7:91582205	G/A	cg17063962	chr7:91808500	NA	-0.91	-9.99	-0.67	1.32e-17	Breast cancer;
TGCT	cis	rs35146811	0.735	rs2272345	chr7:99797031	C/G	cg04778012	chr7:99775508	STAG3;GPC2	0.35	4.93	0.41	2.55e-6	Coronary artery disease;
TGCT	cis	rs13242816	1.000	rs56010123	chr7:116173046	C/T	cg02799643	chr7:116139180	CAV2	-0.43	-5.29	-0.43	5.24e-7	P wave duration;
TGCT	cis	rs2153535	0.580	rs9405391	chr6:8466548	C/T	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs899997	1.000	rs11634628	chr15:79005579	G/A	cg00061860	chr15:78953028	NA	-0.25	-4.61	-0.38	9.69e-6	Coronary artery disease or large artery stroke;
TGCT	cis	rs910316	1.000	rs11159117	chr14:75584867	C/T	cg23033748	chr14:75592666	NEK9	0.27	4.61	0.38	9.79e-6	Height;
TGCT	cis	rs1903068	0.853	rs9312655	chr4:56002665	T/C	cg16572876	chr4:56024045	NA	0.42	4.79	0.39	4.75e-6	Endometriosis;
TGCT	cis	rs10744422	1.000	rs4759355	chr12:123316566	A/G	cg25930673	chr12:123319894	HIP1R	-0.85	-5.01	-0.41	1.86e-6	Schizophrenia;
TGCT	cis	rs7020830	0.571	rs7031314	chr9:37376122	A/T	cg14294708	chr9:37120828	ZCCHC7	-0.94	-9.45	-0.65	2.78e-16	Schizophrenia;
TGCT	cis	rs13242816	1.000	rs62471198	chr7:116107963	T/C	cg02799643	chr7:116139180	CAV2	-0.45	-5.38	-0.44	3.5e-7	P wave duration;
TGCT	cis	rs4478858	0.684	rs10798837	chr1:31719340	C/T	cg07478791	chr1:31886160	SERINC2	-0.49	-4.8	-0.4	4.51e-6	Alcohol dependence;
TGCT	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg24503407	chr1:205819492	PM20D1	0.57	7.93	0.58	1.08e-12	Menarche (age at onset);
TGCT	cis	rs1008375	0.900	rs6812675	chr4:17597549	A/G	cg16339924	chr4:17578868	LAP3	0.84	6.77	0.52	4.62e-10	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.71	-0.39	6.54e-6	Prudent dietary pattern;
TGCT	cis	rs36051895	0.589	rs6476945	chr9:5191793	C/T	cg02405213	chr9:5042618	JAK2	-0.7	-9.3	-0.64	6.3e-16	Pediatric autoimmune diseases;
TGCT	cis	rs2180341	0.842	rs9375492	chr6:127545492	C/T	cg27446573	chr6:127587934	RNF146	-1.06	-8.46	-0.6	6.28e-14	Breast cancer;
TGCT	cis	rs4517514	0.509	rs10830411	chr11:89865532	A/G	cg14505434	chr11:89522851	NA	0.45	4.46	0.37	1.82e-5	Trans fatty acid levels;
TGCT	cis	rs17767294	0.708	rs116146221	chr6:27853392	G/A	cg08851530	chr6:28072375	NA	1.58	6.37	0.5	3.43e-9	Parkinson's disease;
TGCT	cis	rs28374715	0.532	rs3204853	chr15:41689166	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.94	-16.47	-0.83	5.12e-33	Ulcerative colitis;
TGCT	cis	rs7829975	0.667	rs1877119	chr8:8707197	C/G	cg06636001	chr8:8085503	FLJ10661	0.7	6.21	0.49	7.39e-9	Mood instability;
TGCT	cis	rs3096299	0.719	rs2353581	chr16:89518908	T/C	cg02187348	chr16:89574699	SPG7	0.6	6.39	0.5	2.98e-9	Multiple myeloma (IgH translocation);
TGCT	cis	rs8100891	0.734	rs8104048	chr19:32829306	A/G	cg16662424	chr19:32837316	ZNF507	-0.46	-5.54	-0.45	1.76e-7	Neuroticism;
TGCT	cis	rs11190604	1.000	rs12358187	chr10:102284449	C/G	cg23241863	chr10:102295624	HIF1AN	0.68	5.17	0.42	9.14e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7666738	0.962	rs11728816	chr4:98951767	C/T	cg18180107	chr4:99064573	C4orf37	0.56	4.45	0.37	1.9e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs17376456	1.000	rs56046246	chr5:93531545	T/G	cg25358565	chr5:93447407	FAM172A	0.93	7.91	0.58	1.22e-12	Diabetic retinopathy;
TGCT	cis	rs12893668	0.703	rs55751606	chr14:104028806	G/A	cg26031613	chr14:104095156	KLC1	-0.56	-4.7	-0.39	6.83e-6	Reticulocyte count;
TGCT	cis	rs250677	0.687	rs10040624	chr5:148437579	A/G	cg23229984	chr5:148520753	ABLIM3	0.21	4.89	0.4	3.11e-6	Breast cancer;
TGCT	cis	rs734999	0.588	rs2843403	chr1:2529097	T/C	cg18854424	chr1:2615690	NA	-0.5	-5.78	-0.46	5.64e-8	Ulcerative colitis;
TGCT	cis	rs6684514	1.000	rs2277871	chr1:156246742	A/G	cg20302342	chr1:156215951	PAQR6	0.34	4.6	0.38	1.01e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs3751972	1.000	rs3751972	chr17:26206414	C/A	cg02948944	chr17:26242737	NA	0.48	6.89	0.53	2.44e-10	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs473651	0.935	rs578510	chr2:239343140	C/T	cg18131467	chr2:239335373	ASB1	1.02	15.09	0.8	7.51e-30	Multiple system atrophy;
TGCT	cis	rs4730250	0.707	rs4730222	chr7:106810293	G/C	cg02696742	chr7:106810147	HBP1	-0.71	-5.83	-0.46	4.6e-8	Osteoarthritis;
TGCT	cis	rs2050392	0.792	rs303434	chr10:30714440	G/A	cg18806716	chr10:30721971	MAP3K8	-0.48	-5.53	-0.44	1.84e-7	Inflammatory bowel disease;
TGCT	cis	rs896854	0.517	rs896851	chr8:95950251	T/C	cg16049864	chr8:95962084	TP53INP1	-0.55	-6.05	-0.48	1.55e-8	Type 2 diabetes;
TGCT	cis	rs96067	0.711	rs4653164	chr1:36627542	A/G	cg07093915	chr1:36184400	C1orf216	0.47	4.9	0.4	2.94e-6	Corneal structure;
TGCT	cis	rs66887589	0.592	rs2175383	chr4:120215836	C/A	cg24670566	chr4:120433619	PDE5A	0.21	4.57	0.38	1.16e-5	Diastolic blood pressure;
TGCT	trans	rs1496653	0.602	rs34619482	chr3:23374278	A/C	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs1887596	0.624	rs9551298	chr13:27152527	G/A	cg01312412	chr13:27282625	NA	0.27	4.78	0.39	4.81e-6	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs548181	0.736	rs1941558	chr11:125425606	C/T	cg03464685	chr11:125439445	EI24	1.37	10.56	0.69	5.45e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs9894429	0.646	rs6565612	chr17:79602820	C/T	cg21028142	chr17:79581711	NPLOC4	-0.28	-5.71	-0.46	8.05e-8	Eye color traits;
TGCT	cis	rs826838	0.967	rs1719858	chr12:39124505	C/T	cg13010199	chr12:38710504	ALG10B	-0.64	-5.07	-0.41	1.39e-6	Heart rate;
TGCT	cis	rs7104764	1.000	rs7128029	chr11:244141	G/A	cg18336825	chr11:236787	PSMD13;SIRT3	1.07	11.19	0.71	1.61e-20	Menarche (age at onset);
TGCT	cis	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg08564027	chr20:61660810	NA	0.38	7.08	0.54	9.36e-11	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs600231	0.708	rs602838	chr11:65253247	T/G	cg17120908	chr11:65337727	SSSCA1	-0.56	-5.23	-0.42	7.04e-7	Bone mineral density;
TGCT	cis	rs3540	0.554	rs113942266	chr15:91072990	A/G	cg22089800	chr15:90895588	ZNF774	-0.76	-7.98	-0.58	8.23e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs1475911	0.656	rs9980065	chr21:43528072	G/A	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.34	-5.53	-0.44	1.83e-7	IgG glycosylation;
TGCT	cis	rs7412746	0.611	rs4970985	chr1:150887442	C/T	cg09365446	chr1:150670422	GOLPH3L	-0.34	-4.69	-0.39	7.14e-6	Melanoma;
TGCT	cis	rs483180	0.511	rs496195	chr1:120207182	A/G	cg19096424	chr1:120255104	PHGDH	-0.56	-5.24	-0.43	6.8e-7	Macular telangiectasia type 2;
TGCT	cis	rs8044995	0.563	rs3743743	chr16:68397775	C/T	cg05110241	chr16:68378359	PRMT7	-0.36	-4.46	-0.37	1.84e-5	Schizophrenia;
TGCT	cis	rs6831352	0.918	rs2602891	chr4:100043284	C/T	cg12011299	chr4:100065546	ADH4	0.42	4.99	0.41	2e-6	Alcohol dependence;
TGCT	cis	rs2692947	0.537	rs11677429	chr2:96193061	C/T	cg23100626	chr2:96804247	ASTL	0.45	5.33	0.43	4.5e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs7513165	0.551	rs11240688	chr1:204134522	C/T	cg12731349	chr1:204159619	KISS1	0.47	4.69	0.39	7e-6	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
TGCT	cis	rs9811920	0.965	rs10222474	chr3:99862551	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.42	-4.79	-0.4	4.69e-6	Axial length;
TGCT	cis	rs7809950	0.530	rs111865019	chr7:106812246	A/G	cg23024343	chr7:107201750	COG5	-0.37	-5.29	-0.43	5.37e-7	Coronary artery disease;
TGCT	cis	rs34526934	0.608	rs34720456	chr2:177027292	G/A	cg26754761	chr2:177040938	NA	-0.28	-5.22	-0.42	7.15e-7	Obstructive sleep apnea trait (apnea hypopnea index);
TGCT	cis	rs2836974	0.604	rs2854727	chr21:40713787	A/G	cg17971929	chr21:40555470	PSMG1	0.59	5.33	0.43	4.4e-7	Cognitive function;
TGCT	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg05665937	chr4:1216051	CTBP1	0.25	4.75	0.39	5.64e-6	Obesity-related traits;
TGCT	cis	rs9372498	0.505	rs62422250	chr6:118990182	T/C	cg07617317	chr6:118971624	C6orf204	0.46	4.44	0.37	1.98e-5	Diastolic blood pressure;
TGCT	cis	rs739401	0.611	rs7109088	chr11:3027485	G/T	cg25174290	chr11:3078921	CARS	0.5	4.79	0.4	4.6e-6	Longevity;
TGCT	trans	rs208520	0.661	rs704519	chr6:66801136	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-10.75	-0.69	1.87e-19	Exhaled nitric oxide output;
TGCT	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg11890956	chr21:40555474	PSMG1	1.12	12.23	0.74	4.65e-23	Cognitive function;
TGCT	cis	rs2072499	0.833	rs2251847	chr1:156204047	G/A	cg06970220	chr1:156163860	SLC25A44	0.72	5.85	0.46	4.14e-8	Testicular germ cell tumor;
TGCT	cis	rs6076065	0.748	rs2281431	chr20:23399304	C/G	cg11657817	chr20:23433608	CST11	0.31	5.42	0.44	3.02e-7	Facial morphology (factor 15, philtrum width);
TGCT	cis	rs899997	1.000	rs11629824	chr15:79005524	T/G	cg04896959	chr15:78267971	NA	0.36	5.57	0.45	1.52e-7	Coronary artery disease or large artery stroke;
TGCT	cis	rs9467773	0.804	rs2073526	chr6:26374658	C/T	cg07107628	chr6:27210934	NA	0.16	4.48	0.37	1.68e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs11696501	0.739	rs6073822	chr20:44251880	A/G	cg11783356	chr20:44313418	WFDC10B	-0.32	-4.63	-0.38	9.25e-6	Brain structure;
TGCT	cis	rs2675662	0.525	rs12264025	chr10:75494450	A/G	cg23231163	chr10:75533350	FUT11	-0.28	-4.68	-0.39	7.4e-6	Psoriasis vulgaris;Psoriasis;
TGCT	cis	rs6684514	0.961	rs11264463	chr1:156242806	A/G	cg16558208	chr1:156270281	VHLL	0.44	8.92	0.63	5.19e-15	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg09060608	chr5:178986726	RUFY1	-0.61	-7.46	-0.56	1.28e-11	Lung cancer;
TGCT	cis	rs78487399	0.808	rs13409687	chr2:43701151	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-5.45	-0.44	2.63e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs10992471	0.598	rs2398751	chr9:95206240	C/T	cg13798575	chr9:95087839	CENPP;NOL8	0.63	6.25	0.49	5.98e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg07343612	chr16:622815	PIGQ	-0.42	-8.44	-0.6	6.97e-14	Height;
TGCT	cis	rs7590720	0.840	rs705648	chr2:216933792	C/T	cg12620499	chr2:216877984	MREG	0.77	7.37	0.55	2.14e-11	Alcohol dependence;
TGCT	cis	rs1163251	0.837	rs592762	chr1:120247355	A/G	cg19096424	chr1:120255104	PHGDH	0.6	5.93	0.47	2.76e-8	Blood metabolite levels;
TGCT	cis	rs941408	0.515	rs878893	chr19:2781325	A/G	cg06609049	chr19:2785107	THOP1	1.16	13.03	0.76	5.49e-25	Total cholesterol levels;
TGCT	cis	rs8103278	1.000	rs35302007	chr19:46219145	G/C	cg11657440	chr19:46296263	DMWD	-0.56	-5.4	-0.44	3.21e-7	Coronary artery disease;
TGCT	cis	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg08975724	chr8:8085496	FLJ10661	0.64	6.03	0.48	1.77e-8	Mood instability;
TGCT	cis	rs858239	0.730	rs858290	chr7:23248036	A/G	cg05602783	chr7:23145260	KLHL7	-0.64	-5.39	-0.44	3.41e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs6088590	0.687	rs8115656	chr20:33282780	G/C	cg06115741	chr20:33292138	TP53INP2	0.56	4.7	0.39	6.83e-6	Coronary artery disease;
TGCT	trans	rs77457752	0.525	rs1923350	chr9:13898880	T/A	cg23609682	chr1:3070786	PRDM16	0.5	6.79	0.52	4.09e-10	Breast cancer;
TGCT	cis	rs9650657	0.530	rs6982381	chr8:10952500	A/T	cg03192020	chr8:11204681	TDH	-0.51	-4.52	-0.38	1.41e-5	Neuroticism;
TGCT	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg01719998	chr16:89642051	CPNE7	0.45	4.5	0.37	1.52e-5	Vitiligo;
TGCT	cis	rs11690935	1.000	rs312925	chr2:172563922	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.19	-12.83	-0.76	1.7e-24	Schizophrenia;
TGCT	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs35160687	0.901	rs67903513	chr2:86512099	A/C	cg12542933	chr2:85804724	VAMP8	0.4	4.76	0.39	5.24e-6	Night sleep phenotypes;
TGCT	cis	rs10927875	0.632	rs2862162	chr1:16142960	A/C	cg21385522	chr1:16154831	NA	0.95	15.27	0.81	2.89e-30	Dilated cardiomyopathy;
TGCT	cis	rs4325129	0.677	rs4656836	chr1:159500338	A/G	cg07417683	chr1:159440267	NA	-0.37	-4.69	-0.39	7.09e-6	Obesity-related traits;
TGCT	cis	rs9952991	0.941	rs2014857	chr18:12774326	C/T	cg23544223	chr18:12777786	NA	0.63	6.02	0.48	1.85e-8	Inflammatory skin disease;
TGCT	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg10047753	chr17:41438598	NA	0.96	9.86	0.66	2.71e-17	Menopause (age at onset);
TGCT	cis	rs4689388	0.890	rs3821941	chr4:6286954	A/G	cg00701064	chr4:6280414	WFS1	0.45	5.98	0.47	2.18e-8	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs7937682	0.889	rs1789359	chr11:111475995	T/A	cg09085632	chr11:111637200	PPP2R1B	-1.05	-11.39	-0.72	5.21e-21	Primary sclerosing cholangitis;
TGCT	cis	rs7824557	0.564	rs2572386	chr8:11236975	A/G	cg21775007	chr8:11205619	TDH	-0.65	-6.39	-0.5	3.07e-9	Retinal vascular caliber;
TGCT	cis	rs10791097	0.694	rs61910787	chr11:130744473	G/A	cg12179176	chr11:130786555	SNX19	0.84	10.17	0.67	4.95e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9788682	0.747	rs16969894	chr15:78776456	C/T	cg24631222	chr15:78858424	CHRNA5	0.61	4.51	0.38	1.5e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs1801251	0.964	rs6748027	chr2:233629552	T/C	cg08000102	chr2:233561755	GIGYF2	0.63	6.49	0.5	1.88e-9	Coronary artery disease;
TGCT	cis	rs9341808	0.539	rs2490253	chr6:80895870	T/C	cg08355045	chr6:80787529	NA	0.3	5.07	0.41	1.44e-6	Sitting height ratio;
TGCT	cis	rs7943191	0.810	rs7942991	chr11:62337203	A/G	cg11742103	chr11:62369870	EML3;MTA2	-0.51	-5.92	-0.47	2.88e-8	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg22764044	chr5:178986830	RUFY1	0.43	4.57	0.38	1.17e-5	Lung cancer;
TGCT	cis	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg20637647	chr7:64974828	NA	0.92	5.35	0.43	4.11e-7	Diabetic kidney disease;
TGCT	cis	rs12134133	1.000	rs7543117	chr1:207438696	T/C	cg02152968	chr1:207494213	CD55	0.61	4.66	0.39	7.94e-6	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs7829975	0.593	rs2979241	chr8:8303353	G/C	cg08975724	chr8:8085496	FLJ10661	0.54	4.92	0.4	2.73e-6	Mood instability;
TGCT	cis	rs10927875	0.632	rs2862162	chr1:16142960	A/C	cg14742211	chr1:16348397	CLCNKA	0.19	4.57	0.38	1.16e-5	Dilated cardiomyopathy;
TGCT	cis	rs11098499	1.000	rs35643470	chr4:120184948	T/C	cg09307838	chr4:120376055	NA	0.49	4.52	0.38	1.43e-5	Corneal astigmatism;
TGCT	cis	rs8078723	0.966	rs2227322	chr17:38171668	C/G	cg17467752	chr17:38218738	THRA	0.52	4.93	0.41	2.54e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs72627509	0.501	rs13101682	chr4:57735358	G/A	cg26694713	chr4:57773883	REST	0.58	5.91	0.47	3.12e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs7147624	1.000	rs11848209	chr14:66022832	T/A	cg03016385	chr14:66212404	NA	-0.49	-7.08	-0.54	9.33e-11	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs7178572	0.889	rs907388	chr15:77828668	G/A	cg22256960	chr15:77711686	NA	-0.95	-10.78	-0.7	1.59e-19	Type 2 diabetes;
TGCT	cis	rs12261331	1	rs12261331	chr10:82287527	C/T	cg01528321	chr10:82214614	TSPAN14	-0.95	-5.94	-0.47	2.69e-8	Post bronchodilator FEV1;
TGCT	cis	rs2729354	0.729	rs2581923	chr11:57249991	C/T	cg24343310	chr11:57249947	NA	0.28	4.61	0.38	9.8200000000000008e-06	Blood protein levels;
TGCT	cis	rs7584330	0.518	rs6715245	chr2:238445803	C/T	cg14458575	chr2:238380390	NA	0.43	4.55	0.38	1.25e-5	Prostate cancer;
TGCT	cis	rs2204008	0.837	rs2127955	chr12:37969194	A/G	cg26384229	chr12:38710491	ALG10B	0.71	6.21	0.49	7.18e-9	Bladder cancer;
TGCT	cis	rs782590	0.902	rs782601	chr2:55848244	T/C	cg03859395	chr2:55845619	SMEK2	0.9	11.04	0.7	3.81e-20	Metabolic syndrome;
TGCT	cis	rs34638657	0.732	rs11866711	chr16:82201038	A/C	cg09439754	chr16:82129088	HSD17B2	-0.24	-4.53	-0.38	1.37e-5	Lung adenocarcinoma;
TGCT	cis	rs9357506	0.967	rs4714929	chr6:46309940	A/T	cg21115430	chr6:46460003	NA	-0.26	-5.16	-0.42	9.6e-7	Body mass index;
TGCT	cis	rs7824557	0.767	rs28507159	chr8:11166076	C/T	cg21775007	chr8:11205619	TDH	0.58	5.46	0.44	2.46e-7	Retinal vascular caliber;
TGCT	cis	rs732765	0.734	rs12882425	chr14:75189226	A/T	cg06637938	chr14:75390232	RPS6KL1	-0.57	-5.03	-0.41	1.69e-6	Non-small cell lung cancer;
TGCT	cis	rs651907	0.535	rs13084113	chr3:101534039	C/G	cg11279151	chr3:101281821	RG9MTD1	-0.31	-6.5	-0.5	1.8e-9	Colorectal cancer;
TGCT	cis	rs7178424	0.743	rs8032681	chr15:62162243	T/C	cg00456672	chr15:62358751	C2CD4A	-0.31	-4.72	-0.39	6.37e-6	Height;
TGCT	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg11062466	chr8:58055876	NA	0.39	6.0	0.47	2.03e-8	Developmental language disorder (linguistic errors);
TGCT	cis	rs9467773	0.620	rs2451737	chr6:26619041	T/C	cg09904177	chr6:26538194	HMGN4	0.66	6.33	0.49	3.99e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs9788682	0.748	rs2456020	chr15:78868398	C/T	cg24631222	chr15:78858424	CHRNA5	0.81	6.22	0.49	7.06e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs734999	0.549	rs6667564	chr1:2520302	T/C	cg18854424	chr1:2615690	NA	0.49	5.72	0.46	7.65e-8	Ulcerative colitis;
TGCT	cis	rs12541335	0.615	rs4872464	chr8:22153381	G/A	cg07298985	chr8:22133076	PIWIL2	0.33	5.02	0.41	1.77e-6	Hypertriglyceridemia;
TGCT	cis	rs4727027	0.704	rs12535154	chr7:148895304	G/A	cg23583168	chr7:148888333	NA	-0.83	-11.12	-0.71	2.36e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs12360000	0.797	rs12768776	chr10:1901587	C/T	cg26364871	chr10:1889757	NA	0.41	4.64	0.38	8.81e-6	Metabolite levels (Dihydroxy docosatrienoic acid);
TGCT	cis	rs9394841	0.667	rs3747750	chr6:41760372	C/G	cg08135965	chr6:41755394	TOMM6	0.55	5.15	0.42	9.77e-7	Mean corpuscular hemoglobin;Red cell distribution width;
TGCT	cis	rs9948	0.786	rs62156227	chr2:97417942	C/A	cg01990225	chr2:97406019	LMAN2L	-0.88	-4.81	-0.4	4.37e-6	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs1801239	1.000	rs17343073	chr10:16932196	A/T	cg00939682	chr10:16933505	CUBN	0.47	4.46	0.37	1.79e-5	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin excretion;
TGCT	cis	rs2637266	0.703	rs12252157	chr10:78449521	G/A	cg18941641	chr10:78392320	NA	0.4	4.88	0.4	3.24e-6	Pulmonary function;
TGCT	cis	rs7412746	0.658	rs11204750	chr1:150939744	C/A	cg09365446	chr1:150670422	GOLPH3L	0.34	4.72	0.39	6.28e-6	Melanoma;
TGCT	cis	rs7829975	0.840	rs572366	chr8:8578794	A/T	cg08975724	chr8:8085496	FLJ10661	0.57	4.91	0.4	2.86e-6	Mood instability;
TGCT	cis	rs7208859	0.623	rs11657391	chr17:29194287	G/A	cg18442181	chr17:29233375	C17orf42	-0.78	-4.61	-0.38	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs3806843	0.608	rs246042	chr5:140330967	G/A	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs4654899	0.931	rs10799679	chr1:21341776	A/G	cg01072550	chr1:21505969	NA	-0.5	-7.97	-0.58	8.84e-13	Superior frontal gyrus grey matter volume;
TGCT	cis	rs4975709	0.544	rs4975748	chr5:1866025	G/A	cg04156016	chr5:1868137	NA	0.36	5.32	0.43	4.62e-7	Cardiovascular disease risk factors;
TGCT	trans	rs877282	0.898	rs12357995	chr10:765739	T/C	cg22713356	chr15:30763199	NA	1.2	9.39	0.64	3.76e-16	Uric acid levels;
TGCT	cis	rs427394	0.664	rs274697	chr5:6731477	A/C	cg10857441	chr5:6722123	POLS	-0.29	-7.23	-0.54	4.25e-11	Menopause (age at onset);
TGCT	cis	rs7572733	0.534	rs771009	chr2:198691082	A/G	cg00792783	chr2:198669748	PLCL1	0.56	5.08	0.42	1.35e-6	Dermatomyositis;
TGCT	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	16.07	0.82	4.21e-32	Prudent dietary pattern;
TGCT	cis	rs7027203	0.576	rs7851269	chr9:96540530	C/T	cg14598338	chr9:96623480	NA	0.5	7.36	0.55	2.2e-11	DNA methylation (variation);
TGCT	cis	rs7937682	0.562	rs527847	chr11:111369132	A/C	cg09085632	chr11:111637200	PPP2R1B	0.66	6.36	0.5	3.49e-9	Primary sclerosing cholangitis;
TGCT	cis	rs7091068	0.566	rs1326220	chr10:95486155	G/A	cg20715218	chr10:95462985	C10orf4	0.52	4.64	0.38	8.72e-6	Urinary tract infection frequency;
TGCT	cis	rs7806994	1	rs7806994	chr7:56139505	A/T	cg21096502	chr7:56174374	CHCHD2	-0.88	-6.62	-0.51	9.63e-10	PR interval in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7100689	0.784	rs3120977	chr10:82075324	C/G	cg01528321	chr10:82214614	TSPAN14	0.8	7.92	0.58	1.15e-12	Post bronchodilator FEV1;
TGCT	cis	rs1129187	0.755	rs2296804	chr6:42931261	C/G	cg02353165	chr6:42928485	GNMT	0.8	7.13	0.54	7.19e-11	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.63	-5.13	-0.42	1.07e-6	Tonsillectomy;
TGCT	cis	rs9913156	0.841	rs56239958	chr17:4600280	G/C	cg23387401	chr17:4582204	PELP1	0.31	4.68	0.39	7.44e-6	Lymphocyte counts;
TGCT	cis	rs11190604	0.731	rs10883480	chr10:102163821	G/T	cg16342193	chr10:102329863	NA	0.39	5.0	0.41	1.91e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg17971929	chr21:40555470	PSMG1	0.96	8.52	0.61	4.51e-14	Cognitive function;
TGCT	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7213347	0.707	rs216181	chr17:2172753	A/T	cg13315690	chr17:1944831	OVCA2;DPH1	0.39	4.84	0.4	3.75e-6	Total body bone mineral density;
TGCT	cis	rs78487399	0.808	rs6751161	chr2:43752548	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.02	-0.41	1.75e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs939658	0.805	rs35462901	chr15:79442201	C/T	cg17916960	chr15:79447300	NA	-0.49	-7.41	-0.55	1.73e-11	Refractive error;
TGCT	cis	rs1008375	1.000	rs7659718	chr4:17638020	A/C	cg18681998	chr4:17616180	MED28	1.07	11.98	0.73	1.97e-22	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs28595532	0.920	rs115464801	chr4:119730673	T/C	cg14228332	chr4:119757509	SEC24D	1.32	6.38	0.5	3.2e-9	Cannabis dependence symptom count;
TGCT	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	6.04	0.48	1.68e-8	Electroencephalogram traits;
TGCT	trans	rs3780486	0.757	rs10813949	chr9:33123464	G/A	cg04842962	chr6:43655489	MRPS18A	1.19	14.71	0.8	5.62e-29	IgG glycosylation;
TGCT	cis	rs6893807	0.620	rs34483452	chr5:87986314	C/A	cg24804195	chr5:87968844	LOC645323	0.73	4.77	0.39	5.08e-6	Body mass index;
TGCT	cis	rs7666738	0.830	rs13137859	chr4:99050319	A/G	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6460942	0.915	rs62448594	chr7:12442229	C/G	cg06484146	chr7:12443880	VWDE	-0.57	-5.52	-0.44	1.92e-7	Coronary artery disease;
TGCT	cis	rs2455799	0.559	rs1597068	chr3:15913363	G/A	cg12172478	chr3:16357591	RFTN1	-0.36	-5.3	-0.43	5.07e-7	Mean platelet volume;
TGCT	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg06634786	chr22:41940651	POLR3H	-0.88	-8.54	-0.61	3.98e-14	Vitiligo;
TGCT	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg15556689	chr8:8085844	FLJ10661	0.71	6.61	0.51	1.01e-9	Mood instability;
TGCT	cis	rs9372498	0.536	rs12333080	chr6:118845410	A/C	cg07617317	chr6:118971624	C6orf204	0.52	5.55	0.45	1.69e-7	Diastolic blood pressure;
TGCT	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg19626725	chr5:178986131	RUFY1	0.45	5.93	0.47	2.81e-8	Lung cancer;
TGCT	cis	rs7072216	0.763	rs6584198	chr10:100169906	G/C	cg26618903	chr10:100175079	PYROXD2	-0.4	-4.49	-0.37	1.64e-5	Metabolite levels;
TGCT	cis	rs9467773	0.620	rs2494696	chr6:26620894	A/G	cg11502198	chr6:26597334	ABT1	0.53	4.9	0.4	2.95e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs17767294	0.708	rs72847356	chr6:27825594	C/A	cg08851530	chr6:28072375	NA	1.58	7.16	0.54	6.15e-11	Parkinson's disease;
TGCT	cis	rs713587	0.713	rs11125884	chr2:25239264	C/T	cg15423357	chr2:25149977	NA	0.58	5.91	0.47	3.05e-8	Body mass index in non-asthmatics;
TGCT	cis	rs2153535	0.580	rs2327067	chr6:8518482	C/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.55e-8	Motion sickness;
TGCT	cis	rs9329289	0.510	rs10903785	chr10:2550063	C/T	cg07014206	chr10:2547000	NA	-0.28	-4.64	-0.38	8.6e-6	Age-related hearing impairment;
TGCT	cis	rs10992471	1.000	rs10992471	chr9:95559505	A/G	cg13798575	chr9:95087839	CENPP;NOL8	0.62	6.48	0.5	1.93e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs12477438	0.572	rs10170063	chr2:99655639	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-4.62	-0.38	9.47e-6	Chronic sinus infection;
TGCT	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg16423285	chr20:60520624	NA	-0.61	-6.57	-0.51	1.23e-9	Body mass index;
TGCT	cis	rs2758596	0.850	rs2842879	chr1:156163695	G/T	cg25208724	chr1:156163844	SLC25A44	0.83	5.04	0.41	1.61e-6	Paclitaxel disposition in epithelial ovarian cancer;
TGCT	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg06221963	chr1:154839813	KCNN3	-0.7	-11.65	-0.72	1.22e-21	Prostate cancer;
TGCT	cis	rs9330316	0.632	rs2060402	chr2:110329104	C/G	cg25199208	chr2:109402912	CCDC138	-0.42	-4.56	-0.38	1.19e-5	Schizophrenia;
TGCT	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg08509172	chr19:19383838	TM6SF2	-0.34	-4.48	-0.37	1.71e-5	Tonsillectomy;
TGCT	cis	rs2463822	0.583	rs7129536	chr11:62030829	C/T	cg06239285	chr11:62104954	ASRGL1	-0.86	-5.41	-0.44	3.08e-7	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs4332037	0.539	rs1533827	chr7:2074290	A/G	cg25834613	chr7:1915315	MAD1L1	0.53	5.44	0.44	2.78e-7	Bipolar disorder;
TGCT	trans	rs941408	1.000	rs759068	chr19:2792566	G/A	cg19676328	chr12:49525230	TUBA1B	-0.77	-7.88	-0.58	1.43e-12	Total cholesterol levels;
TGCT	cis	rs617219	0.671	rs2607144	chr5:78556798	G/T	cg09550809	chr5:78407562	BHMT	0.42	5.71	0.46	7.98e-8	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg11301795	chr4:187892539	NA	-0.3	-4.46	-0.37	1.83e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3213961	0.554	rs8256	chr2:33789068	C/G	cg04131969	chr2:33951647	MYADML	0.68	5.31	0.43	4.9e-7	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
TGCT	cis	rs4788570	0.566	rs16973112	chr16:71501274	T/C	cg06353428	chr16:71660113	MARVELD3	-1.32	-7.86	-0.58	1.6e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs16866061	1.000	rs1568750	chr2:225342597	A/T	cg12698349	chr2:225449008	CUL3	0.96	9.45	0.65	2.69e-16	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	cis	rs3916	1.000	rs3916	chr12:121177272	G/C	cg21892295	chr12:121157589	UNC119B	-0.22	-4.44	-0.37	1.95e-5	Urinary metabolites (H-NMR features);
TGCT	cis	rs2180341	1.000	rs6569478	chr6:127598619	G/A	cg24812749	chr6:127587940	RNF146	0.99	7.72	0.57	3.33e-12	Breast cancer;
TGCT	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.46	-6.76	-0.52	4.77e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7582180	0.764	rs1946799	chr2:100921136	C/A	cg14675211	chr2:100938903	LONRF2	0.51	4.93	0.4	2.61e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg00684032	chr4:1343700	KIAA1530	0.23	4.93	0.41	2.55e-6	Obesity-related traits;
TGCT	cis	rs362272	0.525	rs910568	chr4:3307373	A/G	cg22655196	chr4:3374909	RGS12	0.23	4.62	0.38	9.41e-6	Serum sulfate level;
TGCT	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg06238570	chr21:40685208	BRWD1	0.68	6.36	0.5	3.5e-9	Cognitive function;
TGCT	cis	rs9291683	0.530	rs998675	chr4:9948829	A/G	cg11266682	chr4:10021025	SLC2A9	0.64	8.48	0.61	5.75e-14	Bone mineral density;
TGCT	cis	rs3617	0.573	rs12492391	chr3:52912296	C/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.5	-4.84	-0.4	3.85e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2180341	0.781	rs6913350	chr6:127570560	C/T	cg27446573	chr6:127587934	RNF146	0.91	8.5	0.61	5.12e-14	Breast cancer;
TGCT	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg15556689	chr8:8085844	FLJ10661	0.87	8.49	0.61	5.45e-14	Systolic blood pressure;
TGCT	cis	rs2180341	0.538	rs4577822	chr6:127712911	T/G	cg24812749	chr6:127587940	RNF146	0.61	5.39	0.44	3.45e-7	Breast cancer;
TGCT	cis	rs6998277	0.553	rs6468837	chr8:103602767	A/G	cg10187029	chr8:103597600	NA	0.51	9.27	0.64	7.41e-16	Migraine;
TGCT	cis	rs7804356	1.000	rs6956088	chr7:26835727	T/A	cg03456212	chr7:26904342	SKAP2	-0.61	-4.67	-0.39	7.59e-6	Type 1 diabetes;
TGCT	cis	rs6589563	0.609	rs57641217	chr11:116632956	C/T	cg01124546	chr11:117515332	DSCAML1	-0.45	-4.93	-0.41	2.54e-6	Eosinophil counts;
TGCT	cis	rs12950390	0.853	rs8078052	chr17:45859434	A/G	cg24803719	chr17:45855879	NA	-0.49	-5.03	-0.41	1.64e-6	IgG glycosylation;
TGCT	cis	rs6754311	0.689	rs191079	chr2:136633771	T/C	cg07169764	chr2:136633963	MCM6	0.65	6.06	0.48	1.5e-8	Mosquito bite size;
TGCT	cis	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg07424592	chr7:64974309	NA	1.4	8.42	0.6	7.87e-14	Diabetic kidney disease;
TGCT	cis	rs13202913	0.733	rs13215869	chr6:151803659	G/A	cg03627880	chr6:151815985	C6orf97	-0.69	-6.43	-0.5	2.53e-9	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg24549020	chr5:56110836	MAP3K1	0.67	5.69	0.45	8.82e-8	Initial pursuit acceleration;
TGCT	cis	rs5769765	0.862	rs9616380	chr22:50312225	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.24	-12.97	-0.76	7.81e-25	Schizophrenia;
TGCT	cis	rs62244186	0.541	rs9859879	chr3:44840166	G/A	cg21672276	chr3:44754072	ZNF502	-0.53	-6.24	-0.49	6.45e-9	Depressive symptoms;
TGCT	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg04944784	chr2:26401820	FAM59B	-0.67	-6.16	-0.48	9.54e-9	Gut microbiome composition (summer);
TGCT	cis	rs7213347	0.707	rs9898390	chr17:2177484	C/G	cg13315690	chr17:1944831	OVCA2;DPH1	-0.37	-4.7	-0.39	6.76e-6	Total body bone mineral density;
TGCT	cis	rs9911578	0.967	rs7222789	chr17:56819853	C/G	cg12560992	chr17:57184187	TRIM37	0.76	9.34	0.64	4.88e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs12497850	0.897	rs6446252	chr3:48911125	C/T	cg05785598	chr3:49045655	WDR6	0.36	4.75	0.39	5.46e-6	Parkinson's disease;
TGCT	cis	rs13191362	0.935	rs34709632	chr6:163048380	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.03	7.35	0.55	2.37e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs265548	0.608	rs265545	chr19:17903465	C/T	cg21960279	chr19:17905606	B3GNT3	0.48	5.3	0.43	5.08e-7	Tumor biomarkers;
TGCT	cis	rs9916302	0.706	rs2338799	chr17:37513941	G/A	cg07936489	chr17:37558343	FBXL20	0.87	6.27	0.49	5.47e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs350251	0.899	rs350277	chr16:12232547	C/T	cg01574788	chr16:12184133	SNX29	0.34	4.48	0.37	1.67e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs11098499	0.566	rs7664440	chr4:120578540	A/G	cg09307838	chr4:120376055	NA	0.65	6.29	0.49	4.94e-9	Corneal astigmatism;
TGCT	cis	rs10779751	0.575	rs2791655	chr1:11128654	A/G	cg08854313	chr1:11322531	MTOR	-0.76	-6.62	-0.51	9.61e-10	Body mass index;
TGCT	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg11635101	chr7:2050016	MAD1L1	-0.21	-4.47	-0.37	1.71e-5	Longevity;Endometriosis;
TGCT	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg10047753	chr17:41438598	NA	0.9	8.32	0.6	1.37e-13	Menopause (age at onset);
TGCT	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg04944784	chr2:26401820	FAM59B	-0.65	-5.91	-0.47	3.04e-8	Gut microbiome composition (summer);
TGCT	cis	rs4595586	0.545	rs7294600	chr12:39373416	A/G	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs7666738	0.609	rs35214820	chr4:98864692	G/A	cg05340658	chr4:99064831	C4orf37	0.57	6.05	0.48	1.61e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2072499	0.932	rs2736613	chr1:156196016	T/C	cg06970220	chr1:156163860	SLC25A44	0.74	5.94	0.47	2.71e-8	Testicular germ cell tumor;
TGCT	cis	rs1568889	0.938	rs11601602	chr11:28233768	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.84	8.67	0.61	2.05e-14	Bipolar disorder;
TGCT	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg09359103	chr1:154839909	KCNN3	-0.66	-12.15	-0.74	7.27e-23	Prostate cancer;
TGCT	cis	rs453301	0.653	rs11784393	chr8:8903134	C/T	cg06636001	chr8:8085503	FLJ10661	0.86	7.66	0.57	4.68e-12	Joint mobility (Beighton score);
TGCT	cis	rs6840360	0.518	rs4696082	chr4:152286935	T/A	cg17479576	chr4:152424074	FAM160A1	-0.45	-4.72	-0.39	6.27e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg22800045	chr5:56110881	MAP3K1	0.54	4.49	0.37	1.58e-5	Initial pursuit acceleration;
TGCT	cis	rs6964587	1.000	rs6969536	chr7:91689351	C/G	cg22709100	chr7:91322751	NA	0.28	4.56	0.38	1.19e-5	Breast cancer;
TGCT	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg17971929	chr21:40555470	PSMG1	0.97	9.51	0.65	1.95e-16	Cognitive function;
TGCT	cis	rs1008375	1.000	rs56308330	chr4:17643050	G/A	cg10189774	chr4:17578691	LAP3	0.58	5.26	0.43	6.24e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	trans	rs4332037	0.901	rs7791899	chr7:1935988	T/C	cg10840412	chr1:235813424	GNG4	1.04	8.16	0.59	3.22e-13	Bipolar disorder;
TGCT	cis	rs2288884	1.000	rs80278704	chr19:52549183	G/A	cg13540795	chr19:52551618	ZNF432	-0.59	-5.02	-0.41	1.79e-6	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg09436375	chr6:42928200	GNMT	0.42	5.41	0.44	3.16e-7	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg24060327	chr5:131705240	SLC22A5	-0.56	-5.6	-0.45	1.34e-7	Breast cancer;
TGCT	cis	rs7772486	0.754	rs9373476	chr6:146139741	C/G	cg23711669	chr6:146136114	FBXO30	0.89	9.8	0.66	3.89e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg06896619	chr17:61851486	DDX42;CCDC47	-0.5	-4.71	-0.39	6.39e-6	Prudent dietary pattern;
TGCT	cis	rs8008270	0.689	rs7158115	chr14:53418339	G/C	cg01926858	chr14:53619558	DDHD1	-0.74	-4.73	-0.39	5.89e-6	Prostate cancer;
TGCT	cis	rs941408	1.000	rs1736183	chr19:2809672	A/G	cg06609049	chr19:2785107	THOP1	0.81	8.22	0.59	2.33e-13	Total cholesterol levels;
TGCT	cis	rs9611519	0.579	rs8136274	chr22:41415311	T/C	cg06634786	chr22:41940651	POLR3H	-0.49	-4.54	-0.38	1.33e-5	Neuroticism;
TGCT	cis	rs950169	0.881	rs34591918	chr15:84950833	C/T	cg17173187	chr15:85201210	NMB	0.58	5.93	0.47	2.77e-8	Schizophrenia;
TGCT	trans	rs877282	0.891	rs34652870	chr10:772218	T/C	cg22713356	chr15:30763199	NA	1.16	10.02	0.67	1.16e-17	Uric acid levels;
TGCT	cis	rs9914544	0.545	rs2892016	chr17:18786776	C/T	cg26378065	chr17:18585709	ZNF286B	0.53	4.63	0.38	9.06e-6	Educational attainment (years of education);
TGCT	cis	rs7216064	1.000	rs9913471	chr17:65874495	C/T	cg12091567	chr17:66097778	LOC651250	-0.87	-6.85	-0.52	3.1e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs11098499	0.754	rs10518300	chr4:120249499	G/T	cg24670566	chr4:120433619	PDE5A	-0.27	-5.22	-0.42	7.23e-7	Corneal astigmatism;
TGCT	cis	rs9790314	0.905	rs7633186	chr3:161003124	A/G	cg03342759	chr3:160939853	NMD3	-0.42	-4.51	-0.38	1.5e-5	Morning vs. evening chronotype;
TGCT	cis	rs514406	0.505	rs6703127	chr1:53180565	C/T	cg25767906	chr1:53392781	SCP2	-0.47	-5.35	-0.43	4.02e-7	Monocyte count;
TGCT	cis	rs1775715	0.707	rs2808087	chr10:32146444	C/G	cg14930904	chr10:32216787	ARHGAP12	0.53	5.1	0.42	1.22e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs2742417	1.000	rs767280	chr3:45771601	C/G	cg04837898	chr3:45731254	SACM1L	-0.53	-5.52	-0.44	1.92e-7	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs908922	0.676	rs7529441	chr1:152531629	A/G	cg20991723	chr1:152506922	NA	-0.44	-5.95	-0.47	2.51e-8	Hair morphology;
TGCT	cis	rs9549367	0.707	rs9549353	chr13:113843427	G/A	cg00898013	chr13:113819073	PROZ	-0.53	-6.94	-0.53	1.89e-10	Platelet distribution width;
TGCT	cis	rs7727544	0.735	rs274559	chr5:131720070	A/G	cg24060327	chr5:131705240	SLC22A5	0.58	6.53	0.51	1.5e-9	Blood metabolite levels;
TGCT	cis	rs7633770	0.841	rs11130100	chr3:46679198	A/T	cg11219411	chr3:46661640	NA	-0.34	-4.72	-0.39	6.31e-6	Coronary artery disease;
TGCT	cis	rs8014204	0.773	rs2241275	chr14:75251440	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.71	-6.82	-0.52	3.56e-10	Caffeine consumption;
TGCT	cis	rs5769765	0.671	rs138817	chr22:50163058	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.39	5.61	0.45	1.27e-7	Schizophrenia;
TGCT	cis	rs6088580	0.634	rs6087587	chr20:33058628	G/T	cg06115741	chr20:33292138	TP53INP2	0.52	4.47	0.37	1.75e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg06238570	chr21:40685208	BRWD1	0.59	5.25	0.43	6.37e-7	Cognitive function;
TGCT	cis	rs2239547	0.522	rs7652131	chr3:52997154	C/T	cg11645453	chr3:52864694	ITIH4	0.32	5.27	0.43	5.93e-7	Schizophrenia;
TGCT	cis	rs7312774	0.609	rs2374656	chr12:107380411	A/C	cg16260113	chr12:107380972	MTERFD3	1.21	5.85	0.47	4.03e-8	Severe influenza A (H1N1) infection;
TGCT	cis	rs7666738	0.761	rs1456210	chr4:98645932	T/G	cg05340658	chr4:99064831	C4orf37	0.43	5.05	0.41	1.51e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11809207	1.000	rs11809207	chr1:26521140	G/A	cg03844060	chr1:26490628	NA	0.25	4.62	0.38	9.44e-6	Height;
TGCT	cis	rs7681440	0.874	rs1372522	chr4:90765280	A/G	cg26578617	chr4:90757533	SNCA	-0.47	-4.87	-0.4	3.34e-6	Dementia with Lewy bodies;
TGCT	cis	rs7439150	0.954	rs6056	chr4:155488821	C/T	cg22130008	chr4:155548532	NA	-0.47	-5.73	-0.46	7.32e-8	Fibrinogen levels;
TGCT	cis	rs709400	0.628	rs11623470	chr14:104004810	T/A	cg26031613	chr14:104095156	KLC1	0.87	9.64	0.65	9.63e-17	Body mass index;
TGCT	cis	rs778371	0.723	rs1973675	chr2:233636450	C/T	cg08000102	chr2:233561755	GIGYF2	-0.73	-8.65	-0.61	2.23e-14	Schizophrenia;
TGCT	cis	rs7584330	0.955	rs6729659	chr2:238385126	T/C	cg08992911	chr2:238395768	MLPH	0.66	5.27	0.43	5.8e-7	Prostate cancer;
TGCT	cis	rs554111	0.891	rs671905	chr1:21047092	A/T	cg08890418	chr1:21044141	KIF17	0.57	6.22	0.49	7.14e-9	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs2243480	1.000	rs313820	chr7:65574466	A/C	cg20637647	chr7:64974828	NA	0.85	4.89	0.4	3e-6	Diabetic kidney disease;
TGCT	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg03609598	chr5:56110824	MAP3K1	-0.59	-4.85	-0.4	3.64e-6	Initial pursuit acceleration;
TGCT	cis	rs35160687	0.871	rs2278105	chr2:86466516	A/G	cg03171300	chr2:86307199	POLR1A	0.33	5.58	0.45	1.42e-7	Night sleep phenotypes;
TGCT	trans	rs66573146	1.000	rs73202122	chr4:7005594	G/A	cg07817883	chr1:32538562	TMEM39B	1.77	8.38	0.6	9.8e-14	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs7937682	0.961	rs552387	chr11:111490047	T/G	cg09085632	chr11:111637200	PPP2R1B	-0.98	-9.75	-0.66	5.19e-17	Primary sclerosing cholangitis;
TGCT	cis	rs11641365	0.517	rs73262667	chr16:88779753	C/T	cg00034003	chr16:88779146	CTU2	0.4	6.09	0.48	1.32e-8	Autism spectrum disorder-related traits;
TGCT	cis	rs6088580	0.634	rs2378134	chr20:32938085	C/T	cg08999081	chr20:33150536	PIGU	-0.26	-4.96	-0.41	2.26e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs9583531	0.600	rs1441042	chr13:111365589	T/G	cg24331049	chr13:111365604	ING1	0.81	7.89	0.58	1.33e-12	Coronary artery disease;
TGCT	cis	rs8037137	0.915	rs2301825	chr15:91528070	C/G	cg22570213	chr15:91497863	RCCD1	0.52	4.89	0.4	3.04e-6	Platelet count;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
TGCT	cis	rs9467773	0.869	rs1796521	chr6:26421392	T/C	cg05738196	chr6:26577821	NA	-0.63	-6.73	-0.52	5.72e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs4788439	0.892	rs17178990	chr16:24921945	C/A	cg07626409	chr16:25250191	ZKSCAN2	0.34	4.53	0.38	1.38e-5	Blood metabolite levels;
TGCT	cis	rs6121246	0.567	rs6060260	chr20:30192907	C/T	cg18721089	chr20:30220636	NA	-0.63	-6.88	-0.53	2.67e-10	Mean corpuscular hemoglobin;
TGCT	cis	rs17345786	0.911	rs10936707	chr3:101324063	G/A	cg12386194	chr3:101231763	SENP7	0.61	5.75	0.46	6.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs17401966	0.838	rs4529713	chr1:10307295	A/G	cg19773385	chr1:10388646	KIF1B	-0.2	-4.5	-0.37	1.54e-5	Hepatocellular carcinoma;
TGCT	cis	rs1371867	0.513	rs1542812	chr8:101207064	G/A	cg06636551	chr8:101224915	SPAG1	0.55	8.12	0.59	3.96e-13	Atrioventricular conduction;
TGCT	cis	rs6964587	0.869	rs10256780	chr7:91527176	T/A	cg17063962	chr7:91808500	NA	-0.86	-9.28	-0.64	6.82e-16	Breast cancer;
TGCT	cis	rs10992471	0.756	rs7848055	chr9:95115492	A/C	cg14631576	chr9:95140430	CENPP	-0.29	-4.73	-0.39	6.1e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs9291683	0.588	rs6857693	chr4:10018435	G/A	cg02734326	chr4:10020555	SLC2A9	0.38	4.54	0.38	1.34e-5	Bone mineral density;
TGCT	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg06634786	chr22:41940651	POLR3H	0.86	8.19	0.59	2.71e-13	Vitiligo;
TGCT	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg03388025	chr16:89894329	SPIRE2	0.48	8.4	0.6	8.77e-14	Vitiligo;
TGCT	cis	rs7635838	0.892	rs9310379	chr3:11434143	C/T	cg00170343	chr3:11313890	ATG7	-0.64	-6.08	-0.48	1.39e-8	HDL cholesterol;
TGCT	cis	rs7267979	1.000	rs4815411	chr20:25350223	A/G	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs72781680	1.000	rs6710426	chr2:24159288	A/G	cg08917208	chr2:24149416	ATAD2B	0.73	4.51	0.38	1.48e-5	Lymphocyte counts;
TGCT	cis	rs838147	0.537	rs632111	chr19:49208978	A/G	cg04599840	chr19:48886497	KDELR1	0.21	4.48	0.37	1.64e-5	Dietary macronutrient intake;
TGCT	cis	rs2334880	0.638	rs35166226	chr16:71443219	T/C	cg06353428	chr16:71660113	MARVELD3	-1.26	-7.14	-0.54	6.98e-11	Malaria;
TGCT	cis	rs6582630	0.599	rs1851114	chr12:38424671	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-4.81	-0.4	4.32e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs13242816	0.881	rs35037267	chr7:116117587	A/T	cg16553024	chr7:116138462	CAV2	-0.45	-4.81	-0.4	4.32e-6	P wave duration;
TGCT	cis	rs5769707	0.632	rs135871	chr22:50008969	A/G	cg05373962	chr22:49881684	NA	-0.29	-4.93	-0.4	2.63e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs9300255	0.543	rs655293	chr12:123528405	G/A	cg00376283	chr12:123451042	ABCB9	0.68	4.95	0.41	2.34e-6	Neutrophil percentage of white cells;
TGCT	cis	rs185694	1.000	rs202083	chr13:30881316	C/T	cg07600127	chr13:30881527	KATNAL1	-0.87	-6.77	-0.52	4.55e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
TGCT	cis	rs986417	1.000	rs10144805	chr14:60927652	T/C	cg27398547	chr14:60952738	C14orf39	1.39	10.61	0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs7223966	1.000	rs8064261	chr17:61705212	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	4.66	0.39	8.03e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs9427116	0.532	rs9426828	chr1:154591489	G/A	cg17218026	chr1:154582156	ADAR	0.31	7.97	0.58	8.71e-13	Blood protein levels;
TGCT	cis	rs7552404	1.000	rs4949875	chr1:76173080	G/A	cg22875332	chr1:76189707	ACADM	0.79	9.77	0.66	4.68e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7666738	0.830	rs7696568	chr4:99005333	A/T	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6867032	0.958	rs4463207	chr5:2017118	G/T	cg26168224	chr5:2018326	NA	0.44	8.03	0.59	6.26e-13	Gut microbiome composition (winter);
TGCT	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg03609598	chr5:56110824	MAP3K1	-0.59	-4.78	-0.39	4.81e-6	Initial pursuit acceleration;
TGCT	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg10802521	chr3:52805072	NEK4	-0.78	-10.02	-0.67	1.12e-17	Bipolar disorder;
TGCT	cis	rs1008375	0.966	rs1860591	chr4:17577329	A/G	cg16339924	chr4:17578868	LAP3	0.75	6.7	0.52	6.41e-10	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	trans	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg17830980	chr10:43048298	ZNF37B	-0.85	-10.98	-0.7	5.08e-20	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7772486	0.875	rs9373485	chr6:146401429	A/T	cg13319975	chr6:146136371	FBXO30	-0.51	-4.48	-0.37	1.69e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.05	8.95	0.63	4.39e-15	Platelet count;
TGCT	cis	rs2760061	0.626	rs1636192	chr1:228124688	A/G	cg18477163	chr1:228402036	OBSCN	-0.32	-6.37	-0.5	3.31e-9	Diastolic blood pressure;
TGCT	cis	rs13242816	0.881	rs55930206	chr7:116172850	C/T	cg02799643	chr7:116139180	CAV2	-0.43	-5.29	-0.43	5.24e-7	P wave duration;
TGCT	cis	rs6964587	0.869	rs6979024	chr7:91481512	T/C	cg17063962	chr7:91808500	NA	-0.86	-9.19	-0.64	1.16e-15	Breast cancer;
TGCT	cis	rs9894429	0.738	rs8077038	chr17:79577127	T/G	cg18240062	chr17:79603768	NPLOC4	-0.84	-9.67	-0.66	8.03e-17	Eye color traits;
TGCT	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg11644478	chr21:40555479	PSMG1	1.02	11.02	0.7	4.19e-20	Cognitive function;
TGCT	cis	rs4654899	0.795	rs61309203	chr1:21118489	A/T	cg01072550	chr1:21505969	NA	-0.49	-7.78	-0.57	2.48e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs2180341	1.000	rs9375499	chr6:127618072	T/C	cg27446573	chr6:127587934	RNF146	1.13	10.12	0.67	6.64e-18	Breast cancer;
TGCT	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg02953382	chr22:24373134	LOC391322	-0.83	-9.22	-0.64	9.47e-16	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	trans	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.83	-8.55	-0.61	3.86e-14	Body mass index;
TGCT	cis	rs4843185	0.576	rs380996	chr16:85728813	A/G	cg26571870	chr16:85723150	GINS2	0.35	4.47	0.37	1.75e-5	Platelet distribution width;
TGCT	cis	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg07424592	chr7:64974309	NA	-1.27	-7.84	-0.58	1.8e-12	Diabetic kidney disease;
TGCT	cis	rs4319547	0.695	rs6488958	chr12:122880704	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.57	-4.5	-0.37	1.53e-5	Body mass index;
TGCT	cis	rs11098499	0.954	rs12507964	chr4:120413061	T/A	cg09307838	chr4:120376055	NA	0.69	6.64	0.51	8.97e-10	Corneal astigmatism;
TGCT	cis	rs4746818	1.000	rs10823313	chr10:70952115	G/A	cg11621586	chr10:70884670	VPS26A	1.21	10.5	0.69	7.7e-19	Left atrial antero-posterior diameter;
TGCT	cis	rs2242116	0.900	rs4683300	chr3:46934292	C/A	cg02527881	chr3:46936655	PTH1R	-0.3	-5.77	-0.46	5.91e-8	Birth weight;
TGCT	cis	rs1635	0.655	rs1416919	chr6:28302884	T/G	cg15743358	chr6:28303923	ZNF323	-1.28	-6.27	-0.49	5.57e-9	Schizophrenia;
TGCT	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg07061783	chr6:25882402	NA	-0.63	-6.68	-0.51	7.27e-10	Blood metabolite levels;
TGCT	cis	rs9443189	0.570	rs504323	chr6:76294965	A/G	cg01950844	chr6:76311363	SENP6	-1.03	-6.5	-0.5	1.77e-9	Prostate cancer;
TGCT	cis	rs10131894	0.611	rs174995	chr14:75434183	T/C	cg08847533	chr14:75593920	NEK9	-0.66	-6.32	-0.49	4.36e-9	Coronary artery disease;
TGCT	trans	rs1908814	0.516	rs58869268	chr8:11797095	G/C	cg15556689	chr8:8085844	FLJ10661	0.75	7.07	0.54	9.74e-11	Neuroticism;
TGCT	cis	rs9467773	1.000	rs1321481	chr6:26538210	A/T	cg26531700	chr6:26746687	NA	0.47	4.57	0.38	1.14e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs3820928	0.967	rs4675118	chr2:227773157	C/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-4.82	-0.4	4.12e-6	Pulmonary function;
TGCT	cis	rs9486719	0.947	rs6916232	chr6:96985959	A/T	cg06623918	chr6:96969491	KIAA0776	1.01	8.81	0.62	9.21e-15	Migraine;Coronary artery disease;
TGCT	trans	rs561341	1.000	rs550264	chr17:30317540	G/T	cg20587970	chr11:113659929	NA	-1.04	-12.57	-0.75	6.97e-24	Hip circumference adjusted for BMI;
TGCT	cis	rs981844	1.000	rs55722886	chr4:154668335	A/G	cg14289246	chr4:154710475	SFRP2	1.01	8.67	0.61	2.02e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs1371867	0.846	rs1788189	chr8:101249762	G/T	cg06636551	chr8:101224915	SPAG1	0.48	6.57	0.51	1.28e-9	Atrioventricular conduction;
TGCT	cis	rs2456568	0.900	rs2511399	chr11:93682156	C/T	cg17595323	chr11:93583763	C11orf90	0.44	5.93	0.47	2.83e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs68170813	0.559	rs78610616	chr7:106951369	T/C	cg02696742	chr7:106810147	HBP1	-0.69	-5.81	-0.46	4.85e-8	Coronary artery disease;
TGCT	cis	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg18876405	chr7:65276391	NA	-0.41	-6.4	-0.5	2.96e-9	Aortic root size;
TGCT	cis	rs459571	0.959	rs392134	chr9:136909008	G/A	cg14405625	chr9:136855902	VAV2	-0.31	-4.64	-0.38	8.85e-6	Platelet distribution width;
TGCT	cis	rs3743266	0.507	rs34092508	chr15:60722979	C/T	cg18480781	chr15:60294291	NA	0.6	4.74	0.39	5.71e-6	Menarche (age at onset);
TGCT	cis	rs713587	0.935	rs11676272	chr2:25141538	A/G	cg01884057	chr2:25150051	NA	0.39	8.07	0.59	5.03e-13	Body mass index in non-asthmatics;
TGCT	cis	rs3820068	0.581	rs78175477	chr1:15948091	C/G	cg05660106	chr1:15850417	CASP9	0.83	8.16	0.59	3.26e-13	Systolic blood pressure;
TGCT	cis	rs7937682	0.824	rs577044	chr11:111490420	G/T	cg09085632	chr11:111637200	PPP2R1B	-0.98	-9.75	-0.66	5.19e-17	Primary sclerosing cholangitis;
TGCT	cis	rs10484885	0.618	rs292241	chr6:90603505	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.4	-4.8	-0.4	4.45e-6	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs7805747	0.961	rs73158188	chr7:151415233	C/T	cg17611936	chr7:151411526	PRKAG2	0.54	6.72	0.52	5.9e-10	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
TGCT	cis	rs36051895	0.632	rs1590803	chr9:5177533	T/C	cg02405213	chr9:5042618	JAK2	-0.77	-10.92	-0.7	7.2e-20	Pediatric autoimmune diseases;
TGCT	cis	rs3087591	1.000	rs1123232	chr17:29423989	A/G	cg24425628	chr17:29625626	OMG;NF1	0.48	7.46	0.56	1.3e-11	Hip circumference;
TGCT	cis	rs6570726	0.791	rs1509214	chr6:145784606	A/C	cg23711669	chr6:146136114	FBXO30	-0.86	-9.64	-0.65	9.5e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9318086	0.901	rs7336730	chr13:24452104	T/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.68	-6.8	-0.52	4.01e-10	Myopia (pathological);
TGCT	cis	rs826838	0.967	rs826876	chr12:39123843	T/C	cg26384229	chr12:38710491	ALG10B	-0.86	-7.76	-0.57	2.68e-12	Heart rate;
TGCT	cis	rs8062405	1.000	rs7498665	chr16:28883241	A/G	cg09754948	chr16:28834200	ATXN2L	0.6	4.46	0.37	1.79e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs9549367	0.713	rs1323315	chr13:113859658	T/C	cg09473364	chr13:112927190	NA	0.29	4.59	0.38	1.06e-5	Platelet distribution width;
TGCT	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.12	0.42	1.15e-6	Prudent dietary pattern;
TGCT	trans	rs11722228	0.508	rs2241473	chr4:10085949	G/A	cg26043149	chr18:55253948	FECH	1.14	11.59	0.72	1.68e-21	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs8078723	0.966	rs57968500	chr17:38145828	A/G	cg17467752	chr17:38218738	THRA	0.55	5.37	0.43	3.68e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs603424	0.512	rs7896618	chr10:102082022	G/A	cg22671421	chr10:102507979	PAX2	-0.57	-4.86	-0.4	3.47e-6	Phospholipid levels (plasma);Palmitic acid (16:0) levels;Palmitoleic acid (16:1n-7) levels;Mean platelet volume;Serum metabolite levels;Blood metabolite levels;Vaccenic acid (18:1n-7) levels;Metabolic traits;Coronary artery disease;Blood metabolite ratios;Glycerophospholipid levels;
TGCT	cis	rs1692580	0.807	rs263535	chr1:2177727	T/C	cg21194808	chr1:2205498	SKI	0.3	5.83	0.46	4.43e-8	Coronary artery disease;
TGCT	cis	rs13191362	0.872	rs73020362	chr6:163005737	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7208859	0.623	rs216433	chr17:28921860	T/C	cg04154034	chr17:28927549	LRRC37B2	0.79	4.8	0.4	4.54e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.01	0.41	1.86e-6	Prudent dietary pattern;
TGCT	cis	rs9486719	1.000	rs13202675	chr6:97028427	C/T	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.0	-0.41	1.9e-6	Migraine;Coronary artery disease;
TGCT	cis	rs2658782	0.547	rs10765602	chr11:93048165	G/T	cg15737290	chr11:93063684	CCDC67	1.03	10.89	0.7	8.5e-20	Pulmonary function decline;
TGCT	cis	rs344364	0.511	rs911391	chr16:1947016	C/A	cg26617929	chr16:1858877	NA	-0.27	-4.9	-0.4	2.99e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs10791323	0.627	rs2723614	chr11:133705871	T/G	cg15485101	chr11:133734466	NA	0.41	5.15	0.42	9.75e-7	Childhood ear infection;
TGCT	cis	rs2153535	0.580	rs969422	chr6:8451780	A/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.76	0.46	6.39e-8	Motion sickness;
TGCT	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg12311346	chr5:56204834	C5orf35	0.68	6.85	0.52	3e-10	Initial pursuit acceleration;
TGCT	cis	rs950169	1.000	rs1911155	chr15:84787635	A/G	cg11189052	chr15:85197271	WDR73	0.72	6.09	0.48	1.32e-8	Schizophrenia;
TGCT	cis	rs9430161	0.611	rs72644043	chr1:11033051	T/A	cg02454025	chr1:11042201	C1orf127	0.97	11.84	0.73	4.24e-22	Ewing sarcoma;
TGCT	cis	rs17376456	0.542	rs10061069	chr5:93071630	G/C	cg25358565	chr5:93447407	FAM172A	0.62	5.89	0.47	3.43e-8	Diabetic retinopathy;
TGCT	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	7.24	0.55	4.17e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs1348850	0.567	rs880897	chr2:178532503	C/T	cg22681709	chr2:178499509	PDE11A	-0.46	-5.95	-0.47	2.58e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs7772486	0.875	rs7766463	chr6:146364453	A/G	cg23711669	chr6:146136114	FBXO30	0.87	9.53	0.65	1.75e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs16867321	0.527	rs1025126	chr2:181590747	A/G	cg12875548	chr2:181044332	NA	-0.35	-4.67	-0.39	7.62e-6	Obesity;
TGCT	cis	rs422249	0.547	rs102275	chr11:61557803	T/C	cg19610905	chr11:61596333	FADS2	-0.94	-8.99	-0.63	3.5e-15	Trans fatty acid levels;
TGCT	cis	rs8177253	0.665	rs4525863	chr3:133436136	C/A	cg01448562	chr3:133502909	NA	-0.26	-4.79	-0.4	4.65e-6	Iron status biomarkers;
TGCT	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg11301795	chr4:187892539	NA	-0.33	-4.88	-0.4	3.19e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6831352	0.918	rs13107558	chr4:100050200	C/A	cg12011299	chr4:100065546	ADH4	-0.38	-5.11	-0.42	1.18e-6	Alcohol dependence;
TGCT	cis	rs4148883	0.689	rs1154415	chr4:99999033	T/C	cg12011299	chr4:100065546	ADH4	0.4	5.94	0.47	2.71e-8	Alcohol dependence;
TGCT	cis	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg20637647	chr7:64974828	NA	-0.95	-5.3	-0.43	5.09e-7	Diabetic kidney disease;
TGCT	cis	rs28595532	0.920	rs56302600	chr4:119770162	T/C	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg18876405	chr7:65276391	NA	0.3	4.69	0.39	7e-6	Aortic root size;
TGCT	cis	rs1949733	0.628	rs2688231	chr4:8490981	G/A	cg11789530	chr4:8429930	ACOX3	0.51	4.81	0.4	4.32e-6	Response to antineoplastic agents;
TGCT	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2108225	1.000	rs989960	chr7:107445727	C/T	cg20438043	chr7:107601757	LAMB1	-0.24	-4.53	-0.38	1.34e-5	Ulcerative colitis;
TGCT	cis	rs2730245	0.527	rs2657362	chr7:158685095	A/G	cg11984989	chr7:158649758	WDR60	1.01	7.85	0.58	1.65e-12	Height;
TGCT	cis	rs858239	0.601	rs7805206	chr7:23160210	C/T	cg05602783	chr7:23145260	KLHL7	-0.69	-6.58	-0.51	1.16e-9	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs12142240	0.738	rs67545510	chr1:46806242	G/T	cg00530320	chr1:46809349	NSUN4	0.29	5.95	0.47	2.58e-8	Menopause (age at onset);
TGCT	cis	rs1008375	1.000	rs1974624	chr4:17650281	A/G	cg10189774	chr4:17578691	LAP3	0.55	4.9	0.4	2.96e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs17102423	0.594	rs1124751	chr14:65567601	C/A	cg11161011	chr14:65562177	MAX	-0.47	-6.42	-0.5	2.57e-9	Obesity-related traits;
TGCT	cis	rs13256369	0.802	rs13255789	chr8:8562791	T/C	cg17143192	chr8:8559678	CLDN23	0.56	5.31	0.43	4.9e-7	Obesity-related traits;
TGCT	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg22963979	chr7:1858916	MAD1L1	-0.31	-4.78	-0.39	4.9e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs78487399	0.808	rs17039131	chr2:43652398	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.45	-5.35	-0.43	4.03e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs12134245	0.776	rs12122066	chr1:92005140	C/T	cg25838465	chr1:92012736	NA	-0.43	-6.91	-0.53	2.22e-10	Breast cancer;
TGCT	cis	rs6598955	0.671	rs17163866	chr1:26648088	A/G	cg04990556	chr1:26633338	UBXN11	0.65	4.54	0.38	1.3e-5	Obesity-related traits;
TGCT	cis	rs2996428	0.667	rs10492942	chr1:3764216	C/T	cg13057898	chr1:3703894	LRRC47	0.22	4.68	0.39	7.24e-6	Red cell distribution width;
TGCT	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	6.23	0.49	6.56e-9	Bipolar disorder;
TGCT	cis	rs17001868	1.000	rs73167022	chr22:40797256	A/T	cg07138101	chr22:40742427	ADSL	0.69	4.65	0.39	8.38e-6	Mammographic density (dense area);
TGCT	cis	rs11673344	0.523	rs7256380	chr19:37532080	T/C	cg08039142	chr19:36980659	ZNF566	0.49	4.5	0.37	1.57e-5	Obesity-related traits;
TGCT	cis	rs3862030	0.839	rs12570859	chr10:104257226	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.52	-4.99	-0.41	2.01e-6	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
TGCT	cis	rs10782582	0.532	rs12132503	chr1:76137762	C/G	cg10523679	chr1:76189770	ACADM	-0.69	-7.16	-0.54	6.4e-11	Daytime sleep phenotypes;
TGCT	cis	rs651907	0.535	rs11716558	chr3:101528481	T/C	cg12386194	chr3:101231763	SENP7	0.47	4.7	0.39	6.87e-6	Colorectal cancer;
TGCT	cis	rs9733	0.526	rs6587542	chr1:150907701	G/T	cg09365446	chr1:150670422	GOLPH3L	0.34	4.71	0.39	6.58e-6	Tonsillectomy;
TGCT	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg05368731	chr17:41323189	NBR1	1.2	14.59	0.79	1.08e-28	Menopause (age at onset);
TGCT	cis	rs910316	0.967	rs11159121	chr14:75666029	A/T	cg11812906	chr14:75593930	NEK9	-0.71	-6.9	-0.53	2.42e-10	Height;
TGCT	cis	rs62244186	0.659	rs56234157	chr3:44516221	G/A	cg15687855	chr3:44754131	ZNF502	-0.43	-5.26	-0.43	6.04e-7	Depressive symptoms;
TGCT	cis	rs4972806	0.849	rs2857541	chr2:177029086	C/T	cg03152288	chr2:177042942	NA	0.6	5.16	0.42	9.57e-7	IgG glycosylation;
TGCT	cis	rs1975974	1.000	rs1985717	chr17:21731807	T/A	cg18423549	chr17:21743878	NA	-0.54	-4.97	-0.41	2.18e-6	Psoriasis;
TGCT	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg03161606	chr19:29218774	NA	0.59	5.71	0.46	7.95e-8	Methadone dose in opioid dependence;
TGCT	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg06212747	chr3:49208901	KLHDC8B	0.66	6.19	0.49	7.94e-9	Menarche (age at onset);
TGCT	cis	rs7666738	0.830	rs1426663	chr4:98990092	T/G	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9300255	0.602	rs6488864	chr12:123618362	G/C	cg00376283	chr12:123451042	ABCB9	0.69	4.89	0.4	3.08e-6	Neutrophil percentage of white cells;
TGCT	cis	rs28595532	0.920	rs17325192	chr4:119780345	A/G	cg14228332	chr4:119757509	SEC24D	-0.76	-5.17	-0.42	9.28e-7	Cannabis dependence symptom count;
TGCT	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg08048268	chr3:133502702	NA	-0.54	-7.22	-0.54	4.68e-11	Iron status biomarkers;
TGCT	cis	rs6754311	0.550	rs10173394	chr2:136522675	C/T	cg07169764	chr2:136633963	MCM6	-0.66	-6.11	-0.48	1.2e-8	Mosquito bite size;
TGCT	cis	rs7264396	0.622	rs3787165	chr20:34228946	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.28	-4.68	-0.39	7.38e-6	Total cholesterol levels;
TGCT	cis	rs7772486	0.875	rs1412080	chr6:146417304	T/C	cg05347473	chr6:146136440	FBXO30	0.53	5.03	0.41	1.71e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11190604	1.000	rs10883493	chr10:102208188	A/T	cg16342193	chr10:102329863	NA	-0.4	-5.31	-0.43	4.85e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs899997	1.000	rs11632672	chr15:79044330	A/G	cg04896959	chr15:78267971	NA	0.35	5.07	0.41	1.4e-6	Coronary artery disease or large artery stroke;
TGCT	cis	rs4319547	1.000	rs1392236	chr12:123074890	C/G	cg23029597	chr12:123009494	RSRC2	-0.31	-5.01	-0.41	1.82e-6	Body mass index;
TGCT	cis	rs9517320	0.534	rs3858778	chr13:99172249	A/C	cg07423050	chr13:99094983	FARP1	0.32	6.23	0.49	6.68e-9	Longevity;
TGCT	trans	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg17830980	chr10:43048298	ZNF37B	-0.86	-10.91	-0.7	7.74e-20	Extrinsic epigenetic age acceleration;
TGCT	cis	rs832540	0.830	rs252907	chr5:56120646	G/A	cg12311346	chr5:56204834	C5orf35	-0.47	-5.03	-0.41	1.7e-6	Coronary artery disease;
TGCT	cis	rs2938670	1	rs2938670	chr15:78740688	T/G	cg18825076	chr15:78729989	IREB2	-0.33	-5.32	-0.43	4.68e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1 in COPD;Post bronchodilator FEV1/FVC ratio in COPD;
TGCT	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg08859206	chr1:53392774	SCP2	0.45	7.01	0.53	1.33e-10	Monocyte count;
TGCT	cis	rs2224391	0.628	rs2773299	chr6:5242169	C/G	cg09085698	chr6:5261316	LYRM4;FARS2	-1.0	-6.12	-0.48	1.16e-8	Height;
TGCT	cis	rs2078087	0.790	rs78517564	chr1:183442324	A/C	cg16263152	chr1:183287819	NMNAT2	0.41	4.83	0.4	3.99e-6	Obesity-related traits;
TGCT	cis	rs7666738	0.606	rs4577589	chr4:99087858	A/G	cg05340658	chr4:99064831	C4orf37	0.44	4.8	0.4	4.5e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4073582	0.595	rs9326370	chr11:65992008	A/G	cg16950941	chr11:66035639	RAB1B	0.59	5.58	0.45	1.42e-7	Gout;
TGCT	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg24829409	chr8:58192753	C8orf71	-0.59	-5.18	-0.42	8.54e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs10791097	0.720	rs7119425	chr11:130733185	C/T	cg05962950	chr11:130786565	SNX19	0.87	10.9	0.7	8.28e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs7917772	0.604	rs4917977	chr10:104363119	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	5.36	0.43	3.84e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7113874	0.569	rs9736791	chr11:8589648	A/G	cg14521421	chr11:8862019	ST5	0.28	4.49	0.37	1.58e-5	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs763121	0.925	rs9835	chr22:39130971	A/G	cg06022373	chr22:39101656	GTPBP1	0.69	6.58	0.51	1.21e-9	Menopause (age at onset);
TGCT	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg11301795	chr4:187892539	NA	-0.31	-4.67	-0.39	7.71e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7523273	0.586	rs2761425	chr1:207894033	C/T	cg22525895	chr1:207977042	MIR29B2	-0.32	-5.28	-0.43	5.49e-7	Schizophrenia;
TGCT	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.7	-6.38	-0.5	3.14e-9	Tonsillectomy;
TGCT	cis	rs2760061	0.598	rs1774755	chr1:228115282	T/G	cg02753203	chr1:228287806	NA	-0.34	-6.64	-0.51	8.94e-10	Diastolic blood pressure;
TGCT	cis	rs7666738	0.830	rs10440379	chr4:98902822	G/T	cg17366294	chr4:99064904	C4orf37	0.67	6.83	0.52	3.3e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2456568	0.548	rs7113080	chr11:93657520	G/A	cg16099599	chr11:93583650	C11orf90	-0.39	-4.61	-0.38	9.94e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	trans	rs57221529	0.600	rs11750269	chr5:666270	G/A	cg11887960	chr12:57824829	NA	1.14	9.58	0.65	1.35e-16	Lung disease severity in cystic fibrosis;
TGCT	cis	rs12681287	0.547	rs6471360	chr8:87513469	C/T	cg27223183	chr8:87520930	FAM82B	0.95	6.95	0.53	1.81e-10	Caudate activity during reward;
TGCT	cis	rs6088590	1.000	rs12626122	chr20:33425800	A/G	cg24642439	chr20:33292090	TP53INP2	0.68	5.9	0.47	3.29e-8	Coronary artery disease;
TGCT	cis	rs951366	0.677	rs1775140	chr1:205672107	C/A	cg14159672	chr1:205819179	PM20D1	0.61	7.32	0.55	2.79e-11	Menarche (age at onset);
TGCT	cis	rs1215050	0.740	rs783936	chr4:98928628	G/T	cg05340658	chr4:99064831	C4orf37	-0.44	-5.35	-0.43	4.13e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs8051431	0.806	rs4788590	chr16:72020294	G/A	cg06353428	chr16:71660113	MARVELD3	0.57	4.54	0.38	1.31e-5	LDL cholesterol levels;
TGCT	cis	rs829418	0.582	rs747662	chr1:21947218	C/G	cg03132729	chr1:21947437	RAP1GAP	-0.62	-4.68	-0.39	7.32e-6	Neurocognitive impairment in HIV-1 infection (continuous);
TGCT	cis	rs4824093	0.610	rs77128035	chr22:50241024	C/T	cg20569369	chr22:51173646	NA	0.27	4.59	0.38	1.09e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs968567	0.501	rs174553	chr11:61575158	A/G	cg19610905	chr11:61596333	FADS2	-1.07	-12.03	-0.73	1.43e-22	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
TGCT	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg05368731	chr17:41323189	NBR1	1.16	13.76	0.78	1.03e-26	Menopause (age at onset);
TGCT	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg01802117	chr1:53393560	SCP2	0.44	5.18	0.42	8.66e-7	Monocyte count;
TGCT	trans	rs2727020	0.521	rs2088526	chr11:49531968	G/A	cg11707556	chr5:10655725	ANKRD33B	0.42	8.63	0.61	2.5e-14	Coronary artery disease;
TGCT	cis	rs3815148	0.569	rs12705406	chr7:106792554	A/G	cg02696742	chr7:106810147	HBP1	0.67	4.59	0.38	1.08e-5	Osteoarthritis;
TGCT	cis	rs2204008	0.693	rs12372025	chr12:38202028	G/A	cg26384229	chr12:38710491	ALG10B	0.86	7.6	0.56	6.23e-12	Bladder cancer;
TGCT	cis	rs6866344	0.570	rs1132336	chr5:178140090	C/T	cg03877680	chr5:178157825	ZNF354A	0.77	6.78	0.52	4.28e-10	Neutrophil percentage of white cells;
TGCT	cis	rs2455799	0.586	rs2345739	chr3:15919294	T/G	cg12172478	chr3:16357591	RFTN1	-0.36	-5.3	-0.43	5.07e-7	Mean platelet volume;
TGCT	cis	rs2721195	0.845	rs4244611	chr8:145739924	G/A	cg15857475	chr8:145742913	RECQL4;LRRC14	0.88	9.57	0.65	1.38e-16	Age at first birth;
TGCT	cis	rs7666738	0.830	rs28417716	chr4:98864859	C/T	cg17366294	chr4:99064904	C4orf37	0.7	7.27	0.55	3.62e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6582630	0.502	rs11495393	chr12:38341194	T/C	cg26384229	chr12:38710491	ALG10B	0.79	6.98	0.53	1.61e-10	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs6088590	1.000	rs6119535	chr20:33442138	A/C	cg24642439	chr20:33292090	TP53INP2	0.65	5.75	0.46	6.61e-8	Coronary artery disease;
TGCT	cis	rs7119	0.651	rs12902948	chr15:77849254	T/C	cg27398640	chr15:77910606	LINGO1	-0.28	-5.2	-0.42	7.99e-7	Type 2 diabetes;
TGCT	cis	rs2708977	0.842	rs10209780	chr2:97140142	T/G	cg14837825	chr2:96917567	TMEM127	0.28	4.68	0.39	7.3e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs259282	0.605	rs66489063	chr19:33108959	C/T	cg26639809	chr19:33781782	NA	0.25	5.04	0.41	1.6e-6	Schizophrenia;
TGCT	cis	rs1670533	1.000	rs6812586	chr4:1069851	A/G	cg20887711	chr4:1340912	KIAA1530	0.69	5.5	0.44	2.03e-7	Recombination rate (females);
TGCT	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	16.07	0.82	4.16e-32	Prudent dietary pattern;
TGCT	cis	rs748404	0.660	rs693510	chr15:43714625	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	4.75	0.39	5.51e-6	Lung cancer;
TGCT	cis	rs11148252	0.595	rs4884522	chr13:53053768	C/A	cg00495681	chr13:53174319	NA	0.68	6.61	0.51	1e-9	Lewy body disease;
TGCT	cis	rs425277	1.000	rs381664	chr1:2088104	A/G	cg03732007	chr1:2071316	PRKCZ	0.26	5.52	0.44	1.89e-7	Height;
TGCT	cis	rs7937682	0.632	rs2070894	chr11:111780837	G/A	cg09085632	chr11:111637200	PPP2R1B	0.84	7.34	0.55	2.4e-11	Primary sclerosing cholangitis;
TGCT	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.54	-0.38	1.33e-5	Bipolar disorder;
TGCT	cis	rs916888	0.610	rs199530	chr17:44836653	C/T	cg01570182	chr17:44337453	NA	-0.72	-6.93	-0.53	2.08e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg00908189	chr16:619842	PIGQ	0.87	10.68	0.69	2.85e-19	Height;
TGCT	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg12310025	chr6:25882481	NA	-0.72	-6.54	-0.51	1.48e-9	Intelligence (multi-trait analysis);
TGCT	trans	rs1496653	0.602	rs35383024	chr3:23492364	T/C	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs8103278	0.507	rs7246377	chr19:46292259	G/A	cg14061069	chr19:46274453	DMPK	0.6	10.22	0.68	3.6e-18	Coronary artery disease;
TGCT	cis	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg12570787	chr5:219185	SDHA;CCDC127	0.66	4.48	0.37	1.64e-5	Breast cancer;
TGCT	cis	rs9388451	0.626	rs1343115	chr6:126069817	C/G	cg05901451	chr6:126070800	HEY2	-1.04	-13.0	-0.76	6.65e-25	Brugada syndrome;
TGCT	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	8.48	0.61	5.53e-14	Platelet count;
TGCT	cis	rs473651	0.904	rs62196716	chr2:239356977	C/G	cg08773314	chr2:239334832	ASB1	0.44	7.37	0.55	2.13e-11	Multiple system atrophy;
TGCT	cis	rs7666738	0.830	rs10014284	chr4:98681951	G/C	cg05340658	chr4:99064831	C4orf37	0.46	5.42	0.44	3.01e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8103278	1.000	rs8102876	chr19:46332842	C/T	cg14061069	chr19:46274453	DMPK	-0.44	-6.14	-0.48	1.04e-8	Coronary artery disease;
TGCT	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.08	0.48	1.37e-8	Bipolar disorder;
TGCT	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.67	4.75	0.39	5.62e-6	Platelet count;
TGCT	cis	rs62244186	1.000	rs62244186	chr3:44739783	G/A	cg11003573	chr3:44754125	ZNF502	-0.44	-5.15	-0.42	9.91e-7	Depressive symptoms;
TGCT	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg09365446	chr1:150670422	GOLPH3L	0.31	4.64	0.38	8.7e-6	Tonsillectomy;
TGCT	cis	rs7507204	0.530	rs4807469	chr19:3443382	G/C	cg08380311	chr19:3435252	NFIC	1.17	15.97	0.82	7.09e-32	Height;
TGCT	cis	rs17293817	0.625	rs10794748	chr10:1421516	A/G	cg27336261	chr10:1975562	NA	-0.31	-4.48	-0.37	1.66e-5	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4455778	0.580	rs7783777	chr7:49082560	G/A	cg26309511	chr7:48887640	NA	0.5	6.47	0.5	2.03e-9	Lung cancer in never smokers;
TGCT	cis	rs514406	0.505	rs448788	chr1:53161620	A/G	cg22166914	chr1:53195759	ZYG11B	-0.46	-7.85	-0.58	1.66e-12	Monocyte count;
TGCT	cis	rs11792861	0.962	rs3750452	chr9:111801353	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.48	4.47	0.37	1.77e-5	Menarche (age at onset);
TGCT	cis	rs16866061	0.888	rs6748341	chr2:225377574	C/G	cg12698349	chr2:225449008	CUL3	0.98	9.06	0.63	2.32e-15	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	cis	rs11190604	1.000	rs10883508	chr10:102294413	G/A	cg23241863	chr10:102295624	HIF1AN	0.7	5.34	0.43	4.2e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7044106	0.762	rs1867254	chr9:123429078	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	6.68	0.51	7.09e-10	Hip circumference adjusted for BMI;
TGCT	cis	rs6570726	0.755	rs2092296	chr6:145893684	A/C	cg05347473	chr6:146136440	FBXO30	0.52	4.95	0.41	2.33e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2251381	0.778	rs722013	chr21:30549245	G/T	cg24692254	chr21:30365293	RNF160	0.74	7.29	0.55	3.15e-11	Selective IgA deficiency;
TGCT	cis	rs2180341	0.538	rs11556354	chr6:127664661	G/A	cg27446573	chr6:127587934	RNF146	0.64	5.87	0.47	3.71e-8	Breast cancer;
TGCT	cis	rs921968	0.541	rs6710383	chr2:219359685	T/G	cg02176678	chr2:219576539	TTLL4	0.48	6.78	0.52	4.32e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs344364	0.529	rs186941	chr16:1930088	T/C	cg26617929	chr16:1858877	NA	0.28	5.19	0.42	8.5e-7	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs1865760	0.865	rs2164485	chr6:25952106	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.64	6.31	0.49	4.56e-9	Height;
TGCT	cis	rs6121246	0.909	rs6058463	chr20:30385192	C/T	cg13852791	chr20:30311386	BCL2L1	0.8	6.12	0.48	1.15e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs778371	0.697	rs11893358	chr2:233636922	T/C	cg08000102	chr2:233561755	GIGYF2	0.72	8.56	0.61	3.68e-14	Schizophrenia;
TGCT	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg14983838	chr19:29218262	NA	0.83	6.85	0.52	3.07e-10	Methadone dose in opioid dependence;
TGCT	cis	rs950169	1.000	rs1818950	chr15:84722521	A/G	cg11189052	chr15:85197271	WDR73	0.72	6.06	0.48	1.53e-8	Schizophrenia;
TGCT	cis	rs6500602	0.702	rs3789038	chr16:4546586	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.31	-4.88	-0.4	3.26e-6	Schizophrenia;
TGCT	cis	rs2370759	0.891	rs76164690	chr10:32590362	T/G	cg01819863	chr10:32635814	EPC1	1.06	6.92	0.53	2.15e-10	Sexual dysfunction (female);
TGCT	cis	rs7043114	0.507	rs10992340	chr9:95209693	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.54	-5.35	-0.43	4.03e-7	Height;
TGCT	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg11644478	chr21:40555479	PSMG1	1.0	10.69	0.69	2.7e-19	Cognitive function;
TGCT	cis	rs2439831	0.702	rs9989313	chr15:44152817	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	6.2	0.49	7.73e-9	Lung cancer in ever smokers;
TGCT	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg13944838	chr5:179740914	GFPT2	0.4	6.42	0.5	2.65e-9	Height;
TGCT	cis	rs12712073	0.845	rs6729966	chr2:100781566	A/G	cg07810366	chr2:100720526	AFF3	-0.35	-5.26	-0.43	6e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs11122272	0.705	rs2491411	chr1:231533448	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-6.53	-0.51	1.55e-9	Hemoglobin concentration;
TGCT	cis	rs72843506	0.722	rs16964352	chr17:20148408	A/G	cg18979559	chr17:20280153	CCDC144C	-0.65	-4.89	-0.4	3.01e-6	Schizophrenia;
TGCT	cis	rs694739	0.628	rs538147	chr11:64129722	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.6	6.02	0.48	1.81e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs9486715	0.867	rs1855533	chr6:97050265	T/C	cg06623918	chr6:96969491	KIAA0776	-1.11	-15.34	-0.81	1.96e-30	Headache;
TGCT	cis	rs950169	0.580	rs11630887	chr15:85193015	A/T	cg17173187	chr15:85201210	NMB	0.59	6.7	0.52	6.63e-10	Schizophrenia;
TGCT	cis	rs2014572	0.967	rs8111977	chr19:57759158	T/A	cg24459738	chr19:57751996	ZNF805	-0.56	-5.6	-0.45	1.29e-7	Hyperactive-impulsive symptoms;
TGCT	trans	rs208520	0.526	rs6913344	chr6:66754285	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.06	-14.91	-0.8	2e-29	Exhaled nitric oxide output;
TGCT	cis	rs9325144	0.555	rs61929925	chr12:38698828	C/A	cg26384229	chr12:38710491	ALG10B	-0.65	-6.05	-0.48	1.62e-8	Morning vs. evening chronotype;
TGCT	cis	rs9303401	0.659	rs61291849	chr17:56909867	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs3733585	0.805	rs882222	chr4:9981294	G/A	cg00071950	chr4:10020882	SLC2A9	0.65	8.23	0.59	2.21e-13	Cleft plate (environmental tobacco smoke interaction);
TGCT	trans	rs2688608	0.901	rs2664282	chr10:75620757	T/C	cg13918328	chr10:52500089	ASAH2B	0.67	6.92	0.53	2.19e-10	Inflammatory bowel disease;
TGCT	cis	rs6089829	0.888	rs4809465	chr20:61671156	G/C	cg08564027	chr20:61660810	NA	0.37	5.98	0.47	2.26e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs10972341	1.000	rs11521201	chr9:35158460	T/C	cg00812861	chr9:35114699	KIAA1539	0.32	4.78	0.39	4.8e-6	Weight;
TGCT	cis	rs9916302	0.706	rs667193	chr17:37448835	T/C	cg07936489	chr17:37558343	FBXL20	0.84	6.23	0.49	6.68e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs2153535	0.580	rs6905237	chr6:8471790	A/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.73	0.46	7.1e-8	Motion sickness;
TGCT	cis	rs16957091	0.647	rs9920061	chr15:43234061	T/C	cg17935677	chr15:44119062	WDR76	0.52	4.7	0.39	6.72e-6	MGMT methylation in smokers;
TGCT	trans	rs525455	1.000	rs1659841	chr10:13102400	A/G	cg21721093	chr17:8906386	NA	0.63	6.62	0.51	9.7e-10	Platelet aggregation;
TGCT	cis	rs12048904	0.619	rs10875346	chr1:101328083	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.85	8.05	0.59	5.63e-13	Multiple sclerosis;
TGCT	cis	rs7267979	0.934	rs2482913	chr20:25405086	T/A	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7312933	0.585	rs7969814	chr12:42669657	C/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.54	5.15	0.42	9.78e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs7914558	1.000	rs2275271	chr10:104814162	T/C	cg15744005	chr10:104629667	AS3MT	-0.38	-4.69	-0.39	7.04e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs4919669	0.668	rs4919666	chr10:104384029	G/A	cg05855489	chr10:104503620	C10orf26	0.71	4.69	0.39	7.18e-6	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs17125944	0.505	rs118053951	chr14:53259829	G/A	cg00686598	chr14:53173677	PSMC6	1.08	6.32	0.49	4.37e-9	Alzheimer's disease (late onset);
TGCT	cis	rs6570726	0.935	rs449377	chr6:145852437	C/G	cg05347473	chr6:146136440	FBXO30	0.5	4.87	0.4	3.27e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6835098	0.692	rs6553680	chr4:174077044	A/G	cg08422745	chr4:174089978	GALNT7	-0.77	-8.6	-0.61	2.87e-14	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs1801239	1.000	rs78786782	chr10:16937775	C/T	cg00939682	chr10:16933505	CUBN	0.48	4.56	0.38	1.23e-5	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin excretion;
TGCT	cis	rs523522	0.962	rs2233676	chr12:120933607	G/A	cg27279351	chr12:120934652	DYNLL1	0.76	6.59	0.51	1.15e-9	High light scatter reticulocyte count;
TGCT	cis	rs896854	0.654	rs1453377	chr8:95969947	C/T	cg13393036	chr8:95962371	TP53INP1	-0.62	-8.39	-0.6	9.08e-14	Type 2 diabetes;
TGCT	cis	rs6586163	0.843	rs1926199	chr10:90746660	G/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.38	-4.78	-0.39	4.79e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs36051895	0.589	rs62543574	chr9:5204090	A/T	cg02405213	chr9:5042618	JAK2	-0.74	-9.28	-0.64	7.07e-16	Pediatric autoimmune diseases;
TGCT	cis	rs7095607	1.000	rs7913582	chr10:69952581	T/C	cg18986048	chr10:69913749	MYPN	0.46	4.93	0.41	2.54e-6	Lung function (FVC);
TGCT	cis	rs2204008	0.805	rs11514348	chr12:38243427	T/C	cg26384229	chr12:38710491	ALG10B	0.86	7.42	0.55	1.6e-11	Bladder cancer;
TGCT	cis	rs9303401	0.659	rs62083436	chr17:57031742	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.67	6.3	0.49	4.7e-9	Cognitive test performance;
TGCT	cis	rs11785400	1.000	rs10099892	chr8:143734608	C/T	cg10596483	chr8:143751796	JRK	0.56	6.02	0.48	1.87e-8	Schizophrenia;
TGCT	cis	rs4730430	0.538	rs10270301	chr7:110133558	C/T	cg14239618	chr7:110281356	NA	0.25	4.7	0.39	6.67e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs2282802	0.617	rs10477348	chr5:139666906	A/T	cg01081189	chr5:139537190	NA	0.28	5.01	0.41	1.84e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7819412	0.669	rs28630509	chr8:10997039	A/G	cg21775007	chr8:11205619	TDH	-0.55	-5.05	-0.41	1.53e-6	Triglycerides;
TGCT	cis	rs9894429	1.000	rs12948099	chr17:79600799	C/G	cg18240062	chr17:79603768	NPLOC4	0.7	7.16	0.54	6.24e-11	Eye color traits;
TGCT	cis	rs6988636	1.000	rs28513831	chr8:124189208	T/C	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs9486715	0.867	rs4839828	chr6:96863326	G/A	cg06623918	chr6:96969491	KIAA0776	1.11	16.62	0.83	2.35e-33	Headache;
TGCT	cis	rs694419	0.602	rs1473980	chr18:60206676	C/T	cg13506219	chr18:60193840	ZCCHC2	0.53	4.74	0.39	5.77e-6	Serum albumin level;
TGCT	cis	rs1903068	0.719	rs1380068	chr4:56003707	C/G	cg09978860	chr4:56023921	NA	0.54	5.76	0.46	6.3e-8	Endometriosis;
TGCT	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg18876405	chr7:65276391	NA	0.35	5.66	0.45	1.01e-7	Aortic root size;
TGCT	cis	rs7044106	0.791	rs10984994	chr9:123478769	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.42	-4.49	-0.37	1.59e-5	Hip circumference adjusted for BMI;
TGCT	cis	rs921968	0.612	rs2384950	chr2:219499719	T/C	cg02176678	chr2:219576539	TTLL4	0.43	6.13	0.48	1.06e-8	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg17178900	chr1:205818956	PM20D1	0.59	7.49	0.56	1.14e-11	Menarche (age at onset);
TGCT	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg11494091	chr17:61959527	GH2	0.61	14.43	0.79	2.59e-28	Prudent dietary pattern;
TGCT	cis	rs4727027	0.870	rs62507509	chr7:148795522	C/T	cg23583168	chr7:148888333	NA	-0.72	-9.11	-0.63	1.8e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	5.99	0.47	2.06e-8	Bipolar disorder;
TGCT	cis	rs1347297	0.526	rs728005	chr2:179251006	C/T	cg03991736	chr2:179345203	MIR548N;PLEKHA3	-0.51	-4.83	-0.4	3.88e-6	Alzheimer disease and age of onset;
TGCT	cis	rs62244186	0.545	rs725866	chr3:44765533	A/G	cg25151919	chr3:44754333	ZNF502	-0.47	-5.45	-0.44	2.56e-7	Depressive symptoms;
TGCT	cis	rs11252926	0.563	rs10795103	chr10:451849	C/A	cg20256804	chr10:444983	DIP2C	-0.22	-4.68	-0.39	7.34e-6	Psychosis in Alzheimer's disease;
TGCT	cis	rs7027203	1.000	rs7864114	chr9:96551954	A/G	cg13679303	chr9:96623674	NA	0.65	9.81	0.66	3.61e-17	DNA methylation (variation);
TGCT	cis	rs11690462	0.963	rs4007242	chr2:26596915	C/T	cg04726446	chr2:26624865	C2orf39	0.43	4.64	0.38	8.58e-6	Coronary artery disease;
TGCT	trans	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg23505145	chr19:12996616	KLF1	0.79	8.3	0.6	1.47e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs74054849	0.717	rs1547032	chr1:15918974	G/A	cg05660106	chr1:15850417	CASP9	0.93	4.76	0.39	5.39e-6	Alcoholic chronic pancreatitis;
TGCT	trans	rs3780486	0.505	rs10758194	chr9:33157419	G/T	cg20290983	chr6:43655470	MRPS18A	0.77	8.36	0.6	1.07e-13	IgG glycosylation;
TGCT	cis	rs11105298	0.891	rs10858854	chr12:89835728	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.67	-4.74	-0.39	5.67e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs1729951	0.575	rs1682333	chr3:136688618	G/A	cg12473912	chr3:136751656	NA	0.39	6.18	0.49	8.36e-9	Neuroticism;
TGCT	cis	rs59107033	0.607	rs62262407	chr3:123122637	T/A	cg04890266	chr3:123102914	ADCY5	-0.38	-5.62	-0.45	1.18e-7	Lymphocyte counts;
TGCT	cis	rs3782455	0.793	rs77046876	chr12:114404271	G/A	cg23502203	chr12:113549970	RASAL1	-0.55	-4.92	-0.4	2.7e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs7267979	1.000	rs6083825	chr20:25366424	T/C	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs12477438	0.520	rs13030961	chr2:99799520	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.15	18.32	0.85	4.52e-37	Chronic sinus infection;
TGCT	cis	rs2204008	0.744	rs11514073	chr12:38399553	A/C	cg13010199	chr12:38710504	ALG10B	0.61	4.82	0.4	4.12e-6	Bladder cancer;
TGCT	cis	rs7824557	0.606	rs1435277	chr8:11196970	C/T	cg21775007	chr8:11205619	TDH	0.74	6.99	0.53	1.49e-10	Retinal vascular caliber;
TGCT	cis	rs9926296	0.572	rs8046872	chr16:89841552	T/C	cg27121462	chr16:89883253	FANCA	0.57	5.3	0.43	5.03e-7	Vitiligo;
TGCT	cis	rs60154123	0.505	rs76426571	chr1:210041634	C/T	cg04352962	chr1:209979756	IRF6	0.69	4.73	0.39	6.04e-6	Coronary artery disease;
TGCT	cis	rs7296418	0.663	rs11057276	chr12:123820397	C/T	cg00376283	chr12:123451042	ABCB9	-0.63	-5.42	-0.44	3.02e-7	Platelet count;
TGCT	cis	rs1990950	0.692	rs1157344	chr5:156836438	A/G	cg25387487	chr5:157003181	ADAM19	0.29	4.47	0.37	1.73e-5	Lung function (FEV1/FVC);
TGCT	cis	rs6570726	0.791	rs2096201	chr6:145934273	C/T	cg23711669	chr6:146136114	FBXO30	0.89	9.69	0.66	7.3e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs17173637	0.510	rs73165509	chr7:150522870	G/C	cg09499965	chr7:151220664	NA	0.3	4.46	0.37	1.84e-5	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs7178572	0.568	rs1389436	chr15:77665848	G/T	cg15453836	chr15:77711506	NA	-0.42	-4.79	-0.4	4.58e-6	Type 2 diabetes;
TGCT	cis	rs11785400	0.793	rs7000765	chr8:143722457	G/A	cg10596483	chr8:143751796	JRK	0.54	5.25	0.43	6.48e-7	Schizophrenia;
TGCT	cis	rs9486719	1.000	rs2472889	chr6:96866803	T/G	cg18709589	chr6:96969512	KIAA0776	0.71	5.21	0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs7681440	0.835	rs7668531	chr4:90791819	G/T	cg26578617	chr4:90757533	SNCA	-0.45	-4.63	-0.38	9.09e-6	Dementia with Lewy bodies;
TGCT	cis	rs8072100	0.967	rs62076549	chr17:45579555	T/G	cg08085267	chr17:45401833	C17orf57	0.44	4.63	0.38	8.96e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	7.76	0.57	2.67e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.55	4.92	0.4	2.74e-6	Prudent dietary pattern;
TGCT	cis	rs28595532	0.920	rs116047800	chr4:119773569	G/T	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs4319547	0.688	rs10847415	chr12:123144293	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.6	-4.83	-0.4	4.03e-6	Body mass index;
TGCT	cis	rs10840270	0.638	rs10770047	chr11:9630969	C/G	cg03787988	chr11:10602522	MRVI1	-0.2	-4.59	-0.38	1.09e-5	Bacteremia;
TGCT	trans	rs1814175	0.616	rs1794131	chr11:49904194	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.51	-0.69	7.2e-19	Height;
TGCT	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg18230493	chr5:56204884	C5orf35	-0.68	-5.85	-0.46	4.13e-8	Initial pursuit acceleration;
TGCT	cis	rs4242434	0.854	rs13258100	chr8:22451116	A/T	cg03733263	chr8:22462867	KIAA1967	1.09	17.25	0.84	9.34e-35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs9399135	0.967	rs4388304	chr6:135309597	T/A	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.36e-6	Red blood cell count;
TGCT	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg10047753	chr17:41438598	NA	0.97	9.87	0.66	2.55e-17	Menopause (age at onset);
TGCT	cis	rs6490294	0.800	rs78783055	chr12:112233495	G/A	cg10833066	chr12:111807467	FAM109A	0.37	4.72	0.39	6.22e-6	Mean platelet volume;
TGCT	cis	rs826838	0.834	rs826874	chr12:39122599	C/A	cg13010199	chr12:38710504	ALG10B	-0.62	-4.94	-0.41	2.49e-6	Heart rate;
TGCT	cis	rs4746818	1.000	rs7916991	chr10:70895373	C/A	cg11621586	chr10:70884670	VPS26A	1.13	8.03	0.58	6.56e-13	Left atrial antero-posterior diameter;
TGCT	cis	rs9486719	0.947	rs12213375	chr6:96902134	A/G	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.86	-0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs3935685	0.874	rs4477663	chr15:78007254	A/G	cg25212270	chr15:78015279	NA	-0.25	-5.48	-0.44	2.32e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1865760	0.865	rs9467652	chr6:25959127	A/G	cg16482183	chr6:26056742	HIST1H1C	0.52	4.84	0.4	3.78e-6	Height;
TGCT	cis	rs7312933	0.702	rs10785333	chr12:42586470	A/G	cg19980929	chr12:42632907	YAF2	-0.47	-6.46	-0.5	2.13e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs1044826	0.692	rs188420	chr3:139233865	G/A	cg00490450	chr3:139108681	COPB2	-0.51	-4.48	-0.37	1.67e-5	Obesity-related traits;
TGCT	cis	rs7914558	0.966	rs11191471	chr10:104702050	T/A	cg15744005	chr10:104629667	AS3MT	-0.41	-5.11	-0.42	1.16e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg06481639	chr22:41940642	POLR3H	-0.71	-6.4	-0.5	2.93e-9	Vitiligo;
TGCT	cis	rs11190604	0.767	rs11190533	chr10:102190792	T/C	cg16342193	chr10:102329863	NA	-0.38	-5.0	-0.41	1.93e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	trans	rs1814175	0.817	rs12290508	chr11:49621037	C/T	cg03929089	chr4:120376271	NA	-0.74	-8.94	-0.63	4.54e-15	Height;
TGCT	cis	rs4595586	0.545	rs7972590	chr12:39376615	A/G	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg11764359	chr7:65958608	NA	-0.61	-5.39	-0.44	3.45e-7	Aortic root size;
TGCT	cis	rs644799	1.000	rs7749	chr11:95565789	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	7.92	0.58	1.12e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.52	-4.98	-0.41	2.04e-6	Longevity;Endometriosis;
TGCT	trans	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg27523141	chr10:43048294	ZNF37B	0.73	8.5	0.61	5.09e-14	Extrinsic epigenetic age acceleration;
TGCT	trans	rs10506458	1.000	rs73127086	chr12:63415626	G/A	cg22491629	chr6:157744540	C6orf35	-0.99	-8.57	-0.61	3.45e-14	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs9677476	0.516	rs59886388	chr2:231995770	G/C	cg07929768	chr2:232055508	NA	0.34	5.26	0.43	6.11e-7	Food antigen IgG levels;
TGCT	cis	rs10782582	0.593	rs11163904	chr1:76121208	A/G	cg10523679	chr1:76189770	ACADM	0.69	7.44	0.56	1.5e-11	Daytime sleep phenotypes;
TGCT	cis	rs9399137	0.507	rs7771310	chr6:135272535	G/A	cg24558204	chr6:135376177	HBS1L	0.49	4.94	0.41	2.49e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
TGCT	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg05665937	chr4:1216051	CTBP1	0.26	5.05	0.41	1.54e-6	Obesity-related traits;
TGCT	cis	rs595982	0.527	rs35087747	chr19:49377918	G/T	cg21252483	chr19:49399788	TULP2	-0.48	-7.32	-0.55	2.8e-11	Red cell distribution width;
TGCT	cis	rs734999	0.545	rs4648356	chr1:2709164	C/A	cg18854424	chr1:2615690	NA	0.45	4.99	0.41	1.99e-6	Ulcerative colitis;
TGCT	cis	rs2153535	0.546	rs1335640	chr6:8485325	A/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs10193935	0.901	rs12615383	chr2:42610551	A/G	cg27598129	chr2:42591480	NA	0.41	5.66	0.45	1e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10779751	0.734	rs2791650	chr1:11132541	G/C	cg08854313	chr1:11322531	MTOR	0.82	7.04	0.53	1.19e-10	Body mass index;
TGCT	cis	rs28595532	0.920	rs114162429	chr4:119741078	T/C	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg11062466	chr8:58055876	NA	0.38	4.62	0.38	9.5e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs13256369	1.000	rs13267501	chr8:8574058	G/A	cg17143192	chr8:8559678	CLDN23	0.63	5.93	0.47	2.8e-8	Obesity-related traits;
TGCT	trans	rs1864729	1.000	rs2028479	chr8:98290772	T/G	cg08679828	chr8:102218111	ZNF706	-1.03	-7.21	-0.54	4.94e-11	Estradiol plasma levels (breast cancer);
TGCT	cis	rs12908161	0.959	rs1051168	chr15:85200520	G/T	cg17173187	chr15:85201210	NMB	0.6	6.74	0.52	5.39e-10	Schizophrenia;
TGCT	cis	rs10488031	0.557	rs34870838	chr7:37108148	C/T	cg06458904	chr7:36312573	EEPD1	0.58	4.79	0.39	4.72e-6	QT interval;
TGCT	cis	rs7833790	0.654	rs7835342	chr8:82698092	A/G	cg06027949	chr8:82754900	SNX16	-0.6	-4.69	-0.39	7.14e-6	Diastolic blood pressure;
TGCT	cis	rs7611238	0.560	rs9870236	chr3:195129741	G/A	cg27323046	chr3:195102265	ACAP2	0.38	5.04	0.41	1.57e-6	Body mass index;
TGCT	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg12000995	chr2:27665139	KRTCAP3	-0.35	-4.46	-0.37	1.84e-5	Total body bone mineral density;
TGCT	cis	rs16939607	1.000	rs62510269	chr8:79012343	A/G	cg21244580	chr8:79934476	NA	0.47	4.68	0.39	7.33e-6	White blood cell count;
TGCT	cis	rs7552404	1.000	rs4949876	chr1:76173377	C/T	cg03433033	chr1:76189801	ACADM	0.83	9.91	0.66	2.13e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs709400	0.663	rs11628969	chr14:103940911	G/A	cg12935359	chr14:103987150	CKB	-0.36	-5.55	-0.45	1.67e-7	Body mass index;
TGCT	cis	rs67311347	1.000	rs11715214	chr3:40403004	C/A	cg13683864	chr3:40499215	RPL14	-1.1	-11.83	-0.73	4.49e-22	Renal cell carcinoma;
TGCT	cis	rs3091242	0.933	rs28633797	chr1:25741629	C/A	cg23205692	chr1:25664452	TMEM50A	0.52	5.38	0.43	3.59e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs10984561	0.881	rs58554876	chr9:122219555	C/G	cg14242995	chr9:122249943	NA	0.69	5.74	0.46	6.79e-8	Pulmonary function decline;
TGCT	cis	rs9611565	0.512	rs45500192	chr22:42177899	A/G	cg17554472	chr22:41940697	POLR3H	-0.46	-4.79	-0.39	4.71e-6	Vitiligo;
TGCT	cis	rs17376456	0.877	rs12374463	chr5:93483569	C/G	cg25358565	chr5:93447407	FAM172A	0.98	8.39	0.6	9.21e-14	Diabetic retinopathy;
TGCT	cis	rs9443645	0.901	rs7767100	chr6:79810533	A/C	cg09184832	chr6:79620586	NA	-0.47	-5.07	-0.41	1.4e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs185694	0.779	rs653221	chr13:30894567	G/C	cg07600127	chr13:30881527	KATNAL1	-0.76	-6.27	-0.49	5.4e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
TGCT	cis	rs11690935	0.632	rs35854151	chr2:172657439	G/A	cg13550731	chr2:172543902	DYNC1I2	0.69	6.04	0.48	1.69e-8	Schizophrenia;
TGCT	cis	rs909674	0.818	rs5750830	chr22:39840828	C/A	cg11247378	chr22:39784982	NA	-0.72	-8.54	-0.61	4.11e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs12286929	0.637	rs3802858	chr11:115078492	T/C	cg16269184	chr11:114127960	NA	0.2	4.49	0.37	1.59e-5	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs453301	0.686	rs13252797	chr8:8861430	A/G	cg15556689	chr8:8085844	FLJ10661	0.61	4.89	0.4	3.04e-6	Joint mobility (Beighton score);
TGCT	cis	rs2721195	0.781	rs10110962	chr8:145780323	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.91	10.04	0.67	9.97e-18	Age at first birth;
TGCT	cis	rs17076896	0.786	rs61956084	chr13:19936305	C/T	cg00777926	chr13:20807375	GJB6	-0.41	-4.82	-0.4	4.03e-6	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg09436375	chr6:42928200	GNMT	-0.4	-5.23	-0.42	7.13e-7	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs9611565	0.694	rs11090056	chr22:42095904	A/C	cg13695892	chr22:41940480	POLR3H	0.84	8.04	0.59	5.93e-13	Vitiligo;
TGCT	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg24675658	chr1:53192096	ZYG11B	-0.71	-8.23	-0.59	2.14e-13	Monocyte count;
TGCT	cis	rs988712	0.705	rs4923460	chr11:27656789	A/C	cg10635145	chr11:27742435	BDNF	0.37	5.02	0.41	1.79e-6	Obesity;
TGCT	cis	rs9467773	1.000	rs6932156	chr6:26571506	T/G	cg09904177	chr6:26538194	HMGN4	0.69	6.84	0.52	3.23e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs11264213	0.901	rs665521	chr1:36445837	T/C	cg07093915	chr1:36184400	C1orf216	0.65	4.47	0.37	1.77e-5	Schizophrenia;
TGCT	cis	rs4285028	0.948	rs1920290	chr3:121672305	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.77	-6.55	-0.51	1.35e-9	Multiple sclerosis;
TGCT	cis	rs3845702	0.736	rs6722147	chr2:180829704	G/A	cg01881094	chr2:180872142	CWC22	-1.03	-6.51	-0.5	1.72e-9	Schizophrenia;
TGCT	cis	rs7843479	0.562	rs11774629	chr8:21859315	C/T	cg17168535	chr8:21777572	XPO7	0.8	7.93	0.58	1.11e-12	Mean corpuscular volume;
TGCT	cis	rs1008375	0.863	rs4698632	chr4:17614894	T/C	cg10189774	chr4:17578691	LAP3	0.57	4.85	0.4	3.56e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9790314	0.871	rs339114	chr3:161109220	C/T	cg03342759	chr3:160939853	NMD3	0.47	5.04	0.41	1.6e-6	Morning vs. evening chronotype;
TGCT	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg21862992	chr11:68658383	NA	0.47	6.45	0.5	2.29e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs6815814	0.950	rs5743563	chr4:38806019	A/G	cg02016764	chr4:38805732	TLR1	-0.35	-5.65	-0.45	1.04e-7	Breast cancer;
TGCT	cis	rs9311474	1.000	rs9311474	chr3:52338852	T/C	cg10802521	chr3:52805072	NEK4	-0.59	-6.4	-0.5	2.91e-9	Electroencephalogram traits;
TGCT	cis	rs903263	1.000	rs10874432	chr1:84673951	T/C	cg09664975	chr1:84543551	PRKACB	0.48	4.57	0.38	1.16e-5	Breast cancer (male);
TGCT	cis	rs344364	0.511	rs911392	chr16:1947259	A/G	cg26617929	chr16:1858877	NA	-0.27	-4.9	-0.4	2.99e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs8078723	0.701	rs2305482	chr17:38140927	A/C	cg17467752	chr17:38218738	THRA	-0.53	-5.37	-0.43	3.8e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs7714584	1.000	rs61530785	chr5:150261364	A/G	cg22134413	chr5:150180641	NA	1.09	7.73	0.57	3.18e-12	Crohn's disease;
TGCT	cis	rs12368653	0.616	rs1027315	chr12:58034192	T/C	cg12615879	chr12:58013172	SLC26A10	0.51	6.25	0.49	6.12e-9	Multiple sclerosis;
TGCT	cis	rs1401999	1.000	rs4148575	chr3:183702275	A/G	cg01324343	chr3:183735012	ABCC5	0.82	10.56	0.69	5.39e-19	Anterior chamber depth;
TGCT	cis	rs4711350	1.000	rs2182659	chr6:33751767	A/G	cg18005901	chr6:33739558	LEMD2	-0.55	-5.89	-0.47	3.39e-8	Schizophrenia;
TGCT	cis	rs9788682	0.747	rs8042494	chr15:78908010	C/T	cg24631222	chr15:78858424	CHRNA5	0.83	6.21	0.49	7.37e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs9549367	0.756	rs2316463	chr13:113901406	C/T	cg00898013	chr13:113819073	PROZ	-0.41	-5.06	-0.41	1.46e-6	Platelet distribution width;
TGCT	cis	rs77741769	0.529	rs2047568	chr12:121243790	A/G	cg25946681	chr12:120654588	PXN	0.19	4.45	0.37	1.85e-5	Mean corpuscular volume;
TGCT	cis	rs2066819	1.000	rs76745316	chr12:56627652	A/C	cg26714650	chr12:56694279	CS	-1.42	-5.7	-0.46	8.43e-8	Psoriasis vulgaris;
TGCT	cis	rs3733585	0.673	rs4455410	chr4:9953297	C/T	cg11266682	chr4:10021025	SLC2A9	0.55	7.36	0.55	2.27e-11	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs782590	0.902	rs782602	chr2:55849309	A/G	cg03859395	chr2:55845619	SMEK2	0.87	10.47	0.68	9.16e-19	Metabolic syndrome;
TGCT	cis	rs9549367	0.789	rs12869947	chr13:113896156	A/G	cg00898013	chr13:113819073	PROZ	-0.41	-5.11	-0.42	1.17e-6	Platelet distribution width;
TGCT	cis	rs9733	0.596	rs72702557	chr1:150680130	A/G	cg09365446	chr1:150670422	GOLPH3L	0.3	4.52	0.38	1.4e-5	Tonsillectomy;
TGCT	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	5.49	0.44	2.14e-7	Menopause (age at onset);
TGCT	trans	rs877282	0.853	rs12779017	chr10:763619	T/C	cg22713356	chr15:30763199	NA	1.2	9.39	0.64	3.76e-16	Uric acid levels;
TGCT	cis	rs7727544	0.654	rs4705849	chr5:131559199	T/A	cg24060327	chr5:131705240	SLC22A5	-0.54	-5.1	-0.42	1.23e-6	Blood metabolite levels;
TGCT	cis	rs1541995	1.000	rs34636500	chr15:96353983	T/A	cg00882281	chr15:96346592	NA	0.29	4.76	0.39	5.31e-6	Photic sneeze reflex;
TGCT	cis	rs6978712	1.000	rs79045902	chr7:127147127	A/G	cg01017541	chr7:127776461	NA	0.76	4.6	0.38	1.01e-5	Medication adherence in chronic diseases;
TGCT	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg13395646	chr4:1353034	KIAA1530	-0.36	-4.57	-0.38	1.14e-5	Obesity-related traits;
TGCT	trans	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg17830980	chr10:43048298	ZNF37B	-0.86	-11.18	-0.71	1.68e-20	Extrinsic epigenetic age acceleration;
TGCT	cis	rs17221829	0.703	rs7944552	chr11:89377208	C/T	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.63	-0.38	9.04e-6	Anxiety in major depressive disorder;
TGCT	cis	rs925228	0.504	rs7568176	chr2:24313758	T/A	cg01493198	chr2:24299560	SF3B14	0.73	4.75	0.39	5.43e-6	Reticulocyte fraction of red cells;Reticulocyte count;
TGCT	cis	rs7552404	1.000	rs7518038	chr1:76154430	G/A	cg22875332	chr1:76189707	ACADM	0.79	9.71	0.66	6.51e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.44	6.72	0.52	5.79e-10	Schizophrenia;
TGCT	cis	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg18252515	chr7:66147081	NA	1.25	7.75	0.57	2.92e-12	Diabetic kidney disease;
TGCT	cis	rs965469	0.895	rs6051844	chr20:3402674	G/T	cg14326260	chr20:3913389	RNF24	0.29	4.54	0.38	1.32e-5	IFN-related cytopenia;
TGCT	cis	rs1865760	0.929	rs2876693	chr6:25954434	C/G	cg16482183	chr6:26056742	HIST1H1C	0.5	4.45	0.37	1.9e-5	Height;
TGCT	cis	rs11153730	0.503	rs283066	chr6:118620064	A/G	cg21191810	chr6:118973309	C6orf204	0.27	4.53	0.38	1.36e-5	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
TGCT	cis	rs4319547	0.695	rs55834409	chr12:122862560	C/G	cg05707623	chr12:122985044	ZCCHC8	0.62	4.87	0.4	3.32e-6	Body mass index;
TGCT	cis	rs10992471	0.603	rs12341817	chr9:95252152	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.6	-5.47	-0.44	2.4e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg01084871	chr4:1340883	KIAA1530	0.66	5.02	0.41	1.73e-6	Longevity;
TGCT	cis	rs41271473	0.526	rs72765760	chr1:228743222	G/A	cg16512390	chr1:228756714	NA	0.72	4.46	0.37	1.85e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	5.71	0.46	8.05e-8	Alzheimer's disease;
TGCT	cis	rs2637266	0.703	rs11001861	chr10:78473552	A/C	cg18941641	chr10:78392320	NA	0.4	4.8	0.4	4.52e-6	Pulmonary function;
TGCT	cis	rs12220898	0.749	rs3996894	chr10:50484369	G/A	cg09603381	chr10:49954066	WDFY4	0.38	4.45	0.37	1.88e-5	Inflammatory biomarkers;
TGCT	cis	rs41271473	0.519	rs9660783	chr1:228886880	C/T	cg10167378	chr1:228756711	NA	0.56	4.65	0.39	8.27e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs17345786	0.906	rs58835747	chr3:101243634	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.85	8.64	0.61	2.38e-14	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg03188948	chr7:1209495	NA	0.42	5.52	0.44	1.89e-7	Longevity;Endometriosis;
TGCT	cis	rs6088590	0.648	rs6058105	chr20:33271719	C/T	cg08999081	chr20:33150536	PIGU	0.24	4.63	0.38	9.14e-6	Coronary artery disease;
TGCT	cis	rs9467773	0.620	rs2494692	chr6:26615223	G/A	cg02458000	chr6:26745757	NA	0.55	5.29	0.43	5.31e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9467773	0.967	rs6924865	chr6:26521353	A/G	cg26531700	chr6:26746687	NA	0.47	4.57	0.38	1.14e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.75	5.41	0.44	3.09e-7	Platelet count;
TGCT	cis	rs71435601	0.628	rs312970	chr2:21369815	A/T	cg25035485	chr2:21266500	APOB	0.49	4.45	0.37	1.92e-5	Cholesterol, total;
TGCT	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg20203395	chr5:56204925	C5orf35	-0.57	-5.03	-0.41	1.69e-6	Initial pursuit acceleration;
TGCT	cis	rs250677	0.522	rs891920	chr5:148369418	G/T	cg18129178	chr5:148520854	ABLIM3	-0.36	-4.69	-0.39	7.23e-6	Breast cancer;
TGCT	cis	rs10782582	0.609	rs5745543	chr1:76365111	A/T	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.52	4.48	0.37	1.66e-5	Daytime sleep phenotypes;
TGCT	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg11890956	chr21:40555474	PSMG1	1.1	12.31	0.74	2.99e-23	Cognitive function;
TGCT	cis	rs9393777	0.513	rs7740197	chr6:26663478	C/T	cg06675483	chr6:26987649	LOC100270746;C6orf41	0.51	4.76	0.39	5.25e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2742417	1.000	rs2742389	chr3:45756683	G/C	cg04837898	chr3:45731254	SACM1L	-0.52	-5.28	-0.43	5.58e-7	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs17376456	0.825	rs10476590	chr5:93244884	A/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.74	4.89	0.4	3.12e-6	Diabetic retinopathy;
TGCT	cis	rs9303401	0.659	rs8074016	chr17:56840587	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs73198271	0.843	rs11775888	chr8:8605698	G/C	ch.8.214553F	chr8:8189620	PRAGMIN	-0.27	-4.73	-0.39	5.95e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs4455778	0.538	rs6583514	chr7:49123556	T/C	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs3858526	0.508	rs10838734	chr11:5876325	T/G	cg05234568	chr11:5960015	NA	-0.47	-4.62	-0.38	9.49e-6	DNA methylation (variation);
TGCT	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg13665807	chr20:60559372	TAF4	-0.46	-4.9	-0.4	2.87e-6	Body mass index;
TGCT	cis	rs3096299	0.679	rs3096322	chr16:89441123	A/G	cg06640241	chr16:89574553	SPG7	-0.63	-5.69	-0.46	8.46e-8	Multiple myeloma (IgH translocation);
TGCT	cis	rs68170813	0.652	rs6958969	chr7:107197755	A/T	cg02696742	chr7:106810147	HBP1	-0.59	-4.71	-0.39	6.61e-6	Coronary artery disease;
TGCT	cis	rs7605378	0.528	rs1704191	chr2:200816393	C/A	cg23649088	chr2:200775458	C2orf69	0.47	10.04	0.67	9.98e-18	Osteoporosis;
TGCT	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg20203395	chr5:56204925	C5orf35	-0.59	-5.12	-0.42	1.12e-6	Initial pursuit acceleration;
TGCT	cis	rs7552404	0.727	rs7547056	chr1:76279267	C/T	cg22875332	chr1:76189707	ACADM	0.64	6.9	0.53	2.32e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs3125734	0.633	rs4979772	chr10:63967600	C/T	cg19640130	chr10:64028056	RTKN2	0.41	5.33	0.43	4.54e-7	Rheumatoid arthritis;
TGCT	cis	rs425277	0.565	rs61775448	chr1:2045376	A/G	cg03732007	chr1:2071316	PRKCZ	-0.24	-5.38	-0.44	3.57e-7	Height;
TGCT	cis	rs2382817	0.580	rs6756265	chr2:219095554	G/A	cg00012203	chr2:219082015	ARPC2	-0.81	-9.41	-0.65	3.47e-16	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs11578119	0.898	rs4363474	chr1:170382898	T/C	cg09767346	chr1:170501363	GORAB	-0.72	-5.72	-0.46	7.52e-8	Male-pattern baldness;
TGCT	cis	rs8141529	0.778	rs763073	chr22:29215542	G/A	cg02153584	chr22:29168773	CCDC117	0.62	5.52	0.44	1.92e-7	Lymphocyte counts;
TGCT	cis	rs12291225	0.585	rs11023194	chr11:14369769	T/C	cg19336497	chr11:14380999	RRAS2	-0.45	-7.26	-0.55	3.67e-11	Sense of smell;
TGCT	cis	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg25427524	chr10:38739819	LOC399744	0.38	7.67	0.57	4.25e-12	Extrinsic epigenetic age acceleration;
TGCT	cis	rs11148252	0.508	rs6561671	chr13:53182314	G/A	cg00495681	chr13:53174319	NA	0.6	5.91	0.47	3.06e-8	Lewy body disease;
TGCT	cis	rs1682825	0.858	rs6795031	chr3:10763012	C/T	cg23512531	chr3:10780469	NA	-0.64	-4.85	-0.4	3.67e-6	Economic and political preferences (feminism/equality);
TGCT	cis	rs4819052	1.000	rs2297284	chr21:46705345	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.73	5.09	0.42	1.28e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs3087591	0.690	rs12103621	chr17:29607235	T/A	cg24425628	chr17:29625626	OMG;NF1	-0.45	-6.52	-0.51	1.62e-9	Hip circumference;
TGCT	cis	rs2277425	0.755	rs2277424	chr13:111522420	A/G	cg04513422	chr13:111522314	C13orf29	-0.56	-7.43	-0.56	1.52e-11	Sitting height ratio;
TGCT	cis	rs2880765	0.835	rs7174323	chr15:86049719	A/C	cg13263323	chr15:86062960	AKAP13	-0.23	-4.82	-0.4	4.1e-6	Coronary artery disease;
TGCT	cis	rs524023	1.000	rs10792441	chr11:64360629	C/T	cg07733098	chr11:64478343	NRXN2	0.31	4.66	0.39	8.01e-6	Urate levels in obese individuals;
TGCT	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg21724239	chr8:58056113	NA	0.41	4.87	0.4	3.33e-6	Developmental language disorder (linguistic errors);
TGCT	trans	rs1814175	0.586	rs2866862	chr11:49954588	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.67	-0.69	2.92e-19	Height;
TGCT	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg23156509	chr2:114033830	PAX8;LOC440839	-0.31	-4.83	-0.4	3.92e-6	Lymphocyte counts;
TGCT	cis	rs4727027	0.754	rs917124	chr7:148851213	C/T	cg23583168	chr7:148888333	NA	-0.69	-7.8	-0.57	2.21e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs9787249	0.957	rs12074147	chr1:40203722	T/C	cg19912559	chr1:40204330	PPIE	0.47	5.42	0.44	2.96e-7	Blood protein levels;
TGCT	cis	rs1865760	0.566	rs9358904	chr6:26068566	C/T	cg17042849	chr6:26104293	HIST1H4C	-0.61	-5.21	-0.42	7.74e-7	Height;
TGCT	cis	rs10754283	0.967	rs10801763	chr1:90120822	C/T	cg03145924	chr1:90228473	NA	-0.4	-4.52	-0.38	1.4e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs41271951	0.512	rs77306500	chr1:151080096	G/C	cg00666978	chr1:150947442	LASS2	0.89	4.64	0.38	8.54e-6	Blood protein levels;
TGCT	cis	rs1801251	1.000	rs6747645	chr2:233571033	C/T	cg25237894	chr2:233734115	C2orf82	-0.29	-5.23	-0.42	7.13e-7	Coronary artery disease;
TGCT	cis	rs2730260	0.537	rs3793223	chr7:158863574	C/A	cg02078164	chr7:157982224	PTPRN2	0.42	4.67	0.39	7.79e-6	Myopia (pathological);
TGCT	cis	rs7172809	0.573	rs58792939	chr15:77548113	C/G	cg22256960	chr15:77711686	NA	-0.48	-4.67	-0.39	7.76e-6	Glucose homeostasis traits;
TGCT	cis	rs72781680	0.799	rs2712084	chr2:24003051	A/G	cg08917208	chr2:24149416	ATAD2B	0.79	4.94	0.41	2.51e-6	Lymphocyte counts;
TGCT	cis	rs6987853	0.814	rs2923415	chr8:42455577	A/G	cg20539142	chr8:42623718	CHRNA6	-0.2	-5.03	-0.41	1.7e-6	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs6840360	0.615	rs12641438	chr4:152607586	A/G	cg22705602	chr4:152727874	NA	-0.32	-5.41	-0.44	3.12e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs28595532	0.920	rs55668908	chr4:119769799	C/T	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs921968	0.643	rs590771	chr2:219369851	C/T	cg02176678	chr2:219576539	TTLL4	0.44	6.33	0.49	4.17e-9	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs113577745	0.623	rs73913932	chr2:10094526	A/G	cg17603321	chr2:9696605	ADAM17	-1.08	-4.74	-0.39	5.79e-6	Breast cancer;
TGCT	cis	rs151997	1.000	rs152690	chr5:50213584	A/T	cg06027927	chr5:50259733	NA	0.47	4.83	0.4	3.9e-6	Callous-unemotional behaviour;
TGCT	cis	rs36051895	0.664	rs10974963	chr9:5101305	G/A	cg02405213	chr9:5042618	JAK2	-0.71	-9.43	-0.65	3.07e-16	Pediatric autoimmune diseases;
TGCT	cis	rs9611565	0.569	rs6002328	chr22:41710034	T/C	cg06634786	chr22:41940651	POLR3H	-0.58	-5.28	-0.43	5.62e-7	Vitiligo;
TGCT	cis	rs733175	0.857	rs10018663	chr4:10004797	C/T	cg11266682	chr4:10021025	SLC2A9	0.52	4.5	0.37	1.55e-5	Psychosis and Alzheimer's disease;
TGCT	cis	rs9921338	0.923	rs6498181	chr16:11427193	C/T	cg00044050	chr16:11439710	C16orf75	-0.91	-7.07	-0.54	1.01e-10	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs4987668	0.786	rs4252383	chr7:142629241	T/C	cg21621906	chr7:142494914	NA	-0.9	-4.62	-0.38	9.48e-6	Cancer;
TGCT	cis	rs13096760	1	rs13096760	chr3:49476806	T/C	cg03060546	chr3:49711283	APEH	0.76	8.69	0.62	1.77e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs12549902	0.966	rs12544241	chr8:41514888	G/A	cg00088007	chr8:41504566	NKX6-3	0.34	5.31	0.43	4.93e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
TGCT	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.75	0.52	5.11e-10	Bipolar disorder;
TGCT	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.58	-5.34	-0.43	4.21e-7	Prudent dietary pattern;
TGCT	cis	rs17345786	1.000	rs3762729	chr3:101308874	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.45	-9.65	-0.65	8.81e-17	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7246657	0.524	rs28542490	chr19:37456584	C/A	cg18154014	chr19:37997991	ZNF793	0.73	4.6	0.38	1.04e-5	Coronary artery calcification;
TGCT	trans	rs1496653	0.602	rs34894979	chr3:23475386	G/A	cg02770683	chr12:57597238	LRP1	0.38	6.89	0.53	2.53e-10	Type 2 diabetes;
TGCT	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg13770153	chr20:60521292	NA	-0.62	-7.94	-0.58	1.02e-12	Body mass index;
TGCT	cis	rs1865760	0.623	rs12216125	chr6:25997458	C/T	cg17691542	chr6:26056736	HIST1H1C	0.64	5.25	0.43	6.45e-7	Height;
TGCT	cis	rs2996428	0.667	rs2368534	chr1:3740640	C/T	cg17848003	chr1:3704513	LRRC47	0.19	5.01	0.41	1.82e-6	Red cell distribution width;
TGCT	cis	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg18252515	chr7:66147081	NA	1.31	8.18	0.59	2.87e-13	Diabetic kidney disease;
TGCT	cis	rs2243480	0.522	rs73150635	chr7:65972490	C/T	cg18252515	chr7:66147081	NA	-1.08	-6.3	-0.49	4.68e-9	Diabetic kidney disease;
TGCT	cis	rs2235642	0.928	rs56289115	chr16:1608934	A/G	cg08296037	chr16:1584118	IFT140;TMEM204	-0.3	-5.34	-0.43	4.26e-7	Coronary artery disease;
TGCT	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	6.53	0.51	1.54e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2013441	1.000	rs2263175	chr17:20128029	C/G	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.61	-0.38	9.96e-6	Obesity-related traits;
TGCT	cis	rs9393692	0.905	rs1125000	chr6:26287256	C/T	cg05868516	chr6:26286170	HIST1H4H	0.61	5.84	0.46	4.31e-8	Educational attainment;
TGCT	cis	rs28595532	0.920	rs114940990	chr4:119758568	A/G	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs9653442	0.545	rs12987212	chr2:100761156	C/T	cg22139774	chr2:100720529	AFF3	-0.36	-5.72	-0.46	7.68e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs1801251	0.929	rs12694917	chr2:233707611	C/T	cg25237894	chr2:233734115	C2orf82	-0.31	-5.44	-0.44	2.75e-7	Coronary artery disease;
TGCT	cis	rs1401999	0.690	rs6768149	chr3:183636195	T/C	cg01324343	chr3:183735012	ABCC5	0.69	8.13	0.59	3.77e-13	Anterior chamber depth;
TGCT	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg18305652	chr10:134549665	INPP5A	0.31	4.93	0.4	2.61e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs6993244	1	rs6993244	chr8:8863059	C/G	cg06636001	chr8:8085503	FLJ10661	0.78	6.97	0.53	1.62e-10	Mean corpuscular hemoglobin;
TGCT	trans	rs941408	1.000	rs1640273	chr19:2803227	C/T	cg19676328	chr12:49525230	TUBA1B	-0.7	-6.66	-0.51	8.07e-10	Total cholesterol levels;
TGCT	cis	rs4642101	0.662	rs9874893	chr3:12833079	C/G	cg05775895	chr3:12838266	CAND2	0.89	9.71	0.66	6.47e-17	QRS complex (12-leadsum);
TGCT	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg21285383	chr16:89894308	SPIRE2	0.48	7.49	0.56	1.12e-11	Vitiligo;
TGCT	cis	rs7772486	0.754	rs864148	chr6:145976675	T/C	cg05347473	chr6:146136440	FBXO30	-0.52	-4.85	-0.4	3.62e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6882046	0.513	rs587490	chr5:88032522	C/T	cg24804195	chr5:87968844	LOC645323	-0.59	-5.9	-0.47	3.31e-8	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg27588902	chr6:42928151	GNMT	-0.4	-4.99	-0.41	1.99e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs7666738	0.830	rs13138920	chr4:99020786	A/G	cg05340658	chr4:99064831	C4orf37	0.48	5.43	0.44	2.92e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs56334439	0.764	rs9852879	chr3:60098201	A/C	cg17894779	chr3:60066405	FHIT	-0.35	-4.81	-0.4	4.3e-6	Myringotomy;
TGCT	cis	rs986417	0.901	rs1884098	chr14:61038944	A/T	cg27398547	chr14:60952738	C14orf39	1.48	10.7	0.69	2.57e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs2933343	0.729	rs813732	chr3:128619357	C/T	cg11901034	chr3:128598214	ACAD9	-0.66	-6.56	-0.51	1.33e-9	IgG glycosylation;
TGCT	cis	rs1729951	0.575	rs12494558	chr3:136678781	C/G	cg12473912	chr3:136751656	NA	0.39	6.18	0.49	8.36e-9	Neuroticism;
TGCT	cis	rs903263	0.965	rs2134648	chr1:84662941	C/T	cg09664975	chr1:84543551	PRKACB	0.48	4.54	0.38	1.31e-5	Breast cancer (male);
TGCT	cis	rs854765	0.624	rs7359509	chr17:17741875	A/G	cg09796270	chr17:17721594	SREBF1	-0.27	-5.19	-0.42	8.39e-7	Total body bone mineral density;
TGCT	cis	rs2180341	0.960	rs1543432	chr6:127698018	T/C	cg27446573	chr6:127587934	RNF146	1.16	10.52	0.69	6.95e-19	Breast cancer;
TGCT	cis	rs12210905	0.688	rs72841397	chr6:27488423	C/A	cg08851530	chr6:28072375	NA	1.32	6.02	0.48	1.85e-8	Hip circumference adjusted for BMI;
TGCT	cis	rs9549260	0.640	rs4943796	chr13:41196016	C/T	cg21288729	chr13:41239152	FOXO1	1.0	10.23	0.68	3.52e-18	Red blood cell count;
TGCT	cis	rs10464366	0.746	rs62442210	chr7:39146328	G/T	cg15212455	chr7:39170539	POU6F2	0.26	5.9	0.47	3.21e-8	IgG glycosylation;
TGCT	cis	rs11785400	0.731	rs4736363	chr8:143742112	C/A	cg24634471	chr8:143751801	JRK	0.55	5.51	0.44	1.99e-7	Schizophrenia;
TGCT	cis	rs2730260	0.537	rs56260213	chr7:158875921	C/T	cg02078164	chr7:157982224	PTPRN2	0.41	4.58	0.38	1.11e-5	Myopia (pathological);
TGCT	cis	rs7224685	0.569	rs34356467	chr17:3978531	G/T	cg09580393	chr17:4869866	SPAG7	-0.39	-4.5	-0.37	1.56e-5	Type 2 diabetes;
TGCT	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg13732083	chr21:47605072	C21orf56	0.34	4.6	0.38	1.02e-5	Testicular germ cell tumor;
TGCT	cis	rs59107033	0.607	rs57572875	chr3:123126268	T/C	cg04890266	chr3:123102914	ADCY5	-0.39	-5.79	-0.46	5.33e-8	Lymphocyte counts;
TGCT	cis	rs6163	0.727	rs284862	chr10:104572081	C/T	cg04362960	chr10:104952993	NT5C2	-0.52	-4.55	-0.38	1.26e-5	Waist circumference;Hip circumference;
TGCT	cis	rs7833790	0.724	rs72603871	chr8:82754460	C/G	cg17211192	chr8:82754475	SNX16	0.97	9.09	0.63	2.04e-15	Diastolic blood pressure;
TGCT	cis	rs7845219	0.544	rs10956930	chr8:95919786	C/G	cg13393036	chr8:95962371	TP53INP1	-0.44	-5.14	-0.42	1.05e-6	Type 2 diabetes;
TGCT	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg20573242	chr4:122745356	CCNA2	0.64	5.76	0.46	6.37e-8	Type 2 diabetes;
TGCT	cis	rs9583531	0.660	rs80030913	chr13:111336866	G/C	cg15747390	chr13:111297551	CARS2	0.88	5.97	0.47	2.32e-8	Coronary artery disease;
TGCT	cis	rs7772486	0.754	rs702324	chr6:146008793	A/G	cg05347473	chr6:146136440	FBXO30	-0.53	-4.86	-0.4	3.42e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4664308	0.870	rs2305818	chr2:161029218	G/A	cg03641300	chr2:160917029	PLA2R1	-0.28	-6.9	-0.53	2.38e-10	Idiopathic membranous nephropathy;
TGCT	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg23982607	chr1:1823379	GNB1	-0.35	-4.61	-0.38	9.8e-6	Body mass index;
TGCT	cis	rs4851266	0.966	rs4851270	chr2:100832656	T/C	cg07810366	chr2:100720526	AFF3	-0.37	-5.33	-0.43	4.53e-7	Educational attainment;
TGCT	cis	rs2204008	0.652	rs11520002	chr12:38022179	G/T	cg26384229	chr12:38710491	ALG10B	0.85	7.63	0.57	5.5e-12	Bladder cancer;
TGCT	cis	rs17270561	1.000	rs12211184	chr6:25823774	G/A	cg17691542	chr6:26056736	HIST1H1C	0.78	4.78	0.39	4.87e-6	Iron status biomarkers;
TGCT	cis	rs12762955	0.561	rs10752022	chr10:1043798	C/T	cg18964960	chr10:1102726	WDR37	-0.69	-6.08	-0.48	1.35e-8	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs28595532	0.920	rs17323034	chr4:119606518	G/A	cg14228332	chr4:119757509	SEC24D	1.0	5.76	0.46	6.22e-8	Cannabis dependence symptom count;
TGCT	cis	rs1933488	0.835	rs9371280	chr6:153414273	T/C	cg24028809	chr6:153414101	RGS17	0.21	4.67	0.39	7.69e-6	Prostate cancer;
TGCT	cis	rs2692947	0.696	rs1724121	chr2:96808549	T/C	cg23100626	chr2:96804247	ASTL	0.44	5.45	0.44	2.57e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs1371867	0.846	rs1788182	chr8:101334620	C/T	cg06002616	chr8:101225028	SPAG1	-0.53	-6.21	-0.49	7.16e-9	Atrioventricular conduction;
TGCT	trans	rs10506458	0.688	rs73127095	chr12:63418283	T/G	cg22491629	chr6:157744540	C6orf35	-0.8	-6.96	-0.53	1.72e-10	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs3784262	0.669	rs4646592	chr15:58302557	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.42	-6.17	-0.48	8.83e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs727563	0.638	rs4820443	chr22:42193913	A/G	cg06481639	chr22:41940642	POLR3H	-0.67	-5.95	-0.47	2.57e-8	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs7666738	0.791	rs62318641	chr4:98816964	T/C	cg05340658	chr4:99064831	C4orf37	0.51	6.03	0.48	1.76e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3617	0.625	rs11715347	chr3:52883070	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	0.49	4.77	0.39	5.04e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg01570182	chr17:44337453	NA	1.07	9.81	0.66	3.57e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7666738	0.753	rs35146453	chr4:98902278	A/G	cg18180107	chr4:99064573	C4orf37	0.53	4.81	0.4	4.23e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1971762	0.542	rs12303370	chr12:54091807	A/C	cg16917193	chr12:54089295	NA	1.27	16.81	0.83	9.11e-34	Height;
TGCT	cis	rs11098499	0.954	rs10008459	chr4:120394231	T/C	cg09307838	chr4:120376055	NA	0.68	6.37	0.5	3.41e-9	Corneal astigmatism;
TGCT	cis	rs3733585	0.699	rs6449176	chr4:9967843	G/A	cg11266682	chr4:10021025	SLC2A9	-0.59	-7.85	-0.58	1.7e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs9883204	0.951	rs6794202	chr3:123093887	C/T	cg04890266	chr3:123102914	ADCY5	0.36	5.08	0.42	1.34e-6	Birth weight;
TGCT	cis	rs854765	0.647	rs712267	chr17:18021607	G/A	cg04398451	chr17:18023971	MYO15A	-0.39	-6.75	-0.52	5e-10	Total body bone mineral density;
TGCT	cis	rs67311347	1.000	rs28707772	chr3:40504666	G/A	cg13409248	chr3:40428643	ENTPD3	0.56	4.45	0.37	1.91e-5	Renal cell carcinoma;
TGCT	cis	rs2239547	0.603	rs71301807	chr3:53085475	C/G	cg11645453	chr3:52864694	ITIH4	0.3	4.8	0.4	4.47e-6	Schizophrenia;
TGCT	cis	rs4253772	0.591	rs6519993	chr22:46656479	A/G	cg09491104	chr22:46646882	C22orf40	-0.63	-6.39	-0.5	3.05e-9	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs2836950	0.585	rs1029004	chr21:40615343	A/G	cg06238570	chr21:40685208	BRWD1	-0.6	-6.31	-0.49	4.57e-9	Menarche (age at onset);
TGCT	cis	rs13008689	0.875	rs12616139	chr2:8522651	C/T	cg11358199	chr2:8453529	NA	0.28	4.61	0.38	1.01e-5	Longevity;
TGCT	cis	rs9357506	1.000	rs6910987	chr6:46307619	A/G	cg21115430	chr6:46460003	NA	-0.26	-5.17	-0.42	9.2e-7	Body mass index;
TGCT	trans	rs11088226	0.681	rs16989507	chr21:33939509	T/G	cg09050820	chr6:167586206	TCP10L2	0.79	7.04	0.53	1.13e-10	Gastritis;
TGCT	cis	rs12908161	1.000	rs17601029	chr15:85347709	A/G	cg12863693	chr15:85201151	NMB	0.42	5.03	0.41	1.7e-6	Schizophrenia;
TGCT	cis	rs9858542	0.953	rs67216675	chr3:49493151	G/T	cg03060546	chr3:49711283	APEH	-0.61	-5.37	-0.43	3.78e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg08564027	chr20:61660810	NA	0.37	6.65	0.51	8.49e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs988712	0.705	rs4923457	chr11:27648580	A/T	cg10635145	chr11:27742435	BDNF	-0.38	-5.23	-0.43	7e-7	Obesity;
TGCT	cis	rs56104184	0.615	rs73061693	chr19:49399941	C/A	cg21252483	chr19:49399788	TULP2	-0.42	-5.89	-0.47	3.47e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs2288884	1.000	rs17835749	chr19:52578695	C/G	cg13540795	chr19:52551618	ZNF432	-0.59	-5.02	-0.41	1.79e-6	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg11845111	chr2:191398756	TMEM194B	0.36	5.51	0.44	1.97e-7	Pulse pressure;
TGCT	trans	rs1496653	0.602	rs13090125	chr3:23581248	G/A	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs1568889	1.000	rs7933332	chr11:28036392	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	8.94	0.63	4.66e-15	Bipolar disorder;
TGCT	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	4.9	0.4	2.99e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs76788097	0.614	rs7151034	chr14:61820669	T/G	cg01084740	chr14:61748243	TMEM30B	-0.65	-4.64	-0.38	8.6e-6	Marginal zone lymphoma;
TGCT	cis	rs1552244	0.700	rs9833566	chr3:9981671	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-6.25	-0.49	6.15e-9	Alzheimer's disease;
TGCT	trans	rs1973993	0.967	rs10875017	chr1:96949526	C/T	cg10631902	chr5:14652156	NA	0.3	6.93	0.53	2.08e-10	Weight;
TGCT	cis	rs1171582	0.545	rs1877792	chr10:61520003	G/T	cg23572703	chr10:62241191	NA	-0.26	-4.46	-0.37	1.84e-5	Alopecia areata;
TGCT	cis	rs10823500	0.748	rs7072230	chr10:71978144	A/G	cg04118878	chr10:71993077	PPA1	0.57	5.25	0.43	6.25e-7	Blood protein levels;
TGCT	cis	rs7786808	0.615	rs1563066	chr7:158194935	A/C	cg01191920	chr7:158217561	PTPRN2	-0.41	-6.14	-0.48	1.03e-8	Obesity-related traits;
TGCT	cis	rs12360000	0.864	rs11250837	chr10:1901013	C/T	cg26364871	chr10:1889757	NA	0.41	4.64	0.38	8.81e-6	Metabolite levels (Dihydroxy docosatrienoic acid);
TGCT	cis	rs10893109	0.967	rs10736534	chr11:123807033	C/A	cg14126608	chr11:122846540	NA	-0.28	-4.58	-0.38	1.12e-5	Facial morphology (factor 13, vertical position of alar curvature relative to upper lip);
TGCT	cis	rs611744	0.647	rs631775	chr8:109252746	T/C	cg21045802	chr8:109455806	TTC35	0.72	7.28	0.55	3.32e-11	Dupuytren's disease;
TGCT	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7267979	1.000	rs2297497	chr20:25297909	C/T	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9325144	0.647	rs61937754	chr12:39060543	T/C	cg26384229	chr12:38710491	ALG10B	-0.56	-5.1	-0.42	1.25e-6	Morning vs. evening chronotype;
TGCT	cis	rs1894292	0.505	rs10938078	chr4:74375447	A/G	cg05868023	chr4:75230803	EREG	-0.54	-4.95	-0.41	2.35e-6	Prostate cancer;
TGCT	cis	rs151997	0.671	rs152099	chr5:50210091	A/G	cg06027927	chr5:50259733	NA	0.56	5.64	0.45	1.11e-7	Callous-unemotional behaviour;
TGCT	cis	rs17376456	0.825	rs13361613	chr5:93272176	C/T	cg25358565	chr5:93447407	FAM172A	1.02	8.11	0.59	4.23e-13	Diabetic retinopathy;
TGCT	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.36	0.55	2.25e-11	Prudent dietary pattern;
TGCT	cis	rs7172809	0.573	rs12324366	chr15:77547102	G/C	cg22256960	chr15:77711686	NA	-0.47	-4.61	-0.38	9.99e-6	Glucose homeostasis traits;
TGCT	cis	rs56116382	0.604	rs9858428	chr3:49877585	G/T	cg00383909	chr3:49044727	WDR6	1.27	6.28	0.49	5.15e-9	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
TGCT	trans	rs916888	0.647	rs199524	chr17:44848438	G/T	cg10053473	chr17:62856997	LRRC37A3	0.4	6.73	0.52	5.74e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs1018836	0.923	rs2213886	chr8:91554163	G/C	cg16814680	chr8:91681699	NA	-0.89	-9.81	-0.66	3.73e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg10047753	chr17:41438598	NA	0.97	9.99	0.67	1.37e-17	Menopause (age at onset);
TGCT	cis	rs910316	1.000	rs2098297	chr14:75619118	G/T	cg08847533	chr14:75593920	NEK9	-0.97	-10.82	-0.7	1.28e-19	Height;
TGCT	cis	rs6025261	0.761	rs6099359	chr20:55509896	G/T	cg04763273	chr20:55502381	NA	-0.28	-4.45	-0.37	1.88e-5	Verbal memory performance (delayed recall level);
TGCT	cis	rs11030122	0.959	rs7118295	chr11:3903103	T/C	cg18678763	chr11:4115507	RRM1	-0.39	-4.48	-0.37	1.66e-5	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs910316	0.712	rs175037	chr14:75465038	T/C	cg11812906	chr14:75593930	NEK9	-0.59	-5.69	-0.45	8.84e-8	Height;
TGCT	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg23758822	chr17:41437982	NA	0.69	6.37	0.5	3.34e-9	Menopause (age at onset);
TGCT	cis	rs7412746	0.658	rs11204739	chr1:150865760	A/G	cg04414720	chr1:150670196	GOLPH3L	0.37	4.5	0.37	1.53e-5	Melanoma;
TGCT	cis	rs9858542	0.537	rs4410472	chr3:49329090	A/T	cg00383909	chr3:49044727	WDR6	0.65	4.44	0.37	1.97e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs7178424	0.875	rs28513564	chr15:62232360	C/T	cg00456672	chr15:62358751	C2CD4A	-0.3	-4.48	-0.37	1.69e-5	Height;
TGCT	trans	rs3780486	0.846	rs10971419	chr9:33124161	T/C	cg20290983	chr6:43655470	MRPS18A	1.18	14.81	0.8	3.33e-29	IgG glycosylation;
TGCT	cis	rs7772486	0.754	rs2328707	chr6:146053498	G/A	cg13319975	chr6:146136371	FBXO30	0.56	5.0	0.41	1.9e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10089	1.000	rs3792866	chr5:127479900	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	7.31	0.55	2.9100000000000002e-11	Ileal carcinoids;
TGCT	cis	rs2014572	0.967	rs11084492	chr19:57756026	A/T	cg24459738	chr19:57751996	ZNF805	-0.54	-5.4	-0.44	3.21e-7	Hyperactive-impulsive symptoms;
TGCT	trans	rs727979	1.000	rs34429158	chr6:149605712	G/A	cg00895196	chr6:22147182	FLJ22536	0.41	6.69	0.51	6.9e-10	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs682748	0.844	rs297206	chr5:17126682	G/A	cg23987134	chr5:17158319	LOC285696	-0.19	-4.44	-0.37	1.97e-5	Hippocampal atrophy;
TGCT	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.67	5.25	0.43	6.3e-7	Lung function (FEV1/FVC);
TGCT	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.54	-5.22	-0.42	7.39e-7	Bipolar disorder;
TGCT	trans	rs17684571	0.938	rs4074101	chr6:56562452	G/A	cg14229071	chr15:89282588	NA	0.52	6.82	0.52	3.54e-10	Schizophrenia;
TGCT	cis	rs9790314	0.905	rs4518145	chr3:160950030	T/C	cg03342759	chr3:160939853	NMD3	-0.42	-4.51	-0.38	1.5e-5	Morning vs. evening chronotype;
TGCT	cis	rs7226408	0.857	rs8094856	chr18:34548299	G/A	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs929354	0.806	rs28446734	chr7:156996775	T/C	cg05182265	chr7:156933206	UBE3C	-0.38	-8.59	-0.61	3.18e-14	Body mass index;
TGCT	cis	rs12681287	0.752	rs7822268	chr8:87306440	G/T	cg27223183	chr8:87520930	FAM82B	-0.85	-6.4	-0.5	2.9e-9	Caudate activity during reward;
TGCT	cis	rs6665290	0.935	rs1929864	chr1:227195500	T/G	cg10327440	chr1:227177885	CDC42BPA	-0.99	-20.13	-0.88	6.85e-41	Myeloid white cell count;
TGCT	cis	rs7772486	0.875	rs2814863	chr6:146347299	C/T	cg23711669	chr6:146136114	FBXO30	-0.87	-9.53	-0.65	1.75e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2251381	0.606	rs8129515	chr21:30520167	C/G	cg24692254	chr21:30365293	RNF160	0.69	6.71	0.52	6.16e-10	Selective IgA deficiency;
TGCT	cis	rs17221829	0.733	rs12283497	chr11:89357907	G/A	cg02982614	chr11:89391479	FOLH1B	-0.28	-4.87	-0.4	3.35e-6	Anxiety in major depressive disorder;
TGCT	cis	rs9921338	0.923	rs7186455	chr16:11427748	A/G	cg00044050	chr16:11439710	C16orf75	-0.93	-7.36	-0.55	2.27e-11	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs36051895	0.623	rs10118267	chr9:5243736	T/C	cg02405213	chr9:5042618	JAK2	-0.7	-8.33	-0.6	1.29e-13	Pediatric autoimmune diseases;
TGCT	cis	rs7429990	0.901	rs6442102	chr3:48152562	A/G	cg11946769	chr3:48343235	NME6	-0.56	-4.61	-0.38	9.72e-6	Educational attainment (years of education);
TGCT	cis	rs7666738	0.546	rs11097591	chr4:98910173	G/A	cg18180107	chr4:99064573	C4orf37	0.53	4.5	0.37	1.55e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs112591243	0.685	rs2839341	chr21:47990008	A/G	cg10657630	chr21:48055338	PRMT2	-1.0	-5.29	-0.43	5.4e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs7570971	0.500	rs13413101	chr2:135859371	A/T	cg07169764	chr2:136633963	MCM6	0.59	5.08	0.42	1.33e-6	Blood metabolite levels;Body mass index;Cholesterol, total;
TGCT	cis	rs7255045	0.742	rs10407116	chr19:12962272	G/A	cg23899408	chr19:12877188	HOOK2	-0.61	-4.99	-0.41	1.97e-6	Mean corpuscular volume;
TGCT	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs1857353	0.803	rs74089245	chr1:75901600	C/T	cg11838876	chr1:75668600	SLC44A5	-0.51	-4.81	-0.4	4.23e-6	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs17253792	0.822	rs10083499	chr14:56066590	T/A	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs3820068	0.581	rs1547031	chr1:15918960	G/A	cg05660106	chr1:15850417	CASP9	0.81	8.15	0.59	3.31e-13	Systolic blood pressure;
TGCT	cis	rs2204008	0.640	rs11520199	chr12:38211026	T/C	cg13010199	chr12:38710504	ALG10B	0.62	4.96	0.41	2.32e-6	Bladder cancer;
TGCT	cis	rs9814567	1.000	rs9834755	chr3:134206845	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.96	-9.19	-0.64	1.16e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg09165964	chr15:75287851	SCAMP5	0.51	4.65	0.39	8.33e-6	Breast cancer;
TGCT	cis	rs2153535	0.580	rs1855769	chr6:8473095	A/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs1008375	1.000	rs4698198	chr4:17656536	G/A	cg10189774	chr4:17578691	LAP3	0.57	5.15	0.42	9.95e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7647973	0.588	rs62262675	chr3:49673662	A/G	cg03034192	chr3:50606346	HEMK1;C3orf18	-0.36	-4.59	-0.38	1.08e-5	Menarche (age at onset);
TGCT	cis	rs9926296	0.715	rs467035	chr16:89740285	C/G	cg01097406	chr16:89675127	NA	-0.31	-5.59	-0.45	1.39e-7	Vitiligo;
TGCT	cis	rs7412746	0.658	rs59988025	chr1:150940358	C/T	cg09365446	chr1:150670422	GOLPH3L	0.34	4.72	0.39	6.28e-6	Melanoma;
TGCT	cis	rs6684514	1.000	rs10908495	chr1:156263940	T/C	cg16558208	chr1:156270281	VHLL	0.46	9.38	0.64	3.92e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs478304	0.654	rs11601509	chr11:65456864	T/C	cg27068330	chr11:65405492	SIPA1	-0.99	-11.36	-0.71	6.13e-21	Acne (severe);
TGCT	trans	rs9951602	0.512	rs1903722	chr18:76646539	G/A	cg02800362	chr5:177631904	HNRNPAB	1.14	13.02	0.76	6.04e-25	Obesity-related traits;
TGCT	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg03161606	chr19:29218774	NA	0.6	5.84	0.46	4.28e-8	Methadone dose in opioid dependence;
TGCT	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.46	4.71	0.39	6.56e-6	Lymphocyte counts;
TGCT	cis	rs1372520	0.623	rs2583975	chr4:90748488	T/C	cg20003494	chr4:90757398	SNCA	-0.59	-4.63	-0.38	9.21e-6	Neuroticism;
TGCT	cis	rs1691799	0.899	rs1168294	chr12:66733988	T/C	cg16791601	chr12:66731901	HELB	-0.28	-6.11	-0.48	1.19e-8	White blood cell count (basophil);
TGCT	cis	rs7089973	0.604	rs2420065	chr10:116583753	A/G	cg03647239	chr10:116582469	FAM160B1	0.58	5.63	0.45	1.16e-7	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.84	-8.92	-0.63	5.13e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs79349575	0.715	rs11657238	chr17:46985634	A/G	cg26022315	chr17:47021804	SNF8	0.54	5.37	0.43	3.73e-7	Type 2 diabetes;
TGCT	cis	rs644799	0.763	rs2950521	chr11:95536870	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	8.74	0.62	1.39e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs910316	0.967	rs2010678	chr14:75567178	C/T	cg08847533	chr14:75593920	NEK9	0.96	10.9	0.7	8.37e-20	Height;
TGCT	cis	rs61677309	1.000	rs1945765	chr11:118182829	T/A	cg11038285	chr11:118016290	SCN4B	-0.49	-4.52	-0.38	1.41e-5	Lung cancer in ever smokers;
TGCT	cis	rs2404602	0.692	rs36070630	chr15:76949259	T/C	cg22467129	chr15:76604101	ETFA	-0.45	-5.11	-0.42	1.17e-6	Blood metabolite levels;
TGCT	cis	rs7819412	0.511	rs35558344	chr8:11434232	C/T	cg21775007	chr8:11205619	TDH	-0.54	-5.13	-0.42	1.07e-6	Triglycerides;
TGCT	cis	rs4555082	1.000	rs4334224	chr14:105759198	C/T	cg10792982	chr14:105748885	BRF1	0.22	4.53	0.38	1.39e-5	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs7191700	0.511	rs12923756	chr16:11359675	C/T	cg00044050	chr16:11439710	C16orf75	-0.81	-8.38	-0.6	9.95e-14	Multiple sclerosis;
TGCT	cis	rs225245	0.791	rs720774	chr17:34017453	T/G	cg05299278	chr17:33885742	SLFN14	0.21	4.5	0.37	1.54e-5	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs62244186	0.711	rs6778410	chr3:44743993	C/T	cg04389838	chr3:44770851	ZNF501	-0.36	-4.73	-0.39	5.91e-6	Depressive symptoms;
TGCT	cis	rs7302981	0.900	rs836180	chr12:50503269	C/T	cg23855989	chr12:50355821	AQP5	0.3	4.44	0.37	2e-5	Systolic blood pressure;
TGCT	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg07167872	chr1:205819463	PM20D1	0.57	7.37	0.55	2.12e-11	Menarche (age at onset);
TGCT	cis	rs12950390	0.853	rs11655112	chr17:45856563	T/C	cg03474202	chr17:45855739	NA	-0.44	-4.51	-0.38	1.5e-5	IgG glycosylation;
TGCT	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg04234412	chr22:24373322	LOC391322	0.93	12.12	0.74	8.62e-23	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs10193935	0.892	rs12612372	chr2:42414035	A/G	cg27598129	chr2:42591480	NA	-0.39	-5.14	-0.42	1.05e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4919044	0.740	rs73319304	chr10:94777045	A/G	cg05127821	chr10:94822908	CYP26C1	-0.77	-5.03	-0.41	1.71e-6	Coronary artery disease;
TGCT	cis	rs9611519	0.929	rs4820423	chr22:41430338	A/T	cg13695892	chr22:41940480	POLR3H	-0.53	-4.62	-0.38	9.54e-6	Neuroticism;
TGCT	cis	rs9911578	1.000	rs437732	chr17:56675861	A/C	cg12560992	chr17:57184187	TRIM37	0.76	9.16	0.64	1.32e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs3892630	0.824	rs12327732	chr19:33221767	C/T	cg22980127	chr19:33182716	NUDT19	0.71	5.15	0.42	9.79e-7	Red blood cell traits;
TGCT	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.85	0.47	4.05e-8	Height;
TGCT	cis	rs9926296	0.632	rs4785716	chr16:89801127	T/C	cg26513180	chr16:89883248	FANCA	0.71	6.86	0.52	2.86e-10	Vitiligo;
TGCT	cis	rs3796352	1.000	rs11706035	chr3:53011868	A/T	cg07884673	chr3:53033167	SFMBT1	0.62	6.19	0.49	8.26e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs2066819	1.000	rs116535779	chr12:56739261	A/G	cg26714650	chr12:56694279	CS	-1.55	-8.12	-0.59	4e-13	Psoriasis vulgaris;
TGCT	cis	rs9527	0.615	rs7917295	chr10:104701187	A/G	cg04362960	chr10:104952993	NT5C2	0.64	5.4	0.44	3.33e-7	Arsenic metabolism;
TGCT	cis	rs910316	0.763	rs2080201	chr14:75629972	C/T	cg11812906	chr14:75593930	NEK9	-0.64	-5.91	-0.47	3.14e-8	Height;
TGCT	cis	rs644799	1.000	rs527899	chr11:95529242	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	8.74	0.62	1.39e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9814567	0.896	rs7642266	chr3:134346025	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-7.29	-0.55	3.14e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs736408	0.812	rs2071507	chr3:52826707	G/A	cg07507251	chr3:52567010	NT5DC2	0.41	5.62	0.45	1.2e-7	Bipolar disorder;
TGCT	cis	rs35306767	0.622	rs66462130	chr10:1022108	C/T	cg18964960	chr10:1102726	WDR37	0.74	5.25	0.43	6.39e-7	Eosinophil percentage of granulocytes;
TGCT	cis	rs7153648	1.000	rs7153648	chr14:61122526	C/G	cg27398547	chr14:60952738	C14orf39	1.47	8.35	0.6	1.12e-13	Prostate cancer;
TGCT	cis	rs7223966	0.960	rs11659013	chr17:61869559	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	4.68	0.39	7.5e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs13256369	1.000	rs10098234	chr8:8576692	G/A	cg06671706	chr8:8559999	CLDN23	0.35	4.69	0.39	6.95e-6	Obesity-related traits;
TGCT	cis	rs2014572	0.967	rs10413037	chr19:57771883	A/G	cg24459738	chr19:57751996	ZNF805	-0.6	-5.92	-0.47	2.96e-8	Hyperactive-impulsive symptoms;
TGCT	cis	rs9581857	0.512	rs9652092	chr13:28074855	T/C	cg22138327	chr13:27999177	GTF3A	0.85	6.02	0.48	1.87e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs2204008	0.713	rs11173567	chr12:38089375	T/C	cg13010199	chr12:38710504	ALG10B	0.6	4.82	0.4	4.06e-6	Bladder cancer;
TGCT	trans	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg17830980	chr10:43048298	ZNF37B	-0.86	-11.18	-0.71	1.68e-20	Extrinsic epigenetic age acceleration;
TGCT	cis	rs17539620	0.628	rs62432729	chr6:154830044	T/C	cg20019720	chr6:154832845	CNKSR3	0.52	4.53	0.38	1.36e-5	Lipoprotein (a) levels;
TGCT	cis	rs7954584	0.710	rs10840641	chr12:122465831	G/T	cg21171335	chr12:122356390	WDR66	0.56	5.48	0.44	2.23e-7	Mean corpuscular volume;
TGCT	cis	rs7582180	0.629	rs34745556	chr2:100942506	A/G	cg08017756	chr2:100939284	LONRF2	-0.3	-4.78	-0.39	4.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1018836	0.544	rs2339154	chr8:91459316	T/C	cg16814680	chr8:91681699	NA	-0.57	-5.59	-0.45	1.4e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs12464483	0.524	rs2256411	chr2:30886860	C/A	cg12454169	chr2:30669597	LCLAT1	0.44	4.87	0.4	3.29e-6	Pre-treatment pain in head and neck squamous cell carcinoma;
TGCT	cis	rs12510870	0.634	rs12508974	chr4:74394321	G/A	cg05868023	chr4:75230803	EREG	-0.55	-4.8	-0.4	4.53e-6	Iris color (b* coordinate);
TGCT	trans	rs61931739	0.500	rs34287388	chr12:34444626	C/A	cg26384229	chr12:38710491	ALG10B	0.73	6.93	0.53	2e-10	Morning vs. evening chronotype;
TGCT	trans	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg17470723	chr8:74884337	TCEB1	0.74	7.08	0.54	9.28e-11	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs807669	0.835	rs1780639	chr22:19174603	T/C	cg02655711	chr22:19163373	SLC25A1	0.42	9.92	0.67	1.94e-17	Metabolite levels;
TGCT	cis	rs7192750	0.586	rs4788571	chr16:71920823	G/A	cg06353428	chr16:71660113	MARVELD3	0.8	7.2	0.54	5.05e-11	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs854765	0.693	rs8079321	chr17:17760789	C/T	cg04398451	chr17:18023971	MYO15A	-0.29	-4.57	-0.38	1.15e-5	Total body bone mineral density;
TGCT	cis	rs7552404	0.924	rs1694419	chr1:76219801	C/T	cg03433033	chr1:76189801	ACADM	0.68	6.95	0.53	1.86e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7659604	1.000	rs10016433	chr4:122664771	A/G	cg19748678	chr4:122722346	EXOSC9	0.57	5.5	0.44	2.07e-7	Type 2 diabetes;
TGCT	cis	rs1215050	0.740	rs700739	chr4:99022546	A/G	cg17366294	chr4:99064904	C4orf37	-0.54	-5.86	-0.47	3.98e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7829975	0.871	rs572307	chr8:8578811	T/C	cg15556689	chr8:8085844	FLJ10661	-0.67	-5.84	-0.46	4.31e-8	Mood instability;
TGCT	cis	rs12908161	0.959	rs12908699	chr15:85240403	G/T	cg17173187	chr15:85201210	NMB	0.59	6.74	0.52	5.44e-10	Schizophrenia;
TGCT	cis	rs295140	1.000	rs13026151	chr2:201164570	T/A	cg04283868	chr2:201171347	SPATS2L	0.63	6.39	0.5	3.03e-9	QT interval;
TGCT	cis	rs7917772	0.636	rs2250580	chr10:104505687	C/G	cg05855489	chr10:104503620	C10orf26	-0.73	-5.35	-0.43	4.1e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2439831	1.000	rs689596	chr15:43761717	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.8	5.7	0.46	8.33e-8	Lung cancer in ever smokers;
TGCT	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg12516959	chr21:47718080	NA	-0.33	-4.58	-0.38	1.1e-5	Testicular germ cell tumor;
TGCT	cis	rs9611565	0.921	rs5751081	chr22:41742788	A/T	cg03806693	chr22:41940476	POLR3H	-0.87	-9.3	-0.64	6.07e-16	Vitiligo;
TGCT	cis	rs919433	0.680	rs7605813	chr2:198375329	C/G	cg00792783	chr2:198669748	PLCL1	0.5	4.6	0.38	1.01e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs250677	1.000	rs36079	chr5:148430504	G/A	cg23229984	chr5:148520753	ABLIM3	0.21	5.28	0.43	5.5e-7	Breast cancer;
TGCT	cis	rs1534166	0.647	rs7355929	chr3:133514190	C/T	cg16414030	chr3:133502952	NA	0.44	5.71	0.46	7.92e-8	Alcohol consumption (transferrin glycosylation);
TGCT	cis	rs6500602	0.535	rs758044	chr16:4431202	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.35	4.95	0.41	2.37e-6	Schizophrenia;
TGCT	cis	rs9549367	0.664	rs9549689	chr13:113848387	G/A	cg18105134	chr13:113819100	PROZ	-0.46	-8.3	-0.6	1.46e-13	Platelet distribution width;
TGCT	cis	rs9611565	0.765	rs132914	chr22:41805749	T/C	cg06634786	chr22:41940651	POLR3H	0.7	6.65	0.51	8.51e-10	Vitiligo;
TGCT	cis	rs986417	0.901	rs1955697	chr14:61028435	T/C	cg27398547	chr14:60952738	C14orf39	1.49	10.43	0.68	1.12e-18	Gut microbiota (bacterial taxa);
TGCT	cis	rs3820928	1.000	rs6723774	chr2:227770592	C/T	cg11843606	chr2:227700838	RHBDD1	0.51	4.51	0.38	1.47e-5	Pulmonary function;
TGCT	trans	rs28735056	0.904	rs62103183	chr18:77626564	A/G	cg05926928	chr17:57297772	GDPD1	0.65	6.74	0.52	5.44e-10	Schizophrenia;
TGCT	cis	rs7829975	0.577	rs7816329	chr8:8543843	G/A	cg17143192	chr8:8559678	CLDN23	-0.52	-5.21	-0.42	7.57e-7	Mood instability;
TGCT	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg03060546	chr3:49711283	APEH	0.58	5.59	0.45	1.38e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs1670533	1.000	rs2014318	chr4:1068778	C/T	cg27284194	chr4:1044797	NA	-0.69	-5.99	-0.47	2.14e-8	Recombination rate (females);
TGCT	cis	rs939658	0.776	rs4778925	chr15:79443791	C/T	cg17916960	chr15:79447300	NA	-0.49	-7.59	-0.56	6.76e-12	Refractive error;
TGCT	cis	rs4727027	0.933	rs917123	chr7:148848358	G/A	cg23583168	chr7:148888333	NA	-0.77	-10.1	-0.67	7.35e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs2762353	0.603	rs10946798	chr6:25781853	T/G	cg03264133	chr6:25882463	NA	0.49	4.94	0.41	2.51e-6	Blood metabolite levels;
TGCT	cis	rs8017423	0.967	rs7146640	chr14:90720114	C/T	cg04374321	chr14:90722782	PSMC1	-0.75	-7.54	-0.56	8.48e-12	Mortality in heart failure;
TGCT	cis	rs6671200	0.541	rs3738170	chr1:95699604	G/C	cg20701556	chr1:95698924	RWDD3	-0.52	-5.27	-0.43	5.76e-7	Stearic acid (18:0) levels;
TGCT	cis	rs8051431	0.876	rs4788589	chr16:72019948	A/T	cg06353428	chr16:71660113	MARVELD3	-0.59	-4.74	-0.39	5.73e-6	LDL cholesterol levels;
TGCT	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg11890956	chr21:40555474	PSMG1	1.11	12.17	0.74	6.69e-23	Cognitive function;
TGCT	cis	rs11578119	0.933	rs12120718	chr1:170394250	A/T	cg09767346	chr1:170501363	GORAB	0.71	5.69	0.46	8.67e-8	Male-pattern baldness;
TGCT	cis	rs6545883	0.868	rs6545887	chr2:61828818	C/G	cg15711740	chr2:61764176	XPO1	-0.6	-5.69	-0.45	8.69e-8	Tuberculosis;
TGCT	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg06481639	chr22:41940642	POLR3H	0.79	6.93	0.53	2.06e-10	Allergic disease (asthma, hay fever or eczema);
TGCT	trans	rs4650994	0.544	rs6675811	chr1:178499068	T/A	cg05059571	chr16:84539110	KIAA1609	-0.54	-11.23	-0.71	1.27e-20	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs72717009	0.825	rs7539468	chr1:161477066	G/A	cg23840854	chr1:161414152	NA	-0.98	-5.86	-0.47	3.95e-8	Rheumatoid arthritis;
TGCT	trans	rs12339966	0.527	rs10756226	chr9:11285409	G/A	cg07173112	chr1:1114698	TTLL10	-0.34	-6.68	-0.51	7.34e-10	Systolic blood pressure;
TGCT	cis	rs12410462	0.681	rs76705164	chr1:227615570	G/A	cg23173402	chr1:227635558	NA	0.64	4.44	0.37	1.97e-5	Major depressive disorder;
TGCT	cis	rs2404602	0.647	rs12913024	chr15:77145216	C/T	cg22467129	chr15:76604101	ETFA	0.46	4.64	0.38	8.6e-6	Blood metabolite levels;
TGCT	cis	rs3749237	0.595	rs4855859	chr3:49526300	C/T	cg07636037	chr3:49044803	WDR6	0.63	6.07	0.48	1.47e-8	Resting heart rate;
TGCT	cis	rs9549260	0.683	rs4941988	chr13:41196006	T/G	cg21288729	chr13:41239152	FOXO1	1.0	10.23	0.68	3.52e-18	Red blood cell count;
TGCT	cis	rs6840360	0.615	rs12647465	chr4:152607318	C/A	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.13	-0.48	1.05e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs80282103	0.867	rs17155821	chr10:1071701	A/G	cg15531433	chr10:1639090	ADARB2	0.41	4.51	0.38	1.46e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.07	-9.63	-0.65	1.01e-16	Platelet count;
TGCT	cis	rs7267979	1.000	rs2482928	chr20:25331530	A/G	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7226408	0.802	rs11664299	chr18:34485969	A/C	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs9660992	0.547	rs748012	chr1:205216573	C/T	cg00857998	chr1:205179979	DSTYK	0.51	4.71	0.39	6.48e-6	Mean corpuscular volume;Mean platelet volume;
TGCT	cis	rs7267979	0.706	rs6138542	chr20:25207773	C/A	cg14121845	chr20:25566513	NINL	0.5	5.45	0.44	2.64e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs12643440	0.538	rs6843399	chr4:17140263	A/G	cg22650099	chr4:17144496	NA	-0.46	-4.7	-0.39	6.79e-6	Metabolite levels (Pyroglutamine);
TGCT	cis	rs2932538	0.922	rs12406906	chr1:113117900	G/T	cg22162597	chr1:113214053	CAPZA1	-0.26	-5.76	-0.46	6.28e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs999943	0.846	rs9348923	chr6:33617924	C/T	cg14003231	chr6:33640908	ITPR3	0.4	4.98	0.41	2.13e-6	Obesity (extreme);
TGCT	cis	rs7772486	0.641	rs960385	chr6:146371074	G/A	cg13319975	chr6:146136371	FBXO30	-0.65	-6.11	-0.48	1.2e-8	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs1814175	0.616	rs1722001	chr11:49894427	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.45	-11.08	-0.71	3.01e-20	Height;
TGCT	cis	rs56104184	0.830	rs73061622	chr19:49358111	C/T	cg21252483	chr19:49399788	TULP2	-0.37	-4.73	-0.39	5.96e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs9383153	1.000	rs9370887	chr6:16329258	G/C	cg13189271	chr6:15365693	JARID2	0.92	4.5	0.37	1.57e-5	Gambling;
TGCT	cis	rs7647973	0.925	rs4955439	chr3:49245645	G/T	cg06212747	chr3:49208901	KLHDC8B	-0.58	-4.74	-0.39	5.85e-6	Menarche (age at onset);
TGCT	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg08219700	chr8:58056026	NA	0.37	6.07	0.48	1.47e-8	Developmental language disorder (linguistic errors);
TGCT	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg06238570	chr21:40685208	BRWD1	0.82	8.95	0.63	4.29e-15	Cognitive function;
TGCT	cis	rs7666738	0.830	rs34870112	chr4:99045815	T/G	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7833790	1.000	rs7833790	chr8:82731157	T/C	cg17211192	chr8:82754475	SNX16	-1.03	-8.73	-0.62	1.44e-14	Diastolic blood pressure;
TGCT	cis	rs7208859	0.673	rs9898858	chr17:29156211	A/T	cg14008862	chr17:28927542	LRRC37B2	0.75	5.1	0.42	1.26e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7178424	0.516	rs12901575	chr15:62338462	C/G	cg00456672	chr15:62358751	C2CD4A	-0.29	-4.45	-0.37	1.88e-5	Height;
TGCT	cis	rs6940638	0.513	rs4424065	chr6:27036456	C/T	cg02458000	chr6:26745757	NA	-0.5	-4.55	-0.38	1.29e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs1348850	0.914	rs12469386	chr2:178358281	A/G	cg22681709	chr2:178499509	PDE11A	0.35	4.69	0.39	6.97e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg01448562	chr3:133502909	NA	-0.33	-6.24	-0.49	6.44e-9	Iron status biomarkers;
TGCT	cis	rs3796352	1.000	rs17052727	chr3:53070914	T/C	cg15956490	chr3:53032818	SFMBT1	0.56	6.51	0.5	1.67e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs9549260	0.755	rs7990923	chr13:41215972	A/G	cg21288729	chr13:41239152	FOXO1	0.97	10.09	0.67	7.57e-18	Red blood cell count;
TGCT	cis	rs11190604	1.000	rs3750719	chr10:102248950	C/G	cg16342193	chr10:102329863	NA	-0.41	-5.34	-0.43	4.32e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs72781680	0.898	rs6712175	chr2:24023431	T/G	cg08917208	chr2:24149416	ATAD2B	0.81	5.01	0.41	1.8e-6	Lymphocyte counts;
TGCT	cis	rs2832191	0.716	rs1888440	chr21:30454484	C/T	cg08807101	chr21:30365312	RNF160	0.65	6.14	0.48	1.03e-8	Dental caries;
TGCT	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.51	-4.97	-0.41	2.18e-6	Prudent dietary pattern;
TGCT	cis	rs9522267	0.535	rs12583489	chr13:112233455	G/A	cg10483660	chr13:112241077	NA	-0.27	-4.61	-0.38	9.78e-6	Hepatitis;
TGCT	cis	rs986417	0.901	rs12886086	chr14:61042091	A/G	cg27398547	chr14:60952738	C14orf39	1.55	9.13	0.63	1.62e-15	Gut microbiota (bacterial taxa);
TGCT	cis	rs992157	1.000	rs736731	chr2:219120588	A/G	cg00012203	chr2:219082015	ARPC2	0.77	8.2	0.59	2.56e-13	Colorectal cancer;
TGCT	cis	rs6545883	0.929	rs2694625	chr2:61616055	G/A	cg15711740	chr2:61764176	XPO1	0.54	4.78	0.39	4.85e-6	Tuberculosis;
TGCT	cis	rs11098499	0.644	rs3986377	chr4:120260270	G/A	cg09307838	chr4:120376055	NA	0.53	5.16	0.42	9.36e-7	Corneal astigmatism;
TGCT	cis	rs8013055	0.846	rs10139744	chr14:105974696	G/A	cg25008857	chr14:105974488	NA	0.27	4.44	0.37	1.98e-5	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.6	-4.99	-0.41	1.97e-6	Lung function (FEV1/FVC);
TGCT	cis	rs2730245	0.527	rs62475645	chr7:158656825	G/A	cg11984989	chr7:158649758	WDR60	1.0	7.7	0.57	3.71e-12	Height;
TGCT	cis	rs4975616	0.714	rs37007	chr5:1352372	G/C	cg07493874	chr5:1342172	CLPTM1L	-0.24	-5.23	-0.43	7.03e-7	Lung cancer;
TGCT	cis	rs1018836	0.923	rs1476427	chr8:91552791	A/G	cg16814680	chr8:91681699	NA	0.82	9.38	0.64	3.97e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs478304	0.654	rs7115734	chr11:65458964	G/A	cg27068330	chr11:65405492	SIPA1	-0.99	-11.36	-0.71	6.13e-21	Acne (severe);
TGCT	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg26818010	chr10:134567672	INPP5A	-0.38	-5.19	-0.42	8.5e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs10791097	0.967	rs1944142	chr11:130717440	C/T	cg05962950	chr11:130786565	SNX19	0.74	7.92	0.58	1.15e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs861020	1.000	rs622832	chr1:209974232	A/C	cg05527609	chr1:210001259	C1orf107	0.9	7.25	0.55	3.93e-11	Orofacial clefts;
TGCT	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg05368731	chr17:41323189	NBR1	1.2	14.59	0.79	1.08e-28	Menopause (age at onset);
TGCT	cis	rs9311474	0.596	rs524986	chr3:52228496	T/C	cg10802521	chr3:52805072	NEK4	-0.56	-6.12	-0.48	1.11e-8	Electroencephalogram traits;
TGCT	cis	rs4711336	1.000	rs764754	chr6:33658310	C/T	cg14003231	chr6:33640908	ITPR3	0.28	4.5	0.37	1.54e-5	Height;
TGCT	cis	rs881375	0.678	rs7031752	chr9:123663482	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	5.68	0.45	9.15e-8	Rheumatoid arthritis;
TGCT	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg08280861	chr8:58055591	NA	0.32	4.49	0.37	1.63e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg25036284	chr2:26402008	FAM59B	0.65	5.19	0.42	8.36e-7	Gut microbiome composition (summer);
TGCT	cis	rs2657888	0.965	rs2657903	chr12:56933722	G/A	cg23002907	chr12:56915593	RBMS2	0.44	6.15	0.48	9.65e-9	Adiponectin levels;
TGCT	cis	rs1577917	0.958	rs2121594	chr6:86576854	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-5.6	-0.45	1.34e-7	Response to antipsychotic treatment;
TGCT	cis	rs2179367	0.959	rs544947	chr6:149723548	A/G	cg03813151	chr6:149778058	ZC3H12D	-0.27	-4.46	-0.37	1.84e-5	Dupuytren's disease;
TGCT	cis	rs586688	0.858	rs492703	chr1:201643782	G/T	cg05779441	chr1:201574716	NA	0.28	4.58	0.38	1.11e-5	Obesity-related traits;
TGCT	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg26116260	chr4:7069785	GRPEL1	1.11	10.79	0.7	1.54e-19	Monocyte percentage of white cells;
TGCT	cis	rs8180040	1.000	rs295449	chr3:47375955	G/A	cg27129171	chr3:47204927	SETD2	0.7	8.88	0.62	6.43e-15	Colorectal cancer;
TGCT	cis	rs9527	0.662	rs10786714	chr10:104598606	G/C	cg15744005	chr10:104629667	AS3MT	-0.48	-5.78	-0.46	5.62e-8	Arsenic metabolism;
TGCT	cis	rs72949976	0.646	rs1441170	chr2:214033563	A/G	cg08319019	chr2:214017104	IKZF2	-0.83	-8.16	-0.59	3.19e-13	Lung cancer;Squamous cell lung carcinoma;
TGCT	cis	rs3820928	0.874	rs3752896	chr2:227886925	C/T	cg11843606	chr2:227700838	RHBDD1	-0.57	-5.23	-0.42	7.12e-7	Pulmonary function;
TGCT	cis	rs4242434	0.927	rs2291232	chr8:22464064	A/G	cg03733263	chr8:22462867	KIAA1967	1.12	19.92	0.87	1.83e-40	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs28595532	0.920	rs114207133	chr4:119755140	T/C	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs6570726	0.967	rs6903252	chr6:145922777	A/G	cg05347473	chr6:146136440	FBXO30	0.53	4.93	0.4	2.61e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs892961	0.867	rs6501955	chr17:75414443	A/G	cg05865280	chr17:75406074	SEPT9	0.28	6.71	0.52	6.16e-10	Airflow obstruction;
TGCT	cis	rs8180040	0.966	rs7628631	chr3:47560863	C/T	cg27129171	chr3:47204927	SETD2	-0.65	-7.54	-0.56	8.69e-12	Colorectal cancer;
TGCT	cis	rs7267979	0.668	rs4815398	chr20:25237338	C/T	cg21995068	chr20:25989032	LOC100134868	0.44	5.14	0.42	1.03e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs929354	0.772	rs1182438	chr7:157027438	G/A	cg05182265	chr7:156933206	UBE3C	0.4	9.05	0.63	2.54e-15	Body mass index;
TGCT	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs13108904	0.604	rs11946375	chr4:1313488	T/C	cg03303774	chr4:1407052	NA	0.3	5.0	0.41	1.91e-6	Obesity-related traits;
TGCT	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg11890956	chr21:40555474	PSMG1	-0.76	-7.42	-0.55	1.64e-11	Cognitive function;
TGCT	cis	rs1784581	1.000	rs1615717	chr6:162400612	C/T	cg17173639	chr6:162384350	PARK2	-0.5	-9.18	-0.64	1.19e-15	Itch intensity from mosquito bite;
TGCT	cis	rs4786125	0.665	rs7201025	chr16:6920592	C/T	cg03623568	chr16:6915990	A2BP1	-0.45	-6.77	-0.52	4.65e-10	Heart rate variability traits (SDNN);
TGCT	cis	rs739401	0.611	rs391188	chr11:3047634	G/A	cg25174290	chr11:3078921	CARS	0.48	4.68	0.39	7.48e-6	Longevity;
TGCT	cis	rs36051895	0.623	rs57707737	chr9:5062844	A/T	cg02405213	chr9:5042618	JAK2	-0.72	-9.66	-0.66	8.38e-17	Pediatric autoimmune diseases;
TGCT	cis	rs7647973	0.593	rs59684465	chr3:49874246	C/T	cg03060546	chr3:49711283	APEH	-0.66	-5.91	-0.47	3.08e-8	Menarche (age at onset);
TGCT	cis	rs4919687	0.550	rs12783444	chr10:104480659	G/A	cg05855489	chr10:104503620	C10orf26	0.55	4.43	0.37	2.01e-5	Colorectal cancer;
TGCT	cis	rs453301	0.682	rs2929308	chr8:9084121	T/A	cg08975724	chr8:8085496	FLJ10661	-0.52	-4.69	-0.39	7.08e-6	Joint mobility (Beighton score);
TGCT	cis	rs6540559	0.673	rs7511996	chr1:210018473	C/A	cg22029157	chr1:209979665	IRF6	0.68	4.88	0.4	3.22e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs17270561	0.723	rs12192635	chr6:25880907	A/T	cg17691542	chr6:26056736	HIST1H1C	0.83	5.85	0.47	4.02e-8	Iron status biomarkers;
TGCT	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg12310025	chr6:25882481	NA	-0.67	-7.28	-0.55	3.31e-11	Blood metabolite levels;
TGCT	cis	rs4654899	1.000	rs10916938	chr1:21446883	A/G	cg01072550	chr1:21505969	NA	-0.51	-8.27	-0.6	1.76e-13	Superior frontal gyrus grey matter volume;
TGCT	cis	rs57994353	0.865	rs34376913	chr9:139378914	T/C	cg13741927	chr9:139327495	INPP5E	-0.23	-5.16	-0.42	9.54e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs2072499	0.833	rs2251847	chr1:156204047	G/A	cg24450063	chr1:156163899	SLC25A44	1.07	11.45	0.72	3.76e-21	Testicular germ cell tumor;
TGCT	cis	rs9296661	0.868	rs1326576	chr6:51667803	G/T	cg00593404	chr6:52377740	TRAM2	-0.27	-4.49	-0.37	1.62e-5	Weight loss (gastric bypass surgery);
TGCT	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg09359103	chr1:154839909	KCNN3	-0.66	-12.15	-0.74	7.27e-23	Prostate cancer;
TGCT	cis	rs36051895	0.559	rs7868706	chr9:5210936	T/G	cg02405213	chr9:5042618	JAK2	-0.67	-8.36	-0.6	1.06e-13	Pediatric autoimmune diseases;
TGCT	cis	rs1865760	0.566	rs9467672	chr6:26083904	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.78	7.49	0.56	1.15e-11	Height;
TGCT	cis	rs28595532	0.920	rs116516492	chr4:119734247	C/G	cg21605333	chr4:119757512	SEC24D	1.66	8.33	0.6	1.28e-13	Cannabis dependence symptom count;
TGCT	cis	rs10992471	0.603	rs7864575	chr9:95304647	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.6	-5.68	-0.45	9.01e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs7666738	0.830	rs13328005	chr4:99055480	T/C	cg18180107	chr4:99064573	C4orf37	0.58	5.28	0.43	5.7e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs13191362	1.000	rs13193282	chr6:163015442	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg22166914	chr1:53195759	ZYG11B	-0.46	-8.42	-0.6	7.72e-14	Monocyte count;
TGCT	cis	rs7666738	0.830	rs13110903	chr4:98946373	A/G	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.42	6.05	0.48	1.57e-8	Lymphocyte counts;
TGCT	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg03934478	chr11:495069	RNH1	0.35	5.82	0.46	4.66e-8	Body mass index;
TGCT	cis	rs68170813	0.559	rs77422419	chr7:106957932	A/G	cg02696742	chr7:106810147	HBP1	-0.69	-5.81	-0.46	4.85e-8	Coronary artery disease;
TGCT	cis	rs6940638	0.744	rs858964	chr6:27142614	C/G	cg16675381	chr6:26757706	NA	-0.46	-4.46	-0.37	1.84e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs11932942	chr4:98998939	T/C	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs881375	1.000	rs10760121	chr9:123647915	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	5.49	0.44	2.15e-7	Rheumatoid arthritis;
TGCT	cis	rs240764	0.658	rs7451736	chr6:101189901	C/T	cg09795085	chr6:101329169	ASCC3	-0.51	-4.51	-0.38	1.45e-5	Neuroticism;
TGCT	cis	rs73198271	0.740	rs10094270	chr8:8646633	G/A	cg15556689	chr8:8085844	FLJ10661	-0.6	-4.46	-0.37	1.8e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs9329289	0.510	rs2029604	chr10:2554700	T/C	cg07014206	chr10:2547000	NA	-0.28	-4.62	-0.38	9.42e-6	Age-related hearing impairment;
TGCT	cis	rs3091242	0.967	rs1053438	chr1:25687901	T/C	cg00786635	chr1:25594202	NA	-0.53	-5.35	-0.43	4.1e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs7267979	1.000	rs2257432	chr20:25271086	T/C	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9473924	0.542	rs9296645	chr6:50831194	A/G	cg14470998	chr6:50812995	TFAP2B	1.35	8.39	0.6	9.05e-14	Body mass index;
TGCT	cis	rs10782582	0.593	rs12131493	chr1:76139172	G/A	cg22875332	chr1:76189707	ACADM	-0.54	-6.18	-0.49	8.3e-9	Daytime sleep phenotypes;
TGCT	cis	rs854765	0.647	rs8066764	chr17:17974668	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	7.23	0.54	4.28e-11	Total body bone mineral density;
TGCT	cis	rs7647973	0.626	rs1078341	chr3:49685592	A/G	cg03060546	chr3:49711283	APEH	0.63	5.63	0.45	1.12e-7	Menarche (age at onset);
TGCT	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg05025164	chr4:1340916	KIAA1530	0.8	6.98	0.53	1.62e-10	Longevity;
TGCT	cis	rs10984561	0.881	rs78544256	chr9:122250437	G/C	cg14242995	chr9:122249943	NA	0.75	6.12	0.48	1.16e-8	Pulmonary function decline;
TGCT	cis	rs753778	0.667	rs6578153	chr8:142209543	C/T	cg18755752	chr8:142205143	DENND3	-0.27	-5.09	-0.42	1.26e-6	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs244731	0.919	rs12652509	chr5:176626441	A/G	cg16006841	chr5:176797999	RGS14	-0.53	-6.95	-0.53	1.88e-10	Urate levels in lean individuals;
TGCT	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg09365446	chr1:150670422	GOLPH3L	0.31	4.64	0.38	8.74e-6	Tonsillectomy;
TGCT	cis	rs208520	0.526	rs4710310	chr6:66802808	T/C	cg07460842	chr6:66804631	NA	-1.07	-14.74	-0.8	4.84e-29	Exhaled nitric oxide output;
TGCT	cis	rs7714584	0.793	rs12653039	chr5:150252631	G/A	cg22134413	chr5:150180641	NA	1.1	8.25	0.6	1.99e-13	Crohn's disease;
TGCT	cis	rs10493773	0.962	rs6698578	chr1:86236676	G/A	cg17807903	chr1:86174739	ZNHIT6	-0.37	-4.52	-0.38	1.44e-5	Urate levels in overweight individuals;
TGCT	cis	rs10791097	0.667	rs2155358	chr11:130740357	T/C	cg12179176	chr11:130786555	SNX19	0.84	10.17	0.67	4.95e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	trans	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.83	9.04	0.63	2.64e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs7607369	0.580	rs7568196	chr2:219652373	G/A	cg01872077	chr2:219646372	CYP27A1	-0.58	-4.8	-0.4	4.54e-6	Red blood cell count;Amyotrophic lateral sclerosis;
TGCT	cis	rs4285028	0.747	rs7153	chr3:121383297	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.92	-7.3	-0.55	3.03e-11	Multiple sclerosis;
TGCT	cis	rs13256369	0.774	rs13248423	chr8:8577602	C/G	cg17143192	chr8:8559678	CLDN23	0.61	5.6	0.45	1.3e-7	Obesity-related traits;
TGCT	cis	rs3820928	0.934	rs4675117	chr2:227769794	A/G	cg11843606	chr2:227700838	RHBDD1	0.51	4.67	0.39	7.64e-6	Pulmonary function;
TGCT	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg02725872	chr8:58115012	NA	-0.38	-5.16	-0.42	9.32e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7174348	1	rs7174348	chr15:78792439	G/A	cg24631222	chr15:78858424	CHRNA5	0.61	4.51	0.38	1.5e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
TGCT	cis	rs9325144	0.602	rs10785590	chr12:38694145	C/T	cg26384229	chr12:38710491	ALG10B	0.66	6.13	0.48	1.09e-8	Morning vs. evening chronotype;
TGCT	cis	rs2932538	0.922	rs12750023	chr1:113118329	G/A	cg22162597	chr1:113214053	CAPZA1	0.27	5.98	0.47	2.24e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs2933343	0.951	rs7648327	chr3:128570708	A/G	cg11901034	chr3:128598214	ACAD9	-0.64	-5.15	-0.42	9.75e-7	IgG glycosylation;
TGCT	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.39	-4.71	-0.39	6.54e-6	Longevity;Endometriosis;
TGCT	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.35	-4.46	-0.37	1.84e-5	Total body bone mineral density;
TGCT	cis	rs7267979	0.816	rs6076358	chr20:25519403	G/T	cg16686733	chr20:25566563	NINL	-0.52	-5.05	-0.41	1.52e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4285028	0.848	rs77630152	chr3:121681194	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.77	-6.55	-0.51	1.35e-9	Multiple sclerosis;
TGCT	cis	rs2439831	0.850	rs28858500	chr15:44156942	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	6.2	0.49	7.73e-9	Lung cancer in ever smokers;
TGCT	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg21285383	chr16:89894308	SPIRE2	0.46	7.34	0.55	2.41e-11	Vitiligo;
TGCT	cis	rs1153858	0.621	rs12913645	chr15:45555066	G/A	cg26924012	chr15:45694286	SPATA5L1	-1.0	-10.91	-0.7	7.59e-20	Homoarginine levels;
TGCT	cis	rs7586879	0.639	rs6749170	chr2:25110962	A/G	cg15423357	chr2:25149977	NA	0.48	4.6	0.38	1.03e-5	Body mass index;
TGCT	cis	rs908922	0.676	rs7518654	chr1:152517845	C/G	cg20991723	chr1:152506922	NA	0.46	6.15	0.48	9.92e-9	Hair morphology;
TGCT	cis	rs6759518	0.655	rs2580382	chr2:27406555	A/G	cg26210250	chr2:26863503	CIB4	-0.78	-4.46	-0.37	1.79e-5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
TGCT	cis	rs11190604	0.945	rs7091356	chr10:102292268	G/C	cg16342193	chr10:102329863	NA	-0.41	-5.31	-0.43	4.85e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9650657	0.740	rs10481451	chr8:10649328	A/G	cg27411982	chr8:10470053	RP1L1	-0.22	-5.02	-0.41	1.75e-6	Neuroticism;
TGCT	cis	rs1005277	0.505	rs200936	chr10:38134935	T/C	cg13531842	chr10:38383804	ZNF37A	-0.39	-4.58	-0.38	1.1e-5	Extrinsic epigenetic age acceleration;
TGCT	cis	rs593531	0.571	rs6592557	chr11:74086642	T/C	cg25592907	chr11:73676012	DNAJB13	0.33	4.81	0.4	4.23e-6	Neuroticism;
TGCT	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg02463440	chr8:22132932	PIWIL2	-0.25	-4.96	-0.41	2.23e-6	Hypertriglyceridemia;
TGCT	cis	rs10892173	0.782	rs6421566	chr11:117671398	G/A	cg07621104	chr11:117668040	DSCAML1	0.51	5.38	0.43	3.59e-7	Myopia;
TGCT	cis	rs3733585	0.605	rs7656624	chr4:10121097	T/C	cg00071950	chr4:10020882	SLC2A9	-0.5	-5.35	-0.43	4.07e-7	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs17376456	0.877	rs28633397	chr5:93447048	A/G	cg25358565	chr5:93447407	FAM172A	0.92	8.38	0.6	9.58e-14	Diabetic retinopathy;
TGCT	cis	rs7193541	0.694	rs8061942	chr16:74691362	C/T	cg01733217	chr16:74700730	RFWD3	1.01	13.54	0.77	3.37e-26	Multiple myeloma;
TGCT	cis	rs7267979	0.706	rs6138542	chr20:25207773	C/A	cg03522245	chr20:25566470	NINL	0.6	6.54	0.51	1.48e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3849570	1.000	rs6548773	chr3:81840222	C/T	cg07356753	chr3:81810745	GBE1	0.82	7.62	0.56	5.6e-12	Waist circumference;Body mass index;
TGCT	cis	rs16866061	0.515	rs11695326	chr2:225415134	A/G	cg12698349	chr2:225449008	CUL3	1.12	15.51	0.81	8.08e-31	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	cis	rs11785400	0.793	rs4567014	chr8:143737690	G/C	cg24634471	chr8:143751801	JRK	0.55	5.51	0.44	1.99e-7	Schizophrenia;
TGCT	cis	rs12497850	0.829	rs12636030	chr3:49182237	A/G	cg06212747	chr3:49208901	KLHDC8B	0.61	5.4	0.44	3.31e-7	Parkinson's disease;
TGCT	cis	rs10791323	0.654	rs2851119	chr11:133706382	T/C	cg03690763	chr11:133734501	NA	-0.3	-4.73	-0.39	6.04e-6	Childhood ear infection;
TGCT	cis	rs4242434	0.927	rs11136092	chr8:22466488	T/G	cg03733263	chr8:22462867	KIAA1967	1.14	20.27	0.88	3.6e-41	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs6570726	0.935	rs384519	chr6:145846017	C/A	cg23711669	chr6:146136114	FBXO30	0.68	6.67	0.51	7.58e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2440129	0.611	rs1042357	chr17:6905061	T/G	cg21237687	chr17:6899380	ALOX12	0.54	5.72	0.46	7.41e-8	Tonsillectomy;
TGCT	cis	rs10193935	0.901	rs6544529	chr2:42510652	A/T	cg27598129	chr2:42591480	NA	-0.42	-5.68	-0.45	9.05e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4242434	0.892	rs71513892	chr8:22456517	C/G	cg03733263	chr8:22462867	KIAA1967	1.13	18.46	0.86	2.23e-37	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs12210905	0.920	rs72839468	chr6:27301734	A/G	cg08851530	chr6:28072375	NA	1.32	5.79	0.46	5.48e-8	Hip circumference adjusted for BMI;
TGCT	cis	rs317689	0.876	rs547332	chr12:69743639	C/G	cg20891283	chr12:69753455	YEATS4	0.63	5.47	0.44	2.42e-7	Response to diuretic therapy;
TGCT	cis	rs12478296	1.000	rs56292923	chr2:243039986	C/T	cg06360820	chr2:242988706	NA	-0.61	-4.66	-0.39	8.13e-6	Obesity-related traits;
TGCT	cis	rs9633740	1.000	rs1870137	chr10:82269848	C/G	cg01528321	chr10:82214614	TSPAN14	1.03	8.28	0.6	1.66e-13	Post bronchodilator FEV1;
TGCT	cis	rs916888	0.647	rs199523	chr17:44848517	C/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.6	-4.63	-0.38	9.07e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg26338869	chr17:61819248	STRADA	-0.53	-4.85	-0.4	3.68e-6	Prudent dietary pattern;
TGCT	cis	rs9303401	1.000	rs9303401	chr17:56847945	C/T	cg12560992	chr17:57184187	TRIM37	0.53	5.44	0.44	2.71e-7	Cognitive test performance;
TGCT	cis	rs7726839	0.574	rs11739866	chr5:636299	C/T	cg20362242	chr5:692897	TPPP	0.52	4.65	0.39	8.29e-6	Obesity-related traits;
TGCT	cis	rs2688608	0.653	rs12775558	chr10:75570868	G/A	cg19442545	chr10:75533431	FUT11	-0.36	-5.7	-0.46	8.14e-8	Inflammatory bowel disease;
TGCT	cis	rs4499344	0.633	rs259271	chr19:33157100	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.85	9.09	0.63	2.01e-15	Mean platelet volume;
TGCT	cis	rs2070488	0.775	rs6780349	chr3:38555178	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.65	-5.88	-0.47	3.59e-8	Electrocardiographic conduction measures;
TGCT	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg04287289	chr16:89883240	FANCA	0.93	12.26	0.74	4.13e-23	Vitiligo;
TGCT	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg11494091	chr17:61959527	GH2	0.61	14.43	0.79	2.59e-28	Prudent dietary pattern;
TGCT	cis	rs55794721	0.509	rs2375313	chr1:25748235	G/A	cg23205692	chr1:25664452	TMEM50A	0.53	5.47	0.44	2.41e-7	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs698813	0.604	rs1596009	chr2:44492102	G/T	cg00619915	chr2:44497795	NA	-0.24	-5.5	-0.44	2.05e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
TGCT	trans	rs3780486	0.846	rs10758192	chr9:33131651	G/A	cg20290983	chr6:43655470	MRPS18A	1.19	14.84	0.8	2.81e-29	IgG glycosylation;
TGCT	cis	rs826838	1.000	rs1393537	chr12:38920961	C/T	cg26384229	chr12:38710491	ALG10B	1.01	9.79	0.66	4.11e-17	Heart rate;
TGCT	cis	rs1550582	0.511	rs28673296	chr8:135474441	G/A	cg17885191	chr8:135476712	NA	0.52	5.11	0.42	1.2e-6	Educational attainment;
TGCT	cis	rs3733585	0.699	rs6449158	chr4:9960459	T/C	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.58	-0.51	1.2e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7959452	0.718	rs10878963	chr12:69717166	T/G	cg20891283	chr12:69753455	YEATS4	0.51	4.77	0.39	4.98e-6	Blood protein levels;
TGCT	cis	rs6598955	0.756	rs10902723	chr1:26568542	T/C	cg04990556	chr1:26633338	UBXN11	-0.89	-11.39	-0.71	5.27e-21	Obesity-related traits;
TGCT	cis	rs2274471	0.680	rs10974996	chr9:5192082	C/G	cg03390472	chr9:5043263	JAK2	0.31	4.49	0.37	1.62e-5	Crohn's disease;
TGCT	cis	rs933688	1.000	rs1035477	chr5:90743325	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.0	8.47	0.61	6.09e-14	Smoking behavior;
TGCT	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg06238570	chr21:40685208	BRWD1	0.69	6.41	0.5	2.71e-9	Cognitive function;
TGCT	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg09365446	chr1:150670422	GOLPH3L	0.31	4.64	0.38	8.74e-6	Tonsillectomy;
TGCT	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg05665937	chr4:1216051	CTBP1	0.25	4.75	0.39	5.64e-6	Obesity-related traits;
TGCT	cis	rs453301	0.658	rs12114954	chr8:8904862	T/G	cg08975724	chr8:8085496	FLJ10661	-0.54	-4.46	-0.37	1.8e-5	Joint mobility (Beighton score);
TGCT	cis	rs13191362	1.000	rs36007635	chr6:163009335	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs1878931	0.545	rs28603	chr16:3449479	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.67	-5.31	-0.43	4.95e-7	Body mass index (adult);
TGCT	cis	rs4654899	0.743	rs17409373	chr1:21188871	C/A	cg01072550	chr1:21505969	NA	-0.47	-7.09	-0.54	8.84e-11	Superior frontal gyrus grey matter volume;
TGCT	cis	rs7727544	0.735	rs4705933	chr5:131678412	G/A	cg24060327	chr5:131705240	SLC22A5	-0.56	-6.26	-0.49	5.61e-9	Blood metabolite levels;
TGCT	cis	rs9814567	0.806	rs4245903	chr3:134317074	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.74	-6.96	-0.53	1.72e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs3796619	1.000	rs11247973	chr4:1094314	G/A	cg27284194	chr4:1044797	NA	0.46	4.5	0.37	1.56e-5	Recombination rate (males);
TGCT	cis	rs5417	1.000	rs5418	chr17:7185092	G/A	cg25256661	chr17:7137939	DVL2	-0.53	-4.97	-0.41	2.13e-6	Diastolic blood pressure;
TGCT	cis	rs10791097	0.694	rs7942621	chr11:130751308	C/G	cg12179176	chr11:130786555	SNX19	0.82	10.15	0.67	5.45e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs3749237	0.595	rs7643845	chr3:49530711	A/G	cg07636037	chr3:49044803	WDR6	0.63	6.07	0.48	1.47e-8	Resting heart rate;
TGCT	cis	rs1023500	0.596	rs5751209	chr22:42451603	A/G	cg15557168	chr22:42548783	NA	-0.19	-4.84	-0.4	3.73e-6	Schizophrenia;
TGCT	cis	rs12579753	1.000	rs34031374	chr12:82235615	G/C	cg07988820	chr12:82153109	PPFIA2	-0.6	-6.48	-0.5	1.91e-9	Resting heart rate;
TGCT	cis	rs7714584	1.000	rs11167518	chr5:150258920	C/A	cg22134413	chr5:150180641	NA	0.74	5.42	0.44	2.97e-7	Crohn's disease;
TGCT	cis	rs11690935	0.632	rs17581284	chr2:172659376	C/T	cg13550731	chr2:172543902	DYNC1I2	0.68	5.97	0.47	2.38e-8	Schizophrenia;
TGCT	cis	rs514406	0.644	rs4926928	chr1:53210163	G/T	cg08859206	chr1:53392774	SCP2	-0.35	-5.01	-0.41	1.84e-6	Monocyte count;
TGCT	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg12311346	chr5:56204834	C5orf35	-0.67	-6.79	-0.52	4.07e-10	Initial pursuit acceleration;
TGCT	cis	rs10465746	0.780	rs11163867	chr1:84384847	C/T	cg10977910	chr1:84465055	TTLL7	0.71	7.15	0.54	6.64e-11	Obesity-related traits;
TGCT	cis	rs727563	0.635	rs5751141	chr22:42107745	A/G	cg17554472	chr22:41940697	POLR3H	0.49	5.14	0.42	1.06e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	trans	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg17470723	chr8:74884337	TCEB1	0.71	6.77	0.52	4.48e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs6815814	0.950	rs4540055	chr4:38803255	A/T	cg02016764	chr4:38805732	TLR1	-0.31	-5.18	-0.42	8.67e-7	Breast cancer;
TGCT	cis	rs17125944	0.505	rs74620173	chr14:53194068	G/T	cg00686598	chr14:53173677	PSMC6	1.19	6.34	0.49	3.96e-9	Alzheimer's disease (late onset);
TGCT	cis	rs7267979	1.000	rs2257985	chr20:25269743	G/T	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.41	-4.46	-0.37	1.82e-5	Longevity;Endometriosis;
TGCT	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg17971929	chr21:40555470	PSMG1	-0.73	-6.7	-0.52	6.49e-10	Cognitive function;
TGCT	cis	rs6570726	0.577	rs403345	chr6:145845171	T/C	cg23711669	chr6:146136114	FBXO30	0.7	6.39	0.5	3.12e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4919669	0.668	rs10883757	chr10:104400133	C/T	cg05855489	chr10:104503620	C10orf26	0.73	4.51	0.38	1.47e-5	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs7043114	0.525	rs1133908	chr9:95068046	C/T	cg14631576	chr9:95140430	CENPP	-0.28	-4.65	-0.39	8.23e-6	Height;
TGCT	cis	rs7666738	0.784	rs4699602	chr4:99034903	T/C	cg17366294	chr4:99064904	C4orf37	0.74	7.5	0.56	1.06e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg11890956	chr21:40555474	PSMG1	-0.71	-6.95	-0.53	1.88e-10	Menarche (age at onset);
TGCT	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg22963979	chr7:1858916	MAD1L1	-0.4	-6.44	-0.5	2.44e-9	Bipolar disorder and schizophrenia;
TGCT	cis	rs782590	0.967	rs17278044	chr2:55748217	G/C	cg18811423	chr2:55921094	PNPT1	0.67	7.1	0.54	8.6e-11	Metabolic syndrome;
TGCT	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg07424592	chr7:64974309	NA	-0.66	-6.62	-0.51	9.9e-10	Calcium levels;
TGCT	cis	rs617219	0.671	rs2591392	chr5:78546293	G/A	cg23514016	chr5:78407564	BHMT	0.34	5.05	0.41	1.51e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg01802117	chr1:53393560	SCP2	0.47	5.77	0.46	5.88e-8	Monocyte count;
TGCT	cis	rs1729951	0.575	rs1682333	chr3:136688618	G/A	cg21827317	chr3:136751795	NA	0.4	5.61	0.45	1.28e-7	Neuroticism;
TGCT	cis	rs4604732	0.574	rs111928142	chr1:247625229	G/T	cg22475246	chr1:246888027	SCCPDH	0.66	4.57	0.38	1.16e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
TGCT	cis	rs2832191	0.679	rs2705659	chr21:30363908	G/C	cg24692254	chr21:30365293	RNF160	0.96	11.17	0.71	1.77e-20	Dental caries;
TGCT	cis	rs8072100	0.807	rs2175290	chr17:45479917	C/A	cg08085267	chr17:45401833	C17orf57	-0.51	-5.71	-0.46	8.06e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg03806693	chr22:41940476	POLR3H	-1.13	-13.26	-0.77	1.59e-25	Vitiligo;
TGCT	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg16680214	chr1:154839983	KCNN3	0.36	8.01	0.58	7.02e-13	Prostate cancer;
TGCT	cis	rs5769765	0.657	rs8136116	chr22:50256886	T/A	cg22709217	chr22:50311962	ALG12;CRELD2	1.0	6.16	0.48	9.32e-9	Schizophrenia;
TGCT	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg03188948	chr7:1209495	NA	0.58	4.69	0.39	6.95e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg09359103	chr1:154839909	KCNN3	-0.67	-13.39	-0.77	7.55e-26	Prostate cancer;
TGCT	cis	rs7772486	0.875	rs9322045	chr6:146384950	C/G	cg23711669	chr6:146136114	FBXO30	0.89	9.47	0.65	2.36e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.18	0.49	8.33e-9	Electroencephalogram traits;
TGCT	cis	rs3752962	0.630	rs6503188	chr17:1950408	G/T	cg24156229	chr17:1948635	NA	-0.39	-7.56	-0.56	7.6e-12	Itch intensity from mosquito bite;
TGCT	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg27425262	chr2:113953981	PSD4;LOC440839	-0.52	-8.2	-0.59	2.52e-13	Lymphocyte counts;
TGCT	cis	rs377070	0.934	rs309392	chr4:123611542	G/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.46	5.16	0.42	9.5e-7	Mosquito bite size;
TGCT	cis	rs6671200	0.607	rs2147587	chr1:95714884	G/A	cg26537280	chr1:95699037	RWDD3	-0.51	-4.9	-0.4	2.94e-6	Stearic acid (18:0) levels;
TGCT	cis	rs1008375	0.932	rs6449315	chr4:17590219	A/G	cg18681998	chr4:17616180	MED28	0.85	8.18	0.59	2.86e-13	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs12580194	0.593	rs61957938	chr12:55747266	C/G	cg10672482	chr12:55725839	OR6C3	-0.51	-4.43	-0.37	2.01e-5	Cancer;
TGCT	cis	rs344364	0.511	rs1742463	chr16:1946110	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.45	-5.08	-0.42	1.35e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs9911578	1.000	rs11869828	chr17:56609525	G/A	cg05425664	chr17:57184151	TRIM37	0.63	6.26	0.49	5.86e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs367943	1.000	rs348956	chr5:112821464	C/T	cg12552261	chr5:112820674	MCC	0.24	4.91	0.4	2.81e-6	Type 2 diabetes;
TGCT	cis	rs2201728	0.967	rs4147531	chr4:100212197	G/A	cg07219303	chr4:100140905	ADH6	-0.36	-5.27	-0.43	5.9e-7	Cardiac Troponin-T levels;
TGCT	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg20203395	chr5:56204925	C5orf35	-0.53	-4.92	-0.4	2.67e-6	Initial pursuit acceleration;
TGCT	cis	rs7772486	0.790	rs9497431	chr6:146248177	T/C	cg05347473	chr6:146136440	FBXO30	-0.51	-4.95	-0.41	2.42e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg11644478	chr21:40555479	PSMG1	-0.52	-4.79	-0.4	4.59e-6	Menarche (age at onset);
TGCT	cis	rs2820315	0.965	rs8028	chr1:201865763	A/G	cg12730843	chr1:201915899	LMOD1	0.27	4.81	0.4	4.25e-6	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
TGCT	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	7.26	0.55	3.81e-11	Platelet count;
TGCT	trans	rs561341	0.941	rs736678	chr17:30347423	G/T	cg20587970	chr11:113659929	NA	-1.05	-13.49	-0.77	4.42e-26	Hip circumference adjusted for BMI;
TGCT	cis	rs7267979	0.934	rs2257464	chr20:25265872	C/T	cg14121845	chr20:25566513	NINL	0.5	5.39	0.44	3.4e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9653442	0.500	rs72819191	chr2:100826572	A/G	cg07810366	chr2:100720526	AFF3	0.39	5.33	0.43	4.39e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.62	5.22	0.42	7.25e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2224391	0.704	rs17139985	chr6:5261603	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.8	-6.12	-0.48	1.13e-8	Height;
TGCT	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg06753367	chr22:24256600	NA	-0.25	-4.73	-0.39	5.98e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.46	0.56	1.3e-11	Prudent dietary pattern;
TGCT	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.71	6.36	0.5	3.53e-9	Tonsillectomy;
TGCT	cis	rs2637266	0.678	rs846612	chr10:78550680	T/C	cg18941641	chr10:78392320	NA	0.39	4.66	0.39	7.93e-6	Pulmonary function;
TGCT	cis	rs7119	0.717	rs11631274	chr15:77816431	A/T	cg27398640	chr15:77910606	LINGO1	-0.25	-4.6	-0.38	1.05e-5	Type 2 diabetes;
TGCT	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg17554472	chr22:41940697	POLR3H	0.43	4.79	0.39	4.73e-6	Vitiligo;
TGCT	cis	rs2932538	0.922	rs36029940	chr1:113106444	T/G	cg22162597	chr1:113214053	CAPZA1	0.28	5.83	0.46	4.4e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs68170813	0.559	rs77013162	chr7:107071674	A/C	cg02696742	chr7:106810147	HBP1	-0.7	-5.59	-0.45	1.41e-7	Coronary artery disease;
TGCT	cis	rs2116941	0.523	rs17000211	chr19:10369086	C/T	cg01850179	chr19:10340795	S1PR2	0.53	6.62	0.51	9.76e-10	Pulse pressure;
TGCT	cis	rs5769765	0.955	rs8135816	chr22:50291976	G/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.39	5.91	0.47	3.12e-8	Schizophrenia;
TGCT	cis	rs2760061	0.545	rs1745423	chr1:228224153	G/T	cg18477163	chr1:228402036	OBSCN	-0.32	-6.75	-0.52	5.11e-10	Diastolic blood pressure;
TGCT	cis	rs1215050	0.791	rs165239	chr4:98682549	C/T	cg05340658	chr4:99064831	C4orf37	0.43	5.4	0.44	3.2e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9902453	1.000	rs57411618	chr17:28273052	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	7.0	0.53	1.44e-10	Coffee consumption (cups per day);
TGCT	cis	rs2370759	1.000	rs76998371	chr10:32631785	A/G	cg01819863	chr10:32635814	EPC1	1.0	9.52	0.65	1.8e-16	Sexual dysfunction (female);
TGCT	cis	rs9581857	0.685	rs12585587	chr13:28024694	G/A	cg22138327	chr13:27999177	GTF3A	0.7	5.01	0.41	1.85e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs57994353	0.600	rs13295852	chr9:139308426	G/A	cg13741927	chr9:139327495	INPP5E	-0.25	-5.54	-0.45	1.71e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs3858526	0.883	rs10769326	chr11:5934358	C/T	cg13902645	chr11:5959945	NA	-0.44	-4.64	-0.38	8.75e-6	DNA methylation (variation);
TGCT	cis	rs34638657	0.732	rs11859473	chr16:82201072	T/C	cg09439754	chr16:82129088	HSD17B2	-0.24	-4.53	-0.38	1.37e-5	Lung adenocarcinoma;
TGCT	cis	rs9341808	0.667	rs7745301	chr6:80922561	G/T	cg08355045	chr6:80787529	NA	0.29	4.88	0.4	3.2e-6	Sitting height ratio;
TGCT	cis	rs797680	0.856	rs693737	chr1:93724924	G/A	cg17826107	chr1:92977322	EVI5	0.24	5.29	0.43	5.47e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs6088580	0.608	rs8114616	chr20:32969092	G/T	cg06115741	chr20:33292138	TP53INP2	-0.51	-4.56	-0.38	1.2e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs9916302	0.904	rs3744348	chr17:37417575	C/G	cg07936489	chr17:37558343	FBXL20	-0.63	-4.99	-0.41	2.03e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg06028808	chr11:68637592	NA	0.52	6.79	0.52	4.1e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs2730245	0.527	rs2709858	chr7:158675266	C/G	cg11984989	chr7:158649758	WDR60	1.01	7.85	0.58	1.65e-12	Height;
TGCT	cis	rs2562456	0.876	rs2681395	chr19:21738140	T/C	cg01304269	chr19:21688519	ZNF429	0.57	4.74	0.39	5.86e-6	Pain;
TGCT	cis	rs17221829	0.549	rs72969202	chr11:89358355	C/T	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.65	-0.39	8.43e-6	Anxiety in major depressive disorder;
TGCT	cis	rs62244186	0.715	rs13321717	chr3:44667455	C/A	cg02073558	chr3:44770973	ZNF501	0.61	5.91	0.47	3.02e-8	Depressive symptoms;
TGCT	cis	rs1008375	0.866	rs2109518	chr4:17572162	G/A	cg18681998	chr4:17616180	MED28	0.93	9.36	0.64	4.4e-16	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs826838	0.868	rs12322306	chr12:39130021	A/G	cg13010199	chr12:38710504	ALG10B	-0.63	-5.06	-0.41	1.46e-6	Heart rate;
TGCT	trans	rs1814175	0.676	rs1721999	chr11:49917372	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.51	-0.69	7.2e-19	Height;
TGCT	cis	rs10504229	0.679	rs72649120	chr8:58040308	C/T	cg08280861	chr8:58055591	NA	0.35	4.94	0.41	2.49e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1580019	0.587	rs9638880	chr7:32552401	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.13	14.1	0.78	1.55e-27	Cognitive ability;
TGCT	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg27121462	chr16:89883253	FANCA	0.81	8.95	0.63	4.42e-15	Vitiligo;
TGCT	trans	rs2727020	0.688	rs11040338	chr11:49360601	A/G	cg15704280	chr7:45808275	SEPT13	0.72	8.33	0.6	1.26e-13	Coronary artery disease;
TGCT	cis	rs1008375	0.966	rs3775927	chr4:17599894	G/T	cg10189774	chr4:17578691	LAP3	0.61	5.35	0.43	4.08e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10744422	1.000	rs7138398	chr12:123341833	G/C	cg25930673	chr12:123319894	HIP1R	-0.86	-5.02	-0.41	1.72e-6	Schizophrenia;
TGCT	cis	rs911263	0.603	rs1956524	chr14:68800393	G/A	cg18825221	chr14:68749962	RAD51L1	0.22	4.46	0.37	1.82e-5	Primary biliary cholangitis;
TGCT	cis	rs854765	0.964	rs854810	chr17:18006421	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.65	-6.31	-0.49	4.57e-9	Total body bone mineral density;
TGCT	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.96	0.41	2.28e-6	Height;
TGCT	cis	rs1008375	1.000	rs10032326	chr4:17630717	A/T	cg16339924	chr4:17578868	LAP3	0.62	5.11	0.42	1.21e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg11644478	chr21:40555479	PSMG1	0.97	10.46	0.68	9.69e-19	Cognitive function;
TGCT	cis	rs2153535	0.580	rs2152348	chr6:8474301	C/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs6500602	0.647	rs4786514	chr16:4576798	A/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	7.85	0.58	1.7e-12	Schizophrenia;
TGCT	cis	rs250677	0.524	rs417413	chr5:148452726	T/C	cg18129178	chr5:148520854	ABLIM3	-0.36	-5.32	-0.43	4.66e-7	Breast cancer;
TGCT	cis	rs11690462	0.963	rs7602910	chr2:26619131	G/T	cg04726446	chr2:26624865	C2orf39	0.42	4.63	0.38	9.27e-6	Coronary artery disease;
TGCT	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg20887711	chr4:1340912	KIAA1530	0.94	7.81	0.57	2.1e-12	Longevity;
TGCT	cis	rs7439150	1.000	rs2227407	chr4:155487984	C/T	cg22130008	chr4:155548532	NA	-0.48	-5.99	-0.47	2.07e-8	Fibrinogen levels;
TGCT	cis	rs78487399	0.808	rs75126888	chr2:43664007	C/T	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.72	4.62	0.38	9.53e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs4906332	1.000	rs35224956	chr14:103900481	A/G	cg26031613	chr14:104095156	KLC1	-0.52	-4.59	-0.38	1.08e-5	Coronary artery disease;
TGCT	cis	rs9611565	0.512	rs1983576	chr22:42166486	G/A	cg13695892	chr22:41940480	POLR3H	0.85	8.06	0.59	5.4e-13	Vitiligo;
TGCT	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg26354017	chr1:205819088	PM20D1	0.68	9.51	0.65	2e-16	Menarche (age at onset);
TGCT	cis	rs7216064	1.000	rs1976054	chr17:65833224	T/G	cg12091567	chr17:66097778	LOC651250	-0.87	-6.76	-0.52	4.7e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs1971762	0.730	rs7963016	chr12:54072819	T/A	cg09709951	chr12:54017699	ATF7	0.35	5.38	0.44	3.52e-7	Height;
TGCT	cis	rs7917772	0.545	rs10786681	chr10:104317357	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	5.36	0.43	3.84e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7829975	0.509	rs2945269	chr8:8115578	G/C	cg06636001	chr8:8085503	FLJ10661	0.82	8.2	0.59	2.55e-13	Mood instability;
TGCT	cis	rs631288	0.557	rs2354434	chr1:146679428	A/G	cg25205988	chr1:146714368	CHD1L	1.33	5.42	0.44	2.97e-7	PR interval in Tripanosoma cruzi seropositivity;
TGCT	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg18876405	chr7:65276391	NA	0.32	4.89	0.4	3.12e-6	Aortic root size;
TGCT	cis	rs10191773	0.522	rs6747639	chr2:112967458	C/T	cg07905836	chr2:113190072	RGPD8;RGPD5	0.43	4.44	0.37	1.96e-5	Yeast infection;
TGCT	cis	rs10883723	0.810	rs7074343	chr10:104283165	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs13108904	0.846	rs9631805	chr4:1283035	T/C	cg03303774	chr4:1407052	NA	-0.33	-4.94	-0.41	2.51e-6	Obesity-related traits;
TGCT	cis	rs877282	0.945	rs11253388	chr10:787852	A/G	cg17470449	chr10:769945	NA	0.3	4.71	0.39	6.53e-6	Uric acid levels;
TGCT	trans	rs77457752	0.562	rs7874765	chr9:13899199	G/C	cg23609682	chr1:3070786	PRDM16	0.5	6.79	0.52	4.09e-10	Breast cancer;
TGCT	cis	rs28595532	0.920	rs115576008	chr4:119736967	T/C	cg21605333	chr4:119757512	SEC24D	1.61	8.95	0.63	4.36e-15	Cannabis dependence symptom count;
TGCT	cis	rs4478858	0.735	rs1566961	chr1:31772450	G/A	cg00250761	chr1:31883323	NA	-0.28	-5.01	-0.41	1.86e-6	Alcohol dependence;
TGCT	cis	rs2797160	1.000	rs2747720	chr6:126009458	A/G	cg05901451	chr6:126070800	HEY2	0.72	6.11	0.48	1.18e-8	Endometrial cancer;
TGCT	cis	rs4381823	0.850	rs116282013	chr2:48160511	G/A	cg16590546	chr2:47169188	MCFD2;TTC7A	-1.13	-4.49	-0.37	1.61e-5	Schizophrenia;
TGCT	cis	rs9325144	0.600	rs6582630	chr12:38743508	A/G	cg26384229	chr12:38710491	ALG10B	-0.61	-5.6	-0.45	1.32e-7	Morning vs. evening chronotype;
TGCT	cis	rs909002	0.789	rs56074668	chr1:32123801	T/C	cg11573219	chr1:32083031	HCRTR1	-0.44	-5.61	-0.45	1.25e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9611565	0.559	rs4822049	chr22:41993496	G/A	cg13695892	chr22:41940480	POLR3H	-0.87	-8.01	-0.58	6.94e-13	Vitiligo;
TGCT	cis	rs45535039	0.506	rs4936467	chr11:119086629	A/T	cg16724696	chr11:118992527	HINFP	-0.66	-6.47	-0.5	2.03e-9	Plateletcrit;
TGCT	cis	rs7809950	0.678	rs6949634	chr7:106984684	G/T	cg23024343	chr7:107201750	COG5	-0.44	-5.94	-0.47	2.66e-8	Coronary artery disease;
TGCT	cis	rs7017914	0.905	rs4571761	chr8:71957173	A/C	cg23757474	chr8:71581111	LACTB2;XKR9	0.55	5.11	0.42	1.17e-6	Bone mineral density;
TGCT	cis	rs2228479	0.850	rs2190808	chr16:89840856	C/T	cg06558623	chr16:89946397	TCF25	0.45	4.52	0.38	1.42e-5	Skin colour saturation;
TGCT	cis	rs2439831	0.867	rs2243434	chr15:43689867	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	6.11	0.48	1.19e-8	Lung cancer in ever smokers;
TGCT	cis	rs12477438	0.520	rs6739579	chr2:99731552	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	13.05	0.76	4.93e-25	Chronic sinus infection;
TGCT	cis	rs2456568	0.771	rs2102333	chr11:93634749	G/A	cg14065697	chr11:93583672	C11orf90	-0.37	-4.63	-0.38	9.11e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs8032315	0.965	rs4932373	chr15:91429287	A/C	cg03209642	chr15:91427605	FES	0.55	5.31	0.43	4.79e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs644799	0.648	rs1255182	chr11:95472391	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.55	5.61	0.45	1.23e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7945705	0.811	rs7119939	chr11:8861543	G/T	cg21881798	chr11:8931708	C11orf17;ST5	0.41	4.56	0.38	1.23e-5	Hemoglobin concentration;
TGCT	cis	rs9790314	0.846	rs6768818	chr3:160951648	A/G	cg03342759	chr3:160939853	NMD3	-0.51	-5.66	-0.45	9.96e-8	Morning vs. evening chronotype;
TGCT	cis	rs2067615	0.560	rs12298717	chr12:107099883	C/T	cg15890332	chr12:107067104	RFX4	-0.28	-5.87	-0.47	3.71e-8	Heart rate;
TGCT	cis	rs9916302	0.904	rs8076494	chr17:37516722	A/G	cg07936489	chr17:37558343	FBXL20	0.55	4.48	0.37	1.69e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg10802521	chr3:52805072	NEK4	-0.78	-10.04	-0.67	9.96e-18	Bipolar disorder;
TGCT	trans	rs7819412	0.511	rs35558344	chr8:11434232	C/T	cg15556689	chr8:8085844	FLJ10661	-0.76	-7.1	-0.54	8.61e-11	Triglycerides;
TGCT	cis	rs4906332	1.000	rs17617832	chr14:103943140	T/C	cg26031613	chr14:104095156	KLC1	-0.52	-4.72	-0.39	6.31e-6	Coronary artery disease;
TGCT	cis	rs4319547	0.956	rs7397990	chr12:123119472	T/C	cg23029597	chr12:123009494	RSRC2	-0.28	-4.67	-0.39	7.68e-6	Body mass index;
TGCT	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg03188948	chr7:1209495	NA	-0.42	-5.24	-0.43	6.56e-7	Longevity;Endometriosis;
TGCT	cis	rs6430585	0.528	rs16832440	chr2:136754183	G/A	cg07169764	chr2:136633963	MCM6	1.25	12.67	0.75	4.02e-24	Corneal structure;
TGCT	cis	rs12220238	0.822	rs2395087	chr10:76082637	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.9	6.28	0.49	5.18e-9	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs9399135	0.838	rs4896126	chr6:135342786	C/A	cg24558204	chr6:135376177	HBS1L	0.5	5.0	0.41	1.89e-6	Red blood cell count;
TGCT	cis	rs6558530	0.777	rs3812477	chr8:1734452	C/G	cg09410841	chr8:1729607	CLN8	0.92	10.46	0.68	9.47e-19	Systolic blood pressure;
TGCT	cis	rs2798269	0.604	rs2798277	chr13:22155781	C/G	cg18095732	chr13:22033692	ZDHHC20	-0.52	-4.65	-0.39	8.43e-6	PR segment;
TGCT	cis	rs12216125	0.801	rs56107510	chr6:25987436	C/A	cg17691542	chr6:26056736	HIST1H1C	0.65	5.18	0.42	8.75e-7	Iron status biomarkers;
TGCT	cis	rs9916302	0.752	rs11078895	chr17:37401051	A/G	cg07936489	chr17:37558343	FBXL20	-0.77	-5.93	-0.47	2.85e-8	Glomerular filtration rate (creatinine);
TGCT	cis	rs4820539	0.934	rs3788348	chr22:23467946	G/C	cg21100191	chr22:23484243	RTDR1	0.88	10.0	0.67	1.28e-17	Bone mineral density;
TGCT	cis	rs1915146	0.546	rs2681919	chr10:126859029	A/G	cg23000734	chr10:126850823	CTBP2	0.46	4.95	0.41	2.35e-6	Menarche (age at onset);
TGCT	cis	rs17125944	0.656	rs74825460	chr14:53390015	C/T	cg00686598	chr14:53173677	PSMC6	0.92	4.54	0.38	1.29e-5	Alzheimer's disease (late onset);
TGCT	cis	rs7572733	0.534	rs1435570	chr2:198731371	T/C	cg00792783	chr2:198669748	PLCL1	0.56	5.08	0.42	1.35e-6	Dermatomyositis;
TGCT	cis	rs2458413	0.669	rs12681140	chr8:105346112	A/C	cg13045555	chr8:105342365	NA	0.4	6.7	0.52	6.51e-10	Paget's disease;
TGCT	cis	rs56235845	0.694	rs11749830	chr5:176766547	G/A	cg06060754	chr5:176797920	RGS14	0.42	6.57	0.51	1.23e-9	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs2440129	0.632	rs15966	chr17:6905643	T/C	cg03404566	chr17:6899310	ALOX12	0.47	5.26	0.43	6.17e-7	Tonsillectomy;
TGCT	cis	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg09021430	chr5:549028	NA	-0.37	-4.98	-0.41	2.07e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs9341808	0.727	rs1324120	chr6:80976125	G/C	cg08355045	chr6:80787529	NA	0.29	4.98	0.41	2.04e-6	Sitting height ratio;
TGCT	cis	rs6964587	1.000	rs9691325	chr7:91731047	G/A	cg17063962	chr7:91808500	NA	0.88	9.61	0.65	1.13e-16	Breast cancer;
TGCT	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg17554472	chr22:41940697	POLR3H	-0.49	-5.26	-0.43	6.14e-7	Vitiligo;
TGCT	cis	rs77669868	0.703	rs61904685	chr11:114072659	G/A	cg01914181	chr11:114070210	ZBTB16	0.31	4.64	0.38	8.61e-6	Monocyte percentage of white cells;
TGCT	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.84	7.5	0.56	1.08e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg08280861	chr8:58055591	NA	0.39	4.86	0.4	3.45e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs55883249	1.000	rs56372340	chr2:9741536	A/G	cg23886495	chr2:9695866	ADAM17	0.82	5.01	0.41	1.86e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs9303401	0.659	rs12946397	chr17:56769979	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.67	6.3	0.49	4.7e-9	Cognitive test performance;
TGCT	cis	rs6912958	0.559	rs242279	chr6:88048191	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.72	7.53	0.56	9.05e-12	Monocyte percentage of white cells;
TGCT	cis	rs7655441	0.964	rs7687679	chr4:80885183	G/A	cg02241357	chr4:80885279	ANTXR2	-0.23	-4.52	-0.38	1.4e-5	Neutrophil percentage of white cells;
TGCT	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg08280861	chr8:58055591	NA	0.4	4.73	0.39	5.97e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7213347	0.581	rs4790881	chr17:2068932	C/A	cg22033759	chr17:1182267	TUSC5	-0.23	-4.73	-0.39	5.94e-6	Total body bone mineral density;
TGCT	cis	rs9902453	1.000	rs4239227	chr17:28389103	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-6.56	-0.51	1.3e-9	Coffee consumption (cups per day);
TGCT	cis	rs3008870	0.920	rs2755253	chr1:67470843	C/T	cg02640540	chr1:67518911	SLC35D1	0.54	4.49	0.37	1.6e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs9549260	0.564	rs6563845	chr13:41318907	A/G	cg21288729	chr13:41239152	FOXO1	0.95	9.29	0.64	6.71e-16	Red blood cell count;
TGCT	cis	rs1964356	0.524	rs7839585	chr8:8854235	C/G	cg08975724	chr8:8085496	FLJ10661	-0.54	-4.65	-0.39	8.26e-6	Mean corpuscular volume;
TGCT	cis	rs6121246	0.909	rs6060923	chr20:30336655	A/C	cg18721089	chr20:30220636	NA	-0.43	-4.75	-0.39	5.54e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs10883723	0.810	rs10883728	chr10:104269301	A/G	cg05855489	chr10:104503620	C10orf26	0.54	4.75	0.39	5.5e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	trans	rs114540395	0.858	rs77564076	chr10:103320818	C/A	cg10198749	chr1:39920707	MACF1	0.55	7.05	0.53	1.11e-10	Schizophrenia;
TGCT	cis	rs8072100	0.967	rs3760370	chr17:45695832	C/T	cg08085267	chr17:45401833	C17orf57	0.43	4.63	0.38	9.02e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs3813567	0.759	rs12594550	chr15:78959037	C/G	cg24631222	chr15:78858424	CHRNA5	-0.67	-4.65	-0.39	8.4e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
TGCT	cis	rs35306767	0.903	rs11253460	chr10:887382	C/G	cg26597838	chr10:835615	NA	0.71	10.12	0.67	6.47e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs9868809	0.881	rs3806694	chr3:48672334	G/C	cg00383909	chr3:49044727	WDR6	0.97	5.08	0.42	1.34e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.36	0.55	2.25e-11	Prudent dietary pattern;
TGCT	cis	rs12464483	0.591	rs4952171	chr2:30886903	G/A	cg12454169	chr2:30669597	LCLAT1	0.5	5.27	0.43	5.97e-7	Pre-treatment pain in head and neck squamous cell carcinoma;
TGCT	cis	rs910316	1.000	rs12589376	chr14:75561152	C/T	cg23033748	chr14:75592666	NEK9	0.28	4.68	0.39	7.29e-6	Height;
TGCT	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.81	5.23	0.42	7.13e-7	Platelet count;
TGCT	cis	rs4824093	0.610	rs73443923	chr22:50285348	C/T	cg17212791	chr22:49483368	NA	0.38	4.49	0.37	1.59e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs4074961	0.527	rs10908356	chr1:38038388	G/A	cg11397548	chr1:38022522	DNALI1	0.42	4.83	0.4	3.93e-6	Axial length;
TGCT	cis	rs12135062	0.851	rs2651925	chr1:3101863	C/G	cg25382214	chr1:3105252	PRDM16	0.3	5.35	0.43	4.04e-7	Migraine;
TGCT	cis	rs7824557	0.628	rs2572387	chr8:11204165	C/T	cg21775007	chr8:11205619	TDH	0.74	7.15	0.54	6.66e-11	Retinal vascular caliber;
TGCT	cis	rs15676	0.783	rs7858732	chr9:131563540	A/G	cg00228799	chr9:131580591	ENDOG	-0.55	-4.76	-0.39	5.19e-6	Blood metabolite levels;
TGCT	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg20887711	chr4:1340912	KIAA1530	0.91	8.25	0.6	1.99e-13	Longevity;
TGCT	trans	rs9951602	0.833	rs9953548	chr18:76640601	C/T	cg02800362	chr5:177631904	HNRNPAB	0.99	7.18	0.54	5.69e-11	Obesity-related traits;
TGCT	cis	rs7675861	1.000	rs11946892	chr4:5850377	T/A	cg14241509	chr4:6196512	JAKMIP1	0.25	4.48	0.37	1.69e-5	Dysphagia;
TGCT	cis	rs2153535	0.580	rs2327057	chr6:8443319	G/A	cg07606381	chr6:8435919	SLC35B3	0.57	5.25	0.43	6.46e-7	Motion sickness;
TGCT	cis	rs67311347	0.955	rs73078170	chr3:40483947	C/T	cg13683864	chr3:40499215	RPL14	-1.22	-13.35	-0.77	9.36e-26	Renal cell carcinoma;
TGCT	cis	rs921968	0.509	rs3856548	chr2:219398164	C/T	cg02176678	chr2:219576539	TTLL4	-0.49	-6.94	-0.53	1.95e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs1865760	0.515	rs2003208	chr6:25940719	G/C	cg03264133	chr6:25882463	NA	-0.51	-5.27	-0.43	5.81e-7	Height;
TGCT	cis	rs7027203	0.797	rs57882762	chr9:96580825	T/G	cg14598338	chr9:96623480	NA	-0.61	-9.39	-0.64	3.74e-16	DNA methylation (variation);
TGCT	cis	rs7267979	1.000	rs2424716	chr20:25423538	G/A	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9902453	0.691	rs140701	chr17:28538532	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	5.91	0.47	3.02e-8	Coffee consumption (cups per day);
TGCT	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg25767906	chr1:53392781	SCP2	-0.6	-7.71	-0.57	3.49e-12	Monocyte count;
TGCT	cis	rs9300255	0.544	rs1716175	chr12:123658388	A/T	cg00376283	chr12:123451042	ABCB9	0.74	5.74	0.46	6.97e-8	Neutrophil percentage of white cells;
TGCT	cis	rs7973719	0.865	rs12830671	chr12:7347278	T/G	cg07052231	chr12:7363540	PEX5	0.38	5.86	0.47	3.95e-8	IgG glycosylation;
TGCT	cis	rs7267979	1.000	rs6083825	chr20:25366424	T/C	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs17221829	0.965	rs10830355	chr11:89443429	C/T	cg02982614	chr11:89391479	FOLH1B	-0.27	-4.67	-0.39	7.67e-6	Anxiety in major depressive disorder;
TGCT	trans	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg27523141	chr10:43048294	ZNF37B	0.7	8.15	0.59	3.36e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg00024416	chr22:24240387	NA	-0.24	-4.59	-0.38	1.06e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7959452	0.562	rs11177630	chr12:69767963	G/C	cg11871910	chr12:69753446	YEATS4	0.82	8.82	0.62	8.61e-15	Blood protein levels;
TGCT	cis	rs7552404	0.727	rs5745390	chr1:76306591	A/C	cg03433033	chr1:76189801	ACADM	0.65	6.73	0.52	5.56e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9486719	0.948	rs2499813	chr6:96875338	T/C	cg18709589	chr6:96969512	KIAA0776	0.71	5.21	0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs713587	1.000	rs713587	chr2:25158281	C/T	cg01884057	chr2:25150051	NA	0.39	8.05	0.59	5.76e-13	Body mass index in non-asthmatics;
TGCT	cis	rs1577917	0.958	rs12196377	chr6:86566775	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-5.02	-0.41	1.74e-6	Response to antipsychotic treatment;
TGCT	cis	rs67478160	0.572	rs8015603	chr14:104293678	C/G	cg26031613	chr14:104095156	KLC1	-0.63	-6.53	-0.51	1.56e-9	Schizophrenia;
TGCT	trans	rs1814175	0.817	rs10769617	chr11:49810421	G/A	cg15704280	chr7:45808275	SEPT13	-0.72	-8.14	-0.59	3.61e-13	Height;
TGCT	cis	rs644799	1.000	rs2508289	chr11:95624669	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.74	7.66	0.57	4.71e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg07507251	chr3:52567010	NT5DC2	0.47	6.7	0.52	6.39e-10	Bipolar disorder;
TGCT	cis	rs533581	0.866	rs562812	chr16:88970944	G/A	cg16701003	chr16:89028210	CBFA2T3	0.41	5.3	0.43	5.11e-7	Social autistic-like traits;
TGCT	cis	rs3812049	0.784	rs2568928	chr5:127487603	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.6	-5.47	-0.44	2.41e-7	Lymphocyte counts;Red cell distribution width;
TGCT	cis	rs7772486	0.558	rs7753273	chr6:146066039	C/T	cg23711669	chr6:146136114	FBXO30	-0.74	-6.63	-0.51	9.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg26818010	chr10:134567672	INPP5A	-0.39	-5.52	-0.44	1.88e-7	Migraine;
TGCT	cis	rs11718455	0.960	rs17076255	chr3:44002093	C/T	cg08738300	chr3:44038990	NA	0.85	6.41	0.5	2.72e-9	Coronary artery disease;
TGCT	cis	rs6681544	0.544	rs993099	chr1:82388902	G/A	cg04226724	chr1:82268649	LPHN2	0.47	4.95	0.41	2.33e-6	Metabolite levels  (X-11787);
TGCT	cis	rs6952808	0.500	rs3823631	chr7:2190100	A/G	cg22963979	chr7:1858916	MAD1L1	-0.38	-5.83	-0.46	4.5e-8	Bipolar disorder and schizophrenia;
TGCT	cis	rs9308731	0.644	rs1837367	chr2:111874551	G/A	cg04202892	chr2:111875749	ACOXL	0.54	6.22	0.49	6.96e-9	Chronic lymphocytic leukemia;
TGCT	cis	rs17376456	0.877	rs10044139	chr5:93407803	T/C	cg25358565	chr5:93447407	FAM172A	0.92	8.38	0.6	9.58e-14	Diabetic retinopathy;
TGCT	cis	rs8056742	1.000	rs11648527	chr16:85093913	A/G	cg00229868	chr16:85520891	NA	0.34	5.1	0.42	1.22e-6	Amyotrophic lateral sclerosis;
TGCT	cis	rs2204008	0.652	rs11520002	chr12:38022179	G/T	cg13010199	chr12:38710504	ALG10B	0.65	5.23	0.42	7.11e-7	Bladder cancer;
TGCT	cis	rs763121	0.962	rs2071887	chr22:38879010	A/T	cg06022373	chr22:39101656	GTPBP1	0.71	6.64	0.51	8.71e-10	Menopause (age at onset);
TGCT	cis	rs9911578	0.757	rs8081906	chr17:56631907	A/T	cg12560992	chr17:57184187	TRIM37	-0.72	-7.62	-0.56	5.74e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs8084125	0.832	rs884472	chr18:74946087	A/G	cg05528293	chr18:74961138	GALR1	0.48	4.8	0.4	4.45e-6	Obesity-related traits;
TGCT	cis	rs1577917	0.958	rs1591438	chr6:86525214	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.23	-0.43	7.01e-7	Response to antipsychotic treatment;
TGCT	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg21171335	chr12:122356390	WDR66	0.68	6.7	0.52	6.4e-10	Mean corpuscular volume;
TGCT	cis	rs1505368	0.567	rs972491	chr2:213316573	A/G	cg20637307	chr2:213403960	ERBB4	-0.67	-7.06	-0.54	1.06e-10	Symmetrical dimethylarginine levels;
TGCT	cis	rs2072499	1.000	rs2241108	chr1:156181007	C/G	cg24450063	chr1:156163899	SLC25A44	1.17	17.17	0.84	1.46e-34	Testicular germ cell tumor;
TGCT	cis	rs9649213	1.000	rs9649213	chr7:98021211	A/G	cg09267113	chr7:98030324	BAIAP2L1	-0.66	-5.71	-0.46	7.97e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs11122272	0.735	rs2486741	chr1:231516450	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.13	-0.54	7.33e-11	Hemoglobin concentration;
TGCT	cis	rs250677	0.522	rs919731	chr5:148352150	T/C	cg18129178	chr5:148520854	ABLIM3	0.38	4.88	0.4	3.23e-6	Breast cancer;
TGCT	cis	rs308403	0.509	rs309376	chr4:123680191	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.82	11.69	0.72	9.78e-22	Blood protein levels;
TGCT	cis	rs3125734	0.571	rs7100401	chr10:64024417	C/G	cg09941381	chr10:64027924	RTKN2	-0.37	-5.64	-0.45	1.1e-7	Rheumatoid arthritis;
TGCT	cis	rs2014511	1.000	rs6848819	chr4:154451678	A/C	cg17385088	chr4:153611560	NA	-0.45	-5.01	-0.41	1.83e-6	Platelet distribution width;Mean platelet volume;
TGCT	cis	rs8016982	0.962	rs8007841	chr14:81647878	C/T	cg01989461	chr14:81687754	GTF2A1	-0.61	-5.09	-0.42	1.29e-6	Schizophrenia;
TGCT	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg17554472	chr22:41940697	POLR3H	0.46	4.71	0.39	6.63e-6	Vitiligo;
TGCT	cis	rs9443645	0.808	rs2050661	chr6:79661125	T/C	cg05283184	chr6:79620031	NA	-0.21	-4.71	-0.39	6.61e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9972944	0.729	rs7502798	chr17:63781615	C/T	cg07283582	chr17:63770753	CCDC46	0.25	4.8	0.4	4.39e-6	Total body bone mineral density;
TGCT	cis	rs116161686	0.500	rs76610459	chr1:210050756	T/G	cg04352962	chr1:209979756	IRF6	0.63	4.48	0.37	1.65e-5	Coronary artery disease;
TGCT	cis	rs12464483	0.524	rs2256411	chr2:30886860	C/A	cg17749961	chr2:30669863	LCLAT1	0.58	4.5	0.37	1.55e-5	Pre-treatment pain in head and neck squamous cell carcinoma;
TGCT	cis	rs9443645	0.901	rs3805747	chr6:79672522	A/G	cg05283184	chr6:79620031	NA	-0.21	-4.71	-0.39	6.61e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	9.52	0.65	1.86e-16	Platelet count;
TGCT	trans	rs931812	0.757	rs35569317	chr8:101907971	T/C	cg20993868	chr7:22813445	NA	0.32	6.63	0.51	9.13e-10	Attention deficit hyperactivity disorder and conduct disorder;
TGCT	cis	rs1215050	0.791	rs684210	chr4:98678740	G/C	cg17366294	chr4:99064904	C4orf37	0.52	5.51	0.44	1.97e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7833790	0.636	rs12544174	chr8:82731477	G/A	cg06027949	chr8:82754900	SNX16	-0.65	-5.03	-0.41	1.69e-6	Diastolic blood pressure;
TGCT	cis	rs7945705	0.935	rs1883098	chr11:8890594	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-5.46	-0.44	2.51e-7	Hemoglobin concentration;
TGCT	cis	rs3820928	0.874	rs1996998	chr2:227840294	C/A	cg11843606	chr2:227700838	RHBDD1	-0.52	-4.58	-0.38	1.1e-5	Pulmonary function;
TGCT	cis	rs12142240	0.698	rs17361805	chr1:46813967	C/T	cg14993813	chr1:46806288	NSUN4	-0.58	-4.75	-0.39	5.54e-6	Menopause (age at onset);
TGCT	cis	rs9393777	0.513	rs13195210	chr6:26646521	C/T	cg15659132	chr6:26577336	NA	-0.75	-5.25	-0.43	6.33e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs10779751	0.960	rs4845857	chr1:11285680	T/C	cg08854313	chr1:11322531	MTOR	0.96	10.15	0.67	5.52e-18	Body mass index;
TGCT	cis	rs72945132	0.882	rs11235953	chr11:70184937	C/T	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs6690583	0.623	rs893618	chr1:85513770	C/T	cg20280350	chr1:85513789	MCOLN3	-0.79	-4.9	-0.4	2.9e-6	Serum sulfate level;
TGCT	cis	rs10242455	0.702	rs76840929	chr7:98945858	T/C	cg13560068	chr7:99070416	ZNF789	1.1	4.68	0.39	7.38e-6	Blood metabolite levels;
TGCT	cis	rs858239	0.600	rs2003555	chr7:23122915	C/T	cg05602783	chr7:23145260	KLHL7	-0.6	-4.99	-0.41	2.02e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs4713675	0.649	rs568901	chr6:33710038	A/G	cg18005901	chr6:33739558	LEMD2	0.49	5.92	0.47	2.88e-8	Plateletcrit;
TGCT	cis	rs9303401	0.538	rs12603174	chr17:56489279	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.6	5.61	0.45	1.23e-7	Cognitive test performance;
TGCT	cis	rs3749237	0.595	rs3870338	chr3:49557051	A/G	cg03060546	chr3:49711283	APEH	0.74	8.46	0.6	6.25e-14	Resting heart rate;
TGCT	cis	rs3806843	0.966	rs2563260	chr5:140137867	C/A	cg19875535	chr5:140030758	IK	-0.37	-6.4	-0.5	2.86e-9	Depressive symptoms (multi-trait analysis);
TGCT	trans	rs7726839	0.540	rs11739847	chr5:609661	G/A	cg11887960	chr12:57824829	NA	1.2	9.35	0.64	4.8e-16	Obesity-related traits;
TGCT	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg09365446	chr1:150670422	GOLPH3L	0.31	4.64	0.38	8.7e-6	Tonsillectomy;
TGCT	trans	rs7698623	0.867	rs4693191	chr4:88797873	C/T	cg01186725	chr1:53905612	FLJ40434	-0.48	-6.63	-0.51	9.21e-10	Cardiovascular disease risk factors;
TGCT	cis	rs2228479	0.702	rs17233441	chr16:89817998	C/G	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs12220238	0.722	rs7901055	chr10:76415029	A/C	cg19889307	chr10:75911429	ADK;AP3M1	-0.6	-4.62	-0.38	9.58e-6	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs28595532	0.841	rs55823625	chr4:119780600	T/A	cg11846333	chr4:119757529	SEC24D	0.92	4.64	0.38	8.74e-6	Cannabis dependence symptom count;
TGCT	cis	rs9581857	0.547	rs9579086	chr13:28058537	T/A	cg22138327	chr13:27999177	GTF3A	0.71	4.43	0.37	2.01e-5	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs7729723	0.533	rs6596433	chr5:137814972	G/A	cg19169342	chr5:137827400	NA	0.33	4.6	0.38	1.04e-5	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);
TGCT	cis	rs7726839	0.540	rs11750321	chr5:599196	C/T	cg09021430	chr5:549028	NA	-0.43	-5.77	-0.46	5.99e-8	Obesity-related traits;
TGCT	cis	rs2239547	0.522	rs7652131	chr3:52997154	C/T	cg10802521	chr3:52805072	NEK4	-0.61	-5.9	-0.47	3.2e-8	Schizophrenia;
TGCT	cis	rs17376456	0.877	rs12716456	chr5:93397557	A/G	cg25358565	chr5:93447407	FAM172A	0.92	8.38	0.6	9.58e-14	Diabetic retinopathy;
TGCT	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg25036284	chr2:26402008	FAM59B	-0.58	-4.61	-0.38	1.01e-5	Gut microbiome composition (summer);
TGCT	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg03351412	chr1:154909251	PMVK	0.52	4.8	0.4	4.4e-6	Prostate cancer;
TGCT	cis	rs7507204	0.906	rs11671513	chr19:3429937	C/T	cg08380311	chr19:3435252	NFIC	0.95	8.01	0.58	7.03e-13	Height;
TGCT	cis	rs1865760	1.000	rs2071301	chr6:25914263	G/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.65	6.3	0.49	4.62e-9	Height;
TGCT	cis	rs7833790	0.724	rs72603871	chr8:82754460	C/G	cg27398817	chr8:82754497	SNX16	0.69	5.52	0.44	1.9e-7	Diastolic blood pressure;
TGCT	cis	rs9486715	0.867	rs9486444	chr6:96963619	A/G	cg06623918	chr6:96969491	KIAA0776	1.1	15.44	0.81	1.17e-30	Headache;
TGCT	trans	rs74910095	0.656	rs11958312	chr5:62937589	G/A	cg02938449	chr2:220419364	OBSL1	0.8	6.75	0.52	4.95e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	trans	rs12339966	0.653	rs11794038	chr9:11327731	C/A	cg03488587	chr11:64876988	C11orf2	0.3	6.9	0.53	2.36e-10	Systolic blood pressure;
TGCT	cis	rs5769707	1.000	rs5769707	chr22:50013402	G/T	cg05373962	chr22:49881684	NA	-0.3	-6.21	-0.49	7.34e-9	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs7772486	0.743	rs9390344	chr6:146012755	C/G	cg05347473	chr6:146136440	FBXO30	-0.49	-4.67	-0.39	7.63e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7647973	0.710	rs1532204	chr3:49609477	C/G	cg03060546	chr3:49711283	APEH	0.63	5.14	0.42	1.03e-6	Menarche (age at onset);
TGCT	cis	rs11098499	0.954	rs71614438	chr4:120371252	G/A	cg09307838	chr4:120376055	NA	0.68	6.53	0.51	1.54e-9	Corneal astigmatism;
TGCT	cis	rs7246657	1.000	rs6508710	chr19:37749886	A/G	cg03233940	chr19:37894644	NA	-0.37	-4.79	-0.39	4.73e-6	Coronary artery calcification;
TGCT	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg11890956	chr21:40555474	PSMG1	1.1	12.16	0.74	7.11e-23	Cognitive function;
TGCT	cis	rs7829975	0.540	rs2976909	chr8:8346690	C/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-5.48	-0.44	2.3e-7	Mood instability;
TGCT	cis	rs7909074	0.798	rs914699	chr10:45377066	A/C	cg04218760	chr10:45406644	TMEM72	-0.3	-5.92	-0.47	2.88e-8	Mean corpuscular volume;
TGCT	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg22535103	chr8:58192502	C8orf71	-0.42	-4.68	-0.39	7.3e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1005224	0.963	rs12887886	chr14:76167846	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.63	-5.64	-0.45	1.09e-7	Large artery stroke;
TGCT	cis	rs10782582	0.593	rs6704444	chr1:76205108	T/C	cg10523679	chr1:76189770	ACADM	-0.67	-6.75	-0.52	4.99e-10	Daytime sleep phenotypes;
TGCT	cis	rs12681288	0.550	rs60530879	chr8:958381	G/C	cg04851639	chr8:1020857	NA	-0.27	-4.45	-0.37	1.85e-5	Schizophrenia;
TGCT	cis	rs2013441	1.000	rs2013441	chr17:20023099	G/A	cg23224458	chr17:20280056	CCDC144C	0.4	4.72	0.39	6.31e-6	Obesity-related traits;
TGCT	cis	rs57590327	0.644	rs62265393	chr3:81526075	G/C	cg07356753	chr3:81810745	GBE1	-0.53	-4.44	-0.37	1.97e-5	Extraversion;
TGCT	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg17971929	chr21:40555470	PSMG1	-0.68	-5.96	-0.47	2.47e-8	Cognitive function;
TGCT	cis	rs8111998	0.826	rs10420648	chr19:22767819	G/A	cg19914732	chr19:22715077	NA	-0.56	-4.51	-0.38	1.46e-5	Corneal structure;
TGCT	cis	rs478304	0.593	rs7120713	chr11:65483374	G/C	cg17480646	chr11:65405466	SIPA1	-0.59	-6.88	-0.53	2.63e-10	Acne (severe);
TGCT	cis	rs2956278	0.717	rs2929750	chr12:84680334	G/A	cg25678815	chr12:85673915	ALX1	-0.54	-4.83	-0.4	3.96e-6	Depressive symptoms;Depressive symptoms (multi-trait analysis);
TGCT	cis	rs55962025	0.804	rs3775061	chr4:3238754	A/G	cg06533319	chr4:3265114	C4orf44	0.24	4.61	0.38	9.98e-6	Parental longevity (mother's age at death);
TGCT	cis	rs6912958	1.000	rs6912958	chr6:88133315	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.68	-6.84	-0.52	3.18e-10	Monocyte percentage of white cells;
TGCT	cis	rs4727027	0.801	rs12666337	chr7:148796253	C/T	cg23583168	chr7:148888333	NA	-0.72	-9.11	-0.63	1.8e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs12497850	0.931	rs3774628	chr3:48801840	C/T	cg05785598	chr3:49045655	WDR6	0.35	4.75	0.39	5.58e-6	Parkinson's disease;
TGCT	cis	rs752010	0.714	rs10890144	chr1:42085397	G/T	cg06885757	chr1:42089581	HIVEP3	0.24	4.58	0.38	1.12e-5	Lupus nephritis in systemic lupus erythematosus;
TGCT	cis	rs9325144	0.625	rs12227353	chr12:38734542	C/T	cg26384229	chr12:38710491	ALG10B	-0.61	-5.58	-0.45	1.43e-7	Morning vs. evening chronotype;
TGCT	cis	rs9788682	0.747	rs8043009	chr15:78908154	G/C	cg24631222	chr15:78858424	CHRNA5	0.78	5.71	0.46	8.03e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	trans	rs8073060	0.586	rs226089	chr17:34016935	C/T	cg19694781	chr19:47549865	TMEM160	-0.6	-13.37	-0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs6831352	0.918	rs17218288	chr4:100058030	A/T	cg12011299	chr4:100065546	ADH4	-0.4	-4.88	-0.4	3.26e-6	Alcohol dependence;
TGCT	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg00149659	chr3:10157352	C3orf10	0.91	5.89	0.47	3.32e-8	Alzheimer's disease;
TGCT	cis	rs3862435	0.572	rs2601165	chr15:90908934	C/G	cg14166756	chr15:90894880	ZNF774	0.29	4.57	0.38	1.15e-5	Response to exercise (triglyceride level interaction);
TGCT	cis	rs9486719	0.948	rs6920913	chr6:96874297	A/G	cg18709589	chr6:96969512	KIAA0776	0.69	5.49	0.44	2.2e-7	Migraine;Coronary artery disease;
TGCT	cis	rs3087591	0.592	rs2342054	chr17:29724708	G/A	cg24425628	chr17:29625626	OMG;NF1	0.4	5.85	0.47	4.05e-8	Hip circumference;
TGCT	trans	rs12339966	0.601	rs57645776	chr9:11290297	C/T	cg03488587	chr11:64876988	C11orf2	0.3	6.7	0.52	6.5e-10	Systolic blood pressure;
TGCT	cis	rs6964587	0.610	rs2888850	chr7:91430027	T/C	cg17063962	chr7:91808500	NA	0.73	6.64	0.51	8.68e-10	Breast cancer;
TGCT	cis	rs3540	0.960	rs8030299	chr15:91026459	G/A	cg22089800	chr15:90895588	ZNF774	0.77	7.25	0.55	4.02e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs910316	1.000	rs4899546	chr14:75594946	G/C	cg11812906	chr14:75593930	NEK9	0.74	7.37	0.55	2.12e-11	Height;
TGCT	cis	rs7772486	0.790	rs1832362	chr6:146179955	C/T	cg13319975	chr6:146136371	FBXO30	-0.5	-4.49	-0.37	1.61e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7666738	0.830	rs921521	chr4:98838339	A/G	cg05340658	chr4:99064831	C4orf37	0.52	6.05	0.48	1.61e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs981844	0.712	rs6855093	chr4:154754050	A/G	cg14289246	chr4:154710475	SFRP2	-0.98	-8.82	-0.62	8.67e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs3091242	0.967	rs665372	chr1:25719235	A/C	cg00786635	chr1:25594202	NA	0.54	5.52	0.44	1.93e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	6.13	0.48	1.06e-8	Bipolar disorder;
TGCT	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg11366901	chr6:160182831	ACAT2	1.03	6.92	0.53	2.14e-10	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg07424592	chr7:64974309	NA	-1.27	-7.84	-0.58	1.8e-12	Diabetic kidney disease;
TGCT	cis	rs79387448	0.745	rs6749440	chr2:103101846	C/T	cg09003973	chr2:102972529	NA	0.88	5.86	0.47	3.87e-8	Gut microbiota (bacterial taxa);
TGCT	cis	rs57920188	0.584	rs12128330	chr1:4092926	G/A	cg20703997	chr1:4087676	NA	0.48	5.81	0.46	5e-8	Interleukin-17 levels;
TGCT	cis	rs12142240	0.698	rs41294476	chr1:46818374	C/A	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs9399135	0.967	rs4896121	chr6:135293645	T/C	cg24558204	chr6:135376177	HBS1L	0.48	4.75	0.39	5.5e-6	Red blood cell count;
TGCT	cis	rs3924048	0.547	rs6678689	chr1:12619904	A/G	cg00291366	chr1:12616550	NA	0.34	5.06	0.41	1.47e-6	Optic cup area;
TGCT	cis	rs9357506	1.000	rs1837898	chr6:46322410	A/G	cg21115430	chr6:46460003	NA	-0.23	-4.54	-0.38	1.34e-5	Body mass index;
TGCT	cis	rs2963155	0.518	rs33389	chr5:142700499	C/T	cg17617527	chr5:142782415	NR3C1	0.84	6.16	0.48	9.5e-9	Breast cancer;
TGCT	cis	rs7267979	0.789	rs2260197	chr20:25284343	T/C	cg16686733	chr20:25566563	NINL	0.49	4.62	0.38	9.44e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg00149659	chr3:10157352	C3orf10	-0.9	-6.17	-0.48	8.88e-9	Alzheimer's disease;
TGCT	cis	rs7772486	0.754	rs6570703	chr6:145957052	C/T	cg23711669	chr6:146136114	FBXO30	0.84	9.16	0.64	1.36e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.71	5.07	0.41	1.4e-6	Platelet count;
TGCT	cis	rs3733585	0.673	rs9994266	chr4:9954450	C/T	cg11266682	chr4:10021025	SLC2A9	-0.55	-7.29	-0.55	3.2e-11	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs11096990	0.656	rs3733284	chr4:39301334	A/G	cg20847110	chr4:39482781	LOC401127	-0.17	-4.82	-0.4	4.05e-6	Cognitive function;
TGCT	cis	rs7635838	0.684	rs2606757	chr3:11358163	T/A	cg00170343	chr3:11313890	ATG7	0.6	5.86	0.47	3.84e-8	HDL cholesterol;
TGCT	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg10295955	chr4:187884368	NA	-0.95	-14.1	-0.78	1.61e-27	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs208520	0.874	rs208515	chr6:66945749	A/G	cg07460842	chr6:66804631	NA	-0.9	-9.15	-0.63	1.45e-15	Exhaled nitric oxide output;
TGCT	cis	rs9467773	1.000	rs6933176	chr6:26540178	G/A	cg05738196	chr6:26577821	NA	0.88	12.5	0.75	1.03e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs896854	0.818	rs13262110	chr8:95926890	C/T	cg23172400	chr8:95962367	TP53INP1	-0.34	-5.51	-0.44	2.02e-7	Type 2 diabetes;
TGCT	cis	rs3820068	0.603	rs6429753	chr1:15900537	A/G	cg05660106	chr1:15850417	CASP9	1.11	13.25	0.77	1.63e-25	Systolic blood pressure;
TGCT	cis	rs35146811	0.695	rs1727132	chr7:99812297	T/C	cg00553149	chr7:99775558	STAG3;GPC2	-0.31	-4.61	-0.38	9.75e-6	Coronary artery disease;
TGCT	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg02725872	chr8:58115012	NA	-0.38	-5.16	-0.42	9.32e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg16680214	chr1:154839983	KCNN3	-0.38	-8.12	-0.59	4e-13	Prostate cancer;
TGCT	cis	rs2708977	0.608	rs631033	chr2:97090430	C/T	cg01950434	chr2:97203154	ARID5A	-0.61	-5.26	-0.43	6.08e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs1129187	0.702	rs2296805	chr6:42928758	T/G	cg09436375	chr6:42928200	GNMT	-0.43	-5.41	-0.44	3.13e-7	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs7635838	0.859	rs9875414	chr3:11453559	A/G	cg00170343	chr3:11313890	ATG7	0.65	6.15	0.48	9.98e-9	HDL cholesterol;
TGCT	cis	rs17345786	0.520	rs1476123	chr3:101313413	C/G	cg12386194	chr3:101231763	SENP7	0.53	5.59	0.45	1.38e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs854765	0.964	rs72827413	chr17:17988299	C/T	cg04398451	chr17:18023971	MYO15A	0.3	4.67	0.39	7.55e-6	Total body bone mineral density;
TGCT	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg23131131	chr22:24373011	LOC391322	-0.8	-8.63	-0.61	2.53e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7666738	1.000	rs35066600	chr4:98991066	C/A	cg17366294	chr4:99064904	C4orf37	0.69	6.39	0.5	3.1e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg02953382	chr22:24373134	LOC391322	-0.57	-5.46	-0.44	2.44e-7	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1205863	0.607	rs1205849	chr6:11940464	G/C	cg07106625	chr6:11870215	NA	0.45	4.68	0.39	7.29e-6	Disc degeneration (lumbar);
TGCT	cis	rs6940638	0.956	rs36048693	chr6:27032711	T/G	cg16898833	chr6:26189333	HIST1H4D	0.72	5.39	0.44	3.37e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg17264618	chr3:40429014	ENTPD3	0.32	4.57	0.38	1.18e-5	Renal cell carcinoma;
TGCT	cis	rs35146811	0.735	rs1637001	chr7:99808151	G/A	cg22906224	chr7:99728672	NA	-0.49	-4.45	-0.37	1.88e-5	Coronary artery disease;
TGCT	cis	rs8141529	0.509	rs7287124	chr22:29239157	A/G	cg02153584	chr22:29168773	CCDC117	0.64	5.25	0.43	6.31e-7	Lymphocyte counts;
TGCT	cis	rs1056053	0.514	rs3127329	chr6:166572362	G/A	cg17219086	chr6:166541254	NA	-0.19	-4.5	-0.37	1.55e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg13342137	chr4:2252803	MXD4	0.17	4.44	0.37	1.94e-5	Obesity-related traits;
TGCT	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg13683864	chr3:40499215	RPL14	-1.19	-13.2	-0.76	2.17e-25	Renal cell carcinoma;
TGCT	cis	rs1401999	0.546	rs4148593	chr3:183649870	A/G	cg01324343	chr3:183735012	ABCC5	0.56	6.19	0.49	8.13e-9	Anterior chamber depth;
TGCT	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg18402987	chr7:1209562	NA	0.81	6.94	0.53	1.9e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2880765	0.835	rs12910373	chr15:86046802	G/C	cg13263323	chr15:86062960	AKAP13	-0.23	-4.82	-0.4	4.1e-6	Coronary artery disease;
TGCT	cis	rs9486719	1.000	rs9373978	chr6:97056255	T/C	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.21	-0.59	2.44e-13	Migraine;Coronary artery disease;
TGCT	trans	rs3780486	0.522	rs7029897	chr9:33124042	T/C	cg20290983	chr6:43655470	MRPS18A	0.79	8.62	0.61	2.64e-14	IgG glycosylation;
TGCT	cis	rs1023500	0.507	rs6002600	chr22:42488906	G/A	cg15557168	chr22:42548783	NA	0.22	5.58	0.45	1.47e-7	Schizophrenia;
TGCT	cis	rs9467773	0.873	rs9295698	chr6:26566099	T/A	cg09904177	chr6:26538194	HMGN4	0.66	6.6	0.51	1.05e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.53	-5.12	-0.42	1.11e-6	Longevity;Endometriosis;
TGCT	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-6.54	-0.51	1.42e-9	Alzheimer's disease;
TGCT	trans	rs9951602	0.512	rs4799244	chr18:76649763	T/C	cg02800362	chr5:177631904	HNRNPAB	1.15	13.03	0.76	5.64e-25	Obesity-related traits;
TGCT	cis	rs17253792	0.822	rs79538158	chr14:56051365	G/T	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs7829975	0.782	rs6990746	chr8:8547811	A/G	cg06636001	chr8:8085503	FLJ10661	-0.6	-5.02	-0.41	1.77e-6	Mood instability;
TGCT	cis	rs1008375	0.966	rs2315645	chr4:17579678	G/C	cg10189774	chr4:17578691	LAP3	0.64	5.61	0.45	1.28e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg08048268	chr3:133502702	NA	-0.65	-9.83	-0.66	3.21e-17	Iron status biomarkers;
TGCT	cis	rs986417	1.000	rs1254286	chr14:60858300	T/C	cg27398547	chr14:60952738	C14orf39	-1.41	-9.11	-0.63	1.75e-15	Gut microbiota (bacterial taxa);
TGCT	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.61	0.38	9.85e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7208859	0.524	rs59923796	chr17:29064919	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	4.87	0.4	3.36e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg02953382	chr22:24373134	LOC391322	-0.85	-10.0	-0.67	1.28e-17	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6460942	0.908	rs73677559	chr7:12270819	A/C	cg06484146	chr7:12443880	VWDE	-0.53	-4.65	-0.39	8.3e-6	Coronary artery disease;
TGCT	cis	rs782590	0.902	rs2586947	chr2:55854009	C/G	cg18811423	chr2:55921094	PNPT1	0.67	7.12	0.54	7.68e-11	Metabolic syndrome;
TGCT	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg08392591	chr16:89556376	ANKRD11	-0.57	-5.42	-0.44	3.02e-7	Multiple myeloma (IgH translocation);
TGCT	cis	rs7659604	0.676	rs6534323	chr4:122695888	G/A	cg23574427	chr4:122746245	BBS7;CCNA2	-0.34	-5.41	-0.44	3.12e-7	Type 2 diabetes;
TGCT	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg22433210	chr17:43662623	NA	-0.97	-6.84	-0.52	3.24e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2708977	0.901	rs6753667	chr2:97160382	G/A	cg01950434	chr2:97203154	ARID5A	-0.66	-5.84	-0.46	4.34e-8	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs4654899	0.758	rs1354792	chr1:21391875	C/T	cg01072550	chr1:21505969	NA	0.57	9.25	0.64	8.18e-16	Superior frontal gyrus grey matter volume;
TGCT	trans	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg21659725	chr3:3221576	CRBN	-0.73	-8.42	-0.6	7.67e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs10779751	1.000	rs2024627	chr1:11298790	T/C	cg08854313	chr1:11322531	MTOR	0.98	9.12	0.63	1.65e-15	Body mass index;
TGCT	cis	rs9341808	0.690	rs9343970	chr6:80881289	C/G	cg08355045	chr6:80787529	NA	0.32	5.64	0.45	1.11e-7	Sitting height ratio;
TGCT	cis	rs9952991	0.883	rs2847293	chr18:12782448	A/T	cg24737193	chr18:12778029	NA	0.53	5.93	0.47	2.8e-8	Inflammatory skin disease;
TGCT	cis	rs7845219	0.544	rs7016078	chr8:95922615	G/A	cg13393036	chr8:95962371	TP53INP1	-0.44	-5.14	-0.42	1.05e-6	Type 2 diabetes;
TGCT	cis	rs9549367	0.789	rs6577035	chr13:113879997	G/A	cg18105134	chr13:113819100	PROZ	-0.33	-5.38	-0.43	3.61e-7	Platelet distribution width;
TGCT	cis	rs7926906	1.000	rs7939348	chr11:90522401	T/A	cg26138821	chr11:89956704	CHORDC1	-0.51	-5.52	-0.44	1.92e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1055129	0.537	rs1135640	chr17:73949540	C/G	cg02678768	chr17:74002944	EVPL	-0.24	-4.54	-0.38	1.32e-5	White matter hyperintensity burden;
TGCT	cis	rs9911578	0.967	rs8072712	chr17:57162464	A/T	cg12560992	chr17:57184187	TRIM37	0.79	9.71	0.66	6.56e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs8078723	1.000	rs1042658	chr17:38173902	C/T	cg17467752	chr17:38218738	THRA	0.52	4.93	0.41	2.54e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs2224391	0.628	rs2753245	chr6:5258092	G/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.95	-5.69	-0.46	8.51e-8	Height;
TGCT	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.12	0.42	1.15e-6	Prudent dietary pattern;
TGCT	cis	rs56116382	0.604	rs9858428	chr3:49877585	G/T	cg08550065	chr3:50336684	HYAL3;NAT6	1.03	4.99	0.41	1.95e-6	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
TGCT	cis	rs2594989	0.943	rs2594970	chr3:11400877	C/T	cg00170343	chr3:11313890	ATG7	0.66	5.11	0.42	1.2e-6	Circulating chemerin levels;
TGCT	cis	rs2228479	0.850	rs62054640	chr16:89823157	C/T	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs853679	0.567	rs9969098	chr6:28398748	G/T	cg18815343	chr6:28367644	ZSCAN12	-0.5	-4.56	-0.38	1.19e-5	Depression;
TGCT	cis	rs9467773	0.620	rs2494701	chr6:26634432	C/T	cg05738196	chr6:26577821	NA	0.88	11.22	0.71	1.33e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg11301795	chr4:187892539	NA	-0.34	-4.9	-0.4	2.97e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs62244186	0.748	rs2888410	chr3:44655476	A/C	cg02073558	chr3:44770973	ZNF501	0.61	5.93	0.47	2.86e-8	Depressive symptoms;
TGCT	cis	rs7432375	0.641	rs835649	chr3:136671890	G/A	cg15507776	chr3:136538369	TMEM22	0.51	5.19	0.42	8.19e-7	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs904251	0.772	rs1812186	chr6:37465916	T/C	cg25019722	chr6:37503610	NA	-0.43	-5.02	-0.41	1.76e-6	Cognitive performance;
TGCT	cis	rs2299587	0.585	rs2073569	chr8:17782158	T/G	cg01800426	chr8:17659068	MTUS1	-0.64	-5.52	-0.44	1.91e-7	Economic and political preferences;
TGCT	cis	rs7714584	1.000	rs11739619	chr5:150264662	A/T	cg22134413	chr5:150180641	NA	0.78	6.12	0.48	1.16e-8	Crohn's disease;
TGCT	cis	rs514475	0.526	rs12201430	chr6:137955515	G/A	cg02673417	chr6:137105249	MAP3K5	0.29	4.45	0.37	1.88e-5	Inflammatory skin disease;
TGCT	cis	rs7178424	0.711	rs3743297	chr15:62149784	T/C	cg00456672	chr15:62358751	C2CD4A	-0.33	-5.03	-0.41	1.71e-6	Height;
TGCT	cis	rs11098499	0.754	rs1849457	chr4:120254355	A/G	cg09307838	chr4:120376055	NA	0.61	5.81	0.46	5.04e-8	Corneal astigmatism;
TGCT	cis	rs3617	0.652	rs60332615	chr3:52867595	C/A	cg10802521	chr3:52805072	NEK4	0.62	7.17	0.54	6e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9411298	0.657	rs4880189	chr9:139923265	A/G	cg14024893	chr9:139943146	ENTPD2	0.37	5.87	0.47	3.81e-8	Monocyte percentage of white cells;
TGCT	cis	rs4566357	1.000	rs6721237	chr2:227923357	T/A	cg11843606	chr2:227700838	RHBDD1	-0.58	-5.31	-0.43	4.92e-7	Coronary artery disease;
TGCT	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg20007245	chr22:24372913	LOC391322	0.82	7.03	0.53	1.2e-10	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs4699052	0.625	rs28397882	chr4:104282836	G/A	cg16532752	chr4:104119610	CENPE	-0.5	-4.75	-0.39	5.48e-6	Testicular germ cell tumor;
TGCT	cis	rs4499344	0.730	rs377044	chr19:33105951	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.86	9.05	0.63	2.48e-15	Mean platelet volume;
TGCT	cis	rs7432375	0.519	rs34799319	chr3:136586618	G/A	cg12473912	chr3:136751656	NA	0.33	4.59	0.38	1.06e-5	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12908161	0.959	rs62019472	chr15:85331493	A/G	cg11189052	chr15:85197271	WDR73	0.71	5.85	0.47	4.1e-8	Schizophrenia;
TGCT	cis	rs35306767	0.903	rs12260800	chr10:927933	T/C	cg20503657	chr10:835505	NA	0.74	10.3	0.68	2.41e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs7216064	1.000	rs11870068	chr17:65944515	A/C	cg12091567	chr17:66097778	LOC651250	-0.82	-6.2	-0.49	7.54e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs1949733	0.701	rs871768	chr4:8454938	G/A	cg13073564	chr4:8508604	NA	-0.42	-4.61	-0.38	9.77e-6	Response to antineoplastic agents;
TGCT	cis	rs4237845	1.000	rs4237845	chr12:58302436	A/G	cg02175503	chr12:58329896	NA	-0.55	-5.86	-0.47	3.86e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs4700695	0.841	rs417074	chr5:65314894	C/T	cg21114390	chr5:65439923	SFRS12	0.6	4.47	0.37	1.71e-5	Facial morphology (factor 19);
TGCT	cis	rs7914558	0.966	rs10450373	chr10:104728616	T/C	cg04362960	chr10:104952993	NT5C2	0.6	5.38	0.44	3.56e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg11965913	chr1:205819406	PM20D1	0.6	9.43	0.65	3.09e-16	Menarche (age at onset);
TGCT	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg17345569	chr6:42928274	GNMT	-0.47	-4.81	-0.4	4.25e-6	Plasma homocysteine levels (post-methionine load test);
TGCT	cis	rs12135062	0.851	rs2651927	chr1:3101762	A/C	cg25382214	chr1:3105252	PRDM16	-0.29	-5.09	-0.42	1.27e-6	Migraine;
TGCT	cis	rs2130392	0.926	rs7680323	chr4:185652871	A/T	cg14471096	chr4:185570637	CCDC111;CASP3	-0.52	-4.95	-0.41	2.33e-6	Kawasaki disease;
TGCT	cis	rs10501293	0.746	rs7929118	chr11:43029294	C/T	cg03447554	chr11:43094025	NA	0.44	6.28	0.49	5.14e-9	Cognitive performance;
TGCT	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg13206674	chr6:150067644	NUP43	0.52	4.46	0.37	1.78e-5	Lung cancer;
TGCT	cis	rs8072100	0.846	rs7214799	chr17:45702099	C/T	cg08085267	chr17:45401833	C17orf57	0.44	4.68	0.39	7.52e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg21171335	chr12:122356390	WDR66	0.68	6.79	0.52	4.16e-10	Mean corpuscular volume;
TGCT	cis	rs13223928	0.516	rs11763949	chr7:3150279	A/C	cg19214707	chr7:3157722	NA	-0.44	-6.2	-0.49	7.57e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
TGCT	cis	rs7666738	0.791	rs13111960	chr4:98976851	C/T	cg17366294	chr4:99064904	C4orf37	0.68	6.94	0.53	1.95e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10507380	0.824	rs77045357	chr13:27925794	C/G	cg25543773	chr13:27185723	WASF3	0.32	4.51	0.38	1.47e-5	Electrocardiographic traits;
TGCT	cis	rs1669338	0.588	rs6784329	chr3:3200013	C/T	cg16797762	chr3:3221439	CRBN	-0.9	-5.72	-0.46	7.43e-8	White matter integrity;
TGCT	cis	rs12682352	0.652	rs3789843	chr8:8724257	C/T	cg15556689	chr8:8085844	FLJ10661	0.66	6.06	0.48	1.52e-8	Neuroticism;
TGCT	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs925228	0.504	rs6755030	chr2:24318343	C/T	cg01493198	chr2:24299560	SF3B14	0.73	4.75	0.39	5.43e-6	Reticulocyte fraction of red cells;Reticulocyte count;
TGCT	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg16680214	chr1:154839983	KCNN3	-0.35	-7.28	-0.55	3.32e-11	Prostate cancer;
TGCT	cis	rs7772486	0.558	rs702322	chr6:146007166	G/A	cg13319975	chr6:146136371	FBXO30	0.68	6.18	0.49	8.39e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9611565	0.918	rs12484074	chr22:41752747	G/A	cg06481639	chr22:41940642	POLR3H	-0.83	-7.02	-0.53	1.3e-10	Vitiligo;
TGCT	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg10802521	chr3:52805072	NEK4	-0.78	-10.0	-0.67	1.26e-17	Electroencephalogram traits;
TGCT	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.72	7.39	0.55	1.87e-11	Menarche (age at onset);
TGCT	cis	rs7267979	0.933	rs1130694	chr20:25276297	G/A	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg11941060	chr3:133502564	NA	-0.29	-6.22	-0.49	7.09e-9	Iron status biomarkers;
TGCT	cis	rs13082711	0.595	rs62255583	chr3:27309704	G/T	cg02860705	chr3:27208620	NA	0.47	7.19	0.54	5.34e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs17345786	0.953	rs78645744	chr3:101327789	T/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.88	9.23	0.64	9.1e-16	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7552167	0.789	rs6424162	chr1:24512576	T/C	cg01960748	chr1:24522592	NA	-0.49	-5.49	-0.44	2.13e-7	Psoriasis vulgaris;
TGCT	cis	rs7772486	0.840	rs11155451	chr6:146422524	A/G	cg13319975	chr6:146136371	FBXO30	-0.51	-4.56	-0.38	1.23e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2721195	0.967	rs1985022	chr8:145684031	C/T	cg15320075	chr8:145703422	NA	0.7	7.13	0.54	7.41e-11	Age at first birth;
TGCT	cis	rs11785400	0.762	rs7007349	chr8:143722673	T/C	cg10596483	chr8:143751796	JRK	0.53	5.2	0.42	8e-7	Schizophrenia;
TGCT	cis	rs642803	0.613	rs565427	chr11:65532825	G/A	cg27068330	chr11:65405492	SIPA1	0.64	5.69	0.46	8.6e-8	Urate levels;
TGCT	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.71	-5.64	-0.45	1.1e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs78487399	0.808	rs78098795	chr2:43840361	G/A	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.67	4.45	0.37	1.89e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs7937682	0.889	rs11213969	chr11:111528441	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.1	-11.66	-0.72	1.13e-21	Primary sclerosing cholangitis;
TGCT	cis	rs2439831	0.867	rs689616	chr15:43761901	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.01	8.37	0.6	1.02e-13	Lung cancer in ever smokers;
TGCT	cis	rs2180341	0.538	rs11154402	chr6:127711932	C/A	cg27446573	chr6:127587934	RNF146	0.64	6.01	0.47	1.95e-8	Breast cancer;
TGCT	cis	rs4820539	0.641	rs5759602	chr22:23489362	C/T	cg14186256	chr22:23484241	RTDR1	-0.83	-9.3	-0.64	6.24e-16	Bone mineral density;
TGCT	cis	rs9796	0.621	rs1659228	chr15:41471978	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.52	-7.17	-0.54	5.94e-11	Menopause (age at onset);
TGCT	cis	rs28595532	0.920	rs10001115	chr4:119781867	A/C	cg21605333	chr4:119757512	SEC24D	1.44	8.24	0.6	2.03e-13	Cannabis dependence symptom count;
TGCT	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg24829409	chr8:58192753	C8orf71	-0.57	-4.82	-0.4	4.14e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs12210905	1.000	rs12192320	chr6:27090305	G/A	cg08851530	chr6:28072375	NA	1.21	5.58	0.45	1.43e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs4851254	0.660	rs10209201	chr2:100672808	C/T	cg07810366	chr2:100720526	AFF3	-0.49	-5.22	-0.42	7.36e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg03709012	chr19:19516395	GATAD2A	-0.76	-6.27	-0.49	5.39e-9	Tonsillectomy;
TGCT	cis	rs7223966	1.000	rs113134232	chr17:61715461	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	4.83	0.4	3.93e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs2486012	1.000	rs1636877	chr1:44387625	G/A	cg12908607	chr1:44402522	ARTN	0.71	5.86	0.47	3.87e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2816062	0.735	rs2816054	chr1:18896431	C/T	cg18795169	chr1:18902165	NA	-0.6	-14.18	-0.79	1.04e-27	Urate levels in lean individuals;
TGCT	cis	rs1044826	0.619	rs7375091	chr3:139090389	T/A	cg00490450	chr3:139108681	COPB2	-0.53	-4.56	-0.38	1.2e-5	Obesity-related traits;
TGCT	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg12963246	chr6:28129442	ZNF389	-0.51	-5.06	-0.41	1.49e-6	Depression;
TGCT	cis	rs6840360	0.693	rs28622593	chr4:152374080	A/G	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.83e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs2361718	0.500	rs8068856	chr17:78100731	A/G	cg02096758	chr17:77394895	HRNBP3	0.24	4.6	0.38	1.01e-5	Yeast infection;
TGCT	cis	rs12142240	0.698	rs61519400	chr1:46855298	A/G	cg00530320	chr1:46809349	NSUN4	0.29	5.79	0.46	5.34e-8	Menopause (age at onset);
TGCT	cis	rs10992471	0.756	rs7043152	chr9:95138499	A/G	cg14631576	chr9:95140430	CENPP	-0.3	-4.97	-0.41	2.21e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs2730245	0.550	rs2709860	chr7:158651156	A/T	cg11984989	chr7:158649758	WDR60	1.02	9.9	0.66	2.22e-17	Height;
TGCT	cis	rs7618915	1.000	rs3852063	chr3:52349204	A/G	cg10802521	chr3:52805072	NEK4	-0.55	-5.65	-0.45	1.02e-7	Bipolar disorder;
TGCT	cis	rs17376456	0.825	rs10214278	chr5:93237679	C/T	cg25358565	chr5:93447407	FAM172A	-1.15	-7.64	-0.57	5.13e-12	Diabetic retinopathy;
TGCT	cis	rs9522267	0.535	rs914037	chr13:112235308	A/G	cg10483660	chr13:112241077	NA	-0.27	-4.61	-0.38	9.78e-6	Hepatitis;
TGCT	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg15921436	chr17:44337874	NA	0.56	7.75	0.57	2.88e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg18402987	chr7:1209562	NA	0.39	4.94	0.41	2.48e-6	Longevity;Endometriosis;
TGCT	cis	rs231513	0.911	rs124721	chr17:41959808	T/C	cg26893861	chr17:41843967	DUSP3	-0.76	-5.45	-0.44	2.62e-7	Cognitive function;
TGCT	cis	rs4727027	0.901	rs12671341	chr7:148805282	T/C	cg23583168	chr7:148888333	NA	-0.72	-9.16	-0.64	1.34e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg10047753	chr17:41438598	NA	0.95	9.61	0.65	1.12e-16	Menopause (age at onset);
TGCT	cis	rs13217239	0.646	rs10456352	chr6:26990358	A/T	cg15659132	chr6:26577336	NA	0.55	5.53	0.44	1.84e-7	Schizophrenia;
TGCT	cis	rs13242816	1.000	rs34325296	chr7:116122409	C/T	cg16553024	chr7:116138462	CAV2	-0.44	-4.59	-0.38	1.05e-5	P wave duration;
TGCT	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg23758822	chr17:41437982	NA	0.71	6.77	0.52	4.56e-10	Menopause (age at onset);
TGCT	cis	rs3770081	1.000	rs6750765	chr2:86300308	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.17	-4.56	-0.38	1.21e-5	Facial emotion recognition (sad faces);
TGCT	cis	rs28595532	0.920	rs114410095	chr4:119731110	G/A	cg14228332	chr4:119757509	SEC24D	1.32	6.38	0.5	3.2e-9	Cannabis dependence symptom count;
TGCT	cis	rs7666738	0.830	rs1426665	chr4:99027764	C/T	cg17366294	chr4:99064904	C4orf37	0.72	7.54	0.56	8.52e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6540559	0.673	rs17015309	chr1:210007218	C/T	cg23283495	chr1:209979779	IRF6	0.6	4.5	0.37	1.54e-5	Cleft lip with or without cleft palate;
TGCT	cis	rs12048904	0.619	rs3737581	chr1:101341083	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.82	7.36	0.55	2.2e-11	Multiple sclerosis;
TGCT	cis	rs67478160	0.619	rs12886363	chr14:104273786	T/C	cg26031613	chr14:104095156	KLC1	-0.63	-6.42	-0.5	2.64e-9	Schizophrenia;
TGCT	cis	rs10089	1.000	rs10089	chr5:127522543	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.82	7.62	0.56	5.65e-12	Ileal carcinoids;
TGCT	cis	rs1577917	1.000	rs12661204	chr6:86678586	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-5.3	-0.43	5.05e-7	Response to antipsychotic treatment;
TGCT	cis	rs75686122	0.892	rs75159425	chr8:104629178	A/G	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs4930561	0.714	rs7130844	chr11:67927517	C/T	cg04465784	chr11:67976953	SUV420H1	-0.4	-5.79	-0.46	5.42e-8	Breast cancer in childhood cancer survivors;IgG glycosylation;
TGCT	cis	rs60843830	1.000	rs6709534	chr2:217334	G/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.72	6.46	0.5	2.19e-9	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs941408	0.515	rs1736193	chr19:2785273	G/C	cg06609049	chr19:2785107	THOP1	1.22	13.43	0.77	6.16e-26	Total cholesterol levels;
TGCT	cis	rs2439831	0.571	rs2470121	chr15:43937618	G/C	cg19166733	chr15:44192098	FRMD5	-0.24	-4.89	-0.4	3.08e-6	Lung cancer in ever smokers;
TGCT	cis	rs2067615	0.524	rs10861646	chr12:107071182	C/T	cg15890332	chr12:107067104	RFX4	0.29	5.77	0.46	5.9e-8	Heart rate;
TGCT	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg18402987	chr7:1209562	NA	0.78	6.64	0.51	8.96e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs137699	0.652	rs137706	chr22:39751400	T/G	cg24399712	chr22:39784796	NA	-0.81	-6.51	-0.5	1.66e-9	IgG glycosylation;
TGCT	cis	rs4285028	0.731	rs2877561	chr3:121712051	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.74	6.22	0.49	7.08e-9	Multiple sclerosis;
TGCT	cis	rs6570726	0.818	rs398812	chr6:145817271	T/C	cg23711669	chr6:146136114	FBXO30	0.71	6.72	0.52	5.91e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4911259	0.513	rs4287835	chr20:31457337	T/C	cg13636640	chr20:31349939	DNMT3B	-0.89	-9.83	-0.66	3.36e-17	Inflammatory bowel disease;
TGCT	cis	rs10744422	1.000	rs10847869	chr12:123328359	C/G	cg25930673	chr12:123319894	HIP1R	-0.85	-5.01	-0.41	1.86e-6	Schizophrenia;
TGCT	cis	rs6570726	0.791	rs4896820	chr6:145894957	T/C	cg05347473	chr6:146136440	FBXO30	0.51	4.78	0.39	4.8e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9325144	0.723	rs11169518	chr12:39177237	C/A	cg26384229	chr12:38710491	ALG10B	-0.61	-5.77	-0.46	5.99e-8	Morning vs. evening chronotype;
TGCT	cis	rs2456568	0.548	rs7117597	chr11:93655091	A/G	cg16099599	chr11:93583650	C11orf90	-0.39	-4.61	-0.38	9.94e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.6	-5.85	-0.47	4.09e-8	Bipolar disorder;
TGCT	cis	rs9733	0.818	rs11204702	chr1:150663507	C/A	cg13175981	chr1:150552382	MCL1	0.43	4.79	0.4	4.61e-6	Tonsillectomy;
TGCT	cis	rs7681440	0.874	rs1372522	chr4:90765280	A/G	cg20003494	chr4:90757398	SNCA	-0.62	-5.93	-0.47	2.74e-8	Dementia with Lewy bodies;
TGCT	cis	rs9611565	0.512	rs8141103	chr22:42136930	T/C	cg06481639	chr22:41940642	POLR3H	0.7	6.1	0.48	1.24e-8	Vitiligo;
TGCT	cis	rs10504229	1.000	rs73591706	chr8:58195633	C/T	cg24829409	chr8:58192753	C8orf71	-0.55	-4.77	-0.39	5.18e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2742417	0.603	rs2673062	chr3:45763635	A/G	cg04837898	chr3:45731254	SACM1L	-0.65	-6.95	-0.53	1.84e-10	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg24060327	chr5:131705240	SLC22A5	-0.56	-5.58	-0.45	1.47e-7	Breast cancer;
TGCT	cis	rs4889911	0.544	rs1285271	chr17:77834197	C/T	cg00646381	chr17:77835854	NA	-0.46	-6.53	-0.51	1.49e-9	Electroencephalogram traits;
TGCT	cis	rs7647973	0.769	rs11130181	chr3:49109919	G/A	cg05785598	chr3:49045655	WDR6	0.39	4.5	0.37	1.56e-5	Menarche (age at onset);
TGCT	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg11644478	chr21:40555479	PSMG1	-0.52	-4.47	-0.37	1.75e-5	Cognitive function;
TGCT	cis	rs11577318	0.853	rs1071849	chr1:26646726	A/G	cg04990556	chr1:26633338	UBXN11	-0.59	-4.94	-0.41	2.47e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg01238044	chr22:24384105	GSTT1	-0.54	-5.13	-0.42	1.09e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs992157	0.804	rs7559525	chr2:219150307	A/G	cg00012203	chr2:219082015	ARPC2	-0.8	-7.98	-0.58	8.26e-13	Colorectal cancer;
TGCT	cis	rs7666738	0.830	rs4699577	chr4:98846513	G/A	cg05340658	chr4:99064831	C4orf37	0.52	6.05	0.48	1.61e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1401999	0.966	rs2037379	chr3:183650330	T/C	cg01324343	chr3:183735012	ABCC5	0.85	11.41	0.72	4.7e-21	Anterior chamber depth;
TGCT	cis	rs2594989	1.000	rs2606742	chr3:11391717	G/A	cg00170343	chr3:11313890	ATG7	0.67	5.04	0.41	1.62e-6	Circulating chemerin levels;
TGCT	cis	rs11096990	0.634	rs3733281	chr4:39271913	T/C	cg20847110	chr4:39482781	LOC401127	-0.16	-4.53	-0.38	1.36e-5	Cognitive function;
TGCT	cis	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg15556689	chr8:8085844	FLJ10661	0.74	6.89	0.53	2.47e-10	Mood instability;
TGCT	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg03352830	chr11:487213	PTDSS2	0.26	4.58	0.38	1.12e-5	Body mass index;
TGCT	cis	rs6582630	0.519	rs7305545	chr12:38349223	G/A	cg13010199	chr12:38710504	ALG10B	0.58	4.52	0.38	1.41e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg04267008	chr7:1944627	MAD1L1	-0.41	-5.45	-0.44	2.65e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs9902453	0.791	rs62068629	chr17:28187596	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	7.18	0.54	5.62e-11	Coffee consumption (cups per day);
TGCT	cis	rs1008375	1.000	rs10939756	chr4:17693867	C/T	cg18681998	chr4:17616180	MED28	0.77	7.35	0.55	2.29e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7726839	0.540	rs11738281	chr5:662547	T/C	cg16624210	chr5:671434	TPPP	0.43	4.96	0.41	2.3e-6	Obesity-related traits;
TGCT	cis	rs11673344	0.504	rs1667378	chr19:37492073	C/A	cg08039142	chr19:36980659	ZNF566	0.52	4.81	0.4	4.23e-6	Obesity-related traits;
TGCT	cis	rs7752195	0.730	rs79249301	chr6:25260918	T/C	cg16898833	chr6:26189333	HIST1H4D	1.18	5.52	0.44	1.89e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6840360	0.571	rs11723395	chr4:152524191	G/A	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.0	-0.58	7.69e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg23708337	chr7:1209742	NA	0.64	5.94	0.47	2.63e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs16867321	0.671	rs890059	chr2:181510905	G/C	cg23363182	chr2:181467187	NA	-0.45	-4.64	-0.38	8.67e-6	Obesity;
TGCT	cis	rs11792861	0.781	rs28361106	chr9:111762385	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.51	4.73	0.39	5.99e-6	Menarche (age at onset);
TGCT	cis	rs796364	1.000	rs10178177	chr2:200829993	G/A	cg17644776	chr2:200775616	C2orf69	0.31	4.85	0.4	3.58e-6	Schizophrenia;
TGCT	cis	rs8072100	0.967	rs4338849	chr17:45512483	A/G	cg08085267	chr17:45401833	C17orf57	-0.51	-5.6	-0.45	1.29e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs433598	0.704	rs151310	chr16:20663135	T/G	cg08248577	chr16:19727447	IQCK;C16orf88	-0.22	-4.94	-0.41	2.47e-6	Schizophrenia;
TGCT	cis	rs77948430	0.655	rs78007284	chr8:13157827	A/C	cg25598624	chr8:12235727	FAM66A	0.31	4.59	0.38	1.08e-5	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs35934224	0.891	rs5993850	chr22:19869703	C/T	cg11182965	chr22:19864308	TXNRD2	-0.38	-5.34	-0.43	4.3e-7	Glaucoma (primary open-angle);
TGCT	cis	rs9902453	0.967	rs1906451	chr17:28515479	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	6.4	0.5	2.85e-9	Coffee consumption (cups per day);
TGCT	cis	rs3008870	0.755	rs2815380	chr1:67510857	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.78	-7.18	-0.54	5.61e-11	Lymphocyte percentage of white cells;
TGCT	cis	rs6862531	0.959	rs72652809	chr5:143092525	T/G	cg06916709	chr5:142092905	NA	-0.64	-4.45	-0.37	1.86e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Delta-6 desaturase activity;
TGCT	cis	rs7584330	0.695	rs6709497	chr2:238368925	C/T	cg14458575	chr2:238380390	NA	0.49	7.88	0.58	1.41e-12	Prostate cancer;
TGCT	cis	rs7296418	0.754	rs1619283	chr12:123717362	A/G	cg00376283	chr12:123451042	ABCB9	0.8	7.23	0.54	4.43e-11	Platelet count;
TGCT	cis	rs79349575	0.783	rs12601858	chr17:47017477	T/C	cg26022315	chr17:47021804	SNF8	0.49	4.9	0.4	2.94e-6	Type 2 diabetes;
TGCT	cis	rs9911578	1.000	rs304299	chr17:56838472	C/G	cg12560992	chr17:57184187	TRIM37	0.76	9.34	0.64	4.88e-16	Intelligence (multi-trait analysis);
TGCT	trans	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg21659725	chr3:3221576	CRBN	0.76	9.02	0.63	2.92e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs7211079	0.582	rs72852528	chr17:78136089	T/C	cg09238746	chr17:78121135	EIF4A3	-0.74	-5.18	-0.42	8.9e-7	Myocardial infarction;
TGCT	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg26338869	chr17:61819248	STRADA	-0.5	-4.58	-0.38	1.12e-5	Prudent dietary pattern;
TGCT	cis	rs11690462	0.963	rs6731447	chr2:26590118	C/T	cg04726446	chr2:26624865	C2orf39	0.44	4.73	0.39	5.97e-6	Coronary artery disease;
TGCT	cis	rs17270561	0.887	rs12201170	chr6:25866247	A/G	cg17691542	chr6:26056736	HIST1H1C	0.82	4.91	0.4	2.76e-6	Iron status biomarkers;
TGCT	cis	rs7267979	0.903	rs6050481	chr20:25224580	C/T	cg14121845	chr20:25566513	NINL	0.5	5.51	0.44	1.95e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4555082	0.645	rs2816605	chr14:105715515	C/T	cg01266790	chr14:105781312	PACS2	0.55	4.51	0.38	1.49e-5	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs514406	0.547	rs377808	chr1:53190359	T/G	cg25767906	chr1:53392781	SCP2	-0.44	-4.78	-0.39	4.84e-6	Monocyte count;
TGCT	cis	rs889312	0.500	rs832580	chr5:56172646	T/C	cg24531977	chr5:56204891	C5orf35	-0.5	-5.09	-0.42	1.28e-6	Breast cancer;Breast cancer (early onset);
TGCT	cis	rs926938	0.527	rs360584	chr1:115463181	G/A	cg12756093	chr1:115239321	AMPD1	0.34	4.95	0.41	2.35e-6	Autism;
TGCT	cis	rs1580019	0.587	rs2392069	chr7:32547154	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.13	14.15	0.79	1.17e-27	Cognitive ability;
TGCT	cis	rs7647973	0.769	rs4974081	chr3:49070499	A/G	cg07636037	chr3:49044803	WDR6	-0.81	-6.68	-0.51	7.37e-10	Menarche (age at onset);
TGCT	cis	rs11785400	1.000	rs13265663	chr8:143732255	A/C	cg10596483	chr8:143751796	JRK	0.54	5.77	0.46	5.95e-8	Schizophrenia;
TGCT	cis	rs11190604	0.943	rs11190581	chr10:102243387	T/G	cg23241863	chr10:102295624	HIF1AN	0.63	4.95	0.41	2.41e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs10089	1.000	rs4836369	chr5:127486462	A/G	cg19767477	chr5:127420684	SLC12A2	-0.43	-4.55	-0.38	1.27e-5	Ileal carcinoids;
TGCT	cis	rs7172809	0.599	rs59386622	chr15:77752693	G/A	cg22256960	chr15:77711686	NA	-0.51	-4.86	-0.4	3.47e-6	Glucose homeostasis traits;
TGCT	cis	rs9972944	0.756	rs2318868	chr17:63767592	G/T	cg07283582	chr17:63770753	CCDC46	-0.26	-5.3	-0.43	5.02e-7	Total body bone mineral density;
TGCT	cis	rs11112613	0.713	rs11112592	chr12:105951702	C/T	cg03607813	chr12:105948248	NA	-0.47	-5.8	-0.46	5.28e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	cis	rs7714584	1.000	rs13361189	chr5:150223387	A/G	cg22134413	chr5:150180641	NA	0.94	7.09	0.54	9.11e-11	Crohn's disease;
TGCT	cis	rs4383453	0.559	rs903574	chr3:123099807	C/G	cg04890266	chr3:123102914	ADCY5	-0.5	-8.34	-0.6	1.2e-13	Gestational age at birth (maternal effect);
TGCT	cis	rs35306767	0.761	rs11253538	chr10:1011166	C/T	cg20503657	chr10:835505	NA	0.57	6.33	0.49	4.06e-9	Eosinophil percentage of granulocytes;
TGCT	cis	rs11209002	0.524	rs982131	chr1:67542360	T/C	cg02640540	chr1:67518911	SLC35D1	0.53	4.45	0.37	1.86e-5	Crohn's disease;
TGCT	cis	rs10992471	0.528	rs3780347	chr9:95266812	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.51	-4.78	-0.39	4.9e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs3213961	0.529	rs6708	chr2:33789534	A/G	cg04131969	chr2:33951647	MYADML	0.68	5.39	0.44	3.46e-7	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
TGCT	cis	rs2204008	0.659	rs4002655	chr12:38169881	T/G	cg13010199	chr12:38710504	ALG10B	0.62	4.89	0.4	3.09e-6	Bladder cancer;
TGCT	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.04	8.75	0.62	1.26e-14	Platelet count;
TGCT	cis	rs933688	1.000	rs10059163	chr5:90742444	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.96	8.43	0.6	7.52e-14	Smoking behavior;
TGCT	cis	rs12477438	0.798	rs6740267	chr2:99561867	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.7	-6.14	-0.48	1.05e-8	Chronic sinus infection;
TGCT	cis	rs1008375	0.872	rs2315552	chr4:17627294	A/G	cg16339924	chr4:17578868	LAP3	0.56	4.66	0.39	7.87e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7618915	0.851	rs34228726	chr3:52322797	A/G	cg10802521	chr3:52805072	NEK4	-0.55	-5.69	-0.45	8.83e-8	Bipolar disorder;
TGCT	cis	rs3806843	0.576	rs251376	chr5:140253689	A/G	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	0.41	4.92	0.4	2.68e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7927592	0.763	rs1193699	chr11:68249480	C/G	cg16797656	chr11:68205561	LRP5	0.26	4.48	0.37	1.67e-5	Total body bone mineral density;
TGCT	trans	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg13615516	chr5:77269221	NA	0.68	8.54	0.61	3.97e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9467711	0.932	rs11966360	chr6:26316982	A/G	cg26531700	chr6:26746687	NA	-0.95	-5.43	-0.44	2.83e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7666738	0.830	rs34244876	chr4:99031336	G/A	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg06112835	chr11:68658793	MRPL21	0.49	8.21	0.59	2.41e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg13695892	chr22:41940480	POLR3H	0.78	7.62	0.56	5.73e-12	Vitiligo;
TGCT	cis	rs9393777	0.513	rs13219181	chr6:27136225	A/G	cg16898833	chr6:26189333	HIST1H4D	0.74	4.48	0.37	1.71e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs35797862	1	rs35797862	chr1:93738515	A/AAG	cg17826107	chr1:92977322	EVI5	0.23	5.12	0.42	1.15e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;Eosinophil counts;
TGCT	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg22963979	chr7:1858916	MAD1L1	0.39	6.34	0.49	3.83e-9	Bipolar disorder and schizophrenia;
TGCT	cis	rs372883	0.648	rs1153292	chr21:30689195	G/T	cg24692254	chr21:30365293	RNF160	-0.53	-4.78	-0.39	4.97e-6	Pancreatic cancer;
TGCT	cis	rs8038465	0.789	rs57909886	chr15:73973662	T/C	cg15420318	chr15:73925796	NPTN	0.74	7.57	0.56	7.25e-12	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg08859206	chr1:53392774	SCP2	0.4	6.01	0.48	1.91e-8	Monocyte count;
TGCT	cis	rs76419734	0.850	rs58775257	chr4:106809983	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	1.0	4.66	0.39	7.95e-6	Post bronchodilator FEV1;
TGCT	cis	rs2806561	0.765	rs682766	chr1:23516397	C/G	cg12483005	chr1:23474871	LUZP1	0.38	4.73	0.39	5.93e-6	Height;
TGCT	cis	rs2948294	0.566	rs13261997	chr8:8112295	C/T	cg15556689	chr8:8085844	FLJ10661	0.78	6.41	0.5	2.74e-9	Red cell distribution width;
TGCT	cis	rs1153858	1.000	rs56669689	chr15:45637729	A/C	cg14582100	chr15:45693742	SPATA5L1	0.48	5.7	0.46	8.17e-8	Homoarginine levels;
TGCT	cis	rs9916302	0.706	rs4795375	chr17:37662932	T/C	cg07936489	chr17:37558343	FBXL20	-0.87	-6.27	-0.49	5.47e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg20203395	chr5:56204925	C5orf35	0.52	4.89	0.4	3.01e-6	Initial pursuit acceleration;
TGCT	cis	rs7226408	0.857	rs72887036	chr18:34475737	A/G	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs7715806	0.500	rs888788	chr5:74988336	C/T	cg19683494	chr5:74908142	NA	0.57	4.93	0.4	2.57e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs9611565	0.592	rs5758405	chr22:42076381	C/A	cg17554472	chr22:41940697	POLR3H	0.5	5.36	0.43	3.92e-7	Vitiligo;
TGCT	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg08859206	chr1:53392774	SCP2	0.33	4.61	0.38	9.7e-6	Monocyte count;
TGCT	cis	rs6545883	0.931	rs778768	chr2:61790289	C/G	cg15711740	chr2:61764176	XPO1	-0.56	-5.08	-0.41	1.37e-6	Tuberculosis;
TGCT	cis	rs8180040	0.726	rs61729713	chr3:47027192	A/G	cg27129171	chr3:47204927	SETD2	-0.7	-8.8	-0.62	9.59e-15	Colorectal cancer;
TGCT	cis	rs7949030	0.626	rs7943191	chr11:62328551	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.61	8.71	0.62	1.65e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs6665290	0.904	rs6684821	chr1:227190233	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.0	-20.5	-0.88	1.18e-41	Myeloid white cell count;
TGCT	cis	rs7552404	0.924	rs1146574	chr1:76202671	A/G	cg03433033	chr1:76189801	ACADM	0.77	9.25	0.64	8.26e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs4851266	0.865	rs11695996	chr2:100854336	C/T	cg22139774	chr2:100720529	AFF3	-0.32	-4.66	-0.39	7.89e-6	Educational attainment;
TGCT	cis	rs669446	0.562	rs4660259	chr1:44194534	A/G	cg12908607	chr1:44402522	ARTN	-0.62	-7.25	-0.55	3.99e-11	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs2180341	0.920	rs1073932	chr6:127682009	G/T	cg27446573	chr6:127587934	RNF146	1.14	10.91	0.7	7.51e-20	Breast cancer;
TGCT	cis	rs8177179	1.000	rs8177179	chr3:133463457	G/A	cg16262614	chr3:133464971	TF	0.34	4.57	0.38	1.15e-5	Iron status biomarkers (transferrin levels);
TGCT	cis	rs12188164	0.686	rs72711369	chr5:420517	C/T	cg26850624	chr5:429559	AHRR	-0.21	-4.98	-0.41	2.06e-6	Cystic fibrosis severity;
TGCT	cis	rs172166	0.516	rs1225710	chr6:28100640	C/T	cg13525197	chr6:28411240	ZSCAN23	0.48	4.65	0.39	8.38e-6	Cardiac Troponin-T levels;
TGCT	cis	rs13424612	1.000	rs4149556	chr2:240915307	C/T	cg26363272	chr2:240904871	NDUFA10	0.28	4.79	0.4	4.65e-6	Odorant perception (isobutyraldehyde);
TGCT	cis	rs17152411	1.000	rs7083336	chr10:126590771	T/C	cg07906193	chr10:126599966	NA	0.42	5.16	0.42	9.55e-7	Height;
TGCT	cis	rs11122272	0.735	rs2246645	chr1:231497393	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-6.68	-0.51	7.25e-10	Hemoglobin concentration;
TGCT	cis	rs2456568	0.867	rs1395384	chr11:93663250	C/T	cg17595323	chr11:93583763	C11orf90	0.46	5.93	0.47	2.85e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs2721811	0.535	rs2721805	chr7:24780316	C/T	cg17569154	chr7:24781545	DFNA5	0.22	4.68	0.39	7.29e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg07424592	chr7:64974309	NA	1.4	8.42	0.6	7.87e-14	Diabetic kidney disease;
TGCT	cis	rs11098499	0.954	rs10031665	chr4:120422852	T/C	cg09307838	chr4:120376055	NA	0.68	6.37	0.5	3.41e-9	Corneal astigmatism;
TGCT	cis	rs9399135	0.967	rs2150681	chr6:135375232	A/G	cg24558204	chr6:135376177	HBS1L	-0.46	-4.58	-0.38	1.11e-5	Red blood cell count;
TGCT	cis	rs2073300	1.000	rs6114141	chr20:23460620	T/G	cg09953122	chr20:23471693	CST8	-0.59	-4.75	-0.39	5.62e-6	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs6918586	0.532	rs198800	chr6:26139933	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.65	-6.2	-0.49	7.65e-9	Schizophrenia;
TGCT	cis	rs12681288	0.676	rs62488537	chr8:1011962	A/C	cg04851639	chr8:1020857	NA	-0.31	-5.17	-0.42	8.94e-7	Schizophrenia;
TGCT	cis	rs10769945	0.730	rs217208	chr11:1974892	C/G	cg02850416	chr11:1986266	NA	-0.26	-4.44	-0.37	1.99e-5	DNA methylation (variation);
TGCT	cis	rs1008375	0.932	rs7697329	chr4:17657853	C/A	cg10189774	chr4:17578691	LAP3	0.53	4.6	0.38	1.04e-5	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9291683	0.538	rs11727199	chr4:10036190	C/T	cg11266682	chr4:10021025	SLC2A9	0.64	8.75	0.62	1.26e-14	Bone mineral density;
TGCT	cis	rs12497850	0.897	rs9884022	chr3:48956862	G/C	cg18654377	chr3:49208889	KLHDC8B	-0.42	-5.48	-0.44	2.23e-7	Parkinson's disease;
TGCT	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7809950	1.000	rs2237672	chr7:107131563	A/C	cg23024343	chr7:107201750	COG5	-0.34	-5.43	-0.44	2.92e-7	Coronary artery disease;
TGCT	cis	rs6490294	0.748	rs7295665	chr12:112379271	T/C	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Mean platelet volume;
TGCT	cis	rs2836633	0.859	rs8132069	chr21:40032611	T/C	cg05519781	chr21:40033154	ERG	0.68	6.54	0.51	1.47e-9	Coronary artery disease;
TGCT	cis	rs1395	0.744	rs7600932	chr2:27474869	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.62	7.72	0.57	3.38e-12	Blood metabolite levels;
TGCT	cis	rs7119038	0.607	rs12365699	chr11:118743286	C/T	cg19308663	chr11:118741387	NA	0.27	4.76	0.39	5.22e-6	Sjögren's syndrome;
TGCT	cis	rs6754311	0.638	rs1011361	chr2:136553639	G/A	cg07169764	chr2:136633963	MCM6	-0.66	-6.04	-0.48	1.63e-8	Mosquito bite size;
TGCT	cis	rs1971762	0.527	rs7972401	chr12:53940046	T/C	cg16917193	chr12:54089295	NA	1.02	10.38	0.68	1.5e-18	Height;
TGCT	cis	rs12681288	0.676	rs6983981	chr8:1016011	A/C	cg04851639	chr8:1020857	NA	-0.36	-6.79	-0.52	4.13e-10	Schizophrenia;
TGCT	trans	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg25482853	chr8:67687455	SGK3	-1.19	-10.3	-0.68	2.4e-18	Obesity-related traits;
TGCT	cis	rs2147959	0.766	rs6703575	chr1:228743667	G/C	cg22700015	chr1:228743131	NA	-0.59	-4.78	-0.39	4.94e-6	Adult asthma;
TGCT	cis	rs3008870	0.755	rs1535365	chr1:67497613	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.78	8.25	0.6	1.95e-13	Lymphocyte percentage of white cells;
TGCT	cis	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg07424592	chr7:64974309	NA	1.4	8.42	0.6	7.87e-14	Diabetic kidney disease;
TGCT	cis	rs1403694	0.695	rs1851665	chr3:186436398	A/G	cg12454167	chr3:186435060	KNG1	0.51	8.67	0.61	1.95e-14	Blood protein levels;
TGCT	cis	rs3820068	0.581	rs2861387	chr1:15951296	G/A	cg05660106	chr1:15850417	CASP9	0.86	8.48	0.61	5.53e-14	Systolic blood pressure;
TGCT	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg18230493	chr5:56204884	C5orf35	-0.68	-5.85	-0.46	4.13e-8	Initial pursuit acceleration;
TGCT	cis	rs9788721	0.836	rs17484235	chr15:78761414	C/G	cg18825076	chr15:78729989	IREB2	-0.34	-5.1	-0.42	1.21e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
TGCT	cis	rs13191362	1.000	rs35575481	chr6:163007746	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs977747	1.000	rs977747	chr1:47684677	T/G	cg03885399	chr1:47691550	TAL1	-0.39	-4.71	-0.39	6.41e-6	Body mass index;
TGCT	cis	rs9611565	0.649	rs6002480	chr22:42176917	A/T	cg13695892	chr22:41940480	POLR3H	-0.79	-7.49	-0.56	1.15e-11	Vitiligo;
TGCT	trans	rs57221529	0.766	rs28563961	chr5:554498	C/G	cg25482853	chr8:67687455	SGK3	1.2	9.97	0.67	1.49e-17	Lung disease severity in cystic fibrosis;
TGCT	cis	rs72627509	0.638	rs7658601	chr4:57781347	C/T	cg26694713	chr4:57773883	REST	0.75	6.77	0.52	4.59e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs4523957	0.614	rs2316512	chr17:2064710	A/T	cg16513277	chr17:2031491	SMG6	-0.2	-4.64	-0.38	8.83e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9911578	0.967	rs4598970	chr17:57076893	T/A	cg12560992	chr17:57184187	TRIM37	-0.78	-9.58	-0.65	1.35e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs12477438	0.520	rs13035311	chr2:99717322	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	12.84	0.76	1.57e-24	Chronic sinus infection;
TGCT	cis	rs3947	1.000	rs1692812	chr8:11703523	T/G	cg02840367	chr8:11660030	FDFT1	0.91	6.66	0.51	7.98e-10	Blood protein levels;
TGCT	cis	rs9467773	0.620	rs1027204	chr6:26639613	T/C	cg05738196	chr6:26577821	NA	0.88	11.22	0.71	1.33e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs2933343	0.700	rs2630257	chr3:128644015	T/C	cg11901034	chr3:128598214	ACAD9	-0.65	-6.05	-0.48	1.55e-8	IgG glycosylation;
TGCT	cis	rs950776	0.518	rs12906846	chr15:78825295	G/A	cg06917634	chr15:78832804	PSMA4	0.95	9.52	0.65	1.81e-16	Sudden cardiac arrest;
TGCT	cis	rs10751667	0.666	rs6597960	chr11:977036	C/T	cg06064525	chr11:970664	AP2A2	-0.36	-8.28	-0.6	1.67e-13	Alzheimer's disease (late onset);
TGCT	cis	rs12497850	0.931	rs9682444	chr3:48852639	A/G	cg05785598	chr3:49045655	WDR6	0.36	4.75	0.39	5.46e-6	Parkinson's disease;
TGCT	cis	rs9650657	0.655	rs4841434	chr8:10586123	T/C	cg27411982	chr8:10470053	RP1L1	-0.21	-4.45	-0.37	1.85e-5	Neuroticism;
TGCT	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.44	-4.98	-0.41	2.05e-6	Lymphocyte counts;
TGCT	cis	rs13191362	1.000	rs34773528	chr6:163088796	G/C	cg21926612	chr6:163149169	PACRG;PARK2	1.17	9.49	0.65	2.19e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	5.8	0.46	5.19e-8	Alzheimer's disease;
TGCT	cis	rs922182	0.721	rs7180239	chr15:64309643	G/A	cg02919090	chr15:64263738	DAPK2	0.25	4.54	0.38	1.3e-5	Blood protein levels;
TGCT	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg03264133	chr6:25882463	NA	-0.53	-5.53	-0.44	1.8e-7	Blood metabolite levels;
TGCT	cis	rs13256369	1.000	rs13271966	chr8:8575472	T/C	cg18904891	chr8:8559673	CLDN23	0.64	5.89	0.47	3.36e-8	Obesity-related traits;
TGCT	cis	rs950776	0.518	rs12903129	chr15:78819606	C/T	cg06917634	chr15:78832804	PSMA4	0.96	9.43	0.65	2.99e-16	Sudden cardiac arrest;
TGCT	cis	rs13088645	0.541	rs9842113	chr3:134192338	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-6.78	-0.52	4.37e-10	Coronary artery disease;
TGCT	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg03609598	chr5:56110824	MAP3K1	0.61	4.93	0.4	2.62e-6	Initial pursuit acceleration;
TGCT	cis	rs2832191	0.791	rs2832179	chr21:30480366	C/T	cg24692254	chr21:30365293	RNF160	-0.95	-10.52	-0.69	7.06e-19	Dental caries;
TGCT	cis	rs138249	1.000	rs138250	chr22:50570361	A/G	cg24864161	chr22:50528282	MOV10L1	0.47	4.78	0.39	4.9100000000000004e-06	Gestational age at birth in labor-initiated deliveries (child effect);
TGCT	cis	rs7681440	0.904	rs1372521	chr4:90765223	G/A	cg01966878	chr4:90757139	SNCA	-0.25	-4.56	-0.38	1.2e-5	Dementia with Lewy bodies;
TGCT	cis	rs10174077	0.687	rs4664491	chr2:152479986	C/T	cg19508488	chr2:152266495	RIF1	0.62	5.83	0.46	4.59e-8	Squamous cell lung carcinoma;
TGCT	cis	rs651907	0.535	rs61396602	chr3:101509046	T/C	cg12386194	chr3:101231763	SENP7	0.48	4.81	0.4	4.36e-6	Colorectal cancer;
TGCT	cis	rs6547741	0.935	rs2384626	chr2:27773648	A/G	cg27432699	chr2:27873401	GPN1	0.19	4.7	0.39	6.92e-6	Oral cavity cancer;
TGCT	cis	rs3091242	0.933	rs35148262	chr1:25766623	A/G	cg10117171	chr1:25599238	RHD	-0.34	-5.5	-0.44	2.05e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs7647973	0.731	rs7617480	chr3:49210732	G/T	cg07690219	chr3:49449608	TCTA;RHOA	0.63	4.83	0.4	3.87e-6	Menarche (age at onset);
TGCT	cis	rs3806843	0.712	rs2530244	chr5:140109155	A/G	cg19875535	chr5:140030758	IK	-0.35	-5.94	-0.47	2.63e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs78487399	0.808	rs72865267	chr2:43726328	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-4.82	-0.4	4.03e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.46	-6.7	-0.52	6.44e-10	Alzheimer's disease;
TGCT	cis	rs3806843	0.576	rs265316	chr5:140290843	T/C	cg09824255	chr5:140014002	CD14	0.25	4.48	0.37	1.69e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs698813	0.674	rs3738985	chr2:44502788	A/C	cg00619915	chr2:44497795	NA	-0.22	-4.95	-0.41	2.35e-6	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
TGCT	cis	rs7208859	0.614	rs9914534	chr17:29202664	G/A	cg18442181	chr17:29233375	C17orf42	-0.79	-4.78	-0.39	4.95e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs17401966	0.838	rs61775885	chr1:10281445	T/C	cg19773385	chr1:10388646	KIF1B	-0.22	-4.65	-0.39	8.41e-6	Hepatocellular carcinoma;
TGCT	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg05368731	chr17:41323189	NBR1	1.2	14.48	0.79	1.98e-28	Menopause (age at onset);
TGCT	cis	rs6912958	0.781	rs6916732	chr6:88259225	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-5.06	-0.41	1.45e-6	Monocyte percentage of white cells;
TGCT	cis	rs514406	0.505	rs427319	chr1:53178807	T/G	cg08859206	chr1:53392774	SCP2	-0.36	-5.23	-0.42	7.05e-7	Monocyte count;
TGCT	cis	rs7226408	0.857	rs56331183	chr18:34621913	G/A	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs9902453	0.874	rs4474741	chr17:28148117	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.74	-6.81	-0.52	3.74e-10	Coffee consumption (cups per day);
TGCT	cis	rs1150668	0.796	rs1005125	chr6:28367355	G/A	cg13525197	chr6:28411240	ZSCAN23	-0.5	-4.87	-0.4	3.3e-6	Pubertal anthropometrics;
TGCT	cis	rs7804356	0.651	rs1030648	chr7:26802672	T/C	cg03456212	chr7:26904342	SKAP2	-0.54	-4.56	-0.38	1.22e-5	Type 1 diabetes;
TGCT	cis	rs514406	0.505	rs269287	chr1:53168842	T/C	cg01802117	chr1:53393560	SCP2	-0.42	-4.85	-0.4	3.64e-6	Monocyte count;
TGCT	cis	rs9818758	0.607	rs11706052	chr3:49064110	A/G	cg00383909	chr3:49044727	WDR6	1.3	6.73	0.52	5.74e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs1670533	1.000	rs2290411	chr4:1051077	T/C	cg27284194	chr4:1044797	NA	0.68	5.87	0.47	3.76e-8	Recombination rate (females);
TGCT	cis	rs10779751	1.000	rs6679878	chr1:11306882	A/G	cg08854313	chr1:11322531	MTOR	0.98	9.12	0.63	1.65e-15	Body mass index;
TGCT	cis	rs10927875	0.864	rs6674071	chr1:16144855	G/C	cg21385522	chr1:16154831	NA	-0.89	-11.06	-0.7	3.27e-20	Dilated cardiomyopathy;
TGCT	cis	rs854765	0.583	rs28428991	chr17:17827649	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.74	7.73	0.57	3.18e-12	Total body bone mineral density;
TGCT	cis	rs868036	0.718	rs4776984	chr15:68118194	A/C	cg05925327	chr15:68127851	NA	-0.51	-5.04	-0.41	1.63e-6	Restless legs syndrome;
TGCT	cis	rs2795502	0.938	rs3121324	chr10:43379515	C/T	cg20628663	chr10:43360327	NA	0.43	6.2	0.49	7.57e-9	Blood protein levels;
TGCT	cis	rs28595532	0.841	rs56046449	chr4:119769302	T/C	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs2120019	0.935	rs8043181	chr15:75380424	T/C	cg09165964	chr15:75287851	SCAMP5	-1.06	-8.28	-0.6	1.63e-13	Blood trace element (Zn levels);
TGCT	cis	rs6570726	0.791	rs9373464	chr6:145907167	T/C	cg05347473	chr6:146136440	FBXO30	0.52	4.93	0.41	2.54e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs72634258	0.519	rs36040967	chr1:7931804	A/G	cg26816564	chr1:7831052	VAMP3	0.65	4.98	0.41	2.11e-6	Inflammatory bowel disease;
TGCT	cis	rs6879260	0.963	rs11748619	chr5:179727399	C/G	cg23221052	chr5:179740743	GFPT2	-0.33	-5.09	-0.42	1.27e-6	Height;
TGCT	cis	rs2762353	0.845	rs1937130	chr6:25787554	T/A	cg03264133	chr6:25882463	NA	0.49	5.14	0.42	1.05e-6	Blood metabolite levels;
TGCT	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg23574427	chr4:122746245	BBS7;CCNA2	-0.34	-5.26	-0.43	6.07e-7	Type 2 diabetes;
TGCT	cis	rs3806843	0.518	rs173471	chr5:140335226	A/G	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs1878931	0.726	rs3843728	chr16:3448251	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.99	12.29	0.74	3.41e-23	Body mass index (adult);
TGCT	cis	rs3733585	0.605	rs56178126	chr4:10123581	C/T	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.36	-0.5	3.55e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg08219700	chr8:58056026	NA	0.41	4.98	0.41	2.11e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6089584	0.927	rs11697597	chr20:60584748	C/T	cg13770153	chr20:60521292	NA	-0.54	-7.35	-0.55	2.31e-11	Body mass index;
TGCT	cis	rs9302065	1.000	rs9302065	chr13:95971016	C/T	cg26751094	chr13:95954534	ABCC4	0.31	5.19	0.42	8.16e-7	Blood metabolite levels;
TGCT	cis	rs28595532	1.000	rs73842212	chr4:119638122	A/G	cg21605333	chr4:119757512	SEC24D	1.36	7.4	0.55	1.82e-11	Cannabis dependence symptom count;
TGCT	cis	rs11532322	1	rs11532322	chr12:123731423	A/G	cg00376283	chr12:123451042	ABCB9	0.79	6.72	0.52	6e-10	Schizophrenia;
TGCT	cis	rs8031584	0.678	rs8035703	chr15:31168472	T/C	cg14829155	chr15:31115871	NA	-0.36	-4.72	-0.39	6.14e-6	Huntington's disease progression;
TGCT	cis	rs13217239	0.572	rs9379958	chr6:27066163	A/C	cg15659132	chr6:26577336	NA	-0.55	-5.37	-0.43	3.7e-7	Schizophrenia;
TGCT	cis	rs7926906	1.000	rs1404532	chr11:90538258	A/T	cg26138821	chr11:89956704	CHORDC1	0.48	5.15	0.42	9.96e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2594989	0.887	rs2443717	chr3:11521493	T/C	cg00170343	chr3:11313890	ATG7	0.7	5.22	0.42	7.17e-7	Circulating chemerin levels;
TGCT	cis	rs9467773	1.000	rs9467797	chr6:26568473	A/T	cg15659132	chr6:26577336	NA	0.88	12.27	0.74	3.83e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs7843479	0.965	rs17581910	chr8:21799626	A/G	cg17168535	chr8:21777572	XPO7	0.65	5.99	0.47	2.14e-8	Mean corpuscular volume;
TGCT	cis	rs7674212	0.581	rs10516496	chr4:103942165	C/T	cg16532752	chr4:104119610	CENPE	-0.58	-5.21	-0.42	7.7300000000000005e-07	Type 2 diabetes;
TGCT	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg24531977	chr5:56204891	C5orf35	-0.77	-7.64	-0.57	5.17e-12	Initial pursuit acceleration;
TGCT	cis	rs9611565	0.879	rs2235845	chr22:41729294	T/G	cg13695892	chr22:41940480	POLR3H	-0.72	-7.33	-0.55	2.61e-11	Vitiligo;
TGCT	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg18876405	chr7:65276391	NA	-0.34	-5.08	-0.41	1.38e-6	Aortic root size;
TGCT	cis	rs11030122	0.632	rs4910596	chr11:4084604	A/G	cg18678763	chr11:4115507	RRM1	-0.48	-5.88	-0.47	3.49e-8	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs7769051	1.000	rs9493454	chr6:133144629	G/T	cg07930552	chr6:133119739	C6orf192	-0.96	-5.08	-0.41	1.37e-6	Type 2 diabetes nephropathy;
TGCT	cis	rs3733585	0.578	rs6837224	chr4:9955255	G/T	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.73	-0.57	3.25e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs9372498	0.505	rs62424173	chr6:118780507	C/G	cg21191810	chr6:118973309	C6orf204	-0.37	-4.77	-0.39	5.03e-6	Diastolic blood pressure;
TGCT	cis	rs9790314	0.586	rs67077657	chr3:161138521	A/G	cg03342759	chr3:160939853	NMD3	-0.53	-5.32	-0.43	4.74e-7	Morning vs. evening chronotype;
TGCT	cis	rs56176327	0.600	rs7628207	chr3:49754970	T/C	cg03034192	chr3:50606346	HEMK1;C3orf18	0.36	4.75	0.39	5.61e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2455799	0.613	rs10510443	chr3:15829127	A/G	cg16303742	chr3:15540471	COLQ	-0.24	-4.51	-0.38	1.47e-5	Mean platelet volume;
TGCT	cis	rs1990950	0.692	rs10070466	chr5:156839607	G/A	cg25387487	chr5:157003181	ADAM19	0.29	4.54	0.38	1.29e-5	Lung function (FEV1/FVC);
TGCT	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg26354017	chr1:205819088	PM20D1	-0.54	-6.83	-0.52	3.45e-10	Monocyte percentage of white cells;
TGCT	cis	rs9914988	0.887	rs28873200	chr17:27149512	A/G	cg20469991	chr17:27169893	C17orf63	-0.72	-5.09	-0.42	1.28e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs2046867	0.862	rs62251657	chr3:72832076	C/T	cg25664220	chr3:72788482	NA	-0.58	-7.21	-0.54	4.9e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7666738	0.830	rs9994346	chr4:99037986	A/G	cg05340658	chr4:99064831	C4orf37	0.48	4.99	0.41	2.03e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2730260	0.537	rs56260213	chr7:158875921	C/T	cg27122614	chr7:157913741	PTPRN2	0.42	4.47	0.37	1.74e-5	Myopia (pathological);
TGCT	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg21644426	chr2:191273491	MFSD6	0.59	5.81	0.46	4.92e-8	Pulse pressure;
TGCT	cis	rs57920188	0.585	rs12124643	chr1:4071209	C/T	cg20703997	chr1:4087676	NA	0.45	5.49	0.44	2.13e-7	Interleukin-17 levels;
TGCT	cis	rs4654899	0.897	rs710311	chr1:21062001	T/C	cg01072550	chr1:21505969	NA	-0.48	-7.56	-0.56	7.78e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs9303401	0.614	rs62084384	chr17:57126842	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.58	5.82	0.46	4.8e-8	Cognitive test performance;
TGCT	cis	rs4568518	0.530	rs10273476	chr7:17998418	G/A	cg03009463	chr7:17980271	SNX13	0.57	4.51	0.38	1.47e-5	Measles;
TGCT	cis	rs12142240	0.698	rs72677592	chr1:46818288	A/G	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	trans	rs877282	1.000	rs877281	chr10:771557	T/G	cg22713356	chr15:30763199	NA	1.2	10.36	0.68	1.66e-18	Uric acid levels;
TGCT	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg21724239	chr8:58056113	NA	0.35	4.76	0.39	5.26e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6918586	0.658	rs198819	chr6:26124430	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.68	-6.46	-0.5	2.15e-9	Schizophrenia;
TGCT	cis	rs3733585	0.699	rs28613263	chr4:9964880	C/T	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.7	-0.57	3.66e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs3015497	0.789	rs11621971	chr14:51124527	C/T	cg04730355	chr14:51134070	SAV1	0.62	6.06	0.48	1.48e-8	Mean platelet volume;
TGCT	cis	rs7666738	0.830	rs36028444	chr4:98968635	G/T	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs911555	0.713	rs11848796	chr14:103978686	T/C	cg12935359	chr14:103987150	CKB	-0.33	-4.66	-0.39	7.91e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7208859	0.673	rs73277978	chr17:29191449	A/G	cg18442181	chr17:29233375	C17orf42	-0.78	-4.61	-0.38	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs2273156	1.000	rs8017191	chr14:35469991	G/A	cg15394648	chr14:35761551	PSMA6	-0.6	-4.48	-0.37	1.69e-5	Immunoglobulin light chain (AL) amyloidosis;
TGCT	trans	rs7824557	0.527	rs2736296	chr8:11234844	G/A	cg15556689	chr8:8085844	FLJ10661	-0.74	-6.7	-0.52	6.42e-10	Retinal vascular caliber;
TGCT	cis	rs9910055	0.762	rs227579	chr17:42223134	A/T	cg19774624	chr17:42201019	HDAC5	0.85	8.95	0.63	4.27e-15	Total body bone mineral density;
TGCT	cis	rs2692947	0.616	rs2301707	chr2:96931846	T/C	cg23100626	chr2:96804247	ASTL	0.5	6.62	0.51	9.75e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg13395646	chr4:1353034	KIAA1530	0.4	4.98	0.41	2.1e-6	Obesity-related traits;
TGCT	cis	rs7542091	1.000	rs7542091	chr1:210031948	G/C	cg23283495	chr1:209979779	IRF6	0.49	4.97	0.41	2.16e-6	Monobrow;
TGCT	cis	rs6426558	0.559	rs2813947	chr1:227459413	G/T	cg10327440	chr1:227177885	CDC42BPA	0.58	6.76	0.52	4.75e-10	Neutrophil percentage of white cells;
TGCT	cis	rs892961	0.932	rs35657663	chr17:75412482	T/C	cg05865280	chr17:75406074	SEPT9	0.28	6.86	0.52	2.9e-10	Airflow obstruction;
TGCT	cis	rs909674	0.690	rs5750825	chr22:39831278	A/G	cg01416388	chr22:39784598	NA	-0.74	-6.78	-0.52	4.37e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg11764359	chr7:65958608	NA	0.61	5.54	0.45	1.76e-7	Aortic root size;
TGCT	cis	rs1215050	0.791	rs9993992	chr4:98810851	C/G	cg17366294	chr4:99064904	C4orf37	0.54	5.79	0.46	5.38e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs908922	0.676	rs7550769	chr1:152531213	G/A	cg20991723	chr1:152506922	NA	0.45	6.05	0.48	1.6e-8	Hair morphology;
TGCT	cis	rs35306767	0.855	rs11253465	chr10:897208	A/C	cg26597838	chr10:835615	NA	0.75	10.61	0.69	4.13e-19	Eosinophil percentage of granulocytes;
TGCT	cis	rs6681544	0.760	rs4970640	chr1:82429237	A/G	cg04226724	chr1:82268649	LPHN2	-0.48	-4.95	-0.41	2.42e-6	Metabolite levels  (X-11787);
TGCT	cis	rs9650657	0.501	rs3021500	chr8:11023997	G/C	cg27411982	chr8:10470053	RP1L1	-0.21	-4.54	-0.38	1.3e-5	Neuroticism;
TGCT	cis	rs2204008	0.687	rs2320523	chr12:38251397	T/C	cg26384229	chr12:38710491	ALG10B	0.84	7.33	0.55	2.58e-11	Bladder cancer;
TGCT	cis	rs3617	0.625	rs6769789	chr3:52874446	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	0.49	4.77	0.39	5.04e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	trans	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.8	-8.32	-0.6	1.31e-13	Body mass index;
TGCT	cis	rs1865760	0.827	rs9295681	chr6:25944117	T/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.65	6.39	0.5	3.02e-9	Height;
TGCT	cis	rs7017914	0.967	rs7012404	chr8:71668698	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.53	-4.9	-0.4	2.87e-6	Bone mineral density;
TGCT	cis	rs1008375	0.966	rs6449329	chr4:17703677	T/C	cg18681998	chr4:17616180	MED28	0.78	7.37	0.55	2.06e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9902453	0.904	rs7208579	chr17:28263067	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.87	8.26	0.6	1.9e-13	Coffee consumption (cups per day);
TGCT	cis	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg02380750	chr20:61661411	NA	0.34	6.02	0.48	1.86e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs6988636	1.000	rs7002021	chr8:124185250	G/A	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs7666738	0.753	rs28463863	chr4:98844444	T/C	cg18180107	chr4:99064573	C4orf37	0.58	5.36	0.43	3.96e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4689388	0.889	rs4629534	chr4:6294124	G/T	cg25554036	chr4:6271136	WFS1	0.54	7.37	0.55	2.11e-11	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs9325144	0.505	rs10785560	chr12:38636622	C/T	cg13010199	chr12:38710504	ALG10B	0.61	5.42	0.44	2.93e-7	Morning vs. evening chronotype;
TGCT	cis	rs2439831	0.867	rs8041132	chr15:43635136	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	6.61	0.51	1e-9	Lung cancer in ever smokers;
TGCT	cis	rs9948	0.786	rs72809850	chr2:97449762	A/C	cg01990225	chr2:97406019	LMAN2L	-0.88	-4.81	-0.4	4.37e-6	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs7918232	0.941	rs7907988	chr10:27444344	T/G	cg14442939	chr10:27389572	ANKRD26	0.8	5.32	0.43	4.7e-7	Breast cancer;
TGCT	cis	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg07424592	chr7:64974309	NA	1.32	8.25	0.6	1.92e-13	Diabetic kidney disease;
TGCT	cis	rs9527	0.615	rs36045108	chr10:104697929	G/A	cg15744005	chr10:104629667	AS3MT	-0.45	-5.31	-0.43	4.9e-7	Arsenic metabolism;
TGCT	cis	rs7666738	0.830	rs2015828	chr4:98984594	A/G	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs546131	0.928	rs550313	chr11:34830919	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.68	6.17	0.48	8.82e-9	Lung disease severity in cystic fibrosis;
TGCT	cis	rs4851266	1.000	rs11686280	chr2:100827718	C/A	cg07810366	chr2:100720526	AFF3	-0.39	-5.55	-0.45	1.65e-7	Educational attainment;
TGCT	cis	rs5751150	1	rs5751150	chr22:42153292	T/G	cg13695892	chr22:41940480	POLR3H	0.87	8.24	0.59	2.06e-13	Cannabis dependence symptom count;
TGCT	cis	rs478304	0.754	rs2004649	chr11:65380916	G/A	cg17480646	chr11:65405466	SIPA1	-0.55	-7.09	-0.54	9.2e-11	Acne (severe);
TGCT	cis	rs8031584	0.918	rs35396566	chr15:31263057	T/C	cg08704250	chr15:31115839	NA	-0.35	-4.53	-0.38	1.38e-5	Huntington's disease progression;
TGCT	trans	rs17685	0.712	rs11770149	chr7:75791644	G/A	cg19862616	chr7:65841803	NCRNA00174	0.52	9.1	0.63	1.93e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs2735413	0.564	rs7201557	chr16:78110059	C/A	cg09132178	chr16:78079569	NA	0.37	4.8	0.4	4.4e-6	Systolic blood pressure (alcohol consumption interaction);
TGCT	cis	rs7312933	0.558	rs1051453	chr12:42852217	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.52	4.99	0.41	2.02e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs7949030	0.765	rs11553576	chr11:62378801	T/C	cg13298116	chr11:62369859	EML3;MTA2	0.65	9.75	0.66	5.01e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs3617	0.522	rs6773650	chr3:52897095	A/T	cg11645453	chr3:52864694	ITIH4	0.26	4.89	0.4	3e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs950169	0.919	rs17300292	chr15:84762568	G/C	cg11189052	chr15:85197271	WDR73	0.69	5.91	0.47	3.07e-8	Schizophrenia;
TGCT	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg11764359	chr7:65958608	NA	0.58	5.34	0.43	4.22e-7	Aortic root size;
TGCT	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg22535103	chr8:58192502	C8orf71	-0.42	-4.79	-0.4	4.7e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7914558	0.966	rs10883805	chr10:104708251	T/C	cg15744005	chr10:104629667	AS3MT	-0.41	-5.11	-0.42	1.16e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs2180341	0.814	rs6905553	chr6:127727407	A/G	cg24812749	chr6:127587940	RNF146	0.76	6.22	0.49	7.07e-9	Breast cancer;
TGCT	cis	rs7264396	0.790	rs2425097	chr20:34308926	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.3	-5.31	-0.43	4.96e-7	Total cholesterol levels;
TGCT	cis	rs9467773	0.620	rs2504600	chr6:26648334	C/A	cg02458000	chr6:26745757	NA	0.51	4.59	0.38	1.08e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs639012	0.582	rs1898895	chr11:85837669	T/C	cg07180834	chr11:85838833	NA	-0.33	-4.71	-0.39	6.61e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs1008375	0.966	rs4515155	chr4:17696477	G/T	cg18681998	chr4:17616180	MED28	0.78	7.35	0.55	2.35e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2404602	0.735	rs4886798	chr15:76673226	A/G	cg22467129	chr15:76604101	ETFA	-0.52	-5.5	-0.44	2.08e-7	Blood metabolite levels;
TGCT	cis	rs2688608	0.967	rs9971040	chr10:75661162	G/C	cg19442545	chr10:75533431	FUT11	-0.3	-4.83	-0.4	3.88e-6	Inflammatory bowel disease;
TGCT	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.07	-9.63	-0.65	1.01e-16	Platelet count;
TGCT	cis	rs12780845	0.522	rs17464824	chr10:17210822	A/C	cg01003015	chr10:17271136	VIM	-0.59	-5.41	-0.44	3.16e-7	Homocysteine levels;
TGCT	cis	rs9859260	0.710	rs366268	chr3:195782177	A/G	cg02975922	chr3:195473998	MUC4	0.25	5.1	0.42	1.24e-6	Mean corpuscular volume;
TGCT	cis	rs617219	0.710	rs10805925	chr5:78539399	A/G	cg23987322	chr5:78407566	BHMT	0.34	4.48	0.37	1.64e-5	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs11190604	1.000	rs2295780	chr10:102305965	A/G	cg16342193	chr10:102329863	NA	-0.43	-5.44	-0.44	2.71e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.5	-4.81	-0.4	4.26e-6	Bipolar disorder;
TGCT	cis	rs2033711	0.654	rs734380	chr19:58898963	A/C	cg13877915	chr19:58951672	ZNF132	0.65	6.37	0.5	3.36e-9	Uric acid clearance;
TGCT	cis	rs2230307	0.656	rs1395332	chr1:100503993	A/C	cg24955406	chr1:100503596	HIAT1	0.74	4.86	0.4	3.41e-6	Carotid intima media thickness;
TGCT	trans	rs4650994	0.967	rs4650998	chr1:178531850	G/A	cg05059571	chr16:84539110	KIAA1609	-0.4	-7.39	-0.55	1.94e-11	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs700651	0.789	rs10190226	chr2:198901564	A/G	cg00792783	chr2:198669748	PLCL1	-0.55	-4.86	-0.4	3.46e-6	Intracranial aneurysm;
TGCT	cis	rs7511006	1.000	rs5771109	chr22:50678571	T/C	cg16473166	chr22:50639996	SELO	0.61	6.1	0.48	1.27e-8	Obesity-related traits;
TGCT	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.91	9.53	0.65	1.78e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs6089829	0.888	rs6011559	chr20:61675620	C/T	cg08045932	chr20:61659980	NA	-0.47	-7.62	-0.56	5.73e-12	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7959452	0.605	rs12819406	chr12:69696400	G/T	cg20891283	chr12:69753455	YEATS4	0.66	6.57	0.51	1.26e-9	Blood protein levels;
TGCT	cis	rs7267979	1.000	rs1047171	chr20:25428786	T/C	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3858526	0.635	rs2045046	chr11:5875867	A/C	cg13902645	chr11:5959945	NA	-0.49	-5.08	-0.42	1.33e-6	DNA methylation (variation);
TGCT	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg13395646	chr4:1353034	KIAA1530	-0.59	-8.0	-0.58	7.57e-13	Obesity-related traits;
TGCT	trans	rs7819412	0.634	rs4841485	chr8:10909936	T/C	cg06636001	chr8:8085503	FLJ10661	0.73	7.2	0.54	5.06e-11	Triglycerides;
TGCT	cis	rs826838	1.000	rs6582619	chr12:38729904	A/G	cg13010199	chr12:38710504	ALG10B	0.83	6.88	0.53	2.58e-10	Heart rate;
TGCT	cis	rs2282802	0.685	rs7730245	chr5:139628163	C/A	cg01081189	chr5:139537190	NA	0.29	5.24	0.43	6.57e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1055129	0.681	rs7221792	chr17:73834690	T/G	cg08125733	chr17:73851984	WBP2	0.56	5.07	0.41	1.44e-6	White matter hyperintensity burden;
TGCT	cis	rs986417	1.000	rs1254255	chr14:60831342	G/A	cg27398547	chr14:60952738	C14orf39	-1.37	-8.31	-0.6	1.44e-13	Gut microbiota (bacterial taxa);
TGCT	cis	rs10089	0.953	rs2016015	chr5:127527253	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.83	8.09	0.59	4.7e-13	Ileal carcinoids;
TGCT	cis	rs10435719	0.902	rs7459983	chr8:11807221	T/C	cg02840367	chr8:11660030	FDFT1	-0.53	-4.51	-0.38	1.5e-5	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs5769707	0.967	rs9616701	chr22:50025546	G/A	cg20744362	chr22:50050164	C22orf34	0.27	4.57	0.38	1.18e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs12477438	0.834	rs10179043	chr2:99687490	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-5.8	-0.46	5.16e-8	Chronic sinus infection;
TGCT	cis	rs709400	0.663	rs62007718	chr14:103940436	G/A	cg12935359	chr14:103987150	CKB	-0.37	-5.69	-0.46	8.55e-8	Body mass index;
TGCT	cis	rs951366	0.677	rs1775140	chr1:205672107	C/A	cg26354017	chr1:205819088	PM20D1	0.56	6.56	0.51	1.31e-9	Menarche (age at onset);
TGCT	cis	rs8038465	0.568	rs62004592	chr15:73878019	A/G	cg15420318	chr15:73925796	NPTN	0.64	6.8	0.52	3.9e-10	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6500602	0.627	rs709632	chr16:4587811	C/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	-0.26	-4.76	-0.39	5.38e-6	Schizophrenia;
TGCT	cis	rs10493773	0.609	rs11161651	chr1:86177816	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.52	-8.16	-0.59	3.27e-13	Urate levels in overweight individuals;
TGCT	cis	rs9443645	0.869	rs10943609	chr6:79676328	A/T	cg09184832	chr6:79620586	NA	-0.49	-5.29	-0.43	5.3e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs5750830	0.597	rs4821889	chr22:39777254	T/C	cg11247378	chr22:39784982	NA	-0.68	-9.79	-0.66	4.06e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs9486719	0.843	rs2499796	chr6:96848364	A/G	cg18709589	chr6:96969512	KIAA0776	0.75	5.13	0.42	1.1e-6	Migraine;Coronary artery disease;
TGCT	cis	rs7017914	0.967	rs13274381	chr8:71765094	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.55	-5.1	-0.42	1.23e-6	Bone mineral density;
TGCT	cis	rs8180040	0.726	rs9843075	chr3:47195630	A/G	cg27129171	chr3:47204927	SETD2	0.66	7.79	0.57	2.35e-12	Colorectal cancer;
TGCT	cis	rs10782582	0.586	rs1856791	chr1:76308942	C/T	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.52	4.53	0.38	1.37e-5	Daytime sleep phenotypes;
TGCT	cis	rs6967414	0.681	rs2881352	chr7:6753511	T/A	cg09896999	chr7:6746977	ZNF12	-0.57	-6.43	-0.5	2.5e-9	Hematocrit;Hemoglobin concentration;
TGCT	cis	rs7666738	0.747	rs2865955	chr4:99040518	A/C	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3733585	0.673	rs4697914	chr4:9952266	G/A	cg00071950	chr4:10020882	SLC2A9	-0.55	-6.63	-0.51	9.3e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg05368731	chr17:41323189	NBR1	1.17	13.8	0.78	7.84e-27	Menopause (age at onset);
TGCT	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.47	0.56	1.28e-11	Prudent dietary pattern;
TGCT	cis	rs7666738	0.830	rs13134216	chr4:98919765	C/T	cg05340658	chr4:99064831	C4orf37	0.53	6.11	0.48	1.21e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs75059851	0.756	rs11223650	chr11:133840647	A/G	cg14047540	chr11:133829660	NA	-0.57	-5.69	-0.45	8.72e-8	Schizophrenia;
TGCT	cis	rs7208859	0.573	rs216443	chr17:28931871	A/G	cg14008862	chr17:28927542	LRRC37B2	0.87	5.31	0.43	4.8e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs11203032	0.831	rs10887922	chr10:90930236	G/A	cg16672925	chr10:90967113	CH25H	0.73	4.5	0.37	1.55e-5	Heart failure;
TGCT	cis	rs1949733	1.000	rs2140337	chr4:8502112	A/G	cg13073564	chr4:8508604	NA	-0.47	-5.05	-0.41	1.55e-6	Response to antineoplastic agents;
TGCT	cis	rs1801251	0.778	rs778340	chr2:233734083	C/T	cg08000102	chr2:233561755	GIGYF2	-0.44	-4.45	-0.37	1.88e-5	Coronary artery disease;
TGCT	cis	rs1371867	1.000	rs1371867	chr8:101330209	A/C	cg06636551	chr8:101224915	SPAG1	-0.36	-4.82	-0.4	4.2e-6	Atrioventricular conduction;
TGCT	cis	rs7267979	1.000	rs2257988	chr20:25270003	T/C	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2303745	0.589	rs1864115	chr19:17393327	G/C	cg04248312	chr19:17393744	ANKLE1	-0.33	-5.55	-0.45	1.62e-7	Systemic lupus erythematosus;
TGCT	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg22963979	chr7:1858916	MAD1L1	0.46	7.4	0.55	1.81e-11	Bipolar disorder and schizophrenia;
TGCT	cis	rs11098499	0.820	rs28535956	chr4:120536858	C/T	cg09307838	chr4:120376055	NA	-0.66	-6.16	-0.48	9.55e-9	Corneal astigmatism;
TGCT	cis	rs9611565	0.512	rs139566	chr22:42199277	A/G	cg03806693	chr22:41940476	POLR3H	-1.02	-10.21	-0.68	4.01e-18	Vitiligo;
TGCT	cis	rs593982	1.000	rs576663	chr11:65498942	G/T	cg08755490	chr11:65554678	OVOL1	1.42	12.09	0.74	1.03e-22	Atopic dermatitis;
TGCT	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg12310025	chr6:25882481	NA	-0.62	-6.42	-0.5	2.62e-9	Blood metabolite levels;
TGCT	cis	rs7760949	0.963	rs9382681	chr6:13915051	A/G	cg27413430	chr6:13925136	RNF182	0.59	5.62	0.45	1.21e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg07636037	chr3:49044803	WDR6	0.88	9.28	0.64	6.89e-16	Menarche (age at onset);
TGCT	cis	rs1801251	1.000	rs283479	chr2:233648754	A/G	cg25237894	chr2:233734115	C2orf82	0.28	4.82	0.4	4.05e-6	Coronary artery disease;
TGCT	cis	rs2361718	0.500	rs4889970	chr17:78096086	C/T	cg09238746	chr17:78121135	EIF4A3	1.08	9.94	0.67	1.82e-17	Yeast infection;
TGCT	cis	rs6490294	0.748	rs111752063	chr12:112297450	G/T	cg10833066	chr12:111807467	FAM109A	0.38	5.43	0.44	2.85e-7	Mean platelet volume;
TGCT	cis	rs12681287	0.547	rs6471360	chr8:87513469	C/T	cg19078186	chr8:87526527	CPNE3	0.37	4.57	0.38	1.15e-5	Caudate activity during reward;
TGCT	cis	rs2594989	0.943	rs62245869	chr3:11439820	G/A	cg00170343	chr3:11313890	ATG7	0.71	5.23	0.43	6.98e-7	Circulating chemerin levels;
TGCT	cis	rs1371867	0.846	rs924057	chr8:101266157	A/G	cg06002616	chr8:101225028	SPAG1	0.53	6.42	0.5	2.67e-9	Atrioventricular conduction;
TGCT	cis	rs739496	0.579	rs6489818	chr12:112310580	G/A	cg10833066	chr12:111807467	FAM109A	0.38	5.67	0.45	9.69e-8	Platelet count;
TGCT	cis	rs881375	1.000	rs4323544	chr9:123647377	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	5.38	0.44	3.52e-7	Rheumatoid arthritis;
TGCT	cis	rs669446	0.562	rs4660260	chr1:44195353	A/G	cg12908607	chr1:44402522	ARTN	-0.63	-7.39	-0.55	1.88e-11	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs936229	0.954	rs936230	chr15:75145098	C/T	cg10253484	chr15:75165896	SCAMP2	0.8	7.17	0.54	5.86e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
TGCT	cis	rs8103278	1.000	rs8108590	chr19:46301620	A/G	cg11657440	chr19:46296263	DMWD	-0.6	-5.78	-0.46	5.75e-8	Coronary artery disease;
TGCT	cis	rs7937682	0.961	rs4936682	chr11:111629743	T/G	cg09085632	chr11:111637200	PPP2R1B	1.14	11.53	0.72	2.4e-21	Primary sclerosing cholangitis;
TGCT	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9914544	1.000	rs59682951	chr17:18800766	G/T	cg26378065	chr17:18585709	ZNF286B	0.54	4.85	0.4	3.62e-6	Educational attainment (years of education);
TGCT	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg09359103	chr1:154839909	KCNN3	0.53	8.49	0.61	5.38e-14	Prostate cancer;
TGCT	cis	rs8180040	1.000	rs2159400	chr3:47375890	T/C	cg27129171	chr3:47204927	SETD2	-0.7	-8.63	-0.61	2.53e-14	Colorectal cancer;
TGCT	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	16.07	0.82	4.16e-32	Prudent dietary pattern;
TGCT	cis	rs826838	1.000	rs11183469	chr12:38752311	G/A	cg13010199	chr12:38710504	ALG10B	0.82	6.86	0.52	2.91e-10	Heart rate;
TGCT	cis	rs367943	0.966	rs444322	chr5:112815399	C/T	cg12552261	chr5:112820674	MCC	-0.24	-4.91	-0.4	2.81e-6	Type 2 diabetes;
TGCT	cis	rs4455778	0.757	rs1072376	chr7:49011373	A/C	cg26309511	chr7:48887640	NA	-0.48	-5.92	-0.47	2.89e-8	Lung cancer in never smokers;
TGCT	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg20203395	chr5:56204925	C5orf35	-0.76	-5.84	-0.46	4.26e-8	Initial pursuit acceleration;
TGCT	cis	rs1670533	0.932	rs610218	chr4:1080083	C/G	cg20887711	chr4:1340912	KIAA1530	0.7	5.55	0.45	1.64e-7	Recombination rate (females);
TGCT	cis	rs9467711	0.606	rs9379857	chr6:26367654	G/C	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs911555	0.755	rs4143998	chr14:103955247	T/C	cg12935359	chr14:103987150	CKB	-0.33	-4.59	-0.38	1.07e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.03	0.41	1.71e-6	Menopause (age at onset);
TGCT	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg11644478	chr21:40555479	PSMG1	0.61	5.72	0.46	7.44e-8	Cognitive function;
TGCT	cis	rs9611565	0.546	rs5758431	chr22:42109917	A/G	cg17554472	chr22:41940697	POLR3H	0.48	5.17	0.42	9e-7	Vitiligo;
TGCT	cis	rs6840360	0.582	rs1372976	chr4:152451453	G/A	cg17479576	chr4:152424074	FAM160A1	-0.62	-6.7	-0.52	6.65e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs11677370	0.603	rs1454242	chr2:3848532	G/A	cg17052675	chr2:3827356	NA	-0.42	-7.13	-0.54	7.31e-11	Type 2 diabetes;
TGCT	cis	rs17102423	0.755	rs8009714	chr14:65573446	G/T	cg11161011	chr14:65562177	MAX	-0.54	-7.49	-0.56	1.15e-11	Obesity-related traits;
TGCT	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg13695892	chr22:41940480	POLR3H	0.92	9.06	0.63	2.36e-15	Vitiligo;
TGCT	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg24399712	chr22:39784796	NA	-1.06	-12.55	-0.75	8.19e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs3772130	0.962	rs9841595	chr3:121483326	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.72	0.39	6.25e-6	Cognitive performance;
TGCT	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	16.1	0.82	3.69e-32	Prudent dietary pattern;
TGCT	cis	rs3820068	0.581	rs67806552	chr1:15927138	T/C	cg05660106	chr1:15850417	CASP9	0.74	7.27	0.55	3.53e-11	Systolic blood pressure;
TGCT	cis	rs1153858	1.000	rs1613559	chr15:45622116	A/G	cg14582100	chr15:45693742	SPATA5L1	0.47	5.59	0.45	1.39e-7	Homoarginine levels;
TGCT	cis	rs9325144	0.555	rs28738714	chr12:38706912	G/A	cg26384229	chr12:38710491	ALG10B	-0.67	-6.17	-0.48	9.08e-9	Morning vs. evening chronotype;
TGCT	cis	rs1075232	0.579	rs58156651	chr15:31749067	C/A	cg01030201	chr15:31746330	NA	-0.93	-5.51	-0.44	1.98e-7	Survival in colorectal cancer (non-distant metastatic);
TGCT	cis	rs6570726	0.791	rs12208019	chr6:145935572	T/C	cg23711669	chr6:146136114	FBXO30	0.89	9.69	0.66	7.3e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg03188948	chr7:1209495	NA	0.59	4.82	0.4	4.06e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7258465	0.931	rs8107347	chr19:18612748	G/A	cg06462663	chr19:18546047	ISYNA1	0.2	4.67	0.39	7.74e-6	Breast cancer;
TGCT	cis	rs3749237	0.576	rs62259939	chr3:49386047	G/A	cg07636037	chr3:49044803	WDR6	0.66	6.27	0.49	5.41e-9	Resting heart rate;
TGCT	cis	rs9926296	0.712	rs2434872	chr16:89716915	C/G	cg01097406	chr16:89675127	NA	0.36	6.22	0.49	6.91e-9	Vitiligo;
TGCT	cis	rs1552244	0.554	rs28667821	chr3:10050767	A/G	cg00149659	chr3:10157352	C3orf10	0.69	4.99	0.41	2.03e-6	Alzheimer's disease;
TGCT	cis	rs57221529	0.709	rs72707023	chr5:667620	G/A	cg16624210	chr5:671434	TPPP	0.42	4.82	0.4	4.2e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs6582630	0.519	rs12368889	chr12:38315160	G/A	cg13010199	chr12:38710504	ALG10B	0.61	4.81	0.4	4.2e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs4891159	0.790	rs72975929	chr18:74144630	G/C	cg24786174	chr18:74118243	ZNF516	-0.53	-7.07	-0.54	9.9e-11	Longevity;
TGCT	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg23758822	chr17:41437982	NA	0.72	6.96	0.53	1.79e-10	Menopause (age at onset);
TGCT	cis	rs62055045	0.656	rs12102284	chr16:71439049	G/A	cg09204302	chr16:70713462	MTSS1L	-0.31	-4.52	-0.38	1.4e-5	Schizophrenia;
TGCT	cis	rs9527	0.615	rs11191485	chr10:104729816	G/C	cg04362960	chr10:104952993	NT5C2	0.66	5.55	0.45	1.66e-7	Arsenic metabolism;
TGCT	cis	rs9467773	1.000	rs9393732	chr6:26530898	G/A	cg09904177	chr6:26538194	HMGN4	0.65	6.53	0.51	1.53e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs8020441	1.000	rs72681673	chr14:51171922	G/A	cg04730355	chr14:51134070	SAV1	0.74	6.12	0.48	1.16e-8	Cognitive performance;
TGCT	cis	rs2295359	0.892	rs2064689	chr1:67653010	G/A	cg08029281	chr1:67600428	NA	0.4	4.68	0.39	7.42e-6	Psoriasis;
TGCT	cis	rs67311347	1.000	rs6762997	chr3:40478151	C/T	cg17264618	chr3:40429014	ENTPD3	0.32	4.76	0.39	5.36e-6	Renal cell carcinoma;
TGCT	cis	rs35771425	0.619	rs7529900	chr1:211442661	C/T	cg26515805	chr1:211431828	RCOR3	-0.44	-4.65	-0.39	8.52e-6	Educational attainment (years of education);
TGCT	cis	rs12477438	0.834	rs1563106	chr2:99701381	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.92	-9.58	-0.65	1.29e-16	Chronic sinus infection;
TGCT	cis	rs3796352	0.881	rs34238610	chr3:53026480	A/T	cg07884673	chr3:53033167	SFMBT1	0.64	6.39	0.5	3.03e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs1865760	0.516	rs9295684	chr6:26069669	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.77	7.45	0.56	1.42e-11	Height;
TGCT	trans	rs66573146	0.656	rs66517061	chr4:6935163	C/G	cg07817883	chr1:32538562	TMEM39B	1.53	7.24	0.55	4.06e-11	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs9611565	1.000	rs5758314	chr22:41762523	T/G	cg03806693	chr22:41940476	POLR3H	-0.89	-9.43	-0.65	3.09e-16	Vitiligo;
TGCT	cis	rs8072100	0.764	rs4794371	chr17:45627693	G/C	cg08085267	chr17:45401833	C17orf57	0.45	4.98	0.41	2.09e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs910187	0.605	rs6124960	chr20:45803866	G/C	cg27589058	chr20:45804311	EYA2	-0.37	-8.15	-0.59	3.35e-13	Migraine;
TGCT	cis	rs7178572	1.000	rs1565756	chr15:77741640	G/A	cg22256960	chr15:77711686	NA	-0.97	-11.06	-0.7	3.31e-20	Type 2 diabetes;
TGCT	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg08355456	chr11:67383691	NA	-0.33	-5.26	-0.43	6.09e-7	Mean corpuscular volume;
TGCT	cis	rs1865760	0.532	rs9295687	chr6:26082710	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.78	7.49	0.56	1.15e-11	Height;
TGCT	cis	rs1483890	0.642	rs1843050	chr3:69403918	C/T	cg22125112	chr3:69402811	FRMD4B	-0.29	-4.97	-0.41	2.15e-6	Resting heart rate;
TGCT	cis	rs1857353	0.901	rs74089244	chr1:75899838	G/A	cg11838876	chr1:75668600	SLC44A5	-0.51	-4.81	-0.4	4.23e-6	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs9894429	0.789	rs7219915	chr17:79591813	C/T	cg21028142	chr17:79581711	NPLOC4	0.3	7.03	0.53	1.2e-10	Eye color traits;
TGCT	cis	rs1372520	0.873	rs2737026	chr4:90779823	A/G	cg01966878	chr4:90757139	SNCA	-0.3	-4.77	-0.39	5.1e-6	Neuroticism;
TGCT	cis	rs7264396	0.635	rs6058378	chr20:34546658	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.04	-0.41	1.58e-6	Total cholesterol levels;
TGCT	cis	rs1008375	1.000	rs2159583	chr4:17658838	T/C	cg18681998	chr4:17616180	MED28	1.01	11.93	0.73	2.54e-22	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9325144	0.505	rs10785560	chr12:38636622	C/T	cg26384229	chr12:38710491	ALG10B	0.73	7.08	0.54	9.4e-11	Morning vs. evening chronotype;
TGCT	cis	rs9811920	0.931	rs7629487	chr3:99860401	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.41	-4.66	-0.39	8.01e-6	Axial length;
TGCT	cis	rs7428	0.502	rs3184781	chr2:85549527	T/C	cg24342717	chr2:85555507	TGOLN2	-0.48	-8.29	-0.6	1.6e-13	Ear protrusion;
TGCT	cis	rs2153535	0.580	rs7453115	chr6:8447261	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.76	0.46	6.39e-8	Motion sickness;
TGCT	cis	rs4733781	0.527	rs11774633	chr8:131190243	C/T	cg16277922	chr8:131349729	ASAP1	0.36	4.97	0.41	2.13e-6	Tuberculosis;
TGCT	cis	rs9443645	0.870	rs9350799	chr6:79723651	C/A	cg09184832	chr6:79620586	NA	-0.45	-4.88	-0.4	3.19e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2153535	0.562	rs10458225	chr6:8386004	G/A	cg23788917	chr6:8435910	SLC35B3	-0.65	-5.92	-0.47	2.92e-8	Motion sickness;
TGCT	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg11764359	chr7:65958608	NA	0.61	5.53	0.44	1.84e-7	Aortic root size;
TGCT	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg11890956	chr21:40555474	PSMG1	1.12	12.45	0.75	1.39e-23	Cognitive function;
TGCT	cis	rs4803468	0.934	rs11880674	chr19:41889423	A/T	cg09537434	chr19:41945824	ATP5SL	-0.9	-10.06	-0.67	9.09e-18	Height;
TGCT	cis	rs9611565	0.559	rs739136	chr22:42100275	C/T	cg13695892	chr22:41940480	POLR3H	-0.88	-8.63	-0.61	2.45e-14	Vitiligo;
TGCT	cis	rs4664308	0.935	rs4520993	chr2:160937673	G/A	cg03641300	chr2:160917029	PLA2R1	-0.28	-6.83	-0.52	3.43e-10	Idiopathic membranous nephropathy;
TGCT	cis	rs35306767	0.807	rs12768348	chr10:899224	T/G	cg20503657	chr10:835505	NA	0.77	11.34	0.71	6.95e-21	Eosinophil percentage of granulocytes;
TGCT	cis	rs4455778	0.691	rs10229690	chr7:49003172	A/G	cg26309511	chr7:48887640	NA	-0.5	-5.96	-0.47	2.45e-8	Lung cancer in never smokers;
TGCT	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg22663859	chr13:21900854	NA	0.36	4.99	0.41	1.97e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	cis	rs12477438	0.834	rs11903311	chr2:99701807	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.69	-6.1	-0.48	1.28e-8	Chronic sinus infection;
TGCT	cis	rs11112613	0.713	rs11112588	chr12:105943801	A/C	cg03607813	chr12:105948248	NA	0.48	5.5	0.44	2.04e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	cis	rs3617	0.625	rs11715347	chr3:52883070	C/T	cg11645453	chr3:52864694	ITIH4	-0.29	-5.71	-0.46	7.84e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4700695	0.719	rs27087	chr5:65453050	G/A	cg21114390	chr5:65439923	SFRS12	-0.84	-7.33	-0.55	2.58e-11	Facial morphology (factor 19);
TGCT	cis	rs9291683	0.588	rs12647117	chr4:10022059	T/C	cg00071950	chr4:10020882	SLC2A9	0.7	9.52	0.65	1.86e-16	Bone mineral density;
TGCT	cis	rs6740731	0.518	rs13034331	chr2:145293097	A/G	cg07679370	chr2:145795797	NA	-0.26	-5.07	-0.41	1.43e-6	Coronary artery disease;
TGCT	cis	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg08847533	chr14:75593920	NEK9	0.7	6.64	0.51	8.92e-10	Height;
TGCT	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.78	6.27	0.49	5.58e-9	Mean platelet volume;
TGCT	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg08280861	chr8:58055591	NA	0.46	5.19	0.42	8.5e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg03060546	chr3:49711283	APEH	0.51	4.91	0.4	2.84e-6	Menarche (age at onset);
TGCT	cis	rs2180341	0.824	rs9321076	chr6:127655614	G/A	cg24812749	chr6:127587940	RNF146	0.98	7.64	0.57	5.06e-12	Breast cancer;
TGCT	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg08219700	chr8:58056026	NA	0.3	4.56	0.38	1.22e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs826838	0.904	rs10876086	chr12:39188208	C/A	cg13010199	chr12:38710504	ALG10B	0.77	6.09	0.48	1.31e-8	Heart rate;
TGCT	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-8.64	-0.61	2.39e-14	Platelet count;
TGCT	cis	rs10256972	0.721	rs10435145	chr7:1065988	C/T	cg09174653	chr7:1063357	C7orf50;MIR339	-0.24	-4.89	-0.4	3.12e-6	Longevity;Endometriosis;
TGCT	cis	rs71636778	0.509	rs35969145	chr1:27259392	G/A	cg23921621	chr1:27994728	IFI6	-0.43	-4.61	-0.38	9.92e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
TGCT	cis	rs1577917	0.696	rs2842617	chr6:86309698	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.55	-5.03	-0.41	1.68e-6	Response to antipsychotic treatment;
TGCT	cis	rs17376456	0.877	rs10066791	chr5:93350255	G/T	cg21475434	chr5:93447410	FAM172A	0.62	4.94	0.41	2.52e-6	Diabetic retinopathy;
TGCT	cis	rs6570726	0.516	rs10457779	chr6:145736663	C/T	cg23711669	chr6:146136114	FBXO30	0.61	5.42	0.44	3.05e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11690935	0.959	rs13419987	chr2:172623914	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.18	-12.58	-0.75	6.59e-24	Schizophrenia;
TGCT	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg03303774	chr4:1407052	NA	0.31	4.87	0.4	3.31e-6	Obesity-related traits;
TGCT	cis	rs7819412	0.807	rs4840542	chr8:10944809	G/T	cg21775007	chr8:11205619	TDH	-0.53	-4.9	-0.4	2.93e-6	Triglycerides;
TGCT	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.46	4.85	0.4	3.59e-6	Lymphocyte counts;
TGCT	cis	rs6840360	0.642	rs2724551	chr4:152355383	T/C	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.83e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs916888	0.821	rs70600	chr17:44860021	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.7	4.82	0.4	4.1e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg01802117	chr1:53393560	SCP2	-0.45	-5.28	-0.43	5.53e-7	Monocyte count;
TGCT	cis	rs11792861	0.888	rs75543406	chr9:111816903	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.49	4.52	0.38	1.44e-5	Menarche (age at onset);
TGCT	cis	rs10875595	0.509	rs115819920	chr5:140663745	A/C	cg20560182	chr5:140700478	TAF7	-0.66	-5.07	-0.41	1.42e-6	Pulmonary function decline;
TGCT	cis	rs13217239	0.646	rs6456767	chr6:27070543	C/T	cg02458000	chr6:26745757	NA	-0.51	-4.57	-0.38	1.18e-5	Schizophrenia;
TGCT	cis	rs6586111	1.000	rs7067994	chr10:82373459	A/G	cg03086067	chr10:82368399	SH2D4B	-0.24	-4.7	-0.39	6.84e-6	Capecitabine sensitivity;
TGCT	cis	rs2153535	0.541	rs7774752	chr6:8468978	C/T	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs854765	0.583	rs8080823	chr17:17864048	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	7.86	0.58	1.58e-12	Total body bone mineral density;
TGCT	cis	rs6448317	0.520	rs13116411	chr4:24928949	G/A	cg21108841	chr4:24914750	CCDC149	-0.75	-7.18	-0.54	5.7e-11	Heschl's gyrus morphology;
TGCT	cis	rs7959452	0.535	rs11177577	chr12:69671791	C/T	cg11871910	chr12:69753446	YEATS4	0.63	6.24	0.49	6.36e-9	Blood protein levels;
TGCT	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	8.0	0.58	7.67e-13	Platelet count;
TGCT	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg05368731	chr17:41323189	NBR1	1.2	14.48	0.79	1.98e-28	Menopause (age at onset);
TGCT	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg03396347	chr1:1875803	NA	-0.36	-6.58	-0.51	1.19e-9	Body mass index;
TGCT	cis	rs4850410	0.554	rs7575709	chr2:197914758	C/A	cg19149314	chr2:197065128	HECW2	0.23	4.51	0.38	1.47e-5	Interferon alpha levels in systemic lupus erythematosus;
TGCT	cis	rs7647973	0.626	rs4855849	chr3:49653378	A/G	cg03060546	chr3:49711283	APEH	0.63	5.63	0.45	1.12e-7	Menarche (age at onset);
TGCT	cis	rs986417	0.748	rs10133403	chr14:60945298	C/T	cg27398547	chr14:60952738	C14orf39	1.39	10.61	0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs763121	0.853	rs4821816	chr22:39113134	G/A	cg06022373	chr22:39101656	GTPBP1	0.75	7.39	0.55	1.92e-11	Menopause (age at onset);
TGCT	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg09323728	chr8:95962352	TP53INP1	-0.54	-7.03	-0.53	1.23e-10	Type 2 diabetes;
TGCT	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg26818010	chr10:134567672	INPP5A	-0.35	-4.76	-0.39	5.21e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs2050392	0.861	rs303448	chr10:30727084	G/T	cg13289132	chr10:30722225	MAP3K8	-0.41	-4.97	-0.41	2.15e-6	Inflammatory bowel disease;
TGCT	cis	rs60843830	1.000	rs60843830	chr2:286756	C/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.74	7.12	0.54	7.67e-11	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.76	5.84	0.46	4.31e-8	Initial pursuit acceleration;
TGCT	cis	rs7264396	0.635	rs6060703	chr20:34529906	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.04	-0.41	1.58e-6	Total cholesterol levels;
TGCT	cis	rs7178424	0.541	rs2899678	chr15:62324723	A/G	cg00456672	chr15:62358751	C2CD4A	-0.29	-4.46	-0.37	1.84e-5	Height;
TGCT	cis	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg18188782	chr20:61659543	NA	0.44	5.38	0.43	3.6e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs4906332	1.000	rs1951389	chr14:103898525	G/C	cg26031613	chr14:104095156	KLC1	-0.52	-4.59	-0.38	1.08e-5	Coronary artery disease;
TGCT	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.29	-4.49	-0.37	1.64e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-6.74	-0.52	5.26e-10	Alzheimer's disease;
TGCT	cis	rs7772486	0.597	rs9386136	chr6:146158300	A/T	cg05347473	chr6:146136440	FBXO30	0.66	6.2	0.49	7.84e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs651907	0.535	rs34648996	chr3:101511202	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.31	-6.4	-0.5	2.91e-9	Colorectal cancer;
TGCT	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg10560079	chr2:191398806	TMEM194B	0.42	5.83	0.46	4.52e-8	Pulse pressure;
TGCT	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg02725872	chr8:58115012	NA	-0.38	-5.16	-0.42	9.32e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7216064	1.000	rs9915108	chr17:65874463	T/C	cg12091567	chr17:66097778	LOC651250	-0.87	-6.85	-0.52	3.1e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs4285028	0.948	rs7651226	chr3:121670802	G/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.77	-6.55	-0.51	1.35e-9	Multiple sclerosis;
TGCT	cis	rs2153535	0.580	rs2184586	chr6:8474182	A/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs3125734	0.633	rs4979774	chr10:63967795	A/T	cg09941381	chr10:64027924	RTKN2	-0.36	-5.61	-0.45	1.23e-7	Rheumatoid arthritis;
TGCT	cis	rs137603	0.623	rs137657	chr22:39733242	G/T	cg01093212	chr22:39715156	SNORD43;RPL3	-0.52	-5.09	-0.42	1.29e-6	Primary biliary cholangitis;
TGCT	cis	rs8038465	0.615	rs11072430	chr15:73981701	A/G	cg15420318	chr15:73925796	NPTN	-0.7	-7.76	-0.57	2.71e-12	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs12753569	1.000	rs12753569	chr1:76484014	G/T	cg00791851	chr1:76518896	NA	-0.35	-4.57	-0.38	1.17e-5	Personality dimensions;
TGCT	cis	rs2153535	0.580	rs6910742	chr6:8448328	G/A	cg07606381	chr6:8435919	SLC35B3	0.53	5.02	0.41	1.79e-6	Motion sickness;
TGCT	trans	rs114540395	0.777	rs114076639	chr10:103333323	G/A	cg10198749	chr1:39920707	MACF1	0.55	7.06	0.54	1.06e-10	Schizophrenia;
TGCT	cis	rs6582630	0.555	rs1829583	chr12:38423161	T/C	cg26384229	chr12:38710491	ALG10B	-0.8	-7.45	-0.56	1.42e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs7772486	0.686	rs9376956	chr6:145949844	T/C	cg05347473	chr6:146136440	FBXO30	0.48	4.53	0.38	1.38e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs35306767	0.623	rs72760941	chr10:1141244	A/G	cg20503657	chr10:835505	NA	0.51	5.41	0.44	3.18e-7	Eosinophil percentage of granulocytes;
TGCT	cis	rs6912958	0.781	rs7750207	chr6:88303967	A/C	cg06598631	chr6:88300029	RARS2;ORC3L	-0.57	-5.22	-0.42	7.36e-7	Monocyte percentage of white cells;
TGCT	trans	rs1814175	0.765	rs1721990	chr11:49912154	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.36	-7.05	-0.53	1.12e-10	Height;
TGCT	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg27121462	chr16:89883253	FANCA	0.82	8.95	0.63	4.3e-15	Vitiligo;
TGCT	cis	rs7412746	0.524	rs58304714	chr1:150831561	T/A	cg04414720	chr1:150670196	GOLPH3L	0.39	4.75	0.39	5.55e-6	Melanoma;
TGCT	trans	rs797680	0.856	rs7537403	chr1:93777724	T/C	cg27528825	chr2:159282178	CCDC148	-0.33	-6.67	-0.51	7.68e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs6671200	1.000	rs933107	chr1:95672229	C/T	cg03123541	chr1:95699097	RWDD3	-0.87	-6.17	-0.48	8.81e-9	Stearic acid (18:0) levels;
TGCT	cis	rs12477438	0.765	rs6749059	chr2:99591021	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-8.66	-0.61	2.13e-14	Chronic sinus infection;
TGCT	cis	rs950169	0.887	rs3860265	chr15:84945185	C/T	cg12863693	chr15:85201151	NMB	0.45	4.96	0.41	2.28e-6	Schizophrenia;
TGCT	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg00343986	chr7:65444356	GUSB	0.23	5.13	0.42	1.08e-6	Aortic root size;
TGCT	cis	rs67311347	0.955	rs73080163	chr3:40533061	G/T	cg17264618	chr3:40429014	ENTPD3	0.33	4.44	0.37	1.98e-5	Renal cell carcinoma;
TGCT	cis	rs7829975	0.539	rs4841012	chr8:8551710	C/A	cg15556689	chr8:8085844	FLJ10661	-0.54	-4.61	-0.38	1e-5	Mood instability;
TGCT	cis	rs4822044	0.568	rs1883370	chr22:42143740	C/A	cg03806693	chr22:41940476	POLR3H	1.0	10.02	0.67	1.11e-17	Cannabis dependence symptom count;
TGCT	cis	rs2282802	0.685	rs6869910	chr5:139629450	T/C	cg01081189	chr5:139537190	NA	0.27	4.84	0.4	3.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2970818	0.831	rs7304949	chr12:4609625	A/G	cg06654103	chr12:4920613	KCNA6	0.19	4.53	0.38	1.39e-5	Phosphorus levels;
TGCT	trans	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg23505145	chr19:12996616	KLF1	0.78	8.12	0.59	4.03e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs514406	0.584	rs7548832	chr1:53193576	A/T	cg24675658	chr1:53192096	ZYG11B	-0.86	-10.85	-0.7	1.07e-19	Monocyte count;
TGCT	cis	rs7666738	0.861	rs10018654	chr4:99002226	A/G	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6121246	0.529	rs6060118	chr20:30171209	T/C	cg10886678	chr20:30946050	ASXL1	-0.67	-4.52	-0.38	1.41e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs950169	0.922	rs11635505	chr15:85097034	A/C	cg17173187	chr15:85201210	NMB	-0.54	-5.84	-0.46	4.2e-8	Schizophrenia;
TGCT	cis	rs9896933	0.830	rs607544	chr17:80768760	C/G	cg20578329	chr17:80767326	TBCD	-0.34	-4.97	-0.41	2.16e-6	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
TGCT	cis	rs12048904	0.505	rs11166508	chr1:101233511	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.69	-5.58	-0.45	1.41e-7	Multiple sclerosis;
TGCT	cis	rs6430585	0.759	rs4954623	chr2:136535876	G/A	cg07169764	chr2:136633963	MCM6	-1.19	-11.11	-0.71	2.49e-20	Corneal structure;
TGCT	cis	rs9467773	0.549	rs9467805	chr6:26583366	C/T	cg02458000	chr6:26745757	NA	0.5	4.65	0.39	8.2e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg17554472	chr22:41940697	POLR3H	0.46	4.71	0.39	6.63e-6	Vitiligo;
TGCT	cis	rs2688608	0.967	rs72814394	chr10:75656325	C/T	cg19442545	chr10:75533431	FUT11	-0.29	-4.71	-0.39	6.5e-6	Inflammatory bowel disease;
TGCT	cis	rs10791097	0.739	rs4936120	chr11:130723452	G/A	cg12179176	chr11:130786555	SNX19	0.75	8.62	0.61	2.66e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs3008870	0.755	rs2815374	chr1:67507387	G/A	cg11518657	chr1:67396239	MIER1	0.48	4.51	0.38	1.49e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs9303401	0.614	rs66480139	chr17:57101538	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.58	5.83	0.46	4.4e-8	Cognitive test performance;
TGCT	cis	rs11785400	1.000	rs4266629	chr8:143736635	A/G	cg10596483	chr8:143751796	JRK	0.55	6.0	0.47	2.04e-8	Schizophrenia;
TGCT	cis	rs12908161	1.000	rs11637142	chr15:85295927	A/G	cg11189052	chr15:85197271	WDR73	0.71	5.89	0.47	3.35e-8	Schizophrenia;
TGCT	cis	rs12900413	0.603	rs12906832	chr15:90301314	C/G	cg24249390	chr15:90295951	MESP1	-0.3	-5.23	-0.42	7.05e-7	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs2832191	0.935	rs11910316	chr21:30519729	G/A	cg08807101	chr21:30365312	RNF160	-0.53	-4.94	-0.41	2.49e-6	Dental caries;
TGCT	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/C	cg16497277	chr3:49208875	KLHDC8B	-0.5	-4.78	-0.39	4.87e-6	Parkinson's disease;
TGCT	cis	rs10465746	0.967	rs11163879	chr1:84444051	T/C	cg10977910	chr1:84465055	TTLL7	0.65	6.54	0.51	1.44e-9	Obesity-related traits;
TGCT	cis	rs9788682	0.747	rs2656073	chr15:78742276	G/T	cg24631222	chr15:78858424	CHRNA5	0.64	4.93	0.4	2.6e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs2677744	0.626	rs2001216	chr15:91498130	T/C	cg23684204	chr15:91497937	RCCD1	0.39	5.92	0.47	2.91e-8	Attention deficit hyperactivity disorder;
TGCT	cis	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg25427524	chr10:38739819	LOC399744	-0.39	-7.88	-0.58	1.44e-12	Extrinsic epigenetic age acceleration;
TGCT	cis	rs9291683	0.595	rs10939665	chr4:10037628	T/C	cg11266682	chr4:10021025	SLC2A9	0.64	8.91	0.62	5.31e-15	Bone mineral density;
TGCT	cis	rs2230307	0.536	rs2893426	chr1:100528200	G/T	cg24955406	chr1:100503596	HIAT1	0.74	4.86	0.4	3.41e-6	Carotid intima media thickness;
TGCT	cis	rs3751972	0.866	rs8082467	chr17:26253468	G/A	cg02948944	chr17:26242737	NA	0.5	6.86	0.52	2.96e-10	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg12311346	chr5:56204834	C5orf35	0.79	6.94	0.53	1.98e-10	Initial pursuit acceleration;
TGCT	cis	rs7769051	1.000	rs10484629	chr6:133117870	A/C	cg07930552	chr6:133119739	C6orf192	0.94	5.04	0.41	1.6e-6	Type 2 diabetes nephropathy;
TGCT	cis	rs9303401	0.614	rs34550282	chr17:57092788	G/A	cg25039879	chr17:56429692	SUPT4H1	0.55	4.93	0.4	2.63e-6	Cognitive test performance;
TGCT	cis	rs12691307	1	rs12691307	chr16:29939877	A/G	cg26859862	chr16:30389551	SEPT1	-0.54	-4.61	-0.38	9.91e-6	Schizophrenia;
TGCT	cis	rs10114408	0.877	rs10821245	chr9:96645614	C/T	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.15	0.82	2.71e-32	Prudent dietary pattern;
TGCT	cis	rs3809566	1.000	rs3809566	chr15:63333724	A/G	cg08198488	chr15:63333792	TPM1	-0.36	-5.36	-0.43	3.83e-7	Platelet count;
TGCT	cis	rs3125734	0.582	rs7904465	chr10:64002393	G/A	cg19640130	chr10:64028056	RTKN2	-0.39	-5.02	-0.41	1.78e-6	Rheumatoid arthritis;
TGCT	cis	rs1256061	0.528	rs10143616	chr14:64740175	G/A	cg21174375	chr14:64681225	SYNE2	0.22	4.73	0.39	5.96e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
TGCT	cis	rs6840360	0.837	rs13146981	chr4:152720703	T/C	cg22705602	chr4:152727874	NA	0.25	4.67	0.39	7.76e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7223966	0.921	rs7225092	chr17:61864005	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	4.68	0.39	7.5e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs3087591	0.615	rs12943365	chr17:29680526	C/G	cg24425628	chr17:29625626	OMG;NF1	0.34	4.84	0.4	3.74e-6	Hip circumference;
TGCT	cis	rs4372836	0.930	rs7607844	chr2:28971738	T/A	cg09522027	chr2:28974177	PPP1CB	-0.59	-4.93	-0.4	2.63e-6	Body mass index;
TGCT	cis	rs3771570	0.901	rs3771587	chr2:242409701	A/G	cg21155796	chr2:242212141	HDLBP	0.93	6.69	0.52	6.74e-10	Prostate cancer;
TGCT	cis	rs9486719	0.843	rs2205754	chr6:96843134	T/C	cg18709589	chr6:96969512	KIAA0776	0.75	5.13	0.42	1.1e-6	Migraine;Coronary artery disease;
TGCT	cis	rs9549367	0.713	rs9549357	chr13:113860121	C/T	cg18105134	chr13:113819100	PROZ	-0.46	-8.5	-0.61	5.06e-14	Platelet distribution width;
TGCT	cis	rs59698941	0.550	rs11739194	chr5:132201230	T/C	cg21474247	chr5:131268130	NA	0.31	4.77	0.39	5.01e-6	Apolipoprotein A-IV levels;
TGCT	cis	rs7614311	0.689	rs56329572	chr3:63846672	G/A	cg22134162	chr3:63841271	THOC7	-0.42	-4.62	-0.38	9.39e-6	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs28595532	0.920	rs17325017	chr4:119774607	A/G	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs35306767	0.903	rs11253458	chr10:882843	T/C	cg26597838	chr10:835615	NA	0.71	10.12	0.67	6.47e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs6540559	0.673	rs926346	chr1:209962204	A/T	cg21951975	chr1:209979733	IRF6	0.68	5.3	0.43	5.17e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs34172651	0.583	rs200541	chr16:24733141	A/G	cg06028605	chr16:24865363	SLC5A11	-0.41	-4.51	-0.38	1.49e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs9325144	0.555	rs7955128	chr12:38684121	A/T	cg26384229	chr12:38710491	ALG10B	0.67	6.42	0.5	2.56e-9	Morning vs. evening chronotype;
TGCT	cis	rs7178572	0.889	rs11857450	chr15:77802791	C/G	cg22256960	chr15:77711686	NA	0.93	10.91	0.7	7.71e-20	Type 2 diabetes;
TGCT	cis	rs12220898	0.749	rs4838486	chr10:50484962	G/A	cg09603381	chr10:49954066	WDFY4	0.38	4.45	0.37	1.88e-5	Inflammatory biomarkers;
TGCT	cis	rs950027	0.620	rs1153860	chr15:45636584	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.79	-8.75	-0.62	1.27e-14	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs60871478	0.636	rs12532761	chr7:905229	C/T	cg00475322	chr7:917719	C7orf20	0.52	5.04	0.41	1.58e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs10197940	0.624	rs17270233	chr2:152372420	A/G	cg19508488	chr2:152266495	RIF1	0.72	6.55	0.51	1.38e-9	Lung cancer;
TGCT	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg16680214	chr1:154839983	KCNN3	-0.36	-7.35	-0.55	2.32e-11	Prostate cancer;
TGCT	cis	rs6570726	0.811	rs375873	chr6:145812371	G/T	cg23711669	chr6:146136114	FBXO30	0.73	6.85	0.52	3e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs28595532	0.920	rs115690307	chr4:119768289	C/T	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs7659604	0.592	rs56077950	chr4:122721412	C/T	cg23574427	chr4:122746245	BBS7;CCNA2	-0.35	-5.39	-0.44	3.47e-7	Type 2 diabetes;
TGCT	cis	rs6733011	0.500	rs6755640	chr2:99445917	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-4.67	-0.39	7.64e-6	Bipolar disorder;
TGCT	cis	rs10501293	0.917	rs7951266	chr11:43110728	C/T	cg03447554	chr11:43094025	NA	0.48	6.54	0.51	1.42e-9	Cognitive performance;
TGCT	cis	rs9972944	0.902	rs9972885	chr17:63771264	G/T	cg07283582	chr17:63770753	CCDC46	0.29	5.95	0.47	2.54e-8	Total body bone mineral density;
TGCT	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg04944784	chr2:26401820	FAM59B	0.64	5.54	0.45	1.69e-7	Gut microbiome composition (summer);
TGCT	cis	rs2204008	0.846	rs2030416	chr12:38465118	A/G	cg26384229	chr12:38710491	ALG10B	-0.8	-7.43	-0.56	1.51e-11	Bladder cancer;
TGCT	cis	rs709400	0.627	rs62007686	chr14:103899344	A/G	cg26031613	chr14:104095156	KLC1	0.85	9.31	0.64	6e-16	Body mass index;
TGCT	cis	rs7845219	0.555	rs1129152	chr8:95888307	C/T	cg13393036	chr8:95962371	TP53INP1	-0.58	-6.99	-0.53	1.46e-10	Type 2 diabetes;
TGCT	cis	rs950776	0.667	rs57728226	chr15:78929350	G/C	cg06917634	chr15:78832804	PSMA4	0.61	4.77	0.39	5.17e-6	Sudden cardiac arrest;
TGCT	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs3540	0.960	rs2238329	chr15:91028401	G/A	cg22089800	chr15:90895588	ZNF774	0.77	7.25	0.55	4.02e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs1552244	0.748	rs9862221	chr3:10059658	G/T	cg00149659	chr3:10157352	C3orf10	0.89	5.6	0.45	1.32e-7	Alzheimer's disease;
TGCT	cis	rs4699052	0.662	rs1516731	chr4:104252694	T/C	cg16532752	chr4:104119610	CENPE	-0.5	-4.92	-0.4	2.71e-6	Testicular germ cell tumor;
TGCT	cis	rs4766566	0.609	rs1344438	chr12:111735954	C/G	cg10833066	chr12:111807467	FAM109A	0.39	7.2	0.54	5.07e-11	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
TGCT	cis	rs565229	0.777	rs551615	chr11:122135614	C/T	cg02159381	chr11:122852523	BSX	0.52	4.62	0.38	9.28e-6	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs9549367	0.789	rs6577031	chr13:113878182	T/C	cg18105134	chr13:113819100	PROZ	0.35	5.74	0.46	7.01e-8	Platelet distribution width;
TGCT	cis	rs896854	0.625	rs4735335	chr8:95973327	G/C	cg23172400	chr8:95962367	TP53INP1	-0.39	-6.52	-0.51	1.59e-9	Type 2 diabetes;
TGCT	cis	rs244731	0.959	rs11740250	chr5:176721272	G/C	cg17509989	chr5:176798049	RGS14	0.64	7.71	0.57	3.49e-12	Urate levels in lean individuals;
TGCT	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	5.03	0.41	1.66e-6	Electroencephalogram traits;
TGCT	cis	rs3733585	0.699	rs62294331	chr4:9959889	A/G	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.67	-0.51	7.44e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs2153535	0.580	rs9378551	chr6:8463744	A/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs763121	0.853	rs2294296	chr22:39053049	T/C	cg06022373	chr22:39101656	GTPBP1	0.77	7.46	0.56	1.35e-11	Menopause (age at onset);
TGCT	cis	rs9818758	0.882	rs74926817	chr3:49378833	C/G	cg00383909	chr3:49044727	WDR6	0.7	4.75	0.39	5.48e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs7267979	1.000	rs884613	chr20:25288505	C/T	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs16986825	0.570	rs5752822	chr22:29266025	A/G	cg02153584	chr22:29168773	CCDC117	0.67	4.5	0.37	1.55e-5	Pancreatic cancer;
TGCT	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg13695892	chr22:41940480	POLR3H	-0.9	-9.03	-0.63	2.7e-15	Vitiligo;
TGCT	cis	rs6430585	0.528	rs10496738	chr2:136751488	C/T	cg07169764	chr2:136633963	MCM6	1.25	12.67	0.75	4.02e-24	Corneal structure;
TGCT	cis	rs3935685	0.874	rs55858810	chr15:78004230	G/T	cg03457338	chr15:78040120	NA	-0.21	-5.54	-0.45	1.72e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7940866	0.838	rs10750455	chr11:130800330	C/T	cg12179176	chr11:130786555	SNX19	0.63	6.28	0.49	5.3300000000000004e-09	Schizophrenia;
TGCT	cis	rs9796	0.866	rs66818965	chr15:41402279	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.47	-6.09	-0.48	1.34e-8	Menopause (age at onset);
TGCT	cis	rs7568458	0.684	rs7593969	chr2:85809670	A/G	cg02493740	chr2:85810744	VAMP5	0.31	5.74	0.46	6.73e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs7666738	0.830	rs28587201	chr4:98991733	C/T	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs586688	0.582	rs1270536	chr1:201670876	A/G	cg07139329	chr1:201708558	NAV1	-0.56	-5.67	-0.45	9.65e-8	Obesity-related traits;
TGCT	cis	rs10875746	0.669	rs10783244	chr12:48664989	A/C	cg20731937	chr12:48336164	NA	0.59	4.52	0.38	1.45e-5	Longevity (90 years and older);
TGCT	cis	rs523522	0.962	rs4767903	chr12:120930046	G/A	cg27279351	chr12:120934652	DYNLL1	0.76	6.59	0.51	1.15e-9	High light scatter reticulocyte count;
TGCT	cis	rs2456568	0.805	rs55649862	chr11:93682888	G/T	cg17595323	chr11:93583763	C11orf90	-0.46	-6.01	-0.47	1.92e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg06618935	chr21:46677482	NA	-0.36	-5.46	-0.44	2.46e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2066819	1.000	rs76151170	chr12:56659320	C/T	cg26714650	chr12:56694279	CS	-1.36	-6.06	-0.48	1.54e-8	Psoriasis vulgaris;
TGCT	cis	rs1395	0.778	rs62128743	chr2:27390169	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.66	8.95	0.63	4.24e-15	Blood metabolite levels;
TGCT	cis	rs7666738	0.830	rs7662199	chr4:99019766	G/A	cg17366294	chr4:99064904	C4orf37	0.7	7.34	0.55	2.41e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2066819	1.000	rs17118403	chr12:56630067	C/T	cg26714650	chr12:56694279	CS	-1.42	-5.7	-0.46	8.43e-8	Psoriasis vulgaris;
TGCT	cis	rs6964587	1.000	rs10274756	chr7:91740796	G/A	cg22709100	chr7:91322751	NA	0.28	4.61	0.38	9.79e-6	Breast cancer;
TGCT	cis	rs4629710	0.617	rs28360555	chr6:131538952	C/A	cg12606694	chr6:131520996	AKAP7	0.39	4.63	0.38	9.14e-6	Multiple myeloma (IgH translocation);
TGCT	cis	rs9899728	0.706	rs9895516	chr17:73020517	T/C	cg00012762	chr17:72744649	SLC9A3R1	-1.0	-4.48	-0.37	1.67e-5	Alzheimer's disease or small vessel stroke;
TGCT	cis	rs3015497	0.663	rs12434932	chr14:51157614	T/C	cg04730355	chr14:51134070	SAV1	-0.62	-5.86	-0.47	3.82e-8	Mean platelet volume;
TGCT	cis	rs6867032	0.527	rs4371796	chr5:1977785	C/T	cg05184729	chr5:1962311	NA	0.27	4.68	0.39	7.31e-6	Gut microbiome composition (winter);
TGCT	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg26338869	chr17:61819248	STRADA	-0.53	-4.83	-0.4	3.91e-6	Prudent dietary pattern;
TGCT	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	8.41	0.6	8.4e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9436747	0.641	rs1343982	chr1:66045251	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.52	4.65	0.39	8.37e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs35883536	0.528	rs1542837	chr1:101029768	T/C	cg06223162	chr1:101003688	GPR88	0.43	8.39	0.6	9.04e-14	Monocyte count;
TGCT	cis	rs1218582	0.741	rs11264291	chr1:154914797	C/T	cg03351412	chr1:154909251	PMVK	0.51	4.78	0.39	4.85e-6	Prostate cancer;
TGCT	cis	rs9388451	0.839	rs9321054	chr6:126079968	A/G	cg05901451	chr6:126070800	HEY2	1.02	15.34	0.81	2e-30	Brugada syndrome;
TGCT	cis	rs9911578	0.835	rs9889419	chr17:56473259	C/T	cg05425664	chr17:57184151	TRIM37	-0.61	-5.88	-0.47	3.6e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9905704	0.647	rs7221274	chr17:57008128	A/G	cg05425664	chr17:57184151	TRIM37	-0.57	-4.44	-0.37	1.97e-5	Testicular germ cell tumor;
TGCT	trans	rs7618501	0.699	rs3733135	chr3:49939587	G/A	cg21659725	chr3:3221576	CRBN	0.77	9.15	0.63	1.42e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs2730245	0.528	rs1188954	chr7:158691417	G/A	cg24397884	chr7:158709396	WDR60	0.35	4.51	0.38	1.5e-5	Height;
TGCT	cis	rs6088580	0.634	rs6088484	chr20:32985961	T/C	cg06115741	chr20:33292138	TP53INP2	-0.55	-4.81	-0.4	4.28e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs950169	0.922	rs2033284	chr15:84946273	C/T	cg11189052	chr15:85197271	WDR73	0.83	6.48	0.5	1.91e-9	Schizophrenia;
TGCT	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg01802117	chr1:53393560	SCP2	-0.42	-4.86	-0.4	3.43e-6	Monocyte count;
TGCT	cis	rs9291683	0.546	rs4575994	chr4:9997979	G/A	cg11266682	chr4:10021025	SLC2A9	0.61	7.66	0.57	4.53e-12	Bone mineral density;
TGCT	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg16325326	chr1:53192061	ZYG11B	-0.71	-8.81	-0.62	9.22e-15	Monocyte count;
TGCT	cis	rs2832191	0.716	rs2297252	chr21:30377104	G/A	cg08807101	chr21:30365312	RNF160	0.64	6.05	0.48	1.59e-8	Dental caries;
TGCT	cis	rs9581857	0.685	rs11839899	chr13:28041780	G/A	cg22138327	chr13:27999177	GTF3A	0.72	4.6	0.38	1.03e-5	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs2933343	0.729	rs789230	chr3:128602558	G/A	cg11901034	chr3:128598214	ACAD9	-0.68	-6.63	-0.51	9.16e-10	IgG glycosylation;
TGCT	cis	rs13191362	1.000	rs73035025	chr6:163000988	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs1129187	0.805	rs1053538	chr6:42903763	C/G	cg27588902	chr6:42928151	GNMT	-0.48	-5.66	-0.45	9.82e-8	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs7246657	0.722	rs10412510	chr19:38075944	A/G	cg18154014	chr19:37997991	ZNF793	0.69	4.63	0.38	9.25e-6	Coronary artery calcification;
TGCT	cis	rs40363	1.000	rs1690441	chr16:3517635	C/G	cg22508957	chr16:3507546	NAT15	0.57	5.33	0.43	4.38e-7	Tuberculosis;
TGCT	cis	rs35000415	0.873	rs34748780	chr7:128700153	A/G	cg06242719	chr7:129414860	MIR183;MIR96	-0.34	-4.67	-0.39	7.58e-6	Systemic lupus erythematosus;
TGCT	cis	rs3617	0.625	rs2535633	chr3:52859630	C/G	cg10802521	chr3:52805072	NEK4	0.6	6.89	0.53	2.46e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs317689	0.581	rs315132	chr12:69761996	G/C	cg20891283	chr12:69753455	YEATS4	0.65	5.74	0.46	6.91e-8	Response to diuretic therapy;
TGCT	cis	rs210152	0.588	rs449978	chr6:33496060	G/A	cg16739976	chr6:34101401	GRM4	-0.64	-5.27	-0.43	5.8e-7	Schizophrenia;
TGCT	cis	rs514406	0.505	rs7543239	chr1:53162416	A/G	cg24675658	chr1:53192096	ZYG11B	-0.74	-8.28	-0.6	1.65e-13	Monocyte count;
TGCT	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg27170947	chr2:26402098	FAM59B	-0.4	-4.63	-0.38	8.93e-6	Gut microbiome composition (summer);
TGCT	cis	rs11754661	1.000	rs11754661	chr6:151207078	G/A	cg11579907	chr6:151412213	MTHFD1L	0.47	4.5	0.37	1.53e-5	Alzheimer's disease (late onset);
TGCT	cis	rs78545713	1.000	rs41266821	chr6:26247198	A/G	cg12260798	chr6:26240519	HIST1H4F	-0.58	-4.89	-0.4	3.06e-6	Iron status biomarkers (total iron binding capacity);
TGCT	trans	rs8073060	0.660	rs34184070	chr17:34003810	A/G	cg19694781	chr19:47549865	TMEM160	-0.6	-13.37	-0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg03188948	chr7:1209495	NA	0.59	4.82	0.4	4.06e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs611744	0.647	rs9969614	chr8:109260581	A/G	cg21045802	chr8:109455806	TTC35	0.71	7.21	0.54	4.78e-11	Dupuytren's disease;
TGCT	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.07	-9.63	-0.65	1.01e-16	Platelet count;
TGCT	cis	rs3809863	0.646	rs9899121	chr17:45395144	C/T	cg08085267	chr17:45401833	C17orf57	-0.69	-8.17	-0.59	2.97e-13	Glaucoma (primary open-angle);
TGCT	cis	rs17473412	0.609	rs1002112	chr5:122872642	G/A	cg15125798	chr5:122621645	NA	-0.53	-4.9	-0.4	2.93e-6	Total body bone mineral density;
TGCT	cis	rs28595532	0.920	rs17257945	chr4:119666465	T/A	cg11846333	chr4:119757529	SEC24D	0.95	4.9	0.4	2.97e-6	Cannabis dependence symptom count;
TGCT	cis	rs56104184	0.775	rs73061699	chr19:49400511	T/C	cg17863274	chr19:49399704	TULP2	-0.54	-7.43	-0.55	1.58e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs7666738	0.830	rs890470	chr4:98923435	A/C	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs546131	0.600	rs7946699	chr11:34820069	G/C	cg06937548	chr11:34938143	PDHX;APIP	0.54	4.58	0.38	1.11e-5	Lung disease severity in cystic fibrosis;
TGCT	trans	rs2727020	0.729	rs1917325	chr11:49370004	G/A	cg03929089	chr4:120376271	NA	-0.74	-8.68	-0.61	1.87e-14	Coronary artery disease;
TGCT	cis	rs77972916	0.505	rs11899984	chr2:43578246	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.4	-6.38	-0.5	3.27e-9	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs295140	1.000	rs12614621	chr2:201171207	G/C	cg04283868	chr2:201171347	SPATS2L	0.63	6.43	0.5	2.46e-9	QT interval;
TGCT	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg24399712	chr22:39784796	NA	-1.06	-12.58	-0.75	6.72e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg23034840	chr1:205782522	SLC41A1	0.5	4.53	0.38	1.39e-5	Menarche (age at onset);
TGCT	cis	rs6582630	0.634	rs10748443	chr12:38734062	G/T	cg26384229	chr12:38710491	ALG10B	0.61	5.65	0.45	1.05e-7	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs8016982	0.674	rs1951614	chr14:81672106	A/G	cg01989461	chr14:81687754	GTF2A1	-0.82	-8.49	-0.61	5.31e-14	Schizophrenia;
TGCT	trans	rs6089829	0.962	rs3746747	chr20:61667631	T/C	cg17470723	chr8:74884337	TCEB1	0.71	6.79	0.52	4.06e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1801251	1.000	rs2100053	chr2:233719516	G/T	cg08000102	chr2:233561755	GIGYF2	-0.63	-6.31	-0.49	4.52e-9	Coronary artery disease;
TGCT	cis	rs7246657	0.663	rs4803276	chr19:38072330	C/A	cg18154014	chr19:37997991	ZNF793	0.69	4.67	0.39	7.74e-6	Coronary artery calcification;
TGCT	cis	rs1997103	0.954	rs2177809	chr7:55378125	T/C	cg17469321	chr7:55412551	NA	0.66	6.94	0.53	1.92e-10	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs67478160	0.595	rs12433109	chr14:104196607	G/A	cg26031613	chr14:104095156	KLC1	-0.76	-7.75	-0.57	2.84e-12	Schizophrenia;
TGCT	cis	rs4285028	0.948	rs71329246	chr3:121680170	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.77	-6.55	-0.51	1.35e-9	Multiple sclerosis;
TGCT	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg18654377	chr3:49208889	KLHDC8B	-0.41	-5.4	-0.44	3.33e-7	Parkinson's disease;
TGCT	cis	rs7762018	0.769	rs4716339	chr6:170063210	C/T	cg15984460	chr6:170744215	NA	-0.35	-4.47	-0.37	1.71e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	cis	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg21775007	chr8:11205619	TDH	0.5	4.85	0.4	3.63e-6	Retinal vascular caliber;
TGCT	cis	rs835154	0.845	rs835155	chr5:14875868	A/G	cg14843632	chr5:14870594	ANKH	-0.35	-4.89	-0.4	3.09e-6	Blood metabolite levels;
TGCT	cis	rs9467773	0.595	rs2451736	chr6:26620544	G/A	cg26531700	chr6:26746687	NA	0.52	5.01	0.41	1.8e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs17490626	0.568	rs12413529	chr10:71211644	G/T	cg12610070	chr10:71211762	TSPAN15	-0.62	-7.15	-0.54	6.52e-11	Thrombosis;
TGCT	cis	rs7923452	0.507	rs612802	chr10:30756441	G/A	cg13289132	chr10:30722225	MAP3K8	-0.39	-4.8	-0.4	4.53e-6	Itch intensity from mosquito bite;
TGCT	cis	rs8042680	0.554	rs59902579	chr15:91515489	C/T	cg23684204	chr15:91497937	RCCD1	0.36	4.67	0.39	7.75e-6	Type 2 diabetes;
TGCT	trans	rs11764590	0.950	rs55683212	chr7:2078855	G/C	cg25206134	chr2:45395956	NA	0.97	7.42	0.55	1.6e-11	Neuroticism;
TGCT	cis	rs10114408	0.959	rs1933674	chr9:96655120	C/T	cg13679303	chr9:96623674	NA	-0.37	-4.76	-0.39	5.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	trans	rs1814175	0.817	rs10769598	chr11:49669326	C/G	cg15704280	chr7:45808275	SEPT13	-0.71	-8.22	-0.59	2.27e-13	Height;
TGCT	cis	rs806215	0.950	rs2073561	chr7:127227769	G/C	cg25922125	chr7:127225783	GCC1	-0.57	-5.96	-0.47	2.44e-8	Type 2 diabetes;
TGCT	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg13395646	chr4:1353034	KIAA1530	-0.39	-4.95	-0.41	2.38e-6	Obesity-related traits;
TGCT	cis	rs4916646	0.668	rs28690226	chr4:11516840	T/C	cg16957523	chr4:11431359	HS3ST1	-0.47	-4.66	-0.39	8.08e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg13342137	chr4:2252803	MXD4	0.17	4.44	0.37	1.94e-5	Obesity-related traits;
TGCT	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg09165964	chr15:75287851	SCAMP5	0.58	5.33	0.43	4.45e-7	Breast cancer;
TGCT	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	1.04	9.22	0.64	9.69e-16	Platelet count;
TGCT	cis	rs13217239	0.646	rs4583981	chr6:26992023	G/T	cg15659132	chr6:26577336	NA	0.55	5.53	0.44	1.84e-7	Schizophrenia;
TGCT	cis	rs12908161	1.000	rs35960805	chr15:85343980	T/G	cg17173187	chr15:85201210	NMB	0.57	6.39	0.5	3.07e-9	Schizophrenia;
TGCT	cis	rs7246657	0.943	rs10413602	chr19:37891492	T/C	cg18154014	chr19:37997991	ZNF793	0.95	6.63	0.51	9.39e-10	Coronary artery calcification;
TGCT	cis	rs1568889	0.887	rs2062269	chr11:28116537	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.92	11.35	0.71	6.62e-21	Bipolar disorder;
TGCT	cis	rs78461346	1.000	rs76313267	chr17:80484137	G/A	cg15014069	chr17:80540666	FOXK2	0.4	5.03	0.41	1.65e-6	3-hydroxypropylmercapturic acid levels in smokers;
TGCT	cis	rs10744422	1.000	rs4759382	chr12:123347609	C/T	cg25930673	chr12:123319894	HIP1R	0.87	5.21	0.42	7.77e-7	Schizophrenia;
TGCT	cis	rs288326	0.561	rs78528869	chr2:183815502	C/T	cg09997497	chr2:183902928	NCKAP1	1.11	4.95	0.41	2.38e-6	Blood protein levels;
TGCT	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg16423285	chr20:60520624	NA	-0.6	-6.41	-0.5	2.76e-9	Body mass index;
TGCT	cis	rs3008870	0.920	rs3008860	chr1:67391003	G/C	cg11518657	chr1:67396239	MIER1	0.52	4.53	0.38	1.39e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs62064224	0.589	rs4132610	chr17:30801441	C/T	cg18200150	chr17:30822561	MYO1D	0.42	5.06	0.41	1.48e-6	Schizophrenia;
TGCT	cis	rs13326165	0.760	rs6763882	chr3:52354772	A/G	cg07884673	chr3:53033167	SFMBT1	-0.36	-4.48	-0.37	1.65e-5	HDL cholesterol;HDL cholesterol levels;
TGCT	trans	rs4332037	0.539	rs868754	chr7:2033780	G/C	cg25206134	chr2:45395956	NA	0.99	7.09	0.54	9.09e-11	Bipolar disorder;
TGCT	cis	rs4689592	0.503	rs66885632	chr4:7053738	T/C	cg26116260	chr4:7069785	GRPEL1	-0.9	-6.76	-0.52	4.9e-10	Monocyte percentage of white cells;
TGCT	cis	rs7809950	1.000	rs28714607	chr7:107106253	T/C	cg23024343	chr7:107201750	COG5	-0.33	-5.24	-0.43	6.69e-7	Coronary artery disease;
TGCT	cis	rs60843830	1.000	rs79716074	chr2:277003	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.7	6.56	0.51	1.33e-9	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs9910055	0.529	rs228757	chr17:42164885	G/C	cg13607699	chr17:42295918	UBTF	-0.64	-5.05	-0.41	1.56e-6	Total body bone mineral density;
TGCT	cis	rs7917772	0.636	rs2863718	chr10:104519631	G/C	cg05855489	chr10:104503620	C10orf26	0.66	5.25	0.43	6.47e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	trans	rs7819412	0.777	rs1057626	chr8:10962800	T/C	cg15556689	chr8:8085844	FLJ10661	-0.71	-6.69	-0.51	6.91e-10	Triglycerides;
TGCT	cis	rs4372836	1.000	rs4372836	chr2:28973883	T/C	cg09522027	chr2:28974177	PPP1CB	-0.59	-5.15	-0.42	1e-6	Body mass index;
TGCT	cis	rs6940638	0.956	rs12199218	chr6:27025281	T/C	cg16898833	chr6:26189333	HIST1H4D	0.72	5.46	0.44	2.52e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs10465746	0.780	rs7550413	chr1:84423891	T/A	cg10977910	chr1:84465055	TTLL7	0.69	7.07	0.54	9.97e-11	Obesity-related traits;
TGCT	cis	rs2739330	0.615	rs2858911	chr22:24297195	G/T	cg00024416	chr22:24240387	NA	-0.25	-4.91	-0.4	2.86e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs11190604	0.945	rs11190553	chr10:102207959	T/C	cg23241863	chr10:102295624	HIF1AN	0.62	4.87	0.4	3.27e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7511006	0.893	rs760743	chr22:50647375	C/T	cg16473166	chr22:50639996	SELO	0.66	6.49	0.5	1.88e-9	Obesity-related traits;
TGCT	cis	rs6754311	0.593	rs10928542	chr2:136410299	G/A	cg07169764	chr2:136633963	MCM6	0.67	5.91	0.47	3.16e-8	Mosquito bite size;
TGCT	cis	rs910316	0.783	rs11850751	chr14:75590113	A/T	cg11812906	chr14:75593930	NEK9	0.73	7.23	0.54	4.36e-11	Height;
TGCT	cis	rs1008375	0.966	rs3796812	chr4:17582051	G/A	cg10189774	chr4:17578691	LAP3	0.58	5.15	0.42	9.89e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7845219	0.544	rs7016078	chr8:95922615	G/A	cg16049864	chr8:95962084	TP53INP1	-0.48	-5.3	-0.43	5.23e-7	Type 2 diabetes;
TGCT	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg11247378	chr22:39784982	NA	-0.73	-9.83	-0.66	3.22e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs7552404	0.961	rs211710	chr1:76109038	G/A	cg03433033	chr1:76189801	ACADM	-0.84	-10.0	-0.67	1.28e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2204008	0.619	rs8189576	chr12:38307275	G/A	cg26384229	chr12:38710491	ALG10B	-0.54	-4.7	-0.39	6.68e-6	Bladder cancer;
TGCT	cis	rs3087591	0.960	rs4263003	chr17:29438508	G/T	cg24425628	chr17:29625626	OMG;NF1	0.49	7.28	0.55	3.29e-11	Hip circumference;
TGCT	cis	rs9325144	0.647	rs12229104	chr12:39110811	T/A	cg10518543	chr12:38710700	ALG10B	-0.48	-4.5	-0.37	1.52e-5	Morning vs. evening chronotype;
TGCT	trans	rs4919669	0.668	rs3824756	chr10:104359350	T/C	cg24066601	chr6:26271455	HIST1H3G	0.66	6.81	0.52	3.7e-10	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs67311347	1.000	rs7628247	chr3:40512682	G/T	cg13683864	chr3:40499215	RPL14	1.17	13.19	0.76	2.34e-25	Renal cell carcinoma;
TGCT	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg12963246	chr6:28129442	ZNF389	0.47	4.74	0.39	5.69e-6	Parkinson's disease;
TGCT	cis	rs826838	1.000	rs826838	chr12:39106731	C/T	cg13010199	chr12:38710504	ALG10B	-0.55	-4.52	-0.38	1.45e-5	Heart rate;
TGCT	cis	rs4819052	1.000	rs4819052	chr21:46699777	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	5.52	0.44	1.87e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs921968	0.541	rs2710246	chr2:219533894	C/T	cg02176678	chr2:219576539	TTLL4	0.44	6.3	0.49	4.77e-9	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs7267979	1.000	rs4815412	chr20:25350325	A/G	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9814567	0.806	rs6806810	chr3:134323522	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-7.21	-0.54	4.87e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	trans	rs11722228	0.549	rs3796818	chr4:10097976	C/T	cg26043149	chr18:55253948	FECH	1.16	11.2	0.71	1.55e-20	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs6570726	0.791	rs440477	chr6:145854188	C/T	cg13319975	chr6:146136371	FBXO30	-0.51	-4.6	-0.38	1.01e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7940866	0.903	rs10791112	chr11:130870215	A/C	cg12179176	chr11:130786555	SNX19	-0.55	-5.59	-0.45	1.41e-7	Schizophrenia;
TGCT	cis	rs4713118	0.523	rs2179096	chr6:27665920	C/T	cg10876282	chr6:28092338	ZSCAN16	0.48	4.86	0.4	3.48e-6	Parkinson's disease;
TGCT	cis	rs13242816	1.000	rs34082946	chr7:116154313	G/A	cg02799643	chr7:116139180	CAV2	-0.44	-5.54	-0.45	1.74e-7	P wave duration;
TGCT	cis	rs12188164	0.686	rs11741946	chr5:421403	G/A	cg22025206	chr5:502436	SLC9A3	-0.26	-4.53	-0.38	1.36e-5	Cystic fibrosis severity;
TGCT	cis	rs11190604	0.767	rs4559620	chr10:102199935	C/T	cg16342193	chr10:102329863	NA	-0.42	-5.26	-0.43	6.02e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs909002	0.925	rs7524405	chr1:32108579	A/C	cg11573219	chr1:32083031	HCRTR1	0.45	5.86	0.47	3.94e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs864745	0.967	rs860262	chr7:28194397	C/A	cg23620719	chr7:28220237	JAZF1	-0.48	-4.54	-0.38	1.33e-5	Crohn's disease;Type 2 diabetes;
TGCT	trans	rs10953454	1.000	rs12535201	chr7:104501521	C/T	cg04208666	chr6:19734707	NA	-0.57	-6.89	-0.53	2.52e-10	Obesity;
TGCT	cis	rs9660180	0.836	rs12038134	chr1:1703865	T/A	cg03396347	chr1:1875803	NA	-0.36	-6.58	-0.51	1.18e-9	Body mass index;
TGCT	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg10802521	chr3:52805072	NEK4	-0.78	-10.0	-0.67	1.26e-17	Bipolar disorder;
TGCT	cis	rs1784581	0.588	rs1789988	chr6:162408472	C/T	cg17173639	chr6:162384350	PARK2	-0.42	-7.14	-0.54	6.78e-11	Itch intensity from mosquito bite;
TGCT	cis	rs2710642	0.821	rs56373728	chr2:63095792	G/A	cg17519650	chr2:63277830	OTX1	0.59	5.33	0.43	4.49e-7	LDL cholesterol levels;LDL cholesterol;
TGCT	cis	rs4242434	0.927	rs3735901	chr8:22462374	T/C	cg03733263	chr8:22462867	KIAA1967	1.15	20.01	0.87	1.19e-40	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs17376456	0.778	rs10476604	chr5:93461838	C/T	cg21475434	chr5:93447410	FAM172A	0.62	5.78	0.46	5.64e-8	Diabetic retinopathy;
TGCT	trans	rs2624839	0.704	rs2624838	chr3:50205642	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.73	6.73	0.52	5.49e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs826838	1.000	rs11169031	chr12:39056738	T/C	cg13010199	chr12:38710504	ALG10B	0.77	6.3	0.49	4.68e-9	Heart rate;
TGCT	trans	rs9383153	1.000	rs2073518	chr6:16332730	T/C	cg22767166	chr8:49833685	SNAI2	0.87	6.64	0.51	9e-10	Gambling;
TGCT	cis	rs3935685	1.000	rs10851896	chr15:78026325	C/T	cg25212270	chr15:78015279	NA	0.28	5.29	0.43	5.34e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg03303774	chr4:1407052	NA	-0.32	-4.92	-0.4	2.7e-6	Obesity-related traits;
TGCT	cis	rs57677839	1	rs57677839	chr11:17028189	G/A	cg15084286	chr11:17036142	PLEKHA7	0.91	12.38	0.74	2.02e-23	Coronary artery disease;
TGCT	cis	rs3892630	0.588	rs7248798	chr19:33303684	G/T	cg22980127	chr19:33182716	NUDT19	0.74	5.98	0.47	2.17e-8	Red blood cell traits;
TGCT	trans	rs1814175	0.791	rs10219223	chr11:49791468	A/T	cg15704280	chr7:45808275	SEPT13	-0.7	-8.08	-0.59	4.89e-13	Height;
TGCT	cis	rs713587	0.776	rs3731623	chr2:25163783	T/C	cg01884057	chr2:25150051	NA	0.39	7.97	0.58	8.81e-13	Body mass index in non-asthmatics;
TGCT	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg25036284	chr2:26402008	FAM59B	-0.57	-4.99	-0.41	2e-6	Gut microbiome composition (summer);
TGCT	cis	rs151997	0.925	rs27579	chr5:50165147	G/A	cg06027927	chr5:50259733	NA	0.47	4.74	0.39	5.75e-6	Callous-unemotional behaviour;
TGCT	cis	rs35883536	0.647	rs59667512	chr1:101046712	C/T	cg10298815	chr1:101004474	GPR88	-0.25	-4.5	-0.37	1.54e-5	Monocyte count;
TGCT	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg26338869	chr17:61819248	STRADA	-0.56	-5.11	-0.42	1.17e-6	Prudent dietary pattern;
TGCT	cis	rs9814567	1.000	rs12490835	chr3:134223730	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.96	-9.19	-0.64	1.16e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs11167764	1.000	rs11167764	chr5:141479065	A/C	cg02659431	chr5:141694439	SPRY4	-0.22	-4.67	-0.39	7.84e-6	Crohn's disease;
TGCT	cis	rs778371	0.874	rs1083522	chr2:233745521	C/T	cg25237894	chr2:233734115	C2orf82	-0.24	-4.47	-0.37	1.71e-5	Schizophrenia;
TGCT	cis	rs9807989	0.811	rs4485584	chr2:102970750	T/C	cg09003973	chr2:102972529	NA	0.64	5.7	0.46	8.28e-8	Asthma;
TGCT	cis	rs2108225	0.837	rs6466186	chr7:107446966	G/C	cg20438043	chr7:107601757	LAMB1	-0.24	-4.49	-0.37	1.63e-5	Ulcerative colitis;
TGCT	cis	rs190945449	1	rs190945449	chr6:26828359	C/T	cg16898833	chr6:26189333	HIST1H4D	1.1	5.46	0.44	2.47e-7	Urinary tract infection frequency;
TGCT	cis	rs2404602	1.000	rs11072603	chr15:76881138	G/T	cg26408565	chr15:76604113	ETFA	-0.38	-4.82	-0.4	4.03e-6	Blood metabolite levels;
TGCT	cis	rs2456568	0.709	rs1354765	chr11:93637776	G/T	cg16099599	chr11:93583650	C11orf90	0.39	4.75	0.39	5.63e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs9430161	0.645	rs6675082	chr1:11033797	T/C	cg02454025	chr1:11042201	C1orf127	0.94	11.31	0.71	8.14e-21	Ewing sarcoma;
TGCT	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg24675658	chr1:53192096	ZYG11B	-0.74	-9.22	-0.64	9.770000000000001e-16	Monocyte count;
TGCT	cis	rs478304	0.651	rs4014195	chr11:65506822	C/G	cg27068330	chr11:65405492	SIPA1	0.96	9.88	0.66	2.5e-17	Acne (severe);
TGCT	cis	rs910316	1.000	rs175512	chr14:75523382	T/C	cg08847533	chr14:75593920	NEK9	-0.95	-10.36	-0.68	1.73e-18	Height;
TGCT	cis	rs7772486	0.875	rs9390377	chr6:146386932	G/A	cg13319975	chr6:146136371	FBXO30	-0.51	-4.48	-0.37	1.69e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg03388025	chr16:89894329	SPIRE2	0.48	8.35	0.6	1.15e-13	Vitiligo;
TGCT	cis	rs669446	0.562	rs11210907	chr1:44191759	C/T	cg12908607	chr1:44402522	ARTN	-0.59	-6.47	-0.5	2.02e-9	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs9733	0.596	rs72702570	chr1:150688196	C/T	cg04414720	chr1:150670196	GOLPH3L	0.37	4.91	0.4	2.76e-6	Tonsillectomy;
TGCT	cis	rs9467773	0.967	rs6456732	chr6:26514445	T/C	cg09904177	chr6:26538194	HMGN4	0.65	6.53	0.51	1.53e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs6121246	0.529	rs6060174	chr20:30183538	G/A	cg18721089	chr20:30220636	NA	-0.63	-6.88	-0.53	2.67e-10	Mean corpuscular hemoglobin;
TGCT	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg19010396	chr19:19431384	KIAA0892;SF4	-0.54	-4.54	-0.38	1.3e-5	Tonsillectomy;
TGCT	cis	rs11249608	0.548	rs2132672	chr5:178457742	A/C	cg01312482	chr5:178451176	ZNF879	-0.49	-4.82	-0.4	4.11e-6	Pubertal anthropometrics;
TGCT	cis	rs6988636	0.892	rs58116120	chr8:124191776	T/G	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs2067615	0.524	rs10778503	chr12:107090616	C/T	cg15890332	chr12:107067104	RFX4	0.29	5.82	0.46	4.61e-8	Heart rate;
TGCT	cis	rs9325144	0.647	rs1386018	chr12:39104360	C/T	cg26384229	chr12:38710491	ALG10B	-0.57	-5.29	-0.43	5.23e-7	Morning vs. evening chronotype;
TGCT	cis	rs9486719	1.000	rs13210597	chr6:96969694	C/A	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.81	-0.62	9.21e-15	Migraine;Coronary artery disease;
TGCT	cis	rs7914558	0.901	rs1926034	chr10:104829102	G/A	cg04362960	chr10:104952993	NT5C2	0.55	4.73	0.39	6.11e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.55	-7.04	-0.53	1.14e-10	Longevity;Endometriosis;
TGCT	cis	rs4803455	0.586	rs4803457	chr19:41861359	T/C	cg09537434	chr19:41945824	ATP5SL	-0.53	-5.25	-0.43	6.35e-7	Migraine;Coronary artery disease;
TGCT	cis	rs4953076	0.573	rs7602070	chr2:44388614	G/A	cg04920474	chr2:44395004	PPM1B	0.61	6.07	0.48	1.45e-8	Height;
TGCT	cis	rs7017914	0.967	rs12679261	chr8:71844649	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.52	-4.81	-0.4	4.3e-6	Bone mineral density;
TGCT	cis	rs7089973	0.604	rs11196942	chr10:116596872	G/A	cg03647239	chr10:116582469	FAM160B1	0.58	5.66	0.45	9.75e-8	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs6430585	0.702	rs746857	chr2:136554890	G/A	cg19039313	chr2:136634366	MCM6	0.24	4.64	0.38	8.84e-6	Corneal structure;
TGCT	cis	rs17767294	0.708	rs72848752	chr6:27878268	A/C	cg08851530	chr6:28072375	NA	1.53	7.17	0.54	6.02e-11	Parkinson's disease;
TGCT	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg10295955	chr4:187884368	NA	-0.97	-14.67	-0.8	7e-29	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7772486	0.654	rs6928007	chr6:146074941	G/A	cg05347473	chr6:146136440	FBXO30	-0.49	-4.52	-0.38	1.42e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2235642	0.787	rs2235646	chr16:1601287	A/G	cg07639376	chr16:1584516	IFT140;TMEM204	-0.34	-6.14	-0.48	1.01e-8	Coronary artery disease;
TGCT	cis	rs9467711	0.720	rs75782365	chr6:26408551	T/G	cg12315302	chr6:26189340	HIST1H4D	0.99	4.44	0.37	1.93e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9611565	0.572	rs139569	chr22:42211141	A/G	cg17554472	chr22:41940697	POLR3H	-0.44	-4.72	-0.39	6.23e-6	Vitiligo;
TGCT	cis	rs17030434	0.954	rs79908936	chr4:154749305	C/T	cg14289246	chr4:154710475	SFRP2	-0.9	-6.97	-0.53	1.65e-10	Electrocardiographic conduction measures;
TGCT	cis	rs9611565	0.649	rs139540	chr22:42178040	C/T	cg06481639	chr22:41940642	POLR3H	-0.58	-4.83	-0.4	4e-6	Vitiligo;
TGCT	cis	rs6933660	0.745	rs3800272	chr6:151744283	A/G	cg17179660	chr6:151773299	C6orf211;RMND1	0.51	4.77	0.39	5e-6	Menarche (age at onset);
TGCT	cis	rs7192750	0.562	rs9888748	chr16:71987851	G/A	cg06353428	chr16:71660113	MARVELD3	0.74	6.6	0.51	1.09e-9	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg13699009	chr12:122356056	WDR66	-0.34	-8.18	-0.59	2.8e-13	Mean corpuscular volume;
TGCT	cis	rs11644362	1.000	rs35972357	chr16:12987664	C/T	cg06890432	chr16:12997467	SHISA9	-0.6	-6.49	-0.5	1.88e-9	Positive affect;Subjective well-being;
TGCT	cis	rs3796619	1.000	rs2290409	chr4:1067249	C/T	cg27284194	chr4:1044797	NA	-0.46	-4.48	-0.37	1.66e-5	Recombination rate (males);
TGCT	cis	rs12549902	1.000	rs12549902	chr8:41509259	C/T	cg00088007	chr8:41504566	NKX6-3	0.34	5.38	0.43	3.59e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
TGCT	cis	rs3806843	0.576	rs246020	chr5:140334771	G/A	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg06558623	chr16:89946397	TCF25	0.56	6.83	0.52	3.38e-10	Skin colour saturation;
TGCT	cis	rs6964587	0.900	rs6465352	chr7:91775117	A/G	cg17063962	chr7:91808500	NA	0.93	10.08	0.67	8.03e-18	Breast cancer;
TGCT	cis	rs3087591	0.666	rs2953016	chr17:29494693	C/G	cg24425628	chr17:29625626	OMG;NF1	0.42	5.56	0.45	1.55e-7	Hip circumference;
TGCT	cis	rs2204008	0.837	rs4432085	chr12:38181146	C/T	cg13010199	chr12:38710504	ALG10B	0.64	5.16	0.42	9.41e-7	Bladder cancer;
TGCT	cis	rs881375	0.933	rs4837804	chr9:123705304	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.44	4.72	0.39	6.28e-6	Rheumatoid arthritis;
TGCT	cis	rs12541335	0.692	rs2290274	chr8:22214374	C/T	cg00420450	chr8:22132641	PIWIL2	0.24	4.53	0.38	1.36e-5	Hypertriglyceridemia;
TGCT	cis	rs3820928	0.904	rs2396431	chr2:227765488	G/A	cg11843606	chr2:227700838	RHBDD1	-0.53	-4.68	-0.39	7.37e-6	Pulmonary function;
TGCT	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg21433313	chr16:3507492	NAT15	0.36	4.61	0.38	9.85e-6	Tuberculosis;
TGCT	cis	rs13256369	0.802	rs1060106	chr8:8561452	A/G	cg17143192	chr8:8559678	CLDN23	0.54	5.03	0.41	1.64e-6	Obesity-related traits;
TGCT	cis	rs68170813	0.559	rs61406169	chr7:106903421	A/T	cg02696742	chr7:106810147	HBP1	-0.69	-5.61	-0.45	1.27e-7	Coronary artery disease;
TGCT	cis	rs9486719	1.000	rs4077932	chr6:96905144	C/T	cg06623918	chr6:96969491	KIAA0776	-0.98	-8.77	-0.62	1.15e-14	Migraine;Coronary artery disease;
TGCT	cis	rs12220238	1.000	rs7083534	chr10:75955672	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.48	0.56	1.16e-11	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs3813359	0.614	rs17059066	chr6:130769858	C/T	cg25049486	chr6:130544510	SAMD3	0.39	4.75	0.39	5.61e-6	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs3749237	0.595	rs11130199	chr3:49538799	T/C	cg07636037	chr3:49044803	WDR6	0.63	5.98	0.47	2.26e-8	Resting heart rate;
TGCT	cis	rs2197308	0.610	rs10880837	chr12:37864924	C/T	cg26384229	chr12:38710491	ALG10B	0.89	7.93	0.58	1.09e-12	Morning vs. evening chronotype;
TGCT	cis	rs6598955	0.671	rs11247909	chr1:26640135	G/A	cg04990556	chr1:26633338	UBXN11	0.64	4.91	0.4	2.78e-6	Obesity-related traits;
TGCT	cis	rs1949733	1.000	rs2631745	chr4:8490530	T/C	cg13073564	chr4:8508604	NA	0.5	5.55	0.45	1.63e-7	Response to antineoplastic agents;
TGCT	cis	rs9583531	0.600	rs6492306	chr13:111361693	G/A	cg24331049	chr13:111365604	ING1	0.74	7.22	0.54	4.61e-11	Coronary artery disease;
TGCT	cis	rs1801251	0.778	rs2592116	chr2:233735709	G/A	cg08000102	chr2:233561755	GIGYF2	-0.44	-4.45	-0.37	1.87e-5	Coronary artery disease;
TGCT	cis	rs6840360	0.554	rs10222838	chr4:152690099	T/C	cg22705602	chr4:152727874	NA	-0.35	-5.94	-0.47	2.62e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9911578	0.967	rs9907940	chr17:56663842	A/G	cg12560992	chr17:57184187	TRIM37	0.76	9.34	0.64	4.88e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs12477438	1.000	rs995617	chr2:99857904	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.96	8.25	0.6	1.96e-13	Chronic sinus infection;
TGCT	cis	rs9914544	0.545	rs12451200	chr17:18778493	A/G	cg26378065	chr17:18585709	ZNF286B	0.53	4.63	0.38	9.06e-6	Educational attainment (years of education);
TGCT	cis	rs5769707	0.681	rs6009803	chr22:50051007	A/G	cg05373962	chr22:49881684	NA	-0.32	-5.52	-0.44	1.87e-7	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs9560113	1.000	rs4773384	chr13:112177987	A/G	cg14154082	chr13:112174009	NA	0.37	5.07	0.41	1.42e-6	Menarche (age at onset);
TGCT	cis	rs1670533	0.932	rs3796620	chr4:1095079	A/G	cg27284194	chr4:1044797	NA	-0.69	-6.07	-0.48	1.45e-8	Recombination rate (females);
TGCT	cis	rs4076764	1.000	rs4469696	chr1:163424565	C/T	cg24596788	chr1:163392923	NA	-0.16	-4.56	-0.38	1.22e-5	Motion sickness;
TGCT	cis	rs7666738	0.830	rs2098934	chr4:98992403	A/G	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7666738	0.609	rs28833816	chr4:98868866	T/C	cg05340658	chr4:99064831	C4orf37	0.56	5.96	0.47	2.4e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9549260	0.755	rs1413482	chr13:41218451	C/T	cg21288729	chr13:41239152	FOXO1	1.01	10.64	0.69	3.45e-19	Red blood cell count;
TGCT	cis	rs11971779	0.715	rs11772771	chr7:139058803	T/C	cg07862535	chr7:139043722	LUC7L2	0.7	5.49	0.44	2.13e-7	Diisocyanate-induced asthma;
TGCT	cis	rs986417	1.000	rs2224410	chr14:60970531	T/C	cg27398547	chr14:60952738	C14orf39	1.39	10.61	0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs1153858	0.943	rs7402632	chr15:45701913	A/T	cg26924012	chr15:45694286	SPATA5L1	1.1	15.34	0.81	2.01e-30	Homoarginine levels;
TGCT	cis	rs17331151	0.512	rs9637477	chr3:52891426	G/C	cg12962167	chr3:53033115	SFMBT1	-0.42	-4.83	-0.4	3.88e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs1903068	0.853	rs9312657	chr4:56003502	G/A	cg09978860	chr4:56023921	NA	0.56	6.34	0.49	3.88e-9	Endometriosis;
TGCT	cis	rs9393777	0.557	rs36034627	chr6:27237363	G/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.55	-4.59	-0.38	1.09e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs12477438	1.000	rs11897712	chr2:99735697	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-5.46	-0.44	2.5e-7	Chronic sinus infection;
TGCT	cis	rs11098499	0.954	rs35063680	chr4:120387102	T/C	cg09307838	chr4:120376055	NA	0.68	6.53	0.51	1.54e-9	Corneal astigmatism;
TGCT	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg05368731	chr17:41323189	NBR1	1.21	14.63	0.8	8.89e-29	Menopause (age at onset);
TGCT	cis	rs739401	0.611	rs450817	chr11:3056712	A/G	cg05729581	chr11:3078854	CARS	-0.55	-5.19	-0.42	8.19e-7	Longevity;
TGCT	cis	rs6815814	0.731	rs11735251	chr4:38773057	T/A	cg02016764	chr4:38805732	TLR1	-0.27	-4.54	-0.38	1.32e-5	Breast cancer;
TGCT	cis	rs6463523	0.933	rs6974151	chr7:758269	T/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.93	11.59	0.72	1.68e-21	Subjective well-being;
TGCT	cis	rs10197940	0.578	rs1061305	chr2:152346979	T/C	cg19508488	chr2:152266495	RIF1	0.59	4.98	0.41	2.11e-6	Lung cancer;
TGCT	trans	rs10506458	0.915	rs998505	chr12:63400018	C/T	cg22491629	chr6:157744540	C6orf35	-0.99	-8.55	-0.61	3.94e-14	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs10464366	0.544	rs4355688	chr7:39158402	C/T	cg15212455	chr7:39170539	POU6F2	0.3	6.63	0.51	9.08e-10	IgG glycosylation;
TGCT	cis	rs473651	0.935	rs541013	chr2:239336492	G/A	cg21699342	chr2:239360505	ASB1	0.18	4.89	0.4	3.05e-6	Multiple system atrophy;
TGCT	cis	rs3772130	0.540	rs7649436	chr3:121562304	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.6	5.56	0.45	1.55e-7	Cognitive performance;
TGCT	cis	rs6969780	0.673	rs2301721	chr7:27196113	C/T	cg17457637	chr7:27170717	HOXA4	-0.44	-4.81	-0.4	4.29e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs11250097	0.507	rs2409779	chr8:11311340	A/T	cg01383082	chr8:11323474	FAM167A	0.27	4.48	0.37	1.66e-5	Neuroticism;
TGCT	cis	rs981844	0.775	rs62323979	chr4:154752935	T/C	cg14289246	chr4:154710475	SFRP2	1.0	8.63	0.61	2.53e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs9549367	0.789	rs71446682	chr13:113894908	A/G	cg18105134	chr13:113819100	PROZ	-0.34	-5.58	-0.45	1.41e-7	Platelet distribution width;
TGCT	cis	rs295140	1.000	rs7599609	chr2:201177653	G/A	cg04283868	chr2:201171347	SPATS2L	0.65	6.66	0.51	7.99e-10	QT interval;
TGCT	cis	rs9906944	0.545	rs1994969	chr17:47080431	G/T	cg20966754	chr17:47091339	IGF2BP1	-0.41	-4.49	-0.37	1.63e-5	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs28595532	0.920	rs115085630	chr4:119741765	T/C	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs9868809	0.505	rs28793701	chr3:48762683	C/G	cg03547606	chr3:48723644	NCKIPSD	0.46	4.55	0.38	1.28e-5	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs908922	0.676	rs493133	chr1:152493875	G/C	cg20991723	chr1:152506922	NA	0.46	6.26	0.49	5.7e-9	Hair morphology;
TGCT	cis	rs4595586	0.545	rs1356265	chr12:39403696	A/G	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs751728	0.638	rs4607416	chr6:33784998	G/C	cg13859433	chr6:33739653	LEMD2	-0.37	-6.45	-0.5	2.21e-9	Crohn's disease;
TGCT	cis	rs950169	0.840	rs62019457	chr15:85102142	T/C	cg11189052	chr15:85197271	WDR73	0.81	6.71	0.52	6.33e-10	Schizophrenia;
TGCT	cis	rs10736390	1.000	rs10736390	chr1:55103945	A/G	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.42	-8.39	-0.6	9.18e-14	Survival in pancreatic cancer;
TGCT	cis	rs12477438	0.798	rs6761570	chr2:99577276	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-8.65	-0.61	2.22e-14	Chronic sinus infection;
TGCT	cis	rs921968	0.541	rs58650092	chr2:219304851	C/A	cg02176678	chr2:219576539	TTLL4	-0.47	-6.59	-0.51	1.15e-9	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs7772486	0.790	rs2265918	chr6:146219164	A/G	cg23711669	chr6:146136114	FBXO30	0.89	10.16	0.67	5.28e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7772486	0.875	rs2777483	chr6:146329235	A/G	cg13319975	chr6:146136371	FBXO30	-0.5	-4.48	-0.37	1.67e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9457247	0.967	rs377753	chr6:167389496	A/T	cg23791538	chr6:167370224	RNASET2	-0.5	-4.98	-0.41	2.08e-6	Crohn's disease;
TGCT	cis	rs1577917	1.000	rs13194429	chr6:86646705	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.54	-0.45	1.73e-7	Response to antipsychotic treatment;
TGCT	cis	rs3845702	0.736	rs12693214	chr2:180825685	G/A	cg01881094	chr2:180872142	CWC22	-1.03	-6.51	-0.5	1.72e-9	Schizophrenia;
TGCT	cis	rs7772486	0.790	rs2254283	chr6:146204289	T/C	cg05347473	chr6:146136440	FBXO30	0.52	5.0	0.41	1.87e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7552404	0.924	rs7544117	chr1:76158246	A/G	cg10523679	chr1:76189770	ACADM	0.9	9.92	0.67	2e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9788682	0.947	rs12439240	chr15:78829091	T/C	cg06917634	chr15:78832804	PSMA4	-0.71	-4.93	-0.4	2.63e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs9911578	0.933	rs74370218	chr17:57095212	C/T	cg12560992	chr17:57184187	TRIM37	-0.78	-9.58	-0.65	1.35e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs986417	0.748	rs10142927	chr14:61041956	A/G	cg18240143	chr14:60952599	C14orf39	0.82	4.51	0.38	1.46e-5	Gut microbiota (bacterial taxa);
TGCT	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg24531977	chr5:56204891	C5orf35	-0.77	-7.61	-0.56	5.83e-12	Initial pursuit acceleration;
TGCT	cis	rs4478858	0.684	rs1546375	chr1:31765968	C/T	cg00250761	chr1:31883323	NA	-0.25	-4.48	-0.37	1.64e-5	Alcohol dependence;
TGCT	cis	rs2760061	0.819	rs708120	chr1:228207651	G/C	cg02753203	chr1:228287806	NA	0.3	5.71	0.46	8.06e-8	Diastolic blood pressure;
TGCT	cis	rs7267979	0.789	rs6076347	chr20:25398790	C/T	cg21995068	chr20:25989032	LOC100134868	0.42	5.07	0.41	1.43e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs612683	0.536	rs1335753	chr1:101027157	G/T	cg06223162	chr1:101003688	GPR88	0.34	5.93	0.47	2.86e-8	Breast cancer;
TGCT	cis	rs2439831	0.681	rs2242067	chr15:43699303	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.04	6.72	0.52	5.82e-10	Lung cancer in ever smokers;
TGCT	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg04287289	chr16:89883240	FANCA	-0.83	-9.77	-0.66	4.58e-17	Vitiligo;
TGCT	cis	rs478304	0.654	rs1074156	chr11:65458169	G/T	cg17480646	chr11:65405466	SIPA1	-0.62	-7.6	-0.56	6.27e-12	Acne (severe);
TGCT	cis	rs7666738	0.830	rs4441757	chr4:98927059	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10791323	0.604	rs2723615	chr11:133704567	C/T	cg03690763	chr11:133734501	NA	-0.35	-5.33	-0.43	4.52e-7	Childhood ear infection;
TGCT	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.72	7.43	0.55	1.57e-11	Menarche (age at onset);
TGCT	cis	rs2239547	0.522	rs6445550	chr3:52983434	G/A	cg11645453	chr3:52864694	ITIH4	0.3	4.88	0.4	3.21e-6	Schizophrenia;
TGCT	cis	rs62209	0.752	rs11256941	chr10:11017020	G/T	cg26901096	chr10:10994189	LOC254312	0.36	5.96	0.47	2.48e-8	Alzheimer's disease (late onset);
TGCT	cis	rs9790314	0.631	rs2061804	chr3:161102474	C/A	cg03342759	chr3:160939853	NMD3	-0.46	-4.93	-0.4	2.57e-6	Morning vs. evening chronotype;
TGCT	cis	rs1538970	0.962	rs4660849	chr1:45819872	A/G	cg05343316	chr1:45956843	TESK2	-0.63	-5.03	-0.41	1.71e-6	Platelet count;
TGCT	cis	rs6540559	0.611	rs17015226	chr1:209970096	C/G	cg22029157	chr1:209979665	IRF6	0.79	5.93	0.47	2.81e-8	Cleft lip with or without cleft palate;
TGCT	cis	rs826838	0.967	rs6580726	chr12:39108623	T/C	cg26384229	chr12:38710491	ALG10B	-0.87	-8.1	-0.59	4.43e-13	Heart rate;
TGCT	cis	rs9814567	1.000	rs4572812	chr3:134291177	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.95	8.76	0.62	1.21e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs651907	0.557	rs35850993	chr3:101437433	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.9	10.87	0.7	9.43e-20	Colorectal cancer;
TGCT	cis	rs4499344	0.556	rs259219	chr19:33138067	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.79	7.83	0.58	1.89e-12	Mean platelet volume;
TGCT	cis	rs1691799	0.867	rs1168311	chr12:66725912	A/C	cg16791601	chr12:66731901	HELB	0.28	6.18	0.49	8.47e-9	White blood cell count (basophil);
TGCT	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs11642862	1.000	rs11641321	chr16:30880319	G/A	cg02466173	chr16:30829666	NA	-0.38	-4.45	-0.37	1.91e-5	Tonsillectomy;
TGCT	cis	rs1532993	0.518	rs9994066	chr4:98591202	T/A	cg05340658	chr4:99064831	C4orf37	-0.41	-4.91	-0.4	2.81e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs7119	0.604	rs2667783	chr15:77862529	G/A	cg27398640	chr15:77910606	LINGO1	0.27	4.78	0.39	4.84e-6	Type 2 diabetes;
TGCT	cis	rs1865760	0.593	rs2097273	chr6:25941310	A/C	cg03264133	chr6:25882463	NA	-0.51	-5.28	-0.43	5.69e-7	Height;
TGCT	cis	rs12497850	0.931	rs6442130	chr3:48778027	A/G	cg05785598	chr3:49045655	WDR6	0.35	4.64	0.38	8.79e-6	Parkinson's disease;
TGCT	cis	rs17253792	0.732	rs28380739	chr14:56088402	G/A	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs2721195	1.000	rs2721195	chr8:145677011	T/C	cg11211951	chr8:145729740	GPT	-0.21	-4.89	-0.4	3e-6	Age at first birth;
TGCT	trans	rs3780486	0.846	rs6476399	chr9:33123013	A/G	cg04842962	chr6:43655489	MRPS18A	1.23	15.36	0.81	1.81e-30	IgG glycosylation;
TGCT	cis	rs7666738	1.000	rs880473	chr4:98922596	C/T	cg18180107	chr4:99064573	C4orf37	0.56	4.45	0.37	1.9e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	5.26	0.43	6.03e-7	Menopause (age at onset);
TGCT	cis	rs5769707	0.521	rs5770633	chr22:50062427	G/A	cg05373962	chr22:49881684	NA	-0.32	-5.47	-0.44	2.43e-7	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs1887596	0.624	rs9553864	chr13:27152649	C/T	cg01312412	chr13:27282625	NA	0.27	4.86	0.4	3.51e-6	Facial morphology (factor 3, length of philtrum);
TGCT	trans	rs62103177	0.810	rs62103194	chr18:77629482	G/A	cg05926928	chr17:57297772	GDPD1	1.22	11.16	0.71	1.85e-20	Opioid sensitivity;
TGCT	cis	rs7249142	0.506	rs8101388	chr19:19293938	A/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.54	5.41	0.44	3.14e-7	IgG glycosylation;
TGCT	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg24549020	chr5:56110836	MAP3K1	0.69	5.91	0.47	3.09e-8	Initial pursuit acceleration;
TGCT	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg20607798	chr8:58055168	NA	0.45	4.59	0.38	1.06e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9952991	0.941	rs2542150	chr18:12779763	G/C	cg24737193	chr18:12778029	NA	0.54	6.03	0.48	1.76e-8	Inflammatory skin disease;
TGCT	cis	rs9394841	0.810	rs1410492	chr6:41907855	G/C	cg08135965	chr6:41755394	TOMM6	0.56	5.35	0.43	4.05e-7	Mean corpuscular hemoglobin;Red cell distribution width;
TGCT	trans	rs1814175	0.645	rs28839231	chr11:50044292	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.84	-0.7	1.13e-19	Height;
TGCT	cis	rs79349575	0.749	rs46521	chr17:46988529	A/G	cg26022315	chr17:47021804	SNF8	0.48	4.82	0.4	4.06e-6	Type 2 diabetes;
TGCT	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg02187348	chr16:89574699	SPG7	0.64	6.82	0.52	3.55e-10	Multiple myeloma (IgH translocation);
TGCT	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg17971929	chr21:40555470	PSMG1	0.93	8.45	0.6	6.46e-14	Cognitive function;
TGCT	cis	rs4642101	0.669	rs1467026	chr3:12830775	G/A	cg05775895	chr3:12838266	CAND2	0.67	7.21	0.54	4.91e-11	QRS complex (12-leadsum);
TGCT	cis	rs7246657	0.722	rs2927742	chr19:38133618	T/C	cg03611452	chr19:38183253	ZNF781	-0.58	-4.67	-0.39	7.7e-6	Coronary artery calcification;
TGCT	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg18876405	chr7:65276391	NA	0.36	5.36	0.43	3.84e-7	Aortic root size;
TGCT	cis	rs7843479	0.601	rs11781959	chr8:21841863	C/G	cg17168535	chr8:21777572	XPO7	0.8	8.02	0.58	6.73e-13	Mean corpuscular volume;
TGCT	cis	rs11105298	0.891	rs10858890	chr12:89907166	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.66	-4.8	-0.4	4.44e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg10150615	chr22:24372951	LOC391322	-0.81	-8.99	-0.63	3.44e-15	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.15	0.82	2.71e-32	Prudent dietary pattern;
TGCT	cis	rs704	0.628	rs241775	chr17:26644668	C/T	cg10342447	chr17:26645325	TMEM97	0.59	5.63	0.45	1.15e-7	Osteoprotegerin levels;
TGCT	cis	rs742614	0.935	rs6057929	chr20:32477633	A/G	cg03217337	chr20:32447030	NA	-0.22	-4.63	-0.38	9.03e-6	Stearic acid (18:0) levels;
TGCT	cis	rs7829975	0.560	rs56094035	chr8:8551622	G/A	cg06636001	chr8:8085503	FLJ10661	-0.61	-5.31	-0.43	4.81e-7	Mood instability;
TGCT	cis	rs1629083	0.935	rs1540191	chr11:118090432	G/A	cg16594165	chr11:118135105	MPZL2	-0.33	-4.7	-0.39	6.73e-6	Lung cancer;
TGCT	cis	rs8072100	0.777	rs9914653	chr17:45537395	T/C	cg08085267	chr17:45401833	C17orf57	-0.46	-5.07	-0.41	1.39e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs9467773	1.000	rs9393729	chr6:26514166	C/T	cg05738196	chr6:26577821	NA	0.88	12.5	0.75	1.03e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs2338224	1.000	rs10942300	chr5:71745412	C/T	cg01187920	chr5:71015162	CARTPT	-0.53	-4.57	-0.38	1.15e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Granulocyte count;Myeloid white cell count;
TGCT	cis	rs497273	0.534	rs608394	chr12:121194053	C/T	cg02419362	chr12:121203948	SPPL3	0.19	4.52	0.38	1.43e-5	Systemic lupus erythematosus;
TGCT	cis	rs1372520	0.627	rs2583964	chr4:90727218	A/G	cg15133208	chr4:90757351	SNCA	-0.52	-6.07	-0.48	1.44e-8	Neuroticism;
TGCT	cis	rs10992471	0.756	rs2516568	chr9:95187380	A/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.61	-6.31	-0.49	4.46e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs2639990	1.000	rs632157	chr18:72911548	G/A	cg03972071	chr18:72917163	ZADH2	0.8	5.4	0.44	3.3e-7	Vascular endothelial growth factor levels;
TGCT	cis	rs2153535	0.580	rs7767756	chr6:8453428	A/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.76	0.46	6.39e-8	Motion sickness;
TGCT	cis	rs7666738	0.830	rs11931166	chr4:99054187	A/T	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12579753	0.879	rs11115010	chr12:82165895	G/T	cg07988820	chr12:82153109	PPFIA2	-0.69	-7.77	-0.57	2.56e-12	Resting heart rate;
TGCT	cis	rs9611565	0.512	rs2050031	chr22:42152266	A/G	cg17554472	chr22:41940697	POLR3H	0.46	4.69	0.39	7.09e-6	Vitiligo;
TGCT	trans	rs1814175	0.817	rs28544182	chr11:50049577	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.26	-0.55	3.77e-11	Height;
TGCT	cis	rs7659604	0.628	rs6838153	chr4:122720999	A/G	cg20573242	chr4:122745356	CCNA2	0.64	5.71	0.46	7.81e-8	Type 2 diabetes;
TGCT	cis	rs709400	0.628	rs12889639	chr14:103860206	G/A	cg12935359	chr14:103987150	CKB	0.34	5.2	0.42	7.86e-7	Body mass index;
TGCT	cis	rs10927875	0.726	rs1763603	chr1:16339809	T/C	cg22431228	chr1:16359049	CLCNKA	-0.25	-4.76	-0.39	5.23e-6	Dilated cardiomyopathy;
TGCT	cis	rs7666738	0.716	rs2865982	chr4:99031661	T/G	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7119	0.717	rs8032405	chr15:77825344	A/G	cg27398640	chr15:77910606	LINGO1	-0.26	-4.68	-0.39	7.4e-6	Type 2 diabetes;
TGCT	cis	rs2075371	1.000	rs2058976	chr7:133981379	G/T	cg11752832	chr7:134001865	SLC35B4	0.69	6.32	0.49	4.19e-9	Mean platelet volume;
TGCT	trans	rs9354352	0.967	rs6455062	chr6:66694131	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	7.89	0.58	1.33e-12	Initial pursuit acceleration in psychotic disorders;
TGCT	trans	rs4332037	1.000	rs4332037	chr7:1950809	C/T	cg25206134	chr2:45395956	NA	1.12	9.49	0.65	2.13e-16	Bipolar disorder;
TGCT	cis	rs763121	0.853	rs6001184	chr22:39052116	C/T	cg06022373	chr22:39101656	GTPBP1	0.77	7.46	0.56	1.35e-11	Menopause (age at onset);
TGCT	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	7.12	0.54	7.55e-11	Platelet count;
TGCT	cis	rs10479542	0.701	rs10479541	chr5:178981003	G/C	cg14851468	chr5:179071604	C5orf60	0.23	4.66	0.39	8.05e-6	Lung cancer;
TGCT	cis	rs854765	0.583	rs9890341	chr17:17823175	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.74	7.69	0.57	3.91e-12	Total body bone mineral density;
TGCT	cis	rs7940866	0.834	rs2324315	chr11:130839772	C/G	cg12179176	chr11:130786555	SNX19	0.62	5.93	0.47	2.75e-8	Schizophrenia;
TGCT	cis	rs449303	1	rs449303	chr14:60605788	A/G	cg00846580	chr14:60632234	DHRS7	0.97	5.29	0.43	5.38e-7	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs61990749	0.597	rs12887282	chr14:78200585	C/A	cg23188588	chr14:78226832	SNW1;C14orf178	0.65	4.59	0.38	1.06e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs6714710	0.603	rs13020776	chr2:98402753	T/A	cg26665480	chr2:98280029	ACTR1B	0.66	6.24	0.49	6.33e-9	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs2072499	1.000	rs2072499	chr1:156169610	A/G	cg24450063	chr1:156163899	SLC25A44	1.17	17.33	0.84	6.21e-35	Testicular germ cell tumor;
TGCT	cis	rs3812831	0.630	rs9562129	chr13:114917152	A/G	cg08824895	chr13:115047677	UPF3A	0.49	4.65	0.39	8.5e-6	Schizophrenia;
TGCT	cis	rs1153858	1.000	rs2467858	chr15:45711492	A/G	cg14582100	chr15:45693742	SPATA5L1	0.47	5.62	0.45	1.22e-7	Homoarginine levels;
TGCT	cis	rs2439831	0.850	rs12442129	chr15:44055856	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	5.91	0.47	3.05e-8	Lung cancer in ever smokers;
TGCT	cis	rs6570726	0.516	rs10484700	chr6:145728933	C/T	cg23711669	chr6:146136114	FBXO30	0.6	5.48	0.44	2.32e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg03264133	chr6:25882463	NA	-0.52	-5.38	-0.44	3.53e-7	Blood metabolite levels;
TGCT	cis	rs7103648	0.966	rs874896	chr11:47418953	C/G	cg20307385	chr11:47447363	PSMC3	1.02	12.18	0.74	6.15e-23	Diastolic blood pressure;Systolic blood pressure;
TGCT	cis	rs11931598	0.514	rs10937779	chr4:7039326	G/A	cg26116260	chr4:7069785	GRPEL1	0.62	5.97	0.47	2.27e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs6570726	0.791	rs6902410	chr6:145905261	G/A	cg23711669	chr6:146136114	FBXO30	0.86	9.54	0.65	1.64e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs8179	0.645	rs10953072	chr7:92256339	A/C	cg15732164	chr7:92237376	CDK6	-0.27	-4.64	-0.38	8.79e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
TGCT	cis	rs1008375	1.000	rs13106338	chr4:17676871	G/T	cg10189774	chr4:17578691	LAP3	-0.59	-5.24	-0.43	6.8e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7919533	0.584	rs2894169	chr10:73524622	A/G	cg00101602	chr10:73857843	ASCC1	0.29	4.56	0.38	1.22e-5	Monocyte count;
TGCT	cis	rs3087591	0.553	rs2854334	chr17:29715500	A/G	cg24425628	chr17:29625626	OMG;NF1	0.4	5.86	0.47	3.98e-8	Hip circumference;
TGCT	cis	rs13188771	0.690	rs12519215	chr5:100898218	A/G	cg10455971	chr5:101119566	NA	0.44	4.45	0.37	1.87e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs3617	0.532	rs9836499	chr3:52904524	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.47	-4.46	-0.37	1.83e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs933688	0.938	rs7708782	chr5:90718517	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.99	8.17	0.59	3.05e-13	Smoking behavior;
TGCT	cis	rs10509586	0.826	rs77211714	chr10:91898746	G/A	cg25278353	chr10:91717815	NA	0.49	4.67	0.39	7.77e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
TGCT	cis	rs17376456	0.825	rs13164315	chr5:93147421	A/G	cg25358565	chr5:93447407	FAM172A	0.9	7.6	0.56	6.43e-12	Diabetic retinopathy;
TGCT	cis	rs35306767	0.855	rs56222464	chr10:867535	C/G	cg20503657	chr10:835505	NA	0.77	11.28	0.71	9.73e-21	Eosinophil percentage of granulocytes;
TGCT	cis	rs904251	0.504	rs12202664	chr6:37481198	A/G	cg01843034	chr6:37503916	NA	-0.55	-7.42	-0.55	1.63e-11	Cognitive performance;
TGCT	cis	rs9372498	0.536	rs62422221	chr6:118925581	T/C	cg21191810	chr6:118973309	C6orf204	-0.38	-4.98	-0.41	2.04e-6	Diastolic blood pressure;
TGCT	cis	rs9611565	0.512	rs4820444	chr22:42202606	A/G	cg06481639	chr22:41940642	POLR3H	0.69	6.02	0.48	1.83e-8	Vitiligo;
TGCT	cis	rs1461503	0.966	rs11218907	chr11:122841562	A/G	cg27398637	chr11:122830231	C11orf63	-0.42	-5.25	-0.43	6.42e-7	Menarche (age at onset);
TGCT	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg10802521	chr3:52805072	NEK4	-0.64	-7.66	-0.57	4.56e-12	Electroencephalogram traits;
TGCT	cis	rs11190604	1.000	rs2295770	chr10:102239829	G/A	cg23241863	chr10:102295624	HIF1AN	0.63	4.95	0.41	2.41e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7586879	0.681	rs6705446	chr2:25118608	T/C	cg15423357	chr2:25149977	NA	0.5	4.89	0.4	3.06e-6	Body mass index;
TGCT	cis	rs78487399	0.808	rs6708735	chr2:43731354	G/A	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.74	4.49	0.37	1.59e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs595982	0.546	rs9941490	chr19:49396737	G/A	cg11637076	chr19:49575188	KCNA7	-0.44	-5.23	-0.43	6.99e-7	Red cell distribution width;
TGCT	cis	rs9910055	1.000	rs9910055	chr17:42283037	C/T	cg19774624	chr17:42201019	HDAC5	-0.85	-8.21	-0.59	2.45e-13	Total body bone mineral density;
TGCT	cis	rs10501293	0.789	rs4755690	chr11:43054680	A/G	cg03447554	chr11:43094025	NA	0.45	6.58	0.51	1.2e-9	Cognitive performance;
TGCT	cis	rs10464366	1.000	rs10464366	chr7:39121500	A/T	cg15212455	chr7:39170539	POU6F2	-0.23	-5.05	-0.41	1.56e-6	IgG glycosylation;
TGCT	cis	rs875971	1.000	rs1144895	chr7:65541307	C/G	cg18876405	chr7:65276391	NA	-0.35	-5.19	-0.42	8.26e-7	Aortic root size;
TGCT	cis	rs10791323	0.604	rs2851116	chr11:133705759	G/A	cg03690763	chr11:133734501	NA	-0.35	-5.34	-0.43	4.31e-7	Childhood ear infection;
TGCT	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.65	6.39	0.5	3.07e-9	Menarche (age at onset);
TGCT	cis	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg17479576	chr4:152424074	FAM160A1	-0.62	-5.89	-0.47	3.32e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs4478858	0.735	rs10798843	chr1:31797094	A/G	cg00250761	chr1:31883323	NA	-0.28	-4.96	-0.41	2.32e-6	Alcohol dependence;
TGCT	cis	rs9486719	1.000	rs12529248	chr6:96895377	T/G	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.21	-0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	trans	rs561341	0.700	rs79272796	chr17:30226974	T/C	cg20587970	chr11:113659929	NA	-0.59	-8.99	-0.63	3.41e-15	Hip circumference adjusted for BMI;
TGCT	cis	rs7714584	1.000	rs12656600	chr5:150311872	A/G	cg22134413	chr5:150180641	NA	1.04	7.46	0.56	1.34e-11	Crohn's disease;
TGCT	cis	rs17221829	0.739	rs55812948	chr11:89446332	T/C	cg02982614	chr11:89391479	FOLH1B	-0.29	-5.09	-0.42	1.3e-6	Anxiety in major depressive disorder;
TGCT	cis	rs950169	0.922	rs8037078	chr15:84818871	A/G	cg11189052	chr15:85197271	WDR73	-0.81	-6.5	-0.5	1.78e-9	Schizophrenia;
TGCT	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg22433210	chr17:43662623	NA	-1.0	-7.13	-0.54	7.26e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	trans	rs62103177	0.673	rs4438371	chr18:77615988	C/T	cg05926928	chr17:57297772	GDPD1	1.06	10.79	0.7	1.52e-19	Opioid sensitivity;
TGCT	cis	rs4285028	0.948	rs7640872	chr3:121697168	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.68	-5.37	-0.43	3.7e-7	Multiple sclerosis;
TGCT	cis	rs13191362	0.810	rs66921603	chr6:162996982	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg06873352	chr17:61820015	STRADA	0.56	6.19	0.49	8.27e-9	Prudent dietary pattern;
TGCT	cis	rs9467711	0.606	rs68072215	chr6:26377927	T/C	cg16898833	chr6:26189333	HIST1H4D	1.1	5.3	0.43	5.01e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg02725872	chr8:58115012	NA	-0.38	-5.16	-0.42	9.32e-7	Developmental language disorder (linguistic errors);
TGCT	trans	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg17470723	chr8:74884337	TCEB1	0.71	6.77	0.52	4.48e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9467773	1.000	rs10484442	chr6:26555879	A/G	cg26531700	chr6:26746687	NA	0.49	4.76	0.39	5.3e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs713587	0.520	rs512419	chr2:25310155	G/T	cg01884057	chr2:25150051	NA	-0.26	-4.87	-0.4	3.36e-6	Body mass index in non-asthmatics;
TGCT	cis	rs7412746	0.611	rs66847267	chr1:150875173	C/A	cg04414720	chr1:150670196	GOLPH3L	0.37	4.46	0.37	1.81e-5	Melanoma;
TGCT	trans	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.85	-8.89	-0.62	6.01e-15	Body mass index;
TGCT	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg16414030	chr3:133502952	NA	-0.61	-9.65	-0.66	8.74e-17	Iron status biomarkers;
TGCT	cis	rs2404602	0.716	rs67204011	chr15:76846555	C/T	cg26408565	chr15:76604113	ETFA	-0.36	-4.71	-0.39	6.44e-6	Blood metabolite levels;
TGCT	cis	rs11175492	0.528	rs61931629	chr12:65027969	G/A	cg18624581	chr12:65153313	GNS	-0.84	-4.64	-0.38	8.75e-6	Platelet count;
TGCT	cis	rs2072499	0.966	rs2842864	chr1:156159217	G/A	cg25208724	chr1:156163844	SLC25A44	1.14	16.72	0.83	1.43e-33	Testicular germ cell tumor;
TGCT	cis	rs2742417	1.000	rs2742438	chr3:45743390	G/T	cg04837898	chr3:45731254	SACM1L	-0.55	-5.68	-0.45	9.22e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs8077577	0.945	rs997315	chr17:18085286	A/G	cg09161412	chr17:18057145	MYO15A	-0.64	-5.2	-0.42	7.92e-7	Obesity-related traits;
TGCT	cis	rs2832077	0.527	rs1048546	chr21:30244877	G/T	cg24692254	chr21:30365293	RNF160	-0.57	-4.82	-0.4	4.13e-6	Cognitive test performance;
TGCT	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg05890377	chr2:74357713	NA	0.42	4.92	0.4	2.68e-6	Gestational age at birth (maternal effect);
TGCT	cis	rs1371867	0.846	rs1660326	chr8:101290447	G/A	cg06002616	chr8:101225028	SPAG1	-0.57	-6.8	-0.52	3.95e-10	Atrioventricular conduction;
TGCT	cis	rs854765	0.647	rs712267	chr17:18021607	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	7.37	0.55	2.15e-11	Total body bone mineral density;
TGCT	cis	rs2730245	0.592	rs2657385	chr7:158649373	A/G	cg24397884	chr7:158709396	WDR60	0.36	4.58	0.38	1.11e-5	Height;
TGCT	cis	rs1403694	0.515	rs1622922	chr3:186449884	C/T	cg12454167	chr3:186435060	KNG1	0.46	7.19	0.54	5.47e-11	Blood protein levels;
TGCT	cis	rs1867631	1.000	rs6665859	chr1:67077555	A/T	cg13052034	chr1:66999238	SGIP1	0.59	5.11	0.42	1.18e-6	Menopause (age at onset);
TGCT	cis	rs155076	1.000	rs261431	chr13:21865738	A/G	cg14456004	chr13:21872349	NA	1.29	10.88	0.7	9.16e-20	White matter hyperintensity burden;
TGCT	cis	rs6988636	0.579	rs28528232	chr8:124189308	G/A	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs514406	0.505	rs269287	chr1:53168842	T/C	cg25767906	chr1:53392781	SCP2	-0.44	-4.83	-0.4	3.93e-6	Monocyte count;
TGCT	cis	rs1891275	0.515	rs2153653	chr10:93495926	T/A	cg07889827	chr10:93443413	NA	-0.32	-6.89	-0.53	2.53e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs2075371	1.000	rs2598286	chr7:133976029	G/A	cg11752832	chr7:134001865	SLC35B4	0.7	6.51	0.5	1.68e-9	Mean platelet volume;
TGCT	cis	rs1568889	0.838	rs7952717	chr11:28261658	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.92	10.85	0.7	1.1e-19	Bipolar disorder;
TGCT	cis	rs2075371	0.796	rs1643040	chr7:134011703	G/C	cg11752832	chr7:134001865	SLC35B4	0.72	6.22	0.49	7.09e-9	Mean platelet volume;
TGCT	cis	rs17376456	0.935	rs10036891	chr5:93171738	T/A	cg25358565	chr5:93447407	FAM172A	0.95	6.14	0.48	1.04e-8	Diabetic retinopathy;
TGCT	cis	rs6964587	0.626	rs6972945	chr7:91549576	C/G	cg17063962	chr7:91808500	NA	-0.76	-7.25	-0.55	3.94e-11	Breast cancer;
TGCT	cis	rs1372520	0.873	rs2583990	chr4:90771499	A/G	cg15133208	chr4:90757351	SNCA	-0.52	-6.26	-0.49	5.61e-9	Neuroticism;
TGCT	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg14983838	chr19:29218262	NA	0.68	4.91	0.4	2.81e-6	Methadone dose in opioid dependence;
TGCT	cis	rs6714710	0.603	rs6757357	chr2:98491750	T/C	cg26665480	chr2:98280029	ACTR1B	0.64	6.03	0.48	1.71e-8	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs77106637	0.860	rs75896506	chr11:72429579	G/A	cg17176195	chr11:71639533	LOC100133315;RNF121	0.66	4.44	0.37	2e-5	Type 2 diabetes;
TGCT	cis	rs34526934	0.524	rs1124052	chr2:177040084	G/A	cg14324370	chr2:177042789	NA	-0.92	-8.73	-0.62	1.45e-14	Obstructive sleep apnea trait (apnea hypopnea index);
TGCT	cis	rs6921919	0.583	rs7775132	chr6:28347013	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.56	-5.33	-0.43	4.48e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs425277	0.958	rs262660	chr1:2086757	A/G	cg24578937	chr1:2090814	PRKCZ	0.32	8.19	0.59	2.64e-13	Height;
TGCT	cis	rs17253792	0.749	rs17747301	chr14:56125030	C/G	cg01858014	chr14:56050164	KTN1	-0.35	-4.65	-0.39	8.23e-6	Putamen volume;
TGCT	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.53	-6.51	-0.5	1.71e-9	Longevity;Endometriosis;
TGCT	cis	rs950776	0.518	rs12910978	chr15:78810017	A/G	cg06917634	chr15:78832804	PSMA4	0.97	9.62	0.65	1.05e-16	Sudden cardiac arrest;
TGCT	cis	rs9443189	0.723	rs2748947	chr6:76437921	C/T	cg01950844	chr6:76311363	SENP6	-0.67	-4.69	-0.39	7.18e-6	Prostate cancer;
TGCT	cis	rs3796352	1.000	rs13069006	chr3:52973305	G/C	cg15956490	chr3:53032818	SFMBT1	0.61	6.11	0.48	1.17e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs4242434	0.672	rs2404654	chr8:22484949	T/C	cg03733263	chr8:22462867	KIAA1967	0.96	13.43	0.77	6.21e-26	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs7258465	0.965	rs7256534	chr19:18586791	C/T	cg06462663	chr19:18546047	ISYNA1	0.2	4.63	0.38	9.01e-6	Breast cancer;
TGCT	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10832169	0.933	rs2697821	chr11:14079358	G/A	cg04547675	chr11:13986162	SPON1	0.51	4.51	0.38	1.46e-5	Blood protein levels;
TGCT	cis	rs2486288	0.656	rs11632920	chr15:45551264	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.7	-7.09	-0.54	8.85e-11	Glomerular filtration rate;
TGCT	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg27454412	chr7:1067447	C7orf50	0.6	4.7	0.39	6.76e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs6782228	0.675	rs2253151	chr3:128330137	T/C	cg15113803	chr3:129247119	RHO	-0.16	-4.5	-0.37	1.57e-5	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
TGCT	cis	rs41271951	0.512	rs41266632	chr1:151042980	C/T	cg00666978	chr1:150947442	LASS2	0.89	4.64	0.38	8.54e-6	Blood protein levels;
TGCT	cis	rs9527	0.590	rs10883843	chr10:104947493	C/G	cg15744005	chr10:104629667	AS3MT	-0.4	-4.63	-0.38	9.04e-6	Arsenic metabolism;
TGCT	cis	rs9788682	1.000	rs35212593	chr15:78831826	G/A	cg24631222	chr15:78858424	CHRNA5	0.92	7.57	0.56	7.51e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9677476	0.908	rs7598478	chr2:232115887	C/T	cg07929768	chr2:232055508	NA	0.3	4.44	0.37	1.97e-5	Food antigen IgG levels;
TGCT	cis	rs6723226	0.806	rs6543658	chr2:32718849	G/A	cg02381751	chr2:32503542	YIPF4	0.51	4.68	0.39	7.34e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7959452	0.557	rs7980883	chr12:69778914	C/T	cg14784868	chr12:69753453	YEATS4	0.83	8.96	0.63	4.14e-15	Blood protein levels;
TGCT	cis	rs8031584	0.872	rs11634761	chr15:31243173	A/C	cg08704250	chr15:31115839	NA	-0.36	-4.99	-0.41	1.98e-6	Huntington's disease progression;
TGCT	cis	rs7666738	0.830	rs1813642	chr4:98852225	G/A	cg17366294	chr4:99064904	C4orf37	0.73	7.59	0.56	6.56e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs651907	0.535	rs11712309	chr3:101519097	T/C	cg12386194	chr3:101231763	SENP7	0.48	4.81	0.4	4.36e-6	Colorectal cancer;
TGCT	cis	rs2153535	0.580	rs9379210	chr6:8461928	C/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg15242686	chr22:24348715	GSTTP1	0.42	5.57	0.45	1.54e-7	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs12220898	0.749	rs10776553	chr10:50482929	C/T	cg09603381	chr10:49954066	WDFY4	0.38	4.52	0.38	1.4e-5	Inflammatory biomarkers;
TGCT	cis	rs9409154	0.823	rs56001232	chr9:118100133	C/T	cg14094498	chr9:119000864	PAPPA	0.26	4.69	0.39	7.2e-6	Visceral adipose tissue adjusted for BMI;
TGCT	cis	rs1483890	0.723	rs900669	chr3:69406802	T/A	cg22125112	chr3:69402811	FRMD4B	0.29	4.71	0.39	6.53e-6	Resting heart rate;
TGCT	cis	rs6840360	0.550	rs7689266	chr4:152561048	T/C	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.0	-0.58	7.69e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs4642101	0.560	rs4535210	chr3:12839617	T/G	cg05775895	chr3:12838266	CAND2	0.67	7.07	0.54	9.95e-11	QRS complex (12-leadsum);
TGCT	trans	rs365060	0.822	rs260691	chr2:109580638	C/T	cg13735819	chr19:2253850	JSRP1	-0.7	-6.64	-0.51	8.97e-10	Beard thickness;
TGCT	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg11941060	chr3:133502564	NA	-0.25	-5.23	-0.43	6.97e-7	Iron status biomarkers;
TGCT	cis	rs9372498	0.536	rs62421536	chr6:118727972	G/A	cg21191810	chr6:118973309	C6orf204	-0.37	-4.79	-0.4	4.62e-6	Diastolic blood pressure;
TGCT	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.89	0.47	3.34e-8	Height;
TGCT	cis	rs79390637	1	rs79390637	chr11:47456867	C/A	cg20307385	chr11:47447363	PSMC3	0.7	6.03	0.48	1.71e-8	Intraocular pressure;
TGCT	cis	rs62244186	0.632	rs1402751	chr3:44594030	C/A	cg02073558	chr3:44770973	ZNF501	0.61	5.94	0.47	2.73e-8	Depressive symptoms;
TGCT	cis	rs3809566	1.000	rs4775612	chr15:63332157	T/C	cg00520135	chr15:63333846	TPM1	-0.44	-5.46	-0.44	2.44e-7	Platelet count;
TGCT	cis	rs4805272	0.849	rs17591205	chr19:29321469	T/C	cg15000279	chr19:29285009	NA	-0.53	-5.71	-0.46	7.96e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
TGCT	cis	rs7666738	0.753	rs9991512	chr4:99007205	T/C	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11948739	0.610	rs2419754	chr5:130252688	T/C	cg08523029	chr5:130500466	HINT1	0.59	4.81	0.4	4.32e-6	Pediatric bone mineral content (hip);
TGCT	cis	rs7312933	0.737	rs10880261	chr12:42573822	T/C	cg19980929	chr12:42632907	YAF2	0.46	6.3	0.49	4.75e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg10047753	chr17:41438598	NA	0.91	8.44	0.6	6.86e-14	Menopause (age at onset);
TGCT	cis	rs28595532	0.920	rs115706007	chr4:119733638	C/T	cg14228332	chr4:119757509	SEC24D	1.32	6.38	0.5	3.2e-9	Cannabis dependence symptom count;
TGCT	cis	rs896854	0.812	rs12546365	chr8:95911477	T/C	cg13393036	chr8:95962371	TP53INP1	-0.58	-7.84	-0.58	1.79e-12	Type 2 diabetes;
TGCT	cis	rs9325144	0.602	rs11169100	chr12:39077861	G/T	cg26384229	chr12:38710491	ALG10B	-0.55	-5.09	-0.42	1.28e-6	Morning vs. evening chronotype;
TGCT	cis	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg13531842	chr10:38383804	ZNF37A	-0.38	-4.51	-0.38	1.49e-5	Extrinsic epigenetic age acceleration;
TGCT	cis	rs6459788	0.657	rs887627	chr7:157237391	G/A	cg03453431	chr7:157225567	NA	-0.4	-5.8	-0.46	5.3e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs12048904	0.512	rs932798	chr1:101249355	G/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.72	-5.76	-0.46	6.32e-8	Multiple sclerosis;
TGCT	cis	rs2153535	0.580	rs7341381	chr6:8470537	A/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg12310025	chr6:25882481	NA	-0.6	-5.29	-0.43	5.28e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7552404	1.000	rs12126607	chr1:76217097	G/A	cg10523679	chr1:76189770	ACADM	0.89	9.53	0.65	1.72e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9325144	0.671	rs7306605	chr12:38730471	C/T	cg26384229	chr12:38710491	ALG10B	0.61	5.58	0.45	1.46e-7	Morning vs. evening chronotype;
TGCT	cis	rs1635	0.512	rs73742545	chr6:28319023	T/G	cg15743358	chr6:28303923	ZNF323	-1.25	-6.08	-0.48	1.37e-8	Schizophrenia;
TGCT	cis	rs9611565	0.512	rs139573	chr22:42214785	G/A	cg17554472	chr22:41940697	POLR3H	-0.46	-4.69	-0.39	7.09e-6	Vitiligo;
TGCT	cis	rs981844	1.000	rs2579916	chr4:154659972	G/T	cg14289246	chr4:154710475	SFRP2	1.01	8.46	0.6	6.31e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs9467773	0.587	rs9467722	chr6:26352566	T/C	cg15659132	chr6:26577336	NA	-0.51	-5.34	-0.43	4.33e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs6582630	0.537	rs11611326	chr12:38547958	C/A	cg13010199	chr12:38710504	ALG10B	0.62	5.02	0.41	1.74e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs12908161	1.000	rs35316992	chr15:85248133	A/G	cg11189052	chr15:85197271	WDR73	0.75	6.29	0.49	5.02e-9	Schizophrenia;
TGCT	cis	rs7552404	0.924	rs1303169	chr1:76195041	T/C	cg03433033	chr1:76189801	ACADM	0.77	9.31	0.64	5.74e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs250677	0.687	rs40523	chr5:148444186	A/T	cg23229984	chr5:148520753	ABLIM3	-0.22	-5.16	-0.42	9.35e-7	Breast cancer;
TGCT	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg06238570	chr21:40685208	BRWD1	-0.81	-8.52	-0.61	4.45e-14	Cognitive function;
TGCT	cis	rs7208859	0.623	rs58908911	chr17:29244558	C/T	cg18442181	chr17:29233375	C17orf42	-0.78	-4.72	-0.39	6.16e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs6912958	0.500	rs4706287	chr6:87806496	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.69	-6.45	-0.5	2.28e-9	Monocyte percentage of white cells;
TGCT	cis	rs11098499	0.954	rs6822679	chr4:120402702	A/C	cg09307838	chr4:120376055	NA	0.69	6.64	0.51	8.97e-10	Corneal astigmatism;
TGCT	cis	rs112217694	1.000	rs112217694	chr4:104641064	G/C	cg24090629	chr4:104641072	TACR3	-0.95	-4.8	-0.4	4.45e-6	Menarche (age at onset);
TGCT	cis	rs113084984	0.642	rs35417544	chr2:11680403	C/T	cg25804072	chr2:10829725	NOL10	0.53	4.62	0.38	9.36e-6	Breast cancer;
TGCT	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg11941060	chr3:133502564	NA	-0.29	-6.14	-0.48	1.02e-8	Iron status biomarkers;
TGCT	cis	rs7267979	1.000	rs6107045	chr20:25441936	G/A	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs67460515	0.892	rs73026974	chr3:160963231	A/C	cg03342759	chr3:160939853	NMD3	-0.49	-5.3	-0.43	5.16e-7	Parkinson's disease;
TGCT	cis	rs116095464	0.558	rs10060089	chr5:205565	G/A	cg12570787	chr5:219185	SDHA;CCDC127	0.71	4.51	0.38	1.48e-5	Breast cancer;
TGCT	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg22433210	chr17:43662623	NA	0.99	7.14	0.54	7.1e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs4253772	0.637	rs9627402	chr22:46702586	C/T	cg24881330	chr22:46731750	TRMU	1.04	5.41	0.44	3.12e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs7666738	0.753	rs7657644	chr4:99057734	T/A	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.44e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7208859	0.623	rs9911997	chr17:29124648	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs17376456	0.877	rs12374470	chr5:93481046	A/G	cg21475434	chr5:93447410	FAM172A	0.64	4.71	0.39	6.42e-6	Diabetic retinopathy;
TGCT	cis	rs6952809	0.532	rs7803015	chr7:2432143	G/A	cg23289794	chr7:2394357	EIF3B	-0.83	-7.09	-0.54	8.92e-11	Multiple sclerosis;
TGCT	cis	rs11190604	1.000	rs11190569	chr10:102227409	C/T	cg23241863	chr10:102295624	HIF1AN	0.59	4.51	0.38	1.46e-5	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg22963979	chr7:1858916	MAD1L1	0.44	7.43	0.56	1.54e-11	Bipolar disorder and schizophrenia;
TGCT	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.9	-6.48	-0.5	1.91e-9	Gut microbiome composition (summer);
TGCT	cis	rs7772486	0.641	rs67882056	chr6:146416301	T/C	cg05347473	chr6:146136440	FBXO30	0.55	5.07	0.41	1.4e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs61990749	0.544	rs2544566	chr14:78181738	C/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.63	4.62	0.38	9.34e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs514406	0.644	rs928451	chr1:53195800	A/G	cg01802117	chr1:53393560	SCP2	0.42	4.92	0.4	2.69e-6	Monocyte count;
TGCT	cis	rs7918232	0.941	rs10829195	chr10:27431564	G/A	cg14442939	chr10:27389572	ANKRD26	0.72	5.35	0.43	4.16e-7	Breast cancer;
TGCT	cis	rs9677476	0.516	rs10202608	chr2:232050653	A/G	cg07929768	chr2:232055508	NA	0.32	5.05	0.41	1.53e-6	Food antigen IgG levels;
TGCT	cis	rs2070433	0.752	rs11701058	chr21:47776382	T/C	cg12379764	chr21:47803548	PCNT	0.66	5.61	0.45	1.25e-7	Lymphocyte counts;
TGCT	cis	rs7552404	0.731	rs6699682	chr1:76340123	A/G	cg03433033	chr1:76189801	ACADM	-0.77	-7.94	-0.58	1.01e-12	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs79349575	0.783	rs12453394	chr17:46994970	G/A	cg26022315	chr17:47021804	SNF8	0.49	4.89	0.4	3.03e-6	Type 2 diabetes;
TGCT	cis	rs12780845	0.540	rs2273735	chr10:17216419	T/C	cg01003015	chr10:17271136	VIM	0.53	4.64	0.38	8.56e-6	Homocysteine levels;
TGCT	cis	rs1865760	1.000	rs6938233	chr6:25914077	C/T	cg16482183	chr6:26056742	HIST1H1C	0.53	4.72	0.39	6.29e-6	Height;
TGCT	cis	rs28595532	0.920	rs114659035	chr4:119740028	C/T	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg24829409	chr8:58192753	C8orf71	-0.59	-4.97	-0.41	2.17e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7914558	1.000	rs4917994	chr10:104811699	C/T	cg15744005	chr10:104629667	AS3MT	-0.38	-4.69	-0.39	7.04e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg18538332	chr22:24372958	LOC391322	-0.82	-9.23	-0.64	9.18e-16	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs835154	1.000	rs2934814	chr5:14872689	C/T	cg14843632	chr5:14870594	ANKH	0.46	7.21	0.54	4.86e-11	Blood metabolite levels;
TGCT	cis	rs2180341	1.000	rs3798850	chr6:127613966	C/T	cg27446573	chr6:127587934	RNF146	1.13	10.12	0.67	6.64e-18	Breast cancer;
TGCT	cis	rs317865	0.737	rs16893097	chr4:16156964	G/T	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.79	5.38	0.44	3.5e-7	Kidney disease (early stage) in type 1 diabetes;
TGCT	cis	rs7666738	0.830	rs28451101	chr4:99001190	T/C	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg08859206	chr1:53392774	SCP2	-0.46	-7.57	-0.56	7.3e-12	Monocyte count;
TGCT	cis	rs7647973	0.710	rs2029591	chr3:49646981	C/T	cg03060546	chr3:49711283	APEH	-0.63	-5.19	-0.42	8.41e-7	Menarche (age at onset);
TGCT	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs10992471	0.603	rs11794346	chr9:95247288	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.61	-5.84	-0.46	4.31e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.51	-4.94	-0.41	2.5e-6	Prudent dietary pattern;
TGCT	cis	rs524281	0.861	rs7946917	chr11:65956577	A/G	cg00563793	chr11:65837595	PACS1	0.52	4.5	0.37	1.55e-5	Electroencephalogram traits;
TGCT	cis	rs7772486	0.875	rs9322046	chr6:146393625	A/G	cg05347473	chr6:146136440	FBXO30	0.52	4.86	0.4	3.48e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs887829	0.507	rs10929301	chr2:234663649	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.26	-4.45	-0.37	1.92e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
TGCT	cis	rs2710642	0.962	rs1828398	chr2:63034870	A/G	cg17519650	chr2:63277830	OTX1	-0.64	-5.86	-0.47	3.97e-8	LDL cholesterol levels;LDL cholesterol;
TGCT	cis	rs7027203	0.828	rs7037960	chr9:96584028	G/A	cg14396892	chr9:96623032	NA	-0.29	-6.22	-0.49	7.08e-9	DNA methylation (variation);
TGCT	cis	rs9467773	1.000	rs9393732	chr6:26530898	G/A	cg05738196	chr6:26577821	NA	0.88	12.5	0.75	1.03e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	0.46	5.74	0.46	6.85e-8	Alzheimer's disease;
TGCT	cis	rs9341808	0.718	rs2874829	chr6:80856097	A/G	cg08355045	chr6:80787529	NA	0.32	5.83	0.46	4.48e-8	Sitting height ratio;
TGCT	cis	rs7226408	0.857	rs11664002	chr18:34526377	C/G	cg06757138	chr18:34340585	FHOD3	0.25	4.73	0.39	6e-6	Obesity-related traits;
TGCT	cis	rs2204008	0.774	rs7959048	chr12:37948276	T/A	cg26384229	chr12:38710491	ALG10B	0.87	7.79	0.57	2.32e-12	Bladder cancer;
TGCT	cis	rs2404602	0.735	rs2468130	chr15:76796496	T/C	cg06069100	chr15:77574588	SGK269	0.26	4.64	0.38	8.81e-6	Blood metabolite levels;
TGCT	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg07298985	chr8:22133076	PIWIL2	-0.33	-5.22	-0.42	7.19e-7	Hypertriglyceridemia;
TGCT	cis	rs72627509	0.904	rs17081935	chr4:57823476	C/T	cg26694713	chr4:57773883	REST	0.73	6.49	0.5	1.89e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg04025307	chr7:1156635	C7orf50	0.24	5.58	0.45	1.43e-7	Longevity;Endometriosis;
TGCT	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg11062466	chr8:58055876	NA	0.44	4.62	0.38	9.46e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs3087591	0.960	rs2269855	chr17:29482878	G/A	cg24425628	chr17:29625626	OMG;NF1	0.48	7.48	0.56	1.16e-11	Hip circumference;
TGCT	cis	rs2762353	0.806	rs6909187	chr6:25785925	C/T	cg03517284	chr6:25882590	NA	0.48	4.86	0.4	3.42e-6	Blood metabolite levels;
TGCT	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg03732007	chr1:2071316	PRKCZ	0.28	6.63	0.51	9.05e-10	Height;
TGCT	cis	rs1401999	0.690	rs3805112	chr3:183645662	C/T	cg01324343	chr3:183735012	ABCC5	0.68	8.01	0.58	7.25e-13	Anterior chamber depth;
TGCT	trans	rs7248779	0.532	rs10153475	chr19:2413961	G/C	cg25835954	chr13:50160062	RCBTB1	0.76	7.04	0.53	1.15e-10	Cortisol levels (saliva);
TGCT	cis	rs6570726	0.791	rs11759979	chr6:145918881	C/T	cg23711669	chr6:146136114	FBXO30	0.89	9.62	0.65	1.06e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs13242816	1.000	rs62471202	chr7:116112562	G/A	cg02799643	chr7:116139180	CAV2	-0.48	-5.52	-0.44	1.87e-7	P wave duration;
TGCT	cis	rs7698623	0.867	rs4693191	chr4:88797873	C/T	cg02735620	chr4:88950514	PKD2	-0.44	-4.81	-0.4	4.22e-6	Cardiovascular disease risk factors;
TGCT	cis	rs4595586	0.545	rs1588970	chr12:39403122	C/A	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg21963583	chr11:68658836	MRPL21	0.35	5.76	0.46	6.33e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7666738	0.830	rs13139024	chr4:99020700	C/T	cg17366294	chr4:99064904	C4orf37	0.68	7.04	0.53	1.17e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12477438	0.765	rs7340412	chr2:99661148	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-7.6	-0.56	6.47e-12	Chronic sinus infection;
TGCT	cis	rs6688613	0.685	rs10800276	chr1:166858941	A/G	cg07049167	chr1:166818506	POGK	-0.24	-5.25	-0.43	6.41e-7	Refractive astigmatism;
TGCT	cis	rs9677476	0.517	rs62197322	chr2:232061520	A/G	cg07929768	chr2:232055508	NA	0.3	4.83	0.4	4.01e-6	Food antigen IgG levels;
TGCT	cis	rs9325144	0.555	rs4882359	chr12:38726679	T/C	cg26384229	chr12:38710491	ALG10B	0.65	6.06	0.48	1.55e-8	Morning vs. evening chronotype;
TGCT	cis	rs3617	0.625	rs2239548	chr3:52854186	A/C	cg11645453	chr3:52864694	ITIH4	0.28	5.45	0.44	2.63e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs13217239	0.646	rs6456767	chr6:27070543	C/T	cg05738196	chr6:26577821	NA	-0.5	-4.77	-0.39	5.05e-6	Schizophrenia;
TGCT	cis	rs9467711	0.606	rs9348712	chr6:26366511	T/A	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs832540	0.629	rs6888317	chr5:56093307	A/G	cg12311346	chr5:56204834	C5orf35	0.48	4.99	0.41	1.98e-6	Coronary artery disease;
TGCT	cis	rs12681288	0.862	rs2701898	chr8:1020812	C/T	cg06709756	chr8:1339049	NA	-0.22	-4.45	-0.37	1.88e-5	Schizophrenia;
TGCT	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg03264133	chr6:25882463	NA	0.52	5.35	0.43	4.04e-7	Blood metabolite levels;
TGCT	cis	rs12200560	0.505	rs984519	chr6:97076223	A/G	cg06623918	chr6:96969491	KIAA0776	-0.54	-4.64	-0.38	8.79e-6	Coronary heart disease;
TGCT	cis	rs6459788	0.605	rs887628	chr7:157237589	G/A	cg06271696	chr7:157225062	NA	-0.29	-5.13	-0.42	1.07e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs4319547	0.695	rs10846746	chr12:122868696	C/T	cg05707623	chr12:122985044	ZCCHC8	0.62	4.87	0.4	3.32e-6	Body mass index;
TGCT	cis	rs7429990	0.896	rs7427648	chr3:48158239	C/T	cg11946769	chr3:48343235	NME6	-0.56	-4.61	-0.38	9.72e-6	Educational attainment (years of education);
TGCT	trans	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg27523141	chr10:43048294	ZNF37B	0.73	8.58	0.61	3.32e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2404602	0.679	rs12900494	chr15:76912504	A/G	cg22467129	chr15:76604101	ETFA	-0.44	-4.98	-0.41	2.07e-6	Blood metabolite levels;
TGCT	trans	rs1814175	0.529	rs10839396	chr11:49852406	G/T	cg11707556	chr5:10655725	ANKRD33B	0.43	9.22	0.64	9.54e-16	Height;
TGCT	trans	rs7615952	0.932	rs13086087	chr3:125646281	A/C	cg07211511	chr3:129823064	LOC729375	-0.48	-8.02	-0.58	6.91e-13	Blood pressure (smoking interaction);
TGCT	cis	rs9640161	0.830	rs11768108	chr7:150064150	C/T	cg10018233	chr7:150070692	REPIN1	0.32	4.7	0.39	6.68e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs2014572	0.967	rs7259978	chr19:57756129	C/T	cg24459738	chr19:57751996	ZNF805	-0.54	-5.4	-0.44	3.21e-7	Hyperactive-impulsive symptoms;
TGCT	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs3785574	0.650	rs2070776	chr17:62007498	A/G	cg11494091	chr17:61959527	GH2	-0.43	-7.51	-0.56	9.92e-12	Height;
TGCT	cis	rs17384381	1.000	rs17384381	chr1:85897570	C/G	cg16011679	chr1:85725395	C1orf52	0.75	6.05	0.48	1.62e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg07424592	chr7:64974309	NA	1.36	8.16	0.59	3.15e-13	Diabetic kidney disease;
TGCT	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg15691649	chr6:25882328	NA	-0.35	-4.55	-0.38	1.25e-5	Blood metabolite levels;
TGCT	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg02187348	chr16:89574699	SPG7	0.61	6.57	0.51	1.25e-9	Multiple myeloma (IgH translocation);
TGCT	cis	rs9443645	0.901	rs9352664	chr6:79566162	G/T	cg05283184	chr6:79620031	NA	-0.22	-4.98	-0.41	2.11e-6	Intelligence (multi-trait analysis);
TGCT	trans	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg21659725	chr3:3221576	CRBN	0.98	15.33	0.81	2.1000000000000002e-30	Intelligence (multi-trait analysis);
TGCT	cis	rs67311347	1.000	rs1119179	chr3:40424929	A/C	cg17264618	chr3:40429014	ENTPD3	-0.32	-4.76	-0.39	5.32e-6	Renal cell carcinoma;
TGCT	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg21862992	chr11:68658383	NA	0.44	6.0	0.47	2e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9894429	0.572	rs112417725	chr17:79578219	A/G	cg18240062	chr17:79603768	NPLOC4	-0.56	-4.92	-0.4	2.67e-6	Eye color traits;
TGCT	cis	rs4595586	0.545	rs12833238	chr12:39373898	T/C	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs12142240	0.698	rs72886911	chr1:46814352	G/A	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg18252515	chr7:66147081	NA	-1.19	-7.51	-0.56	1.02e-11	Diabetic kidney disease;
TGCT	cis	rs4654899	0.802	rs17416732	chr1:21256368	T/C	cg01072550	chr1:21505969	NA	-0.47	-7.06	-0.54	1.03e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs308403	0.568	rs309358	chr4:123653926	G/A	cg10495464	chr4:123653540	BBS12;LOC729338	0.72	6.64	0.51	8.74e-10	Blood protein levels;
TGCT	cis	rs7635838	0.617	rs2606731	chr3:11291615	A/C	cg00170343	chr3:11313890	ATG7	0.67	6.23	0.49	6.74e-9	HDL cholesterol;
TGCT	cis	rs698813	0.572	rs4953076	chr2:44480950	G/C	cg00619915	chr2:44497795	NA	-0.25	-5.7	-0.46	8.13e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
TGCT	cis	rs3091242	0.902	rs36003018	chr1:25784318	A/G	cg09222892	chr1:25734099	RHCE	0.42	7.15	0.54	6.72e-11	Erythrocyte sedimentation rate;
TGCT	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg11764359	chr7:65958608	NA	0.57	5.28	0.43	5.64e-7	Aortic root size;
TGCT	cis	rs7208859	0.623	rs35916850	chr17:29011173	G/A	cg14008862	chr17:28927542	LRRC37B2	0.84	5.1	0.42	1.22e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs10489202	0.608	rs16828093	chr1:168078384	C/T	cg24449463	chr1:168025552	DCAF6	-0.5	-5.13	-0.42	1.08e-6	Schizophrenia;
TGCT	cis	rs9467711	0.516	rs501220	chr6:25873025	C/A	cg03517284	chr6:25882590	NA	-0.75	-5.06	-0.41	1.45e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2456568	0.802	rs8181578	chr11:93637442	G/A	cg16099599	chr11:93583650	C11orf90	-0.4	-5.12	-0.42	1.13e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg19723775	chr5:179050963	HNRNPH1	0.48	4.84	0.4	3.86e-6	Lung cancer;
TGCT	cis	rs7465272	0.500	rs7463655	chr8:143731034	G/C	cg24634471	chr8:143751801	JRK	0.53	5.24	0.43	6.79e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg16414030	chr3:133502952	NA	-0.7	-11.62	-0.72	1.48e-21	Iron status biomarkers;
TGCT	cis	rs3096299	0.781	rs2965819	chr16:89501030	G/T	cg08392591	chr16:89556376	ANKRD11	-0.52	-4.81	-0.4	4.26e-6	Multiple myeloma (IgH translocation);
TGCT	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg08736216	chr1:53307985	ZYG11A	0.24	4.63	0.38	8.98e-6	Monocyte count;
TGCT	cis	rs7209700	0.638	rs4629025	chr17:45337435	A/T	cg21624342	chr17:45890973	OSBPL7	0.18	5.01	0.41	1.86e-6	IgG glycosylation;
TGCT	cis	rs35146811	0.735	rs11767968	chr7:99790971	G/A	cg04778012	chr7:99775508	STAG3;GPC2	0.35	4.93	0.41	2.55e-6	Coronary artery disease;
TGCT	cis	rs4891159	0.756	rs8084155	chr18:74134952	A/G	cg24786174	chr18:74118243	ZNF516	-0.61	-9.69	-0.66	7e-17	Longevity;
TGCT	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg20573242	chr4:122745356	CCNA2	0.55	4.92	0.4	2.69e-6	Type 2 diabetes;
TGCT	cis	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg22121687	chr7:65037720	NA	-0.78	-4.7	-0.39	6.74e-6	Diabetic kidney disease;
TGCT	cis	rs2153535	0.580	rs6597327	chr6:8482157	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs10028773	0.700	rs7690338	chr4:120256468	C/G	cg09307838	chr4:120376055	NA	0.63	6.07	0.48	1.44e-8	Educational attainment;
TGCT	cis	rs7208859	0.673	rs9889968	chr17:29220128	C/A	cg18442181	chr17:29233375	C17orf42	-0.78	-4.61	-0.38	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg16624210	chr5:671434	TPPP	0.42	4.69	0.39	7.07e-6	Obesity-related traits;
TGCT	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.01	8.32	0.6	1.34e-13	Platelet count;
TGCT	cis	rs7267979	0.789	rs2260197	chr20:25284343	T/C	cg13486641	chr20:25479848	NINL	-0.16	-4.57	-0.38	1.17e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7914558	1.000	rs7071373	chr10:104771922	A/G	cg15744005	chr10:104629667	AS3MT	-0.4	-4.97	-0.41	2.21e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs9916302	0.904	rs4511574	chr17:37532916	A/G	cg15445000	chr17:37608096	MED1	0.33	4.72	0.39	6.21e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg20607798	chr8:58055168	NA	0.64	5.89	0.47	3.47e-8	Developmental language disorder (linguistic errors);
TGCT	cis	rs7772486	0.754	rs9386132	chr6:146140751	T/C	cg05347473	chr6:146136440	FBXO30	0.54	5.11	0.42	1.2e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs185694	1.000	rs185694	chr13:30885223	C/T	cg07600127	chr13:30881527	KATNAL1	0.85	6.96	0.53	1.77e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
TGCT	cis	rs6912958	0.515	rs381782	chr6:88040649	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.45	5.88	0.47	3.48e-8	Monocyte percentage of white cells;
TGCT	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg09323728	chr8:95962352	TP53INP1	-0.53	-6.88	-0.53	2.67e-10	Type 2 diabetes;
TGCT	cis	rs12681287	1.000	rs7833786	chr8:87271374	C/T	cg27223183	chr8:87520930	FAM82B	0.76	5.5	0.44	2.11e-7	Caudate activity during reward;
TGCT	trans	rs1814175	0.562	rs1794130	chr11:49903764	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.51	-0.69	7.2e-19	Height;
TGCT	cis	rs56235845	0.694	rs4532376	chr5:176774403	G/A	cg17509989	chr5:176798049	RGS14	0.57	7.78	0.57	2.49e-12	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs4918072	0.637	rs61861137	chr10:105613383	A/G	cg11005552	chr10:105648138	OBFC1	0.4	5.13	0.42	1.1e-6	Coronary artery disease;
TGCT	cis	rs6582630	0.502	rs12815350	chr12:38439921	A/T	cg26384229	chr12:38710491	ALG10B	0.85	7.59	0.56	6.74e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs6940638	0.688	rs9393795	chr6:27217719	G/C	cg15659132	chr6:26577336	NA	-0.57	-5.43	-0.44	2.81e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1505368	0.532	rs2888093	chr2:213328348	G/A	cg20637307	chr2:213403960	ERBB4	0.68	7.1	0.54	8.72e-11	Symmetrical dimethylarginine levels;
TGCT	cis	rs752010	0.714	rs10789403	chr1:42085869	G/A	cg06885757	chr1:42089581	HIVEP3	0.25	4.51	0.38	1.45e-5	Lupus nephritis in systemic lupus erythematosus;
TGCT	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg18876405	chr7:65276391	NA	0.31	4.79	0.4	4.58e-6	Aortic root size;
TGCT	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg22963979	chr7:1858916	MAD1L1	-0.42	-6.64	-0.51	8.7e-10	Schizophrenia;
TGCT	cis	rs6684514	1.000	rs10908498	chr1:156278175	T/C	cg20302342	chr1:156215951	PAQR6	0.36	4.77	0.39	5.1e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs968451	0.756	rs1007117	chr22:39675770	G/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.74	7.55	0.56	8e-12	Primary biliary cholangitis;
TGCT	cis	rs1903068	0.853	rs10012701	chr4:56002776	A/G	cg16572876	chr4:56024045	NA	0.42	4.79	0.39	4.75e-6	Endometriosis;
TGCT	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.0	0.41	1.89e-6	Menopause (age at onset);
TGCT	cis	rs9868809	0.772	rs9883469	chr3:48719637	G/A	cg00383909	chr3:49044727	WDR6	1.24	5.91	0.47	3.1e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs12643440	0.503	rs7699243	chr4:17159265	T/G	cg22650099	chr4:17144496	NA	-0.43	-4.48	-0.37	1.65e-5	Metabolite levels (Pyroglutamine);
TGCT	cis	rs11931598	0.511	rs4689576	chr4:7025523	T/C	cg26116260	chr4:7069785	GRPEL1	0.59	5.52	0.44	1.85e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs35306767	0.903	rs11253475	chr10:907262	C/A	cg26597838	chr10:835615	NA	0.75	10.61	0.69	4.13e-19	Eosinophil percentage of granulocytes;
TGCT	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg26818010	chr10:134567672	INPP5A	-0.37	-5.03	-0.41	1.69e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs4478858	0.746	rs7520439	chr1:31688721	G/C	cg00250761	chr1:31883323	NA	0.29	4.78	0.39	4.9e-6	Alcohol dependence;
TGCT	cis	rs9325144	0.647	rs7316392	chr12:39064381	T/G	cg10518543	chr12:38710700	ALG10B	-0.49	-4.59	-0.38	1.05e-5	Morning vs. evening chronotype;
TGCT	cis	rs4930561	0.714	rs1540209	chr11:67928520	A/C	cg04465784	chr11:67976953	SUV420H1	-0.41	-5.84	-0.46	4.35e-8	Breast cancer in childhood cancer survivors;IgG glycosylation;
TGCT	trans	rs17471911	0.708	rs74663457	chr10:100762323	A/G	cg03484267	chr2:207988651	KLF7	-0.53	-6.79	-0.52	4.24e-10	Neuroticism;
TGCT	cis	rs9394841	0.692	rs3218108	chr6:41902655	C/T	cg08135965	chr6:41755394	TOMM6	0.59	5.46	0.44	2.52e-7	Mean corpuscular hemoglobin;Red cell distribution width;
TGCT	cis	rs71435601	0.699	rs515135	chr2:21286057	T/C	cg16723488	chr2:21266947	APOB	0.63	4.64	0.38	8.8e-6	Cholesterol, total;
TGCT	cis	rs6665290	0.669	rs3795445	chr1:227180947	A/C	cg10327440	chr1:227177885	CDC42BPA	-0.89	-14.71	-0.8	5.67e-29	Myeloid white cell count;
TGCT	cis	rs2658782	1.000	rs2658782	chr11:93166731	T/G	cg18152523	chr11:93063302	CCDC67	-0.64	-5.15	-0.42	9.9e-7	Pulmonary function decline;
TGCT	cis	rs3617	0.539	rs9825369	chr3:52953311	T/C	cg10802521	chr3:52805072	NEK4	0.55	6.42	0.5	2.67e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4689388	0.853	rs11729672	chr4:6293838	A/G	cg00701064	chr4:6280414	WFS1	0.37	4.72	0.39	6.3e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs73058052	0.597	rs7254718	chr19:50073226	A/G	cg09250473	chr19:50168907	IRF3;BCL2L12	0.66	5.76	0.46	6.17e-8	Fibrinogen levels;
TGCT	cis	rs9467711	0.720	rs9348716	chr6:26375658	G/A	cg10795676	chr6:26370623	BTN3A2	-0.47	-4.77	-0.39	5e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs797680	0.822	rs942196	chr1:93802264	T/A	cg17826107	chr1:92977322	EVI5	-0.23	-5.07	-0.41	1.4e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs6735179	0.641	rs10164792	chr2:1753375	G/A	cg08534653	chr2:1747700	PXDN	0.54	4.54	0.38	1.34e-5	Response to antipsychotic treatment;
TGCT	cis	rs2404602	0.692	rs35999717	chr15:77193367	G/C	cg22467129	chr15:76604101	ETFA	-0.48	-5.45	-0.44	2.58e-7	Blood metabolite levels;
TGCT	trans	rs1814175	0.935	rs6485999	chr11:49658986	G/C	cg15704280	chr7:45808275	SEPT13	-0.61	-6.8	-0.52	4.02e-10	Height;
TGCT	cis	rs3782455	1.000	rs16943545	chr12:114406337	T/C	cg11813512	chr12:114660791	NA	-0.59	-4.7	-0.39	6.79e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs1982963	0.950	rs2645749	chr14:52502795	C/A	cg10843707	chr14:52510701	NID2	-0.42	-6.47	-0.5	2.07e-9	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs240764	0.853	rs10457809	chr6:100984400	C/T	cg21058520	chr6:100914733	NA	0.35	4.63	0.38	9.07e-6	Neuroticism;
TGCT	cis	rs35146811	0.806	rs1534310	chr7:99699169	A/T	cg13334819	chr7:99746414	C7orf59	-0.81	-6.92	-0.53	2.13e-10	Coronary artery disease;
TGCT	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.34	0.43	4.23e-7	Prudent dietary pattern;
TGCT	cis	rs7119	0.717	rs8033654	chr15:77825250	T/C	cg27398640	chr15:77910606	LINGO1	-0.26	-4.73	-0.39	6.02e-6	Type 2 diabetes;
TGCT	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg08439880	chr3:133502540	NA	0.35	6.91	0.53	2.3e-10	Iron status biomarkers;
TGCT	cis	rs6840360	0.571	rs4696271	chr4:152509118	G/A	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.0	-0.58	7.69e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs10488084	0.892	rs10281148	chr7:29977943	C/G	cg19198568	chr7:28997866	TRIL	0.75	4.55	0.38	1.27e-5	Estradiol levels;
TGCT	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg05215272	chr17:6899095	ALOX12	0.56	6.72	0.52	6e-10	Tonsillectomy;
TGCT	cis	rs66573146	1.000	rs67067921	chr4:6984341	A/T	cg05069807	chr4:6945702	TBC1D14	0.35	4.94	0.41	2.51e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs11264213	0.901	rs2791962	chr1:36371168	T/C	cg07093915	chr1:36184400	C1orf216	0.66	4.47	0.37	1.73e-5	Schizophrenia;
TGCT	cis	rs1005277	0.505	rs200910	chr10:38108176	C/T	cg25427524	chr10:38739819	LOC399744	-0.37	-7.41	-0.55	1.75e-11	Extrinsic epigenetic age acceleration;
TGCT	cis	rs11030122	0.547	rs10835333	chr11:3957766	A/G	cg18678763	chr11:4115507	RRM1	-0.4	-4.9	-0.4	2.95e-6	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs7772486	0.686	rs4896827	chr6:145953338	T/A	cg23711669	chr6:146136114	FBXO30	0.85	9.48	0.65	2.33e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9796	0.870	rs28501589	chr15:41282534	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.43	-5.68	-0.45	9.16e-8	Menopause (age at onset);
TGCT	cis	rs9911578	1.000	rs2531729	chr17:56539890	C/T	cg05425664	chr17:57184151	TRIM37	-0.63	-6.21	-0.49	7.48e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.45	-4.55	-0.38	1.27e-5	Mean platelet volume;
TGCT	cis	rs9911578	0.692	rs411988	chr17:56709034	G/A	cg05425664	chr17:57184151	TRIM37	-0.49	-4.67	-0.39	7.63e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs3020736	0.500	rs5996111	chr22:42493902	C/T	cg15557168	chr22:42548783	NA	0.22	5.47	0.44	2.34e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg17554472	chr22:41940697	POLR3H	-0.49	-5.26	-0.43	6.14e-7	Vitiligo;
TGCT	cis	rs939658	1.000	rs17175798	chr15:79463960	A/G	cg17916960	chr15:79447300	NA	0.54	8.98	0.63	3.58e-15	Refractive error;
TGCT	cis	rs228437	0.565	rs7754115	chr6:134938220	A/G	cg09872934	chr6:134495829	SGK1	-0.53	-4.6	-0.38	1.03e-5	Melanoma;
TGCT	trans	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg11887960	chr12:57824829	NA	1.14	9.3	0.64	6.29e-16	Lung disease severity in cystic fibrosis;
TGCT	cis	rs11122272	0.735	rs2572249	chr1:231514829	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.14	-0.54	6.86e-11	Hemoglobin concentration;
TGCT	cis	rs6912958	0.712	rs2754262	chr6:88405585	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.46	-4.48	-0.37	1.66e-5	Monocyte percentage of white cells;
TGCT	cis	rs644799	0.542	rs10831416	chr11:95467220	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.56	5.62	0.45	1.18e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7647973	1.000	rs1982861	chr3:49577665	A/G	cg05785598	chr3:49045655	WDR6	0.38	4.6	0.38	1.02e-5	Menarche (age at onset);
TGCT	cis	rs2486012	1.000	rs1636879	chr1:44428680	G/C	cg12908607	chr1:44402522	ARTN	0.75	5.88	0.47	3.49e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs17473412	1.000	rs111295980	chr5:122737257	G/A	cg15125798	chr5:122621645	NA	-0.55	-4.9	-0.4	2.98e-6	Total body bone mineral density;
TGCT	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg18402987	chr7:1209562	NA	0.81	6.94	0.53	1.9e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7631605	0.905	rs60490177	chr3:37254925	G/C	cg17445812	chr3:36986805	TRANK1	0.2	4.43	0.37	2.01e-5	Cerebrospinal P-tau181p levels;
TGCT	cis	rs12257961	0.549	rs11259613	chr10:15382515	A/C	cg10616319	chr10:15468812	NA	0.28	5.17	0.42	9.08e-7	Selective IgA deficiency;
TGCT	cis	rs9341808	0.718	rs4437429	chr6:80828592	A/G	cg08355045	chr6:80787529	NA	0.32	5.83	0.46	4.48e-8	Sitting height ratio;
TGCT	cis	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg20637647	chr7:64974828	NA	0.94	5.16	0.42	9.35e-7	Diabetic kidney disease;
TGCT	trans	rs7819412	0.806	rs10113808	chr8:10926892	C/A	cg15556689	chr8:8085844	FLJ10661	-0.78	-7.51	-0.56	9.97e-12	Triglycerides;
TGCT	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg24829409	chr8:58192753	C8orf71	-0.59	-4.97	-0.41	2.17e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg24503407	chr1:205819492	PM20D1	0.67	10.78	0.7	1.61e-19	Menarche (age at onset);
TGCT	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg22535103	chr8:58192502	C8orf71	-0.41	-4.81	-0.4	4.27e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2075165	0.901	rs2296374	chr1:156287403	T/C	cg20302342	chr1:156215951	PAQR6	0.36	5.36	0.43	3.93e-7	Tonsillectomy;
TGCT	cis	rs8103278	0.793	rs59093775	chr19:46374037	G/A	cg14061069	chr19:46274453	DMPK	-0.41	-5.33	-0.43	4.56e-7	Coronary artery disease;
TGCT	cis	rs6933660	0.800	rs2046371	chr6:151754744	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.6	5.62	0.45	1.22e-7	Menarche (age at onset);
TGCT	cis	rs2095921	1	rs2095921	chr1:11033322	C/G	cg02454025	chr1:11042201	C1orf127	0.94	11.31	0.71	8.14e-21	Male-pattern baldness;
TGCT	cis	rs9329221	0.868	rs7831557	chr8:10280228	C/T	cg21775007	chr8:11205619	TDH	-0.46	-4.55	-0.38	1.24e-5	Neuroticism;
TGCT	cis	rs1801251	1.000	rs1044480	chr2:233633736	A/G	cg25237894	chr2:233734115	C2orf82	0.31	5.62	0.45	1.21e-7	Coronary artery disease;
TGCT	cis	rs36051895	0.553	rs12338854	chr9:5057568	G/C	cg02405213	chr9:5042618	JAK2	-0.78	-11.19	-0.71	1.59e-20	Pediatric autoimmune diseases;
TGCT	cis	rs2832191	0.791	rs8134407	chr21:30476586	G/A	cg08807101	chr21:30365312	RNF160	0.67	6.26	0.49	5.8e-9	Dental caries;
TGCT	cis	rs2120019	1.000	rs35736167	chr15:75332002	T/G	cg09165964	chr15:75287851	SCAMP5	-1.14	-10.22	-0.68	3.76e-18	Blood trace element (Zn levels);
TGCT	cis	rs67311347	0.544	rs6762121	chr3:40355313	G/A	cg17264618	chr3:40429014	ENTPD3	0.3	4.48	0.37	1.69e-5	Renal cell carcinoma;
TGCT	cis	rs2673604	0.600	rs2442975	chr8:133415445	T/A	cg05740582	chr8:133573933	HPYR1	-0.31	-4.48	-0.37	1.65e-5	Interleukin-8 levels;
TGCT	cis	rs9611565	0.649	rs79005	chr22:41835544	G/A	cg06481639	chr22:41940642	POLR3H	0.69	5.92	0.47	2.95e-8	Vitiligo;
TGCT	cis	rs9611565	0.694	rs11090056	chr22:42095904	A/C	cg17554472	chr22:41940697	POLR3H	0.46	4.91	0.4	2.82e-6	Vitiligo;
TGCT	cis	rs6831352	0.918	rs17218141	chr4:100055908	T/C	cg12011299	chr4:100065546	ADH4	-0.4	-4.88	-0.4	3.26e-6	Alcohol dependence;
TGCT	cis	rs7666738	0.830	rs13110498	chr4:98959150	G/A	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10489525	0.687	rs61811044	chr1:115350808	C/T	cg12756093	chr1:115239321	AMPD1	-0.49	-4.51	-0.38	1.47e-5	Autism;
TGCT	cis	rs79387448	0.745	rs17027421	chr2:103159882	A/G	cg09003973	chr2:102972529	NA	0.92	5.89	0.47	3.39e-8	Gut microbiota (bacterial taxa);
TGCT	cis	rs708547	0.836	rs1612191	chr4:57724320	A/C	cg25525207	chr4:57843836	C4orf14;POLR2B	0.52	4.44	0.37	2e-5	Response to bleomycin (chromatid breaks);
TGCT	cis	rs611744	0.870	rs650925	chr8:109196725	T/C	cg21045802	chr8:109455806	TTC35	0.68	6.03	0.48	1.72e-8	Dupuytren's disease;
TGCT	cis	rs8064299	0.574	rs1879455	chr17:72774738	C/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.89	9.97	0.67	1.51e-17	Monocyte count;
TGCT	cis	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg02380750	chr20:61661411	NA	0.34	6.02	0.48	1.86e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs6545883	0.929	rs10190332	chr2:61619267	T/G	cg15711740	chr2:61764176	XPO1	0.5	4.46	0.37	1.78e-5	Tuberculosis;
TGCT	cis	rs7666738	0.800	rs13107147	chr4:99028753	C/T	cg18180107	chr4:99064573	C4orf37	0.55	5.13	0.42	1.1e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs13191362	0.507	rs2846566	chr6:163059714	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.58	-5.11	-0.42	1.17e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg13395646	chr4:1353034	KIAA1530	-0.58	-7.97	-0.58	9.03e-13	Obesity-related traits;
TGCT	cis	rs7586879	0.598	rs6545806	chr2:25124348	G/A	cg15423357	chr2:25149977	NA	0.5	4.89	0.4	3.06e-6	Body mass index;
TGCT	cis	rs476633	0.708	rs9888708	chr15:41446030	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.66	-8.77	-0.62	1.18e-14	Glomerular filtration rate (creatinine);
TGCT	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg09359103	chr1:154839909	KCNN3	-0.65	-12.61	-0.75	5.72e-24	Prostate cancer;
TGCT	cis	rs10540	1.000	rs35996687	chr11:458595	G/A	cg03934478	chr11:495069	RNH1	0.34	5.3	0.43	5.01e-7	Body mass index;
TGCT	cis	rs17068510	0.572	rs73503257	chr8:3875692	A/C	cg25338036	chr8:3047536	CSMD1	-0.46	-4.88	-0.4	3.19e-6	Cerebrospinal fluid clusterin levels;
TGCT	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg18876405	chr7:65276391	NA	0.36	5.58	0.45	1.46e-7	Aortic root size;
TGCT	cis	rs7681440	0.904	rs2301135	chr4:90758389	G/C	cg26578617	chr4:90757533	SNCA	-0.48	-4.95	-0.41	2.35e-6	Dementia with Lewy bodies;
TGCT	cis	rs11711311	0.955	rs7650764	chr3:113414439	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.66	-5.85	-0.46	4.13e-8	IgG glycosylation;
TGCT	cis	rs11578119	0.933	rs4294468	chr1:170433781	G/A	cg09767346	chr1:170501363	GORAB	-0.72	-5.74	-0.46	6.97e-8	Male-pattern baldness;
TGCT	cis	rs9303401	0.580	rs34076823	chr17:57114497	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.65	6.06	0.48	1.54e-8	Cognitive test performance;
TGCT	cis	rs950169	0.845	rs4106951	chr15:84833394	C/G	cg12863693	chr15:85201151	NMB	0.41	4.47	0.37	1.77e-5	Schizophrenia;
TGCT	cis	rs7539409	0.915	rs4001467	chr1:84275858	A/T	cg10977910	chr1:84465055	TTLL7	-0.94	-5.4	-0.44	3.26e-7	Alzheimer's disease;
TGCT	cis	rs8068544	0.818	rs7209012	chr17:40161323	C/T	cg13092355	chr17:39992602	KLHL10;NT5C3L	-0.96	-4.47	-0.37	1.72e-5	Reticulocyte fraction of red cells;Reticulocyte count;
TGCT	cis	rs11098499	0.874	rs9995277	chr4:120108603	G/A	cg09307838	chr4:120376055	NA	0.5	4.57	0.38	1.14e-5	Corneal astigmatism;
TGCT	trans	rs1814175	0.817	rs4881648	chr11:49812901	A/G	cg15704280	chr7:45808275	SEPT13	-0.72	-8.14	-0.59	3.61e-13	Height;
TGCT	cis	rs7017914	0.905	rs2732104	chr8:71923519	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.56	-5.11	-0.42	1.21e-6	Bone mineral density;
TGCT	cis	rs16865717	1.000	rs12991466	chr2:7029725	C/A	cg20486407	chr2:7037101	RSAD2	-0.38	-5.03	-0.41	1.66e-6	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg04546413	chr19:29218101	NA	0.84	7.96	0.58	9.36e-13	Methadone dose in opioid dependence;
TGCT	trans	rs877282	0.898	rs11253341	chr10:765008	G/C	cg22713356	chr15:30763199	NA	1.2	9.39	0.64	3.76e-16	Uric acid levels;
TGCT	cis	rs3796352	1.000	rs33999310	chr3:52883332	G/A	cg07884673	chr3:53033167	SFMBT1	0.62	5.35	0.43	4.16e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs7208859	0.623	rs59029591	chr17:29235746	A/C	cg18442181	chr17:29233375	C17orf42	-0.78	-4.61	-0.38	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs1395	0.744	rs62130714	chr2:27532870	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.62	8.01	0.58	7.07e-13	Blood metabolite levels;
TGCT	cis	rs478304	0.651	rs11227281	chr11:65496558	T/C	cg17480646	chr11:65405466	SIPA1	-0.57	-6.93	-0.53	2.05e-10	Acne (severe);
TGCT	cis	rs9393692	0.905	rs9393693	chr6:26277408	C/A	cg13736514	chr6:26305472	NA	-0.37	-5.42	-0.44	3.01e-7	Educational attainment;
TGCT	cis	rs2204008	0.506	rs11495470	chr12:38026904	C/T	cg26384229	chr12:38710491	ALG10B	0.85	7.77	0.57	2.55e-12	Bladder cancer;
TGCT	cis	rs3824867	0.920	rs4282946	chr11:47456202	G/A	cg20307385	chr11:47447363	PSMC3	0.7	6.03	0.48	1.71e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs3733585	0.699	rs6844787	chr4:9959233	A/G	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.67	-0.51	7.44e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7659604	0.605	rs67772833	chr4:122723106	G/A	cg06713675	chr4:122721982	EXOSC9	-0.62	-8.63	-0.61	2.45e-14	Type 2 diabetes;
TGCT	cis	rs9296092	0.538	rs34222093	chr6:33519584	G/C	cg13560919	chr6:33536144	NA	-0.21	-4.75	-0.39	5.5e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs7552404	1.000	rs211718	chr1:76106675	C/T	cg10523679	chr1:76189770	ACADM	0.9	9.81	0.66	3.56e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7772486	0.754	rs857881	chr6:145970793	C/A	cg23711669	chr6:146136114	FBXO30	-0.92	-10.11	-0.67	6.66e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg06636001	chr8:8085503	FLJ10661	0.77	7.37	0.55	2.12e-11	Mood instability;
TGCT	cis	rs1018836	0.770	rs4324886	chr8:91651943	A/G	cg16814680	chr8:91681699	NA	-0.93	-10.81	-0.7	1.35e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2075371	0.796	rs7780583	chr7:133960716	C/G	cg11752832	chr7:134001865	SLC35B4	0.66	5.5	0.44	2.09e-7	Mean platelet volume;
TGCT	cis	rs12530845	1.000	rs77068811	chr7:135334571	A/G	cg23117316	chr7:135346802	PL-5283	-0.51	-4.83	-0.4	3.98e-6	Red blood cell traits;
TGCT	cis	rs17376456	0.877	rs10078194	chr5:93364310	A/C	cg21475434	chr5:93447410	FAM172A	0.6	4.73	0.39	6.08e-6	Diabetic retinopathy;
TGCT	cis	rs45430	1.000	rs408825	chr21:42743496	A/G	cg22778903	chr21:42741698	MX2	-0.32	-5.37	-0.43	3.67e-7	Melanoma;
TGCT	cis	rs185694	0.947	rs169331	chr13:30878695	G/T	cg07600127	chr13:30881527	KATNAL1	-0.88	-6.7	-0.52	6.43e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
TGCT	cis	rs2795502	0.882	rs2744091	chr10:43339441	A/G	cg20628663	chr10:43360327	NA	-0.42	-6.12	-0.48	1.12e-8	Blood protein levels;
TGCT	cis	rs1577917	0.958	rs12190603	chr6:86475718	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-5.22	-0.42	7.42e-7	Response to antipsychotic treatment;
TGCT	cis	rs7914558	0.966	rs1591915	chr10:104646849	C/T	cg04362960	chr10:104952993	NT5C2	0.58	5.16	0.42	9.65e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs7647973	0.961	rs7626076	chr3:49298139	G/A	cg07636037	chr3:49044803	WDR6	0.7	5.64	0.45	1.11e-7	Menarche (age at onset);
TGCT	cis	rs1568889	0.838	rs7131379	chr11:28085789	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.92	11.35	0.71	6.62e-21	Bipolar disorder;
TGCT	cis	rs73110464	0.609	rs4919752	chr12:53359229	G/C	cg16329197	chr12:53359506	NA	-0.57	-7.96	-0.58	9.34e-13	Cancer (pleiotropy);
TGCT	cis	rs986417	0.711	rs761556	chr14:61061034	T/G	cg27398547	chr14:60952738	C14orf39	1.41	8.43	0.6	7.41e-14	Gut microbiota (bacterial taxa);
TGCT	cis	rs4972806	0.849	rs2857535	chr2:177036211	G/A	cg14324370	chr2:177042789	NA	0.74	6.8	0.52	3.87e-10	IgG glycosylation;
TGCT	cis	rs13102973	0.564	rs4418034	chr4:135886650	T/A	cg14419869	chr4:135874104	NA	0.26	4.6	0.38	1.03e-5	Subjective well-being;
TGCT	cis	rs55692411	0.517	rs62262106	chr3:49991427	A/G	cg14019146	chr3:50243930	SLC38A3	-0.21	-4.44	-0.37	1.98e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs3806843	0.547	rs246054	chr5:140326159	G/A	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs62244186	0.659	rs9855433	chr3:44468065	C/A	cg21672276	chr3:44754072	ZNF502	-0.43	-4.84	-0.4	3.81e-6	Depressive symptoms;
TGCT	cis	rs7523273	0.606	rs2796266	chr1:207922945	C/T	cg22525895	chr1:207977042	MIR29B2	-0.52	-8.36	-0.6	1.09e-13	Schizophrenia;
TGCT	cis	rs736801	0.891	rs11242115	chr5:131826413	G/C	cg02551604	chr5:131831745	NA	0.57	4.71	0.39	6.64e-6	Breast cancer;Mosquito bite size;
TGCT	cis	rs6570726	0.791	rs425999	chr6:145819370	C/A	cg05347473	chr6:146136440	FBXO30	0.53	4.95	0.41	2.4e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6867032	0.958	rs4975798	chr5:2015580	G/A	cg26168224	chr5:2018326	NA	0.43	7.82	0.57	2e-12	Gut microbiome composition (winter);
TGCT	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg10802521	chr3:52805072	NEK4	-0.73	-8.94	-0.63	4.43e-15	Bipolar disorder;
TGCT	cis	rs7264396	0.790	rs3787168	chr20:34233278	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.25	-0.43	6.33e-7	Total cholesterol levels;
TGCT	cis	rs10466239	0.730	rs2245413	chr10:43850568	C/T	cg08951903	chr10:44070173	ZNF239	0.8	4.79	0.4	4.67e-6	Telomere length;
TGCT	cis	rs9357506	1.000	rs9395174	chr6:46313100	A/C	cg21115430	chr6:46460003	NA	-0.23	-4.62	-0.38	9.28e-6	Body mass index;
TGCT	cis	rs6835098	0.520	rs2127896	chr4:174211285	G/A	cg08422745	chr4:174089978	GALNT7	-0.53	-4.61	-0.38	9.8200000000000008e-06	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs9393777	0.513	rs9393741	chr6:26654189	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.59	-4.66	-0.39	8.03e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2299587	0.662	rs7816769	chr8:17768548	G/T	cg01800426	chr8:17659068	MTUS1	0.62	5.31	0.43	5e-7	Economic and political preferences;
TGCT	cis	rs11644362	1.000	rs3843707	chr16:12996788	G/A	cg06890432	chr16:12997467	SHISA9	-0.61	-6.49	-0.5	1.85e-9	Positive affect;Subjective well-being;
TGCT	cis	rs5769765	0.671	rs138833	chr22:50178917	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.93	-8.67	-0.61	2.04e-14	Schizophrenia;
TGCT	cis	rs9479482	1.000	rs9479481	chr6:150357944	A/G	cg03788504	chr6:150331562	NA	-0.24	-4.58	-0.38	1.12e-5	Alopecia areata;
TGCT	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg18876405	chr7:65276391	NA	0.36	5.36	0.43	3.97e-7	Aortic root size;
TGCT	cis	rs7000551	0.725	rs2249102	chr8:22400193	C/G	cg12081754	chr8:22256438	SLC39A14	0.28	4.52	0.38	1.4e-5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs6088590	0.603	rs6579186	chr20:33282198	G/C	cg06115741	chr20:33292138	TP53INP2	0.56	4.7	0.39	6.83e-6	Coronary artery disease;
TGCT	cis	rs34014631	0.786	rs74910253	chr10:103658324	T/C	cg22630918	chr10:102748988	C10orf2	0.42	4.82	0.4	4.15e-6	Coronary artery calcification;
TGCT	cis	rs5760092	0.755	rs5760096	chr22:24247310	A/G	cg23131131	chr22:24373011	LOC391322	-0.52	-4.51	-0.38	1.51e-5	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs9527	0.641	rs10786732	chr10:104762535	T/C	cg04362960	chr10:104952993	NT5C2	0.68	5.7	0.46	8.14e-8	Arsenic metabolism;
TGCT	cis	rs7829975	0.777	rs486781	chr8:8639740	A/G	cg15556689	chr8:8085844	FLJ10661	-0.71	-6.23	-0.49	6.8e-9	Mood instability;
TGCT	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg13770153	chr20:60521292	NA	-0.54	-6.99	-0.53	1.51e-10	Body mass index;
TGCT	cis	rs2067615	0.579	rs4964486	chr12:107140790	A/G	cg15890332	chr12:107067104	RFX4	0.3	5.93	0.47	2.85e-8	Heart rate;
TGCT	cis	rs2688608	0.588	rs10128205	chr10:75469648	C/G	cg23231163	chr10:75533350	FUT11	-0.28	-4.58	-0.38	1.12e-5	Inflammatory bowel disease;
TGCT	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg18876405	chr7:65276391	NA	0.41	6.53	0.51	1.55e-9	Aortic root size;
TGCT	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg18230493	chr5:56204884	C5orf35	-0.68	-5.92	-0.47	2.92e-8	Initial pursuit acceleration;
TGCT	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg20203395	chr5:56204925	C5orf35	-0.56	-4.8	-0.4	4.39e-6	Initial pursuit acceleration;
TGCT	cis	rs7223966	0.921	rs3020612	chr17:61960878	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	5.32	0.43	4.68e-7	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs367615	0.660	rs10061221	chr5:108839038	C/T	cg17395555	chr5:108820864	NA	0.31	5.86	0.47	3.94e-8	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs42648	0.870	rs7783199	chr7:89999305	G/A	cg25739043	chr7:89950458	NA	0.65	6.22	0.49	6.96e-9	Homocysteine levels;
TGCT	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-5.09	-0.42	1.29e-6	Electroencephalogram traits;
TGCT	cis	rs10791097	1.000	rs10791098	chr11:130718711	T/G	cg12179176	chr11:130786555	SNX19	0.65	6.88	0.53	2.57e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs12976411	0.558	rs61027832	chr19:32972530	C/A	cg09385032	chr19:32252709	NA	-0.37	-4.45	-0.37	1.92e-5	Coronary artery disease;
TGCT	cis	rs7246657	0.943	rs7252346	chr19:37914682	G/A	cg18154014	chr19:37997991	ZNF793	0.73	5.38	0.44	3.53e-7	Coronary artery calcification;
TGCT	cis	rs17221829	0.673	rs4753228	chr11:89369157	G/A	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.63	-0.38	9.04e-6	Anxiety in major depressive disorder;
TGCT	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg21724239	chr8:58056113	NA	0.48	5.17	0.42	9.18e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg24503407	chr1:205819492	PM20D1	0.67	10.76	0.69	1.83e-19	Menarche (age at onset);
TGCT	cis	rs2455799	0.613	rs11713820	chr3:15866590	A/G	cg16303742	chr3:15540471	COLQ	0.25	4.74	0.39	5.65e-6	Mean platelet volume;
TGCT	cis	rs1577917	0.958	rs12213331	chr6:86504797	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.23	-0.43	7.01e-7	Response to antipsychotic treatment;
TGCT	cis	rs1018836	0.923	rs756569	chr8:91610957	G/A	cg16814680	chr8:91681699	NA	-0.9	-9.66	-0.66	8.52e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2932538	0.961	rs4839257	chr1:113219388	A/T	cg22162597	chr1:113214053	CAPZA1	-0.26	-5.52	-0.44	1.86e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs1577917	0.958	rs12198061	chr6:86550985	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.29	-0.43	5.34e-7	Response to antipsychotic treatment;
TGCT	cis	rs13256369	1.000	rs7843488	chr8:8576217	C/T	cg18904891	chr8:8559673	CLDN23	0.63	5.84	0.46	4.38e-8	Obesity-related traits;
TGCT	cis	rs9527	0.590	rs10883839	chr10:104920341	A/G	cg04362960	chr10:104952993	NT5C2	0.69	5.75	0.46	6.43e-8	Arsenic metabolism;
TGCT	cis	rs1218582	0.772	rs2061690	chr1:154919080	C/T	cg24250549	chr1:154909240	PMVK	0.6	6.04	0.48	1.67e-8	Prostate cancer;
TGCT	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg11764359	chr7:65958608	NA	-0.53	-4.74	-0.39	5.87e-6	Aortic root size;
TGCT	cis	rs2832077	0.506	rs2832085	chr21:30155258	G/T	cg24692254	chr21:30365293	RNF160	-0.59	-5.18	-0.42	8.61e-7	Cognitive test performance;
TGCT	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg18402987	chr7:1209562	NA	0.39	4.48	0.37	1.67e-5	Longevity;Endometriosis;
TGCT	cis	rs8017423	0.967	rs7150093	chr14:90724661	C/T	cg04374321	chr14:90722782	PSMC1	-0.76	-7.69	-0.57	3.88e-12	Mortality in heart failure;
TGCT	cis	rs2228479	0.850	rs45524643	chr16:89815824	G/A	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs6430585	0.528	rs12464050	chr2:136663110	G/T	cg07169764	chr2:136633963	MCM6	1.25	12.4	0.74	1.85e-23	Corneal structure;
TGCT	cis	rs1451375	1.000	rs6949897	chr7:50621920	C/T	cg18232548	chr7:50535776	DDC	0.43	6.8	0.52	3.98e-10	Malaria;
TGCT	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	16.07	0.82	4.21e-32	Prudent dietary pattern;
TGCT	cis	rs9733	0.526	rs11204698	chr1:150659545	G/A	cg09365446	chr1:150670422	GOLPH3L	0.31	4.64	0.38	8.7e-6	Tonsillectomy;
TGCT	trans	rs608114	0.793	rs472816	chr6:96380745	G/C	cg04008557	chr11:2826328	KCNQ1	-0.65	-6.82	-0.52	3.51e-10	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
TGCT	cis	rs1215050	0.791	rs4699318	chr4:98664370	T/G	cg17366294	chr4:99064904	C4orf37	-0.52	-5.51	-0.44	1.97e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2404602	0.692	rs7174673	chr15:77071998	T/C	cg22467129	chr15:76604101	ETFA	-0.45	-5.11	-0.42	1.18e-6	Blood metabolite levels;
TGCT	cis	rs62244186	0.541	rs9859879	chr3:44840166	G/A	cg11003573	chr3:44754125	ZNF502	-0.47	-5.5	-0.44	2.08e-7	Depressive symptoms;
TGCT	cis	rs3858526	0.635	rs2045046	chr11:5875867	A/C	cg05234568	chr11:5960015	NA	-0.49	-4.69	-0.39	7.16e-6	DNA methylation (variation);
TGCT	cis	rs17401966	0.898	rs12757288	chr1:10323921	T/C	cg19773385	chr1:10388646	KIF1B	-0.2	-4.5	-0.37	1.54e-5	Hepatocellular carcinoma;
TGCT	cis	rs981844	0.775	rs17371545	chr4:154763980	A/G	cg14289246	chr4:154710475	SFRP2	-0.96	-7.75	-0.57	2.85e-12	Response to statins (LDL cholesterol change);
TGCT	trans	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg21659725	chr3:3221576	CRBN	0.73	8.19	0.59	2.76e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg22166914	chr1:53195759	ZYG11B	0.39	6.35	0.5	3.71e-9	Monocyte count;
TGCT	cis	rs4727027	0.899	rs6944096	chr7:148870026	A/G	cg23583168	chr7:148888333	NA	-0.79	-10.43	-0.68	1.14e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs2019216	0.500	rs71371082	chr17:21889647	T/C	cg22648282	chr17:21454238	C17orf51	-0.56	-5.07	-0.41	1.42e-6	Pelvic organ prolapse;
TGCT	cis	rs7208859	0.623	rs59447372	chr17:29057585	C/T	cg14008862	chr17:28927542	LRRC37B2	0.77	4.59	0.38	1.08e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	trans	rs877282	1.000	rs11253369	chr10:773610	C/G	cg22713356	chr15:30763199	NA	1.08	9.57	0.65	1.4e-16	Uric acid levels;
TGCT	cis	rs3617	0.572	rs2256332	chr3:52855865	A/G	cg11645453	chr3:52864694	ITIH4	-0.28	-5.43	-0.44	2.86e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6570726	0.755	rs451699	chr6:145830594	C/G	cg23711669	chr6:146136114	FBXO30	0.89	9.72	0.66	6.02e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1215050	0.791	rs1727278	chr4:98853576	A/G	cg17366294	chr4:99064904	C4orf37	-0.57	-6.12	-0.48	1.13e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2851682	0.706	rs2072113	chr11:61604967	C/T	cg20584555	chr11:61717780	BEST1	-0.34	-4.8	-0.4	4.42e-6	Gestational age at birth (child effect);Trans fatty acid levels;
TGCT	cis	rs8014204	0.869	rs2070599	chr14:75361177	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.7	-6.69	-0.52	6.76e-10	Caffeine consumption;
TGCT	cis	rs66561647	0.719	rs7821928	chr8:128939295	G/A	cg05480350	chr8:128972681	MIR1205;PVT1	0.21	4.45	0.37	1.87e-5	Hemoglobin concentration;
TGCT	cis	rs9372253	1.000	rs11153232	chr6:110716252	G/T	cg13266496	chr6:110720918	DDO	0.46	5.68	0.45	8.89e-8	Platelet distribution width;
TGCT	cis	rs2280018	0.526	rs1510148	chr16:15167379	T/A	cg07549590	chr16:15018862	NA	-0.31	-4.84	-0.4	3.86e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs55794721	0.509	rs12027135	chr1:25775733	A/T	cg10117171	chr1:25599238	RHD	-0.32	-5.17	-0.42	9.25e-7	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs854765	0.534	rs7207461	chr17:17949789	T/G	cg09796270	chr17:17721594	SREBF1	-0.24	-4.7	-0.39	6.8e-6	Total body bone mineral density;
TGCT	cis	rs1008375	0.932	rs13109475	chr4:17677565	C/G	cg16339924	chr4:17578868	LAP3	-0.59	-4.82	-0.4	4.05e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1056053	0.514	rs3099269	chr6:166572242	T/A	cg17219086	chr6:166541254	NA	-0.19	-4.51	-0.38	1.51e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs7095607	0.777	rs7905579	chr10:69926594	G/T	cg18986048	chr10:69913749	MYPN	0.44	5.03	0.41	1.68e-6	Lung function (FVC);
TGCT	cis	rs4389656	0.857	rs274703	chr5:6728372	A/C	cg10857441	chr5:6722123	POLS	-0.22	-4.74	-0.39	5.75e-6	Coronary artery disease;
TGCT	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.94	10.77	0.7	1.71e-19	Platelet count;
TGCT	cis	rs1538970	0.816	rs10789464	chr1:45959102	C/T	cg05343316	chr1:45956843	TESK2	0.81	6.64	0.51	8.93e-10	Platelet count;
TGCT	cis	rs2637266	0.905	rs4357630	chr10:78382883	T/G	cg18941641	chr10:78392320	NA	0.39	4.77	0.39	5.16e-6	Pulmonary function;
TGCT	cis	rs600231	0.665	rs1616810	chr11:65220105	A/G	cg21890820	chr11:65308645	LTBP3	0.38	4.68	0.39	7.36e-6	Bone mineral density;
TGCT	cis	rs2227564	0.620	rs7098573	chr10:75580014	G/A	cg19442545	chr10:75533431	FUT11	-0.32	-4.66	-0.39	8.03e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs2033711	0.936	rs7257999	chr19:58964860	C/G	cg13877915	chr19:58951672	ZNF132	0.83	9.21	0.64	1.03e-15	Uric acid clearance;
TGCT	cis	rs700651	0.856	rs9288280	chr2:198744324	A/G	cg00792783	chr2:198669748	PLCL1	0.56	5.08	0.42	1.35e-6	Intracranial aneurysm;
TGCT	cis	rs7523273	0.512	rs2761435	chr1:207918466	C/G	cg22525895	chr1:207977042	MIR29B2	0.45	7.19	0.54	5.4e-11	Schizophrenia;
TGCT	cis	rs72781680	0.898	rs72782138	chr2:24048162	T/C	cg08917208	chr2:24149416	ATAD2B	0.8	4.93	0.4	2.62e-6	Lymphocyte counts;
TGCT	cis	rs1505368	0.562	rs7569142	chr2:213294557	C/T	cg16329650	chr2:213403929	ERBB4	0.67	6.28	0.49	5.25e-9	Symmetrical dimethylarginine levels;
TGCT	cis	rs936229	0.656	rs12898397	chr15:75130093	T/C	cg10253484	chr15:75165896	SCAMP2	-0.51	-4.7	-0.39	6.93e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
TGCT	cis	rs9467603	1.000	rs9467600	chr6:25792768	C/T	cg16898833	chr6:26189333	HIST1H4D	1.16	5.51	0.44	2.03e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7781977	0.960	rs17732497	chr7:50336073	C/A	cg01139861	chr7:50343298	IKZF1	0.56	6.04	0.48	1.63e-8	IgG glycosylation;
TGCT	cis	rs4972806	0.849	rs2857541	chr2:177029086	C/T	cg14324370	chr2:177042789	NA	0.74	6.89	0.53	2.53e-10	IgG glycosylation;
TGCT	cis	rs12950390	0.853	rs66471233	chr17:45867086	C/T	cg24803719	chr17:45855879	NA	-0.49	-5.03	-0.41	1.64e-6	IgG glycosylation;
TGCT	cis	rs17761864	0.959	rs16952025	chr17:2116798	C/T	cg02171503	chr17:1588363	PRPF8	0.48	4.67	0.39	7.86e-6	Esophageal cancer (squamous cell);
TGCT	cis	rs10464366	0.544	rs953874	chr7:39147916	G/A	cg18850127	chr7:39170497	POU6F2	0.32	6.94	0.53	1.97e-10	IgG glycosylation;
TGCT	cis	rs2721195	1.000	rs6599530	chr8:145677418	C/G	cg11211951	chr8:145729740	GPT	-0.22	-4.99	-0.41	1.95e-6	Age at first birth;
TGCT	trans	rs8073060	0.586	rs225264	chr17:33961335	A/G	cg19694781	chr19:47549865	TMEM160	-0.6	-13.37	-0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs9393692	0.967	rs6456712	chr6:26302573	A/C	cg05868516	chr6:26286170	HIST1H4H	0.62	5.85	0.46	4.17e-8	Educational attainment;
TGCT	cis	rs6484504	0.576	rs2756191	chr11:31135882	A/T	cg26647111	chr11:31128758	NA	0.32	4.53	0.38	1.39e-5	Red blood cell count;
TGCT	cis	rs2153535	0.580	rs2184582	chr6:8447793	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.76	0.46	6.39e-8	Motion sickness;
TGCT	cis	rs826838	0.934	rs10875647	chr12:38856995	G/A	cg13010199	chr12:38710504	ALG10B	0.82	6.85	0.52	3e-10	Heart rate;
TGCT	cis	rs3749237	0.595	rs6784820	chr3:49450864	C/T	cg03060546	chr3:49711283	APEH	-0.76	-8.82	-0.62	8.61e-15	Resting heart rate;
TGCT	cis	rs9303401	0.659	rs62081315	chr17:56781468	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.59	5.99	0.47	2.08e-8	Cognitive test performance;
TGCT	cis	rs6570726	0.526	rs4895674	chr6:145735860	T/G	cg23711669	chr6:146136114	FBXO30	-0.53	-4.72	-0.39	6.31e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9467773	0.620	rs9461276	chr6:26595168	T/C	cg02458000	chr6:26745757	NA	0.51	4.77	0.39	5.08e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1401999	1.000	rs6804242	chr3:183659463	A/T	cg01324343	chr3:183735012	ABCC5	0.82	10.93	0.7	6.83e-20	Anterior chamber depth;
TGCT	cis	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg18252515	chr7:66147081	NA	-1.2	-7.83	-0.58	1.89e-12	Diabetic kidney disease;
TGCT	cis	rs9329221	0.905	rs13254263	chr8:10255181	A/G	cg21775007	chr8:11205619	TDH	-0.53	-4.8	-0.4	4.5e-6	Neuroticism;
TGCT	cis	rs6904897	0.563	rs6569976	chr6:135224753	A/C	cg22676075	chr6:135203613	NA	0.64	6.94	0.53	1.95e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs7937682	0.883	rs529529	chr11:111461128	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.99	-10.02	-0.67	1.16e-17	Primary sclerosing cholangitis;
TGCT	cis	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg26116260	chr4:7069785	GRPEL1	1.13	11.1	0.71	2.59e-20	Monocyte percentage of white cells;
TGCT	cis	rs1775715	0.737	rs2151047	chr10:32102110	G/A	cg14930904	chr10:32216787	ARHGAP12	0.5	4.85	0.4	3.62e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs4654899	0.931	rs7543140	chr1:21180250	G/A	cg01072550	chr1:21505969	NA	0.5	7.97	0.58	9.06e-13	Superior frontal gyrus grey matter volume;
TGCT	cis	rs477895	1.000	rs7947143	chr11:64090422	G/A	cg04317338	chr11:64019027	PLCB3	0.71	5.65	0.45	1.05e-7	Mean platelet volume;
TGCT	cis	rs9467711	0.538	rs35934643	chr6:26355094	G/A	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12210905	1.000	rs9357034	chr6:27243425	C/G	cg08851530	chr6:28072375	NA	1.32	5.78	0.46	5.66e-8	Hip circumference adjusted for BMI;
TGCT	cis	rs10782582	0.593	rs12130832	chr1:76234294	T/C	cg03433033	chr1:76189801	ACADM	-0.55	-6.1	-0.48	1.25e-8	Daytime sleep phenotypes;
TGCT	cis	rs7246657	0.722	rs2972447	chr19:38129736	C/T	cg18154014	chr19:37997991	ZNF793	-0.69	-4.67	-0.39	7.7e-6	Coronary artery calcification;
TGCT	cis	rs1056107	0.931	rs3908939	chr9:114991338	G/C	cg02332936	chr9:115140584	NA	-0.25	-4.45	-0.37	1.89e-5	Colorectal cancer;
TGCT	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg11494091	chr17:61959527	GH2	0.42	7.38	0.55	1.96e-11	Height;
TGCT	cis	rs1215050	0.791	rs165241	chr4:98681112	C/T	cg05340658	chr4:99064831	C4orf37	0.43	5.4	0.44	3.2e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2180341	0.920	rs7756880	chr6:127683999	A/T	cg27446573	chr6:127587934	RNF146	1.21	10.87	0.7	9.57e-20	Breast cancer;
TGCT	cis	rs950027	0.596	rs2467865	chr15:45638307	T/C	cg26924012	chr15:45694286	SPATA5L1	0.79	8.86	0.62	6.92e-15	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg25767906	chr1:53392781	SCP2	-0.57	-7.05	-0.53	1.12e-10	Monocyte count;
TGCT	cis	rs7208859	0.673	rs9915963	chr17:29019643	C/T	cg13385521	chr17:29058706	SUZ12P	0.74	4.65	0.39	8.3e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs908922	0.676	rs4240887	chr1:152530510	C/T	cg20991723	chr1:152506922	NA	-0.45	-6.05	-0.48	1.6e-8	Hair morphology;
TGCT	cis	rs62244186	0.659	rs9819766	chr3:44520980	G/C	cg02073558	chr3:44770973	ZNF501	0.61	5.86	0.47	3.91e-8	Depressive symptoms;
TGCT	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg25036284	chr2:26402008	FAM59B	0.59	4.74	0.39	5.65e-6	Gut microbiome composition (summer);
TGCT	cis	rs72945132	0.825	rs7950280	chr11:70213455	G/T	cg00319359	chr11:70116639	PPFIA1	0.99	7.39	0.55	1.94e-11	Coronary artery disease;
TGCT	cis	rs7552404	1.000	rs7524467	chr1:76194054	C/G	cg10523679	chr1:76189770	ACADM	0.9	9.67	0.66	7.93e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs73198271	0.960	rs12155530	chr8:8610964	C/T	ch.8.214553F	chr8:8189620	PRAGMIN	-0.27	-4.79	-0.39	4.72e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs56804039	0.524	rs4840989	chr8:8405746	C/G	cg14215082	chr8:9055850	NA	-0.45	-4.59	-0.38	1.08e-5	Cervical cancer;
TGCT	cis	rs12220898	0.679	rs4838485	chr10:50484825	T/A	cg06072769	chr10:50146962	WDFY4	0.38	5.07	0.41	1.38e-6	Inflammatory biomarkers;
TGCT	trans	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg17470723	chr8:74884337	TCEB1	0.74	6.92	0.53	2.19e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1577917	0.958	rs11755642	chr6:86450066	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.48	-0.44	2.28e-7	Response to antipsychotic treatment;
TGCT	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs11690935	0.959	rs6754817	chr2:172663394	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.16	-12.41	-0.74	1.73e-23	Schizophrenia;
TGCT	cis	rs7208859	0.562	rs11650923	chr17:29008167	G/A	cg14008862	chr17:28927542	LRRC37B2	0.84	5.1	0.42	1.22e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg07061783	chr6:25882402	NA	0.45	4.83	0.4	3.93e-6	Blood metabolite levels;
TGCT	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.5	-6.21	-0.49	7.17e-9	Longevity;Endometriosis;
TGCT	cis	rs782590	0.902	rs3762513	chr2:55762957	C/T	cg18811423	chr2:55921094	PNPT1	0.67	7.1	0.54	8.56e-11	Metabolic syndrome;
TGCT	cis	rs11588062	0.703	rs11589812	chr1:46858748	C/T	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.48	4.77	0.39	5.18e-6	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs208515	0.525	rs10455593	chr6:66691341	C/T	cg07460842	chr6:66804631	NA	0.88	9.35	0.64	4.63e-16	Exhaled nitric oxide levels;
TGCT	cis	rs17445774	0.857	rs6435043	chr2:200900974	C/G	cg23649088	chr2:200775458	C2orf69	0.49	7.36	0.55	2.19e-11	LDL cholesterol to HDL cholesterol ratio;
TGCT	cis	rs2739330	0.964	rs2739338	chr22:24297130	T/C	cg20007245	chr22:24372913	LOC391322	-0.65	-6.44	-0.5	2.34e-9	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg23205692	chr1:25664452	TMEM50A	0.53	5.42	0.44	2.96e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg16590910	chr6:42928470	GNMT	-0.49	-4.52	-0.38	1.41e-5	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs9976767	0.637	rs9325635	chr21:43823289	G/A	cg23042151	chr21:43824109	UBASH3A	-0.23	-5.04	-0.41	1.62e-6	Type 1 diabetes;
TGCT	cis	rs11690935	0.959	rs6759575	chr2:172689068	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.17	-12.12	-0.74	8.77e-23	Schizophrenia;
TGCT	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg20607798	chr8:58055168	NA	0.59	4.74	0.39	5.73e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg00024416	chr22:24240387	NA	-0.25	-4.7	-0.39	6.69e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs11105298	0.891	rs10858889	chr12:89902604	G/A	cg00757033	chr12:89920650	WDR51B	0.34	5.37	0.43	3.75e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs3008870	1.000	rs2755256	chr1:67471692	A/T	cg08660285	chr1:67390436	MIER1;WDR78	1.1	11.8	0.73	5.15e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs1018836	0.847	rs4735225	chr8:91569100	G/C	cg16814680	chr8:91681699	NA	-0.9	-9.91	-0.66	2.06e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs546131	0.928	rs552171	chr11:34830709	G/T	cg06937548	chr11:34938143	PDHX;APIP	0.68	6.07	0.48	1.47e-8	Lung disease severity in cystic fibrosis;
TGCT	cis	rs12681287	0.608	rs13273338	chr8:87453361	T/G	cg27223183	chr8:87520930	FAM82B	-0.89	-6.43	-0.5	2.54e-9	Caudate activity during reward;
TGCT	cis	rs78487399	0.808	rs13405776	chr2:43739121	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.07	-0.41	1.41e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs6570726	0.791	rs9322029	chr6:145906683	A/G	cg13319975	chr6:146136371	FBXO30	-0.5	-4.51	-0.38	1.48e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg18876405	chr7:65276391	NA	-0.32	-4.93	-0.4	2.63e-6	Aortic root size;
TGCT	cis	rs2486288	0.656	rs6493145	chr15:45573862	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.8	-8.41	-0.6	8.03e-14	Glomerular filtration rate;
TGCT	cis	rs9303401	0.659	rs12150536	chr17:56640834	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.67	6.18	0.49	8.56e-9	Cognitive test performance;
TGCT	cis	rs4319547	0.695	rs7969429	chr12:122875606	A/G	cg08088222	chr12:122070432	ORAI1	0.25	4.49	0.37	1.58e-5	Body mass index;
TGCT	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg00814883	chr7:100076585	TSC22D4	-0.85	-8.62	-0.61	2.62e-14	Platelet count;
TGCT	cis	rs4319547	0.737	rs10846921	chr12:122943376	G/T	cg05707623	chr12:122985044	ZCCHC8	0.59	4.73	0.39	5.99e-6	Body mass index;
TGCT	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg13206674	chr6:150067644	NUP43	0.52	4.51	0.38	1.5e-5	Lung cancer;
TGCT	cis	rs854765	0.647	rs741782	chr17:18019712	T/C	cg04398451	chr17:18023971	MYO15A	-0.39	-6.75	-0.52	5e-10	Total body bone mineral density;
TGCT	cis	rs12049351	0.667	rs34382491	chr1:229620630	G/A	cg12130225	chr1:229698885	NA	0.4	4.71	0.39	6.57e-6	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs2296887	0.841	rs11191252	chr10:104060060	G/C	cg26089160	chr10:104170217	PSD	-0.61	-5.66	-0.45	1.01e-7	Parkinson's disease;
TGCT	cis	rs765787	0.530	rs12439643	chr15:45529767	A/G	cg24006582	chr15:45444508	DUOX1	0.24	5.37	0.43	3.8e-7	Uric acid levels;
TGCT	cis	rs12497850	0.931	rs4974085	chr3:48924900	C/T	cg07636037	chr3:49044803	WDR6	0.95	10.74	0.69	2e-19	Parkinson's disease;
TGCT	cis	rs752092	0.894	rs8043243	chr15:101771453	C/T	cg19997662	chr15:101784653	CHSY1	-0.27	-4.85	-0.4	3.7e-6	Corneal structure;
TGCT	cis	rs17152411	1.000	rs7083298	chr10:126590691	T/C	cg07906193	chr10:126599966	NA	0.42	5.16	0.42	9.55e-7	Height;
TGCT	cis	rs7027203	0.797	rs3996254	chr9:96591239	A/G	cg14598338	chr9:96623480	NA	-0.61	-9.54	-0.65	1.68e-16	DNA methylation (variation);
TGCT	trans	rs1814175	0.781	rs12286395	chr11:49954062	C/G	cg03929089	chr4:120376271	NA	-0.72	-8.53	-0.61	4.24e-14	Height;
TGCT	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg04944784	chr2:26401820	FAM59B	-0.68	-6.13	-0.48	1.1e-8	Gut microbiome composition (summer);
TGCT	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg03188948	chr7:1209495	NA	0.5	5.27	0.43	5.87e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs554111	0.891	rs646786	chr1:21054726	A/G	cg08890418	chr1:21044141	KIF17	0.56	6.04	0.48	1.69e-8	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.62	-5.11	-0.42	1.17e-6	Tonsillectomy;
TGCT	cis	rs2239547	0.618	rs4687663	chr3:52870618	T/A	cg11645453	chr3:52864694	ITIH4	0.35	5.76	0.46	6.35e-8	Schizophrenia;
TGCT	cis	rs6964587	0.967	rs7786031	chr7:91649001	T/G	cg17063962	chr7:91808500	NA	0.91	9.99	0.67	1.32e-17	Breast cancer;
TGCT	cis	rs2721195	0.781	rs10110962	chr8:145780323	C/T	cg11211951	chr8:145729740	GPT	0.24	5.64	0.45	1.1e-7	Age at first birth;
TGCT	cis	rs2228479	0.717	rs34027607	chr16:89808939	T/C	cg04287289	chr16:89883240	FANCA	0.74	4.44	0.37	1.99e-5	Skin colour saturation;
TGCT	cis	rs9910055	1.000	rs9895423	chr17:42285740	T/C	cg19774624	chr17:42201019	HDAC5	-0.85	-8.07	-0.59	5.18e-13	Total body bone mineral density;
TGCT	cis	rs7647973	0.961	rs7626076	chr3:49298139	G/A	cg05785598	chr3:49045655	WDR6	0.39	4.58	0.38	1.13e-5	Menarche (age at onset);
TGCT	cis	rs4654899	0.931	rs4654727	chr1:21214735	C/T	cg01072550	chr1:21505969	NA	0.5	7.95	0.58	9.89e-13	Superior frontal gyrus grey matter volume;
TGCT	cis	rs514406	0.505	rs856721	chr1:53162156	C/A	cg08859206	chr1:53392774	SCP2	-0.34	-4.74	-0.39	5.77e-6	Monocyte count;
TGCT	cis	rs259282	0.605	rs60968670	chr19:33108982	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.52	4.78	0.39	4.94e-6	Schizophrenia;
TGCT	cis	rs295140	0.586	rs4673904	chr2:201163454	A/T	cg04283868	chr2:201171347	SPATS2L	0.6	5.93	0.47	2.75e-8	QT interval;
TGCT	cis	rs6121246	0.529	rs6058152	chr20:30178107	G/A	cg18721089	chr20:30220636	NA	-0.63	-6.86	-0.52	2.95e-10	Mean corpuscular hemoglobin;
TGCT	cis	rs9902453	0.967	rs12602258	chr17:28317657	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.76	6.61	0.51	1.02e-9	Coffee consumption (cups per day);
TGCT	cis	rs911555	0.755	rs12435516	chr14:103954404	T/C	cg23461800	chr14:103021989	NA	-0.35	-4.56	-0.38	1.23e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs9457247	0.534	rs9347170	chr6:167405187	C/T	cg23791538	chr6:167370224	RNASET2	0.61	6.02	0.48	1.85e-8	Crohn's disease;
TGCT	cis	rs7772486	0.902	rs1331643	chr6:146398873	T/A	cg05347473	chr6:146136440	FBXO30	0.55	5.27	0.43	5.86e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs12488721	1	rs12488721	chr3:135992645	T/C	cg12473912	chr3:136751656	NA	0.34	4.85	0.4	3.7e-6	Neuroticism;
TGCT	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg07061783	chr6:25882402	NA	-0.62	-6.15	-0.48	9.71e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7584330	0.554	rs76605518	chr2:238425992	G/A	cg08992911	chr2:238395768	MLPH	0.7	4.72	0.39	6.32e-6	Prostate cancer;
TGCT	cis	rs7772486	0.875	rs2814876	chr6:146304030	C/T	cg23711669	chr6:146136114	FBXO30	0.88	9.48	0.65	2.31e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs754133	0.535	rs7134677	chr12:54441498	C/T	cg16264616	chr12:54390824	NA	0.4	5.56	0.45	1.57e-7	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;
TGCT	cis	rs6570726	0.905	rs396492	chr6:145816180	C/G	cg23711669	chr6:146136114	FBXO30	0.7	6.6	0.51	1.09e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6582630	0.502	rs11181214	chr12:38298313	C/A	cg26384229	chr12:38710491	ALG10B	0.8	7.08	0.54	9.28e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs12579753	0.956	rs7959951	chr12:82231132	T/C	cg07988820	chr12:82153109	PPFIA2	-0.58	-6.25	-0.49	6.15e-9	Resting heart rate;
TGCT	cis	rs4722166	0.564	rs1800797	chr7:22766221	A/G	cg13104385	chr7:22767384	IL6	0.2	4.65	0.39	8.45e-6	Lung cancer;
TGCT	cis	rs2361718	0.900	rs8081698	chr17:78104212	G/A	cg09238746	chr17:78121135	EIF4A3	-0.55	-4.68	-0.39	7.5e-6	Yeast infection;
TGCT	cis	rs911555	0.755	rs2765046	chr14:103980968	G/A	cg12935359	chr14:103987150	CKB	0.36	4.89	0.4	3.03e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7209700	0.662	rs11656865	chr17:45346489	A/G	cg21624342	chr17:45890973	OSBPL7	0.18	4.58	0.38	1.12e-5	IgG glycosylation;
TGCT	cis	rs7511006	0.893	rs5771104	chr22:50651839	C/T	cg19026356	chr22:50624276	TRABD	-0.49	-4.52	-0.38	1.45e-5	Obesity-related traits;
TGCT	cis	rs2288884	0.747	rs11668885	chr19:52591101	C/T	cg13540795	chr19:52551618	ZNF432	-0.65	-5.42	-0.44	2.97e-7	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs4631830	0.900	rs9787697	chr10:51533376	C/T	cg10326726	chr10:51549505	MSMB	-0.27	-5.46	-0.44	2.54e-7	Prostate-specific antigen levels;
TGCT	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2921073	0.509	rs2976931	chr8:8257317	C/A	cg06636001	chr8:8085503	FLJ10661	0.69	6.02	0.48	1.81e-8	Parkinson's disease;
TGCT	cis	rs2404602	0.716	rs12907805	chr15:76690606	C/T	cg22467129	chr15:76604101	ETFA	-0.59	-7.13	-0.54	7.47e-11	Blood metabolite levels;
TGCT	cis	rs28595532	0.920	rs116106661	chr4:119749794	A/G	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs829880	0.570	rs844205	chr12:98846053	A/G	cg25150519	chr12:98850993	NA	0.65	5.77	0.46	5.91e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7584330	0.554	rs79020383	chr2:238425834	G/A	cg08992911	chr2:238395768	MLPH	0.7	4.72	0.39	6.32e-6	Prostate cancer;
TGCT	cis	rs2594989	0.943	rs346070	chr3:11303874	T/C	cg00170343	chr3:11313890	ATG7	0.68	4.9	0.4	2.98e-6	Circulating chemerin levels;
TGCT	cis	rs13256369	1.000	rs13256369	chr8:8577379	T/C	cg06671706	chr8:8559999	CLDN23	0.35	4.7	0.39	6.89e-6	Obesity-related traits;
TGCT	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg08048268	chr3:133502702	NA	-0.7	-11.34	-0.71	6.72e-21	Iron status biomarkers;
TGCT	cis	rs4638749	1.000	rs1466213	chr2:108856607	G/A	cg06795125	chr2:108905320	SULT1C2	-0.39	-4.81	-0.4	4.26e-6	Blood pressure;
TGCT	cis	rs651907	0.557	rs13066768	chr3:101486920	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.51	-4.79	-0.4	4.64e-6	Colorectal cancer;
TGCT	cis	rs11252926	0.574	rs4881254	chr10:453567	C/T	cg20256804	chr10:444983	DIP2C	-0.21	-4.45	-0.37	1.88e-5	Psychosis in Alzheimer's disease;
TGCT	cis	rs2153535	0.542	rs4440510	chr6:8471818	C/T	cg07606381	chr6:8435919	SLC35B3	0.54	5.07	0.41	1.43e-6	Motion sickness;
TGCT	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg00343986	chr7:65444356	GUSB	-0.26	-5.95	-0.47	2.5e-8	Aortic root size;
TGCT	cis	rs1998418	0.611	rs12414136	chr10:126548533	C/G	cg03585084	chr10:126284563	LHPP	-0.28	-4.76	-0.39	5.39e-6	Mean platelet volume;
TGCT	cis	rs4746818	0.818	rs10823302	chr10:70895418	G/T	cg04149295	chr10:70884716	VPS26A	0.79	5.4	0.44	3.22e-7	Left atrial antero-posterior diameter;
TGCT	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	7.24	0.55	4.17e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9916302	0.904	rs588193	chr17:37440439	A/C	cg15445000	chr17:37608096	MED1	-0.31	-4.59	-0.38	1.06e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs739401	0.595	rs6578305	chr11:3001120	C/T	cg05729581	chr11:3078854	CARS	-0.55	-4.93	-0.41	2.54e-6	Longevity;
TGCT	cis	rs938554	0.513	rs3775948	chr4:9995182	G/C	cg00071950	chr4:10020882	SLC2A9	0.57	4.77	0.39	5.07e-6	Blood metabolite levels;
TGCT	cis	rs6089584	0.546	rs6061980	chr20:60618877	G/A	cg13770153	chr20:60521292	NA	-0.41	-5.09	-0.42	1.28e-6	Body mass index;
TGCT	cis	rs67133203	0.659	rs407135	chr12:51411353	G/T	cg01517968	chr12:52348879	ACVR1B	-0.35	-4.52	-0.38	1.44e-5	Urinary tract infection frequency;
TGCT	cis	rs6867032	0.570	rs13166888	chr5:1982966	G/T	cg05184729	chr5:1962311	NA	0.27	4.51	0.38	1.47e-5	Gut microbiome composition (winter);
TGCT	cis	rs1552244	0.554	rs3774207	chr3:9985656	C/T	cg00149659	chr3:10157352	C3orf10	0.61	4.44	0.37	1.97e-5	Alzheimer's disease;
TGCT	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg02038168	chr22:39784481	NA	0.78	6.82	0.52	3.63e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs11105298	0.891	rs4842664	chr12:89938030	G/A	cg00757033	chr12:89920650	WDR51B	0.31	4.66	0.39	7.89e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.36	0.55	2.25e-11	Prudent dietary pattern;
TGCT	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg17554472	chr22:41940697	POLR3H	-0.43	-4.47	-0.37	1.76e-5	Vitiligo;
TGCT	cis	rs2050392	0.624	rs303436	chr10:30731893	G/T	cg18806716	chr10:30721971	MAP3K8	-0.72	-10.07	-0.67	8.65e-18	Inflammatory bowel disease;
TGCT	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.71	7.56	0.56	7.98e-12	Blood metabolite levels;
TGCT	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg04267008	chr7:1944627	MAD1L1	-0.42	-5.4	-0.44	3.3e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs7412746	0.611	rs11204747	chr1:150927152	A/G	cg09365446	chr1:150670422	GOLPH3L	-0.34	-4.72	-0.39	6.35e-6	Melanoma;
TGCT	cis	rs10501293	0.746	rs7131154	chr11:43001206	A/G	cg03447554	chr11:43094025	NA	0.42	5.95	0.47	2.58e-8	Cognitive performance;
TGCT	cis	rs34467563	0.934	rs12542955	chr8:97410618	G/T	cg15747595	chr8:98289880	TSPYL5	-0.43	-4.76	-0.39	5.2e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9372498	0.536	rs62422235	chr6:118971913	G/A	cg07617317	chr6:118971624	C6orf204	0.47	4.81	0.4	4.3e-6	Diastolic blood pressure;
TGCT	cis	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg02380750	chr20:61661411	NA	0.33	5.96	0.47	2.4e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs5760092	0.842	rs5751763	chr22:24247793	T/C	cg25703541	chr22:24373054	LOC391322	-0.8	-6.48	-0.5	1.92e-9	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs17376456	0.825	rs34967135	chr5:93221785	G/A	cg25358565	chr5:93447407	FAM172A	1.01	8.13	0.59	3.77e-13	Diabetic retinopathy;
TGCT	trans	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg13615516	chr5:77269221	NA	0.69	8.57	0.61	3.51e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs617219	0.737	rs6453431	chr5:78493873	G/C	cg23987322	chr5:78407566	BHMT	0.36	4.84	0.4	3.75e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs7666738	0.570	rs11097612	chr4:99079772	T/C	cg17366294	chr4:99064904	C4orf37	0.57	5.34	0.43	4.31e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1670533	1.000	rs641987	chr4:1077542	C/T	cg27284194	chr4:1044797	NA	0.68	5.84	0.46	4.28e-8	Recombination rate (females);
TGCT	cis	rs992157	0.735	rs12990082	chr2:219102332	C/T	cg00012203	chr2:219082015	ARPC2	0.81	9.96	0.67	1.57e-17	Colorectal cancer;
TGCT	cis	rs7945705	0.692	rs2742470	chr11:9004002	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.45	-4.95	-0.41	2.38e-6	Hemoglobin concentration;
TGCT	cis	rs2228479	0.717	rs11649210	chr16:89807233	C/G	cg06558623	chr16:89946397	TCF25	0.41	4.46	0.37	1.83e-5	Skin colour saturation;
TGCT	cis	rs7178572	0.889	rs7171448	chr15:77832316	C/G	cg22256960	chr15:77711686	NA	-0.97	-11.25	-0.71	1.13e-20	Type 2 diabetes;
TGCT	cis	rs6426558	0.537	rs1320494	chr1:227241300	A/T	cg10327440	chr1:227177885	CDC42BPA	0.61	7.41	0.55	1.72e-11	Neutrophil percentage of white cells;
TGCT	cis	rs9341808	0.690	rs2322634	chr6:80874014	A/C	cg08355045	chr6:80787529	NA	0.32	5.64	0.45	1.11e-7	Sitting height ratio;
TGCT	cis	rs6558530	1.000	rs6558530	chr8:1706207	A/G	cg09410841	chr8:1729607	CLN8	0.87	9.5	0.65	2e-16	Systolic blood pressure;
TGCT	cis	rs12220238	0.722	rs7894466	chr10:76401365	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.59	4.54	0.38	1.29e-5	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg13770153	chr20:60521292	NA	-0.48	-6.31	-0.49	4.51e-9	Body mass index;
TGCT	cis	rs752010	0.523	rs10890158	chr1:42117985	C/T	cg06885757	chr1:42089581	HIVEP3	0.28	4.96	0.41	2.27e-6	Lupus nephritis in systemic lupus erythematosus;
TGCT	cis	rs9611565	0.559	rs8139993	chr22:41995335	T/C	cg06634786	chr22:41940651	POLR3H	-0.83	-7.66	-0.57	4.6e-12	Vitiligo;
TGCT	cis	rs10276381	1.000	rs10281214	chr7:28185544	G/C	cg23620719	chr7:28220237	JAZF1	1.01	5.82	0.46	4.75e-8	Crohn's disease;
TGCT	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg03188948	chr7:1209495	NA	0.47	5.81	0.46	4.9e-8	Longevity;Endometriosis;
TGCT	cis	rs5758659	0.714	rs2413668	chr22:42505841	G/A	cg15557168	chr22:42548783	NA	0.18	4.63	0.38	9.14e-6	Cognitive function;
TGCT	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	5.49	0.44	2.14e-7	Menopause (age at onset);
TGCT	cis	rs9899728	0.539	rs12938889	chr17:73039929	A/C	cg27626185	chr17:73056755	KCTD2	0.91	7.86	0.58	1.63e-12	Alzheimer's disease or small vessel stroke;
TGCT	cis	rs6547741	1.000	rs6749052	chr2:27772879	A/T	cg27432699	chr2:27873401	GPN1	0.18	4.66	0.39	8.09e-6	Oral cavity cancer;
TGCT	cis	rs950169	0.881	rs34591918	chr15:84950833	C/T	cg11189052	chr15:85197271	WDR73	0.81	6.22	0.49	6.89e-9	Schizophrenia;
TGCT	cis	rs2456568	0.900	rs2456559	chr11:93668858	A/T	cg16099599	chr11:93583650	C11orf90	-0.39	-4.63	-0.38	9.04e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs4455778	0.757	rs9791574	chr7:49010732	A/C	cg26309511	chr7:48887640	NA	-0.48	-5.89	-0.47	3.42e-8	Lung cancer in never smokers;
TGCT	cis	rs7772486	0.790	rs1854900	chr6:146331382	G/A	cg05347473	chr6:146136440	FBXO30	0.55	5.27	0.43	5.84e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2832191	1.000	rs9984793	chr21:30486471	T/C	cg24692254	chr21:30365293	RNF160	-0.83	-8.71	-0.62	1.58e-14	Dental caries;
TGCT	cis	rs6908034	0.660	rs7750716	chr6:19804839	C/T	cg02682789	chr6:19804855	NA	0.92	5.24	0.43	6.7e-7	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
TGCT	cis	rs7178572	0.962	rs1022172	chr15:77793359	A/G	cg15453836	chr15:77711506	NA	-0.39	-4.51	-0.38	1.46e-5	Type 2 diabetes;
TGCT	cis	rs9534288	0.830	rs1126363	chr13:46633459	C/T	cg15192986	chr13:46630673	CPB2	-0.5	-6.23	-0.49	6.66e-9	Blood protein levels;
TGCT	cis	rs11098499	0.754	rs10006259	chr4:120242145	C/T	cg09307838	chr4:120376055	NA	0.61	5.91	0.47	3.14e-8	Corneal astigmatism;
TGCT	cis	rs13242816	1.000	rs12669740	chr7:116138576	T/C	cg16553024	chr7:116138462	CAV2	-0.44	-5.34	-0.43	4.29e-7	P wave duration;
TGCT	cis	rs1865760	0.622	rs9968910	chr6:26072095	A/C	cg17691542	chr6:26056736	HIST1H1C	0.7	5.48	0.44	2.32e-7	Height;
TGCT	cis	rs887829	0.569	rs4148326	chr2:234673462	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.26	-4.49	-0.37	1.63e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
TGCT	cis	rs7830933	0.780	rs1561105	chr8:23610799	T/G	cg04349084	chr8:23602677	NA	0.24	4.72	0.39	6.22e-6	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
TGCT	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg00149659	chr3:10157352	C3orf10	0.96	6.1	0.48	1.26e-8	Alzheimer's disease;
TGCT	cis	rs9911578	0.835	rs9303398	chr17:56484257	T/C	cg05425664	chr17:57184151	TRIM37	0.61	5.76	0.46	6.33e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs10489525	0.599	rs2335724	chr1:115608444	T/C	cg12756093	chr1:115239321	AMPD1	-0.41	-5.55	-0.45	1.65e-7	Autism;
TGCT	cis	rs10858047	0.831	rs11102826	chr1:115181607	T/A	cg12756093	chr1:115239321	AMPD1	-0.45	-4.73	-0.39	6.09e-6	Autism;
TGCT	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg23708337	chr7:1209742	NA	0.51	4.46	0.37	1.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7666738	0.830	rs13149404	chr4:99070236	A/G	cg17366294	chr4:99064904	C4orf37	0.73	7.45	0.56	1.4e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6121246	0.529	rs6060134	chr20:30176794	A/G	cg13852791	chr20:30311386	BCL2L1	0.69	4.53	0.38	1.36e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs8177253	0.514	rs6790668	chr3:133442481	T/A	cg16262614	chr3:133464971	TF	0.33	4.46	0.37	1.82e-5	Iron status biomarkers;
TGCT	cis	rs7246657	0.722	rs10404031	chr19:38035954	A/G	cg03611452	chr19:38183253	ZNF781	0.58	4.64	0.38	8.62e-6	Coronary artery calcification;
TGCT	cis	rs3782455	0.793	rs2290799	chr12:114404208	G/A	cg23502203	chr12:113549970	RASAL1	-0.55	-4.92	-0.4	2.7e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs10791097	0.690	rs12284540	chr11:130729772	T/C	cg12179176	chr11:130786555	SNX19	0.73	8.64	0.61	2.3e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.78	5.65	0.45	1.03e-7	Platelet count;
TGCT	cis	rs4767364	0.614	rs610303	chr12:112145100	C/A	cg10833066	chr12:111807467	FAM109A	0.31	5.13	0.42	1.09e-6	Oral cavity and pharyngeal cancer;
TGCT	trans	rs2727020	0.729	rs685789	chr11:49241228	G/A	cg15704280	chr7:45808275	SEPT13	0.7	7.47	0.56	1.26e-11	Coronary artery disease;
TGCT	cis	rs3806843	0.549	rs246012	chr5:140336277	C/T	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs10832169	0.933	rs2049724	chr11:14078151	C/T	cg04547675	chr11:13986162	SPON1	-0.51	-4.55	-0.38	1.24e-5	Blood protein levels;
TGCT	cis	rs8020441	0.541	rs113935613	chr14:51163847	C/T	cg04730355	chr14:51134070	SAV1	1.06	8.42	0.6	7.8e-14	Cognitive performance;
TGCT	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	5.11	0.42	1.18e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs250677	0.687	rs1422581	chr5:148437386	C/T	cg23229984	chr5:148520753	ABLIM3	-0.2	-4.65	-0.39	8.53e-6	Breast cancer;
TGCT	cis	rs2797160	0.967	rs6910786	chr6:126017141	A/T	cg05901451	chr6:126070800	HEY2	0.73	6.29	0.49	5.01e-9	Endometrial cancer;
TGCT	cis	rs986417	0.901	rs11627533	chr14:61037801	C/T	cg18240143	chr14:60952599	C14orf39	0.96	4.59	0.38	1.05e-5	Gut microbiota (bacterial taxa);
TGCT	trans	rs2727020	0.595	rs7924311	chr11:49507573	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.36	-7.03	-0.53	1.25e-10	Coronary artery disease;
TGCT	cis	rs11190604	1.000	rs2495753	chr10:102325640	C/T	cg23241863	chr10:102295624	HIF1AN	0.67	4.9	0.4	2.99e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.7	6.33	0.49	4.02e-9	Tonsillectomy;
TGCT	cis	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg07424592	chr7:64974309	NA	-1.27	-7.84	-0.58	1.8e-12	Diabetic kidney disease;
TGCT	cis	rs4665630	0.614	rs12623694	chr2:23887153	A/G	cg08063864	chr2:24346004	PFN4;LOC375190	-0.95	-4.78	-0.39	4.79e-6	Hypertension;
TGCT	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg22535103	chr8:58192502	C8orf71	-0.35	-4.61	-0.38	1e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs6714710	0.603	rs953320	chr2:98606770	T/C	cg26665480	chr2:98280029	ACTR1B	0.66	6.26	0.49	5.84e-9	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs3796352	1.000	rs34340609	chr3:53077276	A/G	cg07884673	chr3:53033167	SFMBT1	0.56	5.96	0.47	2.43e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs8180040	0.966	rs6787422	chr3:47418509	G/T	cg27129171	chr3:47204927	SETD2	0.65	7.74	0.57	2.99e-12	Colorectal cancer;
TGCT	cis	rs3749237	0.595	rs4855861	chr3:49525962	G/T	cg03060546	chr3:49711283	APEH	0.76	8.69	0.62	1.77e-14	Resting heart rate;
TGCT	cis	rs67311347	1.000	rs954589	chr3:40444545	C/T	cg13409248	chr3:40428643	ENTPD3	0.57	4.53	0.38	1.37e-5	Renal cell carcinoma;
TGCT	cis	rs8082590	1	rs8082590	chr17:17958402	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.8	-8.45	-0.6	6.61e-14	Schizophrenia;
TGCT	cis	rs17376456	0.690	rs6892055	chr5:93113023	A/T	cg21475434	chr5:93447410	FAM172A	0.62	4.86	0.4	3.46e-6	Diabetic retinopathy;
TGCT	cis	rs7000551	0.751	rs2449341	chr8:22390937	C/A	cg12081754	chr8:22256438	SLC39A14	0.28	4.54	0.38	1.29e-5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg11890956	chr21:40555474	PSMG1	1.02	9.9	0.66	2.16e-17	Cognitive function;
TGCT	cis	rs9916302	0.904	rs8066704	chr17:37477218	C/T	cg07936489	chr17:37558343	FBXL20	0.65	5.08	0.41	1.36e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs9467711	0.606	rs2393667	chr6:26421345	T/C	cg10795676	chr6:26370623	BTN3A2	-0.45	-4.56	-0.38	1.23e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9291683	0.679	rs2241483	chr4:10099831	A/G	cg00071950	chr4:10020882	SLC2A9	-0.46	-4.9	-0.4	2.97e-6	Bone mineral density;
TGCT	cis	rs6671200	0.607	rs10874908	chr1:95704151	C/G	cg20701556	chr1:95698924	RWDD3	-0.52	-5.34	-0.43	4.26e-7	Stearic acid (18:0) levels;
TGCT	cis	rs12479064	0.724	rs4851203	chr2:99986932	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.77	-6.7	-0.52	6.68e-10	Chronic sinus infection;
TGCT	cis	rs13256369	0.774	rs11777719	chr8:8581038	A/G	cg18904891	chr8:8559673	CLDN23	0.58	5.09	0.42	1.27e-6	Obesity-related traits;
TGCT	cis	rs4654899	0.680	rs2305463	chr1:21180181	C/T	cg01072550	chr1:21505969	NA	0.54	8.72	0.62	1.54e-14	Superior frontal gyrus grey matter volume;
TGCT	cis	rs11671005	0.735	rs12986387	chr19:58927215	C/T	cg13877915	chr19:58951672	ZNF132	0.63	4.99	0.41	1.95e-6	Mean platelet volume;
TGCT	cis	rs904251	0.965	rs62406516	chr6:37439364	C/T	cg25019722	chr6:37503610	NA	-0.47	-6.26	-0.49	5.69e-9	Cognitive performance;
TGCT	cis	rs988712	0.576	rs6265	chr11:27679916	C/T	cg10635145	chr11:27742435	BDNF	-0.45	-5.97	-0.47	2.31e-8	Obesity;
TGCT	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg11494091	chr17:61959527	GH2	0.43	7.51	0.56	9.88e-12	Height;
TGCT	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg06238570	chr21:40685208	BRWD1	0.58	5.22	0.42	7.22e-7	Cognitive function;
TGCT	cis	rs736408	1.000	rs4687552	chr3:52838402	T/C	cg07507251	chr3:52567010	NT5DC2	0.49	6.4	0.5	2.96e-9	Bipolar disorder;
TGCT	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	5.43	0.44	2.89e-7	Alzheimer's disease;
TGCT	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg18305652	chr10:134549665	INPP5A	0.33	5.54	0.45	1.74e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs13191362	1.000	rs34443622	chr6:163208214	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.87	5.59	0.45	1.37e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs10489202	0.826	rs202255	chr1:167988653	A/G	cg24449463	chr1:168025552	DCAF6	-0.5	-5.28	-0.43	5.67e-7	Schizophrenia;
TGCT	trans	rs28735056	0.572	rs4799100	chr18:77640207	A/G	cg05926928	chr17:57297772	GDPD1	-0.83	-9.57	-0.65	1.42e-16	Schizophrenia;
TGCT	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg10150615	chr22:24372951	LOC391322	-0.92	-9.98	-0.67	1.44e-17	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2580764	0.503	rs2972097	chr2:55267545	T/C	cg09592903	chr2:55203963	RTN4	0.27	6.24	0.49	6.34e-9	Mean platelet volume;
TGCT	cis	rs17376456	0.877	rs10050465	chr5:93349963	C/A	cg25358565	chr5:93447407	FAM172A	0.92	8.37	0.6	1.05e-13	Diabetic retinopathy;
TGCT	cis	rs2880765	0.566	rs17553249	chr15:86006694	A/G	cg13263323	chr15:86062960	AKAP13	-0.22	-4.75	-0.39	5.62e-6	Coronary artery disease;
TGCT	cis	rs7267979	0.934	rs4815423	chr20:25387521	A/G	cg16686733	chr20:25566563	NINL	-0.59	-5.97	-0.47	2.28e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs713587	0.520	rs483428	chr2:25305136	A/G	cg01884057	chr2:25150051	NA	0.26	4.89	0.4	3.08e-6	Body mass index in non-asthmatics;
TGCT	cis	rs7666738	0.830	rs17027090	chr4:98897923	G/T	cg05340658	chr4:99064831	C4orf37	0.51	5.93	0.47	2.84e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.52	-6.75	-0.52	5.07e-10	Longevity;Endometriosis;
TGCT	cis	rs2242116	0.833	rs6442038	chr3:46960742	A/G	cg02527881	chr3:46936655	PTH1R	-0.33	-6.17	-0.48	9.07e-9	Birth weight;
TGCT	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg07343612	chr16:622815	PIGQ	-0.42	-8.39	-0.6	9.08e-14	Height;
TGCT	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg13393036	chr8:95962371	TP53INP1	-0.62	-8.38	-0.6	9.62e-14	Type 2 diabetes;
TGCT	cis	rs7044106	0.762	rs7024046	chr9:123419178	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	6.68	0.51	7.09e-10	Hip circumference adjusted for BMI;
TGCT	cis	rs798554	1.000	rs798560	chr7:2758309	A/G	cg04166393	chr7:2884313	GNA12	0.6	4.44	0.37	1.97e-5	Height;
TGCT	cis	rs13217239	0.646	rs7451149	chr6:27057518	A/G	cg26531700	chr6:26746687	NA	-0.72	-7.35	-0.55	2.33e-11	Schizophrenia;
TGCT	cis	rs8177179	0.967	rs6439436	chr3:133453779	C/T	cg16262614	chr3:133464971	TF	-0.35	-4.82	-0.4	4.19e-6	Iron status biomarkers (transferrin levels);
TGCT	cis	rs2832191	0.740	rs13048618	chr21:30458684	A/G	cg24692254	chr21:30365293	RNF160	0.98	11.36	0.71	6.16e-21	Dental caries;
TGCT	cis	rs62064224	0.791	rs11653160	chr17:30717222	A/G	cg18200150	chr17:30822561	MYO1D	0.58	7.69	0.57	3.92e-12	Schizophrenia;
TGCT	cis	rs2404602	0.647	rs2404600	chr15:77173557	C/T	cg22467129	chr15:76604101	ETFA	0.47	4.79	0.4	4.69e-6	Blood metabolite levels;
TGCT	cis	rs8077577	0.945	rs62073609	chr17:18071843	T/C	cg09161412	chr17:18057145	MYO15A	-0.67	-5.44	-0.44	2.69e-7	Obesity-related traits;
TGCT	cis	rs9467773	0.967	rs9461267	chr6:26525455	T/G	cg26531700	chr6:26746687	NA	0.47	4.57	0.38	1.14e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7100689	0.646	rs7899791	chr10:82091950	A/T	cg01528321	chr10:82214614	TSPAN14	0.75	7.49	0.56	1.15e-11	Post bronchodilator FEV1;
TGCT	cis	rs17401966	0.838	rs10492971	chr1:10342975	G/A	cg19773385	chr1:10388646	KIF1B	-0.2	-4.5	-0.37	1.54e-5	Hepatocellular carcinoma;
TGCT	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.02	0.53	1.3e-10	Prudent dietary pattern;
TGCT	cis	rs617791	0.508	rs10791837	chr11:65774596	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.49	4.49	0.37	1.64e-5	Breast cancer;
TGCT	cis	rs7267979	1.000	rs2500443	chr20:25331442	C/T	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11105298	0.891	rs12369195	chr12:89934972	G/C	cg00757033	chr12:89920650	WDR51B	0.3	4.71	0.39	6.56e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs916888	0.821	rs199507	chr17:44858855	A/G	cg17911788	chr17:44343683	NA	0.59	6.13	0.48	1.09e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs1008375	0.966	rs6837664	chr4:17697835	G/C	cg18681998	chr4:17616180	MED28	0.78	7.35	0.55	2.35e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs904251	0.523	rs10947675	chr6:37479972	G/A	cg08126542	chr6:37504118	NA	-0.44	-6.36	-0.5	3.49e-9	Cognitive performance;
TGCT	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg18230493	chr5:56204884	C5orf35	-0.72	-6.07	-0.48	1.44e-8	Initial pursuit acceleration;
TGCT	cis	rs9611519	1.000	rs4820433	chr22:41607065	C/G	cg13695892	chr22:41940480	POLR3H	-0.51	-4.71	-0.39	6.49e-6	Neuroticism;
TGCT	cis	rs7727544	0.636	rs2631365	chr5:131705949	T/C	cg24060327	chr5:131705240	SLC22A5	0.59	6.59	0.51	1.12e-9	Blood metabolite levels;
TGCT	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg11890956	chr21:40555474	PSMG1	1.05	10.55	0.69	5.98e-19	Cognitive function;
TGCT	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg24250549	chr1:154909240	PMVK	0.58	5.63	0.45	1.15e-7	Prostate cancer;
TGCT	cis	rs11718455	1.000	rs9854785	chr3:44031295	A/G	cg08738300	chr3:44038990	NA	0.85	6.49	0.5	1.87e-9	Coronary artery disease;
TGCT	cis	rs7296418	0.961	rs949143	chr12:123595163	G/A	cg00376283	chr12:123451042	ABCB9	0.84	7.58	0.56	7.14e-12	Platelet count;
TGCT	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg12419862	chr22:24373484	LOC391322	-0.81	-8.56	-0.61	3.71e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6500602	0.702	rs9929475	chr16:4540885	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.31	-5.57	-0.45	1.48e-7	Schizophrenia;
TGCT	cis	rs2404602	0.698	rs12909656	chr15:76664378	A/T	cg22467129	chr15:76604101	ETFA	0.45	4.57	0.38	1.14e-5	Blood metabolite levels;
TGCT	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg22891161	chr3:195456627	MUC20	-0.23	-5.35	-0.43	4.08e-7	Pancreatic cancer;
TGCT	cis	rs921968	0.643	rs678218	chr2:219379709	C/A	cg02176678	chr2:219576539	TTLL4	0.38	5.48	0.44	2.31e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs1670533	1.000	rs6812586	chr4:1069851	A/G	cg27284194	chr4:1044797	NA	0.69	5.94	0.47	2.66e-8	Recombination rate (females);
TGCT	cis	rs7100689	0.784	rs10736341	chr10:82061206	C/G	cg01528321	chr10:82214614	TSPAN14	0.8	7.9	0.58	1.29e-12	Post bronchodilator FEV1;
TGCT	cis	rs317689	0.690	rs10878947	chr12:69642683	A/T	cg11871910	chr12:69753446	YEATS4	0.53	4.47	0.37	1.77e-5	Response to diuretic therapy;
TGCT	cis	rs9611565	0.559	rs132765	chr22:42008068	A/G	cg06634786	chr22:41940651	POLR3H	0.89	8.56	0.61	3.56e-14	Vitiligo;
TGCT	cis	rs7614311	0.636	rs73117057	chr3:63915689	A/G	cg22134162	chr3:63841271	THOC7	-0.49	-6.17	-0.48	8.78e-9	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs12210905	0.688	rs12194842	chr6:27367978	A/C	cg08851530	chr6:28072375	NA	1.33	5.85	0.47	4.08e-8	Hip circumference adjusted for BMI;
TGCT	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg27454412	chr7:1067447	C7orf50	0.6	4.72	0.39	6.32e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1018836	0.663	rs12674903	chr8:91475774	T/C	cg16814680	chr8:91681699	NA	-0.85	-8.77	-0.62	1.17e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs72781680	0.846	rs72780198	chr2:24014883	T/A	cg08917208	chr2:24149416	ATAD2B	0.81	5.01	0.41	1.8e-6	Lymphocyte counts;
TGCT	cis	rs6540559	0.808	rs11119358	chr1:210042456	T/C	cg22029157	chr1:209979665	IRF6	0.77	6.04	0.48	1.65e-8	Cleft lip with or without cleft palate;
TGCT	cis	rs2239547	0.525	rs2246556	chr3:53027983	T/C	cg10802521	chr3:52805072	NEK4	0.53	5.58	0.45	1.45e-7	Schizophrenia;
TGCT	cis	rs2153535	0.580	rs2225765	chr6:8481785	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs904251	0.522	rs882322	chr6:37484103	A/G	cg25019722	chr6:37503610	NA	-0.51	-7.96	-0.58	9.09e-13	Cognitive performance;
TGCT	cis	rs9527	0.590	rs7087040	chr10:104799668	G/A	cg15744005	chr10:104629667	AS3MT	-0.4	-4.63	-0.38	9.04e-6	Arsenic metabolism;
TGCT	cis	rs35146811	0.735	rs1636978	chr7:99813912	G/A	cg04778012	chr7:99775508	STAG3;GPC2	-0.36	-5.1	-0.42	1.22e-6	Coronary artery disease;
TGCT	cis	rs7552404	1.000	rs4949874	chr1:76161889	T/C	cg10523679	chr1:76189770	ACADM	0.91	9.92	0.67	2.01e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.56	-5.24	-0.43	6.59e-7	Prudent dietary pattern;
TGCT	cis	rs3741404	0.620	rs882147	chr11:63976689	T/A	cg00022866	chr11:64108440	CCDC88B	0.24	4.55	0.38	1.26e-5	Platelet count;
TGCT	cis	rs2013441	1.000	rs2526460	chr17:20086352	G/A	cg18979559	chr17:20280153	CCDC144C	-0.44	-4.61	-0.38	9.78e-6	Obesity-related traits;
TGCT	cis	rs9473924	0.580	rs67092917	chr6:50815333	G/T	cg14470998	chr6:50812995	TFAP2B	1.36	8.61	0.61	2.74e-14	Body mass index;
TGCT	cis	rs7104764	1.000	rs7128044	chr11:244115	G/A	cg18336825	chr11:236787	PSMD13;SIRT3	1.07	11.19	0.71	1.61e-20	Menarche (age at onset);
TGCT	cis	rs4642101	0.597	rs9839768	chr3:12821403	C/T	cg05775895	chr3:12838266	CAND2	0.92	11.11	0.71	2.54e-20	QRS complex (12-leadsum);
TGCT	cis	rs4237845	0.537	rs11172369	chr12:58280592	T/C	cg23860436	chr12:58378763	NA	0.33	4.54	0.38	1.32e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs12682352	0.602	rs28399241	chr8:8663215	C/T	cg15556689	chr8:8085844	FLJ10661	0.62	5.37	0.43	3.71e-7	Neuroticism;
TGCT	cis	rs2404602	0.536	rs11072599	chr15:76774508	T/C	cg22467129	chr15:76604101	ETFA	-0.5	-5.96	-0.47	2.4e-8	Blood metabolite levels;
TGCT	cis	rs9611565	0.694	rs9611591	chr22:41830212	G/A	cg06481639	chr22:41940642	POLR3H	0.6	5.31	0.43	4.95e-7	Vitiligo;
TGCT	cis	rs7119	0.651	rs35657172	chr15:77847813	T/C	cg27398640	chr15:77910606	LINGO1	-0.28	-5.11	-0.42	1.21e-6	Type 2 diabetes;
TGCT	trans	rs561341	1.000	rs2470267	chr17:30274132	G/A	cg20587970	chr11:113659929	NA	-1.0	-10.69	-0.69	2.67e-19	Hip circumference adjusted for BMI;
TGCT	cis	rs12477438	0.798	rs13393860	chr2:99590397	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-5.97	-0.47	2.3e-8	Chronic sinus infection;
TGCT	cis	rs4253772	0.550	rs6008601	chr22:46705326	C/G	cg24881330	chr22:46731750	TRMU	1.04	5.41	0.44	3.12e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs6430585	0.527	rs62168833	chr2:136449254	G/A	cg07169764	chr2:136633963	MCM6	1.0	9.14	0.63	1.51e-15	Corneal structure;
TGCT	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	6.75	0.52	5.02e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9467711	0.606	rs9393718	chr6:26407482	G/A	cg16898833	chr6:26189333	HIST1H4D	1.12	5.36	0.43	3.91e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12479064	0.505	rs62153764	chr2:99818612	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-6.36	-0.5	3.46e-9	Chronic sinus infection;
TGCT	cis	rs9611565	0.608	rs2003816	chr22:42095140	T/G	cg06634786	chr22:41940651	POLR3H	0.82	7.76	0.57	2.71e-12	Vitiligo;
TGCT	cis	rs1005277	0.505	rs10827835	chr10:38150709	G/A	cg13531842	chr10:38383804	ZNF37A	0.39	4.58	0.38	1.12e-5	Extrinsic epigenetic age acceleration;
TGCT	cis	rs8103278	0.507	rs7260651	chr19:46260245	G/A	cg14061069	chr19:46274453	DMPK	0.63	10.73	0.69	2.08e-19	Coronary artery disease;
TGCT	trans	rs4765905	0.500	rs2239033	chr12:2337746	C/A	cg13866577	chr1:66797481	PDE4B	-0.49	-6.78	-0.52	4.43e-10	Schizophrenia;
TGCT	cis	rs2420915	0.841	rs7072244	chr10:122873026	G/A	cg23234726	chr10:122735589	NA	-0.39	-4.49	-0.37	1.6e-5	Fibrinogen levels;
TGCT	cis	rs2153535	0.542	rs915354	chr6:8440357	T/C	cg07606381	chr6:8435919	SLC35B3	0.57	5.25	0.43	6.38e-7	Motion sickness;
TGCT	cis	rs66731853	0.769	rs657624	chr1:20888348	C/T	cg04087271	chr1:20915334	CDA	-0.52	-6.45	-0.5	2.3e-9	Mean corpuscular volume;
TGCT	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg05064044	chr6:292385	DUSP22	-0.7	-7.29	-0.55	3.15e-11	Menopause (age at onset);
TGCT	cis	rs12458462	0.892	rs12456692	chr18:77482189	C/T	cg11879182	chr18:77439856	CTDP1	0.71	8.06	0.59	5.49e-13	Monocyte count;
TGCT	cis	rs11648796	0.757	rs3809666	chr16:764753	C/G	cg00908189	chr16:619842	PIGQ	0.72	5.83	0.46	4.58e-8	Height;
TGCT	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs1595825	0.891	rs16824631	chr2:198708695	T/G	cg19156104	chr2:198669113	PLCL1	-0.58	-4.44	-0.37	1.99e-5	Ulcerative colitis;
TGCT	cis	rs78456975	0.527	rs10203194	chr2:1558021	A/G	cg12573674	chr2:1569213	NA	-0.45	-4.76	-0.39	5.37e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs9929218	0.581	rs12185157	chr16:68784587	G/A	cg01251360	chr16:68772225	CDH1	-0.25	-4.61	-0.38	9.8200000000000008e-06	Colorectal cancer;
TGCT	cis	rs4824093	0.610	rs12106611	chr22:50242686	G/A	cg14114931	chr22:50943910	LMF2	0.36	4.53	0.38	1.37e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs13191362	1.000	rs34398656	chr6:162999612	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.57	4.94	0.41	2.45e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg06481639	chr22:41940642	POLR3H	-0.73	-6.69	-0.51	6.99e-10	Vitiligo;
TGCT	cis	rs57590327	0.508	rs4399914	chr3:81965477	C/T	cg07356753	chr3:81810745	GBE1	-0.65	-5.69	-0.46	8.57e-8	Extraversion;
TGCT	cis	rs2469997	0.843	rs2470030	chr8:120368991	T/C	cg00681363	chr8:120844660	TAF2	0.69	4.48	0.37	1.64e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs7914558	0.966	rs4532960	chr10:104667406	C/T	cg04362960	chr10:104952993	NT5C2	0.58	5.15	0.42	9.77e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs778371	0.624	rs6733495	chr2:233616709	A/G	cg08000102	chr2:233561755	GIGYF2	0.72	8.68	0.61	1.91e-14	Schizophrenia;
TGCT	cis	rs35146811	0.735	rs11767968	chr7:99790971	G/A	cg13334819	chr7:99746414	C7orf59	-0.74	-6.31	-0.49	4.4e-9	Coronary artery disease;
TGCT	cis	rs12210905	0.688	rs72841398	chr6:27489114	A/C	cg08851530	chr6:28072375	NA	1.34	6.29	0.49	5.02e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs8081395	0.741	rs1292053	chr17:57963537	C/T	cg16369400	chr17:58041258	RNFT1	-0.22	-4.46	-0.37	1.8e-5	White blood cell count;
TGCT	cis	rs2338224	0.800	rs6874695	chr5:71742444	C/T	cg01187920	chr5:71015162	CARTPT	-0.53	-4.57	-0.38	1.15e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Granulocyte count;Myeloid white cell count;
TGCT	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg23205692	chr1:25664452	TMEM50A	0.49	5.07	0.41	1.39e-6	Erythrocyte sedimentation rate;
TGCT	cis	rs907683	0.533	rs12469789	chr2:220293242	C/T	cg15015639	chr2:220282977	DES	0.4	5.11	0.42	1.18e-6	Resting heart rate;
TGCT	cis	rs28785552	0.769	rs28796114	chr19:53234319	T/C	cg10871876	chr19:53194124	ZNF83	0.6	8.53	0.61	4.35e-14	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	7.83	0.58	1.82e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.6	-0.51	1.06e-9	Alzheimer's disease;
TGCT	cis	rs1451375	0.741	rs55738142	chr7:50632326	T/C	cg18232548	chr7:50535776	DDC	0.43	6.57	0.51	1.26e-9	Malaria;
TGCT	cis	rs9902453	0.726	rs4795523	chr17:28176314	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.87	8.39	0.6	8.97e-14	Coffee consumption (cups per day);
TGCT	cis	rs9308731	0.644	rs4849403	chr2:111874037	T/C	cg04202892	chr2:111875749	ACOXL	0.54	6.22	0.49	7.04e-9	Chronic lymphocytic leukemia;
TGCT	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg25767906	chr1:53392781	SCP2	0.5	5.71	0.46	7.74e-8	Monocyte count;
TGCT	cis	rs7809950	0.731	rs2712196	chr7:107128797	G/T	cg23024343	chr7:107201750	COG5	-0.46	-6.9	-0.53	2.4e-10	Coronary artery disease;
TGCT	cis	rs3820928	0.874	rs2229812	chr2:227896886	C/T	cg11843606	chr2:227700838	RHBDD1	-0.54	-4.96	-0.41	2.29e-6	Pulmonary function;
TGCT	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg24675658	chr1:53192096	ZYG11B	-0.78	-9.21	-0.64	1.01e-15	Monocyte count;
TGCT	cis	rs7666738	0.830	rs7680909	chr4:98934604	A/G	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6088580	0.634	rs6059868	chr20:33079460	A/G	cg06115741	chr20:33292138	TP53INP2	0.54	4.63	0.38	9.06e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7786808	0.712	rs12671981	chr7:158202971	G/A	cg01191920	chr7:158217561	PTPRN2	-0.45	-6.84	-0.52	3.22e-10	Obesity-related traits;
TGCT	cis	rs4389656	0.857	rs274713	chr5:6723560	A/C	cg10857441	chr5:6722123	POLS	-0.22	-4.82	-0.4	4.07e-6	Coronary artery disease;
TGCT	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg13395646	chr4:1353034	KIAA1530	-0.39	-4.96	-0.41	2.3e-6	Obesity-related traits;
TGCT	cis	rs6089584	0.927	rs2296083	chr20:60574216	C/T	cg06108461	chr20:60628389	TAF4	-0.58	-8.21	-0.59	2.37e-13	Body mass index;
TGCT	cis	rs68170813	0.559	rs7794965	chr7:106826439	A/G	cg02696742	chr7:106810147	HBP1	0.72	6.28	0.49	5.29e-9	Coronary artery disease;
TGCT	cis	rs7647973	0.922	rs57273516	chr3:49483074	A/G	cg07636037	chr3:49044803	WDR6	0.64	5.26	0.43	6.12e-7	Menarche (age at onset);
TGCT	trans	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg17830980	chr10:43048298	ZNF37B	-0.81	-10.13	-0.67	6.19e-18	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7681440	0.904	rs17192189	chr4:90774928	A/C	cg20003494	chr4:90757398	SNCA	0.51	4.68	0.39	7.52e-6	Dementia with Lewy bodies;
TGCT	cis	rs4478037	0.555	rs60749629	chr3:33105319	G/A	cg19404215	chr3:33155277	CRTAP	1.16	5.14	0.42	1.05e-6	Major depressive disorder;
TGCT	cis	rs10811516	0.501	rs10283817	chr9:21159319	T/C	cg23029519	chr9:21187344	IFNA4	-0.3	-4.61	-0.38	9.72e-6	Response to mepolizumab in severe asthma;
TGCT	cis	rs6570726	0.935	rs372378	chr6:145816227	A/G	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10779751	1.000	rs7524202	chr1:11297762	T/C	cg08854313	chr1:11322531	MTOR	0.98	9.12	0.63	1.65e-15	Body mass index;
TGCT	cis	rs9303401	0.659	rs34170300	chr17:56789905	G/C	cg25039879	chr17:56429692	SUPT4H1	0.52	4.62	0.38	9.48e-6	Cognitive test performance;
TGCT	cis	rs2070488	0.965	rs7373828	chr3:38524311	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	9.17	0.64	1.25e-15	Electrocardiographic conduction measures;
TGCT	cis	rs7937682	0.883	rs1613778	chr11:111456105	G/C	cg09085632	chr11:111637200	PPP2R1B	-0.97	-9.75	-0.66	5.24e-17	Primary sclerosing cholangitis;
TGCT	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg11952622	chr19:58962976	ZNF324B	0.75	6.72	0.52	5.95e-10	Mean platelet volume;
TGCT	cis	rs72945132	0.882	rs7941933	chr11:70123351	G/A	cg00319359	chr11:70116639	PPFIA1	0.97	7.07	0.54	1.01e-10	Coronary artery disease;
TGCT	cis	rs651907	0.557	rs34376498	chr3:101480156	C/T	cg12386194	chr3:101231763	SENP7	0.48	4.68	0.39	7.26e-6	Colorectal cancer;
TGCT	cis	rs6546537	0.785	rs4852863	chr2:69814609	A/T	cg10773587	chr2:69614142	GFPT1	-0.81	-7.43	-0.55	1.57e-11	Serum thyroid-stimulating hormone levels;
TGCT	cis	rs36051895	0.658	rs10974912	chr9:5010885	A/C	cg02405213	chr9:5042618	JAK2	-0.76	-10.25	-0.68	3.06e-18	Pediatric autoimmune diseases;
TGCT	cis	rs12142240	0.698	rs10158236	chr1:46820896	G/T	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs11785400	0.793	rs6996760	chr8:143722386	G/A	cg10596483	chr8:143751796	JRK	0.53	5.23	0.43	7.02e-7	Schizophrenia;
TGCT	cis	rs1667284	0.510	rs1791228	chr18:29179040	C/T	cg15259973	chr18:29078565	DSG2	0.47	4.49	0.37	1.61e-5	Problematic alcohol use in trauma-exposed individuals;
TGCT	cis	rs2013441	0.965	rs7207611	chr17:20204516	C/T	cg18979559	chr17:20280153	CCDC144C	0.49	4.99	0.41	1.97e-6	Obesity-related traits;
TGCT	cis	rs10751667	0.643	rs6597970	chr11:928669	C/A	cg06064525	chr11:970664	AP2A2	-0.35	-8.09	-0.59	4.54e-13	Alzheimer's disease (late onset);
TGCT	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	5.8	0.46	5.19e-8	Alzheimer's disease;
TGCT	cis	rs700590	0.532	rs17558396	chr5:88102281	T/G	cg24804195	chr5:87968844	LOC645323	-0.48	-4.48	-0.37	1.7e-5	Educational attainment (years of education);
TGCT	cis	rs35160687	0.842	rs10200526	chr2:86527599	G/A	cg04877910	chr2:85804641	VAMP8	0.34	4.51	0.38	1.49e-5	Night sleep phenotypes;
TGCT	cis	rs172166	0.516	rs1150670	chr6:28130559	A/G	cg13525197	chr6:28411240	ZSCAN23	-0.48	-4.71	-0.39	6.43e-6	Cardiac Troponin-T levels;
TGCT	cis	rs1008375	0.932	rs9884565	chr4:17655096	A/G	cg16339924	chr4:17578868	LAP3	0.67	5.48	0.44	2.23e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg11764359	chr7:65958608	NA	0.56	5.11	0.42	1.17e-6	Aortic root size;
TGCT	cis	rs35146811	0.695	rs1623264	chr7:99811204	G/C	cg13334819	chr7:99746414	C7orf59	0.74	6.31	0.49	4.4e-9	Coronary artery disease;
TGCT	cis	rs17152411	0.895	rs7900929	chr10:126584999	A/C	cg07906193	chr10:126599966	NA	0.41	5.05	0.41	1.52e-6	Height;
TGCT	cis	rs68170813	0.559	rs77641084	chr7:106970522	G/A	cg02696742	chr7:106810147	HBP1	-0.68	-5.64	-0.45	1.09e-7	Coronary artery disease;
TGCT	cis	rs72781680	0.898	rs2879640	chr2:24043573	T/C	cg08917208	chr2:24149416	ATAD2B	0.8	4.93	0.4	2.62e-6	Lymphocyte counts;
TGCT	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg24531977	chr5:56204891	C5orf35	0.97	9.1	0.63	1.86e-15	Initial pursuit acceleration;
TGCT	cis	rs3733585	0.699	rs7663079	chr4:9966771	T/C	cg00071950	chr4:10020882	SLC2A9	-0.57	-6.85	-0.52	3.12e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs981844	0.712	rs11099915	chr4:154743624	A/G	cg14289246	chr4:154710475	SFRP2	-1.0	-9.26	-0.64	7.7e-16	Response to statins (LDL cholesterol change);
TGCT	cis	rs10883723	0.668	rs12414479	chr10:104420902	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.78	7.31	0.55	2.8e-11	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	4.93	0.4	2.6e-6	Menopause (age at onset);
TGCT	cis	rs17423910	0.950	rs12135034	chr1:66646184	A/G	cg04880992	chr1:67434664	MIER1	-0.31	-4.5	-0.37	1.53e-5	Acute lymphoblastic leukemia (childhood);
TGCT	cis	rs10782582	0.609	rs11584577	chr1:76242378	A/G	cg03433033	chr1:76189801	ACADM	-0.45	-4.6	-0.38	1.02e-5	Daytime sleep phenotypes;
TGCT	cis	rs4319547	0.656	rs3817011	chr12:122819566	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.6	-4.62	-0.38	9.46e-6	Body mass index;
TGCT	cis	rs1992660	0.504	rs10941505	chr5:40399246	G/A	cg01087697	chr5:40835557	RPL37	0.54	4.93	0.4	2.6e-6	Crohn's disease;
TGCT	cis	rs1475911	0.708	rs66994219	chr21:43521647	G/A	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.31	-5.84	-0.46	4.24e-8	IgG glycosylation;
TGCT	cis	rs9534288	0.700	rs4942466	chr13:46597190	A/G	cg15192986	chr13:46630673	CPB2	-0.49	-6.92	-0.53	2.11e-10	Blood protein levels;
TGCT	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	-1.15	-10.22	-0.68	3.75e-18	Platelet count;
TGCT	cis	rs2594989	0.887	rs2454513	chr3:11549596	C/T	cg00170343	chr3:11313890	ATG7	0.65	4.58	0.38	1.13e-5	Circulating chemerin levels;
TGCT	trans	rs4332037	0.950	rs11767515	chr7:1941051	C/T	cg10840412	chr1:235813424	GNG4	1.04	8.16	0.59	3.22e-13	Bipolar disorder;
TGCT	cis	rs911555	0.755	rs6575988	chr14:103900827	G/T	cg12935359	chr14:103987150	CKB	0.32	4.47	0.37	1.73e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs709400	0.859	rs942863	chr14:104021268	C/T	cg26031613	chr14:104095156	KLC1	1.19	16.9	0.83	5.78e-34	Body mass index;
TGCT	cis	rs11190604	0.767	rs11190519	chr10:102175133	C/T	cg16342193	chr10:102329863	NA	-0.39	-5.05	-0.41	1.54e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg20637647	chr7:64974828	NA	0.96	5.61	0.45	1.26e-7	Diabetic kidney disease;
TGCT	cis	rs4466137	1.000	rs4466137	chr5:82985739	A/C	cg16102102	chr5:83017553	HAPLN1	-0.91	-11.43	-0.72	4.29e-21	Prostate cancer;
TGCT	cis	rs4494114	0.967	rs9438991	chr1:39376504	G/A	cg25970120	chr1:39325951	RRAGC	-0.59	-5.86	-0.47	3.9e-8	Blood protein levels;
TGCT	cis	rs11190604	1.000	rs2495751	chr10:102327260	A/G	cg23241863	chr10:102295624	HIF1AN	0.67	5.1	0.42	1.23e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs3007729	1.000	rs3007729	chr1:18795255	A/G	cg13507429	chr1:18807550	KLHDC7A	-0.34	-5.03	-0.41	1.65e-6	Diabetic retinopathy;
TGCT	cis	rs7100689	0.646	rs10749581	chr10:82141651	A/G	cg01528321	chr10:82214614	TSPAN14	-0.81	-8.6	-0.61	2.92e-14	Post bronchodilator FEV1;
TGCT	cis	rs9611565	0.592	rs28750375	chr22:41990644	A/C	cg03806693	chr22:41940476	POLR3H	-1.01	-10.2	-0.68	4.07e-18	Vitiligo;
TGCT	cis	rs4499344	0.526	rs8100915	chr19:33032310	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.64	-5.58	-0.45	1.44e-7	Mean platelet volume;
TGCT	cis	rs3138083	0.607	rs12376134	chr9:35643284	C/T	cg07116010	chr9:35646325	NA	0.82	10.29	0.68	2.44e-18	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);
TGCT	cis	rs11577318	0.853	rs7537477	chr1:26618829	C/T	cg12733254	chr1:26682999	NA	-0.2	-4.67	-0.39	7.71e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs4733770	0.581	rs12550366	chr8:131136047	A/T	cg16277922	chr8:131349729	ASAP1	0.44	6.55	0.51	1.41e-9	Schizophrenia;
TGCT	cis	rs6693567	0.565	rs696615	chr1:150338988	A/C	cg09579323	chr1:150459698	TARS2	0.52	4.57	0.38	1.15e-5	Migraine;
TGCT	cis	rs7523273	0.565	rs3927459	chr1:207883907	A/C	cg22525895	chr1:207977042	MIR29B2	0.32	5.16	0.42	9.52e-7	Schizophrenia;
TGCT	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg13206674	chr6:150067644	NUP43	0.54	4.61	0.38	1e-5	Lung cancer;
TGCT	cis	rs7095607	0.813	rs7908489	chr10:69932557	C/T	cg18986048	chr10:69913749	MYPN	0.44	4.92	0.4	2.64e-6	Lung function (FVC);
TGCT	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg24829409	chr8:58192753	C8orf71	-0.57	-4.72	-0.39	6.14e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs13256369	0.760	rs7839473	chr8:8575836	C/T	cg17143192	chr8:8559678	CLDN23	0.63	5.93	0.47	2.8e-8	Obesity-related traits;
TGCT	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg06634786	chr22:41940651	POLR3H	0.89	8.55	0.61	3.83e-14	Vitiligo;
TGCT	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.5	-5.84	-0.46	4.32e-8	Longevity;Endometriosis;
TGCT	cis	rs28595532	0.841	rs115924581	chr4:119786333	T/C	cg14228332	chr4:119757509	SEC24D	1.26	7.08	0.54	9.26e-11	Cannabis dependence symptom count;
TGCT	cis	rs9402673	0.558	rs9688342	chr6:135323026	A/T	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.36e-6	Reticulocyte count;High light scatter reticulocyte count;
TGCT	cis	rs8013055	0.796	rs28662250	chr14:105996341	C/G	cg23356831	chr14:105996513	TMEM121	0.34	5.04	0.41	1.62e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.54	-0.38	1.33e-5	Bipolar disorder;
TGCT	cis	rs7647973	0.516	rs4499638	chr3:49202782	C/G	cg05785598	chr3:49045655	WDR6	0.37	4.87	0.4	3.34e-6	Menarche (age at onset);
TGCT	cis	rs7017914	0.967	rs1596566	chr8:71698576	A/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.53	-4.98	-0.41	2.09e-6	Bone mineral density;
TGCT	cis	rs244731	0.920	rs244707	chr5:176555636	A/T	cg06060754	chr5:176797920	RGS14	0.44	5.89	0.47	3.45e-8	Urate levels in lean individuals;
TGCT	cis	rs9660180	0.967	rs61422524	chr1:1767565	C/A	cg03396347	chr1:1875803	NA	-0.38	-6.74	-0.52	5.2400000000000005e-10	Body mass index;
TGCT	cis	rs259282	0.605	rs36107586	chr19:33109674	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.6	5.33	0.43	4.48e-7	Schizophrenia;
TGCT	cis	rs2204008	0.635	rs1283298	chr12:38147630	G/A	cg26384229	chr12:38710491	ALG10B	-0.58	-5.08	-0.42	1.34e-6	Bladder cancer;
TGCT	cis	rs7726839	0.540	rs72703083	chr5:595365	C/T	cg20362242	chr5:692897	TPPP	0.53	4.56	0.38	1.22e-5	Obesity-related traits;
TGCT	cis	rs2645424	0.635	rs6980952	chr8:11716473	C/G	cg21281001	chr8:11725306	CTSB	-0.54	-4.49	-0.37	1.59e-5	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
TGCT	cis	rs13191362	1.000	rs34918316	chr6:163005386	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs10032931	0.962	rs7686970	chr4:96457107	G/A	cg17031751	chr4:96469067	UNC5C	-0.41	-4.95	-0.41	2.35e-6	Optic nerve measurement (cup-to-disc ratio);
TGCT	cis	rs854765	0.718	rs6502629	chr17:17869642	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.67	6.54	0.51	1.47e-9	Total body bone mineral density;
TGCT	cis	rs4808199	0.947	rs4808960	chr19:19574277	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.72	5.15	0.42	9.94e-7	Nonalcoholic fatty liver disease;
TGCT	cis	rs1799949	0.965	rs4793237	chr17:41436595	A/T	cg23758822	chr17:41437982	NA	0.65	6.4	0.5	2.97e-9	Menopause (age at onset);
TGCT	cis	rs7666738	0.830	rs6846229	chr4:99016546	C/T	cg18180107	chr4:99064573	C4orf37	0.54	5.03	0.41	1.7e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs988712	0.622	rs10767664	chr11:27725986	T/A	cg10635145	chr11:27742435	BDNF	0.44	6.37	0.5	3.35e-9	Obesity;
TGCT	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg23156509	chr2:114033830	PAX8;LOC440839	-0.31	-4.83	-0.4	3.92e-6	Lymphocyte counts;
TGCT	cis	rs1385374	0.858	rs11059926	chr12:129294244	A/T	cg09035930	chr12:129282057	SLC15A4	-0.55	-4.76	-0.39	5.27e-6	Systemic lupus erythematosus;
TGCT	cis	rs1669338	1.000	rs1669338	chr3:3199635	A/C	cg16797762	chr3:3221439	CRBN	0.69	4.72	0.39	6.15e-6	White matter integrity;
TGCT	cis	rs7666738	0.791	rs13125277	chr4:99009922	T/G	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8077889	0.917	rs72836559	chr17:41913529	C/T	cg26893861	chr17:41843967	DUSP3	1.08	12.97	0.76	7.86e-25	Triglycerides;
TGCT	cis	rs6964587	0.967	rs13233496	chr7:91813035	T/C	cg22709100	chr7:91322751	NA	0.29	4.62	0.38	9.65e-6	Breast cancer;
TGCT	cis	rs6866344	0.697	rs11748495	chr5:178130000	A/G	cg10224037	chr5:178157518	ZNF354A	-0.96	-8.44	-0.6	7.15e-14	Neutrophil percentage of white cells;
TGCT	cis	rs2239547	0.657	rs2276817	chr3:52860936	C/T	cg11645453	chr3:52864694	ITIH4	0.34	5.67	0.45	9.34e-8	Schizophrenia;
TGCT	cis	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg03213289	chr20:61660250	NA	0.68	9.9	0.66	2.25e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7552404	0.924	rs2153126	chr1:76199345	C/G	cg22875332	chr1:76189707	ACADM	0.77	9.49	0.65	2.13e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs3784262	1.000	rs4646627	chr15:58255305	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.49	-7.7	-0.57	3.78e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs9303401	0.659	rs9303399	chr17:56672309	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.67	6.16	0.48	9.32e-9	Cognitive test performance;
TGCT	cis	rs7119	0.717	rs12901471	chr15:77818992	A/G	cg27398640	chr15:77910606	LINGO1	-0.25	-4.61	-0.38	1e-5	Type 2 diabetes;
TGCT	cis	rs611744	0.934	rs1668178	chr8:109191700	A/G	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs11671005	0.651	rs11878203	chr19:58920050	G/A	cg13877915	chr19:58951672	ZNF132	0.63	4.99	0.41	1.99e-6	Mean platelet volume;
TGCT	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.71	6.36	0.5	3.53e-9	Tonsillectomy;
TGCT	cis	rs2762353	0.574	rs9467570	chr6:25699283	C/A	cg03517284	chr6:25882590	NA	0.91	9.09	0.63	1.99e-15	Blood metabolite levels;
TGCT	cis	rs739496	0.614	rs7137889	chr12:112379587	A/G	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs2290402	0.536	rs4690203	chr4:881228	C/T	cg23332689	chr4:987652	IDUA;SLC26A1	0.33	5.0	0.41	1.94e-6	Type 2 diabetes;
TGCT	cis	rs2932538	0.961	rs2932539	chr1:113215786	A/G	cg22162597	chr1:113214053	CAPZA1	-0.28	-6.31	-0.49	4.46e-9	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg20007245	chr22:24372913	LOC391322	-0.66	-6.2	-0.49	7.68e-9	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7666738	0.535	rs6850010	chr4:98971601	A/T	cg17366294	chr4:99064904	C4orf37	0.65	6.3	0.49	4.76e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7666738	0.830	rs3846443	chr4:99032666	G/A	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2932538	0.922	rs6690169	chr1:113114974	A/G	cg22162597	chr1:113214053	CAPZA1	0.27	5.98	0.47	2.24e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs11190604	1.000	rs2489053	chr10:102353341	A/G	cg23241863	chr10:102295624	HIF1AN	0.76	5.49	0.44	2.22e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg13877915	chr19:58951672	ZNF132	0.91	11.55	0.72	2.15e-21	Uric acid clearance;
TGCT	cis	rs6882046	0.513	rs647983	chr5:88048071	T/C	cg24804195	chr5:87968844	LOC645323	-0.57	-5.69	-0.46	8.66e-8	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs57590327	0.679	rs35381070	chr3:81590374	G/A	cg07356753	chr3:81810745	GBE1	-0.54	-4.53	-0.38	1.38e-5	Extraversion;
TGCT	cis	rs12549902	0.800	rs4736999	chr8:41506152	C/G	cg21772509	chr8:41503840	NKX6-3	0.81	9.15	0.63	1.42e-15	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
TGCT	trans	rs1496653	0.602	rs71322185	chr3:23470528	A/G	cg02770683	chr12:57597238	LRP1	0.38	6.89	0.53	2.53e-10	Type 2 diabetes;
TGCT	cis	rs9443645	0.901	rs971994	chr6:79559602	G/C	cg09184832	chr6:79620586	NA	-0.48	-5.35	-0.43	4.01e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs61931739	0.500	rs7298322	chr12:34445489	A/T	cg06521331	chr12:34319734	NA	-0.28	-4.51	-0.38	1.47e-5	Morning vs. evening chronotype;
TGCT	cis	rs13242816	1.000	rs13226307	chr7:116137485	A/T	cg02799643	chr7:116139180	CAV2	0.46	5.92	0.47	3e-8	P wave duration;
TGCT	cis	rs7017914	0.934	rs1389202	chr8:71852285	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.55	-5.29	-0.43	5.4e-7	Bone mineral density;
TGCT	cis	rs669446	0.591	rs607062	chr1:44133016	A/G	cg12908607	chr1:44402522	ARTN	-0.52	-5.89	-0.47	3.37e-8	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs12497850	1.000	rs4858798	chr3:48727112	C/T	cg07636037	chr3:49044803	WDR6	0.92	10.35	0.68	1.74e-18	Parkinson's disease;
TGCT	cis	rs10992471	0.603	rs7865019	chr9:95325631	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.6	-5.71	-0.46	7.82e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs6424115	0.800	rs2229583	chr1:24200983	C/T	cg15997130	chr1:24165203	NA	0.85	9.35	0.64	4.75e-16	Immature fraction of reticulocytes;
TGCT	cis	rs13256369	0.901	rs12681298	chr8:8566235	A/G	cg18904891	chr8:8559673	CLDN23	-0.59	-5.5	-0.44	2.11e-7	Obesity-related traits;
TGCT	cis	rs858239	0.601	rs10224327	chr7:23161820	T/C	cg05602783	chr7:23145260	KLHL7	-0.7	-6.14	-0.48	1.03e-8	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs7127900	0.614	rs11564708	chr11:2206326	C/G	cg08005462	chr11:2212133	NA	-0.28	-4.5	-0.37	1.53e-5	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
TGCT	cis	rs6121246	0.528	rs6060252	chr20:30191084	A/G	cg13852791	chr20:30311386	BCL2L1	0.69	4.54	0.38	1.33e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs2013441	1.000	rs1561974	chr17:20196144	G/A	cg18979559	chr17:20280153	CCDC144C	-0.49	-5.04	-0.41	1.59e-6	Obesity-related traits;
TGCT	cis	rs8056893	0.686	rs10775304	chr16:68411162	C/T	cg02226672	chr16:68398533	SMPD3	0.21	4.47	0.37	1.72e-5	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
TGCT	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg03264133	chr6:25882463	NA	-0.67	-6.3	-0.49	4.73e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7726839	0.540	rs57306627	chr5:597643	T/C	cg20362242	chr5:692897	TPPP	0.53	4.56	0.38	1.22e-5	Obesity-related traits;
TGCT	cis	rs600231	0.508	rs11227202	chr11:65242717	G/A	cg17120908	chr11:65337727	SSSCA1	-0.57	-4.45	-0.37	1.9e-5	Bone mineral density;
TGCT	trans	rs11088226	0.681	rs2833926	chr21:33975279	A/G	cg09050820	chr6:167586206	TCP10L2	0.76	7.3	0.55	3.04e-11	Gastritis;
TGCT	cis	rs739496	0.895	rs7977752	chr12:111850230	G/A	cg10833066	chr12:111807467	FAM109A	0.37	4.95	0.41	2.32e-6	Platelet count;
TGCT	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg08859206	chr1:53392774	SCP2	-0.42	-6.8	-0.52	3.92e-10	Monocyte count;
TGCT	cis	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg20637647	chr7:64974828	NA	0.94	5.16	0.42	9.35e-7	Diabetic kidney disease;
TGCT	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg06873352	chr17:61820015	STRADA	0.58	6.39	0.5	3.01e-9	Prudent dietary pattern;
TGCT	cis	rs138880	0.542	rs9616393	chr22:50314809	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	1.22	7.9	0.58	1.3e-12	Schizophrenia;
TGCT	cis	rs11671005	0.735	rs3826681	chr19:58918764	A/G	cg13877915	chr19:58951672	ZNF132	0.63	4.92	0.4	2.74e-6	Mean platelet volume;
TGCT	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.03	0.41	1.68e-6	Prudent dietary pattern;
TGCT	cis	rs2996428	0.667	rs7545274	chr1:3744261	G/T	cg13057898	chr1:3703894	LRRC47	0.21	4.55	0.38	1.27e-5	Red cell distribution width;
TGCT	cis	rs2153535	0.580	rs9406163	chr6:8466642	C/T	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs10031466	1.000	rs10031466	chr4:189015402	G/A	cg04086012	chr4:189060900	TRIML1	-0.2	-4.53	-0.38	1.38e-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs981844	0.816	rs62325151	chr4:154730595	A/G	cg14289246	chr4:154710475	SFRP2	1.04	9.12	0.63	1.69e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg12570787	chr5:219185	SDHA;CCDC127	0.65	4.46	0.37	1.83e-5	Breast cancer;
TGCT	cis	rs9467711	0.516	rs555460	chr6:25870655	C/T	cg03517284	chr6:25882590	NA	-0.77	-5.18	-0.42	8.65e-7	Autism spectrum disorder or schizophrenia;
TGCT	trans	rs11722228	0.522	rs73212817	chr4:10064011	T/C	cg26043149	chr18:55253948	FECH	1.1	10.46	0.68	9.51e-19	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs6918586	0.658	rs198844	chr6:26108282	C/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.7	-6.6	-0.51	1.05e-9	Schizophrenia;
TGCT	cis	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg25427524	chr10:38739819	LOC399744	-0.38	-7.91	-0.58	1.23e-12	Extrinsic epigenetic age acceleration;
TGCT	cis	rs11578119	0.866	rs12133032	chr1:170353206	G/C	cg09767346	chr1:170501363	GORAB	0.61	4.61	0.38	9.8e-6	Male-pattern baldness;
TGCT	trans	rs10435719	0.867	rs62493601	chr8:11788307	C/T	cg15556689	chr8:8085844	FLJ10661	0.78	7.34	0.55	2.46e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs727505	0.909	rs7810427	chr7:124645103	C/T	cg23710748	chr7:124431027	NA	-0.26	-4.55	-0.38	1.27e-5	Lewy body disease;
TGCT	cis	rs7119038	0.509	rs10892260	chr11:118583525	A/C	cg19308663	chr11:118741387	NA	0.25	4.64	0.38	8.77e-6	Sjögren's syndrome;
TGCT	cis	rs737008	0.922	rs376374	chr16:11370616	G/A	cg00044050	chr16:11439710	C16orf75	-0.68	-6.92	-0.53	2.12e-10	Obesity-related traits;
TGCT	cis	rs6912958	0.525	rs242262	chr6:88018057	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.45	5.9	0.47	3.25e-8	Monocyte percentage of white cells;
TGCT	cis	rs4595586	0.525	rs3914597	chr12:39388693	G/A	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	trans	rs1814175	0.817	rs12277258	chr11:49940216	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.36	-7.05	-0.53	1.13e-10	Height;
TGCT	cis	rs929354	0.772	rs4716460	chr7:156970054	T/C	cg05182265	chr7:156933206	UBE3C	-0.39	-8.79	-0.62	1.03e-14	Body mass index;
TGCT	cis	rs56235845	0.694	rs12055081	chr5:176757191	C/T	cg17509989	chr5:176798049	RGS14	0.55	7.58	0.56	6.89e-12	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs79349575	0.783	rs12602746	chr17:47031741	A/C	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.52	-0.38	1.44e-5	Type 2 diabetes;
TGCT	cis	rs1577917	0.958	rs12216074	chr6:86520002	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-5.53	-0.44	1.82e-7	Response to antipsychotic treatment;
TGCT	cis	rs7617773	0.817	rs11710861	chr3:48297560	C/T	cg11946769	chr3:48343235	NME6	0.72	6.22	0.49	6.83e-9	Coronary artery disease;
TGCT	cis	rs9486715	0.758	rs2971610	chr6:97027380	C/T	cg18709589	chr6:96969512	KIAA0776	-0.87	-8.46	-0.61	6.16e-14	Headache;
TGCT	cis	rs9486719	0.901	rs760619	chr6:96857431	A/G	cg06623918	chr6:96969491	KIAA0776	0.98	8.23	0.59	2.13e-13	Migraine;Coronary artery disease;
TGCT	trans	rs783396	0.685	rs36016898	chr6:107088231	C/T	cg27564810	chr2:201635376	AOX2P	0.5	6.61	0.51	1e-9	Stroke;
TGCT	cis	rs9388451	0.903	rs7758115	chr6:126061502	C/T	cg10911889	chr6:126070802	HEY2	0.48	4.82	0.4	4.09e-6	Brugada syndrome;
TGCT	cis	rs9916302	0.851	rs11078904	chr17:37650569	G/A	cg15445000	chr17:37608096	MED1	0.31	4.59	0.38	1.06e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs7659604	0.540	rs11734075	chr4:122695685	C/T	cg06713675	chr4:122721982	EXOSC9	0.35	4.48	0.37	1.64e-5	Type 2 diabetes;
TGCT	cis	rs4242434	0.726	rs10105545	chr8:22534232	A/G	cg03733263	chr8:22462867	KIAA1967	-1.08	-14.87	-0.8	2.45e-29	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs8103278	1.000	rs8102876	chr19:46332842	C/T	cg11657440	chr19:46296263	DMWD	-0.6	-5.7	-0.46	8.16e-8	Coronary artery disease;
TGCT	cis	rs3733585	0.673	rs7672947	chr4:9961368	G/C	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.67	-0.51	7.44e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7772486	0.875	rs2777476	chr6:146345024	A/G	cg23711669	chr6:146136114	FBXO30	0.89	9.64	0.65	9.38e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2594989	0.943	rs346072	chr3:11306851	A/G	cg00170343	chr3:11313890	ATG7	-0.72	-5.13	-0.42	1.08e-6	Circulating chemerin levels;
TGCT	cis	rs10992471	0.528	rs7022562	chr9:95216340	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.52	-4.91	-0.4	2.8e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs2921073	0.509	rs2976931	chr8:8257317	C/A	cg15556689	chr8:8085844	FLJ10661	0.73	6.64	0.51	8.65e-10	Parkinson's disease;
TGCT	cis	rs644799	0.710	rs12272061	chr11:95524067	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.79	8.65	0.61	2.18e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs3784262	0.669	rs3784259	chr15:58257847	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.42	-6.11	-0.48	1.19e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg18230493	chr5:56204884	C5orf35	-0.68	-5.92	-0.47	2.92e-8	Initial pursuit acceleration;
TGCT	cis	rs2070488	1.000	rs13089394	chr3:38446309	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	9.65	0.65	9.06e-17	Electrocardiographic conduction measures;
TGCT	cis	rs4819052	0.851	rs2236443	chr21:46678174	T/C	cg06618935	chr21:46677482	NA	-0.39	-5.82	-0.46	4.8e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2290402	0.505	rs9328759	chr4:882845	C/T	cg14959580	chr4:1402198	NA	-0.4	-4.44	-0.37	1.99e-5	Type 2 diabetes;
TGCT	cis	rs2602836	0.830	rs2602874	chr4:100039396	A/T	cg13256891	chr4:100009986	ADH5	0.45	4.67	0.39	7.66e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg00908189	chr16:619842	PIGQ	0.87	10.68	0.69	2.85e-19	Height;
TGCT	cis	rs7659604	0.502	rs4315813	chr4:122674866	G/A	cg19748678	chr4:122722346	EXOSC9	-0.51	-5.0	-0.41	1.93e-6	Type 2 diabetes;
TGCT	cis	rs7572733	0.534	rs700672	chr2:198691455	G/A	cg00792783	chr2:198669748	PLCL1	0.56	5.08	0.42	1.35e-6	Dermatomyositis;
TGCT	cis	rs1691799	0.899	rs1168328	chr12:66729250	T/C	cg16791601	chr12:66731901	HELB	-0.28	-6.17	-0.48	8.87e-9	White blood cell count (basophil);
TGCT	cis	rs7917772	0.636	rs7079231	chr10:104527341	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.58	4.85	0.4	3.6e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs62244186	0.541	rs9859879	chr3:44840166	G/A	cg04389838	chr3:44770851	ZNF501	-0.37	-4.81	-0.4	4.37e-6	Depressive symptoms;
TGCT	cis	rs12579753	1.000	rs10862374	chr12:82250809	G/C	cg07988820	chr12:82153109	PPFIA2	-0.6	-6.61	-0.51	1.01e-9	Resting heart rate;
TGCT	cis	rs11696501	0.637	rs6130865	chr20:44211845	C/T	cg11783356	chr20:44313418	WFDC10B	-0.33	-4.66	-0.39	7.97e-6	Brain structure;
TGCT	cis	rs806215	0.950	rs989099	chr7:127220827	A/G	cg25922125	chr7:127225783	GCC1	-0.6	-6.2	-0.49	7.6e-9	Type 2 diabetes;
TGCT	cis	rs7267979	1.000	rs6050544	chr20:25320228	T/A	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9467711	0.606	rs12174631	chr6:26373150	C/T	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs3806843	1.000	rs1548700	chr5:140164889	A/T	cg19875535	chr5:140030758	IK	0.37	6.17	0.48	8.88e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7172809	0.643	rs61097729	chr15:77834358	C/G	cg22256960	chr15:77711686	NA	-0.49	-4.93	-0.4	2.56e-6	Glucose homeostasis traits;
TGCT	cis	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg20362242	chr5:692897	TPPP	0.48	4.51	0.38	1.47e-5	Lung disease severity in cystic fibrosis;
TGCT	cis	rs7412746	0.658	rs2272214	chr1:150931462	C/T	cg09365446	chr1:150670422	GOLPH3L	0.32	4.57	0.38	1.15e-5	Melanoma;
TGCT	cis	rs611744	0.967	rs627604	chr8:109189819	C/G	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs6840360	0.615	rs12503677	chr4:152610543	A/G	cg22705602	chr4:152727874	NA	-0.36	-5.97	-0.47	2.28e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs78487399	0.808	rs6728106	chr2:43683885	A/C	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.66	4.43	0.37	2.01e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs8056446	1.000	rs12716852	chr16:78188738	C/T	cg00663719	chr16:78231199	WWOX	0.27	5.02	0.41	1.72e-6	Pulmonary function (smoking interaction);
TGCT	cis	rs9614461	0.702	rs16993867	chr22:45733199	A/G	cg01808030	chr22:45809952	RIBC2;SMC1B	0.77	4.78	0.39	4.88e-6	Tonsillectomy;
TGCT	cis	rs72781680	0.821	rs12616257	chr2:24135034	A/G	cg08917208	chr2:24149416	ATAD2B	0.74	4.66	0.39	7.9e-6	Lymphocyte counts;
TGCT	cis	rs6463523	0.933	rs6974151	chr7:758269	T/C	cg14391382	chr7:866102	UNC84A	0.21	4.65	0.39	8.29e-6	Subjective well-being;
TGCT	cis	rs950880	0.560	rs11685480	chr2:102927086	G/A	cg09003973	chr2:102972529	NA	-0.52	-4.52	-0.38	1.45e-5	Serum protein levels (sST2);
TGCT	cis	rs12360000	0.770	rs11250852	chr10:1909726	A/G	cg26364871	chr10:1889757	NA	0.41	4.63	0.38	9.26e-6	Metabolite levels (Dihydroxy docosatrienoic acid);
TGCT	cis	rs9341808	0.718	rs3828754	chr6:80900640	C/G	cg08355045	chr6:80787529	NA	0.32	5.6	0.45	1.29e-7	Sitting height ratio;
TGCT	cis	rs6500602	0.610	rs1659499	chr16:4595269	G/A	cg08645402	chr16:4508243	NA	-0.18	-5.16	-0.42	9.69e-7	Schizophrenia;
TGCT	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg07157834	chr1:205819609	PM20D1	0.44	7.12	0.54	7.56e-11	Menarche (age at onset);
TGCT	cis	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg22857025	chr5:266934	NA	-0.34	-6.7	-0.52	6.65e-10	Breast cancer;
TGCT	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg11764359	chr7:65958608	NA	-0.55	-4.98	-0.41	2.1e-6	Aortic root size;
TGCT	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg13770153	chr20:60521292	NA	-0.54	-7.13	-0.54	7.45e-11	Body mass index;
TGCT	trans	rs2727020	0.636	rs10839275	chr11:49438962	T/A	cg15704280	chr7:45808275	SEPT13	-0.73	-8.23	-0.59	2.15e-13	Coronary artery disease;
TGCT	cis	rs2013441	1.000	rs11870147	chr17:20216095	A/G	cg23224458	chr17:20280056	CCDC144C	-0.39	-4.7	-0.39	6.91e-6	Obesity-related traits;
TGCT	cis	rs9296092	0.500	rs9461885	chr6:33521069	G/T	cg13560919	chr6:33536144	NA	-0.21	-4.75	-0.39	5.5e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg06028605	chr16:24865363	SLC5A11	0.41	4.53	0.38	1.36e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs6818045	chr4:99049374	G/A	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2239547	0.657	rs7638524	chr3:52874861	G/A	cg10802521	chr3:52805072	NEK4	-0.65	-6.12	-0.48	1.16e-8	Schizophrenia;
TGCT	cis	rs7772486	0.727	rs10223508	chr6:146285205	C/T	cg23711669	chr6:146136114	FBXO30	-0.85	-9.52	-0.65	1.86e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6940638	0.956	rs12203454	chr6:27031100	C/T	cg26531700	chr6:26746687	NA	-0.6	-4.63	-0.38	9.25e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs11725652	chr4:98878362	G/A	cg05340658	chr4:99064831	C4orf37	0.53	6.1	0.48	1.22e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12134133	1.000	rs7522618	chr1:207417426	A/G	cg02152968	chr1:207494213	CD55	0.61	4.76	0.39	5.4e-6	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs2439831	0.850	rs10163054	chr15:44047638	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	5.91	0.47	3.05e-8	Lung cancer in ever smokers;
TGCT	cis	rs3862435	0.610	rs2601204	chr15:90961518	G/A	cg14166756	chr15:90894880	ZNF774	-0.3	-4.6	-0.38	1.02e-5	Response to exercise (triglyceride level interaction);
TGCT	cis	rs986417	0.892	rs11622577	chr14:60814981	A/T	cg27398547	chr14:60952738	C14orf39	-1.5	-8.03	-0.58	6.38e-13	Gut microbiota (bacterial taxa);
TGCT	cis	rs11644362	1.000	rs11644362	chr16:12994097	T/C	cg06890432	chr16:12997467	SHISA9	-0.61	-6.77	-0.52	4.49e-10	Positive affect;Subjective well-being;
TGCT	cis	rs9916302	0.904	rs7223331	chr17:37482930	A/G	cg15445000	chr17:37608096	MED1	-0.33	-4.71	-0.39	6.46e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7223966	1.000	rs6504168	chr17:61697469	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	4.76	0.39	5.39e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs10791097	0.694	rs876641	chr11:130752040	A/C	cg14779329	chr11:130786720	SNX19	0.29	5.01	0.41	1.85e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs4919694	1.000	rs12252500	chr10:104794984	G/C	cg04362960	chr10:104952993	NT5C2	1.06	7.05	0.53	1.09e-10	Arsenic metabolism;
TGCT	cis	rs28595532	0.920	rs28837152	chr4:119782868	G/A	cg14228332	chr4:119757509	SEC24D	1.19	6.66	0.51	8.07e-10	Cannabis dependence symptom count;
TGCT	cis	rs10206020	0.885	rs13388254	chr2:1577209	A/G	cg12573674	chr2:1569213	NA	-0.46	-5.2	-0.42	7.88e-7	IgG glycosylation;
TGCT	cis	rs17001868	0.527	rs73167009	chr22:40734249	T/C	cg07138101	chr22:40742427	ADSL	0.73	5.38	0.44	3.57e-7	Mammographic density (dense area);
TGCT	cis	rs4499344	0.730	rs392332	chr19:33105743	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.86	9.0	0.63	3.29e-15	Mean platelet volume;
TGCT	cis	rs9549260	0.620	rs9532580	chr13:41244260	T/C	cg21288729	chr13:41239152	FOXO1	0.78	6.18	0.49	8.64e-9	Red blood cell count;
TGCT	cis	rs6582630	0.519	rs4002438	chr12:38484880	C/T	cg26384229	chr12:38710491	ALG10B	0.83	7.6	0.56	6.18e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs12477438	0.501	rs6708878	chr2:99801564	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	10.3	0.68	2.42e-18	Chronic sinus infection;
TGCT	cis	rs11190604	1.000	rs12354411	chr10:102294537	G/A	cg16342193	chr10:102329863	NA	-0.41	-5.37	-0.43	3.78e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs453301	0.686	rs28482034	chr8:8869664	G/A	cg06636001	chr8:8085503	FLJ10661	-0.68	-5.63	-0.45	1.13e-7	Joint mobility (Beighton score);
TGCT	cis	rs9389248	0.690	rs2072826	chr6:135253558	G/C	cg22676075	chr6:135203613	NA	-0.51	-5.11	-0.42	1.17e-6	High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs7666738	0.576	rs7660951	chr4:98651581	T/A	cg17366294	chr4:99064904	C4orf37	0.57	5.29	0.43	5.46e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10791323	0.628	rs10750543	chr11:133718467	G/A	cg03690763	chr11:133734501	NA	-0.32	-4.78	-0.39	4.78e-6	Childhood ear infection;
TGCT	trans	rs2727020	0.688	rs4929894	chr11:49196333	G/C	cg03929089	chr4:120376271	NA	-0.74	-8.38	-0.6	9.81e-14	Coronary artery disease;
TGCT	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg04267008	chr7:1944627	MAD1L1	-0.36	-4.82	-0.4	4.03e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg22920501	chr2:26401640	FAM59B	-0.72	-6.22	-0.49	7.14e-9	Gut microbiome composition (summer);
TGCT	cis	rs17376456	0.877	rs12716456	chr5:93397557	A/G	cg21475434	chr5:93447410	FAM172A	0.59	4.66	0.39	8.09e-6	Diabetic retinopathy;
TGCT	cis	rs3784262	0.692	rs4646581	chr15:58307898	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.42	-6.17	-0.48	8.83e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs2692947	0.537	rs12471472	chr2:96205455	G/A	cg23100626	chr2:96804247	ASTL	0.45	5.34	0.43	4.21e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs208520	0.661	rs7740835	chr6:66865548	G/A	cg07460842	chr6:66804631	NA	-0.92	-9.58	-0.65	1.29e-16	Exhaled nitric oxide output;
TGCT	cis	rs7666738	0.830	rs7664051	chr4:98766970	C/G	cg05340658	chr4:99064831	C4orf37	0.49	5.77	0.46	6.02e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28595532	0.748	rs115651241	chr4:119363509	C/T	cg21605333	chr4:119757512	SEC24D	0.87	5.49	0.44	2.14e-7	Cannabis dependence symptom count;
TGCT	cis	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg13531842	chr10:38383804	ZNF37A	-0.38	-4.51	-0.38	1.49e-5	Extrinsic epigenetic age acceleration;
TGCT	cis	rs250677	0.958	rs17109282	chr5:148416677	A/G	cg18129178	chr5:148520854	ABLIM3	0.39	5.34	0.43	4.31e-7	Breast cancer;
TGCT	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-5.1	-0.42	1.23e-6	Bipolar disorder;
TGCT	cis	rs7017914	0.967	rs34905858	chr8:71659450	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.03	-0.41	1.69e-6	Bone mineral density;
TGCT	cis	rs68170813	0.523	rs12532447	chr7:106940476	C/T	cg02696742	chr7:106810147	HBP1	-0.72	-6.05	-0.48	1.56e-8	Coronary artery disease;
TGCT	cis	rs763014	0.865	rs4006748	chr16:632225	T/C	cg09263875	chr16:632152	PIGQ	0.3	6.4	0.5	2.88e-9	Height;
TGCT	cis	rs2239547	0.563	rs9876403	chr3:52916916	C/T	cg10802521	chr3:52805072	NEK4	-0.59	-5.71	-0.46	7.92e-8	Schizophrenia;
TGCT	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	5.98	0.47	2.27e-8	Bipolar disorder;
TGCT	cis	rs4803468	0.967	rs16975238	chr19:41944985	T/A	cg09537434	chr19:41945824	ATP5SL	0.92	10.44	0.68	1.1e-18	Height;
TGCT	cis	rs501916	1.000	rs565627	chr15:48056735	A/C	cg16110827	chr15:48056943	SEMA6D	-0.17	-5.12	-0.42	1.12e-6	Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs4478037	0.749	rs9681623	chr3:33131375	G/T	cg19404215	chr3:33155277	CRTAP	1.05	6.36	0.5	3.52e-9	Major depressive disorder;
TGCT	cis	rs4689388	0.819	rs12649341	chr4:6294759	G/A	cg14416269	chr4:6271139	WFS1	0.37	4.9	0.4	2.95e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg24549020	chr5:56110836	MAP3K1	-0.7	-5.01	-0.41	1.81e-6	Initial pursuit acceleration;
TGCT	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.54	4.47	0.37	1.77e-5	Tonsillectomy;
TGCT	cis	rs2404602	0.716	rs67920045	chr15:76800084	G/A	cg26408565	chr15:76604113	ETFA	-0.36	-4.75	-0.39	5.56e-6	Blood metabolite levels;
TGCT	cis	rs12200560	0.505	rs9400166	chr6:97077101	G/A	cg06623918	chr6:96969491	KIAA0776	0.59	5.03	0.41	1.71e-6	Coronary heart disease;
TGCT	cis	rs4478858	0.735	rs4531329	chr1:31817810	A/T	cg00250761	chr1:31883323	NA	-0.28	-4.96	-0.41	2.32e-6	Alcohol dependence;
TGCT	cis	rs7209700	0.547	rs16941780	chr17:45343183	A/G	cg21624342	chr17:45890973	OSBPL7	0.19	4.77	0.39	5.02e-6	IgG glycosylation;
TGCT	cis	rs9911578	1.000	rs4372750	chr17:57013803	A/C	cg12560992	chr17:57184187	TRIM37	-0.76	-9.21	-0.64	1.03e-15	Intelligence (multi-trait analysis);
TGCT	trans	rs547116	0.930	rs573900	chr9:113642363	C/T	cg18410444	chr5:89825535	LYSMD3	0.65	6.71	0.52	6.25e-10	Eosinophil counts;
TGCT	cis	rs9326248	0.581	rs7106437	chr11:116992076	T/C	cg20608306	chr11:116969690	SIK3	0.39	4.6	0.38	1.04e-5	Blood protein levels;
TGCT	cis	rs9393777	0.513	rs11967852	chr6:26612870	G/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.59	-5.14	-0.42	1.04e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2235642	0.891	rs2281231	chr16:1601879	A/G	cg07639376	chr16:1584516	IFT140;TMEM204	-0.31	-5.57	-0.45	1.52e-7	Coronary artery disease;
TGCT	cis	rs7772486	0.840	rs11155451	chr6:146422524	A/G	cg05347473	chr6:146136440	FBXO30	0.54	5.11	0.42	1.18e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs514406	0.584	rs12095247	chr1:53193796	A/C	cg01802117	chr1:53393560	SCP2	0.41	4.81	0.4	4.24e-6	Monocyte count;
TGCT	cis	rs7914558	0.966	rs11191471	chr10:104702050	T/A	cg04362960	chr10:104952993	NT5C2	0.58	5.15	0.42	9.77e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs908922	0.676	rs4112786	chr1:152532872	T/A	cg20991723	chr1:152506922	NA	0.44	5.97	0.47	2.29e-8	Hair morphology;
TGCT	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg10802521	chr3:52805072	NEK4	-0.64	-7.66	-0.57	4.56e-12	Electroencephalogram traits;
TGCT	cis	rs617219	0.726	rs1962002	chr5:78430689	T/C	cg09550809	chr5:78407562	BHMT	0.4	5.51	0.44	2.01e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg07424592	chr7:64974309	NA	1.33	7.99	0.58	7.81e-13	Diabetic kidney disease;
TGCT	cis	rs763014	0.931	rs1981483	chr16:630665	G/A	cg00908189	chr16:619842	PIGQ	0.87	10.5	0.69	7.53e-19	Height;
TGCT	cis	rs11924390	0.749	rs822363	chr3:186452991	C/G	cg12454167	chr3:186435060	KNG1	0.44	6.91	0.53	2.24e-10	Adiponectin levels;
TGCT	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg10295955	chr4:187884368	NA	-1.02	-15.6	-0.81	5.02e-31	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs611744	0.604	rs13248461	chr8:109285833	C/T	cg21045802	chr8:109455806	TTC35	0.71	7.33	0.55	2.63e-11	Dupuytren's disease;
TGCT	cis	rs10751667	0.643	rs7942693	chr11:957832	G/A	cg06064525	chr11:970664	AP2A2	-0.35	-8.22	-0.59	2.29e-13	Alzheimer's disease (late onset);
TGCT	cis	rs57590327	0.716	rs56106807	chr3:81765270	A/G	cg07356753	chr3:81810745	GBE1	-0.75	-6.84	-0.52	3.21e-10	Extraversion;
TGCT	cis	rs34779708	0.931	rs11596502	chr10:35387187	A/C	cg03585969	chr10:35415529	CREM	0.42	4.62	0.38	9.42e-6	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs9512730	0.906	rs4771136	chr13:28070769	C/G	cg22138327	chr13:27999177	GTF3A	0.78	5.13	0.42	1.1e-6	Schizophrenia;
TGCT	cis	rs4776059	0.876	rs2414163	chr15:52897478	T/C	cg25063058	chr15:52860530	ARPP19	0.53	4.79	0.4	4.59e-6	Schizophrenia;
TGCT	cis	rs9952991	0.941	rs2847280	chr18:12779342	A/G	cg09945482	chr18:12777974	NA	0.51	4.86	0.4	3.47e-6	Inflammatory skin disease;
TGCT	cis	rs3806843	0.576	rs246003	chr5:140340865	C/G	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg02463440	chr8:22132932	PIWIL2	0.26	5.2	0.42	7.96e-7	Hypertriglyceridemia;
TGCT	cis	rs10507380	0.824	rs9512622	chr13:27904178	C/T	cg25543773	chr13:27185723	WASF3	0.31	4.49	0.37	1.6e-5	Electrocardiographic traits;
TGCT	cis	rs28595532	0.920	rs116023344	chr4:119760263	A/G	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg24846343	chr22:24311635	DDTL	0.23	5.79	0.46	5.54e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2228479	0.850	rs11641552	chr16:89838700	C/A	cg06558623	chr16:89946397	TCF25	0.45	4.52	0.38	1.42e-5	Skin colour saturation;
TGCT	cis	rs4325129	0.871	rs4656827	chr1:159460032	A/G	cg07417683	chr1:159440267	NA	-0.39	-4.68	-0.39	7.51e-6	Obesity-related traits;
TGCT	cis	rs7223966	1.000	rs6504173	chr17:61735056	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	4.96	0.41	2.3e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs1552244	0.554	rs4488814	chr3:10002400	C/T	cg00149659	chr3:10157352	C3orf10	-0.63	-4.67	-0.39	7.66e-6	Alzheimer's disease;
TGCT	cis	rs2153535	0.580	rs4587214	chr6:8454119	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.7	0.46	8.31e-8	Motion sickness;
TGCT	cis	rs11677370	0.561	rs12986995	chr2:3826965	G/A	cg17052675	chr2:3827356	NA	-0.43	-7.81	-0.57	2.04e-12	Type 2 diabetes;
TGCT	cis	rs4654899	0.865	rs12406144	chr1:21347228	A/C	cg01072550	chr1:21505969	NA	-0.46	-6.95	-0.53	1.88e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs6964587	0.626	rs9008	chr7:91502407	C/G	cg17063962	chr7:91808500	NA	-0.76	-7.15	-0.54	6.42e-11	Breast cancer;
TGCT	cis	rs2404602	1.000	rs2404740	chr15:76852143	C/T	cg26408565	chr15:76604113	ETFA	-0.45	-5.75	-0.46	6.55e-8	Blood metabolite levels;
TGCT	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg17971929	chr21:40555470	PSMG1	-0.67	-5.89	-0.47	3.39e-8	Cognitive function;
TGCT	cis	rs67311347	1.000	rs11714912	chr3:40494065	A/G	cg13683864	chr3:40499215	RPL14	0.86	5.85	0.47	4.01e-8	Renal cell carcinoma;
TGCT	cis	rs6840360	0.533	rs13139327	chr4:152728590	A/C	cg22705602	chr4:152727874	NA	-0.36	-6.51	-0.5	1.69e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs9581857	0.579	rs1759861	chr13:27996406	A/C	cg22138327	chr13:27999177	GTF3A	-0.81	-5.85	-0.46	4.17e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs10782582	0.586	rs1796813	chr1:76400403	G/A	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.55	4.7	0.39	6.75e-6	Daytime sleep phenotypes;
TGCT	cis	rs636291	0.517	rs55935829	chr1:10540926	A/T	cg17425144	chr1:10567563	PEX14	0.53	7.51	0.56	1e-11	Prostate cancer;
TGCT	trans	rs7726839	0.540	rs72703087	chr5:598029	C/T	cg25482853	chr8:67687455	SGK3	1.27	10.56	0.69	5.48e-19	Obesity-related traits;
TGCT	cis	rs7666738	0.830	rs13138438	chr4:99050545	C/A	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7647973	1.000	rs9862534	chr3:49598064	A/G	cg05785598	chr3:49045655	WDR6	0.36	4.5	0.37	1.55e-5	Menarche (age at onset);
TGCT	cis	rs9611565	0.921	rs8137373	chr22:41729216	A/G	cg03806693	chr22:41940476	POLR3H	0.97	10.25	0.68	3.06e-18	Vitiligo;
TGCT	cis	rs7412746	0.634	rs12096831	chr1:150864113	T/G	cg09365446	chr1:150670422	GOLPH3L	0.34	4.81	0.4	4.33e-6	Melanoma;
TGCT	cis	rs9457247	0.602	rs2239827	chr6:167490945	G/A	cg07741184	chr6:167504864	NA	0.24	4.7	0.39	6.89e-6	Crohn's disease;
TGCT	cis	rs12220238	0.778	rs10824216	chr10:76409210	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.59	4.55	0.38	1.25e-5	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs4722166	0.630	rs13311199	chr7:22789793	A/C	cg26061582	chr7:22766209	IL6	0.57	7.17	0.54	5.91e-11	Lung cancer;
TGCT	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg04414720	chr1:150670196	GOLPH3L	0.39	5.11	0.42	1.2e-6	Tonsillectomy;
TGCT	cis	rs3796352	1.000	rs13076033	chr3:52898427	T/C	cg15956490	chr3:53032818	SFMBT1	0.57	4.89	0.4	3.01e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs9399135	0.967	rs7741626	chr6:135314182	C/T	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.36e-6	Red blood cell count;
TGCT	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg25036284	chr2:26402008	FAM59B	-0.55	-4.71	-0.39	6.4e-6	Gut microbiome composition (summer);
TGCT	cis	rs1153858	1.000	rs7167900	chr15:45639471	A/G	cg26924012	chr15:45694286	SPATA5L1	1.07	14.56	0.79	1.32e-28	Homoarginine levels;
TGCT	cis	rs7523273	0.505	rs34277355	chr1:207881491	C/A	cg22525895	chr1:207977042	MIR29B2	0.29	4.48	0.37	1.69e-5	Schizophrenia;
TGCT	cis	rs2456568	0.802	rs1506656	chr11:93639813	G/A	cg14065697	chr11:93583672	C11orf90	-0.36	-4.45	-0.37	1.86e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7666738	0.830	rs12233741	chr4:98950296	C/T	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg13615516	chr5:77269221	NA	0.66	8.29	0.6	1.56e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg06713675	chr4:122721982	EXOSC9	-0.68	-9.18	-0.64	1.23e-15	Type 2 diabetes;
TGCT	cis	rs7267979	1.000	rs2257982	chr20:25269630	A/G	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9611519	0.964	rs4820428	chr22:41537589	C/T	cg03806693	chr22:41940476	POLR3H	0.67	6.2	0.49	7.87e-9	Neuroticism;
TGCT	cis	rs1062177	0.724	rs2964590	chr5:151118146	C/G	cg00977110	chr5:151150581	G3BP1	-0.4	-4.67	-0.39	7.7e-6	Preschool internalizing problems;
TGCT	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg05368731	chr17:41323189	NBR1	-1.2	-14.2	-0.79	8.98e-28	Menopause (age at onset);
TGCT	cis	rs151997	0.671	rs493507	chr5:50219675	G/T	cg06027927	chr5:50259733	NA	-0.56	-5.64	-0.45	1.11e-7	Callous-unemotional behaviour;
TGCT	cis	rs9527	0.569	rs10883801	chr10:104677887	A/C	cg04362960	chr10:104952993	NT5C2	0.64	5.4	0.44	3.33e-7	Arsenic metabolism;
TGCT	cis	rs1008375	0.932	rs6844593	chr4:17659039	T/C	cg16339924	chr4:17578868	LAP3	0.66	5.52	0.44	1.89e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7582180	0.629	rs13010911	chr2:100953390	G/C	cg14675211	chr2:100938903	LONRF2	0.5	4.78	0.39	4.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs858239	0.699	rs955187	chr7:23194605	A/G	cg05602783	chr7:23145260	KLHL7	0.64	5.44	0.44	2.77e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs12497850	0.931	rs7431710	chr3:48935583	G/A	cg06212747	chr3:49208901	KLHDC8B	0.62	5.83	0.46	4.42e-8	Parkinson's disease;
TGCT	cis	rs6088590	1.000	rs55753039	chr20:33394940	C/T	cg06115741	chr20:33292138	TP53INP2	0.65	5.48	0.44	2.28e-7	Coronary artery disease;
TGCT	cis	rs4727027	0.901	rs4727018	chr7:148822247	G/C	cg23583168	chr7:148888333	NA	-0.72	-9.18	-0.64	1.18e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs2273156	1.000	rs7141292	chr14:35462906	T/A	cg15394648	chr14:35761551	PSMA6	-0.6	-4.44	-0.37	1.94e-5	Immunoglobulin light chain (AL) amyloidosis;
TGCT	cis	rs8017423	0.900	rs7141887	chr14:90705364	G/T	cg04374321	chr14:90722782	PSMC1	0.77	8.05	0.59	5.68e-13	Mortality in heart failure;
TGCT	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg23131131	chr22:24373011	LOC391322	0.81	8.72	0.62	1.53e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs651907	0.557	rs13099674	chr3:101489629	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	5.02	0.41	1.77e-6	Colorectal cancer;
TGCT	cis	rs10791097	0.694	rs11222369	chr11:130744670	A/G	cg12179176	chr11:130786555	SNX19	0.84	10.17	0.67	4.95e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	trans	rs6089829	0.888	rs4809467	chr20:61671688	A/G	cg17470723	chr8:74884337	TCEB1	0.78	6.83	0.52	3.42e-10	Prostate cancer (SNP x SNP interaction);
TGCT	trans	rs10203711	1.000	rs6713610	chr2:239566874	C/A	cg16021909	chr1:248021091	TRIM58	-0.66	-6.66	-0.51	7.94e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs13424612	0.930	rs12478169	chr2:240951603	C/T	cg26363272	chr2:240904871	NDUFA10	0.28	4.77	0.39	5.18e-6	Odorant perception (isobutyraldehyde);
TGCT	cis	rs2276314	0.857	rs9304155	chr18:33585710	A/C	cg19628046	chr18:33552617	C18orf21	0.52	4.49	0.37	1.64e-5	Endometriosis;Drug-induced torsades de pointes;
TGCT	cis	rs868036	0.634	rs8028313	chr15:68043057	C/G	cg05925327	chr15:68127851	NA	-0.51	-4.97	-0.41	2.2e-6	Restless legs syndrome;
TGCT	cis	rs6570726	0.791	rs418701	chr6:145889992	C/T	cg23711669	chr6:146136114	FBXO30	0.86	9.54	0.65	1.64e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs2535633	0.631	rs2581827	chr3:52966558	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	0.54	4.94	0.41	2.49e-6	Body mass index;
TGCT	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg20637647	chr7:64974828	NA	1.0	5.59	0.45	1.4e-7	Diabetic kidney disease;
TGCT	trans	rs941408	1.000	rs1736179	chr19:2795516	T/A	cg22153745	chr1:153894579	GATAD2B	-0.64	-7.22	-0.54	4.49e-11	Total cholesterol levels;
TGCT	cis	rs4820539	1.000	rs756631	chr22:23463183	A/G	cg14186256	chr22:23484241	RTDR1	0.97	11.78	0.73	5.73e-22	Bone mineral density;
TGCT	cis	rs6921919	0.583	rs9468354	chr6:28337801	T/A	cg18815343	chr6:28367644	ZSCAN12	-0.56	-5.37	-0.43	3.8e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs933688	0.532	rs13165085	chr5:90538448	G/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.54	-4.82	-0.4	4.09e-6	Smoking behavior;
TGCT	cis	rs17253792	0.822	rs17832371	chr14:56162302	C/A	cg01858014	chr14:56050164	KTN1	-0.35	-4.47	-0.37	1.73e-5	Putamen volume;
TGCT	cis	rs2933343	0.700	rs1683779	chr3:128642048	A/G	cg11901034	chr3:128598214	ACAD9	-0.65	-6.08	-0.48	1.37e-8	IgG glycosylation;
TGCT	cis	rs9811920	0.965	rs9837131	chr3:99854514	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.42	-4.79	-0.4	4.67e-6	Axial length;
TGCT	cis	rs2204008	0.515	rs11495471	chr12:38027178	G/A	cg13010199	chr12:38710504	ALG10B	0.65	5.24	0.43	6.68e-7	Bladder cancer;
TGCT	cis	rs1215050	0.791	rs1669745	chr4:98842047	G/A	cg17366294	chr4:99064904	C4orf37	-0.57	-6.13	-0.48	1.08e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.94	7.73	0.57	3.23e-12	Platelet count;
TGCT	cis	rs4849845	0.598	rs3889223	chr2:121024432	A/G	cg24070213	chr2:121070622	NA	0.35	4.8	0.4	4.43e-6	Mean platelet volume;
TGCT	cis	rs2455799	0.573	rs2455830	chr3:15749213	C/T	cg16303742	chr3:15540471	COLQ	-0.26	-4.91	-0.4	2.82e-6	Mean platelet volume;
TGCT	cis	rs6088580	0.634	rs6088512	chr20:33095891	G/A	cg08999081	chr20:33150536	PIGU	0.28	5.56	0.45	1.61e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs2243480	1.000	rs160646	chr7:65556280	C/T	cg18252515	chr7:66147081	NA	-1.1	-7.22	-0.54	4.49e-11	Diabetic kidney disease;
TGCT	cis	rs2836974	0.830	rs2735309	chr21:40715313	C/T	cg17971929	chr21:40555470	PSMG1	0.91	7.93	0.58	1.07e-12	Cognitive function;
TGCT	cis	rs763121	1.000	rs763121	chr22:38879940	C/T	cg06022373	chr22:39101656	GTPBP1	-0.67	-6.37	-0.5	3.4e-9	Menopause (age at onset);
TGCT	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg13397359	chr6:42928475	GNMT	0.66	5.81	0.46	4.9e-8	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs17030434	0.769	rs11727144	chr4:154645181	G/C	cg14289246	chr4:154710475	SFRP2	-0.79	-5.85	-0.47	4.04e-8	Electrocardiographic conduction measures;
TGCT	cis	rs10751667	0.666	rs6597957	chr11:982294	T/A	cg06064525	chr11:970664	AP2A2	-0.35	-7.89	-0.58	1.39e-12	Alzheimer's disease (late onset);
TGCT	cis	rs700651	0.752	rs7592556	chr2:198891021	G/A	cg00792783	chr2:198669748	PLCL1	0.59	5.19	0.42	8.27e-7	Intracranial aneurysm;
TGCT	cis	rs9291683	0.588	rs2240722	chr4:10020757	A/G	cg11266682	chr4:10021025	SLC2A9	0.69	10.28	0.68	2.66e-18	Bone mineral density;
TGCT	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg27454412	chr7:1067447	C7orf50	0.6	4.7	0.39	6.76e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7312933	0.558	rs11181463	chr12:42763636	C/T	cg19980929	chr12:42632907	YAF2	0.43	6.14	0.48	1.05e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs73001065	0.536	rs10408596	chr19:19512657	A/T	cg03709012	chr19:19516395	GATAD2A	0.88	4.69	0.39	7.11e-6	LDL cholesterol;
TGCT	cis	rs7178572	0.568	rs11632941	chr15:77533888	A/G	cg15453836	chr15:77711506	NA	-0.42	-4.79	-0.4	4.68e-6	Type 2 diabetes;
TGCT	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.52	-5.59	-0.45	1.35e-7	Lymphocyte counts;
TGCT	cis	rs2455799	0.559	rs6781202	chr3:15905881	T/C	cg12172478	chr3:16357591	RFTN1	-0.34	-5.14	-0.42	1.02e-6	Mean platelet volume;
TGCT	cis	rs2153535	0.580	rs6929206	chr6:8447961	A/G	cg07606381	chr6:8435919	SLC35B3	0.53	5.02	0.41	1.79e-6	Motion sickness;
TGCT	cis	rs68092024	0.731	rs792840	chr3:99471251	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.49	-5.99	-0.47	2.1e-8	Cleft lip with or without cleft palate;
TGCT	cis	rs62244186	0.659	rs4682745	chr3:44508967	T/C	cg04389838	chr3:44770851	ZNF501	-0.41	-5.7	-0.46	8.13e-8	Depressive symptoms;
TGCT	cis	rs17376456	0.877	rs7701011	chr5:93311456	G/A	cg21475434	chr5:93447410	FAM172A	0.65	4.85	0.4	3.58e-6	Diabetic retinopathy;
TGCT	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg08439880	chr3:133502540	NA	-0.31	-5.87	-0.47	3.69e-8	Iron status biomarkers;
TGCT	cis	rs2204008	0.570	rs1315664	chr12:38138274	A/G	cg26384229	chr12:38710491	ALG10B	-0.58	-5.09	-0.42	1.28e-6	Bladder cancer;
TGCT	cis	rs453301	0.653	rs7005133	chr8:8901222	T/G	cg06636001	chr8:8085503	FLJ10661	0.85	7.69	0.57	3.95e-12	Joint mobility (Beighton score);
TGCT	cis	rs4478858	0.663	rs11591060	chr1:31780012	G/A	cg00250761	chr1:31883323	NA	-0.27	-4.94	-0.41	2.43e-6	Alcohol dependence;
TGCT	cis	rs2996428	0.667	rs113120570	chr1:3770450	G/C	cg13057898	chr1:3703894	LRRC47	0.21	4.64	0.38	8.81e-6	Red cell distribution width;
TGCT	cis	rs6582630	0.555	rs10880421	chr12:38423015	C/T	cg13010199	chr12:38710504	ALG10B	0.61	4.94	0.41	2.52e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs896854	0.846	rs2340584	chr8:95916811	A/G	cg16049864	chr8:95962084	TP53INP1	-0.71	-9.79	-0.66	4.08e-17	Type 2 diabetes;
TGCT	cis	rs7621025	0.599	rs13063987	chr3:136445397	C/G	cg15507776	chr3:136538369	TMEM22	-0.51	-4.65	-0.39	8.23e-6	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
TGCT	cis	rs1552244	0.882	rs56125067	chr3:9984130	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-6.25	-0.49	6.15e-9	Alzheimer's disease;
TGCT	cis	rs1682361	1	rs1682361	chr3:136734014	G/C	cg12473912	chr3:136751656	NA	0.54	10.13	0.67	6.21e-18	Schizophrenia;
TGCT	cis	rs1568889	1.000	rs10767693	chr11:28093926	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.92	11.13	0.71	2.27e-20	Bipolar disorder;
TGCT	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg07507251	chr3:52567010	NT5DC2	-0.46	-6.67	-0.51	7.5e-10	Bipolar disorder;
TGCT	cis	rs8077577	0.836	rs11652964	chr17:18040404	C/T	cg09161412	chr17:18057145	MYO15A	-0.71	-5.67	-0.45	9.44e-8	Obesity-related traits;
TGCT	cis	rs7172809	0.897	rs78412727	chr15:77827185	A/G	cg22256960	chr15:77711686	NA	-0.44	-4.48	-0.37	1.67e-5	Glucose homeostasis traits;
TGCT	cis	rs2204008	0.660	rs2320745	chr12:38239101	T/C	cg26384229	chr12:38710491	ALG10B	0.83	7.18	0.54	5.51e-11	Bladder cancer;
TGCT	cis	rs1008375	0.898	rs7678654	chr4:17575376	T/G	cg18681998	chr4:17616180	MED28	0.92	9.32	0.64	5.46e-16	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs796364	0.715	rs77089299	chr2:201116853	A/G	cg17644776	chr2:200775616	C2orf69	-0.37	-5.05	-0.41	1.53e-6	Schizophrenia;
TGCT	cis	rs4654899	0.772	rs61778530	chr1:21087363	G/C	cg01072550	chr1:21505969	NA	-0.48	-7.17	-0.54	6.05e-11	Superior frontal gyrus grey matter volume;
TGCT	cis	rs12479064	0.724	rs62153852	chr2:99934713	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.58	-4.54	-0.38	1.31e-5	Chronic sinus infection;
TGCT	cis	rs2239815	0.515	rs5752810	chr22:29225523	G/A	cg02153584	chr22:29168773	CCDC117	0.75	5.04	0.41	1.6e-6	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
TGCT	cis	rs7973719	0.769	rs61917956	chr12:7348659	T/C	cg07052231	chr12:7363540	PEX5	0.36	5.6	0.45	1.31e-7	IgG glycosylation;
TGCT	cis	rs17376456	0.825	rs55724660	chr5:93276636	A/G	cg21475434	chr5:93447410	FAM172A	0.65	4.47	0.37	1.72e-5	Diabetic retinopathy;
TGCT	cis	rs7267979	0.966	rs4813557	chr20:25292545	C/T	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs4819052	0.765	rs2838827	chr21:46656146	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	4.76	0.39	5.4e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6540559	0.546	rs57315825	chr1:210030197	C/T	cg21951975	chr1:209979733	IRF6	0.74	5.8	0.46	5.11e-8	Cleft lip with or without cleft palate;
TGCT	cis	rs57590327	0.503	rs12152272	chr3:81911684	G/A	cg07356753	chr3:81810745	GBE1	-0.69	-6.34	-0.49	3.87e-9	Extraversion;
TGCT	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg23758822	chr17:41437982	NA	0.75	7.03	0.53	1.22e-10	Menopause (age at onset);
TGCT	cis	rs6121246	0.529	rs56153385	chr20:30187609	C/T	cg18721089	chr20:30220636	NA	-0.57	-6.22	-0.49	6.83e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs2639990	1.000	rs609303	chr18:72895242	C/T	cg21330207	chr18:72916311	ZADH2	0.51	4.57	0.38	1.16e-5	Vascular endothelial growth factor levels;
TGCT	cis	rs2046867	0.862	rs11920131	chr3:72858630	C/G	cg25664220	chr3:72788482	NA	-0.53	-6.72	-0.52	5.89e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs67478160	0.619	rs12437066	chr14:104236844	A/C	cg26031613	chr14:104095156	KLC1	-0.63	-6.38	-0.5	3.18e-9	Schizophrenia;
TGCT	cis	rs61931739	0.534	rs11053131	chr12:34282109	A/G	cg06521331	chr12:34319734	NA	-0.34	-5.54	-0.45	1.75e-7	Morning vs. evening chronotype;
TGCT	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	5.77	0.46	5.88e-8	Alzheimer's disease;
TGCT	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.69	-7.19	-0.54	5.48e-11	Prostate cancer;
TGCT	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.85	-5.86	-0.47	3.98e-8	Alzheimer's disease;
TGCT	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg13395646	chr4:1353034	KIAA1530	-0.42	-5.1	-0.42	1.22e-6	Longevity;
TGCT	cis	rs7178572	0.568	rs12911371	chr15:77689050	C/T	cg22256960	chr15:77711686	NA	-0.88	-9.16	-0.64	1.32e-15	Type 2 diabetes;
TGCT	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg02187348	chr16:89574699	SPG7	-0.66	-7.47	-0.56	1.27e-11	Multiple myeloma (IgH translocation);
TGCT	cis	rs3749237	0.964	rs62260719	chr3:49852419	G/A	cg03060546	chr3:49711283	APEH	0.69	7.05	0.53	1.12e-10	Resting heart rate;
TGCT	cis	rs7666738	0.830	rs17550630	chr4:99008332	G/T	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12477438	0.798	rs6736064	chr2:99658201	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-8.52	-0.61	4.5e-14	Chronic sinus infection;
TGCT	cis	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg02380750	chr20:61661411	NA	0.33	5.96	0.47	2.4e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs67311347	1.000	rs4973878	chr3:40407565	C/T	cg13683864	chr3:40499215	RPL14	-1.04	-10.79	-0.7	1.54e-19	Renal cell carcinoma;
TGCT	cis	rs4563143	0.514	rs112651366	chr19:29299704	A/T	cg04546413	chr19:29218101	NA	0.74	5.41	0.44	3.16e-7	Methadone dose in opioid dependence;
TGCT	cis	rs6998277	0.830	rs965661	chr8:103597586	C/T	cg10187029	chr8:103597600	NA	0.56	8.83	0.62	8.12e-15	Migraine;
TGCT	cis	rs6582630	0.622	rs11182005	chr12:38441292	G/A	cg26384229	chr12:38710491	ALG10B	-0.54	-4.81	-0.4	4.32e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs6570726	0.791	rs9403730	chr6:145907233	C/T	cg23711669	chr6:146136114	FBXO30	0.86	9.54	0.65	1.64e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1994135	0.617	rs10844642	chr12:33730368	A/C	cg06521331	chr12:34319734	NA	-0.31	-4.86	-0.4	3.5e-6	Resting heart rate;
TGCT	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg17264618	chr3:40429014	ENTPD3	0.34	4.94	0.41	2.52e-6	Renal cell carcinoma;
TGCT	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg03188948	chr7:1209495	NA	0.46	6.43	0.5	2.46e-9	Longevity;Endometriosis;
TGCT	cis	rs919433	0.679	rs10931787	chr2:198520615	A/G	cg00792783	chr2:198669748	PLCL1	0.55	4.88	0.4	3.24e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs10789285	0.650	rs2245318	chr1:69690618	G/A	ch.1.69469992R	chr1:69697404	NA	0.31	4.54	0.38	1.32e-5	Psoriasis;
TGCT	cis	rs1552244	0.706	rs3901800	chr3:9976864	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.41	-5.77	-0.46	5.97e-8	Alzheimer's disease;
TGCT	cis	rs3820068	0.603	rs72647118	chr1:15956535	G/T	cg05660106	chr1:15850417	CASP9	0.84	8.28	0.6	1.64e-13	Systolic blood pressure;
TGCT	cis	rs7523273	0.606	rs2281289	chr1:207978916	C/T	cg22525895	chr1:207977042	MIR29B2	-0.53	-8.94	-0.63	4.6e-15	Schizophrenia;
TGCT	cis	rs28785552	0.800	rs1971063	chr19:53232854	G/C	cg22067481	chr19:53234126	ZNF611	-0.49	-7.21	-0.54	4.87e-11	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs1075232	1.000	rs4450360	chr15:31682030	G/A	cg01030201	chr15:31746330	NA	-1.1	-5.4	-0.44	3.27e-7	Survival in colorectal cancer (non-distant metastatic);
TGCT	cis	rs9486719	1.000	rs12190507	chr6:96898265	T/G	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.86	-0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs11122272	0.735	rs2790878	chr1:231534390	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-6.42	-0.5	2.62e-9	Hemoglobin concentration;
TGCT	cis	rs13256369	0.708	rs11783670	chr8:8559394	G/A	cg18904891	chr8:8559673	CLDN23	0.56	5.0	0.41	1.94e-6	Obesity-related traits;
TGCT	cis	rs9611565	0.921	rs2143695	chr22:41728620	A/G	cg13695892	chr22:41940480	POLR3H	-0.7	-7.1	-0.54	8.35e-11	Vitiligo;
TGCT	cis	rs7192750	0.583	rs8046916	chr16:72047751	C/G	cg06353428	chr16:71660113	MARVELD3	-1.01	-5.21	-0.42	7.62e-7	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs67311347	0.544	rs9833640	chr3:40354941	T/A	cg17264618	chr3:40429014	ENTPD3	0.3	4.48	0.37	1.69e-5	Renal cell carcinoma;
TGCT	cis	rs4808199	0.649	rs17216693	chr19:19666574	T/C	cg03709012	chr19:19516395	GATAD2A	0.9	5.63	0.45	1.12e-7	Nonalcoholic fatty liver disease;
TGCT	cis	rs782590	0.764	rs935177	chr2:55826761	C/G	cg18811423	chr2:55921094	PNPT1	0.55	5.72	0.46	7.65e-8	Metabolic syndrome;
TGCT	cis	rs7809950	1.000	rs2253146	chr7:107200319	A/G	cg23024343	chr7:107201750	COG5	-0.34	-5.26	-0.43	6.08e-7	Coronary artery disease;
TGCT	cis	rs8180040	0.726	rs4234465	chr3:47026885	C/G	cg27129171	chr3:47204927	SETD2	0.67	8.21	0.59	2.41e-13	Colorectal cancer;
TGCT	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg11890956	chr21:40555474	PSMG1	-0.8	-7.89	-0.58	1.38e-12	Cognitive function;
TGCT	cis	rs1061377	0.965	rs3733275	chr4:39122697	C/T	cg24403649	chr4:39172243	NA	0.18	4.44	0.37	1.99e-5	Uric acid levels;
TGCT	cis	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg13531842	chr10:38383804	ZNF37A	0.4	4.45	0.37	1.92e-5	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg12310025	chr6:25882481	NA	0.84	8.43	0.6	7.35e-14	Blood metabolite levels;
TGCT	cis	rs11864453	0.611	rs9926927	chr16:72130556	G/T	cg14768367	chr16:72042858	DHODH	0.52	5.21	0.42	7.61e-7	Fibrinogen levels;
TGCT	cis	rs4689388	0.926	rs4416547	chr4:6293967	G/A	cg14416269	chr4:6271139	WFS1	0.37	4.9	0.4	2.95e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs4845570	0.920	rs1196456	chr1:151737349	T/A	cg07092448	chr1:151763213	TDRKH	1.03	8.1	0.59	4.35e-13	Coronary artery disease;
TGCT	cis	rs2404602	0.569	rs2469249	chr15:76772062	C/T	cg22467129	chr15:76604101	ETFA	0.5	4.99	0.41	2.03e-6	Blood metabolite levels;
TGCT	cis	rs7772486	0.754	rs6910790	chr6:146255330	G/A	cg23711669	chr6:146136114	FBXO30	-0.87	-9.9	-0.66	2.24e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9549260	0.755	rs12585875	chr13:41199531	A/G	cg21288729	chr13:41239152	FOXO1	0.97	10.16	0.67	5.23e-18	Red blood cell count;
TGCT	cis	rs10465746	0.901	rs17534614	chr1:84383079	G/A	cg10977910	chr1:84465055	TTLL7	0.64	6.32	0.49	4.38e-9	Obesity-related traits;
TGCT	cis	rs1577917	0.740	rs2758845	chr6:86334848	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-4.76	-0.39	5.23e-6	Response to antipsychotic treatment;
TGCT	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.07	-9.63	-0.65	1.01e-16	Platelet count;
TGCT	cis	rs6725041	0.819	rs13429136	chr2:213092176	T/C	cg20637307	chr2:213403960	ERBB4	-0.51	-4.49	-0.37	1.64e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg00684032	chr4:1343700	KIAA1530	0.22	4.85	0.4	3.69e-6	Obesity-related traits;
TGCT	cis	rs644799	1.000	rs651445	chr11:95539122	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	8.74	0.62	1.39e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg08736216	chr1:53307985	ZYG11A	-0.29	-5.6	-0.45	1.33e-7	Monocyte count;
TGCT	cis	rs4664308	0.935	rs4520994	chr2:160937750	G/A	cg03641300	chr2:160917029	PLA2R1	-0.28	-6.83	-0.52	3.43e-10	Idiopathic membranous nephropathy;
TGCT	cis	rs9653442	0.527	rs4851258	chr2:100780830	T/C	cg07810366	chr2:100720526	AFF3	-0.36	-5.26	-0.43	6.14e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs3733585	0.699	rs7686538	chr4:9948077	C/T	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.42	-0.55	1.62e-11	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs6582630	0.519	rs11514056	chr12:38284001	G/T	cg26384229	chr12:38710491	ALG10B	0.84	7.33	0.55	2.58e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs6831352	0.918	rs2851247	chr4:100046091	C/G	cg12011299	chr4:100065546	ADH4	-0.44	-5.08	-0.41	1.37e-6	Alcohol dependence;
TGCT	cis	rs12579753	0.917	rs2401003	chr12:82215192	G/A	cg07988820	chr12:82153109	PPFIA2	-0.58	-6.06	-0.48	1.52e-8	Resting heart rate;
TGCT	cis	rs1903068	0.853	rs12498317	chr4:56007093	G/A	cg16572876	chr4:56024045	NA	0.46	5.03	0.41	1.65e-6	Endometriosis;
TGCT	cis	rs2404602	0.735	rs1607015	chr15:76702429	C/T	cg26408565	chr15:76604113	ETFA	0.38	4.49	0.37	1.58e-5	Blood metabolite levels;
TGCT	cis	rs3617	0.503	rs9866243	chr3:52915219	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	0.49	4.83	0.4	3.91e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs3847687	1.000	rs3847687	chr12:131525053	C/T	cg13586425	chr12:131519906	GPR133	-0.33	-5.26	-0.43	6.17e-7	Longevity;
TGCT	cis	rs6754311	0.731	rs7579771	chr2:136580260	T/A	cg07169764	chr2:136633963	MCM6	0.65	6.1	0.48	1.27e-8	Mosquito bite size;
TGCT	cis	rs6460942	0.915	rs2216050	chr7:12304073	T/C	cg06484146	chr7:12443880	VWDE	-0.42	-4.54	-0.38	1.31e-5	Coronary artery disease;
TGCT	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg22433210	chr17:43662623	NA	0.94	8.08	0.59	4.8e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs40363	0.951	rs250632	chr16:3523047	C/T	cg05754148	chr16:3507555	NAT15	0.46	4.67	0.39	7.61e-6	Tuberculosis;
TGCT	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.55	4.92	0.4	2.74e-6	Prudent dietary pattern;
TGCT	cis	rs174479	0.677	rs1000778	chr11:61655305	A/G	cg19610905	chr11:61596333	FADS2	0.61	5.21	0.42	7.77e-7	Sphingolipid levels;
TGCT	cis	rs4689388	0.926	rs28420833	chr4:6279504	G/A	cg00701064	chr4:6280414	WFS1	0.45	6.19	0.49	8e-9	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs137603	0.562	rs137644	chr22:39728139	A/G	cg01093212	chr22:39715156	SNORD43;RPL3	-0.49	-4.74	-0.39	5.78e-6	Primary biliary cholangitis;
TGCT	trans	rs459571	0.839	rs2519831	chr9:136886257	T/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.72	-7.78	-0.57	2.37e-12	Platelet distribution width;
TGCT	cis	rs11577318	0.853	rs7541333	chr1:26622889	C/T	cg12733254	chr1:26682999	NA	-0.21	-4.82	-0.4	4.04e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs6540559	0.673	rs6698154	chr1:210007777	A/G	cg23283495	chr1:209979779	IRF6	0.6	4.5	0.37	1.54e-5	Cleft lip with or without cleft palate;
TGCT	cis	rs7226408	0.857	rs2034215	chr18:34529163	A/C	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs2361718	0.500	rs4889970	chr17:78096086	C/T	cg02096758	chr17:77394895	HRNBP3	-0.25	-4.71	-0.39	6.59e-6	Yeast infection;
TGCT	cis	rs9858542	0.903	rs11921590	chr3:49644193	T/C	cg03060546	chr3:49711283	APEH	-0.63	-5.48	-0.44	2.28e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg06028808	chr11:68637592	NA	0.53	6.86	0.52	2.89e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7819412	0.522	rs13266785	chr8:10989521	G/A	cg21775007	chr8:11205619	TDH	-0.6	-5.27	-0.43	5.9e-7	Triglycerides;
TGCT	cis	rs6964587	1.000	rs11982213	chr7:91722966	A/G	cg17063962	chr7:91808500	NA	0.86	9.47	0.65	2.39e-16	Breast cancer;
TGCT	cis	rs4654899	0.733	rs10916907	chr1:21261088	A/C	cg01072550	chr1:21505969	NA	-0.56	-9.04	-0.63	2.64e-15	Superior frontal gyrus grey matter volume;
TGCT	cis	rs12908161	1.000	rs62019469	chr15:85321220	T/C	cg17173187	chr15:85201210	NMB	0.57	6.4	0.5	2.89e-9	Schizophrenia;
TGCT	cis	rs7086627	0.515	rs10887896	chr10:82210144	A/C	cg01528321	chr10:82214614	TSPAN14	0.65	6.2	0.49	7.78e-9	Post bronchodilator FEV1;
TGCT	cis	rs3812049	0.826	rs6860245	chr5:127367998	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.6	-5.5	-0.44	2.11e-7	Lymphocyte counts;Red cell distribution width;
TGCT	cis	rs9914544	0.545	rs2892015	chr17:18786849	C/T	cg26378065	chr17:18585709	ZNF286B	0.53	4.63	0.38	9.01e-6	Educational attainment (years of education);
TGCT	cis	rs453301	0.686	rs3895823	chr8:8873646	T/C	cg00184457	chr8:8946301	NA	-0.27	-4.92	-0.4	2.72e-6	Joint mobility (Beighton score);
TGCT	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	16.1	0.82	3.69e-32	Prudent dietary pattern;
TGCT	cis	rs10197940	0.662	rs1047957	chr2:152333773	C/T	cg19508488	chr2:152266495	RIF1	0.74	6.66	0.51	7.77e-10	Lung cancer;
TGCT	cis	rs1692580	0.807	rs60635488	chr1:2202572	C/T	cg24578937	chr1:2090814	PRKCZ	0.21	4.6	0.38	1.01e-5	Coronary artery disease;
TGCT	cis	rs9650657	0.836	rs891556	chr8:10623633	G/C	cg27411982	chr8:10470053	RP1L1	-0.21	-4.44	-0.37	1.97e-5	Neuroticism;
TGCT	cis	rs13202913	0.837	rs6906667	chr6:151772569	A/G	cg03627880	chr6:151815985	C6orf97	-0.74	-5.47	-0.44	2.35e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs11167764	0.895	rs13189044	chr5:141471431	A/C	cg08523384	chr5:141488047	NDFIP1	-0.25	-5.11	-0.42	1.2e-6	Crohn's disease;
TGCT	cis	rs78707713	0.560	rs17569412	chr10:71237536	C/A	cg14388049	chr10:71211838	TSPAN15	-0.39	-4.64	-0.38	8.84e-6	Venous thromboembolism;
TGCT	cis	rs12136530	0.577	rs4481878	chr1:19791086	C/A	cg03884082	chr1:19971709	NBL1	-0.43	-4.51	-0.38	1.5e-5	Lead levels in blood;
TGCT	cis	rs854765	0.693	rs4924823	chr17:17764502	A/G	cg09796270	chr17:17721594	SREBF1	-0.24	-4.8	-0.4	4.56e-6	Total body bone mineral density;
TGCT	cis	rs362296	0.698	rs3095072	chr4:3263325	G/A	cg06533319	chr4:3265114	C4orf44	0.23	4.64	0.38	8.87e-6	Parental longevity (mother's age at death);
TGCT	cis	rs7611238	0.560	rs9826999	chr3:195118896	T/A	cg27323046	chr3:195102265	ACAP2	0.37	5.01	0.41	1.81e-6	Body mass index;
TGCT	cis	rs433598	0.894	rs395501	chr16:20683296	C/T	cg08248577	chr16:19727447	IQCK;C16orf88	-0.22	-5.09	-0.42	1.31e-6	Schizophrenia;
TGCT	cis	rs1005277	0.505	rs719569	chr10:38154415	T/G	cg25427524	chr10:38739819	LOC399744	0.37	7.61	0.56	5.93e-12	Extrinsic epigenetic age acceleration;
TGCT	cis	rs9611565	0.879	rs4820437	chr22:41761290	T/C	cg06634786	chr22:41940651	POLR3H	-0.8	-7.65	-0.57	4.81e-12	Vitiligo;
TGCT	cis	rs9549367	0.707	rs9549353	chr13:113843427	G/A	cg18105134	chr13:113819100	PROZ	-0.46	-8.3	-0.6	1.46e-13	Platelet distribution width;
TGCT	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg03396347	chr1:1875803	NA	-0.38	-6.89	-0.53	2.48e-10	Body mass index;
TGCT	cis	rs2842992	0.789	rs3818300	chr6:160201677	G/A	cg11366901	chr6:160182831	ACAT2	1.03	6.92	0.53	2.14e-10	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs10791097	0.694	rs2236717	chr11:130739887	G/T	cg14779329	chr11:130786720	SNX19	0.28	4.82	0.4	4.09e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs11785400	0.793	rs4581034	chr8:143736968	G/A	cg10596483	chr8:143751796	JRK	0.55	5.48	0.44	2.31e-7	Schizophrenia;
TGCT	cis	rs28785552	0.536	rs7260576	chr19:53248626	G/T	cg10871876	chr19:53194124	ZNF83	0.47	5.9	0.47	3.24e-8	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs7178572	1.000	rs12910361	chr15:77782335	A/G	cg15453836	chr15:77711506	NA	-0.4	-4.59	-0.38	1.07e-5	Type 2 diabetes;
TGCT	cis	rs6570726	0.935	rs398060	chr6:145841515	C/T	cg23711669	chr6:146136114	FBXO30	-0.67	-5.93	-0.47	2.75e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg07424592	chr7:64974309	NA	1.27	7.84	0.58	1.8e-12	Diabetic kidney disease;
TGCT	cis	rs1153858	1.000	rs1145085	chr15:45657804	A/G	cg26924012	chr15:45694286	SPATA5L1	0.99	12.23	0.74	4.74e-23	Homoarginine levels;
TGCT	cis	rs6582630	0.532	rs1589394	chr12:38419700	A/C	cg26384229	chr12:38710491	ALG10B	0.62	5.61	0.45	1.23e-7	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs2692947	0.509	rs79546441	chr2:96218872	C/A	cg23100626	chr2:96804247	ASTL	0.41	4.71	0.39	6.59e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs854765	0.583	rs4244602	chr17:17841456	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.76	7.94	0.58	1.04e-12	Total body bone mineral density;
TGCT	cis	rs7927592	0.763	rs4340059	chr11:68362433	A/G	cg16797656	chr11:68205561	LRP5	0.25	4.5	0.37	1.53e-5	Total body bone mineral density;
TGCT	cis	rs17152411	1.000	rs41303609	chr10:126670613	G/T	cg07906193	chr10:126599966	NA	0.41	4.83	0.4	3.97e-6	Height;
TGCT	cis	rs7666738	0.830	rs7694889	chr4:98855596	T/C	cg17366294	chr4:99064904	C4orf37	0.7	7.27	0.55	3.62e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10206020	0.797	rs72778008	chr2:1573182	T/G	cg01028140	chr2:1542097	TPO	-0.32	-4.99	-0.41	1.97e-6	IgG glycosylation;
TGCT	cis	rs2346177	0.519	rs4563285	chr2:46669944	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.46	-4.91	-0.4	2.86e-6	HDL cholesterol;
TGCT	cis	rs2795502	0.882	rs2744087	chr10:43340270	A/C	cg20628663	chr10:43360327	NA	-0.44	-6.23	-0.49	6.74e-9	Blood protein levels;
TGCT	cis	rs950169	0.881	rs150965	chr15:85080527	T/G	cg11189052	chr15:85197271	WDR73	0.83	6.63	0.51	9.25e-10	Schizophrenia;
TGCT	cis	rs7819412	0.668	rs920047	chr8:11087475	C/T	cg21775007	chr8:11205619	TDH	-0.52	-5.0	-0.41	1.92e-6	Triglycerides;
TGCT	cis	rs6540559	0.673	rs6540564	chr1:210019910	T/C	cg23283495	chr1:209979779	IRF6	0.6	4.5	0.37	1.54e-5	Cleft lip with or without cleft palate;
TGCT	cis	rs10875595	0.779	rs1363451	chr5:140658138	G/A	cg20560182	chr5:140700478	TAF7	-0.66	-5.06	-0.41	1.49e-6	Pulmonary function decline;
TGCT	cis	rs79724016	1.000	rs56044825	chr1:42140668	C/T	cg14093106	chr1:42503579	NA	-0.64	-4.5	-0.37	1.53e-5	Breast cancer;
TGCT	cis	rs3809566	0.710	rs4075583	chr15:63340227	C/T	cg08198488	chr15:63333792	TPM1	-0.29	-4.46	-0.37	1.84e-5	Platelet count;
TGCT	cis	rs524281	0.861	rs11607393	chr11:65875149	C/A	cg00563793	chr11:65837595	PACS1	0.54	4.55	0.38	1.24e-5	Electroencephalogram traits;
TGCT	cis	rs6666258	0.961	rs34515871	chr1:154812280	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	0.66	5.28	0.43	5.48e-7	Atrial fibrillation;
TGCT	cis	rs2050392	0.894	rs303430	chr10:30706235	C/A	cg13289132	chr10:30722225	MAP3K8	-0.38	-4.6	-0.38	1.03e-5	Inflammatory bowel disease;
TGCT	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg22920501	chr2:26401640	FAM59B	-0.74	-6.4	-0.5	2.86e-9	Gut microbiome composition (summer);
TGCT	cis	rs17253792	0.822	rs12100949	chr14:56040787	T/C	cg01858014	chr14:56050164	KTN1	-0.36	-4.55	-0.38	1.24e-5	Putamen volume;
TGCT	cis	rs11673344	0.504	rs6510591	chr19:37624088	A/G	cg08039142	chr19:36980659	ZNF566	0.51	4.69	0.39	7.14e-6	Obesity-related traits;
TGCT	cis	rs7726839	0.540	rs72703095	chr5:601789	T/C	cg20362242	chr5:692897	TPPP	0.53	4.56	0.38	1.22e-5	Obesity-related traits;
TGCT	cis	rs11578119	0.933	rs6675683	chr1:170453146	C/G	cg09767346	chr1:170501363	GORAB	0.66	5.29	0.43	5.27e-7	Male-pattern baldness;
TGCT	cis	rs34779708	0.931	rs4934693	chr10:35271844	G/A	cg04310649	chr10:35416472	CREM	-0.51	-4.54	-0.38	1.31e-5	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs17345786	0.906	rs56171035	chr3:101111108	G/C	cg12386194	chr3:101231763	SENP7	0.65	6.39	0.5	3.06e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs367615	1.000	rs58931051	chr5:108907732	A/G	cg17395555	chr5:108820864	NA	0.29	4.6	0.38	1.04e-5	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg18876405	chr7:65276391	NA	0.41	6.53	0.51	1.55e-9	Aortic root size;
TGCT	cis	rs6964587	1.000	rs2888851	chr7:91648341	G/A	cg17063962	chr7:91808500	NA	0.91	9.99	0.67	1.32e-17	Breast cancer;
TGCT	cis	rs3617	0.625	rs11715347	chr3:52883070	C/T	cg10802521	chr3:52805072	NEK4	0.62	7.17	0.54	6e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg20891558	chr2:74357851	NA	-0.55	-6.48	-0.5	1.91e-9	Gestational age at birth (maternal effect);
TGCT	cis	rs748404	0.660	rs542898	chr15:43719392	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	4.75	0.39	5.51e-6	Lung cancer;
TGCT	cis	rs7552404	0.628	rs5745442	chr1:76342858	T/G	cg03433033	chr1:76189801	ACADM	0.76	7.62	0.56	5.6e-12	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg27535305	chr1:53392650	SCP2	-0.29	-5.59	-0.45	1.4e-7	Monocyte count;
TGCT	cis	rs447921	0.861	rs12951513	chr17:74455069	C/T	cg09812376	chr17:74270190	QRICH2	-0.46	-4.74	-0.39	5.66e-6	Mitochondrial DNA levels;
TGCT	cis	rs7014346	0.767	rs7837706	chr8:128423184	G/C	cg04263511	chr8:128962092	PVT1	-0.31	-4.5	-0.37	1.54e-5	Colorectal cancer;
TGCT	cis	rs854765	0.624	rs9891957	chr17:17744439	G/A	cg04398451	chr17:18023971	MYO15A	0.3	4.59	0.38	1.06e-5	Total body bone mineral density;
TGCT	cis	rs3096299	0.667	rs2965947	chr16:89518670	T/C	cg02187348	chr16:89574699	SPG7	0.61	6.45	0.5	2.29e-9	Multiple myeloma (IgH translocation);
TGCT	cis	rs9527	0.590	rs2182348	chr10:104872684	A/G	cg04362960	chr10:104952993	NT5C2	0.7	5.88	0.47	3.57e-8	Arsenic metabolism;
TGCT	cis	rs595982	0.726	rs607356	chr19:49371241	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.37	-4.85	-0.4	3.68e-6	Red cell distribution width;
TGCT	cis	rs9985766	1.000	rs9784426	chr4:151015661	A/G	cg05926478	chr4:151174724	DCLK2	0.26	4.96	0.41	2.31e-6	Coronary artery disease;Myocardial infarction;
TGCT	cis	rs6076065	0.894	rs2243448	chr20:23378345	G/A	cg11657817	chr20:23433608	CST11	0.31	5.47	0.44	2.42e-7	Facial morphology (factor 15, philtrum width);
TGCT	cis	rs9952991	0.941	rs2847280	chr18:12779342	A/G	cg24737193	chr18:12778029	NA	0.54	6.03	0.48	1.76e-8	Inflammatory skin disease;
TGCT	cis	rs7925523	0.891	rs2097853	chr11:61466267	G/T	cg18476690	chr11:61125255	CYBASC3	0.27	4.53	0.38	1.36e-5	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
TGCT	cis	rs853679	0.550	rs1237875	chr6:28173010	A/G	cg12963246	chr6:28129442	ZNF389	-0.49	-4.8	-0.4	4.46e-6	Depression;
TGCT	cis	rs7208859	0.623	rs56325146	chr17:29151024	T/C	cg14008862	chr17:28927542	LRRC37B2	0.74	4.95	0.41	2.35e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg11890956	chr21:40555474	PSMG1	-0.69	-6.72	-0.52	5.89e-10	Menarche (age at onset);
TGCT	cis	rs912057	0.671	rs1294425	chr6:6744292	G/A	cg06612196	chr6:6737390	NA	0.48	6.95	0.53	1.82e-10	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg26338869	chr17:61819248	STRADA	-0.55	-5.08	-0.42	1.34e-6	Prudent dietary pattern;
TGCT	cis	rs6598955	0.694	rs6659387	chr1:26634307	G/A	cg04990556	chr1:26633338	UBXN11	-0.92	-12.17	-0.74	6.52e-23	Obesity-related traits;
TGCT	trans	rs6089829	0.589	rs73921629	chr20:61676036	G/C	cg23505145	chr19:12996616	KLF1	-0.82	-6.62	-0.51	9.6e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1406084	0.636	rs6434941	chr2:154727431	A/G	cg25703346	chr2:154729189	GALNT13	-0.77	-4.6	-0.38	1.03e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3091242	0.967	rs665372	chr1:25719235	A/C	cg10117171	chr1:25599238	RHD	-0.35	-5.72	-0.46	7.6e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg16680214	chr1:154839983	KCNN3	0.36	7.21	0.54	4.8e-11	Prostate cancer;
TGCT	cis	rs6500602	0.592	rs4785966	chr16:4518754	C/T	cg06139259	chr16:4526053	HMOX2;NMRAL1	-0.27	-4.67	-0.39	7.81e-6	Schizophrenia;
TGCT	cis	rs9796	0.870	rs72737704	chr15:41323575	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.41	-5.41	-0.44	3.06e-7	Menopause (age at onset);
TGCT	cis	rs10191773	0.535	rs56187472	chr2:113111668	G/A	cg07905836	chr2:113190072	RGPD8;RGPD5	0.47	4.91	0.4	2.81e-6	Yeast infection;
TGCT	cis	rs2115630	1.000	rs11854313	chr15:85304048	G/C	cg12501888	chr15:85177176	SCAND2	-0.48	-4.49	-0.37	1.6e-5	P wave terminal force;
TGCT	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg06028808	chr11:68637592	NA	0.55	7.21	0.54	4.8e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs13064411	0.696	rs6769516	chr3:113219905	T/C	cg18753928	chr3:113234510	CCDC52	-0.7	-5.75	-0.46	6.6e-8	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs2486288	0.656	rs11632724	chr15:45550791	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.46	-5.59	-0.45	1.38e-7	Glomerular filtration rate;
TGCT	cis	rs986417	1.000	rs10151958	chr14:60977275	T/C	cg27398547	chr14:60952738	C14orf39	1.4	10.8	0.7	1.43e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs8180040	0.553	rs7620997	chr3:47214122	C/T	cg27129171	chr3:47204927	SETD2	-0.67	-7.75	-0.57	2.89e-12	Colorectal cancer;
TGCT	cis	rs7824557	0.614	rs4394351	chr8:11212875	G/C	cg21775007	chr8:11205619	TDH	0.71	6.81	0.52	3.8e-10	Retinal vascular caliber;
TGCT	cis	rs931127	0.658	rs4930305	chr11:65464000	A/G	cg17480646	chr11:65405466	SIPA1	0.42	5.31	0.43	4.97e-7	Systemic lupus erythematosus;
TGCT	trans	rs8073060	0.544	rs225268	chr17:33966224	A/C	cg19694781	chr19:47549865	TMEM160	-0.6	-13.37	-0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs12142240	0.660	rs72886903	chr1:46813860	C/T	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs4843747	0.605	rs28399183	chr16:88107277	G/A	cg06915872	chr16:87998081	BANP	-0.29	-4.46	-0.37	1.8e-5	Menopause (age at onset);
TGCT	cis	rs9840812	0.577	rs503973	chr3:136059537	C/G	cg15507776	chr3:136538369	TMEM22	-0.59	-5.0	-0.41	1.91e-6	Fibrinogen levels;
TGCT	cis	rs17331151	0.541	rs1139106	chr3:52871101	G/A	cg27565382	chr3:53032988	SFMBT1	0.47	5.98	0.47	2.26e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs7904368	0.754	rs17139234	chr10:16849732	G/T	cg14835575	chr10:16859367	RSU1	0.68	7.5	0.56	1.05e-11	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
TGCT	cis	rs4886920	0.694	rs62007851	chr15:78086424	G/A	cg25212270	chr15:78015279	NA	-0.23	-4.75	-0.39	5.57e-6	Neuroticism;
TGCT	cis	rs9916302	0.904	rs602688	chr17:37439496	C/T	cg07936489	chr17:37558343	FBXL20	-0.58	-4.63	-0.38	9.07e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7267979	1.000	rs2258563	chr20:25273435	C/T	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg24829409	chr8:58192753	C8orf71	-0.56	-5.29	-0.43	5.34e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg24829409	chr8:58192753	C8orf71	-0.57	-5.33	-0.43	4.56e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs4566357	0.615	rs10177528	chr2:227913706	G/A	cg11843606	chr2:227700838	RHBDD1	-0.53	-5.0	-0.41	1.93e-6	Coronary artery disease;
TGCT	cis	rs11673344	0.504	rs10403728	chr19:37582471	G/C	cg08039142	chr19:36980659	ZNF566	0.5	4.6	0.38	1.02e-5	Obesity-related traits;
TGCT	cis	rs11105298	0.891	rs10858881	chr12:89891474	T/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.7	-5.02	-0.41	1.79e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs548987	0.529	rs1165164	chr6:25863481	G/A	cg03517284	chr6:25882590	NA	-0.62	-5.18	-0.42	8.78e-7	Homocysteine levels;
TGCT	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg27286337	chr10:134555280	INPP5A	0.39	4.73	0.39	6.02e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs9911578	0.933	rs2632508	chr17:56533235	G/A	cg12560992	chr17:57184187	TRIM37	0.76	9.28	0.64	7.12e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg06618935	chr21:46677482	NA	0.35	5.41	0.44	3.12e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9929218	0.953	rs9927329	chr16:68750331	C/T	cg01251360	chr16:68772225	CDH1	0.3	5.0	0.41	1.88e-6	Colorectal cancer;
TGCT	cis	rs6089584	0.821	rs2273990	chr20:60579149	G/T	cg16423285	chr20:60520624	NA	-0.62	-6.99	-0.53	1.46e-10	Body mass index;
TGCT	cis	rs9393777	0.513	rs9393741	chr6:26654189	A/G	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.53	-4.88	-0.4	3.19e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2486288	0.656	rs2461705	chr15:45570241	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.78	-7.59	-0.56	6.49e-12	Glomerular filtration rate;
TGCT	cis	rs7246657	0.722	rs2291002	chr19:38033926	G/A	cg18154014	chr19:37997991	ZNF793	0.69	4.63	0.38	9.25e-6	Coronary artery calcification;
TGCT	cis	rs796364	1.000	rs4263095	chr2:200830137	A/C	cg17644776	chr2:200775616	C2orf69	-0.31	-4.85	-0.4	3.58e-6	Schizophrenia;
TGCT	cis	rs28595532	0.920	rs115372254	chr4:119771735	T/C	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs1348850	0.747	rs1047884	chr2:178488281	C/G	cg22681709	chr2:178499509	PDE11A	-0.44	-5.46	-0.44	2.44e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg00080972	chr5:178986291	RUFY1	0.51	6.02	0.48	1.85e-8	Lung cancer;
TGCT	cis	rs6089584	0.586	rs2296087	chr20:60584328	T/A	cg13770153	chr20:60521292	NA	-0.45	-5.58	-0.45	1.44e-7	Body mass index;
TGCT	cis	rs4372836	0.541	rs6710080	chr2:28989975	A/G	cg09522027	chr2:28974177	PPP1CB	-0.73	-7.07	-0.54	9.78e-11	Body mass index;
TGCT	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg11890956	chr21:40555474	PSMG1	1.11	12.43	0.74	1.56e-23	Cognitive function;
TGCT	trans	rs7613875	0.600	rs2624848	chr3:50165101	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.88	-9.32	-0.64	5.67e-16	Body mass index;
TGCT	trans	rs208520	0.690	rs864314	chr6:66814830	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-16.44	-0.83	5.98e-33	Exhaled nitric oxide output;
TGCT	cis	rs2980439	0.525	rs2945238	chr8:8170136	A/C	cg08975724	chr8:8085496	FLJ10661	0.53	4.6	0.38	1.01e-5	Neuroticism;
TGCT	cis	rs67311347	0.577	rs2371129	chr3:40248393	C/T	cg13683864	chr3:40499215	RPL14	0.79	7.06	0.54	1.03e-10	Renal cell carcinoma;
TGCT	cis	rs651907	0.535	rs11919389	chr3:101424458	T/C	cg12386194	chr3:101231763	SENP7	0.51	5.0	0.41	1.9e-6	Colorectal cancer;
TGCT	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.51	5.37	0.43	3.71e-7	Menopause (age at onset);
TGCT	cis	rs1008375	0.900	rs6812675	chr4:17597549	A/G	cg10189774	chr4:17578691	LAP3	0.65	5.28	0.43	5.54e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg03709012	chr19:19516395	GATAD2A	-0.67	-5.74	-0.46	6.77e-8	Tonsillectomy;
TGCT	cis	rs28785552	0.966	rs7247272	chr19:53236331	C/T	cg22067481	chr19:53234126	ZNF611	0.47	6.97	0.53	1.63e-10	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs2535633	0.631	rs2710326	chr3:52995444	T/C	cg11645453	chr3:52864694	ITIH4	-0.28	-5.13	-0.42	1.1e-6	Body mass index;
TGCT	trans	rs9329221	0.741	rs58689676	chr8:9806492	T/C	cg06636001	chr8:8085503	FLJ10661	-0.77	-6.92	-0.53	2.17e-10	Neuroticism;
TGCT	cis	rs36051895	0.659	rs3780365	chr9:5068520	T/C	cg02405213	chr9:5042618	JAK2	-0.86	-12.62	-0.75	5.44e-24	Pediatric autoimmune diseases;
TGCT	cis	rs7429990	0.901	rs7374482	chr3:48168390	A/G	cg11946769	chr3:48343235	NME6	-0.54	-4.44	-0.37	1.98e-5	Educational attainment (years of education);
TGCT	cis	rs6088590	1.000	rs6088590	chr20:33313566	T/C	cg06115741	chr20:33292138	TP53INP2	0.67	5.61	0.45	1.24e-7	Coronary artery disease;
TGCT	trans	rs561341	0.941	rs8066558	chr17:30272879	G/T	cg20587970	chr11:113659929	NA	-1.02	-11.06	-0.7	3.39e-20	Hip circumference adjusted for BMI;
TGCT	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	5.03	0.41	1.69e-6	Prudent dietary pattern;
TGCT	cis	rs826838	0.967	rs7965656	chr12:38807244	G/A	cg26384229	chr12:38710491	ALG10B	1.06	10.53	0.69	6.55e-19	Heart rate;
TGCT	cis	rs2197308	0.765	rs12370231	chr12:37917881	T/C	cg13010199	chr12:38710504	ALG10B	0.69	5.48	0.44	2.3e-7	Morning vs. evening chronotype;
TGCT	cis	rs17401966	0.931	rs2276100	chr1:10394536	C/G	cg19773385	chr1:10388646	KIF1B	-0.24	-5.5	-0.44	2.03e-7	Hepatocellular carcinoma;
TGCT	cis	rs72634258	0.519	rs4908713	chr1:7946831	G/A	cg26816564	chr1:7831052	VAMP3	0.64	4.98	0.41	2.05e-6	Inflammatory bowel disease;
TGCT	trans	rs1814175	0.935	rs7950947	chr11:49668369	C/T	cg03929089	chr4:120376271	NA	-0.63	-7.02	-0.53	1.3e-10	Height;
TGCT	cis	rs2692947	0.526	rs4907225	chr2:96576670	C/T	cg13655245	chr2:97463316	CNNM4	0.15	4.51	0.38	1.48e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs533581	0.866	rs4995274	chr16:88970040	T/C	cg16701003	chr16:89028210	CBFA2T3	0.35	4.84	0.4	3.77e-6	Social autistic-like traits;
TGCT	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg14820908	chr5:178986412	RUFY1	0.45	4.72	0.39	6.32e-6	Lung cancer;
TGCT	cis	rs4742903	0.967	rs7871759	chr9:106865438	A/G	cg21169611	chr9:106856078	SMC2	0.49	4.5	0.37	1.56e-5	High-grade serous ovarian cancer;Breast cancer;
TGCT	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg11644478	chr21:40555479	PSMG1	-0.61	-5.73	-0.46	7.32e-8	Cognitive function;
TGCT	cis	rs1372520	0.577	rs2737028	chr4:90717016	A/G	cg20003494	chr4:90757398	SNCA	-0.67	-5.24	-0.43	6.74e-7	Neuroticism;
TGCT	cis	rs7267979	1.000	rs6050599	chr20:25400240	T/C	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs950776	0.714	rs17408276	chr15:78881618	T/C	cg06917634	chr15:78832804	PSMA4	0.66	5.24	0.43	6.65e-7	Sudden cardiac arrest;
TGCT	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.83	0.4	3.87e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7044106	0.762	rs966396	chr9:123453281	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	6.82	0.52	3.48e-10	Hip circumference adjusted for BMI;
TGCT	cis	rs713587	0.875	rs6746013	chr2:25143649	C/G	cg15423357	chr2:25149977	NA	0.62	6.34	0.49	3.94e-9	Body mass index in non-asthmatics;
TGCT	cis	rs4788570	0.655	rs2133773	chr16:71812296	A/G	cg06353428	chr16:71660113	MARVELD3	1.53	12.59	0.75	6.48e-24	Intelligence (multi-trait analysis);
TGCT	trans	rs72913475	0.579	rs113848043	chr18:44176945	G/T	cg26433034	chr7:128430626	CCDC136	0.61	6.63	0.51	9.33e-10	Midgestational circulating levels of PBDEs (fetal genetic effect);
TGCT	cis	rs6977660	0.714	rs2390157	chr7:19786177	G/A	cg07541023	chr7:19748670	TWISTNB	0.81	4.46	0.37	1.81e-5	Thyroid stimulating hormone;
TGCT	cis	rs10791323	0.593	rs2156676	chr11:133715791	G/C	cg03690763	chr11:133734501	NA	-0.32	-4.92	-0.4	2.67e-6	Childhood ear infection;
TGCT	cis	rs902774	0.585	rs7399070	chr12:53355678	G/C	cg19365166	chr12:52695623	KRT86	-0.57	-4.71	-0.39	6.4e-6	Prostate cancer;
TGCT	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg10560079	chr2:191398806	TMEM194B	0.37	5.33	0.43	4.5e-7	Pulse pressure;
TGCT	cis	rs9291683	0.530	rs10939620	chr4:9946132	C/T	cg11266682	chr4:10021025	SLC2A9	-0.62	-8.7	-0.62	1.65e-14	Bone mineral density;
TGCT	cis	rs909674	0.818	rs5757678	chr22:39843409	A/G	cg01416388	chr22:39784598	NA	0.69	6.49	0.5	1.9e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.54	4.88	0.4	3.18e-6	Prudent dietary pattern;
TGCT	cis	rs17376456	0.877	rs10059630	chr5:93459807	C/A	cg21475434	chr5:93447410	FAM172A	0.59	4.66	0.39	8.09e-6	Diabetic retinopathy;
TGCT	cis	rs6570726	0.935	rs432086	chr6:145841593	C/T	cg23711669	chr6:146136114	FBXO30	-0.74	-7.05	-0.53	1.1e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7666738	0.791	rs6853608	chr4:99047916	A/G	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4654899	0.897	rs7545133	chr1:21206143	T/G	cg01072550	chr1:21505969	NA	0.5	7.91	0.58	1.22e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs7523654	0.915	rs10442682	chr1:115864549	C/T	cg07790079	chr1:116021925	NA	-0.35	-4.44	-0.37	1.96e-5	Schizophrenia;
TGCT	cis	rs734999	0.588	rs2843404	chr1:2530558	T/C	cg18854424	chr1:2615690	NA	-0.46	-5.36	-0.43	3.84e-7	Ulcerative colitis;
TGCT	trans	rs208520	0.690	rs851465	chr6:66840293	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-10.43	-0.68	1.13e-18	Exhaled nitric oxide output;
TGCT	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg10150615	chr22:24372951	LOC391322	-1.01	-13.23	-0.77	1.86e-25	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6964587	1.000	rs11971885	chr7:91674807	T/C	cg22709100	chr7:91322751	NA	0.28	4.55	0.38	1.25e-5	Breast cancer;
TGCT	cis	rs377070	0.934	rs309411	chr4:123620150	C/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.48	5.33	0.43	4.52e-7	Mosquito bite size;
TGCT	cis	rs2692947	0.509	rs4907303	chr2:96217234	C/G	cg23100626	chr2:96804247	ASTL	0.41	4.71	0.39	6.59e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs2115630	1.000	rs6496452	chr15:85372645	A/T	cg12501888	chr15:85177176	SCAND2	-0.53	-5.07	-0.41	1.4e-6	P wave terminal force;
TGCT	cis	rs2067615	0.542	rs4433659	chr12:107082496	G/T	cg15890332	chr12:107067104	RFX4	0.29	5.73	0.46	7.31e-8	Heart rate;
TGCT	cis	rs9467711	0.651	rs68194335	chr6:25866243	A/T	cg16898833	chr6:26189333	HIST1H4D	1.19	5.48	0.44	2.29e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs763014	0.898	rs4984897	chr16:632180	G/C	cg27436995	chr16:743998	FBXL16	-0.45	-4.82	-0.4	4.17e-6	Height;
TGCT	cis	rs892961	0.932	rs7207891	chr17:75413922	G/C	cg05865280	chr17:75406074	SEPT9	0.28	6.56	0.51	1.33e-9	Airflow obstruction;
TGCT	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg11871910	chr12:69753446	YEATS4	0.82	8.95	0.63	4.38e-15	Blood protein levels;
TGCT	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg22764044	chr5:178986830	RUFY1	0.5	5.57	0.45	1.49e-7	Lung cancer;
TGCT	cis	rs10744422	0.925	rs2292132	chr12:123332834	T/C	cg25930673	chr12:123319894	HIP1R	-0.86	-5.02	-0.41	1.72e-6	Schizophrenia;
TGCT	cis	rs10833905	0.648	rs2433478	chr11:23034213	T/C	cg06387204	chr11:22647648	FANCF	0.56	5.07	0.41	1.41e-6	Sudden cardiac arrest;
TGCT	cis	rs986417	0.818	rs6573319	chr14:61091913	C/G	cg27398547	chr14:60952738	C14orf39	1.48	8.31	0.6	1.44e-13	Gut microbiota (bacterial taxa);
TGCT	cis	rs9467711	0.606	rs2072803	chr6:26392515	G/C	cg16898833	chr6:26189333	HIST1H4D	1.14	5.55	0.45	1.65e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7179456	0.545	rs605928	chr15:59046163	C/G	cg05156742	chr15:59063176	FAM63B	0.48	4.8	0.4	4.56e-6	Asperger disorder;
TGCT	cis	rs514406	0.505	rs437954	chr1:53173321	C/G	cg24675658	chr1:53192096	ZYG11B	-0.78	-9.22	-0.64	9.75e-16	Monocyte count;
TGCT	cis	rs6988636	1.000	rs10096350	chr8:124184470	T/C	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs5769765	0.954	rs5770707	chr22:50244533	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	1.08	11.84	0.73	4.29e-22	Schizophrenia;
TGCT	cis	rs17253792	0.822	rs28549152	chr14:56091239	A/G	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs1129187	0.782	rs9462860	chr6:42947013	G/C	cg16590910	chr6:42928470	GNMT	-0.49	-4.57	-0.38	1.16e-5	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg10047753	chr17:41438598	NA	-0.79	-8.0	-0.58	7.37e-13	Menopause (age at onset);
TGCT	cis	rs3020736	0.500	rs9620026	chr22:42498578	C/T	cg15557168	chr22:42548783	NA	0.22	5.58	0.45	1.47e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs28595532	0.841	rs115516095	chr4:119760096	A/C	cg21605333	chr4:119757512	SEC24D	1.55	8.04	0.59	6.15e-13	Cannabis dependence symptom count;
TGCT	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg04025307	chr7:1156635	C7orf50	0.22	4.95	0.41	2.41e-6	Longevity;Endometriosis;
TGCT	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg16680214	chr1:154839983	KCNN3	-0.38	-8.26	-0.6	1.85e-13	Prostate cancer;
TGCT	cis	rs4689388	0.609	rs1046319	chr4:6304286	C/T	cg14416269	chr4:6271139	WFS1	0.48	5.76	0.46	6.11e-8	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs2439831	1.000	rs690436	chr15:43761205	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.01	8.37	0.6	1.02e-13	Lung cancer in ever smokers;
TGCT	cis	rs17376456	0.877	rs10064520	chr5:93427358	T/C	cg21475434	chr5:93447410	FAM172A	0.6	4.62	0.38	9.48e-6	Diabetic retinopathy;
TGCT	cis	rs9653442	0.863	rs10865035	chr2:100835734	A/G	cg22139774	chr2:100720529	AFF3	-0.42	-7.5	-0.56	1.04e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs2033711	0.870	rs6510152	chr19:58953319	C/T	cg13877915	chr19:58951672	ZNF132	0.91	11.22	0.71	1.32e-20	Uric acid clearance;
TGCT	cis	rs858239	0.899	rs10262243	chr7:23290987	G/A	cg05602783	chr7:23145260	KLHL7	-0.63	-4.96	-0.41	2.31e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs7959452	0.535	rs7135092	chr12:69658330	T/C	cg14784868	chr12:69753453	YEATS4	0.69	7.03	0.53	1.23e-10	Blood protein levels;
TGCT	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg10802521	chr3:52805072	NEK4	-0.64	-7.48	-0.56	1.16e-11	Electroencephalogram traits;
TGCT	cis	rs17221829	0.525	rs9804670	chr11:89375801	T/C	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.63	-0.38	9.04e-6	Anxiety in major depressive disorder;
TGCT	cis	rs16867321	1.000	rs10185265	chr2:181438860	G/C	cg23363182	chr2:181467187	NA	-0.39	-5.47	-0.44	2.42e-7	Obesity;
TGCT	cis	rs651907	0.535	rs58658478	chr3:101511667	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.86	10.15	0.67	5.47e-18	Colorectal cancer;
TGCT	cis	rs7428	0.520	rs7605890	chr2:85559525	A/C	cg03728395	chr2:85555865	TGOLN2	-0.29	-5.03	-0.41	1.7e-6	Ear protrusion;
TGCT	cis	rs478304	0.654	rs1074155	chr11:65458197	C/T	cg17480646	chr11:65405466	SIPA1	0.61	8.23	0.59	2.15e-13	Acne (severe);
TGCT	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg13628971	chr7:2884303	GNA12	0.55	4.6	0.38	1.04e-5	Height;
TGCT	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.69	4.6	0.38	1.02e-5	Platelet count;
TGCT	trans	rs4650994	1.000	rs10798619	chr1:178532517	A/G	cg05059571	chr16:84539110	KIAA1609	-0.4	-7.39	-0.55	1.94e-11	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs35306767	0.903	rs4522091	chr10:874116	G/T	cg20503657	chr10:835505	NA	0.7	9.83	0.66	3.22e-17	Eosinophil percentage of granulocytes;
TGCT	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg12419862	chr22:24373484	LOC391322	0.87	7.68	0.57	4.09e-12	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs9467773	0.620	rs9467810	chr6:26608261	A/C	cg05738196	chr6:26577821	NA	0.88	11.01	0.7	4.39e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg16325326	chr1:53192061	ZYG11B	-0.7	-8.6	-0.61	2.87e-14	Monocyte count;
TGCT	cis	rs2204008	0.837	rs11168341	chr12:37961951	C/T	cg13010199	chr12:38710504	ALG10B	0.65	5.29	0.43	5.47e-7	Bladder cancer;
TGCT	cis	rs9549260	0.739	rs7330614	chr13:41199421	G/A	cg21288729	chr13:41239152	FOXO1	0.99	10.47	0.69	8.86e-19	Red blood cell count;
TGCT	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.54	4.94	0.41	2.5e-6	Prudent dietary pattern;
TGCT	cis	rs6540559	0.546	rs7551944	chr1:210029430	G/C	cg22029157	chr1:209979665	IRF6	0.79	5.77	0.46	5.96e-8	Cleft lip with or without cleft palate;
TGCT	trans	rs4650994	1.000	rs6660445	chr1:178528871	C/T	cg05059571	chr16:84539110	KIAA1609	-0.4	-7.43	-0.56	1.54e-11	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs9467773	0.595	rs2451736	chr6:26620544	G/A	cg02458000	chr6:26745757	NA	0.55	5.25	0.43	6.28e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2153535	0.563	rs1796687	chr6:8536118	C/G	cg23788917	chr6:8435910	SLC35B3	0.61	5.5	0.44	2.09e-7	Motion sickness;
TGCT	cis	rs10791097	0.547	rs1050078	chr11:130746146	T/C	cg12179176	chr11:130786555	SNX19	0.85	10.17	0.67	4.79e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs3796352	1.000	rs71299622	chr3:52917038	G/A	cg07884673	chr3:53033167	SFMBT1	0.6	4.88	0.4	3.16e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg22920501	chr2:26401640	FAM59B	0.81	6.36	0.5	3.52e-9	Gut microbiome composition (summer);
TGCT	cis	rs4730250	0.640	rs7783562	chr7:106917438	G/T	cg02696742	chr7:106810147	HBP1	-0.68	-5.27	-0.43	5.73e-7	Osteoarthritis;
TGCT	cis	rs7953508	0.659	rs1316739	chr12:93968256	G/A	cg18151635	chr12:93972918	NA	-0.19	-4.47	-0.37	1.71e-5	Pubertal anthropometrics;
TGCT	cis	rs709400	0.663	rs1022736	chr14:103998423	G/C	cg26031613	chr14:104095156	KLC1	0.89	9.8	0.66	3.77e-17	Body mass index;
TGCT	cis	rs7666738	0.830	rs4699597	chr4:99019031	G/A	cg17366294	chr4:99064904	C4orf37	0.68	7.04	0.53	1.17e-10	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg11887960	chr12:57824829	NA	-1.12	-9.19	-0.64	1.16e-15	Obesity-related traits;
TGCT	cis	rs4499344	0.730	rs28416849	chr19:33099758	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	8.81	0.62	9.52e-15	Mean platelet volume;
TGCT	cis	rs11677370	0.603	rs10178523	chr2:3854169	G/A	cg17052675	chr2:3827356	NA	-0.43	-7.08	-0.54	9.26e-11	Type 2 diabetes;
TGCT	cis	rs9430161	0.564	rs12081176	chr1:11034145	T/C	cg02454025	chr1:11042201	C1orf127	0.94	11.31	0.71	8.14e-21	Ewing sarcoma;
TGCT	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.62	-8.99	-0.63	3.4e-15	Longevity;Endometriosis;
TGCT	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg03303774	chr4:1407052	NA	0.3	4.74	0.39	5.79e-6	Obesity-related traits;
TGCT	cis	rs72781680	0.898	rs2339851	chr2:23938883	G/A	cg08917208	chr2:24149416	ATAD2B	0.9	5.58	0.45	1.46e-7	Lymphocyte counts;
TGCT	cis	rs7772486	0.875	rs9373483	chr6:146364194	A/G	cg23711669	chr6:146136114	FBXO30	0.87	9.53	0.65	1.75e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs709400	0.567	rs1961600	chr14:103862144	G/A	cg26031613	chr14:104095156	KLC1	0.85	9.32	0.64	5.53e-16	Body mass index;
TGCT	cis	rs9970334	0.596	rs709209	chr1:6278414	A/G	cg15892785	chr1:6309343	GPR153	-0.39	-4.56	-0.38	1.23e-5	Resting heart rate;
TGCT	cis	rs1461503	0.966	rs10892938	chr11:122841921	A/C	cg27398637	chr11:122830231	C11orf63	-0.42	-5.25	-0.43	6.42e-7	Menarche (age at onset);
TGCT	cis	rs2735413	0.564	rs11859770	chr16:78126734	A/G	cg09132178	chr16:78079569	NA	0.35	4.51	0.38	1.47e-5	Systolic blood pressure (alcohol consumption interaction);
TGCT	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg03452623	chr4:187889614	NA	-0.38	-5.86	-0.47	3.82e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6840360	1.000	rs6846114	chr4:152604558	A/G	cg17479576	chr4:152424074	FAM160A1	0.52	5.31	0.43	4.96e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg21644426	chr2:191273491	MFSD6	0.6	6.01	0.47	1.92e-8	Pulse pressure;
TGCT	cis	rs11252926	0.528	rs11252090	chr10:436547	C/T	cg18196295	chr10:418757	DIP2C	-0.29	-4.86	-0.4	3.46e-6	Psychosis in Alzheimer's disease;
TGCT	trans	rs7819412	0.654	rs4840550	chr8:11029029	T/G	cg15556689	chr8:8085844	FLJ10661	-0.84	-7.91	-0.58	1.19e-12	Triglycerides;
TGCT	cis	rs3782455	1.000	rs75409372	chr12:114405283	C/T	cg10631684	chr12:113795897	PLBD2	-0.8	-5.2	-0.42	7.83e-7	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs9549260	0.592	rs9532588	chr13:41302913	G/A	cg21288729	chr13:41239152	FOXO1	0.92	8.87	0.62	6.71e-15	Red blood cell count;
TGCT	cis	rs7208859	0.623	rs57486336	chr17:29085731	G/T	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs10504229	1.000	rs68114352	chr8:58196081	C/T	cg22535103	chr8:58192502	C8orf71	-0.39	-4.62	-0.38	9.61e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6570726	0.846	rs372904	chr6:145887425	T/C	cg05347473	chr6:146136440	FBXO30	0.52	4.93	0.41	2.54e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9372498	0.505	rs9489493	chr6:118992323	T/C	cg07617317	chr6:118971624	C6orf204	0.45	4.83	0.4	3.93e-6	Diastolic blood pressure;
TGCT	cis	rs2050392	0.762	rs306587	chr10:30722908	G/C	cg18806716	chr10:30721971	MAP3K8	-0.49	-5.65	-0.45	1.04e-7	Inflammatory bowel disease;
TGCT	cis	rs16866061	0.962	rs16825685	chr2:225434256	C/G	cg12698349	chr2:225449008	CUL3	1.01	9.99	0.67	1.35e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	cis	rs907683	0.584	rs2854903	chr2:220288979	C/T	cg15015639	chr2:220282977	DES	-0.4	-4.98	-0.41	2.09e-6	Resting heart rate;
TGCT	cis	rs28595532	0.920	rs56124677	chr4:119772213	C/T	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs9291683	0.692	rs1558489	chr4:10325489	T/A	cg11266682	chr4:10021025	SLC2A9	-0.47	-5.46	-0.44	2.45e-7	Bone mineral density;
TGCT	cis	rs1008375	0.932	rs6845288	chr4:17665498	A/T	cg16339924	chr4:17578868	LAP3	-0.62	-5.0	-0.41	1.91e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg03517284	chr6:25882590	NA	-0.59	-5.24	-0.43	6.78e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7811142	1.000	rs6953107	chr7:100095664	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.92	7.56	0.56	7.89e-12	Platelet count;
TGCT	cis	rs7772486	0.875	rs2777484	chr6:146334162	A/G	cg23711669	chr6:146136114	FBXO30	0.84	9.04	0.63	2.6e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6901250	1.000	rs615199	chr6:117113653	T/C	cg12892004	chr6:117198278	RFX6	0.45	4.98	0.41	2.08e-6	C-reactive protein levels;
TGCT	cis	rs7666738	0.830	rs17548431	chr4:98923768	C/G	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9650657	0.803	rs13276026	chr8:10609955	G/A	cg27411982	chr8:10470053	RP1L1	-0.22	-4.61	-0.38	9.97e-6	Neuroticism;
TGCT	cis	rs57221529	0.713	rs56328416	chr5:591138	G/A	cg16624210	chr5:671434	TPPP	0.41	4.56	0.38	1.19e-5	Lung disease severity in cystic fibrosis;
TGCT	cis	rs4919694	1.000	rs17881215	chr10:104629236	G/C	cg04362960	chr10:104952993	NT5C2	1.05	7.22	0.54	4.57e-11	Arsenic metabolism;
TGCT	cis	rs877282	0.945	rs71489301	chr10:770191	A/G	cg17470449	chr10:769945	NA	0.35	5.19	0.42	8.21e-7	Uric acid levels;
TGCT	cis	rs2456568	0.802	rs11020586	chr11:93638547	G/A	cg26875233	chr11:93583750	C11orf90	-0.48	-6.47	-0.5	2.09e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs6582630	0.555	rs34730221	chr12:38405140	C/T	cg26384229	chr12:38710491	ALG10B	-0.79	-7.16	-0.54	6.29e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs5760092	0.755	rs11090298	chr22:24262061	G/A	cg18538332	chr22:24372958	LOC391322	0.88	7.7	0.57	3.69e-12	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs7568458	0.875	rs2044474	chr2:85758790	G/A	cg17127132	chr2:85788382	GGCX	0.72	6.68	0.51	7.16e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs11190604	1.000	rs10883509	chr10:102296461	C/T	cg16342193	chr10:102329863	NA	-0.42	-5.32	-0.43	4.58e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs4631830	0.869	rs11006207	chr10:51538176	T/C	cg10326726	chr10:51549505	MSMB	-0.26	-5.3	-0.43	5.07e-7	Prostate-specific antigen levels;
TGCT	cis	rs116095464	0.558	rs10075018	chr5:239175	G/A	cg22857025	chr5:266934	NA	-0.34	-6.3	-0.49	4.7e-9	Breast cancer;
TGCT	cis	rs6912958	0.781	rs3934838	chr6:88284699	T/C	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.91	-0.4	2.78e-6	Monocyte percentage of white cells;
TGCT	cis	rs7103648	0.603	rs3740688	chr11:47380340	G/T	cg20307385	chr11:47447363	PSMC3	0.74	7.1	0.54	8.35e-11	Diastolic blood pressure;Systolic blood pressure;
TGCT	cis	rs11098499	0.954	rs28685688	chr4:120420334	T/C	cg09307838	chr4:120376055	NA	0.68	6.37	0.5	3.41e-9	Corneal astigmatism;
TGCT	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs72843506	0.722	rs16942325	chr17:20027063	A/G	cg18979559	chr17:20280153	CCDC144C	-0.64	-4.78	-0.39	4.97e-6	Schizophrenia;
TGCT	cis	rs7917772	0.636	rs7069489	chr10:104525371	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.57	4.78	0.39	4.78e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7178572	0.568	rs1389436	chr15:77665848	G/T	cg22256960	chr15:77711686	NA	-0.87	-9.0	-0.63	3.34e-15	Type 2 diabetes;
TGCT	cis	rs2204008	0.687	rs1733404	chr12:38123395	G/T	cg13010199	chr12:38710504	ALG10B	-0.6	-4.8	-0.4	4.57e-6	Bladder cancer;
TGCT	cis	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg25427524	chr10:38739819	LOC399744	-0.39	-8.05	-0.59	5.9e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs12477438	0.520	rs1453563	chr2:99720267	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	10.3	0.68	2.42e-18	Chronic sinus infection;
TGCT	cis	rs7772486	0.875	rs2224120	chr6:146343280	A/C	cg05347473	chr6:146136440	FBXO30	0.56	5.29	0.43	5.34e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9913156	0.517	rs11868227	chr17:4614539	G/A	cg00122941	chr17:4613640	ARRB2	0.78	7.08	0.54	9.62e-11	Lymphocyte counts;
TGCT	cis	rs514406	0.505	rs431427	chr1:53179094	C/A	cg25767906	chr1:53392781	SCP2	-0.47	-5.35	-0.43	4.15e-7	Monocyte count;
TGCT	cis	rs9581857	0.615	rs9581848	chr13:28003997	C/T	cg22138327	chr13:27999177	GTF3A	0.8	5.52	0.44	1.9e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs6918586	0.658	rs198813	chr6:26128226	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.66	-6.21	-0.49	7.2e-9	Schizophrenia;
TGCT	cis	rs2549003	0.811	rs10072700	chr5:131816903	A/C	cg21138405	chr5:131827807	IRF1	0.23	5.55	0.45	1.68e-7	Asthma (sex interaction);
TGCT	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.07	-9.63	-0.65	1.01e-16	Platelet count;
TGCT	cis	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg18188782	chr20:61659543	NA	-0.44	-5.19	-0.42	8.41e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7714584	1.000	rs10463240	chr5:150256853	A/C	cg22134413	chr5:150180641	NA	0.83	6.53	0.51	1.54e-9	Crohn's disease;
TGCT	cis	rs4820539	1.000	rs13054985	chr22:23458577	G/A	cg14186256	chr22:23484241	RTDR1	0.94	11.29	0.71	8.9e-21	Bone mineral density;
TGCT	cis	rs35883536	0.626	rs34752753	chr1:101045193	T/G	cg10298815	chr1:101004474	GPR88	-0.25	-4.5	-0.37	1.54e-5	Monocyte count;
TGCT	cis	rs2046867	0.908	rs4677206	chr3:72780052	A/T	cg25664220	chr3:72788482	NA	0.53	6.81	0.52	3.8e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs12681288	0.523	rs11137122	chr8:954702	A/G	cg04851639	chr8:1020857	NA	-0.27	-4.47	-0.37	1.75e-5	Schizophrenia;
TGCT	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg24829409	chr8:58192753	C8orf71	-0.48	-4.72	-0.39	6.22e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2046867	0.818	rs17010188	chr3:72870351	T/C	cg25664220	chr3:72788482	NA	-0.56	-7.04	-0.53	1.16e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2274471	0.645	rs10974955	chr9:5090641	G/A	cg03390472	chr9:5043263	JAK2	-0.29	-4.63	-0.38	8.95e-6	Crohn's disease;
TGCT	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg22920501	chr2:26401640	FAM59B	0.81	6.36	0.5	3.52e-9	Gut microbiome composition (summer);
TGCT	cis	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg08045932	chr20:61659980	NA	0.48	9.28	0.64	7.07e-16	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2688608	0.592	rs11000759	chr10:75493726	G/A	cg04320760	chr10:75533139	FUT11	-0.4	-6.25	-0.49	6.11e-9	Inflammatory bowel disease;
TGCT	cis	rs7666738	0.791	rs2903142	chr4:99040071	C/T	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs4650994	0.505	rs2811291	chr1:178574217	C/T	cg05059571	chr16:84539110	KIAA1609	0.51	10.23	0.68	3.51e-18	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg12667521	chr19:29218732	NA	0.53	5.63	0.45	1.16e-7	Methadone dose in opioid dependence;
TGCT	cis	rs12776158	0.901	rs57677741	chr10:71217131	G/A	cg12610070	chr10:71211762	TSPAN15	-0.59	-5.17	-0.42	9.16e-7	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg23205692	chr1:25664452	TMEM50A	0.52	5.36	0.43	3.88e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs10501293	0.956	rs12361827	chr11:43137261	T/C	cg03447554	chr11:43094025	NA	-0.44	-5.66	-0.45	9.93e-8	Cognitive performance;
TGCT	cis	rs1371867	0.817	rs1788179	chr8:101333345	A/G	cg06002616	chr8:101225028	SPAG1	-0.56	-6.58	-0.51	1.2e-9	Atrioventricular conduction;
TGCT	cis	rs7020830	0.867	rs1472169	chr9:37209396	C/T	cg14294708	chr9:37120828	ZCCHC7	1.21	16.19	0.82	2.22e-32	Schizophrenia;
TGCT	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg23982607	chr1:1823379	GNB1	-0.55	-8.57	-0.61	3.52e-14	Body mass index;
TGCT	cis	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg12570787	chr5:219185	SDHA;CCDC127	0.65	4.46	0.37	1.83e-5	Breast cancer;
TGCT	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg18402987	chr7:1209562	NA	0.78	6.64	0.51	8.96e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9436747	0.641	rs11208679	chr1:66049738	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.57	5.16	0.42	9.52e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs2721195	1.000	rs750472	chr8:145701453	A/C	cg11211951	chr8:145729740	GPT	-0.24	-5.66	-0.45	1.01e-7	Age at first birth;
TGCT	cis	rs4253772	0.786	rs4253765	chr22:46622888	C/T	cg09491104	chr22:46646882	C22orf40	-0.46	-4.56	-0.38	1.23e-5	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs9393777	0.513	rs13215020	chr6:26656073	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.59	-4.66	-0.39	8.03e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1801251	1.000	rs1446311	chr2:233705071	G/A	cg25237894	chr2:233734115	C2orf82	-0.33	-5.94	-0.47	2.71e-8	Coronary artery disease;
TGCT	cis	rs3849570	0.673	rs9877408	chr3:81974558	A/G	cg07356753	chr3:81810745	GBE1	-0.64	-5.63	-0.45	1.16e-7	Waist circumference;Body mass index;
TGCT	cis	rs79349575	0.783	rs62075820	chr17:46983171	G/C	cg26022315	chr17:47021804	SNF8	0.48	4.82	0.4	4.06e-6	Type 2 diabetes;
TGCT	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.57	-5.42	-0.44	2.99e-7	Menarche (age at onset);
TGCT	cis	rs4478037	0.822	rs4320035	chr3:33113697	C/G	cg19404215	chr3:33155277	CRTAP	-1.24	-5.97	-0.47	2.36e-8	Major depressive disorder;
TGCT	cis	rs7666738	0.830	rs34628820	chr4:99004764	C/T	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12579753	0.917	rs76240969	chr12:82195236	C/A	cg07988820	chr12:82153109	PPFIA2	-0.59	-6.19	-0.49	7.93e-9	Resting heart rate;
TGCT	cis	rs9814567	0.752	rs4955542	chr3:134328740	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-6.41	-0.5	2.8e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs9972944	0.729	rs1541609	chr17:63773564	G/A	cg07283582	chr17:63770753	CCDC46	0.26	5.05	0.41	1.53e-6	Total body bone mineral density;
TGCT	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg10047753	chr17:41438598	NA	0.96	9.65	0.65	9.13e-17	Menopause (age at onset);
TGCT	cis	rs5769707	0.967	rs5769698	chr22:49997706	A/G	cg20744362	chr22:50050164	C22orf34	0.28	4.58	0.38	1.11e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg00684032	chr4:1343700	KIAA1530	0.22	4.9	0.4	2.93e-6	Obesity-related traits;
TGCT	cis	rs3091242	0.967	rs665372	chr1:25719235	A/C	cg09222892	chr1:25734099	RHCE	-0.44	-7.16	-0.54	6.35e-11	Erythrocyte sedimentation rate;
TGCT	cis	rs6598955	0.671	rs12145403	chr1:26597189	C/T	cg04990556	chr1:26633338	UBXN11	0.7	5.64	0.45	1.09e-7	Obesity-related traits;
TGCT	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.52	5.76	0.46	6.2e-8	Lymphocyte counts;
TGCT	cis	rs2230307	0.505	rs571579	chr1:100617372	G/A	cg24955406	chr1:100503596	HIAT1	-0.72	-4.83	-0.4	3.92e-6	Carotid intima media thickness;
TGCT	cis	rs13323323	0.691	rs9815769	chr3:44663014	A/T	cg04389838	chr3:44770851	ZNF501	-0.43	-4.62	-0.38	9.46e-6	IgG glycosylation;
TGCT	cis	rs3617	0.625	rs11715347	chr3:52883070	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.48	-4.53	-0.38	1.35e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2075371	0.829	rs1993058	chr7:133930361	G/A	cg11752832	chr7:134001865	SLC35B4	0.67	5.54	0.45	1.76e-7	Mean platelet volume;
TGCT	cis	rs7681440	0.904	rs10004413	chr4:90769479	T/C	cg26578617	chr4:90757533	SNCA	-0.46	-4.83	-0.4	3.96e-6	Dementia with Lewy bodies;
TGCT	trans	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg27523141	chr10:43048294	ZNF37B	0.71	8.11	0.59	4.13e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs6988636	1.000	rs60827294	chr8:124187842	T/C	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs7568458	0.684	rs7593969	chr2:85809670	A/G	cg17127132	chr2:85788382	GGCX	-0.51	-4.49	-0.37	1.61e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs9425326	0.508	rs2491432	chr1:183813558	C/G	cg15569801	chr1:184197096	NA	-0.14	-5.03	-0.41	1.7e-6	Antipsychotic drug-induced QTc interval change in schizophrenia;
TGCT	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg00814883	chr7:100076585	TSC22D4	-0.92	-9.76	-0.66	4.73e-17	Platelet count;
TGCT	cis	rs9527	0.615	rs7096452	chr10:104736563	G/A	cg04362960	chr10:104952993	NT5C2	0.66	5.55	0.45	1.66e-7	Arsenic metabolism;
TGCT	cis	rs6496667	0.609	rs7183707	chr15:90883733	G/T	cg22089800	chr15:90895588	ZNF774	0.64	5.43	0.44	2.83e-7	Rheumatoid arthritis;
TGCT	cis	rs9300255	0.602	rs1716167	chr12:123651162	C/T	cg00376283	chr12:123451042	ABCB9	-0.72	-5.55	-0.45	1.65e-7	Neutrophil percentage of white cells;
TGCT	cis	rs72781680	1.000	rs7594510	chr2:24173377	A/G	cg08917208	chr2:24149416	ATAD2B	0.73	4.51	0.38	1.48e-5	Lymphocyte counts;
TGCT	cis	rs7666738	0.830	rs11947027	chr4:99005941	T/C	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6840360	0.593	rs10033405	chr4:152474489	A/G	cg17479576	chr4:152424074	FAM160A1	-0.72	-7.98	-0.58	8.25e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs8141529	0.702	rs469991	chr22:29307859	G/C	cg02153584	chr22:29168773	CCDC117	-0.6	-4.74	-0.39	5.81e-6	Lymphocyte counts;
TGCT	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	16.1	0.82	3.69e-32	Prudent dietary pattern;
TGCT	cis	rs2204008	0.627	rs1851117	chr12:38398987	G/T	cg26384229	chr12:38710491	ALG10B	0.83	7.39	0.55	1.92e-11	Bladder cancer;
TGCT	trans	rs17685	0.884	rs6978677	chr7:75636240	C/T	cg19862616	chr7:65841803	NCRNA00174	0.48	7.14	0.54	6.84e-11	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs9291683	0.530	rs17246501	chr4:9985710	A/C	cg11266682	chr4:10021025	SLC2A9	0.62	8.49	0.61	5.31e-14	Bone mineral density;
TGCT	cis	rs11190604	1.000	rs3793771	chr10:102222957	C/G	cg16342193	chr10:102329863	NA	-0.4	-5.31	-0.43	4.85e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs5769765	0.955	rs8135816	chr22:50291976	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.09	-11.86	-0.73	3.71e-22	Schizophrenia;
TGCT	cis	rs854765	0.663	rs2236513	chr17:17747366	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.69	-6.55	-0.51	1.39e-9	Total body bone mineral density;
TGCT	cis	rs7119	0.689	rs11630557	chr15:77820712	A/G	cg27398640	chr15:77910606	LINGO1	-0.25	-4.61	-0.38	9.7e-6	Type 2 diabetes;
TGCT	cis	rs11190604	1.000	rs7084810	chr10:102297546	A/G	cg16342193	chr10:102329863	NA	-0.41	-5.11	-0.42	1.18e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs10197940	0.624	rs6731486	chr2:152410732	C/T	cg06191203	chr2:152266755	RIF1	0.74	6.95	0.53	1.81e-10	Lung cancer;
TGCT	cis	rs6967414	0.681	rs11979878	chr7:6753803	A/G	cg09896999	chr7:6746977	ZNF12	-0.57	-6.43	-0.5	2.5e-9	Hematocrit;Hemoglobin concentration;
TGCT	cis	rs13191362	1.000	rs13202339	chr6:163081812	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.07	8.36	0.6	1.07e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs6964587	1.000	rs6465343	chr7:91618208	T/C	cg17063962	chr7:91808500	NA	0.91	9.97	0.67	1.53e-17	Breast cancer;
TGCT	cis	rs36051895	0.559	rs72701680	chr9:5207294	A/T	cg02405213	chr9:5042618	JAK2	-0.7	-8.74	-0.62	1.37e-14	Pediatric autoimmune diseases;
TGCT	cis	rs6952808	0.626	rs57633152	chr7:2042547	C/G	cg04267008	chr7:1944627	MAD1L1	-0.41	-5.31	-0.43	4.95e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg07424592	chr7:64974309	NA	-1.27	-7.84	-0.58	1.8e-12	Diabetic kidney disease;
TGCT	cis	rs13256369	1.000	rs12550762	chr8:8576535	T/A	cg18904891	chr8:8559673	CLDN23	0.64	5.87	0.47	3.71e-8	Obesity-related traits;
TGCT	cis	rs9303401	0.659	rs17741087	chr17:56550300	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.61	6.17	0.48	8.95e-9	Cognitive test performance;
TGCT	trans	rs7819412	0.537	rs2127127	chr8:11434792	C/G	cg06636001	chr8:8085503	FLJ10661	-0.73	-6.79	-0.52	4.12e-10	Triglycerides;
TGCT	cis	rs3806843	0.735	rs2563335	chr5:140044292	A/C	cg19875535	chr5:140030758	IK	0.36	6.15	0.48	9.57e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs10791323	0.536	rs1944731	chr11:133726067	G/A	cg03690763	chr11:133734501	NA	-0.3	-4.53	-0.38	1.38e-5	Childhood ear infection;
TGCT	cis	rs9611565	0.649	rs5758442	chr22:42133060	T/C	cg13695892	chr22:41940480	POLR3H	0.84	7.96	0.58	9.2e-13	Vitiligo;
TGCT	trans	rs7618501	1.000	rs6785549	chr3:49736565	G/A	cg21659725	chr3:3221576	CRBN	-0.99	-15.57	-0.81	5.76e-31	Intelligence (multi-trait analysis);
TGCT	cis	rs886126	1.000	rs886126	chr12:111679214	C/T	cg10833066	chr12:111807467	FAM109A	0.32	5.34	0.43	4.35e-7	Coronary heart disease;
TGCT	cis	rs1018836	0.608	rs2142146	chr8:91464808	T/C	cg16814680	chr8:91681699	NA	-0.77	-7.8	-0.57	2.21e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs873917	0.577	rs784611	chr1:40125988	T/A	cg06209491	chr1:40138402	NT5C1A	-0.35	-5.84	-0.46	4.21e-8	Amyotrophic lateral sclerosis;
TGCT	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg22920501	chr2:26401640	FAM59B	-0.79	-6.31	-0.49	4.58e-9	Gut microbiome composition (summer);
TGCT	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.87	-10.4	-0.68	1.33e-18	Prudent dietary pattern;
TGCT	cis	rs34638686	1	rs34638686	chr3:48682658	C/T	cg00383909	chr3:49044727	WDR6	0.9	4.71	0.39	6.49e-6	Educational attainment (years of education);
TGCT	cis	rs2762353	0.574	rs9467574	chr6:25705718	C/G	cg15691649	chr6:25882328	NA	0.48	5.55	0.45	1.63e-7	Blood metabolite levels;
TGCT	cis	rs7095607	0.579	rs6480308	chr10:69952953	T/C	cg18986048	chr10:69913749	MYPN	0.57	6.15	0.48	9.78e-9	Lung function (FVC);
TGCT	cis	rs1061377	1.000	rs9990742	chr4:39121414	G/A	cg24403649	chr4:39172243	NA	0.19	4.47	0.37	1.75e-5	Uric acid levels;
TGCT	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg12564285	chr5:131593104	PDLIM4	0.37	4.44	0.37	1.98e-5	Acylcarnitine levels;
TGCT	cis	rs3947	0.789	rs1293322	chr8:11692638	C/T	cg02840367	chr8:11660030	FDFT1	0.87	6.32	0.49	4.21e-9	Blood protein levels;
TGCT	cis	rs114540395	0.920	rs115066444	chr10:103461443	G/C	cg03300883	chr10:102748874	C10orf2	0.43	4.51	0.38	1.48e-5	Schizophrenia;
TGCT	cis	rs1153858	1.000	rs72623915	chr15:45647433	C/T	cg26924012	chr15:45694286	SPATA5L1	1.09	15.16	0.81	5.15e-30	Homoarginine levels;
TGCT	cis	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg08045932	chr20:61659980	NA	0.48	9.28	0.64	7.07e-16	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9486719	1.000	rs11153067	chr6:97039421	A/T	cg06623918	chr6:96969491	KIAA0776	0.97	7.71	0.57	3.47e-12	Migraine;Coronary artery disease;
TGCT	cis	rs9527	0.590	rs10883836	chr10:104891198	T/C	cg04362960	chr10:104952993	NT5C2	0.69	5.82	0.46	4.78e-8	Arsenic metabolism;
TGCT	cis	rs6089829	0.925	rs4809270	chr20:61676709	C/A	cg18188782	chr20:61659543	NA	0.45	4.94	0.41	2.51e-6	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs77216612	0.835	rs10845621	chr12:12887977	C/T	cg04607235	chr12:12878440	APOLD1	-0.97	-8.51	-0.61	4.81e-14	Lymphocyte counts;
TGCT	cis	rs7666738	0.830	rs10001702	chr4:99065160	T/G	cg05340658	chr4:99064831	C4orf37	0.52	5.79	0.46	5.32e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg26818010	chr10:134567672	INPP5A	0.33	4.92	0.4	2.64e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs2404602	0.669	rs12438540	chr15:76943213	C/G	cg22467129	chr15:76604101	ETFA	-0.45	-5.11	-0.42	1.18e-6	Blood metabolite levels;
TGCT	cis	rs9297145	0.761	rs62473015	chr7:98763301	G/A	cg05967295	chr7:98741636	SMURF1	0.99	12.81	0.75	1.84e-24	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs8070740	1.000	rs4790772	chr17:5330959	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.47	4.44	0.37	1.96e-5	Menopause (age at onset);
TGCT	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg20607798	chr8:58055168	NA	0.61	5.16	0.42	9.71e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs1008375	1.000	rs3815413	chr4:17654648	T/C	cg18681998	chr4:17616180	MED28	1.06	12.43	0.74	1.57e-23	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10875595	0.509	rs115819920	chr5:140663745	A/C	cg24830062	chr5:140700576	TAF7	-0.6	-5.08	-0.42	1.34e-6	Pulmonary function decline;
TGCT	cis	rs9787249	0.957	rs56064244	chr1:40213890	C/T	cg20968010	chr1:40505947	CAP1	-0.53	-5.0	-0.41	1.91e-6	Blood protein levels;
TGCT	cis	rs72781680	0.898	rs17462433	chr2:24012758	T/C	cg08917208	chr2:24149416	ATAD2B	0.81	5.01	0.41	1.8e-6	Lymphocyte counts;
TGCT	cis	rs9611565	0.592	rs12484467	chr22:41957610	T/C	cg06634786	chr22:41940651	POLR3H	-0.82	-7.52	-0.56	9.36e-12	Vitiligo;
TGCT	cis	rs2180341	1.000	rs7756336	chr6:127650299	T/C	cg24812749	chr6:127587940	RNF146	0.98	7.64	0.57	5.06e-12	Breast cancer;
TGCT	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7666738	0.830	rs10029849	chr4:99059362	T/C	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.44e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs73058052	0.597	rs2288921	chr19:50092002	G/T	cg09250473	chr19:50168907	IRF3;BCL2L12	-0.68	-5.61	-0.45	1.23e-7	Fibrinogen levels;
TGCT	cis	rs7666738	0.830	rs35685312	chr4:98858521	G/A	cg18180107	chr4:99064573	C4orf37	0.55	5.14	0.42	1.03e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1372520	0.808	rs1372518	chr4:90757294	A/C	cg20003494	chr4:90757398	SNCA	-0.65	-5.17	-0.42	9.26e-7	Neuroticism;
TGCT	cis	rs4720575	1.000	rs7791050	chr7:47086452	T/C	cg00036614	chr7:47093842	NA	-0.2	-5.08	-0.42	1.35e-6	Angiotensin-converting enzyme inhibitor intolerance;
TGCT	cis	rs904251	0.861	rs1776456	chr6:37484698	C/G	cg25019722	chr6:37503610	NA	-0.49	-6.78	-0.52	4.4e-10	Cognitive performance;
TGCT	cis	rs2153535	0.580	rs7341382	chr6:8470549	A/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs8013055	0.796	rs4075105	chr14:106000231	C/T	cg19700328	chr14:106028568	NA	-0.46	-5.14	-0.42	1.05e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs7829975	0.539	rs940031	chr8:8546848	C/T	cg06636001	chr8:8085503	FLJ10661	-0.59	-5.06	-0.41	1.5e-6	Mood instability;
TGCT	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg04234412	chr22:24373322	LOC391322	-0.89	-9.44	-0.65	2.84e-16	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9948	0.655	rs17119591	chr2:97435557	G/A	cg01990225	chr2:97406019	LMAN2L	-1.01	-5.13	-0.42	1.08e-6	Erectile dysfunction and prostate cancer treatment;
TGCT	trans	rs8073060	0.586	rs7221203	chr17:34015532	T/C	cg19694781	chr19:47549865	TMEM160	-0.6	-13.37	-0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs6582630	0.519	rs11514372	chr12:38308613	T/G	cg26384229	chr12:38710491	ALG10B	0.82	7.23	0.54	4.32e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg05368731	chr17:41323189	NBR1	1.16	13.44	0.77	5.72e-26	Menopause (age at onset);
TGCT	cis	rs151997	0.538	rs62367392	chr5:50270298	T/C	cg06027927	chr5:50259733	NA	0.56	5.72	0.46	7.4e-8	Callous-unemotional behaviour;
TGCT	trans	rs2727020	0.729	rs1917325	chr11:49370004	G/A	cg15704280	chr7:45808275	SEPT13	-0.74	-8.45	-0.6	6.53e-14	Coronary artery disease;
TGCT	cis	rs12477438	1.000	rs73963398	chr2:99887025	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.97	-8.81	-0.62	9.23e-15	Chronic sinus infection;
TGCT	cis	rs9911578	1.000	rs4372750	chr17:57013803	A/C	cg05425664	chr17:57184151	TRIM37	0.62	6.18	0.49	8.33e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7824557	0.545	rs2736303	chr8:11236850	C/T	cg21775007	chr8:11205619	TDH	-0.65	-6.39	-0.5	3.07e-9	Retinal vascular caliber;
TGCT	cis	rs8056742	0.730	rs74033925	chr16:85083032	G/T	cg00229868	chr16:85520891	NA	0.38	5.13	0.42	1.1e-6	Amyotrophic lateral sclerosis;
TGCT	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.45	-6.46	-0.5	2.17e-9	Alzheimer's disease;
TGCT	cis	rs7226408	0.948	rs72885226	chr18:34401806	G/A	cg06757138	chr18:34340585	FHOD3	0.26	4.79	0.4	4.62e-6	Obesity-related traits;
TGCT	cis	rs2816062	0.813	rs2745318	chr1:18895844	C/T	cg18795169	chr1:18902165	NA	0.6	14.1	0.78	1.57e-27	Urate levels in lean individuals;
TGCT	cis	rs669446	0.528	rs7538463	chr1:44196416	T/A	cg12908607	chr1:44402522	ARTN	-0.62	-7.25	-0.55	3.99e-11	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs1577917	1.000	rs12215037	chr6:86727631	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-5.36	-0.43	3.86e-7	Response to antipsychotic treatment;
TGCT	cis	rs910316	1.000	rs8003506	chr14:75586288	A/C	cg11812906	chr14:75593930	NEK9	-0.72	-7.32	-0.55	2.73e-11	Height;
TGCT	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.2	0.42	8.14e-7	Menopause (age at onset);
TGCT	cis	rs7727544	0.735	rs274558	chr5:131721174	A/G	cg24060327	chr5:131705240	SLC22A5	0.58	6.45	0.5	2.23e-9	Blood metabolite levels;
TGCT	cis	rs12500482	0.935	rs12644638	chr4:2413461	C/T	cg01601518	chr4:2404284	ZFYVE28	-0.32	-5.4	-0.44	3.31e-7	Cognitive function;
TGCT	cis	rs7547997	0.615	rs716221	chr1:158303872	C/T	cg03528325	chr1:158223921	CD1A	0.33	4.58	0.38	1.1e-5	QRS duration;
TGCT	cis	rs4654899	0.680	rs4654881	chr1:21209769	T/C	cg01072550	chr1:21505969	NA	0.52	8.4	0.6	8.89e-14	Superior frontal gyrus grey matter volume;
TGCT	cis	rs938554	0.513	rs3775947	chr4:9995240	C/T	cg02734326	chr4:10020555	SLC2A9	0.53	4.92	0.4	2.71e-6	Blood metabolite levels;
TGCT	cis	rs4629710	0.545	rs11755717	chr6:131547028	A/T	cg12606694	chr6:131520996	AKAP7	-0.39	-4.79	-0.39	4.76e-6	Multiple myeloma (IgH translocation);
TGCT	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg08280861	chr8:58055591	NA	0.41	4.63	0.38	8.93e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1670533	1.000	rs7685541	chr4:1058501	G/A	cg20887711	chr4:1340912	KIAA1530	0.71	5.7	0.46	8.33e-8	Recombination rate (females);
TGCT	cis	rs13191362	1.000	rs36007635	chr6:163009335	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg08736216	chr1:53307985	ZYG11A	-0.25	-4.96	-0.41	2.22e-6	Monocyte count;
TGCT	cis	rs3820068	0.581	rs16851851	chr1:15929628	C/G	cg05660106	chr1:15850417	CASP9	0.82	8.02	0.58	6.63e-13	Systolic blood pressure;
TGCT	cis	rs231513	0.906	rs11657450	chr17:42002464	C/T	cg26893861	chr17:41843967	DUSP3	0.74	5.18	0.42	8.54e-7	Cognitive function;
TGCT	cis	rs447735	0.537	rs7190341	chr16:89917537	T/C	cg08627397	chr16:89984028	MC1R	-0.35	-5.21	-0.42	7.79e-7	Hemoglobin concentration;
TGCT	cis	rs682748	0.791	rs1875538	chr5:17145198	C/A	cg23987134	chr5:17158319	LOC285696	-0.23	-5.55	-0.45	1.67e-7	Hippocampal atrophy;
TGCT	cis	rs797680	0.856	rs11164876	chr1:93630510	T/C	cg17826107	chr1:92977322	EVI5	-0.23	-5.0	-0.41	1.88e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs7267979	1.000	rs6083805	chr20:25317356	T/C	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs17767294	0.708	rs77450054	chr6:28083949	G/A	cg08851530	chr6:28072375	NA	1.56	7.22	0.54	4.47e-11	Parkinson's disease;
TGCT	cis	rs1372520	0.684	rs2619347	chr4:90745770	G/A	cg15133208	chr4:90757351	SNCA	-0.5	-5.86	-0.47	4e-8	Neuroticism;
TGCT	cis	rs2836950	0.545	rs2836922	chr21:40516308	C/T	cg11644478	chr21:40555479	PSMG1	-0.59	-5.73	-0.46	7.13e-8	Menarche (age at onset);
TGCT	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg05368731	chr17:41323189	NBR1	1.2	14.48	0.79	1.98e-28	Menopause (age at onset);
TGCT	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg17178900	chr1:205818956	PM20D1	0.58	7.19	0.54	5.32e-11	Menarche (age at onset);
TGCT	cis	rs34754277	0.636	rs1966228	chr1:118144332	C/T	cg03653317	chr1:118165598	FAM46C	0.19	4.65	0.39	8.35e-6	Immature fraction of reticulocytes;
TGCT	cis	rs7605378	0.528	rs281780	chr2:200756331	G/C	cg23649088	chr2:200775458	C2orf69	0.47	9.78	0.66	4.27e-17	Osteoporosis;
TGCT	cis	rs13256369	0.950	rs12548792	chr8:8568031	T/C	cg18904891	chr8:8559673	CLDN23	0.59	5.54	0.45	1.73e-7	Obesity-related traits;
TGCT	trans	rs77457752	0.690	rs10113975	chr9:13912482	A/C	cg12973904	chr7:149457885	NA	0.42	6.88	0.53	2.59e-10	Breast cancer;
TGCT	trans	rs629535	0.814	rs78813708	chr8:70073977	A/G	cg21567404	chr3:27674614	NA	0.57	9.09	0.63	1.94e-15	Dupuytren's disease;
TGCT	cis	rs67311347	1.000	rs10510708	chr3:40404770	A/G	cg13683864	chr3:40499215	RPL14	-1.02	-10.8	-0.7	1.43e-19	Renal cell carcinoma;
TGCT	cis	rs6912958	0.712	rs4706294	chr6:88317675	G/C	cg06598631	chr6:88300029	RARS2;ORC3L	-0.57	-5.2	-0.42	7.9e-7	Monocyte percentage of white cells;
TGCT	trans	rs916888	0.647	rs199523	chr17:44848517	C/A	cg22968622	chr17:43663579	NA	-1.05	-10.06	-0.67	8.89e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs12200560	0.524	rs1413525	chr6:97073096	C/T	cg06623918	chr6:96969491	KIAA0776	0.6	5.17	0.42	8.99e-7	Coronary heart disease;
TGCT	trans	rs2727020	0.521	rs7114564	chr11:49571231	C/T	cg11707556	chr5:10655725	ANKRD33B	0.41	8.24	0.59	2.06e-13	Coronary artery disease;
TGCT	cis	rs6665290	0.582	rs72764213	chr1:227207391	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.92	-16.05	-0.82	4.56e-32	Myeloid white cell count;
TGCT	cis	rs7017914	0.967	rs11989553	chr8:71640899	A/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.03	-0.41	1.69e-6	Bone mineral density;
TGCT	cis	rs7582180	0.629	rs11123826	chr2:100936276	G/T	cg14675211	chr2:100938903	LONRF2	-0.5	-4.88	-0.4	3.18e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs12135062	0.851	rs2651926	chr1:3101820	C/T	cg00254258	chr1:3105189	PRDM16	-0.36	-5.86	-0.47	3.95e-8	Migraine;
TGCT	cis	rs7666738	0.830	rs35939134	chr4:98980311	A/G	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg19901468	chr14:105411992	AHNAK2	0.28	5.93	0.47	2.77e-8	Rheumatoid arthritis;
TGCT	cis	rs9467773	0.967	rs6941022	chr6:26553531	T/C	cg15659132	chr6:26577336	NA	0.89	13.14	0.76	3.05e-25	Intelligence (multi-trait analysis);
TGCT	trans	rs2970818	0.831	rs2970810	chr12:4608103	A/G	cg04106436	chr12:8665373	CLEC4D	0.31	6.81	0.52	3.67e-10	Phosphorus levels;
TGCT	cis	rs9985766	1.000	rs9307863	chr4:151003443	C/T	cg05926478	chr4:151174724	DCLK2	-0.24	-4.6	-0.38	1.03e-5	Coronary artery disease;Myocardial infarction;
TGCT	cis	rs11650494	0.908	rs77488129	chr17:47448970	G/A	cg08112188	chr17:47440006	ZNF652	1.04	5.31	0.43	4.85e-7	Prostate cancer;
TGCT	cis	rs1577917	0.958	rs12196230	chr6:86519960	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-5.21	-0.42	7.64e-7	Response to antipsychotic treatment;
TGCT	trans	rs3107575	0.572	rs73169366	chr3:165320307	C/T	cg15894581	chr15:63889406	FBXL22	0.88	6.83	0.52	3.32e-10	Morning vs. evening chronotype;
TGCT	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg11247378	chr22:39784982	NA	-0.73	-9.59	-0.65	1.22e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs6570726	0.577	rs867056	chr6:145784805	A/C	cg23711669	chr6:146136114	FBXO30	-0.73	-6.83	-0.52	3.43e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9899728	0.539	rs12940199	chr17:73054759	C/T	cg27626185	chr17:73056755	KCTD2	-0.92	-8.01	-0.58	7.17e-13	Alzheimer's disease or small vessel stroke;
TGCT	cis	rs2594989	0.943	rs7622627	chr3:11357419	T/C	cg00170343	chr3:11313890	ATG7	0.66	4.87	0.4	3.39e-6	Circulating chemerin levels;
TGCT	cis	rs13191362	0.935	rs13212137	chr6:163010261	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs61990749	0.597	rs11624101	chr14:78138059	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	-0.61	-4.45	-0.37	1.89e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs2777491	0.957	rs2015781	chr15:41648967	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.75	-10.46	-0.68	9.68e-19	Ulcerative colitis;
TGCT	cis	rs12497850	0.931	rs12493289	chr3:48905161	G/A	cg06212747	chr3:49208901	KLHDC8B	0.62	5.83	0.46	4.42e-8	Parkinson's disease;
TGCT	cis	rs12643440	0.538	rs879572	chr4:17148487	G/C	cg22650099	chr4:17144496	NA	-0.47	-4.78	-0.39	4.83e-6	Metabolite levels (Pyroglutamine);
TGCT	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg01802117	chr1:53393560	SCP2	-0.39	-4.61	-0.38	1e-5	Monocyte count;
TGCT	cis	rs12500482	0.935	rs12644638	chr4:2413461	C/T	cg08330972	chr4:2403930	ZFYVE28	-0.38	-5.35	-0.43	4.15e-7	Cognitive function;
TGCT	cis	rs6570726	0.764	rs9399553	chr6:145873664	A/T	cg23711669	chr6:146136114	FBXO30	0.89	9.93	0.67	1.82e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg14893161	chr1:205819251	PM20D1	0.55	7.63	0.57	5.31e-12	Menarche (age at onset);
TGCT	cis	rs7089973	0.604	rs7919649	chr10:116609576	T/C	cg03647239	chr10:116582469	FAM160B1	0.57	5.48	0.44	2.3e-7	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs9549367	0.789	rs2287250	chr13:113889474	C/T	cg18105134	chr13:113819100	PROZ	0.35	5.81	0.46	4.91e-8	Platelet distribution width;
TGCT	cis	rs523522	0.962	rs2168319	chr12:120933217	C/T	cg27279351	chr12:120934652	DYNLL1	0.77	6.61	0.51	1.02e-9	High light scatter reticulocyte count;
TGCT	cis	rs9467773	0.583	rs1021373	chr6:26632457	G/A	cg05738196	chr6:26577821	NA	0.88	11.22	0.71	1.33e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs473651	0.935	rs558924	chr2:239339511	A/G	cg08773314	chr2:239334832	ASB1	0.45	6.39	0.5	3.05e-9	Multiple system atrophy;
TGCT	cis	rs611744	0.506	rs13280454	chr8:109263240	A/G	cg21045802	chr8:109455806	TTC35	0.7	7.05	0.54	1.07e-10	Dupuytren's disease;
TGCT	cis	rs17376456	0.597	rs7728825	chr5:93384594	T/C	cg25358565	chr5:93447407	FAM172A	-0.62	-5.93	-0.47	2.83e-8	Diabetic retinopathy;
TGCT	cis	rs7172809	0.599	rs74666689	chr15:77786731	C/T	cg22256960	chr15:77711686	NA	-0.51	-4.86	-0.4	3.47e-6	Glucose homeostasis traits;
TGCT	cis	rs7607369	0.526	rs10498060	chr2:219431291	G/A	cg02176678	chr2:219576539	TTLL4	-0.52	-5.82	-0.46	4.79e-8	Red blood cell count;Amyotrophic lateral sclerosis;
TGCT	cis	rs4776059	0.959	rs12898644	chr15:52905233	A/G	cg25063058	chr15:52860530	ARPP19	0.52	4.73	0.39	6.01e-6	Schizophrenia;
TGCT	cis	rs1371867	0.846	rs2439460	chr8:101312665	C/T	cg06002616	chr8:101225028	SPAG1	-0.53	-6.21	-0.49	7.16e-9	Atrioventricular conduction;
TGCT	cis	rs6089584	1.000	rs6089583	chr20:60563624	G/A	cg13770153	chr20:60521292	NA	-0.44	-5.62	-0.45	1.21e-7	Body mass index;
TGCT	cis	rs7524258	0.868	rs1304712	chr1:7270538	C/T	cg04342483	chr1:7259290	CAMTA1	-0.3	-4.45	-0.37	1.89e-5	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs7659604	0.540	rs116452657	chr4:122674147	A/G	cg19748678	chr4:122722346	EXOSC9	-0.51	-5.0	-0.41	1.89e-6	Type 2 diabetes;
TGCT	cis	rs9948	0.655	rs62156216	chr2:97405127	C/T	cg01990225	chr2:97406019	LMAN2L	-1.02	-5.19	-0.42	8.43e-7	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	16.1	0.82	3.69e-32	Prudent dietary pattern;
TGCT	cis	rs6867913	0.709	rs891987	chr5:141467196	A/T	cg01169021	chr5:140792918	PCDHGA4;PCDHGA6;PCDHGA9;PCDHGA1;PCDHGA8;PCDHGA5;PCDHGB1;PCDHGA10;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGB6;PCDHGA7;PCDHGB2;PCDHGB5;PCDHGB3	0.39	4.93	0.4	2.6e-6	Asthma;
TGCT	cis	rs733175	0.857	rs7666545	chr4:10012372	C/T	cg00071950	chr4:10020882	SLC2A9	0.54	4.54	0.38	1.3e-5	Psychosis and Alzheimer's disease;
TGCT	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg10802521	chr3:52805072	NEK4	-0.71	-8.81	-0.62	9.29e-15	Bipolar disorder;
TGCT	cis	rs981844	1.000	rs17371021	chr4:154664295	A/G	cg14289246	chr4:154710475	SFRP2	-0.92	-7.32	-0.55	2.71e-11	Response to statins (LDL cholesterol change);
TGCT	cis	rs1371867	0.641	rs1788209	chr8:101337056	C/T	cg06636551	chr8:101224915	SPAG1	-0.45	-6.12	-0.48	1.13e-8	Atrioventricular conduction;
TGCT	cis	rs9611565	0.512	rs132784	chr22:42052363	G/A	cg03806693	chr22:41940476	POLR3H	1.1	11.41	0.72	4.6e-21	Vitiligo;
TGCT	trans	rs1814175	0.529	rs10839396	chr11:49852406	G/T	cg18944383	chr4:111397179	ENPEP	-0.45	-7.0	-0.53	1.45e-10	Height;
TGCT	cis	rs6088590	0.965	rs13040449	chr20:33358901	T/A	cg24642439	chr20:33292090	TP53INP2	0.7	6.22	0.49	7.12e-9	Coronary artery disease;
TGCT	cis	rs11673344	0.523	rs10406110	chr19:37650929	G/C	cg08039142	chr19:36980659	ZNF566	0.49	4.49	0.37	1.63e-5	Obesity-related traits;
TGCT	cis	rs4253772	0.638	rs6007845	chr22:46718417	A/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.69	-5.31	-0.43	4.82e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs3749237	0.595	rs35701831	chr3:49515000	A/C	cg03060546	chr3:49711283	APEH	0.77	8.86	0.62	6.92e-15	Resting heart rate;
TGCT	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg08280861	chr8:58055591	NA	0.4	4.89	0.4	3.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.82	7.26	0.55	3.65e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs1023500	1.000	rs6002552	chr22:42338351	G/A	cg04692870	chr22:42525206	CYP2D6	-0.35	-5.21	-0.42	7.53e-7	Schizophrenia;
TGCT	cis	rs7647973	0.566	rs57630346	chr3:49086215	T/C	cg07636037	chr3:49044803	WDR6	0.81	6.68	0.51	7.37e-10	Menarche (age at onset);
TGCT	cis	rs858239	0.600	rs10237755	chr7:23131564	A/G	cg05602783	chr7:23145260	KLHL7	-0.64	-5.37	-0.43	3.69e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs881375	0.967	rs10435843	chr9:123668033	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	5.06	0.41	1.49e-6	Rheumatoid arthritis;
TGCT	trans	rs2469997	1.000	rs1599476	chr8:120351800	C/T	cg01792902	chr3:178864926	PIK3CA	0.8	6.91	0.53	2.21e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs3008870	1.000	rs3008873	chr1:67425770	G/A	cg11518657	chr1:67396239	MIER1	0.54	4.61	0.38	9.72e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs655029	0.740	rs610077	chr2:31458190	G/A	cg14018959	chr2:31480232	EHD3	-0.36	-4.89	-0.4	3.08e-6	Mean platelet volume;Platelet distribution width;Platelet count;Plateletcrit;
TGCT	cis	rs11190604	1.000	rs11190540	chr10:102202629	A/G	cg23241863	chr10:102295624	HIF1AN	0.62	4.87	0.4	3.27e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs6912958	0.667	rs7746545	chr6:88090225	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.66	6.8	0.52	3.89e-10	Monocyte percentage of white cells;
TGCT	cis	rs2050392	0.799	rs303429	chr10:30708441	C/T	cg18806716	chr10:30721971	MAP3K8	-0.47	-5.53	-0.44	1.8e-7	Inflammatory bowel disease;
TGCT	cis	rs4242434	0.819	rs6558173	chr8:22492103	A/C	cg03733263	chr8:22462867	KIAA1967	-1.07	-15.28	-0.81	2.69e-30	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs17826219	0.568	rs7213925	chr17:29121634	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Body mass index;
TGCT	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg25204440	chr1:209979598	IRF6	0.7	7.45	0.56	1.4e-11	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
TGCT	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg24675658	chr1:53192096	ZYG11B	-0.85	-10.48	-0.69	8.41e-19	Monocyte count;
TGCT	cis	rs6815814	0.898	rs73236646	chr4:38871385	T/C	cg02016764	chr4:38805732	TLR1	-0.39	-5.81	-0.46	4.87e-8	Breast cancer;
TGCT	cis	rs981844	0.753	rs1105491	chr4:154726634	A/C	cg14289246	chr4:154710475	SFRP2	1.01	9.4	0.65	3.53e-16	Response to statins (LDL cholesterol change);
TGCT	cis	rs7542091	0.666	rs7537070	chr1:210043565	A/G	cg23283495	chr1:209979779	IRF6	0.55	5.47	0.44	2.34e-7	Monobrow;
TGCT	cis	rs9913156	0.515	rs11658808	chr17:4577112	C/T	cg00122941	chr17:4613640	ARRB2	-0.77	-7.4	-0.55	1.82e-11	Lymphocyte counts;
TGCT	cis	rs2013441	1.000	rs2526484	chr17:20103760	A/G	cg18979559	chr17:20280153	CCDC144C	-0.44	-4.61	-0.38	9.78e-6	Obesity-related traits;
TGCT	cis	rs2180341	0.814	rs9401958	chr6:127736357	T/G	cg24812749	chr6:127587940	RNF146	0.76	6.22	0.49	7.07e-9	Breast cancer;
TGCT	cis	rs2486012	1.000	rs3120804	chr1:44405214	T/G	cg12908607	chr1:44402522	ARTN	0.78	6.04	0.48	1.68e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs1865760	1.000	rs2071297	chr6:25924513	C/G	cg16482183	chr6:26056742	HIST1H1C	-0.52	-4.67	-0.39	7.83e-6	Height;
TGCT	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.05	8.68	0.61	1.9e-14	Platelet count;
TGCT	trans	rs3780486	0.846	rs3780490	chr9:33129839	A/G	cg20290983	chr6:43655470	MRPS18A	1.19	14.84	0.8	2.81e-29	IgG glycosylation;
TGCT	cis	rs2637266	0.703	rs846635	chr10:78535132	G/A	cg18941641	chr10:78392320	NA	0.39	4.67	0.39	7.62e-6	Pulmonary function;
TGCT	cis	rs9534288	0.619	rs6561290	chr13:46682460	A/G	cg15192986	chr13:46630673	CPB2	-0.51	-6.11	-0.48	1.17e-8	Blood protein levels;
TGCT	cis	rs12497850	0.931	rs9846123	chr3:49088112	C/T	cg05785598	chr3:49045655	WDR6	-0.36	-4.77	-0.39	5.17e-6	Parkinson's disease;
TGCT	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg09033563	chr22:24373618	LOC391322	-0.52	-5.23	-0.43	6.88e-7	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1570884	0.890	rs7333969	chr13:50123317	C/T	cg08779649	chr13:50194554	NA	0.33	5.25	0.43	6.42e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
TGCT	cis	rs3796352	0.667	rs11720228	chr3:52877270	G/A	cg15956490	chr3:53032818	SFMBT1	0.57	5.25	0.43	6.25e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs902774	0.530	rs11834907	chr12:53350985	C/T	cg05393297	chr12:53359155	NA	-0.84	-5.35	-0.43	4.06e-7	Prostate cancer;
TGCT	cis	rs7666738	0.830	rs1025204	chr4:99023441	G/A	cg17366294	chr4:99064904	C4orf37	0.7	7.18	0.54	5.7e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6430585	1.000	rs6430585	chr2:136506927	A/C	cg07169764	chr2:136633963	MCM6	-0.88	-7.8	-0.57	2.16e-12	Corneal structure;
TGCT	cis	rs908922	0.651	rs564107	chr1:152519295	C/T	cg20991723	chr1:152506922	NA	0.45	6.09	0.48	1.33e-8	Hair morphology;
TGCT	cis	rs367615	0.918	rs10054960	chr5:108866448	C/A	cg17395555	chr5:108820864	NA	0.31	5.01	0.41	1.85e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs1451375	0.698	rs11238214	chr7:50636018	A/G	cg18232548	chr7:50535776	DDC	0.44	6.72	0.52	5.81e-10	Malaria;
TGCT	cis	rs7843479	0.509	rs899428	chr8:21770763	T/C	cg17168535	chr8:21777572	XPO7	0.77	7.4	0.55	1.81e-11	Mean corpuscular volume;
TGCT	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg16325326	chr1:53192061	ZYG11B	0.52	5.84	0.46	4.24e-8	Monocyte count;
TGCT	cis	rs9372498	0.505	rs9320655	chr6:118830981	T/C	cg07617317	chr6:118971624	C6orf204	0.52	5.55	0.45	1.69e-7	Diastolic blood pressure;
TGCT	cis	rs78487399	0.831	rs12469373	chr2:43829191	T/C	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.66	4.67	0.39	7.66e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	trans	rs17471911	0.581	rs1344214	chr10:100758587	A/G	cg03484267	chr2:207988651	KLF7	-0.52	-6.7	-0.52	6.49e-10	Neuroticism;
TGCT	cis	rs6688613	0.685	rs11579987	chr1:166889364	C/G	cg07049167	chr1:166818506	POGK	-0.27	-5.74	-0.46	6.86e-8	Refractive astigmatism;
TGCT	cis	rs72945132	0.882	rs3133179	chr11:70187574	T/G	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs854765	0.663	rs1052299	chr17:17750419	A/G	cg04398451	chr17:18023971	MYO15A	0.3	4.59	0.38	1.09e-5	Total body bone mineral density;
TGCT	cis	rs8077889	0.956	rs4792910	chr17:41840229	T/C	cg26893861	chr17:41843967	DUSP3	1.08	13.44	0.77	5.71e-26	Triglycerides;
TGCT	cis	rs2836633	0.929	rs4514962	chr21:40041753	C/T	cg12884169	chr21:40033163	ERG	0.45	4.85	0.4	3.69e-6	Coronary artery disease;
TGCT	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.03	0.41	1.68e-6	Prudent dietary pattern;
TGCT	cis	rs7666738	0.830	rs13115356	chr4:98933171	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs7819412	0.527	rs7821914	chr8:10805015	A/G	cg15556689	chr8:8085844	FLJ10661	-0.79	-7.29	-0.55	3.22e-11	Triglycerides;
TGCT	cis	rs8072100	1.000	rs11650372	chr17:45721795	G/A	cg08085267	chr17:45401833	C17orf57	-0.47	-5.13	-0.42	1.07e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs791357	0.501	rs791362	chr5:173212127	A/T	cg04561637	chr5:172480106	NA	-0.25	-4.75	-0.39	5.63e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Granulocyte count;Myeloid white cell count;
TGCT	cis	rs1903068	0.853	rs9312656	chr4:56002972	C/G	cg16572876	chr4:56024045	NA	0.42	4.79	0.39	4.75e-6	Endometriosis;
TGCT	cis	rs10875746	0.729	rs11168357	chr12:48412138	G/A	cg20731937	chr12:48336164	NA	0.6	4.99	0.41	1.97e-6	Longevity (90 years and older);
TGCT	cis	rs6598955	0.671	rs10493030	chr1:26561856	T/C	cg04990556	chr1:26633338	UBXN11	0.64	5.11	0.42	1.19e-6	Obesity-related traits;
TGCT	cis	rs7474896	0.515	rs662928	chr10:38316216	G/T	cg13720705	chr10:37990370	NA	-0.35	-4.73	-0.39	5.99e-6	Obesity (extreme);
TGCT	cis	rs2153535	0.580	rs9328479	chr6:8519646	A/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.01	0.41	1.86e-6	Motion sickness;
TGCT	cis	rs9527	0.637	rs7085104	chr10:104628873	A/G	cg04362960	chr10:104952993	NT5C2	0.56	4.86	0.4	3.52e-6	Arsenic metabolism;
TGCT	cis	rs10875746	0.903	rs11168401	chr12:48481519	T/C	cg20731937	chr12:48336164	NA	0.62	4.95	0.41	2.36e-6	Longevity (90 years and older);
TGCT	cis	rs12477438	0.520	rs4850897	chr2:99768419	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	10.3	0.68	2.42e-18	Chronic sinus infection;
TGCT	cis	rs877282	0.898	rs11253343	chr10:765117	C/T	cg17470449	chr10:769945	NA	0.37	5.59	0.45	1.37e-7	Uric acid levels;
TGCT	cis	rs10504229	0.593	rs113184543	chr8:58042950	A/G	cg08280861	chr8:58055591	NA	0.35	4.92	0.4	2.72e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs12142240	0.698	rs6703669	chr1:46862555	C/T	cg00530320	chr1:46809349	NSUN4	0.29	5.79	0.46	5.34e-8	Menopause (age at onset);
TGCT	cis	rs7772486	0.875	rs2748483	chr6:146335560	A/T	cg05347473	chr6:146136440	FBXO30	-0.51	-4.9	-0.4	2.96e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs380904	0.926	rs7842979	chr8:144601896	T/G	cg09317036	chr8:144635547	GSDMD	0.51	4.71	0.39	6.41e-6	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs2204008	0.837	rs7315255	chr12:37949279	G/A	cg26384229	chr12:38710491	ALG10B	0.86	7.77	0.57	2.55e-12	Bladder cancer;
TGCT	cis	rs7605378	1.000	rs769957	chr2:200695524	A/C	cg17644776	chr2:200775616	C2orf69	0.28	5.25	0.43	6.44e-7	Osteoporosis;
TGCT	cis	rs7845219	0.544	rs4735332	chr8:95923660	C/T	cg13393036	chr8:95962371	TP53INP1	-0.44	-5.11	-0.42	1.18e-6	Type 2 diabetes;
TGCT	cis	rs13191362	1.000	rs66594243	chr6:163169024	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.14	9.35	0.64	4.74e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7255045	0.752	rs55730975	chr19:12973039	G/A	cg23899408	chr19:12877188	HOOK2	-0.61	-4.99	-0.41	1.97e-6	Mean corpuscular volume;
TGCT	cis	rs778371	0.723	rs283470	chr2:233656918	G/A	cg08000102	chr2:233561755	GIGYF2	0.69	8.08	0.59	4.87e-13	Schizophrenia;
TGCT	cis	rs4699052	0.928	rs2126473	chr4:104141533	G/C	cg16532752	chr4:104119610	CENPE	-0.59	-5.56	-0.45	1.56e-7	Testicular germ cell tumor;
TGCT	cis	rs3806843	0.576	rs246005	chr5:140339884	A/C	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg03388025	chr16:89894329	SPIRE2	0.49	8.32	0.6	1.38e-13	Vitiligo;
TGCT	cis	rs1008375	1.000	rs6848360	chr4:17634442	G/T	cg18681998	chr4:17616180	MED28	1.07	11.98	0.73	1.97e-22	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	trans	rs7824557	0.564	rs1435275	chr8:11235735	T/C	cg15556689	chr8:8085844	FLJ10661	-0.74	-6.7	-0.52	6.48e-10	Retinal vascular caliber;
TGCT	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg22535103	chr8:58192502	C8orf71	-0.42	-4.79	-0.4	4.7e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1865760	0.566	rs9295688	chr6:26084217	G/A	cg17042849	chr6:26104293	HIST1H4C	-0.63	-5.47	-0.44	2.43e-7	Height;
TGCT	cis	rs941408	0.515	rs1736188	chr19:2782368	A/G	cg06609049	chr19:2785107	THOP1	1.14	13.05	0.76	4.95e-25	Total cholesterol levels;
TGCT	cis	rs4595586	0.545	rs7973338	chr12:39380704	T/C	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs56104184	0.779	rs17206693	chr19:49360252	C/G	cg15549821	chr19:49342101	PLEKHA4	-0.78	-9.08	-0.63	2.09e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs17331151	0.573	rs77223362	chr3:52865125	G/A	cg15956490	chr3:53032818	SFMBT1	0.46	5.75	0.46	6.57e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs9911578	1.000	rs9907499	chr17:56949044	A/G	cg12560992	chr17:57184187	TRIM37	0.76	9.21	0.64	1.03e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs7147624	1.000	rs10135969	chr14:65982345	C/T	cg03016385	chr14:66212404	NA	-0.49	-7.11	-0.54	8.13e-11	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs2797160	0.935	rs12717178	chr6:126016499	G/A	cg05901451	chr6:126070800	HEY2	0.73	6.29	0.49	5.01e-9	Endometrial cancer;
TGCT	cis	rs929354	0.772	rs6459741	chr7:157014553	G/T	cg05182265	chr7:156933206	UBE3C	-0.4	-9.08	-0.63	2.11e-15	Body mass index;
TGCT	cis	rs7926906	1.000	rs4304731	chr11:90523785	C/A	cg26138821	chr11:89956704	CHORDC1	-0.53	-5.69	-0.46	8.52e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs736408	0.562	rs1014969	chr3:52808341	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.61	-5.48	-0.44	2.27e-7	Bipolar disorder;
TGCT	cis	rs3091242	0.935	rs4233043	chr1:25765483	A/G	cg09222892	chr1:25734099	RHCE	-0.43	-7.07	-0.54	1.02e-10	Erythrocyte sedimentation rate;
TGCT	cis	rs7666738	0.830	rs17550630	chr4:99008332	G/T	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3784262	0.669	rs4646559	chr15:58354258	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.42	-6.24	-0.49	6.32e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs6582630	0.519	rs4436613	chr12:38293653	T/C	cg26384229	chr12:38710491	ALG10B	0.82	7.23	0.54	4.32e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs11711311	0.911	rs9831422	chr3:113398195	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.8	-7.16	-0.54	6.18e-11	IgG glycosylation;
TGCT	cis	rs1008375	0.966	rs4698638	chr4:17632988	G/C	cg16339924	chr4:17578868	LAP3	0.66	5.49	0.44	2.22e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2066819	1.000	rs78121408	chr12:56684798	C/T	cg26714650	chr12:56694279	CS	-1.36	-6.06	-0.48	1.54e-8	Psoriasis vulgaris;
TGCT	cis	rs1461503	0.932	rs7944492	chr11:122838745	G/T	cg27398637	chr11:122830231	C11orf63	-0.43	-5.28	-0.43	5.68e-7	Menarche (age at onset);
TGCT	cis	rs6684514	1.000	rs11264464	chr1:156250887	T/G	cg20302342	chr1:156215951	PAQR6	0.34	4.6	0.38	1.01e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs137699	0.695	rs137653	chr22:39732171	A/G	cg24399712	chr22:39784796	NA	0.66	5.77	0.46	5.88e-8	IgG glycosylation;
TGCT	cis	rs28785552	1.000	rs28785552	chr19:53234161	G/A	cg22067481	chr19:53234126	ZNF611	-0.51	-7.5	-0.56	1.09e-11	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs75229567	0.618	rs11177849	chr12:70182473	C/T	cg10114359	chr12:70132523	RAB3IP	-1.35	-6.68	-0.51	7.19e-10	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
TGCT	cis	rs614226	0.935	rs17431717	chr12:120912210	G/A	cg01236616	chr12:121019343	POP5	-1.2	-11.78	-0.73	5.83e-22	Type 1 diabetes nephropathy;
TGCT	cis	rs8084125	0.832	rs62105175	chr18:74948498	T/C	cg07390210	chr18:74961196	GALR1	0.36	4.46	0.37	1.85e-5	Obesity-related traits;
TGCT	cis	rs651907	0.535	rs17347156	chr3:101504674	G/A	cg12386194	chr3:101231763	SENP7	0.46	4.5	0.37	1.57e-5	Colorectal cancer;
TGCT	cis	rs11585357	0.895	rs72633812	chr1:17623140	T/C	cg08277548	chr1:17600880	PADI3	-0.95	-9.6	-0.65	1.15e-16	Hair shape;
TGCT	cis	rs317689	0.918	rs689415	chr12:69738139	A/G	cg14784868	chr12:69753453	YEATS4	-0.53	-4.45	-0.37	1.9e-5	Response to diuretic therapy;
TGCT	cis	rs7120118	0.517	rs61896015	chr11:47279928	C/A	cg13308137	chr11:47528955	CUGBP1	0.33	5.19	0.42	8.16e-7	HDL cholesterol;
TGCT	cis	rs7572733	0.515	rs11887138	chr2:198805838	T/A	cg00792783	chr2:198669748	PLCL1	0.57	5.23	0.43	6.99e-7	Dermatomyositis;
TGCT	cis	rs7100689	0.784	rs10887838	chr10:82161380	G/A	cg01528321	chr10:82214614	TSPAN14	0.87	8.71	0.62	1.62e-14	Post bronchodilator FEV1;
TGCT	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg03388025	chr16:89894329	SPIRE2	0.49	8.53	0.61	4.4e-14	Vitiligo;
TGCT	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg07507251	chr3:52567010	NT5DC2	0.47	6.75	0.52	5.11e-10	Bipolar disorder;
TGCT	cis	rs2404602	0.684	rs11072602	chr15:76873467	T/C	cg23625390	chr15:77176239	SCAPER	-0.37	-4.67	-0.39	7.71e-6	Blood metabolite levels;
TGCT	cis	rs1062177	0.855	rs6884630	chr5:151268997	A/T	cg12924095	chr5:151150029	G3BP1	0.33	4.46	0.37	1.82e-5	Preschool internalizing problems;
TGCT	cis	rs3862030	0.836	rs12771867	chr10:104246691	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-4.61	-0.38	1e-5	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
TGCT	cis	rs75686122	0.772	rs76135007	chr8:104570286	T/C	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs6433895	1.000	rs34714467	chr2:182017987	G/A	cg16904960	chr2:182549928	NA	0.34	4.47	0.37	1.77e-5	Lymphocyte counts;
TGCT	cis	rs986417	0.688	rs1950317	chr14:61022789	T/G	cg27398547	chr14:60952738	C14orf39	1.38	10.8	0.7	1.4e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs6909279	0.648	rs6919923	chr6:151849670	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	0.64	5.79	0.46	5.32e-8	Bone mineral density;
TGCT	cis	rs9296092	0.538	rs9296094	chr6:33520064	A/G	cg13560919	chr6:33536144	NA	-0.2	-4.64	-0.38	8.68e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs11077998	0.935	rs11653926	chr17:80484953	G/A	cg10255544	chr17:80519551	FOXK2	0.23	4.48	0.37	1.69e-5	Reticulocyte fraction of red cells;
TGCT	cis	rs1577917	1.000	rs1415753	chr6:86753074	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.2	-0.42	8.12e-7	Response to antipsychotic treatment;
TGCT	cis	rs926938	0.618	rs360675	chr1:115490918	T/C	cg12756093	chr1:115239321	AMPD1	0.4	5.97	0.47	2.29e-8	Autism;
TGCT	cis	rs6121246	0.529	rs112367115	chr20:30178627	G/A	cg21427119	chr20:30132790	HM13	-0.44	-6.39	-0.5	3.11e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs4566357	1.000	rs4536647	chr2:227921977	A/G	cg11843606	chr2:227700838	RHBDD1	-0.58	-5.31	-0.43	4.92e-7	Coronary artery disease;
TGCT	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg10150615	chr22:24372951	LOC391322	-0.89	-10.54	-0.69	6e-19	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg06108461	chr20:60628389	TAF4	0.68	9.61	0.65	1.12e-16	Body mass index;
TGCT	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg16497277	chr3:49208875	KLHDC8B	-0.49	-4.48	-0.37	1.68e-5	Parkinson's disease;
TGCT	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg12311346	chr5:56204834	C5orf35	-0.63	-6.41	-0.5	2.73e-9	Initial pursuit acceleration;
TGCT	cis	rs9393777	0.513	rs7754159	chr6:26620312	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.55	-5.08	-0.42	1.35e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9527	0.590	rs726010	chr10:104841977	C/T	cg15744005	chr10:104629667	AS3MT	-0.45	-5.24	-0.43	6.64e-7	Arsenic metabolism;
TGCT	cis	rs10431058	0.965	rs1939895	chr11:107483469	C/T	cg18204760	chr11:107461044	ELMOD1;LOC643923	0.68	6.57	0.51	1.22e-9	Common traits (Other);
TGCT	cis	rs509477	1.000	rs7245165	chr18:32567007	C/A	cg23791764	chr18:32556832	MAPRE2	0.55	4.6	0.38	1.04e-5	Cerebrospinal fluid AB1-42 levels;
TGCT	cis	rs7267979	0.932	rs417110	chr20:25458297	T/C	cg14121845	chr20:25566513	NINL	0.49	5.36	0.43	3.83e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7923609	1.000	rs10822161	chr10:65118203	G/A	cg08743896	chr10:65200160	JMJD1C	-0.34	-4.46	-0.37	1.78e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2046867	0.908	rs2322613	chr3:72819453	A/C	cg25664220	chr3:72788482	NA	-0.54	-6.79	-0.52	4.1e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7786808	0.525	rs10253961	chr7:158194858	G/A	cg01191920	chr7:158217561	PTPRN2	0.36	5.16	0.42	9.41e-7	Obesity-related traits;
TGCT	cis	rs12220898	0.749	rs7913006	chr10:50483043	G/T	cg09603381	chr10:49954066	WDFY4	0.38	4.45	0.37	1.88e-5	Inflammatory biomarkers;
TGCT	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg11764359	chr7:65958608	NA	0.59	5.09	0.42	1.28e-6	Aortic root size;
TGCT	cis	rs10883723	0.810	rs12162	chr10:104240498	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	5.78	0.46	5.63e-8	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs9500256	1.000	rs9500256	chr6:58308955	C/T	cg16251399	chr6:58287822	GUSBL2	0.66	6.07	0.48	1.43e-8	Eosinophilic esophagitis (pediatric);
TGCT	cis	rs7727544	0.548	rs4705938	chr5:131694077	A/G	cg24060327	chr5:131705240	SLC22A5	-0.55	-5.83	-0.46	4.49e-8	Blood metabolite levels;
TGCT	cis	rs6088580	0.634	rs6059860	chr20:33063830	A/C	cg08999081	chr20:33150536	PIGU	0.29	5.6	0.45	1.31e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs3812831	0.695	rs422149	chr13:114931086	T/G	cg15513719	chr13:114904418	NA	0.38	4.65	0.39	8.31e-6	Schizophrenia;
TGCT	cis	rs4455778	0.659	rs11185619	chr7:49017248	A/G	cg26309511	chr7:48887640	NA	-0.43	-5.07	-0.41	1.4e-6	Lung cancer in never smokers;
TGCT	cis	rs9650657	0.737	rs4504595	chr8:10655505	A/G	cg27411982	chr8:10470053	RP1L1	-0.24	-5.09	-0.42	1.3e-6	Neuroticism;
TGCT	cis	rs6061231	0.631	rs2427310	chr20:60969929	C/G	cg15674680	chr20:60982522	CABLES2	0.57	4.94	0.41	2.47e-6	Colorectal cancer;
TGCT	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg07157834	chr1:205819609	PM20D1	0.45	7.27	0.55	3.51e-11	Menarche (age at onset);
TGCT	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	6.96	0.53	1.71e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg25660036	chr4:7070649	GRPEL1	-0.62	-5.35	-0.43	4.04e-7	Monocyte percentage of white cells;
TGCT	cis	rs9291683	0.526	rs6827785	chr4:10018205	C/T	cg11266682	chr4:10021025	SLC2A9	0.69	9.11	0.63	1.78e-15	Bone mineral density;
TGCT	cis	rs6684514	1.000	rs12121805	chr1:156257876	A/G	cg16558208	chr1:156270281	VHLL	0.46	9.38	0.64	3.92e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs826838	0.967	rs1684415	chr12:39130099	T/C	cg13010199	chr12:38710504	ALG10B	-0.63	-5.06	-0.41	1.46e-6	Heart rate;
TGCT	cis	rs7647973	1.000	rs1464569	chr3:49460350	A/G	cg05785598	chr3:49045655	WDR6	0.37	4.52	0.38	1.42e-5	Menarche (age at onset);
TGCT	cis	rs17001868	0.614	rs61467436	chr22:40736713	T/C	cg07138101	chr22:40742427	ADSL	0.73	5.38	0.44	3.57e-7	Mammographic density (dense area);
TGCT	cis	rs938554	0.571	rs4144	chr4:10016322	T/C	cg11266682	chr4:10021025	SLC2A9	0.58	5.48	0.44	2.24e-7	Blood metabolite levels;
TGCT	cis	rs8072100	0.967	rs11079784	chr17:45702280	A/G	cg08085267	chr17:45401833	C17orf57	0.43	4.68	0.39	7.53e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs9900497	0.604	rs12949049	chr17:19653310	A/G	cg21692194	chr17:19436881	SLC47A1	0.26	4.5	0.37	1.56e-5	Response to paliperidone in schizophrenia (CGI-S score);
TGCT	cis	rs10242455	0.702	rs57832867	chr7:98966396	C/T	cg13560068	chr7:99070416	ZNF789	1.09	4.66	0.39	8.13e-6	Blood metabolite levels;
TGCT	cis	rs1801251	1.000	rs71421663	chr2:233619131	A/G	cg08000102	chr2:233561755	GIGYF2	0.64	6.56	0.51	1.34e-9	Coronary artery disease;
TGCT	cis	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg20637647	chr7:64974828	NA	0.9	5.29	0.43	5.42e-7	Diabetic kidney disease;
TGCT	cis	rs140365914	1	rs140365914	chr7:155106570	C/T	cg04811098	chr7:155088454	INSIG1	0.32	4.96	0.41	2.23e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs13256369	1.000	rs10098234	chr8:8576692	G/A	cg17143192	chr8:8559678	CLDN23	0.62	5.83	0.46	4.47e-8	Obesity-related traits;
TGCT	trans	rs10506458	1.000	rs73128794	chr12:63445313	C/T	cg22491629	chr6:157744540	C6orf35	-0.96	-8.34	-0.6	1.21e-13	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs2486288	0.656	rs8039354	chr15:45551756	A/G	cg14582100	chr15:45693742	SPATA5L1	0.46	5.59	0.45	1.38e-7	Glomerular filtration rate;
TGCT	cis	rs1577917	0.917	rs13196576	chr6:86534066	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-5.53	-0.44	1.82e-7	Response to antipsychotic treatment;
TGCT	trans	rs1496653	0.602	rs34171096	chr3:23529279	C/G	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs7100689	0.646	rs10887808	chr10:82137367	G/A	cg01528321	chr10:82214614	TSPAN14	0.8	7.72	0.57	3.42e-12	Post bronchodilator FEV1;
TGCT	cis	rs7666738	0.716	rs9994641	chr4:99101605	C/T	cg05340658	chr4:99064831	C4orf37	0.49	5.53	0.44	1.83e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2594989	0.831	rs13324245	chr3:11570769	T/G	cg00170343	chr3:11313890	ATG7	-0.62	-4.56	-0.38	1.19e-5	Circulating chemerin levels;
TGCT	cis	rs3806843	0.966	rs10053945	chr5:140160127	C/T	cg19875535	chr5:140030758	IK	0.37	6.17	0.48	8.88e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs3796352	1.000	rs750474	chr3:53085280	A/C	cg27565382	chr3:53032988	SFMBT1	0.39	4.49	0.37	1.59e-5	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs12681287	0.640	rs28561640	chr8:87425638	G/A	cg27223183	chr8:87520930	FAM82B	0.89	6.36	0.5	3.45e-9	Caudate activity during reward;
TGCT	cis	rs11677370	0.561	rs12711973	chr2:3825339	C/G	cg17052675	chr2:3827356	NA	-0.42	-7.68	-0.57	4.22e-12	Type 2 diabetes;
TGCT	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg23156509	chr2:114033830	PAX8;LOC440839	0.32	4.92	0.4	2.71e-6	Lymphocyte counts;
TGCT	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg03188948	chr7:1209495	NA	0.44	5.79	0.46	5.49e-8	Longevity;Endometriosis;
TGCT	cis	rs7772486	0.875	rs9322044	chr6:146369608	T/C	cg05347473	chr6:146136440	FBXO30	0.57	5.46	0.44	2.47e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6121246	0.909	rs1075698	chr20:30387992	G/C	cg13852791	chr20:30311386	BCL2L1	0.8	6.12	0.48	1.15e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs3751972	0.590	rs34371806	chr17:26264057	T/C	cg02948944	chr17:26242737	NA	-0.46	-5.71	-0.46	7.8e-8	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg11764359	chr7:65958608	NA	0.55	5.08	0.42	1.34e-6	Aortic root size;
TGCT	cis	rs7017914	0.905	rs2732108	chr8:71926099	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.56	-5.11	-0.42	1.21e-6	Bone mineral density;
TGCT	cis	rs56104184	0.775	rs73061695	chr19:49399988	T/C	cg17863274	chr19:49399704	TULP2	-0.54	-7.43	-0.55	1.58e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs2204008	0.603	rs4397954	chr12:38089157	T/C	cg13010199	chr12:38710504	ALG10B	0.65	5.15	0.42	9.75e-7	Bladder cancer;
TGCT	cis	rs7917772	0.503	rs11191330	chr10:104306160	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	8.59	0.61	3.11e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs8017423	0.607	rs10142482	chr14:90848280	G/T	cg04374321	chr14:90722782	PSMC1	-0.49	-4.54	-0.38	1.31e-5	Mortality in heart failure;
TGCT	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg22920501	chr2:26401640	FAM59B	0.81	6.36	0.5	3.52e-9	Gut microbiome composition (summer);
TGCT	cis	rs7095607	0.813	rs960772	chr10:69931674	A/G	cg18986048	chr10:69913749	MYPN	0.44	5.02	0.41	1.72e-6	Lung function (FVC);
TGCT	cis	rs4253772	0.530	rs9615961	chr22:46754993	T/C	cg24881330	chr22:46731750	TRMU	1.06	5.5	0.44	2.08e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg13695892	chr22:41940480	POLR3H	-0.91	-9.07	-0.63	2.18e-15	Vitiligo;
TGCT	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg24549020	chr5:56110836	MAP3K1	0.72	6.03	0.48	1.73e-8	Initial pursuit acceleration;
TGCT	cis	rs62103177	0.810	rs62096746	chr18:77619556	T/A	cg12964065	chr18:77638022	KCNG2	0.37	4.76	0.39	5.4e-6	Opioid sensitivity;
TGCT	cis	rs78366141	0.649	rs76401410	chr4:89694624	A/G	cg01026744	chr4:89619053	NAP1L5;HERC3	1.26	5.58	0.45	1.43e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
TGCT	cis	rs76878669	0.561	rs4630308	chr11:66162587	G/A	cg18002602	chr11:66138449	SLC29A2	0.53	6.57	0.51	1.22e-9	Educational attainment (years of education);
TGCT	cis	rs7551222	0.716	rs4951083	chr1:204582730	A/G	cg09150239	chr1:204347429	NA	0.48	4.61	0.38	9.88e-6	Schizophrenia;
TGCT	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg03188948	chr7:1209495	NA	0.5	5.23	0.43	6.99e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2302464	0.661	rs1807250	chr4:15742592	G/C	cg16359663	chr4:15503662	CC2D2A	-0.35	-4.73	-0.39	5.96e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs6912958	0.712	rs7746465	chr6:88348996	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-4.55	-0.38	1.26e-5	Monocyte percentage of white cells;
TGCT	cis	rs9810089	0.843	rs696081	chr3:136047189	C/T	cg12473912	chr3:136751656	NA	-0.36	-5.14	-0.42	1.04e-6	Gestational age at birth (child effect);
TGCT	cis	rs11112613	0.775	rs61200462	chr12:105969271	G/A	cg03607813	chr12:105948248	NA	0.47	5.66	0.45	1e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	cis	rs4689388	0.926	rs6446480	chr4:6295565	C/T	cg14416269	chr4:6271139	WFS1	0.38	4.89	0.4	3.12e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs6582630	0.555	rs11613249	chr12:38519339	T/C	cg13010199	chr12:38710504	ALG10B	0.59	4.77	0.39	5.14e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs12451471	0.637	rs12452616	chr17:78090081	A/G	cg06718696	chr17:78121285	EIF4A3	-0.75	-6.24	-0.49	6.38e-9	Plateletcrit;Mean corpuscular hemoglobin concentration;
TGCT	cis	rs10254284	1.000	rs6962289	chr7:28161379	C/A	cg23620719	chr7:28220237	JAZF1	-0.54	-4.73	-0.39	5.89e-6	Lymphocyte percentage of white cells;Systemic lupus erythematosus;
TGCT	cis	rs7523273	0.526	rs2745975	chr1:208013620	C/T	cg22525895	chr1:207977042	MIR29B2	-0.53	-9.29	-0.64	6.43e-16	Schizophrenia;
TGCT	cis	rs4722166	0.598	rs4722171	chr7:22785717	A/G	cg26061582	chr7:22766209	IL6	0.58	7.32	0.55	2.77e-11	Lung cancer;
TGCT	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg21285383	chr16:89894308	SPIRE2	0.43	6.51	0.5	1.64e-9	Vitiligo;
TGCT	cis	rs877282	0.898	rs35743076	chr10:758991	C/T	cg17470449	chr10:769945	NA	0.36	5.32	0.43	4.77e-7	Uric acid levels;
TGCT	cis	rs7666738	0.830	rs11947027	chr4:99005941	T/C	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6918586	0.658	rs198803	chr6:26135052	T/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.67	-6.44	-0.5	2.42e-9	Schizophrenia;
TGCT	cis	rs6746896	0.959	rs2271893	chr2:97405440	G/A	cg26085987	chr2:97230376	NA	0.2	4.82	0.4	4.14e-6	Bipolar disorder;
TGCT	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg01585852	chr22:24235823	MIF	-0.22	-4.82	-0.4	4.16e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9399137	0.507	rs35571217	chr6:135290355	T/C	cg24558204	chr6:135376177	HBS1L	0.47	4.78	0.39	4.95e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
TGCT	cis	rs548181	0.577	rs569766	chr11:125532369	G/A	cg03464685	chr11:125439445	EI24	1.27	9.56	0.65	1.46e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs12210905	0.920	rs6911234	chr6:27086859	T/A	cg08851530	chr6:28072375	NA	1.21	5.58	0.45	1.43e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs514406	0.505	rs835609	chr1:53170494	T/C	cg01802117	chr1:53393560	SCP2	-0.43	-4.91	-0.4	2.79e-6	Monocyte count;
TGCT	cis	rs2224391	0.628	rs2773314	chr6:5253800	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.99	-6.43	-0.5	2.46e-9	Height;
TGCT	cis	rs2235642	0.893	rs2076445	chr16:1592266	A/T	cg11375102	chr16:1583810	IFT140;TMEM204	-0.31	-5.53	-0.44	1.78e-7	Coronary artery disease;
TGCT	cis	rs7412746	0.611	rs111842513	chr1:150712926	G/A	cg04414720	chr1:150670196	GOLPH3L	0.37	4.87	0.4	3.27e-6	Melanoma;
TGCT	cis	rs2153535	0.580	rs9393021	chr6:8466123	A/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs9486719	0.947	rs9398072	chr6:96911304	T/C	cg06623918	chr6:96969491	KIAA0776	0.96	8.88	0.62	6.44e-15	Migraine;Coronary artery disease;
TGCT	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg06238570	chr21:40685208	BRWD1	-0.62	-6.3	-0.49	4.82e-9	Menarche (age at onset);
TGCT	cis	rs9644630	0.932	rs4921653	chr8:19359853	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.27	4.7	0.39	6.7e-6	Oropharynx cancer;
TGCT	cis	rs941408	0.515	rs7253128	chr19:2776982	C/T	cg06609049	chr19:2785107	THOP1	1.11	12.98	0.76	7.5e-25	Total cholesterol levels;
TGCT	cis	rs3780378	1.000	rs1328918	chr9:5107394	A/G	cg02405213	chr9:5042618	JAK2	-0.64	-8.35	-0.6	1.15e-13	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs7100689	0.542	rs7096715	chr10:82195949	T/C	cg01528321	chr10:82214614	TSPAN14	0.69	5.77	0.46	6.09e-8	Post bronchodilator FEV1;
TGCT	cis	rs13256369	0.755	rs12550057	chr8:8562268	G/A	cg18904891	chr8:8559673	CLDN23	0.57	5.29	0.43	5.35e-7	Obesity-related traits;
TGCT	cis	rs7944584	0.588	rs2697923	chr11:47363215	G/T	cg20307385	chr11:47447363	PSMC3	-0.79	-7.99	-0.58	8.1e-13	Fasting blood glucose;Fasting blood glucose (BMI interaction);
TGCT	cis	rs10791323	0.569	rs10750552	chr11:133740141	A/C	cg03690763	chr11:133734501	NA	0.29	5.12	0.42	1.16e-6	Childhood ear infection;
TGCT	cis	rs62244186	0.748	rs12635624	chr3:44678498	G/A	cg09333631	chr3:44802604	KIF15;KIAA1143	-0.41	-4.47	-0.37	1.71e-5	Depressive symptoms;
TGCT	cis	rs8038465	0.615	rs6495076	chr15:73982965	G/A	cg15420318	chr15:73925796	NPTN	0.67	7.42	0.55	1.62e-11	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs4891159	0.790	rs77878087	chr18:74116337	G/A	cg24786174	chr18:74118243	ZNF516	-0.62	-9.41	-0.65	3.36e-16	Longevity;
TGCT	cis	rs75059851	0.756	rs2000853	chr11:133838417	A/G	cg14047540	chr11:133829660	NA	-0.53	-5.34	-0.43	4.37e-7	Schizophrenia;
TGCT	cis	rs3796619	1.000	rs55741287	chr4:1094670	T/C	cg27284194	chr4:1044797	NA	0.47	4.45	0.37	1.9e-5	Recombination rate (males);
TGCT	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg09263875	chr16:632152	PIGQ	0.31	6.88	0.53	2.64e-10	Height;
TGCT	cis	rs7104764	1.000	rs6598069	chr11:240664	T/A	cg18336825	chr11:236787	PSMD13;SIRT3	1.07	11.15	0.71	2.05e-20	Menarche (age at onset);
TGCT	cis	rs1505368	0.817	rs1283310	chr2:213273891	A/G	cg20637307	chr2:213403960	ERBB4	0.52	4.85	0.4	3.7e-6	Symmetrical dimethylarginine levels;
TGCT	cis	rs13326165	0.760	rs28481563	chr3:52417638	T/C	cg27565382	chr3:53032988	SFMBT1	0.38	5.06	0.41	1.5e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs7647973	0.769	rs6446204	chr3:49034879	T/C	cg07636037	chr3:49044803	WDR6	0.82	6.59	0.51	1.12e-9	Menarche (age at onset);
TGCT	cis	rs2271316	0.587	rs11078659	chr17:6903944	G/A	cg19536664	chr17:6899085	ALOX12	0.32	5.06	0.41	1.46e-6	Blood metabolite levels;
TGCT	cis	rs9611565	0.592	rs57102627	chr22:41987627	T/C	cg03806693	chr22:41940476	POLR3H	-1.01	-10.2	-0.68	4.07e-18	Vitiligo;
TGCT	cis	rs492146	0.729	rs426013	chr6:52840745	T/C	cg06706454	chr6:52930286	FBXO9	-0.51	-4.64	-0.38	8.63e-6	Epilepsy (remission after treatment);
TGCT	cis	rs921968	0.509	rs626432	chr2:219355658	C/A	cg02176678	chr2:219576539	TTLL4	0.48	6.78	0.52	4.32e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs346785	0.666	rs8072620	chr17:74283253	A/G	cg09812376	chr17:74270190	QRICH2	-0.36	-5.38	-0.44	3.56e-7	White matter hyperintensities in ischemic stroke;
TGCT	cis	rs9913156	0.793	rs56020376	chr17:4560909	A/G	cg00122941	chr17:4613640	ARRB2	0.87	7.38	0.55	1.95e-11	Lymphocyte counts;
TGCT	cis	rs4455778	0.659	rs67170454	chr7:49027518	A/G	cg26309511	chr7:48887640	NA	-0.44	-5.22	-0.42	7.26e-7	Lung cancer in never smokers;
TGCT	cis	rs2447097	0.904	rs2429914	chr17:2277668	T/C	cg27406664	chr17:2294951	MNT	0.26	5.22	0.42	7.44e-7	Autism spectrum disorder;
TGCT	cis	rs9486715	0.830	rs4425602	chr6:96893906	G/A	cg18709589	chr6:96969512	KIAA0776	0.79	7.77	0.57	2.5e-12	Headache;
TGCT	cis	rs9325144	0.647	rs61931899	chr12:38892422	A/G	cg26384229	chr12:38710491	ALG10B	-0.59	-5.48	-0.44	2.28e-7	Morning vs. evening chronotype;
TGCT	cis	rs13424612	1.000	rs7590071	chr2:240900947	G/C	cg26363272	chr2:240904871	NDUFA10	0.31	5.13	0.42	1.08e-6	Odorant perception (isobutyraldehyde);
TGCT	cis	rs2887571	0.955	rs11061818	chr12:1637111	G/A	cg01940102	chr12:1095972	NA	0.25	4.66	0.39	8.17e-6	Bone mineral density;
TGCT	cis	rs6964587	0.869	rs10276682	chr7:91486070	G/A	cg17063962	chr7:91808500	NA	-0.85	-9.05	-0.63	2.54e-15	Breast cancer;
TGCT	cis	rs7666738	0.546	rs11097591	chr4:98910173	G/A	cg17366294	chr4:99064904	C4orf37	0.65	5.98	0.47	2.24e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9443189	0.526	rs775060	chr6:76373567	G/A	cg01950844	chr6:76311363	SENP6	-1.0	-6.14	-0.48	1.01e-8	Prostate cancer;
TGCT	cis	rs1372520	0.684	rs2619355	chr4:90748374	A/C	cg14346243	chr4:90757452	SNCA	-0.67	-5.64	-0.45	1.09e-7	Neuroticism;
TGCT	cis	rs1541995	0.789	rs35717415	chr15:96237165	C/T	cg00882281	chr15:96346592	NA	0.3	4.63	0.38	9.12e-6	Photic sneeze reflex;
TGCT	cis	rs7659604	0.540	rs67150579	chr4:122704331	T/A	cg06713675	chr4:122721982	EXOSC9	0.38	4.7	0.39	6.8e-6	Type 2 diabetes;
TGCT	cis	rs10514758	0.744	rs72947727	chr3:114889697	C/G	cg05943254	chr3:114009756	NA	-0.76	-4.53	-0.38	1.39e-5	Urate levels in obese individuals;
TGCT	cis	rs6121246	0.567	rs7266471	chr20:30220599	T/A	cg18721089	chr20:30220636	NA	-0.65	-6.84	-0.52	3.17e-10	Mean corpuscular hemoglobin;
TGCT	cis	rs6582630	0.555	rs7978749	chr12:38527141	G/T	cg13010199	chr12:38710504	ALG10B	0.61	4.9	0.4	2.91e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs9467773	0.596	rs2451750	chr6:26646579	A/T	cg02458000	chr6:26745757	NA	0.51	4.59	0.38	1.08e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs4664308	0.935	rs6744567	chr2:160933781	C/G	cg03641300	chr2:160917029	PLA2R1	-0.28	-6.83	-0.52	3.43e-10	Idiopathic membranous nephropathy;
TGCT	cis	rs7945705	0.774	rs6486060	chr11:9024630	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.52	5.76	0.46	6.22e-8	Hemoglobin concentration;
TGCT	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg18402987	chr7:1209562	NA	0.74	6.42	0.5	2.6e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs56104184	0.830	rs55966626	chr19:49342396	G/T	cg17863274	chr19:49399704	TULP2	-0.48	-6.07	-0.48	1.44e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg26668828	chr6:292823	DUSP22	-0.84	-8.7	-0.62	1.71e-14	Menopause (age at onset);
TGCT	cis	rs10791323	0.582	rs2723613	chr11:133706696	G/A	cg15485101	chr11:133734466	NA	0.41	5.17	0.42	9.11e-7	Childhood ear infection;
TGCT	cis	rs2455799	0.613	rs2470538	chr3:15717124	G/C	cg16303742	chr3:15540471	COLQ	-0.25	-4.74	-0.39	5.65e-6	Mean platelet volume;
TGCT	cis	rs7666738	0.830	rs6851253	chr4:99029980	A/G	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7829975	0.545	rs13261926	chr8:8551610	T/C	cg15556689	chr8:8085844	FLJ10661	-0.57	-4.89	-0.4	3.01e-6	Mood instability;
TGCT	cis	rs2797160	1.000	rs2747719	chr6:126009214	C/T	cg05901451	chr6:126070800	HEY2	0.72	6.11	0.48	1.18e-8	Endometrial cancer;
TGCT	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.43	4.84	0.4	3.75e-6	Lymphocyte counts;
TGCT	cis	rs7552404	0.727	rs5745427	chr1:76332637	C/A	cg03433033	chr1:76189801	ACADM	-0.59	-5.97	-0.47	2.34e-8	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs4294134	0.608	rs11766433	chr7:135243056	A/G	cg08396481	chr7:135194601	CNOT4	-0.62	-4.81	-0.4	4.25e-6	Paget's disease;
TGCT	cis	rs9400467	0.537	rs78080415	chr6:111537016	T/C	cg15721981	chr6:111408429	SLC16A10	0.73	4.79	0.4	4.71e-6	Blood metabolite levels;Amino acid levels;
TGCT	cis	rs7769051	0.711	rs7758703	chr6:133085417	T/C	cg22852734	chr6:133119734	C6orf192	1.22	6.68	0.51	7.22e-10	Type 2 diabetes nephropathy;
TGCT	cis	rs11098499	0.954	rs6834796	chr4:120414693	A/C	cg09307838	chr4:120376055	NA	0.69	6.64	0.51	8.97e-10	Corneal astigmatism;
TGCT	cis	rs10751667	0.643	rs7395613	chr11:933873	C/T	cg06064525	chr11:970664	AP2A2	-0.35	-8.09	-0.59	4.54e-13	Alzheimer's disease (late onset);
TGCT	cis	rs9308731	1.000	rs6746608	chr2:111892984	C/T	cg04202892	chr2:111875749	ACOXL	-0.43	-4.62	-0.38	9.37e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs6684514	1.000	rs2296375	chr1:156309372	G/C	cg20302342	chr1:156215951	PAQR6	0.36	4.69	0.39	7.06e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs6750047	0.585	rs62136319	chr2:38272950	G/A	cg07380506	chr2:38303506	CYP1B1	0.59	5.36	0.43	3.84e-7	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs1008375	1.000	rs4698198	chr4:17656536	G/A	cg16339924	chr4:17578868	LAP3	0.63	5.33	0.43	4.49e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9393777	0.513	rs9393739	chr6:26646966	T/G	cg15659132	chr6:26577336	NA	-0.75	-5.25	-0.43	6.33e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9467773	0.620	rs2130657	chr6:26650826	C/T	cg11502198	chr6:26597334	ABT1	0.55	4.89	0.4	3.05e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs3862435	0.764	rs2601200	chr15:90955177	C/T	cg14166756	chr15:90894880	ZNF774	-0.29	-4.68	-0.39	7.31e-6	Response to exercise (triglyceride level interaction);
TGCT	cis	rs6840360	0.837	rs4696294	chr4:152713089	C/A	cg22705602	chr4:152727874	NA	0.25	4.57	0.38	1.17e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs611744	0.967	rs596245	chr8:109240822	G/A	cg21045802	chr8:109455806	TTC35	0.51	4.71	0.39	6.61e-6	Dupuytren's disease;
TGCT	cis	rs8056742	0.643	rs55914162	chr16:85063037	T/G	cg00229868	chr16:85520891	NA	0.42	5.17	0.42	9.19e-7	Amyotrophic lateral sclerosis;
TGCT	cis	rs4595586	0.525	rs7313120	chr12:39388027	A/G	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs2274273	0.712	rs6572999	chr14:55527374	T/C	cg01923255	chr14:55878535	KIAA0831	0.57	4.89	0.4	3.03e-6	Protein biomarker;
TGCT	cis	rs641525	1	rs641525	chr8:2740502	T/G	cg06440275	chr8:2005701	MYOM2	-0.42	-4.8	-0.4	4.52e-6	Emphysema-related traits;
TGCT	cis	rs79976124	0.842	rs74881738	chr6:66621825	T/G	cg07460842	chr6:66804631	NA	0.6	5.28	0.43	5.54e-7	Type 2 diabetes;
TGCT	cis	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg22857025	chr5:266934	NA	-0.34	-6.67	-0.51	7.62e-10	Breast cancer;
TGCT	trans	rs4819388	0.751	rs2838532	chr21:45639866	G/T	cg17383793	chr5:52405638	MOCS2	-0.71	-6.73	-0.52	5.65e-10	Celiac disease;
TGCT	cis	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg06636001	chr8:8085503	FLJ10661	0.86	8.11	0.59	4.13e-13	Neuroticism;
TGCT	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg06238570	chr21:40685208	BRWD1	0.59	5.26	0.43	6.2e-7	Cognitive function;
TGCT	cis	rs2439831	0.850	rs28513374	chr15:44125495	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.44	0.37	1.99e-5	Lung cancer in ever smokers;
TGCT	cis	rs7568458	0.837	rs35215812	chr2:85792384	G/A	cg17127132	chr2:85788382	GGCX	0.73	6.97	0.53	1.64e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs9896850	0.551	rs7224668	chr17:79235788	T/C	cg27412613	chr17:79183705	AZI1	-0.23	-4.7	-0.39	6.68e-6	Frontotemporal dementia;
TGCT	cis	rs28595532	0.920	rs114390336	chr4:119771452	C/T	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg20203395	chr5:56204925	C5orf35	-0.58	-4.87	-0.4	3.34e-6	Initial pursuit acceleration;
TGCT	cis	rs7552404	0.727	rs7521344	chr1:76318325	C/T	cg03433033	chr1:76189801	ACADM	-0.59	-6.06	-0.48	1.51e-8	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg12756686	chr19:29218302	NA	0.77	6.61	0.51	1.01e-9	Methadone dose in opioid dependence;
TGCT	cis	rs981844	0.712	rs11099914	chr4:154743519	C/T	cg14289246	chr4:154710475	SFRP2	-1.0	-9.35	-0.64	4.84e-16	Response to statins (LDL cholesterol change);
TGCT	cis	rs10089	1.000	rs6595806	chr5:127499764	A/T	cg19767477	chr5:127420684	SLC12A2	-0.43	-4.61	-0.38	9.87e-6	Ileal carcinoids;
TGCT	cis	rs3733585	0.605	rs4697926	chr4:10124567	G/T	cg11266682	chr4:10021025	SLC2A9	0.53	6.12	0.48	1.13e-8	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs12497850	0.543	rs6446218	chr3:49075513	A/T	cg06212747	chr3:49208901	KLHDC8B	0.61	5.58	0.45	1.43e-7	Parkinson's disease;
TGCT	cis	rs2777491	1.000	rs316610	chr15:41752852	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.75	-11.07	-0.71	3.15e-20	Ulcerative colitis;
TGCT	trans	rs78438709	0.611	rs80232578	chr10:124232915	C/A	cg07989568	chr17:6735152	TEKT1	0.7	6.7	0.52	6.49e-10	Headache;
TGCT	cis	rs2204008	0.591	rs11495396	chr12:38380182	C/T	cg26384229	chr12:38710491	ALG10B	0.83	7.26	0.55	3.72e-11	Bladder cancer;
TGCT	cis	rs15676	0.733	rs2900269	chr9:131569878	G/T	cg14578146	chr9:130637464	AK1	-0.25	-4.65	-0.39	8.34e-6	Blood metabolite levels;
TGCT	cis	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg00343986	chr7:65444356	GUSB	-0.23	-5.08	-0.42	1.33e-6	Aortic root size;
TGCT	cis	rs12477438	0.748	rs7558239	chr2:99640581	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-5.87	-0.47	3.74e-8	Chronic sinus infection;
TGCT	cis	rs3087591	0.708	rs2189525	chr17:29668808	C/T	cg24425628	chr17:29625626	OMG;NF1	-0.41	-5.78	-0.46	5.8e-8	Hip circumference;
TGCT	cis	rs929354	1.000	rs1182414	chr7:157058363	G/A	cg05182265	chr7:156933206	UBE3C	0.32	6.66	0.51	7.99e-10	Body mass index;
TGCT	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg18305652	chr10:134549665	INPP5A	0.35	5.69	0.45	8.83e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs514406	0.505	rs431427	chr1:53179094	C/A	cg22166914	chr1:53195759	ZYG11B	0.45	8.14	0.59	3.47e-13	Monocyte count;
TGCT	cis	rs9926296	0.535	rs36022917	chr16:89893238	A/G	cg05177932	chr16:89631655	NA	0.29	4.93	0.41	2.53e-6	Vitiligo;
TGCT	cis	rs1215050	0.791	rs10856931	chr4:98819306	C/T	cg05340658	chr4:99064831	C4orf37	0.45	5.78	0.46	5.8e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs11648796	0.721	rs3169403	chr16:769247	G/A	cg00908189	chr16:619842	PIGQ	0.8	6.33	0.49	4.04e-9	Height;
TGCT	cis	rs732765	0.734	rs12892937	chr14:75168927	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.57	-4.97	-0.41	2.2e-6	Non-small cell lung cancer;
TGCT	cis	rs3806843	1.000	rs12055222	chr5:140165568	T/C	cg19875535	chr5:140030758	IK	0.37	6.17	0.48	8.88e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs6570726	0.791	rs9322029	chr6:145906683	A/G	cg05347473	chr6:146136440	FBXO30	0.52	4.95	0.41	2.33e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1552244	0.832	rs73024575	chr3:10198200	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.55	-6.53	-0.51	1.5e-9	Alzheimer's disease;
TGCT	trans	rs1814175	0.817	rs4881623	chr11:49804991	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.46	-0.56	1.33e-11	Height;
TGCT	cis	rs35146811	0.844	rs13232115	chr7:99670932	T/C	cg22906224	chr7:99728672	NA	0.52	4.52	0.38	1.41e-5	Coronary artery disease;
TGCT	cis	rs9611565	0.765	rs132905	chr22:41799106	C/A	cg06481639	chr22:41940642	POLR3H	0.6	5.48	0.44	2.23e-7	Vitiligo;
TGCT	cis	rs9818758	0.607	rs67831908	chr3:49313513	T/G	cg07636037	chr3:49044803	WDR6	-1.04	-5.13	-0.42	1.09e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs6430585	0.583	rs76097170	chr2:136593498	C/T	cg07169764	chr2:136633963	MCM6	1.18	11.26	0.71	1.11e-20	Corneal structure;
TGCT	cis	rs35306767	0.807	rs34982663	chr10:852521	C/G	cg26597838	chr10:835615	NA	0.8	11.8	0.73	5.3e-22	Eosinophil percentage of granulocytes;
TGCT	cis	rs2014572	0.967	rs10421632	chr19:57764770	G/A	cg24459738	chr19:57751996	ZNF805	-0.58	-5.7	-0.46	8.38e-8	Hyperactive-impulsive symptoms;
TGCT	cis	rs9393777	0.513	rs9379893	chr6:26584668	A/G	cg05738196	chr6:26577821	NA	0.64	4.5	0.37	1.53e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs11249608	0.548	rs34054398	chr5:178458371	A/G	cg01312482	chr5:178451176	ZNF879	-0.49	-4.82	-0.4	4.11e-6	Pubertal anthropometrics;
TGCT	cis	rs709400	0.663	rs28444993	chr14:103930564	T/C	cg12935359	chr14:103987150	CKB	-0.36	-5.47	-0.44	2.43e-7	Body mass index;
TGCT	cis	rs9796	0.870	rs3986311	chr15:41264339	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.46	-5.96	-0.47	2.45e-8	Menopause (age at onset);
TGCT	cis	rs7542091	0.648	rs688464	chr1:209992539	C/T	cg10074409	chr1:209979377	IRF6	-0.41	-4.48	-0.37	1.68e-5	Monobrow;
TGCT	cis	rs6424115	0.729	rs561733	chr1:24049595	T/G	cg15997130	chr1:24165203	NA	0.67	6.31	0.49	4.56e-9	Immature fraction of reticulocytes;
TGCT	cis	rs854765	0.547	rs4365348	chr17:17912548	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.79	8.41	0.6	8.09e-14	Total body bone mineral density;
TGCT	cis	rs3008870	0.959	rs2985808	chr1:67367741	T/C	cg11518657	chr1:67396239	MIER1	0.53	4.72	0.39	6.16e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs12220898	0.749	rs10857460	chr10:50488542	A/G	cg06072769	chr10:50146962	WDFY4	0.36	4.75	0.39	5.51e-6	Inflammatory biomarkers;
TGCT	cis	rs6582630	0.512	rs11181007	chr12:38266700	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-4.7	-0.39	6.68e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs1949733	0.666	rs3103070	chr4:8508825	A/G	cg13073564	chr4:8508604	NA	0.44	4.69	0.39	7.23e-6	Response to antineoplastic agents;
TGCT	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg27454412	chr7:1067447	C7orf50	0.6	4.7	0.39	6.76e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7914558	1.000	rs943038	chr10:104826261	T/C	cg15744005	chr10:104629667	AS3MT	-0.39	-4.84	-0.4	3.81e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs17473412	0.963	rs11740716	chr5:122701234	A/G	cg15125798	chr5:122621645	NA	-0.59	-5.26	-0.43	6.01e-7	Total body bone mineral density;
TGCT	cis	rs7811142	0.945	rs6974282	chr7:100098295	C/T	cg00814883	chr7:100076585	TSC22D4	-0.89	-9.03	-0.63	2.76e-15	Platelet count;
TGCT	cis	rs28595532	1.000	rs114039398	chr4:119631627	T/C	cg21605333	chr4:119757512	SEC24D	1.36	7.39	0.55	1.89e-11	Cannabis dependence symptom count;
TGCT	cis	rs2282802	0.711	rs1864970	chr5:139633042	T/C	cg01081189	chr5:139537190	NA	0.29	5.18	0.42	8.86e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs36051895	0.626	rs12349785	chr9:5076613	G/C	cg02405213	chr9:5042618	JAK2	-0.75	-9.83	-0.66	3.19e-17	Pediatric autoimmune diseases;
TGCT	cis	rs910316	1.000	rs10149880	chr14:75633008	A/G	cg08847533	chr14:75593920	NEK9	-0.94	-10.45	-0.68	1.01e-18	Height;
TGCT	cis	rs10507380	0.824	rs9512634	chr13:27920452	C/G	cg25543773	chr13:27185723	WASF3	0.34	4.83	0.4	3.97e-6	Electrocardiographic traits;
TGCT	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg00684032	chr4:1343700	KIAA1530	0.23	5.01	0.41	1.79e-6	Obesity-related traits;
TGCT	cis	rs9534288	0.762	rs4941539	chr13:46597067	A/T	cg15192986	chr13:46630673	CPB2	-0.52	-7.53	-0.56	9.22e-12	Blood protein levels;
TGCT	cis	rs7824557	0.679	rs7004362	chr8:11135974	G/A	cg21775007	chr8:11205619	TDH	-0.61	-5.75	-0.46	6.57e-8	Retinal vascular caliber;
TGCT	cis	rs7258465	1.000	rs2303697	chr19:18546678	T/C	cg06462663	chr19:18546047	ISYNA1	0.2	4.54	0.38	1.33e-5	Breast cancer;
TGCT	cis	rs17401966	0.540	rs58014725	chr1:10474457	T/A	cg19773385	chr1:10388646	KIF1B	-0.23	-5.46	-0.44	2.52e-7	Hepatocellular carcinoma;
TGCT	cis	rs1577917	0.958	rs12197463	chr6:86445242	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.17	-0.42	9.02e-7	Response to antipsychotic treatment;
TGCT	cis	rs7267979	1.000	rs2258563	chr20:25273435	C/T	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs67311347	1.000	rs2085115	chr3:40497540	G/T	cg13683864	chr3:40499215	RPL14	-1.2	-13.3	-0.77	1.27e-25	Renal cell carcinoma;
TGCT	cis	rs67311347	0.713	rs73073505	chr3:40310693	C/T	cg13683864	chr3:40499215	RPL14	-0.88	-8.56	-0.61	3.63e-14	Renal cell carcinoma;
TGCT	cis	rs1499614	1.000	rs2141924	chr7:66186246	C/T	cg18252515	chr7:66147081	NA	-1.26	-7.95	-0.58	9.71e-13	Gout;
TGCT	cis	rs9611519	0.929	rs9611466	chr22:41426299	A/T	cg03806693	chr22:41940476	POLR3H	-0.7	-6.22	-0.49	6.88e-9	Neuroticism;
TGCT	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg18230493	chr5:56204884	C5orf35	-0.7	-6.06	-0.48	1.48e-8	Initial pursuit acceleration;
TGCT	cis	rs1005277	0.522	rs1208767	chr10:38042295	G/T	cg25427524	chr10:38739819	LOC399744	-0.33	-6.6	-0.51	1.06e-9	Extrinsic epigenetic age acceleration;
TGCT	cis	rs9902453	0.904	rs9897794	chr17:28296327	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.74	7.11	0.54	8.28e-11	Coffee consumption (cups per day);
TGCT	cis	rs317865	0.867	rs10034143	chr4:16159734	C/T	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.71	4.86	0.4	3.43e-6	Kidney disease (early stage) in type 1 diabetes;
TGCT	cis	rs1018836	0.923	rs62526886	chr8:91627676	G/A	cg16814680	chr8:91681699	NA	-0.86	-9.19	-0.64	1.12e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.49	-4.75	-0.39	5.44e-6	Prudent dietary pattern;
TGCT	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg08439880	chr3:133502540	NA	-0.28	-5.19	-0.42	8.28e-7	Iron status biomarkers;
TGCT	cis	rs35883536	0.626	rs7545966	chr1:101047633	G/A	cg10298815	chr1:101004474	GPR88	-0.25	-4.5	-0.37	1.54e-5	Monocyte count;
TGCT	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.07	0.82	4.17e-32	Prudent dietary pattern;
TGCT	cis	rs9972944	0.651	rs7222415	chr17:63765137	T/C	cg07283582	chr17:63770753	CCDC46	-0.26	-5.31	-0.43	4.87e-7	Total body bone mineral density;
TGCT	cis	rs9330316	0.632	rs4953760	chr2:110313489	A/C	cg25199208	chr2:109402912	CCDC138	-0.42	-4.54	-0.38	1.34e-5	Schizophrenia;
TGCT	cis	rs28595532	0.764	rs17259257	chr4:119778889	C/T	cg14228332	chr4:119757509	SEC24D	1.3	6.62	0.51	9.62e-10	Cannabis dependence symptom count;
TGCT	cis	rs2997447	0.761	rs72886625	chr1:26455319	A/G	cg03844060	chr1:26490628	NA	0.27	4.44	0.37	2e-5	QRS complex (12-leadsum);
TGCT	cis	rs6684514	1.000	rs12023438	chr1:156254358	A/G	cg20302342	chr1:156215951	PAQR6	0.34	4.6	0.38	1.01e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs79387448	0.701	rs11465596	chr2:102987093	C/A	cg09003973	chr2:102972529	NA	1.44	9.99	0.67	1.31e-17	Gut microbiota (bacterial taxa);
TGCT	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg09359103	chr1:154839909	KCNN3	-0.68	-12.57	-0.75	6.97e-24	Prostate cancer;
TGCT	cis	rs7830933	0.780	rs9644033	chr8:23610639	A/T	cg04349084	chr8:23602677	NA	0.25	4.89	0.4	3.09e-6	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
TGCT	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg19010396	chr19:19431384	KIAA0892;SF4	-0.54	-4.54	-0.38	1.3e-5	Tonsillectomy;
TGCT	cis	rs1997103	0.871	rs9649855	chr7:55410222	T/C	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg04944784	chr2:26401820	FAM59B	0.68	6.13	0.48	1.1e-8	Gut microbiome composition (summer);
TGCT	cis	rs7072216	0.763	rs6584200	chr10:100170037	A/G	cg26618903	chr10:100175079	PYROXD2	-0.4	-4.44	-0.37	1.93e-5	Metabolite levels;
TGCT	cis	rs73198271	0.737	rs565203	chr8:8632957	T/C	cg06636001	chr8:8085503	FLJ10661	-0.61	-4.62	-0.38	9.37e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg22963979	chr7:1858916	MAD1L1	-0.34	-5.31	-0.43	4.83e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg25036284	chr2:26402008	FAM59B	0.65	5.19	0.42	8.36e-7	Gut microbiome composition (summer);
TGCT	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg00431813	chr7:1051703	C7orf50	-0.22	-4.7	-0.39	6.93e-6	Longevity;Endometriosis;
TGCT	trans	rs7824557	0.564	rs2736294	chr8:11234626	T/C	cg15556689	chr8:8085844	FLJ10661	-0.74	-6.7	-0.52	6.42e-10	Retinal vascular caliber;
TGCT	cis	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg25427524	chr10:38739819	LOC399744	-0.39	-7.9	-0.58	1.31e-12	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2290402	0.536	rs4690336	chr4:867242	A/G	cg11315544	chr4:1222440	CTBP1	-0.25	-4.52	-0.38	1.45e-5	Type 2 diabetes;
TGCT	cis	rs7833790	0.676	rs7834555	chr8:82697625	A/G	cg17211192	chr8:82754475	SNX16	-0.84	-7.67	-0.57	4.24e-12	Diastolic blood pressure;
TGCT	cis	rs896854	0.540	rs2011567	chr8:95971920	G/A	cg09323728	chr8:95962352	TP53INP1	-0.52	-6.59	-0.51	1.12e-9	Type 2 diabetes;
TGCT	cis	rs9467773	0.620	rs2494701	chr6:26634432	C/T	cg02458000	chr6:26745757	NA	0.53	5.02	0.41	1.76e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1371867	0.846	rs2439458	chr8:101297984	T/C	cg06636551	chr8:101224915	SPAG1	-0.42	-5.65	-0.45	1.06e-7	Atrioventricular conduction;
TGCT	cis	rs1801251	0.928	rs737028	chr2:233640750	T/C	cg25237894	chr2:233734115	C2orf82	0.32	5.68	0.45	8.93e-8	Coronary artery disease;
TGCT	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg05368731	chr17:41323189	NBR1	-1.05	-11.75	-0.73	6.86e-22	Menopause (age at onset);
TGCT	cis	rs9381040	0.655	rs9381029	chr6:41026453	G/C	cg03526776	chr6:41159608	TREML2	0.27	5.27	0.43	5.78e-7	Alzheimer's disease (late onset);
TGCT	cis	rs12220238	1.000	rs10824084	chr10:75911415	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.91	7.98	0.58	8.43e-13	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs1577917	0.958	rs12213431	chr6:86500956	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-4.96	-0.41	2.24e-6	Response to antipsychotic treatment;
TGCT	cis	rs2739330	0.615	rs2858911	chr22:24297195	G/T	cg04234412	chr22:24373322	LOC391322	-0.87	-10.27	-0.68	2.84e-18	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.82	7.8	0.57	2.2e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg12419862	chr22:24373484	LOC391322	0.81	8.51	0.61	4.7e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs4782309	0.544	rs8060579	chr16:88751667	G/C	cg27087555	chr16:88793112	FAM38A	-0.47	-4.71	-0.39	6.51e-6	Hair color;
TGCT	cis	rs611744	0.647	rs579162	chr8:109254842	A/G	cg21045802	chr8:109455806	TTC35	0.72	7.15	0.54	6.44e-11	Dupuytren's disease;
TGCT	cis	rs9677476	0.863	rs58383275	chr2:232063946	T/C	cg07929768	chr2:232055508	NA	0.31	4.49	0.37	1.61e-5	Food antigen IgG levels;
TGCT	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg22168489	chr12:122356033	WDR66	0.22	4.79	0.4	4.59e-6	Mean corpuscular volume;
TGCT	cis	rs9467773	0.869	rs1796520	chr6:26410800	C/T	cg05738196	chr6:26577821	NA	-0.62	-6.65	-0.51	8.38e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs969049	chr4:98988857	C/T	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9611565	0.568	rs5751159	chr22:42175365	G/A	cg13695892	chr22:41940480	POLR3H	0.8	7.65	0.57	4.87e-12	Vitiligo;
TGCT	cis	rs1372520	0.684	rs2583978	chr4:90750326	A/C	cg20003494	chr4:90757398	SNCA	-0.63	-5.09	-0.42	1.3e-6	Neuroticism;
TGCT	cis	rs9399137	0.507	rs4451150	chr6:135279063	T/G	cg24558204	chr6:135376177	HBS1L	0.47	4.78	0.39	4.95e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
TGCT	cis	rs3096299	0.967	rs7205785	chr16:89458984	A/G	cg06640241	chr16:89574553	SPG7	0.64	6.12	0.48	1.12e-8	Multiple myeloma (IgH translocation);
TGCT	cis	rs6570726	0.791	rs7755253	chr6:145858893	C/G	cg05347473	chr6:146136440	FBXO30	0.54	5.15	0.42	1.01e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6920965	0.561	rs9401851	chr6:126181956	T/C	cg05901451	chr6:126070800	HEY2	-0.6	-6.29	-0.49	4.97e-9	High light scatter reticulocyte count;
TGCT	cis	rs711245	0.518	rs11886145	chr2:36825716	C/G	cg01206211	chr2:36825736	FEZ2	0.33	5.56	0.45	1.59e-7	Height;
TGCT	cis	rs3820928	1.000	rs59904960	chr2:227761269	T/C	cg11843606	chr2:227700838	RHBDD1	-0.51	-4.49	-0.37	1.59e-5	Pulmonary function;
TGCT	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg10295955	chr4:187884368	NA	-0.92	-11.9	-0.73	3.04e-22	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs8077577	0.945	rs11653988	chr17:18088833	C/T	cg09161412	chr17:18057145	MYO15A	-0.64	-5.22	-0.42	7.2e-7	Obesity-related traits;
TGCT	cis	rs13082711	0.595	rs1445114	chr3:27345489	C/A	cg02860705	chr3:27208620	NA	0.48	7.57	0.56	7.46e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.04	0.53	1.16e-10	Prudent dietary pattern;
TGCT	cis	rs62103177	0.713	rs3744886	chr18:77659561	G/T	cg12964065	chr18:77638022	KCNG2	0.37	4.75	0.39	5.6e-6	Opioid sensitivity;
TGCT	cis	rs2970818	0.731	rs11063170	chr12:4575084	A/T	cg02722637	chr12:4922070	KCNA6	0.33	4.64	0.38	8.73e-6	Phosphorus levels;
TGCT	cis	rs3902035	0.929	rs62423968	chr6:119010514	T/C	cg07617317	chr6:118971624	C6orf204	0.43	5.01	0.41	1.79e-6	QT interval;
TGCT	cis	rs765787	0.530	rs28524974	chr15:45543528	C/T	cg24006582	chr15:45444508	DUOX1	-0.24	-5.29	-0.43	5.34e-7	Uric acid levels;
TGCT	cis	rs7726839	0.561	rs72703044	chr5:579737	G/A	cg09021430	chr5:549028	NA	-0.37	-5.39	-0.44	3.37e-7	Obesity-related traits;
TGCT	cis	rs2506155	0.752	rs2273466	chr10:33511047	A/G	cg25928881	chr10:32632685	EPC1	0.33	5.03	0.41	1.66e-6	Migraine;
TGCT	cis	rs1519814	0.654	rs1401810	chr8:121015820	C/T	cg22335954	chr8:121166405	COL14A1	-0.38	-4.84	-0.4	3.81e-6	Breast cancer;
TGCT	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg04772025	chr11:68637568	NA	0.6	6.75	0.52	5.08e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs739401	0.588	rs10219272	chr11:3020789	G/A	cg25174290	chr11:3078921	CARS	0.48	4.57	0.38	1.17e-5	Longevity;
TGCT	cis	rs739496	0.579	rs7310605	chr12:112292470	G/A	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs7582180	0.681	rs6754176	chr2:100995691	C/T	cg08017756	chr2:100939284	LONRF2	-0.31	-5.0	-0.41	1.93e-6	Intelligence (multi-trait analysis);
TGCT	trans	rs1496653	0.602	rs71322172	chr3:23400571	G/A	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg08564027	chr20:61660810	NA	0.38	7.08	0.54	9.36e-11	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg07061783	chr6:25882402	NA	-0.84	-8.67	-0.61	1.99e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg03303774	chr4:1407052	NA	0.31	4.96	0.41	2.25e-6	Obesity-related traits;
TGCT	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg04267008	chr7:1944627	MAD1L1	0.37	4.98	0.41	2.08e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs644799	1.000	rs525404	chr11:95566520	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	8.01	0.58	7.27e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs11719291	0.833	rs34037363	chr3:48821036	C/T	cg00383909	chr3:49044727	WDR6	1.26	6.52	0.51	1.58e-9	Cognitive function;
TGCT	cis	rs9611565	0.512	rs964899	chr22:42142386	G/A	cg13695892	chr22:41940480	POLR3H	0.82	7.69	0.57	3.99e-12	Vitiligo;
TGCT	cis	rs9300255	0.596	rs1568427	chr12:123738678	A/G	cg00376283	chr12:123451042	ABCB9	0.78	6.62	0.51	9.59e-10	Neutrophil percentage of white cells;
TGCT	cis	rs6570726	0.599	rs455001	chr6:145854450	A/T	cg05347473	chr6:146136440	FBXO30	0.61	5.68	0.45	9.16e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg23758822	chr17:41437982	NA	0.72	6.77	0.52	4.51e-10	Menopause (age at onset);
TGCT	cis	rs4273100	0.688	rs1467028	chr17:19174874	T/C	cg03910582	chr17:19030146	GRAPL	0.49	5.88	0.47	3.58e-8	Schizophrenia;
TGCT	cis	rs10431058	0.708	rs532859	chr11:107479652	G/A	cg18204760	chr11:107461044	ELMOD1;LOC643923	0.57	4.83	0.4	3.9e-6	Common traits (Other);
TGCT	cis	rs11190604	1.000	rs2489045	chr10:102344754	C/T	cg16342193	chr10:102329863	NA	-0.42	-5.26	-0.43	5.99e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7666738	0.830	rs13137859	chr4:99050319	A/G	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4253772	0.591	rs9615343	chr22:46690824	C/G	cg24881330	chr22:46731750	TRMU	1.04	5.38	0.44	3.54e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs1205863	1.000	rs1205883	chr6:11947911	C/T	cg07106625	chr6:11870215	NA	-0.51	-5.05	-0.41	1.51e-6	Disc degeneration (lumbar);
TGCT	cis	rs9291683	0.609	rs3796836	chr4:10011345	A/G	cg00071950	chr4:10020882	SLC2A9	0.71	9.57	0.65	1.38e-16	Bone mineral density;
TGCT	cis	rs2657888	1.000	rs2657888	chr12:56938383	A/C	cg23002907	chr12:56915593	RBMS2	0.37	5.11	0.42	1.21e-6	Adiponectin levels;
TGCT	cis	rs8180040	0.654	rs9837343	chr3:47177388	C/T	cg27129171	chr3:47204927	SETD2	0.72	8.89	0.62	5.94e-15	Colorectal cancer;
TGCT	cis	rs35160687	0.862	rs12476706	chr2:86528370	C/T	cg03171300	chr2:86307199	POLR1A	0.32	5.44	0.44	2.73e-7	Night sleep phenotypes;
TGCT	cis	rs11711311	0.911	rs34337798	chr3:113396704	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.82	-7.4	-0.55	1.82e-11	IgG glycosylation;
TGCT	cis	rs2235642	0.691	rs2281235	chr16:1603535	T/C	cg00463982	chr16:1583984	IFT140;TMEM204	-0.29	-5.06	-0.41	1.46e-6	Coronary artery disease;
TGCT	cis	rs6570726	0.935	rs380433	chr6:145859601	A/T	cg23711669	chr6:146136114	FBXO30	0.71	7.03	0.53	1.25e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs17718580	0.609	rs59767247	chr14:51044774	C/A	cg04730355	chr14:51134070	SAV1	1.25	8.77	0.62	1.16e-14	Cognitive performance;
TGCT	cis	rs2153535	0.580	rs9379213	chr6:8474945	G/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs8013055	0.796	rs8005568	chr14:105971794	A/G	cg23974065	chr14:106235526	NA	0.33	4.44	0.37	1.98e-5	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg07424592	chr7:64974309	NA	-0.57	-5.55	-0.45	1.65e-7	Calcium levels;
TGCT	cis	rs11031096	0.711	rs10835719	chr11:4203906	A/G	cg18678763	chr11:4115507	RRM1	0.43	5.33	0.43	4.46e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs1577917	1.000	rs12663690	chr6:86640162	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.64	5.22	0.42	7.27e-7	Response to antipsychotic treatment;
TGCT	cis	rs3743162	0.553	rs12900463	chr15:85415386	T/C	cg11189052	chr15:85197271	WDR73	0.65	4.78	0.39	4.97e-6	Alzheimer's disease (age of onset);
TGCT	cis	rs1903068	0.853	rs9312656	chr4:56002972	C/G	cg09978860	chr4:56023921	NA	0.56	6.34	0.49	3.88e-9	Endometriosis;
TGCT	cis	rs10883723	0.773	rs7917402	chr10:104246690	C/T	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs9291683	0.588	rs17246745	chr4:9994583	T/C	cg00071950	chr4:10020882	SLC2A9	0.72	9.19	0.64	1.13e-15	Bone mineral density;
TGCT	cis	rs478304	0.627	rs11604568	chr11:65511336	G/A	cg27068330	chr11:65405492	SIPA1	-0.93	-9.34	-0.64	4.92e-16	Acne (severe);
TGCT	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg11062466	chr8:58055876	NA	0.38	4.62	0.38	9.5e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs514406	0.505	rs416968	chr1:53183513	A/G	cg25767906	chr1:53392781	SCP2	-0.45	-5.17	-0.42	9.14e-7	Monocyte count;
TGCT	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg25767906	chr1:53392781	SCP2	-0.59	-6.92	-0.53	2.12e-10	Monocyte count;
TGCT	cis	rs1903068	0.925	rs1551643	chr4:55994226	T/A	cg01777861	chr4:56023843	NA	0.56	6.43	0.5	2.54e-9	Endometriosis;
TGCT	trans	rs1814175	0.817	rs7947286	chr11:49874657	C/T	cg15704280	chr7:45808275	SEPT13	-0.72	-8.14	-0.59	3.61e-13	Height;
TGCT	cis	rs6671200	0.920	rs35403759	chr1:95702890	C/T	cg20701556	chr1:95698924	RWDD3	0.67	5.63	0.45	1.13e-7	Stearic acid (18:0) levels;
TGCT	cis	rs7027203	0.828	rs3996239	chr9:96611290	T/A	cg13679303	chr9:96623674	NA	-0.66	-10.76	-0.69	1.84e-19	DNA methylation (variation);
TGCT	cis	rs981844	0.712	rs10014763	chr4:154739140	C/T	cg14289246	chr4:154710475	SFRP2	0.96	8.92	0.63	4.99e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs4788570	0.647	rs904764	chr16:71772795	G/A	cg06353428	chr16:71660113	MARVELD3	1.54	12.41	0.74	1.74e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs10435719	0.610	rs76311455	chr8:11790526	C/G	cg02840367	chr8:11660030	FDFT1	-0.54	-4.52	-0.38	1.45e-5	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs611744	0.529	rs13282825	chr8:109263237	T/C	cg21045802	chr8:109455806	TTC35	0.7	7.05	0.54	1.07e-10	Dupuytren's disease;
TGCT	cis	rs10779751	0.770	rs11121696	chr1:11238063	A/G	cg08854313	chr1:11322531	MTOR	-0.84	-6.81	-0.52	3.82e-10	Body mass index;
TGCT	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.66	0.39	8.18e-6	Prudent dietary pattern;
TGCT	cis	rs12681287	0.547	rs7459877	chr8:87505660	G/A	cg27223183	chr8:87520930	FAM82B	-0.95	-6.95	-0.53	1.81e-10	Caudate activity during reward;
TGCT	cis	rs9807989	0.811	rs7608638	chr2:102970289	A/G	cg09003973	chr2:102972529	NA	0.64	5.7	0.46	8.28e-8	Asthma;
TGCT	cis	rs8031584	0.678	rs798125	chr15:31116800	C/T	cg14829155	chr15:31115871	NA	0.37	4.93	0.4	2.59e-6	Huntington's disease progression;
TGCT	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg11890956	chr21:40555474	PSMG1	1.1	12.31	0.74	2.99e-23	Cognitive function;
TGCT	cis	rs2013441	1.000	rs9904928	chr17:20180536	C/T	cg18979559	chr17:20280153	CCDC144C	0.45	4.57	0.38	1.16e-5	Obesity-related traits;
TGCT	cis	rs933688	1.000	rs1035476	chr5:90745976	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.01	8.6	0.61	2.93e-14	Smoking behavior;
TGCT	cis	rs9921222	0.564	rs9923059	chr16:381590	C/A	cg10349874	chr16:420996	TMEM8A;MRPL28	-0.26	-4.64	-0.38	8.86e-6	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs72945132	0.882	rs3781648	chr11:70190058	T/C	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs28595532	0.925	rs116785973	chr4:119611350	G/A	cg21605333	chr4:119757512	SEC24D	1.33	8.02	0.58	6.93e-13	Cannabis dependence symptom count;
TGCT	cis	rs9436747	0.641	rs3790425	chr1:66043112	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	-0.52	-4.65	-0.39	8.37e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg22920501	chr2:26401640	FAM59B	-0.79	-6.35	-0.5	3.68e-9	Gut microbiome composition (summer);
TGCT	cis	rs7017914	0.811	rs4272413	chr8:71636187	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.03	-0.41	1.69e-6	Bone mineral density;
TGCT	trans	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg21659725	chr3:3221576	CRBN	0.75	9.34	0.64	5.1e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg11494091	chr17:61959527	GH2	0.61	14.81	0.8	3.37e-29	Prudent dietary pattern;
TGCT	cis	rs7617773	0.784	rs9850672	chr3:48301172	C/A	cg11946769	chr3:48343235	NME6	0.72	6.19	0.49	8.21e-9	Coronary artery disease;
TGCT	cis	rs2836950	0.772	rs62222988	chr21:40569508	T/C	cg11890956	chr21:40555474	PSMG1	-0.65	-6.2	-0.49	7.55e-9	Menarche (age at onset);
TGCT	cis	rs7582180	0.700	rs11685401	chr2:100976685	A/G	cg08017756	chr2:100939284	LONRF2	-0.31	-5.12	-0.42	1.12e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7267979	0.816	rs405822	chr20:25501314	A/G	cg16686733	chr20:25566563	NINL	0.52	5.05	0.41	1.52e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9611565	0.580	rs5758449	chr22:42140160	C/T	cg03806693	chr22:41940476	POLR3H	0.93	9.08	0.63	2.06e-15	Vitiligo;
TGCT	cis	rs9309473	0.606	rs62149777	chr2:73795364	G/A	cg07208825	chr2:73871855	ALMS1P	0.25	4.79	0.4	4.66e-6	Metabolite levels;
TGCT	cis	rs36051895	0.695	rs2183137	chr9:5026293	A/G	cg02405213	chr9:5042618	JAK2	-0.78	-10.46	-0.68	9.47e-19	Pediatric autoimmune diseases;
TGCT	cis	rs11690935	1.000	rs11678984	chr2:172535848	T/G	cg13550731	chr2:172543902	DYNC1I2	1.2	12.8	0.75	2.01e-24	Schizophrenia;
TGCT	cis	rs877529	0.625	rs139416	chr22:39554749	A/G	cg18708252	chr22:39545030	CBX7	-0.38	-5.33	-0.43	4.41e-7	Multiple myeloma;
TGCT	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg25703541	chr22:24373054	LOC391322	-0.8	-8.28	-0.6	1.68e-13	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg08045932	chr20:61659980	NA	0.48	9.28	0.64	7.07e-16	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7216064	1.000	rs11869819	chr17:65868669	A/C	cg12091567	chr17:66097778	LOC651250	-0.83	-6.49	-0.5	1.9e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs7267979	1.000	rs2259926	chr20:25281733	T/C	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg03264133	chr6:25882463	NA	0.86	8.88	0.62	6.24e-15	Blood metabolite levels;
TGCT	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg16325326	chr1:53192061	ZYG11B	-0.72	-8.82	-0.62	8.8e-15	Monocyte count;
TGCT	cis	rs7666738	0.791	rs2081622	chr4:98927369	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2456568	0.900	rs2456559	chr11:93668858	A/T	cg17595323	chr11:93583763	C11orf90	-0.46	-5.79	-0.46	5.39e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs9811920	0.965	rs9289981	chr3:99868104	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.4	-4.44	-0.37	1.98e-5	Axial length;
TGCT	cis	rs739496	0.527	rs7300320	chr12:112360168	G/A	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs9473924	0.505	rs28360639	chr6:50783501	G/A	cg14470998	chr6:50812995	TFAP2B	1.33	7.94	0.58	1.03e-12	Body mass index;
TGCT	cis	rs79387448	0.701	rs76943877	chr2:102970677	T/C	cg09003973	chr2:102972529	NA	1.47	10.36	0.68	1.69e-18	Gut microbiota (bacterial taxa);
TGCT	cis	rs4273100	0.688	rs28760541	chr17:19172505	A/G	cg01534423	chr17:18965556	NA	0.79	7.13	0.54	7.34e-11	Schizophrenia;
TGCT	cis	rs8017423	0.967	rs4904662	chr14:90729427	G/A	cg04374321	chr14:90722782	PSMC1	0.79	7.89	0.58	1.34e-12	Mortality in heart failure;
TGCT	cis	rs7953249	0.542	rs2244608	chr12:121416988	A/G	cg02403541	chr12:121454288	C12orf43	0.65	5.59	0.45	1.36e-7	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs4478858	0.746	rs7544003	chr1:31689088	C/T	cg00250761	chr1:31883323	NA	0.29	4.78	0.39	4.9e-6	Alcohol dependence;
TGCT	cis	rs9467773	1.000	rs12526680	chr6:26550954	A/G	cg26531700	chr6:26746687	NA	0.48	4.69	0.39	7.1e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7961581	0.748	rs1798078	chr12:71595123	A/T	cg07420333	chr12:71899429	LGR5	0.35	5.06	0.41	1.47e-6	Type 2 diabetes;
TGCT	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg08439880	chr3:133502540	NA	0.31	6.05	0.48	1.56e-8	Iron status biomarkers;
TGCT	cis	rs7223966	1.000	rs73337598	chr17:61732576	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	4.74	0.39	5.8e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs208520	0.909	rs9354410	chr6:67018584	C/T	cg07460842	chr6:66804631	NA	0.73	5.91	0.47	3.07e-8	Exhaled nitric oxide output;
TGCT	cis	rs13326165	0.715	rs11705963	chr3:52371991	T/G	cg07884673	chr3:53033167	SFMBT1	0.4	4.86	0.4	3.45e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs1784581	0.894	rs1790001	chr6:162387504	G/T	cg17173639	chr6:162384350	PARK2	-0.5	-9.35	-0.64	4.63e-16	Itch intensity from mosquito bite;
TGCT	cis	rs910187	0.605	rs6066223	chr20:45803998	A/G	cg27589058	chr20:45804311	EYA2	0.37	8.25	0.6	1.96e-13	Migraine;
TGCT	cis	rs7833790	0.685	rs13255262	chr8:82728024	T/G	cg06027949	chr8:82754900	SNX16	-0.65	-5.03	-0.41	1.69e-6	Diastolic blood pressure;
TGCT	cis	rs1865760	1.000	rs6905887	chr6:25912103	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.65	6.24	0.49	6.27e-9	Height;
TGCT	cis	rs263156	0.967	rs263119	chr6:142892729	A/G	cg18419694	chr6:143832440	FUCA2	-0.39	-4.58	-0.38	1.1e-5	Ear morphology;Lobe size;Lobe attachment;
TGCT	cis	rs2204008	0.748	rs8186658	chr12:38301461	A/C	cg26384229	chr12:38710491	ALG10B	0.76	6.92	0.53	2.16e-10	Bladder cancer;
TGCT	cis	rs2688608	0.592	rs3933085	chr10:75483331	C/T	cg15838173	chr10:75533400	FUT11	-0.31	-5.02	-0.41	1.73e-6	Inflammatory bowel disease;
TGCT	cis	rs1059312	0.932	rs4760589	chr12:129284382	T/C	cg09035930	chr12:129282057	SLC15A4	0.59	11.59	0.72	1.72e-21	Systemic lupus erythematosus;
TGCT	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg03351412	chr1:154909251	PMVK	0.52	4.92	0.4	2.66e-6	Prostate cancer;
TGCT	cis	rs1062177	1.000	rs2347596	chr5:151179199	T/C	cg00977110	chr5:151150581	G3BP1	0.39	4.51	0.38	1.49e-5	Preschool internalizing problems;
TGCT	cis	rs4478037	0.558	rs72854770	chr3:33066743	C/G	cg19404215	chr3:33155277	CRTAP	0.95	4.81	0.4	4.27e-6	Major depressive disorder;
TGCT	cis	rs4727027	0.727	rs3801980	chr7:148878620	T/A	cg15662616	chr7:148823355	ZNF425;ZNF398	0.56	4.6	0.38	1.03e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs9660180	0.967	rs61422524	chr1:1767565	C/A	cg17747265	chr1:1875780	NA	-0.41	-7.55	-0.56	8.27e-12	Body mass index;
TGCT	cis	rs751984	0.925	rs10897165	chr11:61277885	G/A	cg17652291	chr11:60500967	NA	-0.41	-4.58	-0.38	1.1e-5	Diastolic blood pressure;Systolic blood pressure;Mean arterial pressure;
TGCT	cis	rs651907	0.535	rs11717638	chr3:101505468	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.31	-6.4	-0.5	2.91e-9	Colorectal cancer;
TGCT	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg07507251	chr3:52567010	NT5DC2	0.47	6.7	0.52	6.47e-10	Bipolar disorder;
TGCT	cis	rs8017423	0.935	rs7160304	chr14:90752908	G/T	cg04374321	chr14:90722782	PSMC1	0.76	7.46	0.56	1.33e-11	Mortality in heart failure;
TGCT	cis	rs1153858	1.000	rs4775907	chr15:45638647	G/A	cg26924012	chr15:45694286	SPATA5L1	1.07	14.56	0.79	1.32e-28	Homoarginine levels;
TGCT	cis	rs11098499	0.863	rs11933966	chr4:120476715	G/A	cg09307838	chr4:120376055	NA	0.72	6.9	0.53	2.41e-10	Corneal astigmatism;
TGCT	cis	rs6570726	0.935	rs366621	chr6:145861275	A/G	cg23711669	chr6:146136114	FBXO30	0.7	6.78	0.52	4.35e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2013441	1.000	rs1992562	chr17:20218793	A/C	cg18979559	chr17:20280153	CCDC144C	-0.44	-4.59	-0.38	1.06e-5	Obesity-related traits;
TGCT	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg02546618	chr19:19431379	KIAA0892;SF4	-0.62	-5.11	-0.42	1.17e-6	Tonsillectomy;
TGCT	cis	rs7647973	0.577	rs6446247	chr3:49102001	A/T	cg05785598	chr3:49045655	WDR6	0.39	4.52	0.38	1.42e-5	Menarche (age at onset);
TGCT	cis	rs826838	1.000	rs7953227	chr12:38946193	G/A	cg13010199	chr12:38710504	ALG10B	0.78	6.76	0.52	4.7e-10	Heart rate;
TGCT	cis	rs617219	0.698	rs7706045	chr5:78507910	T/G	cg23987322	chr5:78407566	BHMT	0.38	5.07	0.41	1.39e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	trans	rs17685	0.753	rs4573217	chr7:75733946	G/A	cg19862616	chr7:65841803	NCRNA00174	0.49	7.91	0.58	1.24e-12	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs1371867	0.846	rs1660329	chr8:101304048	G/T	cg00191853	chr8:101177733	SPAG1	-0.22	-4.47	-0.37	1.75e-5	Atrioventricular conduction;
TGCT	cis	rs10193935	0.901	rs7601905	chr2:42494144	A/G	cg27598129	chr2:42591480	NA	-0.34	-4.78	-0.39	4.92e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg07167872	chr1:205819463	PM20D1	0.57	7.07	0.54	9.84e-11	Menarche (age at onset);
TGCT	cis	rs9357506	0.935	rs4714925	chr6:46304194	A/G	cg21115430	chr6:46460003	NA	-0.26	-5.13	-0.42	1.06e-6	Body mass index;
TGCT	cis	rs7647973	0.580	rs12637576	chr3:49237334	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.38	-5.02	-0.41	1.75e-6	Menarche (age at onset);
TGCT	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	8.55	0.61	3.84e-14	Platelet count;
TGCT	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.84	-5.44	-0.44	2.71e-7	Alzheimer's disease;
TGCT	cis	rs17376456	0.597	rs7733142	chr5:93322795	C/A	cg21475434	chr5:93447410	FAM172A	-0.64	-5.95	-0.47	2.6e-8	Diabetic retinopathy;
TGCT	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	trans	rs1814175	0.817	rs10839465	chr11:49981554	C/A	cg15704280	chr7:45808275	SEPT13	-0.73	-8.48	-0.61	5.58e-14	Height;
TGCT	cis	rs9831754	0.756	rs12714468	chr3:78445878	A/T	cg06138941	chr3:78371609	NA	-0.4	-4.49	-0.37	1.61e-5	Calcium levels;
TGCT	cis	rs4478858	0.698	rs11802155	chr1:31805012	T/C	cg07478791	chr1:31886160	SERINC2	-0.51	-4.95	-0.41	2.33e-6	Alcohol dependence;
TGCT	cis	rs1669338	0.507	rs4685606	chr3:3177973	T/G	cg16797762	chr3:3221439	CRBN	-0.88	-5.56	-0.45	1.58e-7	White matter integrity;
TGCT	cis	rs9300255	0.602	rs1727314	chr12:123640664	C/A	cg00376283	chr12:123451042	ABCB9	0.73	5.64	0.45	1.09e-7	Neutrophil percentage of white cells;
TGCT	cis	rs10858047	0.883	rs12037358	chr1:115089279	T/C	cg12756093	chr1:115239321	AMPD1	0.45	4.63	0.38	9.24e-6	Autism;
TGCT	cis	rs7666738	0.830	rs2865989	chr4:99067532	G/A	cg05340658	chr4:99064831	C4orf37	0.52	5.79	0.46	5.32e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs13082711	0.513	rs7612102	chr3:27372826	A/G	cg02860705	chr3:27208620	NA	-0.36	-5.39	-0.44	3.43e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs4455778	0.579	rs6969891	chr7:49123598	T/G	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.83e-9	Lung cancer in never smokers;
TGCT	cis	rs192253604	1	rs192253604	chr16:68757769	G/A	cg04413148	chr16:67965867	CTRL	0.57	4.71	0.39	6.59e-6	Asymmetrical dimethylarginine levels;
TGCT	cis	rs7833790	0.724	rs6473310	chr8:82707981	A/G	cg06027949	chr8:82754900	SNX16	-0.67	-5.24	-0.43	6.58e-7	Diastolic blood pressure;
TGCT	cis	rs12681287	0.752	rs10092651	chr8:87247678	A/C	cg27223183	chr8:87520930	FAM82B	-0.81	-5.77	-0.46	5.91e-8	Caudate activity during reward;
TGCT	cis	rs12530845	0.943	rs11984203	chr7:135325947	C/T	cg23117316	chr7:135346802	PL-5283	0.5	4.74	0.39	5.83e-6	Red blood cell traits;
TGCT	cis	rs12971120	1.000	rs2278162	chr18:72175814	A/G	cg26446133	chr18:72167187	CNDP2	-0.33	-6.03	-0.48	1.74e-8	Refractive error;
TGCT	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg11890956	chr21:40555474	PSMG1	-0.76	-7.08	-0.54	9.53e-11	Cognitive function;
TGCT	cis	rs10876993	0.890	rs774887	chr12:58034835	A/G	cg15848620	chr12:58087721	OS9	-0.71	-5.81	-0.46	4.86e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs56235845	0.694	rs11949401	chr5:176765989	A/G	cg17509989	chr5:176798049	RGS14	0.55	7.58	0.56	6.89e-12	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs9372498	0.908	rs72967581	chr6:118699329	G/A	cg21191810	chr6:118973309	C6orf204	-0.5	-4.61	-0.38	9.92e-6	Diastolic blood pressure;
TGCT	cis	rs9790314	0.905	rs6789388	chr3:160970437	G/A	cg03342759	chr3:160939853	NMD3	-0.42	-4.51	-0.38	1.5e-5	Morning vs. evening chronotype;
TGCT	cis	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg03213289	chr20:61660250	NA	0.68	9.9	0.66	2.25e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs17376456	1.000	rs59472588	chr5:93511981	A/G	cg25358565	chr5:93447407	FAM172A	0.94	7.98	0.58	8.22e-13	Diabetic retinopathy;
TGCT	cis	rs28595532	0.920	rs55633605	chr4:119761589	G/A	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	trans	rs34421088	0.560	rs1478898	chr8:11395079	G/A	cg15556689	chr8:8085844	FLJ10661	-0.77	-7.3	-0.55	3.07e-11	Neuroticism;
TGCT	cis	rs4332037	0.539	rs55773130	chr7:2070554	T/C	cg25834613	chr7:1915315	MAD1L1	-0.52	-5.11	-0.42	1.2e-6	Bipolar disorder;
TGCT	cis	rs6683383	1.000	rs3766568	chr1:203101029	A/G	cg04395153	chr1:203052423	MYOG	0.29	4.65	0.39	8.22e-6	Asthma;
TGCT	cis	rs6088580	0.634	rs7271970	chr20:32987666	A/G	cg08999081	chr20:33150536	PIGU	-0.28	-5.51	-0.44	1.96e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs2201728	0.967	rs4147532	chr4:100211786	T/C	cg07219303	chr4:100140905	ADH6	-0.35	-5.15	-0.42	9.78e-7	Cardiac Troponin-T levels;
TGCT	cis	rs3091242	0.866	rs11249249	chr1:25758134	A/G	cg00786635	chr1:25594202	NA	0.59	6.21	0.49	7.29e-9	Erythrocyte sedimentation rate;
TGCT	cis	rs7647973	0.626	rs11130217	chr3:49737323	A/G	cg05785598	chr3:49045655	WDR6	0.42	5.24	0.43	6.67e-7	Menarche (age at onset);
TGCT	cis	rs10791323	0.628	rs1893850	chr11:133705356	T/C	cg03690763	chr11:133734501	NA	-0.35	-5.44	-0.44	2.78e-7	Childhood ear infection;
TGCT	cis	rs9868809	0.772	rs9811318	chr3:48702606	A/G	cg00383909	chr3:49044727	WDR6	0.9	5.42	0.44	3.05e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs2354432	0.505	rs7551766	chr1:146858964	A/G	cg25205988	chr1:146714368	CHD1L	-1.34	-5.79	-0.46	5.52e-8	Mitochondrial DNA levels;
TGCT	cis	rs72781680	0.898	rs72786298	chr2:24083011	C/T	cg08917208	chr2:24149416	ATAD2B	0.9	5.5	0.44	2.06e-7	Lymphocyte counts;
TGCT	cis	rs9527	0.590	rs7910900	chr10:104829898	C/T	cg04362960	chr10:104952993	NT5C2	0.66	5.55	0.45	1.62e-7	Arsenic metabolism;
TGCT	cis	rs7113874	0.589	rs6578968	chr11:8480719	G/T	cg14521421	chr11:8862019	ST5	0.29	4.44	0.37	2e-5	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs6003958	1	rs6003958	chr22:24264089	T/G	cg25703541	chr22:24373054	LOC391322	0.81	6.9	0.53	2.34e-10	S-phenylmercapturic acid levels in smokers;
TGCT	cis	rs2172802	0.659	rs28713421	chr4:62497085	C/T	cg04118610	chr4:62707027	LPHN3	0.42	4.5	0.37	1.55e-5	Partial epilepsies;
TGCT	cis	rs6088580	0.634	rs6088488	chr20:32992631	T/C	cg24642439	chr20:33292090	TP53INP2	-0.49	-4.49	-0.37	1.59e-5	Glomerular filtration rate (creatinine);
TGCT	trans	rs7726839	0.561	rs72703058	chr5:584519	G/A	cg11887960	chr12:57824829	NA	0.98	7.81	0.57	2.09e-12	Obesity-related traits;
TGCT	cis	rs8077577	0.945	rs11655731	chr17:18107525	G/T	cg09161412	chr17:18057145	MYO15A	-0.64	-5.2	-0.42	7.92e-7	Obesity-related traits;
TGCT	cis	rs7819412	0.775	rs34094119	chr8:10935898	A/G	cg21775007	chr8:11205619	TDH	-0.5	-4.61	-0.38	9.74e-6	Triglycerides;
TGCT	cis	rs11648796	0.757	rs66649828	chr16:766078	A/G	cg27144592	chr16:783916	NARFL	0.36	5.06	0.41	1.46e-6	Height;
TGCT	cis	rs9486715	0.838	rs9400034	chr6:96954566	C/T	cg18709589	chr6:96969512	KIAA0776	0.81	7.96	0.58	9.28e-13	Headache;
TGCT	cis	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg20637647	chr7:64974828	NA	0.9	5.31	0.43	4.87e-7	Diabetic kidney disease;
TGCT	cis	rs7208859	0.623	rs3752020	chr17:29111125	T/G	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7635838	0.503	rs9853547	chr3:11396101	C/G	cg00170343	chr3:11313890	ATG7	0.64	6.15	0.48	9.73e-9	HDL cholesterol;
TGCT	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg19748678	chr4:122722346	EXOSC9	0.86	9.13	0.63	1.63e-15	Type 2 diabetes;
TGCT	cis	rs8013055	0.846	rs8013827	chr14:105970176	C/T	cg23356831	chr14:105996513	TMEM121	-0.35	-5.63	-0.45	1.16e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs3885907	0.542	rs4147062	chr13:31320249	A/G	cg22282089	chr13:30686841	NA	0.22	4.49	0.37	1.58e-5	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU);
TGCT	cis	rs9611565	0.512	rs4512	chr22:42206084	G/C	cg03806693	chr22:41940476	POLR3H	-1.04	-10.57	-0.69	5.2e-19	Vitiligo;
TGCT	cis	rs950776	0.616	rs647041	chr15:78880481	T/C	cg06917634	chr15:78832804	PSMA4	-0.65	-5.3	-0.43	5.01e-7	Sudden cardiac arrest;
TGCT	trans	rs10504390	0.656	rs80033165	chr8:66478523	T/A	cg26037026	chr7:1641922	NA	-0.64	-6.83	-0.52	3.39e-10	IgG glycosylation;
TGCT	cis	rs568617	0.859	rs1204650	chr11:65645580	A/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.57	-5.22	-0.42	7.39e-7	Crohn's disease;
TGCT	cis	rs916888	0.779	rs199498	chr17:44865603	A/G	cg17911788	chr17:44343683	NA	-0.51	-5.43	-0.44	2.81e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg04267008	chr7:1944627	MAD1L1	-0.39	-5.18	-0.42	8.84e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	9.52	0.65	1.86e-16	Platelet count;
TGCT	cis	rs56309584	0.673	rs11651993	chr17:8115774	A/G	cg08322244	chr17:8066669	VAMP2	-0.55	-5.47	-0.44	2.4e-7	Initial pursuit acceleration;
TGCT	cis	rs2735413	0.564	rs74715500	chr16:78095412	A/C	cg09132178	chr16:78079569	NA	0.33	4.44	0.37	1.98e-5	Systolic blood pressure (alcohol consumption interaction);
TGCT	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg08219700	chr8:58056026	NA	0.37	4.48	0.37	1.71e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9393692	1.000	rs9393692	chr6:26276650	A/G	cg05868516	chr6:26286170	HIST1H4H	0.62	5.86	0.47	3.96e-8	Educational attainment;
TGCT	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg10295955	chr4:187884368	NA	-0.96	-13.44	-0.77	5.81e-26	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10927875	1.000	rs12138117	chr1:16305279	T/C	cg21385522	chr1:16154831	NA	-0.76	-8.29	-0.6	1.6e-13	Dilated cardiomyopathy;
TGCT	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg00684032	chr4:1343700	KIAA1530	0.23	5.02	0.41	1.73e-6	Obesity-related traits;
TGCT	cis	rs7772486	0.590	rs1890170	chr6:146071839	G/C	cg13319975	chr6:146136371	FBXO30	0.73	6.55	0.51	1.36e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	trans	rs13064411	0.542	rs13082603	chr3:113223362	T/C	cg00307254	chr3:126706825	PLXNA1	0.34	6.78	0.52	4.36e-10	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs137603	0.623	rs137657	chr22:39733242	G/T	cg17798944	chr22:39715225	SNORD43;RPL3	-0.64	-6.96	-0.53	1.77e-10	Primary biliary cholangitis;
TGCT	cis	rs951366	0.870	rs3747973	chr1:205677148	A/G	cg07157834	chr1:205819609	PM20D1	0.35	4.99	0.41	2.03e-6	Menarche (age at onset);
TGCT	cis	rs6598955	0.724	rs7547520	chr1:26592310	C/T	cg04990556	chr1:26633338	UBXN11	-0.91	-11.45	-0.72	3.65e-21	Obesity-related traits;
TGCT	cis	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg07424592	chr7:64974309	NA	1.27	7.84	0.58	1.8e-12	Diabetic kidney disease;
TGCT	cis	rs933688	1.000	rs2367526	chr5:90740525	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.0	8.49	0.61	5.31e-14	Smoking behavior;
TGCT	cis	rs7666738	0.791	rs12233867	chr4:98950233	A/G	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1395	0.961	rs4665965	chr2:27536380	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.49	-6.39	-0.5	3.02e-9	Blood metabolite levels;
TGCT	cis	rs35160687	0.901	rs12714180	chr2:86525323	G/T	cg12542933	chr2:85804724	VAMP8	0.4	4.81	0.4	4.21e-6	Night sleep phenotypes;
TGCT	cis	rs76878669	0.917	rs10896110	chr11:66101978	G/A	cg18002602	chr11:66138449	SLC29A2	-0.51	-5.71	-0.46	7.78e-8	Educational attainment (years of education);
TGCT	cis	rs5769765	0.908	rs138891	chr22:50227741	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.36	5.48	0.44	2.25e-7	Schizophrenia;
TGCT	cis	rs1008375	1.000	rs2058338	chr4:17678600	A/G	cg18681998	chr4:17616180	MED28	-0.99	-12.02	-0.73	1.52e-22	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	trans	rs1814175	0.817	rs10769613	chr11:49769692	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.38	-7.76	-0.57	2.75e-12	Height;
TGCT	cis	rs9467773	0.526	rs9348710	chr6:26360486	A/C	cg05738196	chr6:26577821	NA	-0.63	-6.8	-0.52	3.97e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs832540	0.898	rs331498	chr5:56249842	C/G	cg12311346	chr5:56204834	C5orf35	0.46	4.88	0.4	3.15e-6	Coronary artery disease;
TGCT	cis	rs11120822	0.787	rs11120829	chr1:7123793	A/C	cg20434152	chr1:7120926	CAMTA1	-0.29	-4.58	-0.38	1.11e-5	Stearic acid (18:0) levels;
TGCT	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg24531977	chr5:56204891	C5orf35	-0.77	-7.61	-0.56	5.83e-12	Initial pursuit acceleration;
TGCT	cis	rs4285028	0.948	rs34181646	chr3:121705373	T/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.77	-6.5	-0.5	1.78e-9	Multiple sclerosis;
TGCT	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.02	0.53	1.3e-10	Prudent dietary pattern;
TGCT	cis	rs13020137	1	rs13020137	chr2:130757304	A/G	cg03206401	chr2:130956119	TUBA3E	-0.53	-4.81	-0.4	4.26e-6	Schizophrenia;
TGCT	cis	rs12142240	0.698	rs45449893	chr1:46859024	A/G	cg00530320	chr1:46809349	NSUN4	0.29	5.79	0.46	5.34e-8	Menopause (age at onset);
TGCT	cis	rs6121246	0.908	rs6089094	chr20:30431771	C/T	cg18721089	chr20:30220636	NA	-0.45	-4.98	-0.41	2.12e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs79349575	0.783	rs62075852	chr17:47017176	T/C	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.52	-0.38	1.44e-5	Type 2 diabetes;
TGCT	cis	rs7586879	0.789	rs13398155	chr2:25128550	C/T	cg01884057	chr2:25150051	NA	0.27	4.72	0.39	6.29e-6	Body mass index;
TGCT	cis	rs10501293	0.746	rs7952412	chr11:43017772	C/T	cg03447554	chr11:43094025	NA	0.44	6.32	0.49	4.2e-9	Cognitive performance;
TGCT	cis	rs6570726	0.791	rs7755253	chr6:145858893	C/G	cg13319975	chr6:146136371	FBXO30	-0.51	-4.6	-0.38	1.01e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs904251	0.580	rs62408367	chr6:37444813	G/A	cg08126542	chr6:37504118	NA	-0.39	-5.37	-0.43	3.75e-7	Cognitive performance;
TGCT	cis	rs9913156	0.748	rs55959711	chr17:4562581	C/A	cg00122941	chr17:4613640	ARRB2	0.87	7.38	0.55	1.95e-11	Lymphocyte counts;
TGCT	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg22166914	chr1:53195759	ZYG11B	-0.42	-7.38	-0.55	2.01e-11	Monocyte count;
TGCT	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg07507251	chr3:52567010	NT5DC2	0.48	6.91	0.53	2.24e-10	Bipolar disorder;
TGCT	cis	rs2249625	0.508	rs114505309	chr6:72892383	G/A	cg08500200	chr6:72892038	RIMS1	0.43	4.62	0.38	9.5e-6	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
TGCT	cis	rs11585357	0.501	rs17458091	chr1:17595925	A/G	cg08277548	chr1:17600880	PADI3	-0.72	-5.19	-0.42	8.2e-7	Hair shape;
TGCT	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg10802521	chr3:52805072	NEK4	-0.7	-8.15	-0.59	3.38e-13	Bipolar disorder;
TGCT	cis	rs28595532	0.920	rs56046676	chr4:119766733	A/G	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs7829975	0.509	rs2945269	chr8:8115578	G/C	cg08975724	chr8:8085496	FLJ10661	0.63	6.01	0.47	1.93e-8	Mood instability;
TGCT	cis	rs11030122	0.702	rs10835406	chr11:3992954	G/T	cg18678763	chr11:4115507	RRM1	0.5	6.19	0.49	7.92e-9	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg03517284	chr6:25882590	NA	-0.62	-6.45	-0.5	2.24e-9	Blood metabolite levels;
TGCT	cis	rs2370759	1.000	rs11597888	chr10:32635834	G/A	cg01819863	chr10:32635814	EPC1	1.0	9.52	0.65	1.8e-16	Sexual dysfunction (female);
TGCT	cis	rs11264213	0.901	rs72661632	chr1:36420715	G/A	cg27506609	chr1:36549197	TEKT2	0.41	4.61	0.38	9.88e-6	Schizophrenia;
TGCT	cis	rs7822232	0.908	rs4977164	chr8:145144912	T/G	cg14631276	chr8:145163102	KIAA1875	-0.56	-5.05	-0.41	1.55e-6	Blood metabolite levels;
TGCT	cis	rs12497850	0.931	rs9835307	chr3:48857805	T/C	cg06212747	chr3:49208901	KLHDC8B	0.61	5.62	0.45	1.2e-7	Parkinson's disease;
TGCT	cis	rs3806843	0.576	rs246034	chr5:140332064	A/C	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs4642101	0.824	rs9852222	chr3:12848491	G/T	cg05775895	chr3:12838266	CAND2	0.73	7.24	0.55	4.1e-11	QRS complex (12-leadsum);
TGCT	cis	rs7662987	0.517	rs1311617	chr4:100012425	T/G	cg12011299	chr4:100065546	ADH4	0.4	4.76	0.39	5.33e-6	Smoking initiation;
TGCT	cis	rs10782582	0.593	rs12142247	chr1:76235746	C/T	cg03433033	chr1:76189801	ACADM	-0.55	-6.05	-0.48	1.61e-8	Daytime sleep phenotypes;
TGCT	cis	rs7216064	0.589	rs7213585	chr17:66062316	A/T	cg12091567	chr17:66097778	LOC651250	-1.09	-9.43	-0.65	2.99e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs7833790	0.750	rs10108955	chr8:82690644	C/T	cg27398817	chr8:82754497	SNX16	-0.83	-5.96	-0.47	2.43e-8	Diastolic blood pressure;
TGCT	cis	rs7666738	0.830	rs7686456	chr4:99019695	T/C	cg18180107	chr4:99064573	C4orf37	0.54	5.03	0.41	1.7e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1801251	1.000	rs1867778	chr2:233679644	C/T	cg08000102	chr2:233561755	GIGYF2	-0.64	-6.51	-0.5	1.71e-9	Coronary artery disease;
TGCT	cis	rs259282	0.605	rs34727912	chr19:33110058	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.54	4.91	0.4	2.76e-6	Schizophrenia;
TGCT	cis	rs2463822	0.547	rs72917373	chr11:62024403	C/A	cg06239285	chr11:62104954	ASRGL1	-0.96	-6.14	-0.48	1.01e-8	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	trans	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg21659725	chr3:3221576	CRBN	0.75	9.11	0.63	1.79e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs9527	0.567	rs11191573	chr10:104896816	T/C	cg15744005	chr10:104629667	AS3MT	-0.43	-4.94	-0.41	2.45e-6	Arsenic metabolism;
TGCT	cis	rs2204008	0.744	rs11181635	chr12:38378420	C/T	cg26384229	chr12:38710491	ALG10B	0.84	7.3	0.55	2.97e-11	Bladder cancer;
TGCT	cis	rs7666738	0.791	rs1426674	chr4:98924247	C/A	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1215050	0.791	rs592053	chr4:98732220	C/T	cg05340658	chr4:99064831	C4orf37	0.44	5.51	0.44	1.95e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs11217036	1	rs11217036	chr11:118675772	C/T	cg19308663	chr11:118741387	NA	0.31	6.43	0.5	2.56e-9	Allergy;
TGCT	cis	rs7017914	0.837	rs2732105	chr8:71923645	A/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.56	-5.11	-0.42	1.2e-6	Bone mineral density;
TGCT	cis	rs3749237	0.964	rs1799845	chr3:49847623	A/G	cg10152585	chr3:50297680	NA	0.48	4.58	0.38	1.14e-5	Resting heart rate;
TGCT	cis	rs2070488	0.965	rs9877282	chr3:38541452	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.86	-9.01	-0.63	3.14e-15	Electrocardiographic conduction measures;
TGCT	cis	rs1865760	0.964	rs9295677	chr6:25933712	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.64	6.05	0.48	1.59e-8	Height;
TGCT	cis	rs9467711	0.651	rs9467623	chr6:25860580	G/A	cg16898833	chr6:26189333	HIST1H4D	1.16	5.51	0.44	2.03e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs10779751	0.770	rs12075896	chr1:11200350	C/A	cg08854313	chr1:11322531	MTOR	-0.82	-6.66	-0.51	7.99e-10	Body mass index;
TGCT	cis	rs1801251	1.000	rs283475	chr2:233654381	A/C	cg25237894	chr2:233734115	C2orf82	-0.28	-5.01	-0.41	1.81e-6	Coronary artery disease;
TGCT	cis	rs2798269	0.604	rs6490662	chr13:22153280	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.5	-4.43	-0.37	2.01e-5	PR segment;
TGCT	cis	rs11098499	0.818	rs10008791	chr4:120431469	A/C	cg09307838	chr4:120376055	NA	0.68	6.45	0.5	2.28e-9	Corneal astigmatism;
TGCT	cis	rs9659323	1.000	rs6680737	chr1:119521631	G/A	cg07961512	chr1:119535619	NA	0.44	5.07	0.41	1.4e-6	Body mass index;
TGCT	cis	rs2153535	0.526	rs7748404	chr6:8472500	A/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs17268829	0.927	rs10253362	chr7:94077302	G/T	cg06439941	chr7:93550756	GNG11	-0.24	-4.49	-0.37	1.61e-5	Breast cancer;
TGCT	cis	rs3845702	0.668	rs6759271	chr2:180844303	T/C	cg01881094	chr2:180872142	CWC22	-1.08	-7.0	-0.53	1.39e-10	Schizophrenia;
TGCT	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg06618935	chr21:46677482	NA	-0.36	-5.71	-0.46	7.76e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs28595532	0.841	rs114966236	chr4:119733437	T/C	cg21605333	chr4:119757512	SEC24D	1.66	8.33	0.6	1.28e-13	Cannabis dependence symptom count;
TGCT	cis	rs2730245	0.636	rs710421	chr7:158668575	T/C	cg11984989	chr7:158649758	WDR60	1.08	10.47	0.68	9.26e-19	Height;
TGCT	cis	rs916888	0.738	rs199515	chr17:44856641	C/G	cg17911788	chr17:44343683	NA	0.57	5.82	0.46	4.65e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg07747251	chr5:1868357	NA	0.38	5.28	0.43	5.55e-7	Cardiovascular disease risk factors;
TGCT	cis	rs7246657	0.722	rs10410588	chr19:38042410	C/G	cg03611452	chr19:38183253	ZNF781	0.58	4.64	0.38	8.62e-6	Coronary artery calcification;
TGCT	cis	rs10493773	0.775	rs12738010	chr1:86102575	A/C	cg17807903	chr1:86174739	ZNHIT6	0.45	6.36	0.5	3.47e-9	Urate levels in overweight individuals;
TGCT	cis	rs916888	0.610	rs199442	chr17:44820122	G/A	cg01570182	chr17:44337453	NA	0.83	8.02	0.58	6.61e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	trans	rs72913475	0.579	rs112094677	chr18:44180253	T/C	cg09157302	chr4:25656830	SLC34A2	0.65	6.7	0.52	6.55e-10	Midgestational circulating levels of PBDEs (fetal genetic effect);
TGCT	cis	rs7914558	0.901	rs35525740	chr10:104941112	A/T	cg05855489	chr10:104503620	C10orf26	0.5	4.47	0.37	1.71e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs80264589	1	rs80264589	chr6:26927602	G/A	cg12315302	chr6:26189340	HIST1H4D	0.93	4.48	0.37	1.71e-5	Lung cancer;Intelligence (multi-trait analysis);
TGCT	cis	rs7072216	0.763	rs2274245	chr10:100175082	C/T	cg26618903	chr10:100175079	PYROXD2	-0.4	-4.49	-0.37	1.64e-5	Metabolite levels;
TGCT	cis	rs7666738	0.791	rs10856933	chr4:98958542	C/A	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs739401	0.572	rs384490	chr11:3078885	A/C	cg25174290	chr11:3078921	CARS	0.49	4.77	0.39	5.17e-6	Longevity;
TGCT	cis	rs806215	0.723	rs1090682	chr7:127245159	T/C	cg25922125	chr7:127225783	GCC1	0.59	5.98	0.47	2.17e-8	Type 2 diabetes;
TGCT	cis	rs9467773	1.000	rs9357010	chr6:26527945	C/G	cg05738196	chr6:26577821	NA	0.88	12.9	0.76	1.15e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg10150615	chr22:24372951	LOC391322	1.01	13.23	0.77	1.86e-25	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7172971	0.655	rs11070357	chr15:42340142	G/T	cg05886115	chr15:42349113	NA	0.32	4.92	0.4	2.71e-6	3-hydroxypropylmercapturic acid levels in smokers;
TGCT	trans	rs3780486	0.874	rs10813955	chr9:33141791	C/T	cg20290983	chr6:43655470	MRPS18A	1.18	14.66	0.8	7.66e-29	IgG glycosylation;
TGCT	cis	rs4074961	0.505	rs4653306	chr1:38065390	C/T	cg17933807	chr1:38061675	GNL2	1.09	16.57	0.83	3.19e-33	Axial length;
TGCT	cis	rs7147624	0.766	rs11158597	chr14:65913536	T/G	cg03016385	chr14:66212404	NA	-0.5	-7.18	-0.54	5.64e-11	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs9611565	0.921	rs6002333	chr22:41719469	C/T	cg17554472	chr22:41940697	POLR3H	-0.44	-4.8	-0.4	4.39e-6	Vitiligo;
TGCT	cis	rs6922617	0.685	rs73419209	chr6:41346584	T/A	cg07798131	chr6:41471673	NA	0.98	4.85	0.4	3.6e-6	Alzheimer's disease biomarkers;
TGCT	cis	rs6882046	0.513	rs446219	chr5:88005827	T/C	cg24804195	chr5:87968844	LOC645323	-0.61	-6.15	-0.48	9.97e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs6089829	0.962	rs1116450	chr20:61658210	T/C	cg08045932	chr20:61659980	NA	0.48	9.16	0.64	1.36e-15	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs11085466	1.000	rs75211977	chr19:21760201	G/A	cg02997983	chr19:21646781	NA	-0.64	-4.52	-0.38	1.43e-5	Colorectal or endometrial cancer;
TGCT	cis	rs2180341	0.924	rs6930849	chr6:127630963	A/T	cg24812749	chr6:127587940	RNF146	0.98	7.64	0.57	5.06e-12	Breast cancer;
TGCT	cis	rs7677751	0.767	rs890204	chr4:55064439	C/G	cg17187183	chr4:55093834	PDGFRA	0.47	6.19	0.49	8.05e-9	Corneal astigmatism;
TGCT	cis	rs926938	0.618	rs1286560	chr1:115375930	C/T	cg12756093	chr1:115239321	AMPD1	-0.41	-6.02	-0.48	1.84e-8	Autism;
TGCT	cis	rs12477438	0.501	rs7608938	chr2:99782226	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	10.3	0.68	2.42e-18	Chronic sinus infection;
TGCT	cis	rs2243480	1.000	rs58669269	chr7:65951953	T/C	cg18252515	chr7:66147081	NA	-1.18	-7.56	-0.56	7.99e-12	Diabetic kidney disease;
TGCT	cis	rs2228479	0.867	rs17784386	chr16:89947457	A/G	cg19635926	chr16:89946313	TCF25	0.28	4.8	0.4	4.47e-6	Skin colour saturation;
TGCT	cis	rs2120019	0.938	rs2304903	chr15:75315778	A/G	cg11632617	chr15:75315747	PPCDC	-0.3	-4.44	-0.37	1.95e-5	Blood trace element (Zn levels);
TGCT	cis	rs9399135	0.967	rs9376075	chr6:135296963	A/G	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.36e-6	Red blood cell count;
TGCT	cis	rs1372520	0.684	rs3113355	chr4:90745345	A/T	cg14346243	chr4:90757452	SNCA	-0.67	-5.64	-0.45	1.11e-7	Neuroticism;
TGCT	cis	rs11690935	0.688	rs7600835	chr2:172521827	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.91	-7.83	-0.58	1.87e-12	Schizophrenia;
TGCT	cis	rs7267979	1.000	rs2500404	chr20:25359758	A/C	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.05	0.41	1.54e-6	Prudent dietary pattern;
TGCT	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg05665937	chr4:1216051	CTBP1	0.24	4.63	0.38	8.9e-6	Obesity-related traits;
TGCT	cis	rs9993613	0.875	rs58977516	chr4:73452414	A/T	cg15102770	chr4:73434591	ADAMTS3	0.52	4.71	0.39	6.4e-6	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs2013441	1.000	rs17759923	chr17:20022035	G/A	cg23224458	chr17:20280056	CCDC144C	0.4	4.72	0.39	6.33e-6	Obesity-related traits;
TGCT	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg23758822	chr17:41437982	NA	0.72	6.81	0.52	3.83e-10	Menopause (age at onset);
TGCT	cis	rs2370759	1.000	rs11599522	chr10:32568434	G/C	cg01819863	chr10:32635814	EPC1	1.03	9.87	0.66	2.63e-17	Sexual dysfunction (female);
TGCT	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	5.12	0.42	1.11e-6	Alzheimer's disease;
TGCT	cis	rs4523957	0.553	rs2476355	chr17:2029559	A/G	cg16513277	chr17:2031491	SMG6	-0.2	-4.58	-0.38	1.13e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs2439831	0.850	rs3097773	chr15:43893072	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.83	-5.7	-0.46	8.12e-8	Lung cancer in ever smokers;
TGCT	cis	rs6754311	0.773	rs4988183	chr2:136622046	T/C	cg07169764	chr2:136633963	MCM6	0.76	6.97	0.53	1.7e-10	Mosquito bite size;
TGCT	cis	rs7178572	0.524	rs12914128	chr15:77493875	T/C	cg22256960	chr15:77711686	NA	-0.88	-8.99	-0.63	3.53e-15	Type 2 diabetes;
TGCT	cis	rs7267979	0.932	rs13040655	chr20:25582197	C/T	cg16686733	chr20:25566563	NINL	0.56	5.43	0.44	2.81e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7192750	0.586	rs3794692	chr16:71961339	T/C	cg06353428	chr16:71660113	MARVELD3	0.81	7.15	0.54	6.72e-11	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2439831	0.850	rs28684672	chr15:44107662	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	6.27	0.49	5.48e-9	Lung cancer in ever smokers;
TGCT	cis	rs2354432	0.714	rs7531962	chr1:146746023	G/A	cg25205988	chr1:146714368	CHD1L	-1.25	-7.96	-0.58	9.46e-13	Mitochondrial DNA levels;
TGCT	cis	rs1461503	0.900	rs10892935	chr11:122838590	C/T	cg27398637	chr11:122830231	C11orf63	-0.43	-5.31	-0.43	5e-7	Menarche (age at onset);
TGCT	cis	rs2070433	0.752	rs2839220	chr21:47774330	G/C	cg12379764	chr21:47803548	PCNT	0.64	5.37	0.43	3.68e-7	Lymphocyte counts;
TGCT	cis	rs7659604	0.628	rs3828485	chr4:122722368	G/A	cg23574427	chr4:122746245	BBS7;CCNA2	-0.35	-5.31	-0.43	4.83e-7	Type 2 diabetes;
TGCT	cis	rs7208859	0.673	rs2269916	chr17:29233763	A/G	cg14008862	chr17:28927542	LRRC37B2	0.72	4.66	0.39	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7666738	0.830	rs13125432	chr4:98961253	G/A	cg05340658	chr4:99064831	C4orf37	0.53	5.93	0.47	2.85e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7666738	0.830	rs6854902	chr4:99033416	T/G	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7772486	0.720	rs4896844	chr6:146075224	T/C	cg23711669	chr6:146136114	FBXO30	-0.97	-11.03	-0.7	4.03e-20	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs1908814	0.516	rs7812563	chr8:11794488	T/G	cg15556689	chr8:8085844	FLJ10661	0.75	7.26	0.55	3.66e-11	Neuroticism;
TGCT	cis	rs9467711	0.606	rs9379873	chr6:26402717	T/C	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.68	-0.39	7.4e-6	Autism spectrum disorder or schizophrenia;
TGCT	trans	rs4332037	0.539	rs62444881	chr7:2052318	C/T	cg25206134	chr2:45395956	NA	1.0	7.55	0.56	8.15e-12	Bipolar disorder;
TGCT	cis	rs7267979	0.586	rs6037057	chr20:25182089	T/C	cg14121845	chr20:25566513	NINL	0.45	4.88	0.4	3.23e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4654899	1.000	rs6684976	chr1:21367501	G/A	cg01072550	chr1:21505969	NA	-0.49	-7.87	-0.58	1.47e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs4555082	0.834	rs2816652	chr14:105712493	C/T	cg01266790	chr14:105781312	PACS2	0.55	4.49	0.37	1.58e-5	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs4654899	0.606	rs651085	chr1:21097783	A/G	cg01072550	chr1:21505969	NA	0.53	8.91	0.62	5.45e-15	Superior frontal gyrus grey matter volume;
TGCT	cis	rs7412746	0.588	rs10305664	chr1:150839686	A/C	cg04414720	chr1:150670196	GOLPH3L	0.39	4.75	0.39	5.55e-6	Melanoma;
TGCT	cis	rs7647973	1.000	rs2177268	chr3:49439725	A/T	cg07636037	chr3:49044803	WDR6	-0.72	-5.79	-0.46	5.35e-8	Menarche (age at onset);
TGCT	cis	rs4731207	0.596	rs12540261	chr7:124586837	A/G	cg10503827	chr7:124401702	GPR37	-0.2	-4.63	-0.38	9.26e-6	Cutaneous malignant melanoma;
TGCT	cis	rs6912958	0.781	rs7757636	chr6:88256092	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-5.06	-0.41	1.45e-6	Monocyte percentage of white cells;
TGCT	cis	rs7590720	0.959	rs2372684	chr2:216884764	C/A	cg12620499	chr2:216877984	MREG	0.88	9.65	0.66	8.69e-17	Alcohol dependence;
TGCT	cis	rs1949733	1.000	rs1880023	chr4:8480831	C/T	cg13073564	chr4:8508604	NA	0.49	5.17	0.42	8.98e-7	Response to antineoplastic agents;
TGCT	cis	rs13256369	1.000	rs4841017	chr8:8577093	A/G	cg06671706	chr8:8559999	CLDN23	0.35	4.69	0.39	6.95e-6	Obesity-related traits;
TGCT	cis	rs9296092	0.538	rs9469491	chr6:33521545	A/G	cg13560919	chr6:33536144	NA	0.2	4.59	0.38	1.07e-5	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs11190604	1.000	rs11190595	chr10:102291761	T/C	cg23241863	chr10:102295624	HIF1AN	0.68	5.17	0.42	9.14e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg10047753	chr17:41438598	NA	0.8	6.77	0.52	4.47e-10	Menopause (age at onset);
TGCT	trans	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-1.04	-13.29	-0.77	1.33e-25	Intelligence (multi-trait analysis);
TGCT	trans	rs17818859	0.661	rs6743063	chr2:134652361	T/C	cg15779785	chr12:2521414	CACNA1C	0.62	6.94	0.53	1.92e-10	Neurofibrillary tangles;
TGCT	cis	rs1670533	1.000	rs2045069	chr4:1052206	T/C	cg27284194	chr4:1044797	NA	0.7	5.88	0.47	3.62e-8	Recombination rate (females);
TGCT	cis	rs7666738	0.611	rs34982650	chr4:98819530	T/A	cg17366294	chr4:99064904	C4orf37	0.7	7.45	0.56	1.42e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2204008	0.774	rs11495721	chr12:38337224	A/C	cg26384229	chr12:38710491	ALG10B	0.78	6.87	0.53	2.71e-10	Bladder cancer;
TGCT	cis	rs7845219	0.506	rs12548999	chr8:95929843	C/T	cg13393036	chr8:95962371	TP53INP1	-0.43	-5.02	-0.41	1.76e-6	Type 2 diabetes;
TGCT	cis	rs8070740	0.579	rs28429022	chr17:5354471	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.53	4.72	0.39	6.2e-6	Menopause (age at onset);
TGCT	cis	rs910316	0.935	rs2268620	chr14:75640403	G/A	cg23033748	chr14:75592666	NEK9	-0.29	-4.88	-0.4	3.17e-6	Height;
TGCT	cis	rs4478858	0.681	rs12136293	chr1:31703650	A/G	cg00250761	chr1:31883323	NA	-0.28	-4.68	-0.39	7.5e-6	Alcohol dependence;
TGCT	cis	rs514406	0.644	rs4926928	chr1:53210163	G/T	cg16325326	chr1:53192061	ZYG11B	0.86	12.54	0.75	8.24e-24	Monocyte count;
TGCT	cis	rs10992471	0.603	rs11788523	chr9:95256593	G/A	cg14631576	chr9:95140430	CENPP	-0.31	-4.61	-0.38	9.95e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs4727027	0.782	rs10245343	chr7:148796333	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.6	5.4	0.44	3.33e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs9926296	0.656	rs11861084	chr16:89875710	G/T	cg26513180	chr16:89883248	FANCA	-0.73	-6.89	-0.53	2.53e-10	Vitiligo;
TGCT	cis	rs4727027	0.866	rs2373437	chr7:148779032	T/C	cg23583168	chr7:148888333	NA	-0.69	-8.67	-0.61	2.04e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg11764359	chr7:65958608	NA	0.57	5.28	0.43	5.64e-7	Aortic root size;
TGCT	cis	rs35306767	0.953	rs11253521	chr10:976416	G/C	cg18964960	chr10:1102726	WDR37	0.57	4.67	0.39	7.63e-6	Eosinophil percentage of granulocytes;
TGCT	cis	rs3784262	1.000	rs4646586	chr15:58305344	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.5	-7.82	-0.57	1.98e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs9993613	0.875	rs1518485	chr4:73470972	C/T	cg15102770	chr4:73434591	ADAMTS3	-0.53	-4.79	-0.4	4.62e-6	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs3820928	0.935	rs113195824	chr2:227769139	A/G	cg11843606	chr2:227700838	RHBDD1	-0.53	-4.73	-0.39	6.12e-6	Pulmonary function;
TGCT	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg21862992	chr11:68658383	NA	0.46	6.52	0.51	1.6e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs12497850	0.866	rs6791234	chr3:48996137	A/G	cg05785598	chr3:49045655	WDR6	0.37	4.83	0.4	3.94e-6	Parkinson's disease;
TGCT	cis	rs11741688	0.631	rs4444956	chr5:178325515	A/G	cg09339527	chr5:178322752	ZFP2	-0.32	-5.06	-0.41	1.45e-6	Sleep duration;
TGCT	cis	rs4902562	1.000	rs4902562	chr14:68731458	C/T	cg18825221	chr14:68749962	RAD51L1	0.24	5.0	0.41	1.88e-6	Systemic lupus erythematosus;
TGCT	cis	rs4242434	0.747	rs6986550	chr8:22467870	T/A	cg03733263	chr8:22462867	KIAA1967	1.08	17.08	0.84	2.22e-34	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs9611565	0.525	rs9611549	chr22:41705909	C/G	cg03806693	chr22:41940476	POLR3H	-0.81	-7.85	-0.58	1.69e-12	Vitiligo;
TGCT	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg07343612	chr16:622815	PIGQ	-0.41	-8.15	-0.59	3.29e-13	Height;
TGCT	cis	rs10193935	1.000	rs12612527	chr2:42392099	T/C	cg27598129	chr2:42591480	NA	-0.39	-5.14	-0.42	1.05e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs568617	0.716	rs111953392	chr11:65595697	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.67	5.34	0.43	4.34e-7	Crohn's disease;
TGCT	cis	rs72945132	0.579	rs35077099	chr11:70247970	G/A	cg00319359	chr11:70116639	PPFIA1	0.92	7.0	0.53	1.4e-10	Coronary artery disease;
TGCT	cis	rs4722166	0.695	rs7808122	chr7:22798080	A/G	cg26061582	chr7:22766209	IL6	0.49	6.45	0.5	2.31e-9	Lung cancer;
TGCT	cis	rs9653442	0.564	rs2309753	chr2:100775920	C/A	cg22139774	chr2:100720529	AFF3	-0.34	-5.4	-0.44	3.21e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs7824557	0.527	rs2572449	chr8:11239137	A/G	cg21775007	chr8:11205619	TDH	0.72	6.96	0.53	1.79e-10	Retinal vascular caliber;
TGCT	cis	rs7940866	0.774	rs12420126	chr11:130834811	C/T	cg05962950	chr11:130786565	SNX19	0.74	7.1	0.54	8.74e-11	Schizophrenia;
TGCT	cis	rs7772486	0.875	rs932522	chr6:146374026	A/G	cg13319975	chr6:146136371	FBXO30	0.51	4.6	0.38	1.02e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs514406	0.644	rs4926928	chr1:53210163	G/T	cg24675658	chr1:53192096	ZYG11B	-0.82	-10.33	-0.68	1.99e-18	Monocyte count;
TGCT	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg02493798	chr17:6899577	ALOX12	0.43	4.99	0.41	2.03e-6	Tonsillectomy;
TGCT	trans	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg11887960	chr12:57824829	NA	1.25	10.0	0.67	1.29e-17	Lung disease severity in cystic fibrosis;
TGCT	cis	rs7666738	0.830	rs10028692	chr4:98962585	C/T	cg18180107	chr4:99064573	C4orf37	0.57	5.18	0.42	8.63e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8072100	0.738	rs9895509	chr17:45549618	A/T	cg08085267	chr17:45401833	C17orf57	0.52	5.81	0.46	5e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs4555082	0.718	rs75139030	chr14:105710853	A/AG	cg01266790	chr14:105781312	PACS2	0.55	4.49	0.37	1.58e-5	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs2013441	0.760	rs8080827	chr17:20173936	G/A	cg18979559	chr17:20280153	CCDC144C	-0.44	-4.55	-0.38	1.25e-5	Obesity-related traits;
TGCT	cis	rs909002	0.849	rs2280386	chr1:32086912	A/C	cg11573219	chr1:32083031	HCRTR1	-0.49	-6.45	-0.5	2.26e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs17001868	0.568	rs3788578	chr22:40742921	C/T	cg07138101	chr22:40742427	ADSL	0.72	5.25	0.43	6.46e-7	Mammographic density (dense area);
TGCT	cis	rs9868809	0.505	rs28793701	chr3:48762683	C/G	cg00383909	chr3:49044727	WDR6	1.25	6.74	0.52	5.38e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs858239	0.932	rs858275	chr7:23294144	T/C	cg05602783	chr7:23145260	KLHL7	-0.62	-5.12	-0.42	1.16e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs7582180	0.614	rs1030901	chr2:101007314	G/A	cg08017756	chr2:100939284	LONRF2	-0.3	-4.77	-0.39	5.16e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs908922	0.676	rs1337338	chr1:152511885	G/A	cg20991723	chr1:152506922	NA	0.46	6.18	0.48	8.66e-9	Hair morphology;
TGCT	cis	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.54	5.18	0.42	8.63e-7	Sum eosinophil basophil counts;Eosinophil counts;
TGCT	cis	rs72945132	1.000	rs72945129	chr11:70110808	C/T	cg00319359	chr11:70116639	PPFIA1	0.96	6.82	0.52	3.47e-10	Coronary artery disease;
TGCT	cis	rs35306767	0.714	rs7072554	chr10:1090988	C/T	cg20503657	chr10:835505	NA	0.47	5.25	0.43	6.4e-7	Eosinophil percentage of granulocytes;
TGCT	cis	rs968451	0.865	rs5757610	chr22:39707979	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.83	8.1	0.59	4.48e-13	Primary biliary cholangitis;
TGCT	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg12311346	chr5:56204834	C5orf35	-0.66	-6.63	-0.51	9.22e-10	Initial pursuit acceleration;
TGCT	cis	rs9796	0.558	rs4445868	chr15:41531991	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.54	-6.9	-0.53	2.43e-10	Menopause (age at onset);
TGCT	cis	rs36051895	0.632	rs11790841	chr9:5166273	G/C	cg02405213	chr9:5042618	JAK2	-0.7	-8.84	-0.62	7.69e-15	Pediatric autoimmune diseases;
TGCT	trans	rs2727020	0.729	rs1164666	chr11:49295867	C/T	cg15704280	chr7:45808275	SEPT13	-0.71	-8.04	-0.59	6.04e-13	Coronary artery disease;
TGCT	cis	rs6678914	0.966	rs12032080	chr1:202196697	C/T	cg08883485	chr1:201619787	NAV1	-0.4	-4.71	-0.39	6.45e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
TGCT	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg18876405	chr7:65276391	NA	0.36	5.36	0.43	3.97e-7	Aortic root size;
TGCT	cis	rs346785	0.640	rs11077809	chr17:74284854	A/C	cg09812376	chr17:74270190	QRICH2	-0.37	-5.6	-0.45	1.31e-7	White matter hyperintensities in ischemic stroke;
TGCT	cis	rs13188771	0.690	rs350543	chr5:100864959	C/T	cg10455971	chr5:101119566	NA	0.43	4.53	0.38	1.38e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs6500602	0.727	rs11076836	chr16:4569331	G/A	cg08645402	chr16:4508243	NA	0.19	5.3	0.43	5.14e-7	Schizophrenia;
TGCT	cis	rs9611565	0.512	rs9607841	chr22:42186838	G/A	cg06481639	chr22:41940642	POLR3H	-0.66	-5.75	-0.46	6.46e-8	Vitiligo;
TGCT	cis	rs10193935	0.901	rs222471	chr2:42638057	C/T	cg27598129	chr2:42591480	NA	0.38	5.45	0.44	2.57e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs62380364	0.870	rs4373304	chr5:88152202	T/C	cg22951263	chr5:87985283	NA	-0.46	-4.53	-0.38	1.38e-5	Intelligence (multi-trait analysis);
TGCT	trans	rs66573146	0.901	rs55882710	chr4:7030704	G/A	cg07817883	chr1:32538562	TMEM39B	1.69	8.54	0.61	4.08e-14	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs9611565	0.512	rs5996063	chr22:42168767	G/A	cg13695892	chr22:41940480	POLR3H	0.85	8.06	0.59	5.4e-13	Vitiligo;
TGCT	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg18402987	chr7:1209562	NA	0.47	4.69	0.39	7.03e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs13082711	1.000	rs35944308	chr3:27536356	G/A	cg02860705	chr3:27208620	NA	0.34	4.64	0.38	8.68e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs7584330	0.657	rs7599658	chr2:238352898	A/C	cg14458575	chr2:238380390	NA	-0.52	-7.61	-0.56	5.91e-12	Prostate cancer;
TGCT	cis	rs7914558	0.933	rs1538204	chr10:104733893	T/A	cg04362960	chr10:104952993	NT5C2	0.6	5.34	0.43	4.34e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs939658	0.683	rs11634726	chr15:79465894	A/G	cg17916960	chr15:79447300	NA	-0.43	-6.82	-0.52	3.48e-10	Refractive error;
TGCT	cis	rs11874712	0.931	rs35507656	chr18:43652541	A/C	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	5.11	0.42	1.19e-6	Migraine - clinic-based;
TGCT	cis	rs2067615	0.599	rs3759310	chr12:107166122	C/G	cg15890332	chr12:107067104	RFX4	0.28	5.55	0.45	1.66e-7	Heart rate;
TGCT	cis	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg08975724	chr8:8085496	FLJ10661	0.53	4.87	0.4	3.32e-6	Mood instability;
TGCT	cis	rs2288073	0.965	rs10185445	chr2:24410976	A/C	cg02683114	chr2:24398427	C2orf84	0.24	5.72	0.46	7.53e-8	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg16405210	chr4:1374714	KIAA1530	-0.24	-4.44	-0.37	2e-5	Longevity;
TGCT	cis	rs7017914	0.902	rs6472563	chr8:71969907	A/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.57	-5.28	-0.43	5.57e-7	Bone mineral density;
TGCT	cis	rs9394841	0.667	rs9471653	chr6:41755410	C/G	cg08135965	chr6:41755394	TOMM6	0.55	5.15	0.42	9.77e-7	Mean corpuscular hemoglobin;Red cell distribution width;
TGCT	cis	rs6460942	0.915	rs17541464	chr7:12462675	A/G	cg06484146	chr7:12443880	VWDE	-0.53	-5.59	-0.45	1.36e-7	Coronary artery disease;
TGCT	cis	rs909674	0.514	rs7423	chr22:39781429	C/T	cg11247378	chr22:39784982	NA	-0.74	-10.58	-0.69	4.94e-19	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs9357506	1.000	rs6910951	chr6:46307502	C/T	cg21115430	chr6:46460003	NA	-0.26	-5.17	-0.42	9.2e-7	Body mass index;
TGCT	cis	rs2836950	0.527	rs2836948	chr21:40599677	T/C	cg11644478	chr21:40555479	PSMG1	-0.54	-5.1	-0.42	1.25e-6	Menarche (age at onset);
TGCT	cis	rs3741404	0.609	rs687581	chr11:63871533	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.74	-7.48	-0.56	1.16e-11	Platelet count;
TGCT	cis	rs3099143	1.000	rs3102712	chr15:77058926	G/A	cg21673338	chr15:77095150	SCAPER	-0.53	-5.22	-0.42	7.33e-7	Recalcitrant atopic dermatitis;
TGCT	cis	rs7113874	0.589	rs10840060	chr11:8500045	A/C	cg14521421	chr11:8862019	ST5	-0.29	-4.71	-0.39	6.47e-6	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs36051895	0.632	rs7032616	chr9:5180996	T/C	cg02405213	chr9:5042618	JAK2	-0.74	-10.46	-0.68	9.7e-19	Pediatric autoimmune diseases;
TGCT	cis	rs939658	0.967	rs7172074	chr15:79452726	T/C	cg17916960	chr15:79447300	NA	0.53	8.37	0.6	1.04e-13	Refractive error;
TGCT	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg03388025	chr16:89894329	SPIRE2	0.49	8.58	0.61	3.29e-14	Vitiligo;
TGCT	cis	rs1799949	0.794	rs116409325	chr17:41445460	C/A	cg05368731	chr17:41323189	NBR1	1.19	14.26	0.79	6.45e-28	Menopause (age at onset);
TGCT	cis	rs12580194	0.556	rs73119000	chr12:55736662	G/A	cg10672482	chr12:55725839	OR6C3	-0.51	-4.51	-0.38	1.46e-5	Cancer;
TGCT	cis	rs12477438	1.000	rs12053372	chr2:99810055	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-5.75	-0.46	6.59e-8	Chronic sinus infection;
TGCT	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.29	-4.49	-0.37	1.64e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	6.13	0.48	1.06e-8	Bipolar disorder;
TGCT	cis	rs2708977	1.000	rs10184209	chr2:97337491	G/T	cg01950434	chr2:97203154	ARID5A	0.62	5.68	0.45	9.28e-8	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs11105298	0.891	rs4842654	chr12:89834428	T/A	cg00757033	chr12:89920650	WDR51B	0.34	5.36	0.43	4e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs4285028	0.747	rs4048699	chr3:121404483	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.9	7.24	0.54	4.24e-11	Multiple sclerosis;
TGCT	cis	rs6582630	0.519	rs11609739	chr12:38547969	G/A	cg13010199	chr12:38710504	ALG10B	0.62	5.02	0.41	1.74e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs77741769	0.529	rs525425	chr12:121195625	A/G	cg02419362	chr12:121203948	SPPL3	0.19	4.52	0.38	1.42e-5	Mean corpuscular volume;
TGCT	cis	rs1609391	0.543	rs1347209	chr3:136626697	G/T	cg15507776	chr3:136538369	TMEM22	0.66	6.84	0.52	3.27e-10	Neuroticism;
TGCT	cis	rs12477438	0.520	rs6712704	chr2:99719687	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.82	0.62	8.67e-15	Chronic sinus infection;
TGCT	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg06221963	chr1:154839813	KCNN3	-0.8	-15.37	-0.81	1.66e-30	Prostate cancer;
TGCT	cis	rs2797160	1.000	rs1418639	chr6:125999940	C/T	cg05901451	chr6:126070800	HEY2	-0.74	-6.48	-0.5	1.96e-9	Endometrial cancer;
TGCT	trans	rs6089829	0.962	rs6089826	chr20:61668595	G/A	cg23505145	chr19:12996616	KLF1	0.89	9.9	0.66	2.21e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1577917	1.000	rs1857965	chr6:86630776	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.54	-0.45	1.73e-7	Response to antipsychotic treatment;
TGCT	cis	rs9467773	1.000	rs9467773	chr6:26498426	A/G	cg05738196	chr6:26577821	NA	0.87	12.41	0.74	1.7e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs2120019	1.000	rs2415255	chr15:75332412	A/G	cg17294928	chr15:75287854	SCAMP5	-0.78	-6.12	-0.48	1.14e-8	Blood trace element (Zn levels);
TGCT	cis	rs7043114	0.525	rs7026361	chr9:95138564	A/C	cg13798575	chr9:95087839	CENPP;NOL8	0.54	5.45	0.44	2.61e-7	Height;
TGCT	cis	rs7698623	0.850	rs2045834	chr4:88800642	C/T	cg27387453	chr4:88533842	DSPP	-0.6	-4.53	-0.38	1.35e-5	Cardiovascular disease risk factors;
TGCT	cis	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg03213289	chr20:61660250	NA	0.68	9.99	0.67	1.36e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7959452	0.640	rs4274230	chr12:69700772	T/G	cg14784868	chr12:69753453	YEATS4	0.68	6.95	0.53	1.81e-10	Blood protein levels;
TGCT	cis	rs1552244	0.766	rs34232505	chr3:10186216	T/A	cg00149659	chr3:10157352	C3orf10	1.0	5.69	0.46	8.55e-8	Alzheimer's disease;
TGCT	cis	rs8062405	0.540	rs151226	chr16:28549823	A/C	cg09754948	chr16:28834200	ATXN2L	0.55	4.54	0.38	1.3e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs700651	0.789	rs892514	chr2:198905270	T/C	cg00792783	chr2:198669748	PLCL1	0.59	5.09	0.42	1.28e-6	Intracranial aneurysm;
TGCT	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg22963979	chr7:1858916	MAD1L1	-0.41	-6.25	-0.49	5.93e-9	Bipolar disorder and schizophrenia;
TGCT	cis	rs2404602	0.647	rs118129828	chr15:77015200	T/C	cg23625390	chr15:77176239	SCAPER	-0.38	-4.82	-0.4	4.05e-6	Blood metabolite levels;
TGCT	cis	rs9435341	0.762	rs2878349	chr1:107549245	G/A	cg09367891	chr1:107599246	PRMT6	0.67	5.75	0.46	6.66e-8	Facial morphology (factor 21, depth of nasal alae);
TGCT	cis	rs2204008	0.583	rs12307593	chr12:38317803	A/G	cg26384229	chr12:38710491	ALG10B	0.53	4.68	0.39	7.52e-6	Bladder cancer;
TGCT	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.41	-4.88	-0.4	3.13e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9394841	0.692	rs9394834	chr6:41806793	G/A	cg08135965	chr6:41755394	TOMM6	0.54	4.96	0.41	2.31e-6	Mean corpuscular hemoglobin;Red cell distribution width;
TGCT	cis	rs2730260	0.537	rs3793223	chr7:158863574	C/A	cg27122614	chr7:157913741	PTPRN2	0.43	4.45	0.37	1.87e-5	Myopia (pathological);
TGCT	cis	rs9388451	0.807	rs1268070	chr6:126041164	A/G	cg05901451	chr6:126070800	HEY2	-1.04	-12.92	-0.76	1.04e-24	Brugada syndrome;
TGCT	cis	rs858239	0.601	rs73272048	chr7:23152653	C/G	cg05602783	chr7:23145260	KLHL7	-0.66	-5.54	-0.45	1.75e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg06873352	chr17:61820015	STRADA	0.4	4.47	0.37	1.73e-5	Prudent dietary pattern;
TGCT	cis	rs4786125	0.636	rs7187960	chr16:6919183	G/T	cg03623568	chr16:6915990	A2BP1	-0.45	-6.77	-0.52	4.65e-10	Heart rate variability traits (SDNN);
TGCT	cis	rs1538970	0.504	rs3790585	chr1:46023356	A/T	cg05343316	chr1:45956843	TESK2	0.67	4.88	0.4	3.24e-6	Platelet count;
TGCT	cis	rs17152411	0.895	rs61872117	chr10:126581842	A/G	cg07906193	chr10:126599966	NA	0.43	4.68	0.39	7.47e-6	Height;
TGCT	trans	rs12599106	0.679	rs34584967	chr16:34475725	T/G	cg11235426	chr6:292522	DUSP22	-0.64	-6.75	-0.52	4.94e-10	Menopause (age at onset);
TGCT	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg06713675	chr4:122721982	EXOSC9	-0.69	-9.7	-0.66	6.92e-17	Type 2 diabetes;
TGCT	cis	rs2404602	0.716	rs17362383	chr15:76650702	A/G	cg22467129	chr15:76604101	ETFA	-0.56	-6.78	-0.52	4.34e-10	Blood metabolite levels;
TGCT	cis	rs35306767	0.903	rs11253493	chr10:936931	T/C	cg26597838	chr10:835615	NA	0.75	10.54	0.69	6.3e-19	Eosinophil percentage of granulocytes;
TGCT	cis	rs6882046	0.513	rs625970	chr5:88042296	A/G	cg24804195	chr5:87968844	LOC645323	-0.58	-5.72	-0.46	7.57e-8	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs2692947	0.726	rs13009727	chr2:96769883	C/G	cg22654517	chr2:96458247	NA	-0.21	-4.55	-0.38	1.26e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs2153535	0.580	rs1119691	chr6:8460452	C/T	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs3026101	0.647	rs4790263	chr17:5307084	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.47	4.53	0.38	1.38e-5	Body mass index;
TGCT	cis	rs6964587	1.000	rs7802788	chr7:91736874	A/G	cg22709100	chr7:91322751	NA	0.28	4.56	0.38	1.21e-5	Breast cancer;
TGCT	cis	rs910316	1.000	rs4322591	chr14:75600697	C/T	cg23033748	chr14:75592666	NEK9	0.28	4.79	0.39	4.73e-6	Height;
TGCT	cis	rs13102973	0.682	rs7441468	chr4:135886736	C/T	cg14419869	chr4:135874104	NA	0.26	4.6	0.38	1.03e-5	Subjective well-being;
TGCT	cis	rs6570726	0.791	rs11155432	chr6:145898761	T/C	cg23711669	chr6:146136114	FBXO30	0.86	9.54	0.65	1.64e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4972806	0.814	rs4246626	chr2:177046430	A/C	cg03152288	chr2:177042942	NA	0.52	4.51	0.38	1.5e-5	IgG glycosylation;
TGCT	cis	rs904251	0.704	rs2776873	chr6:37483142	A/G	cg08126542	chr6:37504118	NA	-0.43	-5.31	-0.43	4.88e-7	Cognitive performance;
TGCT	trans	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg25482853	chr8:67687455	SGK3	1.22	10.56	0.69	5.48e-19	Lung disease severity in cystic fibrosis;
TGCT	cis	rs9560113	0.843	rs9555808	chr13:112181284	A/T	cg14154082	chr13:112174009	NA	0.38	5.01	0.41	1.83e-6	Menarche (age at onset);
TGCT	cis	rs2832191	0.740	rs6516890	chr21:30476812	T/A	cg24692254	chr21:30365293	RNF160	0.94	10.58	0.69	4.82e-19	Dental caries;
TGCT	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg12310025	chr6:25882481	NA	-0.53	-5.45	-0.44	2.63e-7	Blood metabolite levels;
TGCT	cis	rs7666738	0.830	rs62321570	chr4:98984276	G/A	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs13064411	0.501	rs13092925	chr3:113209375	C/G	cg00307254	chr3:126706825	PLXNA1	0.34	6.72	0.52	5.79e-10	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs2762353	0.562	rs1165206	chr6:25867566	G/A	cg03517284	chr6:25882590	NA	-0.61	-6.15	-0.48	9.83e-9	Blood metabolite levels;
TGCT	cis	rs7772486	0.754	rs2328709	chr6:146106819	A/G	cg05347473	chr6:146136440	FBXO30	-0.52	-4.83	-0.4	3.97e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6912958	0.781	rs2325064	chr6:88224467	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-5.06	-0.41	1.45e-6	Monocyte percentage of white cells;
TGCT	cis	rs1577917	0.958	rs7453105	chr6:86500761	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-5.53	-0.44	1.82e-7	Response to antipsychotic treatment;
TGCT	cis	rs254781	0.527	rs254778	chr5:88009593	A/G	cg22951263	chr5:87985283	NA	0.56	4.84	0.4	3.75e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg05457628	chr5:178986728	RUFY1	-0.54	-6.26	-0.49	5.7e-9	Lung cancer;
TGCT	cis	rs6988636	1.000	rs28537152	chr8:124189071	T/C	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs67311347	1.000	rs7633809	chr3:40517737	A/G	cg13683864	chr3:40499215	RPL14	1.17	13.19	0.76	2.34e-25	Renal cell carcinoma;
TGCT	cis	rs10992471	0.639	rs10821008	chr9:95487497	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.58	-5.73	-0.46	7.21e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs9818758	0.607	rs4855860	chr3:49526044	A/T	cg08550065	chr3:50336684	HYAL3;NAT6	-1.17	-4.98	-0.41	2.11e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.91	-6.04	-0.48	1.67e-8	Alzheimer's disease;
TGCT	cis	rs7552404	0.727	rs1159214	chr1:76317910	G/T	cg10523679	chr1:76189770	ACADM	-0.67	-6.36	-0.5	3.5e-9	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs6565180	0.888	rs13333093	chr16:30407269	C/A	cg17640201	chr16:30407289	ZNF48	1.04	10.4	0.68	1.35e-18	Tonsillectomy;
TGCT	cis	rs12681287	0.640	rs12679811	chr8:87465370	T/C	cg27223183	chr8:87520930	FAM82B	-0.89	-6.43	-0.5	2.54e-9	Caudate activity during reward;
TGCT	cis	rs3771570	0.901	rs4675944	chr2:242430170	C/T	cg21155796	chr2:242212141	HDLBP	0.89	6.82	0.52	3.55e-10	Prostate cancer;
TGCT	cis	rs783147	1.000	rs783147	chr6:161137990	C/T	cg09810169	chr6:161694730	AGPAT4	-0.49	-4.71	-0.39	6.49e-6	Lp (a) levels;
TGCT	cis	rs6752107	0.967	rs6431661	chr2:234167421	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.2	4.88	0.4	3.17e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs3096299	0.967	rs28644774	chr16:89472181	G/C	cg02187348	chr16:89574699	SPG7	0.47	4.45	0.37	1.9e-5	Multiple myeloma (IgH translocation);
TGCT	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg24503407	chr1:205819492	PM20D1	0.68	10.52	0.69	6.7e-19	Menarche (age at onset);
TGCT	cis	rs4924935	1.000	rs1737947	chr17:18831432	A/G	cg26378065	chr17:18585709	ZNF286B	-0.58	-4.88	-0.4	3.2e-6	Pancreatic cancer;
TGCT	cis	rs6088590	0.707	rs67159833	chr20:33488079	T/C	cg06115741	chr20:33292138	TP53INP2	0.64	4.87	0.4	3.4e-6	Coronary artery disease;
TGCT	cis	rs9638182	0.673	rs13221253	chr7:72922233	A/G	cg14087351	chr7:73037990	MLXIPL	-0.57	-4.52	-0.38	1.4e-5	Triglycerides;
TGCT	cis	rs1215050	0.791	rs2123099	chr4:98803456	A/G	cg05340658	chr4:99064831	C4orf37	0.44	5.51	0.44	2.01e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg10047753	chr17:41438598	NA	0.97	10.04	0.67	1.04e-17	Menopause (age at onset);
TGCT	cis	rs6998277	1.000	rs4734648	chr8:103635994	G/A	cg10187029	chr8:103597600	NA	0.47	5.91	0.47	3.05e-8	Migraine;
TGCT	cis	rs1401999	0.659	rs4912518	chr3:183752027	C/T	cg20387954	chr3:183756860	HTR3D	-0.22	-4.61	-0.38	9.8200000000000008e-06	Anterior chamber depth;
TGCT	cis	rs1062177	1.000	rs2964571	chr5:151171256	C/T	cg12924095	chr5:151150029	G3BP1	0.35	5.09	0.42	1.31e-6	Preschool internalizing problems;
TGCT	cis	rs6500602	0.702	rs1051308	chr16:4560301	A/G	cg08645402	chr16:4508243	NA	-0.17	-4.78	-0.39	4.96e-6	Schizophrenia;
TGCT	cis	rs2404602	1.000	rs12443137	chr15:76840832	G/T	cg26408565	chr15:76604113	ETFA	-0.41	-5.16	-0.42	9.55e-7	Blood metabolite levels;
TGCT	cis	rs9611565	0.504	rs5758452	chr22:42144927	G/A	cg06634786	chr22:41940651	POLR3H	0.78	7.31	0.55	2.85e-11	Vitiligo;
TGCT	cis	rs11175492	0.528	rs12368329	chr12:65031566	A/T	cg18624581	chr12:65153313	GNS	-0.8	-4.57	-0.38	1.17e-5	Platelet count;
TGCT	cis	rs10782582	0.609	rs5745553	chr1:76379135	A/T	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.55	4.74	0.39	5.73e-6	Daytime sleep phenotypes;
TGCT	cis	rs6754311	0.593	rs10195620	chr2:136495619	A/T	cg07169764	chr2:136633963	MCM6	-0.66	-6.12	-0.48	1.11e-8	Mosquito bite size;
TGCT	cis	rs61990749	0.597	rs8003691	chr14:78211225	A/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.65	4.59	0.38	1.06e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs7772486	0.686	rs9390348	chr6:146044748	C/T	cg23711669	chr6:146136114	FBXO30	-0.88	-9.77	-0.66	4.64e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg00343986	chr7:65444356	GUSB	-0.22	-5.01	-0.41	1.84e-6	Aortic root size;
TGCT	cis	rs2180341	1.000	rs6569479	chr6:127606588	A/G	cg27446573	chr6:127587934	RNF146	1.07	9.46	0.65	2.57e-16	Breast cancer;
TGCT	cis	rs35883536	0.626	rs10783140	chr1:101042083	A/G	cg14855972	chr1:101004472	GPR88	-0.24	-4.49	-0.37	1.64e-5	Monocyte count;
TGCT	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg08509172	chr19:19383838	TM6SF2	-0.34	-4.48	-0.37	1.71e-5	Tonsillectomy;
TGCT	cis	rs2075371	0.966	rs2544225	chr7:133995838	A/C	cg11752832	chr7:134001865	SLC35B4	0.7	6.44	0.5	2.41e-9	Mean platelet volume;
TGCT	cis	rs1250248	0.526	rs724617	chr2:216282481	A/G	cg16261737	chr2:216301490	FN1	0.5	4.51	0.38	1.47e-5	Total cholesterol levels;
TGCT	cis	rs9291683	0.588	rs6844329	chr4:10018544	T/C	cg00071950	chr4:10020882	SLC2A9	0.75	10.33	0.68	2.04e-18	Bone mineral density;
TGCT	cis	rs2204008	0.811	rs4882300	chr12:38415224	A/T	cg26384229	chr12:38710491	ALG10B	-0.78	-6.97	-0.53	1.62e-10	Bladder cancer;
TGCT	cis	rs2153535	0.580	rs1119691	chr6:8460452	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs12497850	0.931	rs4072859	chr3:49032205	G/C	cg07636037	chr3:49044803	WDR6	0.96	10.59	0.69	4.61e-19	Parkinson's disease;
TGCT	cis	rs11118844	0.696	rs11118860	chr1:221953558	A/G	cg04222084	chr1:221915650	DUSP10	0.83	5.07	0.41	1.4e-6	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
TGCT	cis	rs17767294	0.708	rs34144478	chr6:27834677	C/T	cg08851530	chr6:28072375	NA	1.58	7.16	0.54	6.15e-11	Parkinson's disease;
TGCT	cis	rs3996993	0.724	rs2749010	chr6:52626572	A/G	cg20803780	chr6:52668592	GSTA1	0.33	4.44	0.37	1.97e-5	Hemoglobin concentration;
TGCT	cis	rs8180040	0.805	rs17410853	chr3:47363971	G/T	cg27129171	chr3:47204927	SETD2	-0.6	-6.52	-0.51	1.63e-9	Colorectal cancer;
TGCT	cis	rs9419702	0.568	rs7075233	chr10:133545170	A/G	cg04492858	chr10:133558786	NA	-0.52	-5.65	-0.45	1.05e-7	Survival in rectal cancer;
TGCT	cis	rs4555082	0.834	rs2735817	chr14:105717796	A/G	cg01266790	chr14:105781312	PACS2	-0.56	-4.56	-0.38	1.21e-5	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg15595755	chr5:1867978	NA	0.46	5.31	0.43	4.79e-7	Cardiovascular disease risk factors;
TGCT	cis	rs11997175	0.740	rs6991071	chr8:33814103	G/A	ch.8.33884649F	chr8:33765107	NA	0.34	5.28	0.43	5.56e-7	Body mass index;
TGCT	cis	rs921968	0.613	rs556497	chr2:219446477	G/A	cg02176678	chr2:219576539	TTLL4	0.44	6.33	0.49	4.17e-9	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs11690935	0.959	rs3770452	chr2:172668682	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.18	-12.55	-0.75	7.86e-24	Schizophrenia;
TGCT	cis	rs10493773	0.502	rs12061951	chr1:86081453	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.39	-4.77	-0.39	5.16e-6	Urate levels in overweight individuals;
TGCT	cis	rs7208859	0.573	rs11656121	chr17:29214043	A/G	cg18442181	chr17:29233375	C17orf42	-0.79	-4.78	-0.39	4.95e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs28595532	0.920	rs56302493	chr4:119772382	A/T	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs4851266	0.898	rs10496346	chr2:100853267	A/G	cg07810366	chr2:100720526	AFF3	0.34	4.85	0.4	3.65e-6	Educational attainment;
TGCT	cis	rs9467711	0.659	rs34605993	chr6:26454363	C/T	cg16898833	chr6:26189333	HIST1H4D	1.26	5.95	0.47	2.59e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs17376456	0.877	rs28575883	chr5:93346035	T/C	cg21475434	chr5:93447410	FAM172A	0.63	4.77	0.39	5.14e-6	Diabetic retinopathy;
TGCT	cis	rs7824557	0.564	rs7839307	chr8:11198792	A/G	cg21775007	chr8:11205619	TDH	0.74	6.99	0.53	1.49e-10	Retinal vascular caliber;
TGCT	cis	rs7746199	0.668	rs34864796	chr6:27459923	G/A	cg02458000	chr6:26745757	NA	-0.94	-4.46	-0.37	1.82e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs3020333	0.653	rs851982	chr6:152024985	T/C	cg22157087	chr6:152012887	ESR1	0.25	5.99	0.47	2.13e-8	Total body bone mineral density;
TGCT	cis	rs3125734	0.633	rs4979782	chr10:63998527	C/T	cg19640130	chr10:64028056	RTKN2	-0.39	-5.04	-0.41	1.64e-6	Rheumatoid arthritis;
TGCT	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg12310025	chr6:25882481	NA	0.52	4.62	0.38	9.65e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs1124253	chr4:98949682	C/T	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg27454412	chr7:1067447	C7orf50	0.56	4.66	0.39	8e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs10992471	0.580	rs10992304	chr9:95085365	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.6	-5.59	-0.45	1.35e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs1775715	0.707	rs1541262	chr10:32179771	A/G	cg14930904	chr10:32216787	ARHGAP12	0.52	5.07	0.41	1.39e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs826838	1.000	rs2129627	chr12:38653036	C/T	cg26384229	chr12:38710491	ALG10B	1.05	10.25	0.68	3.18e-18	Heart rate;
TGCT	cis	rs6700896	0.500	rs12040007	chr1:66080160	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.59	4.56	0.38	1.22e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs7178572	0.633	rs12901130	chr15:77848806	C/T	cg22256960	chr15:77711686	NA	-0.82	-7.32	-0.55	2.69e-11	Type 2 diabetes;
TGCT	cis	rs2120019	0.567	rs8025170	chr15:75170983	A/G	cg09165964	chr15:75287851	SCAMP5	0.85	6.73	0.52	5.72e-10	Blood trace element (Zn levels);
TGCT	cis	rs7830933	0.955	rs57220043	chr8:23602763	A/T	cg04349084	chr8:23602677	NA	0.25	4.9	0.4	2.96e-6	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
TGCT	trans	rs1908814	0.516	rs11250178	chr8:11800234	A/C	cg15556689	chr8:8085844	FLJ10661	0.78	7.35	0.55	2.37e-11	Neuroticism;
TGCT	cis	rs709400	1.000	rs3915733	chr14:104147353	G/A	cg26031613	chr14:104095156	KLC1	1.14	17.16	0.84	1.53e-34	Body mass index;
TGCT	cis	rs12134133	0.719	rs6696142	chr1:207402243	C/T	cg02152968	chr1:207494213	CD55	0.69	4.75	0.39	5.46e-6	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs2228479	0.717	rs12917681	chr16:89810941	C/A	cg27121462	chr16:89883253	FANCA	0.77	4.61	0.38	9.93e-6	Skin colour saturation;
TGCT	cis	rs59197085	0.636	rs2307037	chr7:128449405	G/A	cg00260937	chr7:128520193	KCP	0.47	4.9	0.4	2.92e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
TGCT	cis	rs1670533	0.932	rs13140341	chr4:1054235	T/C	cg27284194	chr4:1044797	NA	0.67	5.79	0.46	5.37e-8	Recombination rate (females);
TGCT	cis	rs12681287	0.647	rs2953510	chr8:87341914	T/C	cg27223183	chr8:87520930	FAM82B	-0.9	-6.71	-0.52	6.12e-10	Caudate activity during reward;
TGCT	cis	rs1801251	1.000	rs6714245	chr2:233580505	T/C	cg25237894	chr2:233734115	C2orf82	0.32	5.68	0.45	8.92e-8	Coronary artery disease;
TGCT	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg24675658	chr1:53192096	ZYG11B	-0.84	-10.27	-0.68	2.8e-18	Monocyte count;
TGCT	cis	rs4953345	0.627	rs11900910	chr2:46557600	C/T	cg12598524	chr2:46088325	PRKCE	-0.24	-4.7	-0.39	6.69e-6	Renal cell carcinoma;
TGCT	cis	rs10464366	0.746	rs12674262	chr7:39141728	G/T	cg18850127	chr7:39170497	POU6F2	0.29	6.38	0.5	3.23e-9	IgG glycosylation;
TGCT	cis	rs751984	0.852	rs11230728	chr11:61277698	A/G	cg17652291	chr11:60500967	NA	-0.41	-4.58	-0.38	1.1e-5	Diastolic blood pressure;Systolic blood pressure;Mean arterial pressure;
TGCT	cis	rs1448094	0.544	rs56330110	chr12:86166666	A/G	cg02569458	chr12:86230093	RASSF9	0.38	4.55	0.38	1.25e-5	Major depressive disorder;
TGCT	cis	rs9467773	0.836	rs1977198	chr6:26466225	A/C	cg15659132	chr6:26577336	NA	0.58	5.98	0.47	2.23e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs1524927	1.000	rs1524927	chr7:96371732	C/T	cg03808172	chr7:96339361	SHFM1	-0.49	-5.34	-0.43	4.22e-7	Total body bone mineral density;
TGCT	cis	rs2050392	0.557	rs306588	chr10:30723593	G/A	cg18806716	chr10:30721971	MAP3K8	-0.7	-9.39	-0.64	3.84e-16	Inflammatory bowel disease;
TGCT	cis	rs5769765	0.565	rs8137232	chr22:50256885	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	1.0	6.16	0.48	9.32e-9	Schizophrenia;
TGCT	cis	rs7091068	0.518	rs4144098	chr10:95432600	C/T	cg20715218	chr10:95462985	C10orf4	0.52	5.56	0.45	1.59e-7	Urinary tract infection frequency;
TGCT	cis	rs13272623	0.502	rs268594	chr8:71513130	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	0.6	5.08	0.42	1.33e-6	IgG glycosylation;
TGCT	cis	rs9522267	0.535	rs9515451	chr13:112234382	A/G	cg10483660	chr13:112241077	NA	-0.27	-4.61	-0.38	9.78e-6	Hepatitis;
TGCT	cis	rs7772486	0.790	rs2253764	chr6:146199881	T/A	cg05347473	chr6:146136440	FBXO30	0.52	4.88	0.4	3.15e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9517302	0.615	rs7983522	chr13:99098055	C/T	cg22223119	chr13:99095684	FARP1	-0.51	-5.67	-0.45	9.51e-8	Obesity-related traits;
TGCT	cis	rs2153535	0.580	rs9406171	chr6:8515362	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.55e-8	Motion sickness;
TGCT	cis	rs11943027	0.818	rs7688418	chr4:38900057	C/G	cg25943096	chr4:38869650	MIR574;FAM114A1	0.33	4.49	0.37	1.6e-5	Alcohol dependence;
TGCT	cis	rs6088580	0.634	rs6142159	chr20:32993035	G/A	cg08999081	chr20:33150536	PIGU	-0.28	-5.51	-0.44	1.96e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs4824093	0.610	rs2208023	chr22:50249983	A/G	cg14114931	chr22:50943910	LMF2	0.36	4.51	0.38	1.51e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs6543140	0.964	rs6543143	chr2:103085420	A/C	cg09003973	chr2:102972529	NA	0.54	4.46	0.37	1.83e-5	Blood protein levels;
TGCT	cis	rs2067615	0.560	rs10467028	chr12:107076405	A/G	cg15890332	chr12:107067104	RFX4	0.3	5.87	0.47	3.69e-8	Heart rate;
TGCT	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg03188948	chr7:1209495	NA	0.71	6.04	0.48	1.68e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs797680	1.000	rs797680	chr1:93716974	G/T	cg17826107	chr1:92977322	EVI5	0.24	5.18	0.42	8.56e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs7607369	0.714	rs4674334	chr2:219622811	T/C	cg02176678	chr2:219576539	TTLL4	-0.5	-6.48	-0.5	1.92e-9	Red blood cell count;Amyotrophic lateral sclerosis;
TGCT	cis	rs71435601	0.600	rs475887	chr2:21389485	T/G	cg25035485	chr2:21266500	APOB	0.51	4.48	0.37	1.64e-5	Cholesterol, total;
TGCT	cis	rs1062177	0.774	rs2964574	chr5:151155711	G/A	cg12924095	chr5:151150029	G3BP1	0.34	5.02	0.41	1.78e-6	Preschool internalizing problems;
TGCT	cis	rs6558530	0.615	rs12674711	chr8:1699608	A/G	cg09410841	chr8:1729607	CLN8	0.72	6.48	0.5	1.98e-9	Systolic blood pressure;
TGCT	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg13342137	chr4:2252803	MXD4	0.17	4.56	0.38	1.19e-5	Obesity-related traits;
TGCT	cis	rs6840360	0.967	rs17027798	chr4:152597540	A/G	cg17479576	chr4:152424074	FAM160A1	-0.49	-5.18	-0.42	8.55e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs6459804	0.566	rs76186270	chr7:157512420	C/T	cg14168080	chr7:157504135	PTPRN2	-0.41	-4.85	-0.4	3.57e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs3087591	0.708	rs10445402	chr17:29661340	G/T	cg24425628	chr17:29625626	OMG;NF1	0.39	5.68	0.45	8.93e-8	Hip circumference;
TGCT	cis	rs908922	0.676	rs10888491	chr1:152492622	A/G	cg20991723	chr1:152506922	NA	0.46	6.28	0.49	5.16e-9	Hair morphology;
TGCT	cis	rs1891275	0.515	rs7911755	chr10:93489817	G/A	cg08448711	chr10:92794806	NA	-0.34	-4.48	-0.37	1.69e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs4851266	1.000	rs13034176	chr2:100833913	G/A	cg22139774	chr2:100720529	AFF3	-0.35	-5.41	-0.44	3.1e-7	Educational attainment;
TGCT	cis	rs10927875	0.501	rs9660676	chr1:16279041	C/T	cg21385522	chr1:16154831	NA	-0.94	-9.6	-0.65	1.15e-16	Dilated cardiomyopathy;
TGCT	cis	rs9467773	1.000	rs11756120	chr6:26529808	G/C	cg15659132	chr6:26577336	NA	0.86	12.21	0.74	5.3e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs9814567	1.000	rs7433663	chr3:134235790	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.92	-8.81	-0.62	9.26e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs7193541	0.662	rs8058133	chr16:74657485	A/T	cg01733217	chr16:74700730	RFWD3	1.03	14.16	0.79	1.15e-27	Multiple myeloma;
TGCT	cis	rs651907	0.535	rs13094911	chr3:101519021	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	4.85	0.4	3.68e-6	Colorectal cancer;
TGCT	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg06108461	chr20:60628389	TAF4	-0.6	-8.5	-0.61	4.95e-14	Body mass index;
TGCT	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg07424592	chr7:64974309	NA	0.62	6.03	0.48	1.71e-8	Calcium levels;
TGCT	trans	rs1814175	0.817	rs4881623	chr11:49804991	C/T	cg03929089	chr4:120376271	NA	-0.7	-8.19	-0.59	2.72e-13	Height;
TGCT	cis	rs6546537	0.824	rs3771543	chr2:69784255	C/T	cg10773587	chr2:69614142	GFPT1	-0.71	-6.88	-0.53	2.63e-10	Serum thyroid-stimulating hormone levels;
TGCT	cis	rs28595532	0.764	rs116788606	chr4:119748849	G/C	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	trans	rs17685	0.712	rs60721456	chr7:75743820	T/A	cg19862616	chr7:65841803	NCRNA00174	0.53	9.28	0.64	7.02e-16	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs858239	0.570	rs10235467	chr7:23148808	C/T	cg05602783	chr7:23145260	KLHL7	-0.66	-5.62	-0.45	1.2e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg21724239	chr8:58056113	NA	0.42	5.04	0.41	1.59e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs67311347	0.956	rs13066971	chr3:40462510	A/T	cg13683864	chr3:40499215	RPL14	1.01	10.44	0.68	1.1e-18	Renal cell carcinoma;
TGCT	cis	rs12935418	0.616	rs8047785	chr16:80969352	T/C	cg07676361	chr16:80966860	NA	-0.35	-4.69	-0.39	6.99e-6	Mean corpuscular volume;
TGCT	cis	rs1008375	0.898	rs2079892	chr4:17577163	G/A	cg18681998	chr4:17616180	MED28	0.94	9.56	0.65	1.44e-16	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg06634786	chr22:41940651	POLR3H	0.7	6.65	0.51	8.51e-10	Vitiligo;
TGCT	cis	rs67311347	1.000	rs17078511	chr3:40396254	A/G	cg17264618	chr3:40429014	ENTPD3	0.31	4.54	0.38	1.32e-5	Renal cell carcinoma;
TGCT	cis	rs7937682	0.889	rs12360825	chr11:111528786	A/T	cg09085632	chr11:111637200	PPP2R1B	-1.03	-10.02	-0.67	1.15e-17	Primary sclerosing cholangitis;
TGCT	cis	rs2439831	0.850	rs12441861	chr15:44060883	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	5.91	0.47	3.05e-8	Lung cancer in ever smokers;
TGCT	cis	rs1371867	0.810	rs1692004	chr8:101247320	T/C	cg00191853	chr8:101177733	SPAG1	0.23	4.55	0.38	1.29e-5	Atrioventricular conduction;
TGCT	cis	rs854765	0.583	rs9913724	chr17:17819101	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.74	7.69	0.57	3.91e-12	Total body bone mineral density;
TGCT	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.68	5.62	0.45	1.18e-7	Tonsillectomy;
TGCT	cis	rs6089584	0.528	rs4925334	chr20:60626769	C/T	cg13770153	chr20:60521292	NA	-0.43	-5.15	-0.42	9.9e-7	Body mass index;
TGCT	trans	rs9650657	0.589	rs12542037	chr8:10758496	G/A	cg15556689	chr8:8085844	FLJ10661	0.81	7.52	0.56	9.58e-12	Neuroticism;
TGCT	cis	rs2013441	1.000	rs2703801	chr17:20100600	T/C	cg18979559	chr17:20280153	CCDC144C	-0.44	-4.61	-0.38	9.78e-6	Obesity-related traits;
TGCT	cis	rs8050907	0.744	rs9938647	chr16:4572151	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.58	4.74	0.39	5.67e-6	Obesity-related traits;
TGCT	cis	rs4851254	0.695	rs12712069	chr2:100766354	C/G	cg23118464	chr2:100721844	AFF3	0.6	4.5	0.37	1.56e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs6032067	0.516	rs2743334	chr20:43919745	A/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.39	-6.27	-0.49	5.39e-9	Blood protein levels;
TGCT	cis	rs9674544	0.757	rs4410130	chr17:47122942	C/T	cg07075026	chr17:47091521	IGF2BP1	0.43	4.5	0.37	1.54e-5	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
TGCT	cis	rs7959452	0.640	rs12370042	chr12:69692420	C/G	cg20891283	chr12:69753455	YEATS4	0.66	6.57	0.51	1.26e-9	Blood protein levels;
TGCT	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg13395646	chr4:1353034	KIAA1530	-0.38	-4.57	-0.38	1.16e-5	Longevity;
TGCT	cis	rs3733585	0.578	rs4466042	chr4:9955367	T/C	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.73	-0.57	3.25e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	trans	rs208520	0.690	rs207096	chr6:66797287	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-10.83	-0.7	1.19e-19	Exhaled nitric oxide output;
TGCT	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	8.0	0.58	7.67e-13	Platelet count;
TGCT	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg06238570	chr21:40685208	BRWD1	0.7	6.09	0.48	1.34e-8	Cognitive function;
TGCT	cis	rs2228479	0.850	rs12597299	chr16:89822364	C/A	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs13217239	0.646	rs7747454	chr6:27034253	T/G	cg02458000	chr6:26745757	NA	-0.5	-4.55	-0.38	1.24e-5	Schizophrenia;
TGCT	cis	rs9902453	1.000	rs28664971	chr17:28437410	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	7.31	0.55	2.88e-11	Coffee consumption (cups per day);
TGCT	cis	rs67311347	0.910	rs7617361	chr3:40373259	G/T	cg13683864	chr3:40499215	RPL14	-0.98	-10.09	-0.67	7.74e-18	Renal cell carcinoma;
TGCT	cis	rs7904368	0.806	rs4612698	chr10:16855070	C/A	cg14835575	chr10:16859367	RSU1	0.7	7.48	0.56	1.19e-11	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
TGCT	cis	rs6906287	0.625	rs9489355	chr6:118685314	A/G	cg21191810	chr6:118973309	C6orf204	0.27	4.58	0.38	1.11e-5	Electrocardiographic conduction measures;
TGCT	cis	rs9611565	0.513	rs739135	chr22:42090069	A/C	cg13695892	chr22:41940480	POLR3H	0.89	8.6	0.61	2.92e-14	Vitiligo;
TGCT	cis	rs1008375	0.966	rs6832962	chr4:17652133	T/C	cg10189774	chr4:17578691	LAP3	0.53	4.6	0.38	1.04e-5	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs288326	0.561	rs77318535	chr2:183857319	C/T	cg09997497	chr2:183902928	NCKAP1	1.12	4.86	0.4	3.52e-6	Blood protein levels;
TGCT	cis	rs8062405	0.558	rs151228	chr16:28563026	A/G	cg09754948	chr16:28834200	ATXN2L	0.55	4.54	0.38	1.3e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	trans	rs561341	0.769	rs7217004	chr17:30178092	A/G	cg20587970	chr11:113659929	NA	0.89	9.02	0.63	2.99e-15	Hip circumference adjusted for BMI;
TGCT	cis	rs2439831	1.000	rs2253708	chr15:43797273	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.01	8.11	0.59	4.19e-13	Lung cancer in ever smokers;
TGCT	cis	rs9486719	0.948	rs11153059	chr6:97014537	T/A	cg06623918	chr6:96969491	KIAA0776	-0.99	-8.05	-0.59	5.65e-13	Migraine;Coronary artery disease;
TGCT	cis	rs854765	0.583	rs7214536	chr17:17852446	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	7.69	0.57	3.98e-12	Total body bone mineral density;
TGCT	cis	rs17376456	0.877	rs9314093	chr5:93333347	G/A	cg21475434	chr5:93447410	FAM172A	0.63	4.77	0.39	5.14e-6	Diabetic retinopathy;
TGCT	cis	rs7772486	0.686	rs6933161	chr6:146081369	G/A	cg05347473	chr6:146136440	FBXO30	-0.5	-4.7	-0.39	6.74e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs17767294	0.708	rs72848774	chr6:27945640	C/T	cg08851530	chr6:28072375	NA	1.56	7.22	0.54	4.47e-11	Parkinson's disease;
TGCT	cis	rs6964587	1.000	rs13231578	chr7:91663266	C/T	cg17063962	chr7:91808500	NA	0.87	9.41	0.65	3.46e-16	Breast cancer;
TGCT	cis	rs7267979	1.000	rs4815426	chr20:25405186	A/C	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1635	0.826	rs7750106	chr6:28223680	C/A	cg15743358	chr6:28303923	ZNF323	-1.1	-4.55	-0.38	1.25e-5	Schizophrenia;
TGCT	cis	rs12468226	0.752	rs116078354	chr2:203001079	T/C	cg26506821	chr2:202639771	ALS2	0.35	4.49	0.37	1.61e-5	Urate levels;
TGCT	cis	rs2579519	0.515	rs4907278	chr2:96392196	C/T	cg23100626	chr2:96804247	ASTL	0.46	5.68	0.45	9.16e-8	Diastolic blood pressure;
TGCT	cis	rs854765	0.693	rs11657074	chr17:17770355	G/A	cg09796270	chr17:17721594	SREBF1	-0.28	-5.63	-0.45	1.13e-7	Total body bone mineral density;
TGCT	cis	rs9581857	0.615	rs61622854	chr13:28023194	T/A	cg22138327	chr13:27999177	GTF3A	0.71	5.12	0.42	1.16e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs2456568	0.503	rs4254038	chr11:93666978	T/C	cg26875233	chr11:93583750	C11orf90	-0.44	-5.2	-0.42	8.13e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	trans	rs2760061	0.784	rs708116	chr1:228198196	C/A	cg16006296	chr10:38738647	LOC399744	-0.31	-7.08	-0.54	9.57e-11	Diastolic blood pressure;
TGCT	cis	rs12971120	0.891	rs11151960	chr18:72177232	G/A	cg25817165	chr18:72167213	CNDP2	-0.27	-4.65	-0.39	8.37e-6	Refractive error;
TGCT	cis	rs7523273	0.568	rs61821293	chr1:208007277	T/G	cg22525895	chr1:207977042	MIR29B2	-0.43	-6.24	-0.49	6.48e-9	Schizophrenia;
TGCT	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg22968622	chr17:43663579	NA	1.31	11.93	0.73	2.49e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs4780401	0.588	rs8191298	chr16:11767055	C/A	cg01061890	chr16:11836724	TXNDC11	-0.46	-4.5	-0.37	1.52e-5	Rheumatoid arthritis;
TGCT	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg13607699	chr17:42295918	UBTF	0.59	5.44	0.44	2.67e-7	Total body bone mineral density;
TGCT	cis	rs4478858	0.684	rs4949374	chr1:31754511	G/C	cg00250761	chr1:31883323	NA	-0.25	-4.52	-0.38	1.45e-5	Alcohol dependence;
TGCT	cis	rs5769765	0.720	rs138820	chr22:50164078	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.97	-9.21	-0.64	1.01e-15	Schizophrenia;
TGCT	cis	rs752010	0.746	rs10890146	chr1:42089389	G/A	cg06885757	chr1:42089581	HIVEP3	0.25	4.56	0.38	1.23e-5	Lupus nephritis in systemic lupus erythematosus;
TGCT	cis	rs11098499	0.780	rs10013652	chr4:120292256	A/G	cg09307838	chr4:120376055	NA	0.55	5.41	0.44	3.07e-7	Corneal astigmatism;
TGCT	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg17971929	chr21:40555470	PSMG1	-0.68	-5.82	-0.46	4.81e-8	Cognitive function;
TGCT	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg01802117	chr1:53393560	SCP2	0.48	5.76	0.46	6.16e-8	Monocyte count;
TGCT	cis	rs4478037	1.000	rs58995409	chr3:33161404	T/C	cg19404215	chr3:33155277	CRTAP	1.33	8.79	0.62	1.04e-14	Major depressive disorder;
TGCT	cis	rs9326248	1.000	rs10790175	chr11:117034729	A/G	cg16524733	chr11:117070046	TAGLN	0.31	4.46	0.37	1.81e-5	Blood protein levels;
TGCT	cis	rs4595586	0.546	rs11609849	chr12:39258090	C/G	cg13010199	chr12:38710504	ALG10B	0.62	4.9	0.4	2.99e-6	Morning vs. evening chronotype;
TGCT	cis	rs1801251	1.000	rs283469	chr2:233656997	G/T	cg08000102	chr2:233561755	GIGYF2	0.63	6.34	0.49	3.84e-9	Coronary artery disease;
TGCT	cis	rs1577917	0.958	rs36042496	chr6:86524214	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-5.53	-0.44	1.82e-7	Response to antipsychotic treatment;
TGCT	cis	rs11190604	0.767	rs74869390	chr10:102189385	A/G	cg16005271	chr10:102321736	NA	0.46	4.67	0.39	7.62e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs929354	0.772	rs2366214	chr7:156992461	A/G	cg05182265	chr7:156933206	UBE3C	-0.39	-8.79	-0.62	1.03e-14	Body mass index;
TGCT	cis	rs67460515	0.892	rs35100811	chr3:161084046	A/C	cg03342759	chr3:160939853	NMD3	-0.52	-5.38	-0.44	3.56e-7	Parkinson's disease;
TGCT	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg11644478	chr21:40555479	PSMG1	1.0	10.69	0.69	2.7e-19	Cognitive function;
TGCT	cis	rs7772486	0.686	rs9390357	chr6:146129347	A/G	cg23711669	chr6:146136114	FBXO30	0.86	9.54	0.65	1.68e-16	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs1496653	0.602	rs13091634	chr3:23509363	T/G	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	trans	rs7824557	0.518	rs11783749	chr8:10802055	G/A	cg15556689	chr8:8085844	FLJ10661	-0.82	-7.42	-0.55	1.66e-11	Retinal vascular caliber;
TGCT	cis	rs1153858	0.621	rs1719237	chr15:45579822	G/A	cg26924012	chr15:45694286	SPATA5L1	1.0	10.91	0.7	7.59e-20	Homoarginine levels;
TGCT	cis	rs9611565	0.559	rs12483860	chr22:41961916	C/T	cg13695892	chr22:41940480	POLR3H	-0.87	-8.17	-0.59	2.95e-13	Vitiligo;
TGCT	cis	rs6450176	1.000	rs3776716	chr5:53298923	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.53	-5.1	-0.42	1.23e-6	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs17376456	0.877	rs35747258	chr5:93310129	C/T	cg21475434	chr5:93447410	FAM172A	0.65	4.85	0.4	3.58e-6	Diabetic retinopathy;
TGCT	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg20999797	chr1:1681921	NA	0.19	4.85	0.4	3.68e-6	Body mass index;
TGCT	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg16680214	chr1:154839983	KCNN3	-0.36	-7.12	-0.54	7.57e-11	Prostate cancer;
TGCT	cis	rs137603	0.644	rs137621	chr22:39710244	G/A	cg01093212	chr22:39715156	SNORD43;RPL3	-0.5	-4.75	-0.39	5.59e-6	Primary biliary cholangitis;
TGCT	cis	rs362272	0.525	rs910568	chr4:3307373	A/G	cg18352616	chr4:3374830	RGS12	0.23	4.47	0.37	1.73e-5	Serum sulfate level;
TGCT	cis	rs6003958	1	rs6003958	chr22:24264089	T/G	cg07205460	chr22:24236375	MIF	0.61	4.81	0.4	4.21e-6	S-phenylmercapturic acid levels in smokers;
TGCT	cis	rs7666738	0.830	rs13136930	chr4:98937933	A/T	cg17366294	chr4:99064904	C4orf37	0.73	7.49	0.56	1.15e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9549260	0.755	rs2721069	chr13:41143720	C/T	cg21288729	chr13:41239152	FOXO1	0.98	10.08	0.67	8.21e-18	Red blood cell count;
TGCT	trans	rs208515	0.560	rs207084	chr6:66776966	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-15.79	-0.82	1.83e-31	Exhaled nitric oxide levels;
TGCT	cis	rs17253792	0.822	rs76819679	chr14:56134672	C/G	cg01858014	chr14:56050164	KTN1	-0.35	-4.65	-0.39	8.23e-6	Putamen volume;
TGCT	cis	rs73198271	0.694	rs113694763	chr8:8647076	C/T	cg15556689	chr8:8085844	FLJ10661	-0.6	-4.46	-0.37	1.8e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs7312933	0.558	rs4768402	chr12:42755576	A/G	cg19980929	chr12:42632907	YAF2	-0.41	-5.76	-0.46	6.18e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs858239	0.539	rs870476	chr7:23193271	C/T	cg05602783	chr7:23145260	KLHL7	-0.59	-4.8	-0.4	4.46e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs1348850	0.519	rs1527407	chr2:178525630	T/G	cg22681709	chr2:178499509	PDE11A	-0.48	-6.08	-0.48	1.36e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs6121246	0.529	rs73235789	chr20:30196148	T/C	cg18721089	chr20:30220636	NA	-0.57	-6.19	-0.49	7.9e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs8033133	0.881	rs4344720	chr15:25324141	C/T	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	-0.26	-4.91	-0.4	2.8e-6	Blood osmolality (transformed sodium);
TGCT	cis	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg25427524	chr10:38739819	LOC399744	-0.39	-7.97	-0.58	8.65e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs9399135	0.660	rs4472368	chr6:135274232	A/G	cg24558204	chr6:135376177	HBS1L	0.5	5.21	0.42	7.48e-7	Red blood cell count;
TGCT	cis	rs2742234	0.794	rs17153156	chr10:43704637	C/G	cg02780029	chr10:43622663	RET	0.25	4.92	0.4	2.72e-6	Hirschsprung disease;
TGCT	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg03452623	chr4:187889614	NA	-0.35	-5.36	-0.43	3.87e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7246657	0.943	rs6508733	chr19:38000548	A/T	cg18154014	chr19:37997991	ZNF793	0.73	5.43	0.44	2.85e-7	Coronary artery calcification;
TGCT	cis	rs7666738	0.791	rs28579101	chr4:98843203	T/C	cg17366294	chr4:99064904	C4orf37	0.72	7.5	0.56	1.07e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28595532	0.920	rs115226628	chr4:119639818	A/G	cg11846333	chr4:119757529	SEC24D	0.92	4.59	0.38	1.07e-5	Cannabis dependence symptom count;
TGCT	cis	rs7552404	0.727	rs4949677	chr1:76266662	T/A	cg22875332	chr1:76189707	ACADM	0.64	6.81	0.52	3.82e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs986417	1.000	rs6573318	chr14:61087985	A/G	cg27398547	chr14:60952738	C14orf39	1.56	8.38	0.6	9.49e-14	Gut microbiota (bacterial taxa);
TGCT	cis	rs7726839	0.561	rs56410216	chr5:583216	C/A	cg09021430	chr5:549028	NA	-0.37	-5.23	-0.42	7.12e-7	Obesity-related traits;
TGCT	cis	rs11190604	1.000	rs10883504	chr10:102280687	G/A	cg16342193	chr10:102329863	NA	-0.43	-5.68	-0.45	8.95e-8	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs6088590	0.735	rs6060001	chr20:33294353	C/T	cg06115741	chr20:33292138	TP53INP2	-0.55	-4.69	-0.39	6.99e-6	Coronary artery disease;
TGCT	cis	rs9303401	0.659	rs7223708	chr17:56896398	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs62244186	0.748	rs12635624	chr3:44678498	G/A	cg02073558	chr3:44770973	ZNF501	0.64	6.25	0.49	5.97e-9	Depressive symptoms;
TGCT	cis	rs11105298	0.891	rs10858871	chr12:89871613	G/A	cg00757033	chr12:89920650	WDR51B	0.34	5.37	0.43	3.75e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs6674176	0.597	rs2352990	chr1:44393276	T/A	cg12908607	chr1:44402522	ARTN	-0.76	-9.36	-0.64	4.58e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs1670533	0.932	rs11731289	chr4:1057773	T/G	cg27284194	chr4:1044797	NA	0.67	5.79	0.46	5.37e-8	Recombination rate (females);
TGCT	cis	rs2013441	1.000	rs2703804	chr17:20107195	T/C	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.61	-0.38	9.96e-6	Obesity-related traits;
TGCT	cis	rs137603	1.000	rs137603	chr22:39694225	A/C	cg17798944	chr22:39715225	SNORD43;RPL3	-0.54	-5.04	-0.41	1.61e-6	Primary biliary cholangitis;
TGCT	cis	rs2046867	0.818	rs6808341	chr3:72914847	A/G	cg25664220	chr3:72788482	NA	-0.54	-7.29	-0.55	3.23e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs939658	0.776	rs68147688	chr15:79443848	G/A	cg17916960	chr15:79447300	NA	-0.49	-7.59	-0.56	6.76e-12	Refractive error;
TGCT	trans	rs797680	0.964	rs624131	chr1:93683210	A/G	cg27528825	chr2:159282178	CCDC148	0.34	6.7	0.52	6.63e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs6860806	0.507	rs2631372	chr5:131703578	C/G	cg24060327	chr5:131705240	SLC22A5	-0.63	-4.98	-0.41	2.05e-6	Breast cancer;
TGCT	cis	rs71636778	0.509	rs61457762	chr1:27284157	C/G	cg23921621	chr1:27994728	IFI6	-0.43	-4.61	-0.38	9.92e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
TGCT	cis	rs9611565	0.918	rs4820438	chr22:41767135	C/T	cg06634786	chr22:41940651	POLR3H	-0.85	-7.92	-0.58	1.12e-12	Vitiligo;
TGCT	cis	rs11673344	0.543	rs12980849	chr19:37651714	C/T	cg08039142	chr19:36980659	ZNF566	0.49	4.49	0.37	1.63e-5	Obesity-related traits;
TGCT	cis	rs2153535	0.563	rs3117071	chr6:8537908	C/T	cg07606381	chr6:8435919	SLC35B3	0.55	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs2933343	0.859	rs789245	chr3:128583580	C/A	cg11901034	chr3:128598214	ACAD9	-0.62	-5.16	-0.42	9.47e-7	IgG glycosylation;
TGCT	cis	rs1847202	0.859	rs6805260	chr3:72933767	C/T	cg25664220	chr3:72788482	NA	-0.36	-4.52	-0.38	1.41e-5	Motion sickness;
TGCT	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg16049864	chr8:95962084	TP53INP1	-0.77	-11.21	-0.71	1.44e-20	Type 2 diabetes;
TGCT	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg02493798	chr17:6899577	ALOX12	0.43	4.74	0.39	5.77e-6	Tonsillectomy;
TGCT	cis	rs6987853	0.931	rs2923444	chr8:42397004	C/T	cg20539142	chr8:42623718	CHRNA6	-0.21	-5.03	-0.41	1.69e-6	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs2688608	0.620	rs12253408	chr10:75495956	G/T	cg04320760	chr10:75533139	FUT11	-0.4	-6.25	-0.49	6.11e-9	Inflammatory bowel disease;
TGCT	cis	rs7843479	0.965	rs2291317	chr8:21827162	C/T	cg17168535	chr8:21777572	XPO7	0.68	6.46	0.5	2.2e-9	Mean corpuscular volume;
TGCT	cis	rs11098499	0.866	rs9995136	chr4:120286845	A/G	cg09307838	chr4:120376055	NA	0.58	5.76	0.46	6.16e-8	Corneal astigmatism;
TGCT	cis	rs539096	0.540	rs3011219	chr1:44306120	A/G	cg12908607	chr1:44402522	ARTN	-0.68	-8.12	-0.59	3.97e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg17971929	chr21:40555470	PSMG1	-0.52	-4.64	-0.38	8.72e-6	Menarche (age at onset);
TGCT	cis	rs72945132	0.882	rs17853270	chr11:70200529	C/T	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs16867321	0.694	rs11889207	chr2:181424527	A/C	cg23363182	chr2:181467187	NA	-0.38	-5.76	-0.46	6.36e-8	Obesity;
TGCT	cis	rs6088580	0.634	rs4911423	chr20:32999386	T/A	cg08999081	chr20:33150536	PIGU	-0.29	-5.65	-0.45	1.02e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs12220238	0.915	rs11001020	chr10:76139217	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.9	6.21	0.49	7.5e-9	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs4919694	0.572	rs7080935	chr10:104929113	C/A	cg04362960	chr10:104952993	NT5C2	0.97	6.81	0.52	3.82e-10	Arsenic metabolism;
TGCT	cis	rs2738048	0.545	rs2978950	chr8:6825284	C/G	cg24860332	chr8:6827800	DEFA10P	-0.44	-6.38	-0.5	3.19e-9	IgA nephropathy;
TGCT	cis	rs8031584	0.752	rs7174744	chr15:31183747	G/A	cg08704250	chr15:31115839	NA	0.38	5.63	0.45	1.12e-7	Huntington's disease progression;
TGCT	cis	rs9814567	0.964	rs12492930	chr3:134222722	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.95	-9.62	-0.65	1.04e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs2692947	0.537	rs1834135	chr2:96244225	C/A	cg23100626	chr2:96804247	ASTL	0.41	4.65	0.39	8.45e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs6693567	0.545	rs35705743	chr1:150451832	G/A	cg09579323	chr1:150459698	TARS2	0.52	4.58	0.38	1.12e-5	Migraine;
TGCT	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg00814883	chr7:100076585	TSC22D4	-0.82	-8.37	-0.6	1.03e-13	Platelet count;
TGCT	cis	rs981844	0.796	rs13140722	chr4:154712203	T/A	cg14289246	chr4:154710475	SFRP2	-1.08	-10.27	-0.68	2.72e-18	Response to statins (LDL cholesterol change);
TGCT	trans	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg27523141	chr10:43048294	ZNF37B	0.73	8.58	0.61	3.32e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7904368	0.754	rs7076955	chr10:16852781	G/A	cg14835575	chr10:16859367	RSU1	0.69	7.72	0.57	3.32e-12	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
TGCT	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg27170947	chr2:26402098	FAM59B	-0.4	-4.63	-0.38	8.93e-6	Gut microbiome composition (summer);
TGCT	cis	rs7659604	0.540	rs9995322	chr4:122675642	G/A	cg19748678	chr4:122722346	EXOSC9	-0.51	-5.0	-0.41	1.89e-6	Type 2 diabetes;
TGCT	cis	rs77948430	0.581	rs76016166	chr8:13157068	C/G	cg25598624	chr8:12235727	FAM66A	0.31	4.53	0.38	1.36e-5	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs854765	0.583	rs8078138	chr17:17811251	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	7.91	0.58	1.2e-12	Total body bone mineral density;
TGCT	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg08859206	chr1:53392774	SCP2	0.39	5.79	0.46	5.41e-8	Monocyte count;
TGCT	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.31	-4.76	-0.39	5.36e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2456568	0.867	rs2462750	chr11:93668590	C/T	cg17595323	chr11:93583763	C11orf90	-0.46	-5.79	-0.46	5.39e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	trans	rs1470506	0.507	rs55985303	chr2:77224951	G/A	cg15576869	chr7:50450374	IKZF1	-0.41	-6.76	-0.52	4.74e-10	IgG glycosylation;
TGCT	cis	rs9911578	0.839	rs7208505	chr17:57187729	C/T	cg12560992	chr17:57184187	TRIM37	0.72	8.6	0.61	2.98e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs826838	1.000	rs11168676	chr12:38977304	A/G	cg13010199	chr12:38710504	ALG10B	0.8	6.77	0.52	4.58e-10	Heart rate;
TGCT	cis	rs1215050	0.846	rs1839903	chr4:98791414	C/T	cg05340658	chr4:99064831	C4orf37	0.46	5.51	0.44	1.94e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg19901468	chr14:105411992	AHNAK2	-0.28	-6.09	-0.48	1.31e-8	Rheumatoid arthritis;
TGCT	cis	rs9467711	0.606	rs34273322	chr6:26415409	T/A	cg10795676	chr6:26370623	BTN3A2	-0.45	-4.56	-0.38	1.23e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs909674	0.818	rs8136980	chr22:39844574	G/A	cg11247378	chr22:39784982	NA	-0.73	-9.24	-0.64	8.56e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs35000415	0.938	rs13227075	chr7:128643297	T/C	cg06242719	chr7:129414860	MIR183;MIR96	-0.31	-4.52	-0.38	1.4e-5	Systemic lupus erythematosus;
TGCT	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg09222892	chr1:25734099	RHCE	-0.43	-6.9	-0.53	2.4e-10	Erythrocyte sedimentation rate;
TGCT	cis	rs62244186	0.659	rs9850129	chr3:44532047	C/T	cg02073558	chr3:44770973	ZNF501	0.56	5.48	0.44	2.25e-7	Depressive symptoms;
TGCT	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg06481639	chr22:41940642	POLR3H	-0.76	-7.05	-0.54	1.08e-10	Vitiligo;
TGCT	cis	rs11098499	0.874	rs10022508	chr4:120115228	A/G	cg09307838	chr4:120376055	NA	0.5	4.64	0.38	8.86e-6	Corneal astigmatism;
TGCT	cis	rs73198271	0.653	rs10099808	chr8:8659873	A/G	cg06636001	chr8:8085503	FLJ10661	0.61	4.53	0.38	1.38e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg21226059	chr5:178986404	RUFY1	0.49	5.31	0.43	4.79e-7	Lung cancer;
TGCT	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg24531977	chr5:56204891	C5orf35	-0.77	-7.61	-0.56	5.83e-12	Initial pursuit acceleration;
TGCT	cis	rs992157	0.735	rs10932765	chr2:219099484	T/C	cg00012203	chr2:219082015	ARPC2	0.81	10.21	0.68	3.88e-18	Colorectal cancer;
TGCT	cis	rs9549260	0.755	rs2701863	chr13:41170140	C/T	cg21288729	chr13:41239152	FOXO1	1.0	10.06	0.67	9.29e-18	Red blood cell count;
TGCT	cis	rs1395	0.925	rs2580754	chr2:27398196	A/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.49	6.7	0.52	6.55e-10	Blood metabolite levels;
TGCT	cis	rs11864453	0.647	rs3852781	chr16:72123556	T/A	cg14768367	chr16:72042858	DHODH	0.52	5.21	0.42	7.61e-7	Fibrinogen levels;
TGCT	cis	rs9560113	0.960	rs61967677	chr13:112174044	A/G	cg14154082	chr13:112174009	NA	0.34	4.58	0.38	1.09e-5	Menarche (age at onset);
TGCT	trans	rs2727020	0.553	rs3907576	chr11:49536639	A/C	cg15704280	chr7:45808275	SEPT13	-0.61	-6.81	-0.52	3.77e-10	Coronary artery disease;
TGCT	cis	rs7731657	0.537	rs72801793	chr5:130376936	A/T	cg08523029	chr5:130500466	HINT1	-0.61	-5.05	-0.41	1.55e-6	Fasting plasma glucose;
TGCT	cis	rs1971762	0.583	rs2365345	chr12:54086820	C/T	cg16917193	chr12:54089295	NA	1.39	18.43	0.86	2.53e-37	Height;
TGCT	cis	rs9640161	0.742	rs2108851	chr7:150019634	T/C	cg10018233	chr7:150070692	REPIN1	0.33	4.74	0.39	5.68e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs9325144	0.555	rs1973292	chr12:38679626	T/C	cg26384229	chr12:38710491	ALG10B	0.66	6.13	0.48	1.09e-8	Morning vs. evening chronotype;
TGCT	cis	rs6545883	0.929	rs6705235	chr2:61713580	G/C	cg15711740	chr2:61764176	XPO1	-0.57	-5.2	-0.42	7.85e-7	Tuberculosis;
TGCT	cis	rs9549367	0.789	rs2287247	chr13:113889212	A/G	cg18105134	chr13:113819100	PROZ	-0.34	-5.49	-0.44	2.18e-7	Platelet distribution width;
TGCT	cis	rs1372520	0.684	rs2619368	chr4:90729747	T/G	cg15133208	chr4:90757351	SNCA	-0.52	-6.07	-0.48	1.44e-8	Neuroticism;
TGCT	cis	rs28595532	0.841	rs114465037	chr4:119778165	A/G	cg21605333	chr4:119757512	SEC24D	1.53	8.87	0.62	6.71e-15	Cannabis dependence symptom count;
TGCT	cis	rs10751667	0.666	rs10902243	chr11:949900	T/C	cg06064525	chr11:970664	AP2A2	-0.35	-8.22	-0.59	2.29e-13	Alzheimer's disease (late onset);
TGCT	cis	rs78487399	0.808	rs17030800	chr2:43671003	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-5.09	-0.42	1.3e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs832540	0.552	rs252924	chr5:56205643	A/G	cg20203395	chr5:56204925	C5orf35	-0.52	-4.58	-0.38	1.12e-5	Coronary artery disease;
TGCT	trans	rs66573146	0.831	rs67315413	chr4:6987910	T/C	cg07817883	chr1:32538562	TMEM39B	1.3	6.83	0.52	3.41e-10	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs9467773	0.595	rs2172007	chr6:26639777	A/C	cg11502198	chr6:26597334	ABT1	0.51	4.61	0.38	9.7e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9915657	0.715	rs34126003	chr17:70106615	G/T	cg06234051	chr17:70120541	SOX9	-0.24	-5.14	-0.42	1.03e-6	Thyroid hormone levels;
TGCT	cis	rs1371867	0.875	rs1660320	chr8:101337579	A/C	cg00191853	chr8:101177733	SPAG1	-0.23	-4.73	-0.39	6.08e-6	Atrioventricular conduction;
TGCT	cis	rs651907	0.557	rs56291106	chr3:101377474	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.35	-7.28	-0.55	3.4e-11	Colorectal cancer;
TGCT	cis	rs7267979	0.903	rs6115118	chr20:25246734	G/A	cg14121845	chr20:25566513	NINL	0.5	5.51	0.44	1.95e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg13866156	chr1:1669148	SLC35E2	-0.21	-5.13	-0.42	1.09e-6	Body mass index;
TGCT	cis	rs4891159	0.513	rs2554831	chr18:74113513	C/G	cg24786174	chr18:74118243	ZNF516	0.7	14.77	0.8	4.27e-29	Longevity;
TGCT	cis	rs28595532	1.000	rs17258106	chr4:119675406	C/T	cg14228332	chr4:119757509	SEC24D	-1.04	-6.06	-0.48	1.52e-8	Cannabis dependence symptom count;
TGCT	cis	rs7824557	0.628	rs3779891	chr8:11183505	G/A	cg21775007	chr8:11205619	TDH	0.66	6.47	0.5	2.08e-9	Retinal vascular caliber;
TGCT	cis	rs763121	0.719	rs9610995	chr22:39057763	C/T	cg06022373	chr22:39101656	GTPBP1	0.77	7.51	0.56	9.9e-12	Menopause (age at onset);
TGCT	cis	rs2692947	0.637	rs1168967	chr2:96826016	A/G	cg23100626	chr2:96804247	ASTL	0.44	5.25	0.43	6.37e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs734999	0.545	rs28690427	chr1:2571823	A/G	cg18854424	chr1:2615690	NA	-0.45	-5.15	-0.42	1e-6	Ulcerative colitis;
TGCT	cis	rs4629710	0.592	rs4424112	chr6:131563788	C/T	cg12606694	chr6:131520996	AKAP7	0.41	4.82	0.4	4.09e-6	Multiple myeloma (IgH translocation);
TGCT	cis	rs11105298	0.891	rs11105319	chr12:89927177	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.69	-4.96	-0.41	2.3e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs9837602	0.507	rs1718244	chr3:99512608	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.58	6.5	0.5	1.78e-9	Breast cancer;
TGCT	cis	rs6671200	0.850	rs259345	chr1:95729649	A/G	cg20701556	chr1:95698924	RWDD3	-0.67	-5.63	-0.45	1.13e-7	Stearic acid (18:0) levels;
TGCT	cis	rs1371867	0.846	rs1660312	chr8:101330634	C/G	cg06636551	chr8:101224915	SPAG1	-0.48	-6.3	-0.49	4.66e-9	Atrioventricular conduction;
TGCT	cis	rs4285028	0.948	rs6790281	chr3:121665543	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.77	-6.5	-0.5	1.78e-9	Multiple sclerosis;
TGCT	cis	rs4081724	0.565	rs73024301	chr19:33803191	C/T	cg18823272	chr19:34111733	CHST8	0.4	4.5	0.37	1.52e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1371867	0.846	rs1788197	chr8:101290928	T/C	cg06002616	chr8:101225028	SPAG1	-0.53	-6.42	-0.5	2.67e-9	Atrioventricular conduction;
TGCT	cis	rs13242816	1.000	rs17138767	chr7:116137677	A/G	cg02799643	chr7:116139180	CAV2	-0.46	-5.92	-0.47	3e-8	P wave duration;
TGCT	cis	rs526231	0.575	rs26822	chr5:102518795	A/G	cg23492399	chr5:102201601	PAM	-0.5	-4.49	-0.37	1.6e-5	Primary biliary cholangitis;
TGCT	cis	rs4383453	0.539	rs16834218	chr3:123097988	T/C	cg04890266	chr3:123102914	ADCY5	-0.5	-8.34	-0.6	1.2e-13	Gestational age at birth (maternal effect);
TGCT	cis	rs11690935	0.632	rs62183783	chr2:172865775	A/G	cg13550731	chr2:172543902	DYNC1I2	0.6	5.23	0.43	7e-7	Schizophrenia;
TGCT	cis	rs10067451	0.606	rs17419291	chr5:87780432	C/T	cg24804195	chr5:87968844	LOC645323	-1.22	-4.67	-0.39	7.7e-6	Photic sneeze reflex;
TGCT	cis	rs12497850	1.000	rs1352420	chr3:48757291	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.43	-5.71	-0.46	8.06e-8	Parkinson's disease;
TGCT	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg10295955	chr4:187884368	NA	-0.99	-15.24	-0.81	3.38e-30	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2657888	1.000	rs2657901	chr12:56933416	A/G	cg23002907	chr12:56915593	RBMS2	0.44	6.15	0.48	9.65e-9	Adiponectin levels;
TGCT	cis	rs9611565	0.503	rs5751156	chr22:42170025	A/G	cg17554472	chr22:41940697	POLR3H	0.45	4.64	0.38	8.54e-6	Vitiligo;
TGCT	cis	rs7772486	0.902	rs1331643	chr6:146398873	T/A	cg23711669	chr6:146136114	FBXO30	0.79	8.32	0.6	1.37e-13	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs12950390	0.893	rs12325760	chr17:45840886	C/T	cg24803719	chr17:45855879	NA	-0.47	-4.75	-0.39	5.6e-6	IgG glycosylation;
TGCT	cis	rs7659604	0.540	rs7698889	chr4:122671324	G/T	cg19748678	chr4:122722346	EXOSC9	-0.51	-4.93	-0.4	2.58e-6	Type 2 diabetes;
TGCT	cis	rs11992186	0.570	rs17628941	chr8:8587534	G/C	cg06636001	chr8:8085503	FLJ10661	-0.58	-4.87	-0.4	3.32e-6	Neuroticism;
TGCT	cis	rs7582180	0.591	rs1030902	chr2:101007178	T/G	cg08017756	chr2:100939284	LONRF2	-0.31	-5.07	-0.41	1.4e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs916888	0.821	rs199507	chr17:44858855	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.7	-4.82	-0.4	4.1e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs3803170	0.513	rs7302763	chr12:111827569	C/T	cg10833066	chr12:111807467	FAM109A	0.36	5.11	0.42	1.17e-6	Mean corpuscular hemoglobin;
TGCT	trans	rs2727020	0.595	rs10839281	chr11:49483373	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.35	-6.79	-0.52	4.14e-10	Coronary artery disease;
TGCT	cis	rs11587400	0.572	rs2268697	chr1:115227493	A/G	cg12756093	chr1:115239321	AMPD1	0.32	4.56	0.38	1.23e-5	Autism;
TGCT	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg09359103	chr1:154839909	KCNN3	-0.65	-12.04	-0.73	1.35e-22	Prostate cancer;
TGCT	cis	rs826838	1.000	rs11183214	chr12:38692938	C/T	cg26384229	chr12:38710491	ALG10B	1.12	11.32	0.71	7.88e-21	Heart rate;
TGCT	cis	rs7568458	0.905	rs10198569	chr2:85794415	C/T	cg17127132	chr2:85788382	GGCX	-0.69	-6.13	-0.48	1.09e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs7818688	0.697	rs11787303	chr8:95972864	C/T	cg16049864	chr8:95962084	TP53INP1	0.54	4.64	0.38	8.87e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs981844	0.922	rs2118863	chr4:154657579	C/T	cg14289246	chr4:154710475	SFRP2	1.01	8.46	0.6	6.31e-14	Response to statins (LDL cholesterol change);
TGCT	trans	rs9467711	1.000	rs9467704	chr6:26319486	A/G	cg20516262	chr7:155325649	CNPY1	-0.56	-6.89	-0.53	2.46e-10	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2562456	0.834	rs2173727	chr19:21673957	C/T	cg25650185	chr19:21324782	ZNF431	0.58	5.04	0.41	1.6e-6	Pain;
TGCT	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg01238044	chr22:24384105	GSTT1	0.58	5.62	0.45	1.18e-7	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg06896619	chr17:61851486	DDX42;CCDC47	-0.51	-4.96	-0.41	2.24e-6	Prudent dietary pattern;
TGCT	trans	rs2727020	0.729	rs1164666	chr11:49295867	C/T	cg03929089	chr4:120376271	NA	-0.72	-8.3	-0.6	1.48e-13	Coronary artery disease;
TGCT	cis	rs7412746	0.611	rs9661876	chr1:150910911	C/T	cg04414720	chr1:150670196	GOLPH3L	0.37	4.46	0.37	1.81e-5	Melanoma;
TGCT	cis	rs7824557	0.751	rs2099456	chr8:11127001	A/C	cg21775007	chr8:11205619	TDH	0.6	5.97	0.47	2.37e-8	Retinal vascular caliber;
TGCT	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg18876405	chr7:65276391	NA	-0.33	-5.02	-0.41	1.72e-6	Aortic root size;
TGCT	cis	rs67311347	0.955	rs6764102	chr3:40378153	C/G	cg13683864	chr3:40499215	RPL14	-1.09	-11.46	-0.72	3.52e-21	Renal cell carcinoma;
TGCT	cis	rs7394190	0.748	rs4746146	chr10:75527197	C/T	cg07699608	chr10:75541558	CHCHD1	0.77	4.86	0.4	3.48e-6	Incident atrial fibrillation;
TGCT	cis	rs2832191	0.967	rs3787660	chr21:30520907	C/T	cg08807101	chr21:30365312	RNF160	0.53	4.97	0.41	2.19e-6	Dental caries;
TGCT	cis	rs2066819	1.000	rs57279772	chr12:56698960	G/A	cg26714650	chr12:56694279	CS	-1.36	-6.06	-0.48	1.54e-8	Psoriasis vulgaris;
TGCT	cis	rs2295359	0.637	rs12044149	chr1:67600686	G/T	cg12940439	chr1:67600707	NA	0.7	7.22	0.54	4.5e-11	Psoriasis;
TGCT	cis	rs1005277	0.505	rs7917943	chr10:38195811	T/A	cg25427524	chr10:38739819	LOC399744	0.37	7.61	0.56	5.93e-12	Extrinsic epigenetic age acceleration;
TGCT	cis	rs514406	0.584	rs11205997	chr1:53195271	G/C	cg25767906	chr1:53392781	SCP2	0.44	4.79	0.4	4.68e-6	Monocyte count;
TGCT	cis	rs10089	1.000	rs3805607	chr5:127477418	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	8.19	0.59	2.7e-13	Ileal carcinoids;
TGCT	cis	rs72949976	0.707	rs62186571	chr2:214038673	C/G	cg08319019	chr2:214017104	IKZF2	-0.75	-6.35	-0.5	3.78e-9	Lung cancer;Squamous cell lung carcinoma;
TGCT	cis	rs11190604	1.000	rs7905961	chr10:102297391	G/C	cg23241863	chr10:102295624	HIF1AN	0.72	5.33	0.43	4.47e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs6558530	0.666	rs7845723	chr8:1697086	T/G	cg09410841	chr8:1729607	CLN8	0.67	6.0	0.47	2.05e-8	Systolic blood pressure;
TGCT	cis	rs17445774	1.000	rs1509833	chr2:200865225	G/A	cg23649088	chr2:200775458	C2orf69	0.51	7.91	0.58	1.24e-12	LDL cholesterol to HDL cholesterol ratio;
TGCT	cis	rs4253772	0.745	rs78023664	chr22:46647844	G/A	cg09491104	chr22:46646882	C22orf40	-0.7	-4.59	-0.38	1.06e-5	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs2404602	0.692	rs72738889	chr15:76992063	G/A	cg22467129	chr15:76604101	ETFA	-0.45	-5.11	-0.42	1.2e-6	Blood metabolite levels;
TGCT	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg11890956	chr21:40555474	PSMG1	-0.71	-6.72	-0.52	5.82e-10	Cognitive function;
TGCT	cis	rs7809950	0.559	rs2248465	chr7:107303628	C/T	cg23024343	chr7:107201750	COG5	0.34	4.95	0.41	2.4e-6	Coronary artery disease;
TGCT	cis	rs7772486	0.754	rs2328707	chr6:146053498	G/A	cg05347473	chr6:146136440	FBXO30	-0.51	-4.66	-0.39	8.17e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.71	0.39	6.53e-6	Prudent dietary pattern;
TGCT	cis	rs854765	0.583	rs4553680	chr17:17857722	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	7.86	0.58	1.58e-12	Total body bone mineral density;
TGCT	cis	rs2658782	1.000	rs2019814	chr11:93168885	A/G	cg18152523	chr11:93063302	CCDC67	-0.64	-5.15	-0.42	9.9e-7	Pulmonary function decline;
TGCT	cis	rs4851266	1.000	rs4851266	chr2:100818479	C/T	cg07810366	chr2:100720526	AFF3	-0.39	-5.59	-0.45	1.37e-7	Educational attainment;
TGCT	cis	rs1971762	0.527	rs7952858	chr12:54039692	C/G	cg16917193	chr12:54089295	NA	1.04	11.29	0.71	8.98e-21	Height;
TGCT	cis	rs72634258	0.554	rs10462018	chr1:7879627	C/T	cg26816564	chr1:7831052	VAMP3	0.84	6.29	0.49	5e-9	Inflammatory bowel disease;
TGCT	cis	rs8062405	1.000	rs62036620	chr16:28833097	A/G	cg09754948	chr16:28834200	ATXN2L	0.61	4.54	0.38	1.34e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg06873352	chr17:61820015	STRADA	0.59	6.44	0.5	2.37e-9	Prudent dietary pattern;
TGCT	cis	rs2762353	0.603	rs9393670	chr6:25789061	A/G	cg12310025	chr6:25882481	NA	0.52	5.19	0.42	8.4e-7	Blood metabolite levels;
TGCT	trans	rs3780486	0.846	rs10813960	chr9:33180362	C/T	cg20290983	chr6:43655470	MRPS18A	1.08	11.36	0.71	6.12e-21	IgG glycosylation;
TGCT	cis	rs7647973	0.710	rs6797299	chr3:49609794	G/T	cg05785598	chr3:49045655	WDR6	0.41	4.66	0.39	8.03e-6	Menarche (age at onset);
TGCT	cis	rs7095607	0.606	rs6480313	chr10:69957928	C/T	cg18986048	chr10:69913749	MYPN	0.57	5.92	0.47	2.89e-8	Lung function (FVC);
TGCT	cis	rs2456568	0.548	rs7105031	chr11:93661207	C/T	cg26875233	chr11:93583750	C11orf90	-0.41	-4.94	-0.41	2.43e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs9916302	0.904	rs7221875	chr17:37543328	G/A	cg07936489	chr17:37558343	FBXL20	0.65	5.08	0.41	1.36e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs28595532	0.920	rs115986613	chr4:119752156	G/A	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs7027203	0.828	rs4744287	chr9:96585567	A/G	cg14396892	chr9:96623032	NA	0.29	6.25	0.49	6.02e-9	DNA methylation (variation);
TGCT	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.0	6.2	0.49	7.85e-9	Alzheimer's disease;
TGCT	cis	rs5769765	0.773	rs138861	chr22:50202276	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.33	4.84	0.4	3.85e-6	Schizophrenia;
TGCT	cis	rs4523957	0.614	rs7208638	chr17:2061334	G/C	cg16513277	chr17:2031491	SMG6	-0.2	-4.64	-0.38	8.83e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs7681440	0.647	rs11941682	chr4:90804316	T/G	cg20003494	chr4:90757398	SNCA	-0.53	-4.71	-0.39	6.56e-6	Dementia with Lewy bodies;
TGCT	cis	rs7666738	0.830	rs6818045	chr4:99049374	G/A	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs877282	0.583	rs11253441	chr10:828288	C/T	cg22713356	chr15:30763199	NA	-0.9	-6.84	-0.52	3.22e-10	Uric acid levels;
TGCT	cis	rs9357506	1.000	rs4714924	chr6:46304015	A/T	cg21115430	chr6:46460003	NA	-0.27	-5.07	-0.41	1.41e-6	Body mass index;
TGCT	cis	rs7772486	0.875	rs2474353	chr6:146323883	G/A	cg23711669	chr6:146136114	FBXO30	0.87	9.47	0.65	2.49e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs17152411	1.000	rs1807099	chr10:126593774	C/T	cg07906193	chr10:126599966	NA	0.42	5.28	0.43	5.6e-7	Height;
TGCT	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg24250549	chr1:154909240	PMVK	0.63	6.25	0.49	6.03e-9	Prostate cancer;
TGCT	cis	rs2268241	0.938	rs28653198	chr21:34782395	A/C	cg14850771	chr21:34775459	IFNGR2	0.61	5.23	0.43	6.88e-7	Obesity-related traits;
TGCT	cis	rs7085104	0.632	rs7097872	chr10:104606636	C/T	cg04362960	chr10:104952993	NT5C2	0.56	4.92	0.4	2.68e-6	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.08	0.48	1.37e-8	Bipolar disorder;
TGCT	cis	rs9611519	0.580	rs8138349	chr22:41412723	C/T	cg03806693	chr22:41940476	POLR3H	-0.64	-6.09	-0.48	1.29e-8	Neuroticism;
TGCT	cis	rs8028182	0.636	rs4886716	chr15:75856022	G/C	cg20655648	chr15:75932815	IMP3	0.59	4.49	0.37	1.62e-5	Sudden cardiac arrest;
TGCT	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg25036284	chr2:26402008	FAM59B	-0.55	-4.71	-0.39	6.45e-6	Gut microbiome composition (summer);
TGCT	cis	rs892961	1.000	rs2117924	chr17:75401310	C/T	cg05865280	chr17:75406074	SEPT9	0.28	6.57	0.51	1.22e-9	Airflow obstruction;
TGCT	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg13206674	chr6:150067644	NUP43	0.52	4.46	0.37	1.78e-5	Lung cancer;
TGCT	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs5769765	1.000	rs8138941	chr22:50290678	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.11	-12.1	-0.74	9.56e-23	Schizophrenia;
TGCT	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg20999797	chr1:1681921	NA	0.18	4.61	0.38	9.89e-6	Body mass index;
TGCT	cis	rs12142240	0.698	rs56284503	chr1:46847127	C/G	cg14993813	chr1:46806288	NSUN4	-0.59	-4.86	-0.4	3.45e-6	Menopause (age at onset);
TGCT	trans	rs10203711	0.933	rs907110	chr2:239566391	C/T	cg16021909	chr1:248021091	TRIM58	-0.66	-6.66	-0.51	7.94e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6540559	0.546	rs7551944	chr1:210029430	G/C	cg12034118	chr1:209979487	IRF6	0.65	4.54	0.38	1.31e-5	Cleft lip with or without cleft palate;
TGCT	cis	rs10751667	0.643	rs7396623	chr11:934104	G/A	cg06064525	chr11:970664	AP2A2	-0.35	-8.28	-0.6	1.65e-13	Alzheimer's disease (late onset);
TGCT	cis	rs78487399	0.808	rs74365854	chr2:43661482	T/A	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.74	4.69	0.39	7.08e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg06028808	chr11:68637592	NA	0.56	7.27	0.55	3.51e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.46	0.56	1.3e-11	Prudent dietary pattern;
TGCT	cis	rs17270561	0.779	rs12209218	chr6:25887776	C/A	cg17042849	chr6:26104293	HIST1H4C	-0.76	-5.36	-0.43	3.98e-7	Iron status biomarkers;
TGCT	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.64	7.0	0.53	1.43e-10	Blood metabolite levels;
TGCT	cis	rs910316	1.000	rs4322591	chr14:75600697	C/T	cg08847533	chr14:75593920	NEK9	0.96	10.86	0.7	1.05e-19	Height;
TGCT	cis	rs899997	1.000	rs9888691	chr15:79010046	T/C	cg04896959	chr15:78267971	NA	0.35	5.55	0.45	1.65e-7	Coronary artery disease or large artery stroke;
TGCT	cis	rs4478858	0.698	rs6655946	chr1:31805728	G/A	cg00250761	chr1:31883323	NA	-0.27	-4.9	-0.4	2.92e-6	Alcohol dependence;
TGCT	cis	rs6964587	0.655	rs6965864	chr7:91595596	A/G	cg17063962	chr7:91808500	NA	0.75	7.1	0.54	8.68e-11	Breast cancer;
TGCT	cis	rs916888	0.647	rs199449	chr17:44808902	G/A	cg15921436	chr17:44337874	NA	0.44	6.62	0.51	9.8e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2404602	0.735	rs11072598	chr15:76764788	T/C	cg22467129	chr15:76604101	ETFA	0.48	5.04	0.41	1.58e-6	Blood metabolite levels;
TGCT	cis	rs9911578	1.000	rs7223955	chr17:56917053	C/A	cg05425664	chr17:57184151	TRIM37	-0.62	-6.18	-0.49	8.33e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs9611565	0.500	rs2011053	chr22:42121278	G/A	cg03806693	chr22:41940476	POLR3H	0.96	9.91	0.66	2.06e-17	Vitiligo;
TGCT	cis	rs11696501	0.688	rs714595	chr20:44330591	G/A	cg11783356	chr20:44313418	WFDC10B	-0.33	-4.49	-0.37	1.6e-5	Brain structure;
TGCT	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg03404566	chr17:6899310	ALOX12	-0.41	-4.83	-0.4	4.01e-6	Tonsillectomy;
TGCT	cis	rs9952991	0.566	rs34846641	chr18:12875975	A/G	cg23544223	chr18:12777786	NA	-0.54	-4.81	-0.4	4.31e-6	Inflammatory skin disease;
TGCT	cis	rs2033711	0.936	rs3794968	chr19:58986799	G/C	cg12042659	chr19:58951599	ZNF132	0.52	4.53	0.38	1.39e-5	Uric acid clearance;
TGCT	trans	rs797680	0.856	rs4240966	chr1:93774812	C/A	cg27528825	chr2:159282178	CCDC148	-0.33	-6.67	-0.51	7.68e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs67478160	0.643	rs3742369	chr14:104251276	T/C	cg26031613	chr14:104095156	KLC1	-0.63	-6.42	-0.5	2.64e-9	Schizophrenia;
TGCT	cis	rs3733585	0.699	rs1079128	chr4:9951221	T/C	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.47	-0.56	1.25e-11	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg18252515	chr7:66147081	NA	-1.14	-6.81	-0.52	3.76e-10	Diabetic kidney disease;
TGCT	cis	rs9296092	0.560	rs7765263	chr6:33525559	A/G	cg13560919	chr6:33536144	NA	-0.23	-5.06	-0.41	1.49e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg25703541	chr22:24373054	LOC391322	-0.81	-8.47	-0.61	6.1e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs4148883	0.675	rs10015824	chr4:100074544	C/G	cg12011299	chr4:100065546	ADH4	0.38	5.71	0.46	7.92e-8	Alcohol dependence;
TGCT	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg22166914	chr1:53195759	ZYG11B	-0.42	-7.46	-0.56	1.29e-11	Monocyte count;
TGCT	cis	rs12291225	0.679	rs11369	chr11:14288096	A/G	cg19336497	chr11:14380999	RRAS2	-0.39	-6.01	-0.47	1.96e-8	Sense of smell;
TGCT	cis	rs453301	0.653	rs1562211	chr8:8902424	A/G	cg15556689	chr8:8085844	FLJ10661	-0.86	-8.12	-0.59	3.9e-13	Joint mobility (Beighton score);
TGCT	cis	rs17461925	0.964	rs10920559	chr1:203035693	A/G	cg21997465	chr1:203055662	MYOG	-0.27	-4.57	-0.38	1.18e-5	Atrial fibrillation;
TGCT	cis	rs6570726	0.791	rs11155433	chr6:145907831	A/G	cg05347473	chr6:146136440	FBXO30	-0.52	-4.85	-0.4	3.59e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg07424592	chr7:64974309	NA	1.33	8.82	0.62	8.94e-15	Diabetic kidney disease;
TGCT	cis	rs9362426	0.672	rs12663865	chr6:88103149	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.46	4.86	0.4	3.53e-6	Depressive episodes in bipolar disorder;
TGCT	trans	rs12339966	0.581	rs11789872	chr9:11332751	A/C	cg03488587	chr11:64876988	C11orf2	0.32	7.03	0.53	1.19e-10	Systolic blood pressure;
TGCT	cis	rs10875746	0.669	rs11168487	chr12:48640709	G/A	cg20731937	chr12:48336164	NA	0.59	4.49	0.37	1.61e-5	Longevity (90 years and older);
TGCT	cis	rs854765	0.583	rs6502622	chr17:17834691	A/G	cg09796270	chr17:17721594	SREBF1	0.24	4.77	0.39	5.16e-6	Total body bone mineral density;
TGCT	cis	rs7324557	0.683	rs9510868	chr13:24383694	A/G	cg16602799	chr13:25254742	ATP12A	0.57	4.45	0.37	1.93e-5	Visceral adipose tissue adjusted for BMI;
TGCT	cis	rs9733	0.519	rs11204717	chr1:150709129	T/A	cg04414720	chr1:150670196	GOLPH3L	0.37	4.87	0.4	3.27e-6	Tonsillectomy;
TGCT	cis	rs17490626	0.568	rs12260685	chr10:71215799	C/T	cg12610070	chr10:71211762	TSPAN15	-0.61	-6.95	-0.53	1.83e-10	Thrombosis;
TGCT	cis	rs7786808	0.649	rs6459879	chr7:158211792	C/G	cg01191920	chr7:158217561	PTPRN2	-0.37	-5.49	-0.44	2.16e-7	Obesity-related traits;
TGCT	cis	rs2075671	0.903	rs62483570	chr7:100300649	C/T	cg20848291	chr7:100343083	ZAN	-0.52	-4.56	-0.38	1.21e-5	Other erythrocyte phenotypes;
TGCT	cis	rs12210905	0.688	rs75968505	chr6:27476996	T/C	cg08851530	chr6:28072375	NA	1.34	6.29	0.49	5.02e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs7513165	0.932	rs12040580	chr1:204148168	T/C	cg12731349	chr1:204159619	KISS1	0.47	5.4	0.44	3.2e-7	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
TGCT	cis	rs9611565	0.649	rs5751144	chr22:42128097	A/G	cg03806693	chr22:41940476	POLR3H	-0.96	-9.91	-0.66	2.06e-17	Vitiligo;
TGCT	cis	rs17030434	0.784	rs17370965	chr4:154650948	C/T	cg14289246	chr4:154710475	SFRP2	-0.85	-7.14	-0.54	6.81e-11	Electrocardiographic conduction measures;
TGCT	cis	rs10197940	0.624	rs3771901	chr2:152432481	G/A	cg19508488	chr2:152266495	RIF1	0.7	6.5	0.5	1.77e-9	Lung cancer;
TGCT	cis	rs11190604	1.000	rs3763695	chr10:102269206	A/G	cg16342193	chr10:102329863	NA	-0.38	-4.89	-0.4	3.06e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs12477438	0.520	rs2171359	chr2:99795360	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	13.05	0.76	4.93e-25	Chronic sinus infection;
TGCT	cis	rs9486715	1.000	rs6905568	chr6:97066382	T/C	cg06623918	chr6:96969491	KIAA0776	-1.08	-13.52	-0.77	3.67e-26	Headache;
TGCT	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg24399712	chr22:39784796	NA	-1.06	-12.52	-0.75	9.19e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs881375	0.678	rs7031752	chr9:123663482	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	4.72	0.39	6.38e-6	Rheumatoid arthritis;
TGCT	cis	rs644799	0.526	rs506180	chr11:95623109	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.49	4.84	0.4	3.75e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs56399783	0.614	rs11772508	chr7:2771504	A/C	cg19731401	chr7:2775893	GNA12	-0.35	-5.12	-0.42	1.13e-6	Childhood ear infection;
TGCT	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg06675538	chr2:114033490	PAX8;LOC440839	-0.42	-4.65	-0.39	8.23e-6	Lymphocyte counts;
TGCT	cis	rs9473924	0.505	rs9296644	chr6:50828247	G/A	cg14470998	chr6:50812995	TFAP2B	1.35	8.39	0.6	9.05e-14	Body mass index;
TGCT	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg06238570	chr21:40685208	BRWD1	-0.79	-8.79	-0.62	1.01e-14	Cognitive function;
TGCT	cis	rs78487399	0.808	rs77791126	chr2:43744050	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.02	-0.41	1.75e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs796364	0.806	rs6435040	chr2:200861161	T/G	cg17644776	chr2:200775616	C2orf69	0.33	5.0	0.41	1.91e-6	Schizophrenia;
TGCT	cis	rs1887596	0.705	rs9553869	chr13:27162757	C/G	cg01312412	chr13:27282625	NA	0.3	5.28	0.43	5.64e-7	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs17376456	0.569	rs2924374	chr5:93151141	T/C	cg25358565	chr5:93447407	FAM172A	-0.75	-6.28	-0.49	5.26e-9	Diabetic retinopathy;
TGCT	cis	rs7647973	1.000	rs1982861	chr3:49577665	A/G	cg07636037	chr3:49044803	WDR6	0.65	5.35	0.43	4.01e-7	Menarche (age at onset);
TGCT	cis	rs6750047	0.515	rs13417487	chr2:38289162	G/T	cg07380506	chr2:38303506	CYP1B1	0.68	6.25	0.49	6.06e-9	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg11890956	chr21:40555474	PSMG1	1.11	12.43	0.74	1.56e-23	Cognitive function;
TGCT	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg24399712	chr22:39784796	NA	-1.03	-11.82	-0.73	4.77e-22	Intelligence (multi-trait analysis);
TGCT	cis	rs2549003	1.000	rs9282763	chr5:131822133	T/C	cg02551604	chr5:131831745	NA	-0.9	-12.1	-0.74	9.75e-23	Asthma (sex interaction);
TGCT	cis	rs7822232	0.908	rs56138570	chr8:145142206	G/A	cg06239191	chr8:145163136	KIAA1875	-0.88	-6.45	-0.5	2.26e-9	Blood metabolite levels;
TGCT	cis	rs3087591	0.960	rs12940303	chr17:29604862	C/T	cg24425628	chr17:29625626	OMG;NF1	0.47	7.39	0.55	1.94e-11	Hip circumference;
TGCT	cis	rs7412746	0.658	rs6656535	chr1:150940357	G/T	cg04414720	chr1:150670196	GOLPH3L	0.38	4.54	0.38	1.3e-5	Melanoma;
TGCT	cis	rs7809950	0.678	rs75617662	chr7:107030439	G/A	cg23024343	chr7:107201750	COG5	-0.46	-6.18	-0.49	8.6e-9	Coronary artery disease;
TGCT	trans	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg17470723	chr8:74884337	TCEB1	0.72	6.94	0.53	1.91e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7703051	0.520	rs13354746	chr5:74619132	C/T	cg07671805	chr5:74907694	NA	0.52	4.64	0.38	8.58e-6	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
TGCT	cis	rs185694	1.000	rs672233	chr13:30899601	G/A	cg07600127	chr13:30881527	KATNAL1	-0.81	-6.53	-0.51	1.53e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
TGCT	cis	rs2836950	0.527	rs2836948	chr21:40599677	T/C	cg11890956	chr21:40555474	PSMG1	-0.7	-6.87	-0.52	2.79e-10	Menarche (age at onset);
TGCT	cis	rs1008375	0.900	rs4698622	chr4:17589557	C/T	cg16339924	chr4:17578868	LAP3	0.84	7.12	0.54	7.64e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg06558623	chr16:89946397	TCF25	0.53	6.65	0.51	8.52e-10	Skin colour saturation;
TGCT	cis	rs6545883	0.540	rs11687956	chr2:61851342	T/C	cg15711740	chr2:61764176	XPO1	0.55	4.9	0.4	2.99e-6	Tuberculosis;
TGCT	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.73	-6.5	-0.5	1.8e-9	Tonsillectomy;
TGCT	cis	rs5769765	0.862	rs9616774	chr22:50290599	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.11	-12.1	-0.74	9.56e-23	Schizophrenia;
TGCT	cis	rs9653442	0.593	rs2309811	chr2:100862359	A/G	cg22139774	chr2:100720529	AFF3	-0.39	-6.48	-0.5	1.97e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs7647973	0.626	rs7649428	chr3:49868876	A/T	cg03034192	chr3:50606346	HEMK1;C3orf18	-0.35	-4.67	-0.39	7.84e-6	Menarche (age at onset);
TGCT	cis	rs77741769	0.529	rs1467283	chr12:121210220	G/C	cg02419362	chr12:121203948	SPPL3	0.19	4.5	0.37	1.54e-5	Mean corpuscular volume;
TGCT	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg03517284	chr6:25882590	NA	-0.65	-5.81	-0.46	4.87e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7246967	0.611	rs73030511	chr19:22826034	T/C	cg05241461	chr19:22816980	ZNF492	0.67	4.51	0.38	1.47e-5	Bronchopulmonary dysplasia;
TGCT	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg11062466	chr8:58055876	NA	0.38	4.62	0.38	9.5e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.51	-4.88	-0.4	3.14e-6	Bipolar disorder;
TGCT	cis	rs10782582	0.593	rs17585530	chr1:76134990	G/A	cg22875332	chr1:76189707	ACADM	-0.55	-6.27	-0.49	5.53e-9	Daytime sleep phenotypes;
TGCT	cis	rs2334880	0.836	rs9939458	chr16:71667131	T/G	cg06353428	chr16:71660113	MARVELD3	1.54	12.33	0.74	2.73e-23	Malaria;
TGCT	cis	rs526231	0.726	rs2288789	chr5:102600524	G/A	cg05225461	chr5:102596755	C5orf30	0.23	4.62	0.38	9.51e-6	Primary biliary cholangitis;
TGCT	cis	rs910316	1.000	rs4903281	chr14:75554361	G/C	cg08847533	chr14:75593920	NEK9	0.96	10.6	0.69	4.3e-19	Height;
TGCT	cis	rs1577917	1.000	rs9647603	chr6:86639341	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.05	-0.41	1.57e-6	Response to antipsychotic treatment;
TGCT	cis	rs2739330	1.000	rs2739330	chr22:24295286	T/C	cg02953382	chr22:24373134	LOC391322	-0.75	-7.83	-0.58	1.87e-12	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs595982	0.661	rs606400	chr19:49371498	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.37	-5.03	-0.41	1.65e-6	Red cell distribution width;
TGCT	cis	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg20362242	chr5:692897	TPPP	0.5	4.6	0.38	1.01e-5	Obesity-related traits;
TGCT	cis	rs10892173	0.765	rs1892903	chr11:117669619	A/G	cg21640587	chr11:117668038	DSCAML1	0.41	4.59	0.38	1.09e-5	Myopia;
TGCT	cis	rs2795502	0.882	rs2744095	chr10:43337949	A/T	cg20628663	chr10:43360327	NA	-0.44	-6.37	-0.5	3.4e-9	Blood protein levels;
TGCT	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg18876405	chr7:65276391	NA	-0.31	-4.81	-0.4	4.3e-6	Aortic root size;
TGCT	cis	rs9993613	0.841	rs1401139	chr4:73477532	T/C	cg15102770	chr4:73434591	ADAMTS3	-0.54	-4.96	-0.41	2.26e-6	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs6921919	0.609	rs9468365	chr6:28357966	A/T	cg18815343	chr6:28367644	ZSCAN12	-0.56	-5.32	-0.43	4.76e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2289681	0.525	rs12451394	chr17:42979592	G/A	cg15193461	chr17:42977049	CCDC103;EFTUD2	-0.67	-5.41	-0.44	3.13e-7	Cognitive function;
TGCT	cis	rs910316	1.000	rs10138183	chr14:75615227	T/C	cg23033748	chr14:75592666	NEK9	0.27	4.6	0.38	1.05e-5	Height;
TGCT	cis	rs860554	0.660	rs832167	chr1:201255782	T/C	cg01022117	chr1:201258280	PKP1	0.33	4.81	0.4	4.29e-6	Panic disorder;
TGCT	cis	rs7412746	0.634	rs2124952	chr1:150923774	T/A	cg04414720	chr1:150670196	GOLPH3L	0.37	4.46	0.37	1.81e-5	Melanoma;
TGCT	cis	rs12532878	0.652	rs62482223	chr7:100198878	C/A	cg19543017	chr7:100164136	AGFG2	-0.33	-4.78	-0.39	4.81e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs6589563	0.737	rs61905088	chr11:116619867	C/A	cg01124546	chr11:117515332	DSCAML1	-0.44	-4.73	-0.39	5.91e-6	Eosinophil counts;
TGCT	cis	rs2456568	0.900	rs2000960	chr11:93682348	C/T	cg17595323	chr11:93583763	C11orf90	-0.46	-6.01	-0.47	1.92e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs61990749	0.597	rs8016416	chr14:78213100	T/A	cg02301378	chr14:78227641	SNW1;C14orf178	0.6	4.45	0.37	1.88e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs9916302	0.706	rs12947506	chr17:37707592	A/G	cg07936489	chr17:37558343	FBXL20	-0.85	-6.18	-0.49	8.27e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs11030122	0.632	rs714380	chr11:4059653	A/T	cg18678763	chr11:4115507	RRM1	-0.48	-5.96	-0.47	2.47e-8	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs79387448	0.626	rs80256362	chr2:103025501	A/G	cg09003973	chr2:102972529	NA	1.3	8.79	0.62	1.02e-14	Gut microbiota (bacterial taxa);
TGCT	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg11905131	chr22:24372483	LOC391322	0.95	11.1	0.71	2.66e-20	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9611519	0.580	rs7286603	chr22:41440061	T/C	cg03806693	chr22:41940476	POLR3H	-0.59	-5.42	-0.44	2.97e-7	Neuroticism;
TGCT	cis	rs6882046	0.513	rs254780	chr5:88019747	G/C	cg24804195	chr5:87968844	LOC645323	-0.57	-5.57	-0.45	1.5e-7	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs5769765	1.000	rs764813	chr22:50286172	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.4	6.02	0.48	1.81e-8	Schizophrenia;
TGCT	cis	rs832540	0.656	rs832567	chr5:56152416	C/A	cg12311346	chr5:56204834	C5orf35	-0.49	-5.13	-0.42	1.08e-6	Coronary artery disease;
TGCT	cis	rs79387448	0.745	rs76746266	chr2:103124920	C/T	cg09003973	chr2:102972529	NA	0.87	5.8	0.46	5.22e-8	Gut microbiota (bacterial taxa);
TGCT	cis	rs9527	0.545	rs12784384	chr10:104957594	G/C	cg15744005	chr10:104629667	AS3MT	-0.41	-4.78	-0.39	4.88e-6	Arsenic metabolism;
TGCT	cis	rs595982	0.559	rs17206700	chr19:49361255	A/G	cg21252483	chr19:49399788	TULP2	-0.41	-6.26	-0.49	5.75e-9	Red cell distribution width;
TGCT	cis	rs1971762	0.583	rs3844370	chr12:54086137	G/C	cg16917193	chr12:54089295	NA	1.36	18.3	0.85	4.98e-37	Height;
TGCT	cis	rs10782582	0.593	rs17848068	chr1:76190216	G/A	cg10523679	chr1:76189770	ACADM	-0.65	-6.74	-0.52	5.35e-10	Daytime sleep phenotypes;
TGCT	trans	rs10504390	0.585	rs79812520	chr8:66507615	T/C	cg15922513	chr12:131561251	GPR133	-0.69	-6.97	-0.53	1.66e-10	IgG glycosylation;
TGCT	cis	rs7010267	0.935	rs11573829	chr8:119959623	T/C	cg17171407	chr8:119960777	TNFRSF11B	0.33	6.18	0.49	8.29e-9	Total body bone mineral density (age 45-60);
TGCT	cis	rs7044106	0.791	rs2416799	chr9:123480866	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	7.05	0.53	1.11e-10	Hip circumference adjusted for BMI;
TGCT	cis	rs6570726	0.818	rs9399555	chr6:145877554	T/C	cg23711669	chr6:146136114	FBXO30	0.84	8.77	0.62	1.14e-14	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs77669868	0.568	rs3825045	chr11:114073200	C/T	cg01914181	chr11:114070210	ZBTB16	0.31	4.65	0.39	8.38e-6	Monocyte percentage of white cells;
TGCT	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg24549020	chr5:56110836	MAP3K1	0.7	6.0	0.47	2.02e-8	Initial pursuit acceleration;
TGCT	cis	rs4730430	0.538	rs4455768	chr7:110134590	A/G	cg14239618	chr7:110281356	NA	-0.25	-4.81	-0.4	4.27e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs12142240	0.738	rs17361749	chr1:46806480	C/T	cg14993813	chr1:46806288	NSUN4	-0.58	-4.78	-0.39	4.78e-6	Menopause (age at onset);
TGCT	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg26354017	chr1:205819088	PM20D1	0.68	9.29	0.64	6.61e-16	Menarche (age at onset);
TGCT	cis	rs6964587	1.000	rs2097739	chr7:91711466	C/T	cg22709100	chr7:91322751	NA	0.28	4.56	0.38	1.19e-5	Breast cancer;
TGCT	cis	rs116095464	0.558	rs7714335	chr5:263513	T/C	cg22857025	chr5:266934	NA	-0.35	-6.87	-0.53	2.7e-10	Breast cancer;
TGCT	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg10802521	chr3:52805072	NEK4	-0.71	-8.79	-0.62	1.04e-14	Bipolar disorder;
TGCT	cis	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	-0.52	-4.81	-0.4	4.32e-6	Bipolar disorder;
TGCT	cis	rs2235642	0.787	rs2235646	chr16:1601287	A/G	cg08296037	chr16:1584118	IFT140;TMEM204	-0.32	-5.72	-0.46	7.62e-8	Coronary artery disease;
TGCT	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg04772025	chr11:68637568	NA	0.6	6.75	0.52	5.19e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs6570726	0.935	rs367612	chr6:145828987	A/G	cg23711669	chr6:146136114	FBXO30	0.69	6.22	0.49	6.89e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7937682	0.737	rs679032	chr11:111423286	G/T	cg09085632	chr11:111637200	PPP2R1B	-0.8	-8.33	-0.6	1.3e-13	Primary sclerosing cholangitis;
TGCT	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	9.44	0.65	2.89e-16	Platelet count;
TGCT	cis	rs986417	0.748	rs10145546	chr14:61100892	A/G	cg27398547	chr14:60952738	C14orf39	1.44	10.1	0.67	7.17e-18	Gut microbiota (bacterial taxa);
TGCT	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg17264618	chr3:40429014	ENTPD3	0.32	4.57	0.38	1.18e-5	Renal cell carcinoma;
TGCT	trans	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg27523141	chr10:43048294	ZNF37B	0.72	8.28	0.6	1.71e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2820315	1.000	rs2644119	chr1:201807776	C/T	cg12730843	chr1:201915899	LMOD1	-0.26	-4.73	-0.39	6.01e-6	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
TGCT	cis	rs4499344	0.556	rs438268	chr19:33109904	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.76	7.52	0.56	9.54e-12	Mean platelet volume;
TGCT	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.49	-5.89	-0.47	3.41e-8	Longevity;Endometriosis;
TGCT	cis	rs6684514	0.542	rs11264472	chr1:156292366	A/G	cg20302342	chr1:156215951	PAQR6	0.36	5.36	0.43	3.93e-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs12908161	0.959	rs17534709	chr15:85314397	G/C	cg17173187	chr15:85201210	NMB	0.58	6.44	0.5	2.43e-9	Schizophrenia;
TGCT	cis	rs2404602	0.583	rs11072580	chr15:76540231	G/A	cg22467129	chr15:76604101	ETFA	-0.65	-8.63	-0.61	2.44e-14	Blood metabolite levels;
TGCT	cis	rs4654899	0.865	rs61779073	chr1:21398740	C/A	cg01072550	chr1:21505969	NA	-0.46	-6.9	-0.53	2.33e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs16866061	0.515	rs3738951	chr2:225368321	A/G	cg12698349	chr2:225449008	CUL3	1.12	15.51	0.81	8.08e-31	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	cis	rs1107366	0.637	rs2044575	chr3:125976368	A/C	cg01346077	chr3:125931526	NA	0.29	4.84	0.4	3.8e-6	Metabolite levels;
TGCT	cis	rs1903068	0.853	rs12505096	chr4:56006102	C/A	cg01777861	chr4:56023843	NA	0.55	6.17	0.48	8.84e-9	Endometriosis;
TGCT	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg06873352	chr17:61820015	STRADA	0.56	6.22	0.49	6.93e-9	Prudent dietary pattern;
TGCT	cis	rs17539620	0.624	rs111484697	chr6:154838903	A/G	cg20019720	chr6:154832845	CNKSR3	0.57	4.9	0.4	2.89e-6	Lipoprotein (a) levels;
TGCT	cis	rs4722585	0.533	rs2237335	chr7:26200213	A/G	cg07876897	chr7:26191696	NFE2L3	0.39	5.25	0.43	6.49e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
TGCT	cis	rs68170813	0.559	rs77185844	chr7:106812916	A/C	cg02696742	chr7:106810147	HBP1	-0.7	-6.06	-0.48	1.52e-8	Coronary artery disease;
TGCT	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg11644478	chr21:40555479	PSMG1	0.98	10.36	0.68	1.68e-18	Cognitive function;
TGCT	cis	rs59698941	0.527	rs1032764	chr5:132185419	A/C	cg27099455	chr5:132201840	GDF9;UQCRQ	0.29	4.95	0.41	2.35e-6	Apolipoprotein A-IV levels;
TGCT	cis	rs6882076	1.000	rs4704727	chr5:156380067	T/G	cg12943317	chr5:156479607	HAVCR1	-0.3	-5.31	-0.43	4.79e-7	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
TGCT	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg11644478	chr21:40555479	PSMG1	0.99	10.5	0.69	7.73e-19	Cognitive function;
TGCT	cis	rs7666738	0.830	rs1967979	chr4:98966201	G/T	cg17366294	chr4:99064904	C4orf37	0.74	7.54	0.56	8.74e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10197940	0.624	rs17270233	chr2:152372420	A/G	cg06191203	chr2:152266755	RIF1	-0.76	-7.11	-0.54	8.05e-11	Lung cancer;
TGCT	cis	rs7267979	0.549	rs6138536	chr20:25182648	A/G	cg03522245	chr20:25566470	NINL	0.52	5.55	0.45	1.67e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2228479	0.850	rs11645916	chr16:89835234	G/A	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs11718455	0.960	rs11917885	chr3:44008013	A/G	cg08738300	chr3:44038990	NA	-0.85	-6.44	-0.5	2.36e-9	Coronary artery disease;
TGCT	cis	rs9549367	0.789	rs7994324	chr13:113906497	T/C	cg18105134	chr13:113819100	PROZ	-0.34	-5.58	-0.45	1.41e-7	Platelet distribution width;
TGCT	cis	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg07424592	chr7:64974309	NA	1.34	8.08	0.59	4.95e-13	Diabetic kidney disease;
TGCT	cis	rs595982	0.559	rs73061632	chr19:49361663	G/A	cg17863274	chr19:49399704	TULP2	-0.48	-6.89	-0.53	2.45e-10	Red cell distribution width;
TGCT	cis	rs79149102	0.579	rs8034149	chr15:75311842	G/C	cg09165964	chr15:75287851	SCAMP5	-1.06	-5.78	-0.46	5.75e-8	Lung cancer;
TGCT	cis	rs1018836	0.608	rs2142147	chr8:91468200	A/G	cg16814680	chr8:91681699	NA	-0.71	-7.27	-0.55	3.49e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7666738	0.753	rs34164013	chr4:98976333	A/G	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28595532	0.920	rs114751999	chr4:119759651	G/A	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs2982552	0.873	rs1856057	chr6:152067869	C/T	cg22157087	chr6:152012887	ESR1	-0.2	-4.65	-0.39	8.39e-6	Bone properties (heel);
TGCT	cis	rs4595586	0.545	rs7970307	chr12:39380760	A/C	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs986417	0.748	rs10142401	chr14:61039403	A/G	cg27398547	chr14:60952738	C14orf39	1.42	10.64	0.69	3.42e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs6903823	0.508	rs1150724	chr6:28250236	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.45	-4.68	-0.39	7.48e-6	Pulmonary function;
TGCT	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg13206674	chr6:150067644	NUP43	0.52	4.51	0.38	1.5e-5	Lung cancer;
TGCT	cis	rs11626933	0.885	rs6575125	chr14:90802463	C/T	cg14092571	chr14:90743983	NA	-0.28	-5.73	-0.46	7.34e-8	Gut microbiota (bacterial taxa);
TGCT	cis	rs861020	0.606	rs689210	chr1:210013723	A/C	cg05527609	chr1:210001259	C1orf107	0.89	8.36	0.6	1.08e-13	Orofacial clefts;
TGCT	cis	rs6964587	0.626	rs10234074	chr7:91520119	C/T	cg17063962	chr7:91808500	NA	-0.76	-7.15	-0.54	6.42e-11	Breast cancer;
TGCT	cis	rs910316	0.763	rs175057	chr14:75489632	C/T	cg08847533	chr14:75593920	NEK9	-0.83	-8.87	-0.62	6.72e-15	Height;
TGCT	cis	rs2204008	0.688	rs12824232	chr12:38175901	G/A	cg13010199	chr12:38710504	ALG10B	0.64	5.16	0.42	9.41e-7	Bladder cancer;
TGCT	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	6.13	0.48	1.08e-8	Bipolar disorder;
TGCT	cis	rs28595532	0.920	rs114611353	chr4:119736607	C/T	cg11846333	chr4:119757529	SEC24D	0.93	4.44	0.37	2e-5	Cannabis dependence symptom count;
TGCT	cis	rs2070488	0.766	rs4679050	chr3:38482007	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.78	7.96	0.58	9.56e-13	Electrocardiographic conduction measures;
TGCT	cis	rs595982	0.517	rs10404905	chr19:49406175	A/T	cg17863274	chr19:49399704	TULP2	0.28	4.47	0.37	1.76e-5	Red cell distribution width;
TGCT	cis	rs7615952	0.733	rs13314847	chr3:125644788	C/T	cg05084668	chr3:125655381	ALG1L	-0.75	-6.07	-0.48	1.41e-8	Blood pressure (smoking interaction);
TGCT	cis	rs1990950	0.654	rs10055004	chr5:156859525	T/C	cg25387487	chr5:157003181	ADAM19	0.29	4.53	0.38	1.37e-5	Lung function (FEV1/FVC);
TGCT	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg01416388	chr22:39784598	NA	-0.72	-7.15	-0.54	6.43e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs933688	0.938	rs10942634	chr5:90658392	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.92	8.52	0.61	4.52e-14	Smoking behavior;
TGCT	cis	rs17376456	0.877	rs13170509	chr5:93378564	T/C	cg21475434	chr5:93447410	FAM172A	0.6	4.62	0.38	9.48e-6	Diabetic retinopathy;
TGCT	cis	rs57994353	0.897	rs3812595	chr9:139369062	C/T	cg13741927	chr9:139327495	INPP5E	-0.25	-5.59	-0.45	1.38e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs78707713	0.560	rs55668536	chr10:71242655	A/G	cg12610070	chr10:71211762	TSPAN15	-0.62	-7.37	-0.55	2.12e-11	Venous thromboembolism;
TGCT	cis	rs9913156	0.707	rs72835625	chr17:4560274	G/A	cg19197139	chr17:4613644	ARRB2	0.86	7.9	0.58	1.32e-12	Lymphocyte counts;
TGCT	cis	rs1775715	0.737	rs2778672	chr10:32122419	T/C	cg14930904	chr10:32216787	ARHGAP12	0.52	5.07	0.41	1.38e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs6088590	0.561	rs6059932	chr20:33175466	C/T	cg08999081	chr20:33150536	PIGU	0.25	4.99	0.41	1.97e-6	Coronary artery disease;
TGCT	cis	rs7666738	0.800	rs10008654	chr4:98820498	C/A	cg18180107	chr4:99064573	C4orf37	0.55	5.25	0.43	6.31e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg23131131	chr22:24373011	LOC391322	-0.77	-8.41	-0.6	8.36e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs501916	0.796	rs75186419	chr15:48043934	G/A	cg16110827	chr15:48056943	SEMA6D	-0.17	-4.84	-0.4	3.74e-6	Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs6912958	0.781	rs2273129	chr6:88182439	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.54	-5.23	-0.43	7.03e-7	Monocyte percentage of white cells;
TGCT	cis	rs17122693	1.000	rs1494176	chr14:51083372	A/C	cg04730355	chr14:51134070	SAV1	1.19	8.84	0.62	8.09e-15	Cognitive performance;
TGCT	cis	rs36051895	0.623	rs72703608	chr9:5258127	A/G	cg02405213	chr9:5042618	JAK2	-0.69	-8.19	-0.59	2.68e-13	Pediatric autoimmune diseases;
TGCT	cis	rs7666738	0.822	rs11097599	chr4:98959562	T/A	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2302464	1.000	rs6844968	chr4:15727264	G/T	cg18497811	chr4:14860861	NA	-0.48	-4.47	-0.37	1.76e-5	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs4711350	0.765	rs756138	chr6:33755711	G/C	cg13859433	chr6:33739653	LEMD2	-0.33	-4.93	-0.4	2.6e-6	Schizophrenia;
TGCT	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg26338869	chr17:61819248	STRADA	0.58	5.15	0.42	9.97e-7	Prudent dietary pattern;
TGCT	cis	rs2204008	0.807	rs4123933	chr12:37973539	G/A	cg26384229	chr12:38710491	ALG10B	0.86	7.77	0.57	2.55e-12	Bladder cancer;
TGCT	cis	rs3749237	0.636	rs1568662	chr3:49521263	A/G	cg03060546	chr3:49711283	APEH	0.76	8.69	0.62	1.77e-14	Resting heart rate;
TGCT	cis	rs2235642	0.893	rs2143285	chr16:1593171	A/G	cg11375102	chr16:1583810	IFT140;TMEM204	-0.3	-5.19	-0.42	8.22e-7	Coronary artery disease;
TGCT	cis	rs4629710	0.592	rs3777476	chr6:131533821	A/C	cg12606694	chr6:131520996	AKAP7	0.39	4.62	0.38	9.58e-6	Multiple myeloma (IgH translocation);
TGCT	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg17554472	chr22:41940697	POLR3H	-0.47	-4.79	-0.4	4.68e-6	Vitiligo;
TGCT	cis	rs10791097	0.694	rs7940027	chr11:130745591	A/G	cg12179176	chr11:130786555	SNX19	0.84	10.15	0.67	5.61e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9549260	0.755	rs2721066	chr13:41156188	C/T	cg21288729	chr13:41239152	FOXO1	-0.98	-10.31	-0.68	2.2e-18	Red blood cell count;
TGCT	cis	rs912057	1.000	rs1294414	chr6:6740366	A/G	cg06612196	chr6:6737390	NA	0.39	4.99	0.41	2.02e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg10047753	chr17:41438598	NA	0.91	8.44	0.6	6.86e-14	Menopause (age at onset);
TGCT	cis	rs9308731	1.000	rs2241843	chr2:111879381	C/A	cg04202892	chr2:111875749	ACOXL	0.43	4.69	0.39	7.05e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs11252926	0.537	rs61836851	chr10:447231	T/C	cg20256804	chr10:444983	DIP2C	-0.21	-4.51	-0.38	1.5e-5	Psychosis in Alzheimer's disease;
TGCT	cis	rs13191362	0.935	rs13219926	chr6:163004213	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs9611565	0.592	rs4822040	chr22:41963553	C/G	cg06634786	chr22:41940651	POLR3H	-0.83	-7.84	-0.58	1.8e-12	Vitiligo;
TGCT	cis	rs7833790	1.000	rs7833384	chr8:82730915	T/C	cg27398817	chr8:82754497	SNX16	-0.84	-6.34	-0.49	3.89e-9	Diastolic blood pressure;
TGCT	cis	rs62244186	0.535	rs59726036	chr3:44850074	G/T	cg21672276	chr3:44754072	ZNF502	-0.52	-5.75	-0.46	6.58e-8	Depressive symptoms;
TGCT	cis	rs6540559	0.546	rs74991018	chr1:210033790	T/G	cg21951975	chr1:209979733	IRF6	0.69	5.18	0.42	8.74e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs58688157	0.960	rs1051390	chr11:613165	G/C	cg16486109	chr11:613632	IRF7	0.36	5.26	0.43	6.02e-7	Systemic lupus erythematosus;
TGCT	cis	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg25660036	chr4:7070649	GRPEL1	-0.63	-5.39	-0.44	3.41e-7	Monocyte percentage of white cells;
TGCT	cis	rs9926296	0.643	rs2159114	chr16:89831841	A/G	cg03388025	chr16:89894329	SPIRE2	0.31	4.61	0.38	9.86e-6	Vitiligo;
TGCT	cis	rs11098499	0.908	rs12504149	chr4:120318577	G/A	cg09307838	chr4:120376055	NA	0.65	6.17	0.48	8.93e-9	Corneal astigmatism;
TGCT	cis	rs7226408	0.842	rs56178761	chr18:34331755	G/A	cg06757138	chr18:34340585	FHOD3	0.29	4.95	0.41	2.4e-6	Obesity-related traits;
TGCT	cis	rs10114408	0.918	rs4460439	chr9:96650564	C/T	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs3820068	0.705	rs4646063	chr1:15829813	G/A	cg05660106	chr1:15850417	CASP9	1.15	12.8	0.75	1.94e-24	Systolic blood pressure;
TGCT	cis	rs28456	1	rs28456	chr11:61589481	A/G	cg19610905	chr11:61596333	FADS2	-1.05	-11.51	-0.72	2.6e-21	Bipolar disorder;
TGCT	cis	rs12477438	0.765	rs62154638	chr2:99639584	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-4.62	-0.38	9.47e-6	Chronic sinus infection;
TGCT	cis	rs1048466	0.744	rs11062945	chr12:540544	C/G	cg26458557	chr12:285704	IQSEC3	0.26	4.55	0.38	1.24e-5	Obesity (early onset extreme);
TGCT	cis	rs6964587	1.000	rs2299238	chr7:91654517	G/A	cg22709100	chr7:91322751	NA	0.27	4.48	0.37	1.68e-5	Breast cancer;
TGCT	cis	rs2456568	0.778	rs2456563	chr11:93678675	C/T	cg16099599	chr11:93583650	C11orf90	-0.37	-4.58	-0.38	1.13e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs1018836	0.632	rs6995399	chr8:91481629	T/C	cg16814680	chr8:91681699	NA	-0.77	-7.99	-0.58	7.8e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs11864453	0.647	rs10492814	chr16:72126514	G/A	cg14768367	chr16:72042858	DHODH	0.52	5.21	0.42	7.61e-7	Fibrinogen levels;
TGCT	cis	rs7678296	0.649	rs73128366	chr4:37241908	T/C	cg18431856	chr4:37245254	KIAA1239	0.69	4.52	0.38	1.45e-5	3-hydroxypropylmercapturic acid levels in smokers;
TGCT	cis	rs62244186	1.000	rs62244186	chr3:44739783	G/A	cg15687855	chr3:44754131	ZNF502	-0.49	-5.97	-0.47	2.36e-8	Depressive symptoms;
TGCT	cis	rs8064299	0.967	rs3744208	chr17:72767565	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.78	7.92	0.58	1.17e-12	Monocyte count;
TGCT	cis	rs7703051	0.513	rs6895057	chr5:74624234	G/A	cg00601450	chr5:74908170	NA	-0.43	-4.52	-0.38	1.41e-5	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
TGCT	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.92	7.41	0.55	1.73e-11	Platelet count;
TGCT	cis	rs61884328	0.733	rs61897852	chr11:47203155	G/A	cg13308137	chr11:47528955	CUGBP1	0.38	4.48	0.37	1.65e-5	Total body bone mineral density (age over 60);
TGCT	cis	rs72634258	0.503	rs34177663	chr1:7833228	A/G	cg26816564	chr1:7831052	VAMP3	0.95	6.88	0.53	2.56e-10	Inflammatory bowel disease;
TGCT	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.46	0.56	1.3e-11	Prudent dietary pattern;
TGCT	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg20007245	chr22:24372913	LOC391322	-0.71	-7.04	-0.53	1.16e-10	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7267979	1.000	rs2258201	chr20:25272490	G/C	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs858239	0.600	rs7787110	chr7:23138474	C/T	cg05602783	chr7:23145260	KLHL7	-0.66	-5.8	-0.46	5.24e-8	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs8180040	0.620	rs11720139	chr3:47036756	C/G	cg27129171	chr3:47204927	SETD2	-0.7	-8.27	-0.6	1.75e-13	Colorectal cancer;
TGCT	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg20887711	chr4:1340912	KIAA1530	0.92	8.12	0.59	3.93e-13	Longevity;
TGCT	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg08280861	chr8:58055591	NA	0.4	4.73	0.39	5.97e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg12270520	chr8:146023939	ZNF517	-0.6	-5.29	-0.43	5.35e-7	Age at first birth;
TGCT	cis	rs9796	0.689	rs6492983	chr15:41436049	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.53	-6.84	-0.52	3.18e-10	Menopause (age at onset);
TGCT	cis	rs2236918	0.710	rs1626057	chr1:242038136	G/C	cg04158730	chr1:242011433	EXO1	0.56	5.16	0.42	9.57e-7	Menopause (age at onset);
TGCT	cis	rs67478160	0.619	rs10083367	chr14:104314183	C/G	cg26031613	chr14:104095156	KLC1	0.69	6.98	0.53	1.59e-10	Schizophrenia;
TGCT	cis	rs8062405	0.540	rs193628	chr16:28582142	G/T	cg00931491	chr16:28608288	SULT1A2	0.3	4.44	0.37	1.94e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg23574427	chr4:122746245	BBS7;CCNA2	-0.34	-5.55	-0.45	1.69e-7	Type 2 diabetes;
TGCT	cis	rs6540559	0.611	rs17015226	chr1:209970096	C/G	cg21951975	chr1:209979733	IRF6	0.72	5.64	0.45	1.08e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs826838	0.935	rs11168761	chr12:38997211	C/A	cg13010199	chr12:38710504	ALG10B	0.82	7.07	0.54	1.01e-10	Heart rate;
TGCT	cis	rs6589563	0.737	rs11825181	chr11:116626258	G/A	cg01124546	chr11:117515332	DSCAML1	-0.44	-4.77	-0.39	5.18e-6	Eosinophil counts;
TGCT	cis	rs7216064	0.953	rs10445361	chr17:65962238	G/T	cg12091567	chr17:66097778	LOC651250	0.77	6.37	0.5	3.38e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs59197085	0.551	rs3807309	chr7:128472138	G/A	cg00260937	chr7:128520193	KCP	0.49	4.87	0.4	3.33e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
TGCT	cis	rs7666738	0.791	rs1896156	chr4:99020882	C/G	cg05340658	chr4:99064831	C4orf37	0.48	5.43	0.44	2.92e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs912057	0.632	rs1294432	chr6:6745027	C/T	cg06612196	chr6:6737390	NA	0.47	6.77	0.52	4.57e-10	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg25036284	chr2:26402008	FAM59B	-0.57	-4.99	-0.41	2e-6	Gut microbiome composition (summer);
TGCT	cis	rs7769051	1.000	rs6934161	chr6:133124077	C/T	cg07930552	chr6:133119739	C6orf192	-0.96	-5.41	-0.44	3.07e-7	Type 2 diabetes nephropathy;
TGCT	cis	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg18252515	chr7:66147081	NA	1.25	7.75	0.57	2.92e-12	Diabetic kidney disease;
TGCT	cis	rs6582630	0.679	rs10785514	chr12:38573689	T/C	cg26384229	chr12:38710491	ALG10B	0.55	5.04	0.41	1.58e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs763014	0.898	rs8050792	chr16:656033	T/C	cg09263875	chr16:632152	PIGQ	0.31	6.76	0.52	4.93e-10	Height;
TGCT	cis	rs36051895	0.632	rs10118930	chr9:5148278	C/T	cg02405213	chr9:5042618	JAK2	-0.72	-9.74	-0.66	5.3e-17	Pediatric autoimmune diseases;
TGCT	cis	rs1008375	0.797	rs6843530	chr4:17593605	G/T	cg18681998	chr4:17616180	MED28	1.0	10.01	0.67	1.2e-17	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1371867	0.555	rs2861348	chr8:101285074	A/G	cg06002616	chr8:101225028	SPAG1	-0.53	-6.42	-0.5	2.67e-9	Atrioventricular conduction;
TGCT	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg03388025	chr16:89894329	SPIRE2	0.53	9.63	0.65	9.95e-17	Vitiligo;
TGCT	cis	rs8031584	0.707	rs4556757	chr15:31188179	C/T	cg08109568	chr15:31115862	NA	-0.35	-4.79	-0.4	4.66e-6	Huntington's disease progression;
TGCT	cis	rs6977660	0.714	rs17141884	chr7:19790280	A/G	cg05791153	chr7:19748676	TWISTNB	-0.84	-5.11	-0.42	1.17e-6	Thyroid stimulating hormone;
TGCT	cis	rs7655441	1.000	rs10000339	chr4:80878580	C/T	cg02241357	chr4:80885279	ANTXR2	-0.23	-4.46	-0.37	1.81e-5	Neutrophil percentage of white cells;
TGCT	cis	rs7666738	0.822	rs13110418	chr4:99046963	G/A	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg01341218	chr17:43662625	NA	1.11	9.15	0.63	1.43e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	trans	rs35851103	0.627	rs6601644	chr8:11847078	G/A	cg06636001	chr8:8085503	FLJ10661	0.78	7.37	0.55	2.11e-11	Neuroticism;
TGCT	cis	rs34526934	0.566	rs34028621	chr2:177042779	C/T	cg14324370	chr2:177042789	NA	-0.91	-8.69	-0.62	1.8e-14	Obstructive sleep apnea trait (apnea hypopnea index);
TGCT	cis	rs6912958	0.559	rs173333	chr6:88047754	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.47	6.29	0.49	5.04e-9	Monocyte percentage of white cells;
TGCT	cis	rs4951018	0.853	rs1573104	chr1:205636907	A/C	cg07167872	chr1:205819463	PM20D1	-0.37	-4.47	-0.37	1.74e-5	Prostate-specific antigen levels;
TGCT	cis	rs78707713	0.511	rs28697194	chr10:71215483	T/C	cg12610070	chr10:71211762	TSPAN15	-0.62	-7.12	-0.54	7.54e-11	Venous thromboembolism;
TGCT	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.06	-9.57	-0.65	1.41e-16	Platelet count;
TGCT	cis	rs7523273	0.606	rs859706	chr1:207962270	G/A	cg22525895	chr1:207977042	MIR29B2	-0.53	-8.99	-0.63	3.49e-15	Schizophrenia;
TGCT	cis	rs9341808	0.667	rs2490244	chr6:80891112	A/T	cg08355045	chr6:80787529	NA	0.31	5.1	0.42	1.26e-6	Sitting height ratio;
TGCT	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg02353165	chr6:42928485	GNMT	-0.97	-9.95	-0.67	1.66e-17	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs9894429	1.000	rs9894429	chr17:79596811	C/T	cg21028142	chr17:79581711	NPLOC4	0.29	6.86	0.52	2.94e-10	Eye color traits;
TGCT	cis	rs9868809	0.772	rs9821797	chr3:48718253	T/A	cg00383909	chr3:49044727	WDR6	0.96	5.85	0.47	4.04e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs9611565	0.506	rs2024566	chr22:41697338	A/G	cg13695892	chr22:41940480	POLR3H	-0.67	-6.2	-0.49	7.58e-9	Vitiligo;
TGCT	cis	rs35306767	0.761	rs11253560	chr10:1047226	T/G	cg20503657	chr10:835505	NA	0.61	6.71	0.52	6.11e-10	Eosinophil percentage of granulocytes;
TGCT	cis	rs763014	0.931	rs2071982	chr16:630405	T/G	cg00908189	chr16:619842	PIGQ	0.87	10.5	0.69	7.53e-19	Height;
TGCT	cis	rs11711311	0.955	rs9830102	chr3:113408302	C/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.8	-7.16	-0.54	6.37e-11	IgG glycosylation;
TGCT	cis	rs1008375	0.900	rs13101742	chr4:17701297	G/A	cg10189774	chr4:17578691	LAP3	-0.58	-4.96	-0.41	2.29e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1008375	0.900	rs4698625	chr4:17599500	G/T	cg18681998	chr4:17616180	MED28	0.87	7.67	0.57	4.29e-12	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs250677	0.687	rs250667	chr5:148455134	A/G	cg18129178	chr5:148520854	ABLIM3	0.47	6.49	0.5	1.87e-9	Breast cancer;
TGCT	cis	rs926938	0.583	rs12401670	chr1:115244337	C/T	cg12756093	chr1:115239321	AMPD1	-0.42	-5.34	-0.43	4.33e-7	Autism;
TGCT	cis	rs1008375	0.966	rs7658240	chr4:17588950	A/G	cg16339924	chr4:17578868	LAP3	-0.82	-7.21	-0.54	4.86e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9486719	0.948	rs11152952	chr6:96894303	A/G	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.86	-0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs7246657	0.722	rs8103647	chr19:38100452	C/A	cg18154014	chr19:37997991	ZNF793	0.69	4.67	0.39	7.71e-6	Coronary artery calcification;
TGCT	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg06238570	chr21:40685208	BRWD1	0.59	5.29	0.43	5.27e-7	Cognitive function;
TGCT	cis	rs9814567	1.000	rs28409322	chr3:134252385	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.96	9.11	0.63	1.79e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs2073300	1.000	rs59283536	chr20:23457575	A/T	cg09953122	chr20:23471693	CST8	-0.59	-4.71	-0.39	6.5e-6	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs11696501	0.739	rs6073846	chr20:44296323	G/T	cg11783356	chr20:44313418	WFDC10B	0.33	4.7	0.39	6.88e-6	Brain structure;
TGCT	trans	rs1814175	0.645	rs866427	chr11:49923853	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.51	-0.69	7.2e-19	Height;
TGCT	cis	rs11098499	0.909	rs71614422	chr4:120359340	G/A	cg09307838	chr4:120376055	NA	0.68	6.53	0.51	1.54e-9	Corneal astigmatism;
TGCT	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg03709012	chr19:19516395	GATAD2A	0.67	5.75	0.46	6.45e-8	Tonsillectomy;
TGCT	cis	rs2455799	0.586	rs1900613	chr3:15903638	G/A	cg12172478	chr3:16357591	RFTN1	-0.36	-5.3	-0.43	5.07e-7	Mean platelet volume;
TGCT	cis	rs806795	0.605	rs6935954	chr6:26255451	A/G	cg00631329	chr6:26305371	NA	-0.33	-5.13	-0.42	1.08e-6	Mosquito bite size;
TGCT	cis	rs2982552	0.844	rs3020343	chr6:152054363	C/T	cg22157087	chr6:152012887	ESR1	0.21	5.09	0.42	1.27e-6	Bone properties (heel);
TGCT	cis	rs7010267	0.773	rs10101385	chr8:119923850	A/G	cg17171407	chr8:119960777	TNFRSF11B	-0.28	-4.94	-0.41	2.46e-6	Total body bone mineral density (age 45-60);
TGCT	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.55	-6.35	-0.5	3.74e-9	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2239785	0.958	rs136162	chr22:36657474	A/G	cg15716373	chr22:36655542	APOL1	-0.44	-5.07	-0.41	1.4e-6	Glomerulosclerosis;
TGCT	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	6.23	0.49	6.56e-9	Bipolar disorder;
TGCT	cis	rs11690462	0.926	rs12615704	chr2:26551903	G/C	cg04726446	chr2:26624865	C2orf39	0.43	4.61	0.38	1e-5	Coronary artery disease;
TGCT	cis	rs3617	0.573	rs62253583	chr3:52928334	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	0.49	4.67	0.39	7.65e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6835098	0.924	rs7672108	chr4:174165126	A/G	cg08422745	chr4:174089978	GALNT7	0.85	9.14	0.63	1.49e-15	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs9911578	0.967	rs6503890	chr17:57064167	A/G	cg12560992	chr17:57184187	TRIM37	0.77	9.3	0.64	6.39e-16	Intelligence (multi-trait analysis);
TGCT	trans	rs1908814	0.516	rs10113145	chr8:11793295	A/G	cg15556689	chr8:8085844	FLJ10661	0.75	7.26	0.55	3.66e-11	Neuroticism;
TGCT	cis	rs7666738	0.830	rs7672720	chr4:98938760	A/T	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9388451	0.505	rs9372828	chr6:126175185	A/T	cg05901451	chr6:126070800	HEY2	-0.7	-7.23	-0.54	4.3e-11	Brugada syndrome;
TGCT	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg16325326	chr1:53192061	ZYG11B	-0.71	-8.82	-0.62	8.9e-15	Monocyte count;
TGCT	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.95	7.54	0.56	8.47e-12	Platelet count;
TGCT	cis	rs3733585	0.699	rs1079128	chr4:9951221	T/C	cg00071950	chr4:10020882	SLC2A9	-0.55	-6.43	-0.5	2.49e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs12712073	0.837	rs11692867	chr2:100759477	G/A	cg07810366	chr2:100720526	AFF3	-0.36	-5.22	-0.42	7.2e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs13122054	chr4:98972974	G/A	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs17331151	0.541	rs11709430	chr3:52862055	G/A	cg15956490	chr3:53032818	SFMBT1	0.47	6.14	0.48	1.03e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs9810089	0.934	rs696520	chr3:136056861	T/C	cg12473912	chr3:136751656	NA	0.35	4.9	0.4	2.92e-6	Gestational age at birth (child effect);
TGCT	cis	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg22857025	chr5:266934	NA	-0.32	-6.53	-0.51	1.5e-9	Breast cancer;
TGCT	cis	rs739496	1.000	rs739496	chr12:111887659	A/G	cg10833066	chr12:111807467	FAM109A	0.38	5.61	0.45	1.24e-7	Platelet count;
TGCT	cis	rs9381040	0.610	rs742495	chr6:41018233	A/G	cg03526776	chr6:41159608	TREML2	0.26	5.14	0.42	1.05e-6	Alzheimer's disease (late onset);
TGCT	cis	rs8072100	0.688	rs8079142	chr17:45442049	G/A	cg08085267	chr17:45401833	C17orf57	-0.51	-5.61	-0.45	1.26e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs8077577	0.945	rs11656035	chr17:18086025	T/C	cg09161412	chr17:18057145	MYO15A	-0.64	-5.2	-0.42	7.92e-7	Obesity-related traits;
TGCT	cis	rs903263	0.965	rs6695851	chr1:84654139	T/A	cg09664975	chr1:84543551	PRKACB	0.47	4.48	0.37	1.65e-5	Breast cancer (male);
TGCT	cis	rs295140	1.000	rs3739121	chr2:201171014	G/C	cg04283868	chr2:201171347	SPATS2L	0.63	6.43	0.5	2.46e-9	QT interval;
TGCT	cis	rs936229	0.813	rs1350193	chr15:75084281	G/C	cg10253484	chr15:75165896	SCAMP2	-0.65	-5.12	-0.42	1.15e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
TGCT	cis	rs9311474	0.713	rs181274	chr3:52233861	T/A	cg10802521	chr3:52805072	NEK4	-0.56	-6.01	-0.47	1.92e-8	Electroencephalogram traits;
TGCT	cis	rs6088580	0.660	rs6087592	chr20:33114503	A/G	cg06115741	chr20:33292138	TP53INP2	0.54	4.6	0.38	1.03e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs394563	0.591	rs237012	chr6:149729198	T/C	cg16235748	chr6:149772707	ZC3H12D	-0.44	-4.92	-0.4	2.74e-6	Dupuytren's disease;
TGCT	cis	rs2856321	1.000	rs11054423	chr12:11859731	A/G	cg26373351	chr12:12031304	ETV6	0.21	4.43	0.37	2.01e-5	Height;
TGCT	cis	rs9296092	0.538	rs62407567	chr6:33537213	A/G	cg13560919	chr6:33536144	NA	-0.23	-4.81	-0.4	4.34e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg00684032	chr4:1343700	KIAA1530	0.22	4.82	0.4	4.11e-6	Obesity-related traits;
TGCT	cis	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg16624210	chr5:671434	TPPP	0.45	4.92	0.4	2.71e-6	Obesity-related traits;
TGCT	cis	rs7089973	0.604	rs2420066	chr10:116583897	A/G	cg03647239	chr10:116582469	FAM160B1	0.58	5.63	0.45	1.16e-7	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	trans	rs3790455	0.610	rs1185700	chr1:156450719	G/A	cg16443977	chr5:115884994	SEMA6A	0.39	6.66	0.51	8.1e-10	Migraine;
TGCT	cis	rs3796352	0.892	rs3821872	chr3:53080555	C/G	cg27565382	chr3:53032988	SFMBT1	-0.41	-4.63	-0.38	9.12e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs4906332	1.000	rs17680085	chr14:103953154	T/C	cg26031613	chr14:104095156	KLC1	-0.51	-4.51	-0.38	1.48e-5	Coronary artery disease;
TGCT	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg13695892	chr22:41940480	POLR3H	-0.91	-9.07	-0.63	2.18e-15	Vitiligo;
TGCT	cis	rs7553035	1.000	rs2166104	chr1:211690818	A/T	cg16589830	chr1:212284214	NA	0.51	4.68	0.39	7.31e-6	Retinopathy in non-diabetics;
TGCT	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.15	0.82	2.71e-32	Prudent dietary pattern;
TGCT	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.5	-4.67	-0.39	7.61e-6	Prudent dietary pattern;
TGCT	cis	rs7772486	0.790	rs2265918	chr6:146219164	A/G	cg05347473	chr6:146136440	FBXO30	0.52	5.0	0.41	1.89e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4654899	1.000	rs4654905	chr1:21509558	A/G	cg01072550	chr1:21505969	NA	-0.5	-8.08	-0.59	4.94e-13	Superior frontal gyrus grey matter volume;
TGCT	cis	rs7192750	0.527	rs30433	chr16:72145404	T/C	cg06353428	chr16:71660113	MARVELD3	1.02	5.08	0.42	1.35e-6	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg25036284	chr2:26402008	FAM59B	-0.57	-4.97	-0.41	2.15e-6	Gut microbiome composition (summer);
TGCT	cis	rs6993813	0.653	rs7017881	chr8:120047857	C/T	cg17171407	chr8:119960777	TNFRSF11B	-0.25	-4.5	-0.37	1.53e-5	Bone mineral density (hip);
TGCT	cis	rs7943203	0.525	rs665293	chr11:108142617	G/A	cg04873221	chr11:107992290	ACAT1	-0.61	-4.96	-0.41	2.3e-6	Red blood cell count;Mean corpuscular volume;
TGCT	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg12963246	chr6:28129442	ZNF389	0.52	5.01	0.41	1.85e-6	Depression;
TGCT	cis	rs17473412	0.963	rs79413938	chr5:122686099	T/C	cg15125798	chr5:122621645	NA	-0.55	-5.09	-0.42	1.28e-6	Total body bone mineral density;
TGCT	cis	rs7714584	1.000	rs11167515	chr5:150239471	G/T	cg22134413	chr5:150180641	NA	1.11	8.03	0.58	6.39e-13	Crohn's disease;
TGCT	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg03188948	chr7:1209495	NA	0.51	5.31	0.43	4.84e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7843479	1.000	rs727694	chr8:21849962	T/C	cg17168535	chr8:21777572	XPO7	0.64	5.78	0.46	5.66e-8	Mean corpuscular volume;
TGCT	cis	rs3087591	1.000	rs984125	chr17:29547254	A/G	cg24425628	chr17:29625626	OMG;NF1	0.46	7.32	0.55	2.77e-11	Hip circumference;
TGCT	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg06618935	chr21:46677482	NA	-0.37	-5.56	-0.45	1.58e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7674212	0.581	rs11946020	chr4:103944742	T/C	cg16532752	chr4:104119610	CENPE	-0.59	-5.19	-0.42	8.28e-7	Type 2 diabetes;
TGCT	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.7	0.52	6.47e-10	Bipolar disorder;
TGCT	cis	rs2288884	1.000	rs2288884	chr19:52532271	C/T	cg13540795	chr19:52551618	ZNF432	-0.58	-5.03	-0.41	1.67e-6	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	trans	rs17685	0.712	rs7794454	chr7:75776010	A/G	cg19862616	chr7:65841803	NCRNA00174	-0.52	-9.02	-0.63	2.88e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs7017914	0.870	rs2732096	chr8:71919980	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.55	-5.1	-0.42	1.24e-6	Bone mineral density;
TGCT	trans	rs2727020	0.734	rs1164663	chr11:49294723	A/T	cg11707556	chr5:10655725	ANKRD33B	0.38	6.8	0.52	3.89e-10	Coronary artery disease;
TGCT	cis	rs6831352	0.918	rs3919370	chr4:100064326	A/T	cg12011299	chr4:100065546	ADH4	-0.42	-4.98	-0.41	2.06e-6	Alcohol dependence;
TGCT	cis	rs2637266	0.967	rs12246436	chr10:78352914	C/T	cg18941641	chr10:78392320	NA	0.42	5.2	0.42	8.09e-7	Pulmonary function;
TGCT	cis	rs6495367	0.803	rs2870111	chr15:79403585	C/T	cg17916960	chr15:79447300	NA	0.38	5.75	0.46	6.65e-8	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg05896524	chr21:47604654	C21orf56	-0.43	-4.76	-0.39	5.21e-6	Testicular germ cell tumor;
TGCT	cis	rs2594989	0.837	rs2454497	chr3:11501597	T/C	cg00170343	chr3:11313890	ATG7	0.69	5.12	0.42	1.16e-6	Circulating chemerin levels;
TGCT	cis	rs7666738	0.680	rs34267968	chr4:99002574	A/T	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs62244186	0.608	rs2888390	chr3:44511405	G/A	cg04389838	chr3:44770851	ZNF501	-0.38	-4.94	-0.41	2.5e-6	Depressive symptoms;
TGCT	cis	rs617219	0.574	rs3930426	chr5:78597535	C/T	cg23514016	chr5:78407564	BHMT	-0.3	-4.51	-0.38	1.49e-5	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs3734905	1.000	rs78099962	chr6:169934984	T/C	cg20469989	chr6:170102314	C6orf120;WDR27	-0.87	-4.66	-0.39	8.1e-6	HIV-1 control;
TGCT	cis	rs7572733	0.534	rs58374969	chr2:198764363	C/T	cg00792783	chr2:198669748	PLCL1	0.59	5.32	0.43	4.73e-7	Dermatomyositis;
TGCT	cis	rs2721195	0.845	rs3816732	chr8:145724275	T/C	cg15857475	chr8:145742913	RECQL4;LRRC14	0.86	8.98	0.63	3.68e-15	Age at first birth;
TGCT	cis	rs67073037	0.955	rs4666151	chr2:29177344	C/A	cg09522027	chr2:28974177	PPP1CB	0.57	4.49	0.37	1.59e-5	Breast cancer;Breast cancer (estrogen-receptor negative);
TGCT	cis	rs7647973	0.516	rs12490393	chr3:49196132	C/T	cg02487422	chr3:49467188	NICN1	0.5	4.75	0.39	5.41e-6	Menarche (age at onset);
TGCT	cis	rs8072100	0.790	rs11656856	chr17:45714671	C/T	cg10024583	chr17:45772800	TBKBP1	-0.45	-4.61	-0.38	9.75e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	trans	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg27523141	chr10:43048294	ZNF37B	0.72	8.34	0.6	1.21e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs208520	0.954	rs1468153	chr6:67009054	A/C	cg07460842	chr6:66804631	NA	0.69	6.06	0.48	1.51e-8	Exhaled nitric oxide output;
TGCT	cis	rs9368481	0.729	rs9379948	chr6:26944783	T/G	cg02458000	chr6:26745757	NA	0.5	4.6	0.38	1.04e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9682041	0.696	rs9872796	chr3:170099393	T/G	cg11886554	chr3:170076028	SKIL	0.83	6.42	0.5	2.66e-9	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs17376456	1.000	rs58734583	chr5:93532155	C/T	cg21475434	chr5:93447410	FAM172A	0.61	4.51	0.38	1.47e-5	Diabetic retinopathy;
TGCT	cis	rs9611565	0.694	rs202641	chr22:41833116	C/T	cg06481639	chr22:41940642	POLR3H	0.69	5.92	0.47	2.95e-8	Vitiligo;
TGCT	cis	rs7666738	0.791	rs1405766	chr4:98965389	T/C	cg18180107	chr4:99064573	C4orf37	0.57	5.18	0.42	8.63e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6484504	0.532	rs11031332	chr11:31278962	T/C	cg26647111	chr11:31128758	NA	-0.35	-4.86	-0.4	3.44e-6	Red blood cell count;
TGCT	cis	rs1008375	0.966	rs11947836	chr4:17697187	A/G	cg10189774	chr4:17578691	LAP3	-0.56	-4.65	-0.38	8.54e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg18402987	chr7:1209562	NA	0.78	6.64	0.51	8.96e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs17376456	0.825	rs17314762	chr5:93231200	C/T	cg21475434	chr5:93447410	FAM172A	0.7	4.86	0.4	3.51e-6	Diabetic retinopathy;
TGCT	cis	rs77741769	0.571	rs3809313	chr12:121329967	T/C	cg02419362	chr12:121203948	SPPL3	0.19	4.5	0.37	1.56e-5	Mean corpuscular volume;
TGCT	cis	rs3816788	0.792	rs10097055	chr8:21872328	A/G	cg17168535	chr8:21777572	XPO7	0.77	7.65	0.57	4.88e-12	Lung cancer in ever smokers;
TGCT	cis	rs9527	0.590	rs7897663	chr10:104905604	T/C	cg15744005	chr10:104629667	AS3MT	-0.41	-4.73	-0.39	6.06e-6	Arsenic metabolism;
TGCT	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.12	14.83	0.8	3.07e-29	Height;
TGCT	cis	rs6752107	0.840	rs2119505	chr2:234154651	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.21	4.98	0.41	2.06e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs67460515	0.892	rs2100238	chr3:161058055	T/A	cg03342759	chr3:160939853	NMD3	-0.52	-5.68	-0.45	9.16e-8	Parkinson's disease;
TGCT	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.2	0.42	8.14e-7	Menopause (age at onset);
TGCT	cis	rs11785400	0.793	rs3735993	chr8:143741170	G/A	cg10596483	chr8:143751796	JRK	0.55	5.49	0.44	2.13e-7	Schizophrenia;
TGCT	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg26338869	chr17:61819248	STRADA	-0.55	-5.08	-0.42	1.34e-6	Prudent dietary pattern;
TGCT	cis	rs1278769	0.786	rs7998551	chr13:113540649	G/T	cg11520003	chr13:113540631	ATP11A	-0.31	-4.65	-0.39	8.41e-6	Interstitial lung disease;
TGCT	cis	rs8020441	0.541	rs59857560	chr14:51158851	G/A	cg04730355	chr14:51134070	SAV1	1.22	9.45	0.65	2.75e-16	Cognitive performance;
TGCT	cis	rs4689388	0.856	rs4308430	chr4:6294095	A/G	cg14416269	chr4:6271139	WFS1	0.37	4.9	0.4	2.95e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs12681287	0.547	rs60982560	chr8:87515046	C/T	cg27223183	chr8:87520930	FAM82B	-0.96	-7.08	-0.54	9.31e-11	Caudate activity during reward;
TGCT	cis	rs11098499	0.954	rs13145352	chr4:120409963	C/T	cg09307838	chr4:120376055	NA	-0.7	-6.58	-0.51	1.21e-9	Corneal astigmatism;
TGCT	cis	rs739496	0.542	rs12423926	chr12:111781055	C/T	cg10833066	chr12:111807467	FAM109A	-0.45	-7.35	-0.55	2.3e-11	Platelet count;
TGCT	cis	rs2249625	0.545	rs2496488	chr6:72875985	A/T	cg08500200	chr6:72892038	RIMS1	-0.42	-4.54	-0.38	1.33e-5	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
TGCT	cis	rs7772486	0.790	rs1854900	chr6:146331382	G/A	cg23711669	chr6:146136114	FBXO30	0.87	9.48	0.65	2.27e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1997103	0.954	rs6593235	chr7:55410986	A/G	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs7582180	0.764	rs12622318	chr2:100927375	T/C	cg14675211	chr2:100938903	LONRF2	0.52	4.98	0.41	2.1e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs13256369	1.000	rs13267501	chr8:8574058	G/A	cg18904891	chr8:8559673	CLDN23	0.64	5.89	0.47	3.36e-8	Obesity-related traits;
TGCT	cis	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg15556689	chr8:8085844	FLJ10661	0.72	6.52	0.51	1.63e-9	Mood instability;
TGCT	cis	rs9611565	0.921	rs2235846	chr22:41741042	G/C	cg17554472	chr22:41940697	POLR3H	-0.4	-4.58	-0.38	1.11e-5	Vitiligo;
TGCT	cis	rs60871478	0.636	rs12534606	chr7:895928	A/G	cg00475322	chr7:917719	C7orf20	0.5	4.87	0.4	3.37e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs9341808	0.591	rs7741013	chr6:80916330	G/A	cg08355045	chr6:80787529	NA	0.3	5.05	0.41	1.51e-6	Sitting height ratio;
TGCT	cis	rs707040	0.921	rs7566094	chr2:155228511	T/C	cg18104148	chr2:154337490	NA	0.19	4.63	0.38	9.05e-6	Sudden cardiac arrest;
TGCT	cis	rs72781680	0.715	rs72796332	chr2:24142060	G/A	cg08917208	chr2:24149416	ATAD2B	0.74	4.66	0.39	7.9e-6	Lymphocyte counts;
TGCT	cis	rs9549367	0.713	rs510160	chr13:113822481	A/G	cg00898013	chr13:113819073	PROZ	0.51	6.41	0.5	2.79e-9	Platelet distribution width;
TGCT	cis	rs2228479	0.850	rs79244293	chr16:89896220	T/C	cg06558623	chr16:89946397	TCF25	0.55	4.77	0.39	5.13e-6	Skin colour saturation;
TGCT	cis	rs2073300	1.000	rs6137976	chr20:23463241	C/T	cg09953122	chr20:23471693	CST8	-0.67	-4.62	-0.38	9.54e-6	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs916888	0.610	rs199442	chr17:44820122	G/A	cg15921436	chr17:44337874	NA	0.43	6.49	0.5	1.89e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs6582630	0.537	rs2204006	chr12:38407098	A/G	cg26384229	chr12:38710491	ALG10B	0.83	7.58	0.56	6.92e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs62244186	0.632	rs1402751	chr3:44594030	C/A	cg10108389	chr3:44770937	ZNF501	-0.46	-4.63	-0.38	9.25e-6	Depressive symptoms;
TGCT	cis	rs9910055	0.762	rs227579	chr17:42223134	A/T	cg13607699	chr17:42295918	UBTF	-0.83	-7.64	-0.57	5.01e-12	Total body bone mineral density;
TGCT	cis	rs77741769	0.571	rs10849807	chr12:121314056	T/C	cg02419362	chr12:121203948	SPPL3	0.19	4.49	0.37	1.63e-5	Mean corpuscular volume;
TGCT	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg21280719	chr6:42927975	GNMT	-0.37	-4.57	-0.38	1.17e-5	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs17030434	0.954	rs17030570	chr4:154755186	A/G	cg14289246	chr4:154710475	SFRP2	0.93	7.27	0.55	3.54e-11	Electrocardiographic conduction measures;
TGCT	cis	rs11690462	0.963	rs13014464	chr2:26581018	C/T	cg11525280	chr2:26624667	C2orf39	0.35	4.47	0.37	1.73e-5	Coronary artery disease;
TGCT	cis	rs3087591	0.683	rs2854303	chr17:29716342	C/G	cg24425628	chr17:29625626	OMG;NF1	0.41	6.03	0.48	1.73e-8	Hip circumference;
TGCT	cis	rs10927875	0.830	rs1763610	chr1:16335527	C/G	cg22431228	chr1:16359049	CLCNKA	0.25	4.88	0.4	3.19e-6	Dilated cardiomyopathy;
TGCT	cis	rs9425326	0.508	rs2500106	chr1:183808474	T/G	cg15569801	chr1:184197096	NA	-0.14	-5.03	-0.41	1.7e-6	Antipsychotic drug-induced QTc interval change in schizophrenia;
TGCT	cis	rs4919694	1.000	rs7099987	chr10:104807926	C/T	cg04362960	chr10:104952993	NT5C2	1.07	7.09	0.54	8.9e-11	Arsenic metabolism;
TGCT	cis	rs6752107	0.967	rs55835501	chr2:234157733	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.21	5.0	0.41	1.87e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs1008375	0.932	rs13134570	chr4:17692863	C/T	cg10189774	chr4:17578691	LAP3	-0.55	-4.64	-0.38	8.7e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4808199	0.948	rs2023883	chr19:19405480	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.68	5.19	0.42	8.51e-7	Nonalcoholic fatty liver disease;
TGCT	cis	rs3829109	0.564	rs11145891	chr9:139293912	T/C	cg13741927	chr9:139327495	INPP5E	-0.24	-5.18	-0.42	8.84e-7	Peak insulin response;Acute insulin response;
TGCT	cis	rs4746818	1.000	rs10762259	chr10:70890929	C/T	cg04149295	chr10:70884716	VPS26A	0.79	5.4	0.44	3.22e-7	Left atrial antero-posterior diameter;
TGCT	cis	rs10032931	0.743	rs1385668	chr4:96459330	A/G	cg17031751	chr4:96469067	UNC5C	-0.41	-5.08	-0.42	1.35e-6	Optic nerve measurement (cup-to-disc ratio);
TGCT	cis	rs2070488	1.000	rs13074025	chr3:38455704	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	9.65	0.65	9.06e-17	Electrocardiographic conduction measures;
TGCT	cis	rs7584330	0.784	rs6724766	chr2:238413600	A/G	cg14458575	chr2:238380390	NA	0.44	6.59	0.51	1.11e-9	Prostate cancer;
TGCT	cis	rs3733585	0.699	rs10017674	chr4:9967053	T/C	cg11266682	chr4:10021025	SLC2A9	-0.59	-7.87	-0.58	1.53e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs854765	0.505	rs2955358	chr17:17946623	A/G	cg04398451	chr17:18023971	MYO15A	0.34	5.42	0.44	2.98e-7	Total body bone mineral density;
TGCT	cis	rs7666738	0.830	rs2114425	chr4:99023967	T/C	cg18180107	chr4:99064573	C4orf37	0.57	5.24	0.43	6.72e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs35306767	0.761	rs11253537	chr10:1010735	G/A	cg18964960	chr10:1102726	WDR37	0.69	4.82	0.4	4.12e-6	Eosinophil percentage of granulocytes;
TGCT	cis	rs4566357	1.000	rs3769637	chr2:227922623	T/C	cg11843606	chr2:227700838	RHBDD1	-0.58	-5.31	-0.43	4.92e-7	Coronary artery disease;
TGCT	cis	rs6759518	0.655	rs1659682	chr2:27410735	C/T	cg26210250	chr2:26863503	CIB4	-0.78	-4.46	-0.37	1.79e-5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
TGCT	cis	rs12540874	0.500	rs12719030	chr7:50485073	T/C	cg18232548	chr7:50535776	DDC	-0.39	-6.75	-0.52	4.98e-10	Systemic sclerosis;
TGCT	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg10047753	chr17:41438598	NA	0.97	9.96	0.67	1.57e-17	Menopause (age at onset);
TGCT	cis	rs7772486	0.686	rs6933161	chr6:146081369	G/A	cg23711669	chr6:146136114	FBXO30	-0.89	-9.88	-0.66	2.48e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-8.69	-0.62	1.82e-14	Platelet count;
TGCT	cis	rs9549367	0.713	rs9549352	chr13:113833221	A/G	cg18105134	chr13:113819100	PROZ	-0.47	-8.06	-0.59	5.42e-13	Platelet distribution width;
TGCT	cis	rs1878931	0.501	rs42329	chr16:3425524	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.75	-7.11	-0.54	7.93e-11	Body mass index (adult);
TGCT	cis	rs7698623	0.717	rs4693893	chr4:88797765	A/G	cg02735620	chr4:88950514	PKD2	-0.44	-4.81	-0.4	4.22e-6	Cardiovascular disease risk factors;
TGCT	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg06238570	chr21:40685208	BRWD1	-0.8	-9.0	-0.63	3.19e-15	Cognitive function;
TGCT	cis	rs1552244	0.832	rs61056817	chr3:10027641	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.86	5.9	0.47	3.18e-8	Alzheimer's disease;
TGCT	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	4.72	0.39	6.28e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs1401999	1.000	rs1402002	chr3:183642794	A/G	cg01324343	chr3:183735012	ABCC5	0.78	10.02	0.67	1.14e-17	Anterior chamber depth;
TGCT	cis	rs6570726	0.791	rs365747	chr6:145866784	C/T	cg23711669	chr6:146136114	FBXO30	0.89	9.93	0.67	1.82e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7666738	0.752	rs62318905	chr4:99036103	T/G	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2730245	0.563	rs2709857	chr7:158685257	T/C	cg11984989	chr7:158649758	WDR60	1.07	10.34	0.68	1.87e-18	Height;
TGCT	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg00814883	chr7:100076585	TSC22D4	-0.92	-9.78	-0.66	4.27e-17	Platelet count;
TGCT	cis	rs12477438	0.520	rs2632283	chr2:99776000	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	14.89	0.8	2.21e-29	Chronic sinus infection;
TGCT	cis	rs3087591	1.000	rs2952978	chr17:29474744	A/C	cg24425628	chr17:29625626	OMG;NF1	0.47	7.52	0.56	9.75e-12	Hip circumference;
TGCT	cis	rs3812831	0.661	rs2987458	chr13:114919835	A/G	cg08824895	chr13:115047677	UPF3A	0.5	4.77	0.39	5.04e-6	Schizophrenia;
TGCT	cis	rs7731657	0.510	rs986496	chr5:130282172	C/T	cg08523029	chr5:130500466	HINT1	0.58	4.84	0.4	3.8e-6	Fasting plasma glucose;
TGCT	cis	rs6815814	0.950	rs56289835	chr4:38811845	G/C	cg02016764	chr4:38805732	TLR1	-0.36	-5.71	-0.46	7.91e-8	Breast cancer;
TGCT	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg26668828	chr6:292823	DUSP22	-0.85	-8.73	-0.62	1.48e-14	Menopause (age at onset);
TGCT	cis	rs3733585	0.673	rs4459990	chr4:9954005	T/C	cg11266682	chr4:10021025	SLC2A9	-0.57	-7.6	-0.56	6.21e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7980687	0.527	rs28533432	chr12:123873242	C/T	cg00376283	chr12:123451042	ABCB9	0.64	5.34	0.43	4.19e-7	Height;Educational attainment;Head circumference (infant);
TGCT	cis	rs3772130	0.962	rs4280673	chr3:121526107	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.72	0.39	6.25e-6	Cognitive performance;
TGCT	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg18538332	chr22:24372958	LOC391322	-0.92	-11.41	-0.72	4.6e-21	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7959452	0.536	rs4761237	chr12:69776461	C/G	cg11871910	chr12:69753446	YEATS4	0.82	8.95	0.63	4.38e-15	Blood protein levels;
TGCT	cis	rs3540	0.533	rs1869179	chr15:90895564	A/C	cg22089800	chr15:90895588	ZNF774	0.82	9.07	0.63	2.24e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs4478858	0.611	rs6425721	chr1:31714807	C/T	cg00250761	chr1:31883323	NA	-0.28	-4.93	-0.4	2.59e-6	Alcohol dependence;
TGCT	cis	rs2742417	0.603	rs2742372	chr3:45783472	T/C	cg04837898	chr3:45731254	SACM1L	-0.67	-7.3	-0.55	3.06e-11	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs2730245	0.527	rs924910	chr7:158672272	C/T	cg11984989	chr7:158649758	WDR60	1.01	7.85	0.58	1.65e-12	Height;
TGCT	cis	rs4499344	0.633	rs259260	chr19:33153261	G/A	cg26639809	chr19:33781782	NA	0.22	4.47	0.37	1.75e-5	Mean platelet volume;
TGCT	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg06481639	chr22:41940642	POLR3H	-0.66	-5.58	-0.45	1.43e-7	Vitiligo;
TGCT	cis	rs3749237	0.964	rs10865959	chr3:49891002	G/C	cg10152585	chr3:50297680	NA	0.52	4.7	0.39	6.83e-6	Resting heart rate;
TGCT	cis	rs727563	0.638	rs4820443	chr22:42193913	A/G	cg13695892	chr22:41940480	POLR3H	-0.8	-7.6	-0.56	6.36e-12	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs999943	0.774	rs12205634	chr6:33611667	C/G	cg14003231	chr6:33640908	ITPR3	0.42	5.27	0.43	5.82e-7	Obesity (extreme);
TGCT	cis	rs6545883	0.929	rs2593625	chr2:61668769	C/T	cg15711740	chr2:61764176	XPO1	-0.56	-5.07	-0.41	1.42e-6	Tuberculosis;
TGCT	cis	rs7726839	0.540	rs3749615	chr5:601485	C/T	cg16624210	chr5:671434	TPPP	0.42	4.73	0.39	5.92e-6	Obesity-related traits;
TGCT	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.44	6.24	0.49	6.47e-9	Lymphocyte counts;
TGCT	cis	rs13326165	0.760	rs390802	chr3:52431671	G/A	cg27565382	chr3:53032988	SFMBT1	0.37	4.9	0.4	2.97e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg11494091	chr17:61959527	GH2	0.61	14.46	0.79	2.18e-28	Prudent dietary pattern;
TGCT	cis	rs713587	0.525	rs11687089	chr2:25082926	T/C	cg01884057	chr2:25150051	NA	0.3	5.66	0.45	9.78e-8	Body mass index in non-asthmatics;
TGCT	cis	rs1865760	0.566	rs9295688	chr6:26084217	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.78	7.49	0.56	1.15e-11	Height;
TGCT	cis	rs8179	0.593	rs6948097	chr7:92281953	C/T	cg15732164	chr7:92237376	CDK6	-0.29	-5.06	-0.41	1.46e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
TGCT	cis	rs67073037	0.826	rs6728138	chr2:29138978	C/T	cg09522027	chr2:28974177	PPP1CB	0.57	4.49	0.37	1.59e-5	Breast cancer;Breast cancer (estrogen-receptor negative);
TGCT	cis	rs6684514	1.000	rs28372828	chr1:156253031	G/C	cg20302342	chr1:156215951	PAQR6	0.34	4.6	0.38	1.01e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs7178572	1.000	rs62007299	chr15:77711719	G/A	cg22256960	chr15:77711686	NA	-0.95	-10.93	-0.7	6.95e-20	Type 2 diabetes;
TGCT	cis	rs10089	1.000	rs10478796	chr5:127436187	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.79	7.6	0.56	6.47e-12	Ileal carcinoids;
TGCT	cis	rs7586879	0.639	rs2033654	chr2:25103108	C/A	cg01884057	chr2:25150051	NA	0.33	6.31	0.49	4.6e-9	Body mass index;
TGCT	cis	rs6121246	0.609	rs1009453	chr20:30404840	C/G	cg13852791	chr20:30311386	BCL2L1	0.81	7.58	0.56	7.06e-12	Mean corpuscular hemoglobin;
TGCT	cis	rs10744422	0.858	rs2292136	chr12:123339344	A/G	cg25930673	chr12:123319894	HIP1R	-0.86	-5.02	-0.41	1.72e-6	Schizophrenia;
TGCT	cis	rs71636778	0.570	rs34026565	chr1:27229976	T/C	cg23921621	chr1:27994728	IFI6	-0.43	-4.61	-0.38	9.95e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
TGCT	cis	rs2239547	0.618	rs13083728	chr3:52868445	G/A	cg10802521	chr3:52805072	NEK4	-0.63	-5.99	-0.47	2.16e-8	Schizophrenia;
TGCT	trans	rs7726839	0.540	rs74553517	chr5:665671	C/T	cg11887960	chr12:57824829	NA	1.15	9.91	0.66	2.07e-17	Obesity-related traits;
TGCT	cis	rs2153535	0.580	rs1414351	chr6:8476634	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs3782455	1.000	rs79001482	chr12:114403542	T/C	cg23502203	chr12:113549970	RASAL1	-0.55	-4.92	-0.4	2.7e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	trans	rs10802346	0.545	rs1361408	chr1:246410054	T/G	cg22732515	chr19:44031385	ETHE1	0.97	8.08	0.59	4.79e-13	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs7666738	0.830	rs4443295	chr4:99044935	G/A	cg18180107	chr4:99064573	C4orf37	0.56	5.08	0.41	1.37e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs40363	1.000	rs1635393	chr16:3520493	C/T	cg05754148	chr16:3507555	NAT15	0.46	4.56	0.38	1.22e-5	Tuberculosis;
TGCT	cis	rs2463822	1.000	rs11231050	chr11:62131660	C/G	cg23876832	chr11:62092739	NA	-0.62	-4.59	-0.38	1.09e-5	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs9611565	0.592	rs4822046	chr22:41987543	G/A	cg06634786	chr22:41940651	POLR3H	-0.89	-8.16	-0.59	3.16e-13	Vitiligo;
TGCT	cis	rs9467773	0.549	rs9467805	chr6:26583366	C/T	cg09904177	chr6:26538194	HMGN4	0.69	6.73	0.52	5.6e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg23758822	chr17:41437982	NA	0.72	6.81	0.52	3.83e-10	Menopause (age at onset);
TGCT	cis	rs9650657	0.615	rs6601534	chr8:10691993	A/G	cg16664915	chr8:10907788	XKR6	-0.29	-4.55	-0.38	1.25e-5	Neuroticism;
TGCT	cis	rs34975555	0.527	rs2299596	chr8:17808730	A/G	cg05315865	chr8:17013409	ZDHHC2	-0.64	-4.5	-0.37	1.53e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
TGCT	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.93	-6.89	-0.53	2.52e-10	Gut microbiome composition (summer);
TGCT	cis	rs12477438	0.520	rs11123765	chr2:99768064	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.06	13.28	0.77	1.43e-25	Chronic sinus infection;
TGCT	cis	rs7264396	0.690	rs2425183	chr20:34450621	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.04	-0.41	1.58e-6	Total cholesterol levels;
TGCT	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg16325326	chr1:53192061	ZYG11B	0.5	5.56	0.45	1.56e-7	Monocyte count;
TGCT	cis	rs6723226	0.764	rs176403	chr2:32637864	C/A	cg02381751	chr2:32503542	YIPF4	-0.56	-5.13	-0.42	1.11e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.84	7.5	0.56	1.08e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs4654899	1.000	rs7554997	chr1:21400139	C/T	cg01072550	chr1:21505969	NA	-0.48	-7.71	-0.57	3.44e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg22535103	chr8:58192502	C8orf71	-0.41	-5.24	-0.43	6.7e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs10504229	0.636	rs77691549	chr8:58055126	G/T	cg08280861	chr8:58055591	NA	0.49	5.52	0.44	1.85e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg07061783	chr6:25882402	NA	-0.65	-6.41	-0.5	2.76e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs4563143	0.675	rs17498203	chr19:29279734	G/T	cg14983838	chr19:29218262	NA	0.86	7.07	0.54	9.71e-11	Methadone dose in opioid dependence;
TGCT	cis	rs4879913	0.801	rs7028425	chr9:35606738	C/G	cg18130437	chr9:35658183	CCDC107;RMRP	-0.46	-4.54	-0.38	1.32e-5	Electroencephalogram traits;
TGCT	cis	rs6089829	0.632	rs62197308	chr20:61660705	T/C	cg08045932	chr20:61659980	NA	-0.31	-4.47	-0.37	1.76e-5	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	trans	rs1814175	0.817	rs1851858	chr11:49855638	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.35	-0.55	2.38e-11	Height;
TGCT	cis	rs4642101	0.640	rs9877049	chr3:12821231	A/G	cg05775895	chr3:12838266	CAND2	0.92	11.11	0.71	2.53e-20	QRS complex (12-leadsum);
TGCT	cis	rs10751667	0.961	rs7396670	chr11:929269	A/G	cg06064525	chr11:970664	AP2A2	-0.31	-6.11	-0.48	1.19e-8	Alzheimer's disease (late onset);
TGCT	cis	rs6460942	0.908	rs6978877	chr7:12232690	A/G	cg06484146	chr7:12443880	VWDE	-0.52	-4.52	-0.38	1.44e-5	Coronary artery disease;
TGCT	cis	rs11626933	1.000	rs59905513	chr14:90749638	T/C	cg14092571	chr14:90743983	NA	-0.3	-6.13	-0.48	1.06e-8	Gut microbiota (bacterial taxa);
TGCT	cis	rs9902453	0.765	rs8071576	chr17:28188554	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.85	8.11	0.59	4.19e-13	Coffee consumption (cups per day);
TGCT	cis	rs11105298	0.891	rs3825330	chr12:89933710	C/T	cg00757033	chr12:89920650	WDR51B	0.29	4.6	0.38	1.01e-5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs12477438	0.834	rs1563108	chr2:99701153	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.69	-6.1	-0.48	1.28e-8	Chronic sinus infection;
TGCT	cis	rs854765	0.647	rs2056842	chr17:18009028	C/T	cg04398451	chr17:18023971	MYO15A	-0.38	-6.48	-0.5	1.91e-9	Total body bone mineral density;
TGCT	cis	rs9527	0.590	rs3781281	chr10:104852648	A/G	cg04362960	chr10:104952993	NT5C2	-0.68	-5.79	-0.46	5.33e-8	Arsenic metabolism;
TGCT	cis	rs7760949	0.852	rs9475801	chr6:13933115	G/A	cg27413430	chr6:13925136	RNF182	0.74	6.83	0.52	3.37e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg08219700	chr8:58056026	NA	0.39	4.69	0.39	6.95e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2404602	0.647	rs34103231	chr15:76912690	A/G	cg22467129	chr15:76604101	ETFA	0.47	4.61	0.38	9.77e-6	Blood metabolite levels;
TGCT	cis	rs9303401	0.527	rs12939313	chr17:56755616	A/T	cg25039879	chr17:56429692	SUPT4H1	0.53	4.55	0.38	1.25e-5	Cognitive test performance;
TGCT	cis	rs28595532	0.920	rs115271785	chr4:119735748	A/T	cg11846333	chr4:119757529	SEC24D	0.93	4.44	0.37	2e-5	Cannabis dependence symptom count;
TGCT	cis	rs4478858	0.735	rs11576603	chr1:31774031	C/T	cg00250761	chr1:31883323	NA	-0.27	-4.94	-0.41	2.43e-6	Alcohol dependence;
TGCT	cis	rs713587	0.571	rs563590	chr2:25331172	A/G	cg01884057	chr2:25150051	NA	-0.26	-5.01	-0.41	1.8e-6	Body mass index in non-asthmatics;
TGCT	cis	rs6088590	1.000	rs910870	chr20:33292893	T/C	cg06115741	chr20:33292138	TP53INP2	0.64	5.58	0.45	1.44e-7	Coronary artery disease;
TGCT	cis	rs4523957	0.620	rs58187837	chr17:2073272	G/C	cg16513277	chr17:2031491	SMG6	-0.2	-4.46	-0.37	1.8e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9303401	0.659	rs17822735	chr17:56620167	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs9467773	1.000	rs6932156	chr6:26571506	T/G	cg05738196	chr6:26577821	NA	0.9	12.48	0.75	1.16e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg08975724	chr8:8085496	FLJ10661	0.49	4.48	0.37	1.7e-5	Mood instability;
TGCT	cis	rs12950390	0.853	rs11079792	chr17:45863311	T/C	cg24803719	chr17:45855879	NA	-0.49	-5.03	-0.41	1.64e-6	IgG glycosylation;
TGCT	cis	rs7172809	0.643	rs16968930	chr15:77843434	T/A	cg22256960	chr15:77711686	NA	-0.47	-4.73	-0.39	5.89e-6	Glucose homeostasis traits;
TGCT	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg06873352	chr17:61820015	STRADA	0.56	6.22	0.49	7.1e-9	Prudent dietary pattern;
TGCT	trans	rs9650657	0.504	rs2409724	chr8:11041642	A/T	cg15556689	chr8:8085844	FLJ10661	-0.85	-8.28	-0.6	1.65e-13	Neuroticism;
TGCT	cis	rs3008870	1.000	rs2065000	chr1:67468124	G/C	cg08660285	chr1:67390436	MIER1;WDR78	-1.07	-11.34	-0.71	6.75e-21	Lymphocyte percentage of white cells;
TGCT	cis	rs2013441	1.000	rs2703806	chr17:20108239	A/T	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.61	-0.38	9.96e-6	Obesity-related traits;
TGCT	cis	rs12541335	0.639	rs3923439	chr8:22170079	G/A	cg26039829	chr8:22132926	PIWIL2	0.26	4.96	0.41	2.32e-6	Hypertriglyceridemia;
TGCT	cis	rs2180341	0.680	rs9388554	chr6:127576234	C/G	cg27446573	chr6:127587934	RNF146	0.91	8.5	0.61	5.12e-14	Breast cancer;
TGCT	cis	rs782590	0.764	rs2586969	chr2:55829392	G/C	cg18811423	chr2:55921094	PNPT1	0.55	5.72	0.46	7.65e-8	Metabolic syndrome;
TGCT	cis	rs478304	0.718	rs1151490	chr11:65390485	A/C	cg17480646	chr11:65405466	SIPA1	0.55	7.19	0.54	5.48e-11	Acne (severe);
TGCT	cis	rs4794202	0.534	rs10428	chr17:45915086	G/A	cg02219949	chr17:45927392	SP6	0.37	4.47	0.37	1.76e-5	Alzheimer's disease (cognitive decline);
TGCT	cis	rs6088590	1.000	rs6120708	chr20:33335526	G/A	cg24642439	chr20:33292090	TP53INP2	0.69	6.17	0.48	8.94e-9	Coronary artery disease;
TGCT	cis	rs350251	0.833	rs350272	chr16:12234773	A/C	cg02910054	chr16:12241554	SNX29	-0.37	-5.13	-0.42	1.08e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs425277	1.000	rs262672	chr1:2080813	G/T	cg03732007	chr1:2071316	PRKCZ	0.26	5.44	0.44	2.77e-7	Height;
TGCT	cis	rs9814567	1.000	rs2056604	chr3:134312648	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.91	-8.83	-0.62	8.17e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs11098499	0.909	rs11723757	chr4:120299669	C/T	cg09307838	chr4:120376055	NA	0.67	6.46	0.5	2.15e-9	Corneal astigmatism;
TGCT	cis	rs2439831	0.850	rs524417	chr15:43772374	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	5.22	0.42	7.24e-7	Lung cancer in ever smokers;
TGCT	cis	rs2456568	1.000	rs2456568	chr11:93691332	A/T	cg14065697	chr11:93583672	C11orf90	-0.37	-4.55	-0.38	1.27e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs4642101	0.855	rs9873475	chr3:12845422	A/G	cg05775895	chr3:12838266	CAND2	0.73	7.24	0.55	4.1e-11	QRS complex (12-leadsum);
TGCT	cis	rs12142240	0.698	rs17357628	chr1:46808462	A/G	cg14993813	chr1:46806288	NSUN4	-0.58	-4.81	-0.4	4.34e-6	Menopause (age at onset);
TGCT	cis	rs2361718	0.501	rs12944619	chr17:78144109	T/C	cg09238746	chr17:78121135	EIF4A3	-1.1	-11.38	-0.71	5.62e-21	Yeast infection;
TGCT	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg10802521	chr3:52805072	NEK4	-0.7	-8.28	-0.6	1.7e-13	Bipolar disorder;
TGCT	cis	rs751728	1.000	rs2296748	chr6:33745071	C/T	cg00334056	chr6:33755658	LEMD2	-0.25	-4.59	-0.38	1.08e-5	Crohn's disease;
TGCT	cis	rs797680	0.821	rs2391254	chr1:93795166	A/T	cg17826107	chr1:92977322	EVI5	-0.23	-5.14	-0.42	1.05e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg07424592	chr7:64974309	NA	1.36	8.15	0.59	3.36e-13	Diabetic kidney disease;
TGCT	cis	rs7772486	0.686	rs9376956	chr6:145949844	T/C	cg13319975	chr6:146136371	FBXO30	-0.5	-4.49	-0.37	1.63e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2204008	0.668	rs1619009	chr12:38120485	G/A	cg26384229	chr12:38710491	ALG10B	-0.58	-5.09	-0.42	1.28e-6	Bladder cancer;
TGCT	cis	rs8103278	1.000	rs7252126	chr19:46302374	T/A	cg11657440	chr19:46296263	DMWD	-0.59	-5.71	-0.46	7.83e-8	Coronary artery disease;
TGCT	cis	rs17818399	0.788	rs13013245	chr2:46806086	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.53	-5.24	-0.43	6.72e-7	Height;
TGCT	cis	rs4499344	0.556	rs259217	chr19:33138368	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.82	8.26	0.6	1.84e-13	Mean platelet volume;
TGCT	trans	rs2469997	1.000	rs2470017	chr8:120361534	G/A	cg01792902	chr3:178864926	PIK3CA	0.83	6.77	0.52	4.49e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs7086627	0.506	rs10749575	chr10:82136921	C/T	cg01528321	chr10:82214614	TSPAN14	0.51	4.45	0.37	1.91e-5	Post bronchodilator FEV1;
TGCT	cis	rs6121246	0.559	rs6060952	chr20:30382108	T/G	cg10886678	chr20:30946050	ASXL1	-0.53	-4.5	-0.37	1.55e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs1865760	0.533	rs1408270	chr6:25873184	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.59	4.68	0.39	7.54e-6	Height;
TGCT	cis	rs11190604	1.000	rs10883510	chr10:102297018	C/T	cg16342193	chr10:102329863	NA	-0.43	-5.3	-0.43	5.03e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs17826219	0.500	rs28452421	chr17:29083980	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Body mass index;
TGCT	cis	rs11677203	1.000	rs11685890	chr2:12564292	C/T	cg00419568	chr2:11919532	LPIN1	-0.2	-4.55	-0.38	1.26e-5	Electroencephalogram traits;
TGCT	cis	rs13223928	0.565	rs10951053	chr7:3155579	C/T	cg19214707	chr7:3157722	NA	-0.46	-6.8	-0.52	3.87e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
TGCT	cis	rs6690583	0.623	rs6672362	chr1:85454881	C/G	cg20280350	chr1:85513789	MCOLN3	-0.74	-5.11	-0.42	1.2e-6	Serum sulfate level;
TGCT	cis	rs7589728	0.620	rs76687350	chr2:88473832	G/A	cg04511125	chr2:88470314	THNSL2	0.63	4.98	0.41	2.04e-6	Plasma clusterin levels;
TGCT	cis	rs6430585	0.878	rs9677760	chr2:136538939	T/A	cg07169764	chr2:136633963	MCM6	-0.88	-7.8	-0.57	2.16e-12	Corneal structure;
TGCT	cis	rs7940866	0.646	rs10894293	chr11:130824213	C/T	cg12179176	chr11:130786555	SNX19	-0.61	-5.77	-0.46	5.87e-8	Schizophrenia;
TGCT	trans	rs11764590	0.715	rs62444907	chr7:2083267	C/T	cg25206134	chr2:45395956	NA	0.97	6.71	0.52	6.05e-10	Neuroticism;
TGCT	cis	rs7208859	0.623	rs8067035	chr17:29102188	T/C	cg13385521	chr17:29058706	SUZ12P	0.82	4.86	0.4	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg09436375	chr6:42928200	GNMT	-0.4	-5.16	-0.42	9.7e-7	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs7169223	0.653	rs3971703	chr15:79092481	G/C	cg21242079	chr15:79101063	ADAMTS7	0.35	5.57	0.45	1.53e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
TGCT	cis	rs7647973	1.000	rs9860055	chr3:49506900	C/T	cg07636037	chr3:49044803	WDR6	-0.7	-5.73	-0.46	7.08e-8	Menarche (age at onset);
TGCT	cis	rs79349575	0.783	rs61576918	chr17:46985593	A/C	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.44	-0.37	1.95e-5	Type 2 diabetes;
TGCT	cis	rs9308731	0.644	rs1439287	chr2:111871897	G/A	cg04202892	chr2:111875749	ACOXL	0.54	6.22	0.49	7.07e-9	Chronic lymphocytic leukemia;
TGCT	cis	rs56235845	0.665	rs4976685	chr5:176766177	C/T	cg16006841	chr5:176797999	RGS14	-0.52	-7.59	-0.56	6.54e-12	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg26338869	chr17:61819248	STRADA	-0.57	-5.23	-0.43	7.02e-7	Prudent dietary pattern;
TGCT	trans	rs1814175	0.676	rs11040647	chr11:49935947	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.51	-0.69	7.2e-19	Height;
TGCT	cis	rs66573146	1.000	rs28384174	chr4:6961107	G/T	cg01220768	chr4:7056774	TADA2B	0.35	4.63	0.38	8.96e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs492146	0.729	rs644100	chr6:52842371	A/C	cg06706454	chr6:52930286	FBXO9	-0.51	-4.66	-0.39	8.12e-6	Epilepsy (remission after treatment);
TGCT	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg08392591	chr16:89556376	ANKRD11	0.57	5.2	0.42	8.01e-7	Multiple myeloma (IgH translocation);
TGCT	cis	rs4689388	0.926	rs10937719	chr4:6295322	C/G	cg25554036	chr4:6271136	WFS1	0.54	7.0	0.53	1.42e-10	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs7192750	0.652	rs150617	chr16:72139396	T/C	cg06353428	chr16:71660113	MARVELD3	1.02	5.25	0.43	6.49e-7	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs13424612	0.896	rs12466838	chr2:240893427	G/A	cg26363272	chr2:240904871	NDUFA10	0.28	4.63	0.38	8.95e-6	Odorant perception (isobutyraldehyde);
TGCT	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.72	-6.47	-0.5	2.04e-9	Tonsillectomy;
TGCT	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg11890956	chr21:40555474	PSMG1	1.11	12.17	0.74	6.69e-23	Cognitive function;
TGCT	cis	rs72843506	0.722	rs5025290	chr17:20205817	A/G	cg18979559	chr17:20280153	CCDC144C	-0.65	-4.86	-0.4	3.54e-6	Schizophrenia;
TGCT	cis	rs7208859	0.673	rs79541516	chr17:29240583	C/T	cg18442181	chr17:29233375	C17orf42	-0.79	-4.72	-0.39	6.22e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs9467773	0.595	rs9366657	chr6:26434914	C/G	cg15659132	chr6:26577336	NA	0.43	4.48	0.37	1.65e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs10791323	0.660	rs10791332	chr11:133732150	A/G	cg15485101	chr11:133734466	NA	0.37	5.0	0.41	1.9e-6	Childhood ear infection;
TGCT	cis	rs6032067	0.516	rs6104085	chr20:43901302	A/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.38	-5.96	-0.47	2.38e-8	Blood protein levels;
TGCT	cis	rs4711350	0.871	rs1998949	chr6:33721457	T/C	cg18005901	chr6:33739558	LEMD2	-0.46	-5.04	-0.41	1.62e-6	Schizophrenia;
TGCT	cis	rs968451	0.789	rs1003643	chr22:39676494	T/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.75	7.4	0.55	1.77e-11	Primary biliary cholangitis;
TGCT	cis	rs2806561	0.704	rs2806570	chr1:23527005	C/T	cg12483005	chr1:23474871	LUZP1	-0.43	-5.35	-0.43	4.02e-7	Height;
TGCT	cis	rs12497850	0.897	rs9681717	chr3:48872998	A/G	cg06212747	chr3:49208901	KLHDC8B	0.6	5.48	0.44	2.32e-7	Parkinson's disease;
TGCT	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg06238570	chr21:40685208	BRWD1	-0.82	-8.76	-0.62	1.19e-14	Cognitive function;
TGCT	cis	rs7635838	0.684	rs2594966	chr3:11325276	A/G	cg00170343	chr3:11313890	ATG7	-0.64	-6.32	-0.49	4.28e-9	HDL cholesterol;
TGCT	cis	rs854765	0.655	rs4470201	chr17:17844870	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.74	7.73	0.57	3.18e-12	Total body bone mineral density;
TGCT	cis	rs2153535	0.580	rs718503	chr6:8527463	A/T	cg07606381	chr6:8435919	SLC35B3	0.53	4.97	0.41	2.22e-6	Motion sickness;
TGCT	cis	rs681343	0.746	rs633372	chr19:49209226	G/A	cg05248581	chr19:49925731	PTH2	0.42	4.57	0.38	1.16e-5	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
TGCT	cis	rs9302001	0.881	rs9524627	chr13:95469890	A/G	cg07483244	chr13:95358924	NA	-0.34	-4.47	-0.37	1.71e-5	Panic disorder;
TGCT	cis	rs7845219	0.539	rs10441538	chr8:95868608	G/A	cg13393036	chr8:95962371	TP53INP1	-0.49	-5.86	-0.47	3.92e-8	Type 2 diabetes;
TGCT	cis	rs9549260	0.664	rs1360719	chr13:41225874	G/C	cg21288729	chr13:41239152	FOXO1	1.01	10.71	0.69	2.36e-19	Red blood cell count;
TGCT	cis	rs7914558	1.000	rs7920251	chr10:104950197	C/T	cg15744005	chr10:104629667	AS3MT	-0.39	-4.84	-0.4	3.83e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-5.09	-0.42	1.29e-6	Electroencephalogram traits;
TGCT	trans	rs2688608	0.901	rs2675671	chr10:75632760	C/T	cg13918328	chr10:52500089	ASAH2B	0.64	6.76	0.52	4.87e-10	Inflammatory bowel disease;
TGCT	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-5.1	-0.42	1.23e-6	Bipolar disorder;
TGCT	cis	rs1801251	1.000	rs3817311	chr2:233612557	C/T	cg25237894	chr2:233734115	C2orf82	0.33	5.95	0.47	2.53e-8	Coronary artery disease;
TGCT	cis	rs2147959	0.882	rs6666241	chr1:228629759	A/G	cg22700015	chr1:228743131	NA	-0.57	-4.53	-0.38	1.35e-5	Adult asthma;
TGCT	cis	rs9916302	0.706	rs9646419	chr17:37597185	A/G	cg07936489	chr17:37558343	FBXL20	-0.87	-6.27	-0.49	5.47e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg21963583	chr11:68658836	MRPL21	0.36	6.17	0.48	9.01e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs28595532	1.000	rs17323012	chr4:119605671	A/G	cg14228332	chr4:119757509	SEC24D	1.04	5.39	0.44	3.43e-7	Cannabis dependence symptom count;
TGCT	cis	rs1008375	0.966	rs6449329	chr4:17703677	T/C	cg10189774	chr4:17578691	LAP3	0.52	4.47	0.37	1.73e-5	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7100689	0.577	rs756208	chr10:82041751	A/G	cg01528321	chr10:82214614	TSPAN14	0.7	6.78	0.52	4.43e-10	Post bronchodilator FEV1;
TGCT	cis	rs1903068	0.597	rs10013070	chr4:55997201	A/G	cg09978860	chr4:56023921	NA	0.54	5.58	0.45	1.43e-7	Endometriosis;
TGCT	cis	rs11122272	0.735	rs2247132	chr1:231493359	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-6.83	-0.52	3.39e-10	Hemoglobin concentration;
TGCT	cis	rs651907	0.557	rs7651406	chr3:101393296	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.24	0.43	6.66e-7	Colorectal cancer;
TGCT	cis	rs6940638	0.606	rs6456771	chr6:27232395	G/A	cg26531700	chr6:26746687	NA	-0.66	-5.29	-0.43	5.31e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9303401	0.659	rs12602389	chr17:56779778	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.67	6.3	0.49	4.7e-9	Cognitive test performance;
TGCT	cis	rs6728642	1.000	rs113863815	chr2:97657813	A/G	cg26665480	chr2:98280029	ACTR1B	-0.96	-5.36	-0.43	3.91e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	cis	rs62380364	0.602	rs606393	chr5:88058163	T/C	cg22951263	chr5:87985283	NA	-0.59	-6.27	-0.49	5.5e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg11494091	chr17:61959527	GH2	0.6	14.31	0.79	5.05e-28	Prudent dietary pattern;
TGCT	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg13012494	chr21:47604986	C21orf56	0.38	4.56	0.38	1.21e-5	Testicular germ cell tumor;
TGCT	cis	rs9611519	0.929	rs4821991	chr22:41440683	T/C	cg13695892	chr22:41940480	POLR3H	-0.55	-4.9	-0.4	2.99e-6	Neuroticism;
TGCT	cis	rs7674212	0.510	rs55715738	chr4:104130189	A/G	cg16532752	chr4:104119610	CENPE	-0.61	-5.56	-0.45	1.61e-7	Type 2 diabetes;
TGCT	cis	rs2677744	0.626	rs868547	chr15:91498760	G/A	cg23684204	chr15:91497937	RCCD1	0.41	6.39	0.5	2.98e-9	Attention deficit hyperactivity disorder;
TGCT	cis	rs17376456	1.000	rs13163610	chr5:93548877	A/C	cg25358565	chr5:93447407	FAM172A	0.94	7.65	0.57	4.96e-12	Diabetic retinopathy;
TGCT	cis	rs9611565	0.918	rs12484074	chr22:41752747	G/A	cg17554472	chr22:41940697	POLR3H	-0.52	-5.17	-0.42	9.26e-7	Vitiligo;
TGCT	cis	rs7172809	0.524	rs4886857	chr15:77576567	T/C	cg22256960	chr15:77711686	NA	-0.47	-4.61	-0.38	9.99e-6	Glucose homeostasis traits;
TGCT	cis	rs28595532	0.844	rs116721336	chr4:119536538	A/G	cg14228332	chr4:119757509	SEC24D	1.0	5.75	0.46	6.54e-8	Cannabis dependence symptom count;
TGCT	cis	rs2639990	0.744	rs640261	chr18:72905808	C/T	cg03972071	chr18:72917163	ZADH2	0.8	5.4	0.44	3.3e-7	Vascular endothelial growth factor levels;
TGCT	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg05665937	chr4:1216051	CTBP1	-0.24	-4.55	-0.38	1.26e-5	Obesity-related traits;
TGCT	cis	rs17534004	1.000	rs35858501	chr13:31472120	C/T	cg13251181	chr13:31481184	C13orf33	0.36	4.99	0.41	1.97e-6	3-hydroxypropylmercapturic acid levels in smokers;
TGCT	cis	rs11785400	0.793	rs4736362	chr8:143741381	G/A	cg24634471	chr8:143751801	JRK	0.56	5.53	0.44	1.81e-7	Schizophrenia;
TGCT	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg09060608	chr5:178986726	RUFY1	0.53	5.89	0.47	3.36e-8	Lung cancer;
TGCT	cis	rs4746818	0.901	rs7914719	chr10:70903832	T/C	cg11621586	chr10:70884670	VPS26A	1.22	10.78	0.7	1.56e-19	Left atrial antero-posterior diameter;
TGCT	cis	rs10276303	1.000	rs10256447	chr7:3338689	A/G	cg26053068	chr7:2691072	TTYH3	-0.17	-4.54	-0.38	1.29e-5	Dupuytren's disease;
TGCT	cis	rs12682352	0.652	rs3789843	chr8:8724257	C/T	cg06636001	chr8:8085503	FLJ10661	0.68	6.25	0.49	5.99e-9	Neuroticism;
TGCT	cis	rs2688608	0.530	rs71507081	chr10:75493136	G/A	cg19442545	chr10:75533431	FUT11	-0.37	-5.77	-0.46	5.89e-8	Inflammatory bowel disease;
TGCT	cis	rs611744	0.647	rs587340	chr8:109246032	C/A	cg21045802	chr8:109455806	TTC35	0.74	7.37	0.55	2.07e-11	Dupuytren's disease;
TGCT	cis	rs12711979	0.765	rs7559461	chr2:3818623	G/A	cg17052675	chr2:3827356	NA	-0.4	-7.89	-0.58	1.34e-12	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg11644478	chr21:40555479	PSMG1	1.0	10.6	0.69	4.32e-19	Cognitive function;
TGCT	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg13393036	chr8:95962371	TP53INP1	-0.63	-8.79	-0.62	1.04e-14	Type 2 diabetes;
TGCT	cis	rs12950390	0.820	rs58391889	chr17:45865959	A/G	cg06532163	chr17:45867833	NA	0.35	5.53	0.44	1.84e-7	IgG glycosylation;
TGCT	cis	rs17376456	0.569	rs7736892	chr5:93205597	G/A	cg21475434	chr5:93447410	FAM172A	-0.7	-5.15	-0.42	1.02e-6	Diabetic retinopathy;
TGCT	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg18876405	chr7:65276391	NA	0.33	4.87	0.4	3.27e-6	Aortic root size;
TGCT	cis	rs6840360	0.571	rs62327272	chr4:152545090	A/C	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.0	-0.58	7.69e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs9393692	0.676	rs1543681	chr6:26187783	G/T	cg00631329	chr6:26305371	NA	-0.32	-4.78	-0.39	4.81e-6	Educational attainment;
TGCT	cis	rs7945705	0.791	rs10769958	chr11:8815115	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.42	-4.64	-0.38	8.87e-6	Hemoglobin concentration;
TGCT	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg06481639	chr22:41940642	POLR3H	-0.74	-6.74	-0.52	5.38e-10	Vitiligo;
TGCT	cis	rs1215050	0.765	rs1530905	chr4:98805705	A/G	cg17366294	chr4:99064904	C4orf37	0.52	5.59	0.45	1.4e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg22433210	chr17:43662623	NA	1.06	7.29	0.55	3.2e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs617791	0.530	rs55947178	chr11:65754230	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	0.5	4.56	0.38	1.2e-5	Breast cancer;
TGCT	cis	rs6570726	0.791	rs9376945	chr6:145828080	T/A	cg23711669	chr6:146136114	FBXO30	0.89	9.72	0.66	6.02e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg10802521	chr3:52805072	NEK4	0.78	10.0	0.67	1.26e-17	Electroencephalogram traits;
TGCT	cis	rs2239547	0.563	rs4687560	chr3:52898121	T/G	cg11645453	chr3:52864694	ITIH4	0.32	5.48	0.44	2.27e-7	Schizophrenia;
TGCT	cis	rs7611238	0.560	rs4677843	chr3:195141022	T/C	cg27323046	chr3:195102265	ACAP2	0.39	5.15	0.42	1.01e-6	Body mass index;
TGCT	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs17384381	1.000	rs71652696	chr1:85831792	A/C	cg16011679	chr1:85725395	C1orf52	0.91	6.64	0.51	8.59e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2115630	0.905	rs1975277	chr15:85329558	C/T	cg11189052	chr15:85197271	WDR73	-0.62	-5.98	-0.47	2.2e-8	P wave terminal force;
TGCT	cis	rs11614913	0.551	rs1867297	chr12:54396971	A/G	cg27482031	chr12:54402697	HOXC8	-0.56	-4.89	-0.4	3.03e-6	Waist circumference adjusted for body mass index;
TGCT	cis	rs7017914	1.000	rs13252719	chr8:71734569	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.55	-5.1	-0.42	1.24e-6	Bone mineral density;
TGCT	cis	rs6840360	0.571	rs11099823	chr4:152510565	T/G	cg17479576	chr4:152424074	FAM160A1	-0.73	-7.94	-0.58	1.03e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs13242816	1.000	rs13235720	chr7:116113663	T/C	cg16553024	chr7:116138462	CAV2	-0.45	-4.75	-0.39	5.64e-6	P wave duration;
TGCT	cis	rs3733631	1.000	rs3733631	chr4:104641103	G/C	cg24090629	chr4:104641072	TACR3	-0.78	-6.33	-0.49	4.08e-9	Menarche (age at onset);
TGCT	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg24250549	chr1:154909240	PMVK	0.63	6.25	0.49	6.03e-9	Prostate cancer;
TGCT	cis	rs41298997	1	rs41298997	chr1:206655331	C/T	cg11166312	chr1:206654246	IKBKE	0.26	5.88	0.47	3.61e-8	Psoriasis;
TGCT	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.34	0.43	4.23e-7	Prudent dietary pattern;
TGCT	cis	rs854765	0.547	rs7212167	chr17:17913504	G/A	cg09796270	chr17:17721594	SREBF1	0.25	5.04	0.41	1.61e-6	Total body bone mineral density;
TGCT	cis	rs4478037	0.749	rs6550204	chr3:33107645	C/T	cg19404215	chr3:33155277	CRTAP	-0.96	-5.69	-0.46	8.54e-8	Major depressive disorder;
TGCT	cis	rs244731	0.959	rs10037110	chr5:176658066	A/T	cg16006841	chr5:176797999	RGS14	-0.56	-7.34	-0.55	2.42e-11	Urate levels in lean individuals;
TGCT	cis	rs11785400	1.000	rs6995314	chr8:143749718	A/G	cg10596483	chr8:143751796	JRK	-0.58	-6.14	-0.48	1.01e-8	Schizophrenia;
TGCT	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg23708337	chr7:1209742	NA	0.6	5.76	0.46	6.27e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs17221829	0.681	rs75322840	chr11:89390394	T/A	cg02982614	chr11:89391479	FOLH1B	-0.25	-4.46	-0.37	1.8e-5	Anxiety in major depressive disorder;
TGCT	cis	rs7666738	0.830	rs7663924	chr4:99037679	A/G	cg17366294	chr4:99064904	C4orf37	-0.69	-7.05	-0.54	1.09e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs67311347	1.000	rs4128740	chr3:40519532	C/A	cg17264618	chr3:40429014	ENTPD3	0.32	4.45	0.37	1.88e-5	Renal cell carcinoma;
TGCT	cis	rs2153535	0.580	rs1414344	chr6:8471365	C/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs797680	0.754	rs12118230	chr1:93651461	T/G	cg17826107	chr1:92977322	EVI5	-0.24	-5.23	-0.43	6.89e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	trans	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg27523141	chr10:43048294	ZNF37B	0.74	8.66	0.61	2.13e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs9467773	0.935	rs4573	chr6:26546808	A/G	cg05738196	chr6:26577821	NA	0.82	10.56	0.69	5.35e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs13217239	0.608	rs6930508	chr6:27053142	T/C	cg26531700	chr6:26746687	NA	-0.68	-6.72	-0.52	5.79e-10	Schizophrenia;
TGCT	cis	rs3008870	1.000	rs11208976	chr1:67434411	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.1	-11.8	-0.73	5.15e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs1372520	0.684	rs1837891	chr4:90736131	C/G	cg15133208	chr4:90757351	SNCA	0.51	6.08	0.48	1.35e-8	Neuroticism;
TGCT	cis	rs9556958	0.708	rs9513435	chr13:99160334	C/G	cg07423050	chr13:99094983	FARP1	-0.23	-4.89	-0.4	3.02e-6	Educational attainment (years of education);
TGCT	cis	rs7666738	0.830	rs35276471	chr4:99068691	A/T	cg17366294	chr4:99064904	C4orf37	0.73	7.45	0.56	1.4e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs548181	0.536	rs503287	chr11:125461788	C/T	cg03464685	chr11:125439445	EI24	1.18	9.17	0.64	1.28e-15	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg06713675	chr4:122721982	EXOSC9	-0.69	-9.7	-0.66	6.92e-17	Type 2 diabetes;
TGCT	cis	rs4242434	0.854	rs3735893	chr8:22452704	A/G	cg03733263	chr8:22462867	KIAA1967	1.09	17.94	0.85	2.96e-36	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg10150615	chr22:24372951	LOC391322	-1.01	-13.09	-0.76	3.96e-25	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs11098499	0.818	rs55825515	chr4:120486402	A/G	cg09307838	chr4:120376055	NA	0.73	6.97	0.53	1.69e-10	Corneal astigmatism;
TGCT	cis	rs1519814	0.616	rs2326428	chr8:121011363	A/G	cg22335954	chr8:121166405	COL14A1	-0.36	-4.52	-0.38	1.44e-5	Breast cancer;
TGCT	cis	rs460214	0.564	rs458465	chr21:40024644	A/T	cg05519781	chr21:40033154	ERG	-0.52	-4.69	-0.39	6.96e-6	Response to cognitive-behavioural therapy in anxiety disorder;
TGCT	cis	rs2721195	0.845	rs756627	chr8:145737286	G/A	cg15320075	chr8:145703422	NA	0.69	6.68	0.51	7.07e-10	Age at first birth;
TGCT	cis	rs9303401	0.538	rs2240259	chr17:56458129	A/C	cg25039879	chr17:56429692	SUPT4H1	0.61	5.23	0.42	7.07e-7	Cognitive test performance;
TGCT	cis	rs8072100	0.846	rs4264433	chr17:45737275	A/T	cg08085267	chr17:45401833	C17orf57	0.47	5.12	0.42	1.11e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs6500602	0.674	rs8051695	chr16:4536621	T/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.26	4.73	0.39	6.13e-6	Schizophrenia;
TGCT	cis	rs9611565	0.802	rs9611571	chr22:41784867	G/A	cg06481639	chr22:41940642	POLR3H	-0.61	-5.49	-0.44	2.17e-7	Vitiligo;
TGCT	cis	rs9329289	0.888	rs11251273	chr10:2540300	G/C	cg15501526	chr10:2543763	NA	0.4	4.79	0.39	4.76e-6	Age-related hearing impairment;
TGCT	cis	rs1867631	1.000	rs10789213	chr1:67128201	T/C	cg13052034	chr1:66999238	SGIP1	0.57	4.87	0.4	3.32e-6	Menopause (age at onset);
TGCT	cis	rs4730250	0.554	rs112665932	chr7:106916121	A/G	cg02696742	chr7:106810147	HBP1	-0.72	-5.29	-0.43	5.34e-7	Osteoarthritis;
TGCT	cis	rs17384381	0.953	rs2284797	chr1:85792383	C/T	cg16011679	chr1:85725395	C1orf52	0.81	6.34	0.49	3.82e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4595586	0.545	rs12823586	chr12:39391677	C/G	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs3809566	0.676	rs11071719	chr15:63329875	C/A	cg08198488	chr15:63333792	TPM1	-0.34	-5.11	-0.42	1.18e-6	Platelet count;
TGCT	cis	rs28374715	0.532	rs11070328	chr15:41651569	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.92	-15.84	-0.82	1.44e-31	Ulcerative colitis;
TGCT	cis	rs28595532	0.920	rs28797314	chr4:119783044	A/G	cg14228332	chr4:119757509	SEC24D	1.19	6.66	0.51	8.07e-10	Cannabis dependence symptom count;
TGCT	cis	rs2295359	0.892	rs11209005	chr1:67618678	A/G	cg08029281	chr1:67600428	NA	0.39	4.57	0.38	1.17e-5	Psoriasis;
TGCT	cis	rs950169	0.840	rs35522895	chr15:84928049	G/A	cg17173187	chr15:85201210	NMB	0.52	5.32	0.43	4.75e-7	Schizophrenia;
TGCT	cis	rs2019216	0.564	rs1518053	chr17:21924272	G/T	cg22648282	chr17:21454238	C17orf51	-0.56	-5.45	-0.44	2.57e-7	Pelvic organ prolapse;
TGCT	cis	rs2412208	0.565	rs11120822	chr1:7113112	G/C	cg20434152	chr1:7120926	CAMTA1	-0.31	-5.07	-0.41	1.42e-6	Survival in sporadic amyotrophic lateral sclerosis;
TGCT	cis	rs9297145	0.585	rs62473049	chr7:98777685	T/C	cg05967295	chr7:98741636	SMURF1	-0.68	-8.35	-0.6	1.12e-13	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs11785400	1.000	rs6995314	chr8:143749718	A/G	cg24634471	chr8:143751801	JRK	-0.58	-6.18	-0.49	8.5e-9	Schizophrenia;
TGCT	cis	rs6547741	0.967	rs4665999	chr2:27834444	T/C	cg27432699	chr2:27873401	GPN1	0.18	4.56	0.38	1.19e-5	Oral cavity cancer;
TGCT	cis	rs11696845	0.626	rs6073537	chr20:43378270	A/G	cg25301532	chr20:43378953	KCNK15	-0.47	-5.15	-0.42	9.92e-7	Obesity-related traits;
TGCT	cis	rs9985766	0.958	rs62339879	chr4:150989105	A/G	cg05926478	chr4:151174724	DCLK2	-0.24	-4.64	-0.38	8.63e-6	Coronary artery disease;Myocardial infarction;
TGCT	cis	rs2116941	1.000	rs2033493	chr19:10340854	A/C	cg01850179	chr19:10340795	S1PR2	-0.74	-9.93	-0.67	1.82e-17	Pulse pressure;
TGCT	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	6.22	0.49	7.14e-9	Alzheimer's disease;
TGCT	cis	rs288326	0.561	rs79096460	chr2:183798677	A/G	cg09997497	chr2:183902928	NCKAP1	1.12	5.0	0.41	1.88e-6	Blood protein levels;
TGCT	cis	rs12478296	0.901	rs7423119	chr2:243005488	T/A	cg06360820	chr2:242988706	NA	-0.6	-4.96	-0.41	2.23e-6	Obesity-related traits;
TGCT	cis	rs3741151	1.000	rs3741151	chr11:73020846	G/T	cg17517138	chr11:73019481	ARHGEF17	1.17	5.55	0.45	1.67e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
TGCT	cis	rs921968	0.643	rs2303561	chr2:219527005	C/T	cg02176678	chr2:219576539	TTLL4	-0.38	-5.47	-0.44	2.34e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs1670533	1.000	rs13135215	chr4:1054364	A/G	cg20887711	chr4:1340912	KIAA1530	0.72	5.55	0.45	1.64e-7	Recombination rate (females);
TGCT	cis	rs2535633	0.631	rs2465101	chr3:52991307	A/T	cg11645453	chr3:52864694	ITIH4	-0.27	-5.02	-0.41	1.77e-6	Body mass index;
TGCT	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg06238570	chr21:40685208	BRWD1	-0.6	-6.21	-0.49	7.27e-9	Menarche (age at onset);
TGCT	cis	rs7216064	0.953	rs62086044	chr17:65970837	G/T	cg12091567	chr17:66097778	LOC651250	-0.79	-5.99	-0.47	2.07e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg09704166	chr2:114031854	PAX8;LOC440839	-0.33	-4.9	-0.4	2.95e-6	Lymphocyte counts;
TGCT	cis	rs1865760	0.964	rs3799373	chr6:25929173	A/C	cg16482183	chr6:26056742	HIST1H1C	0.51	4.57	0.38	1.16e-5	Height;
TGCT	cis	rs116095464	0.558	rs9312979	chr5:222057	A/C	cg22857025	chr5:266934	NA	-0.34	-6.6	-0.51	1.09e-9	Breast cancer;
TGCT	cis	rs2439831	1.000	rs101094	chr15:43787322	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	5.51	0.44	1.95e-7	Lung cancer in ever smokers;
TGCT	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg22963979	chr7:1858916	MAD1L1	-0.42	-6.99	-0.53	1.51e-10	Schizophrenia;
TGCT	cis	rs9303401	0.614	rs66480139	chr17:57101538	G/A	cg25039879	chr17:56429692	SUPT4H1	0.54	4.8	0.4	4.57e-6	Cognitive test performance;
TGCT	cis	rs9611565	0.592	rs5996037	chr22:41965292	A/G	cg06481639	chr22:41940642	POLR3H	-0.67	-5.71	-0.46	7.87e-8	Vitiligo;
TGCT	cis	rs9467711	0.606	rs12173854	chr6:26371679	A/G	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg06238570	chr21:40685208	BRWD1	0.69	6.41	0.5	2.71e-9	Cognitive function;
TGCT	cis	rs4766566	0.568	rs11065857	chr12:111739500	A/G	cg10833066	chr12:111807467	FAM109A	0.4	7.51	0.56	1.01e-11	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
TGCT	trans	rs783396	0.688	rs1676008	chr6:106999132	A/G	cg09013229	chr1:225332226	DNAH14	-0.58	-6.83	-0.52	3.35e-10	Stroke;
TGCT	cis	rs75059851	1.000	rs3802924	chr11:133827733	A/C	cg14047540	chr11:133829660	NA	-0.58	-5.23	-0.43	6.87e-7	Schizophrenia;
TGCT	cis	rs910316	1.000	rs2098297	chr14:75619118	G/T	cg11812906	chr14:75593930	NEK9	-0.74	-7.31	-0.55	2.84e-11	Height;
TGCT	cis	rs11098499	0.657	rs71614442	chr4:120379346	C/T	cg09307838	chr4:120376055	NA	0.68	6.53	0.51	1.54e-9	Corneal astigmatism;
TGCT	cis	rs651907	0.514	rs34301719	chr3:101417993	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.56	5.02	0.41	1.71e-6	Colorectal cancer;
TGCT	cis	rs595982	0.559	rs17272680	chr19:49364511	A/G	cg21252483	chr19:49399788	TULP2	0.42	6.44	0.5	2.44e-9	Red cell distribution width;
TGCT	cis	rs7552404	0.628	rs5745442	chr1:76342858	T/G	cg10523679	chr1:76189770	ACADM	0.84	7.71	0.57	3.49e-12	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7201929	1.000	rs11644151	chr16:28895660	G/A	cg09754948	chr16:28834200	ATXN2L	-0.63	-4.9	-0.4	2.93e-6	QT interval;
TGCT	cis	rs11711311	0.955	rs9860642	chr3:113419211	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.81	-7.2	-0.54	5e-11	IgG glycosylation;
TGCT	cis	rs9733	0.621	rs12746899	chr1:150579678	A/T	cg13175981	chr1:150552382	MCL1	0.54	6.16	0.48	9.42e-9	Tonsillectomy;
TGCT	cis	rs35883536	0.566	rs10783141	chr1:101043897	G/A	cg06223162	chr1:101003688	GPR88	-0.42	-7.93	-0.58	1.11e-12	Monocyte count;
TGCT	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg06634786	chr22:41940651	POLR3H	0.89	8.55	0.61	3.83e-14	Vitiligo;
TGCT	cis	rs916888	0.610	rs199444	chr17:44818276	T/C	cg17911788	chr17:44343683	NA	-0.5	-5.75	-0.46	6.61e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs6582630	0.502	rs11181210	chr12:38298069	G/A	cg26384229	chr12:38710491	ALG10B	0.8	7.08	0.54	9.28e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs12681287	0.577	rs10481197	chr8:87546551	A/T	cg27223183	chr8:87520930	FAM82B	0.94	6.91	0.53	2.24e-10	Caudate activity during reward;
TGCT	trans	rs1814175	0.669	rs12364577	chr11:49707361	A/C	cg03929089	chr4:120376271	NA	-0.6	-6.95	-0.53	1.88e-10	Height;
TGCT	cis	rs7147624	1.000	rs10873192	chr14:66110653	A/G	cg03016385	chr14:66212404	NA	-0.49	-7.08	-0.54	9.33e-11	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs73198271	0.653	rs10087633	chr8:8660444	A/G	cg06636001	chr8:8085503	FLJ10661	-0.6	-4.47	-0.37	1.78e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs2361718	0.522	rs11867921	chr17:78121170	G/T	cg21238619	chr17:78079768	GAA	-0.36	-4.54	-0.38	1.32e-5	Yeast infection;
TGCT	cis	rs6752107	0.967	rs36001488	chr2:234185267	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.2	4.73	0.39	6.08e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs2458413	0.542	rs35723041	chr8:105369123	A/C	cg04554929	chr8:105342491	NA	0.49	5.79	0.46	5.35e-8	Paget's disease;
TGCT	cis	rs644799	0.965	rs11021305	chr11:95498269	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	11.21	0.71	1.39e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs921968	0.510	rs2577761	chr2:219462500	G/A	cg02176678	chr2:219576539	TTLL4	0.48	6.78	0.52	4.32e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs351855	0.642	rs2546095	chr5:176509584	G/T	cg26069374	chr5:176757514	NA	-0.2	-4.58	-0.38	1.12e-5	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2455799	0.613	rs1969095	chr3:15733552	C/T	cg16303742	chr3:15540471	COLQ	-0.26	-4.89	-0.4	3.1e-6	Mean platelet volume;
TGCT	cis	rs319204	0.843	rs488183	chr5:146280359	T/C	cg25021259	chr5:146258546	PPP2R2B	0.35	4.56	0.38	1.23e-5	Schizophrenia;
TGCT	cis	rs3847687	1.000	rs11061291	chr12:131518875	C/T	cg25772418	chr12:131519998	GPR133	-0.31	-5.35	-0.43	4.01e-7	Longevity;
TGCT	cis	rs7523273	0.597	rs6657476	chr1:207960104	G/T	cg22525895	chr1:207977042	MIR29B2	-0.46	-6.74	-0.52	5.2400000000000005e-10	Schizophrenia;
TGCT	trans	rs7618501	0.699	rs1062633	chr3:49924940	T/C	cg21659725	chr3:3221576	CRBN	0.77	9.18	0.64	1.23e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs7639513	0.545	rs55977822	chr3:12704438	C/A	cg23032965	chr3:12705835	RAF1	0.75	6.87	0.52	2.8e-10	Itch intensity from mosquito bite;
TGCT	cis	rs78456975	0.527	rs10184112	chr2:1571112	A/G	cg12573674	chr2:1569213	NA	-0.49	-5.3	-0.43	5.1e-7	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs2762353	0.935	rs1892249	chr6:25768992	A/G	cg03517284	chr6:25882590	NA	0.53	5.48	0.44	2.3e-7	Blood metabolite levels;
TGCT	cis	rs6570726	0.846	rs7773939	chr6:145927384	C/T	cg13319975	chr6:146136371	FBXO30	0.49	4.49	0.37	1.6e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg18876405	chr7:65276391	NA	0.31	4.8	0.4	4.53e-6	Aortic root size;
TGCT	cis	rs2066819	1.000	rs58852079	chr12:56706922	A/C	cg26714650	chr12:56694279	CS	-1.36	-6.06	-0.48	1.54e-8	Psoriasis vulgaris;
TGCT	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.36	0.55	2.25e-11	Prudent dietary pattern;
TGCT	cis	rs6450176	0.625	rs3822499	chr5:53289459	C/G	ch.5.1024479R	chr5:53302184	ARL15	-0.69	-5.58	-0.45	1.45e-7	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs7647973	1.000	rs3866330	chr3:49582994	T/C	cg07636037	chr3:49044803	WDR6	0.6	4.96	0.41	2.22e-6	Menarche (age at onset);
TGCT	cis	rs9467773	0.596	rs2494693	chr6:26619226	T/C	cg09904177	chr6:26538194	HMGN4	0.66	6.33	0.49	3.99e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7412746	0.634	rs2124952	chr1:150923774	T/A	cg09365446	chr1:150670422	GOLPH3L	0.34	4.71	0.39	6.58e-6	Melanoma;
TGCT	cis	rs344364	0.511	rs2906912	chr16:1953151	G/A	cg26617929	chr16:1858877	NA	-0.26	-4.66	-0.39	8.04e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs7666738	0.830	rs4441757	chr4:98927059	T/C	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2836950	0.545	rs2836922	chr21:40516308	C/T	cg06238570	chr21:40685208	BRWD1	-0.61	-6.42	-0.5	2.6e-9	Menarche (age at onset);
TGCT	cis	rs1014246	0.541	rs2011695	chr10:118507219	A/C	cg14919929	chr10:118506882	NA	-0.38	-6.07	-0.48	1.46e-8	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs9291683	0.595	rs11731110	chr4:10037346	T/C	cg00071950	chr4:10020882	SLC2A9	0.68	8.83	0.62	8.22e-15	Bone mineral density;
TGCT	cis	rs651907	0.514	rs11706494	chr3:101509475	A/T	cg12386194	chr3:101231763	SENP7	0.48	4.81	0.4	4.36e-6	Colorectal cancer;
TGCT	cis	rs727505	0.607	rs59635547	chr7:124796371	A/C	cg23710748	chr7:124431027	NA	-0.26	-4.51	-0.38	1.47e-5	Lewy body disease;
TGCT	cis	rs9926296	0.712	rs459920	chr16:89730827	T/C	cg26513180	chr16:89883248	FANCA	-0.67	-6.37	-0.5	3.32e-9	Vitiligo;
TGCT	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg02953382	chr22:24373134	LOC391322	-0.82	-9.18	-0.64	1.21e-15	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg18252515	chr7:66147081	NA	1.25	7.75	0.57	2.92e-12	Diabetic kidney disease;
TGCT	trans	rs72913475	0.579	rs112653862	chr18:44177859	G/A	cg26433034	chr7:128430626	CCDC136	0.61	6.63	0.51	9.33e-10	Midgestational circulating levels of PBDEs (fetal genetic effect);
TGCT	cis	rs11126435	0.844	rs363691	chr2:74841569	C/T	cg19285774	chr2:74907978	SEMA4F	0.24	4.59	0.38	1.08e-5	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg00024416	chr22:24240387	NA	-0.25	-4.76	-0.39	5.27e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	trans	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg27523141	chr10:43048294	ZNF37B	0.73	8.58	0.61	3.32e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs12549025	0.516	rs13257250	chr8:23342959	G/A	cg00472375	chr8:23315376	ENTPD4	0.71	5.42	0.44	2.98e-7	Reticulocyte fraction of red cells;
TGCT	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg10802521	chr3:52805072	NEK4	-0.72	-9.1	-0.63	1.91e-15	Bipolar disorder;
TGCT	cis	rs1933488	0.898	rs1971152	chr6:153425244	G/C	cg24028809	chr6:153414101	RGS17	0.21	4.69	0.39	7.12e-6	Prostate cancer;
TGCT	cis	rs17376456	0.825	rs35496867	chr5:93220400	T/C	cg21475434	chr5:93447410	FAM172A	0.7	4.9	0.4	2.96e-6	Diabetic retinopathy;
TGCT	cis	rs9296092	0.538	rs75501442	chr6:33519493	A/G	cg13560919	chr6:33536144	NA	-0.21	-4.75	-0.39	5.5e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	trans	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.83	-8.69	-0.62	1.76e-14	Body mass index;
TGCT	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg22535103	chr8:58192502	C8orf71	0.42	4.79	0.4	4.7e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4595586	0.545	rs9668716	chr12:39378833	G/T	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg10802521	chr3:52805072	NEK4	-0.7	-8.52	-0.61	4.47e-14	Bipolar disorder;
TGCT	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.61	0.38	9.85e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs832540	0.564	rs33329	chr5:56145068	T/C	cg24531977	chr5:56204891	C5orf35	-0.54	-5.34	-0.43	4.33e-7	Coronary artery disease;
TGCT	cis	rs11696501	0.694	rs7266372	chr20:44266635	T/C	cg11783356	chr20:44313418	WFDC10B	-0.32	-4.63	-0.38	9.25e-6	Brain structure;
TGCT	cis	rs13040088	0.518	rs2427452	chr20:61577275	T/C	cg23096297	chr20:61557774	DIDO1	-0.8	-6.36	-0.5	3.56e-9	Menopause (age at onset);
TGCT	cis	rs7819412	0.668	rs2409714	chr8:11010118	A/G	cg03192020	chr8:11204681	TDH	-0.53	-4.82	-0.4	4.16e-6	Triglycerides;
TGCT	cis	rs2070488	0.896	rs11914389	chr3:38527215	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.89	9.01	0.63	3.09e-15	Electrocardiographic conduction measures;
TGCT	cis	rs6088580	0.601	rs6120668	chr20:33099793	A/G	cg08999081	chr20:33150536	PIGU	0.29	5.57	0.45	1.54e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs28595532	0.841	rs114155681	chr4:119736427	A/G	cg21605333	chr4:119757512	SEC24D	1.61	8.95	0.63	4.36e-15	Cannabis dependence symptom count;
TGCT	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.29	-0.43	5.34e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs10791097	0.547	rs11222371	chr11:130745719	C/T	cg12179176	chr11:130786555	SNX19	0.85	10.17	0.67	4.79e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs4919694	1.000	rs11191445	chr10:104651055	C/T	cg04362960	chr10:104952993	NT5C2	1.06	7.07	0.54	9.73e-11	Arsenic metabolism;
TGCT	cis	rs4478858	0.709	rs937786	chr1:31857869	G/A	cg07478791	chr1:31886160	SERINC2	0.48	4.76	0.39	5.31e-6	Alcohol dependence;
TGCT	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg22920501	chr2:26401640	FAM59B	-0.79	-6.23	-0.49	6.63e-9	Gut microbiome composition (summer);
TGCT	cis	rs669446	0.533	rs3791042	chr1:44219275	T/C	cg12908607	chr1:44402522	ARTN	-0.63	-7.47	-0.56	1.25e-11	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs2562456	0.876	rs2681370	chr19:21736838	T/C	cg25650185	chr19:21324782	ZNF431	-0.64	-5.73	-0.46	7.12e-8	Pain;
TGCT	trans	rs2688608	0.587	rs2894040	chr10:75478159	A/C	cg13918328	chr10:52500089	ASAH2B	0.68	6.7	0.52	6.48e-10	Inflammatory bowel disease;
TGCT	cis	rs3784262	0.692	rs1822205	chr15:58284657	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.44	-6.41	-0.5	2.79e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs2760061	0.626	rs2313118	chr1:228118084	T/C	cg02753203	chr1:228287806	NA	-0.34	-6.57	-0.51	1.24e-9	Diastolic blood pressure;
TGCT	cis	rs6681544	0.544	rs17470277	chr1:82393105	A/C	cg04226724	chr1:82268649	LPHN2	0.47	4.99	0.41	2.02e-6	Metabolite levels  (X-11787);
TGCT	cis	rs797680	0.964	rs4847398	chr1:93578402	C/T	cg17826107	chr1:92977322	EVI5	-0.22	-5.04	-0.41	1.59e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs62244186	0.659	rs9873072	chr3:44516496	G/A	cg02073558	chr3:44770973	ZNF501	0.56	5.48	0.44	2.25e-7	Depressive symptoms;
TGCT	cis	rs7937682	0.632	rs11214029	chr11:111761230	C/T	cg09085632	chr11:111637200	PPP2R1B	0.8	6.72	0.52	5.79e-10	Primary sclerosing cholangitis;
TGCT	cis	rs9952991	0.941	rs60735058	chr18:12795470	T/A	cg24737193	chr18:12778029	NA	-0.52	-5.44	-0.44	2.71e-7	Inflammatory skin disease;
TGCT	cis	rs886427	0.591	rs57768809	chr16:3003947	G/A	cg05630773	chr16:3016717	KREMEN2	0.31	4.52	0.38	1.42e-5	Metabolic syndrome;
TGCT	cis	rs56104184	0.723	rs73063524	chr19:49409004	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.73	-9.15	-0.63	1.47e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs8013055	0.796	rs4074937	chr14:106000977	A/G	cg19700328	chr14:106028568	NA	-0.5	-5.78	-0.46	5.62e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg01341218	chr17:43662625	NA	1.04	7.82	0.57	1.97e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs12780845	0.540	rs11254411	chr10:17201701	A/G	cg01003015	chr10:17271136	VIM	-0.52	-4.71	-0.39	6.42e-6	Homocysteine levels;
TGCT	cis	rs10875595	0.836	rs10062604	chr5:140661932	T/C	cg24830062	chr5:140700576	TAF7	-0.6	-5.07	-0.41	1.42e-6	Pulmonary function decline;
TGCT	cis	rs12477438	0.520	rs11123761	chr2:99705903	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	12.84	0.76	1.57e-24	Chronic sinus infection;
TGCT	cis	rs4819052	0.766	rs4819035	chr21:46645715	A/C	cg06618935	chr21:46677482	NA	-0.35	-4.46	-0.37	1.82e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs11783469	0.522	rs11781808	chr8:23256905	G/A	cg00472375	chr8:23315376	ENTPD4	0.7	5.6	0.45	1.32e-7	Reticulocyte count;
TGCT	cis	rs62244186	0.715	rs11130032	chr3:44704083	G/A	cg09333631	chr3:44802604	KIF15;KIAA1143	-0.42	-4.61	-0.38	9.96e-6	Depressive symptoms;
TGCT	cis	rs7394190	0.748	rs78985317	chr10:75514465	C/T	cg07699608	chr10:75541558	CHCHD1	0.77	4.86	0.4	3.44e-6	Incident atrial fibrillation;
TGCT	cis	rs6964587	0.626	rs1011372	chr7:91509867	T/C	cg17063962	chr7:91808500	NA	-0.76	-7.15	-0.54	6.42e-11	Breast cancer;
TGCT	cis	rs3087591	0.919	rs9913470	chr17:29566575	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.48	-7.43	-0.56	1.53e-11	Hip circumference;
TGCT	cis	rs42648	0.569	rs110360	chr7:89856608	C/T	cg25739043	chr7:89950458	NA	-0.5	-4.83	-0.4	3.91e-6	Homocysteine levels;
TGCT	cis	rs755249	0.727	rs2242500	chr1:40037902	A/G	cg19494946	chr1:39956641	BMP8A	-0.24	-4.52	-0.38	1.43e-5	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs7819412	0.594	rs17724226	chr8:10968926	C/T	cg03192020	chr8:11204681	TDH	-0.48	-4.57	-0.38	1.19e-5	Triglycerides;
TGCT	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg02018176	chr4:1364513	KIAA1530	0.27	4.57	0.38	1.18e-5	Longevity;
TGCT	cis	rs922182	0.613	rs4238401	chr15:64233110	C/T	cg02919090	chr15:64263738	DAPK2	-0.33	-6.14	-0.48	1.05e-8	Blood protein levels;
TGCT	cis	rs13191362	0.507	rs2023036	chr6:163122736	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.61	5.67	0.45	9.31e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs6121246	0.697	rs6088857	chr20:30226764	G/C	cg21427119	chr20:30132790	HM13	-0.37	-5.19	-0.42	8.51e-7	Mean corpuscular hemoglobin;
TGCT	cis	rs7617480	0.544	rs6442129	chr3:48735256	T/C	cg07636037	chr3:49044803	WDR6	0.77	6.37	0.5	3.33e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs10464366	0.746	rs4723822	chr7:39141613	C/T	cg18850127	chr7:39170497	POU6F2	0.27	5.7	0.46	8.11e-8	IgG glycosylation;
TGCT	cis	rs10791323	0.569	rs11533204	chr11:133743644	A/G	cg03690763	chr11:133734501	NA	-0.3	-5.16	-0.42	9.36e-7	Childhood ear infection;
TGCT	cis	rs17001868	0.568	rs55769635	chr22:40790101	G/A	cg07138101	chr22:40742427	ADSL	0.73	5.6	0.45	1.34e-7	Mammographic density (dense area);
TGCT	cis	rs11190604	0.767	rs3750723	chr10:102172989	T/C	cg16005271	chr10:102321736	NA	0.45	4.57	0.38	1.15e-5	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7552404	0.731	rs1493367	chr1:76344011	C/A	cg22875332	chr1:76189707	ACADM	-0.68	-7.11	-0.54	7.96e-11	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs860295	0.580	rs7528441	chr1:155843256	T/G	cg05700447	chr1:155978627	NA	0.21	4.46	0.37	1.8e-5	Body mass index;
TGCT	cis	rs7614311	0.681	rs6801346	chr3:63947128	A/G	cg22134162	chr3:63841271	THOC7	0.46	6.03	0.48	1.77e-8	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs908922	0.676	rs945788	chr1:152512762	A/G	cg20991723	chr1:152506922	NA	0.42	5.58	0.45	1.42e-7	Hair morphology;
TGCT	cis	rs55962025	0.842	rs362306	chr4:3242100	C/T	cg06533319	chr4:3265114	C4orf44	0.23	4.55	0.38	1.27e-5	Parental longevity (mother's age at death);
TGCT	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.2	0.42	8.14e-7	Menopause (age at onset);
TGCT	cis	rs9296092	0.560	rs3846853	chr6:33528194	C/G	cg13560919	chr6:33536144	NA	-0.23	-5.06	-0.41	1.49e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs2249625	0.508	rs60020363	chr6:72844706	C/T	cg24401219	chr6:72892597	RIMS1	0.57	4.46	0.37	1.84e-5	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
TGCT	cis	rs7193541	0.684	rs9931225	chr16:74699293	T/C	cg01733217	chr16:74700730	RFWD3	1.01	13.9	0.78	4.67e-27	Multiple myeloma;
TGCT	cis	rs7208859	0.673	rs2269915	chr17:29233344	C/T	cg18442181	chr17:29233375	C17orf42	-0.78	-4.61	-0.38	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.5	-4.78	-0.39	4.81e-6	Prudent dietary pattern;
TGCT	cis	rs2180341	0.618	rs11961994	chr6:127649350	A/G	cg27446573	chr6:127587934	RNF146	-0.61	-5.53	-0.44	1.83e-7	Breast cancer;
TGCT	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.18	0.49	8.46e-9	Electroencephalogram traits;
TGCT	cis	rs17030434	0.906	rs12643219	chr4:154670798	T/C	cg14289246	chr4:154710475	SFRP2	-0.88	-7.18	-0.54	5.68e-11	Electrocardiographic conduction measures;
TGCT	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg13695892	chr22:41940480	POLR3H	-0.9	-9.03	-0.63	2.7e-15	Vitiligo;
TGCT	cis	rs7043114	0.525	rs6479416	chr9:95053871	G/T	cg14311495	chr9:95764742	FGD3	-0.22	-4.44	-0.37	1.95e-5	Height;
TGCT	cis	rs6667605	0.506	rs10797440	chr1:2541269	A/G	cg18854424	chr1:2615690	NA	0.46	5.36	0.43	4e-7	Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs9300255	0.602	rs4372492	chr12:123697357	T/C	cg00376283	chr12:123451042	ABCB9	0.73	5.67	0.45	9.46e-8	Neutrophil percentage of white cells;
TGCT	cis	rs908922	0.628	rs488393	chr1:152489548	C/T	cg20991723	chr1:152506922	NA	0.48	6.68	0.51	7.17e-10	Hair morphology;
TGCT	cis	rs986417	0.901	rs12436953	chr14:61001546	C/T	cg27398547	chr14:60952738	C14orf39	1.38	10.8	0.7	1.4e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs4566357	0.930	rs12621916	chr2:227923564	T/C	cg11843606	chr2:227700838	RHBDD1	-0.58	-5.31	-0.43	4.92e-7	Coronary artery disease;
TGCT	trans	rs931812	0.895	rs7831714	chr8:101913987	C/T	cg20993868	chr7:22813445	NA	0.4	8.7	0.62	1.66e-14	Attention deficit hyperactivity disorder and conduct disorder;
TGCT	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg24846343	chr22:24311635	DDTL	0.21	5.49	0.44	2.22e-7	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9916302	0.904	rs4794813	chr17:37670994	A/T	cg15445000	chr17:37608096	MED1	0.33	4.93	0.4	2.59e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	5.98	0.47	2.23e-8	Alzheimer's disease;
TGCT	cis	rs2933343	1.000	rs1683782	chr3:128640277	A/G	cg11901034	chr3:128598214	ACAD9	-0.63	-5.13	-0.42	1.08e-6	IgG glycosylation;
TGCT	cis	rs9926296	0.712	rs2434872	chr16:89716915	C/G	cg04287289	chr16:89883240	FANCA	-0.55	-5.06	-0.41	1.48e-6	Vitiligo;
TGCT	cis	rs11741688	0.557	rs6898923	chr5:178330559	C/T	cg09339527	chr5:178322752	ZFP2	-0.29	-4.85	-0.4	3.57e-6	Sleep duration;
TGCT	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg03264133	chr6:25882463	NA	-1.07	-14.31	-0.79	5.01e-28	Urate levels;
TGCT	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg11494091	chr17:61959527	GH2	0.6	14.51	0.79	1.71e-28	Prudent dietary pattern;
TGCT	cis	rs9914988	0.943	rs11652272	chr17:27167973	C/G	cg20469991	chr17:27169893	C17orf63	-0.72	-5.09	-0.42	1.28e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs6088580	0.634	rs6088483	chr20:32984714	T/A	cg24642439	chr20:33292090	TP53INP2	-0.49	-4.49	-0.37	1.59e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs3796352	1.000	rs36090694	chr3:53010742	T/C	cg15956490	chr3:53032818	SFMBT1	0.62	6.82	0.52	3.6e-10	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs6049375	1.000	rs6049366	chr20:24045580	T/C	cg14741141	chr20:24973699	C20orf3	0.87	4.96	0.41	2.31e-6	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs7617773	0.779	rs77957078	chr3:48331286	G/C	cg11946769	chr3:48343235	NME6	0.79	6.8	0.52	3.97e-10	Coronary artery disease;
TGCT	cis	rs7918232	0.830	rs7087033	chr10:27392522	A/G	cg14442939	chr10:27389572	ANKRD26	0.72	5.4	0.44	3.3e-7	Breast cancer;
TGCT	cis	rs916888	0.610	rs199529	chr17:44837217	A/C	cg17911788	chr17:44343683	NA	-0.59	-6.18	-0.49	8.36e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs9952991	0.941	rs2542149	chr18:12779018	G/A	cg24737193	chr18:12778029	NA	0.54	6.03	0.48	1.76e-8	Inflammatory skin disease;
TGCT	cis	rs9914544	0.545	rs4924945	chr17:18813160	A/G	cg26378065	chr17:18585709	ZNF286B	0.51	4.48	0.37	1.66e-5	Educational attainment (years of education);
TGCT	cis	rs9325144	0.723	rs11169482	chr12:39164327	A/T	cg13010199	chr12:38710504	ALG10B	0.51	4.72	0.39	6.28e-6	Morning vs. evening chronotype;
TGCT	cis	rs752010	0.574	rs10890161	chr1:42121623	T/C	cg06885757	chr1:42089581	HIVEP3	0.24	4.56	0.38	1.21e-5	Lupus nephritis in systemic lupus erythematosus;
TGCT	cis	rs78456975	1.000	rs10205916	chr2:1558451	A/T	cg01028140	chr2:1542097	TPO	0.33	4.53	0.38	1.37e-5	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs6754311	0.731	rs10207652	chr2:136588478	T/A	cg07169764	chr2:136633963	MCM6	-0.61	-5.69	-0.46	8.62e-8	Mosquito bite size;
TGCT	cis	rs11105298	0.891	rs11105313	chr12:89923376	A/T	cg08166232	chr12:89918718	WDR51B;GALNT4	0.66	4.78	0.39	4.85e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs2820315	1.000	rs8024	chr1:201845575	C/A	cg12730843	chr1:201915899	LMOD1	-0.27	-4.81	-0.4	4.25e-6	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
TGCT	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.76	0.46	6.35e-8	Height;
TGCT	cis	rs11235843	0.636	rs2140892	chr11:73422879	A/G	cg18195628	chr11:73498948	MRPL48	-0.64	-4.46	-0.37	1.8e-5	Hand grip strength;
TGCT	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg23758822	chr17:41437982	NA	-0.7	-6.6	-0.51	1.1e-9	Menopause (age at onset);
TGCT	cis	rs2729354	1.000	rs2848630	chr11:57356907	T/C	cg24343310	chr11:57249947	NA	0.28	4.8	0.4	4.5e-6	Blood protein levels;
TGCT	cis	rs2153535	0.580	rs6597332	chr6:8504748	C/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs7647973	0.626	rs62262722	chr3:49769419	G/C	cg03060546	chr3:49711283	APEH	-0.59	-4.93	-0.41	2.54e-6	Menarche (age at onset);
TGCT	cis	rs7208859	0.623	rs122898	chr17:28905254	C/T	cg14008862	chr17:28927542	LRRC37B2	-0.9	-5.66	-0.45	1.01e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7208859	0.562	rs8078897	chr17:29106257	T/G	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs10883723	0.773	rs715439	chr10:104257809	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg13944838	chr5:179740914	GFPT2	-0.4	-6.29	-0.49	4.87e-9	Height;
TGCT	cis	rs4642101	0.883	rs6810325	chr3:12840934	T/C	cg05775895	chr3:12838266	CAND2	0.51	4.75	0.39	5.6e-6	QRS complex (12-leadsum);
TGCT	cis	rs79349575	0.783	rs12601955	chr17:47034420	C/T	cg07967210	chr17:47022446	SNF8	0.44	6.15	0.48	9.98e-9	Type 2 diabetes;
TGCT	cis	rs7666738	0.830	rs3857217	chr4:99034347	T/C	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10791323	0.593	rs10791329	chr11:133716356	T/C	cg15485101	chr11:133734466	NA	0.41	5.18	0.42	8.75e-7	Childhood ear infection;
TGCT	trans	rs9650657	0.524	rs10088408	chr8:10817197	C/T	cg06636001	chr8:8085503	FLJ10661	-0.86	-8.43	-0.6	7.52e-14	Neuroticism;
TGCT	cis	rs2066819	1.000	rs35526714	chr12:56634639	G/C	cg26714650	chr12:56694279	CS	-1.29	-5.72	-0.46	7.49e-8	Psoriasis vulgaris;
TGCT	cis	rs9611519	0.732	rs1883826	chr22:41703428	G/A	cg13695892	chr22:41940480	POLR3H	-0.67	-6.28	-0.49	5.18e-9	Neuroticism;
TGCT	cis	rs6484504	0.576	rs208093	chr11:31184400	C/T	cg26647111	chr11:31128758	NA	0.4	5.29	0.43	5.38e-7	Red blood cell count;
TGCT	cis	rs2191566	1.000	rs2356549	chr19:44511202	A/T	cg03039196	chr19:44506973	ZNF230	0.55	4.72	0.39	6.23e-6	Acute lymphoblastic leukemia (childhood);
TGCT	cis	rs3796352	1.000	rs61172708	chr3:52996052	T/G	cg15956490	chr3:53032818	SFMBT1	0.59	6.04	0.48	1.65e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs4460629	0.742	rs11581730	chr1:155082158	A/T	cg23973274	chr1:155060172	NA	-0.26	-4.72	-0.39	6.25e-6	Serum magnesium levels;
TGCT	cis	rs7829975	0.846	rs7005216	chr8:8547110	C/G	cg08975724	chr8:8085496	FLJ10661	-0.54	-4.64	-0.38	8.81e-6	Mood instability;
TGCT	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg01802117	chr1:53393560	SCP2	-0.4	-4.72	-0.39	6.33e-6	Monocyte count;
TGCT	cis	rs73198271	0.773	rs66618176	chr8:8646974	G/C	cg06671706	chr8:8559999	CLDN23	-0.35	-4.5	-0.37	1.52e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs17445774	1.000	rs1509833	chr2:200865225	G/A	cg17644776	chr2:200775616	C2orf69	0.32	5.24	0.43	6.69e-7	LDL cholesterol to HDL cholesterol ratio;
TGCT	cis	rs9467773	0.869	rs1796521	chr6:26421392	T/C	cg09904177	chr6:26538194	HMGN4	-0.5	-4.6	-0.38	1.03e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs5769765	0.955	rs8139758	chr22:50261123	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	1.11	11.76	0.73	6.5e-22	Schizophrenia;
TGCT	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg22920501	chr2:26401640	FAM59B	-0.72	-6.38	-0.5	3.19e-9	Gut microbiome composition (summer);
TGCT	cis	rs7659604	0.502	rs10013916	chr4:122702179	T/G	cg19748678	chr4:122722346	EXOSC9	-0.59	-5.85	-0.47	4.02e-8	Type 2 diabetes;
TGCT	trans	rs2727020	0.729	rs7924782	chr11:49267249	A/G	cg03929089	chr4:120376271	NA	-0.78	-9.21	-0.64	9.98e-16	Coronary artery disease;
TGCT	cis	rs10540	0.730	rs61877766	chr11:512973	T/G	cg03934478	chr11:495069	RNH1	0.32	4.82	0.4	4.16e-6	Body mass index;
TGCT	cis	rs62244186	0.566	rs3762636	chr3:44854563	A/G	cg10108389	chr3:44770937	ZNF501	-0.49	-4.97	-0.41	2.18e-6	Depressive symptoms;
TGCT	cis	rs6845621	0.727	rs11933300	chr4:18896653	A/G	cg12196642	chr4:18937545	NA	-0.25	-4.52	-0.38	1.45e-5	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
TGCT	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg21963583	chr11:68658836	MRPL21	0.38	6.4	0.5	2.84e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs2070488	0.636	rs2284817	chr3:38510388	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.65	5.11	0.42	1.19e-6	Electrocardiographic conduction measures;
TGCT	cis	rs11792861	0.926	rs1333344	chr9:111776224	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.49	4.48	0.37	1.67e-5	Menarche (age at onset);
TGCT	cis	rs17345786	0.798	rs9817043	chr3:101281852	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.63	6.03	0.48	1.71e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2180341	0.814	rs9401959	chr6:127736464	T/C	cg27446573	chr6:127587934	RNF146	0.88	8.07	0.59	5.22e-13	Breast cancer;
TGCT	cis	rs2354432	0.607	rs894471	chr1:146687913	A/G	cg25205988	chr1:146714368	CHD1L	-1.23	-5.96	-0.47	2.43e-8	Mitochondrial DNA levels;
TGCT	cis	rs9486719	0.857	rs9285393	chr6:97020917	C/A	cg18709589	chr6:96969512	KIAA0776	-0.74	-5.72	-0.46	7.69e-8	Migraine;Coronary artery disease;
TGCT	cis	rs7572733	0.515	rs6752458	chr2:198835106	G/T	cg00792783	chr2:198669748	PLCL1	0.57	5.23	0.43	6.99e-7	Dermatomyositis;
TGCT	cis	rs651907	0.557	rs7651404	chr3:101393294	C/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.91	10.9	0.7	8.24e-20	Colorectal cancer;
TGCT	cis	rs7681440	0.967	rs6532191	chr4:90745930	C/T	cg26578617	chr4:90757533	SNCA	-0.47	-4.83	-0.4	3.9e-6	Dementia with Lewy bodies;
TGCT	cis	rs559928	0.553	rs508326	chr11:64176029	C/T	cg12453748	chr11:64085041	PRDX5;TRMT112	-0.55	-4.78	-0.39	4.9100000000000004e-06	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
TGCT	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg11764359	chr7:65958608	NA	-0.62	-5.54	-0.45	1.76e-7	Aortic root size;
TGCT	cis	rs13191362	1.000	rs7769686	chr6:163199467	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.19	0.59	2.72e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg25036284	chr2:26402008	FAM59B	0.65	5.19	0.42	8.36e-7	Mean corpuscular hemoglobin;
TGCT	cis	rs9303401	0.614	rs3087762	chr17:56568680	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.22	0.49	6.83e-9	Cognitive test performance;
TGCT	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs11191270	0.554	rs10444022	chr10:104084889	A/G	cg15320455	chr10:103880129	LDB1	0.86	5.39	0.44	3.48e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs41271951	0.512	rs11204774	chr1:151062957	C/T	cg00666978	chr1:150947442	LASS2	0.89	4.64	0.38	8.54e-6	Blood protein levels;
TGCT	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg21226059	chr5:178986404	RUFY1	-0.62	-7.37	-0.55	2.14e-11	Lung cancer;
TGCT	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs137699	0.604	rs137702	chr22:39750158	T/C	cg11247378	chr22:39784982	NA	-0.61	-6.01	-0.48	1.9e-8	IgG glycosylation;
TGCT	cis	rs1365505	0.600	rs4238381	chr15:50484714	A/T	cg26188685	chr15:50540269	HDC	0.35	6.19	0.49	7.98e-9	Blood metabolite ratios;
TGCT	cis	rs453301	0.686	rs11785819	chr8:8870378	T/G	cg11995313	chr8:8860691	ERI1	0.51	4.46	0.37	1.84e-5	Joint mobility (Beighton score);
TGCT	cis	rs7826238	0.720	rs12546760	chr8:8374836	A/G	cg15556689	chr8:8085844	FLJ10661	-0.6	-5.35	-0.43	4.04e-7	Systolic blood pressure;
TGCT	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg17554472	chr22:41940697	POLR3H	-0.48	-5.15	-0.42	9.89e-7	Vitiligo;
TGCT	cis	rs11250464	0.833	rs4554799	chr10:1407728	C/T	cg20648369	chr10:1411072	ADARB2	-0.32	-4.49	-0.37	1.59e-5	Radiation response;
TGCT	cis	rs763014	0.898	rs4984897	chr16:632180	G/C	cg07343612	chr16:622815	PIGQ	-0.41	-7.87	-0.58	1.52e-12	Height;
TGCT	cis	rs950776	0.642	rs34694149	chr15:78965917	C/T	cg21242079	chr15:79101063	ADAMTS7	-0.31	-4.71	-0.39	6.54e-6	Sudden cardiac arrest;
TGCT	cis	rs7945705	0.902	rs10769980	chr11:9014180	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.48	5.31	0.43	4.95e-7	Hemoglobin concentration;
TGCT	cis	rs2204008	0.840	rs3892363	chr12:38479487	G/A	cg26384229	chr12:38710491	ALG10B	0.83	7.6	0.56	6.18e-12	Bladder cancer;
TGCT	cis	rs4253772	0.513	rs9306512	chr22:46716603	T/C	cg24881330	chr22:46731750	TRMU	0.97	6.37	0.5	3.32e-9	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs765787	0.530	rs4238377	chr15:45541981	A/G	cg24006582	chr15:45444508	DUOX1	-0.25	-5.54	-0.45	1.76e-7	Uric acid levels;
TGCT	cis	rs1843834	0.611	rs1058360	chr2:225449242	A/T	cg22455342	chr2:225449267	CUL3	1.04	10.75	0.69	1.87e-19	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs7926906	1.000	rs10741374	chr11:90521749	C/T	cg26138821	chr11:89956704	CHORDC1	-0.51	-5.52	-0.44	1.92e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9660180	0.836	rs12038134	chr1:1703865	T/A	cg20999797	chr1:1681921	NA	0.18	4.77	0.39	5e-6	Body mass index;
TGCT	cis	rs6860806	0.507	rs200837	chr5:131699958	G/A	cg24060327	chr5:131705240	SLC22A5	-0.77	-8.47	-0.61	6.11e-14	Breast cancer;
TGCT	cis	rs796364	1.000	rs1704186	chr2:200769539	A/C	cg17644776	chr2:200775616	C2orf69	0.31	4.85	0.4	3.58e-6	Schizophrenia;
TGCT	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg24578937	chr1:2090814	PRKCZ	-0.26	-6.31	-0.49	4.4e-9	Height;
TGCT	cis	rs6867913	0.709	rs891987	chr5:141467196	A/T	cg24830494	chr5:140474986	PCDHB2	0.4	4.58	0.38	1.14e-5	Asthma;
TGCT	cis	rs4319547	1.000	rs7307735	chr12:123087442	A/G	cg23029597	chr12:123009494	RSRC2	-0.3	-4.88	-0.4	3.14e-6	Body mass index;
TGCT	cis	rs35160687	0.901	rs10520415	chr2:86498738	C/T	cg03171300	chr2:86307199	POLR1A	-0.32	-5.53	-0.44	1.83e-7	Night sleep phenotypes;
TGCT	trans	rs7618501	0.699	rs9821675	chr3:49902544	A/G	cg21659725	chr3:3221576	CRBN	0.78	9.37	0.64	4.19e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs2439831	0.867	rs2470134	chr15:43849886	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.96	-6.6	-0.51	1.06e-9	Lung cancer in ever smokers;
TGCT	cis	rs6570726	0.846	rs1935616	chr6:145943512	C/T	cg23711669	chr6:146136114	FBXO30	0.84	9.16	0.64	1.36e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs854765	0.647	rs4365346	chr17:17989373	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.68	7.01	0.53	1.33e-10	Total body bone mineral density;
TGCT	trans	rs1908814	0.516	rs4841641	chr8:11798227	G/A	cg15556689	chr8:8085844	FLJ10661	0.75	7.07	0.54	9.74e-11	Neuroticism;
TGCT	cis	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg07424592	chr7:64974309	NA	1.27	7.86	0.58	1.61e-12	Diabetic kidney disease;
TGCT	cis	rs2235642	0.893	rs2076442	chr16:1591112	G/T	cg11375102	chr16:1583810	IFT140;TMEM204	-0.31	-5.53	-0.44	1.84e-7	Coronary artery disease;
TGCT	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.94	7.92	0.58	1.17e-12	Platelet count;
TGCT	cis	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg25809561	chr17:30822961	MYO1D	-0.27	-4.59	-0.38	1.08e-5	Schizophrenia;
TGCT	cis	rs9653442	0.564	rs12992234	chr2:100767886	G/A	cg07810366	chr2:100720526	AFF3	-0.35	-5.26	-0.43	6e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs3796352	1.000	rs750474	chr3:53085280	A/C	cg07884673	chr3:53033167	SFMBT1	0.55	6.0	0.47	1.97e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs1215050	0.547	rs35000521	chr4:98626371	T/C	cg05340658	chr4:99064831	C4orf37	-0.41	-4.96	-0.41	2.3e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs6735179	0.648	rs10469992	chr2:1760091	A/G	cg08534653	chr2:1747700	PXDN	-0.56	-4.67	-0.39	7.58e-6	Response to antipsychotic treatment;
TGCT	cis	rs7772486	0.701	rs11155438	chr6:145950112	C/G	cg05347473	chr6:146136440	FBXO30	0.53	4.97	0.41	2.2e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg03452623	chr4:187889614	NA	-0.36	-5.19	-0.42	8.48e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11671005	0.735	rs3826684	chr19:58918705	T/C	cg13877915	chr19:58951672	ZNF132	0.63	4.92	0.4	2.74e-6	Mean platelet volume;
TGCT	cis	rs3847687	1.000	rs11061290	chr12:131518747	C/T	cg25772418	chr12:131519998	GPR133	-0.32	-5.47	-0.44	2.34e-7	Longevity;
TGCT	cis	rs79349575	0.783	rs15563	chr17:47005193	A/G	cg26022315	chr17:47021804	SNF8	0.5	4.96	0.41	2.25e-6	Type 2 diabetes;
TGCT	cis	rs11971779	0.941	rs1127424	chr7:139107660	A/G	cg07862535	chr7:139043722	LUC7L2	0.79	5.8	0.46	5.13e-8	Diisocyanate-induced asthma;
TGCT	cis	rs7772486	0.840	rs2777478	chr6:146309117	T/C	cg05347473	chr6:146136440	FBXO30	0.54	5.0	0.41	1.91e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs8032315	1.000	rs6227	chr15:91425232	C/T	cg04510874	chr15:91427884	FES	0.48	5.17	0.42	9.21e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs860295	0.580	rs867548	chr1:155880008	G/C	cg13795986	chr1:155880507	RIT1	0.38	4.59	0.38	1.05e-5	Body mass index;
TGCT	cis	rs3845702	1.000	rs259808	chr2:180791419	T/G	cg01881094	chr2:180872142	CWC22	-0.68	-5.99	-0.47	2.15e-8	Schizophrenia;
TGCT	cis	rs1577917	1.000	rs12213149	chr6:86668644	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.13	-0.42	1.07e-6	Response to antipsychotic treatment;
TGCT	cis	rs12711979	0.692	rs6751947	chr2:3820739	G/A	cg17052675	chr2:3827356	NA	-0.4	-7.82	-0.57	2.02e-12	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs2361710	0.669	rs12940486	chr17:78118569	T/C	cg09238746	chr17:78121135	EIF4A3	-0.79	-7.49	-0.56	1.13e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
TGCT	cis	rs7010267	0.551	rs6469801	chr8:120025675	T/C	cg17171407	chr8:119960777	TNFRSF11B	0.26	4.59	0.38	1.06e-5	Total body bone mineral density (age 45-60);
TGCT	cis	rs1997103	0.954	rs4947505	chr7:55409448	T/C	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs7213347	0.780	rs216224	chr17:2156285	T/C	cg20777128	chr17:1945076	DPH1;OVCA2	0.53	4.86	0.4	3.5e-6	Total body bone mineral density;
TGCT	cis	rs6089584	0.566	rs2181589	chr20:60622817	C/T	cg06108461	chr20:60628389	TAF4	0.43	5.46	0.44	2.54e-7	Body mass index;
TGCT	cis	rs10751667	0.961	rs6597954	chr11:987677	G/A	cg06064525	chr11:970664	AP2A2	-0.31	-6.16	-0.48	9.52e-9	Alzheimer's disease (late onset);
TGCT	cis	rs2933343	1.000	rs2933343	chr3:128658492	G/A	cg11901034	chr3:128598214	ACAD9	-0.62	-5.0	-0.41	1.92e-6	IgG glycosylation;
TGCT	cis	rs362272	0.524	rs2857982	chr4:3358665	G/A	cg22655196	chr4:3374909	RGS12	0.22	4.45	0.37	1.86e-5	Serum sulfate level;
TGCT	cis	rs7772486	0.902	rs1125462	chr6:146417832	A/G	cg05347473	chr6:146136440	FBXO30	0.55	5.27	0.43	5.86e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs12541335	0.639	rs3923433	chr8:22169798	A/T	cg26039829	chr8:22132926	PIWIL2	0.27	5.07	0.41	1.39e-6	Hypertriglyceridemia;
TGCT	cis	rs9372498	0.536	rs62421536	chr6:118727972	G/A	cg07617317	chr6:118971624	C6orf204	0.49	5.27	0.43	5.82e-7	Diastolic blood pressure;
TGCT	cis	rs7752195	0.730	rs2744301	chr6:25323143	G/T	cg16898833	chr6:26189333	HIST1H4D	1.16	5.04	0.41	1.62e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs453301	0.686	rs11785634	chr8:8892597	G/T	cg06636001	chr8:8085503	FLJ10661	-0.66	-5.58	-0.45	1.42e-7	Joint mobility (Beighton score);
TGCT	cis	rs9467711	1.000	rs9467707	chr6:26327905	G/C	cg16898833	chr6:26189333	HIST1H4D	1.04	5.51	0.44	1.97e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7089973	0.604	rs7920216	chr10:116611794	G/A	cg03647239	chr10:116582469	FAM160B1	0.58	5.49	0.44	2.2e-7	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg11494091	chr17:61959527	GH2	0.45	7.56	0.56	7.84e-12	Height;
TGCT	cis	rs17114671	1.000	rs4982325	chr14:21156836	A/G	cg19983597	chr14:21852154	SUPT16H	-0.77	-4.49	-0.37	1.58e-5	Blood protein levels;
TGCT	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg09174653	chr7:1063357	C7orf50;MIR339	0.23	4.58	0.38	1.11e-5	Longevity;Endometriosis;
TGCT	cis	rs939658	0.805	rs11635757	chr15:79432737	T/C	cg17916960	chr15:79447300	NA	-0.49	-7.41	-0.55	1.73e-11	Refractive error;
TGCT	cis	rs17253792	0.822	rs7150841	chr14:56088986	T/C	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg07507251	chr3:52567010	NT5DC2	0.47	6.74	0.52	5.33e-10	Electroencephalogram traits;
TGCT	cis	rs7508	0.511	rs208025	chr8:17878170	A/G	cg01800426	chr8:17659068	MTUS1	-0.6	-4.88	-0.4	3.21e-6	Atrial fibrillation;
TGCT	cis	rs9650657	0.506	rs7823296	chr8:10778546	A/G	cg27411982	chr8:10470053	RP1L1	-0.22	-4.54	-0.38	1.32e-5	Neuroticism;
TGCT	cis	rs8013055	0.706	rs8003957	chr14:105971702	A/G	cg25008857	chr14:105974488	NA	0.28	4.52	0.38	1.44e-5	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs6430585	0.702	rs1042712	chr2:136545844	C/G	cg07169764	chr2:136633963	MCM6	-1.19	-11.11	-0.71	2.49e-20	Corneal structure;
TGCT	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg06238570	chr21:40685208	BRWD1	0.7	6.45	0.5	2.3e-9	Cognitive function;
TGCT	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg17971929	chr21:40555470	PSMG1	0.97	9.54	0.65	1.67e-16	Cognitive function;
TGCT	cis	rs864537	0.676	rs2056626	chr1:167420425	T/G	cg22356347	chr1:167427500	CD247	-0.21	-5.34	-0.43	4.26e-7	Celiac disease or Rheumatoid arthritis;Celiac disease;
TGCT	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg13732083	chr21:47605072	C21orf56	0.36	4.63	0.38	9.03e-6	Testicular germ cell tumor;
TGCT	cis	rs7552404	0.731	rs1493367	chr1:76344011	C/A	cg03433033	chr1:76189801	ACADM	-0.76	-7.76	-0.57	2.66e-12	Blood metabolite levels;Acylcarnitine levels;
TGCT	trans	rs4650994	0.524	rs1998544	chr1:178605276	T/C	cg05059571	chr16:84539110	KIAA1609	0.52	10.29	0.68	2.48e-18	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.31	0.43	4.9e-7	Prudent dietary pattern;
TGCT	cis	rs9325144	0.560	rs2387924	chr12:38662883	A/G	cg26384229	chr12:38710491	ALG10B	-0.63	-5.92	-0.47	2.9e-8	Morning vs. evening chronotype;
TGCT	cis	rs797680	0.664	rs4847420	chr1:93845674	A/C	cg17826107	chr1:92977322	EVI5	-0.23	-5.48	-0.44	2.25e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs9902453	0.765	rs12601647	chr17:28164953	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.83	7.95	0.58	9.99e-13	Coffee consumption (cups per day);
TGCT	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg17971929	chr21:40555470	PSMG1	-0.54	-4.83	-0.4	4e-6	Menarche (age at onset);
TGCT	cis	rs2075371	1.000	rs2598292	chr7:133988584	C/G	cg11752832	chr7:134001865	SLC35B4	0.69	6.32	0.49	4.19e-9	Mean platelet volume;
TGCT	cis	rs1867631	1.000	rs11208927	chr1:67089561	T/C	cg13052034	chr1:66999238	SGIP1	0.56	4.75	0.39	5.54e-6	Menopause (age at onset);
TGCT	cis	rs7937682	0.562	rs12275761	chr11:111367083	T/A	cg09085632	chr11:111637200	PPP2R1B	0.69	6.53	0.51	1.49e-9	Primary sclerosing cholangitis;
TGCT	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg06640241	chr16:89574553	SPG7	0.77	8.86	0.62	7.12e-15	Multiple myeloma (IgH translocation);
TGCT	cis	rs9467773	0.836	rs1624440	chr6:26433329	G/A	cg05738196	chr6:26577821	NA	-0.63	-6.86	-0.52	2.91e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs881375	0.934	rs1468671	chr9:123657502	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	5.55	0.45	1.65e-7	Rheumatoid arthritis;
TGCT	cis	rs2742417	1.000	rs938362	chr3:45746365	T/C	cg04837898	chr3:45731254	SACM1L	-0.55	-5.68	-0.45	9.22e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs56235845	0.694	rs36102285	chr5:176774018	C/T	cg06060754	chr5:176797920	RGS14	0.42	6.57	0.51	1.23e-9	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs4689388	0.890	rs4688989	chr4:6290594	T/C	cg14416269	chr4:6271139	WFS1	0.37	4.92	0.4	2.69e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg08677398	chr8:58056175	NA	0.33	4.73	0.39	6.11e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs11250098	0.562	rs6987134	chr8:10804906	T/C	cg21775007	chr8:11205619	TDH	-0.56	-5.09	-0.42	1.3e-6	Morning vs. evening chronotype;
TGCT	cis	rs11249608	0.548	rs7704565	chr5:178473923	G/C	cg21905437	chr5:178450457	ZNF879	0.43	4.49	0.37	1.59e-5	Pubertal anthropometrics;
TGCT	cis	rs1451375	0.698	rs12669770	chr7:50656334	G/A	cg18232548	chr7:50535776	DDC	0.44	6.66	0.51	8e-10	Malaria;
TGCT	cis	rs6484504	0.532	rs10835757	chr11:31281902	C/T	cg26647111	chr11:31128758	NA	-0.35	-4.77	-0.39	5.12e-6	Red blood cell count;
TGCT	cis	rs9393692	0.905	rs6931391	chr6:26279235	G/C	cg05868516	chr6:26286170	HIST1H4H	0.63	5.91	0.47	3.02e-8	Educational attainment;
TGCT	cis	rs34526934	0.608	rs7606110	chr2:177028551	T/C	cg14324370	chr2:177042789	NA	-0.9	-8.57	-0.61	3.41e-14	Obstructive sleep apnea trait (apnea hypopnea index);
TGCT	cis	rs1322512	1.000	rs7744715	chr6:152949026	G/A	cg03415253	chr6:152958462	SYNE1	-0.57	-4.99	-0.41	2e-6	Tonometry;
TGCT	cis	rs7119	0.604	rs1055691	chr15:77864625	G/C	cg27398640	chr15:77910606	LINGO1	0.25	4.64	0.38	8.6e-6	Type 2 diabetes;
TGCT	cis	rs9467773	1.000	rs6926629	chr6:26499903	T/C	cg05738196	chr6:26577821	NA	0.87	12.41	0.74	1.7e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs1729951	0.575	rs747843	chr3:136703130	G/C	cg12473912	chr3:136751656	NA	0.39	6.18	0.49	8.36e-9	Neuroticism;
TGCT	cis	rs9346649	0.606	rs7750135	chr6:168490841	C/A	cg02770688	chr6:168491649	NA	0.31	5.56	0.45	1.56e-7	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
TGCT	cis	rs7772486	0.790	rs2265472	chr6:146220758	G/C	cg23711669	chr6:146136114	FBXO30	0.89	10.16	0.67	5.28e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2288884	1.000	rs17779301	chr19:52539243	A/G	cg13540795	chr19:52551618	ZNF432	0.56	4.94	0.41	2.5e-6	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs72945132	0.882	rs10466703	chr11:70218548	C/T	cg00319359	chr11:70116639	PPFIA1	0.99	7.39	0.55	1.94e-11	Coronary artery disease;
TGCT	cis	rs60843830	1.000	rs3791220	chr2:227066	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.74	7.48	0.56	1.19e-11	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs9300255	0.739	rs10846491	chr12:123753492	C/G	cg00376283	chr12:123451042	ABCB9	0.74	5.71	0.46	7.74e-8	Neutrophil percentage of white cells;
TGCT	cis	rs9926296	0.535	rs36022917	chr16:89893238	A/G	cg26513180	chr16:89883248	FANCA	0.72	7.15	0.54	6.73e-11	Vitiligo;
TGCT	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg26818010	chr10:134567672	INPP5A	-0.37	-5.02	-0.41	1.74e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs4654899	0.714	rs12133972	chr1:21091338	A/T	cg01072550	chr1:21505969	NA	-0.48	-7.17	-0.54	6.05e-11	Superior frontal gyrus grey matter volume;
TGCT	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg14983838	chr19:29218262	NA	0.83	6.85	0.52	3.07e-10	Methadone dose in opioid dependence;
TGCT	cis	rs4325129	1.000	rs67371748	chr1:159489964	T/C	cg07417683	chr1:159440267	NA	-0.46	-4.71	-0.39	6.62e-6	Obesity-related traits;
TGCT	cis	rs13256369	0.802	rs11249888	chr8:8564934	T/C	cg17143192	chr8:8559678	CLDN23	0.57	5.35	0.43	4.09e-7	Obesity-related traits;
TGCT	cis	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg02380750	chr20:61661411	NA	0.33	5.96	0.47	2.4e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs139371	0.550	rs139348	chr22:39507896	C/T	cg18708252	chr22:39545030	CBX7	-0.31	-4.65	-0.39	8.52e-6	Multiple myeloma (IgH translocation);Multiple myeloma (hyperdiploidy);
TGCT	cis	rs2637266	1.000	rs2637267	chr10:78331803	A/G	cg18941641	chr10:78392320	NA	0.4	4.98	0.41	2.09e-6	Pulmonary function;
TGCT	cis	rs1799899	0.826	rs8177321	chr3:133473834	G/T	cg18342939	chr3:134203408	ANAPC13;CEP63	0.55	5.3	0.43	5.23e-7	Alcohol consumption (transferrin glycosylation);
TGCT	trans	rs2688608	0.839	rs2633311	chr10:75598099	C/T	cg13918328	chr10:52500089	ASAH2B	-0.69	-6.68	-0.51	7.15e-10	Inflammatory bowel disease;
TGCT	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg24549020	chr5:56110836	MAP3K1	0.66	5.79	0.46	5.56e-8	Initial pursuit acceleration;
TGCT	cis	rs78456975	0.689	rs10194040	chr2:1543293	T/G	cg01028140	chr2:1542097	TPO	-0.37	-5.3	-0.43	5.13e-7	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs7772486	0.790	rs3923579	chr6:146230232	C/G	cg05347473	chr6:146136440	FBXO30	-0.52	-5.03	-0.41	1.67e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7017914	0.967	rs13258584	chr8:71671579	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.53	-4.9	-0.4	2.87e-6	Bone mineral density;
TGCT	cis	rs9534288	0.763	rs34175925	chr13:46611800	G/A	cg15192986	chr13:46630673	CPB2	-0.53	-7.66	-0.57	4.65e-12	Blood protein levels;
TGCT	cis	rs2066819	1.000	rs2066819	chr12:56750204	C/T	cg26714650	chr12:56694279	CS	-1.36	-5.89	-0.47	3.4e-8	Psoriasis vulgaris;
TGCT	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9325144	0.600	rs61931871	chr12:38829889	G/A	cg10518543	chr12:38710700	ALG10B	-0.49	-4.48	-0.37	1.65e-5	Morning vs. evening chronotype;
TGCT	cis	rs6032067	0.636	rs6032092	chr20:43911886	A/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.4	-6.56	-0.51	1.32e-9	Blood protein levels;
TGCT	cis	rs28595532	0.920	rs115982145	chr4:119605707	A/G	cg21605333	chr4:119757512	SEC24D	1.36	7.24	0.55	4.12e-11	Cannabis dependence symptom count;
TGCT	cis	rs6754311	0.552	rs1030765	chr2:136553188	A/T	cg07169764	chr2:136633963	MCM6	-0.67	-6.14	-0.48	1.01e-8	Mosquito bite size;
TGCT	cis	rs9677476	1.000	rs13415839	chr2:232126534	C/T	cg07929768	chr2:232055508	NA	0.3	4.48	0.37	1.71e-5	Food antigen IgG levels;
TGCT	cis	rs6964587	1.000	rs6969981	chr7:91689461	G/C	cg17063962	chr7:91808500	NA	0.88	9.65	0.66	8.73e-17	Breast cancer;
TGCT	cis	rs7582180	0.629	rs12991172	chr2:100941671	A/G	cg08017756	chr2:100939284	LONRF2	-0.3	-4.78	-0.39	4.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs3862260	0.509	rs1045827	chr1:120162442	C/T	cg16322792	chr1:120165303	ZNF697	-0.35	-7.95	-0.58	9.59e-13	Systemic lupus erythematosus;
TGCT	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.43	-4.74	-0.39	5.87e-6	Longevity;Endometriosis;
TGCT	cis	rs1552244	0.832	rs66597916	chr3:10195407	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.55	-6.53	-0.51	1.5e-9	Alzheimer's disease;
TGCT	cis	rs6121246	0.559	rs6060716	chr20:30274847	C/G	cg13852791	chr20:30311386	BCL2L1	0.82	8.0	0.58	7.65e-13	Mean corpuscular hemoglobin;
TGCT	cis	rs2440129	0.632	rs15966	chr17:6905643	T/C	cg03760483	chr17:6899297	ALOX12	0.48	5.5	0.44	2.11e-7	Tonsillectomy;
TGCT	cis	rs9527	0.525	rs12770034	chr10:104635595	A/G	cg04362960	chr10:104952993	NT5C2	0.56	4.77	0.39	5.06e-6	Arsenic metabolism;
TGCT	trans	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	1.03	13.16	0.76	2.65e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs6032067	0.598	rs2741500	chr20:43944958	G/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.45	-6.76	-0.52	4.76e-10	Blood protein levels;
TGCT	cis	rs7412746	0.621	rs11204749	chr1:150929563	G/A	cg04414720	chr1:150670196	GOLPH3L	0.37	4.46	0.37	1.81e-5	Melanoma;
TGCT	cis	rs6500602	0.701	rs4785968	chr16:4535307	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.39	6.86	0.52	2.91e-10	Schizophrenia;
TGCT	cis	rs904251	0.523	rs10947675	chr6:37479972	G/A	cg25019722	chr6:37503610	NA	-0.52	-7.67	-0.57	4.31e-12	Cognitive performance;
TGCT	cis	rs7178572	0.568	rs11630689	chr15:77520094	C/T	cg15453836	chr15:77711506	NA	-0.44	-4.92	-0.4	2.67e-6	Type 2 diabetes;
TGCT	cis	rs4711350	0.862	rs652049	chr6:33711420	C/T	cg00334056	chr6:33755658	LEMD2	0.31	4.81	0.4	4.31e-6	Schizophrenia;
TGCT	trans	rs5771242	0.518	rs5771258	chr22:50675648	C/A	cg26607758	chr8:91997553	NA	0.69	6.87	0.53	2.76e-10	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
TGCT	cis	rs12510870	0.599	rs28693538	chr4:74450490	T/G	cg05868023	chr4:75230803	EREG	-0.54	-4.76	-0.39	5.33e-6	Iris color (b* coordinate);
TGCT	cis	rs9549260	0.755	rs9532577	chr13:41231542	A/G	cg21288729	chr13:41239152	FOXO1	0.99	10.42	0.68	1.22e-18	Red blood cell count;
TGCT	cis	rs17401966	0.931	rs12137880	chr1:10388620	T/C	cg19773385	chr1:10388646	KIF1B	-0.24	-5.5	-0.44	2.03e-7	Hepatocellular carcinoma;
TGCT	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg08280861	chr8:58055591	NA	0.36	4.67	0.39	7.7e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1729951	0.575	rs835642	chr3:136703365	A/T	cg21827317	chr3:136751795	NA	0.4	5.61	0.45	1.28e-7	Neuroticism;
TGCT	cis	rs7726839	0.540	rs3749618	chr5:602650	A/G	cg09021430	chr5:549028	NA	-0.39	-5.26	-0.43	6.14e-7	Obesity-related traits;
TGCT	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.79	5.34	0.43	4.3e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7017914	0.905	rs3110240	chr8:71930104	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.56	-5.11	-0.42	1.21e-6	Bone mineral density;
TGCT	cis	rs523522	0.962	rs7136951	chr12:120941927	C/T	cg27279351	chr12:120934652	DYNLL1	0.76	6.59	0.51	1.15e-9	High light scatter reticulocyte count;
TGCT	cis	rs250677	0.652	rs1422582	chr5:148436925	T/C	cg23229984	chr5:148520753	ABLIM3	0.22	4.98	0.41	2.05e-6	Breast cancer;
TGCT	cis	rs6570726	0.967	rs403584	chr6:145807010	G/A	cg23711669	chr6:146136114	FBXO30	0.67	6.32	0.49	4.31e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10851411	0.817	rs56357092	chr15:42790529	G/A	cg23803468	chr15:43513504	EPB42	0.28	5.15	0.42	1.01e-6	Glucose homeostasis traits;
TGCT	cis	rs7258465	0.965	rs8100767	chr19:18589088	T/C	cg06462663	chr19:18546047	ISYNA1	0.2	4.63	0.38	9.01e-6	Breast cancer;
TGCT	cis	rs10992471	0.756	rs11792342	chr9:95143668	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.61	-6.31	-0.49	4.46e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs4319547	0.697	rs7974262	chr12:122896385	C/T	cg08088222	chr12:122070432	ORAI1	-0.25	-4.43	-0.37	2.01e-5	Body mass index;
TGCT	cis	rs7666738	0.830	rs3911282	chr4:99037602	T/A	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9894429	0.646	rs58398000	chr17:79576923	G/A	cg21028142	chr17:79581711	NPLOC4	-0.29	-5.95	-0.47	2.56e-8	Eye color traits;
TGCT	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg25767906	chr1:53392781	SCP2	0.48	5.55	0.45	1.62e-7	Monocyte count;
TGCT	cis	rs4595586	0.545	rs2218762	chr12:39397762	G/A	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs3540	0.513	rs2589962	chr15:90921636	G/A	cg22089800	chr15:90895588	ZNF774	0.82	9.04	0.63	2.61e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.06	-9.57	-0.65	1.41e-16	Platelet count;
TGCT	cis	rs9660180	0.967	rs12040325	chr1:1702436	G/A	cg20999797	chr1:1681921	NA	0.18	4.77	0.39	5.09e-6	Body mass index;
TGCT	cis	rs9467773	0.649	rs2145318	chr6:26496603	T/A	cg26531700	chr6:26746687	NA	0.57	5.54	0.45	1.75e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7914558	1.000	rs943038	chr10:104826261	T/C	cg04362960	chr10:104952993	NT5C2	0.59	5.28	0.43	5.56e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs6582630	0.555	rs11182217	chr12:38480030	G/A	cg26384229	chr12:38710491	ALG10B	0.89	8.05	0.59	5.63e-13	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs9383153	1.000	rs9370887	chr6:16329258	G/C	cg20052079	chr6:15504923	JARID2	0.85	4.77	0.39	5.06e-6	Gambling;
TGCT	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg04267008	chr7:1944627	MAD1L1	0.35	4.62	0.38	9.36e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs9611565	0.512	rs768414	chr22:42135751	T/C	cg06634786	chr22:41940651	POLR3H	0.87	8.12	0.59	3.86e-13	Vitiligo;
TGCT	cis	rs12579753	0.709	rs34503239	chr12:82124199	G/T	cg07988820	chr12:82153109	PPFIA2	-0.67	-7.13	-0.54	7.12e-11	Resting heart rate;
TGCT	cis	rs2880765	0.835	rs4842886	chr15:86035773	G/A	cg13263323	chr15:86062960	AKAP13	-0.22	-4.84	-0.4	3.84e-6	Coronary artery disease;
TGCT	cis	rs797680	0.927	rs1000607	chr1:93772001	T/C	cg17826107	chr1:92977322	EVI5	-0.23	-5.1	-0.42	1.24e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs3091242	0.933	rs909833	chr1:25754140	C/G	cg09222892	chr1:25734099	RHCE	-0.43	-7.1	-0.54	8.54e-11	Erythrocyte sedimentation rate;
TGCT	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg06481639	chr22:41940642	POLR3H	-0.72	-6.29	-0.49	4.98e-9	Vitiligo;
TGCT	cis	rs208520	1.000	rs12191403	chr6:66978137	C/T	cg07460842	chr6:66804631	NA	0.78	6.82	0.52	3.61e-10	Exhaled nitric oxide output;
TGCT	cis	rs2535633	0.588	rs2564930	chr3:53017307	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	0.55	5.24	0.43	6.68e-7	Body mass index;
TGCT	cis	rs7552404	1.000	rs28602663	chr1:76235355	C/T	cg22875332	chr1:76189707	ACADM	0.76	8.83	0.62	8.53e-15	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9926296	0.744	rs164749	chr16:89708224	A/C	cg26513180	chr16:89883248	FANCA	-0.56	-5.49	-0.44	2.19e-7	Vitiligo;
TGCT	cis	rs1008375	1.000	rs28552744	chr4:17620165	A/G	cg10189774	chr4:17578691	LAP3	0.6	5.21	0.42	7.64e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg06618935	chr21:46677482	NA	-0.37	-5.83	-0.46	4.48e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.48	-5.53	-0.44	1.83e-7	Longevity;Endometriosis;
TGCT	cis	rs477895	1.000	rs12785488	chr11:64107521	G/A	cg04317338	chr11:64019027	PLCB3	0.69	5.36	0.43	3.98e-7	Mean platelet volume;
TGCT	cis	rs6688613	0.694	rs2075946	chr1:166818566	A/G	cg07049167	chr1:166818506	POGK	0.24	5.09	0.42	1.31e-6	Refractive astigmatism;
TGCT	cis	rs651907	0.535	rs13084113	chr3:101534039	C/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.86	10.43	0.68	1.13e-18	Colorectal cancer;
TGCT	cis	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg07424592	chr7:64974309	NA	1.4	8.42	0.6	7.87e-14	Diabetic kidney disease;
TGCT	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg11062466	chr8:58055876	NA	0.37	4.48	0.37	1.65e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs4372836	0.729	rs12714241	chr2:28969413	T/C	cg09522027	chr2:28974177	PPP1CB	-0.63	-6.25	-0.49	6.12e-9	Body mass index;
TGCT	cis	rs9583531	0.600	rs9555724	chr13:111354110	C/T	cg24331049	chr13:111365604	ING1	-0.74	-7.42	-0.55	1.58e-11	Coronary artery disease;
TGCT	cis	rs2836974	0.799	rs8129303	chr21:40711959	G/A	cg11890956	chr21:40555474	PSMG1	1.0	9.38	0.64	3.9e-16	Cognitive function;
TGCT	cis	rs9896933	0.775	rs615630	chr17:80730527	T/C	cg20578329	chr17:80767326	TBCD	0.32	4.58	0.38	1.1e-5	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
TGCT	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg22963979	chr7:1858916	MAD1L1	-0.44	-7.18	-0.54	5.77e-11	Bipolar disorder and schizophrenia;
TGCT	cis	rs7589728	0.563	rs80324973	chr2:88447264	T/G	cg04511125	chr2:88470314	THNSL2	0.79	6.55	0.51	1.37e-9	Plasma clusterin levels;
TGCT	cis	rs9611565	0.546	rs5758426	chr22:42098763	T/G	cg06481639	chr22:41940642	POLR3H	0.6	5.18	0.42	8.77e-7	Vitiligo;
TGCT	cis	rs11018874	0.709	rs10830428	chr11:89894294	C/G	cg23743573	chr11:89867420	NAALAD2	-0.4	-4.44	-0.37	2e-5	White blood cell types;
TGCT	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg23283495	chr1:209979779	IRF6	0.65	5.53	0.44	1.81e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg00484396	chr16:3507460	NAT15	-0.44	-6.59	-0.51	1.12e-9	Tuberculosis;
TGCT	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg02353165	chr6:42928485	GNMT	0.94	9.64	0.65	9.69e-17	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs36093844	1.000	rs11234452	chr11:85576801	C/T	cg25872744	chr11:85566296	CCDC83	-0.52	-5.09	-0.42	1.31e-6	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
TGCT	cis	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg08045932	chr20:61659980	NA	0.48	9.28	0.64	7.07e-16	Prostate cancer (SNP x SNP interaction);
TGCT	trans	rs77457752	0.525	rs10120716	chr9:13897909	G/A	cg25510823	chr7:47085976	NA	0.45	6.68	0.51	7.21e-10	Breast cancer;
TGCT	trans	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg21659725	chr3:3221576	CRBN	-0.73	-8.48	-0.61	5.64e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs2072499	1.000	rs2072499	chr1:156169610	A/G	cg25208724	chr1:156163844	SLC25A44	1.11	16.13	0.82	3.11e-32	Testicular germ cell tumor;
TGCT	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg26354017	chr1:205819088	PM20D1	0.56	6.81	0.52	3.75e-10	Menarche (age at onset);
TGCT	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg06238570	chr21:40685208	BRWD1	0.69	6.39	0.5	3.07e-9	Cognitive function;
TGCT	trans	rs208520	0.690	rs10455594	chr6:66737894	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	10.83	0.7	1.19e-19	Exhaled nitric oxide output;
TGCT	cis	rs2594989	0.887	rs2442797	chr3:11555935	C/T	cg00170343	chr3:11313890	ATG7	0.63	4.47	0.37	1.77e-5	Circulating chemerin levels;
TGCT	cis	rs981844	0.712	rs10009854	chr4:154741785	C/T	cg14289246	chr4:154710475	SFRP2	-1.0	-9.26	-0.64	7.7e-16	Response to statins (LDL cholesterol change);
TGCT	cis	rs8062405	0.824	rs62034319	chr16:28532188	T/G	cg09754948	chr16:28834200	ATXN2L	0.6	4.64	0.38	8.69e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs2455799	0.573	rs2455833	chr3:15752830	T/C	cg16303742	chr3:15540471	COLQ	-0.26	-4.99	-0.41	2.03e-6	Mean platelet volume;
TGCT	cis	rs3087591	0.708	rs12940802	chr17:29643564	C/A	cg24425628	chr17:29625626	OMG;NF1	0.41	5.82	0.46	4.76e-8	Hip circumference;
TGCT	cis	rs7666738	0.830	rs6843777	chr4:98866635	T/A	cg05340658	chr4:99064831	C4orf37	0.52	6.0	0.47	1.99e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9341808	0.667	rs1575541	chr6:80917485	T/A	cg08355045	chr6:80787529	NA	0.3	5.05	0.41	1.51e-6	Sitting height ratio;
TGCT	cis	rs35306767	0.671	rs11253473	chr10:906826	A/G	cg20503657	chr10:835505	NA	0.75	10.41	0.68	1.3e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs698813	0.674	rs6544751	chr2:44495845	A/G	cg00619915	chr2:44497795	NA	-0.24	-5.41	-0.44	3.11e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
TGCT	trans	rs6089829	0.888	rs4809465	chr20:61671156	G/C	cg17470723	chr8:74884337	TCEB1	0.78	6.83	0.52	3.42e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1008375	0.966	rs1476836	chr4:17585014	G/C	cg18681998	chr4:17616180	MED28	0.94	9.56	0.65	1.44e-16	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs79149102	0.579	rs74247779	chr15:75397131	G/A	cg09165964	chr15:75287851	SCAMP5	-0.92	-4.65	-0.39	8.24e-6	Lung cancer;
TGCT	cis	rs3809566	0.654	rs6494384	chr15:63325607	C/G	cg00520135	chr15:63333846	TPM1	-0.41	-5.03	-0.41	1.66e-6	Platelet count;
TGCT	cis	rs9399135	0.967	rs9321481	chr6:135352648	C/G	cg24558204	chr6:135376177	HBS1L	-0.48	-4.91	-0.4	2.85e-6	Red blood cell count;
TGCT	cis	rs4824093	0.610	rs4141437	chr22:50243719	C/G	cg14114931	chr22:50943910	LMF2	-0.36	-4.53	-0.38	1.37e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs2235642	0.717	rs2236269	chr16:1652614	T/A	cg07639376	chr16:1584516	IFT140;TMEM204	-0.29	-5.03	-0.41	1.66e-6	Coronary artery disease;
TGCT	cis	rs9902453	0.808	rs76515799	chr17:28169491	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	7.17	0.54	5.79e-11	Coffee consumption (cups per day);
TGCT	cis	rs7552404	0.727	rs6678348	chr1:76332463	C/T	cg03433033	chr1:76189801	ACADM	0.59	5.95	0.47	2.53e-8	Blood metabolite levels;Acylcarnitine levels;
TGCT	trans	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg27523141	chr10:43048294	ZNF37B	0.73	8.51	0.61	4.68e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs12220238	1.000	rs73284257	chr10:76000710	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.91	7.36	0.55	2.18e-11	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs4906332	0.811	rs2021965	chr14:103997248	C/A	cg26031613	chr14:104095156	KLC1	0.57	4.6	0.38	1.02e-5	Coronary artery disease;
TGCT	cis	rs2204008	0.729	rs114133083	chr12:38182923	G/C	cg26384229	chr12:38710491	ALG10B	-0.58	-5.09	-0.42	1.28e-6	Bladder cancer;
TGCT	cis	rs9906944	0.707	rs9899931	chr17:47108282	G/A	cg07075026	chr17:47091521	IGF2BP1	-0.43	-4.6	-0.38	1.03e-5	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs7086627	0.515	rs6585994	chr10:82191643	A/G	cg00277334	chr10:82204260	NA	-0.36	-4.9	-0.4	2.94e-6	Post bronchodilator FEV1;
TGCT	trans	rs4919669	0.719	rs11818043	chr10:104391627	A/G	cg24066601	chr6:26271455	HIST1H3G	0.68	6.69	0.51	7e-10	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs4953076	0.573	rs2053456	chr2:44448632	G/A	cg00619915	chr2:44497795	NA	-0.22	-5.05	-0.41	1.52e-6	Height;
TGCT	cis	rs1153858	1.000	rs4271549	chr15:45652730	G/A	cg26924012	chr15:45694286	SPATA5L1	1.09	15.16	0.81	5.15e-30	Homoarginine levels;
TGCT	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg21963583	chr11:68658836	MRPL21	0.38	6.17	0.48	9.07e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7267979	1.000	rs2500436	chr20:25406366	G/C	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7100689	0.784	rs1870142	chr10:82182296	G/A	cg01528321	chr10:82214614	TSPAN14	0.9	9.42	0.65	3.22e-16	Post bronchodilator FEV1;
TGCT	cis	rs7635838	0.684	rs2606758	chr3:11353064	G/A	cg00170343	chr3:11313890	ATG7	0.6	5.86	0.47	3.84e-8	HDL cholesterol;
TGCT	cis	rs35771425	0.572	rs34552796	chr1:211422229	C/T	cg25617285	chr1:211431773	RCOR3	-0.46	-5.03	-0.41	1.65e-6	Educational attainment (years of education);
TGCT	trans	rs1499614	0.803	rs1922723	chr7:66175063	C/T	cg07424592	chr7:64974309	NA	1.35	8.11	0.59	4.14e-13	Gout;
TGCT	cis	rs79349575	0.715	rs62075844	chr17:47002389	G/A	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.51	-0.38	1.48e-5	Type 2 diabetes;
TGCT	cis	rs2637266	1.000	rs2894337	chr10:78344871	C/T	cg18941641	chr10:78392320	NA	0.4	5.02	0.41	1.77e-6	Pulmonary function;
TGCT	cis	rs9486719	0.857	rs2971609	chr6:97039665	A/G	cg18709589	chr6:96969512	KIAA0776	-0.78	-6.38	-0.5	3.24e-9	Migraine;Coronary artery disease;
TGCT	cis	rs6912958	0.781	rs3757368	chr6:88224495	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-5.06	-0.41	1.45e-6	Monocyte percentage of white cells;
TGCT	cis	rs8014204	0.550	rs2302832	chr14:75137664	T/C	cg06637938	chr14:75390232	RPS6KL1	0.64	5.86	0.47	3.82e-8	Caffeine consumption;
TGCT	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs1982963	0.613	rs2749885	chr14:52516567	T/G	cg10843707	chr14:52510701	NID2	-0.27	-4.64	-0.38	8.72e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9660992	0.542	rs17345153	chr1:205179997	A/G	cg03948781	chr1:205179583	DSTYK	0.35	4.53	0.38	1.39e-5	Mean corpuscular volume;Mean platelet volume;
TGCT	trans	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg17830980	chr10:43048298	ZNF37B	-0.81	-10.13	-0.67	6.19e-18	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2299587	0.689	rs2285303	chr8:17797409	A/G	cg01800426	chr8:17659068	MTUS1	-0.65	-5.68	-0.45	9.22e-8	Economic and political preferences;
TGCT	cis	rs4900538	0.855	rs1190537	chr14:102887816	C/T	cg18135206	chr14:102964638	TECPR2	-0.2	-4.53	-0.38	1.39e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs651907	0.535	rs58658478	chr3:101511667	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	4.61	0.38	1.01e-5	Colorectal cancer;
TGCT	cis	rs6088590	0.523	rs6088536	chr20:33189106	T/C	cg06115741	chr20:33292138	TP53INP2	0.51	4.47	0.37	1.76e-5	Coronary artery disease;
TGCT	cis	rs360798	0.532	rs360799	chr2:62953166	G/A	cg17519650	chr2:63277830	OTX1	-0.54	-4.64	-0.38	8.69e-6	Coronary artery disease;
TGCT	cis	rs6088580	0.634	rs3746455	chr20:32957216	G/A	cg08999081	chr20:33150536	PIGU	-0.27	-5.33	-0.43	4.46e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs1005224	0.889	rs12717566	chr14:76147507	C/T	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.57	-4.9	-0.4	2.99e-6	Large artery stroke;
TGCT	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg11941060	chr3:133502564	NA	-0.31	-6.59	-0.51	1.1e-9	Iron status biomarkers;
TGCT	cis	rs854765	0.583	rs6502627	chr17:17849671	C/T	cg09796270	chr17:17721594	SREBF1	0.23	4.45	0.37	1.92e-5	Total body bone mineral density;
TGCT	cis	rs10992471	0.528	rs10820975	chr9:95211922	T/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.51	-4.88	-0.4	3.25e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs10193935	0.901	rs17029411	chr2:42479149	G/A	cg27598129	chr2:42591480	NA	-0.37	-5.12	-0.42	1.12e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7727544	0.582	rs3749756	chr5:131534499	C/T	cg14196790	chr5:131705035	SLC22A5	0.33	4.49	0.37	1.59e-5	Blood metabolite levels;
TGCT	cis	rs10791323	0.604	rs2723605	chr11:133711241	C/G	cg15485101	chr11:133734466	NA	0.39	5.03	0.41	1.71e-6	Childhood ear infection;
TGCT	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg24399712	chr22:39784796	NA	-1.08	-12.62	-0.75	5.47e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.69	5.83	0.46	4.5e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7647973	0.626	rs1996663	chr3:49878264	C/G	cg03060546	chr3:49711283	APEH	-0.61	-5.27	-0.43	5.75e-7	Menarche (age at onset);
TGCT	cis	rs644799	1.000	rs611020	chr11:95567905	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.88	9.12	0.63	1.65e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs478304	0.619	rs10896028	chr11:65432187	A/T	cg17480646	chr11:65405466	SIPA1	-0.63	-8.28	-0.6	1.67e-13	Acne (severe);
TGCT	cis	rs7208859	0.673	rs73277964	chr17:29179201	A/T	cg18442181	chr17:29233375	C17orf42	-0.79	-4.78	-0.39	4.95e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs28595532	1.000	rs55634130	chr4:119655093	C/T	cg21605333	chr4:119757512	SEC24D	1.36	7.39	0.55	1.89e-11	Cannabis dependence symptom count;
TGCT	cis	rs6752107	1.000	rs6431654	chr2:234161769	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.2	4.86	0.4	3.46e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs711830	1.000	rs6433571	chr2:177039578	G/T	cg13092806	chr2:177043255	NA	0.76	6.11	0.48	1.19e-8	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
TGCT	cis	rs9858542	0.953	rs4625	chr3:49572140	A/G	cg03060546	chr3:49711283	APEH	-0.61	-5.37	-0.43	3.78e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs9810089	0.843	rs1279086	chr3:136038574	G/A	cg12473912	chr3:136751656	NA	0.36	5.15	0.42	9.88e-7	Gestational age at birth (child effect);
TGCT	cis	rs4808199	0.895	rs10419672	chr19:19471241	T/C	cg03709012	chr19:19516395	GATAD2A	0.83	6.68	0.51	7.27e-10	Nonalcoholic fatty liver disease;
TGCT	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	7.12	0.54	7.55e-11	Platelet count;
TGCT	cis	rs933688	0.938	rs6866923	chr5:90669352	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.03	9.42	0.65	3.21e-16	Smoking behavior;
TGCT	cis	rs6554196	0.654	rs7684939	chr4:55509189	G/A	cg02821500	chr4:54931072	CHIC2	0.48	4.57	0.38	1.18e-5	Monocyte count;
TGCT	cis	rs7582180	0.715	rs920270	chr2:100917961	T/C	cg14675211	chr2:100938903	LONRF2	0.49	4.8	0.4	4.45e-6	Intelligence (multi-trait analysis);
TGCT	trans	rs2727020	0.757	rs7924526	chr11:49267043	G/A	cg03929089	chr4:120376271	NA	0.73	8.12	0.59	4e-13	Coronary artery disease;
TGCT	cis	rs931127	0.666	rs7932857	chr11:65457493	A/C	cg17480646	chr11:65405466	SIPA1	-0.43	-5.74	-0.46	6.76e-8	Systemic lupus erythematosus;
TGCT	cis	rs600231	0.706	rs11227221	chr11:65319265	T/C	cg21890820	chr11:65308645	LTBP3	-0.38	-4.76	-0.39	5.39e-6	Bone mineral density;
TGCT	cis	rs1903068	0.719	rs1380068	chr4:56003707	C/G	cg16572876	chr4:56024045	NA	0.41	4.5	0.37	1.56e-5	Endometriosis;
TGCT	cis	rs11017221	0.891	rs7905219	chr10:132162712	C/T	cg16316180	chr10:131577011	NA	0.27	4.51	0.38	1.48e-5	Migraine;
TGCT	cis	rs7647973	0.731	rs9831648	chr3:49214303	G/T	cg07636037	chr3:49044803	WDR6	0.62	4.67	0.39	7.61e-6	Menarche (age at onset);
TGCT	cis	rs3806843	0.576	rs155361	chr5:140307284	G/A	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.43	-5.33	-0.43	4.44e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs17376456	0.825	rs13155452	chr5:93164449	C/T	cg25358565	chr5:93447407	FAM172A	-0.86	-7.11	-0.54	8e-11	Diabetic retinopathy;
TGCT	cis	rs7726839	0.540	rs3792720	chr5:643028	T/G	cg09021430	chr5:549028	NA	-0.39	-5.37	-0.43	3.77e-7	Obesity-related traits;
TGCT	cis	rs4805272	0.820	rs10408080	chr19:29341652	T/C	cg15000279	chr19:29285009	NA	0.56	6.32	0.49	4.37e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
TGCT	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	7.86	0.58	1.55e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs727563	0.593	rs132770	chr22:42017264	A/G	cg06481639	chr22:41940642	POLR3H	0.73	6.46	0.5	2.13e-9	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs1348850	0.958	rs11689550	chr2:178456298	A/G	cg22681709	chr2:178499509	PDE11A	-0.41	-5.02	-0.41	1.77e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs6964587	1.000	rs36120033	chr7:91679298	G/A	cg17063962	chr7:91808500	NA	0.88	9.65	0.66	8.73e-17	Breast cancer;
TGCT	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.06	-9.57	-0.65	1.41e-16	Platelet count;
TGCT	cis	rs1023500	0.573	rs133382	chr22:42471774	C/T	cg05082376	chr22:42548792	NA	-0.23	-5.43	-0.44	2.83e-7	Schizophrenia;
TGCT	trans	rs17603886	0.686	rs13323090	chr3:10506644	C/T	cg13546308	chr3:153366155	NA	-0.54	-6.76	-0.52	4.74e-10	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs155076	0.711	rs4770131	chr13:21897468	A/G	cg11317459	chr13:21872234	NA	1.38	12.23	0.74	4.74e-23	White matter hyperintensity burden;
TGCT	cis	rs7635838	0.617	rs346085	chr3:11282724	T/C	cg00170343	chr3:11313890	ATG7	0.64	6.28	0.49	5.27e-9	HDL cholesterol;
TGCT	cis	rs2361718	0.967	rs12942941	chr17:78103013	C/T	cg09238746	chr17:78121135	EIF4A3	-0.52	-4.56	-0.38	1.2e-5	Yeast infection;
TGCT	cis	rs513349	0.964	rs210141	chr6:33546825	T/C	cg07679836	chr6:33548423	BAK1	0.31	4.47	0.37	1.77e-5	Platelet count;
TGCT	cis	rs539096	0.830	rs10789435	chr1:44026053	T/G	cg12908607	chr1:44402522	ARTN	-0.51	-5.28	-0.43	5.57e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg02725872	chr8:58115012	NA	-0.36	-4.81	-0.4	4.33e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs68170813	0.559	rs74745121	chr7:106958037	T/C	cg02696742	chr7:106810147	HBP1	-0.69	-5.81	-0.46	4.85e-8	Coronary artery disease;
TGCT	cis	rs4366490	0.687	rs1954993	chr11:62871896	C/A	cg21002970	chr11:62369079	MTA2	0.61	4.46	0.37	1.79e-5	Conotruncal heart defects;
TGCT	cis	rs2797160	0.967	rs1777182	chr6:126013614	T/A	cg05901451	chr6:126070800	HEY2	0.74	6.12	0.48	1.15e-8	Endometrial cancer;
TGCT	cis	rs12950390	0.853	rs56363619	chr17:45854621	T/C	cg06532163	chr17:45867833	NA	0.35	5.44	0.44	2.76e-7	IgG glycosylation;
TGCT	cis	rs6430585	0.759	rs12467770	chr2:136536095	G/A	cg07169764	chr2:136633963	MCM6	1.21	11.47	0.72	3.36e-21	Corneal structure;
TGCT	cis	rs9674544	0.646	rs6504594	chr17:47142697	C/A	cg20966754	chr17:47091339	IGF2BP1	-0.42	-4.95	-0.41	2.35e-6	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
TGCT	cis	rs11105298	0.891	rs10506972	chr12:89861529	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.7	-5.02	-0.41	1.79e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs1865760	0.516	rs10807007	chr6:26048931	A/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.77	7.39	0.55	1.92e-11	Height;
TGCT	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg00814883	chr7:100076585	TSC22D4	-0.82	-8.37	-0.6	1.03e-13	Platelet count;
TGCT	cis	rs7666738	0.830	rs10014986	chr4:99000687	A/C	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6547741	1.000	rs1919125	chr2:27801403	C/G	cg27432699	chr2:27873401	GPN1	0.18	4.64	0.38	8.54e-6	Oral cavity cancer;
TGCT	cis	rs225245	0.791	rs6505492	chr17:34026597	C/T	cg05299278	chr17:33885742	SLFN14	0.21	4.5	0.37	1.54e-5	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs67366981	0.800	rs55939042	chr14:77691186	T/A	cg06779847	chr14:77687015	TMEM63C	-0.42	-4.54	-0.38	1.33e-5	Obsessive-compulsive symptoms;
TGCT	cis	rs57920188	0.535	rs12129515	chr1:4094101	G/A	cg20703997	chr1:4087676	NA	0.48	5.7	0.46	8.27e-8	Interleukin-17 levels;
TGCT	cis	rs9814567	1.000	rs6763088	chr3:134254989	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.96	9.11	0.63	1.79e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs11098499	0.955	rs1397608	chr4:120161744	A/G	cg24670566	chr4:120433619	PDE5A	0.23	4.45	0.37	1.89e-5	Corneal astigmatism;
TGCT	cis	rs11785400	0.793	rs9297972	chr8:143723660	C/T	cg24634471	chr8:143751801	JRK	0.53	5.33	0.43	4.41e-7	Schizophrenia;
TGCT	cis	rs2663905	1.000	rs2663905	chr15:81359137	G/A	cg09236163	chr15:81426669	C15orf26	-0.45	-4.61	-0.38	9.83e-6	QT interval (drug interaction);
TGCT	trans	rs9929218	0.529	rs2296404	chr16:68729525	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.54	6.81	0.52	3.78e-10	Colorectal cancer;
TGCT	cis	rs3764628	1.000	rs72997355	chr19:18768709	G/A	cg20098710	chr19:19640075	YJEFN3	-0.46	-4.78	-0.39	4.8e-6	Orofacial clefts;
TGCT	cis	rs7226408	0.857	rs34250790	chr18:34447980	T/G	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg13695892	chr22:41940480	POLR3H	-0.91	-8.8	-0.62	9.77e-15	Vitiligo;
TGCT	cis	rs896854	0.573	rs13271375	chr8:95853907	A/G	cg16049864	chr8:95962084	TP53INP1	-0.6	-7.11	-0.54	8.27e-11	Type 2 diabetes;
TGCT	cis	rs6964587	0.869	rs10250014	chr7:91490208	T/C	cg17063962	chr7:91808500	NA	-0.85	-9.05	-0.63	2.54e-15	Breast cancer;
TGCT	cis	rs7843479	0.601	rs4872207	chr8:21842751	C/G	cg17168535	chr8:21777572	XPO7	-0.8	-8.06	-0.59	5.48e-13	Mean corpuscular volume;
TGCT	cis	rs7119	0.931	rs62009087	chr15:77833064	C/T	cg27398640	chr15:77910606	LINGO1	-0.25	-4.68	-0.39	7.4e-6	Type 2 diabetes;
TGCT	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg06618935	chr21:46677482	NA	0.36	5.44	0.44	2.71e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg11494091	chr17:61959527	GH2	-0.6	-13.07	-0.76	4.44e-25	Prudent dietary pattern;
TGCT	cis	rs911555	0.755	rs12436729	chr14:103929889	G/C	cg23461800	chr14:103021989	NA	-0.35	-4.56	-0.38	1.23e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs72945132	0.882	rs66989619	chr11:70202127	G/C	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs711245	0.573	rs7570763	chr2:36800589	A/C	cg15105969	chr2:36825350	FEZ2	-0.61	-5.71	-0.46	7.72e-8	Height;
TGCT	cis	rs4851266	1.000	rs7566527	chr2:100811970	C/T	cg22139774	chr2:100720529	AFF3	-0.34	-4.98	-0.41	2.13e-6	Educational attainment;
TGCT	cis	rs12950390	0.853	rs11655112	chr17:45856563	T/C	cg24803719	chr17:45855879	NA	-0.5	-5.12	-0.42	1.15e-6	IgG glycosylation;
TGCT	cis	rs826838	0.967	rs4768329	chr12:39129394	T/C	cg26384229	chr12:38710491	ALG10B	-0.87	-7.78	-0.57	2.42e-12	Heart rate;
TGCT	cis	rs35306767	0.623	rs72760943	chr10:1143104	G/A	cg26597838	chr10:835615	NA	0.47	4.95	0.41	2.37e-6	Eosinophil percentage of granulocytes;
TGCT	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg17178900	chr1:205818956	PM20D1	-0.52	-6.47	-0.5	2.04e-9	Monocyte percentage of white cells;
TGCT	cis	rs4478858	0.709	rs3766296	chr1:31820223	G/A	cg07478791	chr1:31886160	SERINC2	-0.51	-4.95	-0.41	2.33e-6	Alcohol dependence;
TGCT	cis	rs7940866	0.903	rs10750457	chr11:130850277	T/C	cg05962950	chr11:130786565	SNX19	0.64	6.36	0.5	3.53e-9	Schizophrenia;
TGCT	cis	rs9653442	0.564	rs4851256	chr2:100775045	A/G	cg22139774	chr2:100720529	AFF3	-0.33	-5.34	-0.43	4.25e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	trans	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-1.04	-13.29	-0.77	1.33e-25	Intelligence (multi-trait analysis);
TGCT	trans	rs10435719	0.871	rs7815186	chr8:11792062	C/G	cg15556689	chr8:8085844	FLJ10661	0.75	7.26	0.55	3.66e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs8180040	0.966	rs12632132	chr3:47477019	C/T	cg27129171	chr3:47204927	SETD2	0.66	8.01	0.58	7.07e-13	Colorectal cancer;
TGCT	cis	rs2153535	0.580	rs1335643	chr6:8488021	T/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs921968	0.612	rs832810	chr2:219322430	T/C	cg02176678	chr2:219576539	TTLL4	0.38	5.51	0.44	1.97e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs2742234	0.955	rs2435385	chr10:43665750	A/G	cg02780029	chr10:43622663	RET	-0.26	-4.98	-0.41	2.07e-6	Hirschsprung disease;
TGCT	cis	rs7727544	0.684	rs2631363	chr5:131707095	A/G	cg24060327	chr5:131705240	SLC22A5	0.62	6.77	0.52	4.69e-10	Blood metabolite levels;
TGCT	cis	rs13064411	0.696	rs1486894	chr3:113211513	G/A	cg18753928	chr3:113234510	CCDC52	-0.7	-5.75	-0.46	6.6e-8	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs56176327	0.583	rs7613603	chr3:49812866	C/T	cg03060546	chr3:49711283	APEH	-0.63	-5.63	-0.45	1.12e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg06212747	chr3:49208901	KLHDC8B	0.65	6.23	0.49	6.72e-9	Menarche (age at onset);
TGCT	cis	rs2637266	0.690	rs2579730	chr10:78443441	G/T	cg18941641	chr10:78392320	NA	0.4	4.88	0.4	3.24e-6	Pulmonary function;
TGCT	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg27211696	chr2:191398769	TMEM194B	-0.27	-5.07	-0.41	1.42e-6	Pulse pressure;
TGCT	cis	rs2249625	0.564	rs2496489	chr6:72877338	G/A	cg08500200	chr6:72892038	RIMS1	-0.42	-4.54	-0.38	1.33e-5	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
TGCT	cis	rs631288	0.557	rs920682	chr1:146657523	C/A	cg25205988	chr1:146714368	CHD1L	1.34	5.37	0.43	3.79e-7	PR interval in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg10295955	chr4:187884368	NA	-0.99	-15.24	-0.81	3.38e-30	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6540559	0.611	rs6540563	chr1:210019858	C/G	cg22029157	chr1:209979665	IRF6	0.71	5.09	0.42	1.3e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.48	-5.53	-0.44	1.83e-7	Longevity;Endometriosis;
TGCT	cis	rs6459804	0.503	rs2159470	chr7:157506540	G/A	cg14168080	chr7:157504135	PTPRN2	-0.4	-4.49	-0.37	1.58e-5	Bipolar disorder and schizophrenia;
TGCT	cis	rs3935685	1.000	rs4886904	chr15:78027178	C/T	cg25212270	chr15:78015279	NA	0.32	6.43	0.5	2.54e-9	Intelligence (multi-trait analysis);
TGCT	trans	rs10435719	0.899	rs9329251	chr8:11793606	G/A	cg15556689	chr8:8085844	FLJ10661	0.75	7.26	0.55	3.66e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs3947	0.855	rs1296026	chr8:11697442	C/T	cg02840367	chr8:11660030	FDFT1	0.91	6.65	0.51	8.45e-10	Blood protein levels;
TGCT	cis	rs7226408	0.857	rs11665085	chr18:34469465	C/T	cg06757138	chr18:34340585	FHOD3	0.25	4.88	0.4	3.13e-6	Obesity-related traits;
TGCT	cis	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg20637647	chr7:64974828	NA	0.9	5.31	0.43	4.87e-7	Diabetic kidney disease;
TGCT	cis	rs7666738	0.753	rs17027308	chr4:99091088	T/A	cg18180107	chr4:99064573	C4orf37	0.55	4.94	0.41	2.45e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9611565	0.649	rs738422	chr22:42123399	C/T	cg17554472	chr22:41940697	POLR3H	0.45	4.84	0.4	3.72e-6	Vitiligo;
TGCT	cis	rs9399135	0.967	rs7773126	chr6:135318390	A/G	cg24558204	chr6:135376177	HBS1L	0.46	4.59	0.38	1.09e-5	Red blood cell count;
TGCT	cis	rs7221595	0.673	rs115725560	chr17:3980493	T/A	cg09580393	chr17:4869866	SPAG7	-0.39	-4.5	-0.37	1.56e-5	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
TGCT	cis	rs7635838	0.750	rs2648463	chr3:11403857	G/A	cg00170343	chr3:11313890	ATG7	0.66	6.47	0.5	2.01e-9	HDL cholesterol;
TGCT	cis	rs2486288	0.656	rs2413774	chr15:45549423	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.72	-7.46	-0.56	1.34e-11	Glomerular filtration rate;
TGCT	cis	rs12681288	0.676	rs2701913	chr8:999982	A/T	cg04851639	chr8:1020857	NA	-0.29	-4.73	-0.39	6.03e-6	Schizophrenia;
TGCT	cis	rs2760061	0.599	rs644794	chr1:228148670	T/C	cg18477163	chr1:228402036	OBSCN	-0.32	-6.31	-0.49	4.58e-9	Diastolic blood pressure;
TGCT	cis	rs7017914	0.902	rs6472542	chr8:71654087	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	0.48	4.73	0.39	6.03e-6	Bone mineral density;
TGCT	cis	rs1865760	0.566	rs2032445	chr6:26044812	T/A	cg16482183	chr6:26056742	HIST1H1C	0.57	4.97	0.41	2.21e-6	Height;
TGCT	cis	rs9486719	0.947	rs11757102	chr6:96885073	G/A	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.86	-0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	trans	rs941408	1.000	rs4807332	chr19:2793289	T/C	cg22153745	chr1:153894579	GATAD2B	-0.64	-7.22	-0.54	4.49e-11	Total cholesterol levels;
TGCT	cis	rs77633900	0.614	rs2454453	chr15:76913976	T/A	cg21673338	chr15:77095150	SCAPER	-0.51	-4.82	-0.4	4.09e-6	Non-glioblastoma glioma;Glioma;
TGCT	cis	rs7829975	0.774	rs57312668	chr8:8680477	G/A	cg06636001	chr8:8085503	FLJ10661	0.68	5.98	0.47	2.17e-8	Mood instability;
TGCT	cis	rs200810	0.964	rs28657486	chr6:97769261	T/C	cg16511841	chr6:97730490	C6orf167;MIR548H3	-0.52	-4.46	-0.37	1.81e-5	Body mass index;
TGCT	cis	rs796364	0.662	rs11688415	chr2:201143409	C/T	cg19045956	chr2:200819837	C2orf60;C2orf47	0.67	4.68	0.39	7.3e-6	Schizophrenia;
TGCT	cis	rs6570726	0.791	rs387376	chr6:145822565	T/C	cg23711669	chr6:146136114	FBXO30	0.89	9.72	0.66	6.02e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs8008002	1.000	rs8008002	chr14:75865683	C/T	cg20011974	chr14:75469661	EIF2B2	-0.5	-4.48	-0.37	1.65e-5	Response to paliperidone in schizophrenia (positive Marder score);
TGCT	cis	rs3771570	1.000	rs41266959	chr2:242275579	G/A	cg21155796	chr2:242212141	HDLBP	0.98	6.68	0.51	7.29e-10	Prostate cancer;
TGCT	cis	rs35306767	0.903	rs11253494	chr10:937047	C/T	cg20503657	chr10:835505	NA	0.74	10.3	0.68	2.41e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs858239	0.539	rs10247268	chr7:23187179	G/A	cg05602783	chr7:23145260	KLHL7	-0.68	-5.62	-0.45	1.2e-7	Cerebrospinal fluid biomarker levels;
TGCT	trans	rs6089829	0.925	rs4809270	chr20:61676709	C/A	cg23505145	chr19:12996616	KLF1	0.96	10.09	0.67	7.8e-18	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs11577318	0.853	rs11803933	chr1:26629465	G/C	cg04990556	chr1:26633338	UBXN11	-0.63	-5.83	-0.46	4.58e-8	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs2766692	1.000	rs4905941	chr14:100725438	A/G	cg14866419	chr14:100704911	YY1	0.58	4.7	0.39	6.92e-6	Electroencephalographic traits in alcoholism;
TGCT	cis	rs11031096	0.655	rs1822288	chr11:4212478	C/T	cg18678763	chr11:4115507	RRM1	0.44	5.68	0.45	8.88e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs7829975	0.582	rs448231	chr8:8790059	A/T	cg15556689	chr8:8085844	FLJ10661	-0.64	-6.02	-0.48	1.85e-8	Mood instability;
TGCT	cis	rs8033133	0.602	rs3803326	chr15:25328715	A/G	cg14481604	chr15:25334117	SNORD116-22	-0.24	-5.35	-0.43	4.1e-7	Blood osmolality (transformed sodium);
TGCT	trans	rs74910095	0.530	rs57645565	chr5:62931750	A/G	cg02938449	chr2:220419364	OBSL1	0.8	6.75	0.52	4.95e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs858239	0.539	rs10270695	chr7:23188988	C/T	cg05602783	chr7:23145260	KLHL7	0.63	5.17	0.42	9.04e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs667920	0.575	rs9861150	chr3:136183320	G/T	cg15507776	chr3:136538369	TMEM22	0.55	4.46	0.37	1.84e-5	Coronary artery disease;
TGCT	trans	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg21659725	chr3:3221576	CRBN	-0.75	-9.02	-0.63	2.97e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs394563	0.717	rs548848	chr6:149782009	A/G	cg03678062	chr6:149772716	ZC3H12D	-0.39	-4.83	-0.4	4.03e-6	Dupuytren's disease;
TGCT	cis	rs6490294	0.799	rs6489819	chr12:112328230	C/A	cg10833066	chr12:111807467	FAM109A	0.39	5.81	0.46	4.86e-8	Mean platelet volume;
TGCT	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg11644478	chr21:40555479	PSMG1	-0.63	-5.86	-0.47	3.89e-8	Cognitive function;
TGCT	cis	rs926938	0.563	rs360576	chr1:115459174	A/C	cg12756093	chr1:115239321	AMPD1	-0.42	-6.39	-0.5	3.05e-9	Autism;
TGCT	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.72	7.34	0.55	2.47e-11	Prudent dietary pattern;
TGCT	cis	rs7267979	0.932	rs1985737	chr20:25591468	T/A	cg14121845	chr20:25566513	NINL	0.51	5.52	0.44	1.91e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7226408	0.817	rs72888915	chr18:34521261	T/G	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg22800045	chr5:56110881	MAP3K1	0.53	4.51	0.38	1.46e-5	Initial pursuit acceleration;
TGCT	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.84	7.62	0.56	5.74e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs13242816	1.000	rs13242816	chr7:116189376	C/T	cg02799643	chr7:116139180	CAV2	-0.43	-5.29	-0.43	5.24e-7	P wave duration;
TGCT	cis	rs2120019	1.000	rs7173833	chr15:75369618	C/T	cg09165964	chr15:75287851	SCAMP5	-1.16	-9.38	-0.64	3.97e-16	Blood trace element (Zn levels);
TGCT	cis	rs2637266	1.000	rs12784382	chr10:78378348	G/T	cg18941641	chr10:78392320	NA	0.39	4.88	0.4	3.24e-6	Pulmonary function;
TGCT	cis	rs709400	0.567	rs11624343	chr14:103859156	T/A	cg26031613	chr14:104095156	KLC1	0.85	9.32	0.64	5.53e-16	Body mass index;
TGCT	cis	rs4780401	0.609	rs16958588	chr16:11819330	G/A	cg01061890	chr16:11836724	TXNDC11	-0.6	-5.82	-0.46	4.74e-8	Rheumatoid arthritis;
TGCT	cis	rs611744	0.647	rs2594358	chr8:109256018	A/G	cg21045802	chr8:109455806	TTC35	0.7	6.74	0.52	5.23e-10	Dupuytren's disease;
TGCT	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	7.28	0.55	3.28e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7582180	0.627	rs4407265	chr2:101005846	C/G	cg08017756	chr2:100939284	LONRF2	-0.31	-5.01	-0.41	1.85e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.72	5.19	0.42	8.33e-7	Platelet count;
TGCT	cis	rs6912958	0.605	rs2754247	chr6:88383571	A/G	cg06598631	chr6:88300029	RARS2;ORC3L	-0.53	-4.9	-0.4	2.88e-6	Monocyte percentage of white cells;
TGCT	cis	rs7412746	0.634	rs7521592	chr1:150821691	A/C	cg04414720	chr1:150670196	GOLPH3L	0.39	4.83	0.4	3.97e-6	Melanoma;
TGCT	cis	rs7589728	0.563	rs79892776	chr2:88470593	G/A	cg04511125	chr2:88470314	THNSL2	0.83	6.93	0.53	2e-10	Plasma clusterin levels;
TGCT	cis	rs2153535	0.542	rs1120393	chr6:8486890	G/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs9479482	1.000	rs11155696	chr6:150357283	G/A	cg03788504	chr6:150331562	NA	-0.24	-4.63	-0.38	9.01e-6	Alopecia areata;
TGCT	cis	rs10791097	0.629	rs11222361	chr11:130731424	T/G	cg05962950	chr11:130786565	SNX19	0.84	10.71	0.69	2.4e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	trans	rs10043228	1.000	rs12517508	chr5:115423574	C/T	cg27022334	chr5:167645456	ODZ2	0.4	6.72	0.52	5.92e-10	Asthma or chronic obstructive pulmonary disease;
TGCT	cis	rs155076	1.000	rs12870992	chr13:21846019	A/G	cg14456004	chr13:21872349	NA	1.16	9.07	0.63	2.27e-15	White matter hyperintensity burden;
TGCT	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg07507251	chr3:52567010	NT5DC2	0.48	6.91	0.53	2.24e-10	Bipolar disorder;
TGCT	cis	rs2243480	0.706	rs6460257	chr7:65196780	C/T	cg18252515	chr7:66147081	NA	-0.79	-5.4	-0.44	3.34e-7	Diabetic kidney disease;
TGCT	cis	rs74233809	1.000	rs3781285	chr10:104825665	C/G	cg05855489	chr10:104503620	C10orf26	0.84	4.66	0.39	8.2e-6	Birth weight;
TGCT	cis	rs7223966	0.515	rs2727315	chr17:61961458	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	4.8	0.4	4.55e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs513349	0.964	rs210139	chr6:33543409	A/C	cg07679836	chr6:33548423	BAK1	0.3	4.45	0.37	1.88e-5	Platelet count;
TGCT	cis	rs523522	0.962	rs7488320	chr12:120981630	G/T	cg12219531	chr12:120966889	COQ5	0.83	7.27	0.55	3.46e-11	High light scatter reticulocyte count;
TGCT	cis	rs1008375	1.000	rs1008375	chr4:17682834	T/C	cg10189774	chr4:17578691	LAP3	0.54	5.11	0.42	1.18e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7582180	0.652	rs12997725	chr2:100935136	A/G	cg08017756	chr2:100939284	LONRF2	-0.3	-4.78	-0.39	4.95e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10927875	0.691	rs1048261	chr1:16340951	A/T	cg14742211	chr1:16348397	CLCNKA	0.19	4.48	0.37	1.7e-5	Dilated cardiomyopathy;
TGCT	cis	rs6754311	0.593	rs4954280	chr2:136420690	C/T	cg07169764	chr2:136633963	MCM6	-0.65	-5.87	-0.47	3.74e-8	Mosquito bite size;
TGCT	cis	rs1865760	1.000	rs3799371	chr6:25912816	A/G	cg17042849	chr6:26104293	HIST1H4C	0.5	4.49	0.37	1.61e-5	Height;
TGCT	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.7	0.52	6.47e-10	Bipolar disorder;
TGCT	cis	rs6831352	1.000	rs1126671	chr4:100048414	T/C	cg12011299	chr4:100065546	ADH4	0.41	5.2	0.42	8.11e-7	Alcohol dependence;
TGCT	cis	rs700651	0.789	rs2196176	chr2:198904914	A/G	cg00792783	chr2:198669748	PLCL1	0.59	5.09	0.42	1.28e-6	Intracranial aneurysm;
TGCT	cis	rs73058052	0.569	rs10417980	chr19:50101713	T/C	cg09250473	chr19:50168907	IRF3;BCL2L12	0.68	5.58	0.45	1.42e-7	Fibrinogen levels;
TGCT	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg21285383	chr16:89894308	SPIRE2	0.42	6.41	0.5	2.82e-9	Vitiligo;
TGCT	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg11644478	chr21:40555479	PSMG1	1.04	10.81	0.7	1.38e-19	Cognitive function;
TGCT	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg23758822	chr17:41437982	NA	0.78	7.29	0.55	3.14e-11	Menopause (age at onset);
TGCT	cis	rs7715806	0.500	rs72633983	chr5:75002845	C/T	cg19683494	chr5:74908142	NA	0.57	5.02	0.41	1.76e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs9326248	0.520	rs6589602	chr11:117037065	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.6	5.48	0.44	2.32e-7	Blood protein levels;
TGCT	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.49	-5.52	-0.44	1.87e-7	Longevity;Endometriosis;
TGCT	cis	rs617791	0.530	rs7934543	chr11:65752508	G/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.5	4.56	0.38	1.2e-5	Breast cancer;
TGCT	cis	rs9467711	0.675	rs58825580	chr6:26365679	T/G	cg10795676	chr6:26370623	BTN3A2	-0.44	-4.89	-0.4	3.06e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12681288	0.676	rs2701910	chr8:1001246	G/T	cg04851639	chr8:1020857	NA	-0.32	-5.32	-0.43	4.74e-7	Schizophrenia;
TGCT	cis	rs2982552	0.844	rs2982560	chr6:152055606	A/T	cg22157087	chr6:152012887	ESR1	0.21	5.16	0.42	9.59e-7	Bone properties (heel);
TGCT	cis	rs17881320	0.510	rs7221385	chr17:40562081	C/T	cg05878104	chr17:40932452	WNK4	-0.98	-6.77	-0.52	4.62e-10	Atopic dermatitis;
TGCT	cis	rs1552244	0.832	rs17050674	chr3:10027258	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.83	5.71	0.46	7.72e-8	Alzheimer's disease;
TGCT	cis	rs35883536	0.525	rs2647321	chr1:101032006	T/G	cg10298815	chr1:101004474	GPR88	0.26	4.7	0.39	6.89e-6	Monocyte count;
TGCT	cis	rs2153535	0.580	rs4404802	chr6:8442052	A/G	cg07606381	chr6:8435919	SLC35B3	0.57	5.25	0.43	6.46e-7	Motion sickness;
TGCT	cis	rs6701037	0.625	rs67332874	chr1:175128537	G/A	cg00321850	chr1:175162397	KIAA0040	-0.42	-5.83	-0.46	4.61e-8	Alcohol dependence;
TGCT	cis	rs111803315	1.000	rs112952088	chr14:60027907	C/T	cg22995959	chr14:59931024	GPR135	0.66	4.8	0.4	4.39e-6	Schizophrenia;
TGCT	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg24846343	chr22:24311635	DDTL	0.23	5.61	0.45	1.24e-7	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs929354	0.713	rs6946947	chr7:156948787	T/C	cg05182265	chr7:156933206	UBE3C	-0.39	-8.98	-0.63	3.72e-15	Body mass index;
TGCT	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg27121462	chr16:89883253	FANCA	0.74	7.88	0.58	1.41e-12	Vitiligo;
TGCT	cis	rs514406	0.560	rs1889033	chr1:53211887	A/G	cg24675658	chr1:53192096	ZYG11B	0.83	10.11	0.67	6.99e-18	Monocyte count;
TGCT	cis	rs9303401	0.659	rs17222621	chr17:56695923	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.32	-5.13	-0.42	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	trans	rs12339966	0.581	rs62529409	chr9:11332000	T/G	cg03488587	chr11:64876988	C11orf2	0.32	7.03	0.53	1.19e-10	Systolic blood pressure;
TGCT	cis	rs10782582	0.609	rs56159153	chr1:76353498	T/G	cg03433033	chr1:76189801	ACADM	-0.5	-4.95	-0.41	2.39e-6	Daytime sleep phenotypes;
TGCT	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg11890956	chr21:40555474	PSMG1	1.1	12.31	0.74	2.99e-23	Cognitive function;
TGCT	cis	rs7599312	0.534	rs6735626	chr2:213403972	G/A	cg16329650	chr2:213403929	ERBB4	1.06	16.47	0.83	5.13e-33	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs9911578	1.000	rs302840	chr17:56673079	C/G	cg05425664	chr17:57184151	TRIM37	-0.63	-6.22	-0.49	7.03e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg25036284	chr2:26402008	FAM59B	-0.65	-5.19	-0.42	8.36e-7	Gut microbiome composition (summer);
TGCT	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg01084871	chr4:1340883	KIAA1530	0.59	4.62	0.38	9.57e-6	Longevity;
TGCT	cis	rs17345786	1.000	rs73863360	chr3:101316837	G/A	cg12386194	chr3:101231763	SENP7	0.61	5.75	0.46	6.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6840360	0.582	rs4696259	chr4:152310788	A/G	cg17479576	chr4:152424074	FAM160A1	-0.65	-7.06	-0.54	1.02e-10	Intelligence (multi-trait analysis);
TGCT	trans	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg21659725	chr3:3221576	CRBN	0.73	8.19	0.59	2.76e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs9291683	0.546	rs13146686	chr4:10034933	A/G	cg11266682	chr4:10021025	SLC2A9	0.56	6.24	0.49	6.19e-9	Bone mineral density;
TGCT	cis	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg18252515	chr7:66147081	NA	-1.13	-6.81	-0.52	3.7e-10	Diabetic kidney disease;
TGCT	cis	rs9926296	0.568	rs417323	chr16:89746277	T/G	cg03388025	chr16:89894329	SPIRE2	-0.31	-4.47	-0.37	1.73e-5	Vitiligo;
TGCT	cis	rs28595532	0.841	rs115209862	chr4:119742225	G/A	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs7818688	0.697	rs57890591	chr8:95983130	G/A	cg16049864	chr8:95962084	TP53INP1	0.54	4.64	0.38	8.87e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs7572733	0.534	rs1607375	chr2:198800387	C/T	cg00792783	chr2:198669748	PLCL1	0.57	5.23	0.43	6.99e-7	Dermatomyositis;
TGCT	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg13395646	chr4:1353034	KIAA1530	0.38	4.71	0.39	6.42e-6	Obesity-related traits;
TGCT	cis	rs2439831	0.867	rs2584702	chr15:43684914	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.87	6.04	0.48	1.64e-8	Lung cancer in ever smokers;
TGCT	cis	rs9486719	1.000	rs72931061	chr6:96880285	G/A	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.21	-0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs1801251	1.000	rs2675971	chr2:233726154	A/G	cg25237894	chr2:233734115	C2orf82	-0.33	-5.97	-0.47	2.34e-8	Coronary artery disease;
TGCT	cis	rs6831352	0.918	rs17217949	chr4:100054312	A/G	cg12011299	chr4:100065546	ADH4	-0.4	-4.88	-0.4	3.26e-6	Alcohol dependence;
TGCT	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	5.23	0.43	6.92e-7	Menopause (age at onset);
TGCT	cis	rs11696501	0.688	rs2072974	chr20:44313401	G/A	cg11783356	chr20:44313418	WFDC10B	-0.33	-4.49	-0.37	1.6e-5	Brain structure;
TGCT	cis	rs7666738	0.687	rs6839454	chr4:99073914	T/C	cg18180107	chr4:99064573	C4orf37	0.59	5.27	0.43	5.8e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs36051895	0.623	rs10974939	chr9:5056482	G/T	cg02405213	chr9:5042618	JAK2	-0.75	-9.15	-0.63	1.42e-15	Pediatric autoimmune diseases;
TGCT	cis	rs7666738	0.830	rs28622458	chr4:98916651	A/G	cg17366294	chr4:99064904	C4orf37	0.69	7.2	0.54	5.03e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9291683	0.509	rs6849717	chr4:9958719	T/C	cg00071950	chr4:10020882	SLC2A9	-0.65	-8.23	-0.59	2.24e-13	Bone mineral density;
TGCT	cis	rs1372520	0.564	rs356186	chr4:90705364	A/G	cg01966878	chr4:90757139	SNCA	-0.31	-4.79	-0.4	4.59e-6	Neuroticism;
TGCT	cis	rs10751667	0.600	rs10751672	chr11:948712	T/C	cg06064525	chr11:970664	AP2A2	-0.35	-7.92	-0.58	1.15e-12	Alzheimer's disease (late onset);
TGCT	cis	rs9399135	0.967	rs4895434	chr6:135293365	G/A	cg24558204	chr6:135376177	HBS1L	0.48	4.79	0.39	4.76e-6	Red blood cell count;
TGCT	cis	rs7043114	0.525	rs1053441	chr9:95147840	T/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-5.6	-0.45	1.32e-7	Height;
TGCT	cis	rs2562456	0.876	rs11085465	chr19:21751790	A/G	cg01304269	chr19:21688519	ZNF429	-0.58	-4.74	-0.39	5.78e-6	Pain;
TGCT	cis	rs74417235	0.639	rs7443642	chr5:154053450	A/G	cg08754654	chr5:154026448	NA	-0.57	-5.13	-0.42	1.09e-6	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
TGCT	cis	rs2033711	0.905	rs893186	chr19:58969179	C/A	cg13877915	chr19:58951672	ZNF132	0.85	9.63	0.65	9.76e-17	Uric acid clearance;
TGCT	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	16.04	0.82	4.85e-32	Prudent dietary pattern;
TGCT	cis	rs6430585	0.583	rs7581814	chr2:136641593	C/G	cg07169764	chr2:136633963	MCM6	-1.33	-12.69	-0.75	3.6e-24	Corneal structure;
TGCT	cis	rs4975616	0.869	rs31490	chr5:1344458	G/A	cg07493874	chr5:1342172	CLPTM1L	-0.28	-6.6	-0.51	1.07e-9	Lung cancer;
TGCT	cis	rs11650494	0.522	rs117821438	chr17:47325867	A/T	cg08112188	chr17:47440006	ZNF652	1.06	5.45	0.44	2.65e-7	Prostate cancer;
TGCT	cis	rs2996428	0.601	rs59414187	chr1:3762815	T/C	cg13057898	chr1:3703894	LRRC47	0.22	4.68	0.39	7.24e-6	Red cell distribution width;
TGCT	cis	rs546131	0.928	rs552868	chr11:34830694	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.66	5.84	0.46	4.34e-8	Lung disease severity in cystic fibrosis;
TGCT	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.63	-0.51	9.4e-10	Alzheimer's disease;
TGCT	cis	rs114540395	0.858	rs17760784	chr10:103156416	G/C	cg18276125	chr10:102749041	C10orf2	0.38	4.6	0.38	1.05e-5	Schizophrenia;
TGCT	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-6.74	-0.52	5.26e-10	Alzheimer's disease;
TGCT	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg00080972	chr5:178986291	RUFY1	-0.58	-7.45	-0.56	1.37e-11	Lung cancer;
TGCT	cis	rs1580019	0.844	rs4723159	chr7:32512804	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.86	8.3	0.6	1.46e-13	Cognitive ability;
TGCT	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg07167872	chr1:205819463	PM20D1	-0.54	-6.82	-0.52	3.53e-10	Monocyte percentage of white cells;
TGCT	cis	rs7267979	1.000	rs6037099	chr20:25356876	T/G	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4900538	0.963	rs2273905	chr14:102974999	T/C	cg18135206	chr14:102964638	TECPR2	0.21	5.0	0.41	1.95e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs7267979	0.932	rs417110	chr20:25458297	T/C	cg16686733	chr20:25566563	NINL	0.56	5.69	0.46	8.49e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs7726839	0.574	rs72705014	chr5:619815	C/G	cg25482853	chr8:67687455	SGK3	1.23	9.86	0.66	2.81e-17	Obesity-related traits;
TGCT	cis	rs896854	0.738	rs481887	chr8:95967838	A/G	cg16049864	chr8:95962084	TP53INP1	0.65	7.57	0.56	7.38e-12	Type 2 diabetes;
TGCT	cis	rs7666738	0.830	rs921522	chr4:98841608	C/T	cg05340658	chr4:99064831	C4orf37	0.48	5.05	0.41	1.51e-6	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg17470723	chr8:74884337	TCEB1	0.71	6.77	0.52	4.48e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs6906287	0.609	rs6938041	chr6:118852468	C/A	cg21191810	chr6:118973309	C6orf204	0.26	4.49	0.37	1.58e-5	Electrocardiographic conduction measures;
TGCT	cis	rs10782582	0.569	rs4549990	chr1:76125075	A/G	cg22875332	chr1:76189707	ACADM	-0.54	-6.36	-0.5	3.61e-9	Daytime sleep phenotypes;
TGCT	cis	rs6089584	0.528	rs4925335	chr20:60627034	G/A	cg13770153	chr20:60521292	NA	-0.43	-5.15	-0.42	9.9e-7	Body mass index;
TGCT	cis	rs7772486	0.686	rs9403746	chr6:146103768	C/A	cg13319975	chr6:146136371	FBXO30	0.5	4.62	0.38	9.6e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg04287289	chr16:89883240	FANCA	0.94	11.93	0.73	2.51e-22	Vitiligo;
TGCT	cis	rs7833790	0.636	rs12544174	chr8:82731477	G/A	cg23324259	chr8:82754387	SNX16	-0.61	-4.71	-0.39	6.42e-6	Diastolic blood pressure;
TGCT	cis	rs17345786	0.520	rs1476123	chr3:101313413	C/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.54	5.51	0.44	1.96e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10174077	0.874	rs4664490	chr2:152471923	C/G	cg19508488	chr2:152266495	RIF1	-0.7	-6.69	-0.51	7e-10	Squamous cell lung carcinoma;
TGCT	cis	rs2806561	0.734	rs667211	chr1:23516142	T/C	cg12483005	chr1:23474871	LUZP1	0.38	4.73	0.39	5.93e-6	Height;
TGCT	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg04267008	chr7:1944627	MAD1L1	-0.36	-4.82	-0.4	4.05e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs1008375	1.000	rs4698649	chr4:17692782	A/G	cg18681998	chr4:17616180	MED28	0.76	7.28	0.55	3.42e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg23708337	chr7:1209742	NA	0.6	5.49	0.44	2.2e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9902453	0.845	rs10853135	chr17:28188675	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	7.18	0.54	5.62e-11	Coffee consumption (cups per day);
TGCT	cis	rs7246657	0.941	rs10418729	chr19:37737065	A/C	cg18154014	chr19:37997991	ZNF793	0.86	6.33	0.49	4.04e-9	Coronary artery calcification;
TGCT	cis	rs7727544	0.716	rs7701414	chr5:131585958	A/G	cg21474247	chr5:131268130	NA	0.32	4.71	0.39	6.41e-6	Blood metabolite levels;
TGCT	cis	rs6964587	1.000	rs2237568	chr7:91622676	G/A	cg17063962	chr7:91808500	NA	0.91	9.99	0.67	1.32e-17	Breast cancer;
TGCT	cis	rs7937682	0.883	rs566647	chr11:111466607	A/G	cg09085632	chr11:111637200	PPP2R1B	0.97	9.23	0.64	9.43e-16	Primary sclerosing cholangitis;
TGCT	cis	rs6430585	0.702	rs73958637	chr2:136546927	C/T	cg07169764	chr2:136633963	MCM6	1.21	11.47	0.72	3.36e-21	Corneal structure;
TGCT	cis	rs7809950	0.678	rs7777950	chr7:107004672	T/C	cg23024343	chr7:107201750	COG5	-0.43	-5.85	-0.47	4.12e-8	Coronary artery disease;
TGCT	cis	rs2274273	0.713	rs56725788	chr14:55540101	A/G	cg01923255	chr14:55878535	KIAA0831	0.57	4.89	0.4	3.03e-6	Protein biomarker;
TGCT	cis	rs1541995	1.000	rs4984455	chr15:96357991	G/C	cg00882281	chr15:96346592	NA	0.29	4.76	0.39	5.31e-6	Photic sneeze reflex;
TGCT	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg00684032	chr4:1343700	KIAA1530	0.24	5.13	0.42	1.06e-6	Obesity-related traits;
TGCT	cis	rs1008375	1.000	rs1558378	chr4:17650351	T/C	cg18681998	chr4:17616180	MED28	1.06	12.43	0.74	1.57e-23	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg23172400	chr8:95962367	TP53INP1	-0.39	-6.53	-0.51	1.5e-9	Type 2 diabetes;
TGCT	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg18876405	chr7:65276391	NA	0.36	5.31	0.43	4.87e-7	Aortic root size;
TGCT	cis	rs5769707	0.846	rs5770610	chr22:50036897	A/C	cg10356904	chr22:49881777	NA	-0.22	-4.52	-0.38	1.4e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs651907	0.557	rs17347644	chr3:101547733	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.31	-6.42	-0.5	2.6e-9	Colorectal cancer;
TGCT	cis	rs6570726	0.791	rs1509214	chr6:145784606	A/C	cg05347473	chr6:146136440	FBXO30	-0.49	-4.71	-0.39	6.66e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3845702	0.800	rs6744281	chr2:180844382	G/A	cg01881094	chr2:180872142	CWC22	-1.08	-7.0	-0.53	1.39e-10	Schizophrenia;
TGCT	cis	rs1903068	0.925	rs1551641	chr4:55993915	C/T	cg09978860	chr4:56023921	NA	0.58	6.38	0.5	3.16e-9	Endometriosis;
TGCT	cis	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg08975724	chr8:8085496	FLJ10661	0.63	6.01	0.47	1.91e-8	Mood instability;
TGCT	cis	rs9583531	0.600	rs9555726	chr13:111368316	C/T	cg24331049	chr13:111365604	ING1	0.72	6.89	0.53	2.52e-10	Coronary artery disease;
TGCT	cis	rs748404	0.578	rs507178	chr15:43610135	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	4.75	0.39	5.46e-6	Lung cancer;
TGCT	cis	rs933688	0.759	rs1423593	chr5:90752351	T/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.06	9.27	0.64	7.2e-16	Smoking behavior;
TGCT	cis	rs422249	0.720	rs174455	chr11:61656117	A/G	cg19610905	chr11:61596333	FADS2	-0.67	-6.22	-0.49	6.89e-9	Trans fatty acid levels;
TGCT	cis	rs9818758	0.607	rs34566463	chr3:49245077	T/C	cg07636037	chr3:49044803	WDR6	-1.04	-5.13	-0.42	1.09e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs7666738	0.830	rs11097606	chr4:99011486	C/T	cg05340658	chr4:99064831	C4orf37	0.46	5.13	0.42	1.09e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3858526	0.920	rs11511938	chr11:5928793	A/G	cg13902645	chr11:5959945	NA	-0.44	-4.8	-0.4	4.54e-6	DNA methylation (variation);
TGCT	cis	rs919433	0.617	rs2037590	chr2:198584775	T/A	cg00792783	chr2:198669748	PLCL1	-0.54	-4.96	-0.41	2.25e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs59197085	0.636	rs57573379	chr7:128465646	A/G	cg00260937	chr7:128520193	KCP	0.47	4.98	0.41	2.1e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
TGCT	cis	rs9611565	0.512	rs9611672	chr22:42209922	A/G	cg06481639	chr22:41940642	POLR3H	-0.69	-6.02	-0.48	1.83e-8	Vitiligo;
TGCT	cis	rs9486719	0.843	rs976357	chr6:96849679	C/T	cg18709589	chr6:96969512	KIAA0776	0.75	5.13	0.42	1.1e-6	Migraine;Coronary artery disease;
TGCT	cis	rs67311347	1.000	rs73080137	chr3:40516412	A/G	cg17264618	chr3:40429014	ENTPD3	0.32	4.61	0.38	9.99e-6	Renal cell carcinoma;
TGCT	cis	rs7666738	0.830	rs13144771	chr4:99026935	G/C	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10488084	0.892	rs10226876	chr7:29970171	T/A	cg19198568	chr7:28997866	TRIL	0.75	4.55	0.38	1.27e-5	Estradiol levels;
TGCT	cis	rs6674176	0.932	rs7412307	chr1:44433864	C/G	cg13606994	chr1:44402422	ARTN	0.47	4.7	0.39	6.93e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.63	-6.16	-0.48	9.27e-9	Bipolar disorder;
TGCT	cis	rs10089	0.953	rs4835940	chr5:127406596	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	6.93	0.53	2e-10	Ileal carcinoids;
TGCT	cis	rs9303401	0.659	rs17222523	chr17:56620501	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs2777491	0.957	rs7181911	chr15:41674060	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.76	-10.64	-0.69	3.42e-19	Ulcerative colitis;
TGCT	cis	rs1865760	0.566	rs9379821	chr6:26054268	A/C	cg16482183	chr6:26056742	HIST1H1C	0.58	4.98	0.41	2.12e-6	Height;
TGCT	cis	rs968451	0.789	rs1569501	chr22:39683534	A/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.79	7.84	0.58	1.76e-12	Primary biliary cholangitis;
TGCT	cis	rs10510102	0.630	rs79960726	chr10:123713873	T/A	cg23691251	chr10:123688108	ATE1	-0.59	-4.7	-0.39	6.75e-6	Breast cancer;
TGCT	trans	rs4750440	0.733	rs2446585	chr10:14028086	C/T	cg23544566	chr7:157365643	PTPRN2	-0.38	-6.63	-0.51	9.44e-10	Adiponectin levels;
TGCT	cis	rs1538970	0.962	rs3219489	chr1:45797505	C/G	cg05343316	chr1:45956843	TESK2	0.65	5.2	0.42	8.04e-7	Platelet count;
TGCT	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg03188948	chr7:1209495	NA	0.68	5.8	0.46	5.09e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs12620999	0.941	rs2078469	chr2:237983273	C/G	cg23555395	chr2:238036564	NA	0.28	4.93	0.4	2.57e-6	Systemic lupus erythematosus;
TGCT	cis	rs1056053	0.514	rs3127331	chr6:166572744	C/T	cg17219086	chr6:166541254	NA	-0.19	-4.55	-0.38	1.24e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg04772025	chr11:68637568	NA	0.6	6.77	0.52	4.63e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs17401966	0.894	rs12722830	chr1:10395134	A/G	cg19773385	chr1:10388646	KIF1B	-0.24	-5.5	-0.44	2.03e-7	Hepatocellular carcinoma;
TGCT	cis	rs10779751	0.770	rs10864490	chr1:11236410	A/C	cg08854313	chr1:11322531	MTOR	0.85	8.17	0.59	2.94e-13	Body mass index;
TGCT	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.51	-4.96	-0.41	2.24e-6	Prudent dietary pattern;
TGCT	cis	rs12780845	0.540	rs11254435	chr10:17224426	A/T	cg01003015	chr10:17271136	VIM	0.52	4.61	0.38	9.97e-6	Homocysteine levels;
TGCT	cis	rs4803468	1.000	rs11670757	chr19:41913431	G/T	cg09537434	chr19:41945824	ATP5SL	-0.93	-11.06	-0.7	3.31e-20	Height;
TGCT	cis	rs7220711	1.000	rs59303349	chr17:41793668	A/G	cg26893861	chr17:41843967	DUSP3	0.5	4.49	0.37	1.61e-5	Bone mineral density (spine);Bone mineral density (hip);
TGCT	cis	rs9486719	1.000	rs12210146	chr6:96903962	A/G	cg06623918	chr6:96969491	KIAA0776	0.98	8.77	0.62	1.15e-14	Migraine;Coronary artery disease;
TGCT	cis	rs950776	0.642	rs922691	chr15:78963994	A/G	cg03762349	chr15:79060523	ADAMTS7	0.27	5.4	0.44	3.23e-7	Sudden cardiac arrest;
TGCT	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.54	-4.93	-0.4	2.56e-6	Menarche (age at onset);
TGCT	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg14159672	chr1:205819179	PM20D1	0.72	10.27	0.68	2.85e-18	Menarche (age at onset);
TGCT	cis	rs6121246	0.559	rs10439608	chr20:30258814	T/C	cg13852791	chr20:30311386	BCL2L1	0.82	8.0	0.58	7.65e-13	Mean corpuscular hemoglobin;
TGCT	cis	rs7635838	0.718	rs2248971	chr3:11403441	T/C	cg00170343	chr3:11313890	ATG7	0.66	6.47	0.5	2.01e-9	HDL cholesterol;
TGCT	trans	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	1.03	13.16	0.76	2.65e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs9733	0.628	rs7540874	chr1:150702663	A/C	cg09365446	chr1:150670422	GOLPH3L	0.3	4.52	0.38	1.4e-5	Tonsillectomy;
TGCT	cis	rs1887596	0.624	rs7992057	chr13:27153327	T/A	cg01312412	chr13:27282625	NA	0.29	5.32	0.43	4.77e-7	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs916888	0.738	rs199515	chr17:44856641	C/G	cg15921436	chr17:44337874	NA	-0.5	-6.76	-0.52	4.84e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs6582630	0.599	rs12824838	chr12:38373584	G/T	cg26384229	chr12:38710491	ALG10B	-0.51	-4.55	-0.38	1.24e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs10782582	0.593	rs77208152	chr1:76124255	T/C	cg10523679	chr1:76189770	ACADM	-0.7	-7.51	-0.56	9.94e-12	Daytime sleep phenotypes;
TGCT	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg08683831	chr4:1404607	NA	0.46	4.46	0.37	1.83e-5	Obesity-related traits;
TGCT	cis	rs28595532	0.841	rs114768988	chr4:119744451	T/C	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg18876405	chr7:65276391	NA	0.31	4.79	0.4	4.58e-6	Aortic root size;
TGCT	cis	rs8051431	0.840	rs8062422	chr16:72016839	G/T	cg06353428	chr16:71660113	MARVELD3	0.58	4.62	0.38	9.32e-6	LDL cholesterol levels;
TGCT	cis	rs28595532	1.000	rs56225646	chr4:119651217	T/C	cg14228332	chr4:119757509	SEC24D	1.02	5.37	0.43	3.75e-7	Cannabis dependence symptom count;
TGCT	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg03303774	chr4:1407052	NA	0.32	4.98	0.41	2.1e-6	Obesity-related traits;
TGCT	cis	rs7772486	0.846	rs2492856	chr6:146323928	A/G	cg05347473	chr6:146136440	FBXO30	0.49	4.7	0.39	6.88e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs28595532	0.920	rs114168088	chr4:119772666	G/A	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs9911578	1.000	rs2531732	chr17:56548420	T/A	cg12560992	chr17:57184187	TRIM37	-0.76	-9.28	-0.64	7.12e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs2295359	0.824	rs11209003	chr1:67601132	G/T	cg03340356	chr1:67600835	NA	0.41	4.93	0.4	2.62e-6	Psoriasis;
TGCT	cis	rs9467711	1.000	rs6903015	chr6:26322526	A/G	cg03264133	chr6:25882463	NA	-0.82	-4.48	-0.37	1.65e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2742417	0.603	rs1019129	chr3:45780780	T/C	cg04837898	chr3:45731254	SACM1L	-0.67	-7.3	-0.55	3.06e-11	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg03760483	chr17:6899297	ALOX12	0.47	5.38	0.44	3.55e-7	Tonsillectomy;
TGCT	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.55	-5.58	-0.45	1.41e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs910316	1.000	rs4903284	chr14:75592483	G/C	cg08847533	chr14:75593920	NEK9	0.95	10.55	0.69	5.83e-19	Height;
TGCT	cis	rs28374715	0.733	rs7167706	chr15:41569644	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.86	-13.71	-0.78	1.28e-26	Ulcerative colitis;
TGCT	cis	rs11098499	0.863	rs2306457	chr4:120472839	T/A	cg09307838	chr4:120376055	NA	0.72	6.9	0.53	2.41e-10	Corneal astigmatism;
TGCT	cis	rs4242434	0.927	rs10095121	chr8:22538426	A/G	cg03733263	chr8:22462867	KIAA1967	1.11	17.19	0.84	1.27e-34	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs11718455	0.960	rs11720974	chr3:43999111	G/C	cg08738300	chr3:44038990	NA	0.83	6.19	0.49	8.13e-9	Coronary artery disease;
TGCT	cis	rs79387448	0.745	rs7576324	chr2:103142994	G/A	cg09003973	chr2:102972529	NA	0.91	6.0	0.47	2.06e-8	Gut microbiota (bacterial taxa);
TGCT	cis	rs12620999	1.000	rs28727919	chr2:238003313	C/T	cg23555395	chr2:238036564	NA	0.29	4.89	0.4	3e-6	Systemic lupus erythematosus;
TGCT	trans	rs3107575	0.572	rs73169365	chr3:165319778	T/C	cg04140596	chr1:228404239	OBSCN	0.72	6.63	0.51	9.27e-10	Morning vs. evening chronotype;
TGCT	cis	rs2288884	0.806	rs60193983	chr19:52585912	T/G	cg13540795	chr19:52551618	ZNF432	-0.61	-5.28	-0.43	5.48e-7	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs4074961	0.692	rs11264075	chr1:38083941	C/G	cg17933807	chr1:38061675	GNL2	0.95	11.07	0.71	3.13e-20	Axial length;
TGCT	cis	rs875971	0.597	rs11771318	chr7:66062480	G/T	cg18876405	chr7:65276391	NA	-0.39	-6.2	-0.49	7.65e-9	Aortic root size;
TGCT	cis	rs9611519	0.964	rs20551	chr22:41548008	A/G	cg03806693	chr22:41940476	POLR3H	-0.67	-6.21	-0.49	7.35e-9	Neuroticism;
TGCT	cis	rs1008375	0.544	rs56227066	chr4:17565713	G/A	cg18681998	chr4:17616180	MED28	0.73	7.08	0.54	9.45e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg01017244	chr2:74357527	NA	0.47	7.41	0.55	1.7e-11	Gestational age at birth (maternal effect);
TGCT	cis	rs4901869	0.966	rs12878614	chr14:59339477	A/C	cg02291164	chr14:59296302	NA	0.23	4.49	0.37	1.61e-5	Panic disorder;
TGCT	cis	rs9611565	0.568	rs2413656	chr22:42129357	G/T	cg06634786	chr22:41940651	POLR3H	0.8	7.42	0.55	1.63e-11	Vitiligo;
TGCT	cis	rs3617	0.573	rs2336667	chr3:52916363	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	0.5	4.92	0.4	2.69e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg04287289	chr16:89883240	FANCA	0.93	12.17	0.74	6.69e-23	Vitiligo;
TGCT	cis	rs1157477	0.651	rs55950110	chr18:73887018	C/T	cg07537417	chr18:74332553	NA	-0.65	-4.67	-0.39	7.59e-6	Systolic blood pressure (cigarette smoking interaction);
TGCT	cis	rs67478160	0.643	rs4900594	chr14:104251006	C/T	cg26031613	chr14:104095156	KLC1	-0.63	-6.42	-0.5	2.64e-9	Schizophrenia;
TGCT	cis	rs3784262	0.900	rs12911071	chr15:58314848	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.52	-7.93	-0.58	1.1e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs1570884	0.536	rs1359541	chr13:50158939	A/G	cg03651054	chr13:50194643	NA	0.34	5.57	0.45	1.53e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
TGCT	cis	rs1577917	0.545	rs9450325	chr6:86475814	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.58	4.84	0.4	3.8e-6	Response to antipsychotic treatment;
TGCT	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg06221963	chr1:154839813	KCNN3	-0.73	-11.82	-0.73	4.65e-22	Prostate cancer;
TGCT	cis	rs3087591	1.000	rs4795577	chr17:29456879	T/G	cg24425628	chr17:29625626	OMG;NF1	0.46	7.25	0.55	3.92e-11	Hip circumference;
TGCT	cis	rs7822232	1.000	rs6558296	chr8:145143802	G/A	cg14631276	chr8:145163102	KIAA1875	-0.56	-5.05	-0.41	1.55e-6	Blood metabolite levels;
TGCT	cis	rs10972341	1.000	rs10972350	chr9:35149831	A/G	cg00812861	chr9:35114699	KIAA1539	0.32	4.97	0.41	2.18e-6	Weight;
TGCT	cis	rs9467773	1.000	rs6924838	chr6:26571756	C/T	cg05738196	chr6:26577821	NA	0.9	12.48	0.75	1.16e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs3741404	0.512	rs4980504	chr11:63873083	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.67	-6.28	-0.49	5.22e-9	Platelet count;
TGCT	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg25427524	chr10:38739819	LOC399744	-0.39	-8.05	-0.59	5.9e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs6570726	0.791	rs9403734	chr6:145931459	C/G	cg05347473	chr6:146136440	FBXO30	0.53	4.94	0.41	2.5e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9467773	0.933	rs35355150	chr6:26526039	G/A	cg05738196	chr6:26577821	NA	0.83	10.98	0.7	5.27e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.53	6.16	0.48	9.43e-9	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9527	0.590	rs7089680	chr10:104802071	C/T	cg04362960	chr10:104952993	NT5C2	-0.65	-5.59	-0.45	1.36e-7	Arsenic metabolism;
TGCT	trans	rs12191082	0.646	rs17470473	chr6:46883779	C/T	cg15621338	chr7:128577916	IRF5	-1.22	-6.68	-0.51	7.28e-10	Mean platelet volume;
TGCT	cis	rs7917772	0.503	rs10748825	chr10:104293609	A/G	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1878931	0.543	rs1129568	chr16:3483475	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.9	9.51	0.65	1.93e-16	Body mass index (adult);
TGCT	cis	rs453301	0.506	rs476845	chr8:8622877	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-4.49	-0.37	1.62e-5	Joint mobility (Beighton score);
TGCT	cis	rs13191362	1.000	rs13204013	chr6:163002480	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg06873352	chr17:61820015	STRADA	0.56	6.22	0.49	7.1e-9	Prudent dietary pattern;
TGCT	cis	rs11696501	0.739	rs6073820	chr20:44249272	T/A	cg11783356	chr20:44313418	WFDC10B	-0.33	-4.79	-0.4	4.67e-6	Brain structure;
TGCT	cis	rs6860806	0.507	rs169256	chr5:131688533	A/G	cg16647868	chr5:131706066	SLC22A5	0.3	4.49	0.37	1.62e-5	Breast cancer;
TGCT	cis	rs2486012	0.826	rs3011229	chr1:44328017	A/G	cg12908607	chr1:44402522	ARTN	-0.69	-5.57	-0.45	1.49e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs896854	0.818	rs13262110	chr8:95926890	C/T	cg16049864	chr8:95962084	TP53INP1	-0.71	-9.71	-0.66	6.44e-17	Type 2 diabetes;
TGCT	cis	rs16958440	0.867	rs16949157	chr18:44691324	A/G	cg17192377	chr18:44677553	HDHD2	0.63	4.7	0.39	6.74e-6	Sitting height ratio;
TGCT	cis	rs6912958	0.558	rs7741825	chr6:88327338	G/C	cg06598631	chr6:88300029	RARS2;ORC3L	-0.57	-4.96	-0.41	2.23e-6	Monocyte percentage of white cells;
TGCT	cis	rs78456975	1.000	rs13392535	chr2:1542634	G/T	cg01028140	chr2:1542097	TPO	-0.36	-4.63	-0.38	9.02e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs9291683	0.595	rs35250962	chr4:10048271	C/T	cg00071950	chr4:10020882	SLC2A9	0.68	8.48	0.61	5.73e-14	Bone mineral density;
TGCT	cis	rs9447004	0.584	rs56093139	chr6:74432923	C/T	cg23004174	chr6:74404879	CD109	0.22	4.58	0.38	1.14e-5	Blood protein levels;Calcium levels;
TGCT	cis	rs7523050	0.643	rs35665867	chr1:109395436	G/A	cg08274380	chr1:109419600	GPSM2	1.29	6.23	0.49	6.72e-9	Fat distribution (HIV);
TGCT	cis	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg02503808	chr4:7069936	GRPEL1	-0.97	-7.94	-0.58	1.01e-12	Monocyte percentage of white cells;
TGCT	cis	rs2180341	0.960	rs9398840	chr6:127669744	G/A	cg24812749	chr6:127587940	RNF146	1.01	7.62	0.56	5.59e-12	Breast cancer;
TGCT	cis	rs7819412	0.538	rs4523214	chr8:10970773	T/A	cg21775007	chr8:11205619	TDH	-0.52	-5.03	-0.41	1.67e-6	Triglycerides;
TGCT	cis	rs6429082	0.818	rs167092	chr1:235642359	A/G	cg26050004	chr1:235667680	B3GALNT2	0.62	5.58	0.45	1.43e-7	Adiposity;
TGCT	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg08219700	chr8:58056026	NA	0.3	4.55	0.38	1.24e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9929218	0.731	rs72785179	chr16:68767912	C/T	cg01251360	chr16:68772225	CDH1	0.29	4.95	0.41	2.34e-6	Colorectal cancer;
TGCT	cis	rs9926296	0.656	rs2376882	chr16:89827002	T/C	cg27121462	chr16:89883253	FANCA	0.53	4.99	0.41	2.01e-6	Vitiligo;
TGCT	cis	rs12477438	0.798	rs4850891	chr2:99574642	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-6.21	-0.49	7.35e-9	Chronic sinus infection;
TGCT	cis	rs7715806	0.500	rs17649266	chr5:75001252	C/T	cg19683494	chr5:74908142	NA	-0.54	-4.49	-0.37	1.58e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs7582180	0.627	rs4851312	chr2:101011241	G/A	cg08017756	chr2:100939284	LONRF2	-0.31	-5.01	-0.41	1.86e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2404602	0.532	rs284892	chr15:76721037	A/G	cg22467129	chr15:76604101	ETFA	-0.44	-4.86	-0.4	3.41e-6	Blood metabolite levels;
TGCT	cis	rs9682041	0.877	rs10804841	chr3:170072031	T/A	cg11886554	chr3:170076028	SKIL	0.55	4.58	0.38	1.11e-5	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs2842992	0.789	rs2146163	chr6:160224346	T/C	cg11366901	chr6:160182831	ACAT2	1.03	6.98	0.53	1.59e-10	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs17152411	1.000	rs17152377	chr10:126592852	T/G	cg07906193	chr10:126599966	NA	0.42	5.28	0.43	5.6e-7	Height;
TGCT	trans	rs561341	1.000	rs542132	chr17:30307193	A/T	cg20587970	chr11:113659929	NA	-1.04	-12.57	-0.75	6.97e-24	Hip circumference adjusted for BMI;
TGCT	cis	rs11167764	0.895	rs6882824	chr5:141474300	A/G	cg23435118	chr5:141488016	NDFIP1	-0.27	-4.53	-0.38	1.35e-5	Crohn's disease;
TGCT	cis	rs9560113	1.000	rs9560103	chr13:112174253	G/A	cg14154082	chr13:112174009	NA	0.34	4.58	0.38	1.09e-5	Menarche (age at onset);
TGCT	cis	rs2380220	0.872	rs4546494	chr6:95990626	A/C	cg04719120	chr6:96025338	MANEA	0.68	4.79	0.4	4.59e-6	Behavioural disinhibition (generation interaction);
TGCT	cis	rs1992660	0.504	rs7712308	chr5:40351716	A/G	cg01087697	chr5:40835557	RPL37	0.52	4.7	0.39	6.92e-6	Crohn's disease;
TGCT	cis	rs2204008	0.807	rs11182461	chr12:38539288	T/C	cg13010199	chr12:38710504	ALG10B	0.65	5.18	0.42	8.78e-7	Bladder cancer;
TGCT	cis	rs3806843	0.576	rs246047	chr5:140328337	C/T	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs6088590	0.687	rs73106933	chr20:33287425	T/C	cg06115741	chr20:33292138	TP53INP2	0.58	4.88	0.4	3.14e-6	Coronary artery disease;
TGCT	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg21862992	chr11:68658383	NA	0.46	6.32	0.49	4.31e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs6450176	1.000	rs12654393	chr5:53302620	A/C	ch.5.1024479R	chr5:53302184	ARL15	0.53	5.1	0.42	1.23e-6	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg11764359	chr7:65958608	NA	-0.56	-5.09	-0.42	1.31e-6	Aortic root size;
TGCT	cis	rs7432375	0.901	rs4038587	chr3:136381368	A/C	cg12473912	chr3:136751656	NA	-0.36	-5.06	-0.41	1.5e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs79349575	0.749	rs957557	chr17:47003221	G/T	cg07967210	chr17:47022446	SNF8	0.44	6.12	0.48	1.13e-8	Type 2 diabetes;
TGCT	cis	rs10875746	0.669	rs4760701	chr12:48698518	A/G	cg20731937	chr12:48336164	NA	0.58	4.76	0.39	5.24e-6	Longevity (90 years and older);
TGCT	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.51	-4.61	-0.38	9.89e-6	Menarche (age at onset);
TGCT	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg04025307	chr7:1156635	C7orf50	0.2	4.73	0.39	5.94e-6	Longevity;Endometriosis;
TGCT	cis	rs9976767	0.637	rs9984108	chr21:43825628	T/G	cg23042151	chr21:43824109	UBASH3A	-0.23	-5.14	-0.42	1.02e-6	Type 1 diabetes;
TGCT	trans	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg21659725	chr3:3221576	CRBN	0.63	6.65	0.51	8.42e-10	Resting heart rate;
TGCT	cis	rs849210	0.517	rs13011981	chr2:206202372	A/G	cg11793701	chr2:206547163	NRP2	-0.57	-4.54	-0.38	1.31e-5	Tonsillectomy;
TGCT	cis	rs1670533	1.000	rs4690215	chr4:1054619	G/C	cg20887711	chr4:1340912	KIAA1530	0.71	5.7	0.46	8.33e-8	Recombination rate (females);
TGCT	trans	rs561341	0.941	rs501773	chr17:30314435	T/G	cg20587970	chr11:113659929	NA	-1.05	-12.74	-0.75	2.84e-24	Hip circumference adjusted for BMI;
TGCT	cis	rs6088590	1.000	rs6087626	chr20:33347328	C/T	cg06115741	chr20:33292138	TP53INP2	0.67	5.61	0.45	1.24e-7	Coronary artery disease;
TGCT	cis	rs9796	0.689	rs8032195	chr15:41448790	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.54	-7.03	-0.53	1.2e-10	Menopause (age at onset);
TGCT	cis	rs933688	1.000	rs2367526	chr5:90740525	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.94	8.08	0.59	4.83e-13	Smoking behavior;
TGCT	cis	rs9611519	1.000	rs9611520	chr22:41613303	C/T	cg03806693	chr22:41940476	POLR3H	-0.68	-6.38	-0.5	3.17e-9	Neuroticism;
TGCT	cis	rs854765	0.583	rs10048206	chr17:17866897	A/G	cg09796270	chr17:17721594	SREBF1	0.23	4.55	0.38	1.27e-5	Total body bone mineral density;
TGCT	cis	rs72647484	0.642	rs28617726	chr1:22586280	G/A	cg21876283	chr1:22149684	LDLRAD2;HSPG2	0.27	4.55	0.38	1.26e-5	Colorectal cancer;
TGCT	cis	rs1371867	0.875	rs1788176	chr8:101332112	A/G	cg00191853	chr8:101177733	SPAG1	-0.22	-4.47	-0.37	1.75e-5	Atrioventricular conduction;
TGCT	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	trans	rs561341	1.000	rs527256	chr17:30321293	C/G	cg20587970	chr11:113659929	NA	-1.04	-12.57	-0.75	6.97e-24	Hip circumference adjusted for BMI;
TGCT	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg10802521	chr3:52805072	NEK4	-0.8	-10.49	-0.69	8.31e-19	Electroencephalogram traits;
TGCT	cis	rs17401966	0.931	rs12131441	chr1:10428952	G/A	cg19773385	chr1:10388646	KIF1B	-0.24	-5.5	-0.44	2.03e-7	Hepatocellular carcinoma;
TGCT	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg06634786	chr22:41940651	POLR3H	0.99	7.75	0.57	2.81e-12	Vitiligo;
TGCT	cis	rs9467773	0.935	rs1056668	chr6:26510605	C/T	cg26531700	chr6:26746687	NA	0.61	6.25	0.49	6.06e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg11494091	chr17:61959527	GH2	0.61	14.49	0.79	1.92e-28	Prudent dietary pattern;
TGCT	cis	rs642743	0.517	rs157077	chr10:106037894	C/T	cg00899160	chr10:106034472	GSTO2	-0.4	-5.09	-0.42	1.29e-6	Left ventricular obstructive tract defect (maternal effect);
TGCT	cis	rs2730245	0.527	rs62476464	chr7:158698063	C/T	cg11984989	chr7:158649758	WDR60	1.01	7.85	0.58	1.65e-12	Height;
TGCT	cis	rs858239	0.601	rs764533	chr7:23153875	C/T	cg05602783	chr7:23145260	KLHL7	-0.62	-5.22	-0.42	7.15e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs56114371	0.777	rs200482	chr6:27773904	G/A	cg08798685	chr6:27730294	NA	-0.33	-4.53	-0.38	1.34e-5	Breast cancer;
TGCT	cis	rs6690583	0.623	rs12030730	chr1:85454109	C/G	cg20280350	chr1:85513789	MCOLN3	-0.74	-5.11	-0.42	1.2e-6	Serum sulfate level;
TGCT	cis	rs992157	0.835	rs2292555	chr2:219146882	G/C	cg00012203	chr2:219082015	ARPC2	-0.79	-7.87	-0.58	1.48e-12	Colorectal cancer;
TGCT	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg03188948	chr7:1209495	NA	0.5	7.14	0.54	6.77e-11	Longevity;Endometriosis;
TGCT	cis	rs1568889	1.000	rs61889046	chr11:28297024	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.82	8.61	0.61	2.73e-14	Bipolar disorder;
TGCT	cis	rs9372253	0.934	rs9320327	chr6:110715194	T/A	cg19196401	chr6:110721138	DDO	-0.5	-7.32	-0.55	2.8e-11	Platelet distribution width;
TGCT	cis	rs80033912	0.640	rs6785832	chr3:49224316	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.35	-4.71	-0.39	6.53e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2299587	0.554	rs17634704	chr8:17753306	A/G	cg01800426	chr8:17659068	MTUS1	-0.58	-5.12	-0.42	1.12e-6	Economic and political preferences;
TGCT	cis	rs367943	0.871	rs348940	chr5:112824530	C/A	cg12552261	chr5:112820674	MCC	-0.22	-4.7	-0.39	6.84e-6	Type 2 diabetes;
TGCT	cis	rs10751667	0.666	rs7395823	chr11:942701	T/C	cg06064525	chr11:970664	AP2A2	-0.35	-8.28	-0.6	1.65e-13	Alzheimer's disease (late onset);
TGCT	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg11905131	chr22:24372483	LOC391322	-0.95	-11.19	-0.71	1.58e-20	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1347297	0.526	rs919177	chr2:179258923	C/T	cg03991736	chr2:179345203	MIR548N;PLEKHA3	-0.51	-5.01	-0.41	1.86e-6	Alzheimer disease and age of onset;
TGCT	cis	rs9914988	0.887	rs12451790	chr17:27112000	C/G	cg20469991	chr17:27169893	C17orf63	-0.72	-5.04	-0.41	1.58e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg10047753	chr17:41438598	NA	0.74	7.06	0.54	1.04e-10	Menopause (age at onset);
TGCT	cis	rs10114408	0.959	rs1316472	chr9:96649157	C/G	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs2013441	1.000	rs2013576	chr17:20167692	G/C	cg18979559	chr17:20280153	CCDC144C	-0.45	-4.67	-0.39	7.61e-6	Obesity-related traits;
TGCT	cis	rs7296418	0.961	rs1790121	chr12:123604492	G/A	cg00376283	chr12:123451042	ABCB9	0.83	7.54	0.56	8.67e-12	Platelet count;
TGCT	cis	rs1451375	1.000	rs921450	chr7:50623260	A/G	cg18232548	chr7:50535776	DDC	-0.41	-6.46	-0.5	2.13e-9	Malaria;
TGCT	cis	rs524281	0.861	rs7120326	chr11:65849256	C/T	cg00563793	chr11:65837595	PACS1	0.56	4.74	0.39	5.69e-6	Electroencephalogram traits;
TGCT	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg05368731	chr17:41323189	NBR1	1.2	14.2	0.79	9.05e-28	Menopause (age at onset);
TGCT	cis	rs911555	0.755	rs2765049	chr14:103975039	G/A	cg12935359	chr14:103987150	CKB	0.33	4.57	0.38	1.15e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs765787	0.530	rs1648287	chr15:45516956	T/C	cg24006582	chr15:45444508	DUOX1	-0.25	-5.37	-0.43	3.78e-7	Uric acid levels;
TGCT	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.61	5.06	0.41	1.5e-6	Tonsillectomy;
TGCT	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.82	7.52	0.56	9.42e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs6121246	0.567	rs2811	chr20:30194248	A/G	cg21427119	chr20:30132790	HM13	-0.42	-6.17	-0.48	8.75e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs6450176	0.909	rs67721004	chr5:53290571	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.49	-4.59	-0.38	1.09e-5	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs1865760	1.000	rs3752421	chr6:25918688	G/A	cg16482183	chr6:26056742	HIST1H1C	0.51	4.55	0.38	1.25e-5	Height;
TGCT	cis	rs4819052	0.590	rs414743	chr21:46512075	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.44	0.37	1.99e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs79387448	0.745	rs72993720	chr2:103121269	A/T	cg09003973	chr2:102972529	NA	0.85	5.65	0.45	1.03e-7	Gut microbiota (bacterial taxa);
TGCT	cis	rs1033284	0.748	rs1249433	chr2:141945852	C/T	cg20443778	chr2:142887886	LRP1B	0.47	4.48	0.37	1.66e-5	Blood pressure (smoking interaction);
TGCT	cis	rs2033562	0.505	rs9297327	chr8:103540181	A/C	cg09916692	chr8:103549622	NA	-0.22	-4.47	-0.37	1.71e-5	IgA nephropathy;
TGCT	cis	rs7027203	0.557	rs2490997	chr9:96522109	C/T	cg14598338	chr9:96623480	NA	-0.49	-7.04	-0.53	1.18e-10	DNA methylation (variation);
TGCT	cis	rs35306767	0.903	rs11253495	chr10:937064	C/T	cg26597838	chr10:835615	NA	0.73	10.11	0.67	6.86e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs7666738	0.830	rs35433756	chr4:99070555	C/T	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.44e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9318086	0.935	rs9652081	chr13:24435510	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.68	-6.87	-0.52	2.82e-10	Myopia (pathological);
TGCT	cis	rs524023	0.837	rs12362590	chr11:64352540	T/A	cg07733098	chr11:64478343	NRXN2	0.31	4.56	0.38	1.2e-5	Urate levels in obese individuals;
TGCT	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg03709012	chr19:19516395	GATAD2A	-0.66	-5.7	-0.46	8.46e-8	Tonsillectomy;
TGCT	cis	rs6754311	0.593	rs656326	chr2:136428460	A/C	cg07169764	chr2:136633963	MCM6	0.66	5.89	0.47	3.45e-8	Mosquito bite size;
TGCT	cis	rs10851411	0.908	rs3986280	chr15:42850380	A/G	cg23803468	chr15:43513504	EPB42	0.27	5.19	0.42	8.38e-7	Glucose homeostasis traits;
TGCT	cis	rs12497850	0.897	rs7373778	chr3:48836392	C/G	cg07636037	chr3:49044803	WDR6	0.94	10.39	0.68	1.46e-18	Parkinson's disease;
TGCT	trans	rs9951602	0.512	rs4799246	chr18:76653417	A/G	cg02800362	chr5:177631904	HNRNPAB	1.14	12.9	0.76	1.17e-24	Obesity-related traits;
TGCT	cis	rs2387326	1.000	rs10764751	chr10:129926420	A/C	cg03458096	chr10:129105057	DOCK1	-0.3	-4.67	-0.39	7.78e-6	Select biomarker traits;
TGCT	cis	rs11585357	0.895	rs72633806	chr1:17617943	A/G	cg08277548	chr1:17600880	PADI3	-0.96	-9.78	-0.66	4.35e-17	Hair shape;
TGCT	cis	rs7772486	0.754	rs6937661	chr6:146113299	T/C	cg05347473	chr6:146136440	FBXO30	-0.53	-4.99	-0.41	2.02e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4072705	0.617	rs10283445	chr9:127243637	A/G	cg13476313	chr9:127244764	NR5A1	0.29	4.71	0.39	6.66e-6	Menarche (age at onset);
TGCT	cis	rs6754311	0.681	rs4954493	chr2:136609975	T/C	cg07169764	chr2:136633963	MCM6	-0.66	-6.13	-0.48	1.08e-8	Mosquito bite size;
TGCT	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.73	-0.39	5.93e-6	Prudent dietary pattern;
TGCT	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg11366901	chr6:160182831	ACAT2	0.79	5.81	0.46	4.92e-8	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.45	4.84	0.4	3.81e-6	Menopause (age at onset);
TGCT	cis	rs2072499	0.833	rs2842873	chr1:156204653	C/T	cg06970220	chr1:156163860	SLC25A44	0.66	6.0	0.47	2.01e-8	Testicular germ cell tumor;
TGCT	cis	rs1215050	0.740	rs783938	chr4:99010336	A/T	cg17366294	chr4:99064904	C4orf37	-0.53	-5.41	-0.44	3.06e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs4499344	0.556	rs259231	chr19:33129067	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.83	8.3	0.6	1.52e-13	Mean platelet volume;
TGCT	cis	rs137699	0.959	rs5757631	chr22:39755953	T/C	cg11247378	chr22:39784982	NA	-0.47	-5.2	-0.42	8.13e-7	IgG glycosylation;
TGCT	cis	rs9457247	1.000	rs2757047	chr6:167374489	C/T	cg23791538	chr6:167370224	RNASET2	0.5	4.98	0.41	2.05e-6	Crohn's disease;
TGCT	cis	rs67311347	0.956	rs4974029	chr3:40521318	C/G	cg13683864	chr3:40499215	RPL14	-1.16	-13.09	-0.76	3.9e-25	Renal cell carcinoma;
TGCT	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg04772025	chr11:68637568	NA	0.6	6.74	0.52	5.3e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs644799	0.526	rs530914	chr11:95632156	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.49	4.99	0.41	1.99e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs425277	1.000	rs427811	chr1:2075560	T/G	cg24578937	chr1:2090814	PRKCZ	0.3	7.05	0.53	1.1e-10	Height;
TGCT	cis	rs35883536	0.647	rs10875317	chr1:101045438	G/T	cg06223162	chr1:101003688	GPR88	-0.41	-7.64	-0.57	5.04e-12	Monocyte count;
TGCT	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.67	-0.39	7.73e-6	Prudent dietary pattern;
TGCT	trans	rs2469997	1.000	rs2470028	chr8:120365878	A/G	cg01792902	chr3:178864926	PIK3CA	0.83	6.77	0.52	4.49e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs7552404	0.924	rs67757078	chr1:76169456	G/A	cg10523679	chr1:76189770	ACADM	0.9	9.92	0.67	2e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs12220898	0.619	rs10735221	chr10:50483563	G/A	cg06072769	chr10:50146962	WDFY4	0.38	5.07	0.41	1.38e-6	Inflammatory biomarkers;
TGCT	trans	rs35934224	0.783	rs16984299	chr22:19863593	C/T	cg07537964	chr19:3722604	NA	-0.7	-6.7	-0.52	6.57e-10	Glaucoma (primary open-angle);
TGCT	cis	rs12039431	0.788	rs7535432	chr1:38051585	C/T	cg17933807	chr1:38061675	GNL2	-0.8	-7.91	-0.58	1.24e-12	Epithelial ovarian cancer;
TGCT	cis	rs1048238	0.506	rs848195	chr1:16286522	A/G	cg21385522	chr1:16154831	NA	-0.61	-6.93	-0.53	2.01e-10	Systolic blood pressure;
TGCT	cis	rs9902453	0.934	rs4343336	chr17:28488236	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	6.39	0.5	3.03e-9	Coffee consumption (cups per day);
TGCT	cis	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg03213289	chr20:61660250	NA	0.68	9.99	0.67	1.36e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs12579753	1.000	rs10862368	chr12:82244514	C/T	cg07988820	chr12:82153109	PPFIA2	-0.6	-6.48	-0.5	1.91e-9	Resting heart rate;
TGCT	cis	rs10791097	0.694	rs4436551	chr11:130755739	A/G	cg14779329	chr11:130786720	SNX19	-0.29	-5.0	-0.41	1.95e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	8.55	0.61	3.84e-14	Platelet count;
TGCT	cis	rs13256369	0.802	rs12153	chr8:8560909	G/C	cg18904891	chr8:8559673	CLDN23	0.57	5.27	0.43	5.87e-7	Obesity-related traits;
TGCT	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.72	-4.47	-0.37	1.72e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7772486	0.875	rs2748502	chr6:146298239	A/G	cg05347473	chr6:146136440	FBXO30	0.52	4.92	0.4	2.7e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs68170813	0.559	rs74584447	chr7:106944755	T/C	cg02696742	chr7:106810147	HBP1	-0.69	-5.81	-0.46	4.85e-8	Coronary artery disease;
TGCT	cis	rs644799	0.540	rs10831422	chr11:95478968	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.64	6.14	0.48	1.01e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9399401	0.710	rs12190271	chr6:142681409	A/G	cg03128060	chr6:142623767	GPR126	-0.37	-4.46	-0.37	1.82e-5	Chronic obstructive pulmonary disease;
TGCT	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg01802117	chr1:53393560	SCP2	0.44	5.34	0.43	4.33e-7	Monocyte count;
TGCT	cis	rs2762353	0.935	rs1892249	chr6:25768992	A/G	cg12310025	chr6:25882481	NA	0.53	5.5	0.44	2.03e-7	Blood metabolite levels;
TGCT	cis	rs7618915	0.773	rs10510760	chr3:52650348	G/A	cg10802521	chr3:52805072	NEK4	-0.61	-6.53	-0.51	1.55e-9	Bipolar disorder;
TGCT	cis	rs9611565	0.921	rs6002333	chr22:41719469	C/T	cg06634786	chr22:41940651	POLR3H	-0.72	-6.8	-0.52	3.9e-10	Vitiligo;
TGCT	trans	rs1814175	0.817	rs1818890	chr11:49856882	T/C	cg03929089	chr4:120376271	NA	-0.72	-8.26	-0.6	1.84e-13	Height;
TGCT	cis	rs595982	0.527	rs56021835	chr19:49369989	G/A	cg21252483	chr19:49399788	TULP2	-0.42	-6.39	-0.5	3.02e-9	Red cell distribution width;
TGCT	cis	rs17253792	0.822	rs78323463	chr14:56045451	T/G	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs11098499	0.955	rs35197422	chr4:120169314	T/G	cg24670566	chr4:120433619	PDE5A	0.23	4.58	0.38	1.13e-5	Corneal astigmatism;
TGCT	cis	rs11578119	0.872	rs114909548	chr1:170542820	G/A	cg09767346	chr1:170501363	GORAB	0.59	4.66	0.39	8.03e-6	Male-pattern baldness;
TGCT	cis	rs2836633	0.929	rs8130434	chr21:40036243	C/T	cg12884169	chr21:40033163	ERG	-0.43	-4.69	-0.39	7.2e-6	Coronary artery disease;
TGCT	cis	rs6665290	0.904	rs1343744	chr1:227183022	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.98	-20.16	-0.88	6.05e-41	Myeloid white cell count;
TGCT	cis	rs2288884	1.000	rs76368799	chr19:52561507	A/G	cg15405931	chr19:52693188	PPP2R1A	-0.69	-4.5	-0.37	1.56e-5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs950169	0.922	rs62029585	chr15:84951874	C/G	cg17173187	chr15:85201210	NMB	0.59	5.87	0.47	3.71e-8	Schizophrenia;
TGCT	cis	rs10782582	0.609	rs1770889	chr1:76401166	A/G	cg03433033	chr1:76189801	ACADM	-0.52	-5.13	-0.42	1.07e-6	Daytime sleep phenotypes;
TGCT	cis	rs12580194	1.000	rs12582734	chr12:55689572	C/A	cg20672549	chr12:56432144	IKZF4	0.27	4.75	0.39	5.55e-6	Cancer;
TGCT	cis	rs2153535	0.580	rs9406158	chr6:8464152	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs7246657	0.943	rs7255972	chr19:37933841	T/C	cg18154014	chr19:37997991	ZNF793	0.95	6.52	0.51	1.58e-9	Coronary artery calcification;
TGCT	cis	rs2637266	0.905	rs11001834	chr10:78360494	T/C	cg18941641	chr10:78392320	NA	0.43	5.57	0.45	1.49e-7	Pulmonary function;
TGCT	cis	rs9372498	0.572	rs62422190	chr6:118909235	A/G	cg07617317	chr6:118971624	C6orf204	0.48	5.08	0.42	1.32e-6	Diastolic blood pressure;
TGCT	cis	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg22857025	chr5:266934	NA	-0.34	-6.7	-0.52	6.65e-10	Breast cancer;
TGCT	cis	rs7586879	0.551	rs7565460	chr2:25130073	C/T	cg01884057	chr2:25150051	NA	0.35	6.87	0.53	2.72e-10	Body mass index;
TGCT	cis	rs9383153	0.793	rs9358090	chr6:16348728	G/A	cg14009473	chr6:15502099	JARID2	0.62	4.93	0.4	2.58e-6	Gambling;
TGCT	cis	rs4332037	0.539	rs868754	chr7:2033780	G/C	cg25834613	chr7:1915315	MAD1L1	-0.53	-4.99	-0.41	2.02e-6	Bipolar disorder;
TGCT	cis	rs71435601	0.628	rs312983	chr2:21378580	A/C	cg25035485	chr2:21266500	APOB	0.51	4.48	0.37	1.66e-5	Cholesterol, total;
TGCT	cis	rs2180341	0.924	rs877661	chr6:127587915	T/G	cg27446573	chr6:127587934	RNF146	1.12	10.11	0.67	6.87e-18	Breast cancer;
TGCT	cis	rs459571	0.635	rs379471	chr9:136890649	G/A	cg13789015	chr9:136890014	NCRNA00094	0.39	7.2	0.54	5.17e-11	Platelet distribution width;
TGCT	cis	rs155076	1.000	rs155076	chr13:21870114	A/G	cg11317459	chr13:21872234	NA	-1.3	-11.71	-0.72	8.86e-22	White matter hyperintensity burden;
TGCT	cis	rs9921338	0.887	rs7189044	chr16:11442196	G/C	cg00044050	chr16:11439710	C16orf75	-0.91	-7.1	-0.54	8.47e-11	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs2153535	0.580	rs6918391	chr6:8461178	A/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs114540395	0.925	rs78646802	chr10:103392029	A/G	cg18276125	chr10:102749041	C10orf2	0.41	5.04	0.41	1.58e-6	Schizophrenia;
TGCT	cis	rs7772486	0.806	rs2253648	chr6:146199296	G/A	cg23711669	chr6:146136114	FBXO30	0.88	9.63	0.65	9.94e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs67311347	1.000	rs2305521	chr3:40429183	A/G	cg17264618	chr3:40429014	ENTPD3	0.32	4.76	0.39	5.29e-6	Renal cell carcinoma;
TGCT	cis	rs2120019	1.000	rs35577967	chr15:75354621	G/A	cg17294928	chr15:75287854	SCAMP5	-0.84	-6.3	-0.49	4.75e-9	Blood trace element (Zn levels);
TGCT	cis	rs9303542	0.625	rs7225995	chr17:46596268	G/C	cg25032089	chr17:46643351	HOXB3	0.56	5.5	0.44	2.11e-7	Ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg20607798	chr8:58055168	NA	0.62	5.23	0.43	6.99e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs790123	0.933	rs812596	chr3:122382301	A/T	cg22896480	chr3:122379438	NA	0.2	5.08	0.42	1.35e-6	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs6840360	0.667	rs4266275	chr4:152348064	A/G	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.83e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs950776	0.642	rs12905641	chr15:78964362	A/G	cg21242079	chr15:79101063	ADAMTS7	0.33	5.05	0.41	1.55e-6	Sudden cardiac arrest;
TGCT	cis	rs1577917	0.958	rs1414199	chr6:86522370	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-5.53	-0.44	1.82e-7	Response to antipsychotic treatment;
TGCT	cis	rs26868	0.816	rs26872	chr16:2247644	C/T	cg25665528	chr16:2260870	C16orf79	-0.31	-4.81	-0.4	4.38e-6	Height;
TGCT	cis	rs3892630	0.878	rs1061686	chr19:33204544	C/T	cg22980127	chr19:33182716	NUDT19	-0.62	-5.07	-0.41	1.41e-6	Red blood cell traits;
TGCT	cis	rs9513593	1.000	rs7323390	chr13:99997968	A/G	cg21788972	chr13:99853209	UBAC2	0.56	4.5	0.37	1.52e-5	Psoriasis;
TGCT	cis	rs6565180	0.926	rs4787643	chr16:30393660	G/A	cg17640201	chr16:30407289	ZNF48	0.96	9.04	0.63	2.57e-15	Tonsillectomy;
TGCT	cis	rs9911578	1.000	rs2270097	chr17:56572070	G/A	cg12560992	chr17:57184187	TRIM37	-0.76	-9.14	-0.63	1.48e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs17030434	0.953	rs10010787	chr4:154692059	G/A	cg14289246	chr4:154710475	SFRP2	-0.96	-7.81	-0.57	2.06e-12	Electrocardiographic conduction measures;
TGCT	cis	rs9534288	0.619	rs2146881	chr13:46679598	T/C	cg15192986	chr13:46630673	CPB2	-0.47	-5.61	-0.45	1.26e-7	Blood protein levels;
TGCT	cis	rs651907	0.535	rs17347156	chr3:101504674	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.31	-6.31	-0.49	4.5e-9	Colorectal cancer;
TGCT	cis	rs7727544	0.582	rs10478998	chr5:131516531	G/A	cg24060327	chr5:131705240	SLC22A5	-0.45	-4.5	-0.37	1.55e-5	Blood metabolite levels;
TGCT	cis	rs372883	0.600	rs407712	chr21:30722531	G/A	cg24692254	chr21:30365293	RNF160	-0.54	-4.83	-0.4	3.97e-6	Pancreatic cancer;
TGCT	cis	rs295140	0.507	rs1369842	chr2:201108987	C/A	cg23649088	chr2:200775458	C2orf69	-0.29	-4.92	-0.4	2.68e-6	QT interval;
TGCT	cis	rs2952156	0.684	rs1877031	chr17:37814080	G/A	cg00129232	chr17:37814104	STARD3	-0.22	-4.48	-0.37	1.68e-5	Asthma;
TGCT	cis	rs79387448	0.745	rs2310294	chr2:103165706	A/G	cg09003973	chr2:102972529	NA	0.93	6.03	0.48	1.73e-8	Gut microbiota (bacterial taxa);
TGCT	cis	rs9393692	0.905	rs7746807	chr6:26293338	C/A	cg00631329	chr6:26305371	NA	-0.42	-6.22	-0.49	6.83e-9	Educational attainment;
TGCT	cis	rs854765	0.964	rs2230316	chr17:17997209	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.61	-5.8	-0.46	5.24e-8	Total body bone mineral density;
TGCT	cis	rs8017423	0.967	rs11849641	chr14:90727647	T/C	cg04374321	chr14:90722782	PSMC1	0.76	7.63	0.57	5.3e-12	Mortality in heart failure;
TGCT	cis	rs9372498	0.536	rs72969531	chr6:118729974	C/A	cg21191810	chr6:118973309	C6orf204	-0.37	-4.77	-0.39	5.03e-6	Diastolic blood pressure;
TGCT	cis	rs10769945	0.730	rs217208	chr11:1974892	C/G	cg18032502	chr11:1949113	TNNT3	-0.24	-4.45	-0.37	1.9e-5	DNA methylation (variation);
TGCT	cis	rs9556958	0.708	rs4772092	chr13:99166614	A/G	cg07423050	chr13:99094983	FARP1	-0.23	-4.87	-0.4	3.38e-6	Educational attainment (years of education);
TGCT	cis	rs1532993	0.518	rs10019787	chr4:98629088	C/G	cg05340658	chr4:99064831	C4orf37	-0.41	-4.96	-0.41	2.3e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs17152411	0.843	rs7896051	chr10:126583119	T/C	cg07906193	chr10:126599966	NA	0.43	5.25	0.43	6.46e-7	Height;
TGCT	cis	rs208520	0.507	rs7755710	chr6:66783355	G/A	cg07460842	chr6:66804631	NA	-1.08	-15.95	-0.82	8.03e-32	Exhaled nitric oxide output;
TGCT	cis	rs7666738	0.927	rs4699328	chr4:99055890	C/T	cg17366294	chr4:99064904	C4orf37	0.69	6.9	0.53	2.33e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg04267008	chr7:1944627	MAD1L1	-0.34	-4.59	-0.38	1.08e-5	Bipolar disorder and schizophrenia;
TGCT	cis	rs7805747	0.961	rs17173238	chr7:151406220	A/G	cg17611936	chr7:151411526	PRKAG2	0.5	6.54	0.51	1.43e-9	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
TGCT	cis	rs7582180	0.629	rs11123826	chr2:100936276	G/T	cg08017756	chr2:100939284	LONRF2	0.28	4.62	0.38	9.58e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs11167764	0.945	rs13161849	chr5:141473395	A/G	cg08523384	chr5:141488047	NDFIP1	-0.24	-4.91	-0.4	2.85e-6	Crohn's disease;
TGCT	cis	rs9467773	1.000	rs12526680	chr6:26550954	A/G	cg15659132	chr6:26577336	NA	0.89	13.12	0.76	3.43e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs9549367	0.673	rs3751413	chr13:113854715	C/T	cg09473364	chr13:112927190	NA	0.3	4.68	0.39	7.49e-6	Platelet distribution width;
TGCT	cis	rs2046867	0.818	rs62249875	chr3:72911858	G/A	cg25664220	chr3:72788482	NA	-0.54	-7.27	-0.55	3.61e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs11785400	1.000	rs11785400	chr8:143730456	C/T	cg24634471	chr8:143751801	JRK	0.54	5.85	0.46	4.19e-8	Schizophrenia;
TGCT	cis	rs7267979	0.932	rs433352	chr20:25467992	C/T	cg16686733	chr20:25566563	NINL	-0.57	-5.75	-0.46	6.6e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs74233809	1.000	rs12413046	chr10:104871204	A/G	cg05855489	chr10:104503620	C10orf26	0.84	4.47	0.37	1.71e-5	Birth weight;
TGCT	cis	rs981844	0.683	rs1563462	chr4:154755051	G/A	cg14289246	chr4:154710475	SFRP2	-1.0	-9.01	-0.63	3.04e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs1801251	0.896	rs2197563	chr2:233687080	G/A	cg08000102	chr2:233561755	GIGYF2	-0.59	-6.19	-0.49	7.93e-9	Coronary artery disease;
TGCT	cis	rs4849845	0.637	rs4849851	chr2:121055910	A/C	cg24070213	chr2:121070622	NA	0.35	4.64	0.38	8.58e-6	Mean platelet volume;
TGCT	cis	rs9633740	1.000	rs7896832	chr10:82257570	T/C	cg01528321	chr10:82214614	TSPAN14	1.03	8.42	0.6	7.78e-14	Post bronchodilator FEV1;
TGCT	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg03806693	chr22:41940476	POLR3H	-1.14	-12.97	-0.76	7.76e-25	Vitiligo;
TGCT	cis	rs789852	0.867	rs1773175	chr3:194317732	G/A	cg18000598	chr3:194342907	TMEM44	-0.76	-5.1	-0.42	1.25e-6	QT interval;
TGCT	cis	rs2657888	0.965	rs2657903	chr12:56933722	G/A	cg23932658	chr12:57637574	STAC3	0.48	4.57	0.38	1.18e-5	Adiponectin levels;
TGCT	cis	rs6424115	0.830	rs6424119	chr1:24204143	A/G	cg15997130	chr1:24165203	NA	0.85	8.93	0.63	4.81e-15	Immature fraction of reticulocytes;
TGCT	cis	rs67311347	1.000	rs954589	chr3:40444545	C/T	cg13683864	chr3:40499215	RPL14	-1.19	-13.2	-0.76	2.17e-25	Renal cell carcinoma;
TGCT	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg11941060	chr3:133502564	NA	-0.26	-5.32	-0.43	4.74e-7	Iron status biomarkers;
TGCT	cis	rs473651	0.904	rs508274	chr2:239337723	G/A	cg08773314	chr2:239334832	ASB1	0.47	7.87	0.58	1.54e-12	Multiple system atrophy;
TGCT	cis	rs2204008	0.569	rs11495449	chr12:37995753	C/T	cg13010199	chr12:38710504	ALG10B	0.65	5.22	0.42	7.4e-7	Bladder cancer;
TGCT	cis	rs9393692	0.905	rs7769028	chr6:26267568	C/T	cg00631329	chr6:26305371	NA	-0.43	-6.41	-0.5	2.72e-9	Educational attainment;
TGCT	cis	rs2742417	1.000	rs2673065	chr3:45771222	C/T	cg04837898	chr3:45731254	SACM1L	-0.53	-5.53	-0.45	1.78e-7	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs28595532	0.920	rs114262028	chr4:119734877	C/T	cg14228332	chr4:119757509	SEC24D	1.32	6.38	0.5	3.2e-9	Cannabis dependence symptom count;
TGCT	cis	rs12477438	0.798	rs6542849	chr2:99578493	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-8.65	-0.61	2.22e-14	Chronic sinus infection;
TGCT	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.95	10.14	0.67	5.89e-18	Intelligence (multi-trait analysis);
TGCT	trans	rs11764590	0.715	rs11766468	chr7:2082604	G/A	cg25206134	chr2:45395956	NA	0.97	6.73	0.52	5.68e-10	Neuroticism;
TGCT	cis	rs8072100	0.817	rs12449647	chr17:45548958	C/A	cg08085267	chr17:45401833	C17orf57	-0.47	-5.14	-0.42	1.05e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs4555082	0.874	rs11622166	chr14:105759763	C/A	cg01266790	chr14:105781312	PACS2	0.56	4.64	0.38	8.89e-6	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg16680214	chr1:154839983	KCNN3	-0.38	-8.26	-0.6	1.85e-13	Prostate cancer;
TGCT	cis	rs4242434	0.819	rs1871902	chr8:22470710	G/A	cg03733263	chr8:22462867	KIAA1967	1.08	17.08	0.84	2.28e-34	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs7582180	0.700	rs11685401	chr2:100976685	A/G	cg14675211	chr2:100938903	LONRF2	0.47	4.6	0.38	1.02e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs12142240	0.660	rs112560929	chr1:46822297	A/G	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg20891283	chr12:69753455	YEATS4	0.91	10.46	0.68	9.81e-19	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs7208859	0.623	rs11651857	chr17:28926362	G/T	cg14008862	chr17:28927542	LRRC37B2	0.88	5.32	0.43	4.75e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs4253772	0.513	rs9615345	chr22:46713631	C/T	cg24881330	chr22:46731750	TRMU	0.94	6.05	0.48	1.58e-8	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs1552244	0.608	rs7615408	chr3:10000186	A/G	cg00149659	chr3:10157352	C3orf10	0.67	4.91	0.4	2.85e-6	Alzheimer's disease;
TGCT	cis	rs17152411	1.000	rs12355869	chr10:126645231	G/T	cg07906193	chr10:126599966	NA	0.41	5.11	0.42	1.18e-6	Height;
TGCT	cis	rs707040	0.921	rs719461	chr2:155230619	T/C	cg18104148	chr2:154337490	NA	0.19	4.63	0.38	9.05e-6	Sudden cardiac arrest;
TGCT	cis	rs5769765	0.908	rs9627788	chr22:50300438	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.36	5.13	0.42	1.08e-6	Schizophrenia;
TGCT	cis	rs11098499	0.722	rs17595727	chr4:120262074	C/T	cg09307838	chr4:120376055	NA	-0.54	-5.17	-0.42	9.29e-7	Corneal astigmatism;
TGCT	cis	rs57590327	0.679	rs34674953	chr3:81605113	T/G	cg07356753	chr3:81810745	GBE1	-0.55	-4.54	-0.38	1.3e-5	Extraversion;
TGCT	cis	rs1371867	0.875	rs1660344	chr8:101324659	A/G	cg00191853	chr8:101177733	SPAG1	-0.22	-4.47	-0.37	1.75e-5	Atrioventricular conduction;
TGCT	cis	rs1403694	0.695	rs11927941	chr3:186433046	A/G	cg12454167	chr3:186435060	KNG1	0.5	8.56	0.61	3.65e-14	Blood protein levels;
TGCT	cis	rs1008375	0.646	rs13103430	chr4:17567355	A/C	cg16339924	chr4:17578868	LAP3	-0.69	-5.59	-0.45	1.35e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs601339	1.000	rs1798219	chr12:123180061	A/C	cg11919336	chr12:123188078	GPR109A	0.64	7.86	0.58	1.61e-12	Adiponectin levels;
TGCT	cis	rs9868809	0.505	rs13063223	chr3:48750340	G/A	cg00383909	chr3:49044727	WDR6	1.06	6.28	0.49	5.26e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	5.93	0.47	2.78e-8	Bipolar disorder;
TGCT	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.66	6.16	0.48	9.18e-9	Bipolar disorder;
TGCT	cis	rs7959452	0.535	rs7133487	chr12:69774377	G/A	cg20891283	chr12:69753455	YEATS4	0.83	8.7	0.62	1.68e-14	Blood protein levels;
TGCT	cis	rs7666738	0.830	rs62318504	chr4:98935558	T/G	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7617773	0.780	rs3731550	chr3:48206583	A/C	cg11946769	chr3:48343235	NME6	0.73	6.33	0.49	4.03e-9	Coronary artery disease;
TGCT	cis	rs6921919	0.583	rs1591913	chr6:28351728	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.56	-5.3	-0.43	5.13e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9486719	0.749	rs1009596	chr6:96843688	A/G	cg06623918	chr6:96969491	KIAA0776	0.93	7.08	0.54	9.59e-11	Migraine;Coronary artery disease;
TGCT	cis	rs11690935	0.959	rs10166005	chr2:172607294	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.19	-12.78	-0.75	2.24e-24	Schizophrenia;
TGCT	cis	rs35146811	0.625	rs2906645	chr7:99817859	A/G	cg00553149	chr7:99775558	STAG3;GPC2	-0.32	-4.81	-0.4	4.28e-6	Coronary artery disease;
TGCT	cis	rs6921919	0.583	rs9461459	chr6:28361916	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.56	-5.27	-0.43	5.78e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7552404	1.000	rs7548962	chr1:76139266	G/A	cg10523679	chr1:76189770	ACADM	0.91	9.92	0.67	2.01e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs427394	0.582	rs274662	chr5:6704860	G/A	cg10857441	chr5:6722123	POLS	-0.29	-6.21	-0.49	7.15e-9	Menopause (age at onset);
TGCT	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg16680214	chr1:154839983	KCNN3	-0.35	-7.15	-0.54	6.42e-11	Prostate cancer;
TGCT	cis	rs4988958	0.584	rs7559845	chr2:103046214	T/G	cg03938978	chr2:103052716	IL18RAP	0.27	5.41	0.44	3.17e-7	Asthma (childhood onset);
TGCT	cis	rs1552244	0.554	rs6762594	chr3:9995516	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.32	-4.84	-0.4	3.76e-6	Alzheimer's disease;
TGCT	cis	rs896854	0.530	rs10956934	chr8:95992473	C/A	cg13393036	chr8:95962371	TP53INP1	-0.58	-7.01	-0.53	1.36e-10	Type 2 diabetes;
TGCT	cis	rs11779988	0.501	rs3760	chr8:17886345	T/C	cg01800426	chr8:17659068	MTUS1	-0.68	-5.48	-0.44	2.32e-7	Breast cancer;
TGCT	cis	rs617219	0.737	rs6453431	chr5:78493873	G/C	cg23514016	chr5:78407564	BHMT	0.34	5.15	0.42	9.87e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs4824093	0.610	rs4824113	chr22:50284974	C/T	cg20569369	chr22:51173646	NA	0.29	4.74	0.39	5.73e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs16966142	1.000	rs16966142	chr16:89851033	C/T	cg26513180	chr16:89883248	FANCA	1.02	5.54	0.45	1.73e-7	Caffeine consumption;
TGCT	cis	rs7666738	0.830	rs1120708	chr4:98931260	G/C	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11992186	0.570	rs17628941	chr8:8587534	G/C	cg15556689	chr8:8085844	FLJ10661	-0.56	-4.69	-0.39	7.07e-6	Neuroticism;
TGCT	cis	rs75804782	0.557	rs3769118	chr2:239342542	C/G	cg18131467	chr2:239335373	ASB1	-0.71	-4.44	-0.37	1.98e-5	Morning vs. evening chronotype;Chronotype;
TGCT	trans	rs4650994	0.525	rs2493864	chr1:178545003	A/C	cg05059571	chr16:84539110	KIAA1609	-0.52	-10.29	-0.68	2.45e-18	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs4727027	0.901	rs66800495	chr7:148763702	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	4.97	0.41	2.22e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs4460629	0.742	rs6693477	chr1:155081940	A/G	cg23973274	chr1:155060172	NA	-0.28	-5.13	-0.42	1.07e-6	Serum magnesium levels;
TGCT	cis	rs1682825	0.858	rs58731244	chr3:10756497	G/A	cg23512531	chr3:10780469	NA	0.62	4.53	0.38	1.36e-5	Economic and political preferences (feminism/equality);
TGCT	cis	rs2463822	0.687	rs118012228	chr11:62155914	G/A	cg06239285	chr11:62104954	ASRGL1	-0.94	-6.61	-0.51	1.03e-9	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs2730260	0.537	rs73169246	chr7:158890593	C/T	cg09066883	chr7:157932951	PTPRN2	0.42	4.66	0.39	8.09e-6	Myopia (pathological);
TGCT	cis	rs12464483	0.556	rs2609934	chr2:30895979	G/A	cg12454169	chr2:30669597	LCLAT1	0.45	5.03	0.41	1.67e-6	Pre-treatment pain in head and neck squamous cell carcinoma;
TGCT	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg10047753	chr17:41438598	NA	0.73	6.97	0.53	1.64e-10	Menopause (age at onset);
TGCT	cis	rs4654899	0.758	rs12137408	chr1:21282945	A/G	cg01072550	chr1:21505969	NA	-0.55	-8.89	-0.62	6.13e-15	Superior frontal gyrus grey matter volume;
TGCT	cis	rs9787249	0.957	rs11809515	chr1:40205326	C/A	cg20968010	chr1:40505947	CAP1	-0.53	-5.0	-0.41	1.91e-6	Blood protein levels;
TGCT	cis	rs12367572	0.965	rs7952764	chr12:45246211	C/A	cg04608330	chr12:45269318	NELL2	-0.65	-6.96	-0.53	1.74e-10	Gut microbiome composition (summer);
TGCT	cis	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg08564027	chr20:61660810	NA	0.36	6.66	0.51	7.9e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg24549020	chr5:56110836	MAP3K1	0.68	5.89	0.47	3.46e-8	Initial pursuit acceleration;
TGCT	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.64	7.0	0.53	1.43e-10	Blood metabolite levels;
TGCT	cis	rs2268667	0.647	rs11161609	chr1:85862736	G/T	cg16011679	chr1:85725395	C1orf52	-0.51	-4.62	-0.38	9.51e-6	Asymmetrical dimethylarginine levels;
TGCT	cis	rs11574514	1.000	rs10775302	chr16:67792439	C/T	cg00545966	chr16:67701244	C16orf86;C16orf48	0.73	4.49	0.37	1.63e-5	Crohn's disease;
TGCT	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg21171335	chr12:122356390	WDR66	0.7	7.02	0.53	1.25e-10	Mean corpuscular volume;
TGCT	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.44	-5.85	-0.47	4.09e-8	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg03264133	chr6:25882463	NA	-0.51	-5.37	-0.43	3.77e-7	Blood metabolite levels;
TGCT	cis	rs6598955	0.671	rs11247914	chr1:26648838	G/T	cg04990556	chr1:26633338	UBXN11	0.65	4.59	0.38	1.06e-5	Obesity-related traits;
TGCT	cis	rs62244186	0.566	rs6766221	chr3:44882784	C/T	cg10263370	chr3:44754102	ZNF502	-0.47	-5.67	-0.45	9.47e-8	Depressive symptoms;
TGCT	cis	rs12971120	0.838	rs747176	chr18:72154931	G/A	cg26446133	chr18:72167187	CNDP2	-0.36	-6.38	-0.5	3.22e-9	Refractive error;
TGCT	cis	rs7429990	0.965	rs11709289	chr3:47806649	G/A	cg11946769	chr3:48343235	NME6	0.59	4.44	0.37	1.95e-5	Educational attainment (years of education);
TGCT	cis	rs5769765	1.000	rs738711	chr22:50282603	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	1.11	11.81	0.73	5.03e-22	Schizophrenia;
TGCT	cis	rs1008375	0.966	rs3733576	chr4:17586703	T/C	cg16339924	chr4:17578868	LAP3	0.83	7.21	0.54	4.92e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9473924	0.505	rs9473921	chr6:50828072	C/T	cg14470998	chr6:50812995	TFAP2B	1.35	8.39	0.6	9.05e-14	Body mass index;
TGCT	cis	rs2191566	1.000	rs10418363	chr19:44525463	A/G	cg03039196	chr19:44506973	ZNF230	0.55	4.77	0.39	5.16e-6	Acute lymphoblastic leukemia (childhood);
TGCT	cis	rs6547741	1.000	rs76784350	chr2:27764278	A/G	cg27432699	chr2:27873401	GPN1	0.18	4.44	0.37	1.96e-5	Oral cavity cancer;
TGCT	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg10802521	chr3:52805072	NEK4	-0.71	-8.79	-0.62	1.04e-14	Bipolar disorder;
TGCT	cis	rs7909074	1.000	rs10751361	chr10:45398186	C/A	cg05187965	chr10:45406764	TMEM72	-0.25	-5.3	-0.43	5.07e-7	Mean corpuscular volume;
TGCT	cis	rs6433895	1.000	rs7598960	chr2:182018382	T/G	cg16904960	chr2:182549928	NA	0.34	4.47	0.37	1.77e-5	Lymphocyte counts;
TGCT	cis	rs2985684	0.841	rs12894785	chr14:50049755	G/C	cg04989706	chr14:50066350	PPIL5	-0.53	-4.47	-0.37	1.74e-5	Carotid intima media thickness;
TGCT	cis	rs7666738	0.519	rs13136069	chr4:98819568	C/T	cg18180107	chr4:99064573	C4orf37	0.54	4.61	0.38	9.77e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3820928	0.874	rs6706802	chr2:227850776	A/G	cg11843606	chr2:227700838	RHBDD1	-0.5	-4.48	-0.37	1.7e-5	Pulmonary function;
TGCT	cis	rs7829975	0.536	rs2980439	chr8:8094870	G/A	cg15556689	chr8:8085844	FLJ10661	0.86	8.87	0.62	6.54e-15	Mood instability;
TGCT	cis	rs7412746	0.658	rs11204723	chr1:150731618	T/C	cg09365446	chr1:150670422	GOLPH3L	0.35	5.08	0.42	1.33e-6	Melanoma;
TGCT	cis	rs4149178	0.656	rs9472032	chr6:43294041	C/A	cg07522644	chr6:43142093	SRF	0.66	4.69	0.39	7e-6	Urate levels;
TGCT	cis	rs7208859	0.573	rs73267865	chr17:29064204	C/G	cg14008862	chr17:28927542	LRRC37B2	0.76	4.52	0.38	1.42e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs12291225	0.679	rs11605531	chr11:14291594	A/G	cg19336497	chr11:14380999	RRAS2	-0.38	-5.9	-0.47	3.23e-8	Sense of smell;
TGCT	cis	rs929354	0.742	rs7801905	chr7:156940111	T/C	cg05182265	chr7:156933206	UBE3C	-0.39	-8.98	-0.63	3.72e-15	Body mass index;
TGCT	cis	rs9303401	0.527	rs12939313	chr17:56755616	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.61	5.41	0.44	3.12e-7	Cognitive test performance;
TGCT	cis	rs7923609	0.811	rs10822181	chr10:65325126	G/A	cg08743896	chr10:65200160	JMJD1C	0.33	4.49	0.37	1.6e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7523273	0.586	rs2796276	chr1:207951513	G/A	cg22525895	chr1:207977042	MIR29B2	0.53	8.71	0.62	1.62e-14	Schizophrenia;
TGCT	cis	rs9611565	0.503	rs5751156	chr22:42170025	A/G	cg03806693	chr22:41940476	POLR3H	1.01	10.26	0.68	3.04e-18	Vitiligo;
TGCT	cis	rs28456	1	rs28456	chr11:61589481	A/G	cg01500311	chr11:61656094	FADS3	-0.29	-4.98	-0.41	2.1e-6	Bipolar disorder;
TGCT	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	8.0	0.58	7.67e-13	Platelet count;
TGCT	cis	rs9325144	0.534	rs1973293	chr12:38679575	C/T	cg26384229	chr12:38710491	ALG10B	0.67	6.42	0.5	2.56e-9	Morning vs. evening chronotype;
TGCT	cis	rs7635838	0.686	rs347589	chr3:11288419	A/G	cg00170343	chr3:11313890	ATG7	0.68	6.6	0.51	1.06e-9	HDL cholesterol;
TGCT	cis	rs4409675	0.576	rs7520860	chr1:28232952	C/A	cg23691781	chr1:28212827	C1orf38	0.26	5.44	0.44	2.76e-7	Corneal astigmatism;
TGCT	cis	rs9325144	0.560	rs10785562	chr12:38637419	A/C	cg26384229	chr12:38710491	ALG10B	-0.64	-5.82	-0.46	4.63e-8	Morning vs. evening chronotype;
TGCT	cis	rs6582630	0.638	rs10880644	chr12:38554959	G/A	cg26384229	chr12:38710491	ALG10B	0.52	4.74	0.39	5.65e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs6901004	0.803	rs9400470	chr6:111478131	T/C	cg15721981	chr6:111408429	SLC16A10	-0.51	-4.53	-0.38	1.35e-5	Blood metabolite levels;
TGCT	cis	rs514406	0.698	rs1775540	chr1:53407893	C/A	cg22166914	chr1:53195759	ZYG11B	0.3	4.95	0.41	2.41e-6	Monocyte count;
TGCT	cis	rs1552244	0.554	rs6786636	chr3:10045703	T/C	cg00149659	chr3:10157352	C3orf10	0.69	4.99	0.41	2.03e-6	Alzheimer's disease;
TGCT	cis	rs6582630	0.502	rs1607876	chr12:38355750	T/C	cg26384229	chr12:38710491	ALG10B	0.77	6.73	0.52	5.54e-10	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs7772486	0.641	rs2253757	chr6:146199686	C/T	cg23711669	chr6:146136114	FBXO30	0.76	7.12	0.54	7.5e-11	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg06028808	chr11:68637592	NA	0.53	6.86	0.52	2.89e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	trans	rs7615952	1.000	rs7616044	chr3:125649354	G/C	cg07211511	chr3:129823064	LOC729375	-0.46	-7.65	-0.57	4.78e-12	Blood pressure (smoking interaction);
TGCT	cis	rs2456568	0.835	rs1518578	chr11:93656854	G/T	cg16099599	chr11:93583650	C11orf90	-0.43	-5.09	-0.42	1.27e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg11494091	chr17:61959527	GH2	0.61	14.43	0.79	2.59e-28	Prudent dietary pattern;
TGCT	cis	rs7216064	1.000	rs9912770	chr17:65868233	C/T	cg12091567	chr17:66097778	LOC651250	-0.87	-6.85	-0.52	3.1e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg08280861	chr8:58055591	NA	0.46	6.87	0.52	2.81e-10	Developmental language disorder (linguistic errors);
TGCT	cis	rs6121246	0.559	rs6121243	chr20:30415094	C/G	cg13852791	chr20:30311386	BCL2L1	0.8	7.42	0.55	1.61e-11	Mean corpuscular hemoglobin;
TGCT	cis	rs9818758	0.607	rs9855123	chr3:49229457	C/T	cg07636037	chr3:49044803	WDR6	-1.04	-5.13	-0.42	1.09e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs9486719	0.895	rs12527021	chr6:97025496	C/T	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.0	-0.41	1.9e-6	Migraine;Coronary artery disease;
TGCT	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.52	4.87	0.4	3.3e-6	Prudent dietary pattern;
TGCT	cis	rs13191362	0.507	rs2155506	chr6:163035342	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.58	-5.73	-0.46	7.06e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	trans	rs2688608	0.592	rs11814282	chr10:75490217	T/C	cg13918328	chr10:52500089	ASAH2B	0.68	6.7	0.52	6.48e-10	Inflammatory bowel disease;
TGCT	cis	rs28595532	0.920	rs114544767	chr4:119728364	T/C	cg21605333	chr4:119757512	SEC24D	1.66	8.33	0.6	1.28e-13	Cannabis dependence symptom count;
TGCT	cis	rs9913156	0.793	rs72835633	chr17:4562643	C/T	cg23387401	chr17:4582204	PELP1	0.31	4.57	0.38	1.14e-5	Lymphocyte counts;
TGCT	cis	rs66561647	0.661	rs7387614	chr8:128929353	C/T	cg11792826	chr8:129160931	MIR1208	0.22	5.08	0.42	1.34e-6	Hemoglobin concentration;
TGCT	cis	rs35883536	0.647	rs1335765	chr1:101048612	A/T	cg06223162	chr1:101003688	GPR88	-0.41	-7.64	-0.57	5.04e-12	Monocyte count;
TGCT	cis	rs10875746	0.855	rs73102065	chr12:48492607	T/C	cg20731937	chr12:48336164	NA	0.63	4.96	0.41	2.24e-6	Longevity (90 years and older);
TGCT	cis	rs72627509	0.523	rs12650282	chr4:57733604	A/G	cg26694713	chr4:57773883	REST	-0.57	-5.81	-0.46	4.95e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs11264213	0.591	rs603945	chr1:36490186	C/T	cg27506609	chr1:36549197	TEKT2	-0.31	-4.47	-0.37	1.77e-5	Schizophrenia;
TGCT	cis	rs7104764	0.507	rs7111364	chr11:258542	G/C	cg18336825	chr11:236787	PSMD13;SIRT3	0.76	5.68	0.45	8.96e-8	Menarche (age at onset);
TGCT	cis	rs28830936	0.625	rs8038764	chr15:41907905	A/C	cg17847044	chr15:42102381	MAPKBP1	0.19	5.35	0.43	4.08e-7	Diastolic blood pressure;
TGCT	cis	rs4988958	0.584	rs7589142	chr2:103024660	T/C	cg03938978	chr2:103052716	IL18RAP	0.27	5.41	0.44	3.17e-7	Asthma (childhood onset);
TGCT	cis	rs6908034	0.556	rs7750703	chr6:19804814	C/G	cg02682789	chr6:19804855	NA	0.92	5.24	0.43	6.7e-7	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
TGCT	cis	rs6684514	1.000	rs10908496	chr1:156264000	G/A	cg16558208	chr1:156270281	VHLL	0.46	9.38	0.64	3.92e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs1406084	0.576	rs7604919	chr2:154727550	G/C	cg25703346	chr2:154729189	GALNT13	0.77	4.6	0.38	1.03e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9467773	1.000	rs9461271	chr6:26554968	G/A	cg26531700	chr6:26746687	NA	0.49	4.73	0.39	6.06e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs937254	0.866	rs2453088	chr15:57872653	G/T	cg05276753	chr15:57844149	NA	0.31	4.48	0.37	1.67e-5	HDL cholesterol;
TGCT	cis	rs9467603	0.547	rs4712936	chr6:25417423	G/T	cg16898833	chr6:26189333	HIST1H4D	-1.26	-5.08	-0.42	1.35e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs28595532	0.841	rs115987912	chr4:119737085	C/T	cg14228332	chr4:119757509	SEC24D	1.31	7.06	0.54	1.06e-10	Cannabis dependence symptom count;
TGCT	cis	rs13033859	0.526	rs12477065	chr2:292753	C/T	cg26211041	chr2:776598	NA	-0.27	-4.45	-0.37	1.9e-5	Mitochondrial DNA levels;
TGCT	cis	rs7223966	1.000	rs8078462	chr17:61857937	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	4.68	0.39	7.5e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs2921073	0.509	rs2976931	chr8:8257317	C/A	cg08975724	chr8:8085496	FLJ10661	0.56	5.01	0.41	1.82e-6	Parkinson's disease;
TGCT	cis	rs3733585	0.673	rs4467563	chr4:9953460	A/T	cg00071950	chr4:10020882	SLC2A9	-0.55	-6.58	-0.51	1.21e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg22618164	chr12:122356400	WDR66	-0.7	-6.91	-0.53	2.23e-10	Mean corpuscular volume;
TGCT	cis	rs7584330	0.554	rs74001384	chr2:238424530	T/C	cg08992911	chr2:238395768	MLPH	0.73	5.01	0.41	1.85e-6	Prostate cancer;
TGCT	cis	rs7572733	0.534	rs1435568	chr2:198762879	T/C	cg00792783	chr2:198669748	PLCL1	0.57	5.2	0.42	8.09e-7	Dermatomyositis;
TGCT	cis	rs35306767	0.953	rs11253520	chr10:975961	C/G	cg20503657	chr10:835505	NA	-0.43	-5.89	-0.47	3.42e-8	Eosinophil percentage of granulocytes;
TGCT	cis	rs801193	0.967	rs2420827	chr7:66147101	G/A	cg18876405	chr7:65276391	NA	-0.38	-5.83	-0.46	4.44e-8	Aortic root size;
TGCT	trans	rs1974653	0.672	rs9606240	chr22:20071423	A/G	cg08822737	chr17:71088851	SLC39A11	-0.93	-7.61	-0.56	5.97e-12	Schizophrenia;
TGCT	cis	rs941873	0.900	rs4979861	chr10:81131595	A/G	cg09469691	chr10:81107165	PPIF	0.63	6.38	0.5	3.26e-9	Height;
TGCT	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs4072705	0.646	rs915032	chr9:127245682	G/C	cg13476313	chr9:127244764	NR5A1	0.31	5.09	0.42	1.29e-6	Menarche (age at onset);
TGCT	cis	rs12220238	1.000	rs11000890	chr10:75904073	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.91	7.77	0.57	2.63e-12	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg15556689	chr8:8085844	FLJ10661	0.72	6.38	0.5	3.13e-9	Neuroticism;
TGCT	cis	rs17270561	0.541	rs17586946	chr6:25939053	C/T	cg17042849	chr6:26104293	HIST1H4C	-0.8	-5.68	-0.45	9.14e-8	Iron status biomarkers;
TGCT	cis	rs2486012	1.000	rs3011227	chr1:44325409	G/A	cg12908607	chr1:44402522	ARTN	-0.69	-5.59	-0.45	1.36e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	8.39	0.6	9.03e-14	Platelet count;
TGCT	cis	rs1044826	0.642	rs9833307	chr3:139181370	G/A	cg00490450	chr3:139108681	COPB2	0.52	4.53	0.38	1.39e-5	Obesity-related traits;
TGCT	cis	rs6671200	0.541	rs3738170	chr1:95699604	G/C	cg06440946	chr1:95699313	RWDD3	-0.62	-5.26	-0.43	6.12e-7	Stearic acid (18:0) levels;
TGCT	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg03452623	chr4:187889614	NA	-0.36	-5.34	-0.43	4.32e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs17345786	0.861	rs11707689	chr3:101086475	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.4	-8.36	-0.6	1.09e-13	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6722750	0.840	rs6712700	chr2:64374041	A/G	cg22352474	chr2:64371530	PELI1	0.73	7.09	0.54	9.04e-11	Neuroticism;
TGCT	cis	rs2486012	1.000	rs2906461	chr1:44334228	G/C	cg12908607	chr1:44402522	ARTN	-0.72	-5.68	-0.45	8.89e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9300255	0.602	rs884548	chr12:123634122	A/G	cg00376283	chr12:123451042	ABCB9	0.71	5.54	0.45	1.7e-7	Neutrophil percentage of white cells;
TGCT	cis	rs7829975	1.000	rs7829975	chr8:8548117	T/A	cg06636001	chr8:8085503	FLJ10661	-0.69	-5.94	-0.47	2.67e-8	Mood instability;
TGCT	trans	rs210152	0.588	rs3119024	chr6:33450034	T/C	cg08795360	chr21:41033440	B3GALT5	-0.45	-7.11	-0.54	8.23e-11	Schizophrenia;
TGCT	cis	rs3540	0.513	rs2601181	chr15:90924702	C/T	cg22089800	chr15:90895588	ZNF774	0.82	9.04	0.63	2.61e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs2836950	0.502	rs12627205	chr21:40630027	C/T	cg17971929	chr21:40555470	PSMG1	-0.54	-4.87	-0.4	3.36e-6	Menarche (age at onset);
TGCT	cis	rs35146811	0.700	rs866500	chr7:99840461	A/G	cg22906224	chr7:99728672	NA	-0.51	-4.59	-0.38	1.08e-5	Coronary artery disease;
TGCT	cis	rs9325144	0.555	rs6582576	chr12:38701230	C/T	cg26384229	chr12:38710491	ALG10B	-0.61	-5.83	-0.46	4.42e-8	Morning vs. evening chronotype;
TGCT	cis	rs7586879	0.593	rs11689543	chr2:25130440	A/T	cg15423357	chr2:25149977	NA	0.5	4.88	0.4	3.13e-6	Body mass index;
TGCT	cis	rs9814567	1.000	rs9990351	chr3:134239191	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.92	9.3	0.64	6.19e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs4851266	1.000	rs4851264	chr2:100810188	T/C	cg22139774	chr2:100720529	AFF3	-0.35	-5.23	-0.43	6.99e-7	Educational attainment;
TGCT	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg24399712	chr22:39784796	NA	-1.06	-12.45	-0.75	1.37e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs1997103	1.000	rs6953509	chr7:55412179	G/A	cg17469321	chr7:55412551	NA	0.65	6.75	0.52	5.08e-10	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs12477438	0.520	rs8179690	chr2:99795300	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-1.06	-13.07	-0.76	4.41e-25	Chronic sinus infection;
TGCT	cis	rs10871290	0.881	rs11649338	chr16:74471420	C/T	cg01733217	chr16:74700730	RFWD3	-0.57	-5.46	-0.44	2.54e-7	Breast cancer;
TGCT	cis	rs6582630	0.537	rs1829579	chr12:38420555	A/G	cg13010199	chr12:38710504	ALG10B	0.59	4.79	0.4	4.67e-6	Drug-induced liver injury (flucloxacillin);
TGCT	trans	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.86	9.41	0.65	3.39e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs1878931	0.501	rs9635547	chr16:3416664	C/T	cg05754148	chr16:3507555	NAT15	-0.33	-4.6	-0.38	1.02e-5	Body mass index (adult);
TGCT	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	15.82	0.82	1.53e-31	Prudent dietary pattern;
TGCT	cis	rs1371867	0.846	rs1660326	chr8:101290447	G/A	cg06636551	chr8:101224915	SPAG1	-0.5	-6.88	-0.53	2.61e-10	Atrioventricular conduction;
TGCT	cis	rs4900538	0.927	rs8005804	chr14:102957803	A/G	cg18135206	chr14:102964638	TECPR2	0.21	5.13	0.42	1.08e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg00149659	chr3:10157352	C3orf10	1.18	7.44	0.56	1.44e-11	Alzheimer's disease;
TGCT	cis	rs9486719	0.895	rs11152960	chr6:96900398	A/G	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.86	-0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs2228479	0.850	rs2238531	chr16:89856217	C/G	cg06558623	chr16:89946397	TCF25	0.47	4.58	0.38	1.14e-5	Skin colour saturation;
TGCT	cis	rs2180341	1.000	rs4895822	chr6:127642703	T/C	cg27446573	chr6:127587934	RNF146	1.12	10.11	0.67	6.87e-18	Breast cancer;
TGCT	cis	rs2153535	0.580	rs7766852	chr6:8472417	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.76	0.46	6.16e-8	Motion sickness;
TGCT	cis	rs1670533	0.615	rs59985183	chr4:1087171	G/T	cg27284194	chr4:1044797	NA	0.66	5.85	0.46	4.16e-8	Recombination rate (females);
TGCT	cis	rs1903068	0.657	rs10026340	chr4:55998136	G/A	cg09978860	chr4:56023921	NA	0.54	5.66	0.45	9.93e-8	Endometriosis;
TGCT	cis	rs208520	0.690	rs1885100	chr6:66871047	C/G	cg07460842	chr6:66804631	NA	-0.92	-9.58	-0.65	1.29e-16	Exhaled nitric oxide output;
TGCT	cis	rs8013055	0.796	rs11628497	chr14:105970789	C/T	cg19700328	chr14:106028568	NA	-0.54	-5.92	-0.47	3e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs7819412	0.617	rs10087081	chr8:10974917	C/T	cg21775007	chr8:11205619	TDH	-0.5	-4.85	-0.4	3.59e-6	Triglycerides;
TGCT	cis	rs6570726	0.818	rs9390338	chr6:145908265	A/G	cg23711669	chr6:146136114	FBXO30	0.86	9.28	0.64	7.13e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7523273	0.586	rs2724359	chr1:207935706	A/G	cg22525895	chr1:207977042	MIR29B2	0.53	8.71	0.62	1.62e-14	Schizophrenia;
TGCT	cis	rs7267979	0.866	rs2424699	chr20:25257462	G/A	cg14121845	chr20:25566513	NINL	0.55	5.95	0.47	2.51e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9549367	0.789	rs12866090	chr13:113869410	G/A	cg00898013	chr13:113819073	PROZ	-0.4	-4.92	-0.4	2.75e-6	Platelet distribution width;
TGCT	cis	rs9952991	0.941	rs8096138	chr18:12808140	C/G	cg24737193	chr18:12778029	NA	-0.52	-5.43	-0.44	2.85e-7	Inflammatory skin disease;
TGCT	cis	rs308403	0.509	rs7690409	chr4:123666757	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.82	11.84	0.73	4.22e-22	Blood protein levels;
TGCT	cis	rs7666738	0.791	rs2903142	chr4:99040071	C/T	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9911578	0.730	rs55759249	chr17:57027135	A/G	cg12560992	chr17:57184187	TRIM37	-0.74	-7.04	-0.53	1.18e-10	Intelligence (multi-trait analysis);
TGCT	trans	rs9951602	0.512	rs7240758	chr18:76650677	T/C	cg02800362	chr5:177631904	HNRNPAB	1.15	13.03	0.76	5.64e-25	Obesity-related traits;
TGCT	cis	rs4689388	0.750	rs10001190	chr4:6284633	C/T	cg25554036	chr4:6271136	WFS1	-0.55	-7.72	-0.57	3.32e-12	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs7666738	0.830	rs3907021	chr4:99038668	C/T	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9311474	0.713	rs352167	chr3:52238656	C/T	cg07507251	chr3:52567010	NT5DC2	-0.39	-5.03	-0.41	1.7e-6	Electroencephalogram traits;
TGCT	cis	rs17221829	0.733	rs11018699	chr11:89379962	A/C	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.63	-0.38	9.04e-6	Anxiety in major depressive disorder;
TGCT	cis	rs13256369	0.802	rs12681326	chr8:8566389	G/A	cg18904891	chr8:8559673	CLDN23	0.58	5.4	0.44	3.29e-7	Obesity-related traits;
TGCT	trans	rs2760061	0.819	rs3094914	chr1:228206934	C/T	cg16006296	chr10:38738647	LOC399744	-0.31	-7.12	-0.54	7.75e-11	Diastolic blood pressure;
TGCT	cis	rs986417	1.000	rs1956555	chr14:60968804	A/G	cg27398547	chr14:60952738	C14orf39	1.39	10.61	0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs981844	0.725	rs872453	chr4:154727131	T/C	cg14289246	chr4:154710475	SFRP2	1.04	9.67	0.66	8.17e-17	Response to statins (LDL cholesterol change);
TGCT	cis	rs929354	1.000	rs1182384	chr7:157040642	A/G	cg05182265	chr7:156933206	UBE3C	0.3	6.31	0.49	4.59e-9	Body mass index;
TGCT	cis	rs16958440	0.867	rs79275306	chr18:44711620	G/C	cg17192377	chr18:44677553	HDHD2	0.63	4.7	0.39	6.74e-6	Sitting height ratio;
TGCT	cis	rs6500602	0.673	rs4786512	chr16:4573040	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.28	5.11	0.42	1.19e-6	Schizophrenia;
TGCT	cis	rs3820068	0.580	rs12747696	chr1:16002978	A/G	cg05660106	chr1:15850417	CASP9	0.65	5.82	0.46	4.66e-8	Systolic blood pressure;
TGCT	cis	rs5769707	0.777	rs739243	chr22:50057211	C/T	cg05373962	chr22:49881684	NA	-0.31	-6.13	-0.48	1.1e-8	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg04944784	chr2:26401820	FAM59B	-0.76	-6.34	-0.49	3.94e-9	Gut microbiome composition (summer);
TGCT	cis	rs11122272	0.705	rs2790879	chr1:231534389	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-6.22	-0.49	6.99e-9	Hemoglobin concentration;
TGCT	cis	rs12291225	0.679	rs11238	chr11:14288128	A/C	cg19336497	chr11:14380999	RRAS2	0.39	6.01	0.47	1.96e-8	Sense of smell;
TGCT	cis	rs854765	0.583	rs8065970	chr17:17858771	A/G	cg09796270	chr17:17721594	SREBF1	0.23	4.55	0.38	1.27e-5	Total body bone mineral density;
TGCT	cis	rs4742903	0.967	rs7048372	chr9:106859738	T/C	cg21169611	chr9:106856078	SMC2	0.49	4.6	0.38	1.03e-5	High-grade serous ovarian cancer;Breast cancer;
TGCT	cis	rs10465746	0.967	rs11163861	chr1:84354282	T/C	cg10977910	chr1:84465055	TTLL7	0.63	6.19	0.49	8.08e-9	Obesity-related traits;
TGCT	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg14004847	chr7:1930337	MAD1L1	-0.27	-4.68	-0.39	7.35e-6	Schizophrenia;
TGCT	cis	rs10876993	0.893	rs1678504	chr12:58085498	G/C	cg15848620	chr12:58087721	OS9	-0.73	-5.95	-0.47	2.56e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg06481639	chr22:41940642	POLR3H	-0.74	-6.55	-0.51	1.41e-9	Vitiligo;
TGCT	cis	rs568617	0.716	rs17854357	chr11:65601560	G/C	cg04055107	chr11:65626734	MUS81;CFL1	0.72	5.5	0.44	2.06e-7	Crohn's disease;
TGCT	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg00814883	chr7:100076585	TSC22D4	-0.53	-4.97	-0.41	2.19e-6	Lung function (FEV1/FVC);
TGCT	cis	rs6912958	1.000	rs6937823	chr6:88160386	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.64	-6.31	-0.49	4.58e-9	Monocyte percentage of white cells;
TGCT	cis	rs2204008	0.743	rs2127952	chr12:37995364	G/T	cg13010199	chr12:38710504	ALG10B	0.61	4.89	0.4	3.05e-6	Bladder cancer;
TGCT	cis	rs1461503	0.966	rs7113725	chr11:122843511	G/T	cg27398637	chr11:122830231	C11orf63	-0.43	-5.31	-0.43	5e-7	Menarche (age at onset);
TGCT	cis	rs477895	1.000	rs34292685	chr11:64049021	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.67	5.18	0.42	8.68e-7	Mean platelet volume;
TGCT	cis	rs9527	0.590	rs7067663	chr10:104883650	A/G	cg15744005	chr10:104629667	AS3MT	-0.43	-4.9	-0.4	2.89e-6	Arsenic metabolism;
TGCT	cis	rs1365505	0.600	rs1648350	chr15:50486400	G/A	cg26188685	chr15:50540269	HDC	-0.4	-6.9	-0.53	2.39e-10	Blood metabolite ratios;
TGCT	cis	rs8062405	0.964	rs9972768	chr16:28861734	A/C	cg09754948	chr16:28834200	ATXN2L	0.59	4.45	0.37	1.91e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs7267979	1.000	rs2387881	chr20:25378172	A/G	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7209700	0.742	rs999323	chr17:45371603	T/C	cg21624342	chr17:45890973	OSBPL7	0.2	5.44	0.44	2.68e-7	IgG glycosylation;
TGCT	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg20007245	chr22:24372913	LOC391322	-0.7	-6.93	-0.53	2.09e-10	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg10253484	chr15:75165896	SCAMP2	-0.6	-5.51	-0.44	2.02e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
TGCT	cis	rs244731	1.000	rs244729	chr5:176539018	C/G	cg17509989	chr5:176798049	RGS14	0.57	6.74	0.52	5.35e-10	Urate levels in lean individuals;
TGCT	cis	rs6570726	0.791	rs10457788	chr6:145921136	T/A	cg13319975	chr6:146136371	FBXO30	-0.54	-4.77	-0.39	5.1e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9788682	0.655	rs578776	chr15:78888400	G/A	cg24631222	chr15:78858424	CHRNA5	0.67	5.38	0.43	3.61e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs7552404	0.727	rs6683437	chr1:76316619	G/A	cg03433033	chr1:76189801	ACADM	0.6	6.04	0.48	1.66e-8	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs10489202	0.608	rs3753934	chr1:168074677	C/T	cg24449463	chr1:168025552	DCAF6	-0.53	-5.49	-0.44	2.16e-7	Schizophrenia;
TGCT	cis	rs6882046	0.513	rs2431391	chr5:88046590	C/T	cg24804195	chr5:87968844	LOC645323	-0.6	-6.06	-0.48	1.48e-8	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs1775715	0.707	rs2808073	chr10:32179275	A/G	cg14930904	chr10:32216787	ARHGAP12	0.51	4.98	0.41	2.04e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs910316	0.874	rs61980828	chr14:75630378	G/A	cg23033748	chr14:75592666	NEK9	-0.28	-4.77	-0.39	4.98e-6	Height;
TGCT	cis	rs6089829	0.851	rs6089827	chr20:61668845	C/T	cg02380750	chr20:61661411	NA	0.34	5.98	0.47	2.24e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	5.06	0.41	1.46e-6	Menopause (age at onset);
TGCT	cis	rs7095607	0.560	rs10997955	chr10:69914664	C/T	cg18986048	chr10:69913749	MYPN	0.47	5.14	0.42	1.05e-6	Lung function (FVC);
TGCT	cis	rs12497850	0.931	rs9311430	chr3:48845251	C/T	cg07636037	chr3:49044803	WDR6	0.95	10.74	0.69	2e-19	Parkinson's disease;
TGCT	cis	rs797680	0.753	rs11164881	chr1:93658989	C/A	cg17826107	chr1:92977322	EVI5	-0.24	-5.23	-0.43	6.89e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs61931739	0.500	rs7310576	chr12:34474735	T/C	cg06521331	chr12:34319734	NA	-0.27	-4.53	-0.38	1.37e-5	Morning vs. evening chronotype;
TGCT	cis	rs412000	0.553	rs2680702	chr17:56431549	A/G	cg25039879	chr17:56429692	SUPT4H1	0.57	5.45	0.44	2.66e-7	Primary tooth development (time to first tooth eruption);
TGCT	cis	rs11190604	1.000	rs2495758	chr10:102321900	C/G	cg23241863	chr10:102295624	HIF1AN	0.66	4.87	0.4	3.37e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7698623	0.541	rs7682273	chr4:88781772	C/T	cg27387453	chr4:88533842	DSPP	-0.62	-4.64	-0.38	8.66e-6	Cardiovascular disease risk factors;
TGCT	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg10802521	chr3:52805072	NEK4	-0.78	-10.0	-0.67	1.26e-17	Electroencephalogram traits;
TGCT	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg16423285	chr20:60520624	NA	0.75	9.16	0.64	1.37e-15	Obesity-related traits;
TGCT	cis	rs62244186	0.715	rs10212378	chr3:44667286	C/G	cg02073558	chr3:44770973	ZNF501	0.62	6.07	0.48	1.45e-8	Depressive symptoms;
TGCT	cis	rs6500602	0.627	rs4786494	chr16:4506232	G/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.43	6.24	0.49	6.41e-9	Schizophrenia;
TGCT	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg11494091	chr17:61959527	GH2	0.61	14.5	0.79	1.83e-28	Prudent dietary pattern;
TGCT	trans	rs2760061	0.846	rs3094912	chr1:228209815	T/A	cg16006296	chr10:38738647	LOC399744	-0.31	-7.08	-0.54	9.5e-11	Diastolic blood pressure;
TGCT	cis	rs6495122	0.630	rs12912343	chr15:75251041	C/G	cg09165964	chr15:75287851	SCAMP5	0.52	4.65	0.39	8.45e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
TGCT	cis	rs10489202	0.583	rs203782	chr1:167882386	A/G	cg24449463	chr1:168025552	DCAF6	0.53	6.17	0.48	8.94e-9	Schizophrenia;
TGCT	cis	rs7819412	0.805	rs2409710	chr8:10979821	A/G	cg21775007	chr8:11205619	TDH	-0.51	-4.93	-0.4	2.61e-6	Triglycerides;
TGCT	cis	rs9902453	0.780	rs7210991	chr17:28190961	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	7.18	0.54	5.62e-11	Coffee consumption (cups per day);
TGCT	trans	rs6089829	0.851	rs10854168	chr20:61669550	A/G	cg17470723	chr8:74884337	TCEB1	0.78	6.83	0.52	3.42e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7772486	0.875	rs2814873	chr6:146308932	T/C	cg05347473	chr6:146136440	FBXO30	0.54	5.0	0.41	1.91e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg15242686	chr22:24348715	GSTTP1	-0.42	-5.68	-0.45	9.1e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs782590	0.935	rs2627779	chr2:55892356	A/G	cg03859395	chr2:55845619	SMEK2	0.89	10.38	0.68	1.49e-18	Metabolic syndrome;
TGCT	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg12963246	chr6:28129442	ZNF389	0.52	5.1	0.42	1.23e-6	Depression;
TGCT	cis	rs7666738	0.830	rs4472144	chr4:98956494	G/A	cg18180107	chr4:99064573	C4orf37	0.55	4.98	0.41	2.05e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7226408	0.749	rs62083174	chr18:34314666	C/A	cg06757138	chr18:34340585	FHOD3	0.27	4.79	0.4	4.64e-6	Obesity-related traits;
TGCT	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs12049351	0.774	rs10916504	chr1:229655892	A/T	cg12130225	chr1:229698885	NA	0.38	4.63	0.38	8.95e-6	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs2153535	0.580	rs2327060	chr6:8447111	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.76	0.46	6.39e-8	Motion sickness;
TGCT	cis	rs9486719	1.000	rs2971608	chr6:97039757	T/C	cg18709589	chr6:96969512	KIAA0776	-0.78	-6.38	-0.5	3.24e-9	Migraine;Coronary artery disease;
TGCT	cis	rs6977955	0.838	rs917116	chr7:28172739	T/G	cg23620719	chr7:28220237	JAZF1	0.62	4.86	0.4	3.46e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs6589563	0.609	rs56224630	chr11:116627097	G/A	cg01124546	chr11:117515332	DSCAML1	-0.44	-4.77	-0.39	5.18e-6	Eosinophil counts;
TGCT	cis	rs986417	0.748	rs10150234	chr14:61031284	C/G	cg27398547	chr14:60952738	C14orf39	-1.35	-10.47	-0.69	8.97e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg10802521	chr3:52805072	NEK4	-0.71	-8.79	-0.62	1.04e-14	Bipolar disorder;
TGCT	cis	rs9911578	0.813	rs8066773	chr17:56601552	A/G	cg05425664	chr17:57184151	TRIM37	-0.66	-6.09	-0.48	1.32e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9467773	0.595	rs4320356	chr6:26423560	C/T	cg15659132	chr6:26577336	NA	-0.43	-4.52	-0.38	1.43e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs56804039	0.524	rs4840988	chr8:8403389	C/A	cg14215082	chr8:9055850	NA	-0.47	-4.7	-0.39	6.74e-6	Cervical cancer;
TGCT	cis	rs2932538	0.922	rs12758377	chr1:113137221	C/A	cg22162597	chr1:113214053	CAPZA1	0.27	5.98	0.47	2.24e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs67311347	0.544	rs2123998	chr3:40359005	C/G	cg13683864	chr3:40499215	RPL14	0.85	8.54	0.61	3.96e-14	Renal cell carcinoma;
TGCT	trans	rs1814175	0.669	rs11040473	chr11:49703813	C/T	cg03929089	chr4:120376271	NA	-0.6	-6.95	-0.53	1.88e-10	Height;
TGCT	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg03517284	chr6:25882590	NA	-0.52	-5.29	-0.43	5.3e-7	Blood metabolite levels;
TGCT	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg18876405	chr7:65276391	NA	0.33	4.95	0.41	2.39e-6	Aortic root size;
TGCT	cis	rs10934753	0.560	rs73859048	chr3:125931603	G/A	cg01346077	chr3:125931526	NA	0.39	6.1	0.48	1.26e-8	Plasma homocysteine levels (post-methionine load test);
TGCT	cis	rs2795502	1.000	rs2473119	chr10:43339038	A/T	cg20628663	chr10:43360327	NA	-0.44	-6.37	-0.5	3.4e-9	Blood protein levels;
TGCT	cis	rs992157	0.764	rs4672886	chr2:219185545	C/T	cg00012203	chr2:219082015	ARPC2	-0.71	-6.71	-0.52	6.34e-10	Colorectal cancer;
TGCT	cis	rs3027234	0.724	rs11651453	chr17:8103695	A/G	cg08322244	chr17:8066669	VAMP2	-0.56	-5.21	-0.42	7.76e-7	Telomere length;
TGCT	cis	rs7959452	0.590	rs11177619	chr12:69758871	G/A	cg11871910	chr12:69753446	YEATS4	0.82	8.82	0.62	8.61e-15	Blood protein levels;
TGCT	cis	rs9787249	0.957	rs3738673	chr1:40204823	C/T	cg24920358	chr1:40204285	PPIE	0.57	10.56	0.69	5.57e-19	Blood protein levels;
TGCT	trans	rs208520	1.000	rs208520	chr6:66952828	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.89	-8.42	-0.6	7.99e-14	Exhaled nitric oxide output;
TGCT	cis	rs2562456	0.874	rs2562408	chr19:21709881	C/G	cg01304269	chr19:21688519	ZNF429	-0.55	-4.59	-0.38	1.06e-5	Pain;
TGCT	cis	rs892961	0.932	rs11655686	chr17:75419535	G/A	cg05865280	chr17:75406074	SEPT9	0.27	6.31	0.49	4.45e-9	Airflow obstruction;
TGCT	cis	rs9443645	0.775	rs9359359	chr6:79700980	T/C	cg09184832	chr6:79620586	NA	-0.43	-4.83	-0.4	3.93e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10791097	0.678	rs10894272	chr11:130731081	A/G	cg12179176	chr11:130786555	SNX19	0.77	9.25	0.64	8.44e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs2404602	0.692	rs8024476	chr15:76983954	T/C	cg22467129	chr15:76604101	ETFA	-0.45	-5.11	-0.42	1.2e-6	Blood metabolite levels;
TGCT	cis	rs42648	0.869	rs42611	chr7:89950060	C/A	cg25739043	chr7:89950458	NA	-0.73	-7.29	-0.55	3.2e-11	Homocysteine levels;
TGCT	cis	rs3020736	0.500	rs5996111	chr22:42493902	C/T	cg05082376	chr22:42548792	NA	0.23	5.43	0.44	2.85e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7959452	0.532	rs2291005	chr12:69764388	A/G	cg14784868	chr12:69753453	YEATS4	0.83	8.85	0.62	7.59e-15	Blood protein levels;
TGCT	cis	rs9295536	0.651	rs9460707	chr6:22137648	C/G	cg25792714	chr6:21666554	FLJ22536	0.51	4.68	0.39	7.53e-6	Neuroblastoma;
TGCT	cis	rs10782582	0.593	rs77208152	chr1:76124255	T/C	cg03433033	chr1:76189801	ACADM	-0.63	-7.27	-0.55	3.6e-11	Daytime sleep phenotypes;
TGCT	cis	rs6087990	0.735	rs6057647	chr20:31381690	A/T	cg13636640	chr20:31349939	DNMT3B	0.95	12.38	0.74	2.06e-23	Ulcerative colitis;
TGCT	cis	rs1322512	1.000	rs1727052	chr6:152947175	T/C	cg03415253	chr6:152958462	SYNE1	-0.57	-4.99	-0.41	2e-6	Tonometry;
TGCT	cis	rs6586111	0.967	rs6586110	chr10:82376492	G/A	cg03086067	chr10:82368399	SH2D4B	-0.23	-4.5	-0.37	1.56e-5	Capecitabine sensitivity;
TGCT	cis	rs10131894	0.575	rs1860935	chr14:75432464	G/A	cg08847533	chr14:75593920	NEK9	0.62	5.68	0.45	9.28e-8	Coronary artery disease;
TGCT	cis	rs7091068	0.566	rs7909925	chr10:95507170	A/G	cg20715218	chr10:95462985	C10orf4	0.52	4.62	0.38	9.33e-6	Urinary tract infection frequency;
TGCT	cis	rs7119	0.679	rs12909808	chr15:77816944	A/G	cg27398640	chr15:77910606	LINGO1	-0.25	-4.6	-0.38	1.05e-5	Type 2 diabetes;
TGCT	cis	rs3806843	0.576	rs246006	chr5:140339228	G/A	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs3733585	0.773	rs13107466	chr4:10019390	G/A	cg11266682	chr4:10021025	SLC2A9	0.73	10.98	0.7	5.33e-20	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7647973	0.626	rs11709734	chr3:49745235	G/A	cg05785598	chr3:49045655	WDR6	0.42	5.24	0.43	6.67e-7	Menarche (age at onset);
TGCT	cis	rs6918586	0.658	rs198821	chr6:26123629	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.7	-6.75	-0.52	4.96e-10	Schizophrenia;
TGCT	cis	rs7312933	0.558	rs7965743	chr12:42736822	A/G	cg19980929	chr12:42632907	YAF2	-0.41	-5.76	-0.46	6.18e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs3776081	0.600	rs11167496	chr5:149533956	T/G	cg18424208	chr5:149546337	CDX1	-0.25	-4.53	-0.38	1.37e-5	Blood protein levels;
TGCT	cis	rs763121	0.853	rs138706	chr22:39137834	C/G	cg06022373	chr22:39101656	GTPBP1	0.72	7.0	0.53	1.39e-10	Menopause (age at onset);
TGCT	cis	rs2204008	0.777	rs6582664	chr12:37947022	A/G	cg26384229	chr12:38710491	ALG10B	-0.7	-6.12	-0.48	1.11e-8	Bladder cancer;
TGCT	cis	rs727505	1.000	rs56321835	chr7:124529622	T/C	cg23710748	chr7:124431027	NA	-0.26	-4.49	-0.37	1.6e-5	Lewy body disease;
TGCT	cis	rs2204008	0.715	rs11514282	chr12:38169056	G/T	cg26384229	chr12:38710491	ALG10B	0.86	7.65	0.57	4.87e-12	Bladder cancer;
TGCT	cis	rs595982	0.527	rs73061656	chr19:49372355	G/A	cg17863274	chr19:49399704	TULP2	-0.47	-6.81	-0.52	3.78e-10	Red cell distribution width;
TGCT	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg08683831	chr4:1404607	NA	-0.46	-4.43	-0.37	2.01e-5	Obesity-related traits;
TGCT	cis	rs60843830	0.928	rs55742348	chr2:217563	T/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.73	6.56	0.51	1.29e-9	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs12497850	1.000	rs12493578	chr3:48730116	C/T	cg18654377	chr3:49208889	KLHDC8B	0.44	5.88	0.47	3.56e-8	Parkinson's disease;
TGCT	cis	rs9911578	0.967	rs8082544	chr17:57185807	C/T	cg05425664	chr17:57184151	TRIM37	0.68	6.9	0.53	2.4e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs903263	0.932	rs1021490	chr1:84574282	C/T	cg09664975	chr1:84543551	PRKACB	0.49	4.55	0.38	1.25e-5	Breast cancer (male);
TGCT	cis	rs11250097	0.528	rs36043848	chr8:11309533	A/G	cg21775007	chr8:11205619	TDH	-0.52	-4.68	-0.39	7.53e-6	Neuroticism;
TGCT	cis	rs12220898	0.749	rs6537519	chr10:50479824	G/T	cg06072769	chr10:50146962	WDFY4	-0.32	-4.51	-0.38	1.48e-5	Inflammatory biomarkers;
TGCT	cis	rs13188771	0.651	rs12520498	chr5:100881358	G/A	cg10455971	chr5:101119566	NA	0.44	4.46	0.37	1.83e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs4930561	0.714	rs7945995	chr11:67938302	A/G	cg04465784	chr11:67976953	SUV420H1	-0.38	-5.47	-0.44	2.37e-7	Breast cancer in childhood cancer survivors;IgG glycosylation;
TGCT	cis	rs72781680	0.898	rs55841168	chr2:24007926	T/C	cg08917208	chr2:24149416	ATAD2B	0.81	5.01	0.41	1.8e-6	Lymphocyte counts;
TGCT	cis	rs3902035	0.964	rs118167130	chr6:119009065	G/C	cg07617317	chr6:118971624	C6orf204	0.43	5.01	0.41	1.79e-6	QT interval;
TGCT	cis	rs9326248	0.817	rs1242127	chr11:117076564	A/G	cg16524733	chr11:117070046	TAGLN	-0.32	-4.74	-0.39	5.84e-6	Blood protein levels;
TGCT	cis	rs12477438	0.765	rs72957180	chr2:99694452	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-5.87	-0.47	3.74e-8	Chronic sinus infection;
TGCT	cis	rs7954584	0.616	rs10743186	chr12:122356436	C/T	cg21171335	chr12:122356390	WDR66	0.59	6.19	0.49	8.15e-9	Mean corpuscular volume;
TGCT	cis	rs2839186	0.903	rs61182475	chr21:47707050	T/A	cg13732083	chr21:47605072	C21orf56	0.34	4.55	0.38	1.27e-5	Testicular germ cell tumor;
TGCT	cis	rs7178572	0.568	rs10152181	chr15:77678346	A/G	cg15453836	chr15:77711506	NA	-0.42	-4.78	-0.39	4.92e-6	Type 2 diabetes;
TGCT	cis	rs73058052	0.597	rs10406941	chr19:50091464	A/C	cg09250473	chr19:50168907	IRF3;BCL2L12	0.66	5.23	0.43	6.91e-7	Fibrinogen levels;
TGCT	cis	rs6977955	1.000	rs6977955	chr7:28156887	A/G	cg23620719	chr7:28220237	JAZF1	-0.67	-5.1	-0.42	1.26e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg10819733	chr22:24237672	NA	-0.3	-5.09	-0.42	1.29e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9527	0.569	rs10786730	chr10:104724200	G/A	cg15744005	chr10:104629667	AS3MT	-0.44	-5.19	-0.42	8.3e-7	Arsenic metabolism;
TGCT	trans	rs9650657	0.535	rs7011756	chr8:11019578	C/G	cg15556689	chr8:8085844	FLJ10661	-0.86	-8.58	-0.61	3.26e-14	Neuroticism;
TGCT	cis	rs4988958	0.565	rs12712146	chr2:103008714	C/T	cg03938978	chr2:103052716	IL18RAP	0.26	5.22	0.42	7.15e-7	Asthma (childhood onset);
TGCT	cis	rs1018836	0.847	rs2285231	chr8:91545387	G/T	cg16814680	chr8:91681699	NA	-0.86	-9.52	-0.65	1.82e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs60154123	0.505	rs76426571	chr1:210041634	C/T	cg21951975	chr1:209979733	IRF6	0.69	5.18	0.42	8.74e-7	Coronary artery disease;
TGCT	cis	rs60154123	0.505	rs77990373	chr1:210041111	T/C	cg21951975	chr1:209979733	IRF6	0.69	5.18	0.42	8.74e-7	Coronary artery disease;
TGCT	cis	rs6090919	0.501	rs17366795	chr20:47481831	C/T	cg12392473	chr20:48099331	KCNB1	-0.47	-4.52	-0.38	1.4e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs1552244	0.554	rs3846169	chr3:9997054	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.32	4.94	0.41	2.51e-6	Alzheimer's disease;
TGCT	cis	rs10744422	1.000	rs2292134	chr12:123334033	C/G	cg25930673	chr12:123319894	HIP1R	-0.86	-5.02	-0.41	1.72e-6	Schizophrenia;
TGCT	cis	rs60154123	0.505	rs2206043	chr1:210042983	G/A	cg04352962	chr1:209979756	IRF6	0.69	4.73	0.39	6.04e-6	Coronary artery disease;
TGCT	cis	rs7917772	0.503	rs7093285	chr10:104374815	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.78	7.97	0.58	9.02e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs10716631	1	rs10716631	chr2:219138170	T/G	cg00012203	chr2:219082015	ARPC2	0.77	7.98	0.58	8.28e-13	High light scatter reticulocyte percentage of red cells;Plateletcrit;
TGCT	cis	rs9611565	0.512	rs2050031	chr22:42152266	A/G	cg13695892	chr22:41940480	POLR3H	0.87	8.24	0.59	2.06e-13	Vitiligo;
TGCT	cis	rs56176327	0.532	rs9849038	chr3:49771990	A/G	cg05785598	chr3:49045655	WDR6	0.42	5.24	0.43	6.67e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs288326	0.561	rs75848966	chr2:183878093	A/C	cg09997497	chr2:183902928	NCKAP1	1.11	4.95	0.41	2.38e-6	Blood protein levels;
TGCT	cis	rs782590	0.837	rs782584	chr2:55921116	C/G	cg03859395	chr2:55845619	SMEK2	-0.85	-10.02	-0.67	1.13e-17	Metabolic syndrome;
TGCT	cis	rs7412746	0.552	rs4970980	chr1:150864992	A/C	cg09365446	chr1:150670422	GOLPH3L	0.34	4.71	0.39	6.58e-6	Melanoma;
TGCT	cis	rs7666738	0.830	rs9994346	chr4:99037986	A/G	cg17366294	chr4:99064904	C4orf37	0.73	6.93	0.53	2.07e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1729951	0.575	rs12494558	chr3:136678781	C/G	cg21827317	chr3:136751795	NA	0.4	5.61	0.45	1.28e-7	Neuroticism;
TGCT	cis	rs7937682	0.921	rs11213940	chr11:111433927	C/A	cg09085632	chr11:111637200	PPP2R1B	0.87	7.31	0.55	2.9e-11	Primary sclerosing cholangitis;
TGCT	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg07167872	chr1:205819463	PM20D1	0.59	7.56	0.56	7.74e-12	Menarche (age at onset);
TGCT	cis	rs2046867	0.818	rs62249863	chr3:72868666	G/C	cg25664220	chr3:72788482	NA	-0.56	-7.04	-0.53	1.16e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9902453	0.967	rs4493117	chr17:28489770	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	6.9	0.53	2.37e-10	Coffee consumption (cups per day);
TGCT	cis	rs9990333	0.562	rs58079878	chr3:195827491	T/C	cg14488913	chr3:195402182	SDHAP2	-0.35	-4.44	-0.37	1.95e-5	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);
TGCT	cis	rs941408	0.928	rs2260414	chr19:2796316	G/A	cg06609049	chr19:2785107	THOP1	0.83	8.08	0.59	4.82e-13	Total cholesterol levels;
TGCT	cis	rs28595532	0.920	rs55726697	chr4:119742863	G/A	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs2486288	0.656	rs2413773	chr15:45549442	C/A	cg14582100	chr15:45693742	SPATA5L1	-0.46	-5.59	-0.45	1.38e-7	Glomerular filtration rate;
TGCT	cis	rs2797160	1.000	rs2797154	chr6:126005197	A/G	cg05901451	chr6:126070800	HEY2	-0.74	-6.3	-0.49	4.62e-9	Endometrial cancer;
TGCT	cis	rs950169	0.544	rs62021193	chr15:85170583	C/G	cg12863693	chr15:85201151	NMB	0.44	5.24	0.43	6.63e-7	Schizophrenia;
TGCT	cis	rs4919694	1.000	rs12242000	chr10:104702413	A/C	cg04362960	chr10:104952993	NT5C2	1.06	7.07	0.54	9.73e-11	Arsenic metabolism;
TGCT	cis	rs4824093	0.610	rs12106611	chr22:50242686	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.06	-6.46	-0.5	2.18e-9	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	4.56	0.38	1.21e-5	Prudent dietary pattern;
TGCT	cis	rs2677744	0.719	rs1266492	chr15:91456102	T/C	cg01710897	chr15:91497902	RCCD1	0.34	4.68	0.39	7.35e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs425277	1.000	rs427811	chr1:2075560	T/G	cg03732007	chr1:2071316	PRKCZ	0.25	5.0	0.41	1.93e-6	Height;
TGCT	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg06108461	chr20:60628389	TAF4	-0.69	-10.64	-0.69	3.59e-19	Body mass index;
TGCT	cis	rs651907	0.557	rs35117343	chr3:101445126	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.33	-6.78	-0.52	4.35e-10	Colorectal cancer;
TGCT	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg12923728	chr3:195709715	SDHAP1	-0.36	-7.57	-0.56	7.39e-12	Pancreatic cancer;
TGCT	cis	rs11696845	0.649	rs6031782	chr20:43383832	A/G	cg25301532	chr20:43378953	KCNK15	-0.46	-4.98	-0.41	2.09e-6	Obesity-related traits;
TGCT	cis	rs9372498	0.536	rs9489442	chr6:118885950	A/C	cg21191810	chr6:118973309	C6orf204	-0.37	-4.83	-0.4	4.03e-6	Diastolic blood pressure;
TGCT	cis	rs17152411	1.000	rs17152433	chr10:126670356	G/A	cg07906193	chr10:126599966	NA	0.39	4.79	0.4	4.66e-6	Height;
TGCT	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	0.93	7.77	0.57	2.59e-12	Platelet count;
TGCT	trans	rs77457752	0.525	rs7874947	chr9:13899539	A/C	cg25510823	chr7:47085976	NA	0.45	6.68	0.51	7.04e-10	Breast cancer;
TGCT	cis	rs208520	0.837	rs208486	chr6:66926255	A/T	cg07460842	chr6:66804631	NA	-0.94	-9.3	-0.64	6.32e-16	Exhaled nitric oxide output;
TGCT	cis	rs6430585	0.583	rs4594504	chr2:136625113	A/C	cg07169764	chr2:136633963	MCM6	1.24	12.25	0.74	4.19e-23	Corneal structure;
TGCT	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg18305652	chr10:134549665	INPP5A	0.34	5.39	0.44	3.46e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg18876405	chr7:65276391	NA	0.36	5.41	0.44	3.12e-7	Aortic root size;
TGCT	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg11062466	chr8:58055876	NA	0.38	4.62	0.38	9.5e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4642101	0.611	rs6442331	chr3:12820636	T/G	cg05775895	chr3:12838266	CAND2	0.68	7.27	0.55	3.54e-11	QRS complex (12-leadsum);
TGCT	cis	rs1008375	0.898	rs7670500	chr4:17586957	A/G	cg18681998	chr4:17616180	MED28	0.94	9.56	0.65	1.44e-16	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs57920188	0.640	rs4378174	chr1:4080885	C/T	cg20703997	chr1:4087676	NA	0.44	5.45	0.44	2.64e-7	Interleukin-17 levels;
TGCT	cis	rs8072100	1.000	rs11870935	chr17:45732605	G/A	cg08085267	chr17:45401833	C17orf57	0.47	5.12	0.42	1.14e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs9383153	1.000	rs9370888	chr6:16335544	A/G	cg23850913	chr6:15505452	JARID2	0.96	5.75	0.46	6.42e-8	Gambling;
TGCT	cis	rs10197940	0.578	rs1061305	chr2:152346979	T/C	cg06191203	chr2:152266755	RIF1	-0.61	-5.14	-0.42	1.03e-6	Lung cancer;
TGCT	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	5.86	0.47	3.95e-8	Bipolar disorder;
TGCT	cis	rs13256369	0.951	rs13259955	chr8:8565885	C/G	cg18904891	chr8:8559673	CLDN23	0.59	5.52	0.44	1.93e-7	Obesity-related traits;
TGCT	cis	rs7572733	0.534	rs1607374	chr2:198800440	A/G	cg00792783	chr2:198669748	PLCL1	0.56	5.18	0.42	8.86e-7	Dermatomyositis;
TGCT	cis	rs35306767	0.715	rs12772979	chr10:1034412	C/T	cg18964960	chr10:1102726	WDR37	0.78	5.45	0.44	2.58e-7	Eosinophil percentage of granulocytes;
TGCT	cis	rs6964587	1.000	rs10235941	chr7:91587050	T/G	cg22709100	chr7:91322751	NA	0.27	4.48	0.37	1.68e-5	Breast cancer;
TGCT	trans	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg25482853	chr8:67687455	SGK3	1.16	10.5	0.69	7.91e-19	Lung disease severity in cystic fibrosis;
TGCT	cis	rs75059851	0.756	rs7106715	chr11:133838905	A/G	cg14047540	chr11:133829660	NA	0.52	5.11	0.42	1.18e-6	Schizophrenia;
TGCT	cis	rs28595532	0.920	rs115472708	chr4:119773407	C/T	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.12	15.17	0.81	4.81e-30	Height;
TGCT	cis	rs735396	0.595	rs1169279	chr12:121455873	C/T	cg02403541	chr12:121454288	C12orf43	0.87	9.52	0.65	1.88e-16	N-glycan levels;
TGCT	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg09436375	chr6:42928200	GNMT	-0.42	-5.41	-0.44	3.16e-7	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs79349575	0.783	rs318096	chr17:46975370	G/A	cg07967210	chr17:47022446	SNF8	0.43	6.08	0.48	1.4e-8	Type 2 diabetes;
TGCT	cis	rs968567	0.559	rs174548	chr11:61571348	C/G	cg19610905	chr11:61596333	FADS2	-1.07	-11.76	-0.73	6.62e-22	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
TGCT	cis	rs7582180	0.652	rs11678158	chr2:100932297	T/C	cg14675211	chr2:100938903	LONRF2	0.53	5.11	0.42	1.16e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg03303774	chr4:1407052	NA	0.31	4.93	0.4	2.58e-6	Obesity-related traits;
TGCT	cis	rs986417	0.901	rs1955688	chr14:60989237	G/A	cg27398547	chr14:60952738	C14orf39	1.42	8.85	0.62	7.44e-15	Gut microbiota (bacterial taxa);
TGCT	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg16680214	chr1:154839983	KCNN3	-0.36	-7.33	-0.55	2.59e-11	Prostate cancer;
TGCT	cis	rs7917772	0.582	rs10883753	chr10:104372441	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	5.36	0.43	3.84e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs3858526	1.000	rs3858527	chr11:5959848	G/A	cg05234568	chr11:5960015	NA	-0.44	-4.49	-0.37	1.61e-5	DNA methylation (variation);
TGCT	cis	rs7772486	0.875	rs2474353	chr6:146323883	G/A	cg05347473	chr6:146136440	FBXO30	0.55	5.27	0.43	5.75e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1552244	0.688	rs113940455	chr3:10014165	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-6.71	-0.52	6.05e-10	Alzheimer's disease;
TGCT	cis	rs3741151	1.000	rs74795285	chr11:73033387	A/G	cg17517138	chr11:73019481	ARHGEF17	1.04	5.14	0.42	1.05e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
TGCT	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg03351412	chr1:154909251	PMVK	0.53	4.93	0.4	2.6e-6	Prostate cancer;
TGCT	cis	rs2301573	0.607	rs9837325	chr3:129315831	C/A	cg07730360	chr3:128845626	NA	0.28	5.52	0.44	1.94e-7	Hip circumference;
TGCT	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg06221963	chr1:154839813	KCNN3	-0.73	-12.61	-0.75	5.86e-24	Prostate cancer;
TGCT	cis	rs2549003	1.000	rs2070724	chr5:131822072	A/G	cg02551604	chr5:131831745	NA	-0.9	-12.1	-0.74	9.75e-23	Asthma (sex interaction);
TGCT	cis	rs11098499	0.564	rs11098507	chr4:120288286	G/A	cg09307838	chr4:120376055	NA	0.58	5.7	0.46	8.42e-8	Corneal astigmatism;
TGCT	cis	rs1577917	0.655	rs7742691	chr6:86278691	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.52	4.76	0.39	5.23e-6	Response to antipsychotic treatment;
TGCT	trans	rs7819412	0.511	rs7464263	chr8:11434176	A/T	cg06636001	chr8:8085503	FLJ10661	-0.79	-7.27	-0.55	3.49e-11	Triglycerides;
TGCT	cis	rs6918586	0.557	rs198827	chr6:26121002	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.7	-6.75	-0.52	4.96e-10	Schizophrenia;
TGCT	cis	rs909674	0.818	rs5750830	chr22:39840828	C/A	cg02038168	chr22:39784481	NA	-0.74	-5.76	-0.46	6.36e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs6088580	0.634	rs6088488	chr20:32992631	T/C	cg06115741	chr20:33292138	TP53INP2	-0.55	-4.81	-0.4	4.28e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs4862307	0.836	rs11132220	chr4:184997247	A/T	cg06737308	chr4:185021514	ENPP6	-0.34	-4.99	-0.41	1.96e-6	Serum dimethylarginine levels (asymmetric/symetric ratio);
TGCT	cis	rs9291683	0.588	rs3756236	chr4:10013463	T/A	cg11266682	chr4:10021025	SLC2A9	0.73	11.04	0.7	3.63e-20	Bone mineral density;
TGCT	cis	rs6570726	0.791	rs6570693	chr6:145910841	C/T	cg23711669	chr6:146136114	FBXO30	0.86	9.28	0.64	7.13e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs12048904	0.505	rs6577209	chr1:101255080	A/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.76	6.71	0.52	6.06e-10	Multiple sclerosis;
TGCT	cis	rs3764628	1.000	rs11668413	chr19:18782027	G/A	cg20098710	chr19:19640075	YJEFN3	-0.46	-5.22	-0.42	7.26e-7	Orofacial clefts;
TGCT	cis	rs644799	0.672	rs61902245	chr11:95517737	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.8	9.01	0.63	3.14e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9467711	1.000	rs9467708	chr6:26327956	T/C	cg03264133	chr6:25882463	NA	-0.82	-4.48	-0.37	1.65e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2235642	0.859	rs12599207	chr16:1606445	A/G	cg11375102	chr16:1583810	IFT140;TMEM204	-0.29	-5.08	-0.42	1.35e-6	Coronary artery disease;
TGCT	cis	rs9443645	0.810	rs7753531	chr6:79789996	A/C	cg09184832	chr6:79620586	NA	-0.45	-4.87	-0.4	3.28e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs492146	0.819	rs584124	chr6:52838196	G/A	cg06706454	chr6:52930286	FBXO9	-0.5	-4.63	-0.38	9.12e-6	Epilepsy (remission after treatment);
TGCT	cis	rs763121	0.853	rs2072795	chr22:39064209	A/G	cg06022373	chr22:39101656	GTPBP1	-0.78	-7.56	-0.56	7.78e-12	Menopause (age at onset);
TGCT	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg18402987	chr7:1209562	NA	0.81	6.94	0.53	1.9e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs4788815	0.718	rs6499545	chr16:71889173	C/T	cg06353428	chr16:71660113	MARVELD3	0.83	7.37	0.55	2.07e-11	Metabolite levels;
TGCT	cis	rs2354432	0.607	rs6694347	chr1:146751140	T/C	cg25205988	chr1:146714368	CHD1L	-1.34	-6.07	-0.48	1.44e-8	Mitochondrial DNA levels;
TGCT	cis	rs10197940	0.789	rs2444256	chr2:152280365	C/T	cg19508488	chr2:152266495	RIF1	0.72	6.62	0.51	9.56e-10	Lung cancer;
TGCT	cis	rs12681287	0.711	rs28506490	chr8:87246118	T/C	cg27223183	chr8:87520930	FAM82B	-0.81	-5.77	-0.46	5.91e-8	Caudate activity during reward;
TGCT	cis	rs4319547	0.585	rs7952868	chr12:122846949	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.63	-4.88	-0.4	3.18e-6	Body mass index;
TGCT	cis	rs4074961	0.565	rs10908362	chr1:38061706	G/C	cg11397548	chr1:38022522	DNALI1	0.42	4.81	0.4	4.38e-6	Axial length;
TGCT	cis	rs10838634	0.706	rs11039012	chr11:46883318	A/C	cg18332754	chr11:46939436	LRP4	-0.89	-4.77	-0.39	5.13e-6	Schizophrenia;
TGCT	cis	rs6882046	0.513	rs254779	chr5:88019629	T/C	cg22951263	chr5:87985283	NA	-0.58	-6.18	-0.49	8.49e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	trans	rs5771242	0.776	rs6010198	chr22:50610628	A/G	cg26607758	chr8:91997553	NA	-0.79	-9.26	-0.64	7.59e-16	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
TGCT	cis	rs2230307	0.572	rs2810419	chr1:100643968	C/A	cg24955406	chr1:100503596	HIAT1	-0.73	-4.94	-0.41	2.5e-6	Carotid intima media thickness;
TGCT	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg10047753	chr17:41438598	NA	0.96	9.64	0.65	9.37e-17	Menopause (age at onset);
TGCT	cis	rs61935443	0.666	rs11107781	chr12:95301086	T/A	cg21533806	chr12:95267307	NA	0.58	4.85	0.4	3.7e-6	Schizophrenia;
TGCT	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.31	-4.76	-0.39	5.36e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs6840360	0.571	rs17360385	chr4:152587970	C/A	cg17479576	chr4:152424074	FAM160A1	-0.74	-8.24	-0.59	2.06e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs2933343	0.679	rs789221	chr3:128591625	A/G	cg11901034	chr3:128598214	ACAD9	-0.62	-6.01	-0.48	1.88e-8	IgG glycosylation;
TGCT	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg18876405	chr7:65276391	NA	0.31	4.8	0.4	4.53e-6	Aortic root size;
TGCT	cis	rs12477438	0.677	rs12475034	chr2:99699464	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-5.22	-0.42	7.16e-7	Chronic sinus infection;
TGCT	cis	rs1008375	0.932	rs6449321	chr4:17644472	A/G	cg16339924	chr4:17578868	LAP3	0.67	5.48	0.44	2.23e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg16423285	chr20:60520624	NA	-0.61	-6.64	-0.51	8.67e-10	Body mass index;
TGCT	cis	rs1395	0.778	rs724311	chr2:27441645	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.7	9.47	0.65	2.4e-16	Blood metabolite levels;
TGCT	cis	rs9929218	0.529	rs35854485	chr16:68730855	C/G	cg01251360	chr16:68772225	CDH1	-0.25	-4.57	-0.38	1.15e-5	Colorectal cancer;
TGCT	cis	rs739401	0.595	rs6578304	chr11:2998279	A/G	cg05729581	chr11:3078854	CARS	0.54	4.81	0.4	4.21e-6	Longevity;
TGCT	cis	rs8103278	1.000	rs36091860	chr19:46312880	G/A	cg14061069	chr19:46274453	DMPK	-0.42	-5.86	-0.47	3.86e-8	Coronary artery disease;
TGCT	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg11871910	chr12:69753446	YEATS4	0.88	10.41	0.68	1.28e-18	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs2549003	1.000	rs3846732	chr5:131816087	T/C	cg00255919	chr5:131827918	IRF1	0.22	5.15	0.42	1.01e-6	Asthma (sex interaction);
TGCT	cis	rs7944584	0.655	rs11039183	chr11:47346940	G/A	cg20307385	chr11:47447363	PSMC3	0.8	7.85	0.58	1.7e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
TGCT	cis	rs6901250	0.632	rs339355	chr6:117196503	A/T	cg12892004	chr6:117198278	RFX6	-0.44	-5.48	-0.44	2.3e-7	C-reactive protein levels;
TGCT	cis	rs4319547	0.915	rs10773208	chr12:122970156	T/C	cg23029597	chr12:123009494	RSRC2	-0.29	-4.87	-0.4	3.34e-6	Body mass index;
TGCT	cis	rs6582630	0.502	rs4379906	chr12:38295673	G/A	cg26384229	chr12:38710491	ALG10B	0.77	6.88	0.53	2.6200000000000003e-10	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs644799	1.000	rs514170	chr11:95556696	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	10.52	0.69	6.94e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs921968	0.541	rs72965126	chr2:219330189	C/T	cg02176678	chr2:219576539	TTLL4	-0.47	-6.78	-0.52	4.34e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs2997447	0.846	rs12069719	chr1:26411918	A/G	cg03844060	chr1:26490628	NA	0.27	4.52	0.38	1.41e-5	QRS complex (12-leadsum);
TGCT	cis	rs6582630	0.519	rs11495376	chr12:38284957	A/C	cg26384229	chr12:38710491	ALG10B	0.82	7.18	0.54	5.6e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs12540874	0.931	rs4245555	chr7:50661409	A/G	cg18232548	chr7:50535776	DDC	-0.29	-4.89	-0.4	3.01e-6	Systemic sclerosis;
TGCT	cis	rs9902453	1.000	rs4581755	chr17:28427898	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.74	6.57	0.51	1.22e-9	Coffee consumption (cups per day);
TGCT	cis	rs6459788	0.657	rs887627	chr7:157237391	G/A	cg06271696	chr7:157225062	NA	-0.29	-5.13	-0.42	1.07e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs17767294	0.708	rs72848775	chr6:27949830	A/G	cg08851530	chr6:28072375	NA	1.56	7.22	0.54	4.47e-11	Parkinson's disease;
TGCT	cis	rs826838	0.967	rs11169142	chr12:39085773	A/T	cg13010199	chr12:38710504	ALG10B	-0.59	-4.89	-0.4	3e-6	Heart rate;
TGCT	cis	rs10875746	0.855	rs73102067	chr12:48494426	A/C	cg20731937	chr12:48336164	NA	0.63	4.96	0.41	2.24e-6	Longevity (90 years and older);
TGCT	cis	rs12477438	0.715	rs6724476	chr2:99627316	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-7.6	-0.56	6.47e-12	Chronic sinus infection;
TGCT	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg18876405	chr7:65276391	NA	0.33	4.89	0.4	3.12e-6	Aortic root size;
TGCT	cis	rs1372520	1.000	rs1372520	chr4:90757505	T/C	cg15133208	chr4:90757351	SNCA	-0.5	-5.77	-0.46	5.88e-8	Neuroticism;
TGCT	cis	rs7219014	1	rs7219014	chr17:37624790	A/G	cg15445000	chr17:37608096	MED1	0.33	4.93	0.4	2.59e-6	Urinary metabolites;
TGCT	cis	rs992157	0.764	rs4552182	chr2:219184872	G/T	cg00012203	chr2:219082015	ARPC2	0.7	6.58	0.51	1.16e-9	Colorectal cancer;
TGCT	cis	rs42648	0.935	rs42635	chr7:89966198	T/A	cg25739043	chr7:89950458	NA	-0.76	-7.64	-0.57	5.2e-12	Homocysteine levels;
TGCT	cis	rs11098499	0.909	rs11723839	chr4:120299673	G/A	cg09307838	chr4:120376055	NA	0.62	5.94	0.47	2.66e-8	Corneal astigmatism;
TGCT	cis	rs17401966	0.838	rs12139981	chr1:10390696	T/C	cg19773385	chr1:10388646	KIF1B	-0.23	-5.45	-0.44	2.63e-7	Hepatocellular carcinoma;
TGCT	cis	rs1372520	0.684	rs2583963	chr4:90727088	C/T	cg01966878	chr4:90757139	SNCA	-0.31	-4.84	-0.4	3.8e-6	Neuroticism;
TGCT	trans	rs28735056	0.967	rs56071379	chr18:77647406	G/A	cg05926928	chr17:57297772	GDPD1	-0.68	-7.21	-0.54	4.89e-11	Schizophrenia;
TGCT	cis	rs7777484	0.500	rs2533885	chr7:2835655	C/T	cg11411865	chr7:2701802	TTYH3	0.19	4.51	0.38	1.47e-5	Height;
TGCT	cis	rs12548874	0.618	rs10100651	chr8:95887225	G/C	cg09323728	chr8:95962352	TP53INP1	-0.42	-4.73	-0.39	6.03e-6	Hemoglobin concentration;
TGCT	cis	rs6933660	0.800	rs6930557	chr6:151755806	G/A	cg17179660	chr6:151773299	C6orf211;RMND1	-0.54	-4.92	-0.4	2.64e-6	Menarche (age at onset);
TGCT	cis	rs2929278	0.561	rs3099045	chr15:43923955	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.45	4.5	0.37	1.54e-5	Schizophrenia;
TGCT	cis	rs3916	0.911	rs3999408	chr12:121167387	C/T	cg21892295	chr12:121157589	UNC119B	-0.23	-4.5	-0.37	1.55e-5	Urinary metabolites (H-NMR features);
TGCT	cis	rs6964587	1.000	rs7806157	chr7:91601930	A/G	cg22709100	chr7:91322751	NA	0.27	4.48	0.37	1.68e-5	Breast cancer;
TGCT	cis	rs7246657	0.722	rs1564208	chr19:38041221	A/G	cg18154014	chr19:37997991	ZNF793	0.69	4.63	0.38	9.25e-6	Coronary artery calcification;
TGCT	cis	rs854765	0.583	rs7207043	chr17:17819188	A/G	cg09796270	chr17:17721594	SREBF1	0.24	4.7	0.39	6.83e-6	Total body bone mineral density;
TGCT	cis	rs35306767	0.715	rs17293580	chr10:1034895	T/C	cg26597838	chr10:835615	NA	0.64	7.08	0.54	9.37e-11	Eosinophil percentage of granulocytes;
TGCT	cis	rs3784262	0.904	rs12901462	chr15:58316487	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.52	-7.93	-0.58	1.1e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs8072100	0.713	rs4968257	chr17:45430534	A/G	cg08085267	chr17:45401833	C17orf57	-0.5	-5.63	-0.45	1.14e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs7666738	0.830	rs17027198	chr4:98991085	G/C	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs644799	0.511	rs10831420	chr11:95478209	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.65	6.26	0.49	5.81e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9381040	0.701	rs4711658	chr6:41162891	C/T	cg03526776	chr6:41159608	TREML2	-0.28	-6.15	-0.48	9.78e-9	Alzheimer's disease (late onset);
TGCT	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg10802521	chr3:52805072	NEK4	-0.71	-8.43	-0.6	7.23e-14	Bipolar disorder;
TGCT	cis	rs4653767	1.000	rs708774	chr1:226921530	C/G	cg10327440	chr1:227177885	CDC42BPA	-0.47	-5.24	-0.43	6.64e-7	Parkinson's disease;
TGCT	cis	rs2153535	0.541	rs6905934	chr6:8440043	C/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.58	0.45	1.42e-7	Motion sickness;
TGCT	trans	rs28735056	0.875	rs62103181	chr18:77625652	A/G	cg05926928	chr17:57297772	GDPD1	0.65	6.74	0.52	5.44e-10	Schizophrenia;
TGCT	cis	rs7959452	0.527	rs4761157	chr12:69780907	A/G	cg11871910	chr12:69753446	YEATS4	0.82	8.95	0.63	4.38e-15	Blood protein levels;
TGCT	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg03351412	chr1:154909251	PMVK	0.52	4.92	0.4	2.66e-6	Prostate cancer;
TGCT	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs12200560	0.505	rs211183	chr6:97074723	G/T	cg06623918	chr6:96969491	KIAA0776	-0.56	-4.56	-0.38	1.19e-5	Coronary heart disease;
TGCT	cis	rs2933343	1.000	rs1683776	chr3:128622760	G/T	cg11901034	chr3:128598214	ACAD9	-0.63	-5.13	-0.42	1.08e-6	IgG glycosylation;
TGCT	cis	rs4242434	0.927	rs7843616	chr8:22466541	T/C	cg21658235	chr8:22456391	C8orf58	0.43	4.53	0.38	1.37e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs514406	0.505	rs436363	chr1:53172163	T/C	cg24675658	chr1:53192096	ZYG11B	-0.77	-8.85	-0.62	7.57e-15	Monocyte count;
TGCT	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg17330251	chr7:94953956	PON1	0.51	6.68	0.51	7.16e-10	Paraoxonase activity;
TGCT	cis	rs12210905	1.000	rs41269245	chr6:27100096	G/A	cg08851530	chr6:28072375	NA	1.21	5.58	0.45	1.43e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs10510102	0.872	rs12259144	chr10:123724948	A/G	cg23691251	chr10:123688108	ATE1	-0.59	-4.7	-0.39	6.75e-6	Breast cancer;
TGCT	cis	rs11122272	0.766	rs1435166	chr1:231502310	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-6.92	-0.53	2.19e-10	Hemoglobin concentration;
TGCT	trans	rs1814175	0.817	rs7950856	chr11:49976394	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.36	-7.14	-0.54	6.88e-11	Height;
TGCT	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.49	-6.64	-0.51	8.8e-10	Alzheimer's disease;
TGCT	cis	rs1865760	1.000	rs56118523	chr6:25908975	A/G	cg16482183	chr6:26056742	HIST1H1C	0.55	4.97	0.41	2.19e-6	Height;
TGCT	cis	rs7731657	0.537	rs3962196	chr5:130372512	A/T	cg08523029	chr5:130500466	HINT1	-0.61	-5.08	-0.42	1.34e-6	Fasting plasma glucose;
TGCT	cis	rs12615966	0.932	rs60065121	chr2:105368305	T/C	cg16465502	chr2:105461796	NA	0.75	4.65	0.39	8.22e-6	Pancreatic cancer;
TGCT	cis	rs11105298	0.891	rs10858902	chr12:89927789	A/G	cg00757033	chr12:89920650	WDR51B	0.3	4.65	0.39	8.21e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg03517284	chr6:25882590	NA	0.89	9.16	0.64	1.32e-15	Blood metabolite levels;
TGCT	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	6.18	0.49	8.58e-9	Bipolar disorder;
TGCT	cis	rs78456975	1.000	rs13397299	chr2:1564222	A/C	cg01028140	chr2:1542097	TPO	-0.33	-4.54	-0.38	1.29e-5	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs2228479	0.717	rs34027607	chr16:89808939	T/C	cg27121462	chr16:89883253	FANCA	0.77	4.61	0.38	9.93e-6	Skin colour saturation;
TGCT	cis	rs5769765	0.773	rs7410291	chr22:50300078	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.37	5.21	0.42	7.51e-7	Schizophrenia;
TGCT	cis	rs12478296	0.786	rs72620862	chr2:243044787	T/C	cg06360820	chr2:242988706	NA	-0.61	-4.66	-0.39	8.13e-6	Obesity-related traits;
TGCT	cis	rs7843479	0.898	rs4311656	chr8:21802276	T/G	cg17168535	chr8:21777572	XPO7	0.65	5.99	0.47	2.14e-8	Mean corpuscular volume;
TGCT	cis	rs6940638	0.513	rs4424065	chr6:27036456	C/T	cg05738196	chr6:26577821	NA	-0.54	-5.21	-0.42	7.68e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7726839	0.540	rs72703080	chr5:595238	A/G	cg09021430	chr5:549028	NA	-0.43	-5.83	-0.46	4.57e-8	Obesity-related traits;
TGCT	cis	rs6460942	1.000	rs7808819	chr7:12297440	C/T	cg06484146	chr7:12443880	VWDE	-0.54	-4.81	-0.4	4.33e-6	Coronary artery disease;
TGCT	cis	rs2282802	0.660	rs4463213	chr5:139545748	G/A	cg01081189	chr5:139537190	NA	-0.3	-5.37	-0.43	3.82e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs11958404	0.789	rs72818150	chr5:157484121	A/G	cg05962755	chr5:157440814	NA	0.35	4.56	0.38	1.23e-5	IgG glycosylation;
TGCT	cis	rs9929218	0.906	rs10852450	chr16:68749529	G/A	cg01251360	chr16:68772225	CDH1	0.3	4.94	0.41	2.45e-6	Colorectal cancer;
TGCT	cis	rs1348850	0.872	rs7559521	chr2:178452328	A/G	cg22681709	chr2:178499509	PDE11A	0.41	5.18	0.42	8.85e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs1580019	0.961	rs766657	chr7:32499510	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.81	7.7	0.57	3.71e-12	Cognitive ability;
TGCT	cis	rs1577917	1.000	rs12199516	chr6:86726221	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.54	-0.45	1.73e-7	Response to antipsychotic treatment;
TGCT	cis	rs4468007	0.505	rs4836865	chr9:124620721	G/A	cg01549227	chr9:124980074	LHX6	-0.3	-4.55	-0.38	1.24e-5	Educational attainment;
TGCT	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg15595755	chr5:1867978	NA	0.46	4.88	0.4	3.26e-6	Cardiovascular disease risk factors;
TGCT	cis	rs7647973	0.588	rs4855848	chr3:49653457	C/T	cg03034192	chr3:50606346	HEMK1;C3orf18	0.36	4.75	0.39	5.61e-6	Menarche (age at onset);
TGCT	cis	rs9467711	0.606	rs9393706	chr6:26361500	G/A	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4654899	0.772	rs12404954	chr1:21074727	A/G	cg01072550	chr1:21505969	NA	-0.48	-7.06	-0.54	1.03e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg06238570	chr21:40685208	BRWD1	-0.84	-9.31	-0.64	6.01e-16	Cognitive function;
TGCT	cis	rs7843479	0.965	rs878872	chr8:21834567	A/G	cg17168535	chr8:21777572	XPO7	0.63	5.8	0.46	5.08e-8	Mean corpuscular volume;
TGCT	cis	rs7822232	1.000	rs6558296	chr8:145143802	G/A	cg26272248	chr8:145163034	KIAA1875	-0.49	-4.81	-0.4	4.24e-6	Blood metabolite levels;
TGCT	cis	rs651907	0.557	rs59596156	chr3:101394217	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.57	5.32	0.43	4.62e-7	Colorectal cancer;
TGCT	cis	rs9916302	0.752	rs8071300	chr17:37508524	G/C	cg07936489	chr17:37558343	FBXL20	0.87	6.27	0.49	5.47e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg11301795	chr4:187892539	NA	-0.33	-4.82	-0.4	4.14e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg19723775	chr5:179050963	HNRNPH1	0.47	4.52	0.38	1.42e-5	Lung cancer;
TGCT	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.5	5.64	0.45	1.11e-7	Lymphocyte counts;
TGCT	cis	rs7552404	0.924	rs7550974	chr1:76204185	A/G	cg10523679	chr1:76189770	ACADM	0.89	9.88	0.66	2.42e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9611565	0.649	rs5758434	chr22:42116163	G/A	cg06634786	chr22:41940651	POLR3H	0.82	7.9	0.58	1.3e-12	Vitiligo;
TGCT	cis	rs858239	0.829	rs2268744	chr7:23332280	C/T	cg05602783	chr7:23145260	KLHL7	-0.72	-5.71	-0.46	7.84e-8	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs5750830	0.597	rs4821889	chr22:39777254	T/C	cg01416388	chr22:39784598	NA	-0.63	-6.66	-0.51	8.09e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs12478296	0.685	rs12473450	chr2:242991746	C/T	cg06360820	chr2:242988706	NA	-0.65	-5.18	-0.42	8.6e-7	Obesity-related traits;
TGCT	cis	rs4886920	0.601	rs4589520	chr15:78079434	C/G	cg03457338	chr15:78040120	NA	0.18	4.51	0.38	1.48e-5	Neuroticism;
TGCT	cis	rs9902453	0.542	rs3809789	chr17:27955761	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.83	7.59	0.56	6.48e-12	Coffee consumption (cups per day);
TGCT	cis	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg02503808	chr4:7069936	GRPEL1	1.06	10.42	0.68	1.18e-18	Monocyte percentage of white cells;
TGCT	cis	rs514406	0.683	rs6588440	chr1:53209587	C/T	cg01802117	chr1:53393560	SCP2	0.44	5.14	0.42	1.04e-6	Monocyte count;
TGCT	cis	rs7523273	0.606	rs10449303	chr1:207961058	A/G	cg22525895	chr1:207977042	MIR29B2	-0.52	-8.74	-0.62	1.38e-14	Schizophrenia;
TGCT	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg24549020	chr5:56110836	MAP3K1	0.67	5.78	0.46	5.74e-8	Initial pursuit acceleration;
TGCT	cis	rs10791323	0.569	rs5019134	chr11:133713082	G/C	cg15485101	chr11:133734466	NA	0.39	5.18	0.42	8.85e-7	Childhood ear infection;
TGCT	cis	rs6912958	0.781	rs2300906	chr6:88207155	G/A	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.91	-0.4	2.78e-6	Monocyte percentage of white cells;
TGCT	cis	rs7095607	0.742	rs7914243	chr10:69928679	A/G	cg18986048	chr10:69913749	MYPN	0.46	5.2	0.42	7.88e-7	Lung function (FVC);
TGCT	cis	rs9486719	0.947	rs11757102	chr6:96885073	G/A	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.21	-0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs9467711	0.651	rs17528178	chr6:25983777	C/T	cg16898833	chr6:26189333	HIST1H4D	1.36	6.0	0.47	2.05e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6845621	0.901	rs1452553	chr4:18920030	C/G	cg12196642	chr4:18937545	NA	-0.24	-4.45	-0.37	1.89e-5	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
TGCT	cis	rs611744	0.647	rs4735053	chr8:109260776	A/G	cg21045802	chr8:109455806	TTC35	0.72	7.28	0.55	3.42e-11	Dupuytren's disease;
TGCT	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg22541963	chr20:60982533	CABLES2	-0.58	-4.5	-0.37	1.52e-5	Colorectal cancer;
TGCT	cis	rs9952991	0.941	rs888270	chr18:12774894	G/A	cg23544223	chr18:12777786	NA	-0.63	-5.78	-0.46	5.6e-8	Inflammatory skin disease;
TGCT	cis	rs11190604	1.000	rs10509744	chr10:102271579	C/T	cg23241863	chr10:102295624	HIF1AN	0.68	5.18	0.42	8.56e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7772486	0.869	rs2777473	chr6:146301494	G/A	cg23711669	chr6:146136114	FBXO30	0.77	7.93	0.58	1.08e-12	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11585357	0.947	rs2977304	chr1:17611615	T/C	cg08277548	chr1:17600880	PADI3	0.97	9.95	0.67	1.7e-17	Hair shape;
TGCT	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg03609598	chr5:56110824	MAP3K1	-0.58	-4.7	-0.39	6.72e-6	Initial pursuit acceleration;
TGCT	cis	rs4319547	0.774	rs10773394	chr12:123124778	C/A	cg23029597	chr12:123009494	RSRC2	-0.26	-4.51	-0.38	1.51e-5	Body mass index;
TGCT	cis	rs4970988	0.787	rs1532770	chr1:150725335	G/T	cg09365446	chr1:150670422	GOLPH3L	0.34	4.94	0.41	2.46e-6	Urate levels;
TGCT	cis	rs66569888	0.507	rs67196165	chr2:106886496	C/G	cg16099169	chr2:106886729	NA	-0.48	-6.16	-0.48	9.37e-9	Facial morphology (factor 23);
TGCT	cis	rs5750830	0.645	rs756640	chr22:39779300	G/A	cg24399712	chr22:39784796	NA	-1.04	-13.34	-0.77	1e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.52	-6.86	-0.52	2.9e-10	Lymphocyte counts;
TGCT	cis	rs854765	1.000	rs854765	chr17:18012730	T/C	cg04398451	chr17:18023971	MYO15A	0.31	4.84	0.4	3.83e-6	Total body bone mineral density;
TGCT	cis	rs2404602	0.684	rs4886816	chr15:76874707	A/C	cg23625390	chr15:77176239	SCAPER	-0.37	-4.67	-0.39	7.71e-6	Blood metabolite levels;
TGCT	trans	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg13565492	chr6:43139072	SRF	-0.81	-7.71	-0.57	3.45e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg04267008	chr7:1944627	MAD1L1	-0.38	-5.19	-0.42	8.33e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs6429082	0.702	rs7532018	chr1:235706290	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.58	-4.93	-0.4	2.55e-6	Adiposity;
TGCT	cis	rs950776	0.518	rs8053	chr15:78841220	T/C	cg06917634	chr15:78832804	PSMA4	-0.93	-9.08	-0.63	2.07e-15	Sudden cardiac arrest;
TGCT	cis	rs75686122	0.892	rs79580171	chr8:104514299	T/A	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs34734847	1.000	rs3752531	chr12:121157851	A/G	cg21892295	chr12:121157589	UNC119B	-0.23	-5.52	-0.44	1.89e-7	Mean corpuscular volume;
TGCT	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg06108461	chr20:60628389	TAF4	-0.75	-11.03	-0.7	3.95e-20	Body mass index;
TGCT	cis	rs9811920	0.683	rs813218	chr3:99592596	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.45	-5.33	-0.43	4.52e-7	Axial length;
TGCT	cis	rs10875595	0.836	rs59933130	chr5:140667303	G/A	cg20560182	chr5:140700478	TAF7	-0.64	-4.96	-0.41	2.26e-6	Pulmonary function decline;
TGCT	cis	rs17401966	0.928	rs11121531	chr1:10277357	G/A	cg21474053	chr1:11182049	MTOR	0.19	4.49	0.37	1.58e-5	Hepatocellular carcinoma;
TGCT	cis	rs2224391	0.628	rs2773311	chr6:5250866	A/T	cg09085698	chr6:5261316	LYRM4;FARS2	-1.04	-6.69	-0.51	6.87e-10	Height;
TGCT	cis	rs8180040	0.654	rs4682831	chr3:47027138	A/G	cg27129171	chr3:47204927	SETD2	-0.7	-8.8	-0.62	9.59e-15	Colorectal cancer;
TGCT	cis	rs17761864	0.718	rs8064885	chr17:2047564	G/A	cg02171503	chr17:1588363	PRPF8	-0.5	-4.79	-0.4	4.7e-6	Esophageal cancer (squamous cell);
TGCT	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg22105103	chr4:187893119	NA	0.33	4.62	0.38	9.41e-6	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs4650994	0.525	rs17361286	chr1:178521916	C/G	cg05059571	chr16:84539110	KIAA1609	-0.53	-10.92	-0.7	7.49e-20	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg12923728	chr3:195709715	SDHAP1	-0.36	-7.58	-0.56	6.91e-12	Pancreatic cancer;
TGCT	cis	rs12039431	0.788	rs61776188	chr1:38021326	C/T	cg17933807	chr1:38061675	GNL2	-0.81	-7.89	-0.58	1.34e-12	Epithelial ovarian cancer;
TGCT	cis	rs9549367	0.789	rs6577035	chr13:113879997	G/A	cg00898013	chr13:113819073	PROZ	-0.39	-4.78	-0.39	4.78e-6	Platelet distribution width;
TGCT	cis	rs10779751	0.734	rs1148485	chr1:11148759	G/A	cg08854313	chr1:11322531	MTOR	0.89	7.18	0.54	5.5e-11	Body mass index;
TGCT	cis	rs116095464	0.558	rs10068203	chr5:206618	C/T	cg12570787	chr5:219185	SDHA;CCDC127	0.72	4.52	0.38	1.4e-5	Breast cancer;
TGCT	cis	rs12477438	0.798	rs4850891	chr2:99574642	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-8.58	-0.61	3.24e-14	Chronic sinus infection;
TGCT	cis	rs1008375	0.646	rs13146455	chr4:17565617	T/G	cg16339924	chr4:17578868	LAP3	-0.79	-6.56	-0.51	1.33e-9	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7829975	0.633	rs2979181	chr8:8323088	A/T	cg08975724	chr8:8085496	FLJ10661	0.62	5.97	0.47	2.37e-8	Mood instability;
TGCT	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg22433210	chr17:43662623	NA	0.96	7.9	0.58	1.29e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs9389248	0.690	rs6569982	chr6:135256495	C/G	cg24558204	chr6:135376177	HBS1L	0.47	4.75	0.39	5.43e-6	High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs6840360	0.593	rs4696286	chr4:152606547	G/A	cg17479576	chr4:152424074	FAM160A1	-0.61	-6.29	-0.49	4.86e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs2288073	0.965	rs13395596	chr2:24410738	T/C	cg02683114	chr2:24398427	C2orf84	-0.24	-5.72	-0.46	7.53e-8	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs1023500	0.505	rs134886	chr22:42673856	C/T	cg15557168	chr22:42548783	NA	0.2	4.75	0.39	5.56e-6	Schizophrenia;
TGCT	cis	rs13256369	0.802	rs13255789	chr8:8562791	T/C	cg06671706	chr8:8559999	CLDN23	0.34	4.52	0.38	1.4e-5	Obesity-related traits;
TGCT	cis	rs6570726	0.846	rs426874	chr6:145880630	A/C	cg05347473	chr6:146136440	FBXO30	0.52	4.96	0.41	2.28e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs8177179	0.967	rs10935085	chr3:133459735	C/T	cg16262614	chr3:133464971	TF	0.34	4.62	0.38	9.28e-6	Iron status biomarkers (transferrin levels);
TGCT	cis	rs1981331	1.000	rs1981331	chr21:47995443	A/C	cg23283320	chr21:48055893	PRMT2	1.29	6.09	0.48	1.31e-8	Cerebrospinal fluid t-tau:AB1-42 ratio;
TGCT	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg03806693	chr22:41940476	POLR3H	1.14	12.91	0.76	1.07e-24	Vitiligo;
TGCT	cis	rs6918586	0.658	rs198829	chr6:26118893	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.68	-6.46	-0.5	2.15e-9	Schizophrenia;
TGCT	cis	rs12701220	0.894	rs34712249	chr7:1036634	C/T	cg07217954	chr7:1067459	C7orf50	-0.48	-4.75	-0.39	5.49e-6	Bronchopulmonary dysplasia;
TGCT	cis	rs12220238	0.722	rs4745750	chr10:76394003	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.64	5.19	0.42	8.46e-7	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs7714584	1.000	rs7715981	chr5:150258107	A/G	cg22134413	chr5:150180641	NA	0.78	6.12	0.48	1.16e-8	Crohn's disease;
TGCT	cis	rs3820068	0.608	rs12760450	chr1:16037282	G/A	cg05660106	chr1:15850417	CASP9	0.68	6.34	0.49	3.98e-9	Systolic blood pressure;
TGCT	cis	rs7267979	0.873	rs6037062	chr20:25202892	G/A	cg16686733	chr20:25566563	NINL	0.55	5.71	0.46	7.87e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11688237	0.805	rs10175481	chr2:144545138	T/C	cg07409629	chr2:144282743	ARHGAP15	-0.39	-4.78	-0.39	4.83e-6	Chin dimples;
TGCT	cis	rs735396	0.770	rs1169300	chr12:121431225	G/A	cg02403541	chr12:121454288	C12orf43	0.73	6.5	0.5	1.76e-9	N-glycan levels;
TGCT	cis	rs7246657	0.722	rs2909102	chr19:38167364	C/T	cg18154014	chr19:37997991	ZNF793	-0.67	-4.69	-0.39	6.96e-6	Coronary artery calcification;
TGCT	cis	rs864643	0.812	rs59673755	chr3:39545992	C/G	cg14968361	chr3:39543547	MOBP	0.44	4.63	0.38	9e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs35146811	0.735	rs2272344	chr7:99786819	C/T	cg22906224	chr7:99728672	NA	0.49	4.45	0.37	1.88e-5	Coronary artery disease;
TGCT	cis	rs6087771	0.642	rs6060403	chr20:30221104	C/A	cg21427119	chr20:30132790	HM13	-0.3	-5.05	-0.41	1.53e-6	Subcortical brain region volumes;Putamen volume;
TGCT	cis	rs6964587	0.869	rs7778667	chr7:91520816	C/G	cg17063962	chr7:91808500	NA	-0.86	-9.28	-0.64	6.82e-16	Breast cancer;
TGCT	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg16049864	chr8:95962084	TP53INP1	-0.75	-10.48	-0.69	8.55e-19	Type 2 diabetes;
TGCT	trans	rs77457752	0.525	rs10961293	chr9:13894250	A/G	cg04237666	chr4:83674615	SCD5;MIR575	0.6	6.62	0.51	9.65e-10	Breast cancer;
TGCT	cis	rs2404602	0.735	rs2957614	chr15:76696635	C/T	cg22467129	chr15:76604101	ETFA	-0.45	-4.65	-0.39	8.35e-6	Blood metabolite levels;
TGCT	cis	rs7178572	0.568	rs11072643	chr15:77415508	T/A	cg15453836	chr15:77711506	NA	0.42	4.75	0.39	5.48e-6	Type 2 diabetes;
TGCT	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg13395646	chr4:1353034	KIAA1530	-0.41	-4.72	-0.39	6.23e-6	Longevity;
TGCT	cis	rs3784262	0.643	rs12916872	chr15:58375741	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.42	-6.13	-0.48	1.07e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs9902453	0.935	rs9898424	chr17:28392946	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.74	-6.54	-0.51	1.42e-9	Coffee consumption (cups per day);
TGCT	cis	rs3540	0.533	rs2256097	chr15:90971331	A/T	cg22089800	chr15:90895588	ZNF774	0.76	8.16	0.59	3.24e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs11969893	0.737	rs1854483	chr6:101378117	G/A	cg12253828	chr6:101329408	ASCC3	1.21	6.03	0.48	1.74e-8	Economic and political preferences (immigration/crime);
TGCT	cis	rs56104184	0.830	rs45589039	chr19:49355385	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.84	-10.28	-0.68	2.68e-18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs10838634	1.000	rs7945548	chr11:46900280	A/G	cg18332754	chr11:46939436	LRP4	0.89	4.77	0.39	5.13e-6	Schizophrenia;
TGCT	cis	rs9467773	0.933	rs2024970	chr6:26497520	T/A	cg09904177	chr6:26538194	HMGN4	0.57	5.15	0.42	9.82e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs59751489	chr4:98933802	A/G	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10851411	0.954	rs34643746	chr15:42861567	A/G	cg23803468	chr15:43513504	EPB42	0.27	5.19	0.42	8.38e-7	Glucose homeostasis traits;
TGCT	cis	rs7223966	1.000	rs6504171	chr17:61710010	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	4.76	0.39	5.24e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg00149659	chr3:10157352	C3orf10	0.91	5.89	0.47	3.32e-8	Alzheimer's disease;
TGCT	cis	rs9916302	0.904	rs7503069	chr17:37697128	C/G	cg07936489	chr17:37558343	FBXL20	-0.61	-4.87	-0.4	3.29e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs36051895	0.659	rs12343065	chr9:5083533	C/T	cg02405213	chr9:5042618	JAK2	-0.78	-10.36	-0.68	1.65e-18	Pediatric autoimmune diseases;
TGCT	cis	rs554111	0.891	rs604645	chr1:21043926	T/C	cg08890418	chr1:21044141	KIF17	0.59	6.19	0.49	8.06e-9	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs7666738	0.830	rs34671152	chr4:98978177	C/T	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1775715	0.737	rs2808072	chr10:32205504	A/T	cg14930904	chr10:32216787	ARHGAP12	0.52	5.07	0.41	1.39e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs6964587	1.000	rs35653487	chr7:91745441	C/G	cg22709100	chr7:91322751	NA	0.29	4.66	0.39	8e-6	Breast cancer;
TGCT	cis	rs9549367	0.713	rs510160	chr13:113822481	A/G	cg18105134	chr13:113819100	PROZ	0.47	8.15	0.59	3.4e-13	Platelet distribution width;
TGCT	cis	rs6121246	0.567	rs7361893	chr20:30200751	C/T	cg21427119	chr20:30132790	HM13	-0.39	-5.61	-0.45	1.25e-7	Mean corpuscular hemoglobin;
TGCT	cis	rs67311347	1.000	rs6599094	chr3:40399593	A/G	cg13683864	chr3:40499215	RPL14	-1.02	-10.8	-0.7	1.43e-19	Renal cell carcinoma;
TGCT	trans	rs114540395	0.858	rs7073902	chr10:103291893	A/C	cg10198749	chr1:39920707	MACF1	0.55	7.05	0.53	1.11e-10	Schizophrenia;
TGCT	cis	rs12049351	0.774	rs12125125	chr1:229627666	A/T	cg12130225	chr1:229698885	NA	0.39	4.59	0.38	1.06e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs72615157	0.716	rs75779608	chr7:99768957	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.69	5.42	0.44	3.04e-7	Lung function (FEV1/FVC);
TGCT	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg23758822	chr17:41437982	NA	0.72	6.77	0.52	4.51e-10	Menopause (age at onset);
TGCT	cis	rs514406	0.861	rs11206026	chr1:53281708	G/A	cg24675658	chr1:53192096	ZYG11B	-0.68	-7.71	-0.57	3.45e-12	Monocyte count;
TGCT	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg10047753	chr17:41438598	NA	0.96	9.64	0.65	9.37e-17	Menopause (age at onset);
TGCT	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg22968622	chr17:43663579	NA	1.24	11.44	0.72	3.96e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs3784262	0.527	rs1441815	chr15:58274229	A/C	cg12031962	chr15:58353849	ALDH1A2	-0.36	-5.16	-0.42	9.33e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs6840360	0.967	rs4696105	chr4:152606702	T/G	cg17479576	chr4:152424074	FAM160A1	-0.48	-5.17	-0.42	9.03e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg22857025	chr5:266934	NA	-0.32	-6.58	-0.51	1.18e-9	Breast cancer;
TGCT	cis	rs10838634	1.000	rs10466477	chr11:46782472	C/A	cg18332754	chr11:46939436	LRP4	0.84	4.54	0.38	1.29e-5	Schizophrenia;
TGCT	cis	rs7666738	0.546	rs13148080	chr4:98680947	A/G	cg18180107	chr4:99064573	C4orf37	0.54	4.73	0.39	5.89e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12142240	0.692	rs7529674	chr1:46818508	T/C	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs6121246	0.909	rs7354225	chr20:30296881	C/T	cg13852791	chr20:30311386	BCL2L1	0.68	4.79	0.4	4.6e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs7662987	0.517	rs2602872	chr4:100038996	A/G	cg12011299	chr4:100065546	ADH4	0.39	4.7	0.39	6.79e-6	Smoking initiation;
TGCT	cis	rs2067615	0.524	rs4246257	chr12:107062329	C/T	cg15890332	chr12:107067104	RFX4	0.28	5.56	0.45	1.59e-7	Heart rate;
TGCT	cis	rs6748734	0.817	rs10182575	chr2:241806690	C/T	cg04034577	chr2:241836375	C2orf54	-0.38	-6.02	-0.48	1.85e-8	Urinary metabolites;
TGCT	cis	rs736408	1.000	rs736408	chr3:52835354	C/T	cg07507251	chr3:52567010	NT5DC2	0.45	6.03	0.48	1.78e-8	Bipolar disorder;
TGCT	cis	rs7267979	0.966	rs454723	chr20:25438928	G/C	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2463822	0.583	rs72919477	chr11:62042403	G/C	cg06239285	chr11:62104954	ASRGL1	-0.84	-5.17	-0.42	9.26e-7	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	8.16	0.59	3.1400000000000003e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg13206674	chr6:150067644	NUP43	0.52	4.51	0.38	1.5e-5	Lung cancer;
TGCT	cis	rs911263	0.961	rs1957570	chr14:68729224	A/C	cg18825221	chr14:68749962	RAD51L1	-0.28	-5.64	-0.45	1.1e-7	Primary biliary cholangitis;
TGCT	cis	rs12210905	0.688	rs57075114	chr6:27491169	T/G	cg08851530	chr6:28072375	NA	1.34	6.29	0.49	5.02e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs7726839	0.561	rs3915384	chr5:573395	G/T	cg20362242	chr5:692897	TPPP	0.48	4.59	0.38	1.06e-5	Obesity-related traits;
TGCT	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg24846343	chr22:24311635	DDTL	0.19	4.64	0.38	8.9e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9467711	0.606	rs13212985	chr6:26609989	G/C	cg16898833	chr6:26189333	HIST1H4D	1.26	5.95	0.47	2.59e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7302981	0.967	rs2178173	chr12:50517929	A/G	cg23855989	chr12:50355821	AQP5	-0.3	-4.44	-0.37	2e-5	Systolic blood pressure;
TGCT	cis	rs7677751	0.806	rs1800810	chr4:55094031	C/G	cg17187183	chr4:55093834	PDGFRA	0.53	6.92	0.53	2.19e-10	Corneal astigmatism;
TGCT	cis	rs7819412	0.775	rs4841490	chr8:10936891	T/C	cg21775007	chr8:11205619	TDH	-0.5	-4.61	-0.38	9.83e-6	Triglycerides;
TGCT	cis	rs2251381	0.640	rs2183568	chr21:30484782	A/T	cg24692254	chr21:30365293	RNF160	-0.84	-8.55	-0.61	3.89e-14	Selective IgA deficiency;
TGCT	cis	rs9902453	0.934	rs8079028	chr17:28484234	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	6.9	0.53	2.37e-10	Coffee consumption (cups per day);
TGCT	cis	rs9814567	1.000	rs7619451	chr3:134233238	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-1.04	-8.2	-0.59	2.56e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg11062466	chr8:58055876	NA	0.38	4.5	0.37	1.56e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs1865760	0.865	rs4478388	chr6:25953633	A/G	cg17042849	chr6:26104293	HIST1H4C	-0.52	-4.78	-0.39	4.97e-6	Height;
TGCT	cis	rs6500602	0.627	rs4786494	chr16:4506232	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	7.37	0.55	2.06e-11	Schizophrenia;
TGCT	cis	rs12478296	0.892	rs11893879	chr2:243010411	G/A	cg06360820	chr2:242988706	NA	-0.62	-5.23	-0.43	6.93e-7	Obesity-related traits;
TGCT	cis	rs62380364	0.602	rs591228	chr5:88064809	G/A	cg24804195	chr5:87968844	LOC645323	-0.58	-5.69	-0.45	8.73e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2073300	1.000	rs61080017	chr20:23457569	A/G	cg09953122	chr20:23471693	CST8	-0.59	-4.71	-0.39	6.5e-6	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs782590	0.967	rs1084522	chr2:55843294	A/G	cg18811423	chr2:55921094	PNPT1	0.63	6.81	0.52	3.75e-10	Metabolic syndrome;
TGCT	cis	rs7439150	0.955	rs2227398	chr4:155485138	G/A	cg22130008	chr4:155548532	NA	-0.47	-5.8	-0.46	5.25e-8	Fibrinogen levels;
TGCT	cis	rs6604026	0.524	rs532834	chr1:93468062	A/T	cg17283838	chr1:93427260	FAM69A	0.54	4.58	0.38	1.1e-5	Multiple sclerosis;
TGCT	cis	rs4319547	0.915	rs11058402	chr12:122981053	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.66	-5.32	-0.43	4.71e-7	Body mass index;
TGCT	cis	rs11105298	0.891	rs11105312	chr12:89920733	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.67	-4.91	-0.4	2.78e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg13695892	chr22:41940480	POLR3H	0.89	8.48	0.61	5.62e-14	Vitiligo;
TGCT	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg06873352	chr17:61820015	STRADA	0.58	6.39	0.5	3.01e-9	Prudent dietary pattern;
TGCT	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg11764359	chr7:65958608	NA	-0.54	-4.9	-0.4	2.94e-6	Aortic root size;
TGCT	cis	rs9467773	0.596	rs2451750	chr6:26646579	A/T	cg11502198	chr6:26597334	ABT1	0.55	4.89	0.4	3.05e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10979314	1.000	rs10979314	chr9:111072429	A/G	cg14131431	chr9:110093467	RAD23B	-0.47	-4.56	-0.38	1.23e-5	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs17376456	0.825	rs10038831	chr5:93124115	C/T	cg21475434	chr5:93447410	FAM172A	0.63	4.92	0.4	2.72e-6	Diabetic retinopathy;
TGCT	cis	rs11578119	0.667	rs10919394	chr1:170389788	T/C	cg09767346	chr1:170501363	GORAB	-0.57	-4.7	-0.39	6.94e-6	Male-pattern baldness;
TGCT	cis	rs3892630	0.878	rs6510277	chr19:33183669	C/A	cg22980127	chr19:33182716	NUDT19	0.7	5.18	0.42	8.9e-7	Red blood cell traits;
TGCT	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg03264133	chr6:25882463	NA	-0.64	-5.88	-0.47	3.52e-8	Intelligence (multi-trait analysis);
TGCT	trans	rs4129566	0.641	rs71609829	chr4:174519719	G/A	cg01401824	chr2:159902017	TANC1	0.69	7.24	0.55	4.07e-11	Cocaine dependence;
TGCT	cis	rs62064224	0.702	rs2302277	chr17:30791509	C/G	cg18200150	chr17:30822561	MYO1D	0.6	8.56	0.61	3.73e-14	Schizophrenia;
TGCT	cis	rs797680	0.930	rs2295423	chr1:93581024	T/C	cg17826107	chr1:92977322	EVI5	-0.22	-5.04	-0.41	1.59e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg17264618	chr3:40429014	ENTPD3	0.32	4.57	0.38	1.18e-5	Renal cell carcinoma;
TGCT	cis	rs7714584	1.000	rs75294883	chr5:150196503	T/C	cg22134413	chr5:150180641	NA	1.09	7.71	0.57	3.43e-12	Crohn's disease;
TGCT	cis	rs4654899	1.000	rs3767248	chr1:21276854	A/G	cg01072550	chr1:21505969	NA	-0.49	-7.62	-0.56	5.82e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs3091242	0.933	rs35148262	chr1:25766623	A/G	cg00786635	chr1:25594202	NA	0.56	5.95	0.47	2.54e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg17178900	chr1:205818956	PM20D1	0.41	4.56	0.38	1.22e-5	Menarche (age at onset);
TGCT	cis	rs916888	0.821	rs199509	chr17:44858728	G/A	cg15921436	chr17:44337874	NA	-0.51	-6.96	-0.53	1.77e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs9818758	0.607	rs9990153	chr3:49291883	C/T	cg00383909	chr3:49044727	WDR6	1.28	6.57	0.51	1.23e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.95	7.54	0.56	8.47e-12	Platelet count;
TGCT	cis	rs4919044	0.808	rs12416051	chr10:94788835	C/T	cg05127821	chr10:94822908	CYP26C1	-0.74	-4.83	-0.4	3.95e-6	Coronary artery disease;
TGCT	trans	rs11088226	0.681	rs11700671	chr21:33938621	T/A	cg09050820	chr6:167586206	TCP10L2	0.79	7.04	0.53	1.13e-10	Gastritis;
TGCT	cis	rs1670533	1.000	rs10003009	chr4:1050849	G/A	cg27284194	chr4:1044797	NA	0.68	5.87	0.47	3.76e-8	Recombination rate (females);
TGCT	cis	rs7666738	0.606	rs4699611	chr4:99097492	T/G	cg17366294	chr4:99064904	C4orf37	0.53	4.9	0.4	2.89e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2204008	0.548	rs2320740	chr12:38166421	G/A	cg13010199	chr12:38710504	ALG10B	0.62	4.89	0.4	3.09e-6	Bladder cancer;
TGCT	cis	rs751728	0.717	rs2281816	chr6:33772335	A/G	cg00334056	chr6:33755658	LEMD2	-0.27	-4.91	-0.4	2.85e-6	Crohn's disease;
TGCT	cis	rs2153535	0.580	rs1832101	chr6:8460177	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs986417	0.786	rs2038277	chr14:61083662	G/A	cg27398547	chr14:60952738	C14orf39	1.41	8.43	0.6	7.41e-14	Gut microbiota (bacterial taxa);
TGCT	cis	rs9303401	0.538	rs8078280	chr17:56473132	A/G	cg25039879	chr17:56429692	SUPT4H1	0.55	4.88	0.4	3.26e-6	Cognitive test performance;
TGCT	cis	rs9393777	0.588	rs11967935	chr6:26560672	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.49	-4.52	-0.38	1.41e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg20203395	chr5:56204925	C5orf35	-0.57	-4.8	-0.4	4.5e-6	Initial pursuit acceleration;
TGCT	cis	rs9399135	0.660	rs4440481	chr6:135276696	A/G	cg24558204	chr6:135376177	HBS1L	0.47	5.13	0.42	1.09e-6	Red blood cell count;
TGCT	cis	rs6570726	0.791	rs365869	chr6:145884751	C/T	cg23711669	chr6:146136114	FBXO30	0.89	9.93	0.67	1.82e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6684514	1.000	rs12022194	chr1:156312331	T/A	cg20302342	chr1:156215951	PAQR6	0.36	4.77	0.39	5.1e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs981844	0.740	rs12644642	chr4:154686550	G/C	cg14289246	chr4:154710475	SFRP2	-0.91	-8.31	-0.6	1.38e-13	Response to statins (LDL cholesterol change);
TGCT	cis	rs12510870	0.599	rs66494307	chr4:74448561	G/A	cg05868023	chr4:75230803	EREG	-0.54	-4.76	-0.39	5.33e-6	Iris color (b* coordinate);
TGCT	cis	rs1371867	0.875	rs962452	chr8:101331369	G/A	cg06002616	chr8:101225028	SPAG1	-0.53	-6.21	-0.49	7.16e-9	Atrioventricular conduction;
TGCT	cis	rs6725041	0.819	rs10172865	chr2:213089339	G/A	cg16329650	chr2:213403929	ERBB4	-0.53	-4.52	-0.38	1.44e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs3087591	0.960	rs4435317	chr17:29436512	G/C	cg24425628	chr17:29625626	OMG;NF1	0.47	7.35	0.55	2.37e-11	Hip circumference;
TGCT	cis	rs7681440	1.000	rs7681440	chr4:90756550	C/G	cg26578617	chr4:90757533	SNCA	0.46	4.79	0.4	4.59e-6	Dementia with Lewy bodies;
TGCT	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg13770153	chr20:60521292	NA	-0.54	-7.12	-0.54	7.73e-11	Body mass index;
TGCT	cis	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg02380750	chr20:61661411	NA	0.35	6.27	0.49	5.56e-9	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs40363	0.620	rs1137454	chr16:3533577	C/G	cg05754148	chr16:3507555	NAT15	-0.43	-5.2	-0.42	7.94e-7	Tuberculosis;
TGCT	cis	rs7666738	0.830	rs6846229	chr4:99016546	C/T	cg17366294	chr4:99064904	C4orf37	0.68	7.04	0.53	1.17e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs5760092	0.755	rs3884794	chr22:24251766	C/A	cg15242686	chr22:24348715	GSTTP1	0.49	5.98	0.47	2.17e-8	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs7772486	0.754	rs2328707	chr6:146053498	G/A	cg23711669	chr6:146136114	FBXO30	-0.95	-10.87	-0.7	9.46e-20	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7666738	0.861	rs28829607	chr4:98964325	G/C	cg17366294	chr4:99064904	C4orf37	0.74	7.56	0.56	7.89e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10782582	0.609	rs1630587	chr1:76399787	T/C	cg03433033	chr1:76189801	ACADM	-0.52	-5.13	-0.42	1.07e-6	Daytime sleep phenotypes;
TGCT	cis	rs2439831	0.867	rs12443102	chr15:43932103	G/C	cg19166733	chr15:44192098	FRMD5	-0.24	-4.78	-0.39	4.85e-6	Lung cancer in ever smokers;
TGCT	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg17264618	chr3:40429014	ENTPD3	0.34	4.94	0.41	2.52e-6	Renal cell carcinoma;
TGCT	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.66	0.39	7.92e-6	Prudent dietary pattern;
TGCT	cis	rs3935685	1.000	rs62007780	chr15:78025464	G/T	cg25212270	chr15:78015279	NA	0.31	6.23	0.49	6.71e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs9910055	0.540	rs609292	chr17:42180436	G/A	cg19774624	chr17:42201019	HDAC5	0.73	7.1	0.54	8.3e-11	Total body bone mineral density;
TGCT	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg17554472	chr22:41940697	POLR3H	0.6	5.34	0.43	4.31e-7	Vitiligo;
TGCT	cis	rs9787249	0.957	rs2274949	chr1:40221067	G/A	cg19912559	chr1:40204330	PPIE	0.47	5.52	0.44	1.88e-7	Blood protein levels;
TGCT	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg25811766	chr13:21894605	NA	0.32	4.53	0.38	1.36e-5	White matter hyperintensity burden;
TGCT	cis	rs7095607	0.606	rs6480312	chr10:69957845	C/T	cg18986048	chr10:69913749	MYPN	0.57	5.92	0.47	2.89e-8	Lung function (FVC);
TGCT	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.39	-5.3	-0.43	5.09e-7	Lymphocyte counts;
TGCT	cis	rs62244186	0.659	rs1806579	chr3:44509281	T/C	cg21672276	chr3:44754072	ZNF502	-0.41	-4.66	-0.39	7.99e-6	Depressive symptoms;
TGCT	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg23302884	chr18:44338147	ST8SIA5	-0.41	-4.68	-0.39	7.26e-6	Personality dimensions;
TGCT	cis	rs6700896	0.522	rs67620752	chr1:66157269	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.54	4.44	0.37	1.98e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs7666738	0.830	rs6817645	chr4:99016054	T/C	cg18180107	chr4:99064573	C4orf37	0.54	5.03	0.41	1.7e-6	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg17830980	chr10:43048298	ZNF37B	-0.86	-11.18	-0.71	1.68e-20	Extrinsic epigenetic age acceleration;
TGCT	cis	rs919433	0.617	rs700646	chr2:198608511	C/T	cg00792783	chr2:198669748	PLCL1	0.55	4.89	0.4	3.04e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs7226408	0.842	rs11662247	chr18:34348510	A/G	cg06757138	chr18:34340585	FHOD3	0.29	5.15	0.42	1.01e-6	Obesity-related traits;
TGCT	cis	rs2153535	0.584	rs9502721	chr6:8541379	G/A	cg07606381	chr6:8435919	SLC35B3	0.56	5.16	0.42	9.46e-7	Motion sickness;
TGCT	cis	rs7267979	0.868	rs6107019	chr20:25233985	C/T	cg16686733	chr20:25566563	NINL	0.59	6.06	0.48	1.53e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11642862	0.901	rs77604316	chr16:30921487	G/A	cg01031475	chr16:30004376	HIRIP3	0.23	4.54	0.38	1.34e-5	Tonsillectomy;
TGCT	trans	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.83	8.71	0.62	1.65e-14	Body mass index;
TGCT	cis	rs8017423	0.967	rs6575120	chr14:90725094	C/T	cg04374321	chr14:90722782	PSMC1	0.73	7.63	0.57	5.38e-12	Mortality in heart failure;
TGCT	cis	rs7267979	1.000	rs2257988	chr20:25270003	T/C	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg11764359	chr7:65958608	NA	-0.57	-5.25	-0.43	6.27e-7	Aortic root size;
TGCT	cis	rs916888	0.610	rs199453	chr17:44800946	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.59	4.61	0.38	9.8200000000000008e-06	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg24549020	chr5:56110836	MAP3K1	0.65	5.51	0.44	2.01e-7	Initial pursuit acceleration;
TGCT	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg17554472	chr22:41940697	POLR3H	-0.49	-5.17	-0.42	9.2e-7	Vitiligo;
TGCT	cis	rs17376456	0.825	rs10051878	chr5:93064164	T/G	cg21475434	chr5:93447410	FAM172A	0.63	4.77	0.39	5.03e-6	Diabetic retinopathy;
TGCT	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg11965913	chr1:205819406	PM20D1	0.51	7.19	0.54	5.34e-11	Menarche (age at onset);
TGCT	cis	rs9653442	1.000	rs1160542	chr2:100832155	A/G	cg22139774	chr2:100720529	AFF3	0.42	7.51	0.56	1.02e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs1997103	1.000	rs6968966	chr7:55411356	A/G	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs4689388	0.853	rs13103357	chr4:6294544	A/G	cg25554036	chr4:6271136	WFS1	0.54	7.37	0.55	2.11e-11	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg12310025	chr6:25882481	NA	0.9	9.29	0.64	6.69e-16	Blood metabolite levels;
TGCT	cis	rs950169	0.686	rs12906474	chr15:85109237	A/G	cg17173187	chr15:85201210	NMB	0.45	4.55	0.38	1.24e-5	Schizophrenia;
TGCT	cis	rs8084125	1.000	rs72978665	chr18:74953641	A/G	cg07390210	chr18:74961196	GALR1	0.38	4.63	0.38	9.21e-6	Obesity-related traits;
TGCT	cis	rs2070488	0.965	rs7642472	chr3:38525567	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.88	8.99	0.63	3.5e-15	Electrocardiographic conduction measures;
TGCT	cis	rs259282	0.692	rs17693106	chr19:33125055	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.62	-5.77	-0.46	5.84e-8	Schizophrenia;
TGCT	cis	rs11085466	1.000	rs2292986	chr19:21776332	A/C	cg23026602	chr19:21646605	NA	0.54	4.81	0.4	4.25e-6	Colorectal or endometrial cancer;
TGCT	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg23302884	chr18:44338147	ST8SIA5	-0.41	-4.78	-0.39	4.94e-6	Personality dimensions;
TGCT	cis	rs362296	0.698	rs3135168	chr4:3262699	T/C	cg06533319	chr4:3265114	C4orf44	0.24	4.74	0.39	5.7e-6	Parental longevity (mother's age at death);
TGCT	cis	rs7267979	0.899	rs6115213	chr20:25550372	G/A	cg14121845	chr20:25566513	NINL	0.49	5.36	0.43	3.83e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7586879	0.789	rs17046737	chr2:25127835	C/T	cg01884057	chr2:25150051	NA	0.27	4.72	0.39	6.29e-6	Body mass index;
TGCT	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg11301795	chr4:187892539	NA	-0.34	-5.2	-0.42	7.94e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4389656	0.740	rs412643	chr5:6720715	A/G	cg10857441	chr5:6722123	POLS	-0.22	-4.86	-0.4	3.44e-6	Coronary artery disease;
TGCT	cis	rs6912958	0.781	rs9450752	chr6:88300013	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-5.06	-0.41	1.45e-6	Monocyte percentage of white cells;
TGCT	cis	rs909674	0.514	rs7423	chr22:39781429	C/T	cg02038168	chr22:39784481	NA	-0.73	-6.35	-0.5	3.77e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs10489202	0.632	rs6659713	chr1:168072249	G/T	cg24449463	chr1:168025552	DCAF6	0.49	5.59	0.45	1.36e-7	Schizophrenia;
TGCT	cis	rs7772486	0.790	rs9403750	chr6:146167762	G/A	cg13319975	chr6:146136371	FBXO30	-0.5	-4.49	-0.37	1.61e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3845702	1.000	rs3768839	chr2:180835992	G/A	cg01881094	chr2:180872142	CWC22	-0.66	-5.84	-0.46	4.29e-8	Schizophrenia;
TGCT	cis	rs992157	1.000	rs2292553	chr2:219146803	G/A	cg00012203	chr2:219082015	ARPC2	0.78	8.41	0.6	8.04e-14	Colorectal cancer;
TGCT	cis	rs4253772	0.591	rs9615348	chr22:46729338	C/G	cg24881330	chr22:46731750	TRMU	0.96	4.79	0.4	4.65e-6	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs6840360	0.870	rs7680604	chr4:152469917	C/T	cg17479576	chr4:152424074	FAM160A1	-0.45	-4.88	-0.4	3.15e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7208859	0.623	rs170051	chr17:28914153	G/A	cg14008862	chr17:28927542	LRRC37B2	0.93	5.64	0.45	1.11e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs35306767	0.953	rs35174953	chr10:961191	C/A	cg26597838	chr10:835615	NA	0.66	9.01	0.63	3.04e-15	Eosinophil percentage of granulocytes;
TGCT	cis	rs7552404	0.655	rs5745336	chr1:76273519	G/A	cg22875332	chr1:76189707	ACADM	0.64	6.9	0.53	2.32e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs3087591	0.960	rs2905793	chr17:29470072	C/T	cg24425628	chr17:29625626	OMG;NF1	0.49	7.74	0.57	2.97e-12	Hip circumference;
TGCT	cis	rs9486719	0.857	rs4839833	chr6:96882069	T/C	cg18709589	chr6:96969512	KIAA0776	0.75	6.3	0.49	4.73e-9	Migraine;Coronary artery disease;
TGCT	cis	rs2404602	1.000	rs11072603	chr15:76881138	G/T	cg22467129	chr15:76604101	ETFA	-0.44	-4.86	-0.4	3.41e-6	Blood metabolite levels;
TGCT	cis	rs4727443	0.866	rs13238380	chr7:99629061	C/T	cg13334819	chr7:99746414	C7orf59	0.56	4.71	0.39	6.63e-6	Interstitial lung disease;
TGCT	cis	rs71435601	0.699	rs563290	chr2:21288226	G/A	cg00673290	chr2:21266727	APOB	0.64	4.54	0.38	1.33e-5	Cholesterol, total;
TGCT	trans	rs2727020	0.658	rs10839278	chr11:49450847	G/C	cg03929089	chr4:120376271	NA	-0.77	-9.03	-0.63	2.74e-15	Coronary artery disease;
TGCT	cis	rs5769707	0.839	rs73176988	chr22:49989649	G/T	cg20744362	chr22:50050164	C22orf34	0.27	4.55	0.38	1.25e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs7267979	1.000	rs2027003	chr20:25350498	A/G	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs637571	0.522	rs538954	chr11:65756808	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.68	6.74	0.52	5.42e-10	Eosinophil percentage of white cells;
TGCT	cis	rs3820928	0.874	rs1949807	chr2:227891861	A/G	cg11843606	chr2:227700838	RHBDD1	-0.5	-4.63	-0.38	9.22e-6	Pulmonary function;
TGCT	cis	rs478304	0.651	rs4014192	chr11:65498915	C/T	cg27068330	chr11:65405492	SIPA1	-0.94	-9.4	-0.65	3.49e-16	Acne (severe);
TGCT	cis	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg16624210	chr5:671434	TPPP	0.45	4.92	0.4	2.71e-6	Obesity-related traits;
TGCT	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg06238570	chr21:40685208	BRWD1	-0.6	-6.3	-0.49	4.8e-9	Menarche (age at onset);
TGCT	cis	rs13082711	0.554	rs73055750	chr3:27401505	C/G	cg02860705	chr3:27208620	NA	0.42	5.81	0.46	4.86e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs7940866	0.874	rs10894306	chr11:130873882	A/C	cg12179176	chr11:130786555	SNX19	0.58	5.69	0.46	8.66e-8	Schizophrenia;
TGCT	cis	rs1008375	0.931	rs6813374	chr4:17649494	T/C	cg16339924	chr4:17578868	LAP3	0.67	5.55	0.45	1.68e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs986417	1.000	rs1956554	chr14:60963775	C/T	cg27398547	chr14:60952738	C14orf39	-1.49	-10.81	-0.7	1.38e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs629922	0.642	rs615119	chr11:114072224	T/C	cg01914181	chr11:114070210	ZBTB16	0.27	4.74	0.39	5.65e-6	Paneth cell defects in Crohn's disease;
TGCT	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg11941060	chr3:133502564	NA	-0.29	-6.18	-0.49	8.57e-9	Iron status biomarkers;
TGCT	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.0	-0.47	2.01e-8	Alzheimer's disease;
TGCT	cis	rs74054849	0.717	rs61348093	chr1:15922742	T/G	cg05660106	chr1:15850417	CASP9	0.94	4.83	0.4	3.93e-6	Alcoholic chronic pancreatitis;
TGCT	cis	rs11190604	1.000	rs12355721	chr10:102244911	C/T	cg16342193	chr10:102329863	NA	-0.4	-5.34	-0.43	4.36e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs208520	0.789	rs9351549	chr6:66871851	A/G	cg07460842	chr6:66804631	NA	-0.91	-9.43	-0.65	2.99e-16	Exhaled nitric oxide output;
TGCT	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg20891558	chr2:74357851	NA	0.64	9.46	0.65	2.56e-16	Gestational age at birth (maternal effect);
TGCT	cis	rs916888	0.531	rs183211	chr17:44788310	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.6	4.66	0.39	8.02e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	trans	rs17450420	1.000	rs74240931	chr13:105056429	G/A	cg14737571	chr13:113436568	ATP11A	0.61	6.64	0.51	8.8e-10	Esophageal cancer  (alcohol interaction);
TGCT	cis	rs877282	1.000	rs7100358	chr10:773681	G/A	cg17470449	chr10:769945	NA	0.3	4.79	0.39	4.71e-6	Uric acid levels;
TGCT	cis	rs4478858	0.647	rs11581476	chr1:31717675	C/T	cg00250761	chr1:31883323	NA	-0.28	-4.97	-0.41	2.2e-6	Alcohol dependence;
TGCT	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg09359103	chr1:154839909	KCNN3	-0.67	-12.84	-0.76	1.57e-24	Prostate cancer;
TGCT	cis	rs8180040	0.966	rs11711824	chr3:47468261	C/T	cg27129171	chr3:47204927	SETD2	0.66	7.98	0.58	8.4e-13	Colorectal cancer;
TGCT	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg23708337	chr7:1209742	NA	0.55	5.47	0.44	2.34e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7296418	0.619	rs7139321	chr12:123719528	T/G	cg00376283	chr12:123451042	ABCB9	0.7	6.27	0.49	5.58e-9	Platelet count;
TGCT	cis	rs739496	0.615	rs7962138	chr12:112180177	A/G	cg10833066	chr12:111807467	FAM109A	0.37	5.02	0.41	1.74e-6	Platelet count;
TGCT	cis	rs7666738	0.830	rs11938686	chr4:98964470	A/G	cg18180107	chr4:99064573	C4orf37	0.55	5.0	0.41	1.9e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs782590	0.967	rs17278044	chr2:55748217	G/C	cg03859395	chr2:55845619	SMEK2	0.93	11.51	0.72	2.7e-21	Metabolic syndrome;
TGCT	cis	rs67072384	1.000	rs11235579	chr11:72453095	A/G	cg03713592	chr11:72463424	ARAP1	-0.93	-4.66	-0.39	7.89e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs6558530	0.932	rs7846610	chr8:1706675	C/T	cg09410841	chr8:1729607	CLN8	0.89	9.79	0.66	4.05e-17	Systolic blood pressure;
TGCT	trans	rs208520	0.802	rs851600	chr6:66893754	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.95	-10.32	-0.68	2.12e-18	Exhaled nitric oxide output;
TGCT	cis	rs7208859	0.623	rs11657662	chr17:29076347	A/G	cg14008862	chr17:28927542	LRRC37B2	-0.77	-4.61	-0.38	9.76e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs8013055	0.898	rs8014913	chr14:105977313	T/C	cg25008857	chr14:105974488	NA	0.27	4.65	0.39	8.35e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs7267979	0.586	rs6050445	chr20:25195394	C/T	cg16686733	chr20:25566563	NINL	0.55	5.52	0.44	1.88e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.6	-6.01	-0.48	1.91e-8	Bipolar disorder;
TGCT	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.5	4.79	0.39	4.74e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs42648	0.748	rs10225744	chr7:89946003	T/C	cg25739043	chr7:89950458	NA	-0.63	-6.04	-0.48	1.64e-8	Homocysteine levels;
TGCT	cis	rs7666738	0.791	rs10033211	chr4:98995624	T/A	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6912958	0.781	rs1051148	chr6:88221892	T/G	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.91	-0.4	2.78e-6	Monocyte percentage of white cells;
TGCT	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg13342137	chr4:2252803	MXD4	0.17	4.58	0.38	1.09e-5	Obesity-related traits;
TGCT	cis	rs3087591	0.708	rs2107359	chr17:29697223	A/T	cg24425628	chr17:29625626	OMG;NF1	0.39	5.69	0.46	8.47e-8	Hip circumference;
TGCT	cis	rs7312933	0.558	rs1669936	chr12:42813509	C/A	cg19980929	chr12:42632907	YAF2	-0.4	-5.7	-0.46	8.24e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs2723064	0.516	rs2901749	chr2:65292570	G/T	cg05010058	chr2:65284262	CEP68	0.47	4.48	0.37	1.66e-5	Atrial fibrillation;
TGCT	trans	rs7088591	0.702	rs10491208	chr10:59703352	C/G	cg05779219	chr20:23032166	NA	1.2	7.39	0.55	1.95e-11	Blood pressure;
TGCT	cis	rs3812831	0.695	rs8000778	chr13:114944310	T/C	cg15513719	chr13:114904418	NA	0.36	4.48	0.37	1.69e-5	Schizophrenia;
TGCT	cis	rs12477438	0.520	rs4588238	chr2:99749350	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	13.05	0.76	4.93e-25	Chronic sinus infection;
TGCT	cis	rs2594989	0.887	rs4684071	chr3:11443084	C/G	cg00170343	chr3:11313890	ATG7	0.72	5.35	0.43	4.03e-7	Circulating chemerin levels;
TGCT	cis	rs4727027	0.522	rs6956736	chr7:148893472	G/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.61	4.93	0.4	2.59e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs12142240	0.730	rs56030283	chr1:46823093	C/G	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs1801239	1.000	rs79801018	chr10:16937659	T/C	cg00939682	chr10:16933505	CUBN	0.48	4.56	0.38	1.23e-5	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin excretion;
TGCT	cis	rs9436747	0.653	rs1751479	chr1:66016205	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	-0.5	-4.71	-0.39	6.48e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs4499344	0.658	rs10415040	chr19:33052706	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.66	-5.64	-0.45	1.08e-7	Mean platelet volume;
TGCT	cis	rs13191362	0.935	rs67889271	chr6:163045753	T/G	cg21926612	chr6:163149169	PACRG;PARK2	1.07	8.5	0.61	5.17e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs6909279	0.648	rs6919923	chr6:151849670	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	-0.49	-4.44	-0.37	1.95e-5	Bone mineral density;
TGCT	cis	rs208520	1.000	rs208537	chr6:66963544	A/G	cg07460842	chr6:66804631	NA	-0.83	-7.52	-0.56	9.8e-12	Exhaled nitric oxide output;
TGCT	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	5.02	0.41	1.78e-6	Prudent dietary pattern;
TGCT	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg09060608	chr5:178986726	RUFY1	0.63	7.96	0.58	9.3e-13	Lung cancer;
TGCT	cis	rs7586879	0.616	rs10206196	chr2:25137323	T/C	cg15423357	chr2:25149977	NA	0.51	5.06	0.41	1.44e-6	Body mass index;
TGCT	cis	rs6121246	0.909	rs6060960	chr20:30394517	G/T	cg13852791	chr20:30311386	BCL2L1	-0.8	-6.26	-0.49	5.77e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs66486766	1	rs66486766	chr15:84806060	G/A	cg17173187	chr15:85201210	NMB	0.49	5.13	0.42	1.1e-6	Bipolar disorder lithium response (categorical) or schizophrenia;
TGCT	cis	rs7523050	0.643	rs35662800	chr1:109400816	C/A	cg08274380	chr1:109419600	GPSM2	1.3	6.39	0.5	2.99e-9	Fat distribution (HIV);
TGCT	cis	rs992157	0.835	rs6729058	chr2:219148369	G/A	cg00012203	chr2:219082015	ARPC2	-0.8	-7.98	-0.58	8.26e-13	Colorectal cancer;
TGCT	cis	rs9902453	0.933	rs8080343	chr17:28456758	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	5.41	0.44	3.13e-7	Coffee consumption (cups per day);
TGCT	cis	rs709400	0.633	rs8019578	chr14:103977724	A/G	cg26031613	chr14:104095156	KLC1	0.86	9.54	0.65	1.61e-16	Body mass index;
TGCT	cis	rs7914558	1.000	rs11191539	chr10:104819770	A/G	cg04362960	chr10:104952993	NT5C2	0.61	5.46	0.44	2.44e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs72700829	0.593	rs80350997	chr1:150992010	G/A	cg00666978	chr1:150947442	LASS2	0.9	4.62	0.38	9.37e-6	Schizophrenia;
TGCT	cis	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg06636001	chr8:8085503	FLJ10661	0.59	5.25	0.43	6.51e-7	Mood instability;
TGCT	cis	rs732765	0.648	rs8185	chr14:75408789	T/C	cg15890469	chr14:75408846	PGF	-0.26	-4.64	-0.38	8.68e-6	Non-small cell lung cancer;
TGCT	cis	rs4722166	0.695	rs6946509	chr7:22809490	T/C	cg26061582	chr7:22766209	IL6	0.48	6.04	0.48	1.64e-8	Lung cancer;
TGCT	cis	rs2115630	0.755	rs7169629	chr15:85191274	C/G	cg11189052	chr15:85197271	WDR73	0.66	6.82	0.52	3.6e-10	P wave terminal force;
TGCT	cis	rs7666738	0.791	rs7657399	chr4:98851861	T/C	cg18180107	chr4:99064573	C4orf37	0.55	5.14	0.42	1.03e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6684514	0.961	rs72710222	chr1:156285995	T/C	cg16558208	chr1:156270281	VHLL	0.48	9.6	0.65	1.19e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs9467773	0.620	rs2451741	chr6:26629404	A/G	cg09904177	chr6:26538194	HMGN4	0.67	6.48	0.5	1.94e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs4761974	1.000	rs10876176	chr12:51811832	C/G	cg09925572	chr12:51518419	TFCP2	0.47	4.92	0.4	2.69e-6	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
TGCT	cis	rs739496	0.579	rs7970847	chr12:112281493	T/C	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg23982607	chr1:1823379	GNB1	0.54	8.15	0.59	3.29e-13	Body mass index;
TGCT	cis	rs1372520	0.564	rs2737011	chr4:90746219	T/C	cg14346243	chr4:90757452	SNCA	-0.6	-4.87	-0.4	3.27e-6	Neuroticism;
TGCT	cis	rs7914558	0.966	rs10786719	chr10:104637992	C/T	cg04362960	chr10:104952993	NT5C2	-0.53	-4.7	-0.39	6.9e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs2243480	1.000	rs160646	chr7:65556280	C/T	cg07424592	chr7:64974309	NA	1.26	8.15	0.59	3.36e-13	Diabetic kidney disease;
TGCT	cis	rs447735	0.565	rs10852626	chr16:89914633	T/G	cg08627397	chr16:89984028	MC1R	-0.35	-5.42	-0.44	3.04e-7	Hemoglobin concentration;
TGCT	cis	rs6831352	0.879	rs1230154	chr4:99988659	C/T	cg12011299	chr4:100065546	ADH4	0.41	5.06	0.41	1.49e-6	Alcohol dependence;
TGCT	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg00814883	chr7:100076585	TSC22D4	-0.9	-9.56	-0.65	1.5e-16	Platelet count;
TGCT	cis	rs838147	0.534	rs2638280	chr19:49209318	G/A	cg13540341	chr19:49222985	MAMSTR	-0.36	-4.76	-0.39	5.33e-6	Dietary macronutrient intake;
TGCT	cis	rs9473924	0.632	rs9473926	chr6:50835815	C/T	cg14470998	chr6:50812995	TFAP2B	0.49	4.46	0.37	1.84e-5	Body mass index;
TGCT	cis	rs5167	0.743	rs57204168	chr19:45496776	A/G	cg09555818	chr19:45449301	APOC2	0.23	4.93	0.41	2.53e-6	Blood protein levels;
TGCT	cis	rs514406	0.763	rs7535088	chr1:53215042	A/G	cg01802117	chr1:53393560	SCP2	0.44	5.26	0.43	6.2e-7	Monocyte count;
TGCT	cis	rs986417	1.000	rs12587609	chr14:60928850	C/G	cg27398547	chr14:60952738	C14orf39	1.39	10.61	0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs1059312	0.545	rs12303387	chr12:129276733	C/T	cg09035930	chr12:129282057	SLC15A4	-0.51	-7.53	-0.56	9.02e-12	Systemic lupus erythematosus;
TGCT	cis	rs67311347	1.000	rs67680017	chr3:40533164	C/T	cg13683864	chr3:40499215	RPL14	-1.16	-10.98	-0.7	5.08e-20	Renal cell carcinoma;
TGCT	cis	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg08045932	chr20:61659980	NA	0.49	9.25	0.64	8.4e-16	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9952991	0.566	rs11875687	chr18:12843137	T/C	cg23598886	chr18:12777645	NA	-0.54	-4.73	-0.39	6.11e-6	Inflammatory skin disease;
TGCT	cis	rs4478037	0.558	rs59139633	chr3:33080190	G/T	cg19404215	chr3:33155277	CRTAP	1.04	4.95	0.41	2.36e-6	Major depressive disorder;
TGCT	cis	rs709400	0.628	rs3783394	chr14:103858673	G/A	cg12935359	chr14:103987150	CKB	-0.36	-5.38	-0.43	3.63e-7	Body mass index;
TGCT	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg27436995	chr16:743998	FBXL16	-0.46	-5.08	-0.42	1.35e-6	Height;
TGCT	cis	rs9467773	0.620	rs2451744	chr6:26633463	G/T	cg05738196	chr6:26577821	NA	0.88	11.22	0.71	1.33e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs57994353	0.793	rs33982662	chr9:139324737	C/A	cg13741927	chr9:139327495	INPP5E	-0.27	-6.27	-0.49	5.6e-9	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs12368653	0.666	rs1050045	chr12:58115271	A/G	cg12615879	chr12:58013172	SLC26A10	0.47	5.77	0.46	5.9e-8	Multiple sclerosis;
TGCT	cis	rs7698623	0.850	rs7676119	chr4:88780778	G/A	cg27387453	chr4:88533842	DSPP	-0.61	-4.6	-0.38	1.03e-5	Cardiovascular disease risk factors;
TGCT	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg22920501	chr2:26401640	FAM59B	0.81	6.36	0.5	3.52e-9	Gut microbiome composition (summer);
TGCT	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg00343986	chr7:65444356	GUSB	0.26	6.14	0.48	1.02e-8	Aortic root size;
TGCT	cis	rs12681288	0.862	rs4735981	chr8:1018437	A/C	cg21347738	chr8:1310380	NA	-0.22	-4.55	-0.38	1.26e-5	Schizophrenia;
TGCT	cis	rs7927771	0.832	rs10838697	chr11:47384484	T/A	cg21462715	chr11:47870315	NUP160	0.57	4.63	0.38	9.08e-6	Subjective well-being;
TGCT	cis	rs1799949	0.931	rs9891977	chr17:41437398	A/G	cg10047753	chr17:41438598	NA	0.8	7.34	0.55	2.48e-11	Menopause (age at onset);
TGCT	cis	rs10779751	1.000	rs11121702	chr1:11293147	C/T	cg08854313	chr1:11322531	MTOR	0.97	8.94	0.63	4.53e-15	Body mass index;
TGCT	cis	rs1448094	0.556	rs11614513	chr12:86167756	G/C	cg02569458	chr12:86230093	RASSF9	0.38	4.49	0.37	1.61e-5	Major depressive disorder;
TGCT	cis	rs3741404	0.609	rs635139	chr11:63872210	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.72	7.39	0.55	1.89e-11	Platelet count;
TGCT	trans	rs208515	0.525	rs10944863	chr6:66676238	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.92	10.09	0.67	7.45e-18	Exhaled nitric oxide levels;
TGCT	trans	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg17830980	chr10:43048298	ZNF37B	-0.81	-10.13	-0.67	6.19e-18	Extrinsic epigenetic age acceleration;
TGCT	cis	rs9914544	0.689	rs8073236	chr17:18787182	C/G	cg26378065	chr17:18585709	ZNF286B	0.52	4.72	0.39	6.3e-6	Educational attainment (years of education);
TGCT	trans	rs57221529	0.608	rs11749927	chr5:668842	C/T	cg25482853	chr8:67687455	SGK3	1.13	10.5	0.69	7.9e-19	Lung disease severity in cystic fibrosis;
TGCT	cis	rs4778581	0.864	rs11634397	chr15:80432222	C/T	cg00975263	chr15:81073649	KIAA1199	0.24	4.67	0.39	7.77e-6	Reticulocyte count;Reticulocyte fraction of red cells;
TGCT	cis	rs2295359	0.892	rs17375018	chr1:67655147	A/G	cg08029281	chr1:67600428	NA	-0.42	-4.78	-0.39	4.92e-6	Psoriasis;
TGCT	cis	rs7010267	0.776	rs4407910	chr8:119917117	A/G	cg17171407	chr8:119960777	TNFRSF11B	-0.28	-4.98	-0.41	2.1e-6	Total body bone mineral density (age 45-60);
TGCT	cis	rs62244186	0.659	rs9819766	chr3:44520980	G/C	cg04389838	chr3:44770851	ZNF501	-0.38	-4.94	-0.41	2.45e-6	Depressive symptoms;
TGCT	cis	rs16866061	0.926	rs1523919	chr2:225403615	G/A	cg12698349	chr2:225449008	CUL3	0.98	9.17	0.64	1.27e-15	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.4	5.88	0.47	3.51e-8	Schizophrenia;
TGCT	cis	rs936229	0.656	rs2290572	chr15:75130573	A/G	cg10253484	chr15:75165896	SCAMP2	-0.51	-4.79	-0.4	4.65e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
TGCT	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg20276088	chr3:133502917	NA	-0.28	-5.95	-0.47	2.51e-8	Iron status biomarkers;
TGCT	cis	rs36022378	0.504	rs4688688	chr3:50042690	C/G	cg09562331	chr3:50596116	C3orf18	-0.27	-4.99	-0.41	2e-6	Diastolic blood pressure;
TGCT	cis	rs1552244	0.832	rs73024575	chr3:10198200	C/G	cg00149659	chr3:10157352	C3orf10	1.05	5.81	0.46	4.95e-8	Alzheimer's disease;
TGCT	cis	rs1008375	0.932	rs10029173	chr4:17659598	C/T	cg16339924	chr4:17578868	LAP3	-0.67	-5.48	-0.44	2.23e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs826838	1.000	rs4768328	chr12:39129315	C/T	cg26384229	chr12:38710491	ALG10B	-0.86	-7.7	-0.57	3.65e-12	Heart rate;
TGCT	cis	rs7220711	1.000	rs7220711	chr17:41789965	C/T	cg26893861	chr17:41843967	DUSP3	-0.51	-4.56	-0.38	1.21e-5	Bone mineral density (spine);Bone mineral density (hip);
TGCT	cis	rs4077515	0.901	rs34826348	chr9:139281570	A/C	cg13741927	chr9:139327495	INPP5E	-0.2	-4.69	-0.39	7.19e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs1048238	0.506	rs598371	chr1:16212739	G/A	cg22431228	chr1:16359049	CLCNKA	0.22	4.44	0.37	1.93e-5	Systolic blood pressure;
TGCT	cis	rs1055129	0.537	rs2467100	chr17:73949038	C/G	cg02678768	chr17:74002944	EVPL	0.24	4.59	0.38	1.06e-5	White matter hyperintensity burden;
TGCT	cis	rs12136530	0.577	rs4912002	chr1:19793402	G/T	cg18923740	chr1:19971790	NBL1	0.44	5.45	0.44	2.63e-7	Lead levels in blood;
TGCT	cis	rs7666738	0.830	rs13138059	chr4:99050430	A/G	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9486715	1.000	rs6905737	chr6:97066659	A/T	cg06623918	chr6:96969491	KIAA0776	-1.08	-13.49	-0.77	4.31e-26	Headache;
TGCT	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg15691649	chr6:25882328	NA	-0.35	-4.55	-0.38	1.25e-5	Blood metabolite levels;
TGCT	cis	rs4824093	0.610	rs73441745	chr22:50237606	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.07	-6.51	-0.5	1.67e-9	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs17331151	0.573	rs11718060	chr3:52875546	G/A	cg07884673	chr3:53033167	SFMBT1	0.5	5.62	0.45	1.19e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs7666738	0.830	rs13108705	chr4:99044438	T/C	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7010267	0.805	rs6992497	chr8:119980069	A/G	cg17171407	chr8:119960777	TNFRSF11B	0.32	6.29	0.49	4.95e-9	Total body bone mineral density (age 45-60);
TGCT	cis	rs3008870	0.958	rs12143044	chr1:67460054	A/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.1	-11.8	-0.73	5.15e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs11167764	1.000	rs10057309	chr5:141479870	T/C	cg02659431	chr5:141694439	SPRY4	-0.22	-4.76	-0.39	5.36e-6	Crohn's disease;
TGCT	trans	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg25482853	chr8:67687455	SGK3	1.2	10.44	0.68	1.1e-18	Obesity-related traits;
TGCT	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg19723775	chr5:179050963	HNRNPH1	-0.52	-5.33	-0.43	4.56e-7	Lung cancer;
TGCT	cis	rs9810089	0.934	rs684195	chr3:135993599	A/C	cg12473912	chr3:136751656	NA	0.35	4.9	0.4	2.9e-6	Gestational age at birth (child effect);
TGCT	cis	rs2239547	0.603	rs59989280	chr3:53098875	T/C	cg11645453	chr3:52864694	ITIH4	0.3	4.83	0.4	3.88e-6	Schizophrenia;
TGCT	cis	rs7552404	0.727	rs1144336	chr1:76277421	C/A	cg03433033	chr1:76189801	ACADM	0.66	6.9	0.53	2.36e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9733	0.596	rs2275236	chr1:150669952	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.39	-5.04	-0.41	1.58e-6	Tonsillectomy;
TGCT	cis	rs7959452	0.649	rs4761239	chr12:69776886	T/A	cg11871910	chr12:69753446	YEATS4	0.85	9.02	0.63	2.92e-15	Blood protein levels;
TGCT	cis	rs6490294	0.904	rs7956483	chr12:112424570	A/G	cg10833066	chr12:111807467	FAM109A	0.35	5.13	0.42	1.09e-6	Mean platelet volume;
TGCT	cis	rs9330316	0.591	rs747445	chr2:110352673	G/A	cg03552103	chr2:110373002	SEPT10;ANKRD57	-0.39	-4.5	-0.38	1.51e-5	Schizophrenia;
TGCT	cis	rs79387448	0.655	rs75579337	chr2:102917302	C/A	cg09003973	chr2:102972529	NA	1.34	8.26	0.6	1.89e-13	Gut microbiota (bacterial taxa);
TGCT	cis	rs6484504	0.512	rs2761594	chr11:31318244	A/G	cg26647111	chr11:31128758	NA	0.32	4.64	0.38	8.82e-6	Red blood cell count;
TGCT	cis	rs858239	0.600	rs2072369	chr7:23146189	A/G	cg05602783	chr7:23145260	KLHL7	-0.67	-5.68	-0.45	9.25e-8	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs4372836	0.504	rs6760186	chr2:29087274	T/C	cg09522027	chr2:28974177	PPP1CB	-0.57	-5.63	-0.45	1.14e-7	Body mass index;
TGCT	cis	rs7647973	0.593	rs55997059	chr3:49858661	A/T	cg05785598	chr3:49045655	WDR6	-0.42	-5.23	-0.42	7.11e-7	Menarche (age at onset);
TGCT	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	8.55	0.61	3.84e-14	Platelet count;
TGCT	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg06618935	chr21:46677482	NA	-0.37	-5.56	-0.45	1.58e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7772486	0.875	rs7739371	chr6:146424353	C/G	cg05347473	chr6:146136440	FBXO30	0.56	5.22	0.42	7.31e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6964587	1.000	rs2097739	chr7:91711466	C/T	cg17063962	chr7:91808500	NA	0.88	9.65	0.66	8.73e-17	Breast cancer;
TGCT	cis	rs7772486	0.875	rs2748485	chr6:146332421	T/C	cg13319975	chr6:146136371	FBXO30	-0.5	-4.48	-0.37	1.67e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs67478160	0.704	rs12894254	chr14:104290949	G/C	cg26031613	chr14:104095156	KLC1	-0.63	-6.53	-0.51	1.56e-9	Schizophrenia;
TGCT	cis	rs360798	0.512	rs1420018	chr2:63112500	A/G	cg17519650	chr2:63277830	OTX1	0.59	4.93	0.4	2.57e-6	Coronary artery disease;
TGCT	cis	rs10514758	0.744	rs72947718	chr3:114880959	T/G	cg05943254	chr3:114009756	NA	-0.76	-4.53	-0.38	1.39e-5	Urate levels in obese individuals;
TGCT	cis	rs6831352	0.918	rs17218239	chr4:100057020	G/A	cg12011299	chr4:100065546	ADH4	-0.4	-4.88	-0.4	3.26e-6	Alcohol dependence;
TGCT	cis	rs4273100	0.573	rs4924783	chr17:19253981	A/G	cg01534423	chr17:18965556	NA	-0.79	-7.62	-0.56	5.53e-12	Schizophrenia;
TGCT	cis	rs9733	0.791	rs11800059	chr1:150651175	C/T	cg13175981	chr1:150552382	MCL1	0.43	4.79	0.4	4.64e-6	Tonsillectomy;
TGCT	cis	rs832540	0.931	rs832529	chr5:56229288	C/T	cg12311346	chr5:56204834	C5orf35	-0.43	-4.58	-0.38	1.11e-5	Coronary artery disease;
TGCT	cis	rs6669919	0.967	rs894983	chr1:211675279	T/C	cg26515805	chr1:211431828	RCOR3	-0.39	-4.62	-0.38	9.32e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs3782455	1.000	rs79001482	chr12:114403542	T/C	cg10631684	chr12:113795897	PLBD2	-0.7	-4.61	-0.38	1e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	trans	rs1814175	0.781	rs1851872	chr11:50009770	A/G	cg03929089	chr4:120376271	NA	-0.72	-8.55	-0.61	3.8e-14	Height;
TGCT	cis	rs1901167	0.908	rs2876849	chr5:40979790	A/T	cg02441090	chr5:41871058	OXCT1	-0.31	-4.61	-0.38	9.86e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs6504950	0.720	rs9910653	chr17:52992268	C/T	cg07707039	chr17:53042137	COX11	0.27	4.66	0.39	8.15e-6	Breast cancer;
TGCT	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.4	-6.92	-0.53	2.12e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs1538970	0.924	rs1006216	chr1:45909994	A/G	cg05343316	chr1:45956843	TESK2	0.76	6.19	0.49	7.93e-9	Platelet count;
TGCT	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg16325326	chr1:53192061	ZYG11B	-0.89	-13.12	-0.76	3.31e-25	Monocyte count;
TGCT	cis	rs2075165	0.870	rs12128955	chr1:156243821	C/T	cg20302342	chr1:156215951	PAQR6	0.38	5.62	0.45	1.22e-7	Tonsillectomy;
TGCT	cis	rs3015497	0.587	rs1353204	chr14:51081515	C/T	cg04730355	chr14:51134070	SAV1	-0.58	-5.41	-0.44	3.15e-7	Mean platelet volume;
TGCT	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.59	6.01	0.47	1.92e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.753	rs34164013	chr4:98976333	A/G	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10804591	1.000	rs729208	chr3:129339642	C/G	cg07730360	chr3:128845626	NA	0.2	4.66	0.39	7.91e-6	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Hip circumference adjusted for BMI;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs11585357	0.843	rs72633805	chr1:17617471	A/T	cg08277548	chr1:17600880	PADI3	-0.96	-9.78	-0.66	4.35e-17	Hair shape;
TGCT	cis	rs6665290	0.904	rs11587443	chr1:227187896	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.99	-20.27	-0.88	3.54e-41	Myeloid white cell count;
TGCT	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg24578937	chr1:2090814	PRKCZ	0.26	6.95	0.53	1.8e-10	Height;
TGCT	trans	rs3780486	0.834	rs75443249	chr9:33149207	A/G	cg20290983	chr6:43655470	MRPS18A	1.12	10.71	0.69	2.41e-19	IgG glycosylation;
TGCT	cis	rs8072100	0.817	rs9892497	chr17:45545919	G/A	cg08085267	chr17:45401833	C17orf57	-0.47	-5.14	-0.42	1.05e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs1801251	1.000	rs11555646	chr2:233599904	A/C	cg25237894	chr2:233734115	C2orf82	0.33	5.94	0.47	2.73e-8	Coronary artery disease;
TGCT	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg13206674	chr6:150067644	NUP43	-0.52	-4.51	-0.38	1.5e-5	Lung cancer;
TGCT	cis	rs7226408	0.802	rs59419623	chr18:34450368	G/A	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs4595586	1.000	rs3803020	chr12:39233771	A/G	cg10518543	chr12:38710700	ALG10B	-0.51	-5.09	-0.42	1.31e-6	Morning vs. evening chronotype;
TGCT	cis	rs11098499	0.863	rs3775848	chr4:120447724	C/T	cg09307838	chr4:120376055	NA	0.69	6.53	0.51	1.49e-9	Corneal astigmatism;
TGCT	cis	rs7208859	0.623	rs7503335	chr17:29073962	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7104764	1.000	rs7395328	chr11:242624	T/A	cg18336825	chr11:236787	PSMD13;SIRT3	1.07	11.19	0.71	1.61e-20	Menarche (age at onset);
TGCT	cis	rs6840360	0.582	rs6535796	chr4:152304728	G/A	cg17479576	chr4:152424074	FAM160A1	-0.55	-5.79	-0.46	5.42e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2895526	0.740	rs7072694	chr10:12692577	G/A	cg18283737	chr10:12085149	UPF2	0.46	4.53	0.38	1.38e-5	Headache;
TGCT	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg06481639	chr22:41940642	POLR3H	0.69	5.92	0.47	2.95e-8	Vitiligo;
TGCT	cis	rs10771431	0.810	rs10771418	chr12:9358995	A/G	cg08997352	chr12:9597637	DDX12	-0.29	-6.11	-0.48	1.2e-8	Breast size;
TGCT	cis	rs7772486	0.875	rs1412081	chr6:146409733	A/G	cg23711669	chr6:146136114	FBXO30	0.89	9.47	0.65	2.36e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg20362242	chr5:692897	TPPP	0.48	4.51	0.38	1.47e-5	Lung disease severity in cystic fibrosis;
TGCT	cis	rs4689388	0.853	rs13103357	chr4:6294544	A/G	cg00701064	chr4:6280414	WFS1	0.37	4.72	0.39	6.3e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs4824093	0.535	rs73441802	chr22:50273916	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.13	-6.88	-0.53	2.6e-10	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs6967414	0.786	rs6972017	chr7:6754034	A/G	cg09896999	chr7:6746977	ZNF12	-0.57	-6.42	-0.5	2.62e-9	Hematocrit;Hemoglobin concentration;
TGCT	cis	rs9325144	0.555	rs1825806	chr12:38692547	G/A	cg26384229	chr12:38710491	ALG10B	0.66	6.13	0.48	1.09e-8	Morning vs. evening chronotype;
TGCT	cis	rs12220238	0.915	rs7073139	chr10:76071189	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.9	6.28	0.49	5.18e-9	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg21724239	chr8:58056113	NA	0.38	5.18	0.42	8.82e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6121246	0.609	rs6060983	chr20:30420924	T/C	cg18721089	chr20:30220636	NA	-0.37	-4.53	-0.38	1.35e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs11679640	0.836	rs17682575	chr2:43152304	C/T	cg00705576	chr2:44065259	ABCG5;ABCG8	-0.33	-4.67	-0.39	7.79e-6	White matter hyperintensity burden;
TGCT	cis	rs903263	0.897	rs1472243	chr1:84566165	T/A	cg09664975	chr1:84543551	PRKACB	0.49	4.6	0.38	1.01e-5	Breast cancer (male);
TGCT	cis	rs3892630	0.878	rs114224536	chr19:33211232	A/G	cg22980127	chr19:33182716	NUDT19	0.71	5.23	0.43	6.93e-7	Red blood cell traits;
TGCT	cis	rs12762955	0.687	rs4880470	chr10:1077480	G/A	cg20503657	chr10:835505	NA	-0.39	-4.94	-0.41	2.47e-6	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs1552244	0.554	rs28667821	chr3:10050767	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.33	-4.95	-0.41	2.39e-6	Alzheimer's disease;
TGCT	cis	rs858239	0.539	rs4377861	chr7:23185969	C/T	cg05602783	chr7:23145260	KLHL7	-0.68	-5.62	-0.45	1.2e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg03517284	chr6:25882590	NA	-0.62	-6.45	-0.5	2.24e-9	Blood metabolite levels;
TGCT	cis	rs11098499	0.866	rs13105020	chr4:120285688	G/T	cg09307838	chr4:120376055	NA	0.58	5.76	0.46	6.16e-8	Corneal astigmatism;
TGCT	cis	rs12477438	0.520	rs13022329	chr2:99731189	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	13.05	0.76	4.93e-25	Chronic sinus infection;
TGCT	cis	rs67311347	1.000	rs73080138	chr3:40516417	A/G	cg17264618	chr3:40429014	ENTPD3	0.33	4.81	0.4	4.21e-6	Renal cell carcinoma;
TGCT	cis	rs11971779	0.816	rs11979272	chr7:139074069	C/T	cg07862535	chr7:139043722	LUC7L2	0.79	5.8	0.46	5.13e-8	Diisocyanate-induced asthma;
TGCT	cis	rs1797081	1.000	rs1797081	chr10:16874565	A/G	cg23933602	chr10:16859644	RSU1	1.06	13.37	0.77	8.61e-26	Platelet distribution width;
TGCT	cis	rs2836633	0.929	rs62217519	chr21:40034390	G/A	cg05519781	chr21:40033154	ERG	0.7	6.9	0.53	2.36e-10	Coronary artery disease;
TGCT	cis	rs9329221	0.935	rs3750310	chr8:10283426	G/A	cg12940923	chr8:10282607	MSRA	-0.2	-4.73	-0.39	5.97e-6	Neuroticism;
TGCT	cis	rs2463822	1.000	rs1406384	chr11:62083530	A/G	cg23876832	chr11:62092739	NA	-0.66	-4.87	-0.4	3.39e-6	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6964587	0.933	rs28671255	chr7:91770705	A/G	cg22709100	chr7:91322751	NA	0.28	4.44	0.37	1.96e-5	Breast cancer;
TGCT	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg15691649	chr6:25882328	NA	-0.4	-4.65	-0.39	8.27e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs854765	0.964	rs854810	chr17:18006421	G/C	cg09796270	chr17:17721594	SREBF1	-0.26	-5.22	-0.42	7.3e-7	Total body bone mineral density;
TGCT	cis	rs7208859	0.623	rs9891166	chr17:29111902	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs727505	1.000	rs34986416	chr7:124441017	A/G	cg23710748	chr7:124431027	NA	-0.27	-4.51	-0.38	1.49e-5	Lewy body disease;
TGCT	cis	rs11716531	0.574	rs13075192	chr3:27279235	C/T	cg02860705	chr3:27208620	NA	0.45	7.02	0.53	1.26e-10	Diastolic blood pressure;
TGCT	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg23708337	chr7:1209742	NA	0.64	5.94	0.47	2.63e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2456568	0.709	rs1546400	chr11:93639203	G/A	cg17595323	chr11:93583763	C11orf90	0.47	6.28	0.49	5.09e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs3091242	0.904	rs6661533	chr1:25771715	A/G	cg09222892	chr1:25734099	RHCE	-0.41	-6.8	-0.52	3.99e-10	Erythrocyte sedimentation rate;
TGCT	cis	rs12497850	0.931	rs13064911	chr3:48952385	A/G	cg06212747	chr3:49208901	KLHDC8B	0.61	5.62	0.45	1.2e-7	Parkinson's disease;
TGCT	cis	rs9985766	1.000	rs28513621	chr4:151002394	G/C	cg05926478	chr4:151174724	DCLK2	-0.24	-4.72	-0.39	6.32e-6	Coronary artery disease;Myocardial infarction;
TGCT	cis	rs61990749	0.597	rs6574402	chr14:78267950	C/A	cg23188588	chr14:78226832	SNW1;C14orf178	0.67	4.73	0.39	6.09e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs796364	0.762	rs13030712	chr2:200973569	G/A	cg17644776	chr2:200775616	C2orf69	0.35	6.44	0.5	2.32e-9	Schizophrenia;
TGCT	cis	rs36051895	0.632	rs111573904	chr9:5169804	A/T	cg02405213	chr9:5042618	JAK2	-0.7	-8.91	-0.62	5.25e-15	Pediatric autoimmune diseases;
TGCT	cis	rs8180040	0.726	rs13094672	chr3:47149439	C/T	cg27129171	chr3:47204927	SETD2	0.73	9.48	0.65	2.25e-16	Colorectal cancer;
TGCT	cis	rs12682352	0.652	rs1567398	chr8:8726804	A/C	cg15556689	chr8:8085844	FLJ10661	-0.62	-5.75	-0.46	6.57e-8	Neuroticism;
TGCT	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg22105103	chr4:187893119	NA	0.33	4.76	0.39	5.31e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3902035	0.894	rs62423969	chr6:119010597	A/G	cg07617317	chr6:118971624	C6orf204	0.43	5.01	0.41	1.79e-6	QT interval;
TGCT	cis	rs617219	0.698	rs72764988	chr5:78533584	G/C	cg23987322	chr5:78407566	BHMT	0.36	4.66	0.39	8.06e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs13191362	0.810	rs34714603	chr6:163008078	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.68	5.79	0.46	5.33e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs2153535	0.580	rs6597330	chr6:8492076	T/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs929354	1.000	rs1182413	chr7:157058557	G/A	cg05182265	chr7:156933206	UBE3C	0.32	6.64	0.51	8.98e-10	Body mass index;
TGCT	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg12311346	chr5:56204834	C5orf35	-0.67	-6.82	-0.52	3.63e-10	Initial pursuit acceleration;
TGCT	cis	rs6940638	0.956	rs10946899	chr6:27023694	T/A	cg26531700	chr6:26746687	NA	-0.54	-4.64	-0.38	8.68e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7246657	0.550	rs10411176	chr19:37686953	G/T	cg24025825	chr19:37761650	NA	-0.31	-4.48	-0.37	1.64e-5	Coronary artery calcification;
TGCT	cis	rs36051895	0.554	rs10975027	chr9:5248827	G/A	cg02405213	chr9:5042618	JAK2	-0.7	-8.27	-0.6	1.78e-13	Pediatric autoimmune diseases;
TGCT	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg27535305	chr1:53392650	SCP2	-0.24	-4.69	-0.39	6.96e-6	Monocyte count;
TGCT	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg03352830	chr11:487213	PTDSS2	0.26	4.58	0.38	1.12e-5	Body mass index;
TGCT	cis	rs1008375	0.932	rs2302389	chr4:17661889	T/C	cg16339924	chr4:17578868	LAP3	0.55	4.62	0.38	9.6e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs523522	0.962	rs4767902	chr12:120910004	C/T	cg27279351	chr12:120934652	DYNLL1	0.76	6.58	0.51	1.19e-9	High light scatter reticulocyte count;
TGCT	trans	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg17830980	chr10:43048298	ZNF37B	-0.84	-10.46	-0.68	9.38e-19	Extrinsic epigenetic age acceleration;
TGCT	cis	rs1670533	0.932	rs13106586	chr4:1054182	G/A	cg20887711	chr4:1340912	KIAA1530	0.71	5.7	0.46	8.33e-8	Recombination rate (females);
TGCT	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg14983838	chr19:29218262	NA	0.83	6.76	0.52	4.75e-10	Methadone dose in opioid dependence;
TGCT	cis	rs10875746	0.729	rs1990028	chr12:48408013	A/G	cg20731937	chr12:48336164	NA	0.57	4.8	0.4	4.42e-6	Longevity (90 years and older);
TGCT	cis	rs2153535	0.580	rs6912374	chr6:8456423	T/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs858239	0.600	rs2014768	chr7:23122440	C/A	cg05602783	chr7:23145260	KLHL7	-0.64	-5.37	-0.43	3.69e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs7926906	0.967	rs7112148	chr11:90525925	C/G	cg26138821	chr11:89956704	CHORDC1	-0.53	-5.7	-0.46	8.12e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs644799	1.000	rs474442	chr11:95583995	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.86	9.04	0.63	2.57e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9915657	0.660	rs975772	chr17:70067810	T/G	cg06234051	chr17:70120541	SOX9	-0.25	-5.29	-0.43	5.33e-7	Thyroid hormone levels;
TGCT	cis	rs9916302	0.904	rs11654018	chr17:37703740	C/T	cg15445000	chr17:37608096	MED1	-0.32	-4.6	-0.38	1.02e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs6964587	1.000	rs57816416	chr7:91736078	A/C	cg22709100	chr7:91322751	NA	0.29	4.79	0.4	4.67e-6	Breast cancer;
TGCT	cis	rs17102423	0.731	rs61987429	chr14:65606248	C/T	cg11161011	chr14:65562177	MAX	-0.46	-6.06	-0.48	1.51e-8	Obesity-related traits;
TGCT	cis	rs1215050	0.743	rs6532692	chr4:98648005	C/A	cg05340658	chr4:99064831	C4orf37	-0.43	-5.4	-0.44	3.2e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9814567	0.752	rs4634170	chr3:134335471	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.75	-6.75	-0.52	4.98e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs7681440	0.626	rs6812593	chr4:90817991	C/T	cg20003494	chr4:90757398	SNCA	-0.54	-4.88	-0.4	3.21e-6	Dementia with Lewy bodies;
TGCT	cis	rs4499344	0.664	rs259284	chr19:33163262	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.88	9.49	0.65	2.13e-16	Mean platelet volume;
TGCT	cis	rs9393777	0.778	rs4452638	chr6:27229265	A/G	cg10876282	chr6:28092338	ZSCAN16	-0.69	-4.51	-0.38	1.51e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs2404602	0.622	rs11637296	chr15:77207885	C/A	cg22467129	chr15:76604101	ETFA	0.54	5.4	0.44	3.25e-7	Blood metabolite levels;
TGCT	cis	rs881375	0.967	rs10733648	chr9:123700779	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	5.38	0.43	3.6e-7	Rheumatoid arthritis;
TGCT	cis	rs6088580	0.634	rs6058070	chr20:33103521	G/C	cg08999081	chr20:33150536	PIGU	0.28	5.56	0.45	1.61e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs9394169	0.592	rs4304152	chr6:33723290	C/T	cg13859433	chr6:33739653	LEMD2	-0.32	-5.61	-0.45	1.28e-7	Essential tremor;
TGCT	cis	rs7611238	0.517	rs6437375	chr3:195088100	G/A	cg27323046	chr3:195102265	ACAP2	0.37	5.01	0.41	1.86e-6	Body mass index;
TGCT	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg18402987	chr7:1209562	NA	0.81	6.94	0.53	1.9e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs909002	0.849	rs3753611	chr1:32082486	C/T	cg11573219	chr1:32083031	HCRTR1	-0.46	-6.08	-0.48	1.38e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs13082711	0.555	rs73038733	chr3:27263537	C/G	cg02860705	chr3:27208620	NA	0.46	7.22	0.54	4.63e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs35160687	0.901	rs12472390	chr2:86475083	T/C	cg12542933	chr2:85804724	VAMP8	0.4	4.82	0.4	4.16e-6	Night sleep phenotypes;
TGCT	cis	rs4642101	0.597	rs9839769	chr3:12821405	C/T	cg05775895	chr3:12838266	CAND2	0.92	11.11	0.71	2.54e-20	QRS complex (12-leadsum);
TGCT	cis	rs12643440	0.538	rs882315	chr4:17149123	A/T	cg22650099	chr4:17144496	NA	-0.51	-5.1	-0.42	1.26e-6	Metabolite levels (Pyroglutamine);
TGCT	cis	rs2046867	0.862	rs6805234	chr3:72829869	A/G	cg25664220	chr3:72788482	NA	-0.53	-6.79	-0.52	4.21e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6683273	0.775	rs12567158	chr1:3226833	A/G	cg17435683	chr1:3230609	PRDM16	-0.4	-4.53	-0.38	1.35e-5	QRS duration;
TGCT	cis	rs6867032	1.000	rs2129471	chr5:2016236	C/G	cg26168224	chr5:2018326	NA	0.43	7.96	0.58	9.31e-13	Gut microbiome composition (winter);
TGCT	cis	rs4237845	0.636	rs11172371	chr12:58286188	C/T	cg23860436	chr12:58378763	NA	0.33	4.49	0.37	1.63e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs2760061	0.598	rs605410	chr1:228116281	A/G	cg18477163	chr1:228402036	OBSCN	-0.3	-5.94	-0.47	2.71e-8	Diastolic blood pressure;
TGCT	cis	rs9393692	0.905	rs2393592	chr6:26285560	A/G	cg00631329	chr6:26305371	NA	-0.44	-6.59	-0.51	1.14e-9	Educational attainment;
TGCT	cis	rs12681287	0.517	rs13249753	chr8:87513216	A/G	cg27223183	chr8:87520930	FAM82B	-0.96	-7.04	-0.53	1.16e-10	Caudate activity during reward;
TGCT	cis	rs13177918	0.677	rs13171800	chr5:149824355	G/A	cg14059543	chr5:149831962	NA	-0.71	-9.45	-0.65	2.77e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg10802521	chr3:52805072	NEK4	-0.78	-10.0	-0.67	1.26e-17	Bipolar disorder;
TGCT	cis	rs7267979	1.000	rs422424	chr20:25445446	G/C	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3087591	0.960	rs4795575	chr17:29452625	A/G	cg24425628	chr17:29625626	OMG;NF1	0.47	7.58	0.56	7.13e-12	Hip circumference;
TGCT	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg13395646	chr4:1353034	KIAA1530	0.39	4.75	0.39	5.62e-6	Obesity-related traits;
TGCT	cis	rs7119	0.717	rs11639293	chr15:77810845	T/C	cg27398640	chr15:77910606	LINGO1	-0.25	-4.6	-0.38	1.05e-5	Type 2 diabetes;
TGCT	cis	rs265548	0.646	rs36689	chr19:17910639	A/G	cg04517722	chr19:17905589	B3GNT3	0.47	6.31	0.49	4.46e-9	Tumor biomarkers;
TGCT	cis	rs9291683	0.530	rs73227883	chr4:9979279	T/C	cg11266682	chr4:10021025	SLC2A9	0.63	8.85	0.62	7.35e-15	Bone mineral density;
TGCT	cis	rs9916302	0.706	rs582176	chr17:37453999	T/C	cg07936489	chr17:37558343	FBXL20	0.84	6.23	0.49	6.68e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs2456568	0.867	rs2456569	chr11:93691393	C/A	cg16099599	chr11:93583650	C11orf90	-0.39	-4.77	-0.39	5.16e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs12216125	0.549	rs9358905	chr6:26077839	T/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.77	7.38	0.55	2.03e-11	Iron status biomarkers;
TGCT	cis	rs2334880	0.678	rs7186112	chr16:71840073	A/T	cg06353428	chr16:71660113	MARVELD3	1.53	12.59	0.75	6.48e-24	Malaria;
TGCT	cis	rs13217239	0.646	rs9379956	chr6:27033735	T/C	cg02458000	chr6:26745757	NA	-0.5	-4.55	-0.38	1.24e-5	Schizophrenia;
TGCT	cis	rs7193541	0.929	rs12933037	chr16:74660174	G/A	cg05800356	chr16:74706258	MLKL	0.25	4.53	0.38	1.38e-5	Multiple myeloma;
TGCT	cis	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg09021430	chr5:549028	NA	-0.38	-5.11	-0.42	1.21e-6	Obesity-related traits;
TGCT	cis	rs7660520	0.556	rs4862103	chr4:183735309	G/A	cg04181038	chr4:183730758	NA	0.66	6.03	0.48	1.78e-8	Pediatric autoimmune diseases;
TGCT	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg00684032	chr4:1343700	KIAA1530	0.23	5.01	0.41	1.79e-6	Obesity-related traits;
TGCT	cis	rs9894429	0.816	rs9747093	chr17:79584280	G/A	cg18240062	chr17:79603768	NPLOC4	0.67	6.84	0.52	3.23e-10	Eye color traits;
TGCT	cis	rs7178572	0.568	rs12901297	chr15:77386675	G/A	cg22256960	chr15:77711686	NA	-0.84	-8.32	-0.6	1.34e-13	Type 2 diabetes;
TGCT	cis	rs362296	0.698	rs3095082	chr4:3263617	C/A	cg06533319	chr4:3265114	C4orf44	0.23	4.64	0.38	8.9e-6	Parental longevity (mother's age at death);
TGCT	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg21433313	chr16:3507492	NAT15	0.38	5.03	0.41	1.71e-6	Tuberculosis;
TGCT	cis	rs56104184	0.830	rs45589039	chr19:49355385	C/T	cg17863274	chr19:49399704	TULP2	-0.5	-6.03	-0.48	1.76e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs2688608	0.967	rs2633299	chr10:75656754	T/G	cg19442545	chr10:75533431	FUT11	-0.29	-4.71	-0.39	6.5e-6	Inflammatory bowel disease;
TGCT	cis	rs13256369	1.000	rs12550458	chr8:8567832	G/A	cg17143192	chr8:8559678	CLDN23	0.58	5.55	0.45	1.64e-7	Obesity-related traits;
TGCT	cis	rs10089	1.000	rs10478798	chr5:127442394	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	7.43	0.56	1.53e-11	Ileal carcinoids;
TGCT	cis	rs4788439	0.901	rs74013609	chr16:24995421	C/A	cg07626409	chr16:25250191	ZKSCAN2	0.32	4.45	0.37	1.87e-5	Blood metabolite levels;
TGCT	cis	rs7178572	0.962	rs12324627	chr15:77767539	A/G	cg22256960	chr15:77711686	NA	-0.95	-10.89	-0.7	8.57e-20	Type 2 diabetes;
TGCT	cis	rs9486719	0.895	rs12527021	chr6:97025496	C/T	cg06623918	chr6:96969491	KIAA0776	-0.99	-8.05	-0.59	5.65e-13	Migraine;Coronary artery disease;
TGCT	cis	rs7772486	0.727	rs12190966	chr6:146146820	T/G	cg05347473	chr6:146136440	FBXO30	0.5	4.72	0.39	6.35e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6121246	0.567	rs6060262	chr20:30193071	A/C	cg10886678	chr20:30946050	ASXL1	-0.71	-4.8	-0.4	4.42e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs12220238	1.000	rs7904207	chr10:75884474	A/T	cg19889307	chr10:75911429	ADK;AP3M1	0.91	7.98	0.58	8.43e-13	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.78	-8.0	-0.58	7.45e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg12963246	chr6:28129442	ZNF389	0.52	5.1	0.42	1.23e-6	Depression;
TGCT	cis	rs7666738	0.830	rs10022389	chr4:99022229	T/C	cg17366294	chr4:99064904	C4orf37	0.68	7.04	0.53	1.17e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1385374	0.563	rs12299194	chr12:129264838	A/G	cg09035930	chr12:129282057	SLC15A4	-0.54	-4.76	-0.39	5.33e-6	Systemic lupus erythematosus;
TGCT	cis	rs6977660	0.507	rs28402966	chr7:19774469	A/C	cg07541023	chr7:19748670	TWISTNB	1.01	6.55	0.51	1.39e-9	Thyroid stimulating hormone;
TGCT	trans	rs564343	0.545	rs576836	chr11:65823569	G/C	cg26701943	chr11:108369231	KDELC2	-0.74	-6.92	-0.53	2.11e-10	Obesity (early onset extreme);
TGCT	cis	rs9788721	0.836	rs72738732	chr15:78752188	C/G	cg18825076	chr15:78729989	IREB2	-0.34	-5.11	-0.42	1.18e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
TGCT	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg03806693	chr22:41940476	POLR3H	1.12	12.44	0.75	1.45e-23	Vitiligo;
TGCT	cis	rs6671200	1.000	rs259359	chr1:95709039	A/G	cg20701556	chr1:95698924	RWDD3	-0.65	-5.55	-0.45	1.67e-7	Stearic acid (18:0) levels;
TGCT	cis	rs7959452	0.901	rs1384	chr12:69747834	C/T	cg20891283	chr12:69753455	YEATS4	0.69	6.81	0.52	3.67e-10	Blood protein levels;
TGCT	cis	rs9393692	0.905	rs1124999	chr6:26287043	G/T	cg13736514	chr6:26305472	NA	-0.41	-5.76	-0.46	6.12e-8	Educational attainment;
TGCT	cis	rs17253792	0.822	rs112418863	chr14:56114079	G/A	cg01858014	chr14:56050164	KTN1	-0.35	-4.65	-0.39	8.23e-6	Putamen volume;
TGCT	cis	rs17376456	0.877	rs7701974	chr5:93311417	C/T	cg21475434	chr5:93447410	FAM172A	0.65	4.85	0.4	3.58e-6	Diabetic retinopathy;
TGCT	trans	rs61931739	0.500	rs35391785	chr12:34444478	C/T	cg26384229	chr12:38710491	ALG10B	0.73	6.93	0.53	2e-10	Morning vs. evening chronotype;
TGCT	trans	rs114540395	0.858	rs75919232	chr10:103289312	A/G	cg10198749	chr1:39920707	MACF1	0.55	7.05	0.53	1.11e-10	Schizophrenia;
TGCT	cis	rs11098499	0.863	rs6833334	chr4:120504227	C/T	cg09307838	chr4:120376055	NA	0.68	6.47	0.5	2.02e-9	Corneal astigmatism;
TGCT	cis	rs7208859	0.615	rs216462	chr17:28895897	T/C	cg14008862	chr17:28927542	LRRC37B2	-0.77	-4.47	-0.37	1.78e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	4.92	0.4	2.75e-6	Menopause (age at onset);
TGCT	cis	rs55883249	0.957	rs62119393	chr2:9718247	C/T	cg23886495	chr2:9695866	ADAM17	0.79	4.71	0.39	6.49e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs478304	0.654	rs11601509	chr11:65456864	T/C	cg17480646	chr11:65405466	SIPA1	-0.61	-8.27	-0.6	1.79e-13	Acne (severe);
TGCT	trans	rs3107575	0.572	rs73169366	chr3:165320307	C/T	cg20820622	chr15:70354647	TLE3	0.97	6.63	0.51	9.3e-10	Morning vs. evening chronotype;
TGCT	cis	rs9467711	0.516	rs1165184	chr6:25836257	C/G	cg16898833	chr6:26189333	HIST1H4D	0.7	4.45	0.37	1.9e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs72945132	0.882	rs7122057	chr11:70201430	T/C	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs7095607	0.813	rs7911060	chr10:69929058	T/C	cg18986048	chr10:69913749	MYPN	0.46	5.24	0.43	6.63e-7	Lung function (FVC);
TGCT	cis	rs4563143	0.592	rs12151001	chr19:29283386	C/G	cg12667521	chr19:29218732	NA	0.55	5.9	0.47	3.29e-8	Methadone dose in opioid dependence;
TGCT	cis	rs832540	0.931	rs832399	chr5:56222358	A/T	cg12311346	chr5:56204834	C5orf35	-0.48	-5.18	-0.42	8.6e-7	Coronary artery disease;
TGCT	cis	rs9291768	0.967	rs10939961	chr5:50738478	A/C	cg24549912	chr5:50692281	NA	-0.22	-4.47	-0.37	1.72e-5	Classic bladder exstrophy;
TGCT	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg08280861	chr8:58055591	NA	0.39	4.86	0.4	3.45e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7772486	0.875	rs1929523	chr6:146339989	T/A	cg23711669	chr6:146136114	FBXO30	0.88	9.67	0.66	7.78e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7258465	1.000	rs10425982	chr19:18586519	T/A	cg06462663	chr19:18546047	ISYNA1	0.2	4.63	0.38	9.01e-6	Breast cancer;
TGCT	cis	rs9486719	1.000	rs10457159	chr6:96993139	G/A	cg18709589	chr6:96969512	KIAA0776	-0.76	-5.32	-0.43	4.63e-7	Migraine;Coronary artery disease;
TGCT	cis	rs6688613	0.765	rs56229522	chr1:166816108	T/A	cg07049167	chr1:166818506	POGK	0.21	4.55	0.38	1.26e-5	Refractive astigmatism;
TGCT	cis	rs7089973	0.604	rs2420069	chr10:116605103	A/G	cg03647239	chr10:116582469	FAM160B1	0.59	5.74	0.46	6.72e-8	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs7829975	0.902	rs485107	chr8:8581408	C/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-4.91	-0.4	2.78e-6	Mood instability;
TGCT	cis	rs2439831	1.000	rs689781	chr15:43792097	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	5.51	0.44	1.95e-7	Lung cancer in ever smokers;
TGCT	cis	rs9399137	0.507	rs13196486	chr6:135283874	C/G	cg24558204	chr6:135376177	HBS1L	0.47	4.78	0.39	4.95e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
TGCT	cis	rs9486719	1.000	rs1303852	chr6:96864523	C/T	cg06623918	chr6:96969491	KIAA0776	1.01	8.86	0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	trans	rs1814175	0.645	rs1721997	chr11:49916653	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.51	-0.69	7.2e-19	Height;
TGCT	cis	rs7760949	0.889	rs9396264	chr6:13930342	T/A	cg27413430	chr6:13925136	RNF182	0.73	6.79	0.52	4.22e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs7917772	0.636	rs7088981	chr10:104520423	T/C	cg05855489	chr10:104503620	C10orf26	0.66	5.25	0.43	6.47e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2797160	0.967	rs1777224	chr6:126019527	T/C	cg05901451	chr6:126070800	HEY2	0.71	6.11	0.48	1.16e-8	Endometrial cancer;
TGCT	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg21724239	chr8:58056113	NA	0.39	5.24	0.43	6.67e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6087990	0.842	rs6119279	chr20:31330612	A/G	cg13636640	chr20:31349939	DNMT3B	1.03	14.85	0.8	2.67e-29	Ulcerative colitis;
TGCT	cis	rs3026101	0.697	rs1806267	chr17:5322106	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.49	4.76	0.39	5.25e-6	Body mass index;
TGCT	cis	rs7666738	0.830	rs6831588	chr4:98977356	T/G	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs986417	0.901	rs1950312	chr14:60989784	A/G	cg27398547	chr14:60952738	C14orf39	-1.47	-10.59	-0.69	4.68e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs3806843	0.607	rs246044	chr5:140330656	C/T	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.42	-5.37	-0.43	3.69e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg06634786	chr22:41940651	POLR3H	-0.88	-8.23	-0.59	2.17e-13	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs3733585	0.781	rs13103690	chr4:9972778	T/G	cg11266682	chr4:10021025	SLC2A9	-0.62	-8.54	-0.61	4.06e-14	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs362272	0.545	rs2749783	chr4:3326098	A/C	cg18352616	chr4:3374830	RGS12	0.25	5.07	0.41	1.39e-6	Serum sulfate level;
TGCT	cis	rs250677	1.000	rs36082	chr5:148428844	C/G	cg23229984	chr5:148520753	ABLIM3	0.21	4.95	0.41	2.33e-6	Breast cancer;
TGCT	cis	rs35522438	1	rs35522438	chr7:91872872	A/AT	cg22709100	chr7:91322751	NA	0.28	4.56	0.38	1.2e-5	Breast cancer;
TGCT	cis	rs9303542	0.625	rs17703660	chr17:46567134	T/C	cg25032089	chr17:46643351	HOXB3	0.58	5.96	0.47	2.45e-8	Ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg07507251	chr3:52567010	NT5DC2	0.48	6.67	0.51	7.55e-10	Bipolar disorder;
TGCT	cis	rs11971779	0.680	rs11768023	chr7:139054395	T/A	cg07862535	chr7:139043722	LUC7L2	0.66	5.07	0.41	1.42e-6	Diisocyanate-induced asthma;
TGCT	cis	rs910316	1.000	rs4903281	chr14:75554361	G/C	cg11812906	chr14:75593930	NEK9	0.74	7.25	0.55	3.9e-11	Height;
TGCT	cis	rs6430585	0.591	rs4585083	chr2:136486342	C/T	cg07169764	chr2:136633963	MCM6	1.12	10.49	0.69	8.04e-19	Corneal structure;
TGCT	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg04267008	chr7:1944627	MAD1L1	-0.41	-5.51	-0.44	1.96e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs7568458	0.846	rs6738645	chr2:85783128	T/G	cg17127132	chr2:85788382	GGCX	0.68	6.58	0.51	1.2e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs1371867	0.846	rs1660338	chr8:101242757	C/G	cg06002616	chr8:101225028	SPAG1	-0.52	-6.2	-0.49	7.79e-9	Atrioventricular conduction;
TGCT	cis	rs10883723	0.810	rs2296581	chr10:104242886	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	8.36	0.6	1.1e-13	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs854765	0.547	rs2955359	chr17:17946730	T/C	cg04398451	chr17:18023971	MYO15A	0.34	5.49	0.44	2.21e-7	Total body bone mineral density;
TGCT	cis	rs5417	0.636	rs222851	chr17:7139238	G/A	cg25256661	chr17:7137939	DVL2	0.68	6.66	0.51	7.88e-10	Diastolic blood pressure;
TGCT	cis	rs3796352	1.000	rs3796352	chr3:52913279	C/T	cg07884673	chr3:53033167	SFMBT1	0.6	4.88	0.4	3.16e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg07157834	chr1:205819609	PM20D1	0.49	8.67	0.61	2.01e-14	Menarche (age at onset);
TGCT	cis	rs2832191	0.935	rs67287920	chr21:30523519	C/A	cg24692254	chr21:30365293	RNF160	-0.8	-8.31	-0.6	1.41e-13	Dental caries;
TGCT	cis	rs12257961	0.549	rs56276505	chr10:15382499	G/A	cg10616319	chr10:15468812	NA	0.25	4.71	0.39	6.49e-6	Selective IgA deficiency;
TGCT	cis	rs7172809	0.897	rs907387	chr15:77828751	T/C	cg22256960	chr15:77711686	NA	-0.44	-4.48	-0.37	1.67e-5	Glucose homeostasis traits;
TGCT	cis	rs3733606	0.503	rs11734132	chr4:6891519	C/G	cg27326882	chr4:7789542	AFAP1	-0.26	-5.11	-0.42	1.19e-6	Platelet count;
TGCT	cis	rs67478160	0.608	rs11628787	chr14:104323984	G/A	cg01849466	chr14:104193079	ZFYVE21	0.18	4.5	0.37	1.54e-5	Schizophrenia;
TGCT	cis	rs9902453	0.967	rs62070344	chr17:28476997	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	6.56	0.51	1.32e-9	Coffee consumption (cups per day);
TGCT	cis	rs1894292	0.527	rs2040354	chr4:74367100	C/T	cg05868023	chr4:75230803	EREG	-0.56	-5.02	-0.41	1.78e-6	Prostate cancer;
TGCT	cis	rs896854	0.738	rs2515226	chr8:95965743	G/A	cg16049864	chr8:95962084	TP53INP1	0.64	7.66	0.57	4.51e-12	Type 2 diabetes;
TGCT	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg17264618	chr3:40429014	ENTPD3	0.35	5.09	0.42	1.27e-6	Renal cell carcinoma;
TGCT	cis	rs10193935	0.901	rs10189710	chr2:42573102	C/G	cg27598129	chr2:42591480	NA	-0.4	-5.57	-0.45	1.51e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1023500	0.551	rs4822076	chr22:42364057	C/T	cg05082376	chr22:42548792	NA	-0.22	-4.86	-0.4	3.53e-6	Schizophrenia;
TGCT	cis	rs55883249	1.000	rs62119429	chr2:9743585	G/C	cg23886495	chr2:9695866	ADAM17	0.81	5.0	0.41	1.93e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs2072438	0.503	rs10739590	chr9:123871481	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.44	4.48	0.37	1.65e-5	Rheumatoid arthritis;
TGCT	cis	rs2404602	0.692	rs59088060	chr15:76859974	T/C	cg26408565	chr15:76604113	ETFA	-0.37	-4.78	-0.39	4.9e-6	Blood metabolite levels;
TGCT	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7677751	0.806	rs4864858	chr4:55089953	T/A	cg17187183	chr4:55093834	PDGFRA	0.53	6.87	0.52	2.83e-10	Corneal astigmatism;
TGCT	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.12	15.23	0.81	3.53e-30	Height;
TGCT	cis	rs78487399	0.908	rs61271889	chr2:43825436	C/G	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.66	4.67	0.39	7.66e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs208520	0.690	rs1351867	chr6:66760995	A/G	cg07460842	chr6:66804631	NA	0.96	10.32	0.68	2.1e-18	Exhaled nitric oxide output;
TGCT	cis	rs7399018	0.739	rs7399073	chr12:51614050	C/A	cg25754956	chr12:51612065	POU6F1	0.92	9.95	0.67	1.64e-17	Cisplatin-induced ototoxicity;
TGCT	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg21724239	chr8:58056113	NA	0.42	5.04	0.41	1.59e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2948294	0.524	rs13270062	chr8:8112650	C/A	cg15556689	chr8:8085844	FLJ10661	0.78	6.78	0.52	4.31e-10	Red cell distribution width;
TGCT	cis	rs295137	0.752	rs10931892	chr2:201104997	C/T	cg23649088	chr2:200775458	C2orf69	-0.34	-5.82	-0.46	4.79e-8	Asthma (bronchodilator response);
TGCT	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg05368731	chr17:41323189	NBR1	0.95	9.3	0.64	6.14e-16	Menopause (age at onset);
TGCT	cis	rs2115630	0.967	rs8028490	chr15:85277888	G/A	cg11189052	chr15:85197271	WDR73	-0.62	-6.0	-0.47	2e-8	P wave terminal force;
TGCT	cis	rs9400467	0.537	rs12213673	chr6:111544839	C/T	cg15721981	chr6:111408429	SLC16A10	0.73	4.79	0.4	4.71e-6	Blood metabolite levels;Amino acid levels;
TGCT	cis	rs9372498	0.536	rs9489399	chr6:118767147	C/A	cg21191810	chr6:118973309	C6orf204	-0.37	-4.77	-0.39	5.03e-6	Diastolic blood pressure;
TGCT	cis	rs2982552	0.775	rs2982563	chr6:152052311	T/C	cg22157087	chr6:152012887	ESR1	0.19	4.67	0.39	7.81e-6	Bone properties (heel);
TGCT	cis	rs858239	0.600	rs1468592	chr7:23140647	C/T	cg05602783	chr7:23145260	KLHL7	0.64	5.35	0.43	4.15e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg03609598	chr5:56110824	MAP3K1	-0.58	-4.7	-0.39	6.72e-6	Initial pursuit acceleration;
TGCT	cis	rs77633900	0.614	rs2468123	chr15:76931345	T/C	cg21673338	chr15:77095150	SCAPER	-0.5	-4.82	-0.4	4.07e-6	Non-glioblastoma glioma;Glioma;
TGCT	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg22166914	chr1:53195759	ZYG11B	0.35	5.78	0.46	5.7e-8	Monocyte count;
TGCT	cis	rs6088580	0.609	rs6059844	chr20:33036482	A/G	cg08999081	chr20:33150536	PIGU	0.28	5.7	0.46	8.38e-8	Glomerular filtration rate (creatinine);
TGCT	cis	rs7086627	0.515	rs10887905	chr10:82210855	A/T	cg01528321	chr10:82214614	TSPAN14	0.65	6.21	0.49	7.21e-9	Post bronchodilator FEV1;
TGCT	cis	rs9393777	0.513	rs7759969	chr6:26663096	T/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.63	-5.75	-0.46	6.58e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs1348850	0.668	rs6734426	chr2:178493770	C/T	cg22681709	chr2:178499509	PDE11A	-0.43	-4.48	-0.37	1.65e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs8141529	0.732	rs11556025	chr22:29168755	T/C	cg02153584	chr22:29168773	CCDC117	0.7	6.01	0.47	1.92e-8	Lymphocyte counts;
TGCT	cis	rs6993813	0.505	rs35533151	chr8:120023725	T/G	cg17171407	chr8:119960777	TNFRSF11B	0.26	4.59	0.38	1.06e-5	Bone mineral density (hip);
TGCT	cis	rs2354432	1.000	rs2120003	chr1:146690635	A/G	cg25205988	chr1:146714368	CHD1L	1.17	5.89	0.47	3.38e-8	Mitochondrial DNA levels;
TGCT	cis	rs909685	0.590	rs3747177	chr22:39746168	C/A	cg17798944	chr22:39715225	SNORD43;RPL3	0.79	7.3	0.55	3.03e-11	Rheumatoid arthritis;
TGCT	cis	rs709400	0.659	rs7160366	chr14:103944137	C/T	cg26031613	chr14:104095156	KLC1	0.85	9.72	0.66	5.87e-17	Body mass index;
TGCT	cis	rs9517302	0.615	rs2274053	chr13:99098318	C/T	cg22223119	chr13:99095684	FARP1	-0.65	-7.18	-0.54	5.7e-11	Obesity-related traits;
TGCT	cis	rs1696756	0.877	rs1663223	chr17:77826509	A/G	cg00646381	chr17:77835854	NA	0.42	5.94	0.47	2.71e-8	Glucocorticoid-induced osteonecrosis (age 10 years and older);
TGCT	cis	rs2820315	1.000	rs2678204	chr1:201800511	T/G	cg12730843	chr1:201915899	LMOD1	-0.27	-4.81	-0.4	4.22e-6	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
TGCT	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg14773178	chr5:1868261	NA	0.35	6.19	0.49	7.93e-9	Cardiovascular disease risk factors;
TGCT	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg11494091	chr17:61959527	GH2	0.42	7.28	0.55	3.36e-11	Height;
TGCT	cis	rs2235642	0.653	rs7197288	chr16:1654753	C/A	cg08296037	chr16:1584118	IFT140;TMEM204	-0.28	-4.94	-0.41	2.44e-6	Coronary artery disease;
TGCT	cis	rs7666738	0.791	rs6853608	chr4:99047916	A/G	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs651907	0.557	rs13069443	chr3:101373305	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.91	10.9	0.7	8.24e-20	Colorectal cancer;
TGCT	trans	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg17830980	chr10:43048298	ZNF37B	-0.87	-11.04	-0.7	3.63e-20	Extrinsic epigenetic age acceleration;
TGCT	cis	rs17774123	0.671	rs3843640	chr12:54263812	G/T	cg14212748	chr12:53343703	KRT18	-0.38	-4.65	-0.39	8.31e-6	Diastolic blood pressure;
TGCT	cis	rs4824093	0.610	rs56810176	chr22:50303149	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.07	-5.93	-0.47	2.87e-8	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs2290402	0.536	rs73207791	chr4:865941	A/G	cg23332689	chr4:987652	IDUA;SLC26A1	0.31	4.82	0.4	4.12e-6	Type 2 diabetes;
TGCT	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg22166914	chr1:53195759	ZYG11B	-0.42	-7.46	-0.56	1.33e-11	Monocyte count;
TGCT	cis	rs259282	0.518	rs259257	chr19:33152296	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	1.01	10.27	0.68	2.83e-18	Schizophrenia;
TGCT	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg21016266	chr12:122356598	WDR66	0.53	6.62	0.51	9.94e-10	Mean corpuscular volume;
TGCT	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg11764359	chr7:65958608	NA	0.62	5.57	0.45	1.51e-7	Aortic root size;
TGCT	cis	rs6840360	0.571	rs62327271	chr4:152535916	A/G	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.0	-0.58	7.69e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs6671200	1.000	rs62625008	chr1:95702582	A/G	cg20701556	chr1:95698924	RWDD3	0.67	5.63	0.45	1.13e-7	Stearic acid (18:0) levels;
TGCT	cis	rs7845219	0.525	rs7820818	chr8:95919231	G/A	cg13393036	chr8:95962371	TP53INP1	-0.49	-5.49	-0.44	2.2e-7	Type 2 diabetes;
TGCT	cis	rs2299587	0.554	rs2073564	chr8:17743341	G/A	cg01800426	chr8:17659068	MTUS1	-0.55	-4.96	-0.41	2.25e-6	Economic and political preferences;
TGCT	cis	rs1055129	0.560	rs9891076	chr17:73911715	C/T	cg10935138	chr17:73851978	WBP2	0.54	4.71	0.39	6.58e-6	White matter hyperintensity burden;
TGCT	cis	rs2580764	0.541	rs2968786	chr2:55264859	C/G	cg09592903	chr2:55203963	RTN4	0.27	6.17	0.48	8.73e-9	Mean platelet volume;
TGCT	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg19318889	chr4:1322082	MAEA	0.28	6.7	0.52	6.39e-10	Longevity;
TGCT	cis	rs1971762	0.583	rs12319789	chr12:54090450	G/C	cg16917193	chr12:54089295	NA	1.34	17.67	0.85	1.12e-35	Height;
TGCT	cis	rs74233809	1.000	rs11191531	chr10:104806898	G/C	cg05855489	chr10:104503620	C10orf26	0.76	4.53	0.38	1.36e-5	Birth weight;
TGCT	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg21862992	chr11:68658383	NA	0.46	6.26	0.49	5.67e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs3087591	0.920	rs4795592	chr17:29612620	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.48	-7.37	-0.55	2.08e-11	Hip circumference;
TGCT	cis	rs7267979	1.000	rs2387880	chr20:25377787	T/C	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7635838	0.785	rs2574698	chr3:11557126	G/A	cg00170343	chr3:11313890	ATG7	0.68	6.16	0.48	9.56e-9	HDL cholesterol;
TGCT	cis	rs1577917	0.958	rs1447160	chr6:86546123	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.29	-0.43	5.34e-7	Response to antipsychotic treatment;
TGCT	cis	rs941408	1.000	rs1736180	chr19:2796021	C/T	cg06609049	chr19:2785107	THOP1	0.76	7.24	0.54	4.22e-11	Total cholesterol levels;
TGCT	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6545883	0.899	rs1562309	chr2:61770126	C/A	cg15711740	chr2:61764176	XPO1	-0.57	-5.23	-0.43	6.89e-7	Tuberculosis;
TGCT	cis	rs5769707	0.521	rs6009807	chr22:50058922	A/G	cg05373962	chr22:49881684	NA	-0.32	-5.46	-0.44	2.46e-7	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs3806843	0.548	rs246058	chr5:140325134	G/A	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.66	0.39	8.18e-6	Prudent dietary pattern;
TGCT	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg20607798	chr8:58055168	NA	0.65	5.5	0.44	2.08e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs950027	0.549	rs12909409	chr15:45608582	T/G	cg14582100	chr15:45693742	SPATA5L1	-0.47	-5.89	-0.47	3.46e-8	Response to fenofibrate (adiponectin levels);
TGCT	trans	rs17685	0.753	rs10245584	chr7:75745866	C/T	cg19862616	chr7:65841803	NCRNA00174	0.52	9.01	0.63	3.02e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs7666738	0.861	rs10018654	chr4:99002226	A/G	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7617773	0.780	rs11716848	chr3:48378500	G/A	cg11946769	chr3:48343235	NME6	0.82	6.99	0.53	1.49e-10	Coronary artery disease;
TGCT	cis	rs9677476	0.515	rs2303353	chr2:231944373	A/T	cg27665808	chr2:232055229	NA	0.37	4.68	0.39	7.25e-6	Food antigen IgG levels;
TGCT	trans	rs1814175	0.616	rs28417656	chr11:50040152	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.84	-0.7	1.13e-19	Height;
TGCT	cis	rs2153535	0.580	rs9392224	chr6:8472614	G/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs9952991	0.941	rs2542151	chr18:12779947	G/T	cg24737193	chr18:12778029	NA	0.53	6.01	0.47	1.96e-8	Inflammatory skin disease;
TGCT	cis	rs7429990	0.965	rs34507589	chr3:47874042	C/G	cg11946769	chr3:48343235	NME6	0.59	4.45	0.37	1.87e-5	Educational attainment (years of education);
TGCT	cis	rs4722166	0.597	rs2002792	chr7:22763845	C/G	cg23864514	chr7:22882512	NA	0.21	4.6	0.38	1.03e-5	Lung cancer;
TGCT	cis	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg18252515	chr7:66147081	NA	-1.31	-8.18	-0.59	2.87e-13	Diabetic kidney disease;
TGCT	cis	rs8017423	0.967	rs2282030	chr14:90730265	G/A	cg04374321	chr14:90722782	PSMC1	0.78	7.86	0.58	1.63e-12	Mortality in heart failure;
TGCT	cis	rs6570726	0.791	rs374478	chr6:145840022	C/T	cg05347473	chr6:146136440	FBXO30	0.53	4.95	0.41	2.4e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg04025307	chr7:1156635	C7orf50	0.21	5.13	0.42	1.1e-6	Longevity;Endometriosis;
TGCT	cis	rs11032090	1	rs11032090	chr11:4417129	A/G	cg09983885	chr11:4415245	TRIM21	0.39	4.67	0.39	7.63e-6	Lung cancer;
TGCT	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg03264133	chr6:25882463	NA	-0.64	-6.81	-0.52	3.66e-10	Blood metabolite levels;
TGCT	cis	rs55883249	1.000	rs76964971	chr2:9763904	C/A	cg23886495	chr2:9695866	ADAM17	0.74	4.45	0.37	1.9e-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs594074	0.859	rs570251	chr6:6556378	C/A	cg03251356	chr6:7151709	RREB1	0.31	4.68	0.39	7.38e-6	Diabetic kidney disease;
TGCT	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg17971929	chr21:40555470	PSMG1	0.98	9.57	0.65	1.43e-16	Cognitive function;
TGCT	cis	rs858239	0.600	rs7785842	chr7:23141706	T/A	cg05602783	chr7:23145260	KLHL7	-0.68	-5.75	-0.46	6.69e-8	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs4455778	0.580	rs5004391	chr7:49115629	G/A	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs939658	0.935	rs4778651	chr15:79447810	G/A	cg17916960	chr15:79447300	NA	-0.52	-8.3	-0.6	1.5e-13	Refractive error;
TGCT	trans	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg17830980	chr10:43048298	ZNF37B	-0.86	-11.18	-0.71	1.68e-20	Extrinsic epigenetic age acceleration;
TGCT	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg08280861	chr8:58055591	NA	-0.38	-4.56	-0.38	1.19e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs6500602	0.826	rs7205189	chr16:4460114	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.42	5.27	0.43	5.92e-7	Schizophrenia;
TGCT	cis	rs7818688	0.697	rs78802294	chr8:95977974	G/A	cg16049864	chr8:95962084	TP53INP1	0.54	4.64	0.38	8.87e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	6.94	0.53	1.91e-10	Prudent dietary pattern;
TGCT	cis	rs2456568	0.803	rs10831142	chr11:93640781	A/G	cg17595323	chr11:93583763	C11orf90	0.47	6.56	0.51	1.34e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7833790	0.660	rs67666182	chr8:82772037	A/G	cg06027949	chr8:82754900	SNX16	0.67	5.14	0.42	1.06e-6	Diastolic blood pressure;
TGCT	cis	rs9457247	0.534	rs2757053	chr6:167380338	A/C	cg23791538	chr6:167370224	RNASET2	0.63	6.24	0.49	6.21e-9	Crohn's disease;
TGCT	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg11062466	chr8:58055876	NA	0.43	6.3	0.49	4.61e-9	Developmental language disorder (linguistic errors);
TGCT	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs12477438	0.520	rs2516830	chr2:99773702	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	14.89	0.8	2.21e-29	Chronic sinus infection;
TGCT	cis	rs12438659	1	rs12438659	chr15:78824924	G/A	cg06917634	chr15:78832804	PSMA4	-0.7	-5.01	-0.41	1.83e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs7914558	0.966	rs746293	chr10:104897254	G/T	cg04362960	chr10:104952993	NT5C2	0.62	5.55	0.45	1.66e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg24060327	chr5:131705240	SLC22A5	-0.58	-5.91	-0.47	3.13e-8	Breast cancer;
TGCT	cis	rs4499344	0.920	rs752719	chr19:33086091	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.73	-6.6	-0.51	1.07e-9	Mean platelet volume;
TGCT	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg06873352	chr17:61820015	STRADA	0.58	6.37	0.5	3.32e-9	Prudent dietary pattern;
TGCT	cis	rs6933660	0.720	rs6913515	chr6:151753470	G/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.86	-9.14	-0.63	1.49e-15	Menarche (age at onset);
TGCT	cis	rs7226408	0.857	rs72887051	chr18:34486993	G/A	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs7308134	0.766	rs73032452	chr12:1990683	C/T	cg09189752	chr12:2113749	DCP1B	-0.57	-4.44	-0.37	1.93e-5	QRS duration in Tripanosoma cruzi seropositivity;
TGCT	cis	rs17376456	0.877	rs9314095	chr5:93425495	T/C	cg21475434	chr5:93447410	FAM172A	0.59	4.66	0.39	8.09e-6	Diabetic retinopathy;
TGCT	cis	rs62103177	0.525	rs4799117	chr18:77756604	G/A	cg07235805	chr18:78004237	PARD6G	-0.45	-4.47	-0.37	1.75e-5	Opioid sensitivity;
TGCT	cis	rs7208859	0.673	rs73265633	chr17:29236306	G/T	cg14008862	chr17:28927542	LRRC37B2	0.72	4.66	0.39	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg05368731	chr17:41323189	NBR1	1.08	11.0	0.7	4.76e-20	Menopause (age at onset);
TGCT	cis	rs72615157	0.645	rs76281814	chr7:99846414	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.62	4.82	0.4	4.1e-6	Lung function (FEV1/FVC);
TGCT	cis	rs514406	0.861	rs35581164	chr1:53271373	C/G	cg16325326	chr1:53192061	ZYG11B	0.7	8.67	0.61	2.03e-14	Monocyte count;
TGCT	cis	rs35306767	0.903	rs35370435	chr10:898205	T/C	cg26597838	chr10:835615	NA	0.8	12.11	0.74	9.26e-23	Eosinophil percentage of granulocytes;
TGCT	cis	rs7208859	0.573	rs73267873	chr17:29068457	C/T	cg13385521	chr17:29058706	SUZ12P	0.82	5.04	0.41	1.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7937682	0.924	rs513425	chr11:111504861	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.1	-11.55	-0.72	2.11e-21	Primary sclerosing cholangitis;
TGCT	cis	rs79349575	0.783	rs12601955	chr17:47034420	C/T	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.48	-0.37	1.67e-5	Type 2 diabetes;
TGCT	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg21280719	chr6:42927975	GNMT	-0.37	-4.5	-0.37	1.55e-5	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs9905704	0.671	rs4337355	chr17:56950920	C/T	cg05425664	chr17:57184151	TRIM37	-0.59	-4.69	-0.39	7.16e-6	Testicular germ cell tumor;
TGCT	cis	rs7666738	0.830	rs28615340	chr4:98896922	T/C	cg18180107	chr4:99064573	C4orf37	0.53	4.81	0.4	4.23e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7824557	0.510	rs1435274	chr8:11235910	G/A	cg21775007	chr8:11205619	TDH	-0.67	-6.51	-0.5	1.7e-9	Retinal vascular caliber;
TGCT	cis	rs12681288	0.676	rs7459467	chr8:999359	C/T	cg04851639	chr8:1020857	NA	-0.32	-5.32	-0.43	4.74e-7	Schizophrenia;
TGCT	cis	rs2721195	0.845	rs3816732	chr8:145724275	T/C	cg11211951	chr8:145729740	GPT	0.27	6.46	0.5	2.14e-9	Age at first birth;
TGCT	cis	rs12681288	0.723	rs12545453	chr8:970582	C/T	cg04851639	chr8:1020857	NA	-0.33	-5.54	-0.45	1.74e-7	Schizophrenia;
TGCT	cis	rs9914544	1.000	rs1634411	chr17:18833810	C/T	cg26306683	chr17:18585705	ZNF286B	0.59	5.26	0.43	5.99e-7	Educational attainment (years of education);
TGCT	cis	rs858239	0.539	rs28716381	chr7:23189015	G/A	cg05602783	chr7:23145260	KLHL7	-0.62	-5.03	-0.41	1.67e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs2797160	0.967	rs1739358	chr6:126019736	G/A	cg05901451	chr6:126070800	HEY2	0.73	6.29	0.49	4.85e-9	Endometrial cancer;
TGCT	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	5.06	0.41	1.46e-6	Menopause (age at onset);
TGCT	cis	rs7635838	0.596	rs347599	chr3:11258191	C/T	cg00170343	chr3:11313890	ATG7	-0.51	-4.92	-0.4	2.65e-6	HDL cholesterol;
TGCT	cis	rs7100689	0.646	rs1890889	chr10:82090827	G/T	cg01528321	chr10:82214614	TSPAN14	0.76	7.53	0.56	9.05e-12	Post bronchodilator FEV1;
TGCT	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg19748678	chr4:122722346	EXOSC9	0.9	9.35	0.64	4.81e-16	Type 2 diabetes;
TGCT	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg06618935	chr21:46677482	NA	-0.37	-5.56	-0.45	1.58e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs904251	0.561	rs1757189	chr6:37483727	G/C	cg08126542	chr6:37504118	NA	-0.43	-6.2	-0.49	7.72e-9	Cognitive performance;
TGCT	cis	rs1385374	0.858	rs34888374	chr12:129296536	G/A	cg09035930	chr12:129282057	SLC15A4	-0.55	-4.76	-0.39	5.27e-6	Systemic lupus erythematosus;
TGCT	cis	rs9611519	0.580	rs7286603	chr22:41440061	T/C	cg13695892	chr22:41940480	POLR3H	-0.56	-5.29	-0.43	5.29e-7	Neuroticism;
TGCT	cis	rs7267979	0.932	rs372678	chr20:25465248	G/A	cg14121845	chr20:25566513	NINL	0.49	5.36	0.43	3.83e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11642862	1.000	rs75231191	chr16:30788601	C/T	cg02466173	chr16:30829666	NA	-0.38	-4.57	-0.38	1.16e-5	Tonsillectomy;
TGCT	cis	rs2456568	0.695	rs877341	chr11:93689293	C/T	cg17595323	chr11:93583763	C11orf90	0.4	4.99	0.41	1.98e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs10193935	1.000	rs13399869	chr2:42386041	C/G	cg27598129	chr2:42591480	NA	-0.39	-5.14	-0.42	1.05e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3784262	1.000	rs12907038	chr15:58244032	C/G	cg12031962	chr15:58353849	ALDH1A2	-0.48	-7.39	-0.55	1.9e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs151227923	1	rs151227923	chr7:155106564	C/T	cg06963709	chr7:155150793	NA	0.35	6.84	0.52	3.2e-10	Stem cell growth factor beta levels;
TGCT	trans	rs629535	0.821	rs680993	chr8:70050247	G/A	cg21567404	chr3:27674614	NA	0.57	8.67	0.61	2.01e-14	Dupuytren's disease;
TGCT	cis	rs9581857	0.685	rs12584061	chr13:28024544	C/T	cg22138327	chr13:27999177	GTF3A	0.7	5.01	0.41	1.85e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs9486715	0.867	rs4240553	chr6:96965324	T/C	cg18709589	chr6:96969512	KIAA0776	0.82	8.01	0.58	7.14e-13	Headache;
TGCT	cis	rs8030485	0.730	rs57488047	chr15:79403002	T/C	cg17916960	chr15:79447300	NA	0.34	4.75	0.39	5.54e-6	Left ventricle wall thickness;
TGCT	cis	rs7824557	0.603	rs11250130	chr8:11214455	C/T	cg21775007	chr8:11205619	TDH	-0.66	-6.56	-0.51	1.34e-9	Retinal vascular caliber;
TGCT	cis	rs854765	0.547	rs12150369	chr17:17911014	G/A	cg04398451	chr17:18023971	MYO15A	-0.32	-5.07	-0.41	1.44e-6	Total body bone mineral density;
TGCT	cis	rs2455799	0.559	rs9813577	chr3:15909323	C/T	cg12172478	chr3:16357591	RFTN1	-0.36	-5.49	-0.44	2.18e-7	Mean platelet volume;
TGCT	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg13206674	chr6:150067644	NUP43	0.51	4.47	0.37	1.75e-5	Lung cancer;
TGCT	cis	rs6752107	0.901	rs2289477	chr2:234160345	T/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.2	4.86	0.4	3.46e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	trans	rs77457752	0.525	rs10121526	chr9:13898615	G/A	cg25510823	chr7:47085976	NA	0.45	6.68	0.51	7.21e-10	Breast cancer;
TGCT	cis	rs6964587	0.967	rs10279943	chr7:91587477	G/C	cg22709100	chr7:91322751	NA	0.27	4.48	0.37	1.68e-5	Breast cancer;
TGCT	cis	rs6598955	0.543	rs60676610	chr1:26543421	G/C	cg04990556	chr1:26633338	UBXN11	0.81	7.35	0.55	2.29e-11	Obesity-related traits;
TGCT	cis	rs5769707	0.681	rs9616329	chr22:50026314	G/A	cg06623630	chr22:50017776	C22orf34	-0.26	-4.49	-0.37	1.62e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg04267008	chr7:1944627	MAD1L1	-0.38	-5.2	-0.42	7.97e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs7666738	0.830	rs28728124	chr4:99001116	G/T	cg17366294	chr4:99064904	C4orf37	0.69	6.82	0.52	3.56e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs13082711	0.954	rs34772035	chr3:27468872	C/G	cg02860705	chr3:27208620	NA	0.35	4.83	0.4	3.9e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs7213347	0.707	rs9898390	chr17:2177484	C/G	cg20777128	chr17:1945076	DPH1;OVCA2	-0.5	-4.57	-0.38	1.17e-5	Total body bone mineral density;
TGCT	cis	rs2268241	0.877	rs17887186	chr21:34779202	G/A	cg14850771	chr21:34775459	IFNGR2	0.61	5.23	0.43	6.88e-7	Obesity-related traits;
TGCT	cis	rs71435601	0.574	rs522250	chr2:21387113	T/C	cg25035485	chr2:21266500	APOB	0.51	4.48	0.37	1.64e-5	Cholesterol, total;
TGCT	cis	rs7584330	0.780	rs2292884	chr2:238443226	A/G	cg14458575	chr2:238380390	NA	0.45	6.9	0.53	2.38e-10	Prostate cancer;
TGCT	cis	rs7267979	0.834	rs6115100	chr20:25225938	C/A	cg03522245	chr20:25566470	NINL	0.6	6.58	0.51	1.21e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs62481355	1.000	rs62481355	chr7:127201664	C/T	cg25922125	chr7:127225783	GCC1	-0.42	-4.44	-0.37	1.93e-5	Type 2 diabetes;
TGCT	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg14851468	chr5:179071604	C5orf60	0.22	4.54	0.38	1.32e-5	Lung cancer;
TGCT	cis	rs6540559	0.605	rs3753518	chr1:209977964	G/C	cg21951975	chr1:209979733	IRF6	0.69	5.42	0.44	2.99e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs59197085	0.636	rs730931	chr7:128462273	C/G	cg00260937	chr7:128520193	KCP	0.47	4.98	0.41	2.1e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
TGCT	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg25767906	chr1:53392781	SCP2	-0.55	-6.3	-0.49	4.75e-9	Monocyte count;
TGCT	cis	rs208520	0.526	rs9294682	chr6:66795159	G/A	cg07460842	chr6:66804631	NA	-1.08	-15.95	-0.82	8.03e-32	Exhaled nitric oxide output;
TGCT	cis	rs2153535	0.541	rs6932434	chr6:8467679	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs9911578	1.000	rs4636974	chr17:56965373	C/G	cg12560992	chr17:57184187	TRIM37	0.76	9.21	0.64	1.03e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs4953076	0.573	rs6544746	chr2:44407985	C/T	cg00619915	chr2:44497795	NA	-0.23	-5.1	-0.42	1.24e-6	Height;
TGCT	cis	rs12887734	0.546	rs12885509	chr14:104273325	T/C	cg26031613	chr14:104095156	KLC1	-0.73	-6.28	-0.49	5.3e-9	Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg06636001	chr8:8085503	FLJ10661	0.77	7.37	0.55	2.12e-11	Mood instability;
TGCT	trans	rs1814175	0.791	rs11040472	chr11:49703116	C/T	cg15704280	chr7:45808275	SEPT13	-0.71	-8.23	-0.59	2.14e-13	Height;
TGCT	cis	rs1062177	0.756	rs2964588	chr5:151118386	C/T	cg00977110	chr5:151150581	G3BP1	-0.4	-4.67	-0.39	7.7e-6	Preschool internalizing problems;
TGCT	cis	rs12142240	0.659	rs72677602	chr1:46837487	G/A	cg00530320	chr1:46809349	NSUN4	0.27	5.45	0.44	2.58e-7	Menopause (age at onset);
TGCT	cis	rs9549367	0.774	rs9549696	chr13:113875062	C/T	cg00898013	chr13:113819073	PROZ	-0.37	-4.73	-0.39	5.96e-6	Platelet distribution width;
TGCT	cis	rs9341808	0.618	rs6916507	chr6:80862265	T/C	cg08355045	chr6:80787529	NA	0.32	5.83	0.46	4.48e-8	Sitting height ratio;
TGCT	cis	rs1215050	0.874	rs2167893	chr4:99048464	A/T	cg05340658	chr4:99064831	C4orf37	0.42	5.03	0.41	1.7e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg06618935	chr21:46677482	NA	-0.37	-5.68	-0.45	9.21e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg10802521	chr3:52805072	NEK4	-0.71	-8.81	-0.62	9.29e-15	Bipolar disorder;
TGCT	cis	rs1008375	0.931	rs1860592	chr4:17577028	C/G	cg16339924	chr4:17578868	LAP3	0.8	6.96	0.53	1.73e-10	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7586879	0.639	rs7580081	chr2:25097072	G/C	cg15423357	chr2:25149977	NA	0.47	4.6	0.38	1.02e-5	Body mass index;
TGCT	cis	rs6688613	0.649	rs11584352	chr1:166850372	T/C	cg07049167	chr1:166818506	POGK	0.25	5.23	0.43	6.88e-7	Refractive astigmatism;
TGCT	cis	rs11190604	1.000	rs74210981	chr10:102287520	C/T	cg23241863	chr10:102295624	HIF1AN	0.66	4.87	0.4	3.38e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs1847202	0.826	rs7640629	chr3:72925997	C/T	cg25664220	chr3:72788482	NA	-0.38	-4.88	-0.4	3.13e-6	Motion sickness;
TGCT	cis	rs3125734	0.572	rs7896627	chr10:64046354	T/G	cg09941381	chr10:64027924	RTKN2	-0.33	-4.9	-0.4	2.94e-6	Rheumatoid arthritis;
TGCT	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	8.55	0.61	3.84e-14	Platelet count;
TGCT	cis	rs7940866	0.838	rs12790299	chr11:130803634	A/G	cg05962950	chr11:130786565	SNX19	0.68	6.61	0.51	1.02e-9	Schizophrenia;
TGCT	cis	rs7552404	1.000	rs72686191	chr1:76218319	G/T	cg22875332	chr1:76189707	ACADM	0.78	8.98	0.63	3.55e-15	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs6967414	0.786	rs6948965	chr7:6758547	G/A	cg09896999	chr7:6746977	ZNF12	-0.59	-6.54	-0.51	1.45e-9	Hematocrit;Hemoglobin concentration;
TGCT	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg20607798	chr8:58055168	NA	0.49	4.67	0.39	7.56e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7582180	0.629	rs893416	chr2:100957443	G/A	cg14675211	chr2:100938903	LONRF2	0.5	4.78	0.39	4.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg03213289	chr20:61660250	NA	0.7	10.11	0.67	6.94e-18	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs59197085	0.515	rs2291573	chr7:128444820	A/G	cg00260937	chr7:128520193	KCP	0.46	5.12	0.42	1.15e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
TGCT	cis	rs2255336	0.702	rs7964772	chr12:10520097	G/A	cg16084090	chr12:10586130	KLRC2	0.3	4.65	0.39	8.37e-6	Blood protein levels;
TGCT	cis	rs9467773	1.000	rs9393731	chr6:26529374	C/T	cg15659132	chr6:26577336	NA	0.86	12.21	0.74	5.3e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs9486719	1.000	rs2971603	chr6:97035418	C/T	cg06623918	chr6:96969491	KIAA0776	-1.04	-10.25	-0.68	3.11e-18	Migraine;Coronary artery disease;
TGCT	cis	rs909341	0.868	rs2236508	chr20:62333115	G/A	cg14758556	chr20:62440591	NA	0.29	4.48	0.37	1.71e-5	Atopic dermatitis;
TGCT	cis	rs3824867	0.920	rs7101772	chr11:47449378	A/G	cg20307385	chr11:47447363	PSMC3	-0.69	-5.86	-0.47	3.99e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs72949976	0.934	rs13406406	chr2:214034826	C/T	cg08319019	chr2:214017104	IKZF2	-0.78	-7.15	-0.54	6.61e-11	Lung cancer;Squamous cell lung carcinoma;
TGCT	cis	rs3740393	0.562	rs11191389	chr10:104523018	C/T	cg05855489	chr10:104503620	C10orf26	0.76	6.34	0.5	3.8e-9	Microalbuminuria;
TGCT	cis	rs4455778	0.659	rs10268788	chr7:49048110	G/A	cg26309511	chr7:48887640	NA	0.42	4.98	0.41	2.08e-6	Lung cancer in never smokers;
TGCT	cis	rs60871478	0.588	rs6952577	chr7:872100	C/T	cg15782153	chr7:917662	C7orf20	-0.52	-4.78	-0.39	4.84e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs473651	0.935	rs541128	chr2:239336449	A/G	cg08773314	chr2:239334832	ASB1	0.45	7.5	0.56	1.07e-11	Multiple system atrophy;
TGCT	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg11871910	chr12:69753446	YEATS4	0.88	10.41	0.68	1.28e-18	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg04287289	chr16:89883240	FANCA	-0.91	-11.11	-0.71	2.56e-20	Vitiligo;
TGCT	cis	rs4730250	0.707	rs6946931	chr7:106788621	G/T	cg02696742	chr7:106810147	HBP1	-0.71	-6.08	-0.48	1.35e-8	Osteoarthritis;
TGCT	cis	rs2070488	1.000	rs2276540	chr3:38512507	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.89	9.58	0.65	1.34e-16	Electrocardiographic conduction measures;
TGCT	cis	rs12210905	0.610	rs72845208	chr6:27395664	C/A	cg08851530	chr6:28072375	NA	1.34	6.07	0.48	1.44e-8	Hip circumference adjusted for BMI;
TGCT	cis	rs7552404	0.731	rs5745491	chr1:76350159	T/G	cg22875332	chr1:76189707	ACADM	-0.67	-6.92	-0.53	2.12e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs12477438	0.765	rs7607578	chr2:99669771	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-7.6	-0.56	6.47e-12	Chronic sinus infection;
TGCT	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.65	-6.51	-0.5	1.68e-9	Prostate cancer;
TGCT	cis	rs10501293	0.746	rs7126731	chr11:43007348	T/C	cg03447554	chr11:43094025	NA	0.44	6.31	0.49	4.57e-9	Cognitive performance;
TGCT	cis	rs709400	1.000	rs10135248	chr14:104122310	T/C	cg26031613	chr14:104095156	KLC1	1.14	17.16	0.84	1.53e-34	Body mass index;
TGCT	trans	rs17471911	0.708	rs11189933	chr10:100772538	A/T	cg03484267	chr2:207988651	KLF7	-0.52	-6.7	-0.52	6.49e-10	Neuroticism;
TGCT	cis	rs12142240	0.698	rs66847432	chr1:46832013	G/A	cg00530320	chr1:46809349	NSUN4	0.29	6.03	0.48	1.71e-8	Menopause (age at onset);
TGCT	cis	rs8180040	0.654	rs13078131	chr3:47204939	G/T	cg27129171	chr3:47204927	SETD2	0.77	9.86	0.66	2.77e-17	Colorectal cancer;
TGCT	cis	rs1729951	0.575	rs75976	chr3:136700455	G/A	cg12473912	chr3:136751656	NA	0.39	6.34	0.49	3.84e-9	Neuroticism;
TGCT	cis	rs7949030	0.626	rs11231144	chr11:62328038	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.66	9.69	0.66	7.3e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	trans	rs4824093	0.610	rs77128035	chr22:50241024	C/T	cg09872104	chr7:134855509	C7orf49	-0.9	-7.32	-0.55	2.72e-11	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs11148252	0.553	rs2147692	chr13:53287023	C/G	cg00495681	chr13:53174319	NA	0.73	7.61	0.56	6.01e-12	Lewy body disease;
TGCT	cis	rs7829975	0.811	rs7011229	chr8:8543324	T/C	cg06636001	chr8:8085503	FLJ10661	-0.6	-5.0	-0.41	1.92e-6	Mood instability;
TGCT	trans	rs797680	0.856	rs9432681	chr1:93761896	A/G	cg27528825	chr2:159282178	CCDC148	0.34	6.71	0.52	6.19e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs2486288	0.587	rs12899942	chr15:45547280	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.72	-7.46	-0.56	1.34e-11	Glomerular filtration rate;
TGCT	cis	rs10193935	0.901	rs1439231	chr2:42542884	G/A	cg27598129	chr2:42591480	NA	-0.4	-5.45	-0.44	2.66e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1775715	0.737	rs1023207	chr10:32094890	C/A	cg14930904	chr10:32216787	ARHGAP12	0.52	5.1	0.42	1.26e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg05896524	chr21:47604654	C21orf56	0.42	4.45	0.37	1.91e-5	Testicular germ cell tumor;
TGCT	trans	rs6089829	0.926	rs6011552	chr20:61667894	T/C	cg13615516	chr5:77269221	NA	0.66	8.06	0.59	5.55e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs12681288	0.550	rs58295701	chr8:962136	T/C	cg04851639	chr8:1020857	NA	-0.3	-5.08	-0.41	1.36e-6	Schizophrenia;
TGCT	cis	rs644799	0.710	rs10831433	chr11:95519787	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	9.19	0.64	1.12e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs17253792	0.822	rs9323289	chr14:56106784	G/C	cg01858014	chr14:56050164	KTN1	-0.35	-4.5	-0.37	1.53e-5	Putamen volume;
TGCT	cis	rs11264213	0.901	rs12031138	chr1:36407806	C/T	cg07093915	chr1:36184400	C1orf216	-0.65	-4.47	-0.37	1.77e-5	Schizophrenia;
TGCT	cis	rs28830936	0.510	rs2412640	chr15:42124082	C/T	cg17847044	chr15:42102381	MAPKBP1	0.17	4.73	0.39	6.1e-6	Diastolic blood pressure;
TGCT	cis	rs523522	0.962	rs10849757	chr12:120964014	G/A	cg12219531	chr12:120966889	COQ5	0.83	7.27	0.55	3.46e-11	High light scatter reticulocyte count;
TGCT	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg10150615	chr22:24372951	LOC391322	-0.74	-7.98	-0.58	8.36e-13	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7226408	0.857	rs10502667	chr18:34482449	C/G	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	trans	rs1814175	0.791	rs7395713	chr11:49877887	A/G	cg03929089	chr4:120376271	NA	-0.71	-8.03	-0.58	6.31e-13	Height;
TGCT	cis	rs4654899	1.000	rs6669102	chr1:21355543	A/G	cg01072550	chr1:21505969	NA	-0.48	-7.78	-0.57	2.49e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs7226408	0.857	rs72892516	chr18:34665048	G/A	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs2204008	0.550	rs11495600	chr12:38126654	C/T	cg26384229	chr12:38710491	ALG10B	0.86	7.65	0.57	4.87e-12	Bladder cancer;
TGCT	trans	rs28735056	0.904	rs11520415	chr18:77620620	C/T	cg05926928	chr17:57297772	GDPD1	0.64	6.68	0.51	7.09e-10	Schizophrenia;
TGCT	cis	rs4563143	0.502	rs73029061	chr19:29283980	T/A	cg03161606	chr19:29218774	NA	0.62	6.0	0.47	2e-8	Methadone dose in opioid dependence;
TGCT	cis	rs6740731	0.518	rs16823846	chr2:145299944	C/T	cg07679370	chr2:145795797	NA	0.27	5.36	0.43	3.83e-7	Coronary artery disease;
TGCT	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/A	cg26531700	chr6:26746687	NA	0.6	5.81	0.46	5e-8	Intelligence (multi-trait analysis);
TGCT	trans	rs9951602	0.512	rs7241419	chr18:76640778	C/G	cg02800362	chr5:177631904	HNRNPAB	1.13	12.78	0.75	2.24e-24	Obesity-related traits;
TGCT	cis	rs10782582	0.593	rs11802717	chr1:76124648	C/T	cg10523679	chr1:76189770	ACADM	-0.7	-7.51	-0.56	9.94e-12	Daytime sleep phenotypes;
TGCT	cis	rs9325144	0.647	rs12830095	chr12:38864199	C/T	cg10518543	chr12:38710700	ALG10B	-0.49	-4.46	-0.37	1.81e-5	Morning vs. evening chronotype;
TGCT	cis	rs7959452	0.535	rs7308481	chr12:69659299	A/G	cg11871910	chr12:69753446	YEATS4	0.63	6.24	0.49	6.36e-9	Blood protein levels;
TGCT	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg06238570	chr21:40685208	BRWD1	0.72	6.84	0.52	3.16e-10	Cognitive function;
TGCT	cis	rs4319547	0.955	rs6489159	chr12:123112806	G/A	cg23029597	chr12:123009494	RSRC2	-0.33	-5.35	-0.43	4e-7	Body mass index;
TGCT	cis	rs651907	0.557	rs7645391	chr3:101361506	C/G	cg12386194	chr3:101231763	SENP7	0.52	5.01	0.41	1.87e-6	Colorectal cancer;
TGCT	trans	rs3780486	0.846	rs7849148	chr9:33138352	A/T	cg04842962	chr6:43655489	MRPS18A	1.24	15.76	0.82	2.18e-31	IgG glycosylation;
TGCT	cis	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg20637647	chr7:64974828	NA	0.98	5.48	0.44	2.3e-7	Diabetic kidney disease;
TGCT	cis	rs9611565	0.608	rs202652	chr22:41838792	A/G	cg17554472	chr22:41940697	POLR3H	0.46	4.71	0.39	6.63e-6	Vitiligo;
TGCT	cis	rs7824557	0.628	rs7008205	chr8:11197323	T/G	cg21775007	chr8:11205619	TDH	0.69	6.81	0.52	3.8e-10	Retinal vascular caliber;
TGCT	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg13342137	chr4:2252803	MXD4	0.17	4.56	0.38	1.23e-5	Obesity-related traits;
TGCT	cis	rs1577917	0.740	rs9344542	chr6:86393905	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.5	4.63	0.38	9.26e-6	Response to antipsychotic treatment;
TGCT	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg23302884	chr18:44338147	ST8SIA5	0.4	4.79	0.4	4.67e-6	Personality dimensions;
TGCT	cis	rs7804356	0.651	rs1023712	chr7:26803163	A/C	cg03456212	chr7:26904342	SKAP2	-0.54	-4.6	-0.38	1.04e-5	Type 1 diabetes;
TGCT	cis	rs6684514	1.000	rs12023438	chr1:156254358	A/G	cg16558208	chr1:156270281	VHLL	0.46	9.38	0.64	3.92e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs7267979	0.789	rs6076347	chr20:25398790	C/T	cg16686733	chr20:25566563	NINL	-0.49	-4.64	-0.38	8.6e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs17607347	0.542	rs2336437	chr16:72465604	G/T	cg06220725	chr16:72042591	DHODH	-0.73	-4.83	-0.4	3.96e-6	Intelligence (multi-trait analysis);
TGCT	trans	rs877282	0.853	rs7069720	chr10:754487	A/G	cg22713356	chr15:30763199	NA	1.07	8.27	0.6	1.75e-13	Uric acid levels;
TGCT	cis	rs2404602	1.000	rs12441433	chr15:76816015	G/A	cg22467129	chr15:76604101	ETFA	-0.49	-5.48	-0.44	2.3e-7	Blood metabolite levels;
TGCT	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.34	0.43	4.23e-7	Prudent dietary pattern;
TGCT	cis	rs4148883	0.603	rs6833176	chr4:100131163	G/C	cg12011299	chr4:100065546	ADH4	-0.37	-5.48	-0.44	2.32e-7	Alcohol dependence;
TGCT	cis	rs6908034	0.660	rs7746588	chr6:19804640	C/T	cg02682789	chr6:19804855	NA	0.92	5.24	0.43	6.7e-7	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
TGCT	cis	rs12682352	0.602	rs11783966	chr8:8665147	A/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-5.59	-0.45	1.38e-7	Neuroticism;
TGCT	cis	rs4771122	0.728	rs7992289	chr13:28036430	G/A	cg22138327	chr13:27999177	GTF3A	-0.72	-5.79	-0.46	5.36e-8	Body mass index;
TGCT	trans	rs459571	0.959	rs2520099	chr9:136918139	T/C	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.77	-8.34	-0.6	1.17e-13	Platelet distribution width;
TGCT	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg22764044	chr5:178986830	RUFY1	-0.5	-5.66	-0.45	9.95e-8	Lung cancer;
TGCT	cis	rs6540559	0.673	rs6698154	chr1:210007777	A/G	cg21951975	chr1:209979733	IRF6	0.64	4.82	0.4	4.12e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs8078723	1.000	rs4794824	chr17:38179290	G/A	cg17467752	chr17:38218738	THRA	0.53	5.08	0.42	1.33e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs7216064	1.000	rs56404791	chr17:65893019	T/G	cg12091567	chr17:66097778	LOC651250	-0.84	-6.17	-0.48	8.94e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs6032067	0.636	rs6032094	chr20:43912637	G/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.48	-7.2	-0.54	5.02e-11	Blood protein levels;
TGCT	cis	rs3008870	0.920	rs3008865	chr1:67402838	T/C	cg11518657	chr1:67396239	MIER1	0.54	4.68	0.39	7.24e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs548181	1.000	rs548181	chr11:125461709	A/G	cg03464685	chr11:125439445	EI24	1.2	9.28	0.64	6.78e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg26513180	chr16:89883248	FANCA	1.07	14.86	0.8	2.59e-29	Vitiligo;
TGCT	trans	rs77457752	0.690	rs10123356	chr9:13912564	T/C	cg18948646	chr4:83674694	SCD5;MIR575	0.54	6.62	0.51	9.53e-10	Breast cancer;
TGCT	cis	rs295140	0.605	rs3769471	chr2:201195403	G/A	cg23649088	chr2:200775458	C2orf69	-0.27	-4.49	-0.37	1.62e-5	QT interval;
TGCT	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg22920501	chr2:26401640	FAM59B	-0.79	-6.31	-0.49	4.58e-9	Gut microbiome composition (summer);
TGCT	cis	rs6964587	1.000	rs3753108	chr7:91629984	T/G	cg17063962	chr7:91808500	NA	0.91	9.97	0.67	1.53e-17	Breast cancer;
TGCT	cis	rs4803468	1.000	rs2241706	chr19:41912807	A/G	cg09537434	chr19:41945824	ATP5SL	-0.92	-10.69	-0.69	2.72e-19	Height;
TGCT	cis	rs10392	0.543	rs16987679	chr20:37557185	G/C	cg27552599	chr20:37590471	DHX35	0.37	4.44	0.37	2e-5	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
TGCT	cis	rs6671200	0.607	rs7528790	chr1:95709074	A/G	cg03123541	chr1:95699097	RWDD3	-0.81	-7.26	-0.55	3.81e-11	Stearic acid (18:0) levels;
TGCT	cis	rs3096299	0.719	rs2965818	chr16:89510494	A/G	cg06640241	chr16:89574553	SPG7	0.76	8.51	0.61	4.86e-14	Multiple myeloma (IgH translocation);
TGCT	cis	rs4727027	0.651	rs12704068	chr7:148856153	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.57	5.0	0.41	1.91e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs826838	1.000	rs34254519	chr12:39041235	G/A	cg13010199	chr12:38710504	ALG10B	0.78	6.38	0.5	3.22e-9	Heart rate;
TGCT	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg22508957	chr16:3507546	NAT15	0.5	5.79	0.46	5.49e-8	Tuberculosis;
TGCT	cis	rs9467711	0.651	rs13200797	chr6:26122957	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.57	-4.54	-0.38	1.33e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12477438	0.765	rs10181422	chr2:99558970	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-4.52	-0.38	1.45e-5	Chronic sinus infection;
TGCT	cis	rs2456568	0.548	rs6483280	chr11:93661592	T/C	cg16099599	chr11:93583650	C11orf90	-0.39	-4.66	-0.39	7.9e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs908922	0.676	rs528427	chr1:152511507	G/C	cg20991723	chr1:152506922	NA	0.46	6.18	0.48	8.66e-9	Hair morphology;
TGCT	cis	rs694739	0.628	rs645078	chr11:64135298	A/C	cg02228329	chr11:64053129	BAD;GPR137	0.72	7.05	0.53	1.1e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs3125734	0.633	rs1368157	chr10:64001114	T/C	cg09941381	chr10:64027924	RTKN2	-0.37	-5.59	-0.45	1.41e-7	Rheumatoid arthritis;
TGCT	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg03709012	chr19:19516395	GATAD2A	0.74	6.12	0.48	1.15e-8	Tonsillectomy;
TGCT	cis	rs10883723	0.810	rs7093028	chr10:104259417	A/G	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs2239547	0.522	rs2581805	chr3:52979050	T/C	cg11645453	chr3:52864694	ITIH4	-0.32	-5.24	-0.43	6.56e-7	Schizophrenia;
TGCT	cis	rs2070488	1.000	rs2268757	chr3:38505853	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.89	9.83	0.66	3.21e-17	Electrocardiographic conduction measures;
TGCT	cis	rs514475	0.526	rs12197157	chr6:137952912	C/T	cg02673417	chr6:137105249	MAP3K5	0.29	4.45	0.37	1.88e-5	Inflammatory skin disease;
TGCT	cis	rs6728642	0.803	rs11891457	chr2:97632449	G/T	cg26665480	chr2:98280029	ACTR1B	-0.91	-5.94	-0.47	2.67e-8	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	cis	rs7666738	0.830	rs6532701	chr4:98745134	C/T	cg18180107	chr4:99064573	C4orf37	0.53	5.03	0.41	1.69e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9368481	0.729	rs9379948	chr6:26944783	T/G	cg18867708	chr6:26865862	GUSBL1	0.34	4.49	0.37	1.61e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4595586	0.545	rs6580894	chr12:39371951	A/G	cg10518543	chr12:38710700	ALG10B	0.54	4.61	0.38	9.99e-6	Morning vs. evening chronotype;
TGCT	cis	rs2455799	0.559	rs7635539	chr3:15922908	A/G	cg12172478	chr3:16357591	RFTN1	0.34	5.1	0.42	1.25e-6	Mean platelet volume;
TGCT	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg18876405	chr7:65276391	NA	-0.31	-4.6	-0.38	1.03e-5	Aortic root size;
TGCT	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	8.49	0.61	5.35e-14	Platelet count;
TGCT	cis	rs7666738	0.830	rs7678911	chr4:99057430	C/T	cg17366294	chr4:99064904	C4orf37	0.73	7.45	0.56	1.4e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6940638	0.688	rs9393795	chr6:27217719	G/C	cg26531700	chr6:26746687	NA	-0.58	-5.11	-0.42	1.21e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7824557	0.724	rs2572398	chr8:11178093	A/C	cg21775007	chr8:11205619	TDH	0.56	5.14	0.42	1.05e-6	Retinal vascular caliber;
TGCT	cis	rs79349575	0.783	rs903567	chr17:46980318	C/T	cg26022315	chr17:47021804	SNF8	0.48	4.82	0.4	4.06e-6	Type 2 diabetes;
TGCT	cis	rs2721195	0.845	rs3757966	chr8:145744618	G/A	cg15320075	chr8:145703422	NA	0.7	7.12	0.54	7.58e-11	Age at first birth;
TGCT	cis	rs55692411	0.537	rs35012435	chr3:50031840	C/T	cg14019146	chr3:50243930	SLC38A3	-0.21	-4.44	-0.37	1.98e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs295137	0.799	rs4145969	chr2:201139961	C/T	cg04283868	chr2:201171347	SPATS2L	0.47	4.51	0.38	1.51e-5	Asthma (bronchodilator response);
TGCT	cis	rs9583531	0.600	rs3809344	chr13:111358705	G/A	cg24331049	chr13:111365604	ING1	0.76	7.31	0.55	2.95e-11	Coronary artery disease;
TGCT	cis	rs2862064	0.872	rs6555822	chr5:156473185	A/G	cg12943317	chr5:156479607	HAVCR1	-0.46	-5.59	-0.45	1.35e-7	Platelet count;
TGCT	cis	rs7666738	0.830	rs4440224	chr4:99044924	G/A	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10838634	0.901	rs57485117	chr11:46803700	C/G	cg18332754	chr11:46939436	LRP4	0.84	4.54	0.38	1.29e-5	Schizophrenia;
TGCT	cis	rs9611565	0.513	rs739135	chr22:42090069	A/C	cg03806693	chr22:41940476	POLR3H	1.08	11.79	0.73	5.53e-22	Vitiligo;
TGCT	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg17971929	chr21:40555470	PSMG1	0.96	9.05	0.63	2.44e-15	Cognitive function;
TGCT	cis	rs4808199	0.895	rs10421505	chr19:19459554	C/T	cg03709012	chr19:19516395	GATAD2A	0.8	6.46	0.5	2.13e-9	Nonalcoholic fatty liver disease;
TGCT	cis	rs9467773	0.523	rs2498399	chr6:26706544	T/C	cg05738196	chr6:26577821	NA	0.87	9.67	0.66	7.91e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs6684514	0.961	rs72710222	chr1:156285995	T/C	cg20302342	chr1:156215951	PAQR6	0.35	4.74	0.39	5.77e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs9303401	0.538	rs10515155	chr17:56481944	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.73	6.73	0.52	5.72e-10	Cognitive test performance;
TGCT	cis	rs28595532	0.844	rs115411027	chr4:119490685	T/C	cg14228332	chr4:119757509	SEC24D	1.0	5.75	0.46	6.54e-8	Cannabis dependence symptom count;
TGCT	cis	rs11577318	0.853	rs3795684	chr1:26632781	C/T	cg04990556	chr1:26633338	UBXN11	-0.63	-5.77	-0.46	6.01e-8	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs4383453	0.539	rs903571	chr3:123101250	A/C	cg04890266	chr3:123102914	ADCY5	-0.49	-8.13	-0.59	3.67e-13	Gestational age at birth (maternal effect);
TGCT	cis	rs13326165	0.760	rs35133416	chr3:52359040	C/T	cg07884673	chr3:53033167	SFMBT1	0.39	4.69	0.39	7e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs6912958	0.559	rs242279	chr6:88048191	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.4	4.71	0.39	6.65e-6	Monocyte percentage of white cells;
TGCT	trans	rs10203711	1.000	rs4994756	chr2:239567125	T/C	cg16021909	chr1:248021091	TRIM58	-0.66	-6.66	-0.51	7.94e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6840360	0.870	rs6814554	chr4:152454334	G/A	cg17479576	chr4:152424074	FAM160A1	-0.55	-6.17	-0.48	8.74e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs8013055	0.846	rs35723046	chr14:105970548	C/T	cg19700328	chr14:106028568	NA	-0.53	-5.76	-0.46	6.36e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs644799	0.710	rs10831429	chr11:95508524	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.81	9.02	0.63	2.92e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg24531977	chr5:56204891	C5orf35	-0.77	-7.61	-0.56	5.83e-12	Initial pursuit acceleration;
TGCT	cis	rs7091068	0.671	rs588912	chr10:95402929	T/C	cg20715218	chr10:95462985	C10orf4	-0.54	-5.14	-0.42	1.02e-6	Urinary tract infection frequency;
TGCT	cis	rs2887571	0.580	rs34992552	chr12:1637688	G/A	cg01940102	chr12:1095972	NA	0.26	4.78	0.39	4.92e-6	Bone mineral density;
TGCT	cis	rs40363	0.951	rs72778117	chr16:3531827	T/C	cg05754148	chr16:3507555	NAT15	0.47	4.64	0.38	8.58e-6	Tuberculosis;
TGCT	cis	rs1865760	0.865	rs9467650	chr6:25958235	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.64	6.29	0.49	4.91e-9	Height;
TGCT	cis	rs12479064	0.724	rs2305352	chr2:100015124	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.58	-4.71	-0.39	6.5e-6	Chronic sinus infection;
TGCT	cis	rs2663905	0.611	rs1509559	chr15:81391411	G/A	cg27045999	chr15:81426544	C15orf26	-0.55	-5.52	-0.44	1.89e-7	QT interval (drug interaction);
TGCT	cis	rs4851254	0.584	rs35774174	chr2:100655130	T/A	cg07810366	chr2:100720526	AFF3	-0.47	-4.75	-0.39	5.46e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7786808	0.776	rs11983316	chr7:158209742	A/G	cg01191920	chr7:158217561	PTPRN2	-0.42	-6.48	-0.5	1.95e-9	Obesity-related traits;
TGCT	cis	rs1577917	0.958	rs13213551	chr6:86608701	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.22	-0.42	7.27e-7	Response to antipsychotic treatment;
TGCT	cis	rs617219	0.597	rs10474581	chr5:78578884	G/A	cg23987322	chr5:78407566	BHMT	-0.36	-4.66	-0.39	8.06e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.72	-5.71	-0.46	7.86e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs10197940	0.662	rs10175134	chr2:152299355	G/A	cg06191203	chr2:152266755	RIF1	-0.78	-7.31	-0.55	2.89e-11	Lung cancer;
TGCT	cis	rs6570726	0.935	rs385185	chr6:145814992	A/G	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	8.99	0.63	3.48e-15	Platelet count;
TGCT	cis	rs6582630	0.519	rs8189618	chr12:38276281	A/C	cg26384229	chr12:38710491	ALG10B	0.86	7.48	0.56	1.19e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs941408	0.515	rs2110118	chr19:2775144	T/C	cg06609049	chr19:2785107	THOP1	1.11	12.98	0.76	7.5e-25	Total cholesterol levels;
TGCT	cis	rs3087591	0.922	rs2905801	chr17:29524974	C/T	cg24425628	chr17:29625626	OMG;NF1	0.42	6.22	0.49	7.06e-9	Hip circumference;
TGCT	cis	rs796364	0.570	rs4673491	chr2:200669108	A/G	cg17644776	chr2:200775616	C2orf69	0.34	4.59	0.38	1.07e-5	Schizophrenia;
TGCT	cis	rs7617773	0.832	rs6775114	chr3:48182620	G/C	cg11946769	chr3:48343235	NME6	-0.59	-5.35	-0.43	4.07e-7	Coronary artery disease;
TGCT	cis	rs8032315	0.965	rs12906125	chr15:91427612	G/A	cg04510874	chr15:91427884	FES	0.52	5.78	0.46	5.8e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4919687	0.550	rs12775883	chr10:104485301	G/A	cg05855489	chr10:104503620	C10orf26	0.56	4.51	0.38	1.5e-5	Colorectal cancer;
TGCT	cis	rs174479	0.743	rs174464	chr11:61657926	A/G	cg01500311	chr11:61656094	FADS3	0.28	5.03	0.41	1.68e-6	Sphingolipid levels;
TGCT	cis	rs854765	0.583	rs11078405	chr17:17824978	G/T	cg09796270	chr17:17721594	SREBF1	0.28	5.66	0.45	9.89e-8	Total body bone mineral density;
TGCT	cis	rs9902453	0.866	rs4795529	chr17:28443549	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.76	7.28	0.55	3.38e-11	Coffee consumption (cups per day);
TGCT	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg18876405	chr7:65276391	NA	-0.34	-5.19	-0.42	8.37e-7	Aortic root size;
TGCT	cis	rs7267979	0.866	rs2424698	chr20:25256106	C/T	cg16686733	chr20:25566563	NINL	0.62	6.43	0.5	2.54e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.57	0.38	1.15e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs986417	0.901	rs10483726	chr14:61039476	A/G	cg27398547	chr14:60952738	C14orf39	1.43	10.61	0.69	4.17e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs6540559	0.546	rs57315825	chr1:210030197	C/T	cg22029157	chr1:209979665	IRF6	0.81	6.07	0.48	1.45e-8	Cleft lip with or without cleft palate;
TGCT	cis	rs9534288	0.830	rs940	chr13:46627480	C/G	cg15192986	chr13:46630673	CPB2	-0.52	-6.68	-0.51	7.09e-10	Blood protein levels;
TGCT	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg18402987	chr7:1209562	NA	0.77	6.51	0.5	1.7e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1532993	0.518	rs6532689	chr4:98616963	C/A	cg05340658	chr4:99064831	C4orf37	-0.37	-4.44	-0.37	1.98e-5	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs1723838	1.000	rs1792164	chr11:73548670	G/A	cg26954736	chr11:73693896	UCP2	-1.1	-4.61	-0.38	9.8e-6	Obesity-related traits;
TGCT	cis	rs1215050	0.791	rs2865942	chr4:98737709	G/C	cg17366294	chr4:99064904	C4orf37	0.52	5.57	0.45	1.54e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs11030122	0.547	rs10767723	chr11:3955026	G/T	cg18678763	chr11:4115507	RRM1	-0.39	-4.76	-0.39	5.24e-6	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs17473412	0.609	rs6875515	chr5:122864629	G/A	cg15125798	chr5:122621645	NA	-0.53	-4.9	-0.4	2.93e-6	Total body bone mineral density;
TGCT	cis	rs362272	0.545	rs3129308	chr4:3309272	C/T	cg22655196	chr4:3374909	RGS12	0.26	5.36	0.43	3.83e-7	Serum sulfate level;
TGCT	cis	rs12681287	0.546	rs11539113	chr8:87497176	G/A	cg27223183	chr8:87520930	FAM82B	-0.94	-6.79	-0.52	4.14e-10	Caudate activity during reward;
TGCT	cis	rs62244186	0.715	rs13321717	chr3:44667455	C/A	cg25151919	chr3:44754333	ZNF502	-0.43	-5.01	-0.41	1.8e-6	Depressive symptoms;
TGCT	cis	rs651907	0.557	rs13069443	chr3:101373305	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.03	0.41	1.65e-6	Colorectal cancer;
TGCT	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg24250549	chr1:154909240	PMVK	0.63	6.25	0.49	6.03e-9	Prostate cancer;
TGCT	cis	rs765787	0.530	rs7165889	chr15:45531640	T/C	cg24006582	chr15:45444508	DUOX1	-0.25	-5.53	-0.44	1.82e-7	Uric acid levels;
TGCT	cis	rs13272623	0.502	rs268562	chr8:71494780	G/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.71	-5.89	-0.47	3.47e-8	IgG glycosylation;
TGCT	cis	rs13191362	0.507	rs2023038	chr6:163119280	C/G	cg21926612	chr6:163149169	PACRG;PARK2	-0.61	-5.69	-0.45	8.8e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	trans	rs2610739	0.591	rs12211793	chr6:89189968	G/C	cg05764691	chr16:22927585	HS3ST2	0.41	6.82	0.52	3.51e-10	IgG glycosylation;
TGCT	cis	rs6912958	0.703	rs9353483	chr6:88097180	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.4	5.17	0.42	8.97e-7	Monocyte percentage of white cells;
TGCT	trans	rs2727020	0.553	rs3862350	chr11:49595912	A/C	cg15704280	chr7:45808275	SEPT13	-0.61	-6.89	-0.53	2.47e-10	Coronary artery disease;
TGCT	cis	rs1153858	1.000	rs1145081	chr15:45679667	C/G	cg14582100	chr15:45693742	SPATA5L1	0.48	5.69	0.46	8.56e-8	Homoarginine levels;
TGCT	cis	rs61931739	0.500	rs11053198	chr12:34444013	G/C	cg06521331	chr12:34319734	NA	-0.28	-4.51	-0.38	1.47e-5	Morning vs. evening chronotype;
TGCT	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg17554472	chr22:41940697	POLR3H	-0.51	-5.5	-0.44	2.09e-7	Vitiligo;
TGCT	cis	rs16958440	0.867	rs12326412	chr18:44683594	A/C	cg17192377	chr18:44677553	HDHD2	0.63	4.7	0.39	6.74e-6	Sitting height ratio;
TGCT	cis	rs6831352	0.879	rs1984364	chr4:100070783	A/C	cg12011299	chr4:100065546	ADH4	-0.43	-5.07	-0.41	1.44e-6	Alcohol dependence;
TGCT	cis	rs3096299	0.685	rs3803681	chr16:89544756	C/T	cg06640241	chr16:89574553	SPG7	0.79	8.8	0.62	1.01e-14	Multiple myeloma (IgH translocation);
TGCT	cis	rs11971779	0.680	rs73154134	chr7:139039951	G/A	cg07862535	chr7:139043722	LUC7L2	0.7	5.21	0.42	7.8e-7	Diisocyanate-induced asthma;
TGCT	cis	rs4819052	0.788	rs9978857	chr21:46705155	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	6.65	0.51	8.21e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2832191	0.765	rs2832162	chr21:30461808	G/A	cg08807101	chr21:30365312	RNF160	0.65	6.08	0.48	1.34e-8	Dental caries;
TGCT	cis	rs7727544	0.606	rs11950562	chr5:131652529	A/C	cg24060327	chr5:131705240	SLC22A5	-0.53	-5.7	-0.46	8.23e-8	Blood metabolite levels;
TGCT	cis	rs7258465	1.000	rs10411009	chr19:18606266	A/G	cg06462663	chr19:18546047	ISYNA1	0.2	4.68	0.39	7.45e-6	Breast cancer;
TGCT	cis	rs7731657	0.537	rs2905534	chr5:130242005	C/T	cg08523029	chr5:130500466	HINT1	-0.58	-4.84	-0.4	3.8e-6	Fasting plasma glucose;
TGCT	cis	rs4919669	0.668	rs10883760	chr10:104419465	G/T	cg05855489	chr10:104503620	C10orf26	0.8	4.59	0.38	1.05e-5	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs79349575	0.783	rs4794003	chr17:47029904	C/T	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.52	-0.38	1.44e-5	Type 2 diabetes;
TGCT	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg17554472	chr22:41940697	POLR3H	0.49	5.16	0.42	9.72e-7	Vitiligo;
TGCT	cis	rs3784262	0.740	rs2119859	chr15:58254745	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.42	-6.18	-0.49	8.37e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs9330316	0.632	rs6723295	chr2:110363704	G/A	cg25199208	chr2:109402912	CCDC138	-0.41	-4.44	-0.37	1.99e-5	Schizophrenia;
TGCT	cis	rs9549367	0.789	rs12869947	chr13:113896156	A/G	cg18105134	chr13:113819100	PROZ	-0.34	-5.61	-0.45	1.25e-7	Platelet distribution width;
TGCT	cis	rs5769765	0.837	rs4824110	chr22:50271631	T/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.41	-6.13	-0.48	1.08e-8	Schizophrenia;
TGCT	cis	rs10782582	0.593	rs12131493	chr1:76139172	G/A	cg10523679	chr1:76189770	ACADM	-0.68	-7.05	-0.53	1.12e-10	Daytime sleep phenotypes;
TGCT	cis	rs7072216	0.763	rs7910247	chr10:100172252	C/T	cg26618903	chr10:100175079	PYROXD2	-0.4	-4.49	-0.37	1.64e-5	Metabolite levels;
TGCT	cis	rs838147	0.760	rs412712	chr19:49234299	A/T	cg13540341	chr19:49222985	MAMSTR	0.31	4.48	0.37	1.66e-5	Dietary macronutrient intake;
TGCT	cis	rs11203032	1.000	rs11203031	chr10:90964395	G/T	cg16672925	chr10:90967113	CH25H	0.69	4.68	0.39	7.41e-6	Heart failure;
TGCT	cis	rs6426558	0.502	rs1929858	chr1:227220175	C/A	cg10327440	chr1:227177885	CDC42BPA	0.62	7.52	0.56	9.35e-12	Neutrophil percentage of white cells;
TGCT	cis	rs861020	0.771	rs629150	chr1:209998467	C/T	cg05527609	chr1:210001259	C1orf107	1.02	8.92	0.63	5.16e-15	Orofacial clefts;
TGCT	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.5	5.64	0.45	1.08e-7	Lymphocyte counts;
TGCT	cis	rs9914544	0.545	rs2305064	chr17:18770733	G/A	cg26378065	chr17:18585709	ZNF286B	0.52	4.5	0.37	1.56e-5	Educational attainment (years of education);
TGCT	cis	rs12188164	0.930	rs72717440	chr5:449701	A/T	cg21144161	chr5:423903	AHRR	0.25	4.79	0.4	4.59e-6	Cystic fibrosis severity;
TGCT	cis	rs7572733	0.515	rs12619300	chr2:198786490	A/C	cg00792783	chr2:198669748	PLCL1	-0.57	-5.14	-0.42	1.03e-6	Dermatomyositis;
TGCT	cis	rs9486719	1.000	rs11752584	chr6:96884952	C/A	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.21	-0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs10025174	chr4:98914172	A/G	cg18180107	chr4:99064573	C4orf37	0.53	4.99	0.41	1.98e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9926296	0.687	rs258317	chr16:89732238	C/T	cg01097406	chr16:89675127	NA	0.34	5.95	0.47	2.55e-8	Vitiligo;
TGCT	cis	rs4319547	1.000	rs9705654	chr12:123083508	T/C	cg23029597	chr12:123009494	RSRC2	-0.29	-4.75	-0.39	5.43e-6	Body mass index;
TGCT	cis	rs6665290	0.594	rs17592479	chr1:227173892	T/A	cg10327440	chr1:227177885	CDC42BPA	-0.92	-15.37	-0.81	1.66e-30	Myeloid white cell count;
TGCT	cis	rs453301	0.653	rs7853	chr8:8890814	A/G	cg15556689	chr8:8085844	FLJ10661	0.79	7.34	0.55	2.42e-11	Joint mobility (Beighton score);
TGCT	cis	rs9303401	0.659	rs17222621	chr17:56695923	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs4950928	0.823	rs7541061	chr1:203163367	G/T	cg17014757	chr1:203156097	CHI3L1	0.45	5.39	0.44	3.45e-7	YKL-40 levels;
TGCT	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg08280861	chr8:58055591	NA	0.39	4.86	0.4	3.45e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6429082	0.715	rs2131924	chr1:235580928	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.56	-4.9	-0.4	2.97e-6	Adiposity;
TGCT	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg06873352	chr17:61820015	STRADA	0.58	6.37	0.5	3.32e-9	Prudent dietary pattern;
TGCT	cis	rs1451375	1.000	rs1966839	chr7:50627101	T/C	cg18232548	chr7:50535776	DDC	0.4	6.26	0.49	5.69e-9	Malaria;
TGCT	cis	rs11577318	0.537	rs12030833	chr1:26689220	A/G	cg15090202	chr1:26687087	NA	0.58	4.49	0.37	1.64e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs2304725	0.526	rs1601366	chr3:10829706	G/A	cg15914589	chr3:10206523	IRAK2	0.47	4.48	0.37	1.66e-5	Pulmonary function in asthmatics;
TGCT	cis	rs7208859	0.673	rs11654331	chr17:29165017	A/G	cg18442181	chr17:29233375	C17orf42	-0.79	-4.71	-0.39	6.66e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs11190604	0.767	rs4919459	chr10:102200371	C/T	cg23241863	chr10:102295624	HIF1AN	0.64	4.8	0.4	4.42e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2228479	0.681	rs8044906	chr16:89969603	T/C	cg06558623	chr16:89946397	TCF25	0.4	5.01	0.41	1.8e-6	Skin colour saturation;
TGCT	cis	rs8017423	0.935	rs11624246	chr14:90734826	A/G	cg04374321	chr14:90722782	PSMC1	-0.75	-7.32	-0.55	2.75e-11	Mortality in heart failure;
TGCT	cis	rs12410462	0.502	rs77615958	chr1:227806083	T/C	cg23173402	chr1:227635558	NA	0.69	4.55	0.38	1.24e-5	Major depressive disorder;
TGCT	cis	rs2334880	0.587	rs8058188	chr16:71675136	G/A	cg06353428	chr16:71660113	MARVELD3	0.64	5.16	0.42	9.54e-7	Malaria;
TGCT	cis	rs9467773	0.620	rs2504565	chr6:26656890	G/A	cg26531700	chr6:26746687	NA	0.5	4.56	0.38	1.21e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs6981523	0.553	rs11783890	chr8:11056388	T/C	cg21775007	chr8:11205619	TDH	-0.5	-4.65	-0.39	8.26e-6	Neuroticism;
TGCT	cis	rs7226408	0.901	rs1013833	chr18:34462214	G/A	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs916888	0.610	rs199454	chr17:44800110	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.58	-4.57	-0.38	1.15e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs6701037	0.748	rs11585368	chr1:175135448	G/A	cg00321850	chr1:175162397	KIAA0040	-0.42	-5.83	-0.46	4.61e-8	Alcohol dependence;
TGCT	trans	rs62103177	0.525	rs4799117	chr18:77756604	G/A	cg05926928	chr17:57297772	GDPD1	-0.76	-6.89	-0.53	2.48e-10	Opioid sensitivity;
TGCT	cis	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg25427524	chr10:38739819	LOC399744	-0.39	-8.05	-0.59	5.9e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7523273	0.526	rs2745980	chr1:208018367	A/C	cg22525895	chr1:207977042	MIR29B2	0.55	9.84	0.66	3.08e-17	Schizophrenia;
TGCT	cis	rs909674	0.690	rs1972280	chr22:39831986	T/A	cg11247378	chr22:39784982	NA	-0.73	-8.55	-0.61	3.78e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs79387448	0.745	rs72993760	chr2:103151704	G/A	cg09003973	chr2:102972529	NA	0.97	6.32	0.49	4.33e-9	Gut microbiota (bacterial taxa);
TGCT	cis	rs2439831	0.681	rs2278859	chr15:43632960	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	6.89	0.53	2.52e-10	Lung cancer in ever smokers;
TGCT	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.31	-4.74	-0.39	5.78e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg11494091	chr17:61959527	GH2	0.61	14.81	0.8	3.37e-29	Prudent dietary pattern;
TGCT	cis	rs9611565	0.765	rs132914	chr22:41805749	T/C	cg17554472	chr22:41940697	POLR3H	0.43	4.79	0.39	4.73e-6	Vitiligo;
TGCT	cis	rs6840360	0.593	rs4696286	chr4:152606547	G/A	cg22705602	chr4:152727874	NA	-0.33	-5.5	-0.44	2.09e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2302045	1.000	rs16843245	chr2:242032709	A/G	cg04553960	chr2:241721320	KIF1A	0.71	4.8	0.4	4.56e-6	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio);
TGCT	cis	rs2204008	0.837	rs7974888	chr12:37945215	A/G	cg26384229	chr12:38710491	ALG10B	0.85	7.8	0.57	2.22e-12	Bladder cancer;
TGCT	cis	rs7216064	1.000	rs56393562	chr17:65933918	C/T	cg12091567	chr17:66097778	LOC651250	-0.82	-6.21	-0.49	7.4e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs1577917	0.771	rs9450319	chr6:86427325	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.59	5.07	0.41	1.42e-6	Response to antipsychotic treatment;
TGCT	trans	rs208520	0.690	rs207102	chr6:66795671	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-10.77	-0.7	1.66e-19	Exhaled nitric oxide output;
TGCT	cis	rs4689388	0.727	rs1801213	chr4:6293696	C/G	cg25554036	chr4:6271136	WFS1	0.56	7.14	0.54	6.9e-11	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs700590	0.532	rs10462335	chr5:88088204	G/A	cg24804195	chr5:87968844	LOC645323	-0.49	-4.52	-0.38	1.43e-5	Educational attainment (years of education);
TGCT	cis	rs7666738	0.830	rs28619044	chr4:98789814	G/C	cg05340658	chr4:99064831	C4orf37	0.49	5.75	0.46	6.46e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9399137	0.507	rs7772031	chr6:135259734	G/A	cg24558204	chr6:135376177	HBS1L	-0.51	-5.05	-0.41	1.51e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
TGCT	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg11494091	chr17:61959527	GH2	0.61	14.43	0.79	2.59e-28	Prudent dietary pattern;
TGCT	cis	rs1215050	0.765	rs783947	chr4:99012943	T/C	cg05340658	chr4:99064831	C4orf37	-0.41	-4.99	-0.41	1.95e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs6671200	0.915	rs34266846	chr1:95739748	G/A	cg20701556	chr1:95698924	RWDD3	0.69	5.28	0.43	5.53e-7	Stearic acid (18:0) levels;
TGCT	cis	rs1775715	0.674	rs2778670	chr10:32161676	G/A	cg14930904	chr10:32216787	ARHGAP12	0.54	5.3	0.43	5.12e-7	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs2115630	0.791	rs2008262	chr15:85305270	C/T	cg11189052	chr15:85197271	WDR73	-0.58	-4.94	-0.41	2.45e-6	P wave terminal force;
TGCT	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg08736216	chr1:53307985	ZYG11A	-0.3	-5.99	-0.47	2.09e-8	Monocyte count;
TGCT	cis	rs10193935	1.000	rs4494804	chr2:42395946	A/T	cg27598129	chr2:42591480	NA	-0.39	-5.14	-0.42	1.05e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2046867	0.818	rs17010204	chr3:72879099	G/A	cg25664220	chr3:72788482	NA	-0.52	-5.95	-0.47	2.54e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs13191362	0.507	rs2849525	chr6:163126652	A/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.6	-5.61	-0.45	1.23e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7208859	0.673	rs17826219	chr17:29161845	G/A	cg18442181	chr17:29233375	C17orf42	-0.78	-4.61	-0.38	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7552404	0.628	rs4949686	chr1:76473299	G/C	cg10523679	chr1:76189770	ACADM	0.85	6.88	0.53	2.56e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs3015497	0.653	rs2356455	chr14:51093142	G/A	cg04730355	chr14:51134070	SAV1	-0.63	-6.04	-0.48	1.65e-8	Mean platelet volume;
TGCT	cis	rs1997103	1.000	rs9649781	chr7:55411809	A/G	cg17469321	chr7:55412551	NA	0.61	5.96	0.47	2.42e-8	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs7267979	1.000	rs397119	chr20:25440187	C/A	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10791097	0.694	rs7926167	chr11:130745045	T/C	cg05962950	chr11:130786565	SNX19	0.92	11.55	0.72	2.13e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs10089	0.953	rs2190797	chr5:127352875	C/A	cg19767477	chr5:127420684	SLC12A2	-0.42	-4.44	-0.37	2e-5	Ileal carcinoids;
TGCT	cis	rs7226408	0.857	rs72887048	chr18:34483420	C/A	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	trans	rs3780486	0.718	rs73645257	chr9:33132354	C/T	cg20290983	chr6:43655470	MRPS18A	0.98	7.16	0.54	6.38e-11	IgG glycosylation;
TGCT	trans	rs28595532	0.800	rs67686161	chr4:119336720	C/T	cg26518628	chr1:97050305	NA	-0.56	-6.79	-0.52	4.19e-10	Cannabis dependence symptom count;
TGCT	cis	rs798554	1.000	rs798562	chr7:2757938	C/T	cg04166393	chr7:2884313	GNA12	0.6	4.44	0.37	1.97e-5	Height;
TGCT	cis	rs4727027	1.000	rs4727027	chr7:148869277	C/T	cg23583168	chr7:148888333	NA	-0.73	-9.68	-0.66	7.47e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	trans	rs11722228	0.522	rs73212880	chr4:10115692	T/A	cg26043149	chr18:55253948	FECH	1.14	11.82	0.73	4.58e-22	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs7726839	0.526	rs11960159	chr5:568685	C/T	cg09021430	chr5:549028	NA	-0.42	-5.79	-0.46	5.31e-8	Obesity-related traits;
TGCT	cis	rs7086627	0.515	rs1870147	chr10:82212541	A/T	cg00277334	chr10:82204260	NA	-0.55	-8.42	-0.6	7.84e-14	Post bronchodilator FEV1;
TGCT	cis	rs1023500	0.551	rs61665536	chr22:42512613	A/G	cg05082376	chr22:42548792	NA	0.23	5.43	0.44	2.83e-7	Schizophrenia;
TGCT	cis	rs9325144	0.647	rs17518186	chr12:38883665	T/C	cg26384229	chr12:38710491	ALG10B	-0.61	-5.66	-0.45	1.01e-7	Morning vs. evening chronotype;
TGCT	cis	rs4988958	0.565	rs3755265	chr2:103052816	C/A	cg03938978	chr2:103052716	IL18RAP	0.27	5.41	0.44	3.17e-7	Asthma (childhood onset);
TGCT	cis	rs9486719	0.857	rs2971606	chr6:97043025	C/G	cg06623918	chr6:96969491	KIAA0776	-1.04	-10.25	-0.68	3.11e-18	Migraine;Coronary artery disease;
TGCT	cis	rs6988636	1.000	rs10505430	chr8:124191933	A/G	cg22384356	chr8:124195192	FAM83A	0.42	5.54	0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg17328964	chr8:145687451	CYHR1	-0.54	-8.46	-0.6	6.35e-14	Age at first birth;
TGCT	cis	rs7267979	0.966	rs2257712	chr20:25264910	T/C	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7267979	0.966	rs2500417	chr20:25383287	A/G	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2404602	0.716	rs2404737	chr15:76872217	T/G	cg22467129	chr15:76604101	ETFA	-0.44	-5.05	-0.41	1.51e-6	Blood metabolite levels;
TGCT	cis	rs2486012	1.000	rs2485990	chr1:44396790	G/A	cg12908607	chr1:44402522	ARTN	0.72	5.68	0.45	8.89e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs8180040	0.966	rs11925823	chr3:47443065	C/G	cg27129171	chr3:47204927	SETD2	0.65	7.74	0.57	2.99e-12	Colorectal cancer;
TGCT	cis	rs3617	0.559	rs11915546	chr3:52866845	A/C	cg11645453	chr3:52864694	ITIH4	-0.29	-5.71	-0.46	7.84e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6750047	0.587	rs2163454	chr2:38279170	A/C	cg07380506	chr2:38303506	CYP1B1	0.57	5.07	0.41	1.42e-6	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs4851266	1.000	rs11690335	chr2:100826429	A/G	cg22139774	chr2:100720529	AFF3	-0.35	-5.19	-0.42	8.51e-7	Educational attainment;
TGCT	cis	rs9467773	0.836	rs1977198	chr6:26466225	A/C	cg26531700	chr6:26746687	NA	0.54	5.07	0.41	1.43e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg23302884	chr18:44338147	ST8SIA5	-0.41	-4.71	-0.39	6.41e-6	Personality dimensions;
TGCT	cis	rs9911578	0.967	rs57869245	chr17:57106630	A/G	cg12560992	chr17:57184187	TRIM37	-0.77	-9.62	-0.65	1.03e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs2404602	0.692	rs7350777	chr15:76985441	G/A	cg22467129	chr15:76604101	ETFA	-0.45	-5.11	-0.42	1.2e-6	Blood metabolite levels;
TGCT	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg06873352	chr17:61820015	STRADA	0.55	6.1	0.48	1.26e-8	Prudent dietary pattern;
TGCT	cis	rs6933660	0.720	rs6936936	chr6:151753395	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.88	-9.67	-0.66	8.12e-17	Menarche (age at onset);
TGCT	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg11644478	chr21:40555479	PSMG1	1.03	10.99	0.7	4.96e-20	Cognitive function;
TGCT	cis	rs6121246	0.697	rs6088857	chr20:30226764	G/C	cg13852791	chr20:30311386	BCL2L1	0.74	4.84	0.4	3.77e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs595982	0.527	rs55706579	chr19:49382969	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.69	-8.61	-0.61	2.77e-14	Red cell distribution width;
TGCT	cis	rs5769765	0.720	rs138820	chr22:50164078	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.4	6.03	0.48	1.74e-8	Schizophrenia;
TGCT	cis	rs2013441	1.000	rs3850784	chr17:20185030	A/G	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.63	-0.38	9.19e-6	Obesity-related traits;
TGCT	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	8.16	0.59	3.11e-13	Platelet count;
TGCT	cis	rs10782582	0.593	rs4638068	chr1:76161663	G/A	cg10523679	chr1:76189770	ACADM	-0.69	-7.19	-0.54	5.26e-11	Daytime sleep phenotypes;
TGCT	cis	rs6882046	0.513	rs1081158	chr5:88004616	C/T	cg24804195	chr5:87968844	LOC645323	-0.61	-6.09	-0.48	1.31e-8	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg10047753	chr17:41438598	NA	0.97	9.89	0.66	2.27e-17	Menopause (age at onset);
TGCT	cis	rs12477438	0.765	rs17708262	chr2:99696313	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.8	-8.02	-0.58	6.63e-13	Chronic sinus infection;
TGCT	cis	rs10489202	0.608	rs7556350	chr1:168077797	C/T	cg24449463	chr1:168025552	DCAF6	-0.49	-5.06	-0.41	1.49e-6	Schizophrenia;
TGCT	cis	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg18188782	chr20:61659543	NA	0.44	5.38	0.43	3.6e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs796364	1.000	rs281759	chr2:200787719	T/C	cg17644776	chr2:200775616	C2orf69	0.31	4.85	0.4	3.58e-6	Schizophrenia;
TGCT	cis	rs9362426	1.000	rs173334	chr6:88080223	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.46	5.17	0.42	8.91e-7	Depressive episodes in bipolar disorder;
TGCT	cis	rs478304	0.654	rs10896032	chr11:65459419	C/A	cg27068330	chr11:65405492	SIPA1	-0.99	-11.36	-0.71	6.13e-21	Acne (severe);
TGCT	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	7.24	0.55	4.17e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs3087591	0.920	rs11080150	chr17:29629326	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.49	-7.16	-0.54	6.41e-11	Hip circumference;
TGCT	cis	rs2932538	0.922	rs112363416	chr1:113107543	T/C	cg10983938	chr1:113465962	AFARP1;SLC16A1	0.21	4.44	0.37	1.99e-5	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs3087591	1.000	rs12939853	chr17:29455021	G/A	cg24425628	chr17:29625626	OMG;NF1	0.48	7.4	0.55	1.77e-11	Hip circumference;
TGCT	cis	rs7726839	0.507	rs72703100	chr5:614291	C/T	cg16624210	chr5:671434	TPPP	0.43	4.68	0.39	7.5e-6	Obesity-related traits;
TGCT	trans	rs17685	0.753	rs869804	chr7:75688954	A/G	cg19862616	chr7:65841803	NCRNA00174	0.51	8.94	0.63	4.67e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs7208859	0.623	rs216445	chr17:28933576	A/G	cg13385521	chr17:29058706	SUZ12P	0.81	4.87	0.4	3.39e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs2439831	0.867	rs933941	chr15:43632226	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	6.61	0.51	1e-9	Lung cancer in ever smokers;
TGCT	cis	rs986417	1.000	rs1950319	chr14:61048844	T/C	cg27398547	chr14:60952738	C14orf39	1.62	10.14	0.67	5.7e-18	Gut microbiota (bacterial taxa);
TGCT	trans	rs1814175	0.645	rs28454367	chr11:50045708	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.84	-0.7	1.13e-19	Height;
TGCT	cis	rs9807989	0.811	rs11688568	chr2:102969949	C/T	cg09003973	chr2:102972529	NA	0.64	5.7	0.46	8.28e-8	Asthma;
TGCT	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg03264133	chr6:25882463	NA	0.5	5.31	0.43	4.87e-7	Blood metabolite levels;
TGCT	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg05368731	chr17:41323189	NBR1	1.08	11.0	0.7	4.76e-20	Menopause (age at onset);
TGCT	cis	rs7666738	0.830	rs10012167	chr4:99048579	T/C	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg06108461	chr20:60628389	TAF4	-0.69	-10.44	-0.68	1.09e-18	Body mass index;
TGCT	cis	rs10883723	0.810	rs2296590	chr10:104262628	G/A	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs9972944	0.729	rs10083870	chr17:63773272	C/T	cg07283582	chr17:63770753	CCDC46	0.26	5.04	0.41	1.58e-6	Total body bone mineral density;
TGCT	cis	rs6866344	0.661	rs72812606	chr5:178129094	A/T	cg10224037	chr5:178157518	ZNF354A	0.92	7.9	0.58	1.27e-12	Neutrophil percentage of white cells;
TGCT	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.91	6.75	0.52	5.09e-10	Platelet count;
TGCT	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.65	6.39	0.5	3.11e-9	Menarche (age at onset);
TGCT	cis	rs1941184	0.500	rs8096400	chr18:29017326	C/G	cg14871544	chr18:29027885	DSG3	-0.43	-4.63	-0.38	9.2e-6	Parkinson's disease (age of onset);
TGCT	cis	rs78456975	0.506	rs6756310	chr2:1549809	A/G	cg01028140	chr2:1542097	TPO	-0.32	-4.65	-0.39	8.2e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs17122693	1.000	rs1018039	chr14:51085793	C/T	cg04730355	chr14:51134070	SAV1	1.2	9.06	0.63	2.38e-15	Cognitive performance;
TGCT	cis	rs8014204	0.901	rs2080087	chr14:75365062	C/T	cg06637938	chr14:75390232	RPS6KL1	0.78	7.42	0.55	1.58e-11	Caffeine consumption;
TGCT	cis	rs2075371	0.966	rs2544223	chr7:133995787	A/G	cg11752832	chr7:134001865	SLC35B4	0.7	6.44	0.5	2.41e-9	Mean platelet volume;
TGCT	cis	rs13315871	0.790	rs9825431	chr3:58406694	G/C	cg12435725	chr3:58293450	RPP14	-0.43	-4.47	-0.37	1.71e-5	Cholesterol, total;
TGCT	cis	rs7769051	0.615	rs12209144	chr6:133191064	A/T	cg07930552	chr6:133119739	C6orf192	0.92	4.96	0.41	2.26e-6	Type 2 diabetes nephropathy;
TGCT	cis	rs765787	0.530	rs12904265	chr15:45526713	C/T	cg24006582	chr15:45444508	DUOX1	0.24	5.25	0.43	6.39e-7	Uric acid levels;
TGCT	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg24503407	chr1:205819492	PM20D1	0.6	8.07	0.59	5.23e-13	Menarche (age at onset);
TGCT	cis	rs2637266	1.000	rs1907305	chr10:78339512	C/G	cg18941641	chr10:78392320	NA	0.4	5.02	0.41	1.77e-6	Pulmonary function;
TGCT	cis	rs6725041	0.819	rs11677623	chr2:213082372	A/G	cg20637307	chr2:213403960	ERBB4	-0.51	-4.48	-0.37	1.68e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg00024416	chr22:24240387	NA	-0.25	-4.76	-0.39	5.24e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs17345786	0.906	rs56171035	chr3:101111108	G/C	cg11279151	chr3:101281821	RG9MTD1	-0.4	-8.36	-0.6	1.09e-13	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1801251	0.963	rs13021246	chr2:233623111	T/C	cg08000102	chr2:233561755	GIGYF2	0.64	6.56	0.51	1.34e-9	Coronary artery disease;
TGCT	cis	rs6424115	0.830	rs3123554	chr1:24196401	C/T	cg15997130	chr1:24165203	NA	-0.86	-9.47	-0.65	2.43e-16	Immature fraction of reticulocytes;
TGCT	cis	rs4455778	0.580	rs4270912	chr7:49112335	T/G	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs3796352	1.000	rs13076033	chr3:52898427	T/C	cg07884673	chr3:53033167	SFMBT1	0.62	4.89	0.4	3.07e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs8180040	0.932	rs11712445	chr3:47434552	T/C	cg27129171	chr3:47204927	SETD2	0.65	7.74	0.57	2.99e-12	Colorectal cancer;
TGCT	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg13342137	chr4:2252803	MXD4	0.17	4.55	0.38	1.27e-5	Obesity-related traits;
TGCT	cis	rs10751667	0.666	rs10794347	chr11:939863	G/A	cg06064525	chr11:970664	AP2A2	-0.35	-8.28	-0.6	1.65e-13	Alzheimer's disease (late onset);
TGCT	cis	rs1008375	0.966	rs3796813	chr4:17591648	A/G	cg10189774	chr4:17578691	LAP3	0.67	5.88	0.47	3.63e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2276314	1.000	rs2276314	chr18:33557466	C/T	cg05985134	chr18:33552581	C18orf21	-0.56	-4.93	-0.4	2.57e-6	Endometriosis;Drug-induced torsades de pointes;
TGCT	cis	rs72615157	0.628	rs7801070	chr7:99847147	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.65	5.01	0.41	1.84e-6	Lung function (FEV1/FVC);
TGCT	cis	rs9926296	0.557	rs11076618	chr16:89807705	T/C	cg26513180	chr16:89883248	FANCA	0.73	7.18	0.54	5.53e-11	Vitiligo;
TGCT	cis	rs1218582	0.596	rs4845676	chr1:154827861	C/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.48	-4.58	-0.38	1.13e-5	Prostate cancer;
TGCT	cis	rs896854	0.654	rs13248607	chr8:95986637	T/G	cg23172400	chr8:95962367	TP53INP1	-0.36	-6.14	-0.48	1.04e-8	Type 2 diabetes;
TGCT	cis	rs9611565	0.512	rs9607841	chr22:42186838	G/A	cg13695892	chr22:41940480	POLR3H	-0.84	-7.96	-0.58	9.47e-13	Vitiligo;
TGCT	cis	rs6831352	0.819	rs1154401	chr4:100009738	G/C	cg12011299	chr4:100065546	ADH4	0.41	5.67	0.45	9.35e-8	Alcohol dependence;
TGCT	cis	rs881375	0.967	rs10435844	chr9:123668199	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	5.06	0.41	1.49e-6	Rheumatoid arthritis;
TGCT	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg06753367	chr22:24256600	NA	-0.24	-4.48	-0.37	1.66e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg26338869	chr17:61819248	STRADA	-0.53	-4.94	-0.41	2.48e-6	Prudent dietary pattern;
TGCT	cis	rs1124769	0.502	rs35088194	chr15:51065914	C/A	cg23028286	chr15:51614521	CYP19A1	0.19	4.47	0.37	1.75e-5	Cognitive performance;
TGCT	cis	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg02380750	chr20:61661411	NA	0.34	6.02	0.48	1.86e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs112217694	1.000	rs17249293	chr4:104656784	G/A	cg24090629	chr4:104641072	TACR3	-1.01	-4.96	-0.41	2.29e-6	Menarche (age at onset);
TGCT	cis	rs11077998	0.933	rs6502121	chr17:80531314	A/G	cg10255544	chr17:80519551	FOXK2	0.23	4.44	0.37	1.97e-5	Reticulocyte fraction of red cells;
TGCT	cis	rs12220238	0.822	rs11000979	chr10:76067865	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.88	5.98	0.47	2.22e-8	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs9647570	0.582	rs2052467	chr5:167280536	C/T	cg11091196	chr5:167285540	ODZ2	0.3	4.51	0.38	1.5e-5	Menarche (age at onset);
TGCT	cis	rs3748682	0.861	rs12563037	chr1:38258644	C/G	cg04496824	chr1:38276835	MTF1	-0.21	-4.68	-0.39	7.5e-6	Hypothyroidism;
TGCT	cis	rs6969780	0.632	rs11762730	chr7:27190398	A/C	cg04321618	chr7:27170880	HOXA4	-0.44	-5.05	-0.41	1.55e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs6905628	1	rs6905628	chr6:90344869	C/G	cg23505970	chr6:90529759	MDN1	0.66	5.26	0.43	6e-7	Coronary artery disease;
TGCT	cis	rs2964802	0.505	rs11957751	chr5:10819973	A/G	cg14521931	chr5:10832172	NA	0.27	4.55	0.38	1.29e-5	Major depressive disorder;Recurrent major depressive disorder;
TGCT	cis	rs3784262	0.669	rs4646554	chr15:58355437	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.42	-6.24	-0.49	6.32e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs7681440	0.838	rs1348224	chr4:90761946	G/A	cg20003494	chr4:90757398	SNCA	-0.62	-5.98	-0.47	2.24e-8	Dementia with Lewy bodies;
TGCT	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg24675658	chr1:53192096	ZYG11B	0.7	7.98	0.58	8.42e-13	Monocyte count;
TGCT	cis	rs9916302	0.706	rs8182252	chr17:37727950	T/C	cg03321784	chr17:37729644	NA	-0.43	-4.7	-0.39	6.72e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg14773178	chr5:1868261	NA	0.32	5.58	0.45	1.43e-7	Cardiovascular disease risk factors;
TGCT	cis	rs7582180	0.629	rs12620139	chr2:100943446	A/G	cg14675211	chr2:100938903	LONRF2	0.51	4.95	0.41	2.32e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4285028	0.747	rs1127412	chr3:121414061	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.92	-7.28	-0.55	3.36e-11	Multiple sclerosis;
TGCT	cis	rs10256972	0.642	rs6961424	chr7:1004113	T/C	cg18664915	chr7:1043861	C7orf50	-0.27	-4.86	-0.4	3.5e-6	Longevity;Endometriosis;
TGCT	cis	rs17401966	0.838	rs4846209	chr1:10322054	G/A	cg19773385	chr1:10388646	KIF1B	-0.2	-4.5	-0.37	1.54e-5	Hepatocellular carcinoma;
TGCT	cis	rs1008375	0.866	rs2109518	chr4:17572162	G/A	cg16339924	chr4:17578868	LAP3	0.83	7.27	0.55	3.54e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs492146	0.819	rs612483	chr6:52839958	C/T	cg06706454	chr6:52930286	FBXO9	0.51	4.71	0.39	6.54e-6	Epilepsy (remission after treatment);
TGCT	cis	rs7582180	0.676	rs6542940	chr2:100982144	A/T	cg08017756	chr2:100939284	LONRF2	-0.3	-4.87	-0.4	3.34e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs17376456	0.809	rs12152763	chr5:93405509	T/A	cg25358565	chr5:93447407	FAM172A	0.93	8.37	0.6	1.04e-13	Diabetic retinopathy;
TGCT	cis	rs7474896	0.559	rs1208560	chr10:38221618	A/T	cg13720705	chr10:37990370	NA	-0.34	-4.58	-0.38	1.13e-5	Obesity (extreme);
TGCT	cis	rs4295623	0.559	rs2409836	chr8:11689228	T/G	cg21775007	chr8:11205619	TDH	0.57	5.02	0.41	1.78e-6	Morning vs. evening chronotype;
TGCT	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg06873352	chr17:61820015	STRADA	0.58	6.43	0.5	2.55e-9	Prudent dietary pattern;
TGCT	cis	rs2334880	0.602	rs12444212	chr16:71437689	T/C	cg06353428	chr16:71660113	MARVELD3	-1.16	-7.04	-0.53	1.18e-10	Malaria;
TGCT	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg02725872	chr8:58115012	NA	-0.38	-4.79	-0.39	4.73e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs362272	0.545	rs2749783	chr4:3326098	A/C	cg22655196	chr4:3374909	RGS12	0.24	4.97	0.41	2.13e-6	Serum sulfate level;
TGCT	cis	rs3617	0.573	rs4687680	chr3:52907372	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	5.05	0.41	1.55e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg11890956	chr21:40555474	PSMG1	-0.79	-6.98	-0.53	1.58e-10	Cognitive function;
TGCT	cis	rs7917772	0.532	rs10748829	chr10:104527244	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.58	-4.75	-0.39	5.56e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs6840360	1.000	rs3749561	chr4:152610117	C/T	cg22705602	chr4:152727874	NA	0.25	4.45	0.37	1.92e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs6964587	0.967	rs7788092	chr7:91646198	C/T	cg17063962	chr7:91808500	NA	0.91	9.97	0.67	1.53e-17	Breast cancer;
TGCT	cis	rs1153858	1.000	rs3759899	chr15:45655903	T/C	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.62e-8	Homoarginine levels;
TGCT	cis	rs71435601	0.628	rs559318	chr2:21381490	C/T	cg25035485	chr2:21266500	APOB	0.51	4.48	0.37	1.66e-5	Cholesterol, total;
TGCT	cis	rs11122272	0.735	rs2437147	chr1:231516756	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.13	-0.54	7.33e-11	Hemoglobin concentration;
TGCT	cis	rs4851254	0.618	rs7596359	chr2:100665274	T/G	cg22139774	chr2:100720529	AFF3	-0.44	-4.69	-0.39	7.04e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg18654377	chr3:49208889	KLHDC8B	-0.39	-5.04	-0.41	1.6e-6	Menarche (age at onset);
TGCT	cis	rs3796352	1.000	rs3806692	chr3:53080987	C/G	cg15956490	chr3:53032818	SFMBT1	0.53	6.21	0.49	7.31e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.6	-8.5	-0.61	5.11e-14	Longevity;Endometriosis;
TGCT	cis	rs9916302	0.904	rs7223438	chr17:37521355	T/C	cg15445000	chr17:37608096	MED1	-0.35	-5.05	-0.41	1.53e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7809950	0.599	rs2237658	chr7:106837866	T/G	cg23024343	chr7:107201750	COG5	-0.37	-5.27	-0.43	5.84e-7	Coronary artery disease;
TGCT	cis	rs9393692	0.905	rs34916901	chr6:26286149	G/T	cg00631329	chr6:26305371	NA	-0.44	-6.59	-0.51	1.15e-9	Educational attainment;
TGCT	cis	rs2046867	0.908	rs62251650	chr3:72809823	T/C	cg25664220	chr3:72788482	NA	-0.57	-7.16	-0.54	6.2e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs13188771	0.651	rs3912803	chr5:100881268	T/G	cg18665594	chr5:101119420	NA	0.44	4.47	0.37	1.74e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	trans	rs7819412	0.594	rs7460507	chr8:10969075	C/T	cg15556689	chr8:8085844	FLJ10661	-0.7	-6.86	-0.52	2.97e-10	Triglycerides;
TGCT	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg07061783	chr6:25882402	NA	-0.43	-4.72	-0.39	6.37e-6	Height;
TGCT	cis	rs2956278	0.717	rs2956284	chr12:84690282	A/G	cg25678815	chr12:85673915	ALX1	-0.53	-4.76	-0.39	5.4e-6	Depressive symptoms;Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7267979	1.000	rs404394	chr20:25447896	A/G	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg06713675	chr4:122721982	EXOSC9	-0.68	-9.21	-0.64	1.05e-15	Type 2 diabetes;
TGCT	cis	rs9818758	0.556	rs13086240	chr3:49001409	G/A	cg07636037	chr3:49044803	WDR6	-1.0	-4.98	-0.41	2.11e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs7769051	1.000	rs6910639	chr6:133120553	A/G	cg07930552	chr6:133119739	C6orf192	0.94	5.04	0.41	1.6e-6	Type 2 diabetes nephropathy;
TGCT	cis	rs709400	0.663	rs7158822	chr14:103887868	C/T	cg26031613	chr14:104095156	KLC1	0.84	9.43	0.65	2.98e-16	Body mass index;
TGCT	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg23283495	chr1:209979779	IRF6	0.7	5.71	0.46	7.88e-8	Cleft lip with or without cleft palate;
TGCT	cis	rs2932538	0.922	rs12138335	chr1:113122760	T/C	cg10983938	chr1:113465962	AFARP1;SLC16A1	0.21	4.44	0.37	1.99e-5	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs11190604	1.000	rs9420782	chr10:102235015	G/A	cg23241863	chr10:102295624	HIF1AN	0.63	4.97	0.41	2.2e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7843479	0.932	rs68023663	chr8:21794379	T/C	cg17168535	chr8:21777572	XPO7	0.65	5.99	0.47	2.14e-8	Mean corpuscular volume;
TGCT	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg18876405	chr7:65276391	NA	0.36	5.36	0.43	3.97e-7	Aortic root size;
TGCT	cis	rs8038465	0.622	rs2509	chr15:73859488	A/T	cg15420318	chr15:73925796	NPTN	-0.59	-6.03	-0.48	1.75e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7666738	0.830	rs4699331	chr4:99059816	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.45	0.56	1.4e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs651907	0.557	rs59596156	chr3:101394217	C/T	cg12386194	chr3:101231763	SENP7	0.52	5.1	0.42	1.24e-6	Colorectal cancer;
TGCT	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg04156016	chr5:1868137	NA	0.34	4.89	0.4	3.06e-6	Cardiovascular disease risk factors;
TGCT	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg15691649	chr6:25882328	NA	0.48	5.55	0.45	1.63e-7	Blood metabolite levels;
TGCT	cis	rs6121246	0.738	rs2376996	chr20:30316667	T/A	cg18721089	chr20:30220636	NA	-0.42	-4.65	-0.39	8.2e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg06873352	chr17:61820015	STRADA	0.56	6.12	0.48	1.15e-8	Prudent dietary pattern;
TGCT	cis	rs3806843	1.000	rs6885319	chr5:140200611	A/C	cg19875535	chr5:140030758	IK	0.35	5.86	0.47	3.93e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg02487422	chr3:49467188	NICN1	0.5	4.55	0.38	1.24e-5	Parkinson's disease;
TGCT	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg15242686	chr22:24348715	GSTTP1	0.5	7.4	0.55	1.78e-11	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	trans	rs1814175	0.645	rs1851850	chr11:50012168	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.84	-0.7	1.13e-19	Height;
TGCT	cis	rs3091242	0.900	rs1811832	chr1:25753565	G/A	cg09222892	chr1:25734099	RHCE	-0.42	-6.75	-0.52	5.02e-10	Erythrocyte sedimentation rate;
TGCT	cis	rs12765878	0.603	rs10883944	chr10:105651657	G/T	cg11005552	chr10:105648138	OBFC1	-0.4	-6.19	-0.49	8.13e-9	Coronary artery disease;
TGCT	trans	rs12339966	0.653	rs10733231	chr9:11285060	C/G	cg07173112	chr1:1114698	TTLL10	-0.34	-6.84	-0.52	3.15e-10	Systolic blood pressure;
TGCT	cis	rs5769707	0.681	rs6009803	chr22:50051007	A/G	cg06623630	chr22:50017776	C22orf34	-0.26	-4.51	-0.38	1.45e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs56104184	0.775	rs73061699	chr19:49400511	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.73	-9.15	-0.63	1.47e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs4727027	0.899	rs11771339	chr7:148854132	A/T	cg23583168	chr7:148888333	NA	-0.77	-10.05	-0.67	9.78e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs10193935	0.901	rs10200000	chr2:42442212	A/G	cg27598129	chr2:42591480	NA	-0.37	-5.09	-0.42	1.3e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.03	0.41	1.68e-6	Prudent dietary pattern;
TGCT	cis	rs4253772	0.591	rs6008362	chr22:46652737	G/A	cg09491104	chr22:46646882	C22orf40	-0.62	-6.49	-0.5	1.87e-9	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg24250549	chr1:154909240	PMVK	0.56	5.42	0.44	2.92e-7	Prostate cancer;
TGCT	cis	rs7666738	0.753	rs28463863	chr4:98844444	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.57	0.56	7.47e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9527	0.615	rs10883810	chr10:104727224	A/C	cg15744005	chr10:104629667	AS3MT	-0.44	-5.19	-0.42	8.3e-7	Arsenic metabolism;
TGCT	cis	rs1008375	1.000	rs1121090	chr4:17676437	C/G	cg16339924	chr4:17578868	LAP3	0.53	4.62	0.38	9.58e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs981844	0.683	rs1105496	chr4:154756755	T/C	cg14289246	chr4:154710475	SFRP2	-0.96	-8.97	-0.63	3.91e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs7584330	0.737	rs6431539	chr2:238360708	G/T	cg14458575	chr2:238380390	NA	0.47	7.39	0.55	1.9e-11	Prostate cancer;
TGCT	cis	rs12360000	0.864	rs11250842	chr10:1904284	A/C	cg26364871	chr10:1889757	NA	0.41	4.63	0.38	9.26e-6	Metabolite levels (Dihydroxy docosatrienoic acid);
TGCT	cis	rs931127	0.658	rs4930305	chr11:65464000	A/G	cg27068330	chr11:65405492	SIPA1	0.64	6.18	0.49	8.27e-9	Systemic lupus erythematosus;
TGCT	cis	rs790110	1.000	rs2668336	chr3:122384469	T/A	cg07366462	chr3:123162899	ADCY5	0.42	4.71	0.39	6.54e-6	Acoustic startle blink response;
TGCT	cis	rs9796	0.621	rs2899013	chr15:41492283	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.52	-7.12	-0.54	7.62e-11	Menopause (age at onset);
TGCT	cis	rs916888	0.821	rs199512	chr17:44857352	T/C	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.7	-4.82	-0.4	4.1e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7523273	0.606	rs2761430	chr1:207912408	G/A	cg22525895	chr1:207977042	MIR29B2	0.56	9.32	0.64	5.42e-16	Schizophrenia;
TGCT	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg24829409	chr8:58192753	C8orf71	-0.59	-5.18	-0.42	8.54e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs34286592	0.929	rs1057452	chr16:29833714	A/G	cg07060908	chr16:29884970	SEZ6L2	0.26	4.51	0.38	1.49e-5	Multiple sclerosis;
TGCT	cis	rs12220898	0.749	rs4483512	chr10:50480390	G/A	cg09603381	chr10:49954066	WDFY4	0.39	4.48	0.37	1.68e-5	Inflammatory biomarkers;
TGCT	cis	rs7216064	1.000	rs7212293	chr17:65847325	A/G	cg12091567	chr17:66097778	LOC651250	-0.85	-6.84	-0.52	3.14e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg06618935	chr21:46677482	NA	-0.37	-5.54	-0.45	1.71e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs34014631	1.000	rs80080632	chr10:103710001	T/C	cg22630918	chr10:102748988	C10orf2	0.42	4.78	0.39	4.86e-6	Coronary artery calcification;
TGCT	cis	rs2762353	0.546	rs2294346	chr6:25689487	G/C	cg17042849	chr6:26104293	HIST1H4C	-0.52	-4.74	-0.39	5.83e-6	Blood metabolite levels;
TGCT	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.29	-4.49	-0.37	1.64e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1580019	0.961	rs1580022	chr7:32497712	C/A	cg06627557	chr7:32535165	LSM5;AVL9	0.81	7.61	0.56	5.93e-12	Cognitive ability;
TGCT	cis	rs7617773	0.823	rs9839446	chr3:48194666	T/A	cg11946769	chr3:48343235	NME6	-0.61	-5.45	-0.44	2.6e-7	Coronary artery disease;
TGCT	cis	rs826838	0.904	rs7973992	chr12:39168233	T/C	cg26384229	chr12:38710491	ALG10B	1.0	8.98	0.63	3.56e-15	Heart rate;
TGCT	cis	rs13256369	1.000	rs7004438	chr8:8574379	C/T	cg18904891	chr8:8559673	CLDN23	0.64	5.89	0.47	3.36e-8	Obesity-related traits;
TGCT	cis	rs2933343	0.700	rs2624910	chr3:128650275	G/C	cg11901034	chr3:128598214	ACAD9	-0.65	-6.08	-0.48	1.38e-8	IgG glycosylation;
TGCT	cis	rs2050392	0.929	rs10826798	chr10:30700904	G/A	cg18806716	chr10:30721971	MAP3K8	0.46	5.5	0.44	2.04e-7	Inflammatory bowel disease;
TGCT	cis	rs7809950	1.000	rs2395883	chr7:107089670	T/C	cg23024343	chr7:107201750	COG5	-0.36	-5.63	-0.45	1.12e-7	Coronary artery disease;
TGCT	cis	rs736408	0.812	rs746694	chr3:52826620	C/T	cg07507251	chr3:52567010	NT5DC2	0.45	5.99	0.47	2.1e-8	Bipolar disorder;
TGCT	cis	rs12762955	0.528	rs10903358	chr10:1102386	G/A	cg20503657	chr10:835505	NA	0.57	6.46	0.5	2.21e-9	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs2197308	0.659	rs11181327	chr12:37903171	C/T	cg26384229	chr12:38710491	ALG10B	-0.7	-6.15	-0.48	9.71e-9	Morning vs. evening chronotype;
TGCT	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg13683864	chr3:40499215	RPL14	-1.18	-13.68	-0.78	1.54e-26	Renal cell carcinoma;
TGCT	cis	rs55794721	0.509	rs6699113	chr1:25777743	C/T	cg10117171	chr1:25599238	RHD	-0.32	-5.22	-0.42	7.32e-7	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.76	6.5	0.5	1.8e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs8135665	0.600	rs6519096	chr22:38451389	C/T	cg13116946	chr22:38479732	SLC16A8	0.3	5.77	0.46	5.94e-8	Advanced age-related macular degeneration;Age-related macular degeneration;
TGCT	cis	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg25427524	chr10:38739819	LOC399744	-0.39	-8.05	-0.59	5.9e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2046867	0.862	rs11922180	chr3:72836119	A/G	cg25664220	chr3:72788482	NA	0.56	7.05	0.53	1.1e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs1008375	0.966	rs6449313	chr4:17588320	A/G	cg16339924	chr4:17578868	LAP3	0.77	6.62	0.51	9.84e-10	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7267979	0.966	rs2261790	chr20:25262789	T/C	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg23758822	chr17:41437982	NA	0.75	7.03	0.53	1.22e-10	Menopause (age at onset);
TGCT	cis	rs6748734	1.000	rs10933518	chr2:241838091	A/C	cg04034577	chr2:241836375	C2orf54	-0.41	-6.31	-0.49	4.55e-9	Urinary metabolites;
TGCT	cis	rs2663905	0.611	rs2663924	chr15:81392903	T/G	cg18028999	chr15:81426610	C15orf26	-0.5	-4.66	-0.39	8.07e-6	QT interval (drug interaction);
TGCT	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs28595532	0.920	rs116098781	chr4:119771613	G/A	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs2832191	0.729	rs2832201	chr21:30499841	A/G	cg08807101	chr21:30365312	RNF160	-0.67	-6.13	-0.48	1.1e-8	Dental caries;
TGCT	cis	rs769267	0.965	rs10419245	chr19:19383755	G/A	cg03709012	chr19:19516395	GATAD2A	0.67	5.78	0.46	5.66e-8	Tonsillectomy;
TGCT	trans	rs3780486	0.846	rs7864705	chr9:33140352	A/C	cg04842962	chr6:43655489	MRPS18A	1.22	15.42	0.81	1.27e-30	IgG glycosylation;
TGCT	cis	rs7953508	0.506	rs10859532	chr12:93960917	G/C	cg18151635	chr12:93972918	NA	-0.19	-4.55	-0.38	1.24e-5	Pubertal anthropometrics;
TGCT	cis	rs10782582	0.545	rs111927462	chr1:76195422	A/G	cg22875332	chr1:76189707	ACADM	-0.5	-5.51	-0.44	2e-7	Daytime sleep phenotypes;
TGCT	cis	rs807669	0.548	rs885979	chr22:19198375	T/C	cg02655711	chr22:19163373	SLC25A1	0.3	5.9	0.47	3.22e-8	Metabolite levels;
TGCT	cis	rs9894429	1.000	rs3935543	chr17:79579874	T/C	cg18240062	chr17:79603768	NPLOC4	0.67	6.84	0.52	3.23e-10	Eye color traits;
TGCT	cis	rs4455778	0.626	rs10241999	chr7:49052839	C/G	cg26309511	chr7:48887640	NA	-0.4	-4.86	-0.4	3.53e-6	Lung cancer in never smokers;
TGCT	cis	rs7213347	0.780	rs1555568	chr17:2149505	T/C	cg13315690	chr17:1944831	OVCA2;DPH1	-0.38	-4.69	-0.39	7.1e-6	Total body bone mineral density;
TGCT	cis	rs6582630	0.519	rs11495700	chr12:38288240	A/G	cg26384229	chr12:38710491	ALG10B	0.83	7.29	0.55	3.15e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs10782582	0.593	rs115291524	chr1:76141811	A/G	cg10523679	chr1:76189770	ACADM	-0.68	-7.06	-0.54	1.03e-10	Daytime sleep phenotypes;
TGCT	cis	rs9611565	0.918	rs6002351	chr22:41757223	C/T	cg06634786	chr22:41940651	POLR3H	-0.8	-7.65	-0.57	4.81e-12	Vitiligo;
TGCT	cis	rs2887571	0.505	rs78275802	chr12:1637691	G/A	cg01940102	chr12:1095972	NA	0.26	4.78	0.39	4.92e-6	Bone mineral density;
TGCT	cis	rs7588746	0.868	rs12104649	chr2:201128832	C/T	cg23649088	chr2:200775458	C2orf69	-0.33	-4.72	-0.39	6.33e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	cis	rs7659604	0.539	rs72680779	chr4:122797263	C/T	cg06713675	chr4:122721982	EXOSC9	-0.67	-8.91	-0.62	5.46e-15	Type 2 diabetes;
TGCT	trans	rs10506458	1.000	rs11174759	chr12:63444363	A/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.47	-7.62	-0.56	5.8e-12	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs3931020	0.548	rs17618340	chr1:75247617	G/A	cg17719053	chr1:75198211	TYW3;CRYZ	0.47	4.9	0.4	2.94e-6	Resistin levels;
TGCT	cis	rs72781680	0.950	rs72796402	chr2:24180104	A/G	cg08917208	chr2:24149416	ATAD2B	0.9	5.45	0.44	2.62e-7	Lymphocyte counts;
TGCT	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg18876405	chr7:65276391	NA	0.35	5.2	0.42	8.09e-7	Aortic root size;
TGCT	cis	rs3087591	0.922	rs12950506	chr17:29598392	A/G	cg24425628	chr17:29625626	OMG;NF1	0.47	7.21	0.54	4.8e-11	Hip circumference;
TGCT	cis	rs17122693	1.000	rs72679576	chr14:51090881	G/A	cg04730355	chr14:51134070	SAV1	1.24	8.74	0.62	1.38e-14	Cognitive performance;
TGCT	cis	rs739496	0.843	rs848132	chr12:111989979	C/A	cg10833066	chr12:111807467	FAM109A	0.37	4.96	0.41	2.31e-6	Platelet count;
TGCT	cis	rs10832963	1.000	rs2084220	chr11:18656932	C/T	cg20219074	chr11:18656078	SPTY2D1	0.98	9.86	0.66	2.75e-17	Breast cancer;
TGCT	cis	rs7647973	0.626	rs7649428	chr3:49868876	A/T	cg05785598	chr3:49045655	WDR6	-0.43	-5.38	-0.43	3.63e-7	Menarche (age at onset);
TGCT	cis	rs36051895	0.625	rs12340333	chr9:5176215	C/G	cg02405213	chr9:5042618	JAK2	-0.77	-10.92	-0.7	7.2e-20	Pediatric autoimmune diseases;
TGCT	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	0.65	6.36	0.5	3.55e-9	Prostate cancer;
TGCT	cis	rs1801251	1.000	rs13013142	chr2:233600606	A/G	cg08000102	chr2:233561755	GIGYF2	0.64	6.56	0.51	1.34e-9	Coronary artery disease;
TGCT	cis	rs7829975	0.840	rs572366	chr8:8578794	A/T	cg06636001	chr8:8085503	FLJ10661	0.6	4.92	0.4	2.7e-6	Mood instability;
TGCT	cis	rs68170813	0.599	rs12533516	chr7:106937135	C/T	cg02696742	chr7:106810147	HBP1	-0.69	-5.81	-0.46	4.85e-8	Coronary artery disease;
TGCT	cis	rs9916302	0.904	rs9892055	chr17:37510402	C/T	cg15445000	chr17:37608096	MED1	-0.33	-4.71	-0.39	6.46e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg04287289	chr16:89883240	FANCA	0.93	12.26	0.74	4.13e-23	Vitiligo;
TGCT	cis	rs9486719	0.948	rs11152970	chr6:96909077	A/G	cg06623918	chr6:96969491	KIAA0776	-0.98	-8.77	-0.62	1.15e-14	Migraine;Coronary artery disease;
TGCT	cis	rs7552404	0.727	rs12122939	chr1:76276353	T/C	cg22875332	chr1:76189707	ACADM	0.64	6.9	0.53	2.32e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg10047753	chr17:41438598	NA	0.94	9.17	0.64	1.28e-15	Menopause (age at onset);
TGCT	cis	rs4642101	0.628	rs1003080	chr3:12811628	C/T	cg04715183	chr3:11886989	C3orf31	0.18	4.51	0.38	1.51e-5	QRS complex (12-leadsum);
TGCT	cis	rs10927875	0.800	rs1627145	chr1:16328116	C/T	cg14742211	chr1:16348397	CLCNKA	0.19	4.45	0.37	1.88e-5	Dilated cardiomyopathy;
TGCT	cis	rs10089	1.000	rs4835941	chr5:127430905	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.79	7.6	0.56	6.47e-12	Ileal carcinoids;
TGCT	cis	rs3125734	0.608	rs7905731	chr10:64018472	T/C	cg09941381	chr10:64027924	RTKN2	-0.36	-5.48	-0.44	2.26e-7	Rheumatoid arthritis;
TGCT	cis	rs350251	0.899	rs350275	chr16:12233099	G/C	cg02910054	chr16:12241554	SNX29	0.33	4.57	0.38	1.18e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs4072705	0.967	rs10760369	chr9:127397400	A/G	cg13476313	chr9:127244764	NR5A1	0.29	4.72	0.39	6.13e-6	Menarche (age at onset);
TGCT	cis	rs4233949	0.868	rs7607093	chr2:54659174	G/T	cg14634210	chr2:54682758	SPTBN1	-0.58	-4.87	-0.4	3.31e-6	Bone mineral density;
TGCT	cis	rs3816788	0.792	rs7013323	chr8:21869024	C/G	cg17168535	chr8:21777572	XPO7	0.77	7.84	0.58	1.77e-12	Lung cancer in ever smokers;
TGCT	cis	rs4819052	0.851	rs7279011	chr21:46655995	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.69	6.07	0.48	1.41e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6714710	0.603	rs34502870	chr2:98405929	A/G	cg26665480	chr2:98280029	ACTR1B	0.66	6.24	0.49	6.33e-9	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs10751667	0.666	rs12295141	chr11:947065	G/A	cg06064525	chr11:970664	AP2A2	-0.35	-8.29	-0.6	1.6e-13	Alzheimer's disease (late onset);
TGCT	cis	rs13191362	0.935	rs34035978	chr6:163165336	G/C	cg21926612	chr6:163149169	PACRG;PARK2	0.88	7.8	0.57	2.15e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg03213289	chr20:61660250	NA	0.7	10.11	0.67	6.94e-18	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs6815814	0.950	rs5743571	chr4:38805489	C/T	cg02016764	chr4:38805732	TLR1	-0.35	-5.65	-0.45	1.04e-7	Breast cancer;
TGCT	cis	rs7584330	0.784	rs6724766	chr2:238413600	A/G	cg16989719	chr2:238392110	NA	-0.28	-4.78	-0.39	4.8e-6	Prostate cancer;
TGCT	cis	rs2439831	1.000	rs1814538	chr15:43759774	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.93	-8.02	-0.58	6.8e-13	Lung cancer in ever smokers;
TGCT	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	6.13	0.48	1.06e-8	Bipolar disorder;
TGCT	cis	rs3091242	0.933	rs11249250	chr1:25767609	G/A	cg23205692	chr1:25664452	TMEM50A	0.49	5.17	0.42	9e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs4595586	0.545	rs7958118	chr12:39376685	C/T	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg18402987	chr7:1209562	NA	0.74	6.37	0.5	3.28e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs3020736	0.500	rs7364293	chr22:42506370	C/T	cg15557168	chr22:42548783	NA	0.22	5.58	0.45	1.47e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs5769765	1.000	rs764813	chr22:50286172	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.11	-12.1	-0.74	9.56e-23	Schizophrenia;
TGCT	cis	rs7086627	0.515	rs10887901	chr10:82210581	G/A	cg00277334	chr10:82204260	NA	-0.54	-8.46	-0.61	6.23e-14	Post bronchodilator FEV1;
TGCT	cis	rs9527	0.590	rs1046411	chr10:104837816	G/A	cg15744005	chr10:104629667	AS3MT	-0.38	-4.52	-0.38	1.42e-5	Arsenic metabolism;
TGCT	cis	rs9948	0.529	rs62156222	chr2:97410988	C/A	cg01990225	chr2:97406019	LMAN2L	-1.01	-5.13	-0.42	1.08e-6	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs700590	0.723	rs304159	chr5:88138042	C/T	cg22951263	chr5:87985283	NA	0.57	5.19	0.42	8.52e-7	Educational attainment (years of education);
TGCT	cis	rs6714710	0.580	rs11692470	chr2:98520564	T/C	cg26665480	chr2:98280029	ACTR1B	0.64	6.06	0.48	1.48e-8	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs7916852	0.867	rs7091158	chr10:28387300	A/G	cg15286905	chr10:27530250	ACBD5	-0.45	-4.46	-0.37	1.78e-5	Glaucoma (primary open-angle);
TGCT	cis	rs10206020	0.921	rs11884956	chr2:1566426	A/G	cg01028140	chr2:1542097	TPO	-0.34	-5.32	-0.43	4.61e-7	IgG glycosylation;
TGCT	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg27170947	chr2:26402098	FAM59B	-0.4	-4.63	-0.38	8.93e-6	Gut microbiome composition (summer);
TGCT	cis	rs17108533	0.588	rs12886796	chr14:71301556	A/G	cg23900759	chr14:71108106	TTC9	-1.14	-4.61	-0.38	9.92e-6	Response to antipsychotic treatment in schizophrenia (reasoning);
TGCT	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg11247378	chr22:39784982	NA	-0.74	-9.62	-0.65	1.08e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs367615	0.918	rs17161889	chr5:108855251	A/G	cg17395555	chr5:108820864	NA	-0.3	-4.85	-0.4	3.57e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs735396	0.694	rs2264750	chr12:121450165	C/T	cg15155738	chr12:121454335	C12orf43	0.55	4.76	0.39	5.4e-6	N-glycan levels;
TGCT	cis	rs6484504	0.576	rs208083	chr11:31196880	C/T	cg26647111	chr11:31128758	NA	-0.32	-4.47	-0.37	1.74e-5	Red blood cell count;
TGCT	cis	rs8014204	0.836	rs7150254	chr14:75299101	G/A	cg06637938	chr14:75390232	RPS6KL1	0.7	6.74	0.52	5.37e-10	Caffeine consumption;
TGCT	cis	rs9325144	0.581	rs2730929	chr12:38942739	T/C	cg26384229	chr12:38710491	ALG10B	-0.65	-6.51	-0.5	1.69e-9	Morning vs. evening chronotype;
TGCT	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg05368731	chr17:41323189	NBR1	1.2	14.48	0.79	1.98e-28	Menopause (age at onset);
TGCT	cis	rs2050392	0.931	rs2265189	chr10:30689316	C/T	cg18806716	chr10:30721971	MAP3K8	0.42	4.85	0.4	3.65e-6	Inflammatory bowel disease;
TGCT	cis	rs9611565	0.729	rs137831	chr22:41903813	A/C	cg13695892	chr22:41940480	POLR3H	-0.88	-8.89	-0.62	6.1e-15	Vitiligo;
TGCT	trans	rs797680	0.822	rs6541401	chr1:93738948	G/A	cg27528825	chr2:159282178	CCDC148	0.34	6.71	0.52	6.32e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs4975616	0.836	rs13178866	chr5:1323212	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.3	-4.6	-0.38	1.04e-5	Lung cancer;
TGCT	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.37	-4.58	-0.38	1.11e-5	Menopause (age at onset);
TGCT	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg14851468	chr5:179071604	C5orf60	0.22	4.54	0.38	1.32e-5	Lung cancer;
TGCT	cis	rs12477438	1.000	rs6732980	chr2:99921613	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.81	-6.3	-0.49	4.62e-9	Chronic sinus infection;
TGCT	cis	rs7086627	0.515	rs11202959	chr10:82209672	A/G	cg00277334	chr10:82204260	NA	-0.54	-8.46	-0.61	6.23e-14	Post bronchodilator FEV1;
TGCT	cis	rs3784262	0.528	rs4646589	chr15:58303165	C/T	cg12031962	chr15:58353849	ALDH1A2	0.38	5.43	0.44	2.8e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg07424592	chr7:64974309	NA	1.34	8.08	0.59	4.95e-13	Diabetic kidney disease;
TGCT	trans	rs208520	0.690	rs6929762	chr6:66709277	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	11.22	0.71	1.34e-20	Exhaled nitric oxide output;
TGCT	cis	rs11122272	0.735	rs2808586	chr1:231515559	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.14	-0.54	6.86e-11	Hemoglobin concentration;
TGCT	cis	rs17206232	0.534	rs13165244	chr5:64693002	T/C	cg09571848	chr5:64330935	NA	-0.31	-4.46	-0.37	1.82e-5	Schizophrenia;
TGCT	cis	rs62103177	0.810	rs62103194	chr18:77629482	G/A	cg12964065	chr18:77638022	KCNG2	0.37	4.76	0.39	5.4e-6	Opioid sensitivity;
TGCT	cis	rs4273100	0.646	rs4924990	chr17:19294824	G/T	cg03910582	chr17:19030146	GRAPL	-0.54	-5.44	-0.44	2.73e-7	Schizophrenia;
TGCT	cis	rs6121246	0.542	rs2376990	chr20:30238744	G/A	cg21427119	chr20:30132790	HM13	-0.35	-4.72	-0.39	6.19e-6	Mean corpuscular hemoglobin;
TGCT	trans	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg27523141	chr10:43048294	ZNF37B	0.73	8.4	0.6	8.55e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg06873352	chr17:61820015	STRADA	0.55	6.1	0.48	1.26e-8	Prudent dietary pattern;
TGCT	cis	rs11098499	0.954	rs6820115	chr4:120398182	T/C	cg09307838	chr4:120376055	NA	0.63	6.2	0.49	7.68e-9	Corneal astigmatism;
TGCT	cis	rs910316	0.737	rs175065	chr14:75494983	T/C	cg11812906	chr14:75593930	NEK9	-0.59	-5.59	-0.45	1.38e-7	Height;
TGCT	cis	rs13326165	0.616	rs82825	chr3:52471942	G/A	cg07884673	chr3:53033167	SFMBT1	-0.39	-4.7	-0.39	6.74e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs422249	0.512	rs174574	chr11:61600342	A/C	cg01500311	chr11:61656094	FADS3	0.32	5.69	0.46	8.54e-8	Trans fatty acid levels;
TGCT	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg11644478	chr21:40555479	PSMG1	-0.6	-5.3	-0.43	5.09e-7	Cognitive function;
TGCT	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg03452623	chr4:187889614	NA	-0.34	-4.94	-0.41	2.46e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9905704	0.624	rs34718875	chr17:57072461	G/A	cg12560992	chr17:57184187	TRIM37	0.6	5.52	0.44	1.93e-7	Testicular germ cell tumor;
TGCT	cis	rs7216064	0.601	rs35453056	chr17:66039668	A/G	cg12091567	chr17:66097778	LOC651250	1.08	8.86	0.62	7.21e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs56399783	0.901	rs73049341	chr7:2812255	G/C	cg19731401	chr7:2775893	GNA12	0.35	4.91	0.4	2.76e-6	Childhood ear infection;
TGCT	cis	rs344364	0.511	rs2982433	chr16:1954508	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.4	-4.73	-0.39	6.05e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	6.18	0.49	8.58e-9	Bipolar disorder;
TGCT	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg03264133	chr6:25882463	NA	-0.65	-5.88	-0.47	3.48e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs8017423	1.000	rs4900028	chr14:90685594	C/T	cg04374321	chr14:90722782	PSMC1	0.77	7.93	0.58	1.12e-12	Mortality in heart failure;
TGCT	cis	rs28595532	0.920	rs17259284	chr4:119779298	T/C	cg14228332	chr4:119757509	SEC24D	1.26	7.08	0.54	9.26e-11	Cannabis dependence symptom count;
TGCT	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg11141652	chr22:24348549	GSTTP1	-0.33	-4.58	-0.38	1.1e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs11690935	0.632	rs6737308	chr2:172872042	G/A	cg13550731	chr2:172543902	DYNC1I2	0.6	5.23	0.43	7e-7	Schizophrenia;
TGCT	cis	rs939658	0.805	rs35318825	chr15:79447098	C/A	cg17916960	chr15:79447300	NA	-0.51	-7.83	-0.58	1.84e-12	Refractive error;
TGCT	cis	rs2439831	0.867	rs2245715	chr15:43818052	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.98	7.56	0.56	7.97e-12	Lung cancer in ever smokers;
TGCT	cis	rs899997	0.862	rs4887074	chr15:78952110	G/C	cg00061860	chr15:78953028	NA	-0.33	-5.95	-0.47	2.5e-8	Coronary artery disease or large artery stroke;
TGCT	cis	rs6121246	0.909	rs8126355	chr20:30332660	C/T	cg18721089	chr20:30220636	NA	-0.43	-4.75	-0.39	5.54e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs2016266	0.784	rs10747666	chr12:53716836	G/A	cg16917193	chr12:54089295	NA	0.67	5.2	0.42	8e-7	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs1401999	1.000	rs6767013	chr3:183680102	G/A	cg01324343	chr3:183735012	ABCC5	0.82	10.97	0.7	5.41e-20	Anterior chamber depth;
TGCT	cis	rs34779708	0.931	rs59418206	chr10:35331624	G/A	cg04310649	chr10:35416472	CREM	-0.53	-4.79	-0.4	4.64e-6	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs9902453	0.967	rs9913074	chr17:28481199	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	5.41	0.44	3.13e-7	Coffee consumption (cups per day);
TGCT	cis	rs11948739	0.573	rs12332505	chr5:130337348	T/G	cg08523029	chr5:130500466	HINT1	-0.61	-5.08	-0.42	1.34e-6	Pediatric bone mineral content (hip);
TGCT	cis	rs10883723	0.810	rs10883729	chr10:104273943	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	8.36	0.6	1.1e-13	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs8070128	0.600	rs8071238	chr17:17900990	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.78	7.87	0.58	1.5e-12	Total body bone mineral density;
TGCT	cis	rs6430585	0.528	rs309142	chr2:136715324	T/C	cg07169764	chr2:136633963	MCM6	1.22	11.95	0.73	2.26e-22	Corneal structure;
TGCT	cis	rs4930561	0.739	rs7118045	chr11:67978734	C/G	cg04465784	chr11:67976953	SUV420H1	-0.38	-5.5	-0.44	2.07e-7	Breast cancer in childhood cancer survivors;IgG glycosylation;
TGCT	cis	rs8032315	0.965	rs8027450	chr15:91418394	C/T	cg04510874	chr15:91427884	FES	0.5	5.62	0.45	1.2e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs8180040	1.000	rs11714294	chr3:47339723	G/A	cg27129171	chr3:47204927	SETD2	-0.7	-8.55	-0.61	3.88e-14	Colorectal cancer;
TGCT	cis	rs9467773	0.620	rs3800303	chr6:26598188	A/G	cg15659132	chr6:26577336	NA	0.86	10.93	0.7	6.8e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs17376456	0.569	rs6556834	chr5:93123067	C/T	cg21475434	chr5:93447410	FAM172A	-0.6	-4.9	-0.4	2.92e-6	Diabetic retinopathy;
TGCT	cis	rs4563143	0.592	rs12151001	chr19:29283386	C/G	cg03161606	chr19:29218774	NA	0.62	6.0	0.47	2e-8	Methadone dose in opioid dependence;
TGCT	cis	rs17534004	1.000	rs17534137	chr13:31471920	G/A	cg13251181	chr13:31481184	C13orf33	0.36	4.99	0.41	1.97e-6	3-hydroxypropylmercapturic acid levels in smokers;
TGCT	trans	rs4576506	0.826	rs1929103	chr9:31503499	T/G	cg11445191	chr5:140227765	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA5;PCDHA9;PCDHA3;PCDHA4;PCDHA8	0.98	6.69	0.51	6.76e-10	Psychosis and Alzheimer's disease;
TGCT	cis	rs6725041	0.547	rs59096325	chr2:213203853	C/T	cg20637307	chr2:213403960	ERBB4	-0.53	-4.5	-0.37	1.52e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs4455778	0.579	rs4563839	chr7:49076344	T/A	cg26309511	chr7:48887640	NA	0.5	6.47	0.5	2.07e-9	Lung cancer in never smokers;
TGCT	cis	rs1443512	0.812	rs1867299	chr12:54329975	T/C	cg17708016	chr12:54321992	NA	0.57	4.67	0.39	7.84e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
TGCT	cis	rs61990749	0.597	rs9788540	chr14:78132172	G/C	cg23188588	chr14:78226832	SNW1;C14orf178	-0.67	-4.7	-0.39	6.93e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs3733585	0.673	rs4292332	chr4:9953830	C/A	cg00071950	chr4:10020882	SLC2A9	-0.55	-6.58	-0.51	1.21e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg10935138	chr17:73851978	WBP2	1.0	10.11	0.67	6.79e-18	Psoriasis;
TGCT	cis	rs3796352	0.892	rs35076015	chr3:53026366	C/T	cg07884673	chr3:53033167	SFMBT1	0.64	6.39	0.5	3.03e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg13409248	chr3:40428643	ENTPD3	0.57	4.58	0.38	1.13e-5	Renal cell carcinoma;
TGCT	cis	rs2982552	1.000	rs3020304	chr6:152064464	C/T	cg22157087	chr6:152012887	ESR1	0.19	4.57	0.38	1.15e-5	Bone properties (heel);
TGCT	cis	rs2862064	1.000	rs2055429	chr5:156455113	C/G	cg12943317	chr5:156479607	HAVCR1	-0.48	-5.94	-0.47	2.64e-8	Platelet count;
TGCT	cis	rs11719291	0.584	rs13080725	chr3:49076092	G/A	cg07636037	chr3:49044803	WDR6	-1.04	-5.16	-0.42	9.65e-7	Cognitive function;
TGCT	cis	rs11148252	1.000	rs11148252	chr13:53009048	C/T	cg00495681	chr13:53174319	NA	0.46	4.51	0.38	1.49e-5	Lewy body disease;
TGCT	cis	rs12950390	0.853	rs11079790	chr17:45853626	G/A	cg06532163	chr17:45867833	NA	0.33	5.16	0.42	9.7e-7	IgG glycosylation;
TGCT	cis	rs116095464	0.558	rs9312979	chr5:222057	A/C	cg12570787	chr5:219185	SDHA;CCDC127	0.71	4.75	0.39	5.44e-6	Breast cancer;
TGCT	cis	rs9457247	0.967	rs2757054	chr6:167380501	A/G	cg23791538	chr6:167370224	RNASET2	0.5	4.98	0.41	2.08e-6	Crohn's disease;
TGCT	cis	rs6500602	0.893	rs4786489	chr16:4485527	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.3	5.13	0.42	1.08e-6	Schizophrenia;
TGCT	cis	rs2439831	1.000	rs2467736	chr15:43784917	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	5.51	0.44	1.95e-7	Lung cancer in ever smokers;
TGCT	cis	rs7833790	0.929	rs28464834	chr8:82797356	A/T	cg17211192	chr8:82754475	SNX16	0.95	7.32	0.55	2.79e-11	Diastolic blood pressure;
TGCT	cis	rs73198271	0.920	rs11781542	chr8:8617181	G/T	ch.8.214553F	chr8:8189620	PRAGMIN	-0.27	-4.79	-0.39	4.72e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs7267979	0.780	rs2500413	chr20:25241155	T/C	cg03522245	chr20:25566470	NINL	0.48	4.59	0.38	1.06e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6770219	0.516	rs7635602	chr3:186134939	G/A	cg20306810	chr3:186501757	SNORD2;EIF4A2	0.73	4.45	0.37	1.89e-5	Cerebrospinal T-tau levels;
TGCT	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg25036284	chr2:26402008	FAM59B	-0.65	-5.19	-0.42	8.36e-7	Gut microbiome composition (summer);
TGCT	cis	rs7017914	0.905	rs2732102	chr8:71922872	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	0.55	5.17	0.42	9.24e-7	Bone mineral density;
TGCT	cis	rs12136530	0.593	rs12404362	chr1:19739958	A/G	cg24875000	chr1:19041556	PAX7	-0.26	-4.62	-0.38	9.56e-6	Lead levels in blood;
TGCT	cis	rs79149102	0.579	rs7172065	chr15:75321910	C/T	cg09165964	chr15:75287851	SCAMP5	-1.03	-5.26	-0.43	6.24e-7	Lung cancer;
TGCT	cis	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg02380750	chr20:61661411	NA	-0.34	-5.89	-0.47	3.33e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs10489202	0.632	rs202273	chr1:167919963	A/G	cg24449463	chr1:168025552	DCAF6	-0.6	-7.25	-0.55	3.86e-11	Schizophrenia;
TGCT	cis	rs2288884	0.943	rs11084131	chr19:52514446	G/A	cg13540795	chr19:52551618	ZNF432	-0.56	-4.72	-0.39	6.33e-6	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs6683383	1.000	rs6427990	chr1:203088382	G/T	cg04395153	chr1:203052423	MYOG	-0.26	-4.45	-0.37	1.87e-5	Asthma;
TGCT	cis	rs7267979	0.966	rs2261785	chr20:25262403	C/T	cg03522245	chr20:25566470	NINL	0.62	6.61	0.51	1.04e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs561341	0.783	rs512698	chr17:30292507	G/T	cg20587970	chr11:113659929	NA	-1.03	-10.98	-0.7	5.21e-20	Hip circumference adjusted for BMI;
TGCT	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.92	-6.8	-0.52	3.96e-10	Gut microbiome composition (summer);
TGCT	cis	rs9486719	1.000	rs12530462	chr6:97053514	C/T	cg18709589	chr6:96969512	KIAA0776	-0.74	-5.21	-0.42	7.5e-7	Migraine;Coronary artery disease;
TGCT	cis	rs9814567	0.964	rs6805388	chr3:134173534	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-1.01	-9.71	-0.66	6.38e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs28595532	0.841	rs115852209	chr4:119753465	A/G	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs7089973	0.604	rs1924034	chr10:116578539	C/T	cg03647239	chr10:116582469	FAM160B1	0.59	5.42	0.44	2.94e-7	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs3617	0.625	rs2245647	chr3:52862753	A/G	cg11645453	chr3:52864694	ITIH4	0.28	5.45	0.44	2.63e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs896854	0.714	rs572547	chr8:95966286	A/G	cg23172400	chr8:95962367	TP53INP1	0.36	5.6	0.45	1.33e-7	Type 2 diabetes;
TGCT	cis	rs7647973	1.000	rs11130190	chr3:49402137	T/C	cg05785598	chr3:49045655	WDR6	0.39	4.66	0.39	7.89e-6	Menarche (age at onset);
TGCT	cis	rs9393692	0.645	rs4145910	chr6:26313305	T/C	cg13736514	chr6:26305472	NA	-0.45	-6.67	-0.51	7.52e-10	Educational attainment;
TGCT	cis	rs7666738	0.830	rs6532715	chr4:99016792	G/A	cg05340658	chr4:99064831	C4orf37	0.48	5.43	0.44	2.92e-7	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs2727020	0.729	rs34647977	chr11:49195543	G/A	cg15704280	chr7:45808275	SEPT13	-0.68	-7.44	-0.56	1.47e-11	Coronary artery disease;
TGCT	cis	rs7552404	0.696	rs10518521	chr1:76461214	G/A	cg22875332	chr1:76189707	ACADM	0.63	5.88	0.47	3.48e-8	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs17270561	0.943	rs4478398	chr6:25694684	T/C	cg16482183	chr6:26056742	HIST1H1C	0.7	4.62	0.38	9.56e-6	Iron status biomarkers;
TGCT	cis	rs4711350	0.906	rs4713688	chr6:33789407	T/G	cg18005901	chr6:33739558	LEMD2	-0.57	-5.75	-0.46	6.68e-8	Schizophrenia;
TGCT	cis	rs1461503	0.868	rs10790543	chr11:122838311	A/C	cg27398637	chr11:122830231	C11orf63	-0.43	-5.31	-0.43	5e-7	Menarche (age at onset);
TGCT	cis	rs2463822	0.513	rs72919445	chr11:62029078	A/C	cg06239285	chr11:62104954	ASRGL1	-0.87	-5.56	-0.45	1.56e-7	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs4443100	0.670	rs13056137	chr22:23407261	C/A	cg14186256	chr22:23484241	RTDR1	0.57	4.46	0.37	1.79e-5	Serum parathyroid hormone levels;
TGCT	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg11890956	chr21:40555474	PSMG1	-0.71	-6.38	-0.5	3.18e-9	Cognitive function;
TGCT	cis	rs7267979	0.932	rs449703	chr20:25458559	C/T	cg03522245	chr20:25566470	NINL	0.6	6.46	0.5	2.14e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs968451	0.547	rs11704319	chr22:39722886	A/G	cg01093212	chr22:39715156	SNORD43;RPL3	-0.5	-4.67	-0.39	7.74e-6	Primary biliary cholangitis;
TGCT	cis	rs4455778	0.659	rs2364007	chr7:49016537	G/A	cg26309511	chr7:48887640	NA	-0.43	-5.07	-0.41	1.4e-6	Lung cancer in never smokers;
TGCT	cis	rs3015497	0.653	rs2356456	chr14:51093216	A/T	cg04730355	chr14:51134070	SAV1	-0.62	-5.89	-0.47	3.32e-8	Mean platelet volume;
TGCT	cis	rs7647973	0.626	rs62260720	chr3:49853796	T/A	cg03060546	chr3:49711283	APEH	-0.67	-5.93	-0.47	2.82e-8	Menarche (age at onset);
TGCT	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.01	8.32	0.6	1.34e-13	Platelet count;
TGCT	trans	rs2727020	0.553	rs3862350	chr11:49595912	A/C	cg03929089	chr4:120376271	NA	-0.65	-7.57	-0.56	7.39e-12	Coronary artery disease;
TGCT	cis	rs7904368	0.806	rs12242261	chr10:16872929	T/C	cg14835575	chr10:16859367	RSU1	0.62	5.7	0.46	8.39e-8	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
TGCT	cis	rs6671200	0.850	rs259345	chr1:95729649	A/G	cg26537280	chr1:95699037	RWDD3	-0.7	-5.55	-0.45	1.62e-7	Stearic acid (18:0) levels;
TGCT	cis	rs7727544	0.735	rs270605	chr5:131651811	C/T	cg24060327	chr5:131705240	SLC22A5	-0.58	-6.47	-0.5	2.06e-9	Blood metabolite levels;
TGCT	cis	rs9486719	0.895	rs3734239	chr6:96996244	A/G	cg06623918	chr6:96969491	KIAA0776	-0.99	-7.99	-0.58	7.78e-13	Migraine;Coronary artery disease;
TGCT	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg20887711	chr4:1340912	KIAA1530	0.93	8.51	0.61	4.9e-14	Longevity;
TGCT	cis	rs854765	0.583	rs7213225	chr17:17869111	T/C	cg09796270	chr17:17721594	SREBF1	0.23	4.55	0.38	1.27e-5	Total body bone mineral density;
TGCT	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg26513180	chr16:89883248	FANCA	1.07	14.89	0.8	2.19e-29	Vitiligo;
TGCT	cis	rs71636778	0.509	rs35962879	chr1:27283456	T/C	cg23921621	chr1:27994728	IFI6	-0.43	-4.61	-0.38	9.92e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
TGCT	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.49	-0.37	1.6e-5	Bipolar disorder;
TGCT	trans	rs7618501	0.602	rs7642934	chr3:50174848	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.93	-10.82	-0.7	1.3e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs2050392	0.760	rs10826797	chr10:30690376	A/C	cg13289132	chr10:30722225	MAP3K8	-0.39	-4.87	-0.4	3.3e-6	Inflammatory bowel disease;
TGCT	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg03709012	chr19:19516395	GATAD2A	0.67	5.74	0.46	6.83e-8	Tonsillectomy;
TGCT	cis	rs5769707	0.967	rs763127	chr22:50006078	C/T	cg20744362	chr22:50050164	C22orf34	0.28	4.58	0.38	1.12e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs2637266	1.000	rs2395388	chr10:78357203	C/T	cg18941641	chr10:78392320	NA	0.4	5.01	0.41	1.81e-6	Pulmonary function;
TGCT	cis	rs12142240	0.698	rs55670684	chr1:46835139	C/T	cg00530320	chr1:46809349	NSUN4	0.27	5.55	0.45	1.68e-7	Menopause (age at onset);
TGCT	cis	rs7666738	0.571	rs7683769	chr4:99091742	T/C	cg05340658	chr4:99064831	C4orf37	0.44	4.72	0.39	6.23e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9583531	0.689	rs9588247	chr13:111375571	G/T	cg24331049	chr13:111365604	ING1	-0.9	-8.98	-0.63	3.69e-15	Coronary artery disease;
TGCT	cis	rs2859741	1.000	rs543121	chr1:37497098	T/C	cg09363841	chr1:37513479	NA	-0.2	-4.59	-0.38	1.07e-5	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
TGCT	cis	rs9916302	0.904	rs12450559	chr17:37694709	G/A	cg07936489	chr17:37558343	FBXL20	-0.61	-4.87	-0.4	3.33e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7940866	0.801	rs2113929	chr11:130835974	G/A	cg12179176	chr11:130786555	SNX19	0.63	5.96	0.47	2.39e-8	Schizophrenia;
TGCT	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg15691649	chr6:25882328	NA	0.5	6.02	0.48	1.84e-8	Blood metabolite levels;
TGCT	cis	rs6426558	0.537	rs12039370	chr1:227326472	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.58	-6.91	-0.53	2.21e-10	Neutrophil percentage of white cells;
TGCT	cis	rs9532580	0.710	rs9577090	chr13:41225228	G/T	cg21288729	chr13:41239152	FOXO1	1.02	10.33	0.68	1.95e-18	Mean corpuscular hemoglobin;
TGCT	cis	rs9303401	0.527	rs12939313	chr17:56755616	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.53	5.05	0.41	1.55e-6	Cognitive test performance;
TGCT	cis	rs929354	0.772	rs1182432	chr7:157029176	A/G	cg05182265	chr7:156933206	UBE3C	-0.37	-8.49	-0.61	5.4e-14	Body mass index;
TGCT	cis	rs9549260	0.816	rs7328594	chr13:41253764	T/C	cg21288729	chr13:41239152	FOXO1	1.01	10.06	0.67	8.86e-18	Red blood cell count;
TGCT	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg16414030	chr3:133502952	NA	-0.61	-9.47	-0.65	2.44e-16	Iron status biomarkers;
TGCT	cis	rs1903068	0.925	rs1551641	chr4:55993915	C/T	cg01777861	chr4:56023843	NA	0.56	6.43	0.5	2.54e-9	Endometriosis;
TGCT	cis	rs62244186	0.541	rs3804583	chr3:44884647	G/T	cg10263370	chr3:44754102	ZNF502	-0.45	-5.45	-0.44	2.66e-7	Depressive symptoms;
TGCT	cis	rs910316	0.967	rs175505	chr14:75529619	C/T	cg11812906	chr14:75593930	NEK9	-0.73	-7.01	-0.53	1.38e-10	Height;
TGCT	cis	rs10791323	0.536	rs4937842	chr11:133734542	C/G	cg03690763	chr11:133734501	NA	0.39	7.05	0.54	1.09e-10	Childhood ear infection;
TGCT	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg03388025	chr16:89894329	SPIRE2	0.47	8.06	0.59	5.52e-13	Vitiligo;
TGCT	cis	rs10986311	0.775	rs13300918	chr9:127145290	A/C	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.19	4.67	0.39	7.64e-6	Vitiligo;
TGCT	cis	rs7666738	0.830	rs9995370	chr4:98732145	T/G	cg18180107	chr4:99064573	C4orf37	0.53	5.07	0.41	1.38e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9810089	0.868	rs4630889	chr3:136278251	T/C	cg12473912	chr3:136751656	NA	0.34	4.83	0.4	3.9e-6	Gestational age at birth (child effect);
TGCT	cis	rs908922	0.627	rs1053588	chr1:152488063	C/T	cg20991723	chr1:152506922	NA	0.46	6.41	0.5	2.69e-9	Hair morphology;
TGCT	cis	rs7246657	0.943	rs7255785	chr19:37971683	C/T	cg18154014	chr19:37997991	ZNF793	0.74	5.44	0.44	2.71e-7	Coronary artery calcification;
TGCT	cis	rs7666738	0.753	rs10004827	chr4:99037953	A/C	cg17366294	chr4:99064904	C4orf37	0.74	7.53	0.56	9.32e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9894429	1.000	rs4074916	chr17:79579248	G/A	cg18240062	chr17:79603768	NPLOC4	-0.66	-6.66	-0.51	7.97e-10	Eye color traits;
TGCT	cis	rs7647973	0.580	rs12637576	chr3:49237334	C/T	cg03060546	chr3:49711283	APEH	0.51	4.9	0.4	2.95e-6	Menarche (age at onset);
TGCT	cis	rs13256369	1.000	rs7004438	chr8:8574379	C/T	cg17143192	chr8:8559678	CLDN23	0.63	5.93	0.47	2.8e-8	Obesity-related traits;
TGCT	cis	rs12908161	1.000	rs35524990	chr15:85258203	T/C	cg17173187	chr15:85201210	NMB	0.59	6.77	0.52	4.55e-10	Schizophrenia;
TGCT	cis	rs7698623	0.850	rs716808	chr4:88800136	G/T	cg02735620	chr4:88950514	PKD2	-0.44	-4.78	-0.39	4.95e-6	Cardiovascular disease risk factors;
TGCT	cis	rs17331151	0.573	rs77223362	chr3:52865125	G/A	cg12962167	chr3:53033115	SFMBT1	0.44	4.96	0.41	2.28e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs9902453	0.765	rs2259857	chr17:28097780	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.84	-8.18	-0.59	2.89e-13	Coffee consumption (cups per day);
TGCT	cis	rs12549902	0.966	rs17659386	chr8:41513531	T/C	cg00088007	chr8:41504566	NKX6-3	0.34	5.31	0.43	4.93e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
TGCT	cis	rs66725070	1	rs66725070	chr15:58267416	GACAT/G	cg12031962	chr15:58353849	ALDH1A2	-0.49	-7.74	-0.57	3.01e-12	Barrett's esophagus;
TGCT	cis	rs9640161	0.750	rs55974958	chr7:150037927	C/T	cg10018233	chr7:150070692	REPIN1	0.32	4.78	0.39	4.84e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs78487399	0.808	rs6757251	chr2:43734847	C/T	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.76	4.65	0.39	8.35e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg06112835	chr11:68658793	MRPL21	0.46	8.12	0.59	3.91e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs3796352	0.527	rs11714793	chr3:52924930	A/G	cg07884673	chr3:53033167	SFMBT1	0.5	5.26	0.43	6.15e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs10751667	0.621	rs4075990	chr11:976614	T/C	cg06064525	chr11:970664	AP2A2	-0.36	-8.28	-0.6	1.67e-13	Alzheimer's disease (late onset);
TGCT	cis	rs34779708	0.966	rs113170867	chr10:35450147	C/T	cg04310649	chr10:35416472	CREM	-0.53	-4.71	-0.39	6.66e-6	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs13191362	0.935	rs35378894	chr6:163123933	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.16	9.92	0.67	1.96e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7043114	0.525	rs7020874	chr9:95112560	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-5.54	-0.45	1.72e-7	Height;
TGCT	cis	rs8103278	0.740	rs72626215	chr19:46294136	G/A	cg14061069	chr19:46274453	DMPK	-0.39	-4.99	-0.41	2.02e-6	Coronary artery disease;
TGCT	trans	rs1814175	0.647	rs10839394	chr11:49844747	T/C	cg15704280	chr7:45808275	SEPT13	-0.72	-8.14	-0.59	3.62e-13	Height;
TGCT	cis	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg03213289	chr20:61660250	NA	0.68	9.9	0.66	2.25e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1568889	0.877	rs17310076	chr11:28147590	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	6.46	0.5	2.2e-9	Bipolar disorder;
TGCT	cis	rs35160687	0.901	rs35281683	chr2:86526372	T/C	cg12542933	chr2:85804724	VAMP8	0.4	4.81	0.4	4.21e-6	Night sleep phenotypes;
TGCT	cis	rs9640161	0.789	rs10282458	chr7:150045302	C/T	cg10018233	chr7:150070692	REPIN1	0.31	4.55	0.38	1.25e-5	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs910316	0.737	rs2098251	chr14:75492696	G/A	cg11812906	chr14:75593930	NEK9	0.59	5.59	0.45	1.36e-7	Height;
TGCT	cis	rs7666738	0.830	rs34628820	chr4:99004764	C/T	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10501293	0.675	rs7103629	chr11:43044427	T/A	cg03447554	chr11:43094025	NA	0.45	6.52	0.51	1.64e-9	Cognitive performance;
TGCT	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg06481639	chr22:41940642	POLR3H	-0.74	-6.74	-0.52	5.38e-10	Vitiligo;
TGCT	cis	rs13242816	1.000	rs3779513	chr7:116178992	T/C	cg02799643	chr7:116139180	CAV2	-0.43	-5.29	-0.43	5.24e-7	P wave duration;
TGCT	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg06212747	chr3:49208901	KLHDC8B	0.61	5.51	0.44	1.95e-7	Parkinson's disease;
TGCT	cis	rs317689	0.513	rs317659	chr12:69686132	T/A	cg11871910	chr12:69753446	YEATS4	0.63	6.11	0.48	1.18e-8	Response to diuretic therapy;
TGCT	cis	rs739496	0.615	rs847898	chr12:112163646	A/G	cg10833066	chr12:111807467	FAM109A	0.36	5.06	0.41	1.46e-6	Platelet count;
TGCT	cis	rs7100689	0.556	rs946893	chr10:82023524	A/G	cg01528321	chr10:82214614	TSPAN14	0.7	6.87	0.52	2.78e-10	Post bronchodilator FEV1;
TGCT	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs112591243	0.685	rs2839294	chr21:47917664	T/C	cg10657630	chr21:48055338	PRMT2	1.06	5.21	0.42	7.69e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs2842992	0.830	rs2025190	chr6:160138241	C/T	cg11366901	chr6:160182831	ACAT2	1.01	6.74	0.52	5.42e-10	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs9359856	0.510	rs78649003	chr6:90454644	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.45	-4.66	-0.39	7.9e-6	Bipolar disorder;
TGCT	cis	rs2463822	0.925	rs2513075	chr11:62102408	C/T	cg23876832	chr11:62092739	NA	0.67	4.91	0.4	2.82e-6	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs78545713	0.892	rs76182849	chr6:26257950	C/T	cg12260798	chr6:26240519	HIST1H4F	-0.53	-4.48	-0.37	1.71e-5	Iron status biomarkers (total iron binding capacity);
TGCT	cis	rs1045714	0.895	rs17833498	chr7:2647007	A/G	cg17215154	chr7:2644645	IQCE	-0.28	-4.92	-0.4	2.75e-6	Urate levels in lean individuals;
TGCT	cis	rs11122272	0.735	rs2491408	chr1:231519248	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.13	-0.54	7.33e-11	Hemoglobin concentration;
TGCT	cis	rs7666738	0.830	rs4345191	chr4:98945408	A/G	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2130392	0.886	rs3806796	chr4:185652147	G/A	cg14471096	chr4:185570637	CCDC111;CASP3	-0.52	-4.91	-0.4	2.85e-6	Kawasaki disease;
TGCT	cis	rs8017423	0.626	rs8003363	chr14:90826840	T/C	cg04374321	chr14:90722782	PSMC1	-0.57	-5.61	-0.45	1.27e-7	Mortality in heart failure;
TGCT	cis	rs9362426	0.639	rs5009694	chr6:88131868	A/C	cg10919329	chr6:88182879	SLC35A1	-0.61	-4.61	-0.38	9.99e-6	Depressive episodes in bipolar disorder;
TGCT	cis	rs11112613	0.713	rs11112586	chr12:105939816	C/T	cg03607813	chr12:105948248	NA	0.44	5.52	0.44	1.9e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	cis	rs854765	0.647	rs2056842	chr17:18009028	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	7.52	0.56	9.79e-12	Total body bone mineral density;
TGCT	cis	rs17052344	0.582	rs111876736	chr17:21747067	A/G	cg18423549	chr17:21743878	NA	-0.66	-6.21	-0.49	7.18e-9	Cutaneous psoriasis;
TGCT	cis	rs7192750	0.562	rs2335709	chr16:71938442	G/A	cg06353428	chr16:71660113	MARVELD3	0.8	7.2	0.54	5.05e-11	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs2295359	0.892	rs10789224	chr1:67605134	C/T	cg12940439	chr1:67600707	NA	-0.59	-5.99	-0.47	2.15e-8	Psoriasis;
TGCT	cis	rs13191362	1.000	rs66529337	chr6:163005662	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.68	5.79	0.46	5.33e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs9902453	0.904	rs4598962	chr17:28293948	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	7.25	0.55	4e-11	Coffee consumption (cups per day);
TGCT	cis	rs1008375	0.932	rs4698626	chr4:17605821	G/C	cg10189774	chr4:17578691	LAP3	0.57	4.9	0.4	2.93e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs950169	1.000	rs12902672	chr15:84716986	G/A	cg17173187	chr15:85201210	NMB	0.47	5.22	0.42	7.36e-7	Schizophrenia;
TGCT	cis	rs12497850	0.863	rs4974084	chr3:48939080	G/A	cg06212747	chr3:49208901	KLHDC8B	0.63	5.72	0.46	7.5e-8	Parkinson's disease;
TGCT	cis	rs6988636	0.901	rs2602001	chr8:124195974	T/C	cg23067535	chr8:124195133	FAM83A	0.33	5.07	0.41	1.41e-6	Urinary uromodulin levels;
TGCT	cis	rs711245	1.000	rs848602	chr2:36778372	G/A	cg09467607	chr2:36825704	FEZ2	0.35	4.86	0.4	3.52e-6	Height;
TGCT	cis	rs8013055	0.846	rs10147392	chr14:105978537	T/G	cg23356831	chr14:105996513	TMEM121	0.37	5.55	0.45	1.68e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs12762955	0.561	rs7076107	chr10:1043647	T/C	cg20503657	chr10:835505	NA	-0.41	-5.33	-0.43	4.56e-7	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs6088590	0.965	rs6119534	chr20:33441257	C/T	cg24642439	chr20:33292090	TP53INP2	0.71	6.32	0.49	4.28e-9	Coronary artery disease;
TGCT	cis	rs9486719	1.000	rs11153023	chr6:96968525	C/T	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.86	-0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs2439831	0.717	rs28495368	chr15:43895642	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.84	5.46	0.44	2.5e-7	Lung cancer in ever smokers;
TGCT	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-5.1	-0.42	1.23e-6	Bipolar disorder;
TGCT	cis	rs2933343	1.000	rs789232	chr3:128603080	T/G	cg11901034	chr3:128598214	ACAD9	-0.64	-5.05	-0.41	1.56e-6	IgG glycosylation;
TGCT	cis	rs7833790	0.777	rs1005850	chr8:82692255	G/A	cg27398817	chr8:82754497	SNX16	-0.83	-5.96	-0.47	2.43e-8	Diastolic blood pressure;
TGCT	cis	rs1008375	0.618	rs6842764	chr4:17568420	C/T	cg18681998	chr4:17616180	MED28	-0.76	-6.73	-0.52	5.69e-10	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs75059851	0.756	rs2000852	chr11:133838221	C/T	cg14047540	chr11:133829660	NA	-0.53	-5.34	-0.43	4.37e-7	Schizophrenia;
TGCT	cis	rs12200560	0.505	rs59296768	chr6:97075535	C/T	cg06623918	chr6:96969491	KIAA0776	0.59	5.03	0.41	1.71e-6	Coronary heart disease;
TGCT	cis	rs7020830	0.830	rs12554976	chr9:37244505	G/T	cg14294708	chr9:37120828	ZCCHC7	1.18	15.7	0.82	2.88e-31	Schizophrenia;
TGCT	cis	rs1153858	1.000	rs4534782	chr15:45652933	G/A	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.62e-8	Homoarginine levels;
TGCT	cis	rs2204008	0.818	rs7313608	chr12:38383428	C/A	cg26384229	chr12:38710491	ALG10B	-0.79	-7.02	-0.53	1.26e-10	Bladder cancer;
TGCT	cis	rs3008870	0.755	rs2755271	chr1:67474977	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.81	8.43	0.6	7.53e-14	Lymphocyte percentage of white cells;
TGCT	cis	rs6076065	0.548	rs1112819	chr20:23323987	A/G	cg11657817	chr20:23433608	CST11	0.29	5.07	0.41	1.42e-6	Facial morphology (factor 15, philtrum width);
TGCT	trans	rs1814175	0.817	rs4881645	chr11:49791168	G/A	cg03929089	chr4:120376271	NA	-0.7	-8.19	-0.59	2.72e-13	Height;
TGCT	cis	rs7937682	0.961	rs4935790	chr11:111633014	T/C	cg09085632	chr11:111637200	PPP2R1B	1.16	11.37	0.71	5.71e-21	Primary sclerosing cholangitis;
TGCT	cis	rs11874712	1.000	rs28504655	chr18:43665348	G/A	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	5.23	0.42	7.11e-7	Migraine - clinic-based;
TGCT	cis	rs4689388	0.679	rs1046316	chr4:6304087	A/G	cg25554036	chr4:6271136	WFS1	0.55	6.83	0.52	3.44e-10	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs4713118	0.955	rs9380010	chr6:27683572	A/G	cg10876282	chr6:28092338	ZSCAN16	0.5	4.62	0.38	9.35e-6	Parkinson's disease;
TGCT	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.85	7.0	0.53	1.44e-10	Platelet count;
TGCT	cis	rs7524258	0.868	rs4908607	chr1:7269323	A/G	cg07173049	chr1:7289937	CAMTA1	0.3	4.99	0.41	1.97e-6	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg24675658	chr1:53192096	ZYG11B	-0.84	-10.28	-0.68	2.58e-18	Monocyte count;
TGCT	cis	rs12477438	0.765	rs13406288	chr2:99589585	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-4.62	-0.38	9.47e-6	Chronic sinus infection;
TGCT	cis	rs1847202	0.826	rs11925587	chr3:72952227	A/G	cg25664220	chr3:72788482	NA	0.35	4.51	0.38	1.49e-5	Motion sickness;
TGCT	cis	rs2404602	0.735	rs283789	chr15:76777577	G/A	cg22467129	chr15:76604101	ETFA	-0.48	-4.98	-0.41	2.04e-6	Blood metabolite levels;
TGCT	cis	rs2562456	0.834	rs2173727	chr19:21673957	C/T	cg01304269	chr19:21688519	ZNF429	-0.58	-4.8	-0.4	4.49e-6	Pain;
TGCT	cis	rs9926296	0.572	rs2079671	chr16:89884981	T/C	cg03388025	chr16:89894329	SPIRE2	0.38	5.72	0.46	7.5e-8	Vitiligo;
TGCT	cis	rs9653442	0.545	rs2009094	chr2:100765077	G/A	cg22139774	chr2:100720529	AFF3	-0.36	-5.65	-0.45	1.04e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs9921338	0.961	rs72773830	chr16:11412823	G/C	cg00044050	chr16:11439710	C16orf75	-0.93	-6.96	-0.53	1.7e-10	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs3820068	0.822	rs11581917	chr1:15805722	G/A	cg05660106	chr1:15850417	CASP9	1.13	11.01	0.7	4.37e-20	Systolic blood pressure;
TGCT	cis	rs151349	0.555	rs151343	chr20:57583298	C/G	cg23907860	chr20:57583709	CTSZ	0.19	5.97	0.47	2.34e-8	Platelet distribution width;
TGCT	cis	rs1801251	0.963	rs7562712	chr2:233606580	A/G	cg25237894	chr2:233734115	C2orf82	0.33	5.95	0.47	2.53e-8	Coronary artery disease;
TGCT	cis	rs72781680	0.898	rs55846516	chr2:24158003	T/C	cg08917208	chr2:24149416	ATAD2B	0.73	4.51	0.38	1.48e-5	Lymphocyte counts;
TGCT	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg20887711	chr4:1340912	KIAA1530	0.57	5.16	0.42	9.57e-7	Longevity;
TGCT	cis	rs77972916	0.561	rs72788900	chr2:43559087	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.39	-4.46	-0.37	1.78e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs6964587	1.000	rs35317449	chr7:91637010	G/A	cg22709100	chr7:91322751	NA	0.27	4.48	0.37	1.68e-5	Breast cancer;
TGCT	cis	rs12142240	0.698	rs72885198	chr1:46812888	C/T	cg00530320	chr1:46809349	NSUN4	0.28	5.73	0.46	7.19e-8	Menopause (age at onset);
TGCT	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs904251	0.864	rs2797801	chr6:37487161	A/G	cg08126542	chr6:37504118	NA	-0.44	-5.94	-0.47	2.73e-8	Cognitive performance;
TGCT	cis	rs9858542	0.537	rs35869135	chr3:49359102	A/G	cg08550065	chr3:50336684	HYAL3;NAT6	0.66	4.54	0.38	1.29e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs2982552	0.844	rs2982554	chr6:152058010	G/T	cg22157087	chr6:152012887	ESR1	-0.2	-4.9	-0.4	2.94e-6	Bone properties (heel);
TGCT	cis	rs7582180	0.676	rs11680660	chr2:100931738	G/C	cg14675211	chr2:100938903	LONRF2	0.53	5.24	0.43	6.82e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg19761014	chr17:28927070	LRRC37B2	0.57	4.89	0.4	3.05e-6	Body mass index;
TGCT	cis	rs3820928	0.904	rs2217359	chr2:227759892	C/T	cg11843606	chr2:227700838	RHBDD1	-0.55	-4.94	-0.41	2.42e-6	Pulmonary function;
TGCT	cis	rs2439831	1.000	rs2584726	chr15:43715382	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.8	5.7	0.46	8.33e-8	Lung cancer in ever smokers;
TGCT	cis	rs7027203	0.828	rs4743934	chr9:96581893	A/G	cg14396892	chr9:96623032	NA	-0.29	-6.22	-0.49	7.08e-9	DNA methylation (variation);
TGCT	cis	rs208520	0.690	rs10944872	chr6:66708239	T/G	cg07460842	chr6:66804631	NA	0.96	10.26	0.68	2.92e-18	Exhaled nitric oxide output;
TGCT	cis	rs617219	0.710	rs16876598	chr5:78573970	T/C	cg09550809	chr5:78407562	BHMT	-0.37	-5.24	-0.43	6.65e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs1878931	0.582	rs27231	chr16:3434966	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.77	6.6	0.51	1.06e-9	Body mass index (adult);
TGCT	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.57	5.13	0.42	1.08e-6	Prudent dietary pattern;
TGCT	cis	rs2197308	0.765	rs7295711	chr12:37903631	C/T	cg26384229	chr12:38710491	ALG10B	0.89	7.98	0.58	8.43e-13	Morning vs. evening chronotype;
TGCT	cis	rs4924544	1	rs4924544	chr15:41693455	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.49	-6.8	-0.52	3.93e-10	Eosinophil percentage of white cells;
TGCT	cis	rs2180341	0.618	rs11961994	chr6:127649350	A/G	cg24812749	chr6:127587940	RNF146	-0.59	-5.06	-0.41	1.48e-6	Breast cancer;
TGCT	cis	rs8072100	0.967	rs9894905	chr17:45485982	C/T	cg08085267	chr17:45401833	C17orf57	-0.51	-5.6	-0.45	1.34e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs6964587	1.000	rs7811564	chr7:91663364	A/G	cg22709100	chr7:91322751	NA	0.28	4.56	0.38	1.19e-5	Breast cancer;
TGCT	cis	rs1981331	1.000	rs75843712	chr21:47976115	A/G	cg23283320	chr21:48055893	PRMT2	1.29	5.89	0.47	3.42e-8	Cerebrospinal fluid t-tau:AB1-42 ratio;
TGCT	cis	rs910316	0.967	rs4903293	chr14:75656568	A/G	cg23033748	chr14:75592666	NEK9	-0.27	-4.51	-0.38	1.5e-5	Height;
TGCT	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg02038168	chr22:39784481	NA	-0.77	-6.42	-0.5	2.68e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs6088590	0.965	rs6120727	chr20:33374102	T/C	cg24642439	chr20:33292090	TP53INP2	0.69	6.13	0.48	1.09e-8	Coronary artery disease;
TGCT	cis	rs6089829	0.692	rs6122349	chr20:61664096	T/C	cg03213289	chr20:61660250	NA	0.57	6.76	0.52	4.74e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs13326165	0.585	rs35860312	chr3:52387078	T/C	cg27565382	chr3:53032988	SFMBT1	0.38	5.06	0.41	1.5e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs919433	0.680	rs2124317	chr2:198477606	G/A	cg00792783	chr2:198669748	PLCL1	0.5	4.67	0.39	7.61e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs4689388	0.926	rs4688986	chr4:6285797	C/A	cg14416269	chr4:6271139	WFS1	0.39	5.25	0.43	6.47e-7	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs4304924	0.500	rs12585725	chr13:79220899	C/A	cg01819759	chr13:79234251	RNF219	0.86	7.64	0.57	5.22e-12	Large artery stroke;
TGCT	cis	rs1801251	0.896	rs2197563	chr2:233687080	G/A	cg25237894	chr2:233734115	C2orf82	-0.27	-4.96	-0.41	2.31e-6	Coronary artery disease;
TGCT	cis	rs3015497	0.967	rs8018308	chr14:51122633	T/C	cg04730355	chr14:51134070	SAV1	-0.51	-4.63	-0.38	8.95e-6	Mean platelet volume;
TGCT	cis	rs7937682	0.562	rs10891276	chr11:111370415	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.63	-5.85	-0.47	4.01e-8	Primary sclerosing cholangitis;
TGCT	cis	rs79976124	0.879	rs12214239	chr6:66636059	A/G	cg07460842	chr6:66804631	NA	0.56	5.03	0.41	1.71e-6	Type 2 diabetes;
TGCT	cis	rs7666738	0.830	rs17026973	chr4:98680041	T/A	cg18180107	chr4:99064573	C4orf37	0.53	5.07	0.41	1.41e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs79349575	0.783	rs4793998	chr17:47019899	C/T	cg07967210	chr17:47022446	SNF8	0.44	6.13	0.48	1.1e-8	Type 2 diabetes;
TGCT	cis	rs1008375	0.966	rs6813375	chr4:17649499	T/G	cg16339924	chr4:17578868	LAP3	0.67	5.55	0.45	1.68e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10501293	1.000	rs2862694	chr11:43064753	C/T	cg03447554	chr11:43094025	NA	0.46	6.64	0.51	8.85e-10	Cognitive performance;
TGCT	cis	rs2404602	0.583	rs12438741	chr15:76542114	C/A	cg22467129	chr15:76604101	ETFA	-0.62	-8.06	-0.59	5.34e-13	Blood metabolite levels;
TGCT	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg06481639	chr22:41940642	POLR3H	0.73	6.49	0.5	1.83e-9	Vitiligo;
TGCT	cis	rs6695640	0.857	rs1555663	chr1:17725011	T/C	cg25979543	chr1:17888104	ARHGEF10L	-0.24	-4.6	-0.38	1.03e-5	Mean platelet volume;
TGCT	cis	rs7246657	0.943	rs4802766	chr19:37981933	T/C	cg18154014	chr19:37997991	ZNF793	0.87	5.63	0.45	1.17e-7	Coronary artery calcification;
TGCT	cis	rs12950390	0.853	rs11079792	chr17:45863311	T/C	cg06532163	chr17:45867833	NA	0.37	5.96	0.47	2.45e-8	IgG glycosylation;
TGCT	cis	rs9372498	0.572	rs10484289	chr6:118827836	T/C	cg21191810	chr6:118973309	C6orf204	-0.39	-5.04	-0.41	1.62e-6	Diastolic blood pressure;
TGCT	cis	rs10769945	0.500	rs217203	chr11:1972456	G/C	cg06503573	chr11:1949039	TNNT3	-0.26	-4.59	-0.38	1.08e-5	DNA methylation (variation);
TGCT	cis	rs478304	0.934	rs12801731	chr11:65549606	T/C	cg17480646	chr11:65405466	SIPA1	0.41	5.03	0.41	1.7e-6	Acne (severe);
TGCT	cis	rs9581857	0.547	rs9581868	chr13:28070682	C/T	cg22138327	chr13:27999177	GTF3A	0.73	4.45	0.37	1.87e-5	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs6901250	0.851	rs339313	chr6:117179501	C/T	cg12892004	chr6:117198278	RFX6	-0.55	-6.76	-0.52	4.74e-10	C-reactive protein levels;
TGCT	cis	rs9796	0.745	rs2947493	chr15:41375694	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.52	-6.76	-0.52	4.79e-10	Menopause (age at onset);
TGCT	trans	rs17818859	0.661	rs7594893	chr2:134645345	C/G	cg15779785	chr12:2521414	CACNA1C	-0.59	-6.68	-0.51	7.24e-10	Neurofibrillary tangles;
TGCT	cis	rs9611519	1.000	rs9611519	chr22:41613188	C/T	cg03806693	chr22:41940476	POLR3H	-0.68	-6.38	-0.5	3.17e-9	Neuroticism;
TGCT	cis	rs9914988	0.943	rs2242345	chr17:27185827	C/T	cg20469991	chr17:27169893	C17orf63	0.71	5.15	0.42	9.95e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs12541335	0.639	rs3923433	chr8:22169798	A/T	cg09517075	chr8:22133004	PIWIL2	0.25	4.99	0.41	2.02e-6	Hypertriglyceridemia;
TGCT	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg10802521	chr3:52805072	NEK4	-0.76	-10.05	-0.67	9.74e-18	Bipolar disorder;
TGCT	cis	rs8103278	1.000	rs8108864	chr19:46301671	G/A	cg11657440	chr19:46296263	DMWD	-0.6	-5.78	-0.46	5.75e-8	Coronary artery disease;
TGCT	cis	rs9913156	0.793	rs55974786	chr17:4567564	T/C	cg00122941	chr17:4613640	ARRB2	0.88	7.51	0.56	1.03e-11	Lymphocyte counts;
TGCT	cis	rs9486719	1.000	rs13210597	chr6:96969694	C/A	cg18709589	chr6:96969512	KIAA0776	-0.72	-5.28	-0.43	5.64e-7	Migraine;Coronary artery disease;
TGCT	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg03351412	chr1:154909251	PMVK	0.51	4.82	0.4	4.18e-6	Prostate cancer;
TGCT	cis	rs9436747	0.641	rs12042884	chr1:66053192	C/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.56	5.04	0.41	1.59e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	8.55	0.61	3.84e-14	Platelet count;
TGCT	cis	rs1215050	0.791	rs783950	chr4:98878395	C/T	cg05340658	chr4:99064831	C4orf37	-0.47	-5.94	-0.47	2.62e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs72781680	0.665	rs72788298	chr2:24104293	T/C	cg08917208	chr2:24149416	ATAD2B	0.74	4.66	0.39	7.9e-6	Lymphocyte counts;
TGCT	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg03264133	chr6:25882463	NA	0.86	8.95	0.63	4.38e-15	Blood metabolite levels;
TGCT	cis	rs9467711	0.790	rs35942569	chr6:26339131	A/G	cg05948654	chr6:25930507	SLC17A2	0.36	4.59	0.38	1.06e-5	Autism spectrum disorder or schizophrenia;
TGCT	trans	rs77457752	0.525	rs7874947	chr9:13899539	A/C	cg23609682	chr1:3070786	PRDM16	0.51	6.81	0.52	3.8e-10	Breast cancer;
TGCT	cis	rs72781680	0.665	rs2953028	chr2:24068126	T/C	cg08917208	chr2:24149416	ATAD2B	0.78	4.85	0.4	3.62e-6	Lymphocyte counts;
TGCT	cis	rs11718455	0.960	rs1852037	chr3:44003720	G/T	cg08738300	chr3:44038990	NA	-0.84	-6.35	-0.5	3.75e-9	Coronary artery disease;
TGCT	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg17554472	chr22:41940697	POLR3H	-0.5	-5.37	-0.43	3.72e-7	Vitiligo;
TGCT	cis	rs5769765	0.825	rs9616780	chr22:50292763	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.09	-11.86	-0.73	3.71e-22	Schizophrenia;
TGCT	cis	rs4273100	0.688	rs1467028	chr17:19174874	T/C	cg01534423	chr17:18965556	NA	0.79	7.12	0.54	7.86e-11	Schizophrenia;
TGCT	cis	rs9653442	0.675	rs961788	chr2:100641459	T/C	cg07810366	chr2:100720526	AFF3	-0.4	-6.53	-0.51	1.5e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs478304	0.651	rs11604462	chr11:65551648	G/A	cg17480646	chr11:65405466	SIPA1	-0.55	-6.45	-0.5	2.28e-9	Acne (severe);
TGCT	cis	rs12477438	0.520	rs10865029	chr2:99718298	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	13.05	0.76	4.93e-25	Chronic sinus infection;
TGCT	cis	rs7666738	0.830	rs13121766	chr4:98935766	A/C	cg18180107	chr4:99064573	C4orf37	0.55	4.98	0.41	2.05e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4268898	0.722	rs2288072	chr2:24390517	G/A	cg02683114	chr2:24398427	C2orf84	0.2	4.79	0.4	4.63e-6	Asthma;
TGCT	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg22166914	chr1:53195759	ZYG11B	0.38	6.52	0.51	1.6e-9	Monocyte count;
TGCT	cis	rs4746818	1.000	rs10733850	chr10:70959617	C/T	cg11621586	chr10:70884670	VPS26A	1.1	7.75	0.57	2.8e-12	Left atrial antero-posterior diameter;
TGCT	cis	rs4237845	0.742	rs3751330	chr12:58290226	T/C	cg02175503	chr12:58329896	NA	0.53	5.63	0.45	1.16e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2204008	0.744	rs66474616	chr12:38461564	G/A	cg13010199	chr12:38710504	ALG10B	0.64	5.09	0.42	1.27e-6	Bladder cancer;
TGCT	cis	rs1570884	0.516	rs9535268	chr13:50175478	C/A	cg03651054	chr13:50194643	NA	0.33	5.28	0.43	5.66e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
TGCT	cis	rs3733585	0.673	rs9994266	chr4:9954450	C/T	cg00071950	chr4:10020882	SLC2A9	-0.52	-6.27	-0.49	5.44e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs5769707	0.904	rs7288869	chr22:50015327	C/T	cg20744362	chr22:50050164	C22orf34	0.27	4.44	0.37	1.95e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs61884328	0.733	rs74898661	chr11:47225730	G/A	cg13308137	chr11:47528955	CUGBP1	0.38	4.47	0.37	1.76e-5	Total body bone mineral density (age over 60);
TGCT	cis	rs8064299	0.597	rs6501736	chr17:72775358	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.91	10.11	0.67	6.79e-18	Monocyte count;
TGCT	cis	rs3784262	1.000	rs12910113	chr15:58248373	A/C	cg12031962	chr15:58353849	ALDH1A2	-0.5	-7.69	-0.57	3.95e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs735396	1.000	rs735396	chr12:121438844	T/C	cg02403541	chr12:121454288	C12orf43	0.66	6.27	0.49	5.35e-9	N-glycan levels;
TGCT	cis	rs9467773	0.620	rs9461275	chr6:26590801	C/T	cg05738196	chr6:26577821	NA	0.88	11.13	0.71	2.26e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs17376456	1.000	rs13163610	chr5:93548877	A/C	cg21475434	chr5:93447410	FAM172A	0.65	4.66	0.39	8.09e-6	Diabetic retinopathy;
TGCT	trans	rs4650994	0.524	rs2811299	chr1:178586377	A/G	cg05059571	chr16:84539110	KIAA1609	0.53	10.64	0.69	3.54e-19	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs2338224	1.000	rs12697709	chr5:71747083	A/G	cg01187920	chr5:71015162	CARTPT	-0.53	-4.57	-0.38	1.15e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Granulocyte count;Myeloid white cell count;
TGCT	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg06221963	chr1:154839813	KCNN3	-0.71	-11.67	-0.72	1.1e-21	Prostate cancer;
TGCT	cis	rs854765	0.724	rs62072049	chr17:17906520	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.77	7.86	0.58	1.55e-12	Total body bone mineral density;
TGCT	cis	rs17376456	0.569	rs2045019	chr5:93201971	C/T	cg25358565	chr5:93447407	FAM172A	-0.81	-6.54	-0.51	1.47e-9	Diabetic retinopathy;
TGCT	cis	rs7666738	0.753	rs11932536	chr4:98930105	A/G	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs941408	0.963	rs1640268	chr19:2791469	T/C	cg06609049	chr19:2785107	THOP1	0.82	8.22	0.59	2.31e-13	Total cholesterol levels;
TGCT	cis	rs4081724	0.565	rs7253994	chr19:33805678	T/A	cg18823272	chr19:34111733	CHST8	0.42	4.69	0.39	7.05e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.55	-6.48	-0.5	1.94e-9	Longevity;Endometriosis;
TGCT	cis	rs28595532	0.920	rs116834347	chr4:119774155	C/A	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs478304	0.651	rs12225620	chr11:65505448	T/C	cg27068330	chr11:65405492	SIPA1	-0.95	-9.64	-0.65	9.63e-17	Acne (severe);
TGCT	cis	rs9942416	0.660	rs17563686	chr5:74984818	A/T	cg19683494	chr5:74908142	NA	0.59	6.29	0.49	4.99e-9	Age-related disease endophenotypes;
TGCT	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg10862848	chr6:42927986	GNMT	-0.38	-4.53	-0.38	1.34e-5	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs9303401	0.573	rs35104446	chr17:57180234	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.64	5.87	0.47	3.79e-8	Cognitive test performance;
TGCT	cis	rs11030122	0.673	rs10835601	chr11:4106416	G/A	cg18678763	chr11:4115507	RRM1	-0.47	-5.63	-0.45	1.17e-7	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs2832191	0.716	rs9983051	chr21:30371890	C/T	cg08807101	chr21:30365312	RNF160	0.64	6.03	0.48	1.72e-8	Dental caries;
TGCT	trans	rs2688608	0.901	rs2664280	chr10:75617344	A/T	cg13918328	chr10:52500089	ASAH2B	-0.65	-6.62	-0.51	9.63e-10	Inflammatory bowel disease;
TGCT	cis	rs9611565	0.512	rs1534932	chr22:42150146	C/T	cg17554472	chr22:41940697	POLR3H	0.46	4.8	0.4	4.46e-6	Vitiligo;
TGCT	cis	rs3733585	0.673	rs4560411	chr4:9953361	A/G	cg00071950	chr4:10020882	SLC2A9	-0.55	-6.58	-0.51	1.21e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs611744	0.967	rs2600614	chr8:109198079	T/A	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs10504229	1.000	rs79311869	chr8:58195546	T/C	cg08280861	chr8:58055591	NA	0.36	4.61	0.38	9.98e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs28735056	0.904	rs9967107	chr18:77633343	C/T	cg20368463	chr18:77673604	PQLC1	0.39	4.79	0.39	4.74e-6	Schizophrenia;
TGCT	cis	rs6570726	0.689	rs411785	chr6:145888398	G/A	cg23711669	chr6:146136114	FBXO30	0.89	9.93	0.67	1.82e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg12963246	chr6:28129442	ZNF389	0.52	5.01	0.41	1.85e-6	Depression;
TGCT	cis	rs6750047	0.868	rs1431332	chr2:38280253	G/A	cg07380506	chr2:38303506	CYP1B1	0.59	5.17	0.42	9.08e-7	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs2299587	0.560	rs3913556	chr8:17781401	A/G	cg01800426	chr8:17659068	MTUS1	-0.65	-5.63	-0.45	1.14e-7	Economic and political preferences;
TGCT	cis	rs9383153	1.000	rs2073518	chr6:16332730	T/C	cg13189271	chr6:15365693	JARID2	1.01	5.11	0.42	1.19e-6	Gambling;
TGCT	cis	rs782590	0.902	rs782600	chr2:55848040	T/C	cg03859395	chr2:55845619	SMEK2	0.9	11.04	0.7	3.81e-20	Metabolic syndrome;
TGCT	cis	rs9467773	1.000	rs2208331	chr6:26507319	A/G	cg09904177	chr6:26538194	HMGN4	0.65	6.53	0.51	1.5e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs9341808	0.754	rs978814	chr6:80959912	G/T	cg08355045	chr6:80787529	NA	0.28	4.84	0.4	3.84e-6	Sitting height ratio;
TGCT	cis	rs8062405	1.000	rs62037371	chr16:28890131	C/A	cg09754948	chr16:28834200	ATXN2L	0.6	4.46	0.37	1.79e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs1008375	0.932	rs964012	chr4:17619184	A/G	cg16339924	chr4:17578868	LAP3	0.71	5.7	0.46	8.2e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs17036101	1.000	rs35877199	chr3:12299660	G/A	cg00909094	chr3:12586368	NA	0.5	4.51	0.38	1.5e-5	Type 2 diabetes;
TGCT	cis	rs67311347	1.000	rs13095055	chr3:40505666	G/T	cg17264618	chr3:40429014	ENTPD3	-0.33	-4.85	-0.4	3.66e-6	Renal cell carcinoma;
TGCT	cis	rs832540	0.552	rs702681	chr5:56218029	C/T	cg24531977	chr5:56204891	C5orf35	-0.59	-5.53	-0.44	1.81e-7	Coronary artery disease;
TGCT	cis	rs2933343	0.553	rs35979399	chr3:128697313	G/A	cg11901034	chr3:128598214	ACAD9	-0.57	-5.29	-0.43	5.34e-7	IgG glycosylation;
TGCT	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg20007245	chr22:24372913	LOC391322	-0.74	-7.49	-0.56	1.11e-11	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1062177	1.000	rs12654573	chr5:151207473	T/G	cg00977110	chr5:151150581	G3BP1	0.39	4.46	0.37	1.84e-5	Preschool internalizing problems;
TGCT	cis	rs2120019	0.608	rs8042558	chr15:75320433	G/T	cg09165964	chr15:75287851	SCAMP5	-1.17	-10.87	-0.7	9.5e-20	Blood trace element (Zn levels);
TGCT	cis	rs7246657	0.639	rs3112434	chr19:38198148	G/T	cg03611452	chr19:38183253	ZNF781	-0.56	-4.63	-0.38	8.97e-6	Coronary artery calcification;
TGCT	cis	rs5769765	1.000	rs34774661	chr22:50267508	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	1.11	11.76	0.73	6.5e-22	Schizophrenia;
TGCT	cis	rs4319547	0.695	rs4758662	chr12:122924778	G/A	cg08088222	chr12:122070432	ORAI1	0.26	4.46	0.37	1.84e-5	Body mass index;
TGCT	cis	rs35306767	0.623	rs36051896	chr10:1155747	T/C	cg26597838	chr10:835615	NA	0.52	5.51	0.44	1.96e-7	Eosinophil percentage of granulocytes;
TGCT	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.43	6.17	0.48	8.71e-9	Schizophrenia;
TGCT	cis	rs425277	0.585	rs2222217	chr1:2063164	G/A	cg03732007	chr1:2071316	PRKCZ	-0.28	-6.22	-0.49	6.91e-9	Height;
TGCT	cis	rs367943	1.000	rs348963	chr5:112819027	A/G	cg12552261	chr5:112820674	MCC	-0.25	-5.06	-0.41	1.5e-6	Type 2 diabetes;
TGCT	cis	rs2307449	0.704	rs758131	chr15:89884301	T/A	cg24365117	chr15:89879190	POLG	0.31	4.61	0.38	9.71e-6	Menopause (age at onset);
TGCT	cis	rs11190604	0.767	rs11190531	chr10:102187310	T/A	cg16342193	chr10:102329863	NA	-0.4	-5.02	-0.41	1.74e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2153535	0.607	rs9502722	chr6:8541483	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.61	0.45	1.23e-7	Motion sickness;
TGCT	cis	rs711245	0.518	rs11886145	chr2:36825716	C/G	cg15105969	chr2:36825350	FEZ2	0.64	6.44	0.5	2.41e-9	Height;
TGCT	cis	rs2153535	0.580	rs1932280	chr6:8473654	G/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg10047753	chr17:41438598	NA	0.98	10.04	0.67	1.01e-17	Menopause (age at onset);
TGCT	trans	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg23505145	chr19:12996616	KLF1	0.78	8.12	0.59	4.03e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.09	0.42	1.3e-6	Prudent dietary pattern;
TGCT	cis	rs56104184	0.725	rs4347731	chr19:49385154	A/G	cg21252483	chr19:49399788	TULP2	-0.42	-5.7	-0.46	8.1e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs13242816	1.000	rs17138767	chr7:116137677	A/G	cg16553024	chr7:116138462	CAV2	-0.44	-5.31	-0.43	4.81e-7	P wave duration;
TGCT	trans	rs208520	0.955	rs9453664	chr6:66976079	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.82	7.48	0.56	1.21e-11	Exhaled nitric oxide output;
TGCT	cis	rs981844	0.885	rs62325082	chr4:154661274	A/G	cg14289246	chr4:154710475	SFRP2	1.01	8.46	0.6	6.31e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2730245	0.527	rs2788470	chr7:158649801	G/T	cg11984989	chr7:158649758	WDR60	0.98	7.5	0.56	1.05e-11	Height;
TGCT	trans	rs1496653	0.602	rs34916962	chr3:23528743	G/A	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs9467711	0.606	rs68072215	chr6:26377927	T/C	cg10795676	chr6:26370623	BTN3A2	-0.47	-4.77	-0.39	5.18e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2456568	0.802	rs8181567	chr11:93637209	C/T	cg14065697	chr11:93583672	C11orf90	-0.38	-4.74	-0.39	5.65e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs1538970	1.000	rs17395553	chr1:45864761	C/T	cg05343316	chr1:45956843	TESK2	0.72	5.53	0.44	1.82e-7	Platelet count;
TGCT	trans	rs2727020	0.636	rs11040368	chr11:49453602	C/A	cg15704280	chr7:45808275	SEPT13	-0.77	-8.75	-0.62	1.29e-14	Coronary artery disease;
TGCT	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg24829409	chr8:58192753	C8orf71	-0.56	-5.28	-0.43	5.51e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg24675658	chr1:53192096	ZYG11B	0.77	8.95	0.63	4.31e-15	Monocyte count;
TGCT	cis	rs7017914	0.967	rs35207116	chr8:71708971	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.53	-4.98	-0.41	2.09e-6	Bone mineral density;
TGCT	cis	rs6121246	0.697	rs6088856	chr20:30226543	C/G	cg21427119	chr20:30132790	HM13	-0.36	-4.96	-0.41	2.26e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs1062177	1.000	rs72802204	chr5:151183183	T/C	cg00977110	chr5:151150581	G3BP1	0.4	4.56	0.38	1.23e-5	Preschool internalizing problems;
TGCT	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg11941060	chr3:133502564	NA	-0.31	-6.66	-0.51	7.82e-10	Iron status biomarkers;
TGCT	cis	rs2197308	0.765	rs12824529	chr12:37931656	T/C	cg13010199	chr12:38710504	ALG10B	0.66	5.33	0.43	4.41e-7	Morning vs. evening chronotype;
TGCT	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs9467773	1.000	rs9467797	chr6:26568473	A/T	cg09904177	chr6:26538194	HMGN4	0.69	6.84	0.52	3.23e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs2067615	0.579	rs10507214	chr12:107194461	G/A	cg15890332	chr12:107067104	RFX4	0.28	5.61	0.45	1.27e-7	Heart rate;
TGCT	cis	rs3820068	0.608	rs2057304	chr1:16017710	A/G	cg17385448	chr1:15911702	AGMAT	0.34	4.67	0.39	7.66e-6	Systolic blood pressure;
TGCT	cis	rs6901250	0.523	rs641338	chr6:117086265	C/A	cg12892004	chr6:117198278	RFX6	0.39	5.01	0.41	1.87e-6	C-reactive protein levels;
TGCT	cis	rs12887734	0.524	rs722637	chr14:104261723	G/T	cg26031613	chr14:104095156	KLC1	0.74	6.48	0.5	1.97e-9	Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs514406	0.505	rs269286	chr1:53169018	C/T	cg22166914	chr1:53195759	ZYG11B	-0.43	-7.51	-0.56	1.01e-11	Monocyte count;
TGCT	cis	rs7586879	0.662	rs2384059	chr2:25100338	C/T	cg01884057	chr2:25150051	NA	0.33	6.31	0.49	4.6e-9	Body mass index;
TGCT	cis	rs6840360	0.642	rs2709818	chr4:152382634	A/G	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.82e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs13102973	0.720	rs13122251	chr4:135887466	C/T	cg14419869	chr4:135874104	NA	0.26	4.6	0.38	1.03e-5	Subjective well-being;
TGCT	cis	rs13256369	1.000	rs13271966	chr8:8575472	T/C	cg17143192	chr8:8559678	CLDN23	0.63	5.93	0.47	2.8e-8	Obesity-related traits;
TGCT	cis	rs12780845	0.540	rs10904904	chr10:17240640	G/C	cg01003015	chr10:17271136	VIM	-0.62	-5.69	-0.46	8.55e-8	Homocysteine levels;
TGCT	trans	rs4650994	0.525	rs4650997	chr1:178530744	T/A	cg05059571	chr16:84539110	KIAA1609	-0.54	-11.05	-0.7	3.58e-20	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs78456975	1.000	rs111935361	chr2:1554192	C/A	cg01028140	chr2:1542097	TPO	-0.35	-4.57	-0.38	1.17e-5	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs6121246	0.609	rs6089075	chr20:30392884	A/G	cg10886678	chr20:30946050	ASXL1	-0.57	-4.79	-0.4	4.68e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs422249	0.512	rs174561	chr11:61582708	T/C	cg01500311	chr11:61656094	FADS3	-0.29	-4.98	-0.41	2.1e-6	Trans fatty acid levels;
TGCT	cis	rs77861329	0.920	rs808787	chr3:52203249	G/A	cg08692210	chr3:52188851	WDR51A	0.93	4.79	0.4	4.61e-6	Macrophage inflammatory protein 1b levels;
TGCT	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg20607798	chr8:58055168	NA	0.65	5.43	0.44	2.86e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6693567	0.565	rs12736375	chr1:150411912	T/C	cg09579323	chr1:150459698	TARS2	0.52	4.62	0.38	9.56e-6	Migraine;
TGCT	cis	rs611744	0.967	rs637626	chr8:109235785	G/T	cg21045802	chr8:109455806	TTC35	0.52	4.72	0.39	6.21e-6	Dupuytren's disease;
TGCT	cis	rs2456568	0.695	rs55756119	chr11:93689909	A/G	cg26875233	chr11:93583750	C11orf90	0.39	4.76	0.39	5.28e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs1577917	0.958	rs12665542	chr6:86544443	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.19	-0.42	8.51e-7	Response to antipsychotic treatment;
TGCT	cis	rs9911578	0.967	rs8182277	chr17:57144367	C/T	cg05425664	chr17:57184151	TRIM37	-0.68	-6.9	-0.53	2.4e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs3617	0.573	rs9850563	chr3:52912214	G/A	cg11645453	chr3:52864694	ITIH4	-0.27	-5.22	-0.42	7.32e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9300255	0.620	rs1727311	chr12:123660716	T/G	cg00376283	chr12:123451042	ABCB9	0.74	5.1	0.42	1.22e-6	Neutrophil percentage of white cells;
TGCT	cis	rs1775715	0.769	rs2799030	chr10:32172935	G/T	cg14930904	chr10:32216787	ARHGAP12	0.52	5.07	0.41	1.39e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs7226408	0.842	rs2033117	chr18:34349962	A/T	cg06757138	chr18:34340585	FHOD3	0.32	5.29	0.43	5.29e-7	Obesity-related traits;
TGCT	trans	rs28735056	0.935	rs11662267	chr18:77641902	C/G	cg05926928	chr17:57297772	GDPD1	-0.7	-7.45	-0.56	1.35e-11	Schizophrenia;
TGCT	cis	rs2777491	0.789	rs316617	chr15:41795900	C/T	cg18705301	chr15:41695430	NDUFAF1	0.61	8.15	0.59	3.34e-13	Ulcerative colitis;
TGCT	cis	rs1933488	0.866	rs7756810	chr6:153416133	A/C	cg24028809	chr6:153414101	RGS17	0.21	4.67	0.39	7.69e-6	Prostate cancer;
TGCT	cis	rs2836974	0.583	rs8132993	chr21:40716410	T/C	cg11890956	chr21:40555474	PSMG1	0.76	7.42	0.55	1.63e-11	Cognitive function;
TGCT	cis	rs2455799	0.573	rs2470523	chr3:15768091	G/C	cg16303742	chr3:15540471	COLQ	-0.26	-4.96	-0.41	2.26e-6	Mean platelet volume;
TGCT	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg09365446	chr1:150670422	GOLPH3L	0.31	4.64	0.38	8.7e-6	Tonsillectomy;
TGCT	cis	rs8078723	1.000	rs8070454	chr17:38160754	C/T	cg17467752	chr17:38218738	THRA	0.55	5.34	0.43	4.24e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs11648796	0.879	rs12448432	chr16:778820	G/A	cg27144592	chr16:783916	NARFL	0.46	6.67	0.51	7.68e-10	Height;
TGCT	cis	rs78456975	1.000	rs10208340	chr2:1563100	G/A	cg01028140	chr2:1542097	TPO	-0.33	-4.58	-0.38	1.12e-5	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs13242816	1.000	rs56309428	chr7:116150137	G/T	cg16553024	chr7:116138462	CAV2	-0.44	-5.36	-0.43	3.97e-7	P wave duration;
TGCT	cis	rs7772486	0.764	rs9399569	chr6:146242942	C/T	cg05347473	chr6:146136440	FBXO30	-0.5	-4.85	-0.4	3.68e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4523957	0.651	rs9906968	chr17:2077493	G/C	cg16513277	chr17:2031491	SMG6	-0.2	-4.64	-0.38	8.83e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs1667284	0.935	rs1791161	chr18:29204210	C/T	cg15259973	chr18:29078565	DSG2	0.49	4.66	0.39	8.04e-6	Problematic alcohol use in trauma-exposed individuals;
TGCT	cis	rs2239547	0.522	rs2581779	chr3:53056199	T/C	cg11645453	chr3:52864694	ITIH4	-0.34	-5.34	-0.43	4.36e-7	Schizophrenia;
TGCT	cis	rs2721195	0.743	rs2306386	chr8:145742879	T/C	cg15857475	chr8:145742913	RECQL4;LRRC14	0.85	9.13	0.63	1.58e-15	Age at first birth;
TGCT	cis	rs11112613	0.713	rs10507192	chr12:105948247	A/G	cg03607813	chr12:105948248	NA	0.52	6.36	0.5	3.47e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	cis	rs28785552	0.536	rs10401689	chr19:53248430	T/G	cg22067481	chr19:53234126	ZNF611	-0.45	-6.04	-0.48	1.65e-8	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs1371867	0.846	rs1660329	chr8:101304048	G/T	cg06002616	chr8:101225028	SPAG1	-0.56	-6.58	-0.51	1.2e-9	Atrioventricular conduction;
TGCT	cis	rs9486719	0.843	rs2499789	chr6:96844510	T/C	cg18709589	chr6:96969512	KIAA0776	0.75	5.13	0.42	1.1e-6	Migraine;Coronary artery disease;
TGCT	cis	rs7617773	0.780	rs4511915	chr3:48343858	G/A	cg11946769	chr3:48343235	NME6	0.82	7.09	0.54	9.1e-11	Coronary artery disease;
TGCT	cis	rs74400468	0.529	rs11239742	chr10:43205653	G/A	cg05525499	chr10:43893015	HNRNPF	-0.74	-4.86	-0.4	3.43e-6	Cannabis dependence symptom count;
TGCT	cis	rs1008375	0.966	rs4698642	chr4:17679174	A/T	cg10189774	chr4:17578691	LAP3	0.52	4.89	0.4	3.1e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	trans	rs2727020	0.513	rs10839307	chr11:49609843	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.34	-6.73	-0.52	5.61e-10	Coronary artery disease;
TGCT	cis	rs56104184	0.775	rs117016425	chr19:49400216	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.73	-9.15	-0.63	1.47e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs10789491	1.000	rs11211342	chr1:47163098	T/C	cg15501359	chr1:47185051	KIAA0494	0.82	8.15	0.59	3.35e-13	Response to hepatitis C treatment;
TGCT	cis	rs60871478	0.945	rs62432254	chr7:804175	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.48	4.88	0.4	3.21e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs986417	0.818	rs767603	chr14:61098683	T/C	cg27398547	chr14:60952738	C14orf39	1.57	10.0	0.67	1.28e-17	Gut microbiota (bacterial taxa);
TGCT	cis	rs10876993	0.928	rs1689592	chr12:58057773	C/T	cg15848620	chr12:58087721	OS9	-0.72	-5.88	-0.47	3.56e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs2439831	0.764	rs2447193	chr15:43929733	A/C	cg19166733	chr15:44192098	FRMD5	-0.24	-4.89	-0.4	3.08e-6	Lung cancer in ever smokers;
TGCT	cis	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg07424592	chr7:64974309	NA	1.34	8.08	0.59	4.95e-13	Diabetic kidney disease;
TGCT	cis	rs6589563	0.737	rs56143464	chr11:116627056	G/A	cg20660624	chr11:117307972	DSCAML1	-0.37	-4.92	-0.4	2.71e-6	Eosinophil counts;
TGCT	cis	rs9393777	0.513	rs9368448	chr6:26649355	T/C	cg15659132	chr6:26577336	NA	-0.75	-5.25	-0.43	6.33e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs11190604	1.000	rs7080356	chr10:102266735	A/C	cg16342193	chr10:102329863	NA	-0.39	-5.01	-0.41	1.83e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs13188771	0.651	rs3846602	chr5:100884294	C/A	cg18665594	chr5:101119420	NA	0.44	4.47	0.37	1.74e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs6964587	1.000	rs2237568	chr7:91622676	G/A	cg22709100	chr7:91322751	NA	0.27	4.48	0.37	1.68e-5	Breast cancer;
TGCT	cis	rs6831352	0.703	rs2602862	chr4:100033221	A/G	cg12011299	chr4:100065546	ADH4	0.39	5.2	0.42	8.04e-7	Alcohol dependence;
TGCT	cis	rs7089973	0.624	rs17586888	chr10:116598121	T/C	cg03647239	chr10:116582469	FAM160B1	0.59	5.74	0.46	6.72e-8	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs13411840	1.000	rs6547968	chr2:29880979	G/A	cg06611768	chr2:30145152	ALK	-0.43	-4.61	-0.38	9.96e-6	Glucose homeostasis traits;
TGCT	cis	rs2739330	0.576	rs2858912	chr22:24297197	A/G	cg04234412	chr22:24373322	LOC391322	-0.87	-10.27	-0.68	2.84e-18	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs910187	0.678	rs1046661	chr20:45817149	G/A	cg27589058	chr20:45804311	EYA2	-0.35	-7.6	-0.56	6.23e-12	Migraine;
TGCT	cis	rs929596	0.793	rs2602376	chr2:234582051	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.29	-4.58	-0.38	1.11e-5	Total bilirubin levels in HIV-1 infection;
TGCT	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7666738	0.830	rs1426669	chr4:98945534	C/T	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7617773	0.780	rs35778847	chr3:48346985	G/T	cg11946769	chr3:48343235	NME6	0.82	7.09	0.54	9.1e-11	Coronary artery disease;
TGCT	cis	rs797680	0.856	rs12118262	chr1:93651547	C/T	cg17826107	chr1:92977322	EVI5	0.23	5.01	0.41	1.85e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs709400	0.628	rs6575983	chr14:103869849	C/G	cg12935359	chr14:103987150	CKB	-0.3	-4.73	-0.39	6.12e-6	Body mass index;
TGCT	cis	rs6486730	1.000	rs7953661	chr12:129275823	T/A	cg09035930	chr12:129282057	SLC15A4	0.4	5.87	0.47	3.73e-8	Systemic lupus erythematosus;
TGCT	cis	rs875971	0.793	rs460678	chr7:65527200	C/G	cg11764359	chr7:65958608	NA	0.53	4.64	0.38	8.87e-6	Aortic root size;
TGCT	cis	rs1005224	0.654	rs8005753	chr14:76136086	A/T	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.57	-5.06	-0.41	1.45e-6	Large artery stroke;
TGCT	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg24060327	chr5:131705240	SLC22A5	0.78	8.62	0.61	2.62e-14	Blood metabolite levels;
TGCT	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg11890956	chr21:40555474	PSMG1	1.03	10.54	0.69	6.18e-19	Cognitive function;
TGCT	cis	rs12210905	1.000	rs9379965	chr6:27227061	C/T	cg08851530	chr6:28072375	NA	0.92	4.87	0.4	3.26e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs908922	0.676	rs11584191	chr1:152500428	A/T	cg20991723	chr1:152506922	NA	-0.47	-6.66	-0.51	7.77e-10	Hair morphology;
TGCT	cis	rs6785206	0.554	rs3772158	chr3:128516142	A/C	cg25356066	chr3:128598488	ACAD9	-0.78	-4.45	-0.37	1.91e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg17971929	chr21:40555470	PSMG1	0.96	8.86	0.62	6.96e-15	Cognitive function;
TGCT	cis	rs548987	0.529	rs6456703	chr6:25826119	C/T	cg03517284	chr6:25882590	NA	-0.55	-4.44	-0.37	1.93e-5	Homocysteine levels;
TGCT	cis	rs3771570	1.000	rs3771564	chr2:242355701	G/A	cg21155796	chr2:242212141	HDLBP	0.89	6.33	0.49	4.15e-9	Prostate cancer;
TGCT	cis	rs11148252	0.538	rs2274202	chr13:52722798	C/A	cg00495681	chr13:53174319	NA	0.57	5.86	0.47	3.85e-8	Lewy body disease;
TGCT	cis	rs7213347	0.707	rs216181	chr17:2172753	A/T	cg20777128	chr17:1945076	DPH1;OVCA2	0.51	4.51	0.38	1.48e-5	Total body bone mineral density;
TGCT	cis	rs13424612	0.896	rs878925	chr2:240918502	A/G	cg26363272	chr2:240904871	NDUFA10	0.28	4.79	0.4	4.65e-6	Odorant perception (isobutyraldehyde);
TGCT	cis	rs11105298	0.891	rs12228177	chr12:89862030	G/T	cg00757033	chr12:89920650	WDR51B	0.34	5.37	0.43	3.75e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs2658782	0.526	rs3020062	chr11:93061159	T/C	cg15737290	chr11:93063684	CCDC67	1.05	11.65	0.72	1.24e-21	Pulmonary function decline;
TGCT	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg18876405	chr7:65276391	NA	-0.34	-5.19	-0.42	8.37e-7	Aortic root size;
TGCT	cis	rs6964587	1.000	rs10488512	chr7:91753579	C/T	cg17063962	chr7:91808500	NA	0.87	9.26	0.64	7.82e-16	Breast cancer;
TGCT	cis	rs12200560	0.505	rs211177	chr6:97074088	C/T	cg06623918	chr6:96969491	KIAA0776	0.59	5.03	0.41	1.71e-6	Coronary heart disease;
TGCT	cis	rs7267979	0.903	rs6132819	chr20:25218618	C/G	cg14121845	chr20:25566513	NINL	0.5	5.51	0.44	1.95e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs45509595	0.841	rs370155	chr6:27782031	T/G	cg08798685	chr6:27730294	NA	-0.35	-4.76	-0.39	5.24e-6	Breast cancer;
TGCT	cis	rs7568458	0.905	rs17026396	chr2:85759127	C/T	cg02493740	chr2:85810744	VAMP5	0.27	4.83	0.4	3.93e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs17108533	0.588	rs67204286	chr14:71302188	C/T	cg23900759	chr14:71108106	TTC9	-1.14	-4.61	-0.38	9.92e-6	Response to antipsychotic treatment in schizophrenia (reasoning);
TGCT	cis	rs17376456	0.569	rs17083377	chr5:93164870	C/G	cg25358565	chr5:93447407	FAM172A	0.8	6.68	0.51	7.3e-10	Diabetic retinopathy;
TGCT	cis	rs10883723	0.810	rs10748824	chr10:104274466	T/C	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs7666738	0.830	rs6532715	chr4:99016792	G/A	cg18180107	chr4:99064573	C4orf37	0.54	5.03	0.41	1.7e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7568458	0.870	rs1009	chr2:85808737	A/G	cg02493740	chr2:85810744	VAMP5	-0.26	-4.75	-0.39	5.51e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg02725872	chr8:58115012	NA	-0.35	-4.54	-0.38	1.31e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9913156	0.748	rs55959711	chr17:4562581	C/A	cg23387401	chr17:4582204	PELP1	0.31	4.57	0.38	1.14e-5	Lymphocyte counts;
TGCT	cis	rs9303401	0.659	rs3809724	chr17:57061238	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.61	6.14	0.48	1.03e-8	Cognitive test performance;
TGCT	cis	rs17384381	0.700	rs11161616	chr1:85907625	A/G	cg16011679	chr1:85725395	C1orf52	-0.88	-7.16	-0.54	6.29e-11	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs812925	0.537	rs778139	chr2:61684564	A/G	cg15711740	chr2:61764176	XPO1	0.51	4.69	0.39	7.1e-6	Immature fraction of reticulocytes;
TGCT	cis	rs9611565	0.592	rs5996039	chr22:41981957	A/G	cg06481639	chr22:41940642	POLR3H	-0.62	-5.26	-0.43	6.21e-7	Vitiligo;
TGCT	cis	rs11779988	0.545	rs421290	chr8:17766416	G/C	cg01800426	chr8:17659068	MTUS1	-0.72	-5.55	-0.45	1.65e-7	Breast cancer;
TGCT	cis	rs6542838	0.780	rs981601	chr2:99463882	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.48	-4.78	-0.39	4.79e-6	Fear of minor pain;
TGCT	cis	rs7615952	0.866	rs1976459	chr3:125647486	A/T	cg05084668	chr3:125655381	ALG1L	-0.76	-6.08	-0.48	1.39e-8	Blood pressure (smoking interaction);
TGCT	cis	rs1215050	0.740	rs783949	chr4:99001933	A/G	cg05340658	chr4:99064831	C4orf37	-0.41	-5.03	-0.41	1.69e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs11673344	0.523	rs2562605	chr19:37520204	G/A	cg08039142	chr19:36980659	ZNF566	0.5	4.64	0.38	8.58e-6	Obesity-related traits;
TGCT	cis	rs4077468	0.927	rs1342063	chr1:205912859	C/T	cg26354017	chr1:205819088	PM20D1	-0.41	-4.44	-0.37	1.93e-5	Cystic fibrosis-related diabetes;
TGCT	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg14004847	chr7:1930337	MAD1L1	0.28	4.68	0.39	7.53e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs9733	0.519	rs2184833	chr1:150675483	C/T	cg09365446	chr1:150670422	GOLPH3L	0.3	4.49	0.37	1.63e-5	Tonsillectomy;
TGCT	cis	rs1278769	0.786	rs3742238	chr13:113540425	C/T	cg11520003	chr13:113540631	ATP11A	-0.31	-4.65	-0.39	8.41e-6	Interstitial lung disease;
TGCT	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg12419862	chr22:24373484	LOC391322	-0.79	-8.06	-0.59	5.41e-13	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs908922	0.743	rs10888499	chr1:152532742	C/A	cg20991723	chr1:152506922	NA	0.41	5.15	0.42	9.79e-7	Hair morphology;
TGCT	cis	rs908922	0.887	rs6587688	chr1:152529622	C/T	cg20991723	chr1:152506922	NA	-0.41	-5.21	-0.42	7.66e-7	Hair morphology;
TGCT	cis	rs1865760	0.827	rs9295680	chr6:25944103	T/C	cg16482183	chr6:26056742	HIST1H1C	0.53	4.93	0.4	2.57e-6	Height;
TGCT	cis	rs3806843	0.576	rs155359	chr5:140315425	G/T	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.44	-5.45	-0.44	2.65e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9467773	0.933	rs2024970	chr6:26497520	T/A	cg02458000	chr6:26745757	NA	0.49	4.5	0.37	1.54e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs35160687	0.842	rs11685863	chr2:86554484	G/C	cg03171300	chr2:86307199	POLR1A	-0.27	-4.73	-0.39	6.08e-6	Night sleep phenotypes;
TGCT	cis	rs79149102	0.579	rs59303424	chr15:75370014	G/A	cg09165964	chr15:75287851	SCAMP5	-1.0	-5.42	-0.44	3.02e-7	Lung cancer;
TGCT	cis	rs10751667	0.666	rs4074233	chr11:977685	G/A	cg06064525	chr11:970664	AP2A2	-0.36	-8.28	-0.6	1.67e-13	Alzheimer's disease (late onset);
TGCT	cis	rs17345786	0.906	rs58835747	chr3:101243634	T/C	cg12386194	chr3:101231763	SENP7	0.61	5.75	0.46	6.52e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs62064224	0.546	rs1018866	chr17:30829664	A/C	cg18200150	chr17:30822561	MYO1D	0.53	7.13	0.54	7.31e-11	Schizophrenia;
TGCT	cis	rs6430585	0.528	rs309165	chr2:136667301	T/C	cg07169764	chr2:136633963	MCM6	1.2	11.66	0.72	1.12e-21	Corneal structure;
TGCT	cis	rs992157	0.798	rs4996257	chr2:219162836	C/T	cg00012203	chr2:219082015	ARPC2	0.74	7.19	0.54	5.36e-11	Colorectal cancer;
TGCT	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg12311346	chr5:56204834	C5orf35	0.57	6.13	0.48	1.07e-8	Initial pursuit acceleration;
TGCT	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs3796352	1.000	rs11712653	chr3:53070875	A/C	cg27565382	chr3:53032988	SFMBT1	-0.48	-5.93	-0.47	2.77e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.12	0.54	7.78e-11	Prudent dietary pattern;
TGCT	cis	rs7208859	0.614	rs73265646	chr17:29244023	C/T	cg18442181	chr17:29233375	C17orf42	-0.78	-4.72	-0.39	6.16e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs644799	0.603	rs1255180	chr11:95472134	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.48	4.78	0.39	4.88e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	trans	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.87	-9.34	-0.64	5.1e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs6671200	0.920	rs11165339	chr1:95674064	T/C	cg26537280	chr1:95699037	RWDD3	-0.68	-5.49	-0.44	2.15e-7	Stearic acid (18:0) levels;
TGCT	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg07061783	chr6:25882402	NA	-0.53	-5.09	-0.42	1.29e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs12549902	0.800	rs7825337	chr8:41507237	C/T	cg00088007	chr8:41504566	NKX6-3	0.3	4.8	0.4	4.39e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
TGCT	cis	rs10114408	0.959	rs10761300	chr9:96650042	C/T	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs707040	0.921	rs707035	chr2:155214352	C/T	cg18104148	chr2:154337490	NA	-0.19	-4.76	-0.39	5.4e-6	Sudden cardiac arrest;
TGCT	trans	rs10203711	0.789	rs6431616	chr2:239540279	A/G	cg16021909	chr1:248021091	TRIM58	-0.71	-7.6	-0.56	6.36e-12	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs13191362	1.000	rs66594243	chr6:163169024	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.96	7.55	0.56	8e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs670523	0.596	rs72708239	chr1:155985899	A/G	cg05700447	chr1:155978627	NA	0.25	5.24	0.43	6.59e-7	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs896854	0.540	rs2011567	chr8:95971920	G/A	cg13393036	chr8:95962371	TP53INP1	-0.63	-8.51	-0.61	4.78e-14	Type 2 diabetes;
TGCT	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg00024416	chr22:24240387	NA	-0.25	-4.74	-0.39	5.74e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs295140	0.502	rs12990174	chr2:201240305	C/T	cg04283868	chr2:201171347	SPATS2L	0.51	4.85	0.4	3.59e-6	QT interval;
TGCT	cis	rs28595532	0.920	rs116514715	chr4:119756280	G/T	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9325144	0.647	rs10875953	chr12:39050536	G/C	cg26384229	chr12:38710491	ALG10B	-0.56	-5.11	-0.42	1.18e-6	Morning vs. evening chronotype;
TGCT	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg25703541	chr22:24373054	LOC391322	0.81	8.48	0.61	5.55e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9296661	0.832	rs927858	chr6:51668949	C/T	cg00593404	chr6:52377740	TRAM2	-0.27	-4.49	-0.37	1.6e-5	Weight loss (gastric bypass surgery);
TGCT	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg11247378	chr22:39784982	NA	-0.73	-9.59	-0.65	1.22e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg11764359	chr7:65958608	NA	0.54	5.02	0.41	1.73e-6	Aortic root size;
TGCT	cis	rs11250097	0.507	rs2409779	chr8:11311340	A/T	cg21775007	chr8:11205619	TDH	-0.53	-4.87	-0.4	3.26e-6	Neuroticism;
TGCT	cis	rs76878669	0.561	rs6591217	chr11:66174653	G/A	cg18002602	chr11:66138449	SLC29A2	-0.53	-6.41	-0.5	2.75e-9	Educational attainment (years of education);
TGCT	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg26338869	chr17:61819248	STRADA	-0.56	-5.11	-0.42	1.17e-6	Prudent dietary pattern;
TGCT	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg20573242	chr4:122745356	CCNA2	0.62	5.48	0.44	2.23e-7	Type 2 diabetes;
TGCT	cis	rs2963155	0.518	rs9324918	chr5:142767160	T/C	cg17617527	chr5:142782415	NR3C1	0.85	5.42	0.44	3.01e-7	Breast cancer;
TGCT	cis	rs4665630	0.614	rs7593191	chr2:23884357	C/T	cg08063864	chr2:24346004	PFN4;LOC375190	-1.0	-4.97	-0.41	2.17e-6	Hypertension;
TGCT	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg03395511	chr6:291903	DUSP22	-0.69	-7.14	-0.54	6.9e-11	Menopause (age at onset);
TGCT	cis	rs7918232	0.574	rs10458708	chr10:27455605	C/T	cg14240646	chr10:27532245	ACBD5	-0.46	-7.47	-0.56	1.23e-11	Breast cancer;
TGCT	cis	rs7677751	0.806	rs890203	chr4:55097405	A/C	cg17187183	chr4:55093834	PDGFRA	0.55	7.06	0.54	1.05e-10	Corneal astigmatism;
TGCT	cis	rs4499344	0.730	rs8103269	chr19:33097503	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	8.81	0.62	9.52e-15	Mean platelet volume;
TGCT	cis	rs6728642	0.901	rs10179966	chr2:97845100	C/T	cg26665480	chr2:98280029	ACTR1B	-0.99	-5.77	-0.46	5.85e-8	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	cis	rs2486012	0.826	rs17533707	chr1:44361533	C/T	cg12908607	chr1:44402522	ARTN	0.71	5.86	0.47	3.87e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs1050631	1.000	rs1785916	chr18:33696156	A/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.51	4.95	0.41	2.37e-6	Esophageal squamous cell cancer (length of survival);
TGCT	trans	rs208520	0.874	rs208481	chr6:66922636	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.95	-9.95	-0.67	1.64e-17	Exhaled nitric oxide output;
TGCT	cis	rs9457247	1.000	rs9457247	chr6:167392174	C/T	cg25258033	chr6:167368657	RNASET2	0.18	4.49	0.37	1.63e-5	Crohn's disease;
TGCT	cis	rs737008	0.922	rs28567501	chr16:11378928	C/A	cg00044050	chr16:11439710	C16orf75	-0.69	-6.84	-0.52	3.29e-10	Obesity-related traits;
TGCT	cis	rs858239	0.601	rs10263110	chr7:23160551	G/A	cg05602783	chr7:23145260	KLHL7	-0.65	-5.52	-0.44	1.93e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs4563143	0.675	rs17498203	chr19:29279734	G/T	cg04546413	chr19:29218101	NA	0.86	7.0	0.53	1.45e-10	Methadone dose in opioid dependence;
TGCT	cis	rs9733	0.565	rs7524620	chr1:150616699	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.39	-5.05	-0.41	1.57e-6	Tonsillectomy;
TGCT	cis	rs7000551	0.581	rs4872487	chr8:22256414	C/T	cg12081754	chr8:22256438	SLC39A14	0.34	5.09	0.42	1.31e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs1570884	0.516	rs9535268	chr13:50175478	C/A	cg08779649	chr13:50194554	NA	0.37	5.84	0.46	4.24e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
TGCT	trans	rs1814175	0.607	rs11493324	chr11:50011304	T/C	cg15704280	chr7:45808275	SEPT13	-0.61	-7.07	-0.54	1.01e-10	Height;
TGCT	cis	rs61867294	0.794	rs7896463	chr10:106666355	C/T	cg08000847	chr10:105880925	C10orf78	0.56	4.46	0.37	1.82e-5	Schizophrenia;
TGCT	cis	rs3784262	1.000	rs7178497	chr15:58240333	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.47	-7.12	-0.54	7.5e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	trans	rs4824093	0.610	rs73443906	chr22:50274293	A/G	cg09872104	chr7:134855509	C7orf49	-0.94	-7.68	-0.57	4.2e-12	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs9926296	0.542	rs12599531	chr16:89909401	C/T	cg03388025	chr16:89894329	SPIRE2	-0.36	-5.18	-0.42	8.74e-7	Vitiligo;
TGCT	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg23758822	chr17:41437982	NA	0.75	7.03	0.53	1.22e-10	Menopause (age at onset);
TGCT	cis	rs7100689	0.542	rs7096715	chr10:82195949	T/C	cg00277334	chr10:82204260	NA	-0.43	-5.27	-0.43	5.95e-7	Post bronchodilator FEV1;
TGCT	cis	rs9388451	0.839	rs3799711	chr6:126075313	C/T	cg05901451	chr6:126070800	HEY2	0.99	14.43	0.79	2.64e-28	Brugada syndrome;
TGCT	cis	rs7617773	1.000	rs9832957	chr3:48185266	A/G	cg11946769	chr3:48343235	NME6	-0.58	-5.27	-0.43	5.75e-7	Coronary artery disease;
TGCT	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg02353165	chr6:42928485	GNMT	0.95	9.51	0.65	1.95e-16	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs244731	1.000	rs244730	chr5:176539212	A/G	cg17509989	chr5:176798049	RGS14	-0.54	-6.5	-0.5	1.74e-9	Urate levels in lean individuals;
TGCT	cis	rs4319547	1.000	rs6489156	chr12:123100397	C/T	cg23029597	chr12:123009494	RSRC2	-0.29	-4.75	-0.39	5.43e-6	Body mass index;
TGCT	cis	rs9811920	0.809	rs4928235	chr3:99706870	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.45	5.14	0.42	1.03e-6	Axial length;
TGCT	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg17911788	chr17:44343683	NA	-0.66	-7.02	-0.53	1.25e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs782590	0.967	rs2627759	chr2:55853341	T/C	cg03859395	chr2:55845619	SMEK2	0.93	11.51	0.72	2.61e-21	Metabolic syndrome;
TGCT	cis	rs17376456	0.877	rs10213956	chr5:93460839	C/T	cg21475434	chr5:93447410	FAM172A	0.59	4.66	0.39	8.09e-6	Diabetic retinopathy;
TGCT	cis	rs9527	0.590	rs12785223	chr10:104844011	C/T	cg15744005	chr10:104629667	AS3MT	0.45	5.17	0.42	8.91e-7	Arsenic metabolism;
TGCT	cis	rs9302065	1.000	rs9302065	chr13:95971016	C/T	cg24476569	chr13:95954382	ABCC4	0.43	6.41	0.5	2.71e-9	Blood metabolite levels;
TGCT	cis	rs7428	0.545	rs1053561	chr2:85546052	A/G	cg24342717	chr2:85555507	TGOLN2	-0.47	-8.24	-0.59	2.04e-13	Ear protrusion;
TGCT	cis	rs10484885	0.775	rs55926724	chr6:90417450	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.45	-4.66	-0.39	7.9e-6	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs6754311	0.550	rs3213889	chr2:136511575	A/G	cg07169764	chr2:136633963	MCM6	-0.66	-6.11	-0.48	1.2e-8	Mosquito bite size;
TGCT	cis	rs138880	0.542	rs9616371	chr22:50306338	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.2	-7.39	-0.55	1.9e-11	Schizophrenia;
TGCT	cis	rs9916302	0.904	rs4794807	chr17:37531718	T/A	cg07936489	chr17:37558343	FBXL20	0.65	5.08	0.41	1.36e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg08280861	chr8:58055591	NA	0.37	5.03	0.41	1.66e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2836950	0.565	rs3171465	chr21:40552307	A/G	cg11644478	chr21:40555479	PSMG1	-0.56	-5.23	-0.42	7.09e-7	Menarche (age at onset);
TGCT	cis	rs6545883	0.929	rs2252662	chr2:61670731	T/C	cg15711740	chr2:61764176	XPO1	-0.51	-4.62	-0.38	9.42e-6	Tuberculosis;
TGCT	cis	rs11080466	1.000	rs7228069	chr18:10897713	G/A	cg02393756	chr18:9912783	VAPA	-0.26	-4.71	-0.39	6.56e-6	Non-small cell lung cancer;
TGCT	cis	rs1050631	1.000	rs1539822	chr18:33695943	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	0.51	4.95	0.41	2.37e-6	Esophageal squamous cell cancer (length of survival);
TGCT	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg11764359	chr7:65958608	NA	-0.57	-5.12	-0.42	1.12e-6	Aortic root size;
TGCT	trans	rs1814175	0.817	rs10839397	chr11:49857074	C/T	cg15704280	chr7:45808275	SEPT13	-0.72	-8.14	-0.59	3.61e-13	Height;
TGCT	cis	rs7086627	0.515	rs4933390	chr10:82213081	A/C	cg00277334	chr10:82204260	NA	-0.56	-8.5	-0.61	5e-14	Post bronchodilator FEV1;
TGCT	cis	rs752010	0.806	rs6696511	chr1:42110888	T/C	cg06885757	chr1:42089581	HIVEP3	0.26	4.46	0.37	1.81e-5	Lupus nephritis in systemic lupus erythematosus;
TGCT	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg02463440	chr8:22132932	PIWIL2	0.26	5.02	0.41	1.78e-6	Hypertriglyceridemia;
TGCT	cis	rs12188164	1.000	rs72717411	chr5:429124	C/G	cg21144161	chr5:423903	AHRR	0.26	4.93	0.4	2.59e-6	Cystic fibrosis severity;
TGCT	cis	rs4689388	0.926	rs9998519	chr4:6292909	C/T	cg14416269	chr4:6271139	WFS1	0.37	4.9	0.4	2.95e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs208520	0.526	rs9354366	chr6:66788559	C/T	cg07460842	chr6:66804631	NA	-1.08	-15.95	-0.82	8.03e-32	Exhaled nitric oxide output;
TGCT	cis	rs8017423	0.935	rs59179255	chr14:90691773	A/C	cg04374321	chr14:90722782	PSMC1	0.77	8.03	0.58	6.42e-13	Mortality in heart failure;
TGCT	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg07870213	chr5:140052090	DND1	0.65	7.75	0.57	2.79e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs3806843	0.933	rs10069930	chr5:140163328	T/A	cg19875535	chr5:140030758	IK	0.37	6.25	0.49	5.95e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7552404	0.727	rs1146653	chr1:76280438	A/G	cg22875332	chr1:76189707	ACADM	0.63	6.96	0.53	1.71e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs10883723	0.810	rs10883729	chr10:104273943	A/G	cg05855489	chr10:104503620	C10orf26	-0.58	-5.06	-0.41	1.47e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs6586111	1.000	rs7093787	chr10:82371127	C/T	cg03086067	chr10:82368399	SH2D4B	-0.24	-4.7	-0.39	6.84e-6	Capecitabine sensitivity;
TGCT	cis	rs7918232	0.882	rs788237	chr10:27457932	C/T	cg14442939	chr10:27389572	ANKRD26	-0.82	-5.74	-0.46	6.98e-8	Breast cancer;
TGCT	cis	rs2486012	0.737	rs556667	chr1:44287414	G/T	cg12908607	chr1:44402522	ARTN	-0.68	-5.22	-0.42	7.25e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg17971929	chr21:40555470	PSMG1	-0.52	-4.57	-0.38	1.18e-5	Menarche (age at onset);
TGCT	cis	rs7710178	0.556	rs32080	chr5:156103226	A/G	cg19020398	chr5:156886415	NIPAL4	-0.32	-4.6	-0.38	1.03e-5	Airway responsiveness in chronic obstructive pulmonary disease;
TGCT	trans	rs17685	0.753	rs1639609	chr7:75683581	T/C	cg19862616	chr7:65841803	NCRNA00174	0.52	8.92	0.63	4.95e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs797680	0.897	rs2295424	chr1:93580879	T/C	cg17826107	chr1:92977322	EVI5	-0.22	-4.8	-0.4	4.4e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.61	-5.07	-0.41	1.41e-6	Tonsillectomy;
TGCT	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg03303774	chr4:1407052	NA	-0.33	-5.11	-0.42	1.17e-6	Obesity-related traits;
TGCT	cis	rs9952991	0.882	rs2847274	chr18:12777603	T/C	cg23544223	chr18:12777786	NA	0.64	6.12	0.48	1.15e-8	Inflammatory skin disease;
TGCT	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2204008	0.604	rs11172718	chr12:38069819	T/C	cg13010199	chr12:38710504	ALG10B	0.61	4.89	0.4	3.05e-6	Bladder cancer;
TGCT	cis	rs2072499	0.966	rs1137703	chr1:156184458	T/C	cg25208724	chr1:156163844	SLC25A44	1.08	15.41	0.81	1.37e-30	Testicular germ cell tumor;
TGCT	cis	rs77669868	0.866	rs2735195	chr11:114051192	A/G	cg01914181	chr11:114070210	ZBTB16	-0.31	-5.35	-0.43	4.04e-7	Monocyte percentage of white cells;
TGCT	cis	rs228437	0.565	rs4526208	chr6:134957385	C/T	cg09872934	chr6:134495829	SGK1	-0.58	-4.94	-0.41	2.47e-6	Melanoma;
TGCT	cis	rs11098499	0.863	rs3733525	chr4:120447048	A/G	cg09307838	chr4:120376055	NA	0.69	6.53	0.51	1.49e-9	Corneal astigmatism;
TGCT	cis	rs3812831	0.635	rs6560937	chr13:114945991	C/G	cg15513719	chr13:114904418	NA	0.36	4.46	0.37	1.84e-5	Schizophrenia;
TGCT	cis	rs7772486	0.790	rs9403755	chr6:146231470	C/A	cg23711669	chr6:146136114	FBXO30	-0.87	-9.9	-0.66	2.24e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.18	0.49	8.32e-9	Bipolar disorder;
TGCT	cis	rs950169	0.800	rs4099846	chr15:84956894	C/G	cg12863693	chr15:85201151	NMB	0.45	4.96	0.41	2.28e-6	Schizophrenia;
TGCT	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg18876405	chr7:65276391	NA	0.31	4.8	0.4	4.53e-6	Aortic root size;
TGCT	cis	rs1395	1.000	rs1275537	chr2:27441302	C/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.55	7.47	0.56	1.23e-11	Blood metabolite levels;
TGCT	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	6.13	0.48	1.06e-8	Bipolar disorder;
TGCT	cis	rs4319547	0.737	rs10846920	chr12:122943231	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.6	-4.77	-0.39	5.09e-6	Body mass index;
TGCT	cis	rs763014	0.898	rs916414	chr16:632073	C/T	cg27436995	chr16:743998	FBXL16	-0.45	-4.82	-0.4	4.17e-6	Height;
TGCT	cis	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg26513180	chr16:89883248	FANCA	-0.74	-7.19	-0.54	5.39e-11	Vitiligo;
TGCT	trans	rs7698623	0.850	rs716808	chr4:88800136	G/T	cg01186725	chr1:53905612	FLJ40434	-0.48	-6.61	-0.51	1.01e-9	Cardiovascular disease risk factors;
TGCT	cis	rs59698941	0.527	rs1910075	chr5:132180089	A/T	cg21474247	chr5:131268130	NA	0.32	5.12	0.42	1.15e-6	Apolipoprotein A-IV levels;
TGCT	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg00343986	chr7:65444356	GUSB	0.22	5.01	0.41	1.84e-6	Aortic root size;
TGCT	cis	rs11690935	0.959	rs6705200	chr2:172637600	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.18	-12.58	-0.75	6.59e-24	Schizophrenia;
TGCT	cis	rs9611565	0.512	rs132767	chr22:42009520	C/T	cg17554472	chr22:41940697	POLR3H	-0.47	-4.94	-0.41	2.52e-6	Vitiligo;
TGCT	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.46	-6.36	-0.5	3.55e-9	Alzheimer's disease;
TGCT	cis	rs3772130	0.961	rs13072618	chr3:121391833	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.55	5.02	0.41	1.77e-6	Cognitive performance;
TGCT	cis	rs9443645	0.901	rs4565265	chr6:79741958	A/G	cg09184832	chr6:79620586	NA	-0.48	-5.29	-0.43	5.43e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9660992	0.573	rs1172139	chr1:205213962	G/A	cg00857998	chr1:205179979	DSTYK	0.51	4.68	0.39	7.34e-6	Mean corpuscular volume;Mean platelet volume;
TGCT	cis	rs6988636	0.818	rs59428574	chr8:124166061	G/A	cg27053337	chr8:124217698	FAM83A	0.7	5.14	0.42	1.06e-6	Urinary uromodulin levels;
TGCT	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg14893161	chr1:205819251	PM20D1	0.55	7.8	0.57	2.23e-12	Menarche (age at onset);
TGCT	cis	rs7586879	0.681	rs6723803	chr2:25120713	G/C	cg15423357	chr2:25149977	NA	0.5	4.89	0.4	3.06e-6	Body mass index;
TGCT	cis	rs28735056	0.591	rs2277724	chr18:77694294	C/A	cg20368463	chr18:77673604	PQLC1	-0.48	-5.79	-0.46	5.4e-8	Schizophrenia;
TGCT	cis	rs4843747	0.671	rs72818576	chr16:88111019	C/G	cg06915872	chr16:87998081	BANP	-0.3	-4.52	-0.38	1.44e-5	Menopause (age at onset);
TGCT	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg18876405	chr7:65276391	NA	0.33	4.86	0.4	3.46e-6	Aortic root size;
TGCT	cis	rs6089584	0.927	rs2281734	chr20:60582401	C/A	cg06108461	chr20:60628389	TAF4	-0.59	-8.52	-0.61	4.53e-14	Body mass index;
TGCT	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg06221963	chr1:154839813	KCNN3	0.56	7.82	0.57	1.95e-12	Prostate cancer;
TGCT	cis	rs7937682	0.575	rs7124696	chr11:111747297	A/G	cg09085632	chr11:111637200	PPP2R1B	0.88	8.5	0.61	5.19e-14	Primary sclerosing cholangitis;
TGCT	cis	rs4478858	0.684	rs4949373	chr1:31741577	G/A	cg07478791	chr1:31886160	SERINC2	-0.49	-4.91	-0.4	2.82e-6	Alcohol dependence;
TGCT	cis	rs2455799	0.552	rs2470516	chr3:15759050	T/G	cg16303742	chr3:15540471	COLQ	-0.25	-4.78	-0.39	4.95e-6	Mean platelet volume;
TGCT	cis	rs6430585	0.646	rs12476116	chr2:136497199	A/G	cg07169764	chr2:136633963	MCM6	1.17	10.84	0.7	1.14e-19	Corneal structure;
TGCT	cis	rs2439831	1.000	rs2467426	chr15:43989518	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.96	6.63	0.51	9.05e-10	Lung cancer in ever smokers;
TGCT	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg13770153	chr20:60521292	NA	-0.6	-7.72	-0.57	3.26e-12	Body mass index;
TGCT	cis	rs13242816	0.881	rs12672038	chr7:116187106	G/A	cg02799643	chr7:116139180	CAV2	-0.43	-5.29	-0.43	5.24e-7	P wave duration;
TGCT	cis	rs28595532	0.841	rs114385163	chr4:119737058	C/T	cg21605333	chr4:119757512	SEC24D	1.61	8.95	0.63	4.36e-15	Cannabis dependence symptom count;
TGCT	cis	rs612683	0.518	rs660945	chr1:100831830	A/T	cg06223162	chr1:101003688	GPR88	-0.27	-4.69	-0.39	7.09e-6	Breast cancer;
TGCT	cis	rs1971762	0.527	rs11170590	chr12:53938913	G/A	cg16917193	chr12:54089295	NA	1.02	10.38	0.68	1.5e-18	Height;
TGCT	cis	rs9902453	1.000	rs8065261	chr17:28418041	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.74	-6.52	-0.51	1.63e-9	Coffee consumption (cups per day);
TGCT	cis	rs1008375	1.000	rs6846238	chr4:17629939	A/G	cg18681998	chr4:17616180	MED28	1.02	11.4	0.72	4.89e-21	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7959452	0.640	rs10878957	chr12:69699638	G/C	cg11871910	chr12:69753446	YEATS4	0.63	6.37	0.5	3.41e-9	Blood protein levels;
TGCT	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg18230493	chr5:56204884	C5orf35	0.86	6.85	0.52	3.07e-10	Initial pursuit acceleration;
TGCT	cis	rs3087591	0.960	rs6505232	chr17:29611411	T/C	cg24425628	chr17:29625626	OMG;NF1	-0.47	-7.39	-0.55	1.94e-11	Hip circumference;
TGCT	cis	rs8017423	0.967	rs11621431	chr14:90709221	C/T	cg04374321	chr14:90722782	PSMC1	0.77	8.05	0.59	5.68e-13	Mortality in heart failure;
TGCT	cis	rs68170813	0.527	rs75382408	chr7:107010406	C/T	cg02696742	chr7:106810147	HBP1	-0.71	-5.96	-0.47	2.38e-8	Coronary artery disease;
TGCT	cis	rs7017914	0.905	rs3110252	chr8:71937220	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-4.97	-0.41	2.16e-6	Bone mineral density;
TGCT	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg00343986	chr7:65444356	GUSB	0.21	4.59	0.38	1.07e-5	Aortic root size;
TGCT	cis	rs12681287	0.752	rs10104242	chr8:87247714	G/C	cg27223183	chr8:87520930	FAM82B	-0.81	-5.77	-0.46	5.91e-8	Caudate activity during reward;
TGCT	cis	rs236907	0.812	rs35400839	chr1:171743312	G/A	cg20598894	chr1:171756153	METTL13	-0.19	-4.54	-0.38	1.32e-5	Mean platelet volume;
TGCT	cis	rs7666738	0.579	rs7672718	chr4:98645122	A/G	cg05340658	chr4:99064831	C4orf37	0.47	5.14	0.42	1.02e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs79387448	0.745	rs17027430	chr2:103163237	T/C	cg09003973	chr2:102972529	NA	0.92	5.89	0.47	3.39e-8	Gut microbiota (bacterial taxa);
TGCT	cis	rs2239547	0.603	rs7644973	chr3:53082937	C/T	cg11645453	chr3:52864694	ITIH4	0.3	4.84	0.4	3.73e-6	Schizophrenia;
TGCT	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg03264133	chr6:25882463	NA	-0.64	-5.93	-0.47	2.82e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9443645	0.803	rs1547731	chr6:79776104	A/G	cg09184832	chr6:79620586	NA	-0.48	-5.34	-0.43	4.21e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7639513	0.767	rs13060705	chr3:12710016	C/A	cg23032965	chr3:12705835	RAF1	0.77	8.55	0.61	3.81e-14	Itch intensity from mosquito bite;
TGCT	cis	rs6688613	0.840	rs10918607	chr1:166957803	T/C	cg07049167	chr1:166818506	POGK	0.26	5.18	0.42	8.56e-7	Refractive astigmatism;
TGCT	cis	rs9640161	0.742	rs2108853	chr7:150017589	A/C	cg10018233	chr7:150070692	REPIN1	0.33	4.68	0.39	7.25e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs4273100	0.790	rs2048230	chr17:19276199	G/A	cg01534423	chr17:18965556	NA	0.95	6.38	0.5	3.14e-9	Schizophrenia;
TGCT	trans	rs877282	1.000	rs11253370	chr10:773712	G/A	cg22713356	chr15:30763199	NA	1.15	9.94	0.67	1.76e-17	Uric acid levels;
TGCT	cis	rs6088590	0.610	rs6120663	chr20:33081906	A/C	cg24642439	chr20:33292090	TP53INP2	-0.66	-6.16	-0.48	9.13e-9	Coronary artery disease;
TGCT	cis	rs1887596	0.663	rs9551305	chr13:27249860	A/G	cg01312412	chr13:27282625	NA	0.28	4.98	0.41	2.07e-6	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs2762353	0.845	rs35720558	chr6:25784800	A/C	cg12310025	chr6:25882481	NA	0.51	5.26	0.43	6.17e-7	Blood metabolite levels;
TGCT	cis	rs42648	0.935	rs42644	chr7:89974864	G/A	cg25739043	chr7:89950458	NA	-0.77	-7.82	-0.57	1.96e-12	Homocysteine levels;
TGCT	cis	rs12477438	0.798	rs6740035	chr2:99576578	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-5.97	-0.47	2.3e-8	Chronic sinus infection;
TGCT	cis	rs72627509	0.638	rs1608165	chr4:57894717	G/C	cg26694713	chr4:57773883	REST	0.62	4.62	0.38	9.46e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs1406084	0.578	rs3843318	chr2:154717559	G/A	cg25703346	chr2:154729189	GALNT13	0.77	4.6	0.38	1.03e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11190604	0.767	rs10883477	chr10:102161396	A/G	cg16005271	chr10:102321736	NA	0.46	4.83	0.4	3.93e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2204008	0.616	rs1607852	chr12:38398125	G/A	cg26384229	chr12:38710491	ALG10B	0.84	7.42	0.55	1.62e-11	Bladder cancer;
TGCT	cis	rs11098499	0.644	rs10050092	chr4:120532085	T/C	cg09307838	chr4:120376055	NA	0.62	5.86	0.47	3.86e-8	Corneal astigmatism;
TGCT	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg11366901	chr6:160182831	ACAT2	1.03	6.98	0.53	1.59e-10	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs6586111	1.000	rs7073089	chr10:82371045	C/G	cg03086067	chr10:82368399	SH2D4B	-0.24	-4.7	-0.39	6.84e-6	Capecitabine sensitivity;
TGCT	cis	rs7937682	0.793	rs7130440	chr11:111417779	A/G	cg09085632	chr11:111637200	PPP2R1B	0.65	6.0	0.47	2.04e-8	Primary sclerosing cholangitis;
TGCT	trans	rs853410	0.516	rs9405690	chr6:4005552	C/T	cg13911294	chr9:88951310	ZCCHC6	-0.64	-6.66	-0.51	8.02e-10	Night sleep phenotypes;
TGCT	cis	rs2204008	0.775	rs11182513	chr12:38560252	G/C	cg13010199	chr12:38710504	ALG10B	0.65	5.18	0.42	8.83e-7	Bladder cancer;
TGCT	cis	rs3771570	1.000	rs62190367	chr2:242376276	G/A	cg21155796	chr2:242212141	HDLBP	0.93	6.6	0.51	1.08e-9	Prostate cancer;
TGCT	cis	rs919433	0.679	rs6737060	chr2:198524885	G/C	cg00792783	chr2:198669748	PLCL1	0.55	4.88	0.4	3.24e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg18735214	chr6:43276756	CRIP3	-0.56	-4.88	-0.4	3.24e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs10936602	0.527	rs7628572	chr3:169539649	T/A	cg08193579	chr3:169529701	LRRC34	0.28	5.16	0.42	9.55e-7	Renal cell carcinoma;
TGCT	cis	rs9653442	0.835	rs1561230	chr2:100746642	C/T	cg22139774	chr2:100720529	AFF3	0.43	7.46	0.56	1.31e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs8180040	0.764	rs62246375	chr3:47014464	G/A	cg27129171	chr3:47204927	SETD2	-0.71	-8.9	-0.62	5.56e-15	Colorectal cancer;
TGCT	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg17971929	chr21:40555470	PSMG1	0.67	6.29	0.49	5.06e-9	Cognitive function;
TGCT	cis	rs4319547	0.585	rs10846792	chr12:122882374	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.62	-4.79	-0.4	4.63e-6	Body mass index;
TGCT	cis	rs9858542	0.953	rs35261698	chr3:49537839	C/G	cg03060546	chr3:49711283	APEH	-0.61	-5.37	-0.43	3.78e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs6964587	0.934	rs73226382	chr7:91692760	T/C	cg17063962	chr7:91808500	NA	0.88	9.65	0.66	8.73e-17	Breast cancer;
TGCT	cis	rs9611519	0.828	rs28814423	chr22:41452301	G/A	cg13695892	chr22:41940480	POLR3H	-0.54	-4.82	-0.4	4.15e-6	Neuroticism;
TGCT	cis	rs41271473	0.526	rs10916344	chr1:228737489	C/T	cg10167378	chr1:228756711	NA	0.73	4.57	0.38	1.15e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs7659604	0.628	rs6838153	chr4:122720999	A/G	cg23574427	chr4:122746245	BBS7;CCNA2	-0.35	-5.39	-0.44	3.47e-7	Type 2 diabetes;
TGCT	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg06108461	chr20:60628389	TAF4	-0.69	-10.77	-0.7	1.71e-19	Body mass index;
TGCT	cis	rs7666738	0.830	rs7664340	chr4:99037820	C/T	cg18180107	chr4:99064573	C4orf37	0.55	5.13	0.42	1.1e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs74233809	1.000	rs10883835	chr10:104884208	T/C	cg05855489	chr10:104503620	C10orf26	0.82	4.44	0.37	1.97e-5	Birth weight;
TGCT	cis	rs4604732	0.631	rs12091081	chr1:247623064	C/T	cg22475246	chr1:246888027	SCCPDH	0.67	4.79	0.4	4.57e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
TGCT	cis	rs41308713	0.606	rs77984335	chr20:37073286	G/A	cg09132763	chr20:37064059	LOC388796;SNORA71D	1.34	6.47	0.5	2.09e-9	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
TGCT	cis	rs782590	0.557	rs7592219	chr2:55887176	T/C	cg03859395	chr2:55845619	SMEK2	-0.63	-5.3	-0.43	5.01e-7	Metabolic syndrome;
TGCT	cis	rs6866344	0.697	rs58549512	chr5:178133204	C/T	cg10224037	chr5:178157518	ZNF354A	0.95	8.47	0.61	6.06e-14	Neutrophil percentage of white cells;
TGCT	cis	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg03213289	chr20:61660250	NA	0.68	9.99	0.67	1.36e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.54	5.05	0.41	1.52e-6	Prudent dietary pattern;
TGCT	cis	rs6484504	0.576	rs2065208	chr11:31239457	C/T	cg26647111	chr11:31128758	NA	-0.35	-4.75	-0.39	5.48e-6	Red blood cell count;
TGCT	cis	rs7267979	0.932	rs928121	chr20:25534818	A/G	cg03522245	chr20:25566470	NINL	0.6	6.46	0.5	2.14e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1994135	0.669	rs11052746	chr12:33697473	A/C	cg06521331	chr12:34319734	NA	0.3	4.59	0.38	1.07e-5	Resting heart rate;
TGCT	cis	rs34014631	1.000	rs78142636	chr10:103601727	G/C	cg22630918	chr10:102748988	C10orf2	0.43	4.83	0.4	3.98e-6	Coronary artery calcification;
TGCT	cis	rs2639990	1.000	rs1702831	chr18:72897368	C/A	cg21330207	chr18:72916311	ZADH2	0.51	4.57	0.38	1.16e-5	Vascular endothelial growth factor levels;
TGCT	cis	rs77372450	0.551	rs11739081	chr5:157087119	C/G	cg12606933	chr5:157078573	SOX30	-0.43	-4.69	-0.39	7e-6	Bipolar disorder (body mass index interaction);
TGCT	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg24829409	chr8:58192753	C8orf71	-0.57	-4.72	-0.39	6.14e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs8077577	1.000	rs8077577	chr17:18064730	C/T	cg09161412	chr17:18057145	MYO15A	-0.65	-5.36	-0.43	3.89e-7	Obesity-related traits;
TGCT	cis	rs2242194	0.816	rs11264296	chr1:154994750	T/C	cg24348479	chr1:155007323	DCST1;DCST2	0.27	5.66	0.45	9.97e-8	Schizophrenia;
TGCT	cis	rs2354432	0.607	rs12402309	chr1:146721983	T/A	cg25205988	chr1:146714368	CHD1L	-1.34	-6.07	-0.48	1.44e-8	Mitochondrial DNA levels;
TGCT	cis	rs5769707	0.777	rs8138399	chr22:50044824	C/T	cg05373962	chr22:49881684	NA	-0.31	-6.33	-0.49	4.07e-9	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs910316	1.000	rs4899546	chr14:75594946	G/C	cg08847533	chr14:75593920	NEK9	0.96	10.86	0.7	1.05e-19	Height;
TGCT	cis	rs1372520	0.684	rs10008964	chr4:90744721	G/A	cg14346243	chr4:90757452	SNCA	-0.67	-5.64	-0.45	1.11e-7	Neuroticism;
TGCT	cis	rs910316	0.726	rs12882664	chr14:75446778	C/T	cg11812906	chr14:75593930	NEK9	0.59	5.56	0.45	1.61e-7	Height;
TGCT	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg05457628	chr5:178986728	RUFY1	0.54	6.29	0.49	4.98e-9	Lung cancer;
TGCT	cis	rs7267979	1.000	rs2258879	chr20:25279213	T/C	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9309473	0.660	rs56131703	chr2:73847260	C/T	cg07208825	chr2:73871855	ALMS1P	0.26	5.28	0.43	5.58e-7	Metabolite levels;
TGCT	cis	rs7727544	1.000	rs7727544	chr5:131590534	C/T	cg24060327	chr5:131705240	SLC22A5	-0.62	-6.48	-0.5	1.97e-9	Blood metabolite levels;
TGCT	cis	rs67311347	1.000	rs73080126	chr3:40509153	A/G	cg17264618	chr3:40429014	ENTPD3	0.32	4.45	0.37	1.88e-5	Renal cell carcinoma;
TGCT	cis	rs7267979	1.000	rs6083828	chr20:25369918	T/C	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg13683864	chr3:40499215	RPL14	-1.16	-12.47	-0.75	1.28e-23	Renal cell carcinoma;
TGCT	cis	rs7208859	0.573	rs73277974	chr17:29189869	A/G	cg18442181	chr17:29233375	C17orf42	-0.78	-4.61	-0.38	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7833790	0.660	rs10091077	chr8:82705464	A/G	cg23324259	chr8:82754387	SNX16	-0.58	-4.46	-0.37	1.78e-5	Diastolic blood pressure;
TGCT	cis	rs17102423	0.559	rs11627382	chr14:65480208	A/G	cg11161011	chr14:65562177	MAX	-0.42	-4.94	-0.41	2.46e-6	Obesity-related traits;
TGCT	cis	rs7666738	0.830	rs10014986	chr4:99000687	A/C	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg06481639	chr22:41940642	POLR3H	0.59	5.38	0.44	3.56e-7	Vitiligo;
TGCT	trans	rs7819412	0.745	rs28591576	chr8:11080675	C/T	cg15556689	chr8:8085844	FLJ10661	-0.87	-8.34	-0.6	1.2e-13	Triglycerides;
TGCT	cis	rs1005277	0.505	rs7099777	chr10:38183569	A/C	cg13531842	chr10:38383804	ZNF37A	0.38	4.55	0.38	1.24e-5	Extrinsic epigenetic age acceleration;
TGCT	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg02725872	chr8:58115012	NA	-0.41	-5.42	-0.44	3.01e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs524281	0.692	rs10896076	chr11:65840668	A/G	cg00563793	chr11:65837595	PACS1	0.59	5.36	0.43	3.88e-7	Electroencephalogram traits;
TGCT	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg17971929	chr21:40555470	PSMG1	0.97	9.54	0.65	1.67e-16	Cognitive function;
TGCT	cis	rs1371867	0.810	rs1692004	chr8:101247320	T/C	cg06002616	chr8:101225028	SPAG1	0.53	6.05	0.48	1.55e-8	Atrioventricular conduction;
TGCT	cis	rs7172809	0.599	rs17471697	chr15:77762493	A/G	cg22256960	chr15:77711686	NA	0.53	5.15	0.42	9.86e-7	Glucose homeostasis traits;
TGCT	cis	rs6545883	0.929	rs6707830	chr2:61749472	G/A	cg15711740	chr2:61764176	XPO1	-0.52	-4.78	-0.39	4.78e-6	Tuberculosis;
TGCT	cis	rs3091242	0.933	rs35497030	chr1:25783066	A/G	cg23205692	chr1:25664452	TMEM50A	-0.47	-4.96	-0.41	2.27e-6	Erythrocyte sedimentation rate;
TGCT	cis	rs2147959	0.824	rs6669744	chr1:228684825	T/C	cg22700015	chr1:228743131	NA	-0.61	-4.7	-0.39	6.82e-6	Adult asthma;
TGCT	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg03709012	chr19:19516395	GATAD2A	0.67	5.75	0.46	6.45e-8	Tonsillectomy;
TGCT	cis	rs1372520	0.684	rs2583963	chr4:90727088	C/T	cg15133208	chr4:90757351	SNCA	-0.52	-6.07	-0.48	1.44e-8	Neuroticism;
TGCT	cis	rs1245541	0.720	rs1271933	chr10:73902875	T/C	cg09661010	chr10:73848153	SPOCK2	-0.37	-4.53	-0.38	1.39e-5	Insulin-like growth factors;
TGCT	cis	rs1005277	0.522	rs11011343	chr10:38002698	A/G	cg25427524	chr10:38739819	LOC399744	-0.33	-6.6	-0.51	1.07e-9	Extrinsic epigenetic age acceleration;
TGCT	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg11494091	chr17:61959527	GH2	0.61	14.49	0.79	1.92e-28	Prudent dietary pattern;
TGCT	cis	rs9858542	0.953	rs71324979	chr3:49619651	T/C	cg03060546	chr3:49711283	APEH	-0.63	-5.48	-0.44	2.28e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs4273100	0.541	rs7501702	chr17:19293727	C/T	cg03910582	chr17:19030146	GRAPL	-0.45	-6.22	-0.49	6.97e-9	Schizophrenia;
TGCT	cis	rs7666738	0.830	rs7673880	chr4:99057262	A/G	cg17366294	chr4:99064904	C4orf37	0.69	6.91	0.53	2.31e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10744422	0.920	rs3896871	chr12:123333610	G/T	cg25930673	chr12:123319894	HIP1R	-0.86	-5.02	-0.41	1.72e-6	Schizophrenia;
TGCT	cis	rs7582180	0.629	rs11123827	chr2:100951248	C/G	cg08017756	chr2:100939284	LONRF2	-0.3	-4.87	-0.4	3.27e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6484504	0.532	rs12222329	chr11:31274340	T/C	cg14844989	chr11:31128820	NA	-0.25	-4.89	-0.4	3e-6	Red blood cell count;
TGCT	cis	rs4919669	0.719	rs11818043	chr10:104391627	A/G	cg05855489	chr10:104503620	C10orf26	0.74	4.73	0.39	5.9e-6	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs12479064	0.724	rs3792150	chr2:100041849	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.56	-4.66	-0.39	8e-6	Chronic sinus infection;
TGCT	cis	rs7178572	1.000	rs952472	chr15:77776562	A/C	cg22256960	chr15:77711686	NA	-0.95	-10.89	-0.7	8.57e-20	Type 2 diabetes;
TGCT	cis	rs2840044	1.000	rs7212704	chr17:33898897	C/T	cg05299278	chr17:33885742	SLFN14	-0.23	-5.32	-0.43	4.65e-7	Response to radiotherapy in cancer (late toxicity);
TGCT	cis	rs9486719	0.901	rs13206547	chr6:97006942	T/C	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.21	-0.59	2.44e-13	Migraine;Coronary artery disease;
TGCT	cis	rs4253772	0.513	rs9615345	chr22:46713631	C/T	cg26492175	chr22:47022658	GRAMD4	0.2	4.47	0.37	1.75e-5	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs2562456	0.917	rs2650825	chr19:21699225	A/G	cg25650185	chr19:21324782	ZNF431	-0.52	-4.7	-0.39	6.74e-6	Pain;
TGCT	cis	rs4980532	1	rs4980532	chr11:63680719	C/T	cg04850017	chr11:63683019	RCOR2	0.41	6.88	0.53	2.59e-10	Pulse pressure;
TGCT	cis	rs1857353	1.000	rs12407255	chr1:75876217	G/T	cg11838876	chr1:75668600	SLC44A5	-0.47	-4.56	-0.38	1.2e-5	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs9388451	0.874	rs7739566	chr6:126094757	A/T	cg10911889	chr6:126070802	HEY2	0.54	5.64	0.45	1.09e-7	Brugada syndrome;
TGCT	cis	rs950169	0.922	rs4338765	chr15:84916836	G/T	cg17173187	chr15:85201210	NMB	0.54	5.55	0.45	1.67e-7	Schizophrenia;
TGCT	cis	rs6591182	0.504	rs7116712	chr11:65372518	A/G	cg17480646	chr11:65405466	SIPA1	-0.51	-6.48	-0.5	1.91e-9	Non-alcoholic fatty liver disease histology (lobular);
TGCT	cis	rs2948294	0.588	rs4840913	chr8:8116906	A/C	cg06636001	chr8:8085503	FLJ10661	0.77	6.9	0.53	2.31e-10	Red cell distribution width;
TGCT	cis	rs6570726	0.599	rs455001	chr6:145854450	A/T	cg13319975	chr6:146136371	FBXO30	-0.69	-6.34	-0.49	3.92e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7772486	0.846	rs1474871	chr6:146406294	G/A	cg23711669	chr6:146136114	FBXO30	0.86	9.3	0.64	6.2e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg10802521	chr3:52805072	NEK4	-0.72	-9.1	-0.63	1.91e-15	Bipolar disorder;
TGCT	cis	rs11627546	0.615	rs61980617	chr14:70367189	A/G	cg10496350	chr14:71275911	MAP3K9	-0.89	-4.5	-0.37	1.52e-5	Red blood cell traits;
TGCT	cis	rs116095464	0.558	rs9312978	chr5:221930	C/G	cg22857025	chr5:266934	NA	-0.34	-6.6	-0.51	1.09e-9	Breast cancer;
TGCT	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg19723775	chr5:179050963	HNRNPH1	-0.52	-5.18	-0.42	8.62e-7	Lung cancer;
TGCT	trans	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-1.03	-13.16	-0.76	2.65e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs6840360	0.554	rs61308159	chr4:152728941	G/A	cg22705602	chr4:152727874	NA	0.37	6.54	0.51	1.47e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.54	-5.12	-0.42	1.13e-6	Bipolar disorder;
TGCT	cis	rs6545977	0.531	rs2539981	chr2:63104904	T/C	cg17519650	chr2:63277830	OTX1	0.69	6.57	0.51	1.22e-9	Prostate cancer;
TGCT	cis	rs6663390	0.831	rs11118880	chr1:208085583	T/A	cg03990033	chr1:208084030	CD34	0.54	5.61	0.45	1.26e-7	Facial morphology (factor 18);
TGCT	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg02725872	chr8:58115012	NA	-0.4	-4.78	-0.39	4.78e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg11890956	chr21:40555474	PSMG1	1.04	10.78	0.7	1.56e-19	Cognitive function;
TGCT	cis	rs9325144	0.556	rs34565156	chr12:39028239	G/A	cg26384229	chr12:38710491	ALG10B	-0.61	-5.81	-0.46	4.99e-8	Morning vs. evening chronotype;
TGCT	cis	rs6922617	0.786	rs73417293	chr6:41342880	A/G	cg07798131	chr6:41471673	NA	0.96	4.74	0.39	5.73e-6	Alzheimer's disease biomarkers;
TGCT	cis	rs6733011	0.518	rs12712033	chr2:99457973	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.5	-4.92	-0.4	2.7e-6	Bipolar disorder;
TGCT	cis	rs7937682	0.924	rs1784782	chr11:111525764	A/C	cg09085632	chr11:111637200	PPP2R1B	-1.1	-11.55	-0.72	2.11e-21	Primary sclerosing cholangitis;
TGCT	cis	rs4389656	0.857	rs274699	chr5:6730332	A/C	cg10857441	chr5:6722123	POLS	-0.22	-4.74	-0.39	5.75e-6	Coronary artery disease;
TGCT	cis	rs9303401	0.659	rs7216648	chr17:56790858	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.59	5.99	0.47	2.08e-8	Cognitive test performance;
TGCT	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	8.55	0.61	3.84e-14	Platelet count;
TGCT	cis	rs916888	0.821	rs199514	chr17:44856881	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.73	-5.0	-0.41	1.89e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs4654899	0.549	rs4654873	chr1:21152384	G/A	cg01072550	chr1:21505969	NA	-0.42	-6.15	-0.48	9.87e-9	Superior frontal gyrus grey matter volume;
TGCT	cis	rs9611565	0.559	rs132761	chr22:42004371	C/T	cg06634786	chr22:41940651	POLR3H	0.89	8.56	0.61	3.56e-14	Vitiligo;
TGCT	cis	rs2180341	0.920	rs4472373	chr6:127705983	G/A	cg24812749	chr6:127587940	RNF146	0.99	7.63	0.57	5.24e-12	Breast cancer;
TGCT	cis	rs2637266	1.000	rs12251434	chr10:78345468	C/A	cg18941641	chr10:78392320	NA	0.4	5.02	0.41	1.77e-6	Pulmonary function;
TGCT	trans	rs7618501	0.699	rs9821675	chr3:49902544	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.9	9.84	0.66	3.04e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs736408	0.812	rs2240920	chr3:52831009	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	-0.55	-5.01	-0.41	1.79e-6	Bipolar disorder;
TGCT	cis	rs3806843	0.966	rs2337986	chr5:140160622	C/T	cg19875535	chr5:140030758	IK	0.37	6.34	0.49	3.89e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs986417	0.901	rs10139995	chr14:60947177	G/T	cg27398547	chr14:60952738	C14orf39	1.42	8.68	0.61	1.89e-14	Gut microbiota (bacterial taxa);
TGCT	cis	rs7523050	0.643	rs35050241	chr1:109404876	T/C	cg08274380	chr1:109419600	GPSM2	1.3	6.39	0.5	2.99e-9	Fat distribution (HIV);
TGCT	cis	rs9393777	0.622	rs13191326	chr6:27031029	A/G	cg16898833	chr6:26189333	HIST1H4D	0.98	5.69	0.46	8.64e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs8180040	0.726	rs10461018	chr3:46995242	C/T	cg27129171	chr3:47204927	SETD2	-0.74	-9.5	-0.65	2.08e-16	Colorectal cancer;
TGCT	cis	rs9467773	0.595	rs3846845	chr6:26444915	G/A	cg05738196	chr6:26577821	NA	-0.52	-5.49	-0.44	2.18e-7	Intelligence (multi-trait analysis);
TGCT	trans	rs2469997	1.000	rs2447160	chr8:120374473	G/A	cg01792902	chr3:178864926	PIK3CA	0.83	6.77	0.52	4.49e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs10791097	0.694	rs7940027	chr11:130745591	A/G	cg05962950	chr11:130786565	SNX19	0.92	11.53	0.72	2.38e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs17102423	0.755	rs7154852	chr14:65553822	C/A	cg11161011	chr14:65562177	MAX	-0.55	-7.7	-0.57	3.74e-12	Obesity-related traits;
TGCT	trans	rs17685	0.712	rs2158867	chr7:75815141	C/A	cg19862616	chr7:65841803	NCRNA00174	0.5	8.75	0.62	1.28e-14	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs797680	0.930	rs622608	chr1:93715219	G/A	cg17826107	chr1:92977322	EVI5	0.24	5.3	0.43	5.16e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs2594989	0.779	rs61275424	chr3:11595585	G/C	cg00170343	chr3:11313890	ATG7	-0.68	-5.33	-0.43	4.44e-7	Circulating chemerin levels;
TGCT	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs877529	0.934	rs139419	chr22:39557340	T/G	cg18708252	chr22:39545030	CBX7	-0.35	-4.74	-0.39	5.7e-6	Multiple myeloma;
TGCT	cis	rs7599312	1.000	rs7599312	chr2:213413231	C/T	cg20637307	chr2:213403960	ERBB4	0.6	4.91	0.4	2.82e-6	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs9911578	1.000	rs2611782	chr17:56717956	T/C	cg05425664	chr17:57184151	TRIM37	-0.64	-6.48	-0.5	1.99e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs12510870	0.566	rs10004505	chr4:74437998	G/A	cg05868023	chr4:75230803	EREG	0.55	4.97	0.41	2.18e-6	Iris color (b* coordinate);
TGCT	cis	rs2463822	0.764	rs7125402	chr11:62097259	C/T	cg23876832	chr11:62092739	NA	0.67	4.91	0.4	2.82e-6	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs886126	1.000	rs7973104	chr12:111670774	C/G	cg10833066	chr12:111807467	FAM109A	0.32	5.18	0.42	8.75e-7	Coronary heart disease;
TGCT	cis	rs3096299	0.667	rs2965947	chr16:89518670	T/C	cg08392591	chr16:89556376	ANKRD11	0.6	5.68	0.45	9.12e-8	Multiple myeloma (IgH translocation);
TGCT	cis	rs11190604	0.767	rs7085426	chr10:102163640	T/C	cg16005271	chr10:102321736	NA	0.45	4.74	0.39	5.87e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7772486	0.641	rs2777485	chr6:146334377	G/A	cg13319975	chr6:146136371	FBXO30	-0.68	-6.33	-0.49	4.17e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg19729930	chr2:74357872	NA	0.62	8.94	0.63	4.63e-15	Gestational age at birth (maternal effect);
TGCT	cis	rs7267979	0.509	rs6115218	chr20:25566485	A/G	cg03522245	chr20:25566470	NINL	0.8	8.62	0.61	2.57e-14	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg26116260	chr4:7069785	GRPEL1	1.07	9.88	0.66	2.5e-17	Monocyte percentage of white cells;
TGCT	cis	rs9357506	1.000	rs60870663	chr6:46302975	T/A	cg21115430	chr6:46460003	NA	-0.27	-5.47	-0.44	2.43e-7	Body mass index;
TGCT	cis	rs910316	1.000	rs175492	chr14:75545220	A/C	cg11812906	chr14:75593930	NEK9	0.65	6.27	0.49	5.5e-9	Height;
TGCT	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg02725872	chr8:58115012	NA	-0.41	-4.96	-0.41	2.28e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4455778	1.000	rs4455778	chr7:49119500	G/T	cg26309511	chr7:48887640	NA	0.45	5.22	0.42	7.27e-7	Lung cancer in never smokers;
TGCT	cis	rs17122693	1.000	rs3015444	chr14:51085116	T/C	cg04730355	chr14:51134070	SAV1	1.21	9.01	0.63	3.15e-15	Cognitive performance;
TGCT	cis	rs514406	0.763	rs7535088	chr1:53215042	A/G	cg22166914	chr1:53195759	ZYG11B	-0.41	-7.06	-0.54	1.05e-10	Monocyte count;
TGCT	cis	rs8180040	0.739	rs66539935	chr3:47025327	C/T	cg27129171	chr3:47204927	SETD2	-0.7	-8.7	-0.62	1.7e-14	Colorectal cancer;
TGCT	cis	rs904251	0.802	rs2646933	chr6:37402070	C/G	cg25019722	chr6:37503610	NA	-0.44	-5.01	-0.41	1.81e-6	Cognitive performance;
TGCT	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg03060546	chr3:49711283	APEH	0.57	5.38	0.44	3.51e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs1395	0.778	rs1439768	chr2:27389660	C/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.66	8.95	0.63	4.24e-15	Blood metabolite levels;
TGCT	cis	rs9328448	0.882	rs7750233	chr6:7983040	A/G	cg13863638	chr6:7199401	RREB1	0.19	4.49	0.37	1.64e-5	Coronary artery calcification;
TGCT	cis	rs617219	0.698	rs72764983	chr5:78513806	T/C	cg23987322	chr5:78407566	BHMT	0.37	4.86	0.4	3.52e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs655029	0.678	rs4952073	chr2:31457981	T/C	cg14018959	chr2:31480232	EHD3	-0.36	-4.84	-0.4	3.76e-6	Mean platelet volume;Platelet distribution width;Platelet count;Plateletcrit;
TGCT	cis	rs1245541	0.595	rs7072673	chr10:73865742	A/C	cg10983208	chr10:73848320	SPOCK2	-0.26	-4.57	-0.38	1.18e-5	Insulin-like growth factors;
TGCT	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg03352830	chr11:487213	PTDSS2	0.26	4.46	0.37	1.8e-5	Body mass index;
TGCT	cis	rs28595532	0.920	rs114223775	chr4:119775091	C/T	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs12421382	0.659	rs57978015	chr11:109385473	T/C	cg16359550	chr11:109292809	C11orf87	0.43	4.79	0.39	4.73e-6	Schizophrenia;
TGCT	cis	rs10170846	1.000	rs10170846	chr2:223517705	C/G	cg25565276	chr2:223520875	FARSB	-0.78	-5.94	-0.47	2.67e-8	Schizophrenia (inflammation and infection response interaction);
TGCT	cis	rs6450176	0.909	rs66872223	chr5:53292730	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.49	-4.59	-0.38	1.08e-5	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs7647973	1.000	rs9862534	chr3:49598064	A/G	cg07636037	chr3:49044803	WDR6	0.61	5.11	0.42	1.17e-6	Menarche (age at onset);
TGCT	cis	rs6500602	0.826	rs11076830	chr16:4460049	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.44	5.68	0.45	8.96e-8	Schizophrenia;
TGCT	cis	rs17767294	0.541	rs72845050	chr6:27610070	A/C	cg08851530	chr6:28072375	NA	1.34	6.29	0.49	5.02e-9	Parkinson's disease;
TGCT	cis	rs11190604	1.000	rs10786596	chr10:102282126	C/A	cg23241863	chr10:102295624	HIF1AN	0.7	5.39	0.44	3.36e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg18305652	chr10:134549665	INPP5A	0.31	5.23	0.43	6.87e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs1062177	1.000	rs2964585	chr5:151141895	C/T	cg00977110	chr5:151150581	G3BP1	0.41	4.62	0.38	9.52e-6	Preschool internalizing problems;
TGCT	cis	rs4862307	0.720	rs12650935	chr4:184989565	G/A	cg06737308	chr4:185021514	ENPP6	0.36	5.1	0.42	1.23e-6	Serum dimethylarginine levels (asymmetric/symetric ratio);
TGCT	cis	rs6450176	1.000	rs7736354	chr5:53297591	C/T	ch.5.1024479R	chr5:53302184	ARL15	-0.53	-5.12	-0.42	1.15e-6	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs4700695	0.614	rs251618	chr5:65215939	C/T	cg21114390	chr5:65439923	SFRS12	0.64	4.89	0.4	3.07e-6	Facial morphology (factor 19);
TGCT	cis	rs7666738	0.830	rs34890015	chr4:99023769	A/T	cg18180107	chr4:99064573	C4orf37	0.57	5.24	0.43	6.72e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6089584	0.924	rs6142906	chr20:60552554	G/C	cg06108461	chr20:60628389	TAF4	-0.58	-8.16	-0.59	3.23e-13	Body mass index;
TGCT	cis	rs9393777	0.513	rs9368451	chr6:26654333	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.63	-5.75	-0.46	6.58e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7824557	0.767	rs10104728	chr8:11171300	A/G	cg21775007	chr8:11205619	TDH	0.54	5.16	0.42	9.62e-7	Retinal vascular caliber;
TGCT	cis	rs26868	0.742	rs26848	chr16:2263516	A/G	cg25665528	chr16:2260870	C16orf79	-0.34	-5.71	-0.46	7.88e-8	Height;
TGCT	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs28374715	0.532	rs28477406	chr15:41642036	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.93	-15.82	-0.82	1.59e-31	Ulcerative colitis;
TGCT	cis	rs6912958	0.967	rs6914299	chr6:88149176	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.63	-6.22	-0.49	7.06e-9	Monocyte percentage of white cells;
TGCT	cis	rs13191362	1.000	rs67487119	chr6:163102657	A/C	cg21926612	chr6:163149169	PACRG;PARK2	1.17	9.96	0.67	1.56e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg27454412	chr7:1067447	C7orf50	0.49	4.7	0.39	6.86e-6	Bronchopulmonary dysplasia;
TGCT	cis	rs4700695	0.668	rs153393	chr5:65428707	A/G	cg21114390	chr5:65439923	SFRS12	-0.89	-7.95	-0.58	9.74e-13	Facial morphology (factor 19);
TGCT	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg23982607	chr1:1823379	GNB1	-0.55	-8.57	-0.61	3.52e-14	Body mass index;
TGCT	cis	rs9296661	0.868	rs4715241	chr6:51668490	C/T	cg00593404	chr6:52377740	TRAM2	-0.27	-4.49	-0.37	1.62e-5	Weight loss (gastric bypass surgery);
TGCT	cis	rs7172809	0.599	rs75323552	chr15:77421943	A/T	cg22256960	chr15:77711686	NA	-0.49	-4.63	-0.38	9.17e-6	Glucose homeostasis traits;
TGCT	cis	rs36051895	0.632	rs10815171	chr9:5172567	G/A	cg02405213	chr9:5042618	JAK2	-0.73	-9.91	-0.66	2.12e-17	Pediatric autoimmune diseases;
TGCT	cis	rs651907	0.557	rs7651404	chr3:101393294	C/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.03	0.41	1.65e-6	Colorectal cancer;
TGCT	cis	rs10089	0.953	rs10045113	chr5:127386631	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	6.93	0.53	2e-10	Ileal carcinoids;
TGCT	cis	rs11586313	0.507	rs3856026	chr1:152869763	T/C	cg07796016	chr1:152779584	LCE1C	-0.42	-4.71	-0.39	6.65e-6	Vitamin D levels;
TGCT	cis	rs7267979	1.000	rs6076336	chr20:25319212	C/T	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9527	0.590	rs10883829	chr10:104840635	T/C	cg15744005	chr10:104629667	AS3MT	-0.42	-4.87	-0.4	3.29e-6	Arsenic metabolism;
TGCT	cis	rs3858526	0.874	rs10838879	chr11:5950169	C/T	cg13902645	chr11:5959945	NA	-0.48	-5.0	-0.41	1.95e-6	DNA methylation (variation);
TGCT	cis	rs7513165	1.000	rs7513165	chr1:204147186	C/T	cg12731349	chr1:204159619	KISS1	-0.47	-5.47	-0.44	2.41e-7	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
TGCT	cis	rs4319547	0.656	rs6488951	chr12:122873928	A/G	cg08088222	chr12:122070432	ORAI1	0.25	4.49	0.37	1.58e-5	Body mass index;
TGCT	cis	rs6754311	0.731	rs3769005	chr2:136603366	C/G	cg07169764	chr2:136633963	MCM6	-0.68	-6.17	-0.48	9.08e-9	Mosquito bite size;
TGCT	cis	rs6088590	0.901	rs6087631	chr20:33403509	T/C	cg06115741	chr20:33292138	TP53INP2	0.65	5.45	0.44	2.66e-7	Coronary artery disease;
TGCT	cis	rs539096	0.540	rs3011217	chr1:44303266	C/T	cg12908607	chr1:44402522	ARTN	0.69	8.16	0.59	3.22e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs13191362	1.000	rs34714518	chr6:163080778	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.06	8.07	0.59	5.12e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs1499614	0.901	rs2178742	chr7:66197799	G/A	cg18252515	chr7:66147081	NA	-1.23	-7.53	-0.56	9.12e-12	Gout;
TGCT	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg23574427	chr4:122746245	BBS7;CCNA2	-0.35	-5.31	-0.43	4.84e-7	Type 2 diabetes;
TGCT	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg18402987	chr7:1209562	NA	0.78	6.64	0.51	8.96e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7223966	1.000	rs9901507	chr17:61765524	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	5.17	0.42	8.94e-7	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg06238570	chr21:40685208	BRWD1	0.58	5.2	0.42	7.95e-7	Cognitive function;
TGCT	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg27211696	chr2:191398769	TMEM194B	0.3	5.4	0.44	3.22e-7	Pulse pressure;
TGCT	cis	rs7804356	0.734	rs13229947	chr7:26767430	T/C	cg03456212	chr7:26904342	SKAP2	0.52	4.52	0.38	1.4e-5	Type 1 diabetes;
TGCT	cis	rs9341808	0.718	rs3805920	chr6:80892745	T/C	cg08355045	chr6:80787529	NA	0.32	5.6	0.45	1.29e-7	Sitting height ratio;
TGCT	cis	rs9733	0.519	rs6700022	chr1:150670484	G/T	cg04414720	chr1:150670196	GOLPH3L	-0.35	-4.73	-0.39	5.88e-6	Tonsillectomy;
TGCT	trans	rs11088226	0.681	rs2833903	chr21:33940819	C/T	cg09050820	chr6:167586206	TCP10L2	0.8	7.25	0.55	3.95e-11	Gastritis;
TGCT	cis	rs7945705	0.747	rs2742480	chr11:8993130	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.43	-4.61	-0.38	9.93e-6	Hemoglobin concentration;
TGCT	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg03188948	chr7:1209495	NA	0.59	4.82	0.4	4.06e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9902453	0.740	rs2244247	chr17:28110174	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.84	-8.19	-0.59	2.73e-13	Coffee consumption (cups per day);
TGCT	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg01017244	chr2:74357527	NA	-0.37	-4.87	-0.4	3.37e-6	Gestational age at birth (maternal effect);
TGCT	cis	rs7267979	0.706	rs6037069	chr20:25234166	C/T	cg16686733	chr20:25566563	NINL	0.55	5.58	0.45	1.47e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9902453	0.845	rs2617865	chr17:28049804	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-7.27	-0.55	3.55e-11	Coffee consumption (cups per day);
TGCT	cis	rs6981523	0.517	rs13251510	chr8:10916974	A/G	cg21775007	chr8:11205619	TDH	-0.47	-4.66	-0.39	8.07e-6	Neuroticism;
TGCT	cis	rs9393777	0.513	rs9379905	chr6:26630990	G/A	cg15659132	chr6:26577336	NA	-0.77	-5.48	-0.44	2.26e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs28595532	0.640	rs28649792	chr4:119366463	A/C	cg21605333	chr4:119757512	SEC24D	0.79	5.35	0.43	4.18e-7	Cannabis dependence symptom count;
TGCT	cis	rs7524258	0.868	rs2412153	chr1:7272412	C/T	cg07173049	chr1:7289937	CAMTA1	0.29	4.86	0.4	3.45e-6	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs1552244	0.554	rs3732964	chr3:10048839	C/G	cg00149659	chr3:10157352	C3orf10	0.69	4.99	0.41	2.03e-6	Alzheimer's disease;
TGCT	cis	rs6489785	0.562	rs494632	chr12:121189116	C/T	cg02419362	chr12:121203948	SPPL3	0.21	4.88	0.4	3.23e-6	Longevity;Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs3796352	0.527	rs11714793	chr3:52924930	A/G	cg11137980	chr3:52469226	SEMA3G	0.29	4.83	0.4	3.91e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs7666738	0.830	rs35276471	chr4:99068691	A/T	cg05340658	chr4:99064831	C4orf37	0.52	5.79	0.46	5.32e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg02725872	chr8:58115012	NA	-0.32	-4.78	-0.39	4.79e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9399137	0.507	rs11757723	chr6:135291293	C/T	cg24558204	chr6:135376177	HBS1L	0.46	4.65	0.39	8.46e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
TGCT	cis	rs478304	0.934	rs574483	chr11:65515277	A/G	cg17480646	chr11:65405466	SIPA1	0.43	5.38	0.43	3.62e-7	Acne (severe);
TGCT	cis	rs9818758	0.545	rs11717978	chr3:48969036	T/A	cg07636037	chr3:49044803	WDR6	-1.0	-4.98	-0.41	2.11e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs9303401	0.659	rs72828726	chr17:56951217	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs7772486	0.875	rs1331639	chr6:146431869	A/G	cg23711669	chr6:146136114	FBXO30	-0.87	-9.27	-0.64	7.2e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs950776	0.518	rs952215	chr15:78819153	C/T	cg06917634	chr15:78832804	PSMA4	-0.95	-9.52	-0.65	1.81e-16	Sudden cardiac arrest;
TGCT	cis	rs6938	0.662	rs12487	chr15:75136694	A/G	cg10253484	chr15:75165896	SCAMP2	-0.6	-5.52	-0.44	1.93e-7	Breast cancer;
TGCT	cis	rs992157	0.965	rs62182826	chr2:219148723	C/A	cg00012203	chr2:219082015	ARPC2	0.78	8.39	0.6	9.39e-14	Colorectal cancer;
TGCT	cis	rs904251	0.861	rs1757183	chr6:37484790	C/T	cg08126542	chr6:37504118	NA	0.39	5.44	0.44	2.73e-7	Cognitive performance;
TGCT	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	6.13	0.48	1.06e-8	Bipolar disorder;
TGCT	cis	rs208520	0.690	rs4710564	chr6:66823478	A/G	cg07460842	chr6:66804631	NA	0.94	7.67	0.57	4.32e-12	Exhaled nitric oxide output;
TGCT	trans	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg21659725	chr3:3221576	CRBN	-0.67	-7.53	-0.56	9.05e-12	Body mass index;
TGCT	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.93	7.44	0.56	1.44e-11	Platelet count;
TGCT	cis	rs7523654	1.000	rs7523654	chr1:115861265	A/G	cg07790079	chr1:116021925	NA	-0.37	-4.78	-0.39	4.81e-6	Schizophrenia;
TGCT	cis	rs11587400	0.572	rs2268699	chr1:115227896	G/T	cg12756093	chr1:115239321	AMPD1	0.32	4.52	0.38	1.42e-5	Autism;
TGCT	cis	rs7208859	0.673	rs11649765	chr17:29233888	T/A	cg18442181	chr17:29233375	C17orf42	-0.78	-4.61	-0.38	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7208859	0.623	rs11650973	chr17:29214045	G/A	cg18442181	chr17:29233375	C17orf42	-0.79	-4.78	-0.39	4.95e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs9902453	0.845	rs7218113	chr17:28372130	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.81	-7.67	-0.57	4.37e-12	Coffee consumption (cups per day);
TGCT	cis	rs2880765	0.835	rs11856869	chr15:86029097	C/G	cg13263323	chr15:86062960	AKAP13	-0.22	-4.7	-0.39	6.86e-6	Coronary artery disease;
TGCT	cis	rs55665837	0.559	rs11023210	chr11:14422762	A/G	cg19336497	chr11:14380999	RRAS2	0.33	5.1	0.42	1.23e-6	Vitamin D levels;
TGCT	cis	rs9303542	0.559	rs12951076	chr17:46625109	T/C	cg25032089	chr17:46643351	HOXB3	0.55	5.21	0.42	7.78e-7	Ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs11190604	1.000	rs7079136	chr10:102292709	T/C	cg23241863	chr10:102295624	HIF1AN	0.68	5.17	0.42	9.14e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs6674176	0.593	rs6675620	chr1:44417630	C/T	cg12908607	chr1:44402522	ARTN	-0.67	-8.15	-0.59	3.4e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs1903068	0.853	rs28680424	chr4:56009245	T/C	cg09978860	chr4:56023921	NA	0.56	6.07	0.48	1.45e-8	Endometriosis;
TGCT	cis	rs151997	1.000	rs151997	chr5:50233199	A/G	cg06027927	chr5:50259733	NA	-0.48	-5.0	-0.41	1.92e-6	Callous-unemotional behaviour;
TGCT	cis	rs6460942	0.749	rs62448592	chr7:12435985	A/T	cg06484146	chr7:12443880	VWDE	-0.57	-5.52	-0.44	1.92e-7	Coronary artery disease;
TGCT	cis	rs11098499	0.754	rs2964	chr4:120240131	T/C	cg09307838	chr4:120376055	NA	0.61	5.91	0.47	3.14e-8	Corneal astigmatism;
TGCT	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg05368731	chr17:41323189	NBR1	1.1	10.91	0.7	7.88e-20	Menopause (age at onset);
TGCT	cis	rs9921222	0.597	rs7193109	chr16:413523	T/G	cg12437481	chr16:420112	MRPL28	-0.48	-4.75	-0.39	5.45e-6	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs6933660	0.745	rs6912830	chr6:151743629	A/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.62	6.17	0.48	8.69e-9	Menarche (age at onset);
TGCT	cis	rs6088590	0.561	rs6088528	chr20:33156742	G/A	cg08999081	chr20:33150536	PIGU	0.25	4.99	0.41	1.97e-6	Coronary artery disease;
TGCT	cis	rs7542091	0.666	rs7537070	chr1:210043565	A/G	cg21951975	chr1:209979733	IRF6	0.6	6.1	0.48	1.24e-8	Monobrow;
TGCT	cis	rs651907	0.535	rs11919389	chr3:101424458	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.34	-7.13	-0.54	7.37e-11	Colorectal cancer;
TGCT	cis	rs4304924	0.500	rs2281856	chr13:79207644	C/T	cg05295671	chr13:79234353	RNF219	-0.73	-5.69	-0.45	8.7e-8	Large artery stroke;
TGCT	cis	rs9796	0.717	rs2947494	chr15:41375741	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.52	-6.76	-0.52	4.79e-10	Menopause (age at onset);
TGCT	cis	rs9611565	0.802	rs132916	chr22:41806768	C/G	cg06481639	chr22:41940642	POLR3H	0.57	5.24	0.43	6.79e-7	Vitiligo;
TGCT	cis	rs58688157	0.921	rs12805435	chr11:612355	T/C	cg16486109	chr11:613632	IRF7	0.35	5.18	0.42	8.82e-7	Systemic lupus erythematosus;
TGCT	cis	rs4689388	0.890	rs1801206	chr4:6302707	C/T	cg14416269	chr4:6271139	WFS1	0.41	5.63	0.45	1.14e-7	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs1867631	1.000	rs10889640	chr1:67127851	G/A	cg13052034	chr1:66999238	SGIP1	0.56	4.78	0.39	4.85e-6	Menopause (age at onset);
TGCT	cis	rs9611565	0.512	rs139572	chr22:42214532	C/T	cg13695892	chr22:41940480	POLR3H	-0.87	-8.24	-0.59	2.06e-13	Vitiligo;
TGCT	cis	rs6570726	0.791	rs6570695	chr6:145911286	C/A	cg23711669	chr6:146136114	FBXO30	0.86	9.28	0.64	7.13e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7542091	0.704	rs1883331	chr1:210043483	A/G	cg22029157	chr1:209979665	IRF6	0.64	6.1	0.48	1.23e-8	Monobrow;
TGCT	cis	rs1008375	0.900	rs4698625	chr4:17599500	G/T	cg16339924	chr4:17578868	LAP3	0.84	6.77	0.52	4.62e-10	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10207060	0.500	rs2118399	chr2:240683795	T/C	cg07506560	chr2:240697449	NA	0.43	4.83	0.4	3.99e-6	Obesity-related traits;
TGCT	cis	rs9467773	1.000	rs9986382	chr6:26550619	T/C	cg15659132	chr6:26577336	NA	0.89	13.12	0.76	3.43e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs6430585	0.591	rs3098103	chr2:136656094	T/C	cg07169764	chr2:136633963	MCM6	1.25	12.39	0.74	1.91e-23	Corneal structure;
TGCT	cis	rs4325129	0.677	rs4540655	chr1:159478959	A/G	cg07417683	chr1:159440267	NA	0.35	4.46	0.37	1.84e-5	Obesity-related traits;
TGCT	cis	rs2594989	0.565	rs9848960	chr3:11601360	C/T	cg00170343	chr3:11313890	ATG7	-0.72	-5.41	-0.44	3.15e-7	Circulating chemerin levels;
TGCT	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs11250097	0.506	rs13281992	chr8:11309294	C/T	cg21775007	chr8:11205619	TDH	-0.57	-4.57	-0.38	1.16e-5	Neuroticism;
TGCT	cis	rs425277	0.539	rs3128338	chr1:2046786	G/A	cg03732007	chr1:2071316	PRKCZ	-0.27	-5.9	-0.47	3.26e-8	Height;
TGCT	cis	rs4372836	0.704	rs3190	chr2:29025479	A/G	cg09522027	chr2:28974177	PPP1CB	-0.7	-7.26	-0.55	3.68e-11	Body mass index;
TGCT	cis	rs981844	0.857	rs41320045	chr4:154720615	A/T	cg14289246	chr4:154710475	SFRP2	-1.01	-8.51	-0.61	4.9e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs11098499	0.863	rs36040693	chr4:120477616	A/G	cg09307838	chr4:120376055	NA	0.72	6.9	0.53	2.41e-10	Corneal astigmatism;
TGCT	cis	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg20637647	chr7:64974828	NA	0.95	5.8	0.46	5.3e-8	Diabetic kidney disease;
TGCT	cis	rs986417	0.901	rs1955696	chr14:61028271	A/G	cg27398547	chr14:60952738	C14orf39	1.13	10.75	0.69	1.94e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	4.98	0.41	2.08e-6	Prudent dietary pattern;
TGCT	cis	rs939574	1.000	rs11552796	chr2:220108300	T/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.05	6.38	0.5	3.13e-9	Platelet distribution width;
TGCT	cis	rs78487399	0.808	rs13405076	chr2:43735353	T/C	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.74	4.5	0.37	1.57e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs7043114	0.507	rs10820971	chr9:95161740	G/C	cg14311495	chr9:95764742	FGD3	-0.22	-4.52	-0.38	1.41e-5	Height;
TGCT	cis	rs12935418	0.616	rs62054241	chr16:81004613	G/A	cg07676361	chr16:80966860	NA	-0.35	-4.56	-0.38	1.19e-5	Mean corpuscular volume;
TGCT	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg10047753	chr17:41438598	NA	0.96	9.6	0.65	1.16e-16	Menopause (age at onset);
TGCT	cis	rs12136530	0.562	rs12125959	chr1:19735262	A/G	cg24875000	chr1:19041556	PAX7	-0.26	-4.62	-0.38	9.56e-6	Lead levels in blood;
TGCT	cis	rs12540874	0.542	rs3807562	chr7:50566671	G/A	cg18232548	chr7:50535776	DDC	-0.35	-6.01	-0.48	1.89e-8	Systemic sclerosis;
TGCT	cis	rs208520	0.690	rs74707865	chr6:66717352	A/G	cg07460842	chr6:66804631	NA	0.95	10.11	0.67	6.77e-18	Exhaled nitric oxide output;
TGCT	trans	rs57221529	0.709	rs4957056	chr5:570105	T/C	cg25482853	chr8:67687455	SGK3	1.18	10.06	0.67	9.09e-18	Lung disease severity in cystic fibrosis;
TGCT	cis	rs10788575	1.000	rs76774620	chr10:89751985	A/G	cg03166508	chr10:89453226	PAPSS2	0.32	4.48	0.37	1.68e-5	Type 2 diabetes;
TGCT	cis	rs7267979	1.000	rs6050559	chr20:25329915	A/G	cg16686733	chr20:25566563	NINL	0.6	5.97	0.47	2.29e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6714788	0.565	rs7558817	chr2:100654482	C/A	cg22139774	chr2:100720529	AFF3	-0.41	-6.5	-0.5	1.74e-9	Intelligence (multi-trait analysis);
TGCT	trans	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg17830980	chr10:43048298	ZNF37B	-0.82	-10.2	-0.68	4.02e-18	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2120019	1.000	rs35577967	chr15:75354621	G/A	cg09165964	chr15:75287851	SCAMP5	-1.18	-9.83	-0.66	3.33e-17	Blood trace element (Zn levels);
TGCT	trans	rs2727020	0.615	rs4980435	chr11:49591576	G/A	cg03929089	chr4:120376271	NA	-0.74	-8.99	-0.63	3.54e-15	Coronary artery disease;
TGCT	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-6.74	-0.52	5.26e-10	Alzheimer's disease;
TGCT	cis	rs1420338	1.000	rs1420338	chr7:34143256	G/A	cg01275685	chr7:34179230	BMPER	-0.26	-4.75	-0.39	5.47e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs61990749	0.597	rs10136053	chr14:78155205	G/A	cg23188588	chr14:78226832	SNW1;C14orf178	-0.66	-4.62	-0.38	9.57e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs789852	0.867	rs9288751	chr3:194316294	C/G	cg18000598	chr3:194342907	TMEM44	0.88	5.69	0.46	8.48e-8	QT interval;
TGCT	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg23758822	chr17:41437982	NA	0.72	6.81	0.52	3.77e-10	Menopause (age at onset);
TGCT	cis	rs12220238	0.908	rs11000937	chr10:75998785	A/C	cg19889307	chr10:75911429	ADK;AP3M1	0.92	7.91	0.58	1.21e-12	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs7246657	0.943	rs7248733	chr19:37996361	A/C	cg18154014	chr19:37997991	ZNF793	0.7	4.86	0.4	3.52e-6	Coronary artery calcification;
TGCT	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg20891558	chr2:74357851	NA	0.55	7.44	0.56	1.43e-11	Gestational age at birth (maternal effect);
TGCT	cis	rs1371867	0.810	rs1618528	chr8:101259134	T/C	cg00191853	chr8:101177733	SPAG1	0.22	4.5	0.37	1.53e-5	Atrioventricular conduction;
TGCT	cis	rs62244186	0.659	rs7649834	chr3:44503732	C/T	cg25151919	chr3:44754333	ZNF502	-0.39	-4.57	-0.38	1.15e-5	Depressive symptoms;
TGCT	cis	rs3862030	0.810	rs5870	chr10:104239100	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-4.61	-0.38	1e-5	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
TGCT	cis	rs433598	0.619	rs163264	chr16:20662769	A/G	cg08248577	chr16:19727447	IQCK;C16orf88	-0.22	-4.94	-0.41	2.47e-6	Schizophrenia;
TGCT	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg06238570	chr21:40685208	BRWD1	-0.82	-8.86	-0.62	7.17e-15	Cognitive function;
TGCT	cis	rs68170813	0.641	rs77397573	chr7:107006892	G/A	cg02696742	chr7:106810147	HBP1	-0.73	-5.95	-0.47	2.6e-8	Coronary artery disease;
TGCT	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg16325326	chr1:53192061	ZYG11B	0.61	6.83	0.52	3.33e-10	Monocyte count;
TGCT	cis	rs11779988	0.545	rs208764	chr8:17806270	G/A	cg01800426	chr8:17659068	MTUS1	-0.64	-4.99	-0.41	2.02e-6	Breast cancer;
TGCT	cis	rs3749237	1.000	rs6804655	chr3:49738945	C/T	cg07636037	chr3:49044803	WDR6	0.65	5.75	0.46	6.7e-8	Resting heart rate;
TGCT	cis	rs6754311	0.512	rs12998387	chr2:136507039	A/G	cg07169764	chr2:136633963	MCM6	-0.66	-6.11	-0.48	1.2e-8	Mosquito bite size;
TGCT	cis	rs6087990	0.871	rs1007122	chr20:31346001	C/T	cg13636640	chr20:31349939	DNMT3B	0.99	12.99	0.76	6.87e-25	Ulcerative colitis;
TGCT	cis	rs950169	0.887	rs71395453	chr15:85113490	G/C	cg17173187	chr15:85201210	NMB	0.47	4.93	0.4	2.62e-6	Schizophrenia;
TGCT	cis	rs10654220	1	rs10654220	chr12:123703422	A/AGTT	cg00376283	chr12:123451042	ABCB9	0.73	5.1	0.42	1.26e-6	Platelet count;
TGCT	cis	rs7312933	0.558	rs11181483	chr12:42798384	G/C	cg19980929	chr12:42632907	YAF2	0.42	5.94	0.47	2.67e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs539096	0.560	rs56201009	chr1:44098746	A/G	cg12908607	chr1:44402522	ARTN	-0.53	-5.63	-0.45	1.14e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg00814883	chr7:100076585	TSC22D4	-0.92	-9.76	-0.66	4.73e-17	Platelet count;
TGCT	cis	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg18252515	chr7:66147081	NA	-1.21	-7.89	-0.58	1.36e-12	Diabetic kidney disease;
TGCT	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7216064	0.953	rs1966410	chr17:65837215	T/C	cg12091567	chr17:66097778	LOC651250	-0.87	-6.85	-0.52	3.1e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs12477438	0.501	rs11692336	chr2:99740606	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	10.3	0.68	2.42e-18	Chronic sinus infection;
TGCT	cis	rs7937682	0.564	rs7115263	chr11:111379054	C/A	cg09085632	chr11:111637200	PPP2R1B	0.57	5.05	0.41	1.55e-6	Primary sclerosing cholangitis;
TGCT	cis	rs6722750	0.933	rs4671555	chr2:64411137	C/G	cg22352474	chr2:64371530	PELI1	-0.58	-5.16	-0.42	9.64e-7	Neuroticism;
TGCT	cis	rs1580019	0.885	rs4460269	chr7:32496445	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.79	7.42	0.55	1.63e-11	Cognitive ability;
TGCT	cis	rs62244186	0.545	rs7640654	chr3:44763037	A/C	cg21672276	chr3:44754072	ZNF502	-0.54	-6.25	-0.49	5.94e-9	Depressive symptoms;
TGCT	cis	rs6450176	1.000	rs5024170	chr5:53300827	C/A	ch.5.1024479R	chr5:53302184	ARL15	-0.53	-5.1	-0.42	1.23e-6	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs2404602	0.619	rs7342603	chr15:76982625	C/T	cg22467129	chr15:76604101	ETFA	-0.45	-5.11	-0.42	1.2e-6	Blood metabolite levels;
TGCT	cis	rs9611519	1.000	rs9611505	chr22:41540279	T/C	cg03806693	chr22:41940476	POLR3H	-0.67	-6.2	-0.49	7.87e-9	Neuroticism;
TGCT	cis	rs79387448	0.745	rs17027428	chr2:103163175	G/A	cg09003973	chr2:102972529	NA	0.92	5.89	0.47	3.39e-8	Gut microbiota (bacterial taxa);
TGCT	cis	rs2153535	0.580	rs9505446	chr6:8448691	T/C	cg07606381	chr6:8435919	SLC35B3	0.53	5.02	0.41	1.79e-6	Motion sickness;
TGCT	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg12667521	chr19:29218732	NA	0.51	6.05	0.48	1.57e-8	Methadone dose in opioid dependence;
TGCT	cis	rs911555	0.713	rs2765051	chr14:103972379	T/C	cg12935359	chr14:103987150	CKB	0.33	4.5	0.37	1.52e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs12479064	0.724	rs3087403	chr2:100058870	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.58	-4.9	-0.4	2.99e-6	Chronic sinus infection;
TGCT	cis	rs7666738	0.830	rs17027198	chr4:98991085	G/C	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg20587970	chr11:113659929	NA	-1.03	-10.98	-0.7	5.21e-20	Hip circumference adjusted for BMI;
TGCT	cis	rs1887596	0.663	rs2025413	chr13:27260914	G/A	cg01312412	chr13:27282625	NA	0.3	5.48	0.44	2.32e-7	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs10927875	0.722	rs1763605	chr1:16338925	T/G	cg22431228	chr1:16359049	CLCNKA	-0.26	-4.91	-0.4	2.79e-6	Dilated cardiomyopathy;
TGCT	cis	rs7681440	0.904	rs2301134	chr4:90758945	A/G	cg26578617	chr4:90757533	SNCA	-0.48	-4.95	-0.41	2.35e-6	Dementia with Lewy bodies;
TGCT	cis	rs6582630	0.539	rs35114325	chr12:38320886	G/T	cg26384229	chr12:38710491	ALG10B	-0.52	-4.5	-0.37	1.57e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs7582180	0.638	rs7581011	chr2:100954659	A/G	cg14675211	chr2:100938903	LONRF2	-0.51	-5.02	-0.41	1.72e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs28785552	0.800	rs10853855	chr19:53232293	A/G	cg10871876	chr19:53194124	ZNF83	0.54	7.4	0.55	1.79e-11	Response to paliperidone in schizophrenia (PANSS score);
TGCT	trans	rs28735056	0.933	rs499472	chr18:77589759	C/T	cg05926928	chr17:57297772	GDPD1	-0.71	-7.64	-0.57	5.03e-12	Schizophrenia;
TGCT	cis	rs12042938	0.935	rs751229	chr1:231768539	A/G	cg04892437	chr1:231737901	TSNAX-DISC1	0.44	4.52	0.38	1.4e-5	Neuranatomic and neurocognitive phenotypes;
TGCT	cis	rs2455799	0.573	rs924753	chr3:15706124	C/T	cg16303742	chr3:15540471	COLQ	-0.25	-4.56	-0.38	1.21e-5	Mean platelet volume;
TGCT	cis	rs3806843	0.607	rs246060	chr5:140324749	T/C	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7824557	0.628	rs7831346	chr8:11193530	C/T	cg21775007	chr8:11205619	TDH	0.7	6.86	0.52	2.93e-10	Retinal vascular caliber;
TGCT	cis	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg09307838	chr4:120376055	NA	0.69	5.85	0.46	4.13e-8	Corneal astigmatism;
TGCT	cis	rs9435341	1.000	rs9435341	chr1:107616641	T/C	cg09367891	chr1:107599246	PRMT6	-0.6	-5.38	-0.43	3.61e-7	Facial morphology (factor 21, depth of nasal alae);
TGCT	trans	rs7726839	0.540	rs72707016	chr5:665148	A/G	cg11887960	chr12:57824829	NA	1.15	9.91	0.66	2.07e-17	Obesity-related traits;
TGCT	cis	rs68170813	0.559	rs4730226	chr7:106887274	A/C	cg02696742	chr7:106810147	HBP1	-0.69	-5.61	-0.45	1.27e-7	Coronary artery disease;
TGCT	cis	rs6866344	0.697	rs17184281	chr5:178127563	G/A	cg03877680	chr5:178157825	ZNF354A	0.72	5.61	0.45	1.27e-7	Neutrophil percentage of white cells;
TGCT	cis	rs1008375	0.932	rs7677212	chr4:17675932	A/G	cg18681998	chr4:17616180	MED28	-0.86	-8.49	-0.61	5.19e-14	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs17221829	0.733	rs72952851	chr11:89393495	A/G	cg02982614	chr11:89391479	FOLH1B	-0.27	-4.66	-0.39	7.89e-6	Anxiety in major depressive disorder;
TGCT	cis	rs2303759	0.874	rs10411630	chr19:49891314	C/A	cg22307029	chr19:49891270	CCDC155	0.54	5.09	0.42	1.29e-6	Multiple sclerosis;
TGCT	cis	rs4925386	1.000	rs1889201	chr20:60923075	C/T	cg06026331	chr20:60912101	LAMA5	-0.28	-5.14	-0.42	1.03e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs10751667	1.000	rs7395632	chr11:958789	C/T	cg06064525	chr11:970664	AP2A2	0.31	6.25	0.49	6.16e-9	Alzheimer's disease (late onset);
TGCT	cis	rs1043515	0.748	rs11653487	chr17:36942631	A/G	cg09592244	chr17:37024020	NA	-0.49	-4.79	-0.39	4.77e-6	Height;
TGCT	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg04414720	chr1:150670196	GOLPH3L	0.39	5.04	0.41	1.58e-6	Tonsillectomy;
TGCT	cis	rs6882046	0.533	rs599402	chr5:88043656	G/C	cg24804195	chr5:87968844	LOC645323	-0.57	-5.69	-0.46	8.66e-8	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs1062177	0.826	rs2053063	chr5:151166764	T/C	cg12924095	chr5:151150029	G3BP1	0.34	5.02	0.41	1.78e-6	Preschool internalizing problems;
TGCT	cis	rs709400	0.633	rs8019578	chr14:103977724	A/G	cg12935359	chr14:103987150	CKB	-0.38	-5.7	-0.46	8.3e-8	Body mass index;
TGCT	cis	rs394563	0.775	rs412894	chr6:149781175	G/A	cg03678062	chr6:149772716	ZC3H12D	-0.39	-4.83	-0.4	4.03e-6	Dupuytren's disease;
TGCT	cis	rs6964587	1.000	rs7789492	chr7:91668854	C/T	cg17063962	chr7:91808500	NA	0.88	9.63	0.65	9.8e-17	Breast cancer;
TGCT	cis	rs921968	0.643	rs500317	chr2:219432953	G/C	cg02176678	chr2:219576539	TTLL4	0.44	6.33	0.49	4.17e-9	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs896854	0.684	rs2340534	chr8:95992330	G/A	cg23172400	chr8:95962367	TP53INP1	-0.36	-6.06	-0.48	1.54e-8	Type 2 diabetes;
TGCT	cis	rs17767294	0.708	rs72847370	chr6:27849424	A/T	cg08851530	chr6:28072375	NA	1.58	7.16	0.54	6.15e-11	Parkinson's disease;
TGCT	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg11764359	chr7:65958608	NA	-0.57	-4.99	-0.41	2.03e-6	Aortic root size;
TGCT	cis	rs17376456	1.000	rs12188453	chr5:93560807	G/T	cg25358565	chr5:93447407	FAM172A	-0.98	-7.65	-0.57	4.75e-12	Diabetic retinopathy;
TGCT	cis	rs9921222	0.656	rs12719801	chr16:381141	C/T	cg08923669	chr16:420230	MRPL28	-0.54	-5.34	-0.43	4.24e-7	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs9393777	0.513	rs9393737	chr6:26617306	A/G	cg06675483	chr6:26987649	LOC100270746;C6orf41	0.48	4.59	0.38	1.06e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs2013441	1.000	rs2703785	chr17:20152418	C/T	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.63	-0.38	9.19e-6	Obesity-related traits;
TGCT	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg25036284	chr2:26402008	FAM59B	0.65	5.19	0.42	8.36e-7	Gut microbiome composition (summer);
TGCT	cis	rs2486012	1.000	rs2428957	chr1:44409048	A/G	cg12908607	chr1:44402522	ARTN	0.74	5.92	0.47	2.96e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9926296	0.744	rs154657	chr16:89708096	A/G	cg03388025	chr16:89894329	SPIRE2	0.34	5.21	0.42	7.59e-7	Vitiligo;
TGCT	trans	rs1814175	0.647	rs10839394	chr11:49844747	T/C	cg03929089	chr4:120376271	NA	-0.72	-8.26	-0.6	1.84e-13	Height;
TGCT	cis	rs6840360	0.642	rs7680236	chr4:152409601	A/G	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.82e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs12210905	0.920	rs9348763	chr6:27302919	G/C	cg08851530	chr6:28072375	NA	1.32	5.79	0.46	5.48e-8	Hip circumference adjusted for BMI;
TGCT	cis	rs137699	1.000	rs2049986	chr22:39756854	C/G	cg11247378	chr22:39784982	NA	0.5	5.84	0.46	4.38e-8	IgG glycosylation;
TGCT	cis	rs7043114	0.525	rs7850432	chr9:95130510	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-5.58	-0.45	1.47e-7	Height;
TGCT	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg26354017	chr1:205819088	PM20D1	0.68	9.51	0.65	2e-16	Menarche (age at onset);
TGCT	cis	rs9790314	0.586	rs73021449	chr3:161128941	G/A	cg03342759	chr3:160939853	NMD3	-0.55	-5.66	-0.45	9.91e-8	Morning vs. evening chronotype;
TGCT	cis	rs10489202	0.632	rs202265	chr1:167990231	G/C	cg24449463	chr1:168025552	DCAF6	-0.6	-7.15	-0.54	6.45e-11	Schizophrenia;
TGCT	cis	rs7264396	0.580	rs6119655	chr20:34412049	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.28	-4.74	-0.39	5.7e-6	Total cholesterol levels;
TGCT	cis	rs899997	1.000	rs11072794	chr15:79006582	A/G	cg00061860	chr15:78953028	NA	-0.25	-4.59	-0.38	1.05e-5	Coronary artery disease or large artery stroke;
TGCT	cis	rs7666738	0.791	rs7377018	chr4:99034962	C/T	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg00814883	chr7:100076585	TSC22D4	-0.59	-5.7	-0.46	8.45e-8	Lung function (FEV1/FVC);
TGCT	cis	rs2033711	0.905	rs893186	chr19:58969179	C/A	cg12042659	chr19:58951599	ZNF132	0.56	4.94	0.41	2.51e-6	Uric acid clearance;
TGCT	trans	rs2727020	0.658	rs1851992	chr11:49438110	C/T	cg15704280	chr7:45808275	SEPT13	-0.73	-8.23	-0.59	2.15e-13	Coronary artery disease;
TGCT	cis	rs700590	0.723	rs160043	chr5:88115885	T/A	cg22951263	chr5:87985283	NA	0.55	5.33	0.43	4.45e-7	Educational attainment (years of education);
TGCT	cis	rs9894429	0.608	rs8477	chr17:79618059	C/T	cg18240062	chr17:79603768	NPLOC4	0.56	4.86	0.4	3.49e-6	Eye color traits;
TGCT	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg27535305	chr1:53392650	SCP2	-0.25	-5.06	-0.41	1.47e-6	Monocyte count;
TGCT	cis	rs7666738	0.519	rs28539191	chr4:98821552	C/T	cg18180107	chr4:99064573	C4orf37	0.54	4.61	0.38	9.77e-6	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs1814175	0.754	rs28663627	chr11:50048829	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.26	-0.55	3.77e-11	Height;
TGCT	cis	rs12477438	1.000	rs73963398	chr2:99887025	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.82	-6.44	-0.5	2.4e-9	Chronic sinus infection;
TGCT	cis	rs7246657	0.722	rs1531549	chr19:38088009	T/C	cg18154014	chr19:37997991	ZNF793	0.69	4.67	0.39	7.71e-6	Coronary artery calcification;
TGCT	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.54	4.95	0.41	2.35e-6	Prudent dietary pattern;
TGCT	cis	rs13256369	1.000	rs9329165	chr8:8576642	C/T	cg17143192	chr8:8559678	CLDN23	-0.57	-5.39	-0.44	3.48e-7	Obesity-related traits;
TGCT	cis	rs10056811	0.527	rs55798253	chr5:74380957	A/G	cg19683494	chr5:74908142	NA	0.63	5.06	0.41	1.49e-6	Coronary artery disease;
TGCT	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg06112835	chr11:68658793	MRPL21	0.46	8.1	0.59	4.37e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs79349575	0.783	rs962272	chr17:46978283	A/G	cg26022315	chr17:47021804	SNF8	0.48	4.82	0.4	4.06e-6	Type 2 diabetes;
TGCT	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg06873352	chr17:61820015	STRADA	0.55	6.1	0.48	1.26e-8	Prudent dietary pattern;
TGCT	cis	rs8017423	0.967	rs4904663	chr14:90729565	G/T	cg04374321	chr14:90722782	PSMC1	0.78	7.86	0.58	1.59e-12	Mortality in heart failure;
TGCT	cis	rs7666738	0.830	rs60007031	chr4:98824753	G/C	cg18180107	chr4:99064573	C4orf37	0.55	5.25	0.43	6.31e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9644630	0.870	rs4244453	chr8:19359711	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.27	4.66	0.39	8.01e-6	Oropharynx cancer;
TGCT	cis	rs7120118	0.517	rs3758668	chr11:47270775	C/T	cg13308137	chr11:47528955	CUGBP1	0.33	5.25	0.43	6.32e-7	HDL cholesterol;
TGCT	cis	rs12210905	0.688	rs72845232	chr6:27428126	T/G	cg08851530	chr6:28072375	NA	1.34	6.29	0.49	5.02e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs17331151	0.573	rs76029595	chr3:52868523	C/T	cg11137980	chr3:52469226	SEMA3G	0.29	5.14	0.42	1.04e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs3087591	0.960	rs12942397	chr17:29462498	C/A	cg24425628	chr17:29625626	OMG;NF1	0.48	7.4	0.55	1.77e-11	Hip circumference;
TGCT	cis	rs9393692	0.875	rs12526215	chr6:26262916	T/C	cg00631329	chr6:26305371	NA	-0.44	-6.6	-0.51	1.1e-9	Educational attainment;
TGCT	cis	rs9435341	0.965	rs1762482	chr1:107599002	A/C	cg09367891	chr1:107599246	PRMT6	-0.63	-5.52	-0.44	1.89e-7	Facial morphology (factor 21, depth of nasal alae);
TGCT	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg04944784	chr2:26401820	FAM59B	0.76	6.24	0.49	6.46e-9	Gut microbiome composition (summer);
TGCT	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg04317338	chr11:64019027	PLCB3	0.8	6.61	0.51	1.01e-9	Mean platelet volume;
TGCT	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.7	0.52	6.47e-10	Bipolar disorder;
TGCT	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg11890956	chr21:40555474	PSMG1	1.13	11.5	0.72	2.86e-21	Cognitive function;
TGCT	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg11494091	chr17:61959527	GH2	0.43	7.4	0.55	1.82e-11	Height;
TGCT	cis	rs4730250	0.802	rs77936580	chr7:106946343	G/A	cg02696742	chr7:106810147	HBP1	-0.69	-5.81	-0.46	4.85e-8	Osteoarthritis;
TGCT	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg26818010	chr10:134567672	INPP5A	-0.38	-5.37	-0.43	3.66e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs3617	0.625	rs3774364	chr3:52863605	G/A	cg10802521	chr3:52805072	NEK4	-0.57	-6.56	-0.51	1.34e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7666738	0.519	rs11732209	chr4:98801643	A/G	cg05340658	chr4:99064831	C4orf37	0.51	5.66	0.45	9.78e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6582630	0.502	rs11610978	chr12:38356957	C/G	cg26384229	chr12:38710491	ALG10B	0.78	6.98	0.53	1.56e-10	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs6570726	0.935	rs369458	chr6:145812809	A/G	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.16e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg09359103	chr1:154839909	KCNN3	-0.66	-12.15	-0.74	7.27e-23	Prostate cancer;
TGCT	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.56	-5.49	-0.44	2.13e-7	Electroencephalogram traits;
TGCT	cis	rs1499614	1.000	rs2659911	chr7:66158420	G/A	cg18252515	chr7:66147081	NA	-1.26	-7.95	-0.58	9.71e-13	Gout;
TGCT	cis	rs7258465	1.000	rs34171762	chr19:18559410	G/A	cg06462663	chr19:18546047	ISYNA1	0.2	4.63	0.38	9.01e-6	Breast cancer;
TGCT	cis	rs9914988	1.000	rs9916866	chr17:27183155	C/G	cg20469991	chr17:27169893	C17orf63	0.69	5.05	0.41	1.51e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs9807989	0.765	rs13424006	chr2:102967236	T/C	cg09003973	chr2:102972529	NA	0.64	5.7	0.46	8.28e-8	Asthma;
TGCT	cis	rs3862030	0.839	rs2274351	chr10:104264107	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.52	-4.99	-0.41	2e-6	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
TGCT	cis	rs4820539	1.000	rs4822360	chr22:23482460	A/G	cg21100191	chr22:23484243	RTDR1	0.9	10.72	0.69	2.2e-19	Bone mineral density;
TGCT	trans	rs10156309	0.555	rs16928749	chr8:63273943	C/T	cg03123541	chr1:95699097	RWDD3	0.75	6.72	0.52	5.9e-10	Allergic rhinitis;
TGCT	cis	rs9467773	0.620	rs2494716	chr6:26662736	T/C	cg26531700	chr6:26746687	NA	0.51	4.61	0.38	9.86e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6121246	0.609	rs6087783	chr20:30421224	T/G	cg13852791	chr20:30311386	BCL2L1	0.84	7.59	0.56	6.79e-12	Mean corpuscular hemoglobin;
TGCT	cis	rs992157	0.717	rs3817266	chr2:219142594	C/T	cg00012203	chr2:219082015	ARPC2	-0.79	-7.87	-0.58	1.48e-12	Colorectal cancer;
TGCT	cis	rs2760061	0.819	rs708115	chr1:228198046	C/T	cg18477163	chr1:228402036	OBSCN	0.34	7.19	0.54	5.33e-11	Diastolic blood pressure;
TGCT	cis	rs11105298	0.891	rs10858898	chr12:89922111	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.67	-4.91	-0.4	2.78e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs3733585	0.726	rs4306953	chr4:9955776	G/A	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.73	-0.57	3.25e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs1008375	1.000	rs2058337	chr4:17678649	C/T	cg18681998	chr4:17616180	MED28	0.91	10.02	0.67	1.12e-17	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg14773178	chr5:1868261	NA	0.34	5.62	0.45	1.21e-7	Cardiovascular disease risk factors;
TGCT	cis	rs2204008	0.805	rs12146846	chr12:37985847	C/T	cg26384229	chr12:38710491	ALG10B	0.86	7.77	0.57	2.55e-12	Bladder cancer;
TGCT	cis	rs7586879	0.929	rs6545807	chr2:25124358	C/T	cg01884057	chr2:25150051	NA	0.28	5.03	0.41	1.69e-6	Body mass index;
TGCT	cis	rs17345786	0.520	rs13062677	chr3:101305078	G/A	cg12386194	chr3:101231763	SENP7	0.52	5.52	0.44	1.92e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9549367	0.713	rs556990	chr13:113845059	T/C	cg00898013	chr13:113819073	PROZ	0.53	7.2	0.54	5.17e-11	Platelet distribution width;
TGCT	trans	rs561341	1.000	rs530209	chr17:30315287	A/G	cg20587970	chr11:113659929	NA	-1.04	-12.57	-0.75	6.97e-24	Hip circumference adjusted for BMI;
TGCT	cis	rs7336332	0.598	rs75439483	chr13:28010512	A/G	cg22138327	chr13:27999177	GTF3A	0.8	5.97	0.47	2.35e-8	Weight;
TGCT	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg01802117	chr1:53393560	SCP2	-0.44	-5.52	-0.44	1.86e-7	Monocyte count;
TGCT	cis	rs2204008	0.837	rs12366727	chr12:38365748	A/C	cg26384229	chr12:38710491	ALG10B	0.83	7.24	0.55	4.15e-11	Bladder cancer;
TGCT	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg02725872	chr8:58115012	NA	-0.4	-5.23	-0.42	7.07e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9420	0.961	rs499188	chr11:57434122	C/A	cg23127183	chr11:57508653	C11orf31	-0.45	-4.56	-0.38	1.23e-5	Schizophrenia;
TGCT	cis	rs7705042	0.865	rs11739961	chr5:141508488	A/C	cg23435118	chr5:141488016	NDFIP1	-0.2	-4.43	-0.37	2.01e-5	Asthma;
TGCT	cis	rs151997	0.925	rs27286	chr5:50196324	G/T	cg06027927	chr5:50259733	NA	0.48	4.95	0.41	2.41e-6	Callous-unemotional behaviour;
TGCT	cis	rs6088590	0.965	rs6087619	chr20:33288511	C/G	cg06115741	chr20:33292138	TP53INP2	0.67	5.71	0.46	8.07e-8	Coronary artery disease;
TGCT	cis	rs611744	0.647	rs6981420	chr8:109266694	T/G	cg21045802	chr8:109455806	TTC35	0.7	7.23	0.54	4.3e-11	Dupuytren's disease;
TGCT	cis	rs7917772	0.503	rs61871067	chr10:104295382	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	7.86	0.58	1.59e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg12963246	chr6:28129442	ZNF389	0.52	5.01	0.41	1.85e-6	Depression;
TGCT	trans	rs9388451	0.868	rs10457467	chr6:126045148	T/A	cg05039488	chr6:79577232	IRAK1BP1	-0.76	-8.22	-0.59	2.35e-13	Brugada syndrome;
TGCT	cis	rs12497850	0.931	rs9755490	chr3:48871664	A/C	cg07636037	chr3:49044803	WDR6	0.94	10.39	0.68	1.46e-18	Parkinson's disease;
TGCT	cis	rs72627509	0.638	rs78272732	chr4:57870537	T/A	cg26694713	chr4:57773883	REST	0.62	4.63	0.38	9.06e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs6598955	0.671	rs57386998	chr1:26569821	G/A	cg04990556	chr1:26633338	UBXN11	0.64	5.11	0.42	1.19e-6	Obesity-related traits;
TGCT	cis	rs514406	0.893	rs6588446	chr1:53425260	G/A	cg16325326	chr1:53192061	ZYG11B	-0.61	-6.93	-0.53	2.05e-10	Monocyte count;
TGCT	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.06	-9.6	-0.65	1.15e-16	Platelet count;
TGCT	cis	rs35160687	0.901	rs13017338	chr2:86501553	T/C	cg12542933	chr2:85804724	VAMP8	0.39	4.7	0.39	6.7e-6	Night sleep phenotypes;
TGCT	cis	rs10086908	0.669	rs1456310	chr8:128052433	C/T	cg26031047	chr8:127570723	FAM84B	0.5	4.91	0.4	2.78e-6	Prostate cancer (SNP x SNP interaction);Prostate cancer;
TGCT	cis	rs9952991	0.883	rs2847260	chr18:12775591	C/T	cg09945482	chr18:12777974	NA	0.5	4.75	0.39	5.61e-6	Inflammatory skin disease;
TGCT	cis	rs36051895	0.659	rs67006981	chr9:5070401	A/G	cg02405213	chr9:5042618	JAK2	-0.74	-9.47	-0.65	2.46e-16	Pediatric autoimmune diseases;
TGCT	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg13393036	chr8:95962371	TP53INP1	-0.65	-8.88	-0.62	6.27e-15	Type 2 diabetes;
TGCT	cis	rs1577917	1.000	rs35419329	chr6:86702291	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.54	-0.45	1.73e-7	Response to antipsychotic treatment;
TGCT	cis	rs2242194	0.816	rs6671688	chr1:154994265	T/C	cg12436631	chr1:155007014	DCST1;DCST2	0.26	7.21	0.54	4.84e-11	Schizophrenia;
TGCT	cis	rs903263	0.965	rs11163906	chr1:84594533	T/C	cg09664975	chr1:84543551	PRKACB	0.5	4.74	0.39	5.73e-6	Breast cancer (male);
TGCT	cis	rs9611565	0.592	rs6519270	chr22:42078666	A/G	cg06481639	chr22:41940642	POLR3H	0.6	5.18	0.42	8.77e-7	Vitiligo;
TGCT	cis	rs9913156	0.894	rs35741745	chr17:4620897	A/G	cg00122941	chr17:4613640	ARRB2	0.94	8.09	0.59	4.57e-13	Lymphocyte counts;
TGCT	cis	rs11031096	0.542	rs2412338	chr11:3977521	G/T	cg18678763	chr11:4115507	RRM1	-0.41	-5.09	-0.42	1.27e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs864643	1.000	rs634338	chr3:39564243	C/T	cg14968361	chr3:39543547	MOBP	-0.48	-4.48	-0.37	1.68e-5	Attention deficit hyperactivity disorder;
TGCT	cis	rs1018836	0.884	rs7823461	chr8:91581075	T/C	cg16814680	chr8:91681699	NA	-0.89	-9.58	-0.65	1.3e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1670533	1.000	rs1670533	chr4:1078187	G/A	cg20887711	chr4:1340912	KIAA1530	0.7	5.55	0.45	1.64e-7	Recombination rate (females);
TGCT	cis	rs7208859	0.673	rs61223749	chr17:29163747	G/A	cg14008862	chr17:28927542	LRRC37B2	0.72	4.66	0.39	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs885389	0.924	rs7957882	chr12:131617417	G/T	cg07124762	chr12:131619285	GPR133	-0.31	-6.5	-0.5	1.72e-9	RR interval (heart rate);
TGCT	cis	rs6750047	0.526	rs464603	chr2:38318131	G/C	cg07380506	chr2:38303506	CYP1B1	0.59	5.47	0.44	2.37e-7	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs5769765	0.773	rs9616382	chr22:50312979	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.43	6.08	0.48	1.35e-8	Schizophrenia;
TGCT	cis	rs782590	0.902	rs782600	chr2:55848040	T/C	cg18811423	chr2:55921094	PNPT1	0.65	6.91	0.53	2.23e-10	Metabolic syndrome;
TGCT	cis	rs3784262	0.934	rs7164408	chr15:58259336	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.49	-7.7	-0.57	3.78e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs6740322	0.895	rs10172375	chr2:43572047	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.38	-6.24	-0.49	6.33e-9	Coronary artery disease;
TGCT	cis	rs9467773	1.000	rs1056667	chr6:26510564	T/C	cg05738196	chr6:26577821	NA	0.88	12.49	0.75	1.09e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs7552404	1.000	rs12126607	chr1:76217097	G/A	cg22875332	chr1:76189707	ACADM	0.76	9.2	0.64	1.1e-15	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg15556689	chr8:8085844	FLJ10661	0.72	6.52	0.51	1.63e-9	Mood instability;
TGCT	cis	rs2072499	1.000	rs2540173	chr1:156188214	A/G	cg24450063	chr1:156163899	SLC25A44	1.14	16.5	0.83	4.43e-33	Testicular germ cell tumor;
TGCT	cis	rs7809950	0.871	rs11771278	chr7:107285925	C/T	cg23024343	chr7:107201750	COG5	0.29	4.77	0.39	4.99e-6	Coronary artery disease;
TGCT	cis	rs2456568	0.741	rs9633811	chr11:93628327	A/G	cg14291919	chr11:93583693	C11orf90	0.41	4.53	0.38	1.34e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs10782582	0.593	rs12132750	chr1:76136222	A/G	cg22875332	chr1:76189707	ACADM	-0.54	-6.21	-0.49	7.36e-9	Daytime sleep phenotypes;
TGCT	cis	rs9611565	0.512	rs9607842	chr22:42192722	G/A	cg17554472	chr22:41940697	POLR3H	-0.44	-4.6	-0.38	1.03e-5	Vitiligo;
TGCT	cis	rs6912958	0.559	rs369674	chr6:88043402	C/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.4	-4.7	-0.39	6.83e-6	Monocyte percentage of white cells;
TGCT	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg24675658	chr1:53192096	ZYG11B	-0.7	-7.9	-0.58	1.26e-12	Monocyte count;
TGCT	cis	rs1371867	0.846	rs1660327	chr8:101292206	A/C	cg06002616	chr8:101225028	SPAG1	-0.56	-6.58	-0.51	1.2e-9	Atrioventricular conduction;
TGCT	cis	rs10089	1.000	rs13356473	chr5:127478250	T/G	cg19767477	chr5:127420684	SLC12A2	-0.43	-4.56	-0.38	1.21e-5	Ileal carcinoids;
TGCT	cis	rs2300747	0.872	rs11588376	chr1:117072524	T/C	cg26677431	chr1:117075710	CD58	-0.23	-4.46	-0.37	1.78e-5	Primary biliary cholangitis;Multiple sclerosis;
TGCT	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	5.08	0.42	1.35e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs926938	0.618	rs3121506	chr1:115363207	T/G	cg12756093	chr1:115239321	AMPD1	0.42	6.0	0.47	2.04e-8	Autism;
TGCT	cis	rs3820068	0.705	rs4646109	chr1:15817319	T/C	cg05660106	chr1:15850417	CASP9	1.15	14.12	0.79	1.41e-27	Systolic blood pressure;
TGCT	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.66	0.39	8.18e-6	Prudent dietary pattern;
TGCT	cis	rs4808199	0.895	rs8105984	chr19:19374068	T/C	cg03709012	chr19:19516395	GATAD2A	0.8	6.04	0.48	1.66e-8	Nonalcoholic fatty liver disease;
TGCT	cis	rs9486719	0.843	rs3860231	chr6:97036563	G/A	cg18709589	chr6:96969512	KIAA0776	-0.78	-6.38	-0.5	3.24e-9	Migraine;Coronary artery disease;
TGCT	cis	rs892961	0.899	rs72896163	chr17:75412525	C/T	cg05865280	chr17:75406074	SEPT9	0.28	6.86	0.52	2.9e-10	Airflow obstruction;
TGCT	cis	rs7267979	0.966	rs2424714	chr20:25418681	T/G	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10411936	1.000	rs11878602	chr19:16555153	A/C	cg19006008	chr19:16999768	F2RL3	-0.27	-4.73	-0.39	5.95e-6	White blood cell count;Multiple sclerosis;
TGCT	cis	rs10501293	0.746	rs10768908	chr11:43020214	C/T	cg03447554	chr11:43094025	NA	0.43	6.14	0.48	1.03e-8	Cognitive performance;
TGCT	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg11905131	chr22:24372483	LOC391322	-0.95	-11.13	-0.71	2.26e-20	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9329289	1.000	rs9329289	chr10:2542389	A/G	cg15501526	chr10:2543763	NA	0.39	4.91	0.4	2.8e-6	Age-related hearing impairment;
TGCT	cis	rs66887589	0.616	rs10032299	chr4:120206419	C/T	cg24670566	chr4:120433619	PDE5A	0.21	4.57	0.38	1.14e-5	Diastolic blood pressure;
TGCT	cis	rs9393692	0.905	rs989134	chr6:26336224	A/C	cg00631329	chr6:26305371	NA	-0.4	-5.81	-0.46	4.97e-8	Educational attainment;
TGCT	cis	rs6835098	1.000	rs6814857	chr4:174082805	T/A	cg08422745	chr4:174089978	GALNT7	-0.91	-10.41	-0.68	1.31e-18	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg03303774	chr4:1407052	NA	-0.32	-4.88	-0.4	3.21e-6	Obesity-related traits;
TGCT	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg03517284	chr6:25882590	NA	0.78	8.11	0.59	4.26e-13	Blood metabolite levels;
TGCT	cis	rs7666738	0.800	rs28427190	chr4:98989106	A/G	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7772486	0.658	rs9403737	chr6:145962193	G/T	cg23711669	chr6:146136114	FBXO30	0.88	9.78	0.66	4.39e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg17264618	chr3:40429014	ENTPD3	0.32	4.57	0.38	1.18e-5	Renal cell carcinoma;
TGCT	cis	rs1472147	1.000	rs3736609	chr7:128509319	G/A	cg05395852	chr7:128750384	NA	0.17	4.58	0.38	1.11e-5	Calcium levels;
TGCT	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg04414720	chr1:150670196	GOLPH3L	0.39	5.13	0.42	1.09e-6	Tonsillectomy;
TGCT	cis	rs281408	0.559	rs204248	chr19:49216224	G/C	cg13540341	chr19:49222985	MAMSTR	0.47	7.23	0.54	4.25e-11	Urinary metabolites (H-NMR features);
TGCT	cis	rs1008375	0.932	rs4698628	chr4:17608620	A/G	cg18681998	chr4:17616180	MED28	0.98	10.43	0.68	1.17e-18	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9393692	0.578	rs806795	chr6:26205293	G/A	cg05868516	chr6:26286170	HIST1H4H	0.51	4.87	0.4	3.27e-6	Educational attainment;
TGCT	cis	rs6840360	0.554	rs58751443	chr4:152709905	A/G	cg17479576	chr4:152424074	FAM160A1	-0.51	-5.22	-0.42	7.21e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7617773	0.780	rs77044321	chr3:48349314	C/T	cg11946769	chr3:48343235	NME6	0.82	7.09	0.54	9.1e-11	Coronary artery disease;
TGCT	cis	rs7666738	0.791	rs1426674	chr4:98924247	C/A	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7524258	0.867	rs916392	chr1:7271930	T/C	cg07173049	chr1:7289937	CAMTA1	0.31	5.24	0.43	6.74e-7	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs2228479	0.850	rs17226428	chr16:89842884	T/A	cg06558623	chr16:89946397	TCF25	0.45	4.52	0.38	1.42e-5	Skin colour saturation;
TGCT	cis	rs10114408	0.959	rs10126012	chr9:96634101	C/T	cg13679303	chr9:96623674	NA	-0.35	-4.58	-0.38	1.1e-5	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg03188948	chr7:1209495	NA	0.5	5.23	0.43	6.99e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-5.1	-0.42	1.23e-6	Bipolar disorder;
TGCT	cis	rs950169	0.840	rs2896002	chr15:84945121	A/G	cg12863693	chr15:85201151	NMB	0.45	4.96	0.41	2.28e-6	Schizophrenia;
TGCT	cis	rs734999	0.588	rs2764841	chr1:2529360	G/A	cg18854424	chr1:2615690	NA	-0.5	-5.9	-0.47	3.25e-8	Ulcerative colitis;
TGCT	cis	rs6089584	0.528	rs4925335	chr20:60627034	G/A	cg06108461	chr20:60628389	TAF4	-0.43	-5.2	-0.42	7.98e-7	Body mass index;
TGCT	cis	rs1797081	0.646	rs7090256	chr10:16851949	T/G	cg14835575	chr10:16859367	RSU1	0.45	5.46	0.44	2.47e-7	Platelet distribution width;
TGCT	cis	rs1577917	0.959	rs12201739	chr6:86720739	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.54	-0.45	1.73e-7	Response to antipsychotic treatment;
TGCT	cis	rs9291683	0.530	rs6449196	chr4:9973660	C/T	cg00071950	chr4:10020882	SLC2A9	-0.65	-8.23	-0.59	2.24e-13	Bone mineral density;
TGCT	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg04234412	chr22:24373322	LOC391322	-0.92	-11.65	-0.72	1.19e-21	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs4285028	0.948	rs34837785	chr3:121657776	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.77	-6.5	-0.5	1.78e-9	Multiple sclerosis;
TGCT	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg00814883	chr7:100076585	TSC22D4	-0.9	-9.56	-0.65	1.5e-16	Platelet count;
TGCT	cis	rs12477438	0.520	rs2632277	chr2:99778985	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	18.53	0.86	1.57e-37	Chronic sinus infection;
TGCT	cis	rs6964587	0.839	rs17731846	chr7:91440342	A/G	cg17063962	chr7:91808500	NA	0.87	9.22	0.64	9.51e-16	Breast cancer;
TGCT	cis	rs6998277	0.830	rs7017839	chr8:103610769	G/C	cg10187029	chr8:103597600	NA	0.56	8.73	0.62	1.41e-14	Migraine;
TGCT	cis	rs12643440	0.538	rs10489117	chr4:17145568	G/T	cg22650099	chr4:17144496	NA	-0.49	-5.03	-0.41	1.66e-6	Metabolite levels (Pyroglutamine);
TGCT	cis	rs10114408	0.959	rs2153062	chr9:96653752	A/C	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs8014204	0.935	rs2300596	chr14:75353855	C/T	cg06637938	chr14:75390232	RPS6KL1	0.7	6.76	0.52	4.74e-10	Caffeine consumption;
TGCT	cis	rs71435601	0.600	rs479545	chr2:21389897	T/C	cg25035485	chr2:21266500	APOB	0.51	4.48	0.37	1.64e-5	Cholesterol, total;
TGCT	cis	rs17401966	0.838	rs8019	chr1:10366487	T/G	cg19773385	chr1:10388646	KIF1B	-0.23	-5.04	-0.41	1.6e-6	Hepatocellular carcinoma;
TGCT	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg24399712	chr22:39784796	NA	-1.06	-12.58	-0.75	6.72e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg03188948	chr7:1209495	NA	0.68	5.8	0.46	5.09e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs4713118	0.628	rs9295740	chr6:27689502	G/A	cg10876282	chr6:28092338	ZSCAN16	0.64	5.29	0.43	5.39e-7	Parkinson's disease;
TGCT	cis	rs2832077	0.527	rs2738953	chr21:30238363	G/C	cg24692254	chr21:30365293	RNF160	0.59	4.98	0.41	2.04e-6	Cognitive test performance;
TGCT	cis	rs6121246	0.559	rs6060922	chr20:30333909	C/T	cg13852791	chr20:30311386	BCL2L1	0.82	8.0	0.58	7.65e-13	Mean corpuscular hemoglobin;
TGCT	trans	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg27523141	chr10:43048294	ZNF37B	0.73	8.58	0.61	3.32e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs533581	0.866	rs865102	chr16:88969969	A/G	cg16701003	chr16:89028210	CBFA2T3	0.35	4.78	0.39	4.93e-6	Social autistic-like traits;
TGCT	cis	rs7017914	0.902	rs34882924	chr8:71566308	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.5	-4.68	-0.39	7.37e-6	Bone mineral density;
TGCT	cis	rs7249142	0.573	rs2238668	chr19:19282597	A/G	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.56	5.55	0.45	1.64e-7	IgG glycosylation;
TGCT	cis	rs4906332	1.000	rs12889703	chr14:103872951	T/A	cg26031613	chr14:104095156	KLC1	-0.51	-4.65	-0.39	8.49e-6	Coronary artery disease;
TGCT	cis	rs453301	0.652	rs2043129	chr8:8825504	C/G	cg11995313	chr8:8860691	ERI1	-0.56	-4.95	-0.41	2.35e-6	Joint mobility (Beighton score);
TGCT	cis	rs72781680	0.716	rs2551325	chr2:23979729	C/T	cg08917208	chr2:24149416	ATAD2B	0.75	5.04	0.41	1.59e-6	Lymphocyte counts;
TGCT	cis	rs854765	0.583	rs12452219	chr17:17829423	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	7.77	0.57	2.58e-12	Total body bone mineral density;
TGCT	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg09222892	chr1:25734099	RHCE	-0.42	-6.65	-0.51	8.38e-10	Erythrocyte sedimentation rate;
TGCT	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg06221963	chr1:154839813	KCNN3	-0.82	-15.75	-0.82	2.27e-31	Prostate cancer;
TGCT	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	5.49	0.44	2.17e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs478304	0.651	rs11537193	chr11:65500003	A/C	cg27068330	chr11:65405492	SIPA1	-0.94	-9.4	-0.65	3.49e-16	Acne (severe);
TGCT	cis	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg20637647	chr7:64974828	NA	1.0	5.59	0.45	1.4e-7	Diabetic kidney disease;
TGCT	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg01448562	chr3:133502909	NA	-0.26	-5.06	-0.41	1.49e-6	Iron status biomarkers;
TGCT	cis	rs593982	0.925	rs3953806	chr11:65505153	C/T	cg08755490	chr11:65554678	OVOL1	-1.48	-10.77	-0.7	1.68e-19	Atopic dermatitis;
TGCT	cis	rs9788721	0.836	rs72738736	chr15:78765122	G/T	cg18825076	chr15:78729989	IREB2	-0.32	-5.02	-0.41	1.76e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
TGCT	cis	rs2204008	0.515	rs11495471	chr12:38027178	G/A	cg26384229	chr12:38710491	ALG10B	0.85	7.62	0.56	5.71e-12	Bladder cancer;
TGCT	cis	rs7267979	1.000	rs2184000	chr20:25395878	G/A	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7027203	0.663	rs4428726	chr9:96623559	T/G	cg14396892	chr9:96623032	NA	-0.28	-5.71	-0.46	7.98e-8	DNA methylation (variation);
TGCT	cis	rs9807989	0.507	rs1420094	chr2:103015687	C/T	cg03938978	chr2:103052716	IL18RAP	0.27	5.41	0.44	3.17e-7	Asthma;
TGCT	cis	rs12776158	1.000	rs12776158	chr10:71218094	T/C	cg12610070	chr10:71211762	TSPAN15	-0.59	-5.17	-0.42	9.16e-7	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs6840360	1.000	rs6818667	chr4:152598698	T/C	cg17479576	chr4:152424074	FAM160A1	-0.5	-5.4	-0.44	3.26e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9372253	0.967	rs1055301	chr6:110713042	A/G	cg19196401	chr6:110721138	DDO	-0.48	-7.05	-0.53	1.1e-10	Platelet distribution width;
TGCT	cis	rs13393800	0.536	rs2697801	chr2:233382123	G/A	cg26635044	chr2:233757626	NGEF	0.18	5.0	0.41	1.92e-6	Height;
TGCT	cis	rs11098499	0.691	rs12502524	chr4:120271414	G/A	cg09307838	chr4:120376055	NA	0.56	5.5	0.44	2.05e-7	Corneal astigmatism;
TGCT	cis	rs7824557	0.603	rs6995404	chr8:11182148	C/G	cg21775007	chr8:11205619	TDH	0.62	6.14	0.48	1.03e-8	Retinal vascular caliber;
TGCT	cis	rs4766566	0.590	rs4766567	chr12:111707556	G/A	cg10833066	chr12:111807467	FAM109A	0.33	4.65	0.39	8.5e-6	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
TGCT	cis	rs17270561	0.887	rs9358870	chr6:25719210	T/C	cg15022984	chr6:26056706	HIST1H1C	-0.7	-4.62	-0.38	9.28e-6	Iron status biomarkers;
TGCT	cis	rs62380364	0.805	rs2362109	chr5:88148041	C/T	cg22951263	chr5:87985283	NA	-0.48	-4.62	-0.38	9.39e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs11719291	0.833	rs11709246	chr3:48859498	G/A	cg07636037	chr3:49044803	WDR6	-1.0	-4.98	-0.41	2.11e-6	Cognitive function;
TGCT	cis	rs6060960	0.502	rs15817	chr20:30193538	A/G	cg21427119	chr20:30132790	HM13	-0.38	-5.63	-0.45	1.14e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
TGCT	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg13695892	chr22:41940480	POLR3H	0.93	8.53	0.61	4.2e-14	Vitiligo;
TGCT	cis	rs6988636	0.710	rs73339623	chr8:124140288	A/G	cg22384356	chr8:124195192	FAM83A	-0.42	-4.59	-0.38	1.06e-5	Urinary uromodulin levels;
TGCT	cis	rs796364	0.951	rs281793	chr2:200847990	G/A	cg17644776	chr2:200775616	C2orf69	0.31	4.87	0.4	3.37e-6	Schizophrenia;
TGCT	cis	rs3820068	0.608	rs11544523	chr1:15904318	C/T	cg05660106	chr1:15850417	CASP9	1.16	14.26	0.79	6.71e-28	Systolic blood pressure;
TGCT	cis	rs4788570	0.615	rs4788822	chr16:71681515	A/G	cg06353428	chr16:71660113	MARVELD3	1.52	12.45	0.75	1.36e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs2070488	0.662	rs7375040	chr3:38469116	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.72	5.94	0.47	2.7e-8	Electrocardiographic conduction measures;
TGCT	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg16325326	chr1:53192061	ZYG11B	0.57	6.26	0.49	5.62e-9	Monocyte count;
TGCT	cis	rs1857353	1.000	rs58248429	chr1:75923753	G/A	cg11838876	chr1:75668600	SLC44A5	-0.51	-4.81	-0.4	4.23e-6	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs595982	0.501	rs112370206	chr19:49396623	C/T	cg21252483	chr19:49399788	TULP2	-0.3	-5.05	-0.41	1.54e-6	Red cell distribution width;
TGCT	cis	rs7666738	0.830	rs34135615	chr4:99001325	C/T	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs854765	0.724	rs2955371	chr17:17967397	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.77	-7.93	-0.58	1.1e-12	Total body bone mineral density;
TGCT	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg07343612	chr16:622815	PIGQ	-0.42	-8.4	-0.6	8.47e-14	Height;
TGCT	cis	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg25427524	chr10:38739819	LOC399744	-0.41	-8.54	-0.61	4.04e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs854765	0.547	rs28537385	chr17:17902135	G/A	cg04398451	chr17:18023971	MYO15A	-0.32	-5.15	-0.42	1.01e-6	Total body bone mineral density;
TGCT	cis	rs35306767	0.855	rs55708963	chr10:925712	C/A	cg20503657	chr10:835505	NA	0.77	11.34	0.71	6.95e-21	Eosinophil percentage of granulocytes;
TGCT	cis	rs6912958	0.781	rs6454631	chr6:88225863	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.51	-4.85	-0.4	3.69e-6	Monocyte percentage of white cells;
TGCT	cis	rs752010	0.714	rs6664708	chr1:42083070	G/A	cg06885757	chr1:42089581	HIVEP3	0.25	4.45	0.37	1.92e-5	Lupus nephritis in systemic lupus erythematosus;
TGCT	cis	rs7659604	0.605	rs67772833	chr4:122723106	G/A	cg19748678	chr4:122722346	EXOSC9	0.82	8.75	0.62	1.27e-14	Type 2 diabetes;
TGCT	cis	rs7772486	0.817	rs2144477	chr6:146406248	C/T	cg05347473	chr6:146136440	FBXO30	0.56	5.22	0.42	7.31e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7819412	0.654	rs4840550	chr8:11029029	T/G	cg21775007	chr8:11205619	TDH	-0.56	-5.2	-0.42	8.06e-7	Triglycerides;
TGCT	cis	rs7772486	0.875	rs2748498	chr6:146319166	C/G	cg05347473	chr6:146136440	FBXO30	0.54	5.13	0.42	1.08e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7428	1.000	rs72840063	chr2:85550396	T/A	cg24342717	chr2:85555507	TGOLN2	-0.41	-6.54	-0.51	1.43e-9	Ear protrusion;
TGCT	cis	rs9549367	0.789	rs3850451	chr13:113905812	C/G	cg00898013	chr13:113819073	PROZ	-0.4	-5.03	-0.41	1.64e-6	Platelet distribution width;
TGCT	cis	rs2346177	0.874	rs4953372	chr2:46651624	C/G	cg26688816	chr2:46740690	ATP6V1E2	0.42	4.51	0.38	1.47e-5	HDL cholesterol;
TGCT	cis	rs9910055	0.530	rs2269908	chr17:42294198	G/C	cg19774624	chr17:42201019	HDAC5	-0.71	-7.51	-0.56	9.96e-12	Total body bone mineral density;
TGCT	cis	rs1153858	1.000	rs12595087	chr15:45655232	A/G	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.62e-8	Homoarginine levels;
TGCT	cis	rs4478858	0.611	rs7527645	chr1:31763787	T/C	cg07478791	chr1:31886160	SERINC2	-0.49	-4.91	-0.4	2.82e-6	Alcohol dependence;
TGCT	cis	rs10782582	0.609	rs5745325	chr1:76269460	G/A	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.52	4.54	0.38	1.31e-5	Daytime sleep phenotypes;
TGCT	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg09365446	chr1:150670422	GOLPH3L	0.3	4.49	0.37	1.63e-5	Tonsillectomy;
TGCT	cis	rs612683	0.602	rs12565245	chr1:101019326	T/G	cg06223162	chr1:101003688	GPR88	0.35	6.09	0.48	1.3e-8	Breast cancer;
TGCT	trans	rs3107575	0.572	rs73169365	chr3:165319778	T/C	cg04770195	chr16:53114571	CHD9	1.14	6.64	0.51	8.63e-10	Morning vs. evening chronotype;
TGCT	cis	rs523522	0.962	rs2168319	chr12:120933217	C/T	cg12219531	chr12:120966889	COQ5	0.83	7.28	0.55	3.4e-11	High light scatter reticulocyte count;
TGCT	cis	rs35306767	0.623	rs36051896	chr10:1155747	T/C	cg18964960	chr10:1102726	WDR37	0.65	4.45	0.37	1.93e-5	Eosinophil percentage of granulocytes;
TGCT	cis	rs6448317	0.954	rs12186333	chr4:24919774	T/C	cg21108841	chr4:24914750	CCDC149	-0.63	-4.81	-0.4	4.29e-6	Heschl's gyrus morphology;
TGCT	cis	rs12477438	0.798	rs6736064	chr2:99658201	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-6.1	-0.48	1.22e-8	Chronic sinus infection;
TGCT	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg00684032	chr4:1343700	KIAA1530	0.25	5.09	0.42	1.28e-6	Obesity-related traits;
TGCT	cis	rs1008375	0.932	rs4698630	chr4:17614692	C/G	cg18681998	chr4:17616180	MED28	1.07	11.25	0.71	1.13e-20	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs929354	0.742	rs6459734	chr7:156935454	A/G	cg05182265	chr7:156933206	UBE3C	-0.39	-8.98	-0.63	3.72e-15	Body mass index;
TGCT	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg11890956	chr21:40555474	PSMG1	1.11	12.17	0.74	6.69e-23	Cognitive function;
TGCT	cis	rs1062177	0.502	rs10463321	chr5:151323905	T/G	cg12924095	chr5:151150029	G3BP1	0.4	5.52	0.44	1.93e-7	Preschool internalizing problems;
TGCT	cis	rs6939532	0.648	rs9379862	chr6:26370707	T/C	cg05738196	chr6:26577821	NA	-0.58	-5.0	-0.41	1.89e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7714584	1.000	rs2115069	chr5:150252365	G/A	cg22134413	chr5:150180641	NA	0.88	6.69	0.51	6.89e-10	Crohn's disease;
TGCT	cis	rs8103278	0.507	rs8112282	chr19:46265029	C/T	cg11657440	chr19:46296263	DMWD	0.74	7.77	0.57	2.62e-12	Coronary artery disease;
TGCT	cis	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg18252515	chr7:66147081	NA	-1.31	-8.18	-0.59	2.87e-13	Diabetic kidney disease;
TGCT	cis	rs694419	0.602	rs1606890	chr18:60181802	A/G	cg13506219	chr18:60193840	ZCCHC2	-0.55	-4.93	-0.4	2.58e-6	Serum albumin level;
TGCT	cis	rs7119038	0.818	rs11217032	chr11:118669605	T/A	cg19308663	chr11:118741387	NA	0.31	6.43	0.5	2.56e-9	Sjögren's syndrome;
TGCT	cis	rs2288073	0.965	rs72789923	chr2:24394504	A/C	cg02683114	chr2:24398427	C2orf84	-0.25	-5.61	-0.45	1.26e-7	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs10197940	0.578	rs2432957	chr2:152287897	A/C	cg19508488	chr2:152266495	RIF1	0.59	5.03	0.41	1.71e-6	Lung cancer;
TGCT	cis	rs6752107	0.967	rs3792111	chr2:234179690	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.19	4.7	0.39	6.87e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs4478858	0.698	rs7543348	chr1:31804805	A/C	cg00250761	chr1:31883323	NA	-0.28	-4.96	-0.41	2.32e-6	Alcohol dependence;
TGCT	cis	rs11098499	0.954	rs67265404	chr4:120359270	C/T	cg09307838	chr4:120376055	NA	0.68	6.53	0.51	1.54e-9	Corneal astigmatism;
TGCT	cis	rs2354432	0.556	rs72710311	chr1:146698256	A/G	cg25205988	chr1:146714368	CHD1L	-1.15	-4.8	-0.4	4.49e-6	Mitochondrial DNA levels;
TGCT	cis	rs1784581	0.651	rs1784590	chr6:162389462	C/A	cg17173639	chr6:162384350	PARK2	-0.47	-8.16	-0.59	3.15e-13	Itch intensity from mosquito bite;
TGCT	cis	rs6750047	0.625	rs336037	chr2:38261124	T/C	cg07380506	chr2:38303506	CYP1B1	-0.58	-5.2	-0.42	8.09e-7	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs55883249	0.957	rs62119432	chr2:9753939	C/T	cg23886495	chr2:9695866	ADAM17	0.79	4.66	0.39	8.09e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs926938	0.501	rs360686	chr1:115502524	C/T	cg12756093	chr1:115239321	AMPD1	0.38	5.6	0.45	1.29e-7	Autism;
TGCT	cis	rs28374715	0.787	rs11856169	chr15:41547938	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.83	-11.73	-0.73	7.87e-22	Ulcerative colitis;
TGCT	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg08439880	chr3:133502540	NA	-0.29	-5.42	-0.44	2.93e-7	Iron status biomarkers;
TGCT	cis	rs79976124	0.797	rs79522358	chr6:66641140	C/G	cg07460842	chr6:66804631	NA	0.57	5.22	0.42	7.44e-7	Type 2 diabetes;
TGCT	cis	rs2050392	0.928	rs2250077	chr10:30702929	A/G	cg18806716	chr10:30721971	MAP3K8	-0.46	-5.5	-0.44	2.04e-7	Inflammatory bowel disease;
TGCT	trans	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg27523141	chr10:43048294	ZNF37B	0.73	8.49	0.61	5.22e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2309752	1	rs2309752	chr2:100762169	T/A	cg22139774	chr2:100720529	AFF3	-0.45	-8.1	-0.59	4.29e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs644799	0.562	rs1313288	chr11:95520695	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.57	6.21	0.49	7.25e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7255045	0.742	rs4804738	chr19:12953183	T/G	cg23899408	chr19:12877188	HOOK2	-0.61	-4.94	-0.41	2.48e-6	Mean corpuscular volume;
TGCT	cis	rs6674176	0.660	rs2108202	chr1:44395786	A/G	cg12908607	chr1:44402522	ARTN	0.74	9.15	0.63	1.43e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg11764359	chr7:65958608	NA	-0.56	-5.04	-0.41	1.61e-6	Aortic root size;
TGCT	cis	rs9393777	0.513	rs9393741	chr6:26654189	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.63	-5.75	-0.46	6.58e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs1055129	0.655	rs7216615	chr17:73833910	T/C	cg10935138	chr17:73851978	WBP2	0.51	4.47	0.37	1.72e-5	White matter hyperintensity burden;
TGCT	cis	rs4654899	0.965	rs17418249	chr1:21390582	C/T	cg01072550	chr1:21505969	NA	-0.49	-7.94	-0.58	1.05e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs1008375	0.966	rs1476836	chr4:17585014	G/C	cg10189774	chr4:17578691	LAP3	0.64	5.61	0.45	1.28e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	trans	rs208520	1.000	rs72882086	chr6:66976671	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.86	7.83	0.58	1.85e-12	Exhaled nitric oxide output;
TGCT	cis	rs1801251	0.896	rs4973561	chr2:233687337	C/G	cg25237894	chr2:233734115	C2orf82	-0.27	-5.0	-0.41	1.94e-6	Coronary artery disease;
TGCT	cis	rs11792861	0.619	rs2289481	chr9:111712924	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.67	7.59	0.56	6.76e-12	Menarche (age at onset);
TGCT	cis	rs1018836	0.786	rs10956736	chr8:91602067	C/T	cg16814680	chr8:91681699	NA	-0.71	-7.25	-0.55	3.89e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg11941060	chr3:133502564	NA	-0.29	-6.26	-0.49	5.88e-9	Iron status biomarkers;
TGCT	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg19626725	chr5:178986131	RUFY1	-0.55	-7.38	-0.55	1.96e-11	Lung cancer;
TGCT	cis	rs899997	1.000	rs11633170	chr15:79004642	A/G	cg04896959	chr15:78267971	NA	-0.35	-4.81	-0.4	4.27e-6	Coronary artery disease or large artery stroke;
TGCT	cis	rs8044995	0.563	rs2279540	chr16:68395061	T/C	cg05110241	chr16:68378359	PRMT7	-0.36	-4.46	-0.37	1.84e-5	Schizophrenia;
TGCT	cis	rs709400	0.894	rs56017123	chr14:104075277	G/A	cg26031613	chr14:104095156	KLC1	1.15	16.05	0.82	4.72e-32	Body mass index;
TGCT	cis	rs7666738	0.830	rs4472144	chr4:98956494	G/A	cg17366294	chr4:99064904	C4orf37	0.72	7.39	0.55	1.87e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1997103	1.000	rs4947503	chr7:55409427	G/T	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg20999797	chr1:1681921	NA	0.19	5.16	0.42	9.55e-7	Body mass index;
TGCT	cis	rs11690462	0.963	rs7585892	chr2:26609469	G/A	cg04726446	chr2:26624865	C2orf39	0.43	4.63	0.38	9.15e-6	Coronary artery disease;
TGCT	cis	rs4733781	0.901	rs4733571	chr8:131290664	T/G	cg16277922	chr8:131349729	ASAP1	0.38	4.91	0.4	2.82e-6	Tuberculosis;
TGCT	cis	rs6752107	0.935	rs11688431	chr2:234147175	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.2	4.91	0.4	2.8e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs2997447	0.802	rs61776621	chr1:26459058	C/G	cg03844060	chr1:26490628	NA	0.27	4.44	0.37	2e-5	QRS complex (12-leadsum);
TGCT	cis	rs11614913	0.551	rs1867297	chr12:54396971	A/G	cg05643303	chr12:54402714	HOXC8	-0.71	-5.84	-0.46	4.28e-8	Waist circumference adjusted for body mass index;
TGCT	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg27588902	chr6:42928151	GNMT	-0.56	-6.91	-0.53	2.23e-10	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs7829975	0.536	rs2980439	chr8:8094870	G/A	cg08975724	chr8:8085496	FLJ10661	0.63	5.92	0.47	2.94e-8	Mood instability;
TGCT	cis	rs12477438	0.501	rs11692336	chr2:99740606	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	14.89	0.8	2.21e-29	Chronic sinus infection;
TGCT	cis	rs36051895	0.664	rs17425637	chr9:5110000	C/T	cg02405213	chr9:5042618	JAK2	-0.7	-9.06	-0.63	2.38e-15	Pediatric autoimmune diseases;
TGCT	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg22029157	chr1:209979665	IRF6	0.76	6.24	0.49	6.3e-9	Cleft lip with or without cleft palate;
TGCT	cis	rs62064224	0.791	rs11654833	chr17:30667728	C/T	cg09324608	chr17:30823087	MYO1D	0.24	4.59	0.38	1.09e-5	Schizophrenia;
TGCT	cis	rs3087591	0.708	rs1129506	chr17:29646032	G/A	cg24425628	chr17:29625626	OMG;NF1	0.35	5.01	0.41	1.82e-6	Hip circumference;
TGCT	cis	rs617219	0.596	rs2131977	chr5:78613916	G/C	cg05890484	chr5:78407552	BHMT	-0.38	-5.16	-0.42	9.59e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs8077577	0.895	rs16960983	chr17:18104568	A/T	cg09161412	chr17:18057145	MYO15A	-0.61	-5.15	-0.42	9.98e-7	Obesity-related traits;
TGCT	cis	rs62244186	0.748	rs4682987	chr3:44674996	C/T	cg09333631	chr3:44802604	KIF15;KIAA1143	-0.4	-4.45	-0.37	1.86e-5	Depressive symptoms;
TGCT	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg01570182	chr17:44337453	NA	1.07	9.81	0.66	3.57e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs28595532	0.920	rs116331303	chr4:119754542	T/C	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	trans	rs57221529	0.709	rs72707023	chr5:667620	G/A	cg11887960	chr12:57824829	NA	1.14	9.47	0.65	2.39e-16	Lung disease severity in cystic fibrosis;
TGCT	cis	rs3617	0.573	rs9860296	chr3:52913781	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.56	-0.38	1.2e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs875971	0.862	rs709609	chr7:65560561	A/G	cg11764359	chr7:65958608	NA	-0.56	-4.82	-0.4	4.1e-6	Aortic root size;
TGCT	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg22166914	chr1:53195759	ZYG11B	-0.39	-6.57	-0.51	1.22e-9	Monocyte count;
TGCT	cis	rs2718812	0.766	rs1822744	chr3:133366227	A/G	cg08048268	chr3:133502702	NA	-0.38	-4.73	-0.39	6.03e-6	Iron status biomarkers;
TGCT	cis	rs2637266	0.703	rs846624	chr10:78541381	G/A	cg18941641	chr10:78392320	NA	0.39	4.63	0.38	9.26e-6	Pulmonary function;
TGCT	cis	rs7086627	0.515	rs4934189	chr10:82214792	C/T	cg01528321	chr10:82214614	TSPAN14	0.65	6.22	0.49	7.09e-9	Post bronchodilator FEV1;
TGCT	cis	rs2301573	1.000	rs12635414	chr3:129312981	G/A	cg12216435	chr3:128995479	COPG	0.51	4.52	0.38	1.42e-5	Hip circumference;
TGCT	cis	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg08564027	chr20:61660810	NA	0.37	6.64	0.51	8.71e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg24060327	chr5:131705240	SLC22A5	0.71	7.64	0.57	5.04e-12	Breast cancer;
TGCT	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg24060327	chr5:131705240	SLC22A5	-0.73	-7.83	-0.58	1.83e-12	Breast cancer;
TGCT	cis	rs4563143	0.502	rs73029061	chr19:29283980	T/A	cg14983838	chr19:29218262	NA	0.86	7.07	0.54	9.71e-11	Methadone dose in opioid dependence;
TGCT	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.36	0.55	2.26e-11	Prudent dietary pattern;
TGCT	cis	rs8072100	0.840	rs56952963	chr17:45493826	T/C	cg08085267	chr17:45401833	C17orf57	-0.51	-5.71	-0.46	8.04e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs2180341	1.000	rs7776136	chr6:127638348	A/T	cg27446573	chr6:127587934	RNF146	1.07	9.67	0.66	8.11e-17	Breast cancer;
TGCT	cis	rs7216064	0.684	rs62084675	chr17:66027025	A/G	cg12091567	chr17:66097778	LOC651250	1.07	8.8	0.62	9.68e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs2354432	0.556	rs12568866	chr1:146718430	A/C	cg25205988	chr1:146714368	CHD1L	-1.34	-6.07	-0.48	1.44e-8	Mitochondrial DNA levels;
TGCT	cis	rs3784262	0.631	rs6493980	chr15:58352290	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.42	-6.24	-0.49	6.32e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs13223928	0.565	rs10240820	chr7:3154415	T/C	cg19214707	chr7:3157722	NA	-0.49	-6.96	-0.53	1.72e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
TGCT	cis	rs12142240	0.698	rs17413701	chr1:46818452	A/G	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg18188782	chr20:61659543	NA	0.44	5.37	0.43	3.73e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs854765	0.547	rs2955355	chr17:17948475	G/A	cg09796270	chr17:17721594	SREBF1	-0.26	-5.16	-0.42	9.37e-7	Total body bone mineral density;
TGCT	cis	rs9383153	1.000	rs9370888	chr6:16335544	A/G	cg06493612	chr6:15502050	JARID2	0.63	5.44	0.44	2.77e-7	Gambling;
TGCT	cis	rs1034435	0.755	rs5767173	chr22:48892473	T/C	cg05992904	chr22:48892994	FAM19A5	-0.34	-4.65	-0.39	8.44e-6	Late-onset Alzheimer's disease;
TGCT	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg16325326	chr1:53192061	ZYG11B	-0.84	-11.96	-0.73	2.15e-22	Monocyte count;
TGCT	trans	rs12103	0.749	rs2649599	chr1:1305493	A/G	cg16196077	chr10:64028521	RTKN2	-0.92	-10.18	-0.67	4.67e-18	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs7267979	0.844	rs2257649	chr20:25263457	T/G	cg16686733	chr20:25566563	NINL	0.52	4.93	0.4	2.61e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg13607699	chr17:42295918	UBTF	0.6	5.51	0.44	1.96e-7	Total body bone mineral density;
TGCT	cis	rs244731	0.959	rs4976677	chr5:176629546	G/A	cg16006841	chr5:176797999	RGS14	-0.53	-6.95	-0.53	1.88e-10	Urate levels in lean individuals;
TGCT	cis	rs7552404	0.824	rs1251077	chr1:76189745	C/G	cg03433033	chr1:76189801	ACADM	-0.9	-14.45	-0.79	2.31e-28	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs4654899	0.895	rs10916865	chr1:21136610	C/T	cg01072550	chr1:21505969	NA	0.51	8.07	0.59	5.11e-13	Superior frontal gyrus grey matter volume;
TGCT	cis	rs447735	0.565	rs10852626	chr16:89914633	T/G	cg04287289	chr16:89883240	FANCA	0.69	6.59	0.51	1.15e-9	Hemoglobin concentration;
TGCT	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	8.0	0.58	7.67e-13	Platelet count;
TGCT	cis	rs4984778	0.750	rs7198064	chr16:1272472	C/T	cg07748719	chr16:1272498	TPSG1	0.51	6.51	0.5	1.7e-9	Blood protein levels;
TGCT	cis	rs736408	0.812	rs2071507	chr3:52826707	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	4.62	0.38	9.39e-6	Bipolar disorder;
TGCT	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg08645402	chr16:4508243	NA	0.21	5.02	0.41	1.76e-6	Schizophrenia;
TGCT	cis	rs17401966	0.858	rs61778404	chr1:10432879	A/G	cg19773385	chr1:10388646	KIF1B	-0.24	-5.5	-0.44	2.03e-7	Hepatocellular carcinoma;
TGCT	cis	rs904251	0.523	rs2776920	chr6:37480605	G/A	cg08126542	chr6:37504118	NA	-0.46	-6.64	-0.51	8.96e-10	Cognitive performance;
TGCT	cis	rs9383153	0.793	rs2016498	chr6:16344914	C/T	cg14009473	chr6:15502099	JARID2	0.65	5.76	0.46	6.2e-8	Gambling;
TGCT	cis	rs8017423	0.935	rs9944124	chr14:90791501	T/C	cg04374321	chr14:90722782	PSMC1	0.74	7.09	0.54	8.75e-11	Mortality in heart failure;
TGCT	cis	rs2070488	1.000	rs7373816	chr3:38490443	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	9.66	0.66	8.59e-17	Electrocardiographic conduction measures;
TGCT	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg24399712	chr22:39784796	NA	-1.06	-12.58	-0.75	6.72e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg04317338	chr11:64019027	PLCB3	0.78	6.42	0.5	2.63e-9	Mean platelet volume;
TGCT	cis	rs10946940	1.000	rs10946940	chr6:27560587	A/G	cg10876282	chr6:28092338	ZSCAN16	-0.46	-4.73	-0.39	6.01e-6	Systemic lupus erythematosus;
TGCT	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg11644478	chr21:40555479	PSMG1	-0.65	-5.89	-0.47	3.34e-8	Cognitive function;
TGCT	cis	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg25427524	chr10:38739819	LOC399744	-0.4	-8.36	-0.6	1.05e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs61935443	1.000	rs61935443	chr12:95249764	G/C	cg21533806	chr12:95267307	NA	0.52	4.55	0.38	1.26e-5	Schizophrenia;
TGCT	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	8.55	0.61	3.84e-14	Platelet count;
TGCT	cis	rs7147624	1.000	rs2411349	chr14:66214426	T/C	cg03016385	chr14:66212404	NA	-0.5	-7.11	-0.54	8.15e-11	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs74181299	0.819	rs2252867	chr2:65296280	T/C	cg05010058	chr2:65284262	CEP68	0.43	4.71	0.39	6.58e-6	Pulse pressure;
TGCT	cis	rs7246657	0.941	rs12982333	chr19:37794724	A/G	cg18154014	chr19:37997991	ZNF793	0.81	5.56	0.45	1.61e-7	Coronary artery calcification;
TGCT	cis	rs11971779	0.646	rs58682779	chr7:139084712	C/T	cg07862535	chr7:139043722	LUC7L2	0.79	5.8	0.46	5.13e-8	Diisocyanate-induced asthma;
TGCT	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg10802521	chr3:52805072	NEK4	-0.78	-10.09	-0.67	7.59e-18	Bipolar disorder;
TGCT	cis	rs524281	1.000	rs527897	chr11:65900777	C/T	cg00563793	chr11:65837595	PACS1	0.52	4.67	0.39	7.69e-6	Electroencephalogram traits;
TGCT	cis	rs78487399	0.808	rs7564886	chr2:43733028	G/T	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.74	4.5	0.37	1.57e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs12286929	1.000	rs12286929	chr11:115022404	A/G	cg04017736	chr11:115827165	NA	-0.19	-4.44	-0.37	1.98e-5	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs8077889	0.871	rs8081101	chr17:41904332	C/T	cg26893861	chr17:41843967	DUSP3	1.09	13.08	0.76	4.26e-25	Triglycerides;
TGCT	cis	rs4253772	0.637	rs9627350	chr22:46663017	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.57	4.48	0.37	1.69e-5	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs459571	0.959	rs2810491	chr9:136923331	C/T	cg13789015	chr9:136890014	NCRNA00094	-0.39	-7.04	-0.53	1.16e-10	Platelet distribution width;
TGCT	cis	rs911186	0.812	rs6932590	chr6:27248931	T/C	cg11262757	chr6:27280423	POM121L2	0.6	4.77	0.39	5.04e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7666738	0.753	rs2903143	chr4:99040480	C/T	cg18180107	chr4:99064573	C4orf37	0.56	5.08	0.41	1.37e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs896854	0.654	rs4735337	chr8:95973465	T/C	cg09323728	chr8:95962352	TP53INP1	-0.52	-6.6	-0.51	1.05e-9	Type 2 diabetes;
TGCT	cis	rs6728302	0.557	rs73002000	chr2:233254052	C/T	cg06555452	chr2:233241558	NA	0.36	5.06	0.41	1.49e-6	Height;
TGCT	cis	rs533581	0.816	rs533406	chr16:88974860	A/G	cg16701003	chr16:89028210	CBFA2T3	0.34	4.76	0.39	5.2e-6	Social autistic-like traits;
TGCT	cis	rs1497406	0.744	rs10907282	chr1:16510139	A/G	cg20430773	chr1:16534157	ARHGEF19	0.55	6.11	0.48	1.18e-8	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs35306767	0.761	rs11253557	chr10:1043667	C/T	cg18964960	chr10:1102726	WDR37	0.79	5.55	0.45	1.67e-7	Eosinophil percentage of granulocytes;
TGCT	cis	rs1215050	0.791	rs649866	chr4:98738826	T/C	cg05340658	chr4:99064831	C4orf37	0.44	5.62	0.45	1.2e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7833790	0.724	rs6473309	chr8:82707880	A/G	cg27398817	chr8:82754497	SNX16	-0.68	-5.34	-0.43	4.28e-7	Diastolic blood pressure;
TGCT	cis	rs727505	1.000	rs56387611	chr7:124479180	G/A	cg23710748	chr7:124431027	NA	-0.26	-4.49	-0.37	1.6e-5	Lewy body disease;
TGCT	cis	rs7552167	0.925	rs3932666	chr1:24511566	G/A	cg01960748	chr1:24522592	NA	-0.49	-5.49	-0.44	2.13e-7	Psoriasis vulgaris;
TGCT	cis	rs2639990	1.000	rs632157	chr18:72911548	G/A	cg18449964	chr18:72917101	ZADH2	0.92	6.07	0.48	1.46e-8	Vascular endothelial growth factor levels;
TGCT	cis	rs12477438	0.798	rs6761570	chr2:99577276	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-6.25	-0.49	5.98e-9	Chronic sinus infection;
TGCT	cis	rs9611565	0.512	rs5758436	chr22:42124265	C/T	cg17554472	chr22:41940697	POLR3H	0.47	5.04	0.41	1.63e-6	Vitiligo;
TGCT	cis	rs1008375	0.606	rs6828925	chr4:17561139	C/T	cg18681998	chr4:17616180	MED28	0.75	7.46	0.56	1.34e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs929354	0.742	rs1182396	chr7:157031831	A/C	cg05182265	chr7:156933206	UBE3C	0.39	8.85	0.62	7.32e-15	Body mass index;
TGCT	cis	rs7772486	0.875	rs2748485	chr6:146332421	T/C	cg23711669	chr6:146136114	FBXO30	0.86	9.55	0.65	1.57e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs12765878	0.967	rs10883941	chr10:105650782	C/T	cg11005552	chr10:105648138	OBFC1	0.44	7.7	0.57	3.69e-12	Coronary artery disease;
TGCT	cis	rs17122693	0.748	rs61607560	chr14:51143649	C/T	cg04730355	chr14:51134070	SAV1	1.33	12.04	0.73	1.37e-22	Cognitive performance;
TGCT	cis	rs1129187	0.805	rs1053538	chr6:42903763	C/G	cg18735214	chr6:43276756	CRIP3	-0.53	-4.56	-0.38	1.21e-5	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs3774830	0.967	rs1004375	chr4:5438478	G/A	cg26943120	chr4:5472116	STK32B	0.21	4.63	0.38	8.96e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs13102973	0.720	rs13122447	chr4:135887524	C/T	cg14419869	chr4:135874104	NA	0.26	4.6	0.38	1.03e-5	Subjective well-being;
TGCT	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg17971929	chr21:40555470	PSMG1	0.97	9.4	0.65	3.57e-16	Cognitive function;
TGCT	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg03609598	chr5:56110824	MAP3K1	-0.58	-4.66	-0.39	7.94e-6	Initial pursuit acceleration;
TGCT	cis	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg15556689	chr8:8085844	FLJ10661	0.73	7.28	0.55	3.34e-11	Mood instability;
TGCT	cis	rs314370	1.000	rs12705089	chr7:100465355	C/T	cg10426581	chr7:100472382	SRRT	0.98	10.52	0.69	7e-19	Resting heart rate;
TGCT	cis	rs4851254	0.618	rs7572939	chr2:100654914	A/G	cg22139774	chr2:100720529	AFF3	-0.46	-4.97	-0.41	2.16e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg16680214	chr1:154839983	KCNN3	-0.35	-7.11	-0.54	8.04e-11	Prostate cancer;
TGCT	cis	rs6938	0.596	rs11072511	chr15:75159433	A/G	cg10253484	chr15:75165896	SCAMP2	-0.52	-4.79	-0.39	4.77e-6	Breast cancer;
TGCT	trans	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg21659725	chr3:3221576	CRBN	-0.67	-7.53	-0.56	9.05e-12	Body mass index;
TGCT	cis	rs6582630	0.519	rs11495373	chr12:38275470	T/C	cg13010199	chr12:38710504	ALG10B	0.6	4.65	0.39	8.32e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs3820068	0.705	rs72645808	chr1:15870118	G/C	cg05660106	chr1:15850417	CASP9	1.13	13.14	0.76	3.06e-25	Systolic blood pressure;
TGCT	cis	rs2742417	1.000	rs2742421	chr3:45732515	G/T	cg04837898	chr3:45731254	SACM1L	0.55	5.68	0.45	9.14e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs8044995	0.563	rs56899435	chr16:68395675	G/A	cg05110241	chr16:68378359	PRMT7	-0.36	-4.46	-0.37	1.84e-5	Schizophrenia;
TGCT	cis	rs4891159	0.790	rs4891018	chr18:74127082	A/T	cg24786174	chr18:74118243	ZNF516	-0.59	-8.98	-0.63	3.73e-15	Longevity;
TGCT	trans	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg13615516	chr5:77269221	NA	-0.68	-8.33	-0.6	1.3e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs12477438	0.798	rs4850891	chr2:99574642	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.7	-6.22	-0.49	7.15e-9	Chronic sinus infection;
TGCT	trans	rs561341	0.740	rs11080174	chr17:30208521	C/A	cg20587970	chr11:113659929	NA	0.65	8.98	0.63	3.67e-15	Hip circumference adjusted for BMI;
TGCT	cis	rs2836950	0.585	rs1029004	chr21:40615343	A/G	cg11644478	chr21:40555479	PSMG1	-0.52	-4.84	-0.4	3.78e-6	Menarche (age at onset);
TGCT	cis	rs74233809	1.000	rs10458729	chr10:104841479	C/T	cg05855489	chr10:104503620	C10orf26	0.79	4.56	0.38	1.19e-5	Birth weight;
TGCT	cis	rs11651000	0.817	rs7502875	chr17:45823227	A/C	cg06532163	chr17:45867833	NA	0.35	4.99	0.41	2.01e-6	IgG glycosylation;
TGCT	cis	rs11754661	1.000	rs73011397	chr6:151205678	A/G	cg11579907	chr6:151412213	MTHFD1L	0.54	4.9	0.4	2.99e-6	Alzheimer's disease (late onset);
TGCT	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg10295955	chr4:187884368	NA	0.94	14.0	0.78	2.69e-27	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1008375	0.900	rs6851783	chr4:17578469	A/G	cg10189774	chr4:17578691	LAP3	0.61	5.15	0.42	9.88e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1903068	0.927	rs12331507	chr4:56011889	A/G	cg01777861	chr4:56023843	NA	-0.49	-5.68	-0.45	9.21e-8	Endometriosis;
TGCT	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg06238570	chr21:40685208	BRWD1	0.72	6.58	0.51	1.16e-9	Cognitive function;
TGCT	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg00343986	chr7:65444356	GUSB	-0.22	-4.88	-0.4	3.13e-6	Aortic root size;
TGCT	cis	rs62244186	0.748	rs6441861	chr3:44652287	A/G	cg15687855	chr3:44754131	ZNF502	-0.45	-5.4	-0.44	3.24e-7	Depressive symptoms;
TGCT	cis	rs3820928	0.874	rs1917127	chr2:227895125	A/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-4.96	-0.41	2.29e-6	Pulmonary function;
TGCT	cis	rs3008870	0.916	rs2025608	chr1:67422550	C/T	cg11518657	chr1:67396239	MIER1	0.54	4.61	0.38	9.72e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs1670533	1.000	rs62879260	chr4:1050850	T/C	cg20887711	chr4:1340912	KIAA1530	0.7	5.66	0.45	9.77e-8	Recombination rate (females);
TGCT	cis	rs11754661	1.000	rs73011386	chr6:151196854	C/T	cg01354656	chr6:151411710	MTHFD1L	0.48	4.49	0.37	1.61e-5	Alzheimer's disease (late onset);
TGCT	cis	rs2456568	0.709	rs1354765	chr11:93637776	G/T	cg17595323	chr11:93583763	C11orf90	0.47	6.28	0.49	5.27e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs4455778	0.538	rs4288325	chr7:49130239	G/A	cg26309511	chr7:48887640	NA	0.5	6.47	0.5	2.02e-9	Lung cancer in never smokers;
TGCT	cis	rs7666738	0.830	rs10010223	chr4:99021758	G/A	cg18180107	chr4:99064573	C4orf37	0.54	5.03	0.41	1.7e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2469997	1.000	rs2447171	chr8:120360953	C/T	cg00681363	chr8:120844660	TAF2	0.69	4.48	0.37	1.64e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs7412746	0.658	rs11581757	chr1:150892244	A/G	cg09365446	chr1:150670422	GOLPH3L	0.33	4.73	0.39	6.05e-6	Melanoma;
TGCT	cis	rs79349575	0.749	rs46521	chr17:46988529	A/G	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.44	-0.37	1.95e-5	Type 2 diabetes;
TGCT	cis	rs11190604	1.000	rs7079756	chr10:102302105	G/A	cg23241863	chr10:102295624	HIF1AN	0.72	5.33	0.43	4.52e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7586879	0.616	rs6722587	chr2:25132192	C/A	cg01884057	chr2:25150051	NA	0.36	7.1	0.54	8.43e-11	Body mass index;
TGCT	cis	rs8017423	0.967	rs55894943	chr14:90714799	A/G	cg04374321	chr14:90722782	PSMC1	0.74	7.5	0.56	1.09e-11	Mortality in heart failure;
TGCT	cis	rs7809950	0.954	rs2189839	chr7:107230026	A/G	cg23024343	chr7:107201750	COG5	0.35	5.41	0.44	3.18e-7	Coronary artery disease;
TGCT	cis	rs17152411	0.895	rs7084646	chr10:126585738	T/C	cg07906193	chr10:126599966	NA	0.41	5.05	0.41	1.52e-6	Height;
TGCT	cis	rs561341	0.740	rs11080174	chr17:30208521	C/A	cg13647721	chr17:30228624	UTP6	-0.61	-4.81	-0.4	4.26e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg04287289	chr16:89883240	FANCA	0.93	11.83	0.73	4.42e-22	Vitiligo;
TGCT	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg17971929	chr21:40555470	PSMG1	0.94	9.11	0.63	1.78e-15	Cognitive function;
TGCT	cis	rs6089829	0.926	rs6011552	chr20:61667894	T/C	cg08564027	chr20:61660810	NA	0.36	6.5	0.5	1.77e-9	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs739401	0.611	rs402276	chr11:3051404	C/G	cg05729581	chr11:3078854	CARS	-0.55	-5.15	-0.42	9.85e-7	Longevity;
TGCT	cis	rs9929218	0.529	rs8059194	chr16:68749663	C/T	cg01251360	chr16:68772225	CDH1	-0.26	-4.9	-0.4	2.88e-6	Colorectal cancer;
TGCT	cis	rs7666738	0.791	rs1527516	chr4:98967937	A/C	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs921968	0.541	rs55996799	chr2:219558193	C/G	cg02176678	chr2:219576539	TTLL4	-0.5	-6.98	-0.53	1.56e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs9916302	0.752	rs6503513	chr17:37561613	A/G	cg07936489	chr17:37558343	FBXL20	0.91	7.57	0.56	7.21e-12	Glomerular filtration rate (creatinine);
TGCT	cis	rs11096990	0.634	rs10019594	chr4:39288747	C/T	cg20847110	chr4:39482781	LOC401127	-0.16	-4.51	-0.38	1.48e-5	Cognitive function;
TGCT	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.69	-7.19	-0.54	5.48e-11	Prostate cancer;
TGCT	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg12564285	chr5:131593104	PDLIM4	0.4	4.84	0.4	3.79e-6	Acylcarnitine levels;
TGCT	cis	rs9660992	0.639	rs1151786	chr1:205227760	G/C	cg00857998	chr1:205179979	DSTYK	0.52	4.65	0.39	8.41e-6	Mean corpuscular volume;Mean platelet volume;
TGCT	cis	rs1577917	1.000	rs12205336	chr6:86722367	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.13	-0.42	1.07e-6	Response to antipsychotic treatment;
TGCT	cis	rs9926296	0.624	rs1110331	chr16:89774396	A/G	cg09028487	chr16:89985162	MC1R	-0.52	-4.49	-0.37	1.58e-5	Vitiligo;
TGCT	cis	rs9611565	0.649	rs4822050	chr22:42177453	C/G	cg17554472	chr22:41940697	POLR3H	-0.44	-4.68	-0.39	7.53e-6	Vitiligo;
TGCT	cis	rs2180341	1.000	rs9398837	chr6:127635217	G/A	cg24812749	chr6:127587940	RNF146	0.98	7.64	0.57	5.06e-12	Breast cancer;
TGCT	cis	rs28595532	0.920	rs116105567	chr4:119746204	C/T	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs7666738	0.830	rs1967977	chr4:98966141	A/G	cg05340658	chr4:99064831	C4orf37	0.53	5.93	0.47	2.84e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9443189	0.762	rs2748944	chr6:76436106	A/G	cg01950844	chr6:76311363	SENP6	0.62	4.48	0.37	1.69e-5	Prostate cancer;
TGCT	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg03806693	chr22:41940476	POLR3H	-1.13	-12.67	-0.75	4.12e-24	Vitiligo;
TGCT	cis	rs3960554	0.569	rs10464565	chr7:75869526	T/G	cg19105122	chr7:75896889	SRRM3	0.58	4.98	0.41	2.1e-6	Eotaxin levels;
TGCT	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg02725872	chr8:58115012	NA	-0.36	-4.83	-0.4	3.97e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs12477438	0.798	rs972768	chr2:99682397	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-6.1	-0.48	1.22e-8	Chronic sinus infection;
TGCT	cis	rs4285028	0.656	rs2141487	chr3:121482765	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	1.03	8.75	0.62	1.26e-14	Multiple sclerosis;
TGCT	cis	rs1865760	1.000	rs2071297	chr6:25924513	C/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.65	-6.11	-0.48	1.18e-8	Height;
TGCT	cis	rs7267979	0.816	rs376742	chr20:25487417	A/C	cg03522245	chr20:25566470	NINL	0.56	5.74	0.46	6.76e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1692580	0.807	rs12040414	chr1:2192948	T/C	cg21194808	chr1:2205498	SKI	0.29	5.78	0.46	5.71e-8	Coronary artery disease;
TGCT	cis	rs9818758	0.607	rs56306491	chr3:49314960	G/A	cg00383909	chr3:49044727	WDR6	1.31	6.76	0.52	4.72e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs12188164	0.965	rs11744539	chr5:451425	C/T	cg21144161	chr5:423903	AHRR	0.25	4.79	0.4	4.59e-6	Cystic fibrosis severity;
TGCT	cis	rs2296887	0.591	rs7897947	chr10:104157711	T/G	cg26089160	chr10:104170217	PSD	-0.67	-6.37	-0.5	3.43e-9	Parkinson's disease;
TGCT	cis	rs910316	0.737	rs175071	chr14:75498177	A/G	cg11812906	chr14:75593930	NEK9	-0.58	-5.44	-0.44	2.7e-7	Height;
TGCT	trans	rs7726839	0.794	rs10053310	chr5:595661	C/G	cg25482853	chr8:67687455	SGK3	0.97	7.64	0.57	5.1e-12	Obesity-related traits;
TGCT	cis	rs11122272	0.735	rs2009873	chr1:231499236	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-6.63	-0.51	9.1e-10	Hemoglobin concentration;
TGCT	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg07298985	chr8:22133076	PIWIL2	0.34	5.41	0.44	3.07e-7	Hypertriglyceridemia;
TGCT	cis	rs9368481	0.729	rs9379948	chr6:26944783	T/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.46	5.21	0.42	7.7300000000000005e-07	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7617773	0.780	rs3197223	chr3:48335857	C/T	cg11946769	chr3:48343235	NME6	0.81	6.96	0.53	1.71e-10	Coronary artery disease;
TGCT	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg21017887	chr14:105400489	NA	0.38	5.42	0.44	3.03e-7	Rheumatoid arthritis;
TGCT	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg11247378	chr22:39784982	NA	-0.73	-9.59	-0.65	1.22e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs4822044	0.680	rs8138780	chr22:42097462	A/T	cg06634786	chr22:41940651	POLR3H	0.9	8.74	0.62	1.34e-14	Cannabis dependence symptom count;
TGCT	cis	rs28374715	0.662	rs691907	chr15:41474657	C/G	cg18705301	chr15:41695430	NDUFAF1	0.74	11.02	0.7	4.25e-20	Ulcerative colitis;
TGCT	cis	rs8064299	0.655	rs734232	chr17:72765731	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	0.58	5.43	0.44	2.87e-7	Monocyte count;
TGCT	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg06640241	chr16:89574553	SPG7	0.81	9.38	0.64	4.02e-16	Multiple myeloma (IgH translocation);
TGCT	cis	rs10791097	0.694	rs10160281	chr11:130742788	T/C	cg12179176	chr11:130786555	SNX19	0.84	10.17	0.67	4.95e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs319204	0.843	rs319170	chr5:146290208	T/C	cg25021259	chr5:146258546	PPP2R2B	0.35	4.49	0.37	1.64e-5	Schizophrenia;
TGCT	cis	rs2180341	0.814	rs6919277	chr6:127738050	T/C	cg24812749	chr6:127587940	RNF146	0.75	6.07	0.48	1.41e-8	Breast cancer;
TGCT	cis	rs1372520	0.627	rs2737025	chr4:90719192	A/G	cg14346243	chr4:90757452	SNCA	-0.68	-5.64	-0.45	1.12e-7	Neuroticism;
TGCT	cis	rs7216064	1.000	rs2128792	chr17:65857177	C/T	cg12091567	chr17:66097778	LOC651250	-0.83	-6.49	-0.5	1.9e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs908922	0.605	rs3753448	chr1:152486407	A/C	cg20991723	chr1:152506922	NA	0.47	6.5	0.5	1.73e-9	Hair morphology;
TGCT	cis	rs11190604	0.806	rs76835764	chr10:102193612	C/T	cg16005271	chr10:102321736	NA	0.46	4.69	0.39	6.99e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg24829409	chr8:58192753	C8orf71	0.61	5.15	0.42	1.01e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7424096	0.555	rs75219072	chr2:37225706	C/T	cg14987922	chr2:37194071	STRN	0.52	4.53	0.38	1.37e-5	High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg06873352	chr17:61820015	STRADA	0.56	6.22	0.49	6.93e-9	Prudent dietary pattern;
TGCT	cis	rs1536827	0.688	rs2031922	chr10:135340093	T/C	cg12448312	chr10:135032219	KNDC1	-0.41	-4.65	-0.39	8.42e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs12950390	0.853	rs56387656	chr17:45860189	C/G	cg06532163	chr17:45867833	NA	0.37	5.96	0.47	2.45e-8	IgG glycosylation;
TGCT	trans	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg13615516	chr5:77269221	NA	0.68	8.54	0.61	3.97e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs11252926	0.537	rs4881274	chr10:459940	G/A	cg20256804	chr10:444983	DIP2C	-0.21	-4.47	-0.37	1.74e-5	Psychosis in Alzheimer's disease;
TGCT	cis	rs877426	0.515	rs57506460	chr13:114767789	G/A	cg16820615	chr13:114884918	RASA3	0.28	4.97	0.41	2.17e-6	Facial morphology (factor 14, intercanthal width);
TGCT	cis	rs4891159	0.790	rs59762437	chr18:74153146	G/A	cg24786174	chr18:74118243	ZNF516	-0.54	-7.08	-0.54	9.37e-11	Longevity;
TGCT	cis	rs546131	0.928	rs499183	chr11:34836678	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.62	5.6	0.45	1.31e-7	Lung disease severity in cystic fibrosis;
TGCT	cis	rs12048904	0.930	rs11166529	chr1:101333733	C/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.49	4.46	0.37	1.8e-5	Multiple sclerosis;
TGCT	cis	rs12216125	0.554	rs6942196	chr6:26072804	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.79	7.55	0.56	8.02e-12	Iron status biomarkers;
TGCT	cis	rs595982	0.702	rs623520	chr19:49369943	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.38	-5.16	-0.42	9.34e-7	Red cell distribution width;
TGCT	cis	rs6714710	0.580	rs57804205	chr2:98454472	G/A	cg26665480	chr2:98280029	ACTR1B	0.66	6.26	0.49	5.74e-9	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs4689388	0.926	rs12508672	chr4:6287965	G/A	cg14416269	chr4:6271139	WFS1	0.37	4.87	0.4	3.39e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg03609598	chr5:56110824	MAP3K1	-0.58	-4.7	-0.39	6.72e-6	Initial pursuit acceleration;
TGCT	cis	rs7523050	0.643	rs34367763	chr1:109400805	C/T	cg08274380	chr1:109419600	GPSM2	1.3	6.39	0.5	2.99e-9	Fat distribution (HIV);
TGCT	cis	rs6089584	0.861	rs2180302	chr20:60576369	A/G	cg16423285	chr20:60520624	NA	-0.63	-6.7	-0.52	6.45e-10	Body mass index;
TGCT	trans	rs7618501	0.521	rs3733134	chr3:49939503	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.83	8.73	0.62	1.45e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs986417	1.000	rs10142455	chr14:60980963	G/A	cg27398547	chr14:60952738	C14orf39	1.48	11.21	0.71	1.46e-20	Gut microbiota (bacterial taxa);
TGCT	cis	rs3847687	1.000	rs11061292	chr12:131518981	T/A	cg13586425	chr12:131519906	GPR133	-0.34	-5.33	-0.43	4.47e-7	Longevity;
TGCT	cis	rs78366141	0.536	rs78517451	chr4:89650437	C/A	cg01026744	chr4:89619053	NAP1L5;HERC3	1.15	5.14	0.42	1.03e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
TGCT	cis	rs10992471	0.598	rs3174352	chr9:95219248	A/G	cg13798575	chr9:95087839	CENPP;NOL8	0.64	6.22	0.49	7.07e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs7208859	0.623	rs383436	chr17:28959179	A/G	cg13385521	chr17:29058706	SUZ12P	0.81	4.87	0.4	3.39e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7552404	0.727	rs2172508	chr1:76320215	A/G	cg10523679	chr1:76189770	ACADM	0.68	6.25	0.49	6.11e-9	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2692947	0.794	rs2692893	chr2:96756547	C/T	cg23100626	chr2:96804247	ASTL	0.41	4.84	0.4	3.74e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs950169	0.580	rs4603535	chr15:85173872	C/T	cg17173187	chr15:85201210	NMB	0.62	7.09	0.54	8.99e-11	Schizophrenia;
TGCT	cis	rs7178572	0.568	rs11858641	chr15:77585820	C/T	cg22256960	chr15:77711686	NA	-0.85	-8.73	-0.62	1.4e-14	Type 2 diabetes;
TGCT	cis	rs3888647	0.622	rs4758618	chr11:2995186	A/T	cg05729581	chr11:3078854	CARS	-0.54	-4.82	-0.4	4.19e-6	Type 2 diabetes;
TGCT	cis	rs7584330	0.695	rs6709497	chr2:238368925	C/T	cg08992911	chr2:238395768	MLPH	0.56	4.49	0.37	1.63e-5	Prostate cancer;
TGCT	cis	rs477692	0.625	rs4751104	chr10:131405358	G/A	cg24747557	chr10:131355152	MGMT	0.3	4.59	0.38	1.05e-5	Response to temozolomide;
TGCT	cis	rs60871478	0.636	rs6976929	chr7:901382	C/T	cg00475322	chr7:917719	C7orf20	0.5	4.82	0.4	4.14e-6	Cerebrospinal P-tau181p levels;
TGCT	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg22968622	chr17:43663579	NA	1.3	11.87	0.73	3.46e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs4747241	1.000	rs10740398	chr10:74046191	C/G	cg09661010	chr10:73848153	SPOCK2	0.4	4.46	0.37	1.8e-5	Heschl's gyrus morphology;
TGCT	cis	rs11677416	1.000	rs34015482	chr2:113525745	A/G	cg27083787	chr2:113543245	IL1A	0.17	4.46	0.37	1.83e-5	Response to antipsychotic treatment in schizophrenia (working memory);
TGCT	cis	rs4499344	0.633	rs166311	chr19:33161246	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.87	9.38	0.64	4.1e-16	Mean platelet volume;
TGCT	cis	rs9318086	0.673	rs7981928	chr13:24435180	T/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.8	8.48	0.61	5.49e-14	Myopia (pathological);
TGCT	cis	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg22857025	chr5:266934	NA	-0.33	-6.57	-0.51	1.22e-9	Breast cancer;
TGCT	cis	rs17401966	0.894	rs11587309	chr1:10446596	G/T	cg19773385	chr1:10388646	KIF1B	-0.23	-5.3	-0.43	5.14e-7	Hepatocellular carcinoma;
TGCT	cis	rs10193935	0.901	rs10196091	chr2:42541591	T/C	cg27598129	chr2:42591480	NA	-0.4	-5.55	-0.45	1.68e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7666738	0.830	rs62321570	chr4:98984276	G/A	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12497850	0.931	rs9311430	chr3:48845251	C/T	cg06212747	chr3:49208901	KLHDC8B	0.62	5.83	0.46	4.42e-8	Parkinson's disease;
TGCT	cis	rs17152411	0.793	rs7085829	chr10:126587142	A/G	cg07906193	chr10:126599966	NA	0.41	5.05	0.41	1.52e-6	Height;
TGCT	cis	rs1062177	1.000	rs2915882	chr5:151145436	T/C	cg12924095	chr5:151150029	G3BP1	0.35	5.07	0.41	1.41e-6	Preschool internalizing problems;
TGCT	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg22963979	chr7:1858916	MAD1L1	0.39	5.96	0.47	2.43e-8	Bipolar disorder and schizophrenia;
TGCT	cis	rs4654899	0.897	rs10916859	chr1:21087956	A/G	cg01072550	chr1:21505969	NA	-0.5	-8.03	-0.59	6.32e-13	Superior frontal gyrus grey matter volume;
TGCT	cis	rs9372498	0.536	rs77435770	chr6:118819467	G/A	cg21191810	chr6:118973309	C6orf204	-0.35	-4.72	-0.39	6.2e-6	Diastolic blood pressure;
TGCT	cis	rs1691799	0.899	rs1168295	chr12:66734151	G/C	cg16791601	chr12:66731901	HELB	-0.29	-6.31	-0.49	4.41e-9	White blood cell count (basophil);
TGCT	trans	rs1814175	0.817	rs1818890	chr11:49856882	T/C	cg15704280	chr7:45808275	SEPT13	-0.72	-8.14	-0.59	3.61e-13	Height;
TGCT	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg04166393	chr7:2884313	GNA12	0.56	4.61	0.38	9.9e-6	Height;
TGCT	cis	rs853679	0.546	rs200977	chr6:27854301	T/C	cg08798685	chr6:27730294	NA	-0.36	-5.01	-0.41	1.86e-6	Depression;
TGCT	cis	rs7085104	0.660	rs3781286	chr10:104595719	C/T	cg04362960	chr10:104952993	NT5C2	0.55	4.92	0.4	2.7e-6	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs4499344	0.657	rs4805769	chr19:33049697	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.72	-6.16	-0.48	9.45e-9	Mean platelet volume;
TGCT	cis	rs916888	0.531	rs183211	chr17:44788310	G/A	cg17911788	chr17:44343683	NA	-0.48	-5.65	-0.45	1.05e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7119	0.717	rs12909645	chr15:77816819	A/T	cg27398640	chr15:77910606	LINGO1	-0.25	-4.6	-0.38	1.05e-5	Type 2 diabetes;
TGCT	cis	rs7772486	0.875	rs2492855	chr6:146296926	A/G	cg23711669	chr6:146136114	FBXO30	0.85	9.21	0.64	1.03e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9677476	0.516	rs11893395	chr2:232022981	G/A	cg27665808	chr2:232055229	NA	0.36	4.51	0.38	1.48e-5	Food antigen IgG levels;
TGCT	cis	rs12188164	0.686	rs72711365	chr5:416672	G/A	cg26850624	chr5:429559	AHRR	-0.22	-5.08	-0.41	1.36e-6	Cystic fibrosis severity;
TGCT	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	6.11	0.48	1.17e-8	Alzheimer's disease;
TGCT	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg17747265	chr1:1875780	NA	-0.43	-8.09	-0.59	4.69e-13	Body mass index;
TGCT	cis	rs2242116	0.796	rs4683296	chr3:46973820	G/C	cg23352942	chr3:46931381	PTH1R	0.31	4.44	0.37	1.94e-5	Birth weight;
TGCT	cis	rs6121246	0.909	rs1994250	chr20:30287494	A/G	cg18721089	chr20:30220636	NA	-0.42	-4.65	-0.39	8.2e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs62064224	0.512	rs9912766	chr17:30712780	A/G	cg18200150	chr17:30822561	MYO1D	0.39	4.7	0.39	6.77e-6	Schizophrenia;
TGCT	cis	rs853679	0.546	rs200995	chr6:27813694	C/T	cg08798685	chr6:27730294	NA	0.34	4.77	0.39	5.13e-6	Depression;
TGCT	cis	rs826838	0.616	rs4619214	chr12:38614704	C/A	cg26384229	chr12:38710491	ALG10B	0.55	5.0	0.41	1.93e-6	Heart rate;
TGCT	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.64	-5.14	-0.42	1.04e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg03709012	chr19:19516395	GATAD2A	-0.65	-5.47	-0.44	2.34e-7	Tonsillectomy;
TGCT	cis	rs7818688	0.697	rs74553842	chr8:95984392	C/T	cg16049864	chr8:95962084	TP53INP1	0.54	4.64	0.38	8.87e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs986417	1.000	rs8015462	chr14:61046687	G/A	cg18240143	chr14:60952599	C14orf39	0.88	4.78	0.39	4.84e-6	Gut microbiota (bacterial taxa);
TGCT	cis	rs17152411	1.000	rs17152381	chr10:126592903	T/G	cg07906193	chr10:126599966	NA	0.42	5.28	0.43	5.6e-7	Height;
TGCT	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg01585852	chr22:24235823	MIF	-0.22	-4.79	-0.4	4.65e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7829975	0.560	rs4841013	chr8:8552013	A/G	cg17143192	chr8:8559678	CLDN23	-0.49	-4.94	-0.41	2.44e-6	Mood instability;
TGCT	cis	rs62103177	0.759	rs7227794	chr18:77610925	C/T	cg12964065	chr18:77638022	KCNG2	0.41	5.48	0.44	2.31e-7	Opioid sensitivity;
TGCT	cis	rs7614311	0.552	rs73117078	chr3:63942084	G/A	cg22134162	chr3:63841271	THOC7	-0.47	-5.78	-0.46	5.64e-8	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs7209700	0.777	rs8073827	chr17:45344662	G/T	cg21624342	chr17:45890973	OSBPL7	0.19	5.25	0.43	6.39e-7	IgG glycosylation;
TGCT	cis	rs12902680	0.739	rs12438165	chr15:46407408	C/G	cg13605988	chr15:45421612	DUOX1;DUOXA1	0.33	4.56	0.38	1.23e-5	Neuroticism;
TGCT	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg06640241	chr16:89574553	SPG7	0.8	9.39	0.64	3.77e-16	Multiple myeloma (IgH translocation);
TGCT	cis	rs2153535	0.542	rs9378553	chr6:8472632	T/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.46	-6.36	-0.5	3.55e-9	Alzheimer's disease;
TGCT	cis	rs7100689	0.646	rs9420370	chr10:82073248	C/T	cg01528321	chr10:82214614	TSPAN14	0.75	7.56	0.56	7.74e-12	Post bronchodilator FEV1;
TGCT	cis	rs8180040	0.966	rs6792461	chr3:47473168	C/T	cg27129171	chr3:47204927	SETD2	-0.65	-7.68	-0.57	4.2e-12	Colorectal cancer;
TGCT	cis	rs8051431	0.876	rs9302633	chr16:72013539	T/C	cg06353428	chr16:71660113	MARVELD3	0.59	5.02	0.41	1.73e-6	LDL cholesterol levels;
TGCT	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg13393036	chr8:95962371	TP53INP1	-0.65	-8.82	-0.62	8.57e-15	Type 2 diabetes;
TGCT	cis	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg18252515	chr7:66147081	NA	-1.17	-7.49	-0.56	1.13e-11	Diabetic kidney disease;
TGCT	cis	rs716804	0.654	rs7924499	chr11:10140797	T/C	cg17061862	chr11:9590431	NA	-0.34	-4.5	-0.37	1.53e-5	Neuroticism;
TGCT	cis	rs904251	0.600	rs11756241	chr6:37445101	C/T	cg08126542	chr6:37504118	NA	-0.41	-5.73	-0.46	7.18e-8	Cognitive performance;
TGCT	cis	rs644799	0.511	rs12791736	chr11:95475399	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.59	5.72	0.46	7.49e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9733	0.519	rs6700022	chr1:150670484	G/T	cg09365446	chr1:150670422	GOLPH3L	-0.29	-4.49	-0.37	1.59e-5	Tonsillectomy;
TGCT	cis	rs9303401	0.659	rs11079358	chr17:56920949	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs12484776	0.735	rs6001799	chr22:40539200	G/A	cg07138101	chr22:40742427	ADSL	0.62	4.76	0.39	5.38e-6	Uterine fibroids;
TGCT	cis	rs6582630	0.502	rs10880388	chr12:38401341	A/T	cg26384229	chr12:38710491	ALG10B	0.83	7.39	0.55	1.92e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs7605378	0.528	rs281780	chr2:200756331	G/C	cg19045956	chr2:200819837	C2orf60;C2orf47	0.55	5.87	0.47	3.71e-8	Osteoporosis;
TGCT	cis	rs2429369	0.528	rs2526376	chr17:56427142	A/C	cg12560992	chr17:57184187	TRIM37	0.64	6.62	0.51	9.89e-10	Cognitive function;
TGCT	cis	rs10751667	0.666	rs7395488	chr11:954111	T/C	cg06064525	chr11:970664	AP2A2	-0.35	-8.22	-0.59	2.29e-13	Alzheimer's disease (late onset);
TGCT	cis	rs7147624	0.572	rs72714446	chr14:65933144	G/A	cg03016385	chr14:66212404	NA	0.6	6.69	0.51	6.88e-10	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs12188164	0.610	rs6555242	chr5:416546	A/C	cg22025206	chr5:502436	SLC9A3	-0.24	-4.44	-0.37	1.95e-5	Cystic fibrosis severity;
TGCT	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg04352962	chr1:209979756	IRF6	0.61	4.67	0.39	7.72e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs514406	0.505	rs6688064	chr1:53165609	C/T	cg25767906	chr1:53392781	SCP2	-0.45	-4.85	-0.4	3.59e-6	Monocyte count;
TGCT	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg13683864	chr3:40499215	RPL14	-1.17	-13.35	-0.77	9.44e-26	Renal cell carcinoma;
TGCT	cis	rs2439831	0.850	rs16977798	chr15:44151948	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	6.2	0.49	7.73e-9	Lung cancer in ever smokers;
TGCT	cis	rs6964587	1.000	rs6952389	chr7:91657994	A/G	cg22709100	chr7:91322751	NA	0.27	4.48	0.37	1.68e-5	Breast cancer;
TGCT	cis	rs4727027	0.933	rs13225884	chr7:148857795	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.48	4.44	0.37	1.99e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs950776	0.752	rs2869546	chr15:78907345	C/T	cg06917634	chr15:78832804	PSMA4	-0.65	-5.3	-0.43	5.01e-7	Sudden cardiac arrest;
TGCT	cis	rs72781680	0.716	rs2712086	chr2:24004739	G/C	cg08917208	chr2:24149416	ATAD2B	0.79	4.94	0.41	2.51e-6	Lymphocyte counts;
TGCT	cis	rs7714584	1.000	rs10078968	chr5:150244273	C/A	cg22134413	chr5:150180641	NA	0.83	6.53	0.51	1.54e-9	Crohn's disease;
TGCT	cis	rs735396	1.000	rs1169306	chr12:121438311	C/T	cg02403541	chr12:121454288	C12orf43	0.66	6.34	0.49	3.84e-9	N-glycan levels;
TGCT	cis	rs9467773	1.000	rs9467773	chr6:26498426	A/G	cg26531700	chr6:26746687	NA	0.46	4.55	0.38	1.27e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs210138	0.882	rs407710	chr6:33554257	A/G	cg24505687	chr6:33548425	BAK1	0.45	4.73	0.39	5.98e-6	Testicular germ cell tumor;
TGCT	cis	rs7666738	0.546	rs3911415	chr4:98692401	T/A	cg17366294	chr4:99064904	C4orf37	0.61	5.71	0.46	7.81e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs950169	0.580	rs11635597	chr15:85165699	C/T	cg17173187	chr15:85201210	NMB	0.58	6.62	0.51	9.59e-10	Schizophrenia;
TGCT	cis	rs1348850	0.958	rs4243390	chr2:178468008	G/A	cg22681709	chr2:178499509	PDE11A	-0.39	-4.93	-0.41	2.55e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg08509172	chr19:19383838	TM6SF2	0.35	4.66	0.39	7.96e-6	Tonsillectomy;
TGCT	cis	rs644799	1.000	rs516551	chr11:95588626	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	10.59	0.69	4.6e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs6754311	0.731	rs1470457	chr2:136581848	A/G	cg07169764	chr2:136633963	MCM6	0.73	6.81	0.52	3.81e-10	Mosquito bite size;
TGCT	cis	rs1878931	0.582	rs9921152	chr16:3421199	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.76	6.35	0.5	3.66e-9	Body mass index (adult);
TGCT	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg09263875	chr16:632152	PIGQ	0.31	6.89	0.53	2.52e-10	Height;
TGCT	cis	rs1568889	0.838	rs1525717	chr11:28081205	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.92	11.35	0.71	6.62e-21	Bipolar disorder;
TGCT	cis	rs6088580	0.634	rs6087579	chr20:32985155	A/G	cg24642439	chr20:33292090	TP53INP2	-0.49	-4.49	-0.37	1.59e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs3087591	0.683	rs10512434	chr17:29639590	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.33	-4.78	-0.39	4.79e-6	Hip circumference;
TGCT	cis	rs2273156	1.000	rs2273158	chr14:35465784	A/T	cg24764865	chr14:36295508	BRMS1L	0.58	4.67	0.39	7.72e-6	Immunoglobulin light chain (AL) amyloidosis;
TGCT	cis	rs6952808	0.575	rs2056479	chr7:1954273	G/A	cg22963979	chr7:1858916	MAD1L1	-0.4	-6.15	-0.48	9.97e-9	Bipolar disorder and schizophrenia;
TGCT	cis	rs10501293	1.000	rs7111028	chr11:43060516	C/T	cg03447554	chr11:43094025	NA	0.46	6.64	0.51	8.85e-10	Cognitive performance;
TGCT	trans	rs797680	0.822	rs1057257	chr1:93621483	A/G	cg27528825	chr2:159282178	CCDC148	-0.35	-6.78	-0.52	4.33e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs11190604	0.790	rs11190535	chr10:102197441	A/T	cg16342193	chr10:102329863	NA	-0.41	-5.22	-0.42	7.22e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	trans	rs28735056	0.563	rs55642704	chr18:77688124	C/T	cg05926928	chr17:57297772	GDPD1	-0.67	-6.7	-0.52	6.51e-10	Schizophrenia;
TGCT	cis	rs7781977	0.920	rs7805434	chr7:50340750	G/C	cg01139861	chr7:50343298	IKZF1	0.53	5.63	0.45	1.12e-7	IgG glycosylation;
TGCT	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg01802117	chr1:53393560	SCP2	0.44	5.34	0.43	4.33e-7	Monocyte count;
TGCT	cis	rs11578119	0.933	rs4423075	chr1:170477349	T/C	cg09767346	chr1:170501363	GORAB	0.66	5.29	0.43	5.27e-7	Male-pattern baldness;
TGCT	cis	rs2730245	0.545	rs2788472	chr7:158649304	T/C	cg24397884	chr7:158709396	WDR60	0.37	4.73	0.39	6.11e-6	Height;
TGCT	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2120019	1.000	rs67544533	chr15:75361539	A/G	cg09165964	chr15:75287851	SCAMP5	-1.16	-9.79	-0.66	4e-17	Blood trace element (Zn levels);
TGCT	cis	rs3096299	0.685	rs3803681	chr16:89544756	C/T	cg08392591	chr16:89556376	ANKRD11	0.56	5.15	0.42	1.01e-6	Multiple myeloma (IgH translocation);
TGCT	cis	rs6969780	0.915	rs10085570	chr7:27151188	C/T	cg04317399	chr7:27170313	HOXA4	-0.44	-4.87	-0.4	3.3e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs138249	1.000	rs138209	chr22:50539413	T/C	cg24864161	chr22:50528282	MOV10L1	0.46	4.95	0.41	2.38e-6	Gestational age at birth in labor-initiated deliveries (child effect);
TGCT	cis	rs3862435	0.572	rs76176014	chr15:90923962	G/A	cg14166756	chr15:90894880	ZNF774	-0.32	-5.06	-0.41	1.49e-6	Response to exercise (triglyceride level interaction);
TGCT	cis	rs6570726	1.000	rs1935617	chr6:145943326	C/T	cg23711669	chr6:146136114	FBXO30	0.7	6.43	0.5	2.56e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4253772	0.591	rs6007740	chr22:46654323	A/G	cg09491104	chr22:46646882	C22orf40	0.61	6.41	0.5	2.82e-9	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs12477438	0.501	rs12995473	chr2:99764884	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	8.52	0.61	4.42e-14	Chronic sinus infection;
TGCT	cis	rs9682041	1.000	rs4955588	chr3:170072864	C/A	cg11886554	chr3:170076028	SKIL	0.68	5.37	0.43	3.7e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs2404602	0.669	rs17367297	chr15:77158026	A/C	cg22467129	chr15:76604101	ETFA	-0.47	-5.39	-0.44	3.44e-7	Blood metabolite levels;
TGCT	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs910316	1.000	rs10149880	chr14:75633008	A/G	cg11812906	chr14:75593930	NEK9	-0.75	-7.44	-0.56	1.43e-11	Height;
TGCT	cis	rs367615	0.704	rs55956735	chr5:108845042	A/G	cg17395555	chr5:108820864	NA	0.31	5.86	0.47	3.94e-8	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs9894429	0.789	rs8074989	chr17:79598728	G/C	cg21984481	chr17:79567631	NPLOC4	-0.26	-4.9	-0.4	2.91e-6	Eye color traits;
TGCT	cis	rs950776	0.593	rs601079	chr15:78869579	T/A	cg06917634	chr15:78832804	PSMA4	-0.65	-5.32	-0.43	4.65e-7	Sudden cardiac arrest;
TGCT	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg04944784	chr2:26401820	FAM59B	-0.67	-6.16	-0.48	9.54e-9	Gut microbiome composition (summer);
TGCT	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg08392591	chr16:89556376	ANKRD11	0.57	5.24	0.43	6.61e-7	Multiple myeloma (IgH translocation);
TGCT	cis	rs9807989	0.507	rs6745614	chr2:102991213	A/G	cg03938978	chr2:103052716	IL18RAP	0.26	5.22	0.42	7.15e-7	Asthma;
TGCT	cis	rs11696501	0.688	rs1487310	chr20:44308789	A/G	cg11783356	chr20:44313418	WFDC10B	-0.33	-4.6	-0.38	1.01e-5	Brain structure;
TGCT	cis	rs12220238	0.722	rs11001096	chr10:76413103	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.61	4.76	0.39	5.23e-6	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs9467603	1.000	rs9467613	chr6:25812641	T/C	cg16898833	chr6:26189333	HIST1H4D	1.16	5.51	0.44	2.03e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg27121462	chr16:89883253	FANCA	0.8	8.53	0.61	4.34e-14	Vitiligo;
TGCT	cis	rs7666738	0.753	rs9991512	chr4:99007205	T/C	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3733631	0.948	rs3733632	chr4:104640935	A/G	cg24090629	chr4:104641072	TACR3	-0.77	-6.29	-0.49	4.9e-9	Menarche (age at onset);
TGCT	cis	rs911263	1.000	rs911263	chr14:68753593	C/T	cg18825221	chr14:68749962	RAD51L1	0.28	5.62	0.45	1.22e-7	Primary biliary cholangitis;
TGCT	cis	rs6570726	0.791	rs370112	chr6:145859853	T/G	cg23711669	chr6:146136114	FBXO30	0.89	9.93	0.67	1.82e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7553864	0.614	rs10493796	chr1:87614175	A/G	cg17420885	chr1:87600446	LOC339524	0.38	4.86	0.4	3.5e-6	Smoking behavior;
TGCT	cis	rs7267979	1.000	rs4815418	chr20:25382211	T/G	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.73e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6815814	0.904	rs73236629	chr4:38825449	G/T	cg02016764	chr4:38805732	TLR1	-0.29	-4.46	-0.37	1.83e-5	Breast cancer;
TGCT	cis	rs68170813	0.559	rs17427158	chr7:106824259	G/T	cg02696742	chr7:106810147	HBP1	-0.7	-6.05	-0.48	1.59e-8	Coronary artery disease;
TGCT	cis	rs651907	0.557	rs3864012	chr3:101397623	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.91	11.43	0.72	4.08e-21	Colorectal cancer;
TGCT	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg04352962	chr1:209979756	IRF6	0.62	4.71	0.39	6.56e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs13256369	0.802	rs12541520	chr8:8564146	G/T	cg18904891	chr8:8559673	CLDN23	0.59	5.46	0.44	2.54e-7	Obesity-related traits;
TGCT	cis	rs17102423	0.723	rs8181939	chr14:65555758	G/A	cg11161011	chr14:65562177	MAX	-0.55	-7.7	-0.57	3.74e-12	Obesity-related traits;
TGCT	cis	rs6693567	0.565	rs834225	chr1:150300727	T/C	cg09579323	chr1:150459698	TARS2	0.54	4.79	0.4	4.59e-6	Migraine;
TGCT	cis	rs7811142	0.945	rs6974282	chr7:100098295	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.72	5.02	0.41	1.76e-6	Platelet count;
TGCT	cis	rs56104184	0.779	rs73061627	chr19:49360418	C/T	cg17863274	chr19:49399704	TULP2	-0.44	-5.23	-0.42	7.06e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs3849570	0.533	rs6548782	chr3:81993287	T/G	cg07356753	chr3:81810745	GBE1	-0.54	-4.51	-0.38	1.49e-5	Waist circumference;Body mass index;
TGCT	cis	rs1552244	0.554	rs13081079	chr3:10056348	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.33	-4.95	-0.41	2.39e-6	Alzheimer's disease;
TGCT	cis	rs3733585	0.648	rs67820465	chr4:9975873	A/G	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.52	-0.56	9.77e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7552404	1.000	rs1498312	chr1:76177849	C/T	cg10523679	chr1:76189770	ACADM	0.91	9.92	0.67	2.01e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs3091242	0.809	rs660129	chr1:25727438	C/T	cg00786635	chr1:25594202	NA	0.59	6.09	0.48	1.34e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs7552404	1.000	rs6593585	chr1:76140273	G/A	cg22875332	chr1:76189707	ACADM	0.79	9.77	0.66	4.68e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs6882076	1.000	rs12657266	chr5:156396003	C/T	cg12943317	chr5:156479607	HAVCR1	-0.3	-5.59	-0.45	1.38e-7	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
TGCT	cis	rs9372498	0.536	rs17424234	chr6:118808521	A/G	cg07617317	chr6:118971624	C6orf204	0.5	5.39	0.44	3.36e-7	Diastolic blood pressure;
TGCT	cis	rs950776	0.642	rs58946838	chr15:78961449	A/C	cg03762349	chr15:79060523	ADAMTS7	0.26	5.05	0.41	1.56e-6	Sudden cardiac arrest;
TGCT	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg06634786	chr22:41940651	POLR3H	0.87	8.25	0.6	1.92e-13	Vitiligo;
TGCT	cis	rs3617	0.625	rs2240915	chr3:52859526	T/A	cg10802521	chr3:52805072	NEK4	-0.6	-6.89	-0.53	2.46e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7617480	0.648	rs4858800	chr3:48755820	A/G	cg07636037	chr3:49044803	WDR6	0.77	6.37	0.5	3.33e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs9383153	0.793	rs2016498	chr6:16344914	C/T	cg06493612	chr6:15502050	JARID2	0.63	5.58	0.45	1.46e-7	Gambling;
TGCT	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg23758822	chr17:41437982	NA	0.72	6.81	0.52	3.83e-10	Menopause (age at onset);
TGCT	cis	rs12142240	0.698	rs17413701	chr1:46818452	A/G	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg20203395	chr5:56204925	C5orf35	-0.56	-4.8	-0.4	4.39e-6	Initial pursuit acceleration;
TGCT	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.29	-4.56	-0.38	1.19e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs539096	0.789	rs68191270	chr1:44026180	A/C	cg12908607	chr1:44402522	ARTN	-0.51	-5.28	-0.43	5.57e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7044106	0.762	rs1530370	chr9:123424552	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	6.68	0.51	7.09e-10	Hip circumference adjusted for BMI;
TGCT	cis	rs4378999	0.702	rs4447760	chr3:50950909	C/T	ch.3.1075622R	chr3:50010873	RBM6	0.39	4.86	0.4	3.45e-6	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
TGCT	cis	rs13191362	1.000	rs34653853	chr6:163114362	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.16	9.92	0.67	1.96e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs61897795	0.628	rs174579	chr11:61605613	C/T	cg19610905	chr11:61596333	FADS2	-0.88	-6.75	-0.52	5.07e-10	Neutrophil count;Sum basophil neutrophil counts;
TGCT	cis	rs10876993	0.890	rs7976852	chr12:58100551	T/G	cg15848620	chr12:58087721	OS9	-0.72	-5.94	-0.47	2.73e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs6994316	0.557	rs1456314	chr8:128075690	A/G	cg16485897	chr8:128555993	NA	-0.25	-4.67	-0.39	7.67e-6	Prostate cancer;
TGCT	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg21724239	chr8:58056113	NA	0.39	5.24	0.43	6.73e-7	Developmental language disorder (linguistic errors);
TGCT	trans	rs66573146	1.000	rs67067921	chr4:6984341	A/T	cg07817883	chr1:32538562	TMEM39B	1.66	8.29	0.6	1.56e-13	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs4654899	1.000	rs4654896	chr1:21356930	T/C	cg01072550	chr1:21505969	NA	-0.48	-7.78	-0.57	2.49e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg03609598	chr5:56110824	MAP3K1	-0.59	-4.72	-0.39	6.18e-6	Initial pursuit acceleration;
TGCT	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg10253484	chr15:75165896	SCAMP2	-0.6	-5.51	-0.44	2.02e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
TGCT	cis	rs3858526	0.839	rs10466484	chr11:5943696	A/G	cg13902645	chr11:5959945	NA	-0.44	-4.61	-0.38	9.67e-6	DNA methylation (variation);
TGCT	cis	rs2657888	1.000	rs2657901	chr12:56933416	A/G	cg23932658	chr12:57637574	STAC3	0.48	4.57	0.38	1.18e-5	Adiponectin levels;
TGCT	cis	rs854765	0.663	rs3183702	chr17:17747289	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.69	-6.55	-0.51	1.39e-9	Total body bone mineral density;
TGCT	cis	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg07424592	chr7:64974309	NA	1.27	7.86	0.58	1.61e-12	Diabetic kidney disease;
TGCT	cis	rs73058052	0.935	rs3745473	chr19:50086626	T/C	cg09250473	chr19:50168907	IRF3;BCL2L12	0.87	7.03	0.53	1.24e-10	Fibrinogen levels;
TGCT	cis	rs968567	0.705	rs174572	chr11:61598288	C/T	cg19610905	chr11:61596333	FADS2	-0.99	-9.08	-0.63	2.15e-15	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
TGCT	cis	rs523522	0.962	rs11065149	chr12:120956963	G/A	cg27279351	chr12:120934652	DYNLL1	0.76	6.59	0.51	1.15e-9	High light scatter reticulocyte count;
TGCT	cis	rs1887596	0.590	rs608819	chr13:27106141	C/A	cg01312412	chr13:27282625	NA	-0.28	-4.8	-0.4	4.4e-6	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs3008870	1.000	rs12041926	chr1:67434602	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.06	11.13	0.71	2.26e-20	Lymphocyte percentage of white cells;
TGCT	cis	rs3820068	0.608	rs7516683	chr1:16020502	A/G	cg17385448	chr1:15911702	AGMAT	-0.35	-4.77	-0.39	5.07e-6	Systolic blood pressure;
TGCT	cis	rs10096908	0.892	rs9886512	chr8:41642164	C/G	cg13603914	chr8:41518004	ANK1;MIR486	0.44	4.78	0.39	4.82e-6	Hypertension;Blood pressure traits (multi-trait analysis);Systolic blood pressure;
TGCT	cis	rs9549367	0.789	rs2025247	chr13:113882564	C/G	cg18105134	chr13:113819100	PROZ	-0.34	-5.45	-0.44	2.63e-7	Platelet distribution width;
TGCT	cis	rs1933488	1.000	rs2119992	chr6:153449670	A/T	cg24028809	chr6:153414101	RGS17	0.2	4.53	0.38	1.37e-5	Prostate cancer;
TGCT	cis	rs3784262	0.533	rs12148525	chr15:58196456	A/G	cg12031962	chr15:58353849	ALDH1A2	0.51	6.55	0.51	1.38e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs9611565	0.512	rs9611667	chr22:42187015	C/T	cg06481639	chr22:41940642	POLR3H	-0.66	-5.75	-0.46	6.46e-8	Vitiligo;
TGCT	cis	rs2153535	0.601	rs718504	chr6:8527512	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.55e-8	Motion sickness;
TGCT	cis	rs10089	0.552	rs1351141	chr5:127550055	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.56	-5.03	-0.41	1.7e-6	Ileal carcinoids;
TGCT	cis	rs9291683	0.588	rs3756236	chr4:10013463	T/A	cg02734326	chr4:10020555	SLC2A9	0.38	4.56	0.38	1.22e-5	Bone mineral density;
TGCT	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg17911788	chr17:44343683	NA	-0.65	-6.61	-0.51	1.04e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs11785400	1.000	rs4484678	chr8:143730796	A/G	cg10596483	chr8:143751796	JRK	0.54	5.77	0.46	5.95e-8	Schizophrenia;
TGCT	trans	rs2688608	0.868	rs2688625	chr10:75631548	T/C	cg13918328	chr10:52500089	ASAH2B	0.66	6.85	0.52	3.11e-10	Inflammatory bowel disease;
TGCT	trans	rs11082438	0.786	rs11660485	chr18:42866471	A/C	cg13144432	chr15:100513968	ADAMTS17	-0.7	-6.69	-0.51	6.84e-10	Follicular lymphoma;
TGCT	cis	rs9436747	0.641	rs12038998	chr1:66049128	C/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.53	4.72	0.39	6.28e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs7412746	0.563	rs3768013	chr1:150815411	G/A	cg04414720	chr1:150670196	GOLPH3L	0.4	4.8	0.4	4.49e-6	Melanoma;
TGCT	cis	rs4455778	0.659	rs2058266	chr7:49015988	G/A	cg26309511	chr7:48887640	NA	-0.43	-5.07	-0.41	1.4e-6	Lung cancer in never smokers;
TGCT	cis	rs1692580	0.777	rs10910037	chr1:2184280	T/C	cg24578937	chr1:2090814	PRKCZ	0.24	5.25	0.43	6.42e-7	Coronary artery disease;
TGCT	cis	rs66561647	0.719	rs3739380	chr8:128944507	G/T	cg11792826	chr8:129160931	MIR1208	0.21	4.83	0.4	3.93e-6	Hemoglobin concentration;
TGCT	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg13395646	chr4:1353034	KIAA1530	-0.41	-4.72	-0.39	6.23e-6	Longevity;
TGCT	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg13628971	chr7:2884303	GNA12	0.56	4.6	0.38	1.05e-5	Height;
TGCT	cis	rs12580194	0.593	rs61957924	chr12:55744100	T/C	cg10672482	chr12:55725839	OR6C3	-0.52	-4.66	-0.39	8.13e-6	Cancer;
TGCT	cis	rs12210905	0.688	rs79395596	chr6:27490796	C/T	cg08851530	chr6:28072375	NA	1.34	6.29	0.49	5.02e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs28785552	0.931	rs10406850	chr19:53240807	A/C	cg22067481	chr19:53234126	ZNF611	-0.47	-6.7	-0.52	6.59e-10	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs1891275	0.509	rs34190234	chr10:93443074	A/C	cg07889827	chr10:93443413	NA	-0.33	-6.88	-0.53	2.59e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs17030434	0.953	rs11099905	chr4:154686183	A/G	cg14289246	chr4:154710475	SFRP2	0.88	6.58	0.51	1.18e-9	Electrocardiographic conduction measures;
TGCT	cis	rs7258465	1.000	rs10442	chr19:18545341	A/C	cg06462663	chr19:18546047	ISYNA1	0.2	4.54	0.38	1.33e-5	Breast cancer;
TGCT	cis	rs7772486	0.754	rs6915718	chr6:146100676	A/G	cg13319975	chr6:146136371	FBXO30	0.56	5.01	0.41	1.83e-6	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs629535	1.000	rs644951	chr8:70009082	C/T	cg21567404	chr3:27674614	NA	-0.56	-8.41	-0.6	8.17e-14	Dupuytren's disease;
TGCT	cis	rs7666738	0.830	rs4699593	chr4:98980628	A/G	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6582630	0.599	rs11181807	chr12:38403763	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-4.52	-0.38	1.43e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs56235845	0.694	rs4976643	chr5:176760227	A/C	cg06060754	chr5:176797920	RGS14	0.4	6.33	0.49	3.99e-9	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg21280719	chr6:42927975	GNMT	-0.37	-4.54	-0.38	1.32e-5	Plasma homocysteine levels (post-methionine load test);
TGCT	cis	rs9400467	0.568	rs12204075	chr6:111489059	G/T	cg15721981	chr6:111408429	SLC16A10	0.69	4.5	0.37	1.56e-5	Blood metabolite levels;Amino acid levels;
TGCT	cis	rs2245008	1.000	rs2245008	chr16:83983755	G/A	cg27171569	chr16:83987465	OSGIN1	0.57	5.93	0.47	2.82e-8	Pursuit maintenance gain;
TGCT	cis	rs9611565	0.512	rs5751153	chr22:42156561	T/C	cg13695892	chr22:41940480	POLR3H	0.87	8.24	0.59	2.06e-13	Vitiligo;
TGCT	trans	rs829418	0.582	rs747662	chr1:21947218	C/G	cg24415895	chr10:3598627	NA	0.77	6.7	0.52	6.38e-10	Neurocognitive impairment in HIV-1 infection (continuous);
TGCT	cis	rs9457247	0.967	rs430145	chr6:167410369	C/T	cg23791538	chr6:167370224	RNASET2	-0.49	-4.96	-0.41	2.31e-6	Crohn's disease;
TGCT	cis	rs10197940	0.532	rs13425170	chr2:152387112	A/C	cg19508488	chr2:152266495	RIF1	0.66	5.79	0.46	5.35e-8	Lung cancer;
TGCT	cis	rs58688157	0.774	rs59115876	chr11:613757	A/G	cg16486109	chr11:613632	IRF7	0.36	5.26	0.43	6.02e-7	Systemic lupus erythematosus;
TGCT	cis	rs17270561	0.779	rs12209218	chr6:25887776	C/A	cg17691542	chr6:26056736	HIST1H1C	0.88	6.05	0.48	1.56e-8	Iron status biomarkers;
TGCT	cis	rs73416724	0.610	rs41275944	chr6:43254597	C/A	cg24109273	chr6:43484729	YIPF3;POLR1C	1.15	5.16	0.42	9.32e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1153858	0.668	rs63603561	chr15:45593323	T/A	cg14582100	chr15:45693742	SPATA5L1	-0.47	-5.15	-0.42	9.99e-7	Homoarginine levels;
TGCT	cis	rs6088590	1.000	rs6088607	chr20:33378733	C/T	cg24642439	chr20:33292090	TP53INP2	0.69	6.13	0.48	1.09e-8	Coronary artery disease;
TGCT	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.38	5.06	0.41	1.47e-6	Lymphocyte counts;
TGCT	cis	rs12477438	0.520	rs11123764	chr2:99750677	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	12.84	0.76	1.57e-24	Chronic sinus infection;
TGCT	cis	rs2153535	0.580	rs6941771	chr6:8494452	T/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs6938	0.534	rs11854704	chr15:75221015	C/T	cg09165964	chr15:75287851	SCAMP5	0.54	4.96	0.41	2.29e-6	Breast cancer;
TGCT	cis	rs2795502	1.000	rs2796575	chr10:43374911	A/G	cg20628663	chr10:43360327	NA	0.46	6.56	0.51	1.29e-9	Blood protein levels;
TGCT	cis	rs4319547	1.000	rs7307735	chr12:123087442	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.69	-5.44	-0.44	2.69e-7	Body mass index;
TGCT	cis	rs2486288	0.656	rs9921035	chr15:45546660	C/T	cg03999130	chr15:45571217	NA	-0.51	-4.76	-0.39	5.35e-6	Glomerular filtration rate;
TGCT	trans	rs3780486	0.874	rs10813955	chr9:33141791	C/T	cg04842962	chr6:43655489	MRPS18A	1.21	15.08	0.8	7.73e-30	IgG glycosylation;
TGCT	cis	rs16854884	0.837	rs7644767	chr3:143803092	C/G	cg06585982	chr3:143692056	C3orf58	0.61	4.72	0.39	6.19e-6	Economic and political preferences (feminism/equality);
TGCT	cis	rs6459788	0.720	rs6965466	chr7:157250749	G/T	cg06271696	chr7:157225062	NA	-0.27	-5.06	-0.41	1.5e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs523522	0.962	rs687873	chr12:121019634	G/A	cg27279351	chr12:120934652	DYNLL1	0.74	6.46	0.5	2.19e-9	High light scatter reticulocyte count;
TGCT	cis	rs617219	0.671	rs1316753	chr5:78531337	G/C	cg23514016	chr5:78407564	BHMT	0.32	4.86	0.4	3.43e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs1401999	1.000	rs10937158	chr3:183708439	T/C	cg01324343	chr3:183735012	ABCC5	0.82	10.97	0.7	5.41e-20	Anterior chamber depth;
TGCT	cis	rs35934224	1.000	rs35934224	chr22:19872645	C/T	cg11182965	chr22:19864308	TXNRD2	-0.37	-5.1	-0.42	1.23e-6	Glaucoma (primary open-angle);
TGCT	cis	rs7267979	0.932	rs372678	chr20:25465248	G/A	cg03522245	chr20:25566470	NINL	0.6	6.46	0.5	2.14e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1580019	0.961	rs11768506	chr7:32494788	A/C	cg06627557	chr7:32535165	LSM5;AVL9	0.79	7.42	0.55	1.63e-11	Cognitive ability;
TGCT	cis	rs4796354	0.652	rs4377211	chr17:6696047	T/C	cg04115740	chr17:6690948	FBXO39	0.25	4.54	0.38	1.33e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.65	-5.4	-0.44	3.25e-7	Tonsillectomy;
TGCT	cis	rs1215050	0.791	rs2695472	chr4:98855127	T/C	cg05340658	chr4:99064831	C4orf37	-0.47	-5.9	-0.47	3.18e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9500256	0.967	rs4928431	chr6:58306258	A/G	cg16251399	chr6:58287822	GUSBL2	-0.66	-6.19	-0.49	8.21e-9	Eosinophilic esophagitis (pediatric);
TGCT	cis	rs422249	0.512	rs174546	chr11:61569830	C/T	cg01500311	chr11:61656094	FADS3	-0.33	-5.6	-0.45	1.3e-7	Trans fatty acid levels;
TGCT	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg10802521	chr3:52805072	NEK4	-0.71	-8.81	-0.62	9.29e-15	Bipolar disorder;
TGCT	cis	rs7926906	0.817	rs7941948	chr11:90527549	C/T	cg26138821	chr11:89956704	CHORDC1	-0.52	-5.57	-0.45	1.47e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs6456156	0.819	rs7765739	chr6:167518472	C/T	cg07741184	chr6:167504864	NA	0.22	4.44	0.37	2e-5	Primary biliary cholangitis;
TGCT	cis	rs8068544	0.818	rs79892925	chr17:40171819	A/G	cg13092355	chr17:39992602	KLHL10;NT5C3L	-0.96	-4.47	-0.37	1.72e-5	Reticulocyte fraction of red cells;Reticulocyte count;
TGCT	cis	rs2354432	0.607	rs66486822	chr1:146802653	T/A	cg25205988	chr1:146714368	CHD1L	-1.41	-5.83	-0.46	4.57e-8	Mitochondrial DNA levels;
TGCT	trans	rs57221529	0.766	rs12519469	chr5:581772	A/G	cg11887960	chr12:57824829	NA	1.1	9.83	0.66	3.35e-17	Lung disease severity in cystic fibrosis;
TGCT	cis	rs2070488	0.965	rs13097628	chr3:38521156	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.88	8.99	0.63	3.5e-15	Electrocardiographic conduction measures;
TGCT	cis	rs2404602	0.583	rs12898415	chr15:76574232	C/T	cg26408565	chr15:76604113	ETFA	-0.45	-6.35	-0.5	3.66e-9	Blood metabolite levels;
TGCT	cis	rs3849570	0.615	rs9817070	chr3:81982936	A/G	cg07356753	chr3:81810745	GBE1	-0.61	-5.3	-0.43	5.08e-7	Waist circumference;Body mass index;
TGCT	cis	rs2153535	0.601	rs2143352	chr6:8530248	G/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.01	0.41	1.86e-6	Motion sickness;
TGCT	cis	rs7826238	0.509	rs2948288	chr8:8115304	A/G	cg15556689	chr8:8085844	FLJ10661	0.72	6.87	0.53	2.76e-10	Systolic blood pressure;
TGCT	cis	rs611744	0.583	rs1448148	chr8:109333074	T/A	cg21045802	chr8:109455806	TTC35	0.82	8.94	0.63	4.53e-15	Dupuytren's disease;
TGCT	cis	rs2120019	0.938	rs35911108	chr15:75322179	G/A	cg11632617	chr15:75315747	PPCDC	-0.3	-4.44	-0.37	1.95e-5	Blood trace element (Zn levels);
TGCT	trans	rs459571	0.959	rs2810491	chr9:136923331	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	0.72	7.78	0.57	2.47e-12	Platelet distribution width;
TGCT	cis	rs4319547	0.619	rs10744208	chr12:122931559	C/A	cg05707623	chr12:122985044	ZCCHC8	-0.71	-5.49	-0.44	2.16e-7	Body mass index;
TGCT	cis	rs1801251	1.000	rs6761324	chr2:233582793	T/G	cg08000102	chr2:233561755	GIGYF2	0.63	6.51	0.5	1.72e-9	Coronary artery disease;
TGCT	cis	rs752590	0.945	rs1479	chr2:113975104	T/G	cg27425262	chr2:113953981	PSD4;LOC440839	0.42	4.61	0.38	9.75e-6	Mucinous ovarian carcinoma;
TGCT	cis	rs4654899	0.865	rs10916910	chr1:21283192	G/T	cg01072550	chr1:21505969	NA	-0.46	-6.94	-0.53	1.96e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg04267008	chr7:1944627	MAD1L1	-0.38	-4.91	-0.4	2.82e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg06873352	chr17:61820015	STRADA	0.58	6.42	0.5	2.65e-9	Prudent dietary pattern;
TGCT	cis	rs2013441	1.000	rs2703792	chr17:20166950	G/A	cg23224458	chr17:20280056	CCDC144C	-0.37	-4.47	-0.37	1.72e-5	Obesity-related traits;
TGCT	cis	rs950169	1.000	rs12915234	chr15:84758301	G/A	cg11189052	chr15:85197271	WDR73	0.67	5.68	0.45	9.11e-8	Schizophrenia;
TGCT	cis	rs7937682	0.602	rs4936804	chr11:111743851	A/C	cg09085632	chr11:111637200	PPP2R1B	0.88	8.47	0.61	5.93e-14	Primary sclerosing cholangitis;
TGCT	cis	rs12477438	1.000	rs1922624	chr2:99909958	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.97	-8.81	-0.62	9.23e-15	Chronic sinus infection;
TGCT	cis	rs9811920	0.638	rs793474	chr3:99544380	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.6	-7.02	-0.53	1.32e-10	Axial length;
TGCT	cis	rs7666738	0.546	rs3911415	chr4:98692401	T/A	cg18180107	chr4:99064573	C4orf37	0.54	4.78	0.39	4.95e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs921968	0.541	rs10200507	chr2:219335944	C/A	cg02176678	chr2:219576539	TTLL4	-0.48	-6.84	-0.52	3.21e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs763121	0.785	rs5757199	chr22:39040617	T/G	cg06022373	chr22:39101656	GTPBP1	0.77	7.46	0.56	1.35e-11	Menopause (age at onset);
TGCT	cis	rs4509693	1.000	rs6584392	chr10:102497166	G/A	cg24127310	chr10:102502104	NA	0.68	5.65	0.45	1.06e-7	Alzheimer's disease;
TGCT	cis	rs9905704	0.647	rs10221208	chr17:57047885	T/C	cg12560992	chr17:57184187	TRIM37	0.58	5.16	0.42	9.43e-7	Testicular germ cell tumor;
TGCT	cis	rs28595532	1.000	rs17258106	chr4:119675406	C/T	cg21605333	chr4:119757512	SEC24D	-1.32	-7.98	-0.58	8.28e-13	Cannabis dependence symptom count;
TGCT	cis	rs6674176	0.628	rs3828146	chr1:44428715	C/T	cg13606994	chr1:44402422	ARTN	-0.46	-4.95	-0.41	2.36e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs1577917	0.771	rs4419647	chr6:86225739	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.6	5.27	0.43	5.84e-7	Response to antipsychotic treatment;
TGCT	cis	rs7909074	0.966	rs4948645	chr10:45391481	A/G	cg05187965	chr10:45406764	TMEM72	-0.23	-5.05	-0.41	1.56e-6	Mean corpuscular volume;
TGCT	cis	rs2777491	0.574	rs11635906	chr15:41779260	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.93	-15.65	-0.81	3.87e-31	Ulcerative colitis;
TGCT	cis	rs7588654	1.000	rs7588654	chr2:219983030	C/T	cg06736663	chr2:219754761	WNT10A	0.48	4.85	0.4	3.67e-6	Height;
TGCT	cis	rs453301	0.686	rs6987107	chr8:8893581	A/G	cg00184457	chr8:8946301	NA	-0.26	-4.94	-0.41	2.45e-6	Joint mobility (Beighton score);
TGCT	cis	rs11874712	0.966	rs8093880	chr18:43666786	C/T	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	5.23	0.42	7.11e-7	Migraine - clinic-based;
TGCT	cis	rs614226	1.000	rs1167727	chr12:120965508	C/A	cg01236616	chr12:121019343	POP5	1.26	13.2	0.76	2.23e-25	Type 1 diabetes nephropathy;
TGCT	trans	rs208515	0.525	rs1351866	chr6:66696969	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.93	10.33	0.68	1.96e-18	Exhaled nitric oxide levels;
TGCT	cis	rs1008375	0.931	rs6449328	chr4:17700474	C/T	cg10189774	chr4:17578691	LAP3	0.52	4.47	0.37	1.73e-5	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9296661	0.868	rs1359676	chr6:51668270	T/A	cg00593404	chr6:52377740	TRAM2	-0.27	-4.49	-0.37	1.62e-5	Weight loss (gastric bypass surgery);
TGCT	cis	rs7666738	0.830	rs28417577	chr4:99053007	T/C	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7584330	0.737	rs1497129	chr2:238369184	C/T	cg08992911	chr2:238395768	MLPH	0.56	4.49	0.37	1.63e-5	Prostate cancer;
TGCT	cis	rs200810	0.694	rs17808421	chr6:98013067	A/G	cg16511841	chr6:97730490	C6orf167;MIR548H3	0.66	4.62	0.38	9.56e-6	Body mass index;
TGCT	cis	rs2677744	0.626	rs12905855	chr15:91498429	G/C	cg22570213	chr15:91497863	RCCD1	0.38	4.61	0.38	9.98e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs7149242	0.662	rs4905998	chr14:101181781	A/G	cg11193865	chr14:101193038	DLK1	-0.47	-5.27	-0.43	5.96e-7	Platelet count;
TGCT	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg19318889	chr4:1322082	MAEA	0.17	4.52	0.38	1.45e-5	Obesity-related traits;
TGCT	cis	rs17376456	0.825	rs10078941	chr5:93279029	C/T	cg25358565	chr5:93447407	FAM172A	1.02	8.11	0.59	4.23e-13	Diabetic retinopathy;
TGCT	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg00343986	chr7:65444356	GUSB	-0.23	-5.16	-0.42	9.66e-7	Aortic root size;
TGCT	trans	rs1814175	0.817	rs4881627	chr11:49953955	C/A	cg15704280	chr7:45808275	SEPT13	-0.73	-8.48	-0.61	5.58e-14	Height;
TGCT	cis	rs7267979	0.966	rs2261747	chr20:25261784	G/A	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1278769	1.000	rs1278769	chr13:113536627	C/T	cg17842918	chr13:113540400	ATP11A	-0.31	-4.53	-0.38	1.35e-5	Interstitial lung disease;
TGCT	cis	rs13191362	1.000	rs73016459	chr6:163066323	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.91	6.86	0.52	2.88e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs17376456	0.569	rs11135397	chr5:93214975	G/T	cg25358565	chr5:93447407	FAM172A	0.8	6.53	0.51	1.52e-9	Diabetic retinopathy;
TGCT	cis	rs4906332	1.000	rs4906332	chr14:103980134	A/T	cg26031613	chr14:104095156	KLC1	-0.54	-4.66	-0.39	8.15e-6	Coronary artery disease;
TGCT	cis	rs2549003	0.933	rs7719499	chr5:131814091	C/G	cg00255919	chr5:131827918	IRF1	0.2	4.7	0.39	6.68e-6	Asthma (sex interaction);
TGCT	cis	rs10949834	0.824	rs2285026	chr7:73530404	C/T	cg07137043	chr7:73588983	EIF4H	-0.74	-4.53	-0.38	1.38e-5	Verbal memory performance (residualized delayed recall change);
TGCT	cis	rs10791097	0.506	rs10750446	chr11:130706918	T/C	cg05962950	chr11:130786565	SNX19	-0.61	-6.19	-0.49	7.89e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs2296887	0.841	rs12572826	chr10:104132535	C/T	cg26089160	chr10:104170217	PSD	0.66	4.66	0.39	8.17e-6	Parkinson's disease;
TGCT	cis	rs9611565	0.559	rs132771	chr22:42025350	A/G	cg03806693	chr22:41940476	POLR3H	1.06	11.19	0.71	1.58e-20	Vitiligo;
TGCT	cis	rs752092	0.894	rs8042989	chr15:101770761	T/A	cg19997662	chr15:101784653	CHSY1	-0.27	-4.85	-0.4	3.69e-6	Corneal structure;
TGCT	cis	rs7647973	0.961	rs7626076	chr3:49298139	G/A	cg06212747	chr3:49208901	KLHDC8B	0.6	4.81	0.4	4.35e-6	Menarche (age at onset);
TGCT	cis	rs2404602	1.000	rs2896954	chr15:76851692	C/A	cg26408565	chr15:76604113	ETFA	-0.46	-5.92	-0.47	2.98e-8	Blood metabolite levels;
TGCT	cis	rs4242434	0.927	rs11136092	chr8:22466488	T/G	cg21658235	chr8:22456391	C8orf58	0.43	4.53	0.38	1.36e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs72945132	0.882	rs66627443	chr11:70199036	C/G	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs922182	0.633	rs16947621	chr15:64271660	C/G	cg02919090	chr15:64263738	DAPK2	0.29	5.24	0.43	6.8e-7	Blood protein levels;
TGCT	cis	rs1580019	0.520	rs13228793	chr7:32711465	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.95	8.78	0.62	1.07e-14	Cognitive ability;
TGCT	cis	rs9303401	0.659	rs17222691	chr17:56771096	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.67	6.3	0.49	4.7e-9	Cognitive test performance;
TGCT	cis	rs9902453	0.726	rs3115092	chr17:28036350	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.85	8.57	0.61	3.4e-14	Coffee consumption (cups per day);
TGCT	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg22800045	chr5:56110881	MAP3K1	0.54	4.48	0.37	1.69e-5	Initial pursuit acceleration;
TGCT	cis	rs7208859	0.623	rs56163556	chr17:29101868	G/C	cg13385521	chr17:29058706	SUZ12P	0.82	4.86	0.4	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs9911578	1.000	rs12453459	chr17:56624291	C/T	cg05425664	chr17:57184151	TRIM37	0.63	6.26	0.49	5.86e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7568458	0.846	rs1078004	chr2:85769711	C/G	cg17127132	chr2:85788382	GGCX	0.68	6.59	0.51	1.13e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs1008375	1.000	rs11727312	chr4:17669185	C/T	cg10189774	chr4:17578691	LAP3	0.58	5.22	0.42	7.16e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2404602	0.716	rs2164101	chr15:76749117	A/G	cg26408565	chr15:76604113	ETFA	-0.4	-5.26	-0.43	6.23e-7	Blood metabolite levels;
TGCT	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg20607798	chr8:58055168	NA	0.47	4.66	0.39	7.99e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4919694	0.901	rs12264456	chr10:104830634	C/T	cg04362960	chr10:104952993	NT5C2	1.07	7.2	0.54	5.11e-11	Arsenic metabolism;
TGCT	cis	rs250677	0.687	rs42364	chr5:148438858	T/A	cg18129178	chr5:148520854	ABLIM3	-0.43	-6.29	-0.49	5.05e-9	Breast cancer;
TGCT	cis	rs1205863	1.000	rs1205853	chr6:11942549	T/G	cg07106625	chr6:11870215	NA	0.5	5.04	0.41	1.63e-6	Disc degeneration (lumbar);
TGCT	cis	rs1048238	0.506	rs12023422	chr1:16187625	G/A	cg21385522	chr1:16154831	NA	0.58	6.49	0.5	1.83e-9	Systolic blood pressure;
TGCT	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg06112835	chr11:68658793	MRPL21	0.48	8.09	0.59	4.59e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7666738	0.830	rs2865977	chr4:99017916	C/T	cg05340658	chr4:99064831	C4orf37	0.47	5.41	0.44	3.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1577917	0.917	rs35738006	chr6:86646309	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.13	-0.42	1.07e-6	Response to antipsychotic treatment;
TGCT	cis	rs9911578	1.000	rs2567905	chr17:56782297	T/C	cg05425664	chr17:57184151	TRIM37	-0.63	-6.26	-0.49	5.86e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs6088580	0.634	rs6087588	chr20:33066369	T/C	cg06115741	chr20:33292138	TP53INP2	0.54	4.71	0.39	6.47e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs28374715	0.532	rs28897479	chr15:41690851	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.94	-16.83	-0.83	8.04e-34	Ulcerative colitis;
TGCT	cis	rs12477438	0.765	rs6740054	chr2:99576631	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-5.03	-0.41	1.66e-6	Chronic sinus infection;
TGCT	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg25036284	chr2:26402008	FAM59B	0.6	4.64	0.38	8.63e-6	Gut microbiome composition (summer);
TGCT	cis	rs6964587	0.934	rs1544377	chr7:91687351	A/G	cg22709100	chr7:91322751	NA	0.28	4.56	0.38	1.19e-5	Breast cancer;
TGCT	cis	rs1797081	0.561	rs2603795	chr10:16860256	A/G	cg14835575	chr10:16859367	RSU1	0.43	5.5	0.44	2.06e-7	Platelet distribution width;
TGCT	cis	rs7267979	1.000	rs404394	chr20:25447896	A/G	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs80282103	0.618	rs2279256	chr10:1132852	G/A	cg08668510	chr10:1095578	IDI1	1.07	5.31	0.43	5e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs9372253	1.000	rs2235989	chr6:110714584	A/T	cg01119278	chr6:110721349	DDO	-0.35	-5.61	-0.45	1.28e-7	Platelet distribution width;
TGCT	cis	rs7647973	0.925	rs11130183	chr3:49228946	A/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.57	-4.79	-0.4	4.63e-6	Menarche (age at onset);
TGCT	cis	rs8103278	1.000	rs7258283	chr19:46335511	C/T	cg14061069	chr19:46274453	DMPK	-0.44	-6.29	-0.49	4.97e-9	Coronary artery disease;
TGCT	cis	rs9534288	0.830	rs1126365	chr13:46633196	T/A	cg15192986	chr13:46630673	CPB2	-0.5	-6.23	-0.49	6.66e-9	Blood protein levels;
TGCT	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg21226059	chr5:178986404	RUFY1	-0.45	-4.93	-0.4	2.62e-6	Lung cancer;
TGCT	cis	rs707040	0.843	rs6435170	chr2:155232800	A/C	cg18104148	chr2:154337490	NA	0.19	4.63	0.38	9.05e-6	Sudden cardiac arrest;
TGCT	cis	rs1150668	0.796	rs2531832	chr6:28389222	G/A	cg13525197	chr6:28411240	ZSCAN23	-0.51	-4.99	-0.41	1.96e-6	Pubertal anthropometrics;
TGCT	cis	rs2235642	0.826	rs8048410	chr16:1614097	A/G	cg07341220	chr16:1583899	IFT140;TMEM204	-0.32	-4.75	-0.39	5.55e-6	Coronary artery disease;
TGCT	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg11905131	chr22:24372483	LOC391322	0.71	5.72	0.46	7.55e-8	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs1158570	0.500	rs7846376	chr8:131155443	G/A	cg16277922	chr8:131349729	ASAP1	0.45	5.65	0.45	1.04e-7	Platelet count;
TGCT	cis	rs2742417	0.967	rs2742462	chr3:45774696	G/A	cg04837898	chr3:45731254	SACM1L	-0.53	-5.53	-0.45	1.78e-7	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg05234568	chr11:5960015	NA	-0.46	-5.35	-0.43	4.17e-7	DNA methylation (variation);
TGCT	cis	rs11190604	1.000	rs3763695	chr10:102269206	A/G	cg23241863	chr10:102295624	HIF1AN	0.67	5.13	0.42	1.1e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7213347	0.780	rs216224	chr17:2156285	T/C	cg22033759	chr17:1182267	TUSC5	0.22	4.51	0.38	1.51e-5	Total body bone mineral density;
TGCT	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg07404485	chr7:94953653	PON1	-0.3	-5.11	-0.42	1.2e-6	Paraoxonase activity;
TGCT	cis	rs9653442	0.545	rs11681966	chr2:100759457	A/C	cg07810366	chr2:100720526	AFF3	0.37	5.42	0.44	3e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs7772486	0.686	rs10872579	chr6:145966012	C/G	cg23711669	chr6:146136114	FBXO30	0.87	9.51	0.65	1.93e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9426691	1	rs9426691	chr1:23484904	A/G	cg12483005	chr1:23474871	LUZP1	0.5	5.84	0.46	4.2e-8	Coenzyme Q10 levels;
TGCT	cis	rs9467711	0.606	rs67509210	chr6:26354100	G/T	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg03806693	chr22:41940476	POLR3H	1.02	11.39	0.72	5.21e-21	Vitiligo;
TGCT	cis	rs71435601	0.628	rs529396	chr2:21381268	G/C	cg25035485	chr2:21266500	APOB	0.51	4.49	0.37	1.62e-5	Cholesterol, total;
TGCT	cis	rs2070488	0.574	rs57754356	chr3:38488706	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.8	7.95	0.58	9.86e-13	Electrocardiographic conduction measures;
TGCT	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2729354	0.817	rs2250673	chr11:57268170	T/C	cg24343310	chr11:57249947	NA	0.29	4.73	0.39	6.13e-6	Blood protein levels;
TGCT	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg00343986	chr7:65444356	GUSB	0.26	5.95	0.47	2.56e-8	Aortic root size;
TGCT	cis	rs2249625	0.584	rs2463744	chr6:72875936	C/T	cg08500200	chr6:72892038	RIMS1	-0.42	-4.54	-0.38	1.33e-5	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
TGCT	cis	rs2046867	1.000	rs2046867	chr3:72781075	G/A	cg25664220	chr3:72788482	NA	-0.55	-6.83	-0.52	3.42e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	8.99	0.63	3.48e-15	Platelet count;
TGCT	cis	rs6121246	0.821	rs7265413	chr20:30317923	G/A	cg13852791	chr20:30311386	BCL2L1	0.78	5.8	0.46	5.15e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs6598955	0.671	rs12090258	chr1:26644698	C/T	cg04990556	chr1:26633338	UBXN11	0.62	4.6	0.38	1.04e-5	Obesity-related traits;
TGCT	cis	rs8064299	0.597	rs2166703	chr17:72781812	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.91	10.35	0.68	1.8e-18	Monocyte count;
TGCT	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg03060546	chr3:49711283	APEH	0.54	5.13	0.42	1.11e-6	Menarche (age at onset);
TGCT	cis	rs9972944	0.902	rs12939558	chr17:63772152	A/G	cg07283582	chr17:63770753	CCDC46	0.27	5.27	0.43	5.91e-7	Total body bone mineral density;
TGCT	cis	rs9303542	0.694	rs9906950	chr17:46577167	A/G	cg25032089	chr17:46643351	HOXB3	-0.52	-5.86	-0.47	3.92e-8	Ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs7267979	0.868	rs6138553	chr20:25239233	G/A	cg03522245	chr20:25566470	NINL	0.6	6.45	0.5	2.3e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3782455	1.000	rs77542721	chr12:114402518	C/T	cg10631684	chr12:113795897	PLBD2	-0.7	-4.61	-0.38	1e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs17376456	0.809	rs10476602	chr5:93445255	T/C	cg25358565	chr5:93447407	FAM172A	0.9	8.26	0.6	1.9e-13	Diabetic retinopathy;
TGCT	cis	rs2235649	0.592	rs8051883	chr16:1958978	G/A	cg02432467	chr16:1963432	HS3ST6	-0.31	-4.61	-0.38	9.71e-6	Blood metabolite levels;
TGCT	cis	rs314370	0.951	rs17884589	chr7:100493711	G/A	cg10426581	chr7:100472382	SRRT	1.0	10.93	0.7	6.98e-20	Resting heart rate;
TGCT	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg25703541	chr22:24373054	LOC391322	-0.82	-8.62	-0.61	2.61e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs910316	1.000	rs10873275	chr14:75531460	A/T	cg08847533	chr14:75593920	NEK9	0.96	10.6	0.69	4.3e-19	Height;
TGCT	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg21862992	chr11:68658383	NA	0.44	6.07	0.48	1.42e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9430161	0.579	rs6694011	chr1:11036935	G/A	cg02454025	chr1:11042201	C1orf127	0.92	11.24	0.71	1.21e-20	Ewing sarcoma;
TGCT	cis	rs6684514	1.000	rs12117951	chr1:156305286	G/A	cg16558208	chr1:156270281	VHLL	0.48	9.6	0.65	1.19e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs12477438	0.715	rs6724476	chr2:99627316	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-4.62	-0.38	9.47e-6	Chronic sinus infection;
TGCT	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg08048268	chr3:133502702	NA	-0.66	-9.83	-0.66	3.36e-17	Iron status biomarkers;
TGCT	cis	rs9527	0.641	rs4919684	chr10:104587024	A/G	cg04362960	chr10:104952993	NT5C2	0.63	5.37	0.43	3.77e-7	Arsenic metabolism;
TGCT	cis	rs1018836	1.000	rs1018836	chr8:91570362	A/G	cg16814680	chr8:91681699	NA	-0.8	-8.57	-0.61	3.46e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs611744	0.967	rs603571	chr8:109213893	A/C	cg21045802	chr8:109455806	TTC35	0.52	4.72	0.39	6.21e-6	Dupuytren's disease;
TGCT	cis	rs4851254	0.660	rs4851250	chr2:100729293	T/C	cg22139774	chr2:100720529	AFF3	-0.42	-4.45	-0.37	1.85e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs4711350	0.906	rs4713687	chr6:33789402	T/C	cg18005901	chr6:33739558	LEMD2	-0.57	-5.75	-0.46	6.68e-8	Schizophrenia;
TGCT	cis	rs12367572	0.504	rs7303573	chr12:45519555	A/C	cg04608330	chr12:45269318	NELL2	0.47	4.62	0.38	9.41e-6	Gut microbiome composition (summer);
TGCT	cis	rs2204008	0.805	rs2874289	chr12:38258420	G/A	cg13010199	chr12:38710504	ALG10B	0.63	4.92	0.4	2.71e-6	Bladder cancer;
TGCT	cis	rs4148883	0.651	rs2851301	chr4:100010127	C/T	cg13256891	chr4:100009986	ADH5	0.42	4.49	0.37	1.64e-5	Alcohol dependence;
TGCT	cis	rs9914988	0.943	rs9915673	chr17:27132893	G/C	cg20469991	chr17:27169893	C17orf63	-0.72	-5.09	-0.42	1.28e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs73001065	0.901	rs73004962	chr19:19713069	A/T	cg03709012	chr19:19516395	GATAD2A	1.04	5.1	0.42	1.26e-6	LDL cholesterol;
TGCT	cis	rs10045504	0.502	rs72746031	chr5:38743161	G/A	cg15396434	chr5:38725168	NA	-0.35	-4.47	-0.37	1.73e-5	Night sleep phenotypes;
TGCT	cis	rs2050392	0.737	rs7898978	chr10:30699800	T/C	cg13289132	chr10:30722225	MAP3K8	0.43	5.33	0.43	4.53e-7	Inflammatory bowel disease;
TGCT	cis	rs9457247	0.935	rs427824	chr6:167403918	T/G	cg25258033	chr6:167368657	RNASET2	0.19	4.51	0.38	1.5e-5	Crohn's disease;
TGCT	cis	rs1865760	0.865	rs9467641	chr6:25947236	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.64	6.31	0.49	4.56e-9	Height;
TGCT	cis	rs1371867	0.875	rs2439456	chr8:101336874	C/T	cg00191853	chr8:101177733	SPAG1	-0.23	-4.66	-0.39	8.07e-6	Atrioventricular conduction;
TGCT	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg10053473	chr17:62856997	LRRC37A3	-0.46	-6.98	-0.53	1.59e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg26338869	chr17:61819248	STRADA	-0.53	-4.94	-0.41	2.48e-6	Prudent dietary pattern;
TGCT	cis	rs73110464	0.609	rs727266	chr12:53356411	C/T	cg16329197	chr12:53359506	NA	-0.56	-7.89	-0.58	1.32e-12	Cancer (pleiotropy);
TGCT	cis	rs6880778	0.505	rs12658567	chr5:40391932	G/T	cg01087697	chr5:40835557	RPL37	-0.5	-4.47	-0.37	1.71e-5	Inflammatory bowel disease;
TGCT	cis	rs75686122	0.892	rs77507894	chr8:104580907	T/A	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg17345569	chr6:42928274	GNMT	0.48	4.97	0.41	2.22e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs854765	0.929	rs854766	chr17:18012775	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.61	5.74	0.46	6.9e-8	Total body bone mineral density;
TGCT	cis	rs2637266	1.000	rs7478008	chr10:78355575	T/A	cg18941641	chr10:78392320	NA	0.4	5.01	0.41	1.81e-6	Pulmonary function;
TGCT	cis	rs986417	1.000	rs8021347	chr14:60952773	G/C	cg27398547	chr14:60952738	C14orf39	1.39	10.61	0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs7267979	0.586	rs6050445	chr20:25195394	C/T	cg14121845	chr20:25566513	NINL	0.45	4.81	0.4	4.26e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg25767906	chr1:53392781	SCP2	0.62	7.81	0.57	2.02e-12	Monocyte count;
TGCT	cis	rs6750047	0.585	rs4670235	chr2:38272528	C/T	cg07380506	chr2:38303506	CYP1B1	0.59	5.36	0.43	3.84e-7	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs17125944	0.686	rs7144029	chr14:53333616	G/T	cg00686598	chr14:53173677	PSMC6	-0.86	-4.47	-0.37	1.75e-5	Alzheimer's disease (late onset);
TGCT	cis	rs8084351	0.902	rs7245004	chr18:50716945	C/A	cg24270629	chr18:50823537	DCC	-0.28	-4.61	-0.38	1e-5	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
TGCT	cis	rs7312933	0.526	rs1669892	chr12:42811305	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.58	-5.69	-0.46	8.61e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg22535103	chr8:58192502	C8orf71	-0.44	-5.25	-0.43	6.36e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7666738	0.830	rs62318472	chr4:98926030	G/A	cg05340658	chr4:99064831	C4orf37	0.53	6.02	0.48	1.8e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg22963979	chr7:1858916	MAD1L1	-0.41	-6.75	-0.52	4.97e-10	Schizophrenia;
TGCT	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs11098499	0.619	rs28502463	chr4:120257023	T/C	cg09307838	chr4:120376055	NA	0.63	6.07	0.48	1.44e-8	Corneal astigmatism;
TGCT	cis	rs7027203	1.000	rs7864114	chr9:96551954	A/G	cg14598338	chr9:96623480	NA	0.59	8.65	0.61	2.17e-14	DNA methylation (variation);
TGCT	cis	rs7666738	0.830	rs11097598	chr4:98946057	T/C	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs17685	0.712	rs4552844	chr7:75718095	A/G	cg19862616	chr7:65841803	NCRNA00174	0.52	9.01	0.63	3.02e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs13191362	0.872	rs13206549	chr6:162978032	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.65	5.31	0.43	4.94e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs2013441	1.000	rs2526458	chr17:20092200	C/T	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.61	-0.38	9.96e-6	Obesity-related traits;
TGCT	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg03517284	chr6:25882590	NA	0.89	9.16	0.64	1.32e-15	Blood metabolite levels;
TGCT	cis	rs9811920	0.809	rs4928151	chr3:99767553	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.46	5.18	0.42	8.61e-7	Axial length;
TGCT	cis	rs2580764	0.573	rs13387751	chr2:55227375	C/G	cg09592903	chr2:55203963	RTN4	-0.24	-5.32	-0.43	4.73e-7	Mean platelet volume;
TGCT	cis	rs1577917	1.000	rs12216203	chr6:86675301	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.48	-0.44	2.27e-7	Response to antipsychotic treatment;
TGCT	trans	rs2469997	1.000	rs2470021	chr8:120362644	T/C	cg01792902	chr3:178864926	PIK3CA	0.83	6.77	0.52	4.49e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs2067615	0.560	rs10431462	chr12:107106546	G/A	cg15890332	chr12:107067104	RFX4	0.3	5.88	0.47	3.6e-8	Heart rate;
TGCT	cis	rs6923462	0.642	rs13209685	chr6:7779729	G/T	cg16988958	chr6:7987739	MGC26597	0.26	4.52	0.38	1.4e-5	Lung function (forced vital capacity);
TGCT	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg13695892	chr22:41940480	POLR3H	0.91	9.32	0.64	5.63e-16	Vitiligo;
TGCT	cis	rs76473307	1.000	rs76473307	chr20:57406068	A/C	cg06163629	chr20:57414884	GNASAS;GNAS	-0.64	-4.5	-0.37	1.54e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg12570787	chr5:219185	SDHA;CCDC127	0.65	4.46	0.37	1.83e-5	Breast cancer;
TGCT	cis	rs6570726	0.599	rs4398765	chr6:145935006	C/A	cg13319975	chr6:146136371	FBXO30	-0.68	-6.23	-0.49	6.81e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg11062466	chr8:58055876	NA	0.46	4.88	0.4	3.25e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10540	0.730	rs61876338	chr11:493730	A/G	cg03352830	chr11:487213	PTDSS2	0.26	4.56	0.38	1.23e-5	Body mass index;
TGCT	cis	rs72720396	0.803	rs114993052	chr1:91190855	T/A	cg13456504	chr1:91191583	NA	0.74	5.83	0.46	4.57e-8	Morning vs. evening chronotype;Chronotype;
TGCT	cis	rs7940866	0.804	rs3910267	chr11:130810282	C/T	cg12179176	chr11:130786555	SNX19	0.59	5.82	0.46	4.62e-8	Schizophrenia;
TGCT	cis	rs9300255	0.602	rs1790131	chr12:123701010	G/T	cg00376283	chr12:123451042	ABCB9	0.73	5.67	0.45	9.46e-8	Neutrophil percentage of white cells;
TGCT	cis	rs3806843	0.576	rs246046	chr5:140329264	T/A	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9486719	0.843	rs976357	chr6:96849679	C/T	cg06623918	chr6:96969491	KIAA0776	0.93	7.08	0.54	9.59e-11	Migraine;Coronary artery disease;
TGCT	cis	rs7172809	0.500	rs17385059	chr15:77637812	T/C	cg22256960	chr15:77711686	NA	-0.51	-4.81	-0.4	4.29e-6	Glucose homeostasis traits;
TGCT	cis	rs8056742	0.642	rs60115438	chr16:85047240	T/G	cg00229868	chr16:85520891	NA	0.4	5.09	0.42	1.3e-6	Amyotrophic lateral sclerosis;
TGCT	cis	rs1018836	0.699	rs13271657	chr8:91474599	C/G	cg16814680	chr8:91681699	NA	-0.85	-8.36	-0.6	1.1e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	trans	rs1814175	0.817	rs10839465	chr11:49981554	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.36	-7.14	-0.54	6.88e-11	Height;
TGCT	cis	rs739401	0.611	rs7130841	chr11:3043658	A/G	cg25174290	chr11:3078921	CARS	0.47	4.68	0.39	7.52e-6	Longevity;
TGCT	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg11644478	chr21:40555479	PSMG1	-0.54	-4.89	-0.4	3.02e-6	Menarche (age at onset);
TGCT	cis	rs1865760	0.865	rs9467651	chr6:25958257	C/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.64	6.29	0.49	4.91e-9	Height;
TGCT	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-5.09	-0.42	1.29e-6	Electroencephalogram traits;
TGCT	cis	rs2735413	0.564	rs2344492	chr16:78096226	C/T	cg09132178	chr16:78079569	NA	0.33	4.44	0.37	1.98e-5	Systolic blood pressure (alcohol consumption interaction);
TGCT	cis	rs7267979	0.966	rs2257461	chr20:25265554	A/G	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7267979	0.844	rs6050477	chr20:25221547	C/T	cg03522245	chr20:25566470	NINL	-0.55	-5.95	-0.47	2.49e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3806843	0.648	rs702399	chr5:140024432	C/T	cg19875535	chr5:140030758	IK	-0.35	-6.27	-0.49	5.41e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs10823500	0.777	rs7919014	chr10:71944577	T/C	cg04118878	chr10:71993077	PPA1	0.54	4.96	0.41	2.3e-6	Blood protein levels;
TGCT	cis	rs919433	0.713	rs13411968	chr2:198467141	C/T	cg00792783	chr2:198669748	PLCL1	0.48	4.47	0.37	1.75e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs2370759	1.000	rs78959390	chr10:32616346	C/T	cg01819863	chr10:32635814	EPC1	1.03	10.0	0.67	1.27e-17	Sexual dysfunction (female);
TGCT	cis	rs9291683	0.597	rs11723016	chr4:10126189	A/G	cg11266682	chr4:10021025	SLC2A9	-0.44	-5.33	-0.43	4.44e-7	Bone mineral density;
TGCT	cis	rs6952808	0.609	rs6970034	chr7:1948088	G/A	cg04267008	chr7:1944627	MAD1L1	-0.37	-4.83	-0.4	3.94e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs7772486	0.754	rs4896839	chr6:146019689	T/G	cg23711669	chr6:146136114	FBXO30	-0.93	-10.83	-0.7	1.24e-19	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7113874	0.531	rs10840094	chr11:8627974	T/A	cg14521421	chr11:8862019	ST5	-0.3	-4.61	-0.38	1e-5	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg04944784	chr2:26401820	FAM59B	-0.67	-6.16	-0.48	9.54e-9	Gut microbiome composition (summer);
TGCT	cis	rs35146811	0.735	rs1727130	chr7:99811464	C/G	cg00553149	chr7:99775558	STAG3;GPC2	-0.31	-4.61	-0.38	9.75e-6	Coronary artery disease;
TGCT	cis	rs9372498	0.536	rs9489442	chr6:118885950	A/C	cg07617317	chr6:118971624	C6orf204	0.52	5.54	0.45	1.71e-7	Diastolic blood pressure;
TGCT	cis	rs11754661	1.000	rs78944278	chr6:151207454	C/T	cg01354656	chr6:151411710	MTHFD1L	0.48	4.46	0.37	1.81e-5	Alzheimer's disease (late onset);
TGCT	cis	rs10256972	0.721	rs10435145	chr7:1065988	C/T	cg03188948	chr7:1209495	NA	0.5	6.74	0.52	5.38e-10	Longevity;Endometriosis;
TGCT	cis	rs7586879	0.789	rs13382979	chr2:25131736	G/A	cg01884057	chr2:25150051	NA	0.27	4.64	0.38	8.78e-6	Body mass index;
TGCT	cis	rs7937682	0.889	rs1789355	chr11:111499718	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.11	-11.7	-0.72	9.24e-22	Primary sclerosing cholangitis;
TGCT	cis	rs35306767	0.903	rs11253467	chr10:901244	A/G	cg20503657	chr10:835505	NA	0.75	10.41	0.68	1.3e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs5769765	0.825	rs7511620	chr22:50307932	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.22	-12.54	-0.75	8.41e-24	Schizophrenia;
TGCT	cis	rs10875746	0.669	rs61940962	chr12:48595477	A/C	cg20731937	chr12:48336164	NA	0.6	4.6	0.38	1.01e-5	Longevity (90 years and older);
TGCT	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.43	6.24	0.49	6.39e-9	Schizophrenia;
TGCT	cis	rs6088580	0.634	rs6120650	chr20:33039973	G/A	cg08999081	chr20:33150536	PIGU	0.29	5.74	0.46	6.96e-8	Glomerular filtration rate (creatinine);
TGCT	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg23719950	chr11:63933701	MACROD1	0.64	5.64	0.45	1.07e-7	Mean platelet volume;
TGCT	cis	rs9486715	0.830	rs2475023	chr6:96996833	G/A	cg06623918	chr6:96969491	KIAA0776	-1.1	-14.35	-0.79	3.93e-28	Headache;
TGCT	cis	rs9650657	0.515	rs6601560	chr8:10950866	T/C	cg03192020	chr8:11204681	TDH	-0.52	-4.52	-0.38	1.42e-5	Neuroticism;
TGCT	cis	rs7552404	0.924	rs1146588	chr1:76229787	C/G	cg10523679	chr1:76189770	ACADM	0.82	8.79	0.62	1.05e-14	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9486719	0.857	rs4265039	chr6:96878929	T/C	cg18709589	chr6:96969512	KIAA0776	0.76	6.58	0.51	1.19e-9	Migraine;Coronary artery disease;
TGCT	cis	rs11671005	0.693	rs11669665	chr19:58931885	G/A	cg13877915	chr19:58951672	ZNF132	0.65	5.14	0.42	1.04e-6	Mean platelet volume;
TGCT	cis	rs2637266	0.846	rs2637263	chr10:78322442	G/A	cg18941641	chr10:78392320	NA	0.39	4.94	0.41	2.45e-6	Pulmonary function;
TGCT	cis	rs3008870	0.583	rs3008861	chr1:67396222	T/G	cg11518657	chr1:67396239	MIER1	0.59	4.69	0.39	7.23e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs7833790	0.963	rs7836040	chr8:82698328	G/A	cg27398817	chr8:82754497	SNX16	-0.81	-5.62	-0.45	1.22e-7	Diastolic blood pressure;
TGCT	cis	rs10782582	0.593	rs12131344	chr1:76136437	C/T	cg22875332	chr1:76189707	ACADM	-0.55	-6.04	-0.48	1.68e-8	Daytime sleep phenotypes;
TGCT	cis	rs7727544	0.716	rs6863213	chr5:131575932	C/T	cg24060327	chr5:131705240	SLC22A5	-0.57	-5.6	-0.45	1.3e-7	Blood metabolite levels;
TGCT	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg11644478	chr21:40555479	PSMG1	1.02	10.63	0.69	3.73e-19	Cognitive function;
TGCT	cis	rs854765	0.583	rs4341796	chr17:17839024	C/A	cg09796270	chr17:17721594	SREBF1	0.27	5.55	0.45	1.69e-7	Total body bone mineral density;
TGCT	cis	rs4944092	1.000	rs4944092	chr11:75909619	C/T	cg04588336	chr11:75916460	WNT11	-0.46	-6.36	-0.5	3.56e-9	PR interval;
TGCT	cis	rs1372520	0.684	rs356188	chr4:90691537	T/C	cg20003494	chr4:90757398	SNCA	0.56	4.46	0.37	1.83e-5	Neuroticism;
TGCT	cis	rs3820928	0.839	rs13404750	chr2:227876129	G/A	cg11843606	chr2:227700838	RHBDD1	-0.52	-4.62	-0.38	9.54e-6	Pulmonary function;
TGCT	cis	rs881375	0.678	rs7021049	chr9:123683982	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	5.18	0.42	8.53e-7	Rheumatoid arthritis;
TGCT	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg01416388	chr22:39784598	NA	-0.72	-7.14	-0.54	6.88e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs9796	0.775	rs57393155	chr15:41426251	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.47	-5.99	-0.47	2.14e-8	Menopause (age at onset);
TGCT	cis	rs12477438	0.501	rs2516833	chr2:99777405	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.75	7.25	0.55	3.92e-11	Chronic sinus infection;
TGCT	cis	rs17221829	0.733	rs10765228	chr11:89385132	C/T	cg02982614	chr11:89391479	FOLH1B	-0.25	-4.46	-0.37	1.8e-5	Anxiety in major depressive disorder;
TGCT	cis	rs116161686	0.500	rs55871867	chr1:210051029	A/G	cg21951975	chr1:209979733	IRF6	0.63	4.96	0.41	2.23e-6	Coronary artery disease;
TGCT	cis	rs9291683	0.546	rs13120348	chr4:10053155	C/G	cg11266682	chr4:10021025	SLC2A9	-0.61	-7.76	-0.57	2.7e-12	Bone mineral density;
TGCT	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg25767906	chr1:53392781	SCP2	0.48	5.55	0.45	1.62e-7	Monocyte count;
TGCT	cis	rs6500602	0.634	rs2270365	chr16:4526758	G/A	cg08645402	chr16:4508243	NA	0.17	4.84	0.4	3.86e-6	Schizophrenia;
TGCT	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg11494091	chr17:61959527	GH2	0.43	7.4	0.55	1.82e-11	Height;
TGCT	cis	rs28453840	1	rs28453840	chr2:136522941	G/A	cg07169764	chr2:136633963	MCM6	-0.66	-6.11	-0.48	1.2e-8	Cholesterol, total;
TGCT	cis	rs3772130	0.923	rs3805127	chr3:121556751	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.72	0.39	6.25e-6	Cognitive performance;
TGCT	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.67	-0.39	7.73e-6	Prudent dietary pattern;
TGCT	cis	rs7267979	0.789	rs9927	chr20:25277244	A/G	cg14121845	chr20:25566513	NINL	0.48	4.86	0.4	3.43e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3806843	0.548	rs246055	chr5:140325662	C/T	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	trans	rs459571	0.959	rs392134	chr9:136909008	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.75	-8.08	-0.59	4.97e-13	Platelet distribution width;
TGCT	cis	rs254781	0.550	rs410216	chr5:88004101	G/A	cg22951263	chr5:87985283	NA	-0.56	-5.05	-0.41	1.51e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs13242816	1.000	rs3807993	chr7:116197572	T/A	cg16553024	chr7:116138462	CAV2	-0.43	-5.19	-0.42	8.16e-7	P wave duration;
TGCT	trans	rs7726839	0.540	rs72703092	chr5:599269	G/A	cg11887960	chr12:57824829	NA	1.2	9.56	0.65	1.47e-16	Obesity-related traits;
TGCT	cis	rs9467773	0.587	rs12214031	chr6:26376628	T/C	cg15659132	chr6:26577336	NA	-0.52	-5.27	-0.43	5.83e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7681440	0.904	rs3756063	chr4:90757394	G/C	cg20003494	chr4:90757398	SNCA	-0.61	-5.78	-0.46	5.8e-8	Dementia with Lewy bodies;
TGCT	cis	rs6088590	0.965	rs6058108	chr20:33288655	A/G	cg06115741	chr20:33292138	TP53INP2	0.65	5.49	0.44	2.17e-7	Coronary artery disease;
TGCT	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.0	8.11	0.59	4.07e-13	Platelet count;
TGCT	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg03396347	chr1:1875803	NA	-0.37	-6.7	-0.52	6.62e-10	Body mass index;
TGCT	cis	rs79387448	0.614	rs985523	chr2:102954376	G/A	cg09003973	chr2:102972529	NA	1.34	10.63	0.69	3.78e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs2019216	0.521	rs6565386	chr17:21901755	A/G	cg22648282	chr17:21454238	C17orf51	0.56	5.53	0.45	1.78e-7	Pelvic organ prolapse;
TGCT	cis	rs9894429	1.000	rs7209180	chr17:79581519	C/A	cg18240062	chr17:79603768	NPLOC4	0.67	6.84	0.52	3.23e-10	Eye color traits;
TGCT	cis	rs2469997	1.000	rs2447181	chr8:120354288	T/A	cg00681363	chr8:120844660	TAF2	0.65	4.52	0.38	1.45e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg06640241	chr16:89574553	SPG7	0.82	9.41	0.65	3.39e-16	Multiple myeloma (IgH translocation);
TGCT	cis	rs9399135	0.967	rs12527683	chr6:135324534	C/T	cg24558204	chr6:135376177	HBS1L	0.47	4.75	0.39	5.58e-6	Red blood cell count;
TGCT	cis	rs4555082	0.957	rs8022526	chr14:105756485	A/G	cg10792982	chr14:105748885	BRF1	0.22	4.5	0.37	1.57e-5	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs9435341	0.965	rs55909997	chr1:107581039	G/A	cg09367891	chr1:107599246	PRMT6	0.64	5.71	0.46	7.78e-8	Facial morphology (factor 21, depth of nasal alae);
TGCT	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.48	-0.37	1.66e-5	Bipolar disorder;
TGCT	cis	rs7267979	0.866	rs437635	chr20:25456888	A/G	cg16686733	chr20:25566563	NINL	0.56	5.69	0.46	8.49e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg01585852	chr22:24235823	MIF	-0.22	-4.82	-0.4	4.16e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs11676348	0.755	rs6436026	chr2:218951738	T/A	cg00012203	chr2:219082015	ARPC2	-0.5	-4.63	-0.38	8.99e-6	Ulcerative colitis;
TGCT	cis	rs6684514	0.961	rs12048077	chr1:156299916	T/A	cg20302342	chr1:156215951	PAQR6	0.35	4.74	0.39	5.77e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs17345786	0.861	rs11707689	chr3:101086475	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.84	8.92	0.63	5.05e-15	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10089	1.000	rs4836367	chr5:127482592	A/G	cg19767477	chr5:127420684	SLC12A2	-0.43	-4.55	-0.38	1.27e-5	Ileal carcinoids;
TGCT	trans	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg11887960	chr12:57824829	NA	1.14	9.28	0.64	6.87e-16	Obesity-related traits;
TGCT	cis	rs1018836	0.828	rs1858673	chr8:91551526	C/A	cg16814680	chr8:91681699	NA	-0.75	-7.83	-0.58	1.84e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg07507251	chr3:52567010	NT5DC2	0.47	6.64	0.51	8.85e-10	Bipolar disorder;
TGCT	cis	rs9500256	0.683	rs10458024	chr6:58324089	T/C	cg16251399	chr6:58287822	GUSBL2	0.53	4.47	0.37	1.72e-5	Eosinophilic esophagitis (pediatric);
TGCT	cis	rs765787	0.530	rs12913123	chr15:45516425	C/T	cg24006582	chr15:45444508	DUOX1	0.25	5.33	0.43	4.46e-7	Uric acid levels;
TGCT	cis	rs6964587	1.000	rs411	chr7:91557758	C/G	cg17063962	chr7:91808500	NA	-0.9	-9.67	-0.66	7.91e-17	Breast cancer;
TGCT	cis	rs9357506	1.000	rs6910772	chr6:46307395	C/T	cg21115430	chr6:46460003	NA	-0.26	-5.17	-0.42	9.2e-7	Body mass index;
TGCT	cis	rs9388451	0.839	rs10457469	chr6:126083658	G/A	cg10911889	chr6:126070802	HEY2	0.54	5.64	0.45	1.08e-7	Brugada syndrome;
TGCT	cis	rs854765	0.505	rs4924832	chr17:17897739	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.79	8.06	0.59	5.4e-13	Total body bone mineral density;
TGCT	cis	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg18252515	chr7:66147081	NA	-1.14	-6.81	-0.52	3.76e-10	Diabetic kidney disease;
TGCT	cis	rs734999	0.545	rs10797436	chr1:2538349	G/A	cg18854424	chr1:2615690	NA	0.41	4.58	0.38	1.13e-5	Ulcerative colitis;
TGCT	cis	rs860295	0.540	rs915178	chr1:155978725	C/T	cg05700447	chr1:155978627	NA	0.24	5.09	0.42	1.28e-6	Body mass index;
TGCT	cis	rs514406	0.505	rs12726160	chr1:53175099	A/G	cg08859206	chr1:53392774	SCP2	-0.37	-5.39	-0.44	3.4e-7	Monocyte count;
TGCT	cis	rs892961	0.806	rs35489990	chr17:75412312	T/C	cg05865280	chr17:75406074	SEPT9	0.28	6.86	0.52	2.9e-10	Airflow obstruction;
TGCT	cis	rs8084125	0.832	rs62105166	chr18:74944518	A/G	cg05528293	chr18:74961138	GALR1	0.49	4.84	0.4	3.74e-6	Obesity-related traits;
TGCT	cis	rs6901004	0.771	rs6900781	chr6:111422856	T/A	cg15721981	chr6:111408429	SLC16A10	-0.53	-4.62	-0.38	9.3e-6	Blood metabolite levels;
TGCT	cis	rs7178572	0.524	rs7163503	chr15:77493505	C/A	cg22256960	chr15:77711686	NA	-0.88	-8.99	-0.63	3.53e-15	Type 2 diabetes;
TGCT	cis	rs3764628	0.925	rs11670437	chr19:18783390	C/T	cg20098710	chr19:19640075	YJEFN3	-0.46	-5.23	-0.42	7.11e-7	Orofacial clefts;
TGCT	cis	rs8017423	0.967	rs1959002	chr14:90670994	T/A	cg04374321	chr14:90722782	PSMC1	0.77	7.95	0.58	9.78e-13	Mortality in heart failure;
TGCT	cis	rs9372498	0.536	rs9489457	chr6:118920285	C/T	cg07617317	chr6:118971624	C6orf204	0.49	5.22	0.42	7.37e-7	Diastolic blood pressure;
TGCT	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg10047753	chr17:41438598	NA	0.94	9.17	0.64	1.28e-15	Menopause (age at onset);
TGCT	cis	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg18252515	chr7:66147081	NA	-1.31	-8.18	-0.59	2.87e-13	Diabetic kidney disease;
TGCT	cis	rs6570726	0.791	rs378937	chr6:145834745	C/T	cg23711669	chr6:146136114	FBXO30	0.82	8.59	0.61	3.08e-14	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6714710	0.580	rs1838797	chr2:98454572	G/C	cg26665480	chr2:98280029	ACTR1B	0.66	6.24	0.49	6.33e-9	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs9311474	0.967	rs11717383	chr3:52287468	G/T	cg07507251	chr3:52567010	NT5DC2	0.43	6.0	0.47	2e-8	Electroencephalogram traits;
TGCT	cis	rs7208859	0.623	rs8082537	chr17:29015932	T/C	cg13385521	chr17:29058706	SUZ12P	0.75	4.62	0.38	9.34e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs9443645	0.901	rs4706079	chr6:79615208	G/A	cg09184832	chr6:79620586	NA	-0.49	-5.29	-0.43	5.29e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9902453	0.904	rs9900974	chr17:28364456	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.81	-7.67	-0.57	4.47e-12	Coffee consumption (cups per day);
TGCT	cis	rs782590	0.935	rs62165197	chr2:55801812	C/T	cg18811423	chr2:55921094	PNPT1	0.65	6.93	0.53	2.04e-10	Metabolic syndrome;
TGCT	cis	rs896854	0.625	rs4735335	chr8:95973327	G/C	cg13393036	chr8:95962371	TP53INP1	-0.63	-8.52	-0.61	4.43e-14	Type 2 diabetes;
TGCT	cis	rs921968	0.643	rs598701	chr2:219387005	C/G	cg02176678	chr2:219576539	TTLL4	-0.38	-5.48	-0.44	2.31e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs17221829	0.692	rs2773236	chr11:89454836	C/T	cg02982614	chr11:89391479	FOLH1B	-0.27	-4.88	-0.4	3.23e-6	Anxiety in major depressive disorder;
TGCT	cis	rs9311474	0.935	rs7622851	chr3:52333671	C/G	cg07507251	chr3:52567010	NT5DC2	0.46	6.21	0.49	7.16e-9	Electroencephalogram traits;
TGCT	cis	rs4689388	0.890	rs11732208	chr4:6292716	G/C	cg25554036	chr4:6271136	WFS1	0.54	7.37	0.55	2.11e-11	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs6582630	0.512	rs11182667	chr12:38588392	C/A	cg26384229	chr12:38710491	ALG10B	-0.54	-4.75	-0.39	5.62e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs10540	0.570	rs8176330	chr11:535798	G/A	cg03934478	chr11:495069	RNH1	0.32	4.55	0.38	1.28e-5	Body mass index;
TGCT	cis	rs6582630	0.533	rs4103689	chr12:38702980	A/C	cg26384229	chr12:38710491	ALG10B	0.68	6.28	0.49	5.18e-9	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.71	5.14	0.42	1.02e-6	Platelet count;
TGCT	cis	rs10927875	0.541	rs1739841	chr1:16342727	A/G	cg22431228	chr1:16359049	CLCNKA	-0.29	-6.02	-0.48	1.8e-8	Dilated cardiomyopathy;
TGCT	cis	rs9633740	1.000	rs6586028	chr10:82253984	C/T	cg01528321	chr10:82214614	TSPAN14	1.02	8.53	0.61	4.31e-14	Post bronchodilator FEV1;
TGCT	cis	rs16957091	0.607	rs7182650	chr15:43342878	T/A	cg17935677	chr15:44119062	WDR76	0.56	4.9	0.4	2.93e-6	MGMT methylation in smokers;
TGCT	cis	rs36051895	0.626	rs10283564	chr9:5075628	C/G	cg02405213	chr9:5042618	JAK2	-0.79	-10.23	-0.68	3.48e-18	Pediatric autoimmune diseases;
TGCT	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	5.93	0.47	2.86e-8	Bipolar disorder;
TGCT	cis	rs4689388	0.926	rs4458523	chr4:6289986	G/T	cg14416269	chr4:6271139	WFS1	-0.37	-4.88	-0.4	3.15e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs2933343	0.909	rs1683817	chr3:128651536	G/A	cg11901034	chr3:128598214	ACAD9	-0.63	-5.13	-0.42	1.08e-6	IgG glycosylation;
TGCT	cis	rs3020736	0.500	rs6002604	chr22:42493081	A/T	cg05082376	chr22:42548792	NA	0.23	5.43	0.44	2.83e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9381040	0.610	rs6919961	chr6:41020361	T/A	cg03526776	chr6:41159608	TREML2	0.27	5.43	0.44	2.89e-7	Alzheimer's disease (late onset);
TGCT	cis	rs2404602	0.692	rs2137307	chr15:77149020	T/A	cg22467129	chr15:76604101	ETFA	-0.47	-5.4	-0.44	3.28e-7	Blood metabolite levels;
TGCT	cis	rs4975616	0.686	rs37008	chr5:1351538	C/T	cg26373071	chr5:1325741	CLPTM1L	0.19	5.03	0.41	1.68e-6	Lung cancer;
TGCT	cis	rs6570726	1.000	rs1935615	chr6:145921117	G/T	cg23711669	chr6:146136114	FBXO30	0.65	5.96	0.47	2.4e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs62064224	0.554	rs9901737	chr17:30681354	C/G	cg18200150	chr17:30822561	MYO1D	0.39	4.72	0.39	6.34e-6	Schizophrenia;
TGCT	trans	rs10802346	0.515	rs1113270	chr1:246423217	A/G	cg22732515	chr19:44031385	ETHE1	0.96	8.12	0.59	3.9e-13	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs1372520	0.748	rs2737002	chr4:90753180	A/G	cg20003494	chr4:90757398	SNCA	-0.63	-5.09	-0.42	1.3e-6	Neuroticism;
TGCT	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg06640241	chr16:89574553	SPG7	0.84	9.55	0.65	1.55e-16	Multiple myeloma (IgH translocation);
TGCT	cis	rs17221829	0.733	rs10830304	chr11:89366754	A/G	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.65	-0.39	8.43e-6	Anxiety in major depressive disorder;
TGCT	cis	rs4900538	0.963	rs1998422	chr14:102980993	G/C	cg18135206	chr14:102964638	TECPR2	0.22	5.1	0.42	1.22e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg08509172	chr19:19383838	TM6SF2	-0.36	-4.76	-0.39	5.28e-6	Tonsillectomy;
TGCT	cis	rs7119	0.651	rs8041520	chr15:77839169	C/T	cg27398640	chr15:77910606	LINGO1	-0.27	-5.1	-0.42	1.22e-6	Type 2 diabetes;
TGCT	cis	rs4819852	0.958	rs2238792	chr22:19983213	C/T	cg07821417	chr22:19972146	ARVCF	0.19	4.8	0.4	4.42e-6	Pulse pressure;
TGCT	cis	rs9653442	0.564	rs2309756	chr2:100780269	G/C	cg22139774	chr2:100720529	AFF3	-0.36	-5.69	-0.46	8.67e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs7829975	0.577	rs940030	chr8:8546928	A/G	cg17143192	chr8:8559678	CLDN23	-0.52	-5.26	-0.43	6.11e-7	Mood instability;
TGCT	cis	rs56104184	0.775	rs73061695	chr19:49399988	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.73	-9.15	-0.63	1.47e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs12580194	1.000	rs12582022	chr12:55694360	A/G	cg20672549	chr12:56432144	IKZF4	0.28	4.52	0.38	1.44e-5	Cancer;
TGCT	cis	rs7772486	0.777	rs1546966	chr6:146386018	G/T	cg05347473	chr6:146136440	FBXO30	0.5	4.43	0.37	2.01e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs912057	0.582	rs1294412	chr6:6739854	A/G	cg06612196	chr6:6737390	NA	0.5	7.47	0.56	1.24e-11	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs9308731	0.863	rs17558117	chr2:111940996	A/T	cg04202892	chr2:111875749	ACOXL	0.47	5.13	0.42	1.08e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs72843506	0.722	rs74255392	chr17:20329052	A/G	cg18979559	chr17:20280153	CCDC144C	-0.65	-4.78	-0.39	4.96e-6	Schizophrenia;
TGCT	cis	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg06636001	chr8:8085503	FLJ10661	0.77	7.37	0.55	2.12e-11	Mood instability;
TGCT	cis	rs6087990	0.806	rs4911254	chr20:31357579	C/A	cg13636640	chr20:31349939	DNMT3B	1.07	14.14	0.79	1.28e-27	Ulcerative colitis;
TGCT	cis	rs9611519	0.780	rs9611528	chr22:41648502	T/C	cg03806693	chr22:41940476	POLR3H	-0.73	-6.97	-0.53	1.67e-10	Neuroticism;
TGCT	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.99	-7.28	-0.55	3.39e-11	Gut microbiome composition (summer);
TGCT	cis	rs35883536	0.584	rs56112014	chr1:101037431	A/G	cg06223162	chr1:101003688	GPR88	-0.41	-7.56	-0.56	7.75e-12	Monocyte count;
TGCT	cis	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg22857025	chr5:266934	NA	-0.34	-6.7	-0.52	6.65e-10	Breast cancer;
TGCT	cis	rs6088580	0.634	rs6059850	chr20:33044784	C/G	cg06115741	chr20:33292138	TP53INP2	0.55	4.69	0.39	7.24e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7617773	0.925	rs35942721	chr3:48173069	C/T	cg11946769	chr3:48343235	NME6	0.67	5.34	0.43	4.26e-7	Coronary artery disease;
TGCT	cis	rs2492301	0.540	rs10796907	chr1:37900173	C/T	cg17933807	chr1:38061675	GNL2	0.59	6.21	0.49	7.24e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs12477438	0.765	rs7605734	chr2:99644068	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-4.88	-0.4	3.17e-6	Chronic sinus infection;
TGCT	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg11644478	chr21:40555479	PSMG1	-0.53	-4.57	-0.38	1.17e-5	Cognitive function;
TGCT	cis	rs11864453	0.647	rs3764311	chr16:72125617	C/G	cg14768367	chr16:72042858	DHODH	0.52	5.21	0.42	7.61e-7	Fibrinogen levels;
TGCT	cis	rs477895	1.000	rs7938380	chr11:64034866	G/A	cg04317338	chr11:64019027	PLCB3	0.71	5.75	0.46	6.48e-8	Mean platelet volume;
TGCT	cis	rs6089584	0.526	rs6089316	chr20:60627552	C/T	cg13770153	chr20:60521292	NA	-0.39	-4.61	-0.38	9.96e-6	Body mass index;
TGCT	cis	rs2014572	0.967	rs10412975	chr19:57770554	C/A	cg24459738	chr19:57751996	ZNF805	-0.59	-5.79	-0.46	5.52e-8	Hyperactive-impulsive symptoms;
TGCT	cis	rs6088590	1.000	rs6058111	chr20:33310999	T/C	cg24642439	chr20:33292090	TP53INP2	0.69	6.01	0.48	1.88e-8	Coronary artery disease;
TGCT	cis	rs7226408	0.749	rs11665002	chr18:34314023	C/T	cg06757138	chr18:34340585	FHOD3	0.27	4.86	0.4	3.48e-6	Obesity-related traits;
TGCT	cis	rs78487399	0.808	rs28700209	chr2:43667465	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.24	-0.43	6.79e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs7937612	1.000	rs4938808	chr11:120336902	G/T	cg24566217	chr11:120254723	ARHGEF12	-0.29	-4.48	-0.37	1.66e-5	Intraocular pressure;
TGCT	cis	rs10779751	0.770	rs2791643	chr1:11207269	C/T	cg08854313	chr1:11322531	MTOR	0.82	6.66	0.51	7.99e-10	Body mass index;
TGCT	cis	rs9399135	0.967	rs6902438	chr6:135336587	C/T	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.36e-6	Red blood cell count;
TGCT	cis	rs9302065	0.565	rs2993585	chr13:95961966	G/A	cg24476569	chr13:95954382	ABCC4	-0.54	-8.26	-0.6	1.9e-13	Blood metabolite levels;
TGCT	cis	rs3924048	0.574	rs11121924	chr1:12611629	A/G	cg00291366	chr1:12616550	NA	0.32	4.87	0.4	3.34e-6	Optic cup area;
TGCT	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg11062466	chr8:58055876	NA	0.46	4.89	0.4	3.07e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4808199	0.948	rs2023883	chr19:19405480	G/A	cg03709012	chr19:19516395	GATAD2A	0.79	6.12	0.48	1.14e-8	Nonalcoholic fatty liver disease;
TGCT	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg12310025	chr6:25882481	NA	-0.51	-5.3	-0.43	5.11e-7	Height;
TGCT	cis	rs7095607	0.704	rs1900013	chr10:69953929	A/G	cg18986048	chr10:69913749	MYPN	0.58	6.79	0.52	4.14e-10	Lung function (FVC);
TGCT	cis	rs7617773	0.817	rs3731497	chr3:48226553	T/G	cg11946769	chr3:48343235	NME6	0.76	6.53	0.51	1.54e-9	Coronary artery disease;
TGCT	cis	rs7267979	1.000	rs6076345	chr20:25381895	T/G	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg00475322	chr7:917719	C7orf20	-0.43	-5.79	-0.46	5.46e-8	Perceived unattractiveness to mosquitoes;
TGCT	cis	rs6671200	1.000	rs12755552	chr1:95685026	A/G	cg03123541	chr1:95699097	RWDD3	0.87	6.17	0.48	8.81e-9	Stearic acid (18:0) levels;
TGCT	cis	rs3806843	1.000	rs4404730	chr5:140162610	G/A	cg19875535	chr5:140030758	IK	0.37	6.34	0.49	3.89e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg22963979	chr7:1858916	MAD1L1	-0.35	-5.49	-0.44	2.19e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs7845219	0.544	rs9643352	chr8:95918288	C/T	cg16049864	chr8:95962084	TP53INP1	-0.49	-5.36	-0.43	3.88e-7	Type 2 diabetes;
TGCT	cis	rs4595586	0.545	rs11611625	chr12:39387207	T/C	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs1215050	0.605	rs1817220	chr4:98615196	A/G	cg05340658	chr4:99064831	C4orf37	-0.41	-4.96	-0.41	2.3e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9611565	0.605	rs202638	chr22:41855458	A/G	cg13695892	chr22:41940480	POLR3H	0.92	9.22	0.64	9.72e-16	Vitiligo;
TGCT	cis	rs3751972	0.681	rs4796147	chr17:26186288	A/G	cg02948944	chr17:26242737	NA	0.38	5.37	0.43	3.8e-7	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs4242434	0.927	rs11781149	chr8:22473158	C/T	cg21658235	chr8:22456391	C8orf58	0.43	4.5	0.37	1.54e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs2361718	0.500	rs12451697	chr17:78100690	T/A	cg22255288	chr17:78854418	RPTOR	-0.23	-4.48	-0.37	1.7e-5	Yeast infection;
TGCT	cis	rs9811920	0.609	rs812657	chr3:99566329	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.6	6.82	0.52	3.63e-10	Axial length;
TGCT	cis	rs9911578	0.757	rs8081906	chr17:56631907	A/T	cg05425664	chr17:57184151	TRIM37	0.62	5.56	0.45	1.59e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7772486	0.875	rs864390	chr6:146315035	G/T	cg05347473	chr6:146136440	FBXO30	0.49	4.69	0.39	7.23e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs651907	0.557	rs3094295	chr3:101401995	T/C	cg12386194	chr3:101231763	SENP7	0.53	5.13	0.42	1.08e-6	Colorectal cancer;
TGCT	cis	rs12134133	0.962	rs6673890	chr1:207415133	C/T	cg02152968	chr1:207494213	CD55	0.6	4.65	0.39	8.43e-6	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs9443645	0.901	rs12193319	chr6:79583437	C/A	cg09184832	chr6:79620586	NA	-0.49	-5.29	-0.43	5.29e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg11301795	chr4:187892539	NA	-0.34	-5.25	-0.43	6.33e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7584330	0.554	rs74449293	chr2:238426458	G/A	cg08992911	chr2:238395768	MLPH	0.7	4.72	0.39	6.32e-6	Prostate cancer;
TGCT	cis	rs17253792	0.822	rs80174205	chr14:56058694	T/C	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs36051895	0.623	rs62541541	chr9:5040817	G/C	cg02405213	chr9:5042618	JAK2	-0.76	-10.28	-0.68	2.59e-18	Pediatric autoimmune diseases;
TGCT	cis	rs9467603	1.000	rs9467606	chr6:25809218	A/G	cg16898833	chr6:26189333	HIST1H4D	1.16	5.51	0.44	2.03e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9916302	0.904	rs755500	chr17:37409865	C/T	cg15445000	chr17:37608096	MED1	0.31	4.58	0.38	1.11e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs2075371	1.000	rs1868783	chr7:133975087	A/G	cg11752832	chr7:134001865	SLC35B4	0.7	6.51	0.5	1.68e-9	Mean platelet volume;
TGCT	cis	rs1801251	1.000	rs12474040	chr2:233615345	T/G	cg08000102	chr2:233561755	GIGYF2	0.64	6.52	0.51	1.58e-9	Coronary artery disease;
TGCT	cis	rs509477	0.887	rs595309	chr18:32562402	A/G	cg23791764	chr18:32556832	MAPRE2	0.65	5.31	0.43	4.88e-7	Cerebrospinal fluid AB1-42 levels;
TGCT	cis	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg08564027	chr20:61660810	NA	0.37	6.64	0.51	8.85e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg22963979	chr7:1858916	MAD1L1	-0.34	-5.24	-0.43	6.74e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs74233809	1.000	rs11191575	chr10:104898337	C/T	cg05855489	chr10:104503620	C10orf26	0.82	4.44	0.37	1.97e-5	Birth weight;
TGCT	cis	rs9467711	0.538	rs13191445	chr6:26015489	G/A	cg16898833	chr6:26189333	HIST1H4D	1.34	6.07	0.48	1.47e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.7	-0.39	6.79e-6	Prudent dietary pattern;
TGCT	cis	rs59197085	0.636	rs60894155	chr7:128465755	G/A	cg00260937	chr7:128520193	KCP	0.47	4.98	0.41	2.1e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
TGCT	cis	rs9900497	0.604	rs12949049	chr17:19653310	A/G	cg15323506	chr17:19619410	SLC47A2	0.21	5.1	0.42	1.26e-6	Response to paliperidone in schizophrenia (CGI-S score);
TGCT	cis	rs739496	0.843	rs688812	chr12:111962581	C/T	cg10833066	chr12:111807467	FAM109A	0.37	5.16	0.42	9.31e-7	Platelet count;
TGCT	cis	rs6598955	0.724	rs4659420	chr1:26614333	G/A	cg04990556	chr1:26633338	UBXN11	-0.9	-11.73	-0.73	7.95e-22	Obesity-related traits;
TGCT	cis	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg18252515	chr7:66147081	NA	-1.31	-8.18	-0.59	2.87e-13	Diabetic kidney disease;
TGCT	cis	rs11098499	0.866	rs6857892	chr4:120282696	G/T	cg09307838	chr4:120376055	NA	0.58	5.76	0.46	6.16e-8	Corneal astigmatism;
TGCT	cis	rs10501293	0.662	rs4755686	chr11:42999785	A/C	cg03447554	chr11:43094025	NA	0.44	6.49	0.5	1.81e-9	Cognitive performance;
TGCT	cis	rs9818758	0.556	rs9813813	chr3:49207093	T/A	cg00383909	chr3:49044727	WDR6	1.33	6.94	0.53	1.92e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs2629540	0.781	rs11245362	chr10:126458649	T/C	cg08799069	chr10:126477246	METTL10	-0.3	-4.5	-0.37	1.54e-5	Cocaine dependence;
TGCT	cis	rs6121246	0.567	rs6060247	chr20:30190720	C/G	cg13852791	chr20:30311386	BCL2L1	0.69	4.53	0.38	1.36e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs9611565	0.592	rs9611613	chr22:41961831	T/C	cg06634786	chr22:41940651	POLR3H	-0.88	-8.25	-0.6	1.98e-13	Vitiligo;
TGCT	cis	rs4731207	0.596	rs1600739	chr7:124639606	A/G	cg10503827	chr7:124401702	GPR37	0.21	4.61	0.38	1e-5	Cutaneous malignant melanoma;
TGCT	cis	rs35306767	0.903	rs12254002	chr10:929133	A/G	cg20503657	chr10:835505	NA	-0.68	-9.25	-0.64	8.2e-16	Eosinophil percentage of granulocytes;
TGCT	cis	rs7618915	0.851	rs34228726	chr3:52322797	A/G	cg07507251	chr3:52567010	NT5DC2	0.46	6.11	0.48	1.18e-8	Bipolar disorder;
TGCT	cis	rs11711311	0.747	rs7638378	chr3:113343630	T/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.7	-5.88	-0.47	3.5e-8	IgG glycosylation;
TGCT	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg22535103	chr8:58192502	C8orf71	-0.42	-4.72	-0.39	6.22e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10992471	0.512	rs331379	chr9:95261104	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.51	-4.97	-0.41	2.13e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs1429606	0.744	rs10050759	chr5:87246172	A/T	cg09451457	chr5:87440246	NA	0.69	4.44	0.37	2e-5	Number of children (6+ vs. 0 or 1);
TGCT	cis	rs1124769	0.502	rs28565448	chr15:51079970	C/T	cg23028286	chr15:51614521	CYP19A1	0.19	4.47	0.37	1.75e-5	Cognitive performance;
TGCT	cis	rs7772486	0.701	rs11155438	chr6:145950112	C/G	cg13319975	chr6:146136371	FBXO30	-0.56	-5.06	-0.41	1.46e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs710216	0.619	rs11210771	chr1:43444560	T/C	cg03128534	chr1:43423976	SLC2A1	-0.55	-4.63	-0.38	9.03e-6	Red cell distribution width;
TGCT	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg13385521	chr17:29058706	SUZ12P	-0.71	-4.61	-0.38	9.83e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs2439831	0.867	rs2255440	chr15:43830467	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.8	5.49	0.44	2.21e-7	Lung cancer in ever smokers;
TGCT	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg00684032	chr4:1343700	KIAA1530	0.22	4.73	0.39	5.89e-6	Obesity-related traits;
TGCT	cis	rs854765	0.624	rs12450799	chr17:17730201	T/C	cg09796270	chr17:17721594	SREBF1	-0.25	-4.93	-0.4	2.63e-6	Total body bone mineral density;
TGCT	cis	rs10465746	0.905	rs11163875	chr1:84429605	T/G	cg10977910	chr1:84465055	TTLL7	0.63	6.25	0.49	5.95e-9	Obesity-related traits;
TGCT	cis	rs11190604	0.725	rs9420796	chr10:102323092	G/C	cg23241863	chr10:102295624	HIF1AN	0.71	5.39	0.44	3.39e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs1008375	0.872	rs2315552	chr4:17627294	A/G	cg18681998	chr4:17616180	MED28	0.9	9.64	0.65	9.46e-17	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	5.03	0.41	1.69e-6	Prudent dietary pattern;
TGCT	cis	rs8072100	0.688	rs8075843	chr17:45442363	C/T	cg08085267	chr17:45401833	C17orf57	-0.51	-5.61	-0.45	1.26e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg11941060	chr3:133502564	NA	-0.26	-5.39	-0.44	3.48e-7	Iron status biomarkers;
TGCT	cis	rs4746818	0.793	rs2805914	chr10:70859291	A/G	cg11621586	chr10:70884670	VPS26A	1.15	7.67	0.57	4.34e-12	Left atrial antero-posterior diameter;
TGCT	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg27588902	chr6:42928151	GNMT	-0.49	-5.93	-0.47	2.85e-8	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs1511802	0.666	rs62350519	chr4:187119701	G/A	cg19358738	chr4:186734530	SORBS2	0.17	4.52	0.38	1.43e-5	Blood protein levels;
TGCT	cis	rs9291683	0.530	rs11723970	chr4:9980462	T/C	cg11266682	chr4:10021025	SLC2A9	0.62	8.63	0.61	2.51e-14	Bone mineral density;
TGCT	cis	rs2204008	0.604	rs2320521	chr12:38253789	A/G	cg26384229	chr12:38710491	ALG10B	0.86	7.48	0.56	1.19e-11	Bladder cancer;
TGCT	cis	rs13242816	1.000	rs17138708	chr7:116109062	T/G	cg16553024	chr7:116138462	CAV2	-0.44	-4.53	-0.38	1.34e-5	P wave duration;
TGCT	cis	rs919433	0.679	rs9967823	chr2:198531529	A/G	cg00792783	chr2:198669748	PLCL1	0.54	5.02	0.41	1.77e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs2239547	0.603	rs7644973	chr3:53082937	C/T	cg10802521	chr3:52805072	NEK4	-0.56	-5.12	-0.42	1.15e-6	Schizophrenia;
TGCT	cis	rs6988636	1.000	rs28670850	chr8:124189125	A/G	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs11711311	1.000	rs9879760	chr3:113457948	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.78	-7.13	-0.54	7.14e-11	IgG glycosylation;
TGCT	cis	rs7552404	0.656	rs11161792	chr1:76336746	C/T	cg03433033	chr1:76189801	ACADM	0.6	5.75	0.46	6.43e-8	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs707040	0.961	rs6760603	chr2:155234908	C/T	cg18104148	chr2:154337490	NA	0.19	4.56	0.38	1.2e-5	Sudden cardiac arrest;
TGCT	cis	rs651907	0.557	rs11924013	chr3:101366698	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.12	0.42	1.16e-6	Colorectal cancer;
TGCT	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg18135555	chr8:22132992	PIWIL2	0.3	6.12	0.48	1.13e-8	Hypertriglyceridemia;
TGCT	cis	rs71435601	0.689	rs17042000	chr2:21422928	C/T	cg25035485	chr2:21266500	APOB	-0.56	-4.76	-0.39	5.41e-6	Cholesterol, total;
TGCT	cis	rs3733585	0.699	rs4276278	chr4:9948870	T/C	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.48	-0.5	1.95e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs4642101	0.883	rs11718898	chr3:12848822	T/C	cg05775895	chr3:12838266	CAND2	0.51	4.81	0.4	4.38e-6	QRS complex (12-leadsum);
TGCT	cis	rs62103177	0.525	rs612913	chr18:77845882	A/G	cg07235805	chr18:78004237	PARD6G	-0.51	-4.98	-0.41	2.11e-6	Opioid sensitivity;
TGCT	trans	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg10840412	chr1:235813424	GNG4	1.04	8.16	0.59	3.22e-13	Bipolar disorder;
TGCT	trans	rs17471911	0.708	rs11189937	chr10:100780715	A/G	cg03484267	chr2:207988651	KLF7	0.53	6.79	0.52	4.24e-10	Neuroticism;
TGCT	cis	rs2073300	1.000	rs6132628	chr20:23446734	G/A	cg09953122	chr20:23471693	CST8	-0.64	-4.53	-0.38	1.37e-5	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs112217694	1.000	rs17196160	chr4:104657842	T/C	cg24090629	chr4:104641072	TACR3	-1.01	-4.96	-0.41	2.29e-6	Menarche (age at onset);
TGCT	cis	rs288326	0.561	rs77460513	chr2:183819625	C/T	cg09997497	chr2:183902928	NCKAP1	1.11	4.95	0.41	2.38e-6	Blood protein levels;
TGCT	cis	rs9611565	0.512	rs8141103	chr22:42136930	T/C	cg03806693	chr22:41940476	POLR3H	1.06	10.94	0.7	6.7e-20	Vitiligo;
TGCT	cis	rs910316	0.789	rs175444	chr14:75601782	G/C	cg08847533	chr14:75593920	NEK9	-0.85	-8.58	-0.61	3.22e-14	Height;
TGCT	cis	rs2404602	0.735	rs4886493	chr15:76679026	A/G	cg22467129	chr15:76604101	ETFA	0.46	4.67	0.39	7.85e-6	Blood metabolite levels;
TGCT	cis	rs6087771	0.650	rs6060395	chr20:30219823	G/C	cg13852791	chr20:30311386	BCL2L1	0.82	7.23	0.54	4.29e-11	Subcortical brain region volumes;Putamen volume;
TGCT	trans	rs56011263	0.687	rs4690187	chr4:703813	C/T	cg12575136	chr18:32820987	ZNF397	0.77	9.37	0.64	4.3e-16	White blood cell count;
TGCT	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg10802521	chr3:52805072	NEK4	-0.78	-10.01	-0.67	1.22e-17	Bipolar disorder;
TGCT	cis	rs9500256	0.655	rs12191043	chr6:58346483	C/T	cg16251399	chr6:58287822	GUSBL2	0.56	4.63	0.38	9.04e-6	Eosinophilic esophagitis (pediatric);
TGCT	cis	rs11118844	0.744	rs11118857	chr1:221952209	C/T	cg04222084	chr1:221915650	DUSP10	-0.78	-4.66	-0.39	8.03e-6	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
TGCT	cis	rs17376456	0.877	rs12716457	chr5:93397627	T/C	cg21475434	chr5:93447410	FAM172A	0.59	4.66	0.39	8.09e-6	Diabetic retinopathy;
TGCT	cis	rs4561483	0.549	rs6498251	chr16:11952290	A/G	cg08843971	chr16:11963173	GSPT1	0.25	4.55	0.38	1.24e-5	Testicular germ cell tumor;
TGCT	cis	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg07424592	chr7:64974309	NA	1.26	7.79	0.57	2.25e-12	Diabetic kidney disease;
TGCT	cis	rs7666738	0.830	rs7698771	chr4:98986479	T/G	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3741404	0.791	rs2282491	chr11:63918373	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.88	9.92	0.67	2.01e-17	Platelet count;
TGCT	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg18876405	chr7:65276391	NA	0.31	4.8	0.4	4.53e-6	Aortic root size;
TGCT	cis	rs7267979	0.966	rs3002698	chr20:25303379	C/G	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs13242816	1.000	rs2402078	chr7:116128648	A/C	cg16553024	chr7:116138462	CAV2	-0.45	-5.04	-0.41	1.57e-6	P wave duration;
TGCT	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.51	-4.82	-0.4	4.16e-6	Bipolar disorder;
TGCT	cis	rs6840360	0.593	rs10022023	chr4:152560731	A/G	cg17479576	chr4:152424074	FAM160A1	-0.73	-7.94	-0.58	1.03e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs910316	1.000	rs3742778	chr14:75538217	A/C	cg23033748	chr14:75592666	NEK9	-0.28	-4.64	-0.38	8.62e-6	Height;
TGCT	trans	rs1908814	0.516	rs13275143	chr8:11796990	T/A	cg15556689	chr8:8085844	FLJ10661	0.74	6.77	0.52	4.66e-10	Neuroticism;
TGCT	cis	rs1857353	1.000	rs1858630	chr1:75890640	C/T	cg11838876	chr1:75668600	SLC44A5	-0.51	-4.81	-0.4	4.23e-6	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs1448094	0.511	rs58742237	chr12:86166444	C/T	cg02569458	chr12:86230093	RASSF9	0.38	4.5	0.37	1.57e-5	Major depressive disorder;
TGCT	cis	rs362272	0.545	rs2749785	chr4:3325179	G/C	cg18352616	chr4:3374830	RGS12	0.23	4.5	0.37	1.57e-5	Serum sulfate level;
TGCT	cis	rs7666738	0.830	rs35865860	chr4:98968822	C/T	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7710178	0.525	rs32073	chr5:156112063	A/G	cg19020398	chr5:156886415	NIPAL4	0.3	4.49	0.37	1.61e-5	Airway responsiveness in chronic obstructive pulmonary disease;
TGCT	cis	rs2463822	0.748	rs2513053	chr11:62109473	T/A	cg06239285	chr11:62104954	ASRGL1	0.9	6.34	0.49	3.87e-9	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs6867032	0.834	rs4526149	chr5:1990166	G/A	cg26168224	chr5:2018326	NA	-0.33	-5.16	-0.42	9.67e-7	Gut microbiome composition (winter);
TGCT	cis	rs9814567	0.964	rs3856729	chr3:134200925	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.97	-9.24	-0.64	8.89e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg23172400	chr8:95962367	TP53INP1	-0.39	-6.52	-0.51	1.59e-9	Type 2 diabetes;
TGCT	cis	rs76878669	0.561	rs7940980	chr11:66172910	C/T	cg18002602	chr11:66138449	SLC29A2	-0.53	-6.38	-0.5	3.25e-9	Educational attainment (years of education);
TGCT	trans	rs57221529	0.766	rs12519469	chr5:581772	A/G	cg25482853	chr8:67687455	SGK3	1.2	11.56	0.72	2.06e-21	Lung disease severity in cystic fibrosis;
TGCT	cis	rs10089	0.953	rs758180	chr5:127354423	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	6.75	0.52	5e-10	Ileal carcinoids;
TGCT	cis	rs4711350	0.954	rs11751943	chr6:33729718	G/C	cg00334056	chr6:33755658	LEMD2	-0.31	-4.83	-0.4	3.88e-6	Schizophrenia;
TGCT	cis	rs6429082	0.764	rs291377	chr1:235695186	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.63	-5.58	-0.45	1.43e-7	Adiposity;
TGCT	cis	rs2073300	1.000	rs6137961	chr20:23443102	G/T	cg09953122	chr20:23471693	CST8	-0.64	-4.56	-0.38	1.19e-5	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs7582180	0.629	rs4850926	chr2:100954117	C/T	cg14675211	chr2:100938903	LONRF2	0.5	4.78	0.39	4.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1158570	0.804	rs2185366	chr8:131342722	T/C	cg16277922	chr8:131349729	ASAP1	-0.43	-6.18	-0.49	8.38e-9	Platelet count;
TGCT	trans	rs3780486	0.846	rs3824458	chr9:33144809	C/T	cg04842962	chr6:43655489	MRPS18A	1.2	14.72	0.8	5.46e-29	IgG glycosylation;
TGCT	cis	rs7937682	0.575	rs7950926	chr11:111776437	G/C	cg09085632	chr11:111637200	PPP2R1B	0.94	9.24	0.64	8.92e-16	Primary sclerosing cholangitis;
TGCT	cis	rs10493773	1.000	rs55654440	chr1:86176158	G/C	cg17807903	chr1:86174739	ZNHIT6	-0.38	-4.61	-0.38	9.67e-6	Urate levels in overweight individuals;
TGCT	cis	rs9914544	0.966	rs7210746	chr17:18798593	T/C	cg26378065	chr17:18585709	ZNF286B	0.52	4.73	0.39	5.94e-6	Educational attainment (years of education);
TGCT	cis	rs6701037	0.681	rs1057239	chr1:175130204	G/A	cg00321850	chr1:175162397	KIAA0040	-0.4	-5.29	-0.43	5.37e-7	Alcohol dependence;
TGCT	cis	rs1371867	0.817	rs1660314	chr8:101332953	C/T	cg00191853	chr8:101177733	SPAG1	-0.22	-4.47	-0.37	1.75e-5	Atrioventricular conduction;
TGCT	cis	rs3806843	1.000	rs10477034	chr5:140169730	A/G	cg19875535	chr5:140030758	IK	0.37	6.39	0.5	3.11e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs11792861	0.855	rs116127510	chr9:111868344	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.48	4.48	0.37	1.66e-5	Menarche (age at onset);
TGCT	cis	rs6909279	0.933	rs6557149	chr6:151876413	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	0.51	4.47	0.37	1.75e-5	Bone mineral density;
TGCT	cis	rs9896933	0.832	rs75552659	chr17:80804630	G/A	cg20578329	chr17:80767326	TBCD	-0.35	-4.99	-0.41	1.99e-6	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
TGCT	cis	rs250677	0.522	rs998304	chr5:148382365	C/A	cg18129178	chr5:148520854	ABLIM3	-0.36	-4.69	-0.39	7.23e-6	Breast cancer;
TGCT	cis	rs6089584	0.606	rs6089599	chr20:60576992	A/G	cg06108461	chr20:60628389	TAF4	0.4	4.92	0.4	2.74e-6	Body mass index;
TGCT	trans	rs524675	0.525	rs517536	chr4:13959691	A/T	cg02315626	chr17:27188560	MIR451;MIR144	0.4	6.75	0.52	5.03e-10	Amyotrophic lateral sclerosis in C9orf72 mutation negative individuals;
TGCT	cis	rs9467773	0.596	rs2451750	chr6:26646579	A/T	cg05738196	chr6:26577821	NA	0.88	10.63	0.69	3.68e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs7681440	0.904	rs28750169	chr4:90774303	A/G	cg14346243	chr4:90757452	SNCA	-0.57	-5.5	-0.44	2.04e-7	Dementia with Lewy bodies;
TGCT	cis	rs250677	0.958	rs36067	chr5:148417553	T/G	cg18129178	chr5:148520854	ABLIM3	-0.4	-5.63	-0.45	1.17e-7	Breast cancer;
TGCT	cis	rs7216064	0.953	rs4790905	chr17:65863350	C/A	cg12091567	chr17:66097778	LOC651250	-0.87	-6.85	-0.52	3.1e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs6964587	1.000	rs6956596	chr7:91750107	T/G	cg22709100	chr7:91322751	NA	0.28	4.55	0.38	1.25e-5	Breast cancer;
TGCT	cis	rs11167764	0.895	rs9324865	chr5:141488792	T/C	cg23435118	chr5:141488016	NDFIP1	-0.28	-4.84	-0.4	3.83e-6	Crohn's disease;
TGCT	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg22920501	chr2:26401640	FAM59B	-0.72	-6.22	-0.49	7.14e-9	Gut microbiome composition (summer);
TGCT	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg08439880	chr3:133502540	NA	-0.31	-5.91	-0.47	3.1e-8	Iron status biomarkers;
TGCT	cis	rs8180040	0.966	rs4858868	chr3:47455086	G/A	cg27129171	chr3:47204927	SETD2	0.65	7.74	0.57	2.99e-12	Colorectal cancer;
TGCT	cis	rs1008375	1.000	rs4698198	chr4:17656536	G/A	cg18681998	chr4:17616180	MED28	1.01	11.89	0.73	3.17e-22	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs3540	0.533	rs11633692	chr15:91056043	G/A	cg22089800	chr15:90895588	ZNF774	-0.76	-7.96	-0.58	9.11e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs7914558	0.966	rs7908280	chr10:104816947	C/G	cg04362960	chr10:104952993	NT5C2	0.61	5.48	0.44	2.28e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs9611565	0.512	rs139573	chr22:42214785	G/A	cg06481639	chr22:41940642	POLR3H	-0.69	-6.02	-0.48	1.83e-8	Vitiligo;
TGCT	trans	rs9388451	0.839	rs9401845	chr6:126104118	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.72	-8.04	-0.59	6.03e-13	Brugada syndrome;
TGCT	cis	rs11098499	0.863	rs1010739	chr4:120463471	C/T	cg24670566	chr4:120433619	PDE5A	0.24	4.45	0.37	1.87e-5	Corneal astigmatism;
TGCT	cis	rs1775715	0.707	rs2808079	chr10:32167385	C/T	cg14930904	chr10:32216787	ARHGAP12	0.52	5.07	0.41	1.39e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg04025307	chr7:1156635	C7orf50	0.23	5.57	0.45	1.47e-7	Longevity;Endometriosis;
TGCT	cis	rs9388451	0.513	rs1268069	chr6:126039994	A/C	cg05901451	chr6:126070800	HEY2	-0.87	-9.95	-0.67	1.7e-17	Brugada syndrome;
TGCT	cis	rs11031096	0.655	rs12275560	chr11:4211564	T/C	cg18678763	chr11:4115507	RRM1	-0.45	-5.77	-0.46	6.11e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg05590025	chr7:65112418	INTS4L2	-0.77	-4.5	-0.37	1.52e-5	Diabetic kidney disease;
TGCT	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.7	0.39	6.83e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs1107366	0.513	rs35078897	chr3:125973767	T/C	cg01346077	chr3:125931526	NA	0.32	5.3	0.43	5.03e-7	Metabolite levels;
TGCT	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg23758822	chr17:41437982	NA	0.72	6.96	0.53	1.76e-10	Menopause (age at onset);
TGCT	cis	rs2204008	0.774	rs10400552	chr12:38393577	C/G	cg26384229	chr12:38710491	ALG10B	0.83	7.39	0.55	1.92e-11	Bladder cancer;
TGCT	cis	rs42648	0.902	rs17874789	chr7:90001160	A/T	cg25739043	chr7:89950458	NA	0.65	6.23	0.49	6.69e-9	Homocysteine levels;
TGCT	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.44	4.98	0.41	2.05e-6	Lymphocyte counts;
TGCT	cis	rs9611565	1.000	rs9611565	chr22:41767486	T/C	cg06634786	chr22:41940651	POLR3H	-0.66	-6.16	-0.48	9.24e-9	Vitiligo;
TGCT	cis	rs1903068	0.853	rs17773240	chr4:55999781	T/C	cg01777861	chr4:56023843	NA	0.54	6.38	0.5	3.2e-9	Endometriosis;
TGCT	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg21862992	chr11:68658383	NA	0.46	6.52	0.51	1.62e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs4788570	0.727	rs7204118	chr16:71833658	G/C	cg06353428	chr16:71660113	MARVELD3	1.53	12.59	0.75	6.48e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs933688	1.000	rs7720132	chr5:90745105	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.0	8.47	0.61	6.09e-14	Smoking behavior;
TGCT	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg03264133	chr6:25882463	NA	-0.73	-6.87	-0.53	2.74e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs10838634	1.000	rs2867206	chr11:46854977	C/T	cg18332754	chr11:46939436	LRP4	0.9	4.58	0.38	1.11e-5	Schizophrenia;
TGCT	cis	rs10465746	0.935	rs1871925	chr1:84464468	C/G	cg10977910	chr1:84465055	TTLL7	0.63	6.24	0.49	6.38e-9	Obesity-related traits;
TGCT	cis	rs11997175	0.549	rs4357253	chr8:33652458	G/A	ch.8.33884649F	chr8:33765107	NA	0.28	4.53	0.38	1.35e-5	Body mass index;
TGCT	cis	rs7959452	0.640	rs4761154	chr12:69705362	A/G	cg14784868	chr12:69753453	YEATS4	-0.68	-6.95	-0.53	1.81e-10	Blood protein levels;
TGCT	trans	rs1814175	0.645	rs10742953	chr11:49807491	C/G	cg11707556	chr5:10655725	ANKRD33B	0.45	11.15	0.71	2.03e-20	Height;
TGCT	cis	rs1949733	0.656	rs2631762	chr4:8423122	A/T	cg11789530	chr4:8429930	ACOX3	0.54	4.99	0.41	1.98e-6	Response to antineoplastic agents;
TGCT	cis	rs4730250	0.655	rs75243311	chr7:106890791	C/T	cg02696742	chr7:106810147	HBP1	-0.66	-5.51	-0.44	1.94e-7	Osteoarthritis;
TGCT	cis	rs2227564	0.620	rs7098573	chr10:75580014	G/A	cg23231163	chr10:75533350	FUT11	-0.28	-4.46	-0.37	1.82e-5	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs17767294	0.522	rs41270589	chr6:28403440	G/A	cg08851530	chr6:28072375	NA	1.57	7.31	0.55	2.88e-11	Parkinson's disease;
TGCT	cis	rs7819412	0.775	rs2001329	chr8:10986859	C/T	cg21775007	chr8:11205619	TDH	-0.55	-5.22	-0.42	7.46e-7	Triglycerides;
TGCT	cis	rs1061377	1.000	rs9990755	chr4:39121439	G/T	cg24403649	chr4:39172243	NA	0.18	4.44	0.37	1.99e-5	Uric acid levels;
TGCT	cis	rs523522	0.962	rs10744752	chr12:120900554	T/G	cg12219531	chr12:120966889	COQ5	0.83	7.3	0.55	2.97e-11	High light scatter reticulocyte count;
TGCT	cis	rs80282103	0.618	rs1079390	chr10:1161653	C/A	cg08668510	chr10:1095578	IDI1	1.06	5.03	0.41	1.7e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs12048904	0.930	rs11166529	chr1:101333733	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.55	5.17	0.42	9.05e-7	Multiple sclerosis;
TGCT	cis	rs2153535	0.601	rs1737581	chr6:8539138	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.67	0.45	9.45e-8	Motion sickness;
TGCT	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg12310025	chr6:25882481	NA	-0.74	-6.75	-0.52	4.98e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs7698623	0.850	rs4693891	chr4:88787834	C/T	cg27387453	chr4:88533842	DSPP	-0.61	-4.6	-0.38	1.03e-5	Cardiovascular disease risk factors;
TGCT	cis	rs12497850	0.931	rs28642807	chr3:48926816	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.42	-5.52	-0.44	1.93e-7	Parkinson's disease;
TGCT	cis	rs2439831	0.867	rs2242068	chr15:43699304	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.84	5.32	0.43	4.75e-7	Lung cancer in ever smokers;
TGCT	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg03396347	chr1:1875803	NA	-0.36	-6.46	-0.5	2.14e-9	Body mass index;
TGCT	cis	rs11711311	1.000	rs9827682	chr3:113450251	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.73	-6.83	-0.52	3.45e-10	IgG glycosylation;
TGCT	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.71	0.39	6.53e-6	Prudent dietary pattern;
TGCT	cis	rs6840360	0.615	rs6535816	chr4:152614264	T/C	cg17479576	chr4:152424074	FAM160A1	-0.52	-5.09	-0.42	1.3e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg08564027	chr20:61660810	NA	0.38	7.08	0.54	9.36e-11	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs10744422	1.000	rs921808	chr12:123323135	A/G	cg25930673	chr12:123319894	HIP1R	0.85	5.01	0.41	1.86e-6	Schizophrenia;
TGCT	cis	rs2506155	0.752	rs2300947	chr10:33517262	C/T	cg25928881	chr10:32632685	EPC1	0.31	4.65	0.39	8.31e-6	Migraine;
TGCT	cis	rs5769707	0.681	rs135879	chr22:50018651	C/T	cg05373962	chr22:49881684	NA	-0.3	-5.25	-0.43	6.29e-7	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs6940638	0.956	rs12199218	chr6:27025281	T/C	cg26531700	chr6:26746687	NA	-0.59	-4.47	-0.37	1.77e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs12765878	0.729	rs12573103	chr10:105639241	A/G	cg11005552	chr10:105648138	OBFC1	0.4	6.77	0.52	4.65e-10	Coronary artery disease;
TGCT	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg03188948	chr7:1209495	NA	0.52	5.4	0.44	3.29e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs67478160	0.634	rs2144079	chr14:104258884	C/T	cg26031613	chr14:104095156	KLC1	-0.62	-6.19	-0.49	8.13e-9	Schizophrenia;
TGCT	cis	rs9303401	0.659	rs34382037	chr17:56643550	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs2688608	0.967	rs9971038	chr10:75661149	C/T	cg19442545	chr10:75533431	FUT11	-0.3	-4.83	-0.4	3.88e-6	Inflammatory bowel disease;
TGCT	cis	rs9325144	0.577	rs12314639	chr12:39119869	T/C	cg13010199	chr12:38710504	ALG10B	-0.53	-4.72	-0.39	6.22e-6	Morning vs. evening chronotype;
TGCT	cis	rs939658	0.776	rs35382567	chr15:79440897	C/T	cg17916960	chr15:79447300	NA	-0.49	-7.41	-0.55	1.73e-11	Refractive error;
TGCT	cis	rs9916302	0.706	rs801427	chr17:37436711	A/G	cg07936489	chr17:37558343	FBXL20	-0.84	-6.23	-0.49	6.68e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs7043114	0.525	rs10820964	chr9:95041636	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-5.57	-0.45	1.53e-7	Height;
TGCT	cis	rs7914558	1.000	rs10748838	chr10:104943986	T/A	cg04362960	chr10:104952993	NT5C2	0.61	5.47	0.44	2.42e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg11890956	chr21:40555474	PSMG1	1.14	12.22	0.74	4.93e-23	Cognitive function;
TGCT	cis	rs739496	0.579	rs11066095	chr12:112377537	C/T	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs2013441	1.000	rs2013576	chr17:20167692	G/C	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.63	-0.38	9.19e-6	Obesity-related traits;
TGCT	cis	rs10488031	0.850	rs35721463	chr7:37112015	G/A	cg06458904	chr7:36312573	EEPD1	0.54	4.63	0.38	9.22e-6	QT interval;
TGCT	cis	rs79349575	0.783	rs62078370	chr17:47026836	G/C	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.52	-0.38	1.44e-5	Type 2 diabetes;
TGCT	cis	rs4642101	0.686	rs13085726	chr3:12832672	A/C	cg05775895	chr3:12838266	CAND2	0.91	11.07	0.7	3.17e-20	QRS complex (12-leadsum);
TGCT	cis	rs2836950	0.545	rs2836952	chr21:40616651	G/C	cg11890956	chr21:40555474	PSMG1	-0.69	-6.74	-0.52	5.41e-10	Menarche (age at onset);
TGCT	cis	rs9527	0.569	rs78193706	chr10:104780564	T/C	cg04362960	chr10:104952993	NT5C2	0.65	5.54	0.45	1.73e-7	Arsenic metabolism;
TGCT	cis	rs7833790	0.632	rs6473308	chr8:82707708	G/A	cg06027949	chr8:82754900	SNX16	-0.65	-4.93	-0.41	2.53e-6	Diastolic blood pressure;
TGCT	cis	rs12681287	0.605	rs13262672	chr8:87355812	T/C	cg27223183	chr8:87520930	FAM82B	-0.9	-6.71	-0.52	6.12e-10	Caudate activity during reward;
TGCT	cis	rs11209185	0.509	rs1938424	chr1:68431722	A/G	cg22082780	chr1:68452167	NA	-0.31	-4.66	-0.39	8.01e-6	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs4843185	0.669	rs889502	chr16:85716832	A/G	cg02644593	chr16:85391138	NA	0.22	5.0	0.41	1.92e-6	Platelet distribution width;
TGCT	cis	rs12908161	0.920	rs35738019	chr15:85280210	T/C	cg11189052	chr15:85197271	WDR73	0.7	5.71	0.46	7.73e-8	Schizophrenia;
TGCT	cis	rs2762353	0.845	rs35720558	chr6:25784800	A/C	cg03517284	chr6:25882590	NA	0.5	5.23	0.42	7.13e-7	Blood metabolite levels;
TGCT	cis	rs72634258	0.520	rs4908485	chr1:7907984	A/G	cg26816564	chr1:7831052	VAMP3	0.86	6.29	0.49	5.01e-9	Inflammatory bowel disease;
TGCT	cis	rs6728302	0.557	rs7600132	chr2:233248198	C/A	cg06555452	chr2:233241558	NA	0.37	5.16	0.42	9.6e-7	Height;
TGCT	cis	rs427394	0.582	rs4701751	chr5:6704137	C/T	cg10857441	chr5:6722123	POLS	-0.29	-6.21	-0.49	7.15e-9	Menopause (age at onset);
TGCT	cis	rs4409675	0.576	rs2078328	chr1:28224976	A/G	cg23691781	chr1:28212827	C1orf38	0.25	5.15	0.42	1.01e-6	Corneal astigmatism;
TGCT	cis	rs12541335	0.639	rs68063696	chr8:22153236	A/G	cg18135555	chr8:22132992	PIWIL2	0.29	5.62	0.45	1.21e-7	Hypertriglyceridemia;
TGCT	cis	rs10791097	0.765	rs10894269	chr11:130722789	C/T	cg05962950	chr11:130786565	SNX19	0.83	9.85	0.66	2.99e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs2562456	0.917	rs11085463	chr19:21751302	G/T	cg01304269	chr19:21688519	ZNF429	0.55	4.56	0.38	1.2e-5	Pain;
TGCT	cis	rs9894429	0.966	rs6565604	chr17:79589242	G/A	cg18240062	chr17:79603768	NPLOC4	0.67	6.85	0.52	3.11e-10	Eye color traits;
TGCT	cis	rs12681287	0.604	rs13279589	chr8:87477723	C/T	cg19078186	chr8:87526527	CPNE3	-0.36	-4.45	-0.37	1.86e-5	Caudate activity during reward;
TGCT	cis	rs9916302	0.904	rs585961	chr17:37444036	G/A	cg07936489	chr17:37558343	FBXL20	0.62	4.91	0.4	2.85e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs1467026	0.606	rs9814180	chr3:12818386	A/G	cg05775895	chr3:12838266	CAND2	0.78	7.74	0.57	3.04e-12	P wave duration;
TGCT	cis	rs2404602	0.647	rs4886840	chr15:77179002	A/G	cg23625390	chr15:77176239	SCAPER	-0.39	-5.15	-0.42	9.85e-7	Blood metabolite levels;
TGCT	cis	rs10779751	1.000	rs11121706	chr1:11302065	C/T	cg08854313	chr1:11322531	MTOR	0.98	10.78	0.7	1.5700000000000001e-19	Body mass index;
TGCT	cis	rs7267979	0.844	rs6115188	chr20:25432170	G/T	cg03522245	chr20:25566470	NINL	0.55	5.54	0.45	1.7e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg11644478	chr21:40555479	PSMG1	1.0	10.69	0.69	2.7e-19	Cognitive function;
TGCT	cis	rs2797160	1.000	rs1935772	chr6:125994708	T/C	cg05901451	chr6:126070800	HEY2	-0.74	-6.57	-0.51	1.23e-9	Endometrial cancer;
TGCT	cis	rs8067545	1.000	rs2108980	chr17:19920518	G/A	cg13482628	chr17:19912719	NA	0.54	4.74	0.39	5.86e-6	Schizophrenia;
TGCT	cis	rs12049351	0.774	rs10916495	chr1:229635521	A/G	cg12130225	chr1:229698885	NA	0.39	4.59	0.38	1.06e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs986417	1.000	rs11845369	chr14:60944959	A/G	cg27398547	chr14:60952738	C14orf39	1.39	10.61	0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs6570726	0.791	rs365869	chr6:145884751	C/T	cg05347473	chr6:146136440	FBXO30	0.54	5.15	0.42	1.01e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1843834	0.688	rs2396149	chr2:225601985	G/A	cg22455342	chr2:225449267	CUL3	0.65	6.26	0.49	5.64e-9	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs1372520	0.627	rs2737025	chr4:90719192	A/G	cg20003494	chr4:90757398	SNCA	-0.66	-5.21	-0.42	7.59e-7	Neuroticism;
TGCT	cis	rs1903068	0.962	rs17773813	chr4:56008969	G/A	cg16572876	chr4:56024045	NA	0.44	5.1	0.42	1.23e-6	Endometriosis;
TGCT	cis	rs12908161	1.000	rs35630683	chr15:85349231	T/C	cg17173187	chr15:85201210	NMB	0.57	6.39	0.5	3.07e-9	Schizophrenia;
TGCT	cis	rs2688608	0.967	rs2688609	chr10:75658181	A/G	cg23231163	chr10:75533350	FUT11	0.26	4.49	0.37	1.64e-5	Inflammatory bowel disease;
TGCT	cis	rs1997103	1.000	rs10279035	chr7:55412055	C/T	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg10819733	chr22:24237672	NA	-0.3	-5.02	-0.41	1.78e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9581857	0.579	rs77187836	chr13:27998646	C/A	cg22138327	chr13:27999177	GTF3A	0.78	5.58	0.45	1.43e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs1385374	0.858	rs12305142	chr12:129277490	C/T	cg09035930	chr12:129282057	SLC15A4	-0.5	-4.77	-0.39	4.99e-6	Systemic lupus erythematosus;
TGCT	cis	rs11924390	0.800	rs5030059	chr3:186452455	C/G	cg12454167	chr3:186435060	KNG1	0.44	6.91	0.53	2.24e-10	Adiponectin levels;
TGCT	cis	rs11098499	0.569	rs10023641	chr4:120258410	C/G	cg09307838	chr4:120376055	NA	0.55	5.33	0.43	4.45e-7	Corneal astigmatism;
TGCT	cis	rs5769765	0.955	rs8138687	chr22:50291869	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.39	5.91	0.47	3.12e-8	Schizophrenia;
TGCT	cis	rs826838	0.874	rs11183816	chr12:38834656	T/G	cg13010199	chr12:38710504	ALG10B	0.82	6.85	0.52	3e-10	Heart rate;
TGCT	cis	rs36051895	0.632	rs10974984	chr9:5150427	T/C	cg02405213	chr9:5042618	JAK2	-0.73	-9.46	-0.65	2.54e-16	Pediatric autoimmune diseases;
TGCT	cis	rs7267979	0.844	rs6050477	chr20:25221547	C/T	cg16686733	chr20:25566563	NINL	-0.55	-5.57	-0.45	1.47e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg18876405	chr7:65276391	NA	0.33	4.86	0.4	3.46e-6	Aortic root size;
TGCT	cis	rs6815814	0.950	rs5743560	chr4:38806200	G/T	cg02016764	chr4:38805732	TLR1	-0.35	-5.65	-0.45	1.04e-7	Breast cancer;
TGCT	cis	rs904251	0.600	rs9380673	chr6:37415125	T/C	cg01843034	chr6:37503916	NA	-0.46	-5.89	-0.47	3.44e-8	Cognitive performance;
TGCT	cis	rs12477438	0.520	rs6743355	chr2:99732360	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	13.05	0.76	4.93e-25	Chronic sinus infection;
TGCT	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg03709012	chr19:19516395	GATAD2A	0.77	6.28	0.49	5.18e-9	Tonsillectomy;
TGCT	cis	rs9393777	0.513	rs9379907	chr6:26654318	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.59	-4.66	-0.39	8.03e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6921919	0.583	rs1054372	chr6:28336742	G/T	cg18815343	chr6:28367644	ZSCAN12	-0.56	-5.37	-0.43	3.8e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs11779988	0.545	rs398806	chr8:17786226	T/C	cg01800426	chr8:17659068	MTUS1	-0.7	-5.46	-0.44	2.5e-7	Breast cancer;
TGCT	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg20891283	chr12:69753455	YEATS4	0.91	10.46	0.68	9.81e-19	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg12751644	chr20:60527061	NA	-0.39	-4.59	-0.38	1.07e-5	Body mass index;
TGCT	trans	rs208520	1.000	rs12194996	chr6:66973366	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.82	7.48	0.56	1.21e-11	Exhaled nitric oxide output;
TGCT	cis	rs40363	0.645	rs1690449	chr16:3520893	C/G	cg21433313	chr16:3507492	NAT15	0.38	4.92	0.4	2.68e-6	Tuberculosis;
TGCT	cis	rs35146811	0.586	rs12666107	chr7:99778019	G/C	cg13334819	chr7:99746414	C7orf59	-0.82	-6.99	-0.53	1.54e-10	Coronary artery disease;
TGCT	cis	rs9733	0.596	rs12063547	chr1:150674053	G/T	cg09365446	chr1:150670422	GOLPH3L	-0.29	-4.52	-0.38	1.44e-5	Tonsillectomy;
TGCT	cis	rs12477438	0.798	rs1453561	chr2:99613924	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-8.31	-0.6	1.43e-13	Chronic sinus infection;
TGCT	cis	rs11676348	0.818	rs1126579	chr2:219000734	T/C	cg00012203	chr2:219082015	ARPC2	-0.51	-4.86	-0.4	3.53e-6	Ulcerative colitis;
TGCT	cis	rs4820539	0.966	rs5751590	chr22:23486830	A/C	cg21100191	chr22:23484243	RTDR1	0.92	10.9	0.7	8.12e-20	Bone mineral density;
TGCT	cis	rs10423674	0.526	rs757317	chr19:18819984	C/T	cg14292368	chr19:18793705	CRTC1	-0.53	-4.89	-0.4	3.1e-6	Menarche (age at onset);
TGCT	cis	rs28595532	0.920	rs114223775	chr4:119775091	C/T	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs904251	1.000	rs12212090	chr6:37431808	A/G	cg01843034	chr6:37503916	NA	-0.46	-5.44	-0.44	2.72e-7	Cognitive performance;
TGCT	cis	rs11190604	1.000	rs2273695	chr10:102259568	A/G	cg16342193	chr10:102329863	NA	-0.37	-5.05	-0.41	1.55e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7582180	0.764	rs920269	chr2:100918363	G/A	cg14675211	chr2:100938903	LONRF2	0.49	4.8	0.4	4.45e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6558530	0.965	rs730379	chr8:1708093	A/C	cg09410841	chr8:1729607	CLN8	0.91	10.31	0.68	2.23e-18	Systolic blood pressure;
TGCT	cis	rs7043114	0.525	rs10283572	chr9:95133074	G/A	cg14631576	chr9:95140430	CENPP	-0.28	-4.69	-0.39	6.98e-6	Height;
TGCT	cis	rs56011263	0.687	rs4690188	chr4:703930	G/C	cg17689763	chr4:710664	PCGF3	-0.25	-7.28	-0.55	3.38e-11	White blood cell count;
TGCT	cis	rs7095607	1.000	rs4746740	chr10:69960999	C/T	cg18986048	chr10:69913749	MYPN	0.45	4.86	0.4	3.52e-6	Lung function (FVC);
TGCT	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.9	9.57	0.65	1.42e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs1059312	1.000	rs7135987	chr12:129280117	G/A	cg09035930	chr12:129282057	SLC15A4	0.59	11.76	0.73	6.45e-22	Systemic lupus erythematosus;
TGCT	cis	rs9906944	0.707	rs1523136	chr17:47144532	A/G	cg20966754	chr17:47091339	IGF2BP1	-0.47	-5.33	-0.43	4.46e-7	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs10484885	0.824	rs72919982	chr6:90532600	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.47	-4.58	-0.38	1.11e-5	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs12681287	0.511	rs7839601	chr8:87503839	G/C	cg27223183	chr8:87520930	FAM82B	-0.95	-6.95	-0.53	1.81e-10	Caudate activity during reward;
TGCT	cis	rs7582180	0.764	rs12712075	chr2:100924129	T/C	cg08017756	chr2:100939284	LONRF2	-0.32	-5.26	-0.43	6.1e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9330316	0.506	rs1434167	chr2:110396324	A/G	cg03552103	chr2:110373002	SEPT10;ANKRD57	-0.42	-4.75	-0.39	5.55e-6	Schizophrenia;
TGCT	cis	rs9467603	0.566	rs10214468	chr6:25789390	T/A	cg03517284	chr6:25882590	NA	-0.66	-4.5	-0.37	1.53e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs655029	0.837	rs647316	chr2:31464829	A/G	cg14018959	chr2:31480232	EHD3	-0.38	-5.09	-0.42	1.3e-6	Mean platelet volume;Platelet distribution width;Platelet count;Plateletcrit;
TGCT	cis	rs4654899	0.733	rs10442633	chr1:21265097	C/T	cg01072550	chr1:21505969	NA	-0.56	-9.04	-0.63	2.64e-15	Superior frontal gyrus grey matter volume;
TGCT	trans	rs1814175	0.715	rs11040586	chr11:49858432	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.35	-0.55	2.38e-11	Height;
TGCT	cis	rs10779751	0.922	rs2295080	chr1:11322628	G/T	cg08854313	chr1:11322531	MTOR	0.93	10.45	0.68	1e-18	Body mass index;
TGCT	cis	rs13242816	1.000	rs55803834	chr7:116103141	C/T	cg16553024	chr7:116138462	CAV2	-0.43	-4.8	-0.4	4.41e-6	P wave duration;
TGCT	cis	rs5769707	0.749	rs7286706	chr22:50058346	G/C	cg05373962	chr22:49881684	NA	-0.3	-5.98	-0.47	2.18e-8	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs7666738	0.612	rs6830172	chr4:99093947	G/A	cg18180107	chr4:99064573	C4orf37	0.57	5.07	0.41	1.39e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8077577	1.000	rs2015336	chr17:18073610	A/G	cg09161412	chr17:18057145	MYO15A	-0.63	-5.02	-0.41	1.74e-6	Obesity-related traits;
TGCT	cis	rs7208859	0.623	rs55724095	chr17:29153058	A/G	cg14008862	chr17:28927542	LRRC37B2	0.75	5.06	0.41	1.5e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7555006	0.671	rs11580026	chr1:51476003	A/T	cg10511332	chr1:51166032	FAF1	0.36	4.58	0.38	1.1e-5	Headache;
TGCT	cis	rs6570726	0.935	rs442254	chr6:145849118	T/C	cg23711669	chr6:146136114	FBXO30	0.68	6.67	0.51	7.58e-10	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs8073060	0.586	rs2011897	chr17:34054408	A/T	cg19694781	chr19:47549865	TMEM160	0.6	13.37	0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs539096	0.624	rs603542	chr1:44079411	T/C	cg12908607	chr1:44402522	ARTN	-0.44	-4.86	-0.4	3.55e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7223966	0.921	rs67018565	chr17:61928055	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	4.68	0.39	7.5e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs2204008	0.818	rs1589389	chr12:38416041	G/A	cg26384229	chr12:38710491	ALG10B	-0.79	-7.26	-0.55	3.78e-11	Bladder cancer;
TGCT	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg06618935	chr21:46677482	NA	-0.36	-5.38	-0.44	3.57e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6570726	0.643	rs9403735	chr6:145936591	C/T	cg23711669	chr6:146136114	FBXO30	0.89	9.69	0.66	7.3e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10824037	0.673	rs11000789	chr10:75595226	T/G	cg07699608	chr10:75541558	CHCHD1	0.73	5.15	0.42	9.93e-7	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs13256369	0.802	rs11249888	chr8:8564934	T/C	cg06671706	chr8:8559999	CLDN23	0.34	4.53	0.38	1.38e-5	Obesity-related traits;
TGCT	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.62	-5.32	-0.43	4.67e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7208859	0.573	rs56031503	chr17:29075665	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg15462221	chr8:8086144	FLJ10661	0.56	5.54	0.45	1.74e-7	Neuroticism;
TGCT	cis	rs9911578	0.967	rs12603238	chr17:57130785	C/T	cg12560992	chr17:57184187	TRIM37	-0.79	-9.73	-0.66	5.74e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs9486719	0.895	rs12195315	chr6:96905711	T/G	cg06623918	chr6:96969491	KIAA0776	-0.98	-8.77	-0.62	1.15e-14	Migraine;Coronary artery disease;
TGCT	cis	rs3733585	0.605	rs56178126	chr4:10123581	C/T	cg00071950	chr4:10020882	SLC2A9	-0.51	-5.3	-0.43	5.07e-7	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs3733585	0.673	rs4407505	chr4:9953367	T/G	cg11266682	chr4:10021025	SLC2A9	-0.57	-7.6	-0.56	6.21e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs3784262	0.507	rs1992231	chr15:58190937	A/G	cg12031962	chr15:58353849	ALDH1A2	0.48	6.48	0.5	1.94e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs7086627	0.515	rs10887905	chr10:82210855	A/T	cg00277334	chr10:82204260	NA	-0.54	-8.46	-0.61	6.23e-14	Post bronchodilator FEV1;
TGCT	cis	rs77972916	0.505	rs6719754	chr2:43526386	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.38	-5.66	-0.45	9.81e-8	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs7824557	0.564	rs34964435	chr8:11230206	G/T	cg21775007	chr8:11205619	TDH	-0.61	-5.84	-0.46	4.36e-8	Retinal vascular caliber;
TGCT	cis	rs7582180	0.629	rs11686880	chr2:100956229	C/T	cg14675211	chr2:100938903	LONRF2	0.5	4.69	0.39	7.19e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9611565	0.877	rs3817999	chr22:41747717	A/G	cg03806693	chr22:41940476	POLR3H	1.04	11.79	0.73	5.71e-22	Vitiligo;
TGCT	cis	rs8072100	0.748	rs9912592	chr17:45556945	G/A	cg08085267	chr17:45401833	C17orf57	-0.48	-5.24	-0.43	6.8e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs2760061	0.598	rs2796056	chr1:228122901	G/A	cg02753203	chr1:228287806	NA	-0.34	-6.63	-0.51	9.15e-10	Diastolic blood pressure;
TGCT	cis	rs7666738	0.830	rs6840766	chr4:99016260	C/G	cg05340658	chr4:99064831	C4orf37	0.48	5.43	0.44	2.92e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6912958	0.781	rs9444522	chr6:88309705	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-4.57	-0.38	1.16e-5	Monocyte percentage of white cells;
TGCT	cis	rs7267979	1.000	rs6083862	chr20:25411086	A/T	cg03522245	chr20:25566470	NINL	-0.61	-6.65	-0.51	8.4e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2820315	0.867	rs2820323	chr1:201883160	G/A	cg12730843	chr1:201915899	LMOD1	-0.26	-4.84	-0.4	3.8e-6	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
TGCT	cis	rs736801	0.521	rs2070729	chr5:131819921	G/T	cg02551604	chr5:131831745	NA	-0.77	-8.86	-0.62	7.04e-15	Breast cancer;Mosquito bite size;
TGCT	cis	rs7432375	0.901	rs4408829	chr3:136404683	C/T	cg12473912	chr3:136751656	NA	-0.36	-5.06	-0.41	1.5e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	trans	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg21659725	chr3:3221576	CRBN	-0.65	-7.16	-0.54	6.39e-11	Body mass index;
TGCT	cis	rs910316	0.967	rs12890371	chr14:75593839	T/C	cg11812906	chr14:75593930	NEK9	0.74	7.37	0.55	2.12e-11	Height;
TGCT	cis	rs926938	0.527	rs360665	chr1:115478503	A/T	cg12756093	chr1:115239321	AMPD1	0.34	4.97	0.41	2.19e-6	Autism;
TGCT	cis	rs7582180	0.564	rs2309795	chr2:100954290	G/A	cg08017756	chr2:100939284	LONRF2	-0.3	-4.95	-0.41	2.34e-6	Intelligence (multi-trait analysis);
TGCT	trans	rs10203711	1.000	rs10203711	chr2:239553368	C/T	cg16021909	chr1:248021091	TRIM58	-0.68	-6.93	-0.53	2.04e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1008375	1.000	rs10032326	chr4:17630717	A/T	cg10189774	chr4:17578691	LAP3	0.59	5.12	0.42	1.13e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs17001868	0.568	rs9611314	chr22:40735798	C/G	cg07138101	chr22:40742427	ADSL	0.73	5.38	0.44	3.57e-7	Mammographic density (dense area);
TGCT	cis	rs7615952	0.741	rs13314845	chr3:125644782	C/T	cg05084668	chr3:125655381	ALG1L	-0.75	-6.07	-0.48	1.41e-8	Blood pressure (smoking interaction);
TGCT	cis	rs9549260	0.755	rs4325426	chr13:41216437	C/A	cg21288729	chr13:41239152	FOXO1	0.97	10.09	0.67	7.57e-18	Red blood cell count;
TGCT	cis	rs6876348	0.564	rs2577427	chr5:128311818	C/T	cg02841155	chr5:128301328	SLC27A6	-0.34	-4.51	-0.38	1.51e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs56104184	0.775	rs56146968	chr19:49398847	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.73	-9.15	-0.63	1.47e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	trans	rs797680	0.856	rs569414	chr1:93784901	G/A	cg27528825	chr2:159282178	CCDC148	-0.33	-6.67	-0.51	7.68e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs394563	0.591	rs237028	chr6:149718650	C/T	cg16235748	chr6:149772707	ZC3H12D	-0.44	-4.9	-0.4	2.87e-6	Dupuytren's disease;
TGCT	cis	rs3125734	0.607	rs7923556	chr10:64024648	A/G	cg09941381	chr10:64027924	RTKN2	-0.37	-5.64	-0.45	1.1e-7	Rheumatoid arthritis;
TGCT	cis	rs7107174	0.901	rs10899473	chr11:78042983	A/C	cg12700464	chr11:78128424	GAB2	-0.66	-4.71	-0.39	6.53e-6	Testicular germ cell tumor;
TGCT	cis	rs6582630	0.576	rs2387836	chr12:38560070	A/G	cg26384229	chr12:38710491	ALG10B	0.5	4.68	0.39	7.47e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs1205863	1.000	rs209816	chr6:11951031	A/G	cg07106625	chr6:11870215	NA	0.51	5.05	0.41	1.51e-6	Disc degeneration (lumbar);
TGCT	cis	rs7659604	0.521	rs6822155	chr4:122673274	C/A	cg19748678	chr4:122722346	EXOSC9	-0.51	-5.0	-0.41	1.9e-6	Type 2 diabetes;
TGCT	cis	rs1670533	1.000	rs2100411	chr4:1074412	T/C	cg20887711	chr4:1340912	KIAA1530	0.7	5.55	0.45	1.64e-7	Recombination rate (females);
TGCT	cis	rs2832191	1.000	rs2832191	chr21:30489300	A/C	cg08807101	chr21:30365312	RNF160	-0.49	-4.44	-0.37	1.99e-5	Dental caries;
TGCT	cis	rs7605378	0.658	rs4673507	chr2:200710167	G/C	cg17644776	chr2:200775616	C2orf69	0.36	7.47	0.56	1.26e-11	Osteoporosis;
TGCT	cis	rs244731	0.959	rs7724098	chr5:176659570	G/A	cg16006841	chr5:176797999	RGS14	-0.56	-7.34	-0.55	2.42e-11	Urate levels in lean individuals;
TGCT	cis	rs6688613	1.000	rs10918605	chr1:166955638	A/G	cg07049167	chr1:166818506	POGK	0.21	4.52	0.38	1.43e-5	Refractive astigmatism;
TGCT	cis	rs2749592	0.531	rs1208559	chr10:38221370	T/C	cg25427524	chr10:38739819	LOC399744	0.41	8.54	0.61	4.1e-14	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs9926296	0.632	rs9935559	chr16:89800529	C/T	cg26513180	chr16:89883248	FANCA	-0.7	-6.89	-0.53	2.49e-10	Vitiligo;
TGCT	cis	rs6988636	1.000	rs6983795	chr8:124185296	T/C	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg21862992	chr11:68658383	NA	-0.46	-6.61	-0.51	1.04e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs427394	1.000	rs274672	chr5:6744176	G/A	cg10857441	chr5:6722123	POLS	-0.28	-6.81	-0.52	3.73e-10	Menopause (age at onset);
TGCT	cis	rs17376456	0.825	rs35496867	chr5:93220400	T/C	cg25358565	chr5:93447407	FAM172A	1.01	8.13	0.59	3.77e-13	Diabetic retinopathy;
TGCT	cis	rs7565124	1.000	rs7568106	chr2:20261969	G/A	cg00462460	chr2:20212509	MATN3	-0.43	-4.67	-0.39	7.63e-6	Major depressive disorder;
TGCT	trans	rs9383153	1.000	rs9370888	chr6:16335544	A/G	cg07798593	chr10:80890238	ZMIZ1	0.65	6.82	0.52	3.47e-10	Gambling;
TGCT	cis	rs2239547	0.522	rs2581823	chr3:53022076	C/G	cg10802521	chr3:52805072	NEK4	0.59	5.34	0.43	4.31e-7	Schizophrenia;
TGCT	cis	rs9357506	1.000	rs9367242	chr6:46312875	A/G	cg21115430	chr6:46460003	NA	-0.26	-5.16	-0.42	9.6e-7	Body mass index;
TGCT	cis	rs9796	0.870	rs2925345	chr15:41311799	T/C	cg18705301	chr15:41695430	NDUFAF1	0.41	5.31	0.43	4.82e-7	Menopause (age at onset);
TGCT	cis	rs7312933	0.670	rs10880269	chr12:42606135	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	5.06	0.41	1.45e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg21963583	chr11:68658836	MRPL21	0.33	5.61	0.45	1.28e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs903263	0.965	rs1057738	chr1:84670816	A/C	cg09664975	chr1:84543551	PRKACB	0.49	4.69	0.39	7.19e-6	Breast cancer (male);
TGCT	cis	rs4700695	0.668	rs20768	chr5:65484805	C/T	cg21114390	chr5:65439923	SFRS12	-0.79	-7.23	-0.54	4.31e-11	Facial morphology (factor 19);
TGCT	cis	rs34783982	0.529	rs6496536	chr15:89479975	C/T	cg26213453	chr15:89455860	MFGE8	0.35	4.89	0.4	3.03e-6	Squamous cell lung carcinoma;
TGCT	cis	rs2440129	0.632	rs15966	chr17:6905643	T/C	cg21237687	chr17:6899380	ALOX12	0.54	5.72	0.46	7.41e-8	Tonsillectomy;
TGCT	cis	rs7336332	0.800	rs9805452	chr13:28047908	C/T	cg22138327	chr13:27999177	GTF3A	0.77	6.42	0.5	2.58e-9	Weight;
TGCT	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg08392591	chr16:89556376	ANKRD11	-0.63	-6.1	-0.48	1.24e-8	Multiple myeloma (IgH translocation);
TGCT	cis	rs2075371	0.611	rs34573600	chr7:134018937	C/T	cg11752832	chr7:134001865	SLC35B4	0.63	5.1	0.42	1.23e-6	Mean platelet volume;
TGCT	trans	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg21659725	chr3:3221576	CRBN	-0.76	-9.03	-0.63	2.74e-15	Intelligence (multi-trait analysis);
TGCT	trans	rs1974653	0.672	rs8139591	chr22:20093317	A/G	cg08822737	chr17:71088851	SLC39A11	-0.93	-7.61	-0.56	5.97e-12	Schizophrenia;
TGCT	cis	rs7919533	0.564	rs9415039	chr10:73522694	A/G	cg00101602	chr10:73857843	ASCC1	0.28	4.58	0.38	1.11e-5	Monocyte count;
TGCT	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-6.74	-0.52	5.26e-10	Alzheimer's disease;
TGCT	cis	rs28595532	1.000	rs11938970	chr4:119660152	A/G	cg14228332	chr4:119757509	SEC24D	1.03	5.69	0.46	8.65e-8	Cannabis dependence symptom count;
TGCT	cis	rs1805008	0.535	rs7196459	chr16:90141477	G/T	cg08547343	chr16:90038815	CENPBD1;AFG3L1	-1.08	-4.63	-0.38	8.94e-6	Skin colour saturation;
TGCT	cis	rs4654899	0.833	rs10916919	chr1:21317524	A/G	cg01072550	chr1:21505969	NA	0.46	6.94	0.53	1.96e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs9894429	1.000	rs7213129	chr17:79581573	C/T	cg18240062	chr17:79603768	NPLOC4	0.67	6.84	0.52	3.23e-10	Eye color traits;
TGCT	cis	rs1483890	0.662	rs6780513	chr3:69405494	G/A	cg22125112	chr3:69402811	FRMD4B	0.29	4.74	0.39	5.85e-6	Resting heart rate;
TGCT	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	5.11	0.42	1.18e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9443645	0.901	rs9343843	chr6:79585625	C/T	cg09184832	chr6:79620586	NA	-0.49	-5.29	-0.43	5.29e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9611565	0.694	rs79008	chr22:41850500	C/T	cg06481639	chr22:41940642	POLR3H	-0.72	-6.2	-0.49	7.62e-9	Vitiligo;
TGCT	cis	rs78487399	0.808	rs6746058	chr2:43687542	A/G	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.72	4.62	0.38	9.53e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs4924935	1.000	rs11658555	chr17:18817486	C/T	cg26378065	chr17:18585709	ZNF286B	-0.56	-4.72	-0.39	6.38e-6	Pancreatic cancer;
TGCT	cis	rs17401966	0.838	rs12738317	chr1:10419663	C/T	cg19773385	chr1:10388646	KIF1B	-0.23	-5.38	-0.44	3.57e-7	Hepatocellular carcinoma;
TGCT	cis	rs8067545	0.967	rs1034904	chr17:19927699	A/G	cg13482628	chr17:19912719	NA	-0.54	-4.7	-0.39	6.85e-6	Schizophrenia;
TGCT	cis	rs9611565	0.573	rs9306355	chr22:42111896	A/T	cg13695892	chr22:41940480	POLR3H	0.83	8.18	0.59	2.79e-13	Vitiligo;
TGCT	cis	rs6831352	0.879	rs34360292	chr4:100051303	T/C	cg12011299	chr4:100065546	ADH4	-0.41	-4.92	-0.4	2.72e-6	Alcohol dependence;
TGCT	cis	rs4285028	0.851	rs1986368	chr3:121710969	A/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.77	-6.44	-0.5	2.36e-9	Multiple sclerosis;
TGCT	cis	rs8017423	0.904	rs11622257	chr14:90715014	C/T	cg04374321	chr14:90722782	PSMC1	-0.73	-7.29	-0.55	3.12e-11	Mortality in heart failure;
TGCT	cis	rs614226	0.688	rs75111771	chr12:121009943	T/C	cg01236616	chr12:121019343	POP5	-1.29	-12.97	-0.76	7.75e-25	Type 1 diabetes nephropathy;
TGCT	cis	rs1903068	0.853	rs28411232	chr4:56000009	A/T	cg01777861	chr4:56023843	NA	0.54	6.38	0.5	3.2e-9	Endometriosis;
TGCT	cis	rs11190604	1.000	rs2295772	chr10:102265183	G/A	cg23241863	chr10:102295624	HIF1AN	0.67	5.13	0.42	1.1e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9677476	0.516	rs1035620	chr2:232008305	C/T	cg27665808	chr2:232055229	NA	0.35	4.43	0.37	2.01e-5	Food antigen IgG levels;
TGCT	cis	rs9527	0.615	rs4917991	chr10:104783833	T/C	cg04362960	chr10:104952993	NT5C2	0.65	5.54	0.45	1.73e-7	Arsenic metabolism;
TGCT	cis	rs3771570	1.000	rs62186411	chr2:242236667	A/C	cg21155796	chr2:242212141	HDLBP	0.98	6.68	0.51	7.29e-10	Prostate cancer;
TGCT	cis	rs514406	0.505	rs405208	chr1:53176674	C/T	cg22166914	chr1:53195759	ZYG11B	0.45	7.99	0.58	7.98e-13	Monocyte count;
TGCT	cis	rs617219	0.737	rs1275103	chr5:78448105	C/G	cg09550809	chr5:78407562	BHMT	0.39	5.46	0.44	2.54e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs11098499	0.645	rs72676059	chr4:120290828	C/G	cg09307838	chr4:120376055	NA	0.58	5.75	0.46	6.63e-8	Corneal astigmatism;
TGCT	cis	rs9372253	0.967	rs1055301	chr6:110713042	A/G	cg00083206	chr6:110721305	DDO	-0.4	-6.07	-0.48	1.44e-8	Platelet distribution width;
TGCT	cis	rs9814567	0.896	rs2177602	chr3:134245866	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.95	-9.55	-0.65	1.56e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs950776	0.745	rs36045869	chr15:78929498	C/T	cg06917634	chr15:78832804	PSMA4	0.61	4.77	0.39	5.17e-6	Sudden cardiac arrest;
TGCT	cis	rs477895	0.568	rs12418035	chr11:63871558	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.7	5.87	0.47	3.73e-8	Mean platelet volume;
TGCT	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg17345569	chr6:42928274	GNMT	-0.48	-4.97	-0.41	2.22e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs992157	0.560	rs7578940	chr2:219083318	G/T	cg00012203	chr2:219082015	ARPC2	-0.81	-9.36	-0.64	4.37e-16	Colorectal cancer;
TGCT	cis	rs7954584	0.520	rs1169096	chr12:122465836	G/C	cg13699009	chr12:122356056	WDR66	-0.22	-4.59	-0.38	1.05e-5	Mean corpuscular volume;
TGCT	cis	rs6815814	0.731	rs4504266	chr4:38773754	G/A	cg02016764	chr4:38805732	TLR1	-0.28	-4.73	-0.39	5.94e-6	Breast cancer;
TGCT	cis	rs1008375	0.966	rs10489036	chr4:17697687	A/G	cg18681998	chr4:17616180	MED28	0.82	7.76	0.57	2.71e-12	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs798766	0.953	rs13123646	chr4:1740539	T/C	cg05874882	chr4:1763078	NA	-0.33	-4.56	-0.38	1.2e-5	Bladder cancer;Urinary bladder cancer;
TGCT	trans	rs208520	0.526	rs9351542	chr6:66788571	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.09	-16.9	-0.84	5.6e-34	Exhaled nitric oxide output;
TGCT	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg13665807	chr20:60559372	TAF4	-0.46	-4.94	-0.41	2.48e-6	Body mass index;
TGCT	cis	rs6089829	0.962	rs6089826	chr20:61668595	G/A	cg02380750	chr20:61661411	NA	0.34	5.98	0.47	2.24e-8	Prostate cancer (SNP x SNP interaction);
TGCT	trans	rs208520	0.802	rs4710314	chr6:66883656	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-10.21	-0.68	4.02e-18	Exhaled nitric oxide output;
TGCT	cis	rs6495122	0.699	rs3784789	chr15:75082552	C/G	cg10253484	chr15:75165896	SCAMP2	-0.68	-6.01	-0.48	1.87e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
TGCT	cis	rs8064299	0.632	rs750018	chr17:72771637	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	0.61	5.64	0.45	1.09e-7	Monocyte count;
TGCT	cis	rs7336332	0.628	rs9581854	chr13:28017782	C/T	cg22138327	chr13:27999177	GTF3A	0.83	6.64	0.51	9e-10	Weight;
TGCT	cis	rs7208859	0.673	rs73263755	chr17:29198972	A/G	cg14008862	chr17:28927542	LRRC37B2	0.72	4.66	0.39	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs709400	0.894	rs61996721	chr14:104061352	G/A	cg26031613	chr14:104095156	KLC1	1.16	16.37	0.83	9.05e-33	Body mass index;
TGCT	cis	rs7809950	0.954	rs2520243	chr7:107136973	T/C	cg23024343	chr7:107201750	COG5	-0.35	-5.6	-0.45	1.3e-7	Coronary artery disease;
TGCT	trans	rs17685	0.753	rs10262501	chr7:75668172	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.52	-8.84	-0.62	7.72e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs2235642	0.821	rs8051895	chr16:1602811	A/G	cg11375102	chr16:1583810	IFT140;TMEM204	-0.3	-5.42	-0.44	2.97e-7	Coronary artery disease;
TGCT	cis	rs12134245	0.719	rs61798831	chr1:91996588	C/T	cg02896835	chr1:92012615	NA	-0.27	-4.59	-0.38	1.08e-5	Breast cancer;
TGCT	cis	rs904251	0.766	rs1757175	chr6:37486694	T/C	cg01843034	chr6:37503916	NA	-0.52	-6.35	-0.5	3.64e-9	Cognitive performance;
TGCT	cis	rs9929218	0.551	rs6499193	chr16:68727069	C/T	cg01251360	chr16:68772225	CDH1	-0.28	-5.27	-0.43	5.8e-7	Colorectal cancer;
TGCT	cis	rs9682041	0.877	rs6804688	chr3:170071191	T/G	cg11886554	chr3:170076028	SKIL	0.55	4.58	0.38	1.11e-5	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs78707713	0.535	rs3812705	chr10:71211146	A/G	cg12610070	chr10:71211762	TSPAN15	-0.6	-6.98	-0.53	1.62e-10	Venous thromboembolism;
TGCT	cis	rs1153858	1.000	rs8042786	chr15:45703539	T/C	cg14582100	chr15:45693742	SPATA5L1	0.48	5.67	0.45	9.65e-8	Homoarginine levels;
TGCT	cis	rs6460942	1.000	rs17668923	chr7:12302873	A/T	cg06484146	chr7:12443880	VWDE	-0.54	-4.99	-0.41	2.02e-6	Coronary artery disease;
TGCT	cis	rs13217239	0.646	rs9379956	chr6:27033735	T/C	cg15659132	chr6:26577336	NA	-0.56	-5.55	-0.45	1.62e-7	Schizophrenia;
TGCT	cis	rs8038465	0.904	rs11852484	chr15:73988652	G/A	cg15420318	chr15:73925796	NPTN	0.52	4.59	0.38	1.08e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9372498	0.536	rs9489428	chr6:118852935	T/C	cg21191810	chr6:118973309	C6orf204	-0.37	-4.79	-0.39	4.73e-6	Diastolic blood pressure;
TGCT	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg16680214	chr1:154839983	KCNN3	-0.36	-7.26	-0.55	3.81e-11	Prostate cancer;
TGCT	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.34	0.43	4.23e-7	Prudent dietary pattern;
TGCT	cis	rs12681288	0.792	rs4735972	chr8:998618	A/C	cg04851639	chr8:1020857	NA	-0.35	-5.87	-0.47	3.72e-8	Schizophrenia;
TGCT	cis	rs9644630	0.932	rs4922048	chr8:19360814	A/G	cg01280390	chr8:19363452	CSGALNACT1	0.26	4.62	0.38	9.55e-6	Oropharynx cancer;
TGCT	cis	rs2224391	0.590	rs72813700	chr6:5275531	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-1.06	-5.42	-0.44	2.94e-7	Height;
TGCT	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg07507251	chr3:52567010	NT5DC2	0.48	7.06	0.54	1.05e-10	Bipolar disorder;
TGCT	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg22105103	chr4:187893119	NA	0.31	4.48	0.37	1.66e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2295359	1.000	rs736197	chr1:67607135	G/T	cg12940439	chr1:67600707	NA	0.59	6.16	0.48	9.5e-9	Psoriasis;
TGCT	trans	rs1814175	0.645	rs6486022	chr11:49776137	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.46	-11.72	-0.72	8.37e-22	Height;
TGCT	cis	rs12908161	1.000	rs35726233	chr15:85337800	C/T	cg17173187	chr15:85201210	NMB	0.57	6.39	0.5	3.07e-9	Schizophrenia;
TGCT	cis	rs7666738	0.830	rs28818180	chr4:98953625	A/G	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6570726	0.846	rs6570700	chr6:145931552	A/G	cg23711669	chr6:146136114	FBXO30	0.83	8.63	0.61	2.46e-14	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7666738	0.830	rs10470893	chr4:99038756	C/T	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs60843830	1.000	rs55753056	chr2:243929	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.69	6.48	0.5	1.91e-9	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs1403694	0.695	rs11924390	chr3:186433099	T/C	cg12454167	chr3:186435060	KNG1	0.49	8.15	0.59	3.31e-13	Blood protein levels;
TGCT	cis	rs12780845	0.522	rs725355	chr10:17202865	T/C	cg01003015	chr10:17271136	VIM	-0.52	-4.71	-0.39	6.42e-6	Homocysteine levels;
TGCT	cis	rs10501293	1.000	rs1425850	chr11:43109833	T/C	cg03447554	chr11:43094025	NA	-0.5	-6.92	-0.53	2.09e-10	Cognitive performance;
TGCT	cis	rs380904	0.963	rs410822	chr8:144574611	A/C	cg09317036	chr8:144635547	GSDMD	0.49	4.58	0.38	1.12e-5	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs9467773	0.620	rs2451732	chr6:26622904	A/T	cg05738196	chr6:26577821	NA	-0.89	-10.62	-0.69	4e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs2050392	0.624	rs303436	chr10:30731893	G/T	cg12408189	chr10:30722286	MAP3K8	-0.45	-4.65	-0.39	8.34e-6	Inflammatory bowel disease;
TGCT	cis	rs9914544	0.932	rs11870265	chr17:18820985	A/T	cg26378065	chr17:18585709	ZNF286B	0.53	4.75	0.39	5.64e-6	Educational attainment (years of education);
TGCT	cis	rs9303401	0.659	rs7216648	chr17:56790858	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.67	6.3	0.49	4.7e-9	Cognitive test performance;
TGCT	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg16680214	chr1:154839983	KCNN3	-0.36	-7.71	-0.57	3.44e-12	Prostate cancer;
TGCT	cis	rs7267979	0.866	rs2424699	chr20:25257462	G/A	cg03522245	chr20:25566470	NINL	0.62	6.57	0.51	1.22e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4727027	0.933	rs6961605	chr7:148870108	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	4.59	0.38	1.07e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg25703541	chr22:24373054	LOC391322	-0.84	-8.98	-0.63	3.58e-15	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg17054783	chr10:134559939	INPP5A	0.23	4.48	0.37	1.64e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs9902453	1.000	rs59274738	chr17:28437635	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.74	6.57	0.51	1.22e-9	Coffee consumption (cups per day);
TGCT	cis	rs8033133	0.958	rs6420956	chr15:25309559	T/C	cg14481604	chr15:25334117	SNORD116-22	-0.28	-5.87	-0.47	3.68e-8	Blood osmolality (transformed sodium);
TGCT	cis	rs11096990	0.964	rs6842390	chr4:39263482	C/G	cg14806045	chr4:39367699	RFC1	0.59	4.63	0.38	8.92e-6	Cognitive function;
TGCT	cis	rs9303401	0.614	rs12947982	chr17:57140301	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.63	5.8	0.46	5.11e-8	Cognitive test performance;
TGCT	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg24503407	chr1:205819492	PM20D1	0.59	8.33	0.6	1.3e-13	Menarche (age at onset);
TGCT	cis	rs1008375	0.932	rs3846356	chr4:17614176	C/T	cg10189774	chr4:17578691	LAP3	0.65	5.49	0.44	2.22e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg07061783	chr6:25882402	NA	-0.89	-10.69	-0.69	2.63e-19	Urate levels;
TGCT	cis	rs4517514	0.509	rs11018875	chr11:89876356	T/C	cg14505434	chr11:89522851	NA	0.45	4.46	0.37	1.82e-5	Trans fatty acid levels;
TGCT	cis	rs28595532	0.920	rs115090643	chr4:119729825	C/T	cg14228332	chr4:119757509	SEC24D	1.32	6.38	0.5	3.2e-9	Cannabis dependence symptom count;
TGCT	cis	rs225245	0.817	rs225284	chr17:33933006	A/C	cg05299278	chr17:33885742	SLFN14	0.21	4.44	0.37	1.98e-5	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs9913156	0.517	rs8065068	chr17:4611453	A/T	cg19197139	chr17:4613644	ARRB2	0.73	6.59	0.51	1.14e-9	Lymphocyte counts;
TGCT	cis	rs9611565	0.512	rs5758464	chr22:42171300	A/G	cg06634786	chr22:41940651	POLR3H	0.95	6.61	0.51	1.01e-9	Vitiligo;
TGCT	cis	rs17253792	0.822	rs10148122	chr14:56146694	G/T	cg01858014	chr14:56050164	KTN1	-0.35	-4.62	-0.38	9.37e-6	Putamen volume;
TGCT	trans	rs1814175	0.817	rs3974439	chr11:50022607	G/A	cg03929089	chr4:120376271	NA	-0.72	-8.55	-0.61	3.8e-14	Height;
TGCT	cis	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg07424592	chr7:64974309	NA	1.36	8.08	0.59	4.97e-13	Diabetic kidney disease;
TGCT	cis	rs11190604	1.000	rs11190607	chr10:102303614	C/T	cg23241863	chr10:102295624	HIF1AN	0.7	5.14	0.42	1.02e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs17767294	0.541	rs733743	chr6:28327371	C/G	cg08851530	chr6:28072375	NA	-1.2	-6.39	-0.5	3.01e-9	Parkinson's disease;
TGCT	cis	rs5769707	0.681	rs739236	chr22:50041602	A/G	cg05373962	chr22:49881684	NA	-0.34	-5.66	-0.45	1.01e-7	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs1801251	1.000	rs1446308	chr2:233639309	T/C	cg08000102	chr2:233561755	GIGYF2	0.64	6.56	0.51	1.34e-9	Coronary artery disease;
TGCT	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg22963979	chr7:1858916	MAD1L1	-0.38	-5.73	-0.46	7.15e-8	Bipolar disorder and schizophrenia;
TGCT	cis	rs9868809	0.656	rs13324119	chr3:48710606	G/C	cg00383909	chr3:49044727	WDR6	1.06	6.18	0.49	8.32e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs11741688	0.557	rs6897783	chr5:178330574	G/A	cg09339527	chr5:178322752	ZFP2	-0.29	-4.85	-0.4	3.57e-6	Sleep duration;
TGCT	cis	rs9467773	0.596	rs3001369	chr6:26670969	C/T	cg09904177	chr6:26538194	HMGN4	0.63	5.4	0.44	3.34e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9638182	0.725	rs80189144	chr7:72939939	T/C	cg14087351	chr7:73037990	MLXIPL	-0.57	-4.52	-0.38	1.4e-5	Triglycerides;
TGCT	cis	rs6540559	0.546	rs735693	chr1:210033988	A/C	cg04352962	chr1:209979756	IRF6	0.76	5.37	0.43	3.69e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs6918586	0.658	rs198840	chr6:26112164	T/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.7	-6.6	-0.51	1.07e-9	Schizophrenia;
TGCT	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg19536664	chr17:6899085	ALOX12	0.38	6.05	0.48	1.62e-8	Tonsillectomy;
TGCT	cis	rs3809566	0.676	rs62013179	chr15:63329601	T/G	cg00520135	chr15:63333846	TPM1	-0.4	-4.9	-0.4	2.95e-6	Platelet count;
TGCT	cis	rs1348850	0.914	rs7587604	chr2:178309848	T/A	cg22681709	chr2:178499509	PDE11A	-0.34	-4.47	-0.37	1.72e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs2229238	0.911	rs4379670	chr1:154439865	T/A	cg13067139	chr1:155221277	FAM189B	-0.2	-4.56	-0.38	1.22e-5	Coronary heart disease;
TGCT	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg04944784	chr2:26401820	FAM59B	-0.7	-6.49	-0.5	1.89e-9	Gut microbiome composition (summer);
TGCT	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg12310025	chr6:25882481	NA	-0.78	-8.1	-0.59	4.37e-13	Blood metabolite levels;
TGCT	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg05368731	chr17:41323189	NBR1	1.1	11.12	0.71	2.38e-20	Menopause (age at onset);
TGCT	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg16497277	chr3:49208875	KLHDC8B	-0.53	-5.13	-0.42	1.09e-6	Menarche (age at onset);
TGCT	cis	rs1887596	0.705	rs9551299	chr13:27166335	A/G	cg01312412	chr13:27282625	NA	0.3	5.33	0.43	4.43e-7	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg07507251	chr3:52567010	NT5DC2	0.48	6.91	0.53	2.24e-10	Bipolar disorder;
TGCT	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs28595532	0.920	rs115437723	chr4:119741828	C/T	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs8014204	0.762	rs10139018	chr14:75274292	T/C	cg06637938	chr14:75390232	RPS6KL1	0.55	4.91	0.4	2.81e-6	Caffeine consumption;
TGCT	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg02463440	chr8:22132932	PIWIL2	0.26	5.02	0.41	1.78e-6	Hypertriglyceridemia;
TGCT	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg11062466	chr8:58055876	NA	0.43	4.64	0.38	8.85e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2862064	1.000	rs2862064	chr5:156445827	C/G	cg12943317	chr5:156479607	HAVCR1	-0.38	-5.2	-0.42	8.06e-7	Platelet count;
TGCT	cis	rs7666738	0.830	rs1559859	chr4:99024325	C/T	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1372520	0.532	rs2583972	chr4:90747411	T/G	cg15133208	chr4:90757351	SNCA	-0.5	-5.75	-0.46	6.42e-8	Neuroticism;
TGCT	cis	rs7681440	0.838	rs1348224	chr4:90761946	G/A	cg14346243	chr4:90757452	SNCA	-0.57	-5.61	-0.45	1.24e-7	Dementia with Lewy bodies;
TGCT	cis	rs3935685	0.874	rs11072663	chr15:77999542	A/G	cg03457338	chr15:78040120	NA	-0.22	-5.61	-0.45	1.24e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs4886920	0.694	rs7163336	chr15:78087772	A/G	cg25212270	chr15:78015279	NA	0.23	4.82	0.4	4.04e-6	Neuroticism;
TGCT	cis	rs3806843	0.766	rs2530239	chr5:140062547	C/T	cg19875535	chr5:140030758	IK	-0.35	-5.93	-0.47	2.81e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7264396	0.790	rs6121015	chr20:34243017	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.28	-4.68	-0.39	7.38e-6	Total cholesterol levels;
TGCT	cis	rs453301	0.598	rs1025395	chr8:8836603	G/C	cg11995313	chr8:8860691	ERI1	-0.51	-4.48	-0.37	1.68e-5	Joint mobility (Beighton score);
TGCT	cis	rs4727027	0.866	rs1405124	chr7:148779618	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.54	5.0	0.41	1.93e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs9682041	0.660	rs34158232	chr3:170115360	T/C	cg11886554	chr3:170076028	SKIL	0.62	4.82	0.4	4.11e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs614226	0.748	rs78714658	chr12:121009944	G/A	cg01236616	chr12:121019343	POP5	-1.29	-12.97	-0.76	7.75e-25	Type 1 diabetes nephropathy;
TGCT	cis	rs524281	0.773	rs11227413	chr11:65883696	G/A	cg00563793	chr11:65837595	PACS1	0.56	4.58	0.38	1.12e-5	Electroencephalogram traits;
TGCT	trans	rs525455	1.000	rs1659837	chr10:13103112	C/T	cg21721093	chr17:8906386	NA	0.64	6.7	0.52	6.38e-10	Platelet aggregation;
TGCT	cis	rs7809950	0.678	rs7790080	chr7:107031322	G/A	cg23024343	chr7:107201750	COG5	-0.46	-6.18	-0.49	8.6e-9	Coronary artery disease;
TGCT	cis	rs3096299	0.935	rs3102387	chr16:89432276	A/C	cg06640241	chr16:89574553	SPG7	0.68	6.82	0.52	3.51e-10	Multiple myeloma (IgH translocation);
TGCT	cis	rs11059919	1	rs11059919	chr12:129289190	G/A	cg09035930	chr12:129282057	SLC15A4	0.57	11.13	0.71	2.23e-20	Systemic lupus erythematosus;
TGCT	cis	rs1395	0.744	rs11126932	chr2:27476282	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.62	7.72	0.57	3.38e-12	Blood metabolite levels;
TGCT	cis	rs7666738	0.830	rs17484966	chr4:99014432	T/C	cg17366294	chr4:99064904	C4orf37	0.66	6.75	0.52	5.04e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6546537	0.911	rs4852898	chr2:69872797	C/T	cg10773587	chr2:69614142	GFPT1	-0.78	-6.44	-0.5	2.35e-9	Serum thyroid-stimulating hormone levels;
TGCT	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg09060608	chr5:178986726	RUFY1	0.61	7.14	0.54	6.87e-11	Lung cancer;
TGCT	cis	rs4953076	0.573	rs6734443	chr2:44408282	G/C	cg04920474	chr2:44395004	PPM1B	0.59	5.92	0.47	2.94e-8	Height;
TGCT	cis	rs2075165	0.901	rs2296374	chr1:156287403	T/C	cg16558208	chr1:156270281	VHLL	0.28	5.05	0.41	1.52e-6	Tonsillectomy;
TGCT	cis	rs10927875	0.526	rs2179615	chr1:16282426	G/A	cg21385522	chr1:16154831	NA	-0.94	-9.6	-0.65	1.15e-16	Dilated cardiomyopathy;
TGCT	cis	rs13082711	0.595	rs34453788	chr3:27330153	T/C	cg02860705	chr3:27208620	NA	0.48	7.4	0.55	1.83e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.7	4.86	0.4	3.52e-6	Platelet count;
TGCT	cis	rs6663390	0.831	rs3754171	chr1:208086939	T/C	cg03990033	chr1:208084030	CD34	0.54	5.61	0.45	1.26e-7	Facial morphology (factor 18);
TGCT	cis	rs4455778	0.659	rs11185624	chr7:49028252	T/A	cg26309511	chr7:48887640	NA	-0.44	-5.22	-0.42	7.26e-7	Lung cancer in never smokers;
TGCT	trans	rs7698623	0.850	rs6532020	chr4:88768928	C/T	cg01186725	chr1:53905612	FLJ40434	-0.48	-6.63	-0.51	9.21e-10	Cardiovascular disease risk factors;
TGCT	cis	rs12477438	0.501	rs1133977	chr2:99741984	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-7.04	-0.53	1.18e-10	Chronic sinus infection;
TGCT	cis	rs9916302	0.904	rs4795357	chr17:37569551	T/C	cg07936489	chr17:37558343	FBXL20	-0.63	-4.91	-0.4	2.83e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7666738	0.791	rs11735105	chr4:98937357	C/T	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs732765	0.819	rs714788	chr14:75320043	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.59	-5.02	-0.41	1.72e-6	Non-small cell lung cancer;
TGCT	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg25036284	chr2:26402008	FAM59B	-0.54	-4.69	-0.39	7.11e-6	Gut microbiome composition (summer);
TGCT	cis	rs2046867	0.908	rs1994627	chr3:72783628	A/G	cg25664220	chr3:72788482	NA	0.53	6.61	0.51	1e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6141769	0.542	rs2064934	chr20:31314757	C/G	cg13636640	chr20:31349939	DNMT3B	-0.52	-4.54	-0.38	1.34e-5	Subjective well-being;
TGCT	cis	rs250677	0.958	rs10056942	chr5:148416114	C/A	cg18129178	chr5:148520854	ABLIM3	-0.4	-5.63	-0.45	1.17e-7	Breast cancer;
TGCT	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg20276088	chr3:133502917	NA	-0.24	-4.96	-0.41	2.28e-6	Iron status biomarkers;
TGCT	cis	rs76878669	0.561	rs11823140	chr11:66098322	G/T	cg18002602	chr11:66138449	SLC29A2	-0.52	-6.32	-0.49	4.39e-9	Educational attainment (years of education);
TGCT	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg13607699	chr17:42295918	UBTF	0.84	7.55	0.56	8.34e-12	Total body bone mineral density;
TGCT	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.5	4.67	0.39	7.55e-6	Menarche (age at onset);
TGCT	cis	rs2677744	0.626	rs868547	chr15:91498760	G/A	cg22570213	chr15:91497863	RCCD1	0.39	4.78	0.39	4.9100000000000004e-06	Attention deficit hyperactivity disorder;
TGCT	trans	rs57221529	0.655	rs72704791	chr5:547896	A/G	cg11887960	chr12:57824829	NA	1.12	8.48	0.61	5.54e-14	Lung disease severity in cystic fibrosis;
TGCT	cis	rs36051895	0.587	rs7035915	chr9:5238253	C/T	cg02405213	chr9:5042618	JAK2	-0.73	-9.52	-0.65	1.88e-16	Pediatric autoimmune diseases;
TGCT	cis	rs7714584	1.000	rs59531858	chr5:150247063	T/G	cg22134413	chr5:150180641	NA	1.17	8.71	0.62	1.61e-14	Crohn's disease;
TGCT	cis	rs4746818	1.000	rs7091695	chr10:70964997	A/G	cg11621586	chr10:70884670	VPS26A	-1.11	-7.83	-0.58	1.87e-12	Left atrial antero-posterior diameter;
TGCT	cis	rs4149178	0.722	rs9472031	chr6:43293101	C/T	cg07522644	chr6:43142093	SRF	-0.66	-4.69	-0.39	7e-6	Urate levels;
TGCT	cis	rs3820068	0.705	rs4646031	chr1:15834648	A/G	cg05660106	chr1:15850417	CASP9	1.16	14.82	0.8	3.11e-29	Systolic blood pressure;
TGCT	cis	rs2153535	0.580	rs1034272	chr6:8469335	G/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs6430585	0.528	rs586964	chr2:136652491	G/A	cg07169764	chr2:136633963	MCM6	1.25	12.43	0.74	1.55e-23	Corneal structure;
TGCT	cis	rs4460629	0.521	rs7367897	chr1:155083289	A/T	cg23973274	chr1:155060172	NA	-0.25	-4.51	-0.38	1.5e-5	Serum magnesium levels;
TGCT	cis	rs7809950	1.000	rs3801944	chr7:107255548	T/C	cg23024343	chr7:107201750	COG5	0.36	5.64	0.45	1.1e-7	Coronary artery disease;
TGCT	cis	rs1843834	0.539	rs6739735	chr2:225405253	A/G	cg12698349	chr2:225449008	CUL3	-0.76	-6.29	-0.49	4.91e-9	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg16680214	chr1:154839983	KCNN3	-0.35	-7.11	-0.54	8.04e-11	Prostate cancer;
TGCT	cis	rs868036	0.681	rs4776978	chr15:68108305	A/G	cg05925327	chr15:68127851	NA	-0.5	-4.85	-0.4	3.57e-6	Restless legs syndrome;
TGCT	cis	rs1784581	0.802	rs9458430	chr6:162426517	G/T	cg17173639	chr6:162384350	PARK2	-0.43	-7.5	-0.56	1.09e-11	Itch intensity from mosquito bite;
TGCT	cis	rs9914544	0.966	rs9906795	chr17:18816740	G/A	cg26306683	chr17:18585705	ZNF286B	0.57	4.98	0.41	2.06e-6	Educational attainment (years of education);
TGCT	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.84	7.5	0.56	1.08e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs11122272	0.766	rs2024879	chr1:231528638	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-6.28	-0.49	5.09e-9	Hemoglobin concentration;
TGCT	cis	rs7432375	0.901	rs1017882	chr3:136357705	T/C	cg12473912	chr3:136751656	NA	0.36	5.06	0.41	1.5e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4595586	0.545	rs12814188	chr12:39380853	C/T	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs2204008	0.720	rs11170774	chr12:38021722	C/T	cg26384229	chr12:38710491	ALG10B	-0.7	-6.14	-0.48	1.04e-8	Bladder cancer;
TGCT	cis	rs2963155	0.518	rs56150733	chr5:142765099	T/C	cg17617527	chr5:142782415	NR3C1	0.8	4.92	0.4	2.65e-6	Breast cancer;
TGCT	cis	rs10992471	0.576	rs9409664	chr9:95070095	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.63	-6.09	-0.48	1.29e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs9291683	0.632	rs13101785	chr4:10042915	T/A	cg11266682	chr4:10021025	SLC2A9	0.64	8.75	0.62	1.29e-14	Bone mineral density;
TGCT	trans	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-1.04	-13.29	-0.77	1.33e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg03303774	chr4:1407052	NA	0.29	4.76	0.39	5.36e-6	Obesity-related traits;
TGCT	cis	rs3733585	0.775	rs13124007	chr4:10043931	G/C	cg11266682	chr4:10021025	SLC2A9	0.6	7.52	0.56	9.49e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs13242816	0.881	rs35210394	chr7:116104911	C/G	cg16553024	chr7:116138462	CAV2	-0.43	-4.8	-0.4	4.41e-6	P wave duration;
TGCT	cis	rs6121246	0.567	rs2889488	chr20:30185758	G/A	cg21427119	chr20:30132790	HM13	-0.38	-5.63	-0.45	1.14e-7	Mean corpuscular hemoglobin;
TGCT	cis	rs4566357	1.000	rs6436650	chr2:227925097	C/T	cg11843606	chr2:227700838	RHBDD1	-0.5	-4.49	-0.37	1.59e-5	Coronary artery disease;
TGCT	cis	rs9942416	0.660	rs10462356	chr5:74987108	C/T	cg19683494	chr5:74908142	NA	0.59	6.26	0.49	5.62e-9	Age-related disease endophenotypes;
TGCT	cis	rs644799	1.000	rs568668	chr11:95528209	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	10.57	0.69	5.17e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs611744	0.506	rs4735054	chr8:109261780	A/C	cg21045802	chr8:109455806	TTC35	-0.83	-8.7	-0.62	1.71e-14	Dupuytren's disease;
TGCT	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2675662	0.525	rs12264025	chr10:75494450	A/G	cg15838173	chr10:75533400	FUT11	-0.31	-5.02	-0.41	1.73e-6	Psoriasis vulgaris;Psoriasis;
TGCT	cis	rs9902453	0.584	rs3809790	chr17:27955540	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.85	-7.8	-0.57	2.14e-12	Coffee consumption (cups per day);
TGCT	cis	rs2820315	0.867	rs2819346	chr1:201882087	A/C	cg12730843	chr1:201915899	LMOD1	-0.24	-4.5	-0.38	1.52e-5	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
TGCT	cis	rs7727544	0.716	rs10058655	chr5:131570896	A/T	cg21474247	chr5:131268130	NA	0.32	4.64	0.38	8.57e-6	Blood metabolite levels;
TGCT	cis	rs617219	0.698	rs72764983	chr5:78513806	T/C	cg09550809	chr5:78407562	BHMT	0.41	5.66	0.45	9.78e-8	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg22535103	chr8:58192502	C8orf71	-0.42	-4.79	-0.4	4.7e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs36051895	0.632	rs10815166	chr9:5149920	T/G	cg02405213	chr9:5042618	JAK2	-0.75	-9.73	-0.66	5.75e-17	Pediatric autoimmune diseases;
TGCT	cis	rs7666738	0.753	rs7698541	chr4:98986351	T/A	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9910055	0.571	rs10208	chr17:42300278	C/T	cg13607699	chr17:42295918	UBTF	1.12	14.59	0.79	1.1e-28	Total body bone mineral density;
TGCT	cis	rs11190604	0.767	rs7392696	chr10:102182141	G/A	cg16005271	chr10:102321736	NA	0.46	4.67	0.39	7.62e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7255045	0.788	rs10424001	chr19:12948462	A/G	cg06537894	chr19:12978706	MAST1	-0.49	-4.44	-0.37	1.98e-5	Mean corpuscular volume;
TGCT	cis	rs7246657	0.722	rs954504	chr19:38045394	A/G	cg18154014	chr19:37997991	ZNF793	0.69	4.63	0.38	9.25e-6	Coronary artery calcification;
TGCT	cis	rs9896850	0.513	rs10445407	chr17:79261809	A/C	cg27412613	chr17:79183705	AZI1	0.23	4.48	0.37	1.65e-5	Frontotemporal dementia;
TGCT	cis	rs7617773	0.780	rs11706277	chr3:48360433	A/G	cg11946769	chr3:48343235	NME6	0.8	7.06	0.54	1.03e-10	Coronary artery disease;
TGCT	cis	rs7312933	0.533	rs17551006	chr12:42848738	G/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.52	4.93	0.4	2.62e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs9811216	1.000	rs9831661	chr3:169528523	A/C	cg08193579	chr3:169529701	LRRC34	-0.29	-4.58	-0.38	1.13e-5	Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;
TGCT	cis	rs11105298	0.685	rs117578503	chr12:89836672	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.67	-4.74	-0.39	5.67e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs2594989	0.887	rs7643330	chr3:11442093	A/G	cg00170343	chr3:11313890	ATG7	0.66	4.99	0.41	1.96e-6	Circulating chemerin levels;
TGCT	cis	rs908922	0.676	rs1970283	chr1:152495619	G/C	cg20991723	chr1:152506922	NA	0.46	6.22	0.49	6.97e-9	Hair morphology;
TGCT	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg20203395	chr5:56204925	C5orf35	-0.65	-4.7	-0.39	6.83e-6	Type 2 diabetes;
TGCT	cis	rs7552404	0.691	rs1770890	chr1:76401117	A/G	cg10523679	chr1:76189770	ACADM	-0.8	-7.4	-0.55	1.79e-11	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2562456	0.876	rs7252585	chr19:21657943	C/T	cg01304269	chr19:21688519	ZNF429	-0.57	-4.69	-0.39	7.09e-6	Pain;
TGCT	cis	rs7552404	0.765	rs211717	chr1:76106969	G/A	cg10523679	chr1:76189770	ACADM	-0.92	-10.1	-0.67	7.29e-18	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg19678392	chr7:94953810	PON1	-0.69	-7.82	-0.57	1.92e-12	Paraoxonase activity;
TGCT	cis	rs4803468	1.000	rs6508977	chr19:41909346	A/G	cg09537434	chr19:41945824	ATP5SL	-0.92	-10.69	-0.69	2.72e-19	Height;
TGCT	cis	rs2777491	0.957	rs919961	chr15:41651721	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.75	-10.46	-0.68	9.68e-19	Ulcerative colitis;
TGCT	cis	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg22857025	chr5:266934	NA	-0.34	-6.7	-0.52	6.65e-10	Breast cancer;
TGCT	cis	rs7666738	0.830	rs115712871	chr4:98954535	A/T	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs60843830	0.964	rs7584915	chr2:264227	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.72	6.94	0.53	1.98e-10	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs2456568	0.900	rs2456559	chr11:93668858	A/T	cg26875233	chr11:93583750	C11orf90	-0.46	-5.59	-0.45	1.4e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg05890377	chr2:74357713	NA	0.52	7.0	0.53	1.44e-10	Gestational age at birth (maternal effect);
TGCT	cis	rs7772486	0.875	rs854145	chr6:146349650	C/T	cg23711669	chr6:146136114	FBXO30	0.87	9.51	0.65	1.9e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs8031584	0.752	rs1852035	chr15:31184803	C/G	cg08109568	chr15:31115862	NA	-0.36	-4.85	-0.4	3.7e-6	Huntington's disease progression;
TGCT	cis	rs709400	0.550	rs11626905	chr14:104016066	C/T	cg26031613	chr14:104095156	KLC1	0.77	6.32	0.49	4.33e-9	Body mass index;
TGCT	cis	rs4805272	0.924	rs1363326	chr19:29325650	A/G	cg15000279	chr19:29285009	NA	-0.52	-5.64	-0.45	1.07e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
TGCT	cis	rs6088580	0.634	rs4911423	chr20:32999386	T/A	cg24642439	chr20:33292090	TP53INP2	-0.49	-4.49	-0.37	1.59e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs7528419	0.895	rs583104	chr1:109821307	G/T	cg00908766	chr1:109817496	CELSR2	0.46	4.77	0.39	5.1e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
TGCT	cis	rs263156	0.902	rs263120	chr6:142893857	T/A	cg18419694	chr6:143832440	FUCA2	-0.39	-4.57	-0.38	1.18e-5	Ear morphology;Lobe size;Lobe attachment;
TGCT	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg07806771	chr7:64541737	NA	0.44	4.55	0.38	1.26e-5	Calcium levels;
TGCT	cis	rs9894429	0.966	rs10871499	chr17:79589006	G/A	cg21028142	chr17:79581711	NPLOC4	0.29	6.83	0.52	3.44e-10	Eye color traits;
TGCT	cis	rs780094	0.585	rs7586601	chr2:27584666	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.33	4.5	0.37	1.57e-5	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
TGCT	cis	rs4699052	0.625	rs11734572	chr4:104288620	G/A	cg16532752	chr4:104119610	CENPE	-0.5	-4.75	-0.39	5.48e-6	Testicular germ cell tumor;
TGCT	cis	rs35160687	0.901	rs12620833	chr2:86472870	T/C	cg03171300	chr2:86307199	POLR1A	0.33	5.61	0.45	1.25e-7	Night sleep phenotypes;
TGCT	cis	rs6967414	0.786	rs6463578	chr7:6753050	C/A	cg09896999	chr7:6746977	ZNF12	-0.59	-6.6	-0.51	1.06e-9	Hematocrit;Hemoglobin concentration;
TGCT	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.46	4.86	0.4	3.51e-6	Lymphocyte counts;
TGCT	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.56	-6.9	-0.53	2.43e-10	Longevity;Endometriosis;
TGCT	cis	rs7769051	1.000	rs9493443	chr6:133121349	C/T	cg22852734	chr6:133119734	C6orf192	1.22	7.01	0.53	1.38e-10	Type 2 diabetes nephropathy;
TGCT	cis	rs6964587	0.934	rs1544377	chr7:91687351	A/G	cg17063962	chr7:91808500	NA	0.88	9.65	0.66	8.73e-17	Breast cancer;
TGCT	cis	rs896854	0.654	rs4735337	chr8:95973465	T/C	cg16049864	chr8:95962084	TP53INP1	-0.75	-10.48	-0.69	8.55e-19	Type 2 diabetes;
TGCT	cis	rs3087591	1.000	rs7220483	chr17:29577248	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.47	-7.51	-0.56	1.01e-11	Hip circumference;
TGCT	cis	rs9915657	0.870	rs35271702	chr17:70140516	G/A	cg06234051	chr17:70120541	SOX9	-0.24	-4.77	-0.39	4.99e-6	Thyroid hormone levels;
TGCT	cis	rs2742417	0.967	rs2742441	chr3:45748429	G/A	cg04837898	chr3:45731254	SACM1L	-0.55	-5.68	-0.45	9.22e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs1891498	0.703	rs10900397	chr1:147243153	G/A	cg17941330	chr1:147245494	GJA5	0.36	4.53	0.38	1.36e-5	Cognitive performance;
TGCT	cis	rs881375	0.867	rs10818484	chr9:123661194	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	5.08	0.42	1.34e-6	Rheumatoid arthritis;
TGCT	cis	rs7089973	0.604	rs11196929	chr10:116582080	G/C	cg03647239	chr10:116582469	FAM160B1	0.58	5.63	0.45	1.16e-7	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs9549260	0.755	rs17061503	chr13:41246758	A/G	cg21288729	chr13:41239152	FOXO1	-0.97	-9.76	-0.66	4.95e-17	Red blood cell count;
TGCT	cis	rs6840360	0.558	rs2709821	chr4:152342190	C/T	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.36	-0.5	3.48e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs3796352	1.000	rs3806692	chr3:53080987	C/G	cg27565382	chr3:53032988	SFMBT1	0.41	4.69	0.39	6.97e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs6840360	0.642	rs7678823	chr4:152357119	A/G	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.83e-9	Intelligence (multi-trait analysis);
TGCT	trans	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg17830980	chr10:43048298	ZNF37B	-0.85	-10.98	-0.7	5.08e-20	Extrinsic epigenetic age acceleration;
TGCT	cis	rs1008375	0.931	rs10008337	chr4:17593849	G/C	cg10189774	chr4:17578691	LAP3	0.71	6.05	0.48	1.59e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	trans	rs1814175	0.645	rs10128731	chr11:50023554	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.84	-0.7	1.13e-19	Height;
TGCT	cis	rs8072100	0.666	rs9913014	chr17:45460189	C/T	cg08085267	chr17:45401833	C17orf57	-0.5	-5.47	-0.44	2.38e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs11650776	1	rs11650776	chr17:37641402	G/A	cg07936489	chr17:37558343	FBXL20	-0.61	-4.85	-0.4	3.6e-6	Lung function (FEV1);
TGCT	cis	rs739496	0.615	rs57072497	chr12:112145217	A/T	cg10833066	chr12:111807467	FAM109A	0.36	5.06	0.41	1.46e-6	Platelet count;
TGCT	cis	rs644799	0.544	rs555556	chr11:95618425	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.56	5.58	0.45	1.46e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs1008375	0.966	rs2159582	chr4:17695655	T/C	cg18681998	chr4:17616180	MED28	0.76	7.09	0.54	8.93e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs12643440	0.538	rs4698536	chr4:17142175	C/T	cg22650099	chr4:17144496	NA	-0.46	-4.7	-0.39	6.79e-6	Metabolite levels (Pyroglutamine);
TGCT	cis	rs9733	0.596	rs72702573	chr1:150689050	C/T	cg09365446	chr1:150670422	GOLPH3L	0.3	4.52	0.38	1.4e-5	Tonsillectomy;
TGCT	trans	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg11887960	chr12:57824829	NA	1.2	9.62	0.65	1.04e-16	Lung disease severity in cystic fibrosis;
TGCT	cis	rs2243480	0.901	rs778730	chr7:65823325	T/A	cg18252515	chr7:66147081	NA	-1.22	-7.4	-0.55	1.81e-11	Diabetic kidney disease;
TGCT	cis	rs3020333	0.875	rs2982573	chr6:152010534	A/G	cg22157087	chr6:152012887	ESR1	0.19	4.55	0.38	1.24e-5	Total body bone mineral density;
TGCT	cis	rs611744	0.967	rs684093	chr8:109199355	G/C	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs3617	0.625	rs7617468	chr3:52849549	T/C	cg11645453	chr3:52864694	ITIH4	0.28	5.37	0.43	3.78e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs669446	0.533	rs6429638	chr1:44211010	A/G	cg12908607	chr1:44402522	ARTN	-0.63	-7.47	-0.56	1.22e-11	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs4930103	0.534	rs2063550	chr11:1979223	G/C	cg02850416	chr11:1986266	NA	0.27	4.54	0.38	1.31e-5	DNA methylation (parent-of-origin);DNA methylation (variation);
TGCT	cis	rs7666738	0.830	rs2167892	chr4:99048503	G/C	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2204008	0.548	rs2320740	chr12:38166421	G/A	cg26384229	chr12:38710491	ALG10B	0.86	7.68	0.57	4.17e-12	Bladder cancer;
TGCT	cis	rs7666738	0.783	rs10028584	chr4:98962404	C/T	cg05340658	chr4:99064831	C4orf37	0.53	5.93	0.47	2.85e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg18252515	chr7:66147081	NA	1.2	7.83	0.58	1.89e-12	Diabetic kidney disease;
TGCT	cis	rs2204008	0.626	rs11520260	chr12:38330092	C/T	cg26384229	chr12:38710491	ALG10B	0.83	7.27	0.55	3.51e-11	Bladder cancer;
TGCT	cis	rs1461503	0.932	rs11218909	chr11:122842613	C/T	cg27398637	chr11:122830231	C11orf63	-0.42	-5.25	-0.43	6.42e-7	Menarche (age at onset);
TGCT	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg18538332	chr22:24372958	LOC391322	-0.98	-11.74	-0.73	7.55e-22	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs8038465	0.592	rs1542580	chr15:73935834	C/G	cg15420318	chr15:73925796	NPTN	0.64	6.67	0.51	7.56e-10	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2013441	1.000	rs4924810	chr17:20071819	T/C	cg23224458	chr17:20280056	CCDC144C	0.38	4.61	0.38	9.96e-6	Obesity-related traits;
TGCT	cis	rs7659604	1.000	rs7689722	chr4:122665955	T/C	cg19748678	chr4:122722346	EXOSC9	0.55	5.31	0.43	4.92e-7	Type 2 diabetes;
TGCT	cis	rs986417	1.000	rs761555	chr14:61109543	T/C	cg27398547	chr14:60952738	C14orf39	1.62	8.87	0.62	6.55e-15	Gut microbiota (bacterial taxa);
TGCT	cis	rs926938	0.520	rs969273	chr1:115256669	G/A	cg12756093	chr1:115239321	AMPD1	-0.42	-5.65	-0.45	1.02e-7	Autism;
TGCT	cis	rs1005277	0.540	rs1814077	chr10:37992018	G/C	cg25427524	chr10:38739819	LOC399744	-0.32	-6.24	-0.49	6.41e-9	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7208859	0.673	rs1347360	chr17:28914532	T/C	cg13385521	chr17:29058706	SUZ12P	0.87	5.44	0.44	2.76e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg25036284	chr2:26402008	FAM59B	-0.65	-5.19	-0.42	8.36e-7	Gut microbiome composition (summer);
TGCT	cis	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg08045932	chr20:61659980	NA	0.48	9.28	0.64	7.07e-16	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs11249608	0.548	rs34881171	chr5:178451932	C/T	cg01312482	chr5:178451176	ZNF879	-0.56	-5.5	-0.44	2.09e-7	Pubertal anthropometrics;
TGCT	cis	rs7264396	0.690	rs2425172	chr20:34443893	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.04	-0.41	1.58e-6	Total cholesterol levels;
TGCT	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.76	5.1	0.42	1.22e-6	Alzheimer's disease;
TGCT	cis	rs904251	0.861	rs1757171	chr6:37487044	T/C	cg08126542	chr6:37504118	NA	-0.45	-5.97	-0.47	2.38e-8	Cognitive performance;
TGCT	cis	rs9914988	0.945	rs9279	chr17:27187636	G/T	cg20469991	chr17:27169893	C17orf63	0.69	5.05	0.41	1.51e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs11626933	1.000	rs45463097	chr14:90744188	G/A	cg14092571	chr14:90743983	NA	-0.3	-6.18	-0.48	8.66e-9	Gut microbiota (bacterial taxa);
TGCT	cis	rs17376456	0.825	rs10072232	chr5:93398890	G/A	cg21475434	chr5:93447410	FAM172A	0.59	4.66	0.39	8.09e-6	Diabetic retinopathy;
TGCT	cis	rs477895	0.838	rs11607007	chr11:64007976	C/T	cg23719950	chr11:63933701	MACROD1	-0.68	-5.67	-0.45	9.3e-8	Mean platelet volume;
TGCT	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg25767906	chr1:53392781	SCP2	-0.61	-7.2	-0.54	5.02e-11	Monocyte count;
TGCT	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-5.1	-0.42	1.23e-6	Bipolar disorder;
TGCT	cis	rs6754311	0.593	rs10186843	chr2:136586958	C/A	cg07169764	chr2:136633963	MCM6	-0.61	-5.69	-0.46	8.62e-8	Mosquito bite size;
TGCT	cis	rs17331151	0.505	rs35325270	chr3:52556369	C/T	cg07884673	chr3:53033167	SFMBT1	0.67	4.74	0.39	5.74e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs7104764	0.673	rs3782118	chr11:222620	T/C	cg18336825	chr11:236787	PSMD13;SIRT3	0.96	9.78	0.66	4.29e-17	Menarche (age at onset);
TGCT	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg01585852	chr22:24235823	MIF	-0.23	-5.13	-0.42	1.1e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.62	-6.49	-0.5	1.83e-9	Longevity;Endometriosis;
TGCT	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.85	0.47	4.05e-8	Height;
TGCT	cis	rs1348850	0.598	rs12616259	chr2:178503803	C/T	cg22681709	chr2:178499509	PDE11A	-0.53	-6.55	-0.51	1.38e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	trans	rs56011263	0.687	rs4690188	chr4:703930	G/C	cg12575136	chr18:32820987	ZNF397	0.79	9.58	0.65	1.34e-16	White blood cell count;
TGCT	cis	rs5760092	0.842	rs5760103	chr22:24248781	A/G	cg10150615	chr22:24372951	LOC391322	-0.76	-6.17	-0.48	9.07e-9	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs7666738	0.761	rs28758886	chr4:99059704	C/T	cg05340658	chr4:99064831	C4orf37	0.52	5.79	0.46	5.32e-8	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs9929218	0.551	rs7201437	chr16:68727130	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.41	0.55	1.68e-11	Colorectal cancer;
TGCT	cis	rs7917772	0.503	rs7902306	chr10:104290462	C/T	cg05855489	chr10:104503620	C10orf26	-0.55	-4.64	-0.38	8.67e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs3820928	0.874	rs6740108	chr2:227889559	G/T	cg11843606	chr2:227700838	RHBDD1	0.52	4.82	0.4	4.12e-6	Pulmonary function;
TGCT	cis	rs3818285	0.504	rs7100154	chr10:111650150	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.29	-5.07	-0.41	1.38e-6	Superior crus of antihelix expression;
TGCT	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg27535305	chr1:53392650	SCP2	-0.26	-4.97	-0.41	2.16e-6	Monocyte count;
TGCT	cis	rs11190604	1.000	rs12219789	chr10:102213778	A/G	cg23241863	chr10:102295624	HIF1AN	0.62	4.87	0.4	3.27e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg05985448	chr10:134359359	INPP5A	0.23	4.99	0.41	2.01e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs9467773	0.526	rs10946817	chr6:26364056	C/T	cg05738196	chr6:26577821	NA	-0.63	-6.61	-0.51	1.01e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7917772	0.503	rs2031602	chr10:104307955	G/C	cg05855489	chr10:104503620	C10orf26	-0.6	-5.25	-0.43	6.32e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs60871478	0.704	rs62432895	chr7:822050	C/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.48	4.66	0.39	7.91e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs9796	0.870	rs8042088	chr15:41337487	C/T	cg18705301	chr15:41695430	NDUFAF1	0.39	5.29	0.43	5.42e-7	Menopause (age at onset);
TGCT	cis	rs4455778	0.580	rs10215945	chr7:49096423	G/A	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg12311346	chr5:56204834	C5orf35	0.82	7.65	0.57	4.95e-12	Initial pursuit acceleration;
TGCT	cis	rs7772486	0.790	rs9497435	chr6:146265340	C/A	cg23711669	chr6:146136114	FBXO30	-0.85	-9.7	-0.66	6.73e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs868036	0.718	rs8025790	chr15:68076399	G/T	cg05925327	chr15:68127851	NA	-0.51	-4.94	-0.41	2.52e-6	Restless legs syndrome;
TGCT	cis	rs9372253	1.000	rs9384740	chr6:110716207	G/A	cg19196401	chr6:110721138	DDO	-0.5	-7.33	-0.55	2.59e-11	Platelet distribution width;
TGCT	cis	rs2882877	0.621	rs17198934	chr2:190378371	C/G	cg10752008	chr2:190445175	SLC40A1	0.61	4.5	0.37	1.53e-5	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs9902453	0.817	rs62068620	chr17:28167674	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	7.17	0.54	5.79e-11	Coffee consumption (cups per day);
TGCT	cis	rs2832191	0.791	rs4817270	chr21:30480368	G/A	cg08807101	chr21:30365312	RNF160	-0.66	-6.19	-0.49	8.16e-9	Dental caries;
TGCT	cis	rs28595532	0.920	rs114966881	chr4:119761078	C/G	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs6088580	0.634	rs6120650	chr20:33039973	G/A	cg06115741	chr20:33292138	TP53INP2	0.55	4.85	0.4	3.69e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7681440	0.904	rs28507349	chr4:90767063	G/A	cg01966878	chr4:90757139	SNCA	-0.25	-4.56	-0.38	1.2e-5	Dementia with Lewy bodies;
TGCT	cis	rs7666738	0.830	rs6825211	chr4:98807698	A/T	cg18180107	chr4:99064573	C4orf37	0.53	5.05	0.41	1.51e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9796	0.870	rs8030306	chr15:41261821	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.45	-5.88	-0.47	3.61e-8	Menopause (age at onset);
TGCT	cis	rs1372520	0.623	rs2583975	chr4:90748488	T/C	cg14346243	chr4:90757452	SNCA	-0.6	-4.87	-0.4	3.27e-6	Neuroticism;
TGCT	cis	rs9733	0.519	rs1134067	chr1:150721175	G/T	cg09365446	chr1:150670422	GOLPH3L	0.32	4.73	0.39	6.05e-6	Tonsillectomy;
TGCT	cis	rs80282103	0.618	rs57514701	chr10:1146169	G/A	cg18964960	chr10:1102726	WDR37	0.98	4.57	0.38	1.15e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs17401966	1.000	rs11121532	chr1:10277898	G/T	cg21474053	chr1:11182049	MTOR	0.19	4.49	0.37	1.58e-5	Hepatocellular carcinoma;
TGCT	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg06238570	chr21:40685208	BRWD1	0.72	6.84	0.52	3.16e-10	Cognitive function;
TGCT	cis	rs67311347	0.544	rs67533651	chr3:40338367	T/A	cg13683864	chr3:40499215	RPL14	-0.78	-7.5	-0.56	1.06e-11	Renal cell carcinoma;
TGCT	cis	rs9926296	0.572	rs2376878	chr16:89885161	G/A	cg26513180	chr16:89883248	FANCA	0.75	7.52	0.56	9.5e-12	Vitiligo;
TGCT	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9303401	0.573	rs34097494	chr17:57171917	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.58	5.74	0.46	6.76e-8	Cognitive test performance;
TGCT	cis	rs12579753	0.810	rs1922565	chr12:82135348	T/C	cg07988820	chr12:82153109	PPFIA2	-0.66	-7.47	-0.56	1.25e-11	Resting heart rate;
TGCT	cis	rs2013441	1.000	rs2526464	chr17:20075052	A/G	cg18979559	chr17:20280153	CCDC144C	-0.44	-4.61	-0.38	9.78e-6	Obesity-related traits;
TGCT	cis	rs6938	0.534	rs7495739	chr15:75185670	C/T	cg10253484	chr15:75165896	SCAMP2	0.53	4.88	0.4	3.15e-6	Breast cancer;
TGCT	cis	rs7264396	0.635	rs6060682	chr20:34506331	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.04	-0.41	1.58e-6	Total cholesterol levels;
TGCT	cis	rs950169	0.580	rs35516100	chr15:85195430	C/T	cg12863693	chr15:85201151	NMB	0.46	5.51	0.44	1.97e-7	Schizophrenia;
TGCT	cis	rs4803468	1.000	rs10413735	chr19:41921071	C/T	cg09537434	chr19:41945824	ATP5SL	-0.92	-10.71	-0.69	2.31e-19	Height;
TGCT	cis	rs9929218	1.000	rs28549017	chr16:68758828	G/C	cg01251360	chr16:68772225	CDH1	0.29	4.95	0.41	2.34e-6	Colorectal cancer;
TGCT	cis	rs7635838	0.785	rs2606735	chr3:11400714	A/C	cg00170343	chr3:11313890	ATG7	0.64	6.13	0.48	1.1e-8	HDL cholesterol;
TGCT	cis	rs2046867	0.818	rs11928620	chr3:72863209	A/C	cg25664220	chr3:72788482	NA	-0.56	-7.03	-0.53	1.24e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9910055	0.529	rs425038	chr17:42182028	T/C	cg19774624	chr17:42201019	HDAC5	0.7	6.68	0.51	7.15e-10	Total body bone mineral density;
TGCT	cis	rs6693567	0.545	rs7411534	chr1:150447269	C/T	cg09579323	chr1:150459698	TARS2	0.53	5.04	0.41	1.58e-6	Migraine;
TGCT	cis	rs478304	0.934	rs517115	chr11:65526988	C/T	cg17480646	chr11:65405466	SIPA1	0.43	5.38	0.43	3.62e-7	Acne (severe);
TGCT	cis	rs34638657	0.732	rs7206093	chr16:82201884	G/A	cg09439754	chr16:82129088	HSD17B2	-0.24	-4.53	-0.38	1.37e-5	Lung adenocarcinoma;
TGCT	cis	rs7666738	0.791	rs6833691	chr4:98951508	A/G	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg13393036	chr8:95962371	TP53INP1	-0.65	-8.97	-0.63	3.91e-15	Type 2 diabetes;
TGCT	cis	rs910316	1.000	rs11159117	chr14:75584867	C/T	cg08847533	chr14:75593920	NEK9	0.96	10.92	0.7	7.35e-20	Height;
TGCT	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg08645402	chr16:4508243	NA	0.2	4.93	0.4	2.6e-6	Schizophrenia;
TGCT	cis	rs7666738	0.678	rs7670805	chr4:99008763	A/G	cg17366294	chr4:99064904	C4orf37	0.69	7.0	0.53	1.44e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs908922	0.742	rs499913	chr1:152476743	T/A	cg20991723	chr1:152506922	NA	0.46	5.83	0.46	4.43e-8	Hair morphology;
TGCT	cis	rs11874712	0.966	rs9962380	chr18:43678706	C/T	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	5.14	0.42	1.03e-6	Migraine - clinic-based;
TGCT	cis	rs7666738	0.578	rs1989109	chr4:98881246	T/A	cg05340658	chr4:99064831	C4orf37	0.54	6.13	0.48	1.06e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2688608	0.839	rs2633310	chr10:75594050	G/T	cg19442545	chr10:75533431	FUT11	0.31	4.56	0.38	1.19e-5	Inflammatory bowel disease;
TGCT	cis	rs1008375	1.000	rs2315556	chr4:17670861	T/C	cg18681998	chr4:17616180	MED28	0.9	10.33	0.68	1.96e-18	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs28595532	0.920	rs116205107	chr4:119730910	G/A	cg14228332	chr4:119757509	SEC24D	1.32	6.38	0.5	3.2e-9	Cannabis dependence symptom count;
TGCT	cis	rs12220238	1.000	rs11000924	chr10:75972311	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.78	0.57	2.42e-12	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs1420338	0.839	rs918036	chr7:34181859	A/G	cg01275685	chr7:34179230	BMPER	-0.27	-4.9	-0.4	2.92e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs12368653	0.789	rs17852479	chr12:58126234	C/A	cg12615879	chr12:58013172	SLC26A10	0.52	6.43	0.5	2.5e-9	Multiple sclerosis;
TGCT	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.67	-6.67	-0.51	7.76e-10	Prostate cancer;
TGCT	cis	rs3902035	0.929	rs62423967	chr6:119010336	C/G	cg07617317	chr6:118971624	C6orf204	0.43	5.01	0.41	1.79e-6	QT interval;
TGCT	cis	rs4332037	0.539	rs3823624	chr7:2110346	T/C	cg25834613	chr7:1915315	MAD1L1	-0.52	-5.04	-0.41	1.64e-6	Bipolar disorder;
TGCT	cis	rs5167	0.743	rs57204168	chr19:45496776	A/G	cg13119609	chr19:45449297	APOC2	0.23	4.79	0.4	4.64e-6	Blood protein levels;
TGCT	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg16680214	chr1:154839983	KCNN3	0.34	7.2	0.54	4.97e-11	Prostate cancer;
TGCT	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg02953382	chr22:24373134	LOC391322	0.84	9.86	0.66	2.82e-17	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7192750	0.586	rs12935795	chr16:71987452	G/C	cg06353428	chr16:71660113	MARVELD3	0.74	6.62	0.51	9.68e-10	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs7829975	0.501	rs4840353	chr8:8580570	A/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-4.54	-0.38	1.31e-5	Mood instability;
TGCT	cis	rs6570726	0.599	rs9403725	chr6:145897622	A/T	cg13319975	chr6:146136371	FBXO30	0.7	6.43	0.5	2.5e-9	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs941408	1.000	rs1640271	chr19:2799979	C/T	cg22153745	chr1:153894579	GATAD2B	-0.67	-7.26	-0.55	3.76e-11	Total cholesterol levels;
TGCT	cis	rs6570726	0.791	rs414600	chr6:145879606	G/A	cg13319975	chr6:146136371	FBXO30	-0.51	-4.6	-0.38	1.01e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs889312	0.500	rs33328	chr5:56143419	T/C	cg12311346	chr5:56204834	C5orf35	-0.47	-5.03	-0.41	1.7e-6	Breast cancer;Breast cancer (early onset);
TGCT	cis	rs6754311	0.773	rs309137	chr2:136765951	A/G	cg07169764	chr2:136633963	MCM6	0.61	5.66	0.45	9.86e-8	Mosquito bite size;
TGCT	cis	rs2456568	0.695	rs908748	chr11:93690148	G/A	cg17595323	chr11:93583763	C11orf90	0.4	4.99	0.41	1.98e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.94	7.92	0.58	1.17e-12	Platelet count;
TGCT	cis	rs9942416	0.660	rs193344	chr5:74977854	T/C	cg19683494	chr5:74908142	NA	-0.58	-6.12	-0.48	1.14e-8	Age-related disease endophenotypes;
TGCT	cis	rs7617773	0.780	rs4541431	chr3:48365218	G/C	cg11946769	chr3:48343235	NME6	0.8	6.91	0.53	2.26e-10	Coronary artery disease;
TGCT	cis	rs4919669	0.668	rs10883737	chr10:104320898	C/G	cg05855489	chr10:104503620	C10orf26	0.73	4.71	0.39	6.65e-6	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs7120118	0.517	rs10838694	chr11:47351760	G/A	cg13308137	chr11:47528955	CUGBP1	0.33	5.19	0.42	8.26e-7	HDL cholesterol;
TGCT	cis	rs7103648	0.897	rs11606287	chr11:47407439	C/A	cg20307385	chr11:47447363	PSMC3	1.03	12.12	0.74	8.55e-23	Diastolic blood pressure;Systolic blood pressure;
TGCT	trans	rs10504390	0.656	rs80033165	chr8:66478523	T/A	cg18118147	chr19:51128640	SYT3	-0.77	-6.82	-0.52	3.51e-10	IgG glycosylation;
TGCT	cis	rs873946	0.564	rs2803991	chr10:134557068	A/G	cg05985448	chr10:134359359	INPP5A	0.21	4.6	0.38	1.02e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs4851254	0.550	rs13402299	chr2:100659409	C/T	cg22139774	chr2:100720529	AFF3	-0.46	-5.13	-0.42	1.08e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs13064411	0.696	rs6799610	chr3:113248748	A/C	cg18753928	chr3:113234510	CCDC52	0.66	5.4	0.44	3.29e-7	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs4268898	0.662	rs2288074	chr2:24413595	C/T	cg02683114	chr2:24398427	C2orf84	-0.22	-4.48	-0.37	1.69e-5	Asthma;
TGCT	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg05368731	chr17:41323189	NBR1	1.08	10.88	0.7	9.36e-20	Menopause (age at onset);
TGCT	cis	rs4455778	0.692	rs2191297	chr7:49010701	A/G	cg26309511	chr7:48887640	NA	-0.45	-5.58	-0.45	1.42e-7	Lung cancer in never smokers;
TGCT	cis	rs6978712	0.858	rs17714259	chr7:127147097	T/A	cg01017541	chr7:127776461	NA	0.76	4.6	0.38	1.01e-5	Medication adherence in chronic diseases;
TGCT	cis	rs9883204	1.000	rs2877716	chr3:123094451	A/G	cg04890266	chr3:123102914	ADCY5	-0.36	-5.11	-0.42	1.17e-6	Birth weight;
TGCT	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs4499344	0.730	rs259285	chr19:33164697	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.87	9.38	0.64	3.95e-16	Mean platelet volume;
TGCT	cis	rs4372836	1.000	rs2276547	chr2:28975107	G/C	cg09522027	chr2:28974177	PPP1CB	-0.57	-4.92	-0.4	2.68e-6	Body mass index;
TGCT	cis	rs4455778	0.580	rs34005483	chr7:49094307	A/G	cg26309511	chr7:48887640	NA	0.5	6.45	0.5	2.29e-9	Lung cancer in never smokers;
TGCT	cis	rs10782582	0.593	rs11163915	chr1:76130199	C/T	cg10523679	chr1:76189770	ACADM	-0.68	-7.05	-0.53	1.11e-10	Daytime sleep phenotypes;
TGCT	cis	rs7635838	0.819	rs2454482	chr3:11534031	C/T	cg00170343	chr3:11313890	ATG7	0.68	6.36	0.5	3.46e-9	HDL cholesterol;
TGCT	cis	rs7432375	0.901	rs7648531	chr3:136462223	T/A	cg12473912	chr3:136751656	NA	-0.36	-5.05	-0.41	1.55e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2455799	0.553	rs2262664	chr3:15768097	A/T	cg16303742	chr3:15540471	COLQ	-0.26	-4.96	-0.41	2.26e-6	Mean platelet volume;
TGCT	cis	rs55794721	0.509	rs2982358	chr1:25745204	G/T	cg23205692	chr1:25664452	TMEM50A	0.52	5.38	0.43	3.59e-7	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg16049864	chr8:95962084	TP53INP1	-0.77	-10.92	-0.7	7.16e-20	Type 2 diabetes;
TGCT	cis	rs7674212	0.540	rs2711897	chr4:104023567	C/T	cg16532752	chr4:104119610	CENPE	-0.55	-4.85	-0.4	3.68e-6	Type 2 diabetes;
TGCT	cis	rs7666738	0.830	rs3852123	chr4:98697586	A/G	cg17366294	chr4:99064904	C4orf37	0.71	7.45	0.56	1.41e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs75686122	0.892	rs75861389	chr8:104664993	G/A	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs7223966	1.000	rs2665826	chr17:61944924	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	4.68	0.39	7.5e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs78456975	0.657	rs116217838	chr2:1569173	T/C	cg01028140	chr2:1542097	TPO	-0.33	-5.14	-0.42	1.03e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs62380364	0.542	rs2457979	chr5:88039660	T/A	cg22951263	chr5:87985283	NA	-0.55	-5.93	-0.47	2.83e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs425277	1.000	rs809912	chr1:2078385	C/T	cg24578937	chr1:2090814	PRKCZ	0.32	8.03	0.58	6.41e-13	Height;
TGCT	trans	rs208520	0.690	rs12202913	chr6:66734198	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	11.06	0.7	3.28e-20	Exhaled nitric oxide output;
TGCT	cis	rs17221829	0.965	rs10830361	chr11:89456273	C/A	cg02982614	chr11:89391479	FOLH1B	-0.27	-4.88	-0.4	3.23e-6	Anxiety in major depressive disorder;
TGCT	cis	rs12477438	0.765	rs13390672	chr2:99589829	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-7.6	-0.56	6.47e-12	Chronic sinus infection;
TGCT	cis	rs2302045	1.000	rs75811104	chr2:242052338	C/A	cg04553960	chr2:241721320	KIF1A	-0.7	-4.68	-0.39	7.4e-6	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio);
TGCT	cis	rs10114408	0.959	rs7869842	chr9:96644932	C/T	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg22166914	chr1:53195759	ZYG11B	-0.42	-7.46	-0.56	1.33e-11	Monocyte count;
TGCT	cis	rs7264396	0.790	rs6058293	chr20:34248891	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.25	-0.43	6.33e-7	Total cholesterol levels;
TGCT	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg11062466	chr8:58055876	NA	0.42	4.49	0.37	1.61e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg18402987	chr7:1209562	NA	0.81	6.94	0.53	1.9e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs5769765	0.773	rs58375955	chr22:50312630	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.24	-12.97	-0.76	7.81e-25	Schizophrenia;
TGCT	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg06028808	chr11:68637592	NA	0.53	6.91	0.53	2.23e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs6933660	0.720	rs6914656	chr6:151753421	C/G	cg17179660	chr6:151773299	C6orf211;RMND1	-0.53	-4.81	-0.4	4.28e-6	Menarche (age at onset);
TGCT	cis	rs10904887	1.000	rs10904887	chr10:17188641	T/C	cg01003015	chr10:17271136	VIM	-0.55	-4.96	-0.41	2.23e-6	Telomere length;
TGCT	cis	rs6138458	1.000	rs227651	chr20:24929834	A/G	cg26195577	chr20:24973756	C20orf3	1.2	12.06	0.73	1.2e-22	Blood protein levels;
TGCT	cis	rs797680	0.856	rs4240966	chr1:93774812	C/A	cg17826107	chr1:92977322	EVI5	-0.22	-5.05	-0.41	1.53e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg07870213	chr5:140052090	DND1	0.67	7.91	0.58	1.22e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs6938	0.662	rs12487	chr15:75136694	A/G	cg13906792	chr15:75199810	C15orf17	-0.22	-4.96	-0.41	2.28e-6	Breast cancer;
TGCT	cis	rs10858047	0.883	rs12040830	chr1:115108738	T/C	cg12756093	chr1:115239321	AMPD1	0.47	4.96	0.41	2.27e-6	Autism;
TGCT	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg20064778	chr22:24384315	GSTT1	-0.48	-4.58	-0.38	1.1e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs4455778	0.580	rs7796664	chr7:49117787	C/G	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs7086627	0.515	rs11202963	chr10:82210392	A/G	cg01528321	chr10:82214614	TSPAN14	0.65	6.21	0.49	7.21e-9	Post bronchodilator FEV1;
TGCT	cis	rs7949030	0.653	rs17773169	chr11:62318530	G/T	cg13298116	chr11:62369859	EML3;MTA2	0.65	9.64	0.65	9.48e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7267979	0.966	rs2263204	chr20:25377688	A/T	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4455778	0.659	rs4607558	chr7:49023949	C/T	cg26309511	chr7:48887640	NA	-0.43	-5.07	-0.41	1.4e-6	Lung cancer in never smokers;
TGCT	cis	rs10876993	0.928	rs1689586	chr12:58079586	A/T	cg15848620	chr12:58087721	OS9	-0.72	-5.98	-0.47	2.25e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs9902453	0.765	rs2628180	chr17:28101723	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.84	-8.19	-0.59	2.73e-13	Coffee consumption (cups per day);
TGCT	cis	rs6450176	1.000	rs4334836	chr5:53300835	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.53	-5.1	-0.42	1.23e-6	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs2456568	0.802	rs10765638	chr11:93636171	A/T	cg26875233	chr11:93583750	C11orf90	-0.48	-6.47	-0.5	2.07e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs9814567	1.000	rs6439487	chr3:134260860	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.95	-9.55	-0.65	1.56e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	trans	rs77457752	0.525	rs10961293	chr9:13894250	A/G	cg12973904	chr7:149457885	NA	0.45	6.78	0.52	4.25e-10	Breast cancer;
TGCT	cis	rs6921919	0.583	rs9468370	chr6:28368940	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.55	-5.37	-0.43	3.79e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9906944	0.657	rs4643373	chr17:47123423	T/C	cg10950924	chr17:47092072	IGF2BP1	-0.34	-4.44	-0.37	1.97e-5	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs7208859	0.673	rs9889755	chr17:29234505	A/G	cg18442181	chr17:29233375	C17orf42	0.83	5.39	0.44	3.45e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg14784868	chr12:69753453	YEATS4	0.89	10.48	0.69	8.4e-19	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs6484504	0.532	rs10835756	chr11:31267622	C/T	cg14844989	chr11:31128820	NA	-0.25	-4.84	-0.4	3.76e-6	Red blood cell count;
TGCT	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	6.9	0.53	2.4e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2201728	0.967	rs2866151	chr4:100198512	A/T	cg07219303	chr4:100140905	ADH6	-0.34	-5.1	-0.42	1.22e-6	Cardiac Troponin-T levels;
TGCT	cis	rs6500596	0.506	rs1530088	chr16:4439131	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.4	5.45	0.44	2.62e-7	Schizophrenia;
TGCT	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	0.53	5.1	0.42	1.23e-6	Electroencephalogram traits;
TGCT	cis	rs394563	0.775	rs412894	chr6:149781175	G/A	cg16235748	chr6:149772707	ZC3H12D	-0.42	-4.67	-0.39	7.79e-6	Dupuytren's disease;
TGCT	cis	rs7659604	1.000	rs10005932	chr4:122664782	T/C	cg19748678	chr4:122722346	EXOSC9	0.57	5.5	0.44	2.07e-7	Type 2 diabetes;
TGCT	trans	rs8073060	0.586	rs225305	chr17:33921160	C/T	cg19694781	chr19:47549865	TMEM160	-0.59	-12.7	-0.75	3.37e-24	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg03188948	chr7:1209495	NA	0.63	5.17	0.42	8.92e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1062177	1.000	rs2915877	chr5:151150601	C/G	cg12924095	chr5:151150029	G3BP1	0.35	5.09	0.42	1.31e-6	Preschool internalizing problems;
TGCT	cis	rs1670533	1.000	rs6827357	chr4:1059202	A/C	cg27284194	chr4:1044797	NA	0.67	5.6	0.45	1.29e-7	Recombination rate (females);
TGCT	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg21016266	chr12:122356598	WDR66	0.52	7.48	0.56	1.17e-11	Mean corpuscular volume;
TGCT	cis	rs28595532	1.000	rs114912871	chr4:119697004	G/C	cg21605333	chr4:119757512	SEC24D	1.41	7.28	0.55	3.45e-11	Cannabis dependence symptom count;
TGCT	cis	rs12497850	0.931	rs7626445	chr3:49114544	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.41	-5.4	-0.44	3.33e-7	Parkinson's disease;
TGCT	cis	rs9796	0.621	rs1659227	chr15:41472398	G/A	cg18705301	chr15:41695430	NDUFAF1	0.52	7.17	0.54	5.94e-11	Menopause (age at onset);
TGCT	trans	rs17685	0.753	rs6953665	chr7:75769049	C/T	cg19862616	chr7:65841803	NCRNA00174	0.52	9.01	0.63	3.02e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs1975974	1.000	rs4889703	chr17:21721663	T/C	cg18423549	chr17:21743878	NA	-0.49	-4.76	-0.39	5.3e-6	Psoriasis;
TGCT	cis	rs916888	0.610	rs199436	chr17:44789285	C/T	cg17911788	chr17:44343683	NA	0.43	5.1	0.42	1.21e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg11764359	chr7:65958608	NA	0.55	5.07	0.41	1.42e-6	Aortic root size;
TGCT	cis	rs1800469	0.965	rs12983775	chr19:41857439	G/A	cg09537434	chr19:41945824	ATP5SL	-0.5	-4.59	-0.38	1.06e-5	Colorectal cancer;
TGCT	cis	rs344364	0.636	rs344363	chr16:1972548	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.43	-4.45	-0.37	1.9e-5	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs10465746	0.687	rs6576954	chr1:84323701	C/T	cg10977910	chr1:84465055	TTLL7	-0.59	-5.85	-0.46	4.14e-8	Obesity-related traits;
TGCT	cis	rs7119	0.931	rs59418918	chr15:77833110	A/C	cg27398640	chr15:77910606	LINGO1	-0.25	-4.68	-0.39	7.4e-6	Type 2 diabetes;
TGCT	cis	rs7264396	0.635	rs6058346	chr20:34481043	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.27	-4.47	-0.37	1.76e-5	Total cholesterol levels;
TGCT	cis	rs9926296	0.557	rs11076618	chr16:89807705	T/C	cg08627397	chr16:89984028	MC1R	-0.3	-4.76	-0.39	5.38e-6	Vitiligo;
TGCT	cis	rs896854	0.654	rs4735337	chr8:95973465	T/C	cg13393036	chr8:95962371	TP53INP1	-0.63	-8.52	-0.61	4.43e-14	Type 2 diabetes;
TGCT	cis	rs3008870	0.920	rs975452	chr1:67480190	A/T	cg03991309	chr1:68237761	GNG12	0.27	4.49	0.37	1.6e-5	Lymphocyte percentage of white cells;
TGCT	trans	rs3102947	0.539	rs3111425	chr2:8487785	A/G	cg10290200	chr7:128481295	FLNC	0.29	6.91	0.53	2.3e-10	IgE levels;
TGCT	cis	rs6918586	0.658	rs1572982	chr6:26094367	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.7	6.6	0.51	1.09e-9	Schizophrenia;
TGCT	cis	rs6690583	0.623	rs12042018	chr1:85436937	T/C	cg20280350	chr1:85513789	MCOLN3	-0.67	-4.5	-0.37	1.52e-5	Serum sulfate level;
TGCT	cis	rs28595532	0.920	rs114314373	chr4:119639128	G/A	cg11846333	chr4:119757529	SEC24D	0.95	4.68	0.39	7.54e-6	Cannabis dependence symptom count;
TGCT	cis	rs7590720	0.531	rs6435932	chr2:216906030	T/C	cg12620499	chr2:216877984	MREG	0.76	7.54	0.56	8.75e-12	Alcohol dependence;
TGCT	cis	rs7652177	0.810	rs12629746	chr3:171933069	C/A	cg03587978	chr3:172165696	GHSR	0.29	4.61	0.38	9.75e-6	Height;
TGCT	cis	rs8103278	0.793	rs59093775	chr19:46374037	G/A	cg11657440	chr19:46296263	DMWD	-0.64	-5.92	-0.47	2.94e-8	Coronary artery disease;
TGCT	cis	rs6740322	0.895	rs13384080	chr2:43557363	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.38	-6.54	-0.51	1.45e-9	Coronary artery disease;
TGCT	cis	rs17376456	0.542	rs2043979	chr5:93120782	T/A	cg21475434	chr5:93447410	FAM172A	-0.64	-6.04	-0.48	1.69e-8	Diabetic retinopathy;
TGCT	cis	rs6089829	0.643	rs6011545	chr20:61660038	G/A	cg08045932	chr20:61659980	NA	0.36	5.47	0.44	2.34e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.51	4.52	0.38	1.44e-5	Prudent dietary pattern;
TGCT	cis	rs10411936	1.000	rs11878602	chr19:16555153	A/C	cg14704714	chr19:15740395	CYP4F8	-0.26	-4.57	-0.38	1.16e-5	White blood cell count;Multiple sclerosis;
TGCT	cis	rs11098499	0.820	rs11737395	chr4:120520704	C/G	cg09307838	chr4:120376055	NA	0.69	6.58	0.51	1.18e-9	Corneal astigmatism;
TGCT	cis	rs6088590	1.000	rs6087632	chr20:33407704	A/C	cg06115741	chr20:33292138	TP53INP2	0.65	5.43	0.44	2.82e-7	Coronary artery disease;
TGCT	cis	rs6904897	0.538	rs4639353	chr6:135224328	A/G	cg22676075	chr6:135203613	NA	-0.64	-7.12	-0.54	7.73e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs610932	0.517	rs600550	chr11:59997666	C/T	cg18570331	chr11:60101691	MS4A6E	0.51	4.64	0.38	8.87e-6	Alzheimer's disease;
TGCT	cis	rs10089	1.000	rs73337363	chr5:127483597	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	8.19	0.59	2.64e-13	Ileal carcinoids;
TGCT	cis	rs28489187	0.617	rs2840319	chr1:85886224	C/T	cg16011679	chr1:85725395	C1orf52	-0.48	-4.45	-0.37	1.91e-5	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
TGCT	cis	rs6938	0.534	rs7495739	chr15:75185670	C/T	cg09165964	chr15:75287851	SCAMP5	-0.53	-5.08	-0.42	1.33e-6	Breast cancer;
TGCT	cis	rs10465746	0.780	rs11163865	chr1:84366917	C/T	cg10977910	chr1:84465055	TTLL7	0.66	6.56	0.51	1.31e-9	Obesity-related traits;
TGCT	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg04267008	chr7:1944627	MAD1L1	-0.37	-5.02	-0.41	1.78e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs7666738	0.791	rs10013680	chr4:99023030	G/C	cg18180107	chr4:99064573	C4orf37	0.56	4.91	0.4	2.86e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs17376456	0.877	rs10044066	chr5:93437580	T/C	cg21475434	chr5:93447410	FAM172A	0.59	4.66	0.39	8.09e-6	Diabetic retinopathy;
TGCT	cis	rs78487399	0.710	rs57696714	chr2:43626521	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-4.87	-0.4	3.39e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs250677	0.522	rs3763022	chr5:148381078	A/G	cg18129178	chr5:148520854	ABLIM3	-0.35	-4.86	-0.4	3.43e-6	Breast cancer;
TGCT	cis	rs67311347	1.000	rs9834052	chr3:40399060	G/A	cg13683864	chr3:40499215	RPL14	-1.02	-10.8	-0.7	1.43e-19	Renal cell carcinoma;
TGCT	cis	rs7511006	1.000	rs7364173	chr22:50681029	C/T	cg08875078	chr22:50639485	SELO	-0.5	-4.87	-0.4	3.27e-6	Obesity-related traits;
TGCT	cis	rs7010267	0.711	rs10955908	chr8:119904557	C/A	cg17171407	chr8:119960777	TNFRSF11B	-0.29	-5.06	-0.41	1.5e-6	Total body bone mineral density (age 45-60);
TGCT	cis	rs1801251	1.000	rs4973054	chr2:233710713	G/C	cg25237894	chr2:233734115	C2orf82	-0.33	-5.94	-0.47	2.71e-8	Coronary artery disease;
TGCT	cis	rs9393692	0.875	rs9358917	chr6:26284417	T/C	cg05868516	chr6:26286170	HIST1H4H	0.56	5.35	0.43	4.01e-7	Educational attainment;
TGCT	cis	rs2749592	0.531	rs1208559	chr10:38221370	T/C	cg02002400	chr10:38691563	CDC10L	0.38	4.66	0.39	7.94e-6	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs10782582	0.569	rs1770892	chr1:76389359	T/C	cg10523679	chr1:76189770	ACADM	-0.51	-4.58	-0.38	1.1e-5	Daytime sleep phenotypes;
TGCT	cis	rs10858300	1.000	rs7873100	chr9:137856843	C/G	cg13620366	chr9:138839624	UBAC1	-0.23	-4.45	-0.37	1.9e-5	Blood protein levels;
TGCT	cis	rs7647973	0.667	rs6446286	chr3:49681704	A/G	cg03034192	chr3:50606346	HEMK1;C3orf18	0.36	4.75	0.39	5.61e-6	Menarche (age at onset);
TGCT	cis	rs308403	0.509	rs9990804	chr4:123671984	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.82	11.84	0.73	4.22e-22	Blood protein levels;
TGCT	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg09365446	chr1:150670422	GOLPH3L	0.31	4.64	0.38	8.7e-6	Tonsillectomy;
TGCT	cis	rs2760061	0.583	rs708123	chr1:228220495	A/G	cg02753203	chr1:228287806	NA	0.4	8.17	0.59	2.97e-13	Diastolic blood pressure;
TGCT	cis	rs3774830	0.846	rs11732645	chr4:5454829	C/T	cg26943120	chr4:5472116	STK32B	0.22	4.79	0.4	4.66e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs4654899	0.714	rs12123093	chr1:21114416	C/T	cg01072550	chr1:21505969	NA	-0.47	-7.09	-0.54	8.84e-11	Superior frontal gyrus grey matter volume;
TGCT	cis	rs9916302	0.904	rs8066704	chr17:37477218	C/T	cg15445000	chr17:37608096	MED1	-0.33	-4.71	-0.39	6.46e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs4499344	0.657	rs4805768	chr19:33049678	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.73	-6.21	-0.49	7.33e-9	Mean platelet volume;
TGCT	cis	rs12541335	0.579	rs59283125	chr8:22212311	G/A	cg00420450	chr8:22132641	PIWIL2	0.24	4.46	0.37	1.81e-5	Hypertriglyceridemia;
TGCT	cis	rs9916302	0.904	rs2338755	chr17:37419317	C/T	cg07936489	chr17:37558343	FBXL20	0.62	4.91	0.4	2.85e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg18402987	chr7:1209562	NA	0.46	4.72	0.39	6.39e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9788721	0.640	rs1394371	chr15:78724469	C/T	cg18825076	chr15:78729989	IREB2	-0.33	-4.85	-0.4	3.63e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
TGCT	cis	rs9894429	0.572	rs112417725	chr17:79578219	A/G	cg21028142	chr17:79581711	NPLOC4	-0.29	-5.95	-0.47	2.56e-8	Eye color traits;
TGCT	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg10295955	chr4:187884368	NA	-0.99	-15.24	-0.81	3.38e-30	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg22105103	chr4:187893119	NA	-0.35	-5.02	-0.41	1.76e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg27535305	chr1:53392650	SCP2	-0.24	-4.73	-0.39	5.98e-6	Monocyte count;
TGCT	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.72	-6.47	-0.5	2.04e-9	Tonsillectomy;
TGCT	cis	rs2120019	0.938	rs8040169	chr15:75370958	C/A	cg09165964	chr15:75287851	SCAMP5	-1.07	-8.58	-0.61	3.34e-14	Blood trace element (Zn levels);
TGCT	cis	rs727563	0.593	rs5758461	chr22:42162189	G/C	cg17554472	chr22:41940697	POLR3H	0.46	4.8	0.4	4.46e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.03	0.41	1.71e-6	Menopause (age at onset);
TGCT	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg11764359	chr7:65958608	NA	0.62	5.53	0.44	1.82e-7	Aortic root size;
TGCT	cis	rs10791097	0.667	rs12363163	chr11:130744509	A/G	cg14779329	chr11:130786720	SNX19	0.28	4.82	0.4	4.09e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg22535103	chr8:58192502	C8orf71	-0.42	-5.3	-0.43	5.11e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	8.99	0.63	3.48e-15	Platelet count;
TGCT	cis	rs3806843	0.808	rs6893708	chr5:140125922	T/C	cg19875535	chr5:140030758	IK	-0.34	-5.66	-0.45	1.01e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs76419734	0.510	rs1447097	chr4:106528633	C/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.82	4.67	0.39	7.63e-6	Post bronchodilator FEV1;
TGCT	cis	rs12908161	1.000	rs11638290	chr15:85227636	C/T	cg11189052	chr15:85197271	WDR73	0.75	6.3	0.49	4.8e-9	Schizophrenia;
TGCT	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg11890956	chr21:40555474	PSMG1	-0.7	-6.96	-0.53	1.76e-10	Menarche (age at onset);
TGCT	cis	rs78487399	0.808	rs17030818	chr2:43680318	C/T	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.72	4.62	0.38	9.53e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs11585357	0.947	rs2977303	chr1:17611548	A/T	cg08277548	chr1:17600880	PADI3	-0.96	-9.86	-0.66	2.8e-17	Hair shape;
TGCT	cis	rs6964587	0.836	rs757040	chr7:91552016	A/G	cg17063962	chr7:91808500	NA	-0.84	-8.28	-0.6	1.62e-13	Breast cancer;
TGCT	cis	rs7843479	0.601	rs10866827	chr8:21801141	G/A	cg17168535	chr8:21777572	XPO7	0.81	8.33	0.6	1.25e-13	Mean corpuscular volume;
TGCT	cis	rs4689592	0.503	rs56099074	chr4:7071259	A/G	cg02503808	chr4:7069936	GRPEL1	-1.02	-8.95	-0.63	4.29e-15	Monocyte percentage of white cells;
TGCT	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg11890956	chr21:40555474	PSMG1	1.04	11.03	0.7	3.96e-20	Cognitive function;
TGCT	cis	rs11250097	0.549	rs11784897	chr8:11310442	G/A	cg21775007	chr8:11205619	TDH	-0.53	-4.87	-0.4	3.31e-6	Neuroticism;
TGCT	cis	rs7582180	0.629	rs13031906	chr2:100939524	T/C	cg08017756	chr2:100939284	LONRF2	-0.3	-4.78	-0.39	4.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs11247915	0.561	rs11583258	chr1:26624270	C/T	cg23732845	chr1:26663426	AIM1L	-0.35	-4.54	-0.38	1.3e-5	Obesity-related traits;
TGCT	cis	rs11677370	0.561	rs13003140	chr2:3816759	G/T	cg17052675	chr2:3827356	NA	-0.44	-7.57	-0.56	7.21e-12	Type 2 diabetes;
TGCT	cis	rs739496	0.614	rs9788231	chr12:112385665	A/C	cg10833066	chr12:111807467	FAM109A	0.38	5.61	0.45	1.24e-7	Platelet count;
TGCT	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg11890956	chr21:40555474	PSMG1	1.1	12.31	0.74	2.99e-23	Cognitive function;
TGCT	cis	rs2836633	0.929	rs8130434	chr21:40036243	C/T	cg05519781	chr21:40033154	ERG	-0.7	-6.95	-0.53	1.88e-10	Coronary artery disease;
TGCT	cis	rs9486719	0.948	rs12203657	chr6:96883285	G/A	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.86	-0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs12142240	0.698	rs68083747	chr1:46807416	T/G	cg14993813	chr1:46806288	NSUN4	-0.58	-4.81	-0.4	4.34e-6	Menopause (age at onset);
TGCT	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	6.05	0.48	1.59e-8	Alzheimer's disease;
TGCT	cis	rs7654585	1.000	rs7654585	chr4:25942751	A/G	cg10409131	chr4:25915609	C4orf52	0.75	7.82	0.57	1.99e-12	Obesity-related traits;
TGCT	cis	rs709400	0.663	rs62007683	chr14:103894071	G/T	cg26031613	chr14:104095156	KLC1	0.88	9.61	0.65	1.09e-16	Body mass index;
TGCT	cis	rs4788570	0.543	rs4788820	chr16:71660115	G/C	cg06353428	chr16:71660113	MARVELD3	1.57	12.81	0.75	1.9e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs854765	0.647	rs8066764	chr17:17974668	C/T	cg04398451	chr17:18023971	MYO15A	-0.36	-5.99	-0.47	2.14e-8	Total body bone mineral density;
TGCT	cis	rs6542838	0.611	rs7588441	chr2:99518858	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.51	-4.64	-0.38	8.77e-6	Fear of minor pain;
TGCT	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg19318889	chr4:1322082	MAEA	0.27	6.66	0.51	7.93e-10	Longevity;
TGCT	cis	rs77861329	1.000	rs9847092	chr3:52199453	T/C	cg08692210	chr3:52188851	WDR51A	0.94	4.82	0.4	4.12e-6	Macrophage inflammatory protein 1b levels;
TGCT	cis	rs7824557	0.527	rs2572448	chr8:11239352	G/A	cg21775007	chr8:11205619	TDH	-0.68	-6.6	-0.51	1.08e-9	Retinal vascular caliber;
TGCT	cis	rs9362426	0.943	rs242291	chr6:88077083	A/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.45	-4.95	-0.41	2.37e-6	Depressive episodes in bipolar disorder;
TGCT	cis	rs2688608	0.620	rs7076525	chr10:75512797	C/T	cg04320760	chr10:75533139	FUT11	-0.36	-5.66	-0.45	9.83e-8	Inflammatory bowel disease;
TGCT	cis	rs79387448	0.655	rs79091585	chr2:102917243	C/T	cg09003973	chr2:102972529	NA	1.34	8.26	0.6	1.89e-13	Gut microbiota (bacterial taxa);
TGCT	cis	rs9435341	0.896	rs1730850	chr1:107597988	C/T	cg09367891	chr1:107599246	PRMT6	-0.64	-5.58	-0.45	1.43e-7	Facial morphology (factor 21, depth of nasal alae);
TGCT	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg19626725	chr5:178986131	RUFY1	0.46	5.76	0.46	6.14e-8	Lung cancer;
TGCT	cis	rs7584330	0.737	rs937392	chr2:238367130	C/T	cg14458575	chr2:238380390	NA	0.51	8.14	0.59	3.53e-13	Prostate cancer;
TGCT	cis	rs3812049	0.826	rs34576922	chr5:127364103	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.6	-5.5	-0.44	2.11e-7	Lymphocyte counts;Red cell distribution width;
TGCT	cis	rs7917772	0.629	rs1475646	chr10:104522564	G/T	cg05855489	chr10:104503620	C10orf26	0.67	5.32	0.43	4.77e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs6840360	0.554	rs4643789	chr4:152726691	C/T	cg22705602	chr4:152727874	NA	-0.34	-6.02	-0.48	1.87e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7611238	0.560	rs60177727	chr3:195069337	C/T	cg27323046	chr3:195102265	ACAP2	0.35	4.82	0.4	4.11e-6	Body mass index;
TGCT	cis	rs6087990	0.735	rs2424915	chr20:31378448	C/T	cg13636640	chr20:31349939	DNMT3B	0.96	12.64	0.75	4.78e-24	Ulcerative colitis;
TGCT	cis	rs7208859	0.673	rs56085216	chr17:29217234	T/C	cg18442181	chr17:29233375	C17orf42	-0.79	-4.78	-0.39	4.95e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.48	-0.37	1.66e-5	Bipolar disorder;
TGCT	cis	rs9394169	0.613	rs2395399	chr6:33777432	T/C	cg00334056	chr6:33755658	LEMD2	-0.29	-5.17	-0.42	9.01e-7	Essential tremor;
TGCT	cis	rs765787	0.530	rs12906537	chr15:45520061	T/C	cg24006582	chr15:45444508	DUOX1	0.25	5.38	0.43	3.62e-7	Uric acid levels;
TGCT	cis	rs72781680	0.678	rs56145919	chr2:24088489	A/G	cg08917208	chr2:24149416	ATAD2B	0.75	4.61	0.38	9.75e-6	Lymphocyte counts;
TGCT	cis	rs919433	0.588	rs11690163	chr2:198527507	A/T	cg00792783	chr2:198669748	PLCL1	0.55	4.88	0.4	3.24e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs854765	0.583	rs11871899	chr17:17826748	C/G	cg09796270	chr17:17721594	SREBF1	0.28	5.66	0.45	9.89e-8	Total body bone mineral density;
TGCT	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg06873352	chr17:61820015	STRADA	0.56	6.22	0.49	6.93e-9	Prudent dietary pattern;
TGCT	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg18402987	chr7:1209562	NA	0.66	5.39	0.44	3.36e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7786808	0.527	rs62478405	chr7:158188528	G/A	cg01191920	chr7:158217561	PTPRN2	-0.37	-5.44	-0.44	2.67e-7	Obesity-related traits;
TGCT	cis	rs67460515	0.892	rs4856703	chr3:161047720	G/T	cg03342759	chr3:160939853	NMD3	-0.48	-5.16	-0.42	9.65e-7	Parkinson's disease;
TGCT	cis	rs7119	0.604	rs2271396	chr15:77907535	C/G	cg27398640	chr15:77910606	LINGO1	0.32	6.89	0.53	2.5e-10	Type 2 diabetes;
TGCT	cis	rs10838634	1.000	rs7115038	chr11:46897792	C/G	cg18332754	chr11:46939436	LRP4	-0.89	-4.77	-0.39	5.13e-6	Schizophrenia;
TGCT	cis	rs1570884	0.556	rs2146146	chr13:50170368	C/T	cg03651054	chr13:50194643	NA	0.32	5.26	0.43	6.06e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
TGCT	trans	rs7819412	0.807	rs4840542	chr8:10944809	G/T	cg15556689	chr8:8085844	FLJ10661	-0.88	-8.75	-0.62	1.29e-14	Triglycerides;
TGCT	cis	rs2797160	1.000	rs1739347	chr6:126014157	C/T	cg05901451	chr6:126070800	HEY2	0.73	6.32	0.49	4.36e-9	Endometrial cancer;
TGCT	cis	rs6089584	0.927	rs3787427	chr20:60579789	T/C	cg16423285	chr20:60520624	NA	-0.62	-6.86	-0.52	2.86e-10	Body mass index;
TGCT	cis	rs35883536	0.528	rs1577512	chr1:101030832	G/A	cg06223162	chr1:101003688	GPR88	0.43	8.41	0.6	8.23e-14	Monocyte count;
TGCT	cis	rs12220238	1.000	rs10824075	chr10:75880254	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.91	7.73	0.57	3.14e-12	Soluble interleukin-2 receptor subunit alpha;
TGCT	trans	rs28595532	0.668	rs58467651	chr4:119349011	T/G	cg26518628	chr1:97050305	NA	-0.58	-6.69	-0.51	6.71e-10	Cannabis dependence symptom count;
TGCT	cis	rs7551222	0.750	rs898387	chr1:204579373	A/G	cg09150239	chr1:204347429	NA	-0.5	-5.02	-0.41	1.77e-6	Schizophrenia;
TGCT	cis	rs35306767	0.903	rs12769431	chr10:922633	T/C	cg20503657	chr10:835505	NA	0.74	10.3	0.68	2.41e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs2439831	0.850	rs12442297	chr15:44168470	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.85	5.83	0.46	4.52e-8	Lung cancer in ever smokers;
TGCT	cis	rs4285028	0.603	rs79312528	chr3:121608997	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.78	-6.72	-0.52	5.95e-10	Multiple sclerosis;
TGCT	cis	rs12479064	0.724	rs6748200	chr2:100080895	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.58	-4.71	-0.39	6.62e-6	Chronic sinus infection;
TGCT	cis	rs904251	0.523	rs2776872	chr6:37482787	C/G	cg01843034	chr6:37503916	NA	-0.54	-7.32	-0.55	2.76e-11	Cognitive performance;
TGCT	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg10862848	chr6:42927986	GNMT	-0.39	-4.74	-0.39	5.72e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs10782582	0.609	rs10873797	chr1:76377191	G/T	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.54	4.64	0.38	8.88e-6	Daytime sleep phenotypes;
TGCT	cis	rs79976124	0.837	rs75346757	chr6:66648386	A/T	cg07460842	chr6:66804631	NA	0.58	5.29	0.43	5.33e-7	Type 2 diabetes;
TGCT	cis	rs1903068	0.925	rs1551643	chr4:55994226	T/A	cg16572876	chr4:56024045	NA	0.45	5.08	0.42	1.34e-6	Endometriosis;
TGCT	cis	rs17030434	1.000	rs732680	chr4:154725211	G/A	cg14289246	chr4:154710475	SFRP2	-0.91	-7.2	-0.54	5.18e-11	Electrocardiographic conduction measures;
TGCT	cis	rs877282	0.898	rs11253344	chr10:765162	C/T	cg17470449	chr10:769945	NA	0.37	5.59	0.45	1.37e-7	Uric acid levels;
TGCT	trans	rs10953454	1.000	rs34439336	chr7:104472327	G/T	cg04208666	chr6:19734707	NA	-0.57	-6.89	-0.53	2.54e-10	Obesity;
TGCT	cis	rs514406	0.607	rs6696940	chr1:53203427	C/T	cg16325326	chr1:53192061	ZYG11B	-0.9	-13.18	-0.76	2.44e-25	Monocyte count;
TGCT	cis	rs9467711	0.790	rs66488313	chr6:26631568	G/T	cg16898833	chr6:26189333	HIST1H4D	1.37	6.2	0.49	7.83e-9	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6840360	0.533	rs1397683	chr4:152715916	T/C	cg17479576	chr4:152424074	FAM160A1	0.49	4.96	0.41	2.29e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2204008	0.744	rs11182316	chr12:38499552	G/A	cg26384229	chr12:38710491	ALG10B	0.89	8.14	0.59	3.55e-13	Bladder cancer;
TGCT	cis	rs4689388	0.890	rs6838400	chr4:6295427	C/G	cg14416269	chr4:6271139	WFS1	0.37	4.85	0.4	3.58e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs6840360	0.681	rs9968292	chr4:152297368	T/C	cg17479576	chr4:152424074	FAM160A1	-0.54	-5.83	-0.46	4.47e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs16958440	0.867	rs74845165	chr18:44690852	T/C	cg17192377	chr18:44677553	HDHD2	0.63	4.7	0.39	6.74e-6	Sitting height ratio;
TGCT	cis	rs7439150	0.954	rs72679202	chr4:155475566	A/T	cg22130008	chr4:155548532	NA	-0.43	-5.38	-0.44	3.5e-7	Fibrinogen levels;
TGCT	cis	rs8031584	0.752	rs1852035	chr15:31184803	C/G	cg08704250	chr15:31115839	NA	-0.42	-6.3	-0.49	4.64e-9	Huntington's disease progression;
TGCT	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg03517284	chr6:25882590	NA	-0.66	-5.95	-0.47	2.55e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs4699574	chr4:98725544	C/T	cg05340658	chr4:99064831	C4orf37	0.49	5.77	0.46	6.02e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28595532	0.764	rs115877991	chr4:119728298	C/T	cg21605333	chr4:119757512	SEC24D	1.66	8.33	0.6	1.28e-13	Cannabis dependence symptom count;
TGCT	cis	rs12142240	0.698	rs12385696	chr1:46818836	A/G	cg14993813	chr1:46806288	NSUN4	-0.56	-4.72	-0.39	6.36e-6	Menopause (age at onset);
TGCT	cis	rs514406	0.607	rs1930305	chr1:53195481	G/T	cg22166914	chr1:53195759	ZYG11B	-0.5	-9.42	-0.65	3.19e-16	Monocyte count;
TGCT	cis	rs3617	0.573	rs4687682	chr3:52916939	T/C	cg11645453	chr3:52864694	ITIH4	-0.26	-5.07	-0.41	1.39e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs55794721	0.509	rs11249248	chr1:25753051	T/C	cg23205692	chr1:25664452	TMEM50A	0.5	5.21	0.42	7.56e-7	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs2019216	0.521	rs10871487	chr17:21939193	G/A	cg22648282	chr17:21454238	C17orf51	-0.58	-5.59	-0.45	1.36e-7	Pelvic organ prolapse;
TGCT	cis	rs12049351	0.774	rs12022203	chr1:229658797	C/T	cg12130225	chr1:229698885	NA	0.38	4.59	0.38	1.09e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs9447004	0.583	rs28360541	chr6:74432427	T/G	cg23004174	chr6:74404879	CD109	0.23	5.08	0.42	1.35e-6	Blood protein levels;Calcium levels;
TGCT	cis	rs2933343	0.621	rs789242	chr3:128585707	T/C	cg11901034	chr3:128598214	ACAD9	-0.62	-6.1	-0.48	1.26e-8	IgG glycosylation;
TGCT	cis	rs73198271	0.740	rs10113326	chr8:8647630	A/T	cg06671706	chr8:8559999	CLDN23	-0.35	-4.5	-0.37	1.52e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs2404602	0.583	rs12438741	chr15:76542114	C/A	cg26408565	chr15:76604113	ETFA	-0.46	-6.46	-0.5	2.15e-9	Blood metabolite levels;
TGCT	cis	rs782590	0.557	rs7592219	chr2:55887176	T/C	cg18811423	chr2:55921094	PNPT1	-0.61	-5.3	-0.43	5.2e-7	Metabolic syndrome;
TGCT	cis	rs2439831	1.000	rs689826	chr15:43749916	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.01	8.18	0.59	2.83e-13	Lung cancer in ever smokers;
TGCT	cis	rs7523273	0.606	rs2724391	chr1:207953244	T/C	cg22525895	chr1:207977042	MIR29B2	0.55	9.54	0.65	1.67e-16	Schizophrenia;
TGCT	cis	rs77216612	0.835	rs56692845	chr12:12887811	C/T	cg09462578	chr12:12878428	APOLD1	-1.0	-8.3	-0.6	1.5e-13	Lymphocyte counts;
TGCT	cis	rs8084125	0.832	rs62105180	chr18:74951197	C/G	cg15443732	chr18:74961078	GALR1	0.48	4.7	0.39	6.76e-6	Obesity-related traits;
TGCT	cis	rs5769707	0.609	rs739247	chr22:49996657	T/C	cg06623630	chr22:50017776	C22orf34	-0.26	-4.44	-0.37	1.97e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.0	0.41	1.89e-6	Menopause (age at onset);
TGCT	cis	rs700590	0.723	rs700588	chr5:88108574	G/A	cg22951263	chr5:87985283	NA	0.56	5.4	0.44	3.24e-7	Educational attainment (years of education);
TGCT	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg24531977	chr5:56204891	C5orf35	-0.77	-7.61	-0.56	5.83e-12	Initial pursuit acceleration;
TGCT	cis	rs2228479	0.850	rs1800355	chr16:89813194	C/T	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs56104184	1.000	rs56104184	chr19:49370310	C/T	cg17863274	chr19:49399704	TULP2	-0.36	-5.18	-0.42	8.68e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs5769707	0.935	rs9616332	chr22:50047678	C/G	cg05373962	chr22:49881684	NA	-0.3	-6.19	-0.49	8.22e-9	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs10493389	0.673	rs7553999	chr1:66290125	C/G	cg08716655	chr1:66257732	PDE4B	-0.41	-4.54	-0.38	1.29e-5	Echocardiographic traits;
TGCT	cis	rs8017423	0.630	rs4900038	chr14:90821677	A/G	cg04374321	chr14:90722782	PSMC1	-0.54	-5.41	-0.44	3.13e-7	Mortality in heart failure;
TGCT	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.66	5.08	0.42	1.33e-6	Lung function (FEV1/FVC);
TGCT	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg08280861	chr8:58055591	NA	0.48	5.29	0.43	5.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7777754	0.512	rs11238131	chr7:50538589	T/C	cg18232548	chr7:50535776	DDC	-0.39	-6.01	-0.47	1.91e-8	Response to zileuton treatment in asthma (FEV1 change interaction);
TGCT	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs79349575	0.783	rs12602933	chr17:47029280	G/C	cg26022315	chr17:47021804	SNF8	0.49	4.9	0.4	2.94e-6	Type 2 diabetes;
TGCT	cis	rs4722166	0.508	rs1474347	chr7:22768124	A/C	cg13104385	chr7:22767384	IL6	-0.21	-4.46	-0.37	1.79e-5	Lung cancer;
TGCT	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg20887711	chr4:1340912	KIAA1530	-0.88	-7.99	-0.58	7.85e-13	Longevity;
TGCT	cis	rs10465746	0.775	rs4907186	chr1:84340753	G/T	cg10977910	chr1:84465055	TTLL7	0.68	6.7	0.52	6.46e-10	Obesity-related traits;
TGCT	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg11644478	chr21:40555479	PSMG1	-0.63	-5.83	-0.46	4.45e-8	Cognitive function;
TGCT	cis	rs2549003	1.000	rs2070727	chr5:131820275	C/A	cg21138405	chr5:131827807	IRF1	0.19	4.79	0.4	4.64e-6	Asthma (sex interaction);
TGCT	cis	rs7017914	0.870	rs3110256	chr8:71938136	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-4.97	-0.41	2.16e-6	Bone mineral density;
TGCT	cis	rs9796	0.870	rs12905926	chr15:41283408	G/A	cg18705301	chr15:41695430	NDUFAF1	0.43	5.52	0.44	1.9e-7	Menopause (age at onset);
TGCT	cis	rs1056107	0.898	rs1417111	chr9:114991313	A/T	cg02332936	chr9:115140584	NA	-0.25	-4.45	-0.37	1.89e-5	Colorectal cancer;
TGCT	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg04414720	chr1:150670196	GOLPH3L	0.39	5.04	0.41	1.58e-6	Tonsillectomy;
TGCT	cis	rs6570726	0.791	rs10457788	chr6:145921136	T/A	cg05347473	chr6:146136440	FBXO30	0.53	4.92	0.4	2.74e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs853679	0.546	rs200990	chr6:27815823	T/G	cg10876282	chr6:28092338	ZSCAN16	0.74	4.44	0.37	1.98e-5	Depression;
TGCT	cis	rs13177918	0.750	rs58256223	chr5:149822019	T/A	cg14059543	chr5:149831962	NA	-0.7	-9.26	-0.64	7.92e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs62244186	0.659	rs12489887	chr3:44547124	A/T	cg04389838	chr3:44770851	ZNF501	-0.41	-5.7	-0.46	8.29e-8	Depressive symptoms;
TGCT	cis	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg20637647	chr7:64974828	NA	1.0	5.59	0.45	1.4e-7	Diabetic kidney disease;
TGCT	cis	rs7666738	0.830	rs6848397	chr4:98946738	A/G	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs57590327	0.528	rs4856346	chr3:81502655	T/G	cg07356753	chr3:81810745	GBE1	0.58	4.89	0.4	3.06e-6	Extraversion;
TGCT	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg27170947	chr2:26402098	FAM59B	-0.39	-4.46	-0.37	1.8e-5	Gut microbiome composition (summer);
TGCT	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg21951975	chr1:209979733	IRF6	0.66	5.69	0.45	8.77e-8	Cleft lip with or without cleft palate;
TGCT	cis	rs9457247	0.935	rs427824	chr6:167403918	T/G	cg23791538	chr6:167370224	RNASET2	-0.52	-5.16	-0.42	9.46e-7	Crohn's disease;
TGCT	cis	rs922182	1.000	rs62021495	chr15:64275409	C/T	cg02919090	chr15:64263738	DAPK2	0.29	5.46	0.44	2.47e-7	Blood protein levels;
TGCT	cis	rs11190604	1.000	rs17113137	chr10:102241998	G/C	cg16342193	chr10:102329863	NA	-0.4	-5.35	-0.43	4.1e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7772486	0.790	rs3924498	chr6:146233338	A/T	cg23711669	chr6:146136114	FBXO30	-0.89	-10.38	-0.68	1.54e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11190604	0.767	rs3829162	chr10:102172752	T/G	cg16005271	chr10:102321736	NA	0.45	4.57	0.38	1.15e-5	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	8.0	0.58	7.67e-13	Platelet count;
TGCT	cis	rs17076896	0.786	rs7331051	chr13:19934191	T/C	cg00777926	chr13:20807375	GJB6	-0.37	-4.53	-0.38	1.36e-5	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs3749237	0.595	rs1050088	chr3:49570882	C/T	cg07636037	chr3:49044803	WDR6	-0.62	-5.86	-0.47	3.89e-8	Resting heart rate;
TGCT	cis	rs7542091	0.704	rs9429825	chr1:210052133	C/G	cg22029157	chr1:209979665	IRF6	0.64	6.17	0.48	8.82e-9	Monobrow;
TGCT	cis	rs9807989	0.507	rs4851004	chr2:103009537	A/G	cg03938978	chr2:103052716	IL18RAP	-0.27	-5.41	-0.44	3.17e-7	Asthma;
TGCT	trans	rs2760061	0.819	rs708120	chr1:228207651	G/C	cg16006296	chr10:38738647	LOC399744	-0.31	-7.12	-0.54	7.75e-11	Diastolic blood pressure;
TGCT	cis	rs208515	0.525	rs1484577	chr6:66688397	A/G	cg07460842	chr6:66804631	NA	0.87	9.16	0.64	1.32e-15	Exhaled nitric oxide levels;
TGCT	cis	rs68170813	0.559	rs75723759	chr7:106962407	A/G	cg02696742	chr7:106810147	HBP1	-0.69	-5.61	-0.45	1.27e-7	Coronary artery disease;
TGCT	cis	rs7412746	0.658	rs10305714	chr1:150800655	C/T	cg09365446	chr1:150670422	GOLPH3L	-0.34	-4.99	-0.41	1.99e-6	Melanoma;
TGCT	cis	rs10791097	0.694	rs2155750	chr11:130751261	A/C	cg05962950	chr11:130786565	SNX19	0.91	11.68	0.72	1.01e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs2760061	0.819	rs708115	chr1:228198046	C/T	cg02753203	chr1:228287806	NA	0.31	5.94	0.47	2.62e-8	Diastolic blood pressure;
TGCT	cis	rs739496	0.843	rs638791	chr12:111989236	A/G	cg10833066	chr12:111807467	FAM109A	0.37	4.96	0.41	2.31e-6	Platelet count;
TGCT	cis	rs6671200	0.920	rs35403759	chr1:95702890	C/T	cg03123541	chr1:95699097	RWDD3	0.91	6.4	0.5	2.93e-9	Stearic acid (18:0) levels;
TGCT	cis	rs1322512	0.959	rs1727053	chr6:152947596	A/G	cg03415253	chr6:152958462	SYNE1	-0.57	-4.99	-0.41	2e-6	Tonometry;
TGCT	cis	rs6545883	0.929	rs7561229	chr2:61737990	A/T	cg15711740	chr2:61764176	XPO1	-0.56	-5.17	-0.42	9.02e-7	Tuberculosis;
TGCT	cis	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg20637647	chr7:64974828	NA	1.0	5.59	0.45	1.4e-7	Diabetic kidney disease;
TGCT	cis	rs12257961	0.579	rs10737095	chr10:15382547	C/G	cg10616319	chr10:15468812	NA	-0.25	-4.66	-0.39	8.15e-6	Selective IgA deficiency;
TGCT	cis	rs921968	0.608	rs495855	chr2:219357858	A/G	cg02176678	chr2:219576539	TTLL4	0.38	5.48	0.44	2.31e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs4918072	0.667	rs10430666	chr10:105702425	T/C	cg11005552	chr10:105648138	OBFC1	0.33	4.67	0.39	7.56e-6	Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs13111977	chr4:98953813	G/A	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10795061	0.576	rs6601744	chr10:3711563	C/A	cg13668419	chr10:3197757	PITRM1	-0.19	-5.32	-0.43	4.62e-7	Subjective well-being;
TGCT	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.01	8.32	0.6	1.34e-13	Platelet count;
TGCT	cis	rs611744	0.550	rs1448154	chr8:109281053	T/C	cg21045802	chr8:109455806	TTC35	0.72	7.43	0.56	1.53e-11	Dupuytren's disease;
TGCT	cis	rs1153858	0.723	rs11855527	chr15:45606685	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.45	-4.97	-0.41	2.17e-6	Homoarginine levels;
TGCT	cis	rs6088590	0.561	rs6088528	chr20:33156742	G/A	cg06115741	chr20:33292138	TP53INP2	0.51	4.47	0.37	1.76e-5	Coronary artery disease;
TGCT	cis	rs1113500	0.814	rs893983	chr1:108630338	C/T	cg22161131	chr1:109420278	GPSM2	-0.49	-4.54	-0.38	1.34e-5	Growth-regulated protein alpha levels;
TGCT	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg14820908	chr5:178986412	RUFY1	-0.6	-6.69	-0.51	7.01e-10	Lung cancer;
TGCT	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg11494091	chr17:61959527	GH2	0.61	14.43	0.79	2.59e-28	Prudent dietary pattern;
TGCT	cis	rs734999	0.545	rs6684865	chr1:2546229	A/G	cg18854424	chr1:2615690	NA	-0.43	-4.96	-0.41	2.23e-6	Ulcerative colitis;
TGCT	cis	rs10927875	0.518	rs1763604	chr1:16339772	C/G	cg22431228	chr1:16359049	CLCNKA	-0.28	-5.81	-0.46	4.9e-8	Dilated cardiomyopathy;
TGCT	cis	rs1949733	0.656	rs6845969	chr4:8402465	A/T	cg11789530	chr4:8429930	ACOX3	0.51	4.75	0.39	5.45e-6	Response to antineoplastic agents;
TGCT	cis	rs77741769	0.549	rs57697145	chr12:121333552	T/G	cg02419362	chr12:121203948	SPPL3	0.19	4.5	0.37	1.56e-5	Mean corpuscular volume;
TGCT	cis	rs7666738	0.753	rs1830230	chr4:99026186	G/C	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12900413	0.562	rs11631438	chr15:90300620	C/T	cg24249390	chr15:90295951	MESP1	-0.3	-5.2	-0.42	8.04e-7	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs2997447	0.688	rs17257100	chr1:26439586	C/T	cg03844060	chr1:26490628	NA	0.28	4.55	0.38	1.27e-5	QRS complex (12-leadsum);
TGCT	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg12564285	chr5:131593104	PDLIM4	0.4	4.77	0.39	5.18e-6	Acylcarnitine levels;
TGCT	cis	rs7552404	0.696	rs12140121	chr1:76455001	A/G	cg22875332	chr1:76189707	ACADM	0.64	5.79	0.46	5.47e-8	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9389248	0.690	rs6939543	chr6:135255143	A/G	cg22676075	chr6:135203613	NA	-0.5	-5.04	-0.41	1.59e-6	High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg10047753	chr17:41438598	NA	0.97	9.66	0.66	8.66e-17	Menopause (age at onset);
TGCT	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg02038168	chr22:39784481	NA	-0.72	-6.06	-0.48	1.55e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs6074578	0.621	rs6086355	chr20:140853	C/G	cg16931068	chr20:139680	DEFB127	0.26	4.5	0.37	1.52e-5	Hirschsprung disease;
TGCT	cis	rs7131987	0.903	rs1991114	chr12:29392082	G/T	cg09582351	chr12:29534625	ERGIC2	-0.24	-4.53	-0.38	1.35e-5	QT interval;
TGCT	cis	rs11096990	0.552	rs7655170	chr4:39173604	T/G	cg20847110	chr4:39482781	LOC401127	0.17	4.96	0.41	2.3e-6	Cognitive function;
TGCT	cis	rs7017914	0.902	rs1373480	chr8:71686967	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.53	-4.98	-0.41	2.09e-6	Bone mineral density;
TGCT	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg24675658	chr1:53192096	ZYG11B	-0.71	-8.23	-0.59	2.14e-13	Monocyte count;
TGCT	cis	rs35883536	0.647	rs2647325	chr1:101040195	T/C	cg10298815	chr1:101004474	GPR88	0.24	4.47	0.37	1.76e-5	Monocyte count;
TGCT	cis	rs9859260	0.710	rs366268	chr3:195782177	A/G	cg22891161	chr3:195456627	MUC20	0.23	4.6	0.38	1.04e-5	Mean corpuscular volume;
TGCT	cis	rs916888	0.779	rs199498	chr17:44865603	A/G	cg15921436	chr17:44337874	NA	0.38	5.06	0.41	1.45e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs1552244	0.832	rs73024591	chr3:10203194	A/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.55	-6.55	-0.51	1.38e-9	Alzheimer's disease;
TGCT	cis	rs8177253	0.665	rs4525863	chr3:133436136	C/A	cg16414030	chr3:133502952	NA	-0.5	-6.87	-0.52	2.81e-10	Iron status biomarkers;
TGCT	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.95	9.68	0.66	7.34e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs7681440	1.000	rs7681440	chr4:90756550	C/G	cg20003494	chr4:90757398	SNCA	0.53	4.94	0.41	2.45e-6	Dementia with Lewy bodies;
TGCT	cis	rs1609391	0.543	rs2117009	chr3:136633571	A/T	cg15507776	chr3:136538369	TMEM22	-0.65	-6.73	-0.52	5.6e-10	Neuroticism;
TGCT	cis	rs6569992	0.636	rs55683605	chr6:135487107	C/T	cg22676075	chr6:135203613	NA	0.73	4.97	0.41	2.13e-6	Red blood cell traits;
TGCT	cis	rs13191362	0.935	rs7769048	chr6:163010040	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs4654899	0.604	rs12031023	chr1:21148839	A/G	cg01072550	chr1:21505969	NA	0.55	8.83	0.62	8.24e-15	Superior frontal gyrus grey matter volume;
TGCT	cis	rs4822044	0.560	rs7284839	chr22:42010902	C/T	cg17554472	chr22:41940697	POLR3H	0.5	5.35	0.43	4.07e-7	Cannabis dependence symptom count;
TGCT	cis	rs2549003	0.933	rs7719499	chr5:131814091	C/G	cg21138405	chr5:131827807	IRF1	0.19	4.64	0.38	8.71e-6	Asthma (sex interaction);
TGCT	cis	rs9393692	0.905	rs9357004	chr6:26303319	A/G	cg00631329	chr6:26305371	NA	-0.41	-5.87	-0.47	3.81e-8	Educational attainment;
TGCT	cis	rs9611565	0.512	rs768414	chr22:42135751	T/C	cg03806693	chr22:41940476	POLR3H	1.06	10.94	0.7	6.7e-20	Vitiligo;
TGCT	cis	rs4919694	0.615	rs78384860	chr10:105003019	G/T	cg04362960	chr10:104952993	NT5C2	1.03	6.7	0.52	6.55e-10	Arsenic metabolism;
TGCT	cis	rs595982	0.517	rs10404905	chr19:49406175	A/T	cg15549821	chr19:49342101	PLEKHA4	0.43	5.88	0.47	3.63e-8	Red cell distribution width;
TGCT	cis	rs7973719	0.966	rs1450962	chr12:7320545	A/G	cg07052231	chr12:7363540	PEX5	0.34	5.17	0.42	8.99e-7	IgG glycosylation;
TGCT	cis	rs2439831	0.571	rs2470121	chr15:43937618	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	6.61	0.51	1.03e-9	Lung cancer in ever smokers;
TGCT	cis	rs6912958	0.781	rs9450755	chr6:88303702	T/C	cg06598631	chr6:88300029	RARS2;ORC3L	-0.57	-5.22	-0.42	7.36e-7	Monocyte percentage of white cells;
TGCT	cis	rs2842992	0.789	rs9364536	chr6:160225559	G/C	cg11366901	chr6:160182831	ACAT2	1.03	6.98	0.53	1.59e-10	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs3796352	1.000	rs34979715	chr3:53048960	G/A	cg27565382	chr3:53032988	SFMBT1	0.45	4.58	0.38	1.14e-5	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs732765	0.734	rs2270425	chr14:75179734	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.57	-5.03	-0.41	1.69e-6	Non-small cell lung cancer;
TGCT	cis	rs9811920	0.809	rs6802817	chr3:99779264	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.44	4.94	0.41	2.48e-6	Axial length;
TGCT	cis	rs9677476	0.516	rs3769989	chr2:232011440	C/A	cg07929768	chr2:232055508	NA	0.33	5.24	0.43	6.78e-7	Food antigen IgG levels;
TGCT	cis	rs909002	0.886	rs10798880	chr1:32097088	G/T	cg11573219	chr1:32083031	HCRTR1	-0.48	-6.35	-0.5	3.65e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	5.9	0.47	3.2e-8	Bipolar disorder;
TGCT	cis	rs10751667	0.961	rs7943115	chr11:973885	T/C	cg06064525	chr11:970664	AP2A2	-0.31	-6.25	-0.49	5.89e-9	Alzheimer's disease (late onset);
TGCT	cis	rs826838	0.933	rs980573	chr12:39127811	T/C	cg13010199	chr12:38710504	ALG10B	-0.63	-5.06	-0.41	1.46e-6	Heart rate;
TGCT	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg24060327	chr5:131705240	SLC22A5	-0.76	-8.4	-0.6	8.54e-14	Breast cancer;
TGCT	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg04772025	chr11:68637568	NA	0.59	6.67	0.51	7.71e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs12188164	0.965	rs11745789	chr5:450777	T/C	cg26850624	chr5:429559	AHRR	-0.2	-4.84	-0.4	3.78e-6	Cystic fibrosis severity;
TGCT	cis	rs904251	1.000	rs10947673	chr6:37445079	C/T	cg08126542	chr6:37504118	NA	-0.4	-5.27	-0.43	5.92e-7	Cognitive performance;
TGCT	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg09436375	chr6:42928200	GNMT	-0.4	-5.2	-0.42	8.08e-7	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg13770153	chr20:60521292	NA	-0.54	-7.13	-0.54	7.45e-11	Body mass index;
TGCT	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg02725872	chr8:58115012	NA	-0.43	-5.35	-0.43	4.11e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs858239	0.863	rs274054	chr7:23390467	G/C	cg05602783	chr7:23145260	KLHL7	-0.56	-4.58	-0.38	1.13e-5	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs7772486	0.790	rs2254288	chr6:146204470	G/A	cg23711669	chr6:146136114	FBXO30	0.87	9.99	0.67	1.32e-17	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs3780486	0.718	rs10971418	chr9:33122024	A/C	cg20290983	chr6:43655470	MRPS18A	-1.0	-7.29	-0.55	3.19e-11	IgG glycosylation;
TGCT	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg07157834	chr1:205819609	PM20D1	0.45	7.45	0.56	1.35e-11	Menarche (age at onset);
TGCT	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg13770153	chr20:60521292	NA	0.52	6.68	0.51	7.32e-10	Body mass index;
TGCT	cis	rs7666738	0.609	rs35214820	chr4:98864692	G/A	cg17366294	chr4:99064904	C4orf37	0.67	6.02	0.48	1.86e-8	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg07870213	chr5:140052090	DND1	-0.61	-7.32	-0.55	2.7e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg27535305	chr1:53392650	SCP2	-0.29	-6.13	-0.48	1.08e-8	Monocyte count;
TGCT	cis	rs17712049	0.908	rs62447150	chr7:48199634	G/C	cg16849860	chr7:48352531	ABCA13	0.32	5.26	0.43	6.19e-7	Refractive astigmatism;
TGCT	cis	rs1023500	1.000	rs1023499	chr22:42340582	T/C	cg04692870	chr22:42525206	CYP2D6	-0.33	-5.0	-0.41	1.9e-6	Schizophrenia;
TGCT	cis	rs3087591	0.659	rs8065496	chr17:29720140	T/C	cg24425628	chr17:29625626	OMG;NF1	0.38	5.5	0.44	2.09e-7	Hip circumference;
TGCT	trans	rs6089829	0.888	rs4809467	chr20:61671688	A/G	cg13615516	chr5:77269221	NA	0.73	8.39	0.6	9.12e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs4820539	1.000	rs5759595	chr22:23471624	G/A	cg14186256	chr22:23484241	RTDR1	0.99	12.58	0.75	6.81e-24	Bone mineral density;
TGCT	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg10802521	chr3:52805072	NEK4	-0.78	-10.01	-0.67	1.22e-17	Bipolar disorder;
TGCT	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9393777	0.588	rs11967935	chr6:26560672	A/C	cg15659132	chr6:26577336	NA	-0.76	-5.72	-0.46	7.53e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9372498	0.536	rs62422189	chr6:118907053	C/T	cg07617317	chr6:118971624	C6orf204	0.52	5.43	0.44	2.85e-7	Diastolic blood pressure;
TGCT	cis	rs6534347	0.551	rs925549	chr4:123530993	A/G	cg10583651	chr4:123538969	IL21	0.32	4.79	0.4	4.59e-6	Type 1 diabetes;
TGCT	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg21724239	chr8:58056113	NA	0.47	5.14	0.42	1.05e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs453301	0.507	rs2929306	chr8:9084909	C/T	cg15556689	chr8:8085844	FLJ10661	-0.65	-6.15	-0.48	9.69e-9	Joint mobility (Beighton score);
TGCT	cis	rs1129187	0.702	rs2395943	chr6:42940673	A/G	cg09436375	chr6:42928200	GNMT	-0.41	-5.19	-0.42	8.34e-7	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs986417	0.818	rs12883272	chr14:61015153	A/G	cg27398547	chr14:60952738	C14orf39	1.42	8.85	0.62	7.44e-15	Gut microbiota (bacterial taxa);
TGCT	cis	rs1801251	0.752	rs2592126	chr2:233751377	A/G	cg25237894	chr2:233734115	C2orf82	-0.31	-5.98	-0.47	2.2e-8	Coronary artery disease;
TGCT	cis	rs11719291	0.831	rs11715177	chr3:48763894	G/A	cg00383909	chr3:49044727	WDR6	1.24	6.68	0.51	7.21e-10	Cognitive function;
TGCT	cis	rs7666738	0.830	rs6833822	chr4:98951354	G/A	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12780845	0.540	rs11254413	chr10:17204187	G/A	cg01003015	chr10:17271136	VIM	0.58	5.18	0.42	8.62e-7	Homocysteine levels;
TGCT	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg09222892	chr1:25734099	RHCE	-0.43	-6.98	-0.53	1.6e-10	Erythrocyte sedimentation rate;
TGCT	cis	rs4689388	0.581	rs4688985	chr4:6285715	A/G	cg25554036	chr4:6271136	WFS1	0.56	6.72	0.52	5.99e-10	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs7647973	1.000	rs1464569	chr3:49460350	A/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.53	-4.45	-0.37	1.87e-5	Menarche (age at onset);
TGCT	cis	rs6964587	1.000	rs10234434	chr7:91673308	A/T	cg22709100	chr7:91322751	NA	0.28	4.56	0.38	1.19e-5	Breast cancer;
TGCT	cis	rs1215050	0.755	rs6851840	chr4:98776366	A/G	cg05340658	chr4:99064831	C4orf37	0.44	5.51	0.44	2.01e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs765787	0.530	rs4775834	chr15:45537511	C/T	cg24006582	chr15:45444508	DUOX1	-0.25	-5.54	-0.45	1.76e-7	Uric acid levels;
TGCT	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg06238570	chr21:40685208	BRWD1	0.76	7.13	0.54	7.21e-11	Cognitive function;
TGCT	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg11301795	chr4:187892539	NA	-0.33	-5.05	-0.41	1.51e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg24531977	chr5:56204891	C5orf35	-0.77	-7.61	-0.56	5.83e-12	Initial pursuit acceleration;
TGCT	cis	rs7178572	0.568	rs12443386	chr15:77491389	C/T	cg15453836	chr15:77711506	NA	0.45	5.01	0.41	1.81e-6	Type 2 diabetes;
TGCT	cis	rs10256972	0.721	rs10435145	chr7:1065988	C/T	cg18402987	chr7:1209562	NA	0.4	4.87	0.4	3.39e-6	Longevity;Endometriosis;
TGCT	cis	rs711245	0.572	rs3821150	chr2:36795233	G/A	cg09467607	chr2:36825704	FEZ2	0.39	5.32	0.43	4.58e-7	Height;
TGCT	cis	rs28785552	0.589	rs11669056	chr19:53244443	G/A	cg22067481	chr19:53234126	ZNF611	-0.45	-6.38	-0.5	3.23e-9	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs7149242	0.500	rs10144381	chr14:101173297	C/T	cg18089426	chr14:101175970	NA	0.44	4.98	0.41	2.09e-6	Platelet count;
TGCT	cis	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg07424592	chr7:64974309	NA	1.38	8.17	0.59	3.04e-13	Diabetic kidney disease;
TGCT	cis	rs6088580	0.602	rs6058064	chr20:33086622	A/G	cg08999081	chr20:33150536	PIGU	0.28	5.51	0.44	1.94e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg20887711	chr4:1340912	KIAA1530	-0.7	-6.37	-0.5	3.4e-9	Obesity-related traits;
TGCT	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg03188948	chr7:1209495	NA	0.65	5.45	0.44	2.59e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs3806843	1.000	rs1548701	chr5:140164557	T/C	cg19875535	chr5:140030758	IK	0.37	6.34	0.49	3.89e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs1857353	1.000	rs983331	chr1:75880565	C/G	cg11838876	chr1:75668600	SLC44A5	-0.53	-4.89	-0.4	3.11e-6	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs3796352	1.000	rs36090694	chr3:53010742	T/C	cg07884673	chr3:53033167	SFMBT1	0.64	6.39	0.5	3.03e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs2282802	0.685	rs35214989	chr5:139636127	T/C	cg01081189	chr5:139537190	NA	0.29	5.24	0.43	6.57e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg03188948	chr7:1209495	NA	0.68	5.75	0.46	6.65e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7666738	0.830	rs6819047	chr4:98866902	G/A	cg17366294	chr4:99064904	C4orf37	0.7	7.27	0.55	3.62e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6459788	0.692	rs10807645	chr7:157258979	T/C	cg04274827	chr7:157277617	NA	0.3	5.47	0.44	2.42e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg20203395	chr5:56204925	C5orf35	-0.53	-4.92	-0.4	2.67e-6	Initial pursuit acceleration;
TGCT	cis	rs3733585	0.605	rs4235354	chr4:10122942	C/A	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.45	-0.5	2.28e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs3784262	0.765	rs11631127	chr15:58270009	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.41	-5.94	-0.47	2.71e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs700590	0.603	rs160045	chr5:88140942	G/A	cg22951263	chr5:87985283	NA	0.63	5.8	0.46	5.25e-8	Educational attainment (years of education);
TGCT	cis	rs10131894	0.611	rs175001	chr14:75436452	A/C	cg06637938	chr14:75390232	RPS6KL1	0.52	4.49	0.37	1.64e-5	Coronary artery disease;
TGCT	cis	rs3806843	0.864	rs2531343	chr5:140129346	A/G	cg19875535	chr5:140030758	IK	-0.35	-5.97	-0.47	2.27e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7582180	0.629	rs74177696	chr2:100938481	C/G	cg14675211	chr2:100938903	LONRF2	0.5	4.78	0.39	4.89e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2469997	1.000	rs2447165	chr8:120371318	G/A	cg00681363	chr8:120844660	TAF2	0.69	4.48	0.37	1.64e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs4742903	0.933	rs10820608	chr9:106890840	A/G	cg21169611	chr9:106856078	SMC2	0.51	4.84	0.4	3.81e-6	High-grade serous ovarian cancer;Breast cancer;
TGCT	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg06634786	chr22:41940651	POLR3H	0.95	8.71	0.62	1.61e-14	Vitiligo;
TGCT	cis	rs73058052	0.597	rs7254718	chr19:50073226	A/G	cg14048834	chr19:49990801	RPL13AP5;RPL13A	-0.52	-4.63	-0.38	9.23e-6	Fibrinogen levels;
TGCT	cis	rs9859260	0.744	rs406271	chr3:195776976	T/C	cg02975922	chr3:195473998	MUC4	0.25	5.1	0.42	1.24e-6	Mean corpuscular volume;
TGCT	cis	rs7833790	0.724	rs1054078	chr8:82712153	A/G	cg17211192	chr8:82754475	SNX16	-0.95	-8.83	-0.62	8.45e-15	Diastolic blood pressure;
TGCT	trans	rs4332037	0.539	rs1533827	chr7:2074290	A/G	cg25206134	chr2:45395956	NA	-0.91	-7.01	-0.53	1.32e-10	Bipolar disorder;
TGCT	cis	rs7937840	0.581	rs4963462	chr11:61886672	A/T	cg05871569	chr11:61891931	INCENP	-0.67	-6.16	-0.48	9.49e-9	Breast cancer;
TGCT	cis	rs709400	0.628	rs11621510	chr14:103869620	T/C	cg26031613	chr14:104095156	KLC1	0.85	9.32	0.64	5.54e-16	Body mass index;
TGCT	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg23302884	chr18:44338147	ST8SIA5	-0.43	-4.96	-0.41	2.26e-6	Personality dimensions;
TGCT	cis	rs4808199	0.948	rs1859287	chr19:19422187	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.64	4.75	0.39	5.58e-6	Nonalcoholic fatty liver disease;
TGCT	cis	rs4523957	0.651	rs4790315	chr17:2070529	T/C	cg16513277	chr17:2031491	SMG6	-0.2	-4.64	-0.38	8.83e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs66561647	0.929	rs67423398	chr8:128972220	C/T	cg11792826	chr8:129160931	MIR1208	0.21	4.89	0.4	3.02e-6	Hemoglobin concentration;
TGCT	cis	rs9527	1.000	rs4919690	chr10:104616500	C/T	cg04362960	chr10:104952993	NT5C2	-0.62	-5.18	-0.42	8.61e-7	Arsenic metabolism;
TGCT	cis	rs813218	0.527	rs793450	chr3:99532532	C/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.46	5.27	0.43	5.89e-7	Orofacial clefts;
TGCT	cis	rs76878669	0.561	rs7105015	chr11:66159390	A/G	cg18002602	chr11:66138449	SLC29A2	0.53	6.49	0.5	1.82e-9	Educational attainment (years of education);
TGCT	cis	rs832540	0.931	rs1466008	chr5:56213406	G/C	cg24531977	chr5:56204891	C5orf35	-0.52	-5.18	-0.42	8.65e-7	Coronary artery disease;
TGCT	trans	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg23505145	chr19:12996616	KLF1	0.79	8.3	0.6	1.47e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9902453	0.967	rs1906450	chr17:28515744	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	6.43	0.5	2.49e-9	Coffee consumption (cups per day);
TGCT	cis	rs4919669	0.668	rs10786701	chr10:104412308	C/T	cg05855489	chr10:104503620	C10orf26	0.8	4.7	0.39	6.8e-6	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs56104184	0.775	rs56317021	chr19:49395960	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.73	-9.15	-0.63	1.47e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs10782582	0.609	rs1770889	chr1:76401166	A/G	cg10523679	chr1:76189770	ACADM	-0.58	-5.21	-0.42	7.7e-7	Daytime sleep phenotypes;
TGCT	cis	rs3733589	0.744	rs57897925	chr4:10053281	G/A	cg02734326	chr4:10020555	SLC2A9	-0.99	-4.48	-0.37	1.7e-5	Renal overload gout;
TGCT	cis	rs7914558	1.000	rs7071373	chr10:104771922	A/G	cg04362960	chr10:104952993	NT5C2	0.6	5.34	0.43	4.34e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg25427524	chr10:38739819	LOC399744	-0.39	-8.04	-0.59	5.95e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs11167764	1.000	rs6887599	chr5:141484349	G/A	cg08523384	chr5:141488047	NDFIP1	-0.25	-5.32	-0.43	4.72e-7	Crohn's disease;
TGCT	cis	rs9372498	0.536	rs62422189	chr6:118907053	C/T	cg21191810	chr6:118973309	C6orf204	-0.4	-5.12	-0.42	1.12e-6	Diastolic blood pressure;
TGCT	cis	rs10501293	0.956	rs10768918	chr11:43134481	C/T	cg03447554	chr11:43094025	NA	-0.48	-6.72	-0.52	5.89e-10	Cognitive performance;
TGCT	cis	rs79349575	0.783	rs12602746	chr17:47031741	A/C	cg26022315	chr17:47021804	SNF8	0.49	4.9	0.4	2.94e-6	Type 2 diabetes;
TGCT	cis	rs9467773	0.933	rs35355150	chr6:26526039	G/A	cg26531700	chr6:26746687	NA	0.55	5.57	0.45	1.53e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2797160	1.000	rs1832938	chr6:125988964	G/C	cg05901451	chr6:126070800	HEY2	-0.74	-6.47	-0.5	2.1e-9	Endometrial cancer;
TGCT	cis	rs2439831	1.000	rs2253708	chr15:43797273	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.82	5.71	0.46	7.85e-8	Lung cancer in ever smokers;
TGCT	cis	rs9303401	0.614	rs66480139	chr17:57101538	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.63	5.82	0.46	4.8e-8	Cognitive test performance;
TGCT	cis	rs6570726	0.967	rs365515	chr6:145802833	C/T	cg23711669	chr6:146136114	FBXO30	-0.65	-5.87	-0.47	3.65e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.91	7.47	0.56	1.26e-11	Platelet count;
TGCT	cis	rs10927875	0.541	rs1763601	chr1:16340460	G/T	cg21385522	chr1:16154831	NA	0.46	4.85	0.4	3.64e-6	Dilated cardiomyopathy;
TGCT	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg14983838	chr19:29218262	NA	0.75	6.87	0.53	2.69e-10	Methadone dose in opioid dependence;
TGCT	cis	rs17221829	0.574	rs7930964	chr11:89377313	A/T	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.63	-0.38	9.13e-6	Anxiety in major depressive disorder;
TGCT	cis	rs2236918	0.687	rs2797600	chr1:242029331	C/T	cg04158730	chr1:242011433	EXO1	0.56	5.2	0.42	8.05e-7	Menopause (age at onset);
TGCT	cis	rs3748682	0.861	rs28411034	chr1:38276997	G/A	cg04496824	chr1:38276835	MTF1	0.21	4.61	0.38	1.01e-5	Hypothyroidism;
TGCT	cis	rs13242816	0.881	rs56034786	chr7:116106360	T/C	cg16553024	chr7:116138462	CAV2	-0.43	-4.8	-0.4	4.41e-6	P wave duration;
TGCT	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs877282	0.947	rs7923867	chr10:768094	G/A	cg17470449	chr10:769945	NA	0.34	5.13	0.42	1.1e-6	Uric acid levels;
TGCT	cis	rs1669338	0.588	rs3864049	chr3:3186719	T/G	cg16797762	chr3:3221439	CRBN	-0.89	-5.7	-0.46	8.2e-8	White matter integrity;
TGCT	cis	rs614226	0.938	rs7963543	chr12:120923948	C/A	cg10072921	chr12:121022843	NA	-0.42	-4.65	-0.39	8.28e-6	Type 1 diabetes nephropathy;
TGCT	cis	rs78456975	1.000	rs28742145	chr2:1562671	T/C	cg01028140	chr2:1542097	TPO	-0.33	-4.53	-0.38	1.37e-5	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs62064224	0.791	rs11656289	chr17:30761160	T/C	cg18200150	chr17:30822561	MYO1D	0.6	8.46	0.6	6.37e-14	Schizophrenia;
TGCT	cis	rs11098499	0.618	rs28491261	chr4:120294900	C/A	cg09307838	chr4:120376055	NA	0.66	6.45	0.5	2.22e-9	Corneal astigmatism;
TGCT	cis	rs1670533	0.872	rs13108222	chr4:1054256	C/A	cg20887711	chr4:1340912	KIAA1530	0.71	5.7	0.46	8.33e-8	Recombination rate (females);
TGCT	cis	rs8030485	0.536	rs1915724	chr15:79441027	A/G	cg17916960	chr15:79447300	NA	0.4	6.21	0.49	7.4e-9	Left ventricle wall thickness;
TGCT	cis	rs7586879	0.616	rs10203386	chr2:25136866	T/A	cg15423357	chr2:25149977	NA	0.5	4.98	0.41	2.11e-6	Body mass index;
TGCT	cis	rs6882046	0.513	rs446219	chr5:88005827	T/C	cg22951263	chr5:87985283	NA	-0.58	-6.22	-0.49	6.92e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg12963246	chr6:28129442	ZNF389	0.52	5.1	0.42	1.23e-6	Depression;
TGCT	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs889312	0.500	rs185219	chr5:56136492	A/G	cg12311346	chr5:56204834	C5orf35	-0.47	-5.03	-0.41	1.7e-6	Breast cancer;Breast cancer (early onset);
TGCT	cis	rs2688608	0.592	rs12253429	chr10:75496161	C/G	cg15838173	chr10:75533400	FUT11	-0.31	-5.02	-0.41	1.73e-6	Inflammatory bowel disease;
TGCT	cis	rs6089584	0.526	rs6089619	chr20:60610916	C/T	cg06108461	chr20:60628389	TAF4	-0.42	-5.27	-0.43	5.89e-7	Body mass index;
TGCT	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg18876405	chr7:65276391	NA	0.38	5.89	0.47	3.4e-8	Aortic root size;
TGCT	cis	rs9926296	0.562	rs4785725	chr16:89893243	A/G	cg27121462	chr16:89883253	FANCA	0.53	4.94	0.41	2.48e-6	Vitiligo;
TGCT	cis	rs4268898	0.722	rs11680491	chr2:24416292	T/A	cg02683114	chr2:24398427	C2orf84	0.2	4.86	0.4	3.41e-6	Asthma;
TGCT	cis	rs9581857	0.725	rs9319366	chr13:28017722	C/T	cg22138327	chr13:27999177	GTF3A	0.77	5.47	0.44	2.33e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs3015497	0.594	rs35637875	chr14:51132533	T/G	cg04730355	chr14:51134070	SAV1	-0.62	-6.07	-0.48	1.46e-8	Mean platelet volume;
TGCT	cis	rs6500602	0.964	rs62039173	chr16:4463846	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.31	5.19	0.42	8.4e-7	Schizophrenia;
TGCT	cis	rs9517302	0.615	rs9517306	chr13:99097962	T/C	cg22223119	chr13:99095684	FARP1	-0.61	-6.61	-0.51	1.01e-9	Obesity-related traits;
TGCT	cis	rs7412746	0.658	rs3768016	chr1:150809919	T/C	cg04414720	chr1:150670196	GOLPH3L	0.38	4.69	0.39	7.01e-6	Melanoma;
TGCT	cis	rs372883	0.600	rs2832298	chr21:30743863	C/G	cg24692254	chr21:30365293	RNF160	0.51	4.55	0.38	1.25e-5	Pancreatic cancer;
TGCT	cis	rs6840360	0.573	rs4696257	chr4:152291689	A/G	cg17479576	chr4:152424074	FAM160A1	-0.45	-4.77	-0.39	5.06e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9616064	0.670	rs11090885	chr22:46951637	C/A	cg04500879	chr22:46327243	WNT7B	0.27	4.53	0.38	1.35e-5	Urate levels in obese individuals;
TGCT	cis	rs2180341	0.842	rs7739679	chr6:127545428	G/A	cg24812749	chr6:127587940	RNF146	0.91	6.39	0.5	3.02e-9	Breast cancer;
TGCT	cis	rs57590327	0.503	rs1524557	chr3:81892031	A/G	cg07356753	chr3:81810745	GBE1	-0.67	-6.18	-0.49	8.32e-9	Extraversion;
TGCT	cis	rs6733011	0.628	rs6726156	chr2:99458607	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.47	-4.72	-0.39	6.14e-6	Bipolar disorder;
TGCT	cis	rs6988636	1.000	rs13260798	chr8:124190192	G/A	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs1552244	0.608	rs2075310	chr3:10067651	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.32	-4.67	-0.39	7.58e-6	Alzheimer's disease;
TGCT	cis	rs9787249	0.957	rs3738673	chr1:40204823	C/T	cg19912559	chr1:40204330	PPIE	0.49	5.7	0.46	8.41e-8	Blood protein levels;
TGCT	cis	rs7647973	0.626	rs9835157	chr3:49797769	G/A	cg03034192	chr3:50606346	HEMK1;C3orf18	-0.36	-4.75	-0.39	5.61e-6	Menarche (age at onset);
TGCT	cis	rs2204008	0.684	rs11514164	chr12:38036494	C/T	cg26384229	chr12:38710491	ALG10B	0.85	7.77	0.57	2.56e-12	Bladder cancer;
TGCT	cis	rs9894429	0.646	rs6565609	chr17:79592267	G/A	cg21028142	chr17:79581711	NPLOC4	0.29	5.95	0.47	2.56e-8	Eye color traits;
TGCT	cis	rs3771570	0.901	rs4675963	chr2:242324763	G/A	cg21155796	chr2:242212141	HDLBP	0.84	6.32	0.49	4.39e-9	Prostate cancer;
TGCT	cis	rs9926296	0.682	rs467357	chr16:89717397	A/G	cg26513180	chr16:89883248	FANCA	-0.68	-6.33	-0.49	4.16e-9	Vitiligo;
TGCT	cis	rs10464366	0.560	rs12701692	chr7:39135551	A/G	cg15212455	chr7:39170539	POU6F2	0.23	5.3	0.43	5.16e-7	IgG glycosylation;
TGCT	cis	rs587847	0.737	rs4924143	chr15:37624260	A/C	cg00216138	chr15:37171175	LOC145845	0.3	4.52	0.38	1.43e-5	Intraocular pressure;
TGCT	cis	rs2180341	0.782	rs4487601	chr6:127723521	A/G	cg27446573	chr6:127587934	RNF146	0.8	7.08	0.54	9.53e-11	Breast cancer;
TGCT	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg02353165	chr6:42928485	GNMT	0.94	9.64	0.65	9.69e-17	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs7324557	0.717	rs9553071	chr13:24381379	A/C	cg16602799	chr13:25254742	ATP12A	0.57	4.45	0.37	1.93e-5	Visceral adipose tissue adjusted for BMI;
TGCT	cis	rs644799	0.582	rs1727149	chr11:95497171	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.68	-6.96	-0.53	1.76e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg05552183	chr6:42928497	GNMT	0.58	5.23	0.43	6.89e-7	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs7666738	0.515	rs13118898	chr4:98792893	T/A	cg05340658	chr4:99064831	C4orf37	0.51	5.65	0.45	1.03e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2243480	1.000	rs316315	chr7:65591205	C/T	cg07424592	chr7:64974309	NA	-1.12	-7.33	-0.55	2.55e-11	Diabetic kidney disease;
TGCT	cis	rs10206020	0.921	rs10177509	chr2:1568536	T/C	cg12573674	chr2:1569213	NA	-0.49	-5.41	-0.44	3.17e-7	IgG glycosylation;
TGCT	cis	rs2797160	1.000	rs6927161	chr6:126015954	T/C	cg05901451	chr6:126070800	HEY2	0.73	6.29	0.49	5.01e-9	Endometrial cancer;
TGCT	cis	rs1215050	0.740	rs783929	chr4:98972495	T/A	cg17366294	chr4:99064904	C4orf37	-0.55	-5.8	-0.46	5.23e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg06636001	chr8:8085503	FLJ10661	-0.85	-8.83	-0.62	8.3e-15	Schizophrenia;
TGCT	cis	rs7565124	1.000	rs12471796	chr2:20256192	G/A	cg00462460	chr2:20212509	MATN3	-0.46	-5.01	-0.41	1.85e-6	Major depressive disorder;
TGCT	cis	rs7611238	0.583	rs7621133	chr3:195143983	T/C	cg27323046	chr3:195102265	ACAP2	0.37	4.97	0.41	2.17e-6	Body mass index;
TGCT	cis	rs4862307	0.964	rs4862305	chr4:184996810	A/G	cg06737308	chr4:185021514	ENPP6	0.45	6.71	0.52	6.04e-10	Serum dimethylarginine levels (asymmetric/symetric ratio);
TGCT	cis	rs1943345	0.642	rs642669	chr11:82892454	A/T	cg07047830	chr11:82868014	PCF11	0.53	5.23	0.43	6.89e-7	Obesity-related traits;
TGCT	cis	rs10751667	0.666	rs10902248	chr11:957742	A/G	cg06064525	chr11:970664	AP2A2	-0.35	-8.22	-0.59	2.29e-13	Alzheimer's disease (late onset);
TGCT	cis	rs35306767	0.855	rs11253499	chr10:944090	A/C	cg20503657	chr10:835505	NA	0.75	10.55	0.69	5.67e-19	Eosinophil percentage of granulocytes;
TGCT	trans	rs77457752	0.690	rs17224436	chr9:13912875	C/T	cg23609682	chr1:3070786	PRDM16	-0.52	-7.07	-0.54	9.77e-11	Breast cancer;
TGCT	cis	rs17331151	0.505	rs13086936	chr3:52659079	T/C	cg24616795	chr3:53032891	SFMBT1	0.58	4.85	0.4	3.59e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs6582630	0.519	rs10880576	chr12:38497693	T/C	cg26384229	chr12:38710491	ALG10B	0.82	7.5	0.56	1.07e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs17122693	0.688	rs72681637	chr14:51152761	C/A	cg04730355	chr14:51134070	SAV1	1.32	11.47	0.72	3.4e-21	Cognitive performance;
TGCT	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg21237687	chr17:6899380	ALOX12	0.52	5.59	0.45	1.36e-7	Tonsillectomy;
TGCT	cis	rs797680	0.786	rs1426318	chr1:93847420	A/G	cg17826107	chr1:92977322	EVI5	-0.23	-5.51	-0.44	2.01e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs2739330	1.000	rs2739330	chr22:24295286	T/C	cg12419862	chr22:24373484	LOC391322	-0.8	-8.66	-0.61	2.07e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs3751972	0.911	rs4796222	chr17:26216786	A/G	cg02948944	chr17:26242737	NA	0.49	7.07	0.54	1.02e-10	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs9291683	0.595	rs35501905	chr4:10053431	C/T	cg00071950	chr4:10020882	SLC2A9	0.67	8.39	0.6	9.38e-14	Bone mineral density;
TGCT	cis	rs1949733	1.000	rs868105	chr4:8501030	G/T	cg11789530	chr4:8429930	ACOX3	-0.64	-5.95	-0.47	2.52e-8	Response to antineoplastic agents;
TGCT	cis	rs10788264	0.590	rs2421012	chr10:124063452	G/C	cg09507567	chr10:124027408	NA	0.39	5.46	0.44	2.5e-7	Total body bone mineral density;
TGCT	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg08280861	chr8:58055591	NA	0.39	4.86	0.4	3.45e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs72781680	0.716	rs78332127	chr2:24150163	C/G	cg08917208	chr2:24149416	ATAD2B	0.74	4.66	0.39	7.9e-6	Lymphocyte counts;
TGCT	trans	rs66573146	0.808	rs55942328	chr4:6990960	T/G	cg07817883	chr1:32538562	TMEM39B	1.32	6.94	0.53	1.92e-10	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs7267979	0.789	rs62213729	chr20:25363426	C/T	cg21995068	chr20:25989032	LOC100134868	0.43	5.19	0.42	8.41e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3820928	0.874	rs1917123	chr2:227889783	T/G	cg11843606	chr2:227700838	RHBDD1	-0.55	-5.05	-0.41	1.52e-6	Pulmonary function;
TGCT	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg22166914	chr1:53195759	ZYG11B	-0.46	-8.45	-0.6	6.74e-14	Monocyte count;
TGCT	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg22535103	chr8:58192502	C8orf71	-0.41	-5.24	-0.43	6.57e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs3008870	1.000	rs12132068	chr1:67451924	G/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.1	-11.89	-0.73	3.08e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs3096299	0.933	rs889576	chr16:89429653	A/G	cg05504729	chr16:89399490	ANKRD11	0.2	4.45	0.37	1.92e-5	Multiple myeloma (IgH translocation);
TGCT	cis	rs9788682	0.747	rs2036533	chr15:78781687	G/A	cg24631222	chr15:78858424	CHRNA5	0.61	4.51	0.38	1.5e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs6495122	0.699	rs12905199	chr15:75070196	A/G	cg10253484	chr15:75165896	SCAMP2	-0.68	-5.88	-0.47	3.53e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
TGCT	cis	rs78456975	1.000	rs13413356	chr2:1553849	G/T	cg01028140	chr2:1542097	TPO	-0.35	-4.57	-0.38	1.17e-5	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs12210905	1.000	rs9368493	chr6:27228300	T/G	cg08851530	chr6:28072375	NA	0.94	4.88	0.4	3.17e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs9467711	0.606	rs9358935	chr6:26369587	A/G	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs858239	0.600	rs7790157	chr7:23126998	G/A	cg05602783	chr7:23145260	KLHL7	-0.64	-5.37	-0.43	3.69e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs9926296	0.632	rs2011925	chr16:89814064	T/G	cg08627397	chr16:89984028	MC1R	-0.32	-4.94	-0.41	2.46e-6	Vitiligo;
TGCT	cis	rs2439831	0.850	rs60883262	chr15:44076503	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	5.9	0.47	3.18e-8	Lung cancer in ever smokers;
TGCT	cis	rs9653442	0.866	rs11123811	chr2:100760172	T/C	cg22139774	chr2:100720529	AFF3	-0.45	-8.17	-0.59	2.99e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg06873352	chr17:61820015	STRADA	0.56	6.19	0.49	8.27e-9	Prudent dietary pattern;
TGCT	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg03709012	chr19:19516395	GATAD2A	0.67	5.74	0.46	6.83e-8	Tonsillectomy;
TGCT	cis	rs950169	0.580	rs11630887	chr15:85193015	A/T	cg11189052	chr15:85197271	WDR73	0.77	6.47	0.5	2.1e-9	Schizophrenia;
TGCT	cis	rs6987853	0.686	rs10087350	chr8:42359484	G/A	cg20539142	chr8:42623718	CHRNA6	0.19	4.48	0.37	1.67e-5	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs6598955	0.617	rs11247895	chr1:26599542	G/A	cg04990556	chr1:26633338	UBXN11	0.66	5.0	0.41	1.88e-6	Obesity-related traits;
TGCT	trans	rs28735056	0.904	rs72980087	chr18:77632194	G/A	cg05926928	chr17:57297772	GDPD1	-0.71	-7.6	-0.56	6.2e-12	Schizophrenia;
TGCT	cis	rs9611565	0.512	rs9611667	chr22:42187015	C/T	cg03806693	chr22:41940476	POLR3H	-1.01	-10.3	-0.68	2.33e-18	Vitiligo;
TGCT	cis	rs9486715	1.000	rs9398148	chr6:97063555	A/G	cg18709589	chr6:96969512	KIAA0776	-0.77	-7.12	-0.54	7.74e-11	Headache;
TGCT	cis	rs9549367	0.789	rs2302757	chr13:113909339	A/G	cg00898013	chr13:113819073	PROZ	-0.4	-5.03	-0.41	1.64e-6	Platelet distribution width;
TGCT	cis	rs1018836	0.886	rs10283086	chr8:91616651	G/A	cg16814680	chr8:91681699	NA	-0.83	-8.65	-0.61	2.22e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7605378	0.528	rs1704190	chr2:200760629	G/A	cg19045956	chr2:200819837	C2orf60;C2orf47	0.55	5.87	0.47	3.71e-8	Osteoporosis;
TGCT	cis	rs909674	0.515	rs9611170	chr22:39784845	G/C	cg01416388	chr22:39784598	NA	-0.74	-7.48	-0.56	1.16e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs9611565	0.592	rs12484254	chr22:41962003	T/A	cg17554472	chr22:41940697	POLR3H	-0.48	-4.94	-0.41	2.47e-6	Vitiligo;
TGCT	cis	rs4888262	0.514	rs8048239	chr16:74578317	A/T	cg01733217	chr16:74700730	RFWD3	0.71	7.11	0.54	7.94e-11	Testicular germ cell tumor;
TGCT	cis	rs10464366	0.544	rs6952466	chr7:39155032	A/T	cg15212455	chr7:39170539	POU6F2	0.31	7.11	0.54	7.92e-11	IgG glycosylation;
TGCT	cis	rs782590	0.935	rs782606	chr2:55886602	T/C	cg03859395	chr2:55845619	SMEK2	0.91	10.8	0.7	1.46e-19	Metabolic syndrome;
TGCT	cis	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg08045932	chr20:61659980	NA	0.49	9.23	0.64	9.11e-16	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2963155	0.518	rs853179	chr5:142634773	G/T	cg17617527	chr5:142782415	NR3C1	0.85	6.29	0.49	4.9e-9	Breast cancer;
TGCT	cis	rs12477438	0.798	rs13409996	chr2:99575497	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-8.65	-0.61	2.22e-14	Chronic sinus infection;
TGCT	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg10802521	chr3:52805072	NEK4	-0.72	-9.11	-0.63	1.82e-15	Bipolar disorder;
TGCT	cis	rs7615952	0.551	rs6438945	chr3:125634473	G/A	cg05084668	chr3:125655381	ALG1L	-0.63	-4.62	-0.38	9.36e-6	Blood pressure (smoking interaction);
TGCT	cis	rs2013441	1.000	rs2158473	chr17:20139090	T/C	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.63	-0.38	9.19e-6	Obesity-related traits;
TGCT	cis	rs4803468	1.000	rs2231940	chr19:41944237	T/C	cg09537434	chr19:41945824	ATP5SL	0.91	10.05	0.67	9.48e-18	Height;
TGCT	cis	rs7666738	0.830	rs6830124	chr4:99054872	C/T	cg17366294	chr4:99064904	C4orf37	-0.74	-7.44	-0.56	1.43e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7805747	0.961	rs10265221	chr7:151414329	T/C	cg17611936	chr7:151411526	PRKAG2	0.56	6.71	0.52	6.25e-10	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
TGCT	cis	rs7020830	0.898	rs7846747	chr9:37167539	A/C	cg14294708	chr9:37120828	ZCCHC7	1.27	18.18	0.85	8.66e-37	Schizophrenia;
TGCT	cis	rs7043114	0.525	rs7850432	chr9:95130510	G/A	cg14631576	chr9:95140430	CENPP	-0.27	-4.47	-0.37	1.75e-5	Height;
TGCT	cis	rs11711311	1.000	rs2603792	chr3:113509187	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.7	-6.64	-0.51	8.96e-10	IgG glycosylation;
TGCT	cis	rs12134133	1.000	rs10442696	chr1:207438128	A/T	cg02152968	chr1:207494213	CD55	0.61	4.66	0.39	7.94e-6	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs933688	1.000	rs11948075	chr5:90680579	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.96	8.05	0.59	5.84e-13	Smoking behavior;
TGCT	cis	rs1057239	0.739	rs1014554	chr1:175133626	A/G	cg00321850	chr1:175162397	KIAA0040	0.38	5.04	0.41	1.61e-6	Diastolic blood pressure;
TGCT	cis	rs11792861	0.926	rs1051474	chr9:111881856	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.49	4.6	0.38	1.02e-5	Menarche (age at onset);
TGCT	cis	rs7666738	0.546	rs1813970	chr4:98887167	A/G	cg17366294	chr4:99064904	C4orf37	-0.67	-5.88	-0.47	3.59e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6089829	0.962	rs3746747	chr20:61667631	T/C	cg03213289	chr20:61660250	NA	0.67	9.64	0.65	9.17e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7017914	0.905	rs1389206	chr8:71924862	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.56	-5.11	-0.42	1.21e-6	Bone mineral density;
TGCT	cis	rs9902453	0.817	rs4794861	chr17:28183174	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.74	6.79	0.52	4.12e-10	Coffee consumption (cups per day);
TGCT	cis	rs826838	0.967	rs7963716	chr12:38876090	C/T	cg13010199	chr12:38710504	ALG10B	0.67	5.72	0.46	7.57e-8	Heart rate;
TGCT	cis	rs908922	0.887	rs1415432	chr1:152480654	G/A	cg20991723	chr1:152506922	NA	0.45	5.74	0.46	7e-8	Hair morphology;
TGCT	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg03351412	chr1:154909251	PMVK	0.53	4.93	0.4	2.6e-6	Prostate cancer;
TGCT	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg05872129	chr22:39784769	NA	-0.98	-10.82	-0.7	1.27e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs9549260	0.709	rs9549240	chr13:41186644	T/G	cg21288729	chr13:41239152	FOXO1	1.01	10.53	0.69	6.43e-19	Red blood cell count;
TGCT	cis	rs763014	0.898	rs916416	chr16:632198	T/A	cg09263875	chr16:632152	PIGQ	0.3	6.4	0.5	2.88e-9	Height;
TGCT	cis	rs2204008	0.807	rs12816136	chr12:38456037	A/G	cg26384229	chr12:38710491	ALG10B	-0.8	-7.43	-0.56	1.51e-11	Bladder cancer;
TGCT	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg11301795	chr4:187892539	NA	-0.34	-5.2	-0.42	7.94e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3845702	1.000	rs9989852	chr2:180839707	G/A	cg01881094	chr2:180872142	CWC22	-0.68	-6.06	-0.48	1.51e-8	Schizophrenia;
TGCT	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg04944784	chr2:26401820	FAM59B	0.76	6.24	0.49	6.46e-9	Gut microbiome composition (summer);
TGCT	cis	rs2458413	0.542	rs2853146	chr8:105370179	G/A	cg04554929	chr8:105342491	NA	0.48	5.77	0.46	5.95e-8	Paget's disease;
TGCT	cis	rs380904	0.963	rs410836	chr8:144576849	A/G	cg22012530	chr8:144635309	GSDMD	0.49	4.97	0.41	2.16e-6	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs9399135	0.967	rs2327580	chr6:135364417	A/C	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.21e-6	Red blood cell count;
TGCT	cis	rs4319547	0.656	rs10773075	chr12:122814236	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.6	-4.62	-0.38	9.46e-6	Body mass index;
TGCT	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs7264396	0.790	rs6058283	chr20:34216276	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.28	-4.67	-0.39	7.62e-6	Total cholesterol levels;
TGCT	cis	rs7394579	1	rs7394579	chr11:61581450	A/G	cg19610905	chr11:61596333	FADS2	-0.96	-8.96	-0.63	4.02e-15	Red cell distribution width;Mean platelet volume;
TGCT	cis	rs12549902	0.871	rs4736819	chr8:41509915	C/T	cg00088007	chr8:41504566	NKX6-3	0.3	4.69	0.39	7.04e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
TGCT	cis	rs11190604	1.000	rs11190558	chr10:102209397	C/A	cg16342193	chr10:102329863	NA	-0.4	-5.31	-0.43	4.85e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs6121246	0.529	rs6060296	chr20:30198480	T/C	cg10886678	chr20:30946050	ASXL1	-0.71	-4.8	-0.4	4.39e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs8020441	0.588	rs67963325	chr14:51181339	C/G	cg04730355	chr14:51134070	SAV1	1.01	7.33	0.55	2.58e-11	Cognitive performance;
TGCT	cis	rs68170813	0.559	rs1018947	chr7:106851939	A/T	cg02696742	chr7:106810147	HBP1	-0.71	-5.83	-0.46	4.43e-8	Coronary artery disease;
TGCT	cis	rs12902680	0.710	rs8036009	chr15:46419244	G/A	cg13605988	chr15:45421612	DUOX1;DUOXA1	0.33	4.59	0.38	1.08e-5	Neuroticism;
TGCT	cis	rs7666738	0.830	rs13138059	chr4:99050430	A/G	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs730566	1.000	rs730566	chr3:48487048	G/T	cg07636037	chr3:49044803	WDR6	-0.61	-4.86	-0.4	3.47e-6	Prion diseases;
TGCT	trans	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.88	9.9	0.66	2.18e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs3015497	0.616	rs11157759	chr14:51087263	A/G	cg04730355	chr14:51134070	SAV1	-0.61	-6.01	-0.48	1.89e-8	Mean platelet volume;
TGCT	trans	rs7824557	0.564	rs2572379	chr8:11237480	A/G	cg15556689	chr8:8085844	FLJ10661	-0.74	-6.68	-0.51	7.12e-10	Retinal vascular caliber;
TGCT	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.49	-6.64	-0.51	8.8e-10	Alzheimer's disease;
TGCT	cis	rs8031584	0.697	rs798080	chr15:31122169	T/C	cg14829155	chr15:31115871	NA	0.37	4.9	0.4	2.96e-6	Huntington's disease progression;
TGCT	cis	rs6882046	0.513	rs194225	chr5:88001186	A/G	cg22951263	chr5:87985283	NA	-0.61	-6.54	-0.51	1.47e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg03517284	chr6:25882590	NA	-0.66	-7.18	-0.54	5.71e-11	Blood metabolite levels;
TGCT	cis	rs13242816	1.000	rs62468973	chr7:116125834	G/T	cg02799643	chr7:116139180	CAV2	-0.45	-5.46	-0.44	2.49e-7	P wave duration;
TGCT	cis	rs6671200	0.607	rs1927043	chr1:95667251	G/A	cg06440946	chr1:95699313	RWDD3	-0.65	-5.51	-0.44	1.95e-7	Stearic acid (18:0) levels;
TGCT	cis	rs77140172	0.677	rs77860352	chr4:89627774	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	1.28	5.48	0.44	2.32e-7	Post bronchodilator FEV1;
TGCT	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg05368731	chr17:41323189	NBR1	1.21	14.63	0.8	8.89e-29	Menopause (age at onset);
TGCT	cis	rs12200560	0.505	rs4839848	chr6:97076577	G/A	cg06623918	chr6:96969491	KIAA0776	0.59	5.03	0.41	1.71e-6	Coronary heart disease;
TGCT	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg03180552	chr7:157981849	PTPRN2	0.31	4.77	0.39	5.14e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6003958	1	rs6003958	chr22:24264089	T/G	cg15242686	chr22:24348715	GSTTP1	-0.46	-5.33	-0.43	4.42e-7	S-phenylmercapturic acid levels in smokers;
TGCT	cis	rs2239815	0.515	rs12170231	chr22:29237824	C/T	cg02153584	chr22:29168773	CCDC117	0.67	4.57	0.38	1.17e-5	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
TGCT	cis	rs4629710	0.592	rs749375	chr6:131553692	C/G	cg12606694	chr6:131520996	AKAP7	0.4	4.72	0.39	6.18e-6	Multiple myeloma (IgH translocation);
TGCT	trans	rs11082490	0.947	rs12604912	chr18:43420584	G/C	cg05654096	chr12:106477691	NUAK1	0.55	6.66	0.51	8.03e-10	Response to paliperidone in schizophrenia (positive Marder score);Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs7246657	0.943	rs2126977	chr19:37995747	C/G	cg18154014	chr19:37997991	ZNF793	-0.71	-5.05	-0.41	1.51e-6	Coronary artery calcification;
TGCT	cis	rs11190604	0.943	rs113791644	chr10:102324330	T/G	cg16342193	chr10:102329863	NA	-0.39	-4.65	-0.39	8.29e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs6922269	0.673	rs6902496	chr6:151261637	C/T	cg06091934	chr6:150278437	NA	-0.3	-5.22	-0.42	7.21e-7	Coronary heart disease;
TGCT	cis	rs7236492	0.683	rs78250476	chr18:77198934	G/A	cg15644404	chr18:77186268	NFATC1	-0.35	-4.76	-0.39	5.22e-6	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs317689	0.613	rs315112	chr12:69785926	T/A	cg11871910	chr12:69753446	YEATS4	0.57	5.09	0.42	1.27e-6	Response to diuretic therapy;
TGCT	cis	rs13191362	1.000	rs67747005	chr6:163150845	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.9	7.83	0.58	1.87e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs6503863	1	rs6503863	chr17:56517034	G/A	cg12560992	chr17:57184187	TRIM37	0.61	6.97	0.53	1.65e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg02725872	chr8:58115012	NA	-0.38	-4.66	-0.39	8.13e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs981844	0.617	rs4077965	chr4:154710520	G/C	cg14289246	chr4:154710475	SFRP2	1.08	10.27	0.68	2.72e-18	Response to statins (LDL cholesterol change);
TGCT	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg06634786	chr22:41940651	POLR3H	-0.88	-8.54	-0.61	3.98e-14	Vitiligo;
TGCT	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	16.1	0.82	3.69e-32	Prudent dietary pattern;
TGCT	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7666738	0.819	rs62318904	chr4:99036101	A/T	cg18180107	chr4:99064573	C4orf37	0.59	5.37	0.43	3.73e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2295359	0.892	rs11209004	chr1:67613932	G/A	cg08029281	chr1:67600428	NA	0.4	4.6	0.38	1.02e-5	Psoriasis;
TGCT	cis	rs7953249	0.656	rs1732391	chr12:121392341	C/T	cg02403541	chr12:121454288	C12orf43	-0.62	-5.3	-0.43	5.11e-7	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs13326165	0.760	rs2335640	chr3:52368387	T/C	cg07884673	chr3:53033167	SFMBT1	0.39	4.69	0.39	7e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs6570726	0.755	rs2103633	chr6:145894021	C/T	cg23711669	chr6:146136114	FBXO30	0.86	9.54	0.65	1.64e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs950027	0.967	rs2643718	chr15:45794662	T/C	cg26924012	chr15:45694286	SPATA5L1	0.46	4.85	0.4	3.7e-6	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs11190604	1.000	rs10883499	chr10:102232188	T/A	cg23241863	chr10:102295624	HIF1AN	0.62	4.87	0.4	3.27e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs3858526	0.959	rs61876224	chr11:5952859	G/A	cg05234568	chr11:5960015	NA	-0.44	-4.52	-0.38	1.44e-5	DNA methylation (variation);
TGCT	cis	rs4891159	0.548	rs12454625	chr18:74128751	A/G	cg24786174	chr18:74118243	ZNF516	0.67	13.58	0.77	2.65e-26	Longevity;
TGCT	cis	rs12110303	1	rs12110303	chr5:90662839	G/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	10.08	0.67	8e-18	Breast cancer;
TGCT	cis	rs9807989	0.839	rs11695627	chr2:102970105	A/G	cg09003973	chr2:102972529	NA	0.64	5.7	0.46	8.28e-8	Asthma;
TGCT	cis	rs2070488	0.775	rs6794397	chr3:38559307	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.71	6.89	0.53	2.46e-10	Electrocardiographic conduction measures;
TGCT	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.73	-6.5	-0.5	1.8e-9	Tonsillectomy;
TGCT	cis	rs17345786	0.817	rs11720560	chr3:101328484	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.88	9.23	0.64	9.1e-16	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg06221963	chr1:154839813	KCNN3	-0.73	-12.14	-0.74	8.04e-23	Prostate cancer;
TGCT	cis	rs11688237	0.901	rs4662352	chr2:144559796	T/C	cg07409629	chr2:144282743	ARHGAP15	-0.36	-4.59	-0.38	1.05e-5	Chin dimples;
TGCT	cis	rs2046867	0.818	rs17010195	chr3:72872852	A/G	cg25664220	chr3:72788482	NA	0.52	6.37	0.5	3.28e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs644799	1.000	rs527899	chr11:95529242	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	10.57	0.69	5.17e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs524281	0.861	rs3825067	chr11:65878419	A/G	cg00563793	chr11:65837595	PACS1	-0.53	-4.56	-0.38	1.23e-5	Electroencephalogram traits;
TGCT	cis	rs10193935	0.748	rs11124879	chr2:42697576	C/A	cg27598129	chr2:42591480	NA	0.38	5.14	0.42	1.05e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg22920501	chr2:26401640	FAM59B	-0.72	-6.26	-0.49	5.68e-9	Gut microbiome composition (summer);
TGCT	cis	rs8078723	0.677	rs8073254	chr17:38149350	C/G	cg17467752	chr17:38218738	THRA	-0.53	-5.37	-0.43	3.8e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs11098499	0.865	rs11098513	chr4:120316075	A/G	cg09307838	chr4:120376055	NA	0.7	6.94	0.53	1.9e-10	Corneal astigmatism;
TGCT	cis	rs6988636	1.000	rs57902736	chr8:124189893	G/A	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs9341808	0.628	rs2490245	chr6:80892427	A/G	cg08355045	chr6:80787529	NA	0.31	5.1	0.42	1.26e-6	Sitting height ratio;
TGCT	cis	rs7605378	0.964	rs2689763	chr2:200689555	G/A	cg17644776	chr2:200775616	C2orf69	0.29	5.51	0.44	1.94e-7	Osteoporosis;
TGCT	cis	rs62380364	0.837	rs17487515	chr5:88149291	A/G	cg22951263	chr5:87985283	NA	-0.48	-4.62	-0.38	9.39e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs8141529	0.732	rs5752798	chr22:29181868	A/G	cg02153584	chr22:29168773	CCDC117	0.73	6.22	0.49	7.04e-9	Lymphocyte counts;
TGCT	cis	rs3015497	0.586	rs12587842	chr14:51092562	A/G	cg04730355	chr14:51134070	SAV1	-0.64	-6.04	-0.48	1.64e-8	Mean platelet volume;
TGCT	cis	rs68170813	0.523	rs4730241	chr7:107057361	G/A	cg02696742	chr7:106810147	HBP1	-0.7	-5.68	-0.45	8.91e-8	Coronary artery disease;
TGCT	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg11494091	chr17:61959527	GH2	0.61	14.34	0.79	4.3e-28	Prudent dietary pattern;
TGCT	cis	rs2762353	0.639	rs566530	chr6:25878361	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.49	4.88	0.4	3.23e-6	Blood metabolite levels;
TGCT	cis	rs208520	0.754	rs851594	chr6:66876695	A/G	cg07460842	chr6:66804631	NA	-0.91	-9.43	-0.65	2.99e-16	Exhaled nitric oxide output;
TGCT	cis	rs56104184	0.775	rs73061692	chr19:49399676	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.73	-9.15	-0.63	1.47e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs4523957	0.583	rs4349181	chr17:2040963	A/G	cg16513277	chr17:2031491	SMG6	-0.2	-4.58	-0.38	1.13e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs968451	0.789	rs1569500	chr22:39683515	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.83	8.2	0.59	2.51e-13	Primary biliary cholangitis;
TGCT	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg20607798	chr8:58055168	NA	0.44	4.6	0.38	1.01e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg10802521	chr3:52805072	NEK4	-0.78	-10.01	-0.67	1.22e-17	Bipolar disorder;
TGCT	cis	rs7772486	0.875	rs1412080	chr6:146417304	T/C	cg23711669	chr6:146136114	FBXO30	0.86	9.3	0.64	6.2e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs497273	0.534	rs9431	chr12:121202664	A/C	cg02419362	chr12:121203948	SPPL3	0.19	4.52	0.38	1.43e-5	Systemic lupus erythematosus;
TGCT	cis	rs2455799	0.613	rs13078485	chr3:15883236	T/C	cg16303742	chr3:15540471	COLQ	-0.25	-4.8	-0.4	4.53e-6	Mean platelet volume;
TGCT	cis	rs10489202	0.683	rs7515429	chr1:168066659	A/G	cg24449463	chr1:168025552	DCAF6	-0.55	-5.73	-0.46	7.31e-8	Schizophrenia;
TGCT	cis	rs2730245	0.527	rs842707	chr7:158656012	C/T	cg11984989	chr7:158649758	WDR60	1.0	7.7	0.57	3.71e-12	Height;
TGCT	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	16.07	0.82	4.21e-32	Prudent dietary pattern;
TGCT	cis	rs28595532	0.920	rs55668908	chr4:119769799	C/T	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs79349575	0.783	rs9912829	chr17:46982749	G/C	cg26022315	chr17:47021804	SNF8	0.48	4.82	0.4	4.06e-6	Type 2 diabetes;
TGCT	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg11494091	chr17:61959527	GH2	0.6	14.51	0.79	1.71e-28	Prudent dietary pattern;
TGCT	cis	rs7824557	0.602	rs7833966	chr8:11206220	C/G	cg21775007	chr8:11205619	TDH	0.73	7.08	0.54	9.46e-11	Retinal vascular caliber;
TGCT	cis	rs9677476	0.516	rs2032953	chr2:232035793	C/T	cg07929768	chr2:232055508	NA	0.33	5.24	0.43	6.78e-7	Food antigen IgG levels;
TGCT	cis	rs6433857	0.505	rs1542036	chr2:181350009	A/C	cg23363182	chr2:181467187	NA	-0.32	-4.85	-0.4	3.59e-6	Body mass index;
TGCT	cis	rs10744422	1.000	rs897385	chr12:123341297	A/G	cg25930673	chr12:123319894	HIP1R	-0.86	-5.02	-0.41	1.72e-6	Schizophrenia;
TGCT	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg20007245	chr22:24372913	LOC391322	-0.8	-8.6	-0.61	2.9e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9300255	0.507	rs1615350	chr12:123650335	C/T	cg00376283	chr12:123451042	ABCB9	0.78	6.68	0.51	7.16e-10	Neutrophil percentage of white cells;
TGCT	cis	rs9467773	0.620	rs2130657	chr6:26650826	C/T	cg02458000	chr6:26745757	NA	0.51	4.59	0.38	1.08e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs35306767	0.903	rs11253488	chr10:922482	G/C	cg20503657	chr10:835505	NA	0.74	10.3	0.68	2.41e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs554111	0.634	rs1453265	chr1:21277711	C/T	cg01072550	chr1:21505969	NA	0.35	5.36	0.43	3.88e-7	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.92	-6.8	-0.52	3.96e-10	Gut microbiome composition (summer);
TGCT	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg02725872	chr8:58115012	NA	0.39	4.84	0.4	3.7e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs708686	0.553	rs778809	chr19:5830302	A/G	cg25387410	chr19:5844109	FUT3	0.19	4.45	0.37	1.89e-5	Vitamin B12 levels;
TGCT	cis	rs9650657	0.644	rs6601535	chr8:10695652	G/C	cg16664915	chr8:10907788	XKR6	-0.29	-4.71	-0.39	6.47e-6	Neuroticism;
TGCT	cis	rs7652177	0.905	rs2220895	chr3:171941098	T/C	cg03587978	chr3:172165696	GHSR	0.27	4.46	0.37	1.84e-5	Height;
TGCT	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg18110333	chr6:292329	DUSP22	-0.66	-7.25	-0.55	3.96e-11	Menopause (age at onset);
TGCT	cis	rs6754311	0.731	rs218174	chr2:136658345	C/T	cg07169764	chr2:136633963	MCM6	-0.56	-5.39	-0.44	3.39e-7	Mosquito bite size;
TGCT	cis	rs6725041	0.819	rs4350692	chr2:213090220	T/C	cg20637307	chr2:213403960	ERBB4	-0.52	-4.47	-0.37	1.72e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs9611565	0.649	rs126092	chr22:42178441	A/G	cg03806693	chr22:41940476	POLR3H	0.92	8.66	0.61	2.13e-14	Vitiligo;
TGCT	cis	rs3749237	1.000	rs6804655	chr3:49738945	C/T	cg10152585	chr3:50297680	NA	0.49	4.47	0.37	1.77e-5	Resting heart rate;
TGCT	trans	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg17830980	chr10:43048298	ZNF37B	-0.81	-10.13	-0.67	6.19e-18	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7568458	0.905	rs6547620	chr2:85755928	C/T	cg17127132	chr2:85788382	GGCX	0.72	6.69	0.51	6.94e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs6534347	0.573	rs6829845	chr4:123510766	C/T	cg10583651	chr4:123538969	IL21	0.35	4.68	0.39	7.33e-6	Type 1 diabetes;
TGCT	cis	rs17270561	1.000	rs12211184	chr6:25823774	G/A	cg17042849	chr6:26104293	HIST1H4C	-0.91	-6.17	-0.48	9.01e-9	Iron status biomarkers;
TGCT	cis	rs868036	0.718	rs28399056	chr15:68116010	C/A	cg05925327	chr15:68127851	NA	-0.51	-5.04	-0.41	1.63e-6	Restless legs syndrome;
TGCT	cis	rs1964356	0.967	rs17701675	chr8:8850633	A/G	cg15556689	chr8:8085844	FLJ10661	-0.74	-6.55	-0.51	1.36e-9	Mean corpuscular volume;
TGCT	cis	rs9467711	1.000	rs9467708	chr6:26327956	T/C	cg03517284	chr6:25882590	NA	-0.86	-4.67	-0.39	7.69e-6	Autism spectrum disorder or schizophrenia;
TGCT	trans	rs2624839	0.704	rs13067082	chr3:50221715	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.78	-6.97	-0.53	1.68e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs593982	0.920	rs521678	chr11:65485727	T/G	cg08755490	chr11:65554678	OVOL1	1.37	8.14	0.59	3.46e-13	Atopic dermatitis;
TGCT	cis	rs6964587	1.000	rs10225885	chr7:91671007	A/G	cg22709100	chr7:91322751	NA	0.28	4.56	0.38	1.19e-5	Breast cancer;
TGCT	cis	rs9646954	0.542	rs3828193	chr2:101031561	A/C	cg08017756	chr2:100939284	LONRF2	0.29	4.53	0.38	1.39e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs3820068	0.603	rs7537618	chr1:15977682	G/A	cg05660106	chr1:15850417	CASP9	0.79	7.46	0.56	1.29e-11	Systolic blood pressure;
TGCT	cis	rs981844	0.816	rs74549610	chr4:154710464	C/G	cg14289246	chr4:154710475	SFRP2	1.05	9.32	0.64	5.44e-16	Response to statins (LDL cholesterol change);
TGCT	cis	rs7769051	1.000	rs6910639	chr6:133120553	A/G	cg22852734	chr6:133119734	C6orf192	1.22	6.9	0.53	2.34e-10	Type 2 diabetes nephropathy;
TGCT	cis	rs896854	0.654	rs13248607	chr8:95986637	T/G	cg13393036	chr8:95962371	TP53INP1	-0.59	-8.08	-0.59	4.84e-13	Type 2 diabetes;
TGCT	cis	rs9325144	0.555	rs1843867	chr12:38703855	A/G	cg26384229	chr12:38710491	ALG10B	-0.68	-6.27	-0.49	5.35e-9	Morning vs. evening chronotype;
TGCT	cis	rs1949733	1.000	rs6447875	chr4:8503206	T/C	cg13073564	chr4:8508604	NA	-0.47	-5.05	-0.41	1.55e-6	Response to antineoplastic agents;
TGCT	cis	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg20362242	chr5:692897	TPPP	0.52	4.65	0.39	8.29e-6	Obesity-related traits;
TGCT	cis	rs3617	0.625	rs6445541	chr3:52880128	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	4.67	0.39	7.57e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4072705	0.646	rs7037254	chr9:127245412	C/T	cg13476313	chr9:127244764	NR5A1	-0.31	-5.18	-0.42	8.87e-7	Menarche (age at onset);
TGCT	cis	rs7267979	0.934	rs2261115	chr20:25259807	G/A	cg03522245	chr20:25566470	NINL	0.64	6.81	0.52	3.7e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7824557	0.564	rs2572395	chr8:11235360	A/C	cg21775007	chr8:11205619	TDH	-0.64	-6.25	-0.49	6.11e-9	Retinal vascular caliber;
TGCT	cis	rs4478858	0.698	rs10914370	chr1:31854955	T/C	cg00250761	chr1:31883323	NA	-0.25	-4.45	-0.37	1.88e-5	Alcohol dependence;
TGCT	cis	rs10114408	0.885	rs10821243	chr9:96638066	C/A	cg13679303	chr9:96623674	NA	-0.36	-4.69	-0.39	6.98e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs111803315	1.000	rs111745772	chr14:60011260	A/G	cg22995959	chr14:59931024	GPR135	0.66	4.8	0.4	4.39e-6	Schizophrenia;
TGCT	cis	rs9291683	0.679	rs13137795	chr4:10051506	G/A	cg00071950	chr4:10020882	SLC2A9	0.68	8.55	0.61	3.86e-14	Bone mineral density;
TGCT	cis	rs896854	0.573	rs13271375	chr8:95853907	A/G	cg13393036	chr8:95962371	TP53INP1	-0.51	-6.26	-0.49	5.79e-9	Type 2 diabetes;
TGCT	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg12963246	chr6:28129442	ZNF389	0.51	5.02	0.41	1.73e-6	Depression;
TGCT	cis	rs3087591	1.000	rs2525578	chr17:29711411	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.49	-7.37	-0.55	2.07e-11	Hip circumference;
TGCT	cis	rs61990749	0.597	rs717683	chr14:78255453	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.61	4.52	0.38	1.43e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg23758822	chr17:41437982	NA	0.71	6.77	0.52	4.56e-10	Menopause (age at onset);
TGCT	cis	rs9467711	0.591	rs9467622	chr6:25854644	C/A	cg16898833	chr6:26189333	HIST1H4D	1.16	5.51	0.44	2.03e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7236492	0.688	rs7241538	chr18:77191247	C/T	cg15644404	chr18:77186268	NFATC1	-0.35	-4.67	-0.39	7.83e-6	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs904251	0.797	rs1776460	chr6:37485484	A/G	cg01843034	chr6:37503916	NA	-0.5	-6.03	-0.48	1.71e-8	Cognitive performance;
TGCT	cis	rs2075165	0.901	rs949464	chr1:156272271	C/T	cg16558208	chr1:156270281	VHLL	0.27	4.83	0.4	3.87e-6	Tonsillectomy;
TGCT	cis	rs4663866	1.000	rs34897410	chr2:239182123	T/C	cg17283117	chr2:239148619	HES6	1.0	4.6	0.38	1.03e-5	Irritable bowel syndrome;
TGCT	cis	rs57920188	0.584	rs12080516	chr1:4089613	C/T	cg20703997	chr1:4087676	NA	0.49	6.2	0.49	7.57e-9	Interleukin-17 levels;
TGCT	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	16.05	0.82	4.59e-32	Prudent dietary pattern;
TGCT	cis	rs909674	0.515	rs9611170	chr22:39784845	G/C	cg02038168	chr22:39784481	NA	-0.72	-6.04	-0.48	1.67e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg01448562	chr3:133502909	NA	-0.33	-6.71	-0.52	6.07e-10	Iron status biomarkers;
TGCT	cis	rs11690935	0.921	rs4668414	chr2:172704291	A/C	cg13550731	chr2:172543902	DYNC1I2	-1.17	-12.1	-0.74	9.69e-23	Schizophrenia;
TGCT	cis	rs66573146	1.000	rs56178503	chr4:6961748	C/T	cg01220768	chr4:7056774	TADA2B	0.35	4.63	0.38	8.96e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs910316	0.934	rs8016330	chr14:75657507	G/T	cg08847533	chr14:75593920	NEK9	-0.94	-9.91	-0.66	2.11e-17	Height;
TGCT	cis	rs968567	0.689	rs61897795	chr11:61618169	A/G	cg19610905	chr11:61596333	FADS2	-0.73	-4.61	-0.38	9.71e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
TGCT	cis	rs7582180	0.676	rs11691135	chr2:100934038	C/T	cg08017756	chr2:100939284	LONRF2	-0.3	-4.78	-0.39	4.95e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7208859	0.615	rs216462	chr17:28895897	T/C	cg13385521	chr17:29058706	SUZ12P	-0.9	-5.43	-0.44	2.88e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.04	0.53	1.16e-10	Prudent dietary pattern;
TGCT	cis	rs2749592	0.550	rs7081464	chr10:37883937	C/T	cg25427524	chr10:38739819	LOC399744	0.3	5.5	0.44	2.04e-7	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs17384381	0.636	rs11161615	chr1:85906816	A/G	cg16011679	chr1:85725395	C1orf52	-0.78	-6.73	-0.52	5.6e-10	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs3780486	0.801	rs56687083	chr9:33132134	A/G	cg04842962	chr6:43655489	MRPS18A	1.24	15.83	0.82	1.46e-31	IgG glycosylation;
TGCT	cis	rs1891498	0.625	rs11552588	chr1:147245383	T/C	cg17941330	chr1:147245494	GJA5	0.36	4.76	0.39	5.28e-6	Cognitive performance;
TGCT	cis	rs2549003	1.000	rs6894655	chr5:131818649	T/C	cg21138405	chr5:131827807	IRF1	0.2	5.08	0.41	1.36e-6	Asthma (sex interaction);
TGCT	cis	rs6121246	0.567	rs6120815	chr20:30184866	T/C	cg18721089	chr20:30220636	NA	-0.63	-6.88	-0.53	2.67e-10	Mean corpuscular hemoglobin;
TGCT	cis	rs9486715	0.867	rs11152924	chr6:96877383	A/G	cg06623918	chr6:96969491	KIAA0776	1.11	16.62	0.83	2.35e-33	Headache;
TGCT	cis	rs2732480	0.577	rs2732457	chr12:48758379	A/G	cg04545296	chr12:48745243	ZNF641	-0.35	-4.48	-0.37	1.68e-5	Hemoglobin concentration;Red blood cell count;Hematocrit;
TGCT	cis	rs1215050	0.791	rs165244	chr4:98687889	C/T	cg17366294	chr4:99064904	C4orf37	0.52	5.53	0.45	1.77e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9400467	0.506	rs4639374	chr6:111458270	A/G	cg15721981	chr6:111408429	SLC16A10	0.71	4.59	0.38	1.05e-5	Blood metabolite levels;Amino acid levels;
TGCT	cis	rs9527	0.614	rs4919691	chr10:104624475	A/C	cg04362960	chr10:104952993	NT5C2	0.56	4.79	0.4	4.65e-6	Arsenic metabolism;
TGCT	cis	rs62244186	0.715	rs11130032	chr3:44704083	G/A	cg21672276	chr3:44754072	ZNF502	-0.43	-4.76	-0.39	5.31e-6	Depressive symptoms;
TGCT	cis	rs933688	0.938	rs12110065	chr5:90718474	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.02	8.42	0.6	7.65e-14	Smoking behavior;
TGCT	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg10128416	chr1:75198403	TYW3;CRYZ	-0.42	-4.63	-0.38	9.15e-6	Resistin levels;
TGCT	cis	rs1372520	0.766	rs2583961	chr4:90779758	A/G	cg15133208	chr4:90757351	SNCA	-0.53	-6.26	-0.49	5.76e-9	Neuroticism;
TGCT	cis	rs17387100	0.901	rs73230225	chr4:15983944	C/T	cg13480465	chr4:16795757	LDB2	-0.42	-4.86	-0.4	3.45e-6	Suicide attempts in depression or bipolar disorder;
TGCT	cis	rs6701037	0.566	rs10753091	chr1:175134571	T/C	cg08873628	chr1:175162347	KIAA0040	0.48	4.57	0.38	1.15e-5	Alcohol dependence;
TGCT	cis	rs4285028	0.699	rs73855465	chr3:121574219	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.79	-6.66	-0.51	8.01e-10	Multiple sclerosis;
TGCT	cis	rs11719291	0.915	rs1048940	chr3:48725707	C/T	cg00383909	chr3:49044727	WDR6	1.54	5.91	0.47	3.14e-8	Cognitive function;
TGCT	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg06618935	chr21:46677482	NA	-0.36	-5.37	-0.43	3.7e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9486719	0.947	rs2472908	chr6:96875998	A/T	cg06623918	chr6:96969491	KIAA0776	1.01	8.73	0.62	1.42e-14	Migraine;Coronary artery disease;
TGCT	cis	rs4851254	0.660	rs56037757	chr2:100690130	A/G	cg22139774	chr2:100720529	AFF3	-0.45	-4.91	-0.4	2.75e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs11711311	1.000	rs2305545	chr3:113499733	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.76	-7.16	-0.54	6.29e-11	IgG glycosylation;
TGCT	cis	rs526231	0.853	rs377192	chr5:102603554	C/T	cg05225461	chr5:102596755	C5orf30	0.23	4.62	0.38	9.51e-6	Primary biliary cholangitis;
TGCT	cis	rs11264213	0.901	rs2765013	chr1:36374101	C/T	cg07093915	chr1:36184400	C1orf216	0.67	4.62	0.38	9.5e-6	Schizophrenia;
TGCT	cis	rs9911578	0.757	rs4793954	chr17:56629527	G/T	cg05425664	chr17:57184151	TRIM37	0.59	4.95	0.41	2.38e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs950027	0.620	rs1346267	chr15:45690989	A/G	cg26924012	chr15:45694286	SPATA5L1	0.79	8.8	0.62	1e-14	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs2645424	0.550	rs28577034	chr8:11708715	A/T	cg18999641	chr8:11876646	NA	0.21	4.46	0.37	1.8e-5	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
TGCT	cis	rs2445762	0.518	rs6493496	chr15:51628119	A/T	cg00184732	chr15:51633821	GLDN	0.45	5.09	0.42	1.31e-6	Hormone measurements;
TGCT	cis	rs981844	0.922	rs75543972	chr4:154664792	G/C	cg14289246	chr4:154710475	SFRP2	1.0	8.25	0.6	1.96e-13	Response to statins (LDL cholesterol change);
TGCT	cis	rs31872	0.521	rs246050	chr5:140326860	T/G	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Visceral adipose tissue adjusted for BMI;
TGCT	cis	rs9921338	0.961	rs55707838	chr16:11378075	C/T	cg00044050	chr16:11439710	C16orf75	-0.85	-6.04	-0.48	1.64e-8	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs3096299	0.685	rs3803681	chr16:89544756	C/T	cg02244288	chr16:89573955	SPG7	-0.3	-4.5	-0.37	1.53e-5	Multiple myeloma (IgH translocation);
TGCT	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg08048268	chr3:133502702	NA	-0.65	-9.92	-0.67	2.02e-17	Iron status biomarkers;
TGCT	trans	rs35851103	0.627	rs58602899	chr8:11848833	G/T	cg15556689	chr8:8085844	FLJ10661	0.86	8.71	0.62	1.61e-14	Neuroticism;
TGCT	cis	rs2204008	0.837	rs11181857	chr12:38413255	C/G	cg13010199	chr12:38710504	ALG10B	0.57	4.52	0.38	1.41e-5	Bladder cancer;
TGCT	cis	rs2404602	0.646	rs3764245	chr15:77223176	G/C	cg22467129	chr15:76604101	ETFA	-0.46	-4.67	-0.39	7.65e-6	Blood metabolite levels;
TGCT	cis	rs7845219	0.544	rs10956930	chr8:95919786	C/G	cg16049864	chr8:95962084	TP53INP1	-0.48	-5.3	-0.43	5.23e-7	Type 2 diabetes;
TGCT	cis	rs2235649	0.625	rs56206107	chr16:1947425	A/G	cg02432467	chr16:1963432	HS3ST6	-0.32	-4.86	-0.4	3.45e-6	Blood metabolite levels;
TGCT	cis	rs3733585	0.631	rs4697924	chr4:10124239	A/G	cg00071950	chr4:10020882	SLC2A9	-0.48	-4.93	-0.4	2.57e-6	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs2535633	0.631	rs2710314	chr3:52969128	T/C	cg11645453	chr3:52864694	ITIH4	-0.28	-4.98	-0.41	2.12e-6	Body mass index;
TGCT	cis	rs7267979	0.727	rs4815431	chr20:25532405	T/C	cg16686733	chr20:25566563	NINL	-0.52	-5.05	-0.41	1.52e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7666738	0.830	rs13108871	chr4:98803872	T/C	cg17366294	chr4:99064904	C4orf37	0.65	6.69	0.51	7e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9733	0.543	rs72702558	chr1:150683251	G/A	cg04414720	chr1:150670196	GOLPH3L	0.37	4.91	0.4	2.76e-6	Tonsillectomy;
TGCT	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg11366901	chr6:160182831	ACAT2	1.03	6.98	0.53	1.59e-10	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs7937682	0.889	rs7926485	chr11:111536670	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.14	-11.73	-0.73	7.67e-22	Primary sclerosing cholangitis;
TGCT	cis	rs9303401	0.734	rs8073316	chr17:57211381	A/T	cg12560992	chr17:57184187	TRIM37	-0.46	-4.54	-0.38	1.31e-5	Cognitive test performance;
TGCT	cis	rs60871478	0.636	rs4721600	chr7:871728	C/T	cg00475322	chr7:917719	C7orf20	0.48	4.71	0.39	6.54e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs12220238	1.000	rs11000887	chr10:75897542	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.28	0.55	3.4e-11	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg11965913	chr1:205819406	PM20D1	0.61	9.38	0.64	3.9e-16	Menarche (age at onset);
TGCT	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg16680214	chr1:154839983	KCNN3	-0.36	-7.26	-0.55	3.81e-11	Prostate cancer;
TGCT	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg09359103	chr1:154839909	KCNN3	0.61	11.79	0.73	5.54e-22	Prostate cancer;
TGCT	cis	rs9914544	0.545	rs9903574	chr17:18768582	C/T	cg26378065	chr17:18585709	ZNF286B	0.52	4.5	0.37	1.56e-5	Educational attainment (years of education);
TGCT	cis	rs1443512	0.812	rs1992563	chr12:54330441	G/T	cg17708016	chr12:54321992	NA	0.57	4.67	0.39	7.84e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
TGCT	cis	rs61776719	0.875	rs4072980	chr1:38456106	G/A	cg12658694	chr1:38397304	INPP5B	-0.51	-5.13	-0.42	1.06e-6	Coronary artery disease;
TGCT	cis	rs12681287	0.547	rs71502658	chr8:87478785	T/A	cg27223183	chr8:87520930	FAM82B	-0.89	-6.34	-0.49	3.84e-9	Caudate activity during reward;
TGCT	trans	rs9388451	0.839	rs3966775	chr6:126067655	C/A	cg05039488	chr6:79577232	IRAK1BP1	-0.74	-8.3	-0.6	1.49e-13	Brugada syndrome;
TGCT	cis	rs17608059	0.518	rs4792436	chr17:13972307	T/A	cg11395062	chr17:14139857	CDRT15	-0.43	-6.31	-0.49	4.48e-9	Temperament;
TGCT	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs3806843	0.576	rs246017	chr5:140335060	C/T	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs6545883	0.868	rs7594191	chr2:61840018	A/G	cg15711740	chr2:61764176	XPO1	0.56	5.24	0.43	6.57e-7	Tuberculosis;
TGCT	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg01341218	chr17:43662625	NA	1.04	7.82	0.57	1.97e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg07424592	chr7:64974309	NA	1.33	7.68	0.57	4.1e-12	Diabetic kidney disease;
TGCT	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg11494091	chr17:61959527	GH2	-0.6	-14.54	-0.79	1.46e-28	Prudent dietary pattern;
TGCT	cis	rs5769707	0.592	rs6009783	chr22:50011001	C/G	cg05373962	chr22:49881684	NA	-0.29	-4.97	-0.41	2.16e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs926938	0.841	rs11588144	chr1:115239355	G/A	cg12756093	chr1:115239321	AMPD1	-0.53	-8.21	-0.59	2.4e-13	Autism;
TGCT	cis	rs9913156	0.793	rs72835642	chr17:4573407	T/C	cg23387401	chr17:4582204	PELP1	0.31	4.59	0.38	1.09e-5	Lymphocyte counts;
TGCT	cis	rs2574985	0.548	rs2339506	chr10:52258698	C/T	cg12753529	chr10:51525504	NA	0.23	4.55	0.38	1.27e-5	Subjective well-being;
TGCT	cis	rs9311474	0.935	rs7622851	chr3:52333671	C/G	cg10802521	chr3:52805072	NEK4	-0.59	-6.4	-0.5	2.91e-9	Electroencephalogram traits;
TGCT	cis	rs6547741	0.844	rs7586655	chr2:27915659	A/G	cg27432699	chr2:27873401	GPN1	-0.24	-6.05	-0.48	1.57e-8	Oral cavity cancer;
TGCT	cis	rs3820928	0.839	rs13413292	chr2:227893747	G/C	cg11843606	chr2:227700838	RHBDD1	-0.54	-4.96	-0.41	2.29e-6	Pulmonary function;
TGCT	cis	rs4888262	0.508	rs4888258	chr16:74634198	G/T	cg01733217	chr16:74700730	RFWD3	0.74	7.42	0.55	1.6e-11	Testicular germ cell tumor;
TGCT	cis	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg21775007	chr8:11205619	TDH	-0.53	-5.04	-0.41	1.59e-6	Retinal vascular caliber;
TGCT	cis	rs924607	1.000	rs924607	chr5:610093	C/T	cg04476341	chr5:669733	TPPP	-0.26	-4.86	-0.4	3.55e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg19774624	chr17:42201019	HDAC5	0.79	7.37	0.55	2.08e-11	Total body bone mineral density;
TGCT	cis	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg18252515	chr7:66147081	NA	1.2	7.83	0.58	1.89e-12	Diabetic kidney disease;
TGCT	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg17054783	chr10:134559939	INPP5A	0.23	4.82	0.4	4.09e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs6693567	0.545	rs6699093	chr1:150440451	A/G	cg09579323	chr1:150459698	TARS2	-0.52	-4.62	-0.38	9.55e-6	Migraine;
TGCT	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg03517284	chr6:25882590	NA	-0.58	-5.16	-0.42	9.65e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7267979	1.000	rs6076336	chr20:25319212	C/T	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6062509	0.839	rs3859579	chr20:62301795	A/G	cg27236539	chr20:62289627	RTEL1	0.56	4.63	0.38	9.12e-6	Prostate cancer;
TGCT	cis	rs7226408	0.857	rs2166295	chr18:34488481	G/T	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs9291683	0.668	rs2241474	chr4:10086015	T/C	cg11266682	chr4:10021025	SLC2A9	0.57	6.72	0.52	5.97e-10	Bone mineral density;
TGCT	cis	rs8180040	0.577	rs12493425	chr3:47176946	T/G	cg27129171	chr3:47204927	SETD2	0.7	8.55	0.61	3.75e-14	Colorectal cancer;
TGCT	cis	rs6882046	0.513	rs35148765	chr5:88046158	C/A	cg24804195	chr5:87968844	LOC645323	-0.6	-6.06	-0.48	1.48e-8	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs4727027	0.933	rs12704062	chr7:148827865	G/A	cg23583168	chr7:148888333	NA	-0.72	-9.18	-0.64	1.18e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs877426	0.561	rs77687017	chr13:114827394	C/T	cg16820615	chr13:114884918	RASA3	0.31	4.66	0.39	8.17e-6	Facial morphology (factor 14, intercanthal width);
TGCT	cis	rs2413583	0.591	rs114556035	chr22:39734647	C/T	cg24399712	chr22:39784796	NA	0.82	4.48	0.37	1.69e-5	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs7213347	0.581	rs7209460	chr17:2048713	C/T	cg22033759	chr17:1182267	TUSC5	-0.23	-4.65	-0.39	8.4e-6	Total body bone mineral density;
TGCT	cis	rs1865760	0.516	rs9295684	chr6:26069669	T/C	cg16482183	chr6:26056742	HIST1H1C	0.57	4.99	0.41	1.99e-6	Height;
TGCT	cis	rs9427116	0.502	rs12125166	chr1:154582129	A/G	cg17218026	chr1:154582156	ADAR	-0.29	-7.18	-0.54	5.65e-11	Blood protein levels;
TGCT	cis	rs6032067	0.561	rs2743317	chr20:43936931	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.47	-6.99	-0.53	1.47e-10	Blood protein levels;
TGCT	cis	rs11105298	0.786	rs10777186	chr12:89921277	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.67	-4.91	-0.4	2.78e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs75768999	1	rs75768999	chr10:61690195	C/T	cg14316118	chr10:61668184	CCDC6	0.43	5.5	0.44	2.03e-7	3-hydroxypropylmercapturic acid levels in smokers;
TGCT	cis	rs67311347	0.955	rs60554147	chr3:40472503	T/C	cg13683864	chr3:40499215	RPL14	-1.02	-10.32	-0.68	2.06e-18	Renal cell carcinoma;
TGCT	cis	rs2594989	0.943	rs2252601	chr3:11481234	A/G	cg00170343	chr3:11313890	ATG7	0.71	5.3	0.43	5.06e-7	Circulating chemerin levels;
TGCT	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg05368731	chr17:41323189	NBR1	1.17	13.27	0.77	1.49e-25	Menopause (age at onset);
TGCT	cis	rs7220711	0.967	rs4793022	chr17:41798855	C/G	cg26893861	chr17:41843967	DUSP3	0.51	4.81	0.4	4.32e-6	Bone mineral density (spine);Bone mineral density (hip);
TGCT	cis	rs4253772	0.515	rs6007891	chr22:46756833	C/T	cg24881330	chr22:46731750	TRMU	0.87	4.94	0.41	2.46e-6	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs9527	0.640	rs7089061	chr10:104723015	C/A	cg15744005	chr10:104629667	AS3MT	-0.44	-5.19	-0.42	8.3e-7	Arsenic metabolism;
TGCT	cis	rs111803315	1.000	rs113172694	chr14:59998219	T/C	cg22995959	chr14:59931024	GPR135	0.66	4.8	0.4	4.39e-6	Schizophrenia;
TGCT	cis	rs1153858	1.000	rs67831559	chr15:45649307	G/T	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.62e-8	Homoarginine levels;
TGCT	cis	rs8037137	1.000	rs8037137	chr15:91506637	T/C	cg23684204	chr15:91497937	RCCD1	0.4	4.6	0.38	1.02e-5	Platelet count;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
TGCT	cis	rs7119	0.717	rs8033067	chr15:77825495	G/T	cg27398640	chr15:77910606	LINGO1	-0.26	-4.73	-0.39	6.02e-6	Type 2 diabetes;
TGCT	cis	rs3820068	0.603	rs3766163	chr1:15986547	T/C	cg05660106	chr1:15850417	CASP9	0.81	7.67	0.57	4.28e-12	Systolic blood pressure;
TGCT	cis	rs1008375	0.932	rs6449317	chr4:17631253	T/C	cg16339924	chr4:17578868	LAP3	0.7	5.67	0.45	9.46e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2075371	0.579	rs11766422	chr7:134018160	T/C	cg11752832	chr7:134001865	SLC35B4	0.63	5.07	0.41	1.41e-6	Mean platelet volume;
TGCT	cis	rs8070128	0.583	rs7406982	chr17:17942613	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.79	8.29	0.6	1.59e-13	Total body bone mineral density;
TGCT	cis	rs12477438	0.501	rs34272114	chr2:99737443	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	10.3	0.68	2.42e-18	Chronic sinus infection;
TGCT	cis	rs10464366	0.746	rs11760807	chr7:39142377	G/A	cg18850127	chr7:39170497	POU6F2	0.27	5.7	0.46	8.11e-8	IgG glycosylation;
TGCT	cis	rs10197940	0.624	rs10497082	chr2:152355258	T/C	cg19508488	chr2:152266495	RIF1	0.72	6.55	0.51	1.38e-9	Lung cancer;
TGCT	cis	rs7582180	0.629	rs2309798	chr2:100956949	G/A	cg08017756	chr2:100939284	LONRF2	-0.3	-4.95	-0.41	2.34e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6088580	0.634	rs6141465	chr20:32967314	T/C	cg08999081	chr20:33150536	PIGU	-0.28	-5.51	-0.44	1.96e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs9457247	1.000	rs2769347	chr6:167371737	T/A	cg23791538	chr6:167370224	RNASET2	0.51	5.12	0.42	1.12e-6	Crohn's disease;
TGCT	cis	rs7208859	0.673	rs11657270	chr17:29214387	A/G	cg18442181	chr17:29233375	C17orf42	-0.75	-4.56	-0.38	1.2e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs9611565	0.571	rs2050032	chr22:42152429	C/T	cg06634786	chr22:41940651	POLR3H	0.77	6.89	0.53	2.44e-10	Vitiligo;
TGCT	cis	rs9902453	0.935	rs7220151	chr17:28334710	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.74	-6.59	-0.51	1.12e-9	Coffee consumption (cups per day);
TGCT	cis	rs6684514	1.000	rs12117951	chr1:156305286	G/A	cg20302342	chr1:156215951	PAQR6	0.35	4.74	0.39	5.77e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg19723775	chr5:179050963	HNRNPH1	0.59	5.85	0.46	4.19e-8	Lung cancer;
TGCT	cis	rs17068510	0.572	rs67782723	chr8:3877427	G/C	cg25338036	chr8:3047536	CSMD1	-0.43	-4.51	-0.38	1.47e-5	Cerebrospinal fluid clusterin levels;
TGCT	cis	rs4631830	0.832	rs11005089	chr10:51510813	C/A	cg10326726	chr10:51549505	MSMB	0.27	5.2	0.42	7.86e-7	Prostate-specific antigen levels;
TGCT	cis	rs61884328	0.777	rs61897777	chr11:47133604	C/G	cg13308137	chr11:47528955	CUGBP1	0.38	4.47	0.37	1.76e-5	Total body bone mineral density (age over 60);
TGCT	cis	rs1561288	0.553	rs12233169	chr2:25329272	C/T	cg15423357	chr2:25149977	NA	-0.5	-4.53	-0.38	1.36e-5	Body mass index;
TGCT	cis	rs2997447	0.846	rs3008430	chr1:26390328	A/G	cg19633962	chr1:26362018	EXTL1	-0.68	-4.62	-0.38	9.47e-6	QRS complex (12-leadsum);
TGCT	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg21724239	chr8:58056113	NA	0.47	5.14	0.42	1.05e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs12210905	0.858	rs858988	chr6:27179195	G/A	cg08851530	chr6:28072375	NA	-0.99	-4.79	-0.4	4.65e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs61861422	0.516	rs12412216	chr10:134393338	C/T	cg10843401	chr10:134073911	STK32C	0.3	4.52	0.38	1.4e-5	Primary sclerosing cholangitis;
TGCT	cis	rs2463822	0.583	rs72917379	chr11:62026112	T/C	cg06239285	chr11:62104954	ASRGL1	-0.96	-6.16	-0.48	9.22e-9	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs11673344	0.504	rs6510593	chr19:37634055	A/G	cg08039142	chr19:36980659	ZNF566	0.51	4.69	0.39	6.97e-6	Obesity-related traits;
TGCT	cis	rs595982	0.527	rs17206707	chr19:49361441	A/C	cg17863274	chr19:49399704	TULP2	-0.48	-6.56	-0.51	1.3e-9	Red cell distribution width;
TGCT	cis	rs12908161	1.000	rs34570071	chr15:85280212	T/A	cg12863693	chr15:85201151	NMB	0.44	5.21	0.42	7.63e-7	Schizophrenia;
TGCT	cis	rs4788570	0.547	rs6499538	chr16:71762285	A/C	cg06353428	chr16:71660113	MARVELD3	1.49	13.16	0.76	2.72e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs11148252	0.574	rs3742297	chr13:53278067	T/C	cg02158880	chr13:53174818	NA	0.4	4.84	0.4	3.7e-6	Lewy body disease;
TGCT	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg06618935	chr21:46677482	NA	-0.37	-5.56	-0.45	1.58e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9914544	0.564	rs12451220	chr17:18778421	C/T	cg26378065	chr17:18585709	ZNF286B	0.53	4.63	0.38	9.06e-6	Educational attainment (years of education);
TGCT	cis	rs7224685	0.569	rs12947597	chr17:3999199	A/G	cg09580393	chr17:4869866	SPAG7	0.38	4.48	0.37	1.64e-5	Type 2 diabetes;
TGCT	cis	rs2249625	0.535	rs4616959	chr6:72828200	A/C	cg24401219	chr6:72892597	RIMS1	0.58	4.91	0.4	2.85e-6	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
TGCT	cis	rs4727027	0.901	rs4727019	chr7:148822266	A/G	cg23583168	chr7:148888333	NA	-0.72	-9.18	-0.64	1.18e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs593531	0.571	rs10898981	chr11:74092465	A/C	cg25592907	chr11:73676012	DNAJB13	0.35	5.05	0.41	1.56e-6	Neuroticism;
TGCT	cis	rs2463822	1.000	rs7481995	chr11:62129312	G/C	cg06239285	chr11:62104954	ASRGL1	0.92	6.76	0.52	4.71e-10	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs7044106	0.791	rs4836830	chr9:123483668	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	7.07	0.54	1.01e-10	Hip circumference adjusted for BMI;
TGCT	cis	rs7582180	0.629	rs4850927	chr2:100969067	A/G	cg14675211	chr2:100938903	LONRF2	0.51	4.97	0.41	2.13e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs477895	0.838	rs1058735	chr11:64000410	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.83	6.91	0.53	2.2e-10	Mean platelet volume;
TGCT	cis	rs6840360	0.615	rs1561917	chr4:152479233	G/A	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.03	-0.58	6.46e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs8056742	0.643	rs36121983	chr16:85068419	G/C	cg00229868	chr16:85520891	NA	0.42	5.17	0.42	9.14e-7	Amyotrophic lateral sclerosis;
TGCT	cis	rs9929218	0.581	rs4783676	chr16:68801077	A/C	cg01251360	chr16:68772225	CDH1	-0.25	-4.5	-0.37	1.53e-5	Colorectal cancer;
TGCT	cis	rs6121246	0.909	rs1994249	chr20:30287593	C/T	cg13852791	chr20:30311386	BCL2L1	0.78	5.8	0.46	5.15e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg18402987	chr7:1209562	NA	0.78	6.64	0.51	8.96e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs16854884	0.802	rs6783329	chr3:143798454	T/G	cg06585982	chr3:143692056	C3orf58	0.61	4.72	0.39	6.28e-6	Economic and political preferences (feminism/equality);
TGCT	cis	rs6921919	0.583	rs1361385	chr6:28358320	A/G	cg18815343	chr6:28367644	ZSCAN12	-0.56	-5.32	-0.43	4.76e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9393692	0.572	rs4145878	chr6:26198046	A/T	cg05868516	chr6:26286170	HIST1H4H	0.54	4.86	0.4	3.49e-6	Educational attainment;
TGCT	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.52	-4.45	-0.37	1.92e-5	Height;
TGCT	cis	rs3818285	0.504	rs1973972	chr10:111651133	A/T	cg00817464	chr10:111662876	XPNPEP1	0.28	4.88	0.4	3.21e-6	Superior crus of antihelix expression;
TGCT	cis	rs7412746	0.553	rs59337856	chr1:150746406	G/T	cg09365446	chr1:150670422	GOLPH3L	0.36	5.19	0.42	8.25e-7	Melanoma;
TGCT	cis	rs826838	1.000	rs7975243	chr12:38849220	C/T	cg13010199	chr12:38710504	ALG10B	0.82	6.85	0.52	3e-10	Heart rate;
TGCT	cis	rs910316	0.763	rs175042	chr14:75470833	A/T	cg11812906	chr14:75593930	NEK9	-0.59	-5.59	-0.45	1.38e-7	Height;
TGCT	cis	rs826838	0.559	rs4882276	chr12:38611994	T/C	cg26384229	chr12:38710491	ALG10B	0.55	5.0	0.41	1.93e-6	Heart rate;
TGCT	cis	rs2535633	0.631	rs2710346	chr3:52974152	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	0.57	5.43	0.44	2.84e-7	Body mass index;
TGCT	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	7.41	0.55	1.74e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9952991	0.941	rs888270	chr18:12774894	G/A	cg23598886	chr18:12777645	NA	-0.65	-5.91	-0.47	3.15e-8	Inflammatory skin disease;
TGCT	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg16423285	chr20:60520624	NA	0.61	6.55	0.51	1.39e-9	Body mass index;
TGCT	trans	rs4332037	0.539	rs11762545	chr7:2060775	C/T	cg25206134	chr2:45395956	NA	0.96	7.31	0.55	2.89e-11	Bipolar disorder;
TGCT	cis	rs2479724	0.870	rs3747753	chr6:41753380	G/T	cg08135965	chr6:41755394	TOMM6	-0.49	-4.77	-0.39	5.02e-6	Menarche (age at onset);
TGCT	cis	rs11172134	0.508	rs1800180	chr12:57569513	G/A	cg19258868	chr12:57585184	LRP1	-0.32	-6.14	-0.48	1.01e-8	Urate levels in overweight individuals;
TGCT	cis	rs11690935	0.632	rs6433323	chr2:172873060	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.54	-4.45	-0.37	1.88e-5	Schizophrenia;
TGCT	cis	rs4862750	0.881	rs6813866	chr4:187872161	T/G	cg11301795	chr4:187892539	NA	-0.34	-5.03	-0.41	1.68e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1532993	0.518	rs10014158	chr4:98612677	T/C	cg05340658	chr4:99064831	C4orf37	-0.41	-4.96	-0.41	2.3e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs67311347	0.544	rs1902073	chr3:40333497	C/T	cg13683864	chr3:40499215	RPL14	-0.78	-7.45	-0.56	1.42e-11	Renal cell carcinoma;
TGCT	cis	rs10791097	0.667	rs4937584	chr11:130741761	A/G	cg14779329	chr11:130786720	SNX19	0.28	4.82	0.4	4.09e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs36051895	0.623	rs11790680	chr9:5248768	C/T	cg02405213	chr9:5042618	JAK2	-0.7	-8.27	-0.6	1.78e-13	Pediatric autoimmune diseases;
TGCT	cis	rs4517514	0.509	rs11018875	chr11:89876356	T/C	cg05041596	chr11:89867385	NAALAD2	0.52	4.56	0.38	1.22e-5	Trans fatty acid levels;
TGCT	cis	rs7439150	0.954	rs72679196	chr4:155473549	A/C	cg22130008	chr4:155548532	NA	-0.43	-5.38	-0.44	3.5e-7	Fibrinogen levels;
TGCT	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg04234412	chr22:24373322	LOC391322	-0.94	-12.0	-0.73	1.72e-22	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6088580	0.634	rs6059896	chr20:33111783	T/C	cg08999081	chr20:33150536	PIGU	0.28	5.56	0.45	1.61e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs3829109	0.564	rs10781506	chr9:139271461	C/T	cg13741927	chr9:139327495	INPP5E	-0.23	-4.94	-0.41	2.46e-6	Peak insulin response;Acute insulin response;
TGCT	cis	rs7940866	0.834	rs1594821	chr11:130835883	C/T	cg05962950	chr11:130786565	SNX19	0.78	7.35	0.55	2.37e-11	Schizophrenia;
TGCT	cis	rs904251	0.965	rs62406516	chr6:37439364	C/T	cg08126542	chr6:37504118	NA	-0.4	-5.27	-0.43	5.92e-7	Cognitive performance;
TGCT	cis	rs10423674	0.526	rs2023878	chr19:18834124	A/G	cg14292368	chr19:18793705	CRTC1	0.51	4.66	0.39	7.87e-6	Menarche (age at onset);
TGCT	cis	rs11098499	0.909	rs28884220	chr4:120307211	A/G	cg09307838	chr4:120376055	NA	0.65	6.39	0.5	3.02e-9	Corneal astigmatism;
TGCT	cis	rs523522	0.962	rs11065149	chr12:120956963	G/A	cg12219531	chr12:120966889	COQ5	0.83	7.27	0.55	3.46e-11	High light scatter reticulocyte count;
TGCT	cis	rs11098499	0.754	rs17049949	chr4:120255290	A/G	cg09307838	chr4:120376055	NA	0.63	6.07	0.48	1.44e-8	Corneal astigmatism;
TGCT	trans	rs10802346	0.545	rs1770012	chr1:246426405	A/G	cg22732515	chr19:44031385	ETHE1	0.84	6.8	0.52	3.89e-10	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg03452623	chr4:187889614	NA	-0.34	-4.94	-0.41	2.46e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs422249	0.547	rs174536	chr11:61551927	A/C	cg01500311	chr11:61656094	FADS3	-0.32	-5.51	-0.44	2.02e-7	Trans fatty acid levels;
TGCT	cis	rs904251	0.861	rs1757183	chr6:37484790	C/T	cg25019722	chr6:37503610	NA	0.46	6.49	0.5	1.84e-9	Cognitive performance;
TGCT	cis	rs908922	0.676	rs10888492	chr1:152499908	G/C	cg20991723	chr1:152506922	NA	0.46	6.3	0.49	4.79e-9	Hair morphology;
TGCT	cis	rs1348850	0.914	rs10170667	chr2:178336878	A/G	cg22681709	chr2:178499509	PDE11A	-0.36	-4.71	-0.39	6.46e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg12000995	chr2:27665139	KRTCAP3	-0.35	-4.46	-0.37	1.84e-5	Total body bone mineral density;
TGCT	cis	rs6570726	0.764	rs9322028	chr6:145895797	G/T	cg05347473	chr6:146136440	FBXO30	0.52	4.95	0.41	2.33e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs78487399	0.808	rs7599781	chr2:43678726	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.24	-0.43	6.79e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs8179	0.645	rs42046	chr7:92252203	C/G	cg15732164	chr7:92237376	CDK6	-0.3	-5.24	-0.43	6.81e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
TGCT	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg20573242	chr4:122745356	CCNA2	0.62	5.48	0.44	2.23e-7	Type 2 diabetes;
TGCT	cis	rs892961	0.965	rs312856	chr17:75401598	A/G	cg05865280	chr17:75406074	SEPT9	0.27	6.47	0.5	2.03e-9	Airflow obstruction;
TGCT	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg06634786	chr22:41940651	POLR3H	0.87	8.08	0.59	4.79e-13	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs2760061	0.626	rs596208	chr1:228117982	G/C	cg02753203	chr1:228287806	NA	-0.34	-6.64	-0.51	8.69e-10	Diastolic blood pressure;
TGCT	cis	rs9467711	0.606	rs9379857	chr6:26367654	G/C	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs10876993	0.928	rs2640629	chr12:58065448	C/T	cg15848620	chr12:58087721	OS9	-0.71	-5.95	-0.47	2.5e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs950169	1.000	rs11638394	chr15:84778928	G/A	cg17173187	chr15:85201210	NMB	0.47	5.23	0.43	7.01e-7	Schizophrenia;
TGCT	cis	rs7605378	0.567	rs717915	chr2:200714766	C/T	cg23649088	chr2:200775458	C2orf69	0.47	9.61	0.65	1.14e-16	Osteoporosis;
TGCT	cis	rs7666738	0.830	rs4401456	chr4:98959902	C/T	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10197940	0.662	rs2432945	chr2:152278414	T/C	cg06191203	chr2:152266755	RIF1	-0.71	-6.28	-0.49	5.14e-9	Lung cancer;
TGCT	trans	rs1814175	0.541	rs12287397	chr11:49819799	G/A	cg03929089	chr4:120376271	NA	-0.72	-8.26	-0.6	1.84e-13	Height;
TGCT	cis	rs2013441	0.965	rs2703808	chr17:20109665	A/C	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.61	-0.38	9.96e-6	Obesity-related traits;
TGCT	cis	rs6671200	0.573	rs3820345	chr1:95713175	C/T	cg03123541	chr1:95699097	RWDD3	-0.81	-7.26	-0.55	3.81e-11	Stearic acid (18:0) levels;
TGCT	cis	rs7617773	0.817	rs9818937	chr3:48325281	G/A	cg11946769	chr3:48343235	NME6	0.72	6.16	0.48	9.39e-9	Coronary artery disease;
TGCT	cis	rs8141529	0.764	rs8137969	chr22:29228484	G/C	cg02153584	chr22:29168773	CCDC117	0.68	5.77	0.46	5.95e-8	Lymphocyte counts;
TGCT	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.46	-6.7	-0.52	6.44e-10	Alzheimer's disease;
TGCT	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg07157834	chr1:205819609	PM20D1	-0.36	-5.56	-0.45	1.55e-7	Monocyte percentage of white cells;
TGCT	cis	rs939574	1.000	rs2071385	chr2:220118782	T/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.05	6.46	0.5	2.12e-9	Platelet distribution width;
TGCT	cis	rs3784262	0.669	rs7171261	chr15:58356855	C/G	cg12031962	chr15:58353849	ALDH1A2	0.4	5.86	0.47	3.95e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	trans	rs17471911	0.708	rs2862507	chr10:100807790	T/A	cg03484267	chr2:207988651	KLF7	-0.52	-6.67	-0.51	7.53e-10	Neuroticism;
TGCT	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg06112835	chr11:68658793	MRPL21	-0.39	-6.31	-0.49	4.42e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs227917	0.891	rs6461718	chr7:23664672	G/A	cg12601843	chr7:23510954	IGF2BP3	0.6	4.76	0.39	5.25e-6	Common carotid intima-media thickness in HIV negative individuals;
TGCT	cis	rs2663905	0.706	rs7162859	chr15:81360038	C/T	cg25029264	chr15:81426347	C15orf26	0.61	4.56	0.38	1.21e-5	QT interval (drug interaction);
TGCT	cis	rs12477438	0.748	rs7558239	chr2:99640581	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-8.52	-0.61	4.5e-14	Chronic sinus infection;
TGCT	cis	rs4808199	1.000	rs60321073	chr19:19499598	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.7	5.06	0.41	1.5e-6	Nonalcoholic fatty liver disease;
TGCT	cis	rs2594714	1.000	rs2594713	chr19:13954336	G/T	cg18576835	chr19:13944261	NA	0.39	4.45	0.37	1.92e-5	Breast cancer;
TGCT	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg22920501	chr2:26401640	FAM59B	-0.83	-6.76	-0.52	4.93e-10	Gut microbiome composition (summer);
TGCT	cis	rs11252926	0.537	rs4881255	chr10:453638	T/C	cg18196295	chr10:418757	DIP2C	0.29	4.73	0.39	5.91e-6	Psychosis in Alzheimer's disease;
TGCT	cis	rs1008375	0.900	rs1003413	chr4:17582442	C/T	cg18681998	chr4:17616180	MED28	-0.85	-7.88	-0.58	1.42e-12	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs3733585	0.673	rs6849729	chr4:9958732	T/C	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.7	-0.57	3.69e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg24675658	chr1:53192096	ZYG11B	-0.77	-8.79	-0.62	1.05e-14	Monocyte count;
TGCT	cis	rs9811920	0.541	rs1016914	chr3:99640121	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.59	-6.77	-0.52	4.51e-10	Axial length;
TGCT	cis	rs3784262	0.669	rs1061278	chr15:58246029	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.42	-6.03	-0.48	1.76e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs4953076	0.573	rs2054005	chr2:44401843	C/T	cg04920474	chr2:44395004	PPM1B	0.56	5.58	0.45	1.43e-7	Height;
TGCT	cis	rs7666738	0.830	rs1834645	chr4:98979593	T/A	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg15691649	chr6:25882328	NA	-0.35	-4.55	-0.38	1.25e-5	Blood metabolite levels;
TGCT	cis	rs2439831	0.702	rs495175	chr15:43798684	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.0	7.94	0.58	1.04e-12	Lung cancer in ever smokers;
TGCT	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.04	6.35	0.5	3.65e-9	Gut microbiome composition (summer);
TGCT	cis	rs9399401	0.523	rs171915	chr6:142866845	C/T	cg04461802	chr6:142623433	GPR126	0.54	4.85	0.4	3.7e-6	Chronic obstructive pulmonary disease;
TGCT	cis	rs9341808	0.718	rs9448908	chr6:80898069	C/T	cg08355045	chr6:80787529	NA	0.32	5.6	0.45	1.29e-7	Sitting height ratio;
TGCT	cis	rs514406	0.505	rs269289	chr1:53167151	A/C	cg08859206	chr1:53392774	SCP2	-0.35	-4.99	-0.41	2.01e-6	Monocyte count;
TGCT	cis	rs36051895	0.603	rs11795305	chr9:5179920	G/C	cg02405213	chr9:5042618	JAK2	-0.71	-9.57	-0.65	1.42e-16	Pediatric autoimmune diseases;
TGCT	cis	rs11578119	0.933	rs10919403	chr1:170414584	A/G	cg09767346	chr1:170501363	GORAB	0.71	5.69	0.46	8.66e-8	Male-pattern baldness;
TGCT	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg19774624	chr17:42201019	HDAC5	-0.82	-8.35	-0.6	1.15e-13	Total body bone mineral density;
TGCT	cis	rs7666738	0.830	rs79075162	chr4:98960674	A/T	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9860250	0.606	rs66663898	chr3:100774092	A/G	cg05801080	chr3:100119813	LNP1;TOMM70A	0.54	4.54	0.38	1.29e-5	Optic disc area;
TGCT	cis	rs7940866	0.903	rs10750457	chr11:130850277	T/C	cg12179176	chr11:130786555	SNX19	0.52	5.01	0.41	1.79e-6	Schizophrenia;
TGCT	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	8.99	0.63	3.48e-15	Platelet count;
TGCT	cis	rs6088580	0.634	rs3736762	chr20:33037336	C/T	cg24642439	chr20:33292090	TP53INP2	0.49	4.5	0.37	1.55e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg06238570	chr21:40685208	BRWD1	0.69	6.43	0.5	2.55e-9	Cognitive function;
TGCT	cis	rs9906944	0.707	rs9912906	chr17:47104432	A/T	cg07075026	chr17:47091521	IGF2BP1	-0.43	-4.6	-0.38	1.03e-5	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs7523273	0.526	rs733177	chr1:208046384	C/T	cg22525895	chr1:207977042	MIR29B2	0.34	5.55	0.45	1.63e-7	Schizophrenia;
TGCT	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.46	-6.7	-0.52	6.44e-10	Alzheimer's disease;
TGCT	cis	rs9611519	0.929	rs11090039	chr22:41496800	G/A	cg13695892	chr22:41940480	POLR3H	-0.52	-4.74	-0.39	5.69e-6	Neuroticism;
TGCT	cis	rs5769765	0.862	rs138897	chr22:50231067	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.38	5.72	0.46	7.68e-8	Schizophrenia;
TGCT	cis	rs8180040	0.726	rs4682837	chr3:46999707	C/T	cg27129171	chr3:47204927	SETD2	0.73	9.4	0.65	3.53e-16	Colorectal cancer;
TGCT	cis	rs73198271	0.628	rs76079102	chr8:8591553	A/T	ch.8.214553F	chr8:8189620	PRAGMIN	-0.32	-5.23	-0.42	7.04e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs644799	0.710	rs10765771	chr11:95521044	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.8	9.01	0.63	3.14e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg00908189	chr16:619842	PIGQ	0.87	10.67	0.69	2.91e-19	Height;
TGCT	cis	rs2439831	1.000	rs2439850	chr15:43784854	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	5.51	0.44	1.95e-7	Lung cancer in ever smokers;
TGCT	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg04287289	chr16:89883240	FANCA	0.93	11.96	0.73	2.13e-22	Vitiligo;
TGCT	cis	rs7586879	0.789	rs13035239	chr2:25134000	T/A	cg01884057	chr2:25150051	NA	0.27	4.57	0.38	1.17e-5	Body mass index;
TGCT	cis	rs796364	0.951	rs971232	chr2:200792881	C/T	cg17644776	chr2:200775616	C2orf69	0.31	4.85	0.4	3.58e-6	Schizophrenia;
TGCT	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	5.99	0.47	2.06e-8	Bipolar disorder;
TGCT	cis	rs4148883	0.675	rs34511427	chr4:100105405	G/T	cg12011299	chr4:100065546	ADH4	0.39	5.85	0.46	4.15e-8	Alcohol dependence;
TGCT	cis	rs9611565	0.503	rs5996062	chr22:42167464	C/G	cg06634786	chr22:41940651	POLR3H	0.85	8.15	0.59	3.41e-13	Vitiligo;
TGCT	cis	rs8042680	0.592	rs2001217	chr15:91498246	G/T	cg23684204	chr15:91497937	RCCD1	-0.3	-4.61	-0.38	9.87e-6	Type 2 diabetes;
TGCT	cis	rs854765	0.583	rs11656840	chr17:17837354	C/T	cg09796270	chr17:17721594	SREBF1	0.24	4.77	0.39	5.16e-6	Total body bone mineral density;
TGCT	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs1008375	1.000	rs7694020	chr4:17682597	C/T	cg16339924	chr4:17578868	LAP3	0.52	4.49	0.37	1.63e-5	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg03517284	chr6:25882590	NA	-0.65	-5.73	-0.46	7.15e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.515	rs11733968	chr4:98906448	A/C	cg17366294	chr4:99064904	C4orf37	-0.62	-5.76	-0.46	6.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4242434	0.927	rs7843616	chr8:22466541	T/C	cg03733263	chr8:22462867	KIAA1967	1.13	20.13	0.88	6.96e-41	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs7949030	0.626	rs7930896	chr11:62325272	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.71	9.04	0.63	2.55e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs4788439	0.901	rs72772310	chr16:24995391	A/G	cg07626409	chr16:25250191	ZKSCAN2	0.32	4.45	0.37	1.87e-5	Blood metabolite levels;
TGCT	cis	rs9972944	0.756	rs8076925	chr17:63764616	A/C	cg07283582	chr17:63770753	CCDC46	-0.23	-4.88	-0.4	3.22e-6	Total body bone mineral density;
TGCT	cis	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg20637647	chr7:64974828	NA	-0.95	-5.3	-0.43	5.09e-7	Diabetic kidney disease;
TGCT	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg17971929	chr21:40555470	PSMG1	-0.67	-6.27	-0.49	5.46e-9	Cognitive function;
TGCT	cis	rs12142240	0.698	rs17357676	chr1:46812444	A/G	cg14993813	chr1:46806288	NSUN4	-0.58	-4.79	-0.4	4.68e-6	Menopause (age at onset);
TGCT	cis	rs6840360	0.582	rs11733820	chr4:152316139	T/C	cg17479576	chr4:152424074	FAM160A1	-0.63	-6.8	-0.52	4e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs6570726	1.000	rs405622	chr6:145871897	G/T	cg23711669	chr6:146136114	FBXO30	0.71	6.66	0.51	7.78e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs473651	0.935	rs541128	chr2:239336449	A/G	cg21699342	chr2:239360505	ASB1	0.17	4.78	0.39	4.78e-6	Multiple system atrophy;
TGCT	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.68	5.73	0.46	7.3e-8	Tonsillectomy;
TGCT	cis	rs7043114	0.525	rs10739927	chr9:95052081	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-5.57	-0.45	1.53e-7	Height;
TGCT	cis	rs7552404	0.731	rs10732723	chr1:76392437	C/T	cg10523679	chr1:76189770	ACADM	-0.83	-7.7	-0.57	3.78e-12	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs524023	1.000	rs505802	chr11:64357072	T/C	cg07733098	chr11:64478343	NRXN2	-0.31	-4.64	-0.38	8.56e-6	Urate levels in obese individuals;
TGCT	cis	rs17381785	0.545	rs1494947	chr4:14969983	T/G	cg12377275	chr4:15005593	CPEB2	0.72	7.04	0.53	1.18e-10	Urate levels in overweight individuals;
TGCT	cis	rs7949030	0.504	rs2516633	chr11:62371773	A/C	cg11742103	chr11:62369870	EML3;MTA2	-0.55	-6.57	-0.51	1.24e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7178424	0.742	rs1981917	chr15:62171906	A/G	cg00456672	chr15:62358751	C2CD4A	-0.31	-4.72	-0.39	6.37e-6	Height;
TGCT	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg04267008	chr7:1944627	MAD1L1	-0.41	-5.4	-0.44	3.34e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs4631830	0.720	rs2125771	chr10:51506957	C/T	cg10326726	chr10:51549505	MSMB	-0.23	-4.66	-0.39	8.17e-6	Prostate-specific antigen levels;
TGCT	cis	rs12134245	0.747	rs11164912	chr1:92005191	A/T	cg02896835	chr1:92012615	NA	-0.28	-4.78	-0.39	4.85e-6	Breast cancer;
TGCT	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg03264133	chr6:25882463	NA	-0.52	-5.53	-0.44	1.81e-7	Height;
TGCT	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	6.23	0.49	6.56e-9	Bipolar disorder;
TGCT	cis	rs35146811	0.695	rs858508	chr7:99821381	C/G	cg00553149	chr7:99775558	STAG3;GPC2	-0.32	-4.81	-0.4	4.28e-6	Coronary artery disease;
TGCT	cis	rs3824867	0.920	rs7105907	chr11:47450318	A/T	cg20307385	chr11:47447363	PSMC3	-0.69	-5.86	-0.47	3.99e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs7542091	0.635	rs985431	chr1:210043948	A/T	cg23283495	chr1:209979779	IRF6	0.55	5.47	0.44	2.34e-7	Monobrow;
TGCT	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg13342137	chr4:2252803	MXD4	0.17	4.48	0.37	1.66e-5	Obesity-related traits;
TGCT	cis	rs2050392	0.789	rs303438	chr10:30733493	C/T	cg18806716	chr10:30721971	MAP3K8	0.48	5.55	0.45	1.65e-7	Inflammatory bowel disease;
TGCT	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg00814883	chr7:100076585	TSC22D4	-0.92	-9.76	-0.66	4.73e-17	Platelet count;
TGCT	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg17971929	chr21:40555470	PSMG1	-0.68	-5.96	-0.47	2.42e-8	Cognitive function;
TGCT	cis	rs6542838	0.704	rs56125264	chr2:99516699	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.56	-5.25	-0.43	6.5e-7	Fear of minor pain;
TGCT	cis	rs16854884	0.770	rs1530478	chr3:143819553	C/T	cg06585982	chr3:143692056	C3orf58	0.59	4.64	0.38	8.56e-6	Economic and political preferences (feminism/equality);
TGCT	cis	rs9486719	0.947	rs9386648	chr6:97035656	T/C	cg18709589	chr6:96969512	KIAA0776	-0.74	-5.21	-0.42	7.5e-7	Migraine;Coronary artery disease;
TGCT	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg11764359	chr7:65958608	NA	-0.53	-4.7	-0.39	6.81e-6	Aortic root size;
TGCT	cis	rs9894429	0.646	rs8079963	chr17:79603285	C/T	cg21028142	chr17:79581711	NPLOC4	0.29	5.95	0.47	2.56e-8	Eye color traits;
TGCT	cis	rs9788721	1.000	rs55781567	chr15:78857986	C/G	cg18825076	chr15:78729989	IREB2	-0.3	-4.47	-0.37	1.74e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
TGCT	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg12419862	chr22:24373484	LOC391322	-0.79	-8.23	-0.59	2.19e-13	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs3820928	0.874	rs55748731	chr2:227818629	C/A	cg11843606	chr2:227700838	RHBDD1	-0.53	-4.73	-0.39	5.9e-6	Pulmonary function;
TGCT	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	6.57	0.51	1.28e-9	Alzheimer's disease;
TGCT	cis	rs2836950	0.840	rs12482317	chr21:40588241	A/G	cg11890956	chr21:40555474	PSMG1	-0.65	-6.19	-0.49	7.89e-9	Menarche (age at onset);
TGCT	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg22963979	chr7:1858916	MAD1L1	-0.37	-5.99	-0.47	2.07e-8	Bipolar disorder and schizophrenia;
TGCT	cis	rs1008375	0.932	rs2302391	chr4:17660237	T/C	cg10189774	chr4:17578691	LAP3	0.57	4.88	0.4	3.21e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9640161	0.750	rs3735173	chr7:150020526	C/T	cg17279839	chr7:150038598	RARRES2	0.43	4.59	0.38	1.06e-5	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs11190604	1.000	rs10786597	chr10:102291287	C/T	cg16342193	chr10:102329863	NA	-0.42	-5.37	-0.43	3.74e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg03452623	chr4:187889614	NA	-0.36	-5.3	-0.43	5.01e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs35883536	0.647	rs10875313	chr1:101043057	T/C	cg14855972	chr1:101004472	GPR88	-0.24	-4.49	-0.37	1.64e-5	Monocyte count;
TGCT	cis	rs62244186	0.566	rs2135531	chr3:44881158	C/G	cg10263370	chr3:44754102	ZNF502	-0.45	-5.5	-0.44	2.09e-7	Depressive symptoms;
TGCT	cis	rs1538970	0.924	rs1494812	chr1:45876999	C/T	cg05343316	chr1:45956843	TESK2	0.72	5.53	0.44	1.82e-7	Platelet count;
TGCT	cis	rs4455778	0.580	rs4336559	chr7:49125213	G/C	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs12368653	0.641	rs7311632	chr12:58086340	A/C	cg12615879	chr12:58013172	SLC26A10	0.49	5.9	0.47	3.27e-8	Multiple sclerosis;
TGCT	cis	rs11190604	0.943	rs11190568	chr10:102224277	C/T	cg16342193	chr10:102329863	NA	-0.4	-5.12	-0.42	1.14e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg07424592	chr7:64974309	NA	1.36	7.93	0.58	1.1e-12	Diabetic kidney disease;
TGCT	cis	rs2073300	1.000	rs6137977	chr20:23464191	G/T	cg09953122	chr20:23471693	CST8	-0.67	-4.62	-0.38	9.54e-6	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs9894429	0.646	rs9902264	chr17:79613828	G/A	cg18240062	chr17:79603768	NPLOC4	0.56	4.9	0.4	2.95e-6	Eye color traits;
TGCT	cis	rs9300255	0.739	rs11057210	chr12:123733799	A/G	cg00376283	chr12:123451042	ABCB9	0.71	5.51	0.44	1.98e-7	Neutrophil percentage of white cells;
TGCT	cis	rs694739	1.000	rs1783521	chr11:64106291	T/C	cg02228329	chr11:64053129	BAD;GPR137	0.78	7.74	0.57	2.95e-12	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs4443100	0.631	rs13054904	chr22:23410918	A/T	cg14186256	chr22:23484241	RTDR1	-0.58	-4.68	-0.39	7.29e-6	Serum parathyroid hormone levels;
TGCT	cis	rs981844	0.712	rs1350189	chr4:154744951	A/T	cg14289246	chr4:154710475	SFRP2	-0.99	-8.93	-0.63	4.84e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs9527	0.615	rs11191401	chr10:104573403	A/G	cg04362960	chr10:104952993	NT5C2	0.6	4.82	0.4	4.19e-6	Arsenic metabolism;
TGCT	cis	rs6570726	0.791	rs11155432	chr6:145898761	T/C	cg05347473	chr6:146136440	FBXO30	0.52	4.95	0.41	2.33e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4319547	0.760	rs61954973	chr12:123074168	T/C	cg23029597	chr12:123009494	RSRC2	-0.3	-4.92	-0.4	2.65e-6	Body mass index;
TGCT	cis	rs9906944	0.585	rs11650936	chr17:47072261	C/G	cg07075026	chr17:47091521	IGF2BP1	0.42	4.71	0.39	6.51e-6	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs9430161	0.611	rs12081181	chr1:11034165	T/G	cg02454025	chr1:11042201	C1orf127	0.94	11.31	0.71	8.14e-21	Ewing sarcoma;
TGCT	cis	rs7208859	0.623	rs8075341	chr17:29136565	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs67311347	0.824	rs73073561	chr3:40357298	G/T	cg13683864	chr3:40499215	RPL14	-0.92	-8.87	-0.62	6.51e-15	Renal cell carcinoma;
TGCT	cis	rs523522	0.962	rs10774549	chr12:120891172	C/T	cg27279351	chr12:120934652	DYNLL1	0.74	6.4	0.5	2.95e-9	High light scatter reticulocyte count;
TGCT	cis	rs5758659	0.714	rs5758574	chr22:42481400	G/C	cg15557168	chr22:42548783	NA	0.19	4.92	0.4	2.7e-6	Cognitive function;
TGCT	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg09417038	chr21:47716443	C21orf57	-0.33	-4.56	-0.38	1.19e-5	Testicular germ cell tumor;
TGCT	cis	rs7666738	0.830	rs7684646	chr4:99071062	C/T	cg05340658	chr4:99064831	C4orf37	0.5	5.7	0.46	8.19e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8180040	0.966	rs57346147	chr3:47410564	C/G	cg27129171	chr3:47204927	SETD2	-0.64	-7.39	-0.55	1.89e-11	Colorectal cancer;
TGCT	trans	rs1496653	0.602	rs13072325	chr3:23550989	C/T	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs9911578	0.967	rs4932693	chr17:57110327	T/C	cg12560992	chr17:57184187	TRIM37	-0.79	-9.55	-0.65	1.52e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.03	0.41	1.68e-6	Prudent dietary pattern;
TGCT	cis	rs2742417	1.000	rs1969624	chr3:45734818	C/T	cg04837898	chr3:45731254	SACM1L	0.55	5.68	0.45	9.14e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs1784581	0.507	rs1790020	chr6:162366266	C/T	cg17173639	chr6:162384350	PARK2	-0.41	-6.99	-0.53	1.53e-10	Itch intensity from mosquito bite;
TGCT	cis	rs877282	0.891	rs11253393	chr10:788824	G/T	cg17470449	chr10:769945	NA	0.3	4.71	0.39	6.53e-6	Uric acid levels;
TGCT	cis	rs2204008	0.621	rs7302846	chr12:38072979	A/C	cg26384229	chr12:38710491	ALG10B	0.58	4.96	0.41	2.24e-6	Bladder cancer;
TGCT	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg11890956	chr21:40555474	PSMG1	-0.69	-6.62	-0.51	9.84e-10	Menarche (age at onset);
TGCT	cis	rs9611565	0.605	rs202638	chr22:41855458	A/G	cg17554472	chr22:41940697	POLR3H	0.47	5.0	0.41	1.87e-6	Vitiligo;
TGCT	cis	rs7714584	1.000	rs4958424	chr5:150225036	C/T	cg22134413	chr5:150180641	NA	0.89	6.96	0.53	1.73e-10	Crohn's disease;
TGCT	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg17971929	chr21:40555470	PSMG1	0.98	9.61	0.65	1.14e-16	Cognitive function;
TGCT	cis	rs11785400	1.000	rs3802232	chr8:143746701	A/G	cg10596483	chr8:143751796	JRK	0.56	6.05	0.48	1.61e-8	Schizophrenia;
TGCT	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg07343612	chr16:622815	PIGQ	-0.41	-8.15	-0.59	3.29e-13	Height;
TGCT	cis	rs3772130	0.583	rs7618041	chr3:121566481	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.59	5.43	0.44	2.8e-7	Cognitive performance;
TGCT	cis	rs2485376	0.813	rs1005044	chr10:104152143	C/A	cg26089160	chr10:104170217	PSD	0.52	5.09	0.42	1.3e-6	QT interval;
TGCT	cis	rs62064224	0.818	rs11080180	chr17:30682998	G/A	cg18200150	chr17:30822561	MYO1D	0.58	7.72	0.57	3.35e-12	Schizophrenia;
TGCT	cis	rs7000551	0.581	rs11787182	chr8:22256727	T/C	cg12081754	chr8:22256438	SLC39A14	0.34	4.73	0.39	6.1e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs6964587	1.000	rs7806184	chr7:91601978	A/G	cg17063962	chr7:91808500	NA	0.91	9.99	0.67	1.32e-17	Breast cancer;
TGCT	cis	rs35146811	0.622	rs6946204	chr7:99589125	T/C	cg13334819	chr7:99746414	C7orf59	-0.65	-5.74	-0.46	6.78e-8	Coronary artery disease;
TGCT	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.05	-0.48	1.57e-8	Gut microbiome composition (summer);
TGCT	cis	rs3820928	0.874	rs4234066	chr2:227882180	G/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-4.94	-0.41	2.51e-6	Pulmonary function;
TGCT	cis	rs4676406	0.608	rs6749767	chr2:241588985	A/G	cg23888423	chr2:242254170	SEPT2;HDLBP	-0.46	-4.6	-0.38	1.01e-5	Ulcerative colitis;
TGCT	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg08280861	chr8:58055591	NA	0.4	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2806561	0.514	rs10917360	chr1:23539010	C/T	cg19743168	chr1:23544995	NA	0.45	7.73	0.57	3.21e-12	Height;
TGCT	trans	rs10506458	1.000	rs12425655	chr12:63434463	C/T	cg22491629	chr6:157744540	C6orf35	-0.88	-7.81	-0.57	2.07e-12	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs2688608	0.592	rs7080579	chr10:75504029	T/A	cg23231163	chr10:75533350	FUT11	-0.28	-4.73	-0.39	5.98e-6	Inflammatory bowel disease;
TGCT	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg18876405	chr7:65276391	NA	0.31	4.78	0.39	4.81e-6	Aortic root size;
TGCT	cis	rs10927875	0.541	rs1739843	chr1:16343254	T/C	cg22431228	chr1:16359049	CLCNKA	-0.29	-6.07	-0.48	1.42e-8	Dilated cardiomyopathy;
TGCT	cis	rs28595532	1.000	rs114778020	chr4:119662584	C/A	cg11846333	chr4:119757529	SEC24D	0.95	4.9	0.4	2.97e-6	Cannabis dependence symptom count;
TGCT	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg15659132	chr6:26577336	NA	0.49	4.58	0.38	1.1e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9972944	0.651	rs7221371	chr17:63765174	C/A	cg07283582	chr17:63770753	CCDC46	-0.26	-5.3	-0.43	5.02e-7	Total body bone mineral density;
TGCT	cis	rs2016266	0.819	rs7398228	chr12:53660285	T/C	cg16917193	chr12:54089295	NA	0.67	5.1	0.42	1.25e-6	Bone mineral density (spine);Bone mineral density;
TGCT	trans	rs561341	1.000	rs548957	chr17:30302411	G/A	cg20587970	chr11:113659929	NA	-1.04	-12.57	-0.75	6.97e-24	Hip circumference adjusted for BMI;
TGCT	cis	rs603424	0.593	rs3829159	chr10:102088906	C/T	cg22671421	chr10:102507979	PAX2	-0.54	-4.66	-0.39	7.93e-6	Phospholipid levels (plasma);Palmitic acid (16:0) levels;Palmitoleic acid (16:1n-7) levels;Mean platelet volume;Serum metabolite levels;Blood metabolite levels;Vaccenic acid (18:1n-7) levels;Metabolic traits;Coronary artery disease;Blood metabolite ratios;Glycerophospholipid levels;
TGCT	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg17178900	chr1:205818956	PM20D1	0.56	7.03	0.53	1.2e-10	Menarche (age at onset);
TGCT	cis	rs9393692	0.905	rs9379843	chr6:26289435	A/G	cg13736514	chr6:26305472	NA	-0.41	-5.76	-0.46	6.37e-8	Educational attainment;
TGCT	cis	rs4253772	0.591	rs6007748	chr22:46657798	A/G	cg09491104	chr22:46646882	C22orf40	-0.63	-6.39	-0.5	3.05e-9	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg09021430	chr5:549028	NA	-0.43	-5.83	-0.46	4.57e-8	Obesity-related traits;
TGCT	cis	rs4478858	0.684	rs3737755	chr1:31744168	G/A	cg00250761	chr1:31883323	NA	-0.25	-4.48	-0.37	1.64e-5	Alcohol dependence;
TGCT	cis	rs4862307	0.964	rs76550057	chr4:184998476	C/G	cg06737308	chr4:185021514	ENPP6	0.44	6.47	0.5	2.1e-9	Serum dimethylarginine levels (asymmetric/symetric ratio);
TGCT	cis	rs950169	0.922	rs4842946	chr15:84942331	G/A	cg12863693	chr15:85201151	NMB	0.45	4.96	0.41	2.28e-6	Schizophrenia;
TGCT	cis	rs9911578	1.000	rs9892062	chr17:56976981	G/A	cg12560992	chr17:57184187	TRIM37	0.76	9.21	0.64	1.03e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs2404602	0.716	rs117129193	chr15:76656803	A/G	cg22467129	chr15:76604101	ETFA	-0.57	-6.69	-0.51	6.91e-10	Blood metabolite levels;
TGCT	cis	rs4891159	0.584	rs2848958	chr18:74157068	C/T	cg24786174	chr18:74118243	ZNF516	0.64	11.14	0.71	2.17e-20	Longevity;
TGCT	cis	rs11690935	0.959	rs6724337	chr2:172735329	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.17	-12.1	-0.74	9.69e-23	Schizophrenia;
TGCT	cis	rs7267979	0.873	rs6132822	chr20:25228695	C/T	cg16686733	chr20:25566563	NINL	0.52	4.89	0.4	3.02e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg10047753	chr17:41438598	NA	0.91	8.44	0.6	6.86e-14	Menopause (age at onset);
TGCT	cis	rs17767294	0.708	rs61744109	chr6:28075519	C/T	cg08851530	chr6:28072375	NA	1.56	7.21	0.54	4.9e-11	Parkinson's disease;
TGCT	cis	rs6665290	0.669	rs6426558	chr1:227175367	G/T	cg10327440	chr1:227177885	CDC42BPA	-0.91	-15.34	-0.81	1.98e-30	Myeloid white cell count;
TGCT	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg23262073	chr20:60523788	NA	-0.32	-5.25	-0.43	6.45e-7	Obesity-related traits;
TGCT	cis	rs7180079	0.620	rs1008917	chr15:65059651	A/G	cg03791955	chr15:65024147	NA	0.28	4.48	0.37	1.66e-5	Monocyte count;
TGCT	cis	rs2535633	0.594	rs2581789	chr3:53096230	C/T	cg11645453	chr3:52864694	ITIH4	-0.27	-5.19	-0.42	8.41e-7	Body mass index;
TGCT	cis	rs12620999	0.941	rs10929215	chr2:238037456	G/A	cg23555395	chr2:238036564	NA	-0.32	-5.53	-0.44	1.8e-7	Systemic lupus erythematosus;
TGCT	cis	rs7584330	0.868	rs67071074	chr2:238395429	T/C	cg08992911	chr2:238395768	MLPH	0.62	4.51	0.38	1.49e-5	Prostate cancer;
TGCT	cis	rs425277	0.606	rs2460001	chr1:2111030	T/C	cg12140144	chr1:2984275	FLJ42875;PRDM16	-0.32	-4.48	-0.37	1.7e-5	Height;
TGCT	cis	rs9650657	0.682	rs6989160	chr8:10705360	A/C	cg27411982	chr8:10470053	RP1L1	-0.23	-4.67	-0.39	7.7e-6	Neuroticism;
TGCT	cis	rs425277	0.585	rs3128294	chr1:2065343	G/C	cg12140144	chr1:2984275	FLJ42875;PRDM16	0.37	4.95	0.41	2.33e-6	Height;
TGCT	cis	rs57994353	0.897	rs35526483	chr9:139364940	G/A	cg13741927	chr9:139327495	INPP5E	-0.26	-6.13	-0.48	1.06e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	trans	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg13615516	chr5:77269221	NA	0.67	8.36	0.6	1.09e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs6788371	1.000	rs6788371	chr3:187319124	C/T	cg01598596	chr3:187464648	BCL6	-0.43	-4.65	-0.39	8.31e-6	Pursuit maintenance gain;
TGCT	cis	rs2180341	0.538	rs4577822	chr6:127712911	T/G	cg27446573	chr6:127587934	RNF146	0.64	6.01	0.47	1.95e-8	Breast cancer;
TGCT	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.06	-9.57	-0.65	1.41e-16	Platelet count;
TGCT	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg22920501	chr2:26401640	FAM59B	0.8	6.34	0.49	3.84e-9	Gut microbiome composition (summer);
TGCT	cis	rs3820068	0.603	rs7529759	chr1:15977877	A/G	cg05660106	chr1:15850417	CASP9	0.79	7.46	0.56	1.29e-11	Systolic blood pressure;
TGCT	cis	rs78487399	0.808	rs79845707	chr2:43788801	G/C	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.69	4.59	0.38	1.09e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs35883536	0.647	rs10875328	chr1:101169328	C/T	cg06223162	chr1:101003688	GPR88	-0.39	-6.51	-0.5	1.67e-9	Monocyte count;
TGCT	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.62	-5.11	-0.42	1.17e-6	Tonsillectomy;
TGCT	cis	rs13256369	0.851	rs13271698	chr8:8567539	C/A	cg17143192	chr8:8559678	CLDN23	0.58	5.55	0.45	1.64e-7	Obesity-related traits;
TGCT	cis	rs739401	0.611	rs494427	chr11:3048140	A/G	cg05729581	chr11:3078854	CARS	-0.53	-4.94	-0.41	2.51e-6	Longevity;
TGCT	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg13397359	chr6:42928475	GNMT	0.67	5.93	0.47	2.84e-8	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs16866061	0.517	rs56337305	chr2:225475560	T/C	cg22455342	chr2:225449267	CUL3	0.58	4.93	0.4	2.62e-6	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	cis	rs9810089	0.934	rs10935184	chr3:136153468	T/C	cg12473912	chr3:136751656	NA	0.35	4.96	0.41	2.24e-6	Gestational age at birth (child effect);
TGCT	cis	rs67311347	0.955	rs6599100	chr3:40447362	C/T	cg17264618	chr3:40429014	ENTPD3	0.32	4.76	0.39	5.36e-6	Renal cell carcinoma;
TGCT	cis	rs12595025	1	rs12595025	chr15:91520131	C/T	cg23684204	chr15:91497937	RCCD1	0.4	4.59	0.38	1.07e-5	Mean platelet volume;
TGCT	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.93	7.44	0.56	1.44e-11	Platelet count;
TGCT	cis	rs8072100	0.607	rs9894594	chr17:45461383	A/G	cg08085267	chr17:45401833	C17orf57	-0.51	-5.6	-0.45	1.3e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs477895	0.713	rs3802933	chr11:63988102	C/T	cg04317338	chr11:64019027	PLCB3	0.81	6.87	0.53	2.7e-10	Mean platelet volume;
TGCT	cis	rs4711350	0.954	rs943464	chr6:33731469	A/G	cg00334056	chr6:33755658	LEMD2	0.31	4.79	0.39	4.72e-6	Schizophrenia;
TGCT	cis	rs2274273	0.712	rs7144652	chr14:55537718	G/A	cg01923255	chr14:55878535	KIAA0831	0.57	4.89	0.4	3.03e-6	Protein biomarker;
TGCT	cis	rs7666738	0.830	rs2903152	chr4:99067992	A/G	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.44e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6671200	1.000	rs62625008	chr1:95702582	A/G	cg26537280	chr1:95699037	RWDD3	0.7	5.55	0.45	1.62e-7	Stearic acid (18:0) levels;
TGCT	cis	rs5769765	1.000	rs2295408	chr22:50261051	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.41	-6.07	-0.48	1.47e-8	Schizophrenia;
TGCT	cis	rs3008870	1.000	rs12044278	chr1:67460977	T/C	cg11518657	chr1:67396239	MIER1	-0.54	-4.61	-0.38	9.72e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg02725872	chr8:58115012	NA	-0.37	-4.99	-0.41	1.99e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs921968	0.643	rs612874	chr2:219492924	T/C	cg02176678	chr2:219576539	TTLL4	0.38	5.48	0.44	2.31e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs7659604	0.605	rs1396080	chr4:122740454	T/G	cg20573242	chr4:122745356	CCNA2	0.58	5.37	0.43	3.73e-7	Type 2 diabetes;
TGCT	cis	rs370915	0.542	rs1425953	chr4:187833652	A/C	cg19519643	chr4:187840862	NA	-0.23	-4.66	-0.39	7.89e-6	Gout;
TGCT	cis	rs12188164	1.000	rs12188164	chr5:428236	C/A	cg26850624	chr5:429559	AHRR	-0.2	-4.69	-0.39	7.1e-6	Cystic fibrosis severity;
TGCT	cis	rs5760092	0.842	rs5751763	chr22:24247793	T/C	cg20007245	chr22:24372913	LOC391322	-0.78	-6.39	-0.5	3.11e-9	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs17376456	1.000	rs9968749	chr5:93509559	A/G	cg25358565	chr5:93447407	FAM172A	0.95	7.97	0.58	8.71e-13	Diabetic retinopathy;
TGCT	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	4.82	0.4	4.12e-6	Height;
TGCT	cis	rs713587	0.521	rs6545766	chr2:25077856	C/T	cg01884057	chr2:25150051	NA	0.29	5.37	0.43	3.74e-7	Body mass index in non-asthmatics;
TGCT	cis	rs6545883	0.929	rs2463100	chr2:61659199	C/G	cg15711740	chr2:61764176	XPO1	-0.54	-4.96	-0.41	2.27e-6	Tuberculosis;
TGCT	cis	rs1403694	1.000	rs2651640	chr3:186438393	G/A	cg12454167	chr3:186435060	KNG1	0.42	7.37	0.55	2.15e-11	Blood protein levels;
TGCT	cis	rs854765	0.547	rs4365348	chr17:17912548	C/T	cg04398451	chr17:18023971	MYO15A	-0.31	-5.05	-0.41	1.56e-6	Total body bone mineral density;
TGCT	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg06238570	chr21:40685208	BRWD1	0.69	6.41	0.5	2.71e-9	Cognitive function;
TGCT	cis	rs17221829	0.703	rs12418019	chr11:89391757	T/C	cg02982614	chr11:89391479	FOLH1B	-0.25	-4.46	-0.37	1.8e-5	Anxiety in major depressive disorder;
TGCT	cis	rs9948	0.786	rs62156231	chr2:97425603	G/A	cg01990225	chr2:97406019	LMAN2L	-0.88	-4.81	-0.4	4.37e-6	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs76889437	0.664	rs72807953	chr2:48959451	G/A	cg25061755	chr2:48808114	STON1-GTF2A1L;STON1	0.17	4.49	0.37	1.63e-5	Facial morphology (factor 19);
TGCT	cis	rs1975974	0.574	rs17052370	chr17:21736353	A/G	cg18423549	chr17:21743878	NA	0.62	6.34	0.49	3.93e-9	Psoriasis;
TGCT	trans	rs1814175	0.654	rs7482446	chr11:49779020	A/G	cg15704280	chr7:45808275	SEPT13	-0.69	-8.05	-0.59	5.61e-13	Height;
TGCT	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	14.26	0.79	6.49e-28	Height;
TGCT	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg24675658	chr1:53192096	ZYG11B	-0.69	-7.8	-0.57	2.19e-12	Monocyte count;
TGCT	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg03452623	chr4:187889614	NA	-0.33	-4.94	-0.41	2.42e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7586879	0.639	rs6713978	chr2:25120851	T/C	cg01884057	chr2:25150051	NA	0.35	6.9	0.53	2.39e-10	Body mass index;
TGCT	cis	rs9814567	1.000	rs6766897	chr3:134191303	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.98	-9.42	-0.65	3.18e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs9443645	0.901	rs9343844	chr6:79586463	T/A	cg09184832	chr6:79620586	NA	-0.49	-5.29	-0.43	5.29e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs3764563	1.000	rs4646530	chr19:15735238	A/T	cg20725493	chr19:15740067	CYP4F8	0.49	5.34	0.43	4.2e-7	Inflammatory biomarkers;
TGCT	cis	rs12530845	0.945	rs59664351	chr7:135314717	C/A	cg23117316	chr7:135346802	PL-5283	-0.51	-4.83	-0.4	3.98e-6	Red blood cell traits;
TGCT	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg23172400	chr8:95962367	TP53INP1	-0.38	-6.49	-0.5	1.84e-9	Type 2 diabetes;
TGCT	cis	rs17601876	0.814	rs34712049	chr15:51560064	C/T	cg19946085	chr15:51559439	CYP19A1	-0.33	-4.99	-0.41	2.03e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs17345786	0.906	rs11710016	chr3:101120030	A/C	cg11279151	chr3:101281821	RG9MTD1	0.4	8.36	0.6	1.09e-13	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7267979	1.000	rs2257988	chr20:25270003	T/C	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6430585	0.583	rs6728946	chr2:136635343	C/G	cg07169764	chr2:136633963	MCM6	1.26	12.74	0.75	2.78e-24	Corneal structure;
TGCT	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.78	6.29	0.49	5.04e-9	Mean platelet volume;
TGCT	cis	rs9916302	0.904	rs55689507	chr17:37404436	G/C	cg07936489	chr17:37558343	FBXL20	-0.65	-5.24	-0.43	6.62e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs35264875	1.000	rs72919430	chr11:68829817	G/T	cg02660097	chr11:68866761	NA	0.32	4.8	0.4	4.55e-6	Blond vs. brown hair color;
TGCT	cis	rs9329221	0.905	rs10283145	chr8:10241411	C/T	cg27411982	chr8:10470053	RP1L1	-0.21	-4.6	-0.38	1.05e-5	Neuroticism;
TGCT	cis	rs6087990	0.842	rs4911105	chr20:31330413	G/A	cg13636640	chr20:31349939	DNMT3B	1.03	14.85	0.8	2.67e-29	Ulcerative colitis;
TGCT	cis	rs4803468	0.967	rs4803462	chr19:41908936	T/A	cg09537434	chr19:41945824	ATP5SL	-0.92	-10.64	-0.69	3.55e-19	Height;
TGCT	cis	rs9467711	0.651	rs17526722	chr6:25918855	G/A	cg16898833	chr6:26189333	HIST1H4D	1.23	5.03	0.41	1.65e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7647973	0.826	rs9834535	chr3:49378797	A/T	cg07636037	chr3:49044803	WDR6	0.73	5.93	0.47	2.78e-8	Menarche (age at onset);
TGCT	cis	rs9473924	0.505	rs9473931	chr6:50851411	C/G	cg14470998	chr6:50812995	TFAP2B	1.37	8.44	0.6	7.05e-14	Body mass index;
TGCT	cis	rs7474896	0.515	rs2738203	chr10:38277596	G/A	cg25427524	chr10:38739819	LOC399744	0.34	4.54	0.38	1.3e-5	Obesity (extreme);
TGCT	cis	rs6424115	0.830	rs2501426	chr1:24199364	G/A	cg15997130	chr1:24165203	NA	0.86	9.44	0.65	2.86e-16	Immature fraction of reticulocytes;
TGCT	cis	rs4699052	0.590	rs28728298	chr4:104282850	A/T	cg16532752	chr4:104119610	CENPE	-0.5	-4.75	-0.39	5.48e-6	Testicular germ cell tumor;
TGCT	cis	rs9397585	0.588	rs6932473	chr6:153438573	A/T	cg24028809	chr6:153414101	RGS17	0.22	4.66	0.39	8.15e-6	Body mass index;
TGCT	cis	rs9674544	0.757	rs6504593	chr17:47132819	T/C	cg20966754	chr17:47091339	IGF2BP1	-0.4	-4.47	-0.37	1.74e-5	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
TGCT	cis	rs3806843	0.576	rs246059	chr5:140325010	G/T	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs6922617	0.786	rs73417295	chr6:41344173	C/G	cg07798131	chr6:41471673	NA	0.98	4.85	0.4	3.6e-6	Alzheimer's disease biomarkers;
TGCT	cis	rs9303401	0.614	rs34058624	chr17:57118121	T/C	cg25039879	chr17:56429692	SUPT4H1	0.57	5.14	0.42	1.03e-6	Cognitive test performance;
TGCT	cis	rs28595532	0.920	rs116559327	chr4:119754526	T/G	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg25036284	chr2:26402008	FAM59B	0.65	5.18	0.42	8.59e-7	Gut microbiome composition (summer);
TGCT	cis	rs9972944	0.631	rs6504345	chr17:63757052	T/G	cg07283582	chr17:63770753	CCDC46	-0.24	-4.84	-0.4	3.72e-6	Total body bone mineral density;
TGCT	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg19723775	chr5:179050963	HNRNPH1	0.48	4.76	0.39	5.33e-6	Lung cancer;
TGCT	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg07507251	chr3:52567010	NT5DC2	0.48	6.95	0.53	1.82e-10	Bipolar disorder;
TGCT	cis	rs67311347	0.544	rs9877105	chr3:40333366	T/C	cg13683864	chr3:40499215	RPL14	-0.78	-7.45	-0.56	1.42e-11	Renal cell carcinoma;
TGCT	cis	rs7000551	0.725	rs2248987	chr8:22399002	C/G	cg12081754	chr8:22256438	SLC39A14	0.31	5.03	0.41	1.7e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg03060546	chr3:49711283	APEH	0.59	5.58	0.45	1.41e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs910187	0.571	rs3746489	chr20:45801716	C/T	cg27589058	chr20:45804311	EYA2	-0.39	-8.26	-0.6	1.86e-13	Migraine;
TGCT	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg03709012	chr19:19516395	GATAD2A	0.75	6.2	0.49	7.59e-9	Tonsillectomy;
TGCT	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	5.07	0.41	1.43e-6	Menopause (age at onset);
TGCT	cis	rs4409675	0.576	rs7356	chr1:28218100	T/C	cg23691781	chr1:28212827	C1orf38	0.26	5.32	0.43	4.68e-7	Corneal astigmatism;
TGCT	cis	rs6490294	0.799	rs61670030	chr12:112351854	C/T	cg10833066	chr12:111807467	FAM109A	0.38	5.67	0.45	9.69e-8	Mean platelet volume;
TGCT	cis	rs3617	0.539	rs4687687	chr3:52948332	A/G	cg10802521	chr3:52805072	NEK4	0.57	6.57	0.51	1.22e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1008375	0.966	rs4698621	chr4:17587565	C/T	cg16339924	chr4:17578868	LAP3	0.8	6.96	0.53	1.73e-10	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs524281	0.861	rs7931544	chr11:65917034	C/T	cg00563793	chr11:65837595	PACS1	0.58	4.92	0.4	2.66e-6	Electroencephalogram traits;
TGCT	cis	rs67311347	0.544	rs9833640	chr3:40354941	T/A	cg13683864	chr3:40499215	RPL14	-0.84	-7.85	-0.58	1.71e-12	Renal cell carcinoma;
TGCT	cis	rs968451	0.724	rs5757599	chr22:39670181	A/C	cg17798944	chr22:39715225	SNORD43;RPL3	0.67	6.41	0.5	2.74e-9	Primary biliary cholangitis;
TGCT	cis	rs2191566	0.664	rs55958002	chr19:44543788	A/T	cg03039196	chr19:44506973	ZNF230	0.53	4.47	0.37	1.78e-5	Acute lymphoblastic leukemia (childhood);
TGCT	trans	rs459571	0.959	rs455381	chr9:136905577	C/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.72	-7.83	-0.58	1.87e-12	Platelet distribution width;
TGCT	cis	rs13191362	1.000	rs7764785	chr6:163009967	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg25036284	chr2:26402008	FAM59B	-0.56	-4.78	-0.39	4.9e-6	Gut microbiome composition (summer);
TGCT	cis	rs7772486	0.727	rs2235481	chr6:146056848	T/C	cg13319975	chr6:146136371	FBXO30	0.74	6.68	0.51	7.36e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs67478160	0.643	rs11628332	chr14:104241141	C/T	cg26031613	chr14:104095156	KLC1	-0.64	-6.7	-0.52	6.67e-10	Schizophrenia;
TGCT	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg04944784	chr2:26401820	FAM59B	0.76	6.21	0.49	7.25e-9	Gut microbiome composition (summer);
TGCT	cis	rs10986311	0.654	rs2416927	chr9:127078521	G/C	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.21	-5.01	-0.41	1.82e-6	Vitiligo;
TGCT	cis	rs644799	0.544	rs56298021	chr11:95545113	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.55	5.83	0.46	4.56e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs16867321	0.671	rs12053494	chr2:181493357	T/A	cg23363182	chr2:181467187	NA	-0.47	-4.98	-0.41	2.11e-6	Obesity;
TGCT	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg06238570	chr21:40685208	BRWD1	-0.67	-6.61	-0.51	1.03e-9	Cognitive function;
TGCT	cis	rs72781680	0.821	rs113014365	chr2:24159903	C/T	cg08917208	chr2:24149416	ATAD2B	0.74	4.66	0.39	7.9e-6	Lymphocyte counts;
TGCT	cis	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg00184457	chr8:8946301	NA	-0.24	-4.54	-0.38	1.34e-5	Joint mobility (Beighton score);
TGCT	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg00908189	chr16:619842	PIGQ	0.85	10.4	0.68	1.33e-18	Height;
TGCT	cis	rs4372836	1.000	rs55835850	chr2:28949296	T/C	cg09522027	chr2:28974177	PPP1CB	0.59	4.98	0.41	2.05e-6	Body mass index;
TGCT	cis	rs9906944	0.545	rs11079851	chr17:47092310	G/C	cg07075026	chr17:47091521	IGF2BP1	-0.44	-4.6	-0.38	1.02e-5	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	trans	rs1005277	0.540	rs1814077	chr10:37992018	G/C	cg17830980	chr10:43048298	ZNF37B	-0.63	-6.95	-0.53	1.86e-10	Extrinsic epigenetic age acceleration;
TGCT	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg24399712	chr22:39784796	NA	-1.06	-12.58	-0.75	6.72e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs7727544	0.716	rs11949055	chr5:131576737	T/C	cg22598563	chr5:131563921	P4HA2	-0.29	-4.66	-0.39	7.88e-6	Blood metabolite levels;
TGCT	cis	rs892961	0.867	rs312909	chr17:75413954	T/C	cg05865280	chr17:75406074	SEPT9	0.28	6.73	0.52	5.56e-10	Airflow obstruction;
TGCT	cis	rs2153904	0.793	rs1772145	chr1:205695695	C/T	cg23034840	chr1:205782522	SLC41A1	0.72	5.44	0.44	2.74e-7	Prostate-specific antigen levels;
TGCT	cis	rs9583531	0.527	rs12875067	chr13:111365104	A/G	cg24331049	chr13:111365604	ING1	0.76	7.31	0.55	2.95e-11	Coronary artery disease;
TGCT	cis	rs7226408	0.846	rs2121024	chr18:34488206	G/A	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs1023500	0.596	rs133352	chr22:42434022	C/A	cg15557168	chr22:42548783	NA	-0.21	-5.34	-0.43	4.22e-7	Schizophrenia;
TGCT	cis	rs7216064	0.953	rs62086043	chr17:65968003	A/G	cg12091567	chr17:66097778	LOC651250	-0.78	-5.91	-0.47	3.11e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs611744	0.967	rs686265	chr8:109199763	A/G	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs7312933	0.703	rs1059360	chr12:42554505	A/G	cg19980929	chr12:42632907	YAF2	0.47	6.46	0.5	2.13e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg25036284	chr2:26402008	FAM59B	0.65	5.13	0.42	1.07e-6	Gut microbiome composition (summer);
TGCT	cis	rs12681288	0.550	rs76893867	chr8:962618	G/C	cg04851639	chr8:1020857	NA	-0.3	-5.08	-0.41	1.36e-6	Schizophrenia;
TGCT	cis	rs9902453	1.000	rs62070270	chr17:28263980	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	6.62	0.51	9.51e-10	Coffee consumption (cups per day);
TGCT	cis	rs9914988	0.619	rs35477460	chr17:27320276	C/T	cg17523868	chr17:27313033	SEZ6	-0.56	-4.77	-0.39	5.17e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs6089584	0.606	rs7270666	chr20:60577598	C/T	cg13770153	chr20:60521292	NA	-0.42	-5.13	-0.42	1.08e-6	Body mass index;
TGCT	cis	rs1635	0.655	rs75885713	chr6:28312356	G/A	cg24848467	chr6:28134517	ZNF389	-0.58	-4.7	-0.39	6.75e-6	Schizophrenia;
TGCT	cis	rs6088590	0.965	rs6087639	chr20:33443866	G/A	cg24642439	chr20:33292090	TP53INP2	0.71	6.32	0.49	4.28e-9	Coronary artery disease;
TGCT	cis	rs1534166	0.647	rs9853615	chr3:133519981	C/T	cg20276088	chr3:133502917	NA	-0.22	-4.48	-0.37	1.7e-5	Alcohol consumption (transferrin glycosylation);
TGCT	cis	rs1670533	1.000	rs6599278	chr4:1058798	C/T	cg27284194	chr4:1044797	NA	0.66	5.81	0.46	4.98e-8	Recombination rate (females);
TGCT	cis	rs736408	0.561	rs2276815	chr3:52853747	C/G	cg10802521	chr3:52805072	NEK4	-0.64	-6.51	-0.5	1.69e-9	Bipolar disorder;
TGCT	cis	rs7772486	0.790	rs9497425	chr6:146234197	G/A	cg05347473	chr6:146136440	FBXO30	-0.5	-4.85	-0.4	3.68e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10489202	0.632	rs202259	chr1:167962072	G/A	cg24449463	chr1:168025552	DCAF6	-0.59	-7.11	-0.54	8.22e-11	Schizophrenia;
TGCT	cis	rs367943	1.000	rs348962	chr5:112819086	C/T	cg12552261	chr5:112820674	MCC	0.25	5.01	0.41	1.84e-6	Type 2 diabetes;
TGCT	cis	rs988712	0.607	rs11030084	chr11:27643725	C/T	cg10635145	chr11:27742435	BDNF	-0.37	-4.6	-0.38	1.03e-5	Obesity;
TGCT	cis	rs35934224	0.831	rs1044732	chr22:19863142	T/C	cg11182965	chr22:19864308	TXNRD2	-0.39	-5.24	-0.43	6.67e-7	Glaucoma (primary open-angle);
TGCT	cis	rs8017423	0.838	rs11845950	chr14:90723962	T/A	cg04374321	chr14:90722782	PSMC1	0.76	7.71	0.57	3.59e-12	Mortality in heart failure;
TGCT	cis	rs2296887	0.591	rs11191284	chr10:104164210	G/C	cg26089160	chr10:104170217	PSD	-0.68	-6.13	-0.48	1.1e-8	Parkinson's disease;
TGCT	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg12963246	chr6:28129442	ZNF389	0.51	5.02	0.41	1.73e-6	Depression;
TGCT	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.47	0.56	1.28e-11	Prudent dietary pattern;
TGCT	cis	rs72615157	0.606	rs941288	chr7:99776808	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.62	4.94	0.41	2.51e-6	Lung function (FEV1/FVC);
TGCT	cis	rs6121246	0.580	rs6121016	chr20:30245239	C/T	cg21427119	chr20:30132790	HM13	-0.33	-4.49	-0.37	1.59e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.72	5.14	0.42	1.06e-6	Platelet count;
TGCT	cis	rs10984561	0.737	rs12237970	chr9:122251005	C/G	cg14242995	chr9:122249943	NA	0.73	5.96	0.47	2.46e-8	Pulmonary function decline;
TGCT	cis	rs4783244	0.828	rs9940266	chr16:82653548	C/T	cg09415485	chr16:82663111	CDH13	-0.24	-4.51	-0.38	1.47e-5	Adiponectin levels;
TGCT	cis	rs6666258	1.000	rs34106427	chr1:154813988	G/A	cg06418219	chr1:154948305	SHC1;CKS1B	0.63	5.1	0.42	1.21e-6	Atrial fibrillation;
TGCT	cis	rs13202913	0.709	rs11965449	chr6:151830598	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	0.64	4.62	0.38	9.44e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs3617	0.573	rs62253583	chr3:52928334	G/A	cg11645453	chr3:52864694	ITIH4	-0.27	-5.14	-0.42	1.05e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg22968622	chr17:43663579	NA	-1.23	-10.98	-0.7	5.31e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs10088262	0.629	rs7833650	chr8:124822969	C/T	cg02993010	chr8:124780839	FAM91A1	-0.61	-4.63	-0.38	9.02e-6	Pancreatic cancer;
TGCT	cis	rs35771425	0.509	rs3120782	chr1:211419700	A/T	cg25617285	chr1:211431773	RCOR3	-0.49	-5.68	-0.45	9.25e-8	Educational attainment (years of education);
TGCT	cis	rs6088580	0.634	rs6087588	chr20:33066369	T/C	cg08999081	chr20:33150536	PIGU	0.28	5.6	0.45	1.3e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs10782582	0.609	rs5745325	chr1:76269460	G/A	cg03433033	chr1:76189801	ACADM	-0.5	-4.95	-0.41	2.39e-6	Daytime sleep phenotypes;
TGCT	cis	rs7584330	0.628	rs7591065	chr2:238390739	G/T	cg08992911	chr2:238395768	MLPH	0.72	4.64	0.38	8.67e-6	Prostate cancer;
TGCT	cis	rs66887589	0.616	rs7659403	chr4:120207254	T/A	cg24670566	chr4:120433619	PDE5A	0.21	4.57	0.38	1.14e-5	Diastolic blood pressure;
TGCT	trans	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.82	-8.52	-0.61	4.53e-14	Body mass index;
TGCT	cis	rs3806843	0.568	rs2530232	chr5:140082878	A/G	cg19875535	chr5:140030758	IK	-0.36	-5.93	-0.47	2.79e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7567389	0.568	rs7568070	chr2:127953054	A/C	cg09760422	chr2:128146352	NA	0.38	4.9	0.4	2.98e-6	Self-rated health;
TGCT	cis	rs763121	0.853	rs5750659	chr22:39068789	T/C	cg06022373	chr22:39101656	GTPBP1	0.77	7.46	0.56	1.35e-11	Menopause (age at onset);
TGCT	cis	rs1878931	0.513	rs35160989	chr16:3405506	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.93	10.4	0.68	1.34e-18	Body mass index (adult);
TGCT	cis	rs617219	0.710	rs10474578	chr5:78542290	T/C	cg23987322	chr5:78407566	BHMT	0.35	4.69	0.39	7.07e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs765787	0.530	rs2413784	chr15:45530516	A/C	cg24006582	chr15:45444508	DUOX1	-0.25	-5.53	-0.44	1.82e-7	Uric acid levels;
TGCT	cis	rs8016982	0.855	rs10149681	chr14:81686319	G/A	cg01989461	chr14:81687754	GTF2A1	0.61	5.15	0.42	9.99e-7	Schizophrenia;
TGCT	cis	rs854765	0.583	rs4414547	chr17:17859052	G/T	cg09796270	chr17:17721594	SREBF1	0.23	4.55	0.38	1.27e-5	Total body bone mineral density;
TGCT	cis	rs9467773	0.620	rs2504600	chr6:26648334	C/A	cg15659132	chr6:26577336	NA	0.87	10.72	0.69	2.19e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg22168489	chr12:122356033	WDR66	0.2	4.73	0.39	6.08e-6	Mean corpuscular volume;
TGCT	cis	rs2070488	1.000	rs2268753	chr3:38500189	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.89	9.58	0.65	1.34e-16	Electrocardiographic conduction measures;
TGCT	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg11062466	chr8:58055876	NA	-0.43	-4.64	-0.38	8.84e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10197940	0.624	rs10497082	chr2:152355258	T/C	cg06191203	chr2:152266755	RIF1	-0.76	-7.11	-0.54	8.05e-11	Lung cancer;
TGCT	cis	rs62244186	0.566	rs2135531	chr3:44881158	C/G	cg04389838	chr3:44770851	ZNF501	-0.36	-4.66	-0.39	8.16e-6	Depressive symptoms;
TGCT	cis	rs7044106	0.762	rs7357638	chr9:123389204	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	6.78	0.52	4.27e-10	Hip circumference adjusted for BMI;
TGCT	cis	rs1865760	0.686	rs12210098	chr6:25963966	C/T	cg17042849	chr6:26104293	HIST1H4C	-0.62	-5.16	-0.42	9.63e-7	Height;
TGCT	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg19774624	chr17:42201019	HDAC5	0.89	11.12	0.71	2.32e-20	Total body bone mineral density;
TGCT	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg06873352	chr17:61820015	STRADA	0.56	6.22	0.49	6.93e-9	Prudent dietary pattern;
TGCT	cis	rs7085104	0.591	rs4919683	chr10:104585125	G/T	cg04362960	chr10:104952993	NT5C2	0.54	4.66	0.39	8.08e-6	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs10972341	0.967	rs13285401	chr9:35152858	T/C	cg00812861	chr9:35114699	KIAA1539	0.34	5.24	0.43	6.81e-7	Weight;
TGCT	cis	rs42648	0.869	rs12704518	chr7:89914388	G/T	cg25739043	chr7:89950458	NA	-0.73	-7.31	-0.55	2.87e-11	Homocysteine levels;
TGCT	cis	rs2721195	0.549	rs2958492	chr8:145919126	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.65	6.32	0.49	4.32e-9	Age at first birth;
TGCT	trans	rs1814175	0.817	rs10839351	chr11:49758153	C/T	cg15704280	chr7:45808275	SEPT13	-0.69	-7.93	-0.58	1.08e-12	Height;
TGCT	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg12963246	chr6:28129442	ZNF389	0.52	5.1	0.42	1.23e-6	Depression;
TGCT	cis	rs67478160	0.643	rs12878868	chr14:104233725	G/A	cg26031613	chr14:104095156	KLC1	-0.63	-6.42	-0.5	2.66e-9	Schizophrenia;
TGCT	cis	rs6964587	0.934	rs12531561	chr7:91707780	A/G	cg22709100	chr7:91322751	NA	0.28	4.56	0.38	1.19e-5	Breast cancer;
TGCT	cis	rs4242434	0.927	rs2291231	chr8:22463912	C/T	cg03733263	chr8:22462867	KIAA1967	1.14	20.09	0.87	8.18e-41	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs76419734	0.850	rs112292976	chr4:106779785	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	1.09	4.45	0.37	1.9e-5	Post bronchodilator FEV1;
TGCT	cis	rs1005224	0.853	rs2360035	chr14:76297093	A/T	cg04684003	chr14:76127793	TTLL5;C14orf1	0.54	4.77	0.39	5.11e-6	Large artery stroke;
TGCT	cis	rs7017914	0.935	rs56289931	chr8:71837754	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.03	-0.41	1.71e-6	Bone mineral density;
TGCT	cis	rs2016266	0.859	rs11170507	chr12:53740682	C/A	cg16917193	chr12:54089295	NA	-0.7	-4.68	-0.39	7.49e-6	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs1046896	0.576	rs8082558	chr17:80695501	G/A	cg00960700	chr17:80709150	TBCD	0.51	5.1	0.42	1.24e-6	Glycated hemoglobin levels;
TGCT	trans	rs1814175	0.645	rs4625470	chr11:49983769	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.67	-0.69	2.92e-19	Height;
TGCT	cis	rs4478858	0.684	rs17440445	chr1:31722562	C/T	cg00250761	chr1:31883323	NA	0.27	4.76	0.39	5.29e-6	Alcohol dependence;
TGCT	cis	rs4455778	0.728	rs7796636	chr7:49015314	C/G	cg26309511	chr7:48887640	NA	-0.45	-5.26	-0.43	6.21e-7	Lung cancer in never smokers;
TGCT	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	16.05	0.82	4.59e-32	Prudent dietary pattern;
TGCT	cis	rs7192750	0.538	rs4788582	chr16:71981806	A/G	cg06353428	chr16:71660113	MARVELD3	0.75	6.74	0.52	5.43e-10	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs9911578	0.935	rs7216698	chr17:57007495	G/A	cg12560992	chr17:57184187	TRIM37	0.73	8.7	0.62	1.69e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs651907	0.535	rs34263427	chr3:101507805	A/G	cg12386194	chr3:101231763	SENP7	0.48	4.81	0.4	4.36e-6	Colorectal cancer;
TGCT	cis	rs926938	0.527	rs1391484	chr1:115522366	A/G	cg12756093	chr1:115239321	AMPD1	0.34	4.97	0.41	2.19e-6	Autism;
TGCT	cis	rs9952991	0.883	rs2847260	chr18:12775591	C/T	cg24737193	chr18:12778029	NA	0.53	5.93	0.47	2.8e-8	Inflammatory skin disease;
TGCT	cis	rs7666738	0.606	rs10006414	chr4:99101401	T/C	cg05340658	chr4:99064831	C4orf37	0.42	4.49	0.37	1.62e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7937682	0.855	rs539693	chr11:111477387	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.06	-11.27	-0.71	1.04e-20	Primary sclerosing cholangitis;
TGCT	cis	rs6088590	0.735	rs6060003	chr20:33294945	T/C	cg06115741	chr20:33292138	TP53INP2	0.55	4.68	0.39	7.3e-6	Coronary artery disease;
TGCT	cis	rs4319547	0.915	rs1473553	chr12:122985057	G/T	cg05707623	chr12:122985044	ZCCHC8	-0.66	-5.32	-0.43	4.71e-7	Body mass index;
TGCT	cis	rs7364180	0.582	rs139568	chr22:42210985	C/T	cg06634786	chr22:41940651	POLR3H	0.48	4.69	0.39	7.23e-6	Alzheimer's disease biomarkers;
TGCT	cis	rs2050392	0.861	rs303448	chr10:30727084	G/T	cg18806716	chr10:30721971	MAP3K8	-0.51	-6.0	-0.47	2.05e-8	Inflammatory bowel disease;
TGCT	cis	rs10892173	0.765	rs1892903	chr11:117669619	A/G	cg07621104	chr11:117668040	DSCAML1	0.51	5.61	0.45	1.28e-7	Myopia;
TGCT	cis	rs4499344	0.664	rs4286210	chr19:33101221	T/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	8.81	0.62	9.52e-15	Mean platelet volume;
TGCT	cis	rs992157	0.730	rs4280446	chr2:219184721	T/C	cg00012203	chr2:219082015	ARPC2	0.69	6.41	0.5	2.77e-9	Colorectal cancer;
TGCT	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg02725872	chr8:58115012	NA	-0.38	-5.16	-0.42	9.32e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9381040	0.610	rs9367094	chr6:41017860	T/C	cg03526776	chr6:41159608	TREML2	0.26	5.14	0.42	1.05e-6	Alzheimer's disease (late onset);
TGCT	cis	rs10927875	0.518	rs732286	chr1:16344360	A/G	cg22431228	chr1:16359049	CLCNKA	-0.29	-5.94	-0.47	2.68e-8	Dilated cardiomyopathy;
TGCT	cis	rs644799	0.526	rs693172	chr11:95636618	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.48	4.91	0.4	2.8e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9911578	0.835	rs9889419	chr17:56473259	C/T	cg12560992	chr17:57184187	TRIM37	0.77	9.06	0.63	2.4e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg24578937	chr1:2090814	PRKCZ	0.26	6.95	0.53	1.8e-10	Height;
TGCT	cis	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg07424592	chr7:64974309	NA	1.4	8.42	0.6	7.87e-14	Diabetic kidney disease;
TGCT	cis	rs975752	0.717	rs12253275	chr10:102043477	T/A	cg04750910	chr10:102416409	NA	0.73	4.48	0.37	1.69e-5	Schizophrenia;
TGCT	cis	rs4849845	0.584	rs3896630	chr2:121037018	A/G	cg24070213	chr2:121070622	NA	0.35	4.64	0.38	8.58e-6	Mean platelet volume;
TGCT	cis	rs12477438	0.798	rs12477754	chr2:99628073	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-6.1	-0.48	1.22e-8	Chronic sinus infection;
TGCT	cis	rs9300255	0.543	rs1617156	chr12:123590165	T/C	cg00376283	chr12:123451042	ABCB9	0.7	5.17	0.42	9.08e-7	Neutrophil percentage of white cells;
TGCT	cis	rs7949030	0.653	rs2516634	chr11:62367186	G/A	cg13298116	chr11:62369859	EML3;MTA2	-0.64	-9.62	-0.65	1.04e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs17162190	0.698	rs6673072	chr1:26844074	G/C	cg02450742	chr1:26856648	RPS6KA1	0.54	4.49	0.37	1.62e-5	Mean corpuscular volume;
TGCT	cis	rs3091242	0.933	rs9438905	chr1:25764177	A/G	cg09222892	chr1:25734099	RHCE	-0.43	-7.07	-0.54	1.02e-10	Erythrocyte sedimentation rate;
TGCT	cis	rs9611565	1.000	rs5751086	chr22:41768862	C/T	cg17554472	chr22:41940697	POLR3H	-0.44	-5.07	-0.41	1.4e-6	Vitiligo;
TGCT	cis	rs854765	0.583	rs6502622	chr17:17834691	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.74	7.73	0.57	3.18e-12	Total body bone mineral density;
TGCT	cis	rs13188771	0.578	rs17137390	chr5:100918526	C/T	cg17598923	chr5:101119084	NA	0.49	4.68	0.39	7.46e-6	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs72945132	0.882	rs7129843	chr11:70180381	G/A	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs9611565	0.512	rs5751153	chr22:42156561	T/C	cg03806693	chr22:41940476	POLR3H	1.04	10.57	0.69	5.2e-19	Vitiligo;
TGCT	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs6430585	0.583	rs11886852	chr2:136589379	G/A	cg07169764	chr2:136633963	MCM6	1.05	9.56	0.65	1.46e-16	Corneal structure;
TGCT	cis	rs7666738	0.830	rs7696568	chr4:99005333	A/T	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10504229	1.000	rs67096506	chr8:58195655	G/A	cg21724239	chr8:58056113	NA	0.38	4.76	0.39	5.41e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs12134133	0.752	rs61821051	chr1:207408969	C/G	cg02152968	chr1:207494213	CD55	0.69	4.75	0.39	5.46e-6	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs11840576	0.588	rs331976	chr13:110317769	G/T	cg15975806	chr13:110319607	NA	-0.6	-4.44	-0.37	1.95e-5	Paclitaxel disposition in epithelial ovarian cancer;
TGCT	cis	rs896854	0.654	rs10429443	chr8:95971164	A/G	cg23172400	chr8:95962367	TP53INP1	-0.39	-6.52	-0.51	1.57e-9	Type 2 diabetes;
TGCT	cis	rs10992471	0.756	rs7848055	chr9:95115492	A/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.61	-6.24	-0.49	6.3e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs10791097	0.739	rs11222358	chr11:130730497	G/A	cg05962950	chr11:130786565	SNX19	0.8	9.66	0.66	8.34e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9894429	0.966	rs6565605	chr17:79589359	C/T	cg21028142	chr17:79581711	NPLOC4	0.29	6.83	0.52	3.44e-10	Eye color traits;
TGCT	cis	rs6570726	0.935	rs385134	chr6:145851005	C/T	cg23711669	chr6:146136114	FBXO30	0.68	6.67	0.51	7.58e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs67072384	1.000	rs56693670	chr11:72445143	G/T	cg03713592	chr11:72463424	ARAP1	-0.9	-4.63	-0.38	9.26e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg19626725	chr5:178986131	RUFY1	-0.46	-5.87	-0.47	3.67e-8	Lung cancer;
TGCT	cis	rs4986172	0.881	rs9894577	chr17:43223292	G/A	cg10701640	chr17:43249399	NA	0.39	4.75	0.39	5.52e-6	Height;
TGCT	cis	rs1008375	0.863	rs4590022	chr4:17614434	T/C	cg18681998	chr4:17616180	MED28	1.07	11.25	0.71	1.13e-20	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2072499	1.000	rs2241107	chr1:156182710	C/T	cg24450063	chr1:156163899	SLC25A44	-1.14	-16.55	-0.83	3.47e-33	Testicular germ cell tumor;
TGCT	cis	rs17376456	1.000	rs34013242	chr5:93507947	C/T	cg21475434	chr5:93447410	FAM172A	0.62	4.5	0.37	1.54e-5	Diabetic retinopathy;
TGCT	cis	rs72717009	0.825	rs6671753	chr1:161478708	G/A	cg23840854	chr1:161414152	NA	-1.0	-6.43	-0.5	2.47e-9	Rheumatoid arthritis;
TGCT	cis	rs11190604	1.000	rs11190589	chr10:102275471	A/G	cg16342193	chr10:102329863	NA	-0.42	-5.37	-0.43	3.72e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7208859	0.623	rs1061342	chr17:29114463	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs6495122	0.662	rs12898997	chr15:75090349	C/T	cg10253484	chr15:75165896	SCAMP2	-0.67	-5.88	-0.47	3.51e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
TGCT	cis	rs35146811	0.961	rs35991721	chr7:99728790	G/T	cg22906224	chr7:99728672	NA	0.55	5.05	0.41	1.52e-6	Coronary artery disease;
TGCT	cis	rs9611565	0.729	rs12165508	chr22:41819960	T/C	cg06481639	chr22:41940642	POLR3H	0.59	5.12	0.42	1.12e-6	Vitiligo;
TGCT	cis	rs478304	0.651	rs4930312	chr11:65499719	G/A	cg10518572	chr11:65560635	OVOL1	-0.24	-4.68	-0.39	7.53e-6	Acne (severe);
TGCT	cis	rs34638657	0.702	rs11866709	chr16:82201017	A/G	cg09439754	chr16:82129088	HSD17B2	-0.24	-4.53	-0.38	1.37e-5	Lung adenocarcinoma;
TGCT	cis	rs16866061	1.000	rs72972378	chr2:225372562	A/G	cg12698349	chr2:225449008	CUL3	1.0	9.83	0.66	3.23e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	cis	rs796364	0.806	rs78527234	chr2:200913453	C/T	cg17644776	chr2:200775616	C2orf69	-0.33	-5.0	-0.41	1.91e-6	Schizophrenia;
TGCT	cis	rs12701220	0.817	rs59471534	chr7:1085224	G/A	cg27454412	chr7:1067447	C7orf50	-0.48	-4.45	-0.37	1.87e-5	Bronchopulmonary dysplasia;
TGCT	cis	rs7584330	0.737	rs7595979	chr2:238364492	G/T	cg14458575	chr2:238380390	NA	0.51	8.11	0.59	4.19e-13	Prostate cancer;
TGCT	cis	rs9899728	0.665	rs2307008	chr17:73042682	G/A	cg27626185	chr17:73056755	KCTD2	-0.66	-6.23	-0.49	6.77e-9	Alzheimer's disease or small vessel stroke;
TGCT	cis	rs7772486	0.686	rs1337839	chr6:146010239	A/G	cg23711669	chr6:146136114	FBXO30	-0.85	-9.45	-0.65	2.66e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg04944784	chr2:26401820	FAM59B	-0.76	-6.24	-0.49	6.46e-9	Gut microbiome composition (summer);
TGCT	cis	rs13256369	1.000	rs13282915	chr8:8570891	T/G	cg18904891	chr8:8559673	CLDN23	0.59	5.54	0.45	1.73e-7	Obesity-related traits;
TGCT	cis	rs6867032	0.917	rs10474733	chr5:2004160	A/G	cg26168224	chr5:2018326	NA	-0.38	-5.97	-0.47	2.31e-8	Gut microbiome composition (winter);
TGCT	cis	rs4906332	1.000	rs11625172	chr14:103944912	G/A	cg26031613	chr14:104095156	KLC1	-0.52	-4.72	-0.39	6.31e-6	Coronary artery disease;
TGCT	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg24829409	chr8:58192753	C8orf71	-0.59	-5.18	-0.42	8.54e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9972944	0.691	rs10083837	chr17:63775311	C/G	cg07283582	chr17:63770753	CCDC46	0.26	5.05	0.41	1.53e-6	Total body bone mineral density;
TGCT	cis	rs9677476	0.516	rs6437001	chr2:232013304	G/T	cg07929768	chr2:232055508	NA	0.32	4.97	0.41	2.2e-6	Food antigen IgG levels;
TGCT	cis	rs34526934	0.608	rs7606110	chr2:177028551	T/C	cg26754761	chr2:177040938	NA	-0.28	-5.22	-0.42	7.15e-7	Obstructive sleep apnea trait (apnea hypopnea index);
TGCT	cis	rs17345786	1.000	rs17345786	chr3:101318318	A/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.86	-9.19	-0.64	1.17e-15	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs17685	0.712	rs1637049	chr7:75729975	C/G	cg19862616	chr7:65841803	NCRNA00174	0.48	7.75	0.57	2.84e-12	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg20637647	chr7:64974828	NA	1.0	5.59	0.45	1.4e-7	Diabetic kidney disease;
TGCT	cis	rs7914558	1.000	rs7896547	chr10:104866958	A/G	cg15744005	chr10:104629667	AS3MT	-0.42	-5.21	-0.42	7.57e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs2228479	0.867	rs62056110	chr16:89946388	A/C	cg19635926	chr16:89946313	TCF25	0.28	4.8	0.4	4.47e-6	Skin colour saturation;
TGCT	cis	rs4319547	0.695	rs10773103	chr12:122856532	A/G	cg05707623	chr12:122985044	ZCCHC8	0.62	4.87	0.4	3.32e-6	Body mass index;
TGCT	cis	rs700590	0.632	rs244754	chr5:88144026	A/G	cg22951263	chr5:87985283	NA	0.54	5.06	0.41	1.48e-6	Educational attainment (years of education);
TGCT	cis	rs6906287	0.647	rs12665409	chr6:118685043	G/A	cg21191810	chr6:118973309	C6orf204	0.26	4.46	0.37	1.85e-5	Electrocardiographic conduction measures;
TGCT	cis	rs1697139	0.583	rs6895853	chr5:66541427	T/C	cg11553311	chr5:66541588	NA	0.27	5.82	0.46	4.78e-8	Breast cancer;
TGCT	cis	rs6671200	0.607	rs6671408	chr1:95697091	T/C	cg06440946	chr1:95699313	RWDD3	-0.62	-5.26	-0.43	6.12e-7	Stearic acid (18:0) levels;
TGCT	cis	rs17473412	0.577	rs9327301	chr5:122860170	G/A	cg15125798	chr5:122621645	NA	-0.53	-4.9	-0.4	2.93e-6	Total body bone mineral density;
TGCT	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg11764359	chr7:65958608	NA	0.54	5.02	0.41	1.73e-6	Aortic root size;
TGCT	cis	rs1971256	0.500	rs3912290	chr6:151818297	T/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.75	-4.62	-0.38	9.37e-6	Endometriosis;
TGCT	cis	rs614226	1.000	rs1167727	chr12:120965508	C/A	cg10072921	chr12:121022843	NA	-0.44	-4.74	-0.39	5.78e-6	Type 1 diabetes nephropathy;
TGCT	cis	rs67460515	0.892	rs35310734	chr3:160943209	T/G	cg03342759	chr3:160939853	NMD3	-0.49	-5.2	-0.42	7.93e-7	Parkinson's disease;
TGCT	cis	rs4900538	0.855	rs1209151	chr14:102893756	C/T	cg18135206	chr14:102964638	TECPR2	-0.2	-4.51	-0.38	1.48e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs17345786	0.954	rs17508319	chr3:101318903	G/A	cg12386194	chr3:101231763	SENP7	0.61	5.75	0.46	6.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs941408	1.000	rs2741990	chr19:2796644	C/T	cg19676328	chr12:49525230	TUBA1B	-0.77	-7.83	-0.58	1.84e-12	Total cholesterol levels;
TGCT	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg25767906	chr1:53392781	SCP2	-0.51	-5.97	-0.47	2.32e-8	Monocyte count;
TGCT	cis	rs12477438	0.605	rs4585080	chr2:99557327	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-5.34	-0.43	4.19e-7	Chronic sinus infection;
TGCT	cis	rs514406	0.505	rs269290	chr1:53167027	A/T	cg24675658	chr1:53192096	ZYG11B	-0.74	-8.3	-0.6	1.52e-13	Monocyte count;
TGCT	cis	rs9902453	0.845	rs116840018	chr17:28232049	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.81	7.26	0.55	3.67e-11	Coffee consumption (cups per day);
TGCT	cis	rs3824867	0.920	rs80241400	chr11:47453828	T/C	cg20307385	chr11:47447363	PSMC3	-0.69	-5.86	-0.47	3.99e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs1865760	1.000	rs6910138	chr6:25904352	C/G	cg17042849	chr6:26104293	HIST1H4C	-0.52	-4.68	-0.39	7.33e-6	Height;
TGCT	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg14262678	chr6:151773367	RMND1;C6orf211	-0.51	-4.69	-0.39	7.11e-6	Menarche (age at onset);
TGCT	cis	rs7208859	0.573	rs73267865	chr17:29064204	C/G	cg13385521	chr17:29058706	SUZ12P	0.8	4.87	0.4	3.36e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs2235642	0.685	rs2667681	chr16:1653206	C/T	cg11375102	chr16:1583810	IFT140;TMEM204	-0.27	-4.58	-0.38	1.12e-5	Coronary artery disease;
TGCT	cis	rs1887596	0.672	rs1831466	chr13:27231212	C/G	cg01312412	chr13:27282625	NA	0.29	5.15	0.42	1.01e-6	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs9467773	0.967	rs9358954	chr6:26531178	A/G	cg15659132	chr6:26577336	NA	0.86	12.21	0.74	5.3e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs78487399	0.808	rs17030835	chr2:43686245	C/G	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.74	4.77	0.39	5.16e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs4332037	0.539	rs56180486	chr7:2050747	C/T	cg25834613	chr7:1915315	MAD1L1	-0.52	-5.08	-0.42	1.33e-6	Bipolar disorder;
TGCT	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg24531977	chr5:56204891	C5orf35	-0.77	-7.61	-0.56	5.83e-12	Initial pursuit acceleration;
TGCT	cis	rs6969780	0.673	rs2301721	chr7:27196113	C/T	cg11410718	chr7:27170412	HOXA4	-0.46	-4.57	-0.38	1.18e-5	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs3733585	0.673	rs4459990	chr4:9954005	T/C	cg00071950	chr4:10020882	SLC2A9	-0.55	-6.58	-0.51	1.21e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs4788570	0.527	rs72791971	chr16:71477297	C/G	cg06353428	chr16:71660113	MARVELD3	-1.37	-7.39	-0.55	1.91e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs13064411	0.696	rs7613546	chr3:113228019	G/A	cg18753928	chr3:113234510	CCDC52	-0.71	-5.78	-0.46	5.63e-8	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs644799	0.525	rs3016206	chr11:95536724	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	8.28	0.6	1.66e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs751728	0.626	rs57150921	chr6:33737518	T/C	cg13859433	chr6:33739653	LEMD2	-0.32	-5.6	-0.45	1.29e-7	Crohn's disease;
TGCT	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg23708337	chr7:1209742	NA	0.51	4.5	0.37	1.56e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1005224	0.889	rs10132250	chr14:76124380	C/A	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.66	-6.11	-0.48	1.18e-8	Large artery stroke;
TGCT	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg02487422	chr3:49467188	NICN1	0.53	4.94	0.41	2.43e-6	Menarche (age at onset);
TGCT	cis	rs1801251	0.752	rs2675966	chr2:233735543	T/C	cg08000102	chr2:233561755	GIGYF2	-0.44	-4.45	-0.37	1.87e-5	Coronary artery disease;
TGCT	cis	rs9399135	0.967	rs2183709	chr6:135377091	C/T	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.21e-6	Red blood cell count;
TGCT	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg23574427	chr4:122746245	BBS7;CCNA2	-0.35	-5.31	-0.43	4.79e-7	Type 2 diabetes;
TGCT	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg13393036	chr8:95962371	TP53INP1	-0.63	-8.52	-0.61	4.51e-14	Type 2 diabetes;
TGCT	cis	rs72717009	0.825	rs867624	chr1:161467837	A/T	cg23840854	chr1:161414152	NA	-1.02	-6.37	-0.5	3.42e-9	Rheumatoid arthritis;
TGCT	cis	rs68170813	0.652	rs56949084	chr7:107157387	G/A	cg02696742	chr7:106810147	HBP1	-0.58	-4.47	-0.37	1.74e-5	Coronary artery disease;
TGCT	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs921968	0.541	rs588770	chr2:219494638	T/C	cg02176678	chr2:219576539	TTLL4	0.47	6.7	0.52	6.62e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs6920965	0.563	rs1544292	chr6:126175093	G/C	cg05901451	chr6:126070800	HEY2	-0.58	-5.11	-0.42	1.16e-6	High light scatter reticulocyte count;
TGCT	cis	rs1552244	0.554	rs3846169	chr3:9997054	A/G	cg00149659	chr3:10157352	C3orf10	-0.64	-4.74	-0.39	5.69e-6	Alzheimer's disease;
TGCT	cis	rs17376456	0.877	rs35747258	chr5:93310129	C/T	cg25358565	chr5:93447407	FAM172A	0.98	8.39	0.6	9.01e-14	Diabetic retinopathy;
TGCT	cis	rs11105298	0.838	rs10858862	chr12:89842053	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.67	-4.74	-0.39	5.67e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs7937682	0.883	rs568038	chr11:111432161	A/C	cg09085632	chr11:111637200	PPP2R1B	0.99	10.25	0.68	3.19e-18	Primary sclerosing cholangitis;
TGCT	cis	rs797680	0.856	rs569414	chr1:93784901	G/A	cg17826107	chr1:92977322	EVI5	-0.22	-5.05	-0.41	1.53e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg03264133	chr6:25882463	NA	-0.73	-7.73	-0.57	3.2e-12	Blood metabolite levels;
TGCT	cis	rs9435341	0.896	rs1623927	chr1:107596120	T/C	cg09367891	chr1:107599246	PRMT6	-0.64	-5.5	-0.44	2.07e-7	Facial morphology (factor 21, depth of nasal alae);
TGCT	cis	rs9527	0.571	rs3740400	chr10:104629465	T/G	cg15744005	chr10:104629667	AS3MT	-0.5	-6.4	-0.5	2.92e-9	Arsenic metabolism;
TGCT	cis	rs13394619	0.605	rs12476152	chr2:11747960	T/C	cg07314298	chr2:11723111	GREB1	0.28	4.58	0.38	1.12e-5	Endometriosis;
TGCT	cis	rs1971762	0.545	rs11170632	chr12:54047935	C/T	cg16917193	chr12:54089295	NA	-1.08	-11.6	-0.72	1.59e-21	Height;
TGCT	cis	rs2290402	0.536	rs3775129	chr4:875155	G/A	cg23332689	chr4:987652	IDUA;SLC26A1	0.32	4.92	0.4	2.64e-6	Type 2 diabetes;
TGCT	cis	rs9814567	1.000	rs6763093	chr3:134254995	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.96	9.11	0.63	1.79e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg11494091	chr17:61959527	GH2	0.6	14.54	0.79	1.46e-28	Prudent dietary pattern;
TGCT	cis	rs7731657	0.537	rs4705917	chr5:130206326	A/G	cg08523029	chr5:130500466	HINT1	-0.59	-4.99	-0.41	1.99e-6	Fasting plasma glucose;
TGCT	cis	rs17376456	0.757	rs10066431	chr5:93198204	A/G	cg21475434	chr5:93447410	FAM172A	0.69	4.81	0.4	4.36e-6	Diabetic retinopathy;
TGCT	cis	rs1040555	0.516	rs242547	chr20:31418581	T/C	cg13636640	chr20:31349939	DNMT3B	0.79	8.47	0.61	5.92e-14	Lymphocyte percentage of white cells;
TGCT	cis	rs6500602	0.563	rs917304	chr16:4440426	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.38	5.56	0.45	1.55e-7	Schizophrenia;
TGCT	cis	rs9341808	0.754	rs9361591	chr6:80953255	C/A	cg08355045	chr6:80787529	NA	0.29	5.1	0.42	1.23e-6	Sitting height ratio;
TGCT	cis	rs765787	0.530	rs55920042	chr15:45541577	G/A	cg24006582	chr15:45444508	DUOX1	-0.25	-5.54	-0.45	1.76e-7	Uric acid levels;
TGCT	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg06713675	chr4:122721982	EXOSC9	-0.69	-9.69	-0.66	7.11e-17	Type 2 diabetes;
TGCT	cis	rs3784262	0.528	rs17820966	chr15:58336662	A/G	cg12031962	chr15:58353849	ALDH1A2	0.42	6.3	0.49	4.84e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs7568458	0.660	rs6547623	chr2:85801964	T/A	cg17127132	chr2:85788382	GGCX	0.52	4.9	0.4	2.96e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs17102423	0.559	rs4899160	chr14:65481212	C/T	cg11161011	chr14:65562177	MAX	-0.46	-5.19	-0.42	8.38e-7	Obesity-related traits;
TGCT	cis	rs2456568	0.775	rs1607404	chr11:93660449	C/G	cg17595323	chr11:93583763	C11orf90	-0.47	-6.04	-0.48	1.65e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs3784262	1.000	rs4369598	chr15:58318603	G/T	cg12031962	chr15:58353849	ALDH1A2	-0.52	-7.98	-0.58	8.57e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs9560113	0.960	rs953260	chr13:112173685	C/T	cg14154082	chr13:112174009	NA	0.34	4.58	0.38	1.1e-5	Menarche (age at onset);
TGCT	cis	rs4478858	0.684	rs1532861	chr1:31766491	T/C	cg07478791	chr1:31886160	SERINC2	-0.52	-5.02	-0.41	1.73e-6	Alcohol dependence;
TGCT	cis	rs7909074	0.691	rs11239274	chr10:45393219	A/C	cg04218760	chr10:45406644	TMEM72	0.25	4.83	0.4	3.87e-6	Mean corpuscular volume;
TGCT	cis	rs9296092	0.538	rs62407564	chr6:33534010	C/T	cg13560919	chr6:33536144	NA	-0.23	-4.95	-0.41	2.4e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs611744	0.631	rs681963	chr8:109255032	C/A	cg21045802	chr8:109455806	TTC35	0.72	7.28	0.55	3.32e-11	Dupuytren's disease;
TGCT	cis	rs6688613	0.840	rs6669886	chr1:166956710	T/C	cg07049167	chr1:166818506	POGK	0.26	5.18	0.42	8.56e-7	Refractive astigmatism;
TGCT	cis	rs10089	1.000	rs73337363	chr5:127483597	A/G	cg19767477	chr5:127420684	SLC12A2	-0.43	-4.55	-0.38	1.27e-5	Ileal carcinoids;
TGCT	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg05665937	chr4:1216051	CTBP1	0.24	4.61	0.38	1e-5	Obesity-related traits;
TGCT	cis	rs7647973	1.000	rs1464569	chr3:49460350	A/G	cg07636037	chr3:49044803	WDR6	0.64	5.26	0.43	6.12e-7	Menarche (age at onset);
TGCT	cis	rs68170813	0.641	rs74524528	chr7:107090979	G/A	cg02696742	chr7:106810147	HBP1	-0.65	-5.15	-0.42	1.01e-6	Coronary artery disease;
TGCT	cis	rs910187	0.605	rs8124995	chr20:45811788	G/T	cg27589058	chr20:45804311	EYA2	-0.38	-8.34	-0.6	1.18e-13	Migraine;
TGCT	cis	rs7917772	0.503	rs11191347	chr10:104351617	C/T	cg05855489	chr10:104503620	C10orf26	-0.61	-5.41	-0.44	3.16e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1997103	1.000	rs2177803	chr7:55410773	A/G	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs1334894	1.000	rs72913417	chr6:35546866	C/T	cg24281267	chr6:35479648	TULP1	-0.44	-4.49	-0.37	1.59e-5	Coronary artery disease;
TGCT	cis	rs7659604	0.540	rs28615388	chr4:122678418	C/T	cg19748678	chr4:122722346	EXOSC9	-0.51	-5.0	-0.41	1.92e-6	Type 2 diabetes;
TGCT	cis	rs208520	1.000	rs12190316	chr6:66973365	T/C	cg07460842	chr6:66804631	NA	0.77	6.82	0.52	3.49e-10	Exhaled nitric oxide output;
TGCT	cis	rs6570726	0.577	rs441982	chr6:145842848	A/G	cg23711669	chr6:146136114	FBXO30	0.71	6.29	0.49	4.94e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg10047753	chr17:41438598	NA	0.79	7.5	0.56	1.06e-11	Menopause (age at onset);
TGCT	cis	rs950169	0.959	rs12911210	chr15:84792083	A/C	cg11189052	chr15:85197271	WDR73	0.7	5.9	0.47	3.28e-8	Schizophrenia;
TGCT	cis	rs12477438	0.520	rs11123761	chr2:99705903	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	8.52	0.61	4.42e-14	Chronic sinus infection;
TGCT	cis	rs2404602	0.608	rs17361504	chr15:76601871	A/G	cg22467129	chr15:76604101	ETFA	-0.63	-8.02	-0.58	6.71e-13	Blood metabolite levels;
TGCT	cis	rs2463822	1.000	rs2463825	chr11:62094493	G/A	cg23876832	chr11:62092739	NA	0.67	4.91	0.4	2.82e-6	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs524023	0.957	rs893006	chr11:64365796	C/A	cg07733098	chr11:64478343	NRXN2	0.32	4.76	0.39	5.35e-6	Urate levels in obese individuals;
TGCT	cis	rs4746818	0.818	rs7076011	chr10:70900430	T/C	cg11621586	chr10:70884670	VPS26A	1.21	10.66	0.69	3.17e-19	Left atrial antero-posterior diameter;
TGCT	cis	rs10465746	0.967	rs11163874	chr1:84424437	G/C	cg10977910	chr1:84465055	TTLL7	0.65	6.56	0.51	1.31e-9	Obesity-related traits;
TGCT	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg05368731	chr17:41323189	NBR1	1.1	11.24	0.71	1.23e-20	Menopause (age at onset);
TGCT	trans	rs208515	0.525	rs12193034	chr6:66677866	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.93	10.3	0.68	2.34e-18	Exhaled nitric oxide levels;
TGCT	cis	rs6762477	0.505	rs17304079	chr3:50085153	A/G	cg14019146	chr3:50243930	SLC38A3	-0.21	-4.51	-0.38	1.47e-5	Menarche (age at onset);
TGCT	cis	rs6089829	0.851	rs10854168	chr20:61669550	A/G	cg02380750	chr20:61661411	NA	0.35	5.68	0.45	9.19e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7513165	1.000	rs11240695	chr1:204158132	C/A	cg04791601	chr1:204159016	NA	0.26	4.95	0.41	2.38e-6	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
TGCT	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	7.1	0.54	8.45e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.75	11.22	0.71	1.36e-20	Subjective well-being;
TGCT	cis	rs7091068	0.574	rs10748610	chr10:95462235	C/G	cg20715218	chr10:95462985	C10orf4	0.54	5.07	0.41	1.39e-6	Urinary tract infection frequency;
TGCT	cis	rs600231	0.623	rs587080	chr11:65253800	A/C	cg17120908	chr11:65337727	SSSCA1	-0.56	-5.19	-0.42	8.17e-7	Bone mineral density;
TGCT	cis	rs9911578	1.000	rs3744109	chr17:56594197	C/T	cg12560992	chr17:57184187	TRIM37	-0.76	-9.34	-0.64	4.88e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs2191566	0.960	rs11083733	chr19:44520919	G/C	cg03039196	chr19:44506973	ZNF230	0.52	4.45	0.37	1.87e-5	Acute lymphoblastic leukemia (childhood);
TGCT	cis	rs7617773	0.817	rs11130163	chr3:48312658	T/C	cg11946769	chr3:48343235	NME6	0.73	6.8	0.52	3.86e-10	Coronary artery disease;
TGCT	cis	rs12142240	0.698	rs1475388	chr1:46816465	G/A	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs7584330	0.868	rs13386290	chr2:238393136	G/C	cg08992911	chr2:238395768	MLPH	0.62	4.51	0.38	1.49e-5	Prostate cancer;
TGCT	cis	rs10992471	0.605	rs7872375	chr9:95064843	C/G	cg14311495	chr9:95764742	FGD3	-0.22	-4.44	-0.37	1.95e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.96	7.8	0.57	2.16e-12	Platelet count;
TGCT	cis	rs7267979	0.789	rs6050472	chr20:25219852	A/G	cg16686733	chr20:25566563	NINL	0.49	4.53	0.38	1.36e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg11644478	chr21:40555479	PSMG1	-0.62	-5.81	-0.46	4.87e-8	Cognitive function;
TGCT	cis	rs2072499	1.000	rs2241107	chr1:156182710	C/T	cg06970220	chr1:156163860	SLC25A44	-0.68	-6.01	-0.48	1.88e-8	Testicular germ cell tumor;
TGCT	cis	rs9611565	0.729	rs137831	chr22:41903813	A/C	cg03806693	chr22:41940476	POLR3H	-1.03	-11.06	-0.7	3.38e-20	Vitiligo;
TGCT	cis	rs9611565	0.729	rs169362	chr22:41827589	G/C	cg13695892	chr22:41940480	POLR3H	0.86	8.55	0.61	3.95e-14	Vitiligo;
TGCT	cis	rs55794721	0.509	rs2982358	chr1:25745204	G/T	cg10117171	chr1:25599238	RHD	-0.35	-5.73	-0.46	7.34e-8	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs9910055	0.529	rs408282	chr17:42182267	A/G	cg13607699	chr17:42295918	UBTF	-0.65	-5.39	-0.44	3.34e-7	Total body bone mineral density;
TGCT	cis	rs651907	0.514	rs12636046	chr3:101434448	T/G	cg11279151	chr3:101281821	RG9MTD1	-0.34	-7.02	-0.53	1.27e-10	Colorectal cancer;
TGCT	cis	rs7582180	0.606	rs4851299	chr2:100954191	C/A	cg08017756	chr2:100939284	LONRF2	-0.3	-4.87	-0.4	3.27e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs904251	0.864	rs2797801	chr6:37487161	A/G	cg25019722	chr6:37503610	NA	-0.51	-7.03	-0.53	1.24e-10	Cognitive performance;
TGCT	cis	rs72781680	0.848	rs715646	chr2:24010566	G/A	cg08917208	chr2:24149416	ATAD2B	0.81	5.01	0.41	1.8e-6	Lymphocyte counts;
TGCT	trans	rs34034104	1.000	rs34034104	chr15:40725033	C/A	cg01027929	chr7:26241406	HNRNPA2B1;CBX3	-0.72	-6.68	-0.51	7.22e-10	Itch intensity from mosquito bite adjusted by bite size;Itch intensity from mosquito bite;
TGCT	cis	rs7772486	0.754	rs6915718	chr6:146100676	A/G	cg23711669	chr6:146136114	FBXO30	-0.93	-10.53	-0.69	6.46e-19	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg03303774	chr4:1407052	NA	0.31	4.93	0.4	2.58e-6	Obesity-related traits;
TGCT	cis	rs6671200	0.607	rs10874908	chr1:95704151	C/G	cg06440946	chr1:95699313	RWDD3	-0.62	-5.3	-0.43	5.09e-7	Stearic acid (18:0) levels;
TGCT	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg24531977	chr5:56204891	C5orf35	0.68	7.14	0.54	6.98e-11	Initial pursuit acceleration;
TGCT	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg11845111	chr2:191398756	TMEM194B	0.37	5.65	0.45	1.03e-7	Pulse pressure;
TGCT	trans	rs459571	0.959	rs465724	chr9:136910097	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.73	-7.79	-0.57	2.29e-12	Platelet distribution width;
TGCT	cis	rs763121	0.853	rs5757213	chr22:39053888	C/T	cg06022373	chr22:39101656	GTPBP1	0.77	7.46	0.56	1.35e-11	Menopause (age at onset);
TGCT	cis	rs362272	0.524	rs6819202	chr4:3368264	G/A	cg06533319	chr4:3265114	C4orf44	-0.25	-5.14	-0.42	1.04e-6	Serum sulfate level;
TGCT	cis	rs9470794	0.607	rs1931761	chr6:38202822	C/G	cg03166753	chr6:38683221	NA	0.6	4.53	0.38	1.37e-5	Type 2 diabetes;
TGCT	trans	rs877282	0.891	rs11595385	chr10:800539	A/G	cg22713356	chr15:30763199	NA	1.18	9.92	0.67	1.96e-17	Uric acid levels;
TGCT	cis	rs7119038	0.818	rs10892287	chr11:118642999	C/T	cg19308663	chr11:118741387	NA	-0.27	-5.43	-0.44	2.86e-7	Sjögren's syndrome;
TGCT	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.69	-6.97	-0.53	1.64e-10	Prostate cancer;
TGCT	cis	rs10744422	1.000	rs7959441	chr12:123363825	C/T	cg25930673	chr12:123319894	HIP1R	-0.86	-5.08	-0.42	1.34e-6	Schizophrenia;
TGCT	cis	rs3087591	0.960	rs757384	chr17:29596135	C/T	cg24425628	chr17:29625626	OMG;NF1	0.46	7.28	0.55	3.41e-11	Hip circumference;
TGCT	cis	rs1865760	0.964	rs6932113	chr6:25913098	C/T	cg16482183	chr6:26056742	HIST1H1C	0.55	4.97	0.41	2.19e-6	Height;
TGCT	cis	rs9818758	0.607	rs35060561	chr3:49255503	T/C	cg07636037	chr3:49044803	WDR6	-1.04	-5.13	-0.42	1.09e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs727505	1.000	rs66513837	chr7:124492763	A/G	cg23710748	chr7:124431027	NA	-0.26	-4.49	-0.37	1.6e-5	Lewy body disease;
TGCT	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg24060327	chr5:131705240	SLC22A5	-0.74	-7.84	-0.58	1.73e-12	Acylcarnitine levels;
TGCT	cis	rs8017423	0.967	rs61592400	chr14:90703252	T/C	cg04374321	chr14:90722782	PSMC1	0.77	8.05	0.59	5.68e-13	Mortality in heart failure;
TGCT	cis	rs617219	0.698	rs72764983	chr5:78513806	T/C	cg05890484	chr5:78407552	BHMT	0.39	5.31	0.43	5e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs9389248	0.690	rs2294321	chr6:135253048	T/G	cg22676075	chr6:135203613	NA	-0.51	-5.11	-0.42	1.17e-6	High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs6684514	1.000	rs12024813	chr1:156224529	C/A	cg20302342	chr1:156215951	PAQR6	0.37	4.73	0.39	6e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs10876993	0.928	rs10082911	chr12:58104104	C/A	cg15848620	chr12:58087721	OS9	-0.72	-6.01	-0.48	1.89e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs9359856	0.510	rs4053618	chr6:90459454	G/A	cg13799429	chr6:90582589	CASP8AP2	0.45	4.66	0.39	7.9e-6	Bipolar disorder;
TGCT	cis	rs2303745	0.589	rs11086065	chr19:17395003	A/G	cg04248312	chr19:17393744	ANKLE1	-0.34	-5.7	-0.46	8.29e-8	Systemic lupus erythematosus;
TGCT	cis	rs6547741	0.935	rs6547738	chr2:27852637	A/G	cg27432699	chr2:27873401	GPN1	0.18	4.56	0.38	1.19e-5	Oral cavity cancer;
TGCT	cis	rs2735413	0.564	rs78769909	chr16:78104002	G/A	cg09132178	chr16:78079569	NA	0.35	4.72	0.39	6.29e-6	Systolic blood pressure (alcohol consumption interaction);
TGCT	cis	rs7312933	0.576	rs11181364	chr12:42567800	C/T	cg19980929	chr12:42632907	YAF2	0.47	6.46	0.5	2.13e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs10791097	0.694	rs4937581	chr11:130740335	T/C	cg12179176	chr11:130786555	SNX19	0.84	10.17	0.67	4.95e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs6088580	0.634	rs7271970	chr20:32987666	A/G	cg06115741	chr20:33292138	TP53INP2	-0.53	-4.67	-0.39	7.83e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs2739330	0.576	rs2858912	chr22:24297197	A/G	cg24846343	chr22:24311635	DDTL	0.22	5.68	0.45	9.16e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs10779751	0.770	rs1057079	chr1:11205058	A/G	cg08854313	chr1:11322531	MTOR	-0.81	-7.96	-0.58	9.32e-13	Body mass index;
TGCT	cis	rs72949976	0.646	rs13029384	chr2:214029164	G/A	cg08319019	chr2:214017104	IKZF2	0.87	8.64	0.61	2.34e-14	Lung cancer;Squamous cell lung carcinoma;
TGCT	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg27588902	chr6:42928151	GNMT	-0.51	-6.07	-0.48	1.42e-8	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.55	4.94	0.41	2.44e-6	Prudent dietary pattern;
TGCT	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.56	-7.16	-0.54	6.17e-11	Longevity;Endometriosis;
TGCT	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg07061783	chr6:25882402	NA	-0.57	-5.31	-0.43	4.95e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs4654899	1.000	rs6663452	chr1:21423154	T/C	cg01072550	chr1:21505969	NA	-0.49	-7.88	-0.58	1.41e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs2594989	0.943	rs4580536	chr3:11422319	A/G	cg00170343	chr3:11313890	ATG7	0.67	4.9	0.4	2.9e-6	Circulating chemerin levels;
TGCT	cis	rs7085104	0.552	rs11191414	chr10:104601565	A/T	cg15744005	chr10:104629667	AS3MT	-0.43	-5.37	-0.43	3.77e-7	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg00684032	chr4:1343700	KIAA1530	0.24	5.16	0.42	9.67e-7	Obesity-related traits;
TGCT	cis	rs34783982	0.529	rs1850324	chr15:89472267	A/G	cg26213453	chr15:89455860	MFGE8	0.33	5.25	0.43	6.45e-7	Squamous cell lung carcinoma;
TGCT	trans	rs1814175	0.935	rs6485999	chr11:49658986	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.34	-6.67	-0.51	7.47e-10	Height;
TGCT	cis	rs1670533	1.000	rs604597	chr4:1094151	G/A	cg20518497	chr4:1046821	NA	0.27	4.46	0.37	1.82e-5	Recombination rate (females);
TGCT	cis	rs7666738	0.830	rs28619044	chr4:98789814	G/C	cg17366294	chr4:99064904	C4orf37	0.65	6.79	0.52	4.13e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg11494091	chr17:61959527	GH2	0.61	14.45	0.79	2.29e-28	Prudent dietary pattern;
TGCT	cis	rs889312	0.500	rs11960484	chr5:56109154	C/T	cg12311346	chr5:56204834	C5orf35	0.43	4.66	0.39	8.14e-6	Breast cancer;Breast cancer (early onset);
TGCT	cis	rs8077577	0.895	rs62073602	chr17:18057907	A/G	cg09161412	chr17:18057145	MYO15A	-0.64	-5.3	-0.43	5.21e-7	Obesity-related traits;
TGCT	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg22963979	chr7:1858916	MAD1L1	-0.36	-5.53	-0.44	1.84e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs950169	0.922	rs11631096	chr15:85100929	G/C	cg17173187	chr15:85201210	NMB	0.5	5.04	0.41	1.62e-6	Schizophrenia;
TGCT	cis	rs3540	0.554	rs12900987	chr15:91071776	T/C	cg22089800	chr15:90895588	ZNF774	-0.75	-7.66	-0.57	4.62e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs11779988	0.545	rs422746	chr8:17784486	C/A	cg01800426	chr8:17659068	MTUS1	-0.7	-5.46	-0.44	2.5e-7	Breast cancer;
TGCT	cis	rs3751972	0.590	rs12051730	chr17:26266230	C/T	cg02948944	chr17:26242737	NA	-0.46	-5.55	-0.45	1.65e-7	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs3809566	0.676	rs4775607	chr15:63328007	C/T	cg08198488	chr15:63333792	TPM1	-0.34	-5.26	-0.43	6.02e-7	Platelet count;
TGCT	cis	rs4824093	0.610	rs73441787	chr22:50269646	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.48	4.97	0.41	2.17e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs9990333	0.562	rs12632706	chr3:195815594	C/T	cg14488913	chr3:195402182	SDHAP2	-0.37	-4.64	-0.38	8.57e-6	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);
TGCT	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg27425262	chr2:113953981	PSD4;LOC440839	0.52	8.03	0.59	6.32e-13	Lymphocyte counts;
TGCT	cis	rs9677476	0.608	rs7606037	chr2:232054576	T/C	cg07929768	chr2:232055508	NA	0.34	5.48	0.44	2.26e-7	Food antigen IgG levels;
TGCT	cis	rs6121246	0.529	rs7261354	chr20:30202414	T/C	cg18721089	chr20:30220636	NA	-0.57	-6.19	-0.49	7.9e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs1801251	0.929	rs10933409	chr2:233629386	A/G	cg08000102	chr2:233561755	GIGYF2	0.64	6.56	0.51	1.34e-9	Coronary artery disease;
TGCT	cis	rs453301	0.500	rs7015336	chr8:8830720	G/A	cg06636001	chr8:8085503	FLJ10661	0.76	6.26	0.49	5.85e-9	Joint mobility (Beighton score);
TGCT	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg08280861	chr8:58055591	NA	0.4	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg03213289	chr20:61660250	NA	0.68	9.9	0.66	2.25e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs4478858	0.735	rs10798842	chr1:31778648	A/G	cg00250761	chr1:31883323	NA	-0.27	-4.94	-0.41	2.43e-6	Alcohol dependence;
TGCT	cis	rs933688	0.689	rs12697808	chr5:90605389	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.65	-5.55	-0.45	1.67e-7	Smoking behavior;
TGCT	cis	rs710216	0.917	rs4660691	chr1:43417150	T/G	cg03128534	chr1:43423976	SLC2A1	-0.58	-4.65	-0.39	8.48e-6	Red cell distribution width;
TGCT	cis	rs2303745	0.589	rs6512179	chr19:17399105	T/C	cg02221750	chr19:17393354	ANKLE1	-0.46	-5.87	-0.47	3.73e-8	Systemic lupus erythematosus;
TGCT	cis	rs7829975	0.606	rs7837026	chr8:8801692	T/C	cg08975724	chr8:8085496	FLJ10661	-0.55	-4.57	-0.38	1.15e-5	Mood instability;
TGCT	cis	rs9976767	0.637	rs9784215	chr21:43823736	C/A	cg23042151	chr21:43824109	UBASH3A	-0.23	-5.14	-0.42	1.02e-6	Type 1 diabetes;
TGCT	cis	rs9814567	0.896	rs6799110	chr3:134206749	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.95	-9.62	-0.65	1.04e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs2153535	0.505	rs1335629	chr6:8491863	C/T	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs7914558	0.966	rs56946876	chr10:104653545	T/C	cg15744005	chr10:104629667	AS3MT	-0.41	-5.09	-0.42	1.29e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs763121	0.853	rs9610986	chr22:39025277	T/C	cg06022373	chr22:39101656	GTPBP1	0.78	7.44	0.56	1.48e-11	Menopause (age at onset);
TGCT	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.36	0.55	2.25e-11	Prudent dietary pattern;
TGCT	cis	rs7666738	0.830	rs991168	chr4:98928293	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs2688608	0.620	rs7080350	chr10:75577843	A/G	cg13918328	chr10:52500089	ASAH2B	-0.7	-7.21	-0.54	4.8e-11	Inflammatory bowel disease;
TGCT	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	6.75	0.52	5.02e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	trans	rs7613875	0.600	rs2624848	chr3:50165101	T/C	cg21659725	chr3:3221576	CRBN	-0.71	-7.96	-0.58	9.31e-13	Body mass index;
TGCT	trans	rs2727020	0.521	rs7131163	chr11:49574774	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.42	-8.32	-0.6	1.37e-13	Coronary artery disease;
TGCT	cis	rs9457247	0.967	rs86755	chr6:167403108	T/C	cg23791538	chr6:167370224	RNASET2	-0.49	-4.96	-0.41	2.26e-6	Crohn's disease;
TGCT	cis	rs12497850	0.931	rs7430501	chr3:48890119	C/T	cg07636037	chr3:49044803	WDR6	0.95	10.74	0.69	2e-19	Parkinson's disease;
TGCT	cis	rs10464366	0.571	rs4723825	chr7:39157627	G/C	cg15212455	chr7:39170539	POU6F2	0.3	6.63	0.51	9.08e-10	IgG glycosylation;
TGCT	cis	rs62064224	0.614	rs2286645	chr17:30696292	C/T	cg18200150	chr17:30822561	MYO1D	0.38	4.44	0.37	1.97e-5	Schizophrenia;
TGCT	cis	rs7824557	0.569	rs10106207	chr8:11015338	C/T	cg27411982	chr8:10470053	RP1L1	-0.21	-4.67	-0.39	7.77e-6	Retinal vascular caliber;
TGCT	cis	rs9549367	0.713	rs3024744	chr13:113821477	A/C	cg18105134	chr13:113819100	PROZ	-0.47	-8.19	-0.59	2.73e-13	Platelet distribution width;
TGCT	cis	rs4689388	0.926	rs10937719	chr4:6295322	C/G	cg00701064	chr4:6280414	WFS1	0.37	4.48	0.37	1.65e-5	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs916888	0.779	rs430685	chr17:44859148	T/C	cg01570182	chr17:44337453	NA	-1.01	-9.1	-0.63	1.83e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7191700	0.836	rs28502009	chr16:11426541	G/A	cg00044050	chr16:11439710	C16orf75	0.68	5.67	0.45	9.4e-8	Multiple sclerosis;
TGCT	cis	rs2842992	0.830	rs1535475	chr6:160148935	T/C	cg11366901	chr6:160182831	ACAT2	1.04	6.93	0.53	2.05e-10	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg09359103	chr1:154839909	KCNN3	-0.71	-15.31	-0.81	2.37e-30	Prostate cancer;
TGCT	trans	rs13064411	0.542	rs11537650	chr3:113222036	G/A	cg00307254	chr3:126706825	PLXNA1	0.34	6.78	0.52	4.36e-10	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs11792861	0.781	rs11793272	chr9:111762102	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.5	4.69	0.39	6.99e-6	Menarche (age at onset);
TGCT	trans	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg17830980	chr10:43048298	ZNF37B	-0.86	-11.25	-0.71	1.16e-20	Extrinsic epigenetic age acceleration;
TGCT	cis	rs11696501	0.688	rs6065861	chr20:44311056	A/G	cg11783356	chr20:44313418	WFDC10B	-0.33	-4.49	-0.37	1.6e-5	Brain structure;
TGCT	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-8.64	-0.61	2.39e-14	Platelet count;
TGCT	cis	rs3780378	0.967	rs7857730	chr9:5084049	G/T	cg02405213	chr9:5042618	JAK2	-0.64	-8.62	-0.61	2.61e-14	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg22433210	chr17:43662623	NA	0.96	7.89	0.58	1.39e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7208859	0.673	rs216435	chr17:28922737	G/T	cg14008862	chr17:28927542	LRRC37B2	0.72	4.59	0.38	1.08e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs77972916	0.505	rs6756575	chr2:43528519	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.39	-5.68	-0.45	9.24e-8	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg19318889	chr4:1322082	MAEA	-0.2	-4.91	-0.4	2.8e-6	Obesity-related traits;
TGCT	cis	rs2692947	0.644	rs772154	chr2:97021664	G/T	cg23100626	chr2:96804247	ASTL	0.41	4.97	0.41	2.22e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs860295	0.580	rs2016251	chr1:155914988	C/T	cg05700447	chr1:155978627	NA	0.21	4.44	0.37	1.97e-5	Body mass index;
TGCT	cis	rs12188164	0.930	rs72717436	chr5:448291	C/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.4	-4.71	-0.39	6.42e-6	Cystic fibrosis severity;
TGCT	cis	rs8192284	0.965	rs61812598	chr1:154420087	G/A	cg11650704	chr1:154556575	ADAR	0.26	4.56	0.38	1.19e-5	Fibrinogen;C-reactive protein;Fibrinogen levels;
TGCT	cis	rs16958440	0.867	rs57744138	chr18:44700482	A/C	cg17192377	chr18:44677553	HDHD2	0.63	4.7	0.39	6.74e-6	Sitting height ratio;
TGCT	cis	rs9814567	1.000	rs9826496	chr3:134224437	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.95	-9.62	-0.65	1.04e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs9341808	0.667	rs12209624	chr6:80919133	G/A	cg08355045	chr6:80787529	NA	0.31	5.17	0.42	9.19e-7	Sitting height ratio;
TGCT	cis	rs2228479	0.702	rs62056090	chr16:89930087	T/A	cg06558623	chr16:89946397	TCF25	0.52	4.6	0.38	1.05e-5	Skin colour saturation;
TGCT	cis	rs2562456	0.761	rs35008138	chr19:21731624	A/T	cg25650185	chr19:21324782	ZNF431	-0.64	-5.73	-0.46	7.12e-8	Pain;
TGCT	cis	rs478304	0.593	rs9666878	chr11:65475816	A/C	cg17480646	chr11:65405466	SIPA1	0.61	8.04	0.59	6.16e-13	Acne (severe);
TGCT	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.57	-5.68	-0.45	9.16e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9399135	0.869	rs9402675	chr6:135325794	C/G	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.36e-6	Red blood cell count;
TGCT	trans	rs9383153	1.000	rs9370888	chr6:16335544	A/G	cg07330114	chr3:11624023	VGLL4	1.09	6.84	0.52	3.2e-10	Gambling;
TGCT	cis	rs28595532	1.000	rs73842212	chr4:119638122	A/G	cg11846333	chr4:119757529	SEC24D	0.9	4.52	0.38	1.42e-5	Cannabis dependence symptom count;
TGCT	cis	rs1577917	1.000	rs10455456	chr6:86670322	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.54	-0.45	1.73e-7	Response to antipsychotic treatment;
TGCT	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg21724239	chr8:58056113	NA	0.42	5.04	0.41	1.61e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs17030434	0.911	rs17030490	chr4:154738340	C/T	cg14289246	chr4:154710475	SFRP2	-0.88	-7.09	-0.54	8.77e-11	Electrocardiographic conduction measures;
TGCT	trans	rs1496653	0.602	rs75034324	chr3:23356795	T/G	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs1691799	0.899	rs1168317	chr12:66746225	C/T	cg16791601	chr12:66731901	HELB	-0.28	-6.18	-0.49	8.52e-9	White blood cell count (basophil);
TGCT	cis	rs9486719	0.894	rs34826652	chr6:96899085	A/G	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.21	-0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs7681440	0.904	rs58864428	chr4:90766986	T/C	cg01966878	chr4:90757139	SNCA	-0.25	-4.56	-0.38	1.2e-5	Dementia with Lewy bodies;
TGCT	cis	rs2153535	0.580	rs9406172	chr6:8515464	T/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.01	0.41	1.86e-6	Motion sickness;
TGCT	cis	rs7954584	0.616	rs10743185	chr12:122356435	G/A	cg22618164	chr12:122356400	WDR66	0.53	5.18	0.42	8.83e-7	Mean corpuscular volume;
TGCT	cis	rs35306767	0.953	rs12357633	chr10:957246	C/T	cg20503657	chr10:835505	NA	0.74	10.28	0.68	2.58e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg20573242	chr4:122745356	CCNA2	0.63	5.54	0.45	1.72e-7	Type 2 diabetes;
TGCT	trans	rs877282	0.898	rs11253343	chr10:765117	C/T	cg22713356	chr15:30763199	NA	1.2	9.39	0.64	3.76e-16	Uric acid levels;
TGCT	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg18876405	chr7:65276391	NA	-0.37	-5.57	-0.45	1.52e-7	Cotinine glucuronidation;
TGCT	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg02018176	chr4:1364513	KIAA1530	0.27	4.59	0.38	1.07e-5	Longevity;
TGCT	cis	rs6089584	1.000	rs6089580	chr20:60558976	G/A	cg16423285	chr20:60520624	NA	-0.52	-5.45	-0.44	2.6e-7	Body mass index;
TGCT	cis	rs78487399	0.665	rs17030980	chr2:43751480	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.37	-4.63	-0.38	9.08e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg08045932	chr20:61659980	NA	0.5	8.72	0.62	1.54e-14	Prostate cancer (SNP x SNP interaction);
TGCT	trans	rs459571	0.959	rs378740	chr9:136890876	C/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.71	-7.72	-0.57	3.29e-12	Platelet distribution width;
TGCT	cis	rs727505	1.000	rs28392553	chr7:124442944	C/T	cg23710748	chr7:124431027	NA	-0.27	-4.62	-0.38	9.49e-6	Lewy body disease;
TGCT	cis	rs11711311	1.000	rs9826808	chr3:113455644	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.78	-7.13	-0.54	7.14e-11	IgG glycosylation;
TGCT	cis	rs3820928	0.874	rs13419455	chr2:227850465	C/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-4.58	-0.38	1.1e-5	Pulmonary function;
TGCT	cis	rs4722166	0.630	rs7808457	chr7:22798265	A/T	cg26061582	chr7:22766209	IL6	-0.47	-6.15	-0.48	9.68e-9	Lung cancer;
TGCT	cis	rs4253772	0.591	rs9615938	chr22:46689468	G/A	cg24881330	chr22:46731750	TRMU	1.04	5.38	0.44	3.54e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs4563143	0.514	rs73029079	chr19:29294903	A/G	cg12756686	chr19:29218302	NA	0.67	5.16	0.42	9.34e-7	Methadone dose in opioid dependence;
TGCT	cis	rs7659604	0.643	rs6839054	chr4:122663628	C/T	cg06713675	chr4:122721982	EXOSC9	-0.45	-5.17	-0.42	9.22e-7	Type 2 diabetes;
TGCT	cis	rs3784262	0.643	rs2453280	chr15:58368379	C/T	cg12031962	chr15:58353849	ALDH1A2	0.4	5.72	0.46	7.56e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs3784262	0.669	rs4646626	chr15:58256127	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.42	-6.11	-0.48	1.19e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs6671200	1.000	rs34037437	chr1:95660921	C/G	cg03123541	chr1:95699097	RWDD3	0.87	6.17	0.48	8.81e-9	Stearic acid (18:0) levels;
TGCT	cis	rs28595532	0.920	rs115259971	chr4:119762654	T/C	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs4074961	0.669	rs6687545	chr1:38071195	C/T	cg11397548	chr1:38022522	DNALI1	0.43	4.78	0.39	4.95e-6	Axial length;
TGCT	cis	rs67478160	0.643	rs2295141	chr14:104212949	T/C	cg26031613	chr14:104095156	KLC1	-0.63	-6.53	-0.51	1.56e-9	Schizophrenia;
TGCT	cis	rs3733585	0.699	rs6844787	chr4:9959233	A/G	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.7	-0.57	3.69e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7246657	0.678	rs4802024	chr19:38052193	T/C	cg18154014	chr19:37997991	ZNF793	0.69	4.63	0.38	9.25e-6	Coronary artery calcification;
TGCT	cis	rs2549003	1.000	rs2070727	chr5:131820275	C/A	cg02551604	chr5:131831745	NA	-0.89	-11.95	-0.73	2.33e-22	Asthma (sex interaction);
TGCT	cis	rs6665290	0.904	rs3795451	chr1:227181923	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.98	-19.78	-0.87	3.72e-40	Myeloid white cell count;
TGCT	cis	rs12497850	0.931	rs7647813	chr3:48833348	G/T	cg06212747	chr3:49208901	KLHDC8B	0.62	5.83	0.46	4.42e-8	Parkinson's disease;
TGCT	cis	rs208515	0.525	rs9453538	chr6:66668508	G/A	cg07460842	chr6:66804631	NA	0.85	8.73	0.62	1.41e-14	Exhaled nitric oxide levels;
TGCT	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg25036284	chr2:26402008	FAM59B	-0.57	-5.0	-0.41	1.94e-6	Gut microbiome composition (summer);
TGCT	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg20607798	chr8:58055168	NA	0.62	5.23	0.43	6.99e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs453301	0.686	rs4840389	chr8:8884503	G/C	cg11995313	chr8:8860691	ERI1	0.54	4.73	0.39	6.09e-6	Joint mobility (Beighton score);
TGCT	cis	rs6582630	0.555	rs10880613	chr12:38509553	C/T	cg13010199	chr12:38710504	ALG10B	0.64	5.15	0.42	9.97e-7	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs986417	0.818	rs2351173	chr14:61008755	C/T	cg27398547	chr14:60952738	C14orf39	1.49	10.43	0.68	1.12e-18	Gut microbiota (bacterial taxa);
TGCT	cis	rs2228479	0.850	rs62056102	chr16:89941438	T/C	cg06558623	chr16:89946397	TCF25	0.62	7.04	0.53	1.19e-10	Skin colour saturation;
TGCT	cis	rs9921222	0.656	rs12719801	chr16:381141	C/T	cg12437481	chr16:420112	MRPL28	-0.52	-5.17	-0.42	9.01e-7	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs9467773	1.000	rs1884949	chr6:26568067	G/A	cg09904177	chr6:26538194	HMGN4	0.69	6.84	0.52	3.23e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	-0.78	-5.65	-0.45	1.03e-7	Platelet count;
TGCT	cis	rs3820068	0.581	rs6692461	chr1:15928449	A/G	cg05660106	chr1:15850417	CASP9	0.74	7.27	0.55	3.53e-11	Systolic blood pressure;
TGCT	cis	rs858239	0.601	rs10278776	chr7:23169759	C/T	cg05602783	chr7:23145260	KLHL7	-0.65	-5.48	-0.44	2.32e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs6424115	0.965	rs2502979	chr1:24149315	C/A	cg15997130	chr1:24165203	NA	0.92	10.57	0.69	5.26e-19	Immature fraction of reticulocytes;
TGCT	trans	rs11082438	1.000	rs11082438	chr18:42865210	G/T	cg11115673	chr10:50224628	C10orf72	-0.83	-7.11	-0.54	8.21e-11	Follicular lymphoma;
TGCT	cis	rs9990333	0.526	rs11719682	chr3:195834202	C/T	cg14488913	chr3:195402182	SDHAP2	-0.35	-4.47	-0.37	1.71e-5	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);
TGCT	cis	rs76473307	1.000	rs117182713	chr20:57379444	G/A	cg06163629	chr20:57414884	GNASAS;GNAS	-0.66	-4.53	-0.38	1.39e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs13242816	1.000	rs13243017	chr7:116189371	G/A	cg02799643	chr7:116139180	CAV2	-0.43	-5.29	-0.43	5.24e-7	P wave duration;
TGCT	cis	rs554111	0.634	rs4654875	chr1:21165176	A/G	cg01072550	chr1:21505969	NA	0.33	4.94	0.41	2.43e-6	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs7611238	0.520	rs9848201	chr3:195098843	A/T	cg27323046	chr3:195102265	ACAP2	0.39	5.11	0.42	1.18e-6	Body mass index;
TGCT	cis	rs2073300	1.000	rs6132626	chr20:23444672	T/C	cg09953122	chr20:23471693	CST8	-0.64	-4.56	-0.38	1.19e-5	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs7923609	0.967	rs6479896	chr10:65126832	T/C	cg08743896	chr10:65200160	JMJD1C	-0.34	-4.57	-0.38	1.14e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3540	0.597	rs7498113	chr15:91051192	C/G	cg22089800	chr15:90895588	ZNF774	-0.76	-7.96	-0.58	9.42e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs7267979	0.833	rs4619688	chr20:25244101	C/G	cg14121845	chr20:25566513	NINL	0.5	5.51	0.44	1.95e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg03303774	chr4:1407052	NA	0.32	5.03	0.41	1.69e-6	Obesity-related traits;
TGCT	cis	rs12497850	0.931	rs9840050	chr3:49133310	A/G	cg07636037	chr3:49044803	WDR6	0.96	10.9	0.7	8.39e-20	Parkinson's disease;
TGCT	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg11247378	chr22:39784982	NA	-0.73	-9.83	-0.66	3.22e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs2180341	1.000	rs3798853	chr6:127636823	C/T	cg24812749	chr6:127587940	RNF146	-0.96	-7.45	-0.56	1.42e-11	Breast cancer;
TGCT	cis	rs7267979	0.753	rs404148	chr20:25447931	A/G	cg13486641	chr20:25479848	NINL	-0.16	-4.54	-0.38	1.32e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1008375	0.932	rs6841784	chr4:17626418	G/A	cg16339924	chr4:17578868	LAP3	0.71	5.7	0.46	8.2e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9473924	0.542	rs9473946	chr6:50892950	G/A	cg14470998	chr6:50812995	TFAP2B	1.35	8.21	0.59	2.48e-13	Body mass index;
TGCT	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg24549020	chr5:56110836	MAP3K1	0.7	5.97	0.47	2.34e-8	Initial pursuit acceleration;
TGCT	cis	rs3820068	0.603	rs998032	chr1:15989918	T/C	cg05660106	chr1:15850417	CASP9	0.81	7.67	0.57	4.28e-12	Systolic blood pressure;
TGCT	cis	rs7226408	0.857	rs72888926	chr18:34530957	C/T	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs394563	0.591	rs6570963	chr6:149691355	T/G	cg03678062	chr6:149772716	ZC3H12D	0.38	4.8	0.4	4.4e-6	Dupuytren's disease;
TGCT	cis	rs78456975	0.527	rs10203194	chr2:1558021	A/G	cg01028140	chr2:1542097	TPO	-0.33	-5.12	-0.42	1.14e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs1008375	1.000	rs9991307	chr4:17662408	A/G	cg18681998	chr4:17616180	MED28	0.94	11.11	0.71	2.57e-20	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6964587	0.692	rs2299233	chr7:91626953	C/T	cg17063962	chr7:91808500	NA	-0.73	-6.97	-0.53	1.68e-10	Breast cancer;
TGCT	cis	rs7246657	0.722	rs2075284	chr19:38189616	T/C	cg18154014	chr19:37997991	ZNF793	-0.72	-5.06	-0.41	1.48e-6	Coronary artery calcification;
TGCT	cis	rs3820068	0.608	rs9660255	chr1:16031891	T/G	cg17385448	chr1:15911702	AGMAT	0.34	4.78	0.39	4.97e-6	Systolic blood pressure;
TGCT	cis	rs3806843	1.000	rs10037757	chr5:140197222	G/T	cg19875535	chr5:140030758	IK	0.35	5.73	0.46	7.12e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9326248	0.954	rs521171	chr11:117064693	C/G	cg16524733	chr11:117070046	TAGLN	0.33	4.9	0.4	2.98e-6	Blood protein levels;
TGCT	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg25036284	chr2:26402008	FAM59B	0.67	4.46	0.37	1.79e-5	Gut microbiome composition (summer);
TGCT	trans	rs8073060	0.859	rs17550268	chr17:33874678	T/C	cg19694781	chr19:47549865	TMEM160	0.53	10.2	0.68	4.19e-18	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs9467773	0.620	rs2494700	chr6:26631306	C/T	cg15659132	chr6:26577336	NA	0.86	11.04	0.7	3.71e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs13401104	0.587	rs56146026	chr2:237145629	A/G	cg26422059	chr2:237146110	ASB18	0.57	4.56	0.38	1.19e-5	Educational attainment;
TGCT	cis	rs7267979	0.808	rs84816	chr20:25459919	G/A	cg03522245	chr20:25566470	NINL	0.6	6.37	0.5	3.35e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2191566	0.960	rs12232810	chr19:44525122	A/G	cg03039196	chr19:44506973	ZNF230	0.53	4.48	0.37	1.7e-5	Acute lymphoblastic leukemia (childhood);
TGCT	cis	rs7973719	0.865	rs12820829	chr12:7347534	G/A	cg07052231	chr12:7363540	PEX5	0.37	5.68	0.45	9.04e-8	IgG glycosylation;
TGCT	trans	rs7618501	0.815	rs3819325	chr3:49843723	T/C	cg21659725	chr3:3221576	CRBN	0.99	15.51	0.81	8.11e-31	Intelligence (multi-trait analysis);
TGCT	cis	rs9611565	0.765	rs727563	chr22:41867377	C/T	cg13695892	chr22:41940480	POLR3H	0.86	8.61	0.61	2.75e-14	Vitiligo;
TGCT	cis	rs7588746	0.544	rs2163548	chr2:201226862	C/G	cg19045956	chr2:200819837	C2orf60;C2orf47	-0.64	-4.5	-0.37	1.56e-5	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	cis	rs12893668	0.608	rs12889721	chr14:104034863	C/T	cg26031613	chr14:104095156	KLC1	-0.54	-4.45	-0.37	1.88e-5	Reticulocyte count;
TGCT	cis	rs2463822	0.844	rs72923263	chr11:62161170	C/G	cg06239285	chr11:62104954	ASRGL1	-0.85	-5.54	-0.45	1.76e-7	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs6088580	0.634	rs6058041	chr20:33018008	A/G	cg08999081	chr20:33150536	PIGU	0.28	5.52	0.44	1.89e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs10992471	0.756	rs10992303	chr9:95082804	A/G	cg14631576	chr9:95140430	CENPP	-0.29	-4.72	-0.39	6.22e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs12049351	0.774	rs35464914	chr1:229690232	C/T	cg12130225	chr1:229698885	NA	0.38	4.63	0.38	8.95e-6	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs7429990	0.786	rs11919665	chr3:48085349	A/T	cg11946769	chr3:48343235	NME6	-0.52	-4.44	-0.37	1.95e-5	Educational attainment (years of education);
TGCT	cis	rs7605378	0.688	rs769961	chr2:200712141	C/A	cg19045956	chr2:200819837	C2orf60;C2orf47	0.5	4.72	0.39	6.17e-6	Osteoporosis;
TGCT	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg09365446	chr1:150670422	GOLPH3L	0.31	4.51	0.38	1.5e-5	Tonsillectomy;
TGCT	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.54	4.51	0.38	1.5e-5	Renal function-related traits (BUN);
TGCT	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg13732083	chr21:47605072	C21orf56	-0.37	-4.69	-0.39	7.07e-6	Testicular germ cell tumor;
TGCT	cis	rs9303401	0.659	rs16943176	chr17:56769887	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.59	5.99	0.47	2.08e-8	Cognitive test performance;
TGCT	cis	rs36051895	0.632	rs7030853	chr9:5179002	C/T	cg02405213	chr9:5042618	JAK2	-0.74	-10.54	-0.69	6.32e-19	Pediatric autoimmune diseases;
TGCT	cis	rs9560113	0.881	rs9560111	chr13:112181289	C/T	cg14154082	chr13:112174009	NA	0.38	5.01	0.41	1.83e-6	Menarche (age at onset);
TGCT	cis	rs7072216	0.763	rs2147900	chr10:100174721	T/C	cg26618903	chr10:100175079	PYROXD2	-0.4	-4.49	-0.37	1.64e-5	Metabolite levels;
TGCT	cis	rs9616064	0.813	rs9627512	chr22:46977702	C/T	cg12346269	chr22:46322472	WNT7B	0.22	4.55	0.38	1.24e-5	Urate levels in obese individuals;
TGCT	cis	rs8038465	0.622	rs710086	chr15:73877001	C/T	cg15420318	chr15:73925796	NPTN	0.64	6.76	0.52	4.83e-10	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2580764	0.566	rs2972072	chr2:55295370	G/T	cg09592903	chr2:55203963	RTN4	0.25	5.79	0.46	5.55e-8	Mean platelet volume;
TGCT	cis	rs1801251	0.929	rs10933409	chr2:233629386	A/G	cg25237894	chr2:233734115	C2orf82	0.33	5.95	0.47	2.53e-8	Coronary artery disease;
TGCT	cis	rs2249625	0.545	rs2463743	chr6:72874741	C/T	cg08500200	chr6:72892038	RIMS1	-0.42	-4.54	-0.38	1.33e-5	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
TGCT	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg20607798	chr8:58055168	NA	0.61	5.06	0.41	1.5e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6570726	0.791	rs441290	chr6:145883183	A/G	cg23711669	chr6:146136114	FBXO30	0.84	8.78	0.62	1.07e-14	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9467773	0.967	rs9467775	chr6:26513435	G/A	cg05738196	chr6:26577821	NA	0.88	12.5	0.75	1.03e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs3824867	0.879	rs10742806	chr11:47456226	T/A	cg20307385	chr11:47447363	PSMC3	0.7	6.03	0.48	1.71e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs735396	0.770	rs2259820	chr12:121435342	C/T	cg02403541	chr12:121454288	C12orf43	0.76	7.54	0.56	8.67e-12	N-glycan levels;
TGCT	cis	rs921968	0.643	rs492400	chr2:219349752	C/T	cg02176678	chr2:219576539	TTLL4	0.42	6.17	0.48	8.99e-9	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg02038168	chr22:39784481	NA	-0.78	-6.7	-0.52	6.48e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs1395	0.922	rs1561535	chr2:27471025	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.48	6.25	0.49	6.03e-9	Blood metabolite levels;
TGCT	cis	rs637571	0.510	rs12575663	chr11:65574535	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.67	-6.01	-0.48	1.9e-8	Eosinophil percentage of white cells;
TGCT	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg06634786	chr22:41940651	POLR3H	-0.86	-7.8	-0.57	2.13e-12	Vitiligo;
TGCT	cis	rs11190604	1.000	rs7080356	chr10:102266735	A/C	cg23241863	chr10:102295624	HIF1AN	0.7	5.38	0.43	3.59e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs12544026	0.581	rs472963	chr8:102863119	A/G	cg01952226	chr8:102507382	GRHL2	-0.27	-4.54	-0.38	1.31e-5	Major depression and alcohol dependence;
TGCT	cis	rs394563	0.591	rs237012	chr6:149729198	T/C	cg03678062	chr6:149772716	ZC3H12D	-0.38	-4.74	-0.39	5.83e-6	Dupuytren's disease;
TGCT	cis	rs7010267	0.596	rs7010043	chr8:120011331	G/T	cg17171407	chr8:119960777	TNFRSF11B	0.28	5.09	0.42	1.27e-6	Total body bone mineral density (age 45-60);
TGCT	cis	rs903263	0.870	rs2134649	chr1:84662712	T/G	cg09664975	chr1:84543551	PRKACB	0.47	4.48	0.37	1.65e-5	Breast cancer (male);
TGCT	cis	rs7772486	0.875	rs10872582	chr6:146373061	G/A	cg23711669	chr6:146136114	FBXO30	0.85	9.15	0.63	1.47e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2456568	0.803	rs10831138	chr11:93640468	T/C	cg26875233	chr11:93583750	C11orf90	-0.48	-6.35	-0.5	3.73e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs35306767	0.855	rs12781100	chr10:838636	C/T	cg26597838	chr10:835615	NA	0.81	12.25	0.74	4.2e-23	Eosinophil percentage of granulocytes;
TGCT	cis	rs6690583	0.623	rs6700723	chr1:85514234	C/T	cg20280350	chr1:85513789	MCOLN3	-0.79	-4.9	-0.4	2.9e-6	Serum sulfate level;
TGCT	cis	rs5769707	0.967	rs12485195	chr22:50053871	G/A	cg20744362	chr22:50050164	C22orf34	0.28	4.54	0.38	1.32e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs72945132	0.882	rs72945168	chr11:70131471	G/C	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs62321565	chr4:98976571	G/A	cg18180107	chr4:99064573	C4orf37	0.53	4.89	0.4	3.01e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs5769707	0.967	rs9616701	chr22:50025546	G/A	cg10356904	chr22:49881777	NA	-0.22	-4.52	-0.38	1.4e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg22920501	chr2:26401640	FAM59B	-0.72	-6.38	-0.5	3.19e-9	Gut microbiome composition (summer);
TGCT	cis	rs11673344	0.504	rs4806408	chr19:37588777	C/T	cg08039142	chr19:36980659	ZNF566	0.52	4.86	0.4	3.48e-6	Obesity-related traits;
TGCT	cis	rs10791097	0.967	rs6590512	chr11:130717916	A/G	cg12179176	chr11:130786555	SNX19	-0.63	-6.43	-0.5	2.52e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs11249608	0.548	rs10516150	chr5:178459169	G/C	cg01312482	chr5:178451176	ZNF879	-0.49	-4.85	-0.4	3.62e-6	Pubertal anthropometrics;
TGCT	cis	rs7599312	0.534	rs10207878	chr2:213409337	A/G	cg16329650	chr2:213403929	ERBB4	1.07	15.96	0.82	7.41e-32	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs739401	0.572	rs739399	chr11:3016452	A/G	cg25174290	chr11:3078921	CARS	0.5	4.75	0.39	5.54e-6	Longevity;
TGCT	cis	rs9372498	0.536	rs62422228	chr6:118957276	T/C	cg07617317	chr6:118971624	C6orf204	0.48	5.08	0.42	1.32e-6	Diastolic blood pressure;
TGCT	cis	rs806215	1.000	rs712697	chr7:127247132	T/A	cg25922125	chr7:127225783	GCC1	0.59	5.98	0.47	2.21e-8	Type 2 diabetes;
TGCT	cis	rs2692947	0.537	rs11164049	chr2:96345518	C/T	cg23100626	chr2:96804247	ASTL	0.42	5.29	0.43	5.37e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs9921338	0.886	rs3931015	chr16:11415639	G/A	cg00044050	chr16:11439710	C16orf75	0.95	7.39	0.55	1.92e-11	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs7552404	1.000	rs4949876	chr1:76173377	C/T	cg22875332	chr1:76189707	ACADM	0.79	9.77	0.66	4.68e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs4689388	0.853	rs6446479	chr4:6291737	G/C	cg25554036	chr4:6271136	WFS1	0.55	7.59	0.56	6.58e-12	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs765787	0.530	rs12592055	chr15:45514477	C/T	cg24006582	chr15:45444508	DUOX1	0.25	5.44	0.44	2.7e-7	Uric acid levels;
TGCT	cis	rs9467711	1.000	rs9467701	chr6:26312170	G/C	cg03517284	chr6:25882590	NA	-0.86	-4.67	-0.39	7.69e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12579753	0.871	rs10862363	chr12:82201254	T/A	cg07988820	chr12:82153109	PPFIA2	-0.59	-6.19	-0.49	7.93e-9	Resting heart rate;
TGCT	cis	rs10089	1.000	rs10060181	chr5:127475573	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	7.53	0.56	9.3e-12	Ileal carcinoids;
TGCT	cis	rs2721195	0.781	rs10110962	chr8:145780323	C/T	cg17328964	chr8:145687451	CYHR1	-0.43	-5.94	-0.47	2.68e-8	Age at first birth;
TGCT	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg05368731	chr17:41323189	NBR1	1.19	13.98	0.78	3.03e-27	Menopause (age at onset);
TGCT	cis	rs9325144	0.560	rs13377717	chr12:38639474	T/A	cg26384229	chr12:38710491	ALG10B	-0.65	-6.12	-0.48	1.13e-8	Morning vs. evening chronotype;
TGCT	cis	rs4299518	0.739	rs17279465	chr3:45814748	C/T	cg04837898	chr3:45731254	SACM1L	0.47	4.52	0.38	1.41e-5	Hirschsprung disease;
TGCT	cis	rs4523957	0.620	rs9912385	chr17:2062591	T/G	cg16513277	chr17:2031491	SMG6	-0.2	-4.64	-0.38	8.83e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	trans	rs10435719	0.528	rs13250020	chr8:11789769	A/G	cg15556689	chr8:8085844	FLJ10661	0.73	6.89	0.53	2.55e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs7582180	0.817	rs1437967	chr2:100929072	C/G	cg14675211	chr2:100938903	LONRF2	0.47	4.56	0.38	1.19e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs1857353	1.000	rs4540592	chr1:75883281	C/T	cg11838876	chr1:75668600	SLC44A5	0.51	4.81	0.4	4.23e-6	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs16866061	1.000	rs11694987	chr2:225397409	C/G	cg12698349	chr2:225449008	CUL3	0.95	8.97	0.63	3.83e-15	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	cis	rs36405	0.957	rs36411	chr14:72356551	A/G	cg10066683	chr14:71515513	PCNX	0.24	4.7	0.39	6.69e-6	Yang-deficiency constitution;
TGCT	cis	rs8064299	0.655	rs11655219	chr17:72771293	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	0.6	5.45	0.44	2.56e-7	Monocyte count;
TGCT	cis	rs9611565	0.559	rs5758428	chr22:42106216	G/A	cg13695892	chr22:41940480	POLR3H	0.88	8.63	0.61	2.45e-14	Vitiligo;
TGCT	trans	rs608114	0.793	rs656756	chr6:96380686	G/A	cg04008557	chr11:2826328	KCNQ1	-0.65	-6.82	-0.52	3.51e-10	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
TGCT	cis	rs1005224	1.000	rs1005224	chr14:76173860	A/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.7	-6.12	-0.48	1.14e-8	Large artery stroke;
TGCT	cis	rs9467773	0.620	rs6925087	chr6:26592853	T/A	cg26531700	chr6:26746687	NA	0.5	4.65	0.39	8.29e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.46	0.56	1.3e-11	Prudent dietary pattern;
TGCT	cis	rs514406	0.698	rs1775540	chr1:53407893	C/A	cg16325326	chr1:53192061	ZYG11B	0.5	5.59	0.45	1.38e-7	Monocyte count;
TGCT	cis	rs35828350	1	rs35828350	chr15:85355841	G/A	cg17173187	chr15:85201210	NMB	0.56	6.32	0.49	4.23e-9	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg06481639	chr22:41940642	POLR3H	-0.62	-5.61	-0.45	1.25e-7	Vitiligo;
TGCT	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	15.18	0.81	4.71e-30	Prudent dietary pattern;
TGCT	cis	rs3892630	0.817	rs35408716	chr19:33187961	A/C	cg22980127	chr19:33182716	NUDT19	0.7	5.18	0.42	8.9e-7	Red blood cell traits;
TGCT	cis	rs12780845	0.540	rs12770238	chr10:17209570	C/G	cg01003015	chr10:17271136	VIM	0.54	4.78	0.39	4.87e-6	Homocysteine levels;
TGCT	cis	rs9611565	0.559	rs132761	chr22:42004371	C/T	cg06481639	chr22:41940642	POLR3H	0.74	6.64	0.51	8.88e-10	Vitiligo;
TGCT	cis	rs12497850	0.865	rs13072911	chr3:48962128	T/G	cg18654377	chr3:49208889	KLHDC8B	-0.42	-5.52	-0.44	1.93e-7	Parkinson's disease;
TGCT	cis	rs912330	0.529	rs4772100	chr13:99196573	G/T	cg07423050	chr13:99094983	FARP1	-0.24	-5.19	-0.42	8.43e-7	Alzheimer's disease;
TGCT	cis	rs644799	0.710	rs11021309	chr11:95501898	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.29	0.6	1.54e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9486719	0.947	rs12210834	chr6:96890407	A/T	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.86	-0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs367615	0.842	rs2578484	chr5:108950808	G/A	cg17395555	chr5:108820864	NA	-0.29	-4.89	-0.4	3.09e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg02353165	chr6:42928485	GNMT	0.97	9.95	0.67	1.66e-17	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs9325144	0.647	rs7957185	chr12:38909710	G/A	cg26384229	chr12:38710491	ALG10B	-0.56	-4.87	-0.4	3.34e-6	Morning vs. evening chronotype;
TGCT	cis	rs62244186	0.748	rs4682987	chr3:44674996	C/T	cg10263370	chr3:44754102	ZNF502	-0.42	-5.03	-0.41	1.65e-6	Depressive symptoms;
TGCT	cis	rs7681440	0.935	rs3756059	chr4:90757272	G/A	cg26578617	chr4:90757533	SNCA	-0.48	-4.95	-0.41	2.33e-6	Dementia with Lewy bodies;
TGCT	cis	rs8017423	1.000	rs8015379	chr14:90679432	C/T	cg04374321	chr14:90722782	PSMC1	0.77	7.94	0.58	1.06e-12	Mortality in heart failure;
TGCT	cis	rs4601821	0.823	rs4938015	chr11:113264644	C/T	cg14159747	chr11:113255604	NA	-0.4	-5.11	-0.42	1.17e-6	Alcoholic chronic pancreatitis;
TGCT	cis	rs3760982	0.585	rs10422108	chr19:44294868	C/T	cg12072164	chr19:44306565	LYPD5	0.3	4.45	0.37	1.86e-5	Breast cancer (estrogen-receptor negative);Breast cancer;
TGCT	cis	rs9916302	0.861	rs10491129	chr17:37461643	T/G	cg15445000	chr17:37608096	MED1	-0.31	-4.59	-0.38	1.06e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg26118208	chr10:134322334	NA	0.27	5.13	0.42	1.08e-6	Migraine;
TGCT	cis	rs8180040	0.932	rs1531875	chr3:47452786	G/A	cg27129171	chr3:47204927	SETD2	0.65	7.74	0.57	2.99e-12	Colorectal cancer;
TGCT	cis	rs9611519	0.754	rs4820435	chr22:41652846	G/T	cg06634786	chr22:41940651	POLR3H	-0.59	-5.45	-0.44	2.56e-7	Neuroticism;
TGCT	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg11494091	chr17:61959527	GH2	0.42	7.33	0.55	2.54e-11	Height;
TGCT	cis	rs36051895	0.695	rs62541534	chr9:5028921	C/G	cg02405213	chr9:5042618	JAK2	-0.77	-10.43	-0.68	1.16e-18	Pediatric autoimmune diseases;
TGCT	cis	rs7225537	0.559	rs7214429	chr17:17059872	A/G	cg26176665	chr17:16994978	MPRIP	-0.24	-5.54	-0.45	1.74e-7	Mean platelet volume;
TGCT	cis	rs10986311	0.862	rs1408096	chr9:127107143	C/G	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.19	4.55	0.38	1.28e-5	Vitiligo;
TGCT	cis	rs7267979	0.932	rs1541061	chr20:25521057	G/A	cg16686733	chr20:25566563	NINL	0.56	5.69	0.46	8.49e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg18252515	chr7:66147081	NA	-1.1	-6.4	-0.5	2.85e-9	Diabetic kidney disease;
TGCT	cis	rs4499344	0.730	rs7246338	chr19:33099504	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.85	8.76	0.62	1.23e-14	Mean platelet volume;
TGCT	cis	rs73198271	0.740	rs10113326	chr8:8647630	A/T	cg15556689	chr8:8085844	FLJ10661	-0.6	-4.46	-0.37	1.8e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs9916302	0.800	rs8069451	chr17:37504933	C/T	cg07936489	chr17:37558343	FBXL20	-0.59	-4.6	-0.38	1.04e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs6964587	0.934	rs7811328	chr7:91720931	A/T	cg22709100	chr7:91322751	NA	0.29	4.8	0.4	4.45e-6	Breast cancer;
TGCT	cis	rs909674	0.731	rs4821897	chr22:39835587	A/G	cg11247378	chr22:39784982	NA	-0.74	-8.7	-0.62	1.65e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs9549367	0.789	rs9549698	chr13:113877701	A/G	cg00898013	chr13:113819073	PROZ	-0.42	-5.12	-0.42	1.15e-6	Platelet distribution width;
TGCT	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.64	-5.6	-0.45	1.32e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs3772130	0.923	rs34865234	chr3:121560995	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.62	0.38	9.48e-6	Cognitive performance;
TGCT	cis	rs478304	0.651	rs4930312	chr11:65499719	G/A	cg17480646	chr11:65405466	SIPA1	-0.57	-6.93	-0.53	2.05e-10	Acne (severe);
TGCT	cis	rs17376456	0.757	rs10476591	chr5:93333723	G/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	4.6	0.38	1.03e-5	Diabetic retinopathy;
TGCT	cis	rs6912958	0.712	rs4707383	chr6:88330602	T/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-4.55	-0.38	1.26e-5	Monocyte percentage of white cells;
TGCT	cis	rs4727027	0.800	rs10952796	chr7:148813138	G/C	cg23583168	chr7:148888333	NA	-0.72	-9.16	-0.64	1.34e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs9913156	0.841	rs72824957	chr17:4590496	C/T	cg23387401	chr17:4582204	PELP1	0.31	4.68	0.39	7.44e-6	Lymphocyte counts;
TGCT	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.71	0.39	6.53e-6	Prudent dietary pattern;
TGCT	cis	rs9796	0.870	rs2306083	chr15:41347658	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.42	-5.42	-0.44	2.92e-7	Menopause (age at onset);
TGCT	cis	rs1153858	1.000	rs2461701	chr15:45703391	G/A	cg26924012	chr15:45694286	SPATA5L1	0.99	12.38	0.74	2.11e-23	Homoarginine levels;
TGCT	cis	rs7666738	0.830	rs17027216	chr4:99009152	G/C	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4713675	0.649	rs568901	chr6:33710038	A/G	cg13859433	chr6:33739653	LEMD2	0.3	5.02	0.41	1.73e-6	Plateletcrit;
TGCT	cis	rs6693567	0.565	rs471657	chr1:150276461	G/A	cg09579323	chr1:150459698	TARS2	-0.52	-4.64	-0.38	8.63e-6	Migraine;
TGCT	cis	rs3796352	1.000	rs6445557	chr3:53083969	C/T	cg27565382	chr3:53032988	SFMBT1	-0.41	-4.61	-0.38	9.92e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs4305276	0.557	rs7607996	chr2:241470735	T/C	cg21930842	chr2:241631663	AQP12A	-0.27	-4.72	-0.39	6.38e-6	Mean platelet volume;
TGCT	cis	rs514406	0.505	rs395169	chr1:53174071	G/A	cg22166914	chr1:53195759	ZYG11B	0.45	7.9	0.58	1.29e-12	Monocyte count;
TGCT	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg10802521	chr3:52805072	NEK4	-0.72	-9.11	-0.63	1.82e-15	Bipolar disorder;
TGCT	cis	rs10488031	0.850	rs13243420	chr7:37064595	G/A	cg06458904	chr7:36312573	EEPD1	0.56	4.74	0.39	5.8e-6	QT interval;
TGCT	cis	rs3093024	0.935	rs10946216	chr6:167538897	T/C	cg07741184	chr6:167504864	NA	-0.24	-4.85	-0.4	3.6e-6	Rheumatoid arthritis;
TGCT	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg10802521	chr3:52805072	NEK4	-0.72	-9.11	-0.63	1.82e-15	Bipolar disorder;
TGCT	cis	rs7654585	0.645	rs1123943	chr4:25924426	A/G	cg10409131	chr4:25915609	C4orf52	-0.7	-6.82	-0.52	3.57e-10	Obesity-related traits;
TGCT	cis	rs3091242	0.933	rs10903130	chr1:25769221	A/T	cg09222892	chr1:25734099	RHCE	-0.42	-7.15	-0.54	6.72e-11	Erythrocyte sedimentation rate;
TGCT	cis	rs208520	0.690	rs12192710	chr6:66718137	C/T	cg07460842	chr6:66804631	NA	0.95	10.11	0.67	6.77e-18	Exhaled nitric oxide output;
TGCT	cis	rs4253772	0.637	rs6008339	chr22:46650846	C/T	cg09491104	chr22:46646882	C22orf40	-0.62	-6.49	-0.5	1.87e-9	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg11764359	chr7:65958608	NA	0.6	5.31	0.43	4.78e-7	Aortic root size;
TGCT	cis	rs36051895	0.593	rs12340303	chr9:5176147	C/T	cg02405213	chr9:5042618	JAK2	-0.77	-10.92	-0.7	7.2e-20	Pediatric autoimmune diseases;
TGCT	cis	rs4654899	0.785	rs12070677	chr1:21337322	A/G	cg01072550	chr1:21505969	NA	-0.54	-8.69	-0.62	1.82e-14	Superior frontal gyrus grey matter volume;
TGCT	cis	rs17030434	0.906	rs78436201	chr4:154661755	C/A	cg14289246	chr4:154710475	SFRP2	-0.88	-7.14	-0.54	6.93e-11	Electrocardiographic conduction measures;
TGCT	cis	rs12477438	0.605	rs4585080	chr2:99557327	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-5.33	-0.43	4.48e-7	Chronic sinus infection;
TGCT	cis	rs4776059	1.000	rs4776068	chr15:52947401	G/A	cg25063058	chr15:52860530	ARPP19	0.54	4.86	0.4	3.43e-6	Schizophrenia;
TGCT	cis	rs2439831	0.681	rs2242067	chr15:43699303	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.82	4.7	0.39	6.71e-6	Lung cancer in ever smokers;
TGCT	cis	rs3087591	0.708	rs17885030	chr17:29655218	C/T	cg24425628	chr17:29625626	OMG;NF1	0.39	5.46	0.44	2.45e-7	Hip circumference;
TGCT	cis	rs11122272	0.735	rs971534	chr1:231521971	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-6.94	-0.53	1.98e-10	Hemoglobin concentration;
TGCT	cis	rs1334894	0.892	rs72913412	chr6:35536654	G/A	cg24281267	chr6:35479648	TULP1	-0.43	-4.49	-0.37	1.63e-5	Coronary artery disease;
TGCT	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg13342137	chr4:2252803	MXD4	0.16	4.46	0.37	1.79e-5	Obesity-related traits;
TGCT	cis	rs910316	1.000	rs12897094	chr14:75579416	C/T	cg11812906	chr14:75593930	NEK9	0.75	7.4	0.55	1.77e-11	Height;
TGCT	trans	rs34421088	0.560	rs2467520	chr8:11398953	T/C	cg15556689	chr8:8085844	FLJ10661	-0.75	-7.02	-0.53	1.28e-10	Neuroticism;
TGCT	cis	rs854765	0.547	rs2955355	chr17:17948475	G/A	cg04398451	chr17:18023971	MYO15A	0.33	5.37	0.43	3.76e-7	Total body bone mineral density;
TGCT	cis	rs5769765	1.000	rs5770728	chr22:50259984	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	1.11	11.71	0.72	8.52e-22	Schizophrenia;
TGCT	cis	rs2067615	0.579	rs12312782	chr12:107135647	G/A	cg15890332	chr12:107067104	RFX4	0.3	5.93	0.47	2.85e-8	Heart rate;
TGCT	cis	rs9303401	0.580	rs2013166	chr17:56637630	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs854624	0.892	rs2702954	chr17:34334738	C/T	cg02022384	chr17:34097390	MMP28	0.5	4.67	0.39	7.74e-6	Blood protein levels;
TGCT	cis	rs492146	0.819	rs677636	chr6:52837307	G/A	cg06706454	chr6:52930286	FBXO9	-0.5	-4.63	-0.38	9.12e-6	Epilepsy (remission after treatment);
TGCT	cis	rs9527	0.590	rs7912517	chr10:104905529	G/A	cg04362960	chr10:104952993	NT5C2	0.65	5.59	0.45	1.36e-7	Arsenic metabolism;
TGCT	cis	rs10744422	0.764	rs7957643	chr12:123296118	G/A	cg18912006	chr12:123335444	HIP1R	0.56	4.78	0.39	4.84e-6	Schizophrenia;
TGCT	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg08859206	chr1:53392774	SCP2	0.41	5.98	0.47	2.19e-8	Monocyte count;
TGCT	cis	rs9581857	0.512	rs9652091	chr13:28073509	G/A	cg22138327	chr13:27999177	GTF3A	0.83	5.89	0.47	3.44e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg05552183	chr6:42928497	GNMT	0.52	4.55	0.38	1.25e-5	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs7249142	0.526	rs7256811	chr19:19283551	A/G	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.56	5.55	0.45	1.64e-7	IgG glycosylation;
TGCT	cis	rs7714584	1.000	rs7705542	chr5:150228318	G/A	cg22134413	chr5:150180641	NA	0.83	6.53	0.51	1.54e-9	Crohn's disease;
TGCT	cis	rs42648	0.869	rs42609	chr7:89949855	A/T	cg25739043	chr7:89950458	NA	-0.73	-7.29	-0.55	3.2e-11	Homocysteine levels;
TGCT	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg25767906	chr1:53392781	SCP2	0.6	7.04	0.53	1.15e-10	Monocyte count;
TGCT	cis	rs6582630	0.537	rs66855609	chr12:38299029	T/C	cg26384229	chr12:38710491	ALG10B	0.77	6.88	0.53	2.6200000000000003e-10	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs854765	0.964	rs2230316	chr17:17997209	C/T	cg09796270	chr17:17721594	SREBF1	-0.25	-4.85	-0.4	3.6e-6	Total body bone mineral density;
TGCT	cis	rs854765	0.618	rs9908017	chr17:17774422	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.75	-7.78	-0.57	2.42e-12	Total body bone mineral density;
TGCT	cis	rs9653442	0.648	rs11123805	chr2:100643464	A/G	cg07810366	chr2:100720526	AFF3	-0.4	-6.6	-0.51	1.06e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs10193935	0.605	rs10169492	chr2:42401961	G/T	cg27598129	chr2:42591480	NA	-0.39	-5.14	-0.42	1.05e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6460942	0.908	rs6978857	chr7:12232665	A/G	cg06484146	chr7:12443880	VWDE	-0.52	-4.52	-0.38	1.44e-5	Coronary artery disease;
TGCT	cis	rs6688613	1.000	rs6656999	chr1:166956807	C/G	cg07049167	chr1:166818506	POGK	0.21	4.5	0.37	1.57e-5	Refractive astigmatism;
TGCT	cis	rs10464366	1.000	rs10951593	chr7:39121390	C/T	cg15212455	chr7:39170539	POU6F2	0.23	5.06	0.41	1.49e-6	IgG glycosylation;
TGCT	cis	rs6543140	0.601	rs6543135	chr2:103062406	C/T	cg09003973	chr2:102972529	NA	0.79	6.41	0.5	2.77e-9	Blood protein levels;
TGCT	cis	rs7412746	0.658	rs2089082	chr1:150800090	T/G	cg04414720	chr1:150670196	GOLPH3L	0.38	4.69	0.39	7.01e-6	Melanoma;
TGCT	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg22920501	chr2:26401640	FAM59B	0.81	6.36	0.5	3.52e-9	Gut microbiome composition (summer);
TGCT	cis	rs68170813	0.559	rs80307895	chr7:106907781	T/A	cg02696742	chr7:106810147	HBP1	-0.69	-5.61	-0.45	1.27e-7	Coronary artery disease;
TGCT	cis	rs739496	0.579	rs11066046	chr12:112283881	T/C	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs6429082	0.755	rs291370	chr1:235693041	A/G	cg26050004	chr1:235667680	B3GALNT2	0.66	6.23	0.49	6.65e-9	Adiposity;
TGCT	cis	rs9467773	0.620	rs2451711	chr6:26663110	A/G	cg26531700	chr6:26746687	NA	0.51	4.64	0.38	8.75e-6	Intelligence (multi-trait analysis);
TGCT	trans	rs1864729	1.000	rs2028480	chr8:98290358	C/G	cg08679828	chr8:102218111	ZNF706	-1.08	-7.55	-0.56	8.16e-12	Estradiol plasma levels (breast cancer);
TGCT	cis	rs4727027	0.933	rs7788925	chr7:148831621	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	4.58	0.38	1.13e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg04944784	chr2:26401820	FAM59B	-0.77	-6.36	-0.5	3.61e-9	Gut microbiome composition (summer);
TGCT	cis	rs7568458	0.837	rs3770098	chr2:85805367	C/A	cg17127132	chr2:85788382	GGCX	0.72	6.68	0.51	7.18e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs12908161	0.959	rs62019472	chr15:85331493	A/G	cg17173187	chr15:85201210	NMB	0.55	6.11	0.48	1.17e-8	Schizophrenia;
TGCT	cis	rs8013055	0.846	rs10139300	chr14:105974501	A/G	cg23356831	chr14:105996513	TMEM121	0.41	6.33	0.49	4.01e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs3935685	0.874	rs4595768	chr15:78006290	C/T	cg03457338	chr15:78040120	NA	-0.23	-5.78	-0.46	5.72e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7824557	0.614	rs2060459	chr8:11212599	C/T	cg21775007	chr8:11205619	TDH	0.71	6.81	0.52	3.8e-10	Retinal vascular caliber;
TGCT	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg22920501	chr2:26401640	FAM59B	-0.72	-6.38	-0.5	3.19e-9	Gut microbiome composition (summer);
TGCT	cis	rs10744422	1.000	rs7294991	chr12:123286780	C/T	cg25930673	chr12:123319894	HIP1R	-0.81	-4.63	-0.38	9.1e-6	Schizophrenia;
TGCT	cis	rs6570726	0.791	rs6570695	chr6:145911286	C/A	cg05347473	chr6:146136440	FBXO30	0.51	4.75	0.39	5.42e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs929596	0.785	rs17862875	chr2:234649302	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.34	-5.3	-0.43	5.04e-7	Total bilirubin levels in HIV-1 infection;
TGCT	cis	rs2580764	0.566	rs2968793	chr2:55285024	C/T	cg09592903	chr2:55203963	RTN4	0.26	5.97	0.47	2.27e-8	Mean platelet volume;
TGCT	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.53	-5.0	-0.41	1.89e-6	Bipolar disorder;
TGCT	cis	rs644799	1.000	rs3177463	chr11:95502128	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	11.08	0.71	2.9e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg24531977	chr5:56204891	C5orf35	-0.76	-7.75	-0.57	2.82e-12	Initial pursuit acceleration;
TGCT	trans	rs208520	0.526	rs7776413	chr6:66783241	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.09	-16.9	-0.84	5.6e-34	Exhaled nitric oxide output;
TGCT	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg08645402	chr16:4508243	NA	0.19	4.79	0.4	4.66e-6	Schizophrenia;
TGCT	cis	rs6909430	0.539	rs11968196	chr6:98793832	A/G	cg20000812	chr6:99276697	NA	-0.51	-4.62	-0.38	9.54e-6	Quantitative traits;
TGCT	cis	rs7647973	0.626	rs1078341	chr3:49685592	A/G	cg03034192	chr3:50606346	HEMK1;C3orf18	0.36	4.75	0.39	5.61e-6	Menarche (age at onset);
TGCT	cis	rs56104184	0.668	rs73063523	chr19:49408943	T/C	cg17863274	chr19:49399704	TULP2	-0.54	-7.43	-0.55	1.58e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg11494091	chr17:61959527	GH2	-0.6	-14.53	-0.79	1.48e-28	Prudent dietary pattern;
TGCT	cis	rs4788570	0.697	rs9930015	chr16:71801092	C/G	cg06353428	chr16:71660113	MARVELD3	1.51	11.99	0.73	1.81e-22	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.753	rs7659724	chr4:98944063	C/T	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9527	0.590	rs12775302	chr10:104911356	A/G	cg15744005	chr10:104629667	AS3MT	-0.41	-4.73	-0.39	6.06e-6	Arsenic metabolism;
TGCT	cis	rs3812831	0.695	rs3118895	chr13:114931742	G/A	cg06611532	chr13:114900021	NA	0.35	6.42	0.5	2.57e-9	Schizophrenia;
TGCT	trans	rs1814175	0.781	rs11040681	chr11:49981654	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.36	-7.14	-0.54	6.88e-11	Height;
TGCT	cis	rs3015497	0.789	rs10133849	chr14:51121700	A/G	cg04730355	chr14:51134070	SAV1	-0.65	-6.29	-0.49	4.93e-9	Mean platelet volume;
TGCT	cis	rs7615952	0.799	rs13315434	chr3:125641394	T/G	cg05084668	chr3:125655381	ALG1L	-0.7	-5.74	-0.46	6.93e-8	Blood pressure (smoking interaction);
TGCT	cis	rs11098499	0.866	rs12374244	chr4:120281972	A/T	cg09307838	chr4:120376055	NA	0.58	5.76	0.46	6.16e-8	Corneal astigmatism;
TGCT	cis	rs59107033	0.607	rs62262406	chr3:123122494	T/C	cg04890266	chr3:123102914	ADCY5	-0.36	-5.43	-0.44	2.85e-7	Lymphocyte counts;
TGCT	cis	rs2486012	1.000	rs2428960	chr1:44393146	A/G	cg12908607	chr1:44402522	ARTN	0.73	5.67	0.45	9.51e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7917772	0.560	rs7912339	chr10:104373758	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	5.36	0.43	3.84e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9929218	0.954	rs4485355	chr16:68754730	C/T	cg01251360	chr16:68772225	CDH1	0.29	4.85	0.4	3.68e-6	Colorectal cancer;
TGCT	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg22963979	chr7:1858916	MAD1L1	-0.44	-7.12	-0.54	7.88e-11	Bipolar disorder and schizophrenia;
TGCT	cis	rs5760092	0.755	rs6003959	chr22:24264395	C/T	cg07205460	chr22:24236375	MIF	0.61	4.81	0.4	4.21e-6	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs1153858	0.621	rs12913645	chr15:45555066	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.47	-5.2	-0.42	8.07e-7	Homoarginine levels;
TGCT	cis	rs651907	0.557	rs3864012	chr3:101397623	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.34	-7.08	-0.54	9.37e-11	Colorectal cancer;
TGCT	cis	rs12477438	0.520	rs11677247	chr2:99756358	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	13.05	0.76	4.93e-25	Chronic sinus infection;
TGCT	cis	rs7208859	0.673	rs11656845	chr17:29206164	G/T	cg18442181	chr17:29233375	C17orf42	-0.78	-4.61	-0.38	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs12220238	1.000	rs7076721	chr10:75996682	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.92	7.84	0.58	1.79e-12	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs2562456	0.754	rs55771551	chr19:21746380	C/T	cg25650185	chr19:21324782	ZNF431	-0.66	-5.86	-0.47	3.92e-8	Pain;
TGCT	cis	rs992157	0.560	rs12987130	chr2:219104990	T/C	cg00012203	chr2:219082015	ARPC2	-0.81	-9.21	-0.64	1.03e-15	Colorectal cancer;
TGCT	cis	rs694739	0.628	rs11606081	chr11:64137875	T/C	cg02228329	chr11:64053129	BAD;GPR137	0.69	6.78	0.52	4.25e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs9467773	0.620	rs2504571	chr6:26643435	C/T	cg09904177	chr6:26538194	HMGN4	0.7	6.67	0.51	7.48e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs3935685	0.874	rs34906247	chr15:78004204	A/G	cg25212270	chr15:78015279	NA	0.26	5.57	0.45	1.48e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs35146811	0.735	rs858506	chr7:99820050	T/C	cg00553149	chr7:99775558	STAG3;GPC2	-0.32	-4.81	-0.4	4.28e-6	Coronary artery disease;
TGCT	cis	rs13256369	1.000	rs4840351	chr8:8573148	A/G	cg06671706	chr8:8559999	CLDN23	0.34	4.44	0.37	1.99e-5	Obesity-related traits;
TGCT	cis	rs5769765	0.773	rs9616383	chr22:50313014	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.24	-12.97	-0.76	7.81e-25	Schizophrenia;
TGCT	cis	rs17826219	0.561	rs562840	chr17:28949390	G/T	cg19761014	chr17:28927070	LRRC37B2	0.53	4.63	0.38	9.04e-6	Body mass index;
TGCT	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg22968622	chr17:43663579	NA	-1.23	-10.98	-0.7	5.31e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7672749	0.643	rs7690494	chr4:88800539	A/G	cg05816041	chr4:88786914	NA	-0.52	-4.51	-0.38	1.48e-5	TB-LM or TBLH-BMD (pleiotropy);
TGCT	cis	rs950776	0.642	rs61630816	chr15:78965866	T/C	cg03762349	chr15:79060523	ADAMTS7	0.28	5.42	0.44	2.98e-7	Sudden cardiac arrest;
TGCT	cis	rs7975161	1.000	rs7960443	chr12:104645363	G/A	cg25273343	chr12:104657179	TXNRD1	-0.31	-4.86	-0.4	3.45e-6	Toenail selenium levels;
TGCT	cis	rs12477438	0.765	rs13390672	chr2:99589829	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-4.88	-0.4	3.17e-6	Chronic sinus infection;
TGCT	cis	rs1395	0.744	rs11126929	chr2:27472027	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.6	-7.79	-0.57	2.35e-12	Blood metabolite levels;
TGCT	cis	rs9814567	1.000	rs13087875	chr3:134261123	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.96	9.11	0.63	1.79e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs74233809	0.901	rs17115100	chr10:104591393	G/T	cg05855489	chr10:104503620	C10orf26	0.82	4.62	0.38	9.39e-6	Birth weight;
TGCT	cis	rs10489202	0.608	rs7553238	chr1:168076768	G/A	cg24449463	chr1:168025552	DCAF6	-0.49	-5.06	-0.41	1.49e-6	Schizophrenia;
TGCT	cis	rs11931598	0.509	rs13140943	chr4:6977109	A/G	cg02503808	chr4:7069936	GRPEL1	0.51	4.73	0.39	5.99e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs10114408	0.959	rs10761291	chr9:96640967	C/T	cg13679303	chr9:96623674	NA	-0.36	-4.69	-0.39	6.98e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs7914558	0.966	rs4917997	chr10:104945213	A/G	cg15744005	chr10:104629667	AS3MT	-0.39	-4.73	-0.39	5.91e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.64	-5.6	-0.45	1.32e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs319204	1.000	rs167635	chr5:146260896	T/C	cg25021259	chr5:146258546	PPP2R2B	0.38	4.72	0.39	6.14e-6	Schizophrenia;
TGCT	cis	rs8017423	0.967	rs57793584	chr14:90714833	G/A	cg04374321	chr14:90722782	PSMC1	0.74	7.74	0.57	2.98e-12	Mortality in heart failure;
TGCT	cis	rs9911578	1.000	rs368186	chr17:56736659	A/G	cg12560992	chr17:57184187	TRIM37	0.75	9.21	0.64	1.04e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs13326165	0.760	rs11706108	chr3:52372366	T/C	cg07884673	chr3:53033167	SFMBT1	0.4	4.86	0.4	3.45e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg06028808	chr11:68637592	NA	0.52	6.73	0.52	5.58e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs17826219	0.568	rs9898097	chr17:29072672	T/G	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Body mass index;
TGCT	cis	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg08045932	chr20:61659980	NA	0.48	9.16	0.64	1.36e-15	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs231513	1.000	rs231526	chr17:41951277	T/C	cg26893861	chr17:41843967	DUSP3	-0.94	-6.51	-0.5	1.72e-9	Cognitive function;
TGCT	cis	rs1371867	0.846	rs1692006	chr8:101252462	C/T	cg06636551	chr8:101224915	SPAG1	0.48	6.57	0.51	1.28e-9	Atrioventricular conduction;
TGCT	trans	rs12599106	0.679	rs34584967	chr16:34475725	T/G	cg07332563	chr6:291687	DUSP22	-0.65	-6.72	-0.52	5.92e-10	Menopause (age at onset);
TGCT	cis	rs10504229	0.679	rs16921687	chr8:58053514	T/C	cg08280861	chr8:58055591	NA	0.35	4.88	0.4	3.2e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7829975	0.508	rs1594437	chr8:8825875	T/C	cg15556689	chr8:8085844	FLJ10661	0.67	5.53	0.44	1.79e-7	Mood instability;
TGCT	cis	rs9921338	0.961	rs56010295	chr16:11378907	G/A	cg00044050	chr16:11439710	C16orf75	-0.87	-6.25	-0.49	5.97e-9	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs739496	0.579	rs12321677	chr12:112339015	A/G	cg10833066	chr12:111807467	FAM109A	-0.38	-5.41	-0.44	3.08e-7	Platelet count;
TGCT	cis	rs7584330	0.737	rs60187585	chr2:238365159	C/T	cg14458575	chr2:238380390	NA	0.51	8.14	0.59	3.53e-13	Prostate cancer;
TGCT	cis	rs10782582	0.609	rs2881785	chr1:76318096	T/C	cg10523679	chr1:76189770	ACADM	-0.61	-5.62	-0.45	1.22e-7	Daytime sleep phenotypes;
TGCT	cis	rs9393777	0.528	rs34843552	chr6:27241915	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.55	-5.76	-0.46	6.38e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.753	rs10033138	chr4:98981922	A/C	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2243480	1.000	rs313832	chr7:65550891	G/T	cg20637647	chr7:64974828	NA	0.87	5.3	0.43	5.09e-7	Diabetic kidney disease;
TGCT	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.12	0.54	7.78e-11	Prudent dietary pattern;
TGCT	cis	rs8070740	0.898	rs4578712	chr17:5324431	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	4.77	0.39	5.1e-6	Menopause (age at onset);
TGCT	cis	rs2485376	0.842	rs2145308	chr10:104150999	A/G	cg26089160	chr10:104170217	PSD	0.51	5.07	0.41	1.41e-6	QT interval;
TGCT	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.18	0.49	8.32e-9	Bipolar disorder;
TGCT	cis	rs3935685	0.874	rs4073356	chr15:78008430	C/T	cg03457338	chr15:78040120	NA	-0.23	-6.09	-0.48	1.34e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9926296	0.632	rs72807526	chr16:89775946	A/G	cg26513180	chr16:89883248	FANCA	-0.64	-5.6	-0.45	1.29e-7	Vitiligo;
TGCT	cis	rs10992471	0.553	rs1923599	chr9:95092568	G/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.54	-4.98	-0.41	2.06e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs7208859	0.510	rs216402	chr17:28917126	A/T	cg14008862	chr17:28927542	LRRC37B2	0.94	5.7	0.46	8.41e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs1580019	0.587	rs1597555	chr7:32546118	T/G	cg06627557	chr7:32535165	LSM5;AVL9	1.13	14.15	0.79	1.17e-27	Cognitive ability;
TGCT	cis	rs7113874	0.523	rs7117945	chr11:8532458	C/T	cg14521421	chr11:8862019	ST5	0.28	4.44	0.37	1.99e-5	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs10838634	1.000	rs61898463	chr11:46873406	A/G	cg18332754	chr11:46939436	LRP4	0.89	4.77	0.39	5.13e-6	Schizophrenia;
TGCT	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg12419862	chr22:24373484	LOC391322	-0.85	-9.35	-0.64	4.61e-16	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2447097	0.935	rs2447095	chr17:2293420	A/G	cg27406664	chr17:2294951	MNT	0.3	6.59	0.51	1.16e-9	Autism spectrum disorder;
TGCT	cis	rs2204008	0.575	rs10444564	chr12:38043782	T/C	cg26384229	chr12:38710491	ALG10B	0.85	7.63	0.57	5.5e-12	Bladder cancer;
TGCT	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg24250549	chr1:154909240	PMVK	0.62	6.12	0.48	1.14e-8	Prostate cancer;
TGCT	cis	rs8177179	1.000	rs8177179	chr3:133463457	G/A	cg24879335	chr3:133465180	TF	0.36	4.82	0.4	4.16e-6	Iron status biomarkers (transferrin levels);
TGCT	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg13695892	chr22:41940480	POLR3H	-0.93	-9.19	-0.64	1.15e-15	Vitiligo;
TGCT	cis	rs1018836	0.923	rs10808615	chr8:91569704	A/T	cg16814680	chr8:91681699	NA	-0.9	-9.91	-0.66	2.06e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg07061783	chr6:25882402	NA	-0.59	-5.78	-0.46	5.76e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs4595586	0.546	rs10876163	chr12:39244915	G/A	cg26384229	chr12:38710491	ALG10B	0.65	5.29	0.43	5.43e-7	Morning vs. evening chronotype;
TGCT	cis	rs651907	0.557	rs7651721	chr3:101393583	C/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.03	0.41	1.65e-6	Colorectal cancer;
TGCT	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg11062466	chr8:58055876	NA	0.43	4.64	0.38	8.85e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10782582	0.632	rs77099976	chr1:76240524	T/C	cg03433033	chr1:76189801	ACADM	-0.45	-4.6	-0.38	1.02e-5	Daytime sleep phenotypes;
TGCT	cis	rs114540395	0.687	rs75269434	chr10:103473111	G/C	cg03300883	chr10:102748874	C10orf2	0.42	4.69	0.39	7.16e-6	Schizophrenia;
TGCT	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg15320075	chr8:145703422	NA	-0.72	-7.61	-0.56	5.87e-12	Age at first birth;
TGCT	cis	rs10927875	0.632	rs10927863	chr1:16165247	C/A	cg21385522	chr1:16154831	NA	-1.01	-18.25	-0.85	6.38e-37	Dilated cardiomyopathy;
TGCT	cis	rs7772486	0.686	rs9386131	chr6:146121608	G/A	cg23711669	chr6:146136114	FBXO30	0.86	9.53	0.65	1.74e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs13217239	0.646	rs9393789	chr6:27067028	G/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.42	-4.61	-0.38	9.71e-6	Schizophrenia;
TGCT	cis	rs7945705	1.000	rs7937298	chr11:8867509	G/C	cg21881798	chr11:8931708	C11orf17;ST5	0.43	4.96	0.41	2.3e-6	Hemoglobin concentration;
TGCT	cis	rs13326165	0.760	rs3752819	chr3:52400740	G/C	cg27565382	chr3:53032988	SFMBT1	0.36	4.8	0.4	4.54e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs7809950	0.817	rs11535285	chr7:107143866	A/G	cg23024343	chr7:107201750	COG5	-0.47	-6.89	-0.53	2.54e-10	Coronary artery disease;
TGCT	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.08	0.48	1.37e-8	Bipolar disorder;
TGCT	cis	rs7147624	0.608	rs4902413	chr14:66187091	T/C	cg03016385	chr14:66212404	NA	-0.5	-7.04	-0.53	1.13e-10	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs9902453	0.874	rs62070271	chr17:28268358	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.87	8.26	0.6	1.9e-13	Coffee consumption (cups per day);
TGCT	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg22920501	chr2:26401640	FAM59B	0.8	6.34	0.49	3.84e-9	Gut microbiome composition (summer);
TGCT	cis	rs9914544	0.932	rs11870265	chr17:18820985	A/T	cg26306683	chr17:18585705	ZNF286B	0.58	5.25	0.43	6.53e-7	Educational attainment (years of education);
TGCT	cis	rs57590327	0.679	rs35259664	chr3:81586742	C/G	cg07356753	chr3:81810745	GBE1	-0.55	-4.54	-0.38	1.3e-5	Extraversion;
TGCT	cis	rs7017914	0.934	rs6998024	chr8:71660840	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.03	-0.41	1.69e-6	Bone mineral density;
TGCT	cis	rs9788721	0.836	rs17483721	chr15:78733731	C/T	cg18825076	chr15:78729989	IREB2	0.31	5.11	0.42	1.17e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
TGCT	cis	rs4478858	0.684	rs7515988	chr1:31731061	C/T	cg07478791	chr1:31886160	SERINC2	0.52	5.05	0.41	1.53e-6	Alcohol dependence;
TGCT	trans	rs7726839	0.561	rs72703050	chr5:582917	A/C	cg25482853	chr8:67687455	SGK3	1.07	8.9	0.62	5.55e-15	Obesity-related traits;
TGCT	cis	rs2072499	0.966	rs2842869	chr1:156160696	A/G	cg06970220	chr1:156163860	SLC25A44	0.72	6.3	0.49	4.62e-9	Testicular germ cell tumor;
TGCT	cis	rs9341808	0.644	rs76102095	chr6:80942026	G/C	cg08355045	chr6:80787529	NA	-0.28	-4.52	-0.38	1.45e-5	Sitting height ratio;
TGCT	cis	rs9326248	0.539	rs7120565	chr11:117042949	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.57	5.26	0.43	6.17e-7	Blood protein levels;
TGCT	cis	rs67385638	1.000	rs10837697	chr11:5281018	G/C	cg12559170	chr11:5275217	HBG2	0.48	8.83	0.62	8.46e-15	Hemoglobin levels;
TGCT	cis	rs13191362	0.507	rs2023015	chr6:163060528	A/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.6	-5.72	-0.46	7.61e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs11250098	0.583	rs7001456	chr8:10804865	C/G	cg16664915	chr8:10907788	XKR6	-0.29	-4.5	-0.37	1.52e-5	Morning vs. evening chronotype;
TGCT	cis	rs858239	0.600	rs10256361	chr7:23123885	C/T	cg05602783	chr7:23145260	KLHL7	-0.64	-5.36	-0.43	3.9e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs10779751	0.960	rs4845860	chr1:11324193	A/G	cg08854313	chr1:11322531	MTOR	0.96	9.03	0.63	2.76e-15	Body mass index;
TGCT	cis	rs2204008	0.837	rs11183232	chr12:37941053	A/G	cg13010199	chr12:38710504	ALG10B	0.61	4.93	0.4	2.57e-6	Bladder cancer;
TGCT	cis	rs1421811	0.509	rs7733428	chr5:32689850	G/A	cg16267343	chr5:32710456	NPR3	0.74	6.6	0.51	1.08e-9	Blood pressure;
TGCT	cis	rs1580019	0.523	rs13236410	chr7:32690663	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.59	4.88	0.4	3.18e-6	Cognitive ability;
TGCT	cis	rs3771570	0.901	rs62190410	chr2:242410621	C/T	cg21155796	chr2:242212141	HDLBP	0.93	6.69	0.52	6.74e-10	Prostate cancer;
TGCT	cis	rs2046867	0.818	rs17010184	chr3:72870242	A/T	cg25664220	chr3:72788482	NA	0.56	7.03	0.53	1.24e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7617773	0.963	rs12493256	chr3:48176747	C/T	cg11946769	chr3:48343235	NME6	-0.57	-5.05	-0.41	1.57e-6	Coronary artery disease;
TGCT	cis	rs2073300	1.000	rs6048825	chr20:23457671	T/C	cg09953122	chr20:23471693	CST8	-0.59	-4.71	-0.39	6.5e-6	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs6750047	0.573	rs162329	chr2:38318940	T/C	cg07380506	chr2:38303506	CYP1B1	0.59	5.47	0.44	2.37e-7	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs651907	0.557	rs34181125	chr3:101490278	A/G	cg12386194	chr3:101231763	SENP7	0.48	4.7	0.39	6.71e-6	Colorectal cancer;
TGCT	cis	rs981844	0.712	rs4434231	chr4:154746293	G/T	cg14289246	chr4:154710475	SFRP2	-0.99	-9.24	-0.64	8.63e-16	Response to statins (LDL cholesterol change);
TGCT	cis	rs8179	0.645	rs11771637	chr7:92260161	G/A	cg15732164	chr7:92237376	CDK6	-0.29	-5.06	-0.41	1.46e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
TGCT	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg24578937	chr1:2090814	PRKCZ	0.26	6.52	0.51	1.63e-9	Height;
TGCT	cis	rs2439831	0.867	rs12324572	chr15:43636200	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	6.61	0.51	1e-9	Lung cancer in ever smokers;
TGCT	trans	rs561341	1.000	rs483301	chr17:30293398	G/T	cg20587970	chr11:113659929	NA	-1.03	-10.98	-0.7	5.21e-20	Hip circumference adjusted for BMI;
TGCT	cis	rs2688608	1.000	rs2688608	chr10:75658349	G/T	cg23231163	chr10:75533350	FUT11	-0.26	-4.65	-0.39	8.32e-6	Inflammatory bowel disease;
TGCT	cis	rs13401104	0.587	rs55801537	chr2:237145481	C/T	cg19324714	chr2:237145437	ASB18	0.48	5.03	0.41	1.67e-6	Educational attainment;
TGCT	cis	rs12210905	1.000	rs4636015	chr6:27097316	C/T	cg08851530	chr6:28072375	NA	1.21	5.58	0.45	1.43e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs3020736	0.500	rs6002605	chr22:42494335	A/G	cg15557168	chr22:42548783	NA	0.22	5.58	0.45	1.47e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2204008	0.777	rs11179774	chr12:38219559	A/C	cg26384229	chr12:38710491	ALG10B	0.84	7.43	0.56	1.51e-11	Bladder cancer;
TGCT	cis	rs13177718	0.908	rs7713158	chr5:108179300	G/A	cg20423064	chr5:108166851	FER	-0.58	-5.53	-0.45	1.77e-7	Height;
TGCT	cis	rs9393777	0.920	rs55834529	chr6:27072542	A/G	cg16898833	chr6:26189333	HIST1H4D	1.29	5.83	0.46	4.6e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.59	-5.97	-0.47	2.31e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs11585357	0.895	rs877552	chr1:17631236	C/T	cg08277548	chr1:17600880	PADI3	-0.95	-9.6	-0.65	1.15e-16	Hair shape;
TGCT	cis	rs6866344	0.697	rs62392832	chr5:178134395	T/C	cg03877680	chr5:178157825	ZNF354A	0.75	6.1	0.48	1.25e-8	Neutrophil percentage of white cells;
TGCT	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg04772025	chr11:68637568	NA	0.59	6.69	0.52	6.73e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs752590	0.887	rs7603621	chr2:113953984	G/A	cg27425262	chr2:113953981	PSD4;LOC440839	0.4	4.65	0.39	8.35e-6	Mucinous ovarian carcinoma;
TGCT	cis	rs12142240	0.698	rs67142569	chr1:46828460	C/T	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs8072100	0.790	rs11656856	chr17:45714671	C/T	cg08085267	chr17:45401833	C17orf57	0.46	5.05	0.41	1.55e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs35883536	0.647	rs10875313	chr1:101043057	T/C	cg10298815	chr1:101004474	GPR88	-0.25	-4.73	-0.39	6.03e-6	Monocyte count;
TGCT	cis	rs7714584	0.793	rs7709721	chr5:150246858	A/G	cg22134413	chr5:150180641	NA	0.83	6.53	0.51	1.54e-9	Crohn's disease;
TGCT	cis	rs4595586	0.545	rs4623945	chr12:39364572	A/T	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs7267979	1.000	rs1888999	chr20:25291848	C/T	cg14121845	chr20:25566513	NINL	0.5	5.42	0.44	2.98e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs739401	0.572	rs410820	chr11:3080102	G/A	cg05729581	chr11:3078854	CARS	-0.57	-5.21	-0.42	7.77e-7	Longevity;
TGCT	cis	rs7587476	0.601	rs17489231	chr2:215673739	T/G	cg04004882	chr2:215674386	BARD1	-0.64	-4.99	-0.41	1.98e-6	Neuroblastoma;
TGCT	trans	rs17685	0.753	rs11972240	chr7:75694079	A/C	cg19862616	chr7:65841803	NCRNA00174	0.52	9.01	0.63	3.02e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg03351412	chr1:154909251	PMVK	0.52	4.7	0.39	6.89e-6	Prostate cancer;
TGCT	cis	rs10992471	0.528	rs10429459	chr9:95258119	C/T	cg13798575	chr9:95087839	CENPP;NOL8	0.48	4.44	0.37	1.95e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs67072384	1.000	rs66628852	chr11:72454260	C/A	cg03713592	chr11:72463424	ARAP1	-0.93	-4.66	-0.39	7.89e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	trans	rs1415174	0.958	rs11161995	chr1:87847764	A/G	cg23065576	chr20:25207247	ENTPD6	-0.27	-6.8	-0.52	3.88e-10	Breast cancer;
TGCT	cis	rs11677203	0.958	rs6728483	chr2:12567278	G/A	cg00419568	chr2:11919532	LPIN1	-0.2	-4.47	-0.37	1.72e-5	Electroencephalogram traits;
TGCT	cis	rs13256369	0.901	rs4841015	chr8:8567140	C/G	cg17143192	chr8:8559678	CLDN23	0.58	5.55	0.45	1.64e-7	Obesity-related traits;
TGCT	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.31	-4.82	-0.4	4.12e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg23221052	chr5:179740743	GFPT2	-0.36	-5.75	-0.46	6.7e-8	Height;
TGCT	cis	rs8077889	1.000	rs17675122	chr17:41886190	A/G	cg26893861	chr17:41843967	DUSP3	1.1	12.5	0.75	1.08e-23	Triglycerides;
TGCT	cis	rs9926296	0.632	rs4785717	chr16:89801133	A/G	cg04287289	chr16:89883240	FANCA	0.67	6.64	0.51	8.68e-10	Vitiligo;
TGCT	cis	rs6920965	0.507	rs9385388	chr6:126215296	C/T	cg05901451	chr6:126070800	HEY2	-0.64	-6.47	-0.5	2.02e-9	High light scatter reticulocyte count;
TGCT	cis	rs6750047	0.605	rs59501228	chr2:38261972	A/C	cg07380506	chr2:38303506	CYP1B1	-0.58	-5.2	-0.42	8.09e-7	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs9914988	0.943	rs4795465	chr17:27151498	A/G	cg20469991	chr17:27169893	C17orf63	0.72	5.09	0.42	1.28e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs1215050	0.740	rs2695464	chr4:98980929	T/C	cg05340658	chr4:99064831	C4orf37	-0.43	-5.27	-0.43	5.8e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2439831	1.000	rs690263	chr15:43704465	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	6.22	0.49	6.97e-9	Lung cancer in ever smokers;
TGCT	cis	rs1964356	0.967	rs2953802	chr8:8851881	G/A	cg06636001	chr8:8085503	FLJ10661	0.71	6.21	0.49	7.22e-9	Mean corpuscular volume;
TGCT	cis	rs2013441	1.000	rs2107566	chr17:20103252	C/T	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.62	-0.38	9.59e-6	Obesity-related traits;
TGCT	cis	rs4689388	0.926	rs4458523	chr4:6289986	G/T	cg00701064	chr4:6280414	WFS1	-0.4	-5.11	-0.42	1.2e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	trans	rs66573146	0.831	rs73088564	chr4:6984553	G/C	cg07817883	chr1:32538562	TMEM39B	1.42	7.53	0.56	8.92e-12	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs11711311	0.712	rs3773683	chr3:113341007	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.69	-5.81	-0.46	5.03e-8	IgG glycosylation;
TGCT	cis	rs751728	1.000	rs9394166	chr6:33751122	G/C	cg00334056	chr6:33755658	LEMD2	-0.25	-4.58	-0.38	1.11e-5	Crohn's disease;
TGCT	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9790314	1.000	rs4350933	chr3:160955879	G/T	cg03342759	chr3:160939853	NMD3	-0.43	-4.55	-0.38	1.25e-5	Morning vs. evening chronotype;
TGCT	cis	rs459571	0.959	rs2520099	chr9:136918139	T/C	cg13789015	chr9:136890014	NCRNA00094	0.38	6.66	0.51	7.97e-10	Platelet distribution width;
TGCT	trans	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg17830980	chr10:43048298	ZNF37B	-0.88	-11.22	-0.71	1.37e-20	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg11890956	chr21:40555474	PSMG1	-0.7	-6.87	-0.52	2.79e-10	Menarche (age at onset);
TGCT	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg00024416	chr22:24240387	NA	-0.25	-4.76	-0.39	5.27e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs62103177	0.714	rs28691615	chr18:77612254	C/T	cg12964065	chr18:77638022	KCNG2	0.33	4.63	0.38	9.08e-6	Opioid sensitivity;
TGCT	cis	rs1062177	1.000	rs2915887	chr5:151205504	C/T	cg12924095	chr5:151150029	G3BP1	0.36	5.18	0.42	8.79e-7	Preschool internalizing problems;
TGCT	cis	rs3806843	0.576	rs246036	chr5:140331886	T/G	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg13695892	chr22:41940480	POLR3H	0.91	9.11	0.63	1.79e-15	Vitiligo;
TGCT	cis	rs13394619	1.000	rs4669752	chr2:11727988	G/C	cg07314298	chr2:11723111	GREB1	-0.29	-5.26	-0.43	6.09e-7	Endometriosis;
TGCT	cis	rs1008375	1.000	rs17507481	chr4:17620066	A/G	cg10189774	chr4:17578691	LAP3	0.67	5.84	0.46	4.33e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.43	-4.62	-0.38	9.36e-6	Longevity;Endometriosis;
TGCT	cis	rs826838	1.000	rs11609286	chr12:38875511	A/G	cg13010199	chr12:38710504	ALG10B	-0.82	-6.85	-0.52	3e-10	Heart rate;
TGCT	cis	rs8037137	0.571	rs3743445	chr15:91561182	C/T	cg22570213	chr15:91497863	RCCD1	0.52	4.86	0.4	3.41e-6	Platelet count;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
TGCT	cis	rs17152411	0.895	rs7094381	chr10:126585848	G/A	cg07906193	chr10:126599966	NA	0.41	5.05	0.41	1.52e-6	Height;
TGCT	cis	rs6840360	0.593	rs28602726	chr4:152499788	T/C	cg17479576	chr4:152424074	FAM160A1	-0.73	-7.94	-0.58	1.03e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs13102973	0.645	rs7692242	chr4:135886041	A/G	cg14419869	chr4:135874104	NA	0.26	4.6	0.38	1.03e-5	Subjective well-being;
TGCT	cis	rs7236492	0.572	rs7244366	chr18:77179746	C/T	cg15644404	chr18:77186268	NFATC1	-0.43	-4.5	-0.37	1.57e-5	Inflammatory bowel disease;Crohn's disease;
TGCT	trans	rs9467711	1.000	rs6939799	chr6:26328366	G/A	cg20516262	chr7:155325649	CNPY1	0.54	6.63	0.51	9.34e-10	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7119	0.717	rs12917314	chr15:77818285	T/C	cg27398640	chr15:77910606	LINGO1	-0.25	-4.61	-0.38	9.81e-6	Type 2 diabetes;
TGCT	cis	rs4631830	0.900	rs7914347	chr10:51537431	C/T	cg10326726	chr10:51549505	MSMB	-0.25	-5.27	-0.43	5.77e-7	Prostate-specific antigen levels;
TGCT	cis	rs9814567	1.000	rs9827987	chr3:134272621	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.98	-9.89	-0.66	2.32e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs7552404	0.921	rs10873685	chr1:76218818	A/C	cg03433033	chr1:76189801	ACADM	0.84	9.67	0.66	8.01e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9549367	0.713	rs576463	chr13:113846614	C/T	cg18105134	chr13:113819100	PROZ	0.46	8.58	0.61	3.25e-14	Platelet distribution width;
TGCT	cis	rs13256369	0.802	rs11249887	chr8:8562184	T/C	cg17143192	chr8:8559678	CLDN23	0.54	5.06	0.41	1.47e-6	Obesity-related traits;
TGCT	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.55	-6.35	-0.5	3.74e-9	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs13242816	1.000	rs55833477	chr7:116110375	C/G	cg16553024	chr7:116138462	CAV2	-0.45	-4.75	-0.39	5.64e-6	P wave duration;
TGCT	cis	rs2832191	1.000	rs2832184	chr21:30483265	C/T	cg08807101	chr21:30365312	RNF160	-0.49	-4.48	-0.37	1.65e-5	Dental caries;
TGCT	trans	rs35365539	1	rs35365539	chr3:49794347	A/AC	cg21665057	chr3:196295764	WDR53;FBXO45	-1.03	-13.16	-0.76	2.65e-25	Blood protein levels;
TGCT	cis	rs9486719	1.000	rs9373978	chr6:97056255	T/C	cg18709589	chr6:96969512	KIAA0776	-0.77	-5.47	-0.44	2.38e-7	Migraine;Coronary artery disease;
TGCT	cis	rs11969893	0.737	rs9498439	chr6:101404768	A/T	cg12253828	chr6:101329408	ASCC3	1.36	6.32	0.49	4.33e-9	Economic and political preferences (immigration/crime);
TGCT	cis	rs2046867	0.954	rs1490507	chr3:72781356	G/A	cg25664220	chr3:72788482	NA	0.53	6.61	0.51	1e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs346785	0.692	rs6501880	chr17:74289705	A/G	cg09812376	chr17:74270190	QRICH2	-0.36	-5.33	-0.43	4.43e-7	White matter hyperintensities in ischemic stroke;
TGCT	cis	rs7829975	0.539	rs883647	chr8:8569724	G/A	cg06636001	chr8:8085503	FLJ10661	-0.6	-5.08	-0.42	1.33e-6	Mood instability;
TGCT	cis	rs7267979	1.000	rs2258879	chr20:25279213	T/C	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7666738	0.830	rs1124253	chr4:98949682	C/T	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs114540395	0.925	rs17696674	chr10:103415063	A/T	cg03300883	chr10:102748874	C10orf2	0.43	4.5	0.37	1.52e-5	Schizophrenia;
TGCT	cis	rs2075165	0.836	rs7512751	chr1:156234439	T/G	cg16558208	chr1:156270281	VHLL	0.26	4.46	0.37	1.8e-5	Tonsillectomy;
TGCT	cis	rs7208859	0.673	rs3764421	chr17:29167653	A/C	cg18442181	chr17:29233375	C17orf42	-0.78	-4.61	-0.38	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7020830	0.931	rs13297576	chr9:37142189	A/C	cg14294708	chr9:37120828	ZCCHC7	1.29	19.18	0.86	6.46e-39	Schizophrenia;
TGCT	trans	rs8073060	0.586	rs4796098	chr17:33913436	T/C	cg19694781	chr19:47549865	TMEM160	0.6	13.04	0.76	5.29e-25	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs9811920	0.609	rs793460	chr3:99615733	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.6	-6.82	-0.52	3.63e-10	Axial length;
TGCT	cis	rs6089829	0.747	rs57767914	chr20:61659108	C/G	cg03213289	chr20:61660250	NA	-0.51	-5.59	-0.45	1.38e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs4409675	0.556	rs2064710	chr1:28231154	G/A	cg23691781	chr1:28212827	C1orf38	0.25	5.38	0.43	3.59e-7	Corneal astigmatism;
TGCT	cis	rs2361718	0.933	rs8077849	chr17:78104137	C/T	cg09238746	chr17:78121135	EIF4A3	-0.55	-4.68	-0.39	7.5e-6	Yeast infection;
TGCT	cis	rs11971779	0.838	rs58074268	chr7:139108925	C/T	cg07862535	chr7:139043722	LUC7L2	0.76	5.49	0.44	2.15e-7	Diisocyanate-induced asthma;
TGCT	cis	rs986417	1.000	rs1272688	chr14:60920718	T/C	cg27398547	chr14:60952738	C14orf39	-1.39	-10.61	-0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs17331151	0.505	rs79993196	chr3:52697566	T/C	cg15956490	chr3:53032818	SFMBT1	0.7	5.71	0.46	7.8e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs12477438	0.520	rs13010904	chr2:99754289	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.05	12.89	0.76	1.24e-24	Chronic sinus infection;
TGCT	cis	rs921968	0.541	rs4674310	chr2:219318078	T/C	cg02176678	chr2:219576539	TTLL4	-0.47	-6.78	-0.52	4.34e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs7818688	0.654	rs11783262	chr8:95979816	A/G	cg16049864	chr8:95962084	TP53INP1	0.54	4.64	0.38	8.87e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs3936340	1.000	rs3936340	chr19:48527582	A/G	cg03707168	chr19:49379127	PPP1R15A	-0.6	-4.56	-0.38	1.22e-5	Intelligence;
TGCT	trans	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg21659725	chr3:3221576	CRBN	-0.74	-8.78	-0.62	1.08e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs1215050	0.818	rs1214917	chr4:99080029	G/T	cg05340658	chr4:99064831	C4orf37	0.41	4.82	0.4	4.15e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg19774624	chr17:42201019	HDAC5	0.72	7.69	0.57	3.88e-12	Total body bone mineral density;
TGCT	cis	rs35146811	0.735	rs1043915	chr7:99799845	T/A	cg04778012	chr7:99775508	STAG3;GPC2	0.34	4.61	0.38	9.84e-6	Coronary artery disease;
TGCT	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.79	5.65	0.45	1.06e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7666738	0.830	rs10005173	chr4:98816062	T/C	cg17366294	chr4:99064904	C4orf37	0.7	7.45	0.56	1.42e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7439150	0.954	rs72681204	chr4:155476145	C/A	cg22130008	chr4:155548532	NA	-0.43	-5.43	-0.44	2.87e-7	Fibrinogen levels;
TGCT	cis	rs7666738	0.830	rs17027058	chr4:98864671	G/A	cg17366294	chr4:99064904	C4orf37	0.73	7.59	0.56	6.56e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4273100	1.000	rs16960158	chr17:19163052	A/C	cg01534423	chr17:18965556	NA	0.91	5.95	0.47	2.6e-8	Schizophrenia;
TGCT	cis	rs1887596	0.624	rs4769504	chr13:27130516	A/G	cg01312412	chr13:27282625	NA	0.27	4.74	0.39	5.68e-6	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs9467773	0.967	rs6932865	chr6:26540166	C/A	cg26531700	chr6:26746687	NA	0.47	4.57	0.38	1.14e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs4455778	0.580	rs4291221	chr7:49114465	C/T	cg26309511	chr7:48887640	NA	-0.5	-6.47	-0.5	2.02e-9	Lung cancer in never smokers;
TGCT	cis	rs1348850	0.831	rs7606235	chr2:178401288	T/C	cg22681709	chr2:178499509	PDE11A	-0.36	-4.59	-0.38	1.06e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs2455799	0.552	rs1472697	chr3:15750268	G/A	cg16303742	chr3:15540471	COLQ	-0.25	-4.69	-0.39	6.96e-6	Mean platelet volume;
TGCT	cis	rs1865760	0.516	rs9358903	chr6:26061949	A/C	cg16482183	chr6:26056742	HIST1H1C	0.57	4.99	0.41	1.99e-6	Height;
TGCT	cis	rs7017914	0.902	rs6472562	chr8:71969878	A/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.57	-5.28	-0.43	5.57e-7	Bone mineral density;
TGCT	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg09436375	chr6:42928200	GNMT	-0.4	-5.19	-0.42	8.31e-7	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs7582180	0.638	rs6734316	chr2:100976210	A/G	cg08017756	chr2:100939284	LONRF2	-0.3	-5.0	-0.41	1.93e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4713118	0.513	rs149972	chr6:27983227	C/T	cg10876282	chr6:28092338	ZSCAN16	0.49	4.49	0.37	1.6e-5	Parkinson's disease;
TGCT	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg06238570	chr21:40685208	BRWD1	-0.8	-9.0	-0.63	3.3e-15	Cognitive function;
TGCT	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg11366901	chr6:160182831	ACAT2	1.03	6.92	0.53	2.14e-10	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs57920188	0.535	rs77116992	chr1:4095498	T/A	cg20703997	chr1:4087676	NA	0.48	5.62	0.45	1.19e-7	Interleukin-17 levels;
TGCT	cis	rs2692947	0.673	rs1168965	chr2:96787899	C/G	cg05933789	chr2:97190408	NA	-0.16	-4.61	-0.38	9.67e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs34546498	1	rs34546498	chr6:26961280	C/T	cg12315302	chr6:26189340	HIST1H4D	0.99	4.44	0.37	1.93e-5	Breast cancer;
TGCT	cis	rs7027203	0.717	rs7869328	chr9:96588782	A/G	cg14598338	chr9:96623480	NA	-0.62	-9.51	-0.65	1.96e-16	DNA methylation (variation);
TGCT	trans	rs877282	0.853	rs11595510	chr10:756757	C/G	cg22713356	chr15:30763199	NA	1.01	8.45	0.6	6.58e-14	Uric acid levels;
TGCT	cis	rs4074961	0.565	rs10908362	chr1:38061706	G/C	cg17933807	chr1:38061675	GNL2	1.09	16.99	0.84	3.64e-34	Axial length;
TGCT	cis	rs62244186	0.632	rs1402751	chr3:44594030	C/A	cg21672276	chr3:44754072	ZNF502	-0.43	-4.82	-0.4	4.06e-6	Depressive symptoms;
TGCT	cis	rs9291683	0.546	rs13129453	chr4:10044784	T/C	cg00071950	chr4:10020882	SLC2A9	0.57	6.47	0.5	2.01e-9	Bone mineral density;
TGCT	cis	rs10782582	0.609	rs12138898	chr1:76375183	G/T	cg10523679	chr1:76189770	ACADM	-0.58	-5.24	-0.43	6.74e-7	Daytime sleep phenotypes;
TGCT	cis	rs1008375	1.000	rs11947857	chr4:17691047	T/C	cg16339924	chr4:17578868	LAP3	-0.58	-4.58	-0.38	1.11e-5	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4919669	0.668	rs4146428	chr10:104401721	G/A	cg05855489	chr10:104503620	C10orf26	0.76	4.44	0.37	1.98e-5	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs4478858	0.735	rs7523438	chr1:31788313	C/T	cg07478791	chr1:31886160	SERINC2	0.47	4.6	0.38	1.03e-5	Alcohol dependence;
TGCT	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.41	-4.55	-0.38	1.26e-5	Longevity;Endometriosis;
TGCT	cis	rs2932538	0.885	rs6691025	chr1:113177070	G/T	cg22162597	chr1:113214053	CAPZA1	-0.27	-5.88	-0.47	3.49e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs7617773	0.501	rs12185901	chr3:48382919	G/T	cg11946769	chr3:48343235	NME6	0.55	4.6	0.38	1.02e-5	Coronary artery disease;
TGCT	cis	rs6582630	0.555	rs11610015	chr12:38508856	A/G	cg26384229	chr12:38710491	ALG10B	0.83	7.75	0.57	2.83e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs9894429	0.789	rs9747336	chr17:79584189	C/T	cg21984481	chr17:79567631	NPLOC4	-0.26	-4.9	-0.4	2.91e-6	Eye color traits;
TGCT	cis	rs2204008	0.537	rs11170128	chr12:38006632	G/A	cg26384229	chr12:38710491	ALG10B	0.83	7.2	0.54	4.98e-11	Bladder cancer;
TGCT	cis	rs9399135	1.000	rs9399135	chr6:135368314	G/A	cg24558204	chr6:135376177	HBS1L	0.46	4.6	0.38	1.05e-5	Red blood cell count;
TGCT	cis	rs11122272	0.735	rs2808603	chr1:231537738	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-6.24	-0.49	6.42e-9	Hemoglobin concentration;
TGCT	cis	rs4409675	0.597	rs1000431	chr1:28225114	C/T	cg23691781	chr1:28212827	C1orf38	0.25	5.26	0.43	6.19e-7	Corneal astigmatism;
TGCT	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg19774624	chr17:42201019	HDAC5	-0.86	-9.25	-0.64	8.4e-16	Total body bone mineral density;
TGCT	cis	rs3892630	0.612	rs10413282	chr19:33182751	A/G	cg22980127	chr19:33182716	NUDT19	0.8	6.61	0.51	1.04e-9	Red blood cell traits;
TGCT	cis	rs3774830	0.846	rs17367340	chr4:5457009	T/G	cg26943120	chr4:5472116	STK32B	0.26	6.22	0.49	6.95e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	trans	rs1814175	0.653	rs10839480	chr11:50034556	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.26	-0.55	3.77e-11	Height;
TGCT	cis	rs6500602	0.893	rs934888	chr16:4462832	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.43	5.31	0.43	4.92e-7	Schizophrenia;
TGCT	cis	rs2235642	0.893	rs2076439	chr16:1587277	C/T	cg07639376	chr16:1584516	IFT140;TMEM204	-0.33	-5.76	-0.46	6.11e-8	Coronary artery disease;
TGCT	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg24112000	chr20:60950667	NA	0.37	4.93	0.41	2.53e-6	Colorectal cancer;
TGCT	cis	rs9399137	0.507	rs11754021	chr6:135308375	A/G	cg24558204	chr6:135376177	HBS1L	0.46	4.65	0.39	8.46e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
TGCT	cis	rs10883723	0.773	rs11191313	chr10:104278618	C/T	cg05855489	chr10:104503620	C10orf26	-0.6	-5.18	-0.42	8.85e-7	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs79349575	0.687	rs12602179	chr17:47010034	G/T	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.52	-0.38	1.44e-5	Type 2 diabetes;
TGCT	cis	rs854765	0.583	rs4534911	chr17:17852330	A/G	cg09796270	chr17:17721594	SREBF1	0.27	5.42	0.44	2.99e-7	Total body bone mineral density;
TGCT	cis	rs10170846	0.861	rs4674677	chr2:223529658	G/A	cg25565276	chr2:223520875	FARSB	0.55	4.58	0.38	1.1e-5	Schizophrenia (inflammation and infection response interaction);
TGCT	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg20607798	chr8:58055168	NA	-0.49	-4.51	-0.38	1.46e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2544527	0.586	rs2544534	chr2:15906466	T/C	cg26669897	chr2:15909070	NA	0.42	5.07	0.41	1.39e-6	Pulmonary function (smoking interaction);Pulmonary function;
TGCT	cis	rs73110464	0.562	rs2363634	chr12:53354683	A/G	cg05393297	chr12:53359155	NA	-0.79	-8.34	-0.6	1.18e-13	Cancer (pleiotropy);
TGCT	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg27535305	chr1:53392650	SCP2	-0.27	-5.38	-0.44	3.57e-7	Monocyte count;
TGCT	cis	rs1878931	0.520	rs12447807	chr16:3413896	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.96	11.15	0.71	1.96e-20	Body mass index (adult);
TGCT	cis	rs7647973	0.961	rs11130186	chr3:49275828	A/G	cg07636037	chr3:49044803	WDR6	0.67	5.41	0.44	3.15e-7	Menarche (age at onset);
TGCT	cis	rs9303401	0.659	rs34468504	chr17:56648277	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg08392591	chr16:89556376	ANKRD11	0.56	5.2	0.42	8.06e-7	Multiple myeloma (IgH translocation);
TGCT	cis	rs4851254	0.920	rs11689956	chr2:100795329	T/C	cg23118464	chr2:100721844	AFF3	0.58	4.46	0.37	1.84e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	5.23	0.43	6.92e-7	Menopause (age at onset);
TGCT	cis	rs59107033	0.607	rs9840967	chr3:123127106	A/G	cg04890266	chr3:123102914	ADCY5	0.39	5.94	0.47	2.67e-8	Lymphocyte counts;
TGCT	cis	rs9611565	0.512	rs139573	chr22:42214785	G/A	cg06634786	chr22:41940651	POLR3H	-0.86	-8.01	-0.58	7.16e-13	Vitiligo;
TGCT	cis	rs155076	0.938	rs485361	chr13:21845826	G/T	cg11317459	chr13:21872234	NA	-1.42	-12.02	-0.73	1.53e-22	White matter hyperintensity burden;
TGCT	cis	rs7829975	0.593	rs2921051	chr8:8320104	C/A	cg06636001	chr8:8085503	FLJ10661	0.79	7.89	0.58	1.39e-12	Mood instability;
TGCT	cis	rs9611565	0.765	rs132906	chr22:41799767	G/C	cg17554472	chr22:41940697	POLR3H	0.41	4.55	0.38	1.24e-5	Vitiligo;
TGCT	cis	rs3806843	0.548	rs246056	chr5:140325600	G/A	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.11e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs1401999	0.510	rs17817736	chr3:183720313	A/T	cg01324343	chr3:183735012	ABCC5	-0.48	-5.1	-0.42	1.21e-6	Anterior chamber depth;
TGCT	cis	rs66573146	0.831	rs56300156	chr4:6990813	G/C	cg05069807	chr4:6945702	TBC1D14	0.31	4.85	0.4	3.63e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs1008375	0.931	rs10019482	chr4:17578079	G/A	cg10189774	chr4:17578691	LAP3	0.64	5.61	0.45	1.28e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	trans	rs2727020	0.658	rs4980442	chr11:49445016	G/T	cg03929089	chr4:120376271	NA	-0.74	-8.56	-0.61	3.56e-14	Coronary artery disease;
TGCT	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg08736216	chr1:53307985	ZYG11A	-0.3	-6.06	-0.48	1.48e-8	Monocyte count;
TGCT	cis	rs1577917	0.958	rs12199832	chr6:86652748	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.54	-0.45	1.73e-7	Response to antipsychotic treatment;
TGCT	cis	rs12780845	0.540	rs3824632	chr10:17230999	A/G	cg01003015	chr10:17271136	VIM	0.49	4.53	0.38	1.35e-5	Homocysteine levels;
TGCT	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg10802521	chr3:52805072	NEK4	0.77	9.32	0.64	5.7e-16	Bipolar disorder;
TGCT	cis	rs9467773	0.620	rs2451738	chr6:26618459	A/T	cg02458000	chr6:26745757	NA	-0.54	-5.32	-0.43	4.69e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs4654899	0.758	rs12078457	chr1:21397071	C/T	cg01072550	chr1:21505969	NA	-0.57	-9.35	-0.64	4.68e-16	Superior frontal gyrus grey matter volume;
TGCT	cis	rs56873913	0.904	rs3760708	chr19:50084596	G/C	cg09250473	chr19:50168907	IRF3;BCL2L12	0.65	5.32	0.43	4.59e-7	Schizophrenia;
TGCT	cis	rs734999	0.611	rs10797431	chr1:2501222	G/T	cg18854424	chr1:2615690	NA	0.46	5.34	0.43	4.29e-7	Ulcerative colitis;
TGCT	cis	rs4803468	1.000	rs2304242	chr19:41944616	G/T	cg09537434	chr19:41945824	ATP5SL	0.91	10.05	0.67	9.48e-18	Height;
TGCT	cis	rs28735056	0.904	rs11665111	chr18:77622996	T/C	cg20368463	chr18:77673604	PQLC1	0.39	4.76	0.39	5.21e-6	Schizophrenia;
TGCT	cis	rs12286929	0.576	rs2275997	chr11:115100186	A/G	cg04017736	chr11:115827165	NA	-0.22	-5.8	-0.46	5.14e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs1568889	1.000	rs7945367	chr11:28166272	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	8.68	0.61	1.88e-14	Bipolar disorder;
TGCT	cis	rs611744	0.573	rs1457210	chr8:109261562	A/G	cg21045802	chr8:109455806	TTC35	-0.63	-6.57	-0.51	1.23e-9	Dupuytren's disease;
TGCT	cis	rs10254284	0.959	rs11771411	chr7:28149761	T/C	cg23620719	chr7:28220237	JAZF1	-0.54	-4.81	-0.4	4.38e-6	Lymphocyte percentage of white cells;Systemic lupus erythematosus;
TGCT	cis	rs262150	0.672	rs2730230	chr7:158788529	A/G	cg19418458	chr7:158789849	NA	-0.43	-4.58	-0.38	1.13e-5	Facial morphology (factor 20);
TGCT	cis	rs4455778	0.538	rs6977073	chr7:49115340	C/T	cg26309511	chr7:48887640	NA	0.5	6.55	0.51	1.4e-9	Lung cancer in never smokers;
TGCT	trans	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg17830980	chr10:43048298	ZNF37B	-0.87	-11.3	-0.71	8.81e-21	Extrinsic epigenetic age acceleration;
TGCT	cis	rs10851411	0.908	rs2617236	chr15:42815733	A/T	cg23803468	chr15:43513504	EPB42	0.23	4.46	0.37	1.82e-5	Glucose homeostasis traits;
TGCT	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg11494091	chr17:61959527	GH2	0.61	14.35	0.79	4.1e-28	Prudent dietary pattern;
TGCT	cis	rs1843834	0.858	rs4674933	chr2:225514923	C/T	cg22455342	chr2:225449267	CUL3	0.74	7.46	0.56	1.29e-11	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs12911832	0.701	rs452698	chr15:59105571	A/G	cg05156742	chr15:59063176	FAM63B	0.56	5.25	0.43	6.3e-7	Schizophrenia;
TGCT	cis	rs6840360	0.615	rs6831810	chr4:152461995	A/G	cg17479576	chr4:152424074	FAM160A1	-0.71	-7.74	-0.57	2.95e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs2120019	1.000	rs12903201	chr15:75370776	A/C	cg09165964	chr15:75287851	SCAMP5	-1.07	-8.58	-0.61	3.34e-14	Blood trace element (Zn levels);
TGCT	cis	rs7027203	0.828	rs4744287	chr9:96585567	A/G	cg14598338	chr9:96623480	NA	0.61	9.88	0.66	2.5e-17	DNA methylation (variation);
TGCT	cis	rs7824557	0.767	rs6985146	chr8:11170721	A/C	cg21775007	chr8:11205619	TDH	0.48	4.81	0.4	4.27e-6	Retinal vascular caliber;
TGCT	cis	rs921968	0.541	rs532425	chr2:219434194	A/G	cg02176678	chr2:219576539	TTLL4	0.48	6.78	0.52	4.32e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs11098499	0.909	rs9994810	chr4:120381590	A/G	cg09307838	chr4:120376055	NA	0.71	6.98	0.53	1.57e-10	Corneal astigmatism;
TGCT	cis	rs11175194	0.546	rs73122698	chr12:64210942	C/T	cg17737263	chr12:64537067	SRGAP1	0.37	4.81	0.4	4.26e-6	Epithelial ovarian cancer;
TGCT	cis	rs539096	0.501	rs713191	chr1:44314553	A/G	cg12908607	chr1:44402522	ARTN	-0.64	-7.74	-0.57	3e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg00149659	chr3:10157352	C3orf10	0.92	5.82	0.46	4.71e-8	Alzheimer's disease;
TGCT	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg08859206	chr1:53392774	SCP2	-0.46	-7.42	-0.55	1.64e-11	Monocyte count;
TGCT	cis	rs2708977	1.000	rs34029026	chr2:97250042	T/C	cg01950434	chr2:97203154	ARID5A	0.57	4.9	0.4	2.9e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs6840360	1.000	rs907237	chr4:152601146	T/G	cg17479576	chr4:152424074	FAM160A1	-0.52	-5.59	-0.45	1.37e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs797680	0.856	rs12044657	chr1:93639596	T/C	cg17826107	chr1:92977322	EVI5	-0.23	-5.04	-0.41	1.59e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs11971779	0.680	rs7808740	chr7:139028955	G/T	cg07862535	chr7:139043722	LUC7L2	0.56	4.46	0.37	1.82e-5	Diisocyanate-induced asthma;
TGCT	cis	rs6867032	1.000	rs4246753	chr5:2014721	G/A	cg26168224	chr5:2018326	NA	0.43	7.96	0.58	9.45e-13	Gut microbiome composition (winter);
TGCT	cis	rs3849570	0.695	rs6804587	chr3:81873423	T/C	cg07356753	chr3:81810745	GBE1	-0.6	-5.31	-0.43	4.92e-7	Waist circumference;Body mass index;
TGCT	cis	rs447921	0.861	rs67873924	chr17:74429992	C/G	cg09812376	chr17:74270190	QRICH2	-0.48	-4.71	-0.39	6.4e-6	Mitochondrial DNA levels;
TGCT	cis	rs79149102	0.579	rs6495140	chr15:75306041	T/C	cg09165964	chr15:75287851	SCAMP5	-1.04	-5.71	-0.46	7.93e-8	Lung cancer;
TGCT	cis	rs72781680	0.898	rs12623079	chr2:24103749	G/A	cg08917208	chr2:24149416	ATAD2B	0.78	4.79	0.4	4.69e-6	Lymphocyte counts;
TGCT	cis	rs12971120	1.000	rs2278161	chr18:72176083	T/C	cg26446133	chr18:72167187	CNDP2	-0.33	-6.03	-0.48	1.74e-8	Refractive error;
TGCT	cis	rs10992471	0.598	rs331380	chr9:95256519	C/T	cg13798575	chr9:95087839	CENPP;NOL8	0.63	6.25	0.49	5.98e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs4689388	0.890	rs1801206	chr4:6302707	C/T	cg00701064	chr4:6280414	WFS1	0.43	5.66	0.45	9.73e-8	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg13695892	chr22:41940480	POLR3H	0.89	8.48	0.61	5.62e-14	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs6545883	0.894	rs35292974	chr2:61522047	T/C	cg15711740	chr2:61764176	XPO1	0.54	4.59	0.38	1.09e-5	Tuberculosis;
TGCT	cis	rs8017423	0.967	rs7160032	chr14:90708472	A/G	cg04374321	chr14:90722782	PSMC1	0.77	8.04	0.59	6.19e-13	Mortality in heart failure;
TGCT	cis	rs644799	0.965	rs573758	chr11:95539591	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	8.74	0.62	1.39e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9796	0.870	rs28581803	chr15:41326513	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.41	-5.32	-0.43	4.78e-7	Menopause (age at onset);
TGCT	cis	rs1577917	0.739	rs9344532	chr6:86234070	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.61	5.38	0.43	3.61e-7	Response to antipsychotic treatment;
TGCT	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg04267008	chr7:1944627	MAD1L1	0.36	4.59	0.38	1.05e-5	Bipolar disorder and schizophrenia;
TGCT	cis	rs6684514	1.000	rs7522948	chr1:156275308	C/T	cg16558208	chr1:156270281	VHLL	0.48	10.26	0.68	2.98e-18	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs1801251	0.896	rs79793315	chr2:233690864	C/T	cg08000102	chr2:233561755	GIGYF2	-0.59	-6.22	-0.49	6.86e-9	Coronary artery disease;
TGCT	cis	rs796364	0.616	rs2140486	chr2:200690102	C/T	cg17644776	chr2:200775616	C2orf69	0.34	4.84	0.4	3.76e-6	Schizophrenia;
TGCT	cis	rs2549003	0.870	rs61175929	chr5:131821548	C/G	cg02551604	chr5:131831745	NA	-0.88	-11.45	-0.72	3.69e-21	Asthma (sex interaction);
TGCT	cis	rs12497850	0.931	rs7430501	chr3:48890119	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.41	-5.49	-0.44	2.15e-7	Parkinson's disease;
TGCT	cis	rs4319547	0.656	rs6488951	chr12:122873928	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.62	-4.87	-0.4	3.32e-6	Body mass index;
TGCT	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	5.07	0.41	1.42e-6	Electroencephalogram traits;
TGCT	cis	rs4660261	0.526	rs803680	chr1:44364370	G/C	cg13606994	chr1:44402422	ARTN	-0.42	-4.56	-0.38	1.21e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7959452	0.684	rs11177615	chr12:69754189	G/A	cg20891283	chr12:69753455	YEATS4	0.83	8.52	0.61	4.61e-14	Blood protein levels;
TGCT	cis	rs9303542	0.625	rs62065846	chr17:46592858	G/A	cg25032089	chr17:46643351	HOXB3	0.57	5.74	0.46	6.78e-8	Ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs367943	1.000	rs168365	chr5:112817984	G/A	cg12552261	chr5:112820674	MCC	-0.24	-4.91	-0.4	2.81e-6	Type 2 diabetes;
TGCT	cis	rs9952991	0.883	rs2542147	chr18:12775851	G/T	cg24737193	chr18:12778029	NA	0.53	5.93	0.47	2.8e-8	Inflammatory skin disease;
TGCT	cis	rs7937682	0.562	rs955744	chr11:111374334	C/T	cg09085632	chr11:111637200	PPP2R1B	0.7	6.48	0.5	1.94e-9	Primary sclerosing cholangitis;
TGCT	cis	rs2562456	0.833	rs2968076	chr19:21637101	C/T	cg01304269	chr19:21688519	ZNF429	-0.61	-4.89	-0.4	3.06e-6	Pain;
TGCT	cis	rs7312933	0.558	rs11181466	chr12:42765181	A/T	cg19980929	chr12:42632907	YAF2	0.43	6.03	0.48	1.79e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs9291683	0.527	rs11727087	chr4:10096020	A/G	cg00071950	chr4:10020882	SLC2A9	0.53	5.61	0.45	1.23e-7	Bone mineral density;
TGCT	cis	rs7617773	0.743	rs13081633	chr3:48357281	A/G	cg11946769	chr3:48343235	NME6	0.82	7.09	0.54	9.1e-11	Coronary artery disease;
TGCT	cis	rs9916302	0.861	rs4795376	chr17:37669043	T/C	cg07936489	chr17:37558343	FBXL20	-0.62	-4.88	-0.4	3.2e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs916888	0.821	rs70600	chr17:44860021	C/T	cg01570182	chr17:44337453	NA	1.01	9.1	0.63	1.83e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.1	0.42	1.24e-6	Menopause (age at onset);
TGCT	cis	rs9926296	0.656	rs4522419	chr16:89853307	T/C	cg26513180	chr16:89883248	FANCA	0.74	7.18	0.54	5.51e-11	Vitiligo;
TGCT	cis	rs4409675	0.527	rs12067053	chr1:28227122	T/G	cg23691781	chr1:28212827	C1orf38	0.26	5.44	0.44	2.76e-7	Corneal astigmatism;
TGCT	cis	rs367943	1.000	rs367943	chr5:112809728	C/T	cg12552261	chr5:112820674	MCC	0.26	4.87	0.4	3.37e-6	Type 2 diabetes;
TGCT	cis	rs600231	0.706	rs11227221	chr11:65319265	T/C	cg17120908	chr11:65337727	SSSCA1	0.54	5.07	0.41	1.4e-6	Bone mineral density;
TGCT	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg24675658	chr1:53192096	ZYG11B	-0.76	-9.17	-0.64	1.25e-15	Monocyte count;
TGCT	cis	rs988712	0.587	rs117567901	chr11:27706040	T/C	cg10635145	chr11:27742435	BDNF	-0.43	-6.14	-0.48	1.04e-8	Obesity;
TGCT	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg12310025	chr6:25882481	NA	0.53	4.83	0.4	4.01e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6598955	0.543	rs6698557	chr1:26561220	G/C	cg24519413	chr1:26490540	NA	-0.25	-4.65	-0.39	8.5e-6	Obesity-related traits;
TGCT	cis	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg20637647	chr7:64974828	NA	1.0	5.59	0.45	1.4e-7	Diabetic kidney disease;
TGCT	cis	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg09021430	chr5:549028	NA	-0.43	-5.83	-0.46	4.57e-8	Obesity-related traits;
TGCT	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg05552183	chr6:42928497	GNMT	0.58	5.17	0.42	8.97e-7	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs4746818	1.000	rs4342912	chr10:70959282	T/C	cg04149295	chr10:70884716	VPS26A	0.78	5.32	0.43	4.7e-7	Left atrial antero-posterior diameter;
TGCT	cis	rs35771425	0.518	rs1055565	chr1:211605697	G/A	cg26515805	chr1:211431828	RCOR3	-0.44	-5.04	-0.41	1.64e-6	Educational attainment (years of education);
TGCT	cis	rs6071524	0.508	rs2244193	chr20:37387985	A/G	cg09937324	chr20:37376998	ACTR5	0.54	4.45	0.37	1.91e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs28595532	0.841	rs116587722	chr4:119790517	T/C	cg21605333	chr4:119757512	SEC24D	1.56	8.07	0.59	5.05e-13	Cannabis dependence symptom count;
TGCT	cis	rs7267979	1.000	rs6050602	chr20:25401203	A/G	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9467773	0.869	rs1796521	chr6:26421392	T/C	cg26531700	chr6:26746687	NA	-0.5	-4.82	-0.4	4.06e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9921338	0.961	rs4780358	chr16:11374212	G/T	cg00044050	chr16:11439710	C16orf75	-0.85	-6.07	-0.48	1.47e-8	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs7926906	0.688	rs2213085	chr11:90528586	A/G	cg26138821	chr11:89956704	CHORDC1	-0.44	-4.6	-0.38	1.04e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs4072705	0.615	rs7028021	chr9:127249022	A/G	cg13476313	chr9:127244764	NR5A1	0.29	4.94	0.41	2.45e-6	Menarche (age at onset);
TGCT	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg24060327	chr5:131705240	SLC22A5	-0.55	-5.61	-0.45	1.27e-7	Breast cancer;
TGCT	cis	rs295140	1.000	rs13028959	chr2:201185919	C/A	cg04283868	chr2:201171347	SPATS2L	0.65	6.67	0.51	7.76e-10	QT interval;
TGCT	cis	rs858239	0.539	rs2141306	chr7:23191664	G/A	cg05602783	chr7:23145260	KLHL7	-0.63	-4.98	-0.41	2.09e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs796364	0.568	rs11890894	chr2:201072055	C/T	cg04283868	chr2:201171347	SPATS2L	-0.55	-4.65	-0.39	8.28e-6	Schizophrenia;
TGCT	cis	rs78487399	0.710	rs72879276	chr2:43627101	T/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-4.87	-0.4	3.39e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg18230493	chr5:56204884	C5orf35	-0.68	-5.85	-0.46	4.13e-8	Initial pursuit acceleration;
TGCT	cis	rs7100689	0.516	rs3862532	chr10:82015725	A/C	cg01528321	chr10:82214614	TSPAN14	0.71	6.76	0.52	4.92e-10	Post bronchodilator FEV1;
TGCT	cis	rs7666738	0.753	rs17483788	chr4:98985623	G/A	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1511802	0.666	rs4862663	chr4:187119228	T/A	cg19358738	chr4:186734530	SORBS2	0.17	4.55	0.38	1.27e-5	Blood protein levels;
TGCT	cis	rs7617480	0.648	rs6766238	chr3:48801929	G/A	cg07636037	chr3:49044803	WDR6	0.78	6.5	0.5	1.73e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs9372498	0.536	rs62424172	chr6:118777533	C/A	cg07617317	chr6:118971624	C6orf204	0.5	5.39	0.44	3.37e-7	Diastolic blood pressure;
TGCT	cis	rs2228479	0.850	rs12598316	chr16:89916600	C/A	cg06558623	chr16:89946397	TCF25	0.56	4.86	0.4	3.54e-6	Skin colour saturation;
TGCT	cis	rs2594989	0.945	rs2594969	chr3:11353399	C/G	cg00170343	chr3:11313890	ATG7	0.62	4.69	0.39	7.07e-6	Circulating chemerin levels;
TGCT	cis	rs858239	0.698	rs858295	chr7:23245569	A/G	cg05407003	chr7:23246146	NA	-0.29	-4.59	-0.38	1.05e-5	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs2282802	0.685	rs6867870	chr5:139641896	C/A	cg01081189	chr5:139537190	NA	0.29	5.24	0.43	6.57e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs6490294	0.904	rs12423126	chr12:112429469	C/G	cg10833066	chr12:111807467	FAM109A	0.36	5.11	0.42	1.17e-6	Mean platelet volume;
TGCT	cis	rs62244186	0.711	rs6778410	chr3:44743993	C/T	cg25151919	chr3:44754333	ZNF502	-0.45	-5.31	-0.43	4.93e-7	Depressive symptoms;
TGCT	cis	rs7659604	0.791	rs57316471	chr4:122663939	A/G	cg06713675	chr4:122721982	EXOSC9	-0.5	-6.45	-0.5	2.23e-9	Type 2 diabetes;
TGCT	cis	rs67311347	0.524	rs7649168	chr3:40356158	T/C	cg17264618	chr3:40429014	ENTPD3	0.3	4.48	0.37	1.69e-5	Renal cell carcinoma;
TGCT	cis	rs6714710	0.535	rs13006932	chr2:98370698	T/A	cg26665480	chr2:98280029	ACTR1B	0.69	6.27	0.49	5.37e-9	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs11578119	0.933	rs7511715	chr1:170432995	T/C	cg09767346	chr1:170501363	GORAB	0.71	5.68	0.45	9.07e-8	Male-pattern baldness;
TGCT	cis	rs1865760	0.566	rs3752420	chr6:26027135	G/A	cg16482183	chr6:26056742	HIST1H1C	0.59	5.14	0.42	1.04e-6	Height;
TGCT	cis	rs854765	0.583	rs4257260	chr17:17857003	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	7.69	0.57	3.98e-12	Total body bone mineral density;
TGCT	cis	rs7914558	0.966	rs3758543	chr10:104944744	C/G	cg04362960	chr10:104952993	NT5C2	0.61	5.47	0.44	2.42e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs6866344	0.697	rs56159071	chr5:178127246	T/A	cg03877680	chr5:178157825	ZNF354A	0.73	5.72	0.46	7.46e-8	Neutrophil percentage of white cells;
TGCT	cis	rs4972806	0.739	rs10834	chr2:177042087	A/G	cg03152288	chr2:177042942	NA	0.6	4.87	0.4	3.31e-6	IgG glycosylation;
TGCT	cis	rs8072100	0.701	rs6503807	chr17:45772932	T/C	cg08085267	chr17:45401833	C17orf57	-0.43	-4.82	-0.4	4.04e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs1903068	0.752	rs28517654	chr4:55993468	T/C	cg16572876	chr4:56024045	NA	0.42	4.74	0.39	5.64e-6	Endometriosis;
TGCT	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg18876405	chr7:65276391	NA	0.31	4.8	0.4	4.53e-6	Aortic root size;
TGCT	cis	rs2243480	1.000	rs4718317	chr7:65648901	A/G	cg07424592	chr7:64974309	NA	-1.26	-7.79	-0.57	2.25e-12	Diabetic kidney disease;
TGCT	cis	rs7605378	0.528	rs1704190	chr2:200760629	G/A	cg17644776	chr2:200775616	C2orf69	0.34	7.46	0.56	1.31e-11	Osteoporosis;
TGCT	cis	rs250677	0.687	rs40149	chr5:148444275	A/T	cg18129178	chr5:148520854	ABLIM3	-0.44	-6.57	-0.51	1.27e-9	Breast cancer;
TGCT	cis	rs10875595	0.836	rs2879202	chr5:140668375	G/T	cg24830062	chr5:140700576	TAF7	-0.55	-4.6	-0.38	1.04e-5	Pulmonary function decline;
TGCT	cis	rs6912958	0.559	rs499373	chr6:88042062	A/T	cg10393598	chr6:87862264	NA	-0.31	-4.51	-0.38	1.5e-5	Monocyte percentage of white cells;
TGCT	cis	rs1023500	0.573	rs133374	chr22:42465941	G/A	cg05082376	chr22:42548792	NA	-0.22	-5.41	-0.44	3.18e-7	Schizophrenia;
TGCT	cis	rs6570726	0.537	rs1280279	chr6:145884048	G/T	cg13319975	chr6:146136371	FBXO30	-0.64	-4.91	-0.4	2.79e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg23758822	chr17:41437982	NA	0.71	6.75	0.52	5.16e-10	Menopause (age at onset);
TGCT	cis	rs7949030	0.596	rs71490394	chr11:62370155	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.64	9.48	0.65	2.35e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg06481639	chr22:41940642	POLR3H	-0.72	-6.52	-0.51	1.61e-9	Vitiligo;
TGCT	cis	rs992157	0.798	rs10206064	chr2:219157959	T/C	cg00012203	chr2:219082015	ARPC2	0.81	8.08	0.59	4.97e-13	Colorectal cancer;
TGCT	cis	rs7586879	0.639	rs2033656	chr2:25100902	C/G	cg15423357	chr2:25149977	NA	0.5	4.75	0.39	5.43e-6	Body mass index;
TGCT	cis	rs9325144	0.647	rs11169222	chr12:39105210	C/T	cg10518543	chr12:38710700	ALG10B	-0.49	-4.55	-0.38	1.25e-5	Morning vs. evening chronotype;
TGCT	cis	rs9303401	0.659	rs62083362	chr17:56846464	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	trans	rs4765905	0.500	rs3794297	chr12:2338396	C/T	cg13866577	chr1:66797481	PDE4B	-0.5	-6.85	-0.52	3.03e-10	Schizophrenia;
TGCT	cis	rs1865760	0.566	rs2794720	chr6:26087202	G/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.78	7.49	0.56	1.15e-11	Height;
TGCT	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg06238570	chr21:40685208	BRWD1	-0.83	-9.27	-0.64	7.25e-16	Cognitive function;
TGCT	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg04154034	chr17:28927549	LRRC37B2	-0.8	-4.99	-0.41	1.99e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs11105298	0.891	rs10777162	chr12:89830523	A/G	cg00757033	chr12:89920650	WDR51B	0.31	4.83	0.4	3.92e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs12908161	0.650	rs306206	chr15:85388653	A/G	cg11189052	chr15:85197271	WDR73	0.64	5.16	0.42	9.65e-7	Schizophrenia;
TGCT	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2486288	0.586	rs12909625	chr15:45572053	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.79	-7.73	-0.57	3.24e-12	Glomerular filtration rate;
TGCT	cis	rs2404602	0.647	rs11632765	chr15:76974261	A/T	cg22467129	chr15:76604101	ETFA	-0.45	-4.58	-0.38	1.11e-5	Blood metabolite levels;
TGCT	cis	rs4595586	0.525	rs7136425	chr12:39376005	C/A	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs7949030	0.695	rs11231161	chr11:62378221	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.62	9.29	0.64	6.77e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1215050	0.791	rs1530904	chr4:98805436	A/G	cg05340658	chr4:99064831	C4orf37	0.44	5.51	0.44	2.01e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg03709012	chr19:19516395	GATAD2A	0.74	6.22	0.49	7.04e-9	Tonsillectomy;
TGCT	cis	rs7582180	0.614	rs4149518	chr2:101013649	A/G	cg14675211	chr2:100938903	LONRF2	0.5	4.77	0.39	5.18e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs11677370	0.574	rs10209122	chr2:3871186	C/A	cg17052675	chr2:3827356	NA	-0.39	-5.69	-0.45	8.81e-8	Type 2 diabetes;
TGCT	cis	rs28595532	0.920	rs115240535	chr4:119745395	G/C	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs1476679	1.000	rs1476679	chr7:100004446	C/T	cg13334819	chr7:99746414	C7orf59	0.64	5.51	0.44	1.98e-7	Alzheimer's disease (late onset);
TGCT	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7917772	0.505	rs61869211	chr10:104449836	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	5.76	0.46	6.21e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs3733585	0.781	rs4292328	chr4:9970962	C/T	cg00071950	chr4:10020882	SLC2A9	-0.65	-8.23	-0.59	2.24e-13	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs877282	1.000	rs10904552	chr10:774326	A/G	cg17470449	chr10:769945	NA	0.3	4.8	0.4	4.4e-6	Uric acid levels;
TGCT	cis	rs524281	0.861	rs11227415	chr11:65885459	C/T	cg00563793	chr11:65837595	PACS1	-0.61	-5.21	-0.42	7.79e-7	Electroencephalogram traits;
TGCT	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg21724239	chr8:58056113	NA	0.47	5.14	0.42	1.05e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7824557	0.527	rs2572369	chr8:11238597	C/T	cg21775007	chr8:11205619	TDH	-0.68	-6.67	-0.51	7.76e-10	Retinal vascular caliber;
TGCT	cis	rs9467773	1.000	rs9295695	chr6:26528250	C/T	cg15659132	chr6:26577336	NA	-0.86	-12.17	-0.74	6.64e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg18252515	chr7:66147081	NA	-1.21	-7.89	-0.58	1.36e-12	Diabetic kidney disease;
TGCT	cis	rs7659604	0.967	rs28529384	chr4:122664215	T/C	cg19748678	chr4:122722346	EXOSC9	0.57	5.54	0.45	1.69e-7	Type 2 diabetes;
TGCT	cis	rs77106637	0.860	rs75896506	chr11:72429579	G/A	cg03713592	chr11:72463424	ARAP1	1.23	9.23	0.64	9.14e-16	Type 2 diabetes;
TGCT	cis	rs644799	1.000	rs473148	chr11:95628606	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	9.8	0.66	3.92e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs6426558	0.537	rs689094	chr1:227308909	G/A	cg10327440	chr1:227177885	CDC42BPA	0.58	6.91	0.53	2.21e-10	Neutrophil percentage of white cells;
TGCT	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg17554472	chr22:41940697	POLR3H	-0.49	-5.27	-0.43	5.9e-7	Vitiligo;
TGCT	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg08439880	chr3:133502540	NA	-0.31	-5.91	-0.47	3.1e-8	Iron status biomarkers;
TGCT	cis	rs7226408	0.857	rs55731927	chr18:34731431	A/G	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs360798	0.512	rs2215870	chr2:63132342	C/G	cg17519650	chr2:63277830	OTX1	0.55	4.76	0.39	5.33e-6	Coronary artery disease;
TGCT	cis	rs13326165	0.616	rs82825	chr3:52471942	G/A	cg27565382	chr3:53032988	SFMBT1	-0.37	-4.89	-0.4	3.04e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs2468186	0.583	rs1905775	chr8:120088835	A/G	cg02248809	chr8:120845432	TAF2	-0.45	-4.83	-0.4	4.01e-6	Osteoprotegerin levels;
TGCT	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg11764359	chr7:65958608	NA	0.61	5.59	0.45	1.37e-7	Aortic root size;
TGCT	cis	rs10984561	0.881	rs10984557	chr9:122249690	C/T	cg14242995	chr9:122249943	NA	0.75	6.12	0.48	1.16e-8	Pulmonary function decline;
TGCT	cis	rs7647973	0.667	rs11721148	chr3:49646669	G/A	cg05785598	chr3:49045655	WDR6	0.41	4.66	0.39	8.03e-6	Menarche (age at onset);
TGCT	cis	rs10832169	1.000	rs11023059	chr11:14064392	A/G	cg04547675	chr11:13986162	SPON1	0.51	4.51	0.38	1.49e-5	Blood protein levels;
TGCT	cis	rs7246657	0.943	rs10415024	chr19:37814724	A/G	cg18154014	chr19:37997991	ZNF793	0.98	6.49	0.5	1.87e-9	Coronary artery calcification;
TGCT	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg07636037	chr3:49044803	WDR6	0.95	10.17	0.67	4.99e-18	Parkinson's disease;
TGCT	cis	rs6988636	1.000	rs9987357	chr8:124187620	T/G	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs9916302	0.861	rs11078913	chr17:37671714	G/T	cg07936489	chr17:37558343	FBXL20	-0.61	-4.92	-0.4	2.69e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.63	-0.51	9.04e-10	Alzheimer's disease;
TGCT	trans	rs7726839	0.561	rs4957050	chr5:579066	A/C	cg11887960	chr12:57824829	NA	0.96	8.01	0.58	7.22e-13	Obesity-related traits;
TGCT	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg27454412	chr7:1067447	C7orf50	0.6	4.7	0.39	6.76e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg13695892	chr22:41940480	POLR3H	0.92	8.79	0.62	1.04e-14	Vitiligo;
TGCT	cis	rs4689592	0.546	rs907523	chr4:7052777	A/G	cg06697600	chr4:7070879	GRPEL1	-0.46	-4.66	-0.39	7.87e-6	Monocyte percentage of white cells;
TGCT	cis	rs7772486	0.875	rs7739418	chr6:146359188	G/A	cg23711669	chr6:146136114	FBXO30	0.85	9.44	0.65	2.92e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9926296	0.712	rs258319	chr16:89732024	A/T	cg04287289	chr16:89883240	FANCA	-0.54	-4.96	-0.41	2.23e-6	Vitiligo;
TGCT	cis	rs35306767	0.953	rs11253521	chr10:976416	G/C	cg20503657	chr10:835505	NA	0.59	8.4	0.6	8.84e-14	Eosinophil percentage of granulocytes;
TGCT	cis	rs8078723	1.000	rs59925331	chr17:38169273	C/G	cg17467752	chr17:38218738	THRA	0.52	4.93	0.41	2.54e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs7772486	0.790	rs9403749	chr6:146162239	A/G	cg23711669	chr6:146136114	FBXO30	0.96	11.46	0.72	3.44e-21	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg01516881	chr6:292596	DUSP22	-0.76	-7.92	-0.58	1.16e-12	Menopause (age at onset);
TGCT	cis	rs12484776	0.677	rs6001795	chr22:40530922	G/A	cg07138101	chr22:40742427	ADSL	0.61	4.6	0.38	1.01e-5	Uterine fibroids;
TGCT	cis	rs9910055	0.529	rs170637	chr17:42186868	C/T	cg13607699	chr17:42295918	UBTF	-0.64	-5.24	-0.43	6.82e-7	Total body bone mineral density;
TGCT	cis	rs59197085	0.636	rs3823480	chr7:128468881	G/A	cg00260937	chr7:128520193	KCP	0.47	4.95	0.41	2.36e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
TGCT	cis	rs1577917	0.740	rs2758842	chr6:86308731	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-4.76	-0.39	5.23e-6	Response to antipsychotic treatment;
TGCT	cis	rs9814567	1.000	rs7428326	chr3:134251184	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.95	-9.55	-0.65	1.56e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs7666738	0.830	rs17027198	chr4:98991085	G/C	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg24250549	chr1:154909240	PMVK	0.59	5.87	0.47	3.7e-8	Prostate cancer;
TGCT	cis	rs72781680	0.898	rs72796166	chr2:23939311	G/C	cg08917208	chr2:24149416	ATAD2B	0.9	5.58	0.45	1.46e-7	Lymphocyte counts;
TGCT	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.01	0.41	1.86e-6	Prudent dietary pattern;
TGCT	cis	rs1062177	1.000	rs2964576	chr5:151150602	T/G	cg00977110	chr5:151150581	G3BP1	0.4	4.57	0.38	1.16e-5	Preschool internalizing problems;
TGCT	cis	rs6495367	1.000	rs755362	chr15:79376601	C/T	cg17916960	chr15:79447300	NA	-0.35	-5.03	-0.41	1.67e-6	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs12989701	0.740	rs28434131	chr2:127850292	A/G	cg08168897	chr2:127865431	BIN1	0.57	6.04	0.48	1.69e-8	Alzheimer's disease (late onset);
TGCT	cis	rs7655841	0.773	rs6812361	chr4:129899758	G/A	cg26347359	chr4:129759716	PHF17	0.42	4.9	0.4	2.97e-6	Chronic obstructive pulmonary disease (moderate to severe);
TGCT	cis	rs931608	0.569	rs17461312	chr19:22554107	G/T	cg15554505	chr19:22123728	NA	-0.61	-4.71	-0.39	6.61e-6	Dental caries;Response to statins (LDL cholesterol change);
TGCT	cis	rs8084125	0.832	rs62105182	chr18:74951407	T/C	cg15443732	chr18:74961078	GALR1	0.48	4.7	0.39	6.76e-6	Obesity-related traits;
TGCT	cis	rs2288073	0.965	rs10173949	chr2:24410256	A/C	cg05570707	chr2:24270316	C2orf44	-0.5	-4.49	-0.37	1.58e-5	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs6460942	1.000	rs79964328	chr7:12319392	A/C	cg06484146	chr7:12443880	VWDE	-0.54	-4.55	-0.38	1.26e-5	Coronary artery disease;
TGCT	cis	rs17345786	0.520	rs12638134	chr3:101334609	G/T	cg11279151	chr3:101281821	RG9MTD1	-0.22	-4.44	-0.37	1.94e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6582630	0.519	rs7294292	chr12:38349540	C/T	cg26384229	chr12:38710491	ALG10B	0.83	7.23	0.54	4.33e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs651907	0.557	rs13066768	chr3:101486920	A/T	cg11279151	chr3:101281821	RG9MTD1	0.33	7.05	0.54	1.09e-10	Colorectal cancer;
TGCT	cis	rs2075371	0.933	rs1901214	chr7:133945108	C/T	cg11752832	chr7:134001865	SLC35B4	-0.69	-5.97	-0.47	2.32e-8	Mean platelet volume;
TGCT	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg11062466	chr8:58055876	NA	0.42	4.49	0.37	1.61e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs77372450	0.551	rs62390781	chr5:157061507	G/A	cg19063654	chr5:156516798	HAVCR2	-0.37	-4.43	-0.37	2.01e-5	Bipolar disorder (body mass index interaction);
TGCT	trans	rs1814175	0.647	rs61306292	chr11:49856040	G/C	cg03929089	chr4:120376271	NA	-0.71	-7.92	-0.58	1.16e-12	Height;
TGCT	cis	rs854765	0.647	rs2955365	chr17:18023897	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	7.57	0.56	7.33e-12	Total body bone mineral density;
TGCT	cis	rs6540559	0.673	rs58637469	chr1:209971480	T/A	cg23283495	chr1:209979779	IRF6	0.65	5.04	0.41	1.63e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs9388451	0.839	rs980014	chr6:126068001	T/G	cg10911889	chr6:126070802	HEY2	0.57	6.06	0.48	1.51e-8	Brugada syndrome;
TGCT	cis	rs8072100	0.967	rs7219303	chr17:45737701	A/G	cg08085267	chr17:45401833	C17orf57	0.42	4.6	0.38	1.04e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs1005224	0.963	rs11626062	chr14:76136329	T/C	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.61	-5.73	-0.46	7.21e-8	Large artery stroke;
TGCT	cis	rs12421382	0.543	rs11213094	chr11:109357926	G/A	cg16359550	chr11:109292809	C11orf87	0.68	7.23	0.54	4.37e-11	Schizophrenia;
TGCT	cis	rs17221829	0.673	rs11018676	chr11:89362728	T/C	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.65	-0.39	8.43e-6	Anxiety in major depressive disorder;
TGCT	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg04267008	chr7:1944627	MAD1L1	-0.38	-5.19	-0.42	8.33e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs986417	0.748	rs4901986	chr14:60969333	T/C	cg27398547	chr14:60952738	C14orf39	1.49	10.81	0.7	1.38e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs6598955	0.671	rs12068212	chr1:26612935	C/T	cg04990556	chr1:26633338	UBXN11	0.64	4.91	0.4	2.78e-6	Obesity-related traits;
TGCT	cis	rs5750830	0.594	rs5757647	chr22:39775047	C/A	cg24399712	chr22:39784796	NA	-0.95	-11.01	-0.7	4.37e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs739401	0.527	rs423236	chr11:3065916	C/T	cg25174290	chr11:3078921	CARS	0.47	4.44	0.37	1.99e-5	Longevity;
TGCT	cis	rs8179	0.514	rs11773884	chr7:92285123	A/G	cg15732164	chr7:92237376	CDK6	-0.28	-5.15	-0.42	9.96e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
TGCT	cis	rs12762955	0.561	rs7075141	chr10:1091195	C/T	cg18964960	chr10:1102726	WDR37	-0.56	-4.85	-0.4	3.65e-6	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs7818688	0.697	rs78777150	chr8:95984411	C/G	cg16049864	chr8:95962084	TP53INP1	0.54	4.64	0.38	8.87e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs11122272	0.735	rs2749704	chr1:231526243	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-6.94	-0.53	1.98e-10	Hemoglobin concentration;
TGCT	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg24578937	chr1:2090814	PRKCZ	-0.22	-5.26	-0.43	6.08e-7	Height;
TGCT	cis	rs9467711	0.606	rs12176317	chr6:26372786	A/G	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs75686122	0.892	rs17234986	chr8:104729301	C/T	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs2535633	0.631	rs2710326	chr3:52995444	T/C	cg10802521	chr3:52805072	NEK4	0.56	6.02	0.48	1.86e-8	Body mass index;
TGCT	cis	rs5750830	0.645	rs4821890	chr22:39777523	G/A	cg01416388	chr22:39784598	NA	-0.63	-6.66	-0.51	8.09e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs11971779	0.941	rs7800795	chr7:139080348	A/G	cg07862535	chr7:139043722	LUC7L2	0.79	5.8	0.46	5.13e-8	Diisocyanate-induced asthma;
TGCT	cis	rs7666738	0.753	rs13122897	chr4:98936185	C/A	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3806843	0.932	rs2563257	chr5:140140529	A/G	cg19875535	chr5:140030758	IK	-0.36	-6.17	-0.48	8.74e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs3749237	0.964	rs11717463	chr3:49808981	C/T	cg03060546	chr3:49711283	APEH	0.73	7.1	0.54	8.41e-11	Resting heart rate;
TGCT	cis	rs7698623	0.850	rs4693192	chr4:88797913	T/C	cg02735620	chr4:88950514	PKD2	-0.44	-4.81	-0.4	4.22e-6	Cardiovascular disease risk factors;
TGCT	cis	rs751728	1.000	rs943477	chr6:33750931	T/C	cg00334056	chr6:33755658	LEMD2	-0.25	-4.52	-0.38	1.44e-5	Crohn's disease;
TGCT	cis	rs7829975	0.510	rs332037	chr8:8722675	C/T	cg06636001	chr8:8085503	FLJ10661	0.68	6.26	0.49	5.89e-9	Mood instability;
TGCT	cis	rs1371867	0.810	rs2860518	chr8:101238120	G/T	cg06636551	chr8:101224915	SPAG1	0.45	6.15	0.48	9.76e-9	Atrioventricular conduction;
TGCT	cis	rs6582630	0.502	rs10880450	chr12:38440294	G/C	cg26384229	chr12:38710491	ALG10B	0.83	7.46	0.56	1.32e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs250677	0.958	rs36070	chr5:148417240	T/C	cg18129178	chr5:148520854	ABLIM3	-0.4	-5.63	-0.45	1.17e-7	Breast cancer;
TGCT	cis	rs763121	1.000	rs86796	chr22:38881454	A/C	cg06022373	chr22:39101656	GTPBP1	-0.71	-6.85	-0.52	3.03e-10	Menopause (age at onset);
TGCT	cis	rs7264396	0.635	rs6060673	chr20:34482396	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.29	5.01	0.41	1.85e-6	Total cholesterol levels;
TGCT	cis	rs7909074	0.798	rs10900126	chr10:45386322	G/T	cg04218760	chr10:45406644	TMEM72	-0.28	-5.49	-0.44	2.15e-7	Mean corpuscular volume;
TGCT	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg05896524	chr21:47604654	C21orf56	-0.43	-4.54	-0.38	1.31e-5	Testicular germ cell tumor;
TGCT	cis	rs916888	0.610	rs199452	chr17:44801340	C/T	cg01570182	chr17:44337453	NA	0.76	7.36	0.55	2.22e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs6674176	0.660	rs6680421	chr1:44408969	A/C	cg13606994	chr1:44402422	ARTN	0.49	5.38	0.44	3.57e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs1355223	0.583	rs1396880	chr11:34870552	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.76	-8.22	-0.59	2.3e-13	Systemic lupus erythematosus and Systemic sclerosis;
TGCT	cis	rs911263	0.603	rs2064911	chr14:68807298	T/C	cg18825221	chr14:68749962	RAD51L1	0.22	4.43	0.37	2.01e-5	Primary biliary cholangitis;
TGCT	cis	rs7647973	0.516	rs4955419	chr3:49200692	T/A	cg03060546	chr3:49711283	APEH	0.5	4.72	0.39	6.38e-6	Menarche (age at onset);
TGCT	cis	rs7100689	0.646	rs10400045	chr10:82077032	A/G	cg01528321	chr10:82214614	TSPAN14	0.75	7.49	0.56	1.15e-11	Post bronchodilator FEV1;
TGCT	cis	rs250677	0.522	rs10477400	chr5:148359598	T/C	cg18129178	chr5:148520854	ABLIM3	0.38	4.95	0.41	2.33e-6	Breast cancer;
TGCT	cis	rs12908161	1.000	rs12903134	chr15:85337699	T/A	cg12863693	chr15:85201151	NMB	0.42	5.06	0.41	1.5e-6	Schizophrenia;
TGCT	cis	rs11190604	0.767	rs7076606	chr10:102192267	T/C	cg23241863	chr10:102295624	HIF1AN	0.62	4.79	0.4	4.69e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	trans	rs1496653	0.602	rs35402533	chr3:23357291	T/A	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg27535305	chr1:53392650	SCP2	-0.28	-5.93	-0.47	2.85e-8	Monocyte count;
TGCT	cis	rs3824867	0.920	rs7108143	chr11:47453722	T/G	cg20307385	chr11:47447363	PSMC3	-0.68	-5.78	-0.46	5.75e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs7635838	0.617	rs184700	chr3:11293061	A/G	cg00170343	chr3:11313890	ATG7	0.66	6.53	0.51	1.52e-9	HDL cholesterol;
TGCT	cis	rs3806933	0.522	rs12521169	chr5:110448313	G/A	cg04022379	chr5:110408740	TSLP	0.63	6.52	0.51	1.6e-9	Eosinophilic esophagitis;
TGCT	cis	rs838147	0.505	rs1688264	chr19:49209560	T/G	cg00822241	chr19:49201468	FUT2	0.28	4.54	0.38	1.32e-5	Dietary macronutrient intake;
TGCT	cis	rs6088580	0.634	rs4911420	chr20:32998654	A/G	cg06115741	chr20:33292138	TP53INP2	-0.56	-5.03	-0.41	1.67e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg04944784	chr2:26401820	FAM59B	-0.67	-5.98	-0.47	2.23e-8	Gut microbiome composition (summer);
TGCT	trans	rs7698623	0.850	rs1381958	chr4:88796785	T/C	cg01186725	chr1:53905612	FLJ40434	-0.48	-6.63	-0.51	9.21e-10	Cardiovascular disease risk factors;
TGCT	cis	rs7617480	0.648	rs9284885	chr3:48883100	A/C	cg07636037	chr3:49044803	WDR6	0.77	6.4	0.5	2.91e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs6163	0.508	rs12776506	chr10:104532828	A/G	cg05855489	chr10:104503620	C10orf26	0.6	4.72	0.39	6.21e-6	Waist circumference;Hip circumference;
TGCT	trans	rs2727020	1.000	rs2727020	chr11:49111407	C/G	cg03929089	chr4:120376271	NA	0.71	7.76	0.57	2.74e-12	Coronary artery disease;
TGCT	cis	rs7259965	0.582	rs3895941	chr19:41531212	T/C	cg20630647	chr19:41531805	NA	0.39	6.2	0.49	7.68e-9	Midgestational circulating levels of PBDEs;Midgestational circulating levels of organochlorine pesticides;
TGCT	trans	rs877282	1.000	rs12773872	chr10:771939	T/C	cg22713356	chr15:30763199	NA	1.14	10.05	0.67	9.58e-18	Uric acid levels;
TGCT	cis	rs10791323	0.604	rs2723598	chr11:133711652	G/A	cg03690763	chr11:133734501	NA	-0.31	-4.79	-0.39	4.72e-6	Childhood ear infection;
TGCT	cis	rs6750047	0.573	rs162331	chr2:38319594	C/T	cg07380506	chr2:38303506	CYP1B1	0.59	5.48	0.44	2.32e-7	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs9790314	0.967	rs457272	chr3:161096746	A/G	cg03342759	chr3:160939853	NMD3	-0.44	-4.49	-0.37	1.64e-5	Morning vs. evening chronotype;
TGCT	cis	rs1371867	0.875	rs1788168	chr8:101324960	G/T	cg06636551	chr8:101224915	SPAG1	-0.42	-5.65	-0.45	1.06e-7	Atrioventricular conduction;
TGCT	cis	rs7267979	0.738	rs2892409	chr20:25638138	C/T	cg03522245	chr20:25566470	NINL	0.53	5.43	0.44	2.81e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9650657	0.537	rs11250092	chr8:10786543	A/G	cg27411982	chr8:10470053	RP1L1	0.24	5.2	0.42	8.04e-7	Neuroticism;
TGCT	cis	rs1045714	0.895	rs73035504	chr7:2642878	G/A	cg17215154	chr7:2644645	IQCE	0.28	4.92	0.4	2.75e-6	Urate levels in lean individuals;
TGCT	cis	rs56104184	0.887	rs4801778	chr19:49370609	G/T	cg17863274	chr19:49399704	TULP2	-0.36	-5.18	-0.42	8.68e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs4886920	0.563	rs8040813	chr15:78073289	A/G	cg25212270	chr15:78015279	NA	0.23	4.81	0.4	4.26e-6	Neuroticism;
TGCT	cis	rs617791	0.530	rs10896073	chr11:65762814	T/C	cg09783858	chr11:65769428	EIF1AD;BANF1	0.5	4.56	0.38	1.2e-5	Breast cancer;
TGCT	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg11062466	chr8:58055876	NA	0.46	4.89	0.4	3.07e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9486719	0.948	rs2499817	chr6:96878321	C/T	cg06623918	chr6:96969491	KIAA0776	1.01	8.86	0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.61	0.38	9.85e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs11648796	0.757	rs3809665	chr16:764520	G/C	cg00908189	chr16:619842	PIGQ	0.7	5.7	0.46	8.1e-8	Height;
TGCT	cis	rs10501293	0.675	rs10768912	chr11:43034756	C/T	cg03447554	chr11:43094025	NA	0.44	6.29	0.49	5.05e-9	Cognitive performance;
TGCT	cis	rs2235642	0.893	rs2076440	chr16:1587322	G/A	cg11375102	chr16:1583810	IFT140;TMEM204	-0.31	-5.51	-0.44	2e-7	Coronary artery disease;
TGCT	cis	rs589249	0.889	rs1002655	chr1:37192677	C/G	cg04012535	chr1:37176647	NA	0.32	4.92	0.4	2.74e-6	Neuroticism (multi-trait analysis);Schizophrenia;
TGCT	cis	rs1371867	0.846	rs1660312	chr8:101330634	C/G	cg06002616	chr8:101225028	SPAG1	-0.57	-6.63	-0.51	9.18e-10	Atrioventricular conduction;
TGCT	cis	rs7635838	0.617	rs347587	chr3:11287155	A/G	cg00170343	chr3:11313890	ATG7	-0.65	-6.54	-0.51	1.47e-9	HDL cholesterol;
TGCT	cis	rs36051895	0.659	rs10974944	chr9:5070831	C/G	cg02405213	chr9:5042618	JAK2	-0.74	-8.69	-0.62	1.76e-14	Pediatric autoimmune diseases;
TGCT	cis	rs3806843	0.576	rs246046	chr5:140329264	T/A	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs78461346	1.000	rs78461346	chr17:80524184	G/A	cg15014069	chr17:80540666	FOXK2	0.4	5.04	0.41	1.62e-6	3-hydroxypropylmercapturic acid levels in smokers;
TGCT	trans	rs1415174	0.877	rs2065908	chr1:87847053	T/C	cg23065576	chr20:25207247	ENTPD6	-0.27	-6.8	-0.52	3.88e-10	Breast cancer;
TGCT	cis	rs9560113	0.960	rs1163862	chr13:112174319	C/T	cg14154082	chr13:112174009	NA	0.35	4.93	0.4	2.59e-6	Menarche (age at onset);
TGCT	cis	rs9300255	0.544	rs1790130	chr12:123701270	A/C	cg00376283	chr12:123451042	ABCB9	0.73	5.67	0.45	9.46e-8	Neutrophil percentage of white cells;
TGCT	cis	rs9921338	0.961	rs4390613	chr16:11422836	T/C	cg00044050	chr16:11439710	C16orf75	0.89	6.53	0.51	1.56e-9	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs7666738	0.715	rs61114099	chr4:98931270	C/T	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.85	-10.01	-0.67	1.2e-17	Urate levels;
TGCT	cis	rs2439831	0.850	rs28590651	chr15:44113016	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	6.27	0.49	5.48e-9	Lung cancer in ever smokers;
TGCT	cis	rs4689388	0.926	rs10010131	chr4:6292915	A/G	cg25554036	chr4:6271136	WFS1	0.54	7.37	0.55	2.11e-11	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs7727544	1.000	rs7727038	chr5:131590257	C/T	cg24060327	chr5:131705240	SLC22A5	-0.62	-6.48	-0.5	1.97e-9	Blood metabolite levels;
TGCT	trans	rs7726839	0.507	rs56282020	chr5:596701	T/C	cg11887960	chr12:57824829	NA	1.21	9.64	0.65	9.42e-17	Obesity-related traits;
TGCT	cis	rs523522	0.962	rs3759394	chr12:120933173	C/A	cg12219531	chr12:120966889	COQ5	0.83	7.27	0.55	3.46e-11	High light scatter reticulocyte count;
TGCT	cis	rs6840360	0.642	rs7657670	chr4:152353375	A/G	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.83e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs1334894	0.901	rs1977655	chr6:35521702	G/A	cg24281267	chr6:35479648	TULP1	-0.44	-4.54	-0.38	1.29e-5	Coronary artery disease;
TGCT	cis	rs2456568	0.571	rs12807496	chr11:93693064	A/G	cg17595323	chr11:93583763	C11orf90	0.38	4.62	0.38	9.46e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs3096299	0.900	rs4785666	chr16:89462771	C/G	cg06640241	chr16:89574553	SPG7	0.61	5.76	0.46	6.36e-8	Multiple myeloma (IgH translocation);
TGCT	cis	rs4819852	0.958	rs1034564	chr22:19984013	A/G	cg07821417	chr22:19972146	ARVCF	-0.19	-4.73	-0.39	5.97e-6	Pulse pressure;
TGCT	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg03303774	chr4:1407052	NA	0.3	4.74	0.39	5.79e-6	Obesity-related traits;
TGCT	cis	rs854765	0.822	rs1889014	chr17:17767165	C/T	cg09796270	chr17:17721594	SREBF1	-0.27	-5.41	-0.44	3.16e-7	Total body bone mineral density;
TGCT	cis	rs10489525	0.528	rs360604	chr1:115390019	G/A	cg12756093	chr1:115239321	AMPD1	0.36	4.44	0.37	1.94e-5	Autism;
TGCT	cis	rs9581857	0.685	rs9319372	chr13:28042796	C/T	cg22138327	chr13:27999177	GTF3A	-0.73	-4.98	-0.41	2.07e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs7605378	0.567	rs717915	chr2:200714766	C/T	cg17644776	chr2:200775616	C2orf69	0.34	7.39	0.55	1.88e-11	Osteoporosis;
TGCT	cis	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg07424592	chr7:64974309	NA	1.4	8.42	0.6	7.87e-14	Diabetic kidney disease;
TGCT	cis	rs6570726	0.791	rs6914203	chr6:145899975	C/A	cg23711669	chr6:146136114	FBXO30	0.85	9.24	0.64	8.9e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4919694	0.901	rs12251035	chr10:104671459	A/C	cg04362960	chr10:104952993	NT5C2	1.06	7.07	0.54	9.73e-11	Arsenic metabolism;
TGCT	cis	rs3771570	0.901	rs4675964	chr2:242324760	A/C	cg21155796	chr2:242212141	HDLBP	0.84	6.32	0.49	4.39e-9	Prostate cancer;
TGCT	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg07507251	chr3:52567010	NT5DC2	0.47	6.7	0.52	6.47e-10	Bipolar disorder;
TGCT	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.54	4.96	0.41	2.29e-6	Prudent dietary pattern;
TGCT	cis	rs9916302	0.605	rs12938099	chr17:37612910	T/G	cg07936489	chr17:37558343	FBXL20	-0.87	-6.27	-0.49	5.47e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs6032067	0.516	rs1883829	chr20:43891253	G/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.36	-5.61	-0.45	1.27e-7	Blood protein levels;
TGCT	cis	rs7666738	0.716	rs114187620	chr4:98819534	T/A	cg05340658	chr4:99064831	C4orf37	0.51	6.03	0.48	1.76e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs981844	0.683	rs4696191	chr4:154740668	G/A	cg14289246	chr4:154710475	SFRP2	-1.0	-9.26	-0.64	7.7e-16	Response to statins (LDL cholesterol change);
TGCT	cis	rs13191362	1.000	rs13193282	chr6:163015442	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs1008375	0.800	rs28754811	chr4:17612312	C/T	cg16339924	chr4:17578868	LAP3	0.68	5.56	0.45	1.56e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg03517284	chr6:25882590	NA	-0.69	-6.22	-0.49	7.11e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs2760061	0.626	rs596675	chr1:228117892	G/A	cg02753203	chr1:228287806	NA	-0.34	-6.64	-0.51	8.69e-10	Diastolic blood pressure;
TGCT	cis	rs477895	0.838	rs12798333	chr11:64012784	G/A	cg23719950	chr11:63933701	MACROD1	-0.69	-5.74	-0.46	6.94e-8	Mean platelet volume;
TGCT	cis	rs2439831	1.000	rs471229	chr15:43733994	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.01	8.37	0.6	1.02e-13	Lung cancer in ever smokers;
TGCT	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs3087591	0.639	rs757379	chr17:29724557	G/A	cg24425628	chr17:29625626	OMG;NF1	0.39	5.83	0.46	4.57e-8	Hip circumference;
TGCT	cis	rs9858542	0.953	rs9818590	chr3:49525096	A/G	cg03060546	chr3:49711283	APEH	-0.61	-5.37	-0.43	3.78e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs896854	0.738	rs481887	chr8:95967838	A/G	cg23172400	chr8:95962367	TP53INP1	0.37	5.65	0.45	1.02e-7	Type 2 diabetes;
TGCT	cis	rs651907	0.514	rs12636047	chr3:101434449	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.34	-7.02	-0.53	1.27e-10	Colorectal cancer;
TGCT	cis	rs72949976	0.584	rs12471432	chr2:214022893	A/T	cg08319019	chr2:214017104	IKZF2	0.84	8.41	0.6	8.42e-14	Lung cancer;Squamous cell lung carcinoma;
TGCT	cis	rs7172809	0.643	rs4243046	chr15:77834746	T/C	cg22256960	chr15:77711686	NA	-0.46	-4.62	-0.38	9.65e-6	Glucose homeostasis traits;
TGCT	cis	rs7772486	0.875	rs10872583	chr6:146396699	G/T	cg23711669	chr6:146136114	FBXO30	-0.89	-9.67	-0.66	7.76e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg03407747	chr17:6899364	ALOX12	0.51	5.78	0.46	5.67e-8	Tonsillectomy;
TGCT	cis	rs11874712	1.000	rs13381709	chr18:43670988	C/T	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	5.23	0.42	7.11e-7	Migraine - clinic-based;
TGCT	cis	rs10484885	0.878	rs72921937	chr6:90579863	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.47	-4.58	-0.38	1.11e-5	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs12510870	0.599	rs16849629	chr4:74448351	G/A	cg05868023	chr4:75230803	EREG	-0.54	-4.76	-0.39	5.33e-6	Iris color (b* coordinate);
TGCT	cis	rs72781680	0.752	rs56152044	chr2:23927680	A/G	cg08917208	chr2:24149416	ATAD2B	1.0	5.79	0.46	5.41e-8	Lymphocyte counts;
TGCT	cis	rs11105298	0.786	rs10858897	chr12:89922032	C/A	cg00757033	chr12:89920650	WDR51B	0.32	5.13	0.42	1.11e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg15556689	chr8:8085844	FLJ10661	0.88	9.13	0.63	1.6e-15	Neuroticism;
TGCT	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg24675658	chr1:53192096	ZYG11B	0.89	11.49	0.72	2.91e-21	Monocyte count;
TGCT	cis	rs36051895	0.659	rs62541540	chr9:5040080	A/G	cg02405213	chr9:5042618	JAK2	-0.78	-10.74	-0.69	2.01e-19	Pediatric autoimmune diseases;
TGCT	cis	rs3540	0.512	rs17263706	chr15:91078803	G/T	cg22089800	chr15:90895588	ZNF774	0.71	7.3	0.55	3.05e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs12477438	0.765	rs1054042	chr2:99614396	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-5.43	-0.44	2.89e-7	Chronic sinus infection;
TGCT	cis	rs7246657	0.663	rs4803287	chr19:38079435	A/G	cg03611452	chr19:38183253	ZNF781	0.58	4.64	0.38	8.62e-6	Coronary artery calcification;
TGCT	trans	rs17685	0.712	rs59659102	chr7:75710114	G/A	cg19862616	chr7:65841803	NCRNA00174	0.52	9.01	0.63	3.02e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.57	-5.01	-0.41	1.84e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6992820	0.900	rs12678930	chr8:56726277	A/G	cg06880721	chr8:56792545	LYN	-0.55	-4.68	-0.39	7.33e-6	Mean platelet volume;
TGCT	cis	rs68170813	0.641	rs34084719	chr7:107095227	A/G	cg02696742	chr7:106810147	HBP1	-0.61	-4.98	-0.41	2.07e-6	Coronary artery disease;
TGCT	cis	rs11098499	0.615	rs28551750	chr4:120264901	C/T	cg09307838	chr4:120376055	NA	0.55	5.41	0.44	3.16e-7	Corneal astigmatism;
TGCT	cis	rs36051895	0.623	rs10120337	chr9:5243511	G/A	cg02405213	chr9:5042618	JAK2	-0.73	-9.59	-0.65	1.27e-16	Pediatric autoimmune diseases;
TGCT	cis	rs739496	0.542	rs7399113	chr12:111792848	G/A	cg10833066	chr12:111807467	FAM109A	0.44	7.52	0.56	9.58e-12	Platelet count;
TGCT	cis	rs739496	0.579	rs57427612	chr12:112293996	C/G	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs7439150	0.909	rs2227389	chr4:155483170	C/T	cg22130008	chr4:155548532	NA	-0.47	-5.8	-0.46	5.25e-8	Fibrinogen levels;
TGCT	cis	rs2115630	0.902	rs8023276	chr15:85219638	C/T	cg12863693	chr15:85201151	NMB	-0.34	-4.73	-0.39	5.96e-6	P wave terminal force;
TGCT	cis	rs7312933	0.703	rs10492388	chr12:42608001	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.53	4.62	0.38	9.51e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs1215050	0.791	rs968854	chr4:98837863	T/C	cg05340658	chr4:99064831	C4orf37	0.47	5.9	0.47	3.22e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	5.12	0.42	1.11e-6	Alzheimer's disease;
TGCT	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg25036284	chr2:26402008	FAM59B	-0.54	-4.7	-0.39	6.93e-6	Gut microbiome composition (summer);
TGCT	cis	rs28595532	0.920	rs116145969	chr4:119770908	T/C	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs1218582	0.741	rs705094	chr1:154917314	G/A	cg06221963	chr1:154839813	KCNN3	-0.72	-12.31	-0.74	3.04e-23	Prostate cancer;
TGCT	cis	rs78456975	0.600	rs72776256	chr2:1529595	C/A	cg01028140	chr2:1542097	TPO	-0.36	-4.63	-0.38	9.02e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs7772486	0.641	rs67882056	chr6:146416301	T/C	cg13319975	chr6:146136371	FBXO30	-0.65	-5.95	-0.47	2.5e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9640161	0.750	rs4395803	chr7:150025367	A/C	cg10018233	chr7:150070692	REPIN1	0.33	4.78	0.39	4.94e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs7577262	0.834	rs13028228	chr2:234843309	C/T	cg04621728	chr2:234934131	NA	0.48	4.47	0.37	1.77e-5	Blood pressure measurement (cold pressor test);
TGCT	cis	rs3809566	0.963	rs3809565	chr15:63333619	A/G	cg05507819	chr15:63340323	TPM1	0.49	4.59	0.38	1.09e-5	Platelet count;
TGCT	cis	rs4604732	1.000	rs4604732	chr1:247623872	C/T	cg22475246	chr1:246888027	SCCPDH	-0.59	-4.46	-0.37	1.83e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
TGCT	cis	rs1395	0.961	rs4665963	chr2:27528692	T/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.47	6.18	0.48	8.68e-9	Blood metabolite levels;
TGCT	cis	rs7089973	0.604	rs11196943	chr10:116598865	T/C	cg03647239	chr10:116582469	FAM160B1	0.59	5.74	0.46	6.72e-8	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	trans	rs208520	0.690	rs207082	chr6:66773796	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-11.08	-0.71	3e-20	Exhaled nitric oxide output;
TGCT	cis	rs8031584	0.678	rs798127	chr15:31117403	T/C	cg08109568	chr15:31115862	NA	0.4	5.22	0.42	7.31e-7	Huntington's disease progression;
TGCT	cis	rs709400	0.520	rs28583452	chr14:103938664	C/A	cg26031613	chr14:104095156	KLC1	0.85	9.72	0.66	5.87e-17	Body mass index;
TGCT	cis	rs7937682	0.889	rs564086	chr11:111501079	C/G	cg09085632	chr11:111637200	PPP2R1B	-1.11	-11.65	-0.72	1.21e-21	Primary sclerosing cholangitis;
TGCT	cis	rs28493229	0.708	rs78900506	chr19:41160096	T/C	cg11601297	chr19:41224147	ITPKC;ADCK4	0.57	5.15	0.42	9.78e-7	Kawasaki disease;
TGCT	cis	rs6088590	0.687	rs6088582	chr20:33286798	G/A	cg08999081	chr20:33150536	PIGU	0.27	5.01	0.41	1.81e-6	Coronary artery disease;
TGCT	cis	rs9435341	0.965	rs1335055	chr1:107624563	A/G	cg09367891	chr1:107599246	PRMT6	0.6	5.28	0.43	5.68e-7	Facial morphology (factor 21, depth of nasal alae);
TGCT	cis	rs6912958	0.559	rs242287	chr6:88071825	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.42	5.32	0.43	4.64e-7	Monocyte percentage of white cells;
TGCT	cis	rs231513	0.954	rs231501	chr17:41972303	C/T	cg26893861	chr17:41843967	DUSP3	-0.71	-5.33	-0.43	4.45e-7	Cognitive function;
TGCT	cis	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg20637647	chr7:64974828	NA	-0.9	-5.31	-0.43	4.87e-7	Diabetic kidney disease;
TGCT	cis	rs2795502	0.873	rs1815716	chr10:43410200	G/A	cg20628663	chr10:43360327	NA	0.36	5.47	0.44	2.42e-7	Blood protein levels;
TGCT	cis	rs514406	0.893	rs1242315	chr1:53417181	A/G	cg27535305	chr1:53392650	SCP2	-0.23	-4.52	-0.38	1.4e-5	Monocyte count;
TGCT	cis	rs17764205	0.777	rs112570652	chr19:3255789	G/A	cg18738857	chr19:3606974	TBXA2R	-0.75	-4.65	-0.39	8.31e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg12419862	chr22:24373484	LOC391322	-0.83	-9.36	-0.64	4.58e-16	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg13683864	chr3:40499215	RPL14	1.17	13.19	0.76	2.34e-25	Renal cell carcinoma;
TGCT	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6690583	0.623	rs1371143	chr1:85455532	C/T	cg20280350	chr1:85513789	MCOLN3	-0.74	-5.11	-0.42	1.2e-6	Serum sulfate level;
TGCT	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg18305652	chr10:134549665	INPP5A	0.34	5.75	0.46	6.43e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs12220898	0.619	rs7911371	chr10:50485396	T/C	cg06072769	chr10:50146962	WDFY4	0.38	5.07	0.41	1.38e-6	Inflammatory biomarkers;
TGCT	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg22920501	chr2:26401640	FAM59B	-0.74	-6.4	-0.5	2.86e-9	Gut microbiome composition (summer);
TGCT	cis	rs4372836	0.543	rs11686412	chr2:28992405	A/G	cg09522027	chr2:28974177	PPP1CB	-0.73	-7.07	-0.54	9.78e-11	Body mass index;
TGCT	cis	rs6969780	0.545	rs983184	chr7:27188379	C/T	cg17457637	chr7:27170717	HOXA4	-0.46	-5.11	-0.42	1.19e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs2404602	0.532	rs744336	chr15:76674624	T/C	cg22467129	chr15:76604101	ETFA	-0.43	-4.71	-0.39	6.57e-6	Blood metabolite levels;
TGCT	cis	rs644799	0.625	rs1255175	chr11:95471186	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.48	4.78	0.39	4.88e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs1215050	0.791	rs2123100	chr4:98803747	T/C	cg17366294	chr4:99064904	C4orf37	0.52	5.59	0.45	1.4e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg00024416	chr22:24240387	NA	-0.25	-4.9	-0.4	2.87e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6450176	1.000	rs4311394	chr5:53300662	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.53	-5.1	-0.42	1.23e-6	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs853679	0.607	rs200489	chr6:27798257	T/C	cg08798685	chr6:27730294	NA	-0.36	-5.0	-0.41	1.91e-6	Depression;
TGCT	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg13665807	chr20:60559372	TAF4	-0.46	-4.97	-0.41	2.2e-6	Body mass index;
TGCT	cis	rs2180341	0.814	rs9401958	chr6:127736357	T/G	cg27446573	chr6:127587934	RNF146	0.88	8.07	0.59	5.22e-13	Breast cancer;
TGCT	cis	rs6752107	0.967	rs3816234	chr2:234185999	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.2	4.73	0.39	6.08e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs951366	0.677	rs1775140	chr1:205672107	C/A	cg11965913	chr1:205819406	PM20D1	0.5	6.62	0.51	9.51e-10	Menarche (age at onset);
TGCT	cis	rs34014631	1.000	rs79839205	chr10:103628939	T/C	cg22630918	chr10:102748988	C10orf2	0.46	5.12	0.42	1.13e-6	Coronary artery calcification;
TGCT	cis	rs4820539	1.000	rs5759596	chr22:23475750	G/A	cg21100191	chr22:23484243	RTDR1	0.89	10.78	0.7	1.61e-19	Bone mineral density;
TGCT	cis	rs11098499	0.954	rs3733520	chr4:120423480	C/G	cg09307838	chr4:120376055	NA	0.7	6.81	0.52	3.69e-10	Corneal astigmatism;
TGCT	cis	rs7809950	0.768	rs2701678	chr7:107283711	A/G	cg23024343	chr7:107201750	COG5	0.44	6.2	0.49	7.8e-9	Coronary artery disease;
TGCT	cis	rs2637266	0.653	rs846614	chr10:78549265	A/C	cg18941641	chr10:78392320	NA	0.39	4.62	0.38	9.6e-6	Pulmonary function;
TGCT	cis	rs7104764	1.000	rs7104764	chr11:229977	G/A	cg18336825	chr11:236787	PSMD13;SIRT3	1.05	10.79	0.7	1.48e-19	Menarche (age at onset);
TGCT	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-6.74	-0.52	5.26e-10	Alzheimer's disease;
TGCT	cis	rs9534288	0.830	rs1409435	chr13:46631660	G/A	cg15192986	chr13:46630673	CPB2	-0.5	-6.23	-0.49	6.66e-9	Blood protein levels;
TGCT	cis	rs8050907	0.744	rs10438587	chr16:4522160	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.53	4.57	0.38	1.15e-5	Obesity-related traits;
TGCT	cis	rs1395	0.778	rs62128747	chr2:27412605	T/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.64	8.74	0.62	1.37e-14	Blood metabolite levels;
TGCT	cis	rs12765878	0.967	rs10883940	chr10:105650598	G/A	cg11005552	chr10:105648138	OBFC1	0.44	7.7	0.57	3.69e-12	Coronary artery disease;
TGCT	cis	rs12478296	1.000	rs7603984	chr2:243047294	A/G	cg06360820	chr2:242988706	NA	-0.81	-5.3	-0.43	5.1e-7	Obesity-related traits;
TGCT	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg23758822	chr17:41437982	NA	0.72	6.91	0.53	2.23e-10	Menopause (age at onset);
TGCT	cis	rs10782582	0.586	rs5745383	chr1:76288590	G/C	cg03433033	chr1:76189801	ACADM	-0.5	-4.98	-0.41	2.11e-6	Daytime sleep phenotypes;
TGCT	cis	rs9926296	0.535	rs36022917	chr16:89893238	A/G	cg08627397	chr16:89984028	MC1R	-0.3	-4.78	-0.39	4.93e-6	Vitiligo;
TGCT	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg21226059	chr5:178986404	RUFY1	0.63	7.66	0.57	4.7e-12	Lung cancer;
TGCT	cis	rs28595532	1.000	rs11098451	chr4:119717673	C/T	cg21605333	chr4:119757512	SEC24D	1.18	7.55	0.56	8.01e-12	Cannabis dependence symptom count;
TGCT	cis	rs6964587	1.000	rs61244255	chr7:91751662	C/T	cg17063962	chr7:91808500	NA	0.89	9.51	0.65	1.95e-16	Breast cancer;
TGCT	cis	rs1371867	0.846	rs1660353	chr8:101250907	C/T	cg00191853	chr8:101177733	SPAG1	0.23	4.86	0.4	3.42e-6	Atrioventricular conduction;
TGCT	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg20887711	chr4:1340912	KIAA1530	-0.58	-4.97	-0.41	2.17e-6	Obesity-related traits;
TGCT	cis	rs2153535	0.580	rs915350	chr6:8443486	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.63	0.45	1.15e-7	Motion sickness;
TGCT	cis	rs8179	0.645	rs66939011	chr7:92265798	T/C	cg15732164	chr7:92237376	CDK6	-0.27	-4.66	-0.39	8.16e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
TGCT	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg24846343	chr22:24311635	DDTL	0.23	5.85	0.46	4.19e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2762353	0.935	rs3757131	chr6:25783909	C/T	cg03264133	chr6:25882463	NA	0.49	5.23	0.43	7e-7	Blood metabolite levels;
TGCT	cis	rs12497850	0.931	rs9876848	chr3:48844059	G/A	cg07636037	chr3:49044803	WDR6	0.94	10.39	0.68	1.46e-18	Parkinson's disease;
TGCT	cis	rs4595586	0.545	rs4438082	chr12:39363870	C/T	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs12451471	0.559	rs34746710	chr17:78079224	G/A	cg06718696	chr17:78121285	EIF4A3	0.71	5.89	0.47	3.42e-8	Plateletcrit;Mean corpuscular hemoglobin concentration;
TGCT	trans	rs208520	0.526	rs7775830	chr6:66755249	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.06	14.9	0.8	2.08e-29	Exhaled nitric oxide output;
TGCT	cis	rs7552404	0.883	rs2185436	chr1:76203783	A/G	cg22875332	chr1:76189707	ACADM	0.77	9.49	0.65	2.13e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg00814883	chr7:100076585	TSC22D4	-0.85	-8.62	-0.61	2.62e-14	Platelet count;
TGCT	cis	rs9517302	0.512	rs9517305	chr13:99097910	G/C	cg22223119	chr13:99095684	FARP1	-0.53	-5.77	-0.46	6e-8	Obesity-related traits;
TGCT	cis	rs9467773	0.967	rs7753565	chr6:26560012	A/G	cg09904177	chr6:26538194	HMGN4	0.66	6.6	0.51	1.05e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs3008870	0.701	rs2815367	chr1:67500762	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.78	8.2	0.59	2.61e-13	Lymphocyte percentage of white cells;
TGCT	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg22166914	chr1:53195759	ZYG11B	-0.39	-6.57	-0.51	1.22e-9	Monocyte count;
TGCT	cis	rs853679	0.527	rs707907	chr6:28291240	A/G	cg18815343	chr6:28367644	ZSCAN12	-0.46	-4.79	-0.4	4.62e-6	Depression;
TGCT	cis	rs10791097	0.694	rs2236711	chr11:130739284	G/A	cg05962950	chr11:130786565	SNX19	0.92	11.55	0.72	2.13e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs17718580	0.536	rs2047150	chr14:51086387	A/G	cg04730355	chr14:51134070	SAV1	1.21	9.01	0.63	3.15e-15	Cognitive performance;
TGCT	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg03806693	chr22:41940476	POLR3H	-1.13	-13.26	-0.77	1.59e-25	Vitiligo;
TGCT	cis	rs2836974	0.653	rs8130556	chr21:40516872	C/T	cg11644478	chr21:40555479	PSMG1	1.04	10.91	0.7	7.9e-20	Cognitive function;
TGCT	cis	rs7666738	0.830	rs6532721	chr4:99048015	G/A	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg20637647	chr7:64974828	NA	0.89	4.95	0.41	2.37e-6	Diabetic kidney disease;
TGCT	cis	rs7772486	0.727	rs4896843	chr6:146063451	T/C	cg23711669	chr6:146136114	FBXO30	-0.97	-11.02	-0.7	4.06e-20	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9372498	0.536	rs9489433	chr6:118867006	G/A	cg21191810	chr6:118973309	C6orf204	-0.37	-4.79	-0.39	4.73e-6	Diastolic blood pressure;
TGCT	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	5.99	0.47	2.06e-8	Bipolar disorder;
TGCT	cis	rs4654899	0.802	rs76122612	chr1:21243059	C/T	cg01072550	chr1:21505969	NA	-0.46	-6.94	-0.53	1.96e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs4988958	0.565	rs10206291	chr2:103038863	T/C	cg03938978	chr2:103052716	IL18RAP	0.27	5.4	0.44	3.31e-7	Asthma (childhood onset);
TGCT	trans	rs1814175	0.791	rs1722011	chr11:49899340	G/C	cg03929089	chr4:120376271	NA	-0.71	-8.06	-0.59	5.34e-13	Height;
TGCT	cis	rs9527	0.590	rs2281877	chr10:104866062	C/T	cg15744005	chr10:104629667	AS3MT	-0.43	-4.9	-0.4	2.89e-6	Arsenic metabolism;
TGCT	cis	rs6450176	1.000	rs3776715	chr5:53299095	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.53	-5.1	-0.42	1.23e-6	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs35306767	0.903	rs12244253	chr10:889320	G/T	cg26597838	chr10:835615	NA	0.71	10.12	0.67	6.47e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs3947	0.865	rs1296028	chr8:11698747	A/G	cg02840367	chr8:11660030	FDFT1	0.87	6.34	0.49	3.96e-9	Blood protein levels;
TGCT	cis	rs6964587	1.000	rs12539231	chr7:91634963	G/A	cg17063962	chr7:91808500	NA	0.91	9.99	0.67	1.32e-17	Breast cancer;
TGCT	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.34	0.43	4.23e-7	Prudent dietary pattern;
TGCT	trans	rs1814175	0.745	rs7483456	chr11:49774613	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.38	-7.76	-0.57	2.75e-12	Height;
TGCT	cis	rs6591341	0.515	rs599301	chr11:68189945	G/C	cg16797656	chr11:68205561	LRP5	0.29	5.12	0.42	1.16e-6	Lean body mass;
TGCT	cis	rs13191362	1.000	rs68144677	chr6:163149024	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.17	9.35	0.64	4.74e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs3020333	0.875	rs2941740	chr6:152009638	A/G	cg22157087	chr6:152012887	ESR1	0.2	4.95	0.41	2.41e-6	Total body bone mineral density;
TGCT	cis	rs67311347	0.544	rs7644181	chr3:40355665	A/G	cg13683864	chr3:40499215	RPL14	0.81	7.55	0.56	8.09e-12	Renal cell carcinoma;
TGCT	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	0.55	5.19	0.42	8.2e-7	Bipolar disorder;
TGCT	cis	rs2997447	0.761	rs61776616	chr1:26455812	C/T	cg03844060	chr1:26490628	NA	0.27	4.44	0.37	2e-5	QRS complex (12-leadsum);
TGCT	cis	rs523522	0.962	rs4766968	chr12:120947788	G/C	cg27279351	chr12:120934652	DYNLL1	0.76	6.59	0.51	1.15e-9	High light scatter reticulocyte count;
TGCT	cis	rs1008375	1.000	rs3846357	chr4:17635887	A/T	cg16339924	chr4:17578868	LAP3	0.66	5.49	0.44	2.22e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	trans	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg27523141	chr10:43048294	ZNF37B	0.74	8.66	0.61	2.13e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg12310025	chr6:25882481	NA	0.79	8.09	0.59	4.59e-13	Blood metabolite levels;
TGCT	cis	rs903263	0.601	rs12746741	chr1:84539576	C/T	cg09664975	chr1:84543551	PRKACB	-0.51	-5.2	-0.42	7.96e-7	Breast cancer (male);
TGCT	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	5.8	0.46	5.19e-8	Alzheimer's disease;
TGCT	cis	rs9467711	0.516	rs523383	chr6:25869848	A/G	cg12310025	chr6:25882481	NA	-0.75	-5.07	-0.41	1.41e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4654899	0.965	rs10753513	chr1:21492168	T/C	cg01072550	chr1:21505969	NA	0.51	8.23	0.59	2.18e-13	Superior frontal gyrus grey matter volume;
TGCT	cis	rs2580764	0.540	rs10210840	chr2:55226009	G/A	cg09592903	chr2:55203963	RTN4	-0.26	-5.67	-0.45	9.51e-8	Mean platelet volume;
TGCT	cis	rs72949976	0.646	rs1441169	chr2:214033530	A/G	cg08319019	chr2:214017104	IKZF2	0.87	8.54	0.61	4.02e-14	Lung cancer;Squamous cell lung carcinoma;
TGCT	cis	rs11190604	1.000	rs2495754	chr10:102324812	C/T	cg23241863	chr10:102295624	HIF1AN	0.68	5.17	0.42	9.18e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs12477438	0.748	rs4851185	chr2:99666497	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-4.62	-0.38	9.47e-6	Chronic sinus infection;
TGCT	cis	rs826838	0.838	rs11183646	chr12:38799846	A/T	cg13010199	chr12:38710504	ALG10B	0.82	6.85	0.52	3e-10	Heart rate;
TGCT	cis	rs1153858	1.000	rs4774577	chr15:45644685	A/C	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.62e-8	Homoarginine levels;
TGCT	cis	rs896854	0.654	rs896846	chr8:95972453	G/A	cg16049864	chr8:95962084	TP53INP1	-0.75	-10.47	-0.69	9.05e-19	Type 2 diabetes;
TGCT	cis	rs9467773	1.000	rs9467782	chr6:26542773	G/A	cg26531700	chr6:26746687	NA	0.47	4.57	0.38	1.14e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs1801251	1.000	rs10933412	chr2:233707226	G/C	cg08000102	chr2:233561755	GIGYF2	-0.63	-6.46	-0.5	2.2e-9	Coronary artery disease;
TGCT	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg22166914	chr1:53195759	ZYG11B	-0.42	-7.46	-0.56	1.33e-11	Monocyte count;
TGCT	cis	rs1887596	0.705	rs653920	chr13:27228192	C/T	cg01312412	chr13:27282625	NA	0.28	5.12	0.42	1.15e-6	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs7647973	0.626	rs1352889	chr3:49652148	T/C	cg03034192	chr3:50606346	HEMK1;C3orf18	0.36	4.75	0.39	5.61e-6	Menarche (age at onset);
TGCT	cis	rs2486288	0.656	rs12911186	chr15:45551423	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.72	-7.46	-0.56	1.34e-11	Glomerular filtration rate;
TGCT	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.54	4.47	0.37	1.77e-5	Tonsillectomy;
TGCT	cis	rs4780401	0.609	rs11639945	chr16:11824056	T/G	cg01061890	chr16:11836724	TXNDC11	-0.57	-5.42	-0.44	3.05e-7	Rheumatoid arthritis;
TGCT	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg16423285	chr20:60520624	NA	-0.61	-6.51	-0.5	1.7e-9	Body mass index;
TGCT	cis	rs3806843	0.576	rs246036	chr5:140331886	T/G	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg11644478	chr21:40555479	PSMG1	1.0	10.32	0.68	2.15e-18	Cognitive function;
TGCT	cis	rs4906332	1.000	rs35366629	chr14:103903054	A/G	cg26031613	chr14:104095156	KLC1	-0.53	-4.72	-0.39	6.2e-6	Coronary artery disease;
TGCT	cis	rs12477438	0.765	rs6542846	chr2:99563654	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.55	-4.66	-0.39	8.14e-6	Chronic sinus infection;
TGCT	cis	rs2692947	0.727	rs749459	chr2:96795714	G/A	cg22654517	chr2:96458247	NA	0.22	4.87	0.4	3.37e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs909674	0.865	rs5757684	chr22:39851584	G/A	cg24399712	chr22:39784796	NA	-1.06	-11.24	-0.71	1.23e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs7772486	0.790	rs7742333	chr6:146159029	A/G	cg05347473	chr6:146136440	FBXO30	-0.48	-4.47	-0.37	1.71e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs17376456	0.877	rs12153501	chr5:93360866	T/G	cg25358565	chr5:93447407	FAM172A	0.92	8.4	0.6	8.88e-14	Diabetic retinopathy;
TGCT	cis	rs17767294	0.614	rs72849214	chr6:28187215	G/A	cg08851530	chr6:28072375	NA	1.46	6.76	0.52	4.79e-10	Parkinson's disease;
TGCT	cis	rs11264213	0.901	rs631202	chr1:36449099	G/C	cg27506609	chr1:36549197	TEKT2	0.4	4.7	0.39	6.83e-6	Schizophrenia;
TGCT	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	16.05	0.82	4.59e-32	Prudent dietary pattern;
TGCT	cis	rs7666738	0.830	rs35951881	chr4:98999474	A/C	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9677476	0.542	rs7595464	chr2:231967610	A/G	cg27665808	chr2:232055229	NA	0.36	4.6	0.38	1.03e-5	Food antigen IgG levels;
TGCT	cis	rs9443645	0.901	rs9352669	chr6:79584141	T/G	cg05283184	chr6:79620031	NA	-0.22	-4.98	-0.41	2.11e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs8180040	0.726	rs2385867	chr3:47059323	C/T	cg27129171	chr3:47204927	SETD2	0.76	9.8	0.66	3.91e-17	Colorectal cancer;
TGCT	cis	rs9905704	0.671	rs4337355	chr17:56950920	C/T	cg12560992	chr17:57184187	TRIM37	0.57	4.9	0.4	2.87e-6	Testicular germ cell tumor;
TGCT	cis	rs2404602	0.692	rs60658665	chr15:77042508	T/C	cg22467129	chr15:76604101	ETFA	-0.45	-5.11	-0.42	1.18e-6	Blood metabolite levels;
TGCT	cis	rs2243480	1.000	rs313824	chr7:65581207	C/T	cg18252515	chr7:66147081	NA	-1.24	-8.1	-0.59	4.35e-13	Diabetic kidney disease;
TGCT	cis	rs6840360	0.642	rs2709816	chr4:152380269	T/C	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.82e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs16958440	0.867	rs78547658	chr18:44669852	C/T	cg17192377	chr18:44677553	HDHD2	0.63	4.7	0.39	6.74e-6	Sitting height ratio;
TGCT	cis	rs7568458	0.870	rs1010	chr2:85808982	C/T	cg02493740	chr2:85810744	VAMP5	0.27	4.77	0.39	4.99e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs2204008	0.744	rs8186814	chr12:38335169	C/T	cg26384229	chr12:38710491	ALG10B	0.83	7.27	0.55	3.51e-11	Bladder cancer;
TGCT	cis	rs10197940	0.789	rs2444256	chr2:152280365	C/T	cg06191203	chr2:152266755	RIF1	-0.74	-6.87	-0.52	2.79e-10	Lung cancer;
TGCT	cis	rs514406	0.505	rs437954	chr1:53173321	C/G	cg25767906	chr1:53392781	SCP2	-0.46	-5.09	-0.42	1.29e-6	Monocyte count;
TGCT	cis	rs2479724	0.901	rs6458244	chr6:41790455	C/T	cg08135965	chr6:41755394	TOMM6	-0.48	-4.79	-0.4	4.65e-6	Menarche (age at onset);
TGCT	cis	rs1008375	1.000	rs55939327	chr4:17642937	T/A	cg18681998	chr4:17616180	MED28	1.01	11.89	0.73	3.17e-22	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs59698941	0.550	rs11748737	chr5:132201070	C/T	cg27099455	chr5:132201840	GDF9;UQCRQ	0.3	5.02	0.41	1.75e-6	Apolipoprotein A-IV levels;
TGCT	cis	rs67460515	0.892	rs4856757	chr3:160999418	A/T	cg03342759	chr3:160939853	NMD3	-0.49	-5.3	-0.43	5.16e-7	Parkinson's disease;
TGCT	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg24549020	chr5:56110836	MAP3K1	0.66	5.79	0.46	5.56e-8	Initial pursuit acceleration;
TGCT	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg04267008	chr7:1944627	MAD1L1	-0.41	-5.46	-0.44	2.54e-7	Bipolar disorder and schizophrenia;
TGCT	trans	rs10506458	1.000	rs1009539	chr12:63414655	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	0.47	7.57	0.56	7.43e-12	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs13188771	0.525	rs10477735	chr5:100918100	T/C	cg18665594	chr5:101119420	NA	0.46	4.56	0.38	1.22e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs9929218	1.000	rs7200690	chr16:68778457	C/T	cg01251360	chr16:68772225	CDH1	0.29	4.87	0.4	3.27e-6	Colorectal cancer;
TGCT	cis	rs17767294	0.708	rs72847332	chr6:27773776	G/A	cg08851530	chr6:28072375	NA	1.54	7.3	0.55	3.1e-11	Parkinson's disease;
TGCT	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg18876405	chr7:65276391	NA	-0.31	-4.93	-0.4	2.61e-6	Calcium levels;
TGCT	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg10053473	chr17:62856997	LRRC37A3	0.46	6.8	0.52	3.99e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg08439880	chr3:133502540	NA	0.33	6.24	0.49	6.4e-9	Iron status biomarkers;
TGCT	cis	rs78487399	0.710	rs6731998	chr2:43677273	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.24	-0.43	6.79e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs62244186	0.608	rs2888390	chr3:44511405	G/A	cg15687855	chr3:44754131	ZNF502	-0.44	-5.11	-0.42	1.18e-6	Depressive symptoms;
TGCT	cis	rs9296092	0.538	rs80012910	chr6:33519542	G/A	cg13560919	chr6:33536144	NA	-0.21	-4.75	-0.39	5.5e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs75059851	0.756	rs11223658	chr11:133843216	G/A	cg14047540	chr11:133829660	NA	-0.58	-5.77	-0.46	6.07e-8	Schizophrenia;
TGCT	cis	rs12701220	0.522	rs12334290	chr7:1054517	A/G	cg03188948	chr7:1209495	NA	0.42	4.49	0.37	1.62e-5	Bronchopulmonary dysplasia;
TGCT	cis	rs3774830	0.679	rs195121	chr4:5436104	C/T	cg26943120	chr4:5472116	STK32B	-0.25	-5.62	-0.45	1.18e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7611238	0.538	rs1353133	chr3:195160052	A/G	cg27323046	chr3:195102265	ACAP2	0.33	4.44	0.37	1.96e-5	Body mass index;
TGCT	cis	rs11190604	0.945	rs7091356	chr10:102292268	G/C	cg23241863	chr10:102295624	HIF1AN	0.7	5.36	0.43	3.93e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg02725872	chr8:58115012	NA	-0.41	-4.96	-0.41	2.28e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7552404	0.731	rs2029683	chr1:76341643	T/G	cg22875332	chr1:76189707	ACADM	-0.68	-7.11	-0.54	7.96e-11	Blood metabolite levels;Acylcarnitine levels;
TGCT	trans	rs931812	0.825	rs34235568	chr8:101895761	C/T	cg20993868	chr7:22813445	NA	0.42	9.03	0.63	2.75e-15	Attention deficit hyperactivity disorder and conduct disorder;
TGCT	cis	rs2299587	0.637	rs6586677	chr8:17890687	A/G	cg04898035	chr8:17640624	MTUS1	-0.22	-4.75	-0.39	5.59e-6	Economic and political preferences;
TGCT	cis	rs11648796	0.757	rs6600231	chr16:766485	A/G	cg07343612	chr16:622815	PIGQ	0.34	5.02	0.41	1.75e-6	Height;
TGCT	cis	rs10464366	0.544	rs4723824	chr7:39153698	T/C	cg18850127	chr7:39170497	POU6F2	0.33	7.24	0.55	4.1e-11	IgG glycosylation;
TGCT	cis	rs589249	0.853	rs1002656	chr1:37192741	C/T	cg04012535	chr1:37176647	NA	0.32	4.87	0.4	3.28e-6	Neuroticism (multi-trait analysis);Schizophrenia;
TGCT	cis	rs858239	0.601	rs6980224	chr7:23149137	C/T	cg05602783	chr7:23145260	KLHL7	-0.63	-5.33	-0.43	4.55e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs10883723	0.810	rs7072351	chr10:104265047	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	8.36	0.6	1.1e-13	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg03517284	chr6:25882590	NA	-0.63	-5.44	-0.44	2.73e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg11905131	chr22:24372483	LOC391322	-1.0	-12.0	-0.73	1.73e-22	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs3820068	0.581	rs6429762	chr1:15945595	A/C	cg05660106	chr1:15850417	CASP9	0.8	7.94	0.58	1.03e-12	Systolic blood pressure;
TGCT	cis	rs5769765	0.913	rs2319462	chr22:50263370	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	1.11	11.76	0.73	6.5e-22	Schizophrenia;
TGCT	cis	rs6088580	0.634	rs6087587	chr20:33058628	G/T	cg08999081	chr20:33150536	PIGU	0.29	5.66	0.45	9.97e-8	Glomerular filtration rate (creatinine);
TGCT	cis	rs12497850	0.931	rs7647813	chr3:48833348	G/T	cg05785598	chr3:49045655	WDR6	0.35	4.72	0.39	6.35e-6	Parkinson's disease;
TGCT	cis	rs9399135	0.935	rs4445070	chr6:135309212	C/T	cg24558204	chr6:135376177	HBS1L	0.48	4.75	0.39	5.5e-6	Red blood cell count;
TGCT	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg12667521	chr19:29218732	NA	0.54	5.72	0.46	7.65e-8	Methadone dose in opioid dependence;
TGCT	cis	rs8077889	1.000	rs2342310	chr17:41866199	T/C	cg26893861	chr17:41843967	DUSP3	1.08	13.1	0.76	3.73e-25	Triglycerides;
TGCT	cis	rs2486288	0.656	rs7166580	chr15:45571209	C/G	cg14582100	chr15:45693742	SPATA5L1	-0.46	-5.32	-0.43	4.71e-7	Glomerular filtration rate;
TGCT	cis	rs9527	0.641	rs34130454	chr10:104903638	A/G	cg15744005	chr10:104629667	AS3MT	-0.42	-4.86	-0.4	3.41e-6	Arsenic metabolism;
TGCT	cis	rs6835098	1.000	rs4695826	chr4:174089426	T/G	cg08422745	chr4:174089978	GALNT7	-0.94	-11.2	-0.71	1.48e-20	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs7809950	1.000	rs2250414	chr7:107140987	T/G	cg23024343	chr7:107201750	COG5	-0.35	-5.54	-0.45	1.72e-7	Coronary artery disease;
TGCT	cis	rs9467773	0.583	rs2498380	chr6:26643996	C/G	cg26531700	chr6:26746687	NA	-0.52	-4.94	-0.41	2.5e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10782582	0.593	rs17647178	chr1:76210524	A/G	cg22875332	chr1:76189707	ACADM	-0.49	-5.39	-0.44	3.35e-7	Daytime sleep phenotypes;
TGCT	cis	rs3087591	0.639	rs757378	chr17:29722619	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.39	-5.68	-0.45	9.08e-8	Hip circumference;
TGCT	cis	rs13040088	1.000	rs12480870	chr20:61543606	A/C	cg23096297	chr20:61557774	DIDO1	1.19	9.82	0.66	3.46e-17	Menopause (age at onset);
TGCT	cis	rs17102423	0.692	rs762810	chr14:65544367	C/A	cg11161011	chr14:65562177	MAX	-0.55	-7.68	-0.57	4.15e-12	Obesity-related traits;
TGCT	cis	rs6840360	0.607	rs2724565	chr4:152350305	A/G	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.83e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs12908161	1.000	rs35524990	chr15:85258203	T/C	cg12863693	chr15:85201151	NMB	0.46	5.51	0.44	1.95e-7	Schizophrenia;
TGCT	cis	rs3812049	0.737	rs790154	chr5:127501235	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.57	5.18	0.42	8.76e-7	Lymphocyte counts;Red cell distribution width;
TGCT	cis	rs11864453	0.612	rs12708925	chr16:72122706	A/T	cg14768367	chr16:72042858	DHODH	0.52	5.21	0.42	7.61e-7	Fibrinogen levels;
TGCT	cis	rs7169223	0.615	rs11630027	chr15:79096983	C/A	cg03762349	chr15:79060523	ADAMTS7	-0.26	-5.49	-0.44	2.18e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
TGCT	cis	rs9467711	0.606	rs9379864	chr6:26372584	G/A	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs11648796	0.717	rs10682	chr16:767430	C/G	cg00908189	chr16:619842	PIGQ	0.72	5.89	0.47	3.42e-8	Height;
TGCT	cis	rs76878669	0.516	rs7104570	chr11:66159098	A/G	cg18002602	chr11:66138449	SLC29A2	0.53	6.49	0.5	1.82e-9	Educational attainment (years of education);
TGCT	cis	rs950776	0.642	rs7178007	chr15:78965254	G/A	cg21242079	chr15:79101063	ADAMTS7	-0.31	-4.84	-0.4	3.74e-6	Sudden cardiac arrest;
TGCT	cis	rs4455778	0.501	rs35433930	chr7:49059052	T/C	cg26309511	chr7:48887640	NA	0.52	6.8	0.52	3.99e-10	Lung cancer in never smokers;
TGCT	cis	rs42648	0.596	rs194513	chr7:89850170	G/T	cg25739043	chr7:89950458	NA	-0.49	-4.69	-0.39	7.02e-6	Homocysteine levels;
TGCT	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.07	6.31	0.49	4.6e-9	Gut microbiome composition (summer);
TGCT	cis	rs3806843	1.000	rs4151680	chr5:140186657	A/G	cg19875535	chr5:140030758	IK	0.35	5.85	0.47	4.01e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs3784262	0.669	rs12915989	chr15:58315736	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.43	-6.27	-0.49	5.58e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs9393777	0.546	rs9366673	chr6:26893329	C/G	cg15659132	chr6:26577336	NA	-0.68	-4.7	-0.39	6.94e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1372520	0.684	rs2583979	chr4:90750588	A/T	cg14346243	chr4:90757452	SNCA	-0.67	-5.64	-0.45	1.09e-7	Neuroticism;
TGCT	cis	rs7017914	0.967	rs59992214	chr8:71599545	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.03	-0.41	1.69e-6	Bone mineral density;
TGCT	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs3820068	0.871	rs11585808	chr1:15805662	C/T	cg05660106	chr1:15850417	CASP9	1.13	11.01	0.7	4.37e-20	Systolic blood pressure;
TGCT	cis	rs7226408	1.000	rs72883550	chr18:34361547	G/A	cg06757138	chr18:34340585	FHOD3	0.28	4.76	0.39	5.23e-6	Obesity-related traits;
TGCT	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg00024416	chr22:24240387	NA	0.35	5.99	0.47	2.14e-8	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs9556958	0.708	rs9513435	chr13:99160334	C/G	cg15168958	chr13:99100528	FARP1	0.21	4.7	0.39	6.91e-6	Educational attainment (years of education);
TGCT	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7937682	0.632	rs7112886	chr11:111743232	T/C	cg09085632	chr11:111637200	PPP2R1B	0.81	7.14	0.54	6.97e-11	Primary sclerosing cholangitis;
TGCT	cis	rs2964802	0.505	rs6876703	chr5:10831629	G/A	cg14521931	chr5:10832172	NA	-0.27	-4.59	-0.38	1.06e-5	Major depressive disorder;Recurrent major depressive disorder;
TGCT	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg15320075	chr8:145703422	NA	0.7	7.24	0.55	4.07e-11	Age at first birth;
TGCT	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg07507251	chr3:52567010	NT5DC2	0.48	6.79	0.52	4.12e-10	Bipolar disorder;
TGCT	trans	rs7618501	0.519	rs3774750	chr3:50208406	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.79	-8.22	-0.59	2.36e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs1372520	0.873	rs983361	chr4:90761944	T/G	cg20003494	chr4:90757398	SNCA	-0.67	-5.69	-0.46	8.62e-8	Neuroticism;
TGCT	cis	rs7772486	0.790	rs2249147	chr6:146184999	T/C	cg05347473	chr6:146136440	FBXO30	0.52	4.88	0.4	3.26e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2282802	0.635	rs397463	chr5:139584275	C/G	cg01081189	chr5:139537190	NA	-0.28	-5.07	-0.41	1.43e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7914558	0.966	rs1890185	chr10:104748718	A/G	cg04362960	chr10:104952993	NT5C2	0.6	5.42	0.44	2.99e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs8016982	0.674	rs2288499	chr14:81660997	C/T	cg01989461	chr14:81687754	GTF2A1	0.78	7.94	0.58	1.06e-12	Schizophrenia;
TGCT	cis	rs62244186	0.659	rs9873072	chr3:44516496	G/A	cg10263370	chr3:44754102	ZNF502	-0.4	-4.8	-0.4	4.4e-6	Depressive symptoms;
TGCT	cis	rs208520	0.909	rs62414639	chr6:67023706	G/A	cg07460842	chr6:66804631	NA	0.69	5.72	0.46	7.53e-8	Exhaled nitric oxide output;
TGCT	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg20203395	chr5:56204925	C5orf35	0.79	6.24	0.49	6.41e-9	Initial pursuit acceleration;
TGCT	cis	rs2153535	0.541	rs9328471	chr6:8468842	T/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg11905131	chr22:24372483	LOC391322	-0.82	-8.0	-0.58	7.68e-13	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg27170947	chr2:26402098	FAM59B	-0.4	-4.55	-0.38	1.25e-5	Gut microbiome composition (summer);
TGCT	cis	rs6693567	0.545	rs6664703	chr1:150459087	G/C	cg09579323	chr1:150459698	TARS2	0.52	4.58	0.38	1.12e-5	Migraine;
TGCT	cis	rs9527	0.590	rs2274339	chr10:104860053	T/A	cg15744005	chr10:104629667	AS3MT	-0.41	-4.8	-0.4	4.46e-6	Arsenic metabolism;
TGCT	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.89	9.34	0.64	5.06e-16	Platelet count;
TGCT	trans	rs10435719	0.867	rs6999030	chr8:11795308	G/A	cg15556689	chr8:8085844	FLJ10661	0.75	7.26	0.55	3.66e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs6565180	0.926	rs4788409	chr16:30393771	G/A	cg17640201	chr16:30407289	ZNF48	0.96	9.04	0.63	2.57e-15	Tonsillectomy;
TGCT	cis	rs7246657	0.722	rs16958861	chr19:38124179	G/A	cg18154014	chr19:37997991	ZNF793	0.68	4.57	0.38	1.18e-5	Coronary artery calcification;
TGCT	cis	rs1865760	0.865	rs6929805	chr6:25950834	T/A	cg17042849	chr6:26104293	HIST1H4C	-0.52	-4.78	-0.39	4.97e-6	Height;
TGCT	cis	rs9467773	1.000	rs12526680	chr6:26550954	A/G	cg05738196	chr6:26577821	NA	0.91	13.11	0.76	3.53e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg19318889	chr4:1322082	MAEA	0.28	6.63	0.51	9.18e-10	Longevity;
TGCT	cis	rs11190604	1.000	rs11816840	chr10:102309220	G/C	cg16342193	chr10:102329863	NA	-0.39	-4.95	-0.41	2.36e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs4730250	0.707	rs257381	chr7:106803963	T/C	cg02696742	chr7:106810147	HBP1	-0.7	-5.68	-0.45	8.9e-8	Osteoarthritis;
TGCT	cis	rs796364	0.616	rs769956	chr2:200693720	C/T	cg17644776	chr2:200775616	C2orf69	-0.34	-4.84	-0.4	3.76e-6	Schizophrenia;
TGCT	cis	rs7973719	0.868	rs7315553	chr12:7353838	A/C	cg07052231	chr12:7363540	PEX5	0.36	5.6	0.45	1.34e-7	IgG glycosylation;
TGCT	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg13607699	chr17:42295918	UBTF	0.79	7.23	0.54	4.29e-11	Total body bone mineral density;
TGCT	trans	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg06636001	chr8:8085503	FLJ10661	-0.81	-8.56	-0.61	3.74e-14	Neuroticism;
TGCT	cis	rs9811920	0.809	rs766778	chr3:99751480	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.45	5.02	0.41	1.79e-6	Axial length;
TGCT	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg21016266	chr12:122356598	WDR66	0.52	6.4	0.5	2.83e-9	Mean corpuscular volume;
TGCT	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg13699009	chr12:122356056	WDR66	0.29	5.72	0.46	7.44e-8	Mean corpuscular volume;
TGCT	cis	rs12142240	0.698	rs12385695	chr1:46819021	A/G	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs6088590	0.648	rs6059991	chr20:33280836	C/T	cg08999081	chr20:33150536	PIGU	0.27	5.01	0.41	1.81e-6	Coronary artery disease;
TGCT	cis	rs10088262	0.591	rs13270541	chr8:124794849	G/A	cg02993010	chr8:124780839	FAM91A1	-0.63	-5.13	-0.42	1.08e-6	Pancreatic cancer;
TGCT	cis	rs17253792	0.822	rs75351812	chr14:56082192	G/A	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg02503808	chr4:7069936	GRPEL1	-0.94	-9.06	-0.63	2.36e-15	Monocyte percentage of white cells;
TGCT	cis	rs669446	0.558	rs594293	chr1:44109199	A/G	cg12908607	chr1:44402522	ARTN	-0.55	-5.9	-0.47	3.25e-8	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs7840202	0.506	rs7827839	chr8:103353730	C/T	cg22150661	chr8:104032860	ATP6V1C1	0.3	4.64	0.38	8.9e-6	Rate of cognitive decline in mild cognitive impairment (time interaction);Gestational age at birth in labor-initiated deliveries (child effect);
TGCT	cis	rs6940638	0.615	rs9393801	chr6:27242681	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.43	-4.5	-0.37	1.52e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs4595586	0.545	rs1303887	chr12:39366523	C/T	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs709400	0.633	rs8013101	chr14:103951772	G/C	cg26031613	chr14:104095156	KLC1	0.84	9.5	0.65	2.08e-16	Body mass index;
TGCT	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg01341218	chr17:43662625	NA	-0.82	-7.6	-0.56	6.45e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	trans	rs11088226	0.681	rs2833906	chr21:33945521	G/T	cg09050820	chr6:167586206	TCP10L2	0.82	7.4	0.55	1.8e-11	Gastritis;
TGCT	cis	rs2239547	0.522	rs2581805	chr3:52979050	T/C	cg10802521	chr3:52805072	NEK4	0.64	6.12	0.48	1.11e-8	Schizophrenia;
TGCT	cis	rs6912958	0.630	rs9450726	chr6:88236728	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.51	-4.64	-0.38	8.6e-6	Monocyte percentage of white cells;
TGCT	cis	rs7681440	0.626	rs1372510	chr4:90817259	G/A	cg10208370	chr4:90758469	SNCA	-0.57	-5.41	-0.44	3.05e-7	Dementia with Lewy bodies;
TGCT	cis	rs12257961	0.549	rs7900826	chr10:15382981	C/A	cg10616319	chr10:15468812	NA	0.25	4.66	0.39	8.15e-6	Selective IgA deficiency;
TGCT	cis	rs1865760	0.566	rs2858993	chr6:26087856	T/A	cg17042849	chr6:26104293	HIST1H4C	-0.65	-5.52	-0.44	1.89e-7	Height;
TGCT	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg06238570	chr21:40685208	BRWD1	-0.62	-6.42	-0.5	2.57e-9	Menarche (age at onset);
TGCT	cis	rs9788682	1.000	rs35212593	chr15:78831826	G/A	cg06917634	chr15:78832804	PSMA4	-0.7	-4.86	-0.4	3.47e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg09359103	chr1:154839909	KCNN3	-0.66	-12.08	-0.74	1.09e-22	Prostate cancer;
TGCT	cis	rs4700695	0.841	rs706681	chr5:65317913	G/T	cg21114390	chr5:65439923	SFRS12	0.62	4.62	0.38	9.51e-6	Facial morphology (factor 19);
TGCT	cis	rs35306767	0.903	rs17159970	chr10:935601	T/C	cg26597838	chr10:835615	NA	0.75	10.54	0.69	6.3e-19	Eosinophil percentage of granulocytes;
TGCT	cis	rs4455778	0.600	rs4255086	chr7:49109798	T/A	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs494003	1.000	rs11227288	chr11:65516588	G/C	cg04293602	chr11:65553660	OVOL1	0.36	4.62	0.38	9.28e-6	Systemic lupus erythematosus;
TGCT	cis	rs200810	0.694	rs59740076	chr6:97996564	T/G	cg16511841	chr6:97730490	C6orf167;MIR548H3	-0.65	-4.45	-0.37	1.91e-5	Body mass index;
TGCT	cis	rs10992471	0.603	rs2094281	chr9:95290654	C/G	cg14631576	chr9:95140430	CENPP	0.3	4.8	0.4	4.42e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs3770081	1.000	rs78646493	chr2:86283195	A/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.17	-4.56	-0.38	1.21e-5	Facial emotion recognition (sad faces);
TGCT	cis	rs2243480	1.000	rs58669269	chr7:65951953	T/C	cg20637647	chr7:64974828	NA	0.91	5.33	0.43	4.55e-7	Diabetic kidney disease;
TGCT	cis	rs13102973	0.674	rs11730572	chr4:135885397	C/T	cg14419869	chr4:135874104	NA	0.26	4.55	0.38	1.28e-5	Subjective well-being;
TGCT	cis	rs8013055	0.846	rs11624007	chr14:105992183	A/C	cg19700328	chr14:106028568	NA	-0.53	-5.79	-0.46	5.32e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs9682041	0.668	rs6784631	chr3:170100476	T/C	cg11886554	chr3:170076028	SKIL	0.88	6.41	0.5	2.82e-9	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs7255374	0.566	rs11666982	chr19:41531368	T/G	cg20630647	chr19:41531805	NA	0.38	6.57	0.51	1.23e-9	DDT metabolite (p,p'-DDE levels);
TGCT	cis	rs13191362	0.935	rs4273664	chr6:162955494	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.66	5.11	0.42	1.17e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.01	8.32	0.6	1.34e-13	Platelet count;
TGCT	cis	rs10986311	0.706	rs7854989	chr9:127133584	T/C	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.18	4.63	0.38	9.02e-6	Vitiligo;
TGCT	cis	rs9517320	0.534	rs912330	chr13:99131294	C/T	cg07423050	chr13:99094983	FARP1	-0.26	-4.79	-0.4	4.58e-6	Longevity;
TGCT	cis	rs9318086	0.753	rs9553094	chr13:24474613	A/G	cg16267784	chr13:24449046	MIPEP	0.22	4.46	0.37	1.79e-5	Myopia (pathological);
TGCT	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg05872129	chr22:39784769	NA	-0.97	-10.56	-0.69	5.57e-19	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs6430585	0.528	rs309152	chr2:136657252	C/T	cg07169764	chr2:136633963	MCM6	-1.11	-10.8	-0.7	1.46e-19	Corneal structure;
TGCT	cis	rs7666738	0.830	rs2865978	chr4:99017946	G/T	cg05340658	chr4:99064831	C4orf37	0.48	5.43	0.44	2.92e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7635838	0.617	rs346071	chr3:11305584	A/T	cg00170343	chr3:11313890	ATG7	-0.62	-6.13	-0.48	1.07e-8	HDL cholesterol;
TGCT	cis	rs2617583	0.530	rs10060889	chr5:1456803	A/G	cg13982541	chr5:1466431	LPCAT1	0.19	4.55	0.38	1.28e-5	Breast cancer;
TGCT	cis	rs2594989	0.779	rs111827101	chr3:11587736	T/C	cg00170343	chr3:11313890	ATG7	-0.68	-5.1	-0.42	1.26e-6	Circulating chemerin levels;
TGCT	cis	rs10501293	0.746	rs7110938	chr11:43007392	G/A	cg03447554	chr11:43094025	NA	0.43	6.19	0.49	8.04e-9	Cognitive performance;
TGCT	cis	rs2797160	1.000	rs6933302	chr6:126016951	T/C	cg05901451	chr6:126070800	HEY2	0.73	6.29	0.49	5.01e-9	Endometrial cancer;
TGCT	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg18305652	chr10:134549665	INPP5A	0.34	5.51	0.44	2.02e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs6429082	0.518	rs1812350	chr1:235659920	C/A	cg26050004	chr1:235667680	B3GALNT2	0.83	8.86	0.62	7.1e-15	Adiposity;
TGCT	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg08859206	chr1:53392774	SCP2	0.39	5.98	0.47	2.23e-8	Monocyte count;
TGCT	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg19010396	chr19:19431384	KIAA0892;SF4	0.54	4.47	0.37	1.77e-5	Tonsillectomy;
TGCT	cis	rs4699052	0.662	rs2866645	chr4:104239201	A/G	cg16532752	chr4:104119610	CENPE	-0.58	-5.86	-0.47	3.96e-8	Testicular germ cell tumor;
TGCT	cis	rs7552404	0.627	rs12127049	chr1:76353248	G/A	cg03433033	chr1:76189801	ACADM	0.76	7.55	0.56	8.35e-12	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs1524927	0.933	rs12704874	chr7:96340744	A/G	cg03808172	chr7:96339361	SHFM1	0.49	5.06	0.41	1.45e-6	Total body bone mineral density;
TGCT	cis	rs28785552	0.931	rs10424385	chr19:53239133	C/G	cg22067481	chr19:53234126	ZNF611	-0.49	-7.05	-0.53	1.1e-10	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs644148	0.836	rs2686774	chr19:44999827	T/C	cg15540054	chr19:45004280	ZNF180	-0.65	-5.33	-0.43	4.48e-7	Personality dimensions;
TGCT	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg13607699	chr17:42295918	UBTF	0.59	5.31	0.43	4.88e-7	Total body bone mineral density;
TGCT	cis	rs6669384	0.774	rs7550821	chr1:208029947	C/T	cg22525895	chr1:207977042	MIR29B2	-0.4	-5.72	-0.46	7.44e-8	Immune response to measles vaccine (measles-specific neutralising antibody titre);
TGCT	cis	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg20637647	chr7:64974828	NA	-0.89	-4.99	-0.41	2.01e-6	Diabetic kidney disease;
TGCT	cis	rs12220898	0.749	rs10735220	chr10:50473635	A/G	cg09603381	chr10:49954066	WDFY4	0.38	4.45	0.37	1.85e-5	Inflammatory biomarkers;
TGCT	cis	rs1008375	1.000	rs4235388	chr4:17682030	G/A	cg16339924	chr4:17578868	LAP3	0.56	4.82	0.4	4.1e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10754283	0.967	rs10737707	chr1:90119304	A/G	cg03145924	chr1:90228473	NA	-0.4	-4.52	-0.38	1.4e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs25422	0.938	rs7356858	chr6:118765814	G/C	cg21191810	chr6:118973309	C6orf204	-0.37	-4.77	-0.39	5.03e-6	Renal cell carcinoma;
TGCT	cis	rs7208859	0.673	rs55904046	chr17:29215391	G/A	cg18442181	chr17:29233375	C17orf42	-0.78	-4.61	-0.38	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs346785	0.692	rs6501882	chr17:74289875	C/T	cg09812376	chr17:74270190	QRICH2	-0.36	-5.33	-0.43	4.43e-7	White matter hyperintensities in ischemic stroke;
TGCT	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg11494091	chr17:61959527	GH2	0.6	14.48	0.79	1.94e-28	Prudent dietary pattern;
TGCT	cis	rs7267979	0.868	rs6138546	chr20:25216534	G/A	cg03522245	chr20:25566470	NINL	0.6	6.57	0.51	1.22e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg20203395	chr5:56204925	C5orf35	0.59	5.12	0.42	1.12e-6	Initial pursuit acceleration;
TGCT	cis	rs9457247	1.000	rs397713	chr6:167386714	G/A	cg25258033	chr6:167368657	RNASET2	0.18	4.49	0.37	1.63e-5	Crohn's disease;
TGCT	cis	rs7666738	0.649	rs28865589	chr4:98954279	C/A	cg18180107	chr4:99064573	C4orf37	0.56	5.05	0.41	1.53e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs909685	1.000	rs2069235	chr22:39747780	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.63	6.08	0.48	1.36e-8	Rheumatoid arthritis;
TGCT	cis	rs1865760	0.613	rs2071300	chr6:25914572	C/T	cg12310025	chr6:25882481	NA	-0.55	-5.84	-0.46	4.23e-8	Height;
TGCT	cis	rs3027009	0.881	rs61828178	chr1:159159041	G/T	cg27303699	chr1:158224869	CD1A	-0.4	-4.72	-0.39	6.34e-6	Lean body mass and age at menarche (combined);
TGCT	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	6.23	0.49	6.56e-9	Bipolar disorder;
TGCT	cis	rs2066819	1.000	rs773664	chr12:56702176	C/T	cg26714650	chr12:56694279	CS	1.53	8.28	0.6	1.67e-13	Psoriasis vulgaris;
TGCT	cis	rs13256369	0.851	rs11249889	chr8:8564992	G/T	cg18904891	chr8:8559673	CLDN23	0.59	5.46	0.44	2.54e-7	Obesity-related traits;
TGCT	cis	rs6582630	0.555	rs11181657	chr12:38381858	T/C	cg26384229	chr12:38710491	ALG10B	-0.81	-7.13	-0.54	7.23e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs6088580	0.634	rs4911418	chr20:32994257	G/A	cg24642439	chr20:33292090	TP53INP2	-0.49	-4.49	-0.37	1.59e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs514406	0.763	rs6685599	chr1:53213172	G/A	cg22166914	chr1:53195759	ZYG11B	-0.41	-7.06	-0.54	1.05e-10	Monocyte count;
TGCT	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg11062466	chr8:58055876	NA	0.38	4.62	0.38	9.5e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs12422267	0.609	rs10128884	chr12:132621624	C/T	cg09764611	chr12:132620959	NA	-0.32	-4.9	-0.4	2.94e-6	Plasma amyloid beta peptide concentrations (ABx-40);
TGCT	cis	rs80033912	0.626	rs71324982	chr3:49669948	G/A	cg07636037	chr3:49044803	WDR6	0.62	5.04	0.41	1.57e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6424115	0.644	rs2267960	chr1:24068544	T/C	cg15997130	chr1:24165203	NA	0.62	6.36	0.5	3.5e-9	Immature fraction of reticulocytes;
TGCT	cis	rs1953600	1.000	rs1953600	chr10:81911725	A/G	cg04850286	chr10:81895943	PLAC9	0.39	4.54	0.38	1.3e-5	Sarcoidosis;
TGCT	cis	rs2739330	1.000	rs2739330	chr22:24295286	T/C	cg10150615	chr22:24372951	LOC391322	-0.97	-12.64	-0.75	4.94e-24	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg11644478	chr21:40555479	PSMG1	-0.53	-4.55	-0.38	1.28e-5	Cognitive function;
TGCT	cis	rs8067545	1.000	rs8067545	chr17:19912710	T/C	cg13482628	chr17:19912719	NA	0.55	4.83	0.4	3.98e-6	Schizophrenia;
TGCT	cis	rs921968	0.608	rs7598056	chr2:219352511	A/C	cg02176678	chr2:219576539	TTLL4	0.44	6.33	0.49	4.17e-9	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs61935443	0.666	rs73218073	chr12:95314346	A/G	cg21533806	chr12:95267307	NA	0.57	4.75	0.39	5.43e-6	Schizophrenia;
TGCT	cis	rs2730245	0.527	rs712197	chr7:158660846	C/G	cg11984989	chr7:158649758	WDR60	1.01	7.8	0.57	2.2e-12	Height;
TGCT	cis	rs6840360	0.642	rs2709828	chr4:152355268	C/T	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.83e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs12477438	0.765	rs6542846	chr2:99563654	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-4.55	-0.38	1.25e-5	Chronic sinus infection;
TGCT	cis	rs12510870	0.674	rs1528918	chr4:74452590	C/T	cg05868023	chr4:75230803	EREG	-0.55	-4.74	-0.39	5.71e-6	Iris color (b* coordinate);
TGCT	cis	rs7246657	0.722	rs3095726	chr19:38229824	T/C	cg18154014	chr19:37997991	ZNF793	-0.71	-4.88	-0.4	3.24e-6	Coronary artery calcification;
TGCT	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg02725872	chr8:58115012	NA	-0.39	-5.15	-0.42	1.01e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg13397359	chr6:42928475	GNMT	0.72	6.48	0.5	1.93e-9	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs172166	0.694	rs9295760	chr6:28147385	G/A	cg10876282	chr6:28092338	ZSCAN16	0.49	4.53	0.38	1.37e-5	Cardiac Troponin-T levels;
TGCT	cis	rs2932538	0.961	rs3795820	chr1:113163042	C/A	cg22162597	chr1:113214053	CAPZA1	-0.28	-5.85	-0.47	4.01e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.63	-6.34	-0.5	3.79e-9	Bipolar disorder;
TGCT	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg06238570	chr21:40685208	BRWD1	0.68	6.32	0.49	4.3e-9	Cognitive function;
TGCT	cis	rs10791097	0.694	rs7125622	chr11:130743388	T/C	cg05962950	chr11:130786565	SNX19	0.92	11.55	0.72	2.13e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs2455799	0.634	rs62243671	chr3:15921098	C/T	cg16303742	chr3:15540471	COLQ	-0.24	-4.61	-0.38	9.69e-6	Mean platelet volume;
TGCT	cis	rs7666738	0.830	rs11721726	chr4:98996314	T/C	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg02038168	chr22:39784481	NA	-0.77	-6.41	-0.5	2.78e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg03452623	chr4:187889614	NA	-0.37	-5.7	-0.46	8.2e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg12034118	chr1:209979487	IRF6	0.58	4.48	0.37	1.66e-5	Cleft lip with or without cleft palate;
TGCT	cis	rs2204008	0.582	rs11179135	chr12:38204689	A/C	cg26384229	chr12:38710491	ALG10B	0.78	6.56	0.51	1.32e-9	Bladder cancer;
TGCT	cis	rs2730245	1.000	rs2657365	chr7:158722753	A/T	cg11984989	chr7:158649758	WDR60	-0.94	-8.49	-0.61	5.3e-14	Height;
TGCT	cis	rs926938	0.812	rs11102832	chr1:115244253	G/C	cg12756093	chr1:115239321	AMPD1	-0.43	-5.97	-0.47	2.28e-8	Autism;
TGCT	cis	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg18252515	chr7:66147081	NA	-1.13	-6.81	-0.52	3.7e-10	Diabetic kidney disease;
TGCT	cis	rs826838	1.000	rs1719830	chr12:39096992	T/G	cg26384229	chr12:38710491	ALG10B	-0.85	-8.1	-0.59	4.39e-13	Heart rate;
TGCT	cis	rs3026101	0.624	rs1806261	chr17:5317008	A/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.45	4.47	0.37	1.73e-5	Body mass index;
TGCT	cis	rs6598955	0.670	rs12733645	chr1:26540356	G/T	cg04990556	chr1:26633338	UBXN11	-0.89	-11.24	-0.71	1.2e-20	Obesity-related traits;
TGCT	cis	rs1153858	1.000	rs1890565	chr15:45663299	T/C	cg26924012	chr15:45694286	SPATA5L1	1.09	15.16	0.81	5.15e-30	Homoarginine levels;
TGCT	cis	rs7267979	1.000	rs2482919	chr20:25299756	T/C	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs28595532	1.000	rs17323012	chr4:119605671	A/G	cg11846333	chr4:119757529	SEC24D	0.95	4.68	0.39	7.49e-6	Cannabis dependence symptom count;
TGCT	cis	rs9952991	0.943	rs9952753	chr18:12780463	A/C	cg24737193	chr18:12778029	NA	0.53	5.93	0.47	2.8e-8	Inflammatory skin disease;
TGCT	cis	rs4851266	0.966	rs13018640	chr2:100821545	T/C	cg07810366	chr2:100720526	AFF3	-0.41	-5.82	-0.46	4.72e-8	Educational attainment;
TGCT	cis	rs2050392	0.590	rs694346	chr10:30711929	C/T	cg13289132	chr10:30722225	MAP3K8	-0.46	-5.69	-0.45	8.77e-8	Inflammatory bowel disease;
TGCT	cis	rs2880765	0.835	rs4360875	chr15:86040394	A/G	cg13263323	chr15:86062960	AKAP13	-0.23	-4.83	-0.4	4e-6	Coronary artery disease;
TGCT	cis	rs10197940	0.550	rs77233070	chr2:152416477	G/A	cg06191203	chr2:152266755	RIF1	-0.67	-5.99	-0.47	2.09e-8	Lung cancer;
TGCT	cis	rs2073300	1.000	rs79255223	chr20:23443559	G/T	cg09953122	chr20:23471693	CST8	-0.64	-4.56	-0.38	1.19e-5	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs9486715	0.867	rs926277	chr6:96868837	T/A	cg06623918	chr6:96969491	KIAA0776	1.11	16.62	0.83	2.35e-33	Headache;
TGCT	cis	rs1670533	1.000	rs4690212	chr4:1054898	T/C	cg20887711	chr4:1340912	KIAA1530	0.71	5.7	0.46	8.33e-8	Recombination rate (females);
TGCT	cis	rs3780378	0.870	rs2149556	chr9:5059440	C/T	cg02405213	chr9:5042618	JAK2	-0.64	-8.93	-0.63	4.87e-15	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	trans	rs3780486	0.846	rs10116966	chr9:33122370	T/A	cg20290983	chr6:43655470	MRPS18A	1.21	15.13	0.81	5.99e-30	IgG glycosylation;
TGCT	cis	rs2012796	0.743	rs12435764	chr14:81836866	A/C	cg02996355	chr14:81879375	NA	0.58	5.75	0.46	6.46e-8	Night sleep phenotypes;
TGCT	cis	rs6542838	0.641	rs10192266	chr2:99521837	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.56	-5.27	-0.43	5.77e-7	Fear of minor pain;
TGCT	cis	rs2115536	1.000	rs11637477	chr15:80193295	C/T	cg00225070	chr15:80189496	MTHFS	0.62	5.58	0.45	1.42e-7	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs9790314	0.934	rs462413	chr3:161101587	T/C	cg03342759	chr3:160939853	NMD3	-0.44	-4.57	-0.38	1.15e-5	Morning vs. evening chronotype;
TGCT	cis	rs9914544	1.000	rs67411574	chr17:18797337	A/G	cg26378065	chr17:18585709	ZNF286B	0.52	4.73	0.39	5.94e-6	Educational attainment (years of education);
TGCT	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	4.93	0.41	2.53e-6	Alzheimer's disease;
TGCT	cis	rs617219	0.671	rs2591392	chr5:78546293	G/A	cg23987322	chr5:78407566	BHMT	0.35	4.56	0.38	1.23e-5	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg24250549	chr1:154909240	PMVK	0.63	6.25	0.49	6.03e-9	Prostate cancer;
TGCT	cis	rs79149102	0.579	rs6495138	chr15:75304692	A/G	cg09165964	chr15:75287851	SCAMP5	-1.04	-5.71	-0.46	7.93e-8	Lung cancer;
TGCT	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg20203395	chr5:56204925	C5orf35	-0.57	-4.84	-0.4	3.85e-6	Initial pursuit acceleration;
TGCT	cis	rs2204008	0.805	rs11179579	chr12:38213957	A/C	cg26384229	chr12:38710491	ALG10B	0.84	7.45	0.56	1.37e-11	Bladder cancer;
TGCT	cis	rs6725041	0.792	rs1533768	chr2:213089875	T/A	cg20637307	chr2:213403960	ERBB4	-0.52	-4.47	-0.37	1.72e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs1372520	0.577	rs2737021	chr4:90739992	T/A	cg14346243	chr4:90757452	SNCA	-0.68	-5.57	-0.45	1.48e-7	Neuroticism;
TGCT	cis	rs7681440	1.000	rs1471483	chr4:90754292	A/G	cg20003494	chr4:90757398	SNCA	-0.55	-4.95	-0.41	2.35e-6	Dementia with Lewy bodies;
TGCT	cis	rs9527	0.545	rs7894588	chr10:104756030	A/T	cg15744005	chr10:104629667	AS3MT	-0.49	-5.32	-0.43	4.62e-7	Arsenic metabolism;
TGCT	cis	rs12477438	0.501	rs11683188	chr2:99724512	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.75	7.25	0.55	3.92e-11	Chronic sinus infection;
TGCT	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg16325326	chr1:53192061	ZYG11B	-0.71	-8.81	-0.62	9.22e-15	Monocyte count;
TGCT	cis	rs9457247	1.000	rs398278	chr6:167388169	A/G	cg25258033	chr6:167368657	RNASET2	0.2	4.84	0.4	3.85e-6	Crohn's disease;
TGCT	cis	rs6988636	1.000	rs10096350	chr8:124184470	T/C	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs5769707	0.967	rs9616333	chr22:50050847	G/A	cg05373962	chr22:49881684	NA	-0.32	-6.65	-0.51	8.38e-10	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs1005277	0.522	rs7090858	chr10:38003670	A/C	cg25427524	chr10:38739819	LOC399744	0.36	7.15	0.54	6.46e-11	Extrinsic epigenetic age acceleration;
TGCT	cis	rs9929218	0.906	rs34565494	chr16:68741769	C/T	cg01251360	chr16:68772225	CDH1	0.29	4.77	0.39	5.03e-6	Colorectal cancer;
TGCT	cis	rs6500602	0.647	rs3747600	chr16:4586222	A/G	cg08645402	chr16:4508243	NA	0.18	5.05	0.41	1.54e-6	Schizophrenia;
TGCT	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg03303774	chr4:1407052	NA	0.3	4.78	0.39	4.82e-6	Obesity-related traits;
TGCT	cis	rs5769707	0.967	rs17182154	chr22:49990470	A/G	cg10356904	chr22:49881777	NA	-0.23	-4.77	-0.39	5.14e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs9372253	1.000	rs9374170	chr6:110712991	A/G	cg00083206	chr6:110721305	DDO	-0.4	-6.07	-0.48	1.44e-8	Platelet distribution width;
TGCT	cis	rs2067615	0.542	rs4964184	chr12:107070425	A/T	cg15890332	chr12:107067104	RFX4	0.29	5.73	0.46	7.31e-8	Heart rate;
TGCT	cis	rs1670533	1.000	rs11725984	chr4:1087338	C/T	cg27284194	chr4:1044797	NA	0.68	5.95	0.47	2.59e-8	Recombination rate (females);
TGCT	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.13	0.82	3.12e-32	Prudent dietary pattern;
TGCT	cis	rs9388451	0.874	rs3734634	chr6:126111800	G/A	cg10911889	chr6:126070802	HEY2	0.48	4.97	0.41	2.18e-6	Brugada syndrome;
TGCT	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg14893161	chr1:205819251	PM20D1	0.52	6.83	0.52	3.3e-10	Menarche (age at onset);
TGCT	cis	rs7727544	0.684	rs270602	chr5:131656700	T/C	cg24060327	chr5:131705240	SLC22A5	-0.57	-6.19	-0.49	8.19e-9	Blood metabolite levels;
TGCT	cis	rs7100689	0.646	rs1934693	chr10:82125650	T/C	cg01528321	chr10:82214614	TSPAN14	0.8	7.76	0.57	2.7e-12	Post bronchodilator FEV1;
TGCT	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg24675658	chr1:53192096	ZYG11B	-0.7	-8.15	-0.59	3.44e-13	Monocyte count;
TGCT	cis	rs12478296	0.685	rs67829386	chr2:242992276	T/A	cg06360820	chr2:242988706	NA	-0.61	-4.68	-0.39	7.26e-6	Obesity-related traits;
TGCT	cis	rs17376456	0.877	rs10476526	chr5:93461916	G/A	cg21475434	chr5:93447410	FAM172A	0.59	4.66	0.39	8.09e-6	Diabetic retinopathy;
TGCT	cis	rs9952991	0.941	rs2542151	chr18:12779947	G/T	cg09945482	chr18:12777974	NA	0.5	4.82	0.4	4.07e-6	Inflammatory skin disease;
TGCT	cis	rs7224685	0.569	rs7213885	chr17:4018489	T/A	cg09580393	chr17:4869866	SPAG7	-0.38	-4.46	-0.37	1.82e-5	Type 2 diabetes;
TGCT	cis	rs35160687	0.842	rs10200619	chr2:86548848	T/C	cg03171300	chr2:86307199	POLR1A	-0.27	-4.81	-0.4	4.34e-6	Night sleep phenotypes;
TGCT	cis	rs17767294	0.522	rs78037434	chr6:27848898	A/T	cg08851530	chr6:28072375	NA	1.58	7.16	0.54	6.15e-11	Parkinson's disease;
TGCT	cis	rs3885907	0.542	rs4147063	chr13:31319954	A/G	cg22282089	chr13:30686841	NA	-0.22	-4.56	-0.38	1.21e-5	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU);
TGCT	cis	rs9916302	0.904	rs602688	chr17:37439496	C/T	cg15445000	chr17:37608096	MED1	0.31	4.57	0.38	1.16e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs12681288	0.823	rs12681230	chr8:994422	G/A	cg04851639	chr8:1020857	NA	-0.34	-5.75	-0.46	6.43e-8	Schizophrenia;
TGCT	cis	rs6840360	0.642	rs7684462	chr4:152348422	T/G	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.83e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs11711311	1.000	rs11711311	chr3:113430599	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.78	-7.13	-0.54	7.14e-11	IgG glycosylation;
TGCT	cis	rs60871478	0.541	rs56964970	chr7:910791	G/C	cg00475322	chr7:917719	C7orf20	0.52	5.04	0.41	1.58e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs8062405	0.824	rs4788083	chr16:28545449	A/G	cg09754948	chr16:28834200	ATXN2L	0.61	4.82	0.4	4.12e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs34245846	0.769	rs12084791	chr1:154824973	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	0.74	5.93	0.47	2.84e-8	Atrial fibrillation;
TGCT	cis	rs2456568	0.900	rs2511399	chr11:93682156	C/T	cg16099599	chr11:93583650	C11orf90	0.39	4.81	0.4	4.35e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7772486	0.754	rs12199362	chr6:146118225	A/G	cg13319975	chr6:146136371	FBXO30	-0.58	-5.24	-0.43	6.75e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6088590	0.561	rs764597	chr20:33161225	C/T	cg06115741	chr20:33292138	TP53INP2	0.51	4.47	0.37	1.76e-5	Coronary artery disease;
TGCT	cis	rs61884328	0.657	rs12578030	chr11:47234601	A/G	cg13308137	chr11:47528955	CUGBP1	0.38	4.56	0.38	1.23e-5	Total body bone mineral density (age over 60);
TGCT	cis	rs7666738	0.830	rs13125537	chr4:98978428	A/G	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs514406	0.584	rs7548832	chr1:53193576	A/T	cg16325326	chr1:53192061	ZYG11B	0.89	12.96	0.76	8.21e-25	Monocyte count;
TGCT	cis	rs7949030	0.622	rs34894392	chr11:62374821	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.63	9.23	0.64	9.4e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.84	-7.63	-0.57	5.48e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7769051	0.711	rs6569847	chr6:133083187	C/A	cg22852734	chr6:133119734	C6orf192	1.17	6.33	0.49	4.15e-9	Type 2 diabetes nephropathy;
TGCT	cis	rs13191362	1.000	rs35103567	chr6:163183400	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.94	6.76	0.52	4.71e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs2663905	1.000	rs2663905	chr15:81359137	G/A	cg18837035	chr15:81426597	C15orf26	-0.58	-5.24	-0.43	6.56e-7	QT interval (drug interaction);
TGCT	cis	rs7582180	0.652	rs4851311	chr2:100980398	C/T	cg14675211	chr2:100938903	LONRF2	0.5	4.68	0.39	7.26e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg21285383	chr16:89894308	SPIRE2	0.44	7.03	0.53	1.23e-10	Vitiligo;
TGCT	cis	rs1420338	1.000	rs918038	chr7:34153768	A/G	cg01275685	chr7:34179230	BMPER	-0.26	-4.83	-0.4	3.96e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs1451375	0.698	rs56766899	chr7:50648938	T/C	cg18232548	chr7:50535776	DDC	0.44	6.72	0.52	5.81e-10	Malaria;
TGCT	cis	rs350251	0.899	rs350275	chr16:12233099	G/C	cg01574788	chr16:12184133	SNX29	0.34	4.48	0.37	1.67e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	5.38	0.44	3.58e-7	Alzheimer's disease;
TGCT	cis	rs4478858	0.647	rs11577679	chr1:31726185	T/C	cg07478791	chr1:31886160	SERINC2	-0.52	-5.03	-0.41	1.67e-6	Alcohol dependence;
TGCT	trans	rs2727020	0.894	rs2866361	chr11:49372481	A/G	cg03929089	chr4:120376271	NA	-0.67	-7.01	-0.53	1.38e-10	Coronary artery disease;
TGCT	cis	rs9583531	0.760	rs9521916	chr13:111385509	A/G	cg24331049	chr13:111365604	ING1	-0.6	-4.46	-0.37	1.8e-5	Coronary artery disease;
TGCT	cis	rs11247915	0.569	rs869139	chr1:26527699	T/C	cg23732845	chr1:26663426	AIM1L	0.32	4.52	0.38	1.45e-5	Obesity-related traits;
TGCT	cis	rs7607369	0.714	rs1344643	chr2:219584975	G/C	cg02176678	chr2:219576539	TTLL4	-0.49	-6.44	-0.5	2.34e-9	Red blood cell count;Amyotrophic lateral sclerosis;
TGCT	cis	rs1372520	0.748	rs990085	chr4:90754771	A/G	cg15133208	chr4:90757351	SNCA	-0.5	-5.86	-0.47	4e-8	Neuroticism;
TGCT	cis	rs7020830	0.861	rs6476622	chr9:37308049	T/A	cg14294708	chr9:37120828	ZCCHC7	1.17	15.12	0.81	6.56e-30	Schizophrenia;
TGCT	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg16325326	chr1:53192061	ZYG11B	0.6	6.97	0.53	1.68e-10	Monocyte count;
TGCT	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg11905131	chr22:24372483	LOC391322	-0.95	-11.19	-0.71	1.64e-20	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs17001868	0.568	rs9611325	chr22:40782490	G/A	cg07138101	chr22:40742427	ADSL	0.73	5.47	0.44	2.38e-7	Mammographic density (dense area);
TGCT	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg21951975	chr1:209979733	IRF6	0.66	5.69	0.45	8.77e-8	Cleft lip with or without cleft palate;
TGCT	cis	rs13064411	0.696	rs869343	chr3:113226705	C/T	cg10517650	chr3:113235015	CCDC52	-0.32	-4.45	-0.37	1.85e-5	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs74417235	0.684	rs13186731	chr5:154056002	C/T	cg08754654	chr5:154026448	NA	0.58	5.53	0.44	1.84e-7	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
TGCT	cis	rs2439831	0.867	rs3101443	chr15:43912372	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.84	5.46	0.44	2.5e-7	Lung cancer in ever smokers;
TGCT	cis	rs9522267	0.535	rs9515452	chr13:112234553	A/G	cg10483660	chr13:112241077	NA	-0.27	-4.61	-0.38	9.78e-6	Hepatitis;
TGCT	cis	rs933688	0.941	rs6452954	chr5:90735692	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.88	8.2	0.59	2.51e-13	Smoking behavior;
TGCT	cis	rs17741873	0.779	rs12572101	chr10:75600651	A/G	cg07699608	chr10:75541558	CHCHD1	0.75	5.44	0.44	2.7e-7	Paclitaxel disposition in epithelial ovarian cancer;
TGCT	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg10047753	chr17:41438598	NA	0.97	10.04	0.67	1.04e-17	Menopause (age at onset);
TGCT	cis	rs7744392	0.557	rs6919334	chr6:35341875	G/A	cg06087101	chr6:35551932	FKBP5	0.61	4.56	0.38	1.21e-5	Cataracts in type 2 diabetes;
TGCT	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	9.52	0.65	1.86e-16	Platelet count;
TGCT	cis	rs17345786	0.861	rs79181492	chr3:101216021	G/A	cg12386194	chr3:101231763	SENP7	0.65	6.39	0.5	3.06e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7926906	0.840	rs7926034	chr11:90514796	A/G	cg26138821	chr11:89956704	CHORDC1	-0.52	-5.55	-0.45	1.66e-7	Intelligence (multi-trait analysis);
TGCT	trans	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg17830980	chr10:43048298	ZNF37B	-0.87	-11.3	-0.71	8.5e-21	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7192750	0.652	rs150617	chr16:72139396	T/C	cg14768367	chr16:72042858	DHODH	0.86	4.51	0.38	1.47e-5	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg26338869	chr17:61819248	STRADA	-0.53	-4.87	-0.4	3.38e-6	Prudent dietary pattern;
TGCT	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg04267008	chr7:1944627	MAD1L1	-0.34	-4.49	-0.37	1.63e-5	Bipolar disorder and schizophrenia;
TGCT	cis	rs7804356	0.906	rs17323934	chr7:26904330	C/G	cg03456212	chr7:26904342	SKAP2	0.6	4.57	0.38	1.16e-5	Type 1 diabetes;
TGCT	cis	rs72945132	0.882	rs61177215	chr11:70129534	G/A	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs9611565	0.559	rs4822048	chr22:41988225	C/T	cg17554472	chr22:41940697	POLR3H	-0.52	-5.37	-0.43	3.79e-7	Vitiligo;
TGCT	cis	rs9522267	0.535	rs9522296	chr13:112234340	C/T	cg10483660	chr13:112241077	NA	0.27	4.61	0.38	9.72e-6	Hepatitis;
TGCT	cis	rs56399783	0.901	rs55767077	chr7:2774608	C/T	cg19731401	chr7:2775893	GNA12	0.36	5.07	0.41	1.4e-6	Childhood ear infection;
TGCT	cis	rs709400	0.598	rs11627529	chr14:104004557	C/T	cg26031613	chr14:104095156	KLC1	0.89	9.8	0.66	3.77e-17	Body mass index;
TGCT	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7666738	0.716	rs11721453	chr4:99045485	G/T	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7588654	0.793	rs16859517	chr2:219949184	A/G	cg19394737	chr2:219892361	CCDC108	0.35	4.55	0.38	1.27e-5	Height;
TGCT	cis	rs10876993	0.928	rs2640631	chr12:58067532	A/T	cg15848620	chr12:58087721	OS9	-0.73	-5.99	-0.47	2.12e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs8026198	0.568	rs58712247	chr15:42616288	C/CA	cg20699549	chr15:42567973	GANC	0.33	4.98	0.41	2.06e-6	Fibrinogen levels;
TGCT	cis	rs4906332	0.840	rs34161327	chr14:103857325	G/A	cg26031613	chr14:104095156	KLC1	-0.52	-4.77	-0.39	5.12e-6	Coronary artery disease;
TGCT	cis	rs6032067	0.561	rs2743317	chr20:43936931	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.32	-4.6	-0.38	1.02e-5	Blood protein levels;
TGCT	cis	rs941408	0.515	rs759067	chr19:2775668	C/T	cg06609049	chr19:2785107	THOP1	1.17	13.17	0.76	2.56e-25	Total cholesterol levels;
TGCT	cis	rs12039431	0.706	rs61605574	chr1:37973943	G/A	cg17933807	chr1:38061675	GNL2	-0.76	-7.21	-0.54	4.81e-11	Epithelial ovarian cancer;
TGCT	cis	rs13064411	0.696	rs7610638	chr3:113139656	A/G	cg10517650	chr3:113235015	CCDC52	-0.35	-4.63	-0.38	9.06e-6	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs2067615	0.579	rs1922438	chr12:107085171	C/G	cg15890332	chr12:107067104	RFX4	0.3	5.88	0.47	3.6e-8	Heart rate;
TGCT	cis	rs2302464	1.000	rs60913985	chr4:15728294	C/G	cg18497811	chr4:14860861	NA	-0.49	-4.5	-0.37	1.57e-5	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs12188164	0.965	rs11745789	chr5:450777	T/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.4	-4.71	-0.39	6.42e-6	Cystic fibrosis severity;
TGCT	cis	rs10089	0.953	rs114881127	chr5:127369661	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	6.93	0.53	2e-10	Ileal carcinoids;
TGCT	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg15462221	chr8:8086144	FLJ10661	-0.57	-5.29	-0.43	5.23e-7	Neuroticism;
TGCT	cis	rs28595532	0.844	rs116721336	chr4:119536538	A/G	cg11846333	chr4:119757529	SEC24D	0.93	5.08	0.42	1.32e-6	Cannabis dependence symptom count;
TGCT	cis	rs35146811	0.586	rs6946168	chr7:99598286	C/T	cg13334819	chr7:99746414	C7orf59	-0.77	-6.67	-0.51	7.61e-10	Coronary artery disease;
TGCT	cis	rs2742417	1.000	rs17328701	chr3:45734258	A/G	cg04837898	chr3:45731254	SACM1L	-0.55	-5.68	-0.45	9.14e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs1008375	1.000	rs7697889	chr4:17617961	G/T	cg10189774	chr4:17578691	LAP3	0.54	4.78	0.39	4.9100000000000004e-06	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4711350	0.954	rs1536500	chr6:33723383	T/C	cg18005901	chr6:33739558	LEMD2	-0.46	-4.96	-0.41	2.27e-6	Schizophrenia;
TGCT	cis	rs35160687	0.901	rs7571424	chr2:86539160	A/G	cg03171300	chr2:86307199	POLR1A	0.31	5.32	0.43	4.66e-7	Night sleep phenotypes;
TGCT	cis	rs2204008	0.774	rs11615665	chr12:38328162	T/A	cg13010199	chr12:38710504	ALG10B	0.58	4.55	0.38	1.26e-5	Bladder cancer;
TGCT	cis	rs459571	0.792	rs55923934	chr9:136888233	C/G	cg13789015	chr9:136890014	NCRNA00094	0.39	7.13	0.54	7.37e-11	Platelet distribution width;
TGCT	cis	rs7197653	0.667	rs7190070	chr16:68353983	C/T	cg05110241	chr16:68378359	PRMT7	-0.37	-4.5	-0.37	1.55e-5	Magnesium levels;
TGCT	cis	rs13191362	0.935	rs66635391	chr6:162964577	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.66	5.11	0.42	1.17e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg12570787	chr5:219185	SDHA;CCDC127	0.65	4.46	0.37	1.83e-5	Breast cancer;
TGCT	cis	rs11190604	1.000	rs2295770	chr10:102239829	G/A	cg16342193	chr10:102329863	NA	-0.4	-5.34	-0.43	4.36e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg08219700	chr8:58056026	NA	0.4	4.87	0.4	3.36e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7226408	0.857	rs72888928	chr18:34531073	C/T	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs9517320	0.534	rs3825430	chr13:99129653	C/T	cg07423050	chr13:99094983	FARP1	-0.28	-5.5	-0.44	2.06e-7	Longevity;
TGCT	cis	rs17030434	0.911	rs115948674	chr4:154742052	G/T	cg14289246	chr4:154710475	SFRP2	-0.9	-7.03	-0.53	1.2e-10	Electrocardiographic conduction measures;
TGCT	cis	rs6901250	0.569	rs621486	chr6:117089143	T/C	cg12892004	chr6:117198278	RFX6	0.37	4.77	0.39	5.09e-6	C-reactive protein levels;
TGCT	cis	rs861020	0.630	rs585627	chr1:210004199	C/G	cg05527609	chr1:210001259	C1orf107	0.86	7.54	0.56	8.69e-12	Orofacial clefts;
TGCT	cis	rs6912958	0.781	rs4334949	chr6:88290150	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-5.06	-0.41	1.45e-6	Monocyte percentage of white cells;
TGCT	cis	rs3617	0.573	rs4687682	chr3:52916939	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.48	-4.52	-0.38	1.41e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs350251	0.934	rs183008	chr16:12201691	C/T	cg01574788	chr16:12184133	SNX29	-0.35	-4.52	-0.38	1.45e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs12882406	0.607	rs4270088	chr14:23806190	A/G	cg16420801	chr14:23816088	SLC22A17	-0.29	-4.74	-0.39	5.8e-6	Body mass index;
TGCT	cis	rs6496667	0.642	rs62019395	chr15:91066309	G/T	cg22089800	chr15:90895588	ZNF774	0.64	4.49	0.37	1.62e-5	Rheumatoid arthritis;
TGCT	cis	rs12762955	0.507	rs10737004	chr10:1039019	T/C	cg18964960	chr10:1102726	WDR37	-0.68	-5.93	-0.47	2.77e-8	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	5.71	0.46	8.05e-8	Alzheimer's disease;
TGCT	cis	rs8016982	0.593	rs7160569	chr14:81713686	C/T	cg01989461	chr14:81687754	GTF2A1	0.76	7.5	0.56	1.09e-11	Schizophrenia;
TGCT	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg17554472	chr22:41940697	POLR3H	-0.49	-5.27	-0.43	5.9e-7	Vitiligo;
TGCT	cis	rs6545883	0.929	rs10200055	chr2:61628017	T/A	cg15711740	chr2:61764176	XPO1	0.53	4.7	0.39	6.67e-6	Tuberculosis;
TGCT	cis	rs12142240	0.770	rs112869704	chr1:46780285	C/T	cg00530320	chr1:46809349	NSUN4	0.25	4.81	0.4	4.3e-6	Menopause (age at onset);
TGCT	cis	rs57590327	0.503	rs7426937	chr3:81881360	T/C	cg07356753	chr3:81810745	GBE1	-0.65	-5.67	-0.45	9.68e-8	Extraversion;
TGCT	cis	rs35306767	0.953	rs10904583	chr10:983498	T/C	cg26597838	chr10:835615	NA	0.56	7.7	0.57	3.66e-12	Eosinophil percentage of granulocytes;
TGCT	cis	rs4294134	0.608	rs11760746	chr7:135244015	G/A	cg08396481	chr7:135194601	CNOT4	-0.62	-4.81	-0.4	4.25e-6	Paget's disease;
TGCT	cis	rs6088580	0.634	rs4911421	chr20:32998948	T/C	cg06115741	chr20:33292138	TP53INP2	-0.55	-4.81	-0.4	4.28e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs6582630	0.519	rs11514078	chr12:38408817	G/C	cg26384229	chr12:38710491	ALG10B	0.87	7.8	0.57	2.17e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs3796352	1.000	rs71301808	chr3:53085577	C/G	cg07884673	chr3:53033167	SFMBT1	0.58	5.99	0.47	2.11e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs9674544	0.646	rs8069452	chr17:47140999	A/G	cg20966754	chr17:47091339	IGF2BP1	0.42	4.96	0.41	2.25e-6	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
TGCT	cis	rs10493773	0.532	rs12064199	chr1:86187073	A/T	cg17807903	chr1:86174739	ZNHIT6	-0.52	-8.2	-0.59	2.63e-13	Urate levels in overweight individuals;
TGCT	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg10802521	chr3:52805072	NEK4	-0.73	-8.95	-0.63	4.37e-15	Electroencephalogram traits;
TGCT	cis	rs10197940	0.624	rs3771901	chr2:152432481	G/A	cg06191203	chr2:152266755	RIF1	-0.76	-7.24	-0.55	4.11e-11	Lung cancer;
TGCT	cis	rs2439831	0.867	rs2264876	chr15:43757419	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.01	8.18	0.59	2.83e-13	Lung cancer in ever smokers;
TGCT	cis	rs4494114	0.967	rs7532880	chr1:39297734	T/C	cg25970120	chr1:39325951	RRAGC	-0.66	-6.8	-0.52	3.99e-10	Blood protein levels;
TGCT	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg10802521	chr3:52805072	NEK4	-0.71	-8.79	-0.62	1.04e-14	Bipolar disorder;
TGCT	cis	rs7572733	0.534	rs700688	chr2:198723833	A/G	cg00792783	chr2:198669748	PLCL1	-0.55	-4.92	-0.4	2.68e-6	Dermatomyositis;
TGCT	cis	rs1215050	0.765	rs687795	chr4:98754912	C/G	cg05340658	chr4:99064831	C4orf37	0.44	5.52	0.44	1.85e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs3020736	0.500	rs7364293	chr22:42506370	C/T	cg05082376	chr22:42548792	NA	0.23	5.43	0.44	2.83e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	8.0	0.58	7.67e-13	Platelet count;
TGCT	cis	rs1878931	0.582	rs27232	chr16:3436782	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.76	-6.4	-0.5	2.83e-9	Body mass index (adult);
TGCT	cis	rs7666738	0.830	rs7697315	chr4:98938764	T/C	cg05340658	chr4:99064831	C4orf37	0.53	6.02	0.48	1.8e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg22618164	chr12:122356400	WDR66	0.66	6.28	0.49	5.32e-9	Mean corpuscular volume;
TGCT	cis	rs11098499	0.743	rs11098501	chr4:120252017	T/G	cg09307838	chr4:120376055	NA	0.61	5.91	0.47	3.14e-8	Corneal astigmatism;
TGCT	cis	rs9858542	0.953	rs34588335	chr3:49407660	G/C	cg03060546	chr3:49711283	APEH	-0.64	-5.61	-0.45	1.27e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs4654899	0.680	rs3890762	chr1:21198265	G/A	cg01072550	chr1:21505969	NA	0.55	8.93	0.63	4.85e-15	Superior frontal gyrus grey matter volume;
TGCT	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	6.94	0.53	1.9e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs526231	0.819	rs568999	chr5:102601358	G/C	cg05225461	chr5:102596755	C5orf30	0.23	4.62	0.38	9.51e-6	Primary biliary cholangitis;
TGCT	cis	rs6896969	0.510	rs7730306	chr5:40423257	C/A	cg01087697	chr5:40835557	RPL37	0.56	5.03	0.41	1.69e-6	Multiple sclerosis;
TGCT	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.07	0.82	4.17e-32	Prudent dietary pattern;
TGCT	cis	rs1801251	1.000	rs6761324	chr2:233582793	T/G	cg25237894	chr2:233734115	C2orf82	0.32	5.81	0.46	5.01e-8	Coronary artery disease;
TGCT	cis	rs523522	0.962	rs4767903	chr12:120930046	G/A	cg12219531	chr12:120966889	COQ5	0.83	7.27	0.55	3.46e-11	High light scatter reticulocyte count;
TGCT	cis	rs35146811	0.807	rs6465761	chr7:99620277	G/C	cg13334819	chr7:99746414	C7orf59	-0.81	-7.25	-0.55	3.95e-11	Coronary artery disease;
TGCT	cis	rs2243480	0.666	rs1880311	chr7:65276752	G/C	cg20637647	chr7:64974828	NA	-0.96	-4.95	-0.41	2.4e-6	Diabetic kidney disease;
TGCT	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	6.13	0.48	1.06e-8	Bipolar disorder;
TGCT	cis	rs2201728	1.000	rs6818892	chr4:100158920	G/C	cg07219303	chr4:100140905	ADH6	-0.35	-5.22	-0.42	7.29e-7	Cardiac Troponin-T levels;
TGCT	cis	rs10088262	0.540	rs6988602	chr8:124788502	C/T	cg20713898	chr8:124780851	FAM91A1	0.78	5.43	0.44	2.84e-7	Pancreatic cancer;
TGCT	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg26119090	chr2:26468346	HADHA;HADHB	0.97	7.19	0.54	5.48e-11	Gut microbiome composition (summer);
TGCT	cis	rs514406	0.929	rs12145105	chr1:53340564	T/C	cg08859206	chr1:53392774	SCP2	-0.4	-6.07	-0.48	1.47e-8	Monocyte count;
TGCT	cis	rs7296418	0.738	rs10846489	chr12:123743927	A/G	cg00376283	chr12:123451042	ABCB9	-0.74	-6.67	-0.51	7.62e-10	Platelet count;
TGCT	cis	rs13242816	1.000	rs13235720	chr7:116113663	T/C	cg02799643	chr7:116139180	CAV2	-0.48	-5.52	-0.44	1.87e-7	P wave duration;
TGCT	cis	rs17376456	0.877	rs7734897	chr5:93305402	G/A	cg25358565	chr5:93447407	FAM172A	0.98	8.39	0.6	9.01e-14	Diabetic retinopathy;
TGCT	cis	rs861020	0.630	rs686582	chr1:210008673	A/C	cg05527609	chr1:210001259	C1orf107	0.89	8.36	0.6	1.08e-13	Orofacial clefts;
TGCT	cis	rs13191362	1.000	rs13207671	chr6:162979056	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.57	4.94	0.41	2.45e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs651907	0.535	rs12631513	chr3:101517476	A/C	cg12386194	chr3:101231763	SENP7	0.48	4.81	0.4	4.36e-6	Colorectal cancer;
TGCT	cis	rs7666738	0.609	rs35214820	chr4:98864692	G/A	cg24818145	chr4:99064322	C4orf37	0.53	4.52	0.38	1.41e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs832540	0.629	rs10940512	chr5:56082094	G/C	cg12311346	chr5:56204834	C5orf35	-0.47	-4.79	-0.4	4.6e-6	Coronary artery disease;
TGCT	cis	rs3751972	0.590	rs71372355	chr17:26265885	C/A	cg02948944	chr17:26242737	NA	-0.46	-5.6	-0.45	1.31e-7	Fractional exhaled nitric oxide (childhood);
TGCT	trans	rs4650994	1.000	rs17276527	chr1:178520680	G/A	cg05059571	chr16:84539110	KIAA1609	-0.4	-7.43	-0.56	1.54e-11	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs4819052	0.565	rs35776291	chr21:46706142	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.64	6.31	0.49	4.59e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg22535103	chr8:58192502	C8orf71	-0.42	-4.79	-0.4	4.7e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs950169	1.000	rs12902672	chr15:84716986	G/A	cg11189052	chr15:85197271	WDR73	0.7	5.94	0.47	2.64e-8	Schizophrenia;
TGCT	cis	rs916888	0.610	rs199438	chr17:44791643	G/A	cg01570182	chr17:44337453	NA	0.74	7.02	0.53	1.29e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg00814883	chr7:100076585	TSC22D4	-0.91	-9.48	-0.65	2.3e-16	Platelet count;
TGCT	cis	rs2412208	0.545	rs2275910	chr1:7068679	A/G	cg09549827	chr1:6484616	ESPN	0.27	4.72	0.39	6.38e-6	Survival in sporadic amyotrophic lateral sclerosis;
TGCT	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg00024416	chr22:24240387	NA	-0.25	-4.71	-0.39	6.61e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs3845702	0.736	rs16867131	chr2:180848651	A/G	cg01881094	chr2:180872142	CWC22	-0.99	-6.3	-0.49	4.76e-9	Schizophrenia;
TGCT	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg03188948	chr7:1209495	NA	0.47	5.65	0.45	1.04e-7	Longevity;Endometriosis;
TGCT	cis	rs6912958	0.514	rs1980792	chr6:87889917	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.66	-6.67	-0.51	7.5e-10	Monocyte percentage of white cells;
TGCT	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg24531977	chr5:56204891	C5orf35	0.5	5.08	0.42	1.35e-6	Type 2 diabetes;
TGCT	cis	rs1153858	1.000	rs2056493	chr15:45648272	A/G	cg26924012	chr15:45694286	SPATA5L1	1.08	15.28	0.81	2.78e-30	Homoarginine levels;
TGCT	cis	rs13256369	0.802	rs13281933	chr8:8562665	C/A	cg18904891	chr8:8559673	CLDN23	0.58	5.4	0.44	3.23e-7	Obesity-related traits;
TGCT	cis	rs12477438	0.501	rs12613624	chr2:99732741	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.05	-14.89	-0.8	2.21e-29	Chronic sinus infection;
TGCT	cis	rs7666738	0.830	rs7657179	chr4:98948569	G/A	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4285028	0.699	rs6771068	chr3:121478745	A/T	cg01951420	chr3:121553821	IQCB1;EAF2	1.03	8.69	0.62	1.84e-14	Multiple sclerosis;
TGCT	cis	rs9398235	0.673	rs2073210	chr6:110729973	A/C	cg19196401	chr6:110721138	DDO	-0.46	-4.47	-0.37	1.77e-5	Systemic lupus erythematosus;
TGCT	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg03188948	chr7:1209495	NA	0.43	5.56	0.45	1.6e-7	Longevity;Endometriosis;
TGCT	cis	rs877282	0.898	rs11253347	chr10:765769	A/G	cg17470449	chr10:769945	NA	0.37	5.59	0.45	1.37e-7	Uric acid levels;
TGCT	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs3796352	1.000	rs71301808	chr3:53085577	C/G	cg15956490	chr3:53032818	SFMBT1	0.57	6.52	0.51	1.59e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs1976403	0.633	rs1780324	chr1:21821757	A/G	cg17800788	chr1:21766015	NBPF3	0.25	4.58	0.38	1.1e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs561341	1.000	rs55643307	chr17:30263074	T/C	cg20587970	chr11:113659929	NA	-0.9	-7.84	-0.58	1.78e-12	Hip circumference adjusted for BMI;
TGCT	cis	rs9787249	0.874	rs7520588	chr1:40214525	T/A	cg19912559	chr1:40204330	PPIE	0.49	5.7	0.46	8.41e-8	Blood protein levels;
TGCT	cis	rs7010267	0.740	rs11573885	chr8:119949165	T/C	cg17171407	chr8:119960777	TNFRSF11B	-0.25	-4.44	-0.37	2e-5	Total body bone mineral density (age 45-60);
TGCT	cis	rs7226408	0.857	rs72887089	chr18:34506836	C/T	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs10193935	0.901	rs6727657	chr2:42632117	A/G	cg27598129	chr2:42591480	NA	-0.37	-5.23	-0.42	7.1e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11671005	0.735	rs3764529	chr19:58945089	A/G	cg13877915	chr19:58951672	ZNF132	0.63	5.0	0.41	1.95e-6	Mean platelet volume;
TGCT	cis	rs11676348	0.755	rs13410318	chr2:219022910	T/G	cg00012203	chr2:219082015	ARPC2	0.54	5.2	0.42	7.86e-7	Ulcerative colitis;
TGCT	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.54	-5.17	-0.42	9.07e-7	Menarche (age at onset);
TGCT	cis	rs9611565	0.546	rs132793	chr22:42063681	A/G	cg03806693	chr22:41940476	POLR3H	1.06	11.07	0.71	3.09e-20	Vitiligo;
TGCT	cis	rs709400	0.628	rs72708854	chr14:103864885	T/C	cg26031613	chr14:104095156	KLC1	0.85	9.32	0.64	5.54e-16	Body mass index;
TGCT	trans	rs66573146	1.000	rs6812771	chr4:6964048	G/A	cg07817883	chr1:32538562	TMEM39B	1.56	8.31	0.6	1.45e-13	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs4363385	0.510	rs6677674	chr1:153037601	A/G	cg04546999	chr1:152956429	SPRR1A	-0.26	-4.63	-0.38	9.15e-6	Inflammatory skin disease;
TGCT	cis	rs2115630	1.000	rs11854291	chr15:85363708	T/C	cg11189052	chr15:85197271	WDR73	-0.62	-5.89	-0.47	3.35e-8	P wave terminal force;
TGCT	cis	rs617219	0.737	rs13158309	chr5:78463395	C/T	cg23987322	chr5:78407566	BHMT	-0.36	-4.83	-0.4	4.01e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs12477438	0.798	rs972768	chr2:99682397	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-5.87	-0.47	3.74e-8	Chronic sinus infection;
TGCT	cis	rs11031096	0.628	rs10835735	chr11:4211865	G/C	cg18678763	chr11:4115507	RRM1	-0.45	-5.83	-0.46	4.41e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs2204008	0.580	rs36118148	chr12:38411812	G/A	cg26384229	chr12:38710491	ALG10B	-0.54	-4.81	-0.4	4.32e-6	Bladder cancer;
TGCT	cis	rs7647973	0.593	rs7652179	chr3:49808618	T/A	cg05785598	chr3:49045655	WDR6	-0.42	-4.88	-0.4	3.23e-6	Menarche (age at onset);
TGCT	cis	rs1865760	0.551	rs9461230	chr6:26019240	G/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.78	7.55	0.56	8.31e-12	Height;
TGCT	cis	rs7809950	0.678	rs7788330	chr7:106985648	G/T	cg23024343	chr7:107201750	COG5	-0.43	-5.85	-0.47	4.12e-8	Coronary artery disease;
TGCT	cis	rs7647973	1.000	rs2140270	chr3:49439440	A/G	cg05785598	chr3:49045655	WDR6	-0.4	-4.67	-0.39	7.57e-6	Menarche (age at onset);
TGCT	cis	rs9393777	0.513	rs1104871	chr6:26665235	T/G	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.5	-4.72	-0.39	6.15e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7258465	1.000	rs8103622	chr19:18572834	C/T	cg06462663	chr19:18546047	ISYNA1	0.21	4.63	0.38	9.14e-6	Breast cancer;
TGCT	cis	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg17143192	chr8:8559678	CLDN23	0.54	5.09	0.42	1.31e-6	Obesity-related traits;
TGCT	cis	rs7666738	0.830	rs13124904	chr4:98856973	T/C	cg17366294	chr4:99064904	C4orf37	0.7	7.27	0.55	3.62e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7635838	0.684	rs2594965	chr3:11323799	G/C	cg00170343	chr3:11313890	ATG7	0.64	6.35	0.5	3.65e-9	HDL cholesterol;
TGCT	cis	rs1670533	1.000	rs11731320	chr4:1057916	T/A	cg27284194	chr4:1044797	NA	0.67	5.79	0.46	5.37e-8	Recombination rate (females);
TGCT	cis	rs2380220	0.541	rs72928283	chr6:96082490	A/C	cg04719120	chr6:96025338	MANEA	-0.69	-5.11	-0.42	1.18e-6	Behavioural disinhibition (generation interaction);
TGCT	trans	rs797680	0.856	rs687394	chr1:93713917	G/A	cg27528825	chr2:159282178	CCDC148	0.35	6.88	0.53	2.65e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs9326248	0.817	rs1242127	chr11:117076564	A/G	cg11861562	chr11:117069780	TAGLN	-0.28	-4.57	-0.38	1.17e-5	Blood protein levels;
TGCT	cis	rs9916302	0.904	rs6503519	chr17:37706578	A/G	cg15445000	chr17:37608096	MED1	0.31	4.5	0.37	1.53e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs4372836	1.000	rs4549034	chr2:28972579	C/T	cg09522027	chr2:28974177	PPP1CB	-0.59	-5.15	-0.42	1e-6	Body mass index;
TGCT	cis	rs319204	0.877	rs640656	chr5:146287119	G/A	cg25021259	chr5:146258546	PPP2R2B	0.35	4.52	0.38	1.4e-5	Schizophrenia;
TGCT	trans	rs9348739	1	rs9348739	chr6:26923099	G/C	cg15633603	chr2:190399258	NA	0.4	6.95	0.53	1.81e-10	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs8180040	0.726	rs4078466	chr3:47126543	C/T	cg27129171	chr3:47204927	SETD2	0.76	9.8	0.66	3.91e-17	Colorectal cancer;
TGCT	cis	rs1629083	0.967	rs1715456	chr11:118123517	A/G	cg16594165	chr11:118135105	MPZL2	-0.34	-4.75	-0.39	5.6e-6	Lung cancer;
TGCT	cis	rs9300255	0.568	rs1790102	chr12:123704890	G/A	cg00376283	chr12:123451042	ABCB9	0.73	5.67	0.45	9.46e-8	Neutrophil percentage of white cells;
TGCT	cis	rs806215	0.526	rs114283033	chr7:127530017	G/A	cg11539674	chr7:127291444	SND1	-0.36	-4.65	-0.39	8.46e-6	Type 2 diabetes;
TGCT	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg06212747	chr3:49208901	KLHDC8B	0.65	6.23	0.49	6.72e-9	Menarche (age at onset);
TGCT	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg12311346	chr5:56204834	C5orf35	-0.67	-6.77	-0.52	4.59e-10	Initial pursuit acceleration;
TGCT	cis	rs13191362	0.935	rs35942036	chr6:163163297	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.96	7.62	0.56	5.6e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs11209002	0.614	rs7552205	chr1:67551741	C/A	cg02640540	chr1:67518911	SLC35D1	0.55	4.65	0.39	8.42e-6	Crohn's disease;
TGCT	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg11644478	chr21:40555479	PSMG1	1.03	11.02	0.7	4.14e-20	Cognitive function;
TGCT	trans	rs1814175	0.781	rs28681334	chr11:50051177	C/T	cg03929089	chr4:120376271	NA	-0.72	-8.55	-0.61	3.8e-14	Height;
TGCT	cis	rs4253772	0.591	rs739165	chr22:46684528	C/T	cg24881330	chr22:46731750	TRMU	1.04	5.38	0.44	3.54e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg03188948	chr7:1209495	NA	0.46	6.15	0.48	9.9e-9	Longevity;Endometriosis;
TGCT	cis	rs78487399	0.808	rs10189235	chr2:43745520	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-4.87	-0.4	3.28e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs7208859	0.524	rs59913838	chr17:29101563	A/T	cg13385521	chr17:29058706	SUZ12P	0.82	4.86	0.4	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs35146811	0.625	rs858514	chr7:99825748	A/G	cg04778012	chr7:99775508	STAG3;GPC2	-0.36	-5.1	-0.42	1.22e-6	Coronary artery disease;
TGCT	cis	rs6570726	0.599	rs455001	chr6:145854450	A/T	cg23711669	chr6:146136114	FBXO30	0.7	6.44	0.5	2.41e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10782582	0.609	rs2029680	chr1:76363505	A/C	cg10523679	chr1:76189770	ACADM	-0.58	-5.31	-0.43	4.92e-7	Daytime sleep phenotypes;
TGCT	cis	rs2115630	0.967	rs7171167	chr15:85239123	A/T	cg11189052	chr15:85197271	WDR73	-0.66	-6.45	-0.5	2.24e-9	P wave terminal force;
TGCT	cis	rs263156	1.000	rs263156	chr6:142907515	T/G	cg18419694	chr6:143832440	FUCA2	-0.4	-4.65	-0.39	8.22e-6	Ear morphology;Lobe size;Lobe attachment;
TGCT	cis	rs7107174	0.688	rs2063724	chr11:78133077	T/C	cg12700464	chr11:78128424	GAB2	-0.69	-4.6	-0.38	1.03e-5	Testicular germ cell tumor;
TGCT	cis	rs7666738	0.830	rs1876192	chr4:98727555	T/C	cg05340658	chr4:99064831	C4orf37	0.49	5.77	0.46	6.02e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs483180	0.531	rs541503	chr1:120208297	A/G	cg19096424	chr1:120255104	PHGDH	-0.57	-5.35	-0.43	4.02e-7	Macular telangiectasia type 2;
TGCT	cis	rs6940638	0.531	rs12211984	chr6:26986054	G/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.4	4.47	0.37	1.76e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs33794	0.901	rs33780	chr3:45289715	C/T	cg18645101	chr3:44551900	NA	0.55	4.82	0.4	4.08e-6	Lung function (forced expiratory volume in 1 second);
TGCT	cis	rs2594989	0.887	rs2442797	chr3:11555935	C/T	cg26283222	chr3:11613257	VGLL4	-0.25	-5.35	-0.43	4.07e-7	Circulating chemerin levels;
TGCT	cis	rs17331151	0.512	rs9637477	chr3:52891426	G/C	cg07884673	chr3:53033167	SFMBT1	-0.5	-5.77	-0.46	5.86e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs34779708	0.931	rs35126129	chr10:35452141	G/A	cg04310649	chr10:35416472	CREM	-0.53	-4.71	-0.39	6.66e-6	Inflammatory bowel disease;Crohn's disease;
TGCT	trans	rs10953454	1.000	rs10216243	chr7:104513624	G/T	cg04208666	chr6:19734707	NA	-0.57	-6.89	-0.53	2.54e-10	Obesity;
TGCT	cis	rs9581857	0.725	rs117947621	chr13:28022267	T/C	cg22138327	chr13:27999177	GTF3A	0.78	5.57	0.45	1.51e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs9467773	0.583	rs1021373	chr6:26632457	G/A	cg15659132	chr6:26577336	NA	0.86	11.04	0.7	3.71e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs7772486	0.720	rs7752286	chr6:146072662	C/T	cg05347473	chr6:146136440	FBXO30	-0.54	-4.95	-0.41	2.33e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7267979	0.844	rs1555330	chr20:25232097	A/C	cg03522245	chr20:25566470	NINL	0.57	5.67	0.45	9.54e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	4.97	0.41	2.14e-6	Menopause (age at onset);
TGCT	cis	rs4919694	0.901	rs10509763	chr10:104776391	G/A	cg04362960	chr10:104952993	NT5C2	1.06	7.05	0.53	1.09e-10	Arsenic metabolism;
TGCT	cis	rs1008375	0.966	rs4698619	chr4:17580955	G/A	cg10189774	chr4:17578691	LAP3	0.64	5.61	0.45	1.28e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg02725872	chr8:58115012	NA	-0.38	-5.16	-0.42	9.32e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs698833	0.509	rs6715202	chr2:44516282	A/G	cg23552047	chr2:44669647	C2orf34	0.29	4.65	0.39	8.25e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
TGCT	cis	rs10883723	0.738	rs715438	chr10:104258303	C/T	cg05855489	chr10:104503620	C10orf26	-0.58	-5.06	-0.41	1.47e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs11671005	0.616	rs12980907	chr19:58956326	C/T	cg13877915	chr19:58951672	ZNF132	0.62	4.89	0.4	3.06e-6	Mean platelet volume;
TGCT	cis	rs8062405	1.000	rs62037364	chr16:28868695	G/A	cg09754948	chr16:28834200	ATXN2L	0.59	4.45	0.37	1.91e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs10883723	0.703	rs7898410	chr10:104245858	T/C	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs319204	1.000	rs561789	chr5:146242078	C/G	cg25021259	chr5:146258546	PPP2R2B	0.36	4.53	0.38	1.37e-5	Schizophrenia;
TGCT	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg13695892	chr22:41940480	POLR3H	-0.89	-9.04	-0.63	2.61e-15	Vitiligo;
TGCT	cis	rs28595532	0.668	rs56410164	chr4:119331625	A/G	cg11846333	chr4:119757529	SEC24D	0.72	4.51	0.38	1.48e-5	Cannabis dependence symptom count;
TGCT	cis	rs1008375	0.897	rs2315554	chr4:17660407	T/C	cg18681998	chr4:17616180	MED28	0.96	10.34	0.68	1.84e-18	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs5760092	0.755	rs3884794	chr22:24251766	C/A	cg20007245	chr22:24372913	LOC391322	-0.78	-6.92	-0.53	2.19e-10	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	trans	rs10953454	1.000	rs10262655	chr7:104480132	G/T	cg04208666	chr6:19734707	NA	-0.57	-6.89	-0.53	2.52e-10	Obesity;
TGCT	cis	rs4746818	0.892	rs2394505	chr10:70871598	A/G	cg04149295	chr10:70884716	VPS26A	-0.68	-4.56	-0.38	1.19e-5	Left atrial antero-posterior diameter;
TGCT	cis	rs17152411	0.895	rs11245420	chr10:126586469	T/C	cg07906193	chr10:126599966	NA	0.41	5.05	0.41	1.52e-6	Height;
TGCT	cis	rs2013441	1.000	rs972966	chr17:20030992	G/C	cg18979559	chr17:20280153	CCDC144C	0.46	4.83	0.4	3.92e-6	Obesity-related traits;
TGCT	cis	rs17539620	0.624	rs7770107	chr6:154836862	A/G	cg20019720	chr6:154832845	CNKSR3	0.57	5.02	0.41	1.72e-6	Lipoprotein (a) levels;
TGCT	cis	rs3821902	0.646	rs55955229	chr3:64015425	T/C	cg22134162	chr3:63841271	THOC7	-0.32	-4.85	-0.4	3.7e-6	Breast cancer;
TGCT	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg18402987	chr7:1209562	NA	0.67	5.93	0.47	2.77e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9914544	0.933	rs11871889	chr17:18771425	T/C	cg26306683	chr17:18585705	ZNF286B	0.57	5.08	0.41	1.36e-6	Educational attainment (years of education);
TGCT	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg09323728	chr8:95962352	TP53INP1	-0.54	-6.89	-0.53	2.54e-10	Type 2 diabetes;
TGCT	cis	rs782590	0.783	rs7594279	chr2:55812073	T/G	cg03859395	chr2:55845619	SMEK2	0.91	11.16	0.71	1.9e-20	Metabolic syndrome;
TGCT	cis	rs13242816	0.881	rs35037267	chr7:116117587	A/T	cg02799643	chr7:116139180	CAV2	-0.49	-5.61	-0.45	1.27e-7	P wave duration;
TGCT	cis	rs12580194	0.556	rs61249728	chr12:55728922	A/G	cg10672482	chr12:55725839	OR6C3	-0.56	-4.89	-0.4	3.1e-6	Cancer;
TGCT	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	9.52	0.65	1.86e-16	Platelet count;
TGCT	cis	rs17376456	0.825	rs28534784	chr5:93063332	C/A	cg21475434	chr5:93447410	FAM172A	0.66	5.15	0.42	9.97e-7	Diabetic retinopathy;
TGCT	cis	rs76473307	1.000	rs6026538	chr20:57389420	C/T	cg06163629	chr20:57414884	GNASAS;GNAS	0.62	4.65	0.39	8.25e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs7975161	0.572	rs7299669	chr12:104568919	C/T	cg25273343	chr12:104657179	TXNRD1	-0.44	-5.61	-0.45	1.26e-7	Toenail selenium levels;
TGCT	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg11062466	chr8:58055876	NA	0.44	4.68	0.39	7.38e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg20887711	chr4:1340912	KIAA1530	-0.71	-6.43	-0.5	2.45e-9	Obesity-related traits;
TGCT	cis	rs4803455	0.565	rs11670143	chr19:41864971	A/G	cg09537434	chr19:41945824	ATP5SL	-0.54	-5.28	-0.43	5.66e-7	Migraine;Coronary artery disease;
TGCT	cis	rs6657613	0.903	rs9435734	chr1:17311190	A/G	cg21692666	chr1:17199302	NA	-0.42	-4.54	-0.38	1.31e-5	Hip circumference adjusted for BMI;
TGCT	cis	rs2710642	0.849	rs4671450	chr2:62981869	C/A	cg17519650	chr2:63277830	OTX1	-0.58	-5.06	-0.41	1.48e-6	LDL cholesterol levels;LDL cholesterol;
TGCT	cis	rs2933343	0.630	rs75824035	chr3:128652985	T/C	cg11901034	chr3:128598214	ACAD9	-0.67	-6.43	-0.5	2.46e-9	IgG glycosylation;
TGCT	cis	rs9972944	0.702	rs6416947	chr17:63763970	C/A	cg07283582	chr17:63770753	CCDC46	-0.26	-5.29	-0.43	5.45e-7	Total body bone mineral density;
TGCT	cis	rs372883	0.648	rs1153291	chr21:30689070	G/T	cg24692254	chr21:30365293	RNF160	-0.53	-4.64	-0.38	8.82e-6	Pancreatic cancer;
TGCT	cis	rs644148	0.730	rs2686766	chr19:44991595	T/G	cg15540054	chr19:45004280	ZNF180	-0.61	-4.49	-0.37	1.62e-5	Personality dimensions;
TGCT	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg09436375	chr6:42928200	GNMT	-0.4	-5.16	-0.42	9.7e-7	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9303401	0.659	rs7224276	chr17:56897827	C/T	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs42648	0.617	rs11563435	chr7:89900207	A/C	cg25739043	chr7:89950458	NA	-0.55	-5.12	-0.42	1.13e-6	Homocysteine levels;
TGCT	cis	rs7824557	0.606	rs2736270	chr8:11192593	G/A	cg21775007	chr8:11205619	TDH	0.73	6.97	0.53	1.68e-10	Retinal vascular caliber;
TGCT	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg23719950	chr11:63933701	MACROD1	-0.7	-5.91	-0.47	3.09e-8	Mean platelet volume;
TGCT	cis	rs3087591	0.960	rs2905794	chr17:29470002	G/A	cg24425628	chr17:29625626	OMG;NF1	0.49	7.74	0.57	2.97e-12	Hip circumference;
TGCT	cis	rs7223966	1.000	rs13380863	chr17:61780793	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	4.6	0.38	1.04e-5	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg20276088	chr3:133502917	NA	-0.3	-6.27	-0.49	5.42e-9	Iron status biomarkers;
TGCT	cis	rs72781680	0.898	rs12623316	chr2:24087857	A/G	cg08917208	chr2:24149416	ATAD2B	0.77	4.69	0.39	7.06e-6	Lymphocyte counts;
TGCT	cis	rs9341808	0.718	rs10080237	chr6:80854470	T/C	cg08355045	chr6:80787529	NA	0.32	5.83	0.46	4.48e-8	Sitting height ratio;
TGCT	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg04632378	chr13:21900426	NA	0.43	5.04	0.41	1.6e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	cis	rs12497850	0.931	rs13064911	chr3:48952385	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.42	-5.52	-0.44	1.93e-7	Parkinson's disease;
TGCT	cis	rs6918586	0.636	rs198817	chr6:26126524	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.68	-6.46	-0.5	2.13e-9	Schizophrenia;
TGCT	cis	rs1532993	0.518	rs1508461	chr4:98582199	T/A	cg05340658	chr4:99064831	C4orf37	-0.41	-4.8	-0.4	4.45e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs858239	0.601	rs929507	chr7:23166664	G/C	cg05602783	chr7:23145260	KLHL7	-0.65	-5.48	-0.44	2.32e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs6840360	0.571	rs62327274	chr4:152548012	C/T	cg17479576	chr4:152424074	FAM160A1	-0.71	-7.72	-0.57	3.41e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs897984	0.683	rs13337900	chr16:30822409	G/A	cg02466173	chr16:30829666	NA	-0.28	-4.65	-0.39	8.2e-6	Dementia with Lewy bodies;
TGCT	cis	rs7208859	0.524	rs11653098	chr17:29122501	C/T	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7681440	0.904	rs28750169	chr4:90774303	A/G	cg26578617	chr4:90757533	SNCA	-0.46	-4.73	-0.39	6.01e-6	Dementia with Lewy bodies;
TGCT	cis	rs2832191	0.791	rs2832197	chr21:30497790	T/C	cg08807101	chr21:30365312	RNF160	-0.62	-5.8	-0.46	5.14e-8	Dental caries;
TGCT	cis	rs7267979	0.966	rs2482923	chr20:25308981	T/C	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg16049864	chr8:95962084	TP53INP1	-0.77	-10.92	-0.7	7.16e-20	Type 2 diabetes;
TGCT	cis	rs4927850	0.501	rs9881504	chr3:195656614	A/G	cg12923728	chr3:195709715	SDHAP1	-0.26	-4.96	-0.41	2.31e-6	Pancreatic cancer;
TGCT	cis	rs6558174	0.965	rs6558172	chr8:22492052	C/T	cg03733263	chr8:22462867	KIAA1967	0.62	4.96	0.41	2.26e-6	Breast cancer;
TGCT	cis	rs921968	0.573	rs684776	chr2:219324016	T/C	cg02176678	chr2:219576539	TTLL4	0.49	6.82	0.52	3.62e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs6490294	0.904	rs11066098	chr12:112388128	A/T	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Mean platelet volume;
TGCT	cis	rs11718455	0.960	rs34241796	chr3:44000394	A/T	cg08738300	chr3:44038990	NA	0.83	6.19	0.49	8.13e-9	Coronary artery disease;
TGCT	cis	rs2153535	0.580	rs9328483	chr6:8521295	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.55e-8	Motion sickness;
TGCT	cis	rs11785400	0.963	rs6990126	chr8:143728387	T/C	cg10596483	chr8:143751796	JRK	0.54	5.84	0.46	4.34e-8	Schizophrenia;
TGCT	cis	rs595982	0.527	rs73061658	chr19:49372376	G/C	cg15549821	chr19:49342101	PLEKHA4	-0.69	-9.16	-0.64	1.35e-15	Red cell distribution width;
TGCT	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7246657	0.943	rs7255952	chr19:37988797	A/G	cg18154014	chr19:37997991	ZNF793	0.8	5.47	0.44	2.33e-7	Coronary artery calcification;
TGCT	cis	rs2836974	0.831	rs4375956	chr21:40521788	G/A	cg11890956	chr21:40555474	PSMG1	1.11	12.1	0.74	9.93e-23	Cognitive function;
TGCT	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg11141652	chr22:24348549	GSTTP1	-0.35	-4.85	-0.4	3.67e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg03188948	chr7:1209495	NA	0.45	5.88	0.47	3.56e-8	Longevity;Endometriosis;
TGCT	cis	rs17270561	0.887	rs717551	chr6:25855624	T/C	cg16482183	chr6:26056742	HIST1H1C	0.86	5.62	0.45	1.2e-7	Iron status biomarkers;
TGCT	cis	rs2762353	0.574	rs9467570	chr6:25699283	C/A	cg15691649	chr6:25882328	NA	0.51	5.98	0.47	2.2e-8	Blood metabolite levels;
TGCT	cis	rs6977660	0.714	rs10251774	chr7:19790489	T/C	cg05791153	chr7:19748676	TWISTNB	0.88	5.05	0.41	1.52e-6	Thyroid stimulating hormone;
TGCT	cis	rs7552404	0.924	rs114752222	chr1:76180878	C/T	cg10523679	chr1:76189770	ACADM	0.9	9.92	0.67	2e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7635838	0.892	rs7372723	chr3:11466511	G/A	cg00170343	chr3:11313890	ATG7	0.66	6.25	0.49	6.1e-9	HDL cholesterol;
TGCT	cis	rs4144743	1.000	rs4144744	chr17:45323262	A/G	cg18085866	chr17:45331354	ITGB3	-0.72	-4.8	-0.4	4.39e-6	Body mass index;
TGCT	cis	rs10892173	0.566	rs10892174	chr11:117672565	A/C	cg07621104	chr11:117668040	DSCAML1	0.73	7.95	0.58	9.58e-13	Myopia;
TGCT	cis	rs9435341	0.929	rs1762509	chr1:107592959	A/G	cg09367891	chr1:107599246	PRMT6	-0.64	-5.5	-0.44	2.07e-7	Facial morphology (factor 21, depth of nasal alae);
TGCT	cis	rs208520	0.690	rs4710311	chr6:66823223	C/T	cg07460842	chr6:66804631	NA	-0.86	-8.29	-0.6	1.54e-13	Exhaled nitric oxide output;
TGCT	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg00149659	chr3:10157352	C3orf10	-0.94	-6.0	-0.47	2e-8	Alzheimer's disease;
TGCT	cis	rs2836633	0.929	rs2836602	chr21:40039169	A/T	cg05519781	chr21:40033154	ERG	-0.68	-6.71	-0.52	6.27e-10	Coronary artery disease;
TGCT	cis	rs5769707	0.632	rs135877	chr22:50014002	A/G	cg05373962	chr22:49881684	NA	-0.29	-4.92	-0.4	2.7e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2228479	0.702	rs62056087	chr16:89920383	C/A	cg06558623	chr16:89946397	TCF25	0.55	4.86	0.4	3.55e-6	Skin colour saturation;
TGCT	cis	rs4819052	0.679	rs2255761	chr21:46683622	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.62	6.01	0.47	1.93e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs66823261	0.778	rs2906332	chr8:194943	C/T	cg27532244	chr8:182981	ZNF596;RPL23AP53	-0.89	-7.16	-0.54	6.2e-11	Breast cancer (estrogen-receptor negative);Breast cancer;
TGCT	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg18876405	chr7:65276391	NA	-0.32	-4.82	-0.4	4.1e-6	Aortic root size;
TGCT	cis	rs3008870	1.000	rs1137656	chr1:67451602	A/C	cg08660285	chr1:67390436	MIER1;WDR78	-1.1	-11.8	-0.73	5.15e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs7804356	1.000	rs3801842	chr7:26830263	C/T	cg03456212	chr7:26904342	SKAP2	-0.63	-4.88	-0.4	3.19e-6	Type 1 diabetes;
TGCT	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg10047753	chr17:41438598	NA	0.76	6.86	0.52	2.95e-10	Menopause (age at onset);
TGCT	cis	rs7647973	0.626	rs11720705	chr3:49753788	A/G	cg05785598	chr3:49045655	WDR6	0.42	5.24	0.43	6.67e-7	Menarche (age at onset);
TGCT	cis	rs2204008	0.502	rs2387275	chr12:38142836	G/A	cg13010199	chr12:38710504	ALG10B	0.69	5.38	0.43	3.59e-7	Bladder cancer;
TGCT	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	15.94	0.82	8.5e-32	Prudent dietary pattern;
TGCT	cis	rs7647973	1.000	rs2312462	chr3:49601255	A/G	cg05785598	chr3:49045655	WDR6	0.38	4.65	0.39	8.31e-6	Menarche (age at onset);
TGCT	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg23758822	chr17:41437982	NA	0.72	6.91	0.53	2.23e-10	Menopause (age at onset);
TGCT	cis	rs2721195	0.549	rs2958492	chr8:145919126	C/T	cg12270520	chr8:146023939	ZNF517	0.5	4.44	0.37	1.94e-5	Age at first birth;
TGCT	cis	rs12142240	0.698	rs6690075	chr1:46819848	G/A	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs9325144	0.600	rs61931871	chr12:38829889	G/A	cg26384229	chr12:38710491	ALG10B	-0.57	-5.12	-0.42	1.14e-6	Morning vs. evening chronotype;
TGCT	trans	rs9951602	0.512	rs9946115	chr18:76654531	A/C	cg02800362	chr5:177631904	HNRNPAB	1.13	12.84	0.76	1.57e-24	Obesity-related traits;
TGCT	cis	rs2180341	0.574	rs13192350	chr6:127677762	G/T	cg24812749	chr6:127587940	RNF146	0.62	5.14	0.42	1.04e-6	Breast cancer;
TGCT	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg05665937	chr4:1216051	CTBP1	0.26	5.12	0.42	1.13e-6	Obesity-related traits;
TGCT	cis	rs250677	0.559	rs17109198	chr5:148369712	C/T	cg18129178	chr5:148520854	ABLIM3	-0.36	-4.69	-0.39	7.23e-6	Breast cancer;
TGCT	cis	rs9467773	0.506	rs9393709	chr6:26365147	C/T	cg15659132	chr6:26577336	NA	-0.5	-5.05	-0.41	1.53e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg11301795	chr4:187892539	NA	-0.3	-4.48	-0.37	1.69e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs155076	0.702	rs482731	chr13:21846075	G/A	cg11317459	chr13:21872234	NA	-1.42	-12.02	-0.73	1.53e-22	White matter hyperintensity burden;
TGCT	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg12310025	chr6:25882481	NA	-0.62	-6.42	-0.5	2.63e-9	Blood metabolite levels;
TGCT	cis	rs35146811	0.660	rs6465760	chr7:99591418	A/G	cg13334819	chr7:99746414	C7orf59	0.65	5.76	0.46	6.21e-8	Coronary artery disease;
TGCT	cis	rs12142240	0.698	rs6667861	chr1:46815749	T/C	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	6.09	0.48	1.32e-8	Mean platelet volume;
TGCT	cis	rs7666738	0.830	rs1593570	chr4:99017058	T/C	cg05340658	chr4:99064831	C4orf37	0.48	5.43	0.44	2.92e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7726839	0.540	rs72703087	chr5:598029	C/T	cg09021430	chr5:549028	NA	-0.43	-5.77	-0.46	5.99e-8	Obesity-related traits;
TGCT	cis	rs17030434	0.822	rs7686027	chr4:154680269	T/G	cg14289246	chr4:154710475	SFRP2	0.9	7.0	0.53	1.41e-10	Electrocardiographic conduction measures;
TGCT	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg13393036	chr8:95962371	TP53INP1	-0.65	-8.82	-0.62	8.57e-15	Type 2 diabetes;
TGCT	cis	rs1371867	0.846	rs1788196	chr8:101290088	C/T	cg06002616	chr8:101225028	SPAG1	-0.53	-6.21	-0.49	7.16e-9	Atrioventricular conduction;
TGCT	cis	rs2303759	0.830	rs7257053	chr19:49894456	C/G	cg22307029	chr19:49891270	CCDC155	0.56	5.34	0.43	4.27e-7	Multiple sclerosis;
TGCT	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.52	4.77	0.39	5.18e-6	Prudent dietary pattern;
TGCT	cis	rs10791323	0.604	rs2257010	chr11:133712348	G/A	cg03690763	chr11:133734501	NA	-0.32	-5.07	-0.41	1.4e-6	Childhood ear infection;
TGCT	cis	rs4803468	0.905	rs284662	chr19:41932275	T/C	cg09537434	chr19:41945824	ATP5SL	-0.88	-9.46	-0.65	2.61e-16	Height;
TGCT	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg25036284	chr2:26402008	FAM59B	-0.65	-5.18	-0.42	8.59e-7	Gut microbiome composition (summer);
TGCT	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg06238570	chr21:40685208	BRWD1	-0.63	-6.48	-0.5	1.95e-9	Menarche (age at onset);
TGCT	cis	rs6964587	1.000	rs2301559	chr7:91746727	T/C	cg22709100	chr7:91322751	NA	0.29	4.66	0.39	8e-6	Breast cancer;
TGCT	cis	rs514406	0.548	rs6670871	chr1:53212082	A/C	cg08859206	chr1:53392774	SCP2	0.36	5.12	0.42	1.14e-6	Monocyte count;
TGCT	cis	rs9910055	0.529	rs170637	chr17:42186868	C/T	cg19774624	chr17:42201019	HDAC5	0.78	7.55	0.56	8.01e-12	Total body bone mineral density;
TGCT	cis	rs67311347	0.544	rs2887965	chr3:40334154	A/G	cg13683864	chr3:40499215	RPL14	0.8	7.48	0.56	1.18e-11	Renal cell carcinoma;
TGCT	cis	rs9611565	0.512	rs5758439	chr22:42131762	C/T	cg06481639	chr22:41940642	POLR3H	0.7	6.1	0.48	1.24e-8	Vitiligo;
TGCT	cis	rs11997175	0.574	rs872489	chr8:33646401	T/C	ch.8.33884649F	chr8:33765107	NA	0.28	4.53	0.38	1.35e-5	Body mass index;
TGCT	cis	rs6748734	1.000	rs3936203	chr2:241834654	C/T	cg04034577	chr2:241836375	C2orf54	0.4	6.32	0.49	4.22e-9	Urinary metabolites;
TGCT	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg11764359	chr7:65958608	NA	-0.55	-5.0	-0.41	1.94e-6	Aortic root size;
TGCT	cis	rs151997	0.962	rs26088	chr5:50172670	T/G	cg06027927	chr5:50259733	NA	0.44	4.52	0.38	1.42e-5	Callous-unemotional behaviour;
TGCT	cis	rs514406	0.505	rs374662	chr1:53164549	C/A	cg24675658	chr1:53192096	ZYG11B	-0.74	-8.3	-0.6	1.52e-13	Monocyte count;
TGCT	cis	rs904251	0.828	rs1757178	chr6:37486310	C/T	cg25019722	chr6:37503610	NA	0.51	6.84	0.52	3.24e-10	Cognitive performance;
TGCT	cis	rs36051895	0.664	rs10117565	chr9:5094461	G/A	cg02405213	chr9:5042618	JAK2	-0.72	-9.52	-0.65	1.85e-16	Pediatric autoimmune diseases;
TGCT	cis	rs2677744	0.719	rs2106673	chr15:91452595	A/G	cg23684204	chr15:91497937	RCCD1	0.36	5.17	0.42	9.11e-7	Attention deficit hyperactivity disorder;
TGCT	cis	rs7572733	0.534	rs700670	chr2:198687284	T/C	cg00792783	chr2:198669748	PLCL1	0.56	5.08	0.42	1.35e-6	Dermatomyositis;
TGCT	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg05665937	chr4:1216051	CTBP1	0.25	5.03	0.41	1.7e-6	Obesity-related traits;
TGCT	cis	rs8072100	0.807	rs4561509	chr17:45781799	G/A	cg08085267	chr17:45401833	C17orf57	-0.49	-5.67	-0.45	9.45e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs6690583	0.524	rs6680422	chr1:85451945	C/T	cg20280350	chr1:85513789	MCOLN3	-0.74	-5.11	-0.42	1.2e-6	Serum sulfate level;
TGCT	cis	rs2836950	0.501	rs13047518	chr21:40707307	G/A	cg22974920	chr21:40686053	BRWD1	-0.5	-4.46	-0.37	1.8e-5	Menarche (age at onset);
TGCT	cis	rs6121246	0.909	rs6058450	chr20:30343911	G/A	cg18721089	chr20:30220636	NA	-0.43	-4.75	-0.39	5.54e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs1670533	1.000	rs2045066	chr4:1052401	C/T	cg20887711	chr4:1340912	KIAA1530	0.63	4.92	0.4	2.7e-6	Recombination rate (females);
TGCT	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg23302884	chr18:44338147	ST8SIA5	-0.41	-4.68	-0.39	7.26e-6	Personality dimensions;
TGCT	cis	rs4478037	0.822	rs9865342	chr3:33118631	G/A	cg19404215	chr3:33155277	CRTAP	1.28	6.37	0.5	3.33e-9	Major depressive disorder;
TGCT	cis	rs1729951	0.575	rs10935213	chr3:136693459	A/G	cg21827317	chr3:136751795	NA	0.4	5.63	0.45	1.16e-7	Neuroticism;
TGCT	cis	rs950169	0.922	rs4586394	chr15:84822385	G/A	cg11189052	chr15:85197271	WDR73	-0.82	-6.5	-0.5	1.73e-9	Schizophrenia;
TGCT	cis	rs740474	0.652	rs251022	chr5:140892643	T/C	cg24137543	chr5:140893634	NA	0.46	4.57	0.38	1.16e-5	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs2742417	0.967	rs2742419	chr3:45731929	G/A	cg04837898	chr3:45731254	SACM1L	-0.55	-5.67	-0.45	9.39e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs16939607	0.822	rs2128019	chr8:78994159	G/T	cg21244580	chr8:79934476	NA	0.49	5.38	0.43	3.64e-7	White blood cell count;
TGCT	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg27535305	chr1:53392650	SCP2	-0.25	-4.65	-0.38	8.53e-6	Monocyte count;
TGCT	cis	rs12478296	1.000	rs55767645	chr2:242999350	G/A	cg06360820	chr2:242988706	NA	-0.76	-4.93	-0.41	2.55e-6	Obesity-related traits;
TGCT	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg06238570	chr21:40685208	BRWD1	0.8	9.11	0.63	1.74e-15	Cognitive function;
TGCT	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg13699009	chr12:122356056	WDR66	0.28	6.26	0.49	5.63e-9	Mean corpuscular volume;
TGCT	cis	rs2070488	1.000	rs36006749	chr3:38443312	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	9.66	0.66	8.43e-17	Electrocardiographic conduction measures;
TGCT	cis	rs7017914	0.902	rs3098866	chr8:71916574	A/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.57	-5.31	-0.43	4.8e-7	Bone mineral density;
TGCT	cis	rs950169	0.656	rs11632395	chr15:85145793	C/A	cg17173187	chr15:85201210	NMB	0.5	5.37	0.43	3.76e-7	Schizophrenia;
TGCT	cis	rs73198271	0.751	rs617813	chr8:8635888	A/G	cg06671706	chr8:8559999	CLDN23	-0.35	-4.56	-0.38	1.19e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs939658	0.805	rs8024813	chr15:79427260	A/G	cg17916960	chr15:79447300	NA	-0.49	-7.59	-0.56	6.76e-12	Refractive error;
TGCT	cis	rs6866344	0.697	rs61247551	chr5:178133503	G/A	cg03877680	chr5:178157825	ZNF354A	0.75	6.1	0.48	1.25e-8	Neutrophil percentage of white cells;
TGCT	trans	rs1496653	0.602	rs13071171	chr3:23585115	G/T	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.55	5.39	0.44	3.47e-7	Menarche (age at onset);
TGCT	cis	rs539096	0.872	rs663618	chr1:44043105	T/C	cg12908607	chr1:44402522	ARTN	-0.5	-5.21	-0.42	7.49e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg11890956	chr21:40555474	PSMG1	1.11	12.48	0.75	1.21e-23	Cognitive function;
TGCT	cis	rs554111	0.593	rs9426660	chr1:21520449	A/G	cg01072550	chr1:21505969	NA	-0.37	-5.58	-0.45	1.45e-7	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs6835098	0.646	rs10012395	chr4:174078772	A/G	cg08422745	chr4:174089978	GALNT7	-0.77	-8.6	-0.61	2.87e-14	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs6582630	0.638	rs4882309	chr12:38448595	A/G	cg26384229	chr12:38710491	ALG10B	-0.54	-4.79	-0.4	4.57e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs11118844	0.843	rs12403995	chr1:221921377	C/A	cg04222084	chr1:221915650	DUSP10	-0.78	-5.42	-0.44	2.96e-7	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
TGCT	cis	rs853679	0.546	rs200949	chr6:27835435	A/G	cg01031101	chr6:28227091	NKAPL	-0.49	-4.66	-0.39	8.09e-6	Depression;
TGCT	cis	rs3820068	0.608	rs7552400	chr1:16035892	A/G	cg05660106	chr1:15850417	CASP9	0.67	6.48	0.5	1.96e-9	Systolic blood pressure;
TGCT	cis	rs1975974	0.574	rs59896566	chr17:21733621	C/T	cg18423549	chr17:21743878	NA	-0.61	-5.99	-0.47	2.14e-8	Psoriasis;
TGCT	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg12963246	chr6:28129442	ZNF389	0.47	4.66	0.39	8.12e-6	Parkinson's disease;
TGCT	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg07870213	chr5:140052090	DND1	0.65	7.75	0.57	2.79e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	trans	rs1496653	0.602	rs13066741	chr3:23426332	C/T	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg08045932	chr20:61659980	NA	0.48	9.28	0.64	7.07e-16	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs4733781	0.933	rs9643252	chr8:131332667	G/A	cg16277922	chr8:131349729	ASAP1	0.36	4.65	0.39	8.22e-6	Tuberculosis;
TGCT	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg23758822	chr17:41437982	NA	0.72	6.96	0.53	1.76e-10	Menopause (age at onset);
TGCT	cis	rs7666738	0.512	rs6532704	chr4:98777562	C/T	cg17366294	chr4:99064904	C4orf37	0.52	5.59	0.45	1.4e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs76878669	0.515	rs947978	chr11:66108660	C/T	cg18002602	chr11:66138449	SLC29A2	0.53	6.45	0.5	2.23e-9	Educational attainment (years of education);
TGCT	trans	rs4332037	0.851	rs1403175	chr7:1964357	A/T	cg25206134	chr2:45395956	NA	-1.1	-9.53	-0.65	1.75e-16	Bipolar disorder;
TGCT	trans	rs1814175	0.791	rs9787917	chr11:49937281	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.36	-7.05	-0.53	1.13e-10	Height;
TGCT	cis	rs2836974	0.931	rs2776309	chr21:40715791	A/G	cg17971929	chr21:40555470	PSMG1	0.91	7.93	0.58	1.07e-12	Cognitive function;
TGCT	cis	rs9682041	0.825	rs6785326	chr3:170095145	T/C	cg07589077	chr3:170072950	NA	0.31	4.7	0.39	6.94e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs7666738	0.753	rs2865957	chr4:99040725	G/A	cg05340658	chr4:99064831	C4orf37	0.52	5.94	0.47	2.68e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10927875	0.632	rs4661667	chr1:16162731	C/T	cg14742211	chr1:16348397	CLCNKA	-0.19	-4.68	-0.39	7.38e-6	Dilated cardiomyopathy;
TGCT	cis	rs595982	0.726	rs607356	chr19:49371241	T/C	cg21252483	chr19:49399788	TULP2	-0.31	-5.25	-0.43	6.47e-7	Red cell distribution width;
TGCT	cis	rs9916302	0.706	rs12937013	chr17:37665571	G/A	cg07936489	chr17:37558343	FBXL20	-0.87	-6.27	-0.49	5.47e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs858239	0.539	rs6949363	chr7:23192394	A/G	cg05602783	chr7:23145260	KLHL7	-0.63	-5.03	-0.41	1.67e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs6882046	0.513	rs601942	chr5:88031820	T/C	cg24804195	chr5:87968844	LOC645323	-0.59	-5.9	-0.47	3.31e-8	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs1696756	0.638	rs1285274	chr17:77829907	G/A	cg00646381	chr17:77835854	NA	0.44	6.6	0.51	1.06e-9	Glucocorticoid-induced osteonecrosis (age 10 years and older);
TGCT	cis	rs68170813	0.559	rs79564258	chr7:107059803	C/A	cg02696742	chr7:106810147	HBP1	-0.71	-5.9	-0.47	3.17e-8	Coronary artery disease;
TGCT	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg20607798	chr8:58055168	NA	0.65	5.43	0.44	2.86e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs12541335	0.639	rs4872468	chr8:22179844	G/C	cg18135555	chr8:22132992	PIWIL2	0.3	6.21	0.49	7.5e-9	Hypertriglyceridemia;
TGCT	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg07507251	chr3:52567010	NT5DC2	0.47	6.6	0.51	1.05e-9	Bipolar disorder;
TGCT	cis	rs4642101	0.537	rs4997708	chr3:12839603	G/A	cg05775895	chr3:12838266	CAND2	0.67	7.07	0.54	9.95e-11	QRS complex (12-leadsum);
TGCT	cis	rs11190604	0.731	rs10883480	chr10:102163821	G/T	cg23241863	chr10:102295624	HIF1AN	-0.63	-4.82	-0.4	4.06e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg01341218	chr17:43662625	NA	1.08	8.78	0.62	1.12e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs231513	0.906	rs75508812	chr17:42003397	G/A	cg26893861	chr17:41843967	DUSP3	0.73	5.12	0.42	1.12e-6	Cognitive function;
TGCT	cis	rs7666738	0.830	rs4699580	chr4:98930673	T/C	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4478858	0.709	rs3766296	chr1:31820223	G/A	cg00250761	chr1:31883323	NA	-0.28	-4.96	-0.41	2.32e-6	Alcohol dependence;
TGCT	cis	rs999943	0.846	rs9357162	chr6:33613344	G/A	cg14003231	chr6:33640908	ITPR3	0.39	4.9	0.4	2.97e-6	Obesity (extreme);
TGCT	cis	rs10510102	0.515	rs11200285	chr10:123713446	G/C	cg23691251	chr10:123688108	ATE1	-0.59	-4.7	-0.39	6.75e-6	Breast cancer;
TGCT	cis	rs7267979	0.966	rs4815425	chr20:25398876	G/C	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs734999	0.588	rs78506337	chr1:2537095	G/A	cg18854424	chr1:2615690	NA	0.45	5.03	0.41	1.66e-6	Ulcerative colitis;
TGCT	cis	rs7081476	0.826	rs73596338	chr10:27259964	G/C	cg08717896	chr10:27541913	LOC387646	-0.77	-4.76	-0.39	5.21e-6	Age-related diseases and mortality;Age-related diseases, mortality and associated endophenotypes;
TGCT	cis	rs7635838	0.785	rs2606738	chr3:11396562	T/C	cg00170343	chr3:11313890	ATG7	0.64	6.21	0.49	7.42e-9	HDL cholesterol;
TGCT	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg13683864	chr3:40499215	RPL14	-1.19	-13.31	-0.77	1.2e-25	Renal cell carcinoma;
TGCT	cis	rs9527	0.830	rs10883790	chr10:104640955	A/C	cg04362960	chr10:104952993	NT5C2	0.62	5.06	0.41	1.46e-6	Arsenic metabolism;
TGCT	cis	rs9303401	0.659	rs62081315	chr17:56781468	T/C	cg25039879	chr17:56429692	SUPT4H1	0.52	4.62	0.38	9.48e-6	Cognitive test performance;
TGCT	cis	rs10056811	0.510	rs10058171	chr5:74407991	C/T	cg19683494	chr5:74908142	NA	0.63	5.06	0.41	1.49e-6	Coronary artery disease;
TGCT	cis	rs939658	1.000	rs34286854	chr15:79454374	C/T	cg17916960	chr15:79447300	NA	-0.53	-8.63	-0.61	2.55e-14	Refractive error;
TGCT	cis	rs13343954	0.778	rs10425586	chr19:33543337	G/T	cg07624008	chr19:33672378	NA	-0.28	-4.76	-0.39	5.22e-6	Colorectal cancer;
TGCT	cis	rs2075371	1.000	rs1862047	chr7:133978078	G/C	cg11752832	chr7:134001865	SLC35B4	0.7	6.51	0.5	1.68e-9	Mean platelet volume;
TGCT	cis	rs7666738	0.830	rs1025203	chr4:99023073	G/A	cg17366294	chr4:99064904	C4orf37	0.71	7.0	0.53	1.4e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs76878669	0.561	rs10750784	chr11:66110666	A/G	cg18002602	chr11:66138449	SLC29A2	-0.51	-6.18	-0.49	8.42e-9	Educational attainment (years of education);
TGCT	cis	rs9291683	0.588	rs35438220	chr4:9999398	C/T	cg11266682	chr4:10021025	SLC2A9	0.66	9.23	0.64	9.39e-16	Bone mineral density;
TGCT	cis	rs539096	0.540	rs37452	chr1:44297573	A/C	cg12908607	chr1:44402522	ARTN	-0.68	-8.12	-0.59	3.97e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs12257961	0.521	rs10796280	chr10:15375511	A/T	cg10616319	chr10:15468812	NA	-0.25	-4.56	-0.38	1.2e-5	Selective IgA deficiency;
TGCT	cis	rs7666738	0.606	rs6839946	chr4:99076132	A/C	cg17366294	chr4:99064904	C4orf37	0.61	5.73	0.46	7.22e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4478858	0.698	rs4949385	chr1:31793256	C/T	cg07478791	chr1:31886160	SERINC2	-0.51	-4.94	-0.41	2.47e-6	Alcohol dependence;
TGCT	cis	rs3099143	1.000	rs7174048	chr15:77165416	T/C	cg21673338	chr15:77095150	SCAPER	0.52	5.05	0.41	1.54e-6	Recalcitrant atopic dermatitis;
TGCT	cis	rs7100689	0.753	rs1361458	chr10:82090339	A/T	cg01528321	chr10:82214614	TSPAN14	0.8	7.92	0.58	1.15e-12	Post bronchodilator FEV1;
TGCT	cis	rs610932	0.517	rs1285231	chr11:59979408	T/C	cg18570331	chr11:60101691	MS4A6E	0.52	4.84	0.4	3.79e-6	Alzheimer's disease;
TGCT	cis	rs11642862	1.000	rs112234000	chr16:30778808	G/A	cg02466173	chr16:30829666	NA	-0.39	-4.68	-0.39	7.24e-6	Tonsillectomy;
TGCT	cis	rs2777491	1.000	rs11631770	chr15:41737059	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.72	-10.39	-0.68	1.39e-18	Ulcerative colitis;
TGCT	cis	rs9357506	1.000	rs1345059	chr6:46307051	T/C	cg21115430	chr6:46460003	NA	-0.26	-5.17	-0.42	9.2e-7	Body mass index;
TGCT	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	5.71	0.46	8.05e-8	Alzheimer's disease;
TGCT	cis	rs1729951	0.575	rs1654904	chr3:136681149	T/C	cg21827317	chr3:136751795	NA	0.4	5.61	0.45	1.28e-7	Neuroticism;
TGCT	cis	rs9300255	0.739	rs1402275	chr12:123750895	A/G	cg00376283	chr12:123451042	ABCB9	0.74	5.71	0.46	7.74e-8	Neutrophil percentage of white cells;
TGCT	cis	rs2239547	0.618	rs4687658	chr3:52860366	C/G	cg11645453	chr3:52864694	ITIH4	0.34	5.67	0.45	9.34e-8	Schizophrenia;
TGCT	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg16423285	chr20:60520624	NA	0.74	9.09	0.63	2.02e-15	Obesity-related traits;
TGCT	trans	rs877282	0.898	rs36064821	chr10:760952	C/T	cg22713356	chr15:30763199	NA	1.17	9.15	0.63	1.44e-15	Uric acid levels;
TGCT	trans	rs797680	0.856	rs6688230	chr1:93641124	C/T	cg27528825	chr2:159282178	CCDC148	-0.35	-6.85	-0.52	3.08e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs1129187	0.702	rs2395943	chr6:42940673	A/G	cg02353165	chr6:42928485	GNMT	0.8	7.13	0.54	7.19e-11	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs1568889	0.592	rs7110074	chr11:28469325	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.68	5.25	0.43	6.39e-7	Bipolar disorder;
TGCT	cis	rs9814567	1.000	rs7432268	chr3:134242051	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.96	-9.11	-0.63	1.79e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs506338	0.517	rs490192	chr11:64471369	C/T	cg19395706	chr11:64412079	NRXN2	0.52	6.36	0.5	3.45e-9	Body mass index;Urate levels;
TGCT	cis	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg20362242	chr5:692897	TPPP	0.48	4.51	0.38	1.47e-5	Lung disease severity in cystic fibrosis;
TGCT	cis	rs7523273	0.597	rs2761437	chr1:207923081	A/G	cg22525895	chr1:207977042	MIR29B2	0.44	6.5	0.5	1.79e-9	Schizophrenia;
TGCT	cis	rs2230307	0.536	rs581097	chr1:100515920	C/T	cg24955406	chr1:100503596	HIAT1	0.74	4.86	0.4	3.41e-6	Carotid intima media thickness;
TGCT	cis	rs6500602	0.927	rs7200817	chr16:4480598	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.3	5.09	0.42	1.28e-6	Schizophrenia;
TGCT	cis	rs910316	0.967	rs2024653	chr14:75595154	G/A	cg11812906	chr14:75593930	NEK9	0.73	7.23	0.54	4.36e-11	Height;
TGCT	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.51	-4.74	-0.39	5.67e-6	Menarche (age at onset);
TGCT	cis	rs8103278	1.000	rs36091860	chr19:46312880	G/A	cg11657440	chr19:46296263	DMWD	-0.59	-5.72	-0.46	7.54e-8	Coronary artery disease;
TGCT	cis	rs1008375	1.000	rs13106338	chr4:17676871	G/T	cg18681998	chr4:17616180	MED28	-0.86	-8.78	-0.62	1.07e-14	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1153858	1.000	rs1346268	chr15:45673029	T/C	cg26924012	chr15:45694286	SPATA5L1	1.09	15.16	0.81	5.15e-30	Homoarginine levels;
TGCT	cis	rs2486012	1.000	rs2486007	chr1:44434613	A/G	cg12908607	chr1:44402522	ARTN	0.71	5.8	0.46	5.08e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs734999	0.967	rs7544646	chr1:2496649	C/G	cg18854424	chr1:2615690	NA	0.44	5.26	0.43	6.23e-7	Ulcerative colitis;
TGCT	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg06112835	chr11:68658793	MRPL21	0.49	8.02	0.58	6.66e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs6430585	0.527	rs12467569	chr2:136413847	T/C	cg07169764	chr2:136633963	MCM6	0.96	8.46	0.61	6.24e-14	Corneal structure;
TGCT	cis	rs6977660	0.714	rs10260866	chr7:19793151	T/C	cg07541023	chr7:19748670	TWISTNB	0.85	4.84	0.4	3.74e-6	Thyroid stimulating hormone;
TGCT	cis	rs877282	0.898	rs12354872	chr10:763362	G/A	cg17470449	chr10:769945	NA	0.36	5.17	0.42	9.01e-7	Uric acid levels;
TGCT	cis	rs7829975	0.777	rs560544	chr8:8637429	G/A	cg17143192	chr8:8559678	CLDN23	-0.46	-4.45	-0.37	1.88e-5	Mood instability;
TGCT	cis	rs7726839	0.574	rs72705014	chr5:619815	C/G	cg09021430	chr5:549028	NA	-0.46	-6.07	-0.48	1.42e-8	Obesity-related traits;
TGCT	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg03806693	chr22:41940476	POLR3H	-1.11	-13.11	-0.76	3.63e-25	Vitiligo;
TGCT	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg20573242	chr4:122745356	CCNA2	0.62	5.48	0.44	2.23e-7	Type 2 diabetes;
TGCT	cis	rs3096299	0.933	rs3096297	chr16:89453155	T/G	cg06640241	chr16:89574553	SPG7	0.62	5.99	0.47	2.1e-8	Multiple myeloma (IgH translocation);
TGCT	cis	rs7666738	0.830	rs62321587	chr4:98997958	T/C	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs910187	0.597	rs1883885	chr20:45795456	T/C	cg27589058	chr20:45804311	EYA2	-0.37	-7.01	-0.53	1.37e-10	Migraine;
TGCT	cis	rs6693567	0.565	rs10888584	chr1:150476406	C/G	cg09579323	chr1:150459698	TARS2	0.53	4.63	0.38	9.01e-6	Migraine;
TGCT	cis	rs7605378	0.528	rs1704191	chr2:200816393	C/A	cg19045956	chr2:200819837	C2orf60;C2orf47	0.53	5.57	0.45	1.48e-7	Osteoporosis;
TGCT	cis	rs3806843	0.771	rs2563334	chr5:140107065	C/G	cg19875535	chr5:140030758	IK	-0.37	-6.19	-0.49	7.89e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9291683	0.552	rs11736410	chr4:10017241	G/A	cg11266682	chr4:10021025	SLC2A9	0.73	10.98	0.7	5.33e-20	Bone mineral density;
TGCT	cis	rs7731657	0.537	rs72801738	chr5:130207637	A/G	cg08523029	chr5:130500466	HINT1	-0.59	-4.9	-0.4	2.87e-6	Fasting plasma glucose;
TGCT	cis	rs153916	0.643	rs466748	chr5:95010028	T/C	cg26072123	chr5:95066710	RHOBTB3	-0.44	-4.63	-0.38	9.23e-6	Pulmonary function;
TGCT	cis	rs7010267	0.596	rs12682278	chr8:120032328	C/T	cg17171407	chr8:119960777	TNFRSF11B	-0.26	-5.1	-0.42	1.21e-6	Total body bone mineral density (age 45-60);
TGCT	cis	rs2070488	1.000	rs2268758	chr3:38514049	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	9.75	0.66	5e-17	Electrocardiographic conduction measures;
TGCT	cis	rs7662987	0.517	rs2851286	chr4:100014976	A/G	cg12011299	chr4:100065546	ADH4	-0.42	-5.0	-0.41	1.91e-6	Smoking initiation;
TGCT	cis	rs2075165	0.901	rs7542798	chr1:156224304	A/G	cg20302342	chr1:156215951	PAQR6	0.39	5.67	0.45	9.49e-8	Tonsillectomy;
TGCT	cis	rs9611565	0.546	rs132793	chr22:42063681	A/G	cg13695892	chr22:41940480	POLR3H	0.85	8.05	0.59	5.7e-13	Vitiligo;
TGCT	cis	rs7940866	0.809	rs11222410	chr11:130833994	A/G	cg05962950	chr11:130786565	SNX19	0.69	6.87	0.53	2.73e-10	Schizophrenia;
TGCT	cis	rs7017914	0.967	rs6982406	chr8:71654608	T/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.03	-0.41	1.69e-6	Bone mineral density;
TGCT	cis	rs17102423	0.755	rs12880781	chr14:65576257	C/T	cg11161011	chr14:65562177	MAX	-0.54	-7.49	-0.56	1.15e-11	Obesity-related traits;
TGCT	cis	rs11677370	0.603	rs10171309	chr2:3851690	C/T	cg17052675	chr2:3827356	NA	-0.39	-6.74	-0.52	5.41e-10	Type 2 diabetes;
TGCT	cis	rs7666738	0.512	rs6532704	chr4:98777562	C/T	cg05340658	chr4:99064831	C4orf37	0.44	5.51	0.44	2.01e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4595586	0.563	rs11169769	chr12:39233134	C/G	cg13010199	chr12:38710504	ALG10B	0.6	4.72	0.39	6.26e-6	Morning vs. evening chronotype;
TGCT	cis	rs17736589	0.789	rs62075626	chr17:76814400	A/G	cg05761277	chr17:76356738	SOCS3	-0.54	-4.53	-0.38	1.36e-5	Ulcerative colitis;
TGCT	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg21644426	chr2:191273491	MFSD6	-0.54	-5.22	-0.42	7.42e-7	Pulse pressure;
TGCT	cis	rs3808502	0.563	rs12541800	chr8:11423072	A/G	cg21775007	chr8:11205619	TDH	0.52	4.66	0.39	8.06e-6	Neuroticism;
TGCT	cis	rs1580019	0.961	rs958217	chr7:32493417	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.73	7.08	0.54	9.24e-11	Cognitive ability;
TGCT	cis	rs12145833	0.538	rs10754798	chr1:243309958	A/G	cg02356786	chr1:243265016	LOC731275	-0.56	-5.17	-0.42	9.04e-7	Obesity (early onset extreme);
TGCT	cis	rs11626933	1.000	rs4559843	chr14:90747488	T/C	cg14092571	chr14:90743983	NA	-0.3	-6.05	-0.48	1.6e-8	Gut microbiota (bacterial taxa);
TGCT	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg04267008	chr7:1944627	MAD1L1	-0.38	-5.03	-0.41	1.65e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs1371867	1.000	rs1371867	chr8:101330209	A/C	cg00191853	chr8:101177733	SPAG1	-0.22	-4.64	-0.38	8.84e-6	Atrioventricular conduction;
TGCT	cis	rs7772486	0.754	rs4896839	chr6:146019689	T/G	cg13319975	chr6:146136371	FBXO30	0.52	4.68	0.39	7.31e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7772486	0.875	rs7739418	chr6:146359188	G/A	cg05347473	chr6:146136440	FBXO30	0.52	4.93	0.41	2.54e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7843479	1.000	rs17615788	chr8:21814739	C/T	cg17168535	chr8:21777572	XPO7	0.65	5.99	0.47	2.14e-8	Mean corpuscular volume;
TGCT	cis	rs9796	0.870	rs11855248	chr15:41276158	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.43	-5.66	-0.45	9.84e-8	Menopause (age at onset);
TGCT	cis	rs12908161	0.960	rs34452033	chr15:85221993	A/G	cg11189052	chr15:85197271	WDR73	0.75	6.3	0.49	4.8e-9	Schizophrenia;
TGCT	cis	rs4076943	0.634	rs7111444	chr11:11269833	T/A	cg21653586	chr11:10530636	NA	0.49	4.99	0.41	1.99e-6	Post bronchodilator FEV1;
TGCT	cis	rs9682041	0.561	rs6790483	chr3:170154406	G/A	cg11886554	chr3:170076028	SKIL	0.94	6.65	0.51	8.16e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs42648	0.819	rs2285399	chr7:89969878	A/G	cg25739043	chr7:89950458	NA	-0.67	-6.46	-0.5	2.11e-9	Homocysteine levels;
TGCT	cis	rs62103177	0.564	rs1864529	chr18:77748975	G/A	cg07235805	chr18:78004237	PARD6G	-0.47	-4.53	-0.38	1.35e-5	Opioid sensitivity;
TGCT	cis	rs453301	0.686	rs6748	chr8:8890802	C/T	cg00184457	chr8:8946301	NA	-0.26	-4.94	-0.41	2.45e-6	Joint mobility (Beighton score);
TGCT	cis	rs2692947	0.566	rs11676901	chr2:96370571	A/C	cg23100626	chr2:96804247	ASTL	0.42	5.07	0.41	1.41e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs7020830	0.898	rs6476617	chr9:37200103	G/A	cg14294708	chr9:37120828	ZCCHC7	1.17	16.61	0.83	2.5e-33	Schizophrenia;
TGCT	cis	rs6087990	0.735	rs1003522	chr20:31368560	T/C	cg13636640	chr20:31349939	DNMT3B	0.95	12.05	0.73	1.28e-22	Ulcerative colitis;
TGCT	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.71	5.14	0.42	1.02e-6	Platelet count;
TGCT	trans	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg13615516	chr5:77269221	NA	0.68	8.54	0.61	3.97e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs728996	0.561	rs1326559	chr6:51652335	A/G	cg20180370	chr6:50691003	TFAP2D	-0.49	-4.7	-0.39	6.71e-6	Weight loss (gastric bypass surgery);
TGCT	cis	rs28595532	0.841	rs114123875	chr4:119733408	A/G	cg21605333	chr4:119757512	SEC24D	1.66	8.33	0.6	1.28e-13	Cannabis dependence symptom count;
TGCT	cis	rs6087771	0.926	rs6058431	chr20:30297133	C/T	cg10886678	chr20:30946050	ASXL1	-0.57	-4.86	-0.4	3.44e-6	Subcortical brain region volumes;Putamen volume;
TGCT	cis	rs7178572	1.000	rs11633054	chr15:77747276	A/G	cg15453836	chr15:77711506	NA	-0.4	-4.59	-0.38	1.07e-5	Type 2 diabetes;
TGCT	cis	rs227917	1.000	rs227923	chr7:23655548	C/A	cg12601843	chr7:23510954	IGF2BP3	0.58	4.6	0.38	1.01e-5	Common carotid intima-media thickness in HIV negative individuals;
TGCT	cis	rs7666738	0.830	rs1365458	chr4:98950961	C/T	cg17366294	chr4:99064904	C4orf37	0.74	7.43	0.55	1.56e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs422249	0.547	rs102275	chr11:61557803	T/C	cg20584555	chr11:61717780	BEST1	-0.23	-4.49	-0.37	1.6e-5	Trans fatty acid levels;
TGCT	cis	rs9457247	1.000	rs404222	chr6:167402150	G/A	cg25258033	chr6:167368657	RNASET2	0.19	4.51	0.38	1.5e-5	Crohn's disease;
TGCT	trans	rs10802346	0.545	rs12134404	chr1:246372144	A/G	cg13514129	chr1:39547527	MACF1	0.83	7.33	0.55	2.59e-11	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.99	8.16	0.59	3.26e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs8014204	0.736	rs2111705	chr14:75261641	G/A	cg06637938	chr14:75390232	RPS6KL1	0.58	5.12	0.42	1.15e-6	Caffeine consumption;
TGCT	cis	rs3947	1.000	rs1736084	chr8:11703657	C/T	cg02840367	chr8:11660030	FDFT1	0.9	6.51	0.5	1.64e-9	Blood protein levels;
TGCT	cis	rs9911578	1.000	rs12453049	chr17:56611372	C/T	cg12560992	chr17:57184187	TRIM37	-0.76	-9.34	-0.64	4.88e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs9916302	0.851	rs4390625	chr17:37620347	A/G	cg07936489	chr17:37558343	FBXL20	-0.62	-4.91	-0.4	2.85e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg16325326	chr1:53192061	ZYG11B	-0.85	-11.97	-0.73	1.98e-22	Monocyte count;
TGCT	cis	rs9296092	0.560	rs17627049	chr6:33537802	G/T	cg13560919	chr6:33536144	NA	-0.21	-4.78	-0.39	4.8e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.08	0.48	1.37e-8	Bipolar disorder;
TGCT	cis	rs1580019	0.563	rs764483	chr7:32578150	A/T	cg07520158	chr7:32535189	LSM5;AVL9	0.58	4.9	0.4	2.9e-6	Cognitive ability;
TGCT	cis	rs2046867	0.628	rs62249880	chr3:72918940	C/T	cg25664220	chr3:72788482	NA	-0.43	-5.79	-0.46	5.35e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6076065	0.748	rs6048779	chr20:23374709	C/G	cg11657817	chr20:23433608	CST11	0.31	5.47	0.44	2.42e-7	Facial morphology (factor 15, philtrum width);
TGCT	cis	rs8141529	0.732	rs3788409	chr22:29198151	T/G	cg02153584	chr22:29168773	CCDC117	0.67	5.68	0.45	9.04e-8	Lymphocyte counts;
TGCT	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg07507251	chr3:52567010	NT5DC2	0.46	6.68	0.51	7.37e-10	Bipolar disorder;
TGCT	cis	rs6500602	0.592	rs4785966	chr16:4518754	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.44	-7.58	-0.56	7.14e-12	Schizophrenia;
TGCT	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg13607699	chr17:42295918	UBTF	0.59	5.45	0.44	2.61e-7	Total body bone mineral density;
TGCT	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg18230493	chr5:56204884	C5orf35	-0.68	-5.92	-0.47	2.92e-8	Initial pursuit acceleration;
TGCT	cis	rs765787	0.530	rs11854294	chr15:45527996	A/G	cg24006582	chr15:45444508	DUOX1	-0.25	-5.54	-0.45	1.75e-7	Uric acid levels;
TGCT	cis	rs2354432	0.607	rs11579626	chr1:146741960	A/C	cg25205988	chr1:146714368	CHD1L	-1.34	-6.07	-0.48	1.44e-8	Mitochondrial DNA levels;
TGCT	cis	rs9916302	0.904	rs3744348	chr17:37417575	C/G	cg15445000	chr17:37608096	MED1	0.33	4.84	0.4	3.8e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs9467603	0.858	rs972087	chr6:25872579	A/G	cg16898833	chr6:26189333	HIST1H4D	1.05	5.43	0.44	2.82e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9650657	0.683	rs7836366	chr8:10585683	A/G	cg27411982	chr8:10470053	RP1L1	-0.21	-4.51	-0.38	1.46e-5	Neuroticism;
TGCT	cis	rs10114408	0.959	rs1987334	chr9:96635909	G/C	cg13679303	chr9:96623674	NA	-0.36	-4.69	-0.39	6.98e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs7666738	0.515	rs13118898	chr4:98792893	T/A	cg17366294	chr4:99064904	C4orf37	0.61	5.69	0.46	8.47e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7246657	0.943	rs10422967	chr19:37850137	T/C	cg18154014	chr19:37997991	ZNF793	0.97	6.49	0.5	1.82e-9	Coronary artery calcification;
TGCT	cis	rs3784262	0.669	rs10851632	chr15:58242475	A/T	cg12031962	chr15:58353849	ALDH1A2	-0.43	-6.14	-0.48	1e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs7904368	0.754	rs12269366	chr10:16850344	G/A	cg14835575	chr10:16859367	RSU1	0.68	7.32	0.55	2.77e-11	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
TGCT	cis	rs60871478	1.000	rs60871478	chr7:827325	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.5	4.86	0.4	3.54e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs2688608	0.592	rs11000760	chr10:75493734	G/A	cg04320760	chr10:75533139	FUT11	-0.4	-6.25	-0.49	6.11e-9	Inflammatory bowel disease;
TGCT	trans	rs4650994	0.544	rs2476560	chr1:178594919	A/G	cg05059571	chr16:84539110	KIAA1609	0.52	10.37	0.68	1.56e-18	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs2898681	0.521	rs115874483	chr4:53728272	G/A	cg00791764	chr4:53727839	RASL11B	0.54	4.58	0.38	1.1e-5	Optic nerve measurement (cup area);
TGCT	cis	rs11785400	1.000	rs4518642	chr8:143737396	T/C	cg24634471	chr8:143751801	JRK	0.57	6.12	0.48	1.11e-8	Schizophrenia;
TGCT	cis	rs763014	0.865	rs4006748	chr16:632225	T/C	cg00908189	chr16:619842	PIGQ	0.87	10.5	0.69	7.53e-19	Height;
TGCT	cis	rs10791097	0.720	rs6590518	chr11:130733530	C/T	cg05962950	chr11:130786565	SNX19	0.9	11.14	0.71	2.13e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs4689388	0.890	rs4689398	chr4:6302199	C/T	cg14416269	chr4:6271139	WFS1	0.41	5.51	0.44	1.98e-7	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs2404602	0.684	rs1011084	chr15:77007480	C/G	cg22467129	chr15:76604101	ETFA	0.47	4.7	0.39	6.84e-6	Blood metabolite levels;
TGCT	cis	rs317689	0.718	rs315130	chr12:69761444	T/C	cg14784868	chr12:69753453	YEATS4	0.56	4.63	0.38	8.93e-6	Response to diuretic therapy;
TGCT	cis	rs9291683	0.609	rs55959894	chr4:10026580	G/A	cg00071950	chr4:10020882	SLC2A9	0.7	9.41	0.65	3.47e-16	Bone mineral density;
TGCT	cis	rs78487399	0.710	rs75514072	chr2:43750224	G/C	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.76	4.68	0.39	7.27e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs28595532	0.841	rs114735834	chr4:119772722	G/A	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	trans	rs7824557	0.545	rs2572380	chr8:11237477	A/G	cg15556689	chr8:8085844	FLJ10661	-0.74	-6.68	-0.51	7.12e-10	Retinal vascular caliber;
TGCT	cis	rs12989701	0.877	rs7557280	chr2:127873161	T/A	cg08168897	chr2:127865431	BIN1	0.53	5.77	0.46	6.05e-8	Alzheimer's disease (late onset);
TGCT	cis	rs7914558	0.933	rs10883814	chr10:104737404	T/C	cg05855489	chr10:104503620	C10orf26	0.51	4.53	0.38	1.39e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs11677416	1.000	rs72825514	chr2:113527706	G/T	cg27083787	chr2:113543245	IL1A	0.17	4.46	0.37	1.83e-5	Response to antipsychotic treatment in schizophrenia (working memory);
TGCT	cis	rs6754311	0.773	rs680428	chr2:136630757	A/G	cg07169764	chr2:136633963	MCM6	-0.65	-6.06	-0.48	1.5e-8	Mosquito bite size;
TGCT	cis	rs4975616	0.869	rs401681	chr5:1322087	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.32	-5.0	-0.41	1.92e-6	Lung cancer;
TGCT	cis	rs477895	1.000	rs12785488	chr11:64107521	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.7	5.35	0.43	4.17e-7	Mean platelet volume;
TGCT	cis	rs9486719	1.000	rs11152951	chr6:96894135	C/G	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.21	-0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs896854	0.812	rs12546365	chr8:95911477	T/C	cg09323728	chr8:95962352	TP53INP1	-0.49	-6.26	-0.49	5.8e-9	Type 2 diabetes;
TGCT	cis	rs4699052	0.599	rs11938459	chr4:104233989	T/C	cg16532752	chr4:104119610	CENPE	-0.47	-4.56	-0.38	1.2e-5	Testicular germ cell tumor;
TGCT	cis	rs2439831	0.681	rs2278858	chr15:43632755	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	5.82	0.46	4.77e-8	Lung cancer in ever smokers;
TGCT	cis	rs9611565	0.512	rs132767	chr22:42009520	C/T	cg13695892	chr22:41940480	POLR3H	-0.8	-7.41	-0.55	1.71e-11	Vitiligo;
TGCT	trans	rs8097348	0.593	rs9965002	chr18:1710504	G/A	cg20681184	chr1:9750813	PIK3CD	-0.43	-6.78	-0.52	4.33e-10	Exercise (leisure time);
TGCT	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg06028808	chr11:68637592	NA	0.51	6.66	0.51	7.87e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs1372520	0.567	rs2619349	chr4:90746646	G/T	cg20003494	chr4:90757398	SNCA	-0.63	-5.09	-0.42	1.3e-6	Neuroticism;
TGCT	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	7.37	0.55	2.06e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs72945132	0.882	rs72947012	chr11:70149472	G/A	cg00319359	chr11:70116639	PPFIA1	0.97	7.07	0.54	1.01e-10	Coronary artery disease;
TGCT	cis	rs6490294	0.583	rs4767296	chr12:112463366	T/C	cg10833066	chr12:111807467	FAM109A	0.34	5.32	0.43	4.67e-7	Mean platelet volume;
TGCT	cis	rs11122272	0.766	rs2739511	chr1:231526490	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.73	-7.29	-0.55	3.25e-11	Hemoglobin concentration;
TGCT	trans	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg27523141	chr10:43048294	ZNF37B	-0.74	-8.46	-0.6	6.33e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg16423285	chr20:60520624	NA	-0.6	-6.41	-0.5	2.76e-9	Body mass index;
TGCT	cis	rs114540395	0.925	rs77449307	chr10:103385599	A/C	cg18276125	chr10:102749041	C10orf2	0.39	4.68	0.39	7.31e-6	Schizophrenia;
TGCT	cis	rs8180040	1.000	rs8180040	chr3:47388947	A/T	cg27129171	chr3:47204927	SETD2	0.7	8.63	0.61	2.53e-14	Colorectal cancer;
TGCT	cis	rs7014346	0.767	rs10956366	chr8:128423491	G/A	cg04263511	chr8:128962092	PVT1	-0.33	-4.71	-0.39	6.51e-6	Colorectal cancer;
TGCT	cis	rs6831352	0.959	rs6532795	chr4:100042221	C/T	cg12011299	chr4:100065546	ADH4	-0.42	-5.22	-0.42	7.16e-7	Alcohol dependence;
TGCT	cis	rs713587	0.563	rs2384057	chr2:25100167	C/G	cg01884057	chr2:25150051	NA	0.31	5.82	0.46	4.63e-8	Body mass index in non-asthmatics;
TGCT	cis	rs9987353	0.544	rs2929469	chr8:9062656	T/G	cg15556689	chr8:8085844	FLJ10661	0.54	5.13	0.42	1.1e-6	Recombination measurement;
TGCT	trans	rs629535	0.773	rs655299	chr8:70074534	C/T	cg21567404	chr3:27674614	NA	0.57	9.09	0.63	1.94e-15	Dupuytren's disease;
TGCT	cis	rs10479542	0.806	rs4700836	chr5:178976393	A/G	cg19626725	chr5:178986131	RUFY1	0.44	5.46	0.44	2.49e-7	Lung cancer;
TGCT	cis	rs6964587	1.000	rs2282968	chr7:91580287	A/C	cg17063962	chr7:91808500	NA	-0.91	-9.88	-0.66	2.45e-17	Breast cancer;
TGCT	cis	rs6840360	1.000	rs6839074	chr4:152603357	A/G	cg17479576	chr4:152424074	FAM160A1	0.46	4.91	0.4	2.86e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg17971929	chr21:40555470	PSMG1	0.98	9.51	0.65	1.95e-16	Cognitive function;
TGCT	cis	rs7666738	0.830	rs28810677	chr4:99043193	C/T	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1865760	0.566	rs9467672	chr6:26083904	C/T	cg17042849	chr6:26104293	HIST1H4C	-0.63	-5.47	-0.44	2.43e-7	Height;
TGCT	cis	rs9467773	0.595	rs7767847	chr6:26597893	A/T	cg09904177	chr6:26538194	HMGN4	0.67	6.3	0.49	4.72e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs3806843	0.966	rs11953833	chr5:140155123	T/A	cg19875535	chr5:140030758	IK	0.36	6.17	0.48	8.74e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs6752107	0.837	rs3792108	chr2:234184952	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.2	4.73	0.39	6.08e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg02038168	chr22:39784481	NA	-0.77	-6.65	-0.51	8.24e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	1.000	rs7666738	chr4:98968077	C/T	cg17366294	chr4:99064904	C4orf37	0.76	6.93	0.53	2.03e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6733011	0.500	rs2280142	chr2:99434872	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-4.76	-0.39	5.33e-6	Bipolar disorder;
TGCT	cis	rs7584330	0.695	rs77922291	chr2:238366317	T/G	cg14458575	chr2:238380390	NA	0.51	8.14	0.59	3.53e-13	Prostate cancer;
TGCT	cis	rs78461346	1.000	rs7504089	chr17:80484851	G/A	cg15014069	chr17:80540666	FOXK2	0.4	5.03	0.41	1.65e-6	3-hydroxypropylmercapturic acid levels in smokers;
TGCT	cis	rs7474896	0.583	rs10764144	chr10:37975732	G/C	cg25427524	chr10:38739819	LOC399744	-0.31	-4.86	-0.4	3.44e-6	Obesity (extreme);
TGCT	cis	rs16957091	0.647	rs8041432	chr15:43358759	C/T	cg17935677	chr15:44119062	WDR76	0.54	4.83	0.4	3.88e-6	MGMT methylation in smokers;
TGCT	cis	rs10883723	0.810	rs6584507	chr10:104254623	G/A	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs2013441	1.000	rs3850783	chr17:20184501	C/T	cg18979559	chr17:20280153	CCDC144C	0.44	4.61	0.38	9.78e-6	Obesity-related traits;
TGCT	cis	rs12477438	0.765	rs7605734	chr2:99644068	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-4.62	-0.38	9.47e-6	Chronic sinus infection;
TGCT	cis	rs9911578	0.839	rs1871751	chr17:57190368	A/G	cg12560992	chr17:57184187	TRIM37	0.71	8.14	0.59	3.63e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs17376456	0.569	rs10067754	chr5:93093110	T/A	cg25358565	chr5:93447407	FAM172A	0.74	6.42	0.5	2.66e-9	Diabetic retinopathy;
TGCT	cis	rs2322633	0.515	rs1892474	chr6:80862349	G/A	cg08355045	chr6:80787529	NA	0.33	4.89	0.4	3.06e-6	Height;
TGCT	cis	rs644799	0.710	rs666398	chr11:95551136	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	8.48	0.61	5.55e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs11122272	0.735	rs2790890	chr1:231514567	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.14	-0.54	6.86e-11	Hemoglobin concentration;
TGCT	cis	rs6964587	1.000	rs12533199	chr7:91757393	C/T	cg22709100	chr7:91322751	NA	0.29	4.69	0.39	6.98e-6	Breast cancer;
TGCT	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg04944784	chr2:26401820	FAM59B	0.76	6.24	0.49	6.46e-9	Gut microbiome composition (summer);
TGCT	cis	rs1577917	1.000	rs35760725	chr6:86648985	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.05	-0.41	1.57e-6	Response to antipsychotic treatment;
TGCT	cis	rs1018836	0.544	rs2063978	chr8:91459525	C/T	cg16814680	chr8:91681699	NA	-0.57	-5.56	-0.45	1.56e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs77106637	1.000	rs11602858	chr11:72615069	C/G	cg03713592	chr11:72463424	ARAP1	0.83	5.43	0.44	2.87e-7	Type 2 diabetes;
TGCT	cis	rs1008375	0.966	rs10939758	chr4:17698255	C/T	cg18681998	chr4:17616180	MED28	0.78	7.35	0.55	2.35e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4478037	0.558	rs57225144	chr3:33078354	G/C	cg19404215	chr3:33155277	CRTAP	1.04	4.95	0.41	2.36e-6	Major depressive disorder;
TGCT	cis	rs554111	0.614	rs10799661	chr1:21040079	C/A	cg08890418	chr1:21044141	KIF17	0.47	4.62	0.38	9.65e-6	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs1580019	0.563	rs764483	chr7:32578150	A/T	cg06627557	chr7:32535165	LSM5;AVL9	1.17	15.04	0.8	9.9e-30	Cognitive ability;
TGCT	cis	rs34638657	0.732	rs10514532	chr16:82200337	C/T	cg09439754	chr16:82129088	HSD17B2	0.27	5.16	0.42	9.62e-7	Lung adenocarcinoma;
TGCT	cis	rs1215050	0.791	rs165250	chr4:98696259	G/A	cg17366294	chr4:99064904	C4orf37	0.52	5.61	0.45	1.27e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg01585852	chr22:24235823	MIF	-0.21	-4.6	-0.38	1.02e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	trans	rs10953454	1.000	rs12705281	chr7:104475567	C/T	cg04208666	chr6:19734707	NA	-0.57	-6.89	-0.53	2.54e-10	Obesity;
TGCT	cis	rs1580019	0.922	rs1466147	chr7:32486262	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.9	8.65	0.61	2.27e-14	Cognitive ability;
TGCT	cis	rs11822910	0.737	rs2729389	chr11:57211646	A/G	cg00522883	chr11:57194120	SLC43A3	-0.31	-4.74	-0.39	5.75e-6	Platelet distribution width;
TGCT	cis	rs7582180	0.629	rs11686880	chr2:100956229	C/T	cg08017756	chr2:100939284	LONRF2	-0.3	-4.72	-0.39	6.18e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs765787	0.530	rs2554453	chr15:45522107	A/G	cg24006582	chr15:45444508	DUOX1	-0.26	-5.64	-0.45	1.12e-7	Uric acid levels;
TGCT	cis	rs4253772	0.591	rs9627324	chr22:46656511	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.55	4.46	0.37	1.84e-5	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs6912958	0.559	rs6921504	chr6:88058972	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.44	5.71	0.46	7.78e-8	Monocyte percentage of white cells;
TGCT	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg22920501	chr2:26401640	FAM59B	-0.71	-6.1	-0.48	1.27e-8	Gut microbiome composition (summer);
TGCT	trans	rs2727020	0.701	rs7949044	chr11:49597334	C/T	cg03929089	chr4:120376271	NA	-0.66	-7.12	-0.54	7.88e-11	Coronary artery disease;
TGCT	cis	rs2346177	0.875	rs2346178	chr2:46647061	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.43	-4.75	-0.39	5.45e-6	HDL cholesterol;
TGCT	cis	rs72627509	0.951	rs17087335	chr4:57838583	G/T	cg26694713	chr4:57773883	REST	0.75	6.45	0.5	2.32e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs79349575	0.756	rs2643361	chr17:46977462	T/G	cg26022315	chr17:47021804	SNF8	0.49	4.89	0.4	3.04e-6	Type 2 diabetes;
TGCT	cis	rs2847281	0.761	rs592390	chr18:12822314	T/C	cg23598886	chr18:12777645	NA	0.38	4.61	0.38	9.83e-6	C-reactive protein levels;Esophageal cancer (squamous cell);
TGCT	cis	rs61990749	0.597	rs11623088	chr14:78137735	G/A	cg23188588	chr14:78226832	SNW1;C14orf178	-0.67	-4.68	-0.39	7.39e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs514406	0.584	rs11205997	chr1:53195271	G/C	cg01802117	chr1:53393560	SCP2	0.42	4.92	0.4	2.69e-6	Monocyte count;
TGCT	cis	rs11716531	0.537	rs7626646	chr3:27268316	G/T	cg02860705	chr3:27208620	NA	0.4	6.03	0.48	1.76e-8	Diastolic blood pressure;
TGCT	cis	rs910316	0.591	rs7157158	chr14:75457238	A/G	cg11812906	chr14:75593930	NEK9	0.58	5.56	0.45	1.6e-7	Height;
TGCT	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.1	0.42	1.24e-6	Menopause (age at onset);
TGCT	cis	rs2201728	0.967	rs12507573	chr4:100226324	A/C	cg07219303	chr4:100140905	ADH6	0.32	4.56	0.38	1.22e-5	Cardiac Troponin-T levels;
TGCT	cis	rs2153535	0.580	rs4960433	chr6:8523697	A/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.07	0.41	1.4e-6	Motion sickness;
TGCT	cis	rs6912958	0.728	rs6923230	chr6:88213949	T/C	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.91	-0.4	2.78e-6	Monocyte percentage of white cells;
TGCT	cis	rs265548	0.608	rs265544	chr19:17903479	G/C	cg16744531	chr19:17905626	B3GNT3	0.4	4.92	0.4	2.65e-6	Tumor biomarkers;
TGCT	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg11644478	chr21:40555479	PSMG1	1.03	11.02	0.7	4.14e-20	Cognitive function;
TGCT	cis	rs10484885	0.887	rs17707738	chr6:90602735	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.43	-4.46	-0.37	1.8e-5	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs17376456	0.825	rs12153021	chr5:93073913	A/G	cg21475434	chr5:93447410	FAM172A	0.65	4.85	0.4	3.58e-6	Diabetic retinopathy;
TGCT	cis	rs12549902	0.966	rs4737000	chr8:41509727	A/C	cg00088007	chr8:41504566	NKX6-3	0.34	5.38	0.43	3.59e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
TGCT	cis	rs4077515	0.839	rs3812570	chr9:139275204	A/C	cg13741927	chr9:139327495	INPP5E	-0.19	-4.59	-0.38	1.05e-5	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
TGCT	trans	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg17470723	chr8:74884337	TCEB1	0.71	6.77	0.52	4.48e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2721195	0.743	rs2306386	chr8:145742879	T/C	cg15320075	chr8:145703422	NA	0.65	6.33	0.49	4.07e-9	Age at first birth;
TGCT	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg04772025	chr11:68637568	NA	0.6	6.78	0.52	4.32e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg27121462	chr16:89883253	FANCA	0.77	8.39	0.6	8.98e-14	Vitiligo;
TGCT	cis	rs7582180	0.629	rs2164847	chr2:100958715	C/T	cg08017756	chr2:100939284	LONRF2	-0.3	-4.87	-0.4	3.27e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs739401	0.611	rs12284275	chr11:3024384	T/C	cg05729581	chr11:3078854	CARS	-0.52	-4.71	-0.39	6.44e-6	Longevity;
TGCT	cis	rs6896969	0.510	rs6880419	chr5:40428913	C/T	cg01087697	chr5:40835557	RPL37	0.56	5.04	0.41	1.62e-6	Multiple sclerosis;
TGCT	cis	rs9527	0.615	rs10883804	chr10:104706520	G/A	cg15744005	chr10:104629667	AS3MT	-0.45	-5.31	-0.43	4.9e-7	Arsenic metabolism;
TGCT	cis	rs7818382	1.000	rs7818382	chr8:96054000	C/T	cg13393036	chr8:95962371	TP53INP1	-0.43	-4.85	-0.4	3.7e-6	Alzheimer's disease (late onset);
TGCT	cis	rs11112613	0.762	rs17037312	chr12:105950085	C/T	cg03607813	chr12:105948248	NA	0.52	6.0	0.47	2.03e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg23708337	chr7:1209742	NA	0.56	5.1	0.42	1.25e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9549367	0.662	rs3818334	chr13:113825174	C/G	cg18105134	chr13:113819100	PROZ	-0.47	-8.14	-0.59	3.6e-13	Platelet distribution width;
TGCT	cis	rs7513165	0.935	rs12097666	chr1:204162212	A/G	cg04791601	chr1:204159016	NA	0.26	5.14	0.42	1.04e-6	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
TGCT	cis	rs4478858	0.735	rs6679360	chr1:31817936	G/T	cg07478791	chr1:31886160	SERINC2	-0.47	-4.54	-0.38	1.32e-5	Alcohol dependence;
TGCT	cis	rs12762955	0.507	rs7095853	chr10:1040798	T/C	cg26597838	chr10:835615	NA	-0.47	-6.26	-0.49	5.7e-9	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs2303745	0.589	rs11086065	chr19:17395003	A/G	cg02221750	chr19:17393354	ANKLE1	-0.48	-6.28	-0.49	5.17e-9	Systemic lupus erythematosus;
TGCT	cis	rs600231	0.683	rs588298	chr11:65253574	A/G	cg17120908	chr11:65337727	SSSCA1	-0.56	-5.05	-0.41	1.54e-6	Bone mineral density;
TGCT	cis	rs9393777	0.778	rs77666565	chr6:26851415	G/A	cg16898833	chr6:26189333	HIST1H4D	1.13	5.55	0.45	1.65e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7552404	1.000	rs7533888	chr1:76160449	A/C	cg10523679	chr1:76189770	ACADM	0.91	9.92	0.67	2.01e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs986417	0.901	rs1884095	chr14:61017024	C/G	cg27398547	chr14:60952738	C14orf39	1.42	8.85	0.62	7.44e-15	Gut microbiota (bacterial taxa);
TGCT	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs10504229	0.861	rs60346509	chr8:58196050	G/T	cg24829409	chr8:58192753	C8orf71	-0.55	-4.77	-0.39	5.18e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9788682	1.000	rs57064725	chr15:78833036	C/A	cg06917634	chr15:78832804	PSMA4	-0.7	-4.86	-0.4	3.47e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs35146811	0.735	rs6465766	chr7:99785671	A/G	cg22906224	chr7:99728672	NA	0.49	4.45	0.37	1.88e-5	Coronary artery disease;
TGCT	cis	rs208515	0.525	rs12191500	chr6:66668681	A/G	cg07460842	chr6:66804631	NA	0.85	8.73	0.62	1.41e-14	Exhaled nitric oxide levels;
TGCT	cis	rs6088590	0.931	rs6088617	chr20:33408036	G/A	cg06115741	chr20:33292138	TP53INP2	0.65	5.43	0.44	2.82e-7	Coronary artery disease;
TGCT	cis	rs17221829	0.614	rs2388202	chr11:89374231	T/C	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.63	-0.38	9.04e-6	Anxiety in major depressive disorder;
TGCT	cis	rs1775715	0.651	rs2808033	chr10:32194127	A/T	cg14930904	chr10:32216787	ARHGAP12	0.53	5.03	0.41	1.66e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg20887711	chr4:1340912	KIAA1530	0.78	6.53	0.51	1.51e-9	Longevity;
TGCT	cis	rs68170813	0.559	rs3779498	chr7:106923158	C/G	cg02696742	chr7:106810147	HBP1	-0.69	-5.81	-0.46	4.85e-8	Coronary artery disease;
TGCT	cis	rs3091242	0.967	rs3093614	chr1:25677844	T/A	cg00786635	chr1:25594202	NA	-0.53	-5.35	-0.43	4.08e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs9467773	1.000	rs9467779	chr6:26536687	A/T	cg15659132	chr6:26577336	NA	-0.83	-11.51	-0.72	2.61e-21	Intelligence (multi-trait analysis);
TGCT	cis	rs35785195	0.593	rs35746281	chr12:114236586	C/T	cg11070030	chr12:114232702	NA	0.26	4.45	0.37	1.87e-5	Daytime sleep phenotypes;
TGCT	cis	rs1075232	0.826	rs12437800	chr15:31671432	A/G	cg01030201	chr15:31746330	NA	-1.01	-5.26	-0.43	6.07e-7	Survival in colorectal cancer (non-distant metastatic);
TGCT	cis	rs7296418	0.961	rs1727307	chr12:123575742	A/G	cg00376283	chr12:123451042	ABCB9	0.82	7.08	0.54	9.57e-11	Platelet count;
TGCT	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.73	6.7	0.52	6.4e-10	Prudent dietary pattern;
TGCT	cis	rs6901004	0.933	rs12208141	chr6:111572138	A/G	cg15721981	chr6:111408429	SLC16A10	-0.52	-4.48	-0.37	1.66e-5	Blood metabolite levels;
TGCT	cis	rs7091068	0.671	rs1764322	chr10:95406276	T/G	cg20715218	chr10:95462985	C10orf4	-0.54	-5.12	-0.42	1.11e-6	Urinary tract infection frequency;
TGCT	trans	rs10435719	0.902	rs7459983	chr8:11807221	T/C	cg15556689	chr8:8085844	FLJ10661	0.79	7.5	0.56	1.09e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs67478160	0.643	rs11626377	chr14:104234357	G/A	cg26031613	chr14:104095156	KLC1	-0.63	-6.57	-0.51	1.25e-9	Schizophrenia;
TGCT	cis	rs2456568	0.741	rs2102332	chr11:93635281	G/T	cg14065697	chr11:93583672	C11orf90	-0.37	-4.63	-0.38	9.11e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7681440	0.874	rs1372525	chr4:90776165	G/A	cg14346243	chr4:90757452	SNCA	-0.56	-5.47	-0.44	2.41e-7	Dementia with Lewy bodies;
TGCT	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg07870213	chr5:140052090	DND1	0.59	7.11	0.54	8.14e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	trans	rs208520	1.000	rs12199876	chr6:66989469	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.83	7.46	0.56	1.31e-11	Exhaled nitric oxide output;
TGCT	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg11644478	chr21:40555479	PSMG1	-0.54	-5.1	-0.42	1.25e-6	Menarche (age at onset);
TGCT	trans	rs561341	0.609	rs7214626	chr17:30190989	G/A	cg20587970	chr11:113659929	NA	0.67	8.22	0.59	2.35e-13	Hip circumference adjusted for BMI;
TGCT	cis	rs478304	0.651	rs4014195	chr11:65506822	C/G	cg17480646	chr11:65405466	SIPA1	0.55	6.69	0.51	7.02e-10	Acne (severe);
TGCT	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg17971929	chr21:40555470	PSMG1	-0.51	-4.47	-0.37	1.74e-5	Menarche (age at onset);
TGCT	cis	rs8037137	0.571	rs3743445	chr15:91561182	C/T	cg23684204	chr15:91497937	RCCD1	0.4	4.5	0.37	1.57e-5	Platelet count;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
TGCT	cis	rs317865	0.737	rs73234648	chr4:16193602	T/C	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.78	5.11	0.42	1.18e-6	Kidney disease (early stage) in type 1 diabetes;
TGCT	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.48	-0.37	1.66e-5	Bipolar disorder;
TGCT	cis	rs4455778	0.735	rs10250566	chr7:49020113	C/A	cg26309511	chr7:48887640	NA	-0.43	-5.07	-0.41	1.4e-6	Lung cancer in never smokers;
TGCT	cis	rs7647973	1.000	rs8897	chr3:49460407	A/G	cg05785598	chr3:49045655	WDR6	0.36	4.52	0.38	1.45e-5	Menarche (age at onset);
TGCT	cis	rs10876993	0.855	rs1689604	chr12:58048304	T/C	cg15848620	chr12:58087721	OS9	-0.72	-5.82	-0.46	4.71e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs700651	0.789	rs882954	chr2:198907444	A/G	cg00792783	chr2:198669748	PLCL1	0.61	5.31	0.43	4.98e-7	Intracranial aneurysm;
TGCT	cis	rs4788570	0.578	rs7204992	chr16:71658444	G/A	cg06353428	chr16:71660113	MARVELD3	1.56	12.61	0.75	5.63e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs8051431	0.876	rs7185190	chr16:72019164	T/C	cg06353428	chr16:71660113	MARVELD3	0.57	4.54	0.38	1.31e-5	LDL cholesterol levels;
TGCT	cis	rs1008375	0.863	rs7680984	chr4:17600884	A/G	cg10189774	chr4:17578691	LAP3	0.74	6.19	0.49	8.18e-9	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4843185	0.637	rs4143866	chr16:85716366	A/G	cg06784122	chr16:85688175	KIAA0182	0.27	4.51	0.38	1.46e-5	Platelet distribution width;
TGCT	cis	rs1215050	0.740	rs1214997	chr4:99041533	A/T	cg17366294	chr4:99064904	C4orf37	0.58	6.17	0.48	8.78e-9	Waist-to-hip ratio adjusted for body mass index;
TGCT	trans	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg21659725	chr3:3221576	CRBN	0.98	15.33	0.81	2.1000000000000002e-30	Intelligence (multi-trait analysis);
TGCT	cis	rs68170813	0.559	rs2023892	chr7:106847686	C/T	cg02696742	chr7:106810147	HBP1	0.68	5.74	0.46	7e-8	Coronary artery disease;
TGCT	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg02891314	chr5:179741120	GFPT2	-0.41	-7.16	-0.54	6.21e-11	Height;
TGCT	cis	rs2797160	1.000	rs2747717	chr6:126008435	A/G	cg05901451	chr6:126070800	HEY2	0.72	6.11	0.48	1.18e-8	Endometrial cancer;
TGCT	cis	rs7714584	1.000	rs7709650	chr5:150246685	C/T	cg22134413	chr5:150180641	NA	0.93	6.99	0.53	1.52e-10	Crohn's disease;
TGCT	cis	rs9467711	1.000	rs6939799	chr6:26328366	G/A	cg26531700	chr6:26746687	NA	-0.94	-5.09	-0.42	1.28e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7659604	0.537	rs6815973	chr4:122663430	A/T	cg19748678	chr4:122722346	EXOSC9	-0.76	-6.82	-0.52	3.48e-10	Type 2 diabetes;
TGCT	cis	rs7615952	0.736	rs9862893	chr3:125686974	A/G	cg05084668	chr3:125655381	ALG1L	-0.81	-5.69	-0.46	8.63e-8	Blood pressure (smoking interaction);
TGCT	cis	rs4845570	0.920	rs11810571	chr1:151762308	C/G	cg07092448	chr1:151763213	TDRKH	1.11	9.43	0.65	3.09e-16	Coronary artery disease;
TGCT	cis	rs62103177	0.733	rs62103232	chr18:77635553	G/A	cg12964065	chr18:77638022	KCNG2	0.38	4.8	0.4	4.4e-6	Opioid sensitivity;
TGCT	cis	rs28595532	0.920	rs114938162	chr4:119756407	T/G	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs1018836	0.923	rs1858674	chr8:91580665	G/T	cg16814680	chr8:91681699	NA	-0.89	-9.58	-0.65	1.3e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.54	-4.62	-0.38	9.47e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs8103278	1.000	rs1548029	chr19:46309203	A/C	cg14061069	chr19:46274453	DMPK	-0.42	-5.82	-0.46	4.68e-8	Coronary artery disease;
TGCT	cis	rs752010	0.619	rs6702659	chr1:42112236	T/C	cg06885757	chr1:42089581	HIVEP3	0.28	5.02	0.41	1.78e-6	Lupus nephritis in systemic lupus erythematosus;
TGCT	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg22920501	chr2:26401640	FAM59B	-0.79	-5.33	-0.43	4.49e-7	Gut microbiome composition (summer);
TGCT	cis	rs13242816	1.000	rs34936262	chr7:116160022	G/A	cg16553024	chr7:116138462	CAV2	-0.45	-5.27	-0.43	5.81e-7	P wave duration;
TGCT	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg04317338	chr11:64019027	PLCB3	0.79	6.5	0.5	1.77e-9	Mean platelet volume;
TGCT	cis	rs2456568	0.802	rs8181567	chr11:93637209	C/T	cg16099599	chr11:93583650	C11orf90	-0.4	-5.12	-0.42	1.13e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs6500602	0.627	rs9934267	chr16:4534366	G/C	cg08645402	chr16:4508243	NA	0.2	5.01	0.41	1.86e-6	Schizophrenia;
TGCT	cis	rs614226	1.000	rs541126	chr12:120972396	C/T	cg10072921	chr12:121022843	NA	0.44	4.74	0.39	5.78e-6	Type 1 diabetes nephropathy;
TGCT	cis	rs11648796	0.721	rs743987	chr16:769566	C/G	cg00908189	chr16:619842	PIGQ	0.8	6.33	0.49	4.04e-9	Height;
TGCT	cis	rs1059312	0.932	rs4760593	chr12:129287220	A/G	cg09035930	chr12:129282057	SLC15A4	0.58	11.18	0.71	1.67e-20	Systemic lupus erythematosus;
TGCT	cis	rs67478160	0.643	rs4900600	chr14:104291839	A/G	cg26031613	chr14:104095156	KLC1	-0.63	-6.53	-0.51	1.56e-9	Schizophrenia;
TGCT	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg26531700	chr6:26746687	NA	-0.54	-4.87	-0.4	3.36e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs17826219	0.706	rs8071236	chr17:29100002	T/C	cg13385521	chr17:29058706	SUZ12P	0.82	4.86	0.4	3.52e-6	Body mass index;
TGCT	cis	rs66569888	0.507	rs17032699	chr2:106886471	A/G	cg15412446	chr2:106886593	NA	-0.53	-6.76	-0.52	4.9e-10	Facial morphology (factor 23);
TGCT	cis	rs8077577	0.945	rs62073611	chr17:18071961	C/G	cg09161412	chr17:18057145	MYO15A	-0.67	-5.44	-0.44	2.69e-7	Obesity-related traits;
TGCT	cis	rs17826219	0.714	rs11650821	chr17:28968150	T/C	cg14008862	chr17:28927542	LRRC37B2	0.88	5.32	0.43	4.75e-7	Body mass index;
TGCT	cis	rs4843747	0.671	rs28465438	chr16:88103714	G/A	cg06915872	chr16:87998081	BANP	-0.3	-4.61	-0.38	9.69e-6	Menopause (age at onset);
TGCT	cis	rs6558530	0.666	rs6558523	chr8:1702504	T/C	cg09410841	chr8:1729607	CLN8	0.71	6.43	0.5	2.56e-9	Systolic blood pressure;
TGCT	cis	rs2288278	0.580	rs11652746	chr17:46592811	A/G	cg25032089	chr17:46643351	HOXB3	-0.42	-5.0	-0.41	1.87e-6	Hand grip strength;
TGCT	cis	rs7824557	0.688	rs2572397	chr8:11176403	G/A	cg21775007	chr8:11205619	TDH	0.56	5.14	0.42	1.05e-6	Retinal vascular caliber;
TGCT	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg18876405	chr7:65276391	NA	0.33	5.05	0.41	1.55e-6	Aortic root size;
TGCT	cis	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg07424592	chr7:64974309	NA	1.4	8.42	0.6	7.87e-14	Diabetic kidney disease;
TGCT	cis	rs10489525	0.599	rs7516121	chr1:115604317	A/G	cg12756093	chr1:115239321	AMPD1	-0.41	-5.51	-0.44	1.96e-7	Autism;
TGCT	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg00343986	chr7:65444356	GUSB	-0.2	-4.51	-0.38	1.51e-5	Aortic root size;
TGCT	cis	rs7599312	0.534	rs2371615	chr2:213405660	G/T	cg16329650	chr2:213403929	ERBB4	1.06	16.53	0.83	3.82e-33	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs3858526	0.959	rs10838901	chr11:5959128	G/A	cg05234568	chr11:5960015	NA	-0.45	-4.54	-0.38	1.3e-5	DNA methylation (variation);
TGCT	cis	rs4366490	1.000	rs7948969	chr11:62907048	A/C	cg21002970	chr11:62369079	MTA2	0.87	4.69	0.39	6.98e-6	Conotruncal heart defects;
TGCT	cis	rs2594989	0.943	rs1391903	chr3:11423271	C/G	cg00170343	chr3:11313890	ATG7	-0.67	-4.99	-0.41	2.01e-6	Circulating chemerin levels;
TGCT	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.94	7.92	0.58	1.17e-12	Platelet count;
TGCT	cis	rs11098499	0.954	rs10031483	chr4:120422636	T/C	cg09307838	chr4:120376055	NA	0.68	6.37	0.5	3.41e-9	Corneal astigmatism;
TGCT	cis	rs9467773	0.549	rs9467805	chr6:26583366	C/T	cg26531700	chr6:26746687	NA	0.5	4.74	0.39	5.69e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2153535	0.580	rs1577468	chr6:8444266	C/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.58	0.45	1.42e-7	Motion sickness;
TGCT	cis	rs79349575	0.811	rs80032154	chr17:47014992	C/A	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.5	-0.37	1.53e-5	Type 2 diabetes;
TGCT	cis	rs1372520	0.577	rs2737028	chr4:90717016	A/G	cg14346243	chr4:90757452	SNCA	-0.68	-5.58	-0.45	1.43e-7	Neuroticism;
TGCT	trans	rs2688608	0.698	rs2633323	chr10:75694826	G/A	cg13918328	chr10:52500089	ASAH2B	0.68	6.89	0.53	2.56e-10	Inflammatory bowel disease;
TGCT	cis	rs17152411	0.895	rs11245419	chr10:126586392	A/T	cg07906193	chr10:126599966	NA	0.41	5.05	0.41	1.52e-6	Height;
TGCT	cis	rs9549260	0.564	rs6563844	chr13:41298190	T/C	cg21288729	chr13:41239152	FOXO1	0.91	8.35	0.6	1.12e-13	Red blood cell count;
TGCT	cis	rs561341	0.663	rs72821936	chr17:30224068	C/G	cg13647721	chr17:30228624	UTP6	0.6	5.32	0.43	4.72e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs10782582	0.569	rs1770892	chr1:76389359	T/C	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.55	4.76	0.39	5.28e-6	Daytime sleep phenotypes;
TGCT	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg22535103	chr8:58192502	C8orf71	-0.42	-4.79	-0.4	4.7e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1532993	0.518	rs3974914	chr4:98605767	G/A	cg05340658	chr4:99064831	C4orf37	-0.41	-4.96	-0.41	2.3e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs13326165	0.760	rs34762015	chr3:52366044	G/A	cg27565382	chr3:53032988	SFMBT1	0.37	4.89	0.4	3.1e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs698813	0.674	rs7590224	chr2:44501209	T/G	cg00619915	chr2:44497795	NA	-0.22	-5.06	-0.41	1.48e-6	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
TGCT	cis	rs72717009	0.825	rs10494360	chr1:161475750	G/A	cg23840854	chr1:161414152	NA	-0.98	-5.87	-0.47	3.79e-8	Rheumatoid arthritis;
TGCT	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg22968622	chr17:43663579	NA	1.29	11.02	0.7	4.06e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7833790	0.963	rs6473312	chr8:82732515	C/A	cg17211192	chr8:82754475	SNX16	-1.06	-8.63	-0.61	2.54e-14	Diastolic blood pressure;
TGCT	cis	rs2075371	0.830	rs2077671	chr7:133951204	C/T	cg11752832	chr7:134001865	SLC35B4	0.68	5.89	0.47	3.32e-8	Mean platelet volume;
TGCT	cis	rs2239785	0.959	rs136159	chr22:36657023	T/C	cg15716373	chr22:36655542	APOL1	-0.42	-4.85	-0.4	3.59e-6	Glomerulosclerosis;
TGCT	cis	rs10782582	0.609	rs2029682	chr1:76341619	T/C	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.52	4.53	0.38	1.37e-5	Daytime sleep phenotypes;
TGCT	cis	rs1008375	1.000	rs2315560	chr4:17677305	C/G	cg18681998	chr4:17616180	MED28	0.89	10.29	0.68	2.47e-18	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs362272	0.505	rs13104157	chr4:3366950	T/C	cg18352616	chr4:3374830	RGS12	0.26	5.27	0.43	5.79e-7	Serum sulfate level;
TGCT	cis	rs6490294	0.904	rs9630276	chr12:112404838	G/A	cg10833066	chr12:111807467	FAM109A	0.38	5.67	0.45	9.69e-8	Mean platelet volume;
TGCT	cis	rs35146811	0.735	rs1727133	chr7:99812870	C/T	cg04778012	chr7:99775508	STAG3;GPC2	-0.35	-4.93	-0.41	2.55e-6	Coronary artery disease;
TGCT	cis	rs2153535	0.601	rs718504	chr6:8527512	A/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.01	0.41	1.86e-6	Motion sickness;
TGCT	cis	rs4466137	0.953	rs6869030	chr5:83007311	C/T	cg16102102	chr5:83017553	HAPLN1	-1.11	-11.15	-0.71	1.97e-20	Prostate cancer;
TGCT	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg18876405	chr7:65276391	NA	0.36	5.7	0.46	8.31e-8	Aortic root size;
TGCT	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg26338869	chr17:61819248	STRADA	-0.53	-4.85	-0.4	3.68e-6	Prudent dietary pattern;
TGCT	cis	rs9929218	0.551	rs3785134	chr16:68728938	C/T	cg01251360	chr16:68772225	CDH1	-0.27	-5.16	-0.42	9.67e-7	Colorectal cancer;
TGCT	cis	rs9894429	1.000	rs7223613	chr17:79574803	C/T	cg21028142	chr17:79581711	NPLOC4	-0.29	-6.81	-0.52	3.83e-10	Eye color traits;
TGCT	cis	rs7552404	0.691	rs5745449	chr1:76344711	A/T	cg22875332	chr1:76189707	ACADM	-0.68	-7.11	-0.54	7.96e-11	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg00684032	chr4:1343700	KIAA1530	-0.22	-4.71	-0.39	6.57e-6	Obesity-related traits;
TGCT	cis	rs72781680	0.752	rs72796116	chr2:23913769	C/T	cg08917208	chr2:24149416	ATAD2B	1.0	5.79	0.46	5.41e-8	Lymphocyte counts;
TGCT	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	5.38	0.44	3.58e-7	Alzheimer's disease;
TGCT	cis	rs2288073	0.965	rs10173173	chr2:24415461	G/T	cg02683114	chr2:24398427	C2orf84	0.25	5.67	0.45	9.72e-8	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs6921919	0.515	rs1558205	chr6:28382262	A/C	cg13525197	chr6:28411240	ZSCAN23	0.46	4.44	0.37	1.95e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs77972916	0.609	rs72790903	chr2:43561985	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.39	-4.46	-0.37	1.78e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs6684514	1.000	rs12118238	chr1:156235221	G/A	cg20302342	chr1:156215951	PAQR6	0.35	4.64	0.38	8.77e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs6964587	0.900	rs6465352	chr7:91775117	A/G	cg22709100	chr7:91322751	NA	0.29	4.62	0.38	9.33e-6	Breast cancer;
TGCT	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs68170813	0.559	rs7800443	chr7:106910723	G/A	cg02696742	chr7:106810147	HBP1	-0.69	-5.61	-0.45	1.27e-7	Coronary artery disease;
TGCT	cis	rs346785	0.692	rs2279053	chr17:74287389	C/T	cg09812376	chr17:74270190	QRICH2	0.37	5.68	0.45	9.02e-8	White matter hyperintensities in ischemic stroke;
TGCT	cis	rs6967414	0.792	rs6954012	chr7:6755724	A/C	cg09896999	chr7:6746977	ZNF12	-0.56	-6.34	-0.49	3.83e-9	Hematocrit;Hemoglobin concentration;
TGCT	cis	rs9837602	0.529	rs793459	chr3:99520591	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.58	6.71	0.52	6.1e-10	Breast cancer;
TGCT	cis	rs422249	0.547	rs174533	chr11:61549025	G/A	cg01500311	chr11:61656094	FADS3	-0.34	-5.63	-0.45	1.16e-7	Trans fatty acid levels;
TGCT	cis	rs2050392	0.517	rs7096279	chr10:30759608	C/T	cg18806716	chr10:30721971	MAP3K8	-0.46	-5.43	-0.44	2.79e-7	Inflammatory bowel disease;
TGCT	cis	rs2832077	0.527	rs2776210	chr21:30268558	A/G	cg24692254	chr21:30365293	RNF160	0.62	5.48	0.44	2.26e-7	Cognitive test performance;
TGCT	cis	rs7666738	0.791	rs34152299	chr4:98929862	G/C	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg23708337	chr7:1209742	NA	0.51	4.46	0.37	1.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7940866	0.774	rs10894292	chr11:130820757	C/T	cg05962950	chr11:130786565	SNX19	0.68	6.75	0.52	5.03e-10	Schizophrenia;
TGCT	cis	rs7172809	0.573	rs78481361	chr15:77654784	C/T	cg22256960	chr15:77711686	NA	-0.51	-4.81	-0.4	4.29e-6	Glucose homeostasis traits;
TGCT	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg22963979	chr7:1858916	MAD1L1	-0.4	-6.04	-0.48	1.63e-8	Bipolar disorder and schizophrenia;
TGCT	cis	rs9916302	0.904	rs8068427	chr17:37511517	G/A	cg07936489	chr17:37558343	FBXL20	0.63	4.91	0.4	2.83e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs524281	0.692	rs2452681	chr11:65814842	G/A	cg00563793	chr11:65837595	PACS1	-0.54	-4.92	-0.4	2.69e-6	Electroencephalogram traits;
TGCT	cis	rs6426558	0.502	rs2813970	chr1:227410637	C/T	cg10327440	chr1:227177885	CDC42BPA	0.58	6.52	0.51	1.62e-9	Neutrophil percentage of white cells;
TGCT	cis	rs7267979	1.000	rs7020	chr20:25278600	G/A	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7781977	0.782	rs9886239	chr7:50336551	A/C	cg01139861	chr7:50343298	IKZF1	0.52	5.75	0.46	6.62e-8	IgG glycosylation;
TGCT	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg17178900	chr1:205818956	PM20D1	0.56	7.03	0.53	1.2e-10	Menarche (age at onset);
TGCT	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg11644478	chr21:40555479	PSMG1	-0.52	-4.9	-0.4	2.98e-6	Menarche (age at onset);
TGCT	cis	rs2235642	0.821	rs2281234	chr16:1602938	A/G	cg07341220	chr16:1583899	IFT140;TMEM204	-0.29	-4.56	-0.38	1.23e-5	Coronary artery disease;
TGCT	cis	rs10782582	0.609	rs76260657	chr1:76338017	C/T	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.52	4.53	0.38	1.37e-5	Daytime sleep phenotypes;
TGCT	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg20607798	chr8:58055168	NA	0.49	4.67	0.39	7.56e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs11676855	0.924	rs11680626	chr2:235927511	A/T	cg14917874	chr2:235941519	SH3BP4	-0.23	-5.02	-0.41	1.75e-6	Dialysis-related mortality;
TGCT	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg26338869	chr17:61819248	STRADA	-0.55	-5.02	-0.41	1.73e-6	Prudent dietary pattern;
TGCT	cis	rs854765	1.000	rs854765	chr17:18012730	T/C	cg09796270	chr17:17721594	SREBF1	-0.27	-5.26	-0.43	6.14e-7	Total body bone mineral density;
TGCT	cis	rs367943	0.966	rs455435	chr5:112799412	T/C	cg12552261	chr5:112820674	MCC	-0.24	-4.91	-0.4	2.81e-6	Type 2 diabetes;
TGCT	cis	rs4478037	0.558	rs56106158	chr3:33081833	A/G	cg19404215	chr3:33155277	CRTAP	1.09	5.31	0.43	4.86e-7	Major depressive disorder;
TGCT	cis	rs694739	1.000	rs1783521	chr11:64106291	T/C	cg23796481	chr11:64053134	BAD;GPR137	0.68	7.11	0.54	8.07e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs10484885	0.752	rs72921948	chr6:90582560	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.55	-6.49	-0.5	1.87e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs12681287	0.640	rs13252046	chr8:87477751	G/T	cg27223183	chr8:87520930	FAM82B	-0.89	-6.41	-0.5	2.8e-9	Caudate activity during reward;
TGCT	cis	rs2964802	0.505	rs6865234	chr5:10829742	C/A	cg14521931	chr5:10832172	NA	-0.26	-4.46	-0.37	1.78e-5	Major depressive disorder;Recurrent major depressive disorder;
TGCT	cis	rs2594989	0.837	rs7642031	chr3:11453754	G/A	cg00170343	chr3:11313890	ATG7	0.72	5.37	0.43	3.8e-7	Circulating chemerin levels;
TGCT	cis	rs3772130	0.962	rs9839617	chr3:121516577	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.72	0.39	6.25e-6	Cognitive performance;
TGCT	cis	rs713587	0.713	rs4665276	chr2:25213333	C/T	cg01884057	chr2:25150051	NA	-0.38	-7.82	-0.57	1.95e-12	Body mass index in non-asthmatics;
TGCT	cis	rs62064224	0.765	rs62065463	chr17:30732405	G/T	cg18200150	chr17:30822561	MYO1D	0.58	7.84	0.58	1.73e-12	Schizophrenia;
TGCT	cis	rs11249608	0.548	rs17078988	chr5:178459283	A/G	cg01312482	chr5:178451176	ZNF879	-0.47	-4.68	-0.39	7.41e-6	Pubertal anthropometrics;
TGCT	cis	rs9985766	1.000	rs28374205	chr4:150997822	A/G	cg05926478	chr4:151174724	DCLK2	-0.24	-4.64	-0.38	8.63e-6	Coronary artery disease;Myocardial infarction;
TGCT	cis	rs78487399	0.808	rs10169346	chr2:43741105	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.07	-0.41	1.41e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs17376456	0.935	rs13156002	chr5:93508931	G/A	cg25358565	chr5:93447407	FAM172A	0.95	7.97	0.58	8.71e-13	Diabetic retinopathy;
TGCT	cis	rs3617	0.572	rs2245538	chr3:52852060	T/C	cg10802521	chr3:52805072	NEK4	-0.6	-6.89	-0.53	2.46e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs11650494	0.831	rs7216993	chr17:47454263	A/G	cg08112188	chr17:47440006	ZNF652	0.92	5.02	0.41	1.74e-6	Prostate cancer;
TGCT	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg24675658	chr1:53192096	ZYG11B	0.7	7.98	0.58	8.59e-13	Monocyte count;
TGCT	cis	rs12971120	1.000	rs734559	chr18:72179579	G/A	cg26446133	chr18:72167187	CNDP2	-0.33	-6.03	-0.48	1.74e-8	Refractive error;
TGCT	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.31	-4.76	-0.39	5.36e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg04025307	chr7:1156635	C7orf50	0.2	4.73	0.39	5.94e-6	Longevity;Endometriosis;
TGCT	cis	rs8013055	0.706	rs8003957	chr14:105971702	A/G	cg19700328	chr14:106028568	NA	-0.57	-6.12	-0.48	1.12e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.07	0.48	1.47e-8	Bipolar disorder;
TGCT	cis	rs4372836	1.000	rs4666119	chr2:28975690	C/G	cg09522027	chr2:28974177	PPP1CB	-0.62	-5.43	-0.44	2.87e-7	Body mass index;
TGCT	cis	rs12188164	1.000	rs34847072	chr5:437862	G/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.4	-4.74	-0.39	5.75e-6	Cystic fibrosis severity;
TGCT	cis	rs2742417	0.603	rs2742449	chr3:45764544	T/C	cg04837898	chr3:45731254	SACM1L	-0.65	-6.95	-0.53	1.84e-10	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs67311347	1.000	rs11539046	chr3:40503809	G/A	cg17264618	chr3:40429014	ENTPD3	-0.32	-4.64	-0.38	8.57e-6	Renal cell carcinoma;
TGCT	cis	rs344364	0.511	rs2917515	chr16:1945271	G/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.45	-5.08	-0.42	1.35e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	trans	rs61931739	0.500	rs7306435	chr12:34482933	A/G	cg26384229	chr12:38710491	ALG10B	-0.79	-7.45	-0.56	1.36e-11	Morning vs. evening chronotype;
TGCT	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg06873352	chr17:61820015	STRADA	0.55	6.13	0.48	1.09e-8	Prudent dietary pattern;
TGCT	cis	rs12477438	0.798	rs1453561	chr2:99613924	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-5.75	-0.46	6.58e-8	Chronic sinus infection;
TGCT	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg11764359	chr7:65958608	NA	0.61	5.47	0.44	2.35e-7	Aortic root size;
TGCT	cis	rs7572733	0.555	rs7420608	chr2:198915930	A/T	cg00792783	chr2:198669748	PLCL1	0.57	4.97	0.41	2.14e-6	Dermatomyositis;
TGCT	cis	rs2760061	0.819	rs964941	chr1:228193857	G/A	cg18477163	chr1:228402036	OBSCN	0.34	7.16	0.54	6.26e-11	Diastolic blood pressure;
TGCT	cis	rs7914558	1.000	rs12255047	chr10:104760752	G/A	cg05855489	chr10:104503620	C10orf26	0.51	4.53	0.38	1.39e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.0	8.22	0.59	2.32e-13	Platelet count;
TGCT	cis	rs7918232	0.941	rs10741128	chr10:27411509	G/A	cg14442939	chr10:27389572	ANKRD26	0.72	5.35	0.43	4.16e-7	Breast cancer;
TGCT	cis	rs114540395	0.925	rs115878498	chr10:103447267	G/A	cg03300883	chr10:102748874	C10orf2	0.44	4.89	0.4	3.06e-6	Schizophrenia;
TGCT	cis	rs6582630	0.599	rs8175936	chr12:38426315	C/G	cg26384229	chr12:38710491	ALG10B	-0.54	-4.81	-0.4	4.32e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs73058052	0.597	rs11083979	chr19:50096144	T/C	cg09250473	chr19:50168907	IRF3;BCL2L12	0.65	5.22	0.42	7.33e-7	Fibrinogen levels;
TGCT	cis	rs826838	0.935	rs1684406	chr12:39127265	A/G	cg26384229	chr12:38710491	ALG10B	-0.86	-7.72	-0.57	3.37e-12	Heart rate;
TGCT	cis	rs1371867	0.641	rs1788209	chr8:101337056	C/T	cg00191853	chr8:101177733	SPAG1	-0.23	-4.73	-0.39	6.08e-6	Atrioventricular conduction;
TGCT	cis	rs514475	0.526	rs12201110	chr6:137954963	G/A	cg02673417	chr6:137105249	MAP3K5	0.29	4.45	0.37	1.88e-5	Inflammatory skin disease;
TGCT	cis	rs244731	0.959	rs6872021	chr5:176610012	G/A	cg16006841	chr5:176797999	RGS14	-0.53	-6.95	-0.53	1.88e-10	Urate levels in lean individuals;
TGCT	cis	rs892961	0.932	rs12452788	chr17:75406866	T/C	cg05865280	chr17:75406074	SEPT9	0.28	6.75	0.52	5.04e-10	Airflow obstruction;
TGCT	cis	rs7192750	0.586	rs8058118	chr16:71959733	T/C	cg06353428	chr16:71660113	MARVELD3	0.81	7.15	0.54	6.72e-11	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs514406	0.584	rs12095247	chr1:53193796	A/C	cg24675658	chr1:53192096	ZYG11B	0.86	10.84	0.7	1.11e-19	Monocyte count;
TGCT	cis	rs2766547	0.669	rs1831030	chr6:35706933	C/T	cg01618151	chr6:35707957	C6orf81	-0.27	-4.6	-0.38	1.04e-5	Eosinophil percentage of granulocytes;
TGCT	cis	rs910316	0.726	rs175040	chr14:75469555	A/G	cg11812906	chr14:75593930	NEK9	-0.58	-5.55	-0.45	1.67e-7	Height;
TGCT	cis	rs10504229	1.000	rs67096506	chr8:58195655	G/A	cg08280861	chr8:58055591	NA	0.36	4.61	0.38	9.98e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg21963583	chr11:68658836	MRPL21	0.39	6.34	0.49	3.91e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7681440	0.967	rs1372517	chr4:90755909	G/A	cg14346243	chr4:90757452	SNCA	-0.58	-5.74	-0.46	6.79e-8	Dementia with Lewy bodies;
TGCT	cis	rs7103648	0.966	rs1377416	chr11:47416746	C/T	cg20307385	chr11:47447363	PSMC3	1.01	11.91	0.73	2.85e-22	Diastolic blood pressure;Systolic blood pressure;
TGCT	cis	rs12220238	1.000	rs10824151	chr10:76092179	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.95	6.66	0.51	8.08e-10	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs11190604	1.000	rs7071271	chr10:102264824	G/A	cg23241863	chr10:102295624	HIF1AN	0.67	5.13	0.42	1.1e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2439831	1.000	rs471229	chr15:43733994	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.8	5.7	0.46	8.33e-8	Lung cancer in ever smokers;
TGCT	cis	rs2836974	0.931	rs2989330	chr21:40716209	A/G	cg11644478	chr21:40555479	PSMG1	0.87	7.35	0.55	2.36e-11	Cognitive function;
TGCT	cis	rs9921338	0.781	rs7205925	chr16:11462478	C/T	cg00044050	chr16:11439710	C16orf75	-0.63	-4.68	-0.39	7.33e-6	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs6598955	0.543	rs6699798	chr1:26556442	G/T	cg04990556	chr1:26633338	UBXN11	0.8	7.3	0.55	3.01e-11	Obesity-related traits;
TGCT	cis	rs6121246	0.909	rs7272062	chr20:30259145	A/G	cg13852791	chr20:30311386	BCL2L1	0.78	5.8	0.46	5.15e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs290268	1.000	rs188313	chr9:93548302	C/T	cg02608019	chr9:93564028	SYK	0.48	4.8	0.4	4.42e-6	Platelet count;
TGCT	cis	rs11098499	0.863	rs6534139	chr4:120449456	A/G	cg09307838	chr4:120376055	NA	-0.71	-6.47	-0.5	2.03e-9	Corneal astigmatism;
TGCT	cis	rs17125944	0.686	rs55685925	chr14:53334546	A/G	cg00686598	chr14:53173677	PSMC6	-0.87	-4.5	-0.37	1.53e-5	Alzheimer's disease (late onset);
TGCT	cis	rs11148252	0.774	rs7993748	chr13:52941631	C/T	cg00495681	chr13:53174319	NA	0.55	5.42	0.44	3e-7	Lewy body disease;
TGCT	cis	rs7582180	0.629	rs6757754	chr2:100951273	C/T	cg08017756	chr2:100939284	LONRF2	0.3	4.95	0.41	2.34e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1371867	0.846	rs1660323	chr8:101278724	T/A	cg00191853	chr8:101177733	SPAG1	-0.22	-4.5	-0.37	1.53e-5	Atrioventricular conduction;
TGCT	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg06896619	chr17:61851486	DDX42;CCDC47	0.53	5.56	0.45	1.58e-7	Prudent dietary pattern;
TGCT	cis	rs1055129	0.560	rs56248937	chr17:73915153	T/A	cg10935138	chr17:73851978	WBP2	0.54	4.71	0.39	6.58e-6	White matter hyperintensity burden;
TGCT	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg25036284	chr2:26402008	FAM59B	0.65	5.19	0.42	8.36e-7	Gut microbiome composition (summer);
TGCT	cis	rs3540	0.574	rs2601205	chr15:90961813	A/G	cg22089800	chr15:90895588	ZNF774	0.76	8.15	0.59	3.42e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs7959452	0.590	rs56054057	chr12:69775972	C/T	cg20891283	chr12:69753455	YEATS4	0.83	8.7	0.62	1.68e-14	Blood protein levels;
TGCT	cis	rs6570726	1.000	rs374464	chr6:145846679	A/C	cg23711669	chr6:146136114	FBXO30	0.68	6.26	0.49	5.81e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs13393800	0.536	rs2697802	chr2:233381175	C/T	cg26635044	chr2:233757626	NGEF	0.17	4.89	0.4	3.11e-6	Height;
TGCT	cis	rs909674	0.731	rs6001594	chr22:39837472	C/T	cg11247378	chr22:39784982	NA	-0.73	-8.47	-0.61	5.86e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs7611238	0.560	rs6771771	chr3:195083233	T/A	cg27323046	chr3:195102265	ACAP2	0.39	5.1	0.42	1.25e-6	Body mass index;
TGCT	cis	rs10791323	0.572	rs4412766	chr11:133742811	A/C	cg15485101	chr11:133734466	NA	0.41	5.83	0.46	4.6e-8	Childhood ear infection;
TGCT	cis	rs9436747	0.777	rs1475398	chr1:65983257	C/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.58	5.05	0.41	1.51e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs7095607	0.813	rs4451608	chr10:69933238	C/A	cg18986048	chr10:69913749	MYPN	0.46	5.24	0.43	6.65e-7	Lung function (FVC);
TGCT	cis	rs910316	0.664	rs2098252	chr14:75492732	T/C	cg08847533	chr14:75593920	NEK9	0.84	8.77	0.62	1.16e-14	Height;
TGCT	cis	rs9527	0.571	rs3740400	chr10:104629465	T/G	cg04362960	chr10:104952993	NT5C2	0.56	4.83	0.4	4e-6	Arsenic metabolism;
TGCT	cis	rs66569888	0.507	rs11673736	chr2:106886935	T/C	cg15412446	chr2:106886593	NA	-0.53	-6.8	-0.52	3.87e-10	Facial morphology (factor 23);
TGCT	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg06212747	chr3:49208901	KLHDC8B	0.61	5.51	0.44	1.95e-7	Parkinson's disease;
TGCT	cis	rs62380364	0.602	rs665324	chr5:88055517	T/C	cg24804195	chr5:87968844	LOC645323	-0.57	-5.56	-0.45	1.59e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs6582630	0.502	rs4559747	chr12:38436235	G/A	cg26384229	chr12:38710491	ALG10B	0.83	7.58	0.56	6.92e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs79057730	0.599	rs112891948	chr7:816059	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.65	6.07	0.48	1.42e-8	Initial pursuit acceleration;
TGCT	cis	rs4820539	1.000	rs5759595	chr22:23471624	G/A	cg21100191	chr22:23484243	RTDR1	0.89	10.61	0.69	4.23e-19	Bone mineral density;
TGCT	cis	rs6993813	0.620	rs12056346	chr8:120042191	T/C	cg17171407	chr8:119960777	TNFRSF11B	0.26	4.66	0.39	8.02e-6	Bone mineral density (hip);
TGCT	cis	rs12142240	0.698	rs55971480	chr1:46823206	G/T	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs992157	0.764	rs1870123	chr2:219187698	G/A	cg00012203	chr2:219082015	ARPC2	0.71	6.65	0.51	8.23e-10	Colorectal cancer;
TGCT	cis	rs7267979	0.966	rs2261698	chr20:25259910	A/G	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg06896619	chr17:61851486	DDX42;CCDC47	-0.51	-4.96	-0.41	2.24e-6	Prudent dietary pattern;
TGCT	cis	rs3792900	0.509	rs6596299	chr5:135570567	A/C	cg00308130	chr5:135415190	NA	0.32	4.72	0.39	6.26e-6	Insomnia;Blood protein levels;
TGCT	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg05785598	chr3:49045655	WDR6	0.39	5.17	0.42	9.24e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs62244186	0.715	rs11130032	chr3:44704083	G/A	cg02073558	chr3:44770973	ZNF501	0.63	6.03	0.48	1.77e-8	Depressive symptoms;
TGCT	cis	rs11264213	0.591	rs619666	chr1:36488956	C/T	cg27506609	chr1:36549197	TEKT2	-0.31	-4.47	-0.37	1.77e-5	Schizophrenia;
TGCT	cis	rs1371867	0.817	rs7846076	chr8:101327629	A/G	cg06636551	chr8:101224915	SPAG1	-0.42	-5.65	-0.45	1.06e-7	Atrioventricular conduction;
TGCT	cis	rs208520	0.742	rs208454	chr6:66907783	T/C	cg07460842	chr6:66804631	NA	-0.9	-9.14	-0.63	1.54e-15	Exhaled nitric oxide output;
TGCT	cis	rs244731	0.959	rs4976677	chr5:176629546	G/A	cg06060754	chr5:176797920	RGS14	-0.44	-6.2	-0.49	7.79e-9	Urate levels in lean individuals;
TGCT	cis	rs3096299	0.967	rs7205785	chr16:89458984	A/G	cg02187348	chr16:89574699	SPG7	0.5	4.7	0.39	6.85e-6	Multiple myeloma (IgH translocation);
TGCT	cis	rs5750830	0.594	rs6001568	chr22:39775786	G/A	cg02038168	chr22:39784481	NA	-0.63	-5.38	-0.44	3.5e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs28595532	1.000	rs116030177	chr4:119650768	T/C	cg21605333	chr4:119757512	SEC24D	1.36	7.39	0.55	1.89e-11	Cannabis dependence symptom count;
TGCT	trans	rs797680	0.789	rs35940311	chr1:93663604	G/A	cg27528825	chr2:159282178	CCDC148	-0.35	-6.95	-0.53	1.87e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs17433780	0.504	rs1409150	chr1:89473175	A/G	cg09516651	chr1:89888402	LOC400759	0.24	5.03	0.41	1.69e-6	Carotid intima media thickness;
TGCT	cis	rs10782582	0.593	rs12132750	chr1:76136222	A/G	cg10523679	chr1:76189770	ACADM	-0.68	-7.05	-0.53	1.11e-10	Daytime sleep phenotypes;
TGCT	cis	rs17253792	0.822	rs17747083	chr14:56110594	T/C	cg01858014	chr14:56050164	KTN1	-0.35	-4.5	-0.37	1.53e-5	Putamen volume;
TGCT	cis	rs10927875	0.541	rs1048334	chr1:16340761	T/C	cg21385522	chr1:16154831	NA	0.46	4.85	0.4	3.64e-6	Dilated cardiomyopathy;
TGCT	cis	rs4927850	0.529	rs6800500	chr3:195833507	T/C	cg02975922	chr3:195473998	MUC4	-0.24	-4.68	-0.39	7.34e-6	Pancreatic cancer;
TGCT	cis	rs11785400	1.000	rs7002932	chr8:143738816	C/A	cg24634471	chr8:143751801	JRK	0.57	6.12	0.48	1.11e-8	Schizophrenia;
TGCT	cis	rs4711350	0.953	rs1951930	chr6:33782655	C/A	cg18005901	chr6:33739558	LEMD2	-0.57	-5.8	-0.46	5.11e-8	Schizophrenia;
TGCT	cis	rs7044106	0.708	rs920745	chr9:123429943	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.61	6.47	0.5	2.01e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs10791097	0.694	rs7106973	chr11:130758113	G/A	cg05962950	chr11:130786565	SNX19	0.94	12.01	0.73	1.58e-22	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs7647973	1.000	rs12583	chr3:49571462	G/T	cg07636037	chr3:49044803	WDR6	-0.59	-4.6	-0.38	1.03e-5	Menarche (age at onset);
TGCT	cis	rs9467711	0.591	rs28360595	chr6:26030044	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.59	-4.63	-0.38	9.26e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs739496	0.843	rs7398705	chr12:112016016	A/C	cg10833066	chr12:111807467	FAM109A	-0.37	-5.41	-0.44	3.17e-7	Platelet count;
TGCT	cis	rs6138458	0.743	rs3746330	chr20:24999795	A/G	cg26195577	chr20:24973756	C20orf3	1.02	9.35	0.64	4.61e-16	Blood protein levels;
TGCT	cis	rs2721173	0.619	rs997258	chr8:145903077	C/A	cg15320075	chr8:145703422	NA	-0.64	-5.84	-0.46	4.31e-8	Educational attainment;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
TGCT	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.75	5.41	0.44	3.09e-7	Platelet count;
TGCT	cis	rs6582630	0.576	rs4882372	chr12:38356609	C/A	cg26384229	chr12:38710491	ALG10B	-0.52	-4.51	-0.38	1.5e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg13866156	chr1:1669148	SLC35E2	-0.21	-5.12	-0.42	1.11e-6	Body mass index;
TGCT	cis	rs4901869	0.966	rs4901870	chr14:59334221	A/T	cg02291164	chr14:59296302	NA	-0.25	-4.65	-0.39	8.39e-6	Panic disorder;
TGCT	cis	rs2963155	0.518	rs864355	chr5:142633229	A/G	cg17617527	chr5:142782415	NR3C1	0.85	6.29	0.49	4.9e-9	Breast cancer;
TGCT	cis	rs3733585	0.660	rs13122290	chr4:9933832	A/G	cg00071950	chr4:10020882	SLC2A9	-0.61	-7.25	-0.55	3.96e-11	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs9653442	0.835	rs11694875	chr2:100732845	A/G	cg22139774	chr2:100720529	AFF3	0.45	7.92	0.58	1.17e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs7635838	0.827	rs9826044	chr3:11458075	A/G	cg00170343	chr3:11313890	ATG7	0.64	6.16	0.48	9.46e-9	HDL cholesterol;
TGCT	cis	rs6500602	0.701	rs11643057	chr16:4544505	C/T	cg08645402	chr16:4508243	NA	0.21	5.36	0.43	3.98e-7	Schizophrenia;
TGCT	cis	rs236907	0.859	rs17596081	chr1:171746276	G/T	cg20598894	chr1:171756153	METTL13	-0.18	-4.53	-0.38	1.34e-5	Mean platelet volume;
TGCT	cis	rs8141529	0.732	rs5762815	chr22:29205076	A/G	cg02153584	chr22:29168773	CCDC117	0.67	5.68	0.45	9.04e-8	Lymphocyte counts;
TGCT	cis	rs7647973	0.626	rs62262672	chr3:49655927	T/A	cg03034192	chr3:50606346	HEMK1;C3orf18	-0.36	-4.59	-0.38	1.08e-5	Menarche (age at onset);
TGCT	cis	rs6547741	0.967	rs4665986	chr2:27755168	G/A	cg27432699	chr2:27873401	GPN1	0.18	4.62	0.38	9.37e-6	Oral cavity cancer;
TGCT	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg26039829	chr8:22132926	PIWIL2	0.25	4.67	0.39	7.62e-6	Hypertriglyceridemia;
TGCT	cis	rs13064411	0.696	rs2129434	chr3:113138763	A/C	cg18753928	chr3:113234510	CCDC52	-0.71	-5.62	-0.45	1.23e-7	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs7772486	0.806	rs2265477	chr6:146212338	T/C	cg05347473	chr6:146136440	FBXO30	0.53	5.23	0.43	6.96e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2458413	0.500	rs2514666	chr8:105351943	C/T	cg04554929	chr8:105342491	NA	0.5	6.07	0.48	1.42e-8	Paget's disease;
TGCT	cis	rs9443645	0.901	rs2152951	chr6:79762172	A/G	cg09184832	chr6:79620586	NA	0.44	4.9	0.4	2.95e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10114408	0.918	rs4475560	chr9:96662067	T/C	cg13679303	chr9:96623674	NA	-0.36	-4.63	-0.38	9.04e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs514406	0.536	rs878957	chr1:53197559	C/T	cg25767906	chr1:53392781	SCP2	0.49	5.37	0.43	3.73e-7	Monocyte count;
TGCT	cis	rs9611565	0.879	rs5758311	chr22:41759375	G/T	cg17554472	chr22:41940697	POLR3H	-0.45	-4.91	-0.4	2.84e-6	Vitiligo;
TGCT	cis	rs2296887	0.841	rs945781	chr10:104085921	A/G	cg26089160	chr10:104170217	PSD	0.6	5.53	0.44	1.79e-7	Parkinson's disease;
TGCT	cis	rs587847	0.708	rs12902322	chr15:37623366	A/G	cg00216138	chr15:37171175	LOC145845	0.3	4.52	0.38	1.43e-5	Intraocular pressure;
TGCT	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg07507251	chr3:52567010	NT5DC2	0.47	6.6	0.51	1.05e-9	Bipolar disorder;
TGCT	cis	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg20362242	chr5:692897	TPPP	0.48	4.51	0.38	1.47e-5	Lung disease severity in cystic fibrosis;
TGCT	cis	rs4803468	0.967	rs7259900	chr19:41889429	A/T	cg09537434	chr19:41945824	ATP5SL	-0.89	-9.96	-0.67	1.6e-17	Height;
TGCT	cis	rs8032315	0.965	rs35346340	chr15:91427872	G/C	cg03209642	chr15:91427605	FES	0.52	4.91	0.4	2.81e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1150668	0.796	rs2247002	chr6:28397951	G/C	cg13525197	chr6:28411240	ZSCAN23	-0.53	-5.14	-0.42	1.03e-6	Pubertal anthropometrics;
TGCT	cis	rs9894429	0.789	rs8074989	chr17:79598728	G/C	cg18240062	chr17:79603768	NPLOC4	0.84	9.67	0.66	8.03e-17	Eye color traits;
TGCT	cis	rs112591243	0.685	rs2839362	chr21:48024626	G/A	cg10657630	chr21:48055338	PRMT2	1.05	6.12	0.48	1.12e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs478304	0.514	rs75601653	chr11:65483370	C/G	cg12758867	chr11:65354231	EHBP1L1	0.26	4.48	0.37	1.67e-5	Acne (severe);
TGCT	cis	rs9682041	0.932	rs6782252	chr3:170133639	C/T	cg11886554	chr3:170076028	SKIL	0.87	6.38	0.5	3.18e-9	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs9916302	0.904	rs12952384	chr17:37669536	T/C	cg15445000	chr17:37608096	MED1	0.32	4.66	0.39	8.18e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs60843830	1.000	rs3791221	chr2:226933	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.75	7.55	0.56	8.02e-12	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg00989853	chr1:209979345	IRF6	0.41	4.66	0.39	8.16e-6	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
TGCT	cis	rs9611565	0.802	rs9611577	chr22:41793090	T/G	cg06634786	chr22:41940651	POLR3H	-0.72	-6.68	-0.51	7.15e-10	Vitiligo;
TGCT	cis	rs1865760	0.566	rs7772312	chr6:26049616	G/C	cg17042849	chr6:26104293	HIST1H4C	-0.62	-5.41	-0.44	3.18e-7	Height;
TGCT	cis	rs6570726	0.791	rs383841	chr6:145888329	G/T	cg23711669	chr6:146136114	FBXO30	-0.89	-9.93	-0.67	1.82e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg07636037	chr3:49044803	WDR6	-0.85	-8.88	-0.62	6.21e-15	Menarche (age at onset);
TGCT	cis	rs6424115	0.767	rs11591202	chr1:24102080	A/C	cg15997130	chr1:24165203	NA	-0.69	-6.7	-0.52	6.61e-10	Immature fraction of reticulocytes;
TGCT	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg19761014	chr17:28927070	LRRC37B2	0.55	4.77	0.39	5.12e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg07424592	chr7:64974309	NA	1.38	8.17	0.59	3.04e-13	Diabetic kidney disease;
TGCT	cis	rs453301	0.624	rs2979256	chr8:8871710	C/T	cg15556689	chr8:8085844	FLJ10661	0.76	6.59	0.51	1.13e-9	Joint mobility (Beighton score);
TGCT	cis	rs12908161	0.959	rs12906348	chr15:85329421	A/C	cg11189052	chr15:85197271	WDR73	0.71	5.92	0.47	2.93e-8	Schizophrenia;
TGCT	cis	rs9611565	0.546	rs5758431	chr22:42109917	A/G	cg06634786	chr22:41940651	POLR3H	0.89	9.09	0.63	1.96e-15	Vitiligo;
TGCT	cis	rs1723838	1.000	rs2886812	chr11:73605159	T/G	cg18195628	chr11:73498948	MRPL48	0.92	4.5	0.38	1.51e-5	Obesity-related traits;
TGCT	cis	rs2980439	0.517	rs712253	chr8:8103782	C/T	cg08975724	chr8:8085496	FLJ10661	-0.54	-4.84	-0.4	3.84e-6	Neuroticism;
TGCT	cis	rs3892630	0.588	rs1976501	chr19:33208155	C/T	cg22980127	chr19:33182716	NUDT19	0.77	6.36	0.5	3.47e-9	Red blood cell traits;
TGCT	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg09177884	chr7:1199841	ZFAND2A	-0.69	-5.47	-0.44	2.41e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2795502	1.000	rs3121323	chr10:43377166	A/G	cg20628663	chr10:43360327	NA	-0.46	-6.63	-0.51	9.28e-10	Blood protein levels;
TGCT	cis	rs7089973	0.604	rs765174	chr10:116601888	C/T	cg03647239	chr10:116582469	FAM160B1	0.59	5.74	0.46	6.72e-8	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs4786125	0.665	rs1565633	chr16:6919428	G/C	cg03623568	chr16:6915990	A2BP1	-0.45	-6.77	-0.52	4.65e-10	Heart rate variability traits (SDNN);
TGCT	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.78	6.27	0.49	5.58e-9	Mean platelet volume;
TGCT	cis	rs9952991	0.566	rs514000	chr18:12854072	C/T	cg23598886	chr18:12777645	NA	0.55	4.77	0.39	5.06e-6	Inflammatory skin disease;
TGCT	cis	rs11098499	0.754	rs9999724	chr4:120239944	C/T	cg09307838	chr4:120376055	NA	0.61	5.91	0.47	3.14e-8	Corneal astigmatism;
TGCT	cis	rs9921192	0.967	rs3747571	chr16:4323983	A/G	cg00021532	chr16:4324280	TFAP4	0.83	9.57	0.65	1.39e-16	Prostate-specific antigen levels;
TGCT	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg07061783	chr6:25882402	NA	-0.42	-4.51	-0.38	1.51e-5	Blood metabolite levels;
TGCT	cis	rs12477438	0.520	rs6542869	chr2:99783403	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	8.52	0.61	4.42e-14	Chronic sinus infection;
TGCT	cis	rs228437	0.657	rs9402619	chr6:134910055	A/C	cg09872934	chr6:134495829	SGK1	0.61	4.83	0.4	3.89e-6	Melanoma;
TGCT	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg03188948	chr7:1209495	NA	0.71	6.04	0.48	1.68e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7191439	0.858	rs11076701	chr16:88774525	A/G	cg27087555	chr16:88793112	FAM38A	-0.51	-6.05	-0.48	1.55e-8	Plateletcrit;
TGCT	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg25767906	chr1:53392781	SCP2	0.48	5.56	0.45	1.57e-7	Monocyte count;
TGCT	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg13012494	chr21:47604986	C21orf56	-0.39	-4.66	-0.39	7.88e-6	Testicular germ cell tumor;
TGCT	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.28	4.87	0.4	3.31e-6	Schizophrenia;
TGCT	cis	rs7937682	0.855	rs7109592	chr11:111533105	C/A	cg09085632	chr11:111637200	PPP2R1B	-1.14	-11.73	-0.73	7.67e-22	Primary sclerosing cholangitis;
TGCT	cis	rs2354432	0.599	rs4950423	chr1:146854539	T/C	cg25205988	chr1:146714368	CHD1L	1.32	5.88	0.47	3.62e-8	Mitochondrial DNA levels;
TGCT	trans	rs208515	0.525	rs10455593	chr6:66691341	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.93	10.3	0.68	2.34e-18	Exhaled nitric oxide levels;
TGCT	cis	rs4886920	0.563	rs12915515	chr15:78075555	A/T	cg25212270	chr15:78015279	NA	-0.23	-4.87	-0.4	3.37e-6	Neuroticism;
TGCT	cis	rs734999	0.545	rs12730932	chr1:2559589	T/G	cg18854424	chr1:2615690	NA	-0.45	-5.15	-0.42	1e-6	Ulcerative colitis;
TGCT	cis	rs55883249	1.000	rs62119422	chr2:9726599	A/G	cg23886495	chr2:9695866	ADAM17	0.77	4.69	0.39	7.19e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs6754311	0.834	rs12465802	chr2:136381348	A/G	cg07169764	chr2:136633963	MCM6	-0.53	-4.69	-0.39	7.11e-6	Mosquito bite size;
TGCT	cis	rs2742234	0.955	rs2503849	chr10:43672776	G/A	cg02780029	chr10:43622663	RET	-0.26	-4.94	-0.41	2.49e-6	Hirschsprung disease;
TGCT	cis	rs6088580	0.634	rs4911419	chr20:32995873	G/A	cg24642439	chr20:33292090	TP53INP2	-0.49	-4.49	-0.37	1.59e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs6840360	0.615	rs12503677	chr4:152610543	A/G	cg17479576	chr4:152424074	FAM160A1	-0.54	-5.28	-0.43	5.69e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg06634786	chr22:41940651	POLR3H	-0.72	-6.68	-0.51	7.15e-10	Vitiligo;
TGCT	cis	rs17270561	1.000	rs17270561	chr6:25820439	A/C	cg17691542	chr6:26056736	HIST1H1C	-0.76	-4.88	-0.4	3.2e-6	Iron status biomarkers;
TGCT	cis	rs698813	0.572	rs12712914	chr2:44478649	C/G	cg00619915	chr2:44497795	NA	-0.24	-5.61	-0.45	1.26e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
TGCT	cis	rs2692947	0.599	rs7561198	chr2:96774981	C/G	cg23100626	chr2:96804247	ASTL	-0.42	-5.0	-0.41	1.92e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs7660520	0.524	rs4862100	chr4:183732709	G/T	cg04181038	chr4:183730758	NA	0.65	6.11	0.48	1.2e-8	Pediatric autoimmune diseases;
TGCT	cis	rs896854	0.812	rs12546365	chr8:95911477	T/C	cg23172400	chr8:95962367	TP53INP1	-0.34	-5.55	-0.45	1.65e-7	Type 2 diabetes;
TGCT	cis	rs7584330	0.554	rs56853932	chr2:238428327	T/C	cg08992911	chr2:238395768	MLPH	0.67	4.52	0.38	1.41e-5	Prostate cancer;
TGCT	cis	rs34734847	0.933	rs7975067	chr12:121099454	G/A	cg21892295	chr12:121157589	UNC119B	-0.19	-4.51	-0.38	1.47e-5	Mean corpuscular volume;
TGCT	cis	rs9486719	1.000	rs2142653	chr6:96871520	C/A	cg06623918	chr6:96969491	KIAA0776	1.01	8.86	0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	trans	rs877282	0.629	rs78997110	chr10:764388	A/G	cg22713356	chr15:30763199	NA	1.2	9.39	0.64	3.76e-16	Uric acid levels;
TGCT	trans	rs208520	0.754	rs851593	chr6:66875783	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	10.31	0.68	2.29e-18	Exhaled nitric oxide output;
TGCT	cis	rs4919669	0.668	rs11191343	chr10:104345225	G/A	cg05855489	chr10:104503620	C10orf26	0.73	4.71	0.39	6.65e-6	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs909674	0.818	rs8136980	chr22:39844574	G/A	cg01416388	chr22:39784598	NA	-0.69	-6.62	-0.51	9.49e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs7940866	0.903	rs2324316	chr11:130872353	G/T	cg05962950	chr11:130786565	SNX19	0.69	6.64	0.51	8.78e-10	Schizophrenia;
TGCT	cis	rs17387100	0.551	rs2677783	chr4:16020318	G/A	cg13480465	chr4:16795757	LDB2	-0.42	-5.33	-0.43	4.56e-7	Suicide attempts in depression or bipolar disorder;
TGCT	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg06028808	chr11:68637592	NA	0.51	6.66	0.51	7.87e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9443645	0.901	rs9361466	chr6:79618352	T/C	cg09184832	chr6:79620586	NA	-0.49	-5.29	-0.43	5.29e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs4595586	0.525	rs7970652	chr12:39374873	T/C	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs4664308	1.000	rs6707458	chr2:160914540	G/T	cg03641300	chr2:160917029	PLA2R1	-0.26	-6.42	-0.5	2.61e-9	Idiopathic membranous nephropathy;
TGCT	cis	rs6582630	0.615	rs3914894	chr12:38480280	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-4.79	-0.4	4.57e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs4523957	0.651	rs9910413	chr17:2081419	G/A	cg16513277	chr17:2031491	SMG6	-0.2	-4.64	-0.38	8.83e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs6519955	0.796	rs4072455	chr22:46422938	T/C	cg05468064	chr22:46423449	NA	0.58	6.07	0.48	1.47e-8	Dupuytren's disease;
TGCT	cis	rs4319547	0.656	rs10734918	chr12:122921512	A/C	cg05707623	chr12:122985044	ZCCHC8	-0.69	-5.38	-0.44	3.58e-7	Body mass index;
TGCT	cis	rs7647973	0.516	rs4499638	chr3:49202782	C/G	cg02487422	chr3:49467188	NICN1	0.49	4.53	0.38	1.38e-5	Menarche (age at onset);
TGCT	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	5.02	0.41	1.78e-6	Prudent dietary pattern;
TGCT	cis	rs6429082	0.755	rs291384	chr1:235644300	C/T	cg26050004	chr1:235667680	B3GALNT2	0.59	5.26	0.43	6.02e-7	Adiposity;
TGCT	cis	rs3540	0.920	rs7182658	chr15:91019248	A/T	cg22089800	chr15:90895588	ZNF774	0.72	6.46	0.5	2.16e-9	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg17554472	chr22:41940697	POLR3H	-0.5	-5.37	-0.43	3.72e-7	Vitiligo;
TGCT	cis	rs7929679	0.875	rs1891291	chr11:34813620	T/C	cg18414381	chr11:34642885	EHF	-0.24	-4.8	-0.4	4.52e-6	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
TGCT	cis	rs7412746	0.611	rs2864873	chr1:150814174	A/G	cg09365446	chr1:150670422	GOLPH3L	0.37	5.34	0.43	4.18e-7	Melanoma;
TGCT	cis	rs11578119	0.902	rs1591150	chr1:170426839	A/G	cg09767346	chr1:170501363	GORAB	-0.72	-5.7	-0.46	8.13e-8	Male-pattern baldness;
TGCT	cis	rs2762353	0.574	rs4419666	chr6:25693274	C/T	cg03264133	chr6:25882463	NA	0.87	8.61	0.61	2.72e-14	Blood metabolite levels;
TGCT	cis	rs60871478	0.898	rs4725241	chr7:796883	C/T	cg05535760	chr7:792225	HEATR2	0.32	4.51	0.38	1.49e-5	Cerebrospinal P-tau181p levels;
TGCT	cis	rs2013441	1.000	rs2703801	chr17:20100600	T/C	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.61	-0.38	9.96e-6	Obesity-related traits;
TGCT	cis	rs7586879	0.575	rs6744205	chr2:25133148	T/C	cg01884057	chr2:25150051	NA	0.36	7.1	0.54	8.63e-11	Body mass index;
TGCT	cis	rs3924048	0.559	rs4580	chr1:12628188	T/C	cg00291366	chr1:12616550	NA	0.31	4.89	0.4	3.08e-6	Optic cup area;
TGCT	cis	rs4727027	0.870	rs1568945	chr7:148874112	T/G	cg23583168	chr7:148888333	NA	-0.74	-9.81	-0.66	3.64e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs4319547	0.695	rs10773152	chr12:122910180	T/C	cg08088222	chr12:122070432	ORAI1	0.26	4.53	0.38	1.34e-5	Body mass index;
TGCT	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg23131131	chr22:24373011	LOC391322	-0.81	-8.72	-0.62	1.53e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9486719	1.000	rs2499804	chr6:96861216	A/G	cg06623918	chr6:96969491	KIAA0776	1.01	8.86	0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs7662596	chr4:99019962	G/T	cg05340658	chr4:99064831	C4orf37	0.48	5.43	0.44	2.92e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11190604	1.000	rs4919469	chr10:102298855	C/A	cg16342193	chr10:102329863	NA	-0.41	-5.11	-0.42	1.18e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9341808	0.644	rs62408577	chr6:80942024	T/A	cg08355045	chr6:80787529	NA	-0.28	-4.52	-0.38	1.45e-5	Sitting height ratio;
TGCT	cis	rs1775715	0.737	rs2778661	chr10:32159191	C/T	cg14930904	chr10:32216787	ARHGAP12	0.52	5.07	0.41	1.39e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs6061231	0.755	rs11699160	chr20:60958651	T/C	cg15674680	chr20:60982522	CABLES2	0.5	4.47	0.37	1.74e-5	Colorectal cancer;
TGCT	cis	rs9733	0.596	rs1136808	chr1:150702717	G/C	cg04414720	chr1:150670196	GOLPH3L	0.37	4.91	0.4	2.76e-6	Tonsillectomy;
TGCT	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg00343986	chr7:65444356	GUSB	-0.23	-5.16	-0.42	9.45e-7	Aortic root size;
TGCT	cis	rs11208691	0.513	rs60466849	chr1:66107714	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.58	4.53	0.38	1.35e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs9611565	0.625	rs2076199	chr22:41903743	G/T	cg17554472	chr22:41940697	POLR3H	-0.44	-4.77	-0.39	5.17e-6	Vitiligo;
TGCT	trans	rs629535	0.514	rs55653755	chr8:70154383	A/C	cg21567404	chr3:27674614	NA	-0.51	-7.55	-0.56	8.15e-12	Dupuytren's disease;
TGCT	cis	rs4074961	0.669	rs4652964	chr1:38078300	A/G	cg11397548	chr1:38022522	DNALI1	0.43	4.78	0.39	4.95e-6	Axial length;
TGCT	cis	rs9650657	0.615	rs6601536	chr8:10696311	C/G	cg16664915	chr8:10907788	XKR6	-0.29	-4.6	-0.38	1.05e-5	Neuroticism;
TGCT	cis	rs853679	0.567	rs16894106	chr6:28400339	G/A	cg18815343	chr6:28367644	ZSCAN12	-0.5	-4.56	-0.38	1.19e-5	Depression;
TGCT	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg10047753	chr17:41438598	NA	0.97	9.99	0.67	1.37e-17	Menopause (age at onset);
TGCT	cis	rs12145833	0.538	rs61833885	chr1:243397188	C/A	cg02356786	chr1:243265016	LOC731275	0.6	5.18	0.42	8.64e-7	Obesity (early onset extreme);
TGCT	cis	rs7635838	0.859	rs9869977	chr3:11480081	C/A	cg00170343	chr3:11313890	ATG7	0.64	6.06	0.48	1.5e-8	HDL cholesterol;
TGCT	cis	rs17741873	0.836	rs10824039	chr10:75602849	G/A	cg07699608	chr10:75541558	CHCHD1	0.7	4.75	0.39	5.43e-6	Paclitaxel disposition in epithelial ovarian cancer;
TGCT	cis	rs9811920	0.609	rs7636447	chr3:99612677	G/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.6	-6.82	-0.52	3.63e-10	Axial length;
TGCT	cis	rs796364	0.616	rs6718118	chr2:200691852	G/T	cg17644776	chr2:200775616	C2orf69	-0.34	-4.84	-0.4	3.76e-6	Schizophrenia;
TGCT	cis	rs7666738	0.791	rs2865953	chr4:99040319	C/T	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7809950	1.000	rs67982599	chr7:107100104	T/G	cg23024343	chr7:107201750	COG5	-0.34	-5.43	-0.44	2.92e-7	Coronary artery disease;
TGCT	cis	rs12142240	0.698	rs58162700	chr1:46816659	T/A	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs1865760	0.516	rs9393683	chr6:26066198	A/G	cg17042849	chr6:26104293	HIST1H4C	-0.66	-5.85	-0.47	4.02e-8	Height;
TGCT	cis	rs12477438	0.520	rs6739579	chr2:99731552	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.82	0.62	8.67e-15	Chronic sinus infection;
TGCT	cis	rs12477438	0.520	rs11677247	chr2:99756358	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.82	0.62	8.67e-15	Chronic sinus infection;
TGCT	cis	rs7666738	0.791	rs28579101	chr4:98843203	T/C	cg05340658	chr4:99064831	C4orf37	0.53	6.17	0.48	8.71e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1008375	1.000	rs9291659	chr4:17662360	A/C	cg18681998	chr4:17616180	MED28	0.94	11.11	0.71	2.57e-20	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4389656	0.883	rs34338480	chr5:6712854	T/C	cg10857441	chr5:6722123	POLS	0.22	4.47	0.37	1.73e-5	Coronary artery disease;
TGCT	trans	rs797680	0.786	rs7532195	chr1:93617403	T/G	cg27528825	chr2:159282178	CCDC148	-0.35	-6.78	-0.52	4.27e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	trans	rs11764590	0.671	rs62444906	chr7:2083161	G/T	cg25206134	chr2:45395956	NA	0.97	6.73	0.52	5.68e-10	Neuroticism;
TGCT	cis	rs9296661	0.868	rs2225051	chr6:51668394	C/T	cg00593404	chr6:52377740	TRAM2	-0.27	-4.49	-0.37	1.62e-5	Weight loss (gastric bypass surgery);
TGCT	cis	rs9611565	0.918	rs9611562	chr22:41760172	T/G	cg17554472	chr22:41940697	POLR3H	-0.5	-5.2	-0.42	8.14e-7	Vitiligo;
TGCT	cis	rs7829975	0.501	rs74345345	chr8:8578435	C/G	cg17143192	chr8:8559678	CLDN23	-0.52	-5.25	-0.43	6.29e-7	Mood instability;
TGCT	cis	rs35306767	0.903	rs17159950	chr10:875287	T/G	cg26597838	chr10:835615	NA	0.71	10.12	0.67	6.47e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs644799	1.000	rs546809	chr11:95579938	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	9.9	0.66	2.27e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs3806843	0.735	rs809635	chr5:140081791	A/G	cg19875535	chr5:140030758	IK	-0.37	-6.23	-0.49	6.51e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs11190604	0.767	rs4919458	chr10:102177728	G/A	cg16342193	chr10:102329863	NA	0.37	4.79	0.39	4.73e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg08859206	chr1:53392774	SCP2	-0.42	-6.4	-0.5	2.95e-9	Monocyte count;
TGCT	cis	rs950169	0.840	rs4842853	chr15:84942304	G/T	cg17173187	chr15:85201210	NMB	0.58	5.93	0.47	2.77e-8	Schizophrenia;
TGCT	cis	rs7552404	1.000	rs4949879	chr1:76237143	G/A	cg22875332	chr1:76189707	ACADM	0.76	8.83	0.62	8.53e-15	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs4073582	0.595	rs555360	chr11:65960061	T/C	cg16950941	chr11:66035639	RAB1B	-0.55	-5.21	-0.42	7.79e-7	Gout;
TGCT	cis	rs7666738	0.830	rs13328005	chr4:99055480	T/C	cg05340658	chr4:99064831	C4orf37	0.53	6.02	0.48	1.87e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs904251	0.504	rs2797795	chr6:37480683	T/C	cg01843034	chr6:37503916	NA	-0.56	-7.56	-0.56	7.84e-12	Cognitive performance;
TGCT	cis	rs11031096	0.542	rs1452048	chr11:3965428	G/T	cg18678763	chr11:4115507	RRM1	-0.42	-5.14	-0.42	1.05e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.63	-0.51	9.04e-10	Alzheimer's disease;
TGCT	cis	rs17345786	0.861	rs17402964	chr3:101067945	C/T	cg12386194	chr3:101231763	SENP7	0.66	6.45	0.5	2.29e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs245880	0.765	rs245893	chr7:29191507	G/C	cg17163760	chr7:29186267	CPVL	-0.39	-4.89	-0.4	3.12e-6	Warfarin maintenance dose;
TGCT	cis	rs295140	0.605	rs296818	chr2:201176944	C/T	cg23649088	chr2:200775458	C2orf69	0.27	4.43	0.37	2.01e-5	QT interval;
TGCT	cis	rs4919694	1.000	rs12241091	chr10:104808997	G/A	cg04362960	chr10:104952993	NT5C2	1.07	7.09	0.54	8.9e-11	Arsenic metabolism;
TGCT	trans	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg17830980	chr10:43048298	ZNF37B	-0.81	-10.13	-0.67	6.19e-18	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2594989	0.943	rs2443713	chr3:11537540	T/G	cg26283222	chr3:11613257	VGLL4	-0.21	-4.49	-0.37	1.6e-5	Circulating chemerin levels;
TGCT	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.61	-4.74	-0.39	5.85e-6	Lung function (FEV1/FVC);
TGCT	cis	rs4925386	1.000	rs4925389	chr20:60922512	G/A	cg06026331	chr20:60912101	LAMA5	-0.28	-5.11	-0.42	1.16e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs2153535	0.601	rs9502715	chr6:8455709	C/T	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs6748734	1.000	rs4293565	chr2:241834770	A/G	cg04034577	chr2:241836375	C2orf54	-0.4	-6.34	-0.49	3.87e-9	Urinary metabolites;
TGCT	cis	rs1552244	1.000	rs13433680	chr3:10136390	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.49	-6.45	-0.5	2.27e-9	Alzheimer's disease;
TGCT	cis	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg20637647	chr7:64974828	NA	-0.92	-5.09	-0.42	1.26e-6	Diabetic kidney disease;
TGCT	cis	rs17423910	1.000	rs17423605	chr1:66677481	A/G	cg04880992	chr1:67434664	MIER1	-0.34	-4.69	-0.39	7.1e-6	Acute lymphoblastic leukemia (childhood);
TGCT	cis	rs4285028	0.699	rs12629742	chr3:121614895	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.79	-6.62	-0.51	9.97e-10	Multiple sclerosis;
TGCT	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.45	-4.89	-0.4	3.04e-6	Blood metabolite levels;
TGCT	cis	rs6998277	0.830	rs6468836	chr8:103602630	A/G	cg10187029	chr8:103597600	NA	0.56	8.85	0.62	7.44e-15	Migraine;
TGCT	cis	rs236907	0.859	rs2181216	chr1:171744655	A/G	cg20598894	chr1:171756153	METTL13	-0.19	-4.51	-0.38	1.46e-5	Mean platelet volume;
TGCT	cis	rs4242434	0.927	rs10099846	chr8:22534178	C/T	cg03733263	chr8:22462867	KIAA1967	-1.15	-19.4	-0.87	2.29e-39	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs7953508	0.506	rs930316	chr12:93967035	A/G	cg18151635	chr12:93972918	NA	-0.19	-4.52	-0.38	1.41e-5	Pubertal anthropometrics;
TGCT	cis	rs12421382	0.659	rs11213103	chr11:109385935	A/G	cg16359550	chr11:109292809	C11orf87	0.4	4.47	0.37	1.76e-5	Schizophrenia;
TGCT	cis	rs200259120	1	rs200259120	chr18:9719323	TATAAATAA/T	cg24441185	chr18:9708096	RAB31	-0.79	-6.0	-0.47	2.04e-8	Strep throat;
TGCT	cis	rs7681440	0.967	rs6532191	chr4:90745930	C/T	cg14346243	chr4:90757452	SNCA	-0.57	-5.55	-0.45	1.64e-7	Dementia with Lewy bodies;
TGCT	cis	rs2072499	0.722	rs61462713	chr1:156161682	C/T	cg25208724	chr1:156163844	SLC25A44	1.01	9.25	0.64	8.38e-16	Testicular germ cell tumor;
TGCT	cis	rs4746818	1.000	rs10998614	chr10:70923347	G/T	cg11621586	chr10:70884670	VPS26A	1.23	10.93	0.7	6.87e-20	Left atrial antero-posterior diameter;
TGCT	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg24250549	chr1:154909240	PMVK	0.66	6.5	0.5	1.73e-9	Prostate cancer;
TGCT	cis	rs4680	0.737	rs2239393	chr22:19950428	A/G	cg22546130	chr22:19950026	COMT	-0.35	-5.25	-0.43	6.47e-7	Blood metabolite levels;
TGCT	cis	rs2153535	0.580	rs1414349	chr6:8472290	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs7953249	0.618	rs2650000	chr12:121388962	G/T	cg02403541	chr12:121454288	C12orf43	0.66	5.96	0.47	2.45e-8	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs2013441	1.000	rs2165897	chr17:20209721	T/C	cg18979559	chr17:20280153	CCDC144C	-0.49	-4.99	-0.41	1.97e-6	Obesity-related traits;
TGCT	cis	rs6490294	0.632	rs10849966	chr12:112100773	T/A	cg10833066	chr12:111807467	FAM109A	0.34	5.15	0.42	1e-6	Mean platelet volume;
TGCT	cis	rs4788815	0.513	rs12929547	chr16:71794734	A/G	cg06353428	chr16:71660113	MARVELD3	1.53	12.17	0.74	6.57e-23	Metabolite levels;
TGCT	cis	rs6450176	0.909	rs3776720	chr5:53296158	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.53	-5.1	-0.42	1.23e-6	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs9653442	1.000	rs9653442	chr2:100825367	A/G	cg22139774	chr2:100720529	AFF3	0.43	7.68	0.57	4.15e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg08219700	chr8:58056026	NA	0.3	4.53	0.38	1.35e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2982552	0.844	rs3020347	chr6:152056962	T/G	cg22157087	chr6:152012887	ESR1	0.21	5.23	0.43	6.99e-7	Bone properties (heel);
TGCT	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.2	0.42	8.14e-7	Menopause (age at onset);
TGCT	cis	rs2075371	0.933	rs2544201	chr7:133963561	C/G	cg11752832	chr7:134001865	SLC35B4	0.69	6.1	0.48	1.26e-8	Mean platelet volume;
TGCT	cis	rs9902453	0.904	rs4461132	chr17:28423430	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	7.31	0.55	2.88e-11	Coffee consumption (cups per day);
TGCT	cis	rs7020830	0.823	rs13285624	chr9:37129496	T/G	cg14294708	chr9:37120828	ZCCHC7	1.26	17.63	0.85	1.37e-35	Schizophrenia;
TGCT	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg08509172	chr19:19383838	TM6SF2	-0.36	-4.67	-0.39	7.66e-6	Tonsillectomy;
TGCT	cis	rs739401	0.595	rs402806	chr11:3066432	A/G	cg05729581	chr11:3078854	CARS	-0.59	-5.46	-0.44	2.45e-7	Longevity;
TGCT	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg11764359	chr7:65958608	NA	-0.55	-5.08	-0.42	1.34e-6	Aortic root size;
TGCT	cis	rs782590	0.967	rs1823893	chr2:55788921	T/C	cg03859395	chr2:55845619	SMEK2	0.93	11.51	0.72	2.61e-21	Metabolic syndrome;
TGCT	cis	rs12762955	0.561	rs11253567	chr10:1054444	A/G	cg20503657	chr10:835505	NA	0.4	5.22	0.42	7.18e-7	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs2180341	0.782	rs6912196	chr6:127722732	C/G	cg27446573	chr6:127587934	RNF146	0.8	7.08	0.54	9.53e-11	Breast cancer;
TGCT	cis	rs8177179	0.967	rs6782434	chr3:133438834	C/G	cg24879335	chr3:133465180	TF	0.37	5.02	0.41	1.72e-6	Iron status biomarkers (transferrin levels);
TGCT	cis	rs2469997	1.000	rs2469999	chr8:120354695	G/A	cg00681363	chr8:120844660	TAF2	0.65	4.52	0.38	1.45e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs2795502	1.000	rs2795496	chr10:43337842	G/A	cg20628663	chr10:43360327	NA	-0.45	-6.39	-0.5	3.05e-9	Blood protein levels;
TGCT	cis	rs7089973	0.604	rs12218498	chr10:116578489	T/C	cg03647239	chr10:116582469	FAM160B1	0.58	5.31	0.43	4.95e-7	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.97	-7.19	-0.54	5.48e-11	Gut microbiome composition (summer);
TGCT	cis	rs2073300	1.000	rs6137975	chr20:23461778	A/G	cg09953122	chr20:23471693	CST8	0.6	4.71	0.39	6.63e-6	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	trans	rs9650657	0.501	rs3021500	chr8:11023997	G/C	cg15556689	chr8:8085844	FLJ10661	-0.9	-9.07	-0.63	2.23e-15	Neuroticism;
TGCT	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg27535305	chr1:53392650	SCP2	-0.28	-5.68	-0.45	9.1e-8	Monocyte count;
TGCT	cis	rs254781	0.505	rs664366	chr5:88055761	A/G	cg22951263	chr5:87985283	NA	-0.58	-5.73	-0.46	7.2e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9549260	0.712	rs9532564	chr13:41160579	C/G	cg21288729	chr13:41239152	FOXO1	0.65	4.49	0.37	1.61e-5	Red blood cell count;
TGCT	cis	rs854765	0.547	rs9913277	chr17:17919749	G/T	cg04398451	chr17:18023971	MYO15A	-0.31	-5.05	-0.41	1.56e-6	Total body bone mineral density;
TGCT	cis	rs2046867	0.568	rs1553376	chr3:72828151	T/C	cg25664220	chr3:72788482	NA	-0.54	-6.72	-0.52	5.99e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	trans	rs3780486	0.846	rs7850878	chr9:33126570	A/G	cg20290983	chr6:43655470	MRPS18A	1.19	14.84	0.8	2.81e-29	IgG glycosylation;
TGCT	cis	rs2637266	0.905	rs3923669	chr10:78375047	T/C	cg18941641	chr10:78392320	NA	0.4	4.73	0.39	6.03e-6	Pulmonary function;
TGCT	trans	rs9951602	0.512	rs9955812	chr18:76650954	T/A	cg02800362	chr5:177631904	HNRNPAB	1.15	13.03	0.76	5.64e-25	Obesity-related traits;
TGCT	cis	rs7089973	0.604	rs11819372	chr10:116594934	A/G	cg03647239	chr10:116582469	FAM160B1	0.61	5.93	0.47	2.79e-8	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs7586879	1.000	rs7608185	chr2:25115432	G/C	cg01884057	chr2:25150051	NA	0.28	5.03	0.41	1.69e-6	Body mass index;
TGCT	cis	rs11690935	0.959	rs6758704	chr2:172655097	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.19	-12.78	-0.75	2.24e-24	Schizophrenia;
TGCT	cis	rs986417	1.000	rs4901994	chr14:61090202	C/T	cg27398547	chr14:60952738	C14orf39	1.57	8.48	0.61	5.63e-14	Gut microbiota (bacterial taxa);
TGCT	cis	rs2836950	0.565	rs7279497	chr21:40531306	A/G	cg11890956	chr21:40555474	PSMG1	0.69	6.84	0.52	3.15e-10	Menarche (age at onset);
TGCT	cis	rs9682041	0.932	rs1525362	chr3:170070702	C/T	cg07589077	chr3:170072950	NA	0.3	4.87	0.4	3.33e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs7819412	0.807	rs9657519	chr8:10945439	A/G	cg21775007	chr8:11205619	TDH	-0.53	-4.9	-0.4	2.93e-6	Triglycerides;
TGCT	trans	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg21659725	chr3:3221576	CRBN	0.75	9.02	0.63	2.97e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg13665807	chr20:60559372	TAF4	-0.46	-5.0	-0.41	1.92e-6	Body mass index;
TGCT	cis	rs7772486	0.686	rs9403746	chr6:146103768	C/A	cg23711669	chr6:146136114	FBXO30	-0.86	-9.74	-0.66	5.4e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg06238570	chr21:40685208	BRWD1	0.68	6.32	0.49	4.3e-9	Cognitive function;
TGCT	cis	rs6790105	1	rs6790105	chr3:49393409	C/T	cg05785598	chr3:49045655	WDR6	0.39	4.65	0.39	8.28e-6	Childhood ear infection;
TGCT	cis	rs1801251	1.000	rs12990821	chr2:233617585	C/G	cg08000102	chr2:233561755	GIGYF2	0.64	6.56	0.51	1.34e-9	Coronary artery disease;
TGCT	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg15320075	chr8:145703422	NA	0.7	7.38	0.55	1.99e-11	Age at first birth;
TGCT	cis	rs6500602	0.561	rs62039231	chr16:4519548	A/G	cg08645402	chr16:4508243	NA	0.18	4.81	0.4	4.34e-6	Schizophrenia;
TGCT	cis	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg03213289	chr20:61660250	NA	0.7	10.69	0.69	2.64e-19	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs12497850	0.864	rs12493001	chr3:49181885	A/G	cg07636037	chr3:49044803	WDR6	0.94	9.88	0.66	2.51e-17	Parkinson's disease;
TGCT	cis	rs9611565	0.512	rs4822052	chr22:42193741	G/A	cg06481639	chr22:41940642	POLR3H	-0.66	-6.02	-0.48	1.87e-8	Vitiligo;
TGCT	cis	rs12477438	0.520	rs13009147	chr2:99803998	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	13.05	0.76	4.93e-25	Chronic sinus infection;
TGCT	cis	rs807669	0.903	rs1780642	chr22:19170604	T/C	cg02655711	chr22:19163373	SLC25A1	0.42	10.01	0.67	1.23e-17	Metabolite levels;
TGCT	cis	rs6860806	1.000	rs6860806	chr5:131640536	C/T	cg24060327	chr5:131705240	SLC22A5	0.6	6.64	0.51	9e-10	Breast cancer;
TGCT	cis	rs11190604	1.000	rs4919468	chr10:102288343	G/C	cg23241863	chr10:102295624	HIF1AN	0.66	4.87	0.4	3.38e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs3820068	0.603	rs6660234	chr1:15962590	T/C	cg05660106	chr1:15850417	CASP9	0.83	8.19	0.59	2.78e-13	Systolic blood pressure;
TGCT	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg01341218	chr17:43662625	NA	0.85	7.37	0.55	2.11e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs4478858	0.806	rs6686845	chr1:31708796	A/T	cg00250761	chr1:31883323	NA	-0.34	-6.25	-0.49	5.94e-9	Alcohol dependence;
TGCT	cis	rs2282802	0.711	rs3777095	chr5:139660916	G/A	cg01081189	chr5:139537190	NA	0.28	5.06	0.41	1.46e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4478858	0.735	rs11590120	chr1:31792324	A/G	cg07478791	chr1:31886160	SERINC2	-0.47	-4.52	-0.38	1.43e-5	Alcohol dependence;
TGCT	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg18876405	chr7:65276391	NA	-0.35	-5.1	-0.42	1.24e-6	Aortic root size;
TGCT	cis	rs4478858	0.684	rs2050816	chr1:31721708	G/T	cg07478791	chr1:31886160	SERINC2	-0.51	-4.89	-0.4	3.11e-6	Alcohol dependence;
TGCT	cis	rs700651	0.757	rs6748683	chr2:198878008	T/A	cg00792783	chr2:198669748	PLCL1	0.59	5.27	0.43	5.72e-7	Intracranial aneurysm;
TGCT	cis	rs611744	0.625	rs11779824	chr8:109278689	G/A	cg21045802	chr8:109455806	TTC35	0.72	7.44	0.56	1.46e-11	Dupuytren's disease;
TGCT	cis	rs651907	0.557	rs7651721	chr3:101393583	C/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.91	10.9	0.7	8.24e-20	Colorectal cancer;
TGCT	cis	rs7147624	0.938	rs7151148	chr14:65936665	G/C	cg03016385	chr14:66212404	NA	-0.5	-7.18	-0.54	5.64e-11	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs7666738	0.515	rs13142498	chr4:98792443	G/T	cg17366294	chr4:99064904	C4orf37	0.62	5.78	0.46	5.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10791323	0.569	rs2257004	chr11:133712473	C/T	cg15485101	chr11:133734466	NA	0.4	5.27	0.43	5.83e-7	Childhood ear infection;
TGCT	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg06238570	chr21:40685208	BRWD1	-0.84	-9.31	-0.64	6.01e-16	Cognitive function;
TGCT	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.11	-0.48	1.16e-8	Alzheimer's disease;
TGCT	cis	rs7772486	0.754	rs13214277	chr6:146136125	G/T	cg23711669	chr6:146136114	FBXO30	0.94	10.7	0.69	2.56e-19	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9467773	1.000	rs9467796	chr6:26568411	A/G	cg15659132	chr6:26577336	NA	0.88	12.27	0.74	3.83e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs78487399	0.808	rs7601093	chr2:43710807	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.41	-5.26	-0.43	6.23e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs2204008	0.837	rs4312131	chr12:38181087	G/T	cg26384229	chr12:38710491	ALG10B	0.86	7.65	0.57	4.87e-12	Bladder cancer;
TGCT	cis	rs66573146	1.000	rs28729690	chr4:6962061	C/T	cg00086871	chr4:6988644	TBC1D14	0.98	4.57	0.38	1.16e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs35306767	0.622	rs66462130	chr10:1022108	C/T	cg26597838	chr10:835615	NA	0.58	6.42	0.5	2.64e-9	Eosinophil percentage of granulocytes;
TGCT	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg03452623	chr4:187889614	NA	0.33	4.82	0.4	4.12e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2721195	1.000	rs750472	chr8:145701453	A/C	cg15320075	chr8:145703422	NA	-0.73	-7.57	-0.56	7.57e-12	Age at first birth;
TGCT	cis	rs2677744	0.626	rs3743452	chr15:91497515	C/T	cg01710897	chr15:91497902	RCCD1	-0.33	-4.5	-0.37	1.53e-5	Attention deficit hyperactivity disorder;
TGCT	cis	rs6674176	0.660	rs11210936	chr1:44391438	A/T	cg12908607	chr1:44402522	ARTN	-0.75	-9.27	-0.64	7.36e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs3816788	0.596	rs4872083	chr8:21770372	C/T	cg17168535	chr8:21777572	XPO7	0.75	7.28	0.55	3.29e-11	Lung cancer in ever smokers;
TGCT	cis	rs7267979	0.808	rs84816	chr20:25459919	G/A	cg14121845	chr20:25566513	NINL	0.49	5.27	0.43	5.87e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3782455	1.000	rs117139141	chr12:114402939	T/G	cg10631684	chr12:113795897	PLBD2	-0.7	-4.61	-0.38	1e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs12681287	0.604	rs71502657	chr8:87478781	T/A	cg27223183	chr8:87520930	FAM82B	-0.88	-6.22	-0.49	6.84e-9	Caudate activity during reward;
TGCT	cis	rs514406	0.505	rs425520	chr1:53179805	C/G	cg08859206	chr1:53392774	SCP2	-0.36	-5.23	-0.42	7.05e-7	Monocyte count;
TGCT	cis	rs4851266	1.000	rs11690335	chr2:100826429	A/G	cg07810366	chr2:100720526	AFF3	-0.38	-5.44	-0.44	2.7e-7	Educational attainment;
TGCT	cis	rs8017423	0.647	rs4904674	chr14:90817412	G/A	cg04374321	chr14:90722782	PSMC1	-0.58	-5.73	-0.46	7.04e-8	Mortality in heart failure;
TGCT	cis	rs514406	0.505	rs269290	chr1:53167027	A/T	cg25767906	chr1:53392781	SCP2	-0.45	-4.85	-0.4	3.59e-6	Monocyte count;
TGCT	cis	rs9357506	1.000	rs4714926	chr6:46304245	A/G	cg21115430	chr6:46460003	NA	-0.26	-5.16	-0.42	9.37e-7	Body mass index;
TGCT	cis	rs854765	0.583	rs62064156	chr17:17822480	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.76	7.94	0.58	1.04e-12	Total body bone mineral density;
TGCT	cis	rs7772486	0.790	rs9791313	chr6:146266172	T/C	cg05347473	chr6:146136440	FBXO30	-0.5	-4.85	-0.4	3.68e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg06238570	chr21:40685208	BRWD1	0.7	6.46	0.5	2.16e-9	Cognitive function;
TGCT	cis	rs77741769	0.571	rs35905305	chr12:121328082	T/G	cg02419362	chr12:121203948	SPPL3	0.19	4.5	0.37	1.56e-5	Mean corpuscular volume;
TGCT	cis	rs6964587	1.000	rs7802668	chr7:91648939	A/G	cg17063962	chr7:91808500	NA	0.9	9.7	0.66	6.73e-17	Breast cancer;
TGCT	cis	rs9650657	0.707	rs4593498	chr8:10655470	C/G	cg27411982	chr8:10470053	RP1L1	-0.24	-5.09	-0.42	1.3e-6	Neuroticism;
TGCT	trans	rs208520	0.661	rs207099	chr6:66796373	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-10.77	-0.7	1.66e-19	Exhaled nitric oxide output;
TGCT	cis	rs10465746	0.658	rs980418	chr1:84365653	T/G	cg10977910	chr1:84465055	TTLL7	0.68	6.7	0.52	6.46e-10	Obesity-related traits;
TGCT	cis	rs7772486	0.875	rs7766463	chr6:146364453	A/G	cg05347473	chr6:146136440	FBXO30	0.56	5.42	0.44	2.96e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11122272	0.525	rs2749713	chr1:231537921	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-6.28	-0.49	5.32e-9	Hemoglobin concentration;
TGCT	cis	rs7267979	1.000	rs884613	chr20:25288505	C/T	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3796352	0.527	rs11714793	chr3:52924930	A/G	cg12962167	chr3:53033115	SFMBT1	0.43	4.47	0.37	1.73e-5	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs6433857	0.536	rs1901750	chr2:181350739	C/T	cg23363182	chr2:181467187	NA	-0.32	-4.85	-0.4	3.59e-6	Body mass index;
TGCT	cis	rs2370759	1.000	rs79442609	chr10:32608749	C/T	cg01819863	chr10:32635814	EPC1	1.03	10.03	0.67	1.05e-17	Sexual dysfunction (female);
TGCT	cis	rs3820068	0.705	rs41270255	chr1:15892980	G/A	cg05660106	chr1:15850417	CASP9	1.17	14.8	0.8	3.47e-29	Systolic blood pressure;
TGCT	cis	rs700651	0.789	rs1976772	chr2:198868201	G/T	cg00792783	chr2:198669748	PLCL1	0.6	5.33	0.43	4.39e-7	Intracranial aneurysm;
TGCT	cis	rs1008375	0.966	rs3796812	chr4:17582051	G/A	cg16339924	chr4:17578868	LAP3	0.75	6.67	0.51	7.4e-10	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7590720	1.000	rs934156	chr2:216901482	C/T	cg12620499	chr2:216877984	MREG	-0.83	-8.13	-0.59	3.65e-13	Alcohol dependence;
TGCT	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg18654377	chr3:49208889	KLHDC8B	-0.38	-5.03	-0.41	1.69e-6	Menarche (age at onset);
TGCT	cis	rs7584330	0.554	rs3751107	chr2:238427251	G/A	cg08992911	chr2:238395768	MLPH	0.7	4.72	0.39	6.32e-6	Prostate cancer;
TGCT	cis	rs7226408	0.857	rs72890516	chr18:34591601	C/G	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs3771570	0.901	rs55811034	chr2:242406245	C/T	cg21155796	chr2:242212141	HDLBP	0.93	6.69	0.52	6.74e-10	Prostate cancer;
TGCT	cis	rs1215050	0.547	rs10017524	chr4:98588142	C/T	cg05340658	chr4:99064831	C4orf37	-0.38	-4.49	-0.37	1.59e-5	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg04267008	chr7:1944627	MAD1L1	-0.37	-4.93	-0.4	2.58e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs17001868	0.568	rs9607699	chr22:40737036	G/A	cg07138101	chr22:40742427	ADSL	0.73	5.38	0.44	3.57e-7	Mammographic density (dense area);
TGCT	cis	rs34065801	0.584	rs1171086	chr13:36512158	G/A	cg03563146	chr13:37393157	RFXAP	-0.48	-4.49	-0.37	1.6e-5	Breast size;
TGCT	cis	rs597539	0.521	rs7943745	chr11:68605828	A/G	cg21862992	chr11:68658383	NA	-0.34	-4.75	-0.39	5.64e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9611565	0.559	rs13056262	chr22:42081921	A/G	cg06481639	chr22:41940642	POLR3H	0.73	6.57	0.51	1.27e-9	Vitiligo;
TGCT	cis	rs797680	0.789	rs531514	chr1:93700212	C/T	cg17826107	chr1:92977322	EVI5	0.24	5.29	0.43	5.47e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs9303401	0.659	rs7210432	chr17:56668170	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs3617	0.573	rs9850563	chr3:52912214	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	-0.52	-4.98	-0.41	2.06e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7523273	1.000	rs12410786	chr1:207976205	T/A	cg22525895	chr1:207977042	MIR29B2	-0.49	-8.66	-0.61	2.07e-14	Schizophrenia;
TGCT	cis	rs12497850	0.931	rs4072859	chr3:49032205	G/C	cg18654377	chr3:49208889	KLHDC8B	-0.42	-5.43	-0.44	2.85e-7	Parkinson's disease;
TGCT	cis	rs9611565	0.559	rs7290990	chr22:41964357	C/A	cg17554472	chr22:41940697	POLR3H	-0.48	-4.94	-0.41	2.47e-6	Vitiligo;
TGCT	cis	rs10927875	0.722	rs6660685	chr1:16346988	A/G	cg22431228	chr1:16359049	CLCNKA	-0.25	-4.64	-0.38	8.84e-6	Dilated cardiomyopathy;
TGCT	cis	rs1541995	0.792	rs12903841	chr15:96239277	G/A	cg00882281	chr15:96346592	NA	0.3	4.82	0.4	4.07e-6	Photic sneeze reflex;
TGCT	cis	rs6988636	1.000	rs59601467	chr8:124193488	C/T	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg20637647	chr7:64974828	NA	0.92	5.36	0.43	3.87e-7	Diabetic kidney disease;
TGCT	cis	rs1348850	0.914	rs4893950	chr2:178304885	T/C	cg22681709	chr2:178499509	PDE11A	-0.35	-4.5	-0.37	1.54e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg05785598	chr3:49045655	WDR6	0.36	4.78	0.39	4.78e-6	Menarche (age at onset);
TGCT	cis	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg20637647	chr7:64974828	NA	0.88	5.12	0.42	1.13e-6	Diabetic kidney disease;
TGCT	cis	rs17376456	0.569	rs10476520	chr5:93058290	A/C	cg25358565	chr5:93447407	FAM172A	0.76	6.68	0.51	7.23e-10	Diabetic retinopathy;
TGCT	cis	rs3096299	0.738	rs9929606	chr16:89527537	C/T	cg08392591	chr16:89556376	ANKRD11	0.54	4.75	0.39	5.63e-6	Multiple myeloma (IgH translocation);
TGCT	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg18876405	chr7:65276391	NA	0.35	5.2	0.42	7.81e-7	Aortic root size;
TGCT	cis	rs6671200	0.541	rs3738170	chr1:95699604	G/C	cg26537280	chr1:95699037	RWDD3	-0.51	-4.73	-0.39	6.03e-6	Stearic acid (18:0) levels;
TGCT	cis	rs12776158	0.901	rs56979471	chr10:71216760	G/A	cg12610070	chr10:71211762	TSPAN15	-0.55	-4.83	-0.4	3.87e-6	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs7681440	1.000	rs1471483	chr4:90754292	A/G	cg26578617	chr4:90757533	SNCA	-0.47	-4.69	-0.39	6.97e-6	Dementia with Lewy bodies;
TGCT	cis	rs7631605	0.905	rs61489663	chr3:37261734	T/A	cg17445812	chr3:36986805	TRANK1	0.21	4.66	0.39	8.17e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs74181299	0.964	rs1009358	chr2:65276452	C/T	cg05010058	chr2:65284262	CEP68	-0.43	-4.97	-0.41	2.15e-6	Pulse pressure;
TGCT	cis	rs2657888	1.000	rs2657890	chr12:56938577	C/T	cg23002907	chr12:56915593	RBMS2	0.38	5.24	0.43	6.83e-7	Adiponectin levels;
TGCT	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.44	0.44	2.74e-7	Tonsillectomy;
TGCT	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg17971929	chr21:40555470	PSMG1	0.98	9.57	0.65	1.43e-16	Cognitive function;
TGCT	cis	rs7010267	0.572	rs2450083	chr8:120063542	T/C	cg17171407	chr8:119960777	TNFRSF11B	0.29	5.42	0.44	2.98e-7	Total body bone mineral density (age 45-60);
TGCT	cis	rs7568458	0.660	rs2289972	chr2:85766545	C/T	cg17127132	chr2:85788382	GGCX	0.52	4.63	0.38	9.19e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs17376456	0.877	rs10060160	chr5:93387879	G/A	cg21475434	chr5:93447410	FAM172A	0.6	4.62	0.38	9.48e-6	Diabetic retinopathy;
TGCT	cis	rs9399135	0.967	rs9389258	chr6:135361140	T/C	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.28e-6	Red blood cell count;
TGCT	cis	rs10832963	0.594	rs1550869	chr11:18613498	G/T	cg09201001	chr11:18656081	SPTY2D1	0.68	6.31	0.49	4.43e-9	Breast cancer;
TGCT	cis	rs6969780	1.000	rs1801085	chr7:27168590	A/G	cg04321618	chr7:27170880	HOXA4	0.52	4.59	0.38	1.08e-5	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs514406	0.758	rs532242	chr1:53308665	C/G	cg16325326	chr1:53192061	ZYG11B	0.7	8.39	0.6	9.13e-14	Monocyte count;
TGCT	cis	rs854765	0.619	rs6502636	chr17:17983817	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.68	7.01	0.53	1.33e-10	Total body bone mineral density;
TGCT	cis	rs59197085	0.748	rs62479619	chr7:128463864	G/A	cg00260937	chr7:128520193	KCP	0.47	4.98	0.41	2.1e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
TGCT	cis	rs4820539	0.502	rs4820543	chr22:23542535	A/G	cg14186256	chr22:23484241	RTDR1	0.81	8.41	0.6	8.08e-14	Bone mineral density;
TGCT	cis	rs9611565	0.512	rs5751147	chr22:42139054	G/A	cg03806693	chr22:41940476	POLR3H	1.06	10.94	0.7	6.7e-20	Vitiligo;
TGCT	cis	rs9467711	0.659	rs13220261	chr6:26499185	C/T	cg16898833	chr6:26189333	HIST1H4D	1.24	5.61	0.45	1.26e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs8062405	0.754	rs151179	chr16:28487056	A/G	cg09754948	chr16:28834200	ATXN2L	0.6	4.66	0.39	8.02e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs9611565	0.512	rs139566	chr22:42199277	A/G	cg06634786	chr22:41940651	POLR3H	-0.84	-7.7	-0.57	3.66e-12	Vitiligo;
TGCT	cis	rs7542091	0.739	rs10863793	chr1:210037420	G/A	cg23283495	chr1:209979779	IRF6	0.49	4.82	0.4	4.15e-6	Monobrow;
TGCT	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9640161	0.789	rs3735174	chr7:150020489	T/C	cg10018233	chr7:150070692	REPIN1	0.32	4.65	0.39	8.41e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs751728	0.865	rs751726	chr6:33764386	G/A	cg13859433	chr6:33739653	LEMD2	-0.39	-7.08	-0.54	9.45e-11	Crohn's disease;
TGCT	cis	rs7647973	0.925	rs11130183	chr3:49228946	A/G	cg05785598	chr3:49045655	WDR6	0.38	4.68	0.39	7.48e-6	Menarche (age at onset);
TGCT	cis	rs1552244	0.832	rs115415687	chr3:10195704	C/T	cg00149659	chr3:10157352	C3orf10	1.05	5.81	0.46	4.95e-8	Alzheimer's disease;
TGCT	cis	rs4727027	0.901	rs34201592	chr7:148842403	C/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	4.55	0.38	1.25e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs586688	1.000	rs571723	chr1:201642628	C/G	cg05779441	chr1:201574716	NA	0.29	4.69	0.39	7.2e-6	Obesity-related traits;
TGCT	cis	rs4919669	0.777	rs10883765	chr10:104456686	T/C	cg05855489	chr10:104503620	C10orf26	0.73	4.45	0.37	1.91e-5	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs9357506	0.935	rs1345056	chr6:46306707	A/G	cg21115430	chr6:46460003	NA	-0.26	-5.17	-0.42	9.2e-7	Body mass index;
TGCT	cis	rs11252926	0.574	rs7068976	chr10:453112	A/G	cg20256804	chr10:444983	DIP2C	-0.21	-4.45	-0.37	1.88e-5	Psychosis in Alzheimer's disease;
TGCT	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	trans	rs2688608	0.620	rs7098444	chr10:75580042	C/T	cg13918328	chr10:52500089	ASAH2B	0.7	7.07	0.54	9.81e-11	Inflammatory bowel disease;
TGCT	cis	rs9467773	1.000	rs9467778	chr6:26534743	T/C	cg26531700	chr6:26746687	NA	0.47	4.57	0.38	1.14e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs6121246	0.821	rs3181073	chr20:30307199	A/C	cg13852791	chr20:30311386	BCL2L1	-0.78	-5.8	-0.46	5.15e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs2549003	1.000	rs2548997	chr5:131835395	C/T	cg02551604	chr5:131831745	NA	0.85	10.91	0.7	7.6e-20	Asthma (sex interaction);
TGCT	cis	rs10892173	0.716	rs12792357	chr11:117666595	C/T	cg21640587	chr11:117668038	DSCAML1	0.46	5.1	0.42	1.23e-6	Myopia;
TGCT	cis	rs3780378	0.935	rs2230724	chr9:5081780	G/A	cg03508284	chr9:4985524	JAK2	-0.47	-4.44	-0.37	1.97e-5	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs4506170	0.943	rs72712308	chr8:128333220	T/C	cg07795030	chr8:128802207	NA	-0.21	-4.56	-0.38	1.23e-5	Prostate cancer;
TGCT	cis	rs9400467	0.537	rs73530952	chr6:111486242	G/A	cg15721981	chr6:111408429	SLC16A10	0.69	4.5	0.37	1.56e-5	Blood metabolite levels;Amino acid levels;
TGCT	cis	rs11190604	1.000	rs1080698	chr10:102295114	G/T	cg16342193	chr10:102329863	NA	-0.44	-5.68	-0.45	8.88e-8	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2013441	0.965	rs2703820	chr17:20121479	G/A	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.61	-0.38	9.96e-6	Obesity-related traits;
TGCT	cis	rs514406	0.607	rs1930305	chr1:53195481	G/T	cg01802117	chr1:53393560	SCP2	0.42	4.92	0.4	2.69e-6	Monocyte count;
TGCT	cis	rs2594989	0.887	rs2442799	chr3:11488640	A/G	cg00170343	chr3:11313890	ATG7	0.68	4.99	0.41	2.01e-6	Circulating chemerin levels;
TGCT	cis	rs539096	0.831	rs650729	chr1:44042539	C/G	cg12908607	chr1:44402522	ARTN	-0.5	-5.21	-0.42	7.49e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs3820068	0.581	rs72645895	chr1:15931709	G/A	cg05660106	chr1:15850417	CASP9	0.82	8.02	0.58	6.63e-13	Systolic blood pressure;
TGCT	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.38	5.08	0.42	1.33e-6	Lymphocyte counts;
TGCT	cis	rs3733585	0.699	rs60045583	chr4:9971950	G/A	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.62	-0.56	5.57e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs8072100	0.676	rs9905308	chr17:45409386	T/A	cg08085267	chr17:45401833	C17orf57	-0.51	-5.66	-0.45	9.97e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs7208859	0.673	rs73277978	chr17:29191449	A/G	cg14008862	chr17:28927542	LRRC37B2	0.72	4.66	0.39	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs2708977	0.901	rs2579505	chr2:97167962	T/C	cg01950434	chr2:97203154	ARID5A	-0.7	-6.37	-0.5	3.44e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs2235642	0.928	rs9932984	chr16:1605051	A/G	cg00463982	chr16:1583984	IFT140;TMEM204	-0.28	-4.74	-0.39	5.81e-6	Coronary artery disease;
TGCT	cis	rs2688608	0.967	rs1815076	chr10:75659886	C/T	cg19442545	chr10:75533431	FUT11	-0.3	-4.86	-0.4	3.55e-6	Inflammatory bowel disease;
TGCT	cis	rs67072384	0.818	rs2291292	chr11:72467013	C/T	cg03713592	chr11:72463424	ARAP1	-0.96	-4.79	-0.4	4.71e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs9291683	0.507	rs6845554	chr4:10013173	T/G	cg11266682	chr4:10021025	SLC2A9	0.69	9.24	0.64	8.6e-16	Bone mineral density;
TGCT	cis	rs10193935	0.901	rs222463	chr2:42644080	A/G	cg27598129	chr2:42591480	NA	-0.32	-4.65	-0.39	8.33e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8017423	0.967	rs2277514	chr14:90723059	T/C	cg04374321	chr14:90722782	PSMC1	0.76	7.71	0.57	3.59e-12	Mortality in heart failure;
TGCT	cis	rs7772486	0.681	rs9390343	chr6:146010527	A/T	cg23711669	chr6:146136114	FBXO30	-0.81	-8.65	-0.61	2.25e-14	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6840360	0.615	rs9884167	chr4:152470799	A/G	cg17479576	chr4:152424074	FAM160A1	-0.72	-7.96	-0.58	9.32e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg12311346	chr5:56204834	C5orf35	-0.67	-6.77	-0.52	4.59e-10	Initial pursuit acceleration;
TGCT	cis	rs861020	0.606	rs695140	chr1:210005061	G/A	cg05527609	chr1:210001259	C1orf107	0.86	7.54	0.56	8.69e-12	Orofacial clefts;
TGCT	cis	rs6138458	0.828	rs6132785	chr20:24993414	T/C	cg26195577	chr20:24973756	C20orf3	1.04	9.62	0.65	1.04e-16	Blood protein levels;
TGCT	cis	rs6088580	0.634	rs6120669	chr20:33105028	T/C	cg08999081	chr20:33150536	PIGU	0.29	5.57	0.45	1.54e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.83	-5.65	-0.45	1.05e-7	Alzheimer's disease;
TGCT	trans	rs114540395	0.858	rs116952915	chr10:103265796	C/T	cg10198749	chr1:39920707	MACF1	0.55	7.12	0.54	7.73e-11	Schizophrenia;
TGCT	cis	rs9640161	0.702	rs1962004	chr7:150020381	G/A	cg10018233	chr7:150070692	REPIN1	0.32	4.58	0.38	1.09e-5	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg03303774	chr4:1407052	NA	0.32	4.78	0.39	4.94e-6	Obesity-related traits;
TGCT	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.33	-5.17	-0.42	9.08e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9677476	1.000	rs6704770	chr2:232109816	T/G	cg07929768	chr2:232055508	NA	0.3	4.48	0.37	1.71e-5	Food antigen IgG levels;
TGCT	cis	rs7727544	0.557	rs715285	chr5:131485383	A/G	cg24060327	chr5:131705240	SLC22A5	-0.47	-4.74	-0.39	5.66e-6	Blood metabolite levels;
TGCT	cis	rs68170813	0.559	rs5002976	chr7:107050620	C/G	cg02696742	chr7:106810147	HBP1	-0.68	-5.44	-0.44	2.69e-7	Coronary artery disease;
TGCT	cis	rs2072499	0.898	rs2758609	chr1:156202868	G/A	cg06970220	chr1:156163860	SLC25A44	0.71	5.87	0.47	3.81e-8	Testicular germ cell tumor;
TGCT	cis	rs12220238	1.000	rs8255	chr10:75879750	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.91	7.94	0.58	1.02e-12	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs910316	0.934	rs8006587	chr14:75664939	A/G	cg11812906	chr14:75593930	NEK9	0.74	6.83	0.52	3.46e-10	Height;
TGCT	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg10802521	chr3:52805072	NEK4	-0.78	-10.01	-0.67	1.23e-17	Electroencephalogram traits;
TGCT	cis	rs12142240	0.698	rs61519400	chr1:46855298	A/G	cg14993813	chr1:46806288	NSUN4	-0.59	-4.86	-0.4	3.45e-6	Menopause (age at onset);
TGCT	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg11965913	chr1:205819406	PM20D1	0.53	7.54	0.56	8.56e-12	Menarche (age at onset);
TGCT	cis	rs4889855	0.585	rs17848706	chr17:78704618	G/T	cg16591659	chr17:78472290	NA	0.31	4.69	0.39	7.21e-6	Fractional excretion of uric acid;
TGCT	cis	rs7267979	1.000	rs397119	chr20:25440187	C/A	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg12570787	chr5:219185	SDHA;CCDC127	-0.7	-4.7	-0.39	6.83e-6	Breast cancer;
TGCT	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg18876405	chr7:65276391	NA	0.32	4.89	0.4	3.12e-6	Aortic root size;
TGCT	cis	rs1008375	0.966	rs2010053	chr4:17583806	A/C	cg10189774	chr4:17578691	LAP3	0.64	5.61	0.45	1.28e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg02353165	chr6:42928485	GNMT	1.07	12.13	0.74	8.27e-23	Alzheimer's disease in APOE e4+ carriers;
TGCT	trans	rs9650657	0.572	rs11250098	chr8:10818607	A/G	cg06636001	chr8:8085503	FLJ10661	-0.86	-8.31	-0.6	1.44e-13	Neuroticism;
TGCT	cis	rs11711311	0.784	rs13081931	chr3:113349928	G/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.72	-6.03	-0.48	1.71e-8	IgG glycosylation;
TGCT	cis	rs4824093	0.610	rs58671506	chr22:50288983	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.11	-6.76	-0.52	4.86e-10	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs12753569	0.748	rs6668566	chr1:76507675	C/G	cg00791851	chr1:76518896	NA	0.36	4.65	0.39	8.34e-6	Personality dimensions;
TGCT	cis	rs1857353	1.000	rs10493575	chr1:75903516	G/A	cg11838876	chr1:75668600	SLC44A5	-0.47	-4.56	-0.38	1.2e-5	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs7666738	0.830	rs4699598	chr4:99019158	C/T	cg18180107	chr4:99064573	C4orf37	0.53	4.8	0.4	4.49e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7666738	0.830	rs28451101	chr4:99001190	T/C	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs526231	0.543	rs6880911	chr5:102307471	T/C	cg23492399	chr5:102201601	PAM	-0.53	-4.56	-0.38	1.23e-5	Primary biliary cholangitis;
TGCT	cis	rs9527	0.590	rs7901197	chr10:104840433	C/T	cg04362960	chr10:104952993	NT5C2	0.66	5.55	0.45	1.62e-7	Arsenic metabolism;
TGCT	cis	rs12477438	0.520	rs11123765	chr2:99768064	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.89	9.05	0.63	2.42e-15	Chronic sinus infection;
TGCT	cis	rs7937682	0.924	rs10891283	chr11:111527672	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.12	-11.81	-0.73	4.86e-22	Primary sclerosing cholangitis;
TGCT	cis	rs6894249	1.000	rs6894249	chr5:131797547	A/G	cg02551604	chr5:131831745	NA	-0.53	-5.01	-0.41	1.85e-6	Asthma;
TGCT	cis	rs72843506	0.722	rs74255387	chr17:20101383	G/A	cg18979559	chr17:20280153	CCDC144C	-0.71	-5.1	-0.42	1.26e-6	Schizophrenia;
TGCT	cis	rs367615	0.959	rs4957830	chr5:108911758	G/T	cg17395555	chr5:108820864	NA	0.29	4.6	0.38	1.04e-5	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg08048268	chr3:133502702	NA	-0.73	-11.42	-0.72	4.54e-21	Iron status biomarkers;
TGCT	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg22920501	chr2:26401640	FAM59B	-0.81	-6.36	-0.5	3.52e-9	Gut microbiome composition (summer);
TGCT	cis	rs9341808	0.527	rs2505946	chr6:80810683	A/G	cg08355045	chr6:80787529	NA	0.34	6.13	0.48	1.07e-8	Sitting height ratio;
TGCT	cis	rs9372498	0.706	rs9489396	chr6:118761703	A/C	cg21191810	chr6:118973309	C6orf204	-0.37	-4.77	-0.39	5.03e-6	Diastolic blood pressure;
TGCT	cis	rs7216064	0.531	rs62084683	chr17:66031725	A/G	cg12091567	chr17:66097778	LOC651250	1.07	8.8	0.62	9.68e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs12210905	1.000	rs12210905	chr6:27151309	A/G	cg08851530	chr6:28072375	NA	1.12	5.43	0.44	2.82e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs7208859	0.623	rs55814012	chr17:29077697	T/A	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs3087591	0.708	rs2854320	chr17:29694063	C/A	cg24425628	chr17:29625626	OMG;NF1	0.39	5.55	0.45	1.65e-7	Hip circumference;
TGCT	cis	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg15462221	chr8:8086144	FLJ10661	-0.56	-5.32	-0.43	4.74e-7	Neuroticism;
TGCT	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9807989	0.839	rs9808453	chr2:102971306	C/A	cg09003973	chr2:102972529	NA	0.64	5.7	0.46	8.28e-8	Asthma;
TGCT	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	-0.45	-4.84	-0.4	3.81e-6	Menopause (age at onset);
TGCT	cis	rs899997	0.773	rs11072783	chr15:78965966	G/A	cg00061860	chr15:78953028	NA	-0.33	-5.21	-0.42	7.75e-7	Coronary artery disease or large artery stroke;
TGCT	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.72	5.19	0.42	8.33e-7	Platelet count;
TGCT	cis	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg08045932	chr20:61659980	NA	0.48	9.28	0.64	7.07e-16	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs12908161	0.959	rs2175567	chr15:85200946	C/G	cg17173187	chr15:85201210	NMB	0.6	6.74	0.52	5.37e-10	Schizophrenia;
TGCT	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg25036284	chr2:26402008	FAM59B	-0.62	-4.9	-0.4	2.94e-6	Gut microbiome composition (summer);
TGCT	cis	rs12477438	0.501	rs9941561	chr2:99753829	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	16.87	0.83	6.81e-34	Chronic sinus infection;
TGCT	cis	rs2439831	0.702	rs3784275	chr15:44091386	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	5.35	0.43	4.02e-7	Lung cancer in ever smokers;
TGCT	cis	rs3806843	0.868	rs2563291	chr5:140119599	T/A	cg19875535	chr5:140030758	IK	-0.35	-5.94	-0.47	2.67e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs71435601	0.600	rs560844	chr2:21389108	A/G	cg25035485	chr2:21266500	APOB	0.51	4.48	0.37	1.64e-5	Cholesterol, total;
TGCT	cis	rs10791097	0.547	rs3829271	chr11:130753912	T/A	cg05962950	chr11:130786565	SNX19	0.94	11.87	0.73	3.48e-22	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9326248	0.817	rs1242127	chr11:117076564	A/G	cg26566898	chr11:117069891	TAGLN	-0.34	-4.98	-0.41	2.06e-6	Blood protein levels;
TGCT	cis	rs854765	0.693	rs11657074	chr17:17770355	G/A	cg04398451	chr17:18023971	MYO15A	0.29	4.56	0.38	1.19e-5	Total body bone mineral density;
TGCT	cis	rs57920188	0.584	rs12080562	chr1:4089697	C/A	cg20703997	chr1:4087676	NA	0.49	6.12	0.48	1.11e-8	Interleukin-17 levels;
TGCT	trans	rs7698623	0.850	rs4693894	chr4:88797798	C/T	cg01186725	chr1:53905612	FLJ40434	-0.48	-6.63	-0.51	9.21e-10	Cardiovascular disease risk factors;
TGCT	cis	rs6866344	0.661	rs72812606	chr5:178129094	A/T	cg03877680	chr5:178157825	ZNF354A	0.72	5.65	0.45	1.05e-7	Neutrophil percentage of white cells;
TGCT	cis	rs986417	0.901	rs11627533	chr14:61037801	C/T	cg27398547	chr14:60952738	C14orf39	1.62	10.36	0.68	1.69e-18	Gut microbiota (bacterial taxa);
TGCT	cis	rs929354	0.772	rs3802126	chr7:156970281	G/A	cg05182265	chr7:156933206	UBE3C	-0.39	-8.79	-0.62	1.03e-14	Body mass index;
TGCT	cis	rs12908161	0.960	rs62019463	chr15:85288087	G/A	cg17173187	chr15:85201210	NMB	0.57	6.38	0.5	3.25e-9	Schizophrenia;
TGCT	cis	rs4455778	0.724	rs993872	chr7:48993694	T/G	cg26309511	chr7:48887640	NA	-0.49	-5.95	-0.47	2.51e-8	Lung cancer in never smokers;
TGCT	cis	rs782590	0.774	rs782632	chr2:55898290	C/G	cg18811423	chr2:55921094	PNPT1	0.65	6.76	0.52	4.79e-10	Metabolic syndrome;
TGCT	cis	rs514406	0.644	rs928451	chr1:53195800	A/G	cg25767906	chr1:53392781	SCP2	0.44	4.79	0.4	4.68e-6	Monocyte count;
TGCT	cis	rs910316	1.000	rs10142626	chr14:75555636	A/T	cg11812906	chr14:75593930	NEK9	0.74	7.38	0.55	1.97e-11	Height;
TGCT	cis	rs4253772	0.591	rs11703435	chr22:46685563	C/T	cg24881330	chr22:46731750	TRMU	1.04	5.38	0.44	3.54e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs75686122	0.892	rs2388725	chr8:104633089	C/T	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs9915657	0.966	rs1042673	chr17:70121339	A/G	cg06234051	chr17:70120541	SOX9	-0.29	-5.62	-0.45	1.17e-7	Thyroid hormone levels;
TGCT	cis	rs16865717	1.000	rs12989595	chr2:7029483	A/G	cg20486407	chr2:7037101	RSAD2	0.39	5.18	0.42	8.8e-7	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs587847	0.737	rs2069194	chr15:37665211	G/A	cg00216138	chr15:37171175	LOC145845	0.31	4.45	0.37	1.91e-5	Intraocular pressure;
TGCT	cis	rs644799	0.932	rs10831447	chr11:95663017	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.96	-7.37	-0.55	2.08e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs6912958	0.559	rs451829	chr6:88041919	A/G	cg10393598	chr6:87862264	NA	-0.31	-4.5	-0.37	1.55e-5	Monocyte percentage of white cells;
TGCT	cis	rs6840360	0.571	rs62327270	chr4:152533618	C/T	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.0	-0.58	7.69e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg27170947	chr2:26402098	FAM59B	-0.39	-4.46	-0.37	1.8e-5	Gut microbiome composition (summer);
TGCT	cis	rs9611565	0.512	rs1534932	chr22:42150146	C/T	cg03806693	chr22:41940476	POLR3H	1.02	10.49	0.69	7.92e-19	Vitiligo;
TGCT	cis	rs4886920	0.518	rs4624137	chr15:78078903	A/G	cg03457338	chr15:78040120	NA	0.24	5.28	0.43	5.48e-7	Neuroticism;
TGCT	cis	rs2841277	0.676	rs10438246	chr14:105410183	T/C	cg21017887	chr14:105400489	NA	0.36	5.15	0.42	9.89e-7	Rheumatoid arthritis;
TGCT	cis	rs7772486	0.686	rs9376961	chr6:146048737	C/T	cg23711669	chr6:146136114	FBXO30	0.85	9.68	0.66	7.67e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10791097	0.547	rs11222371	chr11:130745719	C/T	cg05962950	chr11:130786565	SNX19	0.93	11.63	0.72	1.37e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	trans	rs2727020	0.558	rs1164675	chr11:49325972	C/T	cg03929089	chr4:120376271	NA	0.65	6.89	0.53	2.46e-10	Coronary artery disease;
TGCT	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.45	-6.56	-0.51	1.28e-9	Alzheimer's disease;
TGCT	cis	rs8074700	0.518	rs9646424	chr17:46705605	C/A	cg05487507	chr17:46671861	LOC404266;HOXB5	0.45	4.99	0.41	2.03e-6	Body mass index in non-asthmatics;
TGCT	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg17554472	chr22:41940697	POLR3H	-0.49	-5.27	-0.43	5.9e-7	Vitiligo;
TGCT	cis	rs2455799	0.573	rs2470520	chr3:15762920	C/T	cg16303742	chr3:15540471	COLQ	-0.26	-4.96	-0.41	2.26e-6	Mean platelet volume;
TGCT	cis	rs55962025	0.842	rs362267	chr4:3243218	C/T	cg06533319	chr4:3265114	C4orf44	0.23	4.44	0.37	2e-5	Parental longevity (mother's age at death);
TGCT	cis	rs9467711	0.606	rs34622023	chr6:26362119	A/T	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg11890956	chr21:40555474	PSMG1	-0.69	-6.79	-0.52	4.22e-10	Menarche (age at onset);
TGCT	cis	rs10197940	0.662	rs4592848	chr2:152337822	G/A	cg19508488	chr2:152266495	RIF1	0.72	6.58	0.51	1.2e-9	Lung cancer;
TGCT	cis	rs111803315	0.661	rs111876050	chr14:59994667	T/C	cg22995959	chr14:59931024	GPR135	0.66	4.8	0.4	4.39e-6	Schizophrenia;
TGCT	cis	rs13217239	0.646	rs4269366	chr6:27016413	C/T	cg05738196	chr6:26577821	NA	0.49	4.71	0.39	6.42e-6	Schizophrenia;
TGCT	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7666738	0.830	rs34244876	chr4:99031336	G/A	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8017423	0.647	rs4904679	chr14:90821801	C/T	cg04374321	chr14:90722782	PSMC1	-0.54	-5.41	-0.44	3.13e-7	Mortality in heart failure;
TGCT	cis	rs4919044	0.808	rs7895700	chr10:94791099	A/G	cg05127821	chr10:94822908	CYP26C1	-0.74	-4.83	-0.4	3.95e-6	Coronary artery disease;
TGCT	cis	rs7095607	1.000	rs7081213	chr10:69954290	G/A	cg18986048	chr10:69913749	MYPN	0.46	4.93	0.41	2.54e-6	Lung function (FVC);
TGCT	cis	rs11741688	0.557	rs6897783	chr5:178330574	G/A	cg08270223	chr5:178322770	ZFP2	-0.37	-5.49	-0.44	2.14e-7	Sleep duration;
TGCT	cis	rs6540559	0.546	rs74991018	chr1:210033790	T/G	cg04352962	chr1:209979756	IRF6	0.69	4.73	0.39	6.04e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs2075671	0.903	rs11520986	chr7:100276994	A/G	cg20848291	chr7:100343083	ZAN	-0.52	-4.56	-0.38	1.21e-5	Other erythrocyte phenotypes;
TGCT	cis	rs1372520	0.684	rs2583979	chr4:90750588	A/T	cg20003494	chr4:90757398	SNCA	-0.63	-5.09	-0.42	1.3e-6	Neuroticism;
TGCT	cis	rs7666738	0.830	rs11944035	chr4:98931618	C/T	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4786125	0.920	rs6500851	chr16:6896521	A/G	cg03623568	chr16:6915990	A2BP1	-0.35	-4.76	-0.39	5.25e-6	Heart rate variability traits (SDNN);
TGCT	cis	rs4285028	0.747	rs3772126	chr3:121354583	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.93	-7.37	-0.55	2.1e-11	Multiple sclerosis;
TGCT	cis	rs7833790	0.654	rs7835342	chr8:82698092	A/G	cg27398817	chr8:82754497	SNX16	-0.58	-4.66	-0.39	8.19e-6	Diastolic blood pressure;
TGCT	cis	rs7959452	0.640	rs10878957	chr12:69699638	G/C	cg14784868	chr12:69753453	YEATS4	0.68	6.93	0.53	2.03e-10	Blood protein levels;
TGCT	cis	rs9393777	0.513	rs9393741	chr6:26654189	A/G	cg15659132	chr6:26577336	NA	-0.75	-5.25	-0.43	6.33e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs6831352	0.819	rs1230158	chr4:99990186	T/C	cg12011299	chr4:100065546	ADH4	0.4	5.46	0.44	2.5e-7	Alcohol dependence;
TGCT	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg06634786	chr22:41940651	POLR3H	-0.9	-8.98	-0.63	3.59e-15	Vitiligo;
TGCT	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs3008870	1.000	rs3008856	chr1:67387901	T/C	cg03991309	chr1:68237761	GNG12	0.27	4.56	0.38	1.23e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs11098499	0.954	rs7687843	chr4:120421211	C/T	cg09307838	chr4:120376055	NA	0.68	6.37	0.5	3.41e-9	Corneal astigmatism;
TGCT	cis	rs9916302	0.706	rs6503500	chr17:37485925	C/T	cg07936489	chr17:37558343	FBXL20	-0.78	-5.83	-0.46	4.59e-8	Glomerular filtration rate (creatinine);
TGCT	cis	rs17376456	0.825	rs35426871	chr5:93291613	C/T	cg25358565	chr5:93447407	FAM172A	1.02	8.11	0.59	4.23e-13	Diabetic retinopathy;
TGCT	cis	rs9611565	0.512	rs9611667	chr22:42187015	C/T	cg17554472	chr22:41940697	POLR3H	-0.46	-4.79	-0.39	4.71e-6	Vitiligo;
TGCT	cis	rs7666738	0.822	rs28512427	chr4:98919029	G/A	cg17366294	chr4:99064904	C4orf37	0.71	7.25	0.55	3.96e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8077577	1.000	rs7207276	chr17:18065737	G/C	cg09161412	chr17:18057145	MYO15A	-0.67	-5.44	-0.44	2.69e-7	Obesity-related traits;
TGCT	cis	rs736801	1.000	rs736801	chr5:131833599	C/T	cg02551604	chr5:131831745	NA	0.56	4.57	0.38	1.14e-5	Breast cancer;Mosquito bite size;
TGCT	cis	rs1865760	0.613	rs2071300	chr6:25914572	C/T	cg03264133	chr6:25882463	NA	-0.54	-5.78	-0.46	5.69e-8	Height;
TGCT	cis	rs17376456	0.542	rs35672980	chr5:93284877	A/T	cg21475434	chr5:93447410	FAM172A	-0.62	-5.97	-0.47	2.3e-8	Diabetic retinopathy;
TGCT	cis	rs12477438	0.520	rs2516827	chr2:99772565	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	13.05	0.76	4.93e-25	Chronic sinus infection;
TGCT	cis	rs12049351	0.774	rs34405887	chr1:229618634	C/T	cg12130225	chr1:229698885	NA	0.39	4.59	0.38	1.06e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs9443645	0.869	rs1567168	chr6:79536455	G/T	cg09184832	chr6:79620586	NA	-0.46	-4.94	-0.41	2.49e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs11250097	0.549	rs11784897	chr8:11310442	G/A	cg01383082	chr8:11323474	FAM167A	0.28	4.54	0.38	1.3e-5	Neuroticism;
TGCT	cis	rs7267979	0.549	rs6138536	chr20:25182648	A/G	cg14121845	chr20:25566513	NINL	0.43	4.64	0.38	8.62e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs12681287	0.511	rs9297923	chr8:87548989	T/C	cg27223183	chr8:87520930	FAM82B	0.94	6.91	0.53	2.24e-10	Caudate activity during reward;
TGCT	cis	rs6570726	0.791	rs370654	chr6:145879005	C/G	cg13319975	chr6:146136371	FBXO30	-0.51	-4.6	-0.38	1.01e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.6	-8.54	-0.61	4.04e-14	Longevity;Endometriosis;
TGCT	cis	rs6582630	0.555	rs56228141	chr12:38518652	T/G	cg26384229	chr12:38710491	ALG10B	0.84	7.68	0.57	4.16e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs763014	0.865	rs710924	chr16:633353	T/C	cg07343612	chr16:622815	PIGQ	-0.39	-7.36	-0.55	2.26e-11	Height;
TGCT	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg08280861	chr8:58055591	NA	0.4	4.56	0.38	1.22e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs6840360	0.571	rs2165789	chr4:152510130	A/T	cg17479576	chr4:152424074	FAM160A1	-0.71	-7.72	-0.57	3.41e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs208520	0.690	rs207108	chr6:66794096	T/C	cg07460842	chr6:66804631	NA	-0.94	-9.86	-0.66	2.74e-17	Exhaled nitric oxide output;
TGCT	cis	rs3820068	0.581	rs68052904	chr1:15916714	T/C	cg05660106	chr1:15850417	CASP9	0.8	8.06	0.59	5.6e-13	Systolic blood pressure;
TGCT	cis	rs2282802	0.660	rs6873248	chr5:139683762	A/G	cg01081189	chr5:139537190	NA	-0.29	-5.31	-0.43	5e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9357506	1.000	rs12055407	chr6:46306474	A/G	cg21115430	chr6:46460003	NA	-0.26	-5.17	-0.42	9.2e-7	Body mass index;
TGCT	cis	rs62103177	0.713	rs62103186	chr18:77627574	G/C	cg12964065	chr18:77638022	KCNG2	0.37	4.76	0.39	5.4e-6	Opioid sensitivity;
TGCT	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg05985448	chr10:134359359	INPP5A	0.22	4.83	0.4	3.89e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs7937682	0.883	rs484834	chr11:111465761	G/C	cg09085632	chr11:111637200	PPP2R1B	-0.99	-9.99	-0.67	1.34e-17	Primary sclerosing cholangitis;
TGCT	cis	rs2692947	0.616	rs2301707	chr2:96931846	T/C	cg22654517	chr2:96458247	NA	0.22	4.9	0.4	2.92e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs1949733	0.656	rs2688224	chr4:8404700	C/G	cg11789530	chr4:8429930	ACOX3	0.48	4.47	0.37	1.71e-5	Response to antineoplastic agents;
TGCT	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.98	-13.09	-0.76	4.1e-25	Prudent dietary pattern;
TGCT	cis	rs4906332	1.000	rs55930273	chr14:103960298	G/A	cg26031613	chr14:104095156	KLC1	-0.51	-4.51	-0.38	1.48e-5	Coronary artery disease;
TGCT	cis	rs2456568	0.803	rs10765641	chr11:93640312	T/C	cg17595323	chr11:93583763	C11orf90	-0.46	-6.24	-0.49	6.46e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7727544	0.631	rs13357280	chr5:131600187	A/G	cg21474247	chr5:131268130	NA	0.3	4.44	0.37	1.94e-5	Blood metabolite levels;
TGCT	cis	rs2224391	0.628	rs2773318	chr6:5258843	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-1.04	-6.48	-0.5	1.94e-9	Height;
TGCT	cis	rs11731606	0.508	rs28623728	chr4:95290861	C/T	cg00507259	chr4:95128692	SMARCAD1	0.64	4.78	0.39	4.97e-6	Mean platelet volume;
TGCT	trans	rs210152	0.541	rs35432298	chr6:33457013	T/A	cg08795360	chr21:41033440	B3GALT5	0.45	7.11	0.54	8.23e-11	Schizophrenia;
TGCT	cis	rs554111	0.634	rs34740989	chr1:21316782	C/T	cg01072550	chr1:21505969	NA	0.36	5.43	0.44	2.9e-7	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs950169	0.922	rs11639244	chr15:84832650	G/A	cg17173187	chr15:85201210	NMB	0.54	5.52	0.44	1.94e-7	Schizophrenia;
TGCT	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg13665807	chr20:60559372	TAF4	-0.5	-5.23	-0.43	6.92e-7	Body mass index;
TGCT	cis	rs4689388	0.926	rs9998835	chr4:6293237	C/G	cg00701064	chr4:6280414	WFS1	0.37	4.72	0.39	6.3e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs6733011	0.604	rs12712035	chr2:99461298	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.47	-4.75	-0.39	5.58e-6	Bipolar disorder;
TGCT	cis	rs8072100	0.666	rs9913503	chr17:45776330	T/G	cg08085267	chr17:45401833	C17orf57	-0.46	-5.17	-0.42	9.01e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs7714584	1.000	rs75071288	chr5:150224379	C/T	cg22134413	chr5:150180641	NA	0.89	6.96	0.53	1.73e-10	Crohn's disease;
TGCT	cis	rs8031584	0.678	rs3122	chr15:31170290	A/T	cg14829155	chr15:31115871	NA	0.38	4.82	0.4	4.12e-6	Huntington's disease progression;
TGCT	cis	rs4653767	1.000	rs10495249	chr1:226919119	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.46	-5.07	-0.41	1.41e-6	Parkinson's disease;
TGCT	cis	rs57221529	0.655	rs72704791	chr5:547896	A/G	cg09021430	chr5:549028	NA	-0.4	-5.1	-0.42	1.22e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs9807989	0.571	rs10208293	chr2:102966310	G/A	cg09003973	chr2:102972529	NA	0.83	6.8	0.52	3.98e-10	Asthma;
TGCT	cis	rs10088262	0.629	rs1367829	chr8:124797135	A/G	cg02993010	chr8:124780839	FAM91A1	-0.63	-5.13	-0.42	1.08e-6	Pancreatic cancer;
TGCT	cis	rs6089584	0.507	rs6061990	chr20:60628429	T/G	cg13665807	chr20:60559372	TAF4	-0.44	-4.77	-0.39	5.09e-6	Body mass index;
TGCT	cis	rs12477438	0.520	rs11123765	chr2:99768064	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.15	18.47	0.86	2.08e-37	Chronic sinus infection;
TGCT	cis	rs1153858	1.000	rs12437840	chr15:45669055	C/A	cg26924012	chr15:45694286	SPATA5L1	1.09	15.08	0.8	7.99e-30	Homoarginine levels;
TGCT	cis	rs7599312	0.534	rs7607373	chr2:213409719	G/A	cg20637307	chr2:213403960	ERBB4	0.91	11.34	0.71	7.02e-21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg05368731	chr17:41323189	NBR1	1.01	10.1	0.67	7.21e-18	Menopause (age at onset);
TGCT	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg06640241	chr16:89574553	SPG7	0.77	8.97	0.63	3.82e-15	Multiple myeloma (IgH translocation);
TGCT	cis	rs6831352	1.000	rs6831352	chr4:100063525	T/C	cg12011299	chr4:100065546	ADH4	0.42	5.26	0.43	6.06e-7	Alcohol dependence;
TGCT	cis	rs1784581	0.775	rs7755404	chr6:162427731	T/C	cg17173639	chr6:162384350	PARK2	0.42	7.38	0.55	2.03e-11	Itch intensity from mosquito bite;
TGCT	cis	rs11779988	0.545	rs10095047	chr8:17750328	T/C	cg01800426	chr8:17659068	MTUS1	-0.57	-5.09	-0.42	1.27e-6	Breast cancer;
TGCT	cis	rs10751667	0.666	rs10902239	chr11:946484	A/G	cg06064525	chr11:970664	AP2A2	0.35	8.12	0.59	4.04e-13	Alzheimer's disease (late onset);
TGCT	cis	rs1153858	1.000	rs12439274	chr15:45636667	A/G	cg26924012	chr15:45694286	SPATA5L1	1.08	14.12	0.79	1.39e-27	Homoarginine levels;
TGCT	cis	rs2235642	0.785	rs1057983	chr16:1660274	A/G	cg10465839	chr16:1584050	IFT140;TMEM204	-0.28	-4.58	-0.38	1.11e-5	Coronary artery disease;
TGCT	cis	rs2204008	0.774	rs2387811	chr12:38369794	C/A	cg13010199	chr12:38710504	ALG10B	0.6	4.74	0.39	5.76e-6	Bladder cancer;
TGCT	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg11494091	chr17:61959527	GH2	0.61	14.43	0.79	2.59e-28	Prudent dietary pattern;
TGCT	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg20999797	chr1:1681921	NA	0.18	4.78	0.39	4.93e-6	Body mass index;
TGCT	trans	rs1814175	0.653	rs10839480	chr11:50034556	C/T	cg03929089	chr4:120376271	NA	-0.72	-8.55	-0.61	3.8e-14	Height;
TGCT	cis	rs6690583	0.512	rs7547224	chr1:85456902	T/C	cg20280350	chr1:85513789	MCOLN3	-0.79	-5.27	-0.43	5.77e-7	Serum sulfate level;
TGCT	cis	rs10465746	0.780	rs10874423	chr1:84374071	C/T	cg10977910	chr1:84465055	TTLL7	0.66	6.65	0.51	8.38e-10	Obesity-related traits;
TGCT	cis	rs2019216	0.542	rs3829569	chr17:21909222	T/C	cg22648282	chr17:21454238	C17orf51	-0.56	-5.45	-0.44	2.57e-7	Pelvic organ prolapse;
TGCT	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	16.07	0.82	4.21e-32	Prudent dietary pattern;
TGCT	cis	rs11249608	0.548	rs62393072	chr5:178450056	C/T	cg01312482	chr5:178451176	ZNF879	-0.56	-5.5	-0.44	2.09e-7	Pubertal anthropometrics;
TGCT	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg25703541	chr22:24373054	LOC391322	-0.81	-7.82	-0.57	1.93e-12	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7584330	0.737	rs1497128	chr2:238369211	A/G	cg14458575	chr2:238380390	NA	0.49	8.05	0.59	5.71e-13	Prostate cancer;
TGCT	cis	rs1055129	0.655	rs8067076	chr17:73837142	G/T	cg10935138	chr17:73851978	WBP2	-0.51	-4.48	-0.37	1.68e-5	White matter hyperintensity burden;
TGCT	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	5.68	0.45	9.24e-8	Height;
TGCT	cis	rs35146811	0.844	rs4424195	chr7:99642745	A/G	cg13334819	chr7:99746414	C7orf59	-0.8	-6.87	-0.52	2.81e-10	Coronary artery disease;
TGCT	trans	rs17471911	0.708	rs6584231	chr10:100784115	G/A	cg03484267	chr2:207988651	KLF7	-0.52	-6.7	-0.52	6.49e-10	Neuroticism;
TGCT	cis	rs9291683	0.588	rs3796829	chr4:10019138	C/G	cg02734326	chr4:10020555	SLC2A9	0.38	4.54	0.38	1.34e-5	Bone mineral density;
TGCT	cis	rs17376456	0.757	rs6859757	chr5:93206042	C/T	cg25358565	chr5:93447407	FAM172A	0.99	7.65	0.57	4.94e-12	Diabetic retinopathy;
TGCT	cis	rs7639513	0.767	rs9861271	chr3:12707620	A/C	cg23032965	chr3:12705835	RAF1	0.77	8.55	0.61	3.81e-14	Itch intensity from mosquito bite;
TGCT	cis	rs11690935	0.959	rs67204065	chr2:172672624	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.03	-9.98	-0.67	1.45e-17	Schizophrenia;
TGCT	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg07061783	chr6:25882402	NA	-0.43	-4.61	-0.38	9.88e-6	Blood metabolite levels;
TGCT	cis	rs6500602	0.727	rs55939215	chr16:4541390	C/G	cg08645402	chr16:4508243	NA	0.18	5.06	0.41	1.44e-6	Schizophrenia;
TGCT	cis	rs2197308	0.619	rs4002730	chr12:37876400	T/C	cg26384229	chr12:38710491	ALG10B	0.89	7.98	0.58	8.43e-13	Morning vs. evening chronotype;
TGCT	cis	rs1008375	0.898	rs4698623	chr4:17594702	T/C	cg10189774	chr4:17578691	LAP3	0.68	5.74	0.46	6.99e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg07507251	chr3:52567010	NT5DC2	0.46	6.66	0.51	7.92e-10	Bipolar disorder;
TGCT	cis	rs7267979	1.000	rs6083804	chr20:25317060	A/G	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs12134245	1.000	rs12134245	chr1:92021464	C/T	cg02896835	chr1:92012615	NA	-0.26	-4.45	-0.37	1.88e-5	Breast cancer;
TGCT	cis	rs9300255	0.566	rs1716169	chr12:123716930	A/T	cg00376283	chr12:123451042	ABCB9	0.66	4.59	0.38	1.08e-5	Neutrophil percentage of white cells;
TGCT	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg17554472	chr22:41940697	POLR3H	-0.48	-5.15	-0.42	9.89e-7	Vitiligo;
TGCT	cis	rs2836974	0.931	rs2989330	chr21:40716209	A/G	cg06238570	chr21:40685208	BRWD1	0.58	4.63	0.38	8.99e-6	Cognitive function;
TGCT	cis	rs3947	0.756	rs1613883	chr8:11699632	T/A	cg02840367	chr8:11660030	FDFT1	0.91	6.7	0.52	6.58e-10	Blood protein levels;
TGCT	cis	rs523522	0.962	rs10744752	chr12:120900554	T/G	cg27279351	chr12:120934652	DYNLL1	0.76	6.54	0.51	1.46e-9	High light scatter reticulocyte count;
TGCT	cis	rs2204008	0.744	rs11181635	chr12:38378420	C/T	cg13010199	chr12:38710504	ALG10B	0.6	4.74	0.39	5.76e-6	Bladder cancer;
TGCT	cis	rs5758659	0.504	rs133367	chr22:42463366	A/G	cg05082376	chr22:42548792	NA	0.21	5.24	0.43	6.65e-7	Cognitive function;
TGCT	cis	rs2235642	0.750	rs2859310	chr16:1656765	C/T	cg08296037	chr16:1584118	IFT140;TMEM204	0.29	4.98	0.41	2.06e-6	Coronary artery disease;
TGCT	trans	rs877282	1.000	rs877282	chr10:771532	G/A	cg22713356	chr15:30763199	NA	1.2	10.36	0.68	1.66e-18	Uric acid levels;
TGCT	cis	rs992157	0.560	rs4674275	chr2:219097738	G/A	cg00012203	chr2:219082015	ARPC2	-0.81	-9.41	-0.65	3.47e-16	Colorectal cancer;
TGCT	cis	rs2115630	0.936	rs8033459	chr15:85253258	C/T	cg24513567	chr15:85260248	SEC11A	-0.34	-4.47	-0.37	1.76e-5	P wave terminal force;
TGCT	cis	rs9611519	0.589	rs8138917	chr22:41412425	T/C	cg13695892	chr22:41940480	POLR3H	-0.55	-5.14	-0.42	1.04e-6	Neuroticism;
TGCT	cis	rs56399783	0.901	rs73049305	chr7:2778755	C/T	cg19731401	chr7:2775893	GNA12	0.36	5.07	0.41	1.4e-6	Childhood ear infection;
TGCT	cis	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg18252515	chr7:66147081	NA	-1.13	-6.81	-0.52	3.7e-10	Diabetic kidney disease;
TGCT	cis	rs910316	0.726	rs175040	chr14:75469555	A/G	cg08847533	chr14:75593920	NEK9	-0.84	-9.11	-0.63	1.75e-15	Height;
TGCT	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg13012494	chr21:47604986	C21orf56	-0.41	-5.05	-0.41	1.53e-6	Testicular germ cell tumor;
TGCT	cis	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg11764359	chr7:65958608	NA	0.49	4.65	0.39	8.38e-6	Aortic root size;
TGCT	cis	rs617219	0.710	rs2255913	chr5:78562399	G/C	cg09550809	chr5:78407562	BHMT	0.37	5.24	0.43	6.65e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs1372520	0.684	rs2619368	chr4:90729747	T/G	cg26578617	chr4:90757533	SNCA	-0.52	-4.44	-0.37	1.99e-5	Neuroticism;
TGCT	cis	rs74233809	1.000	rs12219901	chr10:104840967	A/G	cg05855489	chr10:104503620	C10orf26	0.79	4.56	0.38	1.19e-5	Birth weight;
TGCT	cis	rs4888262	0.545	rs7184754	chr16:74667864	C/T	cg01733217	chr16:74700730	RFWD3	0.73	7.23	0.54	4.25e-11	Testicular germ cell tumor;
TGCT	cis	rs9902453	0.868	rs9890075	chr17:28470464	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	6.9	0.53	2.37e-10	Coffee consumption (cups per day);
TGCT	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg06873352	chr17:61820015	STRADA	0.55	6.13	0.48	1.09e-8	Prudent dietary pattern;
TGCT	cis	rs514406	0.505	rs395169	chr1:53174071	G/A	cg16325326	chr1:53192061	ZYG11B	0.85	11.98	0.73	1.93e-22	Monocyte count;
TGCT	cis	rs1865760	0.663	rs9379815	chr6:25980116	T/A	cg16482183	chr6:26056742	HIST1H1C	0.56	5.05	0.41	1.52e-6	Height;
TGCT	cis	rs78487399	0.808	rs116451849	chr2:43662911	A/C	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.74	4.69	0.39	7.08e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs4595586	0.870	rs10876208	chr12:39287667	G/T	cg10518543	chr12:38710700	ALG10B	-0.47	-4.6	-0.38	1.04e-5	Morning vs. evening chronotype;
TGCT	cis	rs11105298	0.891	rs10858894	chr12:89914261	T/C	cg00757033	chr12:89920650	WDR51B	0.34	5.46	0.44	2.52e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs6490294	0.583	rs4346023	chr12:112285542	C/T	cg10833066	chr12:111807467	FAM109A	-0.3	-4.82	-0.4	4.05e-6	Mean platelet volume;
TGCT	cis	rs350251	0.868	rs350278	chr16:12232402	T/C	cg02910054	chr16:12241554	SNX29	0.33	4.57	0.38	1.18e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs6912958	0.559	rs451465	chr6:88043372	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.69	-6.99	-0.53	1.48e-10	Monocyte percentage of white cells;
TGCT	cis	rs3540	0.574	rs2256388	chr15:90969335	A/C	cg22089800	chr15:90895588	ZNF774	-0.76	-8.15	-0.59	3.42e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs713587	1.000	rs713587	chr2:25158281	C/T	cg15423357	chr2:25149977	NA	0.63	6.43	0.5	2.55e-9	Body mass index in non-asthmatics;
TGCT	cis	rs6558530	0.666	rs10113471	chr8:1695827	C/A	cg09410841	chr8:1729607	CLN8	0.67	6.0	0.47	2.05e-8	Systolic blood pressure;
TGCT	cis	rs6860806	0.507	rs270614	chr5:131640813	G/A	cg24060327	chr5:131705240	SLC22A5	-0.73	-7.65	-0.57	4.87e-12	Breast cancer;
TGCT	cis	rs4595586	0.545	rs1303886	chr12:39366876	G/A	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs9300255	0.506	rs11057251	chr12:123791227	A/G	cg00376283	chr12:123451042	ABCB9	-0.66	-5.67	-0.45	9.67e-8	Neutrophil percentage of white cells;
TGCT	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9902453	0.791	rs3115090	chr17:28035014	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.85	8.57	0.61	3.4e-14	Coffee consumption (cups per day);
TGCT	cis	rs7826238	0.502	rs10503377	chr8:8378422	C/T	cg06636001	chr8:8085503	FLJ10661	0.63	5.17	0.42	9.02e-7	Systolic blood pressure;
TGCT	cis	rs7095607	0.606	rs7095774	chr10:69957554	C/T	cg18986048	chr10:69913749	MYPN	0.56	5.87	0.47	3.76e-8	Lung function (FVC);
TGCT	cis	rs6840360	0.607	rs6815320	chr4:152432500	T/C	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.82e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs939574	1.000	rs908196	chr2:220088248	A/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-1.04	-6.48	-0.5	1.91e-9	Platelet distribution width;
TGCT	cis	rs62064224	0.560	rs12162135	chr17:30805795	A/C	cg18200150	chr17:30822561	MYO1D	0.53	7.35	0.55	2.33e-11	Schizophrenia;
TGCT	cis	rs4689388	0.889	rs4629534	chr4:6294124	G/T	cg14416269	chr4:6271139	WFS1	0.37	4.9	0.4	2.95e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs7666738	0.830	rs6532721	chr4:99048015	G/A	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1008375	1.000	rs2109522	chr4:17658645	T/A	cg10189774	chr4:17578691	LAP3	0.57	5.15	0.42	9.95e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9330316	0.654	rs3934873	chr2:110286299	G/A	cg25199208	chr2:109402912	CCDC138	0.42	4.65	0.39	8.37e-6	Schizophrenia;
TGCT	cis	rs59698941	0.527	rs1557852	chr5:132181800	G/A	cg27099455	chr5:132201840	GDF9;UQCRQ	0.29	4.94	0.41	2.52e-6	Apolipoprotein A-IV levels;
TGCT	cis	rs939658	1.000	rs8031504	chr15:79458589	G/T	cg17916960	chr15:79447300	NA	0.54	8.64	0.61	2.42e-14	Refractive error;
TGCT	cis	rs854765	0.583	rs4553680	chr17:17857722	A/G	cg09796270	chr17:17721594	SREBF1	0.26	5.31	0.43	4.88e-7	Total body bone mineral density;
TGCT	cis	rs13108904	0.710	rs11937232	chr4:1207597	G/C	cg05665937	chr4:1216051	CTBP1	0.26	5.16	0.42	9.43e-7	Obesity-related traits;
TGCT	cis	rs7772486	0.727	rs10447449	chr6:146138707	A/G	cg23711669	chr6:146136114	FBXO30	0.89	9.9	0.66	2.27e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4972806	0.814	rs1446575	chr2:177047801	A/C	cg14324370	chr2:177042789	NA	0.68	6.49	0.5	1.89e-9	IgG glycosylation;
TGCT	cis	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg07424592	chr7:64974309	NA	1.31	8.12	0.59	3.98e-13	Diabetic kidney disease;
TGCT	cis	rs9341808	0.718	rs9448893	chr6:80837239	A/G	cg08355045	chr6:80787529	NA	0.32	5.83	0.46	4.48e-8	Sitting height ratio;
TGCT	cis	rs5769765	0.955	rs5769767	chr22:50276909	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	1.11	11.76	0.73	6.5e-22	Schizophrenia;
TGCT	cis	rs4700695	0.614	rs251286	chr5:65212769	A/G	cg21114390	chr5:65439923	SFRS12	0.68	4.8	0.4	4.54e-6	Facial morphology (factor 19);
TGCT	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg07092213	chr7:1199455	ZFAND2A	-0.43	-4.64	-0.38	8.8e-6	Longevity;Endometriosis;
TGCT	cis	rs6547741	0.717	rs2178197	chr2:27860551	C/T	cg27432699	chr2:27873401	GPN1	0.24	6.01	0.47	1.96e-8	Oral cavity cancer;
TGCT	cis	rs28595532	1.000	rs116030177	chr4:119650768	T/C	cg11846333	chr4:119757529	SEC24D	0.92	4.59	0.38	1.07e-5	Cannabis dependence symptom count;
TGCT	cis	rs614226	1.000	rs1167725	chr12:120968559	A/T	cg10072921	chr12:121022843	NA	-0.44	-4.74	-0.39	5.78e-6	Type 1 diabetes nephropathy;
TGCT	cis	rs7312933	0.558	rs55702525	chr12:42814309	T/C	cg19980929	chr12:42632907	YAF2	-0.4	-5.7	-0.46	8.24e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs2847281	0.587	rs2542157	chr18:12787247	T/G	cg23598886	chr18:12777645	NA	0.37	4.66	0.39	8.02e-6	C-reactive protein levels;Esophageal cancer (squamous cell);
TGCT	cis	rs4845570	0.831	rs11588634	chr1:151780686	T/A	cg07092448	chr1:151763213	TDRKH	-1.17	-8.37	-0.6	1e-13	Coronary artery disease;
TGCT	cis	rs4824093	0.610	rs9627798	chr22:50317857	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.15	-4.45	-0.37	1.86e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs9467711	0.790	rs35162296	chr6:26318262	C/T	cg05948654	chr6:25930507	SLC17A2	0.34	4.54	0.38	1.29e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6964587	1.000	rs9690778	chr7:91735299	A/G	cg22709100	chr7:91322751	NA	0.29	4.79	0.4	4.67e-6	Breast cancer;
TGCT	cis	rs17376456	0.877	rs10055340	chr5:93317644	T/C	cg21475434	chr5:93447410	FAM172A	0.65	4.85	0.4	3.58e-6	Diabetic retinopathy;
TGCT	cis	rs9393692	0.905	rs6908328	chr6:26292855	C/A	cg00631329	chr6:26305371	NA	-0.42	-6.22	-0.49	6.83e-9	Educational attainment;
TGCT	cis	rs2730245	0.505	rs2657360	chr7:158673604	A/G	cg24397884	chr7:158709396	WDR60	0.37	4.93	0.4	2.63e-6	Height;
TGCT	cis	rs1670533	1.000	rs629261	chr4:1086763	A/C	cg27284194	chr4:1044797	NA	0.68	5.95	0.47	2.59e-8	Recombination rate (females);
TGCT	cis	rs1018836	0.663	rs2205152	chr8:91483618	C/T	cg16814680	chr8:91681699	NA	0.83	8.39	0.6	9.07e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7772486	0.875	rs2748482	chr6:146336532	T/C	cg05347473	chr6:146136440	FBXO30	0.56	5.29	0.43	5.34e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11690462	0.963	rs2384362	chr2:26630389	A/T	cg04726446	chr2:26624865	C2orf39	-0.44	-4.8	-0.4	4.45e-6	Coronary artery disease;
TGCT	cis	rs6831352	0.837	rs2924583	chr4:100044640	T/C	cg12011299	chr4:100065546	ADH4	0.41	4.92	0.4	2.72e-6	Alcohol dependence;
TGCT	cis	rs12142240	0.621	rs13374968	chr1:46843908	T/G	cg00530320	chr1:46809349	NSUN4	0.29	5.88	0.47	3.51e-8	Menopause (age at onset);
TGCT	cis	rs17490626	0.568	rs12260685	chr10:71215799	C/T	cg14388049	chr10:71211838	TSPAN15	-0.39	-4.47	-0.37	1.71e-5	Thrombosis;
TGCT	cis	rs2153535	0.580	rs9406164	chr6:8470048	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs826838	0.935	rs11169508	chr12:39173385	C/T	cg13010199	chr12:38710504	ALG10B	0.78	6.16	0.48	9.26e-9	Heart rate;
TGCT	cis	rs9926296	0.744	rs164748	chr16:89708292	C/G	cg03388025	chr16:89894329	SPIRE2	-0.34	-5.21	-0.42	7.59e-7	Vitiligo;
TGCT	cis	rs11690935	0.885	rs7602037	chr2:172817794	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.89	-7.89	-0.58	1.33e-12	Schizophrenia;
TGCT	cis	rs422249	0.512	rs174576	chr11:61603510	C/A	cg01500311	chr11:61656094	FADS3	-0.32	-5.69	-0.46	8.54e-8	Trans fatty acid levels;
TGCT	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg23221052	chr5:179740743	GFPT2	-0.35	-5.58	-0.45	1.41e-7	Height;
TGCT	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg24675658	chr1:53192096	ZYG11B	0.71	8.15	0.59	3.39e-13	Monocyte count;
TGCT	cis	rs7647973	0.626	rs9830730	chr3:49675875	G/C	cg05785598	chr3:49045655	WDR6	0.42	5.24	0.43	6.67e-7	Menarche (age at onset);
TGCT	cis	rs9291683	0.509	rs6849717	chr4:9958719	T/C	cg11266682	chr4:10021025	SLC2A9	-0.62	-8.62	-0.61	2.56e-14	Bone mineral density;
TGCT	cis	rs9527	0.590	rs7087459	chr10:104790999	T/C	cg04362960	chr10:104952993	NT5C2	0.66	5.57	0.45	1.48e-7	Arsenic metabolism;
TGCT	cis	rs4733781	0.563	rs6985563	chr8:131332344	C/T	cg16277922	chr8:131349729	ASAP1	0.43	6.28	0.49	5.19e-9	Tuberculosis;
TGCT	cis	rs6867913	0.709	rs891987	chr5:141467196	A/T	cg23435118	chr5:141488016	NDFIP1	0.25	4.63	0.38	9.08e-6	Asthma;
TGCT	cis	rs250677	0.687	rs168750	chr5:148446756	A/G	cg23229984	chr5:148520753	ABLIM3	0.21	4.89	0.4	3.11e-6	Breast cancer;
TGCT	cis	rs4700695	0.719	rs27584	chr5:65445232	G/A	cg21114390	chr5:65439923	SFRS12	-0.84	-7.45	-0.56	1.35e-11	Facial morphology (factor 19);
TGCT	cis	rs11190604	1.000	rs11190599	chr10:102295420	C/T	cg16342193	chr10:102329863	NA	-0.41	-5.37	-0.43	3.78e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7666738	0.830	rs34273190	chr4:99004568	C/T	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7017914	0.967	rs4628281	chr8:71839164	T/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.52	-4.71	-0.39	6.62e-6	Bone mineral density;
TGCT	cis	rs7666738	0.830	rs7691433	chr4:98968118	A/T	cg17366294	chr4:99064904	C4orf37	0.69	6.63	0.51	9.14e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg12963246	chr6:28129442	ZNF389	0.52	5.1	0.42	1.23e-6	Depression;
TGCT	cis	rs1692580	0.840	rs262679	chr1:2169792	C/T	cg21194808	chr1:2205498	SKI	0.28	5.33	0.43	4.44e-7	Coronary artery disease;
TGCT	cis	rs6840360	0.571	rs11939356	chr4:152505234	G/C	cg17479576	chr4:152424074	FAM160A1	-0.72	-7.81	-0.57	2.09e-12	Intelligence (multi-trait analysis);
TGCT	trans	rs1814175	0.533	rs4528310	chr11:49983106	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.67	-0.69	2.92e-19	Height;
TGCT	cis	rs344364	0.529	rs186941	chr16:1930088	T/C	cg09830162	chr16:1889614	FAHD1;C16orf73	0.45	5.35	0.43	4.1e-7	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs7524258	0.900	rs6670323	chr1:7301947	C/A	cg07173049	chr1:7289937	CAMTA1	0.3	4.83	0.4	3.91e-6	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs9467711	0.538	rs9467626	chr6:25873746	C/A	cg16898833	chr6:26189333	HIST1H4D	1.16	5.51	0.44	2.03e-7	Autism spectrum disorder or schizophrenia;
TGCT	trans	rs210152	0.588	rs210131	chr6:33535466	T/C	cg15679064	chr19:49134105	DBP	1.22	6.8	0.52	4.01e-10	Schizophrenia;
TGCT	cis	rs12541335	0.507	rs9644047	chr8:22158670	T/A	cg26039829	chr8:22132926	PIWIL2	0.28	5.17	0.42	9e-7	Hypertriglyceridemia;
TGCT	cis	rs1475911	0.708	rs8129075	chr21:43523430	G/T	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.32	-6.07	-0.48	1.47e-8	IgG glycosylation;
TGCT	cis	rs8180040	0.966	rs13079098	chr3:47442863	A/G	cg27129171	chr3:47204927	SETD2	0.67	7.78	0.57	2.43e-12	Colorectal cancer;
TGCT	cis	rs9443645	0.901	rs7749916	chr6:79814192	A/G	cg09184832	chr6:79620586	NA	-0.47	-5.07	-0.41	1.4e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2075371	0.863	rs2075370	chr7:133967812	A/G	cg11752832	chr7:134001865	SLC35B4	0.69	6.1	0.48	1.26e-8	Mean platelet volume;
TGCT	cis	rs514406	0.698	rs11206043	chr1:53402552	C/T	cg27535305	chr1:53392650	SCP2	-0.28	-5.9	-0.47	3.26e-8	Monocyte count;
TGCT	cis	rs9473924	0.505	rs9473949	chr6:50909659	T/A	cg14470998	chr6:50812995	TFAP2B	1.35	8.39	0.6	9.05e-14	Body mass index;
TGCT	cis	rs9858542	0.953	rs10640	chr3:49454277	G/A	cg03060546	chr3:49711283	APEH	-0.63	-5.55	-0.45	1.67e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs9372498	0.505	rs17080456	chr6:118985938	G/C	cg21191810	chr6:118973309	C6orf204	-0.37	-4.71	-0.39	6.4e-6	Diastolic blood pressure;
TGCT	cis	rs6964587	0.626	rs7807765	chr7:91531974	C/A	cg17063962	chr7:91808500	NA	-0.76	-7.18	-0.54	5.68e-11	Breast cancer;
TGCT	cis	rs2562456	0.917	rs6511256	chr19:21693315	G/T	cg01304269	chr19:21688519	ZNF429	-0.55	-4.59	-0.38	1.06e-5	Pain;
TGCT	cis	rs6570726	0.577	rs406868	chr6:145809983	C/T	cg13319975	chr6:146136371	FBXO30	-0.64	-5.69	-0.46	8.55e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs17114671	1.000	rs4982326	chr14:21157936	G/A	cg19983597	chr14:21852154	SUPT16H	0.84	4.62	0.38	9.54e-6	Blood protein levels;
TGCT	cis	rs13191362	1.000	rs13212608	chr6:163032128	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.69	4.96	0.41	2.28e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7267979	0.966	rs910996	chr20:25264196	A/G	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.54	-0.38	1.33e-5	Bipolar disorder;
TGCT	cis	rs10782582	0.532	rs78106188	chr1:76137836	A/G	cg22875332	chr1:76189707	ACADM	-0.55	-6.28	-0.49	5.25e-9	Daytime sleep phenotypes;
TGCT	cis	rs7226408	1.000	rs72883558	chr18:34372036	A/G	cg06757138	chr18:34340585	FHOD3	0.28	4.76	0.39	5.23e-6	Obesity-related traits;
TGCT	cis	rs6089584	0.927	rs2296083	chr20:60574216	C/T	cg13770153	chr20:60521292	NA	-0.53	-6.98	-0.53	1.58e-10	Body mass index;
TGCT	cis	rs2228479	0.850	rs62056063	chr16:89903680	C/T	cg06558623	chr16:89946397	TCF25	0.55	4.86	0.4	3.55e-6	Skin colour saturation;
TGCT	cis	rs8028182	0.501	rs11072553	chr15:75932777	C/T	cg20655648	chr15:75932815	IMP3	0.61	4.88	0.4	3.24e-6	Sudden cardiac arrest;
TGCT	cis	rs12142240	0.698	rs17361763	chr1:46810670	T/C	cg14993813	chr1:46806288	NSUN4	-0.58	-4.81	-0.4	4.34e-6	Menopause (age at onset);
TGCT	cis	rs7582180	0.629	rs10202326	chr2:100950237	A/G	cg08017756	chr2:100939284	LONRF2	-0.3	-4.95	-0.41	2.34e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg13607699	chr17:42295918	UBTF	0.58	5.35	0.43	4.02e-7	Total body bone mineral density;
TGCT	cis	rs2549003	1.000	rs2070722	chr5:131824486	A/C	cg21138405	chr5:131827807	IRF1	0.17	4.48	0.37	1.68e-5	Asthma (sex interaction);
TGCT	cis	rs7772486	0.682	rs1337840	chr6:146042558	T/C	cg23711669	chr6:146136114	FBXO30	-0.83	-8.95	-0.63	4.23e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs644799	1.000	rs586238	chr11:95560371	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	11.15	0.71	2.01e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg03264133	chr6:25882463	NA	-1.11	-14.8	-0.8	3.6e-29	Urate levels;
TGCT	trans	rs7553035	1.000	rs2166104	chr1:211690818	A/T	cg14538319	chr15:93464153	CHD2	0.6	7.31	0.55	2.85e-11	Retinopathy in non-diabetics;
TGCT	cis	rs950027	0.620	rs1426932	chr15:45687256	T/C	cg26924012	chr15:45694286	SPATA5L1	0.8	9.1	0.63	1.83e-15	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs9788682	1.000	rs61204066	chr15:78815298	G/A	cg06917634	chr15:78832804	PSMA4	-0.7	-5.17	-0.42	9.22e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg03264133	chr6:25882463	NA	-0.62	-5.72	-0.46	7.56e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs523522	0.962	rs12814055	chr12:120987391	G/A	cg12219531	chr12:120966889	COQ5	0.83	7.27	0.55	3.46e-11	High light scatter reticulocyte count;
TGCT	cis	rs9467773	0.620	rs2451711	chr6:26663110	A/G	cg15659132	chr6:26577336	NA	0.87	10.79	0.7	1.52e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs7552404	0.731	rs61770552	chr1:76373050	T/C	cg03433033	chr1:76189801	ACADM	0.76	7.2	0.54	5.19e-11	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7191439	0.674	rs4782429	chr16:88792097	A/G	cg27087555	chr16:88793112	FAM38A	-0.41	-5.36	-0.43	3.84e-7	Plateletcrit;
TGCT	cis	rs17376456	0.877	rs13153245	chr5:93374891	G/A	cg25358565	chr5:93447407	FAM172A	0.89	7.45	0.56	1.41e-11	Diabetic retinopathy;
TGCT	cis	rs7829975	0.511	rs2976906	chr8:8342415	A/T	cg15556689	chr8:8085844	FLJ10661	0.63	6.09	0.48	1.3e-8	Mood instability;
TGCT	cis	rs9311474	0.967	rs610060	chr3:52273421	G/A	cg10802521	chr3:52805072	NEK4	0.53	5.79	0.46	5.56e-8	Electroencephalogram traits;
TGCT	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg08392591	chr16:89556376	ANKRD11	0.56	5.33	0.43	4.52e-7	Multiple myeloma (IgH translocation);
TGCT	cis	rs10507380	0.824	rs79809567	chr13:27924952	T/C	cg25543773	chr13:27185723	WASF3	0.32	4.52	0.38	1.45e-5	Electrocardiographic traits;
TGCT	cis	rs727563	0.635	rs713988	chr22:42159072	A/G	cg03806693	chr22:41940476	POLR3H	1.04	10.57	0.69	5.2e-19	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs1972863	1.000	rs1972863	chr4:94579511	G/A	cg20305610	chr4:95373302	PDLIM5	-0.52	-4.56	-0.38	1.23e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7833790	0.660	rs1451995	chr8:82746123	G/C	cg23324259	chr8:82754387	SNX16	0.61	4.71	0.39	6.42e-6	Diastolic blood pressure;
TGCT	cis	rs36051895	0.623	rs10975031	chr9:5253153	G/T	cg02405213	chr9:5042618	JAK2	-0.73	-9.79	-0.66	4.1e-17	Pediatric autoimmune diseases;
TGCT	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.04	13.09	0.76	3.91e-25	Prudent dietary pattern;
TGCT	cis	rs210152	0.588	rs35817932	chr6:33457926	T/C	cg16739976	chr6:34101401	GRM4	0.55	4.63	0.38	9.26e-6	Schizophrenia;
TGCT	cis	rs11098499	0.954	rs10024844	chr4:120311528	A/G	cg09307838	chr4:120376055	NA	0.65	6.39	0.5	3.02e-9	Corneal astigmatism;
TGCT	cis	rs172166	0.769	rs149965	chr6:28018689	T/A	cg10876282	chr6:28092338	ZSCAN16	0.5	4.6	0.38	1.01e-5	Cardiac Troponin-T levels;
TGCT	cis	rs12142240	0.698	rs1053627	chr1:46827728	A/C	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs7264396	0.508	rs6060739	chr20:34567592	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.28	-4.97	-0.41	2.21e-6	Total cholesterol levels;
TGCT	cis	rs2153535	0.541	rs6938688	chr6:8521629	G/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.55e-8	Motion sickness;
TGCT	cis	rs3741404	0.757	rs2282492	chr11:63918589	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.87	9.86	0.66	2.77e-17	Platelet count;
TGCT	cis	rs1150668	0.796	rs9468372	chr6:28379361	T/A	cg13525197	chr6:28411240	ZSCAN23	-0.52	-5.08	-0.42	1.33e-6	Pubertal anthropometrics;
TGCT	cis	rs1008375	0.900	rs7658447	chr4:17579415	T/C	cg18681998	chr4:17616180	MED28	0.83	7.51	0.56	1.02e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs868036	0.718	rs7170185	chr15:68117300	T/A	cg05925327	chr15:68127851	NA	-0.51	-5.04	-0.41	1.63e-6	Restless legs syndrome;
TGCT	cis	rs7192750	0.501	rs6499542	chr16:71859830	A/T	cg06353428	chr16:71660113	MARVELD3	0.83	7.67	0.57	4.29e-12	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs4595586	0.870	rs1516558	chr12:39283119	A/G	cg10518543	chr12:38710700	ALG10B	-0.48	-4.73	-0.39	5.91e-6	Morning vs. evening chronotype;
TGCT	cis	rs523522	0.962	rs11065154	chr12:120971417	T/C	cg12219531	chr12:120966889	COQ5	0.83	7.27	0.55	3.46e-11	High light scatter reticulocyte count;
TGCT	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg22968622	chr17:43663579	NA	1.28	10.87	0.7	9.49e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs926938	0.563	rs360635	chr1:115420518	A/C	cg12756093	chr1:115239321	AMPD1	0.41	6.44	0.5	2.37e-9	Autism;
TGCT	cis	rs9393692	0.905	rs7747133	chr6:26293470	C/T	cg13736514	chr6:26305472	NA	-0.41	-5.77	-0.46	6.03e-8	Educational attainment;
TGCT	cis	rs3947	0.951	rs1692814	chr8:11704298	T/C	cg02840367	chr8:11660030	FDFT1	0.89	6.47	0.5	2e-9	Blood protein levels;
TGCT	cis	rs2721195	1.000	rs6599530	chr8:145677418	C/G	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.82	-8.64	-0.61	2.39e-14	Age at first birth;
TGCT	cis	rs10782582	0.564	rs17647711	chr1:76241710	C/G	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.51	4.59	0.38	1.06e-5	Daytime sleep phenotypes;
TGCT	cis	rs7666738	0.830	rs13122456	chr4:98936011	A/G	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6840360	1.000	rs1105536	chr4:152605027	C/T	cg17479576	chr4:152424074	FAM160A1	-0.47	-4.87	-0.4	3.28e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs765787	0.530	rs2433227	chr15:45517119	A/T	cg24006582	chr15:45444508	DUOX1	-0.26	-5.62	-0.45	1.19e-7	Uric acid levels;
TGCT	cis	rs9467603	0.688	rs13191296	chr6:25684606	C/T	cg16898833	chr6:26189333	HIST1H4D	1.36	6.05	0.48	1.56e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7119038	0.818	rs10892279	chr11:118611781	G/A	cg19308663	chr11:118741387	NA	0.22	4.57	0.38	1.17e-5	Sjögren's syndrome;
TGCT	cis	rs55794721	0.509	rs7554255	chr1:25778106	C/T	cg23205692	chr1:25664452	TMEM50A	0.48	5.07	0.41	1.42e-6	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg00080972	chr5:178986291	RUFY1	0.56	6.86	0.52	2.95e-10	Lung cancer;
TGCT	cis	rs3960554	0.569	rs1894761	chr7:75876754	C/T	cg19105122	chr7:75896889	SRRM3	-0.54	-4.62	-0.38	9.59e-6	Eotaxin levels;
TGCT	cis	rs9814567	0.964	rs1534028	chr3:134284639	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.94	-9.18	-0.64	1.2e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs7666738	0.830	rs13130923	chr4:99046281	T/C	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs453301	0.631	rs17700611	chr8:8793654	A/G	cg15556689	chr8:8085844	FLJ10661	-0.61	-5.26	-0.43	6.1e-7	Joint mobility (Beighton score);
TGCT	cis	rs10992471	0.603	rs7868013	chr9:95240173	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.62	-5.79	-0.46	5.39e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs6752107	1.000	rs13391356	chr2:234170369	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.19	4.61	0.38	9.73e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs2046867	0.862	rs62251645	chr3:72805733	T/C	cg25664220	chr3:72788482	NA	-0.56	-7.15	-0.54	6.59e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs4843747	0.671	rs72818577	chr16:88111181	G/A	cg06915872	chr16:87998081	BANP	-0.3	-4.58	-0.38	1.1e-5	Menopause (age at onset);
TGCT	cis	rs8072100	0.817	rs11869940	chr17:45578435	T/A	cg08085267	chr17:45401833	C17orf57	0.44	4.63	0.38	8.96e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs7086627	0.515	rs11202960	chr10:82209807	G/A	cg00277334	chr10:82204260	NA	-0.54	-8.46	-0.61	6.23e-14	Post bronchodilator FEV1;
TGCT	cis	rs7937840	0.581	rs4963461	chr11:61884044	G/A	cg05871569	chr11:61891931	INCENP	0.7	6.44	0.5	2.38e-9	Breast cancer;
TGCT	trans	rs7726839	0.794	rs10474792	chr5:600058	G/A	cg25482853	chr8:67687455	SGK3	0.99	7.83	0.58	1.85e-12	Obesity-related traits;
TGCT	cis	rs3784262	0.528	rs4238327	chr15:58336218	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.43	-6.38	-0.5	3.14e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	trans	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg23505145	chr19:12996616	KLF1	0.79	8.3	0.6	1.47e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9398235	0.929	rs2073211	chr6:110729270	A/G	cg19196401	chr6:110721138	DDO	0.47	4.48	0.37	1.67e-5	Systemic lupus erythematosus;
TGCT	cis	rs2204008	0.658	rs11495742	chr12:38395688	C/A	cg26384229	chr12:38710491	ALG10B	0.89	7.9	0.58	1.26e-12	Bladder cancer;
TGCT	cis	rs7027203	0.595	rs7846827	chr9:96546525	C/T	cg14598338	chr9:96623480	NA	0.5	7.2	0.54	5.11e-11	DNA methylation (variation);
TGCT	trans	rs6740731	0.518	rs34586719	chr2:145295647	C/T	cg03855592	chr7:113034122	NA	0.42	6.83	0.52	3.31e-10	Coronary artery disease;
TGCT	cis	rs1555895	0.576	rs4881536	chr10:848058	A/G	cg02193355	chr10:851439	NA	0.23	5.23	0.43	6.88e-7	Survival in rectal cancer;
TGCT	cis	rs9467773	0.620	rs2504566	chr6:26660488	G/C	cg09904177	chr6:26538194	HMGN4	0.68	6.27	0.49	5.41e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs709400	0.628	rs12879085	chr14:103874420	G/A	cg26031613	chr14:104095156	KLC1	-0.83	-9.19	-0.64	1.17e-15	Body mass index;
TGCT	cis	rs6671200	0.790	rs640527	chr1:95705615	G/A	cg03123541	chr1:95699097	RWDD3	-0.91	-6.4	-0.5	2.93e-9	Stearic acid (18:0) levels;
TGCT	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs12711979	0.509	rs10178286	chr2:3823821	A/G	cg17052675	chr2:3827356	NA	0.53	12.1	0.74	9.98e-23	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs9291683	0.588	rs3756236	chr4:10013463	T/A	cg00071950	chr4:10020882	SLC2A9	0.76	10.38	0.68	1.55e-18	Bone mineral density;
TGCT	cis	rs7617773	0.780	rs6793223	chr3:48364101	C/T	cg11946769	chr3:48343235	NME6	0.8	6.91	0.53	2.26e-10	Coronary artery disease;
TGCT	trans	rs208520	0.661	rs7766144	chr6:66827795	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-10.56	-0.69	5.53e-19	Exhaled nitric oxide output;
TGCT	cis	rs624899	0.655	rs8109248	chr19:11641375	C/T	cg12854483	chr19:11649671	CNN1	0.63	5.91	0.47	3.12e-8	Presence of antiphospholipid antibodies;
TGCT	cis	rs7980687	0.527	rs1626703	chr12:123710835	A/C	cg00376283	chr12:123451042	ABCB9	0.78	6.61	0.51	1.05e-9	Height;Educational attainment;Head circumference (infant);
TGCT	cis	rs6088590	0.610	rs6120663	chr20:33081906	A/C	cg06115741	chr20:33292138	TP53INP2	-0.64	-5.68	-0.45	8.9e-8	Coronary artery disease;
TGCT	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.55	-4.83	-0.4	4.02e-6	Height;
TGCT	cis	rs9926296	0.712	rs258330	chr16:89729574	T/G	cg21285383	chr16:89894308	SPIRE2	-0.32	-4.52	-0.38	1.42e-5	Vitiligo;
TGCT	cis	rs586688	0.625	rs609396	chr1:201655233	C/T	cg07139329	chr1:201708558	NAV1	-0.52	-5.32	-0.43	4.74e-7	Obesity-related traits;
TGCT	cis	rs9486719	0.843	rs2472876	chr6:96845723	A/G	cg06623918	chr6:96969491	KIAA0776	0.93	7.08	0.54	9.59e-11	Migraine;Coronary artery disease;
TGCT	cis	rs7582180	0.764	rs10460478	chr2:100919735	G/A	cg14675211	chr2:100938903	LONRF2	0.49	4.8	0.4	4.45e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2070488	0.965	rs13093640	chr3:38487176	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	9.66	0.66	8.59e-17	Electrocardiographic conduction measures;
TGCT	cis	rs7647973	0.626	rs1996664	chr3:49878395	A/G	cg05785598	chr3:49045655	WDR6	-0.42	-5.32	-0.43	4.71e-7	Menarche (age at onset);
TGCT	cis	rs1046896	0.594	rs9914570	chr17:80783721	C/T	cg03160526	chr17:80928410	B3GNTL1	0.34	4.73	0.39	5.95e-6	Glycated hemoglobin levels;
TGCT	cis	rs10089	1.000	rs10060181	chr5:127475573	A/G	cg19767477	chr5:127420684	SLC12A2	-0.43	-4.56	-0.38	1.21e-5	Ileal carcinoids;
TGCT	cis	rs7919533	0.564	rs9415041	chr10:73524184	G/A	cg00101602	chr10:73857843	ASCC1	0.29	4.56	0.38	1.22e-5	Monocyte count;
TGCT	cis	rs7843479	0.965	rs11135742	chr8:21802910	A/T	cg17168535	chr8:21777572	XPO7	0.65	5.99	0.47	2.14e-8	Mean corpuscular volume;
TGCT	cis	rs425277	0.628	rs3128340	chr1:2047496	C/G	cg03732007	chr1:2071316	PRKCZ	-0.28	-6.09	-0.48	1.28e-8	Height;
TGCT	cis	rs4319547	0.656	rs7975747	chr12:122816995	C/T	cg08088222	chr12:122070432	ORAI1	0.27	4.74	0.39	5.83e-6	Body mass index;
TGCT	cis	rs28595532	0.920	rs115084148	chr4:119739290	A/G	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs877529	0.934	rs139418	chr22:39557162	A/C	cg18708252	chr22:39545030	CBX7	-0.35	-4.74	-0.39	5.7e-6	Multiple myeloma;
TGCT	cis	rs11785400	1.000	rs4518642	chr8:143737396	T/C	cg10596483	chr8:143751796	JRK	0.56	6.05	0.48	1.61e-8	Schizophrenia;
TGCT	cis	rs6912958	0.935	rs2179844	chr6:88165773	C/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.37	-4.74	-0.39	5.79e-6	Monocyte percentage of white cells;
TGCT	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg23283495	chr1:209979779	IRF6	0.67	5.65	0.45	1.03e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg18538332	chr22:24372958	LOC391322	0.86	7.4	0.55	1.79e-11	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs7666738	0.546	rs34621463	chr4:98793357	G/C	cg05340658	chr4:99064831	C4orf37	0.51	5.65	0.45	1.03e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg16414030	chr3:133502952	NA	0.67	11.56	0.72	2.02e-21	Iron status biomarkers;
TGCT	cis	rs12142240	0.698	rs56130131	chr1:46861306	A/C	cg00530320	chr1:46809349	NSUN4	0.29	5.79	0.46	5.34e-8	Menopause (age at onset);
TGCT	cis	rs12548874	0.607	rs12543492	chr8:95891843	C/A	cg16049864	chr8:95962084	TP53INP1	-0.58	-6.87	-0.53	2.74e-10	Hemoglobin concentration;
TGCT	cis	rs1008375	0.863	rs2058336	chr4:17608299	T/C	cg18681998	chr4:17616180	MED28	0.98	10.43	0.68	1.17e-18	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7119	0.717	rs11634174	chr15:77811232	A/T	cg27398640	chr15:77910606	LINGO1	-0.25	-4.55	-0.38	1.26e-5	Type 2 diabetes;
TGCT	cis	rs7666738	0.830	rs2903150	chr4:99027184	T/C	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4720575	0.931	rs10242850	chr7:47099868	A/C	cg00036614	chr7:47093842	NA	-0.21	-5.28	-0.43	5.69e-7	Angiotensin-converting enzyme inhibitor intolerance;
TGCT	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg04944784	chr2:26401820	FAM59B	-0.67	-6.16	-0.48	9.54e-9	Gut microbiome composition (summer);
TGCT	cis	rs2816958	0.708	rs2821329	chr1:200082360	T/C	cg07971716	chr1:199773294	NA	0.47	4.6	0.38	1.02e-5	Ulcerative colitis;Inflammatory bowel disease;
TGCT	cis	rs11690935	0.959	rs10204501	chr2:172588865	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.18	-12.51	-0.75	9.78e-24	Schizophrenia;
TGCT	cis	rs4568518	0.501	rs6966247	chr7:17989247	A/G	cg03009463	chr7:17980271	SNX13	0.57	4.57	0.38	1.18e-5	Measles;
TGCT	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.18e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs1023500	0.552	rs133368	chr22:42463689	T/C	cg05082376	chr22:42548792	NA	-0.23	-5.44	-0.44	2.72e-7	Schizophrenia;
TGCT	cis	rs116095464	0.510	rs10057501	chr5:239545	T/C	cg22857025	chr5:266934	NA	-0.34	-6.7	-0.52	6.65e-10	Breast cancer;
TGCT	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg16423285	chr20:60520624	NA	-0.77	-9.89	-0.66	2.34e-17	Obesity-related traits;
TGCT	trans	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg20587970	chr11:113659929	NA	-1.03	-10.98	-0.7	5.21e-20	Hip circumference adjusted for BMI;
TGCT	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	5.23	0.43	6.93e-7	Height;
TGCT	cis	rs4654899	1.000	rs6426668	chr1:21396596	T/C	cg01072550	chr1:21505969	NA	-0.49	-7.88	-0.58	1.41e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs35146811	0.660	rs3779046	chr7:99779243	A/G	cg00553149	chr7:99775558	STAG3;GPC2	0.31	4.61	0.38	9.75e-6	Coronary artery disease;
TGCT	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg06634786	chr22:41940651	POLR3H	-0.89	-8.45	-0.6	6.78e-14	Vitiligo;
TGCT	cis	rs1403694	0.695	rs11919484	chr3:186432839	G/T	cg12454167	chr3:186435060	KNG1	0.5	8.56	0.61	3.65e-14	Blood protein levels;
TGCT	cis	rs13256369	0.756	rs13280759	chr8:8562995	G/T	cg17143192	chr8:8559678	CLDN23	0.56	5.31	0.43	4.9e-7	Obesity-related traits;
TGCT	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg11062466	chr8:58055876	NA	0.37	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs910316	0.763	rs175036	chr14:75464295	C/T	cg11812906	chr14:75593930	NEK9	-0.59	-5.69	-0.45	8.84e-8	Height;
TGCT	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg18876405	chr7:65276391	NA	0.35	5.66	0.45	1.01e-7	Aortic root size;
TGCT	cis	rs2302045	1.000	rs2270044	chr2:242056924	A/G	cg20856893	chr2:242997758	NA	-0.56	-4.66	-0.39	8.02e-6	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio);
TGCT	cis	rs7267979	0.903	rs6115109	chr20:25239667	G/A	cg16686733	chr20:25566563	NINL	0.59	6.06	0.48	1.53e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6882046	0.513	rs647983	chr5:88048071	T/C	cg22951263	chr5:87985283	NA	-0.55	-5.88	-0.47	3.54e-8	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg14983838	chr19:29218262	NA	0.83	6.81	0.52	3.8e-10	Methadone dose in opioid dependence;
TGCT	cis	rs17473412	0.609	rs78154385	chr5:122858945	A/G	cg15125798	chr5:122621645	NA	-0.54	-4.94	-0.41	2.5e-6	Total body bone mineral density;
TGCT	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg17264618	chr3:40429014	ENTPD3	0.32	4.57	0.38	1.18e-5	Renal cell carcinoma;
TGCT	cis	rs28595532	0.920	rs115090643	chr4:119729825	C/T	cg21605333	chr4:119757512	SEC24D	1.66	8.33	0.6	1.28e-13	Cannabis dependence symptom count;
TGCT	cis	rs7916697	0.947	rs9783176	chr10:70002393	A/T	cg18338521	chr10:69995036	NA	-0.28	-4.47	-0.37	1.75e-5	Optic disc area;
TGCT	cis	rs2303745	0.589	rs6512182	chr19:17399476	G/T	cg02221750	chr19:17393354	ANKLE1	-0.46	-5.87	-0.47	3.73e-8	Systemic lupus erythematosus;
TGCT	trans	rs1814175	0.645	rs10839382	chr11:49823172	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.45	-11.09	-0.71	2.8e-20	Height;
TGCT	cis	rs7666738	0.791	rs13127542	chr4:98949159	C/T	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2760061	0.819	rs708114	chr1:228197496	G/A	cg02753203	chr1:228287806	NA	0.31	5.94	0.47	2.62e-8	Diastolic blood pressure;
TGCT	cis	rs9682041	1.000	rs57508070	chr3:170074374	C/A	cg11886554	chr3:170076028	SKIL	0.84	6.34	0.49	3.84e-9	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs7412746	0.611	rs11204748	chr1:150927369	G/T	cg09365446	chr1:150670422	GOLPH3L	0.34	4.71	0.39	6.58e-6	Melanoma;
TGCT	cis	rs2806561	0.765	rs2806557	chr1:23503372	T/A	cg12483005	chr1:23474871	LUZP1	0.37	4.84	0.4	3.74e-6	Height;
TGCT	cis	rs6088580	0.668	rs1205340	chr20:32923871	G/A	cg08999081	chr20:33150536	PIGU	-0.24	-4.74	-0.39	5.68e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs3617	0.625	rs2240915	chr3:52859526	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	4.59	0.38	1.08e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg25427524	chr10:38739819	LOC399744	-0.39	-8.04	-0.59	5.95e-13	Extrinsic epigenetic age acceleration;
TGCT	trans	rs941408	0.928	rs2260414	chr19:2796316	G/A	cg22153745	chr1:153894579	GATAD2B	-0.63	-6.84	-0.52	3.15e-10	Total cholesterol levels;
TGCT	cis	rs2549003	1.000	rs2549003	chr5:131829297	A/G	cg21138405	chr5:131827807	IRF1	0.18	4.72	0.39	6.31e-6	Asthma (sex interaction);
TGCT	cis	rs13191362	0.935	rs35537826	chr6:163145867	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.13	8.92	0.63	5.03e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs9549367	0.789	rs9549715	chr13:113908240	G/C	cg00898013	chr13:113819073	PROZ	-0.4	-5.03	-0.41	1.64e-6	Platelet distribution width;
TGCT	cis	rs2729354	0.903	rs1846568	chr11:57357714	A/C	cg24343310	chr11:57249947	NA	0.29	5.16	0.42	9.56e-7	Blood protein levels;
TGCT	cis	rs6088590	0.561	rs6059926	chr20:33164804	C/T	cg08999081	chr20:33150536	PIGU	0.25	4.99	0.41	1.97e-6	Coronary artery disease;
TGCT	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg03264133	chr6:25882463	NA	-0.64	-5.85	-0.47	4.08e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7586879	0.687	rs11892869	chr2:25096692	A/T	cg15423357	chr2:25149977	NA	0.46	4.47	0.37	1.72e-5	Body mass index;
TGCT	cis	rs858239	0.570	rs10242166	chr7:23162799	A/G	cg05602783	chr7:23145260	KLHL7	-0.65	-5.52	-0.44	1.93e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs523522	0.571	rs11065120	chr12:120875456	C/T	cg12219531	chr12:120966889	COQ5	0.7	4.76	0.39	5.23e-6	High light scatter reticulocyte count;
TGCT	cis	rs10936602	0.527	rs1920119	chr3:169540397	T/C	cg08193579	chr3:169529701	LRRC34	0.28	5.16	0.42	9.55e-7	Renal cell carcinoma;
TGCT	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg03264133	chr6:25882463	NA	-0.61	-6.51	-0.5	1.69e-9	Blood metabolite levels;
TGCT	cis	rs7674212	0.507	rs223322	chr4:103800194	G/A	cg16532752	chr4:104119610	CENPE	-0.62	-5.59	-0.45	1.41e-7	Type 2 diabetes;
TGCT	cis	rs66887589	0.616	rs6843509	chr4:120220196	G/A	cg24670566	chr4:120433619	PDE5A	0.21	4.57	0.38	1.17e-5	Diastolic blood pressure;
TGCT	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg03303774	chr4:1407052	NA	0.29	4.71	0.39	6.55e-6	Obesity-related traits;
TGCT	cis	rs2204008	0.575	rs10444564	chr12:38043782	T/C	cg13010199	chr12:38710504	ALG10B	0.65	5.23	0.42	7.11e-7	Bladder cancer;
TGCT	cis	rs916888	0.821	rs199506	chr17:44859031	A/G	cg01570182	chr17:44337453	NA	-1.01	-9.1	-0.63	1.83e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg25427524	chr10:38739819	LOC399744	-0.39	-8.22	-0.59	2.35e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7044106	0.791	rs10985009	chr9:123493039	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.51	-5.64	-0.45	1.09e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs881375	0.933	rs7859805	chr9:123664123	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	5.06	0.41	1.49e-6	Rheumatoid arthritis;
TGCT	cis	rs17221829	0.965	rs10830370	chr11:89461535	G/T	cg02982614	chr11:89391479	FOLH1B	-0.3	-5.29	-0.43	5.47e-7	Anxiety in major depressive disorder;
TGCT	cis	rs7246657	0.943	rs10404602	chr19:37825633	A/T	cg18154014	chr19:37997991	ZNF793	0.98	6.49	0.5	1.87e-9	Coronary artery calcification;
TGCT	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.97	-8.51	-0.61	4.86e-14	Platelet count;
TGCT	cis	rs806215	1.000	rs698406	chr7:127255285	C/G	cg25922125	chr7:127225783	GCC1	0.58	5.86	0.47	3.92e-8	Type 2 diabetes;
TGCT	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	6.75	0.52	5.18e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs4727027	0.933	rs12704063	chr7:148827909	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	4.58	0.38	1.13e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs9611565	0.512	rs5751147	chr22:42139054	G/A	cg06634786	chr22:41940651	POLR3H	0.87	8.12	0.59	3.86e-13	Vitiligo;
TGCT	cis	rs10782582	0.593	rs11589276	chr1:76105545	G/A	cg22875332	chr1:76189707	ACADM	-0.52	-6.26	-0.49	5.72e-9	Daytime sleep phenotypes;
TGCT	cis	rs9914988	1.000	rs9914988	chr17:27183104	G/A	cg20469991	chr17:27169893	C17orf63	0.69	5.05	0.41	1.51e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs9926296	0.632	rs7206546	chr16:89799079	C/T	cg03388025	chr16:89894329	SPIRE2	-0.32	-4.74	-0.39	5.8e-6	Vitiligo;
TGCT	cis	rs1865760	0.865	rs9393678	chr6:25945819	C/T	cg17042849	chr6:26104293	HIST1H4C	-0.52	-4.78	-0.39	4.97e-6	Height;
TGCT	cis	rs28595532	0.920	rs116091383	chr4:119635518	A/G	cg14228332	chr4:119757509	SEC24D	1.02	5.37	0.43	3.75e-7	Cannabis dependence symptom count;
TGCT	cis	rs1008375	1.000	rs3815414	chr4:17606659	A/G	cg16339924	chr4:17578868	LAP3	-0.63	-5.31	-0.43	4.86e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2070488	0.662	rs7652475	chr3:38481341	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.72	5.94	0.47	2.7e-8	Electrocardiographic conduction measures;
TGCT	cis	rs908922	0.676	rs4845780	chr1:152488846	T/G	cg20991723	chr1:152506922	NA	0.47	6.71	0.52	6.16e-10	Hair morphology;
TGCT	cis	rs7917772	0.536	rs17783771	chr10:104410736	C/T	cg05855489	chr10:104503620	C10orf26	-0.59	-4.91	-0.4	2.76e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs6582630	0.519	rs12372510	chr12:38293074	T/C	cg26384229	chr12:38710491	ALG10B	0.78	6.91	0.53	2.24e-10	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs7542091	0.704	rs12022221	chr1:210046178	A/C	cg22029157	chr1:209979665	IRF6	0.59	5.76	0.46	6.28e-8	Monobrow;
TGCT	cis	rs9611565	0.592	rs5996038	chr22:41965300	T/C	cg06481639	chr22:41940642	POLR3H	-0.67	-5.71	-0.46	7.87e-8	Vitiligo;
TGCT	trans	rs16860537	1.000	rs74713356	chr1:183236667	T/C	cg10317387	chr2:88470873	THNSL2	-0.67	-6.62	-0.51	9.68e-10	Systemic lupus erythematosus and Systemic sclerosis;
TGCT	trans	rs6089829	0.888	rs4809465	chr20:61671156	G/C	cg13615516	chr5:77269221	NA	0.73	8.39	0.6	9.12e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs6558530	0.640	rs4875889	chr8:1695291	C/G	cg09410841	chr8:1729607	CLN8	0.67	5.88	0.47	3.61e-8	Systolic blood pressure;
TGCT	cis	rs8062405	0.679	rs72793818	chr16:28893137	G/A	cg09754948	chr16:28834200	ATXN2L	0.6	4.48	0.37	1.65e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg03517284	chr6:25882590	NA	0.5	4.56	0.38	1.23e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg02975922	chr3:195473998	MUC4	-0.24	-5.47	-0.44	2.4e-7	Pancreatic cancer;
TGCT	cis	rs11105298	0.891	rs10858865	chr12:89846476	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.67	-4.74	-0.39	5.67e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs1062746	0.771	rs10514621	chr16:87369578	G/T	cg02258303	chr16:87377426	FBXO31	-0.17	-4.47	-0.37	1.72e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
TGCT	cis	rs838147	0.537	rs504963	chr19:49208865	G/A	cg04599840	chr19:48886497	KDELR1	0.22	4.49	0.37	1.61e-5	Dietary macronutrient intake;
TGCT	cis	rs2073300	1.000	rs6048826	chr20:23458050	C/A	cg09953122	chr20:23471693	CST8	-0.59	-4.75	-0.39	5.62e-6	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs1519814	0.659	rs7829279	chr8:121023514	A/G	cg22335954	chr8:121166405	COL14A1	-0.37	-4.73	-0.39	6.06e-6	Breast cancer;
TGCT	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.71	-6.3	-0.49	4.82e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	trans	rs3780486	0.846	rs10971438	chr9:33180308	A/G	cg04842962	chr6:43655489	MRPS18A	1.12	12.0	0.73	1.71e-22	IgG glycosylation;
TGCT	cis	rs7829975	0.711	rs1039916	chr8:8685854	A/G	cg08975724	chr8:8085496	FLJ10661	0.59	5.27	0.43	5.74e-7	Mood instability;
TGCT	cis	rs9858542	0.953	rs11713474	chr3:49611457	A/G	cg03060546	chr3:49711283	APEH	-0.63	-5.48	-0.44	2.28e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs9473924	0.542	rs2744504	chr6:50798668	G/C	cg14470998	chr6:50812995	TFAP2B	1.33	7.94	0.58	1.03e-12	Body mass index;
TGCT	cis	rs2153535	0.580	rs9406165	chr6:8488837	C/T	cg07606381	chr6:8435919	SLC35B3	0.54	5.05	0.41	1.51e-6	Motion sickness;
TGCT	cis	rs9549367	0.713	rs9549681	chr13:113829873	T/C	cg00898013	chr13:113819073	PROZ	-0.55	-7.05	-0.53	1.12e-10	Platelet distribution width;
TGCT	cis	rs1723838	0.510	rs45523540	chr11:73692990	G/A	cg26954736	chr11:73693896	UCP2	-1.41	-6.38	-0.5	3.22e-9	Obesity-related traits;
TGCT	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg22166914	chr1:53195759	ZYG11B	0.33	5.38	0.43	3.6e-7	Monocyte count;
TGCT	cis	rs950169	0.650	rs12902052	chr15:85125838	A/T	cg17173187	chr15:85201210	NMB	0.47	4.87	0.4	3.39e-6	Schizophrenia;
TGCT	cis	rs10791097	0.694	rs4370948	chr11:130755700	A/C	cg05962950	chr11:130786565	SNX19	0.91	11.71	0.72	8.72e-22	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs2120019	1.000	rs12910644	chr15:75358388	A/G	cg09165964	chr15:75287851	SCAMP5	-1.18	-9.83	-0.66	3.33e-17	Blood trace element (Zn levels);
TGCT	cis	rs6754311	0.551	rs2304599	chr2:136528004	C/G	cg07169764	chr2:136633963	MCM6	-0.71	-6.47	-0.5	2.09e-9	Mosquito bite size;
TGCT	cis	rs1048238	0.506	rs1262788	chr1:16215608	G/C	cg22431228	chr1:16359049	CLCNKA	0.24	4.74	0.39	5.8e-6	Systolic blood pressure;
TGCT	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg06481639	chr22:41940642	POLR3H	-0.72	-6.52	-0.51	1.61e-9	Vitiligo;
TGCT	cis	rs7666738	0.606	rs10006454	chr4:99080361	G/A	cg05340658	chr4:99064831	C4orf37	0.44	4.8	0.4	4.5e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7208859	0.623	rs11651857	chr17:28926362	G/T	cg13385521	chr17:29058706	SUZ12P	0.81	4.87	0.4	3.39e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs6920965	0.509	rs575811	chr6:126162282	T/C	cg05901451	chr6:126070800	HEY2	0.56	5.0	0.41	1.94e-6	High light scatter reticulocyte count;
TGCT	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg06238570	chr21:40685208	BRWD1	0.63	5.29	0.43	5.45e-7	Cognitive function;
TGCT	cis	rs67311347	1.000	rs951560	chr3:40463471	A/G	cg13683864	chr3:40499215	RPL14	-1.04	-10.79	-0.7	1.54e-19	Renal cell carcinoma;
TGCT	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg03388025	chr16:89894329	SPIRE2	0.51	8.89	0.62	5.97e-15	Vitiligo;
TGCT	cis	rs3748682	0.861	rs28625842	chr1:38310786	G/A	cg04496824	chr1:38276835	MTF1	0.21	4.61	0.38	1.01e-5	Hypothyroidism;
TGCT	cis	rs7267979	1.000	rs6107047	chr20:25442097	G/A	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11122272	0.735	rs2739510	chr1:231526718	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-6.3	-0.49	4.72e-9	Hemoglobin concentration;
TGCT	cis	rs28785552	0.800	rs10853854	chr19:53232128	A/G	cg10871876	chr19:53194124	ZNF83	-0.46	-6.26	-0.49	5.63e-9	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs6547741	1.000	rs6547741	chr2:27855924	G/A	cg27432699	chr2:27873401	GPN1	0.18	4.63	0.38	9.05e-6	Oral cavity cancer;
TGCT	trans	rs7819412	0.654	rs6987059	chr8:11071057	A/G	cg15556689	chr8:8085844	FLJ10661	-0.75	-6.72	-0.52	5.82e-10	Triglycerides;
TGCT	cis	rs2404602	0.740	rs34924128	chr15:76965169	T/G	cg22467129	chr15:76604101	ETFA	-0.45	-5.11	-0.42	1.2e-6	Blood metabolite levels;
TGCT	cis	rs72781680	0.898	rs72796152	chr2:23933626	G/A	cg08917208	chr2:24149416	ATAD2B	0.76	4.6	0.38	1.03e-5	Lymphocyte counts;
TGCT	cis	rs13242816	1.000	rs35505552	chr7:116104867	T/A	cg02799643	chr7:116139180	CAV2	-0.45	-5.38	-0.44	3.5e-7	P wave duration;
TGCT	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg22968622	chr17:43663579	NA	-0.99	-9.5	-0.65	2.03e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg24060327	chr5:131705240	SLC22A5	-0.66	-6.85	-0.52	3.07e-10	Acylcarnitine levels;
TGCT	cis	rs4499344	0.577	rs259289	chr19:33164927	G/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.87	9.38	0.64	3.95e-16	Mean platelet volume;
TGCT	cis	rs9638182	0.725	rs111837003	chr7:72907459	C/T	cg14087351	chr7:73037990	MLXIPL	-0.57	-4.52	-0.38	1.4e-5	Triglycerides;
TGCT	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg27535305	chr1:53392650	SCP2	-0.25	-4.77	-0.39	5.07e-6	Monocyte count;
TGCT	cis	rs7647973	0.626	rs4855845	chr3:49687043	T/C	cg03034192	chr3:50606346	HEMK1;C3orf18	0.36	4.76	0.39	5.27e-6	Menarche (age at onset);
TGCT	cis	rs12908161	1.000	rs12912388	chr15:85344550	T/A	cg17173187	chr15:85201210	NMB	0.57	6.39	0.5	3.07e-9	Schizophrenia;
TGCT	cis	rs651907	0.640	rs771573	chr3:101620896	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.64	6.49	0.5	1.88e-9	Colorectal cancer;
TGCT	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg21862992	chr11:68658383	NA	0.44	6.07	0.48	1.42e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs2760061	0.784	rs1745414	chr1:228212159	T/A	cg18477163	chr1:228402036	OBSCN	0.35	7.47	0.56	1.22e-11	Diastolic blood pressure;
TGCT	cis	rs11098499	0.865	rs10032158	chr4:120391632	C/T	cg09307838	chr4:120376055	NA	0.69	6.56	0.51	1.31e-9	Corneal astigmatism;
TGCT	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg03709012	chr19:19516395	GATAD2A	-0.76	-6.48	-0.5	1.93e-9	Tonsillectomy;
TGCT	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6121246	0.609	rs6060983	chr20:30420924	T/C	cg13852791	chr20:30311386	BCL2L1	0.84	7.49	0.56	1.1e-11	Mean corpuscular hemoglobin;
TGCT	cis	rs231513	0.906	rs11653808	chr17:42005366	A/T	cg26893861	chr17:41843967	DUSP3	0.73	5.1	0.42	1.25e-6	Cognitive function;
TGCT	cis	rs3829109	0.564	rs4307444	chr9:139279634	C/T	cg13741927	chr9:139327495	INPP5E	-0.23	-4.83	-0.4	4.03e-6	Peak insulin response;Acute insulin response;
TGCT	cis	rs1215050	0.791	rs165252	chr4:98758728	A/C	cg05340658	chr4:99064831	C4orf37	0.44	5.52	0.44	1.85e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs3027009	0.881	rs12045546	chr1:159132532	A/G	cg11719576	chr1:158153771	CD1D	0.37	4.62	0.38	9.55e-6	Lean body mass and age at menarche (combined);
TGCT	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg00814883	chr7:100076585	TSC22D4	-0.85	-8.49	-0.61	5.27e-14	Platelet count;
TGCT	cis	rs59107033	0.607	rs73188507	chr3:123126674	T/C	cg04890266	chr3:123102914	ADCY5	-0.38	-5.29	-0.43	5.31e-7	Lymphocyte counts;
TGCT	trans	rs941408	1.000	rs941410	chr19:2787329	G/A	cg19676328	chr12:49525230	TUBA1B	-0.69	-6.66	-0.51	7.89e-10	Total cholesterol levels;
TGCT	cis	rs9858542	0.953	rs12330269	chr3:49513910	G/A	cg03060546	chr3:49711283	APEH	-0.61	-5.37	-0.43	3.78e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs28493229	0.708	rs10407889	chr19:41161078	T/C	cg11601297	chr19:41224147	ITPKC;ADCK4	0.57	5.15	0.42	9.78e-7	Kawasaki disease;
TGCT	cis	rs644799	0.710	rs473852	chr11:95568757	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.77	7.46	0.56	1.28e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs2299587	0.519	rs3850746	chr8:17787536	C/T	cg01800426	chr8:17659068	MTUS1	0.64	5.52	0.44	1.91e-7	Economic and political preferences;
TGCT	cis	rs1538970	0.924	rs12046816	chr1:45891543	G/T	cg05343316	chr1:45956843	TESK2	0.78	6.29	0.49	4.97e-9	Platelet count;
TGCT	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg08280861	chr8:58055591	NA	0.4	4.73	0.39	5.97e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs74233809	0.591	rs284853	chr10:104574642	T/A	cg05855489	chr10:104503620	C10orf26	-0.73	-4.99	-0.41	1.96e-6	Birth weight;
TGCT	cis	rs4476553	0.868	rs2280041	chr4:4709657	G/A	cg05554346	chr4:4145468	NA	0.4	4.73	0.39	5.9e-6	Response to amphetamines;
TGCT	cis	rs2204008	0.665	rs11495668	chr12:38221018	C/T	cg26384229	chr12:38710491	ALG10B	0.84	7.43	0.56	1.51e-11	Bladder cancer;
TGCT	cis	rs7103648	0.618	rs11039284	chr11:47564785	A/G	cg20307385	chr11:47447363	PSMC3	0.9	8.49	0.61	5.41e-14	Diastolic blood pressure;Systolic blood pressure;
TGCT	cis	rs877282	0.898	rs11253356	chr10:768604	G/A	cg17470449	chr10:769945	NA	0.28	4.44	0.37	1.97e-5	Uric acid levels;
TGCT	cis	rs3733585	0.624	rs76574510	chr4:9953252	T/A	cg00071950	chr4:10020882	SLC2A9	-0.55	-6.58	-0.51	1.21e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7666738	0.609	rs28833816	chr4:98868866	T/C	cg17366294	chr4:99064904	C4orf37	0.65	5.93	0.47	2.83e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs73001065	0.711	rs58489806	chr19:19456917	C/T	cg03709012	chr19:19516395	GATAD2A	0.92	4.62	0.38	9.41e-6	LDL cholesterol;
TGCT	cis	rs2549003	1.000	rs2548999	chr5:131831058	G/T	cg21138405	chr5:131827807	IRF1	-0.18	-4.52	-0.38	1.44e-5	Asthma (sex interaction);
TGCT	cis	rs11864453	0.713	rs9926156	chr16:72142895	G/C	cg14768367	chr16:72042858	DHODH	0.51	4.91	0.4	2.77e-6	Fibrinogen levels;
TGCT	cis	rs7833790	0.632	rs6415653	chr8:82702536	A/G	cg06027949	chr8:82754900	SNX16	-0.67	-5.02	-0.41	1.77e-6	Diastolic blood pressure;
TGCT	cis	rs506338	0.517	rs17146216	chr11:64451281	C/G	cg19395706	chr11:64412079	NRXN2	0.53	6.26	0.49	5.62e-9	Body mass index;Urate levels;
TGCT	cis	rs4820539	0.966	rs2267000	chr22:23455366	A/G	cg14186256	chr22:23484241	RTDR1	0.92	10.9	0.7	8.32e-20	Bone mineral density;
TGCT	cis	rs2243480	1.000	rs410128	chr7:65603173	C/T	cg18252515	chr7:66147081	NA	-1.14	-7.01	-0.53	1.37e-10	Diabetic kidney disease;
TGCT	cis	rs67311347	1.000	rs11715214	chr3:40403004	C/A	cg17264618	chr3:40429014	ENTPD3	0.31	4.59	0.38	1.09e-5	Renal cell carcinoma;
TGCT	trans	rs877282	0.891	rs11253406	chr10:796297	G/A	cg22713356	chr15:30763199	NA	1.18	10.55	0.69	5.81e-19	Uric acid levels;
TGCT	cis	rs12643440	0.538	rs4280726	chr4:17139547	T/C	cg22650099	chr4:17144496	NA	-0.44	-4.45	-0.37	1.86e-5	Metabolite levels (Pyroglutamine);
TGCT	cis	rs5167	0.743	rs8111069	chr19:45483438	A/C	cg09555818	chr19:45449301	APOC2	0.23	5.02	0.41	1.78e-6	Blood protein levels;
TGCT	cis	rs10883723	0.810	rs3818470	chr10:104263675	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs7607369	0.580	rs7594289	chr2:219652286	A/G	cg02176678	chr2:219576539	TTLL4	-0.45	-5.86	-0.47	3.89e-8	Red blood cell count;Amyotrophic lateral sclerosis;
TGCT	cis	rs28595532	0.920	rs115084148	chr4:119739290	A/G	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs2742417	1.000	rs2742435	chr3:45740863	C/T	cg04837898	chr3:45731254	SACM1L	-0.51	-5.41	-0.44	3.08e-7	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs6546537	0.550	rs7568057	chr2:69877783	T/G	cg10773587	chr2:69614142	GFPT1	-0.51	-4.49	-0.37	1.6e-5	Serum thyroid-stimulating hormone levels;
TGCT	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg25036284	chr2:26402008	FAM59B	-0.57	-4.97	-0.41	2.15e-6	Gut microbiome composition (summer);
TGCT	cis	rs80282103	0.618	rs74117831	chr10:1145707	A/C	cg18964960	chr10:1102726	WDR37	0.98	4.57	0.38	1.15e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs208520	0.690	rs207119	chr6:66786408	C/T	cg07460842	chr6:66804631	NA	-0.94	-9.86	-0.66	2.74e-17	Exhaled nitric oxide output;
TGCT	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg11764359	chr7:65958608	NA	0.58	5.33	0.43	4.47e-7	Aortic root size;
TGCT	cis	rs6032067	0.561	rs6032104	chr20:43932412	G/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.48	-7.03	-0.53	1.2e-10	Blood protein levels;
TGCT	cis	rs858239	0.720	rs10227559	chr7:23272144	G/A	cg05602783	chr7:23145260	KLHL7	-0.69	-5.38	-0.43	3.59e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs7786808	0.644	rs4909081	chr7:158200785	G/A	cg01191920	chr7:158217561	PTPRN2	-0.42	-6.33	-0.49	4.13e-9	Obesity-related traits;
TGCT	cis	rs28785552	0.769	rs7253672	chr19:53243212	G/C	cg10871876	chr19:53194124	ZNF83	0.54	7.66	0.57	4.61e-12	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs17253792	0.822	rs75991559	chr14:56092419	A/T	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs7659604	0.540	rs13113421	chr4:122670064	G/A	cg19748678	chr4:122722346	EXOSC9	-0.5	-4.83	-0.4	3.93e-6	Type 2 diabetes;
TGCT	cis	rs7255045	0.664	rs4614850	chr19:12974636	G/T	cg06537894	chr19:12978706	MAST1	-0.49	-4.48	-0.37	1.69e-5	Mean corpuscular volume;
TGCT	cis	rs7264396	0.790	rs6060516	chr20:34214368	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.28	-4.67	-0.39	7.62e-6	Total cholesterol levels;
TGCT	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg17554472	chr22:41940697	POLR3H	0.43	4.6	0.38	1.01e-5	Vitiligo;
TGCT	cis	rs17376456	0.877	rs7701011	chr5:93311456	G/A	cg25358565	chr5:93447407	FAM172A	0.98	8.39	0.6	9.01e-14	Diabetic retinopathy;
TGCT	cis	rs11785400	0.642	rs4256574	chr8:143725705	C/T	cg10596483	chr8:143751796	JRK	0.53	5.3	0.43	5.12e-7	Schizophrenia;
TGCT	cis	rs806215	1.000	rs806214	chr7:127237003	C/T	cg25922125	chr7:127225783	GCC1	-0.56	-6.11	-0.48	1.16e-8	Type 2 diabetes;
TGCT	cis	rs2153535	0.580	rs1414346	chr6:8471574	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs11651000	0.625	rs2074190	chr17:45811210	A/G	cg06532163	chr17:45867833	NA	0.33	5.27	0.43	5.75e-7	IgG glycosylation;
TGCT	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.12	0.42	1.15e-6	Prudent dietary pattern;
TGCT	cis	rs9549367	0.673	rs3751413	chr13:113854715	C/T	cg18105134	chr13:113819100	PROZ	0.43	7.77	0.57	2.58e-12	Platelet distribution width;
TGCT	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg05665937	chr4:1216051	CTBP1	0.24	4.64	0.38	8.83e-6	Obesity-related traits;
TGCT	cis	rs1205863	1.000	rs1205865	chr6:11943612	A/G	cg07106625	chr6:11870215	NA	0.51	5.05	0.41	1.51e-6	Disc degeneration (lumbar);
TGCT	cis	rs57590327	0.508	rs4605572	chr3:81965751	A/G	cg07356753	chr3:81810745	GBE1	-0.67	-5.89	-0.47	3.42e-8	Extraversion;
TGCT	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.62	-0.51	9.69e-10	Alzheimer's disease;
TGCT	cis	rs2303745	0.589	rs8103523	chr19:17398269	A/G	cg02221750	chr19:17393354	ANKLE1	-0.46	-5.87	-0.47	3.7e-8	Systemic lupus erythematosus;
TGCT	cis	rs9467773	0.511	rs11755443	chr6:26891603	T/C	cg05738196	chr6:26577821	NA	0.68	6.47	0.5	2.02e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg00343986	chr7:65444356	GUSB	-0.23	-5.16	-0.42	9.66e-7	Aortic root size;
TGCT	cis	rs9611565	0.918	rs28638318	chr22:41753059	G/A	cg17554472	chr22:41940697	POLR3H	-0.49	-5.22	-0.42	7.33e-7	Vitiligo;
TGCT	cis	rs2066819	1.000	rs74673257	chr12:56638077	T/C	cg26714650	chr12:56694279	CS	-1.32	-6.2	-0.49	7.69e-9	Psoriasis vulgaris;
TGCT	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg17971929	chr21:40555470	PSMG1	-0.51	-4.55	-0.38	1.24e-5	Menarche (age at onset);
TGCT	cis	rs10791323	0.569	rs10791328	chr11:133713730	A/G	cg03690763	chr11:133734501	NA	-0.32	-5.07	-0.41	1.4e-6	Childhood ear infection;
TGCT	cis	rs12701220	0.817	rs1058727	chr7:1087095	A/G	cg27454412	chr7:1067447	C7orf50	-0.47	-4.54	-0.38	1.34e-5	Bronchopulmonary dysplasia;
TGCT	trans	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg27523141	chr10:43048294	ZNF37B	0.71	8.26	0.6	1.86e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2072499	0.833	rs2251847	chr1:156204047	G/A	cg25208724	chr1:156163844	SLC25A44	0.98	10.36	0.68	1.7e-18	Testicular germ cell tumor;
TGCT	cis	rs1949733	0.958	rs3103069	chr4:8509451	T/G	cg13073564	chr4:8508604	NA	0.45	4.72	0.39	6.21e-6	Response to antineoplastic agents;
TGCT	cis	rs854765	0.686	rs8065497	chr17:17782649	A/G	cg09796270	chr17:17721594	SREBF1	-0.27	-5.45	-0.44	2.66e-7	Total body bone mineral density;
TGCT	cis	rs739496	0.615	rs688920	chr12:112157262	C/T	cg10833066	chr12:111807467	FAM109A	0.35	5.18	0.42	8.83e-7	Platelet count;
TGCT	cis	rs79149102	0.579	rs7342601	chr15:75306795	G/T	cg09165964	chr15:75287851	SCAMP5	1.04	5.73	0.46	7.2e-8	Lung cancer;
TGCT	cis	rs9913156	0.517	rs7215300	chr17:4608622	T/C	cg19197139	chr17:4613644	ARRB2	-0.61	-5.82	-0.46	4.82e-8	Lymphocyte counts;
TGCT	cis	rs3733585	0.699	rs7676733	chr4:9966956	G/A	cg00071950	chr4:10020882	SLC2A9	-0.57	-6.85	-0.52	3.12e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs4843747	0.605	rs4072779	chr16:88107290	C/T	cg06915872	chr16:87998081	BANP	-0.29	-4.46	-0.37	1.8e-5	Menopause (age at onset);
TGCT	cis	rs1878931	0.597	rs37814	chr16:3455247	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.71	-5.53	-0.44	1.83e-7	Body mass index (adult);
TGCT	cis	rs10782582	0.609	rs6656501	chr1:76266126	A/C	cg10523679	chr1:76189770	ACADM	-0.58	-5.38	-0.43	3.6e-7	Daytime sleep phenotypes;
TGCT	cis	rs1215050	1.000	rs1215050	chr4:98849826	A/G	cg05340658	chr4:99064831	C4orf37	-0.48	-5.7	-0.46	8.27e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1371867	0.875	rs2439456	chr8:101336874	C/T	cg06002616	chr8:101225028	SPAG1	-0.54	-6.36	-0.5	3.57e-9	Atrioventricular conduction;
TGCT	cis	rs10876993	0.893	rs7979246	chr12:58092554	A/G	cg15848620	chr12:58087721	OS9	-0.71	-5.79	-0.46	5.49e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs67073037	0.955	rs4666132	chr2:29136489	G/T	cg09522027	chr2:28974177	PPP1CB	0.57	4.49	0.37	1.59e-5	Breast cancer;Breast cancer (estrogen-receptor negative);
TGCT	cis	rs17601876	0.814	rs11636639	chr15:51563092	T/G	cg19946085	chr15:51559439	CYP19A1	-0.33	-5.07	-0.41	1.42e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs10186029	0.708	rs4672673	chr2:213981463	A/G	cg08319019	chr2:214017104	IKZF2	0.65	5.97	0.47	2.35e-8	Systemic sclerosis;
TGCT	cis	rs7809950	0.678	rs2395868	chr7:106897500	C/T	cg23024343	chr7:107201750	COG5	0.43	5.93	0.47	2.78e-8	Coronary artery disease;
TGCT	cis	rs910316	0.737	rs175043	chr14:75471803	G/A	cg11812906	chr14:75593930	NEK9	-0.59	-5.59	-0.45	1.38e-7	Height;
TGCT	cis	rs17253792	0.822	rs79618862	chr14:56093971	C/T	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs3015497	1.000	rs4075253	chr14:51107737	G/A	cg04730355	chr14:51134070	SAV1	-0.51	-4.59	-0.38	1.08e-5	Mean platelet volume;
TGCT	trans	rs7618501	1.000	rs4855867	chr3:49745822	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-1.04	-13.29	-0.77	1.33e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs12579753	0.917	rs7138533	chr12:82187885	C/G	cg07988820	chr12:82153109	PPFIA2	-0.59	-6.19	-0.49	7.93e-9	Resting heart rate;
TGCT	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg06238570	chr21:40685208	BRWD1	-0.8	-8.75	-0.62	1.29e-14	Cognitive function;
TGCT	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg25036284	chr2:26402008	FAM59B	-0.57	-4.97	-0.41	2.15e-6	Gut microbiome composition (summer);
TGCT	cis	rs637571	0.558	rs10896064	chr11:65641033	G/C	cg26695010	chr11:65641043	EFEMP2	0.61	6.22	0.49	6.86e-9	Eosinophil percentage of white cells;
TGCT	cis	rs877282	0.945	rs35342920	chr10:790484	T/C	cg17470449	chr10:769945	NA	0.3	4.82	0.4	4.14e-6	Uric acid levels;
TGCT	cis	rs2299587	0.554	rs2073562	chr8:17742929	A/G	cg04898035	chr8:17640624	MTUS1	-0.2	-4.67	-0.39	7.77e-6	Economic and political preferences;
TGCT	cis	rs981844	0.961	rs6827685	chr4:154662227	C/T	cg14289246	chr4:154710475	SFRP2	1.0	8.35	0.6	1.17e-13	Response to statins (LDL cholesterol change);
TGCT	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg11644478	chr21:40555479	PSMG1	-0.55	-4.77	-0.39	5.08e-6	Cognitive function;
TGCT	cis	rs4953076	0.573	rs67537903	chr2:44422111	G/A	cg04920474	chr2:44395004	PPM1B	0.58	5.71	0.46	7.87e-8	Height;
TGCT	cis	rs6460942	0.915	rs17444141	chr7:12460971	T/G	cg06484146	chr7:12443880	VWDE	-0.57	-5.54	-0.45	1.71e-7	Coronary artery disease;
TGCT	cis	rs7674212	0.510	rs2720468	chr4:104085153	A/G	cg16532752	chr4:104119610	CENPE	-0.58	-5.37	-0.43	3.66e-7	Type 2 diabetes;
TGCT	cis	rs7552404	1.000	rs7513559	chr1:76173744	A/G	cg22875332	chr1:76189707	ACADM	0.79	9.77	0.66	4.68e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs1577917	0.916	rs4706252	chr6:86555180	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.29	-0.43	5.34e-7	Response to antipsychotic treatment;
TGCT	cis	rs6684514	1.000	rs11264468	chr1:156274585	C/G	cg20302342	chr1:156215951	PAQR6	0.34	4.6	0.38	1.01e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs1990950	0.692	rs6885845	chr5:156859610	G/C	cg25387487	chr5:157003181	ADAM19	0.31	4.78	0.39	4.78e-6	Lung function (FEV1/FVC);
TGCT	cis	rs9640161	0.750	rs3800780	chr7:150027284	C/A	cg10018233	chr7:150070692	REPIN1	0.32	4.63	0.38	8.99e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs7666738	0.716	rs13136721	chr4:99085602	G/A	cg05340658	chr4:99064831	C4orf37	0.5	5.5	0.44	2.07e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg08280861	chr8:58055591	NA	0.49	5.76	0.46	6.39e-8	Developmental language disorder (linguistic errors);
TGCT	cis	rs7586879	0.558	rs6718510	chr2:25122323	A/C	cg15423357	chr2:25149977	NA	0.5	4.89	0.4	3.06e-6	Body mass index;
TGCT	cis	rs1903068	1.000	rs4516787	chr4:56010165	C/T	cg01777861	chr4:56023843	NA	-0.55	-6.5	-0.5	1.72e-9	Endometriosis;
TGCT	cis	rs17401966	0.898	rs12117635	chr1:10317445	C/T	cg19773385	chr1:10388646	KIF1B	-0.21	-4.73	-0.39	6e-6	Hepatocellular carcinoma;
TGCT	cis	rs7267979	0.903	rs2500423	chr20:25374882	G/A	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs17345786	1.000	rs3804775	chr3:101306507	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	4.69	0.39	7.21e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7833790	0.700	rs7825180	chr8:82723991	T/A	cg17211192	chr8:82754475	SNX16	-0.95	-8.83	-0.62	8.45e-15	Diastolic blood pressure;
TGCT	cis	rs6545883	0.931	rs12713437	chr2:61722904	C/T	cg15711740	chr2:61764176	XPO1	-0.54	-4.95	-0.41	2.39e-6	Tuberculosis;
TGCT	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg08645402	chr16:4508243	NA	0.2	5.01	0.41	1.86e-6	Schizophrenia;
TGCT	cis	rs2073300	1.000	rs6137957	chr20:23437384	G/A	cg09953122	chr20:23471693	CST8	-0.66	-4.64	-0.38	8.6e-6	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs7917772	0.636	rs2482499	chr10:104516246	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.59	4.79	0.39	4.77e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.51	-4.95	-0.41	2.34e-6	Prudent dietary pattern;
TGCT	cis	rs6430585	0.697	rs7607174	chr2:136513670	T/A	cg07169764	chr2:136633963	MCM6	1.2	11.43	0.72	4.14e-21	Corneal structure;
TGCT	cis	rs7949030	0.626	rs11231145	chr11:62328854	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.71	9.07	0.63	2.23e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs968451	0.865	rs2076125	chr22:39711351	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.83	8.32	0.6	1.31e-13	Primary biliary cholangitis;
TGCT	cis	rs7647973	0.516	rs4955419	chr3:49200692	T/A	cg05785598	chr3:49045655	WDR6	0.36	4.84	0.4	3.82e-6	Menarche (age at onset);
TGCT	cis	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg08045932	chr20:61659980	NA	0.48	9.24	0.64	8.5e-16	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs28595532	0.925	rs28627331	chr4:119665345	T/C	cg21605333	chr4:119757512	SEC24D	1.4	7.94	0.58	1.04e-12	Cannabis dependence symptom count;
TGCT	cis	rs617219	0.710	rs6874525	chr5:78574237	C/T	cg23987322	chr5:78407566	BHMT	-0.35	-4.69	-0.39	7.07e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs7666738	0.830	rs7678567	chr4:99057346	A/G	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.44e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg07061783	chr6:25882402	NA	-0.5	-5.4	-0.44	3.29e-7	Blood metabolite levels;
TGCT	cis	rs7945705	0.934	rs1988709	chr11:8882890	A/T	cg21881798	chr11:8931708	C11orf17;ST5	0.43	4.94	0.41	2.5e-6	Hemoglobin concentration;
TGCT	cis	rs8017423	0.967	rs11844225	chr14:90726676	G/A	cg04374321	chr14:90722782	PSMC1	0.76	7.88	0.58	1.44e-12	Mortality in heart failure;
TGCT	cis	rs3960554	0.569	rs4728618	chr7:75865059	T/C	cg19105122	chr7:75896889	SRRM3	0.6	5.01	0.41	1.86e-6	Eotaxin levels;
TGCT	cis	rs8179	0.645	rs11765954	chr7:92280695	A/G	cg15732164	chr7:92237376	CDK6	-0.3	-5.35	-0.43	4.14e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
TGCT	cis	rs1577917	0.958	rs12198876	chr6:86525476	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.46	-0.44	2.47e-7	Response to antipsychotic treatment;
TGCT	cis	rs929354	0.742	rs7785227	chr7:156999297	C/T	cg05182265	chr7:156933206	UBE3C	-0.39	-8.79	-0.62	1.03e-14	Body mass index;
TGCT	cis	rs709400	0.663	rs17617941	chr14:103953032	T/C	cg26031613	chr14:104095156	KLC1	0.85	9.5	0.65	2.07e-16	Body mass index;
TGCT	cis	rs2895526	1.000	rs2895526	chr10:12726061	A/T	cg18283737	chr10:12085149	UPF2	0.45	4.48	0.37	1.64e-5	Headache;
TGCT	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg21963583	chr11:68658836	MRPL21	0.36	6.02	0.48	1.81e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs17221829	0.739	rs7945443	chr11:89372622	T/C	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.63	-0.38	9.04e-6	Anxiety in major depressive disorder;
TGCT	cis	rs2730245	0.550	rs2657364	chr7:158683825	T/C	cg11984989	chr7:158649758	WDR60	1.02	9.51	0.65	1.95e-16	Height;
TGCT	cis	rs2235642	0.787	rs2235646	chr16:1601287	A/G	cg11375102	chr16:1583810	IFT140;TMEM204	-0.32	-5.73	-0.46	7.16e-8	Coronary artery disease;
TGCT	cis	rs5769765	1.000	rs5770741	chr22:50270215	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	1.11	11.76	0.73	6.5e-22	Schizophrenia;
TGCT	cis	rs6988636	1.000	rs4282551	chr8:124185916	G/A	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs3796352	1.000	rs11717619	chr3:53003179	A/C	cg07884673	chr3:53033167	SFMBT1	0.62	6.19	0.49	8.26e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	trans	rs2688608	0.592	rs11000758	chr10:75493610	A/T	cg13918328	chr10:52500089	ASAH2B	0.68	6.7	0.52	6.48e-10	Inflammatory bowel disease;
TGCT	cis	rs1949733	0.655	rs2631736	chr4:8478421	C/G	cg13073564	chr4:8508604	NA	0.43	4.74	0.39	5.8e-6	Response to antineoplastic agents;
TGCT	cis	rs4595586	0.545	rs12809206	chr12:39388748	A/C	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs1729951	0.575	rs747842	chr3:136703121	A/C	cg21827317	chr3:136751795	NA	0.4	5.61	0.45	1.28e-7	Neuroticism;
TGCT	cis	rs1552244	0.507	rs6443274	chr3:9995288	A/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.32	-4.85	-0.4	3.57e-6	Alzheimer's disease;
TGCT	cis	rs11077998	0.933	rs4239021	chr17:80531826	T/C	cg10255544	chr17:80519551	FOXK2	0.23	4.44	0.37	1.96e-5	Reticulocyte fraction of red cells;
TGCT	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg23708337	chr7:1209742	NA	0.44	4.99	0.41	2e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs3820068	0.705	rs58424111	chr1:15868470	A/C	cg05660106	chr1:15850417	CASP9	1.16	14.82	0.8	3.11e-29	Systolic blood pressure;
TGCT	cis	rs12477438	0.798	rs2045057	chr2:99684929	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-8.52	-0.61	4.5e-14	Chronic sinus infection;
TGCT	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg16414030	chr3:133502952	NA	0.63	9.94	0.67	1.8e-17	Iron status biomarkers;
TGCT	cis	rs3008870	1.000	rs3008855	chr1:67386204	A/G	cg03991309	chr1:68237761	GNG12	-0.27	-4.6	-0.38	1.04e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs2204008	0.805	rs7296063	chr12:37964775	T/G	cg13010199	chr12:38710504	ALG10B	0.65	5.29	0.43	5.47e-7	Bladder cancer;
TGCT	cis	rs789852	0.867	rs708632	chr3:194325325	C/T	cg18000598	chr3:194342907	TMEM44	-0.81	-5.27	-0.43	5.87e-7	QT interval;
TGCT	cis	rs1577917	0.570	rs114854865	chr6:86554236	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.29	-0.43	5.34e-7	Response to antipsychotic treatment;
TGCT	cis	rs1580019	0.587	rs6951955	chr7:32548761	A/T	cg06627557	chr7:32535165	LSM5;AVL9	1.13	14.15	0.79	1.17e-27	Cognitive ability;
TGCT	cis	rs9486719	1.000	rs72931061	chr6:96880285	G/A	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.86	-0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs9653442	0.545	rs4851252	chr2:100757280	C/T	cg22139774	chr2:100720529	AFF3	-0.38	-5.82	-0.46	4.68e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg10802521	chr3:52805072	NEK4	-0.78	-10.01	-0.67	1.22e-17	Bipolar disorder;
TGCT	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg03395511	chr6:291903	DUSP22	-0.7	-7.09	-0.54	9.19e-11	Menopause (age at onset);
TGCT	cis	rs6671200	0.831	rs9659908	chr1:95656127	C/T	cg20701556	chr1:95698924	RWDD3	0.65	5.58	0.45	1.43e-7	Stearic acid (18:0) levels;
TGCT	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.61	4.99	0.41	1.98e-6	Lung function (FEV1/FVC);
TGCT	cis	rs12893668	0.616	rs58033365	chr14:104030901	T/C	cg26031613	chr14:104095156	KLC1	-0.54	-4.45	-0.37	1.88e-5	Reticulocyte count;
TGCT	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg24250549	chr1:154909240	PMVK	0.57	5.36	0.43	3.88e-7	Prostate cancer;
TGCT	cis	rs73815153	0.744	rs7712571	chr5:180463033	A/G	cg00299286	chr5:180478185	BTNL9	0.86	4.95	0.41	2.36e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
TGCT	cis	rs7937612	1.000	rs894839	chr11:120337705	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.29	-4.61	-0.38	9.71e-6	Intraocular pressure;
TGCT	cis	rs2710642	0.962	rs7557501	chr2:63086639	C/T	cg17519650	chr2:63277830	OTX1	0.64	5.94	0.47	2.7e-8	LDL cholesterol levels;LDL cholesterol;
TGCT	cis	rs3011225	0.710	rs3011222	chr1:44317545	C/T	cg12908607	chr1:44402522	ARTN	-0.64	-7.74	-0.57	3e-12	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs918629	0.679	rs6883880	chr5:95271173	A/T	cg16656078	chr5:95278638	ELL2	-0.28	-4.55	-0.38	1.25e-5	IgG glycosylation;
TGCT	cis	rs2637266	1.000	rs2579749	chr10:78332105	T/C	cg18941641	chr10:78392320	NA	0.4	4.98	0.41	2.09e-6	Pulmonary function;
TGCT	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg06238570	chr21:40685208	BRWD1	-0.8	-9.08	-0.63	2.07e-15	Cognitive function;
TGCT	cis	rs4727027	0.866	rs35599790	chr7:148806012	C/T	cg23583168	chr7:148888333	NA	-0.72	-9.16	-0.64	1.34e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs7617773	0.925	rs6442105	chr3:48182326	A/G	cg11946769	chr3:48343235	NME6	-0.59	-5.36	-0.43	3.96e-7	Coronary artery disease;
TGCT	cis	rs34526934	0.566	rs9141	chr2:177037970	T/C	cg23561606	chr2:177418561	NA	-0.45	-4.47	-0.37	1.71e-5	Obstructive sleep apnea trait (apnea hypopnea index);
TGCT	cis	rs9436747	0.641	rs1343981	chr1:66045328	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.52	4.65	0.39	8.37e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs4900538	0.855	rs72698602	chr14:102880454	T/C	cg18135206	chr14:102964638	TECPR2	-0.2	-4.53	-0.38	1.39e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	trans	rs1814175	0.817	rs11040700	chr11:50023832	C/T	cg03929089	chr4:120376271	NA	-0.72	-8.55	-0.61	3.8e-14	Height;
TGCT	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg04317338	chr11:64019027	PLCB3	0.76	6.27	0.49	5.45e-9	Mean platelet volume;
TGCT	cis	rs700651	0.789	rs6434949	chr2:198855510	T/A	cg00792783	chr2:198669748	PLCL1	0.57	5.1	0.42	1.24e-6	Intracranial aneurysm;
TGCT	cis	rs11785400	1.000	rs11785400	chr8:143730456	C/T	cg10596483	chr8:143751796	JRK	0.54	5.77	0.46	5.95e-8	Schizophrenia;
TGCT	cis	rs9818758	0.607	rs11719220	chr3:49245201	A/G	cg00383909	chr3:49044727	WDR6	1.28	6.57	0.51	1.23e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg00024416	chr22:24240387	NA	-0.25	-4.65	-0.39	8.31e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7312933	0.618	rs12366848	chr12:42682215	A/G	cg19980929	chr12:42632907	YAF2	0.41	5.61	0.45	1.26e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs7959452	0.535	rs1350166	chr12:69636314	G/T	cg11871910	chr12:69753446	YEATS4	0.62	6.2	0.49	7.84e-9	Blood protein levels;
TGCT	cis	rs13326165	0.760	rs11714402	chr3:52391735	G/T	cg07884673	chr3:53033167	SFMBT1	-0.35	-4.56	-0.38	1.21e-5	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs9467711	0.606	rs9393714	chr6:26373740	G/T	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg25036284	chr2:26402008	FAM59B	-0.54	-4.7	-0.39	6.93e-6	Gut microbiome composition (summer);
TGCT	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.9	6.65	0.51	8.41e-10	Gut microbiome composition (summer);
TGCT	cis	rs969930	0.526	rs4738043	chr8:70775307	T/A	cg03719092	chr8:70744881	SLCO5A1	-0.47	-5.04	-0.41	1.6e-6	Lower body strength;
TGCT	cis	rs7312933	0.558	rs11181502	chr12:42823833	A/G	cg19980929	chr12:42632907	YAF2	0.42	5.91	0.47	3.05e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs6500602	0.793	rs4785964	chr16:4484613	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.38	4.7	0.39	6.78e-6	Schizophrenia;
TGCT	trans	rs7618501	1.000	rs4855867	chr3:49745822	C/T	cg21659725	chr3:3221576	CRBN	-0.99	-15.57	-0.81	5.76e-31	Intelligence (multi-trait analysis);
TGCT	cis	rs929354	0.742	rs2051877	chr7:157008813	A/T	cg05182265	chr7:156933206	UBE3C	-0.41	-9.16	-0.64	1.33e-15	Body mass index;
TGCT	cis	rs35146811	0.735	rs1637001	chr7:99808151	G/A	cg13334819	chr7:99746414	C7orf59	0.74	6.31	0.49	4.4e-9	Coronary artery disease;
TGCT	cis	rs1372520	0.684	rs2197120	chr4:90729602	A/G	cg01966878	chr4:90757139	SNCA	-0.31	-4.84	-0.4	3.8e-6	Neuroticism;
TGCT	cis	rs7089973	0.872	rs7072364	chr10:116620840	G/A	cg03647239	chr10:116582469	FAM160B1	0.53	4.73	0.39	6.08e-6	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs4689388	0.853	rs13108780	chr4:6294630	A/G	cg00701064	chr4:6280414	WFS1	0.37	4.72	0.39	6.3e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs9811920	0.535	rs792831	chr3:99473720	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.39	4.6	0.38	1.04e-5	Axial length;
TGCT	cis	rs514406	0.763	rs7535088	chr1:53215042	A/G	cg08859206	chr1:53392774	SCP2	0.4	5.88	0.47	3.56e-8	Monocyte count;
TGCT	cis	rs3770081	0.536	rs7562837	chr2:86306251	T/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.1	-6.55	-0.51	1.38e-9	Facial emotion recognition (sad faces);
TGCT	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg23758822	chr17:41437982	NA	0.67	6.68	0.51	7.33e-10	Menopause (age at onset);
TGCT	cis	rs1008375	0.800	rs10008598	chr4:17607323	T/C	cg10189774	chr4:17578691	LAP3	0.65	5.53	0.44	1.84e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs11673344	0.523	rs8108509	chr19:37551272	T/C	cg08039142	chr19:36980659	ZNF566	0.5	4.62	0.38	9.48e-6	Obesity-related traits;
TGCT	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg11644478	chr21:40555479	PSMG1	-0.49	-4.57	-0.38	1.17e-5	Menarche (age at onset);
TGCT	cis	rs9457247	0.508	rs6902119	chr6:167505791	T/C	cg07741184	chr6:167504864	NA	0.27	5.25	0.43	6.4e-7	Crohn's disease;
TGCT	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg18538332	chr22:24372958	LOC391322	1.04	11.73	0.73	7.89e-22	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7731657	0.537	rs12516770	chr5:130222575	T/C	cg08523029	chr5:130500466	HINT1	-0.6	-5.0	-0.41	1.92e-6	Fasting plasma glucose;
TGCT	cis	rs3771570	1.000	rs1056801	chr2:242292307	T/C	cg21155796	chr2:242212141	HDLBP	0.94	6.69	0.51	6.9e-10	Prostate cancer;
TGCT	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg00684032	chr4:1343700	KIAA1530	0.24	4.91	0.4	2.82e-6	Obesity-related traits;
TGCT	cis	rs8017423	1.000	rs1959001	chr14:90667739	G/A	cg04374321	chr14:90722782	PSMC1	0.77	7.96	0.58	9.31e-13	Mortality in heart failure;
TGCT	cis	rs1568657	0.666	rs55751241	chr15:83752643	T/C	cg05615147	chr15:83735916	BTBD1	-0.6	-4.9	-0.4	2.95e-6	Kawasaki disease;
TGCT	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg17264618	chr3:40429014	ENTPD3	0.32	4.57	0.38	1.18e-5	Renal cell carcinoma;
TGCT	cis	rs6665290	0.901	rs7535826	chr1:227213968	A/C	cg10327440	chr1:227177885	CDC42BPA	0.9	16.32	0.83	1.16e-32	Myeloid white cell count;
TGCT	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg11764359	chr7:65958608	NA	0.56	5.0	0.41	1.92e-6	Aortic root size;
TGCT	cis	rs9611565	0.512	rs5996063	chr22:42168767	G/A	cg03806693	chr22:41940476	POLR3H	1.02	10.49	0.69	7.92e-19	Vitiligo;
TGCT	cis	rs12048904	0.964	rs17123467	chr1:101331760	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.55	5.14	0.42	1.04e-6	Multiple sclerosis;
TGCT	cis	rs2295359	0.824	rs4655679	chr1:67599657	A/G	cg08029281	chr1:67600428	NA	-0.38	-4.46	-0.37	1.85e-5	Psoriasis;
TGCT	cis	rs13064447	0.874	rs13058951	chr3:12752381	C/T	cg20675869	chr3:12750130	NA	0.18	4.59	0.38	1.08e-5	Major depression and alcohol dependence;
TGCT	cis	rs765787	0.556	rs2413778	chr15:45539397	C/A	cg24006582	chr15:45444508	DUOX1	-0.25	-5.54	-0.45	1.76e-7	Uric acid levels;
TGCT	cis	rs7246657	0.653	rs4805207	chr19:37673733	G/A	cg24025825	chr19:37761650	NA	-0.32	-5.02	-0.41	1.79e-6	Coronary artery calcification;
TGCT	cis	rs10791097	0.694	rs10791100	chr11:130738946	T/A	cg05962950	chr11:130786565	SNX19	0.92	11.55	0.72	2.13e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9467773	0.620	rs2494694	chr6:26619328	A/T	cg09904177	chr6:26538194	HMGN4	0.66	6.33	0.49	3.99e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7586879	0.575	rs6721750	chr2:25128719	A/G	cg15423357	chr2:25149977	NA	0.5	4.89	0.4	3.06e-6	Body mass index;
TGCT	cis	rs12627970	0.565	rs2072872	chr22:39713128	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.88	11.02	0.7	4.09e-20	Inflammatory bowel disease;
TGCT	cis	rs8050907	0.744	rs1362625	chr16:4526310	G/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.53	4.57	0.38	1.15e-5	Obesity-related traits;
TGCT	cis	rs35306767	0.855	rs2050944	chr10:918910	T/C	cg26597838	chr10:835615	NA	0.75	10.56	0.69	5.62e-19	Eosinophil percentage of granulocytes;
TGCT	trans	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg20587970	chr11:113659929	NA	-1.04	-12.57	-0.75	6.97e-24	Hip circumference adjusted for BMI;
TGCT	cis	rs6964587	0.967	rs12538325	chr7:91757479	A/G	cg17063962	chr7:91808500	NA	0.89	9.39	0.64	3.84e-16	Breast cancer;
TGCT	cis	rs6032067	0.598	rs2741500	chr20:43944958	G/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.32	-4.72	-0.39	6.35e-6	Blood protein levels;
TGCT	cis	rs3806843	0.548	rs246038	chr5:140331699	A/G	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	trans	rs1005277	0.522	rs289649	chr10:37975384	T/C	cg17830980	chr10:43048298	ZNF37B	-0.66	-7.47	-0.56	1.22e-11	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7666738	0.830	rs6848404	chr4:98946750	A/G	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg05665937	chr4:1216051	CTBP1	0.22	4.47	0.37	1.75e-5	Obesity-related traits;
TGCT	cis	rs66573146	1.000	rs55672215	chr4:6970529	T/C	cg00086871	chr4:6988644	TBC1D14	0.89	4.51	0.38	1.47e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs67073037	0.955	rs4665437	chr2:29171381	A/G	cg09522027	chr2:28974177	PPP1CB	-0.57	-4.49	-0.37	1.59e-5	Breast cancer;Breast cancer (estrogen-receptor negative);
TGCT	cis	rs6570726	0.935	rs425717	chr6:145838620	A/T	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7666738	0.716	rs6817529	chr4:99023213	T/C	cg05340658	chr4:99064831	C4orf37	0.48	5.43	0.44	2.92e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2295359	0.892	rs6688383	chr1:67655954	C/T	cg08029281	chr1:67600428	NA	-0.41	-4.73	-0.39	5.91e-6	Psoriasis;
TGCT	cis	rs12210905	1.000	rs6902012	chr6:27243767	C/T	cg08851530	chr6:28072375	NA	-1.16	-5.14	-0.42	1.02e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs9486715	1.000	rs9486725	chr6:97061159	C/T	cg18709589	chr6:96969512	KIAA0776	-0.81	-7.71	-0.57	3.5e-12	Headache;
TGCT	cis	rs7617480	0.648	rs4858830	chr3:48734002	T/C	cg07636037	chr3:49044803	WDR6	0.77	6.37	0.5	3.33e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs9486719	1.000	rs11756315	chr6:97008678	A/G	cg18709589	chr6:96969512	KIAA0776	0.67	4.84	0.4	3.85e-6	Migraine;Coronary artery disease;
TGCT	cis	rs3862260	0.509	rs10923879	chr1:120163831	A/G	cg16322792	chr1:120165303	ZNF697	0.35	8.4	0.6	8.92e-14	Systemic lupus erythematosus;
TGCT	cis	rs2832191	0.791	rs7282843	chr21:30475226	A/G	cg08807101	chr21:30365312	RNF160	0.64	6.01	0.48	1.91e-8	Dental caries;
TGCT	cis	rs2721195	1.000	rs2721195	chr8:145677011	T/C	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.8	-8.29	-0.6	1.61e-13	Age at first birth;
TGCT	cis	rs6671200	0.573	rs3820345	chr1:95713175	C/T	cg06440946	chr1:95699313	RWDD3	-0.62	-5.3	-0.43	5.09e-7	Stearic acid (18:0) levels;
TGCT	trans	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg23505145	chr19:12996616	KLF1	0.79	8.3	0.6	1.47e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs12579753	1.000	rs7300900	chr12:82166821	G/T	cg07988820	chr12:82153109	PPFIA2	-0.65	-6.79	-0.52	4.09e-10	Resting heart rate;
TGCT	cis	rs9467773	0.584	rs1021372	chr6:26632444	T/C	cg02458000	chr6:26745757	NA	0.53	5.02	0.41	1.76e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg24829409	chr8:58192753	C8orf71	-0.59	-5.18	-0.42	8.54e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs12478296	1.000	rs6739247	chr2:243039189	C/A	cg06360820	chr2:242988706	NA	-0.58	-4.47	-0.37	1.76e-5	Obesity-related traits;
TGCT	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.68	5.62	0.45	1.18e-7	Tonsillectomy;
TGCT	cis	rs892961	0.867	rs1079354	chr17:75415713	C/T	cg05865280	chr17:75406074	SEPT9	0.29	6.78	0.52	4.27e-10	Airflow obstruction;
TGCT	cis	rs4252435	0.614	rs10265881	chr7:142602578	G/A	cg09833174	chr7:143059591	FAM131B	-0.96	-4.52	-0.38	1.41e-5	Cancer;
TGCT	cis	rs2832191	0.720	rs2832194	chr21:30494250	T/C	cg24692254	chr21:30365293	RNF160	-0.92	-9.97	-0.67	1.45e-17	Dental caries;
TGCT	cis	rs4862307	0.733	rs7686028	chr4:184994669	T/C	cg06737308	chr4:185021514	ENPP6	-0.34	-4.83	-0.4	4e-6	Serum dimethylarginine levels (asymmetric/symetric ratio);
TGCT	cis	rs11658309	1	rs11658309	chr17:17762247	T/G	cg09796270	chr17:17721594	SREBF1	-0.24	-4.78	-0.39	4.77e-6	Strep throat;
TGCT	cis	rs875971	0.628	rs6974355	chr7:65841981	A/G	cg18876405	chr7:65276391	NA	0.41	6.33	0.49	3.99e-9	Aortic root size;
TGCT	cis	rs7226408	0.857	rs2121023	chr18:34488414	C/T	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs1153858	0.943	rs1145079	chr15:45681761	T/C	cg14582100	chr15:45693742	SPATA5L1	0.48	5.69	0.46	8.56e-8	Homoarginine levels;
TGCT	cis	rs7824557	0.569	rs7816601	chr8:11205593	T/C	cg21775007	chr8:11205619	TDH	0.71	6.7	0.52	6.36e-10	Retinal vascular caliber;
TGCT	cis	rs9435341	0.965	rs9435441	chr1:107603330	C/G	cg09367891	chr1:107599246	PRMT6	-0.63	-5.42	-0.44	3.03e-7	Facial morphology (factor 21, depth of nasal alae);
TGCT	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.12	0.42	1.15e-6	Prudent dietary pattern;
TGCT	cis	rs11098499	0.754	rs1511017	chr4:120250805	G/A	cg09307838	chr4:120376055	NA	0.61	5.91	0.47	3.14e-8	Corneal astigmatism;
TGCT	cis	rs6547741	0.967	rs4665995	chr2:27813827	T/G	cg27432699	chr2:27873401	GPN1	0.18	4.65	0.38	8.53e-6	Oral cavity cancer;
TGCT	cis	rs593982	0.777	rs72941015	chr11:65457514	A/C	cg08755490	chr11:65554678	OVOL1	-1.26	-6.96	-0.53	1.71e-10	Atopic dermatitis;
TGCT	cis	rs4951018	0.853	rs1573104	chr1:205636907	A/C	cg24503407	chr1:205819492	PM20D1	-0.36	-4.62	-0.38	9.63e-6	Prostate-specific antigen levels;
TGCT	cis	rs9916302	0.898	rs8072297	chr17:37478048	A/T	cg07936489	chr17:37558343	FBXL20	0.6	4.53	0.38	1.38e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs12541335	0.579	rs59283125	chr8:22212311	G/A	cg02463440	chr8:22132932	PIWIL2	0.27	5.21	0.42	7.67e-7	Hypertriglyceridemia;
TGCT	cis	rs17253792	0.732	rs79014965	chr14:56117551	T/G	cg01858014	chr14:56050164	KTN1	-0.35	-4.47	-0.37	1.71e-5	Putamen volume;
TGCT	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.46	-6.7	-0.52	6.44e-10	Alzheimer's disease;
TGCT	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg23758822	chr17:41437982	NA	0.72	6.85	0.52	3.09e-10	Menopause (age at onset);
TGCT	cis	rs644799	0.648	rs1255181	chr11:95472148	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.48	4.78	0.39	4.88e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs71435601	0.628	rs525172	chr2:21382976	T/G	cg25035485	chr2:21266500	APOB	0.51	4.48	0.37	1.64e-5	Cholesterol, total;
TGCT	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.54	-7.01	-0.53	1.37e-10	Longevity;Endometriosis;
TGCT	cis	rs2147959	0.766	rs10753451	chr1:228715019	G/T	cg22700015	chr1:228743131	NA	-0.63	-5.26	-0.43	6.17e-7	Adult asthma;
TGCT	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs42648	0.869	rs1134956	chr7:89938680	C/T	cg25739043	chr7:89950458	NA	-0.71	-7.09	-0.54	8.84e-11	Homocysteine levels;
TGCT	cis	rs4689388	0.890	rs4689397	chr4:6299387	G/A	cg00701064	chr4:6280414	WFS1	0.44	5.81	0.46	4.99e-8	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs2197308	0.669	rs11173675	chr12:38091486	A/G	cg26384229	chr12:38710491	ALG10B	0.59	5.11	0.42	1.19e-6	Morning vs. evening chronotype;
TGCT	cis	rs1153858	1.000	rs2467863	chr15:45641880	G/A	cg14582100	chr15:45693742	SPATA5L1	0.49	5.82	0.46	4.73e-8	Homoarginine levels;
TGCT	cis	rs854765	0.964	rs2230316	chr17:17997209	C/T	cg04398451	chr17:18023971	MYO15A	0.3	4.77	0.39	5.02e-6	Total body bone mineral density;
TGCT	cis	rs4808199	0.947	rs2163804	chr19:19575965	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.73	5.16	0.42	9.65e-7	Nonalcoholic fatty liver disease;
TGCT	cis	rs1801251	0.752	rs2675966	chr2:233735543	T/C	cg25237894	chr2:233734115	C2orf82	-0.29	-5.63	-0.45	1.14e-7	Coronary artery disease;
TGCT	cis	rs3138083	0.623	rs3138087	chr9:35645779	C/A	cg07116010	chr9:35646325	NA	0.84	10.25	0.68	3.08e-18	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);
TGCT	cis	rs6088580	0.634	rs2378133	chr20:32919505	C/G	cg06115741	chr20:33292138	TP53INP2	-0.54	-4.74	-0.39	5.7e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs67311347	1.000	rs7625736	chr3:40441345	C/G	cg17264618	chr3:40429014	ENTPD3	-0.31	-4.59	-0.38	1.08e-5	Renal cell carcinoma;
TGCT	cis	rs9926296	0.682	rs467357	chr16:89717397	A/G	cg03388025	chr16:89894329	SPIRE2	-0.35	-5.05	-0.41	1.53e-6	Vitiligo;
TGCT	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg03517284	chr6:25882590	NA	-0.64	-5.49	-0.44	2.17e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9372253	1.000	rs9372253	chr6:110716136	C/T	cg00083206	chr6:110721305	DDO	-0.43	-6.46	-0.5	2.2e-9	Platelet distribution width;
TGCT	cis	rs12643440	0.538	rs16894433	chr4:17143112	A/C	cg22650099	chr4:17144496	NA	-0.46	-4.7	-0.39	6.79e-6	Metabolite levels (Pyroglutamine);
TGCT	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg06873352	chr17:61820015	STRADA	0.58	6.39	0.5	3.01e-9	Prudent dietary pattern;
TGCT	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg11062466	chr8:58055876	NA	0.38	4.5	0.37	1.56e-5	Developmental language disorder (linguistic errors);
TGCT	trans	rs4650994	0.525	rs2493858	chr1:178541210	A/G	cg05059571	chr16:84539110	KIAA1609	-0.54	-11.16	-0.71	1.91e-20	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs34638657	0.500	rs7405197	chr16:82169833	C/A	cg09439754	chr16:82129088	HSD17B2	-0.24	-4.86	-0.4	3.51e-6	Lung adenocarcinoma;
TGCT	cis	rs6540559	0.611	rs11810817	chr1:210011747	C/G	cg21951975	chr1:209979733	IRF6	0.63	4.76	0.39	5.36e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs806215	0.526	rs62481450	chr7:127568983	C/T	cg11539674	chr7:127291444	SND1	-0.36	-4.65	-0.39	8.37e-6	Type 2 diabetes;
TGCT	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg06112835	chr11:68658793	MRPL21	0.46	7.8	0.57	2.18e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs10193935	1.000	rs13424523	chr2:42413562	T/G	cg27598129	chr2:42591480	NA	-0.39	-5.14	-0.42	1.05e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4253772	0.515	rs6008591	chr22:46703664	T/C	cg24881330	chr22:46731750	TRMU	1.04	5.41	0.44	3.12e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs9911578	0.757	rs4793954	chr17:56629527	G/T	cg12560992	chr17:57184187	TRIM37	-0.73	-7.23	-0.54	4.32e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs907683	0.584	rs2070927	chr2:220282955	C/T	cg15015639	chr2:220282977	DES	0.37	4.77	0.39	5.05e-6	Resting heart rate;
TGCT	cis	rs9611565	0.512	rs139562	chr22:42196684	G/C	cg13695892	chr22:41940480	POLR3H	-0.83	-7.77	-0.57	2.51e-12	Vitiligo;
TGCT	cis	rs4805272	0.962	rs4805277	chr19:29330943	C/G	cg15000279	chr19:29285009	NA	-0.51	-5.65	-0.45	1.04e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
TGCT	cis	rs6136489	0.583	rs6136477	chr20:1922534	G/C	cg17747171	chr20:2633605	NOP56;SNORD110	0.54	4.75	0.39	5.46e-6	Platelet distribution width;Mean platelet volume;
TGCT	cis	rs3791556	1.000	rs3791556	chr2:240112972	G/A	cg03281426	chr2:240109471	HDAC4	0.28	4.46	0.37	1.82e-5	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs28595532	0.920	rs17258050	chr4:119672019	G/A	cg14228332	chr4:119757509	SEC24D	1.06	5.67	0.45	9.69e-8	Cannabis dependence symptom count;
TGCT	cis	rs79349575	0.749	rs1057902	chr17:47005588	C/T	cg27201301	chr17:47039149	GIP	0.26	4.63	0.38	9.2e-6	Type 2 diabetes;
TGCT	cis	rs9915657	0.870	rs918081	chr17:70127808	G/A	cg06234051	chr17:70120541	SOX9	-0.26	-5.28	-0.43	5.57e-7	Thyroid hormone levels;
TGCT	cis	rs79976124	0.797	rs74995761	chr6:66640216	G/A	cg07460842	chr6:66804631	NA	0.57	5.09	0.42	1.26e-6	Type 2 diabetes;
TGCT	cis	rs2120019	0.938	rs35911108	chr15:75322179	G/A	cg17294928	chr15:75287854	SCAMP5	-0.79	-6.27	-0.49	5.46e-9	Blood trace element (Zn levels);
TGCT	cis	rs3806843	0.583	rs408652	chr5:140330013	T/G	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.42	-5.24	-0.43	6.76e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs4252435	0.520	rs76184304	chr7:142633490	C/G	cg09833174	chr7:143059591	FAM131B	-1.03	-4.71	-0.39	6.56e-6	Cancer;
TGCT	cis	rs748404	0.631	rs8042688	chr15:43638525	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	4.72	0.39	6.3e-6	Lung cancer;
TGCT	cis	rs5769707	0.967	rs763126	chr22:49988574	G/T	cg10356904	chr22:49881777	NA	0.23	4.68	0.39	7.36e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs17741873	0.836	rs2254266	chr10:75601688	T/C	cg07699608	chr10:75541558	CHCHD1	0.69	4.87	0.4	3.27e-6	Paclitaxel disposition in epithelial ovarian cancer;
TGCT	cis	rs7568458	0.837	rs3770098	chr2:85805367	C/A	cg02493740	chr2:85810744	VAMP5	-0.27	-4.85	-0.4	3.63e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs910316	1.000	rs3742773	chr14:75579643	A/G	cg08847533	chr14:75593920	NEK9	0.95	10.61	0.69	4.09e-19	Height;
TGCT	cis	rs7772486	0.686	rs9399565	chr6:146081906	G/T	cg05347473	chr6:146136440	FBXO30	-0.5	-4.7	-0.39	6.74e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1031925	0.640	rs4687775	chr3:51769206	A/C	cg10583097	chr3:51429234	RBM15B	0.55	5.07	0.41	1.42e-6	Melanoma;
TGCT	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.46	0.56	1.3e-11	Prudent dietary pattern;
TGCT	cis	rs854765	0.583	rs8070128	chr17:17804725	C/T	cg09796270	chr17:17721594	SREBF1	-0.27	-5.61	-0.45	1.24e-7	Total body bone mineral density;
TGCT	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg06112835	chr11:68658793	MRPL21	0.46	8.12	0.59	3.91e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs2228479	0.850	rs74251568	chr16:89903416	A/C	cg06558623	chr16:89946397	TCF25	0.55	4.86	0.4	3.55e-6	Skin colour saturation;
TGCT	cis	rs66561647	0.895	rs9649959	chr8:128972721	C/T	cg11792826	chr8:129160931	MIR1208	-0.19	-4.49	-0.37	1.6e-5	Hemoglobin concentration;
TGCT	cis	rs2963155	0.518	rs10482614	chr5:142782402	C/T	cg17617527	chr5:142782415	NR3C1	0.86	5.51	0.44	2.02e-7	Breast cancer;
TGCT	cis	rs12510870	0.599	rs13144296	chr4:74453988	A/G	cg05868023	chr4:75230803	EREG	-0.55	-4.74	-0.39	5.71e-6	Iris color (b* coordinate);
TGCT	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.0	0.41	1.89e-6	Menopause (age at onset);
TGCT	cis	rs9733	0.519	rs11807450	chr1:150677719	C/T	cg09365446	chr1:150670422	GOLPH3L	0.3	4.55	0.38	1.24e-5	Tonsillectomy;
TGCT	cis	rs933688	1.000	rs6865495	chr5:90746424	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.93	8.39	0.6	9.04e-14	Smoking behavior;
TGCT	cis	rs10197940	0.545	rs2444267	chr2:152308611	T/G	cg19508488	chr2:152266495	RIF1	0.59	4.94	0.41	2.52e-6	Lung cancer;
TGCT	cis	rs4731207	0.596	rs12537431	chr7:124586556	G/A	cg10503827	chr7:124401702	GPR37	-0.21	-4.53	-0.38	1.37e-5	Cutaneous malignant melanoma;
TGCT	cis	rs477895	1.000	rs41294396	chr11:64078581	G/A	cg23719950	chr11:63933701	MACROD1	-0.59	-4.6	-0.38	1.01e-5	Mean platelet volume;
TGCT	cis	rs981844	1.000	rs2606335	chr4:154656536	T/C	cg14289246	chr4:154710475	SFRP2	1.01	8.46	0.6	6.31e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs10465746	0.967	rs12407641	chr1:84368115	T/C	cg10977910	chr1:84465055	TTLL7	0.63	6.19	0.49	8.08e-9	Obesity-related traits;
TGCT	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg08975724	chr8:8085496	FLJ10661	0.53	4.74	0.39	5.88e-6	Mood instability;
TGCT	cis	rs7927771	0.832	rs7105851	chr11:47383275	T/C	cg21462715	chr11:47870315	NUP160	-0.57	-4.63	-0.38	9.08e-6	Subjective well-being;
TGCT	cis	rs6714710	0.580	rs11690737	chr2:98461953	C/T	cg26665480	chr2:98280029	ACTR1B	0.66	6.18	0.49	8.38e-9	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs10927875	0.597	rs61782184	chr1:16150976	G/A	cg21385522	chr1:16154831	NA	-1.0	-17.44	-0.84	3.61e-35	Dilated cardiomyopathy;
TGCT	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg11644478	chr21:40555479	PSMG1	1.0	10.6	0.69	4.32e-19	Cognitive function;
TGCT	cis	rs9443189	0.570	rs7755068	chr6:76405700	A/G	cg01950844	chr6:76311363	SENP6	1.0	6.24	0.49	6.35e-9	Prostate cancer;
TGCT	cis	rs992157	0.710	rs10169718	chr2:219103580	C/T	cg00012203	chr2:219082015	ARPC2	-0.81	-9.9	-0.66	2.21e-17	Colorectal cancer;
TGCT	cis	rs447921	0.861	rs17596582	chr17:74438120	A/T	cg09812376	chr17:74270190	QRICH2	0.42	4.49	0.37	1.6e-5	Mitochondrial DNA levels;
TGCT	cis	rs2288073	0.896	rs13404513	chr2:24410780	G/A	cg02683114	chr2:24398427	C2orf84	-0.24	-5.72	-0.46	7.53e-8	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs7267979	1.000	rs4815409	chr20:25346697	C/A	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs12291225	0.585	rs12270374	chr11:14375079	T/C	cg19336497	chr11:14380999	RRAS2	-0.43	-7.02	-0.53	1.3100000000000001e-10	Sense of smell;
TGCT	cis	rs362272	0.545	rs2749782	chr4:3339761	A/G	cg18352616	chr4:3374830	RGS12	0.24	4.89	0.4	3.02e-6	Serum sulfate level;
TGCT	cis	rs6681544	0.760	rs7413275	chr1:82417552	T/G	cg04226724	chr1:82268649	LPHN2	-0.46	-4.68	-0.39	7.4e-6	Metabolite levels  (X-11787);
TGCT	cis	rs289997	0.777	rs73277029	chr7:25591710	C/T	cg14064488	chr7:26331273	SNX10	-0.34	-4.54	-0.38	1.33e-5	Breast cancer;
TGCT	trans	rs10435719	0.780	rs9692662	chr8:11789863	C/T	cg15556689	chr8:8085844	FLJ10661	0.74	7.04	0.53	1.17e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs3774830	0.714	rs17464616	chr4:5465004	G/A	cg26943120	chr4:5472116	STK32B	0.22	4.82	0.4	4.15e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg06238570	chr21:40685208	BRWD1	-0.61	-6.2	-0.49	7.83e-9	Menarche (age at onset);
TGCT	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg21862992	chr11:68658383	NA	0.46	6.52	0.51	1.6e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs76473307	1.000	rs117968747	chr20:57397505	A/G	cg06163629	chr20:57414884	GNASAS;GNAS	-0.67	-4.53	-0.38	1.34e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs4523957	0.614	rs2984941	chr17:2031543	A/G	cg16513277	chr17:2031491	SMG6	-0.21	-4.74	-0.39	5.72e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9611565	0.607	rs132792	chr22:42062822	C/T	cg03806693	chr22:41940476	POLR3H	0.95	9.44	0.65	2.92e-16	Vitiligo;
TGCT	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg09417038	chr21:47716443	C21orf57	0.31	4.45	0.37	1.89e-5	Testicular germ cell tumor;
TGCT	cis	rs11105298	0.891	rs10858872	chr12:89872932	C/T	cg00757033	chr12:89920650	WDR51B	0.34	5.37	0.43	3.75e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg18252515	chr7:66147081	NA	-1.22	-7.98	-0.58	8.46e-13	Diabetic kidney disease;
TGCT	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg22920501	chr2:26401640	FAM59B	-0.74	-6.4	-0.5	2.86e-9	Gut microbiome composition (summer);
TGCT	cis	rs13315871	1.000	rs4362735	chr3:58429893	C/G	cg12435725	chr3:58293450	RPP14	-0.44	-4.53	-0.38	1.37e-5	Cholesterol, total;
TGCT	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg03351412	chr1:154909251	PMVK	-0.53	-4.93	-0.4	2.6e-6	Prostate cancer;
TGCT	cis	rs8056742	1.000	rs16975170	chr16:85092575	C/T	cg04622164	chr16:85157906	NA	0.61	5.11	0.42	1.16e-6	Amyotrophic lateral sclerosis;
TGCT	cis	rs2115630	0.936	rs11073663	chr15:85260268	A/G	cg12501888	chr15:85177176	SCAND2	-0.49	-4.72	-0.39	6.39e-6	P wave terminal force;
TGCT	cis	rs858239	0.633	rs858300	chr7:23244631	A/G	cg05602783	chr7:23145260	KLHL7	-0.65	-5.47	-0.44	2.4e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs28595532	0.800	rs111626798	chr4:119352517	C/T	cg21605333	chr4:119757512	SEC24D	0.87	5.49	0.44	2.14e-7	Cannabis dependence symptom count;
TGCT	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.12	15.17	0.81	4.81e-30	Height;
TGCT	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg11764359	chr7:65958608	NA	0.61	5.53	0.44	1.84e-7	Aortic root size;
TGCT	cis	rs6582630	0.598	rs10880614	chr12:38509766	G/A	cg26384229	chr12:38710491	ALG10B	-0.54	-4.79	-0.4	4.57e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg05025164	chr4:1340916	KIAA1530	0.78	6.44	0.5	2.36e-9	Longevity;
TGCT	cis	rs71636778	0.509	rs17360994	chr1:27278573	T/C	cg23921621	chr1:27994728	IFI6	-0.43	-4.61	-0.38	9.92e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
TGCT	cis	rs981844	1.000	rs62325092	chr4:154668674	T/C	cg14289246	chr4:154710475	SFRP2	1.01	8.67	0.61	2.02e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs10832169	1.000	rs10832169	chr11:14066486	G/A	cg04547675	chr11:13986162	SPON1	0.51	4.51	0.38	1.49e-5	Blood protein levels;
TGCT	cis	rs3824867	0.920	rs3740685	chr11:47468791	C/T	cg20307385	chr11:47447363	PSMC3	0.69	5.93	0.47	2.74e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs4799461	0.740	rs7506216	chr18:35125862	C/T	cg27332583	chr18:35150602	NA	0.29	4.74	0.39	5.79e-6	Neuroticism;
TGCT	cis	rs9394841	0.667	rs9471667	chr6:41776681	T/C	cg08135965	chr6:41755394	TOMM6	0.55	5.15	0.42	9.77e-7	Mean corpuscular hemoglobin;Red cell distribution width;
TGCT	cis	rs7647973	0.626	rs4855846	chr3:49683526	G/A	cg03060546	chr3:49711283	APEH	0.63	5.63	0.45	1.12e-7	Menarche (age at onset);
TGCT	cis	rs7578199	0.576	rs3771586	chr2:242401002	A/G	cg21155796	chr2:242212141	HDLBP	0.51	4.63	0.38	9.19e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs7615952	0.736	rs13063122	chr3:125643860	G/A	cg05084668	chr3:125655381	ALG1L	-0.76	-6.21	-0.49	7.3e-9	Blood pressure (smoking interaction);
TGCT	cis	rs713587	0.713	rs12618252	chr2:25207950	G/A	cg01884057	chr2:25150051	NA	-0.38	-7.81	-0.57	2.04e-12	Body mass index in non-asthmatics;
TGCT	cis	rs35934224	0.831	rs13057374	chr22:19871097	C/G	cg11182965	chr22:19864308	TXNRD2	-0.38	-5.34	-0.43	4.3e-7	Glaucoma (primary open-angle);
TGCT	cis	rs909002	0.811	rs7545321	chr1:32122164	A/G	cg11573219	chr1:32083031	HCRTR1	-0.43	-5.28	-0.43	5.52e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9362426	1.000	rs242271	chr6:88082029	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.47	5.09	0.42	1.3e-6	Depressive episodes in bipolar disorder;
TGCT	cis	rs6754311	0.731	rs309160	chr2:136685228	C/T	cg07169764	chr2:136633963	MCM6	0.62	5.75	0.46	6.66e-8	Mosquito bite size;
TGCT	cis	rs11190604	0.697	rs10748795	chr10:102194818	A/T	cg16342193	chr10:102329863	NA	0.4	4.99	0.41	2.04e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs860554	0.660	rs832169	chr1:201256771	C/T	cg01022117	chr1:201258280	PKP1	0.34	5.17	0.42	9.18e-7	Panic disorder;
TGCT	cis	rs7666738	0.753	rs28390295	chr4:99028497	C/A	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg12751644	chr20:60527061	NA	-0.52	-7.13	-0.54	7.26e-11	Obesity-related traits;
TGCT	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg12667521	chr19:29218732	NA	0.53	5.63	0.45	1.16e-7	Methadone dose in opioid dependence;
TGCT	cis	rs523522	0.962	rs7471	chr12:120941215	T/C	cg12219531	chr12:120966889	COQ5	0.83	7.27	0.55	3.46e-11	High light scatter reticulocyte count;
TGCT	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg11062466	chr8:58055876	NA	0.37	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9549367	0.789	rs2287247	chr13:113889212	A/G	cg00898013	chr13:113819073	PROZ	-0.4	-4.92	-0.4	2.7e-6	Platelet distribution width;
TGCT	cis	rs4930561	0.714	rs7122250	chr11:67946472	T/C	cg04465784	chr11:67976953	SUV420H1	-0.38	-5.47	-0.44	2.37e-7	Breast cancer in childhood cancer survivors;IgG glycosylation;
TGCT	cis	rs41308713	0.786	rs8116471	chr20:37034694	A/C	cg09132763	chr20:37064059	LOC388796;SNORA71D	1.26	5.95	0.47	2.53e-8	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
TGCT	cis	rs916888	0.821	rs415430	chr17:44859144	C/T	cg17911788	chr17:44343683	NA	0.59	6.13	0.48	1.09e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2033711	0.905	rs1077420	chr19:58968875	A/C	cg13877915	chr19:58951672	ZNF132	0.85	9.82	0.66	3.48e-17	Uric acid clearance;
TGCT	trans	rs1814175	0.817	rs12290508	chr11:49621037	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.38	-7.79	-0.57	2.31e-12	Height;
TGCT	cis	rs11711311	1.000	rs2603789	chr3:113470479	T/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.72	-6.74	-0.52	5.36e-10	IgG glycosylation;
TGCT	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg08219700	chr8:58056026	NA	0.39	4.74	0.39	5.64e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg13206674	chr6:150067644	NUP43	0.52	4.51	0.38	1.5e-5	Lung cancer;
TGCT	cis	rs4699052	0.963	rs11943325	chr4:104178393	T/C	cg16532752	chr4:104119610	CENPE	-0.55	-4.97	-0.41	2.19e-6	Testicular germ cell tumor;
TGCT	cis	rs3806843	0.868	rs2262574	chr5:140123635	G/T	cg19875535	chr5:140030758	IK	-0.34	-5.68	-0.45	8.89e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.69	-7.06	-0.54	1.07e-10	Prostate cancer;
TGCT	cis	rs6542838	0.611	rs13006398	chr2:99522323	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.56	-5.08	-0.42	1.35e-6	Fear of minor pain;
TGCT	cis	rs9911578	0.813	rs12452313	chr17:57129882	C/A	cg05425664	chr17:57184151	TRIM37	0.67	6.14	0.48	1.04e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2282802	0.635	rs270162	chr5:139539090	A/G	cg01081189	chr5:139537190	NA	-0.28	-5.16	-0.42	9.51e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2836974	0.931	rs2989330	chr21:40716209	A/G	cg17971929	chr21:40555470	PSMG1	0.88	7.1	0.54	8.62e-11	Cognitive function;
TGCT	cis	rs10751667	0.666	rs7396509	chr11:956761	G/A	cg06064525	chr11:970664	AP2A2	-0.35	-8.22	-0.59	2.29e-13	Alzheimer's disease (late onset);
TGCT	cis	rs2243480	1.000	rs160634	chr7:65528664	C/T	cg18252515	chr7:66147081	NA	1.03	7.24	0.55	4.11e-11	Diabetic kidney disease;
TGCT	cis	rs2288278	0.601	rs60154639	chr17:46575562	G/A	cg25032089	chr17:46643351	HOXB3	-0.42	-5.03	-0.41	1.68e-6	Hand grip strength;
TGCT	cis	rs75686122	0.892	rs78235073	chr8:104647541	G/T	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg24060327	chr5:131705240	SLC22A5	-0.59	-6.09	-0.48	1.32e-8	Acylcarnitine levels;
TGCT	cis	rs6845621	0.754	rs7680497	chr4:18885282	T/C	cg12196642	chr4:18937545	NA	-0.24	-4.51	-0.38	1.5e-5	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
TGCT	cis	rs10949662	1.000	rs11765189	chr7:157535977	A/G	cg11757124	chr7:157526947	PTPRN2	-0.4	-4.65	-0.39	8.2e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs12643440	0.538	rs4698538	chr4:17150001	T/G	cg22650099	chr4:17144496	NA	-0.47	-4.84	-0.4	3.86e-6	Metabolite levels (Pyroglutamine);
TGCT	cis	rs1499614	1.000	rs2659903	chr7:66180931	G/A	cg18252515	chr7:66147081	NA	-1.26	-7.95	-0.58	9.71e-13	Gout;
TGCT	cis	rs6540559	0.611	rs17015226	chr1:209970096	C/G	cg23283495	chr1:209979779	IRF6	0.69	5.37	0.43	3.68e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs10771431	0.782	rs10771415	chr12:9358223	C/T	cg08997352	chr12:9597637	DDX12	-0.3	-5.87	-0.47	3.72e-8	Breast size;
TGCT	cis	rs36051895	0.632	rs7040922	chr9:5174829	A/G	cg02405213	chr9:5042618	JAK2	0.79	11.03	0.7	3.99e-20	Pediatric autoimmune diseases;
TGCT	cis	rs477895	0.838	rs35090903	chr11:64000598	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.83	6.91	0.53	2.2e-10	Mean platelet volume;
TGCT	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg04287289	chr16:89883240	FANCA	-0.67	-6.78	-0.52	4.35e-10	Vitiligo;
TGCT	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg20891283	chr12:69753455	YEATS4	0.9	10.36	0.68	1.69e-18	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs7809950	0.953	rs3094383	chr7:107143164	G/A	cg23024343	chr7:107201750	COG5	-0.35	-5.54	-0.45	1.72e-7	Coronary artery disease;
TGCT	cis	rs12257961	0.521	rs10796279	chr10:15375400	A/T	cg10616319	chr10:15468812	NA	-0.25	-4.56	-0.38	1.2e-5	Selective IgA deficiency;
TGCT	cis	rs11122272	0.735	rs2790886	chr1:231529491	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-6.34	-0.49	3.83e-9	Hemoglobin concentration;
TGCT	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg00149659	chr3:10157352	C3orf10	1.1	6.89	0.53	2.45e-10	Alzheimer's disease;
TGCT	cis	rs2243480	0.615	rs34363376	chr7:65939536	T/C	cg07424592	chr7:64974309	NA	1.29	8.01	0.58	7.16e-13	Diabetic kidney disease;
TGCT	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg17971929	chr21:40555470	PSMG1	-0.65	-5.56	-0.45	1.56e-7	Cognitive function;
TGCT	cis	rs6840360	0.571	rs12648420	chr4:152543434	G/C	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.0	-0.58	7.69e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs9436747	0.667	rs7519977	chr1:66033496	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.52	4.5	0.37	1.55e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs651907	0.557	rs13066768	chr3:101486920	A/T	cg12386194	chr3:101231763	SENP7	-0.47	-4.59	-0.38	1.07e-5	Colorectal cancer;
TGCT	cis	rs523522	0.962	rs12814055	chr12:120987391	G/A	cg27279351	chr12:120934652	DYNLL1	0.76	6.59	0.51	1.15e-9	High light scatter reticulocyte count;
TGCT	cis	rs10510102	0.872	rs12261371	chr10:123726201	A/C	cg23691251	chr10:123688108	ATE1	-0.59	-4.7	-0.39	6.75e-6	Breast cancer;
TGCT	cis	rs1215050	0.791	rs1215054	chr4:98863009	T/G	cg05340658	chr4:99064831	C4orf37	-0.47	-5.9	-0.47	3.18e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9427116	0.502	rs7531982	chr1:154596122	A/T	cg17218026	chr1:154582156	ADAR	0.3	7.7	0.57	3.74e-12	Blood protein levels;
TGCT	cis	rs10782582	0.609	rs1001160	chr1:76358591	A/C	cg10523679	chr1:76189770	ACADM	-0.58	-5.38	-0.43	3.6e-7	Daytime sleep phenotypes;
TGCT	cis	rs35306767	0.953	rs7908138	chr10:962978	C/T	cg26597838	chr10:835615	NA	0.66	9.01	0.63	3.04e-15	Eosinophil percentage of granulocytes;
TGCT	cis	rs910187	0.641	rs6018327	chr20:45813126	C/T	cg27589058	chr20:45804311	EYA2	-0.35	-7.55	-0.56	8.3e-12	Migraine;
TGCT	cis	rs2645424	0.666	rs2272767	chr8:11711059	C/T	cg18999641	chr8:11876646	NA	0.21	4.53	0.38	1.39e-5	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
TGCT	cis	rs9650657	0.504	rs10109167	chr8:11033525	C/T	cg21775007	chr8:11205619	TDH	-0.49	-4.56	-0.38	1.19e-5	Neuroticism;
TGCT	cis	rs62244186	1.000	rs62244186	chr3:44739783	G/A	cg10263370	chr3:44754102	ZNF502	-0.45	-5.43	-0.44	2.89e-7	Depressive symptoms;
TGCT	cis	rs9818758	0.556	rs116432667	chr3:48947589	C/T	cg07636037	chr3:49044803	WDR6	-1.0	-4.98	-0.41	2.11e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs12477438	0.520	rs6542863	chr2:99725138	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.82	0.62	8.67e-15	Chronic sinus infection;
TGCT	cis	rs6988636	1.000	rs28600861	chr8:124189063	C/T	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs3820068	0.580	rs12746773	chr1:16001588	C/T	cg05660106	chr1:15850417	CASP9	0.65	5.82	0.46	4.66e-8	Systolic blood pressure;
TGCT	cis	rs4455778	0.580	rs4917034	chr7:49113788	T/C	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs1348850	0.632	rs1358328	chr2:178517532	G/A	cg22681709	chr2:178499509	PDE11A	-0.5	-6.0	-0.47	1.99e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg24578937	chr1:2090814	PRKCZ	-0.25	-6.21	-0.49	7.4e-9	Height;
TGCT	cis	rs174601	0.861	rs174584	chr11:61610750	G/A	cg01500311	chr11:61656094	FADS3	-0.32	-5.42	-0.44	2.96e-7	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
TGCT	cis	rs9368481	0.729	rs10946881	chr6:26914611	C/T	cg02458000	chr6:26745757	NA	0.61	5.41	0.44	3.1e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2115630	1.000	rs1030863	chr15:85282635	C/T	cg11189052	chr15:85197271	WDR73	-0.63	-6.04	-0.48	1.67e-8	P wave terminal force;
TGCT	cis	rs2075165	0.901	rs7522860	chr1:156275281	C/T	cg16558208	chr1:156270281	VHLL	0.29	5.39	0.44	3.43e-7	Tonsillectomy;
TGCT	cis	rs9549260	0.755	rs7333037	chr13:41215256	A/T	cg21288729	chr13:41239152	FOXO1	0.97	10.09	0.67	7.57e-18	Red blood cell count;
TGCT	cis	rs7267979	1.000	rs398036	chr20:25439850	C/T	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10791097	0.694	rs2236717	chr11:130739887	G/T	cg12179176	chr11:130786555	SNX19	0.84	10.17	0.67	4.95e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs4372836	0.729	rs10198789	chr2:28968811	C/T	cg09522027	chr2:28974177	PPP1CB	-0.63	-6.25	-0.49	6.12e-9	Body mass index;
TGCT	trans	rs208520	0.690	rs207114	chr6:66791703	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-10.93	-0.7	7.05e-20	Exhaled nitric oxide output;
TGCT	cis	rs1008375	0.898	rs9998130	chr4:17593905	A/G	cg16339924	chr4:17578868	LAP3	0.83	6.98	0.53	1.54e-10	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	trans	rs3780486	0.846	rs10813950	chr9:33127640	A/G	cg20290983	chr6:43655470	MRPS18A	-0.95	-7.85	-0.58	1.64e-12	IgG glycosylation;
TGCT	cis	rs7781977	1.000	rs7781977	chr7:50346134	C/T	cg01139861	chr7:50343298	IKZF1	0.54	5.67	0.45	9.61e-8	IgG glycosylation;
TGCT	cis	rs138055607	1	rs138055607	chr10:75450901	C/G	cg07699608	chr10:75541558	CHCHD1	0.7	4.84	0.4	3.79e-6	Initial pursuit acceleration;
TGCT	cis	rs7267979	0.816	rs443009	chr20:25499817	A/G	cg03522245	chr20:25566470	NINL	-0.48	-4.87	-0.4	3.34e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs854765	0.547	rs28537385	chr17:17902135	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.78	8.1	0.59	4.3e-13	Total body bone mineral density;
TGCT	cis	rs2486012	1.000	rs17474535	chr1:44353084	A/G	cg12908607	chr1:44402522	ARTN	0.71	5.86	0.47	3.87e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg13732083	chr21:47605072	C21orf56	0.34	4.48	0.37	1.68e-5	Testicular germ cell tumor;
TGCT	cis	rs514406	0.893	rs1242315	chr1:53417181	A/G	cg08859206	chr1:53392774	SCP2	-0.41	-6.27	-0.49	5.57e-9	Monocyte count;
TGCT	cis	rs2882877	0.513	rs10206897	chr2:190459793	A/T	cg10752008	chr2:190445175	SLC40A1	-0.76	-6.87	-0.53	2.74e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs6582630	0.576	rs4882375	chr12:38371939	G/T	cg26384229	chr12:38710491	ALG10B	-0.52	-4.51	-0.38	1.5e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg00684032	chr4:1343700	KIAA1530	0.25	5.09	0.42	1.31e-6	Obesity-related traits;
TGCT	cis	rs9943465	0.539	rs7068530	chr10:131990328	T/C	cg00179795	chr10:131695114	EBF3	-0.36	-4.63	-0.38	9.19e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs7267979	0.966	rs2263204	chr20:25377688	A/T	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg07507251	chr3:52567010	NT5DC2	0.47	6.7	0.52	6.47e-10	Bipolar disorder;
TGCT	cis	rs6490294	0.904	rs7304572	chr12:112525073	C/T	cg10833066	chr12:111807467	FAM109A	0.37	5.58	0.45	1.46e-7	Mean platelet volume;
TGCT	cis	rs11252926	0.550	rs10795122	chr10:466830	C/T	cg13477178	chr10:375248	DIP2C	-0.24	-4.45	-0.37	1.88e-5	Psychosis in Alzheimer's disease;
TGCT	cis	rs4478858	0.735	rs4949393	chr1:31851875	G/A	cg07478791	chr1:31886160	SERINC2	-0.49	-4.73	-0.39	5.88e-6	Alcohol dependence;
TGCT	cis	rs9611519	0.590	rs4821980	chr22:41415479	C/G	cg06634786	chr22:41940651	POLR3H	-0.49	-4.54	-0.38	1.33e-5	Neuroticism;
TGCT	cis	rs6964587	0.692	rs12536220	chr7:91805595	T/G	cg17063962	chr7:91808500	NA	0.74	6.94	0.53	1.93e-10	Breast cancer;
TGCT	trans	rs877282	0.947	rs7475589	chr10:767479	C/G	cg22713356	chr15:30763199	NA	1.17	9.64	0.65	9.24e-17	Uric acid levels;
TGCT	cis	rs302972	0.826	rs303011	chr6:25080848	A/C	cg18428180	chr6:24646492	KIAA0319	-1.03	-4.51	-0.38	1.49e-5	Creatinine levels in ischemic stroke;
TGCT	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.61	0.38	9.85e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9467773	1.000	rs6930120	chr6:26555484	A/G	cg09904177	chr6:26538194	HMGN4	0.66	6.6	0.51	1.05e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs2153535	0.580	rs9406161	chr6:8466144	G/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg00149659	chr3:10157352	C3orf10	0.81	5.21	0.42	7.72e-7	Alzheimer's disease;
TGCT	cis	rs1865760	1.000	rs9348698	chr6:25929689	T/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.65	6.18	0.49	8.63e-9	Height;
TGCT	cis	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg18252515	chr7:66147081	NA	1.2	7.83	0.58	1.89e-12	Diabetic kidney disease;
TGCT	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.07	0.48	1.47e-8	Bipolar disorder;
TGCT	cis	rs1691799	0.867	rs1495497	chr12:66770020	A/T	cg16791601	chr12:66731901	HELB	-0.28	-5.88	-0.47	3.51e-8	White blood cell count (basophil);
TGCT	cis	rs13191362	0.507	rs2846535	chr6:163034019	T/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.58	-5.72	-0.46	7.5e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs981844	1.000	rs2606329	chr4:154654643	A/C	cg14289246	chr4:154710475	SFRP2	1.05	8.74	0.62	1.39e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs68170813	0.559	rs12534676	chr7:106943640	G/A	cg02696742	chr7:106810147	HBP1	-0.69	-5.81	-0.46	4.85e-8	Coronary artery disease;
TGCT	cis	rs10426930	0.752	rs10401934	chr19:5038715	C/T	cg09001777	chr19:5851504	FUT3	0.21	4.46	0.37	1.78e-5	Monocyte percentage of white cells;
TGCT	cis	rs1023500	0.551	rs4822076	chr22:42364057	C/T	cg04692870	chr22:42525206	CYP2D6	0.32	5.06	0.41	1.47e-6	Schizophrenia;
TGCT	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg07424592	chr7:64974309	NA	-0.65	-6.34	-0.49	3.83e-9	Calcium levels;
TGCT	trans	rs1973993	0.934	rs588660	chr1:96886604	G/A	cg10631902	chr5:14652156	NA	0.35	7.94	0.58	1.04e-12	Weight;
TGCT	cis	rs7647973	1.000	rs1009051	chr3:49521549	G/A	cg07690219	chr3:49449608	TCTA;RHOA	-0.53	-4.45	-0.37	1.87e-5	Menarche (age at onset);
TGCT	cis	rs514406	0.621	rs928452	chr1:53195926	G/C	cg08859206	chr1:53392774	SCP2	0.34	4.82	0.4	4.1e-6	Monocyte count;
TGCT	cis	rs4819052	0.679	rs2838859	chr21:46684517	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.64	6.19	0.49	8.26e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6693567	0.565	rs12731296	chr1:150411787	A/G	cg09579323	chr1:150459698	TARS2	0.52	4.62	0.38	9.56e-6	Migraine;
TGCT	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg08048268	chr3:133502702	NA	-0.64	-9.25	-0.64	8.35e-16	Iron status biomarkers;
TGCT	cis	rs12908161	0.920	rs35738019	chr15:85280210	T/C	cg17173187	chr15:85201210	NMB	0.59	6.57	0.51	1.22e-9	Schizophrenia;
TGCT	cis	rs9581857	0.685	rs9319371	chr13:28042564	A/G	cg22138327	chr13:27999177	GTF3A	0.72	4.6	0.38	1.03e-5	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg07424592	chr7:64974309	NA	-0.57	-5.55	-0.45	1.65e-7	Calcium levels;
TGCT	cis	rs7100689	0.646	rs1340374	chr10:82129114	C/T	cg01528321	chr10:82214614	TSPAN14	0.8	7.76	0.57	2.7e-12	Post bronchodilator FEV1;
TGCT	cis	rs7085104	0.700	rs743572	chr10:104597152	A/G	cg05855489	chr10:104503620	C10orf26	0.54	4.88	0.4	3.15e-6	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs75229567	0.618	rs1882194	chr12:70215086	C/G	cg10114359	chr12:70132523	RAB3IP	-1.06	-5.93	-0.47	2.81e-8	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
TGCT	cis	rs514406	0.698	rs1672913	chr1:53408326	A/T	cg08859206	chr1:53392774	SCP2	-0.45	-7.37	-0.55	2.16e-11	Monocyte count;
TGCT	cis	rs62244186	0.659	rs56231820	chr3:44530329	C/T	cg10263370	chr3:44754102	ZNF502	-0.39	-4.8	-0.4	4.41e-6	Depressive symptoms;
TGCT	cis	rs17665859	0.844	rs17738513	chr8:446359	G/T	cg17960703	chr8:356704	FBXO25	-1.4	-5.27	-0.43	5.9e-7	Bilirubin levels;
TGCT	cis	rs916888	0.697	rs199516	chr17:44856485	C/T	cg01570182	chr17:44337453	NA	-1.01	-9.24	-0.64	8.71e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs6460942	0.908	rs6956500	chr7:12232120	T/C	cg06484146	chr7:12443880	VWDE	-0.57	-4.74	-0.39	5.65e-6	Coronary artery disease;
TGCT	trans	rs7618501	1.000	rs6775384	chr3:49853073	G/A	cg21659725	chr3:3221576	CRBN	0.98	15.33	0.81	2.08e-30	Intelligence (multi-trait analysis);
TGCT	cis	rs17376456	0.877	rs10476596	chr5:93367074	C/T	cg21475434	chr5:93447410	FAM172A	-0.6	-4.62	-0.38	9.48e-6	Diabetic retinopathy;
TGCT	cis	rs981844	0.712	rs1037646	chr4:154738015	C/T	cg14289246	chr4:154710475	SFRP2	-1.0	-9.32	-0.64	5.46e-16	Response to statins (LDL cholesterol change);
TGCT	cis	rs3847687	0.966	rs3847689	chr12:131525534	T/G	cg13586425	chr12:131519906	GPR133	-0.33	-5.26	-0.43	6.17e-7	Longevity;
TGCT	cis	rs11209185	0.509	rs1926279	chr1:68450681	A/G	cg22082780	chr1:68452167	NA	0.31	4.67	0.39	7.66e-6	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs651907	0.514	rs12636046	chr3:101434448	T/G	cg12386194	chr3:101231763	SENP7	0.51	4.9	0.4	2.89e-6	Colorectal cancer;
TGCT	cis	rs13256369	0.951	rs13259955	chr8:8565885	C/G	cg06671706	chr8:8559999	CLDN23	0.34	4.59	0.38	1.09e-5	Obesity-related traits;
TGCT	cis	rs2456568	0.803	rs10831142	chr11:93640781	A/G	cg14065697	chr11:93583672	C11orf90	0.4	5.02	0.41	1.78e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs6546537	0.868	rs62133967	chr2:69891708	G/C	cg10773587	chr2:69614142	GFPT1	-0.82	-7.07	-0.54	1.01e-10	Serum thyroid-stimulating hormone levels;
TGCT	cis	rs62380364	0.692	rs61104616	chr5:88163771	G/A	cg22951263	chr5:87985283	NA	-0.52	-5.32	-0.43	4.77e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs617219	0.671	rs6414979	chr5:78548010	T/G	cg23987322	chr5:78407566	BHMT	0.36	4.66	0.39	8.06e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.63	-0.51	9.04e-10	Alzheimer's disease;
TGCT	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg06618935	chr21:46677482	NA	0.36	5.76	0.46	6.18e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs4788570	0.566	rs1804984	chr16:71481520	T/A	cg06353428	chr16:71660113	MARVELD3	-1.32	-7.86	-0.58	1.6e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs4366490	0.848	rs2839987	chr11:62904137	T/G	cg21002970	chr11:62369079	MTA2	0.87	4.67	0.39	7.78e-6	Conotruncal heart defects;
TGCT	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg08736216	chr1:53307985	ZYG11A	-0.25	-4.92	-0.4	2.7e-6	Monocyte count;
TGCT	cis	rs9359856	0.623	rs1179907	chr6:90324849	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.43	-4.69	-0.39	7.15e-6	Bipolar disorder;
TGCT	cis	rs10883723	0.810	rs1884929	chr10:104275418	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg12963246	chr6:28129442	ZNF389	0.52	5.01	0.41	1.85e-6	Parkinson's disease;
TGCT	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	5.08	0.42	1.35e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg26818010	chr10:134567672	INPP5A	-0.38	-5.21	-0.42	7.61e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs2115630	0.936	rs8033459	chr15:85253258	C/T	cg12863693	chr15:85201151	NMB	-0.33	-4.51	-0.38	1.48e-5	P wave terminal force;
TGCT	cis	rs9291683	0.588	rs4697705	chr4:10108127	G/A	cg11266682	chr4:10021025	SLC2A9	-0.43	-5.16	-0.42	9.47e-7	Bone mineral density;
TGCT	cis	rs9894429	0.966	rs10871499	chr17:79589006	G/A	cg18240062	chr17:79603768	NPLOC4	0.67	6.85	0.52	3.11e-10	Eye color traits;
TGCT	cis	rs7267979	0.873	rs6132822	chr20:25228695	C/T	cg14121845	chr20:25566513	NINL	0.47	4.84	0.4	3.73e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs912057	0.526	rs1294400	chr6:6733421	A/G	cg06612196	chr6:6737390	NA	-0.46	-6.77	-0.52	4.57e-10	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs9443645	0.901	rs6937465	chr6:79570345	G/T	cg09184832	chr6:79620586	NA	-0.48	-5.17	-0.42	9.23e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1865760	1.000	rs3799371	chr6:25912816	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.65	-6.36	-0.5	3.54e-9	Height;
TGCT	trans	rs2688608	0.736	rs2227566	chr10:75673731	C/T	cg13918328	chr10:52500089	ASAH2B	0.68	6.8	0.52	3.96e-10	Inflammatory bowel disease;
TGCT	cis	rs11948739	0.539	rs1119863	chr5:130282399	T/G	cg08523029	chr5:130500466	HINT1	0.6	4.9	0.4	2.88e-6	Pediatric bone mineral content (hip);
TGCT	cis	rs911555	0.723	rs6575991	chr14:103908433	C/T	cg23461800	chr14:103021989	NA	-0.34	-4.5	-0.37	1.57e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs4141404	0.701	rs1985531	chr22:31566177	T/G	cg02404636	chr22:31891804	SFI1	-0.31	-4.65	-0.39	8.51e-6	Paclitaxel-induced neuropathy;
TGCT	cis	rs227584	0.663	rs2040810	chr17:42243771	C/T	cg19774624	chr17:42201019	HDAC5	0.64	6.82	0.52	3.47e-10	Bone mineral density (hip);Bone mineral density;
TGCT	cis	rs3776081	0.555	rs56293808	chr5:149538157	T/C	cg18424208	chr5:149546337	CDX1	-0.25	-4.57	-0.38	1.16e-5	Blood protein levels;
TGCT	cis	rs7568458	0.709	rs2028898	chr2:85777270	G/A	cg02493740	chr2:85810744	VAMP5	-0.28	-5.26	-0.43	6.1e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs155076	1.000	rs2783107	chr13:21837532	C/A	cg11317459	chr13:21872234	NA	-1.42	-12.02	-0.73	1.53e-22	White matter hyperintensity burden;
TGCT	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg24829409	chr8:58192753	C8orf71	-0.57	-5.37	-0.43	3.74e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs11065961	1	rs11065961	chr12:112023067	G/A	cg10833066	chr12:111807467	FAM109A	-0.37	-5.99	-0.47	2.15e-8	Platelet distribution width;
TGCT	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg05368731	chr17:41323189	NBR1	1.02	11.4	0.72	5.02e-21	Menopause (age at onset);
TGCT	cis	rs12142240	0.698	rs17357635	chr1:46808668	G/A	cg14993813	chr1:46806288	NSUN4	-0.58	-4.81	-0.4	4.34e-6	Menopause (age at onset);
TGCT	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg24829409	chr8:58192753	C8orf71	-0.55	-5.2	-0.42	8.06e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9467773	0.595	rs4320356	chr6:26423560	C/T	cg05738196	chr6:26577821	NA	-0.52	-5.52	-0.44	1.88e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs826838	0.585	rs12296822	chr12:38625829	A/T	cg26384229	chr12:38710491	ALG10B	-0.54	-4.74	-0.39	5.87e-6	Heart rate;
TGCT	cis	rs2721195	1.000	rs1871541	chr8:145681713	G/T	cg15320075	chr8:145703422	NA	-0.68	-6.82	-0.52	3.52e-10	Age at first birth;
TGCT	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg21862992	chr11:68658383	NA	0.46	6.52	0.51	1.6e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs12188164	1.000	rs72717412	chr5:429381	C/T	cg21144161	chr5:423903	AHRR	0.26	4.93	0.4	2.59e-6	Cystic fibrosis severity;
TGCT	trans	rs1908814	0.516	rs60176945	chr8:11796674	T/C	cg15556689	chr8:8085844	FLJ10661	0.75	7.07	0.54	9.74e-11	Neuroticism;
TGCT	cis	rs2115630	0.645	rs2292463	chr15:85175750	A/G	cg11189052	chr15:85197271	WDR73	-0.75	-7.17	-0.54	5.89e-11	P wave terminal force;
TGCT	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7666738	0.830	rs9999200	chr4:99030690	A/C	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7017914	0.967	rs13255735	chr8:71859739	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.55	-5.29	-0.43	5.4e-7	Bone mineral density;
TGCT	cis	rs1894292	0.527	rs1997333	chr4:74374425	G/A	cg05868023	chr4:75230803	EREG	0.56	5.05	0.41	1.56e-6	Prostate cancer;
TGCT	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg06028808	chr11:68637592	NA	0.52	6.67	0.51	7.43e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7264396	0.561	rs2050930	chr20:34579397	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.28	-4.81	-0.4	4.29e-6	Total cholesterol levels;
TGCT	cis	rs4851254	0.626	rs71413861	chr2:100673501	A/G	cg22139774	chr2:100720529	AFF3	-0.45	-4.91	-0.4	2.75e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg03404566	chr17:6899310	ALOX12	0.45	5.12	0.42	1.14e-6	Tonsillectomy;
TGCT	cis	rs7095607	0.606	rs4746737	chr10:69959779	T/C	cg18986048	chr10:69913749	MYPN	0.59	6.2	0.49	7.86e-9	Lung function (FVC);
TGCT	cis	rs854765	0.583	rs4925125	chr17:17794444	T/C	cg09796270	chr17:17721594	SREBF1	-0.23	-4.69	-0.39	7.14e-6	Total body bone mineral density;
TGCT	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg23172400	chr8:95962367	TP53INP1	-0.38	-6.49	-0.5	1.84e-9	Type 2 diabetes;
TGCT	cis	rs2204008	0.555	rs7310307	chr12:38107497	G/T	cg26384229	chr12:38710491	ALG10B	0.85	7.57	0.56	7.57e-12	Bladder cancer;
TGCT	cis	rs6882076	1.000	rs6878680	chr5:156387137	G/C	cg12943317	chr5:156479607	HAVCR1	-0.29	-5.27	-0.43	5.93e-7	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
TGCT	cis	rs3806843	0.517	rs246031	chr5:140333107	G/A	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg03934478	chr11:495069	RNH1	0.35	5.77	0.46	6.03e-8	Body mass index;
TGCT	cis	rs1008375	0.897	rs6820164	chr4:17630115	G/A	cg10189774	chr4:17578691	LAP3	0.64	5.47	0.44	2.42e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg17509989	chr5:176798049	RGS14	-0.77	-12.25	-0.74	4.2e-23	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg18230493	chr5:56204884	C5orf35	-0.68	-5.85	-0.46	4.13e-8	Initial pursuit acceleration;
TGCT	cis	rs909674	0.690	rs5750825	chr22:39831278	A/G	cg11247378	chr22:39784982	NA	-0.73	-8.55	-0.61	3.78e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs13217239	0.646	rs6456767	chr6:27070543	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.42	-4.61	-0.38	9.71e-6	Schizophrenia;
TGCT	cis	rs9611519	0.929	rs73174660	chr22:41437304	T/C	cg13695892	chr22:41940480	POLR3H	-0.55	-4.9	-0.4	2.99e-6	Neuroticism;
TGCT	cis	rs7552404	0.807	rs2066183	chr1:76153745	A/G	cg03433033	chr1:76189801	ACADM	0.82	9.89	0.66	2.31e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg06238570	chr21:40685208	BRWD1	-0.8	-9.1	-0.63	1.91e-15	Cognitive function;
TGCT	cis	rs4242434	0.927	rs13264187	chr8:22506098	C/T	cg03733263	chr8:22462867	KIAA1967	1.15	17.7	0.85	9.76e-36	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg25036284	chr2:26402008	FAM59B	0.65	5.19	0.42	8.36e-7	Gut microbiome composition (summer);
TGCT	cis	rs7897654	0.571	rs12767543	chr10:104631663	G/A	cg15744005	chr10:104629667	AS3MT	-0.45	-4.52	-0.38	1.45e-5	Schizophrenia;
TGCT	cis	rs2204008	0.806	rs7305409	chr12:38349133	G/A	cg26384229	chr12:38710491	ALG10B	0.83	7.25	0.55	4e-11	Bladder cancer;
TGCT	cis	rs4478858	0.735	rs10914344	chr1:31769025	T/C	cg07478791	chr1:31886160	SERINC2	-0.49	-4.92	-0.4	2.73e-6	Alcohol dependence;
TGCT	cis	rs10779751	0.922	rs11121708	chr1:11307253	G/C	cg08854313	chr1:11322531	MTOR	0.98	9.12	0.63	1.65e-15	Body mass index;
TGCT	cis	rs2739330	0.964	rs2739338	chr22:24297130	T/C	cg15242686	chr22:24348715	GSTTP1	0.43	5.95	0.47	2.54e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs17376456	0.569	rs10076965	chr5:93094972	G/A	cg21475434	chr5:93447410	FAM172A	0.61	4.95	0.41	2.35e-6	Diabetic retinopathy;
TGCT	cis	rs916888	0.779	rs430685	chr17:44859148	T/C	cg15921436	chr17:44337874	NA	-0.51	-6.96	-0.53	1.77e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs9308731	0.644	rs1054873	chr2:111876148	G/A	cg04202892	chr2:111875749	ACOXL	0.54	6.22	0.49	6.95e-9	Chronic lymphocytic leukemia;
TGCT	cis	rs9807841	0.670	rs8099926	chr19:10778647	A/G	cg17848348	chr19:10766748	ILF3	-0.4	-4.58	-0.38	1.12e-5	Inflammatory skin disease;
TGCT	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg04772025	chr11:68637568	NA	0.6	6.69	0.52	6.8e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7639513	0.767	rs2348201	chr3:12711696	A/G	cg23032965	chr3:12705835	RAF1	0.78	8.62	0.61	2.61e-14	Itch intensity from mosquito bite;
TGCT	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg11764359	chr7:65958608	NA	-0.55	-4.98	-0.41	2.1e-6	Aortic root size;
TGCT	cis	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg15556689	chr8:8085844	FLJ10661	0.67	6.08	0.48	1.38e-8	Mood instability;
TGCT	cis	rs7666738	0.830	rs28451001	chr4:98924544	T/A	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7119	0.651	rs12904200	chr15:77845902	C/G	cg27398640	chr15:77910606	LINGO1	-0.28	-5.11	-0.42	1.21e-6	Type 2 diabetes;
TGCT	cis	rs8017423	0.935	rs10147186	chr14:90779879	G/C	cg04374321	chr14:90722782	PSMC1	0.74	7.09	0.54	8.75e-11	Mortality in heart failure;
TGCT	cis	rs9650657	0.572	rs11250098	chr8:10818607	A/G	cg21775007	chr8:11205619	TDH	-0.53	-5.0	-0.41	1.93e-6	Neuroticism;
TGCT	cis	rs17152411	1.000	rs7092008	chr10:126638226	G/A	cg07906193	chr10:126599966	NA	0.41	5.11	0.42	1.18e-6	Height;
TGCT	cis	rs4906332	0.966	rs7401563	chr14:103964425	G/A	cg26031613	chr14:104095156	KLC1	-0.51	-4.51	-0.38	1.48e-5	Coronary artery disease;
TGCT	cis	rs4253772	0.591	rs6008538	chr22:46685963	G/A	cg24881330	chr22:46731750	TRMU	0.96	6.38	0.5	3.18e-9	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	5.93	0.47	2.8e-8	Bipolar disorder;
TGCT	trans	rs57221529	0.709	rs72703090	chr5:598314	C/T	cg11887960	chr12:57824829	NA	1.2	9.56	0.65	1.47e-16	Lung disease severity in cystic fibrosis;
TGCT	cis	rs2115630	1.000	rs10220733	chr15:85280864	G/A	cg11189052	chr15:85197271	WDR73	-0.63	-6.04	-0.48	1.67e-8	P wave terminal force;
TGCT	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg10047753	chr17:41438598	NA	-0.94	-9.23	-0.64	9.06e-16	Menopause (age at onset);
TGCT	cis	rs9393692	0.905	rs4412192	chr6:26290377	A/G	cg00631329	chr6:26305371	NA	0.41	6.09	0.48	1.34e-8	Educational attainment;
TGCT	cis	rs6964587	0.967	rs12531966	chr7:91765840	A/G	cg22709100	chr7:91322751	NA	0.29	4.58	0.38	1.13e-5	Breast cancer;
TGCT	cis	rs56104184	0.830	rs28556985	chr19:49351149	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.81	-9.48	-0.65	2.33e-16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.44	6.28	0.49	5.28e-9	Lymphocyte counts;
TGCT	cis	rs7568458	0.846	rs6705839	chr2:85761279	A/T	cg17127132	chr2:85788382	GGCX	0.56	5.39	0.44	3.47e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs782590	0.967	rs1975487	chr2:55809054	A/G	cg03859395	chr2:55845619	SMEK2	0.91	11.13	0.71	2.26e-20	Metabolic syndrome;
TGCT	cis	rs7666738	0.830	rs12233741	chr4:98950296	C/T	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1008375	0.966	rs2286773	chr4:17616214	C/A	cg16339924	chr4:17578868	LAP3	0.68	5.6	0.45	1.33e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	trans	rs9929218	0.508	rs6499194	chr16:68744100	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.62	8.1	0.59	4.5e-13	Colorectal cancer;
TGCT	cis	rs2885056	0.800	rs8105074	chr19:10708692	A/G	cg04833646	chr19:10679720	CDKN2D	0.96	9.21	0.64	1.01e-15	Red cell distribution width;
TGCT	cis	rs9807989	0.765	rs6704565	chr2:102967431	G/A	cg09003973	chr2:102972529	NA	0.64	5.7	0.46	8.28e-8	Asthma;
TGCT	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	5.35	0.43	4.14e-7	Height;
TGCT	cis	rs2692947	0.644	rs1030864	chr2:96822373	A/G	cg22654517	chr2:96458247	NA	0.23	4.91	0.4	2.8e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs617219	0.659	rs13182512	chr5:78573790	A/T	cg09550809	chr5:78407562	BHMT	-0.37	-5.24	-0.43	6.65e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.37	-4.44	-0.37	1.98e-5	Total body bone mineral density;
TGCT	cis	rs514406	0.570	rs1332776	chr1:53189816	C/T	cg24675658	chr1:53192096	ZYG11B	-0.88	-12.64	-0.75	4.86e-24	Monocyte count;
TGCT	cis	rs6121246	0.522	rs6088736	chr20:30195166	C/G	cg13852791	chr20:30311386	BCL2L1	0.69	4.54	0.38	1.33e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs7524258	0.868	rs4243824	chr1:7289777	G/A	cg07173049	chr1:7289937	CAMTA1	0.29	4.91	0.4	2.81e-6	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs7666738	0.830	rs11947578	chr4:98930462	T/G	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs681343	1.000	rs679574	chr19:49206108	C/G	cg13540341	chr19:49222985	MAMSTR	-0.33	-4.48	-0.37	1.69e-5	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
TGCT	cis	rs12478296	0.901	rs58906257	chr2:243028248	T/C	cg06360820	chr2:242988706	NA	-0.58	-4.62	-0.38	9.32e-6	Obesity-related traits;
TGCT	cis	rs9902453	1.000	rs56280226	chr17:28429575	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.74	6.57	0.51	1.22e-9	Coffee consumption (cups per day);
TGCT	cis	rs17401966	0.838	rs912963	chr1:10348042	C/T	cg19773385	chr1:10388646	KIF1B	-0.21	-4.79	-0.4	4.59e-6	Hepatocellular carcinoma;
TGCT	cis	rs9291683	0.588	rs34501273	chr4:9996996	C/T	cg00071950	chr4:10020882	SLC2A9	0.74	9.16	0.64	1.33e-15	Bone mineral density;
TGCT	cis	rs17253792	0.822	rs77415412	chr14:56154146	A/G	cg01858014	chr14:56050164	KTN1	-0.35	-4.62	-0.38	9.37e-6	Putamen volume;
TGCT	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg11494091	chr17:61959527	GH2	0.42	7.46	0.56	1.29e-11	Height;
TGCT	cis	rs7100689	0.622	rs10887798	chr10:82131613	G/A	cg01528321	chr10:82214614	TSPAN14	0.78	7.61	0.56	5.85e-12	Post bronchodilator FEV1;
TGCT	cis	rs62244186	0.714	rs2293600	chr3:44599103	G/T	cg10263370	chr3:44754102	ZNF502	0.43	5.1	0.42	1.21e-6	Depressive symptoms;
TGCT	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg00149659	chr3:10157352	C3orf10	1.18	7.44	0.56	1.44e-11	Alzheimer's disease;
TGCT	cis	rs9682041	0.877	rs9682908	chr3:170072010	C/T	cg11886554	chr3:170076028	SKIL	0.55	4.58	0.38	1.11e-5	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.54	4.74	0.39	5.79e-6	Prudent dietary pattern;
TGCT	cis	rs1577917	0.740	rs12212560	chr6:86342679	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.54	-4.87	-0.4	3.28e-6	Response to antipsychotic treatment;
TGCT	cis	rs9790314	0.846	rs4560315	chr3:160982132	G/T	cg03342759	chr3:160939853	NMD3	-0.51	-5.66	-0.45	9.96e-8	Morning vs. evening chronotype;
TGCT	cis	rs10255878	0.500	rs11975657	chr7:97040014	C/T	cg01534613	chr7:96337050	SHFM1	0.29	4.44	0.37	1.97e-5	Adverse response to radiation therapy;
TGCT	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg27286337	chr10:134555280	INPP5A	0.42	5.28	0.43	5.56e-7	Migraine;
TGCT	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.85	-8.21	-0.59	2.42e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9443645	0.901	rs9352670	chr6:79584433	A/G	cg09184832	chr6:79620586	NA	-0.49	-5.29	-0.43	5.29e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1334894	1.000	rs113244441	chr6:35528690	C/A	cg24281267	chr6:35479648	TULP1	-0.43	-4.47	-0.37	1.78e-5	Coronary artery disease;
TGCT	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	0.48	6.74	0.52	5.26e-10	Alzheimer's disease;
TGCT	cis	rs4689388	0.889	rs13101355	chr4:6293446	T/C	cg25554036	chr4:6271136	WFS1	0.54	7.37	0.55	2.11e-11	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs3812831	0.695	rs423237	chr13:114930955	C/T	cg15513719	chr13:114904418	NA	0.38	4.65	0.39	8.31e-6	Schizophrenia;
TGCT	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg02725872	chr8:58115012	NA	-0.39	-4.83	-0.4	3.9e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9611565	0.503	rs5751156	chr22:42170025	A/G	cg06481639	chr22:41940642	POLR3H	0.68	5.95	0.47	2.59e-8	Vitiligo;
TGCT	cis	rs7772486	0.790	rs9497424	chr6:146225271	C/A	cg23711669	chr6:146136114	FBXO30	-0.85	-9.77	-0.66	4.46e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9640161	0.830	rs13307276	chr7:150061525	T/C	cg10018233	chr7:150070692	REPIN1	0.31	4.73	0.39	5.9e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg00149659	chr3:10157352	C3orf10	0.91	5.89	0.47	3.32e-8	Alzheimer's disease;
TGCT	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg06618935	chr21:46677482	NA	-0.37	-4.94	-0.41	2.5e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs4455778	0.580	rs6952911	chr7:49092794	C/T	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs4555082	0.874	rs2816620	chr14:105732704	G/T	cg01266790	chr14:105781312	PACS2	0.56	4.6	0.38	1.04e-5	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs10254284	0.885	rs10276070	chr7:28150689	T/C	cg23620719	chr7:28220237	JAZF1	-0.53	-4.69	-0.39	7.18e-6	Lymphocyte percentage of white cells;Systemic lupus erythematosus;
TGCT	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg08859206	chr1:53392774	SCP2	0.4	5.96	0.47	2.46e-8	Monocyte count;
TGCT	trans	rs1814175	0.817	rs10839318	chr11:49657511	G/C	cg03929089	chr4:120376271	NA	-0.74	-8.94	-0.63	4.49e-15	Height;
TGCT	cis	rs4237845	0.788	rs6581157	chr12:58288793	C/T	cg23860436	chr12:58378763	NA	0.37	5.31	0.43	4.9e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.69	4.91	0.4	2.75e-6	Platelet count;
TGCT	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg23205692	chr1:25664452	TMEM50A	-0.47	-4.88	-0.4	3.21e-6	Erythrocyte sedimentation rate;
TGCT	cis	rs7698623	0.850	rs4693892	chr4:88796983	T/G	cg02735620	chr4:88950514	PKD2	-0.44	-4.81	-0.4	4.22e-6	Cardiovascular disease risk factors;
TGCT	cis	rs1692580	0.870	rs262680	chr1:2167149	C/T	cg24578937	chr1:2090814	PRKCZ	0.21	4.68	0.39	7.54e-6	Coronary artery disease;
TGCT	cis	rs922182	0.569	rs7180050	chr15:64263784	G/A	cg02919090	chr15:64263738	DAPK2	0.36	6.87	0.53	2.76e-10	Blood protein levels;
TGCT	cis	rs10501293	0.746	rs7929831	chr11:43006825	G/A	cg03447554	chr11:43094025	NA	0.44	6.28	0.49	5.2e-9	Cognitive performance;
TGCT	cis	rs9388451	0.657	rs4895799	chr6:126052729	C/T	cg05901451	chr6:126070800	HEY2	-0.92	-9.7	-0.66	6.85e-17	Brugada syndrome;
TGCT	cis	rs344364	0.511	rs1742473	chr16:1953095	T/C	cg26617929	chr16:1858877	NA	-0.26	-4.66	-0.39	8.04e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs9527	0.615	rs12248123	chr10:104735366	A/G	cg15744005	chr10:104629667	AS3MT	-0.47	-5.57	-0.45	1.47e-7	Arsenic metabolism;
TGCT	cis	rs881375	1.000	rs7037140	chr9:123656327	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	5.34	0.43	4.31e-7	Rheumatoid arthritis;
TGCT	cis	rs9942416	0.650	rs2640646	chr5:74977458	A/T	cg19683494	chr5:74908142	NA	-0.6	-6.37	-0.5	3.39e-9	Age-related disease endophenotypes;
TGCT	cis	rs6121246	0.559	rs6087779	chr20:30370566	T/C	cg13852791	chr20:30311386	BCL2L1	0.82	8.0	0.58	7.65e-13	Mean corpuscular hemoglobin;
TGCT	cis	rs7208859	0.623	rs11657662	chr17:29076347	A/G	cg13385521	chr17:29058706	SUZ12P	-0.8	-4.85	-0.4	3.66e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs10883723	0.810	rs2296586	chr10:104245575	C/T	cg05855489	chr10:104503620	C10orf26	-0.55	-4.88	-0.4	3.21e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs7172809	0.548	rs75329354	chr15:77668065	C/T	cg22256960	chr15:77711686	NA	-0.51	-4.79	-0.4	4.65e-6	Glucose homeostasis traits;
TGCT	cis	rs2921036	0.545	rs4840975	chr8:8363258	C/T	cg15556689	chr8:8085844	FLJ10661	-0.56	-4.98	-0.41	2.04e-6	Neuroticism;
TGCT	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg11965913	chr1:205819406	PM20D1	0.51	7.2	0.54	5.16e-11	Menarche (age at onset);
TGCT	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg11301795	chr4:187892539	NA	-0.34	-5.03	-0.41	1.68e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11696501	0.694	rs6130870	chr20:44263263	T/C	cg11783356	chr20:44313418	WFDC10B	-0.32	-4.63	-0.38	9.25e-6	Brain structure;
TGCT	cis	rs6840360	0.573	rs7692939	chr4:152258455	C/T	cg17479576	chr4:152424074	FAM160A1	-0.42	-4.51	-0.38	1.5e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs1030877	0.557	rs2278501	chr2:105979506	C/T	cg02079111	chr2:105885981	TGFBRAP1	-0.17	-5.28	-0.43	5.65e-7	Obesity-related traits;
TGCT	trans	rs731174	0.592	rs6699887	chr1:38192604	G/A	cg19725343	chr19:51830960	IGLON5	-0.63	-7.19	-0.54	5.35e-11	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs12210905	0.688	rs72841376	chr6:27456321	G/A	cg08851530	chr6:28072375	NA	1.34	6.29	0.49	5.02e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs7714584	1.000	rs7714415	chr5:150270292	A/G	cg22134413	chr5:150180641	NA	0.78	6.12	0.48	1.16e-8	Crohn's disease;
TGCT	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg03709012	chr19:19516395	GATAD2A	-0.66	-5.7	-0.46	8.46e-8	Tonsillectomy;
TGCT	cis	rs526231	0.853	rs35802	chr5:102607585	A/T	cg05225461	chr5:102596755	C5orf30	0.23	4.65	0.39	8.39e-6	Primary biliary cholangitis;
TGCT	cis	rs7614311	0.594	rs2280162	chr3:63997491	C/T	cg22134162	chr3:63841271	THOC7	-0.31	-4.49	-0.37	1.59e-5	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs7666738	0.830	rs6831588	chr4:98977356	T/G	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs17767294	0.708	rs72845896	chr6:27697645	C/G	cg08851530	chr6:28072375	NA	1.56	7.38	0.55	1.95e-11	Parkinson's disease;
TGCT	cis	rs2033711	0.783	rs11671113	chr19:58958087	C/T	cg13877915	chr19:58951672	ZNF132	0.91	11.5	0.72	2.79e-21	Uric acid clearance;
TGCT	cis	rs7772486	0.686	rs857875	chr6:145980033	T/G	cg23711669	chr6:146136114	FBXO30	-0.83	-9.29	-0.64	6.68e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7582180	0.602	rs7585582	chr2:100998030	G/C	cg08017756	chr2:100939284	LONRF2	-0.31	-5.0	-0.41	1.93e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.791	rs7377018	chr4:99034962	C/T	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs614226	0.516	rs1794748	chr12:120953758	A/G	cg01236616	chr12:121019343	POP5	1.26	13.2	0.76	2.23e-25	Type 1 diabetes nephropathy;
TGCT	cis	rs13242816	0.881	rs17138706	chr7:116109019	A/G	cg02799643	chr7:116139180	CAV2	-0.48	-5.45	-0.44	2.56e-7	P wave duration;
TGCT	cis	rs8038465	0.571	rs7176654	chr15:73999006	C/T	cg15420318	chr15:73925796	NPTN	-0.59	-5.81	-0.46	4.97e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9467773	1.000	rs1321481	chr6:26538210	A/T	cg15659132	chr6:26577336	NA	0.86	12.21	0.74	5.3e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg22166914	chr1:53195759	ZYG11B	0.37	6.41	0.5	2.77e-9	Monocyte count;
TGCT	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg17054783	chr10:134559939	INPP5A	0.26	5.21	0.42	7.76e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs7100689	0.577	rs7901663	chr10:82153488	C/G	cg01528321	chr10:82214614	TSPAN14	0.68	6.8	0.52	4e-10	Post bronchodilator FEV1;
TGCT	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.72	5.19	0.42	8.33e-7	Platelet count;
TGCT	cis	rs7208859	0.623	rs9916725	chr17:29107471	A/C	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs2204008	0.744	rs11519905	chr12:38222959	G/A	cg13010199	chr12:38710504	ALG10B	0.62	4.87	0.4	3.26e-6	Bladder cancer;
TGCT	cis	rs2116941	1.000	rs8104426	chr19:10338676	G/T	cg01850179	chr19:10340795	S1PR2	0.76	10.43	0.68	1.14e-18	Pulse pressure;
TGCT	cis	rs1371867	0.513	rs1542812	chr8:101207064	G/A	cg00191853	chr8:101177733	SPAG1	0.29	6.45	0.5	2.26e-9	Atrioventricular conduction;
TGCT	cis	rs79349575	0.783	rs4294857	chr17:46983391	G/A	cg26022315	chr17:47021804	SNF8	0.48	4.82	0.4	4.06e-6	Type 2 diabetes;
TGCT	cis	rs11711311	0.868	rs13091621	chr3:113481977	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.72	-6.74	-0.52	5.36e-10	IgG glycosylation;
TGCT	cis	rs2742234	0.504	rs7093409	chr10:43740067	A/G	cg02780029	chr10:43622663	RET	0.26	4.91	0.4	2.84e-6	Hirschsprung disease;
TGCT	cis	rs2456568	0.771	rs8181530	chr11:93638678	G/A	cg14065697	chr11:93583672	C11orf90	-0.38	-4.74	-0.39	5.65e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs2346177	0.576	rs1530621	chr2:46688688	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.41	-4.49	-0.37	1.62e-5	HDL cholesterol;
TGCT	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg00343986	chr7:65444356	GUSB	0.26	6.14	0.48	1.05e-8	Aortic root size;
TGCT	cis	rs35160687	0.862	rs13024964	chr2:86511868	G/A	cg03171300	chr2:86307199	POLR1A	0.32	5.39	0.44	3.35e-7	Night sleep phenotypes;
TGCT	cis	rs11785400	0.793	rs4567014	chr8:143737690	G/C	cg10596483	chr8:143751796	JRK	0.55	5.48	0.44	2.29e-7	Schizophrenia;
TGCT	cis	rs10736390	1.000	rs11206402	chr1:55104317	G/C	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.42	-8.1	-0.59	4.34e-13	Survival in pancreatic cancer;
TGCT	cis	rs6121246	0.529	rs6060296	chr20:30198480	T/C	cg13852791	chr20:30311386	BCL2L1	0.7	4.68	0.39	7.29e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs4294134	0.608	rs11763242	chr7:135242973	T/G	cg08396481	chr7:135194601	CNOT4	-0.62	-4.81	-0.4	4.25e-6	Paget's disease;
TGCT	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg15462221	chr8:8086144	FLJ10661	-0.53	-4.71	-0.39	6.46e-6	Systolic blood pressure;
TGCT	cis	rs35306767	0.904	rs10904584	chr10:983747	A/T	cg20503657	chr10:835505	NA	0.58	7.98	0.58	8.43e-13	Eosinophil percentage of granulocytes;
TGCT	cis	rs4494114	1.000	rs10890491	chr1:39354602	G/A	cg25970120	chr1:39325951	RRAGC	-0.6	-6.19	-0.49	8.1e-9	Blood protein levels;
TGCT	cis	rs6088590	1.000	rs6119516	chr20:33328024	C/T	cg06115741	chr20:33292138	TP53INP2	0.66	5.38	0.44	3.54e-7	Coronary artery disease;
TGCT	cis	rs10984561	0.881	rs12235333	chr9:122247927	A/G	cg14242995	chr9:122249943	NA	0.75	6.41	0.5	2.7e-9	Pulmonary function decline;
TGCT	cis	rs7666738	0.791	rs34790496	chr4:98930516	C/T	cg05340658	chr4:99064831	C4orf37	0.53	6.02	0.48	1.8e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg17554472	chr22:41940697	POLR3H	-0.49	-5.27	-0.43	5.9e-7	Vitiligo;
TGCT	cis	rs9291683	0.530	rs4697698	chr4:9942577	C/T	cg00071950	chr4:10020882	SLC2A9	0.68	8.55	0.61	3.91e-14	Bone mineral density;
TGCT	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg18876405	chr7:65276391	NA	-0.34	-5.19	-0.42	8.37e-7	Aortic root size;
TGCT	cis	rs9372498	0.536	rs62424199	chr6:118827252	G/A	cg21191810	chr6:118973309	C6orf204	-0.36	-4.77	-0.39	5.1e-6	Diastolic blood pressure;
TGCT	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg14159672	chr1:205819179	PM20D1	0.62	7.38	0.55	1.99e-11	Menarche (age at onset);
TGCT	cis	rs7208859	0.623	rs3752021	chr17:29111043	G/C	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs861020	0.606	rs629224	chr1:210005071	C/T	cg05527609	chr1:210001259	C1orf107	0.86	7.54	0.56	8.69e-12	Orofacial clefts;
TGCT	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg24829409	chr8:58192753	C8orf71	-0.55	-5.17	-0.42	9.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6484504	0.576	rs208072	chr11:31141288	A/G	cg26647111	chr11:31128758	NA	0.33	4.69	0.39	7.09e-6	Red blood cell count;
TGCT	cis	rs3806843	0.832	rs2531360	chr5:140116664	G/A	cg19875535	chr5:140030758	IK	-0.34	-5.75	-0.46	6.6e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs1775715	0.737	rs11817598	chr10:32206259	A/G	cg14930904	chr10:32216787	ARHGAP12	0.52	5.07	0.41	1.39e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs6089584	0.888	rs6142927	chr20:60605848	A/G	cg13665807	chr20:60559372	TAF4	-0.48	-5.1	-0.42	1.22e-6	Body mass index;
TGCT	cis	rs2637266	0.745	rs241	chr10:78444456	G/T	cg18941641	chr10:78392320	NA	0.37	4.5	0.37	1.57e-5	Pulmonary function;
TGCT	cis	rs12477438	0.520	rs6542870	chr2:99796638	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	13.05	0.76	4.93e-25	Chronic sinus infection;
TGCT	cis	rs68170813	0.559	rs7794598	chr7:106826381	C/T	cg02696742	chr7:106810147	HBP1	-0.73	-6.54	-0.51	1.41e-9	Coronary artery disease;
TGCT	cis	rs6089829	0.888	rs4809268	chr20:61675249	C/G	cg08045932	chr20:61659980	NA	0.5	8.69	0.62	1.75e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1843834	0.755	rs10194591	chr2:225574276	T/A	cg22455342	chr2:225449267	CUL3	0.66	6.28	0.49	5.25e-9	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs3784262	0.935	rs4646636	chr15:58251034	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.5	-7.63	-0.57	5.26e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg00684032	chr4:1343700	KIAA1530	0.23	4.93	0.41	2.55e-6	Obesity-related traits;
TGCT	cis	rs611744	0.967	rs630492	chr8:109215368	C/T	cg21045802	chr8:109455806	TTC35	-0.52	-4.79	-0.4	4.63e-6	Dupuytren's disease;
TGCT	trans	rs1005277	0.505	rs7917943	chr10:38195811	T/A	cg17830980	chr10:43048298	ZNF37B	0.74	8.59	0.61	3.11e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg14893161	chr1:205819251	PM20D1	0.57	8.2	0.59	2.5e-13	Menarche (age at onset);
TGCT	cis	rs13191362	1.000	rs13200329	chr6:163004418	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.57	4.94	0.41	2.45e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs2455799	0.613	rs13096622	chr3:15837656	A/G	cg16303742	chr3:15540471	COLQ	-0.25	-4.88	-0.4	3.19e-6	Mean platelet volume;
TGCT	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg27535305	chr1:53392650	SCP2	-0.27	-5.47	-0.44	2.39e-7	Monocyte count;
TGCT	cis	rs4700695	0.719	rs27588	chr5:65459360	C/A	cg21114390	chr5:65439923	SFRS12	-0.84	-7.33	-0.55	2.58e-11	Facial morphology (factor 19);
TGCT	cis	rs35160687	0.901	rs35762338	chr2:86513553	G/A	cg12542933	chr2:85804724	VAMP8	0.4	4.79	0.39	4.75e-6	Night sleep phenotypes;
TGCT	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg18402987	chr7:1209562	NA	0.38	4.86	0.4	3.51e-6	Longevity;Endometriosis;
TGCT	cis	rs10791323	0.569	rs10791328	chr11:133713730	A/G	cg15485101	chr11:133734466	NA	0.42	5.45	0.44	2.62e-7	Childhood ear infection;
TGCT	cis	rs7043114	0.525	rs7864630	chr9:95267560	A/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-5.37	-0.43	3.72e-7	Height;
TGCT	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs651907	0.535	rs11707250	chr3:101509371	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.51	-4.86	-0.4	3.51e-6	Colorectal cancer;
TGCT	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg20203395	chr5:56204925	C5orf35	-0.61	-5.35	-0.43	4.05e-7	Initial pursuit acceleration;
TGCT	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2439831	1.000	rs1814538	chr15:43759774	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.78	-5.91	-0.47	3.04e-8	Lung cancer in ever smokers;
TGCT	cis	rs79349575	0.783	rs62075839	chr17:46996434	G/C	cg26022315	chr17:47021804	SNF8	0.49	4.89	0.4	3.03e-6	Type 2 diabetes;
TGCT	trans	rs208520	0.690	rs12192710	chr6:66718137	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	11.06	0.7	3.28e-20	Exhaled nitric oxide output;
TGCT	cis	rs1057239	0.510	rs3766694	chr1:175143207	T/C	cg14847009	chr1:175162515	KIAA0040	-0.35	-5.16	-0.42	9.35e-7	Diastolic blood pressure;
TGCT	cis	rs6725041	0.819	rs4350692	chr2:213090220	T/C	cg16329650	chr2:213403929	ERBB4	-0.53	-4.52	-0.38	1.44e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs6920364	1	rs6920364	chr6:167376466	G/C	cg25258033	chr6:167368657	RNASET2	-0.2	-4.82	-0.4	4.19e-6	Lung cancer;
TGCT	cis	rs17221829	0.617	rs11018677	chr11:89362820	C/T	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.67	-0.39	7.58e-6	Anxiety in major depressive disorder;
TGCT	cis	rs28785552	0.931	rs10424385	chr19:53239133	C/G	cg04754360	chr19:53238445	ZNF611	-0.71	-5.64	-0.45	1.11e-7	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs2549003	1.000	rs6894655	chr5:131818649	T/C	cg02551604	chr5:131831745	NA	-0.89	-11.77	-0.73	6.36e-22	Asthma (sex interaction);
TGCT	cis	rs933688	0.639	rs332530	chr5:90789810	G/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.88	7.6	0.56	6.19e-12	Smoking behavior;
TGCT	cis	rs12477438	0.520	rs4850897	chr2:99768419	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	14.89	0.8	2.21e-29	Chronic sinus infection;
TGCT	cis	rs9467773	0.595	rs7767847	chr6:26597893	A/T	cg11502198	chr6:26597334	ABT1	0.54	4.96	0.41	2.31e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9583531	0.689	rs9521905	chr13:111352600	G/A	cg24331049	chr13:111365604	ING1	-0.88	-8.19	-0.59	2.68e-13	Coronary artery disease;
TGCT	cis	rs9914988	0.943	rs9894335	chr17:27138483	C/A	cg20469991	chr17:27169893	C17orf63	-0.72	-5.09	-0.42	1.28e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	trans	rs4332037	0.906	rs62442903	chr7:1953416	G/A	cg25206134	chr2:45395956	NA	1.06	9.01	0.63	3.03e-15	Bipolar disorder;
TGCT	cis	rs9682041	0.866	rs6444926	chr3:170133235	T/C	cg11886554	chr3:170076028	SKIL	0.87	6.38	0.5	3.18e-9	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs4919694	0.572	rs12243903	chr10:104906992	T/C	cg04362960	chr10:104952993	NT5C2	0.97	6.81	0.52	3.82e-10	Arsenic metabolism;
TGCT	cis	rs4824093	0.610	rs56810176	chr22:50303149	G/C	cg20569369	chr22:51173646	NA	0.29	4.56	0.38	1.19e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs28735056	0.660	rs12454454	chr18:77674634	C/T	cg20368463	chr18:77673604	PQLC1	-0.55	-6.67	-0.51	7.65e-10	Schizophrenia;
TGCT	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	5.88	0.47	3.59e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2153535	0.601	rs9379224	chr6:8538413	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.67	0.45	9.45e-8	Motion sickness;
TGCT	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	5.12	0.42	1.11e-6	Alzheimer's disease;
TGCT	cis	rs7582180	0.764	rs11691684	chr2:100921776	T/A	cg14675211	chr2:100938903	LONRF2	0.49	4.8	0.4	4.49e-6	Intelligence (multi-trait analysis);
TGCT	trans	rs7819412	0.775	rs2898257	chr8:10935368	A/C	cg06636001	chr8:8085503	FLJ10661	-0.77	-7.07	-0.54	1.01e-10	Triglycerides;
TGCT	cis	rs910316	0.967	rs1071989	chr14:75564659	G/T	cg08847533	chr14:75593920	NEK9	0.96	10.6	0.69	4.3e-19	Height;
TGCT	cis	rs7226408	0.948	rs72883595	chr18:34392790	T/C	cg06757138	chr18:34340585	FHOD3	0.26	4.79	0.4	4.62e-6	Obesity-related traits;
TGCT	cis	rs9611565	0.512	rs6002474	chr22:42168181	A/G	cg03806693	chr22:41940476	POLR3H	1.02	10.49	0.69	7.92e-19	Vitiligo;
TGCT	cis	rs9902453	1.000	rs9912741	chr17:28359511	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-6.56	-0.51	1.3e-9	Coffee consumption (cups per day);
TGCT	cis	rs9326248	1.000	rs585849	chr11:117069061	A/G	cg26566898	chr11:117069891	TAGLN	0.35	4.95	0.41	2.32e-6	Blood protein levels;
TGCT	cis	rs8077889	1.000	rs59044152	chr17:41888747	A/G	cg26893861	chr17:41843967	DUSP3	1.1	12.5	0.75	1.08e-23	Triglycerides;
TGCT	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg08975724	chr8:8085496	FLJ10661	0.53	4.58	0.38	1.12e-5	Mood instability;
TGCT	cis	rs2997447	0.739	rs3008224	chr1:26389647	G/A	cg19633962	chr1:26362018	EXTL1	-0.68	-4.62	-0.38	9.47e-6	QRS complex (12-leadsum);
TGCT	cis	rs7666738	0.830	rs6839203	chr4:98839814	C/G	cg18180107	chr4:99064573	C4orf37	0.56	5.17	0.42	9.04e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6908034	0.769	rs6916589	chr6:19761363	T/G	cg02682789	chr6:19804855	NA	0.81	4.64	0.38	8.61e-6	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
TGCT	cis	rs6087771	0.642	rs6060411	chr20:30222139	T/C	cg18721089	chr20:30220636	NA	-0.42	-5.19	-0.42	8.31e-7	Subcortical brain region volumes;Putamen volume;
TGCT	cis	rs8072100	0.935	rs12150231	chr17:45717091	G/A	cg08085267	chr17:45401833	C17orf57	0.47	5.13	0.42	1.07e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs76473307	1.000	rs79820260	chr20:57420268	G/A	cg06163629	chr20:57414884	GNASAS;GNAS	-0.64	-4.5	-0.37	1.54e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs10782582	0.586	rs1796813	chr1:76400403	G/A	cg03433033	chr1:76189801	ACADM	-0.5	-4.95	-0.41	2.34e-6	Daytime sleep phenotypes;
TGCT	cis	rs9858542	1.000	rs9836291	chr3:49697459	G/A	cg03060546	chr3:49711283	APEH	-0.67	-6.09	-0.48	1.28e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs10782582	0.609	rs1159215	chr1:76317869	A/T	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.51	4.53	0.38	1.34e-5	Daytime sleep phenotypes;
TGCT	cis	rs1005277	0.522	rs7072977	chr10:37940440	C/A	cg25427524	chr10:38739819	LOC399744	-0.35	-7.04	-0.53	1.18e-10	Extrinsic epigenetic age acceleration;
TGCT	cis	rs17767294	0.708	rs72851182	chr6:28106699	G/T	cg08851530	chr6:28072375	NA	1.56	7.22	0.54	4.47e-11	Parkinson's disease;
TGCT	cis	rs7809950	0.954	rs2520247	chr7:107143946	A/T	cg23024343	chr7:107201750	COG5	-0.35	-5.54	-0.45	1.72e-7	Coronary artery disease;
TGCT	cis	rs10782582	0.609	rs5745545	chr1:76377356	A/G	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.55	4.72	0.39	6.24e-6	Daytime sleep phenotypes;
TGCT	cis	rs2562456	0.720	rs6511250	chr19:21656046	C/T	cg25650185	chr19:21324782	ZNF431	0.56	4.85	0.4	3.68e-6	Pain;
TGCT	cis	rs3087591	0.960	rs12603885	chr17:29466722	C/T	cg24425628	chr17:29625626	OMG;NF1	0.49	7.65	0.57	4.83e-12	Hip circumference;
TGCT	trans	rs11764590	0.715	rs55770986	chr7:2087823	T/C	cg25206134	chr2:45395956	NA	0.97	6.72	0.52	5.86e-10	Neuroticism;
TGCT	cis	rs9393692	0.846	rs9366651	chr6:26336696	G/T	cg00631329	chr6:26305371	NA	-0.38	-5.6	-0.45	1.31e-7	Educational attainment;
TGCT	cis	rs9993613	0.875	rs1518487	chr4:73466458	G/C	cg15102770	chr4:73434591	ADAMTS3	0.51	4.8	0.4	4.47e-6	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs611744	0.870	rs638905	chr8:109203406	A/G	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	trans	rs114540395	0.858	rs77209663	chr10:103300166	G/A	cg10198749	chr1:39920707	MACF1	0.55	7.05	0.53	1.11e-10	Schizophrenia;
TGCT	cis	rs7829975	0.626	rs332040	chr8:8730488	G/A	cg15556689	chr8:8085844	FLJ10661	0.67	6.22	0.49	6.82e-9	Mood instability;
TGCT	cis	rs4788570	0.615	rs7193549	chr16:71649416	T/C	cg06353428	chr16:71660113	MARVELD3	1.55	12.96	0.76	8.29e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs4595586	0.545	rs12811619	chr12:39392196	T/C	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs7824557	0.614	rs7816606	chr8:11205602	T/C	cg21775007	chr8:11205619	TDH	0.71	6.77	0.52	4.57e-10	Retinal vascular caliber;
TGCT	cis	rs208520	0.690	rs851459	chr6:66813989	A/G	cg07460842	chr6:66804631	NA	-0.93	-9.66	-0.66	8.29e-17	Exhaled nitric oxide output;
TGCT	cis	rs7264396	0.790	rs6058288	chr20:34228680	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.28	4.68	0.39	7.38e-6	Total cholesterol levels;
TGCT	cis	rs8013055	0.796	rs8021330	chr14:106002352	C/A	cg23356831	chr14:105996513	TMEM121	0.35	5.71	0.46	7.75e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs1448094	0.556	rs11611968	chr12:86168022	G/A	cg02569458	chr12:86230093	RASSF9	0.38	4.49	0.37	1.61e-5	Major depressive disorder;
TGCT	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg22433210	chr17:43662623	NA	-1.01	-7.25	-0.55	3.91e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs12950390	0.853	rs55745341	chr17:45855778	G/C	cg06532163	chr17:45867833	NA	0.33	5.2	0.42	8.03e-7	IgG glycosylation;
TGCT	cis	rs858239	0.601	rs10239760	chr7:23149950	C/T	cg05602783	chr7:23145260	KLHL7	-0.72	-6.17	-0.48	8.95e-9	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs9467773	1.000	rs9467787	chr6:26556769	G/T	cg05738196	chr6:26577821	NA	0.91	13.19	0.76	2.28e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs17345786	0.861	rs11711808	chr3:101235101	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.42	-8.68	-0.61	1.85e-14	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	6.14	0.48	1.03e-8	Bipolar disorder;
TGCT	cis	rs7178424	0.516	rs12595300	chr15:62324519	T/C	cg00456672	chr15:62358751	C2CD4A	-0.29	-4.46	-0.37	1.84e-5	Height;
TGCT	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2243480	0.522	rs431168	chr7:65511604	G/T	cg18252515	chr7:66147081	NA	-1.13	-6.09	-0.48	1.29e-8	Diabetic kidney disease;
TGCT	cis	rs3796352	0.527	rs11716506	chr3:52944328	C/T	cg07884673	chr3:53033167	SFMBT1	0.46	4.68	0.39	7.39e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs7772486	0.754	rs864148	chr6:145976675	T/C	cg13319975	chr6:146136371	FBXO30	0.57	5.19	0.42	8.17e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9952991	1.000	rs9952991	chr18:12780464	G/A	cg23544223	chr18:12777786	NA	0.62	5.85	0.47	4.05e-8	Inflammatory skin disease;
TGCT	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg21724239	chr8:58056113	NA	0.42	5.04	0.41	1.59e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs12497850	0.644	rs11928552	chr3:48739883	T/C	cg16497277	chr3:49208875	KLHDC8B	-0.49	-4.53	-0.38	1.36e-5	Parkinson's disease;
TGCT	cis	rs7246657	0.943	rs7255407	chr19:37933936	G/A	cg18154014	chr19:37997991	ZNF793	0.73	5.38	0.44	3.53e-7	Coronary artery calcification;
TGCT	cis	rs13217239	0.646	rs10946891	chr6:26973215	T/C	cg15659132	chr6:26577336	NA	0.55	5.55	0.45	1.62e-7	Schizophrenia;
TGCT	cis	rs6733011	0.582	rs2280256	chr2:99449174	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-4.92	-0.4	2.66e-6	Bipolar disorder;
TGCT	cis	rs17539620	0.624	rs62432743	chr6:154836214	T/G	cg20019720	chr6:154832845	CNKSR3	0.57	5.02	0.41	1.72e-6	Lipoprotein (a) levels;
TGCT	cis	rs31872	0.520	rs246053	chr5:140326290	T/A	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Visceral adipose tissue adjusted for BMI;
TGCT	cis	rs9399135	0.967	rs4895436	chr6:135295001	G/A	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.36e-6	Red blood cell count;
TGCT	cis	rs2677744	1.000	rs1266489	chr15:91458485	G/A	cg22288577	chr15:91498497	RCCD1	0.47	4.83	0.4	3.95e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs7020830	0.823	rs7019699	chr9:37125081	C/A	cg14294708	chr9:37120828	ZCCHC7	1.31	20.37	0.88	2.24e-41	Schizophrenia;
TGCT	cis	rs6088580	0.601	rs6059872	chr20:33082775	C/A	cg08999081	chr20:33150536	PIGU	0.29	5.57	0.45	1.54e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs13191362	1.000	rs66529337	chr6:163005662	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.57	4.94	0.41	2.45e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs9549260	0.609	rs9315781	chr13:41264053	T/C	cg21288729	chr13:41239152	FOXO1	0.9	8.44	0.6	7.07e-14	Red blood cell count;
TGCT	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg26119090	chr2:26468346	HADHA;HADHB	1.0	7.42	0.55	1.64e-11	Gut microbiome composition (summer);
TGCT	cis	rs8031584	0.678	rs3122	chr15:31170290	A/T	cg08704250	chr15:31115839	NA	0.45	6.16	0.48	9.25e-9	Huntington's disease progression;
TGCT	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.43	6.28	0.49	5.19e-9	Schizophrenia;
TGCT	cis	rs2070488	0.965	rs35091896	chr3:38443320	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.96	10.52	0.69	6.73e-19	Electrocardiographic conduction measures;
TGCT	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg11764359	chr7:65958608	NA	0.59	5.32	0.43	4.66e-7	Aortic root size;
TGCT	cis	rs1949733	1.000	rs2631740	chr4:8484106	C/A	cg13073564	chr4:8508604	NA	0.48	5.13	0.42	1.08e-6	Response to antineoplastic agents;
TGCT	cis	rs2439831	0.867	rs28415933	chr15:43635800	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	8.65	0.61	2.26e-14	Lung cancer in ever smokers;
TGCT	cis	rs9913156	0.789	rs55999196	chr17:4600655	A/G	cg19197139	chr17:4613644	ARRB2	0.83	7.74	0.57	3.03e-12	Lymphocyte counts;
TGCT	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg16680214	chr1:154839983	KCNN3	-0.42	-8.81	-0.62	9.12e-15	Prostate cancer;
TGCT	cis	rs2204008	0.811	rs2139752	chr12:38370398	C/T	cg26384229	chr12:38710491	ALG10B	0.84	7.39	0.55	1.91e-11	Bladder cancer;
TGCT	cis	rs8180040	0.800	rs11920354	chr3:47262246	C/A	cg27129171	chr3:47204927	SETD2	-0.67	-7.84	-0.58	1.77e-12	Colorectal cancer;
TGCT	cis	rs3087591	1.000	rs8068801	chr17:29570587	G/T	cg24425628	chr17:29625626	OMG;NF1	-0.48	-7.48	-0.56	1.18e-11	Hip circumference;
TGCT	cis	rs1018836	0.608	rs1015994	chr8:91465011	T/C	cg16814680	chr8:91681699	NA	-0.72	-7.55	-0.56	8.16e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs939658	0.967	rs11629665	chr15:79457133	C/T	cg17916960	chr15:79447300	NA	0.49	7.91	0.58	1.21e-12	Refractive error;
TGCT	cis	rs79057730	0.599	rs34411410	chr7:811721	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.74	5.59	0.45	1.36e-7	Initial pursuit acceleration;
TGCT	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.54	4.99	0.41	2.03e-6	Prudent dietary pattern;
TGCT	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg22920501	chr2:26401640	FAM59B	-0.73	-6.44	-0.5	2.35e-9	Gut microbiome composition (summer);
TGCT	cis	rs9899728	0.520	rs12936866	chr17:73052050	A/G	cg27626185	chr17:73056755	KCTD2	-0.92	-8.01	-0.58	7.17e-13	Alzheimer's disease or small vessel stroke;
TGCT	cis	rs9796	0.516	rs28473405	chr15:41293170	C/T	cg26219294	chr15:41245916	CHAC1	0.38	4.64	0.38	8.83e-6	Menopause (age at onset);
TGCT	cis	rs17473412	0.963	rs76431217	chr5:122697458	G/A	cg15125798	chr5:122621645	NA	-0.56	-5.02	-0.41	1.75e-6	Total body bone mineral density;
TGCT	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.46	-5.43	-0.44	2.9e-7	Alzheimer's disease;
TGCT	cis	rs7647973	0.626	rs9830730	chr3:49675875	G/C	cg03060546	chr3:49711283	APEH	0.63	5.63	0.45	1.12e-7	Menarche (age at onset);
TGCT	cis	rs1670533	1.000	rs13119276	chr4:1051574	T/C	cg27284194	chr4:1044797	NA	0.68	5.8	0.46	5.11e-8	Recombination rate (females);
TGCT	cis	rs4273100	0.688	rs12938803	chr17:19204432	A/C	cg03910582	chr17:19030146	GRAPL	-0.46	-5.17	-0.42	9.23e-7	Schizophrenia;
TGCT	cis	rs7120118	0.517	rs3758671	chr11:47273089	G/C	cg13308137	chr11:47528955	CUGBP1	0.33	5.19	0.42	8.16e-7	HDL cholesterol;
TGCT	cis	rs78456975	0.574	rs13412980	chr2:1545231	C/A	cg01028140	chr2:1542097	TPO	-0.39	-5.51	-0.44	1.97e-7	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs55962025	0.842	rs362272	chr4:3234980	C/T	cg06533319	chr4:3265114	C4orf44	0.23	4.54	0.38	1.31e-5	Parental longevity (mother's age at death);
TGCT	cis	rs35146811	0.807	rs6953441	chr7:99617067	G/A	cg13334819	chr7:99746414	C7orf59	-0.82	-7.38	-0.55	2.05e-11	Coronary artery disease;
TGCT	cis	rs1474256	0.630	rs79015977	chr15:79450147	G/A	cg17916960	chr15:79447300	NA	0.39	5.38	0.44	3.56e-7	Bronchopulmonary dysplasia;
TGCT	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-5.18	-0.42	8.6e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7666738	0.830	rs4323111	chr4:98952276	A/G	cg05340658	chr4:99064831	C4orf37	0.53	6.02	0.48	1.8e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6701037	0.782	rs12760073	chr1:175139295	G/T	cg00321850	chr1:175162397	KIAA0040	-0.41	-5.51	-0.44	1.95e-7	Alcohol dependence;
TGCT	cis	rs68170813	0.559	rs3801963	chr7:106898036	C/T	cg02696742	chr7:106810147	HBP1	-0.66	-5.51	-0.44	1.94e-7	Coronary artery disease;
TGCT	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg20203395	chr5:56204925	C5orf35	-0.56	-4.67	-0.39	7.83e-6	Initial pursuit acceleration;
TGCT	cis	rs4730250	0.707	rs80095766	chr7:106901394	G/T	cg02696742	chr7:106810147	HBP1	-0.66	-5.51	-0.44	1.94e-7	Osteoarthritis;
TGCT	cis	rs9921192	1.000	rs9921192	chr16:4349111	T/C	cg00021532	chr16:4324280	TFAP4	0.75	7.96	0.58	9.23e-13	Prostate-specific antigen levels;
TGCT	cis	rs3806843	0.900	rs2563287	chr5:140124786	C/T	cg19875535	chr5:140030758	IK	0.35	5.81	0.46	4.92e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2153535	0.580	rs6597326	chr6:8482019	A/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs4824093	0.610	rs60036544	chr22:50264019	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.48	4.97	0.41	2.17e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs7258465	1.000	rs10413237	chr19:18548249	A/C	cg06462663	chr19:18546047	ISYNA1	0.2	4.56	0.38	1.21e-5	Breast cancer;
TGCT	cis	rs9467773	0.620	rs2451737	chr6:26619041	T/C	cg05738196	chr6:26577821	NA	0.87	11.3	0.71	8.47e-21	Intelligence (multi-trait analysis);
TGCT	cis	rs1150668	0.796	rs2531825	chr6:28349264	C/T	cg19488431	chr6:28601329	NA	0.2	4.63	0.38	9.19e-6	Pubertal anthropometrics;
TGCT	cis	rs7647973	0.626	rs35129566	chr3:49866584	T/G	cg05785598	chr3:49045655	WDR6	-0.42	-5.32	-0.43	4.71e-7	Menarche (age at onset);
TGCT	cis	rs10858047	0.824	rs222502	chr1:115165472	T/A	cg12756093	chr1:115239321	AMPD1	-0.47	-4.96	-0.41	2.27e-6	Autism;
TGCT	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg06221963	chr1:154839813	KCNN3	0.72	13.42	0.77	6.35e-26	Prostate cancer;
TGCT	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg22963979	chr7:1858916	MAD1L1	-0.38	-6.04	-0.48	1.64e-8	Bipolar disorder and schizophrenia;
TGCT	cis	rs36051895	0.632	rs10114315	chr9:5125741	G/A	cg02405213	chr9:5042618	JAK2	-0.75	-10.16	-0.67	5.11e-18	Pediatric autoimmune diseases;
TGCT	cis	rs9807989	0.839	rs4851565	chr2:102971481	C/A	cg09003973	chr2:102972529	NA	0.64	5.7	0.46	8.28e-8	Asthma;
TGCT	cis	rs2742417	1.000	rs1877934	chr3:45753295	G/A	cg04837898	chr3:45731254	SACM1L	-0.55	-5.72	-0.46	7.45e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs9296092	0.538	rs62405948	chr6:33522753	A/C	cg13560919	chr6:33536144	NA	-0.21	-4.75	-0.39	5.5e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs7428	0.527	rs1053560	chr2:85546192	C/T	cg03728395	chr2:85555865	TGOLN2	-0.32	-5.51	-0.44	2.02e-7	Ear protrusion;
TGCT	cis	rs7208859	0.623	rs7208088	chr17:29143667	C/T	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg08736216	chr1:53307985	ZYG11A	-0.26	-5.01	-0.41	1.83e-6	Monocyte count;
TGCT	cis	rs11118844	0.843	rs7518806	chr1:221915633	T/A	cg04222084	chr1:221915650	DUSP10	-0.88	-5.95	-0.47	2.59e-8	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
TGCT	cis	rs7772486	0.875	rs7739371	chr6:146424353	C/G	cg23711669	chr6:146136114	FBXO30	0.91	9.95	0.67	1.67e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4253772	0.591	rs11704614	chr22:46691936	A/G	cg24881330	chr22:46731750	TRMU	1.04	5.38	0.44	3.54e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs8177179	0.967	rs4078166	chr3:133435979	C/A	cg16262614	chr3:133464971	TF	0.35	4.73	0.39	6.04e-6	Iron status biomarkers (transferrin levels);
TGCT	cis	rs523522	0.962	rs651627	chr12:121009198	C/T	cg27279351	chr12:120934652	DYNLL1	0.74	6.46	0.5	2.19e-9	High light scatter reticulocyte count;
TGCT	cis	rs7085104	0.700	rs7096183	chr10:104609466	T/C	cg15744005	chr10:104629667	AS3MT	-0.45	-5.8	-0.46	5.2e-8	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs17331151	0.505	rs71299610	chr3:52641703	T/G	cg07884673	chr3:53033167	SFMBT1	0.75	5.59	0.45	1.35e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	trans	rs7726839	0.540	rs72707016	chr5:665148	A/G	cg25482853	chr8:67687455	SGK3	1.19	10.53	0.69	6.56e-19	Obesity-related traits;
TGCT	cis	rs7246657	1.000	rs10426297	chr19:37798373	A/G	cg18154014	chr19:37997991	ZNF793	0.81	5.56	0.45	1.61e-7	Coronary artery calcification;
TGCT	cis	rs71281886	1	rs71281886	chr3:48352568	C/CA	cg11946769	chr3:48343235	NME6	0.82	7.03	0.53	1.23e-10	Breast cancer;
TGCT	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg17345569	chr6:42928274	GNMT	-0.47	-4.81	-0.4	4.25e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	trans	rs11992162	0.621	rs9774603	chr8:11777406	C/T	cg15556689	chr8:8085844	FLJ10661	-0.79	-6.77	-0.52	4.69e-10	Monocyte count;
TGCT	cis	rs9858542	0.537	rs9818758	chr3:49382925	G/A	cg00383909	chr3:49044727	WDR6	0.7	4.75	0.39	5.48e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs6940638	0.744	rs858964	chr6:27142614	C/G	cg26531700	chr6:26746687	NA	0.63	5.73	0.46	7.17e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs1371867	0.846	rs1788199	chr8:101292854	A/G	cg06002616	chr8:101225028	SPAG1	-0.56	-6.58	-0.51	1.2e-9	Atrioventricular conduction;
TGCT	cis	rs12477438	0.520	rs6741772	chr2:99738961	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	17.16	0.84	1.49e-34	Chronic sinus infection;
TGCT	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg12311346	chr5:56204834	C5orf35	0.79	6.87	0.53	2.76e-10	Initial pursuit acceleration;
TGCT	cis	rs67072384	1.000	rs2886367	chr11:72455034	C/T	cg03713592	chr11:72463424	ARAP1	-0.93	-4.66	-0.39	7.89e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs11122272	0.668	rs2808616	chr1:231554993	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.66	6.37	0.5	3.33e-9	Hemoglobin concentration;
TGCT	cis	rs77972916	0.611	rs11693190	chr2:43602415	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.4	-6.2	-0.49	7.52e-9	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs7937682	0.824	rs539524	chr11:111477325	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.04	-11.09	-0.71	2.89e-20	Primary sclerosing cholangitis;
TGCT	cis	rs981844	0.712	rs897610	chr4:154755439	C/A	cg14289246	chr4:154710475	SFRP2	-0.96	-8.97	-0.63	3.91e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs6582630	0.555	rs11182193	chr12:38474090	C/G	cg26384229	chr12:38710491	ALG10B	0.83	7.6	0.56	6.18e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs6754311	0.550	rs1438307	chr2:136499166	A/C	cg07169764	chr2:136633963	MCM6	0.65	6.03	0.48	1.76e-8	Mosquito bite size;
TGCT	cis	rs2820315	1.000	rs2250377	chr1:201860626	A/G	cg12730843	chr1:201915899	LMOD1	0.27	4.73	0.39	5.98e-6	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
TGCT	cis	rs6964587	0.900	rs4279	chr7:91764128	C/A	cg17063962	chr7:91808500	NA	0.92	9.77	0.66	4.5e-17	Breast cancer;
TGCT	cis	rs200810	0.664	rs35997403	chr6:98030207	T/C	cg16511841	chr6:97730490	C6orf167;MIR548H3	-0.65	-4.44	-0.37	1.94e-5	Body mass index;
TGCT	cis	rs4788570	0.697	rs6499540	chr16:71822250	A/C	cg06353428	chr16:71660113	MARVELD3	1.53	12.59	0.75	6.48e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg25036284	chr2:26402008	FAM59B	-0.54	-4.7	-0.39	6.93e-6	Gut microbiome composition (summer);
TGCT	cis	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg07424592	chr7:64974309	NA	1.27	7.28	0.55	3.29e-11	Diabetic kidney disease;
TGCT	cis	rs10986311	0.862	rs2416924	chr9:127108146	A/T	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.2	4.79	0.4	4.57e-6	Vitiligo;
TGCT	cis	rs79349575	0.721	rs4794004	chr17:47038471	C/T	cg07967210	chr17:47022446	SNF8	0.44	5.94	0.47	2.68e-8	Type 2 diabetes;
TGCT	cis	rs10972341	0.904	rs10972352	chr9:35151320	A/T	cg00812861	chr9:35114699	KIAA1539	0.33	5.06	0.41	1.44e-6	Weight;
TGCT	cis	rs3008870	0.959	rs56707923	chr1:67388016	T/C	cg11518657	chr1:67396239	MIER1	0.52	4.53	0.38	1.39e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs10791323	0.569	rs2156679	chr11:133742304	C/T	cg03690763	chr11:133734501	NA	-0.3	-5.16	-0.42	9.36e-7	Childhood ear infection;
TGCT	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg03188948	chr7:1209495	NA	0.65	5.39	0.44	3.36e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs61867294	0.597	rs2050801	chr10:106694346	G/A	cg08000847	chr10:105880925	C10orf78	0.49	4.43	0.37	2.01e-5	Schizophrenia;
TGCT	cis	rs611744	0.967	rs650968	chr8:109211055	C/G	cg21045802	chr8:109455806	TTC35	0.52	4.72	0.39	6.21e-6	Dupuytren's disease;
TGCT	cis	rs9894429	0.789	rs7502346	chr17:79603741	T/C	cg18240062	chr17:79603768	NPLOC4	0.84	9.67	0.66	8.03e-17	Eye color traits;
TGCT	cis	rs28374715	0.783	rs11635269	chr15:41570710	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.82	-12.81	-0.75	1.87e-24	Ulcerative colitis;
TGCT	cis	rs12484776	0.685	rs1807579	chr22:40528220	T/C	cg07138101	chr22:40742427	ADSL	0.62	4.82	0.4	4.09e-6	Uterine fibroids;
TGCT	cis	rs806215	1.000	rs806219	chr7:127240094	A/C	cg00893242	chr7:127291580	SND1	0.43	4.5	0.37	1.54e-5	Type 2 diabetes;
TGCT	cis	rs155076	1.000	rs484365	chr13:21845944	G/T	cg14456004	chr13:21872349	NA	-1.32	-10.82	-0.7	1.25e-19	White matter hyperintensity burden;
TGCT	cis	rs738144	0.542	rs4303811	chr22:39157755	A/G	cg06022373	chr22:39101656	GTPBP1	-0.77	-5.14	-0.42	1.05e-6	IgG glycosylation;
TGCT	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg08280861	chr8:58055591	NA	0.4	5.57	0.45	1.49e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs4642101	0.824	rs9820977	chr3:12842932	G/A	cg05775895	chr3:12838266	CAND2	0.73	7.24	0.55	4.1e-11	QRS complex (12-leadsum);
TGCT	cis	rs12136530	0.593	rs9287046	chr1:19736395	C/G	cg24875000	chr1:19041556	PAX7	-0.25	-4.47	-0.37	1.72e-5	Lead levels in blood;
TGCT	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg04267008	chr7:1944627	MAD1L1	-0.41	-5.45	-0.44	2.65e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs79349575	0.783	rs318095	chr17:46974734	T/C	cg26022315	chr17:47021804	SNF8	0.48	4.65	0.39	8.39e-6	Type 2 diabetes;
TGCT	cis	rs11690462	0.794	rs2384364	chr2:26541427	C/G	cg15315096	chr2:27193331	MAPRE3	0.52	4.46	0.37	1.8e-5	Coronary artery disease;
TGCT	cis	rs8084125	0.832	rs62105172	chr18:74946703	C/T	cg05528293	chr18:74961138	GALR1	0.48	4.8	0.4	4.45e-6	Obesity-related traits;
TGCT	cis	rs9911578	1.000	rs12938772	chr17:56776320	T/C	cg12560992	chr17:57184187	TRIM37	0.76	9.34	0.64	4.88e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs10789285	0.681	rs2249230	chr1:69701497	A/T	ch.1.69469992R	chr1:69697404	NA	0.3	4.46	0.37	1.82e-5	Psoriasis;
TGCT	cis	rs12134245	0.776	rs625525	chr1:91997593	C/T	cg25838465	chr1:92012736	NA	-0.41	-7.0	-0.53	1.44e-10	Breast cancer;
TGCT	cis	rs6964587	0.934	rs6465344	chr7:91640273	G/A	cg17063962	chr7:91808500	NA	0.91	9.97	0.67	1.53e-17	Breast cancer;
TGCT	cis	rs727505	1.000	rs28523990	chr7:124436139	C/T	cg23710748	chr7:124431027	NA	-0.27	-4.53	-0.38	1.4e-5	Lewy body disease;
TGCT	cis	rs66573146	1.000	rs59683609	chr4:6964910	C/G	cg05069807	chr4:6945702	TBC1D14	0.31	4.6	0.38	1.03e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs12477438	0.765	rs62154638	chr2:99639584	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-4.88	-0.4	3.17e-6	Chronic sinus infection;
TGCT	cis	rs1997103	1.000	rs1965556	chr7:55403584	C/G	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs6121246	0.522	rs6088736	chr20:30195166	C/G	cg18721089	chr20:30220636	NA	-0.63	-6.88	-0.53	2.67e-10	Mean corpuscular hemoglobin;
TGCT	trans	rs7819412	0.668	rs2409714	chr8:11010118	A/G	cg15556689	chr8:8085844	FLJ10661	-0.73	-6.79	-0.52	4.14e-10	Triglycerides;
TGCT	cis	rs12477438	0.520	rs2516829	chr2:99773201	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.03	12.17	0.74	6.51e-23	Chronic sinus infection;
TGCT	cis	rs5769765	1.000	rs5769764	chr22:50270784	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.41	-6.13	-0.48	1.08e-8	Schizophrenia;
TGCT	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg06481639	chr22:41940642	POLR3H	-0.74	-6.74	-0.52	5.38e-10	Vitiligo;
TGCT	cis	rs13256369	1.000	rs4840352	chr8:8573508	A/G	cg18904891	chr8:8559673	CLDN23	0.62	5.67	0.45	9.47e-8	Obesity-related traits;
TGCT	cis	rs9906944	0.545	rs11079850	chr17:47092252	G/T	cg07075026	chr17:47091521	IGF2BP1	-0.44	-4.6	-0.38	1.02e-5	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs1801251	1.000	rs3816334	chr2:233708806	A/G	cg25237894	chr2:233734115	C2orf82	-0.33	-5.94	-0.47	2.71e-8	Coronary artery disease;
TGCT	cis	rs2120019	1.000	rs7162900	chr15:75368017	T/C	cg09165964	chr15:75287851	SCAMP5	-1.09	-8.86	-0.62	7.08e-15	Blood trace element (Zn levels);
TGCT	cis	rs2242194	0.844	rs11264295	chr1:154987526	C/T	cg24348479	chr1:155007323	DCST1;DCST2	0.27	5.73	0.46	7.17e-8	Schizophrenia;
TGCT	cis	rs926938	0.505	rs360629	chr1:115414733	A/G	cg12756093	chr1:115239321	AMPD1	0.41	6.44	0.5	2.37e-9	Autism;
TGCT	cis	rs2070488	1.000	rs7373805	chr3:38455439	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	9.65	0.65	9.06e-17	Electrocardiographic conduction measures;
TGCT	cis	rs2361718	0.522	rs11867921	chr17:78121170	G/T	cg27614120	chr17:77386099	HRNBP3	0.26	4.56	0.38	1.22e-5	Yeast infection;
TGCT	cis	rs62244186	0.566	rs55852922	chr3:44826188	A/G	cg10108389	chr3:44770937	ZNF501	-0.49	-4.9	-0.4	2.92e-6	Depressive symptoms;
TGCT	cis	rs9611519	0.929	rs9611465	chr22:41426139	G/A	cg13695892	chr22:41940480	POLR3H	-0.53	-4.62	-0.38	9.54e-6	Neuroticism;
TGCT	cis	rs981844	0.775	rs17371261	chr4:154738479	G/T	cg14289246	chr4:154710475	SFRP2	-1.0	-8.8	-0.62	9.95e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs6815814	0.851	rs9715769	chr4:38774489	A/C	cg02016764	chr4:38805732	TLR1	-0.35	-5.67	-0.45	9.56e-8	Breast cancer;
TGCT	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg03264133	chr6:25882463	NA	-0.88	-8.54	-0.61	4.08e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs877282	1.000	rs11253369	chr10:773610	C/G	cg17470449	chr10:769945	NA	0.31	5.23	0.43	6.96e-7	Uric acid levels;
TGCT	cis	rs916888	0.821	rs199509	chr17:44858728	G/A	cg01570182	chr17:44337453	NA	-1.01	-9.1	-0.63	1.83e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs200895692	1	rs200895692	chr1:43421956	CGCCTGTAATCCCAG/C	cg12656391	chr1:43425156	SLC2A1	-0.55	-5.43	-0.44	2.92e-7	Monocyte count;
TGCT	cis	rs7582180	0.663	rs6542930	chr2:100944383	T/A	cg08017756	chr2:100939284	LONRF2	-0.3	-5.01	-0.41	1.79e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7584330	0.518	rs78856668	chr2:238438055	A/C	cg14458575	chr2:238380390	NA	0.43	4.52	0.38	1.44e-5	Prostate cancer;
TGCT	cis	rs367943	0.933	rs451453	chr5:112808970	G/C	cg12552261	chr5:112820674	MCC	-0.24	-4.91	-0.4	2.81e-6	Type 2 diabetes;
TGCT	cis	rs9788333	0.788	rs35007728	chr13:21893221	G/C	cg04632378	chr13:21900426	NA	0.41	4.55	0.38	1.27e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	cis	rs9611565	0.729	rs169362	chr22:41827589	G/C	cg17554472	chr22:41940697	POLR3H	0.46	5.0	0.41	1.89e-6	Vitiligo;
TGCT	cis	rs9929218	0.861	rs4783667	chr16:68752878	C/A	cg01251360	chr16:68772225	CDH1	0.3	4.83	0.4	3.92e-6	Colorectal cancer;
TGCT	trans	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.86	9.4	0.65	3.49e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs835154	0.900	rs835153	chr5:14877474	A/G	cg14843632	chr5:14870594	ANKH	0.44	6.52	0.5	1.64e-9	Blood metabolite levels;
TGCT	trans	rs10203711	0.966	rs4293520	chr2:239567184	A/C	cg16021909	chr1:248021091	TRIM58	-0.66	-6.66	-0.51	7.94e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs796364	0.616	rs2689762	chr2:200687204	G/T	cg17644776	chr2:200775616	C2orf69	0.35	4.96	0.41	2.29e-6	Schizophrenia;
TGCT	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg24829409	chr8:58192753	C8orf71	-0.59	-4.97	-0.41	2.17e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg07507251	chr3:52567010	NT5DC2	0.47	6.53	0.51	1.55e-9	Bipolar disorder;
TGCT	cis	rs13392177	0.637	rs61041183	chr2:219056380	G/A	cg00012203	chr2:219082015	ARPC2	0.79	8.34	0.6	1.23e-13	Pyoderma gangrenosum in inflammatory bowel disease;
TGCT	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg20999797	chr1:1681921	NA	0.19	4.83	0.4	4.01e-6	Body mass index;
TGCT	cis	rs881375	0.631	rs10739577	chr9:123668854	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	5.31	0.43	4.92e-7	Rheumatoid arthritis;
TGCT	cis	rs2920503	1.000	rs2920503	chr3:12324230	C/T	cg04748988	chr3:12329223	PPARG	0.63	5.46	0.44	2.46e-7	LDL cholesterol;
TGCT	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg13395646	chr4:1353034	KIAA1530	-0.39	-4.97	-0.41	2.2e-6	Obesity-related traits;
TGCT	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg15595755	chr5:1867978	NA	0.45	5.13	0.42	1.08e-6	Cardiovascular disease risk factors;
TGCT	cis	rs7120118	0.517	rs2290149	chr11:47345916	T/C	cg13308137	chr11:47528955	CUGBP1	0.33	5.04	0.41	1.63e-6	HDL cholesterol;
TGCT	cis	rs6840360	0.642	rs2709819	chr4:152383832	A/G	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.31	-0.49	4.44e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs4383453	0.539	rs12633849	chr3:123102862	T/C	cg04890266	chr3:123102914	ADCY5	-0.49	-7.91	-0.58	1.23e-12	Gestational age at birth (maternal effect);
TGCT	trans	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg27523141	chr10:43048294	ZNF37B	0.72	8.28	0.6	1.71e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7179456	0.545	rs585192	chr15:59052210	T/C	cg05156742	chr15:59063176	FAM63B	0.5	4.8	0.4	4.45e-6	Asperger disorder;
TGCT	cis	rs9535307	0.769	rs9535306	chr13:50290817	A/G	cg08779649	chr13:50194554	NA	0.41	4.81	0.4	4.35e-6	Obesity-related traits;
TGCT	cis	rs6586163	0.872	rs1926201	chr10:90746360	G/C	cg03111039	chr10:90751583	FAS;ACTA2	-0.37	-4.59	-0.38	1.06e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg07424592	chr7:64974309	NA	1.4	8.42	0.6	7.87e-14	Diabetic kidney disease;
TGCT	trans	rs2624839	0.629	rs2526397	chr3:50187790	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.76	-6.73	-0.52	5.5e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs858239	0.539	rs3950345	chr7:23191114	T/C	cg05602783	chr7:23145260	KLHL7	-0.63	-4.98	-0.41	2.09e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs7666738	0.800	rs28427190	chr4:98989106	A/G	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1218582	0.772	rs2061690	chr1:154919080	C/T	cg09359103	chr1:154839909	KCNN3	-0.65	-12.28	-0.74	3.6e-23	Prostate cancer;
TGCT	cis	rs9916302	0.904	rs13341996	chr17:37536862	C/T	cg15445000	chr17:37608096	MED1	-0.33	-4.71	-0.39	6.46e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs4253772	0.515	rs6007891	chr22:46756833	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.73	4.85	0.4	3.56e-6	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs3947	1.000	rs2645425	chr8:11701278	G/A	cg02840367	chr8:11660030	FDFT1	0.91	6.7	0.52	6.58e-10	Blood protein levels;
TGCT	cis	rs34526934	0.566	rs35563571	chr2:177044459	T/G	cg14324370	chr2:177042789	NA	-0.91	-8.6	-0.61	2.9e-14	Obstructive sleep apnea trait (apnea hypopnea index);
TGCT	cis	rs35160687	0.736	rs6746198	chr2:86542113	A/G	cg03171300	chr2:86307199	POLR1A	-0.27	-4.73	-0.39	6.06e-6	Night sleep phenotypes;
TGCT	cis	rs5769765	0.955	rs9616366	chr22:50301178	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.37	5.21	0.42	7.51e-7	Schizophrenia;
TGCT	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg22800045	chr5:56110881	MAP3K1	0.53	4.49	0.37	1.64e-5	Initial pursuit acceleration;
TGCT	cis	rs600231	0.719	rs7114809	chr11:65251444	A/G	cg17120908	chr11:65337727	SSSCA1	-0.56	-5.21	-0.42	7.77e-7	Bone mineral density;
TGCT	cis	rs28595532	0.920	rs115472708	chr4:119773407	C/T	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs17376456	0.825	rs67328989	chr5:93243133	T/A	cg25358565	chr5:93447407	FAM172A	1.01	7.9	0.58	1.29e-12	Diabetic retinopathy;
TGCT	cis	rs919433	0.617	rs700638	chr2:198588950	A/C	cg00792783	chr2:198669748	PLCL1	0.53	4.69	0.39	6.95e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs12497850	0.931	rs11705888	chr3:48817289	T/C	cg07636037	chr3:49044803	WDR6	0.95	10.74	0.69	2e-19	Parkinson's disease;
TGCT	cis	rs73198271	1.000	rs11776513	chr8:8609057	T/C	ch.8.214553F	chr8:8189620	PRAGMIN	-0.27	-4.57	-0.38	1.17e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs4851254	0.660	rs35869550	chr2:100684578	T/A	cg22139774	chr2:100720529	AFF3	-0.45	-4.91	-0.4	2.75e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs12711979	0.765	rs897069	chr2:3818947	C/T	cg17052675	chr2:3827356	NA	0.4	7.89	0.58	1.34e-12	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs12048904	0.964	rs8888	chr1:101338324	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.48	4.58	0.38	1.12e-5	Multiple sclerosis;
TGCT	cis	rs28595532	0.920	rs116634064	chr4:119736514	C/T	cg14228332	chr4:119757509	SEC24D	1.31	7.06	0.54	1.06e-10	Cannabis dependence symptom count;
TGCT	cis	rs10032931	0.717	rs970689	chr4:96460537	A/G	cg17031751	chr4:96469067	UNC5C	-0.36	-4.48	-0.37	1.7e-5	Optic nerve measurement (cup-to-disc ratio);
TGCT	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	6.13	0.48	1.06e-8	Bipolar disorder;
TGCT	cis	rs12541335	0.692	rs2290274	chr8:22214374	C/T	cg02463440	chr8:22132932	PIWIL2	0.27	5.21	0.42	7.6e-7	Hypertriglyceridemia;
TGCT	cis	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg25427524	chr10:38739819	LOC399744	-0.41	-8.55	-0.61	3.9e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2594989	0.943	rs11128550	chr3:11466828	C/T	cg00170343	chr3:11313890	ATG7	-0.65	-4.75	-0.39	5.51e-6	Circulating chemerin levels;
TGCT	cis	rs7605378	0.528	rs281780	chr2:200756331	G/C	cg17644776	chr2:200775616	C2orf69	0.34	7.46	0.56	1.31e-11	Osteoporosis;
TGCT	cis	rs13217239	0.646	rs10946898	chr6:27003884	T/C	cg15659132	chr6:26577336	NA	0.54	5.44	0.44	2.78e-7	Schizophrenia;
TGCT	cis	rs7027203	0.576	rs7865043	chr9:96549004	G/T	cg14598338	chr9:96623480	NA	0.52	7.51	0.56	1.01e-11	DNA methylation (variation);
TGCT	cis	rs2806561	0.765	rs641032	chr1:23513980	C/T	cg12483005	chr1:23474871	LUZP1	-0.37	-4.67	-0.39	7.86e-6	Height;
TGCT	cis	rs727563	0.636	rs2413653	chr22:42106996	T/C	cg13695892	chr22:41940480	POLR3H	0.88	8.63	0.61	2.45e-14	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs904251	0.600	rs11756241	chr6:37445101	C/T	cg01843034	chr6:37503916	NA	-0.47	-6.03	-0.48	1.78e-8	Cognitive performance;
TGCT	trans	rs7726839	0.507	rs72703100	chr5:614291	C/T	cg25482853	chr8:67687455	SGK3	1.23	9.86	0.66	2.81e-17	Obesity-related traits;
TGCT	cis	rs7772486	0.603	rs2223411	chr6:146028767	T/C	cg23711669	chr6:146136114	FBXO30	-0.73	-6.84	-0.52	3.19e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.91	0.4	2.83e-6	Height;
TGCT	cis	rs832540	0.866	rs832579	chr5:56164943	A/G	cg12311346	chr5:56204834	C5orf35	-0.46	-5.0	-0.41	1.87e-6	Coronary artery disease;
TGCT	cis	rs950027	0.549	rs11070452	chr15:45594836	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.72	-7.39	-0.55	1.86e-11	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs902774	0.530	rs11834907	chr12:53350985	C/T	cg03404339	chr12:52639319	KRT7	0.41	4.46	0.37	1.85e-5	Prostate cancer;
TGCT	cis	rs12887734	0.524	rs12588797	chr14:104300020	C/T	cg26031613	chr14:104095156	KLC1	0.72	6.2	0.49	7.61e-9	Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9583531	0.600	rs4773241	chr13:111363021	A/G	cg24331049	chr13:111365604	ING1	0.76	7.31	0.55	2.95e-11	Coronary artery disease;
TGCT	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg25036284	chr2:26402008	FAM59B	-0.57	-4.97	-0.41	2.15e-6	Gut microbiome composition (summer);
TGCT	cis	rs2657888	0.529	rs12316930	chr12:56885816	C/G	cg23002907	chr12:56915593	RBMS2	-0.37	-4.66	-0.39	7.9e-6	Adiponectin levels;
TGCT	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg11764359	chr7:65958608	NA	-0.52	-4.75	-0.39	5.45e-6	Aortic root size;
TGCT	cis	rs2463822	0.925	rs1881535	chr11:62121623	C/T	cg06239285	chr11:62104954	ASRGL1	0.92	6.76	0.52	4.71e-10	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs6099314	0.920	rs6014857	chr20:55453688	A/G	cg18918007	chr20:54975754	CSTF1	0.27	4.52	0.38	1.44e-5	Chronic obstructive pulmonary disease (moderate to severe);
TGCT	cis	rs6088590	1.000	rs6058111	chr20:33310999	T/C	cg06115741	chr20:33292138	TP53INP2	0.66	5.39	0.44	3.37e-7	Coronary artery disease;
TGCT	cis	rs751728	0.687	rs4711355	chr6:33759906	G/T	cg13859433	chr6:33739653	LEMD2	-0.33	-5.78	-0.46	5.71e-8	Crohn's disease;
TGCT	cis	rs9926296	0.744	rs164747	chr16:89708680	T/G	cg26513180	chr16:89883248	FANCA	-0.61	-5.76	-0.46	6.13e-8	Vitiligo;
TGCT	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	5.02	0.41	1.78e-6	Prudent dietary pattern;
TGCT	cis	rs9527	0.615	rs11191485	chr10:104729816	G/C	cg15744005	chr10:104629667	AS3MT	-0.44	-5.19	-0.42	8.3e-7	Arsenic metabolism;
TGCT	cis	rs11761231	1.000	rs4348414	chr7:131369298	C/T	cg08326674	chr7:132266446	PLXNA4	0.23	4.57	0.38	1.14e-5	Rheumatoid arthritis;
TGCT	cis	rs447921	0.861	rs62084971	chr17:74425318	T/G	cg09812376	chr17:74270190	QRICH2	0.48	4.71	0.39	6.4e-6	Mitochondrial DNA levels;
TGCT	cis	rs763121	1.000	rs138464	chr22:38906432	C/T	cg06022373	chr22:39101656	GTPBP1	-0.7	-6.69	-0.52	6.75e-10	Menopause (age at onset);
TGCT	cis	rs6665290	0.904	rs6677602	chr1:227187838	G/T	cg10327440	chr1:227177885	CDC42BPA	-0.85	-11.61	-0.72	1.54e-21	Myeloid white cell count;
TGCT	cis	rs6725041	0.819	rs10048796	chr2:213083326	C/G	cg16329650	chr2:213403929	ERBB4	-0.54	-4.61	-0.38	9.88e-6	QT interval (ambient particulate matter interaction);
TGCT	cis	rs2115630	1.000	rs4633690	chr15:85361960	C/T	cg09876464	chr15:85330779	ZNF592	0.2	4.56	0.38	1.21e-5	P wave terminal force;
TGCT	cis	rs6089829	0.851	rs6089827	chr20:61668845	C/T	cg03213289	chr20:61660250	NA	0.7	10.08	0.67	8.1e-18	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs137603	0.966	rs470079	chr22:39708333	T/C	cg17798944	chr22:39715225	SNORD43;RPL3	-0.57	-5.68	-0.45	9.16e-8	Primary biliary cholangitis;
TGCT	cis	rs11696501	0.688	rs6104293	chr20:44326298	T/C	cg11783356	chr20:44313418	WFDC10B	-0.33	-4.49	-0.37	1.6e-5	Brain structure;
TGCT	cis	rs6933660	0.646	rs6911456	chr6:151778934	A/G	cg17179660	chr6:151773299	C6orf211;RMND1	-0.58	-5.47	-0.44	2.41e-7	Menarche (age at onset);
TGCT	cis	rs12479064	0.724	rs10496336	chr2:99996165	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.74	-6.33	-0.49	4.06e-9	Chronic sinus infection;
TGCT	cis	rs910187	0.678	rs3818009	chr20:45816514	C/T	cg27589058	chr20:45804311	EYA2	-0.35	-7.58	-0.56	7.14e-12	Migraine;
TGCT	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg06873352	chr17:61820015	STRADA	0.55	6.1	0.48	1.26e-8	Prudent dietary pattern;
TGCT	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.29	-4.51	-0.38	1.51e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9733	0.818	rs11204695	chr1:150657011	T/G	cg13175981	chr1:150552382	MCL1	0.43	4.79	0.4	4.64e-6	Tonsillectomy;
TGCT	cis	rs939574	0.790	rs114196239	chr2:220094307	G/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.11	5.34	0.43	4.31e-7	Platelet distribution width;
TGCT	cis	rs611744	0.967	rs660065	chr8:109191932	G/C	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	trans	rs10435719	0.899	rs7815595	chr8:11792351	C/A	cg15556689	chr8:8085844	FLJ10661	0.75	7.26	0.55	3.66e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs17102423	0.731	rs942629	chr14:65539318	A/G	cg11161011	chr14:65562177	MAX	-0.46	-6.14	-0.48	1.04e-8	Obesity-related traits;
TGCT	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg06873352	chr17:61820015	STRADA	0.56	6.22	0.49	7.1e-9	Prudent dietary pattern;
TGCT	cis	rs9300255	0.722	rs10773008	chr12:123800820	A/G	cg00376283	chr12:123451042	ABCB9	0.65	4.57	0.38	1.17e-5	Neutrophil percentage of white cells;
TGCT	cis	rs7524258	0.903	rs4908450	chr1:7292756	T/C	cg04342483	chr1:7259290	CAMTA1	-0.31	-4.49	-0.37	1.6e-5	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg04944784	chr2:26401820	FAM59B	-0.67	-6.16	-0.48	9.54e-9	Gut microbiome composition (summer);
TGCT	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg08859206	chr1:53392774	SCP2	0.4	5.97	0.47	2.38e-8	Monocyte count;
TGCT	cis	rs826838	1.000	rs4575342	chr12:38663831	G/A	cg26384229	chr12:38710491	ALG10B	1.05	10.25	0.68	3.18e-18	Heart rate;
TGCT	cis	rs10510102	0.872	rs7076727	chr10:123706515	A/G	cg23691251	chr10:123688108	ATE1	-0.59	-4.7	-0.39	6.75e-6	Breast cancer;
TGCT	cis	rs708547	0.792	rs7667084	chr4:57727435	T/C	cg25525207	chr4:57843836	C4orf14;POLR2B	0.52	4.44	0.37	1.94e-5	Response to bleomycin (chromatid breaks);
TGCT	cis	rs12580194	0.593	rs7959124	chr12:55726957	A/G	cg10672482	chr12:55725839	OR6C3	-0.56	-4.89	-0.4	3.1e-6	Cancer;
TGCT	trans	rs4332037	0.950	rs11771828	chr7:1941003	T/C	cg25206134	chr2:45395956	NA	1.1	9.34	0.64	5.11e-16	Bipolar disorder;
TGCT	cis	rs7568458	0.684	rs3731828	chr2:85806266	C/T	cg17127132	chr2:85788382	GGCX	0.51	4.58	0.38	1.1e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs3020736	0.500	rs8143153	chr22:42515637	G/C	cg15557168	chr22:42548783	NA	0.22	5.58	0.45	1.47e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs8017423	0.536	rs11625794	chr14:90811229	C/T	cg04374321	chr14:90722782	PSMC1	0.52	4.93	0.4	2.61e-6	Mortality in heart failure;
TGCT	cis	rs9393777	0.513	rs13210025	chr6:26654817	A/C	cg15659132	chr6:26577336	NA	-0.75	-5.25	-0.43	6.33e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs919433	0.679	rs10497806	chr2:198508951	G/A	cg00792783	chr2:198669748	PLCL1	0.56	5.03	0.41	1.68e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg12963246	chr6:28129442	ZNF389	0.51	5.02	0.41	1.73e-6	Depression;
TGCT	cis	rs17152411	0.895	rs7079416	chr10:126587312	C/G	cg07906193	chr10:126599966	NA	0.41	5.05	0.41	1.52e-6	Height;
TGCT	cis	rs6460942	0.908	rs3887296	chr7:12257966	A/G	cg06484146	chr7:12443880	VWDE	-0.55	-4.68	-0.39	7.25e-6	Coronary artery disease;
TGCT	cis	rs7119	0.637	rs2667775	chr15:77864802	T/G	cg27398640	chr15:77910606	LINGO1	0.27	4.78	0.39	4.92e-6	Type 2 diabetes;
TGCT	cis	rs35000415	1.000	rs35000415	chr7:128585616	C/T	cg06242719	chr7:129414860	MIR183;MIR96	-0.32	-4.51	-0.38	1.5e-5	Systemic lupus erythematosus;
TGCT	cis	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg07424592	chr7:64974309	NA	1.27	7.84	0.58	1.8e-12	Diabetic kidney disease;
TGCT	cis	rs9357506	1.000	rs6911147	chr6:46307628	C/T	cg21115430	chr6:46460003	NA	-0.26	-5.17	-0.42	9.2e-7	Body mass index;
TGCT	cis	rs9473924	0.542	rs9473923	chr6:50833565	A/T	cg14470998	chr6:50812995	TFAP2B	1.35	8.39	0.6	9.05e-14	Body mass index;
TGCT	cis	rs7666738	0.723	rs35327100	chr4:98977788	C/A	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3751972	0.590	rs10512428	chr17:26268925	G/C	cg02948944	chr17:26242737	NA	-0.45	-5.54	-0.45	1.75e-7	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs60871478	0.636	rs7792072	chr7:886239	C/T	cg15782153	chr7:917662	C7orf20	0.54	4.92	0.4	2.74e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs3087591	0.683	rs7502556	chr17:29642430	T/C	cg24425628	chr17:29625626	OMG;NF1	0.39	5.87	0.47	3.67e-8	Hip circumference;
TGCT	cis	rs9653442	0.900	rs4851269	chr2:100830348	C/T	cg22139774	chr2:100720529	AFF3	0.38	6.18	0.49	8.42e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs9430161	0.598	rs34350247	chr1:11034460	A/G	cg02454025	chr1:11042201	C1orf127	0.94	11.41	0.72	4.75e-21	Ewing sarcoma;
TGCT	cis	rs1691799	0.806	rs1168319	chr12:66744857	T/A	cg16791601	chr12:66731901	HELB	-0.28	-6.18	-0.49	8.52e-9	White blood cell count (basophil);
TGCT	cis	rs1348850	0.567	rs4144276	chr2:178523420	T/C	cg22681709	chr2:178499509	PDE11A	-0.48	-6.19	-0.49	8.16e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs56309584	0.521	rs11651599	chr17:8179512	A/G	cg08322244	chr17:8066669	VAMP2	-0.57	-5.31	-0.43	4.89e-7	Initial pursuit acceleration;
TGCT	cis	rs17221829	0.536	rs7943784	chr11:89377310	G/A	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.63	-0.38	9.13e-6	Anxiety in major depressive disorder;
TGCT	cis	rs9921222	1.000	rs10794639	chr16:377367	A/G	cg00101154	chr16:420108	MRPL28	-0.58	-7.04	-0.53	1.13e-10	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs6669919	0.553	rs12568639	chr1:211675300	G/A	cg10512769	chr1:211675356	NA	-0.25	-4.6	-0.38	1.01e-5	Intelligence (multi-trait analysis);
TGCT	trans	rs10022799	0.725	rs9996643	chr4:168137082	G/A	cg08507725	chr4:8239220	SH3TC1	0.37	6.89	0.53	2.53e-10	Cognitive function;
TGCT	cis	rs7647973	0.554	rs13096480	chr3:49658084	A/G	cg05785598	chr3:49045655	WDR6	0.42	5.24	0.43	6.67e-7	Menarche (age at onset);
TGCT	cis	rs7267979	1.000	rs2258201	chr20:25272490	G/C	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg07061783	chr6:25882402	NA	-0.85	-8.68	-0.61	1.94e-14	Intelligence (multi-trait analysis);
TGCT	trans	rs1496653	0.557	rs71317829	chr3:23325990	G/T	cg02770683	chr12:57597238	LRP1	0.36	6.66	0.51	8.06e-10	Type 2 diabetes;
TGCT	cis	rs875971	0.862	rs2460432	chr7:65554385	C/T	cg11764359	chr7:65958608	NA	-0.56	-4.82	-0.4	4.04e-6	Aortic root size;
TGCT	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg19678392	chr7:94953810	PON1	0.58	6.42	0.5	2.67e-9	Paraoxonase activity;
TGCT	cis	rs314370	0.521	rs314308	chr7:100420878	C/T	cg10426581	chr7:100472382	SRRT	0.72	7.41	0.55	1.69e-11	Resting heart rate;
TGCT	cis	rs2070488	1.000	rs34258593	chr3:38464565	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	9.67	0.66	8.06e-17	Electrocardiographic conduction measures;
TGCT	cis	rs4252435	0.614	rs4252393	chr7:142628482	C/G	cg09833174	chr7:143059591	FAM131B	0.88	4.64	0.38	8.69e-6	Cancer;
TGCT	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg04267008	chr7:1944627	MAD1L1	-0.4	-5.3	-0.43	5.03e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs34526934	0.619	rs17336374	chr2:177068638	T/G	cg14324370	chr2:177042789	NA	-0.64	-4.92	-0.4	2.72e-6	Obstructive sleep apnea trait (apnea hypopnea index);
TGCT	cis	rs2735413	0.564	rs80225322	chr16:78095753	C/A	cg09132178	chr16:78079569	NA	0.33	4.44	0.37	1.98e-5	Systolic blood pressure (alcohol consumption interaction);
TGCT	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg22968622	chr17:43663579	NA	-1.23	-10.98	-0.7	5.31e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs6424115	0.679	rs2294495	chr1:24075876	C/T	cg15997130	chr1:24165203	NA	-0.65	-6.03	-0.48	1.73e-8	Immature fraction of reticulocytes;
TGCT	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	8.99	0.63	3.48e-15	Platelet count;
TGCT	cis	rs76878669	0.754	rs10896113	chr11:66117111	C/T	cg18002602	chr11:66138449	SLC29A2	-0.5	-5.71	-0.46	7.72e-8	Educational attainment (years of education);
TGCT	cis	rs3947	0.851	rs1736089	chr8:11705870	G/A	cg02840367	chr8:11660030	FDFT1	0.92	6.72	0.52	5.93e-10	Blood protein levels;
TGCT	cis	rs8064299	0.584	rs2384957	chr17:72784630	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.87	10.03	0.67	1.06e-17	Monocyte count;
TGCT	cis	rs66573146	1.000	rs55833486	chr4:6978729	C/A	cg05069807	chr4:6945702	TBC1D14	0.32	5.01	0.41	1.83e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs6964587	0.626	rs10243083	chr7:91552530	G/A	cg17063962	chr7:91808500	NA	-0.76	-7.25	-0.55	3.94e-11	Breast cancer;
TGCT	cis	rs2197308	0.765	rs10880643	chr12:37926452	C/T	cg26384229	chr12:38710491	ALG10B	-0.7	-6.15	-0.48	9.71e-9	Morning vs. evening chronotype;
TGCT	cis	rs12762955	0.529	rs2387213	chr10:1051420	C/T	cg26597838	chr10:835615	NA	0.46	6.13	0.48	1.1e-8	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs7829975	0.535	rs4841005	chr8:8501230	A/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-5.1	-0.42	1.22e-6	Mood instability;
TGCT	cis	rs2075371	0.501	rs1643051	chr7:134025372	A/G	cg11752832	chr7:134001865	SLC35B4	-0.6	-5.21	-0.42	7.57e-7	Mean platelet volume;
TGCT	cis	rs4788570	0.667	rs8052910	chr16:71790221	A/G	cg06353428	chr16:71660113	MARVELD3	1.53	12.17	0.74	6.57e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs7772486	0.846	rs866473	chr6:146353414	A/C	cg05347473	chr6:146136440	FBXO30	0.57	5.51	0.44	2.02e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2153535	0.601	rs9393030	chr6:8516489	C/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.01	0.41	1.86e-6	Motion sickness;
TGCT	cis	rs9308731	0.644	rs3789065	chr2:111915022	C/G	cg04202892	chr2:111875749	ACOXL	0.55	6.48	0.5	1.94e-9	Chronic lymphocytic leukemia;
TGCT	cis	rs7246657	0.722	rs10417576	chr19:38119212	A/C	cg18154014	chr19:37997991	ZNF793	0.69	4.67	0.39	7.7e-6	Coronary artery calcification;
TGCT	cis	rs9818758	0.607	rs5030795	chr3:49141116	C/T	cg00383909	chr3:49044727	WDR6	1.18	6.77	0.52	4.48e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs4803468	1.000	rs1473248	chr19:41923314	C/T	cg09537434	chr19:41945824	ATP5SL	0.92	10.72	0.69	2.21e-19	Height;
TGCT	cis	rs12477438	0.798	rs12473029	chr2:99637961	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.67	-5.89	-0.47	3.39e-8	Chronic sinus infection;
TGCT	cis	rs9814567	0.806	rs13076825	chr3:134317239	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.77	6.92	0.53	2.15e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	trans	rs7088591	0.702	rs10491208	chr10:59703352	C/G	cg15976763	chr18:24443729	AQP4	0.59	6.79	0.52	4.06e-10	Blood pressure;
TGCT	cis	rs7584330	0.822	rs13390494	chr2:238388792	G/A	cg08992911	chr2:238395768	MLPH	0.67	5.44	0.44	2.69e-7	Prostate cancer;
TGCT	cis	rs61990749	0.544	rs176979	chr14:78198072	A/C	cg23188588	chr14:78226832	SNW1;C14orf178	0.65	4.59	0.38	1.06e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs259282	0.524	rs4805006	chr19:33124136	G/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.6	5.81	0.46	4.85e-8	Schizophrenia;
TGCT	cis	rs7772486	0.754	rs9386133	chr6:146141213	A/G	cg23711669	chr6:146136114	FBXO30	0.84	9.43	0.65	3.05e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1018836	0.923	rs9693182	chr8:91621876	T/C	cg16814680	chr8:91681699	NA	-0.86	-9.19	-0.64	1.12e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs12701220	0.744	rs2030958	chr7:1076010	G/T	cg07217954	chr7:1067459	C7orf50	-0.48	-4.7	-0.39	6.84e-6	Bronchopulmonary dysplasia;
TGCT	cis	rs986417	1.000	rs996285	chr14:60869837	T/G	cg27398547	chr14:60952738	C14orf39	-1.42	-8.68	-0.61	1.89e-14	Gut microbiota (bacterial taxa);
TGCT	cis	rs854765	0.551	rs6502626	chr17:17849450	C/T	cg09796270	chr17:17721594	SREBF1	0.23	4.46	0.37	1.82e-5	Total body bone mineral density;
TGCT	cis	rs1023500	0.573	rs133378	chr22:42467695	G/C	cg05082376	chr22:42548792	NA	-0.23	-5.49	-0.44	2.21e-7	Schizophrenia;
TGCT	cis	rs9653442	0.545	rs12987209	chr2:100761148	C/T	cg22139774	chr2:100720529	AFF3	-0.36	-5.72	-0.46	7.68e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs7412746	0.658	rs11204750	chr1:150939744	C/A	cg04414720	chr1:150670196	GOLPH3L	0.38	4.54	0.38	1.3e-5	Melanoma;
TGCT	cis	rs921968	0.613	rs6436066	chr2:219578361	T/G	cg02176678	chr2:219576539	TTLL4	-0.34	-4.45	-0.37	1.88e-5	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs9303401	0.573	rs62081879	chr17:57181524	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.64	5.87	0.47	3.79e-8	Cognitive test performance;
TGCT	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg11764359	chr7:65958608	NA	0.61	5.53	0.44	1.84e-7	Aortic root size;
TGCT	cis	rs4319547	0.695	rs10734915	chr12:122873408	A/C	cg08088222	chr12:122070432	ORAI1	0.25	4.45	0.37	1.89e-5	Body mass index;
TGCT	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg18876405	chr7:65276391	NA	0.31	4.78	0.39	4.81e-6	Aortic root size;
TGCT	cis	rs7647973	0.516	rs4955418	chr3:49200627	A/G	cg07636037	chr3:49044803	WDR6	0.86	8.75	0.62	1.33e-14	Menarche (age at onset);
TGCT	cis	rs892961	0.932	rs7208336	chr17:75412932	T/C	cg05865280	chr17:75406074	SEPT9	0.28	6.86	0.52	2.9e-10	Airflow obstruction;
TGCT	cis	rs7523273	0.606	rs2724388	chr1:207933577	T/G	cg22525895	chr1:207977042	MIR29B2	0.52	8.49	0.61	5.2e-14	Schizophrenia;
TGCT	cis	rs4409675	0.576	rs6660899	chr1:28214281	G/C	cg23691781	chr1:28212827	C1orf38	0.25	5.26	0.43	6.19e-7	Corneal astigmatism;
TGCT	cis	rs3764563	1.000	rs11673070	chr19:15746095	A/G	cg20725493	chr19:15740067	CYP4F8	-0.45	-4.44	-0.37	1.93e-5	Inflammatory biomarkers;
TGCT	cis	rs1577917	0.771	rs7452605	chr6:86240951	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.61	5.32	0.43	4.64e-7	Response to antipsychotic treatment;
TGCT	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg24060327	chr5:131705240	SLC22A5	-0.61	-6.37	-0.5	3.32e-9	Acylcarnitine levels;
TGCT	cis	rs7949030	0.591	rs35880596	chr11:62369884	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.6	8.45	0.6	6.69e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs10197940	0.686	rs12616688	chr2:152242099	C/G	cg06191203	chr2:152266755	RIF1	-0.83	-7.95	-0.58	9.67e-13	Lung cancer;
TGCT	cis	rs911555	0.887	rs2071407	chr14:103987140	T/C	cg12935359	chr14:103987150	CKB	-0.35	-5.01	-0.41	1.86e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6988636	1.000	rs6983795	chr8:124185296	T/C	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs2562456	0.550	rs4809143	chr19:21772728	C/A	cg13978929	chr19:21580086	ZNF493	-0.56	-4.72	-0.39	6.29e-6	Pain;
TGCT	cis	rs6969780	0.722	rs4722666	chr7:27197601	C/G	cg17457637	chr7:27170717	HOXA4	-0.44	-4.81	-0.4	4.29e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs1048238	0.506	rs10737911	chr1:16167855	C/T	cg21385522	chr1:16154831	NA	-0.6	-6.92	-0.53	2.11e-10	Systolic blood pressure;
TGCT	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.66	6.27	0.49	5.39e-9	Initial pursuit acceleration;
TGCT	cis	rs6752107	1.000	rs10165561	chr2:234172915	G/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.19	4.65	0.39	8.35e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs1475911	0.671	rs12483409	chr21:43521902	G/A	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.27	-5.33	-0.43	4.5e-7	IgG glycosylation;
TGCT	cis	rs4766566	0.694	rs3847952	chr12:111746678	T/G	cg10833066	chr12:111807467	FAM109A	0.4	7.5	0.56	1.07e-11	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
TGCT	cis	rs9372498	0.536	rs62424198	chr6:118827247	A/G	cg07617317	chr6:118971624	C6orf204	0.47	5.1	0.42	1.23e-6	Diastolic blood pressure;
TGCT	trans	rs7618501	0.966	rs9882639	chr3:49799475	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	1.03	13.16	0.76	2.65e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg18876405	chr7:65276391	NA	-0.41	-6.34	-0.5	3.8e-9	Aortic root size;
TGCT	cis	rs2153535	0.580	rs9378556	chr6:8514695	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.55e-8	Motion sickness;
TGCT	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg04772025	chr11:68637568	NA	-0.58	-6.52	-0.51	1.6e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs2303759	0.918	rs1054770	chr19:49878115	G/A	cg22307029	chr19:49891270	CCDC155	0.56	5.29	0.43	5.38e-7	Multiple sclerosis;
TGCT	cis	rs6909279	0.678	rs6557143	chr6:151848611	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	0.62	5.67	0.45	9.47e-8	Bone mineral density;
TGCT	cis	rs8180040	0.845	rs295441	chr3:47333295	T/A	cg27129171	chr3:47204927	SETD2	0.7	8.89	0.62	5.88e-15	Colorectal cancer;
TGCT	cis	rs6450176	0.951	rs255757	chr5:53309371	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.49	-4.58	-0.38	1.13e-5	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs17401966	1.000	rs12141416	chr1:10327867	A/G	cg19773385	chr1:10388646	KIF1B	-0.21	-4.6	-0.38	1.02e-5	Hepatocellular carcinoma;
TGCT	cis	rs6121246	0.529	rs6088814	chr20:30218172	C/T	cg21427119	chr20:30132790	HM13	-0.43	-6.17	-0.48	8.86e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs4843185	0.667	rs4143865	chr16:85716612	T/A	cg06784122	chr16:85688175	KIAA0182	0.27	4.51	0.38	1.46e-5	Platelet distribution width;
TGCT	cis	rs10782582	0.593	rs2147039	chr1:76143166	C/T	cg03433033	chr1:76189801	ACADM	-0.66	-7.6	-0.56	6.31e-12	Daytime sleep phenotypes;
TGCT	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg10802521	chr3:52805072	NEK4	-0.78	-10.0	-0.67	1.26e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs1801251	0.893	rs6733151	chr2:233592341	A/C	cg25237894	chr2:233734115	C2orf82	0.32	5.81	0.46	4.94e-8	Coronary artery disease;
TGCT	cis	rs7824557	0.527	rs2572446	chr8:11239565	C/T	cg21775007	chr8:11205619	TDH	-0.68	-6.6	-0.51	1.08e-9	Retinal vascular caliber;
TGCT	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg18876405	chr7:65276391	NA	0.35	5.21	0.42	7.76e-7	Aortic root size;
TGCT	cis	rs427394	0.593	rs880993	chr5:6732120	C/G	cg10857441	chr5:6722123	POLS	-0.28	-6.08	-0.48	1.38e-8	Menopause (age at onset);
TGCT	cis	rs67311347	1.000	rs73080165	chr3:40533062	G/T	cg17264618	chr3:40429014	ENTPD3	0.33	4.44	0.37	1.98e-5	Renal cell carcinoma;
TGCT	cis	rs2070488	0.804	rs7646429	chr3:38467713	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.78	7.97	0.58	8.66e-13	Electrocardiographic conduction measures;
TGCT	cis	rs651907	0.535	rs4342086	chr3:101503765	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.31	-6.4	-0.5	2.91e-9	Colorectal cancer;
TGCT	cis	rs13185784	0.632	rs4469167	chr5:179650964	C/T	cg04734276	chr5:178882605	NA	0.31	4.78	0.39	4.83e-6	TRAIL levels;
TGCT	cis	rs7666738	0.830	rs6832568	chr4:98994061	G/A	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28595532	0.920	rs114564223	chr4:119729953	A/G	cg14228332	chr4:119757509	SEC24D	1.32	6.38	0.5	3.2e-9	Cannabis dependence symptom count;
TGCT	cis	rs3008870	0.583	rs17497947	chr1:67457199	G/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.97	-8.16	-0.59	3.17e-13	Lymphocyte percentage of white cells;
TGCT	cis	rs4851254	0.618	rs35840153	chr2:100669829	A/G	cg22139774	chr2:100720529	AFF3	-0.43	-4.63	-0.38	9.26e-6	Intelligence (multi-trait analysis);
TGCT	trans	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg13615516	chr5:77269221	NA	0.69	8.57	0.61	3.51e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7599312	0.534	rs6735626	chr2:213403972	G/A	cg20637307	chr2:213403960	ERBB4	0.91	11.8	0.73	5.21e-22	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7824557	0.527	rs2736296	chr8:11234844	G/A	cg21775007	chr8:11205619	TDH	-0.65	-6.4	-0.5	2.97e-9	Retinal vascular caliber;
TGCT	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg03188948	chr7:1209495	NA	0.47	6.15	0.48	9.79e-9	Longevity;Endometriosis;
TGCT	cis	rs2404602	0.647	rs10851889	chr15:77023336	C/T	cg23625390	chr15:77176239	SCAPER	-0.36	-4.56	-0.38	1.21e-5	Blood metabolite levels;
TGCT	cis	rs12134245	0.776	rs61548854	chr1:92001536	C/T	cg07090678	chr1:91966139	CDC7	0.35	4.75	0.39	5.58e-6	Breast cancer;
TGCT	cis	rs79349575	0.783	rs4794000	chr17:47022755	C/G	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.52	-0.38	1.44e-5	Type 2 diabetes;
TGCT	cis	rs77204473	1.000	rs17120157	chr11:116812628	C/T	cg14727452	chr11:117283767	CEP164	-0.37	-4.51	-0.38	1.49e-5	Eosinophil counts;Sum eosinophil basophil counts;
TGCT	cis	rs2742417	1.000	rs9821974	chr3:45784963	T/C	cg04837898	chr3:45731254	SACM1L	-0.53	-5.52	-0.44	1.92e-7	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg12923728	chr3:195709715	SDHAP1	-0.36	-7.58	-0.56	6.91e-12	Pancreatic cancer;
TGCT	cis	rs2956278	0.717	rs2947124	chr12:84679239	C/G	cg25678815	chr12:85673915	ALX1	-0.54	-4.83	-0.4	3.96e-6	Depressive symptoms;Depressive symptoms (multi-trait analysis);
TGCT	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs3806843	0.735	rs2530240	chr5:140060547	T/C	cg19875535	chr5:140030758	IK	-0.36	-6.15	-0.48	9.57e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2204008	0.687	rs2320523	chr12:38251397	T/C	cg13010199	chr12:38710504	ALG10B	0.59	4.61	0.38	9.88e-6	Bladder cancer;
TGCT	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs1420338	0.933	rs10253869	chr7:34149922	A/G	cg01275685	chr7:34179230	BMPER	-0.27	-4.94	-0.41	2.52e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg03732007	chr1:2071316	PRKCZ	0.28	6.63	0.51	9.05e-10	Height;
TGCT	cis	rs986417	0.901	rs1955696	chr14:61028271	A/G	cg18240143	chr14:60952599	C14orf39	0.64	4.46	0.37	1.81e-5	Gut microbiota (bacterial taxa);
TGCT	cis	rs7666738	0.830	rs35491210	chr4:99003364	T/C	cg05340658	chr4:99064831	C4orf37	0.49	5.6	0.45	1.31e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1371867	0.810	rs1618528	chr8:101259134	T/C	cg06636551	chr8:101224915	SPAG1	0.49	6.83	0.52	3.32e-10	Atrioventricular conduction;
TGCT	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg08859206	chr1:53392774	SCP2	0.48	7.82	0.57	1.97e-12	Monocyte count;
TGCT	cis	rs2228479	0.850	rs17227064	chr16:89816314	A/G	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs9818758	0.607	rs9880088	chr3:49178990	G/A	cg00383909	chr3:49044727	WDR6	1.28	6.57	0.51	1.23e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs10791097	0.694	rs6590520	chr11:130747386	C/G	cg14779329	chr11:130786720	SNX19	0.28	4.79	0.4	4.63e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg17971929	chr21:40555470	PSMG1	0.94	9.06	0.63	2.38e-15	Cognitive function;
TGCT	cis	rs13393800	0.536	rs2697804	chr2:233380020	A/G	cg26635044	chr2:233757626	NGEF	-0.17	-5.13	-0.42	1.09e-6	Height;
TGCT	cis	rs7666738	0.830	rs13138920	chr4:99020786	A/G	cg18180107	chr4:99064573	C4orf37	0.54	5.03	0.41	1.7e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2777491	0.915	rs28583065	chr15:41608470	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.76	-10.72	-0.69	2.3e-19	Ulcerative colitis;
TGCT	cis	rs4820539	1.000	rs5751589	chr22:23475762	A/G	cg14186256	chr22:23484241	RTDR1	-0.97	-12.31	-0.74	2.96e-23	Bone mineral density;
TGCT	cis	rs1153858	0.943	rs67045941	chr15:45677011	A/G	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.62e-8	Homoarginine levels;
TGCT	cis	rs4631830	0.932	rs4581397	chr10:51532367	A/G	cg10326726	chr10:51549505	MSMB	-0.24	-4.92	-0.4	2.66e-6	Prostate-specific antigen levels;
TGCT	cis	rs6940638	0.956	rs10946899	chr6:27023694	T/A	cg15659132	chr6:26577336	NA	-0.58	-5.4	-0.44	3.33e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs10858047	0.883	rs2137365	chr1:115078685	C/G	cg12756093	chr1:115239321	AMPD1	-0.4	-4.46	-0.37	1.78e-5	Autism;
TGCT	cis	rs7772486	0.754	rs4360151	chr6:146255079	A/C	cg05347473	chr6:146136440	FBXO30	-0.5	-4.85	-0.4	3.68e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg05665937	chr4:1216051	CTBP1	0.25	4.68	0.39	7.33e-6	Obesity-related traits;
TGCT	cis	rs763121	0.886	rs1013339	chr22:38974680	C/T	cg06022373	chr22:39101656	GTPBP1	0.82	8.4	0.6	8.68e-14	Menopause (age at onset);
TGCT	cis	rs6993813	0.593	rs10086835	chr8:120040181	C/T	cg17171407	chr8:119960777	TNFRSF11B	0.26	4.66	0.39	8.02e-6	Bone mineral density (hip);
TGCT	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg03452623	chr4:187889614	NA	-0.36	-5.51	-0.44	1.97e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9653442	0.564	rs2309753	chr2:100775920	C/A	cg07810366	chr2:100720526	AFF3	-0.34	-5.13	-0.42	1.1e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs4237845	0.611	rs10877036	chr12:58321650	A/G	cg02175503	chr12:58329896	NA	-0.62	-6.89	-0.53	2.45e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs12484776	0.786	rs73165040	chr22:40538602	C/T	cg07138101	chr22:40742427	ADSL	0.62	4.76	0.39	5.38e-6	Uterine fibroids;
TGCT	trans	rs877282	1.000	rs7100358	chr10:773681	G/A	cg22713356	chr15:30763199	NA	1.15	9.94	0.67	1.76e-17	Uric acid levels;
TGCT	cis	rs7611238	0.560	rs6803763	chr3:195078942	A/C	cg27323046	chr3:195102265	ACAP2	0.37	4.93	0.4	2.56e-6	Body mass index;
TGCT	cis	rs6671200	1.000	rs10747468	chr1:95686291	C/T	cg20701556	chr1:95698924	RWDD3	0.62	5.58	0.45	1.43e-7	Stearic acid (18:0) levels;
TGCT	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.49	-5.65	-0.45	1.03e-7	Longevity;Endometriosis;
TGCT	cis	rs17376456	1.000	rs13154249	chr5:93550508	C/T	cg21475434	chr5:93447410	FAM172A	0.65	4.66	0.39	8.09e-6	Diabetic retinopathy;
TGCT	cis	rs78487399	0.808	rs7591387	chr2:43756032	C/T	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.78	4.84	0.4	3.8e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs2014572	0.901	rs35658377	chr19:57755627	T/G	cg24459738	chr19:57751996	ZNF805	-0.54	-5.4	-0.44	3.21e-7	Hyperactive-impulsive symptoms;
TGCT	cis	rs10504229	0.861	rs57314710	chr8:58196051	T/C	cg22535103	chr8:58192502	C8orf71	-0.39	-4.62	-0.38	9.61e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg08048268	chr3:133502702	NA	0.69	10.86	0.7	1.01e-19	Iron status biomarkers;
TGCT	cis	rs9308731	1.000	rs13396983	chr2:111900598	A/G	cg04202892	chr2:111875749	ACOXL	0.43	4.62	0.38	9.43e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs7584330	0.554	rs6760890	chr2:238400645	G/A	cg14458575	chr2:238380390	NA	0.56	5.13	0.42	1.08e-6	Prostate cancer;
TGCT	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.57	-4.97	-0.41	2.15e-6	Height;
TGCT	cis	rs832540	0.629	rs3309	chr5:56092779	A/T	cg12311346	chr5:56204834	C5orf35	0.45	4.48	0.37	1.69e-5	Coronary artery disease;
TGCT	cis	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg22121687	chr7:65037720	NA	-0.78	-4.7	-0.39	6.74e-6	Diabetic kidney disease;
TGCT	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg16325326	chr1:53192061	ZYG11B	0.67	7.68	0.57	4.03e-12	Monocyte count;
TGCT	cis	rs3008870	1.000	rs912797	chr1:67413478	A/G	cg03991309	chr1:68237761	GNG12	0.27	4.57	0.38	1.18e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs61867294	0.544	rs1525396	chr10:106692748	A/C	cg08000847	chr10:105880925	C10orf78	0.49	4.43	0.37	2.01e-5	Schizophrenia;
TGCT	cis	rs13326165	0.760	rs498946	chr3:52434967	T/C	cg07884673	chr3:53033167	SFMBT1	0.39	4.87	0.4	3.29e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs1903068	0.853	rs73236111	chr4:56019068	A/C	cg09978860	chr4:56023921	NA	0.55	5.88	0.47	3.53e-8	Endometriosis;
TGCT	cis	rs9549367	0.789	rs9549705	chr13:113888425	T/C	cg00898013	chr13:113819073	PROZ	-0.4	-4.92	-0.4	2.7e-6	Platelet distribution width;
TGCT	cis	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg22857025	chr5:266934	NA	-0.32	-6.58	-0.51	1.18e-9	Breast cancer;
TGCT	cis	rs7044106	0.791	rs735110	chr9:123488940	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	7.88	0.58	1.46e-12	Hip circumference adjusted for BMI;
TGCT	cis	rs10927875	0.894	rs10927878	chr1:16319957	C/T	cg21385522	chr1:16154831	NA	-0.63	-7.07	-0.54	9.8e-11	Dilated cardiomyopathy;
TGCT	cis	rs2963155	0.518	rs72801054	chr5:142687742	T/C	cg17617527	chr5:142782415	NR3C1	0.84	5.71	0.46	8.05e-8	Breast cancer;
TGCT	cis	rs6598955	0.640	rs4233460	chr1:26633387	A/G	cg04990556	chr1:26633338	UBXN11	-0.92	-12.17	-0.74	6.52e-23	Obesity-related traits;
TGCT	cis	rs9911578	1.000	rs3744108	chr17:56585872	G/C	cg05425664	chr17:57184151	TRIM37	0.63	6.21	0.49	7.37e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs3087591	0.597	rs731759	chr17:29722809	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.37	-5.42	-0.44	2.93e-7	Hip circumference;
TGCT	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg26338869	chr17:61819248	STRADA	-0.53	-4.85	-0.4	3.68e-6	Prudent dietary pattern;
TGCT	cis	rs9818758	0.556	rs116432667	chr3:48947589	C/T	cg00383909	chr3:49044727	WDR6	1.26	6.52	0.51	1.58e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg20887711	chr4:1340912	KIAA1530	0.95	8.36	0.6	1.08e-13	Longevity;
TGCT	cis	rs7267979	0.702	rs449801	chr20:25491847	C/T	cg13486641	chr20:25479848	NINL	-0.15	-4.55	-0.38	1.28e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2933343	0.700	rs1683777	chr3:128624880	T/G	cg11901034	chr3:128598214	ACAD9	-0.63	-6.06	-0.48	1.54e-8	IgG glycosylation;
TGCT	cis	rs9926296	0.632	rs9935559	chr16:89800529	C/T	cg04287289	chr16:89883240	FANCA	-0.64	-6.46	-0.5	2.12e-9	Vitiligo;
TGCT	cis	rs7666738	0.830	rs7662389	chr4:99019892	G/A	cg18180107	chr4:99064573	C4orf37	0.53	4.69	0.39	7.05e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2742417	0.603	rs2253979	chr3:45773320	A/G	cg04837898	chr3:45731254	SACM1L	-0.67	-7.3	-0.55	3.06e-11	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg14820908	chr5:178986412	RUFY1	0.45	4.56	0.38	1.23e-5	Lung cancer;
TGCT	cis	rs12497850	0.931	rs12493289	chr3:48905161	G/A	cg05785598	chr3:49045655	WDR6	0.35	4.72	0.39	6.35e-6	Parkinson's disease;
TGCT	cis	rs3748682	0.731	rs3891572	chr1:38298876	C/T	cg04496824	chr1:38276835	MTF1	0.21	4.55	0.38	1.26e-5	Hypothyroidism;
TGCT	cis	rs17221829	0.764	rs12146462	chr11:89385374	T/C	cg02982614	chr11:89391479	FOLH1B	-0.25	-4.46	-0.37	1.8e-5	Anxiety in major depressive disorder;
TGCT	cis	rs2019216	0.542	rs12450889	chr17:21889379	A/G	cg22648282	chr17:21454238	C17orf51	-0.55	-5.44	-0.44	2.68e-7	Pelvic organ prolapse;
TGCT	cis	rs12477438	0.520	rs13798	chr2:99813614	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	8.83	0.62	8.31e-15	Chronic sinus infection;
TGCT	cis	rs9308731	0.644	rs56952027	chr2:111877104	C/T	cg04202892	chr2:111875749	ACOXL	0.54	6.25	0.49	6.18e-9	Chronic lymphocytic leukemia;
TGCT	cis	rs2816958	0.708	rs2816972	chr1:200085004	A/G	cg07971716	chr1:199773294	NA	0.5	4.77	0.39	5e-6	Ulcerative colitis;Inflammatory bowel disease;
TGCT	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg19010396	chr19:19431384	KIAA0892;SF4	-0.54	-4.54	-0.38	1.3e-5	Tonsillectomy;
TGCT	cis	rs13064447	0.874	rs9310408	chr3:12757726	T/C	cg20675869	chr3:12750130	NA	0.19	4.92	0.4	2.68e-6	Major depression and alcohol dependence;
TGCT	cis	rs986417	1.000	rs10149915	chr14:60943110	G/A	cg27398547	chr14:60952738	C14orf39	1.39	10.61	0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg06108461	chr20:60628389	TAF4	-0.75	-11.02	-0.7	4.27e-20	Body mass index;
TGCT	cis	rs6558174	0.802	rs6558171	chr8:22487422	T/C	cg03733263	chr8:22462867	KIAA1967	0.6	4.8	0.4	4.41e-6	Breast cancer;
TGCT	cis	rs3812831	0.695	rs3118895	chr13:114931742	G/A	cg15513719	chr13:114904418	NA	0.38	4.65	0.39	8.31e-6	Schizophrenia;
TGCT	cis	rs208520	0.690	rs207112	chr6:66792092	C/T	cg07460842	chr6:66804631	NA	-0.94	-9.86	-0.66	2.74e-17	Exhaled nitric oxide output;
TGCT	cis	rs9300255	0.602	rs1626899	chr12:123708063	A/G	cg00376283	chr12:123451042	ABCB9	0.73	5.67	0.45	9.46e-8	Neutrophil percentage of white cells;
TGCT	cis	rs826838	0.510	rs10506129	chr12:39224242	A/T	cg13010199	chr12:38710504	ALG10B	0.6	4.7	0.39	6.75e-6	Heart rate;
TGCT	cis	rs4499344	0.622	rs7259049	chr19:33056594	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.65	-5.5	-0.44	2.1e-7	Mean platelet volume;
TGCT	cis	rs17376456	0.825	rs28610997	chr5:93248374	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.74	4.76	0.39	5.26e-6	Diabetic retinopathy;
TGCT	cis	rs7091068	0.671	rs591392	chr10:95406081	G/A	cg20715218	chr10:95462985	C10orf4	-0.54	-5.15	-0.42	9.95e-7	Urinary tract infection frequency;
TGCT	cis	rs4711350	0.765	rs943473	chr6:33743651	G/C	cg00334056	chr6:33755658	LEMD2	-0.27	-4.47	-0.37	1.75e-5	Schizophrenia;
TGCT	cis	rs6570726	0.791	rs7765687	chr6:145915100	A/C	cg23711669	chr6:146136114	FBXO30	0.85	8.98	0.63	3.55e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7726839	0.540	rs72703092	chr5:599269	G/A	cg20362242	chr5:692897	TPPP	0.53	4.56	0.38	1.22e-5	Obesity-related traits;
TGCT	cis	rs12780845	0.505	rs10795459	chr10:17244124	C/T	cg01003015	chr10:17271136	VIM	-0.62	-5.74	-0.46	6.8e-8	Homocysteine levels;
TGCT	cis	rs929354	1.000	rs1182381	chr7:157043473	G/A	cg05182265	chr7:156933206	UBE3C	0.3	6.31	0.49	4.59e-9	Body mass index;
TGCT	cis	rs12579753	0.917	rs11115058	chr12:82263427	T/C	cg07988820	chr12:82153109	PPFIA2	-0.51	-5.37	-0.43	3.66e-7	Resting heart rate;
TGCT	cis	rs1609391	0.561	rs9289523	chr3:136635589	C/G	cg15507776	chr3:136538369	TMEM22	0.65	6.81	0.52	3.72e-10	Neuroticism;
TGCT	cis	rs933688	1.000	rs7720132	chr5:90745105	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.04	8.8	0.62	9.68e-15	Smoking behavior;
TGCT	cis	rs11122272	0.701	rs2790894	chr1:231505587	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.14	-0.54	6.86e-11	Hemoglobin concentration;
TGCT	cis	rs112217694	0.867	rs77585392	chr4:104643797	G/A	cg24090629	chr4:104641072	TACR3	-1.0	-5.19	-0.42	8.44e-7	Menarche (age at onset);
TGCT	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg00149659	chr3:10157352	C3orf10	0.91	5.89	0.47	3.32e-8	Alzheimer's disease;
TGCT	cis	rs6540559	0.673	rs17015361	chr1:210018901	C/G	cg22029157	chr1:209979665	IRF6	0.68	4.88	0.4	3.22e-6	Cleft lip with or without cleft palate;
TGCT	trans	rs629535	0.773	rs686683	chr8:70070364	G/A	cg21567404	chr3:27674614	NA	0.57	9.11	0.63	1.82e-15	Dupuytren's disease;
TGCT	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg06112835	chr11:68658793	MRPL21	0.48	8.14	0.59	3.49e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs12497850	0.865	rs7649458	chr3:48920127	C/T	cg06212747	chr3:49208901	KLHDC8B	0.62	5.83	0.46	4.42e-8	Parkinson's disease;
TGCT	cis	rs554111	0.686	rs519209	chr1:21043790	C/T	cg08890418	chr1:21044141	KIF17	-0.49	-5.59	-0.45	1.41e-7	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg13012494	chr21:47604986	C21orf56	0.4	4.88	0.4	3.21e-6	Testicular germ cell tumor;
TGCT	cis	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg07424592	chr7:64974309	NA	1.4	8.42	0.6	7.87e-14	Diabetic kidney disease;
TGCT	cis	rs6570726	0.846	rs870491	chr6:145933390	T/G	cg23711669	chr6:146136114	FBXO30	0.83	8.67	0.61	2.02e-14	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9341808	0.667	rs3805919	chr6:80906809	C/G	cg08355045	chr6:80787529	NA	0.3	4.98	0.41	2.07e-6	Sitting height ratio;
TGCT	cis	rs7089973	0.604	rs7095816	chr10:116585109	T/C	cg03647239	chr10:116582469	FAM160B1	0.6	5.75	0.46	6.62e-8	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs11711311	1.000	rs13073843	chr3:113449150	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.78	-7.13	-0.54	7.14e-11	IgG glycosylation;
TGCT	cis	rs7474896	0.559	rs2738185	chr10:38247736	G/A	cg13720705	chr10:37990370	NA	-0.34	-4.51	-0.38	1.46e-5	Obesity (extreme);
TGCT	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6750047	1.000	rs6750047	chr2:38276549	A/G	cg07380506	chr2:38303506	CYP1B1	0.62	5.63	0.45	1.12e-7	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs7614311	0.636	rs66490742	chr3:63913653	G/A	cg22134162	chr3:63841271	THOC7	-0.48	-6.11	-0.48	1.2e-8	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs1865760	0.593	rs9295678	chr6:25937033	G/A	cg12310025	chr6:25882481	NA	-0.52	-5.28	-0.43	5.47e-7	Height;
TGCT	cis	rs7302981	0.967	rs35549836	chr12:50553202	C/T	cg23855989	chr12:50355821	AQP5	0.3	4.5	0.38	1.52e-5	Systolic blood pressure;
TGCT	trans	rs324780	0.544	rs3112090	chr12:83917047	C/T	cg27144766	chr5:150604977	CCDC69	0.24	6.63	0.51	9.29e-10	Vertical cup-disc ratio;
TGCT	cis	rs478304	0.651	rs4930313	chr11:65500428	C/T	cg17480646	chr11:65405466	SIPA1	-0.57	-6.93	-0.53	2.05e-10	Acne (severe);
TGCT	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg06753367	chr22:24256600	NA	-0.23	-4.5	-0.37	1.52e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs910316	0.967	rs2024653	chr14:75595154	G/A	cg08847533	chr14:75593920	NEK9	0.95	10.55	0.69	5.83e-19	Height;
TGCT	cis	rs11190604	0.673	rs10883498	chr10:102228709	T/A	cg16342193	chr10:102329863	NA	-0.4	-5.31	-0.43	4.85e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs4654899	0.802	rs17410008	chr1:21220701	G/C	cg01072550	chr1:21505969	NA	-0.47	-7.09	-0.54	8.84e-11	Superior frontal gyrus grey matter volume;
TGCT	cis	rs36051895	0.589	rs10491650	chr9:5203054	C/T	cg02405213	chr9:5042618	JAK2	0.69	8.41	0.6	8.24e-14	Pediatric autoimmune diseases;
TGCT	cis	rs8017423	0.904	rs4603489	chr14:90760607	A/G	cg04374321	chr14:90722782	PSMC1	-0.74	-7.09	-0.54	9.2e-11	Mortality in heart failure;
TGCT	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg24531977	chr5:56204891	C5orf35	0.68	7.22	0.54	4.69e-11	Initial pursuit acceleration;
TGCT	cis	rs4141404	0.748	rs2232176	chr22:31536133	A/C	cg01546248	chr22:31477006	SMTN	-0.61	-4.54	-0.38	1.33e-5	Paclitaxel-induced neuropathy;
TGCT	cis	rs9811920	0.809	rs35422475	chr3:99711545	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.45	5.14	0.42	1.03e-6	Axial length;
TGCT	cis	rs651907	0.535	rs11712309	chr3:101519097	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.31	-6.4	-0.5	2.91e-9	Colorectal cancer;
TGCT	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg11301795	chr4:187892539	NA	-0.33	-4.82	-0.4	4.14e-6	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs2727020	0.566	rs10839234	chr11:49185524	C/T	cg15704280	chr7:45808275	SEPT13	-0.67	-7.51	-0.56	1.02e-11	Coronary artery disease;
TGCT	trans	rs7618501	1.000	rs11716575	chr3:49744890	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-1.04	-13.29	-0.77	1.33e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs9796	0.516	rs28473405	chr15:41293170	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.5	-6.45	-0.5	2.22e-9	Menopause (age at onset);
TGCT	cis	rs9443645	0.901	rs2050663	chr6:79753394	T/C	cg09184832	chr6:79620586	NA	-0.48	-5.24	-0.43	6.81e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs17376456	0.877	rs9885329	chr5:93380278	G/A	cg25358565	chr5:93447407	FAM172A	0.93	8.37	0.6	1.04e-13	Diabetic retinopathy;
TGCT	cis	rs9381040	0.610	rs9381028	chr6:41025081	C/A	cg03526776	chr6:41159608	TREML2	0.27	5.29	0.43	5.37e-7	Alzheimer's disease (late onset);
TGCT	cis	rs7829975	0.523	rs9644774	chr8:8559832	G/A	cg17143192	chr8:8559678	CLDN23	-0.5	-4.92	-0.4	2.73e-6	Mood instability;
TGCT	cis	rs2204008	0.545	rs1663283	chr12:38132039	G/A	cg26384229	chr12:38710491	ALG10B	-0.58	-5.09	-0.42	1.28e-6	Bladder cancer;
TGCT	cis	rs1205863	1.000	rs209814	chr6:11951861	C/G	cg07106625	chr6:11870215	NA	0.51	5.05	0.41	1.51e-6	Disc degeneration (lumbar);
TGCT	cis	rs10789207	0.576	rs6690186	chr1:67003479	T/C	cg22855438	chr1:67395917	MIER1	-0.7	-4.49	-0.37	1.61e-5	Resting heart rate;
TGCT	cis	rs78487399	0.808	rs6726917	chr2:43753913	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.07	-0.41	1.41e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs9814567	0.712	rs9838467	chr3:134332222	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-6.41	-0.5	2.8e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg22166914	chr1:53195759	ZYG11B	-0.36	-5.91	-0.47	3.06e-8	Monocyte count;
TGCT	cis	rs4631830	0.900	rs7920517	chr10:51532621	G/A	cg10326726	chr10:51549505	MSMB	-0.27	-5.38	-0.43	3.6e-7	Prostate-specific antigen levels;
TGCT	cis	rs13191362	1.000	rs67046187	chr6:163068532	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.91	6.86	0.52	2.88e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs797680	0.856	rs7513705	chr1:93666349	T/C	cg17826107	chr1:92977322	EVI5	-0.23	-5.03	-0.41	1.67e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg11890956	chr21:40555474	PSMG1	1.11	12.48	0.75	1.21e-23	Cognitive function;
TGCT	cis	rs2241685	0.850	rs7582679	chr2:1942742	A/G	cg21862353	chr2:1801628	MYT1L	-0.52	-4.77	-0.39	5.05e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg07424592	chr7:64974309	NA	1.36	8.15	0.59	3.36e-13	Diabetic kidney disease;
TGCT	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-5.79	-0.46	5.39e-8	Alzheimer's disease;
TGCT	trans	rs2070856	0.655	rs116067827	chr20:23699577	G/A	cg13434034	chr8:135477110	NA	0.78	6.65	0.51	8.27e-10	Blood protein levels;
TGCT	cis	rs2456568	0.867	rs1395384	chr11:93663250	C/T	cg16099599	chr11:93583650	C11orf90	0.38	4.51	0.38	1.51e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs3824867	0.676	rs7104366	chr11:47462115	G/A	cg20307385	chr11:47447363	PSMC3	0.7	6.03	0.48	1.71e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs9611565	0.506	rs1883825	chr22:41703408	A/G	cg03806693	chr22:41940476	POLR3H	-0.75	-7.26	-0.55	3.78e-11	Vitiligo;
TGCT	cis	rs644799	0.672	rs11021347	chr11:95653494	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.75	7.57	0.56	7.54e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs6582630	0.576	rs4403871	chr12:38292193	G/A	cg26384229	chr12:38710491	ALG10B	-0.54	-4.7	-0.39	6.68e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs114540395	0.920	rs115066444	chr10:103461443	G/C	cg18276125	chr10:102749041	C10orf2	0.42	4.92	0.4	2.65e-6	Schizophrenia;
TGCT	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg20276088	chr3:133502917	NA	-0.24	-5.07	-0.41	1.41e-6	Iron status biomarkers;
TGCT	cis	rs10927875	0.757	rs4661679	chr1:16321010	C/T	cg21385522	chr1:16154831	NA	0.51	5.31	0.43	4.96e-7	Dilated cardiomyopathy;
TGCT	cis	rs6087990	0.735	rs2424920	chr20:31385452	T/C	cg13636640	chr20:31349939	DNMT3B	0.95	12.38	0.74	2.08e-23	Ulcerative colitis;
TGCT	cis	rs9902453	0.934	rs7211246	chr17:28485762	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	5.41	0.44	3.13e-7	Coffee consumption (cups per day);
TGCT	cis	rs13256369	1.000	rs13267501	chr8:8574058	G/A	cg06671706	chr8:8559999	CLDN23	0.35	4.62	0.38	9.35e-6	Obesity-related traits;
TGCT	cis	rs4919694	1.000	rs78893207	chr10:104796138	T/C	cg04362960	chr10:104952993	NT5C2	1.06	7.05	0.53	1.09e-10	Arsenic metabolism;
TGCT	cis	rs5769765	0.908	rs138864	chr22:50204712	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.38	5.75	0.46	6.53e-8	Schizophrenia;
TGCT	cis	rs9914544	0.564	rs11868520	chr17:18770367	A/G	cg26378065	chr17:18585709	ZNF286B	0.52	4.5	0.37	1.56e-5	Educational attainment (years of education);
TGCT	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg20203395	chr5:56204925	C5orf35	-0.53	-4.92	-0.4	2.67e-6	Initial pursuit acceleration;
TGCT	cis	rs858239	0.665	rs858305	chr7:23242830	C/G	cg05407003	chr7:23246146	NA	0.28	4.52	0.38	1.43e-5	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs617219	0.737	rs13158309	chr5:78463395	C/T	cg23514016	chr5:78407564	BHMT	-0.34	-5.17	-0.42	9.08e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	trans	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg23505145	chr19:12996616	KLF1	0.79	8.3	0.6	1.47e-13	Prostate cancer (SNP x SNP interaction);
TGCT	trans	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg13565492	chr6:43139072	SRF	-0.81	-7.71	-0.57	3.45e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7192750	0.586	rs8050651	chr16:71881444	C/G	cg06353428	chr16:71660113	MARVELD3	0.8	7.26	0.55	3.8e-11	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs2836974	0.545	rs3167757	chr21:40714478	C/T	cg11644478	chr21:40555479	PSMG1	0.63	6.09	0.48	1.34e-8	Cognitive function;
TGCT	trans	rs1814175	0.817	rs10839351	chr11:49758153	C/T	cg03929089	chr4:120376271	NA	-0.69	-7.97	-0.58	8.64e-13	Height;
TGCT	cis	rs9926296	0.569	rs4785708	chr16:89796569	C/T	cg03388025	chr16:89894329	SPIRE2	-0.31	-4.63	-0.38	9.05e-6	Vitiligo;
TGCT	cis	rs250677	1.000	rs250676	chr5:148425518	A/T	cg23229984	chr5:148520753	ABLIM3	0.21	4.98	0.41	2.05e-6	Breast cancer;
TGCT	cis	rs921968	0.509	rs832813	chr2:219354569	T/C	cg02176678	chr2:219576539	TTLL4	0.46	6.6	0.51	1.08e-9	Mean corpuscular hemoglobin concentration;
TGCT	trans	rs561341	0.654	rs6505265	chr17:30172580	C/T	cg20587970	chr11:113659929	NA	0.67	8.2	0.59	2.57e-13	Hip circumference adjusted for BMI;
TGCT	cis	rs7267979	1.000	rs404394	chr20:25447896	A/G	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg24503407	chr1:205819492	PM20D1	0.42	5.17	0.42	9.1e-7	Menarche (age at onset);
TGCT	cis	rs9308731	0.644	rs7593638	chr2:111876941	A/C	cg04202892	chr2:111875749	ACOXL	0.54	6.25	0.49	6.1e-9	Chronic lymphocytic leukemia;
TGCT	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg09177884	chr7:1199841	ZFAND2A	-0.6	-6.31	-0.49	4.58e-9	Longevity;Endometriosis;
TGCT	cis	rs2820315	1.000	rs2820309	chr1:201834944	A/G	cg12730843	chr1:201915899	LMOD1	-0.25	-4.54	-0.38	1.32e-5	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
TGCT	cis	rs2456568	0.778	rs7940973	chr11:93682045	C/G	cg26875233	chr11:93583750	C11orf90	0.41	5.22	0.42	7.28e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs3931020	0.530	rs12125889	chr1:75241971	A/G	cg17719053	chr1:75198211	TYW3;CRYZ	0.48	4.81	0.4	4.32e-6	Resistin levels;
TGCT	cis	rs2948294	0.566	rs13261997	chr8:8112295	C/T	cg15462221	chr8:8086144	FLJ10661	-0.59	-4.82	-0.4	4.11e-6	Red cell distribution width;
TGCT	cis	rs3540	0.960	rs8030722	chr15:90974920	G/A	cg22089800	chr15:90895588	ZNF774	0.74	6.88	0.53	2.59e-10	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs2980439	0.783	rs2948305	chr8:8098577	G/A	cg15556689	chr8:8085844	FLJ10661	0.88	9.0	0.63	3.23e-15	Neuroticism;
TGCT	cis	rs7617773	0.780	rs6442111	chr3:48312060	G/C	cg11946769	chr3:48343235	NME6	0.72	6.2	0.49	7.83e-9	Coronary artery disease;
TGCT	cis	rs6460942	0.908	rs6978768	chr7:12232366	G/A	cg06484146	chr7:12443880	VWDE	-0.53	-4.6	-0.38	1.03e-5	Coronary artery disease;
TGCT	cis	rs77741769	0.571	rs1696357	chr12:121348649	A/G	cg02419362	chr12:121203948	SPPL3	0.19	4.45	0.37	1.87e-5	Mean corpuscular volume;
TGCT	cis	rs7226408	0.857	rs72887052	chr18:34487296	A/C	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs7772486	0.790	rs2256998	chr6:146207657	A/C	cg05347473	chr6:146136440	FBXO30	0.52	5.0	0.41	1.87e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6912958	0.559	rs107690	chr6:88069352	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.68	-7.08	-0.54	9.23e-11	Monocyte percentage of white cells;
TGCT	cis	rs12579753	1.000	rs7966755	chr12:82221604	A/G	cg07988820	chr12:82153109	PPFIA2	-0.6	-6.48	-0.5	1.91e-9	Resting heart rate;
TGCT	cis	rs8072100	0.840	rs12453233	chr17:45454570	C/T	cg08085267	chr17:45401833	C17orf57	-0.47	-5.09	-0.42	1.28e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg00908189	chr16:619842	PIGQ	0.87	10.68	0.69	2.85e-19	Height;
TGCT	cis	rs17376456	0.569	rs12653528	chr5:93212833	T/C	cg25358565	chr5:93447407	FAM172A	-0.81	-6.54	-0.51	1.47e-9	Diabetic retinopathy;
TGCT	cis	rs1061377	0.965	rs7677729	chr4:39121990	C/T	cg24403649	chr4:39172243	NA	0.18	4.44	0.37	1.99e-5	Uric acid levels;
TGCT	cis	rs62064224	0.533	rs11657826	chr17:30790386	T/A	cg18200150	chr17:30822561	MYO1D	0.59	8.48	0.61	5.5e-14	Schizophrenia;
TGCT	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg25811766	chr13:21894605	NA	0.28	5.38	0.44	3.53e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	cis	rs67311347	0.544	rs13062243	chr3:40336789	G/A	cg13683864	chr3:40499215	RPL14	-0.78	-7.5	-0.56	1.06e-11	Renal cell carcinoma;
TGCT	cis	rs2239547	0.657	rs12496077	chr3:52886241	G/A	cg11645453	chr3:52864694	ITIH4	0.35	5.77	0.46	5.97e-8	Schizophrenia;
TGCT	cis	rs13082711	0.554	rs13087873	chr3:27392326	C/T	cg02860705	chr3:27208620	NA	0.43	6.0	0.47	2.03e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs7264396	0.690	rs2425170	chr20:34442672	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.27	-4.47	-0.37	1.76e-5	Total cholesterol levels;
TGCT	cis	rs4242434	0.927	rs3736147	chr8:22471824	A/G	cg21658235	chr8:22456391	C8orf58	-0.43	-4.5	-0.37	1.54e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs9549367	0.826	rs9549710	chr13:113898064	A/C	cg00898013	chr13:113819073	PROZ	-0.4	-5.03	-0.41	1.64e-6	Platelet distribution width;
TGCT	cis	rs13392177	0.660	rs10932762	chr2:219076213	G/C	cg00012203	chr2:219082015	ARPC2	-0.79	-8.02	-0.58	6.73e-13	Pyoderma gangrenosum in inflammatory bowel disease;
TGCT	cis	rs7647973	0.560	rs7638154	chr3:49299375	C/A	cg18654377	chr3:49208889	KLHDC8B	-0.38	-5.03	-0.41	1.69e-6	Menarche (age at onset);
TGCT	cis	rs77861329	1.000	rs876782	chr3:52107909	C/T	cg08692210	chr3:52188851	WDR51A	-0.84	-4.56	-0.38	1.2e-5	Macrophage inflammatory protein 1b levels;
TGCT	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	-0.82	-9.11	-0.63	1.79e-15	Menarche (age at onset);
TGCT	cis	rs7267979	1.000	rs6083813	chr20:25337671	A/G	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg08045932	chr20:61659980	NA	0.48	9.16	0.64	1.36e-15	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7666738	0.927	rs4699328	chr4:99055890	C/T	cg18180107	chr4:99064573	C4orf37	0.57	5.26	0.43	6.03e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg02725872	chr8:58115012	NA	-0.39	-5.15	-0.42	1.01e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2404602	0.716	rs7179142	chr15:76698268	G/A	cg26408565	chr15:76604113	ETFA	-0.41	-5.42	-0.44	2.92e-7	Blood metabolite levels;
TGCT	cis	rs1801251	0.963	rs6739638	chr2:233576015	G/A	cg25237894	chr2:233734115	C2orf82	0.31	5.52	0.44	1.92e-7	Coronary artery disease;
TGCT	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.18	0.49	8.33e-9	Electroencephalogram traits;
TGCT	cis	rs5771225	0.544	rs1555048	chr22:50688348	A/G	cg16473166	chr22:50639996	SELO	0.67	5.37	0.43	3.68e-7	Late-onset Alzheimer's disease;
TGCT	cis	rs6969780	0.545	rs983184	chr7:27188379	C/T	cg03724423	chr7:27170755	HOXA4	-0.43	-4.59	-0.38	1.05e-5	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs6700896	0.500	rs4655754	chr1:66114747	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	-0.57	-4.56	-0.38	1.19e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs12620999	0.878	rs59725626	chr2:237970010	G/A	cg23555395	chr2:238036564	NA	0.28	4.97	0.41	2.19e-6	Systemic lupus erythematosus;
TGCT	cis	rs7666738	0.753	rs11097594	chr4:98944486	A/G	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6901250	0.568	rs4946198	chr6:117176599	C/T	cg12892004	chr6:117198278	RFX6	-0.47	-5.37	-0.43	3.7e-7	C-reactive protein levels;
TGCT	cis	rs8067545	0.717	rs9907788	chr17:20008903	T/C	cg13482628	chr17:19912719	NA	0.53	4.51	0.38	1.49e-5	Schizophrenia;
TGCT	cis	rs1124769	0.502	rs12148865	chr15:51078597	C/G	cg23028286	chr15:51614521	CYP19A1	0.2	4.51	0.38	1.46e-5	Cognitive performance;
TGCT	cis	rs2153535	0.601	rs9502715	chr6:8455709	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs11030122	0.702	rs1349583	chr11:3972236	G/A	cg18678763	chr11:4115507	RRM1	-0.49	-6.27	-0.49	5.56e-9	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs2658782	0.951	rs2608214	chr11:93148665	C/T	cg18152523	chr11:93063302	CCDC67	-0.62	-5.14	-0.42	1.03e-6	Pulmonary function decline;
TGCT	trans	rs8073060	0.586	rs9303690	chr17:34005513	C/T	cg19694781	chr19:47549865	TMEM160	-0.62	-14.07	-0.78	1.86e-27	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs2230307	0.536	rs496798	chr1:100507990	G/A	cg24955406	chr1:100503596	HIAT1	0.74	4.86	0.4	3.41e-6	Carotid intima media thickness;
TGCT	cis	rs7017914	0.905	rs2639960	chr8:71922139	A/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.55	-5.1	-0.42	1.24e-6	Bone mineral density;
TGCT	cis	rs6032067	0.929	rs2664581	chr20:43804522	A/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.39	-4.96	-0.41	2.31e-6	Blood protein levels;
TGCT	cis	rs1008375	1.000	rs10009541	chr4:17682218	C/T	cg10189774	chr4:17578691	LAP3	-0.53	-4.69	-0.39	7.14e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7647973	0.961	rs11130186	chr3:49275828	A/G	cg05785598	chr3:49045655	WDR6	0.39	4.61	0.38	9.91e-6	Menarche (age at onset);
TGCT	cis	rs8033133	0.881	rs3803328	chr15:25330550	T/A	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	-0.27	-5.09	-0.42	1.32e-6	Blood osmolality (transformed sodium);
TGCT	cis	rs7829975	0.539	rs883647	chr8:8569724	G/A	cg17143192	chr8:8559678	CLDN23	-0.52	-5.14	-0.42	1.02e-6	Mood instability;
TGCT	cis	rs6770219	0.516	rs7635507	chr3:186134871	G/A	cg20306810	chr3:186501757	SNORD2;EIF4A2	0.73	4.45	0.37	1.89e-5	Cerebrospinal T-tau levels;
TGCT	cis	rs9467773	1.000	rs6926629	chr6:26499903	T/C	cg15659132	chr6:26577336	NA	0.84	11.93	0.73	2.59e-22	Intelligence (multi-trait analysis);
TGCT	cis	rs7258465	1.000	rs8105994	chr19:18593553	A/G	cg06462663	chr19:18546047	ISYNA1	0.21	4.76	0.39	5.35e-6	Breast cancer;
TGCT	cis	rs2440129	0.591	rs312466	chr17:6899221	G/A	cg05215272	chr17:6899095	ALOX12	-0.51	-6.29	-0.49	4.9e-9	Tonsillectomy;
TGCT	cis	rs2562456	0.793	rs7259708	chr19:21750648	T/C	cg25650185	chr19:21324782	ZNF431	-0.66	-5.86	-0.47	3.92e-8	Pain;
TGCT	cis	rs2276314	0.857	rs28530656	chr18:33588700	C/T	cg19628046	chr18:33552617	C18orf21	-0.51	-4.46	-0.37	1.79e-5	Endometriosis;Drug-induced torsades de pointes;
TGCT	cis	rs11792861	0.926	rs3750451	chr9:111822866	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.48	4.47	0.37	1.73e-5	Menarche (age at onset);
TGCT	cis	rs7824557	0.614	rs17741537	chr8:11213092	A/G	cg21775007	chr8:11205619	TDH	0.71	6.81	0.52	3.73e-10	Retinal vascular caliber;
TGCT	cis	rs7681440	0.904	rs28734152	chr4:90767359	C/T	cg26578617	chr4:90757533	SNCA	-0.47	-4.87	-0.4	3.34e-6	Dementia with Lewy bodies;
TGCT	cis	rs12681288	0.644	rs2123058	chr8:1000304	A/G	cg04851639	chr8:1020857	NA	-0.29	-4.8	-0.4	4.54e-6	Schizophrenia;
TGCT	cis	rs7178572	0.568	rs11854193	chr15:77458136	C/A	cg15453836	chr15:77711506	NA	-0.45	-4.99	-0.41	2.02e-6	Type 2 diabetes;
TGCT	cis	rs477895	1.000	rs7939107	chr11:64034773	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	5.32	0.43	4.6e-7	Mean platelet volume;
TGCT	cis	rs6952808	0.609	rs34967784	chr7:1949507	T/G	cg22963979	chr7:1858916	MAD1L1	-0.39	-5.89	-0.47	3.36e-8	Bipolar disorder and schizophrenia;
TGCT	cis	rs13217239	0.646	rs9393789	chr6:27067028	G/T	cg15659132	chr6:26577336	NA	-0.55	-5.37	-0.43	3.7e-7	Schizophrenia;
TGCT	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.48	-4.55	-0.38	1.27e-5	Longevity;Endometriosis;
TGCT	cis	rs3087591	0.922	rs2341348	chr17:29534867	C/T	cg24425628	chr17:29625626	OMG;NF1	0.48	6.99	0.53	1.52e-10	Hip circumference;
TGCT	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg25036284	chr2:26402008	FAM59B	-0.74	-5.29	-0.43	5.28e-7	Gut microbiome composition (summer);
TGCT	cis	rs9311474	0.713	rs352170	chr3:52236077	A/G	cg07507251	chr3:52567010	NT5DC2	0.4	5.32	0.43	4.68e-7	Electroencephalogram traits;
TGCT	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.68	5.62	0.45	1.18e-7	Tonsillectomy;
TGCT	cis	rs9513627	0.573	rs12431100	chr13:100184918	C/G	cg15490075	chr13:100150979	NA	-0.68	-4.55	-0.38	1.25e-5	Obesity-related traits;
TGCT	cis	rs2677744	0.962	rs1266486	chr15:91460284	T/C	cg23684204	chr15:91497937	RCCD1	0.34	5.15	0.42	1e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs9810089	0.786	rs10935183	chr3:136149139	C/T	cg12473912	chr3:136751656	NA	0.36	5.1	0.42	1.22e-6	Gestational age at birth (child effect);
TGCT	cis	rs75229567	0.618	rs35394896	chr12:70188346	T/A	cg10114359	chr12:70132523	RAB3IP	1.06	5.95	0.47	2.6e-8	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
TGCT	trans	rs1814175	0.791	rs10839395	chr11:49846274	G/T	cg15704280	chr7:45808275	SEPT13	-0.72	-8.14	-0.59	3.61e-13	Height;
TGCT	cis	rs2115536	1.000	rs11072871	chr15:80197931	T/C	cg00225070	chr15:80189496	MTHFS	0.58	5.15	0.42	9.94e-7	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs35306767	0.714	rs7075188	chr10:1088746	G/T	cg20503657	chr10:835505	NA	-0.45	-4.91	-0.4	2.87e-6	Eosinophil percentage of granulocytes;
TGCT	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg07870213	chr5:140052090	DND1	-0.61	-7.28	-0.55	3.35e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs231513	0.906	rs179586	chr17:41999094	T/C	cg26893861	chr17:41843967	DUSP3	-0.71	-5.03	-0.41	1.67e-6	Cognitive function;
TGCT	cis	rs2535633	0.602	rs2581816	chr3:53014657	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.55	-5.32	-0.43	4.66e-7	Body mass index;
TGCT	cis	rs1215050	0.765	rs783925	chr4:98969881	T/C	cg17366294	chr4:99064904	C4orf37	-0.55	-5.8	-0.46	5.23e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs910316	0.967	rs175502	chr14:75533679	A/G	cg08847533	chr14:75593920	NEK9	-0.95	-10.3	-0.68	2.33e-18	Height;
TGCT	cis	rs10984561	0.881	rs7039410	chr9:122251769	T/G	cg14242995	chr9:122249943	NA	0.73	5.96	0.47	2.46e-8	Pulmonary function decline;
TGCT	cis	rs7208859	0.623	rs7217984	chr17:29092766	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs2688608	0.592	rs7909802	chr10:75484186	G/C	cg04320760	chr10:75533139	FUT11	-0.4	-6.25	-0.49	6.11e-9	Inflammatory bowel disease;
TGCT	cis	rs6088580	0.634	rs4911423	chr20:32999386	T/A	cg06115741	chr20:33292138	TP53INP2	-0.55	-4.81	-0.4	4.28e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs67311347	1.000	rs6795475	chr3:40489281	A/G	cg13683864	chr3:40499215	RPL14	-1.04	-10.81	-0.7	1.34e-19	Renal cell carcinoma;
TGCT	cis	rs7017914	0.905	rs2639951	chr8:71927225	C/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.56	-5.11	-0.42	1.21e-6	Bone mineral density;
TGCT	cis	rs3091242	0.933	rs35497030	chr1:25783066	A/G	cg00786635	chr1:25594202	NA	-0.52	-5.54	-0.45	1.71e-7	Erythrocyte sedimentation rate;
TGCT	trans	rs2727020	0.729	rs2866328	chr11:49282421	A/G	cg15704280	chr7:45808275	SEPT13	0.73	8.33	0.6	1.27e-13	Coronary artery disease;
TGCT	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg24250549	chr1:154909240	PMVK	0.66	6.5	0.5	1.73e-9	Prostate cancer;
TGCT	cis	rs9467773	1.000	rs3736782	chr6:26505403	C/A	cg05738196	chr6:26577821	NA	0.88	12.49	0.75	1.09e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs3087591	0.922	rs757383	chr17:29596045	C/G	cg24425628	chr17:29625626	OMG;NF1	0.47	7.46	0.56	1.3e-11	Hip circumference;
TGCT	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg23172400	chr8:95962367	TP53INP1	-0.38	-6.49	-0.5	1.84e-9	Type 2 diabetes;
TGCT	cis	rs1153858	1.000	rs4625670	chr15:45652926	C/T	cg26924012	chr15:45694286	SPATA5L1	1.09	15.16	0.81	5.15e-30	Homoarginine levels;
TGCT	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs765787	0.530	rs11854690	chr15:45516016	C/T	cg24006582	chr15:45444508	DUOX1	-0.26	-5.62	-0.45	1.19e-7	Uric acid levels;
TGCT	trans	rs9650657	0.513	rs7005884	chr8:10796472	A/G	cg15556689	chr8:8085844	FLJ10661	-0.8	-7.38	-0.55	1.96e-11	Neuroticism;
TGCT	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg03351412	chr1:154909251	PMVK	0.53	4.83	0.4	3.89e-6	Prostate cancer;
TGCT	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg07157834	chr1:205819609	PM20D1	0.42	6.65	0.51	8.2e-10	Menarche (age at onset);
TGCT	cis	rs9457247	0.846	rs2757052	chr6:167380174	T/C	cg23791538	chr6:167370224	RNASET2	0.5	4.98	0.41	2.08e-6	Crohn's disease;
TGCT	cis	rs8017423	0.647	rs12883357	chr14:90815032	A/G	cg04374321	chr14:90722782	PSMC1	-0.57	-5.6	-0.45	1.33e-7	Mortality in heart failure;
TGCT	cis	rs7267979	1.000	rs7343481	chr20:25300113	C/T	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg20587970	chr11:113659929	NA	0.8	9.45	0.65	2.65e-16	Hip circumference adjusted for BMI;
TGCT	cis	rs896854	0.738	rs1713669	chr8:95958637	C/G	cg09323728	chr8:95962352	TP53INP1	-0.44	-5.26	-0.43	6.04e-7	Type 2 diabetes;
TGCT	cis	rs7193541	0.684	rs4888265	chr16:74683737	T/C	cg01733217	chr16:74700730	RFWD3	1.0	13.03	0.76	5.7e-25	Multiple myeloma;
TGCT	cis	rs6674176	1.000	rs11210937	chr1:44405563	T/C	cg13606994	chr1:44402422	ARTN	-0.52	-5.07	-0.41	1.39e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg08045932	chr20:61659980	NA	0.49	9.25	0.64	8.4e-16	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs6430585	0.528	rs309166	chr2:136667487	C/T	cg07169764	chr2:136633963	MCM6	1.19	11.56	0.72	2.02e-21	Corneal structure;
TGCT	cis	rs7804356	1.000	rs73065521	chr7:26831409	C/A	cg03456212	chr7:26904342	SKAP2	-0.62	-4.71	-0.39	6.51e-6	Type 1 diabetes;
TGCT	cis	rs9394841	0.692	rs9381095	chr6:41806708	T/A	cg08135965	chr6:41755394	TOMM6	0.54	4.96	0.41	2.31e-6	Mean corpuscular hemoglobin;Red cell distribution width;
TGCT	cis	rs9993613	0.875	rs11728435	chr4:73509826	T/C	cg15102770	chr4:73434591	ADAMTS3	0.52	4.87	0.4	3.28e-6	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg25427524	chr10:38739819	LOC399744	-0.39	-8.04	-0.59	5.95e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs4517514	0.509	rs11018894	chr11:89904238	C/A	cg05041596	chr11:89867385	NAALAD2	0.55	5.14	0.42	1.05e-6	Trans fatty acid levels;
TGCT	cis	rs12220238	1.000	rs11000901	chr10:75919971	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.06	0.54	1.05e-10	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs12136530	0.593	rs11578302	chr1:19724835	A/G	cg24875000	chr1:19041556	PAX7	-0.27	-4.61	-0.38	9.8200000000000008e-06	Lead levels in blood;
TGCT	cis	rs36051895	0.664	rs3824433	chr9:5113577	C/T	cg02405213	chr9:5042618	JAK2	-0.75	-10.29	-0.68	2.45e-18	Pediatric autoimmune diseases;
TGCT	cis	rs7666738	0.830	rs13144771	chr4:99026935	G/C	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg08859206	chr1:53392774	SCP2	0.4	5.96	0.47	2.46e-8	Monocyte count;
TGCT	cis	rs17108533	0.588	rs35201218	chr14:71302023	C/T	cg23900759	chr14:71108106	TTC9	-1.14	-4.61	-0.38	9.92e-6	Response to antipsychotic treatment in schizophrenia (reasoning);
TGCT	cis	rs4918072	0.798	rs2067831	chr10:105643223	G/C	cg11005552	chr10:105648138	OBFC1	0.4	5.28	0.43	5.58e-7	Coronary artery disease;
TGCT	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg03452623	chr4:187889614	NA	-0.36	-5.34	-0.43	4.32e-7	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs1496653	0.602	rs35027557	chr3:23552752	C/G	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg08280861	chr8:58055591	NA	0.4	4.73	0.39	5.97e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4273100	0.790	rs60166680	chr17:19277544	C/G	cg23267110	chr17:19140637	EPN2	-0.74	-4.48	-0.37	1.68e-5	Schizophrenia;
TGCT	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg24503407	chr1:205819492	PM20D1	0.43	4.48	0.37	1.67e-5	Parkinson's disease;
TGCT	cis	rs208515	0.525	rs12193034	chr6:66677866	C/T	cg07460842	chr6:66804631	NA	0.88	9.35	0.64	4.63e-16	Exhaled nitric oxide levels;
TGCT	cis	rs72843506	0.656	rs16959946	chr17:20172447	A/G	cg18979559	chr17:20280153	CCDC144C	-0.65	-4.92	-0.4	2.67e-6	Schizophrenia;
TGCT	cis	rs2404602	0.967	rs2083762	chr15:76907376	T/C	cg26408565	chr15:76604113	ETFA	-0.37	-4.65	-0.39	8.21e-6	Blood metabolite levels;
TGCT	cis	rs2836950	0.501	rs11088470	chr21:40689162	A/G	cg06238570	chr21:40685208	BRWD1	-0.63	-6.44	-0.5	2.42e-9	Menarche (age at onset);
TGCT	cis	rs2742417	1.000	rs2673034	chr3:45755138	A/G	cg04837898	chr3:45731254	SACM1L	-0.52	-5.28	-0.43	5.58e-7	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg06636001	chr8:8085503	FLJ10661	0.73	7.19	0.54	5.43e-11	Mood instability;
TGCT	cis	rs4808199	0.948	rs12982276	chr19:19459800	T/C	cg03709012	chr19:19516395	GATAD2A	0.8	6.46	0.5	2.13e-9	Nonalcoholic fatty liver disease;
TGCT	cis	rs2742417	1.000	rs1877933	chr3:45753487	C/T	cg04837898	chr3:45731254	SACM1L	-0.55	-5.72	-0.46	7.45e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs7044106	0.762	rs12003646	chr9:123470621	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	6.83	0.52	3.4e-10	Hip circumference adjusted for BMI;
TGCT	cis	rs28785552	0.931	rs10406850	chr19:53240807	A/C	cg10871876	chr19:53194124	ZNF83	0.57	8.16	0.59	3.1400000000000003e-13	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg27170947	chr2:26402098	FAM59B	-0.43	-4.48	-0.37	1.69e-5	Gut microbiome composition (summer);
TGCT	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.61	-8.69	-0.62	1.8e-14	Longevity;Endometriosis;
TGCT	cis	rs7666738	0.518	rs13133925	chr4:98706398	G/T	cg18180107	chr4:99064573	C4orf37	0.54	4.78	0.39	4.93e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7666738	0.830	rs13121558	chr4:99002848	G/A	cg18180107	chr4:99064573	C4orf37	0.5	4.46	0.37	1.79e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1406084	0.636	rs3842900	chr2:154717391	G/C	cg25703346	chr2:154729189	GALNT13	0.77	4.6	0.38	1.03e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6088590	0.687	rs6088580	chr20:33285053	G/C	cg06115741	chr20:33292138	TP53INP2	0.57	4.86	0.4	3.51e-6	Coronary artery disease;
TGCT	trans	rs17685	0.884	rs8565	chr7:75630274	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.47	-7.26	-0.55	3.81e-11	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs892961	0.932	rs312853	chr17:75406045	T/G	cg05865280	chr17:75406074	SEPT9	0.27	6.69	0.52	6.81e-10	Airflow obstruction;
TGCT	cis	rs67311347	0.544	rs2278927	chr3:40350447	G/A	cg13683864	chr3:40499215	RPL14	-0.8	-7.58	-0.56	6.86e-12	Renal cell carcinoma;
TGCT	cis	rs763121	0.853	rs2179142	chr22:39037954	G/A	cg06022373	chr22:39101656	GTPBP1	0.81	7.91	0.58	1.21e-12	Menopause (age at onset);
TGCT	cis	rs11252926	0.537	rs61836851	chr10:447231	T/C	cg18196295	chr10:418757	DIP2C	0.3	4.89	0.4	3.1e-6	Psychosis in Alzheimer's disease;
TGCT	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg06112835	chr11:68658793	MRPL21	0.48	8.13	0.59	3.78e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg22963979	chr7:1858916	MAD1L1	-0.35	-5.5	-0.44	2.08e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs3862260	0.509	rs10802124	chr1:120164252	G/A	cg11530693	chr1:120165357	ZNF697	0.21	4.75	0.39	5.48e-6	Systemic lupus erythematosus;
TGCT	cis	rs67311347	1.000	rs9849992	chr3:40402140	C/T	cg13683864	chr3:40499215	RPL14	-1.1	-11.83	-0.73	4.49e-22	Renal cell carcinoma;
TGCT	cis	rs2797160	1.000	rs4897153	chr6:126003403	A/G	cg05901451	chr6:126070800	HEY2	-0.74	-6.3	-0.49	4.62e-9	Endometrial cancer;
TGCT	cis	rs611744	0.967	rs678387	chr8:109242730	G/C	cg21045802	chr8:109455806	TTC35	0.5	4.57	0.38	1.18e-5	Dupuytren's disease;
TGCT	cis	rs7169223	0.615	rs8038189	chr15:79099026	G/C	cg03762349	chr15:79060523	ADAMTS7	-0.25	-4.91	-0.4	2.83e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
TGCT	cis	rs12579753	0.810	rs1922565	chr12:82135348	T/C	cg21231944	chr12:82153410	PPFIA2	-0.33	-4.48	-0.37	1.68e-5	Resting heart rate;
TGCT	cis	rs910187	0.624	rs6063077	chr20:45787261	C/T	cg27589058	chr20:45804311	EYA2	-0.36	-6.75	-0.52	4.97e-10	Migraine;
TGCT	cis	rs9381040	0.610	rs2294694	chr6:41046177	G/A	cg03526776	chr6:41159608	TREML2	0.27	5.34	0.43	4.21e-7	Alzheimer's disease (late onset);
TGCT	cis	rs9611565	0.559	rs4822048	chr22:41988225	C/T	cg03806693	chr22:41940476	POLR3H	-1.11	-11.64	-0.72	1.26e-21	Vitiligo;
TGCT	cis	rs4704846	1.000	rs6861025	chr5:156519097	C/T	cg12943317	chr5:156479607	HAVCR1	-0.31	-4.56	-0.38	1.21e-5	Blood protein levels;
TGCT	cis	rs6424115	0.557	rs35904775	chr1:24180623	T/C	cg15997130	chr1:24165203	NA	-0.91	-10.51	-0.69	7.36e-19	Immature fraction of reticulocytes;
TGCT	cis	rs2439831	0.850	rs558656	chr15:43723514	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.01	8.37	0.6	1.02e-13	Lung cancer in ever smokers;
TGCT	cis	rs669446	0.558	rs620851	chr1:44110489	A/G	cg12908607	chr1:44402522	ARTN	-0.55	-5.9	-0.47	3.25e-8	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs2932538	0.922	rs3790611	chr1:113067792	A/G	cg22162597	chr1:113214053	CAPZA1	0.27	5.92	0.47	2.95e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs4689388	0.890	rs11732208	chr4:6292716	G/C	cg14416269	chr4:6271139	WFS1	0.37	4.9	0.4	2.95e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs739401	0.595	rs402806	chr11:3066432	A/G	cg25174290	chr11:3078921	CARS	0.47	4.5	0.37	1.53e-5	Longevity;
TGCT	cis	rs9486715	1.000	rs9373985	chr6:97063522	C/G	cg06623918	chr6:96969491	KIAA0776	-1.08	-13.52	-0.77	3.67e-26	Headache;
TGCT	trans	rs5771242	0.518	rs6010216	chr22:50679471	C/T	cg26607758	chr8:91997553	NA	0.72	7.33	0.55	2.55e-11	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
TGCT	cis	rs10931896	0.531	rs296801	chr2:201142812	C/T	cg17644776	chr2:200775616	C2orf69	0.27	4.8	0.4	4.45e-6	Systolic blood pressure;
TGCT	cis	rs739496	0.843	rs583140	chr12:111985954	G/A	cg10833066	chr12:111807467	FAM109A	0.35	4.52	0.38	1.42e-5	Platelet count;
TGCT	cis	rs9443645	0.670	rs79209669	chr6:79719623	C/G	cg09184832	chr6:79620586	NA	-0.48	-5.34	-0.43	4.21e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs68170813	0.559	rs11769861	chr7:106979559	T/C	cg02696742	chr7:106810147	HBP1	-0.68	-5.64	-0.45	1.09e-7	Coronary artery disease;
TGCT	cis	rs13242816	1.000	rs35800776	chr7:116110069	C/A	cg02799643	chr7:116139180	CAV2	-0.45	-4.84	-0.4	3.76e-6	P wave duration;
TGCT	cis	rs2760061	0.599	rs849903	chr1:228137659	T/C	cg18477163	chr1:228402036	OBSCN	-0.32	-6.21	-0.49	7.19e-9	Diastolic blood pressure;
TGCT	cis	rs3796352	1.000	rs35576914	chr3:53092270	G/A	cg27565382	chr3:53032988	SFMBT1	0.43	4.6	0.38	1.01e-5	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs5769765	0.825	rs7511620	chr22:50307932	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.44	6.19	0.49	8.01e-9	Schizophrenia;
TGCT	cis	rs11711311	1.000	rs9830978	chr3:113455940	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.78	-7.13	-0.54	7.14e-11	IgG glycosylation;
TGCT	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg00814883	chr7:100076585	TSC22D4	-0.85	-8.62	-0.61	2.62e-14	Platelet count;
TGCT	cis	rs67311347	1.000	rs2305522	chr3:40429358	A/G	cg13683864	chr3:40499215	RPL14	-1.05	-11.13	-0.71	2.2e-20	Renal cell carcinoma;
TGCT	cis	rs9902453	0.872	rs34698290	chr17:28500465	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	6.56	0.51	1.32e-9	Coffee consumption (cups per day);
TGCT	cis	rs6427419	0.934	rs874844	chr1:158067047	A/C	cg07184316	chr1:157669111	FCRL3	0.24	4.52	0.38	1.43e-5	Obesity-related traits;
TGCT	cis	rs12926788	0.689	rs1862450	chr16:24856775	A/G	cg06028605	chr16:24865363	SLC5A11	-0.43	-4.87	-0.4	3.34e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1577917	0.958	rs12205492	chr6:86475976	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.48	-0.44	2.28e-7	Response to antipsychotic treatment;
TGCT	cis	rs12142240	0.738	rs41293275	chr1:46806429	A/T	cg00530320	chr1:46809349	NSUN4	0.29	5.95	0.47	2.58e-8	Menopause (age at onset);
TGCT	cis	rs896854	0.654	rs10104909	chr8:95977973	C/T	cg16049864	chr8:95962084	TP53INP1	-0.72	-10.19	-0.67	4.46e-18	Type 2 diabetes;
TGCT	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg21724239	chr8:58056113	NA	0.42	5.04	0.41	1.59e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs12142240	0.698	rs55971480	chr1:46823206	G/T	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs7781977	0.644	rs10269380	chr7:50354512	G/A	cg01139861	chr7:50343298	IKZF1	0.5	5.91	0.47	3.13e-8	IgG glycosylation;
TGCT	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg01802117	chr1:53393560	SCP2	0.47	5.77	0.46	5.88e-8	Monocyte count;
TGCT	cis	rs4499344	1.000	rs4499344	chr19:33073431	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.79	-7.14	-0.54	6.92e-11	Mean platelet volume;
TGCT	cis	rs6750047	0.932	rs2116232	chr2:38268718	C/A	cg07380506	chr2:38303506	CYP1B1	0.59	5.28	0.43	5.71e-7	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs6671200	1.000	rs259346	chr1:95728746	G/T	cg20701556	chr1:95698924	RWDD3	0.67	5.63	0.45	1.13e-7	Stearic acid (18:0) levels;
TGCT	cis	rs4638749	1.000	rs12616140	chr2:108867728	A/G	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.69	-0.39	6.95e-6	Blood pressure;
TGCT	cis	rs1800469	1.000	rs1982072	chr19:41864509	T/A	cg09537434	chr19:41945824	ATP5SL	-0.51	-4.64	-0.38	8.66e-6	Colorectal cancer;
TGCT	cis	rs4285028	0.747	rs9824235	chr3:121432177	G/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.91	-6.89	-0.53	2.47e-10	Multiple sclerosis;
TGCT	cis	rs6840360	0.606	rs10028035	chr4:152347825	T/G	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.83e-9	Intelligence (multi-trait analysis);
TGCT	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg22433210	chr17:43662623	NA	-0.9	-6.71	-0.52	6.31e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs4319547	0.728	rs61954974	chr12:123074169	T/C	cg23029597	chr12:123009494	RSRC2	-0.3	-4.92	-0.4	2.65e-6	Body mass index;
TGCT	cis	rs2303759	0.874	rs8108669	chr19:49845895	C/T	cg22307029	chr19:49891270	CCDC155	0.55	5.14	0.42	1.02e-6	Multiple sclerosis;
TGCT	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.54	-5.2	-0.42	7.97e-7	Menarche (age at onset);
TGCT	cis	rs826838	0.935	rs1160162	chr12:38959795	G/A	cg13010199	chr12:38710504	ALG10B	0.8	6.77	0.52	4.58e-10	Heart rate;
TGCT	cis	rs12291225	0.585	rs4517475	chr11:14386145	A/G	cg19336497	chr11:14380999	RRAS2	-0.46	-7.45	-0.56	1.38e-11	Sense of smell;
TGCT	cis	rs17221829	0.829	rs11018737	chr11:89427132	A/G	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.46	-0.37	1.83e-5	Anxiety in major depressive disorder;
TGCT	cis	rs763121	0.853	rs2072794	chr22:39150543	G/T	cg06022373	chr22:39101656	GTPBP1	0.76	6.73	0.52	5.68e-10	Menopause (age at onset);
TGCT	cis	rs7216064	1.000	rs4569324	chr17:65872750	C/T	cg12091567	chr17:66097778	LOC651250	-0.83	-6.49	-0.5	1.9e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs12477438	0.520	rs12621007	chr2:99791946	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.05	13.31	0.77	1.16e-25	Chronic sinus infection;
TGCT	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs10540	1.000	rs12417570	chr11:462684	C/T	cg03934478	chr11:495069	RNH1	0.33	5.08	0.42	1.33e-6	Body mass index;
TGCT	cis	rs2204008	0.570	rs12318341	chr12:38251087	T/C	cg26384229	chr12:38710491	ALG10B	-0.54	-4.7	-0.39	6.68e-6	Bladder cancer;
TGCT	cis	rs9467711	0.606	rs72841536	chr6:26378288	T/A	cg16898833	chr6:26189333	HIST1H4D	1.1	5.3	0.43	5.01e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg18538332	chr22:24372958	LOC391322	-0.88	-9.89	-0.66	2.28e-17	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7681440	0.746	rs1442134	chr4:90819154	A/G	cg20003494	chr4:90757398	SNCA	-0.53	-4.94	-0.41	2.42e-6	Dementia with Lewy bodies;
TGCT	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.67	-6.63	-0.51	9.37e-10	Prostate cancer;
TGCT	cis	rs9682041	0.696	rs6786542	chr3:170105378	C/T	cg11886554	chr3:170076028	SKIL	0.62	4.82	0.4	4.11e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs711830	1.000	rs1549334	chr2:177039197	G/A	cg13092806	chr2:177043255	NA	0.74	5.95	0.47	2.58e-8	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
TGCT	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg10047753	chr17:41438598	NA	0.84	7.61	0.56	5.9e-12	Menopause (age at onset);
TGCT	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg24829409	chr8:58192753	C8orf71	-0.51	-4.45	-0.37	1.88e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs644799	1.000	rs568668	chr11:95528209	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	8.74	0.62	1.39e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7552404	0.921	rs10873685	chr1:76218818	A/C	cg22875332	chr1:76189707	ACADM	0.78	9.11	0.63	1.8e-15	Blood metabolite levels;Acylcarnitine levels;
TGCT	trans	rs1814175	0.935	rs11040438	chr11:49622521	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.34	-6.67	-0.51	7.47e-10	Height;
TGCT	cis	rs3820068	0.581	rs72645861	chr1:15920314	A/G	cg05660106	chr1:15850417	CASP9	0.84	8.27	0.6	1.8e-13	Systolic blood pressure;
TGCT	cis	rs7216064	0.953	rs4791048	chr17:65848994	G/A	cg12091567	chr17:66097778	LOC651250	-0.84	-6.8	-0.52	4.01e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs854765	0.583	rs66531105	chr17:17809001	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.74	7.77	0.57	2.63e-12	Total body bone mineral density;
TGCT	cis	rs4918072	0.917	rs35041090	chr10:105648686	G/A	cg11005552	chr10:105648138	OBFC1	0.4	5.34	0.43	4.26e-7	Coronary artery disease;
TGCT	cis	rs10858047	0.883	rs7556270	chr1:115178041	T/C	cg12756093	chr1:115239321	AMPD1	-0.45	-4.73	-0.39	6.09e-6	Autism;
TGCT	cis	rs10504229	0.906	rs2270609	chr8:58194684	G/A	cg24829409	chr8:58192753	C8orf71	-0.55	-4.83	-0.4	3.91e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6696846	0.691	rs11240370	chr1:205118336	T/G	cg03948781	chr1:205179583	DSTYK	0.34	4.47	0.37	1.72e-5	Red blood cell count;
TGCT	cis	rs11992186	0.597	rs77717027	chr8:8591632	T/C	cg17143192	chr8:8559678	CLDN23	-0.51	-5.02	-0.41	1.79e-6	Neuroticism;
TGCT	cis	rs11731606	0.508	rs17021533	chr4:95280587	C/T	cg00507259	chr4:95128692	SMARCAD1	0.63	4.72	0.39	6.18e-6	Mean platelet volume;
TGCT	cis	rs1023500	0.507	rs6002600	chr22:42488906	G/A	cg05082376	chr22:42548792	NA	0.23	5.43	0.44	2.83e-7	Schizophrenia;
TGCT	cis	rs6598955	0.671	rs6686100	chr1:26617338	G/C	cg04990556	chr1:26633338	UBXN11	0.64	4.91	0.4	2.78e-6	Obesity-related traits;
TGCT	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg14456004	chr13:21872349	NA	1.25	12.41	0.74	1.76e-23	White matter hyperintensity burden;
TGCT	cis	rs9291683	0.527	rs73212848	chr4:10093299	T/C	cg11266682	chr4:10021025	SLC2A9	-0.57	-6.84	-0.52	3.15e-10	Bone mineral density;
TGCT	cis	rs9583531	0.600	rs7330080	chr13:111367115	C/T	cg24331049	chr13:111365604	ING1	0.74	7.15	0.54	6.44e-11	Coronary artery disease;
TGCT	cis	rs17125944	0.505	rs75838476	chr14:53242362	G/A	cg00686598	chr14:53173677	PSMC6	1.08	6.32	0.49	4.37e-9	Alzheimer's disease (late onset);
TGCT	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg13695892	chr22:41940480	POLR3H	-0.93	-9.17	-0.64	1.26e-15	Vitiligo;
TGCT	cis	rs644799	1.000	rs564675	chr11:95561873	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.82	8.63	0.61	2.52e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs35146811	0.844	rs4729576	chr7:99692594	G/A	cg13334819	chr7:99746414	C7orf59	-0.81	-6.91	-0.53	2.23e-10	Coronary artery disease;
TGCT	cis	rs62244186	0.593	rs9814298	chr3:44871899	T/A	cg21672276	chr3:44754072	ZNF502	-0.52	-5.92	-0.47	2.97e-8	Depressive symptoms;
TGCT	cis	rs7681440	0.935	rs3756059	chr4:90757272	G/A	cg20003494	chr4:90757398	SNCA	-0.61	-5.77	-0.46	5.89e-8	Dementia with Lewy bodies;
TGCT	cis	rs4788570	0.615	rs2334880	chr16:71653637	A/G	cg06353428	chr16:71660113	MARVELD3	1.55	13.15	0.76	2.84e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs950169	0.922	rs4842939	chr15:84827966	C/T	cg11189052	chr15:85197271	WDR73	-0.8	-6.6	-0.51	1.07e-9	Schizophrenia;
TGCT	cis	rs12220898	0.749	rs4310533	chr10:50482625	C/G	cg25968469	chr10:49687287	ARHGAP22	0.25	4.47	0.37	1.78e-5	Inflammatory biomarkers;
TGCT	cis	rs2072499	1.000	rs2241107	chr1:156182710	C/T	cg25208724	chr1:156163844	SLC25A44	-1.08	-15.52	-0.81	7.74e-31	Testicular germ cell tumor;
TGCT	cis	rs67478160	0.619	rs11628481	chr14:104241499	C/T	cg26031613	chr14:104095156	KLC1	-0.63	-6.57	-0.51	1.25e-9	Schizophrenia;
TGCT	cis	rs740474	0.652	rs251022	chr5:140892643	T/C	cg00076195	chr5:140892677	NA	0.42	4.86	0.4	3.42e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs57221529	0.766	rs12519469	chr5:581772	A/G	cg09021430	chr5:549028	NA	-0.37	-5.3	-0.43	5.09e-7	Lung disease severity in cystic fibrosis;
TGCT	cis	rs8062405	0.540	rs480400	chr16:28574615	A/G	cg09754948	chr16:28834200	ATXN2L	0.54	4.52	0.38	1.41e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs12210905	1.000	rs72843607	chr6:27110715	C/A	cg08851530	chr6:28072375	NA	1.21	5.58	0.45	1.43e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs7949030	0.626	rs11231154	chr11:62362293	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.7	8.89	0.62	5.98e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2456568	0.571	rs1105113	chr11:93693323	G/A	cg17595323	chr11:93583763	C11orf90	0.38	4.62	0.38	9.46e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg22963979	chr7:1858916	MAD1L1	-0.39	-6.52	-0.51	1.63e-9	Bipolar disorder and schizophrenia;
TGCT	cis	rs17270561	0.579	rs10456326	chr6:25919662	G/A	cg17042849	chr6:26104293	HIST1H4C	-0.78	-5.66	-0.45	9.93e-8	Iron status biomarkers;
TGCT	cis	rs10782582	0.609	rs2881785	chr1:76318096	T/C	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.52	4.47	0.37	1.72e-5	Daytime sleep phenotypes;
TGCT	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg07507251	chr3:52567010	NT5DC2	0.47	6.84	0.52	3.14e-10	Electroencephalogram traits;
TGCT	cis	rs2120019	0.938	rs8040169	chr15:75370958	C/A	cg17294928	chr15:75287854	SCAMP5	-0.86	-6.62	-0.51	9.55e-10	Blood trace element (Zn levels);
TGCT	cis	rs4727027	0.704	rs2269972	chr7:148914047	C/T	cg23583168	chr7:148888333	NA	0.83	10.69	0.69	2.62e-19	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs9303401	0.659	rs12946397	chr17:56769979	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.59	5.99	0.47	2.08e-8	Cognitive test performance;
TGCT	cis	rs2688608	0.620	rs7098444	chr10:75580042	C/T	cg19442545	chr10:75533431	FUT11	-0.36	-5.67	-0.45	9.61e-8	Inflammatory bowel disease;
TGCT	cis	rs2463822	1.000	rs11231050	chr11:62131660	C/G	cg06239285	chr11:62104954	ASRGL1	-0.91	-6.69	-0.51	7e-10	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs4919669	0.777	rs5011218	chr10:104401218	A/C	cg05855489	chr10:104503620	C10orf26	0.76	4.44	0.37	1.98e-5	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs6582630	0.548	rs1607870	chr12:38385964	G/T	cg26384229	chr12:38710491	ALG10B	-0.52	-4.51	-0.38	1.5e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs8103278	0.507	rs1865116	chr19:46294510	G/A	cg14061069	chr19:46274453	DMPK	0.62	10.67	0.69	3.04e-19	Coronary artery disease;
TGCT	cis	rs9467711	0.606	rs9358936	chr6:26370657	A/G	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2242116	1.000	rs2168443	chr3:46947087	A/T	cg27129171	chr3:47204927	SETD2	-0.59	-5.71	-0.46	7.93e-8	Birth weight;
TGCT	trans	rs877282	0.838	rs11253408	chr10:796374	T/C	cg22713356	chr15:30763199	NA	1.18	10.55	0.69	5.81e-19	Uric acid levels;
TGCT	cis	rs1023500	0.529	rs133375	chr22:42466509	C/G	cg05082376	chr22:42548792	NA	-0.23	-5.44	-0.44	2.75e-7	Schizophrenia;
TGCT	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg03709012	chr19:19516395	GATAD2A	0.75	6.2	0.49	7.59e-9	Tonsillectomy;
TGCT	cis	rs7829975	0.577	rs79495969	chr8:8545250	G/A	cg17143192	chr8:8559678	CLDN23	-0.52	-5.21	-0.42	7.57e-7	Mood instability;
TGCT	cis	rs9302001	0.960	rs9524624	chr13:95464661	G/A	cg07483244	chr13:95358924	NA	0.37	4.76	0.39	5.29e-6	Panic disorder;
TGCT	cis	rs4566357	0.615	rs10198406	chr2:227913539	A/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-5.25	-0.43	6.53e-7	Coronary artery disease;
TGCT	cis	rs9638182	0.725	rs7797566	chr7:72896395	A/C	cg14087351	chr7:73037990	MLXIPL	-0.57	-4.52	-0.38	1.4e-5	Triglycerides;
TGCT	trans	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg27523141	chr10:43048294	ZNF37B	0.7	8.15	0.59	3.36e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7829975	0.533	rs7820146	chr8:8699757	T/A	cg06636001	chr8:8085503	FLJ10661	0.71	6.25	0.49	6.17e-9	Mood instability;
TGCT	cis	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg03213289	chr20:61660250	NA	0.7	10.02	0.67	1.14e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs8030485	0.728	rs28415942	chr15:79384850	C/T	cg17916960	chr15:79447300	NA	0.33	4.49	0.37	1.63e-5	Left ventricle wall thickness;
TGCT	cis	rs9911578	1.000	rs2009948	chr17:56611920	A/C	cg12560992	chr17:57184187	TRIM37	-0.76	-9.34	-0.64	4.88e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs3809566	1.000	rs3809566	chr15:63333724	A/G	cg24483493	chr15:63333476	TPM1	-0.26	-4.46	-0.37	1.85e-5	Platelet count;
TGCT	cis	rs10750165	0.644	rs10790343	chr11:119630480	A/G	cg18567470	chr11:120208005	ARHGEF12	0.42	4.7	0.39	6.91e-6	Aggressiveness in attention deficit hyperactivity disorder;
TGCT	cis	rs7208859	0.573	rs60724269	chr17:29113273	G/T	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs3796352	0.892	rs11718388	chr3:53076415	G/A	cg07884673	chr3:53033167	SFMBT1	0.6	6.24	0.49	6.25e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs9611565	0.625	rs12483991	chr22:41935285	A/G	cg06481639	chr22:41940642	POLR3H	-0.63	-5.76	-0.46	6.21e-8	Vitiligo;
TGCT	cis	rs7258465	1.000	rs4808136	chr19:18618867	A/G	cg06462663	chr19:18546047	ISYNA1	-0.21	-4.78	-0.39	4.86e-6	Breast cancer;
TGCT	cis	rs7095607	0.813	rs7088768	chr10:69933421	A/T	cg18986048	chr10:69913749	MYPN	0.44	5.02	0.41	1.72e-6	Lung function (FVC);
TGCT	cis	rs72772090	0.522	rs17398914	chr5:96005180	A/C	cg19084281	chr5:95765746	PCSK1	0.56	4.47	0.37	1.77e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg11941060	chr3:133502564	NA	-0.3	-6.41	-0.5	2.69e-9	Iron status biomarkers;
TGCT	cis	rs4494114	0.629	rs9439074	chr1:39296300	G/A	cg25970120	chr1:39325951	RRAGC	-0.52	-5.02	-0.41	1.74e-6	Blood protein levels;
TGCT	cis	rs896854	0.738	rs509594	chr8:95967156	C/G	cg23172400	chr8:95962367	TP53INP1	0.36	5.6	0.45	1.29e-7	Type 2 diabetes;
TGCT	cis	rs427394	0.659	rs274678	chr5:6752385	A/G	cg10857441	chr5:6722123	POLS	0.29	5.91	0.47	3.09e-8	Menopause (age at onset);
TGCT	cis	rs8017423	0.647	rs12883844	chr14:90820519	T/C	cg04374321	chr14:90722782	PSMC1	-0.56	-5.62	-0.45	1.19e-7	Mortality in heart failure;
TGCT	cis	rs1499614	1.000	rs2707838	chr7:66159201	C/T	cg18252515	chr7:66147081	NA	-1.26	-7.95	-0.58	9.71e-13	Gout;
TGCT	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg24399712	chr22:39784796	NA	-0.92	-10.84	-0.7	1.17e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs9911578	0.967	rs2429369	chr17:56501420	A/G	cg05425664	chr17:57184151	TRIM37	-0.62	-6.16	-0.48	9.42e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs6735179	0.643	rs10200618	chr2:1746140	A/C	cg20311673	chr2:1746207	PXDN	0.27	4.49	0.37	1.59e-5	Response to antipsychotic treatment;
TGCT	cis	rs7312933	0.703	rs11181378	chr12:42600658	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	5.06	0.41	1.45e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs28595532	0.920	rs55758547	chr4:119769475	T/C	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs526231	0.853	rs187579	chr5:102604933	A/C	cg05225461	chr5:102596755	C5orf30	0.23	4.62	0.38	9.51e-6	Primary biliary cholangitis;
TGCT	cis	rs344364	0.511	rs2982447	chr16:1947413	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	0.44	4.91	0.4	2.75e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg21724239	chr8:58056113	NA	0.4	5.01	0.41	1.8e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg08280861	chr8:58055591	NA	0.37	4.8	0.4	4.55e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7267979	0.932	rs1985737	chr20:25591468	T/A	cg16686733	chr20:25566563	NINL	0.55	5.54	0.45	1.7e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs17331151	0.573	rs3755801	chr3:52865798	G/A	cg27565382	chr3:53032988	SFMBT1	0.46	5.89	0.47	3.45e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs4372836	0.504	rs10183665	chr2:28995226	A/G	cg09522027	chr2:28974177	PPP1CB	-0.52	-5.22	-0.42	7.4e-7	Body mass index;
TGCT	cis	rs9467773	0.935	rs1056668	chr6:26510605	C/T	cg09904177	chr6:26538194	HMGN4	0.58	5.6	0.45	1.28e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7226408	0.857	rs72887032	chr18:34473233	T/C	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs6964587	1.000	rs6974607	chr7:91750116	G/A	cg22709100	chr7:91322751	NA	0.28	4.55	0.38	1.25e-5	Breast cancer;
TGCT	trans	rs1814175	0.817	rs12277258	chr11:49940216	T/C	cg15704280	chr7:45808275	SEPT13	-0.71	-8.0	-0.58	7.45e-13	Height;
TGCT	cis	rs7617773	0.780	rs36121690	chr3:48345511	C/T	cg11946769	chr3:48343235	NME6	0.82	7.09	0.54	9.1e-11	Coronary artery disease;
TGCT	cis	rs28595532	0.920	rs116023344	chr4:119760263	A/G	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.46	0.56	1.3e-11	Prudent dietary pattern;
TGCT	cis	rs7769051	0.711	rs6569847	chr6:133083187	C/A	cg07930552	chr6:133119739	C6orf192	0.88	4.57	0.38	1.18e-5	Type 2 diabetes nephropathy;
TGCT	cis	rs2486288	0.656	rs11632651	chr15:45550838	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.72	-7.46	-0.56	1.34e-11	Glomerular filtration rate;
TGCT	cis	rs12908161	0.959	rs61074241	chr15:85333396	C/T	cg17173187	chr15:85201210	NMB	0.51	5.56	0.45	1.56e-7	Schizophrenia;
TGCT	cis	rs76878669	0.793	rs7924580	chr11:66080770	C/T	cg18002602	chr11:66138449	SLC29A2	-0.52	-5.71	-0.46	8.01e-8	Educational attainment (years of education);
TGCT	cis	rs72615157	0.628	rs7801070	chr7:99847147	T/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.63	-5.16	-0.42	9.65e-7	Lung function (FEV1/FVC);
TGCT	cis	rs78487399	0.665	rs6753942	chr2:43749436	T/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.39	-4.68	-0.39	7.51e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs6867032	0.958	rs4975797	chr5:2015573	G/A	cg26168224	chr5:2018326	NA	0.43	7.82	0.57	2e-12	Gut microbiome composition (winter);
TGCT	cis	rs1865760	0.516	rs9295684	chr6:26069669	T/C	cg17042849	chr6:26104293	HIST1H4C	-0.66	-5.85	-0.47	4.02e-8	Height;
TGCT	cis	rs2562456	0.561	rs12610883	chr19:21750059	A/G	cg25650185	chr19:21324782	ZNF431	-0.66	-5.86	-0.47	3.92e-8	Pain;
TGCT	cis	rs7192750	0.586	rs12444521	chr16:71941698	A/T	cg06353428	chr16:71660113	MARVELD3	0.83	7.32	0.55	2.74e-11	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs2404602	0.716	rs66754747	chr15:76828568	G/A	cg22467129	chr15:76604101	ETFA	-0.48	-5.53	-0.44	1.81e-7	Blood metabolite levels;
TGCT	cis	rs2201841	0.921	rs12567232	chr1:67728018	G/A	cg25131922	chr1:68698529	GPR177	0.44	4.66	0.39	8.11e-6	Ulcerative colitis;Psoriasis;Crohn's disease;
TGCT	cis	rs9303401	0.659	rs17822807	chr17:56687190	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg21644426	chr2:191273491	MFSD6	-0.6	-5.91	-0.47	3.12e-8	Pulse pressure;
TGCT	cis	rs1008375	0.966	rs4698636	chr4:17632834	T/C	cg10189774	chr4:17578691	LAP3	0.64	5.81	0.46	4.97e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	trans	rs17685	0.712	rs60232511	chr7:75800082	A/G	cg19862616	chr7:65841803	NCRNA00174	0.5	8.46	0.6	6.36e-14	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs826838	1.000	rs11514441	chr12:38775190	C/T	cg13010199	chr12:38710504	ALG10B	0.82	6.86	0.52	2.91e-10	Heart rate;
TGCT	cis	rs916888	0.531	rs183211	chr17:44788310	G/A	cg01570182	chr17:44337453	NA	0.76	7.25	0.55	3.88e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7772486	0.686	rs7739735	chr6:146123536	G/A	cg05347473	chr6:146136440	FBXO30	0.47	4.48	0.37	1.7e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs17270561	0.887	rs12201170	chr6:25866247	A/G	cg16482183	chr6:26056742	HIST1H1C	0.87	5.67	0.45	9.5e-8	Iron status biomarkers;
TGCT	cis	rs2882877	0.735	rs994227	chr2:190432467	T/C	cg10752008	chr2:190445175	SLC40A1	0.67	5.26	0.43	6.24e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg06481639	chr22:41940642	POLR3H	-0.73	-6.64	-0.51	8.91e-10	Vitiligo;
TGCT	cis	rs3806843	0.576	rs155360	chr5:140309016	C/T	cg09824255	chr5:140014002	CD14	0.25	4.54	0.38	1.32e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs1008375	1.000	rs7654345	chr4:17691796	A/G	cg18681998	chr4:17616180	MED28	0.76	7.28	0.55	3.42e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs12478296	0.901	rs56318767	chr2:243046591	T/A	cg06360820	chr2:242988706	NA	-0.61	-4.66	-0.39	8.13e-6	Obesity-related traits;
TGCT	cis	rs9467773	0.620	rs2451711	chr6:26663110	A/G	cg05738196	chr6:26577821	NA	0.88	10.71	0.69	2.37e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg23758822	chr17:41437982	NA	0.72	6.81	0.52	3.77e-10	Menopause (age at onset);
TGCT	cis	rs6088590	1.000	rs3787222	chr20:33333040	T/A	cg06115741	chr20:33292138	TP53INP2	0.68	5.69	0.45	8.67e-8	Coronary artery disease;
TGCT	cis	rs739496	0.615	rs602276	chr12:112133924	G/A	cg10833066	chr12:111807467	FAM109A	0.37	4.79	0.39	4.76e-6	Platelet count;
TGCT	cis	rs1215050	0.791	rs1648546	chr4:98899294	T/C	cg05340658	chr4:99064831	C4orf37	-0.46	-5.82	-0.46	4.74e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg11764359	chr7:65958608	NA	-0.54	-4.86	-0.4	3.45e-6	Aortic root size;
TGCT	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg21963583	chr11:68658836	MRPL21	0.36	6.1	0.48	1.25e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7412746	0.658	rs57818453	chr1:150763139	G/A	cg04414720	chr1:150670196	GOLPH3L	0.38	4.73	0.39	6.04e-6	Melanoma;
TGCT	cis	rs561341	0.739	rs1978116	chr17:30220978	A/C	cg13647721	chr17:30228624	UTP6	0.62	4.92	0.4	2.72e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs929354	0.772	rs1182441	chr7:157026650	A/G	cg05182265	chr7:156933206	UBE3C	0.4	9.05	0.63	2.54e-15	Body mass index;
TGCT	cis	rs2742417	0.624	rs2673068	chr3:45768981	G/A	cg04837898	chr3:45731254	SACM1L	-0.63	-6.62	-0.51	9.64e-10	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs4644046	0.515	rs10948625	chr6:51429472	G/C	cg14391730	chr6:52021665	NA	0.31	4.46	0.37	1.8e-5	Coronary artery disease;
TGCT	cis	rs2692947	0.526	rs58719199	chr2:96578247	G/A	cg13655245	chr2:97463316	CNNM4	0.15	4.51	0.38	1.48e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg12310025	chr6:25882481	NA	-0.65	-5.86	-0.47	3.84e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs938554	0.571	rs7696092	chr4:10025320	C/A	cg11266682	chr4:10021025	SLC2A9	0.56	5.5	0.44	2.05e-7	Blood metabolite levels;
TGCT	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg03264133	chr6:25882463	NA	-0.86	-8.32	-0.6	1.32e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs8072100	0.539	rs36043200	chr17:45629406	G/A	cg08085267	chr17:45401833	C17orf57	0.47	5.15	0.42	1.01e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs17376456	1.000	rs9968691	chr5:93509756	C/G	cg25358565	chr5:93447407	FAM172A	0.95	7.97	0.58	8.71e-13	Diabetic retinopathy;
TGCT	cis	rs4689592	0.554	rs66925245	chr4:7071999	C/T	cg02503808	chr4:7069936	GRPEL1	-1.01	-8.75	-0.62	1.27e-14	Monocyte percentage of white cells;
TGCT	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg03303774	chr4:1407052	NA	0.31	4.87	0.4	3.31e-6	Obesity-related traits;
TGCT	cis	rs12900413	0.603	rs2882677	chr15:90299514	C/T	cg24249390	chr15:90295951	MESP1	-0.29	-5.11	-0.42	1.19e-6	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs9859260	0.744	rs539816	chr3:195784076	T/A	cg22891161	chr3:195456627	MUC20	0.23	4.6	0.38	1.04e-5	Mean corpuscular volume;
TGCT	cis	rs9611565	0.512	rs139566	chr22:42199277	A/G	cg13695892	chr22:41940480	POLR3H	-0.86	-8.04	-0.59	6.03e-13	Vitiligo;
TGCT	cis	rs9467773	1.000	rs2393670	chr6:26535541	A/G	cg09904177	chr6:26538194	HMGN4	0.65	6.53	0.51	1.53e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs12142240	0.659	rs111723629	chr1:46853361	G/T	cg14993813	chr1:46806288	NSUN4	-0.59	-4.86	-0.4	3.45e-6	Menopause (age at onset);
TGCT	cis	rs7714584	1.000	rs114244137	chr5:150264753	C/A	cg22134413	chr5:150180641	NA	0.78	6.12	0.48	1.16e-8	Crohn's disease;
TGCT	cis	rs1867631	1.000	rs11208928	chr1:67089562	G/T	cg13052034	chr1:66999238	SGIP1	0.59	4.93	0.41	2.53e-6	Menopause (age at onset);
TGCT	cis	rs6500602	0.727	rs6500607	chr16:4503631	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.26	4.9	0.4	2.95e-6	Schizophrenia;
TGCT	cis	rs4788570	0.615	rs9888756	chr16:71740477	G/A	cg06353428	chr16:71660113	MARVELD3	1.55	12.69	0.75	3.63e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs8013055	0.796	rs4074937	chr14:106000977	A/G	cg23356831	chr14:105996513	TMEM121	0.39	6.45	0.5	2.22e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs7255045	0.742	rs10407116	chr19:12962272	G/A	cg06537894	chr19:12978706	MAST1	-0.49	-4.48	-0.37	1.69e-5	Mean corpuscular volume;
TGCT	cis	rs10769945	0.592	rs1635155	chr11:1972919	G/T	cg06679296	chr11:1949032	TNNT3	-0.25	-4.57	-0.38	1.16e-5	DNA methylation (variation);
TGCT	cis	rs9905759	0.603	rs4130509	chr17:7930778	C/T	cg15403654	chr17:7747012	KDM6B	0.46	4.95	0.41	2.39e-6	Childhood ear infection;
TGCT	cis	rs12681287	0.640	rs7816629	chr8:87350788	A/T	cg27223183	chr8:87520930	FAM82B	-0.9	-6.71	-0.52	6.12e-10	Caudate activity during reward;
TGCT	cis	rs10782582	0.593	rs12126155	chr1:76131555	C/G	cg03433033	chr1:76189801	ACADM	-0.64	-7.32	-0.55	2.78e-11	Daytime sleep phenotypes;
TGCT	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg04944784	chr2:26401820	FAM59B	0.76	6.24	0.49	6.46e-9	Gut microbiome composition (summer);
TGCT	cis	rs11673344	0.583	rs7254411	chr19:37525871	G/A	cg08039142	chr19:36980659	ZNF566	0.52	4.83	0.4	3.9e-6	Obesity-related traits;
TGCT	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.12	0.54	7.78e-11	Prudent dietary pattern;
TGCT	cis	rs968567	0.638	rs7943728	chr11:61547068	G/A	cg19610905	chr11:61596333	FADS2	-0.8	-4.9	-0.4	2.96e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
TGCT	cis	rs1008375	0.931	rs979823	chr4:17700176	G/A	cg18681998	chr4:17616180	MED28	0.8	7.63	0.57	5.41e-12	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2439831	0.850	rs12441984	chr15:44126285	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.9	6.3	0.49	4.62e-9	Lung cancer in ever smokers;
TGCT	cis	rs9325144	0.647	rs11168104	chr12:38857616	G/T	cg10518543	chr12:38710700	ALG10B	-0.48	-4.46	-0.37	1.84e-5	Morning vs. evening chronotype;
TGCT	cis	rs7312933	0.566	rs11181454	chr12:42746486	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.58	-5.7	-0.46	8.24e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs10992471	0.565	rs12552866	chr9:95110549	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.63	-6.13	-0.48	1.1e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs7568458	0.591	rs55971080	chr2:85812746	T/C	cg02493740	chr2:85810744	VAMP5	-0.34	-6.31	-0.49	4.52e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs7584330	0.780	rs937395	chr2:238378749	T/C	cg14458575	chr2:238380390	NA	0.51	8.41	0.6	8.33e-14	Prostate cancer;
TGCT	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.28	4.92	0.4	2.73e-6	Schizophrenia;
TGCT	cis	rs7818688	0.697	rs11784140	chr8:95987480	G/T	cg16049864	chr8:95962084	TP53INP1	0.54	4.64	0.38	8.87e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs7523273	0.526	rs558248	chr1:208047435	A/G	cg22525895	chr1:207977042	MIR29B2	-0.33	-5.35	-0.43	4.02e-7	Schizophrenia;
TGCT	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg15556689	chr8:8085844	FLJ10661	-0.84	-9.23	-0.64	9.23e-16	Neuroticism;
TGCT	cis	rs4925386	0.840	rs6142738	chr20:60919960	C/T	cg06026331	chr20:60912101	LAMA5	-0.4	-6.81	-0.52	3.82e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs62380364	0.602	rs640177	chr5:88002084	T/A	cg22951263	chr5:87985283	NA	-0.61	-6.53	-0.51	1.49e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs892961	0.932	rs67415822	chr17:75412678	A/G	cg05865280	chr17:75406074	SEPT9	0.28	6.86	0.52	2.9e-10	Airflow obstruction;
TGCT	trans	rs561341	0.556	rs41290963	chr17:30396390	C/T	cg20587970	chr11:113659929	NA	-1.0	-8.24	-0.59	2.08e-13	Hip circumference adjusted for BMI;
TGCT	cis	rs12472274	0.941	rs11677230	chr2:239092054	T/C	cg17459225	chr2:239074497	NA	0.33	4.88	0.4	3.23e-6	Phospholipid levels (plasma);
TGCT	cis	rs1519814	0.668	rs7836786	chr8:121006826	G/A	cg22335954	chr8:121166405	COL14A1	-0.36	-4.55	-0.38	1.26e-5	Breast cancer;
TGCT	cis	rs7598759	0.548	rs11693738	chr2:232360484	C/T	cg19187155	chr2:232395269	NMUR1	0.48	5.62	0.45	1.2e-7	Noise-induced hearing loss;
TGCT	cis	rs13191362	0.507	rs1079020	chr6:163066596	C/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.6	-5.29	-0.43	5.44e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs79149102	0.579	rs7181942	chr15:75300623	G/C	cg09165964	chr15:75287851	SCAMP5	-1.04	-5.71	-0.46	7.93e-8	Lung cancer;
TGCT	cis	rs929354	1.000	rs1182452	chr7:157053618	G/A	cg05182265	chr7:156933206	UBE3C	0.32	6.63	0.51	9.07e-10	Body mass index;
TGCT	cis	rs7809950	1.000	rs10273733	chr7:107258121	A/G	cg23024343	chr7:107201750	COG5	0.3	4.62	0.38	9.29e-6	Coronary artery disease;
TGCT	trans	rs561341	1.000	rs473356	chr17:30321762	G/C	cg20587970	chr11:113659929	NA	-1.04	-12.57	-0.75	6.97e-24	Hip circumference adjusted for BMI;
TGCT	cis	rs1843834	0.539	rs1494109	chr2:225441833	G/A	cg12698349	chr2:225449008	CUL3	0.78	6.41	0.5	2.77e-9	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs1971256	0.500	rs6925359	chr6:151798783	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.74	-4.49	-0.37	1.63e-5	Endometriosis;
TGCT	cis	rs36051895	0.632	rs11788963	chr9:5120157	C/A	cg02405213	chr9:5042618	JAK2	-0.71	-9.55	-0.65	1.57e-16	Pediatric autoimmune diseases;
TGCT	cis	rs7589728	0.563	rs4972044	chr2:88466196	T/C	cg04511125	chr2:88470314	THNSL2	0.83	6.93	0.53	2e-10	Plasma clusterin levels;
TGCT	cis	rs7666738	0.830	rs1111541	chr4:99033860	A/G	cg18180107	chr4:99064573	C4orf37	-0.59	-5.4	-0.44	3.23e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8072100	0.575	rs1221385	chr17:45527574	T/G	cg08085267	chr17:45401833	C17orf57	-0.43	-4.61	-0.38	9.85e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	6.14	0.48	1.03e-8	Bipolar disorder;
TGCT	cis	rs9633740	1.000	rs7097656	chr10:82250831	T/C	cg01528321	chr10:82214614	TSPAN14	1.0	8.33	0.6	1.25e-13	Post bronchodilator FEV1;
TGCT	cis	rs950169	0.959	rs12911210	chr15:84792083	A/C	cg12863693	chr15:85201151	NMB	0.39	4.62	0.38	9.33e-6	Schizophrenia;
TGCT	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg04944784	chr2:26401820	FAM59B	0.76	6.24	0.49	6.46e-9	Gut microbiome composition (summer);
TGCT	cis	rs7568458	0.846	rs6547621	chr2:85774676	G/A	cg02493740	chr2:85810744	VAMP5	-0.29	-5.47	-0.44	2.37e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg27436995	chr16:743998	FBXL16	-0.47	-5.13	-0.42	1.07e-6	Height;
TGCT	cis	rs9929218	0.507	rs62057805	chr16:68742390	G/C	cg01251360	chr16:68772225	CDH1	-0.25	-4.57	-0.38	1.18e-5	Colorectal cancer;
TGCT	cis	rs12477438	0.834	rs11903311	chr2:99701807	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.92	-9.58	-0.65	1.29e-16	Chronic sinus infection;
TGCT	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg18876405	chr7:65276391	NA	0.31	4.79	0.4	4.65e-6	Aortic root size;
TGCT	cis	rs5750830	0.645	rs756640	chr22:39779300	G/A	cg01416388	chr22:39784598	NA	-0.63	-6.3	-0.49	4.69e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs36051895	0.622	rs10815143	chr9:5009541	G/A	cg02405213	chr9:5042618	JAK2	-0.78	-11.02	-0.7	4.05e-20	Pediatric autoimmune diseases;
TGCT	cis	rs6912958	0.500	rs4707352	chr6:87929705	G/A	cg10393598	chr6:87862264	NA	0.3	4.44	0.37	1.99e-5	Monocyte percentage of white cells;
TGCT	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.69	-7.06	-0.54	1.07e-10	Prostate cancer;
TGCT	cis	rs9549260	0.753	rs4943794	chr13:41173408	G/C	cg21288729	chr13:41239152	FOXO1	0.67	4.68	0.39	7.31e-6	Red blood cell count;
TGCT	cis	rs7552404	0.696	rs1417405	chr1:76457797	T/C	cg22875332	chr1:76189707	ACADM	0.63	5.51	0.44	1.97e-7	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs10791097	0.694	rs7926167	chr11:130745045	T/C	cg12179176	chr11:130786555	SNX19	0.84	10.17	0.67	4.95e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs7208859	0.623	rs9899268	chr17:29150255	T/C	cg13385521	chr17:29058706	SUZ12P	0.81	4.85	0.4	3.68e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7666738	0.830	rs10516426	chr4:99035827	A/G	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs72781680	0.898	rs56303870	chr2:24086944	G/A	cg08917208	chr2:24149416	ATAD2B	0.77	4.69	0.39	7.06e-6	Lymphocyte counts;
TGCT	cis	rs12681288	0.523	rs112307130	chr8:962483	G/A	cg04851639	chr8:1020857	NA	-0.29	-4.76	-0.39	5.27e-6	Schizophrenia;
TGCT	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg23283495	chr1:209979779	IRF6	0.67	5.7	0.46	8.12e-8	Cleft lip with or without cleft palate;
TGCT	cis	rs2180341	0.618	rs12210968	chr6:127596985	A/G	cg27446573	chr6:127587934	RNF146	0.65	5.79	0.46	5.52e-8	Breast cancer;
TGCT	cis	rs9926296	0.682	rs258328	chr16:89730314	C/T	cg01097406	chr16:89675127	NA	0.34	5.88	0.47	3.54e-8	Vitiligo;
TGCT	cis	rs12479064	0.724	rs6748200	chr2:100080895	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.73	-6.42	-0.5	2.58e-9	Chronic sinus infection;
TGCT	cis	rs10493773	0.775	rs11161662	chr1:86185040	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.43	-6.18	-0.49	8.46e-9	Urate levels in overweight individuals;
TGCT	cis	rs6121246	0.529	rs6060210	chr20:30187681	C/T	cg13852791	chr20:30311386	BCL2L1	0.69	4.54	0.38	1.33e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs4072705	0.967	rs4838208	chr9:127528035	C/A	cg13476313	chr9:127244764	NR5A1	0.28	4.57	0.38	1.18e-5	Menarche (age at onset);
TGCT	cis	rs6121246	0.909	rs1075698	chr20:30387992	G/C	cg18721089	chr20:30220636	NA	-0.43	-4.75	-0.39	5.54e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg13395646	chr4:1353034	KIAA1530	-0.41	-5.08	-0.42	1.33e-6	Longevity;
TGCT	cis	rs9581857	0.579	rs75872792	chr13:27996064	G/T	cg22138327	chr13:27999177	GTF3A	0.81	5.55	0.45	1.68e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs7617773	0.817	rs9834095	chr3:48327751	G/A	cg11946769	chr3:48343235	NME6	0.74	6.34	0.49	3.97e-9	Coronary artery disease;
TGCT	cis	rs933688	1.000	rs6867091	chr5:90734333	C/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.08	10.69	0.69	2.68e-19	Smoking behavior;
TGCT	cis	rs826838	1.000	rs11169031	chr12:39056738	T/C	cg26384229	chr12:38710491	ALG10B	1.01	9.58	0.65	1.31e-16	Heart rate;
TGCT	cis	rs9916302	0.904	rs11078898	chr17:37536480	A/G	cg07936489	chr17:37558343	FBXL20	0.64	4.98	0.41	2.1e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg20849893	chr7:64541193	NA	0.48	4.81	0.4	4.3e-6	Calcium levels;
TGCT	cis	rs826838	1.000	rs10506122	chr12:38699232	A/G	cg26384229	chr12:38710491	ALG10B	0.97	9.5	0.65	2.02e-16	Heart rate;
TGCT	cis	rs7119	0.636	rs34020536	chr15:77819586	G/A	cg27398640	chr15:77910606	LINGO1	-0.25	-4.55	-0.38	1.27e-5	Type 2 diabetes;
TGCT	cis	rs10992471	0.598	rs2031262	chr9:95170368	A/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.63	-6.22	-0.49	6.86e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg22433210	chr17:43662623	NA	-1.0	-7.13	-0.54	7.26e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7119038	0.818	rs10892280	chr11:118611817	C/T	cg19308663	chr11:118741387	NA	0.28	5.34	0.43	4.29e-7	Sjögren's syndrome;
TGCT	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg27170947	chr2:26402098	FAM59B	-0.39	-4.46	-0.37	1.8e-5	Gut microbiome composition (summer);
TGCT	cis	rs9527	0.615	rs7080462	chr10:104736699	T/C	cg15744005	chr10:104629667	AS3MT	-0.44	-5.19	-0.42	8.3e-7	Arsenic metabolism;
TGCT	cis	rs6500602	0.610	rs1659499	chr16:4595269	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.3	-5.67	-0.45	9.66e-8	Schizophrenia;
TGCT	cis	rs1008375	0.932	rs4698628	chr4:17608620	A/G	cg10189774	chr4:17578691	LAP3	0.57	4.9	0.4	2.93e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6071524	0.508	rs911721	chr20:37399874	C/T	cg09937324	chr20:37376998	ACTR5	0.61	4.69	0.39	7.22e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg06636001	chr8:8085503	FLJ10661	-0.71	-6.42	-0.5	2.59e-9	Mood instability;
TGCT	cis	rs1153858	1.000	rs7169587	chr15:45640379	A/G	cg26924012	chr15:45694286	SPATA5L1	1.07	14.56	0.79	1.32e-28	Homoarginine levels;
TGCT	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg18402987	chr7:1209562	NA	0.7	5.67	0.45	9.66e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs35883536	0.609	rs1855631	chr1:101040010	C/T	cg06223162	chr1:101003688	GPR88	-0.43	-8.27	-0.6	1.73e-13	Monocyte count;
TGCT	cis	rs4900538	0.928	rs1190551	chr14:102911508	A/G	cg18135206	chr14:102964638	TECPR2	-0.22	-5.31	-0.43	4.81e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs7172809	0.535	rs17385296	chr15:77646338	A/C	cg22256960	chr15:77711686	NA	-0.51	-4.81	-0.4	4.29e-6	Glucose homeostasis traits;
TGCT	cis	rs11172134	0.508	rs1800194	chr12:57567762	C/T	cg19258868	chr12:57585184	LRP1	-0.32	-6.0	-0.47	2.05e-8	Urate levels in overweight individuals;
TGCT	cis	rs10489202	0.608	rs6659593	chr1:168072152	A/T	cg24449463	chr1:168025552	DCAF6	-0.54	-5.7	-0.46	8.13e-8	Schizophrenia;
TGCT	cis	rs2229238	0.911	rs73023339	chr1:154510852	C/T	cg13067139	chr1:155221277	FAM189B	0.2	4.51	0.38	1.47e-5	Coronary heart disease;
TGCT	cis	rs12579753	0.879	rs1922552	chr12:82158093	G/T	cg21231944	chr12:82153410	PPFIA2	-0.34	-4.64	-0.38	8.84e-6	Resting heart rate;
TGCT	cis	rs62244186	0.545	rs9284880	chr3:44759389	C/T	cg25151919	chr3:44754333	ZNF502	-0.47	-5.45	-0.44	2.56e-7	Depressive symptoms;
TGCT	cis	rs9372498	0.536	rs17080292	chr6:118850266	A/G	cg21191810	chr6:118973309	C6orf204	-0.37	-4.79	-0.39	4.73e-6	Diastolic blood pressure;
TGCT	cis	rs2120019	0.938	rs8033925	chr15:75311959	A/G	cg11632617	chr15:75315747	PPCDC	-0.3	-4.44	-0.37	1.95e-5	Blood trace element (Zn levels);
TGCT	cis	rs1903068	1.000	rs4516787	chr4:56010165	C/T	cg09978860	chr4:56023921	NA	-0.58	-6.64	-0.51	8.88e-10	Endometriosis;
TGCT	cis	rs7246657	0.943	rs34603719	chr19:37794528	T/G	cg18154014	chr19:37997991	ZNF793	0.91	6.21	0.49	7.22e-9	Coronary artery calcification;
TGCT	cis	rs7666738	0.830	rs6819047	chr4:98866902	G/A	cg18180107	chr4:99064573	C4orf37	0.55	5.14	0.42	1.03e-6	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs1814175	0.791	rs11040513	chr11:49778153	G/C	cg15704280	chr7:45808275	SEPT13	-0.69	-8.05	-0.59	5.61e-13	Height;
TGCT	trans	rs208520	0.661	rs207090	chr6:66783963	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-10.7	-0.69	2.47e-19	Exhaled nitric oxide output;
TGCT	cis	rs2921073	0.605	rs2976933	chr8:8254875	A/G	cg06636001	chr8:8085503	FLJ10661	0.51	4.58	0.38	1.12e-5	Parkinson's disease;
TGCT	cis	rs9443645	0.687	rs6915558	chr6:79769056	A/T	cg09184832	chr6:79620586	NA	-0.48	-5.34	-0.43	4.21e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs35146811	0.555	rs1981549	chr7:99541636	A/G	cg13334819	chr7:99746414	C7orf59	-0.6	-5.1	-0.42	1.22e-6	Coronary artery disease;
TGCT	trans	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg20587970	chr11:113659929	NA	-1.04	-12.57	-0.75	6.97e-24	Hip circumference adjusted for BMI;
TGCT	cis	rs4820792	0.623	rs6519761	chr22:29101600	A/G	cg03733026	chr22:29445468	ZNRF3	0.26	4.9	0.4	2.94e-6	Breast size;
TGCT	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.92	0.4	2.75e-6	Electroencephalogram traits;
TGCT	cis	rs1395	1.000	rs1275522	chr2:27426878	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.5	-6.65	-0.51	8.27e-10	Blood metabolite levels;
TGCT	cis	rs9430161	0.611	rs12081197	chr1:11034239	T/C	cg02454025	chr1:11042201	C1orf127	0.94	11.31	0.71	8.14e-21	Ewing sarcoma;
TGCT	cis	rs17387100	0.551	rs1517598	chr4:16020664	T/C	cg13480465	chr4:16795757	LDB2	-0.42	-5.33	-0.43	4.56e-7	Suicide attempts in depression or bipolar disorder;
TGCT	cis	rs9393692	0.645	rs766406	chr6:26319588	G/T	cg00631329	chr6:26305371	NA	-0.48	-7.28	-0.55	3.41e-11	Educational attainment;
TGCT	cis	rs7714584	1.000	rs1428551	chr5:150259832	G/A	cg22134413	chr5:150180641	NA	0.83	6.27	0.49	5.47e-9	Crohn's disease;
TGCT	cis	rs1691799	0.899	rs2951656	chr12:66732273	T/G	cg16791601	chr12:66731901	HELB	-0.27	-5.99	-0.47	2.14e-8	White blood cell count (basophil);
TGCT	cis	rs7043114	0.525	rs10739927	chr9:95052081	G/T	cg14311495	chr9:95764742	FGD3	-0.22	-4.44	-0.37	1.95e-5	Height;
TGCT	cis	rs79349575	0.783	rs12601955	chr17:47034420	C/T	cg27201301	chr17:47039149	GIP	0.25	4.47	0.37	1.72e-5	Type 2 diabetes;
TGCT	cis	rs7044106	0.762	rs1158553	chr9:123400974	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	6.93	0.53	2.01e-10	Hip circumference adjusted for BMI;
TGCT	trans	rs7864133	1.000	rs12377364	chr9:84103358	G/T	cg23451063	chr7:1059876	C7orf50	0.62	7.18	0.54	5.76e-11	Post bronchodilator FEV1 in COPD;
TGCT	cis	rs28595532	0.925	rs56200441	chr4:119497440	T/G	cg14228332	chr4:119757509	SEC24D	1.0	5.75	0.46	6.54e-8	Cannabis dependence symptom count;
TGCT	cis	rs10791097	0.703	rs11222360	chr11:130730871	C/T	cg05962950	chr11:130786565	SNX19	0.84	10.43	0.68	1.16e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	trans	rs61931739	0.500	rs11615231	chr12:34413330	T/C	cg26384229	chr12:38710491	ALG10B	0.73	6.89	0.53	2.44e-10	Morning vs. evening chronotype;
TGCT	cis	rs2688608	0.592	rs13013	chr10:75562161	C/A	cg15838173	chr10:75533400	FUT11	-0.3	-4.77	-0.39	5e-6	Inflammatory bowel disease;
TGCT	cis	rs9611565	0.608	rs2003816	chr22:42095140	T/G	cg13695892	chr22:41940480	POLR3H	0.84	8.04	0.59	5.93e-13	Vitiligo;
TGCT	cis	rs875971	1.000	rs1167612	chr7:65567976	C/A	cg18876405	chr7:65276391	NA	-0.34	-5.26	-0.43	6.23e-7	Aortic root size;
TGCT	cis	rs11785400	0.793	rs10956992	chr8:143736235	A/C	cg24634471	chr8:143751801	JRK	0.55	5.53	0.44	1.85e-7	Schizophrenia;
TGCT	cis	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg07424592	chr7:64974309	NA	-1.31	-7.72	-0.57	3.33e-12	Diabetic kidney disease;
TGCT	cis	rs6121246	0.567	rs6120879	chr20:30202961	T/C	cg13852791	chr20:30311386	BCL2L1	0.7	4.58	0.38	1.1e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs17253792	0.822	rs76472022	chr14:56053660	C/T	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs4727027	0.704	rs12535115	chr7:148895087	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	4.45	0.37	1.9e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs7666738	0.830	rs7698771	chr4:98986479	T/G	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4808199	0.895	rs7252888	chr19:19628037	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.72	4.85	0.4	3.62e-6	Nonalcoholic fatty liver disease;
TGCT	cis	rs79349575	0.749	rs318093	chr17:46989354	A/G	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.45	-0.37	1.93e-5	Type 2 diabetes;
TGCT	cis	rs2354432	0.607	rs68080346	chr1:146708484	T/C	cg25205988	chr1:146714368	CHD1L	-1.15	-4.8	-0.4	4.49e-6	Mitochondrial DNA levels;
TGCT	cis	rs11167764	1.000	rs6580220	chr5:141480558	G/A	cg08523384	chr5:141488047	NDFIP1	-0.25	-5.19	-0.42	8.44e-7	Crohn's disease;
TGCT	cis	rs2072499	0.750	rs7534339	chr1:156156219	A/G	cg25208724	chr1:156163844	SLC25A44	1.0	9.15	0.63	1.46e-15	Testicular germ cell tumor;
TGCT	cis	rs2412208	0.527	rs4436414	chr1:7120915	G/A	cg20434152	chr1:7120926	CAMTA1	-0.3	-4.93	-0.4	2.56e-6	Survival in sporadic amyotrophic lateral sclerosis;
TGCT	cis	rs6988636	1.000	rs6988636	chr8:124185970	A/G	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.48	-0.37	1.66e-5	Bipolar disorder;
TGCT	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg10047753	chr17:41438598	NA	0.95	9.61	0.65	1.12e-16	Menopause (age at onset);
TGCT	cis	rs4727027	0.727	rs1568944	chr7:148873497	A/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.54	4.57	0.38	1.18e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	trans	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg25482853	chr8:67687455	SGK3	1.17	11.24	0.71	1.19e-20	Lung disease severity in cystic fibrosis;
TGCT	cis	rs3784262	0.669	rs3742959	chr15:58249113	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.44	-6.34	-0.49	3.96e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs4595586	0.545	rs1607042	chr12:39368028	A/G	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs1865760	1.000	rs9393675	chr6:25930116	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.65	6.18	0.49	8.63e-9	Height;
TGCT	cis	rs6964587	0.872	rs57969083	chr7:91665627	A/T	cg17063962	chr7:91808500	NA	0.9	9.89	0.66	2.3e-17	Breast cancer;
TGCT	cis	rs2235649	0.561	rs12599786	chr16:1965257	T/G	cg02432467	chr16:1963432	HS3ST6	-0.31	-4.59	-0.38	1.09e-5	Blood metabolite levels;
TGCT	trans	rs1496653	0.602	rs71322173	chr3:23400823	A/G	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs56104184	0.830	rs17206679	chr19:49342237	C/G	cg15549821	chr19:49342101	PLEKHA4	-0.87	-11.91	-0.73	2.81e-22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs9560113	1.000	rs4771757	chr13:112176379	G/T	cg14154082	chr13:112174009	NA	0.34	4.65	0.39	8.49e-6	Menarche (age at onset);
TGCT	cis	rs17376456	0.877	rs13173952	chr5:93307557	A/T	cg25358565	chr5:93447407	FAM172A	0.98	8.39	0.6	9.01e-14	Diabetic retinopathy;
TGCT	cis	rs10883723	0.810	rs61873733	chr10:104251458	G/A	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs9549367	0.737	rs9549712	chr13:113902355	G/A	cg00898013	chr13:113819073	PROZ	-0.4	-5.03	-0.41	1.64e-6	Platelet distribution width;
TGCT	cis	rs55882075	0.967	rs59666900	chr5:179147641	C/T	cg14593053	chr5:179126677	CANX	0.47	4.89	0.4	3.12e-6	Monocyte percentage of white cells;
TGCT	cis	rs10791097	0.694	rs10160281	chr11:130742788	T/C	cg14779329	chr11:130786720	SNX19	0.28	4.82	0.4	4.09e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	5.53	0.44	1.8e-7	Alzheimer's disease;
TGCT	cis	rs2832191	0.740	rs13048618	chr21:30458684	A/G	cg08807101	chr21:30365312	RNF160	0.65	6.14	0.48	1.03e-8	Dental caries;
TGCT	cis	rs1887596	0.624	rs9553861	chr13:27146449	A/G	cg01312412	chr13:27282625	NA	-0.27	-4.86	-0.4	3.54e-6	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs7647973	1.000	rs4241407	chr3:49600319	C/T	cg07636037	chr3:49044803	WDR6	0.65	5.35	0.43	4.01e-7	Menarche (age at onset);
TGCT	cis	rs1008375	0.898	rs4698620	chr4:17587361	C/T	cg16339924	chr4:17578868	LAP3	0.8	6.96	0.53	1.73e-10	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9611565	0.569	rs6002328	chr22:41710034	T/C	cg13695892	chr22:41940480	POLR3H	-0.64	-6.03	-0.48	1.78e-8	Vitiligo;
TGCT	cis	rs4689592	0.583	rs12501362	chr4:7083563	C/T	cg02503808	chr4:7069936	GRPEL1	-0.78	-7.39	-0.55	1.87e-11	Monocyte percentage of white cells;
TGCT	trans	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.8	-8.32	-0.6	1.31e-13	Body mass index;
TGCT	cis	rs3820068	0.655	rs59605679	chr1:15863796	T/G	cg05660106	chr1:15850417	CASP9	1.16	14.82	0.8	3.11e-29	Systolic blood pressure;
TGCT	trans	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.83	-8.69	-0.62	1.76e-14	Body mass index;
TGCT	cis	rs4372836	1.000	rs11688129	chr2:28952581	T/C	cg09522027	chr2:28974177	PPP1CB	0.59	5.15	0.42	1e-6	Body mass index;
TGCT	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg27286337	chr10:134555280	INPP5A	0.4	4.74	0.39	5.71e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs6912958	0.512	rs910563	chr6:88058885	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.44	5.71	0.46	7.78e-8	Monocyte percentage of white cells;
TGCT	cis	rs4888262	0.526	rs8057279	chr16:74627303	C/T	cg01733217	chr16:74700730	RFWD3	0.74	7.42	0.55	1.6e-11	Testicular germ cell tumor;
TGCT	cis	rs7017914	0.967	rs1902614	chr8:71656167	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.03	-0.41	1.69e-6	Bone mineral density;
TGCT	cis	rs12497850	0.931	rs6446253	chr3:48911443	C/T	cg05785598	chr3:49045655	WDR6	0.35	4.72	0.39	6.35e-6	Parkinson's disease;
TGCT	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	16.04	0.82	5e-32	Prudent dietary pattern;
TGCT	cis	rs17253792	0.822	rs77990307	chr14:56070049	T/C	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs10779751	1.000	rs6670821	chr1:11308762	T/C	cg08854313	chr1:11322531	MTOR	0.98	9.12	0.63	1.65e-15	Body mass index;
TGCT	cis	rs6547741	0.935	rs4260197	chr2:27794150	C/G	cg27432699	chr2:27873401	GPN1	-0.19	-4.68	-0.39	7.41e-6	Oral cavity cancer;
TGCT	cis	rs67311347	1.000	rs6762251	chr3:40531136	A/G	cg02782426	chr3:40428986	ENTPD3	-0.4	-4.57	-0.38	1.15e-5	Renal cell carcinoma;
TGCT	cis	rs2235642	0.928	rs2076435	chr16:1607574	C/T	cg08296037	chr16:1584118	IFT140;TMEM204	-0.31	-5.47	-0.44	2.39e-7	Coronary artery disease;
TGCT	cis	rs1577917	0.682	rs6909767	chr6:86228109	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.53	4.84	0.4	3.74e-6	Response to antipsychotic treatment;
TGCT	cis	rs1008375	0.897	rs6820164	chr4:17630115	G/A	cg18681998	chr4:17616180	MED28	1.0	10.26	0.68	2.93e-18	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9291683	0.588	rs3733586	chr4:9997534	C/T	cg11266682	chr4:10021025	SLC2A9	0.66	9.38	0.64	4.02e-16	Bone mineral density;
TGCT	cis	rs7917772	0.503	rs11191326	chr10:104302959	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.92	-6.8	-0.52	3.96e-10	Gut microbiome composition (summer);
TGCT	cis	rs367615	0.918	rs4576198	chr5:108867350	T/G	cg17395555	chr5:108820864	NA	0.31	5.01	0.41	1.85e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs984222	0.501	rs1361906	chr1:119484644	C/T	cg18199617	chr1:120311653	HMGCS2	0.19	4.5	0.37	1.57e-5	Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;
TGCT	cis	rs60843830	0.661	rs11674325	chr2:105517	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.62	5.52	0.44	1.92e-7	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg20607798	chr8:58055168	NA	0.56	4.66	0.39	7.88e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7103411	0.637	rs6416056	chr11:27646745	A/G	cg10635145	chr11:27742435	BDNF	-0.32	-4.56	-0.38	1.2e-5	Menarche (age at onset);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
TGCT	cis	rs6866344	0.697	rs62392832	chr5:178134395	T/C	cg10224037	chr5:178157518	ZNF354A	0.95	8.47	0.61	6.06e-14	Neutrophil percentage of white cells;
TGCT	cis	rs3772130	1.000	rs17691170	chr3:121357626	G/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.54	4.95	0.41	2.41e-6	Cognitive performance;
TGCT	cis	rs9926296	0.572	rs2376878	chr16:89885161	G/A	cg08627397	chr16:89984028	MC1R	-0.3	-4.79	-0.4	4.65e-6	Vitiligo;
TGCT	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg08280861	chr8:58055591	NA	0.39	4.57	0.38	1.17e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg07424592	chr7:64974309	NA	1.26	7.79	0.57	2.25e-12	Diabetic kidney disease;
TGCT	trans	rs10435719	0.902	rs6601633	chr8:11805173	C/T	cg15556689	chr8:8085844	FLJ10661	-0.73	-7.03	-0.53	1.2e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs9611565	0.592	rs8779	chr22:42070276	T/C	cg06481639	chr22:41940642	POLR3H	0.73	6.57	0.51	1.27e-9	Vitiligo;
TGCT	cis	rs7666738	0.830	rs4699598	chr4:99019158	C/T	cg05340658	chr4:99064831	C4orf37	0.48	5.5	0.44	2.12e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10791097	0.547	rs10791101	chr11:130739133	C/T	cg12179176	chr11:130786555	SNX19	0.85	10.17	0.67	4.79e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs4372836	0.729	rs4665436	chr2:29090227	T/C	cg09522027	chr2:28974177	PPP1CB	0.67	6.95	0.53	1.84e-10	Body mass index;
TGCT	cis	rs7937682	1.000	rs10502147	chr11:111569931	G/A	cg09085632	chr11:111637200	PPP2R1B	1.04	9.55	0.65	1.58e-16	Primary sclerosing cholangitis;
TGCT	cis	rs478304	0.654	rs10896032	chr11:65459419	C/A	cg17480646	chr11:65405466	SIPA1	-0.61	-8.27	-0.6	1.79e-13	Acne (severe);
TGCT	cis	rs9650657	0.589	rs10107145	chr8:10758213	A/G	cg27411982	chr8:10470053	RP1L1	-0.21	-4.64	-0.38	8.87e-6	Neuroticism;
TGCT	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg03452623	chr4:187889614	NA	-0.34	-4.94	-0.41	2.46e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.54	-6.63	-0.51	9.33e-10	Longevity;Endometriosis;
TGCT	cis	rs6988636	0.579	rs28528232	chr8:124189308	G/A	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs9660180	0.780	rs12038111	chr1:1703849	T/C	cg03396347	chr1:1875803	NA	-0.36	-6.58	-0.51	1.18e-9	Body mass index;
TGCT	cis	rs1008375	0.932	rs12500947	chr4:17603424	C/T	cg16339924	chr4:17578868	LAP3	0.76	6.09	0.48	1.28e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	trans	rs57221529	0.766	rs72706606	chr5:558609	T/C	cg11887960	chr12:57824829	NA	1.15	9.35	0.64	4.71e-16	Lung disease severity in cystic fibrosis;
TGCT	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg00343986	chr7:65444356	GUSB	-0.23	-5.01	-0.41	1.79e-6	Aortic root size;
TGCT	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg24060327	chr5:131705240	SLC22A5	-0.55	-5.43	-0.44	2.81e-7	Breast cancer;
TGCT	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg12963246	chr6:28129442	ZNF389	0.51	5.02	0.41	1.73e-6	Depression;
TGCT	cis	rs11190604	1.000	rs10883502	chr10:102238343	T/G	cg16342193	chr10:102329863	NA	-0.4	-5.34	-0.43	4.36e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	trans	rs7819412	0.634	rs6987767	chr8:10910066	T/C	cg06636001	chr8:8085503	FLJ10661	0.73	7.2	0.54	5.14e-11	Triglycerides;
TGCT	cis	rs17221829	1.000	rs17221829	chr11:89466732	A/C	cg02982614	chr11:89391479	FOLH1B	0.3	5.29	0.43	5.45e-7	Anxiety in major depressive disorder;
TGCT	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg12310025	chr6:25882481	NA	-0.78	-8.1	-0.59	4.37e-13	Blood metabolite levels;
TGCT	cis	rs7772486	0.840	rs2777478	chr6:146309117	T/C	cg23711669	chr6:146136114	FBXO30	0.89	9.5	0.65	2.02e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9952991	0.566	rs514000	chr18:12854072	C/T	cg23544223	chr18:12777786	NA	0.54	4.71	0.39	6.43e-6	Inflammatory skin disease;
TGCT	cis	rs8031584	0.958	rs1043742	chr15:31232581	A/C	cg08704250	chr15:31115839	NA	-0.35	-4.9	-0.4	2.97e-6	Huntington's disease progression;
TGCT	cis	rs9611565	0.546	rs739134	chr22:42089623	T/C	cg03806693	chr22:41940476	POLR3H	1.06	11.74	0.73	7.15e-22	Vitiligo;
TGCT	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg07343612	chr16:622815	PIGQ	-0.42	-8.45	-0.6	6.8e-14	Height;
TGCT	cis	rs10984561	0.881	rs57572849	chr9:122256522	T/A	cg14242995	chr9:122249943	NA	0.74	6.01	0.47	1.96e-8	Pulmonary function decline;
TGCT	cis	rs6845621	0.754	rs6820563	chr4:18887467	G/A	cg12196642	chr4:18937545	NA	-0.24	-4.47	-0.37	1.76e-5	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
TGCT	cis	rs79149102	0.522	rs11072519	chr15:75278340	T/C	cg09165964	chr15:75287851	SCAMP5	-1.08	-6.04	-0.48	1.66e-8	Lung cancer;
TGCT	cis	rs3809566	0.613	rs16946330	chr15:63324501	C/G	cg08198488	chr15:63333792	TPM1	0.32	4.68	0.39	7.3e-6	Platelet count;
TGCT	cis	rs6987853	0.933	rs2974341	chr8:42398302	T/A	cg20539142	chr8:42623718	CHRNA6	-0.21	-5.03	-0.41	1.69e-6	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.74	5.21	0.42	7.56e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs13256369	0.802	rs13256404	chr8:8562974	T/C	cg06671706	chr8:8559999	CLDN23	0.34	4.52	0.38	1.4e-5	Obesity-related traits;
TGCT	cis	rs6089584	0.606	rs2144674	chr20:60576579	G/A	cg06108461	chr20:60628389	TAF4	-0.4	-4.86	-0.4	3.47e-6	Body mass index;
TGCT	cis	rs4523957	0.583	rs2984943	chr17:2030135	T/C	cg16513277	chr17:2031491	SMG6	-0.2	-4.58	-0.38	1.13e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9868809	0.881	rs13063312	chr3:48661985	G/A	cg00383909	chr3:49044727	WDR6	0.97	5.08	0.42	1.34e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs9902453	0.765	rs3102562	chr17:28040403	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.84	8.39	0.6	9.14e-14	Coffee consumption (cups per day);
TGCT	cis	rs4478858	0.735	rs1566963	chr1:31772206	G/A	cg07478791	chr1:31886160	SERINC2	-0.52	-5.03	-0.41	1.67e-6	Alcohol dependence;
TGCT	cis	rs12887734	0.566	rs8548	chr14:104199580	A/C	cg26031613	chr14:104095156	KLC1	-0.71	-5.94	-0.47	2.7e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs17030434	0.775	rs4696493	chr4:154680007	T/C	cg14289246	chr4:154710475	SFRP2	0.9	7.0	0.53	1.41e-10	Electrocardiographic conduction measures;
TGCT	cis	rs7552404	0.924	rs1858536	chr1:76161595	G/T	cg03433033	chr1:76189801	ACADM	0.82	9.89	0.66	2.31e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs10466239	0.803	rs60739384	chr10:43868029	G/A	cg14116799	chr10:43800154	NA	-0.56	-4.48	-0.37	1.69e-5	Telomere length;
TGCT	cis	rs4911259	0.533	rs6058931	chr20:31471012	C/T	cg13636640	chr20:31349939	DNMT3B	-0.87	-9.47	-0.65	2.42e-16	Inflammatory bowel disease;
TGCT	cis	rs7674212	0.541	rs17217473	chr4:104114742	A/C	cg16532752	chr4:104119610	CENPE	-0.58	-5.37	-0.43	3.66e-7	Type 2 diabetes;
TGCT	cis	rs2730260	0.578	rs56375711	chr7:158854935	G/A	cg18387198	chr7:157949267	PTPRN2	0.45	4.44	0.37	1.96e-5	Myopia (pathological);
TGCT	cis	rs9300255	0.568	rs1727300	chr12:123664205	C/T	cg00376283	chr12:123451042	ABCB9	0.72	5.61	0.45	1.27e-7	Neutrophil percentage of white cells;
TGCT	cis	rs12701220	0.894	rs8591	chr7:1036799	C/T	cg07217954	chr7:1067459	C7orf50	-0.48	-4.79	-0.39	4.76e-6	Bronchopulmonary dysplasia;
TGCT	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg22105103	chr4:187893119	NA	0.33	4.67	0.39	7.83e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1568889	0.838	rs7127069	chr11:28325412	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.93	10.99	0.7	4.8e-20	Bipolar disorder;
TGCT	cis	rs2456568	0.802	rs10831136	chr11:93636860	T/C	cg26875233	chr11:93583750	C11orf90	-0.48	-6.47	-0.5	2.07e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs9303401	0.659	rs17222523	chr17:56620501	A/G	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs10791097	0.748	rs4937580	chr11:130734270	T/C	cg14779329	chr11:130786720	SNX19	0.29	5.12	0.42	1.16e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9810089	0.814	rs696518	chr3:136120300	A/C	cg12473912	chr3:136751656	NA	0.36	5.04	0.41	1.58e-6	Gestational age at birth (child effect);
TGCT	cis	rs916888	0.610	rs199438	chr17:44791643	G/A	cg15921436	chr17:44337874	NA	0.41	6.17	0.48	8.72e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7681440	0.904	rs12331318	chr4:90770255	A/G	cg14346243	chr4:90757452	SNCA	-0.55	-5.36	-0.43	3.99e-7	Dementia with Lewy bodies;
TGCT	cis	rs12220898	0.619	rs7911371	chr10:50485396	T/C	cg09603381	chr10:49954066	WDFY4	0.38	4.45	0.37	1.88e-5	Inflammatory biomarkers;
TGCT	cis	rs9640161	0.789	rs6964110	chr7:150041836	A/C	cg10018233	chr7:150070692	REPIN1	0.31	4.67	0.39	7.76e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	4.76	0.39	5.19e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7666738	0.822	rs28367231	chr4:98845726	G/T	cg18180107	chr4:99064573	C4orf37	0.55	5.1	0.42	1.22e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9383153	1.000	rs9370887	chr6:16329258	G/C	cg06493612	chr6:15502050	JARID2	0.59	4.74	0.39	5.7e-6	Gambling;
TGCT	cis	rs3820068	0.581	rs6693694	chr1:15980135	G/T	cg05660106	chr1:15850417	CASP9	0.79	7.46	0.56	1.29e-11	Systolic blood pressure;
TGCT	cis	rs2070488	0.804	rs13085153	chr3:38461279	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.78	7.9	0.58	1.26e-12	Electrocardiographic conduction measures;
TGCT	cis	rs4699052	0.963	rs6816055	chr4:104143160	T/C	cg16532752	chr4:104119610	CENPE	-0.58	-5.46	-0.44	2.43e-7	Testicular germ cell tumor;
TGCT	cis	rs2268241	0.938	rs9978223	chr21:34770358	G/A	cg14850771	chr21:34775459	IFNGR2	0.6	5.15	0.42	1.01e-6	Obesity-related traits;
TGCT	cis	rs9611565	0.921	rs5751077	chr22:41720728	G/C	cg17554472	chr22:41940697	POLR3H	-0.39	-4.49	-0.37	1.58e-5	Vitiligo;
TGCT	cis	rs4595586	0.545	rs11615718	chr12:39395335	A/G	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs7772486	0.764	rs2265471	chr6:146220250	G/A	cg05347473	chr6:146136440	FBXO30	0.52	5.0	0.41	1.89e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs28595532	0.920	rs116401323	chr4:119721727	C/T	cg21605333	chr4:119757512	SEC24D	1.72	8.99	0.63	3.52e-15	Cannabis dependence symptom count;
TGCT	cis	rs72781680	1.000	rs74704838	chr2:24158270	C/A	cg08917208	chr2:24149416	ATAD2B	0.73	4.51	0.38	1.48e-5	Lymphocyte counts;
TGCT	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg06481639	chr22:41940642	POLR3H	-0.74	-6.74	-0.52	5.38e-10	Vitiligo;
TGCT	cis	rs4595586	0.545	rs12812262	chr12:39392567	T/A	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg08859206	chr1:53392774	SCP2	-0.49	-7.71	-0.57	3.61e-12	Monocyte count;
TGCT	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg10295955	chr4:187884368	NA	-0.94	-13.14	-0.76	3.11e-25	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs8180040	0.629	rs7426969	chr3:47091355	T/C	cg27129171	chr3:47204927	SETD2	0.71	8.55	0.61	3.9e-14	Colorectal cancer;
TGCT	cis	rs7647973	1.000	rs7613491	chr3:49508976	T/C	cg07636037	chr3:49044803	WDR6	-0.73	-5.87	-0.47	3.65e-8	Menarche (age at onset);
TGCT	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.31	0.43	4.9e-7	Prudent dietary pattern;
TGCT	cis	rs3096299	0.933	rs3114848	chr16:89452771	G/A	cg06640241	chr16:89574553	SPG7	0.65	6.25	0.49	6.15e-9	Multiple myeloma (IgH translocation);
TGCT	cis	rs8064299	0.597	rs3785539	chr17:72775099	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.91	10.11	0.67	6.79e-18	Monocyte count;
TGCT	cis	rs17387100	0.551	rs2677788	chr4:16018363	G/A	cg13480465	chr4:16795757	LDB2	-0.42	-5.33	-0.43	4.56e-7	Suicide attempts in depression or bipolar disorder;
TGCT	cis	rs7843479	0.965	rs11775479	chr8:21859991	C/T	cg17168535	chr8:21777572	XPO7	0.64	5.82	0.46	4.81e-8	Mean corpuscular volume;
TGCT	cis	rs1577917	0.740	rs6926049	chr6:86266133	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.61	5.32	0.43	4.64e-7	Response to antipsychotic treatment;
TGCT	cis	rs7819412	0.715	rs2409727	chr8:11043236	C/T	cg21775007	chr8:11205619	TDH	-0.51	-4.66	-0.39	7.89e-6	Triglycerides;
TGCT	cis	rs6695640	0.854	rs2526830	chr1:17728119	A/G	cg25979543	chr1:17888104	ARHGEF10L	-0.25	-4.61	-0.38	9.87e-6	Mean platelet volume;
TGCT	cis	rs4851254	0.921	rs11679078	chr2:100757881	C/G	cg23118464	chr2:100721844	AFF3	0.7	5.17	0.42	9.07e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg08677398	chr8:58056175	NA	0.35	4.7	0.39	6.72e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs59197085	0.636	rs57072537	chr7:128435596	G/C	cg00260937	chr7:128520193	KCP	0.46	4.78	0.39	4.96e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
TGCT	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg20849893	chr7:64541193	NA	0.5	5.16	0.42	9.37e-7	Calcium levels;
TGCT	cis	rs9486719	1.000	rs2472880	chr6:96860130	G/A	cg18709589	chr6:96969512	KIAA0776	0.71	5.21	0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.11	14.68	0.8	6.95e-29	Height;
TGCT	cis	rs2013441	1.000	rs2080673	chr17:20062395	C/A	cg23224458	chr17:20280056	CCDC144C	0.38	4.61	0.38	9.96e-6	Obesity-related traits;
TGCT	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg01585852	chr22:24235823	MIF	-0.22	-4.68	-0.39	7.49e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2688608	0.967	rs72814394	chr10:75656325	C/T	cg23231163	chr10:75533350	FUT11	-0.25	-4.45	-0.37	1.89e-5	Inflammatory bowel disease;
TGCT	cis	rs1691799	0.899	rs1168320	chr12:66744849	C/T	cg16791601	chr12:66731901	HELB	-0.28	-6.18	-0.49	8.52e-9	White blood cell count (basophil);
TGCT	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg23758822	chr17:41437982	NA	0.72	6.81	0.52	3.77e-10	Menopause (age at onset);
TGCT	cis	rs3796352	1.000	rs35849389	chr3:53005235	A/G	cg15956490	chr3:53032818	SFMBT1	0.61	6.76	0.52	4.92e-10	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs9916302	0.904	rs9898170	chr17:37510092	T/C	cg07936489	chr17:37558343	FBXL20	0.63	4.91	0.4	2.83e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg27454412	chr7:1067447	C7orf50	0.6	4.7	0.39	6.76e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs72615157	0.634	rs7789890	chr7:99800559	G/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.6	-5.05	-0.41	1.54e-6	Lung function (FEV1/FVC);
TGCT	cis	rs2692947	0.696	rs1724121	chr2:96808549	T/C	cg22654517	chr2:96458247	NA	0.23	5.22	0.42	7.29e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg17554472	chr22:41940697	POLR3H	0.49	5.06	0.41	1.44e-6	Vitiligo;
TGCT	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg25036284	chr2:26402008	FAM59B	-0.56	-4.9	-0.4	2.88e-6	Gut microbiome composition (summer);
TGCT	cis	rs9650657	0.515	rs6601560	chr8:10950866	T/C	cg21775007	chr8:11205619	TDH	-0.54	-5.03	-0.41	1.7e-6	Neuroticism;
TGCT	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg11764359	chr7:65958608	NA	0.59	5.28	0.43	5.53e-7	Aortic root size;
TGCT	cis	rs9357506	1.000	rs6934148	chr6:46307787	T/A	cg21115430	chr6:46460003	NA	-0.26	-5.17	-0.42	9.2e-7	Body mass index;
TGCT	trans	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg17470723	chr8:74884337	TCEB1	0.71	6.77	0.52	4.48e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	9.52	0.65	1.86e-16	Platelet count;
TGCT	cis	rs67311347	0.955	rs4974068	chr3:40376929	T/C	cg13409248	chr3:40428643	ENTPD3	0.54	4.47	0.37	1.72e-5	Renal cell carcinoma;
TGCT	cis	rs1215050	0.791	rs7688192	chr4:98900798	G/T	cg05340658	chr4:99064831	C4orf37	-0.46	-5.82	-0.46	4.74e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs10464366	0.571	rs4723825	chr7:39157627	G/C	cg18850127	chr7:39170497	POU6F2	0.33	7.16	0.54	6.13e-11	IgG glycosylation;
TGCT	cis	rs3858526	0.920	rs11511938	chr11:5928793	A/G	cg05234568	chr11:5960015	NA	-0.44	-4.6	-0.38	1.03e-5	DNA methylation (variation);
TGCT	cis	rs6912958	0.559	rs376633	chr6:88042785	T/C	cg10393598	chr6:87862264	NA	-0.31	-4.5	-0.37	1.55e-5	Monocyte percentage of white cells;
TGCT	cis	rs763014	0.931	rs2071982	chr16:630405	T/G	cg07343612	chr16:622815	PIGQ	-0.41	-7.87	-0.58	1.52e-12	Height;
TGCT	cis	rs6760805	0.606	rs12693273	chr2:182112233	G/A	cg15587571	chr2:181849325	UBE2E3	-0.3	-4.45	-0.37	1.9e-5	Lymphocyte counts;
TGCT	cis	rs6867913	0.709	rs2338874	chr5:141466926	G/A	cg01311360	chr5:140792558	PCDHGA4;PCDHGA6;PCDHGA9;PCDHGA1;PCDHGA8;PCDHGA5;PCDHGB1;PCDHGB4;PCDHGA3;PCDHGA10;PCDHGA2;PCDHGB6;PCDHGA7;PCDHGB2;PCDHGB5;PCDHGB3	-0.42	-4.84	-0.4	3.75e-6	Asthma;
TGCT	cis	rs2657888	0.560	rs6581096	chr12:56878120	G/A	cg23002907	chr12:56915593	RBMS2	-0.38	-4.78	-0.39	4.81e-6	Adiponectin levels;
TGCT	cis	rs9993613	0.875	rs1878756	chr4:73478415	C/T	cg15102770	chr4:73434591	ADAMTS3	0.49	4.72	0.39	6.34e-6	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs6918586	0.658	rs198814	chr6:26127759	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.66	-6.22	-0.49	7.01e-9	Schizophrenia;
TGCT	cis	rs7617480	0.648	rs9882443	chr3:48749064	G/A	cg07636037	chr3:49044803	WDR6	0.77	6.25	0.49	6.14e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	6.22	0.49	7.14e-9	Alzheimer's disease;
TGCT	cis	rs3820068	0.506	rs17448966	chr1:15990983	T/G	cg05660106	chr1:15850417	CASP9	0.77	7.41	0.55	1.7e-11	Systolic blood pressure;
TGCT	cis	rs9910055	0.573	rs228768	chr17:42191893	A/C	cg13607699	chr17:42295918	UBTF	0.6	5.72	0.46	7.67e-8	Total body bone mineral density;
TGCT	cis	rs1635	0.826	rs4713159	chr6:28283772	G/A	cg15743358	chr6:28303923	ZNF323	-1.34	-5.96	-0.47	2.44e-8	Schizophrenia;
TGCT	cis	rs10466239	0.730	rs2243492	chr10:43849358	C/T	cg08951903	chr10:44070173	ZNF239	-0.79	-4.91	-0.4	2.8e-6	Telomere length;
TGCT	cis	rs1406084	0.636	rs12693841	chr2:154724818	A/C	cg25703346	chr2:154729189	GALNT13	-0.77	-4.6	-0.38	1.03e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9929218	0.559	rs55907909	chr16:68805805	C/T	cg01251360	chr16:68772225	CDH1	-0.25	-4.49	-0.37	1.63e-5	Colorectal cancer;
TGCT	cis	rs9581857	0.685	rs9579084	chr13:28028201	A/G	cg22138327	chr13:27999177	GTF3A	-0.7	-5.35	-0.43	4.05e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs4474465	0.850	rs10751292	chr11:78242201	C/G	cg26707845	chr11:78719384	ODZ4	-0.34	-4.68	-0.39	7.39e-6	Alzheimer's disease (survival time);
TGCT	cis	rs1153858	1.000	rs4775895	chr15:45617957	T/A	cg14582100	chr15:45693742	SPATA5L1	0.48	5.66	0.45	9.96e-8	Homoarginine levels;
TGCT	cis	rs7226408	0.948	rs11662126	chr18:34408318	A/G	cg06757138	chr18:34340585	FHOD3	0.26	4.79	0.4	4.62e-6	Obesity-related traits;
TGCT	cis	rs10992471	0.630	rs10453241	chr9:95198887	C/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.54	-5.3	-0.43	5.16e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs4478858	0.839	rs10798834	chr1:31708977	G/A	cg00250761	chr1:31883323	NA	-0.3	-5.66	-0.45	9.88e-8	Alcohol dependence;
TGCT	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg11644478	chr21:40555479	PSMG1	0.99	10.5	0.69	7.73e-19	Cognitive function;
TGCT	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	7.24	0.55	4.17e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg04995860	chr1:53192072	ZYG11B	-0.41	-4.48	-0.37	1.65e-5	Monocyte count;
TGCT	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg22535103	chr8:58192502	C8orf71	-0.41	-4.81	-0.4	4.27e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg01448562	chr3:133502909	NA	-0.33	-6.58	-0.51	1.16e-9	Iron status biomarkers;
TGCT	cis	rs11585357	1.000	rs11585357	chr1:17601165	C/T	cg08277548	chr1:17600880	PADI3	-0.97	-9.95	-0.67	1.7e-17	Hair shape;
TGCT	cis	rs1975974	0.511	rs113941161	chr17:21741346	T/C	cg18423549	chr17:21743878	NA	-0.66	-6.21	-0.49	7.18e-9	Psoriasis;
TGCT	cis	rs13242816	1.000	rs12672236	chr7:116111369	A/G	cg16553024	chr7:116138462	CAV2	0.44	4.74	0.39	5.74e-6	P wave duration;
TGCT	cis	rs6484504	0.576	rs208091	chr11:31190099	G/C	cg26647111	chr11:31128758	NA	-0.34	-4.63	-0.38	9.09e-6	Red blood cell count;
TGCT	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg13628971	chr7:2884303	GNA12	-0.56	-4.44	-0.37	1.96e-5	Height;
TGCT	cis	rs35934224	0.783	rs28360650	chr22:19857061	A/G	cg11182965	chr22:19864308	TXNRD2	-0.36	-4.95	-0.41	2.33e-6	Glaucoma (primary open-angle);
TGCT	cis	rs2235642	0.893	rs8051295	chr16:1588087	A/G	cg11375102	chr16:1583810	IFT140;TMEM204	-0.31	-5.42	-0.44	2.95e-7	Coronary artery disease;
TGCT	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg27286337	chr10:134555280	INPP5A	0.41	5.13	0.42	1.07e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs7267979	1.000	rs2482928	chr20:25331530	A/G	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs709400	0.663	rs7152202	chr14:103886757	A/G	cg12935359	chr14:103987150	CKB	-0.35	-5.41	-0.44	3.17e-7	Body mass index;
TGCT	cis	rs651907	0.557	rs34457525	chr3:101435225	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.34	-7.02	-0.53	1.27e-10	Colorectal cancer;
TGCT	cis	rs10510102	0.872	rs12247367	chr10:123721071	G/A	cg23691251	chr10:123688108	ATE1	-0.59	-4.7	-0.39	6.75e-6	Breast cancer;
TGCT	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg26513180	chr16:89883248	FANCA	1.04	14.54	0.79	1.42e-28	Vitiligo;
TGCT	cis	rs72781680	0.898	rs17762609	chr2:24114729	G/T	cg08917208	chr2:24149416	ATAD2B	0.78	4.79	0.4	4.69e-6	Lymphocyte counts;
TGCT	cis	rs10089	1.000	rs4835945	chr5:127526481	C/A	cg19767477	chr5:127420684	SLC12A2	-0.42	-4.47	-0.37	1.77e-5	Ileal carcinoids;
TGCT	cis	rs5769707	0.967	rs2051626	chr22:50008973	G/A	cg10356904	chr22:49881777	NA	-0.24	-4.81	-0.4	4.35e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg13944838	chr5:179740914	GFPT2	-0.4	-6.32	-0.49	4.35e-9	Height;
TGCT	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6831352	0.918	rs13110764	chr4:100062466	C/T	cg12011299	chr4:100065546	ADH4	-0.4	-4.94	-0.41	2.51e-6	Alcohol dependence;
TGCT	cis	rs2280018	0.526	rs2966129	chr16:15152927	A/C	cg07549590	chr16:15018862	NA	0.35	5.24	0.43	6.59e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs9473924	0.542	rs36093098	chr6:50833931	G/A	cg14470998	chr6:50812995	TFAP2B	1.33	7.94	0.58	1.05e-12	Body mass index;
TGCT	cis	rs7267979	0.873	rs6083853	chr20:25404541	T/C	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1577917	0.771	rs9362230	chr6:86305013	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.58	-0.45	1.43e-7	Response to antipsychotic treatment;
TGCT	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg13395646	chr4:1353034	KIAA1530	-0.6	-8.06	-0.59	5.55e-13	Obesity-related traits;
TGCT	cis	rs926938	0.618	rs360624	chr1:115409476	A/C	cg12756093	chr1:115239321	AMPD1	0.41	6.19	0.49	8.06e-9	Autism;
TGCT	cis	rs11997175	0.574	rs12541661	chr8:33649856	T/G	ch.8.33884649F	chr8:33765107	NA	0.28	4.53	0.38	1.35e-5	Body mass index;
TGCT	cis	rs539096	0.874	rs2842175	chr1:44023615	G/A	cg12908607	chr1:44402522	ARTN	0.55	5.51	0.44	2e-7	Intelligence (multi-trait analysis);
TGCT	trans	rs210152	0.588	rs35817932	chr6:33457926	T/C	cg08795360	chr21:41033440	B3GALT5	0.41	6.67	0.51	7.51e-10	Schizophrenia;
TGCT	cis	rs9788721	0.802	rs56219465	chr15:78742579	A/G	cg18825076	chr15:78729989	IREB2	-0.33	-5.22	-0.42	7.38e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
TGCT	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg22683308	chr4:1340831	KIAA1530	-0.67	-6.31	-0.49	4.6e-9	Longevity;
TGCT	cis	rs35883536	0.609	rs2647327	chr1:101041766	C/T	cg06223162	chr1:101003688	GPR88	0.42	7.93	0.58	1.11e-12	Monocyte count;
TGCT	cis	rs2797160	0.904	rs1612274	chr6:126014907	C/A	cg05901451	chr6:126070800	HEY2	0.77	6.72	0.52	5.88e-10	Endometrial cancer;
TGCT	cis	rs7000551	0.606	rs7844699	chr8:22248920	G/T	cg12081754	chr8:22256438	SLC39A14	-0.3	-4.5	-0.37	1.55e-5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs12048904	0.964	rs3188491	chr1:101338482	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.5	4.54	0.38	1.31e-5	Multiple sclerosis;
TGCT	cis	rs78487399	0.908	rs57066469	chr2:43843813	C/T	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.65	4.58	0.38	1.12e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs1153858	1.000	rs4534782	chr15:45652933	G/A	cg26924012	chr15:45694286	SPATA5L1	1.09	15.16	0.81	5.15e-30	Homoarginine levels;
TGCT	cis	rs2980439	0.783	rs2955587	chr8:8098079	A/G	cg08975724	chr8:8085496	FLJ10661	0.58	5.4	0.44	3.29e-7	Neuroticism;
TGCT	cis	rs73198271	0.628	rs11777742	chr8:8589858	C/T	ch.8.214553F	chr8:8189620	PRAGMIN	-0.32	-5.23	-0.42	7.04e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs72945132	0.882	rs7935969	chr11:70194175	G/A	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs55883249	0.958	rs113937820	chr2:9746668	A/G	cg23886495	chr2:9695866	ADAM17	0.82	5.0	0.41	1.89e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	trans	rs561341	1.000	rs7214017	chr17:30332220	T/C	cg20587970	chr11:113659929	NA	-1.05	-12.74	-0.75	2.84e-24	Hip circumference adjusted for BMI;
TGCT	cis	rs1348850	0.914	rs8941	chr2:178406481	C/T	cg22681709	chr2:178499509	PDE11A	-0.34	-4.53	-0.38	1.34e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs514475	0.526	rs9688558	chr6:137956333	G/A	cg02673417	chr6:137105249	MAP3K5	0.29	4.45	0.37	1.88e-5	Inflammatory skin disease;
TGCT	cis	rs11650494	0.908	rs73340392	chr17:47358308	G/A	cg08112188	chr17:47440006	ZNF652	1.05	5.4	0.44	3.32e-7	Prostate cancer;
TGCT	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg00814883	chr7:100076585	TSC22D4	-0.92	-9.76	-0.66	4.73e-17	Platelet count;
TGCT	cis	rs7666738	0.830	rs7657497	chr4:99044028	A/G	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11190604	0.652	rs76629555	chr10:102191417	T/C	cg23241863	chr10:102295624	HIF1AN	0.62	4.79	0.4	4.69e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs72700829	0.576	rs6695311	chr1:151002758	G/A	cg00666978	chr1:150947442	LASS2	0.89	4.64	0.38	8.54e-6	Schizophrenia;
TGCT	cis	rs7666738	0.606	rs4637413	chr4:99088151	A/G	cg17366294	chr4:99064904	C4orf37	0.57	5.34	0.43	4.31e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2050392	0.590	rs2065723	chr10:30720462	A/T	cg13289132	chr10:30722225	MAP3K8	-0.46	-5.57	-0.45	1.47e-7	Inflammatory bowel disease;
TGCT	cis	rs7829975	0.626	rs332040	chr8:8730488	G/A	cg08975724	chr8:8085496	FLJ10661	0.57	5.27	0.43	5.92e-7	Mood instability;
TGCT	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg03609598	chr5:56110824	MAP3K1	-0.59	-4.78	-0.39	4.81e-6	Initial pursuit acceleration;
TGCT	trans	rs10506458	0.915	rs998506	chr12:63400017	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.47	-7.58	-0.56	6.97e-12	Hemostatic factors and hematological phenotypes;
TGCT	trans	rs12038357	0.867	rs11802217	chr1:34963866	C/G	cg06277588	chr6:13489246	GFOD1	0.52	7.09	0.54	8.88e-11	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs4820539	0.708	rs5751591	chr22:23489042	G/A	cg14186256	chr22:23484241	RTDR1	0.81	8.79	0.62	1.02e-14	Bone mineral density;
TGCT	cis	rs11674184	0.686	rs2358039	chr2:11729606	A/G	cg07314298	chr2:11723111	GREB1	-0.4	-6.87	-0.53	2.77e-10	Endometriosis;
TGCT	cis	rs174551	1	rs174551	chr11:61573684	T/C	cg01500311	chr11:61656094	FADS3	-0.3	-5.25	-0.43	6.42e-7	LDL cholesterol;
TGCT	cis	rs7552404	1.000	rs4949879	chr1:76237143	G/A	cg10523679	chr1:76189770	ACADM	0.9	9.48	0.65	2.34e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	trans	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.87	-9.4	-0.65	3.62e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs2562456	0.917	rs2562471	chr19:21715819	C/T	cg25650185	chr19:21324782	ZNF431	0.61	5.38	0.43	3.6e-7	Pain;
TGCT	cis	rs2688608	0.901	rs2459446	chr10:75601596	C/T	cg19442545	chr10:75533431	FUT11	0.3	4.54	0.38	1.29e-5	Inflammatory bowel disease;
TGCT	cis	rs453301	0.598	rs10104303	chr8:8834528	A/T	cg15556689	chr8:8085844	FLJ10661	0.72	6.53	0.51	1.52e-9	Joint mobility (Beighton score);
TGCT	cis	rs7647973	0.961	rs4955443	chr3:49286618	T/G	cg05785598	chr3:49045655	WDR6	0.39	4.61	0.38	9.91e-6	Menarche (age at onset);
TGCT	cis	rs9560113	1.000	rs9560107	chr13:112180146	G/A	cg14154082	chr13:112174009	NA	0.37	5.07	0.41	1.42e-6	Menarche (age at onset);
TGCT	cis	rs6545883	0.894	rs2177962	chr2:61588070	T/A	cg15711740	chr2:61764176	XPO1	0.55	4.73	0.39	6.08e-6	Tuberculosis;
TGCT	cis	rs4566648	0.553	rs7658518	chr4:84160279	C/T	cg05523065	chr4:83483483	TMEM150C	0.44	4.5	0.37	1.54e-5	Monocyte count;
TGCT	cis	rs6938	0.618	rs11072514	chr15:75221865	T/A	cg09165964	chr15:75287851	SCAMP5	0.55	5.03	0.41	1.67e-6	Breast cancer;
TGCT	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg07507251	chr3:52567010	NT5DC2	0.47	6.7	0.52	6.47e-10	Bipolar disorder;
TGCT	cis	rs4919044	0.756	rs835257	chr10:94779801	T/A	cg05127821	chr10:94822908	CYP26C1	-0.77	-5.03	-0.41	1.71e-6	Coronary artery disease;
TGCT	cis	rs4478858	0.595	rs4949387	chr1:31803440	T/A	cg07478791	chr1:31886160	SERINC2	-0.51	-4.95	-0.41	2.33e-6	Alcohol dependence;
TGCT	cis	rs916888	0.647	rs199524	chr17:44848438	G/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.6	-4.63	-0.38	9.07e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs16867321	0.671	rs13386747	chr2:181499171	C/T	cg23363182	chr2:181467187	NA	-0.45	-4.71	-0.39	6.57e-6	Obesity;
TGCT	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.33	0.43	4.5e-7	Prudent dietary pattern;
TGCT	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg18305652	chr10:134549665	INPP5A	0.35	5.94	0.47	2.73e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs9868809	0.505	rs11719291	chr3:48735706	A/G	cg00383909	chr3:49044727	WDR6	0.98	5.67	0.45	9.63e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs2204008	0.683	rs12370288	chr12:38127740	G/A	cg13010199	chr12:38710504	ALG10B	0.67	5.31	0.43	4.83e-7	Bladder cancer;
TGCT	cis	rs6840360	0.593	rs7654294	chr4:152690975	T/C	cg17479576	chr4:152424074	FAM160A1	-0.53	-5.28	-0.43	5.53e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg13395646	chr4:1353034	KIAA1530	-0.39	-4.97	-0.41	2.2e-6	Obesity-related traits;
TGCT	cis	rs6500602	0.592	rs28789232	chr16:4447552	C/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.35	5.18	0.42	8.63e-7	Schizophrenia;
TGCT	cis	rs7147624	1.000	rs7147624	chr14:65865625	G/T	cg03016385	chr14:66212404	NA	0.49	7.16	0.54	6.19e-11	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs11190604	1.000	rs11190597	chr10:102293676	A/T	cg23241863	chr10:102295624	HIF1AN	0.67	5.12	0.42	1.12e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs10751667	0.643	rs10751666	chr11:941933	C/T	cg06064525	chr11:970664	AP2A2	-0.34	-8.09	-0.59	4.71e-13	Alzheimer's disease (late onset);
TGCT	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.46	-5.42	-0.44	2.96e-7	Longevity;Endometriosis;
TGCT	cis	rs35160687	0.901	rs34048420	chr2:86529748	A/G	cg12542933	chr2:85804724	VAMP8	0.41	4.9	0.4	2.97e-6	Night sleep phenotypes;
TGCT	cis	rs8014204	0.816	rs28426374	chr14:75346740	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.54	-4.72	-0.39	6.15e-6	Caffeine consumption;
TGCT	cis	rs9430161	0.645	rs12081186	chr1:11034195	T/C	cg02454025	chr1:11042201	C1orf127	0.94	11.31	0.71	8.14e-21	Ewing sarcoma;
TGCT	cis	rs6582630	0.555	rs4601853	chr12:38435569	G/A	cg26384229	chr12:38710491	ALG10B	0.84	7.7	0.57	3.77e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg17179660	chr6:151773299	C6orf211;RMND1	-0.5	-4.59	-0.38	1.07e-5	Menarche (age at onset);
TGCT	cis	rs9467773	1.000	rs1321479	chr6:26501897	C/T	cg15659132	chr6:26577336	NA	-0.84	-12.16	-0.74	7.03e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs2033711	0.503	rs7254299	chr19:58884965	A/G	cg13877915	chr19:58951672	ZNF132	0.51	5.06	0.41	1.5e-6	Uric acid clearance;
TGCT	cis	rs2456568	0.802	rs1395387	chr11:93639307	A/T	cg17595323	chr11:93583763	C11orf90	-0.48	-6.52	-0.51	1.58e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs9291683	0.632	rs10939669	chr4:10045827	A/G	cg11266682	chr4:10021025	SLC2A9	0.64	8.75	0.62	1.29e-14	Bone mineral density;
TGCT	cis	rs950169	0.845	rs4106951	chr15:84833394	C/G	cg17173187	chr15:85201210	NMB	0.54	5.52	0.44	1.87e-7	Schizophrenia;
TGCT	cis	rs6701037	0.681	rs13374887	chr1:175131962	A/T	cg08873628	chr1:175162347	KIAA0040	0.48	4.67	0.39	7.58e-6	Alcohol dependence;
TGCT	cis	rs2729354	0.779	rs2511984	chr11:57278733	T/C	cg24343310	chr11:57249947	NA	0.29	4.68	0.39	7.49e-6	Blood protein levels;
TGCT	cis	rs4629710	0.592	rs9492864	chr6:131531306	A/T	cg12606694	chr6:131520996	AKAP7	0.39	4.58	0.38	1.11e-5	Multiple myeloma (IgH translocation);
TGCT	cis	rs2718812	0.719	rs1867505	chr3:133411052	T/C	cg08048268	chr3:133502702	NA	0.38	4.67	0.39	7.62e-6	Iron status biomarkers;
TGCT	cis	rs4783244	0.526	rs11647188	chr16:82648514	A/G	cg09415485	chr16:82663111	CDH13	0.25	4.58	0.38	1.13e-5	Adiponectin levels;
TGCT	cis	rs778371	0.748	rs2675953	chr2:233749565	G/C	cg25237894	chr2:233734115	C2orf82	-0.24	-4.47	-0.37	1.71e-5	Schizophrenia;
TGCT	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7226408	0.857	rs57233384	chr18:34546721	A/G	cg06757138	chr18:34340585	FHOD3	0.24	4.61	0.38	9.97e-6	Obesity-related traits;
TGCT	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg17554472	chr22:41940697	POLR3H	-0.49	-5.12	-0.42	1.11e-6	Vitiligo;
TGCT	cis	rs807669	0.525	rs738904	chr22:19167385	C/A	cg02655711	chr22:19163373	SLC25A1	0.25	4.67	0.39	7.78e-6	Metabolite levels;
TGCT	cis	rs9486719	0.947	rs11153071	chr6:97039741	G/A	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.32	-0.6	1.32e-13	Migraine;Coronary artery disease;
TGCT	cis	rs986417	0.818	rs10144990	chr14:60927816	T/C	cg27398547	chr14:60952738	C14orf39	1.42	8.68	0.61	1.89e-14	Gut microbiota (bacterial taxa);
TGCT	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg23034840	chr1:205782522	SLC41A1	0.64	6.02	0.48	1.8e-8	Monocyte percentage of white cells;
TGCT	cis	rs3780378	0.935	rs2149560	chr9:5082106	G/T	cg03508284	chr9:4985524	JAK2	-0.47	-4.44	-0.37	1.97e-5	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs1153858	1.000	rs11070456	chr15:45686835	G/A	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.62e-8	Homoarginine levels;
TGCT	cis	rs17401966	0.931	rs12408430	chr1:10323339	T/A	cg19773385	chr1:10388646	KIF1B	-0.21	-4.55	-0.38	1.24e-5	Hepatocellular carcinoma;
TGCT	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	7.03	0.53	1.23e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs10880689	1	rs10880689	chr12:37930102	A/G	cg13010199	chr12:38710504	ALG10B	0.61	4.93	0.4	2.57e-6	Resting heart rate;
TGCT	cis	rs7666738	0.830	rs6848404	chr4:98946750	A/G	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7949030	0.626	rs35587183	chr11:62318656	C/T	cg13298116	chr11:62369859	EML3;MTA2	0.6	7.23	0.54	4.38e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg23574427	chr4:122746245	BBS7;CCNA2	-0.35	-5.35	-0.43	4.15e-7	Type 2 diabetes;
TGCT	cis	rs10791097	0.748	rs4937580	chr11:130734270	T/C	cg05962950	chr11:130786565	SNX19	0.88	10.99	0.7	4.85e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	trans	rs3808502	0.503	rs2061830	chr8:11397457	C/G	cg15556689	chr8:8085844	FLJ10661	0.78	7.9	0.58	1.32e-12	Neuroticism;
TGCT	cis	rs7552404	0.690	rs12723575	chr1:76335203	T/C	cg03433033	chr1:76189801	ACADM	-0.59	-5.97	-0.47	2.34e-8	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs826838	0.967	rs980572	chr12:39127673	A/C	cg13010199	chr12:38710504	ALG10B	0.64	5.25	0.43	6.45e-7	Heart rate;
TGCT	cis	rs9916302	0.851	rs7225096	chr17:37664443	T/C	cg15445000	chr17:37608096	MED1	0.31	4.59	0.38	1.06e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs11711311	0.955	rs12636536	chr3:113474226	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.79	-7.32	-0.55	2.75e-11	IgG glycosylation;
TGCT	cis	rs7044106	0.791	rs10984998	chr9:123481516	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	4.97	0.41	2.13e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs3733585	0.699	rs6856127	chr4:9965443	T/C	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.7	-0.57	3.69e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs28595532	0.920	rs115841156	chr4:119740073	C/T	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg27436995	chr16:743998	FBXL16	-0.47	-5.13	-0.42	1.07e-6	Height;
TGCT	cis	rs2469997	1.000	rs2447160	chr8:120374473	G/A	cg00681363	chr8:120844660	TAF2	0.69	4.48	0.37	1.64e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs79387448	0.745	rs17027341	chr2:103136559	A/G	cg09003973	chr2:102972529	NA	0.81	5.21	0.42	7.75e-7	Gut microbiota (bacterial taxa);
TGCT	cis	rs1577917	1.000	rs12216328	chr6:86703418	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.54	-0.45	1.73e-7	Response to antipsychotic treatment;
TGCT	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2760061	0.583	rs1745413	chr1:228212456	A/G	cg18477163	chr1:228402036	OBSCN	0.34	7.06	0.54	1.04e-10	Diastolic blood pressure;
TGCT	cis	rs12497850	0.931	rs4974087	chr3:48919232	A/G	cg07636037	chr3:49044803	WDR6	0.94	10.39	0.68	1.46e-18	Parkinson's disease;
TGCT	cis	rs950880	0.560	rs10189202	chr2:102930380	A/G	cg09003973	chr2:102972529	NA	-0.51	-4.49	-0.37	1.59e-5	Serum protein levels (sST2);
TGCT	cis	rs910316	0.967	rs11624893	chr14:75660124	A/G	cg11812906	chr14:75593930	NEK9	-0.72	-6.79	-0.52	4.14e-10	Height;
TGCT	cis	rs926938	0.563	rs360645	chr1:115427218	A/G	cg12756093	chr1:115239321	AMPD1	0.4	6.31	0.49	4.55e-9	Autism;
TGCT	trans	rs4919669	0.668	rs17114810	chr10:104391545	C/T	cg24066601	chr6:26271455	HIST1H3G	0.68	6.69	0.51	7e-10	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs881375	0.715	rs10818482	chr9:123648085	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.4	-4.56	-0.38	1.23e-5	Rheumatoid arthritis;
TGCT	cis	rs711245	0.518	rs11886145	chr2:36825716	C/G	cg09467607	chr2:36825704	FEZ2	0.37	5.81	0.46	5.01e-8	Height;
TGCT	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg05665937	chr4:1216051	CTBP1	0.24	4.47	0.37	1.72e-5	Obesity-related traits;
TGCT	cis	rs5769765	0.955	rs5769767	chr22:50276909	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.41	-6.13	-0.48	1.08e-8	Schizophrenia;
TGCT	cis	rs11098499	0.874	rs12509054	chr4:120115075	A/C	cg09307838	chr4:120376055	NA	0.5	4.64	0.38	8.86e-6	Corneal astigmatism;
TGCT	cis	rs9916302	0.706	rs4287601	chr17:37513852	T/C	cg07936489	chr17:37558343	FBXL20	0.87	6.27	0.49	5.47e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs3087591	0.708	rs964288	chr17:29679246	G/A	cg24425628	chr17:29625626	OMG;NF1	0.39	5.52	0.44	1.87e-7	Hip circumference;
TGCT	cis	rs62244186	0.715	rs13321717	chr3:44667455	C/A	cg10263370	chr3:44754102	ZNF502	-0.44	-5.25	-0.43	6.37e-7	Depressive symptoms;
TGCT	cis	rs4455778	0.626	rs6583485	chr7:49014353	A/G	cg26309511	chr7:48887640	NA	-0.45	-5.56	-0.45	1.6e-7	Lung cancer in never smokers;
TGCT	cis	rs9303401	0.538	rs2240258	chr17:56458183	C/A	cg25039879	chr17:56429692	SUPT4H1	0.61	5.25	0.43	6.47e-7	Cognitive test performance;
TGCT	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg08280861	chr8:58055591	NA	0.5	5.52	0.44	1.93e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs899997	1.000	rs11072800	chr15:79045857	C/T	cg04896959	chr15:78267971	NA	-0.3	-4.46	-0.37	1.79e-5	Coronary artery disease or large artery stroke;
TGCT	cis	rs75565482	0.546	rs12091766	chr1:168463133	A/G	cg09922481	chr1:168698463	DPT	0.54	4.51	0.38	1.45e-5	Emphysema imaging phenotypes;
TGCT	cis	rs4788570	0.667	rs9929840	chr16:71800942	C/T	cg06353428	chr16:71660113	MARVELD3	-1.57	-11.92	-0.73	2.63e-22	Intelligence (multi-trait analysis);
TGCT	cis	rs7010267	0.740	rs6993910	chr8:119950781	C/T	cg17171407	chr8:119960777	TNFRSF11B	-0.25	-4.44	-0.37	2e-5	Total body bone mineral density (age 45-60);
TGCT	cis	rs9928842	0.770	rs8048371	chr16:75275547	C/T	cg09066997	chr16:75300724	BCAR1	0.27	4.79	0.39	4.72e-6	Alcoholic chronic pancreatitis;
TGCT	cis	rs9611565	0.546	rs34077262	chr22:42061639	A/G	cg13695892	chr22:41940480	POLR3H	0.8	7.59	0.56	6.62e-12	Vitiligo;
TGCT	cis	rs9611565	0.570	rs12159188	chr22:42121125	A/T	cg17554472	chr22:41940697	POLR3H	0.46	5.0	0.41	1.91e-6	Vitiligo;
TGCT	cis	rs7211079	0.505	rs60323863	chr17:78125086	A/G	cg09238746	chr17:78121135	EIF4A3	-0.76	-5.2	-0.42	7.86e-7	Myocardial infarction;
TGCT	cis	rs7666738	0.830	rs6831219	chr4:98993576	C/A	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	7.55	0.56	8.19e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9311474	1.000	rs2276834	chr3:52325759	A/G	cg07507251	chr3:52567010	NT5DC2	0.46	6.21	0.49	7.16e-9	Electroencephalogram traits;
TGCT	cis	rs10992471	0.528	rs1924244	chr9:95224952	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.52	-4.91	-0.4	2.8e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs4918072	0.667	rs11191874	chr10:105711107	T/C	cg11005552	chr10:105648138	OBFC1	0.33	4.6	0.38	1.03e-5	Coronary artery disease;
TGCT	cis	rs9894429	0.646	rs7406828	chr17:79619226	A/G	cg21028142	chr17:79581711	NPLOC4	-0.29	-6.07	-0.48	1.45e-8	Eye color traits;
TGCT	trans	rs561341	0.739	rs6505267	chr17:30225950	A/C	cg20587970	chr11:113659929	NA	-0.65	-9.12	-0.63	1.65e-15	Hip circumference adjusted for BMI;
TGCT	cis	rs7246657	0.943	rs4801803	chr19:37966923	A/G	cg18154014	chr19:37997991	ZNF793	-0.95	-6.63	-0.51	9.39e-10	Coronary artery calcification;
TGCT	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg17554472	chr22:41940697	POLR3H	0.47	4.91	0.4	2.87e-6	Vitiligo;
TGCT	cis	rs765787	0.530	rs12440238	chr15:45512905	T/C	cg24006582	chr15:45444508	DUOX1	0.25	5.35	0.43	4.11e-7	Uric acid levels;
TGCT	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg12311346	chr5:56204834	C5orf35	-0.67	-6.82	-0.52	3.63e-10	Initial pursuit acceleration;
TGCT	cis	rs72945132	0.769	rs680571	chr11:70187441	G/A	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs904251	0.523	rs2797794	chr6:37480604	T/C	cg25019722	chr6:37503610	NA	-0.53	-7.98	-0.58	8.18e-13	Cognitive performance;
TGCT	cis	rs9328448	1.000	rs2326980	chr6:7990901	A/G	cg13863638	chr6:7199401	RREB1	0.19	4.57	0.38	1.15e-5	Coronary artery calcification;
TGCT	cis	rs7568458	0.870	rs6733913	chr2:85757379	T/C	cg17127132	chr2:85788382	GGCX	0.72	6.69	0.51	6.94e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs478304	0.900	rs502468	chr11:65525119	T/G	cg27068330	chr11:65405492	SIPA1	0.75	7.57	0.56	7.2e-12	Acne (severe);
TGCT	cis	rs9902453	0.845	rs3115101	chr17:28041627	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	7.27	0.55	3.55e-11	Coffee consumption (cups per day);
TGCT	cis	rs4713118	0.629	rs172165	chr6:28020814	T/G	cg12963246	chr6:28129442	ZNF389	0.45	4.55	0.38	1.27e-5	Parkinson's disease;
TGCT	cis	rs2188554	0.958	rs73480753	chr7:117027181	C/T	cg09181792	chr7:117119393	CFTR	0.51	4.43	0.37	2.01e-5	Esophageal adenocarcinoma;
TGCT	cis	rs9467773	0.565	rs6925047	chr6:26521435	C/G	cg15659132	chr6:26577336	NA	0.73	9.04	0.63	2.64e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs4727027	0.933	rs4727028	chr7:148874666	A/G	cg23583168	chr7:148888333	NA	0.72	9.42	0.65	3.26e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs796364	0.906	rs281789	chr2:200780698	T/G	cg17644776	chr2:200775616	C2orf69	0.31	4.85	0.4	3.58e-6	Schizophrenia;
TGCT	cis	rs9660992	0.573	rs12126439	chr1:205200720	C/T	cg00857998	chr1:205179979	DSTYK	0.51	4.68	0.39	7.34e-6	Mean corpuscular volume;Mean platelet volume;
TGCT	cis	rs11098499	0.866	rs3756156	chr4:120524841	G/A	cg09307838	chr4:120376055	NA	0.67	6.29	0.49	5.06e-9	Corneal astigmatism;
TGCT	cis	rs7178572	1.000	rs8034133	chr15:77763712	C/G	cg15453836	chr15:77711506	NA	-0.4	-4.59	-0.38	1.07e-5	Type 2 diabetes;
TGCT	cis	rs3806933	0.522	rs13179305	chr5:110444474	G/A	cg04022379	chr5:110408740	TSLP	0.58	6.0	0.47	1.97e-8	Eosinophilic esophagitis;
TGCT	cis	rs2692947	0.683	rs62153700	chr2:96581338	C/T	cg23100626	chr2:96804247	ASTL	0.5	5.9	0.47	3.24e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg20887711	chr4:1340912	KIAA1530	0.91	7.95	0.58	1e-12	Longevity;
TGCT	cis	rs916888	0.610	rs199452	chr17:44801340	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.59	4.61	0.38	9.8200000000000008e-06	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7267979	1.000	rs2257809	chr20:25266476	C/T	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1878931	0.597	rs2680221	chr16:3462595	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.71	-5.62	-0.45	1.18e-7	Body mass index (adult);
TGCT	cis	rs7043114	0.525	rs10116241	chr9:95240546	T/C	cg14311495	chr9:95764742	FGD3	-0.22	-4.44	-0.37	1.98e-5	Height;
TGCT	cis	rs1865760	0.566	rs9379825	chr6:26083871	C/A	cg16482183	chr6:26056742	HIST1H1C	0.58	4.97	0.41	2.13e-6	Height;
TGCT	cis	rs9303401	0.659	rs34426768	chr17:56683385	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs6121246	0.529	rs6060144	chr20:30178624	A/G	cg18721089	chr20:30220636	NA	-0.63	-6.68	-0.51	7.29e-10	Mean corpuscular hemoglobin;
TGCT	cis	rs1712517	0.524	rs4917384	chr10:104995788	T/C	cg04362960	chr10:104952993	NT5C2	0.59	4.66	0.39	7.89e-6	Migraine;
TGCT	cis	rs7020830	0.898	rs308523	chr9:37338785	C/T	cg14294708	chr9:37120828	ZCCHC7	1.11	14.41	0.79	2.97e-28	Schizophrenia;
TGCT	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg08280861	chr8:58055591	NA	0.41	4.63	0.38	8.93e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs427394	0.796	rs274683	chr5:6747950	T/A	cg10857441	chr5:6722123	POLS	-0.23	-4.98	-0.41	2.11e-6	Menopause (age at onset);
TGCT	cis	rs1372520	0.873	rs983361	chr4:90761944	T/G	cg26578617	chr4:90757533	SNCA	-0.5	-4.52	-0.38	1.42e-5	Neuroticism;
TGCT	cis	rs9346649	0.967	rs6915427	chr6:168490000	A/T	cg02770688	chr6:168491649	NA	0.27	5.08	0.41	1.36e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
TGCT	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.52	-5.54	-0.45	1.74e-7	Lymphocyte counts;
TGCT	cis	rs2963155	0.518	rs852978	chr5:142690596	T/C	cg17617527	chr5:142782415	NR3C1	0.85	6.31	0.49	4.42e-9	Breast cancer;
TGCT	cis	rs734999	0.566	rs6664969	chr1:2534978	G/A	cg18854424	chr1:2615690	NA	0.43	4.96	0.41	2.31e-6	Ulcerative colitis;
TGCT	cis	rs78487399	0.908	rs12467151	chr2:43813764	A/G	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.66	4.67	0.39	7.66e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs26868	0.742	rs26848	chr16:2263516	A/G	cg11648456	chr16:2261069	C16orf79	-0.26	-5.18	-0.42	8.64e-7	Height;
TGCT	cis	rs11785400	0.793	rs4430070	chr8:143729184	G/C	cg24634471	chr8:143751801	JRK	0.53	5.24	0.43	6.79e-7	Schizophrenia;
TGCT	cis	rs62244186	0.606	rs6798590	chr3:44556861	T/A	cg02073558	chr3:44770973	ZNF501	0.66	6.19	0.49	8.13e-9	Depressive symptoms;
TGCT	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg00684032	chr4:1343700	KIAA1530	0.23	5.01	0.41	1.79e-6	Obesity-related traits;
TGCT	cis	rs6570726	0.791	rs6902404	chr6:145905254	G/A	cg05347473	chr6:146136440	FBXO30	0.51	4.78	0.39	4.8e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs916888	0.821	rs199504	chr17:44861003	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.72	-4.93	-0.4	2.57e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs804280	0.505	rs804271	chr8:11627214	C/A	cg26752888	chr8:11627280	NEIL2	-0.57	-5.26	-0.43	6.15e-7	Myopia (pathological);
TGCT	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.53	4.76	0.39	5.37e-6	Prudent dietary pattern;
TGCT	cis	rs7949030	0.591	rs11231156	chr11:62366454	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.7	8.89	0.62	5.98e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs644799	0.542	rs10831418	chr11:95468828	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.6	5.9	0.47	3.17e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9790314	0.905	rs7611367	chr3:161003182	A/G	cg03342759	chr3:160939853	NMD3	0.41	4.51	0.38	1.51e-5	Morning vs. evening chronotype;
TGCT	cis	rs77972916	0.561	rs10167415	chr2:43552460	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.42	-5.81	-0.46	4.84e-8	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs9914988	0.943	rs28847895	chr17:27172520	T/C	cg20469991	chr17:27169893	C17orf63	-0.68	-5.01	-0.41	1.87e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs1008375	0.966	rs1860591	chr4:17577329	A/G	cg18681998	chr4:17616180	MED28	0.88	9.23	0.64	9.32e-16	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs12477438	0.798	rs10202452	chr2:99569409	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-6.28	-0.49	5.3e-9	Chronic sinus infection;
TGCT	cis	rs9868809	0.881	rs2286652	chr3:48689192	G/A	cg07636037	chr3:49044803	WDR6	-0.88	-4.54	-0.38	1.32e-5	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs2334880	0.610	rs8051767	chr16:71731720	C/T	cg06353428	chr16:71660113	MARVELD3	1.56	12.9	0.76	1.14e-24	Malaria;
TGCT	cis	rs514406	0.763	rs6685599	chr1:53213172	G/A	cg08736216	chr1:53307985	ZYG11A	0.25	4.77	0.39	4.98e-6	Monocyte count;
TGCT	cis	rs1125355	0.690	rs1356173	chr2:159651973	G/A	cg21992932	chr2:159651813	DAPL1	-0.23	-4.43	-0.37	2.01e-5	Alzheimer's disease in APOE e4+ carriers;
TGCT	trans	rs8073060	0.614	rs225279	chr17:33974214	A/G	cg19694781	chr19:47549865	TMEM160	-0.6	-13.37	-0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs7172809	0.643	rs80347838	chr15:77841783	A/G	cg22256960	chr15:77711686	NA	-0.48	-4.84	-0.4	3.84e-6	Glucose homeostasis traits;
TGCT	cis	rs4319547	0.586	rs7956480	chr12:122817507	A/G	cg08088222	chr12:122070432	ORAI1	0.27	4.78	0.39	4.94e-6	Body mass index;
TGCT	cis	rs10927875	0.526	rs35340817	chr1:16178917	T/C	cg21385522	chr1:16154831	NA	-0.91	-9.29	-0.64	6.69e-16	Dilated cardiomyopathy;
TGCT	cis	rs7772486	0.790	rs9497431	chr6:146248177	T/C	cg23711669	chr6:146136114	FBXO30	-0.88	-10.27	-0.68	2.84e-18	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs561341	0.941	rs7215147	chr17:30266711	G/A	cg20587970	chr11:113659929	NA	-0.95	-10.83	-0.7	1.21e-19	Hip circumference adjusted for BMI;
TGCT	cis	rs7584330	0.868	rs2325839	chr2:238386286	T/C	cg14458575	chr2:238380390	NA	0.55	8.27	0.6	1.78e-13	Prostate cancer;
TGCT	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg13395646	chr4:1353034	KIAA1530	-0.38	-4.72	-0.39	6.28e-6	Obesity-related traits;
TGCT	trans	rs66573146	0.831	rs67602077	chr4:7024244	A/G	cg07817883	chr1:32538562	TMEM39B	1.7	8.44	0.6	7.06e-14	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs453301	0.631	rs28572014	chr8:8793607	C/T	cg15556689	chr8:8085844	FLJ10661	-0.63	-5.37	-0.43	3.82e-7	Joint mobility (Beighton score);
TGCT	cis	rs3784262	0.542	rs2899611	chr15:58327347	A/C	cg12031962	chr15:58353849	ALDH1A2	-0.39	-5.84	-0.46	4.33e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs6840360	0.593	rs59350867	chr4:152695935	G/A	cg17479576	chr4:152424074	FAM160A1	-0.53	-5.26	-0.43	5.99e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs6671200	0.920	rs259350	chr1:95724831	G/C	cg26537280	chr1:95699037	RWDD3	-0.7	-5.55	-0.45	1.62e-7	Stearic acid (18:0) levels;
TGCT	cis	rs12908161	1.000	rs12912388	chr15:85344550	T/A	cg12863693	chr15:85201151	NMB	0.42	5.06	0.41	1.5e-6	Schizophrenia;
TGCT	cis	rs6500602	0.627	rs9934267	chr16:4534366	G/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.28	4.92	0.4	2.73e-6	Schizophrenia;
TGCT	cis	rs1153858	1.000	rs1145074	chr15:45703824	T/A	cg26924012	chr15:45694286	SPATA5L1	0.98	12.23	0.74	4.72e-23	Homoarginine levels;
TGCT	cis	rs35146811	0.735	rs1637001	chr7:99808151	G/A	cg04778012	chr7:99775508	STAG3;GPC2	-0.35	-4.93	-0.41	2.55e-6	Coronary artery disease;
TGCT	cis	rs6074578	0.535	rs1858592	chr20:138606	A/G	cg16931068	chr20:139680	DEFB127	0.28	4.56	0.38	1.21e-5	Hirschsprung disease;
TGCT	cis	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg18252515	chr7:66147081	NA	-1.2	-7.83	-0.58	1.89e-12	Diabetic kidney disease;
TGCT	cis	rs7592578	0.713	rs60915953	chr2:191331304	G/C	cg11845111	chr2:191398756	TMEM194B	-0.41	-4.54	-0.38	1.32e-5	Diastolic blood pressure;
TGCT	cis	rs2439831	0.867	rs2447196	chr15:43893818	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.89	-6.57	-0.51	1.25e-9	Lung cancer in ever smokers;
TGCT	cis	rs2832191	0.791	rs7283853	chr21:30498515	G/A	cg24692254	chr21:30365293	RNF160	-0.86	-9.11	-0.63	1.83e-15	Dental caries;
TGCT	cis	rs7191439	0.674	rs4782430	chr16:88792047	A/G	cg27087555	chr16:88793112	FAM38A	-0.41	-5.56	-0.45	1.57e-7	Plateletcrit;
TGCT	cis	rs11264213	0.591	rs3754076	chr1:36549157	A/G	cg27506609	chr1:36549197	TEKT2	-0.4	-6.54	-0.51	1.48e-9	Schizophrenia;
TGCT	cis	rs7267979	0.586	rs6037057	chr20:25182089	T/C	cg16686733	chr20:25566563	NINL	0.53	5.43	0.44	2.9e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs523522	0.962	rs12309824	chr12:120990582	A/C	cg12219531	chr12:120966889	COQ5	0.8	7.15	0.54	6.6e-11	High light scatter reticulocyte count;
TGCT	cis	rs3749237	1.000	rs11920900	chr3:49823024	G/C	cg03060546	chr3:49711283	APEH	0.73	7.58	0.56	7.07e-12	Resting heart rate;
TGCT	cis	rs9308731	1.000	rs1980045	chr2:111904541	A/G	cg04202892	chr2:111875749	ACOXL	0.43	4.45	0.37	1.92e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs11030122	0.632	rs7925954	chr11:3982746	A/T	cg18678763	chr11:4115507	RRM1	-0.41	-5.09	-0.42	1.27e-6	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs877282	1.000	rs877281	chr10:771557	T/G	cg17470449	chr10:769945	NA	0.31	4.77	0.39	5.04e-6	Uric acid levels;
TGCT	trans	rs7618501	1.000	rs4855862	chr3:49748833	C/T	cg21659725	chr3:3221576	CRBN	-0.99	-15.57	-0.81	5.76e-31	Intelligence (multi-trait analysis);
TGCT	cis	rs2188554	1.000	rs2188554	chr7:117040117	A/G	cg09181792	chr7:117119393	CFTR	0.51	4.57	0.38	1.15e-5	Esophageal adenocarcinoma;
TGCT	cis	rs1061377	1.000	rs7675782	chr4:39121668	G/A	cg24403649	chr4:39172243	NA	0.18	4.44	0.37	1.99e-5	Uric acid levels;
TGCT	cis	rs2235642	0.893	rs2076442	chr16:1591112	G/T	cg08296037	chr16:1584118	IFT140;TMEM204	-0.31	-5.43	-0.44	2.84e-7	Coronary artery disease;
TGCT	cis	rs7845219	0.544	rs9643351	chr8:95917290	C/T	cg13393036	chr8:95962371	TP53INP1	-0.44	-5.14	-0.42	1.05e-6	Type 2 diabetes;
TGCT	cis	rs986417	1.000	rs2144114	chr14:61064210	T/C	cg27398547	chr14:60952738	C14orf39	1.41	8.43	0.6	7.41e-14	Gut microbiota (bacterial taxa);
TGCT	cis	rs7824557	0.564	rs2572389	chr8:11236392	T/C	cg21775007	chr8:11205619	TDH	-0.65	-6.39	-0.5	3.07e-9	Retinal vascular caliber;
TGCT	cis	rs10782582	0.545	rs12138018	chr1:76186794	T/C	cg03433033	chr1:76189801	ACADM	-0.62	-6.81	-0.52	3.69e-10	Daytime sleep phenotypes;
TGCT	cis	rs617219	0.726	rs1275105	chr5:78444148	T/C	cg23987322	chr5:78407566	BHMT	0.35	4.68	0.39	7.3e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs2034088	0.591	rs4968166	chr17:404537	C/T	cg04370829	chr17:406249	NA	-0.36	-5.26	-0.43	6.01e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg21017887	chr14:105400489	NA	0.36	5.14	0.42	1.04e-6	Rheumatoid arthritis;
TGCT	cis	rs11096990	0.593	rs7685619	chr4:39213399	T/G	cg20847110	chr4:39482781	LOC401127	0.16	4.58	0.38	1.13e-5	Cognitive function;
TGCT	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg12419862	chr22:24373484	LOC391322	0.87	10.28	0.68	2.65e-18	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2404602	0.692	rs12594556	chr15:77165363	G/A	cg26408565	chr15:76604113	ETFA	-0.36	-4.52	-0.38	1.41e-5	Blood metabolite levels;
TGCT	cis	rs796364	0.806	rs1605900	chr2:200870197	C/G	cg17644776	chr2:200775616	C2orf69	0.33	5.0	0.41	1.91e-6	Schizophrenia;
TGCT	cis	rs11249608	0.548	rs11960161	chr5:178453837	A/G	cg23951258	chr5:178450506	ZNF879	0.45	4.61	0.38	9.7e-6	Pubertal anthropometrics;
TGCT	cis	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg12570787	chr5:219185	SDHA;CCDC127	0.65	4.46	0.37	1.83e-5	Breast cancer;
TGCT	cis	rs6722750	0.651	rs2901646	chr2:64414892	A/G	cg22352474	chr2:64371530	PELI1	0.51	4.52	0.38	1.45e-5	Neuroticism;
TGCT	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg22963979	chr7:1858916	MAD1L1	-0.45	-7.4	-0.55	1.76e-11	Bipolar disorder and schizophrenia;
TGCT	cis	rs56104184	0.775	rs55981795	chr19:49401952	A/C	cg17863274	chr19:49399704	TULP2	-0.54	-7.43	-0.55	1.58e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	trans	rs10506458	0.915	rs17687426	chr12:63397900	G/C	cg22491629	chr6:157744540	C6orf35	-0.99	-8.55	-0.61	3.94e-14	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs2147959	0.941	rs7524236	chr1:228630395	C/T	cg22700015	chr1:228743131	NA	0.56	4.45	0.37	1.91e-5	Adult asthma;
TGCT	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg15691649	chr6:25882328	NA	-0.35	-4.55	-0.38	1.25e-5	Blood metabolite levels;
TGCT	cis	rs57994353	0.897	rs72775772	chr9:139356738	C/T	cg13741927	chr9:139327495	INPP5E	-0.26	-6.0	-0.47	2.05e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs9611565	0.592	rs4822040	chr22:41963553	C/G	cg17554472	chr22:41940697	POLR3H	-0.45	-4.73	-0.39	5.94e-6	Vitiligo;
TGCT	cis	rs259282	0.605	rs28615461	chr19:33110149	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.54	4.91	0.4	2.76e-6	Schizophrenia;
TGCT	cis	rs853679	0.550	rs1150692	chr6:28173957	A/G	cg12963246	chr6:28129442	ZNF389	0.5	4.88	0.4	3.15e-6	Depression;
TGCT	cis	rs4862750	0.832	rs4862744	chr4:187877074	T/A	cg11301795	chr4:187892539	NA	-0.32	-4.72	-0.39	6.32e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2046867	0.628	rs7617996	chr3:72915315	C/T	cg25664220	chr3:72788482	NA	-0.41	-5.67	-0.45	9.38e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg04944784	chr2:26401820	FAM59B	0.72	5.92	0.47	3e-8	Gut microbiome composition (summer);
TGCT	cis	rs911555	1.000	rs2756127	chr14:104000183	C/T	cg12935359	chr14:103987150	CKB	0.35	4.99	0.41	2.03e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs16957091	0.647	rs16957422	chr15:43393646	G/A	cg17935677	chr15:44119062	WDR76	0.56	4.73	0.39	5.94e-6	MGMT methylation in smokers;
TGCT	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg11062466	chr8:58055876	NA	0.37	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2832191	0.636	rs8131295	chr21:30516819	A/T	cg24692254	chr21:30365293	RNF160	-0.61	-5.38	-0.43	3.62e-7	Dental caries;
TGCT	trans	rs2469997	1.000	rs2470008	chr8:120359366	C/T	cg01792902	chr3:178864926	PIK3CA	0.83	6.77	0.52	4.49e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs8180040	0.966	rs2291298	chr3:47555142	C/A	cg27129171	chr3:47204927	SETD2	0.62	7.34	0.55	2.41e-11	Colorectal cancer;
TGCT	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.74	5.77	0.46	6e-8	Lung function (FEV1/FVC);
TGCT	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg23758822	chr17:41437982	NA	0.72	6.81	0.52	3.83e-10	Menopause (age at onset);
TGCT	cis	rs12541335	0.692	rs2290274	chr8:22214374	C/T	cg09517075	chr8:22133004	PIWIL2	0.25	4.96	0.41	2.29e-6	Hypertriglyceridemia;
TGCT	cis	rs751728	1.000	rs1359781	chr6:33762104	T/C	cg13859433	chr6:33739653	LEMD2	-0.39	-7.08	-0.54	9.45e-11	Crohn's disease;
TGCT	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg17971929	chr21:40555470	PSMG1	0.67	6.26	0.49	5.74e-9	Cognitive function;
TGCT	cis	rs12902680	0.739	rs28894739	chr15:46420019	G/A	cg13605988	chr15:45421612	DUOX1;DUOXA1	0.32	4.52	0.38	1.4e-5	Neuroticism;
TGCT	cis	rs2921073	0.510	rs2976945	chr8:8270871	G/T	cg06636001	chr8:8085503	FLJ10661	0.65	5.45	0.44	2.59e-7	Parkinson's disease;
TGCT	cis	rs4076764	0.914	rs10753614	chr1:163365903	C/T	cg24596788	chr1:163392923	NA	0.17	4.9	0.4	2.99e-6	Motion sickness;
TGCT	cis	rs2882877	0.648	rs35000023	chr2:190375710	G/T	cg10752008	chr2:190445175	SLC40A1	0.61	4.48	0.37	1.68e-5	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs174479	0.647	rs174461	chr11:61657401	A/C	cg01500311	chr11:61656094	FADS3	0.28	5.03	0.41	1.68e-6	Sphingolipid levels;
TGCT	cis	rs603446	1.000	rs603446	chr11:116654435	C/T	cg20608306	chr11:116969690	SIK3	0.41	4.74	0.39	5.85e-6	Triglycerides;
TGCT	cis	rs5769707	0.732	rs135865	chr22:50004829	G/A	cg05373962	chr22:49881684	NA	-0.31	-5.97	-0.47	2.34e-8	Monocyte count;Monocyte percentage of white cells;
TGCT	trans	rs1814175	0.817	rs2866545	chr11:49630824	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.38	-7.57	-0.56	7.52e-12	Height;
TGCT	cis	rs1008375	1.000	rs6811887	chr4:17640858	C/T	cg18681998	chr4:17616180	MED28	1.0	11.93	0.73	2.54e-22	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6570726	0.693	rs450921	chr6:145864260	C/T	cg13319975	chr6:146136371	FBXO30	-0.51	-4.6	-0.38	1.01e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7666738	0.830	rs13121558	chr4:99002848	G/A	cg05340658	chr4:99064831	C4orf37	0.47	5.19	0.42	8.29e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9894429	0.752	rs7502883	chr17:79588557	T/C	cg18240062	chr17:79603768	NPLOC4	0.84	9.67	0.66	8.1e-17	Eye color traits;
TGCT	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg05368731	chr17:41323189	NBR1	1.21	14.63	0.8	8.89e-29	Menopause (age at onset);
TGCT	cis	rs926938	0.527	rs11084	chr1:115537933	A/G	cg12756093	chr1:115239321	AMPD1	0.34	4.97	0.41	2.19e-6	Autism;
TGCT	cis	rs12643440	0.538	rs62296683	chr4:17137441	C/G	cg22650099	chr4:17144496	NA	-0.46	-4.66	-0.39	8.14e-6	Metabolite levels (Pyroglutamine);
TGCT	cis	rs9905704	0.647	rs2036730	chr17:57038282	A/G	cg05425664	chr17:57184151	TRIM37	-0.6	-4.75	-0.39	5.47e-6	Testicular germ cell tumor;
TGCT	cis	rs7523273	0.606	rs2488252	chr1:207938228	C/T	cg22525895	chr1:207977042	MIR29B2	0.53	8.71	0.62	1.62e-14	Schizophrenia;
TGCT	cis	rs11105298	0.891	rs10858899	chr12:89923811	G/C	cg00757033	chr12:89920650	WDR51B	0.32	5.13	0.42	1.11e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs66573146	1.000	rs7675281	chr4:7002120	C/T	cg05069807	chr4:6945702	TBC1D14	0.38	5.12	0.42	1.11e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs4233949	0.897	rs6752877	chr2:54661569	A/C	cg14634210	chr2:54682758	SPTBN1	-0.58	-4.83	-0.4	3.9e-6	Bone mineral density;
TGCT	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs3782455	0.793	rs2290801	chr12:114404424	C/G	cg23502203	chr12:113549970	RASAL1	-0.55	-4.92	-0.4	2.7e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs1887596	0.588	rs523019	chr13:27109968	A/T	cg01312412	chr13:27282625	NA	-0.26	-4.49	-0.37	1.62e-5	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs9921222	0.509	rs3743883	chr16:404750	T/C	cg00101154	chr16:420108	MRPL28	-0.55	-5.67	-0.45	9.41e-8	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs346785	0.965	rs443970	chr17:74303370	G/A	cg09812376	chr17:74270190	QRICH2	-0.39	-5.72	-0.46	7.49e-8	White matter hyperintensities in ischemic stroke;
TGCT	cis	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg06636001	chr8:8085503	FLJ10661	0.68	5.95	0.47	2.61e-8	Mood instability;
TGCT	cis	rs9611565	0.512	rs6002474	chr22:42168181	A/G	cg17554472	chr22:41940697	POLR3H	0.46	4.8	0.4	4.46e-6	Vitiligo;
TGCT	trans	rs4332037	1.000	rs62442899	chr7:1948454	C/T	cg25206134	chr2:45395956	NA	1.11	9.39	0.64	3.79e-16	Bipolar disorder;
TGCT	cis	rs7954584	0.813	rs12827200	chr12:122451278	G/A	cg21171335	chr12:122356390	WDR66	0.55	5.34	0.43	4.21e-7	Mean corpuscular volume;
TGCT	cis	rs9611565	0.644	rs2413652	chr22:42097238	C/T	cg03806693	chr22:41940476	POLR3H	0.97	9.76	0.66	4.74e-17	Vitiligo;
TGCT	cis	rs2535633	0.631	rs2710346	chr3:52974152	C/T	cg11645453	chr3:52864694	ITIH4	-0.28	-5.05	-0.41	1.54e-6	Body mass index;
TGCT	cis	rs28595532	0.841	rs115924581	chr4:119786333	T/C	cg11846333	chr4:119757529	SEC24D	0.92	4.64	0.38	8.74e-6	Cannabis dependence symptom count;
TGCT	cis	rs42648	0.905	rs42622	chr7:89956824	A/G	cg25739043	chr7:89950458	NA	-0.75	-7.62	-0.56	5.63e-12	Homocysteine levels;
TGCT	cis	rs11948739	0.537	rs12518203	chr5:130233745	G/A	cg08523029	chr5:130500466	HINT1	-0.59	-4.93	-0.4	2.58e-6	Pediatric bone mineral content (hip);
TGCT	cis	rs7666738	0.830	rs34070283	chr4:98893027	A/T	cg05340658	chr4:99064831	C4orf37	0.52	6.02	0.48	1.81e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6545977	0.531	rs2539982	chr2:63111004	G/A	cg17519650	chr2:63277830	OTX1	0.72	7.2	0.54	5.17e-11	Prostate cancer;
TGCT	cis	rs6490294	0.651	rs440	chr12:112228714	T/C	cg10833066	chr12:111807467	FAM109A	0.37	4.72	0.39	6.22e-6	Mean platelet volume;
TGCT	cis	rs3087591	1.000	rs9902893	chr17:29625638	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.47	-7.51	-0.56	1.01e-11	Hip circumference;
TGCT	cis	rs7264396	0.790	rs6058297	chr20:34271861	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.25	-0.43	6.33e-7	Total cholesterol levels;
TGCT	cis	rs9926296	0.632	rs4785717	chr16:89801133	A/G	cg08627397	chr16:89984028	MC1R	-0.32	-5.18	-0.42	8.68e-7	Vitiligo;
TGCT	cis	rs7769051	1.000	rs9493445	chr6:133125409	C/T	cg07930552	chr6:133119739	C6orf192	0.93	5.0	0.41	1.87e-6	Type 2 diabetes nephropathy;
TGCT	cis	rs10782582	0.609	rs1796810	chr1:76403305	C/T	cg03433033	chr1:76189801	ACADM	-0.52	-5.06	-0.41	1.44e-6	Daytime sleep phenotypes;
TGCT	cis	rs1865760	0.663	rs9348704	chr6:26000393	A/C	cg16482183	chr6:26056742	HIST1H1C	0.57	5.13	0.42	1.08e-6	Height;
TGCT	cis	rs10465746	0.967	rs10493744	chr1:84444752	C/T	cg10977910	chr1:84465055	TTLL7	-0.63	-6.23	-0.49	6.49e-9	Obesity-related traits;
TGCT	cis	rs11969893	0.850	rs9498409	chr6:101299966	G/A	cg12253828	chr6:101329408	ASCC3	1.36	6.32	0.49	4.33e-9	Economic and political preferences (immigration/crime);
TGCT	cis	rs265548	0.595	rs265543	chr19:17904260	T/G	cg04517722	chr19:17905589	B3GNT3	0.46	5.96	0.47	2.42e-8	Tumor biomarkers;
TGCT	cis	rs910316	0.687	rs175059	chr14:75490667	T/C	cg11812906	chr14:75593930	NEK9	-0.59	-5.59	-0.45	1.36e-7	Height;
TGCT	cis	rs12497850	0.931	rs7430501	chr3:48890119	C/T	cg06212747	chr3:49208901	KLHDC8B	0.62	5.83	0.46	4.42e-8	Parkinson's disease;
TGCT	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg11905131	chr22:24372483	LOC391322	-0.95	-11.19	-0.71	1.64e-20	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs317689	0.718	rs315122	chr12:69771073	G/T	cg14784868	chr12:69753453	YEATS4	0.54	4.58	0.38	1.11e-5	Response to diuretic therapy;
TGCT	cis	rs6582630	0.623	rs12299293	chr12:38436288	G/A	cg26384229	chr12:38710491	ALG10B	-0.54	-4.81	-0.4	4.32e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.69	-5.47	-0.44	2.41e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.0	7.42	0.55	1.64e-11	Gut microbiome composition (summer);
TGCT	cis	rs6089584	0.861	rs2180302	chr20:60576369	A/G	cg13770153	chr20:60521292	NA	-0.55	-7.02	-0.53	1.27e-10	Body mass index;
TGCT	cis	rs12367572	0.930	rs10880695	chr12:45233261	T/C	cg04608330	chr12:45269318	NELL2	-0.5	-4.68	-0.39	7.33e-6	Gut microbiome composition (summer);
TGCT	cis	rs67311347	0.544	rs7652439	chr3:40349948	G/T	cg13683864	chr3:40499215	RPL14	-0.76	-6.62	-0.51	9.6e-10	Renal cell carcinoma;
TGCT	cis	rs6940638	0.662	rs7759694	chr6:27240956	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.43	-4.55	-0.38	1.28e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs36051895	0.632	rs1328919	chr9:5166548	C/T	cg02405213	chr9:5042618	JAK2	-0.74	-9.77	-0.66	4.49e-17	Pediatric autoimmune diseases;
TGCT	cis	rs2455799	0.634	rs62243670	chr3:15918990	C/T	cg16303742	chr3:15540471	COLQ	-0.24	-4.64	-0.38	8.68e-6	Mean platelet volume;
TGCT	cis	rs4975616	0.839	rs2447853	chr5:1333077	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.28	-6.52	-0.51	1.63e-9	Lung cancer;
TGCT	cis	rs727563	0.593	rs5758461	chr22:42162189	G/C	cg13695892	chr22:41940480	POLR3H	0.85	8.06	0.59	5.4e-13	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg20203395	chr5:56204925	C5orf35	-0.57	-4.84	-0.4	3.8e-6	Initial pursuit acceleration;
TGCT	cis	rs12579753	0.917	rs12311988	chr12:82177209	C/A	cg07988820	chr12:82153109	PPFIA2	-0.59	-6.19	-0.49	7.93e-9	Resting heart rate;
TGCT	cis	rs60871478	0.898	rs4725241	chr7:796883	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.44	4.51	0.38	1.46e-5	Cerebrospinal P-tau181p levels;
TGCT	cis	rs13424612	1.000	rs4149551	chr2:240921463	C/T	cg26363272	chr2:240904871	NDUFA10	0.29	4.9	0.4	2.99e-6	Odorant perception (isobutyraldehyde);
TGCT	cis	rs7432375	0.566	rs835636	chr3:136674500	A/C	cg15507776	chr3:136538369	TMEM22	0.54	5.68	0.45	9.18e-8	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2836974	0.604	rs2854727	chr21:40713787	A/G	cg11644478	chr21:40555479	PSMG1	0.62	5.83	0.46	4.48e-8	Cognitive function;
TGCT	cis	rs9914544	0.564	rs8072860	chr17:18807884	T/C	cg26378065	chr17:18585709	ZNF286B	0.51	4.5	0.37	1.53e-5	Educational attainment (years of education);
TGCT	cis	rs1385374	0.858	rs11059923	chr12:129293057	G/A	cg09035930	chr12:129282057	SLC15A4	-0.55	-4.76	-0.39	5.27e-6	Systemic lupus erythematosus;
TGCT	cis	rs4973397	0.810	rs12694890	chr2:232276553	A/T	cg09339159	chr2:232260559	B3GNT7	-0.53	-4.55	-0.38	1.27e-5	Anti-saccade response;
TGCT	cis	rs12458462	0.892	rs2242174	chr18:77458037	T/C	cg11879182	chr18:77439856	CTDP1	0.71	8.16	0.59	3.11e-13	Monocyte count;
TGCT	cis	rs7666738	0.716	rs7656233	chr4:99079237	G/A	cg17366294	chr4:99064904	C4orf37	0.71	6.87	0.53	2.73e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg05025164	chr4:1340916	KIAA1530	0.68	5.65	0.45	1.05e-7	Longevity;
TGCT	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg00814883	chr7:100076585	TSC22D4	-0.92	-9.76	-0.66	4.73e-17	Platelet count;
TGCT	cis	rs61935443	0.673	rs11107770	chr12:95275147	C/T	cg21533806	chr12:95267307	NA	-0.5	-4.5	-0.37	1.52e-5	Schizophrenia;
TGCT	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg25427524	chr10:38739819	LOC399744	-0.4	-8.25	-0.6	1.91e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7296418	0.961	rs12425850	chr12:123501972	T/C	cg00376283	chr12:123451042	ABCB9	0.86	8.06	0.59	5.57e-13	Platelet count;
TGCT	cis	rs1371867	0.875	rs1371868	chr8:101330267	C/T	cg00191853	chr8:101177733	SPAG1	-0.22	-4.47	-0.37	1.75e-5	Atrioventricular conduction;
TGCT	cis	rs9302001	0.960	rs1408651	chr13:95460891	G/A	cg07483244	chr13:95358924	NA	0.37	4.81	0.4	4.22e-6	Panic disorder;
TGCT	cis	rs9926296	0.572	rs2079671	chr16:89884981	T/C	cg21285383	chr16:89894308	SPIRE2	0.34	4.87	0.4	3.36e-6	Vitiligo;
TGCT	cis	rs916888	0.697	rs199516	chr17:44856485	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.75	-5.26	-0.43	6.07e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs1062177	0.950	rs59580263	chr5:151269577	T/A	cg12924095	chr5:151150029	G3BP1	0.37	5.04	0.41	1.59e-6	Preschool internalizing problems;
TGCT	cis	rs806215	1.000	rs712703	chr7:127257498	C/T	cg25922125	chr7:127225783	GCC1	-0.58	-6.05	-0.48	1.56e-8	Type 2 diabetes;
TGCT	cis	rs6570726	0.791	rs9373466	chr6:145912016	T/C	cg05347473	chr6:146136440	FBXO30	0.51	4.75	0.39	5.42e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg26408565	chr15:76604113	ETFA	0.35	4.53	0.38	1.36e-5	Blood metabolite levels;
TGCT	cis	rs80282103	0.571	rs56183119	chr10:1068370	C/T	cg08668510	chr10:1095578	IDI1	1.1	5.19	0.42	8.32e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs9303401	0.659	rs12602808	chr17:56698420	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs3806843	0.735	rs2563314	chr5:140047289	A/G	cg19875535	chr5:140030758	IK	-0.36	-6.15	-0.48	9.57e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9467773	1.000	rs10946834	chr6:26533664	G/C	cg15659132	chr6:26577336	NA	0.86	12.21	0.74	5.3e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs9811920	0.683	rs10936003	chr3:99667565	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.45	5.33	0.43	4.52e-7	Axial length;
TGCT	cis	rs9393692	0.645	rs28446029	chr6:26305801	C/G	cg00631329	chr6:26305371	NA	-0.46	-6.91	-0.53	2.23e-10	Educational attainment;
TGCT	trans	rs1814175	0.541	rs12287397	chr11:49819799	G/A	cg15704280	chr7:45808275	SEPT13	-0.72	-8.14	-0.59	3.61e-13	Height;
TGCT	trans	rs7819412	0.511	rs2409799	chr8:11435927	G/C	cg06636001	chr8:8085503	FLJ10661	-0.76	-6.96	-0.53	1.71e-10	Triglycerides;
TGCT	cis	rs4788570	0.538	rs72797713	chr16:71534208	G/A	cg06353428	chr16:71660113	MARVELD3	-1.32	-7.86	-0.58	1.6e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs2404602	0.716	rs8025134	chr15:76781729	C/T	cg26408565	chr15:76604113	ETFA	-0.39	-5.24	-0.43	6.74e-7	Blood metabolite levels;
TGCT	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg10047753	chr17:41438598	NA	0.79	7.58	0.56	7.06e-12	Menopause (age at onset);
TGCT	cis	rs1857353	1.000	rs114407954	chr1:75871366	C/A	cg11838876	chr1:75668600	SLC44A5	-0.47	-4.56	-0.38	1.2e-5	Whole-brain volume (Alzheimer's disease interaction);
TGCT	trans	rs9388451	0.839	rs980014	chr6:126068001	T/G	cg05039488	chr6:79577232	IRAK1BP1	-0.74	-8.29	-0.6	1.61e-13	Brugada syndrome;
TGCT	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2073300	1.000	rs6048824	chr20:23457645	C/A	cg09953122	chr20:23471693	CST8	-0.59	-4.71	-0.39	6.5e-6	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs6969780	0.632	rs11762730	chr7:27190398	A/C	cg17457637	chr7:27170717	HOXA4	-0.36	-4.48	-0.37	1.71e-5	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs539096	0.500	rs2906457	chr1:44338575	A/C	cg13606994	chr1:44402422	ARTN	-0.42	-4.52	-0.38	1.44e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs3015497	0.789	rs2356457	chr14:51116863	C/T	cg04730355	chr14:51134070	SAV1	-0.65	-6.27	-0.49	5.6e-9	Mean platelet volume;
TGCT	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg11644478	chr21:40555479	PSMG1	-0.49	-4.57	-0.38	1.17e-5	Menarche (age at onset);
TGCT	cis	rs7010267	0.692	rs2073618	chr8:119964052	G/C	cg17171407	chr8:119960777	TNFRSF11B	0.25	4.45	0.37	1.86e-5	Total body bone mineral density (age 45-60);
TGCT	cis	rs1903068	0.925	rs1551645	chr4:55994314	T/G	cg09978860	chr4:56023921	NA	0.58	6.38	0.5	3.16e-9	Endometriosis;
TGCT	cis	rs13217239	0.572	rs9379958	chr6:27066163	A/C	cg05738196	chr6:26577821	NA	-0.5	-4.77	-0.39	5.05e-6	Schizophrenia;
TGCT	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.71	5.14	0.42	1.02e-6	Platelet count;
TGCT	cis	rs9653442	0.835	rs7565967	chr2:100744683	G/T	cg07810366	chr2:100720526	AFF3	-0.47	-7.82	-0.57	1.99e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs9788682	1.000	rs2036534	chr15:78826948	T/C	cg06917634	chr15:78832804	PSMA4	-0.71	-4.93	-0.4	2.63e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs1448094	0.556	rs4897831	chr12:86168248	C/T	cg02569458	chr12:86230093	RASSF9	0.37	4.46	0.37	1.83e-5	Major depressive disorder;
TGCT	cis	rs904251	0.523	rs2776874	chr6:37483197	C/T	cg25019722	chr6:37503610	NA	-0.48	-7.81	-0.57	2.09e-12	Cognitive performance;
TGCT	cis	rs9394841	0.667	rs9357366	chr6:41786976	T/G	cg08135965	chr6:41755394	TOMM6	0.55	5.15	0.42	9.77e-7	Mean corpuscular hemoglobin;Red cell distribution width;
TGCT	cis	rs71435601	0.628	rs530474	chr2:21381435	G/A	cg25035485	chr2:21266500	APOB	0.51	4.48	0.37	1.66e-5	Cholesterol, total;
TGCT	cis	rs17221829	0.549	rs9666894	chr11:89358359	G/A	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.65	-0.39	8.43e-6	Anxiety in major depressive disorder;
TGCT	cis	rs617219	0.671	rs2591388	chr5:78557241	A/G	cg09550809	chr5:78407562	BHMT	0.39	5.17	0.42	9.09e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs12950390	0.893	rs4794110	chr17:45847230	A/G	cg06532163	chr17:45867833	NA	0.31	5.33	0.43	4.49e-7	IgG glycosylation;
TGCT	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	4.89	0.4	3e-6	Menopause (age at onset);
TGCT	cis	rs7017914	0.905	rs3098870	chr8:71929935	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.56	-5.11	-0.42	1.21e-6	Bone mineral density;
TGCT	cis	rs6969780	0.915	rs4722657	chr7:27157756	G/A	cg04321618	chr7:27170880	HOXA4	-0.5	-4.81	-0.4	4.35e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	trans	rs2235808	0.554	rs6031453	chr20:42833144	C/T	cg01217180	chr20:25176214	ENTPD6	0.96	6.63	0.51	9.44e-10	Glomerular filtration rate (creatinine);
TGCT	cis	rs11098499	0.754	rs12506610	chr4:120241659	T/C	cg09307838	chr4:120376055	NA	0.61	5.91	0.47	3.14e-8	Corneal astigmatism;
TGCT	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg09060608	chr5:178986726	RUFY1	0.49	5.59	0.45	1.36e-7	Lung cancer;
TGCT	cis	rs7258465	1.000	rs2278238	chr19:18576484	T/C	cg06462663	chr19:18546047	ISYNA1	0.2	4.63	0.38	9.01e-6	Breast cancer;
TGCT	cis	rs1865760	0.613	rs2071300	chr6:25914572	C/T	cg03517284	chr6:25882590	NA	-0.5	-5.18	-0.42	8.55e-7	Height;
TGCT	cis	rs724767	1.000	rs73065951	chr3:193721651	T/A	cg19410732	chr3:194305082	NA	-0.65	-4.68	-0.39	7.33e-6	Estradiol plasma levels (breast cancer);
TGCT	cis	rs2862064	0.932	rs1553319	chr5:156479001	T/A	cg12943317	chr5:156479607	HAVCR1	-0.46	-5.54	-0.45	1.74e-7	Platelet count;
TGCT	cis	rs7432375	0.899	rs6439655	chr3:136466599	A/G	cg12473912	chr3:136751656	NA	-0.36	-5.11	-0.42	1.19e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs10193935	1.000	rs12618105	chr2:42414146	T/G	cg27598129	chr2:42591480	NA	-0.39	-5.14	-0.42	1.05e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6546537	0.826	rs2704443	chr2:69889338	A/C	cg10773587	chr2:69614142	GFPT1	-0.82	-7.07	-0.54	1.01e-10	Serum thyroid-stimulating hormone levels;
TGCT	trans	rs629535	0.814	rs62513373	chr8:70080753	C/T	cg21567404	chr3:27674614	NA	-0.57	-8.99	-0.63	3.38e-15	Dupuytren's disease;
TGCT	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg24578937	chr1:2090814	PRKCZ	-0.23	-5.38	-0.44	3.57e-7	Height;
TGCT	cis	rs3820928	0.904	rs10933161	chr2:227764872	A/G	cg11843606	chr2:227700838	RHBDD1	-0.53	-4.68	-0.39	7.31e-6	Pulmonary function;
TGCT	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg10047753	chr17:41438598	NA	0.96	9.6	0.65	1.16e-16	Menopause (age at onset);
TGCT	cis	rs6938	0.596	rs11072511	chr15:75159433	A/G	cg09165964	chr15:75287851	SCAMP5	0.55	5.18	0.42	8.56e-7	Breast cancer;
TGCT	cis	rs6733011	0.519	rs6739097	chr2:99458601	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-4.85	-0.4	3.55e-6	Bipolar disorder;
TGCT	cis	rs8077577	0.895	rs11078412	chr17:18100618	C/T	cg09161412	chr17:18057145	MYO15A	0.63	5.06	0.41	1.46e-6	Obesity-related traits;
TGCT	cis	rs1801251	0.964	rs10933411	chr2:233706847	A/G	cg08000102	chr2:233561755	GIGYF2	-0.63	-6.46	-0.5	2.2e-9	Coronary artery disease;
TGCT	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg04608855	chr19:58913158	NA	0.58	5.64	0.45	1.11e-7	Uric acid clearance;
TGCT	cis	rs1355223	0.583	rs2956076	chr11:34874124	T/C	cg11058730	chr11:34937778	PDHX;APIP	0.79	8.54	0.61	4.08e-14	Systemic lupus erythematosus and Systemic sclerosis;
TGCT	cis	rs7223966	1.000	rs11657120	chr17:61857218	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	4.68	0.39	7.5e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs7582180	0.544	rs13026570	chr2:100939498	A/C	cg14675211	chr2:100938903	LONRF2	0.49	4.75	0.39	5.48e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1691799	0.899	rs1168314	chr12:66746937	A/G	cg16791601	chr12:66731901	HELB	-0.28	-6.17	-0.48	8.87e-9	White blood cell count (basophil);
TGCT	cis	rs950169	0.840	rs62029595	chr15:84955301	C/T	cg11189052	chr15:85197271	WDR73	0.81	6.22	0.49	6.89e-9	Schizophrenia;
TGCT	cis	rs2456568	0.802	rs10765639	chr11:93636194	G/A	cg17595323	chr11:93583763	C11orf90	-0.47	-6.44	-0.5	2.38e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg23708337	chr7:1209742	NA	0.56	5.08	0.42	1.34e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7617773	0.963	rs12495221	chr3:48179178	C/T	cg11946769	chr3:48343235	NME6	-0.58	-5.14	-0.42	1.03e-6	Coronary artery disease;
TGCT	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg20887711	chr4:1340912	KIAA1530	-0.88	-8.34	-0.6	1.21e-13	Longevity;
TGCT	cis	rs4925386	1.000	rs4925382	chr20:60918542	G/C	cg06026331	chr20:60912101	LAMA5	-0.3	-5.5	-0.44	2.12e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs1891275	0.515	rs7098763	chr10:93444827	C/T	cg07889827	chr10:93443413	NA	-0.33	-6.99	-0.53	1.53e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg06873352	chr17:61820015	STRADA	0.53	5.82	0.46	4.67e-8	Prudent dietary pattern;
TGCT	cis	rs1008375	0.897	rs1006723	chr4:17618524	G/A	cg16339924	chr4:17578868	LAP3	0.68	5.49	0.44	2.14e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7267979	0.844	rs6107017	chr20:25232300	A/G	cg14121845	chr20:25566513	NINL	0.49	4.96	0.41	2.24e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg01585852	chr22:24235823	MIF	-0.21	-4.56	-0.38	1.23e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7726839	0.540	rs61731455	chr5:665295	A/G	cg16624210	chr5:671434	TPPP	0.42	4.89	0.4	3.06e-6	Obesity-related traits;
TGCT	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg11890956	chr21:40555474	PSMG1	1.12	12.59	0.75	6.25e-24	Cognitive function;
TGCT	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	5.03	0.41	1.69e-6	Prudent dietary pattern;
TGCT	cis	rs9926296	0.607	rs2079672	chr16:89884917	A/G	cg03388025	chr16:89894329	SPIRE2	-0.34	-5.01	-0.41	1.81e-6	Vitiligo;
TGCT	cis	rs13177918	0.603	rs2748241	chr5:149827494	C/T	cg14059543	chr5:149831962	NA	-0.7	-10.23	-0.68	3.52e-18	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs2932538	0.922	rs12750621	chr1:113206502	G/C	cg10983938	chr1:113465962	AFARP1;SLC16A1	0.21	4.51	0.38	1.51e-5	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs79387448	1.000	rs79387448	chr2:103215410	C/T	cg09003973	chr2:102972529	NA	0.91	5.44	0.44	2.71e-7	Gut microbiota (bacterial taxa);
TGCT	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg11062466	chr8:58055876	NA	0.38	4.62	0.38	9.5e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg11494091	chr17:61959527	GH2	0.62	15.19	0.81	4.3e-30	Prudent dietary pattern;
TGCT	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg05754148	chr16:3507555	NAT15	0.41	4.93	0.4	2.63e-6	Tuberculosis;
TGCT	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg24846343	chr22:24311635	DDTL	0.23	5.7	0.46	8.19e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg06634786	chr22:41940651	POLR3H	-0.86	-8.34	-0.6	1.18e-13	Vitiligo;
TGCT	trans	rs1814175	0.616	rs1722020	chr11:49904189	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.51	-0.69	7.24e-19	Height;
TGCT	cis	rs8032315	0.895	rs4932370	chr15:91404705	A/G	cg03209642	chr15:91427605	FES	-0.52	-4.96	-0.41	2.24e-6	Autism spectrum disorder or schizophrenia;
TGCT	trans	rs11722228	0.521	rs56403947	chr4:10112529	T/G	cg26043149	chr18:55253948	FECH	1.17	12.23	0.74	4.71e-23	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs11122272	0.735	rs2572248	chr1:231514942	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.14	-0.54	6.86e-11	Hemoglobin concentration;
TGCT	cis	rs854765	0.964	rs854764	chr17:18011750	A/G	cg00306284	chr17:18855313	SLC5A10	-0.24	-4.51	-0.38	1.5e-5	Total body bone mineral density;
TGCT	cis	rs1971762	0.730	rs12830769	chr12:54087705	G/A	cg09709951	chr12:54017699	ATF7	0.36	5.2	0.42	7.91e-7	Height;
TGCT	cis	rs950169	1.000	rs950169	chr15:84706461	C/T	cg17173187	chr15:85201210	NMB	0.49	5.45	0.44	2.64e-7	Schizophrenia;
TGCT	cis	rs8081395	0.775	rs2526355	chr17:57953233	G/C	cg16369400	chr17:58041258	RNFT1	0.23	4.47	0.37	1.72e-5	White blood cell count;
TGCT	cis	rs80282103	0.618	rs74120451	chr10:1126866	T/C	cg08668510	chr10:1095578	IDI1	1.09	5.31	0.43	4.98e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs17122693	1.000	rs1018036	chr14:51085429	C/T	cg04730355	chr14:51134070	SAV1	1.21	9.01	0.63	3.15e-15	Cognitive performance;
TGCT	cis	rs2153535	0.580	rs9379210	chr6:8461928	C/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs9303401	0.527	rs12946522	chr17:56768103	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.62	5.52	0.44	1.93e-7	Cognitive test performance;
TGCT	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg23103009	chr10:134564232	INPP5A	0.28	4.44	0.37	1.94e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg17554472	chr22:41940697	POLR3H	0.5	5.16	0.42	9.35e-7	Vitiligo;
TGCT	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg04267008	chr7:1944627	MAD1L1	-0.34	-4.44	-0.37	1.99e-5	Bipolar disorder and schizophrenia;
TGCT	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg23574427	chr4:122746245	BBS7;CCNA2	-0.34	-5.31	-0.43	4.82e-7	Type 2 diabetes;
TGCT	cis	rs10791097	0.694	rs2155749	chr11:130751094	G/T	cg14779329	chr11:130786720	SNX19	0.29	5.01	0.41	1.85e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg18402987	chr7:1209562	NA	0.7	5.71	0.46	7.73e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs77633900	0.614	rs2459363	chr15:76874952	T/C	cg21673338	chr15:77095150	SCAPER	-0.52	-4.83	-0.4	3.88e-6	Non-glioblastoma glioma;Glioma;
TGCT	cis	rs57590327	0.679	rs13094809	chr3:81666806	G/A	cg07356753	chr3:81810745	GBE1	-0.62	-5.01	-0.41	1.85e-6	Extraversion;
TGCT	cis	rs2677744	0.626	rs11854429	chr15:91489685	C/T	cg23684204	chr15:91497937	RCCD1	-0.36	-5.44	-0.44	2.69e-7	Attention deficit hyperactivity disorder;
TGCT	cis	rs7666738	0.830	rs9996098	chr4:98867740	T/C	cg18180107	chr4:99064573	C4orf37	0.55	5.14	0.42	1.03e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10489525	0.502	rs12026930	chr1:115597836	G/A	cg12756093	chr1:115239321	AMPD1	-0.41	-5.8	-0.46	5.26e-8	Autism;
TGCT	cis	rs2120019	0.938	rs3850093	chr15:75318482	A/G	cg09165964	chr15:75287851	SCAMP5	1.21	10.33	0.68	2.05e-18	Blood trace element (Zn levels);
TGCT	cis	rs7666738	0.791	rs2081622	chr4:98927369	T/C	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2280018	0.526	rs2966128	chr16:15153389	G/T	cg07549590	chr16:15018862	NA	-0.35	-5.24	-0.43	6.59e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.73	-0.39	5.93e-6	Prudent dietary pattern;
TGCT	cis	rs1008375	0.898	rs61047804	chr4:17593965	G/A	cg16339924	chr4:17578868	LAP3	0.81	6.69	0.52	6.75e-10	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4986172	0.539	rs12603813	chr17:43196584	T/C	cg10701640	chr17:43249399	NA	0.45	5.42	0.44	3.03e-7	Height;
TGCT	cis	rs11864453	0.611	rs1050361	chr16:72130203	C/G	cg14768367	chr16:72042858	DHODH	0.52	5.21	0.42	7.61e-7	Fibrinogen levels;
TGCT	cis	rs6906287	0.647	rs11153753	chr6:118836153	T/C	cg21191810	chr6:118973309	C6orf204	0.26	4.49	0.37	1.58e-5	Electrocardiographic conduction measures;
TGCT	cis	rs909674	0.690	rs1972280	chr22:39831986	T/A	cg24399712	chr22:39784796	NA	-1.06	-10.99	-0.7	4.84e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs4285214	0.715	rs10079692	chr5:124025450	A/G	cg15082166	chr5:124005151	ZNF608	-0.36	-4.89	-0.4	3.08e-6	Survival in pancreatic cancer;
TGCT	cis	rs3741404	0.620	rs11231722	chr11:63967770	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.79	8.19	0.59	2.77e-13	Platelet count;
TGCT	cis	rs4727027	0.737	rs10278971	chr7:148780659	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	4.77	0.39	5.09e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs6450176	0.538	rs12186486	chr5:53306549	T/A	ch.5.1024479R	chr5:53302184	ARL15	-0.87	-6.8	-0.52	3.92e-10	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs9399135	0.967	rs7763836	chr6:135362378	T/C	cg24558204	chr6:135376177	HBS1L	0.46	4.56	0.38	1.22e-5	Red blood cell count;
TGCT	cis	rs12367572	0.965	rs1506676	chr12:45237401	T/C	cg04608330	chr12:45269318	NELL2	-0.5	-4.65	-0.39	8.44e-6	Gut microbiome composition (summer);
TGCT	cis	rs11190604	1.000	rs10883496	chr10:102221931	T/C	cg23241863	chr10:102295624	HIF1AN	0.62	4.87	0.4	3.27e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs651907	0.557	rs11711079	chr3:101386918	G/A	cg12386194	chr3:101231763	SENP7	0.53	5.13	0.42	1.08e-6	Colorectal cancer;
TGCT	cis	rs3008870	0.709	rs62883160	chr1:67392889	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.79	8.43	0.6	7.38e-14	Lymphocyte percentage of white cells;
TGCT	cis	rs4888262	0.526	rs4888253	chr16:74583146	C/T	cg01733217	chr16:74700730	RFWD3	0.71	7.11	0.54	7.94e-11	Testicular germ cell tumor;
TGCT	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg12000995	chr2:27665139	KRTCAP3	-0.39	-4.72	-0.39	6.14e-6	Total body bone mineral density;
TGCT	cis	rs796364	1.000	rs281760	chr2:200787804	A/G	cg17644776	chr2:200775616	C2orf69	0.31	4.85	0.4	3.58e-6	Schizophrenia;
TGCT	cis	rs8060598	0.528	rs4785452	chr16:50842077	T/C	cg04429994	chr16:51093890	NA	0.18	4.89	0.4	3.05e-6	Leprosy;
TGCT	cis	rs4727027	0.866	rs1358062	chr7:148783743	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.54	5.04	0.41	1.57e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs7843479	0.601	rs727693	chr8:21850116	A/G	cg17168535	chr8:21777572	XPO7	0.8	7.93	0.58	1.11e-12	Mean corpuscular volume;
TGCT	cis	rs12049351	0.722	rs6703347	chr1:229626166	A/T	cg12130225	chr1:229698885	NA	0.39	4.59	0.38	1.06e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg09359103	chr1:154839909	KCNN3	0.74	15.9	0.82	1.02e-31	Prostate cancer;
TGCT	cis	rs13256369	1.000	rs1109619	chr8:8571616	G/T	cg06671706	chr8:8559999	CLDN23	0.34	4.59	0.38	1.09e-5	Obesity-related traits;
TGCT	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg00684032	chr4:1343700	KIAA1530	-0.22	-4.73	-0.39	6.06e-6	Obesity-related traits;
TGCT	cis	rs1153858	1.000	rs11858495	chr15:45637662	A/G	cg26924012	chr15:45694286	SPATA5L1	-1.06	-12.44	-0.75	1.44e-23	Homoarginine levels;
TGCT	cis	rs7647973	0.626	rs7649428	chr3:49868876	A/T	cg03060546	chr3:49711283	APEH	-0.63	-5.57	-0.45	1.52e-7	Menarche (age at onset);
TGCT	cis	rs12421382	0.511	rs2212430	chr11:109289538	C/T	cg16359550	chr11:109292809	C11orf87	0.69	7.54	0.56	8.55e-12	Schizophrenia;
TGCT	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.5	-6.94	-0.53	1.89e-10	Alzheimer's disease;
TGCT	cis	rs933688	1.000	rs985434	chr5:90744509	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.0	8.47	0.61	6.09e-14	Smoking behavior;
TGCT	cis	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg13531842	chr10:38383804	ZNF37A	-0.38	-4.51	-0.38	1.49e-5	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7267979	1.000	rs2259837	chr20:25280205	T/C	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg11644478	chr21:40555479	PSMG1	-0.58	-5.1	-0.42	1.23e-6	Cognitive function;
TGCT	cis	rs7975161	0.520	rs9739833	chr12:104737430	A/T	cg25273343	chr12:104657179	TXNRD1	-0.35	-4.72	-0.39	6.28e-6	Toenail selenium levels;
TGCT	cis	rs7772486	0.875	rs13198450	chr6:146370524	C/A	cg05347473	chr6:146136440	FBXO30	0.57	5.51	0.44	2.02e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11098499	0.657	rs9996569	chr4:120299004	G/C	cg09307838	chr4:120376055	NA	0.65	6.39	0.5	3.02e-9	Corneal astigmatism;
TGCT	cis	rs7246657	0.722	rs3829688	chr19:38077100	T/C	cg18154014	chr19:37997991	ZNF793	0.69	4.63	0.38	9.25e-6	Coronary artery calcification;
TGCT	cis	rs546131	0.890	rs485845	chr11:34830389	G/T	cg06937548	chr11:34938143	PDHX;APIP	-0.67	-5.94	-0.47	2.65e-8	Lung disease severity in cystic fibrosis;
TGCT	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg04267008	chr7:1944627	MAD1L1	-0.4	-5.28	-0.43	5.67e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs1008375	1.000	rs2872958	chr4:17665032	A/G	cg18681998	chr4:17616180	MED28	0.94	11.11	0.71	2.49e-20	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs981844	1.000	rs72731672	chr4:154664925	G/T	cg14289246	chr4:154710475	SFRP2	1.0	8.25	0.6	1.96e-13	Response to statins (LDL cholesterol change);
TGCT	cis	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg08564027	chr20:61660810	NA	0.38	7.08	0.54	9.36e-11	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9916302	0.904	rs55660616	chr17:37684990	C/A	cg07936489	chr17:37558343	FBXL20	-0.61	-4.92	-0.4	2.69e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs62064224	0.589	rs9889607	chr17:30785585	A/C	cg18200150	chr17:30822561	MYO1D	-0.38	-4.66	-0.39	8.03e-6	Schizophrenia;
TGCT	cis	rs473651	0.935	rs515412	chr2:239345394	A/T	cg18131467	chr2:239335373	ASB1	0.97	13.84	0.78	6.56e-27	Multiple system atrophy;
TGCT	cis	rs7714584	1.000	rs11748553	chr5:150184553	A/G	cg22134413	chr5:150180641	NA	1.13	8.18	0.59	2.91e-13	Crohn's disease;
TGCT	cis	rs1865760	0.566	rs9295686	chr6:26081983	G/C	cg16482183	chr6:26056742	HIST1H1C	0.58	4.97	0.41	2.13e-6	Height;
TGCT	cis	rs514406	0.505	rs387436	chr1:53179376	C/T	cg24675658	chr1:53192096	ZYG11B	0.79	9.71	0.66	6.32e-17	Monocyte count;
TGCT	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg23758822	chr17:41437982	NA	0.7	6.6	0.51	1.1e-9	Menopause (age at onset);
TGCT	cis	rs7086627	0.515	rs7077373	chr10:82211615	C/T	cg01528321	chr10:82214614	TSPAN14	0.65	6.21	0.49	7.21e-9	Post bronchodilator FEV1;
TGCT	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg00343986	chr7:65444356	GUSB	0.23	5.13	0.42	1.08e-6	Aortic root size;
TGCT	cis	rs13202913	0.748	rs2859824	chr6:151815865	C/A	cg03627880	chr6:151815985	C6orf97	-0.62	-5.75	-0.46	6.43e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs7523050	0.643	rs35907086	chr1:109406625	A/G	cg08274380	chr1:109419600	GPSM2	1.3	6.39	0.5	2.99e-9	Fat distribution (HIV);
TGCT	cis	rs4494114	1.000	rs4589074	chr1:39354508	T/G	cg25970120	chr1:39325951	RRAGC	-0.6	-6.19	-0.49	8.1e-9	Blood protein levels;
TGCT	cis	rs7666738	0.830	rs11935588	chr4:98979862	A/G	cg17366294	chr4:99064904	C4orf37	-0.71	-7.11	-0.54	7.99e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg21724239	chr8:58056113	NA	0.34	4.54	0.38	1.31e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs1153858	1.000	rs1153849	chr15:45695695	G/A	cg14582100	chr15:45693742	SPATA5L1	0.47	5.62	0.45	1.22e-7	Homoarginine levels;
TGCT	cis	rs4642101	0.512	rs9813960	chr3:12818205	A/G	cg05775895	chr3:12838266	CAND2	0.76	7.82	0.57	2e-12	QRS complex (12-leadsum);
TGCT	cis	rs72781680	0.821	rs12623521	chr2:24181670	C/T	cg08917208	chr2:24149416	ATAD2B	0.72	4.5	0.37	1.56e-5	Lymphocyte counts;
TGCT	cis	rs2456568	0.805	rs55784864	chr11:93682887	G/A	cg16099599	chr11:93583650	C11orf90	-0.39	-4.69	-0.39	7.11e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs9788682	0.948	rs59133824	chr15:78833450	C/A	cg24631222	chr15:78858424	CHRNA5	0.92	7.57	0.56	7.51e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg02353165	chr6:42928485	GNMT	0.99	9.9	0.66	2.25e-17	Alzheimer's disease in APOE e4+ carriers;
TGCT	trans	rs2288327	0.557	rs7577862	chr2:179352857	G/A	cg18634211	chr1:26737262	LIN28	0.91	6.86	0.52	2.86e-10	Atrial fibrillation;
TGCT	cis	rs4879913	0.801	rs7047802	chr9:35591601	G/A	cg18130437	chr9:35658183	CCDC107;RMRP	-0.5	-4.95	-0.41	2.38e-6	Electroencephalogram traits;
TGCT	cis	rs7412746	0.611	rs36008098	chr1:150856806	G/A	cg09365446	chr1:150670422	GOLPH3L	0.35	5.0	0.41	1.87e-6	Melanoma;
TGCT	cis	rs3008870	1.000	rs12044278	chr1:67460977	T/C	cg03991309	chr1:68237761	GNG12	-0.27	-4.53	-0.38	1.36e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs447921	0.813	rs4419085	chr17:74443683	C/T	cg09812376	chr17:74270190	QRICH2	0.47	4.97	0.41	2.17e-6	Mitochondrial DNA levels;
TGCT	cis	rs501916	1.000	rs648627	chr15:48055738	C/T	cg16110827	chr15:48056943	SEMA6D	-0.17	-5.12	-0.42	1.12e-6	Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs4803468	1.000	rs284663	chr19:41932612	C/T	cg09537434	chr19:41945824	ATP5SL	-0.91	-10.05	-0.67	9.48e-18	Height;
TGCT	cis	rs231513	0.954	rs231506	chr17:41970191	A/G	cg26893861	chr17:41843967	DUSP3	-0.71	-5.14	-0.42	1.05e-6	Cognitive function;
TGCT	cis	rs17253792	0.749	rs74979160	chr14:56097568	G/A	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs7267979	1.000	rs6050626	chr20:25428261	T/C	cg03522245	chr20:25566470	NINL	0.63	6.84	0.52	3.25e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6912958	0.559	rs242287	chr6:88071825	C/T	cg10393598	chr6:87862264	NA	-0.32	-4.48	-0.37	1.67e-5	Monocyte percentage of white cells;
TGCT	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.12	0.42	1.12e-6	Prudent dietary pattern;
TGCT	cis	rs7772486	0.651	rs1292338	chr6:145967471	A/C	cg23711669	chr6:146136114	FBXO30	-0.83	-8.98	-0.63	3.75e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4851266	1.000	rs11687241	chr2:100824595	A/G	cg07810366	chr2:100720526	AFF3	-0.41	-5.82	-0.46	4.72e-8	Educational attainment;
TGCT	cis	rs7647973	0.807	rs4955416	chr3:49108428	T/C	cg07636037	chr3:49044803	WDR6	0.79	6.56	0.51	1.32e-9	Menarche (age at onset);
TGCT	cis	rs9788682	0.747	rs8042059	chr15:78907859	A/C	cg24631222	chr15:78858424	CHRNA5	0.77	5.91	0.47	3.06e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	6.75	0.52	5.02e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs13191362	0.872	rs13196631	chr6:163001588	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs3820928	0.874	rs13383070	chr2:227904939	C/T	cg11843606	chr2:227700838	RHBDD1	-0.53	-5.03	-0.41	1.7e-6	Pulmonary function;
TGCT	cis	rs1865760	0.622	rs10946807	chr6:26079638	T/C	cg16482183	chr6:26056742	HIST1H1C	0.68	5.62	0.45	1.17e-7	Height;
TGCT	cis	rs13217239	0.646	rs9379956	chr6:27033735	T/C	cg05738196	chr6:26577821	NA	-0.51	-4.92	-0.4	2.71e-6	Schizophrenia;
TGCT	cis	rs739496	0.579	rs4767068	chr12:112281013	A/G	cg10833066	chr12:111807467	FAM109A	0.38	5.61	0.45	1.24e-7	Platelet count;
TGCT	cis	rs362272	0.524	rs881816	chr4:3365366	A/G	cg22655196	chr4:3374909	RGS12	0.22	4.45	0.37	1.86e-5	Serum sulfate level;
TGCT	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg18402987	chr7:1209562	NA	0.37	4.55	0.38	1.25e-5	Longevity;Endometriosis;
TGCT	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg11301795	chr4:187892539	NA	-0.34	-5.25	-0.43	6.45e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg02725872	chr8:58115012	NA	-0.38	-4.76	-0.39	5.39e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9381040	0.610	rs6941090	chr6:41043465	G/A	cg03526776	chr6:41159608	TREML2	0.27	5.34	0.43	4.21e-7	Alzheimer's disease (late onset);
TGCT	cis	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg25427524	chr10:38739819	LOC399744	-0.38	-7.91	-0.58	1.23e-12	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg07507251	chr3:52567010	NT5DC2	0.47	6.7	0.52	6.47e-10	Bipolar disorder;
TGCT	cis	rs910316	0.934	rs7141705	chr14:75655352	G/C	cg23033748	chr14:75592666	NEK9	-0.27	-4.51	-0.38	1.5e-5	Height;
TGCT	cis	rs7659604	0.628	rs3828485	chr4:122722368	G/A	cg06713675	chr4:122721982	EXOSC9	-0.7	-9.58	-0.65	1.32e-16	Type 2 diabetes;
TGCT	cis	rs7542091	0.813	rs2049999	chr1:210031331	A/G	cg05527609	chr1:210001259	C1orf107	-0.51	-4.51	-0.38	1.48e-5	Monobrow;
TGCT	cis	rs59197085	0.534	rs2307039	chr7:128449355	A/G	cg00260937	chr7:128520193	KCP	0.47	4.9	0.4	2.92e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
TGCT	cis	rs6688613	1.000	rs7528849	chr1:166954870	A/G	cg07049167	chr1:166818506	POGK	0.22	4.72	0.39	6.29e-6	Refractive astigmatism;
TGCT	cis	rs4319547	0.915	rs7966094	chr12:123115771	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.68	-5.42	-0.44	3.02e-7	Body mass index;
TGCT	cis	rs208520	0.690	rs12213575	chr6:66735989	A/G	cg07460842	chr6:66804631	NA	0.95	10.11	0.67	6.77e-18	Exhaled nitric oxide output;
TGCT	cis	rs9902453	0.765	rs1531553	chr17:28066752	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.84	-8.4	-0.6	8.88e-14	Coffee consumption (cups per day);
TGCT	cis	rs10883723	0.773	rs715439	chr10:104257809	A/C	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg02463440	chr8:22132932	PIWIL2	0.26	5.16	0.42	9.37e-7	Hypertriglyceridemia;
TGCT	cis	rs7772486	0.875	rs6570736	chr6:146388320	C/T	cg23711669	chr6:146136114	FBXO30	0.89	9.47	0.65	2.36e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1784581	0.802	rs6455787	chr6:162411378	G/A	cg17173639	chr6:162384350	PARK2	0.42	7.3	0.55	3.02e-11	Itch intensity from mosquito bite;
TGCT	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg24531977	chr5:56204891	C5orf35	-0.68	-7.22	-0.54	4.69e-11	Initial pursuit acceleration;
TGCT	cis	rs9926296	0.632	rs4785717	chr16:89801133	A/G	cg27121462	chr16:89883253	FANCA	0.55	5.06	0.41	1.45e-6	Vitiligo;
TGCT	cis	rs9611565	0.559	rs5758412	chr22:42080803	T/A	cg06634786	chr22:41940651	POLR3H	0.9	8.74	0.62	1.34e-14	Vitiligo;
TGCT	cis	rs595982	0.527	rs55670257	chr19:49382654	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.69	-8.7	-0.62	1.73e-14	Red cell distribution width;
TGCT	cis	rs61884328	0.535	rs4647735	chr11:47253075	T/A	cg13308137	chr11:47528955	CUGBP1	0.39	5.41	0.44	3.13e-7	Total body bone mineral density (age over 60);
TGCT	cis	rs5750830	0.597	rs4821889	chr22:39777254	T/C	cg05872129	chr22:39784769	NA	-0.9	-10.38	-0.68	1.51e-18	Intelligence (multi-trait analysis);
TGCT	cis	rs9393692	1.000	rs2393593	chr6:26285683	T/C	cg05868516	chr6:26286170	HIST1H4H	0.62	5.75	0.46	6.64e-8	Educational attainment;
TGCT	cis	rs3749237	0.964	rs1799845	chr3:49847623	A/G	cg03060546	chr3:49711283	APEH	0.71	7.31	0.55	2.8e-11	Resting heart rate;
TGCT	cis	rs16957091	0.647	rs3759792	chr15:43252764	A/G	cg17935677	chr15:44119062	WDR76	0.53	4.7	0.39	6.83e-6	MGMT methylation in smokers;
TGCT	cis	rs710216	0.917	rs900837	chr1:43412793	A/G	cg03128534	chr1:43423976	SLC2A1	-0.56	-4.53	-0.38	1.35e-5	Red cell distribution width;
TGCT	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg03806693	chr22:41940476	POLR3H	-1.13	-13.26	-0.77	1.59e-25	Vitiligo;
TGCT	cis	rs3776081	0.600	rs2302273	chr5:149535255	G/A	cg18424208	chr5:149546337	CDX1	-0.25	-4.48	-0.37	1.66e-5	Blood protein levels;
TGCT	cis	rs1348850	0.914	rs4893961	chr2:178411075	A/G	cg22681709	chr2:178499509	PDE11A	-0.36	-4.77	-0.39	5.03e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs1570884	0.516	rs9316463	chr13:50176844	G/A	cg03651054	chr13:50194643	NA	0.33	5.28	0.43	5.66e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
TGCT	cis	rs7246657	0.524	rs10411251	chr19:37428755	C/T	cg18154014	chr19:37997991	ZNF793	0.69	4.51	0.38	1.46e-5	Coronary artery calcification;
TGCT	trans	rs12339966	0.581	rs62529407	chr9:11331229	C/A	cg03488587	chr11:64876988	C11orf2	0.32	7.03	0.53	1.19e-10	Systolic blood pressure;
TGCT	cis	rs17376456	0.877	rs28539612	chr5:93499099	C/T	cg25358565	chr5:93447407	FAM172A	0.97	8.32	0.6	1.34e-13	Diabetic retinopathy;
TGCT	cis	rs1008375	1.000	rs2159584	chr4:17620568	G/A	cg10189774	chr4:17578691	LAP3	0.6	5.21	0.42	7.64e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs986417	0.688	rs8018111	chr14:60964347	A/G	cg27398547	chr14:60952738	C14orf39	1.39	10.61	0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs6665290	0.935	rs1929863	chr1:227195728	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.0	-20.65	-0.88	6.07e-42	Myeloid white cell count;
TGCT	cis	rs4595586	0.545	rs1156705	chr12:39372672	C/T	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs3020333	0.653	rs851983	chr6:152024415	A/G	cg22157087	chr6:152012887	ESR1	0.23	5.65	0.45	1.04e-7	Total body bone mineral density;
TGCT	cis	rs9902453	1.000	rs4074170	chr17:28381141	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-6.56	-0.51	1.3e-9	Coffee consumption (cups per day);
TGCT	cis	rs4372836	0.729	rs4666122	chr2:29092850	G/T	cg09522027	chr2:28974177	PPP1CB	0.67	6.91	0.53	2.24e-10	Body mass index;
TGCT	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg03188948	chr7:1209495	NA	0.55	4.56	0.38	1.2e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg15242686	chr22:24348715	GSTTP1	0.49	7.11	0.54	8.12e-11	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9467603	0.592	rs1184498	chr6:25864882	G/C	cg16898833	chr6:26189333	HIST1H4D	0.75	4.61	0.38	9.91e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs881375	0.967	rs1548783	chr9:123658639	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	5.59	0.45	1.38e-7	Rheumatoid arthritis;
TGCT	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg25767906	chr1:53392781	SCP2	0.5	5.83	0.46	4.53e-8	Monocyte count;
TGCT	cis	rs3820068	0.705	rs4646087	chr1:15822404	A/G	cg05660106	chr1:15850417	CASP9	1.18	13.63	0.77	2.04e-26	Systolic blood pressure;
TGCT	cis	rs11148252	1.000	rs4886018	chr13:52990717	C/T	cg00495681	chr13:53174319	NA	0.46	4.51	0.38	1.49e-5	Lewy body disease;
TGCT	cis	rs644799	1.000	rs500054	chr11:95593806	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	10.89	0.7	8.66e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs28595532	0.764	rs115011450	chr4:119778171	C/T	cg21605333	chr4:119757512	SEC24D	1.53	8.87	0.62	6.71e-15	Cannabis dependence symptom count;
TGCT	cis	rs61867294	0.501	rs7907824	chr10:106711060	G/A	cg08000847	chr10:105880925	C10orf78	0.48	4.46	0.37	1.81e-5	Schizophrenia;
TGCT	cis	rs9309473	0.607	rs6740173	chr2:73602266	C/G	cg20560298	chr2:73613845	ALMS1	-0.41	-4.54	-0.38	1.31e-5	Metabolite levels;
TGCT	cis	rs903263	0.965	rs6576960	chr1:84593913	T/G	cg09664975	chr1:84543551	PRKACB	0.5	4.67	0.39	7.62e-6	Breast cancer (male);
TGCT	cis	rs1371867	0.726	rs1660333	chr8:101309989	A/G	cg06002616	chr8:101225028	SPAG1	-0.55	-6.38	-0.5	3.14e-9	Atrioventricular conduction;
TGCT	cis	rs7698623	0.850	rs4693892	chr4:88796983	T/G	cg27387453	chr4:88533842	DSPP	-0.61	-4.6	-0.38	1.03e-5	Cardiovascular disease risk factors;
TGCT	cis	rs7772486	0.754	rs6932863	chr6:146021255	A/T	cg23711669	chr6:146136114	FBXO30	-0.93	-10.83	-0.7	1.24e-19	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs941408	1.000	rs1076448	chr19:2792343	G/A	cg06609049	chr19:2785107	THOP1	0.8	7.95	0.58	9.77e-13	Total cholesterol levels;
TGCT	cis	rs9788682	1.000	rs12441426	chr15:78812329	T/C	cg06917634	chr15:78832804	PSMA4	-0.71	-5.21	-0.42	7.71e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs9916302	0.904	rs9905432	chr17:37555918	C/A	cg15445000	chr17:37608096	MED1	-0.34	-4.8	-0.4	4.43e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs727563	0.552	rs4822045	chr22:41985958	C/A	cg17554472	chr22:41940697	POLR3H	-0.52	-5.37	-0.43	3.79e-7	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg18252515	chr7:66147081	NA	-1.31	-8.18	-0.59	2.87e-13	Diabetic kidney disease;
TGCT	cis	rs1949733	0.598	rs4696838	chr4:8540349	A/G	cg13073564	chr4:8508604	NA	0.49	4.8	0.4	4.48e-6	Response to antineoplastic agents;
TGCT	cis	rs9430161	0.611	rs12081197	chr1:11034239	T/C	cg27631724	chr1:11040367	C1orf127	0.53	6.05	0.48	1.58e-8	Ewing sarcoma;
TGCT	cis	rs6831352	0.589	rs2602836	chr4:100014805	C/T	cg12011299	chr4:100065546	ADH4	-0.37	-4.73	-0.39	5.98e-6	Alcohol dependence;
TGCT	cis	rs7267979	0.789	rs4815400	chr20:25292560	T/C	cg14121845	chr20:25566513	NINL	-0.45	-4.6	-0.38	1.02e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs938554	0.657	rs7679724	chr4:9985376	G/T	cg00071950	chr4:10020882	SLC2A9	0.49	4.56	0.38	1.2e-5	Blood metabolite levels;
TGCT	cis	rs422249	0.720	rs174455	chr11:61656117	A/G	cg01500311	chr11:61656094	FADS3	-0.43	-9.35	-0.64	4.84e-16	Trans fatty acid levels;
TGCT	cis	rs739401	0.566	rs7931504	chr11:3026712	C/T	cg25174290	chr11:3078921	CARS	0.5	4.79	0.4	4.6e-6	Longevity;
TGCT	cis	rs17331151	0.541	rs1139106	chr3:52871101	G/A	cg07884673	chr3:53033167	SFMBT1	0.49	5.61	0.45	1.26e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg19748678	chr4:122722346	EXOSC9	0.9	9.35	0.64	4.81e-16	Type 2 diabetes;
TGCT	cis	rs67460515	0.892	rs2054710	chr3:161090616	C/T	cg03342759	chr3:160939853	NMD3	-0.52	-5.38	-0.44	3.56e-7	Parkinson's disease;
TGCT	cis	rs10779751	1.000	rs11121698	chr1:11267283	C/T	cg08854313	chr1:11322531	MTOR	0.92	10.28	0.68	2.6e-18	Body mass index;
TGCT	cis	rs7010267	0.870	rs7014574	chr8:119977077	C/T	cg17171407	chr8:119960777	TNFRSF11B	0.32	6.21	0.49	7.44e-9	Total body bone mineral density (age 45-60);
TGCT	cis	rs4372836	0.504	rs12185717	chr2:29069551	C/A	cg09522027	chr2:28974177	PPP1CB	-0.57	-5.55	-0.45	1.63e-7	Body mass index;
TGCT	cis	rs7923609	1.000	rs7910927	chr10:65138910	T/G	cg08743896	chr10:65200160	JMJD1C	-0.34	-4.57	-0.38	1.15e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs12286929	0.600	rs4445669	chr11:115045237	C/T	cg04017736	chr11:115827165	NA	0.2	4.83	0.4	4.02e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7267979	1.000	rs3761117	chr20:25388070	G/A	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7786877	0.508	rs11765509	chr7:100310990	T/G	cg16850897	chr7:100343110	ZAN	-0.47	-4.45	-0.37	1.9e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs1577917	0.958	rs12192033	chr6:86472559	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-5.22	-0.42	7.42e-7	Response to antipsychotic treatment;
TGCT	trans	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.88	-9.51	-0.65	1.92e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs155076	1.000	rs12870992	chr13:21846019	A/G	cg11317459	chr13:21872234	NA	1.28	10.32	0.68	2.1e-18	White matter hyperintensity burden;
TGCT	cis	rs4850410	0.581	rs12990099	chr2:197908096	T/G	cg19149314	chr2:197065128	HECW2	0.23	4.51	0.38	1.46e-5	Interferon alpha levels in systemic lupus erythematosus;
TGCT	cis	rs1903068	0.853	rs9312656	chr4:56002972	C/G	cg01777861	chr4:56023843	NA	0.53	6.21	0.49	7.2e-9	Endometriosis;
TGCT	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg11494091	chr17:61959527	GH2	0.61	14.81	0.8	3.37e-29	Prudent dietary pattern;
TGCT	cis	rs739496	0.615	rs666951	chr12:112136583	C/A	cg10833066	chr12:111807467	FAM109A	0.36	5.06	0.41	1.46e-6	Platelet count;
TGCT	trans	rs901683	0.702	rs73292848	chr10:46169752	T/C	cg03466342	chr12:52753899	KRT85	-0.6	-7.24	-0.55	4.23e-11	Red blood cell traits;Mean corpuscular volume;
TGCT	cis	rs3820928	0.967	rs2396435	chr2:227778397	G/A	cg11843606	chr2:227700838	RHBDD1	-0.53	-4.73	-0.39	5.89e-6	Pulmonary function;
TGCT	cis	rs11771526	0.901	rs2191000	chr7:32275098	C/A	cg27532318	chr7:32358331	NA	0.56	4.61	0.38	9.78e-6	Body mass index;
TGCT	cis	rs8017423	0.967	rs55667096	chr14:90714798	C/T	cg04374321	chr14:90722782	PSMC1	0.74	7.74	0.57	2.98e-12	Mortality in heart failure;
TGCT	cis	rs1018836	0.859	rs10808614	chr8:91569677	C/G	cg16814680	chr8:91681699	NA	-0.75	-7.85	-0.58	1.71e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs736408	0.562	rs1014969	chr3:52808341	G/A	cg10802521	chr3:52805072	NEK4	-0.82	-9.71	-0.66	6.55e-17	Bipolar disorder;
TGCT	cis	rs12681288	0.823	rs6994989	chr8:1007284	C/A	cg04851639	chr8:1020857	NA	-0.36	-6.29	-0.49	4.97e-9	Schizophrenia;
TGCT	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg03396347	chr1:1875803	NA	-0.36	-6.58	-0.51	1.19e-9	Body mass index;
TGCT	cis	rs4595586	0.545	rs12828866	chr12:39391925	C/A	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs7237497	0.532	rs515151	chr18:12860934	G/C	cg23598886	chr18:12777645	NA	0.56	4.91	0.4	2.77e-6	Inflammatory skin disease;
TGCT	cis	rs6088590	0.965	rs6058108	chr20:33288655	A/G	cg24642439	chr20:33292090	TP53INP2	0.68	6.14	0.48	1.02e-8	Coronary artery disease;
TGCT	cis	rs910316	0.575	rs12889133	chr14:75465089	C/T	cg08847533	chr14:75593920	NEK9	0.71	6.77	0.52	4.59e-10	Height;
TGCT	cis	rs12210905	1.000	rs12153912	chr6:27179829	A/G	cg08851530	chr6:28072375	NA	-0.87	-4.87	-0.4	3.34e-6	Hip circumference adjusted for BMI;
TGCT	trans	rs4650994	1.000	rs12138541	chr1:178518707	G/A	cg05059571	chr16:84539110	KIAA1609	-0.4	-7.43	-0.56	1.54e-11	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs9788682	0.633	rs2656070	chr15:78730252	A/G	cg24631222	chr15:78858424	CHRNA5	-0.65	-4.87	-0.4	3.38e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs6121246	0.567	rs6058197	chr20:30194899	A/G	cg18721089	chr20:30220636	NA	-0.63	-6.88	-0.53	2.67e-10	Mean corpuscular hemoglobin;
TGCT	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg17971929	chr21:40555470	PSMG1	0.98	9.57	0.65	1.43e-16	Cognitive function;
TGCT	cis	rs1635	0.655	rs73742536	chr6:28303243	G/A	cg15743358	chr6:28303923	ZNF323	-1.28	-6.27	-0.49	5.57e-9	Schizophrenia;
TGCT	cis	rs11585357	0.709	rs735281	chr1:17616194	T/C	cg08277548	chr1:17600880	PADI3	0.96	9.72	0.66	5.97e-17	Hair shape;
TGCT	cis	rs10782582	0.593	rs4638068	chr1:76161663	G/A	cg22875332	chr1:76189707	ACADM	-0.55	-6.35	-0.5	3.77e-9	Daytime sleep phenotypes;
TGCT	cis	rs8013055	0.796	rs35592422	chr14:105996593	G/C	cg19700328	chr14:106028568	NA	-0.51	-5.67	-0.45	9.58e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs9611565	0.500	rs10775759	chr22:42088158	T/C	cg13695892	chr22:41940480	POLR3H	0.9	9.02	0.63	2.89e-15	Vitiligo;
TGCT	cis	rs9911578	1.000	rs9904879	chr17:56864422	G/A	cg05425664	chr17:57184151	TRIM37	-0.63	-6.26	-0.49	5.86e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7474896	0.583	rs11011347	chr10:38019264	G/A	cg13720705	chr10:37990370	NA	0.34	4.9	0.4	2.9e-6	Obesity (extreme);
TGCT	cis	rs76954792	0.826	rs62062240	chr17:30026212	C/T	cg18427091	chr17:30115417	NA	-0.35	-4.55	-0.38	1.24e-5	Coronary artery disease;
TGCT	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg00684032	chr4:1343700	KIAA1530	-0.23	-4.93	-0.4	2.58e-6	Obesity-related traits;
TGCT	cis	rs492146	0.765	rs622902	chr6:52846474	G/A	cg06706454	chr6:52930286	FBXO9	-0.53	-4.95	-0.41	2.36e-6	Epilepsy (remission after treatment);
TGCT	cis	rs8078723	1.000	rs4795418	chr17:38164851	T/C	cg17467752	chr17:38218738	THRA	0.54	5.22	0.42	7.25e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs7617773	0.817	rs6791930	chr3:48329900	A/G	cg11946769	chr3:48343235	NME6	0.74	6.34	0.49	3.97e-9	Coronary artery disease;
TGCT	cis	rs981844	1.000	rs2251994	chr4:154654097	C/T	cg14289246	chr4:154710475	SFRP2	1.02	8.53	0.61	4.35e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg13531842	chr10:38383804	ZNF37A	-0.38	-4.55	-0.38	1.25e-5	Extrinsic epigenetic age acceleration;
TGCT	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg05985448	chr10:134359359	INPP5A	0.22	4.75	0.39	5.54e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs1915146	0.967	rs7086481	chr10:126844523	A/T	cg05090351	chr10:126851162	NA	-0.43	-4.96	-0.41	2.25e-6	Menarche (age at onset);
TGCT	cis	rs2535633	0.602	rs6801235	chr3:53009595	T/C	cg11645453	chr3:52864694	ITIH4	0.25	4.66	0.39	8.13e-6	Body mass index;
TGCT	cis	rs910316	1.000	rs910316	chr14:75626042	A/C	cg23033748	chr14:75592666	NEK9	0.28	4.77	0.39	4.98e-6	Height;
TGCT	cis	rs7809950	0.678	rs2237661	chr7:106863123	T/C	cg23024343	chr7:107201750	COG5	-0.43	-5.91	-0.47	3.13e-8	Coronary artery disease;
TGCT	cis	rs73110464	0.609	rs6580923	chr12:53358352	A/G	cg05393297	chr12:53359155	NA	-0.79	-8.43	-0.6	7.2e-14	Cancer (pleiotropy);
TGCT	cis	rs11031096	0.655	rs34295904	chr11:4206701	C/A	cg18678763	chr11:4115507	RRM1	-0.45	-5.84	-0.46	4.31e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs763121	0.853	rs5757208	chr22:39049230	A/C	cg06022373	chr22:39101656	GTPBP1	0.77	7.46	0.56	1.35e-11	Menopause (age at onset);
TGCT	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg08859206	chr1:53392774	SCP2	0.4	6.05	0.48	1.58e-8	Monocyte count;
TGCT	cis	rs7439150	1.000	rs1800790	chr4:155483708	G/A	cg22130008	chr4:155548532	NA	-0.48	-5.91	-0.47	3.02e-8	Fibrinogen levels;
TGCT	cis	rs13256369	0.802	rs35382339	chr8:8559255	G/A	cg17143192	chr8:8559678	CLDN23	0.54	4.86	0.4	3.53e-6	Obesity-related traits;
TGCT	cis	rs2204008	0.682	rs2320517	chr12:38259239	A/T	cg13010199	chr12:38710504	ALG10B	0.64	4.97	0.41	2.15e-6	Bladder cancer;
TGCT	cis	rs1401999	0.674	rs562	chr3:183637845	T/C	cg01324343	chr3:183735012	ABCC5	0.73	8.93	0.63	4.76e-15	Anterior chamber depth;
TGCT	cis	rs1385374	0.858	rs11059933	chr12:129303593	T/C	cg09035930	chr12:129282057	SLC15A4	-0.55	-4.76	-0.39	5.27e-6	Systemic lupus erythematosus;
TGCT	cis	rs10504229	1.000	rs59708460	chr8:58196526	G/A	cg24829409	chr8:58192753	C8orf71	-0.55	-4.74	-0.39	5.83e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7666738	0.830	rs4472144	chr4:98956494	G/A	cg05340658	chr4:99064831	C4orf37	0.53	6.02	0.48	1.8e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1670533	1.000	rs13107058	chr4:1054379	G/A	cg27284194	chr4:1044797	NA	0.69	5.71	0.46	7.76e-8	Recombination rate (females);
TGCT	trans	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg27523141	chr10:43048294	ZNF37B	0.72	8.36	0.6	1.09e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7100689	0.784	rs4258322	chr10:82184770	T/C	cg01528321	chr10:82214614	TSPAN14	0.9	9.42	0.65	3.22e-16	Post bronchodilator FEV1;
TGCT	cis	rs6728642	0.803	rs11891458	chr2:97632450	G/T	cg26665480	chr2:98280029	ACTR1B	-0.91	-5.94	-0.47	2.67e-8	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	cis	rs6495367	1.000	rs6495367	chr15:79375347	C/T	cg17916960	chr15:79447300	NA	0.34	4.82	0.4	4.08e-6	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs4727027	0.901	rs1137432	chr7:148801658	C/T	cg23583168	chr7:148888333	NA	-0.72	-9.11	-0.63	1.8e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs6121246	0.609	rs2149281	chr20:30417918	G/A	cg13852791	chr20:30311386	BCL2L1	0.77	7.01	0.53	1.34e-10	Mean corpuscular hemoglobin;
TGCT	cis	rs2562456	0.793	rs627522	chr19:21495804	C/T	cg01304269	chr19:21688519	ZNF429	0.54	4.45	0.37	1.87e-5	Pain;
TGCT	cis	rs3741404	0.594	rs11231704	chr11:63898182	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.68	-5.92	-0.47	2.88e-8	Platelet count;
TGCT	cis	rs694739	1.000	rs499425	chr11:64105929	A/G	cg02228329	chr11:64053129	BAD;GPR137	-0.78	-7.87	-0.58	1.54e-12	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg05368731	chr17:41323189	NBR1	1.16	13.7	0.78	1.41e-26	Menopause (age at onset);
TGCT	cis	rs10832963	1.000	rs10832962	chr11:18656271	C/T	cg09201001	chr11:18656081	SPTY2D1	1.04	11.77	0.73	6.2e-22	Breast cancer;
TGCT	cis	rs7267979	1.000	rs2257808	chr20:25266450	G/C	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7681440	0.904	rs6532192	chr4:90764131	G/A	cg26578617	chr4:90757533	SNCA	-0.49	-5.1	-0.42	1.26e-6	Dementia with Lewy bodies;
TGCT	cis	rs1008375	0.932	rs4698626	chr4:17605821	G/C	cg18681998	chr4:17616180	MED28	0.98	10.43	0.68	1.17e-18	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4268898	0.722	rs7564420	chr2:24414002	C/T	cg02683114	chr2:24398427	C2orf84	-0.2	-4.89	-0.4	3.01e-6	Asthma;
TGCT	cis	rs2228479	0.867	rs17784386	chr16:89947457	A/G	cg06558623	chr16:89946397	TCF25	0.56	6.83	0.52	3.38e-10	Skin colour saturation;
TGCT	cis	rs9396146	0.609	rs3734672	chr6:13787578	C/T	cg25000576	chr6:13769806	NA	0.35	4.56	0.38	1.21e-5	Yeast infection;
TGCT	cis	rs2046867	0.818	rs62249862	chr3:72867949	G/C	cg25664220	chr3:72788482	NA	-0.56	-7.04	-0.53	1.16e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs892961	0.899	rs7222532	chr17:75413302	G/C	cg05865280	chr17:75406074	SEPT9	0.28	6.86	0.52	2.9e-10	Airflow obstruction;
TGCT	cis	rs7547997	0.615	rs12038925	chr1:158319449	G/A	cg03528325	chr1:158223921	CD1A	0.34	4.71	0.39	6.65e-6	QRS duration;
TGCT	cis	rs1008375	1.000	rs2286771	chr4:17643848	G/A	cg16339924	chr4:17578868	LAP3	0.63	5.33	0.43	4.49e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.66	-6.72	-0.52	5.84e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg00814883	chr7:100076585	TSC22D4	-0.9	-9.56	-0.65	1.5e-16	Platelet count;
TGCT	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg06238570	chr21:40685208	BRWD1	0.73	6.66	0.51	8.12e-10	Cognitive function;
TGCT	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.61	5.06	0.41	1.5e-6	Tonsillectomy;
TGCT	cis	rs2153535	0.541	rs1414352	chr6:8485547	A/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs7523050	0.642	rs12044219	chr1:109481236	T/C	cg08274380	chr1:109419600	GPSM2	1.03	5.92	0.47	2.91e-8	Fat distribution (HIV);
TGCT	cis	rs12681287	0.605	rs2953509	chr8:87343194	C/T	cg27223183	chr8:87520930	FAM82B	-0.9	-6.71	-0.52	6.12e-10	Caudate activity during reward;
TGCT	cis	rs4660261	0.545	rs803682	chr1:44362623	G/A	cg13606994	chr1:44402422	ARTN	-0.42	-4.52	-0.38	1.44e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs2303745	0.589	rs891018	chr19:17396761	C/T	cg02221750	chr19:17393354	ANKLE1	0.49	6.64	0.51	8.88e-10	Systemic lupus erythematosus;
TGCT	cis	rs10986311	0.722	rs17315546	chr9:127148229	C/T	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.19	4.73	0.39	5.91e-6	Vitiligo;
TGCT	cis	rs3858526	0.959	rs11039723	chr11:5956002	G/C	cg05234568	chr11:5960015	NA	-0.44	-4.5	-0.37	1.57e-5	DNA methylation (variation);
TGCT	cis	rs7267979	0.932	rs367666	chr20:25449818	T/C	cg16686733	chr20:25566563	NINL	0.56	5.61	0.45	1.26e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2730260	0.537	rs3793223	chr7:158863574	C/A	cg09066883	chr7:157932951	PTPRN2	0.44	4.83	0.4	3.96e-6	Myopia (pathological);
TGCT	cis	rs2895526	0.902	rs7077657	chr10:12668814	C/G	cg18283737	chr10:12085149	UPF2	0.51	4.97	0.41	2.18e-6	Headache;
TGCT	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg13866156	chr1:1669148	SLC35E2	0.2	4.44	0.37	1.94e-5	Body mass index;
TGCT	cis	rs2066819	1.000	rs2306694	chr12:56680636	C/T	cg26714650	chr12:56694279	CS	1.36	6.06	0.48	1.54e-8	Psoriasis vulgaris;
TGCT	cis	rs854765	0.647	rs854814	chr17:18003648	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	7.41	0.55	1.72e-11	Total body bone mineral density;
TGCT	cis	rs28595532	0.920	rs56227053	chr4:119772460	C/T	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs6121246	0.567	rs6088796	chr20:30213229	C/T	cg21427119	chr20:30132790	HM13	-0.43	-6.17	-0.48	8.86e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs2180341	0.695	rs6569487	chr6:127726196	C/T	cg27446573	chr6:127587934	RNF146	-0.74	-7.46	-0.56	1.28e-11	Breast cancer;
TGCT	cis	rs2342371	0.848	rs5016648	chr3:196207989	A/G	cg15048948	chr3:196158458	UBXN7	-0.54	-4.62	-0.38	9.56e-6	Fat distribution (HIV);
TGCT	cis	rs9914544	1.000	rs8066385	chr17:18761133	C/T	cg26378065	chr17:18585709	ZNF286B	0.52	4.73	0.39	5.94e-6	Educational attainment (years of education);
TGCT	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg11764359	chr7:65958608	NA	0.58	5.34	0.43	4.22e-7	Aortic root size;
TGCT	cis	rs7772486	0.659	rs9376957	chr6:146011064	C/T	cg23711669	chr6:146136114	FBXO30	-0.85	-9.45	-0.65	2.66e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg06481639	chr22:41940642	POLR3H	0.74	6.59	0.51	1.11e-9	Vitiligo;
TGCT	cis	rs2688608	0.967	rs72814394	chr10:75656325	C/T	cg02947784	chr10:75434997	AGAP5	0.16	4.56	0.38	1.21e-5	Inflammatory bowel disease;
TGCT	cis	rs17270561	0.525	rs10484432	chr6:26008876	G/A	cg17042849	chr6:26104293	HIST1H4C	-0.81	-5.71	-0.46	7.76e-8	Iron status biomarkers;
TGCT	trans	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg21659725	chr3:3221576	CRBN	-0.7	-7.98	-0.58	8.35e-13	Body mass index;
TGCT	trans	rs208520	0.690	rs12189780	chr6:66759619	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	11.22	0.71	1.34e-20	Exhaled nitric oxide output;
TGCT	cis	rs10276381	0.786	rs10281102	chr7:28243473	A/G	cg23620719	chr7:28220237	JAZF1	0.95	5.75	0.46	6.52e-8	Crohn's disease;
TGCT	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg06028808	chr11:68637592	NA	0.51	6.62	0.51	9.55e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs709400	0.604	rs7158144	chr14:103887615	A/G	cg26031613	chr14:104095156	KLC1	0.86	9.43	0.65	2.96e-16	Body mass index;
TGCT	cis	rs9916302	0.861	rs3889368	chr17:37683231	C/T	cg07936489	chr17:37558343	FBXL20	-0.61	-4.92	-0.4	2.69e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs709400	0.628	rs6575983	chr14:103869849	C/G	cg26031613	chr14:104095156	KLC1	0.76	8.89	0.62	5.88e-15	Body mass index;
TGCT	cis	rs1568889	0.838	rs10835273	chr11:28156598	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.92	11.01	0.7	4.33e-20	Bipolar disorder;
TGCT	cis	rs861020	1.000	rs642961	chr1:209989270	A/G	cg05527609	chr1:210001259	C1orf107	0.93	7.67	0.57	4.25e-12	Orofacial clefts;
TGCT	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7666738	0.791	rs1527516	chr4:98967937	A/C	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4689388	0.647	rs9997824	chr4:6283253	T/C	cg14416269	chr4:6271139	WFS1	0.38	4.78	0.39	4.95e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs611744	0.967	rs686584	chr8:109192357	G/A	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs10464366	0.544	rs4540324	chr7:39185299	G/C	cg18850127	chr7:39170497	POU6F2	0.33	7.18	0.54	5.5e-11	IgG glycosylation;
TGCT	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg12963246	chr6:28129442	ZNF389	-0.48	-4.85	-0.4	3.65e-6	Depression;
TGCT	cis	rs3733585	0.673	rs4314284	chr4:9956096	C/T	cg00071950	chr4:10020882	SLC2A9	-0.58	-6.98	-0.53	1.57e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg26354017	chr1:205819088	PM20D1	0.55	6.66	0.51	7.98e-10	Monocyte percentage of white cells;
TGCT	trans	rs2727020	0.688	rs2734002	chr11:49234162	A/G	cg15704280	chr7:45808275	SEPT13	0.7	7.64	0.57	5e-12	Coronary artery disease;
TGCT	cis	rs17331151	0.573	rs2276818	chr3:52864635	A/G	cg27565382	chr3:53032988	SFMBT1	0.47	5.96	0.47	2.42e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs9755467	0.539	rs4974430	chr3:127168018	A/T	cg26017091	chr3:126748781	PLXNA1	0.19	4.63	0.38	9.18e-6	Educational attainment (years of education);
TGCT	cis	rs6964587	1.000	rs7806157	chr7:91601930	A/G	cg17063962	chr7:91808500	NA	0.91	9.99	0.67	1.32e-17	Breast cancer;
TGCT	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg07157834	chr1:205819609	PM20D1	0.42	6.7	0.52	6.47e-10	Menarche (age at onset);
TGCT	cis	rs892961	1.000	rs11653743	chr17:75401923	C/A	cg05865280	chr17:75406074	SEPT9	0.29	6.82	0.52	3.6e-10	Airflow obstruction;
TGCT	cis	rs77633900	0.614	rs280008	chr15:77011815	T/C	cg21673338	chr15:77095150	SCAPER	-0.51	-5.12	-0.42	1.11e-6	Non-glioblastoma glioma;Glioma;
TGCT	cis	rs6570726	0.905	rs377143	chr6:145834220	C/T	cg23711669	chr6:146136114	FBXO30	0.67	6.05	0.48	1.58e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4689388	0.782	rs4262051	chr4:6281775	G/A	cg14416269	chr4:6271139	WFS1	0.4	5.13	0.42	1.07e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg03303774	chr4:1407052	NA	0.31	4.93	0.4	2.58e-6	Obesity-related traits;
TGCT	cis	rs67478160	0.595	rs2295146	chr14:104199356	C/T	cg26031613	chr14:104095156	KLC1	-0.74	-7.51	-0.56	9.92e-12	Schizophrenia;
TGCT	cis	rs12289510	1.000	rs12289510	chr11:124947051	C/T	cg03868193	chr11:124958746	SLC37A2	0.36	4.73	0.39	6.1e-6	Platelet-derived growth factor BB levels;
TGCT	cis	rs2249625	0.545	rs2463746	chr6:72876954	C/G	cg08500200	chr6:72892038	RIMS1	-0.42	-4.54	-0.38	1.33e-5	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
TGCT	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg04944784	chr2:26401820	FAM59B	-0.68	-6.13	-0.48	1.1e-8	Gut microbiome composition (summer);
TGCT	cis	rs8017423	0.935	rs17188598	chr14:90722473	A/T	cg04374321	chr14:90722782	PSMC1	0.76	7.69	0.57	3.88e-12	Mortality in heart failure;
TGCT	cis	rs7567389	0.599	rs6430938	chr2:128162623	A/G	cg02161262	chr2:127865248	BIN1	-0.51	-4.6	-0.38	1.01e-5	Self-rated health;
TGCT	cis	rs6089584	1.000	rs3787425	chr20:60559256	C/T	cg16423285	chr20:60520624	NA	-0.52	-5.45	-0.44	2.6e-7	Body mass index;
TGCT	cis	rs2549003	1.000	rs2070725	chr5:131821788	C/T	cg00255919	chr5:131827918	IRF1	0.2	4.65	0.39	8.22e-6	Asthma (sex interaction);
TGCT	trans	rs28735056	0.967	rs498541	chr18:77589655	G/A	cg05926928	chr17:57297772	GDPD1	-0.71	-7.64	-0.57	5.03e-12	Schizophrenia;
TGCT	cis	rs7267979	0.844	rs6083851	chr20:25401235	G/A	cg03522245	chr20:25566470	NINL	-0.55	-5.55	-0.45	1.68e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs586688	0.625	rs688122	chr1:201653344	T/C	cg07139329	chr1:201708558	NAV1	-0.52	-5.29	-0.43	5.27e-7	Obesity-related traits;
TGCT	cis	rs2760061	0.583	rs1745413	chr1:228212456	A/G	cg02753203	chr1:228287806	NA	0.39	7.91	0.58	1.2e-12	Diastolic blood pressure;
TGCT	cis	rs459571	0.920	rs2520094	chr9:136919985	A/T	cg13789015	chr9:136890014	NCRNA00094	0.37	6.32	0.49	4.31e-9	Platelet distribution width;
TGCT	cis	rs6845621	0.870	rs1377150	chr4:18922754	C/G	cg12196642	chr4:18937545	NA	0.26	4.64	0.38	8.81e-6	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
TGCT	cis	rs1552244	0.816	rs9847657	chr3:10173492	G/T	cg00149659	chr3:10157352	C3orf10	0.79	5.58	0.45	1.41e-7	Alzheimer's disease;
TGCT	cis	rs4812048	0.793	rs62205397	chr20:57597011	C/T	cg24457521	chr20:57607420	ATP5E	-0.7	-4.64	-0.38	8.78e-6	Mean platelet volume;
TGCT	cis	rs2288884	1.000	rs2288884	chr19:52532271	C/T	cg15405931	chr19:52693188	PPP2R1A	-0.69	-4.6	-0.38	1.03e-5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs12950390	0.853	rs11655336	chr17:45858836	A/G	cg24803719	chr17:45855879	NA	0.5	5.19	0.42	8.41e-7	IgG glycosylation;
TGCT	cis	rs2463822	1.000	rs72921501	chr11:62115622	A/T	cg06239285	chr11:62104954	ASRGL1	-0.94	-6.62	-0.51	9.63e-10	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs7582180	0.614	rs1530031	chr2:101009326	T/C	cg08017756	chr2:100939284	LONRF2	-0.3	-4.77	-0.39	5.18e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs2167892	chr4:99048503	G/C	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2153535	0.580	rs6937186	chr6:8494493	A/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs1372520	0.684	rs2737030	chr4:90710099	C/T	cg20003494	chr4:90757398	SNCA	-0.6	-4.83	-0.4	3.89e-6	Neuroticism;
TGCT	cis	rs4843747	0.671	rs28671027	chr16:88116323	G/A	cg06915872	chr16:87998081	BANP	-0.3	-4.57	-0.38	1.14e-5	Menopause (age at onset);
TGCT	cis	rs11578119	1.000	rs11578119	chr1:170501456	C/T	cg09767346	chr1:170501363	GORAB	0.64	5.11	0.42	1.16e-6	Male-pattern baldness;
TGCT	cis	rs7647973	0.626	rs62260723	chr3:49872124	T/C	cg03034192	chr3:50606346	HEMK1;C3orf18	-0.34	-4.51	-0.38	1.5e-5	Menarche (age at onset);
TGCT	cis	rs9644031	1	rs9644031	chr8:23359280	C/A	cg00472375	chr8:23315376	ENTPD4	0.61	4.53	0.38	1.37e-5	Mean corpuscular volume;
TGCT	cis	rs9650657	0.501	rs3021500	chr8:11023997	G/C	cg21775007	chr8:11205619	TDH	-0.56	-5.28	-0.43	5.59e-7	Neuroticism;
TGCT	cis	rs2760061	0.583	rs1774757	chr1:228211135	C/G	cg02753203	chr1:228287806	NA	0.39	7.85	0.58	1.67e-12	Diastolic blood pressure;
TGCT	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.61	0.51	1.01e-9	Bipolar disorder;
TGCT	cis	rs7917772	0.505	rs61869211	chr10:104449836	A/G	cg05855489	chr10:104503620	C10orf26	-0.68	-5.57	-0.45	1.52e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg17554472	chr22:41940697	POLR3H	0.48	4.95	0.41	2.39e-6	Vitiligo;
TGCT	cis	rs478304	0.593	rs9666878	chr11:65475816	A/C	cg27068330	chr11:65405492	SIPA1	0.97	10.59	0.69	4.53e-19	Acne (severe);
TGCT	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg24829409	chr8:58192753	C8orf71	-0.57	-5.35	-0.43	4.03e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs11167764	0.945	rs13161849	chr5:141473395	A/G	cg23435118	chr5:141488016	NDFIP1	-0.28	-4.58	-0.38	1.1e-5	Crohn's disease;
TGCT	cis	rs7769051	0.522	rs7738256	chr6:133113066	C/G	cg22852734	chr6:133119734	C6orf192	1.23	4.59	0.38	1.06e-5	Type 2 diabetes nephropathy;
TGCT	cis	rs10464366	1.000	rs10951593	chr7:39121390	C/T	cg18850127	chr7:39170497	POU6F2	0.23	5.03	0.41	1.66e-6	IgG glycosylation;
TGCT	cis	rs4494114	1.000	rs4607833	chr1:39354272	G/C	cg25970120	chr1:39325951	RRAGC	-0.6	-6.19	-0.49	8.1e-9	Blood protein levels;
TGCT	cis	rs12368653	0.666	rs799267	chr12:58113158	C/T	cg12615879	chr12:58013172	SLC26A10	0.49	5.89	0.47	3.39e-8	Multiple sclerosis;
TGCT	cis	rs9457247	1.000	rs439553	chr6:167391212	A/G	cg25258033	chr6:167368657	RNASET2	0.18	4.49	0.37	1.63e-5	Crohn's disease;
TGCT	cis	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg20637647	chr7:64974828	NA	0.96	5.59	0.45	1.41e-7	Diabetic kidney disease;
TGCT	cis	rs644799	1.000	rs12786522	chr11:95522858	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	8.51	0.61	4.7e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs12291225	0.585	rs10832246	chr11:14380828	G/A	cg19336497	chr11:14380999	RRAS2	-0.44	-7.14	-0.54	6.96e-11	Sense of smell;
TGCT	trans	rs8073060	0.586	rs225294	chr17:33925762	G/A	cg19694781	chr19:47549865	TMEM160	-0.6	-13.04	-0.76	5.29e-25	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs6540559	0.808	rs11119358	chr1:210042456	T/C	cg21951975	chr1:209979733	IRF6	0.69	5.63	0.45	1.16e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs10992471	0.598	rs7867300	chr9:95183107	A/G	cg13798575	chr9:95087839	CENPP;NOL8	0.52	4.81	0.4	4.32e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs3793683	1.000	rs3793683	chr10:134568387	G/T	cg27286337	chr10:134555280	INPP5A	-0.46	-7.29	-0.55	3.16e-11	Migraine;
TGCT	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg08280861	chr8:58055591	NA	0.38	4.81	0.4	4.36e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg11644478	chr21:40555479	PSMG1	1.03	10.32	0.68	2.12e-18	Cognitive function;
TGCT	cis	rs6933660	0.720	rs6936936	chr6:151753395	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.5	4.76	0.39	5.36e-6	Menarche (age at onset);
TGCT	cis	rs6490294	0.747	rs7978068	chr12:112501766	T/G	cg10833066	chr12:111807467	FAM109A	0.37	5.44	0.44	2.68e-7	Mean platelet volume;
TGCT	cis	rs4713118	0.588	rs200994	chr6:27813813	A/C	cg18675097	chr6:28227127	NKAPL	0.37	4.69	0.39	7.13e-6	Parkinson's disease;
TGCT	cis	rs4808199	0.947	rs4808960	chr19:19574277	G/C	cg03709012	chr19:19516395	GATAD2A	1.0	7.8	0.57	2.23e-12	Nonalcoholic fatty liver disease;
TGCT	cis	rs6003958	1	rs6003958	chr22:24264089	T/G	cg18538332	chr22:24372958	LOC391322	0.89	7.91	0.58	1.21e-12	S-phenylmercapturic acid levels in smokers;
TGCT	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.54	-0.38	1.33e-5	Bipolar disorder;
TGCT	cis	rs5750830	0.594	rs5757648	chr22:39775156	G/A	cg05872129	chr22:39784769	NA	-0.84	-8.83	-0.62	8.39e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs6912958	0.559	rs376633	chr6:88042785	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.41	4.81	0.4	4.22e-6	Monocyte percentage of white cells;
TGCT	cis	rs6121246	0.909	rs1994251	chr20:30287328	T/G	cg18721089	chr20:30220636	NA	-0.42	-4.65	-0.39	8.2e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs12049351	0.665	rs6663689	chr1:229630163	C/T	cg12130225	chr1:229698885	NA	0.39	4.59	0.38	1.06e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs2688608	0.620	rs11000767	chr10:75516626	G/T	cg19442545	chr10:75533431	FUT11	-0.36	-5.74	-0.46	6.99e-8	Inflammatory bowel disease;
TGCT	cis	rs12477438	0.798	rs12477754	chr2:99628073	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-5.87	-0.47	3.74e-8	Chronic sinus infection;
TGCT	cis	rs1008375	1.000	rs13149474	chr4:17688582	G/A	cg16339924	chr4:17578868	LAP3	-0.61	-4.81	-0.4	4.33e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2204008	0.777	rs8189597	chr12:38307739	G/C	cg26384229	chr12:38710491	ALG10B	-0.81	-7.05	-0.53	1.13e-10	Bladder cancer;
TGCT	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg16414030	chr3:133502952	NA	0.6	9.35	0.64	4.64e-16	Iron status biomarkers;
TGCT	cis	rs7772486	0.875	rs9399573	chr6:146403255	A/T	cg05347473	chr6:146136440	FBXO30	0.55	5.14	0.42	1.05e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs877529	0.625	rs714016	chr22:39532554	G/T	cg18708252	chr22:39545030	CBX7	0.35	5.1	0.42	1.23e-6	Multiple myeloma;
TGCT	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg10802521	chr3:52805072	NEK4	-0.8	-9.8	-0.66	3.79e-17	Bipolar disorder;
TGCT	cis	rs13401104	0.587	rs7581196	chr2:237151098	A/C	cg19324714	chr2:237145437	ASB18	-0.46	-4.88	-0.4	3.17e-6	Educational attainment;
TGCT	cis	rs5769707	0.681	rs8137111	chr22:50043750	G/A	cg05373962	chr22:49881684	NA	-0.31	-5.31	-0.43	4.99e-7	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs7666738	0.800	rs7683737	chr4:99070880	A/T	cg05340658	chr4:99064831	C4orf37	0.52	5.79	0.46	5.32e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2410601	0.503	rs7843518	chr8:18925159	C/T	cg19414122	chr8:18896631	NA	-0.27	-4.51	-0.38	1.51e-5	Urinary albumin excretion rate in type 1 diabetes;
TGCT	cis	rs2688608	0.618	rs28553894	chr10:75489843	C/A	cg15838173	chr10:75533400	FUT11	-0.31	-5.16	-0.42	9.66e-7	Inflammatory bowel disease;
TGCT	cis	rs554111	1.000	rs554111	chr1:21042300	C/G	cg08890418	chr1:21044141	KIF17	0.57	6.03	0.48	1.73e-8	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs11718455	1.000	rs28731098	chr3:44019816	A/C	cg08738300	chr3:44038990	NA	0.88	6.65	0.51	8.52e-10	Coronary artery disease;
TGCT	trans	rs4332037	0.539	rs55993248	chr7:2071132	A/G	cg25206134	chr2:45395956	NA	0.97	7.42	0.55	1.6e-11	Bipolar disorder;
TGCT	cis	rs9611565	1.000	rs5751086	chr22:41768862	C/T	cg06634786	chr22:41940651	POLR3H	-0.63	-6.07	-0.48	1.46e-8	Vitiligo;
TGCT	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg06418219	chr1:154948305	SHC1;CKS1B	-0.68	-6.73	-0.52	5.48e-10	Prostate cancer;
TGCT	cis	rs9467773	1.000	rs10946834	chr6:26533664	G/C	cg09904177	chr6:26538194	HMGN4	0.65	6.53	0.51	1.53e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs9733	0.744	rs3754211	chr1:150951857	G/A	cg09365446	chr1:150670422	GOLPH3L	0.34	5.02	0.41	1.74e-6	Tonsillectomy;
TGCT	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg24531977	chr5:56204891	C5orf35	-0.76	-7.34	-0.55	2.45e-11	Initial pursuit acceleration;
TGCT	cis	rs2012796	0.956	rs6574646	chr14:81819809	A/G	cg02996355	chr14:81879375	NA	0.47	4.61	0.38	9.68e-6	Night sleep phenotypes;
TGCT	cis	rs68170813	0.559	rs3823960	chr7:107009349	T/C	cg02696742	chr7:106810147	HBP1	-0.7	-5.7	-0.46	8.16e-8	Coronary artery disease;
TGCT	cis	rs9295536	0.620	rs6915330	chr6:22136172	C/G	cg25792714	chr6:21666554	FLJ22536	-0.52	-4.72	-0.39	6.22e-6	Neuroblastoma;
TGCT	cis	rs2204008	0.576	rs11519979	chr12:37999413	C/T	cg26384229	chr12:38710491	ALG10B	0.86	7.77	0.57	2.55e-12	Bladder cancer;
TGCT	cis	rs8141529	0.702	rs469992	chr22:29314899	T/C	cg02153584	chr22:29168773	CCDC117	-0.62	-4.89	-0.4	3.05e-6	Lymphocyte counts;
TGCT	cis	rs2806561	0.606	rs218341	chr1:23294153	G/C	cg12483005	chr1:23474871	LUZP1	0.41	5.27	0.43	5.89e-7	Height;
TGCT	cis	rs66573146	1.000	rs66712119	chr4:6965428	A/T	cg05069807	chr4:6945702	TBC1D14	0.31	4.6	0.38	1.03e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs7100689	0.784	rs6585986	chr10:82171559	T/C	cg01528321	chr10:82214614	TSPAN14	0.94	9.82	0.66	3.45e-17	Post bronchodilator FEV1;
TGCT	cis	rs4517514	0.509	rs11018869	chr11:89865168	A/G	cg14505434	chr11:89522851	NA	0.45	4.46	0.37	1.82e-5	Trans fatty acid levels;
TGCT	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg18402987	chr7:1209562	NA	0.7	5.67	0.45	9.66e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg22433210	chr17:43662623	NA	0.94	8.08	0.59	4.8e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs10875746	0.768	rs4760676	chr12:48421663	G/A	cg20731937	chr12:48336164	NA	0.72	6.09	0.48	1.34e-8	Longevity (90 years and older);
TGCT	cis	rs10927875	1.000	rs10927875	chr1:16299312	A/G	cg22431228	chr1:16359049	CLCNKA	-0.25	-4.55	-0.38	1.24e-5	Dilated cardiomyopathy;
TGCT	cis	rs6089584	0.893	rs6089306	chr20:60574868	G/A	cg16423285	chr20:60520624	NA	-0.63	-6.97	-0.53	1.66e-10	Body mass index;
TGCT	cis	rs798766	1.000	rs798741	chr4:1712413	A/G	cg05874882	chr4:1763078	NA	-0.36	-4.96	-0.41	2.28e-6	Bladder cancer;Urinary bladder cancer;
TGCT	cis	rs9733	0.596	rs34600506	chr1:150687808	C/G	cg09365446	chr1:150670422	GOLPH3L	0.3	4.52	0.38	1.4e-5	Tonsillectomy;
TGCT	cis	rs9653442	0.564	rs11902705	chr2:100795207	A/G	cg22139774	chr2:100720529	AFF3	0.31	4.78	0.39	4.81e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs5757676	1.000	rs5757676	chr22:39841700	T/C	cg24399712	chr22:39784796	NA	-0.98	-8.16	-0.59	3.18e-13	IgG glycosylation;
TGCT	cis	rs7552404	0.727	rs12122939	chr1:76276353	T/C	cg10523679	chr1:76189770	ACADM	0.75	7.21	0.54	4.89e-11	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs112591243	0.685	rs115448966	chr21:47988420	G/A	cg10657630	chr21:48055338	PRMT2	1.0	5.29	0.43	5.4e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs2230307	0.536	rs6677998	chr1:100461046	G/A	cg24955406	chr1:100503596	HIAT1	0.75	4.88	0.4	3.2e-6	Carotid intima media thickness;
TGCT	cis	rs7523050	0.730	rs34182354	chr1:109416340	C/T	cg08274380	chr1:109419600	GPSM2	1.35	6.86	0.52	2.89e-10	Fat distribution (HIV);
TGCT	cis	rs28595532	0.920	rs115446044	chr4:119754635	T/C	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs78366141	0.536	rs80239864	chr4:89698183	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	1.26	5.46	0.44	2.54e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
TGCT	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.51	-4.82	-0.4	4.16e-6	Bipolar disorder;
TGCT	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg25660036	chr4:7070649	GRPEL1	-0.66	-5.82	-0.46	4.71e-8	Monocyte percentage of white cells;
TGCT	cis	rs2046867	0.908	rs6771413	chr3:72790308	G/A	cg25664220	chr3:72788482	NA	-0.54	-6.8	-0.52	3.96e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs916888	0.821	rs199505	chr17:44859410	A/G	cg17911788	chr17:44343683	NA	0.59	6.13	0.48	1.09e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg24531977	chr5:56204891	C5orf35	0.69	7.29	0.55	3.25e-11	Initial pursuit acceleration;
TGCT	cis	rs35306767	0.761	rs12773961	chr10:1013215	C/G	cg18964960	chr10:1102726	WDR37	0.7	4.91	0.4	2.84e-6	Eosinophil percentage of granulocytes;
TGCT	cis	rs748404	0.631	rs3809482	chr15:43661802	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	4.72	0.39	6.3e-6	Lung cancer;
TGCT	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg03709012	chr19:19516395	GATAD2A	0.67	5.75	0.46	6.45e-8	Tonsillectomy;
TGCT	cis	rs9682041	1.000	rs9682041	chr3:170091902	C/T	cg07589077	chr3:170072950	NA	0.3	4.54	0.38	1.3e-5	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs7772486	0.754	rs702319	chr6:146006117	T/C	cg13319975	chr6:146136371	FBXO30	0.52	4.68	0.39	7.31e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs12497850	0.931	rs6791542	chr3:48787219	A/G	cg07636037	chr3:49044803	WDR6	0.95	10.62	0.69	3.95e-19	Parkinson's disease;
TGCT	cis	rs8067545	0.967	rs4924801	chr17:19921070	T/C	cg13482628	chr17:19912719	NA	0.56	4.82	0.4	4.18e-6	Schizophrenia;
TGCT	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg07343612	chr16:622815	PIGQ	-0.42	-8.39	-0.6	9.08e-14	Height;
TGCT	cis	rs17253792	0.822	rs79024594	chr14:56092997	T/G	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs594074	0.951	rs559443	chr6:6558928	A/G	cg03251356	chr6:7151709	RREB1	-0.37	-4.85	-0.4	3.62e-6	Diabetic kidney disease;
TGCT	cis	rs7772486	0.686	rs6570701	chr6:145954090	A/G	cg23711669	chr6:146136114	FBXO30	0.85	9.48	0.65	2.33e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg17971929	chr21:40555470	PSMG1	0.98	9.61	0.65	1.14e-16	Cognitive function;
TGCT	cis	rs1577917	0.740	rs7775864	chr6:86247759	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.54	4.87	0.4	3.29e-6	Response to antipsychotic treatment;
TGCT	cis	rs9653442	0.511	rs6739695	chr2:100859622	A/G	cg07810366	chr2:100720526	AFF3	-0.4	-6.08	-0.48	1.35e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs11673344	0.503	rs1667370	chr19:37490220	A/T	cg08039142	chr19:36980659	ZNF566	0.56	5.24	0.43	6.67e-7	Obesity-related traits;
TGCT	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg18876405	chr7:65276391	NA	0.34	5.06	0.41	1.5e-6	Aortic root size;
TGCT	cis	rs7809950	1.000	rs2178497	chr7:107278901	T/C	cg23024343	chr7:107201750	COG5	0.34	5.3	0.43	5.01e-7	Coronary artery disease;
TGCT	cis	rs362272	0.505	rs10155132	chr4:3369500	A/G	cg18352616	chr4:3374830	RGS12	0.24	5.02	0.41	1.76e-6	Serum sulfate level;
TGCT	cis	rs10501293	0.746	rs1565252	chr11:43009119	A/C	cg03447554	chr11:43094025	NA	0.44	6.25	0.49	5.97e-9	Cognitive performance;
TGCT	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg05025164	chr4:1340916	KIAA1530	-0.75	-6.57	-0.51	1.23e-9	Longevity;
TGCT	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.67	-7.32	-0.55	2.74e-11	Blood metabolite levels;
TGCT	cis	rs2180341	0.920	rs1073931	chr6:127681762	A/T	cg27446573	chr6:127587934	RNF146	1.14	10.91	0.7	7.51e-20	Breast cancer;
TGCT	cis	rs6831352	0.918	rs13133633	chr4:100058697	C/G	cg12011299	chr4:100065546	ADH4	-0.4	-4.88	-0.4	3.26e-6	Alcohol dependence;
TGCT	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg13695892	chr22:41940480	POLR3H	0.89	8.48	0.61	5.62e-14	Vitiligo;
TGCT	cis	rs12681288	0.862	rs4735981	chr8:1018437	A/C	cg04851639	chr8:1020857	NA	-0.37	-6.77	-0.52	4.49e-10	Schizophrenia;
TGCT	cis	rs7804356	1.000	rs3801840	chr7:26832986	A/G	cg03456212	chr7:26904342	SKAP2	-0.63	-4.78	-0.39	4.84e-6	Type 1 diabetes;
TGCT	cis	rs10037670	0.530	rs59459154	chr5:153819672	G/A	cg21964928	chr5:153872958	NA	0.25	4.49	0.37	1.63e-5	Behavioural disinhibition (generation interaction);
TGCT	cis	rs7635838	0.892	rs9814907	chr3:11438645	G/A	cg00170343	chr3:11313890	ATG7	0.65	6.26	0.49	5.79e-9	HDL cholesterol;
TGCT	cis	rs9915657	0.660	rs12602039	chr17:70089384	A/G	cg06234051	chr17:70120541	SOX9	-0.25	-5.13	-0.42	1.1e-6	Thyroid hormone levels;
TGCT	cis	rs2153535	0.580	rs6926759	chr6:8456176	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs6815814	0.950	rs5743794	chr4:38832727	C/T	cg02016764	chr4:38805732	TLR1	-0.32	-4.91	-0.4	2.75e-6	Breast cancer;
TGCT	cis	rs853679	0.546	rs200949	chr6:27835435	A/G	cg10876282	chr6:28092338	ZSCAN16	0.75	4.45	0.37	1.88e-5	Depression;
TGCT	cis	rs2456568	0.775	rs1607404	chr11:93660449	C/G	cg16099599	chr11:93583650	C11orf90	-0.39	-4.57	-0.38	1.15e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs10779751	0.762	rs1074078	chr1:11326788	C/T	cg08854313	chr1:11322531	MTOR	-0.82	-8.61	-0.61	2.7e-14	Body mass index;
TGCT	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg18876405	chr7:65276391	NA	0.33	4.95	0.41	2.39e-6	Aortic root size;
TGCT	cis	rs3617	0.573	rs2336668	chr3:52919096	G/T	cg05573699	chr3:52720067	GNL3;PBRM1	0.5	4.92	0.4	2.69e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs10186029	0.676	rs10187830	chr2:213964796	C/G	cg08319019	chr2:214017104	IKZF2	0.62	5.76	0.46	6.13e-8	Systemic sclerosis;
TGCT	cis	rs12580194	0.593	rs7971053	chr12:55729947	A/C	cg10672482	chr12:55725839	OR6C3	-0.56	-4.89	-0.4	3.1e-6	Cancer;
TGCT	cis	rs909674	0.690	rs5750823	chr22:39829973	C/T	cg01416388	chr22:39784598	NA	-0.74	-6.78	-0.52	4.37e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs36051895	0.623	rs3780382	chr9:5232299	G/A	cg02405213	chr9:5042618	JAK2	-0.68	-7.9	-0.58	1.3e-12	Pediatric autoimmune diseases;
TGCT	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg04156016	chr5:1868137	NA	0.31	4.46	0.37	1.81e-5	Cardiovascular disease risk factors;
TGCT	cis	rs13256369	0.851	rs13249700	chr8:8563637	C/T	cg18904891	chr8:8559673	CLDN23	0.59	5.46	0.44	2.54e-7	Obesity-related traits;
TGCT	cis	rs244731	0.959	rs9313752	chr5:176645435	G/T	cg06060754	chr5:176797920	RGS14	-0.47	-6.4	-0.5	2.86e-9	Urate levels in lean individuals;
TGCT	cis	rs7104764	1.000	rs2293167	chr11:211644	A/G	cg18336825	chr11:236787	PSMD13;SIRT3	-1.02	-10.54	-0.69	6.26e-19	Menarche (age at onset);
TGCT	cis	rs9858542	0.537	rs34915642	chr3:49358646	G/A	cg00383909	chr3:49044727	WDR6	0.71	4.89	0.4	3.09e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs2729354	0.768	rs2581922	chr11:57265400	C/T	cg24343310	chr11:57249947	NA	0.28	4.67	0.39	7.56e-6	Blood protein levels;
TGCT	cis	rs9611565	0.625	rs12483991	chr22:41935285	A/G	cg17554472	chr22:41940697	POLR3H	-0.48	-5.37	-0.43	3.71e-7	Vitiligo;
TGCT	cis	rs12711979	1.000	rs6542655	chr2:3872434	T/C	cg17052675	chr2:3827356	NA	-0.32	-5.85	-0.46	4.12e-8	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs10875746	0.855	rs12310999	chr12:48447658	A/G	cg20731937	chr12:48336164	NA	0.62	4.95	0.41	2.36e-6	Longevity (90 years and older);
TGCT	cis	rs7104764	1.000	rs10902114	chr11:246234	A/G	cg18336825	chr11:236787	PSMD13;SIRT3	1.07	11.19	0.71	1.61e-20	Menarche (age at onset);
TGCT	cis	rs6748734	1.000	rs4675868	chr2:241828542	A/C	cg04034577	chr2:241836375	C2orf54	-0.4	-6.32	-0.49	4.22e-9	Urinary metabolites;
TGCT	cis	rs11250097	0.528	rs36043848	chr8:11309533	A/G	cg01383082	chr8:11323474	FAM167A	0.29	4.84	0.4	3.78e-6	Neuroticism;
TGCT	cis	rs6121246	0.909	rs6060633	chr20:30263317	G/T	cg18721089	chr20:30220636	NA	-0.42	-4.65	-0.39	8.2e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs10791097	0.694	rs11222370	chr11:130744767	T/G	cg12179176	chr11:130786555	SNX19	0.84	10.17	0.67	4.95e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs8016982	0.633	rs7141288	chr14:81710232	C/A	cg01989461	chr14:81687754	GTF2A1	0.79	7.79	0.57	2.26e-12	Schizophrenia;
TGCT	cis	rs112217694	1.000	rs61117475	chr4:104654578	C/A	cg24090629	chr4:104641072	TACR3	-1.0	-5.19	-0.42	8.44e-7	Menarche (age at onset);
TGCT	cis	rs9549367	0.713	rs3024757	chr13:113823186	G/T	cg00898013	chr13:113819073	PROZ	-0.52	-6.19	-0.49	7.89e-9	Platelet distribution width;
TGCT	cis	rs9291683	0.679	rs2241483	chr4:10099831	A/G	cg11266682	chr4:10021025	SLC2A9	-0.47	-5.45	-0.44	2.58e-7	Bone mineral density;
TGCT	cis	rs7095607	0.777	rs10762191	chr10:69920031	C/A	cg18986048	chr10:69913749	MYPN	0.41	4.48	0.37	1.66e-5	Lung function (FVC);
TGCT	cis	rs7144547	0.803	rs8008602	chr14:81890171	T/A	cg02996355	chr14:81879375	NA	-0.78	-8.39	-0.6	9.44e-14	Prudent dietary pattern;
TGCT	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg06618935	chr21:46677482	NA	-0.42	-5.21	-0.42	7.76e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs1552244	0.554	rs7638846	chr3:10048601	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.32	-4.71	-0.39	6.47e-6	Alzheimer's disease;
TGCT	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-4.93	-0.4	2.62e-6	Bipolar disorder;
TGCT	cis	rs9513593	1.000	rs2182954	chr13:99937082	A/G	cg21788972	chr13:99853209	UBAC2	0.54	4.55	0.38	1.28e-5	Psoriasis;
TGCT	cis	rs2766692	1.000	rs35788933	chr14:100743555	C/T	cg14866419	chr14:100704911	YY1	0.57	4.54	0.38	1.3e-5	Electroencephalographic traits in alcoholism;
TGCT	cis	rs10089	1.000	rs72794396	chr5:127501386	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.85	8.02	0.58	6.93e-13	Ileal carcinoids;
TGCT	cis	rs360798	0.532	rs1022110	chr2:63046039	T/G	cg17519650	chr2:63277830	OTX1	-0.64	-5.5	-0.44	2.07e-7	Coronary artery disease;
TGCT	cis	rs10256972	0.669	rs10229964	chr7:1051776	A/G	cg00431813	chr7:1051703	C7orf50	-0.26	-5.59	-0.45	1.35e-7	Longevity;Endometriosis;
TGCT	cis	rs7209700	1.000	rs7209700	chr17:45351118	A/G	cg21624342	chr17:45890973	OSBPL7	0.17	4.77	0.39	5.14e-6	IgG glycosylation;
TGCT	cis	rs6882046	0.513	rs185291	chr5:88006764	T/C	cg24804195	chr5:87968844	LOC645323	-0.61	-6.15	-0.48	9.97e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg13866156	chr1:1669148	SLC35E2	-0.23	-5.52	-0.44	1.9e-7	Body mass index;
TGCT	cis	rs910316	0.523	rs4026175	chr14:75502240	C/A	cg08847533	chr14:75593920	NEK9	0.72	6.82	0.52	3.54e-10	Height;
TGCT	cis	rs9468199	0.510	rs72847322	chr6:27740054	C/T	cg08851530	chr6:28072375	NA	1.54	7.3	0.55	3.1e-11	Parkinson's disease;
TGCT	cis	rs17270561	1.000	rs12200962	chr6:25828986	T/C	cg17042849	chr6:26104293	HIST1H4C	-0.91	-6.17	-0.48	9.01e-9	Iron status biomarkers;
TGCT	cis	rs35306767	0.855	rs11253468	chr10:903261	G/A	cg20503657	chr10:835505	NA	0.75	10.41	0.68	1.3e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs8180040	0.654	rs6773521	chr3:47234419	A/G	cg27129171	chr3:47204927	SETD2	-0.7	-8.35	-0.6	1.13e-13	Colorectal cancer;
TGCT	cis	rs2688608	0.967	rs1815076	chr10:75659886	C/T	cg04320760	chr10:75533139	FUT11	-0.3	-4.57	-0.38	1.18e-5	Inflammatory bowel disease;
TGCT	cis	rs2228479	0.850	rs62056061	chr16:89901767	G/A	cg06558623	chr16:89946397	TCF25	0.55	4.86	0.4	3.55e-6	Skin colour saturation;
TGCT	cis	rs7917772	0.582	rs4917973	chr10:104333700	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	5.36	0.43	3.84e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2836950	0.545	rs2836956	chr21:40623018	C/G	cg11644478	chr21:40555479	PSMG1	0.52	4.84	0.4	3.77e-6	Menarche (age at onset);
TGCT	cis	rs6882046	0.513	rs194225	chr5:88001186	A/G	cg24804195	chr5:87968844	LOC645323	-0.59	-5.71	-0.46	7.88e-8	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs2228479	0.850	rs117675822	chr16:89919081	C/A	cg06558623	chr16:89946397	TCF25	0.55	4.86	0.4	3.55e-6	Skin colour saturation;
TGCT	cis	rs1215050	0.765	rs687795	chr4:98754912	C/G	cg17366294	chr4:99064904	C4orf37	0.52	5.61	0.45	1.27e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9916302	0.904	rs9944411	chr17:37483599	T/C	cg15445000	chr17:37608096	MED1	-0.35	-5.05	-0.41	1.53e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs4654899	1.000	rs6689819	chr1:21472395	A/T	cg01072550	chr1:21505969	NA	-0.5	-8.07	-0.59	5.13e-13	Superior frontal gyrus grey matter volume;
TGCT	cis	rs6840360	0.554	rs10222838	chr4:152690099	T/C	cg17479576	chr4:152424074	FAM160A1	-0.52	-5.2	-0.42	8.05e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs11031096	0.683	rs55898672	chr11:4189284	G/C	cg18678763	chr11:4115507	RRM1	-0.46	-6.03	-0.48	1.78e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs7017914	0.905	rs3110242	chr8:71932967	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-4.97	-0.41	2.16e-6	Bone mineral density;
TGCT	cis	rs6969780	0.630	rs3735530	chr7:27189982	C/T	cg04317399	chr7:27170313	HOXA4	-0.44	-4.9	-0.4	2.94e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs4148883	0.651	rs10020052	chr4:100086331	C/G	cg12011299	chr4:100065546	ADH4	0.39	5.85	0.47	4.03e-8	Alcohol dependence;
TGCT	cis	rs7267979	1.000	rs2500432	chr20:25290512	A/C	cg16686733	chr20:25566563	NINL	0.6	6.15	0.48	9.59e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg08045932	chr20:61659980	NA	0.48	9.28	0.64	7.07e-16	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs826838	1.000	rs1095575	chr12:39110284	C/G	cg13010199	chr12:38710504	ALG10B	-0.6	-4.85	-0.4	3.56e-6	Heart rate;
TGCT	trans	rs804280	0.542	rs34117651	chr8:11791617	G/C	cg15556689	chr8:8085844	FLJ10661	0.75	7.26	0.55	3.66e-11	Myopia (pathological);
TGCT	cis	rs12765878	0.812	rs2475214	chr10:105660986	T/C	cg11005552	chr10:105648138	OBFC1	-0.44	-7.29	-0.55	3.12e-11	Coronary artery disease;
TGCT	cis	rs6088590	0.965	rs910869	chr20:33292777	C/T	cg06115741	chr20:33292138	TP53INP2	0.67	5.77	0.46	5.93e-8	Coronary artery disease;
TGCT	cis	rs896854	0.738	rs1713669	chr8:95958637	C/G	cg23172400	chr8:95962367	TP53INP1	-0.36	-5.79	-0.46	5.33e-8	Type 2 diabetes;
TGCT	cis	rs6141769	0.542	rs6057625	chr20:31304994	G/A	cg13636640	chr20:31349939	DNMT3B	-0.51	-4.48	-0.37	1.68e-5	Subjective well-being;
TGCT	cis	rs9467773	0.583	rs2498380	chr6:26643996	C/G	cg11502198	chr6:26597334	ABT1	-0.53	-4.93	-0.4	2.6e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7178424	0.711	rs4283171	chr15:62172384	G/T	cg00456672	chr15:62358751	C2CD4A	-0.31	-4.72	-0.39	6.37e-6	Height;
TGCT	cis	rs2204008	0.558	rs66545149	chr12:38204694	A/G	cg26384229	chr12:38710491	ALG10B	0.78	6.56	0.51	1.32e-9	Bladder cancer;
TGCT	trans	rs4083482	1.000	rs16927393	chr11:35375388	A/G	cg12303247	chr1:155853542	SYT11	0.7	6.63	0.51	9.21e-10	Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid);
TGCT	cis	rs4711336	1.000	rs2296741	chr6:33659557	C/T	cg14003231	chr6:33640908	ITPR3	0.29	4.7	0.39	6.79e-6	Height;
TGCT	cis	rs1055129	0.655	rs7216615	chr17:73833910	T/C	cg08125733	chr17:73851984	WBP2	0.52	4.68	0.39	7.51e-6	White matter hyperintensity burden;
TGCT	cis	rs11190604	1.000	rs4919471	chr10:102299239	A/G	cg23241863	chr10:102295624	HIF1AN	0.73	4.95	0.41	2.35e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7647973	0.516	rs12490393	chr3:49196132	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.54	-5.2	-0.42	7.97e-7	Menarche (age at onset);
TGCT	cis	rs7772486	0.686	rs6570705	chr6:145961201	C/T	cg13319975	chr6:146136371	FBXO30	-0.5	-4.49	-0.37	1.63e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7824557	0.507	rs7010590	chr8:11062882	C/T	cg21775007	chr8:11205619	TDH	0.52	5.15	0.42	1.01e-6	Retinal vascular caliber;
TGCT	cis	rs11822910	0.911	rs2250887	chr11:57202184	G/A	cg00522883	chr11:57194120	SLC43A3	0.32	4.58	0.38	1.1e-5	Platelet distribution width;
TGCT	cis	rs73036520	0.846	rs17356664	chr19:45740771	C/T	cg20198684	chr19:45742032	NA	0.28	5.32	0.43	4.78e-7	Monocyte percentage of white cells;
TGCT	cis	rs1488864	1.000	rs10769689	chr11:6347116	A/T	cg12755421	chr11:6342214	PRKCDBP	-0.56	-4.57	-0.38	1.18e-5	Smooth-surface caries;
TGCT	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	16.03	0.82	5.32e-32	Prudent dietary pattern;
TGCT	cis	rs9948	0.655	rs57582887	chr2:97406354	A/C	cg01990225	chr2:97406019	LMAN2L	-1.02	-5.19	-0.42	8.43e-7	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs9325144	0.647	rs11168104	chr12:38857616	G/T	cg26384229	chr12:38710491	ALG10B	-0.6	-5.49	-0.44	2.2e-7	Morning vs. evening chronotype;
TGCT	cis	rs9291683	0.507	rs3775940	chr4:10025163	A/T	cg00071950	chr4:10020882	SLC2A9	0.62	7.37	0.55	2.1e-11	Bone mineral density;
TGCT	cis	rs6938	0.618	rs12912839	chr15:75221245	C/T	cg10253484	chr15:75165896	SCAMP2	-0.57	-5.05	-0.41	1.53e-6	Breast cancer;
TGCT	cis	rs1990950	0.605	rs4704863	chr5:156879727	C/T	cg25387487	chr5:157003181	ADAM19	0.39	5.95	0.47	2.58e-8	Lung function (FEV1/FVC);
TGCT	cis	rs12220777	1.000	rs11201660	chr10:81854531	A/G	cg03267442	chr10:82210566	NA	-0.38	-4.68	-0.39	7.54e-6	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs7223966	1.000	rs11079511	chr17:61858537	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	4.62	0.38	9.63e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg13531842	chr10:38383804	ZNF37A	-0.38	-4.52	-0.38	1.41e-5	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg18538332	chr22:24372958	LOC391322	-0.98	-12.03	-0.73	1.42e-22	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7698623	0.850	rs6532019	chr4:88768672	C/T	cg27387453	chr4:88533842	DSPP	-0.61	-4.64	-0.38	8.7e-6	Cardiovascular disease risk factors;
TGCT	cis	rs3733585	0.781	rs13103879	chr4:9972879	T/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-8.03	-0.58	6.51e-13	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs3087591	0.639	rs2342052	chr17:29721011	T/C	cg24425628	chr17:29625626	OMG;NF1	0.4	5.87	0.47	3.67e-8	Hip circumference;
TGCT	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs881375	0.967	rs7034492	chr9:123687211	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	5.12	0.42	1.14e-6	Rheumatoid arthritis;
TGCT	cis	rs739401	0.527	rs418832	chr11:3072236	C/T	cg05729581	chr11:3078854	CARS	-0.57	-5.31	-0.43	4.86e-7	Longevity;
TGCT	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg12963246	chr6:28129442	ZNF389	0.51	5.02	0.41	1.73e-6	Depression;
TGCT	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg00149659	chr3:10157352	C3orf10	0.91	5.89	0.47	3.32e-8	Alzheimer's disease;
TGCT	cis	rs12039431	0.666	rs177347	chr1:37964322	G/C	cg17933807	chr1:38061675	GNL2	-0.76	-7.21	-0.54	4.81e-11	Epithelial ovarian cancer;
TGCT	cis	rs377070	0.966	rs368931	chr4:123631597	G/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.49	5.42	0.44	3.03e-7	Mosquito bite size;
TGCT	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg11644478	chr21:40555479	PSMG1	-0.61	-5.74	-0.46	6.75e-8	Cognitive function;
TGCT	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs1371867	0.775	rs6511	chr8:101252680	T/C	cg06002616	chr8:101225028	SPAG1	0.55	6.34	0.49	3.87e-9	Atrioventricular conduction;
TGCT	cis	rs2652822	0.550	rs12593078	chr15:63517347	A/G	cg12855773	chr15:63363890	TPM1	-0.17	-5.11	-0.42	1.16e-6	Metabolic traits;
TGCT	cis	rs7267979	0.866	rs437635	chr20:25456888	A/G	cg14121845	chr20:25566513	NINL	0.49	5.36	0.43	3.83e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9457247	0.534	rs9356551	chr6:167400345	T/C	cg23791538	chr6:167370224	RNASET2	0.61	6.02	0.48	1.85e-8	Crohn's disease;
TGCT	cis	rs362272	0.524	rs2749781	chr4:3346617	T/C	cg22655196	chr4:3374909	RGS12	0.26	5.21	0.42	7.55e-7	Serum sulfate level;
TGCT	cis	rs68170813	0.559	rs2395880	chr7:107074264	A/G	cg02696742	chr7:106810147	HBP1	-0.71	-5.9	-0.47	3.17e-8	Coronary artery disease;
TGCT	cis	rs7772486	0.754	rs6937661	chr6:146113299	T/C	cg23711669	chr6:146136114	FBXO30	-0.93	-10.49	-0.69	8.22e-19	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7267979	1.000	rs6050561	chr20:25334855	C/T	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1153858	0.621	rs2687512	chr15:45581495	T/C	cg26924012	chr15:45694286	SPATA5L1	-1.0	-10.84	-0.7	1.12e-19	Homoarginine levels;
TGCT	cis	rs4242434	0.819	rs6558167	chr8:22473850	T/C	cg03733263	chr8:22462867	KIAA1967	1.07	16.48	0.83	4.9e-33	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs617219	0.698	rs7445125	chr5:78507417	A/G	cg09550809	chr5:78407562	BHMT	0.41	5.7	0.46	8.14e-8	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs6430585	0.528	rs309161	chr2:136688749	A/G	cg07169764	chr2:136633963	MCM6	-1.19	-11.63	-0.72	1.33e-21	Corneal structure;
TGCT	cis	rs5167	0.566	rs60876330	chr19:45488133	C/T	cg13119609	chr19:45449297	APOC2	0.24	4.64	0.38	8.62e-6	Blood protein levels;
TGCT	cis	rs12220238	1.000	rs11000905	chr10:75925532	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.06	0.54	1.05e-10	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs13315871	1.000	rs9844128	chr3:58391127	C/T	cg12435725	chr3:58293450	RPP14	-0.43	-4.47	-0.37	1.71e-5	Cholesterol, total;
TGCT	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg26338869	chr17:61819248	STRADA	-0.57	-5.16	-0.42	9.43e-7	Prudent dietary pattern;
TGCT	cis	rs295140	0.647	rs295132	chr2:201233502	A/G	cg04283868	chr2:201171347	SPATS2L	0.53	5.16	0.42	9.63e-7	QT interval;
TGCT	cis	rs9916302	0.652	rs9903269	chr17:37742383	A/T	cg07936489	chr17:37558343	FBXL20	-0.7	-5.49	-0.44	2.21e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs79057730	0.599	rs79272827	chr7:807015	C/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.75	5.67	0.45	9.59e-8	Initial pursuit acceleration;
TGCT	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg23302884	chr18:44338147	ST8SIA5	-0.4	-4.58	-0.38	1.11e-5	Personality dimensions;
TGCT	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg07507251	chr3:52567010	NT5DC2	0.47	6.75	0.52	5.11e-10	Bipolar disorder;
TGCT	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	8.39	0.6	9.03e-14	Platelet count;
TGCT	cis	rs7178572	0.524	rs11853287	chr15:77399371	A/G	cg22256960	chr15:77711686	NA	-0.85	-8.71	-0.62	1.61e-14	Type 2 diabetes;
TGCT	cis	rs6964587	1.000	rs1859114	chr7:91682848	T/C	cg22709100	chr7:91322751	NA	0.28	4.56	0.38	1.19e-5	Breast cancer;
TGCT	cis	rs34638657	0.536	rs2967327	chr16:82188657	C/T	cg09439754	chr16:82129088	HSD17B2	-0.22	-4.8	-0.4	4.55e-6	Lung adenocarcinoma;
TGCT	cis	rs1691799	0.836	rs1184552	chr12:66756215	A/G	cg16791601	chr12:66731901	HELB	-0.29	-6.16	-0.48	9.12e-9	White blood cell count (basophil);
TGCT	cis	rs4642101	0.662	rs3901664	chr3:12824660	T/C	cg05775895	chr3:12838266	CAND2	0.92	11.15	0.71	2.02e-20	QRS complex (12-leadsum);
TGCT	trans	rs4650994	0.525	rs2761463	chr1:178557137	T/C	cg05059571	chr16:84539110	KIAA1609	0.52	10.34	0.68	1.86e-18	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg08048268	chr3:133502702	NA	0.65	9.81	0.66	3.64e-17	Iron status biomarkers;
TGCT	cis	rs8031584	0.678	rs36047941	chr15:31159235	A/G	cg08109568	chr15:31115862	NA	-0.38	-5.03	-0.41	1.67e-6	Huntington's disease progression;
TGCT	cis	rs12477438	0.734	rs4851184	chr2:99666434	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-8.52	-0.61	4.5e-14	Chronic sinus infection;
TGCT	cis	rs669446	0.561	rs531459	chr1:44090675	T/C	cg12908607	chr1:44402522	ARTN	-0.54	-5.68	-0.45	8.9e-8	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs4906332	1.000	rs34479426	chr14:103881823	G/C	cg26031613	chr14:104095156	KLC1	-0.51	-4.63	-0.38	9.17e-6	Coronary artery disease;
TGCT	cis	rs35934224	0.783	rs7284106	chr22:19857549	T/C	cg11182965	chr22:19864308	TXNRD2	-0.36	-4.95	-0.41	2.33e-6	Glaucoma (primary open-angle);
TGCT	cis	rs765787	0.530	rs28897155	chr15:45533974	T/C	cg24006582	chr15:45444508	DUOX1	-0.25	-5.53	-0.44	1.82e-7	Uric acid levels;
TGCT	cis	rs7666738	0.753	rs4699604	chr4:99056353	T/C	cg17366294	chr4:99064904	C4orf37	0.72	7.39	0.55	1.9e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3733585	0.699	rs6449171	chr4:9965998	C/T	cg11266682	chr4:10021025	SLC2A9	0.56	7.45	0.56	1.37e-11	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs67460515	1.000	rs67460515	chr3:161068566	T/C	cg03342759	chr3:160939853	NMD3	-0.52	-5.38	-0.44	3.56e-7	Parkinson's disease;
TGCT	cis	rs9814567	1.000	rs1138273	chr3:134261437	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.96	-9.11	-0.63	1.79e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs137603	0.644	rs470082	chr22:39715140	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	-0.66	-7.1	-0.54	8.7e-11	Primary biliary cholangitis;
TGCT	cis	rs76878669	0.561	rs7125752	chr11:66162419	C/T	cg18002602	chr11:66138449	SLC29A2	-0.54	-6.62	-0.51	9.59e-10	Educational attainment (years of education);
TGCT	cis	rs7726839	0.540	rs57306627	chr5:597643	T/C	cg09021430	chr5:549028	NA	-0.43	-5.77	-0.46	5.99e-8	Obesity-related traits;
TGCT	cis	rs1568079	0.530	rs7070259	chr10:125243654	A/G	cg04278168	chr10:124578263	NA	-0.45	-4.64	-0.38	8.9e-6	Body mass index;
TGCT	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-5.1	-0.42	1.23e-6	Electroencephalogram traits;
TGCT	cis	rs1048238	0.506	rs848209	chr1:16256007	T/C	cg21385522	chr1:16154831	NA	-0.58	-6.39	-0.5	3.09e-9	Systolic blood pressure;
TGCT	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg11062466	chr8:58055876	NA	0.38	4.62	0.38	9.5e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs916888	0.647	rs199523	chr17:44848517	C/A	cg16520312	chr17:43971471	MAPT;LOC100128977	0.48	4.67	0.39	7.86e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs6740322	0.748	rs6544636	chr2:43487486	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.4	-5.81	-0.46	4.91e-8	Coronary artery disease;
TGCT	cis	rs1865760	0.515	rs2003208	chr6:25940719	G/C	cg03517284	chr6:25882590	NA	-0.48	-4.78	-0.39	4.78e-6	Height;
TGCT	cis	rs4268898	0.662	rs55661701	chr2:24400769	A/C	cg02683114	chr2:24398427	C2orf84	-0.23	-4.56	-0.38	1.19e-5	Asthma;
TGCT	cis	rs72387598	1	rs72387598	chr1:45922977	CAT/C	cg05343316	chr1:45956843	TESK2	0.86	6.87	0.53	2.7e-10	Platelet distribution width;
TGCT	cis	rs903263	0.965	rs12760594	chr1:84596910	C/T	cg09664975	chr1:84543551	PRKACB	0.5	4.74	0.39	5.73e-6	Breast cancer (male);
TGCT	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg06418219	chr1:154948305	SHC1;CKS1B	-0.64	-6.58	-0.51	1.21e-9	Prostate cancer;
TGCT	cis	rs4975616	0.869	rs401681	chr5:1322087	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.28	-6.64	-0.51	8.68e-10	Lung cancer;
TGCT	cis	rs709400	0.663	rs17617941	chr14:103953032	T/C	cg12935359	chr14:103987150	CKB	-0.38	-5.78	-0.46	5.69e-8	Body mass index;
TGCT	cis	rs2070997	0.517	rs9762	chr9:133762553	A/G	cg01000188	chr9:133769184	QRFP	0.28	4.63	0.38	8.98e-6	Response to amphetamines;
TGCT	cis	rs245880	0.740	rs245902	chr7:29194919	T/A	cg17163760	chr7:29186267	CPVL	-0.41	-5.08	-0.42	1.35e-6	Warfarin maintenance dose;
TGCT	cis	rs28595532	0.920	rs116246794	chr4:119732491	C/T	cg21605333	chr4:119757512	SEC24D	1.66	8.33	0.6	1.28e-13	Cannabis dependence symptom count;
TGCT	cis	rs9972944	0.756	rs7215462	chr17:63770498	T/C	cg07283582	chr17:63770753	CCDC46	-0.26	-5.27	-0.43	5.91e-7	Total body bone mineral density;
TGCT	cis	rs1008375	0.931	rs10939734	chr4:17570709	C/T	cg18681998	chr4:17616180	MED28	0.94	9.51	0.65	1.93e-16	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	trans	rs7819412	0.745	rs6601569	chr8:11073578	C/T	cg15556689	chr8:8085844	FLJ10661	-0.76	-7.35	-0.55	2.28e-11	Triglycerides;
TGCT	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg13395646	chr4:1353034	KIAA1530	-0.39	-5.11	-0.42	1.19e-6	Longevity;
TGCT	cis	rs854765	0.663	rs3183702	chr17:17747289	A/G	cg09796270	chr17:17721594	SREBF1	-0.24	-4.52	-0.38	1.43e-5	Total body bone mineral density;
TGCT	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg22963979	chr7:1858916	MAD1L1	-0.43	-6.78	-0.52	4.36e-10	Bipolar disorder and schizophrenia;
TGCT	cis	rs9653442	0.609	rs2576678	chr2:100704810	T/C	cg07810366	chr2:100720526	AFF3	-0.43	-7.29	-0.55	3.26e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs7523273	0.565	rs34355011	chr1:207887322	T/G	cg22525895	chr1:207977042	MIR29B2	0.35	5.7	0.46	8.31e-8	Schizophrenia;
TGCT	cis	rs9814567	0.762	rs13079012	chr3:134247706	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.83	6.48	0.5	1.99e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs6088580	0.634	rs6088475	chr20:32964987	T/C	cg06115741	chr20:33292138	TP53INP2	-0.53	-4.67	-0.39	7.83e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs9868809	0.772	rs9883469	chr3:48719637	G/A	cg15315015	chr3:49131774	QRICH1	0.98	4.65	0.38	8.53e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs10193935	0.892	rs7574609	chr2:42388468	C/A	cg27598129	chr2:42591480	NA	-0.39	-5.14	-0.42	1.05e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7666738	0.830	rs10029849	chr4:99059362	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.45	0.56	1.4e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4975616	0.686	rs37011	chr5:1348798	A/T	cg07493874	chr5:1342172	CLPTM1L	-0.26	-6.04	-0.48	1.65e-8	Lung cancer;
TGCT	cis	rs909002	1.000	rs2292993	chr1:32140733	C/T	cg11573219	chr1:32083031	HCRTR1	-0.4	-4.87	-0.4	3.32e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9303401	0.614	rs35308719	chr17:57163501	C/T	cg25039879	chr17:56429692	SUPT4H1	0.55	4.9	0.4	2.93e-6	Cognitive test performance;
TGCT	cis	rs6570726	0.905	rs419575	chr6:145840174	A/G	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg13866156	chr1:1669148	SLC35E2	-0.22	-5.23	-0.42	7.05e-7	Body mass index;
TGCT	cis	rs2013441	0.965	rs8071665	chr17:20209943	T/C	cg18979559	chr17:20280153	CCDC144C	-0.49	-4.99	-0.41	1.97e-6	Obesity-related traits;
TGCT	cis	rs2066819	1.000	rs11171803	chr12:56718422	T/C	cg26714650	chr12:56694279	CS	-1.36	-6.06	-0.48	1.54e-8	Psoriasis vulgaris;
TGCT	cis	rs2072499	0.778	rs41265025	chr1:156163906	C/T	cg25208724	chr1:156163844	SLC25A44	1.01	9.29	0.64	6.58e-16	Testicular germ cell tumor;
TGCT	cis	rs1008375	0.897	rs2315554	chr4:17660407	T/C	cg10189774	chr4:17578691	LAP3	0.53	4.61	0.38	1e-5	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2066819	1.000	rs76430365	chr12:56699993	A/C	cg26714650	chr12:56694279	CS	-1.36	-6.06	-0.48	1.54e-8	Psoriasis vulgaris;
TGCT	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg04025307	chr7:1156635	C7orf50	0.22	5.35	0.43	4.09e-7	Longevity;Endometriosis;
TGCT	cis	rs28595532	0.920	rs115850161	chr4:119732447	T/C	cg21605333	chr4:119757512	SEC24D	1.66	8.33	0.6	1.28e-13	Cannabis dependence symptom count;
TGCT	cis	rs748404	0.660	rs2439845	chr15:43722610	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	4.75	0.39	5.51e-6	Lung cancer;
TGCT	cis	rs7599312	0.586	rs7565257	chr2:213388276	G/A	cg16329650	chr2:213403929	ERBB4	0.55	4.62	0.38	9.45e-6	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs10789491	0.951	rs35050319	chr1:47103886	C/A	cg15501359	chr1:47185051	KIAA0494	-0.85	-8.33	-0.6	1.26e-13	Response to hepatitis C treatment;
TGCT	cis	rs6570726	0.577	rs9497315	chr6:145791967	C/T	cg13319975	chr6:146136371	FBXO30	0.64	5.69	0.46	8.55e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10791097	0.592	rs4936122	chr11:130734264	A/C	cg05962950	chr11:130786565	SNX19	0.9	11.39	0.72	5.2e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg15556689	chr8:8085844	FLJ10661	-0.69	-6.22	-0.49	6.86e-9	Mood instability;
TGCT	cis	rs7914558	0.933	rs12763665	chr10:104653717	G/A	cg04362960	chr10:104952993	NT5C2	0.58	5.16	0.42	9.65e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs4689388	0.890	rs4689397	chr4:6299387	G/A	cg25554036	chr4:6271136	WFS1	0.56	7.94	0.58	1.06e-12	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs7824557	0.767	rs7003241	chr8:11169075	A/G	cg21775007	chr8:11205619	TDH	0.58	5.46	0.44	2.46e-7	Retinal vascular caliber;
TGCT	cis	rs3803170	0.513	rs10849946	chr12:111830485	C/G	cg10833066	chr12:111807467	FAM109A	-0.34	-5.36	-0.43	3.97e-7	Mean corpuscular hemoglobin;
TGCT	cis	rs73001065	0.901	rs3794991	chr19:19610596	C/T	cg03709012	chr19:19516395	GATAD2A	1.07	5.24	0.43	6.67e-7	LDL cholesterol;
TGCT	cis	rs1008375	1.000	rs6811887	chr4:17640858	C/T	cg16339924	chr4:17578868	LAP3	0.64	5.47	0.44	2.42e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1941023	0.503	rs4939349	chr11:60135880	G/A	cg08716584	chr11:60157161	MS4A7	-0.31	-4.56	-0.38	1.21e-5	Congenital heart disease (maternal effect);
TGCT	cis	rs7973719	0.833	rs11044332	chr12:7358768	C/A	cg07052231	chr12:7363540	PEX5	0.37	5.74	0.46	6.97e-8	IgG glycosylation;
TGCT	cis	rs6459788	0.527	rs6980250	chr7:157228710	C/T	cg06271696	chr7:157225062	NA	-0.35	-6.51	-0.5	1.65e-9	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	trans	rs1814175	0.765	rs1794141	chr11:49914135	G/C	cg15704280	chr7:45808275	SEPT13	-0.71	-8.0	-0.58	7.45e-13	Height;
TGCT	cis	rs1532993	0.518	rs2174937	chr4:98552585	G/A	cg05340658	chr4:99064831	C4orf37	-0.42	-5.05	-0.41	1.57e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg23982607	chr1:1823379	GNB1	-0.55	-8.57	-0.61	3.52e-14	Body mass index;
TGCT	cis	rs6840360	0.615	rs7669465	chr4:152609289	C/T	cg22705602	chr4:152727874	NA	-0.31	-5.07	-0.41	1.41e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10992471	0.580	rs7030920	chr9:95122952	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.6	-5.5	-0.44	2.09e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs1045714	0.895	rs4721867	chr7:2643352	A/G	cg17215154	chr7:2644645	IQCE	-0.27	-4.76	-0.39	5.19e-6	Urate levels in lean individuals;
TGCT	cis	rs250677	0.617	rs166106	chr5:148447061	T/C	cg18129178	chr5:148520854	ABLIM3	-0.42	-5.74	-0.46	6.77e-8	Breast cancer;
TGCT	cis	rs208520	0.874	rs208491	chr6:66928459	C/G	cg07460842	chr6:66804631	NA	-0.94	-9.3	-0.64	6.32e-16	Exhaled nitric oxide output;
TGCT	cis	rs2948294	0.588	rs7011221	chr8:8114246	C/T	cg15462221	chr8:8086144	FLJ10661	-0.6	-5.11	-0.42	1.2e-6	Red cell distribution width;
TGCT	cis	rs13064411	0.501	rs13092925	chr3:113209375	C/G	cg18753928	chr3:113234510	CCDC52	-0.54	-4.58	-0.38	1.12e-5	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs524023	0.957	rs893007	chr11:64365668	C/A	cg07733098	chr11:64478343	NRXN2	0.32	4.83	0.4	3.9e-6	Urate levels in obese individuals;
TGCT	cis	rs12532878	0.652	rs11768465	chr7:100198386	C/T	cg19543017	chr7:100164136	AGFG2	-0.32	-4.71	-0.39	6.4e-6	Mean corpuscular hemoglobin;
TGCT	trans	rs1814175	0.817	rs1851860	chr11:49861310	A/C	cg15704280	chr7:45808275	SEPT13	-0.7	-8.0	-0.58	7.59e-13	Height;
TGCT	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg04234412	chr22:24373322	LOC391322	0.92	10.83	0.7	1.2e-19	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6163	0.588	rs12763284	chr10:104508202	C/T	cg22532475	chr10:104410764	TRIM8	-0.17	-4.54	-0.38	1.32e-5	Waist circumference;Hip circumference;
TGCT	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg10047753	chr17:41438598	NA	0.77	7.43	0.56	1.52e-11	Menopause (age at onset);
TGCT	cis	rs9611519	0.507	rs12484525	chr22:41443877	G/C	cg13695892	chr22:41940480	POLR3H	-0.58	-5.57	-0.45	1.52e-7	Neuroticism;
TGCT	cis	rs112591243	0.685	rs117443865	chr21:47959731	C/G	cg10657630	chr21:48055338	PRMT2	1.06	5.21	0.42	7.69e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg21226059	chr5:178986404	RUFY1	0.62	7.13	0.54	7.36e-11	Lung cancer;
TGCT	cis	rs2153535	0.580	rs9392220	chr6:8457946	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs524281	0.648	rs10896089	chr11:65936292	A/G	cg00563793	chr11:65837595	PACS1	0.57	4.97	0.41	2.13e-6	Electroencephalogram traits;
TGCT	cis	rs6748734	1.000	rs6751693	chr2:241837332	T/C	cg04034577	chr2:241836375	C2orf54	-0.4	-6.3	-0.49	4.63e-9	Urinary metabolites;
TGCT	cis	rs35146811	0.660	rs3779045	chr7:99779259	T/C	cg13334819	chr7:99746414	C7orf59	-0.74	-6.31	-0.49	4.4e-9	Coronary artery disease;
TGCT	cis	rs57994353	0.897	rs3812594	chr9:139368953	G/A	cg13741927	chr9:139327495	INPP5E	-0.24	-5.55	-0.45	1.66e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs13256369	0.951	rs13260947	chr8:8565883	A/G	cg17143192	chr8:8559678	CLDN23	0.58	5.55	0.45	1.64e-7	Obesity-related traits;
TGCT	cis	rs2832191	0.632	rs1984011	chr21:30337831	T/A	cg08807101	chr21:30365312	RNF160	-0.63	-5.72	-0.46	7.47e-8	Dental caries;
TGCT	cis	rs7584330	0.784	rs1463795	chr2:238412392	C/G	cg14458575	chr2:238380390	NA	-0.45	-6.77	-0.52	4.52e-10	Prostate cancer;
TGCT	cis	rs10207060	0.500	rs4365487	chr2:240706803	T/C	cg15726768	chr2:241314588	NA	-0.32	-4.49	-0.37	1.63e-5	Obesity-related traits;
TGCT	cis	rs7772486	0.875	rs9322048	chr6:146400439	A/G	cg23711669	chr6:146136114	FBXO30	0.86	9.3	0.64	6.2e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs8077889	0.917	rs4793038	chr17:41916761	A/T	cg26893861	chr17:41843967	DUSP3	1.06	12.21	0.74	5.35e-23	Triglycerides;
TGCT	cis	rs7772486	0.790	rs2247666	chr6:146220409	C/A	cg05347473	chr6:146136440	FBXO30	0.53	5.08	0.42	1.35e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs35306767	0.859	rs11817793	chr10:878895	C/T	cg20503657	chr10:835505	NA	0.72	10.36	0.68	1.73e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg27425262	chr2:113953981	PSD4;LOC440839	-0.52	-8.2	-0.59	2.56e-13	Lymphocyte counts;
TGCT	cis	rs12908161	0.853	rs12912342	chr15:85248216	T/C	cg11189052	chr15:85197271	WDR73	0.68	6.43	0.5	2.55e-9	Schizophrenia;
TGCT	cis	rs734999	0.588	rs4648653	chr1:2535895	C/T	cg18854424	chr1:2615690	NA	0.43	4.91	0.4	2.77e-6	Ulcerative colitis;
TGCT	cis	rs9677476	0.657	rs11897387	chr2:232122576	T/C	cg07929768	chr2:232055508	NA	0.32	5.08	0.41	1.38e-6	Food antigen IgG levels;
TGCT	cis	rs7086627	0.515	rs1870147	chr10:82212541	A/T	cg01528321	chr10:82214614	TSPAN14	0.67	6.36	0.5	3.61e-9	Post bronchodilator FEV1;
TGCT	cis	rs3796352	1.000	rs11713290	chr3:52971579	G/A	cg07884673	chr3:53033167	SFMBT1	0.6	5.53	0.44	1.82e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	trans	rs1973993	0.567	rs2800431	chr1:97000998	C/T	cg10631902	chr5:14652156	NA	0.37	9.49	0.65	2.22e-16	Weight;
TGCT	cis	rs6733011	0.628	rs6713991	chr2:99464384	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.48	-4.78	-0.39	4.78e-6	Bipolar disorder;
TGCT	cis	rs11785400	0.731	rs9720504	chr8:143725502	T/C	cg10596483	chr8:143751796	JRK	0.53	5.3	0.43	5.12e-7	Schizophrenia;
TGCT	cis	rs765787	0.530	rs2554455	chr15:45521304	T/C	cg24006582	chr15:45444508	DUOX1	-0.25	-5.38	-0.43	3.63e-7	Uric acid levels;
TGCT	cis	rs4455778	0.536	rs38770	chr7:48940586	A/G	cg26309511	chr7:48887640	NA	0.46	5.51	0.44	1.98e-7	Lung cancer in never smokers;
TGCT	cis	rs858239	0.539	rs2141305	chr7:23191899	T/C	cg05602783	chr7:23145260	KLHL7	-0.63	-4.98	-0.41	2.09e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs10089	0.953	rs2016015	chr5:127527253	T/C	cg19767477	chr5:127420684	SLC12A2	-0.43	-4.54	-0.38	1.3e-5	Ileal carcinoids;
TGCT	cis	rs9916302	0.706	rs6503521	chr17:37715551	A/C	cg03321784	chr17:37729644	NA	-0.43	-4.55	-0.38	1.28e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs7826238	0.623	rs2976893	chr8:8338219	G/T	cg08975724	chr8:8085496	FLJ10661	-0.58	-5.52	-0.44	1.88e-7	Systolic blood pressure;
TGCT	trans	rs2727020	0.576	rs10839305	chr11:49598733	T/C	cg03929089	chr4:120376271	NA	-0.76	-9.26	-0.64	7.66e-16	Coronary artery disease;
TGCT	cis	rs2299587	0.554	rs2073567	chr8:17754034	G/A	cg01800426	chr8:17659068	MTUS1	-0.58	-5.11	-0.42	1.18e-6	Economic and political preferences;
TGCT	cis	rs797680	0.856	rs11164902	chr1:93778794	A/G	cg17826107	chr1:92977322	EVI5	-0.22	-5.05	-0.41	1.53e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs6540559	0.546	rs59435160	chr1:210030730	C/A	cg22029157	chr1:209979665	IRF6	0.84	6.31	0.49	4.44e-9	Cleft lip with or without cleft palate;
TGCT	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg11764359	chr7:65958608	NA	0.61	5.53	0.44	1.79e-7	Aortic root size;
TGCT	cis	rs4523957	0.651	rs8068642	chr17:2060353	T/C	cg16513277	chr17:2031491	SMG6	-0.2	-4.64	-0.38	8.83e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9467773	1.000	rs9467797	chr6:26568473	A/T	cg26531700	chr6:26746687	NA	0.5	4.85	0.4	3.64e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4076764	0.846	rs12035840	chr1:163419177	G/C	cg24596788	chr1:163392923	NA	-0.17	-4.84	-0.4	3.8e-6	Motion sickness;
TGCT	cis	rs7726839	0.540	rs61731455	chr5:665295	A/G	cg09021430	chr5:549028	NA	-0.4	-5.64	-0.45	1.08e-7	Obesity-related traits;
TGCT	cis	rs3820068	0.608	rs12740492	chr1:16048951	A/T	cg17385448	chr1:15911702	AGMAT	0.36	4.76	0.39	5.21e-6	Systolic blood pressure;
TGCT	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg20891283	chr12:69753455	YEATS4	0.83	8.7	0.62	1.68e-14	Blood protein levels;
TGCT	cis	rs614226	0.938	rs7972244	chr12:120994872	A/G	cg01236616	chr12:121019343	POP5	1.26	13.2	0.76	2.23e-25	Type 1 diabetes nephropathy;
TGCT	cis	rs7703051	0.585	rs918623	chr5:74596682	A/C	cg07671805	chr5:74907694	NA	0.49	4.46	0.37	1.84e-5	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
TGCT	cis	rs4776059	1.000	rs1863512	chr15:52959687	C/T	cg25063058	chr15:52860530	ARPP19	0.54	4.79	0.4	4.6e-6	Schizophrenia;
TGCT	cis	rs6912958	0.781	rs9450739	chr6:88268271	G/A	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.91	-0.4	2.78e-6	Monocyte percentage of white cells;
TGCT	cis	rs7772486	0.558	rs7753273	chr6:146066039	C/T	cg13319975	chr6:146136371	FBXO30	0.73	6.55	0.51	1.36e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs17433780	0.523	rs6701673	chr1:89525812	C/G	cg09516651	chr1:89888402	LOC400759	0.26	5.15	0.42	1.01e-6	Carotid intima media thickness;
TGCT	cis	rs12220898	0.749	rs10776553	chr10:50482929	C/T	cg06072769	chr10:50146962	WDFY4	0.38	5.15	0.42	1.02e-6	Inflammatory biomarkers;
TGCT	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg12751644	chr20:60527061	NA	0.51	7.01	0.53	1.35e-10	Obesity-related traits;
TGCT	cis	rs8141529	0.732	rs5997408	chr22:29207915	G/A	cg02153584	chr22:29168773	CCDC117	0.68	5.9	0.47	3.31e-8	Lymphocyte counts;
TGCT	cis	rs8067545	0.750	rs1421174	chr17:19950190	G/T	cg13482628	chr17:19912719	NA	0.55	4.7	0.39	6.78e-6	Schizophrenia;
TGCT	cis	rs12367572	0.965	rs11182706	chr12:45223339	T/C	cg04608330	chr12:45269318	NELL2	-0.5	-4.68	-0.39	7.33e-6	Gut microbiome composition (summer);
TGCT	cis	rs10875595	0.836	rs10067231	chr5:140673429	C/T	cg20560182	chr5:140700478	TAF7	-0.64	-4.91	-0.4	2.76e-6	Pulmonary function decline;
TGCT	cis	rs644799	0.710	rs11021311	chr11:95505227	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.81	9.02	0.63	2.92e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg03517284	chr6:25882590	NA	0.5	4.48	0.37	1.65e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg11764359	chr7:65958608	NA	-0.61	-5.51	-0.44	1.96e-7	Aortic root size;
TGCT	cis	rs4242434	0.927	rs11778693	chr8:22462852	T/C	cg21658235	chr8:22456391	C8orf58	0.43	4.53	0.38	1.36e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.63	-0.51	9.04e-10	Alzheimer's disease;
TGCT	cis	rs4494114	1.000	rs4491033	chr1:39352083	A/C	cg25970120	chr1:39325951	RRAGC	-0.53	-5.44	-0.44	2.72e-7	Blood protein levels;
TGCT	cis	rs11122272	0.735	rs2808611	chr1:231548480	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.66	6.2	0.49	7.88e-9	Hemoglobin concentration;
TGCT	cis	rs5769765	1.000	rs4597652	chr22:50270570	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	1.11	11.76	0.73	6.5e-22	Schizophrenia;
TGCT	cis	rs1008375	0.966	rs4698621	chr4:17587565	C/T	cg18681998	chr4:17616180	MED28	0.94	9.56	0.65	1.44e-16	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7267979	0.744	rs6050463	chr20:25208990	G/A	cg03522245	chr20:25566470	NINL	0.53	5.3	0.43	5.01e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7513165	0.611	rs4951314	chr1:204152933	G/A	cg12731349	chr1:204159619	KISS1	0.53	5.19	0.42	8.33e-7	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
TGCT	cis	rs6988636	0.579	rs28528232	chr8:124189308	G/A	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs2637266	0.791	rs2395392	chr10:78359933	C/A	cg18941641	chr10:78392320	NA	0.42	5.39	0.44	3.4e-7	Pulmonary function;
TGCT	cis	rs8072100	0.713	rs4968228	chr17:45497548	T/C	cg08085267	chr17:45401833	C17orf57	-0.51	-5.64	-0.45	1.11e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs9929218	0.954	rs112225541	chr16:68755165	C/T	cg01251360	chr16:68772225	CDH1	0.29	4.87	0.4	3.39e-6	Colorectal cancer;
TGCT	cis	rs7312933	0.592	rs1551210	chr12:42865874	C/T	cg19980929	chr12:42632907	YAF2	0.43	6.16	0.48	9.17e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs6701037	0.681	rs13374887	chr1:175131962	A/T	cg00321850	chr1:175162397	KIAA0040	0.44	6.03	0.48	1.7e-8	Alcohol dependence;
TGCT	cis	rs798766	1.000	rs7682402	chr4:1743343	G/A	cg05874882	chr4:1763078	NA	-0.36	-4.83	-0.4	3.87e-6	Bladder cancer;Urinary bladder cancer;
TGCT	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg12963246	chr6:28129442	ZNF389	0.51	5.02	0.41	1.73e-6	Depression;
TGCT	cis	rs698813	0.604	rs58667148	chr2:44481443	G/A	cg00619915	chr2:44497795	NA	-0.25	-5.7	-0.46	8.13e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
TGCT	cis	rs854765	0.964	rs72827413	chr17:17988299	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.65	-6.2	-0.49	7.84e-9	Total body bone mineral density;
TGCT	cis	rs2721195	1.000	rs1871541	chr8:145681713	G/T	cg11211951	chr8:145729740	GPT	-0.21	-4.89	-0.4	3e-6	Age at first birth;
TGCT	cis	rs10927875	0.632	rs904911	chr1:16126932	C/T	cg21385522	chr1:16154831	NA	-0.96	-15.62	-0.81	4.59e-31	Dilated cardiomyopathy;
TGCT	cis	rs3924048	0.574	rs12410270	chr1:12612843	G/A	cg00291366	chr1:12616550	NA	0.33	4.93	0.4	2.6e-6	Optic cup area;
TGCT	cis	rs7192750	0.586	rs2335713	chr16:71904291	T/C	cg06353428	chr16:71660113	MARVELD3	0.83	7.37	0.55	2.07e-11	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs8180040	1.000	rs1638676	chr3:47327651	A/G	cg27129171	chr3:47204927	SETD2	0.7	8.89	0.62	5.88e-15	Colorectal cancer;
TGCT	cis	rs7258465	1.000	rs10403249	chr19:18604942	T/C	cg06462663	chr19:18546047	ISYNA1	0.2	4.67	0.39	7.74e-6	Breast cancer;
TGCT	cis	rs1008375	0.932	rs9291660	chr4:17663414	A/G	cg16339924	chr4:17578868	LAP3	0.63	5.22	0.42	7.22e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg11494091	chr17:61959527	GH2	0.42	7.46	0.56	1.34e-11	Height;
TGCT	cis	rs8179	0.761	rs42034	chr7:92239144	A/G	cg15732164	chr7:92237376	CDK6	-0.3	-5.34	-0.43	4.37e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
TGCT	cis	rs7681440	0.904	rs6817001	chr4:90766019	C/T	cg26578617	chr4:90757533	SNCA	-0.47	-4.87	-0.4	3.34e-6	Dementia with Lewy bodies;
TGCT	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg03709012	chr19:19516395	GATAD2A	0.67	5.75	0.46	6.45e-8	Tonsillectomy;
TGCT	cis	rs7017914	0.967	rs7814648	chr8:71603984	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.03	-0.41	1.69e-6	Bone mineral density;
TGCT	cis	rs11030122	0.547	rs10767720	chr11:3953297	T/C	cg18678763	chr11:4115507	RRM1	-0.39	-4.76	-0.39	5.24e-6	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs2239547	0.522	rs2581779	chr3:53056199	T/C	cg10802521	chr3:52805072	NEK4	0.6	5.38	0.44	3.52e-7	Schizophrenia;
TGCT	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg22968622	chr17:43663579	NA	-1.24	-11.14	-0.71	2.12e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7027203	0.576	rs7848045	chr9:96551824	G/A	cg14598338	chr9:96623480	NA	0.5	7.25	0.55	3.86e-11	DNA methylation (variation);
TGCT	cis	rs2486288	0.656	rs9920290	chr15:45548035	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.46	-5.59	-0.45	1.38e-7	Glomerular filtration rate;
TGCT	cis	rs453301	0.597	rs7001187	chr8:8792782	G/A	cg06636001	chr8:8085503	FLJ10661	-0.69	-5.92	-0.47	2.9e-8	Joint mobility (Beighton score);
TGCT	cis	rs3820068	0.608	rs10927831	chr1:16028373	T/G	cg05660106	chr1:15850417	CASP9	0.64	5.99	0.47	2.09e-8	Systolic blood pressure;
TGCT	cis	rs950169	0.881	rs34591918	chr15:84950833	C/T	cg12863693	chr15:85201151	NMB	0.45	4.96	0.41	2.28e-6	Schizophrenia;
TGCT	cis	rs1577917	1.000	rs2812972	chr6:86669880	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.05	-0.41	1.57e-6	Response to antipsychotic treatment;
TGCT	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg08280861	chr8:58055591	NA	0.49	5.38	0.43	3.64e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7914558	1.000	rs7094843	chr10:104806654	A/C	cg15744005	chr10:104629667	AS3MT	-0.38	-4.69	-0.39	7.04e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs4891159	0.527	rs34956524	chr18:74130480	A/G	cg24786174	chr18:74118243	ZNF516	0.67	13.58	0.77	2.65e-26	Longevity;
TGCT	cis	rs4523957	0.620	rs9892754	chr17:2084565	G/T	cg16513277	chr17:2031491	SMG6	-0.2	-4.64	-0.38	8.83e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs2239547	0.618	rs4687663	chr3:52870618	T/A	cg10802521	chr3:52805072	NEK4	-0.63	-5.96	-0.47	2.41e-8	Schizophrenia;
TGCT	cis	rs11190604	1.000	rs3793706	chr10:102269085	A/C	cg23241863	chr10:102295624	HIF1AN	-0.7	-5.38	-0.43	3.59e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs16867321	0.694	rs4666853	chr2:181439671	C/T	cg23363182	chr2:181467187	NA	0.4	6.02	0.48	1.87e-8	Obesity;
TGCT	cis	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg18252515	chr7:66147081	NA	-1.13	-6.81	-0.52	3.7e-10	Diabetic kidney disease;
TGCT	cis	rs7647973	1.000	rs3870341	chr3:49584745	A/G	cg05785598	chr3:49045655	WDR6	0.38	4.76	0.39	5.38e-6	Menarche (age at onset);
TGCT	cis	rs8077889	0.956	rs17742347	chr17:41846468	A/G	cg26893861	chr17:41843967	DUSP3	-1.08	-13.44	-0.77	5.71e-26	Triglycerides;
TGCT	cis	rs4081724	0.572	rs12151047	chr19:33810278	G/T	cg18823272	chr19:34111733	CHST8	0.42	4.69	0.39	7.11e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs28595532	0.920	rs114678295	chr4:119756281	C/T	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs6545883	0.862	rs1880866	chr2:61698972	G/C	cg15711740	chr2:61764176	XPO1	-0.52	-4.69	-0.39	7.01e-6	Tuberculosis;
TGCT	cis	rs2153535	0.580	rs1414350	chr6:8472331	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg18252515	chr7:66147081	NA	-1.22	-7.16	-0.54	6.34e-11	Diabetic kidney disease;
TGCT	cis	rs5769765	0.862	rs9616386	chr22:50313179	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.24	-12.97	-0.76	7.81e-25	Schizophrenia;
TGCT	cis	rs4237845	0.816	rs61935769	chr12:58294344	G/A	cg02175503	chr12:58329896	NA	0.52	4.77	0.39	5.09e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs611744	0.560	rs58605513	chr8:109279122	A/C	cg21045802	chr8:109455806	TTC35	0.72	7.43	0.56	1.53e-11	Dupuytren's disease;
TGCT	cis	rs4700695	0.614	rs394828	chr5:65209552	C/T	cg21114390	chr5:65439923	SFRS12	0.67	4.69	0.39	7.07e-6	Facial morphology (factor 19);
TGCT	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg09359103	chr1:154839909	KCNN3	-0.66	-12.15	-0.74	7.27e-23	Prostate cancer;
TGCT	cis	rs344364	0.511	rs1742469	chr16:1950244	C/T	cg26617929	chr16:1858877	NA	-0.27	-4.9	-0.4	2.99e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs9303401	0.614	rs3803752	chr17:56540267	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.71	6.74	0.52	5.45e-10	Cognitive test performance;
TGCT	cis	rs8062405	1.000	rs7187776	chr16:28857645	A/G	cg09754948	chr16:28834200	ATXN2L	0.64	4.98	0.41	2.07e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs7086627	0.515	rs7088877	chr10:82208860	C/G	cg01528321	chr10:82214614	TSPAN14	0.65	6.21	0.49	7.21e-9	Post bronchodilator FEV1;
TGCT	cis	rs950776	0.518	rs4243083	chr15:78833830	C/G	cg06917634	chr15:78832804	PSMA4	-0.95	-9.52	-0.65	1.81e-16	Sudden cardiac arrest;
TGCT	cis	rs7647973	0.593	rs1799844	chr3:49847642	G/A	cg03034192	chr3:50606346	HEMK1;C3orf18	-0.37	-4.69	-0.39	7.03e-6	Menarche (age at onset);
TGCT	cis	rs11578119	0.933	rs10800526	chr1:170480292	C/T	cg09767346	chr1:170501363	GORAB	-0.71	-5.64	-0.45	1.11e-7	Male-pattern baldness;
TGCT	cis	rs7584330	0.652	rs7607231	chr2:238372896	T/C	cg14458575	chr2:238380390	NA	0.48	7.57	0.56	7.54e-12	Prostate cancer;
TGCT	cis	rs10504229	0.593	rs11781042	chr8:57993056	A/T	cg08280861	chr8:58055591	NA	0.34	4.69	0.39	7.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1372520	0.684	rs1442148	chr4:90748846	T/A	cg14346243	chr4:90757452	SNCA	-0.67	-5.64	-0.45	1.09e-7	Neuroticism;
TGCT	cis	rs3617	0.539	rs11922975	chr3:52936763	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	0.52	5.06	0.41	1.48e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2282802	0.685	rs6889283	chr5:139653439	G/T	cg01081189	chr5:139537190	NA	0.28	5.15	0.42	9.75e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs3125734	0.608	rs7905731	chr10:64018472	T/C	cg05499367	chr10:63213510	TMEM26	-0.33	-4.48	-0.37	1.67e-5	Rheumatoid arthritis;
TGCT	cis	rs34638657	0.732	rs12597171	chr16:82200119	A/G	cg09439754	chr16:82129088	HSD17B2	0.26	4.83	0.4	4.01e-6	Lung adenocarcinoma;
TGCT	cis	rs6570726	0.791	rs12205752	chr6:145896118	A/G	cg05347473	chr6:146136440	FBXO30	0.52	4.95	0.41	2.33e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs921968	0.541	rs549026	chr2:219339283	T/C	cg02176678	chr2:219576539	TTLL4	0.48	6.78	0.52	4.32e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs2120019	1.000	rs2083731	chr15:75368538	A/C	cg17294928	chr15:75287854	SCAMP5	-0.85	-6.5	-0.5	1.78e-9	Blood trace element (Zn levels);
TGCT	cis	rs11031096	0.711	rs10835694	chr11:4178757	G/C	cg18678763	chr11:4115507	RRM1	-0.44	-5.75	-0.46	6.48e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs7267979	0.816	rs3746337	chr20:25208272	C/T	cg14121845	chr20:25566513	NINL	0.49	5.02	0.41	1.75e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.75	5.41	0.44	3.09e-7	Platelet count;
TGCT	cis	rs7178572	0.568	rs7175674	chr15:77670910	C/T	cg22256960	chr15:77711686	NA	-0.88	-9.16	-0.64	1.32e-15	Type 2 diabetes;
TGCT	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg22963979	chr7:1858916	MAD1L1	-0.4	-6.44	-0.5	2.44e-9	Bipolar disorder and schizophrenia;
TGCT	cis	rs9915657	0.870	rs12600458	chr17:70130545	C/T	cg06234051	chr17:70120541	SOX9	-0.24	-4.82	-0.4	4.16e-6	Thyroid hormone levels;
TGCT	cis	rs644799	0.965	rs10831430	chr11:95509638	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	8.46	0.6	6.27e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs79149102	0.579	rs12593476	chr15:75282092	A/C	cg09165964	chr15:75287851	SCAMP5	-1.09	-6.08	-0.48	1.39e-8	Lung cancer;
TGCT	cis	rs3020736	0.500	rs6002597	chr22:42488160	C/A	cg15557168	chr22:42548783	NA	0.22	5.47	0.44	2.34e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs8017423	0.935	rs3742667	chr14:90767856	T/C	cg04374321	chr14:90722782	PSMC1	-0.73	-6.71	-0.52	6.06e-10	Mortality in heart failure;
TGCT	cis	rs936229	0.813	rs2301249	chr15:75092384	T/C	cg10253484	chr15:75165896	SCAMP2	-0.64	-5.11	-0.42	1.16e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
TGCT	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg11764359	chr7:65958608	NA	0.61	5.5	0.44	2.1e-7	Aortic root size;
TGCT	trans	rs4332037	0.707	rs10268797	chr7:1873756	C/G	cg25206134	chr2:45395956	NA	-0.87	-6.98	-0.53	1.59e-10	Bipolar disorder;
TGCT	cis	rs11731606	0.508	rs6827755	chr4:95309170	C/T	cg00507259	chr4:95128692	SMARCAD1	0.63	4.67	0.39	7.66e-6	Mean platelet volume;
TGCT	cis	rs2153535	0.580	rs2327050	chr6:8440630	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.58	0.45	1.42e-7	Motion sickness;
TGCT	cis	rs1570884	0.516	rs7330830	chr13:50167929	T/A	cg08779649	chr13:50194554	NA	0.38	6.1	0.48	1.25e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
TGCT	cis	rs245880	0.740	rs245889	chr7:29190626	C/T	cg17163760	chr7:29186267	CPVL	-0.42	-5.28	-0.43	5.71e-7	Warfarin maintenance dose;
TGCT	cis	rs9341808	0.667	rs3805913	chr6:80927322	A/G	cg08355045	chr6:80787529	NA	0.3	5.0	0.41	1.91e-6	Sitting height ratio;
TGCT	cis	rs7945705	0.747	rs10840158	chr11:9020897	A/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.46	-4.98	-0.41	2.11e-6	Hemoglobin concentration;
TGCT	cis	rs11125080	1.000	rs11125079	chr2:46732215	C/T	cg14327359	chr2:47419263	NA	-0.41	-4.59	-0.38	1.07e-5	Anti-saccade response;Anti-saccade error rate in psychotic disorders;
TGCT	cis	rs9993613	0.750	rs12643350	chr4:73535169	G/T	cg15102770	chr4:73434591	ADAMTS3	0.51	4.46	0.37	1.83e-5	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs4722166	0.630	rs12537614	chr7:22789551	C/G	cg26061582	chr7:22766209	IL6	0.6	5.96	0.47	2.39e-8	Lung cancer;
TGCT	trans	rs2727020	0.729	rs685789	chr11:49241228	G/A	cg03929089	chr4:120376271	NA	0.71	7.69	0.57	3.98e-12	Coronary artery disease;
TGCT	cis	rs17767294	0.708	rs72847361	chr6:27834216	G/T	cg08851530	chr6:28072375	NA	1.58	7.16	0.54	6.15e-11	Parkinson's disease;
TGCT	cis	rs116095464	0.558	rs10060089	chr5:205565	G/A	cg22857025	chr5:266934	NA	-0.34	-6.42	-0.5	2.63e-9	Breast cancer;
TGCT	cis	rs3749237	0.595	rs35701831	chr3:49515000	A/C	cg07636037	chr3:49044803	WDR6	0.63	5.98	0.47	2.26e-8	Resting heart rate;
TGCT	cis	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg20637647	chr7:64974828	NA	0.93	5.2	0.42	8.11e-7	Diabetic kidney disease;
TGCT	cis	rs2067615	0.579	rs10778510	chr12:107162965	A/G	cg15890332	chr12:107067104	RFX4	-0.29	-5.75	-0.46	6.56e-8	Heart rate;
TGCT	cis	rs1784581	0.674	rs3016555	chr6:162391421	T/C	cg17173639	chr6:162384350	PARK2	-0.46	-8.18	-0.59	2.92e-13	Itch intensity from mosquito bite;
TGCT	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg09436375	chr6:42928200	GNMT	-0.41	-5.18	-0.42	8.65e-7	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.0	7.42	0.55	1.64e-11	Gut microbiome composition (summer);
TGCT	cis	rs11785400	0.793	rs11785376	chr8:143730412	C/T	cg24634471	chr8:143751801	JRK	0.53	5.24	0.43	6.79e-7	Schizophrenia;
TGCT	cis	rs5769707	0.616	rs6009786	chr22:50015145	A/G	cg05373962	chr22:49881684	NA	-0.29	-4.97	-0.41	2.16e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs9399135	1.000	rs4895435	chr6:135293463	C/A	cg24558204	chr6:135376177	HBS1L	0.48	4.79	0.39	4.76e-6	Red blood cell count;
TGCT	cis	rs9486719	1.000	rs34236778	chr6:96884556	C/A	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.21	-0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	trans	rs16870629	0.541	rs2334955	chr5:1062444	A/G	cg04701034	chr14:52536175	NID2	-0.74	-8.37	-0.6	1.01e-13	QT interval;
TGCT	cis	rs711245	0.574	rs1179494	chr2:36809496	C/G	cg15105969	chr2:36825350	FEZ2	-0.52	-4.52	-0.38	1.4e-5	Height;
TGCT	cis	rs7424096	0.613	rs111805423	chr2:37248924	G/T	cg14987922	chr2:37194071	STRN	0.52	4.65	0.39	8.4e-6	High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs6674176	0.597	rs9326136	chr1:44390392	A/G	cg13606994	chr1:44402422	ARTN	0.51	5.5	0.44	2.07e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs7949030	0.688	rs11231155	chr11:62365619	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.7	9.04	0.63	2.65e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2932538	0.922	rs12750621	chr1:113206502	G/C	cg22162597	chr1:113214053	CAPZA1	0.28	5.98	0.47	2.2e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs6060960	0.502	rs15817	chr20:30193538	A/G	cg13852791	chr20:30311386	BCL2L1	0.69	4.65	0.39	8.44e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
TGCT	cis	rs9811920	0.809	rs1384062	chr3:99597928	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.44	-4.99	-0.41	1.97e-6	Axial length;
TGCT	cis	rs9291683	0.546	rs7442336	chr4:10045783	G/A	cg00071950	chr4:10020882	SLC2A9	0.57	6.47	0.5	2.01e-9	Bone mineral density;
TGCT	cis	rs9467773	0.620	rs2130657	chr6:26650826	C/T	cg05738196	chr6:26577821	NA	0.88	10.63	0.69	3.68e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg22963979	chr7:1858916	MAD1L1	-0.4	-6.38	-0.5	3.12e-9	Bipolar disorder and schizophrenia;
TGCT	cis	rs9549367	0.713	rs9577211	chr13:113830718	G/C	cg00898013	chr13:113819073	PROZ	-0.57	-7.68	-0.57	4.14e-12	Platelet distribution width;
TGCT	cis	rs5769707	0.967	rs9616327	chr22:50010891	G/A	cg10356904	chr22:49881777	NA	-0.23	-4.68	-0.39	7.53e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs7666738	0.830	rs17483521	chr4:98974058	A/T	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4563143	0.675	rs56407818	chr19:29279379	G/A	cg03161606	chr19:29218774	NA	0.62	6.0	0.47	2e-8	Methadone dose in opioid dependence;
TGCT	cis	rs854765	0.547	rs2955356	chr17:17964717	G/A	cg04398451	chr17:18023971	MYO15A	0.33	5.39	0.44	3.47e-7	Total body bone mineral density;
TGCT	cis	rs9902453	0.780	rs10445384	chr17:28182685	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	7.27	0.55	3.59e-11	Coffee consumption (cups per day);
TGCT	cis	rs3087591	0.919	rs11080148	chr17:29609922	T/C	cg24425628	chr17:29625626	OMG;NF1	-0.43	-6.29	-0.49	4.94e-9	Hip circumference;
TGCT	cis	rs74233809	0.892	rs11191447	chr10:104652323	C/T	cg05855489	chr10:104503620	C10orf26	0.74	4.45	0.37	1.87e-5	Birth weight;
TGCT	cis	rs13191362	1.000	rs67046187	chr6:163068532	C/A	cg21926612	chr6:163149169	PACRG;PARK2	1.06	8.12	0.59	3.96e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs473651	0.935	rs472357	chr2:239355454	A/G	cg21699342	chr2:239360505	ASB1	-0.17	-4.69	-0.39	7.05e-6	Multiple system atrophy;
TGCT	cis	rs4237845	0.715	rs4760340	chr12:58275176	A/T	cg03728296	chr12:58013271	SLC26A10	-0.4	-4.49	-0.37	1.58e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs9467773	0.620	rs2494692	chr6:26615223	G/A	cg05738196	chr6:26577821	NA	0.88	11.4	0.72	5.07e-21	Intelligence (multi-trait analysis);
TGCT	cis	rs6088590	1.000	rs2236270	chr20:33523155	G/T	cg24642439	chr20:33292090	TP53INP2	0.67	5.52	0.44	1.92e-7	Coronary artery disease;
TGCT	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg06634786	chr22:41940651	POLR3H	-0.88	-8.54	-0.61	3.98e-14	Vitiligo;
TGCT	cis	rs2288884	0.943	rs3752120	chr19:52552021	C/T	cg13540795	chr19:52551618	ZNF432	-0.59	-5.02	-0.41	1.79e-6	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs9534288	0.797	rs2182482	chr13:46582654	T/A	cg15192986	chr13:46630673	CPB2	-0.53	-7.62	-0.56	5.82e-12	Blood protein levels;
TGCT	cis	rs2299587	0.560	rs11987695	chr8:17781085	A/G	cg01800426	chr8:17659068	MTUS1	-0.64	-5.52	-0.44	1.91e-7	Economic and political preferences;
TGCT	trans	rs7613875	0.654	rs3774751	chr3:50209053	G/T	cg21659725	chr3:3221576	CRBN	-0.7	-7.99	-0.58	8.03e-13	Body mass index;
TGCT	cis	rs7264396	0.570	rs1970576	chr20:34336720	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.25	-0.43	6.33e-7	Total cholesterol levels;
TGCT	cis	rs4689388	0.890	rs4481292	chr4:6298375	C/T	cg25554036	chr4:6271136	WFS1	0.56	7.87	0.58	1.48e-12	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs78487399	0.808	rs6728106	chr2:43683885	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.45	-5.79	-0.46	5.47e-8	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs7255045	0.702	rs2293682	chr19:12989560	G/A	cg23899408	chr19:12877188	HOOK2	-0.62	-5.07	-0.41	1.39e-6	Mean corpuscular volume;
TGCT	cis	rs7267979	0.966	rs2261795	chr20:25263136	T/C	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg14820908	chr5:178986412	RUFY1	0.46	4.82	0.4	4.1e-6	Lung cancer;
TGCT	cis	rs137699	0.568	rs137682	chr22:39738425	A/C	cg24399712	chr22:39784796	NA	-0.72	-5.41	-0.44	3.16e-7	IgG glycosylation;
TGCT	cis	rs2204008	0.712	rs12371182	chr12:38321143	A/C	cg13010199	chr12:38710504	ALG10B	0.61	4.81	0.4	4.2e-6	Bladder cancer;
TGCT	cis	rs1691799	0.867	rs1027400	chr12:66760922	A/T	cg16791601	chr12:66731901	HELB	-0.28	-6.03	-0.48	1.76e-8	White blood cell count (basophil);
TGCT	cis	rs208520	0.526	rs6913344	chr6:66754285	A/C	cg07460842	chr6:66804631	NA	-1.03	-13.83	-0.78	6.68e-27	Exhaled nitric oxide output;
TGCT	cis	rs868036	0.645	rs4776972	chr15:68083436	A/C	cg27219399	chr15:67835830	MAP2K5	0.34	4.49	0.37	1.6e-5	Restless legs syndrome;
TGCT	cis	rs7223966	0.921	rs2854207	chr17:61947107	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	4.51	0.38	1.5e-5	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs1865760	1.000	rs3799371	chr6:25912816	A/G	cg16482183	chr6:26056742	HIST1H1C	-0.53	-4.82	-0.4	4.09e-6	Height;
TGCT	trans	rs877282	1.000	rs34257857	chr10:772993	C/A	cg22713356	chr15:30763199	NA	1.16	10.02	0.67	1.16e-17	Uric acid levels;
TGCT	cis	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg19635926	chr16:89946313	TCF25	0.27	4.58	0.38	1.11e-5	Skin colour saturation;
TGCT	cis	rs36051895	0.554	rs7856773	chr9:5204705	T/C	cg02405213	chr9:5042618	JAK2	-0.75	-9.5	-0.65	2.05e-16	Pediatric autoimmune diseases;
TGCT	cis	rs17767294	1.000	rs17767294	chr6:28054198	A/G	cg08851530	chr6:28072375	NA	1.07	5.6	0.45	1.31e-7	Parkinson's disease;
TGCT	cis	rs7178572	0.568	rs12900433	chr15:77495028	T/C	cg15453836	chr15:77711506	NA	-0.44	-4.91	-0.4	2.86e-6	Type 2 diabetes;
TGCT	cis	rs6570726	0.935	rs379164	chr6:145829093	A/T	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1670533	1.000	rs6822863	chr4:1055606	G/A	cg20887711	chr4:1340912	KIAA1530	0.69	5.48	0.44	2.32e-7	Recombination rate (females);
TGCT	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg14820908	chr5:178986412	RUFY1	-0.59	-6.47	-0.5	2.08e-9	Lung cancer;
TGCT	cis	rs682748	0.810	rs34630503	chr5:17139285	A/T	cg23987134	chr5:17158319	LOC285696	-0.21	-5.19	-0.42	8.4e-7	Hippocampal atrophy;
TGCT	cis	rs9910055	0.530	rs2269908	chr17:42294198	G/C	cg13607699	chr17:42295918	UBTF	0.96	11.07	0.7	3.21e-20	Total body bone mineral density;
TGCT	cis	rs12579753	0.797	rs1922561	chr12:82152640	C/A	cg07988820	chr12:82153109	PPFIA2	-0.66	-7.01	-0.53	1.32e-10	Resting heart rate;
TGCT	cis	rs12210905	0.688	rs12215289	chr6:27468705	T/C	cg08851530	chr6:28072375	NA	1.34	6.29	0.49	5.02e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs7267979	1.000	rs6115153	chr20:25325567	T/C	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.79	-8.24	-0.59	2.06e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.71	6.36	0.5	3.53e-9	Tonsillectomy;
TGCT	trans	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg21659725	chr3:3221576	CRBN	0.67	7.53	0.56	9.05e-12	Body mass index;
TGCT	cis	rs4900538	0.963	rs8017980	chr14:102961341	C/G	cg18135206	chr14:102964638	TECPR2	0.22	5.19	0.42	8.24e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs9372253	0.645	rs7753212	chr6:110700229	T/C	cg19196401	chr6:110721138	DDO	-0.42	-5.75	-0.46	6.45e-8	Platelet distribution width;
TGCT	cis	rs854765	0.583	rs7503334	chr17:17779458	C/T	cg09796270	chr17:17721594	SREBF1	-0.27	-5.5	-0.44	2.04e-7	Total body bone mineral density;
TGCT	trans	rs7726839	0.561	rs4957049	chr5:579080	C/A	cg11887960	chr12:57824829	NA	0.96	8.01	0.58	7.22e-13	Obesity-related traits;
TGCT	cis	rs3784262	0.669	rs3784257	chr15:58262974	C/T	cg12031962	chr15:58353849	ALDH1A2	0.42	6.16	0.48	9.41e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	trans	rs931812	0.757	rs13251801	chr8:101902629	A/T	cg20993868	chr7:22813445	NA	0.32	6.63	0.51	9.13e-10	Attention deficit hyperactivity disorder and conduct disorder;
TGCT	cis	rs12477438	0.501	rs12619780	chr2:99707307	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.1	16.08	0.82	4.04e-32	Chronic sinus infection;
TGCT	cis	rs2180341	1.000	rs2144742	chr6:127595786	C/A	cg27446573	chr6:127587934	RNF146	1.13	10.12	0.67	6.64e-18	Breast cancer;
TGCT	cis	rs4769475	1.000	rs7320397	chr13:26730629	G/A	cg19000612	chr13:26506281	ATP8A2	0.34	4.66	0.39	8.12e-6	Response to Homoharringtonine (cytotoxicity);
TGCT	cis	rs2019216	0.500	rs908696	chr17:21940987	T/G	cg22648282	chr17:21454238	C17orf51	-0.58	-4.95	-0.41	2.37e-6	Pelvic organ prolapse;
TGCT	cis	rs2658782	0.547	rs3133454	chr11:93059019	A/C	cg15737290	chr11:93063684	CCDC67	1.05	11.65	0.72	1.24e-21	Pulmonary function decline;
TGCT	cis	rs61884328	0.789	rs61897788	chr11:47181051	A/T	cg13308137	chr11:47528955	CUGBP1	0.38	4.44	0.37	1.94e-5	Total body bone mineral density (age over 60);
TGCT	cis	rs453301	0.658	rs3855900	chr8:8901921	A/G	cg15556689	chr8:8085844	FLJ10661	-0.66	-5.39	-0.44	3.47e-7	Joint mobility (Beighton score);
TGCT	cis	rs231513	0.954	rs231510	chr17:41966470	T/C	cg26893861	chr17:41843967	DUSP3	-0.71	-5.21	-0.42	7.57e-7	Cognitive function;
TGCT	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg10207240	chr12:122356781	WDR66	0.34	4.66	0.39	8.03e-6	Mean corpuscular volume;
TGCT	cis	rs586688	0.556	rs1256473	chr1:201652342	T/G	cg07139329	chr1:201708558	NAV1	-0.51	-5.29	-0.43	5.27e-7	Obesity-related traits;
TGCT	cis	rs9400467	0.537	rs12211045	chr6:111498116	C/T	cg15721981	chr6:111408429	SLC16A10	0.78	4.7	0.39	6.66e-6	Blood metabolite levels;Amino acid levels;
TGCT	cis	rs57221529	0.766	rs72703075	chr5:592819	C/T	cg09021430	chr5:549028	NA	-0.42	-5.55	-0.45	1.64e-7	Lung disease severity in cystic fibrosis;
TGCT	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg17264618	chr3:40429014	ENTPD3	0.34	4.94	0.41	2.52e-6	Renal cell carcinoma;
TGCT	cis	rs2033711	0.936	rs7257999	chr19:58964860	C/G	cg03735888	chr19:58951602	ZNF132	0.55	4.83	0.4	3.98e-6	Uric acid clearance;
TGCT	cis	rs4654899	0.758	rs6690574	chr1:21504279	G/A	cg01072550	chr1:21505969	NA	-0.58	-9.63	-0.65	9.9900000000000006e-17	Superior frontal gyrus grey matter volume;
TGCT	cis	rs11112613	0.653	rs59504344	chr12:105950837	C/T	cg03607813	chr12:105948248	NA	0.51	6.11	0.48	1.19e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	cis	rs11614913	0.509	rs12300425	chr12:54395082	G/T	cg05643303	chr12:54402714	HOXC8	-0.72	-6.15	-0.48	9.66e-9	Waist circumference adjusted for body mass index;
TGCT	cis	rs7104764	0.957	rs56357554	chr11:204715	C/T	cg18336825	chr11:236787	PSMD13;SIRT3	-1.02	-10.55	-0.69	5.9e-19	Menarche (age at onset);
TGCT	cis	rs9611565	0.512	rs45500192	chr22:42177899	A/G	cg06481639	chr22:41940642	POLR3H	-0.66	-5.75	-0.46	6.46e-8	Vitiligo;
TGCT	cis	rs11085466	1.000	rs4399664	chr19:21778026	C/T	cg23026602	chr19:21646605	NA	-0.53	-4.55	-0.38	1.28e-5	Colorectal or endometrial cancer;
TGCT	cis	rs2046867	0.908	rs62251601	chr3:72786768	C/G	cg25664220	chr3:72788482	NA	-0.56	-7.03	-0.53	1.25e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg06221963	chr1:154839813	KCNN3	-0.75	-12.65	-0.75	4.66e-24	Prostate cancer;
TGCT	cis	rs7267979	0.966	rs2387882	chr20:25378802	C/T	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4332037	0.539	rs11762636	chr7:2061111	C/A	cg25834613	chr7:1915315	MAD1L1	-0.51	-4.99	-0.41	1.95e-6	Bipolar disorder;
TGCT	cis	rs763121	0.853	rs138705	chr22:39133803	C/T	cg06022373	chr22:39101656	GTPBP1	0.8	7.56	0.56	7.77e-12	Menopause (age at onset);
TGCT	cis	rs7940866	0.834	rs10894298	chr11:130840571	C/A	cg05962950	chr11:130786565	SNX19	0.73	7.14	0.54	6.99e-11	Schizophrenia;
TGCT	cis	rs9674544	0.556	rs1390154	chr17:47071483	A/G	cg20966754	chr17:47091339	IGF2BP1	-0.43	-4.71	-0.39	6.46e-6	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
TGCT	cis	rs2463822	0.583	rs72917377	chr11:62025930	A/G	cg06239285	chr11:62104954	ASRGL1	-0.96	-6.16	-0.48	9.22e-9	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs57143961	1	rs57143961	chr19:16533225	C/CT	cg14704714	chr19:15740395	CYP4F8	-0.32	-4.44	-0.37	1.97e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs10540	0.730	rs34690033	chr11:492677	G/C	cg03934478	chr11:495069	RNH1	0.36	5.84	0.46	4.21e-8	Body mass index;
TGCT	cis	rs2153535	0.580	rs6597335	chr6:8527714	T/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.01	0.41	1.86e-6	Motion sickness;
TGCT	cis	rs9457247	1.000	rs10946199	chr6:167404492	G/A	cg23791538	chr6:167370224	RNASET2	-0.49	-4.96	-0.41	2.26e-6	Crohn's disease;
TGCT	cis	rs11785400	0.793	rs4736367	chr8:143742477	G/A	cg10596483	chr8:143751796	JRK	0.55	5.48	0.44	2.29e-7	Schizophrenia;
TGCT	cis	rs7617773	0.780	rs35297395	chr3:48342882	C/T	cg11946769	chr3:48343235	NME6	0.82	7.09	0.54	9.1e-11	Coronary artery disease;
TGCT	cis	rs892961	0.932	rs7216909	chr17:75405234	A/G	cg05865280	chr17:75406074	SEPT9	0.28	6.48	0.5	1.92e-9	Airflow obstruction;
TGCT	cis	rs9362426	0.708	rs7744793	chr6:88102040	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.44	4.81	0.4	4.29e-6	Depressive episodes in bipolar disorder;
TGCT	cis	rs7937682	0.889	rs1940529	chr11:111498523	G/C	cg09085632	chr11:111637200	PPP2R1B	-1.1	-11.28	-0.71	9.81e-21	Primary sclerosing cholangitis;
TGCT	cis	rs7681440	0.874	rs1442154	chr4:90775761	C/G	cg20003494	chr4:90757398	SNCA	-0.56	-5.35	-0.43	4.11e-7	Dementia with Lewy bodies;
TGCT	cis	rs1719271	1.000	rs1719271	chr15:65183801	C/T	cg26157579	chr15:65137040	PLEKHO2	0.35	4.59	0.38	1.09e-5	Platelet count;
TGCT	cis	rs2235642	0.750	rs2859310	chr16:1656765	C/T	cg00463982	chr16:1583984	IFT140;TMEM204	0.27	4.53	0.38	1.37e-5	Coronary artery disease;
TGCT	cis	rs2070488	0.775	rs2051213	chr3:38560254	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.7	6.64	0.51	8.65e-10	Electrocardiographic conduction measures;
TGCT	cis	rs10197940	0.624	rs10497081	chr2:152353395	T/G	cg19508488	chr2:152266495	RIF1	0.72	6.55	0.51	1.38e-9	Lung cancer;
TGCT	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg26338869	chr17:61819248	STRADA	-0.53	-4.94	-0.41	2.48e-6	Prudent dietary pattern;
TGCT	cis	rs67073037	0.868	rs4666142	chr2:29171544	A/G	cg09522027	chr2:28974177	PPP1CB	0.57	4.49	0.37	1.59e-5	Breast cancer;Breast cancer (estrogen-receptor negative);
TGCT	cis	rs854765	0.647	rs854791	chr17:18029857	C/T	cg04398451	chr17:18023971	MYO15A	-0.38	-6.45	-0.5	2.26e-9	Total body bone mineral density;
TGCT	cis	rs67311347	0.955	rs12487955	chr3:40412853	T/C	cg13683864	chr3:40499215	RPL14	-1.12	-11.9	-0.73	2.94e-22	Renal cell carcinoma;
TGCT	cis	rs9611565	0.568	rs2413656	chr22:42129357	G/T	cg13695892	chr22:41940480	POLR3H	0.83	7.96	0.58	9.24e-13	Vitiligo;
TGCT	cis	rs1797081	0.967	rs780633	chr10:16863161	C/T	cg14835575	chr10:16859367	RSU1	0.44	5.31	0.43	4.92e-7	Platelet distribution width;
TGCT	cis	rs2282802	0.685	rs2337082	chr5:139649201	G/A	cg01081189	chr5:139537190	NA	0.28	5.15	0.42	9.75e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs4076764	0.801	rs4571944	chr1:163367975	T/C	cg24596788	chr1:163392923	NA	-0.17	-5.19	-0.42	8.2e-7	Motion sickness;
TGCT	cis	rs3806843	0.576	rs246027	chr5:140333601	A/G	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg00960700	chr17:80709150	TBCD	-0.49	-4.99	-0.41	1.97e-6	Glycated hemoglobin levels;
TGCT	cis	rs6964587	1.000	rs4727267	chr7:91570290	G/C	cg17063962	chr7:91808500	NA	-0.9	-9.67	-0.66	7.91e-17	Breast cancer;
TGCT	cis	rs7824557	0.547	rs2572370	chr8:11238587	A/G	cg21775007	chr8:11205619	TDH	-0.75	-7.08	-0.54	9.52e-11	Retinal vascular caliber;
TGCT	cis	rs7809950	1.000	rs4727684	chr7:107226470	C/T	cg23024343	chr7:107201750	COG5	-0.33	-5.13	-0.42	1.09e-6	Coronary artery disease;
TGCT	cis	rs2688608	0.868	rs2688625	chr10:75631548	T/C	cg04320760	chr10:75533139	FUT11	-0.32	-4.93	-0.4	2.61e-6	Inflammatory bowel disease;
TGCT	cis	rs4713118	0.662	rs9380046	chr6:28030499	T/C	cg12963246	chr6:28129442	ZNF389	0.45	4.51	0.38	1.48e-5	Parkinson's disease;
TGCT	cis	rs9467773	0.566	rs66972160	chr6:26359306	T/C	cg05738196	chr6:26577821	NA	-0.63	-6.8	-0.52	3.97e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs4076943	0.634	rs7111708	chr11:11270284	A/T	cg21653586	chr11:10530636	NA	0.49	4.97	0.41	2.14e-6	Post bronchodilator FEV1;
TGCT	cis	rs9807989	0.507	rs10203558	chr2:103027640	T/C	cg03938978	chr2:103052716	IL18RAP	0.27	5.41	0.44	3.17e-7	Asthma;
TGCT	cis	rs137699	0.695	rs137653	chr22:39732171	A/G	cg11247378	chr22:39784982	NA	0.46	5.0	0.41	1.92e-6	IgG glycosylation;
TGCT	cis	rs7786808	0.530	rs7785656	chr7:158184164	C/G	cg01191920	chr7:158217561	PTPRN2	-0.35	-4.92	-0.4	2.64e-6	Obesity-related traits;
TGCT	cis	rs6964587	0.967	rs4729015	chr7:91561592	T/G	cg17063962	chr7:91808500	NA	-0.9	-9.67	-0.66	7.91e-17	Breast cancer;
TGCT	cis	rs13256369	0.901	rs13251887	chr8:8568678	G/A	cg17143192	chr8:8559678	CLDN23	0.58	5.56	0.45	1.56e-7	Obesity-related traits;
TGCT	cis	rs1552244	0.832	rs67145301	chr3:10197314	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.1	6.25	0.49	6.06e-9	Alzheimer's disease;
TGCT	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.91	0.4	2.83e-6	Height;
TGCT	cis	rs72717009	0.825	rs7552317	chr1:161479438	C/T	cg23840854	chr1:161414152	NA	-0.97	-5.92	-0.47	2.93e-8	Rheumatoid arthritis;
TGCT	cis	rs4722166	0.630	rs12700390	chr7:22777129	G/T	cg26061582	chr7:22766209	IL6	0.57	7.36	0.55	2.27e-11	Lung cancer;
TGCT	cis	rs12188164	1.000	rs72717414	chr5:429818	C/G	cg26850624	chr5:429559	AHRR	-0.2	-4.81	-0.4	4.22e-6	Cystic fibrosis severity;
TGCT	cis	rs3087591	0.919	rs12603838	chr17:29408059	C/T	cg24425628	chr17:29625626	OMG;NF1	0.47	7.31	0.55	2.94e-11	Hip circumference;
TGCT	cis	rs3733585	0.736	rs4543113	chr4:10008305	G/A	cg00071950	chr4:10020882	SLC2A9	0.62	7.05	0.53	1.12e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs453301	0.568	rs13281377	chr8:8811564	C/T	cg06636001	chr8:8085503	FLJ10661	0.74	5.99	0.47	2.1e-8	Joint mobility (Beighton score);
TGCT	cis	rs9611565	0.921	rs2143695	chr22:41728620	A/G	cg06634786	chr22:41940651	POLR3H	-0.59	-5.59	-0.45	1.36e-7	Vitiligo;
TGCT	cis	rs1577917	1.000	rs12192992	chr6:86609915	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.13	-0.42	1.07e-6	Response to antipsychotic treatment;
TGCT	cis	rs17718580	0.536	rs59807161	chr14:51091475	G/C	cg04730355	chr14:51134070	SAV1	1.24	8.74	0.62	1.38e-14	Cognitive performance;
TGCT	cis	rs1692580	0.777	rs10910037	chr1:2184280	T/C	cg21194808	chr1:2205498	SKI	0.29	5.5	0.44	2.06e-7	Coronary artery disease;
TGCT	trans	rs2749592	0.531	rs994804	chr10:37900140	A/C	cg17830980	chr10:43048298	ZNF37B	0.65	6.85	0.52	3.1e-10	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg21963583	chr11:68658836	MRPL21	0.36	6.09	0.48	1.3e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs10883723	0.810	rs3781289	chr10:104244991	G/T	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs9341808	0.754	rs6918172	chr6:81019242	A/G	cg08355045	chr6:80787529	NA	0.27	4.61	0.38	9.8200000000000008e-06	Sitting height ratio;
TGCT	cis	rs9611565	0.625	rs2076199	chr22:41903743	G/T	cg06481639	chr22:41940642	POLR3H	-0.55	-4.77	-0.39	5.11e-6	Vitiligo;
TGCT	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg24549020	chr5:56110836	MAP3K1	0.67	5.78	0.46	5.74e-8	Initial pursuit acceleration;
TGCT	cis	rs9362426	1.000	rs406900	chr6:88085447	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.46	5.19	0.42	8.5e-7	Depressive episodes in bipolar disorder;
TGCT	cis	rs79349575	0.651	rs4378658	chr17:46993370	G/A	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.51	-0.38	1.48e-5	Type 2 diabetes;
TGCT	cis	rs11105298	0.891	rs10858906	chr12:89934474	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.67	-4.85	-0.4	3.63e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs7937682	0.575	rs11604704	chr11:111764396	G/A	cg09085632	chr11:111637200	PPP2R1B	0.91	8.56	0.61	3.6e-14	Primary sclerosing cholangitis;
TGCT	trans	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg17470723	chr8:74884337	TCEB1	0.72	6.94	0.53	1.91e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs56235845	0.694	rs12055081	chr5:176757191	C/T	cg16006841	chr5:176797999	RGS14	0.5	7.45	0.56	1.38e-11	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs4295623	0.559	rs4841600	chr8:11688148	T/C	cg02840367	chr8:11660030	FDFT1	-0.66	-5.38	-0.43	3.63e-7	Morning vs. evening chronotype;
TGCT	cis	rs4746818	1.000	rs7899844	chr10:70949694	A/G	cg11621586	chr10:70884670	VPS26A	1.21	10.5	0.69	7.7e-19	Left atrial antero-posterior diameter;
TGCT	cis	rs7760949	0.852	rs9464423	chr6:13931851	A/G	cg27413430	chr6:13925136	RNF182	0.74	6.83	0.52	3.37e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs57590327	0.503	rs13066091	chr3:81589912	T/C	cg07356753	chr3:81810745	GBE1	-0.61	-5.1	-0.42	1.24e-6	Extraversion;
TGCT	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg02725872	chr8:58115012	NA	-0.39	-4.74	-0.39	5.67e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs62388641	0.539	rs56304710	chr6:1542576	C/T	cg01806741	chr6:1527072	NA	-0.3	-4.63	-0.38	9.19e-6	Daytime sleep phenotypes;
TGCT	cis	rs74705753	1.000	rs74705753	chr22:42201517	A/G	cg03806693	chr22:41940476	POLR3H	-1.04	-5.02	-0.41	1.72e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1395	1.000	rs2014252	chr2:27462405	T/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.51	6.76	0.52	4.84e-10	Blood metabolite levels;
TGCT	cis	rs986417	0.551	rs1956553	chr14:60952298	T/A	cg27398547	chr14:60952738	C14orf39	1.39	10.61	0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs992157	0.710	rs7569907	chr2:219070551	C/T	cg00012203	chr2:219082015	ARPC2	0.81	10.19	0.68	4.34e-18	Colorectal cancer;
TGCT	trans	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg11887960	chr12:57824829	NA	1.16	9.59	0.65	1.25e-16	Lung disease severity in cystic fibrosis;
TGCT	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6088580	0.634	rs6059850	chr20:33044784	C/G	cg08999081	chr20:33150536	PIGU	0.29	5.59	0.45	1.37e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs4252435	0.520	rs7797896	chr7:142641189	T/C	cg09833174	chr7:143059591	FAM131B	-1.02	-4.65	-0.39	8.26e-6	Cancer;
TGCT	cis	rs3806843	0.576	rs251376	chr5:140253689	A/G	cg07102913	chr5:140593443	PCDHB13	0.48	4.59	0.38	1.06e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs4851266	1.000	rs893246	chr2:100814917	T/C	cg22139774	chr2:100720529	AFF3	-0.36	-5.38	-0.44	3.55e-7	Educational attainment;
TGCT	cis	rs9325144	0.647	rs1875609	chr12:39018259	C/T	cg13010199	chr12:38710504	ALG10B	-0.51	-4.58	-0.38	1.13e-5	Morning vs. evening chronotype;
TGCT	cis	rs7264396	0.790	rs6060542	chr20:34249061	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.25	-0.43	6.33e-7	Total cholesterol levels;
TGCT	cis	rs17376456	0.866	rs13356088	chr5:93423479	C/T	cg25358565	chr5:93447407	FAM172A	0.87	6.63	0.51	9.2e-10	Diabetic retinopathy;
TGCT	cis	rs11190604	1.000	rs10883512	chr10:102308516	A/G	cg23241863	chr10:102295624	HIF1AN	0.68	5.13	0.42	1.08e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs57920188	0.568	rs10915665	chr1:4093717	G/T	cg20703997	chr1:4087676	NA	0.47	5.03	0.41	1.71e-6	Interleukin-17 levels;
TGCT	cis	rs2243480	1.000	rs958550	chr7:65635679	C/T	cg20637647	chr7:64974828	NA	-0.9	-5.21	-0.42	7.51e-7	Diabetic kidney disease;
TGCT	trans	rs4650994	1.000	rs4077194	chr1:178533832	A/C	cg05059571	chr16:84539110	KIAA1609	0.38	7.17	0.54	5.97e-11	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs9372498	0.536	rs13437605	chr6:118899014	C/T	cg21191810	chr6:118973309	C6orf204	-0.39	-5.04	-0.41	1.59e-6	Diastolic blood pressure;
TGCT	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg27535305	chr1:53392650	SCP2	-0.24	-4.9	-0.4	2.94e-6	Monocyte count;
TGCT	cis	rs5769707	0.681	rs4824068	chr22:50024801	G/A	cg06623630	chr22:50017776	C22orf34	-0.27	-4.7	-0.39	6.81e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs11249608	0.548	rs34054398	chr5:178458371	A/G	cg23951258	chr5:178450506	ZNF879	0.44	4.56	0.38	1.22e-5	Pubertal anthropometrics;
TGCT	cis	rs9341808	0.718	rs3812121	chr6:80968727	A/G	cg08355045	chr6:80787529	NA	0.29	4.95	0.41	2.37e-6	Sitting height ratio;
TGCT	cis	rs208520	0.690	rs864314	chr6:66814830	G/A	cg07460842	chr6:66804631	NA	-1.07	-15.41	-0.81	1.34e-30	Exhaled nitric oxide output;
TGCT	cis	rs12477438	0.501	rs6727749	chr2:99793590	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.75	7.25	0.55	3.92e-11	Chronic sinus infection;
TGCT	cis	rs910316	0.763	rs175014	chr14:75456927	A/G	cg08847533	chr14:75593920	NEK9	-0.86	-9.08	-0.63	2.05e-15	Height;
TGCT	cis	rs7091068	0.550	rs7901909	chr10:95492508	C/T	cg20715218	chr10:95462985	C10orf4	0.5	5.7	0.46	8.21e-8	Urinary tract infection frequency;
TGCT	trans	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg24694675	chr1:76082066	NA	-0.64	-6.63	-0.51	9.42e-10	Bipolar disorder and schizophrenia;
TGCT	cis	rs539096	0.872	rs3828150	chr1:44050856	T/C	cg12908607	chr1:44402522	ARTN	-0.48	-4.83	-0.4	3.93e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9443645	0.901	rs9448580	chr6:79551812	C/G	cg09184832	chr6:79620586	NA	-0.47	-5.23	-0.43	6.98e-7	Intelligence (multi-trait analysis);
TGCT	trans	rs797680	0.856	rs2765545	chr1:93677269	G/A	cg27528825	chr2:159282178	CCDC148	-0.35	-6.88	-0.53	2.65e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs832540	0.864	rs832576	chr5:56163255	C/A	cg12311346	chr5:56204834	C5orf35	-0.49	-5.37	-0.43	3.73e-7	Coronary artery disease;
TGCT	cis	rs9467711	0.606	rs9358937	chr6:26374274	C/G	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	trans	rs829418	0.582	rs747662	chr1:21947218	C/G	cg07081061	chr6:3350901	SLC22A23	-0.71	-6.88	-0.53	2.6e-10	Neurocognitive impairment in HIV-1 infection (continuous);
TGCT	cis	rs1205863	1.000	rs960414	chr6:11946676	G/A	cg07106625	chr6:11870215	NA	0.51	5.05	0.41	1.51e-6	Disc degeneration (lumbar);
TGCT	cis	rs763014	0.833	rs916415	chr16:632115	G/A	cg07343612	chr16:622815	PIGQ	-0.41	-7.87	-0.58	1.52e-12	Height;
TGCT	cis	rs9611565	0.512	rs139560	chr22:42194962	A/G	cg06481639	chr22:41940642	POLR3H	-0.67	-5.95	-0.47	2.57e-8	Vitiligo;
TGCT	cis	rs868036	0.681	rs9920643	chr15:68104314	C/T	cg05925327	chr15:68127851	NA	-0.5	-4.85	-0.4	3.57e-6	Restless legs syndrome;
TGCT	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg11644478	chr21:40555479	PSMG1	-0.61	-5.72	-0.46	7.44e-8	Cognitive function;
TGCT	cis	rs6121246	0.609	rs1009453	chr20:30404840	C/G	cg10886678	chr20:30946050	ASXL1	-0.57	-4.79	-0.4	4.68e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs12142240	0.698	rs17361812	chr1:46814008	C/T	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs9467773	1.000	rs6910899	chr6:26524339	A/G	cg05738196	chr6:26577821	NA	0.88	12.5	0.75	1.03e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs4918072	0.728	rs7099351	chr10:105710933	A/G	cg11005552	chr10:105648138	OBFC1	0.34	4.47	0.37	1.75e-5	Coronary artery disease;
TGCT	cis	rs57590327	0.503	rs1464790	chr3:81852923	A/T	cg07356753	chr3:81810745	GBE1	0.67	6.15	0.48	9.91e-9	Extraversion;
TGCT	cis	rs797680	0.754	rs3767964	chr1:93815490	T/C	cg17826107	chr1:92977322	EVI5	-0.24	-5.65	-0.45	1.05e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs4642101	0.561	rs4560285	chr3:12809066	G/A	cg05775895	chr3:12838266	CAND2	0.49	4.75	0.39	5.58e-6	QRS complex (12-leadsum);
TGCT	cis	rs319204	0.843	rs319161	chr5:146300154	T/C	cg25021259	chr5:146258546	PPP2R2B	0.37	4.59	0.38	1.06e-5	Schizophrenia;
TGCT	cis	rs7809950	1.000	rs4727681	chr7:107096144	T/C	cg23024343	chr7:107201750	COG5	-0.33	-5.27	-0.43	5.81e-7	Coronary artery disease;
TGCT	cis	rs711245	0.573	rs3770796	chr2:36799515	T/C	cg09467607	chr2:36825704	FEZ2	0.33	4.67	0.39	7.72e-6	Height;
TGCT	cis	rs6570726	0.905	rs406799	chr6:145821837	G/C	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs17767294	0.615	rs72845058	chr6:27647420	T/C	cg08851530	chr6:28072375	NA	1.56	7.38	0.55	1.95e-11	Parkinson's disease;
TGCT	cis	rs73001065	0.636	rs11668104	chr19:19426181	G/A	cg03709012	chr19:19516395	GATAD2A	0.87	4.66	0.39	8.18e-6	LDL cholesterol;
TGCT	cis	rs727505	1.000	rs10233596	chr7:124556659	A/G	cg23710748	chr7:124431027	NA	-0.26	-4.49	-0.37	1.63e-5	Lewy body disease;
TGCT	trans	rs7726839	0.718	rs6887972	chr5:597274	C/G	cg11887960	chr12:57824829	NA	0.95	7.37	0.55	2.12e-11	Obesity-related traits;
TGCT	cis	rs6988636	0.710	rs62521806	chr8:124161054	C/T	cg27053337	chr8:124217698	FAM83A	0.71	5.42	0.44	3e-7	Urinary uromodulin levels;
TGCT	cis	rs11031096	0.502	rs4910598	chr11:4101368	C/T	cg18678763	chr11:4115507	RRM1	-0.45	-5.42	-0.44	2.96e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs981844	0.712	rs62325150	chr4:154728117	T/G	cg14289246	chr4:154710475	SFRP2	1.04	9.67	0.66	8.17e-17	Response to statins (LDL cholesterol change);
TGCT	trans	rs7824557	0.564	rs2437152	chr8:11235497	G/A	cg15556689	chr8:8085844	FLJ10661	-0.74	-6.7	-0.52	6.48e-10	Retinal vascular caliber;
TGCT	cis	rs61867294	0.597	rs6584641	chr10:106691096	C/T	cg08000847	chr10:105880925	C10orf78	-0.49	-4.46	-0.37	1.8e-5	Schizophrenia;
TGCT	cis	rs6748734	0.817	rs10182575	chr2:241806690	C/T	cg07537917	chr2:241836409	C2orf54	-0.2	-4.47	-0.37	1.71e-5	Urinary metabolites;
TGCT	cis	rs225245	0.817	rs225269	chr17:33967931	G/T	cg05299278	chr17:33885742	SLFN14	0.21	4.5	0.37	1.53e-5	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs1733410	0.504	rs11181874	chr12:37912890	C/A	cg26384229	chr12:38710491	ALG10B	-0.7	-6.15	-0.48	9.71e-9	Morning vs. evening chronotype;
TGCT	cis	rs2180341	0.920	rs9398836	chr6:127576497	T/G	cg24812749	chr6:127587940	RNF146	0.93	7.35	0.55	2.36e-11	Breast cancer;
TGCT	cis	rs6754311	0.773	rs632632	chr2:136638216	A/G	cg07169764	chr2:136633963	MCM6	0.6	5.71	0.46	7.98e-8	Mosquito bite size;
TGCT	cis	rs12048904	0.619	rs10783153	chr1:101328230	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.85	8.05	0.59	5.63e-13	Multiple sclerosis;
TGCT	cis	rs7666738	0.830	rs11727653	chr4:99001774	T/C	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg18904891	chr8:8559673	CLDN23	0.59	5.54	0.45	1.75e-7	Obesity-related traits;
TGCT	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg12310025	chr6:25882481	NA	-0.62	-6.53	-0.51	1.53e-9	Blood metabolite levels;
TGCT	cis	rs2224391	0.590	rs2753235	chr6:5252182	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	1.01	6.92	0.53	2.18e-10	Height;
TGCT	cis	rs12136530	0.593	rs9287047	chr1:19736534	T/C	cg24875000	chr1:19041556	PAX7	-0.26	-4.62	-0.38	9.56e-6	Lead levels in blood;
TGCT	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.47	-4.88	-0.4	3.15e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.92	10.02	0.67	1.16e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg11890956	chr21:40555474	PSMG1	0.8	7.66	0.57	4.53e-12	Cognitive function;
TGCT	cis	rs10858047	0.883	rs222493	chr1:115128087	A/G	cg12756093	chr1:115239321	AMPD1	-0.47	-4.96	-0.41	2.27e-6	Autism;
TGCT	cis	rs34014631	0.892	rs79550344	chr10:103613098	G/A	cg22630918	chr10:102748988	C10orf2	0.43	4.8	0.4	4.57e-6	Coronary artery calcification;
TGCT	cis	rs912057	0.833	rs1294421	chr6:6743149	A/C	cg06612196	chr6:6737390	NA	0.37	4.88	0.4	3.17e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs9928842	0.765	rs6564222	chr16:75225044	A/G	cg09066997	chr16:75300724	BCAR1	0.28	5.14	0.42	1.06e-6	Alcoholic chronic pancreatitis;
TGCT	trans	rs4332037	0.707	rs62435130	chr7:1890002	C/T	cg25206134	chr2:45395956	NA	0.96	8.2	0.59	2.59e-13	Bipolar disorder;
TGCT	cis	rs586688	1.000	rs586688	chr1:201630955	G/A	cg05779441	chr1:201574716	NA	0.29	4.7	0.39	6.78e-6	Obesity-related traits;
TGCT	trans	rs7819412	0.668	rs2409715	chr8:11010136	A/T	cg15556689	chr8:8085844	FLJ10661	-0.81	-7.28	-0.55	3.44e-11	Triglycerides;
TGCT	cis	rs4918072	0.754	rs4918065	chr10:105617578	T/C	cg11005552	chr10:105648138	OBFC1	0.4	5.15	0.42	9.8e-7	Coronary artery disease;
TGCT	cis	rs736408	0.581	rs3617	chr3:52833805	C/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.5	-4.66	-0.39	8.06e-6	Bipolar disorder;
TGCT	cis	rs611744	0.870	rs633794	chr8:109174702	A/G	cg21045802	chr8:109455806	TTC35	0.68	6.08	0.48	1.4e-8	Dupuytren's disease;
TGCT	cis	rs9916302	0.904	rs1966916	chr17:37425238	T/G	cg07936489	chr17:37558343	FBXL20	-0.62	-4.91	-0.4	2.77e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs1153858	1.000	rs1346268	chr15:45673029	T/C	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.62e-8	Homoarginine levels;
TGCT	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2274273	0.745	rs8005399	chr14:55542845	A/G	cg01923255	chr14:55878535	KIAA0831	0.56	4.59	0.38	1.09e-5	Protein biomarker;
TGCT	trans	rs1814175	0.817	rs4881658	chr11:49941123	G/A	cg03929089	chr4:120376271	NA	-0.7	-7.87	-0.58	1.51e-12	Height;
TGCT	cis	rs10791097	0.967	rs10750450	chr11:130719061	G/T	cg12179176	chr11:130786555	SNX19	0.65	6.88	0.53	2.63e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs11122272	0.701	rs2486725	chr1:231540288	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-6.28	-0.49	5.32e-9	Hemoglobin concentration;
TGCT	cis	rs57920188	0.585	rs12127463	chr1:4079127	C/T	cg20703997	chr1:4087676	NA	0.46	5.71	0.46	8.05e-8	Interleukin-17 levels;
TGCT	cis	rs4727027	0.868	rs10952799	chr7:148840772	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	4.55	0.38	1.25e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs6918586	0.616	rs1056314	chr6:26114653	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.7	6.6	0.51	1.09e-9	Schizophrenia;
TGCT	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg11494091	chr17:61959527	GH2	0.61	14.81	0.8	3.37e-29	Prudent dietary pattern;
TGCT	cis	rs7843479	0.601	rs9969551	chr8:21860007	T/C	cg17168535	chr8:21777572	XPO7	0.8	7.93	0.58	1.11e-12	Mean corpuscular volume;
TGCT	trans	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg17830980	chr10:43048298	ZNF37B	-0.81	-10.13	-0.67	6.19e-18	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7296418	0.885	rs1051434	chr12:123641200	C/T	cg05973401	chr12:123451056	ABCB9	0.54	4.47	0.37	1.71e-5	Platelet count;
TGCT	cis	rs2033711	0.870	rs4801583	chr19:58918405	A/G	cg13877915	chr19:58951672	ZNF132	0.87	10.88	0.7	9.34e-20	Uric acid clearance;
TGCT	cis	rs929354	0.772	rs3802125	chr7:156970563	A/C	cg05182265	chr7:156933206	UBE3C	-0.37	-8.21	-0.59	2.42e-13	Body mass index;
TGCT	cis	rs911555	0.504	rs61995761	chr14:104075712	T/C	cg26031613	chr14:104095156	KLC1	0.61	5.6	0.45	1.34e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs17401966	0.867	rs61775872	chr1:10279308	T/C	cg19773385	chr1:10388646	KIF1B	-0.22	-4.65	-0.39	8.41e-6	Hepatocellular carcinoma;
TGCT	cis	rs7267979	1.000	rs7019	chr20:25278278	C/T	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7666738	0.830	rs58696666	chr4:99006913	C/T	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7666738	0.830	rs7662948	chr4:99020132	G/C	cg05340658	chr4:99064831	C4orf37	0.46	5.13	0.42	1.09e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs68170813	0.562	rs17429825	chr7:107050731	C/T	cg02696742	chr7:106810147	HBP1	-0.7	-5.68	-0.45	8.91e-8	Coronary artery disease;
TGCT	cis	rs12497850	1.000	rs6788650	chr3:48749543	T/C	cg06212747	chr3:49208901	KLHDC8B	0.62	5.94	0.47	2.65e-8	Parkinson's disease;
TGCT	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg22920501	chr2:26401640	FAM59B	-0.78	-6.26	-0.49	5.88e-9	Gut microbiome composition (summer);
TGCT	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.63	5.12	0.42	1.11e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs3806843	0.548	rs246055	chr5:140325662	C/T	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7098414	0.531	rs4120852	chr10:82018594	G/T	cg01528321	chr10:82214614	TSPAN14	0.63	5.67	0.45	9.43e-8	Post bronchodilator FEV1;
TGCT	cis	rs9910055	0.573	rs228768	chr17:42191893	A/C	cg19774624	chr17:42201019	HDAC5	-0.64	-6.85	-0.52	3.1e-10	Total body bone mineral density;
TGCT	cis	rs5769765	1.000	rs4824106	chr22:50267822	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	1.11	11.76	0.73	6.5e-22	Schizophrenia;
TGCT	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg18402987	chr7:1209562	NA	0.78	6.64	0.51	8.96e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7772486	0.686	rs702314	chr6:146003510	G/A	cg05347473	chr6:146136440	FBXO30	-0.48	-4.51	-0.38	1.47e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9534288	0.699	rs1467665	chr13:46662919	C/T	cg15192986	chr13:46630673	CPB2	-0.51	-6.02	-0.48	1.87e-8	Blood protein levels;
TGCT	cis	rs11209002	0.614	rs12140736	chr1:67586671	T/C	cg02640540	chr1:67518911	SLC35D1	0.56	4.62	0.38	9.4e-6	Crohn's disease;
TGCT	cis	rs2346177	1.000	rs12619985	chr2:46641627	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.43	-4.64	-0.38	8.81e-6	HDL cholesterol;
TGCT	cis	rs5769765	0.954	rs5770707	chr22:50244533	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.37	-5.7	-0.46	8.42e-8	Schizophrenia;
TGCT	cis	rs4720575	1.000	rs917108	chr7:47088047	A/G	cg00036614	chr7:47093842	NA	-0.21	-5.14	-0.42	1.02e-6	Angiotensin-converting enzyme inhibitor intolerance;
TGCT	cis	rs7681440	0.874	rs10028246	chr4:90766704	G/A	cg20003494	chr4:90757398	SNCA	-0.62	-5.93	-0.47	2.74e-8	Dementia with Lewy bodies;
TGCT	cis	rs709400	0.628	rs1951392	chr14:103853367	T/G	cg12935359	chr14:103987150	CKB	-0.38	-5.59	-0.45	1.35e-7	Body mass index;
TGCT	cis	rs11874712	1.000	rs1800640	chr18:43671400	A/G	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.51	4.84	0.4	3.81e-6	Migraine - clinic-based;
TGCT	cis	rs10876993	0.749	rs703832	chr12:58024626	G/C	cg15848620	chr12:58087721	OS9	-0.76	-5.73	-0.46	7.12e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs10838634	1.000	rs7123729	chr11:46830575	T/C	cg18332754	chr11:46939436	LRP4	0.9	4.59	0.38	1.05e-5	Schizophrenia;
TGCT	cis	rs7246657	0.882	rs10412043	chr19:37826626	A/C	cg18154014	chr19:37997991	ZNF793	0.72	5.18	0.42	8.64e-7	Coronary artery calcification;
TGCT	cis	rs4786125	0.587	rs12920700	chr16:6926397	C/T	cg03623568	chr16:6915990	A2BP1	-0.43	-6.42	-0.5	2.62e-9	Heart rate variability traits (SDNN);
TGCT	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg11965913	chr1:205819406	PM20D1	0.49	6.62	0.51	9.88e-10	Menarche (age at onset);
TGCT	cis	rs12510870	0.599	rs28407399	chr4:74448433	T/G	cg05868023	chr4:75230803	EREG	-0.54	-4.76	-0.39	5.33e-6	Iris color (b* coordinate);
TGCT	cis	rs8008270	0.648	rs17125955	chr14:53406442	T/C	cg01926858	chr14:53619558	DDHD1	-0.76	-4.61	-0.38	9.89e-6	Prostate cancer;
TGCT	cis	rs2594989	0.623	rs6802055	chr3:11470642	T/A	cg00170343	chr3:11313890	ATG7	0.86	5.27	0.43	5.97e-7	Circulating chemerin levels;
TGCT	cis	rs4372836	0.715	rs66904522	chr2:29080892	A/C	cg09522027	chr2:28974177	PPP1CB	0.67	6.94	0.53	1.89e-10	Body mass index;
TGCT	cis	rs4499344	0.526	rs17832981	chr19:33034461	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.7	6.0	0.47	2.03e-8	Mean platelet volume;
TGCT	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	5.53	0.44	1.8e-7	Alzheimer's disease;
TGCT	cis	rs4595586	0.545	rs925829	chr12:39364167	A/G	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs28595532	0.920	rs114928651	chr4:119734194	T/C	cg14228332	chr4:119757509	SEC24D	1.32	6.38	0.5	3.2e-9	Cannabis dependence symptom count;
TGCT	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg03303774	chr4:1407052	NA	-0.32	-4.92	-0.4	2.7e-6	Obesity-related traits;
TGCT	cis	rs9486719	1.000	rs12205655	chr6:96891733	T/A	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.86	-0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs1997103	1.000	rs6973450	chr7:55396537	A/G	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs12220898	0.749	rs4838377	chr10:50488101	C/G	cg06072769	chr10:50146962	WDFY4	0.36	4.78	0.39	4.88e-6	Inflammatory biomarkers;
TGCT	cis	rs6733011	0.628	rs10188156	chr2:99465875	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.47	-4.68	-0.39	7.34e-6	Bipolar disorder;
TGCT	cis	rs651907	0.557	rs34181125	chr3:101490278	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.32	-6.66	-0.51	7.93e-10	Colorectal cancer;
TGCT	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg05985448	chr10:134359359	INPP5A	0.22	4.92	0.4	2.74e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs921968	1.000	rs921968	chr2:219272294	G/T	cg02176678	chr2:219576539	TTLL4	0.34	4.82	0.4	4.05e-6	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg04944784	chr2:26401820	FAM59B	-0.67	-6.05	-0.48	1.62e-8	Gut microbiome composition (summer);
TGCT	cis	rs12950390	0.853	rs8071192	chr17:45856141	A/G	cg24803719	chr17:45855879	NA	-0.5	-5.12	-0.42	1.15e-6	IgG glycosylation;
TGCT	cis	rs2013441	1.000	rs34712254	chr17:20049308	C/T	cg18979559	chr17:20280153	CCDC144C	0.44	4.61	0.38	9.78e-6	Obesity-related traits;
TGCT	cis	rs1371867	0.846	rs1788191	chr8:101260844	C/T	cg06002616	chr8:101225028	SPAG1	0.57	6.77	0.52	4.48e-10	Atrioventricular conduction;
TGCT	cis	rs782590	0.935	rs782649	chr2:55860308	T/C	cg03859395	chr2:55845619	SMEK2	0.94	11.41	0.72	4.58e-21	Metabolic syndrome;
TGCT	cis	rs7010267	0.869	rs1982763	chr8:119947828	C/T	cg17171407	chr8:119960777	TNFRSF11B	-0.33	-6.2	-0.49	7.72e-9	Total body bone mineral density (age 45-60);
TGCT	cis	rs7246657	0.722	rs2972438	chr19:38210847	A/G	cg18154014	chr19:37997991	ZNF793	0.74	5.28	0.43	5.63e-7	Coronary artery calcification;
TGCT	cis	rs9902453	0.765	rs6505143	chr17:28150585	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.83	7.95	0.58	9.99e-13	Coffee consumption (cups per day);
TGCT	cis	rs7726839	0.540	rs28364691	chr5:664084	G/A	cg09021430	chr5:549028	NA	-0.4	-5.64	-0.45	1.08e-7	Obesity-related traits;
TGCT	cis	rs4638749	1.000	rs1466211	chr2:108856412	G/A	cg06795125	chr2:108905320	SULT1C2	-0.39	-4.81	-0.4	4.26e-6	Blood pressure;
TGCT	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg27454412	chr7:1067447	C7orf50	0.6	4.72	0.39	6.32e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2229238	0.911	rs6681207	chr1:154517217	T/C	cg13067139	chr1:155221277	FAM189B	0.21	4.48	0.37	1.68e-5	Coronary heart disease;
TGCT	cis	rs1670533	1.000	rs7669399	chr4:1058478	T/G	cg27284194	chr4:1044797	NA	0.68	5.88	0.47	3.56e-8	Recombination rate (females);
TGCT	cis	rs7010267	0.744	rs2062377	chr8:120007420	T/A	cg17171407	chr8:119960777	TNFRSF11B	0.28	5.14	0.42	1.03e-6	Total body bone mineral density (age 45-60);
TGCT	cis	rs7666738	0.830	rs13101352	chr4:98957544	C/T	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs17376456	0.877	rs10476597	chr5:93367172	C/T	cg21475434	chr5:93447410	FAM172A	-0.69	-4.97	-0.41	2.21e-6	Diabetic retinopathy;
TGCT	cis	rs7095607	0.813	rs2087345	chr10:69922843	T/C	cg18986048	chr10:69913749	MYPN	0.48	5.57	0.45	1.54e-7	Lung function (FVC);
TGCT	cis	rs2404602	0.684	rs12437981	chr15:76842401	A/G	cg23625390	chr15:77176239	SCAPER	-0.38	-4.68	-0.39	7.3e-6	Blood metabolite levels;
TGCT	cis	rs72717009	0.825	rs7529225	chr1:161479352	G/A	cg23840854	chr1:161414152	NA	-0.97	-5.65	-0.45	1.03e-7	Rheumatoid arthritis;
TGCT	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9653442	0.593	rs7597861	chr2:100853187	G/A	cg22139774	chr2:100720529	AFF3	-0.39	-6.33	-0.49	4.13e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs35000415	0.938	rs12535158	chr7:128625019	C/T	cg06242719	chr7:129414860	MIR183;MIR96	-0.31	-4.52	-0.38	1.4e-5	Systemic lupus erythematosus;
TGCT	cis	rs4765905	0.500	rs2239033	chr12:2337746	C/A	cg07807026	chr12:2041581	NA	-0.25	-4.45	-0.37	1.91e-5	Schizophrenia;
TGCT	cis	rs8072100	1.000	rs4794048	chr17:45763073	A/C	cg08085267	chr17:45401833	C17orf57	-0.43	-4.73	-0.39	6.01e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs425277	0.628	rs3107145	chr1:2047547	G/A	cg03732007	chr1:2071316	PRKCZ	-0.28	-6.2	-0.49	7.52e-9	Height;
TGCT	cis	rs4972806	0.775	rs2857534	chr2:177035676	G/T	cg03152288	chr2:177042942	NA	0.62	5.45	0.44	2.6e-7	IgG glycosylation;
TGCT	cis	rs644799	0.648	rs1016031	chr11:95473365	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.56	-5.44	-0.44	2.69e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs1371867	0.846	rs1660338	chr8:101242757	C/G	cg00191853	chr8:101177733	SPAG1	-0.23	-4.86	-0.4	3.42e-6	Atrioventricular conduction;
TGCT	cis	rs7412746	0.646	rs10399947	chr1:150861960	G/A	cg09365446	chr1:150670422	GOLPH3L	0.34	4.81	0.4	4.33e-6	Melanoma;
TGCT	cis	rs2456568	0.802	rs1108910	chr11:93629677	C/T	cg16099599	chr11:93583650	C11orf90	0.41	4.99	0.41	2.03e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs8017423	0.529	rs12898020	chr14:90835752	A/G	cg04374321	chr14:90722782	PSMC1	-0.53	-4.7	-0.39	6.71e-6	Mortality in heart failure;
TGCT	cis	rs514406	0.698	rs1672913	chr1:53408326	A/T	cg22166914	chr1:53195759	ZYG11B	0.3	4.95	0.41	2.41e-6	Monocyte count;
TGCT	cis	rs8051149	0.793	rs12445334	chr16:87871213	G/A	cg01412419	chr16:87856264	NA	0.49	5.79	0.46	5.38e-8	Blood metabolite levels;
TGCT	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	16.05	0.82	4.59e-32	Prudent dietary pattern;
TGCT	cis	rs7714584	1.000	rs7724558	chr5:150328866	T/C	cg22134413	chr5:150180641	NA	0.89	5.24	0.43	6.8e-7	Crohn's disease;
TGCT	cis	rs13064411	0.542	rs9846539	chr3:113228688	A/G	cg18753928	chr3:113234510	CCDC52	-0.56	-4.72	-0.39	6.3e-6	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs4900538	0.821	rs2009575	chr14:102820787	C/T	cg18135206	chr14:102964638	TECPR2	-0.22	-5.09	-0.42	1.31e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs9467773	0.595	rs2237236	chr6:26451553	A/G	cg05738196	chr6:26577821	NA	-0.51	-5.51	-0.44	2.03e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs3820068	0.577	rs41270271	chr1:15913582	G/C	cg05660106	chr1:15850417	CASP9	1.05	11.89	0.73	3.11e-22	Systolic blood pressure;
TGCT	cis	rs2721811	0.570	rs2721803	chr7:24781532	C/T	cg17569154	chr7:24781545	DFNA5	0.22	4.77	0.39	5.15e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs1371867	0.846	rs1660327	chr8:101292206	A/C	cg06636551	chr8:101224915	SPAG1	-0.48	-6.52	-0.51	1.62e-9	Atrioventricular conduction;
TGCT	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg02487422	chr3:49467188	NICN1	0.49	4.46	0.37	1.85e-5	Parkinson's disease;
TGCT	cis	rs2288884	0.708	rs59104696	chr19:52555170	C/T	cg15405931	chr19:52693188	PPP2R1A	-0.64	-4.5	-0.38	1.51e-5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs12477438	0.765	rs28648058	chr2:99696417	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.8	-8.02	-0.58	6.63e-13	Chronic sinus infection;
TGCT	cis	rs763121	0.853	rs6001191	chr22:39074452	T/C	cg06022373	chr22:39101656	GTPBP1	0.77	7.46	0.56	1.35e-11	Menopause (age at onset);
TGCT	cis	rs2456568	0.508	rs1607403	chr11:93660514	A/G	cg26875233	chr11:93583750	C11orf90	-0.41	-4.97	-0.41	2.14e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg21724239	chr8:58056113	NA	0.45	4.8	0.4	4.39e-6	Developmental language disorder (linguistic errors);
TGCT	trans	rs7824557	0.564	rs2736293	chr8:11234613	T/A	cg15556689	chr8:8085844	FLJ10661	-0.74	-6.7	-0.52	6.42e-10	Retinal vascular caliber;
TGCT	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg04234412	chr22:24373322	LOC391322	-0.86	-9.6	-0.65	1.17e-16	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg11905131	chr22:24372483	LOC391322	0.94	11.12	0.71	2.42e-20	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2933343	0.621	rs789241	chr3:128585752	G/A	cg11901034	chr3:128598214	ACAD9	-0.64	-6.16	-0.48	9.37e-9	IgG glycosylation;
TGCT	cis	rs2456568	0.900	rs2000960	chr11:93682348	C/T	cg14065697	chr11:93583672	C11orf90	-0.38	-4.58	-0.38	1.13e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs41271951	0.512	rs12058128	chr1:151106113	C/T	cg00666978	chr1:150947442	LASS2	0.89	4.64	0.38	8.54e-6	Blood protein levels;
TGCT	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg13695892	chr22:41940480	POLR3H	-0.92	-9.33	-0.64	5.22e-16	Vitiligo;
TGCT	cis	rs9916302	0.706	rs9906612	chr17:37547631	A/C	cg07936489	chr17:37558343	FBXL20	0.86	6.12	0.48	1.15e-8	Glomerular filtration rate (creatinine);
TGCT	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.62	-5.11	-0.42	1.17e-6	Tonsillectomy;
TGCT	trans	rs608114	0.623	rs507546	chr6:96375839	C/T	cg04008557	chr11:2826328	KCNQ1	-0.65	-6.82	-0.52	3.51e-10	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
TGCT	cis	rs3771570	0.786	rs62186396	chr2:242221219	A/G	cg21155796	chr2:242212141	HDLBP	0.98	6.68	0.51	7.29e-10	Prostate cancer;
TGCT	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg17971929	chr21:40555470	PSMG1	0.97	9.54	0.65	1.63e-16	Cognitive function;
TGCT	cis	rs2204008	0.614	rs4578492	chr12:38036350	T/C	cg13010199	chr12:38710504	ALG10B	0.65	5.23	0.42	7.11e-7	Bladder cancer;
TGCT	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.55	4.92	0.4	2.74e-6	Prudent dietary pattern;
TGCT	cis	rs2562456	0.874	rs2562417	chr19:21711202	T/C	cg01304269	chr19:21688519	ZNF429	-0.55	-4.59	-0.38	1.06e-5	Pain;
TGCT	trans	rs12599106	0.679	rs34584967	chr16:34475725	T/G	cg01516881	chr6:292596	DUSP22	-0.71	-7.54	-0.56	8.6e-12	Menopause (age at onset);
TGCT	cis	rs3820068	0.577	rs9728986	chr1:16040603	G/A	cg17385448	chr1:15911702	AGMAT	0.35	4.99	0.41	1.96e-6	Systolic blood pressure;
TGCT	cis	rs4727027	0.933	rs1044358	chr7:148879951	C/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	4.77	0.39	5.16e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs2239785	0.920	rs136154	chr22:36656138	A/T	cg15716373	chr22:36655542	APOL1	-0.41	-4.75	-0.39	5.58e-6	Glomerulosclerosis;
TGCT	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg11644478	chr21:40555479	PSMG1	-0.53	-4.96	-0.41	2.23e-6	Menarche (age at onset);
TGCT	cis	rs6426551	0.958	rs6702917	chr1:226547174	C/T	cg18564989	chr1:226411057	MIXL1	-0.48	-4.8	-0.4	4.44e-6	Coronary artery disease;
TGCT	cis	rs3806843	0.648	rs2530233	chr5:140082876	A/G	cg19875535	chr5:140030758	IK	-0.37	-6.23	-0.49	6.51e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2172802	1.000	rs12642315	chr4:62448934	C/G	cg04118610	chr4:62707027	LPHN3	-0.41	-4.83	-0.4	3.92e-6	Partial epilepsies;
TGCT	cis	rs225245	0.817	rs225255	chr17:33955243	A/G	cg05299278	chr17:33885742	SLFN14	-0.21	-4.64	-0.38	8.76e-6	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs28595532	0.841	rs115725150	chr4:119768647	T/A	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs9291683	0.507	rs3775940	chr4:10025163	A/T	cg11266682	chr4:10021025	SLC2A9	0.64	8.48	0.61	5.5e-14	Bone mineral density;
TGCT	cis	rs524281	0.861	rs7935336	chr11:65865325	C/T	cg00563793	chr11:65837595	PACS1	0.55	4.62	0.38	9.44e-6	Electroencephalogram traits;
TGCT	cis	rs826838	0.967	rs10875979	chr12:39095149	G/A	cg13010199	chr12:38710504	ALG10B	0.71	5.78	0.46	5.59e-8	Heart rate;
TGCT	cis	rs9427116	0.702	rs884618	chr1:154601157	A/G	cg17218026	chr1:154582156	ADAR	0.28	7.06	0.54	1.06e-10	Blood protein levels;
TGCT	cis	rs6500602	0.702	rs2058812	chr16:4524443	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.26	4.86	0.4	3.44e-6	Schizophrenia;
TGCT	cis	rs3125734	0.633	rs10740068	chr10:63982254	A/C	cg19640130	chr10:64028056	RTKN2	-0.39	-5.11	-0.42	1.19e-6	Rheumatoid arthritis;
TGCT	cis	rs910316	1.000	rs2268617	chr14:75608728	G/A	cg23033748	chr14:75592666	NEK9	0.29	4.9	0.4	2.95e-6	Height;
TGCT	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg18230493	chr5:56204884	C5orf35	-0.68	-5.92	-0.47	2.92e-8	Initial pursuit acceleration;
TGCT	cis	rs3806843	0.576	rs246007	chr5:140338748	C/T	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7267979	1.000	rs2257420	chr20:25275890	C/A	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs1416584	1.000	rs12683691	chr9:8220627	T/A	cg26401796	chr12:5574420	NTF3	0.6	6.85	0.52	3.04e-10	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs899997	1.000	rs11629824	chr15:79005524	T/G	cg00061860	chr15:78953028	NA	-0.25	-4.61	-0.38	9.69e-6	Coronary artery disease or large artery stroke;
TGCT	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg07636037	chr3:49044803	WDR6	0.88	9.28	0.64	6.89e-16	Menarche (age at onset);
TGCT	cis	rs854765	0.583	rs62064158	chr17:17826935	T/C	cg09796270	chr17:17721594	SREBF1	0.24	4.77	0.39	5.16e-6	Total body bone mineral density;
TGCT	cis	rs28595532	0.920	rs56303276	chr4:119723514	C/T	cg21605333	chr4:119757512	SEC24D	1.72	8.99	0.63	3.52e-15	Cannabis dependence symptom count;
TGCT	cis	rs6840360	1.000	rs10007015	chr4:152603528	C/G	cg17479576	chr4:152424074	FAM160A1	-0.48	-5.16	-0.42	9.63e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg09323728	chr8:95962352	TP53INP1	-0.52	-6.69	-0.52	6.78e-10	Type 2 diabetes;
TGCT	cis	rs7258465	0.931	rs7249020	chr19:18608147	A/G	cg06462663	chr19:18546047	ISYNA1	0.2	4.67	0.39	7.74e-6	Breast cancer;
TGCT	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg09323728	chr8:95962352	TP53INP1	-0.51	-6.46	-0.5	2.13e-9	Type 2 diabetes;
TGCT	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg04234412	chr22:24373322	LOC391322	0.93	11.89	0.73	3.2e-22	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6582630	0.555	rs10880544	chr12:38473464	G/C	cg13010199	chr12:38710504	ALG10B	0.58	4.72	0.39	6.16e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs12701220	0.894	rs2141274	chr7:1034717	G/A	cg07217954	chr7:1067459	C7orf50	-0.49	-4.89	-0.4	3.09e-6	Bronchopulmonary dysplasia;
TGCT	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg11644478	chr21:40555479	PSMG1	-0.57	-4.86	-0.4	3.44e-6	Cognitive function;
TGCT	cis	rs35883536	0.588	rs10465764	chr1:101105030	A/G	cg06223162	chr1:101003688	GPR88	0.33	5.41	0.44	3.15e-7	Monocyte count;
TGCT	cis	rs709400	0.628	rs7154246	chr14:103876794	G/A	cg12935359	chr14:103987150	CKB	0.34	5.19	0.42	8.36e-7	Body mass index;
TGCT	cis	rs5769707	0.681	rs8140095	chr22:50043795	A/G	cg06623630	chr22:50017776	C22orf34	-0.27	-4.67	-0.39	7.81e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs7267979	1.000	rs2258135	chr20:25272323	C/A	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs854765	0.547	rs4643387	chr17:17972973	C/T	cg09796270	chr17:17721594	SREBF1	0.26	5.05	0.41	1.53e-6	Total body bone mineral density;
TGCT	cis	rs8014252	0.803	rs10135356	chr14:71030355	T/C	cg11204974	chr14:71022665	NA	-0.53	-4.49	-0.37	1.63e-5	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
TGCT	cis	rs36051895	0.695	rs12347727	chr9:5000811	A/G	cg02405213	chr9:5042618	JAK2	-0.76	-10.04	-0.67	1e-17	Pediatric autoimmune diseases;
TGCT	cis	rs1008375	0.931	rs2315558	chr4:17674558	C/A	cg18681998	chr4:17616180	MED28	0.93	10.58	0.69	4.83e-19	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7772486	0.875	rs2814869	chr6:146315509	G/A	cg05347473	chr6:146136440	FBXO30	0.54	5.13	0.42	1.1e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4713118	0.699	rs200978	chr6:27853168	C/G	cg18675097	chr6:28227127	NKAPL	-0.35	-4.47	-0.37	1.72e-5	Parkinson's disease;
TGCT	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg17971929	chr21:40555470	PSMG1	-0.51	-4.55	-0.38	1.25e-5	Menarche (age at onset);
TGCT	cis	rs634534	0.563	rs470192	chr11:65724291	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.6	6.03	0.48	1.75e-8	Sum eosinophil basophil counts;Eosinophil counts;
TGCT	cis	rs11190604	1.000	rs11190569	chr10:102227409	C/T	cg16342193	chr10:102329863	NA	-0.41	-5.44	-0.44	2.67e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs1723838	0.826	rs1466218	chr11:73589184	G/T	cg18195628	chr11:73498948	MRPL48	0.93	4.55	0.38	1.28e-5	Obesity-related traits;
TGCT	cis	rs1580019	0.523	rs13236410	chr7:32690663	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.14	13.49	0.77	4.38e-26	Cognitive ability;
TGCT	cis	rs17253792	0.822	rs17683728	chr14:56060389	C/T	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs7843479	0.965	rs9314269	chr8:21804989	A/G	cg17168535	chr8:21777572	XPO7	0.65	5.99	0.47	2.14e-8	Mean corpuscular volume;
TGCT	cis	rs4478037	1.000	rs4074417	chr3:33161153	A/C	cg19404215	chr3:33155277	CRTAP	1.28	8.55	0.61	3.75e-14	Major depressive disorder;
TGCT	cis	rs6570726	0.791	rs9497357	chr6:145912888	G/A	cg23711669	chr6:146136114	FBXO30	0.88	9.32	0.64	5.56e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7523273	0.565	rs4081159	chr1:207885479	G/A	cg22525895	chr1:207977042	MIR29B2	0.35	5.69	0.45	8.78e-8	Schizophrenia;
TGCT	cis	rs826838	0.967	rs7963716	chr12:38876090	C/T	cg26384229	chr12:38710491	ALG10B	0.94	9.68	0.66	7.64e-17	Heart rate;
TGCT	cis	rs4699052	0.625	rs11097808	chr4:104263130	G/A	cg16532752	chr4:104119610	CENPE	-0.5	-4.92	-0.4	2.71e-6	Testicular germ cell tumor;
TGCT	cis	rs13191362	0.935	rs67673890	chr6:163107647	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.16	9.92	0.67	1.96e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs11112613	0.775	rs7299470	chr12:105961773	G/A	cg03607813	chr12:105948248	NA	0.46	5.56	0.45	1.6e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	cis	rs7635838	0.819	rs2454476	chr3:11545442	G/A	cg00170343	chr3:11313890	ATG7	0.67	6.13	0.48	1.1e-8	HDL cholesterol;
TGCT	cis	rs6693567	0.565	rs4926395	chr1:150405298	T/C	cg09579323	chr1:150459698	TARS2	0.52	4.6	0.38	1.03e-5	Migraine;
TGCT	cis	rs9549367	0.713	rs9549356	chr13:113851633	A/G	cg18105134	chr13:113819100	PROZ	-0.46	-8.3	-0.6	1.46e-13	Platelet distribution width;
TGCT	cis	rs116095464	0.558	rs9312957	chr5:202194	C/T	cg12570787	chr5:219185	SDHA;CCDC127	0.73	4.63	0.38	9.01e-6	Breast cancer;
TGCT	cis	rs7666738	0.753	rs4699604	chr4:99056353	T/C	cg18180107	chr4:99064573	C4orf37	0.56	5.08	0.41	1.37e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9467711	0.790	rs10484439	chr6:26309908	G/A	cg05948654	chr6:25930507	SLC17A2	0.34	4.54	0.38	1.29e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6754311	0.593	rs1438305	chr2:136502792	C/G	cg07169764	chr2:136633963	MCM6	-0.66	-6.11	-0.48	1.2e-8	Mosquito bite size;
TGCT	trans	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg17470723	chr8:74884337	TCEB1	0.72	6.94	0.53	1.91e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs765787	0.530	rs4775844	chr15:45542048	T/C	cg24006582	chr15:45444508	DUOX1	-0.25	-5.54	-0.45	1.76e-7	Uric acid levels;
TGCT	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg06873352	chr17:61820015	STRADA	0.58	6.37	0.5	3.32e-9	Prudent dietary pattern;
TGCT	cis	rs7647973	0.710	rs6446284	chr3:49616997	A/G	cg03060546	chr3:49711283	APEH	0.63	5.14	0.42	1.03e-6	Menarche (age at onset);
TGCT	cis	rs7772486	0.875	rs2777481	chr6:146310036	G/T	cg05347473	chr6:146136440	FBXO30	0.51	4.76	0.39	5.34e-6	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg23505145	chr19:12996616	KLF1	0.76	7.98	0.58	8.44e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2637266	1.000	rs2130799	chr10:78322922	C/T	cg18941641	chr10:78392320	NA	0.38	4.72	0.39	6.21e-6	Pulmonary function;
TGCT	cis	rs2153535	0.580	rs2152347	chr6:8474281	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs42648	0.935	rs42659	chr7:89981958	A/G	cg25739043	chr7:89950458	NA	-0.65	-6.22	-0.49	6.96e-9	Homocysteine levels;
TGCT	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg11494091	chr17:61959527	GH2	0.6	14.51	0.79	1.71e-28	Prudent dietary pattern;
TGCT	cis	rs7043114	0.525	rs10283572	chr9:95133074	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-5.58	-0.45	1.42e-7	Height;
TGCT	cis	rs7833790	0.636	rs12544174	chr8:82731477	G/A	cg27398817	chr8:82754497	SNX16	-0.67	-5.34	-0.43	4.27e-7	Diastolic blood pressure;
TGCT	cis	rs9640161	0.789	rs2373751	chr7:150021599	G/C	cg10018233	chr7:150070692	REPIN1	0.32	4.58	0.38	1.1e-5	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs73058052	0.569	rs2116922	chr19:50103252	G/A	cg09250473	chr19:50168907	IRF3;BCL2L12	0.68	5.58	0.45	1.42e-7	Fibrinogen levels;
TGCT	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg20607798	chr8:58055168	NA	0.45	4.59	0.38	1.06e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9911578	0.900	rs8067264	chr17:57182793	G/C	cg12560992	chr17:57184187	TRIM37	0.79	9.71	0.66	6.56e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs17030434	0.815	rs78638854	chr4:154648804	C/T	cg14289246	chr4:154710475	SFRP2	-0.85	-6.45	-0.5	2.28e-9	Electrocardiographic conduction measures;
TGCT	cis	rs4563143	0.514	rs73029076	chr19:29292032	G/T	cg04546413	chr19:29218101	NA	0.73	5.38	0.43	3.65e-7	Methadone dose in opioid dependence;
TGCT	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg18876405	chr7:65276391	NA	0.36	5.44	0.44	2.7e-7	Aortic root size;
TGCT	cis	rs17601876	0.786	rs2414100	chr15:51562420	T/A	cg19946085	chr15:51559439	CYP19A1	-0.33	-5.06	-0.41	1.45e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs76788097	0.614	rs7151034	chr14:61820669	T/G	cg11001769	chr14:61748440	TMEM30B	-0.52	-4.55	-0.38	1.24e-5	Marginal zone lymphoma;
TGCT	cis	rs933688	1.000	rs10474353	chr5:90732285	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	8.86	0.62	7.17e-15	Smoking behavior;
TGCT	cis	rs6495367	1.000	rs1007366	chr15:79379541	G/A	cg17916960	chr15:79447300	NA	0.36	5.12	0.42	1.14e-6	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs6088580	0.634	rs1205334	chr20:32930369	T/C	cg08999081	chr20:33150536	PIGU	-0.26	-4.98	-0.41	2.06e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs4730250	0.707	rs10953537	chr7:107027905	G/A	cg02696742	chr7:106810147	HBP1	-0.67	-5.36	-0.43	3.86e-7	Osteoarthritis;
TGCT	cis	rs7582180	0.700	rs4851303	chr2:100962064	T/C	cg08017756	chr2:100939284	LONRF2	-0.3	-5.0	-0.41	1.93e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg20203395	chr5:56204925	C5orf35	-0.59	-5.12	-0.42	1.12e-6	Initial pursuit acceleration;
TGCT	cis	rs7104764	0.957	rs3782120	chr11:206089	G/A	cg18336825	chr11:236787	PSMD13;SIRT3	-1.02	-10.55	-0.69	5.9e-19	Menarche (age at onset);
TGCT	cis	rs9436747	0.667	rs6657632	chr1:66038666	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.53	4.88	0.4	3.21e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs13217239	0.574	rs9366680	chr6:27006123	A/T	cg02458000	chr6:26745757	NA	0.49	4.6	0.38	1.03e-5	Schizophrenia;
TGCT	trans	rs941408	1.000	rs1640272	chr19:2800192	A/T	cg19676328	chr12:49525230	TUBA1B	-0.71	-6.93	-0.53	2.07e-10	Total cholesterol levels;
TGCT	cis	rs72634258	0.554	rs35123409	chr1:7878568	C/T	cg26816564	chr1:7831052	VAMP3	0.87	6.3	0.49	4.76e-9	Inflammatory bowel disease;
TGCT	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg11764359	chr7:65958608	NA	-0.57	-5.07	-0.41	1.4e-6	Aortic root size;
TGCT	cis	rs9611565	0.592	rs4822046	chr22:41987543	G/A	cg17554472	chr22:41940697	POLR3H	-0.52	-5.37	-0.43	3.79e-7	Vitiligo;
TGCT	cis	rs151997	0.962	rs27273	chr5:50181074	G/A	cg06027927	chr5:50259733	NA	0.46	4.61	0.38	9.69e-6	Callous-unemotional behaviour;
TGCT	cis	rs1153858	1.000	rs12594857	chr15:45667178	A/G	cg26924012	chr15:45694286	SPATA5L1	1.09	15.16	0.81	5.15e-30	Homoarginine levels;
TGCT	cis	rs4499344	0.623	rs11670818	chr19:33099854	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.81	8.12	0.59	3.9e-13	Mean platelet volume;
TGCT	cis	rs9467773	0.620	rs2494701	chr6:26634432	C/T	cg09904177	chr6:26538194	HMGN4	0.67	6.48	0.5	1.94e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg12667521	chr19:29218732	NA	0.53	5.61	0.45	1.25e-7	Methadone dose in opioid dependence;
TGCT	trans	rs3780486	0.846	rs6476399	chr9:33123013	A/G	cg20290983	chr6:43655470	MRPS18A	1.21	15.13	0.81	5.99e-30	IgG glycosylation;
TGCT	cis	rs7584330	0.826	rs72620825	chr2:238381243	G/A	cg14458575	chr2:238380390	NA	0.61	9.36	0.64	4.53e-16	Prostate cancer;
TGCT	cis	rs2230307	0.505	rs641458	chr1:100578672	G/C	cg24955406	chr1:100503596	HIAT1	-0.77	-5.23	-0.43	6.91e-7	Carotid intima media thickness;
TGCT	cis	rs1372520	0.627	rs2583964	chr4:90727218	A/G	cg26578617	chr4:90757533	SNCA	-0.52	-4.44	-0.37	1.99e-5	Neuroticism;
TGCT	cis	rs17741873	0.779	rs4746154	chr10:75629396	G/A	cg07699608	chr10:75541558	CHCHD1	0.79	5.64	0.45	1.07e-7	Paclitaxel disposition in epithelial ovarian cancer;
TGCT	cis	rs9467773	0.620	rs3800303	chr6:26598188	A/G	cg09904177	chr6:26538194	HMGN4	0.67	6.3	0.49	4.72e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs4455778	0.536	rs38774	chr7:48939388	C/T	cg26309511	chr7:48887640	NA	0.48	5.68	0.45	9.01e-8	Lung cancer in never smokers;
TGCT	cis	rs7959452	0.535	rs2305641	chr12:69646914	C/T	cg20891283	chr12:69753455	YEATS4	0.63	6.09	0.48	1.32e-8	Blood protein levels;
TGCT	cis	rs17122693	0.748	rs8014572	chr14:51095780	C/A	cg04730355	chr14:51134070	SAV1	1.24	10.9	0.7	8.04e-20	Cognitive performance;
TGCT	cis	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg07424592	chr7:64974309	NA	1.31	8.14	0.59	3.55e-13	Diabetic kidney disease;
TGCT	cis	rs7666738	0.830	rs13137808	chr4:99047095	T/C	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg13342137	chr4:2252803	MXD4	0.17	4.56	0.38	1.23e-5	Obesity-related traits;
TGCT	cis	rs7698623	0.850	rs4693891	chr4:88787834	C/T	cg02735620	chr4:88950514	PKD2	-0.44	-4.81	-0.4	4.22e-6	Cardiovascular disease risk factors;
TGCT	cis	rs1215050	0.791	rs11729826	chr4:98657190	G/T	cg17366294	chr4:99064904	C4orf37	-0.52	-5.51	-0.44	1.97e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs67311347	0.955	rs11719205	chr3:40417258	G/A	cg17264618	chr3:40429014	ENTPD3	0.32	4.76	0.39	5.36e-6	Renal cell carcinoma;
TGCT	cis	rs9788682	0.948	rs28498264	chr15:78837673	C/T	cg24631222	chr15:78858424	CHRNA5	0.94	7.61	0.56	5.94e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs11190604	1.000	rs2489035	chr10:102319395	C/T	cg16342193	chr10:102329863	NA	-0.39	-5.0	-0.41	1.92e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs12762955	0.561	rs2620942	chr10:1048398	C/T	cg26597838	chr10:835615	NA	0.47	6.32	0.49	4.23e-9	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs4851251	1.000	rs62150284	chr2:100784118	T/C	cg07810366	chr2:100720526	AFF3	0.39	5.1	0.42	1.22e-6	Educational attainment (years of education);
TGCT	cis	rs1215050	0.791	rs10856931	chr4:98819306	C/T	cg17366294	chr4:99064904	C4orf37	0.56	6.05	0.48	1.57e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg20887711	chr4:1340912	KIAA1530	0.95	8.36	0.6	1.08e-13	Longevity;
TGCT	cis	rs1865760	1.000	rs7770139	chr6:25925823	A/G	cg16482183	chr6:26056742	HIST1H1C	0.51	4.59	0.38	1.06e-5	Height;
TGCT	cis	rs1577917	0.958	rs2324817	chr6:86462654	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.27	-0.43	5.96e-7	Response to antipsychotic treatment;
TGCT	cis	rs7226408	0.901	rs10502671	chr18:34741111	C/T	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs651907	0.535	rs4342086	chr3:101503765	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.86	10.4	0.68	1.35e-18	Colorectal cancer;
TGCT	cis	rs11864453	0.713	rs9925763	chr16:72142595	C/A	cg14768367	chr16:72042858	DHODH	0.52	4.98	0.41	2.04e-6	Fibrinogen levels;
TGCT	cis	rs10876993	0.928	rs1689587	chr12:58075398	A/G	cg15848620	chr12:58087721	OS9	-0.71	-5.77	-0.46	5.92e-8	Celiac disease or Rheumatoid arthritis;
TGCT	trans	rs2688482	0.512	rs3103954	chr3:195516630	G/T	cg17952111	chr19:54960355	LENG8	0.84	6.99	0.53	1.52e-10	Lung disease severity in cystic fibrosis;
TGCT	cis	rs72781680	0.678	rs11125293	chr2:24102423	A/G	cg08917208	chr2:24149416	ATAD2B	0.79	4.94	0.41	2.51e-6	Lymphocyte counts;
TGCT	cis	rs7584330	0.826	rs7604315	chr2:238381729	C/G	cg08992911	chr2:238395768	MLPH	0.61	4.75	0.39	5.62e-6	Prostate cancer;
TGCT	cis	rs1334894	1.000	rs12527893	chr6:35585099	T/C	cg24281267	chr6:35479648	TULP1	-0.44	-4.73	-0.39	5.95e-6	Coronary artery disease;
TGCT	cis	rs9830388	0.584	rs3104243	chr3:23463993	C/T	cg25382821	chr3:23496403	UBE2E2	0.25	4.53	0.38	1.38e-5	RR interval (tricyclic/tetracyclic antidepressant use interaction);
TGCT	cis	rs1783925	1.000	rs610236	chr11:125297925	T/A	cg03464685	chr11:125439445	EI24	-0.55	-4.55	-0.38	1.24e-5	Formal thought disorder in schizophrenia;
TGCT	cis	rs7681440	0.669	rs7693616	chr4:90792230	G/T	cg10208370	chr4:90758469	SNCA	0.55	5.09	0.42	1.31e-6	Dementia with Lewy bodies;
TGCT	cis	rs1577917	0.958	rs13207354	chr6:86700263	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.54	-0.45	1.73e-7	Response to antipsychotic treatment;
TGCT	cis	rs642803	0.613	rs489574	chr11:65542739	C/T	cg27068330	chr11:65405492	SIPA1	0.64	5.69	0.46	8.6e-8	Urate levels;
TGCT	cis	rs10514758	0.744	rs34711605	chr3:114924122	T/G	cg05943254	chr3:114009756	NA	-0.76	-4.53	-0.38	1.39e-5	Urate levels in obese individuals;
TGCT	cis	rs46522	0.585	rs79049364	chr17:47014991	T/A	cg26022315	chr17:47021804	SNF8	0.52	5.17	0.42	9.24e-7	Coronary heart disease;
TGCT	cis	rs75646498	0.571	rs77241922	chr15:29859371	T/A	cg08904058	chr15:29859427	FAM189A1	-0.47	-4.53	-0.38	1.38e-5	Diisocyanate-induced asthma;
TGCT	cis	rs3087591	0.920	rs4795571	chr17:29398369	G/A	cg24425628	chr17:29625626	OMG;NF1	0.49	7.4	0.55	1.76e-11	Hip circumference;
TGCT	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg14008862	chr17:28927542	LRRC37B2	-0.74	-4.8	-0.4	4.44e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs514406	0.505	rs447581	chr1:53177098	T/C	cg22166914	chr1:53195759	ZYG11B	0.45	7.99	0.58	7.98e-13	Monocyte count;
TGCT	trans	rs17277593	0.517	rs34414566	chr9:13875448	G/A	cg24852548	chr4:57522632	HOPX	0.73	6.82	0.52	3.57e-10	Endometriosis;
TGCT	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg08859206	chr1:53392774	SCP2	0.4	5.96	0.47	2.46e-8	Monocyte count;
TGCT	cis	rs6840360	0.615	rs6836249	chr4:152465829	T/G	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.03	-0.58	6.46e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs2688608	0.592	rs11000757	chr10:75486815	T/C	cg23231163	chr10:75533350	FUT11	-0.28	-4.68	-0.39	7.4e-6	Inflammatory bowel disease;
TGCT	cis	rs7017914	0.905	rs3110257	chr8:71938151	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-4.97	-0.41	2.16e-6	Bone mineral density;
TGCT	cis	rs9916302	0.821	rs12938268	chr17:37572139	G/A	cg07936489	chr17:37558343	FBXL20	-0.63	-4.91	-0.4	2.83e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs858239	1.000	rs166663	chr7:23316742	A/C	cg05602783	chr7:23145260	KLHL7	-0.55	-4.46	-0.37	1.85e-5	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs909674	0.690	rs1972280	chr22:39831986	T/A	cg01416388	chr22:39784598	NA	-0.74	-6.78	-0.52	4.37e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg18188782	chr20:61659543	NA	0.44	5.37	0.43	3.73e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs6088580	0.634	rs4277599	chr20:33008905	A/G	cg06115741	chr20:33292138	TP53INP2	-0.51	-4.44	-0.37	1.98e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs826838	0.872	rs826878	chr12:39088837	A/T	cg13010199	chr12:38710504	ALG10B	-0.56	-4.6	-0.38	1.04e-5	Heart rate;
TGCT	cis	rs7727544	0.642	rs7705189	chr5:131623358	C/T	cg24060327	chr5:131705240	SLC22A5	0.51	4.94	0.41	2.48e-6	Blood metabolite levels;
TGCT	cis	rs1215050	0.669	rs783962	chr4:98884473	G/A	cg05340658	chr4:99064831	C4orf37	-0.45	-5.47	-0.44	2.39e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg04287289	chr16:89883240	FANCA	0.92	11.69	0.72	9.94e-22	Vitiligo;
TGCT	cis	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg08564027	chr20:61660810	NA	0.37	6.85	0.52	3.1e-10	Prostate cancer (SNP x SNP interaction);
TGCT	trans	rs2688608	0.592	rs7909802	chr10:75484186	G/C	cg13918328	chr10:52500089	ASAH2B	0.68	6.7	0.52	6.48e-10	Inflammatory bowel disease;
TGCT	cis	rs2777491	0.872	rs11267024	chr15:41576241	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.71	-9.22	-0.64	9.96e-16	Ulcerative colitis;
TGCT	cis	rs6540559	0.673	rs17317411	chr1:209961314	C/T	cg23283495	chr1:209979779	IRF6	-0.63	-4.59	-0.38	1.07e-5	Cleft lip with or without cleft palate;
TGCT	cis	rs113084984	0.642	rs13021546	chr2:11681043	G/T	cg25804072	chr2:10829725	NOL10	0.52	4.58	0.38	1.1e-5	Breast cancer;
TGCT	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg20849893	chr7:64541193	NA	0.5	5.22	0.42	7.27e-7	Calcium levels;
TGCT	cis	rs526231	0.747	rs39984	chr5:102597292	G/T	cg05225461	chr5:102596755	C5orf30	0.22	4.49	0.37	1.64e-5	Primary biliary cholangitis;
TGCT	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg08392591	chr16:89556376	ANKRD11	0.53	5.0	0.41	1.89e-6	Multiple myeloma (IgH translocation);
TGCT	cis	rs11190604	1.000	rs4919465	chr10:102221703	C/T	cg16342193	chr10:102329863	NA	-0.4	-5.31	-0.43	4.85e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs12681287	0.640	rs34794500	chr8:87449995	G/A	cg27223183	chr8:87520930	FAM82B	-0.89	-6.43	-0.5	2.54e-9	Caudate activity during reward;
TGCT	cis	rs8062405	0.824	rs28698667	chr16:28533071	C/T	cg09754948	chr16:28834200	ATXN2L	0.58	4.57	0.38	1.14e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg26338869	chr17:61819248	STRADA	-0.55	-5.08	-0.42	1.34e-6	Prudent dietary pattern;
TGCT	trans	rs4650994	0.625	rs6681348	chr1:178526271	A/C	cg05059571	chr16:84539110	KIAA1609	-0.41	-7.67	-0.57	4.37e-12	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs4788439	0.901	rs8049531	chr16:24979232	G/A	cg07626409	chr16:25250191	ZKSCAN2	0.32	4.45	0.37	1.87e-5	Blood metabolite levels;
TGCT	cis	rs35000415	0.566	rs35144535	chr7:128721777	A/G	cg06242719	chr7:129414860	MIR183;MIR96	-0.3	-4.58	-0.38	1.1e-5	Systemic lupus erythematosus;
TGCT	cis	rs7824557	0.564	rs55758514	chr8:11230259	A/T	cg21775007	chr8:11205619	TDH	-0.61	-5.82	-0.46	4.66e-8	Retinal vascular caliber;
TGCT	cis	rs9790314	0.871	rs466626	chr3:161103629	A/C	cg03342759	chr3:160939853	NMD3	-0.47	-4.96	-0.41	2.23e-6	Morning vs. evening chronotype;
TGCT	cis	rs1534166	0.601	rs13324779	chr3:133510413	G/A	cg16414030	chr3:133502952	NA	0.45	5.81	0.46	4.92e-8	Alcohol consumption (transferrin glycosylation);
TGCT	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	5.06	0.41	1.46e-6	Menopause (age at onset);
TGCT	cis	rs62244186	0.541	rs9859879	chr3:44840166	G/A	cg25151919	chr3:44754333	ZNF502	-0.46	-5.48	-0.44	2.26e-7	Depressive symptoms;
TGCT	cis	rs7666738	0.830	rs28878289	chr4:98855181	C/T	cg05340658	chr4:99064831	C4orf37	0.52	6.0	0.47	1.98e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6893807	0.778	rs16903285	chr5:87978252	T/C	cg24804195	chr5:87968844	LOC645323	0.78	4.6	0.38	1.04e-5	Body mass index;
TGCT	cis	rs11148252	0.755	rs116860555	chr13:52936937	C/T	cg00495681	chr13:53174319	NA	-0.49	-4.64	-0.38	8.75e-6	Lewy body disease;
TGCT	cis	rs2562456	0.874	rs9304986	chr19:21682062	G/A	cg01304269	chr19:21688519	ZNF429	-0.55	-4.59	-0.38	1.06e-5	Pain;
TGCT	cis	rs12477438	0.765	rs17708262	chr2:99696313	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-5.23	-0.43	6.94e-7	Chronic sinus infection;
TGCT	cis	rs36051895	0.632	rs7029084	chr9:5174638	T/C	cg02405213	chr9:5042618	JAK2	-0.77	-10.92	-0.7	7.34e-20	Pediatric autoimmune diseases;
TGCT	cis	rs6840360	0.615	rs6535816	chr4:152614264	T/C	cg22705602	chr4:152727874	NA	-0.36	-6.01	-0.48	1.91e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7107174	0.688	rs11237489	chr11:78130325	G/A	cg12700464	chr11:78128424	GAB2	-0.67	-4.46	-0.37	1.83e-5	Testicular germ cell tumor;
TGCT	cis	rs7666738	0.753	rs4699604	chr4:99056353	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.92	0.47	2.91e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6570726	0.791	rs6570692	chr6:145904401	T/A	cg23711669	chr6:146136114	FBXO30	0.86	9.54	0.65	1.64e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg06238570	chr21:40685208	BRWD1	0.7	6.45	0.5	2.3e-9	Cognitive function;
TGCT	cis	rs28595532	0.920	rs113034745	chr4:119750044	T/C	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs11577318	0.579	rs11548246	chr1:26697166	G/A	cg15090202	chr1:26687087	NA	0.58	4.43	0.37	2.01e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs231513	0.681	rs35362475	chr17:42012813	C/A	cg26893861	chr17:41843967	DUSP3	0.76	4.64	0.38	8.65e-6	Cognitive function;
TGCT	cis	rs10875746	0.951	rs2228500	chr12:48526712	A/G	cg20731937	chr12:48336164	NA	-0.64	-5.02	-0.41	1.76e-6	Longevity (90 years and older);
TGCT	cis	rs2439831	1.000	rs2264239	chr15:43765533	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.8	5.7	0.46	8.33e-8	Lung cancer in ever smokers;
TGCT	cis	rs7666738	0.830	rs13139078	chr4:99020774	C/T	cg17366294	chr4:99064904	C4orf37	0.68	7.04	0.53	1.17e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.66	0.39	8.18e-6	Prudent dietary pattern;
TGCT	cis	rs28595532	0.920	rs55633605	chr4:119761589	G/A	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs13102973	0.965	rs7656209	chr4:135875550	G/A	cg14419869	chr4:135874104	NA	0.24	4.46	0.37	1.83e-5	Subjective well-being;
TGCT	cis	rs9929218	0.859	rs9936682	chr16:68748223	A/G	cg01251360	chr16:68772225	CDH1	0.31	5.03	0.41	1.67e-6	Colorectal cancer;
TGCT	cis	rs7568458	0.709	rs762684	chr2:85782023	G/A	cg17127132	chr2:85788382	GGCX	0.51	4.58	0.38	1.12e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs10751667	0.643	rs7396046	chr11:937176	T/C	cg06064525	chr11:970664	AP2A2	-0.35	-8.28	-0.6	1.65e-13	Alzheimer's disease (late onset);
TGCT	cis	rs262150	0.502	rs73167295	chr7:158782949	T/A	cg01219135	chr7:158766336	NA	-0.44	-4.63	-0.38	9.13e-6	Facial morphology (factor 20);
TGCT	cis	rs6866344	0.570	rs1071881	chr5:178135917	C/T	cg10224037	chr5:178157518	ZNF354A	0.95	9.24	0.64	8.55e-16	Neutrophil percentage of white cells;
TGCT	cis	rs6988636	1.000	rs13260798	chr8:124190192	G/A	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs7917772	0.502	rs4919670	chr10:104515799	C/A	cg05855489	chr10:104503620	C10orf26	0.73	6.06	0.48	1.48e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs79349575	0.811	rs1057897	chr17:47005509	T/G	cg26022315	chr17:47021804	SNF8	0.49	4.9	0.4	2.94e-6	Type 2 diabetes;
TGCT	cis	rs2204008	0.775	rs12099736	chr12:38344111	C/G	cg26384229	chr12:38710491	ALG10B	0.82	7.22	0.54	4.5e-11	Bladder cancer;
TGCT	cis	rs7225537	0.559	rs4985730	chr17:17016726	T/C	cg26176665	chr17:16994978	MPRIP	0.24	5.76	0.46	6.16e-8	Mean platelet volume;
TGCT	cis	rs7178572	0.633	rs7162637	chr15:77843365	A/G	cg22256960	chr15:77711686	NA	-0.82	-7.51	-0.56	1.03e-11	Type 2 diabetes;
TGCT	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.29	-4.49	-0.37	1.64e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.66	5.43	0.44	2.84e-7	Tonsillectomy;
TGCT	cis	rs478304	0.651	rs78412025	chr11:65495696	T/C	cg27068330	chr11:65405492	SIPA1	-0.94	-9.4	-0.65	3.54e-16	Acne (severe);
TGCT	cis	rs35000415	0.638	rs77508372	chr7:128721797	T/G	cg06242719	chr7:129414860	MIR183;MIR96	-0.3	-4.58	-0.38	1.1e-5	Systemic lupus erythematosus;
TGCT	cis	rs5769765	1.000	rs5770755	chr22:50280136	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	1.11	11.76	0.73	6.4e-22	Schizophrenia;
TGCT	cis	rs7829975	0.514	rs2920991	chr8:8259117	T/A	cg08975724	chr8:8085496	FLJ10661	0.56	5.01	0.41	1.82e-6	Mood instability;
TGCT	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.18	0.49	8.32e-9	Electroencephalogram traits;
TGCT	cis	rs7772486	0.686	rs6570701	chr6:145954090	A/G	cg13319975	chr6:146136371	FBXO30	-0.52	-4.78	-0.39	4.81e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10927875	0.688	rs2009371	chr1:16348083	A/T	cg22431228	chr1:16359049	CLCNKA	-0.25	-4.64	-0.38	8.84e-6	Dilated cardiomyopathy;
TGCT	cis	rs7171869	1	rs7171869	chr15:78900909	A/G	cg24631222	chr15:78858424	CHRNA5	-0.88	-6.66	-0.51	7.79e-10	Post bronchodilator FEV1;
TGCT	cis	rs1997103	1.000	rs4947500	chr7:55407270	C/A	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs7829975	0.509	rs7838674	chr8:8797073	A/T	cg06636001	chr8:8085503	FLJ10661	-0.7	-6.19	-0.49	8.23e-9	Mood instability;
TGCT	cis	rs908922	0.676	rs10888494	chr1:152514709	T/C	cg20991723	chr1:152506922	NA	0.46	6.17	0.48	8.79e-9	Hair morphology;
TGCT	cis	rs290268	1.000	rs290274	chr9:93546913	C/T	cg02608019	chr9:93564028	SYK	0.49	4.89	0.4	3.09e-6	Platelet count;
TGCT	cis	rs9364220	0.646	rs2029489	chr6:168496038	A/G	cg02770688	chr6:168491649	NA	-0.31	-5.88	-0.47	3.59e-8	Attention deficit hyperactivity disorder (inattention symptoms);Attention deficit hyperactivity disorder (combined symptoms);
TGCT	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg22168489	chr12:122356033	WDR66	0.22	4.76	0.39	5.26e-6	Mean corpuscular volume;
TGCT	trans	rs28735056	0.933	rs56181785	chr18:77633629	G/A	cg05926928	chr17:57297772	GDPD1	-0.71	-7.55	-0.56	8.06e-12	Schizophrenia;
TGCT	cis	rs10114408	0.959	rs10124030	chr9:96652310	T/A	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs7937682	0.924	rs10891284	chr11:111527737	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.12	-11.81	-0.73	4.86e-22	Primary sclerosing cholangitis;
TGCT	cis	rs6076065	0.748	rs6048750	chr20:23334192	T/G	cg11657817	chr20:23433608	CST11	0.31	5.29	0.43	5.46e-7	Facial morphology (factor 15, philtrum width);
TGCT	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg22663859	chr13:21900854	NA	0.36	4.99	0.41	1.97e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	cis	rs12510870	0.588	rs10938085	chr4:74396579	A/G	cg05868023	chr4:75230803	EREG	0.54	4.73	0.39	5.93e-6	Iris color (b* coordinate);
TGCT	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg11062466	chr8:58055876	NA	-0.36	-4.6	-0.38	1.04e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs911555	1.000	rs911555	chr14:103999347	G/C	cg12935359	chr14:103987150	CKB	0.35	4.99	0.41	2.03e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs17387100	0.515	rs2677791	chr4:16024136	G/A	cg13480465	chr4:16795757	LDB2	-0.39	-5.11	-0.42	1.2e-6	Suicide attempts in depression or bipolar disorder;
TGCT	cis	rs68170813	0.559	rs4515482	chr7:107072681	A/C	cg02696742	chr7:106810147	HBP1	-0.71	-5.9	-0.47	3.17e-8	Coronary artery disease;
TGCT	cis	rs240764	0.548	rs12206838	chr6:101180128	G/A	cg09795085	chr6:101329169	ASCC3	-0.51	-4.51	-0.38	1.48e-5	Neuroticism;
TGCT	cis	rs137699	0.652	rs2413589	chr22:39755689	C/T	cg05872129	chr22:39784769	NA	0.54	4.5	0.37	1.54e-5	IgG glycosylation;
TGCT	cis	rs6921919	0.609	rs9461455	chr6:28329731	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.57	-5.33	-0.43	4.47e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs10779751	0.734	rs7533211	chr1:11132965	G/C	cg08854313	chr1:11322531	MTOR	0.84	8.3	0.6	1.47e-13	Body mass index;
TGCT	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg24578937	chr1:2090814	PRKCZ	0.26	6.95	0.53	1.8e-10	Height;
TGCT	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.52	-4.97	-0.41	2.13e-6	Longevity;Endometriosis;
TGCT	cis	rs2288073	0.965	rs10199334	chr2:24392618	T/C	cg02683114	chr2:24398427	C2orf84	-0.25	-5.61	-0.45	1.26e-7	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs1865760	0.892	rs9379806	chr6:25940958	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.66	6.2	0.49	7.8e-9	Height;
TGCT	cis	rs2836950	0.565	rs3171465	chr21:40552307	A/G	cg11890956	chr21:40555474	PSMG1	-0.73	-7.15	-0.54	6.65e-11	Menarche (age at onset);
TGCT	cis	rs9640161	0.750	rs11764936	chr7:150025915	G/T	cg17279839	chr7:150038598	RARRES2	0.43	4.48	0.37	1.69e-5	Blood protein levels;Circulating chemerin levels;
TGCT	trans	rs77457752	0.532	rs77481510	chr9:13902347	G/A	cg23609682	chr1:3070786	PRDM16	0.51	6.81	0.52	3.8e-10	Breast cancer;
TGCT	cis	rs7829975	0.511	rs2980426	chr8:8145609	T/C	cg15556689	chr8:8085844	FLJ10661	0.88	8.41	0.6	8.32e-14	Mood instability;
TGCT	cis	rs7605378	1.000	rs769958	chr2:200695901	G/A	cg17644776	chr2:200775616	C2orf69	0.28	5.33	0.43	4.51e-7	Osteoporosis;
TGCT	cis	rs6933660	0.745	rs9322320	chr6:151751908	C/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.88	-9.67	-0.66	8.12e-17	Menarche (age at onset);
TGCT	cis	rs6714710	0.603	rs78006955	chr2:98455510	G/C	cg26665480	chr2:98280029	ACTR1B	0.66	6.24	0.49	6.33e-9	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg26338869	chr17:61819248	STRADA	-0.55	-5.04	-0.41	1.6e-6	Prudent dietary pattern;
TGCT	cis	rs9640161	0.750	rs61421252	chr7:150037972	T/C	cg10018233	chr7:150070692	REPIN1	0.32	4.78	0.39	4.84e-6	Blood protein levels;Circulating chemerin levels;
TGCT	trans	rs114540395	0.858	rs7900797	chr10:103192220	A/G	cg10198749	chr1:39920707	MACF1	0.56	7.44	0.56	1.47e-11	Schizophrenia;
TGCT	cis	rs950169	0.922	rs11630760	chr15:85113337	G/T	cg11189052	chr15:85197271	WDR73	0.77	6.44	0.5	2.34e-9	Schizophrenia;
TGCT	cis	rs793571	0.650	rs12899638	chr15:58920275	G/A	cg05156742	chr15:59063176	FAM63B	0.57	5.36	0.43	3.9e-7	Schizophrenia;
TGCT	cis	rs554111	0.963	rs601329	chr1:21044161	A/G	cg08890418	chr1:21044141	KIF17	0.59	6.23	0.49	6.74e-9	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs9653442	0.593	rs10865036	chr2:100860595	A/G	cg22139774	chr2:100720529	AFF3	-0.39	-6.4	-0.5	2.93e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs9916302	0.706	rs903507	chr17:37726423	A/G	cg03321784	chr17:37729644	NA	0.44	4.58	0.38	1.1e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs1552244	0.554	rs6762397	chr3:10007840	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.3	-4.7	-0.39	6.82e-6	Alzheimer's disease;
TGCT	cis	rs1372520	0.873	rs2736989	chr4:90776257	T/C	cg14346243	chr4:90757452	SNCA	-0.62	-5.26	-0.43	6.17e-7	Neuroticism;
TGCT	cis	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg05590025	chr7:65112418	INTS4L2	-0.77	-4.5	-0.37	1.52e-5	Diabetic kidney disease;
TGCT	cis	rs2762353	0.935	rs3757131	chr6:25783909	C/T	cg12310025	chr6:25882481	NA	0.51	5.26	0.43	6.17e-7	Blood metabolite levels;
TGCT	cis	rs6912958	0.667	rs7746545	chr6:88090225	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.44	5.86	0.47	4e-8	Monocyte percentage of white cells;
TGCT	cis	rs9733	0.596	rs72702585	chr1:150696427	G/A	cg09365446	chr1:150670422	GOLPH3L	0.3	4.52	0.38	1.4e-5	Tonsillectomy;
TGCT	trans	rs11662586	0.517	rs7228070	chr18:77698967	C/T	cg05926928	chr17:57297772	GDPD1	0.78	7.64	0.57	5.01e-12	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
TGCT	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg10047753	chr17:41438598	NA	0.96	9.64	0.65	9.37e-17	Menopause (age at onset);
TGCT	cis	rs9650657	0.648	rs7833945	chr8:10700266	T/G	cg27411982	chr8:10470053	RP1L1	-0.22	-4.58	-0.38	1.12e-5	Neuroticism;
TGCT	cis	rs933688	1.000	rs9293568	chr5:90737845	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.94	8.08	0.59	4.83e-13	Smoking behavior;
TGCT	cis	rs78456975	1.000	rs11898988	chr2:1560336	G/A	cg01028140	chr2:1542097	TPO	-0.33	-4.53	-0.38	1.37e-5	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs6089829	0.925	rs4809270	chr20:61676709	C/A	cg08045932	chr20:61659980	NA	0.5	8.72	0.62	1.54e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs6088590	0.965	rs6119534	chr20:33441257	C/T	cg06115741	chr20:33292138	TP53INP2	0.64	5.22	0.42	7.36e-7	Coronary artery disease;
TGCT	cis	rs9898058	0.660	rs9915811	chr17:47786332	G/C	cg10517230	chr17:48661425	CACNA1G	0.47	4.51	0.38	1.48e-5	Milk allergy;
TGCT	cis	rs344364	0.511	rs1742468	chr16:1950243	C/G	cg26617929	chr16:1858877	NA	-0.27	-4.9	-0.4	2.99e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs17253792	0.822	rs74824071	chr14:56095142	T/G	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs344364	0.511	rs2982455	chr16:1950498	T/G	cg26617929	chr16:1858877	NA	-0.27	-4.75	-0.39	5.6e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	trans	rs34421088	0.548	rs2618443	chr8:11384556	A/G	cg15556689	chr8:8085844	FLJ10661	-0.71	-6.63	-0.51	9.32e-10	Neuroticism;
TGCT	cis	rs9650657	0.740	rs7002282	chr8:10666993	A/G	cg27411982	chr8:10470053	RP1L1	-0.22	-4.9	-0.4	2.95e-6	Neuroticism;
TGCT	cis	rs2274459	0.500	rs10947426	chr6:33637897	A/C	cg00898486	chr6:34006557	GRM4	0.32	4.92	0.4	2.65e-6	Obesity (extreme);
TGCT	cis	rs12134245	0.719	rs61798831	chr1:91996588	C/T	cg07090678	chr1:91966139	CDC7	0.35	4.75	0.39	5.58e-6	Breast cancer;
TGCT	cis	rs2963155	0.518	rs55817235	chr5:142765733	C/T	cg17617527	chr5:142782415	NR3C1	0.8	4.92	0.4	2.65e-6	Breast cancer;
TGCT	cis	rs7523273	0.565	rs2796239	chr1:207902206	G/A	cg22525895	chr1:207977042	MIR29B2	-0.33	-5.31	-0.43	4.87e-7	Schizophrenia;
TGCT	cis	rs2463822	0.858	rs2463836	chr11:62126494	A/G	cg06239285	chr11:62104954	ASRGL1	0.92	6.76	0.52	4.71e-10	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs950169	0.922	rs4586394	chr15:84822385	G/A	cg17173187	chr15:85201210	NMB	-0.56	-5.74	-0.46	6.84e-8	Schizophrenia;
TGCT	cis	rs28595532	0.920	rs115982145	chr4:119605707	A/G	cg11846333	chr4:119757529	SEC24D	0.95	4.68	0.39	7.54e-6	Cannabis dependence symptom count;
TGCT	cis	rs17102423	0.593	rs11624558	chr14:65615653	T/C	cg11161011	chr14:65562177	MAX	-0.46	-5.83	-0.46	4.56e-8	Obesity-related traits;
TGCT	cis	rs2688608	0.592	rs12253429	chr10:75496161	C/G	cg23231163	chr10:75533350	FUT11	-0.28	-4.68	-0.39	7.4e-6	Inflammatory bowel disease;
TGCT	cis	rs9311474	0.713	rs352166	chr3:52238677	C/T	cg10802521	chr3:52805072	NEK4	-0.61	-6.98	-0.53	1.59e-10	Electroencephalogram traits;
TGCT	cis	rs4851254	0.618	rs35730185	chr2:100648085	G/A	cg07810366	chr2:100720526	AFF3	-0.46	-4.64	-0.38	8.78e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10875746	0.903	rs11168386	chr12:48467977	C/T	cg20731937	chr12:48336164	NA	0.62	4.95	0.41	2.36e-6	Longevity (90 years and older);
TGCT	cis	rs2749592	0.918	rs11011388	chr10:38155210	C/T	cg25427524	chr10:38739819	LOC399744	0.35	5.18	0.42	8.84e-7	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs9291683	0.588	rs12506364	chr4:10023448	C/T	cg11266682	chr4:10021025	SLC2A9	0.68	9.96	0.67	1.58e-17	Bone mineral density;
TGCT	cis	rs2180341	0.618	rs12199451	chr6:127597780	C/G	cg24812749	chr6:127587940	RNF146	0.64	5.46	0.44	2.52e-7	Breast cancer;
TGCT	trans	rs1496653	0.602	rs13065646	chr3:23556657	G/T	cg02770683	chr12:57597238	LRP1	0.36	6.66	0.51	8.06e-10	Type 2 diabetes;
TGCT	cis	rs9486719	0.741	rs976356	chr6:96849437	T/A	cg18709589	chr6:96969512	KIAA0776	0.75	5.13	0.42	1.1e-6	Migraine;Coronary artery disease;
TGCT	cis	rs7267979	0.966	rs2145126	chr20:25263648	G/A	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6964587	1.000	rs2188155	chr7:91599825	A/C	cg17063962	chr7:91808500	NA	0.91	9.99	0.67	1.32e-17	Breast cancer;
TGCT	cis	rs6500602	0.527	rs13338333	chr16:4443250	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.38	5.52	0.44	1.88e-7	Schizophrenia;
TGCT	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg18876405	chr7:65276391	NA	-0.36	-5.69	-0.45	8.79e-8	Aortic root size;
TGCT	trans	rs1814175	0.511	rs61905634	chr11:49819736	G/A	cg03929089	chr4:120376271	NA	-0.72	-8.26	-0.6	1.84e-13	Height;
TGCT	cis	rs13256369	0.760	rs7816171	chr8:8575835	T/C	cg18904891	chr8:8559673	CLDN23	0.64	5.89	0.47	3.36e-8	Obesity-related traits;
TGCT	cis	rs9929218	1.000	rs17772363	chr16:68788909	G/T	cg01251360	chr16:68772225	CDH1	0.29	4.89	0.4	3.01e-6	Colorectal cancer;
TGCT	cis	rs9379774	0.623	rs1876372	chr6:25442464	C/T	cg13320114	chr6:26216906	HIST1H2AE;HIST1H2BG	0.75	4.72	0.39	6.18e-6	Coronary artery disease;
TGCT	cis	rs9926296	0.632	rs1800286	chr16:89869761	T/C	cg21285383	chr16:89894308	SPIRE2	0.34	4.52	0.38	1.43e-5	Vitiligo;
TGCT	cis	rs12134245	0.776	rs12124682	chr1:91995542	A/G	cg25838465	chr1:92012736	NA	-0.41	-6.57	-0.51	1.23e-9	Breast cancer;
TGCT	cis	rs2836950	0.520	rs2836966	chr21:40637521	A/G	cg17971929	chr21:40555470	PSMG1	-0.54	-4.83	-0.4	4e-6	Menarche (age at onset);
TGCT	cis	rs564309	0.681	rs1150917	chr1:228607395	T/C	cg22700015	chr1:228743131	NA	-0.75	-4.5	-0.37	1.55e-5	Hip circumference (psychosocial stress interaction);
TGCT	cis	rs9311474	0.713	rs352169	chr3:52236762	C/T	cg10802521	chr3:52805072	NEK4	-0.58	-6.37	-0.5	3.43e-9	Electroencephalogram traits;
TGCT	cis	rs11190604	0.767	rs7085426	chr10:102163640	T/C	cg16342193	chr10:102329863	NA	-0.39	-5.05	-0.41	1.54e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9457247	0.967	rs2149092	chr6:167372978	C/T	cg23791538	chr6:167370224	RNASET2	0.51	5.13	0.42	1.11e-6	Crohn's disease;
TGCT	cis	rs7226408	0.857	rs72887063	chr18:34493121	A/G	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	trans	rs2727020	0.615	rs35423199	chr11:49514914	T/C	cg15704280	chr7:45808275	SEPT13	-0.75	-8.81	-0.62	9.51e-15	Coronary artery disease;
TGCT	cis	rs2637266	0.934	rs2395408	chr10:78380929	G/A	cg18941641	chr10:78392320	NA	0.4	4.73	0.39	6.03e-6	Pulmonary function;
TGCT	cis	rs55882075	0.750	rs13184690	chr5:179146993	T/C	cg14593053	chr5:179126677	CANX	0.48	5.4	0.44	3.23e-7	Monocyte percentage of white cells;
TGCT	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg10295955	chr4:187884368	NA	-1.02	-15.6	-0.81	5.02e-31	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.43	-5.07	-0.41	1.42e-6	Alzheimer's disease;
TGCT	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg00343986	chr7:65444356	GUSB	-0.21	-4.83	-0.4	3.87e-6	Calcium levels;
TGCT	cis	rs7027203	0.576	rs11792101	chr9:96535470	C/T	cg13679303	chr9:96623674	NA	0.53	7.67	0.57	4.34e-12	DNA methylation (variation);
TGCT	cis	rs7714584	1.000	rs11167519	chr5:150265407	C/T	cg22134413	chr5:150180641	NA	0.78	6.12	0.48	1.16e-8	Crohn's disease;
TGCT	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg11890956	chr21:40555474	PSMG1	-0.76	-7.44	-0.56	1.48e-11	Cognitive function;
TGCT	cis	rs9467711	0.606	rs72841536	chr6:26378288	T/A	cg10795676	chr6:26370623	BTN3A2	-0.47	-4.77	-0.39	5.18e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg06640241	chr16:89574553	SPG7	-0.79	-9.08	-0.63	2.09e-15	Multiple myeloma (IgH translocation);
TGCT	cis	rs7909074	0.831	rs2065466	chr10:45384047	T/C	cg04218760	chr10:45406644	TMEM72	-0.29	-5.63	-0.45	1.15e-7	Mean corpuscular volume;
TGCT	cis	rs9611519	0.589	rs8138917	chr22:41412425	T/C	cg06634786	chr22:41940651	POLR3H	-0.53	-4.84	-0.4	3.83e-6	Neuroticism;
TGCT	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg01802117	chr1:53393560	SCP2	-0.46	-5.43	-0.44	2.84e-7	Monocyte count;
TGCT	cis	rs9467711	1.000	rs9467701	chr6:26312170	G/C	cg02458000	chr6:26745757	NA	-1.05	-5.8	-0.46	5.29e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs17331151	0.505	rs71299613	chr3:52698805	G/A	cg07884673	chr3:53033167	SFMBT1	0.75	5.59	0.45	1.35e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs4808199	0.649	rs34755166	chr19:19665581	G/A	cg03709012	chr19:19516395	GATAD2A	0.9	5.63	0.45	1.12e-7	Nonalcoholic fatty liver disease;
TGCT	trans	rs10203711	1.000	rs907107	chr2:239565780	T/C	cg16021909	chr1:248021091	TRIM58	-0.66	-6.64	-0.51	8.76e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2404602	0.716	rs8039545	chr15:76707247	A/G	cg26408565	chr15:76604113	ETFA	-0.42	-5.43	-0.44	2.8e-7	Blood metabolite levels;
TGCT	cis	rs7267979	1.000	rs4815426	chr20:25405186	A/C	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4808199	0.894	rs10418051	chr19:19397789	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.72	5.81	0.46	4.95e-8	Nonalcoholic fatty liver disease;
TGCT	cis	rs7681440	0.933	rs10005233	chr4:90743331	C/T	cg26578617	chr4:90757533	SNCA	-0.47	-4.83	-0.4	3.91e-6	Dementia with Lewy bodies;
TGCT	cis	rs6598955	0.515	rs61776655	chr1:26541430	T/C	cg04990556	chr1:26633338	UBXN11	-0.89	-11.3	-0.71	8.55e-21	Obesity-related traits;
TGCT	cis	rs6121246	0.559	rs6060944	chr20:30372114	G/A	cg13852791	chr20:30311386	BCL2L1	0.82	7.92	0.58	1.16e-12	Mean corpuscular hemoglobin;
TGCT	cis	rs35934224	0.724	rs35374520	chr22:19851149	A/G	cg11182965	chr22:19864308	TXNRD2	-0.36	-4.95	-0.41	2.33e-6	Glaucoma (primary open-angle);
TGCT	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg14893161	chr1:205819251	PM20D1	-0.52	-7.5	-0.56	1.05e-11	Monocyte percentage of white cells;
TGCT	cis	rs6693567	0.565	rs10157197	chr1:150250636	G/A	cg09579323	chr1:150459698	TARS2	-0.57	-5.22	-0.42	7.27e-7	Migraine;
TGCT	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.0	0.41	1.89e-6	Menopause (age at onset);
TGCT	cis	rs6558530	0.626	rs6558524	chr8:1702512	T/G	cg09410841	chr8:1729607	CLN8	0.72	6.49	0.5	1.87e-9	Systolic blood pressure;
TGCT	cis	rs9653442	0.527	rs4850923	chr2:100782256	A/C	cg22139774	chr2:100720529	AFF3	-0.34	-5.28	-0.43	5.56e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs2204008	0.569	rs11495449	chr12:37995753	C/T	cg26384229	chr12:38710491	ALG10B	0.87	7.79	0.57	2.32e-12	Bladder cancer;
TGCT	cis	rs13082711	0.522	rs864241	chr3:27332674	T/C	cg02860705	chr3:27208620	NA	0.34	5.58	0.45	1.43e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs5769765	0.954	rs910799	chr22:50278568	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	1.14	12.65	0.75	4.51e-24	Schizophrenia;
TGCT	cis	rs7949030	0.596	rs11231138	chr11:62316195	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.64	9.18	0.64	1.21e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9300255	0.602	rs1106240	chr12:123626982	C/T	cg00376283	chr12:123451042	ABCB9	0.72	4.96	0.41	2.31e-6	Neutrophil percentage of white cells;
TGCT	cis	rs2229238	0.866	rs61403567	chr1:154504927	T/C	cg13067139	chr1:155221277	FAM189B	0.2	4.51	0.38	1.47e-5	Coronary heart disease;
TGCT	cis	rs9611565	0.877	rs3817999	chr22:41747717	A/G	cg06481639	chr22:41940642	POLR3H	0.63	5.61	0.45	1.25e-7	Vitiligo;
TGCT	cis	rs11167764	1.000	rs7730511	chr5:141480418	T/C	cg02659431	chr5:141694439	SPRY4	-0.22	-4.71	-0.39	6.46e-6	Crohn's disease;
TGCT	cis	rs71636778	0.509	rs17340509	chr1:27274700	A/G	cg23921621	chr1:27994728	IFI6	-0.43	-4.61	-0.38	9.92e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
TGCT	cis	rs35146811	0.555	rs2527898	chr7:99534030	C/G	cg13334819	chr7:99746414	C7orf59	-0.6	-5.05	-0.41	1.52e-6	Coronary artery disease;
TGCT	cis	rs8141529	0.632	rs5762803	chr22:29193638	G/C	cg02153584	chr22:29168773	CCDC117	0.76	6.36	0.5	3.56e-9	Lymphocyte counts;
TGCT	cis	rs4746818	1.000	rs7071904	chr10:70903005	C/T	cg11621586	chr10:70884670	VPS26A	1.22	10.78	0.7	1.56e-19	Left atrial antero-posterior diameter;
TGCT	cis	rs1949733	0.656	rs6845969	chr4:8402465	A/T	cg13073564	chr4:8508604	NA	-0.47	-5.32	-0.43	4.59e-7	Response to antineoplastic agents;
TGCT	cis	rs12458462	0.892	rs2242175	chr18:77464406	G/A	cg11879182	chr18:77439856	CTDP1	0.69	8.12	0.59	3.98e-13	Monocyte count;
TGCT	cis	rs4664308	1.000	rs17831161	chr2:160909360	A/G	cg03641300	chr2:160917029	PLA2R1	-0.26	-6.53	-0.51	1.49e-9	Idiopathic membranous nephropathy;
TGCT	cis	rs651907	0.557	rs62284198	chr3:101474699	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.33	-6.69	-0.51	7.01e-10	Colorectal cancer;
TGCT	cis	rs3008870	1.000	rs2755248	chr1:67492624	A/G	cg03991309	chr1:68237761	GNG12	0.27	4.5	0.37	1.56e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs2072499	0.722	rs61462713	chr1:156161682	C/T	cg24450063	chr1:156163899	SLC25A44	1.11	10.16	0.67	5.03e-18	Testicular germ cell tumor;
TGCT	cis	rs9457247	0.935	rs9348211	chr6:167375173	G/C	cg25258033	chr6:167368657	RNASET2	-0.2	-4.82	-0.4	4.19e-6	Crohn's disease;
TGCT	cis	rs12510870	0.599	rs34859660	chr4:74452233	A/C	cg05868023	chr4:75230803	EREG	-0.55	-4.74	-0.39	5.71e-6	Iris color (b* coordinate);
TGCT	cis	rs6088590	1.000	rs55753039	chr20:33394940	C/T	cg24642439	chr20:33292090	TP53INP2	0.68	6.12	0.48	1.11e-8	Coronary artery disease;
TGCT	cis	rs12477438	0.520	rs7604557	chr2:99747829	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.15	18.47	0.86	2.08e-37	Chronic sinus infection;
TGCT	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg22535103	chr8:58192502	C8orf71	-0.4	-4.71	-0.39	6.62e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs5757676	1.000	rs5757676	chr22:39841700	T/C	cg01416388	chr22:39784598	NA	-0.7	-5.62	-0.45	1.21e-7	IgG glycosylation;
TGCT	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg03452623	chr4:187889614	NA	-0.34	-4.94	-0.41	2.46e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7714584	1.000	rs6579806	chr5:150271084	C/T	cg22134413	chr5:150180641	NA	0.78	6.12	0.48	1.16e-8	Crohn's disease;
TGCT	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg11494091	chr17:61959527	GH2	0.61	14.63	0.8	8.78e-29	Prudent dietary pattern;
TGCT	cis	rs9467773	1.000	rs2255070	chr6:26501777	C/G	cg15659132	chr6:26577336	NA	0.84	11.72	0.73	8.07e-22	Intelligence (multi-trait analysis);
TGCT	cis	rs422249	0.512	rs174578	chr11:61605499	T/A	cg01500311	chr11:61656094	FADS3	-0.33	-5.69	-0.46	8.6e-8	Trans fatty acid levels;
TGCT	cis	rs111803315	1.000	rs112555934	chr14:59977232	T/C	cg22995959	chr14:59931024	GPR135	0.66	4.8	0.4	4.39e-6	Schizophrenia;
TGCT	cis	rs36405	1.000	rs36412	chr14:72356535	A/G	cg10066683	chr14:71515513	PCNX	0.24	4.45	0.37	1.87e-5	Yang-deficiency constitution;
TGCT	cis	rs2204008	0.840	rs3892363	chr12:38479487	G/A	cg13010199	chr12:38710504	ALG10B	0.58	4.72	0.39	6.16e-6	Bladder cancer;
TGCT	cis	rs6484504	0.576	rs58702363	chr11:31246397	C/A	cg26647111	chr11:31128758	NA	-0.34	-4.73	-0.39	5.88e-6	Red blood cell count;
TGCT	cis	rs4273100	0.850	rs11204306	chr17:19267371	A/G	cg01534423	chr17:18965556	NA	0.94	6.42	0.5	2.66e-9	Schizophrenia;
TGCT	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg12963246	chr6:28129442	ZNF389	0.52	5.1	0.42	1.23e-6	Depression;
TGCT	cis	rs59197085	0.636	rs60324735	chr7:128465450	A/G	cg00260937	chr7:128520193	KCP	0.47	4.98	0.41	2.1e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
TGCT	cis	rs17221829	0.733	rs11018679	chr11:89362869	G/T	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.67	-0.39	7.58e-6	Anxiety in major depressive disorder;
TGCT	cis	rs35883536	1.000	rs11583008	chr1:101085094	A/G	cg06223162	chr1:101003688	GPR88	0.31	4.89	0.4	3.07e-6	Monocyte count;
TGCT	cis	rs4566357	0.964	rs4296416	chr2:227921926	C/T	cg11843606	chr2:227700838	RHBDD1	-0.59	-5.37	-0.43	3.8e-7	Coronary artery disease;
TGCT	cis	rs11098499	0.954	rs7656252	chr4:120404268	T/C	cg09307838	chr4:120376055	NA	0.69	6.64	0.51	8.97e-10	Corneal astigmatism;
TGCT	cis	rs644799	0.601	rs7902	chr11:95565288	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.62	5.6	0.45	1.32e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs10276381	1.000	rs10260837	chr7:28181129	C/T	cg23620719	chr7:28220237	JAZF1	0.99	5.75	0.46	6.58e-8	Crohn's disease;
TGCT	cis	rs9399135	0.967	rs1014020	chr6:135334426	C/A	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.36e-6	Red blood cell count;
TGCT	cis	rs317689	0.819	rs317685	chr12:69715457	A/G	cg11871910	chr12:69753446	YEATS4	-0.53	-4.61	-0.38	9.74e-6	Response to diuretic therapy;
TGCT	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.29	-4.49	-0.37	1.64e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs308403	0.509	rs13122636	chr4:123671045	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.85	12.28	0.74	3.54e-23	Blood protein levels;
TGCT	cis	rs7586879	0.861	rs10164466	chr2:25114069	T/C	cg01884057	chr2:25150051	NA	0.27	4.81	0.4	4.36e-6	Body mass index;
TGCT	cis	rs6733011	0.628	rs4850888	chr2:99456946	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-4.63	-0.38	9.16e-6	Bipolar disorder;
TGCT	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg07167872	chr1:205819463	PM20D1	0.58	7.5	0.56	1.09e-11	Menarche (age at onset);
TGCT	cis	rs1994135	0.715	rs10844625	chr12:33693006	C/T	cg06521331	chr12:34319734	NA	-0.3	-4.69	-0.39	6.97e-6	Resting heart rate;
TGCT	cis	rs7582180	0.739	rs10195793	chr2:100925803	A/G	cg08017756	chr2:100939284	LONRF2	-0.32	-5.26	-0.43	6.1e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs10479542	0.929	rs7718673	chr5:178980009	C/T	cg21226059	chr5:178986404	RUFY1	-0.44	-4.62	-0.38	9.37e-6	Lung cancer;
TGCT	cis	rs10510102	0.808	rs17102804	chr10:123727880	A/G	cg23691251	chr10:123688108	ATE1	-0.59	-4.7	-0.39	6.75e-6	Breast cancer;
TGCT	cis	rs6504340	0.600	rs2325946	chr17:46584631	G/C	cg25032089	chr17:46643351	HOXB3	-0.52	-5.82	-0.46	4.61e-8	Primary tooth development (number of teeth);
TGCT	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.31	-4.82	-0.4	4.12e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs8017423	0.967	rs55962513	chr14:90729460	C/G	cg04374321	chr14:90722782	PSMC1	0.78	7.86	0.58	1.59e-12	Mortality in heart failure;
TGCT	cis	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg13531842	chr10:38383804	ZNF37A	0.39	4.58	0.38	1.12e-5	Extrinsic epigenetic age acceleration;
TGCT	cis	rs10751667	1.000	rs7394449	chr11:962190	T/C	cg06064525	chr11:970664	AP2A2	-0.33	-6.53	-0.51	1.54e-9	Alzheimer's disease (late onset);
TGCT	cis	rs7772486	0.790	rs2814880	chr6:146208937	T/G	cg05347473	chr6:146136440	FBXO30	0.52	5.0	0.41	1.87e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6061231	0.793	rs2427320	chr20:60976723	A/G	cg24112000	chr20:60950667	NA	-0.39	-5.06	-0.41	1.48e-6	Colorectal cancer;
TGCT	cis	rs881375	1.000	rs1953126	chr9:123640500	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.39	4.56	0.38	1.19e-5	Rheumatoid arthritis;
TGCT	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs7412746	0.611	rs4319334	chr1:150766822	G/A	cg09365446	chr1:150670422	GOLPH3L	0.32	4.6	0.38	1.04e-5	Melanoma;
TGCT	cis	rs8056742	0.642	rs66677993	chr16:85048238	C/G	cg00229868	chr16:85520891	NA	0.41	4.89	0.4	3.09e-6	Amyotrophic lateral sclerosis;
TGCT	cis	rs45430	1.000	rs416981	chr21:42745414	G/A	cg22778903	chr21:42741698	MX2	0.32	5.21	0.42	7.61e-7	Melanoma;
TGCT	cis	rs6815814	0.731	rs10776482	chr4:38774785	A/G	cg02016764	chr4:38805732	TLR1	-0.28	-4.79	-0.4	4.63e-6	Breast cancer;
TGCT	cis	rs7614311	0.731	rs73117087	chr3:63948696	A/G	cg22134162	chr3:63841271	THOC7	-0.46	-5.87	-0.47	3.73e-8	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs11671005	0.735	rs11667591	chr19:58937637	G/A	cg13877915	chr19:58951672	ZNF132	0.63	4.97	0.41	2.14e-6	Mean platelet volume;
TGCT	cis	rs11249608	0.548	rs11960161	chr5:178453837	A/G	cg21905437	chr5:178450457	ZNF879	0.43	4.5	0.37	1.53e-5	Pubertal anthropometrics;
TGCT	cis	rs7927592	0.513	rs630225	chr11:68194611	A/C	cg16797656	chr11:68205561	LRP5	0.28	5.08	0.41	1.36e-6	Total body bone mineral density;
TGCT	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg24531977	chr5:56204891	C5orf35	0.69	7.29	0.55	3.25e-11	Initial pursuit acceleration;
TGCT	cis	rs7172809	0.599	rs17471431	chr15:77749068	T/C	cg22256960	chr15:77711686	NA	-0.51	-4.86	-0.4	3.47e-6	Glucose homeostasis traits;
TGCT	cis	rs9914988	1.000	rs901975	chr17:27189774	A/G	cg20469991	chr17:27169893	C17orf63	0.69	5.06	0.41	1.5e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs1475911	0.744	rs12481958	chr21:43517269	A/G	cg19766460	chr21:43528205	UMODL1;C21orf128	0.45	6.35	0.5	3.68e-9	IgG glycosylation;
TGCT	cis	rs2070488	0.965	rs6599209	chr3:38558197	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.83	-8.45	-0.6	6.78e-14	Electrocardiographic conduction measures;
TGCT	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg09177884	chr7:1199841	ZFAND2A	-0.5	-4.68	-0.39	7.46e-6	Longevity;Endometriosis;
TGCT	cis	rs2562456	0.874	rs2562408	chr19:21709881	C/G	cg25650185	chr19:21324782	ZNF431	0.61	5.38	0.43	3.6e-7	Pain;
TGCT	cis	rs7937612	0.965	rs10892570	chr11:120274501	G/T	cg24566217	chr11:120254723	ARHGEF12	-0.28	-4.56	-0.38	1.2e-5	Intraocular pressure;
TGCT	trans	rs62103177	0.810	rs62103187	chr18:77627633	G/C	cg05926928	chr17:57297772	GDPD1	1.22	11.16	0.71	1.85e-20	Opioid sensitivity;
TGCT	cis	rs7666738	0.888	rs13110683	chr4:98983368	G/C	cg05340658	chr4:99064831	C4orf37	0.49	4.88	0.4	3.14e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9814567	0.806	rs4535271	chr3:134321669	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.76	-7.11	-0.54	8.15e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs4689388	0.750	rs10755148	chr4:6295064	A/G	cg25554036	chr4:6271136	WFS1	0.51	6.79	0.52	4.21e-10	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs2456568	0.835	rs8181533	chr11:93638614	C/T	cg17595323	chr11:93583763	C11orf90	-0.47	-6.52	-0.51	1.58e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs9549260	0.785	rs10507484	chr13:41218134	T/C	cg21288729	chr13:41239152	FOXO1	0.99	10.35	0.68	1.79e-18	Red blood cell count;
TGCT	cis	rs6061231	0.631	rs927133	chr20:60972109	C/T	cg15674680	chr20:60982522	CABLES2	0.57	4.91	0.4	2.81e-6	Colorectal cancer;
TGCT	cis	rs17221829	0.703	rs12365715	chr11:89374075	G/T	cg02982614	chr11:89391479	FOLH1B	-0.27	-4.85	-0.4	3.63e-6	Anxiety in major depressive disorder;
TGCT	cis	rs2456568	0.548	rs6483281	chr11:93661840	G/C	cg17595323	chr11:93583763	C11orf90	-0.42	-5.26	-0.43	6.25e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg01802117	chr1:53393560	SCP2	0.43	5.13	0.42	1.1e-6	Monocyte count;
TGCT	trans	rs4332037	0.539	rs55993248	chr7:2071132	A/G	cg10840412	chr1:235813424	GNG4	0.95	6.94	0.53	1.97e-10	Bipolar disorder;
TGCT	cis	rs1511802	0.666	rs13106826	chr4:187125168	T/A	cg19358738	chr4:186734530	SORBS2	0.18	4.57	0.38	1.18e-5	Blood protein levels;
TGCT	trans	rs10504390	0.656	rs78912269	chr8:66511446	C/T	cg15922513	chr12:131561251	GPR133	-0.69	-6.97	-0.53	1.66e-10	IgG glycosylation;
TGCT	cis	rs9467773	0.620	rs2101581	chr6:26622769	G/T	cg05738196	chr6:26577821	NA	0.88	11.31	0.71	8.33e-21	Intelligence (multi-trait analysis);
TGCT	cis	rs2404602	0.967	rs7167613	chr15:77041192	C/A	cg26408565	chr15:76604113	ETFA	-0.37	-4.64	-0.38	8.88e-6	Blood metabolite levels;
TGCT	cis	rs34421088	0.506	rs4841519	chr8:11146228	A/T	cg03192020	chr8:11204681	TDH	0.51	4.51	0.38	1.46e-5	Neuroticism;
TGCT	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg17971929	chr21:40555470	PSMG1	-0.7	-6.32	-0.49	4.38e-9	Cognitive function;
TGCT	cis	rs380904	0.963	rs410836	chr8:144576849	A/G	cg01134012	chr8:144635316	GSDMD	0.49	4.51	0.38	1.49e-5	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs765787	0.505	rs12593605	chr15:45497448	T/A	cg24006582	chr15:45444508	DUOX1	0.25	5.26	0.43	6.23e-7	Uric acid levels;
TGCT	cis	rs1475911	1.000	rs55645900	chr21:43515728	G/T	cg19766460	chr21:43528205	UMODL1;C21orf128	0.51	6.7	0.52	6.42e-10	IgG glycosylation;
TGCT	cis	rs4285028	0.747	rs11928871	chr3:121483388	G/C	cg01951420	chr3:121553821	IQCB1;EAF2	-1.03	-8.75	-0.62	1.26e-14	Multiple sclerosis;
TGCT	trans	rs10825036	0.567	rs437228	chr10:55333482	T/C	cg03092930	chr2:132586330	NA	0.53	7.07	0.54	9.91e-11	Disease-free survival in breast cancer;
TGCT	cis	rs7223966	1.000	rs6504167	chr17:61693194	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	4.81	0.4	4.22e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs4499344	0.556	rs259236	chr19:33116122	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.8	7.9	0.58	1.26e-12	Mean platelet volume;
TGCT	cis	rs10037055	1.000	rs10037055	chr5:176691279	G/T	cg18465082	chr5:176734745	MXD3	0.27	4.43	0.37	2.01e-5	Migraine without aura;
TGCT	cis	rs12478296	0.901	rs7420176	chr2:243005277	G/A	cg06360820	chr2:242988706	NA	-0.6	-4.96	-0.41	2.23e-6	Obesity-related traits;
TGCT	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg04234412	chr22:24373322	LOC391322	-0.9	-10.44	-0.68	1.07e-18	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7552404	0.731	rs11161857	chr1:76370228	G/C	cg10523679	chr1:76189770	ACADM	0.83	7.23	0.54	4.29e-11	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs611744	0.870	rs2212703	chr8:109198401	G/C	cg21045802	chr8:109455806	TTC35	0.68	6.03	0.48	1.72e-8	Dupuytren's disease;
TGCT	cis	rs9549367	0.789	rs34568744	chr13:113894564	G/T	cg18105134	chr13:113819100	PROZ	-0.34	-5.52	-0.44	1.9e-7	Platelet distribution width;
TGCT	cis	rs11190604	1.000	rs3793772	chr10:102222825	A/G	cg23241863	chr10:102295624	HIF1AN	0.61	4.71	0.39	6.59e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs523522	0.962	rs4766969	chr12:120988238	A/G	cg12219531	chr12:120966889	COQ5	0.83	7.27	0.55	3.46e-11	High light scatter reticulocyte count;
TGCT	cis	rs7824557	0.564	rs4631424	chr8:11236809	T/C	cg21775007	chr8:11205619	TDH	-0.65	-6.39	-0.5	3.07e-9	Retinal vascular caliber;
TGCT	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg12963246	chr6:28129442	ZNF389	0.52	5.01	0.41	1.85e-6	Depression;
TGCT	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg26338869	chr17:61819248	STRADA	-0.53	-4.87	-0.4	3.29e-6	Prudent dietary pattern;
TGCT	cis	rs7149242	1.000	rs7149242	chr14:101159416	G/T	cg18089426	chr14:101175970	NA	0.45	4.81	0.4	4.3e-6	Platelet count;
TGCT	cis	rs12142240	0.698	rs67487250	chr1:46811333	T/C	cg14993813	chr1:46806288	NSUN4	-0.58	-4.81	-0.4	4.34e-6	Menopause (age at onset);
TGCT	cis	rs2439831	0.850	rs28504496	chr15:44016883	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	5.93	0.47	2.85e-8	Lung cancer in ever smokers;
TGCT	cis	rs4654899	0.680	rs12407731	chr1:21254789	C/T	cg01072550	chr1:21505969	NA	-0.52	-8.56	-0.61	3.7e-14	Superior frontal gyrus grey matter volume;
TGCT	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg13397359	chr6:42928475	GNMT	0.73	6.8	0.52	3.86e-10	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs1799899	0.826	rs6796795	chr3:133466222	A/G	cg18342939	chr3:134203408	ANAPC13;CEP63	0.48	4.91	0.4	2.85e-6	Alcohol consumption (transferrin glycosylation);
TGCT	cis	rs7666738	0.546	rs13149516	chr4:98913030	T/A	cg05340658	chr4:99064831	C4orf37	0.59	6.52	0.51	1.62e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg17971929	chr21:40555470	PSMG1	0.93	8.72	0.62	1.49e-14	Cognitive function;
TGCT	cis	rs12541595	0.686	rs34011925	chr8:125901855	T/C	cg01919908	chr8:126310179	NSMCE2	-0.18	-4.51	-0.38	1.5e-5	Left ventricle diastolic internal dimension;
TGCT	cis	rs9902453	0.740	rs2628189	chr17:28088813	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.83	-8.18	-0.59	2.86e-13	Coffee consumption (cups per day);
TGCT	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg20007245	chr22:24372913	LOC391322	-0.71	-6.96	-0.53	1.71e-10	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg22963979	chr7:1858916	MAD1L1	0.45	7.65	0.57	4.92e-12	Schizophrenia;
TGCT	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg02891314	chr5:179741120	GFPT2	-0.41	-7.09	-0.54	8.81e-11	Height;
TGCT	cis	rs1008375	1.000	rs7436403	chr4:17692685	T/G	cg18681998	chr4:17616180	MED28	-0.79	-7.33	-0.55	2.58e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4689388	0.890	rs4501291	chr4:6298582	C/T	cg00701064	chr4:6280414	WFS1	0.44	5.77	0.46	5.96e-8	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs6684514	0.961	rs10908497	chr1:156274740	G/A	cg20302342	chr1:156215951	PAQR6	0.34	4.6	0.38	1.01e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs7296418	0.630	rs11608305	chr12:123791165	C/G	cg00376283	chr12:123451042	ABCB9	0.65	5.53	0.44	1.79e-7	Platelet count;
TGCT	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	8.55	0.61	3.84e-14	Platelet count;
TGCT	cis	rs2228479	0.850	rs62052212	chr16:89981960	G/A	cg06558623	chr16:89946397	TCF25	0.58	6.67	0.51	7.45e-10	Skin colour saturation;
TGCT	cis	rs7246657	0.722	rs1975937	chr19:38091932	A/T	cg03611452	chr19:38183253	ZNF781	0.59	4.72	0.39	6.14e-6	Coronary artery calcification;
TGCT	cis	rs7772486	0.754	rs697054	chr6:146003770	C/T	cg23711669	chr6:146136114	FBXO30	0.91	10.55	0.69	5.67e-19	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs34779708	0.966	rs12769484	chr10:35465746	G/A	cg03585969	chr10:35415529	CREM	0.43	4.52	0.38	1.4e-5	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs9913156	0.707	rs9902000	chr17:4582426	A/C	cg23387401	chr17:4582204	PELP1	-0.3	-4.55	-0.38	1.25e-5	Lymphocyte counts;
TGCT	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg05025164	chr4:1340916	KIAA1530	0.55	4.76	0.39	5.33e-6	Longevity;
TGCT	trans	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg27523141	chr10:43048294	ZNF37B	0.73	8.58	0.61	3.32e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs9611565	0.512	rs139571	chr22:42214238	G/A	cg17554472	chr22:41940697	POLR3H	-0.46	-4.69	-0.39	7.09e-6	Vitiligo;
TGCT	cis	rs9309473	0.514	rs62149659	chr2:73585196	C/T	cg07208825	chr2:73871855	ALMS1P	0.27	5.11	0.42	1.21e-6	Metabolite levels;
TGCT	cis	rs274567	0.501	rs272856	chr5:131687081	G/C	cg24060327	chr5:131705240	SLC22A5	-0.75	-8.27	-0.6	1.8e-13	Blood metabolite levels;
TGCT	cis	rs1514658	0.903	rs7674055	chr4:119272958	T/C	cg21605333	chr4:119757512	SEC24D	-0.5	-4.5	-0.37	1.56e-5	Congenital heart disease (maternal effect);
TGCT	cis	rs7926906	1.000	rs7944479	chr11:90524289	T/C	cg26138821	chr11:89956704	CHORDC1	-0.51	-5.52	-0.44	1.92e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs10791323	0.582	rs2851120	chr11:133708065	A/G	cg15485101	chr11:133734466	NA	0.38	5.0	0.41	1.95e-6	Childhood ear infection;
TGCT	cis	rs7618915	1.000	rs3844291	chr3:52341215	A/C	cg10802521	chr3:52805072	NEK4	-0.57	-5.92	-0.47	2.9e-8	Bipolar disorder;
TGCT	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg11494091	chr17:61959527	GH2	0.42	6.96	0.53	1.76e-10	Height;
TGCT	cis	rs3784262	0.669	rs12915508	chr15:58302036	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.43	-6.27	-0.49	5.58e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs6598955	0.640	rs6667826	chr1:26531408	T/C	cg04990556	chr1:26633338	UBXN11	-0.89	-11.04	-0.7	3.67e-20	Obesity-related traits;
TGCT	cis	rs6087990	0.735	rs2424921	chr20:31385814	C/T	cg13636640	chr20:31349939	DNMT3B	0.97	12.49	0.75	1.08e-23	Ulcerative colitis;
TGCT	cis	rs727563	0.635	rs713988	chr22:42159072	A/G	cg17554472	chr22:41940697	POLR3H	0.46	4.69	0.39	7.09e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs1878931	0.624	rs27241	chr16:3447282	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.76	-6.45	-0.5	2.3e-9	Body mass index (adult);
TGCT	cis	rs9653442	0.675	rs2871326	chr2:100662010	T/C	cg07810366	chr2:100720526	AFF3	-0.42	-7.07	-0.54	9.86e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs651907	0.557	rs11712748	chr3:101383562	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.34	-7.08	-0.54	9.37e-11	Colorectal cancer;
TGCT	cis	rs3733585	0.699	rs7683283	chr4:9969974	T/C	cg11266682	chr4:10021025	SLC2A9	-0.59	-7.85	-0.58	1.63e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs2282300	0.956	rs654710	chr11:30394303	A/G	cg25418670	chr11:30344373	C11orf46	0.4	5.13	0.42	1.08e-6	Morning vs. evening chronotype;
TGCT	cis	rs13242816	1.000	rs1018859	chr7:116067347	C/T	cg16553024	chr7:116138462	CAV2	-0.48	-5.31	-0.43	4.89e-7	P wave duration;
TGCT	trans	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg27523141	chr10:43048294	ZNF37B	0.73	8.5	0.61	5.09e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg12288994	chr5:1860383	NA	0.24	4.52	0.38	1.42e-5	Cardiovascular disease risk factors;
TGCT	cis	rs3617	0.625	rs7652667	chr3:52866535	C/A	cg05573699	chr3:52720067	GNL3;PBRM1	0.49	4.77	0.39	5.04e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2075165	0.901	rs6701440	chr1:156249505	A/G	cg20302342	chr1:156215951	PAQR6	0.36	5.38	0.44	3.56e-7	Tonsillectomy;
TGCT	cis	rs8017423	0.935	rs11628906	chr14:90738002	C/T	cg04374321	chr14:90722782	PSMC1	-0.75	-7.32	-0.55	2.67e-11	Mortality in heart failure;
TGCT	cis	rs7824557	0.614	rs2060456	chr8:11213363	C/T	cg21775007	chr8:11205619	TDH	0.68	6.46	0.5	2.16e-9	Retinal vascular caliber;
TGCT	cis	rs8180040	0.620	rs6767907	chr3:47162661	C/T	cg27129171	chr3:47204927	SETD2	-0.7	-8.49	-0.61	5.34e-14	Colorectal cancer;
TGCT	cis	rs7027203	0.576	rs7874836	chr9:96559370	C/T	cg14598338	chr9:96623480	NA	-0.54	-7.8	-0.57	2.19e-12	DNA methylation (variation);
TGCT	cis	rs60843830	0.661	rs7561648	chr2:105171	G/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.54	4.51	0.38	1.45e-5	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs7666738	0.830	rs10005120	chr4:99038200	A/G	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2486288	0.656	rs8040185	chr15:45552081	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.46	-5.59	-0.45	1.38e-7	Glomerular filtration rate;
TGCT	cis	rs72781680	0.752	rs7578606	chr2:23902360	T/C	cg08917208	chr2:24149416	ATAD2B	1.0	5.56	0.45	1.59e-7	Lymphocyte counts;
TGCT	cis	rs2535633	0.631	rs6799185	chr3:53101580	C/T	cg10802521	chr3:52805072	NEK4	-0.52	-5.44	-0.44	2.77e-7	Body mass index;
TGCT	cis	rs9325144	0.624	rs12231544	chr12:38901956	C/T	cg26384229	chr12:38710491	ALG10B	-0.6	-5.48	-0.44	2.31e-7	Morning vs. evening chronotype;
TGCT	cis	rs7666738	0.830	rs2114426	chr4:98933130	C/T	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9611565	0.570	rs12159188	chr22:42121125	A/T	cg03806693	chr22:41940476	POLR3H	1.02	10.91	0.7	7.73e-20	Vitiligo;
TGCT	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg18402987	chr7:1209562	NA	0.78	6.58	0.51	1.16e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs4930561	0.714	rs6591335	chr11:67976812	T/C	cg04465784	chr11:67976953	SUV420H1	-0.38	-5.5	-0.44	2.07e-7	Breast cancer in childhood cancer survivors;IgG glycosylation;
TGCT	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg20887711	chr4:1340912	KIAA1530	-0.58	-4.97	-0.41	2.17e-6	Obesity-related traits;
TGCT	cis	rs9906944	0.707	rs12942084	chr17:47114392	A/G	cg07075026	chr17:47091521	IGF2BP1	-0.43	-4.6	-0.38	1.03e-5	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs8017423	0.967	rs17188605	chr14:90722579	C/T	cg04374321	chr14:90722782	PSMC1	0.76	7.71	0.57	3.59e-12	Mortality in heart failure;
TGCT	cis	rs1670533	1.000	rs11247971	chr4:1053580	A/G	cg27284194	chr4:1044797	NA	0.66	5.69	0.45	8.85e-8	Recombination rate (females);
TGCT	cis	rs9534288	0.797	rs9534287	chr13:46603926	A/C	cg15192986	chr13:46630673	CPB2	-0.52	-7.53	-0.56	9.22e-12	Blood protein levels;
TGCT	cis	rs1059312	1.000	rs3825180	chr12:129279242	A/G	cg09035930	chr12:129282057	SLC15A4	-0.56	-11.07	-0.71	3.1e-20	Systemic lupus erythematosus;
TGCT	cis	rs295140	0.605	rs295149	chr2:201175244	A/G	cg23649088	chr2:200775458	C2orf69	-0.28	-4.52	-0.38	1.42e-5	QT interval;
TGCT	cis	rs8051431	0.840	rs8056943	chr16:72008854	G/A	cg06353428	chr16:71660113	MARVELD3	0.58	4.98	0.41	2.07e-6	LDL cholesterol levels;
TGCT	cis	rs2153535	0.601	rs9502719	chr6:8541032	A/G	cg07606381	chr6:8435919	SLC35B3	0.56	5.16	0.42	9.46e-7	Motion sickness;
TGCT	cis	rs72781680	0.821	rs72796325	chr2:24134537	G/A	cg08917208	chr2:24149416	ATAD2B	0.74	4.66	0.39	7.9e-6	Lymphocyte counts;
TGCT	cis	rs9831754	0.906	rs2102601	chr3:78410536	G/A	cg06138941	chr3:78371609	NA	-0.47	-5.01	-0.41	1.87e-6	Calcium levels;
TGCT	cis	rs17030434	0.871	rs74380369	chr4:154730273	C/T	cg14289246	chr4:154710475	SFRP2	-0.9	-7.58	-0.56	7.16e-12	Electrocardiographic conduction measures;
TGCT	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg01802117	chr1:53393560	SCP2	0.43	5.12	0.42	1.14e-6	Monocyte count;
TGCT	cis	rs13064411	0.696	rs9869318	chr3:113146271	T/C	cg18753928	chr3:113234510	CCDC52	-0.7	-5.12	-0.42	1.12e-6	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs938554	0.513	rs3775948	chr4:9995182	G/C	cg02734326	chr4:10020555	SLC2A9	0.53	4.92	0.4	2.71e-6	Blood metabolite levels;
TGCT	cis	rs2204008	0.805	rs11514348	chr12:38243427	T/C	cg13010199	chr12:38710504	ALG10B	0.64	5.01	0.41	1.85e-6	Bladder cancer;
TGCT	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	15.27	0.81	2.85e-30	Prudent dietary pattern;
TGCT	cis	rs7635838	0.617	rs346084	chr3:11281159	C/T	cg00170343	chr3:11313890	ATG7	0.64	6.28	0.49	5.27e-9	HDL cholesterol;
TGCT	cis	rs4711336	1.000	rs11759396	chr6:33656654	C/G	cg14003231	chr6:33640908	ITPR3	0.28	4.49	0.37	1.58e-5	Height;
TGCT	cis	rs981844	0.740	rs1020702	chr4:154685712	A/C	cg14289246	chr4:154710475	SFRP2	-0.91	-8.31	-0.6	1.38e-13	Response to statins (LDL cholesterol change);
TGCT	cis	rs778371	0.915	rs748002	chr2:233757679	G/A	cg08000102	chr2:233561755	GIGYF2	-0.6	-6.31	-0.49	4.46e-9	Schizophrenia;
TGCT	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.4	-4.45	-0.37	1.85e-5	Longevity;Endometriosis;
TGCT	cis	rs514406	0.505	rs6703127	chr1:53180565	C/T	cg24675658	chr1:53192096	ZYG11B	-0.8	-9.66	-0.66	8.35e-17	Monocyte count;
TGCT	cis	rs12477438	0.520	rs34766932	chr2:99737273	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	8.52	0.61	4.42e-14	Chronic sinus infection;
TGCT	cis	rs709400	0.633	rs7160208	chr14:103965528	G/A	cg26031613	chr14:104095156	KLC1	0.84	9.5	0.65	2.08e-16	Body mass index;
TGCT	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg02487422	chr3:49467188	NICN1	0.55	5.32	0.43	4.77e-7	Menarche (age at onset);
TGCT	cis	rs68170813	0.559	rs78440378	chr7:106962782	C/A	cg02696742	chr7:106810147	HBP1	-0.69	-5.61	-0.45	1.27e-7	Coronary artery disease;
TGCT	cis	rs362296	0.671	rs1006798	chr4:3258373	A/G	cg06533319	chr4:3265114	C4orf44	0.24	4.52	0.38	1.44e-5	Parental longevity (mother's age at death);
TGCT	cis	rs2742417	0.609	rs11709306	chr3:45773732	G/A	cg04837898	chr3:45731254	SACM1L	-0.67	-7.3	-0.55	3.06e-11	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs10466239	0.730	rs12221341	chr10:43857330	C/G	cg12891252	chr10:43902500	HNRNPF	-0.74	-4.95	-0.41	2.4e-6	Telomere length;
TGCT	cis	rs1971762	0.527	rs1247957	chr12:53961493	G/T	cg16917193	chr12:54089295	NA	-1.04	-10.73	-0.69	2.06e-19	Height;
TGCT	cis	rs2242116	0.796	rs2290546	chr3:46965197	C/G	cg02527881	chr3:46936655	PTH1R	-0.33	-6.09	-0.48	1.29e-8	Birth weight;
TGCT	trans	rs10802346	0.524	rs10802356	chr1:246385857	T/C	cg13514129	chr1:39547527	MACF1	0.96	8.52	0.61	4.45e-14	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs9359856	0.510	rs17294495	chr6:90445753	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.45	-4.66	-0.39	7.9e-6	Bipolar disorder;
TGCT	cis	rs9527	0.571	rs12765337	chr10:104635344	G/C	cg04362960	chr10:104952993	NT5C2	0.56	4.77	0.39	5.06e-6	Arsenic metabolism;
TGCT	trans	rs6931743	1	rs6931743	chr6:19236109	G/A	cg05334032	chr14:105041531	NA	0.66	6.74	0.52	5.38e-10	3-hydroxypropylmercapturic acid levels in smokers;
TGCT	cis	rs295140	0.502	rs3754797	chr2:201242293	G/A	cg04283868	chr2:201171347	SPATS2L	0.52	4.98	0.41	2.06e-6	QT interval;
TGCT	cis	rs6684514	1.000	rs12141236	chr1:156302575	A/C	cg16558208	chr1:156270281	VHLL	0.48	9.6	0.65	1.19e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs6754311	0.731	rs309164	chr2:136691825	T/C	cg07169764	chr2:136633963	MCM6	0.69	6.43	0.5	2.49e-9	Mosquito bite size;
TGCT	trans	rs56011263	0.687	rs11734460	chr4:705074	C/T	cg12575136	chr18:32820987	ZNF397	0.77	9.37	0.64	4.3e-16	White blood cell count;
TGCT	cis	rs1538970	0.962	rs4660301	chr1:45820149	T/A	cg05343316	chr1:45956843	TESK2	0.64	5.06	0.41	1.47e-6	Platelet count;
TGCT	cis	rs2982552	0.873	rs2152751	chr6:152069999	A/G	cg22157087	chr6:152012887	ESR1	0.2	4.77	0.39	5e-6	Bone properties (heel);
TGCT	cis	rs4727027	0.680	rs6464941	chr7:148826352	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.17	0.42	9.03e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs7044106	0.791	rs7036766	chr9:123479621	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	6.99	0.53	1.48e-10	Hip circumference adjusted for BMI;
TGCT	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg08280861	chr8:58055591	NA	0.51	5.73	0.46	7.17e-8	Developmental language disorder (linguistic errors);
TGCT	cis	rs62244186	0.520	rs2372828	chr3:44784949	A/G	cg11003573	chr3:44754125	ZNF502	0.45	5.08	0.42	1.32e-6	Depressive symptoms;
TGCT	cis	rs7552404	0.924	rs1303169	chr1:76195041	T/C	cg22875332	chr1:76189707	ACADM	0.72	9.02	0.63	2.88e-15	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs4478858	0.735	rs10798843	chr1:31797094	A/G	cg07478791	chr1:31886160	SERINC2	-0.51	-4.95	-0.41	2.33e-6	Alcohol dependence;
TGCT	cis	rs2458413	0.542	rs2002812	chr8:105365234	C/T	cg04554929	chr8:105342491	NA	0.49	5.9	0.47	3.21e-8	Paget's disease;
TGCT	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs889312	0.500	rs832566	chr5:56151744	C/T	cg12311346	chr5:56204834	C5orf35	-0.44	-4.67	-0.39	7.74e-6	Breast cancer;Breast cancer (early onset);
TGCT	cis	rs7666738	0.753	rs13122897	chr4:98936185	C/A	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1975974	1.000	rs1985718	chr17:21731656	C/T	cg18423549	chr17:21743878	NA	-0.58	-5.39	-0.44	3.34e-7	Psoriasis;
TGCT	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg10150615	chr22:24372951	LOC391322	-1.01	-13.22	-0.76	1.96e-25	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7149242	0.696	rs7141210	chr14:101182470	T/C	cg11193865	chr14:101193038	DLK1	-0.48	-5.41	-0.44	3.15e-7	Platelet count;
TGCT	cis	rs10751667	0.666	rs7103585	chr11:971166	T/C	cg06064525	chr11:970664	AP2A2	-0.36	-8.28	-0.6	1.67e-13	Alzheimer's disease (late onset);
TGCT	cis	rs74233809	1.000	rs79668541	chr10:104793904	C/T	cg05855489	chr10:104503620	C10orf26	0.77	4.55	0.38	1.27e-5	Birth weight;
TGCT	trans	rs877282	0.838	rs34912955	chr10:772222	T/C	cg22713356	chr15:30763199	NA	1.16	10.02	0.67	1.16e-17	Uric acid levels;
TGCT	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg11941060	chr3:133502564	NA	-0.29	-6.15	-0.48	9.6e-9	Iron status biomarkers;
TGCT	cis	rs6582630	0.555	rs7133706	chr12:38475465	G/A	cg26384229	chr12:38710491	ALG10B	-0.81	-7.57	-0.56	7.38e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg03188948	chr7:1209495	NA	0.71	6.04	0.48	1.68e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9467773	0.620	rs2451731	chr6:26624822	A/C	cg05738196	chr6:26577821	NA	0.88	11.22	0.71	1.33e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs3096299	1.000	rs3096299	chr16:89448663	G/A	cg06640241	chr16:89574553	SPG7	0.7	7.0	0.53	1.44e-10	Multiple myeloma (IgH translocation);
TGCT	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg08859206	chr1:53392774	SCP2	0.4	5.96	0.47	2.46e-8	Monocyte count;
TGCT	cis	rs3784262	0.669	rs12914455	chr15:58312096	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.42	-6.17	-0.48	8.83e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs4889911	0.544	rs2587498	chr17:77830737	G/A	cg00646381	chr17:77835854	NA	0.44	6.6	0.51	1.06e-9	Electroencephalogram traits;
TGCT	cis	rs4252435	0.614	rs78357866	chr7:142629280	T/G	cg09833174	chr7:143059591	FAM131B	-1.03	-4.71	-0.39	6.56e-6	Cancer;
TGCT	cis	rs7666738	0.830	rs35276471	chr4:99068691	A/T	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.44e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs875971	0.651	rs313829	chr7:65552497	A/G	cg07424592	chr7:64974309	NA	0.61	5.02	0.41	1.74e-6	Aortic root size;
TGCT	cis	rs13256369	0.755	rs12680167	chr8:8562467	A/G	cg18904891	chr8:8559673	CLDN23	0.59	5.43	0.44	2.82e-7	Obesity-related traits;
TGCT	cis	rs4919694	1.000	rs7083328	chr10:104769268	G/A	cg04362960	chr10:104952993	NT5C2	1.06	7.05	0.53	1.09e-10	Arsenic metabolism;
TGCT	cis	rs416603	0.967	rs7191538	chr16:11363389	C/G	cg00044050	chr16:11439710	C16orf75	-0.81	-8.38	-0.6	9.95e-14	Type 1 diabetes;
TGCT	cis	rs7091068	0.616	rs7901507	chr10:95505424	C/G	cg20715218	chr10:95462985	C10orf4	0.53	4.71	0.39	6.57e-6	Urinary tract infection frequency;
TGCT	cis	rs9346649	0.630	rs4235913	chr6:168491697	T/C	cg02770688	chr6:168491649	NA	0.34	6.05	0.48	1.6e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
TGCT	cis	rs12497850	0.765	rs12487580	chr3:49182932	G/A	cg06212747	chr3:49208901	KLHDC8B	0.61	5.55	0.45	1.66e-7	Parkinson's disease;
TGCT	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg04414720	chr1:150670196	GOLPH3L	0.39	5.04	0.41	1.59e-6	Tonsillectomy;
TGCT	cis	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg08564027	chr20:61660810	NA	0.37	6.64	0.51	8.85e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs17539620	0.624	rs871068	chr6:154837514	C/A	cg20019720	chr6:154832845	CNKSR3	0.57	5.02	0.41	1.72e-6	Lipoprotein (a) levels;
TGCT	cis	rs7666738	0.753	rs17483788	chr4:98985623	G/A	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4951018	0.853	rs1573104	chr1:205636907	A/C	cg14159672	chr1:205819179	PM20D1	-0.39	-4.45	-0.37	1.85e-5	Prostate-specific antigen levels;
TGCT	cis	rs9486719	1.000	rs2472890	chr6:96867646	C/T	cg18709589	chr6:96969512	KIAA0776	0.71	5.21	0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg10802521	chr3:52805072	NEK4	-0.78	-10.0	-0.67	1.26e-17	Bipolar disorder;
TGCT	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg11941060	chr3:133502564	NA	-0.26	-5.32	-0.43	4.74e-7	Iron status biomarkers;
TGCT	cis	rs11792861	1.000	rs11792861	chr9:111809295	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.49	4.54	0.38	1.29e-5	Menarche (age at onset);
TGCT	cis	rs1371867	0.846	rs959022	chr8:101295992	T/A	cg06002616	chr8:101225028	SPAG1	-0.56	-6.58	-0.51	1.2e-9	Atrioventricular conduction;
TGCT	cis	rs8002180	0.959	rs7317112	chr13:95923523	C/T	cg24476569	chr13:95954382	ABCC4	-0.38	-4.71	-0.39	6.51e-6	Blood metabolite levels;
TGCT	cis	rs12200560	0.505	rs211172	chr6:97070691	C/A	cg06623918	chr6:96969491	KIAA0776	0.59	5.02	0.41	1.76e-6	Coronary heart disease;
TGCT	trans	rs7819412	0.511	rs2409797	chr8:11433780	T/C	cg06636001	chr8:8085503	FLJ10661	-0.78	-7.03	-0.53	1.25e-10	Triglycerides;
TGCT	cis	rs57590327	0.679	rs35628094	chr3:81605371	C/A	cg07356753	chr3:81810745	GBE1	-0.55	-4.54	-0.38	1.3e-5	Extraversion;
TGCT	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg11890956	chr21:40555474	PSMG1	-0.69	-6.81	-0.52	3.7e-10	Menarche (age at onset);
TGCT	cis	rs950169	0.580	rs17598114	chr15:85171317	C/T	cg12863693	chr15:85201151	NMB	0.44	5.2	0.42	7.82e-7	Schizophrenia;
TGCT	cis	rs74544699	1.000	rs79472060	chr4:74837932	G/A	cg16072462	chr4:74847758	PF4	0.76	4.86	0.4	3.49e-6	Growth-regulated protein alpha levels;
TGCT	cis	rs67478160	0.609	rs1547604	chr14:104270659	A/T	cg01849466	chr14:104193079	ZFYVE21	-0.17	-4.44	-0.37	1.94e-5	Schizophrenia;
TGCT	cis	rs904251	0.861	rs1757169	chr6:37487076	G/T	cg25019722	chr6:37503610	NA	-0.5	-6.92	-0.53	2.17e-10	Cognitive performance;
TGCT	cis	rs7542091	0.704	rs4133950	chr1:210044393	C/G	cg00989853	chr1:209979345	IRF6	0.43	4.58	0.38	1.12e-5	Monobrow;
TGCT	cis	rs2066819	1.000	rs2371454	chr12:56647243	A/G	cg26714650	chr12:56694279	CS	1.33	6.24	0.49	6.46e-9	Psoriasis vulgaris;
TGCT	cis	rs35306767	0.855	rs12771179	chr10:872347	A/G	cg20503657	chr10:835505	NA	0.77	11.34	0.71	6.95e-21	Eosinophil percentage of granulocytes;
TGCT	cis	rs9467711	1.000	rs6939799	chr6:26328366	G/A	cg02458000	chr6:26745757	NA	-1.05	-5.8	-0.46	5.29e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs910316	0.967	rs11624893	chr14:75660124	A/G	cg08847533	chr14:75593920	NEK9	-0.94	-9.91	-0.66	2.11e-17	Height;
TGCT	cis	rs8014204	0.804	rs35641442	chr14:75207263	G/A	cg06637938	chr14:75390232	RPS6KL1	0.74	7.31	0.55	2.81e-11	Caffeine consumption;
TGCT	cis	rs2075371	0.933	rs2544182	chr7:133949793	C/T	cg11752832	chr7:134001865	SLC35B4	0.7	6.05	0.48	1.57e-8	Mean platelet volume;
TGCT	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg17911788	chr17:44343683	NA	-0.62	-6.7	-0.52	6.65e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	trans	rs1814175	0.585	rs4881661	chr11:50000117	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.84	-0.7	1.13e-19	Height;
TGCT	trans	rs804280	0.509	rs9886639	chr8:11784529	G/T	cg15556689	chr8:8085844	FLJ10661	0.8	7.54	0.56	8.53e-12	Myopia (pathological);
TGCT	cis	rs10791323	0.569	rs10791335	chr11:133739571	A/T	cg15485101	chr11:133734466	NA	0.38	5.54	0.45	1.7e-7	Childhood ear infection;
TGCT	cis	rs9527	0.590	rs10883834	chr10:104881402	T/C	cg04362960	chr10:104952993	NT5C2	0.7	5.88	0.47	3.57e-8	Arsenic metabolism;
TGCT	cis	rs2013441	1.000	rs2526483	chr17:20112216	A/G	cg18979559	chr17:20280153	CCDC144C	-0.44	-4.61	-0.38	9.78e-6	Obesity-related traits;
TGCT	cis	rs2404602	0.608	rs12439484	chr15:76602937	A/C	cg22467129	chr15:76604101	ETFA	-0.63	-8.12	-0.59	3.98e-13	Blood metabolite levels;
TGCT	cis	rs710216	0.843	rs710220	chr1:43415346	G/T	cg03128534	chr1:43423976	SLC2A1	0.59	4.83	0.4	3.93e-6	Red cell distribution width;
TGCT	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg05025164	chr4:1340916	KIAA1530	0.79	6.64	0.51	8.6e-10	Longevity;
TGCT	cis	rs17376456	0.825	rs34967135	chr5:93221785	G/A	cg21475434	chr5:93447410	FAM172A	0.7	4.9	0.4	2.96e-6	Diabetic retinopathy;
TGCT	cis	rs12449000	1	rs12449000	chr16:89872970	T/C	cg27121462	chr16:89883253	FANCA	0.73	7.17	0.54	5.81e-11	Schizophrenia;
TGCT	cis	rs9611565	0.580	rs5758449	chr22:42140160	C/T	cg13695892	chr22:41940480	POLR3H	0.84	7.96	0.58	9.2e-13	Vitiligo;
TGCT	cis	rs7666738	0.791	rs17549003	chr4:98969132	A/C	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4478858	0.684	rs4949372	chr1:31738857	G/A	cg00250761	chr1:31883323	NA	-0.26	-4.55	-0.38	1.28e-5	Alcohol dependence;
TGCT	cis	rs11696845	0.626	rs1111032	chr20:43378770	A/G	cg25301532	chr20:43378953	KCNK15	0.47	5.15	0.42	9.92e-7	Obesity-related traits;
TGCT	cis	rs9443645	0.901	rs9443638	chr6:79720867	T/A	cg09184832	chr6:79620586	NA	-0.48	-5.34	-0.43	4.21e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs12142240	0.692	rs7532149	chr1:46824932	A/C	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs57024841	0.562	rs2071006	chr9:139839904	G/T	cg00693599	chr9:139836323	FBXW5	-0.22	-5.03	-0.41	1.68e-6	Beta-trace protein levels;
TGCT	cis	rs9467773	1.000	rs1884946	chr6:26545308	C/G	cg05738196	chr6:26577821	NA	0.88	12.49	0.75	1.11e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs9788682	1.000	rs7181245	chr15:78814389	C/T	cg24631222	chr15:78858424	CHRNA5	0.89	7.68	0.57	4.22e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs9468199	1.000	rs9468199	chr6:27681215	G/A	cg27179866	chr6:27740120	NA	0.39	4.5	0.37	1.52e-5	Parkinson's disease;
TGCT	cis	rs7914558	1.000	rs11191539	chr10:104819770	A/G	cg15744005	chr10:104629667	AS3MT	-0.38	-4.69	-0.39	7.04e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs17122693	0.748	rs72681607	chr14:51115866	T/C	cg04730355	chr14:51134070	SAV1	1.35	12.44	0.75	1.47e-23	Cognitive performance;
TGCT	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg10047753	chr17:41438598	NA	0.95	9.5	0.65	2.09e-16	Menopause (age at onset);
TGCT	cis	rs4727027	0.866	rs35599790	chr7:148806012	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	4.6	0.38	1.04e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs453301	0.658	rs9650616	chr8:8869199	T/G	cg00184457	chr8:8946301	NA	-0.26	-4.71	-0.39	6.41e-6	Joint mobility (Beighton score);
TGCT	cis	rs2404602	0.583	rs12898415	chr15:76574232	C/T	cg22467129	chr15:76604101	ETFA	-0.61	-7.93	-0.58	1.07e-12	Blood metabolite levels;
TGCT	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg11890956	chr21:40555474	PSMG1	0.8	7.51	0.56	1e-11	Cognitive function;
TGCT	cis	rs11195062	0.521	rs4918485	chr10:111949323	A/T	cg00817464	chr10:111662876	XPNPEP1	0.27	4.52	0.38	1.4e-5	Multiple myeloma;
TGCT	cis	rs6835098	1.000	rs4561909	chr4:174086937	A/T	cg08422745	chr4:174089978	GALNT7	-1.0	-10.07	-0.67	8.62e-18	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs11030122	0.702	rs12286710	chr11:3967171	T/G	cg18678763	chr11:4115507	RRM1	-0.49	-6.27	-0.49	5.56e-9	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs889312	0.532	rs6877300	chr5:56008916	C/T	cg17801930	chr5:56009405	NA	-0.25	-4.57	-0.38	1.18e-5	Breast cancer;Breast cancer (early onset);
TGCT	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg25036284	chr2:26402008	FAM59B	-0.57	-4.99	-0.41	2e-6	Gut microbiome composition (summer);
TGCT	cis	rs7552404	0.960	rs12134854	chr1:76137606	A/G	cg22875332	chr1:76189707	ACADM	0.8	10.09	0.67	7.7e-18	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs1205863	1.000	rs1205877	chr6:11945807	G/A	cg07106625	chr6:11870215	NA	0.51	5.05	0.41	1.51e-6	Disc degeneration (lumbar);
TGCT	cis	rs3733585	0.673	rs4235348	chr4:9951968	T/C	cg00071950	chr4:10020882	SLC2A9	-0.55	-6.63	-0.51	9.3e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	trans	rs10506458	1.000	rs11174759	chr12:63444363	A/T	cg22491629	chr6:157744540	C6orf35	-0.96	-8.34	-0.6	1.21e-13	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs12049351	0.719	rs10916499	chr1:229641078	T/G	cg12130225	chr1:229698885	NA	0.39	4.6	0.38	1.02e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs7829975	0.514	rs2979139	chr8:8268313	A/G	cg15556689	chr8:8085844	FLJ10661	0.71	6.27	0.49	5.47e-9	Mood instability;
TGCT	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg11764359	chr7:65958608	NA	-0.57	-5.25	-0.43	6.27e-7	Aortic root size;
TGCT	cis	rs6906287	0.647	rs12206329	chr6:118863789	G/T	cg21191810	chr6:118973309	C6orf204	0.26	4.49	0.37	1.58e-5	Electrocardiographic conduction measures;
TGCT	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg08736216	chr1:53307985	ZYG11A	-0.27	-5.37	-0.43	3.74e-7	Monocyte count;
TGCT	cis	rs61990749	0.597	rs176971	chr14:78191599	T/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.6	4.45	0.37	1.88e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs10193935	0.901	rs13393459	chr2:42463124	C/T	cg27598129	chr2:42591480	NA	-0.39	-5.15	-0.42	9.84e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9357506	1.000	rs58585138	chr6:46302987	A/G	cg21115430	chr6:46460003	NA	-0.27	-5.47	-0.44	2.43e-7	Body mass index;
TGCT	cis	rs3008870	1.000	rs2985817	chr1:67398607	G/C	cg11518657	chr1:67396239	MIER1	0.54	4.68	0.39	7.24e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs2456568	0.802	rs11020586	chr11:93638547	G/A	cg14065697	chr11:93583672	C11orf90	-0.38	-4.74	-0.39	5.65e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs6728642	0.614	rs113485946	chr2:97866442	T/C	cg26665480	chr2:98280029	ACTR1B	-0.97	-4.85	-0.4	3.69e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	cis	rs362272	0.524	rs6819202	chr4:3368264	G/A	cg18352616	chr4:3374830	RGS12	0.24	5.04	0.41	1.6e-6	Serum sulfate level;
TGCT	cis	rs644799	0.862	rs1150361	chr11:95633805	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.82	9.32	0.64	5.46e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg22920501	chr2:26401640	FAM59B	0.81	6.36	0.5	3.52e-9	Gut microbiome composition (summer);
TGCT	cis	rs2880765	0.835	rs56406982	chr15:86036379	G/A	cg13263323	chr15:86062960	AKAP13	-0.22	-4.84	-0.4	3.84e-6	Coronary artery disease;
TGCT	cis	rs10791323	0.582	rs2723613	chr11:133706696	G/A	cg03690763	chr11:133734501	NA	-0.35	-5.38	-0.44	3.5e-7	Childhood ear infection;
TGCT	cis	rs6121246	0.954	rs6060978	chr20:30416893	G/A	cg18721089	chr20:30220636	NA	-0.45	-4.93	-0.4	2.56e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs12497850	0.931	rs6446253	chr3:48911443	C/T	cg06212747	chr3:49208901	KLHDC8B	0.62	5.83	0.46	4.42e-8	Parkinson's disease;
TGCT	cis	rs9341808	0.558	rs2322635	chr6:80897210	A/G	cg08355045	chr6:80787529	NA	0.31	5.01	0.41	1.81e-6	Sitting height ratio;
TGCT	cis	rs1153858	1.000	rs4775937	chr15:45678614	C/A	cg26924012	chr15:45694286	SPATA5L1	1.09	15.08	0.8	7.99e-30	Homoarginine levels;
TGCT	cis	rs3806843	0.771	rs801174	chr5:140112712	C/T	cg19875535	chr5:140030758	IK	-0.37	-6.19	-0.49	7.89e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg25036284	chr2:26402008	FAM59B	-0.52	-4.59	-0.38	1.08e-5	Gut microbiome composition (summer);
TGCT	cis	rs9611519	0.964	rs4820428	chr22:41537589	C/T	cg13695892	chr22:41940480	POLR3H	0.51	4.57	0.38	1.16e-5	Neuroticism;
TGCT	cis	rs6519955	0.860	rs8136098	chr22:46425646	A/G	cg05468064	chr22:46423449	NA	0.54	5.62	0.45	1.21e-7	Dupuytren's disease;
TGCT	cis	rs2013441	0.965	rs2703790	chr17:20163209	G/A	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.63	-0.38	9.19e-6	Obesity-related traits;
TGCT	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg00343986	chr7:65444356	GUSB	0.24	5.29	0.43	5.43e-7	Aortic root size;
TGCT	cis	rs2404602	0.716	rs12437627	chr15:76845050	T/C	cg22467129	chr15:76604101	ETFA	-0.55	-6.51	-0.5	1.65e-9	Blood metabolite levels;
TGCT	trans	rs1557351	0.512	rs17751615	chr18:54730479	A/T	cg02701435	chr19:4903909	ARRDC5	0.6	7.06	0.54	1.02e-10	Multiple sclerosis (age of onset);
TGCT	cis	rs2832191	0.716	rs1984012	chr21:30392472	T/C	cg08807101	chr21:30365312	RNF160	0.64	6.06	0.48	1.52e-8	Dental caries;
TGCT	cis	rs7014346	0.767	rs11998706	chr8:128422098	C/G	cg04263511	chr8:128962092	PVT1	-0.31	-4.5	-0.37	1.54e-5	Colorectal cancer;
TGCT	cis	rs12142240	0.698	rs41294458	chr1:46810304	T/C	cg00530320	chr1:46809349	NSUN4	0.29	5.88	0.47	3.63e-8	Menopause (age at onset);
TGCT	cis	rs42648	0.596	rs194511	chr7:89846727	A/G	cg25739043	chr7:89950458	NA	-0.51	-4.85	-0.4	3.65e-6	Homocysteine levels;
TGCT	cis	rs7937682	0.575	rs34695265	chr11:111719128	T/C	cg09085632	chr11:111637200	PPP2R1B	0.88	8.32	0.6	1.31e-13	Primary sclerosing cholangitis;
TGCT	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg11890956	chr21:40555474	PSMG1	1.12	11.39	0.72	5.25e-21	Cognitive function;
TGCT	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.29	-4.54	-0.38	1.32e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs35306767	0.903	rs12762228	chr10:880854	G/A	cg26597838	chr10:835615	NA	0.8	12.11	0.74	9.26e-23	Eosinophil percentage of granulocytes;
TGCT	cis	rs6840360	1.000	rs6840360	chr4:152604031	C/T	cg17479576	chr4:152424074	FAM160A1	-0.49	-5.3	-0.43	5.05e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs6460942	0.908	rs6979124	chr7:12232551	G/T	cg06484146	chr7:12443880	VWDE	-0.52	-4.52	-0.38	1.44e-5	Coronary artery disease;
TGCT	cis	rs2637266	0.967	rs4553314	chr10:78358244	C/T	cg18941641	chr10:78392320	NA	0.41	4.86	0.4	3.51e-6	Pulmonary function;
TGCT	cis	rs79349575	0.749	rs8182364	chr17:47018025	A/G	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.52	-0.38	1.44e-5	Type 2 diabetes;
TGCT	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg22963979	chr7:1858916	MAD1L1	-0.46	-7.22	-0.54	4.49e-11	Bipolar disorder and schizophrenia;
TGCT	cis	rs910316	1.000	rs13099	chr14:75599155	G/A	cg11812906	chr14:75593930	NEK9	-0.73	-7.08	-0.54	9.66e-11	Height;
TGCT	cis	rs7119038	0.509	rs10892257	chr11:118579327	G/A	cg19308663	chr11:118741387	NA	0.24	4.5	0.37	1.54e-5	Sjögren's syndrome;
TGCT	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg09359103	chr1:154839909	KCNN3	-0.71	-14.71	-0.8	5.71e-29	Prostate cancer;
TGCT	cis	rs9818758	0.607	rs34823813	chr3:49749976	G/A	cg07636037	chr3:49044803	WDR6	-0.99	-4.74	-0.39	5.85e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs4819852	1.000	rs1034565	chr22:19984211	A/G	cg07821417	chr22:19972146	ARVCF	-0.18	-4.7	-0.39	6.94e-6	Pulse pressure;
TGCT	cis	rs10851411	0.789	rs12898937	chr15:42770853	G/A	cg23803468	chr15:43513504	EPB42	-0.24	-4.75	-0.39	5.44e-6	Glucose homeostasis traits;
TGCT	cis	rs2153535	0.601	rs330105	chr6:8543981	A/C	cg07606381	chr6:8435919	SLC35B3	0.56	5.16	0.42	9.56e-7	Motion sickness;
TGCT	cis	rs10883723	0.810	rs7912901	chr10:104277440	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs35771425	0.500	rs3738199	chr1:211545344	A/G	cg26515805	chr1:211431828	RCOR3	-0.46	-5.28	-0.43	5.52e-7	Educational attainment (years of education);
TGCT	cis	rs2404602	0.647	rs4312276	chr15:77164361	T/C	cg22467129	chr15:76604101	ETFA	0.47	4.79	0.4	4.69e-6	Blood metabolite levels;
TGCT	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg23302884	chr18:44338147	ST8SIA5	0.45	5.23	0.42	7.06e-7	Personality dimensions;
TGCT	cis	rs9393777	0.720	rs35212793	chr6:26998693	T/C	cg16898833	chr6:26189333	HIST1H4D	0.97	5.95	0.47	2.6e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs1008375	1.000	rs2058338	chr4:17678600	A/G	cg16339924	chr4:17578868	LAP3	-0.53	-4.5	-0.37	1.56e-5	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs56309584	0.673	rs11650444	chr17:8106317	C/T	cg08322244	chr17:8066669	VAMP2	-0.55	-5.16	-0.42	9.44e-7	Initial pursuit acceleration;
TGCT	cis	rs2688608	0.592	rs11000759	chr10:75493726	G/A	cg23231163	chr10:75533350	FUT11	-0.28	-4.68	-0.39	7.4e-6	Inflammatory bowel disease;
TGCT	cis	rs968567	0.539	rs174549	chr11:61571382	A/G	cg01500311	chr11:61656094	FADS3	0.28	4.94	0.41	2.52e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
TGCT	cis	rs12477438	0.520	rs6717729	chr2:99756941	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.03	12.86	0.76	1.46e-24	Chronic sinus infection;
TGCT	cis	rs9611565	0.592	rs5996039	chr22:41981957	A/G	cg06634786	chr22:41940651	POLR3H	-0.83	-7.66	-0.57	4.6e-12	Vitiligo;
TGCT	cis	rs9976767	0.608	rs2277797	chr21:43823910	A/G	cg23042151	chr21:43824109	UBASH3A	-0.22	-4.87	-0.4	3.4e-6	Type 1 diabetes;
TGCT	cis	rs1008375	0.966	rs10939736	chr4:17581617	T/A	cg16339924	chr4:17578868	LAP3	0.8	6.96	0.53	1.73e-10	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs11761231	1.000	rs4348414	chr7:131369298	C/T	cg23399222	chr7:130417715	KLF14	0.25	4.6	0.38	1.04e-5	Rheumatoid arthritis;
TGCT	cis	rs10431058	0.930	rs11212297	chr11:107475371	T/C	cg18204760	chr11:107461044	ELMOD1;LOC643923	0.74	7.08	0.54	9.56e-11	Common traits (Other);
TGCT	cis	rs11264213	0.591	rs538638	chr1:36534644	G/T	cg27506609	chr1:36549197	TEKT2	-0.31	-4.47	-0.37	1.77e-5	Schizophrenia;
TGCT	cis	rs7267979	0.586	rs6050431	chr20:25183908	C/T	cg03522245	chr20:25566470	NINL	0.5	5.27	0.43	5.88e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs56104184	0.775	rs56349331	chr19:49403009	T/A	cg17863274	chr19:49399704	TULP2	-0.54	-7.43	-0.55	1.58e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs62244186	0.659	rs7649834	chr3:44503732	C/T	cg10263370	chr3:44754102	ZNF502	-0.39	-4.8	-0.4	4.41e-6	Depressive symptoms;
TGCT	cis	rs2980439	0.607	rs2980419	chr8:8114141	A/T	cg15556689	chr8:8085844	FLJ10661	0.75	6.78	0.52	4.3e-10	Neuroticism;
TGCT	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg03188948	chr7:1209495	NA	0.7	6.21	0.49	7.43e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs67311347	0.956	rs12633446	chr3:40505661	G/A	cg17264618	chr3:40429014	ENTPD3	-0.33	-4.8	-0.4	4.51e-6	Renal cell carcinoma;
TGCT	cis	rs2228479	0.850	rs12597296	chr16:89822331	C/T	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs911263	0.563	rs12883719	chr14:68810217	G/T	cg18825221	chr14:68749962	RAD51L1	0.22	4.46	0.37	1.82e-5	Primary biliary cholangitis;
TGCT	cis	rs2933343	0.700	rs789239	chr3:128633808	T/C	cg11901034	chr3:128598214	ACAD9	-0.63	-6.04	-0.48	1.68e-8	IgG glycosylation;
TGCT	cis	rs9810089	0.843	rs556788	chr3:136027549	A/G	cg12473912	chr3:136751656	NA	0.35	4.91	0.4	2.77e-6	Gestational age at birth (child effect);
TGCT	cis	rs614226	0.744	rs787832	chr12:120986801	A/G	cg10072921	chr12:121022843	NA	-0.44	-4.74	-0.39	5.78e-6	Type 1 diabetes nephropathy;
TGCT	cis	rs7584330	0.554	rs6760913	chr2:238400702	C/T	cg14458575	chr2:238380390	NA	0.55	5.27	0.43	5.73e-7	Prostate cancer;
TGCT	cis	rs3858526	0.959	rs4758219	chr11:5951846	G/C	cg05234568	chr11:5960015	NA	-0.48	-4.77	-0.39	5.08e-6	DNA methylation (variation);
TGCT	cis	rs11718455	0.881	rs17076257	chr3:44006787	C/T	cg08738300	chr3:44038990	NA	0.85	6.34	0.49	3.94e-9	Coronary artery disease;
TGCT	cis	rs3091242	0.935	rs4233043	chr1:25765483	A/G	cg10117171	chr1:25599238	RHD	-0.32	-5.17	-0.42	9e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg21963583	chr11:68658836	MRPL21	0.37	6.24	0.49	6.47e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs909674	0.818	rs5757678	chr22:39843409	A/G	cg02038168	chr22:39784481	NA	0.67	5.22	0.42	7.39e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs908922	0.676	rs491077	chr1:152519570	C/A	cg20991723	chr1:152506922	NA	0.45	6.09	0.48	1.33e-8	Hair morphology;
TGCT	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg04267008	chr7:1944627	MAD1L1	-0.34	-4.57	-0.38	1.14e-5	Schizophrenia;
TGCT	cis	rs9650657	0.572	rs4841465	chr8:10819854	C/T	cg21775007	chr8:11205619	TDH	-0.53	-4.97	-0.41	2.22e-6	Neuroticism;
TGCT	cis	rs6089584	0.566	rs6061972	chr20:60610245	C/T	cg13770153	chr20:60521292	NA	-0.39	-4.77	-0.39	5.17e-6	Body mass index;
TGCT	cis	rs1215050	0.791	rs9993992	chr4:98810851	C/G	cg05340658	chr4:99064831	C4orf37	0.44	5.57	0.45	1.53e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs797680	0.754	rs10874777	chr1:93862020	T/C	cg17826107	chr1:92977322	EVI5	-0.23	-5.41	-0.44	3.14e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs9653442	1.000	rs7580200	chr2:100811903	G/T	cg07810366	chr2:100720526	AFF3	0.46	7.66	0.57	4.58e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs4478858	0.735	rs6676354	chr1:31800746	A/T	cg00250761	chr1:31883323	NA	-0.28	-4.96	-0.41	2.32e-6	Alcohol dependence;
TGCT	cis	rs9291683	0.668	rs2241474	chr4:10086015	T/C	cg00071950	chr4:10020882	SLC2A9	0.58	6.28	0.49	5.18e-9	Bone mineral density;
TGCT	cis	rs7119	0.717	rs12910512	chr15:77817253	C/A	cg27398640	chr15:77910606	LINGO1	-0.26	-4.65	-0.39	8.42e-6	Type 2 diabetes;
TGCT	cis	rs939574	0.656	rs6710315	chr2:220137991	A/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-1.06	-5.13	-0.42	1.07e-6	Platelet distribution width;
TGCT	cis	rs1215050	0.791	rs2865942	chr4:98737709	G/C	cg05340658	chr4:99064831	C4orf37	0.44	5.63	0.45	1.15e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2050392	0.894	rs2480277	chr10:30703513	G/T	cg18806716	chr10:30721971	MAP3K8	0.47	5.59	0.45	1.35e-7	Inflammatory bowel disease;
TGCT	cis	rs9858542	0.953	rs9878943	chr3:49434654	G/A	cg03060546	chr3:49711283	APEH	-0.63	-5.49	-0.44	2.18e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg23758822	chr17:41437982	NA	0.71	6.99	0.53	1.49e-10	Menopause (age at onset);
TGCT	cis	rs11785400	0.762	rs7017931	chr8:143726728	A/G	cg10596483	chr8:143751796	JRK	0.53	5.3	0.43	5.12e-7	Schizophrenia;
TGCT	cis	rs826838	0.967	rs826855	chr12:39114888	T/C	cg26384229	chr12:38710491	ALG10B	-0.86	-7.76	-0.57	2.68e-12	Heart rate;
TGCT	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg11494091	chr17:61959527	GH2	0.61	14.81	0.8	3.37e-29	Prudent dietary pattern;
TGCT	cis	rs4727027	0.727	rs3801980	chr7:148878620	T/A	cg23583168	chr7:148888333	NA	-0.68	-7.82	-0.57	1.98e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs7208859	0.573	rs4055105	chr17:29102550	A/G	cg13385521	chr17:29058706	SUZ12P	0.82	4.86	0.4	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs1635	0.826	rs3800324	chr6:28264681	G/A	cg15743358	chr6:28303923	ZNF323	-1.34	-5.96	-0.47	2.44e-8	Schizophrenia;
TGCT	cis	rs7945705	0.902	rs10743093	chr11:8869129	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.42	4.86	0.4	3.53e-6	Hemoglobin concentration;
TGCT	cis	rs9486719	0.843	rs3860230	chr6:97036560	T/A	cg18709589	chr6:96969512	KIAA0776	-0.77	-6.26	-0.49	5.65e-9	Migraine;Coronary artery disease;
TGCT	trans	rs9383153	1.000	rs2073518	chr6:16332730	T/C	cg19402885	chr12:15475236	PTPRO	0.92	6.69	0.51	6.85e-10	Gambling;
TGCT	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.75	5.41	0.44	3.09e-7	Platelet count;
TGCT	cis	rs3741151	1.000	rs75912489	chr11:73073846	G/A	cg17517138	chr11:73019481	ARHGEF17	0.94	4.71	0.39	6.45e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
TGCT	cis	rs17401966	0.867	rs10492973	chr1:10398985	T/C	cg19773385	chr1:10388646	KIF1B	-0.23	-5.45	-0.44	2.63e-7	Hepatocellular carcinoma;
TGCT	cis	rs55962025	0.883	rs82332	chr4:3225466	A/G	cg06533319	chr4:3265114	C4orf44	0.24	4.72	0.39	6.24e-6	Parental longevity (mother's age at death);
TGCT	cis	rs709400	0.663	rs11628213	chr14:103952453	A/C	cg26031613	chr14:104095156	KLC1	0.85	9.5	0.65	2.07e-16	Body mass index;
TGCT	cis	rs3008870	1.000	rs3008859	chr1:67390999	G/C	cg11518657	chr1:67396239	MIER1	0.52	4.53	0.38	1.39e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg22535103	chr8:58192502	C8orf71	-0.4	-5.13	-0.42	1.08e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7647973	0.925	rs9881860	chr3:49352522	A/T	cg07636037	chr3:49044803	WDR6	0.72	5.8	0.46	5.09e-8	Menarche (age at onset);
TGCT	cis	rs7949030	0.622	rs34894392	chr11:62374821	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.6	8.72	0.62	1.53e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg07636037	chr3:49044803	WDR6	-0.89	-9.27	-0.64	7.32e-16	Menarche (age at onset);
TGCT	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg23708337	chr7:1209742	NA	0.71	6.31	0.49	4.42e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg20007245	chr22:24372913	LOC391322	0.7	6.93	0.53	2.09e-10	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2188554	0.740	rs213944	chr7:117190066	C/T	cg08576598	chr7:116962626	WNT2	-0.36	-4.64	-0.38	8.54e-6	Esophageal adenocarcinoma;
TGCT	cis	rs12449000	1	rs12449000	chr16:89872970	T/C	cg04287289	chr16:89883240	FANCA	0.94	11.27	0.71	1.04e-20	Schizophrenia;
TGCT	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg26818010	chr10:134567672	INPP5A	-0.35	-4.48	-0.37	1.65e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs11690935	0.632	rs12991740	chr2:172885996	C/T	cg13550731	chr2:172543902	DYNC1I2	0.64	5.65	0.45	1.02e-7	Schizophrenia;
TGCT	cis	rs9916302	0.904	rs8076494	chr17:37516722	A/G	cg15445000	chr17:37608096	MED1	-0.32	-5.02	-0.41	1.79e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs10256972	0.504	rs3735687	chr7:1066297	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.49	-5.61	-0.45	1.28e-7	Longevity;Endometriosis;
TGCT	cis	rs4776059	1.000	rs12914502	chr15:52911335	A/G	cg25063058	chr15:52860530	ARPP19	0.53	4.76	0.39	5.22e-6	Schizophrenia;
TGCT	cis	rs2228479	0.702	rs2074963	chr16:89877269	T/C	cg06558623	chr16:89946397	TCF25	0.57	4.88	0.4	3.2e-6	Skin colour saturation;
TGCT	trans	rs13064411	0.542	rs7631335	chr3:113209166	C/T	cg00307254	chr3:126706825	PLXNA1	0.34	6.72	0.52	5.79e-10	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs2224391	0.628	rs2753223	chr6:5244317	C/A	cg09085698	chr6:5261316	LYRM4;FARS2	-1.04	-6.69	-0.51	6.87e-10	Height;
TGCT	cis	rs4851266	0.898	rs13010010	chr2:100852734	C/T	cg22139774	chr2:100720529	AFF3	-0.32	-4.72	-0.39	6.3e-6	Educational attainment;
TGCT	cis	rs1994135	0.692	rs1579909	chr12:33694780	T/C	cg06521331	chr12:34319734	NA	-0.3	-4.69	-0.39	6.97e-6	Resting heart rate;
TGCT	cis	rs7666738	0.830	rs13101766	chr4:98957696	C/A	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9303401	0.659	rs62081314	chr17:56778328	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.59	5.99	0.47	2.08e-8	Cognitive test performance;
TGCT	cis	rs12135062	0.755	rs1553287	chr1:3101277	G/A	cg00254258	chr1:3105189	PRDM16	-0.31	-4.97	-0.41	2.18e-6	Migraine;
TGCT	cis	rs74233809	1.000	rs11191519	chr10:104784918	C/T	cg05855489	chr10:104503620	C10orf26	0.76	4.53	0.38	1.36e-5	Birth weight;
TGCT	cis	rs3008870	0.583	rs2031495	chr1:67421714	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.97	8.16	0.59	3.17e-13	Lymphocyte percentage of white cells;
TGCT	cis	rs514406	0.525	rs269291	chr1:53189297	C/T	cg22166914	chr1:53195759	ZYG11B	0.5	9.38	0.64	4.09e-16	Monocyte count;
TGCT	cis	rs57504626	1	rs57504626	chr19:19720399	C/T	cg03709012	chr19:19516395	GATAD2A	1.04	5.1	0.42	1.26e-6	Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
TGCT	cis	rs4713118	0.955	rs9368529	chr6:27684631	G/A	cg10876282	chr6:28092338	ZSCAN16	0.51	4.75	0.39	5.46e-6	Parkinson's disease;
TGCT	cis	rs1577917	0.876	rs4618490	chr6:86518403	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-5.51	-0.44	1.99e-7	Response to antipsychotic treatment;
TGCT	cis	rs1008375	0.966	rs6833808	chr4:17652526	T/A	cg10189774	chr4:17578691	LAP3	0.61	5.33	0.43	4.55e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg03188948	chr7:1209495	NA	0.49	7.01	0.53	1.32e-10	Longevity;Endometriosis;
TGCT	cis	rs9814567	1.000	rs1863913	chr3:134200205	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.93	-9.28	-0.64	7.11e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs11249608	0.636	rs13361077	chr5:178449174	G/C	cg21905437	chr5:178450457	ZNF879	0.45	4.48	0.37	1.67e-5	Pubertal anthropometrics;
TGCT	trans	rs4650994	0.525	rs10913574	chr1:178536482	G/C	cg05059571	chr16:84539110	KIAA1609	-0.54	-11.05	-0.7	3.58e-20	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs28595532	0.920	rs116146507	chr4:119749556	A/G	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs1997103	0.822	rs940878	chr7:55419663	A/G	cg17469321	chr7:55412551	NA	0.61	5.91	0.47	3.03e-8	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs1670533	1.000	rs10084888	chr4:1053814	G/T	cg27284194	chr4:1044797	NA	0.67	5.77	0.46	5.9e-8	Recombination rate (females);
TGCT	cis	rs9303401	0.659	rs16943326	chr17:57050365	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.67	6.38	0.5	3.24e-9	Cognitive test performance;
TGCT	trans	rs8073060	0.586	rs2523116	chr17:34025460	T/C	cg19694781	chr19:47549865	TMEM160	-0.6	-13.37	-0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs2120019	1.000	rs8033837	chr15:75353975	A/C	cg11632617	chr15:75315747	PPCDC	-0.32	-4.67	-0.39	7.58e-6	Blood trace element (Zn levels);
TGCT	cis	rs9611519	0.780	rs3171692	chr22:41642212	C/T	cg03806693	chr22:41940476	POLR3H	-0.75	-7.07	-0.54	9.78e-11	Neuroticism;
TGCT	cis	rs6728642	0.708	rs56807297	chr2:97861340	A/C	cg26665480	chr2:98280029	ACTR1B	-0.98	-5.58	-0.45	1.42e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	cis	rs1008375	1.000	rs10805357	chr4:17652352	G/A	cg16339924	chr4:17578868	LAP3	0.63	5.33	0.43	4.49e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6570726	0.791	rs435671	chr6:145881215	A/G	cg23711669	chr6:146136114	FBXO30	0.89	9.93	0.67	1.82e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg08564027	chr20:61660810	NA	0.37	6.64	0.51	8.85e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs11098499	0.954	rs7681544	chr4:120411255	T/C	cg09307838	chr4:120376055	NA	0.69	6.64	0.51	8.97e-10	Corneal astigmatism;
TGCT	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg02725872	chr8:58115012	NA	-0.38	-5.05	-0.41	1.55e-6	Developmental language disorder (linguistic errors);
TGCT	trans	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg25482853	chr8:67687455	SGK3	1.16	10.5	0.69	7.91e-19	Lung disease severity in cystic fibrosis;
TGCT	trans	rs10435719	0.678	rs74724594	chr8:11790576	C/A	cg15556689	chr8:8085844	FLJ10661	0.76	7.18	0.54	5.62e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs12134133	1.000	rs11580382	chr1:207418392	A/C	cg02152968	chr1:207494213	CD55	0.61	4.83	0.4	3.92e-6	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs7829975	0.514	rs2920983	chr8:8268063	G/C	cg06636001	chr8:8085503	FLJ10661	0.71	6.22	0.49	7.04e-9	Mood instability;
TGCT	cis	rs782590	0.517	rs13013133	chr2:55889466	G/A	cg03859395	chr2:55845619	SMEK2	-0.62	-5.17	-0.42	8.94e-7	Metabolic syndrome;
TGCT	cis	rs7843479	1.000	rs2054711	chr8:21818060	A/G	cg17168535	chr8:21777572	XPO7	0.65	5.99	0.47	2.14e-8	Mean corpuscular volume;
TGCT	cis	rs4478858	0.684	rs11579845	chr1:31736248	A/G	cg07478791	chr1:31886160	SERINC2	-0.49	-4.91	-0.4	2.82e-6	Alcohol dependence;
TGCT	cis	rs12497850	0.931	rs9682444	chr3:48852639	A/G	cg06212747	chr3:49208901	KLHDC8B	0.61	5.62	0.45	1.2e-7	Parkinson's disease;
TGCT	cis	rs10927875	0.541	rs1739842	chr1:16342848	T/G	cg22431228	chr1:16359049	CLCNKA	-0.29	-6.02	-0.48	1.8e-8	Dilated cardiomyopathy;
TGCT	cis	rs7666738	0.830	rs4699574	chr4:98725544	C/T	cg17366294	chr4:99064904	C4orf37	0.65	6.78	0.52	4.31e-10	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs11992162	0.529	rs6995037	chr8:11780887	A/G	cg15556689	chr8:8085844	FLJ10661	-0.79	-6.77	-0.52	4.69e-10	Monocyte count;
TGCT	cis	rs459571	0.796	rs10993894	chr9:136884511	C/T	cg14405625	chr9:136855902	VAV2	-0.3	-4.44	-0.37	1.99e-5	Platelet distribution width;
TGCT	cis	rs6138458	1.000	rs227618	chr20:24909472	T/C	cg26195577	chr20:24973756	C20orf3	1.2	12.04	0.73	1.35e-22	Blood protein levels;
TGCT	cis	rs6500602	0.787	rs7204624	chr16:4459834	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.42	5.22	0.42	7.34e-7	Schizophrenia;
TGCT	cis	rs617791	0.530	rs7952056	chr11:65744597	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.49	4.48	0.37	1.67e-5	Breast cancer;
TGCT	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg10876282	chr6:28092338	ZSCAN16	0.51	4.69	0.39	6.99e-6	Cardiac Troponin-T levels;
TGCT	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg22963979	chr7:1858916	MAD1L1	-0.32	-4.95	-0.41	2.39e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs6665290	0.904	rs2297418	chr1:227192579	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.0	-20.5	-0.88	1.18e-41	Myeloid white cell count;
TGCT	cis	rs8180040	0.620	rs1811652	chr3:47208698	C/G	cg27129171	chr3:47204927	SETD2	-0.7	-8.33	-0.6	1.26e-13	Colorectal cancer;
TGCT	cis	rs9291683	0.588	rs3733586	chr4:9997534	C/T	cg00071950	chr4:10020882	SLC2A9	0.7	9.39	0.64	3.88e-16	Bone mineral density;
TGCT	cis	rs7584330	1.000	rs7584330	chr2:238387228	A/G	cg14458575	chr2:238380390	NA	0.49	7.53	0.56	9.28e-12	Prostate cancer;
TGCT	cis	rs28595532	0.841	rs116093021	chr4:119763872	C/G	cg21605333	chr4:119757512	SEC24D	1.55	8.04	0.59	6.15e-13	Cannabis dependence symptom count;
TGCT	cis	rs1005224	0.889	rs2059382	chr14:76158916	T/C	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.67	-5.99	-0.47	2.07e-8	Large artery stroke;
TGCT	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9297145	0.761	rs112155177	chr7:98747963	C/T	cg05967295	chr7:98741636	SMURF1	1.01	12.87	0.76	1.33e-24	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs7267979	0.932	rs4280527	chr20:25544014	A/G	cg14121845	chr20:25566513	NINL	0.48	5.16	0.42	9.69e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3806843	0.576	rs251370	chr5:140246287	C/T	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	0.42	5.03	0.41	1.69e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs72781680	0.898	rs72788302	chr2:24107246	C/T	cg08917208	chr2:24149416	ATAD2B	0.9	5.6	0.45	1.29e-7	Lymphocyte counts;
TGCT	cis	rs12541335	0.639	rs4565458	chr8:22154133	T/C	cg18135555	chr8:22132992	PIWIL2	0.29	5.71	0.46	7.76e-8	Hypertriglyceridemia;
TGCT	cis	rs9911578	1.000	rs391370	chr17:56675050	A/C	cg12560992	chr17:57184187	TRIM37	0.76	9.16	0.64	1.32e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg22963979	chr7:1858916	MAD1L1	-0.39	-6.16	-0.48	9.33e-9	Bipolar disorder and schizophrenia;
TGCT	cis	rs4727027	0.782	rs10245343	chr7:148796333	T/C	cg23583168	chr7:148888333	NA	-0.65	-7.35	-0.55	2.36e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs4234284	0.556	rs7650549	chr3:126968288	C/T	cg26312807	chr3:127057048	NA	-0.5	-4.6	-0.38	1.03e-5	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
TGCT	cis	rs67311347	1.000	rs9882171	chr3:40518821	G/A	cg13683864	chr3:40499215	RPL14	-1.14	-12.22	-0.74	4.89e-23	Renal cell carcinoma;
TGCT	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg25036284	chr2:26402008	FAM59B	-0.54	-4.7	-0.39	6.93e-6	Gut microbiome composition (summer);
TGCT	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg03188948	chr7:1209495	NA	0.68	5.8	0.46	5.09e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs909674	0.818	rs5757681	chr22:39845547	A/G	cg24399712	chr22:39784796	NA	-1.06	-11.27	-0.71	1.01e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs854765	0.624	rs9902941	chr17:17733760	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.69	-6.52	-0.5	1.64e-9	Total body bone mineral density;
TGCT	cis	rs12541335	0.536	rs4266653	chr8:22169087	A/G	cg26039829	chr8:22132926	PIWIL2	0.25	4.8	0.4	4.56e-6	Hypertriglyceridemia;
TGCT	cis	rs6500602	0.674	rs8051695	chr16:4536621	T/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.43	6.45	0.5	2.24e-9	Schizophrenia;
TGCT	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg12963246	chr6:28129442	ZNF389	0.52	5.01	0.41	1.85e-6	Depression;
TGCT	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.9	7.25	0.55	3.93e-11	Platelet count;
TGCT	cis	rs7586879	0.639	rs13407913	chr2:25097644	A/G	cg15423357	chr2:25149977	NA	0.46	4.47	0.37	1.72e-5	Body mass index;
TGCT	cis	rs9486715	0.867	rs9486181	chr6:96868132	G/A	cg06623918	chr6:96969491	KIAA0776	1.11	16.62	0.83	2.35e-33	Headache;
TGCT	cis	rs6570726	0.791	rs12205752	chr6:145896118	A/G	cg13319975	chr6:146136371	FBXO30	-0.5	-4.51	-0.38	1.48e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7412746	0.611	rs752376	chr1:150941381	C/T	cg09365446	chr1:150670422	GOLPH3L	0.34	4.7	0.39	6.76e-6	Melanoma;
TGCT	cis	rs11098499	0.863	rs3736115	chr4:120488703	A/G	cg09307838	chr4:120376055	NA	-0.71	-6.1	-0.48	1.22e-8	Corneal astigmatism;
TGCT	cis	rs36051895	0.659	rs10121491	chr9:5046935	T/C	cg02405213	chr9:5042618	JAK2	-0.78	-10.85	-0.7	1.1e-19	Pediatric autoimmune diseases;
TGCT	trans	rs7819412	0.775	rs4841489	chr8:10936811	A/G	cg06636001	chr8:8085503	FLJ10661	-0.77	-7.08	-0.54	9.66e-11	Triglycerides;
TGCT	cis	rs77106637	0.932	rs3814730	chr11:72555553	G/A	cg03713592	chr11:72463424	ARAP1	0.87	5.88	0.47	3.52e-8	Type 2 diabetes;
TGCT	cis	rs35146811	0.844	rs10281368	chr7:99655897	A/G	cg13334819	chr7:99746414	C7orf59	-0.81	-7.0	-0.53	1.43e-10	Coronary artery disease;
TGCT	cis	rs7523050	0.730	rs7519107	chr1:109399367	A/C	cg08274380	chr1:109419600	GPSM2	1.3	6.39	0.5	2.99e-9	Fat distribution (HIV);
TGCT	cis	rs6088580	0.634	rs4911422	chr20:32999345	T/C	cg08999081	chr20:33150536	PIGU	-0.29	-5.65	-0.45	1.02e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs941873	0.868	rs2145998	chr10:81121696	T/A	cg09469691	chr10:81107165	PPIF	0.55	5.42	0.44	2.93e-7	Height;
TGCT	cis	rs7829975	0.582	rs11783950	chr8:8597831	A/C	cg06636001	chr8:8085503	FLJ10661	-0.66	-5.81	-0.46	4.89e-8	Mood instability;
TGCT	cis	rs10791323	0.569	rs1119851	chr11:133742842	T/C	cg03690763	chr11:133734501	NA	-0.3	-5.16	-0.42	9.36e-7	Childhood ear infection;
TGCT	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.92	-6.8	-0.52	3.96e-10	Gut microbiome composition (summer);
TGCT	cis	rs6459788	0.693	rs11981578	chr7:157250133	C/T	cg06271696	chr7:157225062	NA	-0.27	-4.94	-0.41	2.46e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	trans	rs12655019	0.920	rs12657064	chr5:56220999	G/A	cg25190722	chr1:3801660	DFFB	0.65	7.42	0.55	1.63e-11	Breast cancer (early onset);
TGCT	cis	rs74054849	0.571	rs77157441	chr1:15941508	G/A	cg05660106	chr1:15850417	CASP9	0.86	4.47	0.37	1.71e-5	Alcoholic chronic pancreatitis;
TGCT	cis	rs35522438	1	rs35522438	chr7:91872872	A/AT	cg17063962	chr7:91808500	NA	0.91	9.85	0.66	2.94e-17	Breast cancer;
TGCT	cis	rs2224391	0.628	rs2753222	chr6:5242075	T/A	cg09085698	chr6:5261316	LYRM4;FARS2	-1.0	-6.12	-0.48	1.16e-8	Height;
TGCT	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	5.38	0.44	3.58e-7	Alzheimer's disease;
TGCT	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg11644478	chr21:40555479	PSMG1	-0.62	-5.73	-0.46	7.03e-8	Cognitive function;
TGCT	cis	rs4654899	0.931	rs10753506	chr1:21141022	A/G	cg01072550	chr1:21505969	NA	0.49	7.71	0.57	3.49e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs2153535	0.580	rs2143355	chr6:8517856	T/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.01	0.41	1.86e-6	Motion sickness;
TGCT	cis	rs7769051	1.000	rs7761365	chr6:133101561	T/A	cg07930552	chr6:133119739	C6orf192	0.93	5.0	0.41	1.87e-6	Type 2 diabetes nephropathy;
TGCT	cis	rs9549367	0.713	rs11620600	chr13:113829090	G/A	cg00898013	chr13:113819073	PROZ	-0.55	-7.05	-0.53	1.12e-10	Platelet distribution width;
TGCT	cis	rs28595532	0.920	rs114547492	chr4:119773078	G/C	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs7772486	0.875	rs2777483	chr6:146329235	A/G	cg05347473	chr6:146136440	FBXO30	0.52	4.98	0.41	2.12e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs13191362	0.872	rs73020362	chr6:163005737	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs1800813	0.515	rs34148754	chr4:55057049	G/A	cg17187183	chr4:55093834	PDGFRA	0.41	4.9	0.4	2.94e-6	Corneal curvature;
TGCT	cis	rs7552404	0.731	rs2029683	chr1:76341643	T/G	cg10523679	chr1:76189770	ACADM	-0.83	-7.8	-0.57	2.24e-12	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2440129	0.632	rs13396	chr17:6905624	T/C	cg03404566	chr17:6899310	ALOX12	0.47	5.26	0.43	6.17e-7	Tonsillectomy;
TGCT	cis	rs9818758	0.607	rs73074866	chr3:49626666	C/T	cg00383909	chr3:49044727	WDR6	1.31	6.63	0.51	9.3e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs7523273	0.565	rs2985104	chr1:207892012	C/T	cg22525895	chr1:207977042	MIR29B2	-0.35	-5.67	-0.45	9.4e-8	Schizophrenia;
TGCT	cis	rs3091242	0.836	rs35346083	chr1:25788425	C/A	cg09222892	chr1:25734099	RHCE	0.4	6.43	0.5	2.46e-9	Erythrocyte sedimentation rate;
TGCT	cis	rs7246657	0.722	rs2972438	chr19:38210847	A/G	cg03611452	chr19:38183253	ZNF781	0.53	4.44	0.37	1.95e-5	Coronary artery calcification;
TGCT	cis	rs7772486	0.875	rs1929523	chr6:146339989	T/A	cg13319975	chr6:146136371	FBXO30	-0.51	-4.56	-0.38	1.23e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10197940	0.578	rs6718372	chr2:152345871	C/G	cg19508488	chr2:152266495	RIF1	0.59	4.98	0.41	2.11e-6	Lung cancer;
TGCT	cis	rs17152411	1.000	rs17152411	chr10:126649516	A/G	cg07906193	chr10:126599966	NA	0.37	4.64	0.38	8.78e-6	Height;
TGCT	cis	rs492146	0.765	rs316140	chr6:52846188	C/T	cg06706454	chr6:52930286	FBXO9	-0.51	-4.66	-0.39	8.12e-6	Epilepsy (remission after treatment);
TGCT	cis	rs7666738	0.830	rs35822567	chr4:98654138	G/A	cg17366294	chr4:99064904	C4orf37	0.62	6.4	0.5	2.94e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9487051	0.714	rs6902892	chr6:109627601	G/T	cg01475377	chr6:109611718	NA	-0.3	-4.73	-0.39	6.01e-6	Reticulocyte fraction of red cells;
TGCT	cis	rs6939532	0.522	rs13218591	chr6:26376832	T/C	cg05738196	chr6:26577821	NA	-0.51	-4.96	-0.41	2.22e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg27454412	chr7:1067447	C7orf50	0.6	4.72	0.39	6.32e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7267979	0.932	rs449370	chr20:25451180	A/G	cg14121845	chr20:25566513	NINL	-0.5	-5.38	-0.43	3.61e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs4332037	0.950	rs10267593	chr7:1937261	G/A	cg25206134	chr2:45395956	NA	0.96	7.99	0.58	8.02e-13	Bipolar disorder;
TGCT	cis	rs9926296	0.593	rs6500456	chr16:89888341	T/C	cg27121462	chr16:89883253	FANCA	0.54	5.0	0.41	1.87e-6	Vitiligo;
TGCT	cis	rs9534288	0.913	rs9534298	chr13:46625566	C/G	cg15192986	chr13:46630673	CPB2	-0.49	-6.18	-0.49	8.64e-9	Blood protein levels;
TGCT	cis	rs7208859	0.623	rs60890550	chr17:29030861	A/G	cg14008862	chr17:28927542	LRRC37B2	0.76	4.63	0.38	9.23e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs13088645	0.532	rs9857134	chr3:134161607	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.66	6.03	0.48	1.71e-8	Coronary artery disease;
TGCT	cis	rs929843	1	rs929843	chr16:70045748	A/C	cg09409435	chr16:70099608	PDXDC2	0.85	7.28	0.55	3.36e-11	Menarche (age at onset);
TGCT	cis	rs112591243	0.685	rs4819269	chr21:48023532	A/G	cg05707788	chr21:47165437	NA	0.52	4.59	0.38	1.06e-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs17253792	0.822	rs74935793	chr14:56143277	G/A	cg01858014	chr14:56050164	KTN1	-0.35	-4.62	-0.38	9.37e-6	Putamen volume;
TGCT	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg26818010	chr10:134567672	INPP5A	-0.35	-4.48	-0.37	1.65e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg11890956	chr21:40555474	PSMG1	-0.77	-6.92	-0.53	2.13e-10	Cognitive function;
TGCT	cis	rs10193935	0.901	rs10201586	chr2:42622594	C/G	cg27598129	chr2:42591480	NA	-0.37	-5.23	-0.42	7.1e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6912958	0.559	rs2985039	chr6:88041757	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.39	4.48	0.37	1.66e-5	Monocyte percentage of white cells;
TGCT	trans	rs551517	0.541	rs498328	chr9:113643828	C/G	cg18410444	chr5:89825535	LYSMD3	-0.65	-6.62	-0.51	9.91e-10	Post bronchodilator FEV1 in COPD;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
TGCT	cis	rs7666738	0.800	rs7684523	chr4:98983175	G/T	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs908922	0.676	rs1053590	chr1:152488428	T/C	cg20991723	chr1:152506922	NA	0.48	6.72	0.52	5.75e-10	Hair morphology;
TGCT	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg19626725	chr5:178986131	RUFY1	0.45	5.7	0.46	8.11e-8	Lung cancer;
TGCT	trans	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg21659725	chr3:3221576	CRBN	-0.99	-15.57	-0.81	5.76e-31	Intelligence (multi-trait analysis);
TGCT	cis	rs77741769	0.571	rs4766979	chr12:121281748	G/A	cg02419362	chr12:121203948	SPPL3	0.19	4.5	0.37	1.58e-5	Mean corpuscular volume;
TGCT	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg11494091	chr17:61959527	GH2	0.61	14.8	0.8	3.65e-29	Prudent dietary pattern;
TGCT	cis	rs7246657	0.943	rs10415358	chr19:37808863	C/A	cg18154014	chr19:37997991	ZNF793	0.98	6.49	0.5	1.87e-9	Coronary artery calcification;
TGCT	cis	rs62244186	0.566	rs55901755	chr3:44834707	C/T	cg18722847	chr3:44754129	ZNF502	-0.4	-4.49	-0.37	1.59e-5	Depressive symptoms;
TGCT	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg24675658	chr1:53192096	ZYG11B	0.7	7.98	0.58	8.59e-13	Monocyte count;
TGCT	cis	rs12681288	0.862	rs34510005	chr8:1018943	T/C	cg06709756	chr8:1339049	NA	-0.23	-4.52	-0.38	1.42e-5	Schizophrenia;
TGCT	cis	rs68170813	0.559	rs6964798	chr7:106933013	C/G	cg02696742	chr7:106810147	HBP1	-0.69	-5.81	-0.46	4.85e-8	Coronary artery disease;
TGCT	cis	rs6840360	0.571	rs7664663	chr4:152508014	G/C	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.0	-0.58	7.69e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg06873352	chr17:61820015	STRADA	0.55	6.13	0.48	1.09e-8	Prudent dietary pattern;
TGCT	cis	rs1215050	0.791	rs7688192	chr4:98900798	G/T	cg17366294	chr4:99064904	C4orf37	-0.53	-5.69	-0.45	8.67e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs56104184	0.830	rs17272645	chr19:49342366	C/G	cg21252483	chr19:49399788	TULP2	0.36	4.99	0.41	2e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs6894249	0.874	rs11745587	chr5:131796922	A/G	cg02551604	chr5:131831745	NA	0.54	5.39	0.44	3.45e-7	Asthma;
TGCT	cis	rs11696501	0.637	rs6104298	chr20:44327774	A/G	cg11783356	chr20:44313418	WFDC10B	-0.33	-4.49	-0.37	1.6e-5	Brain structure;
TGCT	cis	rs6933660	0.646	rs6911456	chr6:151778934	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-1.05	-14.06	-0.78	1.99e-27	Menarche (age at onset);
TGCT	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg13665807	chr20:60559372	TAF4	-0.46	-4.94	-0.41	2.48e-6	Body mass index;
TGCT	cis	rs35146811	0.844	rs59261051	chr7:99650429	C/T	cg13334819	chr7:99746414	C7orf59	-0.81	-6.82	-0.52	3.49e-10	Coronary artery disease;
TGCT	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs57920188	0.584	rs10915657	chr1:4092904	T/C	cg20703997	chr1:4087676	NA	0.49	5.5	0.44	2.03e-7	Interleukin-17 levels;
TGCT	cis	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg20637647	chr7:64974828	NA	0.9	5.06	0.41	1.45e-6	Diabetic kidney disease;
TGCT	cis	rs4820539	1.000	rs916583	chr22:23469267	C/T	cg21100191	chr22:23484243	RTDR1	0.89	10.51	0.69	7.38e-19	Bone mineral density;
TGCT	cis	rs826838	0.935	rs1601579	chr12:39178606	G/C	cg26384229	chr12:38710491	ALG10B	1.0	8.98	0.63	3.56e-15	Heart rate;
TGCT	cis	rs6570726	0.846	rs453834	chr6:145886261	T/C	cg23711669	chr6:146136114	FBXO30	0.84	8.89	0.62	6.14e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs8063761	0.689	rs4785763	chr16:90066936	G/T	cg08547343	chr16:90038815	CENPBD1;AFG3L1	-0.52	-4.6	-0.38	1.03e-5	Squamous cell carcinoma;
TGCT	cis	rs9527	0.641	rs34130454	chr10:104903638	A/G	cg04362960	chr10:104952993	NT5C2	0.68	5.76	0.46	6.3e-8	Arsenic metabolism;
TGCT	cis	rs1163251	0.902	rs483360	chr1:120200606	C/T	cg19096424	chr1:120255104	PHGDH	-0.57	-5.27	-0.43	5.97e-7	Blood metabolite levels;
TGCT	trans	rs7726839	0.540	rs3749618	chr5:602650	A/G	cg25482853	chr8:67687455	SGK3	1.22	10.58	0.69	4.8e-19	Obesity-related traits;
TGCT	cis	rs9303401	0.659	rs16943326	chr17:57050365	C/T	cg25039879	chr17:56429692	SUPT4H1	0.51	4.57	0.38	1.16e-5	Cognitive test performance;
TGCT	cis	rs6570726	0.791	rs408443	chr6:145874643	T/C	cg23711669	chr6:146136114	FBXO30	0.89	9.93	0.67	1.82e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3733585	0.673	rs4519796	chr4:9955936	A/G	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.73	-0.57	3.25e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.07	-9.6	-0.65	1.17e-16	Platelet count;
TGCT	cis	rs7267979	0.816	rs6115094	chr20:25210827	A/G	cg16686733	chr20:25566563	NINL	0.48	4.45	0.37	1.86e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs55883249	0.957	rs10495572	chr2:9734859	C/G	cg23886495	chr2:9695866	ADAM17	-0.81	-5.0	-0.41	1.93e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs61776719	0.500	rs11210866	chr1:38449565	T/C	cg26398791	chr1:38455867	SF3A3	-0.47	-4.56	-0.38	1.19e-5	Coronary artery disease;
TGCT	cis	rs868036	0.718	rs3784710	chr15:68072458	T/C	cg05925327	chr15:68127851	NA	-0.5	-4.81	-0.4	4.34e-6	Restless legs syndrome;
TGCT	cis	rs13256369	0.950	rs13270006	chr8:8574197	C/A	cg17143192	chr8:8559678	CLDN23	0.63	5.93	0.47	2.8e-8	Obesity-related traits;
TGCT	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg11764359	chr7:65958608	NA	-0.54	-4.9	-0.4	2.94e-6	Aortic root size;
TGCT	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg00149659	chr3:10157352	C3orf10	-1.2	-7.56	-0.56	7.9e-12	Alzheimer's disease;
TGCT	cis	rs12681288	0.963	rs35220148	chr8:1027602	G/A	cg04851639	chr8:1020857	NA	-0.35	-6.06	-0.48	1.5e-8	Schizophrenia;
TGCT	cis	rs7246657	0.551	rs10407224	chr19:37651470	G/T	cg24025825	chr19:37761650	NA	-0.3	-4.82	-0.4	4.17e-6	Coronary artery calcification;
TGCT	cis	rs11098499	0.863	rs1383533	chr4:120434576	G/A	cg09307838	chr4:120376055	NA	0.69	6.53	0.51	1.49e-9	Corneal astigmatism;
TGCT	cis	rs2486012	1.000	rs783301	chr1:44369009	C/T	cg12908607	chr1:44402522	ARTN	0.71	5.86	0.47	3.87e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2760061	0.819	rs708114	chr1:228197496	G/A	cg18477163	chr1:228402036	OBSCN	0.34	7.19	0.54	5.33e-11	Diastolic blood pressure;
TGCT	cis	rs796364	1.000	rs1509835	chr2:200814809	C/G	cg17644776	chr2:200775616	C2orf69	0.3	4.77	0.39	5.12e-6	Schizophrenia;
TGCT	cis	rs2153535	0.601	rs969420	chr6:8451966	T/A	cg07606381	chr6:8435919	SLC35B3	0.53	5.02	0.41	1.79e-6	Motion sickness;
TGCT	cis	rs2180341	0.618	rs12529077	chr6:127634244	G/T	cg27446573	chr6:127587934	RNF146	0.65	5.79	0.46	5.52e-8	Breast cancer;
TGCT	cis	rs2204008	0.643	rs1315347	chr12:38162494	C/T	cg26384229	chr12:38710491	ALG10B	-0.58	-5.08	-0.42	1.33e-6	Bladder cancer;
TGCT	cis	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg18252515	chr7:66147081	NA	1.25	7.75	0.57	2.92e-12	Diabetic kidney disease;
TGCT	cis	rs600231	0.665	rs2105608	chr11:65228618	T/A	cg17120908	chr11:65337727	SSSCA1	-0.53	-4.86	-0.4	3.43e-6	Bone mineral density;
TGCT	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg07870213	chr5:140052090	DND1	0.65	7.75	0.57	2.79e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs6964587	1.000	rs7802668	chr7:91648939	A/G	cg22709100	chr7:91322751	NA	0.28	4.49	0.37	1.61e-5	Breast cancer;
TGCT	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg24399712	chr22:39784796	NA	1.0	11.31	0.71	8.1899999999999992e-21	Intelligence (multi-trait analysis);
TGCT	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg08683831	chr4:1404607	NA	-0.46	-4.43	-0.37	2.01e-5	Obesity-related traits;
TGCT	cis	rs6671200	0.920	rs11165339	chr1:95674064	T/C	cg20701556	chr1:95698924	RWDD3	-0.65	-5.58	-0.45	1.43e-7	Stearic acid (18:0) levels;
TGCT	cis	rs854765	0.547	rs2955356	chr17:17964717	G/A	cg09796270	chr17:17721594	SREBF1	-0.26	-5.17	-0.42	9.05e-7	Total body bone mineral density;
TGCT	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg03517284	chr6:25882590	NA	-0.61	-5.5	-0.44	2.12e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1334894	0.901	rs7768598	chr6:35520651	A/G	cg24281267	chr6:35479648	TULP1	0.42	4.5	0.37	1.54e-5	Coronary artery disease;
TGCT	cis	rs12681287	0.640	rs7832493	chr8:87371533	A/C	cg27223183	chr8:87520930	FAM82B	0.9	6.71	0.52	6.12e-10	Caudate activity during reward;
TGCT	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg13732083	chr21:47605072	C21orf56	0.35	4.69	0.39	7.17e-6	Testicular germ cell tumor;
TGCT	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg00934597	chr7:893267	UNC84A	0.2	4.49	0.37	1.58e-5	Perceived unattractiveness to mosquitoes;
TGCT	cis	rs10489202	0.683	rs4657730	chr1:168072738	A/T	cg24449463	chr1:168025552	DCAF6	-0.53	-5.62	-0.45	1.2e-7	Schizophrenia;
TGCT	cis	rs2197308	0.765	rs11182900	chr12:37934009	C/T	cg26384229	chr12:38710491	ALG10B	0.87	7.83	0.58	1.85e-12	Morning vs. evening chronotype;
TGCT	cis	rs713587	0.563	rs11686663	chr2:25107759	C/T	cg01884057	chr2:25150051	NA	0.31	5.96	0.47	2.43e-8	Body mass index in non-asthmatics;
TGCT	cis	rs73198271	1.000	rs11784958	chr8:8607781	C/A	ch.8.214553F	chr8:8189620	PRAGMIN	-0.27	-4.57	-0.38	1.17e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg23221052	chr5:179740743	GFPT2	-0.35	-5.6	-0.45	1.34e-7	Height;
TGCT	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg25767906	chr1:53392781	SCP2	0.48	5.55	0.45	1.62e-7	Monocyte count;
TGCT	cis	rs6988636	0.534	rs73337894	chr8:124123010	T/C	cg27053337	chr8:124217698	FAM83A	0.56	4.9	0.4	2.88e-6	Urinary uromodulin levels;
TGCT	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg03264133	chr6:25882463	NA	-0.51	-5.37	-0.43	3.77e-7	Blood metabolite levels;
TGCT	cis	rs9467773	0.620	rs2504592	chr6:26640951	C/G	cg15659132	chr6:26577336	NA	0.86	10.81	0.7	1.36e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs10193935	1.000	rs10195776	chr2:42425098	G/A	cg27598129	chr2:42591480	NA	-0.39	-5.14	-0.42	1.05e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11651000	0.654	rs12451801	chr17:45820975	T/C	cg06532163	chr17:45867833	NA	0.34	4.9	0.4	2.95e-6	IgG glycosylation;
TGCT	cis	rs4765913	0.874	rs4765914	chr12:2420377	A/G	cg14310533	chr12:2046230	NA	0.24	4.46	0.37	1.81e-5	Bipolar disorder;
TGCT	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg11890956	chr21:40555474	PSMG1	-0.8	-7.62	-0.56	5.74e-12	Cognitive function;
TGCT	cis	rs2456568	0.802	rs10831136	chr11:93636860	T/C	cg14065697	chr11:93583672	C11orf90	-0.37	-4.63	-0.38	9.11e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs12579753	0.879	rs7958657	chr12:82135067	G/A	cg07988820	chr12:82153109	PPFIA2	-0.68	-7.32	-0.55	2.7e-11	Resting heart rate;
TGCT	cis	rs727505	0.954	rs59283092	chr7:124678282	T/C	cg23710748	chr7:124431027	NA	-0.26	-4.51	-0.38	1.49e-5	Lewy body disease;
TGCT	cis	rs9560113	1.000	rs4773379	chr13:112176088	G/C	cg14154082	chr13:112174009	NA	0.34	4.5	0.37	1.52e-5	Menarche (age at onset);
TGCT	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg16145915	chr7:1198662	ZFAND2A	-0.46	-5.47	-0.44	2.36e-7	Longevity;Endometriosis;
TGCT	cis	rs11711311	1.000	rs2242108	chr3:113433903	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.78	-7.13	-0.54	7.14e-11	IgG glycosylation;
TGCT	cis	rs909674	0.731	rs4821897	chr22:39835587	A/G	cg05872129	chr22:39784769	NA	-1.03	-10.02	-0.67	1.11e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg02725872	chr8:58115012	NA	-0.38	-5.16	-0.42	9.32e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg23758822	chr17:41437982	NA	0.71	6.75	0.52	5.16e-10	Menopause (age at onset);
TGCT	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	5.24	0.43	6.73e-7	Menopause (age at onset);
TGCT	cis	rs295140	1.000	rs7578220	chr2:201183701	A/G	cg04283868	chr2:201171347	SPATS2L	0.65	6.67	0.51	7.63e-10	QT interval;
TGCT	cis	rs17125944	0.505	rs2274275	chr14:53235728	G/T	cg00686598	chr14:53173677	PSMC6	1.08	6.32	0.49	4.37e-9	Alzheimer's disease (late onset);
TGCT	cis	rs3806843	0.520	rs246051	chr5:140326464	G/A	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	trans	rs2727020	0.521	rs7930855	chr11:49521660	C/T	cg11707556	chr5:10655725	ANKRD33B	0.42	8.63	0.61	2.5e-14	Coronary artery disease;
TGCT	cis	rs9303401	0.614	rs3087762	chr17:56568680	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.71	6.74	0.52	5.45e-10	Cognitive test performance;
TGCT	cis	rs36051895	0.659	rs61284219	chr9:5062816	C/A	cg02405213	chr9:5042618	JAK2	-0.8	-11.72	-0.73	8.06e-22	Pediatric autoimmune diseases;
TGCT	cis	rs12142240	0.698	rs68191463	chr1:46808695	T/C	cg00530320	chr1:46809349	NSUN4	0.29	5.88	0.47	3.63e-8	Menopause (age at onset);
TGCT	cis	rs9341808	0.754	rs1324121	chr6:80946077	A/G	cg08355045	chr6:80787529	NA	0.29	5.1	0.42	1.23e-6	Sitting height ratio;
TGCT	cis	rs4900538	0.892	rs4906208	chr14:102956489	G/C	cg18135206	chr14:102964638	TECPR2	0.21	5.13	0.42	1.08e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs11167764	1.000	rs3761757	chr5:141488219	A/C	cg23435118	chr5:141488016	NDFIP1	-0.28	-4.84	-0.4	3.83e-6	Crohn's disease;
TGCT	cis	rs3540	0.553	rs4031431	chr15:90990782	G/T	cg22089800	chr15:90895588	ZNF774	0.76	8.13	0.59	3.83e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs7149242	0.961	rs7142683	chr14:101158882	A/G	cg18089426	chr14:101175970	NA	-0.45	-4.7	-0.39	6.79e-6	Platelet count;
TGCT	cis	rs6430585	0.528	rs499483	chr2:136652524	G/A	cg07169764	chr2:136633963	MCM6	1.25	12.39	0.74	1.91e-23	Corneal structure;
TGCT	cis	rs9972944	0.692	rs8071561	chr17:63763434	C/T	cg07283582	chr17:63770753	CCDC46	-0.26	-5.24	-0.43	6.6e-7	Total body bone mineral density;
TGCT	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg01585852	chr22:24235823	MIF	0.22	4.82	0.4	4.16e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs8177253	0.509	rs6762415	chr3:133478557	T/G	cg08048268	chr3:133502702	NA	-0.56	-6.53	-0.51	1.54e-9	Iron status biomarkers;
TGCT	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg24531977	chr5:56204891	C5orf35	0.85	7.52	0.56	9.7e-12	Initial pursuit acceleration;
TGCT	cis	rs60871478	0.636	rs73045423	chr7:893952	G/A	cg00475322	chr7:917719	C7orf20	0.5	4.87	0.4	3.37e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs7944584	0.632	rs11039159	chr11:47294021	G/T	cg20307385	chr11:47447363	PSMC3	0.79	7.81	0.57	2.08e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
TGCT	cis	rs6752107	0.935	rs10929322	chr2:234149702	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	-0.2	-4.91	-0.4	2.83e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	trans	rs9383153	1.000	rs9370888	chr6:16335544	A/G	cg22767166	chr8:49833685	SNAI2	0.84	6.62	0.51	9.69e-10	Gambling;
TGCT	cis	rs9309473	0.583	rs11126397	chr2:73588733	C/T	cg20560298	chr2:73613845	ALMS1	-0.41	-4.54	-0.38	1.31e-5	Metabolite levels;
TGCT	cis	rs903263	0.965	rs6695305	chr1:84593401	T/A	cg09664975	chr1:84543551	PRKACB	0.49	4.6	0.38	1.01e-5	Breast cancer (male);
TGCT	cis	rs208520	0.706	rs851601	chr6:66893853	G/A	cg07460842	chr6:66804631	NA	-0.9	-9.33	-0.64	5.29e-16	Exhaled nitric oxide output;
TGCT	cis	rs1801251	0.896	rs7573208	chr2:233696701	C/A	cg08000102	chr2:233561755	GIGYF2	-0.59	-6.23	-0.49	6.64e-9	Coronary artery disease;
TGCT	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg01448562	chr3:133502909	NA	-0.33	-6.68	-0.51	7.33e-10	Iron status biomarkers;
TGCT	cis	rs55823223	0.564	rs4572466	chr17:73846314	A/C	cg08125733	chr17:73851984	WBP2	0.88	8.95	0.63	4.39e-15	Psoriasis;
TGCT	cis	rs7258465	1.000	rs10409505	chr19:18590251	C/G	cg06462663	chr19:18546047	ISYNA1	0.2	4.63	0.38	9.01e-6	Breast cancer;
TGCT	cis	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg02380750	chr20:61661411	NA	0.34	6.02	0.48	1.86e-8	Prostate cancer (SNP x SNP interaction);
TGCT	trans	rs208520	0.690	rs6932475	chr6:66863155	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-10.43	-0.68	1.13e-18	Exhaled nitric oxide output;
TGCT	cis	rs9858542	1.000	rs4283605	chr3:49678651	A/G	cg03060546	chr3:49711283	APEH	-0.67	-6.09	-0.48	1.28e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	trans	rs8073060	0.544	rs8072676	chr17:33999517	C/T	cg19694781	chr19:47549865	TMEM160	-0.59	-13.15	-0.76	2.9e-25	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs910316	0.967	rs4899549	chr14:75647494	G/A	cg23033748	chr14:75592666	NEK9	-0.29	-4.93	-0.41	2.55e-6	Height;
TGCT	cis	rs2153535	0.601	rs2327054	chr6:8443130	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.58	0.45	1.42e-7	Motion sickness;
TGCT	cis	rs8031584	0.578	rs1088473	chr15:31139298	A/G	cg14829155	chr15:31115871	NA	0.36	4.72	0.39	6.14e-6	Huntington's disease progression;
TGCT	cis	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg13531842	chr10:38383804	ZNF37A	-0.38	-4.51	-0.38	1.49e-5	Extrinsic epigenetic age acceleration;
TGCT	cis	rs514406	0.505	rs431459	chr1:53183230	T/G	cg22166914	chr1:53195759	ZYG11B	0.45	8.18	0.59	2.87e-13	Monocyte count;
TGCT	cis	rs7829975	0.577	rs940032	chr8:8546343	C/T	cg06636001	chr8:8085503	FLJ10661	-0.6	-5.18	-0.42	8.83e-7	Mood instability;
TGCT	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.82	7.52	0.56	9.42e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs1372520	0.748	rs2737002	chr4:90753180	A/G	cg01966878	chr4:90757139	SNCA	-0.3	-4.76	-0.39	5.2e-6	Neuroticism;
TGCT	cis	rs12681287	0.517	rs34596274	chr8:87517679	C/T	cg19078186	chr8:87526527	CPNE3	-0.36	-4.49	-0.37	1.59e-5	Caudate activity during reward;
TGCT	cis	rs7552167	0.925	rs3932664	chr1:24511663	G/T	cg01960748	chr1:24522592	NA	-0.44	-5.01	-0.41	1.87e-6	Psoriasis vulgaris;
TGCT	cis	rs3782455	1.000	rs75596675	chr12:114401944	A/G	cg23502203	chr12:113549970	RASAL1	-0.55	-4.92	-0.4	2.7e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs56399783	0.901	rs17132624	chr7:2778496	G/A	cg19731401	chr7:2775893	GNA12	0.36	5.07	0.41	1.4e-6	Childhood ear infection;
TGCT	cis	rs6671200	0.541	rs7555339	chr1:95691579	G/A	cg06440946	chr1:95699313	RWDD3	-0.62	-5.34	-0.43	4.22e-7	Stearic acid (18:0) levels;
TGCT	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg13695892	chr22:41940480	POLR3H	-0.91	-9.07	-0.63	2.18e-15	Vitiligo;
TGCT	cis	rs3749237	0.964	rs13084243	chr3:49821878	G/C	cg03060546	chr3:49711283	APEH	0.73	7.58	0.56	7.07e-12	Resting heart rate;
TGCT	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg26119090	chr2:26468346	HADHA;HADHB	1.0	7.42	0.55	1.64e-11	Gut microbiome composition (summer);
TGCT	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg23205692	chr1:25664452	TMEM50A	0.5	5.17	0.42	9.02e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs6088590	1.000	rs6088607	chr20:33378733	C/T	cg06115741	chr20:33292138	TP53INP2	0.66	5.51	0.44	2.01e-7	Coronary artery disease;
TGCT	cis	rs2455799	0.614	rs2121735	chr3:15871201	C/G	cg12172478	chr3:16357591	RFTN1	-0.29	-4.48	-0.37	1.7e-5	Mean platelet volume;
TGCT	cis	rs1062177	0.826	rs2915822	chr5:151130901	G/T	cg12924095	chr5:151150029	G3BP1	-0.34	-4.93	-0.4	2.62e-6	Preschool internalizing problems;
TGCT	cis	rs1475911	0.708	rs66994219	chr21:43521647	G/A	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.27	-5.2	-0.42	7.81e-7	IgG glycosylation;
TGCT	cis	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg08045932	chr20:61659980	NA	0.48	9.16	0.64	1.36e-15	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs236907	0.859	rs2232819	chr1:171755182	G/A	cg20598894	chr1:171756153	METTL13	-0.2	-4.54	-0.38	1.31e-5	Mean platelet volume;
TGCT	cis	rs7666738	0.924	rs13124368	chr4:99039615	T/C	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12477438	0.520	rs7572660	chr2:99788582	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.12	15.78	0.82	1.91e-31	Chronic sinus infection;
TGCT	cis	rs2046867	0.644	rs56947804	chr3:72788435	T/C	cg25664220	chr3:72788482	NA	-0.56	-7.17	-0.54	6.04e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9368481	0.700	rs6911401	chr6:26913214	C/G	cg02458000	chr6:26745757	NA	0.6	5.28	0.43	5.6e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9911578	1.000	rs9904879	chr17:56864422	G/A	cg12560992	chr17:57184187	TRIM37	0.76	9.34	0.64	4.88e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs7824557	0.591	rs2736283	chr8:11225910	A/G	cg21775007	chr8:11205619	TDH	-0.74	-7.67	-0.57	4.37e-12	Retinal vascular caliber;
TGCT	cis	rs367943	1.000	rs348958	chr5:112821137	G/A	cg12552261	chr5:112820674	MCC	-0.24	-4.91	-0.4	2.81e-6	Type 2 diabetes;
TGCT	cis	rs12477438	0.765	rs62156363	chr2:99693324	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-4.88	-0.4	3.17e-6	Chronic sinus infection;
TGCT	cis	rs28595532	1.000	rs41455648	chr4:119718030	A/G	cg21605333	chr4:119757512	SEC24D	1.38	8.0	0.58	7.43e-13	Cannabis dependence symptom count;
TGCT	cis	rs2463822	0.844	rs2513737	chr11:62119495	G/C	cg23876832	chr11:62092739	NA	0.63	4.68	0.39	7.29e-6	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg09365446	chr1:150670422	GOLPH3L	0.31	4.64	0.38	8.7e-6	Tonsillectomy;
TGCT	cis	rs2046867	0.908	rs62251636	chr3:72792650	A/G	cg25664220	chr3:72788482	NA	-0.56	-7.15	-0.54	6.59e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg03452623	chr4:187889614	NA	0.34	5.19	0.42	8.44e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs506338	0.517	rs530252	chr11:64443465	T/C	cg19395706	chr11:64412079	NRXN2	0.5	6.05	0.48	1.58e-8	Body mass index;Urate levels;
TGCT	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg04352962	chr1:209979756	IRF6	0.64	4.89	0.4	3.12e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs6087990	0.735	rs2424922	chr20:31386449	T/C	cg13636640	chr20:31349939	DNMT3B	0.95	12.3	0.74	3.25e-23	Ulcerative colitis;
TGCT	cis	rs6750047	0.781	rs4670809	chr2:38277364	A/C	cg07380506	chr2:38303506	CYP1B1	0.55	4.79	0.4	4.7e-6	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs929354	0.742	rs2006844	chr7:157002851	G/A	cg05182265	chr7:156933206	UBE3C	-0.39	-8.77	-0.62	1.19e-14	Body mass index;
TGCT	cis	rs9611565	0.592	rs5996038	chr22:41965300	T/C	cg13695892	chr22:41940480	POLR3H	-0.87	-8.17	-0.59	2.95e-13	Vitiligo;
TGCT	cis	rs4713118	0.662	rs9380045	chr6:28025279	A/G	cg12963246	chr6:28129442	ZNF389	0.45	4.55	0.38	1.27e-5	Parkinson's disease;
TGCT	cis	rs986417	0.892	rs74060153	chr14:60794488	T/A	cg27398547	chr14:60952738	C14orf39	-1.47	-6.28	-0.49	5.17e-9	Gut microbiota (bacterial taxa);
TGCT	cis	rs10789285	0.650	rs2245330	chr1:69690808	G/A	ch.1.69469992R	chr1:69697404	NA	0.31	4.54	0.38	1.32e-5	Psoriasis;
TGCT	cis	rs9913156	0.517	rs8065068	chr17:4611453	A/T	cg00122941	chr17:4613640	ARRB2	0.83	7.26	0.55	3.77e-11	Lymphocyte counts;
TGCT	cis	rs10193935	0.901	rs1496329	chr2:42688797	T/C	cg27598129	chr2:42591480	NA	0.39	5.36	0.43	3.85e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2204008	0.744	rs11168870	chr12:37973333	A/G	cg26384229	chr12:38710491	ALG10B	0.86	7.77	0.57	2.55e-12	Bladder cancer;
TGCT	cis	rs6815814	0.861	rs28393318	chr4:38784267	A/G	cg02016764	chr4:38805732	TLR1	-0.28	-4.52	-0.38	1.41e-5	Breast cancer;
TGCT	cis	rs941408	1.000	rs4807332	chr19:2793289	T/C	cg06609049	chr19:2785107	THOP1	0.79	7.79	0.57	2.36e-12	Total cholesterol levels;
TGCT	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg04944784	chr2:26401820	FAM59B	-0.77	-6.37	-0.5	3.27e-9	Gut microbiome composition (summer);
TGCT	cis	rs7617773	0.817	rs6796490	chr3:48237104	A/C	cg11946769	chr3:48343235	NME6	0.76	7.23	0.54	4.42e-11	Coronary artery disease;
TGCT	cis	rs8037137	0.915	rs79253100	chr15:91551876	C/T	cg22570213	chr15:91497863	RCCD1	0.51	4.69	0.39	6.96e-6	Platelet count;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
TGCT	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.82	7.39	0.55	1.85e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6964587	0.967	rs58673519	chr7:91823887	T/G	cg17063962	chr7:91808500	NA	0.91	9.8	0.66	3.82e-17	Breast cancer;
TGCT	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg06618935	chr21:46677482	NA	-0.37	-5.56	-0.45	1.58e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs12762955	0.507	rs7070724	chr10:1040138	C/T	cg18964960	chr10:1102726	WDR37	-0.72	-6.21	-0.49	7.49e-9	Response to angiotensin II receptor blocker therapy;
TGCT	trans	rs324780	0.504	rs1387939	chr12:83912829	T/G	cg27144766	chr5:150604977	CCDC69	0.24	6.63	0.51	9.29e-10	Vertical cup-disc ratio;
TGCT	trans	rs57221529	0.766	rs12521051	chr5:560440	A/G	cg25482853	chr8:67687455	SGK3	-1.18	-10.06	-0.67	9.09e-18	Lung disease severity in cystic fibrosis;
TGCT	cis	rs28595532	1.000	rs115004746	chr4:119642137	C/T	cg21605333	chr4:119757512	SEC24D	1.36	7.4	0.55	1.81e-11	Cannabis dependence symptom count;
TGCT	cis	rs3849570	1.000	rs9818006	chr3:81828230	A/C	cg07356753	chr3:81810745	GBE1	-0.68	-5.77	-0.46	5.87e-8	Waist circumference;Body mass index;
TGCT	cis	rs73001065	0.551	rs56397647	chr19:19642795	C/T	cg03709012	chr19:19516395	GATAD2A	0.93	4.98	0.41	2.1e-6	LDL cholesterol;
TGCT	cis	rs2721173	0.619	rs997258	chr8:145903077	C/A	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.93	-9.9	-0.66	2.19e-17	Educational attainment;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
TGCT	cis	rs2334880	0.678	rs12922597	chr16:71452393	T/C	cg06353428	chr16:71660113	MARVELD3	-1.0	-6.72	-0.52	5.97e-10	Malaria;
TGCT	cis	rs7044106	0.762	rs4837789	chr9:123426256	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	4.56	0.38	1.21e-5	Hip circumference adjusted for BMI;
TGCT	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg21724239	chr8:58056113	NA	0.38	5.18	0.42	8.82e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9650657	0.707	rs10097283	chr8:10659406	G/C	cg27411982	chr8:10470053	RP1L1	-0.23	-5.11	-0.42	1.18e-6	Neuroticism;
TGCT	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg22963979	chr7:1858916	MAD1L1	-0.37	-5.67	-0.45	9.59e-8	Bipolar disorder and schizophrenia;
TGCT	cis	rs9818758	0.545	rs9853352	chr3:49813258	C/T	cg00383909	chr3:49044727	WDR6	-1.31	-6.76	-0.52	4.72e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs265548	0.595	rs265543	chr19:17904260	T/G	cg03316864	chr19:17906309	B3GNT3	0.43	5.0	0.41	1.88e-6	Tumor biomarkers;
TGCT	cis	rs7666738	0.830	rs10019087	chr4:99030211	C/T	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6504950	0.705	rs17745123	chr17:52988232	G/T	cg07707039	chr17:53042137	COX11	0.28	4.66	0.39	8.03e-6	Breast cancer;
TGCT	cis	rs6815814	0.950	rs5743580	chr4:38804405	C/T	cg02016764	chr4:38805732	TLR1	-0.35	-5.65	-0.45	1.04e-7	Breast cancer;
TGCT	cis	rs6121246	0.567	rs6088796	chr20:30213229	C/T	cg13852791	chr20:30311386	BCL2L1	0.7	4.58	0.38	1.1e-5	Mean corpuscular hemoglobin;
TGCT	trans	rs28595532	0.623	rs17516540	chr4:119278443	A/G	cg26518628	chr1:97050305	NA	-0.6	-7.07	-0.54	1.01e-10	Cannabis dependence symptom count;
TGCT	cis	rs9868809	0.881	rs2276852	chr3:48666923	A/G	cg00383909	chr3:49044727	WDR6	0.83	4.64	0.38	8.57e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs9899728	0.572	rs9915968	chr17:73059616	G/C	cg27626185	chr17:73056755	KCTD2	-0.46	-4.49	-0.37	1.59e-5	Alzheimer's disease or small vessel stroke;
TGCT	cis	rs185694	1.000	rs653251	chr13:30894542	C/T	cg07600127	chr13:30881527	KATNAL1	-0.79	-6.56	-0.51	1.34e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
TGCT	cis	rs950776	0.545	rs34275594	chr15:78981282	A/C	cg21242079	chr15:79101063	ADAMTS7	-0.31	-5.06	-0.41	1.48e-6	Sudden cardiac arrest;
TGCT	cis	rs727563	0.594	rs132807	chr22:42071584	T/C	cg17554472	chr22:41940697	POLR3H	0.49	5.22	0.42	7.4e-7	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs10833905	0.680	rs10833893	chr11:23027431	T/G	cg06387204	chr11:22647648	FANCF	-0.55	-5.07	-0.41	1.44e-6	Sudden cardiac arrest;
TGCT	cis	rs68170813	0.559	rs10953532	chr7:106881808	C/T	cg02696742	chr7:106810147	HBP1	-0.69	-5.61	-0.45	1.27e-7	Coronary artery disease;
TGCT	cis	rs617219	0.574	rs7732681	chr5:78595246	C/T	cg09550809	chr5:78407562	BHMT	-0.34	-4.58	-0.38	1.11e-5	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs10479542	0.929	rs7718673	chr5:178980009	C/T	cg00080972	chr5:178986291	RUFY1	-0.43	-4.92	-0.4	2.75e-6	Lung cancer;
TGCT	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	6.18	0.49	8.58e-9	Bipolar disorder;
TGCT	cis	rs2880765	0.835	rs6496027	chr15:86049988	C/T	cg13263323	chr15:86062960	AKAP13	-0.23	-4.96	-0.41	2.28e-6	Coronary artery disease;
TGCT	cis	rs7043114	0.563	rs10820986	chr9:95312961	T/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.54	-5.26	-0.43	6.07e-7	Height;
TGCT	cis	rs7607369	0.714	rs4674332	chr2:219604326	C/T	cg02176678	chr2:219576539	TTLL4	0.5	6.61	0.51	1.04e-9	Red blood cell count;Amyotrophic lateral sclerosis;
TGCT	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg22166914	chr1:53195759	ZYG11B	-0.35	-5.81	-0.46	4.89e-8	Monocyte count;
TGCT	cis	rs1322512	1.000	rs2758812	chr6:152965908	C/T	cg03415253	chr6:152958462	SYNE1	-0.5	-4.53	-0.38	1.38e-5	Tonometry;
TGCT	cis	rs61897795	0.628	rs93923	chr11:61613745	C/T	cg19610905	chr11:61596333	FADS2	-0.81	-6.26	-0.49	5.64e-9	Neutrophil count;Sum basophil neutrophil counts;
TGCT	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg11247378	chr22:39784982	NA	0.66	8.79	0.62	1.04e-14	IgG glycosylation;
TGCT	cis	rs765787	0.530	rs4775835	chr15:45537553	T/C	cg24006582	chr15:45444508	DUOX1	-0.25	-5.54	-0.45	1.76e-7	Uric acid levels;
TGCT	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg21724239	chr8:58056113	NA	-0.42	-5.04	-0.41	1.59e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg06618935	chr21:46677482	NA	-0.36	-5.61	-0.45	1.25e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.54	4.88	0.4	3.18e-6	Prudent dietary pattern;
TGCT	cis	rs428668	0.681	rs430961	chr5:150700559	C/G	cg11125805	chr5:150678162	SLC36A3	0.26	5.9	0.47	3.19e-8	Skin aging (microtopography measurement);
TGCT	cis	rs10927875	0.691	rs1048261	chr1:16340951	A/T	cg22431228	chr1:16359049	CLCNKA	-0.25	-4.77	-0.39	5.1e-6	Dilated cardiomyopathy;
TGCT	cis	rs806215	1.000	rs806215	chr7:127237312	T/C	cg00893242	chr7:127291580	SND1	-0.42	-4.46	-0.37	1.84e-5	Type 2 diabetes;
TGCT	cis	rs7772486	0.875	rs1331637	chr6:146337087	T/C	cg05347473	chr6:146136440	FBXO30	0.56	5.29	0.43	5.34e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs367615	0.660	rs4632850	chr5:108832883	C/G	cg17395555	chr5:108820864	NA	0.31	5.9	0.47	3.17e-8	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs651907	0.535	rs11707250	chr3:101509371	A/T	cg11279151	chr3:101281821	RG9MTD1	0.31	6.52	0.51	1.56e-9	Colorectal cancer;
TGCT	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg06112835	chr11:68658793	MRPL21	0.46	7.79	0.57	2.3e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.55	4.92	0.4	2.74e-6	Prudent dietary pattern;
TGCT	cis	rs12579753	0.912	rs4417392	chr12:82158722	C/A	cg21231944	chr12:82153410	PPFIA2	-0.34	-4.63	-0.38	8.95e-6	Resting heart rate;
TGCT	cis	rs2637266	0.967	rs4979898	chr10:78355672	G/A	cg18941641	chr10:78392320	NA	0.4	5.01	0.41	1.81e-6	Pulmonary function;
TGCT	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.9	7.25	0.55	3.93e-11	Platelet count;
TGCT	cis	rs4680	0.737	rs3810595	chr22:19949644	G/C	cg22546130	chr22:19950026	COMT	-0.35	-5.26	-0.43	6.21e-7	Blood metabolite levels;
TGCT	cis	rs587847	0.597	rs10162992	chr15:37763299	T/C	cg00216138	chr15:37171175	LOC145845	0.31	4.55	0.38	1.26e-5	Intraocular pressure;
TGCT	cis	rs9739070	1	rs9739070	chr12:123771032	A/G	cg00376283	chr12:123451042	ABCB9	0.7	4.78	0.39	4.84e-6	Allergy;
TGCT	cis	rs2115630	0.641	rs11073613	chr15:85185893	G/A	cg11189052	chr15:85197271	WDR73	-0.73	-7.39	-0.55	1.9e-11	P wave terminal force;
TGCT	cis	rs7777484	0.534	rs2258709	chr7:2832365	C/T	cg25467336	chr7:2757616	NA	0.24	4.63	0.38	8.93e-6	Height;
TGCT	cis	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg08975724	chr8:8085496	FLJ10661	-0.64	-6.03	-0.48	1.77e-8	Mood instability;
TGCT	cis	rs9916302	0.904	rs11078915	chr17:37715426	T/C	cg07936489	chr17:37558343	FBXL20	-0.61	-4.87	-0.4	3.29e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7834745	0.553	rs1485286	chr8:119950668	C/T	cg17171407	chr8:119960777	TNFRSF11B	-0.29	-4.55	-0.38	1.24e-5	Eosinophil counts;Sum eosinophil basophil counts;
TGCT	cis	rs3733585	0.673	rs10018204	chr4:9964570	C/T	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.7	-0.57	3.69e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.84	-7.5	-0.56	1.08e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg26338869	chr17:61819248	STRADA	-0.55	-5.08	-0.42	1.34e-6	Prudent dietary pattern;
TGCT	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.07	-9.63	-0.65	1.01e-16	Platelet count;
TGCT	cis	rs2692947	0.666	rs10183151	chr2:96774786	T/G	cg05933789	chr2:97190408	NA	-0.17	-4.95	-0.41	2.34e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs7727544	0.545	rs10074490	chr5:131340032	C/T	cg24060327	chr5:131705240	SLC22A5	-0.54	-4.68	-0.39	7.27e-6	Blood metabolite levels;
TGCT	cis	rs9354352	0.935	rs9354354	chr6:66699333	A/G	cg07460842	chr6:66804631	NA	-0.64	-6.64	-0.51	8.69e-10	Initial pursuit acceleration in psychotic disorders;
TGCT	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg18876405	chr7:65276391	NA	-0.36	-5.41	-0.44	3.12e-7	Aortic root size;
TGCT	cis	rs6484504	0.532	rs7117286	chr11:31283810	T/A	cg14844989	chr11:31128820	NA	-0.24	-4.66	-0.39	7.87e-6	Red blood cell count;
TGCT	cis	rs9902453	0.934	rs12453172	chr17:28441590	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	6.55	0.51	1.4e-9	Coffee consumption (cups per day);
TGCT	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg24250549	chr1:154909240	PMVK	0.47	4.49	0.37	1.58e-5	Prostate cancer;
TGCT	cis	rs6748734	0.843	rs6749674	chr2:241834501	G/C	cg04034577	chr2:241836375	C2orf54	-0.4	-6.32	-0.49	4.22e-9	Urinary metabolites;
TGCT	cis	rs7937612	1.000	rs7937612	chr11:120278688	T/C	cg24566217	chr11:120254723	ARHGEF12	-0.28	-4.44	-0.37	1.96e-5	Intraocular pressure;
TGCT	cis	rs7917772	0.503	rs7096072	chr10:104299976	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	8.36	0.6	1.1e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs11676348	0.818	rs6436033	chr2:218983763	A/G	cg00012203	chr2:219082015	ARPC2	-0.52	-4.98	-0.41	2.08e-6	Ulcerative colitis;
TGCT	cis	rs3749237	0.595	rs4855861	chr3:49525962	G/T	cg02487422	chr3:49467188	NICN1	0.61	6.29	0.49	5.08e-9	Resting heart rate;
TGCT	cis	rs8072100	0.701	rs8078309	chr17:45774072	T/C	cg08085267	chr17:45401833	C17orf57	-0.43	-4.82	-0.4	4.04e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs35306767	0.903	rs12260800	chr10:927933	T/C	cg26597838	chr10:835615	NA	0.75	10.54	0.69	6.3e-19	Eosinophil percentage of granulocytes;
TGCT	cis	rs968451	1.000	rs62228376	chr22:39701097	G/C	cg17798944	chr22:39715225	SNORD43;RPL3	0.87	7.73	0.57	3.17e-12	Primary biliary cholangitis;
TGCT	cis	rs3733585	0.673	rs4627861	chr4:9954238	T/G	cg11266682	chr4:10021025	SLC2A9	-0.57	-7.6	-0.56	6.21e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs11673344	0.504	rs10403975	chr19:37573074	A/G	cg08039142	chr19:36980659	ZNF566	0.5	4.6	0.38	1.01e-5	Obesity-related traits;
TGCT	cis	rs797680	0.856	rs9432681	chr1:93761896	A/G	cg17826107	chr1:92977322	EVI5	0.23	5.1	0.42	1.24e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs6484504	0.532	rs2616799	chr11:31319044	T/C	cg26647111	chr11:31128758	NA	0.32	4.64	0.38	8.82e-6	Red blood cell count;
TGCT	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg07636037	chr3:49044803	WDR6	0.95	9.94	0.67	1.78e-17	Parkinson's disease;
TGCT	cis	rs910316	0.934	rs4903278	chr14:75535019	C/A	cg08847533	chr14:75593920	NEK9	0.95	10.3	0.68	2.36e-18	Height;
TGCT	trans	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg20587970	chr11:113659929	NA	-0.97	-11.47	-0.72	3.31e-21	Hip circumference adjusted for BMI;
TGCT	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg09033563	chr22:24373618	LOC391322	-0.52	-5.06	-0.41	1.46e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6693567	0.565	rs3754214	chr1:150478623	T/C	cg09579323	chr1:150459698	TARS2	0.52	4.63	0.38	9.26e-6	Migraine;
TGCT	cis	rs9653442	0.545	rs11123813	chr2:100765692	C/T	cg22139774	chr2:100720529	AFF3	-0.35	-5.58	-0.45	1.45e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg11764359	chr7:65958608	NA	0.61	5.53	0.44	1.84e-7	Aortic root size;
TGCT	cis	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg26116260	chr4:7069785	GRPEL1	1.06	10.07	0.67	8.61e-18	Monocyte percentage of white cells;
TGCT	cis	rs832540	0.931	rs1466008	chr5:56213406	G/C	cg12311346	chr5:56204834	C5orf35	-0.47	-4.97	-0.41	2.15e-6	Coronary artery disease;
TGCT	cis	rs2013441	1.000	rs4924809	chr17:20044673	C/T	cg18979559	chr17:20280153	CCDC144C	0.44	4.61	0.38	9.78e-6	Obesity-related traits;
TGCT	cis	rs7666738	0.830	rs6817645	chr4:99016054	T/C	cg05340658	chr4:99064831	C4orf37	0.48	5.43	0.44	2.92e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs208520	0.837	rs208471	chr6:66916749	A/C	cg07460842	chr6:66804631	NA	-0.9	-9.16	-0.64	1.34e-15	Exhaled nitric oxide output;
TGCT	cis	rs36051895	0.559	rs12342390	chr9:5211297	G/A	cg02405213	chr9:5042618	JAK2	-0.65	-8.06	-0.59	5.34e-13	Pediatric autoimmune diseases;
TGCT	cis	rs941898	0.625	rs6575763	chr14:100571762	A/G	cg19757573	chr14:101506246	MIR654;MIR376B;MIR376A2;MIR300;MIR376A1	0.15	4.67	0.39	7.66e-6	White matter hyperintensity burden;
TGCT	cis	rs6866344	0.570	rs1132338	chr5:178139442	T/G	cg03877680	chr5:178157825	ZNF354A	0.77	6.79	0.52	4.12e-10	Neutrophil percentage of white cells;
TGCT	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.71	0.39	6.53e-6	Prudent dietary pattern;
TGCT	cis	rs8016982	0.633	rs7160342	chr14:81713427	G/C	cg01989461	chr14:81687754	GTF2A1	0.76	7.5	0.56	1.09e-11	Schizophrenia;
TGCT	cis	rs9303401	0.592	rs12936771	chr17:56725052	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs3849570	0.533	rs6548784	chr3:81995889	G/A	cg07356753	chr3:81810745	GBE1	-0.56	-4.67	-0.39	7.73e-6	Waist circumference;Body mass index;
TGCT	cis	rs1406084	0.526	rs1373584	chr2:154723354	G/C	cg25703346	chr2:154729189	GALNT13	0.77	4.6	0.38	1.03e-5	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg17470723	chr8:74884337	TCEB1	0.74	7.16	0.54	6.16e-11	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs72781680	0.756	rs2712059	chr2:24020539	T/C	cg08917208	chr2:24149416	ATAD2B	0.79	4.94	0.41	2.51e-6	Lymphocyte counts;
TGCT	cis	rs3806843	0.966	rs6579965	chr5:140168811	T/G	cg19875535	chr5:140030758	IK	0.37	6.34	0.49	3.89e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg11644478	chr21:40555479	PSMG1	-0.95	-10.52	-0.69	6.69e-19	Cognitive function;
TGCT	cis	rs10501293	1.000	rs10838010	chr11:43122962	T/C	cg03447554	chr11:43094025	NA	-0.49	-6.73	-0.52	5.72e-10	Cognitive performance;
TGCT	trans	rs3822625	0.541	rs76679228	chr5:56199511	C/T	cg25190722	chr1:3801660	DFFB	0.56	6.67	0.51	7.53e-10	Breast cancer (early onset);
TGCT	cis	rs7772486	0.790	rs2265919	chr6:146221753	A/G	cg05347473	chr6:146136440	FBXO30	0.52	5.0	0.41	1.89e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4808199	0.895	rs10421505	chr19:19459554	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.71	5.73	0.46	7.17e-8	Nonalcoholic fatty liver disease;
TGCT	cis	rs1799949	1.000	rs4793236	chr17:41436440	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	5.49	0.44	2.14e-7	Menopause (age at onset);
TGCT	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg22618164	chr12:122356400	WDR66	0.69	6.52	0.51	1.6e-9	Mean corpuscular volume;
TGCT	cis	rs6912958	0.728	rs7773906	chr6:88251869	T/A	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.91	-0.4	2.78e-6	Monocyte percentage of white cells;
TGCT	cis	rs954108	0.522	rs7983818	chr13:29383182	A/C	cg11788234	chr13:29393811	NA	-0.49	-6.84	-0.52	3.26e-10	Obesity-related traits;
TGCT	cis	rs4788570	0.511	rs4788830	chr16:71732267	A/G	cg06353428	chr16:71660113	MARVELD3	1.57	13.04	0.76	5.38e-25	Intelligence (multi-trait analysis);
TGCT	trans	rs28735056	0.584	rs35614280	chr18:77636679	C/G	cg05926928	chr17:57297772	GDPD1	0.86	9.32	0.64	5.69e-16	Schizophrenia;
TGCT	cis	rs3015497	1.000	rs3015497	chr14:51113398	T/C	cg04730355	chr14:51134070	SAV1	-0.54	-4.74	-0.39	5.8e-6	Mean platelet volume;
TGCT	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg23302884	chr18:44338147	ST8SIA5	-0.41	-4.7	-0.39	6.77e-6	Personality dimensions;
TGCT	cis	rs9359856	0.510	rs2768936	chr6:90441851	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.45	-4.66	-0.39	7.9e-6	Bipolar disorder;
TGCT	cis	rs12620999	1.000	rs13004252	chr2:238035408	C/A	cg23555395	chr2:238036564	NA	-0.29	-4.69	-0.39	7.03e-6	Systemic lupus erythematosus;
TGCT	cis	rs2455799	0.517	rs1447647	chr3:15933465	C/T	cg12172478	chr3:16357591	RFTN1	-0.33	-4.78	-0.39	4.86e-6	Mean platelet volume;
TGCT	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.37	4.86	0.4	3.54e-6	Lymphocyte counts;
TGCT	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg15320075	chr8:145703422	NA	0.71	7.34	0.55	2.45e-11	Age at first birth;
TGCT	cis	rs7666738	0.830	rs10012003	chr4:99064881	A/G	cg05340658	chr4:99064831	C4orf37	0.52	5.86	0.47	3.86e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2075371	1.000	rs2598294	chr7:133991690	C/T	cg11752832	chr7:134001865	SLC35B4	0.69	6.32	0.49	4.19e-9	Mean platelet volume;
TGCT	cis	rs9814567	0.806	rs9839705	chr3:134323819	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-7.21	-0.54	4.87e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg06028808	chr11:68637592	NA	0.51	6.66	0.51	7.87e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs5769765	0.773	rs9616206	chr22:50310847	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.22	-12.49	-0.75	1.11e-23	Schizophrenia;
TGCT	cis	rs2456568	0.548	rs10466335	chr11:93663820	G/C	cg26875233	chr11:93583750	C11orf90	-0.41	-5.0	-0.41	1.87e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7089973	0.668	rs7077148	chr10:116644896	A/G	cg03647239	chr10:116582469	FAM160B1	0.58	5.42	0.44	2.94e-7	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs72945132	0.882	rs7945389	chr11:70158876	C/A	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs6121246	0.567	rs6120815	chr20:30184866	T/C	cg13852791	chr20:30311386	BCL2L1	0.69	4.54	0.38	1.33e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs2439831	0.850	rs544122	chr15:43775732	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.94	6.52	0.51	1.58e-9	Lung cancer in ever smokers;
TGCT	cis	rs6496667	0.558	rs61653706	chr15:91076654	G/A	cg22089800	chr15:90895588	ZNF774	0.71	5.45	0.44	2.63e-7	Rheumatoid arthritis;
TGCT	cis	rs2066819	1.000	rs76466034	chr12:56719450	G/A	cg26714650	chr12:56694279	CS	-1.36	-6.06	-0.48	1.54e-8	Psoriasis vulgaris;
TGCT	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs12477438	0.520	rs2964969	chr2:99782811	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	13.05	0.76	4.93e-25	Chronic sinus infection;
TGCT	cis	rs1008375	0.931	rs7672369	chr4:17604825	A/G	cg16339924	chr4:17578868	LAP3	0.74	5.92	0.47	3e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.67	-6.61	-0.51	1.01e-9	Prostate cancer;
TGCT	cis	rs3087591	1.000	rs2854332	chr17:29712378	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.48	-7.26	-0.55	3.66e-11	Hip circumference;
TGCT	cis	rs4455778	0.580	rs6583509	chr7:49122419	A/G	cg26309511	chr7:48887640	NA	-0.51	-6.64	-0.51	8.83e-10	Lung cancer in never smokers;
TGCT	cis	rs986417	1.000	rs1116853	chr14:60917476	A/G	cg27398547	chr14:60952738	C14orf39	1.37	8.92	0.63	5.07e-15	Gut microbiota (bacterial taxa);
TGCT	cis	rs9646954	0.542	rs4149513	chr2:101022726	C/T	cg14675211	chr2:100938903	LONRF2	0.5	4.76	0.39	5.2e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7412746	0.634	rs3754212	chr1:150738200	A/G	cg04414720	chr1:150670196	GOLPH3L	0.38	4.73	0.39	6.04e-6	Melanoma;
TGCT	cis	rs3824867	0.879	rs10769267	chr11:47460098	C/T	cg20307385	chr11:47447363	PSMC3	0.7	6.03	0.48	1.71e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs9894429	0.646	rs7406828	chr17:79619226	A/G	cg18240062	chr17:79603768	NPLOC4	-0.57	-5.05	-0.41	1.53e-6	Eye color traits;
TGCT	cis	rs4919044	0.808	rs835280	chr10:94811786	A/G	cg05127821	chr10:94822908	CYP26C1	-0.75	-4.85	-0.4	3.66e-6	Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs35951881	chr4:98999474	A/C	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2338224	1.000	rs4703886	chr5:71745985	C/T	cg01187920	chr5:71015162	CARTPT	-0.53	-4.57	-0.38	1.15e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Granulocyte count;Myeloid white cell count;
TGCT	trans	rs621559	0.535	rs678101	chr1:43671495	T/C	cg19324027	chr2:74699582	MRPL53	0.87	6.75	0.52	5.12e-10	Telomere length;
TGCT	cis	rs60871478	1.000	rs4397290	chr7:828493	T/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	-0.47	-4.48	-0.37	1.7e-5	Cerebrospinal P-tau181p levels;
TGCT	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg10802521	chr3:52805072	NEK4	-0.72	-9.11	-0.63	1.82e-15	Bipolar disorder;
TGCT	cis	rs5769707	0.967	rs12485195	chr22:50053871	G/A	cg05373962	chr22:49881684	NA	-0.32	-6.66	-0.51	7.86e-10	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs7267979	0.668	rs2387977	chr20:25599776	C/T	cg14121845	chr20:25566513	NINL	-0.45	-5.08	-0.41	1.36e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg25767906	chr1:53392781	SCP2	-0.51	-6.22	-0.49	6.83e-9	Monocyte count;
TGCT	cis	rs11209002	0.614	rs4655673	chr1:67555018	T/C	cg02640540	chr1:67518911	SLC35D1	0.55	4.63	0.38	8.99e-6	Crohn's disease;
TGCT	cis	rs12908161	0.920	rs35758837	chr15:85311382	C/T	cg17173187	chr15:85201210	NMB	0.57	6.4	0.5	2.89e-9	Schizophrenia;
TGCT	cis	rs7100689	0.753	rs1572816	chr10:82137600	A/G	cg01528321	chr10:82214614	TSPAN14	0.88	8.51	0.61	4.73e-14	Post bronchodilator FEV1;
TGCT	cis	rs7843479	1.000	rs67385415	chr8:21853733	T/C	cg17168535	chr8:21777572	XPO7	0.63	5.71	0.46	7.71e-8	Mean corpuscular volume;
TGCT	cis	rs3749237	0.595	rs6797765	chr3:49423976	A/G	cg02487422	chr3:49467188	NICN1	0.59	6.01	0.47	1.92e-8	Resting heart rate;
TGCT	cis	rs7953249	0.807	rs7970695	chr12:121423376	G/A	cg02403541	chr12:121454288	C12orf43	-0.53	-4.56	-0.38	1.23e-5	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs4889855	0.530	rs4889863	chr17:78550468	C/T	cg16591659	chr17:78472290	NA	-0.28	-4.45	-0.37	1.89e-5	Fractional excretion of uric acid;
TGCT	cis	rs4788570	0.566	rs72791974	chr16:71478574	A/T	cg06353428	chr16:71660113	MARVELD3	-1.31	-7.67	-0.57	4.46e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs56104184	0.830	rs17272658	chr19:49355405	C/T	cg21252483	chr19:49399788	TULP2	-0.41	-5.21	-0.42	7.47e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs4566357	0.539	rs10933164	chr2:227860671	A/G	cg11843606	chr2:227700838	RHBDD1	-0.76	-6.43	-0.5	2.49e-9	Coronary artery disease;
TGCT	cis	rs12220238	1.000	rs10824083	chr10:75911342	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.91	7.98	0.58	8.43e-13	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg00814883	chr7:100076585	TSC22D4	-0.85	-8.53	-0.61	4.23e-14	Platelet count;
TGCT	cis	rs711830	0.931	rs6755766	chr2:177043205	T/C	cg13092806	chr2:177043255	NA	0.77	6.12	0.48	1.14e-8	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
TGCT	cis	rs9527	0.590	rs10883830	chr10:104851285	G/A	cg04362960	chr10:104952993	NT5C2	0.67	5.76	0.46	6.28e-8	Arsenic metabolism;
TGCT	trans	rs7726839	0.526	rs11960158	chr5:568665	C/T	cg25482853	chr8:67687455	SGK3	1.1	8.74	0.62	1.34e-14	Obesity-related traits;
TGCT	cis	rs6725041	0.792	rs1533769	chr2:213089956	A/C	cg20637307	chr2:213403960	ERBB4	-0.52	-4.47	-0.37	1.72e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs3733585	0.699	rs7676733	chr4:9966956	G/A	cg11266682	chr4:10021025	SLC2A9	-0.59	-7.87	-0.58	1.53e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs682748	0.755	rs2402349	chr5:17122819	T/C	cg23987134	chr5:17158319	LOC285696	-0.21	-4.98	-0.41	2.1e-6	Hippocampal atrophy;
TGCT	cis	rs1348850	0.567	rs12994392	chr2:178536640	A/G	cg22681709	chr2:178499509	PDE11A	-0.49	-6.15	-0.48	9.86e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs7119	0.717	rs11635567	chr15:77819515	A/G	cg27398640	chr15:77910606	LINGO1	-0.26	-4.66	-0.39	7.98e-6	Type 2 diabetes;
TGCT	cis	rs933688	0.938	rs6869048	chr5:90664322	G/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.08	10.13	0.67	6.16e-18	Smoking behavior;
TGCT	cis	rs16854884	0.741	rs55909524	chr3:143794734	T/C	cg06585982	chr3:143692056	C3orf58	0.61	4.72	0.39	6.19e-6	Economic and political preferences (feminism/equality);
TGCT	cis	rs11112613	0.713	rs60865625	chr12:105940256	A/C	cg03607813	chr12:105948248	NA	0.45	4.98	0.41	2.05e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	cis	rs7666738	0.716	rs28792413	chr4:99083707	G/A	cg05340658	chr4:99064831	C4orf37	0.5	5.5	0.44	2.07e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg13342137	chr4:2252803	MXD4	0.17	4.47	0.37	1.71e-5	Obesity-related traits;
TGCT	cis	rs1532993	0.518	rs28838303	chr4:98616189	G/A	cg05340658	chr4:99064831	C4orf37	-0.41	-4.96	-0.41	2.3e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs9534288	0.912	rs4941540	chr13:46604710	C/T	cg15192986	chr13:46630673	CPB2	-0.51	-6.62	-0.51	9.95e-10	Blood protein levels;
TGCT	cis	rs7829975	0.560	rs17154599	chr8:8551418	C/T	cg06636001	chr8:8085503	FLJ10661	-0.6	-5.35	-0.43	4.13e-7	Mood instability;
TGCT	cis	rs7542091	0.637	rs9429826	chr1:210052146	G/A	cg23283495	chr1:209979779	IRF6	0.54	5.28	0.43	5.66e-7	Monobrow;
TGCT	cis	rs2456568	0.802	rs1395387	chr11:93639307	A/T	cg16099599	chr11:93583650	C11orf90	-0.4	-4.99	-0.41	1.98e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs2594989	0.943	rs9878389	chr3:11457099	T/G	cg00170343	chr3:11313890	ATG7	0.67	5.12	0.42	1.13e-6	Circulating chemerin levels;
TGCT	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg09060608	chr5:178986726	RUFY1	0.49	5.67	0.45	9.29e-8	Lung cancer;
TGCT	cis	rs9326248	1.000	rs10790175	chr11:117034729	A/G	cg11861562	chr11:117069780	TAGLN	0.28	4.64	0.38	8.74e-6	Blood protein levels;
TGCT	cis	rs208520	0.955	rs12204033	chr6:67001525	T/C	cg07460842	chr6:66804631	NA	0.69	5.83	0.46	4.48e-8	Exhaled nitric oxide output;
TGCT	cis	rs6582630	0.572	rs1969363	chr12:38514872	A/G	cg26384229	chr12:38710491	ALG10B	0.57	5.01	0.41	1.85e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs12477438	0.765	rs1054042	chr2:99614396	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.79	-7.94	-0.58	1.06e-12	Chronic sinus infection;
TGCT	cis	rs877282	0.853	rs11595507	chr10:756703	C/T	cg17470449	chr10:769945	NA	0.32	4.91	0.4	2.76e-6	Uric acid levels;
TGCT	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg15462221	chr8:8086144	FLJ10661	-0.54	-4.88	-0.4	3.22e-6	Systolic blood pressure;
TGCT	cis	rs1322512	0.760	rs2038615	chr6:152927267	C/T	cg03415253	chr6:152958462	SYNE1	0.5	4.93	0.4	2.61e-6	Tonometry;
TGCT	trans	rs12339966	0.615	rs62529419	chr9:11336618	G/T	cg03488587	chr11:64876988	C11orf2	0.32	7.0	0.53	1.42e-10	Systolic blood pressure;
TGCT	cis	rs2180341	1.000	rs9388561	chr6:127634921	C/T	cg27446573	chr6:127587934	RNF146	1.12	10.11	0.67	6.87e-18	Breast cancer;
TGCT	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg13206674	chr6:150067644	NUP43	0.52	4.46	0.37	1.78e-5	Lung cancer;
TGCT	cis	rs2242116	0.727	rs7635480	chr3:46968227	T/C	cg02527881	chr3:46936655	PTH1R	-0.29	-5.44	-0.44	2.77e-7	Birth weight;
TGCT	cis	rs73198271	0.740	rs28402110	chr8:8647249	C/A	cg15556689	chr8:8085844	FLJ10661	-0.6	-4.46	-0.37	1.8e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs1023500	0.505	rs134885	chr22:42673811	C/G	cg05082376	chr22:42548792	NA	-0.21	-4.47	-0.37	1.76e-5	Schizophrenia;
TGCT	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg17054783	chr10:134559939	INPP5A	0.24	4.78	0.39	4.95e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs3820928	0.935	rs10203363	chr2:227896976	C/T	cg11843606	chr2:227700838	RHBDD1	-0.54	-4.96	-0.41	2.29e-6	Pulmonary function;
TGCT	cis	rs12477438	0.798	rs4851179	chr2:99568774	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-6.57	-0.51	1.27e-9	Chronic sinus infection;
TGCT	cis	rs2456568	0.778	rs7940973	chr11:93682045	C/G	cg17595323	chr11:93583763	C11orf90	0.4	5.27	0.43	5.97e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs2456568	0.802	rs1574515	chr11:93629643	T/C	cg17595323	chr11:93583763	C11orf90	-0.47	-6.49	-0.5	1.85e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs4689388	0.926	rs10937718	chr4:6295217	T/C	cg14416269	chr4:6271139	WFS1	0.37	4.9	0.4	2.95e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs9296092	0.538	rs75652975	chr6:33516251	C/T	cg13560919	chr6:33536144	NA	-0.2	-4.63	-0.38	9.25e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg22963979	chr7:1858916	MAD1L1	-0.35	-5.25	-0.43	6.34e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs9787249	1.000	rs9787249	chr1:40212878	G/A	cg19912559	chr1:40204330	PPIE	0.49	5.7	0.46	8.41e-8	Blood protein levels;
TGCT	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg00475322	chr7:917719	C7orf20	0.5	6.52	0.51	1.63e-9	Perceived unattractiveness to mosquitoes;
TGCT	cis	rs17076896	0.786	rs7339224	chr13:19934027	C/T	cg00777926	chr13:20807375	GJB6	-0.37	-4.53	-0.38	1.36e-5	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg00149659	chr3:10157352	C3orf10	0.96	6.1	0.48	1.26e-8	Alzheimer's disease;
TGCT	cis	rs916888	0.821	rs199514	chr17:44856881	G/A	cg05721485	chr17:44071124	MAPT	-0.25	-4.44	-0.37	1.96e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs1355223	0.583	rs1553757	chr11:34867089	G/A	cg24088639	chr11:34937564	PDHX;APIP	-0.5	-4.51	-0.38	1.45e-5	Systemic lupus erythematosus and Systemic sclerosis;
TGCT	cis	rs2046867	0.908	rs113001746	chr3:72824260	C/T	cg25664220	chr3:72788482	NA	-0.53	-6.71	-0.52	6.19e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs17767294	0.708	rs72847343	chr6:27790833	A/G	cg08851530	chr6:28072375	NA	1.54	7.3	0.55	3.1e-11	Parkinson's disease;
TGCT	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg10047753	chr17:41438598	NA	0.97	9.67	0.66	7.94e-17	Menopause (age at onset);
TGCT	cis	rs28595532	0.920	rs17257945	chr4:119666465	T/A	cg14228332	chr4:119757509	SEC24D	1.06	5.75	0.46	6.55e-8	Cannabis dependence symptom count;
TGCT	cis	rs9379850	0.730	rs9393738	chr6:26620658	G/A	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.48	-4.59	-0.38	1.06e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs3947	1.000	rs3947	chr8:11702375	G/A	cg02840367	chr8:11660030	FDFT1	0.91	6.7	0.52	6.58e-10	Blood protein levels;
TGCT	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.45	-5.37	-0.43	3.72e-7	Alzheimer's disease;
TGCT	cis	rs12210905	0.610	rs12204953	chr6:27396737	G/A	cg08851530	chr6:28072375	NA	1.34	6.07	0.48	1.44e-8	Hip circumference adjusted for BMI;
TGCT	cis	rs12530845	0.945	rs12540273	chr7:135333854	T/G	cg23117316	chr7:135346802	PL-5283	-0.51	-4.83	-0.4	3.98e-6	Red blood cell traits;
TGCT	cis	rs4253772	0.513	rs6008612	chr22:46707907	G/A	cg24881330	chr22:46731750	TRMU	0.97	6.37	0.5	3.32e-9	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs3733585	0.753	rs1122141	chr4:9947278	T/C	cg00071950	chr4:10020882	SLC2A9	-0.64	-7.92	-0.58	1.18e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs858239	0.730	rs858290	chr7:23248036	A/G	cg05407003	chr7:23246146	NA	-0.28	-4.54	-0.38	1.29e-5	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg00149659	chr3:10157352	C3orf10	1.17	7.24	0.55	4.13e-11	Alzheimer's disease;
TGCT	cis	rs7223966	1.000	rs3817181	chr17:61776538	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	4.51	0.38	1.49e-5	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs8051431	0.876	rs1122531	chr16:72012772	C/T	cg06353428	chr16:71660113	MARVELD3	0.59	5.02	0.41	1.73e-6	LDL cholesterol levels;
TGCT	cis	rs7246657	0.525	rs1667351	chr19:37478027	A/T	cg18154014	chr19:37997991	ZNF793	0.67	5.37	0.43	3.75e-7	Coronary artery calcification;
TGCT	cis	rs806215	0.547	rs62481385	chr7:127410711	G/A	cg11539674	chr7:127291444	SND1	-0.37	-4.72	-0.39	6.35e-6	Type 2 diabetes;
TGCT	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg11890956	chr21:40555474	PSMG1	-0.68	-6.67	-0.51	7.62e-10	Menarche (age at onset);
TGCT	cis	rs17221829	0.673	rs10765225	chr11:89384988	T/C	cg02982614	chr11:89391479	FOLH1B	-0.25	-4.46	-0.37	1.8e-5	Anxiety in major depressive disorder;
TGCT	cis	rs7772486	0.623	rs735535	chr6:146036829	C/T	cg23711669	chr6:146136114	FBXO30	-0.89	-10.12	-0.67	6.37e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6964587	1.000	rs13224513	chr7:91601465	G/A	cg17063962	chr7:91808500	NA	0.91	9.99	0.67	1.32e-17	Breast cancer;
TGCT	cis	rs9467773	0.967	rs7753565	chr6:26560012	A/G	cg26531700	chr6:26746687	NA	0.49	4.73	0.39	6.06e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs11098499	0.865	rs11722183	chr4:120280597	A/C	cg09307838	chr4:120376055	NA	0.66	6.56	0.51	1.29e-9	Corneal astigmatism;
TGCT	cis	rs10504229	0.680	rs11777459	chr8:58044241	A/T	cg11062466	chr8:58055876	NA	0.34	4.57	0.38	1.16e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs1670533	0.932	rs2248083	chr4:1052166	A/C	cg20887711	chr4:1340912	KIAA1530	0.74	5.84	0.46	4.22e-8	Recombination rate (females);
TGCT	cis	rs74233809	0.901	rs77335224	chr10:104636276	C/T	cg05855489	chr10:104503620	C10orf26	0.79	4.56	0.38	1.19e-5	Birth weight;
TGCT	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg03352830	chr11:487213	PTDSS2	0.26	4.58	0.38	1.12e-5	Body mass index;
TGCT	cis	rs2070488	1.000	rs3792527	chr3:38493212	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	9.66	0.66	8.59e-17	Electrocardiographic conduction measures;
TGCT	cis	rs6424115	0.771	rs2229586	chr1:24200903	G/C	cg15997130	chr1:24165203	NA	0.87	9.52	0.65	1.79e-16	Immature fraction of reticulocytes;
TGCT	cis	rs801193	0.548	rs2659891	chr7:66201114	A/G	cg11764359	chr7:65958608	NA	0.54	4.79	0.4	4.68e-6	Aortic root size;
TGCT	cis	rs858239	0.831	rs7796541	chr7:23389073	G/T	cg05602783	chr7:23145260	KLHL7	-0.65	-5.8	-0.46	5.13e-8	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs477895	0.568	rs34838337	chr11:63870892	T/C	cg04317338	chr11:64019027	PLCB3	0.7	6.04	0.48	1.69e-8	Mean platelet volume;
TGCT	cis	rs9810089	0.802	rs10935182	chr3:136137422	G/A	cg12473912	chr3:136751656	NA	0.35	5.1	0.42	1.26e-6	Gestational age at birth (child effect);
TGCT	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg07507251	chr3:52567010	NT5DC2	0.47	6.64	0.51	8.85e-10	Bipolar disorder;
TGCT	cis	rs2836950	0.501	rs11702505	chr21:40700614	G/T	cg11890956	chr21:40555474	PSMG1	-0.64	-5.97	-0.47	2.38e-8	Menarche (age at onset);
TGCT	cis	rs7845219	0.525	rs10956931	chr8:95930301	A/G	cg16049864	chr8:95962084	TP53INP1	-0.44	-4.75	-0.39	5.61e-6	Type 2 diabetes;
TGCT	cis	rs79149102	0.579	rs79916508	chr15:75373721	A/C	cg09165964	chr15:75287851	SCAMP5	-1.0	-5.42	-0.44	3.02e-7	Lung cancer;
TGCT	cis	rs10089	1.000	rs13356473	chr5:127478250	T/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	7.53	0.56	9.3e-12	Ileal carcinoids;
TGCT	trans	rs1814175	0.817	rs4084376	chr11:49831160	T/C	cg03929089	chr4:120376271	NA	-0.72	-8.26	-0.6	1.84e-13	Height;
TGCT	cis	rs6701037	0.566	rs10489326	chr1:175134677	A/G	cg08873628	chr1:175162347	KIAA0040	0.48	4.57	0.38	1.15e-5	Alcohol dependence;
TGCT	cis	rs1355223	0.583	rs2915177	chr11:34880266	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.8	8.94	0.63	4.49e-15	Systemic lupus erythematosus and Systemic sclerosis;
TGCT	cis	rs7044106	0.791	rs12554440	chr9:123485333	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	5.62	0.45	1.22e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs7394190	0.748	rs11000773	chr10:75534115	G/T	cg07699608	chr10:75541558	CHCHD1	0.79	5.44	0.44	2.72e-7	Incident atrial fibrillation;
TGCT	cis	rs854765	0.647	rs854770	chr17:18019048	A/G	cg04398451	chr17:18023971	MYO15A	-0.39	-6.75	-0.52	5e-10	Total body bone mineral density;
TGCT	cis	rs4455778	0.659	rs9642330	chr7:49032828	A/C	cg26309511	chr7:48887640	NA	0.44	5.22	0.42	7.26e-7	Lung cancer in never smokers;
TGCT	cis	rs2562456	0.755	rs1879234	chr19:21704479	T/G	cg25650185	chr19:21324782	ZNF431	0.61	5.38	0.43	3.6e-7	Pain;
TGCT	cis	rs4688759	0.609	rs113176147	chr3:49534439	G/T	cg00383909	chr3:49044727	WDR6	1.47	6.03	0.48	1.75e-8	Blood protein levels;
TGCT	cis	rs259282	0.524	rs1559180	chr19:33127443	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.6	5.82	0.46	4.63e-8	Schizophrenia;
TGCT	cis	rs7809950	0.815	rs62482495	chr7:106965009	A/G	cg23024343	chr7:107201750	COG5	-0.43	-5.85	-0.47	4.12e-8	Coronary artery disease;
TGCT	cis	rs7572733	0.534	rs1589162	chr2:198782692	A/G	cg00792783	chr2:198669748	PLCL1	0.58	5.05	0.41	1.52e-6	Dermatomyositis;
TGCT	cis	rs10089	1.000	rs13357268	chr5:127423051	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	7.29	0.55	3.16e-11	Ileal carcinoids;
TGCT	cis	rs4949454	0.542	rs10914457	chr1:32094261	A/C	cg13919466	chr1:32135498	COL16A1	0.37	5.1	0.42	1.23e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.546	rs10461174	chr4:98698293	G/A	cg18180107	chr4:99064573	C4orf37	0.54	4.78	0.39	4.93e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6570726	0.935	rs110289	chr6:145865176	C/G	cg05347473	chr6:146136440	FBXO30	0.49	4.54	0.38	1.29e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg08280861	chr8:58055591	NA	0.4	4.56	0.38	1.22e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs3125734	0.608	rs7094950	chr10:64019744	T/C	cg09941381	chr10:64027924	RTKN2	-0.36	-5.49	-0.44	2.19e-7	Rheumatoid arthritis;
TGCT	cis	rs1865760	0.566	rs9348706	chr6:26065481	G/C	cg17042849	chr6:26104293	HIST1H4C	-0.63	-5.5	-0.44	2.1e-7	Height;
TGCT	cis	rs2016266	0.855	rs930900	chr12:53727545	T/C	cg16917193	chr12:54089295	NA	0.64	4.56	0.38	1.23e-5	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs992157	0.798	rs12053514	chr2:219167965	C/T	cg00012203	chr2:219082015	ARPC2	-0.82	-8.13	-0.59	3.76e-13	Colorectal cancer;
TGCT	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg03709012	chr19:19516395	GATAD2A	-0.76	-6.42	-0.5	2.64e-9	Tonsillectomy;
TGCT	cis	rs12477438	0.798	rs12473029	chr2:99637961	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-6.18	-0.49	8.51e-9	Chronic sinus infection;
TGCT	cis	rs9948	0.655	rs61742095	chr2:97366088	T/C	cg01990225	chr2:97406019	LMAN2L	-1.01	-5.13	-0.42	1.08e-6	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs10992471	0.603	rs9299405	chr9:95284873	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.59	-5.61	-0.45	1.26e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs611744	0.967	rs660816	chr8:109178048	C/T	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg12570787	chr5:219185	SDHA;CCDC127	-0.73	-5.16	-0.42	9.52e-7	Breast cancer;
TGCT	cis	rs36051895	0.622	rs10974952	chr9:5079828	A/T	cg02405213	chr9:5042618	JAK2	-0.78	-10.08	-0.67	8.17e-18	Pediatric autoimmune diseases;
TGCT	cis	rs739496	0.527	rs3752632	chr12:112376297	C/T	cg10833066	chr12:111807467	FAM109A	0.38	5.61	0.45	1.24e-7	Platelet count;
TGCT	cis	rs9303401	0.659	rs12935851	chr17:56600244	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs10510102	0.872	rs12265542	chr10:123728255	A/G	cg23691251	chr10:123688108	ATE1	-0.59	-4.7	-0.39	6.75e-6	Breast cancer;
TGCT	cis	rs4494114	1.000	rs880303	chr1:39340282	C/T	cg25970120	chr1:39325951	RRAGC	-0.6	-6.23	-0.49	6.58e-9	Blood protein levels;
TGCT	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg02975922	chr3:195473998	MUC4	-0.24	-5.47	-0.44	2.4e-7	Pancreatic cancer;
TGCT	cis	rs7617773	0.817	rs11709691	chr3:48303669	A/G	cg11946769	chr3:48343235	NME6	0.76	6.64	0.51	8.76e-10	Coronary artery disease;
TGCT	cis	rs7804356	0.651	rs7803699	chr7:26814173	T/C	cg03456212	chr7:26904342	SKAP2	-0.54	-4.6	-0.38	1.04e-5	Type 1 diabetes;
TGCT	cis	rs42648	0.935	rs7793743	chr7:90031619	G/A	cg25739043	chr7:89950458	NA	0.62	5.99	0.47	2.08e-8	Homocysteine levels;
TGCT	cis	rs7267979	1.000	rs7267979	chr20:25298087	C/T	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9916302	0.706	rs4795385	chr17:37733148	A/G	cg07936489	chr17:37558343	FBXL20	0.84	6.16	0.48	9.13e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs58688157	0.960	rs1055382	chr11:612182	T/C	cg16486109	chr11:613632	IRF7	0.35	5.18	0.42	8.82e-7	Systemic lupus erythematosus;
TGCT	cis	rs7666738	0.830	rs1593570	chr4:99017058	T/C	cg18180107	chr4:99064573	C4orf37	0.54	5.03	0.41	1.7e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8017423	0.740	rs7152196	chr14:90703900	G/T	cg04374321	chr14:90722782	PSMC1	0.77	8.04	0.59	6.19e-13	Mortality in heart failure;
TGCT	cis	rs7178572	0.568	rs7167794	chr15:77635875	T/C	cg15453836	chr15:77711506	NA	-0.42	-4.79	-0.4	4.68e-6	Type 2 diabetes;
TGCT	cis	rs4629710	0.568	rs9492880	chr6:131565962	G/T	cg12606694	chr6:131520996	AKAP7	0.38	4.44	0.37	1.97e-5	Multiple myeloma (IgH translocation);
TGCT	cis	rs35883536	0.626	rs10493933	chr1:101111282	A/G	cg06223162	chr1:101003688	GPR88	-0.38	-6.71	-0.52	6.07e-10	Monocyte count;
TGCT	cis	rs3008870	0.677	rs2815354	chr1:67483642	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.97	8.09	0.59	4.6e-13	Lymphocyte percentage of white cells;
TGCT	cis	rs9467773	1.000	rs11756120	chr6:26529808	G/C	cg05738196	chr6:26577821	NA	0.88	12.5	0.75	1.03e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs2797160	0.651	rs1268066	chr6:126035041	C/T	cg05901451	chr6:126070800	HEY2	0.75	6.67	0.51	7.42e-10	Endometrial cancer;
TGCT	trans	rs629535	0.767	rs72654070	chr8:70079369	G/A	cg21567404	chr3:27674614	NA	-0.57	-8.99	-0.63	3.38e-15	Dupuytren's disease;
TGCT	cis	rs9467711	0.606	rs9379901	chr6:26603866	T/C	cg16898833	chr6:26189333	HIST1H4D	1.02	5.25	0.43	6.32e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9913156	0.576	rs2036656	chr17:4622071	C/G	cg00122941	chr17:4613640	ARRB2	-0.77	-6.91	-0.53	2.22e-10	Lymphocyte counts;
TGCT	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7568458	0.709	rs2592551	chr2:85780131	G/A	cg17127132	chr2:85788382	GGCX	0.51	4.58	0.38	1.12e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs7267979	1.000	rs6138575	chr20:25438952	G/A	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9911578	0.935	rs9911753	chr17:56983174	G/A	cg12560992	chr17:57184187	TRIM37	0.73	8.7	0.62	1.69e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs76878669	0.561	rs4244813	chr11:66129488	G/C	cg18002602	chr11:66138449	SLC29A2	0.54	6.62	0.51	9.76e-10	Educational attainment (years of education);
TGCT	cis	rs35146811	0.844	rs34031156	chr7:99677917	T/A	cg13334819	chr7:99746414	C7orf59	-0.79	-6.8	-0.52	3.94e-10	Coronary artery disease;
TGCT	cis	rs9486719	0.843	rs2499787	chr6:96841762	G/C	cg06623918	chr6:96969491	KIAA0776	0.9	6.41	0.5	2.73e-9	Migraine;Coronary artery disease;
TGCT	cis	rs9733	0.650	rs12406712	chr1:150545084	C/A	cg13175981	chr1:150552382	MCL1	0.52	5.6	0.45	1.32e-7	Tonsillectomy;
TGCT	cis	rs9916302	0.904	rs7208274	chr17:37513796	C/T	cg07936489	chr17:37558343	FBXL20	0.65	5.08	0.41	1.36e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg07092213	chr7:1199455	ZFAND2A	0.43	4.59	0.38	1.05e-5	Longevity;Endometriosis;
TGCT	cis	rs1182196	0.502	rs757786	chr7:2836019	C/T	cg11411865	chr7:2701802	TTYH3	0.19	4.52	0.38	1.44e-5	Plateletcrit;
TGCT	cis	rs4886920	0.518	rs12902224	chr15:78076272	T/C	cg03457338	chr15:78040120	NA	0.24	5.21	0.42	7.79e-7	Neuroticism;
TGCT	cis	rs2153535	0.580	rs9505455	chr6:8478622	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs9467711	0.720	rs9348716	chr6:26375658	G/A	cg16898833	chr6:26189333	HIST1H4D	1.1	5.3	0.43	5.16e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs60871478	1.000	rs62432860	chr7:807522	G/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.46	4.6	0.38	1.04e-5	Cerebrospinal P-tau181p levels;
TGCT	cis	rs2797160	0.651	rs1268092	chr6:126029043	A/G	cg05901451	chr6:126070800	HEY2	-0.76	-7.14	-0.54	6.93e-11	Endometrial cancer;
TGCT	cis	rs79149102	0.579	rs7163390	chr15:75280426	T/C	cg09165964	chr15:75287851	SCAMP5	-1.08	-6.09	-0.48	1.32e-8	Lung cancer;
TGCT	cis	rs1008375	1.000	rs10805359	chr4:17684886	A/G	cg10189774	chr4:17578691	LAP3	0.52	4.71	0.39	6.54e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs12946454	0.696	rs4792819	chr17:43247957	A/C	cg10701640	chr17:43249399	NA	0.52	7.24	0.55	4.11e-11	Systolic blood pressure;
TGCT	cis	rs308403	0.533	rs12644866	chr4:123667604	T/A	cg10495464	chr4:123653540	BBS12;LOC729338	0.81	11.72	0.73	8.06e-22	Blood protein levels;
TGCT	cis	rs9457247	1.000	rs402749	chr6:167386104	C/T	cg25258033	chr6:167368657	RNASET2	0.18	4.49	0.37	1.63e-5	Crohn's disease;
TGCT	cis	rs6671200	1.000	rs6678964	chr1:95694268	C/T	cg01206378	chr1:95698827	RWDD3	0.55	4.58	0.38	1.11e-5	Stearic acid (18:0) levels;
TGCT	cis	rs7804356	0.651	rs3801857	chr7:26811484	C/T	cg03456212	chr7:26904342	SKAP2	-0.54	-4.6	-0.38	1.04e-5	Type 1 diabetes;
TGCT	cis	rs9527	0.615	rs10883781	chr10:104581130	A/G	cg04362960	chr10:104952993	NT5C2	0.59	4.73	0.39	5.97e-6	Arsenic metabolism;
TGCT	cis	rs28595532	0.920	rs56150431	chr4:119764786	T/C	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs60871478	1.000	rs62432242	chr7:797715	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.46	4.64	0.38	8.77e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs6430585	0.583	rs7561565	chr2:136640787	A/C	cg07169764	chr2:136633963	MCM6	1.22	11.9	0.73	3.03e-22	Corneal structure;
TGCT	cis	rs1577917	0.958	rs12192546	chr6:86476484	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.68	5.53	0.44	1.82e-7	Response to antipsychotic treatment;
TGCT	cis	rs3776081	0.568	rs7720799	chr5:149523777	C/T	cg18424208	chr5:149546337	CDX1	-0.26	-4.75	-0.39	5.5e-6	Blood protein levels;
TGCT	cis	rs1513670	0.686	rs9303538	chr17:41814083	G/A	cg20702314	chr17:41856518	DUSP3;C17orf105	-0.54	-4.46	-0.37	1.78e-5	Bone mineral density (hip);
TGCT	cis	rs4654899	1.000	rs885363	chr1:21325360	C/A	cg01072550	chr1:21505969	NA	-0.5	-7.94	-0.58	1.04e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg09704166	chr2:114031854	PAX8;LOC440839	-0.32	-4.82	-0.4	4.04e-6	Lymphocyte counts;
TGCT	cis	rs10465746	0.780	rs10874424	chr1:84424033	C/T	cg10977910	chr1:84465055	TTLL7	0.69	7.07	0.54	9.97e-11	Obesity-related traits;
TGCT	cis	rs11719291	0.651	rs1134043	chr3:49200137	G/T	cg03060546	chr3:49711283	APEH	-0.69	-4.75	-0.39	5.49e-6	Cognitive function;
TGCT	cis	rs9941219	0.528	rs7191218	chr16:50436394	C/T	cg08560952	chr16:50278816	NA	0.36	4.55	0.38	1.28e-5	Liver enzyme levels (alanine transaminase);
TGCT	cis	rs2739330	0.576	rs2858912	chr22:24297197	A/G	cg00024416	chr22:24240387	NA	-0.25	-4.91	-0.4	2.86e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1480597	0.518	rs7097094	chr10:45210690	A/C	cg12063947	chr10:45878068	ALOX5	0.27	4.54	0.38	1.32e-5	Parkinson's disease;
TGCT	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg10802521	chr3:52805072	NEK4	-0.67	-8.06	-0.59	5.58e-13	Bipolar disorder;
TGCT	cis	rs2404602	0.692	rs12904198	chr15:77146978	G/A	cg26408565	chr15:76604113	ETFA	-0.36	-4.53	-0.38	1.36e-5	Blood metabolite levels;
TGCT	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7659604	0.540	rs10001092	chr4:122677177	C/T	cg19748678	chr4:122722346	EXOSC9	-0.51	-5.0	-0.41	1.89e-6	Type 2 diabetes;
TGCT	cis	rs710216	0.843	rs10890232	chr1:43416514	C/T	cg03128534	chr1:43423976	SLC2A1	0.61	5.02	0.41	1.79e-6	Red cell distribution width;
TGCT	cis	rs514406	0.758	rs532242	chr1:53308665	C/G	cg22166914	chr1:53195759	ZYG11B	0.41	7.09	0.54	9.16e-11	Monocyte count;
TGCT	cis	rs2579519	0.547	rs11683523	chr2:96544855	T/C	cg23100626	chr2:96804247	ASTL	0.37	4.49	0.37	1.62e-5	Diastolic blood pressure;
TGCT	cis	rs782590	0.522	rs12329050	chr2:55894428	G/A	cg18811423	chr2:55921094	PNPT1	-0.6	-5.88	-0.47	3.61e-8	Metabolic syndrome;
TGCT	cis	rs1153858	1.000	rs12909158	chr15:45621174	A/G	cg26924012	chr15:45694286	SPATA5L1	1.07	14.49	0.79	1.89e-28	Homoarginine levels;
TGCT	cis	rs5769765	0.740	rs2103932	chr22:50272515	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.41	-6.13	-0.48	1.08e-8	Schizophrenia;
TGCT	cis	rs3741151	1.000	rs7129663	chr11:73045129	C/T	cg17517138	chr11:73019481	ARHGEF17	1.22	6.25	0.49	5.95e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
TGCT	cis	rs28595532	0.920	rs116607127	chr4:119731072	T/C	cg21605333	chr4:119757512	SEC24D	1.66	8.33	0.6	1.28e-13	Cannabis dependence symptom count;
TGCT	cis	rs7772486	0.790	rs2814879	chr6:146201743	T/C	cg05347473	chr6:146136440	FBXO30	0.52	4.88	0.4	3.15e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3091242	0.933	rs9438904	chr1:25756860	T/C	cg23205692	chr1:25664452	TMEM50A	0.5	5.2	0.42	8.14e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs6879260	1.000	rs10903252	chr5:179733934	T/C	cg13944838	chr5:179740914	GFPT2	-0.4	-6.42	-0.5	2.66e-9	Height;
TGCT	cis	rs6121246	0.609	rs2149281	chr20:30417918	G/A	cg18721089	chr20:30220636	NA	-0.36	-4.6	-0.38	1.04e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs56104184	0.690	rs56312501	chr19:49395933	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.45	-5.89	-0.47	3.37e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs2742234	0.955	rs2075910	chr10:43614230	G/A	cg02780029	chr10:43622663	RET	-0.25	-4.85	-0.4	3.64e-6	Hirschsprung disease;
TGCT	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.49	-4.76	-0.39	5.34e-6	Bipolar disorder;
TGCT	cis	rs12142240	0.698	rs112068407	chr1:46822291	T/C	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs7727544	1.000	rs10076701	chr5:131596419	A/G	cg24060327	chr5:131705240	SLC22A5	-0.57	-6.03	-0.48	1.75e-8	Blood metabolite levels;
TGCT	cis	rs1035144	0.510	rs12432357	chr14:81299468	A/G	cg06600135	chr14:81408086	NA	-0.57	-5.35	-0.43	4.18e-7	Male sexual orientation;
TGCT	cis	rs7666738	0.791	rs2081621	chr4:98926753	C/A	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12210905	1.000	rs9368499	chr6:27254332	C/T	cg08851530	chr6:28072375	NA	1.29	5.49	0.44	2.19e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg27588902	chr6:42928151	GNMT	-0.56	-6.93	-0.53	2.08e-10	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs6545883	0.929	rs10173974	chr2:61748900	C/G	cg15711740	chr2:61764176	XPO1	-0.57	-5.29	-0.43	5.25e-7	Tuberculosis;
TGCT	cis	rs6061231	0.631	rs2427310	chr20:60969929	C/G	cg24112000	chr20:60950667	NA	-0.35	-4.98	-0.41	2.12e-6	Colorectal cancer;
TGCT	cis	rs76788097	0.614	rs7151034	chr14:61820669	T/G	cg15891218	chr14:61748354	TMEM30B	-0.68	-4.63	-0.38	9.1e-6	Marginal zone lymphoma;
TGCT	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs2229238	0.823	rs61275241	chr1:154504887	T/G	cg13067139	chr1:155221277	FAM189B	0.2	4.51	0.38	1.47e-5	Coronary heart disease;
TGCT	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg11890956	chr21:40555474	PSMG1	1.11	12.39	0.74	1.95e-23	Cognitive function;
TGCT	cis	rs10411936	1.000	rs10411936	chr19:16548375	C/T	cg19006008	chr19:16999768	F2RL3	-0.27	-4.73	-0.39	5.88e-6	White blood cell count;Multiple sclerosis;
TGCT	cis	rs12681287	0.752	rs4472493	chr8:87251914	C/T	cg27223183	chr8:87520930	FAM82B	-0.8	-5.67	-0.45	9.58e-8	Caudate activity during reward;
TGCT	cis	rs1692580	0.840	rs263526	chr1:2173504	T/C	cg24578937	chr1:2090814	PRKCZ	0.24	5.32	0.43	4.74e-7	Coronary artery disease;
TGCT	trans	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg23505145	chr19:12996616	KLF1	0.78	8.12	0.59	4.03e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7511006	0.893	rs2038049	chr22:50654888	G/C	cg19026356	chr22:50624276	TRABD	-0.5	-4.6	-0.38	1.01e-5	Obesity-related traits;
TGCT	cis	rs7098414	0.511	rs7898787	chr10:82156042	G/A	cg00277334	chr10:82204260	NA	-0.38	-4.98	-0.41	2.08e-6	Post bronchodilator FEV1;
TGCT	trans	rs1814175	0.791	rs9787917	chr11:49937281	C/T	cg15704280	chr7:45808275	SEPT13	-0.71	-8.0	-0.58	7.45e-13	Height;
TGCT	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg10411590	chr13:21900810	NA	0.34	4.75	0.39	5.46e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	cis	rs1775715	0.678	rs7096139	chr10:32217404	A/C	cg14930904	chr10:32216787	ARHGAP12	0.49	4.61	0.38	9.88e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg12000995	chr2:27665139	KRTCAP3	-0.39	-4.62	-0.38	9.61e-6	Total body bone mineral density;
TGCT	cis	rs79976124	0.800	rs6918860	chr6:66637741	G/C	cg07460842	chr6:66804631	NA	0.58	5.12	0.42	1.14e-6	Type 2 diabetes;
TGCT	cis	rs7731657	0.537	rs2419934	chr5:130295768	T/C	cg08523029	chr5:130500466	HINT1	-0.58	-4.84	-0.4	3.8e-6	Fasting plasma glucose;
TGCT	trans	rs7726839	0.540	rs72703083	chr5:595365	C/T	cg11887960	chr12:57824829	NA	1.2	9.56	0.65	1.47e-16	Obesity-related traits;
TGCT	cis	rs7744392	1.000	rs6922548	chr6:35353523	A/G	cg06087101	chr6:35551932	FKBP5	0.61	4.56	0.38	1.21e-5	Cataracts in type 2 diabetes;
TGCT	cis	rs317689	0.918	rs689415	chr12:69738139	A/G	cg11871910	chr12:69753446	YEATS4	-0.57	-4.88	-0.4	3.13e-6	Response to diuretic therapy;
TGCT	cis	rs2637266	0.967	rs2579748	chr10:78328313	T/C	cg18941641	chr10:78392320	NA	0.41	4.98	0.41	2.05e-6	Pulmonary function;
TGCT	cis	rs3812831	0.695	rs7998546	chr13:114939914	C/G	cg06611532	chr13:114900021	NA	0.31	5.64	0.45	1.07e-7	Schizophrenia;
TGCT	cis	rs174479	0.647	rs174457	chr11:61656975	T/C	cg19610905	chr11:61596333	FADS2	0.59	5.09	0.42	1.27e-6	Sphingolipid levels;
TGCT	cis	rs6860540	0.504	rs4704871	chr5:156919806	A/G	cg25387487	chr5:157003181	ADAM19	-0.31	-4.65	-0.39	8.21e-6	Inflammatory skin disease;
TGCT	cis	rs6831352	0.819	rs13832	chr4:99993075	C/A	cg12011299	chr4:100065546	ADH4	0.41	5.7	0.46	8.36e-8	Alcohol dependence;
TGCT	cis	rs3784262	0.692	rs4646590	chr15:58303137	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.42	-6.17	-0.48	8.85e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs72781680	1.000	rs11125372	chr2:24257582	A/T	cg08917208	chr2:24149416	ATAD2B	-0.81	-4.44	-0.37	1.99e-5	Lymphocyte counts;
TGCT	cis	rs9457247	0.967	rs443570	chr6:167389925	G/A	cg23791538	chr6:167370224	RNASET2	-0.5	-4.98	-0.41	2.08e-6	Crohn's disease;
TGCT	cis	rs7772486	0.754	rs9386133	chr6:146141213	A/G	cg05347473	chr6:146136440	FBXO30	0.49	4.73	0.39	6.04e-6	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg23505145	chr19:12996616	KLF1	0.96	10.09	0.67	7.8e-18	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2302464	1.000	rs58978163	chr4:15728008	G/A	cg18497811	chr4:14860861	NA	-0.48	-4.47	-0.37	1.76e-5	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs28595532	0.920	rs112097820	chr4:119746532	G/A	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs6061231	1.000	rs11908473	chr20:60957770	C/G	cg24112000	chr20:60950667	NA	-0.36	-5.17	-0.42	9.03e-7	Colorectal cancer;
TGCT	cis	rs6582630	0.519	rs11182021	chr12:38443709	A/T	cg26384229	chr12:38710491	ALG10B	-0.8	-7.45	-0.56	1.42e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs1215050	0.765	rs783925	chr4:98969881	T/C	cg05340658	chr4:99064831	C4orf37	-0.43	-5.27	-0.43	5.8e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	16.1	0.82	3.69e-32	Prudent dietary pattern;
TGCT	cis	rs7824557	0.627	rs7838897	chr8:11207326	C/A	cg21775007	chr8:11205619	TDH	0.73	7.03	0.53	1.23e-10	Retinal vascular caliber;
TGCT	cis	rs4845570	1.000	rs6673002	chr1:151743275	G/T	cg07092448	chr1:151763213	TDRKH	1.17	8.92	0.63	5.08e-15	Coronary artery disease;
TGCT	cis	rs1008375	0.966	rs3775923	chr4:17585625	T/C	cg18681998	chr4:17616180	MED28	0.85	8.18	0.59	2.86e-13	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs704	0.790	rs4795434	chr17:26716917	G/T	cg10342447	chr17:26645325	TMEM97	-0.51	-4.91	-0.4	2.84e-6	Osteoprotegerin levels;
TGCT	cis	rs4253772	0.530	rs79354880	chr22:46746419	C/A	cg24881330	chr22:46731750	TRMU	1.06	5.5	0.44	2.08e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs7246657	0.678	rs2972446	chr19:38129893	G/A	cg03611452	chr19:38183253	ZNF781	-0.59	-4.76	-0.39	5.34e-6	Coronary artery calcification;
TGCT	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.7	-5.57	-0.45	1.48e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7582180	0.715	rs764828	chr2:100908634	A/C	cg14675211	chr2:100938903	LONRF2	0.46	4.55	0.38	1.28e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs3008870	1.000	rs11208976	chr1:67434411	A/G	cg11518657	chr1:67396239	MIER1	-0.54	-4.61	-0.38	9.72e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs7208859	0.725	rs9897673	chr17:29243366	T/C	cg14008862	chr17:28927542	LRRC37B2	0.67	4.65	0.39	8.47e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs66573146	0.831	rs6832482	chr4:7023433	A/T	cg05069807	chr4:6945702	TBC1D14	0.32	5.14	0.42	1.04e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs9467711	1.000	rs9467704	chr6:26319486	A/G	cg03517284	chr6:25882590	NA	0.87	4.68	0.39	7.52e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1403694	0.695	rs3774292	chr3:186433574	A/T	cg12454167	chr3:186435060	KNG1	0.51	8.67	0.61	1.95e-14	Blood protein levels;
TGCT	cis	rs17253792	0.822	rs78922774	chr14:56115302	T/A	cg01858014	chr14:56050164	KTN1	-0.35	-4.65	-0.39	8.23e-6	Putamen volume;
TGCT	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg19626725	chr5:178986131	RUFY1	0.5	6.38	0.5	3.15e-9	Lung cancer;
TGCT	trans	rs66573146	1.000	rs55688389	chr4:7030689	C/G	cg07817883	chr1:32538562	TMEM39B	1.81	8.44	0.6	6.87e-14	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg10117171	chr1:25599238	RHD	-0.37	-6.02	-0.48	1.86e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs7010267	0.543	rs6469803	chr8:120040538	G/A	cg17171407	chr8:119960777	TNFRSF11B	0.26	4.59	0.38	1.06e-5	Total body bone mineral density (age 45-60);
TGCT	cis	rs1568889	0.838	rs7131053	chr11:28143312	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.92	11.24	0.71	1.22e-20	Bipolar disorder;
TGCT	cis	rs10089	1.000	rs2898096	chr5:127433214	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	8.19	0.59	2.7e-13	Ileal carcinoids;
TGCT	cis	rs763121	0.853	rs6001185	chr22:39052155	G/A	cg06022373	chr22:39101656	GTPBP1	0.77	7.46	0.56	1.35e-11	Menopause (age at onset);
TGCT	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg06028808	chr11:68637592	NA	0.53	6.83	0.52	3.33e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs644799	1.000	rs509720	chr11:95562771	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.82	8.63	0.61	2.52e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs2228479	0.717	rs1061647	chr16:89806063	G/C	cg06558623	chr16:89946397	TCF25	0.45	4.51	0.38	1.47e-5	Skin colour saturation;
TGCT	cis	rs727563	0.635	rs2899348	chr22:42164516	C/G	cg06634786	chr22:41940651	POLR3H	0.85	8.15	0.59	3.41e-13	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs208520	0.690	rs2144081	chr6:66824972	G/A	cg07460842	chr6:66804631	NA	-0.95	-9.88	-0.66	2.43e-17	Exhaled nitric oxide output;
TGCT	cis	rs7666738	0.715	rs116787789	chr4:98718720	G/A	cg17366294	chr4:99064904	C4orf37	0.65	6.72	0.52	5.97e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7617773	0.780	rs13082859	chr3:48344675	C/T	cg11946769	chr3:48343235	NME6	0.82	7.09	0.54	9.1e-11	Coronary artery disease;
TGCT	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg06618935	chr21:46677482	NA	-0.36	-5.39	-0.44	3.4e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs3812831	0.654	rs367312	chr13:114930195	G/A	cg06611532	chr13:114900021	NA	0.29	5.5	0.44	2.09e-7	Schizophrenia;
TGCT	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg15921436	chr17:44337874	NA	0.55	7.71	0.57	3.46e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs909674	0.865	rs5757682	chr22:39848259	T/G	cg24399712	chr22:39784796	NA	-1.05	-11.03	-0.7	3.84e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs7635838	0.596	rs443503	chr3:11261912	A/T	cg00170343	chr3:11313890	ATG7	-0.62	-5.71	-0.46	7.92e-8	HDL cholesterol;
TGCT	cis	rs6688613	0.694	rs12562794	chr1:166828957	A/G	cg07049167	chr1:166818506	POGK	0.25	5.28	0.43	5.7e-7	Refractive astigmatism;
TGCT	cis	rs2730260	0.537	rs73169248	chr7:158891742	T/G	cg09066883	chr7:157932951	PTPRN2	0.42	4.66	0.39	8.09e-6	Myopia (pathological);
TGCT	cis	rs9457247	1.000	rs4710147	chr6:167374239	G/A	cg25258033	chr6:167368657	RNASET2	-0.18	-4.48	-0.37	1.65e-5	Crohn's disease;
TGCT	cis	rs2012796	0.956	rs10450940	chr14:81825326	C/A	cg02996355	chr14:81879375	NA	0.47	4.61	0.38	9.68e-6	Night sleep phenotypes;
TGCT	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg08280861	chr8:58055591	NA	0.4	4.73	0.39	5.97e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6754311	0.593	rs11679508	chr2:136474098	A/T	cg07169764	chr2:136633963	MCM6	-0.67	-6.08	-0.48	1.41e-8	Mosquito bite size;
TGCT	cis	rs11785400	0.753	rs9773415	chr8:143731170	G/A	cg10596483	chr8:143751796	JRK	0.53	5.21	0.42	7.5e-7	Schizophrenia;
TGCT	cis	rs7267979	1.000	rs4815420	chr20:25383979	C/T	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6500602	0.627	rs863501	chr16:4588394	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.39	-7.09	-0.54	9.1e-11	Schizophrenia;
TGCT	cis	rs2742417	0.603	rs2673032	chr3:45756927	C/T	cg04837898	chr3:45731254	SACM1L	-0.66	-7.02	-0.53	1.27e-10	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs3824867	0.959	rs4237544	chr11:47454271	G/T	cg20307385	chr11:47447363	PSMC3	-0.69	-6.07	-0.48	1.41e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs28595532	0.920	rs55640619	chr4:119761999	C/T	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.54	-7.0	-0.53	1.42e-10	Longevity;Endometriosis;
TGCT	trans	rs941408	1.000	rs1736184	chr19:2810248	G/A	cg19676328	chr12:49525230	TUBA1B	-0.77	-7.34	-0.55	2.43e-11	Total cholesterol levels;
TGCT	cis	rs59197085	0.515	rs2402938	chr7:128444295	T/C	cg00260937	chr7:128520193	KCP	0.46	5.12	0.42	1.15e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
TGCT	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.44	-5.3	-0.43	5.01e-7	Longevity;Endometriosis;
TGCT	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg17747265	chr1:1875780	NA	-0.39	-7.32	-0.55	2.73e-11	Body mass index;
TGCT	cis	rs28595532	0.920	rs114051506	chr4:119772893	A/T	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs7666738	0.830	rs79075162	chr4:98960674	A/T	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9911578	0.933	rs2531726	chr17:56522533	C/T	cg12560992	chr17:57184187	TRIM37	-0.7	-8.63	-0.61	2.53e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs6500602	0.702	rs6500605	chr16:4502410	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.28	5.18	0.42	8.68e-7	Schizophrenia;
TGCT	cis	rs5167	0.566	rs7253458	chr19:45482570	C/T	cg13119609	chr19:45449297	APOC2	0.23	4.65	0.39	8.26e-6	Blood protein levels;
TGCT	cis	rs651907	0.514	rs10936744	chr3:101433440	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.34	-7.02	-0.53	1.27e-10	Colorectal cancer;
TGCT	cis	rs17818399	0.749	rs35625984	chr2:46805908	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.53	-5.24	-0.43	6.72e-7	Height;
TGCT	cis	rs524023	0.914	rs2666559	chr11:64439227	G/T	cg19395706	chr11:64412079	NRXN2	-0.43	-5.16	-0.42	9.33e-7	Urate levels in obese individuals;
TGCT	cis	rs7681440	0.647	rs11941682	chr4:90804316	T/G	cg10208370	chr4:90758469	SNCA	-0.56	-5.27	-0.43	5.93e-7	Dementia with Lewy bodies;
TGCT	trans	rs2727020	0.587	rs1164658	chr11:49298551	C/A	cg03929089	chr4:120376271	NA	0.72	8.44	0.6	7.15e-14	Coronary artery disease;
TGCT	cis	rs13256369	0.802	rs13255789	chr8:8562791	T/C	cg18904891	chr8:8559673	CLDN23	0.58	5.4	0.44	3.23e-7	Obesity-related traits;
TGCT	cis	rs854765	0.547	rs2955355	chr17:17948475	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.8	-8.46	-0.61	6.18e-14	Total body bone mineral density;
TGCT	cis	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg18252515	chr7:66147081	NA	-1.31	-8.18	-0.59	2.87e-13	Diabetic kidney disease;
TGCT	cis	rs921968	0.541	rs3845835	chr2:219342284	T/C	cg02176678	chr2:219576539	TTLL4	-0.48	-6.84	-0.52	3.21e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs3845702	0.736	rs56401468	chr2:180857757	C/T	cg01881094	chr2:180872142	CWC22	1.06	6.66	0.51	8.12e-10	Schizophrenia;
TGCT	cis	rs1670533	1.000	rs6858612	chr4:1053353	C/T	cg20887711	chr4:1340912	KIAA1530	0.57	4.48	0.37	1.65e-5	Recombination rate (females);
TGCT	cis	rs13256369	0.950	rs12548792	chr8:8568031	T/C	cg17143192	chr8:8559678	CLDN23	0.58	5.56	0.45	1.56e-7	Obesity-related traits;
TGCT	cis	rs2153535	0.580	rs1577467	chr6:8444241	G/A	cg07606381	chr6:8435919	SLC35B3	0.57	5.25	0.43	6.46e-7	Motion sickness;
TGCT	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs68170813	0.559	rs10953536	chr7:107021691	G/A	cg02696742	chr7:106810147	HBP1	-0.68	-5.44	-0.44	2.69e-7	Coronary artery disease;
TGCT	cis	rs6754311	0.551	rs313519	chr2:136439517	A/C	cg07169764	chr2:136633963	MCM6	0.63	5.62	0.45	1.19e-7	Mosquito bite size;
TGCT	cis	rs28595532	0.920	rs115484560	chr4:119756781	T/G	cg14228332	chr4:119757509	SEC24D	1.29	6.0	0.47	1.98e-8	Cannabis dependence symptom count;
TGCT	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg03709012	chr19:19516395	GATAD2A	0.74	6.22	0.49	7.04e-9	Tonsillectomy;
TGCT	cis	rs7552404	0.727	rs4949677	chr1:76266662	T/A	cg10523679	chr1:76189770	ACADM	0.75	7.12	0.54	7.71e-11	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs3796352	0.764	rs11714902	chr3:53101544	G/C	cg15956490	chr3:53032818	SFMBT1	0.6	6.81	0.52	3.78e-10	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs250677	0.522	rs1432801	chr5:148390979	T/C	cg18129178	chr5:148520854	ABLIM3	-0.35	-4.58	-0.38	1.12e-5	Breast cancer;
TGCT	cis	rs877282	0.945	rs11253397	chr10:789774	A/G	cg17470449	chr10:769945	NA	0.3	4.82	0.4	4.14e-6	Uric acid levels;
TGCT	cis	rs4332037	0.539	rs11982455	chr7:1911458	A/C	cg25834613	chr7:1915315	MAD1L1	-0.47	-4.63	-0.38	8.98e-6	Bipolar disorder;
TGCT	cis	rs12908161	1.000	rs12908549	chr15:85322351	C/G	cg12863693	chr15:85201151	NMB	0.43	5.12	0.42	1.15e-6	Schizophrenia;
TGCT	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg01416388	chr22:39784598	NA	-0.72	-7.15	-0.54	6.43e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs13242816	1.000	rs62471189	chr7:116101588	G/A	cg16553024	chr7:116138462	CAV2	-0.46	-5.15	-0.42	9.77e-7	P wave duration;
TGCT	trans	rs561341	0.714	rs75861674	chr17:30304317	A/G	cg20587970	chr11:113659929	NA	-1.04	-12.58	-0.75	6.7e-24	Hip circumference adjusted for BMI;
TGCT	cis	rs57994353	0.897	rs72775778	chr9:139381128	G/A	cg13741927	chr9:139327495	INPP5E	-0.23	-5.12	-0.42	1.12e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs9300255	0.568	rs1627724	chr12:123638580	T/A	cg00376283	chr12:123451042	ABCB9	0.73	5.64	0.45	1.09e-7	Neutrophil percentage of white cells;
TGCT	cis	rs11190604	0.767	rs10883483	chr10:102174244	T/C	cg16342193	chr10:102329863	NA	-0.39	-5.05	-0.41	1.54e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs651907	0.535	rs1460097	chr3:101497569	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.31	-6.52	-0.51	1.56e-9	Colorectal cancer;
TGCT	cis	rs6912958	0.781	rs9450738	chr6:88267314	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-5.06	-0.41	1.45e-6	Monocyte percentage of white cells;
TGCT	cis	rs11711311	0.747	rs11928494	chr3:113343219	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.68	-5.83	-0.46	4.6e-8	IgG glycosylation;
TGCT	cis	rs17162190	0.559	rs4402166	chr1:26850406	C/T	cg02450742	chr1:26856648	RPS6KA1	0.54	4.49	0.37	1.62e-5	Mean corpuscular volume;
TGCT	cis	rs7772486	0.875	rs9399572	chr6:146362945	T/G	cg23711669	chr6:146136114	FBXO30	0.87	9.53	0.65	1.75e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6831352	0.918	rs1042365	chr4:100045500	G/T	cg12011299	chr4:100065546	ADH4	-0.42	-5.14	-0.42	1.04e-6	Alcohol dependence;
TGCT	cis	rs2070488	0.932	rs4678604	chr3:38444273	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	9.66	0.66	8.43e-17	Electrocardiographic conduction measures;
TGCT	cis	rs7819412	0.537	rs2127127	chr8:11434792	C/G	cg21775007	chr8:11205619	TDH	-0.53	-5.06	-0.41	1.45e-6	Triglycerides;
TGCT	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg03934478	chr11:495069	RNH1	0.33	5.08	0.42	1.33e-6	Body mass index;
TGCT	cis	rs778371	0.958	rs778341	chr2:233728801	C/A	cg08000102	chr2:233561755	GIGYF2	-0.56	-5.99	-0.47	2.12e-8	Schizophrenia;
TGCT	cis	rs1018836	0.665	rs7000724	chr8:91516335	A/T	cg16814680	chr8:91681699	NA	-0.74	-7.47	-0.56	1.22e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs12477438	0.520	rs13018891	chr2:99755099	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.82	0.62	8.67e-15	Chronic sinus infection;
TGCT	cis	rs7819412	0.818	rs11989439	chr8:11055597	C/A	cg21775007	chr8:11205619	TDH	-0.49	-4.55	-0.38	1.27e-5	Triglycerides;
TGCT	cis	rs6866344	0.570	rs1079487	chr5:178136005	G/A	cg10224037	chr5:178157518	ZNF354A	0.99	9.62	0.65	1.03e-16	Neutrophil percentage of white cells;
TGCT	trans	rs1814175	0.754	rs7103235	chr11:49699191	A/G	cg15704280	chr7:45808275	SEPT13	-0.7	-8.14	-0.59	3.51e-13	Height;
TGCT	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9399137	0.507	rs4520025	chr6:135278619	G/T	cg24558204	chr6:135376177	HBS1L	0.47	4.78	0.39	4.95e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
TGCT	cis	rs12135062	0.538	rs2651929	chr1:3101353	C/T	cg25382214	chr1:3105252	PRDM16	0.22	4.44	0.37	2.01e-5	Migraine;
TGCT	cis	rs3617	0.573	rs3821873	chr3:52913006	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	0.51	4.97	0.41	2.18e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7191439	0.858	rs4390574	chr16:88776297	T/C	cg27087555	chr16:88793112	FAM38A	-0.5	-5.49	-0.44	2.16e-7	Plateletcrit;
TGCT	cis	rs4689592	0.503	rs11945642	chr4:7051065	G/C	cg02503808	chr4:7069936	GRPEL1	-0.94	-7.53	-0.56	9.02e-12	Monocyte percentage of white cells;
TGCT	cis	rs919433	0.617	rs10460394	chr2:198548741	G/A	cg00792783	chr2:198669748	PLCL1	-0.56	-5.11	-0.42	1.21e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs929596	0.755	rs4148325	chr2:234673309	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.33	-5.5	-0.44	2.12e-7	Total bilirubin levels in HIV-1 infection;
TGCT	cis	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg02503808	chr4:7069936	GRPEL1	0.97	9.11	0.63	1.78e-15	Monocyte percentage of white cells;
TGCT	cis	rs7511006	0.893	rs760743	chr22:50647375	C/T	cg08875078	chr22:50639485	SELO	0.57	5.45	0.44	2.59e-7	Obesity-related traits;
TGCT	cis	rs9611565	0.512	rs139560	chr22:42194962	A/G	cg06634786	chr22:41940651	POLR3H	-0.82	-7.77	-0.57	2.62e-12	Vitiligo;
TGCT	cis	rs9911578	0.967	rs6503893	chr17:57149695	G/A	cg05425664	chr17:57184151	TRIM37	-0.68	-6.9	-0.53	2.4e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs13326165	0.760	rs13059674	chr3:52371789	T/G	cg27565382	chr3:53032988	SFMBT1	0.37	4.9	0.4	2.97e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs13242816	0.881	rs35062002	chr7:116142458	G/A	cg16553024	chr7:116138462	CAV2	-0.44	-5.36	-0.43	3.97e-7	P wave duration;
TGCT	cis	rs6688613	1.000	rs6688613	chr1:166951869	A/G	cg07049167	chr1:166818506	POGK	-0.21	-4.52	-0.38	1.43e-5	Refractive astigmatism;
TGCT	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg08048268	chr3:133502702	NA	-0.64	-9.81	-0.66	3.59e-17	Iron status biomarkers;
TGCT	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg06873352	chr17:61820015	STRADA	0.58	6.39	0.5	3.01e-9	Prudent dietary pattern;
TGCT	cis	rs2549003	1.000	rs7735073	chr5:131815357	G/A	cg00255919	chr5:131827918	IRF1	0.22	5.15	0.42	1.01e-6	Asthma (sex interaction);
TGCT	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg09165964	chr15:75287851	SCAMP5	0.58	5.33	0.43	4.45e-7	Breast cancer;
TGCT	cis	rs909341	0.537	rs12481497	chr20:62385541	G/A	cg14758556	chr20:62440591	NA	0.4	5.74	0.46	6.9e-8	Atopic dermatitis;
TGCT	cis	rs2016266	0.859	rs7953656	chr12:53738433	G/T	cg16917193	chr12:54089295	NA	0.66	4.54	0.38	1.33e-5	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.68	4.89	0.4	3e-6	Platelet count;
TGCT	trans	rs1005277	0.540	rs7903942	chr10:37929276	C/T	cg17830980	chr10:43048298	ZNF37B	0.67	7.5	0.56	1.07e-11	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2204008	0.837	rs11495722	chr12:38337245	G/A	cg13010199	chr12:38710504	ALG10B	0.61	4.77	0.39	5.11e-6	Bladder cancer;
TGCT	cis	rs12468579	0.503	rs1168	chr2:191829777	C/T	cg21497043	chr2:191745649	GLS	0.51	4.66	0.39	8.05e-6	JT interval (sulfonylurea treatment interaction);
TGCT	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs11578119	0.689	rs6689586	chr1:170392301	C/T	cg09767346	chr1:170501363	GORAB	-0.57	-4.7	-0.39	6.94e-6	Male-pattern baldness;
TGCT	cis	rs826838	0.967	rs7136593	chr12:39128265	C/T	cg26384229	chr12:38710491	ALG10B	-0.86	-7.7	-0.57	3.65e-12	Heart rate;
TGCT	cis	rs6088590	1.000	rs11696546	chr20:33452999	C/G	cg24642439	chr20:33292090	TP53INP2	0.7	5.98	0.47	2.17e-8	Coronary artery disease;
TGCT	cis	rs62103177	0.759	rs9956512	chr18:77607517	G/A	cg12964065	chr18:77638022	KCNG2	0.41	5.48	0.44	2.31e-7	Opioid sensitivity;
TGCT	cis	rs13242816	1.000	rs56180538	chr7:116079711	C/T	cg16553024	chr7:116138462	CAV2	-0.47	-5.23	-0.43	6.88e-7	P wave duration;
TGCT	cis	rs6456156	0.792	rs10946213	chr6:167516095	A/G	cg07741184	chr6:167504864	NA	-0.23	-4.7	-0.39	6.8e-6	Primary biliary cholangitis;
TGCT	cis	rs765787	0.530	rs1631533	chr15:45518628	C/T	cg24006582	chr15:45444508	DUOX1	-0.26	-5.62	-0.45	1.19e-7	Uric acid levels;
TGCT	cis	rs4975709	0.569	rs2353583	chr5:1858834	G/C	cg14773178	chr5:1868261	NA	0.34	5.62	0.45	1.18e-7	Cardiovascular disease risk factors;
TGCT	cis	rs2239547	0.618	rs3733047	chr3:52871929	A/G	cg10802521	chr3:52805072	NEK4	0.6	6.07	0.48	1.44e-8	Schizophrenia;
TGCT	cis	rs860295	0.557	rs6696019	chr1:155864977	T/C	cg05700447	chr1:155978627	NA	0.23	4.72	0.39	6.14e-6	Body mass index;
TGCT	cis	rs9611565	0.921	rs5751080	chr22:41736267	A/G	cg13695892	chr22:41940480	POLR3H	-0.72	-7.37	-0.55	2.15e-11	Vitiligo;
TGCT	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs3812831	0.572	rs3118896	chr13:114931769	C/G	cg08824895	chr13:115047677	UPF3A	0.5	5.02	0.41	1.75e-6	Schizophrenia;
TGCT	cis	rs8031584	0.706	rs2177670	chr15:31157751	G/T	cg08704250	chr15:31115839	NA	-0.43	-6.31	-0.49	4.47e-9	Huntington's disease progression;
TGCT	cis	rs7711186	0.655	rs75315590	chr5:178020818	A/T	cg17371294	chr5:178012716	COL23A1	-0.57	-4.71	-0.39	6.39e-6	Urate levels in obese individuals;
TGCT	trans	rs17685	0.712	rs10271413	chr7:75754858	G/A	cg19862616	chr7:65841803	NCRNA00174	0.52	8.96	0.63	4.04e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs67311347	1.000	rs9875245	chr3:40442280	G/T	cg17264618	chr3:40429014	ENTPD3	0.32	4.57	0.38	1.18e-5	Renal cell carcinoma;
TGCT	cis	rs10782582	0.593	rs12130832	chr1:76234294	T/C	cg22875332	chr1:76189707	ACADM	-0.45	-4.98	-0.41	2.06e-6	Daytime sleep phenotypes;
TGCT	cis	rs7829975	0.633	rs2979181	chr8:8323088	A/T	cg15556689	chr8:8085844	FLJ10661	0.71	6.71	0.52	6.06e-10	Mood instability;
TGCT	cis	rs2404602	0.536	rs12915248	chr15:76765615	A/T	cg22467129	chr15:76604101	ETFA	-0.49	-5.95	-0.47	2.53e-8	Blood metabolite levels;
TGCT	cis	rs6586163	0.527	rs3740286	chr10:90751340	A/G	cg03111039	chr10:90751583	FAS;ACTA2	0.6	7.77	0.57	2.59e-12	Chronic lymphocytic leukemia;
TGCT	cis	rs1784581	0.722	rs1619122	chr6:162400198	G/T	cg17173639	chr6:162384350	PARK2	-0.47	-8.25	-0.6	1.94e-13	Itch intensity from mosquito bite;
TGCT	cis	rs9583531	0.689	rs9521913	chr13:111382058	C/T	cg24331049	chr13:111365604	ING1	-0.88	-8.83	-0.62	8.12e-15	Coronary artery disease;
TGCT	cis	rs4455778	0.659	rs2364008	chr7:49017001	A/G	cg26309511	chr7:48887640	NA	-0.43	-5.07	-0.41	1.4e-6	Lung cancer in never smokers;
TGCT	cis	rs7727544	0.570	rs7701237	chr5:131534381	C/T	cg14196790	chr5:131705035	SLC22A5	0.33	4.49	0.37	1.59e-5	Blood metabolite levels;
TGCT	cis	rs56104184	0.775	rs73061694	chr19:49399978	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.73	-9.15	-0.63	1.47e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg11764359	chr7:65958608	NA	-0.55	-4.99	-0.41	1.98e-6	Aortic root size;
TGCT	cis	rs2180341	0.960	rs9375503	chr6:127677071	T/C	cg27446573	chr6:127587934	RNF146	1.21	10.87	0.7	9.57e-20	Breast cancer;
TGCT	cis	rs727563	0.635	rs5758444	chr22:42133921	T/A	cg03806693	chr22:41940476	POLR3H	1.06	10.94	0.7	6.7e-20	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs5769765	1.000	rs4824112	chr22:50284345	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.42	6.28	0.49	5.18e-9	Schizophrenia;
TGCT	cis	rs2594989	0.943	rs2594995	chr3:11369117	A/G	cg00170343	chr3:11313890	ATG7	-0.67	-5.06	-0.41	1.44e-6	Circulating chemerin levels;
TGCT	cis	rs478304	0.934	rs1193692	chr11:65504069	A/C	cg17480646	chr11:65405466	SIPA1	0.43	5.24	0.43	6.71e-7	Acne (severe);
TGCT	cis	rs9611565	0.694	rs9611591	chr22:41830212	G/A	cg17554472	chr22:41940697	POLR3H	0.47	5.17	0.42	8.97e-7	Vitiligo;
TGCT	cis	rs7824557	0.591	rs2293859	chr8:11216761	T/G	cg21775007	chr8:11205619	TDH	0.69	6.65	0.51	8.29e-10	Retinal vascular caliber;
TGCT	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg11965913	chr1:205819406	PM20D1	-0.46	-6.44	-0.5	2.34e-9	Monocyte percentage of white cells;
TGCT	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg17971929	chr21:40555470	PSMG1	-0.51	-4.47	-0.37	1.74e-5	Menarche (age at onset);
TGCT	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg22920501	chr2:26401640	FAM59B	-0.79	-6.31	-0.49	4.58e-9	Gut microbiome composition (summer);
TGCT	cis	rs2439831	0.850	rs28718261	chr15:44043793	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	5.91	0.47	3.05e-8	Lung cancer in ever smokers;
TGCT	cis	rs669446	0.527	rs585711	chr1:44099863	G/T	cg12908607	chr1:44402522	ARTN	-0.54	-5.68	-0.45	8.9e-8	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs7824557	0.602	rs10110557	chr8:11207508	T/C	cg21775007	chr8:11205619	TDH	0.73	7.03	0.53	1.23e-10	Retinal vascular caliber;
TGCT	cis	rs7246657	0.525	rs997516	chr19:37474264	T/C	cg18154014	chr19:37997991	ZNF793	0.73	4.58	0.38	1.11e-5	Coronary artery calcification;
TGCT	cis	rs59197085	0.818	rs4472439	chr7:128466635	G/A	cg00260937	chr7:128520193	KCP	0.47	4.95	0.41	2.36e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
TGCT	cis	rs7677751	0.767	rs6831380	chr4:55076345	G/A	cg17187183	chr4:55093834	PDGFRA	0.48	6.4	0.5	2.84e-9	Corneal astigmatism;
TGCT	cis	rs4631830	0.863	rs10826127	chr10:51530757	G/A	cg10326726	chr10:51549505	MSMB	-0.27	-5.38	-0.43	3.6e-7	Prostate-specific antigen levels;
TGCT	cis	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg18252515	chr7:66147081	NA	-1.2	-7.83	-0.58	1.89e-12	Diabetic kidney disease;
TGCT	cis	rs4730250	0.554	rs76257331	chr7:106916279	G/A	cg02696742	chr7:106810147	HBP1	-0.68	-5.2	-0.42	8.03e-7	Osteoarthritis;
TGCT	cis	rs9303401	0.659	rs35539277	chr17:56853833	G/A	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg13342137	chr4:2252803	MXD4	-0.17	-4.44	-0.37	2e-5	Obesity-related traits;
TGCT	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg06634786	chr22:41940651	POLR3H	0.87	8.2	0.59	2.56e-13	Vitiligo;
TGCT	cis	rs1783925	0.881	rs643446	chr11:125306472	T/C	cg03464685	chr11:125439445	EI24	-0.6	-5.04	-0.41	1.63e-6	Formal thought disorder in schizophrenia;
TGCT	cis	rs208520	0.560	rs2351880	chr6:66863707	G/A	cg07460842	chr6:66804631	NA	-0.92	-9.58	-0.65	1.29e-16	Exhaled nitric oxide output;
TGCT	cis	rs12210905	1.000	rs9348758	chr6:27255238	T/G	cg08851530	chr6:28072375	NA	1.29	5.49	0.44	2.19e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs7208859	0.623	rs34756112	chr17:29113016	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs4253772	0.678	rs9627281	chr22:46644168	A/G	cg09491104	chr22:46646882	C22orf40	-0.5	-5.35	-0.43	4.04e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs6815814	0.847	rs11725309	chr4:38783848	T/C	cg02016764	chr4:38805732	TLR1	-0.36	-5.54	-0.45	1.71e-7	Breast cancer;
TGCT	cis	rs149866169	1	rs149866169	chr6:27441723	T/A	cg26587870	chr6:27730563	NA	-0.47	-4.49	-0.37	1.6e-5	Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Subjective well-being (multi-trait analysis);Lung cancer;Squamous cell lung carcinoma;
TGCT	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg03517284	chr6:25882590	NA	0.64	5.8	0.46	5.28e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	-0.51	-5.37	-0.43	3.71e-7	Menopause (age at onset);
TGCT	cis	rs6088580	0.634	rs6087580	chr20:32992592	A/G	cg06115741	chr20:33292138	TP53INP2	-0.52	-4.52	-0.38	1.44e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs9302065	0.595	rs1547746	chr13:95964267	G/A	cg24476569	chr13:95954382	ABCC4	-0.48	-6.93	-0.53	2.08e-10	Blood metabolite levels;
TGCT	cis	rs2836633	0.965	rs2836621	chr21:40054149	C/T	cg05519781	chr21:40033154	ERG	0.55	5.48	0.44	2.24e-7	Coronary artery disease;
TGCT	cis	rs76878669	0.538	rs1546358	chr11:66175261	G/C	cg18002602	chr11:66138449	SLC29A2	0.53	6.41	0.5	2.75e-9	Educational attainment (years of education);
TGCT	cis	rs6484504	0.576	rs11031324	chr11:31250299	T/C	cg14844989	chr11:31128820	NA	-0.25	-4.88	-0.4	3.24e-6	Red blood cell count;
TGCT	cis	rs35000415	0.938	rs71581958	chr7:128665542	C/T	cg06242719	chr7:129414860	MIR183;MIR96	-0.31	-4.52	-0.38	1.4e-5	Systemic lupus erythematosus;
TGCT	cis	rs950169	0.580	rs1061737	chr15:85183790	G/C	cg11189052	chr15:85197271	WDR73	0.73	6.01	0.47	1.96e-8	Schizophrenia;
TGCT	cis	rs2255336	0.608	rs7957681	chr12:10518822	G/A	cg16084090	chr12:10586130	KLRC2	0.3	4.62	0.38	9.55e-6	Blood protein levels;
TGCT	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.69	4.91	0.4	2.75e-6	Platelet count;
TGCT	cis	rs2180341	0.722	rs9388555	chr6:127576363	G/A	cg27446573	chr6:127587934	RNF146	0.98	8.94	0.63	4.63e-15	Breast cancer;
TGCT	cis	rs2439831	0.764	rs12324584	chr15:43683446	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	8.14	0.59	3.58e-13	Lung cancer in ever smokers;
TGCT	trans	rs524675	0.581	rs527273	chr4:13957156	G/A	cg02315626	chr17:27188560	MIR451;MIR144	0.42	6.87	0.53	2.82e-10	Amyotrophic lateral sclerosis in C9orf72 mutation negative individuals;
TGCT	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.34	0.43	4.23e-7	Prudent dietary pattern;
TGCT	cis	rs909674	0.734	rs5757675	chr22:39838892	G/T	cg02038168	chr22:39784481	NA	-0.71	-5.56	-0.45	1.55e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs877282	0.898	rs11253338	chr10:759559	C/T	cg17470449	chr10:769945	NA	0.33	4.85	0.4	3.58e-6	Uric acid levels;
TGCT	cis	rs9467773	0.869	rs9295689	chr6:26455811	T/C	cg15659132	chr6:26577336	NA	0.61	6.86	0.52	2.96e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs2153535	0.541	rs9379207	chr6:8458186	C/T	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs9818758	0.505	rs11716159	chr3:49631585	G/A	cg07636037	chr3:49044803	WDR6	-0.98	-4.72	-0.39	6.18e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs6683383	1.000	rs722915	chr1:203087657	C/T	cg04395153	chr1:203052423	MYOG	-0.27	-4.48	-0.37	1.66e-5	Asthma;
TGCT	cis	rs12220238	1.000	rs10824102	chr10:75948915	C/A	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.06	0.54	1.05e-10	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs3099143	1.000	rs35645941	chr15:77140302	C/T	cg21673338	chr15:77095150	SCAPER	-0.52	-5.05	-0.41	1.54e-6	Recalcitrant atopic dermatitis;
TGCT	cis	rs6582630	0.576	rs2222345	chr12:38356020	G/A	cg26384229	chr12:38710491	ALG10B	-0.53	-4.66	-0.39	8.04e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg08048268	chr3:133502702	NA	-0.53	-7.17	-0.54	5.89e-11	Iron status biomarkers;
TGCT	cis	rs854765	0.583	rs4413022	chr17:17858280	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	7.69	0.57	3.98e-12	Total body bone mineral density;
TGCT	cis	rs514406	0.505	rs269286	chr1:53169018	C/T	cg24675658	chr1:53192096	ZYG11B	0.77	8.88	0.62	6.42e-15	Monocyte count;
TGCT	cis	rs2072499	0.833	rs2251636	chr1:156202809	G/C	cg25208724	chr1:156163844	SLC25A44	0.96	12.22	0.74	4.94e-23	Testicular germ cell tumor;
TGCT	cis	rs6087990	0.735	rs2424906	chr20:31359109	A/G	cg13636640	chr20:31349939	DNMT3B	0.95	12.44	0.75	1.49e-23	Ulcerative colitis;
TGCT	cis	rs288326	0.561	rs41270217	chr2:183850877	C/T	cg09997497	chr2:183902928	NCKAP1	1.11	4.95	0.41	2.38e-6	Blood protein levels;
TGCT	cis	rs782590	0.807	rs782572	chr2:55912120	T/C	cg03859395	chr2:55845619	SMEK2	0.82	9.59	0.65	1.27e-16	Metabolic syndrome;
TGCT	cis	rs9948	0.786	rs56797569	chr2:97413555	G/T	cg01990225	chr2:97406019	LMAN2L	-0.88	-4.81	-0.4	4.37e-6	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs7552404	0.731	rs10873787	chr1:76367797	G/A	cg22875332	chr1:76189707	ACADM	0.7	6.84	0.52	3.26e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg20637647	chr7:64974828	NA	1.0	5.59	0.45	1.4e-7	Diabetic kidney disease;
TGCT	cis	rs11711311	1.000	rs12637067	chr3:113527606	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.76	-7.16	-0.54	6.29e-11	IgG glycosylation;
TGCT	cis	rs4389656	0.695	rs1532333	chr5:6770502	C/T	cg12187999	chr5:6845652	NA	-0.34	-4.78	-0.39	4.94e-6	Coronary artery disease;
TGCT	cis	rs7659604	0.702	rs6826506	chr4:122710865	T/G	cg19748678	chr4:122722346	EXOSC9	0.9	9.48	0.65	2.3e-16	Type 2 diabetes;
TGCT	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg08736216	chr1:53307985	ZYG11A	-0.24	-4.74	-0.39	5.75e-6	Monocyte count;
TGCT	cis	rs1153858	1.000	rs12101539	chr15:45650666	C/G	cg26924012	chr15:45694286	SPATA5L1	1.09	15.16	0.81	5.15e-30	Homoarginine levels;
TGCT	cis	rs877282	0.842	rs7092986	chr10:756373	G/A	cg17470449	chr10:769945	NA	0.32	4.91	0.4	2.76e-6	Uric acid levels;
TGCT	cis	rs3091242	0.933	rs9645452	chr1:25668326	C/T	cg09222892	chr1:25734099	RHCE	0.44	7.1	0.54	8.59e-11	Erythrocyte sedimentation rate;
TGCT	cis	rs3782455	1.000	rs78363483	chr12:114401643	T/C	cg10631684	chr12:113795897	PLBD2	-0.7	-4.61	-0.38	1e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs6570726	0.967	rs450973	chr6:145863065	C/A	cg05347473	chr6:146136440	FBXO30	0.5	4.44	0.37	1.99e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs651907	0.535	rs34063583	chr3:101509948	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.31	-6.4	-0.5	2.91e-9	Colorectal cancer;
TGCT	cis	rs67311347	0.869	rs9832311	chr3:40381322	A/T	cg13683864	chr3:40499215	RPL14	-1.11	-11.84	-0.73	4.15e-22	Renal cell carcinoma;
TGCT	cis	rs7819412	0.875	rs6981523	chr8:11061792	C/T	cg27411982	chr8:10470053	RP1L1	-0.2	-4.46	-0.37	1.84e-5	Triglycerides;
TGCT	cis	rs7611238	0.560	rs1994881	chr3:195140441	T/C	cg27323046	chr3:195102265	ACAP2	0.37	4.97	0.41	2.19e-6	Body mass index;
TGCT	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg03517284	chr6:25882590	NA	-0.62	-6.45	-0.5	2.23e-9	Blood metabolite levels;
TGCT	cis	rs7119	0.635	rs907374	chr15:77884026	C/T	cg27398640	chr15:77910606	LINGO1	0.33	6.9	0.53	2.37e-10	Type 2 diabetes;
TGCT	cis	rs2439831	1.000	rs527921	chr15:43770416	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.82	-5.29	-0.43	5.3e-7	Lung cancer in ever smokers;
TGCT	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg21226059	chr5:178986404	RUFY1	0.51	5.4	0.44	3.2e-7	Lung cancer;
TGCT	cis	rs7617773	0.817	rs3731534	chr3:48211777	C/T	cg11946769	chr3:48343235	NME6	0.76	6.67	0.51	7.6e-10	Coronary artery disease;
TGCT	trans	rs10203711	1.000	rs907108	chr2:239566285	T/C	cg16021909	chr1:248021091	TRIM58	-0.66	-6.64	-0.51	8.76e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs8028182	0.636	rs8030802	chr15:75813153	A/G	cg20655648	chr15:75932815	IMP3	0.59	4.62	0.38	9.55e-6	Sudden cardiac arrest;
TGCT	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg22029157	chr1:209979665	IRF6	0.76	6.24	0.49	6.3e-9	Cleft lip with or without cleft palate;
TGCT	cis	rs9348729	1	rs9348729	chr6:26664268	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.61	-4.95	-0.41	2.33e-6	Intelligence (multi-trait analysis);
TGCT	trans	rs877282	0.945	rs12767287	chr10:787310	A/G	cg22713356	chr15:30763199	NA	1.16	10.26	0.68	3.01e-18	Uric acid levels;
TGCT	cis	rs2046867	0.908	rs62251639	chr3:72801214	G/A	cg25664220	chr3:72788482	NA	-0.56	-7.03	-0.53	1.25e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9467711	1.000	rs9467707	chr6:26327905	G/C	cg26531700	chr6:26746687	NA	-0.94	-5.09	-0.42	1.28e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7017914	0.967	rs10089583	chr8:71849484	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.52	-4.81	-0.4	4.3e-6	Bone mineral density;
TGCT	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg08280861	chr8:58055591	NA	0.4	4.73	0.39	5.97e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs986417	1.000	rs2350900	chr14:60938681	T/A	cg27398547	chr14:60952738	C14orf39	1.31	8.57	0.61	3.4e-14	Gut microbiota (bacterial taxa);
TGCT	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg25036284	chr2:26402008	FAM59B	0.65	5.19	0.42	8.36e-7	Gut microbiome composition (summer);
TGCT	cis	rs704	0.628	rs1128162	chr17:26721791	C/A	cg10342447	chr17:26645325	TMEM97	-0.47	-4.69	-0.39	7.21e-6	Osteoprotegerin levels;
TGCT	cis	rs3733585	0.624	rs7376154	chr4:9952587	C/A	cg00071950	chr4:10020882	SLC2A9	-0.55	-6.63	-0.51	9.3e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	trans	rs3780486	0.757	rs10758189	chr9:33125804	A/G	cg20290983	chr6:43655470	MRPS18A	1.15	14.06	0.78	1.98e-27	IgG glycosylation;
TGCT	cis	rs73058052	0.530	rs10421333	chr19:50086080	A/G	cg09250473	chr19:50168907	IRF3;BCL2L12	0.65	5.22	0.42	7.36e-7	Fibrinogen levels;
TGCT	cis	rs514406	0.505	rs427319	chr1:53178807	T/G	cg16325326	chr1:53192061	ZYG11B	0.85	12.13	0.74	8.13e-23	Monocyte count;
TGCT	cis	rs6540559	0.673	rs41305104	chr1:209950848	G/A	cg23283495	chr1:209979779	IRF6	0.63	4.7	0.39	6.71e-6	Cleft lip with or without cleft palate;
TGCT	trans	rs1814175	0.817	rs6486046	chr11:49997017	T/C	cg15704280	chr7:45808275	SEPT13	-0.73	-8.48	-0.61	5.58e-14	Height;
TGCT	cis	rs6969780	0.722	rs3823764	chr7:27187753	C/T	cg07317062	chr7:27170388	HOXA4	-0.44	-4.62	-0.38	9.57e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs7833790	0.724	rs10958045	chr8:82722994	T/C	cg06027949	chr8:82754900	SNX16	-0.65	-5.03	-0.41	1.69e-6	Diastolic blood pressure;
TGCT	cis	rs61776719	0.520	rs12569027	chr1:38449163	C/T	cg26398791	chr1:38455867	SF3A3	-0.47	-4.56	-0.38	1.19e-5	Coronary artery disease;
TGCT	cis	rs7582180	0.614	rs10193204	chr2:101004540	A/G	cg08017756	chr2:100939284	LONRF2	0.28	4.53	0.38	1.37e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs9790314	0.586	rs11710086	chr3:161125858	A/T	cg03342759	chr3:160939853	NMD3	-0.55	-5.7	-0.46	8.15e-8	Morning vs. evening chronotype;
TGCT	cis	rs4566357	0.615	rs10178098	chr2:227914425	C/T	cg11843606	chr2:227700838	RHBDD1	-0.54	-5.25	-0.43	6.53e-7	Coronary artery disease;
TGCT	cis	rs7772486	0.720	rs1890171	chr6:146072114	T/C	cg23711669	chr6:146136114	FBXO30	-0.97	-11.03	-0.7	4.03e-20	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1075232	0.522	rs57924788	chr15:31749722	G/A	cg01030201	chr15:31746330	NA	-0.65	-4.46	-0.37	1.85e-5	Survival in colorectal cancer (non-distant metastatic);
TGCT	cis	rs2739330	0.615	rs2858911	chr22:24297195	G/T	cg25703541	chr22:24373054	LOC391322	-0.81	-8.7	-0.62	1.68e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7172809	0.599	rs17471753	chr15:77763809	C/T	cg22256960	chr15:77711686	NA	-0.51	-4.86	-0.4	3.47e-6	Glucose homeostasis traits;
TGCT	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.07	-9.63	-0.65	1.01e-16	Platelet count;
TGCT	cis	rs6484504	0.576	rs11031323	chr11:31245413	T/G	cg26647111	chr11:31128758	NA	-0.34	-4.73	-0.39	5.88e-6	Red blood cell count;
TGCT	cis	rs17826219	0.706	rs9893922	chr17:29068425	T/C	cg14008862	chr17:28927542	LRRC37B2	0.76	4.52	0.38	1.42e-5	Body mass index;
TGCT	cis	rs6912958	1.000	rs2207144	chr6:88150816	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.37	-4.74	-0.39	5.79e-6	Monocyte percentage of white cells;
TGCT	cis	rs6964587	0.610	rs6942852	chr7:91437883	A/C	cg17063962	chr7:91808500	NA	0.73	6.71	0.52	6.06e-10	Breast cancer;
TGCT	cis	rs295140	1.000	rs7584810	chr2:201167772	G/A	cg04283868	chr2:201171347	SPATS2L	0.63	6.43	0.5	2.46e-9	QT interval;
TGCT	cis	rs7412746	0.658	rs12097963	chr1:150870450	T/C	cg09365446	chr1:150670422	GOLPH3L	0.34	4.71	0.39	6.58e-6	Melanoma;
TGCT	trans	rs3780486	0.846	rs10813950	chr9:33127640	A/G	cg04842962	chr6:43655489	MRPS18A	-1.11	-9.81	-0.66	3.67e-17	IgG glycosylation;
TGCT	cis	rs453301	0.686	rs1045527	chr8:8890041	A/G	cg11995313	chr8:8860691	ERI1	0.5	4.5	0.37	1.56e-5	Joint mobility (Beighton score);
TGCT	cis	rs2594989	0.887	rs2454498	chr3:11500953	A/G	cg00170343	chr3:11313890	ATG7	0.69	5.12	0.42	1.16e-6	Circulating chemerin levels;
TGCT	cis	rs11997175	0.574	rs4538830	chr8:33653741	C/G	ch.8.33884649F	chr8:33765107	NA	0.28	4.54	0.38	1.33e-5	Body mass index;
TGCT	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg03303774	chr4:1407052	NA	0.27	4.56	0.38	1.2e-5	Obesity-related traits;
TGCT	cis	rs4851254	0.660	rs1821830	chr2:100680279	C/T	cg07810366	chr2:100720526	AFF3	-0.49	-5.22	-0.42	7.36e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7635838	0.653	rs2606749	chr3:11373635	A/G	cg00170343	chr3:11313890	ATG7	0.62	6.09	0.48	1.29e-8	HDL cholesterol;
TGCT	cis	rs1008375	0.932	rs12500947	chr4:17603424	C/T	cg10189774	chr4:17578691	LAP3	0.67	5.69	0.45	8.77e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10791097	0.720	rs6590515	chr11:130733365	A/G	cg12179176	chr11:130786555	SNX19	-0.84	-10.73	-0.69	2.18e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs3741151	0.892	rs7125949	chr11:73009084	G/A	cg17517138	chr11:73019481	ARHGEF17	0.93	5.04	0.41	1.59e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
TGCT	cis	rs11741688	0.597	rs6880072	chr5:178334480	G/C	cg09339527	chr5:178322752	ZFP2	-0.29	-4.85	-0.4	3.57e-6	Sleep duration;
TGCT	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg00684032	chr4:1343700	KIAA1530	0.24	5.14	0.42	1.05e-6	Obesity-related traits;
TGCT	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg11764359	chr7:65958608	NA	-0.6	-5.47	-0.44	2.43e-7	Aortic root size;
TGCT	cis	rs6998277	0.830	rs6468838	chr8:103609336	T/C	cg10187029	chr8:103597600	NA	0.56	8.82	0.62	8.69e-15	Migraine;
TGCT	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.08	0.48	1.37e-8	Bipolar disorder;
TGCT	cis	rs6969780	0.915	rs886339	chr7:27190670	A/C	cg04321618	chr7:27170880	HOXA4	-0.52	-4.5	-0.38	1.51e-5	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs601339	1.000	rs525215	chr12:123179771	G/A	cg11919336	chr12:123188078	GPR109A	0.64	7.86	0.58	1.61e-12	Adiponectin levels;
TGCT	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	5.38	0.44	3.58e-7	Alzheimer's disease;
TGCT	cis	rs6933660	0.720	rs6914656	chr6:151753421	C/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.88	-9.67	-0.66	8.12e-17	Menarche (age at onset);
TGCT	cis	rs13191362	0.507	rs2846536	chr6:163033492	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.59	5.98	0.47	2.21e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs6456156	0.526	rs3093025	chr6:167532731	A/G	cg07741184	chr6:167504864	NA	-0.23	-4.66	-0.39	7.98e-6	Primary biliary cholangitis;
TGCT	cis	rs2228479	0.717	rs17233678	chr16:89809962	T/C	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	7.12	0.54	7.55e-11	Platelet count;
TGCT	cis	rs6141769	0.542	rs7360824	chr20:31315158	A/G	cg13636640	chr20:31349939	DNMT3B	-0.51	-4.48	-0.37	1.68e-5	Subjective well-being;
TGCT	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg20999797	chr1:1681921	NA	0.18	4.66	0.39	7.9e-6	Body mass index;
TGCT	cis	rs73198271	0.710	rs11779565	chr8:8680020	G/A	cg06671706	chr8:8559999	CLDN23	-0.35	-4.46	-0.37	1.84e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs57590327	0.503	rs2372905	chr3:81504592	C/G	cg07356753	chr3:81810745	GBE1	0.58	4.89	0.4	3.06e-6	Extraversion;
TGCT	cis	rs7666738	0.962	rs13147921	chr4:99069296	C/G	cg17366294	chr4:99064904	C4orf37	0.76	6.63	0.51	9.04e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg03407747	chr17:6899364	ALOX12	0.53	5.72	0.46	7.68e-8	Tonsillectomy;
TGCT	cis	rs854765	0.663	rs3744115	chr17:17749822	G/A	cg09796270	chr17:17721594	SREBF1	-0.3	-5.86	-0.47	3.85e-8	Total body bone mineral density;
TGCT	cis	rs1023500	0.573	rs8135801	chr22:42475568	A/G	cg05082376	chr22:42548792	NA	0.23	5.43	0.44	2.83e-7	Schizophrenia;
TGCT	cis	rs60843830	0.964	rs7584915	chr2:264227	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.75	7.57	0.56	7.28e-12	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs3806843	0.548	rs246057	chr5:140325583	A/G	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	trans	rs11088226	0.681	rs1015047	chr21:33949423	A/G	cg09050820	chr6:167586206	TCP10L2	0.74	7.3	0.55	2.96e-11	Gastritis;
TGCT	cis	rs7635838	0.819	rs2454478	chr3:11541885	A/G	cg00170343	chr3:11313890	ATG7	0.67	6.26	0.49	5.88e-9	HDL cholesterol;
TGCT	cis	rs9653442	0.564	rs2164711	chr2:100775422	G/T	cg07810366	chr2:100720526	AFF3	-0.34	-5.13	-0.42	1.1e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg01516881	chr6:292596	DUSP22	-0.71	-7.45	-0.56	1.35e-11	Menopause (age at onset);
TGCT	cis	rs6831352	0.918	rs29001224	chr4:100047373	G/A	cg12011299	chr4:100065546	ADH4	-0.41	-4.92	-0.4	2.72e-6	Alcohol dependence;
TGCT	cis	rs6582630	0.555	rs11182202	chr12:38476451	C/G	cg26384229	chr12:38710491	ALG10B	0.83	7.6	0.56	6.18e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs736408	0.608	rs4687657	chr3:52852538	G/T	cg11645453	chr3:52864694	ITIH4	0.31	5.34	0.43	4.24e-7	Bipolar disorder;
TGCT	cis	rs2786098	0.577	rs10922305	chr1:197821769	C/T	cg00114966	chr1:197893920	LHX9	-0.38	-4.62	-0.38	9.54e-6	Asthma;
TGCT	cis	rs9291683	0.669	rs887733	chr4:10183108	T/C	cg11266682	chr4:10021025	SLC2A9	-0.45	-4.95	-0.41	2.36e-6	Bone mineral density;
TGCT	cis	rs1008375	1.000	rs1008375	chr4:17682834	T/C	cg16339924	chr4:17578868	LAP3	0.53	4.69	0.39	7.15e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	trans	rs1005277	0.505	rs200910	chr10:38108176	C/T	cg17830980	chr10:43048298	ZNF37B	-0.72	-8.22	-0.59	2.27e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs9443189	0.570	rs7770824	chr6:76408189	G/A	cg01950844	chr6:76311363	SENP6	1.0	6.24	0.49	6.35e-9	Prostate cancer;
TGCT	cis	rs11748023	0.605	rs155949	chr5:139523684	A/G	cg01081189	chr5:139537190	NA	0.26	4.62	0.38	9.47e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	8.13	0.59	3.82e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg11764359	chr7:65958608	NA	0.61	5.53	0.44	1.79e-7	Aortic root size;
TGCT	cis	rs7666738	0.830	rs7687958	chr4:99014495	T/C	cg18180107	chr4:99064573	C4orf37	0.54	5.03	0.41	1.7e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4819052	0.679	rs4819053	chr21:46711357	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.61	-5.89	-0.47	3.45e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs1568889	1.000	rs7937117	chr11:28370038	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	7.92	0.58	1.13e-12	Bipolar disorder;
TGCT	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg06221963	chr1:154839813	KCNN3	0.8	15.27	0.81	2.9e-30	Prostate cancer;
TGCT	cis	rs9942416	0.660	rs2047059	chr5:75008193	T/C	cg02573091	chr5:74908125	NA	0.44	4.95	0.41	2.4e-6	Age-related disease endophenotypes;
TGCT	cis	rs12497850	0.897	rs6795025	chr3:49081247	T/C	cg07636037	chr3:49044803	WDR6	0.97	10.64	0.69	3.45e-19	Parkinson's disease;
TGCT	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg03264133	chr6:25882463	NA	-0.66	-6.03	-0.48	1.76e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9581857	0.547	rs17753121	chr13:28052613	T/C	cg22138327	chr13:27999177	GTF3A	0.74	4.82	0.4	4.15e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs35160687	0.798	rs11127029	chr2:86554625	C/G	cg03171300	chr2:86307199	POLR1A	-0.27	-4.59	-0.38	1.07e-5	Night sleep phenotypes;
TGCT	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg10862848	chr6:42927986	GNMT	0.38	4.72	0.39	6.35e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs8016982	0.662	rs9806020	chr14:81668555	A/C	cg01989461	chr14:81687754	GTF2A1	0.62	4.65	0.39	8.47e-6	Schizophrenia;
TGCT	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg18402987	chr7:1209562	NA	0.47	4.69	0.39	7.03e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9972944	0.899	rs9972954	chr17:63771050	T/C	cg07283582	chr17:63770753	CCDC46	0.28	5.89	0.47	3.36e-8	Total body bone mineral density;
TGCT	cis	rs7666738	0.830	rs11097605	chr4:98985167	T/C	cg18180107	chr4:99064573	C4orf37	0.53	4.89	0.4	3.01e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs644799	0.965	rs11021317	chr11:95517576	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	11.08	0.71	2.9e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs6912958	0.535	rs1753154	chr6:88032843	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.43	5.57	0.45	1.51e-7	Monocyte percentage of white cells;
TGCT	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.36	-4.45	-0.37	1.9e-5	Total body bone mineral density;
TGCT	cis	rs9926296	0.744	rs154656	chr16:89708003	T/A	cg01097406	chr16:89675127	NA	0.35	6.22	0.49	6.81e-9	Vitiligo;
TGCT	cis	rs9733	0.569	rs11588404	chr1:150688529	C/A	cg04414720	chr1:150670196	GOLPH3L	0.37	4.91	0.4	2.76e-6	Tonsillectomy;
TGCT	cis	rs9858542	0.953	rs9837341	chr3:49664767	A/G	cg03060546	chr3:49711283	APEH	-0.65	-5.72	-0.46	7.7e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs7845219	0.544	rs6987400	chr8:95921295	T/C	cg13393036	chr8:95962371	TP53INP1	-0.44	-5.14	-0.42	1.05e-6	Type 2 diabetes;
TGCT	cis	rs75229567	0.618	rs11495622	chr12:70161286	G/A	cg10114359	chr12:70132523	RAB3IP	1.35	6.71	0.52	6.17e-10	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
TGCT	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg06212747	chr3:49208901	KLHDC8B	0.6	5.44	0.44	2.75e-7	Parkinson's disease;
TGCT	cis	rs7945705	0.783	rs11042125	chr11:8938049	A/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.45	-5.16	-0.42	9.67e-7	Hemoglobin concentration;
TGCT	cis	rs7726839	0.794	rs11739663	chr5:594083	A/G	cg09021430	chr5:549028	NA	-0.41	-5.87	-0.47	3.65e-8	Obesity-related traits;
TGCT	cis	rs9611565	0.729	rs169362	chr22:41827589	G/C	cg06634786	chr22:41940651	POLR3H	0.81	7.71	0.57	3.43e-12	Vitiligo;
TGCT	cis	rs35306767	0.855	rs11253468	chr10:903261	G/A	cg26597838	chr10:835615	NA	0.75	10.61	0.69	4.13e-19	Eosinophil percentage of granulocytes;
TGCT	cis	rs988712	0.672	rs16917237	chr11:27702383	A/C	cg10635145	chr11:27742435	BDNF	0.42	5.7	0.46	8.44e-8	Obesity;
TGCT	cis	rs951366	0.870	rs3747973	chr1:205677148	A/G	cg24503407	chr1:205819492	PM20D1	0.43	5.08	0.42	1.34e-6	Menarche (age at onset);
TGCT	trans	rs208520	0.586	rs208442	chr6:66900618	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.74	-7.75	-0.57	2.86e-12	Exhaled nitric oxide output;
TGCT	cis	rs17376456	0.569	rs6895356	chr5:93060781	A/G	cg21475434	chr5:93447410	FAM172A	0.65	5.42	0.44	2.93e-7	Diabetic retinopathy;
TGCT	cis	rs7666738	0.830	rs2865949	chr4:99039967	A/G	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg23505145	chr19:12996616	KLF1	0.78	8.12	0.59	4.03e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9583531	0.891	rs61969072	chr13:111380701	T/G	cg24331049	chr13:111365604	ING1	-0.76	-5.34	-0.43	4.34e-7	Coronary artery disease;
TGCT	cis	rs910316	0.763	rs13712	chr14:75483812	T/C	cg08847533	chr14:75593920	NEK9	0.84	9.12	0.63	1.69e-15	Height;
TGCT	cis	rs9325144	0.505	rs6582691	chr12:38806894	T/C	cg13010199	chr12:38710504	ALG10B	-0.65	-5.48	-0.44	2.26e-7	Morning vs. evening chronotype;
TGCT	cis	rs56104184	0.690	rs56312501	chr19:49395933	T/C	cg21252483	chr19:49399788	TULP2	-0.28	-4.46	-0.37	1.8e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs12477438	0.798	rs6740035	chr2:99576578	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-6.25	-0.49	5.98e-9	Chronic sinus infection;
TGCT	cis	rs4699052	0.928	rs10516502	chr4:104214616	A/G	cg16532752	chr4:104119610	CENPE	-0.53	-4.8	-0.4	4.42e-6	Testicular germ cell tumor;
TGCT	cis	rs453301	0.658	rs6986044	chr8:8874786	G/C	cg15556689	chr8:8085844	FLJ10661	-0.61	-5.05	-0.41	1.52e-6	Joint mobility (Beighton score);
TGCT	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg24829409	chr8:58192753	C8orf71	-0.51	-4.93	-0.41	2.54e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs775227	0.574	rs34049435	chr3:113099499	C/T	cg18753928	chr3:113234510	CCDC52	-0.64	-4.67	-0.39	7.75e-6	Dental caries;
TGCT	cis	rs78487399	0.731	rs13395302	chr2:43706350	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.42	-5.37	-0.43	3.75e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg11941060	chr3:133502564	NA	-0.29	-6.14	-0.48	1.02e-8	Iron status biomarkers;
TGCT	cis	rs4953076	0.573	rs9973609	chr2:44450435	T/C	cg00619915	chr2:44497795	NA	-0.23	-5.08	-0.41	1.36e-6	Height;
TGCT	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	6.75	0.52	5.18e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs11249608	0.636	rs13359572	chr5:178449276	T/C	cg01312482	chr5:178451176	ZNF879	-0.58	-5.77	-0.46	5.94e-8	Pubertal anthropometrics;
TGCT	cis	rs8177253	0.555	rs4481157	chr3:133464684	G/A	cg24879335	chr3:133465180	TF	0.36	4.72	0.39	6.19e-6	Iron status biomarkers;
TGCT	cis	rs3858526	0.959	rs11039540	chr11:5928334	C/T	cg05234568	chr11:5960015	NA	-0.44	-4.6	-0.38	1.03e-5	DNA methylation (variation);
TGCT	cis	rs1153858	1.000	rs1288775	chr15:45661678	T/A	cg26924012	chr15:45694286	SPATA5L1	0.99	12.23	0.74	4.74e-23	Homoarginine levels;
TGCT	cis	rs1865760	1.000	rs9393675	chr6:25930116	G/A	cg17042849	chr6:26104293	HIST1H4C	-0.5	-4.44	-0.37	2e-5	Height;
TGCT	cis	rs3849570	0.615	rs6766011	chr3:81986136	G/A	cg07356753	chr3:81810745	GBE1	-0.62	-5.43	-0.44	2.82e-7	Waist circumference;Body mass index;
TGCT	cis	rs35934224	0.724	rs16984286	chr22:19858114	A/G	cg11182965	chr22:19864308	TXNRD2	-0.38	-5.22	-0.42	7.16e-7	Glaucoma (primary open-angle);
TGCT	cis	rs78456975	0.568	rs115482599	chr2:1571960	A/G	cg12573674	chr2:1569213	NA	-0.48	-5.13	-0.42	1.1e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg20637647	chr7:64974828	NA	0.92	5.36	0.43	3.87e-7	Diabetic kidney disease;
TGCT	cis	rs2832191	0.791	rs2832181	chr21:30481371	G/T	cg24692254	chr21:30365293	RNF160	-0.95	-10.52	-0.69	7.06e-19	Dental caries;
TGCT	cis	rs13064411	0.696	rs9860549	chr3:113148368	G/A	cg18753928	chr3:113234510	CCDC52	-0.67	-5.12	-0.42	1.14e-6	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs3096299	0.728	rs1011749	chr16:89510869	G/C	cg06640241	chr16:89574553	SPG7	0.77	8.61	0.61	2.82e-14	Multiple myeloma (IgH translocation);
TGCT	cis	rs9467711	0.606	rs9379852	chr6:26357278	A/G	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9309473	0.687	rs6706235	chr2:73613558	C/G	cg20560298	chr2:73613845	ALMS1	-0.48	-5.39	-0.44	3.36e-7	Metabolite levels;
TGCT	cis	rs67311347	0.910	rs7651204	chr3:40512835	C/T	cg17264618	chr3:40429014	ENTPD3	-0.32	-4.64	-0.38	8.57e-6	Renal cell carcinoma;
TGCT	cis	rs9611565	0.729	rs203319	chr22:41914593	C/T	cg06481639	chr22:41940642	POLR3H	-0.63	-5.74	-0.46	6.81e-8	Vitiligo;
TGCT	cis	rs10972341	1.000	rs10972341	chr9:35141705	C/T	cg00812861	chr9:35114699	KIAA1539	-0.3	-4.46	-0.37	1.79e-5	Weight;
TGCT	cis	rs9611565	0.512	rs715498	chr22:42148467	G/A	cg13695892	chr22:41940480	POLR3H	0.85	8.06	0.59	5.4e-13	Vitiligo;
TGCT	cis	rs651907	0.535	rs1460097	chr3:101497569	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	4.86	0.4	3.51e-6	Colorectal cancer;
TGCT	cis	rs9611565	0.512	rs8141103	chr22:42136930	T/C	cg13695892	chr22:41940480	POLR3H	0.89	8.43	0.6	7.37e-14	Vitiligo;
TGCT	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs12048904	0.541	rs1571046	chr1:101299216	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.82	7.43	0.56	1.5e-11	Multiple sclerosis;
TGCT	cis	rs6690583	0.562	rs11588919	chr1:85442813	A/T	cg20280350	chr1:85513789	MCOLN3	-0.69	-4.48	-0.37	1.68e-5	Serum sulfate level;
TGCT	trans	rs3780486	0.846	rs6476402	chr9:33148552	G/A	cg04842962	chr6:43655489	MRPS18A	1.18	14.79	0.8	3.8e-29	IgG glycosylation;
TGCT	cis	rs10883723	0.775	rs2296579	chr10:104241375	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs35306767	0.903	rs11812523	chr10:915638	C/T	cg26597838	chr10:835615	NA	0.75	10.54	0.69	6.3e-19	Eosinophil percentage of granulocytes;
TGCT	cis	rs7589728	0.514	rs78204719	chr2:88460747	G/C	cg04511125	chr2:88470314	THNSL2	0.72	5.94	0.47	2.71e-8	Plasma clusterin levels;
TGCT	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.55	-5.66	-0.45	1e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs4953076	0.573	rs9973609	chr2:44450435	T/C	cg04920474	chr2:44395004	PPM1B	0.6	6.02	0.48	1.81e-8	Height;
TGCT	cis	rs9443645	0.901	rs9448596	chr6:79629429	T/C	cg05283184	chr6:79620031	NA	-0.21	-4.71	-0.39	6.61e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6714788	0.503	rs1370356	chr2:100675241	G/C	cg07810366	chr2:100720526	AFF3	-0.39	-5.57	-0.45	1.54e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9527	0.535	rs4917999	chr10:104963051	C/G	cg04362960	chr10:104952993	NT5C2	-0.73	-6.12	-0.48	1.11e-8	Arsenic metabolism;
TGCT	cis	rs7267979	1.000	rs6115168	chr20:25372891	C/A	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2455799	0.613	rs2654654	chr3:15789242	C/T	cg16303742	chr3:15540471	COLQ	-0.25	-4.88	-0.4	3.18e-6	Mean platelet volume;
TGCT	cis	rs1568889	1.000	rs34337978	chr11:28136746	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	9.0	0.63	3.18e-15	Bipolar disorder;
TGCT	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg11890956	chr21:40555474	PSMG1	-0.72	-6.58	-0.51	1.21e-9	Cognitive function;
TGCT	cis	rs3821902	0.646	rs56359789	chr3:64016911	T/C	cg22134162	chr3:63841271	THOC7	-0.32	-4.73	-0.39	6.09e-6	Breast cancer;
TGCT	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.29	-4.49	-0.37	1.64e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs61884328	0.584	rs74924988	chr11:47279765	G/A	cg13308137	chr11:47528955	CUGBP1	0.42	5.82	0.46	4.68e-8	Total body bone mineral density (age over 60);
TGCT	cis	rs9611519	0.639	rs7290458	chr22:41476337	C/T	cg03806693	chr22:41940476	POLR3H	0.5	4.54	0.38	1.34e-5	Neuroticism;
TGCT	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg24799795	chr11:5959658	NA	0.42	5.19	0.42	8.35e-7	DNA methylation (variation);
TGCT	cis	rs2439831	0.867	rs2412780	chr15:43655794	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	6.61	0.51	1e-9	Lung cancer in ever smokers;
TGCT	cis	rs1008375	0.966	rs4698642	chr4:17679174	A/T	cg18681998	chr4:17616180	MED28	0.88	10.28	0.68	2.7e-18	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs250677	0.687	rs168750	chr5:148446756	A/G	cg18129178	chr5:148520854	ABLIM3	-0.43	-6.29	-0.49	5.05e-9	Breast cancer;
TGCT	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg04944784	chr2:26401820	FAM59B	0.76	6.24	0.49	6.46e-9	Gut microbiome composition (summer);
TGCT	cis	rs9733	0.621	rs6669122	chr1:150591732	A/G	cg13175981	chr1:150552382	MCL1	0.53	6.08	0.48	1.39e-8	Tonsillectomy;
TGCT	cis	rs9611565	0.503	rs5996062	chr22:42167464	C/G	cg03806693	chr22:41940476	POLR3H	1.02	10.49	0.69	7.92e-19	Vitiligo;
TGCT	cis	rs9341808	0.935	rs9343974	chr6:80924645	A/G	cg08355045	chr6:80787529	NA	0.27	4.68	0.39	7.39e-6	Sitting height ratio;
TGCT	cis	rs10823500	0.549	rs10999204	chr10:72007306	G/A	cg04118878	chr10:71993077	PPA1	0.57	5.4	0.44	3.27e-7	Blood protein levels;
TGCT	cis	rs1865760	0.573	rs7450342	chr6:25919480	T/C	cg03264133	chr6:25882463	NA	-0.46	-4.72	-0.39	6.36e-6	Height;
TGCT	cis	rs10838634	1.000	rs9735937	chr11:46809382	G/A	cg18332754	chr11:46939436	LRP4	0.89	4.45	0.37	1.85e-5	Schizophrenia;
TGCT	cis	rs79349575	0.783	rs17635252	chr17:47006950	T/C	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.52	-0.38	1.44e-5	Type 2 diabetes;
TGCT	cis	rs9921192	1.000	rs251733	chr16:4321605	A/T	cg00021532	chr16:4324280	TFAP4	0.84	9.73	0.66	5.68e-17	Prostate-specific antigen levels;
TGCT	cis	rs9399135	0.967	rs11754783	chr6:135347661	T/A	cg24558204	chr6:135376177	HBS1L	0.5	5.0	0.41	1.89e-6	Red blood cell count;
TGCT	cis	rs2070488	0.965	rs4679060	chr3:38536261	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.87	-8.97	-0.63	3.85e-15	Electrocardiographic conduction measures;
TGCT	cis	rs317689	0.690	rs547827	chr12:69669703	G/A	cg14784868	chr12:69753453	YEATS4	0.53	4.51	0.38	1.5e-5	Response to diuretic therapy;
TGCT	cis	rs28595532	0.920	rs114639588	chr4:119736176	T/C	cg21605333	chr4:119757512	SEC24D	1.61	8.95	0.63	4.36e-15	Cannabis dependence symptom count;
TGCT	cis	rs2456568	0.802	rs1395386	chr11:93639331	A/G	cg17595323	chr11:93583763	C11orf90	0.45	6.12	0.48	1.13e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs11105298	0.891	rs12369195	chr12:89934972	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.7	-5.02	-0.41	1.78e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs9905704	0.647	rs12944274	chr17:57041293	C/G	cg12560992	chr17:57184187	TRIM37	-0.58	-5.05	-0.41	1.53e-6	Testicular germ cell tumor;
TGCT	cis	rs7172809	0.574	rs907398	chr15:77772003	G/A	cg22256960	chr15:77711686	NA	-0.51	-4.86	-0.4	3.47e-6	Glucose homeostasis traits;
TGCT	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg11764359	chr7:65958608	NA	0.55	5.08	0.42	1.34e-6	Aortic root size;
TGCT	cis	rs587847	0.895	rs28507799	chr15:37630205	A/G	cg22444584	chr15:37174661	LOC145845	0.31	4.45	0.37	1.91e-5	Intraocular pressure;
TGCT	cis	rs3008870	1.000	rs6673462	chr1:67461857	A/C	cg03991309	chr1:68237761	GNG12	-0.27	-4.53	-0.38	1.36e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs74400468	0.529	rs10128322	chr10:43206700	G/T	cg05525499	chr10:43893015	HNRNPF	-0.73	-4.81	-0.4	4.33e-6	Cannabis dependence symptom count;
TGCT	cis	rs10131894	0.575	rs6574203	chr14:75429846	T/C	cg08847533	chr14:75593920	NEK9	0.67	6.11	0.48	1.17e-8	Coronary artery disease;
TGCT	cis	rs6866344	0.570	rs1079487	chr5:178136005	G/A	cg03877680	chr5:178157825	ZNF354A	0.77	6.65	0.51	8.23e-10	Neutrophil percentage of white cells;
TGCT	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg00149659	chr3:10157352	C3orf10	1.18	7.44	0.56	1.44e-11	Alzheimer's disease;
TGCT	cis	rs1005224	0.927	rs1981899	chr14:76175594	G/A	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.61	-4.91	-0.4	2.79e-6	Large artery stroke;
TGCT	cis	rs9486715	1.000	rs3798297	chr6:97062835	C/T	cg06623918	chr6:96969491	KIAA0776	-1.08	-13.59	-0.77	2.61e-26	Headache;
TGCT	cis	rs2880765	0.835	rs12324277	chr15:86041735	G/A	cg13263323	chr15:86062960	AKAP13	-0.23	-4.82	-0.4	4.1e-6	Coronary artery disease;
TGCT	cis	rs9467603	0.920	rs13213957	chr6:25786226	T/C	cg16898833	chr6:26189333	HIST1H4D	1.34	6.07	0.48	1.47e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9549367	0.707	rs9549353	chr13:113843427	G/A	cg09473364	chr13:112927190	NA	-0.3	-4.6	-0.38	1.01e-5	Platelet distribution width;
TGCT	cis	rs116095464	0.558	rs9687621	chr5:229194	C/T	cg12570787	chr5:219185	SDHA;CCDC127	0.72	4.78	0.39	4.89e-6	Breast cancer;
TGCT	cis	rs7513165	0.935	rs4951316	chr1:204161490	C/T	cg12731349	chr1:204159619	KISS1	-0.49	-5.62	-0.45	1.19e-7	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
TGCT	cis	rs7584330	0.868	rs7569197	chr2:238383073	A/G	cg08992911	chr2:238395768	MLPH	0.64	5.13	0.42	1.07e-6	Prostate cancer;
TGCT	cis	rs9487051	0.676	rs6913093	chr6:109636205	T/C	cg01475377	chr6:109611718	NA	-0.32	-4.86	-0.4	3.54e-6	Reticulocyte fraction of red cells;
TGCT	cis	rs6988636	0.710	rs62521806	chr8:124161054	C/T	cg22384356	chr8:124195192	FAM83A	-0.39	-4.57	-0.38	1.19e-5	Urinary uromodulin levels;
TGCT	cis	rs7959452	0.535	rs11615712	chr12:69619736	A/T	cg11871910	chr12:69753446	YEATS4	-0.62	-6.08	-0.48	1.4e-8	Blood protein levels;
TGCT	cis	rs2153535	0.580	rs6900007	chr6:8474035	C/T	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs7582180	0.629	rs2309796	chr2:100954385	C/T	cg14675211	chr2:100938903	LONRF2	0.53	5.16	0.42	9.36e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs4891159	0.790	rs8087557	chr18:74116848	G/C	cg24786174	chr18:74118243	ZNF516	-0.65	-10.7	-0.69	2.46e-19	Longevity;
TGCT	cis	rs9906944	0.707	rs729003	chr17:47117775	C/T	cg20966754	chr17:47091339	IGF2BP1	-0.45	-5.17	-0.42	9.27e-7	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs7829975	0.577	rs17684466	chr8:8545233	G/A	cg06636001	chr8:8085503	FLJ10661	-0.61	-5.17	-0.42	9.06e-7	Mood instability;
TGCT	cis	rs35146811	0.700	rs4729579	chr7:99780282	C/G	cg04778012	chr7:99775508	STAG3;GPC2	0.35	4.93	0.41	2.55e-6	Coronary artery disease;
TGCT	cis	rs7209700	1.000	rs7209700	chr17:45351118	A/G	cg17185639	chr17:45330862	ITGB3	0.18	4.57	0.38	1.15e-5	IgG glycosylation;
TGCT	cis	rs3806843	0.547	rs246048	chr5:140327900	G/A	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs709400	0.643	rs11621777	chr14:104072090	A/G	cg26031613	chr14:104095156	KLC1	1.15	16.05	0.82	4.72e-32	Body mass index;
TGCT	cis	rs62244186	0.520	rs2372828	chr3:44784949	A/G	cg15687855	chr3:44754131	ZNF502	0.52	6.31	0.49	4.59e-9	Depressive symptoms;
TGCT	cis	rs6089829	0.888	rs4809467	chr20:61671688	A/G	cg02380750	chr20:61661411	NA	0.35	5.68	0.45	9.19e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7940866	0.845	rs10894294	chr11:130830748	G/T	cg12179176	chr11:130786555	SNX19	0.6	4.9	0.4	2.89e-6	Schizophrenia;
TGCT	cis	rs68170813	0.563	rs6979198	chr7:107197694	T/G	cg02696742	chr7:106810147	HBP1	-0.63	-5.19	-0.42	8.46e-7	Coronary artery disease;
TGCT	cis	rs6540559	0.673	rs11805830	chr1:209984969	C/T	cg21951975	chr1:209979733	IRF6	0.69	5.42	0.44	2.99e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs910316	1.000	rs175442	chr14:75603564	T/C	cg08847533	chr14:75593920	NEK9	-0.94	-10.33	-0.68	2.03e-18	Height;
TGCT	cis	rs644799	1.000	rs557079	chr11:95530125	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	8.74	0.62	1.39e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs11098499	0.866	rs72676074	chr4:120359841	A/C	cg09307838	chr4:120376055	NA	0.69	6.63	0.51	9.32e-10	Corneal astigmatism;
TGCT	cis	rs7223966	1.000	rs9891018	chr17:61827856	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	4.68	0.39	7.5e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs2594989	0.779	rs2443702	chr3:11586435	C/T	cg00170343	chr3:11313890	ATG7	-0.68	-5.03	-0.41	1.65e-6	Circulating chemerin levels;
TGCT	cis	rs6840360	1.000	rs1105535	chr4:152605170	A/G	cg17479576	chr4:152424074	FAM160A1	-0.47	-4.87	-0.4	3.28e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg04546413	chr19:29218101	NA	0.73	6.61	0.51	1.02e-9	Methadone dose in opioid dependence;
TGCT	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.08	0.48	1.37e-8	Bipolar disorder;
TGCT	cis	rs72781680	1.000	rs72796359	chr2:24160545	T/C	cg08917208	chr2:24149416	ATAD2B	0.85	5.28	0.43	5.53e-7	Lymphocyte counts;
TGCT	cis	rs7811142	1.000	rs6953107	chr7:100095664	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	8.48	0.61	5.53e-14	Platelet count;
TGCT	cis	rs12477438	0.520	rs1044575	chr2:99812070	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	16.87	0.83	6.81e-34	Chronic sinus infection;
TGCT	cis	rs155076	1.000	rs261404	chr13:21858162	T/G	cg14456004	chr13:21872349	NA	-1.27	-10.27	-0.68	2.79e-18	White matter hyperintensity burden;
TGCT	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs34014631	0.786	rs74348615	chr10:103584682	G/A	cg22630918	chr10:102748988	C10orf2	0.43	4.83	0.4	3.98e-6	Coronary artery calcification;
TGCT	cis	rs9467773	0.620	rs9461276	chr6:26595168	T/C	cg05738196	chr6:26577821	NA	0.88	11.13	0.71	2.26e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs7617773	1.000	rs12496784	chr3:48186267	C/T	cg11946769	chr3:48343235	NME6	-0.61	-5.51	-0.44	2.02e-7	Coronary artery disease;
TGCT	cis	rs9790314	0.543	rs1349352	chr3:161118486	C/T	cg03342759	chr3:160939853	NMD3	-0.55	-5.7	-0.46	8.15e-8	Morning vs. evening chronotype;
TGCT	cis	rs2204008	0.805	rs4589389	chr12:37946120	C/A	cg26384229	chr12:38710491	ALG10B	-0.7	-6.28	-0.49	5.12e-9	Bladder cancer;
TGCT	cis	rs1153858	1.000	rs2461702	chr15:45647427	A/G	cg14582100	chr15:45693742	SPATA5L1	0.48	5.69	0.46	8.56e-8	Homoarginine levels;
TGCT	cis	rs9787249	0.957	rs2274949	chr1:40221067	G/A	cg20968010	chr1:40505947	CAP1	-0.5	-4.7	-0.39	6.72e-6	Blood protein levels;
TGCT	trans	rs877282	0.755	rs11253399	chr10:790030	T/A	cg22713356	chr15:30763199	NA	0.95	8.14	0.59	3.51e-13	Uric acid levels;
TGCT	trans	rs6762477	0.748	rs11714286	chr3:50185508	G/A	cg21659725	chr3:3221576	CRBN	-0.68	-7.58	-0.56	6.91e-12	Menarche (age at onset);
TGCT	cis	rs11209185	0.509	rs9326077	chr1:68452192	A/G	cg22082780	chr1:68452167	NA	0.32	5.19	0.42	8.22e-7	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.08	0.48	1.37e-8	Bipolar disorder;
TGCT	cis	rs73635312	0.850	rs17506027	chr10:8995460	A/G	cg20281962	chr10:8089733	NA	-0.73	-4.43	-0.37	2.01e-5	Basal cell carcinoma;
TGCT	trans	rs3780486	0.846	rs7873903	chr9:33142728	G/A	cg04842962	chr6:43655489	MRPS18A	1.21	14.37	0.79	3.68e-28	IgG glycosylation;
TGCT	cis	rs10089	0.904	rs2195921	chr5:127489754	A/C	cg19767477	chr5:127420684	SLC12A2	-0.43	-4.55	-0.38	1.27e-5	Ileal carcinoids;
TGCT	cis	rs9556958	0.635	rs4529985	chr13:99167120	G/C	cg07423050	chr13:99094983	FARP1	-0.23	-4.81	-0.4	4.37e-6	Educational attainment (years of education);
TGCT	cis	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg07424592	chr7:64974309	NA	1.32	8.15	0.59	3.39e-13	Diabetic kidney disease;
TGCT	cis	rs6912958	0.781	rs9450712	chr6:88193175	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.54	-5.23	-0.43	7.03e-7	Monocyte percentage of white cells;
TGCT	cis	rs611744	0.625	rs6469168	chr8:109288399	G/T	cg21045802	chr8:109455806	TTC35	0.74	7.77	0.57	2.59e-12	Dupuytren's disease;
TGCT	cis	rs6545977	1.000	rs6545977	chr2:63301164	G/A	cg17519650	chr2:63277830	OTX1	-0.73	-7.85	-0.58	1.68e-12	Prostate cancer;
TGCT	cis	rs7091068	0.662	rs829106	chr10:95441742	G/T	cg20715218	chr10:95462985	C10orf4	0.49	4.49	0.37	1.61e-5	Urinary tract infection frequency;
TGCT	cis	rs7584330	0.554	rs7582964	chr2:238385766	C/T	cg08992911	chr2:238395768	MLPH	-0.88	-5.15	-0.42	9.94e-7	Prostate cancer;
TGCT	cis	rs950776	0.518	rs12916999	chr15:78826912	C/T	cg06917634	chr15:78832804	PSMA4	0.95	9.52	0.65	1.81e-16	Sudden cardiac arrest;
TGCT	cis	rs10411936	0.962	rs10402422	chr19:16475388	G/A	cg19006008	chr19:16999768	F2RL3	0.29	5.02	0.41	1.74e-6	White blood cell count;Multiple sclerosis;
TGCT	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.04	0.53	1.16e-10	Prudent dietary pattern;
TGCT	cis	rs924607	0.583	rs12516251	chr5:608939	C/T	cg18765565	chr5:669397	TPPP	-0.48	-4.61	-0.38	9.96e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	trans	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg27523141	chr10:43048294	ZNF37B	0.74	8.61	0.61	2.7e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs11239930	0.538	rs17160592	chr1:146555193	T/C	cg00044796	chr1:146552390	NA	-0.34	-4.46	-0.37	1.84e-5	AIDS progression;
TGCT	cis	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg18252515	chr7:66147081	NA	1.2	7.83	0.58	1.89e-12	Diabetic kidney disease;
TGCT	cis	rs8017423	0.967	rs11621045	chr14:90714003	C/T	cg04374321	chr14:90722782	PSMC1	0.72	7.55	0.56	8.1e-12	Mortality in heart failure;
TGCT	cis	rs28595532	0.764	rs115877991	chr4:119728298	C/T	cg14228332	chr4:119757509	SEC24D	1.32	6.38	0.5	3.2e-9	Cannabis dependence symptom count;
TGCT	cis	rs10507380	0.824	rs77197829	chr13:27924604	G/T	cg25543773	chr13:27185723	WASF3	0.32	4.52	0.38	1.45e-5	Electrocardiographic traits;
TGCT	cis	rs1577917	1.000	rs955197	chr6:86729675	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.2	-0.42	7.94e-7	Response to antipsychotic treatment;
TGCT	cis	rs5769707	0.967	rs9616327	chr22:50010891	G/A	cg05373962	chr22:49881684	NA	-0.3	-6.16	-0.48	9.42e-9	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg26338869	chr17:61819248	STRADA	-0.55	-5.08	-0.42	1.34e-6	Prudent dietary pattern;
TGCT	cis	rs5769707	0.609	rs739247	chr22:49996657	T/C	cg05373962	chr22:49881684	NA	-0.3	-5.16	-0.42	9.59e-7	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs2469997	0.858	rs1551785	chr8:120352397	T/A	cg00681363	chr8:120844660	TAF2	0.65	4.45	0.37	1.9e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs2288278	0.543	rs11869101	chr17:46568013	T/G	cg25032089	chr17:46643351	HOXB3	-0.41	-5.01	-0.41	1.86e-6	Hand grip strength;
TGCT	cis	rs4953076	0.573	rs6738023	chr2:44405931	T/C	cg00619915	chr2:44497795	NA	-0.22	-5.01	-0.41	1.82e-6	Height;
TGCT	cis	rs13242816	1.000	rs12672236	chr7:116111369	A/G	cg02799643	chr7:116139180	CAV2	0.47	5.5	0.44	2.08e-7	P wave duration;
TGCT	cis	rs7552404	0.889	rs380075	chr1:76106961	T/A	cg22875332	chr1:76189707	ACADM	-0.79	-9.72	-0.66	6.2e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs4689388	0.926	rs6446480	chr4:6295565	C/T	cg25554036	chr4:6271136	WFS1	0.53	7.28	0.55	3.4e-11	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs9467773	1.000	rs2208331	chr6:26507319	A/G	cg26531700	chr6:26746687	NA	0.47	4.56	0.38	1.19e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs6089829	0.962	rs3746747	chr20:61667631	T/C	cg18188782	chr20:61659543	NA	0.44	5.36	0.43	3.87e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg18252515	chr7:66147081	NA	-1.09	-6.4	-0.5	2.88e-9	Diabetic kidney disease;
TGCT	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg09323728	chr8:95962352	TP53INP1	-0.53	-6.88	-0.53	2.67e-10	Type 2 diabetes;
TGCT	cis	rs1355223	0.583	rs2941041	chr11:34874734	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.78	8.67	0.61	2e-14	Systemic lupus erythematosus and Systemic sclerosis;
TGCT	cis	rs17401966	0.540	rs4846221	chr1:10472026	C/A	cg19773385	chr1:10388646	KIF1B	-0.22	-5.22	-0.42	7.29e-7	Hepatocellular carcinoma;
TGCT	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg13607699	chr17:42295918	UBTF	0.59	5.31	0.43	4.88e-7	Total body bone mineral density;
TGCT	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg06636001	chr8:8085503	FLJ10661	0.7	6.34	0.5	3.8e-9	Mood instability;
TGCT	cis	rs62244186	0.748	rs6441861	chr3:44652287	A/G	cg11003573	chr3:44754125	ZNF502	-0.41	-4.69	-0.39	6.98e-6	Depressive symptoms;
TGCT	cis	rs4722166	0.573	rs35436671	chr7:22775508	G/A	cg05265849	chr7:22767390	IL6	0.23	4.51	0.38	1.5e-5	Lung cancer;
TGCT	cis	rs7824557	0.564	rs2572379	chr8:11237480	A/G	cg21775007	chr8:11205619	TDH	-0.65	-6.39	-0.5	3.07e-9	Retinal vascular caliber;
TGCT	cis	rs765787	0.530	rs2899379	chr15:45534799	C/T	cg24006582	chr15:45444508	DUOX1	0.24	5.25	0.43	6.52e-7	Uric acid levels;
TGCT	cis	rs62185668	0.693	rs6077967	chr20:10919774	T/C	cg17778165	chr20:10414372	MKKS	-0.58	-4.53	-0.38	1.35e-5	Urinary bladder cancer;
TGCT	cis	rs4595586	0.545	rs12826080	chr12:39387772	A/G	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg12963246	chr6:28129442	ZNF389	0.52	5.1	0.42	1.23e-6	Depression;
TGCT	cis	rs3733585	0.699	rs4473653	chr4:9971058	A/G	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.68	-0.57	4.13e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7552404	1.000	rs9662166	chr1:76235906	C/A	cg10523679	chr1:76189770	ACADM	0.9	9.48	0.65	2.34e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs11792861	0.962	rs3829084	chr9:111801724	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.48	-4.45	-0.37	1.9e-5	Menarche (age at onset);
TGCT	cis	rs4144743	0.938	rs35439279	chr17:45321694	C/T	cg18085866	chr17:45331354	ITGB3	-0.7	-4.67	-0.39	7.69e-6	Body mass index;
TGCT	cis	rs994533	0.674	rs12694416	chr2:218289497	A/C	cg25097514	chr2:219157373	TMBIM1;PNKD	-0.34	-4.46	-0.37	1.79e-5	Height;
TGCT	cis	rs1375194	0.558	rs13418410	chr2:33800899	C/A	cg04131969	chr2:33951647	MYADML	-0.58	-5.22	-0.42	7.3e-7	Response to antidepressants in depression;
TGCT	cis	rs73110464	0.505	rs2638503	chr12:53307369	C/G	cg16329197	chr12:53359506	NA	-0.31	-4.61	-0.38	9.68e-6	Cancer (pleiotropy);
TGCT	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg18538332	chr22:24372958	LOC391322	0.84	7.23	0.54	4.44e-11	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs7666738	0.830	rs34412187	chr4:99010454	A/G	cg18180107	chr4:99064573	C4orf37	0.54	5.03	0.41	1.7e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs16957091	0.647	rs7176957	chr15:43336802	C/T	cg17935677	chr15:44119062	WDR76	0.52	4.71	0.39	6.44e-6	MGMT methylation in smokers;
TGCT	cis	rs9296092	0.517	rs6911036	chr6:33471652	C/G	cg13560919	chr6:33536144	NA	-0.22	-4.49	-0.37	1.6e-5	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs9611565	0.592	rs5996037	chr22:41965292	A/G	cg03806693	chr22:41940476	POLR3H	-1.08	-11.36	-0.71	6.34e-21	Vitiligo;
TGCT	cis	rs7809950	1.000	rs2237673	chr7:107131580	T/C	cg23024343	chr7:107201750	COG5	-0.33	-5.32	-0.43	4.78e-7	Coronary artery disease;
TGCT	cis	rs9653442	0.900	rs2309837	chr2:100837567	T/C	cg22139774	chr2:100720529	AFF3	-0.39	-6.27	-0.49	5.59e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs17376456	0.542	rs1453003	chr5:93151611	T/C	cg21475434	chr5:93447410	FAM172A	-0.62	-5.06	-0.41	1.45e-6	Diabetic retinopathy;
TGCT	cis	rs1843834	0.539	rs2068244	chr2:225440011	A/G	cg12698349	chr2:225449008	CUL3	-0.78	-6.3	-0.49	4.75e-9	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg06873352	chr17:61820015	STRADA	0.58	6.39	0.5	3.01e-9	Prudent dietary pattern;
TGCT	cis	rs9549260	0.785	rs2253001	chr13:41145330	A/T	cg21288729	chr13:41239152	FOXO1	1.0	10.34	0.68	1.86e-18	Red blood cell count;
TGCT	cis	rs12479064	0.724	rs2309618	chr2:99974473	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.74	-6.33	-0.49	4.06e-9	Chronic sinus infection;
TGCT	cis	rs797680	0.786	rs555161	chr1:93676314	A/G	cg17826107	chr1:92977322	EVI5	-0.24	-5.29	-0.43	5.47e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	trans	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg27523141	chr10:43048294	ZNF37B	0.74	8.66	0.61	2.17e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs3849570	0.615	rs1851918	chr3:81980557	C/T	cg07356753	chr3:81810745	GBE1	-0.61	-5.45	-0.44	2.61e-7	Waist circumference;Body mass index;
TGCT	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg10047753	chr17:41438598	NA	0.97	10.04	0.67	1.04e-17	Menopause (age at onset);
TGCT	cis	rs7666738	0.830	rs1593569	chr4:99017485	C/G	cg18180107	chr4:99064573	C4orf37	0.54	5.03	0.41	1.65e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs78487399	0.808	rs6726917	chr2:43753913	A/C	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.76	4.68	0.39	7.27e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs6831352	0.877	rs29001183	chr4:100056539	C/T	cg12011299	chr4:100065546	ADH4	-0.4	-4.88	-0.4	3.26e-6	Alcohol dependence;
TGCT	cis	rs208520	0.690	rs12213928	chr6:66762978	G/A	cg07460842	chr6:66804631	NA	0.96	10.32	0.68	2.1e-18	Exhaled nitric oxide output;
TGCT	cis	rs854765	0.718	rs12943500	chr17:17790588	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.65	-6.47	-0.5	2.03e-9	Total body bone mineral density;
TGCT	cis	rs1857353	0.901	rs17644957	chr1:75877394	A/G	cg11838876	chr1:75668600	SLC44A5	-0.47	-4.56	-0.38	1.2e-5	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs4409675	0.576	rs10751724	chr1:28215631	C/T	cg23691781	chr1:28212827	C1orf38	0.26	5.32	0.43	4.68e-7	Corneal astigmatism;
TGCT	cis	rs9911578	0.900	rs717828	chr17:56535932	A/G	cg12560992	chr17:57184187	TRIM37	0.76	9.28	0.64	7.12e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs2075371	0.829	rs9641970	chr7:134004887	C/A	cg11752832	chr7:134001865	SLC35B4	0.74	6.69	0.51	6.91e-10	Mean platelet volume;
TGCT	cis	rs1061377	1.000	rs12646251	chr4:39134371	G/A	cg24403649	chr4:39172243	NA	0.2	4.59	0.38	1.09e-5	Uric acid levels;
TGCT	cis	rs12620999	0.941	rs10803654	chr2:238036570	C/T	cg23555395	chr2:238036564	NA	-0.31	-5.51	-0.44	2.02e-7	Systemic lupus erythematosus;
TGCT	cis	rs35883536	0.626	rs11799819	chr1:101049382	G/A	cg06223162	chr1:101003688	GPR88	-0.43	-8.04	-0.59	5.96e-13	Monocyte count;
TGCT	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg00149659	chr3:10157352	C3orf10	0.78	4.99	0.41	2.04e-6	Alzheimer's disease;
TGCT	cis	rs7072216	0.763	rs6584204	chr10:100173580	C/G	cg26618903	chr10:100175079	PYROXD2	-0.4	-4.49	-0.37	1.64e-5	Metabolite levels;
TGCT	cis	rs7552404	1.000	rs9662166	chr1:76235906	C/A	cg03433033	chr1:76189801	ACADM	0.82	9.39	0.64	3.73e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	trans	rs2469997	0.925	rs2470011	chr8:120359937	G/C	cg01792902	chr3:178864926	PIK3CA	0.83	6.77	0.52	4.49e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg27454412	chr7:1067447	C7orf50	0.6	4.72	0.39	6.32e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs921968	0.541	rs581013	chr2:219432040	G/T	cg02176678	chr2:219576539	TTLL4	0.48	6.78	0.52	4.32e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs7267979	0.966	rs7270835	chr20:25435067	C/T	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	6.75	0.52	5.02e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6696846	0.740	rs11240369	chr1:205115099	G/A	cg03948781	chr1:205179583	DSTYK	0.34	4.47	0.37	1.72e-5	Red blood cell count;
TGCT	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg25036284	chr2:26402008	FAM59B	-0.57	-4.99	-0.41	2e-6	Gut microbiome composition (summer);
TGCT	cis	rs3540	0.512	rs3862437	chr15:91084632	A/G	cg22089800	chr15:90895588	ZNF774	-0.74	-7.59	-0.56	6.78e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs7647973	1.000	rs11130190	chr3:49402137	T/C	cg07636037	chr3:49044803	WDR6	0.71	5.76	0.46	6.26e-8	Menarche (age at onset);
TGCT	cis	rs2404602	0.632	rs34338978	chr15:77226805	T/C	cg26408565	chr15:76604113	ETFA	-0.37	-4.63	-0.38	9.04e-6	Blood metabolite levels;
TGCT	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/A	cg02458000	chr6:26745757	NA	0.65	6.35	0.5	3.7e-9	Intelligence (multi-trait analysis);
TGCT	trans	rs28595532	0.641	rs72670220	chr4:119300053	A/G	cg26518628	chr1:97050305	NA	-0.61	-7.34	-0.55	2.45e-11	Cannabis dependence symptom count;
TGCT	cis	rs35160687	0.901	rs12472676	chr2:86510815	T/C	cg03171300	chr2:86307199	POLR1A	0.32	5.52	0.44	1.88e-7	Night sleep phenotypes;
TGCT	cis	rs3008870	1.000	rs2985795	chr1:67426223	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.1	11.8	0.73	5.15e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs644148	0.836	rs2686775	chr19:45000059	C/T	cg15540054	chr19:45004280	ZNF180	-0.64	-5.25	-0.43	6.3e-7	Personality dimensions;
TGCT	cis	rs2235642	0.893	rs2076445	chr16:1592266	A/T	cg07341220	chr16:1583899	IFT140;TMEM204	-0.3	-4.7	-0.39	6.94e-6	Coronary artery disease;
TGCT	cis	rs3015497	0.616	rs7152874	chr14:51046040	C/G	cg04730355	chr14:51134070	SAV1	-0.62	-6.13	-0.48	1.07e-8	Mean platelet volume;
TGCT	cis	rs6988636	1.000	rs9987357	chr8:124187620	T/G	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs3764400	0.567	rs67345313	chr17:46302201	T/C	cg02340556	chr17:46797764	NA	0.42	4.51	0.38	1.46e-5	Body mass index;
TGCT	cis	rs7542091	0.704	rs2142907	chr1:210039505	T/C	cg22029157	chr1:209979665	IRF6	0.65	6.3	0.49	4.63e-9	Monobrow;
TGCT	cis	rs2075371	0.966	rs1646676	chr7:133999267	G/A	cg11752832	chr7:134001865	SLC35B4	0.7	6.31	0.49	4.39e-9	Mean platelet volume;
TGCT	cis	rs8032315	0.965	rs8027450	chr15:91418394	C/T	cg05211768	chr15:91427848	FES	0.49	5.0	0.41	1.93e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6589563	0.609	rs10466589	chr11:116611985	G/A	cg01124546	chr11:117515332	DSCAML1	-0.43	-4.68	-0.39	7.39e-6	Eosinophil counts;
TGCT	cis	rs36051895	0.623	rs6476955	chr9:5256533	C/G	cg02405213	chr9:5042618	JAK2	-0.7	-8.47	-0.61	5.88e-14	Pediatric autoimmune diseases;
TGCT	cis	rs12908161	1.000	rs35960805	chr15:85343980	T/G	cg11189052	chr15:85197271	WDR73	0.71	5.87	0.47	3.68e-8	Schizophrenia;
TGCT	cis	rs903263	0.965	rs12756529	chr1:84664815	T/C	cg09664975	chr1:84543551	PRKACB	0.48	4.53	0.38	1.39e-5	Breast cancer (male);
TGCT	cis	rs7914558	0.902	rs3736922	chr10:104850632	A/G	cg15744005	chr10:104629667	AS3MT	0.4	4.95	0.41	2.35e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	5.23	0.43	6.92e-7	Menopause (age at onset);
TGCT	cis	rs62244186	0.541	rs62244226	chr3:44831831	G/A	cg18722847	chr3:44754129	ZNF502	-0.4	-4.49	-0.37	1.63e-5	Depressive symptoms;
TGCT	cis	rs1552244	0.554	rs2272122	chr3:10047975	C/G	cg00149659	chr3:10157352	C3orf10	0.69	4.99	0.41	2.03e-6	Alzheimer's disease;
TGCT	cis	rs2663905	0.611	rs1509559	chr15:81391411	G/A	cg09236163	chr15:81426669	C15orf26	-0.52	-5.58	-0.45	1.47e-7	QT interval (drug interaction);
TGCT	cis	rs2455799	0.594	rs11928773	chr3:15925135	A/G	cg16303742	chr3:15540471	COLQ	-0.24	-4.64	-0.38	8.68e-6	Mean platelet volume;
TGCT	cis	rs10892173	0.545	rs115865940	chr11:117666711	C/T	cg21640587	chr11:117668038	DSCAML1	0.65	7.53	0.56	9.06e-12	Myopia;
TGCT	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9942416	0.660	rs17563863	chr5:74998334	G/A	cg19683494	chr5:74908142	NA	0.57	6.37	0.5	3.33e-9	Age-related disease endophenotypes;
TGCT	cis	rs7091068	0.550	rs7079013	chr10:95487878	A/C	cg20715218	chr10:95462985	C10orf4	0.5	5.95	0.47	2.59e-8	Urinary tract infection frequency;
TGCT	cis	rs9611565	0.559	rs5758412	chr22:42080803	T/A	cg06481639	chr22:41940642	POLR3H	0.73	6.57	0.51	1.27e-9	Vitiligo;
TGCT	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg06238570	chr21:40685208	BRWD1	-0.62	-6.33	-0.49	4.04e-9	Menarche (age at onset);
TGCT	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg13770153	chr20:60521292	NA	-0.54	-7.13	-0.54	7.45e-11	Body mass index;
TGCT	trans	rs57221529	0.709	rs72707023	chr5:667620	G/A	cg25482853	chr8:67687455	SGK3	1.2	10.45	0.68	1.03e-18	Lung disease severity in cystic fibrosis;
TGCT	cis	rs9399135	0.967	rs6902954	chr6:135313994	C/A	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.36e-6	Red blood cell count;
TGCT	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.78	6.25	0.49	6.17e-9	Mean platelet volume;
TGCT	cis	rs7660520	0.557	rs76004373	chr4:183731011	C/G	cg04181038	chr4:183730758	NA	0.65	6.12	0.48	1.12e-8	Pediatric autoimmune diseases;
TGCT	cis	rs2842992	0.830	rs2758313	chr6:160154099	C/G	cg11366901	chr6:160182831	ACAT2	1.02	7.09	0.54	8.89e-11	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs9787249	0.957	rs7547787	chr1:40220806	C/T	cg20968010	chr1:40505947	CAP1	-0.48	-4.44	-0.37	2e-5	Blood protein levels;
TGCT	cis	rs4478858	0.735	rs2271072	chr1:31840426	C/G	cg07478791	chr1:31886160	SERINC2	-0.51	-4.93	-0.41	2.55e-6	Alcohol dependence;
TGCT	cis	rs11955175	1.000	rs75728011	chr5:40797505	A/C	cg17351974	chr5:40835760	RPL37	0.87	5.92	0.47	2.98e-8	Bipolar disorder and schizophrenia;
TGCT	cis	rs9393777	0.513	rs9368451	chr6:26654333	A/G	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.53	-4.88	-0.4	3.19e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs35306767	0.855	rs56222464	chr10:867535	C/G	cg26597838	chr10:835615	NA	0.8	12.0	0.73	1.67e-22	Eosinophil percentage of granulocytes;
TGCT	cis	rs10193935	0.901	rs222479	chr2:42656857	T/G	cg27598129	chr2:42591480	NA	-0.32	-4.75	-0.39	5.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg10802521	chr3:52805072	NEK4	-0.69	-8.09	-0.59	4.65e-13	Bipolar disorder;
TGCT	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg04287289	chr16:89883240	FANCA	0.91	11.66	0.72	1.15e-21	Vitiligo;
TGCT	cis	rs28595532	0.920	rs114789346	chr4:119748652	G/A	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs1865760	0.865	rs9393677	chr6:25945815	G/A	cg16482183	chr6:26056742	HIST1H1C	0.53	4.88	0.4	3.14e-6	Height;
TGCT	cis	rs79149102	0.579	rs7168638	chr15:75280826	T/C	cg09165964	chr15:75287851	SCAMP5	-1.09	-6.08	-0.48	1.39e-8	Lung cancer;
TGCT	cis	rs11204677	1	rs11204677	chr1:150574695	C/G	cg13175981	chr1:150552382	MCL1	0.54	6.16	0.48	9.42e-9	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
TGCT	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2130392	0.926	rs7679215	chr4:185635311	C/T	cg14471096	chr4:185570637	CCDC111;CASP3	-0.52	-4.76	-0.39	5.33e-6	Kawasaki disease;
TGCT	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg17264618	chr3:40429014	ENTPD3	0.34	4.94	0.41	2.52e-6	Renal cell carcinoma;
TGCT	cis	rs7552404	1.000	rs72686191	chr1:76218319	G/T	cg03433033	chr1:76189801	ACADM	0.84	9.57	0.65	1.39e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7191700	0.836	rs12708722	chr16:11428905	T/A	cg00044050	chr16:11439710	C16orf75	0.68	5.65	0.45	1.05e-7	Multiple sclerosis;
TGCT	cis	rs11031096	0.655	rs1372806	chr11:4212308	C/T	cg18678763	chr11:4115507	RRM1	-0.44	-5.69	-0.46	8.66e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs59586681	0.542	rs2064846	chr20:2233252	C/T	cg04428163	chr20:1294021	SDCBP2	0.39	4.51	0.38	1.51e-5	Basal cell carcinoma;
TGCT	cis	rs11098499	0.863	rs10009626	chr4:120470005	T/C	cg09307838	chr4:120376055	NA	0.72	6.87	0.52	2.81e-10	Corneal astigmatism;
TGCT	cis	rs2439831	0.850	rs28413704	chr15:44148427	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	6.2	0.49	7.73e-9	Lung cancer in ever smokers;
TGCT	cis	rs35934224	0.783	rs12106549	chr22:19846987	G/T	cg11182965	chr22:19864308	TXNRD2	-0.35	-4.8	-0.4	4.55e-6	Glaucoma (primary open-angle);
TGCT	cis	rs35146811	0.695	rs858508	chr7:99821381	C/G	cg04778012	chr7:99775508	STAG3;GPC2	-0.36	-5.1	-0.42	1.22e-6	Coronary artery disease;
TGCT	cis	rs3734729	0.702	rs4870392	chr6:150566068	A/G	cg16439130	chr6:149658548	MAP3K7IP2	0.47	4.85	0.4	3.58e-6	Pulmonary function;Pulmonary function (smoking interaction);
TGCT	cis	rs7511006	0.858	rs2294402	chr22:50654428	T/G	cg08875078	chr22:50639485	SELO	0.56	5.52	0.44	1.86e-7	Obesity-related traits;
TGCT	cis	rs10791323	0.693	rs10750544	chr11:133718740	A/G	cg15485101	chr11:133734466	NA	0.35	4.44	0.37	1.95e-5	Childhood ear infection;
TGCT	cis	rs1008375	0.898	rs10008445	chr4:17593978	G/T	cg10189774	chr4:17578691	LAP3	0.71	6.05	0.48	1.59e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4499344	0.526	rs8111902	chr19:33032243	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.64	-5.58	-0.45	1.44e-7	Mean platelet volume;
TGCT	cis	rs782590	0.837	rs2627769	chr2:55927288	G/C	cg03859395	chr2:55845619	SMEK2	0.84	9.73	0.66	5.7e-17	Metabolic syndrome;
TGCT	cis	rs6964587	1.000	rs6969981	chr7:91689461	G/C	cg22709100	chr7:91322751	NA	0.28	4.56	0.38	1.19e-5	Breast cancer;
TGCT	cis	rs473651	0.967	rs483042	chr2:239335320	A/G	cg08773314	chr2:239334832	ASB1	0.46	7.79	0.57	2.33e-12	Multiple system atrophy;
TGCT	cis	rs9677476	0.516	rs1025107	chr2:232034342	C/T	cg27665808	chr2:232055229	NA	0.35	4.43	0.37	2.01e-5	Food antigen IgG levels;
TGCT	cis	rs7267979	0.934	rs2482913	chr20:25405086	T/A	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11247915	0.622	rs4072445	chr1:26664219	T/C	cg23732845	chr1:26663426	AIM1L	-0.37	-4.7	-0.39	6.89e-6	Obesity-related traits;
TGCT	cis	rs2153535	0.580	rs7748455	chr6:8453625	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.76	0.46	6.39e-8	Motion sickness;
TGCT	cis	rs7226408	0.948	rs1426755	chr18:34410831	A/G	cg06757138	chr18:34340585	FHOD3	0.26	4.79	0.4	4.62e-6	Obesity-related traits;
TGCT	cis	rs1008375	0.931	rs7672369	chr4:17604825	A/G	cg18681998	chr4:17616180	MED28	1.05	11.09	0.71	2.85e-20	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg26338869	chr17:61819248	STRADA	-0.55	-5.08	-0.41	1.38e-6	Prudent dietary pattern;
TGCT	cis	rs13427251	0.868	rs1901284	chr2:100146040	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.56	5.42	0.44	2.96e-7	Chronic sinus infection;
TGCT	trans	rs208520	0.609	rs208436	chr6:66897470	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.74	-7.75	-0.57	2.86e-12	Exhaled nitric oxide output;
TGCT	cis	rs7707921	0.522	rs4703537	chr5:81480371	C/T	cg15871215	chr5:81402204	ATG10	0.25	4.89	0.4	3.04e-6	Breast cancer;
TGCT	cis	rs1552244	0.554	rs2272121	chr3:10047680	A/G	cg00149659	chr3:10157352	C3orf10	0.69	4.99	0.41	2.03e-6	Alzheimer's disease;
TGCT	cis	rs9972944	0.756	rs9907969	chr17:63754860	G/T	cg07283582	chr17:63770753	CCDC46	-0.26	-5.03	-0.41	1.65e-6	Total body bone mineral density;
TGCT	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg17054783	chr10:134559939	INPP5A	0.24	4.83	0.4	3.92e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs9807989	0.507	rs2041739	chr2:102994333	A/G	cg03938978	chr2:103052716	IL18RAP	-0.25	-5.01	-0.41	1.8e-6	Asthma;
TGCT	cis	rs909002	0.849	rs10753257	chr1:32086089	G/A	cg11573219	chr1:32083031	HCRTR1	-0.49	-6.39	-0.5	3.06e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs6840360	0.571	rs4696279	chr4:152560449	G/A	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.0	-0.58	7.69e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs10510102	0.872	rs11200269	chr10:123693536	A/G	cg23691251	chr10:123688108	ATE1	-0.58	-4.58	-0.38	1.11e-5	Breast cancer;
TGCT	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg23758822	chr17:41437982	NA	0.69	6.37	0.5	3.34e-9	Menopause (age at onset);
TGCT	cis	rs9796	0.866	rs2176998	chr15:41420807	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.47	-6.2	-0.49	7.6e-9	Menopause (age at onset);
TGCT	cis	rs12681288	0.712	rs2600488	chr8:1021266	A/C	cg04851639	chr8:1020857	NA	-0.37	-6.86	-0.52	2.92e-10	Schizophrenia;
TGCT	cis	rs17384381	1.000	rs12128907	chr1:85891385	A/G	cg16011679	chr1:85725395	C1orf52	0.8	6.44	0.5	2.39e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7178572	0.524	rs12904088	chr15:77399397	C/G	cg15453836	chr15:77711506	NA	-0.4	-4.54	-0.38	1.31e-5	Type 2 diabetes;
TGCT	cis	rs137603	0.623	rs470075	chr22:39686806	G/A	cg01093212	chr22:39715156	SNORD43;RPL3	-0.53	-4.85	-0.4	3.55e-6	Primary biliary cholangitis;
TGCT	cis	rs6088580	0.634	rs1205336	chr20:32926336	G/A	cg08999081	chr20:33150536	PIGU	-0.24	-4.74	-0.39	5.68e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs4654899	0.802	rs7517642	chr1:21252696	T/C	cg01072550	chr1:21505969	NA	-0.47	-7.06	-0.54	1.03e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs6598955	0.612	rs12738188	chr1:26548029	G/C	cg04990556	chr1:26633338	UBXN11	-0.89	-11.55	-0.72	2.18e-21	Obesity-related traits;
TGCT	trans	rs330048	0.545	rs11249913	chr8:9143521	G/T	cg15556689	chr8:8085844	FLJ10661	-0.67	-6.96	-0.53	1.77e-10	Systemic lupus erythematosus;
TGCT	cis	rs9858542	0.953	rs9827021	chr3:49514764	C/A	cg03060546	chr3:49711283	APEH	-0.61	-5.37	-0.43	3.78e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs2249625	0.523	rs2463707	chr6:72861732	G/A	cg24401219	chr6:72892597	RIMS1	-0.54	-4.7	-0.39	6.92e-6	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
TGCT	cis	rs12497850	0.931	rs7643368	chr3:48992855	T/G	cg06212747	chr3:49208901	KLHDC8B	0.6	5.43	0.44	2.82e-7	Parkinson's disease;
TGCT	cis	rs1215050	0.755	rs9991112	chr4:98651479	A/C	cg05340658	chr4:99064831	C4orf37	-0.43	-5.4	-0.44	3.2e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg24399712	chr22:39784796	NA	-1.07	-12.53	-0.75	8.77e-24	Intelligence (multi-trait analysis);
TGCT	trans	rs28735056	0.660	rs12454454	chr18:77674634	C/T	cg05926928	chr17:57297772	GDPD1	-0.7	-6.79	-0.52	4.06e-10	Schizophrenia;
TGCT	cis	rs6671200	1.000	rs259354	chr1:95718205	T/C	cg20701556	chr1:95698924	RWDD3	-0.67	-5.63	-0.45	1.13e-7	Stearic acid (18:0) levels;
TGCT	cis	rs295140	0.773	rs13007517	chr2:201129729	C/T	cg04283868	chr2:201171347	SPATS2L	0.52	5.2	0.42	8.14e-7	QT interval;
TGCT	cis	rs68170813	0.559	rs12537342	chr7:106943563	T/C	cg02696742	chr7:106810147	HBP1	-0.69	-5.81	-0.46	4.85e-8	Coronary artery disease;
TGCT	cis	rs5750830	0.594	rs5757648	chr22:39775156	G/A	cg24399712	chr22:39784796	NA	-0.95	-11.01	-0.7	4.37e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs919433	0.617	rs700642	chr2:198600730	G/T	cg00792783	chr2:198669748	PLCL1	-0.57	-5.32	-0.43	4.74e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg27286337	chr10:134555280	INPP5A	0.4	4.86	0.4	3.52e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs62084913	0.511	rs895690	chr17:72784649	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	0.57	5.89	0.47	3.44e-8	Breast cancer;
TGCT	cis	rs7523050	0.730	rs12734623	chr1:109442654	A/G	cg08274380	chr1:109419600	GPSM2	1.35	6.86	0.52	2.89e-10	Fat distribution (HIV);
TGCT	cis	rs929354	0.772	rs6459737	chr7:156975136	G/A	cg05182265	chr7:156933206	UBE3C	-0.39	-8.79	-0.62	1.03e-14	Body mass index;
TGCT	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	6.75	0.52	5.02e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6725041	0.819	rs10175497	chr2:213082649	A/G	cg20637307	chr2:213403960	ERBB4	-0.51	-4.48	-0.37	1.68e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg23172400	chr8:95962367	TP53INP1	-0.38	-6.31	-0.49	4.42e-9	Type 2 diabetes;
TGCT	cis	rs7208859	0.673	rs4131618	chr17:29204801	C/T	cg18442181	chr17:29233375	C17orf42	-0.79	-4.78	-0.39	4.95e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs12477438	0.520	rs11689265	chr2:99799267	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.05	13.31	0.77	1.16e-25	Chronic sinus infection;
TGCT	cis	rs7208859	0.623	rs77009951	chr17:29080650	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs4808199	0.847	rs34647936	chr19:19548239	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.69	4.99	0.41	1.98e-6	Nonalcoholic fatty liver disease;
TGCT	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg05665937	chr4:1216051	CTBP1	0.24	4.61	0.38	1e-5	Obesity-related traits;
TGCT	cis	rs17270561	0.525	rs10484432	chr6:26008876	G/A	cg16482183	chr6:26056742	HIST1H1C	0.97	7.36	0.55	2.21e-11	Iron status biomarkers;
TGCT	cis	rs9733	0.650	rs11204684	chr1:150608894	A/G	cg13175981	chr1:150552382	MCL1	0.51	5.75	0.46	6.61e-8	Tonsillectomy;
TGCT	cis	rs60154123	0.505	rs76101197	chr1:210044089	T/C	cg22029157	chr1:209979665	IRF6	0.79	5.78	0.46	5.6e-8	Coronary artery disease;
TGCT	cis	rs76419734	0.850	rs72673889	chr4:106810547	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	1.01	4.61	0.38	9.7e-6	Post bronchodilator FEV1;
TGCT	cis	rs7017914	0.840	rs13254851	chr8:71689034	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.53	-4.98	-0.41	2.09e-6	Bone mineral density;
TGCT	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg06618935	chr21:46677482	NA	-0.37	-5.56	-0.45	1.58e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2549003	0.870	rs10053046	chr5:131821558	A/G	cg21138405	chr5:131827807	IRF1	0.19	4.79	0.4	4.64e-6	Asthma (sex interaction);
TGCT	cis	rs9443645	0.901	rs9361480	chr6:79724429	C/T	cg09184832	chr6:79620586	NA	-0.5	-5.58	-0.45	1.46e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs6063312	0.518	rs6122718	chr20:47346225	A/G	cg18078177	chr20:47281410	PREX1	-0.38	-4.63	-0.38	9e-6	Tonometry;
TGCT	cis	rs6582630	0.519	rs11609739	chr12:38547969	G/A	cg26384229	chr12:38710491	ALG10B	0.85	7.75	0.57	2.91e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs778371	0.723	rs12999865	chr2:233627250	T/C	cg08000102	chr2:233561755	GIGYF2	0.72	8.68	0.61	1.91e-14	Schizophrenia;
TGCT	cis	rs259282	0.605	rs36107586	chr19:33109674	G/A	cg26639809	chr19:33781782	NA	0.23	4.53	0.38	1.39e-5	Schizophrenia;
TGCT	cis	rs8038465	0.662	rs57771618	chr15:73967578	T/C	cg15420318	chr15:73925796	NPTN	0.71	7.52	0.56	9.44e-12	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs644799	1.000	rs12291986	chr11:95523030	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	10.57	0.69	5.17e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs2153535	0.546	rs9378559	chr6:8539058	A/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.6	0.45	1.33e-7	Motion sickness;
TGCT	cis	rs6484504	0.576	rs11031323	chr11:31245413	T/G	cg14844989	chr11:31128820	NA	-0.23	-4.51	-0.38	1.47e-5	Red blood cell count;
TGCT	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg03264133	chr6:25882463	NA	-0.52	-4.76	-0.39	5.32e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs367615	0.918	rs13173339	chr5:108871318	T/A	cg17395555	chr5:108820864	NA	0.29	4.71	0.39	6.59e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg07157834	chr1:205819609	PM20D1	0.44	7.03	0.53	1.21e-10	Menarche (age at onset);
TGCT	cis	rs7666738	0.753	rs13120995	chr4:98972762	A/G	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs763121	0.853	rs4821809	chr22:39065743	G/C	cg06022373	chr22:39101656	GTPBP1	0.77	7.57	0.56	7.47e-12	Menopause (age at onset);
TGCT	cis	rs4699052	0.739	rs1607094	chr4:104225413	G/A	cg16532752	chr4:104119610	CENPE	-0.5	-4.73	-0.39	5.91e-6	Testicular germ cell tumor;
TGCT	cis	rs28595532	0.920	rs17324821	chr4:119770716	A/G	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs9807989	0.839	rs3755276	chr2:102978459	C/T	cg09003973	chr2:102972529	NA	0.67	6.03	0.48	1.75e-8	Asthma;
TGCT	cis	rs523522	0.962	rs509445	chr12:121017243	A/C	cg27279351	chr12:120934652	DYNLL1	0.76	6.43	0.5	2.51e-9	High light scatter reticulocyte count;
TGCT	cis	rs6570726	0.846	rs439035	chr6:145887990	G/C	cg23711669	chr6:146136114	FBXO30	0.84	8.89	0.62	6.14e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9926296	0.681	rs12923946	chr16:89821080	C/T	cg04287289	chr16:89883240	FANCA	0.68	6.86	0.52	2.83e-10	Vitiligo;
TGCT	cis	rs6674176	1.000	rs11210937	chr1:44405563	T/C	cg12908607	chr1:44402522	ARTN	-0.82	-9.42	-0.65	3.12e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs7267979	1.000	rs6037086	chr20:25306338	A/G	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1008375	1.000	rs10440301	chr4:17663199	G/A	cg10189774	chr4:17578691	LAP3	0.53	4.68	0.39	7.26e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6460942	0.659	rs13247187	chr7:12551851	T/C	cg06484146	chr7:12443880	VWDE	-0.53	-4.92	-0.4	2.66e-6	Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs9995386	chr4:98907826	T/C	cg05340658	chr4:99064831	C4orf37	0.53	6.32	0.49	4.21e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg04944784	chr2:26401820	FAM59B	0.61	6.02	0.48	1.87e-8	Gut microbiome composition (summer);
TGCT	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg06896619	chr17:61851486	DDX42;CCDC47	-0.54	-5.36	-0.43	3.83e-7	Prudent dietary pattern;
TGCT	cis	rs7617773	0.817	rs11707606	chr3:48237087	A/C	cg11946769	chr3:48343235	NME6	0.76	6.67	0.51	7.6e-10	Coronary artery disease;
TGCT	cis	rs1801251	0.711	rs778339	chr2:233739678	T/C	cg25237894	chr2:233734115	C2orf82	-0.29	-5.61	-0.45	1.23e-7	Coronary artery disease;
TGCT	cis	rs9443645	0.901	rs1572585	chr6:79690576	C/T	cg09184832	chr6:79620586	NA	-0.48	-5.34	-0.43	4.21e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs11239930	0.538	rs4950362	chr1:146559883	A/G	cg00044796	chr1:146552390	NA	-0.35	-4.5	-0.37	1.54e-5	AIDS progression;
TGCT	cis	rs10465746	0.714	rs12730621	chr1:84433745	C/G	cg10977910	chr1:84465055	TTLL7	0.69	7.04	0.53	1.14e-10	Obesity-related traits;
TGCT	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg26338869	chr17:61819248	STRADA	-0.53	-4.85	-0.4	3.68e-6	Prudent dietary pattern;
TGCT	cis	rs617219	0.698	rs12189248	chr5:78517143	A/G	cg23987322	chr5:78407566	BHMT	-0.37	-4.94	-0.41	2.48e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg24531977	chr5:56204891	C5orf35	-0.77	-7.61	-0.56	5.83e-12	Initial pursuit acceleration;
TGCT	cis	rs2180341	1.000	rs9401950	chr6:127655485	C/T	cg24812749	chr6:127587940	RNF146	0.98	7.64	0.57	5.06e-12	Breast cancer;
TGCT	cis	rs11190604	1.000	rs11190552	chr10:102206607	G/A	cg23241863	chr10:102295624	HIF1AN	0.62	4.87	0.4	3.27e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9467773	1.000	rs9393731	chr6:26529374	C/T	cg05738196	chr6:26577821	NA	0.88	12.5	0.75	1.03e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg11062466	chr8:58055876	NA	0.42	4.46	0.37	1.84e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2440129	0.632	rs13396	chr17:6905624	T/C	cg21237687	chr17:6899380	ALOX12	0.54	5.72	0.46	7.41e-8	Tonsillectomy;
TGCT	cis	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg07424592	chr7:64974309	NA	1.35	7.62	0.56	5.53e-12	Diabetic kidney disease;
TGCT	trans	rs2469997	0.858	rs2470007	chr8:120358833	T/G	cg01792902	chr3:178864926	PIK3CA	0.83	6.77	0.52	4.49e-10	Hypertension (SNP x SNP interaction);
TGCT	trans	rs629535	0.773	rs681534	chr8:70056964	A/C	cg21567404	chr3:27674614	NA	0.56	8.82	0.62	8.75e-15	Dupuytren's disease;
TGCT	cis	rs6570726	0.935	rs425731	chr6:145834151	A/G	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg19010396	chr19:19431384	KIAA0892;SF4	-0.54	-4.54	-0.38	1.3e-5	Tonsillectomy;
TGCT	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg07636037	chr3:49044803	WDR6	0.95	10.21	0.68	3.98e-18	Parkinson's disease;
TGCT	cis	rs7089973	0.604	rs7904188	chr10:116610271	G/C	cg03647239	chr10:116582469	FAM160B1	0.59	5.74	0.46	6.72e-8	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs2456568	1.000	rs2456568	chr11:93691332	A/T	cg16099599	chr11:93583650	C11orf90	-0.39	-4.86	-0.4	3.48e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs4851266	1.000	rs12619178	chr2:100838157	C/T	cg07810366	chr2:100720526	AFF3	-0.37	-5.33	-0.43	4.53e-7	Educational attainment;
TGCT	cis	rs593982	0.920	rs487264	chr11:65481465	A/C	cg08755490	chr11:65554678	OVOL1	1.27	7.71	0.57	3.56e-12	Atopic dermatitis;
TGCT	cis	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg06697600	chr4:7070879	GRPEL1	-0.43	-4.46	-0.37	1.81e-5	Monocyte percentage of white cells;
TGCT	cis	rs2535633	0.631	rs2710326	chr3:52995444	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	0.56	5.29	0.43	5.37e-7	Body mass index;
TGCT	trans	rs459571	0.715	rs401826	chr9:136890591	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.71	-7.53	-0.56	9.17e-12	Platelet distribution width;
TGCT	cis	rs1891275	0.508	rs2096079	chr10:93496667	C/G	cg07889827	chr10:93443413	NA	-0.32	-6.8	-0.52	4e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs12048904	0.505	rs11166511	chr1:101240686	G/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.78	-6.84	-0.52	3.2e-10	Multiple sclerosis;
TGCT	cis	rs2797780	1.000	rs2776882	chr6:37508075	T/C	cg00985040	chr6:37553208	NA	0.24	4.77	0.39	5.04e-6	Systemic lupus erythematosus;
TGCT	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg20887711	chr4:1340912	KIAA1530	0.91	8.34	0.6	1.22e-13	Longevity;
TGCT	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg27286337	chr10:134555280	INPP5A	0.41	4.9	0.4	2.97e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs60154123	0.505	rs1319435	chr1:210047618	C/T	cg21951975	chr1:209979733	IRF6	-0.65	-4.72	-0.39	6.19e-6	Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs7696715	chr4:98938486	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg11062466	chr8:58055876	NA	0.43	4.58	0.38	1.11e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	6.78	0.52	4.27e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs1577917	1.000	rs1577919	chr6:86757296	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.2	-0.42	8.12e-7	Response to antipsychotic treatment;
TGCT	cis	rs7528684	0.779	rs7529060	chr1:157725264	T/G	cg17134153	chr1:157670328	FCRL3	-0.26	-4.58	-0.38	1.11e-5	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;
TGCT	cis	rs651907	0.737	rs9844218	chr3:101584983	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.63	-6.66	-0.51	8.05e-10	Colorectal cancer;
TGCT	cis	rs17601876	0.623	rs1062033	chr15:51547938	C/G	cg19946085	chr15:51559439	CYP19A1	-0.34	-4.84	-0.4	3.73e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs514406	0.505	rs7543239	chr1:53162416	A/G	cg22166914	chr1:53195759	ZYG11B	0.44	7.64	0.57	5.13e-12	Monocyte count;
TGCT	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg26818010	chr10:134567672	INPP5A	-0.36	-4.82	-0.4	4.08e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs16866061	1.000	rs72974269	chr2:225454907	C/T	cg12698349	chr2:225449008	CUL3	1.0	9.4	0.64	3.62e-16	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	cis	rs62064224	0.614	rs8065246	chr17:30682274	T/C	cg18200150	chr17:30822561	MYO1D	0.39	4.7	0.39	6.66e-6	Schizophrenia;
TGCT	cis	rs3020333	0.875	rs3020334	chr6:152012956	A/G	cg22157087	chr6:152012887	ESR1	0.19	4.65	0.39	8.27e-6	Total body bone mineral density;
TGCT	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg00684032	chr4:1343700	KIAA1530	-0.22	-4.73	-0.39	6.06e-6	Obesity-related traits;
TGCT	cis	rs2072499	0.898	rs2758609	chr1:156202868	G/A	cg25208724	chr1:156163844	SLC25A44	0.97	10.22	0.68	3.76e-18	Testicular germ cell tumor;
TGCT	cis	rs4950928	0.887	rs7556099	chr1:203166198	C/G	cg17014757	chr1:203156097	CHI3L1	-0.36	-4.56	-0.38	1.22e-5	YKL-40 levels;
TGCT	cis	rs12210905	0.920	rs9379975	chr6:27295808	T/A	cg08851530	chr6:28072375	NA	1.29	5.45	0.44	2.65e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg06028808	chr11:68637592	NA	0.54	6.88	0.53	2.63e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs2224391	0.628	rs2753237	chr6:5252675	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-1.0	-6.49	-0.5	1.9e-9	Height;
TGCT	cis	rs6430585	0.941	rs60963894	chr2:136539670	T/G	cg07169764	chr2:136633963	MCM6	0.89	7.96	0.58	9.17e-13	Corneal structure;
TGCT	cis	rs9926296	0.656	rs2376881	chr16:89827011	C/G	cg27121462	chr16:89883253	FANCA	0.57	5.41	0.44	3.15e-7	Vitiligo;
TGCT	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg06873352	chr17:61820015	STRADA	-0.58	-6.3	-0.49	4.66e-9	Prudent dietary pattern;
TGCT	cis	rs12681288	0.550	rs72507624	chr8:961324	G/A	cg04851639	chr8:1020857	NA	-0.29	-4.76	-0.39	5.27e-6	Schizophrenia;
TGCT	cis	rs8031584	0.958	rs61997079	chr15:31238271	G/C	cg08704250	chr15:31115839	NA	-0.36	-4.96	-0.41	2.29e-6	Huntington's disease progression;
TGCT	cis	rs9894429	0.683	rs112612275	chr17:79552604	C/A	cg21984481	chr17:79567631	NPLOC4	0.26	4.83	0.4	3.98e-6	Eye color traits;
TGCT	cis	rs921943	0.554	rs163132	chr5:78285921	A/G	cg18828365	chr5:78281819	ARSB	0.35	4.6	0.38	1.05e-5	Blood and toenail selenium levels;Blood trace element (Se levels);
TGCT	cis	rs1580019	0.961	rs4460271	chr7:32496503	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.79	7.42	0.55	1.63e-11	Cognitive ability;
TGCT	cis	rs1008375	0.544	rs56227066	chr4:17565713	G/A	cg10189774	chr4:17578691	LAP3	0.58	5.32	0.43	4.76e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs36051895	0.632	rs10815164	chr9:5131312	T/A	cg02405213	chr9:5042618	JAK2	-0.71	-9.55	-0.65	1.57e-16	Pediatric autoimmune diseases;
TGCT	cis	rs2439831	0.867	rs11856184	chr15:43919162	A/C	cg19166733	chr15:44192098	FRMD5	-0.24	-4.89	-0.4	3.08e-6	Lung cancer in ever smokers;
TGCT	cis	rs9810089	0.872	rs527888	chr3:136031358	G/C	cg12473912	chr3:136751656	NA	0.35	4.91	0.4	2.77e-6	Gestational age at birth (child effect);
TGCT	cis	rs7647973	0.961	rs62259943	chr3:49425167	A/G	cg07636037	chr3:49044803	WDR6	-0.72	-5.7	-0.46	8.28e-8	Menarche (age at onset);
TGCT	cis	rs7147624	0.938	rs10467734	chr14:65913947	C/T	cg03016385	chr14:66212404	NA	-0.5	-7.18	-0.54	5.64e-11	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs6684514	1.000	rs3806409	chr1:156252291	A/G	cg16558208	chr1:156270281	VHLL	0.46	9.38	0.64	3.92e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs4268898	0.760	rs4665675	chr2:24468132	C/T	cg02683114	chr2:24398427	C2orf84	-0.21	-4.87	-0.4	3.39e-6	Asthma;
TGCT	cis	rs3818285	0.515	rs12258440	chr10:111676799	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.32	-5.51	-0.44	2.03e-7	Superior crus of antihelix expression;
TGCT	cis	rs3771570	0.901	rs62190413	chr2:242417950	G/A	cg21155796	chr2:242212141	HDLBP	0.92	6.63	0.51	9.25e-10	Prostate cancer;
TGCT	cis	rs8017423	0.967	rs2277516	chr14:90722824	G/C	cg04374321	chr14:90722782	PSMC1	0.76	7.71	0.57	3.59e-12	Mortality in heart failure;
TGCT	cis	rs13064411	0.696	rs7624994	chr3:113228009	T/C	cg10517650	chr3:113235015	CCDC52	-0.32	-4.45	-0.37	1.85e-5	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs66561647	0.661	rs35851359	chr8:128935626	G/C	cg11792826	chr8:129160931	MIR1208	0.21	4.87	0.4	3.38e-6	Hemoglobin concentration;
TGCT	cis	rs7833790	1.000	rs7833384	chr8:82730915	T/C	cg23324259	chr8:82754387	SNX16	-0.65	-4.49	-0.37	1.59e-5	Diastolic blood pressure;
TGCT	cis	rs882732	0.576	rs10139508	chr14:95035399	A/G	cg24754598	chr14:95966488	NA	0.24	4.64	0.38	8.75e-6	Blood protein levels;
TGCT	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg08219700	chr8:58056026	NA	0.3	4.55	0.38	1.25e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs61524473	1	rs61524473	chr15:45646283	T/C	cg26924012	chr15:45694286	SPATA5L1	1.09	15.16	0.81	5.15e-30	Metabolite levels (small molecules and protein measures);
TGCT	cis	rs7582180	0.790	rs13020451	chr2:100927131	T/G	cg08017756	chr2:100939284	LONRF2	-0.32	-5.26	-0.43	6.1e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs6546537	1.000	rs17036866	chr2:69857711	T/C	cg10773587	chr2:69614142	GFPT1	-0.77	-6.5	-0.5	1.79e-9	Serum thyroid-stimulating hormone levels;
TGCT	cis	rs3796352	1.000	rs11712653	chr3:53070875	A/C	cg07884673	chr3:53033167	SFMBT1	-0.62	-7.53	-0.56	9.25e-12	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs4325129	0.651	rs11265220	chr1:159494324	T/C	cg07417683	chr1:159440267	NA	0.37	4.64	0.38	8.54e-6	Obesity-related traits;
TGCT	cis	rs7172809	0.561	rs76746801	chr15:77789773	C/T	cg22256960	chr15:77711686	NA	-0.51	-4.86	-0.4	3.47e-6	Glucose homeostasis traits;
TGCT	cis	rs10791097	0.547	rs3829271	chr11:130753912	T/A	cg12179176	chr11:130786555	SNX19	0.86	10.31	0.68	2.26e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs1008375	0.931	rs7672369	chr4:17604825	A/G	cg10189774	chr4:17578691	LAP3	0.65	5.53	0.44	1.84e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs950776	0.518	rs12910100	chr15:78822667	C/T	cg06917634	chr15:78832804	PSMA4	0.95	9.52	0.65	1.81e-16	Sudden cardiac arrest;
TGCT	trans	rs9329221	0.741	rs58689676	chr8:9806492	T/C	cg15556689	chr8:8085844	FLJ10661	-0.82	-7.76	-0.57	2.7e-12	Neuroticism;
TGCT	cis	rs6089584	0.927	rs2296083	chr20:60574216	C/T	cg16423285	chr20:60520624	NA	-0.63	-6.97	-0.53	1.66e-10	Body mass index;
TGCT	cis	rs992157	0.764	rs13020391	chr2:219184436	C/T	cg00012203	chr2:219082015	ARPC2	-0.74	-6.77	-0.52	4.62e-10	Colorectal cancer;
TGCT	cis	rs7615952	0.866	rs13063119	chr3:125643847	G/A	cg05084668	chr3:125655381	ALG1L	-0.76	-6.21	-0.49	7.3e-9	Blood pressure (smoking interaction);
TGCT	cis	rs12049351	0.774	rs11805194	chr1:229631734	T/C	cg12130225	chr1:229698885	NA	0.39	4.59	0.38	1.06e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.71	0.39	6.53e-6	Prudent dietary pattern;
TGCT	cis	rs6840360	0.593	rs867800	chr4:152691470	T/C	cg17479576	chr4:152424074	FAM160A1	-0.53	-5.26	-0.43	5.99e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs11627546	0.528	rs61980573	chr14:70362467	G/A	cg10496350	chr14:71275911	MAP3K9	-1.01	-4.93	-0.41	2.54e-6	Red blood cell traits;
TGCT	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg06028808	chr11:68637592	NA	-0.52	-6.74	-0.52	5.39e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs1933488	0.931	rs9397587	chr6:153416912	G/A	cg24028809	chr6:153414101	RGS17	0.21	4.67	0.39	7.69e-6	Prostate cancer;
TGCT	cis	rs9341808	0.667	rs3828753	chr6:80912746	C/T	cg08355045	chr6:80787529	NA	0.3	4.98	0.41	2.07e-6	Sitting height ratio;
TGCT	cis	rs7917772	0.636	rs1475644	chr10:104491164	G/A	cg05855489	chr10:104503620	C10orf26	-0.66	-5.31	-0.43	5e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs10464366	0.571	rs13233049	chr7:39187536	C/T	cg15212455	chr7:39170539	POU6F2	0.3	6.73	0.52	5.66e-10	IgG glycosylation;
TGCT	cis	rs611744	0.870	rs613179	chr8:109166006	G/A	cg21045802	chr8:109455806	TTC35	0.69	6.06	0.48	1.51e-8	Dupuytren's disease;
TGCT	trans	rs3780486	0.846	rs73484568	chr9:33132492	G/A	cg20290983	chr6:43655470	MRPS18A	1.19	14.84	0.8	2.81e-29	IgG glycosylation;
TGCT	cis	rs9948	0.737	rs878064	chr2:97438552	G/C	cg01990225	chr2:97406019	LMAN2L	-0.79	-4.96	-0.41	2.27e-6	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs735396	0.770	rs2257764	chr12:121446446	T/A	cg02403541	chr12:121454288	C12orf43	-0.77	-7.48	-0.56	1.16e-11	N-glycan levels;
TGCT	cis	rs7647973	0.560	rs7638154	chr3:49299375	C/A	cg06212747	chr3:49208901	KLHDC8B	0.67	6.36	0.5	3.57e-9	Menarche (age at onset);
TGCT	cis	rs9486715	0.867	rs4839842	chr6:96955387	A/T	cg18709589	chr6:96969512	KIAA0776	0.82	8.01	0.58	7.14e-13	Headache;
TGCT	cis	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg18252515	chr7:66147081	NA	-1.09	-6.4	-0.5	2.88e-9	Diabetic kidney disease;
TGCT	cis	rs7826238	0.564	rs2921053	chr8:8319963	G/C	cg15556689	chr8:8085844	FLJ10661	0.73	6.9	0.53	2.38e-10	Systolic blood pressure;
TGCT	cis	rs9921338	0.961	rs4315353	chr16:11414160	T/C	cg00044050	chr16:11439710	C16orf75	0.95	7.39	0.55	1.92e-11	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs9326248	0.911	rs474339	chr11:117059552	G/A	cg16524733	chr11:117070046	TAGLN	0.33	4.95	0.41	2.33e-6	Blood protein levels;
TGCT	cis	rs11209185	0.527	rs11209186	chr1:68434340	A/G	cg22082780	chr1:68452167	NA	-0.31	-4.66	-0.39	8.01e-6	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs2153535	0.580	rs1932281	chr6:8473765	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs12477438	0.734	rs4851184	chr2:99666434	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-6.1	-0.48	1.22e-8	Chronic sinus infection;
TGCT	cis	rs7937682	0.632	rs3944619	chr11:111774743	A/G	cg09085632	chr11:111637200	PPP2R1B	0.84	7.34	0.55	2.4e-11	Primary sclerosing cholangitis;
TGCT	cis	rs9300255	0.596	rs11057202	chr12:123720775	G/T	cg00376283	chr12:123451042	ABCB9	0.79	6.72	0.52	6e-10	Neutrophil percentage of white cells;
TGCT	cis	rs7829975	0.711	rs4481596	chr8:8704330	G/C	cg08975724	chr8:8085496	FLJ10661	0.56	5.04	0.41	1.6e-6	Mood instability;
TGCT	cis	rs6500602	0.702	rs11076834	chr16:4549583	C/G	cg08645402	chr16:4508243	NA	0.19	5.23	0.43	6.9e-7	Schizophrenia;
TGCT	cis	rs447921	0.861	rs4789297	chr17:74447351	G/T	cg09812376	chr17:74270190	QRICH2	-0.42	-4.54	-0.38	1.29e-5	Mitochondrial DNA levels;
TGCT	cis	rs155076	1.000	rs564685	chr13:21846879	A/G	cg14456004	chr13:21872349	NA	-1.32	-10.82	-0.7	1.25e-19	White matter hyperintensity burden;
TGCT	cis	rs7666738	0.830	rs11727612	chr4:99001662	T/C	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7926906	0.715	rs7127256	chr11:90525490	C/T	cg26138821	chr11:89956704	CHORDC1	0.49	5.03	0.41	1.69e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	5.02	0.41	1.78e-6	Prudent dietary pattern;
TGCT	cis	rs3008870	1.000	rs3008894	chr1:67377739	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.08	11.27	0.71	1.02e-20	Lymphocyte percentage of white cells;
TGCT	trans	rs783396	0.685	rs67667413	chr6:107086560	G/A	cg27564810	chr2:201635376	AOX2P	0.5	6.61	0.51	1e-9	Stroke;
TGCT	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg13683864	chr3:40499215	RPL14	1.16	12.09	0.74	1.04e-22	Renal cell carcinoma;
TGCT	cis	rs7208859	0.623	rs11650271	chr17:29213943	C/T	cg14008862	chr17:28927542	LRRC37B2	0.72	4.66	0.39	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg23708337	chr7:1209742	NA	0.51	4.46	0.37	1.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7089973	0.565	rs7082836	chr10:116646237	G/A	cg03647239	chr10:116582469	FAM160B1	0.55	5.04	0.41	1.64e-6	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs12681287	0.752	rs4463401	chr8:87250309	C/T	cg27223183	chr8:87520930	FAM82B	-0.8	-5.67	-0.45	9.58e-8	Caudate activity during reward;
TGCT	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg11890956	chr21:40555474	PSMG1	1.13	12.1	0.74	1e-22	Cognitive function;
TGCT	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg24503407	chr1:205819492	PM20D1	0.42	5.17	0.42	9.1e-7	Menarche (age at onset);
TGCT	cis	rs7647973	0.626	rs4855845	chr3:49687043	T/C	cg03060546	chr3:49711283	APEH	0.65	5.7	0.46	8.3e-8	Menarche (age at onset);
TGCT	cis	rs7917772	0.503	rs7896841	chr10:104294665	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	8.36	0.6	1.1e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs62244186	0.659	rs56234157	chr3:44516221	G/A	cg10108389	chr3:44770937	ZNF501	-0.48	-4.97	-0.41	2.13e-6	Depressive symptoms;
TGCT	cis	rs9902453	0.765	rs2264302	chr17:28057095	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.84	-8.39	-0.6	9.14e-14	Coffee consumption (cups per day);
TGCT	cis	rs8070740	0.841	rs2189337	chr17:5326178	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.49	4.88	0.4	3.15e-6	Menopause (age at onset);
TGCT	cis	rs644799	1.000	rs623191	chr11:95548359	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	10.57	0.69	5.17e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs16867321	0.588	rs1919156	chr2:181456978	C/T	cg23363182	chr2:181467187	NA	-0.41	-6.04	-0.48	1.69e-8	Obesity;
TGCT	cis	rs9467773	0.967	rs9461267	chr6:26525455	T/G	cg05738196	chr6:26577821	NA	0.88	12.5	0.75	1.03e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs61990749	0.597	rs17106157	chr14:78146878	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	-0.66	-4.65	-0.39	8.45e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg23758822	chr17:41437982	NA	0.72	6.96	0.53	1.79e-10	Menopause (age at onset);
TGCT	cis	rs62244186	0.748	rs2888410	chr3:44655476	A/C	cg15687855	chr3:44754131	ZNF502	-0.46	-5.54	-0.45	1.69e-7	Depressive symptoms;
TGCT	cis	rs8031584	0.918	rs34331396	chr15:31248736	C/G	cg08704250	chr15:31115839	NA	-0.36	-4.98	-0.41	2.07e-6	Huntington's disease progression;
TGCT	cis	rs8180040	0.701	rs7625067	chr3:47095305	T/C	cg27129171	chr3:47204927	SETD2	0.74	9.79	0.66	4.15e-17	Colorectal cancer;
TGCT	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg03188948	chr7:1209495	NA	0.63	5.71	0.46	7.71e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9381040	0.655	rs9381031	chr6:41044957	A/T	cg03526776	chr6:41159608	TREML2	0.27	5.34	0.43	4.21e-7	Alzheimer's disease (late onset);
TGCT	cis	rs72781680	0.898	rs17462670	chr2:24026579	T/C	cg08917208	chr2:24149416	ATAD2B	0.81	5.01	0.41	1.8e-6	Lymphocyte counts;
TGCT	cis	rs2535633	0.631	rs2710314	chr3:52969128	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	0.54	4.88	0.4	3.22e-6	Body mass index;
TGCT	cis	rs826838	0.935	rs1601579	chr12:39178606	G/C	cg13010199	chr12:38710504	ALG10B	0.78	6.16	0.48	9.26e-9	Heart rate;
TGCT	cis	rs2153535	0.542	rs9393012	chr6:8439809	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.58	0.45	1.42e-7	Motion sickness;
TGCT	cis	rs66887589	0.616	rs11732621	chr4:120212883	A/C	cg24670566	chr4:120433619	PDE5A	0.21	4.61	0.38	9.68e-6	Diastolic blood pressure;
TGCT	cis	rs11651000	0.857	rs16947078	chr17:45825500	A/G	cg06532163	chr17:45867833	NA	0.37	5.23	0.43	6.97e-7	IgG glycosylation;
TGCT	cis	rs8077577	0.895	rs6502640	chr17:18122485	G/A	cg09161412	chr17:18057145	MYO15A	-0.6	-4.79	-0.4	4.61e-6	Obesity-related traits;
TGCT	cis	rs2204008	0.506	rs11495470	chr12:38026904	C/T	cg13010199	chr12:38710504	ALG10B	0.61	4.9	0.4	2.88e-6	Bladder cancer;
TGCT	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg20887711	chr4:1340912	KIAA1530	-0.76	-6.57	-0.51	1.22e-9	Longevity;
TGCT	cis	rs3806843	0.900	rs2563279	chr5:140131535	G/A	cg19875535	chr5:140030758	IK	-0.36	-5.96	-0.47	2.41e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs6543140	0.964	rs1035126	chr2:103019981	C/T	cg09003973	chr2:102972529	NA	0.57	4.8	0.4	4.45e-6	Blood protein levels;
TGCT	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg00024416	chr22:24240387	NA	-0.25	-4.84	-0.4	3.81e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9359856	0.564	rs72915904	chr6:90421412	C/A	cg13799429	chr6:90582589	CASP8AP2	-0.48	-4.51	-0.38	1.49e-5	Bipolar disorder;
TGCT	cis	rs909674	0.662	rs2899318	chr22:39837625	A/G	cg05872129	chr22:39784769	NA	-0.98	-9.4	-0.65	3.51e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs11785400	0.793	rs11785012	chr8:143748355	G/A	cg10596483	chr8:143751796	JRK	0.55	5.34	0.43	4.27e-7	Schizophrenia;
TGCT	cis	rs9640161	0.789	rs10952250	chr7:150025966	T/C	cg17279839	chr7:150038598	RARRES2	0.43	4.66	0.39	7.91e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs62244186	0.659	rs56231820	chr3:44530329	C/T	cg02073558	chr3:44770973	ZNF501	0.57	5.66	0.45	9.81e-8	Depressive symptoms;
TGCT	cis	rs7552404	1.000	rs11161521	chr1:76216330	T/C	cg10523679	chr1:76189770	ACADM	0.89	9.53	0.65	1.72e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs6893807	0.778	rs1501673	chr5:87963600	G/A	cg24804195	chr5:87968844	LOC645323	0.82	5.14	0.42	1.03e-6	Body mass index;
TGCT	cis	rs6754311	0.593	rs313522	chr2:136430866	T/A	cg07169764	chr2:136633963	MCM6	0.65	5.79	0.46	5.38e-8	Mosquito bite size;
TGCT	cis	rs9527	0.590	rs2274339	chr10:104860053	T/A	cg04362960	chr10:104952993	NT5C2	0.68	5.82	0.46	4.81e-8	Arsenic metabolism;
TGCT	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg04234412	chr22:24373322	LOC391322	-0.91	-10.4	-0.68	1.31e-18	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6049375	1.000	rs6036628	chr20:24044396	A/G	cg14741141	chr20:24973699	C20orf3	0.74	4.67	0.39	7.81e-6	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg16325326	chr1:53192061	ZYG11B	-0.71	-8.82	-0.62	8.9e-15	Monocyte count;
TGCT	cis	rs3087591	0.664	rs2525565	chr17:29666588	T/C	cg24425628	chr17:29625626	OMG;NF1	0.39	5.56	0.45	1.57e-7	Hip circumference;
TGCT	cis	rs7432375	0.610	rs60574021	chr3:136520281	C/G	cg15507776	chr3:136538369	TMEM22	0.55	5.63	0.45	1.15e-7	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs17331151	0.505	rs35325270	chr3:52556369	C/T	cg15956490	chr3:53032818	SFMBT1	0.63	4.8	0.4	4.48e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.48	-5.53	-0.44	1.83e-7	Longevity;Endometriosis;
TGCT	cis	rs59107033	0.607	rs12496583	chr3:123121286	C/T	cg04890266	chr3:123102914	ADCY5	0.36	5.36	0.43	3.9e-7	Lymphocyte counts;
TGCT	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg25703541	chr22:24373054	LOC391322	0.81	8.47	0.61	5.88e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs17030434	0.953	rs10014299	chr4:154700858	A/G	cg14289246	chr4:154710475	SFRP2	-0.95	-7.52	-0.56	9.48e-12	Electrocardiographic conduction measures;
TGCT	cis	rs595982	0.510	rs3826817	chr19:49401444	C/T	cg21252483	chr19:49399788	TULP2	-0.29	-5.12	-0.42	1.13e-6	Red cell distribution width;
TGCT	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg12419862	chr22:24373484	LOC391322	-0.79	-8.23	-0.59	2.19e-13	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2153535	0.580	rs4960411	chr6:8438231	C/G	cg07606381	chr6:8435919	SLC35B3	0.57	5.25	0.43	6.46e-7	Motion sickness;
TGCT	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg18538332	chr22:24372958	LOC391322	-1.02	-13.36	-0.77	9.13e-26	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg19748678	chr4:122722346	EXOSC9	0.9	9.34	0.64	4.9e-16	Type 2 diabetes;
TGCT	cis	rs6570726	0.935	rs369214	chr6:145856709	G/A	cg05347473	chr6:146136440	FBXO30	0.49	4.54	0.38	1.29e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs752590	0.720	rs2305132	chr2:113956941	T/A	cg27425262	chr2:113953981	PSD4;LOC440839	0.4	4.63	0.38	9.02e-6	Mucinous ovarian carcinoma;
TGCT	cis	rs78456975	1.000	rs6730391	chr2:1566838	A/C	cg01028140	chr2:1542097	TPO	-0.33	-4.54	-0.38	1.29e-5	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs3796352	1.000	rs4478072	chr3:53106125	G/T	cg07884673	chr3:53033167	SFMBT1	0.57	6.03	0.48	1.78e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs11605924	0.934	rs7945565	chr11:45878992	A/G	ch.11.939596F	chr11:45881766	CRY2	-0.38	-4.61	-0.38	9.73e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
TGCT	cis	rs7095607	0.813	rs7905259	chr10:69926610	A/C	cg18986048	chr10:69913749	MYPN	0.44	5.03	0.41	1.68e-6	Lung function (FVC);
TGCT	cis	rs2832191	0.755	rs2832192	chr21:30491173	G/T	cg08807101	chr21:30365312	RNF160	-0.62	-5.79	-0.46	5.38e-8	Dental caries;
TGCT	cis	rs497273	0.517	rs580240	chr12:121199903	T/G	cg02419362	chr12:121203948	SPPL3	0.19	4.52	0.38	1.43e-5	Systemic lupus erythematosus;
TGCT	cis	rs2033711	0.936	rs7257999	chr19:58964860	C/G	cg04608855	chr19:58913158	NA	0.61	5.93	0.47	2.86e-8	Uric acid clearance;
TGCT	cis	rs877282	0.945	rs11599043	chr10:777972	C/T	cg17470449	chr10:769945	NA	0.31	5.02	0.41	1.76e-6	Uric acid levels;
TGCT	cis	rs7772486	0.875	rs2814873	chr6:146308932	T/C	cg23711669	chr6:146136114	FBXO30	0.89	9.5	0.65	2.02e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7833790	0.724	rs10958045	chr8:82722994	T/C	cg17211192	chr8:82754475	SNX16	-0.95	-8.83	-0.62	8.45e-15	Diastolic blood pressure;
TGCT	cis	rs6840360	0.615	rs12647465	chr4:152607318	C/A	cg22705602	chr4:152727874	NA	-0.32	-5.44	-0.44	2.71e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs6912958	0.728	rs6923230	chr6:88213949	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-5.06	-0.41	1.45e-6	Monocyte percentage of white cells;
TGCT	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg21862992	chr11:68658383	NA	0.45	6.11	0.48	1.21e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg00024416	chr22:24240387	NA	-0.26	-4.93	-0.4	2.61e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs10782582	0.609	rs1630302	chr1:76412090	A/T	cg03433033	chr1:76189801	ACADM	-0.52	-5.06	-0.41	1.44e-6	Daytime sleep phenotypes;
TGCT	trans	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg23505145	chr19:12996616	KLF1	0.79	8.3	0.6	1.47e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg13607699	chr17:42295918	UBTF	-0.83	-7.37	-0.55	2.14e-11	Total body bone mineral density;
TGCT	cis	rs3741404	0.931	rs594942	chr11:64006292	T/C	cg19570321	chr11:63258214	HRASLS5	-0.45	-5.18	-0.42	8.76e-7	Platelet count;
TGCT	cis	rs4888262	0.545	rs4243108	chr16:74692453	A/G	cg01733217	chr16:74700730	RFWD3	-0.74	-7.5	-0.56	1.05e-11	Testicular germ cell tumor;
TGCT	trans	rs74976893	1.000	rs2429935	chr17:69719420	A/G	cg25743221	chr6:152501416	SYNE1	0.94	6.78	0.52	4.46e-10	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
TGCT	cis	rs3774830	0.748	rs7698146	chr4:5465476	G/A	cg26943120	chr4:5472116	STK32B	0.22	4.82	0.4	4.15e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2070997	0.715	rs11244164	chr9:133736116	A/G	cg01000188	chr9:133769184	QRFP	0.26	4.49	0.37	1.59e-5	Response to amphetamines;
TGCT	cis	rs2594989	1.000	rs2594989	chr3:11316143	C/T	cg00170343	chr3:11313890	ATG7	0.67	5.23	0.42	7.12e-7	Circulating chemerin levels;
TGCT	cis	rs2404602	0.647	rs11631959	chr15:77040048	T/C	cg23625390	chr15:77176239	SCAPER	-0.38	-4.79	-0.39	4.75e-6	Blood metabolite levels;
TGCT	cis	rs7267979	0.727	rs4815431	chr20:25532405	T/C	cg03522245	chr20:25566470	NINL	-0.56	-5.79	-0.46	5.51e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6570726	0.738	rs6925594	chr6:145898454	T/C	cg23711669	chr6:146136114	FBXO30	0.86	9.54	0.65	1.64e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9916302	0.904	rs12600751	chr17:37553651	G/C	cg15445000	chr17:37608096	MED1	-0.36	-5.09	-0.42	1.31e-6	Glomerular filtration rate (creatinine);
TGCT	trans	rs1499614	1.000	rs2707838	chr7:66159201	C/T	cg07424592	chr7:64974309	NA	1.35	8.11	0.59	4.14e-13	Gout;
TGCT	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.65	-6.18	-0.49	8.55e-9	Bipolar disorder;
TGCT	cis	rs72615157	0.628	rs7801070	chr7:99847147	T/G	cg00814883	chr7:100076585	TSC22D4	-0.58	-5.56	-0.45	1.57e-7	Lung function (FEV1/FVC);
TGCT	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg10150615	chr22:24372951	LOC391322	0.84	7.28	0.55	3.42e-11	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs2745967	0.529	rs658347	chr1:208058924	C/T	cg22525895	chr1:207977042	MIR29B2	-0.36	-5.65	-0.45	1.03e-7	Resting heart rate;
TGCT	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg00149659	chr3:10157352	C3orf10	1.17	7.24	0.55	4.13e-11	Alzheimer's disease;
TGCT	cis	rs8072100	0.846	rs6503796	chr17:45765249	T/C	cg08085267	chr17:45401833	C17orf57	-0.49	-5.3	-0.43	5.16e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs8017423	0.967	rs2277515	chr14:90723000	A/G	cg04374321	chr14:90722782	PSMC1	0.76	7.71	0.57	3.59e-12	Mortality in heart failure;
TGCT	cis	rs77633900	0.614	rs2439982	chr15:76925071	T/G	cg21673338	chr15:77095150	SCAPER	-0.5	-4.82	-0.4	4.07e-6	Non-glioblastoma glioma;Glioma;
TGCT	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg27425262	chr2:113953981	PSD4;LOC440839	-0.52	-8.2	-0.59	2.53e-13	Lymphocyte counts;
TGCT	cis	rs6671200	1.000	rs76064624	chr1:95661033	A/G	cg26537280	chr1:95699037	RWDD3	0.68	5.49	0.44	2.15e-7	Stearic acid (18:0) levels;
TGCT	cis	rs950169	1.000	rs12903820	chr15:84723820	A/G	cg11189052	chr15:85197271	WDR73	0.69	5.91	0.47	3.14e-8	Schizophrenia;
TGCT	cis	rs7824557	0.707	rs3808518	chr8:11143272	A/C	cg21775007	chr8:11205619	TDH	-0.6	-5.79	-0.46	5.49e-8	Retinal vascular caliber;
TGCT	cis	rs2236918	0.687	rs1776176	chr1:242012554	C/T	cg04158730	chr1:242011433	EXO1	0.57	5.31	0.43	4.82e-7	Menopause (age at onset);
TGCT	cis	rs9611565	0.570	rs12159188	chr22:42121125	A/T	cg06634786	chr22:41940651	POLR3H	0.86	8.54	0.61	4.12e-14	Vitiligo;
TGCT	cis	rs11711311	1.000	rs2242109	chr3:113434100	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.78	-7.13	-0.54	7.14e-11	IgG glycosylation;
TGCT	cis	rs9677476	0.608	rs6437005	chr2:232055735	A/G	cg07929768	chr2:232055508	NA	0.35	5.64	0.45	1.09e-7	Food antigen IgG levels;
TGCT	cis	rs6582630	0.519	rs11181998	chr12:38439970	C/A	cg13010199	chr12:38710504	ALG10B	0.59	4.79	0.4	4.67e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg27454412	chr7:1067447	C7orf50	0.56	4.5	0.37	1.55e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs3806843	0.576	rs246043	chr5:140330924	G/A	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs6740731	0.518	rs35766785	chr2:145295628	C/T	cg07679370	chr2:145795797	NA	0.29	5.63	0.45	1.14e-7	Coronary artery disease;
TGCT	cis	rs9534288	0.700	rs9316178	chr13:46570449	A/G	cg15192986	chr13:46630673	CPB2	-0.53	-7.62	-0.56	5.82e-12	Blood protein levels;
TGCT	cis	rs9913156	0.789	rs56003988	chr17:4600764	G/A	cg00122941	chr17:4613640	ARRB2	0.88	7.63	0.57	5.46e-12	Lymphocyte counts;
TGCT	cis	rs4455778	0.580	rs4275185	chr7:49114615	C/G	cg26309511	chr7:48887640	NA	0.5	6.47	0.5	2.07e-9	Lung cancer in never smokers;
TGCT	cis	rs2574985	0.530	rs4935727	chr10:52277400	G/A	cg12753529	chr10:51525504	NA	0.23	4.67	0.39	7.62e-6	Subjective well-being;
TGCT	cis	rs4372836	0.504	rs3768666	chr2:29005870	C/T	cg09522027	chr2:28974177	PPP1CB	-0.56	-5.65	-0.45	1.06e-7	Body mass index;
TGCT	cis	rs4148883	0.504	rs2000864	chr4:100123776	A/C	cg12011299	chr4:100065546	ADH4	0.36	4.99	0.41	1.95e-6	Alcohol dependence;
TGCT	cis	rs804280	0.564	rs4639	chr8:11644751	A/G	cg26752888	chr8:11627280	NEIL2	-0.56	-5.16	-0.42	9.44e-7	Myopia (pathological);
TGCT	cis	rs1865760	0.534	rs2032444	chr6:26046744	T/G	cg17691542	chr6:26056736	HIST1H1C	0.71	5.55	0.45	1.69e-7	Height;
TGCT	cis	rs11785400	0.793	rs1137521	chr8:143739162	C/T	cg10596483	chr8:143751796	JRK	0.55	5.48	0.44	2.29e-7	Schizophrenia;
TGCT	trans	rs9951602	0.512	rs12607612	chr18:76651799	G/A	cg02800362	chr5:177631904	HNRNPAB	1.14	12.9	0.76	1.17e-24	Obesity-related traits;
TGCT	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg27211696	chr2:191398769	TMEM194B	0.28	5.28	0.43	5.54e-7	Pulse pressure;
TGCT	cis	rs1903068	0.853	rs12331597	chr4:55997914	T/C	cg09978860	chr4:56023921	NA	0.59	6.55	0.51	1.38e-9	Endometriosis;
TGCT	trans	rs210152	0.588	rs210131	chr6:33535466	T/C	cg08795360	chr21:41033440	B3GALT5	-0.47	-7.42	-0.55	1.59e-11	Schizophrenia;
TGCT	cis	rs72634258	0.572	rs66692705	chr1:7938565	T/C	cg26816564	chr1:7831052	VAMP3	0.65	4.98	0.41	2.11e-6	Inflammatory bowel disease;
TGCT	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg22535103	chr8:58192502	C8orf71	-0.4	-5.13	-0.42	1.08e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs911555	0.570	rs752624	chr14:104020454	T/C	cg26031613	chr14:104095156	KLC1	0.57	5.19	0.42	8.39e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7818688	0.697	rs77402106	chr8:95970484	C/T	cg16049864	chr8:95962084	TP53INP1	0.54	4.64	0.38	8.87e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs9372498	0.505	rs9481811	chr6:118801174	T/C	cg07617317	chr6:118971624	C6orf204	0.51	5.52	0.44	1.92e-7	Diastolic blood pressure;
TGCT	cis	rs6089584	0.816	rs4134440	chr20:60624296	A/G	cg06108461	chr20:60628389	TAF4	-0.75	-11.02	-0.7	4.27e-20	Body mass index;
TGCT	cis	rs12780845	0.505	rs10795462	chr10:17245119	A/C	cg01003015	chr10:17271136	VIM	-0.63	-5.69	-0.46	8.67e-8	Homocysteine levels;
TGCT	cis	rs17270561	1.000	rs17270561	chr6:25820439	A/C	cg16482183	chr6:26056742	HIST1H1C	-0.77	-5.23	-0.43	6.93e-7	Iron status biomarkers;
TGCT	cis	rs10791097	0.547	rs1050078	chr11:130746146	T/C	cg14779329	chr11:130786720	SNX19	0.29	4.79	0.4	4.58e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg11965913	chr1:205819406	PM20D1	-0.44	-4.8	-0.4	4.41e-6	Parkinson's disease;
TGCT	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	8.55	0.61	3.84e-14	Platelet count;
TGCT	cis	rs3770081	1.000	rs11899576	chr2:86256193	G/A	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.18	-4.81	-0.4	4.33e-6	Facial emotion recognition (sad faces);
TGCT	trans	rs561341	1.000	rs501957	chr17:30314504	C/T	cg20587970	chr11:113659929	NA	-1.04	-12.57	-0.75	6.97e-24	Hip circumference adjusted for BMI;
TGCT	cis	rs612683	0.599	rs2809823	chr1:101003762	C/A	cg09408571	chr1:101003634	GPR88	0.3	4.77	0.39	5.1e-6	Breast cancer;
TGCT	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg13752114	chr3:195489708	MUC4	0.32	4.71	0.39	6.56e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs12908161	0.959	rs12908699	chr15:85240403	G/T	cg12863693	chr15:85201151	NMB	0.46	5.53	0.44	1.79e-7	Schizophrenia;
TGCT	cis	rs3008870	1.000	rs12117131	chr1:67451922	C/T	cg03991309	chr1:68237761	GNG12	-0.27	-4.53	-0.38	1.36e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs17253792	0.822	rs8009239	chr14:56062490	A/G	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs6688613	0.685	rs2142615	chr1:166922731	G/C	cg07049167	chr1:166818506	POGK	0.25	5.13	0.42	1.08e-6	Refractive astigmatism;
TGCT	cis	rs910316	0.737	rs108621	chr14:75480637	T/C	cg11812906	chr14:75593930	NEK9	-0.58	-5.41	-0.44	3.16e-7	Height;
TGCT	cis	rs17253792	0.822	rs78429067	chr14:56092551	G/A	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg17911788	chr17:44343683	NA	-0.65	-6.61	-0.51	1.04e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2370759	1.000	rs79487858	chr10:32616405	T/C	cg01819863	chr10:32635814	EPC1	1.03	10.0	0.67	1.27e-17	Sexual dysfunction (female);
TGCT	cis	rs1167827	1.000	rs1167827	chr7:75163169	A/G	cg09919756	chr7:75617850	TMEM120A	-0.21	-4.61	-0.38	1e-5	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs4776059	1.000	rs62023352	chr15:52889448	T/C	cg25063058	chr15:52860530	ARPP19	0.54	4.81	0.4	4.23e-6	Schizophrenia;
TGCT	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg11941060	chr3:133502564	NA	-0.29	-6.14	-0.48	1.02e-8	Iron status biomarkers;
TGCT	trans	rs57221529	0.766	rs12522140	chr5:587261	C/A	cg11887960	chr12:57824829	NA	1.14	9.3	0.64	6.29e-16	Lung disease severity in cystic fibrosis;
TGCT	trans	rs7726839	0.507	rs60068988	chr5:597668	T/C	cg11887960	chr12:57824829	NA	1.2	9.56	0.65	1.47e-16	Obesity-related traits;
TGCT	cis	rs2288278	0.601	rs11652125	chr17:46597109	T/G	cg25032089	chr17:46643351	HOXB3	-0.42	-5.01	-0.41	1.86e-6	Hand grip strength;
TGCT	cis	rs6674176	0.597	rs6671164	chr1:44403489	G/T	cg13606994	chr1:44402422	ARTN	-0.48	-5.19	-0.42	8.24e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs12620999	0.774	rs2875726	chr2:237954576	T/C	cg23555395	chr2:238036564	NA	0.26	4.56	0.38	1.21e-5	Systemic lupus erythematosus;
TGCT	cis	rs8111998	0.826	rs10418805	chr19:22765991	A/G	cg19914732	chr19:22715077	NA	-0.56	-4.51	-0.38	1.46e-5	Corneal structure;
TGCT	cis	rs614226	1.000	rs580016	chr12:120933977	T/C	cg17541002	chr12:121714889	CAMKK2	0.24	4.46	0.37	1.83e-5	Type 1 diabetes nephropathy;
TGCT	cis	rs7267979	0.789	rs6083820	chr20:25354178	G/A	cg13486641	chr20:25479848	NINL	0.16	4.57	0.38	1.17e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs904251	0.772	rs1224127	chr6:37417556	G/A	cg01843034	chr6:37503916	NA	-0.44	-4.52	-0.38	1.43e-5	Cognitive performance;
TGCT	cis	rs1670533	0.697	rs658846	chr4:1084723	G/C	cg27284194	chr4:1044797	NA	0.64	5.09	0.42	1.26e-6	Recombination rate (females);
TGCT	cis	rs6740322	0.857	rs11690012	chr2:43542480	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.4	-6.71	-0.52	6.14e-10	Coronary artery disease;
TGCT	cis	rs4631830	0.863	rs57263518	chr10:51519154	A/G	cg10326726	chr10:51549505	MSMB	-0.26	-5.27	-0.43	5.78e-7	Prostate-specific antigen levels;
TGCT	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg11890956	chr21:40555474	PSMG1	1.1	11.97	0.73	2e-22	Cognitive function;
TGCT	cis	rs8062405	0.824	rs28772958	chr16:28535305	A/G	cg09754948	chr16:28834200	ATXN2L	0.63	5.01	0.41	1.79e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs908922	0.676	rs4112785	chr1:152533115	G/C	cg20991723	chr1:152506922	NA	0.44	5.91	0.47	3.08e-8	Hair morphology;
TGCT	cis	rs9952991	0.709	rs11874945	chr18:12754775	T/C	cg23598886	chr18:12777645	NA	-0.65	-4.66	-0.39	8.08e-6	Inflammatory skin disease;
TGCT	cis	rs288326	0.561	rs74869113	chr2:183858306	C/T	cg09997497	chr2:183902928	NCKAP1	1.11	4.95	0.41	2.38e-6	Blood protein levels;
TGCT	trans	rs2688608	0.592	rs10824032	chr10:75528130	G/A	cg13918328	chr10:52500089	ASAH2B	0.68	6.81	0.52	3.67e-10	Inflammatory bowel disease;
TGCT	cis	rs7945705	0.902	rs2016942	chr11:8938787	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.49	5.52	0.44	1.89e-7	Hemoglobin concentration;
TGCT	cis	rs7104764	0.957	rs6598075	chr11:207275	C/G	cg18336825	chr11:236787	PSMD13;SIRT3	-0.99	-10.18	-0.67	4.61e-18	Menarche (age at onset);
TGCT	cis	rs858239	0.539	rs2178140	chr7:23191625	G/C	cg05602783	chr7:23145260	KLHL7	-0.63	-4.98	-0.41	2.09e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs10032931	0.962	rs10030217	chr4:96457804	A/T	cg03008707	chr4:96468962	UNC5C	-0.33	-4.48	-0.37	1.65e-5	Optic nerve measurement (cup-to-disc ratio);
TGCT	cis	rs73198271	0.563	rs74556999	chr8:8548459	C/T	ch.8.214553F	chr8:8189620	PRAGMIN	-0.31	-5.1	-0.42	1.25e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs3809566	0.676	rs62013179	chr15:63329601	T/G	cg08198488	chr15:63333792	TPM1	-0.33	-4.97	-0.41	2.15e-6	Platelet count;
TGCT	cis	rs903263	0.901	rs11163908	chr1:84597803	A/T	cg09664975	chr1:84543551	PRKACB	0.5	4.67	0.39	7.62e-6	Breast cancer (male);
TGCT	cis	rs10791097	0.667	rs1893019	chr11:130756664	C/G	cg12179176	chr11:130786555	SNX19	0.83	9.92	0.67	1.94e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9309473	0.607	rs7567343	chr2:73596605	C/A	cg20560298	chr2:73613845	ALMS1	-0.41	-4.54	-0.38	1.31e-5	Metabolite levels;
TGCT	cis	rs7666738	0.830	rs1876192	chr4:98727555	T/C	cg18180107	chr4:99064573	C4orf37	0.53	5.07	0.41	1.38e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9549367	0.774	rs9549696	chr13:113875062	C/T	cg18105134	chr13:113819100	PROZ	-0.31	-5.29	-0.43	5.41e-7	Platelet distribution width;
TGCT	cis	rs460214	0.564	rs464519	chr21:40024182	A/G	cg05519781	chr21:40033154	ERG	-0.53	-4.55	-0.38	1.24e-5	Response to cognitive-behavioural therapy in anxiety disorder;
TGCT	cis	rs7809950	1.000	rs2712214	chr7:107188031	G/A	cg23024343	chr7:107201750	COG5	-0.35	-5.4	-0.44	3.21e-7	Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs34212748	chr4:99068708	G/A	cg05340658	chr4:99064831	C4orf37	0.52	5.79	0.46	5.32e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10858047	0.883	rs6701882	chr1:115181249	C/T	cg12756093	chr1:115239321	AMPD1	-0.45	-4.73	-0.39	6.09e-6	Autism;
TGCT	cis	rs12510870	0.598	rs12643650	chr4:74408727	G/A	cg05868023	chr4:75230803	EREG	0.56	5.14	0.42	1.06e-6	Iris color (b* coordinate);
TGCT	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg27436995	chr16:743998	FBXL16	-0.47	-5.12	-0.42	1.12e-6	Height;
TGCT	cis	rs2153904	0.793	rs12564209	chr1:205720212	C/G	cg23034840	chr1:205782522	SLC41A1	-0.82	-4.97	-0.41	2.19e-6	Prostate-specific antigen levels;
TGCT	cis	rs858239	0.669	rs1006709	chr7:23140099	C/T	cg00469287	chr7:23338798	C7orf30	0.42	4.5	0.38	1.51e-5	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs9646954	0.542	rs4149510	chr2:101023635	G/A	cg14675211	chr2:100938903	LONRF2	0.5	4.76	0.39	5.2e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs55794721	0.509	rs909834	chr1:25757996	A/G	cg10117171	chr1:25599238	RHD	-0.34	-5.63	-0.45	1.15e-7	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs2235642	0.891	rs2281231	chr16:1601879	A/G	cg00463982	chr16:1583984	IFT140;TMEM204	-0.27	-4.66	-0.39	8.15e-6	Coronary artery disease;
TGCT	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg25703541	chr22:24373054	LOC391322	-0.94	-11.48	-0.72	3.07e-21	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg10802521	chr3:52805072	NEK4	-0.72	-9.1	-0.63	1.91e-15	Bipolar disorder;
TGCT	cis	rs9302001	0.626	rs9561696	chr13:95469626	A/G	cg07483244	chr13:95358924	NA	-0.36	-4.56	-0.38	1.19e-5	Panic disorder;
TGCT	cis	rs9674544	0.757	rs4410130	chr17:47122942	C/T	cg20966754	chr17:47091339	IGF2BP1	0.45	4.99	0.41	2.02e-6	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
TGCT	cis	rs7547997	0.615	rs716221	chr1:158303872	C/T	cg07950803	chr1:158223934	CD1A	0.31	4.68	0.39	7.4e-6	QRS duration;
TGCT	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.62	5.28	0.43	5.61e-7	Tonsillectomy;
TGCT	cis	rs9467711	0.523	rs9379853	chr6:26357635	A/G	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4938534	0.785	rs1944926	chr11:111287287	T/G	cg24049888	chr11:111250129	POU2AF1	-0.26	-4.54	-0.38	1.3e-5	Primary biliary cholangitis;
TGCT	trans	rs17685	0.725	rs4728548	chr7:75654632	A/T	cg19862616	chr7:65841803	NCRNA00174	-0.47	-6.97	-0.53	1.65e-10	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs7617773	0.817	rs17786132	chr3:48249420	C/G	cg11946769	chr3:48343235	NME6	0.76	6.67	0.51	7.6e-10	Coronary artery disease;
TGCT	cis	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg07424592	chr7:64974309	NA	1.31	7.72	0.57	3.33e-12	Diabetic kidney disease;
TGCT	cis	rs6964587	1.000	rs6952671	chr7:91597934	C/A	cg17063962	chr7:91808500	NA	0.91	9.99	0.67	1.32e-17	Breast cancer;
TGCT	cis	rs933688	1.000	rs2367526	chr5:90740525	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.03	8.74	0.62	1.33e-14	Smoking behavior;
TGCT	cis	rs9308731	1.000	rs6542334	chr2:111907214	G/A	cg04202892	chr2:111875749	ACOXL	0.42	4.52	0.38	1.45e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs7103648	1.000	rs11039225	chr11:47430599	G/A	cg20307385	chr11:47447363	PSMC3	1.02	12.61	0.75	5.75e-24	Diastolic blood pressure;Systolic blood pressure;
TGCT	cis	rs701145	0.938	rs1086056	chr3:154088411	T/G	cg17054900	chr3:154042577	DHX36	0.49	4.48	0.37	1.69e-5	Coronary artery disease;
TGCT	trans	rs877282	0.945	rs10904550	chr10:774177	C/T	cg22713356	chr15:30763199	NA	1.11	9.86	0.66	2.79e-17	Uric acid levels;
TGCT	cis	rs1696756	0.877	rs2587500	chr17:77827362	A/T	cg00646381	chr17:77835854	NA	0.43	6.11	0.48	1.21e-8	Glucocorticoid-induced osteonecrosis (age 10 years and older);
TGCT	cis	rs3796352	0.527	rs11714793	chr3:52924930	A/G	cg15956490	chr3:53032818	SFMBT1	0.47	5.4	0.44	3.27e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs6424115	0.760	rs2999566	chr1:24051124	A/G	cg15997130	chr1:24165203	NA	0.67	6.31	0.49	4.56e-9	Immature fraction of reticulocytes;
TGCT	cis	rs10504229	0.593	rs1442127	chr8:57992136	T/C	cg08280861	chr8:58055591	NA	0.34	4.69	0.39	7.23e-6	Developmental language disorder (linguistic errors);
TGCT	trans	rs3780486	0.541	rs10738909	chr9:33148834	T/C	cg20290983	chr6:43655470	MRPS18A	0.78	8.36	0.6	1.08e-13	IgG glycosylation;
TGCT	cis	rs4713118	0.955	rs9468206	chr6:27690453	G/T	cg10876282	chr6:28092338	ZSCAN16	0.5	4.67	0.39	7.86e-6	Parkinson's disease;
TGCT	cis	rs3741404	0.895	rs1860368	chr11:63994692	T/C	cg19570321	chr11:63258214	HRASLS5	-0.46	-5.28	-0.43	5.67e-7	Platelet count;
TGCT	cis	rs7412746	0.553	rs59337856	chr1:150746406	G/T	cg04414720	chr1:150670196	GOLPH3L	0.38	4.73	0.39	6.04e-6	Melanoma;
TGCT	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg18876405	chr7:65276391	NA	0.32	4.89	0.4	3.1e-6	Aortic root size;
TGCT	cis	rs12497850	0.864	rs4955410	chr3:49181218	A/G	cg07636037	chr3:49044803	WDR6	0.94	10.1	0.67	7.08e-18	Parkinson's disease;
TGCT	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg03806693	chr22:41940476	POLR3H	-1.13	-13.26	-0.77	1.59e-25	Vitiligo;
TGCT	cis	rs854765	0.654	rs9911281	chr17:17762457	G/C	cg09796270	chr17:17721594	SREBF1	-0.24	-4.8	-0.4	4.56e-6	Total body bone mineral density;
TGCT	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg23758822	chr17:41437982	NA	0.6	4.85	0.4	3.63e-6	Menopause (age at onset);
TGCT	cis	rs13202913	0.652	rs9371528	chr6:151832668	G/A	cg03627880	chr6:151815985	C6orf97	-0.55	-5.35	-0.43	4.1e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs4689388	0.853	rs6446479	chr4:6291737	G/C	cg14416269	chr4:6271139	WFS1	0.4	5.29	0.43	5.44e-7	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs2742417	1.000	rs1534876	chr3:45741257	G/T	cg04837898	chr3:45731254	SACM1L	-0.52	-5.24	-0.43	6.71e-7	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg08280861	chr8:58055591	NA	0.4	4.76	0.39	5.34e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs28595532	0.920	rs115154776	chr4:119774803	A/G	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg00024416	chr22:24240387	NA	-0.26	-4.99	-0.41	2e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6490294	0.799	rs2339941	chr12:112490764	G/T	cg10833066	chr12:111807467	FAM109A	0.37	5.44	0.44	2.68e-7	Mean platelet volume;
TGCT	cis	rs68170813	0.523	rs111590023	chr7:107055323	T/C	cg02696742	chr7:106810147	HBP1	-0.71	-5.9	-0.47	3.17e-8	Coronary artery disease;
TGCT	cis	rs896854	0.684	rs2340534	chr8:95992330	G/A	cg13393036	chr8:95962371	TP53INP1	-0.58	-7.95	-0.58	1e-12	Type 2 diabetes;
TGCT	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg16325326	chr1:53192061	ZYG11B	0.6	6.91	0.53	2.3e-10	Monocyte count;
TGCT	cis	rs1372520	0.684	rs2619355	chr4:90748374	A/C	cg20003494	chr4:90757398	SNCA	-0.63	-5.09	-0.42	1.3e-6	Neuroticism;
TGCT	cis	rs7772486	0.782	rs7747576	chr6:146277827	C/T	cg23711669	chr6:146136114	FBXO30	-0.87	-9.69	-0.66	6.98e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs56104184	0.723	rs73063524	chr19:49409004	T/C	cg17863274	chr19:49399704	TULP2	-0.54	-7.43	-0.55	1.58e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs911555	0.547	rs8006994	chr14:103841296	C/T	cg12935359	chr14:103987150	CKB	-0.32	-4.56	-0.38	1.21e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7769051	0.522	rs7775241	chr6:133109022	T/C	cg07930552	chr6:133119739	C6orf192	1.28	5.03	0.41	1.69e-6	Type 2 diabetes nephropathy;
TGCT	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg11890956	chr21:40555474	PSMG1	-0.8	-7.22	-0.54	4.51e-11	Cognitive function;
TGCT	cis	rs3749237	0.595	rs1464566	chr3:49459376	T/C	cg03060546	chr3:49711283	APEH	0.77	8.86	0.62	6.92e-15	Resting heart rate;
TGCT	cis	rs1008375	0.966	rs4698638	chr4:17632988	G/C	cg10189774	chr4:17578691	LAP3	0.62	5.5	0.44	2.08e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7095607	0.606	rs6480311	chr10:69956848	T/C	cg18986048	chr10:69913749	MYPN	0.56	5.87	0.47	3.76e-8	Lung function (FVC);
TGCT	cis	rs10514758	0.744	rs72947752	chr3:114932571	C/T	cg05943254	chr3:114009756	NA	-0.76	-4.53	-0.38	1.39e-5	Urate levels in obese individuals;
TGCT	cis	rs10501293	0.667	rs4565888	chr11:42986051	G/A	cg03447554	chr11:43094025	NA	0.44	6.43	0.5	2.5e-9	Cognitive performance;
TGCT	cis	rs9858542	0.537	rs115753735	chr3:49355005	T/C	cg08550065	chr3:50336684	HYAL3;NAT6	0.66	4.68	0.39	7.43e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs11190604	0.767	rs10883491	chr10:102196071	G/T	cg16005271	chr10:102321736	NA	0.46	4.68	0.39	7.39e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9291683	0.566	rs13122689	chr4:10044648	A/G	cg11266682	chr4:10021025	SLC2A9	0.6	7.52	0.56	9.49e-12	Bone mineral density;
TGCT	cis	rs59197085	0.636	rs17165226	chr7:128453626	C/G	cg00260937	chr7:128520193	KCP	-0.43	-4.92	-0.4	2.68e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
TGCT	cis	rs614226	1.000	rs1614223	chr12:120964043	T/C	cg10072921	chr12:121022843	NA	-0.44	-4.74	-0.39	5.78e-6	Type 1 diabetes nephropathy;
TGCT	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg08645402	chr16:4508243	NA	0.19	4.83	0.4	4e-6	Schizophrenia;
TGCT	cis	rs7223966	1.000	rs11870797	chr17:61804622	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	4.68	0.39	7.5e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs7666738	0.753	rs13137152	chr4:98938044	A/T	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg16680214	chr1:154839983	KCNN3	0.36	7.19	0.54	5.36e-11	Prostate cancer;
TGCT	cis	rs1023500	0.551	rs133355	chr22:42440285	G/A	cg15557168	chr22:42548783	NA	-0.21	-5.28	-0.43	5.69e-7	Schizophrenia;
TGCT	cis	rs9303542	0.625	rs11868098	chr17:46570869	C/G	cg25032089	chr17:46643351	HOXB3	-0.52	-5.62	-0.45	1.22e-7	Ovarian cancer;Epithelial ovarian cancer;
TGCT	trans	rs335810	1.000	rs1704083	chr15:60504055	C/T	cg22845496	chr15:54303927	UNC13C	1.01	7.3	0.55	3.06e-11	Type 2 diabetes;
TGCT	cis	rs910316	0.967	rs4903292	chr14:75656245	A/G	cg11812906	chr14:75593930	NEK9	0.71	7.05	0.53	1.13e-10	Height;
TGCT	cis	rs10782582	0.586	rs12130324	chr1:76370012	A/G	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.54	4.6	0.38	1.02e-5	Daytime sleep phenotypes;
TGCT	cis	rs72627509	0.951	rs72627508	chr4:57831564	C/G	cg26694713	chr4:57773883	REST	0.75	6.72	0.52	5.99e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg06873352	chr17:61820015	STRADA	0.56	6.15	0.48	9.93e-9	Prudent dietary pattern;
TGCT	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg02891314	chr5:179741120	GFPT2	0.41	7.12	0.54	7.57e-11	Height;
TGCT	cis	rs7119038	0.818	rs76704408	chr11:118683327	G/T	cg19308663	chr11:118741387	NA	0.27	5.56	0.45	1.61e-7	Sjögren's syndrome;
TGCT	cis	rs752590	0.943	rs13407583	chr2:113967740	G/A	cg27425262	chr2:113953981	PSD4;LOC440839	0.41	4.62	0.38	9.37e-6	Mucinous ovarian carcinoma;
TGCT	cis	rs35000415	0.688	rs12537284	chr7:128717906	G/A	cg06242719	chr7:129414860	MIR183;MIR96	-0.3	-4.58	-0.38	1.1e-5	Systemic lupus erythematosus;
TGCT	cis	rs17253792	0.822	rs112739186	chr14:56065167	A/T	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs151997	0.962	rs39955	chr5:50187501	C/A	cg06027927	chr5:50259733	NA	0.46	4.78	0.39	4.84e-6	Callous-unemotional behaviour;
TGCT	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg03452623	chr4:187889614	NA	-0.36	-5.46	-0.44	2.45e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg07507251	chr3:52567010	NT5DC2	0.48	6.95	0.53	1.87e-10	Electroencephalogram traits;
TGCT	cis	rs7447593	0.626	rs3812036	chr5:176813404	C/T	cg06060754	chr5:176797920	RGS14	0.51	7.51	0.56	9.94e-12	Urinary electrolytes (magnesium/calcium ratio);
TGCT	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg00024416	chr22:24240387	NA	-0.25	-4.68	-0.39	7.42e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg12963246	chr6:28129442	ZNF389	0.52	5.01	0.41	1.85e-6	Depression;
TGCT	cis	rs12477438	0.765	rs7591794	chr2:99567514	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.64	-0.45	1.08e-7	Chronic sinus infection;
TGCT	cis	rs9517302	0.847	rs9517300	chr13:99095057	T/C	cg22223119	chr13:99095684	FARP1	-0.7	-9.17	-0.64	1.25e-15	Obesity-related traits;
TGCT	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg17054783	chr10:134559939	INPP5A	-0.22	-4.8	-0.4	4.46e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs8042680	0.554	rs8035844	chr15:91519642	C/T	cg22570213	chr15:91497863	RCCD1	0.43	4.54	0.38	1.33e-5	Type 2 diabetes;
TGCT	cis	rs739496	0.579	rs7974772	chr12:112332283	C/T	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs9611565	0.504	rs5758452	chr22:42144927	G/A	cg17554472	chr22:41940697	POLR3H	0.43	4.61	0.38	9.67e-6	Vitiligo;
TGCT	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg27588902	chr6:42928151	GNMT	-0.56	-6.8	-0.52	4.02e-10	Plasma homocysteine levels (post-methionine load test);
TGCT	cis	rs10411936	0.962	rs10404046	chr19:16477255	G/C	cg19006008	chr19:16999768	F2RL3	0.27	4.75	0.39	5.53e-6	White blood cell count;Multiple sclerosis;
TGCT	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7666738	0.830	rs28852677	chr4:99039509	T/G	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs208520	1.000	rs72882102	chr6:66983408	C/A	cg07460842	chr6:66804631	NA	0.78	6.82	0.52	3.61e-10	Exhaled nitric oxide output;
TGCT	cis	rs1476679	1.000	rs34919929	chr7:100012334	G/A	cg13334819	chr7:99746414	C7orf59	0.72	6.03	0.48	1.71e-8	Alzheimer's disease (late onset);
TGCT	trans	rs797680	0.856	rs7526112	chr1:93747683	T/G	cg27528825	chr2:159282178	CCDC148	0.34	6.72	0.52	5.93e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs12533831	0.556	rs2253592	chr7:150878260	C/G	cg04712895	chr7:150801789	AGAP3	0.19	4.67	0.39	7.7e-6	Childhood ear infection;
TGCT	cis	rs9549367	0.826	rs2302755	chr13:113898418	C/T	cg18105134	chr13:113819100	PROZ	-0.35	-5.85	-0.47	4.05e-8	Platelet distribution width;
TGCT	cis	rs7666738	1.000	rs13144055	chr4:99026849	A/G	cg05340658	chr4:99064831	C4orf37	0.46	4.57	0.38	1.18e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11719291	0.831	rs11715177	chr3:48763894	G/A	cg03547606	chr3:48723644	NCKIPSD	0.46	4.56	0.38	1.21e-5	Cognitive function;
TGCT	cis	rs12549902	0.871	rs4736819	chr8:41509915	C/T	cg21772509	chr8:41503840	NKX6-3	0.8	8.71	0.62	1.63e-14	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
TGCT	cis	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg20637647	chr7:64974828	NA	0.89	4.95	0.41	2.37e-6	Diabetic kidney disease;
TGCT	cis	rs4689388	0.647	rs9997824	chr4:6283253	T/C	cg25554036	chr4:6271136	WFS1	0.53	6.84	0.52	3.19e-10	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs644799	1.000	rs566204	chr11:95580926	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	9.73	0.66	5.62e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg18402987	chr7:1209562	NA	0.78	6.64	0.51	8.96e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs34734847	0.787	rs695948	chr12:121149596	A/G	cg21892295	chr12:121157589	UNC119B	-0.21	-4.94	-0.41	2.47e-6	Mean corpuscular volume;
TGCT	cis	rs751728	1.000	rs3806108	chr6:33767579	C/G	cg13859433	chr6:33739653	LEMD2	-0.4	-7.46	-0.56	1.33e-11	Crohn's disease;
TGCT	cis	rs58365266	1.000	rs58365266	chr3:195813757	C/T	cg01181863	chr3:195395398	SDHAP2	-0.46	-4.87	-0.4	3.3e-6	Red cell distribution width;
TGCT	cis	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg18252515	chr7:66147081	NA	-1.18	-7.51	-0.56	9.96e-12	Diabetic kidney disease;
TGCT	cis	rs644799	0.965	rs11021313	chr11:95506907	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	10.82	0.7	1.31e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs2455799	0.559	rs4685268	chr3:15923510	C/A	cg12172478	chr3:16357591	RFTN1	-0.34	-5.14	-0.42	1.02e-6	Mean platelet volume;
TGCT	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg22105103	chr4:187893119	NA	0.34	4.62	0.38	9.32e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg08645402	chr16:4508243	NA	0.2	4.82	0.4	4.04e-6	Schizophrenia;
TGCT	cis	rs2115630	0.967	rs8028490	chr15:85277888	G/A	cg17173187	chr15:85201210	NMB	-0.39	-4.85	-0.4	3.67e-6	P wave terminal force;
TGCT	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg24531977	chr5:56204891	C5orf35	-0.93	-8.14	-0.59	3.61e-13	Initial pursuit acceleration;
TGCT	cis	rs7829975	0.533	rs1039917	chr8:8718850	C/T	cg06636001	chr8:8085503	FLJ10661	0.75	6.9	0.53	2.31e-10	Mood instability;
TGCT	cis	rs9393692	0.905	rs6916289	chr6:26289122	A/T	cg00631329	chr6:26305371	NA	-0.41	-6.09	-0.48	1.34e-8	Educational attainment;
TGCT	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg22920501	chr2:26401640	FAM59B	-0.72	-6.38	-0.5	3.19e-9	Gut microbiome composition (summer);
TGCT	cis	rs72615157	0.634	rs7789890	chr7:99800559	G/T	cg00814883	chr7:100076585	TSC22D4	-0.52	-5.14	-0.42	1.06e-6	Lung function (FEV1/FVC);
TGCT	cis	rs6988636	1.000	rs60827294	chr8:124187842	T/C	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs3782455	0.793	rs2290798	chr12:114404143	C/T	cg10631684	chr12:113795897	PLBD2	-0.7	-4.61	-0.38	1e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg22920501	chr2:26401640	FAM59B	-0.8	-6.34	-0.5	3.8e-9	Gut microbiome composition (summer);
TGCT	cis	rs7959452	0.640	rs1598543	chr12:69688757	G/T	cg14784868	chr12:69753453	YEATS4	0.68	6.95	0.53	1.81e-10	Blood protein levels;
TGCT	cis	rs4819052	0.959	rs9976074	chr21:46655638	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.81	6.65	0.51	8.18e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs10504229	0.906	rs28447218	chr8:58170813	T/G	cg24829409	chr8:58192753	C8orf71	-0.51	-4.99	-0.41	2.01e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9653442	0.564	rs6707067	chr2:100767232	G/A	cg07810366	chr2:100720526	AFF3	-0.35	-5.26	-0.43	6e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs6429082	0.523	rs704718	chr1:235666159	A/T	cg26050004	chr1:235667680	B3GALNT2	0.82	9.15	0.63	1.46e-15	Adiposity;
TGCT	cis	rs2721195	0.874	rs2721197	chr8:145727705	A/G	cg17328964	chr8:145687451	CYHR1	-0.39	-5.32	-0.43	4.78e-7	Age at first birth;
TGCT	cis	rs2153535	0.580	rs2143354	chr6:8517907	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.55e-8	Motion sickness;
TGCT	cis	rs4478858	0.775	rs6701861	chr1:31708125	A/C	cg00250761	chr1:31883323	NA	-0.3	-5.71	-0.46	7.91e-8	Alcohol dependence;
TGCT	cis	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg20637647	chr7:64974828	NA	0.89	4.99	0.41	2.01e-6	Diabetic kidney disease;
TGCT	cis	rs9926296	0.744	rs6860	chr16:89711120	C/T	cg26513180	chr16:89883248	FANCA	-0.66	-6.08	-0.48	1.38e-8	Vitiligo;
TGCT	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg11062466	chr8:58055876	NA	0.37	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg12140144	chr1:2984275	FLJ42875;PRDM16	-0.32	-4.46	-0.37	1.81e-5	Height;
TGCT	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg06713675	chr4:122721982	EXOSC9	-0.62	-8.5	-0.61	5.12e-14	Type 2 diabetes;
TGCT	cis	rs4240897	0.935	rs2236055	chr1:12042261	A/G	cg13216073	chr1:12042593	MFN2	0.19	5.83	0.46	4.45e-8	Tuberculosis;
TGCT	cis	rs2549003	0.811	rs10035166	chr5:131823927	C/T	cg00255919	chr5:131827918	IRF1	-0.19	-4.52	-0.38	1.44e-5	Asthma (sex interaction);
TGCT	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg23758822	chr17:41437982	NA	0.71	6.75	0.52	5.16e-10	Menopause (age at onset);
TGCT	cis	rs7666738	0.753	rs10033138	chr4:98981922	A/C	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28374715	0.532	rs7164211	chr15:41705041	A/T	cg18705301	chr15:41695430	NDUFAF1	-0.93	-17.29	-0.84	7.63e-35	Ulcerative colitis;
TGCT	cis	rs1801251	1.000	rs2592102	chr2:233726772	G/T	cg25237894	chr2:233734115	C2orf82	-0.33	-5.97	-0.47	2.34e-8	Coronary artery disease;
TGCT	cis	rs317689	0.600	rs478188	chr12:69639215	A/G	cg11871910	chr12:69753446	YEATS4	0.54	4.47	0.37	1.72e-5	Response to diuretic therapy;
TGCT	cis	rs950776	0.545	rs28444683	chr15:78984507	C/A	cg03762349	chr15:79060523	ADAMTS7	0.29	6.3	0.49	4.7e-9	Sudden cardiac arrest;
TGCT	cis	rs2762353	0.574	rs4419666	chr6:25693274	C/T	cg12310025	chr6:25882481	NA	0.91	8.98	0.63	3.56e-15	Blood metabolite levels;
TGCT	cis	rs2639990	1.000	rs2639990	chr18:72915551	T/C	cg03972071	chr18:72917163	ZADH2	0.83	5.63	0.45	1.14e-7	Vascular endothelial growth factor levels;
TGCT	cis	rs9911578	1.000	rs7223955	chr17:56917053	C/A	cg12560992	chr17:57184187	TRIM37	0.76	9.21	0.64	1.03e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2721195	0.549	rs2620666	chr8:145703413	T/C	cg11211951	chr8:145729740	GPT	0.23	5.55	0.45	1.62e-7	Age at first birth;
TGCT	cis	rs10465746	0.935	rs11163878	chr1:84442654	G/A	cg10977910	chr1:84465055	TTLL7	0.63	6.23	0.49	6.49e-9	Obesity-related traits;
TGCT	cis	rs2816062	0.710	rs2816052	chr1:18895536	T/C	cg18795169	chr1:18902165	NA	-0.6	-14.18	-0.79	1.04e-27	Urate levels in lean individuals;
TGCT	cis	rs12615966	0.932	rs58391435	chr2:105368520	A/G	cg16465502	chr2:105461796	NA	0.75	4.65	0.39	8.22e-6	Pancreatic cancer;
TGCT	cis	rs35306767	0.953	rs10904583	chr10:983498	T/C	cg20503657	chr10:835505	NA	0.58	8.09	0.59	4.54e-13	Eosinophil percentage of granulocytes;
TGCT	cis	rs611744	0.810	rs672161	chr8:109164182	G/A	cg21045802	chr8:109455806	TTC35	0.69	6.06	0.48	1.51e-8	Dupuytren's disease;
TGCT	cis	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg20637647	chr7:64974828	NA	-0.9	-5.06	-0.41	1.45e-6	Diabetic kidney disease;
TGCT	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg23708337	chr7:1209742	NA	0.6	5.57	0.45	1.53e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9517320	0.515	rs61969456	chr13:99174799	C/G	cg07423050	chr13:99094983	FARP1	-0.28	-5.64	-0.45	1.11e-7	Longevity;
TGCT	cis	rs5769765	1.000	rs768619	chr22:50287266	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.11	-12.1	-0.74	9.56e-23	Schizophrenia;
TGCT	cis	rs9926296	0.607	rs11076629	chr16:89875259	T/C	cg27121462	chr16:89883253	FANCA	0.58	5.23	0.43	6.88e-7	Vitiligo;
TGCT	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg08859206	chr1:53392774	SCP2	-0.43	-6.71	-0.52	6.09e-10	Monocyte count;
TGCT	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg17747265	chr1:1875780	NA	0.39	7.34	0.55	2.52e-11	Body mass index;
TGCT	cis	rs6459680	0.504	rs1881008	chr7:156259409	T/A	cg02321112	chr7:156810523	NA	0.35	4.47	0.37	1.74e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs2204008	0.837	rs11183232	chr12:37941053	A/G	cg26384229	chr12:38710491	ALG10B	0.85	7.82	0.57	1.94e-12	Bladder cancer;
TGCT	cis	rs526231	0.819	rs35801	chr5:102608213	G/T	cg05225461	chr5:102596755	C5orf30	0.23	4.65	0.39	8.39e-6	Primary biliary cholangitis;
TGCT	cis	rs67072384	1.000	rs72966113	chr11:72450970	C/T	cg03713592	chr11:72463424	ARAP1	-0.93	-4.66	-0.39	7.89e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs4799461	0.773	rs9953231	chr18:35150526	G/A	cg27332583	chr18:35150602	NA	0.29	4.46	0.37	1.83e-5	Neuroticism;
TGCT	cis	rs7582180	0.700	rs2309852	chr2:100982527	T/C	cg08017756	chr2:100939284	LONRF2	-0.31	-4.95	-0.41	2.32e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4891159	0.790	rs689885	chr18:74110563	T/G	cg24786174	chr18:74118243	ZNF516	0.62	9.53	0.65	1.73e-16	Longevity;
TGCT	cis	rs6688613	1.000	rs7550698	chr1:166951081	A/G	cg07049167	chr1:166818506	POGK	0.21	4.5	0.37	1.57e-5	Refractive astigmatism;
TGCT	cis	rs1372520	0.684	rs2737010	chr4:90746466	G/A	cg14346243	chr4:90757452	SNCA	-0.67	-5.64	-0.45	1.09e-7	Neuroticism;
TGCT	cis	rs3087591	0.960	rs2952984	chr17:29469614	T/C	cg24425628	chr17:29625626	OMG;NF1	0.51	7.9	0.58	1.25e-12	Hip circumference;
TGCT	trans	rs3780486	0.505	rs10117038	chr9:33122626	T/C	cg04842962	chr6:43655489	MRPS18A	0.82	8.89	0.62	5.88e-15	IgG glycosylation;
TGCT	cis	rs59698941	0.550	rs11748063	chr5:132200943	C/T	cg27099455	chr5:132201840	GDF9;UQCRQ	0.3	5.02	0.41	1.75e-6	Apolipoprotein A-IV levels;
TGCT	cis	rs10782582	0.609	rs5745430	chr1:76332994	C/T	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.52	4.53	0.38	1.37e-5	Daytime sleep phenotypes;
TGCT	cis	rs3796352	0.667	rs11720228	chr3:52877270	G/A	cg27565382	chr3:53032988	SFMBT1	0.49	4.47	0.37	1.75e-5	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg15242686	chr22:24348715	GSTTP1	0.44	6.02	0.48	1.86e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1865760	0.827	rs9295681	chr6:25944117	T/G	cg17042849	chr6:26104293	HIST1H4C	-0.5	-4.55	-0.38	1.27e-5	Height;
TGCT	cis	rs6138458	0.585	rs1007881	chr20:25014385	A/G	cg26195577	chr20:24973756	C20orf3	1.01	9.23	0.64	9.14e-16	Blood protein levels;
TGCT	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg18135555	chr8:22132992	PIWIL2	0.29	5.61	0.45	1.23e-7	Hypertriglyceridemia;
TGCT	cis	rs1570884	0.536	rs1359541	chr13:50158939	A/G	cg08779649	chr13:50194554	NA	0.38	6.25	0.49	5.89e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
TGCT	trans	rs7726839	0.540	rs72703080	chr5:595238	A/G	cg11887960	chr12:57824829	NA	1.2	9.65	0.65	8.99e-17	Obesity-related traits;
TGCT	cis	rs9296092	0.538	rs35381461	chr6:33519751	T/C	cg13560919	chr6:33536144	NA	-0.21	-4.75	-0.39	5.5e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs2439831	0.681	rs526450	chr15:43599325	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.12	9.1	0.63	1.91e-15	Lung cancer in ever smokers;
TGCT	cis	rs11122272	0.735	rs2244994	chr1:231537127	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-6.5	-0.5	1.77e-9	Hemoglobin concentration;
TGCT	cis	rs2242116	0.592	rs6442039	chr3:46960797	C/G	cg27129171	chr3:47204927	SETD2	0.57	5.0	0.41	1.91e-6	Birth weight;
TGCT	cis	rs752092	0.855	rs7171515	chr15:101769618	C/T	cg25114630	chr15:101792522	CHSY1	0.5	4.7	0.39	6.7e-6	Corneal structure;
TGCT	cis	rs7917772	0.507	rs2778036	chr10:104485725	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	5.45	0.44	2.61e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg02675527	chr2:114030824	PAX8;LOC440839	-0.52	-6.89	-0.53	2.52e-10	Lymphocyte counts;
TGCT	cis	rs6964587	0.869	rs10241720	chr7:91527367	G/T	cg17063962	chr7:91808500	NA	-0.86	-9.28	-0.64	6.82e-16	Breast cancer;
TGCT	cis	rs9549260	0.755	rs2297627	chr13:41233931	A/G	cg21288729	chr13:41239152	FOXO1	0.96	9.98	0.67	1.45e-17	Red blood cell count;
TGCT	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg06896619	chr17:61851486	DDX42;CCDC47	-0.51	-4.91	-0.4	2.81e-6	Prudent dietary pattern;
TGCT	trans	rs916888	0.647	rs199524	chr17:44848438	G/T	cg22433210	chr17:43662623	NA	-0.92	-7.55	-0.56	8e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs11971779	0.625	rs10260850	chr7:139003602	G/T	cg07862535	chr7:139043722	LUC7L2	0.59	4.66	0.39	7.89e-6	Diisocyanate-induced asthma;
TGCT	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg21280719	chr6:42927975	GNMT	-0.37	-4.52	-0.38	1.41e-5	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg18402987	chr7:1209562	NA	0.81	6.94	0.53	1.9e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2404602	0.647	rs907593	chr15:77196953	G/A	cg22467129	chr15:76604101	ETFA	0.55	5.52	0.44	1.9e-7	Blood metabolite levels;
TGCT	cis	rs13191362	1.000	rs34714518	chr6:163080778	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.91	6.83	0.52	3.35e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs782590	0.967	rs782586	chr2:55836165	A/C	cg03859395	chr2:55845619	SMEK2	0.92	11.37	0.71	5.88e-21	Metabolic syndrome;
TGCT	cis	rs2288884	0.943	rs11084132	chr19:52514580	C/T	cg15405931	chr19:52693188	PPP2R1A	-0.69	-4.47	-0.37	1.77e-5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs4886920	0.518	rs4624137	chr15:78078903	A/G	cg25212270	chr15:78015279	NA	-0.28	-5.12	-0.42	1.16e-6	Neuroticism;
TGCT	cis	rs2549003	0.966	rs10065633	chr5:131816716	T/C	cg00255919	chr5:131827918	IRF1	0.22	5.15	0.42	1.01e-6	Asthma (sex interaction);
TGCT	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg00343986	chr7:65444356	GUSB	-0.2	-4.47	-0.37	1.75e-5	Aortic root size;
TGCT	cis	rs26868	0.816	rs26871	chr16:2248133	G/A	cg26873644	chr16:2260806	C16orf79	-0.24	-4.8	-0.4	4.51e-6	Height;
TGCT	cis	rs896854	0.846	rs13254283	chr8:95914103	G/T	cg13393036	chr8:95962371	TP53INP1	-0.59	-8.0	-0.58	7.34e-13	Type 2 diabetes;
TGCT	cis	rs1670533	1.000	rs604597	chr4:1094151	G/A	cg27284194	chr4:1044797	NA	-0.7	-6.06	-0.48	1.53e-8	Recombination rate (females);
TGCT	cis	rs7927771	0.832	rs67116452	chr11:47385194	G/A	cg21462715	chr11:47870315	NUP160	0.57	4.63	0.38	9.08e-6	Subjective well-being;
TGCT	trans	rs1814175	0.817	rs10769598	chr11:49669326	C/G	cg03929089	chr4:120376271	NA	-0.71	-8.34	-0.6	1.21e-13	Height;
TGCT	cis	rs477895	1.000	rs2276014	chr11:64081445	G/A	cg04317338	chr11:64019027	PLCB3	0.71	5.65	0.45	1.05e-7	Mean platelet volume;
TGCT	cis	rs72781680	0.716	rs2712056	chr2:23959131	C/T	cg08917208	chr2:24149416	ATAD2B	0.78	5.26	0.43	6.01e-7	Lymphocyte counts;
TGCT	cis	rs76878669	0.561	rs12794121	chr11:66126169	G/T	cg18002602	chr11:66138449	SLC29A2	0.54	6.62	0.51	9.76e-10	Educational attainment (years of education);
TGCT	cis	rs9467711	0.790	rs72843784	chr6:26498758	G/T	cg16898833	chr6:26189333	HIST1H4D	1.35	5.89	0.47	3.43e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7953508	0.506	rs1316740	chr12:93968288	C/A	cg18151635	chr12:93972918	NA	-0.19	-4.52	-0.38	1.41e-5	Pubertal anthropometrics;
TGCT	cis	rs6964587	0.967	rs17164315	chr7:91659150	C/G	cg17063962	chr7:91808500	NA	0.91	9.99	0.67	1.32e-17	Breast cancer;
TGCT	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg06896619	chr17:61851486	DDX42;CCDC47	0.51	4.96	0.41	2.24e-6	Prudent dietary pattern;
TGCT	cis	rs7312933	0.703	rs7957471	chr12:42545591	G/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	5.06	0.41	1.45e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs1008375	0.574	rs7670135	chr4:17566221	G/T	cg10189774	chr4:17578691	LAP3	0.62	5.65	0.45	1.05e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg08859206	chr1:53392774	SCP2	-0.46	-7.42	-0.55	1.64e-11	Monocyte count;
TGCT	cis	rs11614913	0.509	rs12300425	chr12:54395082	G/T	cg16264616	chr12:54390824	NA	0.34	4.84	0.4	3.76e-6	Waist circumference adjusted for body mass index;
TGCT	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg20203395	chr5:56204925	C5orf35	0.53	4.92	0.4	2.67e-6	Initial pursuit acceleration;
TGCT	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg23708337	chr7:1209742	NA	0.55	5.45	0.44	2.62e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7772486	0.875	rs2814877	chr6:146299763	C/G	cg05347473	chr6:146136440	FBXO30	0.53	5.0	0.41	1.87e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7666738	0.830	rs13115356	chr4:98933171	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs174479	0.647	rs174454	chr11:61650747	A/G	cg19610905	chr11:61596333	FADS2	-0.61	-5.22	-0.42	7.32e-7	Sphingolipid levels;
TGCT	cis	rs804280	0.662	rs11784764	chr8:11610874	C/T	cg26752888	chr8:11627280	NEIL2	0.7	5.47	0.44	2.42e-7	Myopia (pathological);
TGCT	cis	rs2721195	0.614	rs12719778	chr8:145879883	T/C	cg15320075	chr8:145703422	NA	0.64	5.84	0.46	4.31e-8	Age at first birth;
TGCT	cis	rs10501293	1.000	rs2114087	chr11:43133002	G/C	cg03447554	chr11:43094025	NA	-0.48	-6.72	-0.52	5.89e-10	Cognitive performance;
TGCT	cis	rs7192750	0.562	rs4788566	chr16:71893470	T/C	cg06353428	chr16:71660113	MARVELD3	0.8	7.26	0.55	3.8e-11	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs10089	1.000	rs10061367	chr5:127449021	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	7.41	0.55	1.72e-11	Ileal carcinoids;
TGCT	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg14893161	chr1:205819251	PM20D1	0.57	8.17	0.59	2.97e-13	Menarche (age at onset);
TGCT	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.15	0.82	2.71e-32	Prudent dietary pattern;
TGCT	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg11317459	chr13:21872234	NA	1.32	13.31	0.77	1.2e-25	White matter hyperintensity burden;
TGCT	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg04414720	chr1:150670196	GOLPH3L	0.39	5.04	0.41	1.58e-6	Tonsillectomy;
TGCT	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg06418219	chr1:154948305	SHC1;CKS1B	0.5	4.73	0.39	5.92e-6	Prostate cancer;
TGCT	cis	rs67478160	0.619	rs12885018	chr14:104273812	A/G	cg26031613	chr14:104095156	KLC1	-0.64	-6.57	-0.51	1.23e-9	Schizophrenia;
TGCT	cis	rs1113500	0.787	rs4571989	chr1:108631344	G/A	cg22161131	chr1:109420278	GPSM2	0.49	4.54	0.38	1.34e-5	Growth-regulated protein alpha levels;
TGCT	cis	rs453301	0.624	rs2288673	chr8:8860276	G/T	cg06636001	chr8:8085503	FLJ10661	0.8	7.14	0.54	7.09e-11	Joint mobility (Beighton score);
TGCT	cis	rs56104184	0.830	rs55966626	chr19:49342396	G/T	cg21252483	chr19:49399788	TULP2	-0.42	-5.58	-0.45	1.46e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs4478858	0.684	rs10798838	chr1:31719450	G/A	cg07478791	chr1:31886160	SERINC2	-0.49	-4.8	-0.4	4.51e-6	Alcohol dependence;
TGCT	cis	rs4478037	1.000	rs58864038	chr3:33161355	G/A	cg19404215	chr3:33155277	CRTAP	1.28	8.55	0.61	3.75e-14	Major depressive disorder;
TGCT	cis	rs7599312	0.586	rs4404217	chr2:213385817	G/A	cg16329650	chr2:213403929	ERBB4	0.55	4.62	0.38	9.45e-6	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7178572	0.568	rs1191196	chr15:77646504	C/T	cg15453836	chr15:77711506	NA	0.42	4.79	0.4	4.68e-6	Type 2 diabetes;
TGCT	cis	rs2239547	0.657	rs12488303	chr3:52862003	G/A	cg11645453	chr3:52864694	ITIH4	0.34	5.67	0.45	9.34e-8	Schizophrenia;
TGCT	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg16325326	chr1:53192061	ZYG11B	0.61	6.79	0.52	4.18e-10	Monocyte count;
TGCT	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	trans	rs10504390	0.656	rs76479008	chr8:66486620	G/T	cg18118147	chr19:51128640	SYT3	-0.77	-6.81	-0.52	3.71e-10	IgG glycosylation;
TGCT	cis	rs644799	1.000	rs500054	chr11:95593806	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.04	0.59	6.21e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs67311347	1.000	rs13073003	chr3:40504326	C/T	cg13683864	chr3:40499215	RPL14	1.14	12.22	0.74	4.89e-23	Renal cell carcinoma;
TGCT	cis	rs6815814	0.950	rs73236617	chr4:38793860	C/G	cg02016764	chr4:38805732	TLR1	-0.34	-5.4	-0.44	3.2e-7	Breast cancer;
TGCT	cis	rs57590327	0.503	rs13075250	chr3:81907952	T/C	cg07356753	chr3:81810745	GBE1	-0.67	-6.16	-0.48	9.35e-9	Extraversion;
TGCT	cis	rs2075165	0.901	rs1043165	chr1:156220056	T/C	cg16558208	chr1:156270281	VHLL	0.26	4.5	0.37	1.52e-5	Tonsillectomy;
TGCT	cis	rs1163251	0.902	rs627707	chr1:120217133	C/G	cg19096424	chr1:120255104	PHGDH	0.56	5.29	0.43	5.46e-7	Blood metabolite levels;
TGCT	cis	rs7666738	0.830	rs10011009	chr4:98981749	G/A	cg05340658	chr4:99064831	C4orf37	0.5	5.84	0.46	4.35e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs861020	0.630	rs627069	chr1:210004613	C/G	cg05527609	chr1:210001259	C1orf107	0.86	7.54	0.56	8.69e-12	Orofacial clefts;
TGCT	cis	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg18252515	chr7:66147081	NA	-1.09	-6.4	-0.5	2.88e-9	Diabetic kidney disease;
TGCT	cis	rs7772486	0.625	rs9390355	chr6:146112942	C/T	cg23711669	chr6:146136114	FBXO30	-0.86	-9.74	-0.66	5.4e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7312933	0.701	rs10880260	chr12:42561398	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	4.99	0.41	1.99e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg06238570	chr21:40685208	BRWD1	0.69	6.43	0.5	2.55e-9	Cognitive function;
TGCT	cis	rs9549260	0.755	rs7993233	chr13:41219434	T/A	cg21288729	chr13:41239152	FOXO1	1.01	10.71	0.69	2.36e-19	Red blood cell count;
TGCT	cis	rs210138	0.882	rs407710	chr6:33554257	A/G	cg07679836	chr6:33548423	BAK1	0.35	4.63	0.38	9.12e-6	Testicular germ cell tumor;
TGCT	cis	rs9303401	0.659	rs12150536	chr17:56640834	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.59	5.88	0.47	3.62e-8	Cognitive test performance;
TGCT	cis	rs950169	0.920	rs17300048	chr15:84749477	C/T	cg11189052	chr15:85197271	WDR73	0.69	5.91	0.47	3.14e-8	Schizophrenia;
TGCT	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.5	-4.61	-0.38	9.7e-6	Prudent dietary pattern;
TGCT	cis	rs2099527	0.504	rs1548256	chr10:52268572	A/T	cg12753529	chr10:51525504	NA	0.23	4.54	0.38	1.32e-5	Life satisfaction;
TGCT	cis	rs9430161	0.644	rs34365965	chr1:11034442	G/A	cg02454025	chr1:11042201	C1orf127	0.94	11.41	0.72	4.75e-21	Ewing sarcoma;
TGCT	cis	rs4478858	0.735	rs10798842	chr1:31778648	A/G	cg07478791	chr1:31886160	SERINC2	-0.48	-4.61	-0.38	1e-5	Alcohol dependence;
TGCT	cis	rs68170813	0.559	rs7804979	chr7:106999453	C/G	cg02696742	chr7:106810147	HBP1	-0.73	-5.95	-0.47	2.6e-8	Coronary artery disease;
TGCT	cis	rs10927875	0.632	rs4481843	chr1:16128205	G/A	cg21385522	chr1:16154831	NA	-0.96	-15.62	-0.81	4.59e-31	Dilated cardiomyopathy;
TGCT	cis	rs12220238	0.915	rs12217890	chr10:76024496	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.91	6.27	0.49	5.39e-9	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs35146811	0.696	rs1727124	chr7:99804104	T/G	cg13334819	chr7:99746414	C7orf59	0.74	6.32	0.49	4.34e-9	Coronary artery disease;
TGCT	cis	rs6570726	0.791	rs436156	chr6:145874873	A/G	cg05347473	chr6:146136440	FBXO30	0.54	5.15	0.42	1.01e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11085466	1.000	rs73552468	chr19:21772097	G/A	cg02997983	chr19:21646781	NA	-0.6	-4.59	-0.38	1.06e-5	Colorectal or endometrial cancer;
TGCT	cis	rs694419	0.579	rs9965948	chr18:60201864	T/G	cg13506219	chr18:60193840	ZCCHC2	-0.53	-4.78	-0.39	4.82e-6	Serum albumin level;
TGCT	cis	rs17221829	0.703	rs4237550	chr11:89360585	C/T	cg02982614	chr11:89391479	FOLH1B	-0.28	-4.87	-0.4	3.35e-6	Anxiety in major depressive disorder;
TGCT	cis	rs11792861	0.816	rs3763643	chr9:111695607	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.53	5.0	0.41	1.88e-6	Menarche (age at onset);
TGCT	cis	rs929354	0.772	rs2051876	chr7:157009037	A/G	cg05182265	chr7:156933206	UBE3C	0.39	8.77	0.62	1.16e-14	Body mass index;
TGCT	cis	rs5769707	0.967	rs5770585	chr22:50007874	G/A	cg10356904	chr22:49881777	NA	-0.23	-4.69	-0.39	7.05e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs1552244	0.832	rs115415687	chr3:10195704	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.1	6.25	0.49	6.06e-9	Alzheimer's disease;
TGCT	cis	rs7714584	1.000	rs11740172	chr5:150300278	A/G	cg22134413	chr5:150180641	NA	1.01	7.24	0.55	4.17e-11	Crohn's disease;
TGCT	trans	rs9985766	1.000	rs28654919	chr4:151017407	C/T	cg02993991	chr19:4064177	ZBTB7A	0.57	6.7	0.52	6.59e-10	Coronary artery disease;Myocardial infarction;
TGCT	cis	rs7731657	0.537	rs7726927	chr5:130215211	G/T	cg08523029	chr5:130500466	HINT1	-0.55	-4.83	-0.4	3.86e-6	Fasting plasma glucose;
TGCT	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg16325326	chr1:53192061	ZYG11B	0.59	7.1	0.54	8.48e-11	Monocyte count;
TGCT	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg22433210	chr17:43662623	NA	-0.94	-7.97	-0.58	8.83e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2795502	1.000	rs1581702	chr10:43344246	G/A	cg20628663	chr10:43360327	NA	0.45	6.42	0.5	2.61e-9	Blood protein levels;
TGCT	cis	rs861020	1.000	rs7555285	chr1:209970355	C/G	cg05527609	chr1:210001259	C1orf107	-0.92	-7.72	-0.57	3.42e-12	Orofacial clefts;
TGCT	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg03934478	chr11:495069	RNH1	0.35	5.77	0.46	6.03e-8	Body mass index;
TGCT	cis	rs1395	0.922	rs6547521	chr2:27488432	G/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.51	6.64	0.51	8.74e-10	Blood metabolite levels;
TGCT	cis	rs453301	0.571	rs2929452	chr8:9084465	G/A	cg06636001	chr8:8085503	FLJ10661	-0.56	-4.97	-0.41	2.14e-6	Joint mobility (Beighton score);
TGCT	cis	rs2580764	0.565	rs35631428	chr2:55244438	G/A	cg09592903	chr2:55203963	RTN4	-0.27	-6.09	-0.48	1.3e-8	Mean platelet volume;
TGCT	cis	rs9611565	0.546	rs739129	chr22:42118249	G/A	cg17554472	chr22:41940697	POLR3H	0.47	5.04	0.41	1.63e-6	Vitiligo;
TGCT	cis	rs28595532	0.841	rs115725150	chr4:119768647	T/A	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs13191362	1.000	rs2156257	chr6:163100710	G/T	cg21926612	chr6:163149169	PACRG;PARK2	1.17	9.96	0.67	1.56e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs478304	0.934	rs498354	chr11:65528213	A/G	cg17480646	chr11:65405466	SIPA1	0.43	5.38	0.43	3.62e-7	Acne (severe);
TGCT	cis	rs17221829	0.733	rs7945304	chr11:89372524	T/C	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.63	-0.38	9.04e-6	Anxiety in major depressive disorder;
TGCT	cis	rs992157	0.798	rs2382819	chr2:219155909	G/T	cg00012203	chr2:219082015	ARPC2	-0.77	-7.41	-0.55	1.68e-11	Colorectal cancer;
TGCT	cis	rs6121246	0.697	rs7269866	chr20:30232504	G/A	cg21427119	chr20:30132790	HM13	-0.37	-5.19	-0.42	8.51e-7	Mean corpuscular hemoglobin;
TGCT	cis	rs523522	0.923	rs10774553	chr12:120954984	T/C	cg12219531	chr12:120966889	COQ5	0.83	7.27	0.55	3.46e-11	High light scatter reticulocyte count;
TGCT	cis	rs7914558	0.902	rs3736922	chr10:104850632	A/G	cg04362960	chr10:104952993	NT5C2	-0.53	-4.61	-0.38	9.97e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs2439831	1.000	rs2584725	chr15:43793135	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.01	8.19	0.59	2.67e-13	Lung cancer in ever smokers;
TGCT	cis	rs60843830	0.928	rs62114494	chr2:211317	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.69	6.26	0.49	5.66e-9	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs10256972	0.514	rs2140578	chr7:1214003	T/C	cg22907277	chr7:1156413	C7orf50	0.2	4.48	0.37	1.7e-5	Longevity;Endometriosis;
TGCT	cis	rs2440129	0.632	rs15966	chr17:6905643	T/C	cg02493798	chr17:6899577	ALOX12	0.43	4.65	0.39	8.35e-6	Tonsillectomy;
TGCT	cis	rs7296418	0.961	rs1790106	chr12:123591596	G/T	cg13010344	chr12:123464640	ARL6IP4	-0.32	-4.46	-0.37	1.81e-5	Platelet count;
TGCT	cis	rs11783469	0.524	rs17089283	chr8:23335762	A/T	cg00472375	chr8:23315376	ENTPD4	0.68	5.11	0.42	1.17e-6	Reticulocyte count;
TGCT	cis	rs921968	0.643	rs659185	chr2:219335935	C/T	cg02176678	chr2:219576539	TTLL4	0.38	5.48	0.44	2.31e-7	Mean corpuscular hemoglobin concentration;
TGCT	trans	rs7618501	0.521	rs3774759	chr3:49939120	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.8	8.36	0.6	1.06e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs28595532	1.000	rs11098451	chr4:119717673	C/T	cg14228332	chr4:119757509	SEC24D	0.91	5.64	0.45	1.08e-7	Cannabis dependence symptom count;
TGCT	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg10802521	chr3:52805072	NEK4	0.61	6.91	0.53	2.23e-10	Bipolar disorder;
TGCT	cis	rs713587	0.935	rs4430895	chr2:25161386	C/T	cg01884057	chr2:25150051	NA	0.39	7.9	0.58	1.29e-12	Body mass index in non-asthmatics;
TGCT	cis	rs9517320	0.534	rs4772088	chr13:99138270	T/G	cg20487152	chr13:99095054	FARP1	-0.25	-4.63	-0.38	8.94e-6	Longevity;
TGCT	cis	rs10193935	1.000	rs4048	chr2:42424595	A/C	cg27598129	chr2:42591480	NA	-0.39	-5.14	-0.42	1.05e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg13732083	chr21:47605072	C21orf56	0.36	4.57	0.38	1.14e-5	Testicular germ cell tumor;
TGCT	cis	rs6880778	0.505	rs10473183	chr5:40370251	T/C	cg01087697	chr5:40835557	RPL37	0.53	4.83	0.4	3.95e-6	Inflammatory bowel disease;
TGCT	cis	rs3087591	0.960	rs7212264	chr17:29454766	C/T	cg24425628	chr17:29625626	OMG;NF1	0.49	7.28	0.55	3.29e-11	Hip circumference;
TGCT	cis	rs6831352	0.879	rs4699717	chr4:100066137	C/T	cg12011299	chr4:100065546	ADH4	-0.43	-5.07	-0.41	1.44e-6	Alcohol dependence;
TGCT	cis	rs2204008	0.837	rs11495548	chr12:38076756	C/T	cg13010199	chr12:38710504	ALG10B	0.65	5.24	0.43	6.69e-7	Bladder cancer;
TGCT	cis	rs2108225	0.967	rs7785790	chr7:107449896	C/T	cg20438043	chr7:107601757	LAMB1	0.24	4.46	0.37	1.78e-5	Ulcerative colitis;
TGCT	cis	rs877282	0.838	rs34778553	chr10:796865	T/C	cg17470449	chr10:769945	NA	0.3	4.82	0.4	4.14e-6	Uric acid levels;
TGCT	cis	rs5769765	0.817	rs8142561	chr22:50291750	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.09	-11.86	-0.73	3.71e-22	Schizophrenia;
TGCT	cis	rs1008375	1.000	rs10012335	chr4:17628630	C/G	cg10189774	chr4:17578691	LAP3	0.59	5.13	0.42	1.06e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9479482	1.000	rs11155697	chr6:150357423	C/T	cg03788504	chr6:150331562	NA	-0.24	-4.63	-0.38	9.01e-6	Alopecia areata;
TGCT	cis	rs17331151	0.573	rs2276818	chr3:52864635	A/G	cg15956490	chr3:53032818	SFMBT1	0.46	5.75	0.46	6.57e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs2692947	0.770	rs72823920	chr2:96430876	G/A	cg23100626	chr2:96804247	ASTL	0.37	4.44	0.37	1.93e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs4746818	1.000	rs906218	chr10:70960913	C/T	cg11621586	chr10:70884670	VPS26A	1.21	9.94	0.67	1.73e-17	Left atrial antero-posterior diameter;
TGCT	trans	rs10504390	0.527	rs4392943	chr8:66523799	C/A	cg18118147	chr19:51128640	SYT3	-0.77	-6.85	-0.52	2.99e-10	IgG glycosylation;
TGCT	cis	rs11585357	0.557	rs17378462	chr1:17595702	C/T	cg08277548	chr1:17600880	PADI3	-0.72	-5.01	-0.41	1.84e-6	Hair shape;
TGCT	cis	rs9911578	0.867	rs4793941	chr17:56472366	G/A	cg05425664	chr17:57184151	TRIM37	0.61	5.86	0.47	4e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7267979	0.966	rs2261720	chr20:25260641	T/G	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9399135	0.935	rs949547	chr6:135343499	C/G	cg24558204	chr6:135376177	HBS1L	0.5	5.0	0.41	1.89e-6	Red blood cell count;
TGCT	cis	rs2371030	0.965	rs12998879	chr2:211583332	G/A	cg18417063	chr2:211583084	NA	-0.31	-4.45	-0.37	1.91e-5	Non-small cell lung cancer;
TGCT	cis	rs2970818	0.831	rs2970810	chr12:4608103	A/G	cg02722637	chr12:4922070	KCNA6	0.32	5.75	0.46	6.67e-8	Phosphorus levels;
TGCT	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg06873352	chr17:61820015	STRADA	0.56	6.22	0.49	7.1e-9	Prudent dietary pattern;
TGCT	cis	rs4689388	0.926	rs10937718	chr4:6295217	T/C	cg25554036	chr4:6271136	WFS1	0.54	7.37	0.55	2.11e-11	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs2197308	0.765	rs68029712	chr12:37906585	T/G	cg13010199	chr12:38710504	ALG10B	0.67	5.34	0.43	4.33e-7	Morning vs. evening chronotype;
TGCT	cis	rs826415	0.864	rs41276588	chr1:118148384	G/A	cg11819305	chr1:117910798	MAN1A2	0.5	4.47	0.37	1.78e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs9549367	0.713	rs3024764	chr13:113824314	A/G	cg18105134	chr13:113819100	PROZ	-0.47	-8.58	-0.61	3.23e-14	Platelet distribution width;
TGCT	cis	rs208515	0.525	rs12215007	chr6:66671008	C/T	cg07460842	chr6:66804631	NA	-0.86	-8.95	-0.63	4.31e-15	Exhaled nitric oxide levels;
TGCT	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg03264133	chr6:25882463	NA	-0.65	-5.88	-0.47	3.48e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs11992186	0.597	rs11781841	chr8:8595263	T/A	cg15556689	chr8:8085844	FLJ10661	-0.56	-4.66	-0.39	8.09e-6	Neuroticism;
TGCT	cis	rs79057730	0.599	rs4720893	chr7:804434	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.66	6.27	0.49	5.39e-9	Initial pursuit acceleration;
TGCT	cis	rs3008870	0.959	rs1886686	chr1:67390468	C/G	cg08660285	chr1:67390436	MIER1;WDR78	1.1	12.09	0.74	1.01e-22	Lymphocyte percentage of white cells;
TGCT	trans	rs77457752	0.525	rs10120716	chr9:13897909	G/A	cg23609682	chr1:3070786	PRDM16	0.5	6.79	0.52	4.09e-10	Breast cancer;
TGCT	cis	rs3820068	0.871	rs76155024	chr1:15807142	T/C	cg05660106	chr1:15850417	CASP9	1.13	11.01	0.7	4.37e-20	Systolic blood pressure;
TGCT	cis	rs12780845	0.505	rs10904893	chr10:17204944	T/C	cg01003015	chr10:17271136	VIM	-0.51	-4.47	-0.37	1.76e-5	Homocysteine levels;
TGCT	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg03352830	chr11:487213	PTDSS2	0.26	4.46	0.37	1.8e-5	Body mass index;
TGCT	cis	rs3749237	0.595	rs4955412	chr3:49418168	A/C	cg03060546	chr3:49711283	APEH	0.77	8.87	0.62	6.79e-15	Resting heart rate;
TGCT	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg18876405	chr7:65276391	NA	0.37	5.85	0.47	4.02e-8	Aortic root size;
TGCT	cis	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg18252515	chr7:66147081	NA	-1.31	-8.18	-0.59	2.87e-13	Diabetic kidney disease;
TGCT	cis	rs10949834	0.642	rs2356530	chr7:73533221	T/A	cg07137043	chr7:73588983	EIF4H	-0.74	-4.53	-0.38	1.38e-5	Verbal memory performance (residualized delayed recall change);
TGCT	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg20203395	chr5:56204925	C5orf35	-0.71	-5.58	-0.45	1.44e-7	Type 2 diabetes;
TGCT	cis	rs3087591	1.000	rs2107360	chr17:29697901	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.48	-7.28	-0.55	3.31e-11	Hip circumference;
TGCT	cis	rs41271951	0.512	rs114222784	chr1:151084781	C/T	cg00666978	chr1:150947442	LASS2	0.89	4.64	0.38	8.54e-6	Blood protein levels;
TGCT	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2677744	0.626	rs3743452	chr15:91497515	C/T	cg22570213	chr15:91497863	RCCD1	-0.41	-5.04	-0.41	1.6e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs9527	0.662	rs10883783	chr10:104591152	T/A	cg15744005	chr10:104629667	AS3MT	-0.48	-5.82	-0.46	4.72e-8	Arsenic metabolism;
TGCT	cis	rs1799949	1.000	rs4793236	chr17:41436440	T/C	cg23758822	chr17:41437982	NA	0.69	6.41	0.5	2.75e-9	Menopause (age at onset);
TGCT	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg27286337	chr10:134555280	INPP5A	0.37	4.54	0.38	1.3e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs2013441	0.965	rs9896221	chr17:20180337	G/A	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.63	-0.38	9.19e-6	Obesity-related traits;
TGCT	cis	rs7829975	0.774	rs35039922	chr8:8675325	A/T	cg15556689	chr8:8085844	FLJ10661	0.68	6.15	0.48	1e-8	Mood instability;
TGCT	cis	rs11971779	0.680	rs66491565	chr7:139088977	C/G	cg07862535	chr7:139043722	LUC7L2	0.71	5.55	0.45	1.63e-7	Diisocyanate-induced asthma;
TGCT	cis	rs10276381	0.786	rs73300665	chr7:28227024	G/A	cg23620719	chr7:28220237	JAZF1	0.95	5.75	0.46	6.52e-8	Crohn's disease;
TGCT	cis	rs7119038	0.629	rs10892272	chr11:118602707	C/G	cg19308663	chr11:118741387	NA	0.23	4.57	0.38	1.16e-5	Sjögren's syndrome;
TGCT	cis	rs12580194	0.593	rs12099665	chr12:55731191	G/T	cg10672482	chr12:55725839	OR6C3	-0.54	-4.77	-0.39	5.17e-6	Cancer;
TGCT	cis	rs4253772	0.575	rs6008684	chr22:46719100	C/G	cg24881330	chr22:46731750	TRMU	1.01	4.96	0.41	2.22e-6	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.53	-5.13	-0.42	1.09e-6	Menarche (age at onset);
TGCT	cis	rs483180	0.512	rs866321	chr1:120224469	T/C	cg19096424	chr1:120255104	PHGDH	0.59	5.58	0.45	1.43e-7	Macular telangiectasia type 2;
TGCT	cis	rs7267979	0.816	rs404775	chr20:25481117	A/G	cg16686733	chr20:25566563	NINL	0.52	5.05	0.41	1.52e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9435341	1.000	rs1762484	chr1:107613923	A/C	cg09367891	chr1:107599246	PRMT6	-0.62	-5.17	-0.42	8.93e-7	Facial morphology (factor 21, depth of nasal alae);
TGCT	cis	rs7213347	0.780	rs170041	chr17:2170216	C/T	cg13315690	chr17:1944831	OVCA2;DPH1	0.38	4.69	0.39	7.1e-6	Total body bone mineral density;
TGCT	trans	rs208520	0.690	rs4386800	chr6:66755242	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	10.83	0.7	1.19e-19	Exhaled nitric oxide output;
TGCT	cis	rs2692947	0.666	rs10183151	chr2:96774786	T/G	cg23100626	chr2:96804247	ASTL	-0.39	-4.61	-0.38	1e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs4253772	0.591	rs6519994	chr22:46656805	A/G	cg09491104	chr22:46646882	C22orf40	0.63	6.39	0.5	3.05e-9	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs4478037	1.000	rs61433006	chr3:33162363	T/A	cg19404215	chr3:33155277	CRTAP	1.33	8.79	0.62	1.04e-14	Major depressive disorder;
TGCT	cis	rs4808199	0.895	rs4808196	chr19:19476520	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.7	4.94	0.41	2.48e-6	Nonalcoholic fatty liver disease;
TGCT	cis	rs73001065	0.792	rs16996148	chr19:19658472	G/T	cg03709012	chr19:19516395	GATAD2A	1.08	5.49	0.44	2.14e-7	LDL cholesterol;
TGCT	cis	rs523522	1.000	rs1563333	chr12:120934407	C/T	cg12219531	chr12:120966889	COQ5	0.83	7.27	0.55	3.46e-11	High light scatter reticulocyte count;
TGCT	cis	rs28595532	0.920	rs115294251	chr4:119772833	C/T	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs6460942	0.732	rs73677576	chr7:12286535	G/A	cg06484146	chr7:12443880	VWDE	-0.54	-4.82	-0.4	4.13e-6	Coronary artery disease;
TGCT	cis	rs752010	0.714	rs6600384	chr1:42085141	A/G	cg06885757	chr1:42089581	HIVEP3	-0.25	-4.77	-0.39	5.05e-6	Lupus nephritis in systemic lupus erythematosus;
TGCT	cis	rs4478858	0.684	rs1546375	chr1:31765968	C/T	cg07478791	chr1:31886160	SERINC2	-0.48	-4.6	-0.38	1.05e-5	Alcohol dependence;
TGCT	cis	rs7772486	0.840	rs2474355	chr6:146312540	C/G	cg05347473	chr6:146136440	FBXO30	0.54	5.17	0.42	9.22e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs611744	0.967	rs671139	chr8:109191260	C/T	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs7937682	0.924	rs11213968	chr11:111527629	G/C	cg09085632	chr11:111637200	PPP2R1B	-1.12	-11.78	-0.73	5.92e-22	Primary sclerosing cholangitis;
TGCT	cis	rs7666738	0.830	rs1896154	chr4:99021161	T/C	cg18180107	chr4:99064573	C4orf37	0.54	5.03	0.41	1.7e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9549260	0.564	rs7998086	chr13:41268924	T/C	cg21288729	chr13:41239152	FOXO1	0.93	9.21	0.64	1.05e-15	Red blood cell count;
TGCT	cis	rs4819852	0.958	rs2238784	chr22:19972559	G/A	cg07821417	chr22:19972146	ARVCF	0.19	4.79	0.4	4.7e-6	Pulse pressure;
TGCT	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg22963979	chr7:1858916	MAD1L1	-0.45	-7.4	-0.55	1.78e-11	Bipolar disorder and schizophrenia;
TGCT	cis	rs330071	0.686	rs4841139	chr8:9249210	C/T	cg11995313	chr8:8860691	ERI1	-0.49	-4.68	-0.39	7.31e-6	Acne (severe);
TGCT	cis	rs6570726	1.000	rs6570699	chr6:145920732	G/A	cg23711669	chr6:146136114	FBXO30	0.65	5.96	0.47	2.4e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs926938	0.527	rs360583	chr1:115462743	C/T	cg12756093	chr1:115239321	AMPD1	0.34	4.95	0.41	2.35e-6	Autism;
TGCT	cis	rs2239547	0.563	rs4687560	chr3:52898121	T/G	cg10802521	chr3:52805072	NEK4	-0.59	-5.7	-0.46	8.37e-8	Schizophrenia;
TGCT	cis	rs3617	0.573	rs12638968	chr3:52919447	T/A	cg05573699	chr3:52720067	GNL3;PBRM1	0.5	4.92	0.4	2.69e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7819412	0.521	rs13256092	chr8:11000377	A/T	cg21775007	chr8:11205619	TDH	-0.52	-4.55	-0.38	1.24e-5	Triglycerides;
TGCT	cis	rs35264875	0.808	rs2305498	chr11:68866914	G/A	cg02660097	chr11:68866761	NA	0.31	4.88	0.4	3.17e-6	Blond vs. brown hair color;
TGCT	cis	rs1570884	0.516	rs7330830	chr13:50167929	T/A	cg03651054	chr13:50194643	NA	0.34	5.45	0.44	2.6e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
TGCT	cis	rs7584330	0.737	rs12465714	chr2:238365637	C/T	cg14458575	chr2:238380390	NA	0.51	8.14	0.59	3.53e-13	Prostate cancer;
TGCT	cis	rs42648	0.790	rs42637	chr7:89969831	A/G	cg25739043	chr7:89950458	NA	-0.62	-6.1	-0.48	1.24e-8	Homocysteine levels;
TGCT	cis	rs10791323	0.572	rs10791334	chr11:133735810	A/C	cg15485101	chr11:133734466	NA	0.43	6.18	0.49	8.32e-9	Childhood ear infection;
TGCT	cis	rs593982	0.920	rs645621	chr11:65490756	T/C	cg08755490	chr11:65554678	OVOL1	1.34	7.74	0.57	2.98e-12	Atopic dermatitis;
TGCT	cis	rs2677744	1.000	rs4773	chr15:91463842	G/A	cg23684204	chr15:91497937	RCCD1	0.34	5.1	0.42	1.24e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs62064224	0.791	rs11654833	chr17:30667728	C/T	cg25809561	chr17:30822961	MYO1D	0.29	4.73	0.39	6.03e-6	Schizophrenia;
TGCT	cis	rs17594362	0.573	rs79034467	chr13:42147535	C/T	cg09909069	chr13:41860793	NA	-0.36	-4.45	-0.37	1.86e-5	Multiple sclerosis;
TGCT	cis	rs6901250	1.000	rs6901250	chr6:117114025	A/G	cg12892004	chr6:117198278	RFX6	-0.44	-4.92	-0.4	2.69e-6	C-reactive protein levels;
TGCT	cis	rs79349575	0.651	rs4378658	chr17:46993370	G/A	cg07967210	chr17:47022446	SNF8	0.44	6.12	0.48	1.13e-8	Type 2 diabetes;
TGCT	cis	rs9393777	0.513	rs13195210	chr6:26646521	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.59	-4.66	-0.39	8.03e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg13395646	chr4:1353034	KIAA1530	-0.39	-4.76	-0.39	5.34e-6	Obesity-related traits;
TGCT	cis	rs3091242	0.933	rs932372	chr1:25755014	G/A	cg10117171	chr1:25599238	RHD	-0.35	-5.75	-0.46	6.69e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs10152811	0.675	rs55882120	chr15:86818162	A/G	cg21672992	chr15:86584249	NA	0.27	4.55	0.38	1.24e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg10411590	chr13:21900810	NA	0.34	4.75	0.39	5.46e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	cis	rs9467773	0.572	rs62394558	chr6:26604650	G/A	cg15659132	chr6:26577336	NA	0.84	9.93	0.67	1.82e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg12963246	chr6:28129442	ZNF389	0.51	5.02	0.41	1.73e-6	Depression;
TGCT	cis	rs6121246	0.954	rs73241710	chr20:30424956	G/A	cg18721089	chr20:30220636	NA	-0.45	-5.0	-0.41	1.9e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs1580019	0.563	rs10486509	chr7:32585443	C/G	cg07520158	chr7:32535189	LSM5;AVL9	-0.57	-5.02	-0.41	1.78e-6	Cognitive ability;
TGCT	cis	rs11242417	0.786	rs11746476	chr5:137511540	T/C	ch.5.2533981R	chr5:137298291	FAM13B	-0.39	-4.47	-0.37	1.72e-5	Immune reponse to smallpox (secreted IL-12p40);
TGCT	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg08219700	chr8:58056026	NA	0.29	4.5	0.37	1.54e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs6964587	0.773	rs17757926	chr7:91987702	T/C	cg17063962	chr7:91808500	NA	0.83	8.18	0.59	2.83e-13	Breast cancer;
TGCT	cis	rs1150668	0.799	rs1150707	chr6:28197605	C/T	cg13525197	chr6:28411240	ZSCAN23	-0.47	-4.61	-0.38	9.84e-6	Pubertal anthropometrics;
TGCT	cis	rs938554	0.578	rs7663032	chr4:9993838	C/T	cg11266682	chr4:10021025	SLC2A9	0.51	5.1	0.42	1.23e-6	Blood metabolite levels;
TGCT	cis	rs35146811	0.735	rs858505	chr7:99819577	G/A	cg00553149	chr7:99775558	STAG3;GPC2	-0.32	-4.81	-0.4	4.28e-6	Coronary artery disease;
TGCT	cis	rs7267979	1.000	rs6037121	chr20:25428311	G/A	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs28595532	0.844	rs80188901	chr4:119500014	C/T	cg21605333	chr4:119757512	SEC24D	1.36	7.24	0.55	4.15e-11	Cannabis dependence symptom count;
TGCT	cis	rs28595532	0.920	rs116795224	chr4:119734570	C/T	cg14228332	chr4:119757509	SEC24D	1.32	6.38	0.5	3.2e-9	Cannabis dependence symptom count;
TGCT	cis	rs2016266	0.859	rs10876433	chr12:53734114	G/A	cg16917193	chr12:54089295	NA	-0.7	-4.62	-0.38	9.55e-6	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg15556689	chr8:8085844	FLJ10661	0.83	8.1	0.59	4.45e-13	Systolic blood pressure;
TGCT	cis	rs2288073	1.000	rs6708328	chr2:24412413	A/G	cg02683114	chr2:24398427	C2orf84	-0.25	-5.73	-0.46	7.14e-8	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs10267417	0.544	rs2072185	chr7:19748700	G/A	cg05791153	chr7:19748676	TWISTNB	1.33	13.99	0.78	2.88e-27	Night sleep phenotypes;
TGCT	cis	rs7582180	0.790	rs4851288	chr2:100920451	T/C	cg14675211	chr2:100938903	LONRF2	0.46	4.52	0.38	1.43e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs12519773	0.526	rs7714485	chr5:92515301	A/C	cg04854328	chr5:92914828	FLJ42709	-0.3	-4.58	-0.38	1.12e-5	Migraine;
TGCT	cis	rs941408	0.515	rs2110118	chr19:2775144	T/C	cg26465405	chr19:3039745	TLE2	-0.22	-4.52	-0.38	1.44e-5	Total cholesterol levels;
TGCT	cis	rs9549260	0.564	rs7998724	chr13:41324793	G/T	cg21288729	chr13:41239152	FOXO1	0.99	9.68	0.66	7.68e-17	Red blood cell count;
TGCT	cis	rs1635	0.655	rs73742544	chr6:28317536	T/A	cg15743358	chr6:28303923	ZNF323	-1.3	-4.94	-0.41	2.45e-6	Schizophrenia;
TGCT	cis	rs6540559	1.000	rs6696825	chr1:209982372	A/G	cg22029157	chr1:209979665	IRF6	0.78	6.29	0.49	5.01e-9	Cleft lip with or without cleft palate;
TGCT	cis	rs2115630	0.645	rs2292463	chr15:85175750	A/G	cg17173187	chr15:85201210	NMB	-0.49	-5.99	-0.47	2.15e-8	P wave terminal force;
TGCT	cis	rs13336428	0.730	rs28653458	chr16:1525850	T/C	cg26690334	chr16:1524521	CLCN7	-0.4	-6.87	-0.52	2.78e-10	Bone mineral density;
TGCT	cis	rs6540559	0.611	rs926347	chr1:209965193	T/C	cg21951975	chr1:209979733	IRF6	0.68	5.3	0.43	5.17e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs1215050	0.755	rs811479	chr4:98727398	A/T	cg05340658	chr4:99064831	C4orf37	0.44	5.51	0.44	1.95e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs765787	0.530	rs12903149	chr15:45539076	G/A	cg24006582	chr15:45444508	DUOX1	0.24	5.23	0.43	6.85e-7	Uric acid levels;
TGCT	trans	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.86	9.38	0.64	3.95e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs78487399	0.710	rs7572923	chr2:43685109	C/A	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.74	4.77	0.39	5.16e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs11096990	0.634	rs10029074	chr4:39292502	T/G	cg20847110	chr4:39482781	LOC401127	-0.16	-4.51	-0.38	1.48e-5	Cognitive function;
TGCT	cis	rs7772486	0.846	rs1331636	chr6:146338826	T/C	cg23711669	chr6:146136114	FBXO30	0.88	9.67	0.66	7.78e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg07167872	chr1:205819463	PM20D1	0.68	9.92	0.67	2.01e-17	Menarche (age at onset);
TGCT	cis	rs34014631	0.786	rs75773111	chr10:103658180	T/C	cg22630918	chr10:102748988	C10orf2	0.42	4.82	0.4	4.15e-6	Coronary artery calcification;
TGCT	cis	rs7954584	0.616	rs10743185	chr12:122356435	G/A	cg10207240	chr12:122356781	WDR66	0.34	4.68	0.39	7.53e-6	Mean corpuscular volume;
TGCT	cis	rs6992820	0.967	rs6996402	chr8:56752230	G/C	cg06880721	chr8:56792545	LYN	-0.55	-4.71	-0.39	6.4e-6	Mean platelet volume;
TGCT	cis	rs7267979	1.000	rs2387880	chr20:25377787	T/C	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3774830	1.000	rs6827240	chr4:5440224	G/T	cg26943120	chr4:5472116	STK32B	0.21	4.62	0.38	9.37e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs28595532	0.841	rs116452272	chr4:119770802	T/C	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs4499344	0.633	rs259271	chr19:33157100	A/G	cg26639809	chr19:33781782	NA	0.22	4.47	0.37	1.75e-5	Mean platelet volume;
TGCT	cis	rs7954584	0.520	rs1169095	chr12:122465738	G/A	cg13699009	chr12:122356056	WDR66	-0.22	-4.59	-0.38	1.05e-5	Mean corpuscular volume;
TGCT	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg03188948	chr7:1209495	NA	0.71	6.04	0.48	1.68e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs986417	0.748	rs1955700	chr14:61046481	A/G	cg18240143	chr14:60952599	C14orf39	0.82	4.51	0.38	1.46e-5	Gut microbiota (bacterial taxa);
TGCT	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg00149659	chr3:10157352	C3orf10	1.2	7.56	0.56	7.9e-12	Alzheimer's disease;
TGCT	cis	rs2153535	0.623	rs6597338	chr6:8533508	A/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.01	0.41	1.86e-6	Motion sickness;
TGCT	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg03188948	chr7:1209495	NA	0.52	5.4	0.44	3.29e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs35934224	0.891	rs13054713	chr22:19867914	C/A	cg11182965	chr22:19864308	TXNRD2	-0.38	-5.3	-0.43	5.08e-7	Glaucoma (primary open-angle);
TGCT	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg07507251	chr3:52567010	NT5DC2	0.49	7.06	0.54	1.06e-10	Bipolar disorder;
TGCT	cis	rs9393777	0.513	rs9379907	chr6:26654318	C/T	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.53	-4.88	-0.4	3.19e-6	Intelligence (multi-trait analysis);
TGCT	trans	rs7819412	0.511	rs35558344	chr8:11434232	C/T	cg06636001	chr8:8085503	FLJ10661	-0.8	-7.51	-0.56	1.03e-11	Triglycerides;
TGCT	cis	rs2197308	0.765	rs12370231	chr12:37917881	T/C	cg26384229	chr12:38710491	ALG10B	0.88	7.7	0.57	3.71e-12	Morning vs. evening chronotype;
TGCT	cis	rs2204008	0.645	rs9989043	chr12:38238505	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-4.46	-0.37	1.8e-5	Bladder cancer;
TGCT	cis	rs11098499	0.615	rs28850368	chr4:120554313	G/A	cg09307838	chr4:120376055	NA	0.62	5.86	0.47	3.86e-8	Corneal astigmatism;
TGCT	cis	rs7772486	0.875	rs2748490	chr6:146329681	G/T	cg23711669	chr6:146136114	FBXO30	0.82	8.92	0.63	5.14e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs62103177	0.673	rs7242867	chr18:77603270	A/T	cg12964065	chr18:77638022	KCNG2	0.33	4.63	0.38	9.06e-6	Opioid sensitivity;
TGCT	cis	rs7651039	0.641	rs2455823	chr3:15666856	T/C	cg16303742	chr3:15540471	COLQ	0.25	4.56	0.38	1.19e-5	Coronary heart disease;
TGCT	cis	rs11105298	0.891	rs4842661	chr12:89930399	A/G	cg00757033	chr12:89920650	WDR51B	0.29	4.46	0.37	1.78e-5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs7677751	0.806	rs6850748	chr4:55099164	T/G	cg17187183	chr4:55093834	PDGFRA	0.55	7.06	0.54	1.05e-10	Corneal astigmatism;
TGCT	cis	rs11578119	0.933	rs3923079	chr1:170462467	A/G	cg09767346	chr1:170501363	GORAB	-0.68	-5.41	-0.44	3.18e-7	Male-pattern baldness;
TGCT	cis	rs12468226	1.000	rs111542497	chr2:203195092	G/T	cg26506821	chr2:202639771	ALS2	0.32	4.46	0.37	1.84e-5	Urate levels;
TGCT	cis	rs3812049	0.737	rs1112956	chr5:127433798	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.63	-5.8	-0.46	5.2e-8	Lymphocyte counts;Red cell distribution width;
TGCT	cis	rs3809566	0.963	rs4775608	chr15:63331940	A/G	cg08198488	chr15:63333792	TPM1	-0.35	-5.23	-0.43	7e-7	Platelet count;
TGCT	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg26818010	chr10:134567672	INPP5A	-0.39	-5.51	-0.44	1.96e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs2404602	0.692	rs67010831	chr15:76965308	T/G	cg22467129	chr15:76604101	ETFA	-0.45	-5.11	-0.42	1.2e-6	Blood metabolite levels;
TGCT	cis	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg12570787	chr5:219185	SDHA;CCDC127	0.65	4.46	0.37	1.83e-5	Breast cancer;
TGCT	cis	rs2952156	1.000	rs2643194	chr17:37853048	C/T	cg19468946	chr17:37922297	IKZF3	-0.19	-4.46	-0.37	1.82e-5	Asthma;
TGCT	cis	rs7091068	0.671	rs604489	chr10:95405408	T/C	cg20715218	chr10:95462985	C10orf4	-0.54	-5.15	-0.42	9.95e-7	Urinary tract infection frequency;
TGCT	cis	rs4409675	0.549	rs72872888	chr1:28239809	G/A	cg23691781	chr1:28212827	C1orf38	0.28	5.82	0.46	4.66e-8	Corneal astigmatism;
TGCT	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg03188948	chr7:1209495	NA	0.53	4.86	0.4	3.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7666738	0.830	rs10031190	chr4:98908683	C/A	cg17366294	chr4:99064904	C4orf37	0.71	7.33	0.55	2.63e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2486012	0.678	rs3011218	chr1:44303329	T/A	cg12908607	chr1:44402522	ARTN	-0.71	-5.54	-0.45	1.77e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9486715	0.929	rs2025044	chr6:97067028	A/G	cg06623918	chr6:96969491	KIAA0776	-1.09	-13.44	-0.77	5.74e-26	Headache;
TGCT	cis	rs13242816	1.000	rs13221364	chr7:116083544	C/T	cg02799643	chr7:116139180	CAV2	-0.5	-5.4	-0.44	3.32e-7	P wave duration;
TGCT	cis	rs2486012	1.000	rs2906467	chr1:44320476	C/A	cg12908607	chr1:44402522	ARTN	-0.72	-5.68	-0.45	8.89e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs11792861	0.781	rs11789252	chr9:111762010	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.5	4.69	0.39	6.99e-6	Menarche (age at onset);
TGCT	cis	rs7582180	0.629	rs11685406	chr2:100946638	A/G	cg08017756	chr2:100939284	LONRF2	-0.3	-4.87	-0.4	3.27e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9916302	0.861	rs7503514	chr17:37669884	G/C	cg07936489	chr17:37558343	FBXL20	-0.62	-4.88	-0.4	3.2e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg14893161	chr1:205819251	PM20D1	0.53	7.2	0.54	5.19e-11	Menarche (age at onset);
TGCT	cis	rs4845570	0.850	rs4618976	chr1:151766588	A/G	cg07092448	chr1:151763213	TDRKH	1.16	9.41	0.65	3.38e-16	Coronary artery disease;
TGCT	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs889312	0.500	rs832566	chr5:56151744	C/T	cg24531977	chr5:56204891	C5orf35	-0.48	-4.78	-0.39	4.9e-6	Breast cancer;Breast cancer (early onset);
TGCT	cis	rs644148	0.967	rs613876	chr19:44968788	T/C	cg15540054	chr19:45004280	ZNF180	-0.59	-5.18	-0.42	8.71e-7	Personality dimensions;
TGCT	cis	rs7267979	1.000	rs2500446	chr20:25339664	C/T	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6570726	0.935	rs12663205	chr6:145818378	G/A	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10419226	0.625	rs12974777	chr19:18765663	C/T	cg14292368	chr19:18793705	CRTC1	-0.49	-5.42	-0.44	2.98e-7	Barrett's esophagus;Esophageal adenocarcinoma;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs986417	1.000	rs986417	chr14:60858761	C/T	cg23984976	chr14:60032921	C14orf38	-0.5	-4.63	-0.38	9.07e-6	Gut microbiota (bacterial taxa);
TGCT	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg02788857	chr8:22132959	PIWIL2	0.28	5.15	0.42	9.82e-7	Hypertriglyceridemia;
TGCT	cis	rs688020	1.000	rs673500	chr7:4229445	C/G	cg24441899	chr7:4244372	SDK1	-0.39	-4.94	-0.41	2.43e-6	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;
TGCT	cis	rs72945132	0.619	rs34053053	chr11:70260598	C/T	cg00319359	chr11:70116639	PPFIA1	0.99	6.52	0.51	1.56e-9	Coronary artery disease;
TGCT	cis	rs2197308	0.715	rs11181816	chr12:37911626	A/G	cg26384229	chr12:38710491	ALG10B	-0.7	-6.15	-0.48	9.71e-9	Morning vs. evening chronotype;
TGCT	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg11644478	chr21:40555479	PSMG1	0.9	8.01	0.58	7.21e-13	Cognitive function;
TGCT	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	-0.39	-4.61	-0.38	1e-5	Menopause (age at onset);
TGCT	cis	rs9911578	0.935	rs9911753	chr17:56983174	G/A	cg05425664	chr17:57184151	TRIM37	-0.56	-5.42	-0.44	2.99e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7547997	0.615	rs73029766	chr1:158320989	G/A	cg07950803	chr1:158223934	CD1A	0.31	4.71	0.39	6.42e-6	QRS duration;
TGCT	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	9.52	0.65	1.86e-16	Platelet count;
TGCT	cis	rs2549003	0.934	rs2549006	chr5:131827065	A/G	cg21138405	chr5:131827807	IRF1	-0.18	-4.46	-0.37	1.82e-5	Asthma (sex interaction);
TGCT	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg03732007	chr1:2071316	PRKCZ	-0.27	-5.96	-0.47	2.42e-8	Height;
TGCT	cis	rs13217239	0.646	rs12209886	chr6:26984757	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.4	4.47	0.37	1.76e-5	Schizophrenia;
TGCT	cis	rs12142240	0.698	rs72890727	chr1:46860237	G/A	cg14993813	chr1:46806288	NSUN4	-0.59	-4.86	-0.4	3.45e-6	Menopause (age at onset);
TGCT	cis	rs7940866	0.903	rs1820353	chr11:130870765	A/G	cg05962950	chr11:130786565	SNX19	0.62	6.14	0.48	1.05e-8	Schizophrenia;
TGCT	cis	rs910187	0.678	rs3818013	chr20:45816639	A/G	cg27589058	chr20:45804311	EYA2	-0.35	-7.6	-0.56	6.23e-12	Migraine;
TGCT	cis	rs9457247	0.967	rs425039	chr6:167410527	C/T	cg23791538	chr6:167370224	RNASET2	-0.49	-4.96	-0.41	2.31e-6	Crohn's disease;
TGCT	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg05368731	chr17:41323189	NBR1	1.17	13.48	0.77	4.54e-26	Menopause (age at onset);
TGCT	cis	rs11249608	0.636	rs62393070	chr5:178447943	A/G	cg21905437	chr5:178450457	ZNF879	0.45	4.53	0.38	1.38e-5	Pubertal anthropometrics;
TGCT	cis	rs138249	0.902	rs138240	chr22:50564181	A/C	cg24864161	chr22:50528282	MOV10L1	-0.47	-5.02	-0.41	1.77e-6	Gestational age at birth in labor-initiated deliveries (child effect);
TGCT	cis	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg25660036	chr4:7070649	GRPEL1	0.59	4.62	0.38	9.55e-6	Monocyte percentage of white cells;
TGCT	cis	rs2456568	0.548	rs10501809	chr11:93666263	C/G	cg26875233	chr11:93583750	C11orf90	-0.43	-5.25	-0.43	6.44e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs10791097	0.720	rs6590517	chr11:130733505	C/T	cg05962950	chr11:130786565	SNX19	0.9	10.98	0.7	5.34e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs478304	0.903	rs1151502	chr11:65503485	G/C	cg27068330	chr11:65405492	SIPA1	0.75	7.39	0.55	1.93e-11	Acne (severe);
TGCT	trans	rs208520	1.000	rs208536	chr6:66963440	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.88	-8.21	-0.59	2.37e-13	Exhaled nitric oxide output;
TGCT	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg25036284	chr2:26402008	FAM59B	-0.65	-5.18	-0.42	8.8e-7	Gut microbiome composition (summer);
TGCT	cis	rs2404602	0.716	rs17364076	chr15:76760891	C/T	cg22467129	chr15:76604101	ETFA	-0.55	-6.71	-0.52	6.16e-10	Blood metabolite levels;
TGCT	cis	rs6426558	0.559	rs485234	chr1:227317747	A/G	cg10327440	chr1:227177885	CDC42BPA	0.58	6.91	0.53	2.21e-10	Neutrophil percentage of white cells;
TGCT	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg03806693	chr22:41940476	POLR3H	1.01	11.44	0.72	3.94e-21	Vitiligo;
TGCT	trans	rs12599106	0.629	rs1391904	chr16:34548934	C/T	cg18110333	chr6:292329	DUSP22	-0.68	-7.5	-0.56	1.08e-11	Menopause (age at onset);
TGCT	cis	rs2153535	0.541	rs4637688	chr6:8446501	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.71	0.46	7.86e-8	Motion sickness;
TGCT	cis	rs950169	0.580	rs11634320	chr15:85172183	A/C	cg12863693	chr15:85201151	NMB	-0.46	-5.56	-0.45	1.6e-7	Schizophrenia;
TGCT	cis	rs9611565	0.512	rs2899349	chr22:42164660	T/C	cg13695892	chr22:41940480	POLR3H	0.85	8.06	0.59	5.4e-13	Vitiligo;
TGCT	cis	rs2070488	0.775	rs9838614	chr3:38537671	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.66	-6.0	-0.47	2.05e-8	Electrocardiographic conduction measures;
TGCT	cis	rs11122272	0.735	rs2749709	chr1:231530476	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-6.34	-0.49	3.83e-9	Hemoglobin concentration;
TGCT	cis	rs10751667	0.961	rs10794358	chr11:985547	C/T	cg06064525	chr11:970664	AP2A2	-0.31	-6.16	-0.48	9.52e-9	Alzheimer's disease (late onset);
TGCT	cis	rs10114408	0.959	rs10125611	chr9:96646491	G/A	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs6570726	0.620	rs367693	chr6:145815949	G/A	cg23711669	chr6:146136114	FBXO30	0.71	6.51	0.5	1.72e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs76473307	1.000	rs116859592	chr20:57419988	T/C	cg06163629	chr20:57414884	GNASAS;GNAS	-0.64	-4.5	-0.37	1.54e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs2242116	0.793	rs9855938	chr3:46957298	G/A	cg27129171	chr3:47204927	SETD2	0.63	6.13	0.48	1.08e-8	Birth weight;
TGCT	cis	rs17152411	0.895	rs7086128	chr10:126587373	A/G	cg07906193	chr10:126599966	NA	0.41	5.05	0.41	1.52e-6	Height;
TGCT	cis	rs9653442	0.545	rs4490209	chr2:100766711	C/G	cg22139774	chr2:100720529	AFF3	-0.35	-5.56	-0.45	1.57e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs11792861	0.926	rs17628095	chr9:111889172	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.49	-4.58	-0.38	1.1e-5	Menarche (age at onset);
TGCT	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg16049864	chr8:95962084	TP53INP1	-0.76	-11.14	-0.71	2.13e-20	Type 2 diabetes;
TGCT	cis	rs116161686	0.500	rs55871867	chr1:210051029	A/G	cg04352962	chr1:209979756	IRF6	0.63	4.48	0.37	1.65e-5	Coronary artery disease;
TGCT	cis	rs7226408	0.857	rs56049218	chr18:34429685	C/T	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs6450176	1.000	rs6876198	chr5:53303595	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.51	-4.58	-0.38	1.13e-5	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs2721195	0.874	rs2721197	chr8:145727705	A/G	cg15320075	chr8:145703422	NA	0.69	6.75	0.52	5.13e-10	Age at first birth;
TGCT	cis	rs2637266	1.000	rs10219023	chr10:78364537	G/A	cg18941641	chr10:78392320	NA	0.39	4.88	0.4	3.24e-6	Pulmonary function;
TGCT	cis	rs7833790	1.000	rs28696138	chr8:82770794	G/A	cg17211192	chr8:82754475	SNX16	1.06	8.51	0.61	4.89e-14	Diastolic blood pressure;
TGCT	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg05754148	chr16:3507555	NAT15	0.41	4.9	0.4	2.9e-6	Tuberculosis;
TGCT	cis	rs10206020	0.759	rs11903889	chr2:1576601	C/T	cg12573674	chr2:1569213	NA	-0.46	-5.2	-0.42	7.88e-7	IgG glycosylation;
TGCT	cis	rs9527	0.544	rs1572578	chr10:104822431	C/G	cg15744005	chr10:104629667	AS3MT	-0.42	-4.87	-0.4	3.29e-6	Arsenic metabolism;
TGCT	cis	rs2290402	0.536	rs56080039	chr4:886519	G/A	cg23332689	chr4:987652	IDUA;SLC26A1	0.33	5.0	0.41	1.94e-6	Type 2 diabetes;
TGCT	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.72	-7.32	-0.55	2.76e-11	Prudent dietary pattern;
TGCT	cis	rs644799	0.965	rs573758	chr11:95539591	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	10.57	0.69	5.17e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9814567	1.000	rs6802654	chr3:134217072	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.95	-9.62	-0.65	1.04e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs7095607	0.777	rs7919994	chr10:69931144	T/G	cg18986048	chr10:69913749	MYPN	0.46	5.24	0.43	6.63e-7	Lung function (FVC);
TGCT	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg24829409	chr8:58192753	C8orf71	0.59	4.97	0.41	2.17e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1023500	0.573	rs133377	chr22:42466950	C/T	cg15557168	chr22:42548783	NA	-0.22	-5.58	-0.45	1.47e-7	Schizophrenia;
TGCT	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg04267008	chr7:1944627	MAD1L1	-0.34	-4.45	-0.37	1.87e-5	Bipolar disorder and schizophrenia;
TGCT	cis	rs6733011	0.508	rs4850889	chr2:99521385	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.57	-5.44	-0.44	2.74e-7	Bipolar disorder;
TGCT	cis	rs7119	0.679	rs34075648	chr15:77847802	G/C	cg27398640	chr15:77910606	LINGO1	-0.28	-5.11	-0.42	1.21e-6	Type 2 diabetes;
TGCT	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	6.11	0.48	1.19e-8	Bipolar disorder;
TGCT	cis	rs968567	0.539	rs174549	chr11:61571382	A/G	cg19610905	chr11:61596333	FADS2	0.99	10.68	0.69	2.87e-19	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
TGCT	cis	rs9788682	0.694	rs10851906	chr15:78774676	A/G	cg24631222	chr15:78858424	CHRNA5	0.61	4.53	0.38	1.37e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs910316	1.000	rs3742780	chr14:75505008	G/C	cg08847533	chr14:75593920	NEK9	0.96	10.6	0.69	4.36e-19	Height;
TGCT	cis	rs73198271	0.694	rs114184516	chr8:8647082	A/G	cg06671706	chr8:8559999	CLDN23	-0.35	-4.5	-0.37	1.52e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs36051895	0.632	rs7850425	chr9:5170645	G/T	cg02405213	chr9:5042618	JAK2	-0.72	-9.46	-0.65	2.63e-16	Pediatric autoimmune diseases;
TGCT	cis	rs2832191	0.740	rs2012645	chr21:30445961	G/A	cg24692254	chr21:30365293	RNF160	0.98	11.36	0.71	6.16e-21	Dental caries;
TGCT	cis	rs2033711	0.870	rs1465789	chr19:58946056	C/T	cg12042659	chr19:58951599	ZNF132	0.52	4.6	0.38	1.03e-5	Uric acid clearance;
TGCT	cis	rs10992471	0.603	rs6479422	chr9:95190694	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.62	-5.94	-0.47	2.62e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg21724239	chr8:58056113	NA	-0.39	-4.65	-0.39	8.45e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7772486	0.875	rs1125461	chr6:146417653	C/T	cg23711669	chr6:146136114	FBXO30	0.89	9.5	0.65	2.1e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1865760	0.865	rs9467641	chr6:25947236	T/C	cg16482183	chr6:26056742	HIST1H1C	0.53	4.88	0.4	3.14e-6	Height;
TGCT	cis	rs6121246	0.697	rs6088856	chr20:30226543	C/G	cg13852791	chr20:30311386	BCL2L1	0.73	4.75	0.39	5.43e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs12220898	0.749	rs10857456	chr10:50474756	A/G	cg09603381	chr10:49954066	WDFY4	0.38	4.45	0.37	1.85e-5	Inflammatory biomarkers;
TGCT	cis	rs71435601	0.628	rs1652419	chr2:21385649	C/T	cg25035485	chr2:21266500	APOB	0.51	4.48	0.37	1.64e-5	Cholesterol, total;
TGCT	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg18402987	chr7:1209562	NA	0.4	4.6	0.38	1.04e-5	Longevity;Endometriosis;
TGCT	cis	rs710216	0.917	rs1681859	chr1:43411829	G/A	cg03128534	chr1:43423976	SLC2A1	0.61	4.46	0.37	1.81e-5	Red cell distribution width;
TGCT	cis	rs8016982	0.609	rs8009519	chr14:81702503	C/G	cg01989461	chr14:81687754	GTF2A1	0.84	8.65	0.61	2.22e-14	Schizophrenia;
TGCT	cis	rs2153535	0.580	rs1932285	chr6:8477719	T/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs425277	0.527	rs3107144	chr1:2045380	C/A	cg03732007	chr1:2071316	PRKCZ	-0.24	-5.38	-0.44	3.57e-7	Height;
TGCT	cis	rs992157	0.804	rs6758540	chr2:219138625	A/G	cg00012203	chr2:219082015	ARPC2	-0.78	-7.64	-0.57	5.16e-12	Colorectal cancer;
TGCT	cis	rs76878669	0.606	rs1785639	chr11:66100430	G/A	cg18002602	chr11:66138449	SLC29A2	0.52	6.5	0.5	1.76e-9	Educational attainment (years of education);
TGCT	cis	rs9527	0.590	rs34104646	chr10:104896078	T/A	cg15744005	chr10:104629667	AS3MT	-0.43	-4.94	-0.41	2.45e-6	Arsenic metabolism;
TGCT	cis	rs77972916	0.536	rs62137421	chr2:43594091	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.33	-4.61	-0.38	1.01e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg18402987	chr7:1209562	NA	0.74	6.19	0.49	7.92e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs929354	0.772	rs6969244	chr7:157004012	A/G	cg05182265	chr7:156933206	UBE3C	-0.39	-8.77	-0.62	1.19e-14	Body mass index;
TGCT	cis	rs6969780	0.673	rs2301721	chr7:27196113	C/T	cg04321618	chr7:27170880	HOXA4	-0.52	-5.18	-0.42	8.67e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs11098499	0.863	rs3822191	chr4:120428101	A/T	cg09307838	chr4:120376055	NA	0.68	6.37	0.5	3.36e-9	Corneal astigmatism;
TGCT	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg24578937	chr1:2090814	PRKCZ	-0.26	-6.91	-0.53	2.21e-10	Height;
TGCT	cis	rs9660992	0.710	rs1768586	chr1:205238275	A/G	cg00857998	chr1:205179979	DSTYK	0.52	4.56	0.38	1.19e-5	Mean corpuscular volume;Mean platelet volume;
TGCT	cis	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg15556689	chr8:8085844	FLJ10661	0.67	6.2	0.49	7.84e-9	Mood instability;
TGCT	cis	rs476633	0.691	rs2164996	chr15:41536624	A/G	cg11362250	chr15:42265079	EHD4	-0.35	-4.48	-0.37	1.68e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs2013441	1.000	rs2526483	chr17:20112216	A/G	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.61	-0.38	9.96e-6	Obesity-related traits;
TGCT	cis	rs68170813	0.559	rs77150993	chr7:106817100	G/T	cg02696742	chr7:106810147	HBP1	-0.7	-6.05	-0.48	1.59e-8	Coronary artery disease;
TGCT	cis	rs3091242	0.933	rs61775167	chr1:25780893	A/G	cg00786635	chr1:25594202	NA	-0.52	-5.56	-0.45	1.59e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg21963583	chr11:68658836	MRPL21	0.36	5.99	0.47	2.1e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg00814883	chr7:100076585	TSC22D4	-0.55	-5.42	-0.44	3.01e-7	Lung function (FEV1/FVC);
TGCT	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg09263875	chr16:632152	PIGQ	0.31	6.89	0.53	2.52e-10	Height;
TGCT	cis	rs9993613	0.808	rs1401153	chr4:73432895	C/T	cg15102770	chr4:73434591	ADAMTS3	0.51	4.57	0.38	1.16e-5	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg06028808	chr11:68637592	NA	0.53	6.87	0.52	2.78e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs13217239	0.646	rs7747454	chr6:27034253	T/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.42	-4.6	-0.38	1.01e-5	Schizophrenia;
TGCT	cis	rs68170813	0.559	rs7779062	chr7:106880195	T/A	cg02696742	chr7:106810147	HBP1	-0.66	-5.51	-0.44	1.94e-7	Coronary artery disease;
TGCT	cis	rs7647973	0.593	rs1799844	chr3:49847642	G/A	cg03060546	chr3:49711283	APEH	-0.62	-5.23	-0.43	6.88e-7	Menarche (age at onset);
TGCT	cis	rs4780401	0.609	rs4781142	chr16:11808806	T/C	cg01061890	chr16:11836724	TXNDC11	-0.6	-5.82	-0.46	4.74e-8	Rheumatoid arthritis;
TGCT	cis	rs950169	1.000	rs950169	chr15:84706461	C/T	cg11189052	chr15:85197271	WDR73	0.7	6.02	0.48	1.82e-8	Schizophrenia;
TGCT	cis	rs2862064	0.932	rs1809941	chr5:156482459	G/T	cg12943317	chr5:156479607	HAVCR1	-0.48	-6.14	-0.48	1.05e-8	Platelet count;
TGCT	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg17054783	chr10:134559939	INPP5A	0.23	4.64	0.38	8.63e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs3829109	0.564	rs10781511	chr9:139280766	G/A	cg13741927	chr9:139327495	INPP5E	-0.23	-4.88	-0.4	3.19e-6	Peak insulin response;Acute insulin response;
TGCT	cis	rs2115630	0.645	rs6496284	chr15:85178270	A/G	cg12863693	chr15:85201151	NMB	-0.36	-4.71	-0.39	6.42e-6	P wave terminal force;
TGCT	cis	rs9467773	0.620	rs2504600	chr6:26648334	C/A	cg05738196	chr6:26577821	NA	0.88	10.63	0.69	3.68e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg21724239	chr8:58056113	NA	0.42	5.04	0.41	1.59e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1153858	0.943	rs7402632	chr15:45701913	A/T	cg14582100	chr15:45693742	SPATA5L1	0.48	5.67	0.45	9.65e-8	Homoarginine levels;
TGCT	cis	rs6060960	0.502	rs6057968	chr20:30082779	A/T	cg18721089	chr20:30220636	NA	-0.55	-5.74	-0.46	6.72e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
TGCT	trans	rs1814175	0.645	rs1722000	chr11:49917928	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.51	-0.69	7.2e-19	Height;
TGCT	cis	rs60871478	0.730	rs73042471	chr7:927762	G/A	cg15782153	chr7:917662	C7orf20	0.55	4.89	0.4	3.11e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs7666738	0.830	rs10856936	chr4:99011319	T/C	cg17366294	chr4:99064904	C4orf37	0.67	6.97	0.53	1.69e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4455778	0.759	rs1860514	chr7:49006428	G/T	cg26309511	chr7:48887640	NA	-0.5	-5.98	-0.47	2.22e-8	Lung cancer in never smokers;
TGCT	cis	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg15556689	chr8:8085844	FLJ10661	0.68	6.21	0.49	7.2e-9	Mood instability;
TGCT	cis	rs62244186	0.659	rs12489887	chr3:44547124	A/T	cg10263370	chr3:44754102	ZNF502	-0.4	-4.8	-0.4	4.4e-6	Depressive symptoms;
TGCT	cis	rs12478296	1.000	rs57603292	chr2:243028537	G/A	cg06360820	chr2:242988706	NA	-0.81	-5.39	-0.44	3.36e-7	Obesity-related traits;
TGCT	cis	rs2180341	0.920	rs6916990	chr6:127698759	G/A	cg24812749	chr6:127587940	RNF146	0.99	7.63	0.57	5.24e-12	Breast cancer;
TGCT	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg16228356	chr17:43848958	NA	-0.26	-4.53	-0.38	1.37e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7223966	1.000	rs9899788	chr17:61756384	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	5.05	0.41	1.51e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs9527	0.622	rs12779263	chr10:104886533	G/T	cg04362960	chr10:104952993	NT5C2	0.74	6.23	0.49	6.77e-9	Arsenic metabolism;
TGCT	cis	rs3806843	0.576	rs265316	chr5:140290843	T/C	cg07102913	chr5:140593443	PCDHB13	-0.48	-4.71	-0.39	6.57e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7631605	0.905	rs11714716	chr3:37269678	A/G	cg17445812	chr3:36986805	TRANK1	0.22	4.86	0.4	3.43e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs1395	0.778	rs1978881	chr2:27400850	C/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.65	9.03	0.63	2.73e-15	Blood metabolite levels;
TGCT	cis	rs735396	0.694	rs2264750	chr12:121450165	C/T	cg02403541	chr12:121454288	C12orf43	0.77	7.48	0.56	1.16e-11	N-glycan levels;
TGCT	cis	rs7772486	0.686	rs6570701	chr6:145954090	A/G	cg05347473	chr6:146136440	FBXO30	0.48	4.56	0.38	1.19e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs651907	0.557	rs62284199	chr3:101478531	T/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.86	10.34	0.68	1.93e-18	Colorectal cancer;
TGCT	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs611744	0.870	rs57723916	chr8:109191433	A/T	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	trans	rs1814175	0.645	rs7115592	chr11:50013243	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.84	-0.7	1.13e-19	Height;
TGCT	cis	rs6964587	1.000	rs34043009	chr7:91578447	T/C	cg17063962	chr7:91808500	NA	-0.91	-9.99	-0.67	1.32e-17	Breast cancer;
TGCT	cis	rs7647973	1.000	rs940045	chr3:49449638	G/A	cg05785598	chr3:49045655	WDR6	0.37	4.52	0.38	1.42e-5	Menarche (age at onset);
TGCT	cis	rs25422	0.938	rs7356858	chr6:118765814	G/C	cg07617317	chr6:118971624	C6orf204	0.5	5.39	0.44	3.37e-7	Renal cell carcinoma;
TGCT	cis	rs9611565	0.512	rs139572	chr22:42214532	C/T	cg03806693	chr22:41940476	POLR3H	-1.04	-10.57	-0.69	5.2e-19	Vitiligo;
TGCT	trans	rs7819412	0.807	rs10105315	chr8:10932203	G/C	cg15556689	chr8:8085844	FLJ10661	-0.81	-7.79	-0.57	2.36e-12	Triglycerides;
TGCT	cis	rs4804368	1.000	rs12460089	chr19:7190716	T/C	cg04811526	chr19:8009138	TIMM44	0.52	4.5	0.38	1.52e-5	Renal cell carcinoma;
TGCT	cis	rs13242816	1.000	rs13247015	chr7:116095623	A/C	cg16553024	chr7:116138462	CAV2	-0.46	-5.18	-0.42	8.58e-7	P wave duration;
TGCT	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg03264133	chr6:25882463	NA	0.86	8.5	0.61	5.01e-14	Blood metabolite levels;
TGCT	cis	rs433598	0.765	rs163268	chr16:20660553	A/G	cg08248577	chr16:19727447	IQCK;C16orf88	-0.22	-4.92	-0.4	2.68e-6	Schizophrenia;
TGCT	cis	rs7746199	0.736	rs17693963	chr6:27710165	A/C	cg10876282	chr6:28092338	ZSCAN16	0.95	4.95	0.41	2.4e-6	Gait speed in old age;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9807989	0.839	rs4988958	chr2:102968285	T/C	cg09003973	chr2:102972529	NA	0.64	5.7	0.46	8.28e-8	Asthma;
TGCT	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg17054783	chr10:134559939	INPP5A	0.24	4.83	0.4	3.92e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs2637266	0.703	rs6480836	chr10:78446866	C/T	cg18941641	chr10:78392320	NA	0.4	4.88	0.4	3.24e-6	Pulmonary function;
TGCT	cis	rs9517302	0.544	rs2281766	chr13:99098882	A/C	cg22223119	chr13:99095684	FARP1	-0.6	-6.41	-0.5	2.71e-9	Obesity-related traits;
TGCT	cis	rs1401999	0.650	rs3792585	chr3:183646222	A/G	cg01324343	chr3:183735012	ABCC5	0.67	7.98	0.58	8.16e-13	Anterior chamber depth;
TGCT	cis	rs8016982	0.698	rs12590764	chr14:81704417	G/A	cg01989461	chr14:81687754	GTF2A1	0.77	7.16	0.54	6.37e-11	Schizophrenia;
TGCT	cis	rs7572733	0.534	rs700673	chr2:198692929	A/G	cg00792783	chr2:198669748	PLCL1	0.56	5.08	0.42	1.35e-6	Dermatomyositis;
TGCT	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg12310025	chr6:25882481	NA	-0.62	-6.42	-0.5	2.63e-9	Blood metabolite levels;
TGCT	cis	rs4788570	0.513	rs2113223	chr16:71607915	A/G	cg06353428	chr16:71660113	MARVELD3	-1.29	-10.45	-0.68	1e-18	Intelligence (multi-trait analysis);
TGCT	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg20276088	chr3:133502917	NA	-0.24	-5.06	-0.41	1.5e-6	Iron status biomarkers;
TGCT	cis	rs2842992	0.830	rs2758352	chr6:160122921	A/G	cg11366901	chr6:160182831	ACAT2	1.01	6.67	0.51	7.61e-10	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs7937682	0.924	rs4630327	chr11:111539327	C/T	cg09085632	chr11:111637200	PPP2R1B	1.11	12.06	0.73	1.25e-22	Primary sclerosing cholangitis;
TGCT	cis	rs9325144	0.505	rs6582691	chr12:38806894	T/C	cg26384229	chr12:38710491	ALG10B	-0.83	-7.83	-0.58	1.89e-12	Morning vs. evening chronotype;
TGCT	cis	rs3796352	1.000	rs11712653	chr3:53070875	A/C	cg12962167	chr3:53033115	SFMBT1	-0.44	-4.97	-0.41	2.17e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs7646507	0.826	rs13071639	chr3:172546930	C/T	cg10532262	chr3:172428426	NCEH1	0.92	4.69	0.39	7.21e-6	Obesity-related traits;
TGCT	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg08280861	chr8:58055591	NA	0.4	4.73	0.39	5.97e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs8180040	0.620	rs9858443	chr3:47086048	G/A	cg27129171	chr3:47204927	SETD2	0.71	8.55	0.61	3.9e-14	Colorectal cancer;
TGCT	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg20607798	chr8:58055168	NA	0.45	4.59	0.38	1.06e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7208859	0.673	rs216440	chr17:28928309	A/T	cg19761014	chr17:28927070	LRRC37B2	0.53	4.63	0.38	9.04e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	trans	rs7176093	0.665	rs17581281	chr15:86386197	C/T	cg03164243	chr17:17717894	MIR33B;SREBF1	0.38	6.92	0.53	2.18e-10	Aging traits;
TGCT	cis	rs9595066	0.941	rs9533777	chr13:44708720	C/T	cg04068111	chr13:44716778	NA	0.47	4.6	0.38	1.04e-5	Schizophrenia;
TGCT	trans	rs66573146	1.000	rs55913461	chr4:7017509	C/T	cg07817883	chr1:32538562	TMEM39B	1.69	8.36	0.6	1.1e-13	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs3087591	0.708	rs7406783	chr17:29689980	A/G	cg24425628	chr17:29625626	OMG;NF1	0.39	5.52	0.44	1.87e-7	Hip circumference;
TGCT	cis	rs113577745	0.725	rs41264179	chr2:10102735	T/C	cg17603321	chr2:9696605	ADAM17	-1.15	-5.09	-0.42	1.31e-6	Breast cancer;
TGCT	cis	rs6770219	0.516	rs7632528	chr3:186134307	C/A	cg20306810	chr3:186501757	SNORD2;EIF4A2	0.73	4.45	0.37	1.89e-5	Cerebrospinal T-tau levels;
TGCT	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg11905131	chr22:24372483	LOC391322	-0.95	-11.19	-0.71	1.64e-20	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg19570321	chr11:63258214	HRASLS5	0.44	4.87	0.4	3.35e-6	Platelet count;
TGCT	cis	rs28595532	0.920	rs56212415	chr4:119737731	C/T	cg21605333	chr4:119757512	SEC24D	1.61	8.95	0.63	4.36e-15	Cannabis dependence symptom count;
TGCT	cis	rs2688608	0.620	rs11000767	chr10:75516626	G/T	cg23231163	chr10:75533350	FUT11	-0.28	-4.86	-0.4	3.51e-6	Inflammatory bowel disease;
TGCT	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.01	0.41	1.86e-6	Prudent dietary pattern;
TGCT	cis	rs7833790	1.000	rs7833790	chr8:82731157	T/C	cg27398817	chr8:82754497	SNX16	-0.8	-5.98	-0.47	2.2e-8	Diastolic blood pressure;
TGCT	cis	rs10779751	1.000	rs12124983	chr1:11286178	C/T	cg08854313	chr1:11322531	MTOR	-0.92	-10.28	-0.68	2.6e-18	Body mass index;
TGCT	cis	rs9527	0.615	rs12248123	chr10:104735366	A/G	cg04362960	chr10:104952993	NT5C2	0.67	5.69	0.45	8.72e-8	Arsenic metabolism;
TGCT	cis	rs9581857	0.725	rs9581853	chr13:28016236	T/C	cg22138327	chr13:27999177	GTF3A	0.77	5.47	0.44	2.33e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs10465746	0.725	rs2024591	chr1:84329235	C/T	cg10977910	chr1:84465055	TTLL7	0.66	6.61	0.51	1.03e-9	Obesity-related traits;
TGCT	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg08280861	chr8:58055591	NA	0.44	4.6	0.38	1.01e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9549260	0.709	rs4943795	chr13:41173433	C/T	cg21288729	chr13:41239152	FOXO1	-0.94	-8.14	-0.59	3.64e-13	Red blood cell count;
TGCT	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	5.52	0.44	1.86e-7	Height;
TGCT	cis	rs3806843	0.576	rs246047	chr5:140328337	C/T	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7937682	0.564	rs11600652	chr11:111754368	A/T	cg09085632	chr11:111637200	PPP2R1B	0.92	8.7	0.62	1.7e-14	Primary sclerosing cholangitis;
TGCT	cis	rs9677476	0.516	rs2303349	chr2:232030861	A/G	cg07929768	chr2:232055508	NA	0.33	5.21	0.42	7.7300000000000005e-07	Food antigen IgG levels;
TGCT	cis	rs5760092	0.842	rs5751763	chr22:24247793	T/C	cg15242686	chr22:24348715	GSTTP1	0.47	5.3	0.43	5.14e-7	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs2956278	0.717	rs7976572	chr12:84684995	A/T	cg25678815	chr12:85673915	ALX1	-0.53	-4.76	-0.39	5.4e-6	Depressive symptoms;Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2688608	0.869	rs2250140	chr10:75612881	T/C	cg19442545	chr10:75533431	FUT11	-0.31	-4.94	-0.41	2.48e-6	Inflammatory bowel disease;
TGCT	cis	rs4253772	0.591	rs6008545	chr22:46686375	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.66	4.77	0.39	5.13e-6	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs4478858	0.735	rs6670067	chr1:31842947	C/T	cg07478791	chr1:31886160	SERINC2	-0.49	-4.66	-0.39	7.9e-6	Alcohol dependence;
TGCT	cis	rs1865760	0.566	rs2032449	chr6:26026599	G/C	cg16482183	chr6:26056742	HIST1H1C	0.59	5.14	0.42	1.04e-6	Height;
TGCT	cis	rs6089829	0.851	rs10854168	chr20:61669550	A/G	cg08564027	chr20:61660810	NA	0.37	5.98	0.47	2.26e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg06028808	chr11:68637592	NA	0.53	6.86	0.52	2.89e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs61990749	0.597	rs28534379	chr14:78172140	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	-0.63	-4.62	-0.38	9.34e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs35146811	0.735	rs1727139	chr7:99815367	C/T	cg00553149	chr7:99775558	STAG3;GPC2	-0.31	-4.61	-0.38	9.75e-6	Coronary artery disease;
TGCT	cis	rs17133449	0.718	rs11252674	chr10:4753422	C/T	cg04530666	chr10:3759553	NA	-0.3	-5.04	-0.41	1.58e-6	Major depressive disorder;
TGCT	cis	rs9383153	1.000	rs9383153	chr6:16343056	A/G	cg06493612	chr6:15502050	JARID2	0.59	4.88	0.4	3.16e-6	Gambling;
TGCT	cis	rs7666738	0.861	rs5010991	chr4:98972179	A/G	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs72949976	0.734	rs62189579	chr2:214016984	T/A	cg08319019	chr2:214017104	IKZF2	-0.83	-7.53	-0.56	8.95e-12	Lung cancer;Squamous cell lung carcinoma;
TGCT	cis	rs7666738	0.893	rs11729640	chr4:99052699	C/T	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11098499	0.754	rs2036857	chr4:120249240	T/C	cg09307838	chr4:120376055	NA	0.61	5.91	0.47	3.14e-8	Corneal astigmatism;
TGCT	cis	rs11250098	0.583	rs73196860	chr8:10814133	A/G	cg21775007	chr8:11205619	TDH	-0.55	-5.0	-0.41	1.9e-6	Morning vs. evening chronotype;
TGCT	cis	rs4808199	0.948	rs8108647	chr19:19427623	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.65	4.72	0.39	6.18e-6	Nonalcoholic fatty liver disease;
TGCT	trans	rs1814175	0.867	rs7926002	chr11:49616018	A/G	cg15704280	chr7:45808275	SEPT13	-0.61	-6.75	-0.52	5e-10	Height;
TGCT	trans	rs17471911	0.708	rs11189938	chr10:100780869	C/G	cg03484267	chr2:207988651	KLF7	-0.52	-6.7	-0.52	6.49e-10	Neuroticism;
TGCT	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg20849893	chr7:64541193	NA	0.5	5.17	0.42	9.05e-7	Calcium levels;
TGCT	cis	rs853679	0.585	rs201001	chr6:27808899	T/C	cg10876282	chr6:28092338	ZSCAN16	0.58	4.79	0.39	4.76e-6	Depression;
TGCT	cis	rs7715806	0.500	rs10515213	chr5:74980572	C/T	cg19683494	chr5:74908142	NA	-0.56	-5.07	-0.41	1.43e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs7000551	0.751	rs1482337	chr8:22395509	A/G	cg12081754	chr8:22256438	SLC39A14	-0.28	-4.46	-0.37	1.85e-5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	trans	rs561341	0.609	rs11658984	chr17:30186612	C/T	cg20587970	chr11:113659929	NA	0.66	8.12	0.59	3.98e-13	Hip circumference adjusted for BMI;
TGCT	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	5.71	0.46	8.05e-8	Alzheimer's disease;
TGCT	cis	rs7523273	0.565	rs2104303	chr1:207886684	C/T	cg22525895	chr1:207977042	MIR29B2	-0.35	-5.82	-0.46	4.72e-8	Schizophrenia;
TGCT	cis	rs2404602	0.647	rs12903586	chr15:77168240	G/A	cg23625390	chr15:77176239	SCAPER	-0.39	-5.05	-0.41	1.55e-6	Blood metabolite levels;
TGCT	cis	rs17345786	0.511	rs13061565	chr3:101392270	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.91	10.9	0.7	8.24e-20	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.51	-4.82	-0.4	4.16e-6	Bipolar disorder;
TGCT	cis	rs9790314	0.540	rs35462273	chr3:160991877	C/T	cg03342759	chr3:160939853	NMD3	-0.51	-5.42	-0.44	2.98e-7	Morning vs. evening chronotype;
TGCT	cis	rs2956278	0.603	rs2947132	chr12:84691481	C/T	cg25678815	chr12:85673915	ALX1	-0.53	-4.76	-0.39	5.4e-6	Depressive symptoms;Depressive symptoms (multi-trait analysis);
TGCT	cis	rs6938	0.575	rs12902515	chr15:75160998	G/C	cg09165964	chr15:75287851	SCAMP5	0.53	5.08	0.42	1.33e-6	Breast cancer;
TGCT	cis	rs35160687	0.862	rs17737955	chr2:86508014	C/T	cg03171300	chr2:86307199	POLR1A	0.32	5.35	0.43	4.05e-7	Night sleep phenotypes;
TGCT	trans	rs459571	0.959	rs2073818	chr9:136918662	C/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.79	-8.59	-0.61	3.1e-14	Platelet distribution width;
TGCT	trans	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg21659725	chr3:3221576	CRBN	-0.98	-15.33	-0.81	2.1000000000000002e-30	Intelligence (multi-trait analysis);
TGCT	cis	rs2224391	0.628	rs9504365	chr6:5256116	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-1.0	-6.11	-0.48	1.21e-8	Height;
TGCT	cis	rs1008375	0.902	rs6844984	chr4:17651304	C/G	cg18681998	chr4:17616180	MED28	1.02	12.01	0.73	1.65e-22	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1691799	0.899	rs1168303	chr12:66738586	A/G	cg16791601	chr12:66731901	HELB	-0.28	-6.11	-0.48	1.19e-8	White blood cell count (basophil);
TGCT	cis	rs1729951	0.575	rs361243	chr3:136697786	C/T	cg21827317	chr3:136751795	NA	0.4	5.6	0.45	1.28e-7	Neuroticism;
TGCT	cis	rs6987853	0.830	rs4361746	chr8:42355041	C/T	cg20539142	chr8:42623718	CHRNA6	0.19	4.52	0.38	1.44e-5	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs11235843	0.636	rs6592531	chr11:73412354	C/T	cg18195628	chr11:73498948	MRPL48	-0.64	-4.52	-0.38	1.42e-5	Hand grip strength;
TGCT	cis	rs6723226	0.961	rs13010404	chr2:32848854	T/G	cg02381751	chr2:32503542	YIPF4	-0.52	-4.82	-0.4	4.18e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7264396	0.635	rs6060709	chr20:34536022	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.04	-0.41	1.58e-6	Total cholesterol levels;
TGCT	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg06753367	chr22:24256600	NA	-0.24	-4.66	-0.39	7.89e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2932538	0.922	rs12048528	chr1:113210534	A/C	cg22162597	chr1:113214053	CAPZA1	-0.28	-6.31	-0.49	4.46e-9	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs1403694	0.515	rs710448	chr3:186452885	A/G	cg12454167	chr3:186435060	KNG1	0.44	6.91	0.53	2.24e-10	Blood protein levels;
TGCT	cis	rs1062177	1.000	rs2964571	chr5:151171256	C/T	cg00977110	chr5:151150581	G3BP1	0.4	4.57	0.38	1.16e-5	Preschool internalizing problems;
TGCT	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg22535103	chr8:58192502	C8orf71	-0.42	-4.72	-0.39	6.22e-6	Developmental language disorder (linguistic errors);
TGCT	trans	rs208520	0.690	rs3846808	chr6:66818604	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-10.98	-0.7	5.08e-20	Exhaled nitric oxide output;
TGCT	cis	rs79149102	0.649	rs75985113	chr15:75379312	C/T	cg09165964	chr15:75287851	SCAMP5	-1.02	-5.43	-0.44	2.87e-7	Lung cancer;
TGCT	cis	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg08045932	chr20:61659980	NA	0.48	9.28	0.64	7.07e-16	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs3733585	0.699	rs6844316	chr4:9958977	A/G	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.67	-0.51	7.44e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs4237845	0.788	rs1962047	chr12:58292707	G/A	cg23860436	chr12:58378763	NA	0.35	4.92	0.4	2.7e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10791323	0.604	rs2853116	chr11:133707063	A/G	cg15485101	chr11:133734466	NA	0.41	5.17	0.42	9.21e-7	Childhood ear infection;
TGCT	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg03188948	chr7:1209495	NA	0.49	6.93	0.53	2.07e-10	Longevity;Endometriosis;
TGCT	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.76	5.05	0.41	1.51e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs910316	0.967	rs4899551	chr14:75660246	C/G	cg08847533	chr14:75593920	NEK9	-0.94	-10.15	-0.67	5.35e-18	Height;
TGCT	cis	rs7726839	0.540	rs72707016	chr5:665148	A/G	cg09021430	chr5:549028	NA	-0.4	-5.64	-0.45	1.08e-7	Obesity-related traits;
TGCT	cis	rs7223966	1.000	rs9903903	chr17:61762044	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	5.05	0.41	1.51e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs9814567	0.702	rs9871226	chr3:134331466	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-6.41	-0.5	2.8e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg05457628	chr5:178986728	RUFY1	0.54	6.32	0.49	4.19e-9	Lung cancer;
TGCT	cis	rs3803170	0.513	rs11065884	chr12:111818701	A/G	cg10833066	chr12:111807467	FAM109A	0.35	5.51	0.44	1.94e-7	Mean corpuscular hemoglobin;
TGCT	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg08219700	chr8:58056026	NA	0.39	5.06	0.41	1.5e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2760061	0.569	rs621631	chr1:228114728	A/G	cg02753203	chr1:228287806	NA	-0.34	-6.64	-0.51	8.94e-10	Diastolic blood pressure;
TGCT	cis	rs3749237	0.964	rs11714957	chr3:49776178	C/T	cg07636037	chr3:49044803	WDR6	0.64	5.63	0.45	1.13e-7	Resting heart rate;
TGCT	cis	rs56399783	0.901	rs73049327	chr7:2795544	T/G	cg19731401	chr7:2775893	GNA12	0.35	4.92	0.4	2.7e-6	Childhood ear infection;
TGCT	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg20203395	chr5:56204925	C5orf35	-0.56	-4.96	-0.41	2.31e-6	Initial pursuit acceleration;
TGCT	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2019216	0.521	rs9807074	chr17:21930856	T/C	cg22648282	chr17:21454238	C17orf51	-0.59	-5.89	-0.47	3.46e-8	Pelvic organ prolapse;
TGCT	cis	rs236907	0.859	rs56377810	chr1:171757657	A/C	cg20598894	chr1:171756153	METTL13	-0.2	-4.54	-0.38	1.31e-5	Mean platelet volume;
TGCT	cis	rs7772486	0.720	rs991507	chr6:146023609	G/A	cg05347473	chr6:146136440	FBXO30	-0.52	-4.85	-0.4	3.61e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9914544	0.564	rs9907723	chr17:18758853	T/C	cg26378065	chr17:18585709	ZNF286B	0.53	4.59	0.38	1.09e-5	Educational attainment (years of education);
TGCT	cis	rs9611565	0.506	rs4822020	chr22:41700203	C/T	cg13695892	chr22:41940480	POLR3H	-0.67	-6.2	-0.49	7.58e-9	Vitiligo;
TGCT	cis	rs617219	0.710	rs2591386	chr5:78561373	C/T	cg23514016	chr5:78407564	BHMT	0.32	4.86	0.4	3.48e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs4237845	0.611	rs7298370	chr12:58318897	C/T	cg02175503	chr12:58329896	NA	0.69	7.42	0.55	1.63e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs1395	0.744	rs11679220	chr2:27476378	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.65	8.48	0.61	5.54e-14	Blood metabolite levels;
TGCT	cis	rs6570726	0.620	rs367693	chr6:145815949	G/A	cg05347473	chr6:146136440	FBXO30	0.62	5.72	0.46	7.48e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg12310025	chr6:25882481	NA	-0.62	-6.42	-0.5	2.63e-9	Blood metabolite levels;
TGCT	cis	rs3820068	0.603	rs56032936	chr1:15970953	T/C	cg05660106	chr1:15850417	CASP9	0.83	8.16	0.59	3.25e-13	Systolic blood pressure;
TGCT	cis	rs17030434	0.627	rs17371643	chr4:154769372	C/T	cg14289246	chr4:154710475	SFRP2	-0.85	-7.05	-0.54	1.07e-10	Electrocardiographic conduction measures;
TGCT	cis	rs2769264	0.505	rs11801791	chr1:151387508	C/T	cg18801370	chr1:151430492	POGZ	0.64	6.17	0.48	8.77e-9	Blood trace element (Cu levels);
TGCT	cis	rs7829975	0.536	rs2980439	chr8:8094870	G/A	cg15462221	chr8:8086144	FLJ10661	-0.53	-4.89	-0.4	3.11e-6	Mood instability;
TGCT	cis	rs612683	0.599	rs2809823	chr1:101003762	C/A	cg10298815	chr1:101004474	GPR88	0.25	4.74	0.39	5.67e-6	Breast cancer;
TGCT	cis	rs6430585	0.527	rs12465544	chr2:136451676	C/T	cg07169764	chr2:136633963	MCM6	1.0	9.14	0.63	1.51e-15	Corneal structure;
TGCT	cis	rs2735413	0.564	rs73580867	chr16:78120953	C/T	cg09132178	chr16:78079569	NA	0.35	4.51	0.38	1.47e-5	Systolic blood pressure (alcohol consumption interaction);
TGCT	cis	rs11264213	0.901	rs682686	chr1:36443778	T/A	cg07093915	chr1:36184400	C1orf216	0.65	4.47	0.37	1.77e-5	Schizophrenia;
TGCT	cis	rs10791097	0.609	rs3751039	chr11:130773076	A/G	cg14779329	chr11:130786720	SNX19	-0.28	-4.8	-0.4	4.55e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9467711	0.790	rs67777156	chr6:26633711	T/A	cg12315302	chr6:26189340	HIST1H4D	0.99	4.44	0.37	1.93e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2455799	0.613	rs11920540	chr3:15854608	G/A	cg16303742	chr3:15540471	COLQ	-0.25	-4.88	-0.4	3.19e-6	Mean platelet volume;
TGCT	cis	rs9916302	0.904	rs801426	chr17:37441109	C/T	cg07936489	chr17:37558343	FBXL20	0.65	5.05	0.41	1.53e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7000551	0.715	rs34649162	chr8:22314730	T/C	cg12081754	chr8:22256438	SLC39A14	0.3	5.04	0.41	1.59e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs13191362	0.935	rs66923841	chr6:163177317	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.94	6.76	0.52	4.71e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs921968	0.607	rs529474	chr2:219463283	C/T	cg02176678	chr2:219576539	TTLL4	0.38	5.48	0.44	2.31e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs826838	1.000	rs11609286	chr12:38875511	A/G	cg26384229	chr12:38710491	ALG10B	-1.06	-10.68	-0.69	2.84e-19	Heart rate;
TGCT	cis	rs2075371	0.501	rs1646653	chr7:134024686	A/G	cg11752832	chr7:134001865	SLC35B4	0.61	5.18	0.42	8.64e-7	Mean platelet volume;
TGCT	cis	rs896854	0.625	rs4735336	chr8:95973410	A/C	cg23172400	chr8:95962367	TP53INP1	0.36	6.04	0.48	1.7e-8	Type 2 diabetes;
TGCT	cis	rs2456568	0.900	rs877340	chr11:93689292	A/T	cg26875233	chr11:93583750	C11orf90	-0.45	-5.65	-0.45	1.03e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs208520	0.779	rs208451	chr6:66906155	G/A	cg07460842	chr6:66804631	NA	-0.9	-9.14	-0.63	1.54e-15	Exhaled nitric oxide output;
TGCT	cis	rs9911578	1.000	rs8076121	chr17:57041699	G/A	cg12560992	chr17:57184187	TRIM37	0.76	9.21	0.64	1.03e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg01802117	chr1:53393560	SCP2	0.43	5.12	0.42	1.14e-6	Monocyte count;
TGCT	cis	rs9527	0.545	rs10883847	chr10:104958284	C/T	cg04362960	chr10:104952993	NT5C2	0.68	5.73	0.46	7.14e-8	Arsenic metabolism;
TGCT	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg11644478	chr21:40555479	PSMG1	-0.86	-8.29	-0.6	1.54e-13	Cognitive function;
TGCT	trans	rs208520	0.690	rs2144081	chr6:66824972	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-10.72	-0.69	2.28e-19	Exhaled nitric oxide output;
TGCT	cis	rs7542091	0.635	rs985431	chr1:210043948	A/T	cg21951975	chr1:209979733	IRF6	0.6	6.1	0.48	1.24e-8	Monobrow;
TGCT	cis	rs2243480	1.000	rs160633	chr7:65528228	T/C	cg18252515	chr7:66147081	NA	-1.13	-7.39	-0.55	1.94e-11	Diabetic kidney disease;
TGCT	trans	rs7618501	1.000	rs6775384	chr3:49853073	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	1.03	13.16	0.76	2.7e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs7119038	0.774	rs10892290	chr11:118653503	G/T	cg19308663	chr11:118741387	NA	0.31	6.13	0.48	1.06e-8	Sjögren's syndrome;
TGCT	cis	rs78487399	0.808	rs7586101	chr2:43669851	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.43	5.45	0.44	2.63e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg21016266	chr12:122356598	WDR66	0.5	7.11	0.54	7.97e-11	Mean corpuscular volume;
TGCT	cis	rs3749237	0.964	rs34522271	chr3:49808517	A/G	cg10152585	chr3:50297680	NA	0.5	4.59	0.38	1.08e-5	Resting heart rate;
TGCT	cis	rs2842992	0.830	rs1998365	chr6:160179535	A/T	cg11366901	chr6:160182831	ACAT2	1.03	6.92	0.53	2.14e-10	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs9993613	0.841	rs6852061	chr4:73436699	G/A	cg15102770	chr4:73434591	ADAMTS3	0.53	4.82	0.4	4.11e-6	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs7666738	0.830	rs7657497	chr4:99044028	A/G	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7666738	0.830	rs10049627	chr4:99025272	A/C	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg19010396	chr19:19431384	KIAA0892;SF4	-0.54	-4.54	-0.38	1.3e-5	Tonsillectomy;
TGCT	cis	rs7752195	0.643	rs76426173	chr6:25317752	T/C	cg16898833	chr6:26189333	HIST1H4D	1.2	5.18	0.42	8.53e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7698623	0.850	rs4693883	chr4:88770174	A/G	cg02735620	chr4:88950514	PKD2	-0.44	-4.81	-0.4	4.22e-6	Cardiovascular disease risk factors;
TGCT	cis	rs2486288	0.656	rs9921025	chr15:45546602	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.46	-5.59	-0.45	1.38e-7	Glomerular filtration rate;
TGCT	cis	rs11031096	0.589	rs935130	chr11:4213530	A/G	cg18678763	chr11:4115507	RRM1	-0.43	-5.54	-0.45	1.77e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs2188554	0.785	rs2518881	chr7:117172731	A/G	cg08576598	chr7:116962626	WNT2	-0.36	-4.71	-0.39	6.55e-6	Esophageal adenocarcinoma;
TGCT	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2549003	1.000	rs10068129	chr5:131821246	A/G	cg21138405	chr5:131827807	IRF1	-0.18	-4.69	-0.39	7.03e-6	Asthma (sex interaction);
TGCT	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg09417038	chr21:47716443	C21orf57	0.33	5.03	0.41	1.67e-6	Testicular germ cell tumor;
TGCT	cis	rs9787249	0.874	rs12094291	chr1:40226046	G/A	cg20968010	chr1:40505947	CAP1	-0.5	-4.68	-0.39	7.29e-6	Blood protein levels;
TGCT	cis	rs7095607	0.606	rs7095492	chr10:69957375	C/T	cg18986048	chr10:69913749	MYPN	0.56	5.87	0.47	3.76e-8	Lung function (FVC);
TGCT	cis	rs3749237	0.557	rs7631908	chr3:49425707	T/G	cg07636037	chr3:49044803	WDR6	0.64	6.04	0.48	1.63e-8	Resting heart rate;
TGCT	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs10751667	0.643	rs10794350	chr11:946070	A/G	cg06064525	chr11:970664	AP2A2	-0.34	-7.95	-0.58	9.9e-13	Alzheimer's disease (late onset);
TGCT	cis	rs6540559	0.673	rs17015183	chr1:209948711	A/C	cg23283495	chr1:209979779	IRF6	0.67	5.23	0.43	6.85e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs617219	0.684	rs2896766	chr5:78586493	A/G	cg05890484	chr5:78407552	BHMT	-0.34	-4.63	-0.38	8.97e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs6426558	0.681	rs10495274	chr1:227175253	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.69	-7.85	-0.58	1.72e-12	Neutrophil percentage of white cells;
TGCT	cis	rs7829975	0.606	rs7819827	chr8:8797055	G/C	cg06636001	chr8:8085503	FLJ10661	-0.7	-6.19	-0.49	8.23e-9	Mood instability;
TGCT	cis	rs12643440	0.530	rs551555	chr4:17231715	C/G	cg23316648	chr4:17096664	NA	-0.24	-4.47	-0.37	1.73e-5	Metabolite levels (Pyroglutamine);
TGCT	cis	rs9303401	0.615	rs35288118	chr17:56600748	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs68092024	0.731	rs793479	chr3:99488232	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.5	5.94	0.47	2.64e-8	Cleft lip with or without cleft palate;
TGCT	cis	rs6429082	0.818	rs210037	chr1:235649501	A/G	cg26050004	chr1:235667680	B3GALNT2	0.59	5.26	0.43	6.02e-7	Adiposity;
TGCT	cis	rs10858047	0.883	rs4543788	chr1:115179501	C/T	cg12756093	chr1:115239321	AMPD1	-0.45	-4.73	-0.39	6.09e-6	Autism;
TGCT	cis	rs854765	0.587	rs4077828	chr17:17833644	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.74	7.73	0.57	3.18e-12	Total body bone mineral density;
TGCT	cis	rs9916302	0.653	rs11657058	chr17:37699378	T/G	cg07936489	chr17:37558343	FBXL20	-0.84	-6.16	-0.48	9.13e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.31	-4.76	-0.39	5.36e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1372520	0.564	rs2737011	chr4:90746219	T/C	cg01966878	chr4:90757139	SNCA	-0.3	-4.64	-0.38	8.54e-6	Neuroticism;
TGCT	cis	rs78487399	0.520	rs7609256	chr2:43672499	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-5.09	-0.42	1.3e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs7267979	0.706	rs6138542	chr20:25207773	C/A	cg16686733	chr20:25566563	NINL	0.59	6.06	0.48	1.54e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs873946	0.689	rs2803993	chr10:134550606	T/C	cg18305652	chr10:134549665	INPP5A	0.31	4.91	0.4	2.83e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs36207871	1	rs36207871	chr12:56684496	TAGGAA/T	cg26714650	chr12:56694279	CS	1.53	8.28	0.6	1.67e-13	Inflammatory skin disease;
TGCT	cis	rs524281	0.861	rs11227411	chr11:65879478	C/T	cg00563793	chr11:65837595	PACS1	0.55	4.62	0.38	9.28e-6	Electroencephalogram traits;
TGCT	cis	rs1891275	0.515	rs1418161	chr10:93484655	C/G	cg07889827	chr10:93443413	NA	-0.32	-6.74	-0.52	5.19e-10	Intelligence (multi-trait analysis);
TGCT	trans	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg23505145	chr19:12996616	KLF1	0.79	8.3	0.6	1.47e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2997447	0.633	rs6665062	chr1:26362001	C/T	cg19633962	chr1:26362018	EXTL1	-0.7	-4.72	-0.39	6.3e-6	QRS complex (12-leadsum);
TGCT	cis	rs13223928	0.541	rs17132968	chr7:3136074	T/G	cg19214707	chr7:3157722	NA	-0.43	-5.77	-0.46	5.93e-8	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
TGCT	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg20203395	chr5:56204925	C5orf35	-0.59	-5.12	-0.42	1.12e-6	Initial pursuit acceleration;
TGCT	cis	rs16854884	0.789	rs34096668	chr3:143794483	C/T	cg06585982	chr3:143692056	C3orf58	0.62	4.82	0.4	4.11e-6	Economic and political preferences (feminism/equality);
TGCT	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs6912958	0.781	rs4464759	chr6:88282621	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-5.06	-0.41	1.45e-6	Monocyte percentage of white cells;
TGCT	cis	rs76878669	0.561	rs56321771	chr11:66161072	C/T	cg18002602	chr11:66138449	SLC29A2	0.53	6.57	0.51	1.22e-9	Educational attainment (years of education);
TGCT	cis	rs3858526	0.959	rs1840179	chr11:5949148	A/G	cg13902645	chr11:5959945	NA	-0.48	-5.0	-0.41	1.95e-6	DNA methylation (variation);
TGCT	cis	rs666930	0.519	rs483180	chr1:120267505	C/G	cg19096424	chr1:120255104	PHGDH	-0.64	-5.66	-0.45	1.01e-7	Breast cancer;
TGCT	cis	rs6089584	0.606	rs7270469	chr20:60577258	G/A	cg06108461	chr20:60628389	TAF4	-0.4	-5.02	-0.41	1.74e-6	Body mass index;
TGCT	cis	rs55962025	0.883	rs362273	chr4:3227419	A/G	cg06533319	chr4:3265114	C4orf44	0.24	4.63	0.38	9.13e-6	Parental longevity (mother's age at death);
TGCT	cis	rs240764	0.853	rs12660725	chr6:100978570	C/T	cg21058520	chr6:100914733	NA	0.35	4.63	0.38	9.07e-6	Neuroticism;
TGCT	cis	rs12776158	0.901	rs12414706	chr10:71214729	G/A	cg12610070	chr10:71211762	TSPAN15	-0.55	-4.83	-0.4	3.87e-6	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs881375	0.900	rs1930786	chr9:123691469	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	4.99	0.41	2.03e-6	Rheumatoid arthritis;
TGCT	cis	rs2032447	0.677	rs199737	chr6:25933538	A/T	cg03264133	chr6:25882463	NA	-0.73	-6.94	-0.53	1.97e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs12188164	0.965	rs72717438	chr5:448663	C/T	cg26850624	chr5:429559	AHRR	-0.2	-4.84	-0.4	3.78e-6	Cystic fibrosis severity;
TGCT	cis	rs72945132	0.660	rs67433166	chr11:70121604	T/A	cg00319359	chr11:70116639	PPFIA1	0.99	7.24	0.55	4.12e-11	Coronary artery disease;
TGCT	trans	rs77457752	0.690	rs12349396	chr9:13912144	T/C	cg12973904	chr7:149457885	NA	0.46	7.07	0.54	9.92e-11	Breast cancer;
TGCT	cis	rs3138083	0.645	rs12376747	chr9:35639629	C/G	cg07116010	chr9:35646325	NA	0.82	10.29	0.68	2.44e-18	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);
TGCT	cis	rs1975974	1.000	rs111981054	chr17:21725592	C/G	cg18423549	chr17:21743878	NA	-0.55	-5.06	-0.41	1.49e-6	Psoriasis;
TGCT	cis	rs2742417	0.935	rs2742442	chr3:45748599	T/A	cg04837898	chr3:45731254	SACM1L	-0.55	-5.68	-0.45	9.22e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	trans	rs3780486	0.957	rs10971434	chr9:33168891	C/A	cg20290983	chr6:43655470	MRPS18A	1.13	10.89	0.7	8.6e-20	IgG glycosylation;
TGCT	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg24531977	chr5:56204891	C5orf35	0.7	7.39	0.55	1.91e-11	Initial pursuit acceleration;
TGCT	cis	rs2346177	1.000	rs2346177	chr2:46642249	A/G	cg26688816	chr2:46740690	ATP6V1E2	0.41	4.5	0.37	1.54e-5	HDL cholesterol;
TGCT	cis	rs1005224	0.895	rs11624114	chr14:76131800	A/G	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.6	-5.67	-0.45	9.59e-8	Large artery stroke;
TGCT	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.51	-4.97	-0.41	2.18e-6	Prudent dietary pattern;
TGCT	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg03732007	chr1:2071316	PRKCZ	0.28	6.63	0.51	9.05e-10	Height;
TGCT	cis	rs79349575	0.715	rs4793997	chr17:47019672	C/A	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.52	-0.38	1.44e-5	Type 2 diabetes;
TGCT	cis	rs739496	0.615	rs4648328	chr12:112222788	C/T	cg10833066	chr12:111807467	FAM109A	0.36	4.67	0.39	7.74e-6	Platelet count;
TGCT	cis	rs3806843	0.741	rs4912597	chr5:140106857	C/G	cg19875535	chr5:140030758	IK	-0.37	-6.19	-0.49	7.89e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9291683	0.609	rs12500810	chr4:10031068	G/A	cg00071950	chr4:10020882	SLC2A9	0.67	8.64	0.61	2.31e-14	Bone mineral density;
TGCT	cis	rs1008375	1.000	rs7671752	chr4:17661398	C/T	cg16339924	chr4:17578868	LAP3	0.58	4.96	0.41	2.29e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2016266	0.855	rs1056692	chr12:53687387	A/G	cg16917193	chr12:54089295	NA	-0.71	-5.18	-0.42	8.57e-7	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg22857025	chr5:266934	NA	-0.34	-6.7	-0.52	6.65e-10	Breast cancer;
TGCT	cis	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg07424592	chr7:64974309	NA	1.4	8.42	0.6	7.87e-14	Diabetic kidney disease;
TGCT	cis	rs10972341	1.000	rs4879869	chr9:35141508	C/T	cg00812861	chr9:35114699	KIAA1539	0.34	5.06	0.41	1.47e-6	Weight;
TGCT	cis	rs28374715	0.532	rs7168431	chr15:41672384	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.93	-16.21	-0.82	2.08e-32	Ulcerative colitis;
TGCT	cis	rs7091068	0.671	rs1096025	chr10:95404701	T/C	cg20715218	chr10:95462985	C10orf4	-0.54	-5.15	-0.42	9.95e-7	Urinary tract infection frequency;
TGCT	cis	rs7267979	1.000	rs2258135	chr20:25272323	C/A	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7216064	0.765	rs6504550	chr17:65894542	A/G	cg12091567	chr17:66097778	LOC651250	-0.76	-5.79	-0.46	5.42e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs4824093	0.610	rs73441745	chr22:50237606	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.45	4.64	0.38	8.83e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-6.74	-0.52	5.26e-10	Alzheimer's disease;
TGCT	cis	rs13191362	1.000	rs67747005	chr6:163150845	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.69	5.81	0.46	4.87e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs651907	0.557	rs17411983	chr3:101399126	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.55	-5.03	-0.41	1.65e-6	Colorectal cancer;
TGCT	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg24060327	chr5:131705240	SLC22A5	-0.66	-6.87	-0.53	2.75e-10	Acylcarnitine levels;
TGCT	cis	rs9814567	0.752	rs4306899	chr3:134334513	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.75	6.75	0.52	4.98e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs9581857	0.547	rs78273785	chr13:28052884	T/C	cg22138327	chr13:27999177	GTF3A	0.74	4.82	0.4	4.15e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs10037670	0.608	rs73285282	chr5:153821966	G/C	cg21964928	chr5:153872958	NA	0.26	4.59	0.38	1.09e-5	Behavioural disinhibition (generation interaction);
TGCT	cis	rs6840360	0.967	rs7667197	chr4:152613952	G/A	cg22705602	chr4:152727874	NA	-0.25	-4.47	-0.37	1.71e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs10779751	0.887	rs6686835	chr1:11305316	G/A	cg08854313	chr1:11322531	MTOR	0.99	10.58	0.69	4.78e-19	Body mass index;
TGCT	cis	rs476633	0.708	rs13329237	chr15:41450808	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.59	-7.88	-0.58	1.42e-12	Glomerular filtration rate (creatinine);
TGCT	cis	rs6987853	0.830	rs2272685	chr8:42354102	C/T	cg20539142	chr8:42623718	CHRNA6	0.19	4.52	0.38	1.44e-5	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs11785400	0.793	rs4430070	chr8:143729184	G/C	cg10596483	chr8:143751796	JRK	0.53	5.21	0.42	7.5e-7	Schizophrenia;
TGCT	cis	rs3091242	1.000	rs646867	chr1:25709258	A/C	cg23205692	chr1:25664452	TMEM50A	0.51	5.23	0.42	7.13e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs6733011	0.578	rs10181972	chr2:99497284	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-4.76	-0.39	5.3e-6	Bipolar disorder;
TGCT	cis	rs12950390	0.853	rs56363619	chr17:45854621	T/C	cg24803719	chr17:45855879	NA	-0.47	-4.76	-0.39	5.24e-6	IgG glycosylation;
TGCT	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg04234412	chr22:24373322	LOC391322	-0.94	-11.83	-0.73	4.5e-22	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2242116	0.796	rs7623898	chr3:46974172	C/T	cg23352942	chr3:46931381	PTH1R	0.31	4.44	0.37	1.94e-5	Birth weight;
TGCT	cis	rs12497850	0.931	rs7616815	chr3:48779715	C/T	cg07636037	chr3:49044803	WDR6	0.95	10.8	0.7	1.46e-19	Parkinson's disease;
TGCT	cis	rs1018836	0.828	rs7006279	chr8:91605364	A/G	cg16814680	chr8:91681699	NA	-0.71	-7.25	-0.55	3.89e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg02953382	chr22:24373134	LOC391322	-0.77	-7.9	-0.58	1.27e-12	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2469997	0.925	rs2447170	chr8:120361421	C/T	cg00681363	chr8:120844660	TAF2	0.69	4.48	0.37	1.64e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg02038168	chr22:39784481	NA	-0.79	-6.79	-0.52	4.07e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs9611565	1.000	rs1109151	chr22:41752944	A/G	cg06481639	chr22:41940642	POLR3H	-0.57	-5.07	-0.41	1.4e-6	Vitiligo;
TGCT	cis	rs727505	0.607	rs10464674	chr7:124791551	A/G	cg23710748	chr7:124431027	NA	-0.26	-4.51	-0.38	1.47e-5	Lewy body disease;
TGCT	cis	rs7086627	0.515	rs12245180	chr10:82211897	C/G	cg00277334	chr10:82204260	NA	-0.54	-8.46	-0.61	6.23e-14	Post bronchodilator FEV1;
TGCT	cis	rs6671200	0.607	rs6671408	chr1:95697091	T/C	cg03123541	chr1:95699097	RWDD3	-0.8	-7.03	-0.53	1.24e-10	Stearic acid (18:0) levels;
TGCT	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg00431813	chr7:1051703	C7orf50	-0.21	-4.47	-0.37	1.76e-5	Longevity;Endometriosis;
TGCT	cis	rs9318086	0.776	rs1326130	chr13:24447664	A/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.62	6.16	0.48	9.35e-9	Myopia (pathological);
TGCT	cis	rs7072216	0.727	rs7913541	chr10:100172479	A/G	cg26618903	chr10:100175079	PYROXD2	-0.4	-4.49	-0.37	1.64e-5	Metabolite levels;
TGCT	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg12311346	chr5:56204834	C5orf35	-0.63	-6.36	-0.5	3.5e-9	Initial pursuit acceleration;
TGCT	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg05896524	chr21:47604654	C21orf56	-0.43	-4.54	-0.38	1.31e-5	Testicular germ cell tumor;
TGCT	cis	rs28595532	0.702	rs72670256	chr4:119391043	G/A	cg11846333	chr4:119757529	SEC24D	0.69	4.51	0.38	1.48e-5	Cannabis dependence symptom count;
TGCT	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg22920501	chr2:26401640	FAM59B	-0.79	-6.31	-0.49	4.6e-9	Gut microbiome composition (summer);
TGCT	cis	rs67072384	1.000	rs5008485	chr11:72455152	C/T	cg03713592	chr11:72463424	ARAP1	-0.93	-4.66	-0.39	7.89e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs4786125	0.665	rs1492371	chr16:6921285	A/C	cg03623568	chr16:6915990	A2BP1	-0.45	-6.77	-0.52	4.65e-10	Heart rate variability traits (SDNN);
TGCT	cis	rs6460942	0.915	rs6966791	chr7:12439714	T/C	cg06484146	chr7:12443880	VWDE	-0.57	-5.52	-0.44	1.92e-7	Coronary artery disease;
TGCT	cis	rs9972944	0.729	rs10512505	chr17:63776696	A/G	cg07283582	chr17:63770753	CCDC46	0.27	5.19	0.42	8.35e-7	Total body bone mineral density;
TGCT	cis	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg25427524	chr10:38739819	LOC399744	-0.39	-8.04	-0.59	5.95e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2797160	0.602	rs4897150	chr6:125985540	C/T	cg05901451	chr6:126070800	HEY2	-0.84	-7.89	-0.58	1.33e-12	Endometrial cancer;
TGCT	cis	rs9381040	0.701	rs722442	chr6:41089681	A/G	cg03526776	chr6:41159608	TREML2	0.24	4.95	0.41	2.33e-6	Alzheimer's disease (late onset);
TGCT	cis	rs4319547	0.656	rs7135419	chr12:122911861	T/A	cg08088222	chr12:122070432	ORAI1	0.26	4.53	0.38	1.34e-5	Body mass index;
TGCT	cis	rs3749237	0.595	rs11720264	chr3:49580347	C/T	cg07636037	chr3:49044803	WDR6	0.63	6.07	0.48	1.47e-8	Resting heart rate;
TGCT	cis	rs2204008	0.774	rs7304438	chr12:38361146	T/G	cg26384229	chr12:38710491	ALG10B	0.83	7.23	0.54	4.44e-11	Bladder cancer;
TGCT	cis	rs11190604	1.000	rs7090431	chr10:102261753	A/G	cg16342193	chr10:102329863	NA	-0.39	-5.01	-0.41	1.83e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg15691649	chr6:25882328	NA	0.5	6.02	0.48	1.84e-8	Blood metabolite levels;
TGCT	cis	rs7226408	0.842	rs56239982	chr18:34331754	T/A	cg06757138	chr18:34340585	FHOD3	0.29	4.95	0.41	2.4e-6	Obesity-related traits;
TGCT	cis	rs735396	0.770	rs1169301	chr12:121431300	C/T	cg02403541	chr12:121454288	C12orf43	0.73	6.51	0.5	1.68e-9	N-glycan levels;
TGCT	cis	rs9902453	1.000	rs7212497	chr17:28335949	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.74	-6.59	-0.51	1.12e-9	Coffee consumption (cups per day);
TGCT	cis	rs2692947	0.832	rs2579550	chr2:96741944	G/A	cg23100626	chr2:96804247	ASTL	0.4	4.75	0.39	5.55e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs12579753	1.000	rs66646148	chr12:82248520	T/G	cg07988820	chr12:82153109	PPFIA2	-0.6	-6.61	-0.51	1.02e-9	Resting heart rate;
TGCT	cis	rs9905704	0.647	rs9901655	chr17:56987142	G/A	cg12560992	chr17:57184187	TRIM37	0.58	4.93	0.4	2.57e-6	Testicular germ cell tumor;
TGCT	cis	rs6882046	0.513	rs185291	chr5:88006764	T/C	cg22951263	chr5:87985283	NA	-0.58	-6.22	-0.49	6.92e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs4268898	0.722	rs4665253	chr2:24382546	G/A	cg02683114	chr2:24398427	C2orf84	0.19	4.57	0.38	1.14e-5	Asthma;
TGCT	cis	rs7017914	0.935	rs7826483	chr8:71702893	T/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.52	-4.8	-0.4	4.53e-6	Bone mineral density;
TGCT	cis	rs704	0.605	rs2227736	chr17:26693231	G/C	cg10342447	chr17:26645325	TMEM97	-0.6	-6.02	-0.48	1.8e-8	Osteoprotegerin levels;
TGCT	cis	rs644799	1.000	rs644799	chr11:95564259	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	9.97	0.67	1.46e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs2243480	1.000	rs709607	chr7:65449541	C/G	cg20637647	chr7:64974828	NA	-1.03	-5.75	-0.46	6.45e-8	Diabetic kidney disease;
TGCT	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.65	-6.51	-0.5	1.68e-9	Prostate cancer;
TGCT	cis	rs7474896	0.609	rs1830612	chr10:37999883	A/G	cg13720705	chr10:37990370	NA	0.33	4.91	0.4	2.86e-6	Obesity (extreme);
TGCT	cis	rs7086627	0.515	rs2125040	chr10:82208422	G/C	cg00277334	chr10:82204260	NA	-0.54	-8.46	-0.61	6.23e-14	Post bronchodilator FEV1;
TGCT	cis	rs1008375	1.000	rs7697889	chr4:17617961	G/T	cg18681998	chr4:17616180	MED28	1.01	11.57	0.72	1.95e-21	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4149178	0.722	rs10948072	chr6:43307861	G/A	cg12269535	chr6:43142014	SRF	0.56	4.7	0.39	6.76e-6	Urate levels;
TGCT	cis	rs1008375	0.898	rs9998130	chr4:17593905	A/G	cg10189774	chr4:17578691	LAP3	0.64	5.41	0.44	3.1e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg06238570	chr21:40685208	BRWD1	0.69	6.41	0.5	2.71e-9	Cognitive function;
TGCT	cis	rs1580019	0.562	rs4720064	chr7:32559638	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.13	14.23	0.79	7.81e-28	Cognitive ability;
TGCT	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg13206674	chr6:150067644	NUP43	0.52	4.51	0.38	1.5e-5	Lung cancer;
TGCT	cis	rs698813	0.604	rs12712917	chr2:44482190	A/G	cg00619915	chr2:44497795	NA	-0.24	-5.68	-0.45	9.26e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
TGCT	cis	rs8051431	0.840	rs8047837	chr16:72010728	G/A	cg06353428	chr16:71660113	MARVELD3	0.59	5.02	0.41	1.73e-6	LDL cholesterol levels;
TGCT	trans	rs7618501	0.521	rs34654589	chr3:49911449	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.82	8.47	0.61	6.11e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg02487422	chr3:49467188	NICN1	0.55	5.32	0.43	4.77e-7	Menarche (age at onset);
TGCT	cis	rs11190604	0.943	rs7085261	chr10:102209811	G/A	cg16342193	chr10:102329863	NA	-0.4	-5.31	-0.43	4.85e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg07424592	chr7:64974309	NA	1.36	8.08	0.59	4.97e-13	Diabetic kidney disease;
TGCT	cis	rs7584330	0.554	rs74001383	chr2:238424418	T/C	cg08992911	chr2:238395768	MLPH	0.73	5.01	0.41	1.85e-6	Prostate cancer;
TGCT	cis	rs6138458	1.000	rs227615	chr20:24908721	T/C	cg26195577	chr20:24973756	C20orf3	1.2	12.04	0.73	1.35e-22	Blood protein levels;
TGCT	cis	rs75059851	0.756	rs11223659	chr11:133844708	G/A	cg14047540	chr11:133829660	NA	-0.58	-5.77	-0.46	6.07e-8	Schizophrenia;
TGCT	cis	rs12200560	0.505	rs984520	chr6:97076454	A/G	cg06623918	chr6:96969491	KIAA0776	-0.61	-5.25	-0.43	6.53e-7	Coronary heart disease;
TGCT	cis	rs4148883	0.675	rs10000357	chr4:100099942	G/C	cg12011299	chr4:100065546	ADH4	0.39	5.85	0.47	4.03e-8	Alcohol dependence;
TGCT	cis	rs7208859	0.623	rs11657990	chr17:29124200	C/T	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs9549367	0.789	rs9549361	chr13:113898329	C/T	cg18105134	chr13:113819100	PROZ	0.34	5.51	0.44	1.96e-7	Platelet distribution width;
TGCT	cis	rs3902035	0.964	rs1891715	chr6:119004731	A/G	cg07617317	chr6:118971624	C6orf204	-0.43	-5.08	-0.41	1.37e-6	QT interval;
TGCT	cis	rs7937682	0.737	rs663763	chr11:111422217	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.8	-8.33	-0.6	1.3e-13	Primary sclerosing cholangitis;
TGCT	cis	rs698833	0.506	rs4952705	chr2:44499867	T/C	cg00619915	chr2:44497795	NA	-0.22	-4.99	-0.41	2.02e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
TGCT	cis	rs9393692	0.875	rs6939589	chr6:26289203	C/T	cg00631329	chr6:26305371	NA	0.44	6.48	0.5	1.95e-9	Educational attainment;
TGCT	cis	rs9611565	0.512	rs715498	chr22:42148467	G/A	cg06634786	chr22:41940651	POLR3H	0.85	8.15	0.59	3.41e-13	Vitiligo;
TGCT	cis	rs9952991	0.941	rs2542150	chr18:12779763	G/C	cg09945482	chr18:12777974	NA	0.51	4.86	0.4	3.47e-6	Inflammatory skin disease;
TGCT	cis	rs651907	0.514	rs10936744	chr3:101433440	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.89	10.45	0.68	1.02e-18	Colorectal cancer;
TGCT	cis	rs3749237	1.000	rs2291542	chr3:49751585	C/T	cg07636037	chr3:49044803	WDR6	0.64	5.55	0.45	1.68e-7	Resting heart rate;
TGCT	cis	rs6840360	0.533	rs13147021	chr4:152722688	A/C	cg22705602	chr4:152727874	NA	0.33	6.0	0.47	2.01e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg22857025	chr5:266934	NA	-0.31	-6.32	-0.49	4.33e-9	Breast cancer;
TGCT	cis	rs13064411	0.627	rs28710051	chr3:113143531	G/A	cg10517650	chr3:113235015	CCDC52	-0.35	-4.63	-0.38	9.06e-6	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs614226	0.935	rs3887875	chr12:120895749	A/G	cg01236616	chr12:121019343	POP5	-1.23	-12.24	-0.74	4.57e-23	Type 1 diabetes nephropathy;
TGCT	cis	rs3806843	0.547	rs246048	chr5:140327900	G/A	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs11031096	0.782	rs10767845	chr11:4156922	C/T	cg18678763	chr11:4115507	RRM1	-0.52	-6.66	-0.51	7.83e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs1552244	0.554	rs13079240	chr3:10047246	C/T	cg00149659	chr3:10157352	C3orf10	0.69	4.99	0.41	2.03e-6	Alzheimer's disease;
TGCT	cis	rs61990749	0.597	rs1477260	chr14:78256818	G/C	cg02301378	chr14:78227641	SNW1;C14orf178	0.6	4.45	0.37	1.88e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg10295955	chr4:187884368	NA	-0.98	-14.77	-0.8	4.24e-29	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs12615966	0.789	rs6758786	chr2:105367587	A/G	cg16465502	chr2:105461796	NA	-0.75	-4.7	-0.39	6.76e-6	Pancreatic cancer;
TGCT	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg22168489	chr12:122356033	WDR66	0.22	4.76	0.39	5.3e-6	Mean corpuscular volume;
TGCT	cis	rs3008870	1.000	rs2815352	chr1:67482104	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.08	11.47	0.72	3.32e-21	Lymphocyte percentage of white cells;
TGCT	cis	rs9916302	0.904	rs8077104	chr17:37530510	A/G	cg07936489	chr17:37558343	FBXL20	0.65	5.08	0.41	1.36e-6	Glomerular filtration rate (creatinine);
TGCT	trans	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg17830980	chr10:43048298	ZNF37B	0.73	8.35	0.6	1.13e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2404602	0.735	rs2454450	chr15:76831236	G/A	cg22467129	chr15:76604101	ETFA	0.44	4.56	0.38	1.22e-5	Blood metabolite levels;
TGCT	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	4.67	0.39	7.7e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7312933	0.558	rs11181502	chr12:42823833	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.54	5.14	0.42	1.06e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs6546537	0.562	rs1985342	chr2:69758927	C/T	cg10773587	chr2:69614142	GFPT1	-0.87	-9.17	-0.64	1.31e-15	Serum thyroid-stimulating hormone levels;
TGCT	cis	rs10193935	0.901	rs6724626	chr2:42689757	C/G	cg27598129	chr2:42591480	NA	0.39	5.39	0.44	3.39e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7584330	0.738	rs4402703	chr2:238374957	T/A	cg14458575	chr2:238380390	NA	0.48	7.62	0.56	5.63e-12	Prostate cancer;
TGCT	cis	rs9818758	0.607	rs3923475	chr3:49055788	G/T	cg00383909	chr3:49044727	WDR6	1.3	6.73	0.52	5.74e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	trans	rs4650994	0.816	rs2811304	chr1:178596794	A/T	cg05059571	chr16:84539110	KIAA1609	0.4	7.53	0.56	8.98e-12	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.56	5.53	0.44	1.83e-7	Menarche (age at onset);
TGCT	cis	rs9549367	0.713	rs56002882	chr13:113830694	T/C	cg00898013	chr13:113819073	PROZ	-0.55	-7.05	-0.53	1.12e-10	Platelet distribution width;
TGCT	cis	rs4555082	0.834	rs11622165	chr14:105759761	C/A	cg01266790	chr14:105781312	PACS2	0.56	4.64	0.38	8.89e-6	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs7617773	0.743	rs71323397	chr3:48374874	A/G	cg11946769	chr3:48343235	NME6	0.81	6.96	0.53	1.71e-10	Coronary artery disease;
TGCT	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg13695892	chr22:41940480	POLR3H	-0.91	-9.11	-0.63	1.82e-15	Vitiligo;
TGCT	cis	rs4455778	0.538	rs4326333	chr7:49125565	A/T	cg26309511	chr7:48887640	NA	0.5	6.51	0.5	1.66e-9	Lung cancer in never smokers;
TGCT	cis	rs7959452	0.503	rs7300266	chr12:69654187	A/G	cg14784868	chr12:69753453	YEATS4	0.69	7.13	0.54	7.26e-11	Blood protein levels;
TGCT	cis	rs10791097	0.568	rs4411284	chr11:130738568	A/C	cg05962950	chr11:130786565	SNX19	0.91	11.51	0.72	2.63e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs7246657	0.722	rs2972447	chr19:38129736	C/T	cg03611452	chr19:38183253	ZNF781	-0.59	-4.76	-0.39	5.34e-6	Coronary artery calcification;
TGCT	cis	rs7845219	0.544	rs2945554	chr8:95939594	C/A	cg16049864	chr8:95962084	TP53INP1	-0.49	-5.42	-0.44	2.98e-7	Type 2 diabetes;
TGCT	cis	rs74233809	1.000	rs943037	chr10:104835919	C/T	cg05855489	chr10:104503620	C10orf26	0.82	4.58	0.38	1.12e-5	Birth weight;
TGCT	cis	rs9913156	0.793	rs55974786	chr17:4567564	T/C	cg23387401	chr17:4582204	PELP1	0.31	4.59	0.38	1.09e-5	Lymphocyte counts;
TGCT	cis	rs9534288	0.762	rs9534285	chr13:46601902	T/C	cg15192986	chr13:46630673	CPB2	-0.52	-7.53	-0.56	9.22e-12	Blood protein levels;
TGCT	cis	rs7647973	0.626	rs9835157	chr3:49797769	G/A	cg03060546	chr3:49711283	APEH	-0.63	-5.63	-0.45	1.12e-7	Menarche (age at onset);
TGCT	cis	rs10751667	0.643	rs10902245	chr11:953014	C/T	cg06064525	chr11:970664	AP2A2	0.35	8.01	0.58	7.17e-13	Alzheimer's disease (late onset);
TGCT	cis	rs13067306	1.000	rs13067306	chr3:94243713	C/T	cg16274205	chr3:94243571	NA	0.42	4.86	0.4	3.48e-6	Blood pressure measurement (high sodium intervention);
TGCT	cis	rs1018836	0.923	rs2105965	chr8:91537690	T/C	cg16814680	chr8:91681699	NA	-0.88	-9.89	-0.66	2.34e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9916302	0.851	rs7220650	chr17:37487168	A/G	cg07936489	chr17:37558343	FBXL20	0.65	5.05	0.41	1.53e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg08280861	chr8:58055591	NA	0.4	4.73	0.39	5.97e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs3096299	0.658	rs34590044	chr16:89543157	A/C	cg02187348	chr16:89574699	SPG7	0.62	6.86	0.52	2.85e-10	Multiple myeloma (IgH translocation);
TGCT	cis	rs151997	0.962	rs27272	chr5:50181865	A/G	cg06027927	chr5:50259733	NA	0.46	4.61	0.38	9.69e-6	Callous-unemotional behaviour;
TGCT	cis	rs10791097	0.967	rs10791099	chr11:130718813	G/C	cg12179176	chr11:130786555	SNX19	0.65	6.88	0.53	2.63e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg13732083	chr21:47605072	C21orf56	0.34	4.52	0.38	1.44e-5	Testicular germ cell tumor;
TGCT	cis	rs6088590	0.561	rs11167239	chr20:33140472	G/A	cg06115741	chr20:33292138	TP53INP2	0.54	4.72	0.39	6.29e-6	Coronary artery disease;
TGCT	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg04414720	chr1:150670196	GOLPH3L	0.37	4.91	0.4	2.76e-6	Melanoma;
TGCT	cis	rs6076065	0.722	rs6048760	chr20:23345844	G/T	cg11657817	chr20:23433608	CST11	-0.32	-5.39	-0.44	3.49e-7	Facial morphology (factor 15, philtrum width);
TGCT	cis	rs7208859	0.673	rs9891179	chr17:29208160	G/T	cg18442181	chr17:29233375	C17orf42	-0.78	-4.61	-0.38	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg09222892	chr1:25734099	RHCE	0.42	6.88	0.53	2.61e-10	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs7568458	0.663	rs699664	chr2:85780536	A/G	cg17127132	chr2:85788382	GGCX	-0.5	-4.83	-0.4	3.89e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs4242434	0.689	rs4872006	chr8:22536502	T/C	cg03733263	chr8:22462867	KIAA1967	-1.08	-15.57	-0.81	5.71e-31	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs7666738	0.791	rs2903151	chr4:99027218	T/C	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11098499	0.738	rs72918577	chr4:120326701	G/A	cg09307838	chr4:120376055	NA	0.7	6.7	0.52	6.57e-10	Corneal astigmatism;
TGCT	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg06481639	chr22:41940642	POLR3H	-0.69	-6.15	-0.48	9.84e-9	Vitiligo;
TGCT	cis	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg18252515	chr7:66147081	NA	1.25	7.75	0.57	2.92e-12	Diabetic kidney disease;
TGCT	cis	rs3091242	0.967	rs3091240	chr1:25676935	G/T	cg23205692	chr1:25664452	TMEM50A	0.53	5.46	0.44	2.5e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs6740322	0.696	rs11685054	chr2:43474295	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.39	-6.15	-0.48	9.74e-9	Coronary artery disease;
TGCT	cis	rs17152411	0.895	rs61872119	chr10:126583534	A/G	cg07906193	chr10:126599966	NA	0.41	5.05	0.41	1.52e-6	Height;
TGCT	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg18876405	chr7:65276391	NA	0.36	5.69	0.46	8.66e-8	Aortic root size;
TGCT	cis	rs7945705	0.967	rs7123861	chr11:8892323	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.43	4.86	0.4	3.42e-6	Hemoglobin concentration;
TGCT	cis	rs4563143	0.514	rs73029081	chr19:29295583	C/G	cg14983838	chr19:29218262	NA	0.71	5.19	0.42	8.21e-7	Methadone dose in opioid dependence;
TGCT	cis	rs7528419	1.000	rs7528419	chr1:109817192	A/G	cg00908766	chr1:109817496	CELSR2	-0.53	-5.43	-0.44	2.86e-7	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
TGCT	cis	rs7402982	0.625	rs4966009	chr15:99203496	C/T	cg03437748	chr15:99193247	IGF1R	0.45	4.45	0.37	1.86e-5	Birth weight;
TGCT	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.36	-4.58	-0.38	1.11e-5	Autism spectrum disorder or schizophrenia;
TGCT	trans	rs57221529	0.766	rs72703065	chr5:588123	C/A	cg11887960	chr12:57824829	NA	1.14	9.3	0.64	6.29e-16	Lung disease severity in cystic fibrosis;
TGCT	cis	rs12478296	0.901	rs73007142	chr2:243010852	T/C	cg06360820	chr2:242988706	NA	-0.86	-5.89	-0.47	3.44e-8	Obesity-related traits;
TGCT	cis	rs12549902	0.800	rs7825494	chr8:41507350	C/T	cg21772509	chr8:41503840	NKX6-3	0.82	9.16	0.64	1.34e-15	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
TGCT	cis	rs62103177	0.810	rs62103192	chr18:77629050	A/T	cg12964065	chr18:77638022	KCNG2	0.37	4.76	0.39	5.4e-6	Opioid sensitivity;
TGCT	trans	rs2727020	0.521	rs1909220	chr11:49572109	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.4	-7.59	-0.56	6.71e-12	Coronary artery disease;
TGCT	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg13699009	chr12:122356056	WDR66	0.29	6.56	0.51	1.32e-9	Mean corpuscular volume;
TGCT	cis	rs704	0.628	rs241775	chr17:26644668	C/T	cg10494684	chr17:26645200	TMEM97	0.44	4.51	0.38	1.5e-5	Osteoprotegerin levels;
TGCT	cis	rs7226408	0.842	rs62083201	chr18:34347836	A/G	cg06757138	chr18:34340585	FHOD3	0.29	5.15	0.42	1.01e-6	Obesity-related traits;
TGCT	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	trans	rs28595532	0.748	rs72670258	chr4:119391660	A/T	cg26518628	chr1:97050305	NA	-0.54	-6.79	-0.52	4.14e-10	Cannabis dependence symptom count;
TGCT	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg07870213	chr5:140052090	DND1	0.67	7.94	0.58	1.03e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	trans	rs208520	0.690	rs4710311	chr6:66823223	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.89	-8.9	-0.62	5.76e-15	Exhaled nitric oxide output;
TGCT	cis	rs80282103	0.867	rs74117668	chr10:1076620	C/T	cg18964960	chr10:1102726	WDR37	1.09	4.69	0.39	7.15e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs2070488	0.804	rs1870914	chr3:38494220	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.77	7.45	0.56	1.37e-11	Electrocardiographic conduction measures;
TGCT	cis	rs9486719	1.000	rs10872018	chr6:97026429	G/A	cg06623918	chr6:96969491	KIAA0776	-0.99	-8.05	-0.59	5.65e-13	Migraine;Coronary artery disease;
TGCT	cis	rs523522	0.962	rs3893104	chr12:120903936	G/A	cg27279351	chr12:120934652	DYNLL1	0.76	6.54	0.51	1.46e-9	High light scatter reticulocyte count;
TGCT	cis	rs4891159	0.790	rs72975925	chr18:74143902	G/A	cg24786174	chr18:74118243	ZNF516	-0.53	-7.05	-0.53	1.12e-10	Longevity;
TGCT	cis	rs6121246	0.909	rs2376992	chr20:30263418	T/C	cg13852791	chr20:30311386	BCL2L1	0.78	5.8	0.46	5.15e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs3540	0.618	rs11609	chr15:91043765	C/G	cg22089800	chr15:90895588	ZNF774	-0.75	-7.58	-0.56	6.9e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg22166914	chr1:53195759	ZYG11B	-0.46	-8.42	-0.6	7.72e-14	Monocyte count;
TGCT	cis	rs208520	0.690	rs12201156	chr6:66720874	G/T	cg07460842	chr6:66804631	NA	0.95	10.11	0.67	6.77e-18	Exhaled nitric oxide output;
TGCT	cis	rs16957091	0.647	rs28796057	chr15:43188764	C/T	cg17935677	chr15:44119062	WDR76	0.52	4.71	0.39	6.44e-6	MGMT methylation in smokers;
TGCT	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg04154034	chr17:28927549	LRRC37B2	0.78	4.98	0.41	2.07e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7666738	0.830	rs4292342	chr4:98959870	A/T	cg17366294	chr4:99064904	C4orf37	0.71	7.35	0.55	2.35e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12681287	0.547	rs7837569	chr8:87507366	C/T	cg27223183	chr8:87520930	FAM82B	-0.95	-6.95	-0.53	1.81e-10	Caudate activity during reward;
TGCT	cis	rs7236492	0.515	rs76804350	chr18:77180607	C/T	cg15644404	chr18:77186268	NFATC1	-0.43	-4.5	-0.37	1.57e-5	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs1975974	0.935	rs11870387	chr17:21730236	G/C	cg18423549	chr17:21743878	NA	-0.58	-5.39	-0.44	3.34e-7	Psoriasis;
TGCT	cis	rs7914558	0.966	rs2065977	chr10:104729415	C/T	cg04362960	chr10:104952993	NT5C2	0.6	5.34	0.43	4.34e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg09021430	chr5:549028	NA	-0.37	-5.16	-0.42	9.7e-7	Lung disease severity in cystic fibrosis;
TGCT	cis	rs231513	0.911	rs124722	chr17:41956002	T/G	cg26893861	chr17:41843967	DUSP3	-0.71	-5.33	-0.43	4.45e-7	Cognitive function;
TGCT	cis	rs7260538	0.773	rs1552223	chr19:41525952	A/G	cg27089200	chr19:41531976	NA	-0.41	-5.5	-0.44	2.06e-7	DDT metabolite (p,p'-DDE levels);
TGCT	cis	rs6554196	0.743	rs6831020	chr4:55500226	C/A	cg02821500	chr4:54931072	CHIC2	0.49	4.45	0.37	1.89e-5	Monocyte count;
TGCT	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg20203395	chr5:56204925	C5orf35	-0.56	-4.8	-0.4	4.39e-6	Initial pursuit acceleration;
TGCT	cis	rs4654899	0.897	rs3736880	chr1:21097727	G/A	cg01072550	chr1:21505969	NA	-0.49	-7.89	-0.58	1.37e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs12908161	0.853	rs11633788	chr15:85305142	T/A	cg17173187	chr15:85201210	NMB	0.41	4.82	0.4	4.2e-6	Schizophrenia;
TGCT	cis	rs733175	0.855	rs10022499	chr4:10006537	C/A	cg11266682	chr4:10021025	SLC2A9	0.47	4.63	0.38	9.05e-6	Psychosis and Alzheimer's disease;
TGCT	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg03404566	chr17:6899310	ALOX12	0.44	5.15	0.42	9.77e-7	Tonsillectomy;
TGCT	cis	rs9467711	0.659	rs36033628	chr6:26456074	T/G	cg16898833	chr6:26189333	HIST1H4D	1.26	5.95	0.47	2.59e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12477438	0.798	rs6732579	chr2:99560239	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.67	-5.79	-0.46	5.36e-8	Chronic sinus infection;
TGCT	cis	rs7582180	0.625	rs11892034	chr2:100938952	T/C	cg14675211	chr2:100938903	LONRF2	0.51	4.95	0.41	2.32e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2153535	0.580	rs965706	chr6:8464708	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs4372836	0.729	rs6547874	chr2:28982030	A/G	cg09522027	chr2:28974177	PPP1CB	-0.68	-6.93	-0.53	2e-10	Body mass index;
TGCT	cis	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg18252515	chr7:66147081	NA	-1.14	-6.81	-0.52	3.76e-10	Diabetic kidney disease;
TGCT	cis	rs7119038	0.779	rs73005502	chr11:118697906	A/G	cg19308663	chr11:118741387	NA	0.3	5.88	0.47	3.49e-8	Sjögren's syndrome;
TGCT	cis	rs7772486	0.534	rs34541797	chr6:146205304	A/G	cg13319975	chr6:146136371	FBXO30	-0.63	-5.67	-0.45	9.51e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs5769765	0.542	rs5770725	chr22:50256309	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	1.02	6.31	0.49	4.46e-9	Schizophrenia;
TGCT	cis	rs854765	0.583	rs8078105	chr17:17853782	T/C	cg09796270	chr17:17721594	SREBF1	0.23	4.55	0.38	1.27e-5	Total body bone mineral density;
TGCT	cis	rs10510102	0.872	rs7077035	chr10:123706645	A/G	cg23691251	chr10:123688108	ATE1	-0.59	-4.7	-0.39	6.75e-6	Breast cancer;
TGCT	trans	rs2727020	0.658	rs7111215	chr11:49430552	T/C	cg15704280	chr7:45808275	SEPT13	-0.73	-8.26	-0.6	1.91e-13	Coronary artery disease;
TGCT	cis	rs1153858	1.000	rs12909158	chr15:45621174	A/G	cg14582100	chr15:45693742	SPATA5L1	0.48	5.65	0.45	1.05e-7	Homoarginine levels;
TGCT	cis	rs36051895	0.623	rs76960049	chr9:5064548	G/A	cg02405213	chr9:5042618	JAK2	-0.83	-12.29	-0.74	3.38e-23	Pediatric autoimmune diseases;
TGCT	cis	rs2594989	0.831	rs7651886	chr3:11572728	A/G	cg26283222	chr3:11613257	VGLL4	-0.2	-4.45	-0.37	1.89e-5	Circulating chemerin levels;
TGCT	cis	rs9905704	0.624	rs34718875	chr17:57072461	G/A	cg05425664	chr17:57184151	TRIM37	-0.61	-5.09	-0.42	1.3e-6	Testicular germ cell tumor;
TGCT	cis	rs548987	0.529	rs6456703	chr6:25826119	C/T	cg03264133	chr6:25882463	NA	-0.54	-4.44	-0.37	1.99e-5	Homocysteine levels;
TGCT	cis	rs11018874	0.735	rs4307680	chr11:89900630	A/C	cg05041596	chr11:89867385	NAALAD2	0.55	5.07	0.41	1.4e-6	White blood cell types;
TGCT	trans	rs114540395	0.858	rs76807333	chr10:103234534	C/T	cg10198749	chr1:39920707	MACF1	0.55	7.12	0.54	7.73e-11	Schizophrenia;
TGCT	cis	rs6840360	0.555	rs4554052	chr4:152726610	T/C	cg22705602	chr4:152727874	NA	0.33	6.0	0.47	2.01e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs6460942	0.915	rs62447638	chr7:12484667	G/A	cg06484146	chr7:12443880	VWDE	-0.61	-5.43	-0.44	2.87e-7	Coronary artery disease;
TGCT	cis	rs3792900	0.509	rs6596299	chr5:135570567	A/C	cg16684184	chr5:135415129	NA	0.26	4.83	0.4	3.96e-6	Insomnia;Blood protein levels;
TGCT	cis	rs4953076	0.574	rs4953074	chr2:44464629	C/T	cg04920474	chr2:44395004	PPM1B	0.59	5.91	0.47	3.04e-8	Height;
TGCT	cis	rs74054849	0.717	rs3856275	chr1:15918676	C/T	cg05660106	chr1:15850417	CASP9	-0.81	-4.5	-0.37	1.54e-5	Alcoholic chronic pancreatitis;
TGCT	cis	rs3617	0.539	rs11130331	chr3:52956918	G/A	cg11645453	chr3:52864694	ITIH4	-0.28	-5.39	-0.44	3.41e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9926296	1.000	rs9926296	chr16:89818089	A/G	cg04287289	chr16:89883240	FANCA	0.78	8.6	0.61	2.98e-14	Vitiligo;
TGCT	cis	rs72945132	0.882	rs7128969	chr11:70205017	C/A	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs2710642	0.962	rs7567923	chr2:63085848	C/T	cg17519650	chr2:63277830	OTX1	-0.59	-5.34	-0.43	4.28e-7	LDL cholesterol levels;LDL cholesterol;
TGCT	cis	rs494003	1.000	rs72922733	chr11:65520746	A/G	cg04293602	chr11:65553660	OVOL1	0.37	4.77	0.39	5.13e-6	Systemic lupus erythematosus;
TGCT	cis	rs35883536	0.565	rs2647322	chr1:101031962	G/T	cg06223162	chr1:101003688	GPR88	0.42	8.14	0.59	3.53e-13	Monocyte count;
TGCT	cis	rs2243480	1.000	rs709607	chr7:65449541	C/G	cg18252515	chr7:66147081	NA	1.27	7.7	0.57	3.73e-12	Diabetic kidney disease;
TGCT	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.84	7.5	0.56	1.08e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9640161	0.789	rs34311995	chr7:150059255	T/C	cg10018233	chr7:150070692	REPIN1	0.31	4.62	0.38	9.57e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.69	-7.06	-0.54	1.07e-10	Prostate cancer;
TGCT	cis	rs6815814	0.808	rs7673348	chr4:38845198	G/A	cg02016764	chr4:38805732	TLR1	-0.29	-4.68	-0.39	7.51e-6	Breast cancer;
TGCT	cis	rs35160687	0.901	rs11127026	chr2:86531748	C/T	cg04877910	chr2:85804641	VAMP8	0.34	4.51	0.38	1.49e-5	Night sleep phenotypes;
TGCT	cis	rs4294134	0.608	rs35229763	chr7:135246305	A/G	cg08396481	chr7:135194601	CNOT4	-0.62	-4.81	-0.4	4.25e-6	Paget's disease;
TGCT	cis	rs7267979	1.000	rs11100	chr20:25281184	G/C	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2463822	0.583	rs11600383	chr11:62060451	A/G	cg23876832	chr11:62092739	NA	0.6	4.69	0.39	7.17e-6	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs35146811	0.695	rs858508	chr7:99821381	C/G	cg22906224	chr7:99728672	NA	-0.5	-4.51	-0.38	1.48e-5	Coronary artery disease;
TGCT	cis	rs1577917	0.798	rs7772384	chr6:86639680	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.54	-0.45	1.73e-7	Response to antipsychotic treatment;
TGCT	cis	rs933688	1.000	rs6862125	chr5:90724598	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.97	8.45	0.6	6.56e-14	Smoking behavior;
TGCT	cis	rs2075371	0.966	rs2244690	chr7:133987039	A/G	cg11752832	chr7:134001865	SLC35B4	0.69	6.32	0.49	4.19e-9	Mean platelet volume;
TGCT	cis	rs1878931	0.501	rs28735976	chr16:3418419	G/A	cg22508957	chr16:3507546	NAT15	-0.38	-4.98	-0.41	2.1e-6	Body mass index (adult);
TGCT	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg17178900	chr1:205818956	PM20D1	0.58	7.02	0.53	1.27e-10	Menarche (age at onset);
TGCT	cis	rs4889855	0.578	rs7216808	chr17:78484187	A/G	cg16591659	chr17:78472290	NA	-0.35	-5.57	-0.45	1.48e-7	Fractional excretion of uric acid;
TGCT	cis	rs9443645	0.901	rs9443622	chr6:79582790	C/T	cg05283184	chr6:79620031	NA	-0.22	-4.98	-0.41	2.11e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6912958	0.754	rs1051131	chr6:88221546	A/G	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.91	-0.4	2.78e-6	Monocyte percentage of white cells;
TGCT	cis	rs5769765	0.773	rs4075331	chr22:50302850	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.11	-10.96	-0.7	5.67e-20	Schizophrenia;
TGCT	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg23758822	chr17:41437982	NA	0.72	6.81	0.52	3.83e-10	Menopause (age at onset);
TGCT	cis	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg02380750	chr20:61661411	NA	0.34	6.02	0.48	1.86e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1475911	1.000	rs55645900	chr21:43515728	G/T	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.27	-4.85	-0.4	3.56e-6	IgG glycosylation;
TGCT	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg01577475	chr2:114033581	PAX8;LOC440839	-0.44	-4.75	-0.39	5.42e-6	Lymphocyte counts;
TGCT	trans	rs7824557	0.564	rs2572399	chr8:11234520	A/G	cg15556689	chr8:8085844	FLJ10661	-0.74	-6.7	-0.52	6.42e-10	Retinal vascular caliber;
TGCT	cis	rs909674	0.775	rs8138462	chr22:39839670	G/C	cg11247378	chr22:39784982	NA	-0.73	-8.98	-0.63	3.69e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs3733585	0.638	rs6449155	chr4:9956547	T/G	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.73	-0.57	3.25e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs2243480	1.000	rs1404147	chr7:65264524	C/T	cg07424592	chr7:64974309	NA	1.11	8.02	0.58	6.87e-13	Diabetic kidney disease;
TGCT	cis	rs7820838	0.548	rs6468119	chr8:32401561	A/G	cg22651812	chr8:32095135	NRG1	-0.22	-4.79	-0.4	4.65e-6	Post bronchodilator FEV1/FVC ratio in COPD;Lung cancer;
TGCT	cis	rs751728	0.664	rs2296744	chr6:33740382	G/A	cg13859433	chr6:33739653	LEMD2	-0.32	-5.72	-0.46	7.4e-8	Crohn's disease;
TGCT	cis	rs7666738	0.830	rs10012271	chr4:99065154	A/C	cg17366294	chr4:99064904	C4orf37	0.73	7.45	0.56	1.4e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10883723	0.810	rs7094366	chr10:104274730	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs858239	0.600	rs6960001	chr7:23130876	T/C	cg05602783	chr7:23145260	KLHL7	-0.64	-5.37	-0.43	3.69e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs6138458	1.000	rs227621	chr20:24910528	A/C	cg26195577	chr20:24973756	C20orf3	1.2	12.04	0.73	1.35e-22	Blood protein levels;
TGCT	cis	rs362296	0.698	rs362283	chr4:3259558	T/C	cg06533319	chr4:3265114	C4orf44	0.24	4.45	0.37	1.86e-5	Parental longevity (mother's age at death);
TGCT	cis	rs6570726	0.846	rs397311	chr6:145806701	C/T	cg23711669	chr6:146136114	FBXO30	-0.7	-6.86	-0.52	2.9e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10509586	1.000	rs17503635	chr10:91734598	C/T	cg25278353	chr10:91717815	NA	0.49	4.72	0.39	6.32e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
TGCT	cis	rs9942416	0.660	rs60423072	chr5:75006113	T/A	cg19683494	chr5:74908142	NA	0.57	5.95	0.47	2.5e-8	Age-related disease endophenotypes;
TGCT	cis	rs6543140	0.964	rs6734203	chr2:103080066	G/C	cg09003973	chr2:102972529	NA	0.55	4.56	0.38	1.2e-5	Blood protein levels;
TGCT	cis	rs6570726	0.738	rs7746330	chr6:145899257	A/C	cg05347473	chr6:146136440	FBXO30	0.54	5.12	0.42	1.14e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg02380750	chr20:61661411	NA	0.34	6.02	0.48	1.86e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs6918586	0.658	rs198830	chr6:26118246	T/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.68	-6.46	-0.5	2.15e-9	Schizophrenia;
TGCT	cis	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg18188782	chr20:61659543	NA	0.44	5.38	0.43	3.6e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9467711	0.790	rs13204572	chr6:26189356	G/C	cg16898833	chr6:26189333	HIST1H4D	1.44	6.24	0.49	6.22e-9	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7098414	0.511	rs7898787	chr10:82156042	G/A	cg01528321	chr10:82214614	TSPAN14	0.56	4.98	0.41	2.07e-6	Post bronchodilator FEV1;
TGCT	cis	rs12902680	0.739	rs1578910	chr15:46391797	G/A	cg13605988	chr15:45421612	DUOX1;DUOXA1	0.32	4.5	0.37	1.56e-5	Neuroticism;
TGCT	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg08280861	chr8:58055591	NA	0.41	4.66	0.39	8.1e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs11731606	0.508	rs10000820	chr4:95313493	G/A	cg00507259	chr4:95128692	SMARCAD1	0.65	4.8	0.4	4.43e-6	Mean platelet volume;
TGCT	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg23758822	chr17:41437982	NA	0.7	6.6	0.51	1.1e-9	Menopause (age at onset);
TGCT	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg03303774	chr4:1407052	NA	0.38	5.88	0.47	3.49e-8	Obesity-related traits;
TGCT	cis	rs7666738	0.791	rs13149968	chr4:99070262	G/T	cg05340658	chr4:99064831	C4orf37	0.52	5.79	0.46	5.32e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12530845	1.000	rs6975251	chr7:135328689	C/G	cg23117316	chr7:135346802	PL-5283	-0.51	-4.83	-0.4	3.98e-6	Red blood cell traits;
TGCT	cis	rs17221829	0.710	rs12421890	chr11:89391799	C/T	cg02982614	chr11:89391479	FOLH1B	-0.25	-4.46	-0.37	1.8e-5	Anxiety in major depressive disorder;
TGCT	cis	rs7542091	0.579	rs34638782	chr1:210032055	C/G	cg21951975	chr1:209979733	IRF6	0.48	4.89	0.4	3.01e-6	Monobrow;
TGCT	cis	rs11250098	0.583	rs73196860	chr8:10814133	A/G	cg16664915	chr8:10907788	XKR6	-0.31	-4.95	-0.41	2.35e-6	Morning vs. evening chronotype;
TGCT	cis	rs7617773	0.780	rs13066758	chr3:48343877	G/A	cg11946769	chr3:48343235	NME6	0.82	7.09	0.54	9.1e-11	Coronary artery disease;
TGCT	cis	rs7617773	0.817	rs35414021	chr3:48293524	G/C	cg11946769	chr3:48343235	NME6	0.76	6.67	0.51	7.64e-10	Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs28497822	chr4:98906873	C/T	cg17366294	chr4:99064904	C4orf37	0.67	6.94	0.53	1.91e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2469997	1.000	rs2470008	chr8:120359366	C/T	cg00681363	chr8:120844660	TAF2	0.69	4.48	0.37	1.64e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs732765	0.734	rs12323361	chr14:75171706	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.57	-4.97	-0.41	2.2e-6	Non-small cell lung cancer;
TGCT	cis	rs1614887	1	rs1614887	chr6:26393021	A/G	cg05738196	chr6:26577821	NA	0.5	5.21	0.42	7.66e-7	Intelligence (multi-trait analysis);Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11578119	0.933	rs10919418	chr1:170443986	A/G	cg09767346	chr1:170501363	GORAB	-0.7	-5.48	-0.44	2.32e-7	Male-pattern baldness;
TGCT	cis	rs422249	0.512	rs99780	chr11:61596633	C/T	cg19610905	chr11:61596333	FADS2	-0.97	-9.93	-0.67	1.9e-17	Trans fatty acid levels;
TGCT	cis	rs9341808	0.650	rs6909546	chr6:80869923	C/G	cg08355045	chr6:80787529	NA	0.32	5.64	0.45	1.11e-7	Sitting height ratio;
TGCT	cis	rs3749237	0.595	rs3924462	chr3:49524236	T/G	cg02487422	chr3:49467188	NICN1	0.61	6.29	0.49	5.08e-9	Resting heart rate;
TGCT	cis	rs28595532	0.841	rs114107504	chr4:119771080	T/C	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs4788570	0.655	rs1392484	chr16:71822101	T/A	cg06353428	chr16:71660113	MARVELD3	1.53	12.59	0.75	6.48e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs9611565	0.512	rs2899349	chr22:42164660	T/C	cg03806693	chr22:41940476	POLR3H	1.02	10.49	0.69	7.92e-19	Vitiligo;
TGCT	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg23574427	chr4:122746245	BBS7;CCNA2	-0.34	-5.31	-0.43	4.82e-7	Type 2 diabetes;
TGCT	cis	rs7180079	0.620	rs2733382	chr15:64856394	A/G	cg03791955	chr15:65024147	NA	-0.28	-4.46	-0.37	1.81e-5	Monocyte count;
TGCT	cis	rs736408	0.608	rs35004449	chr3:52852897	G/T	cg10802521	chr3:52805072	NEK4	-0.64	-6.51	-0.5	1.69e-9	Bipolar disorder;
TGCT	cis	rs11190604	0.767	rs7078070	chr10:102166415	A/C	cg23241863	chr10:102295624	HIF1AN	0.6	4.57	0.38	1.17e-5	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9389248	0.690	rs2072826	chr6:135253558	G/C	cg24558204	chr6:135376177	HBS1L	-0.47	-4.81	-0.4	4.35e-6	High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs12643440	0.502	rs56163730	chr4:17143120	A/G	cg22650099	chr4:17144496	NA	-0.46	-4.7	-0.39	6.79e-6	Metabolite levels (Pyroglutamine);
TGCT	cis	rs6430585	0.583	rs59213715	chr2:136646582	A/C	cg07169764	chr2:136633963	MCM6	1.21	11.72	0.72	8.21e-22	Corneal structure;
TGCT	cis	rs7937682	0.883	rs1784776	chr11:111472392	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.07	-11.27	-0.71	1.04e-20	Primary sclerosing cholangitis;
TGCT	cis	rs797680	0.789	rs7539307	chr1:93652703	G/A	cg17826107	chr1:92977322	EVI5	-0.23	-5.03	-0.41	1.67e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs6558530	0.730	rs10097891	chr8:1726809	C/A	cg09410841	chr8:1729607	CLN8	0.85	9.98	0.67	1.44e-17	Systolic blood pressure;
TGCT	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg03395511	chr6:291903	DUSP22	-0.64	-6.62	-0.51	9.7e-10	Menopause (age at onset);
TGCT	cis	rs7267979	1.000	rs2424710	chr20:25283886	C/G	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7020830	0.898	rs13289199	chr9:37278064	A/T	cg14294708	chr9:37120828	ZCCHC7	1.12	13.76	0.78	9.91e-27	Schizophrenia;
TGCT	cis	rs1005224	1.000	rs1005224	chr14:76173860	A/T	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.55	-4.66	-0.39	8.03e-6	Large artery stroke;
TGCT	cis	rs9660992	0.590	rs1779411	chr1:205238530	C/T	cg00857998	chr1:205179979	DSTYK	0.52	4.54	0.38	1.29e-5	Mean corpuscular volume;Mean platelet volume;
TGCT	cis	rs11785400	0.731	rs4644221	chr8:143736984	C/T	cg10596483	chr8:143751796	JRK	-0.54	-5.49	-0.44	2.19e-7	Schizophrenia;
TGCT	cis	rs796364	1.000	rs11694369	chr2:200741720	G/A	cg17644776	chr2:200775616	C2orf69	-0.31	-4.69	-0.39	7.18e-6	Schizophrenia;
TGCT	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg22168489	chr12:122356033	WDR66	0.22	4.78	0.39	4.96e-6	Mean corpuscular volume;
TGCT	cis	rs938554	0.744	rs13129697	chr4:9926967	T/G	cg00071950	chr4:10020882	SLC2A9	-0.5	-4.78	-0.39	4.93e-6	Blood metabolite levels;
TGCT	cis	rs6459788	0.527	rs6980250	chr7:157228710	C/T	cg03453431	chr7:157225567	NA	-0.56	-9.25	-0.64	8.11e-16	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs910316	1.000	rs175436	chr14:75608683	C/G	cg11812906	chr14:75593930	NEK9	-0.71	-6.67	-0.51	7.42e-10	Height;
TGCT	trans	rs1814175	0.647	rs28456013	chr11:50047629	T/C	cg15704280	chr7:45808275	SEPT13	-0.6	-6.79	-0.52	4.13e-10	Height;
TGCT	cis	rs12142240	0.698	rs68112720	chr1:46813888	T/C	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs7917772	0.502	rs10748827	chr10:104368336	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.8	8.21	0.59	2.44e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9914988	0.943	rs9902953	chr17:27139834	C/A	cg20469991	chr17:27169893	C17orf63	-0.71	-4.97	-0.41	2.18e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg03161606	chr19:29218774	NA	0.6	5.79	0.46	5.33e-8	Methadone dose in opioid dependence;
TGCT	cis	rs7178572	0.568	rs12900433	chr15:77495028	T/C	cg22256960	chr15:77711686	NA	-0.88	-8.99	-0.63	3.53e-15	Type 2 diabetes;
TGCT	cis	rs7727544	0.548	rs4705938	chr5:131694077	A/G	cg14196790	chr5:131705035	SLC22A5	0.34	4.59	0.38	1.06e-5	Blood metabolite levels;
TGCT	cis	rs12580194	0.593	rs7313465	chr12:55736863	C/T	cg10672482	chr12:55725839	OR6C3	-0.51	-4.6	-0.38	1.02e-5	Cancer;
TGCT	cis	rs7072216	0.655	rs3830025	chr10:100176104	A/G	cg26618903	chr10:100175079	PYROXD2	-0.42	-4.44	-0.37	1.93e-5	Metabolite levels;
TGCT	cis	rs9611565	0.918	rs28638318	chr22:41753059	G/A	cg13695892	chr22:41940480	POLR3H	-0.87	-8.35	-0.6	1.14e-13	Vitiligo;
TGCT	trans	rs12655019	0.920	rs6450410	chr5:56206701	A/G	cg25190722	chr1:3801660	DFFB	0.62	7.17	0.54	5.87e-11	Breast cancer (early onset);
TGCT	cis	rs12900413	0.603	rs12911871	chr15:90301429	T/C	cg24249390	chr15:90295951	MESP1	-0.3	-5.2	-0.42	8.04e-7	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs2760061	0.626	rs2796057	chr1:228124414	G/C	cg02753203	chr1:228287806	NA	-0.34	-6.63	-0.51	9.15e-10	Diastolic blood pressure;
TGCT	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg00814883	chr7:100076585	TSC22D4	-0.86	-8.76	-0.62	1.21e-14	Platelet count;
TGCT	cis	rs79349575	0.783	rs4793996	chr17:47019597	T/C	cg26022315	chr17:47021804	SNF8	0.49	4.9	0.4	2.94e-6	Type 2 diabetes;
TGCT	cis	rs7662987	0.517	rs3018048	chr4:100005538	C/T	cg12011299	chr4:100065546	ADH4	0.38	4.71	0.39	6.42e-6	Smoking initiation;
TGCT	cis	rs8180040	0.966	rs6765990	chr3:47542894	G/A	cg27129171	chr3:47204927	SETD2	0.66	8.01	0.58	7.07e-13	Colorectal cancer;
TGCT	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	6.22	0.49	7.14e-9	Alzheimer's disease;
TGCT	cis	rs6752107	0.967	rs10210302	chr2:234158839	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.2	4.86	0.4	3.46e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.28	-0.43	5.51e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs10197940	0.662	rs2432945	chr2:152278414	T/C	cg19508488	chr2:152266495	RIF1	0.74	6.66	0.51	7.77e-10	Lung cancer;
TGCT	cis	rs4601821	0.823	rs10891546	chr11:113265292	C/T	cg14159747	chr11:113255604	NA	-0.45	-5.52	-0.44	1.91e-7	Alcoholic chronic pancreatitis;
TGCT	cis	rs739496	0.615	rs2339818	chr12:112046476	T/C	cg10833066	chr12:111807467	FAM109A	0.36	4.98	0.41	2.1e-6	Platelet count;
TGCT	cis	rs9653442	0.527	rs10176782	chr2:100782827	C/A	cg07810366	chr2:100720526	AFF3	-0.36	-5.26	-0.43	6.14e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg06108461	chr20:60628389	TAF4	-0.69	-10.77	-0.7	1.71e-19	Body mass index;
TGCT	cis	rs9394169	0.818	rs1547671	chr6:33777260	C/T	cg00334056	chr6:33755658	LEMD2	-0.23	-4.47	-0.37	1.76e-5	Essential tremor;
TGCT	cis	rs1878931	0.501	rs17136359	chr16:3420814	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.77	-7.14	-0.54	7.09e-11	Body mass index (adult);
TGCT	cis	rs9790314	0.846	rs12495310	chr3:160970956	T/A	cg03342759	chr3:160939853	NMD3	-0.51	-5.66	-0.45	9.96e-8	Morning vs. evening chronotype;
TGCT	cis	rs473651	0.935	rs35080527	chr2:239351387	T/C	cg08773314	chr2:239334832	ASB1	0.45	7.5	0.56	1.07e-11	Multiple system atrophy;
TGCT	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg02953382	chr22:24373134	LOC391322	0.77	8.01	0.58	7.12e-13	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs644799	1.000	rs12786522	chr11:95522858	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	11.0	0.7	4.62e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9914544	0.564	rs1859083	chr17:18843306	C/T	cg26378065	chr17:18585709	ZNF286B	-0.49	-4.56	-0.38	1.21e-5	Educational attainment (years of education);
TGCT	cis	rs2439831	0.717	rs28495368	chr15:43895642	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.93	6.64	0.51	8.7e-10	Lung cancer in ever smokers;
TGCT	cis	rs4237845	0.537	rs7969844	chr12:58278271	C/T	cg23860436	chr12:58378763	NA	0.34	4.75	0.39	5.48e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6690583	0.623	rs12041012	chr1:85515644	G/A	cg20280350	chr1:85513789	MCOLN3	-0.79	-4.99	-0.41	1.98e-6	Serum sulfate level;
TGCT	cis	rs9926296	0.632	rs1800286	chr16:89869761	T/C	cg27121462	chr16:89883253	FANCA	0.61	5.51	0.44	2.03e-7	Vitiligo;
TGCT	cis	rs35883536	0.605	rs2133118	chr1:101034337	C/T	cg10298815	chr1:101004474	GPR88	-0.25	-4.61	-0.38	9.74e-6	Monocyte count;
TGCT	cis	rs9419702	0.538	rs9322837	chr10:133539229	G/A	cg04492858	chr10:133558786	NA	0.57	6.1	0.48	1.25e-8	Survival in rectal cancer;
TGCT	cis	rs2229238	0.911	rs6672087	chr1:154516122	A/C	cg13067139	chr1:155221277	FAM189B	0.2	4.45	0.37	1.87e-5	Coronary heart disease;
TGCT	cis	rs78487399	0.808	rs17031001	chr2:43761218	T/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.4	-4.72	-0.39	6.22e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.54	4.47	0.37	1.77e-5	Tonsillectomy;
TGCT	cis	rs9928842	0.882	rs8048956	chr16:75254966	C/G	cg09066997	chr16:75300724	BCAR1	-0.27	-5.02	-0.41	1.79e-6	Alcoholic chronic pancreatitis;
TGCT	cis	rs3809566	0.963	rs12148057	chr15:63331509	A/T	cg00520135	chr15:63333846	TPM1	-0.44	-5.46	-0.44	2.44e-7	Platelet count;
TGCT	cis	rs6598955	1.000	rs10902728	chr1:26598281	T/C	cg04990556	chr1:26633338	UBXN11	0.84	9.5	0.65	2e-16	Obesity-related traits;
TGCT	cis	rs9486719	1.000	rs12208011	chr6:96991105	G/A	cg18709589	chr6:96969512	KIAA0776	-0.76	-5.32	-0.43	4.63e-7	Migraine;Coronary artery disease;
TGCT	cis	rs4319547	0.626	rs12423420	chr12:122938466	G/A	cg23029597	chr12:123009494	RSRC2	-0.27	-4.46	-0.37	1.8e-5	Body mass index;
TGCT	cis	rs709400	0.663	rs11623869	chr14:103883633	G/T	cg12935359	chr14:103987150	CKB	-0.35	-5.33	-0.43	4.54e-7	Body mass index;
TGCT	cis	rs9634489	0.502	rs9513143	chr13:97085570	A/G	cg11411106	chr13:97107445	HS6ST3	-0.28	-5.13	-0.42	1.09e-6	Body mass index;
TGCT	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg27286337	chr10:134555280	INPP5A	0.43	5.08	0.42	1.33e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs303386	0.501	rs4908302	chr1:99583122	A/C	cg03593336	chr1:99471295	LPPR5	0.27	5.54	0.45	1.7e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors);Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin);
TGCT	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg06618935	chr21:46677482	NA	-0.37	-5.56	-0.45	1.58e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs8028182	0.636	rs8036758	chr15:75817562	G/A	cg20655648	chr15:75932815	IMP3	0.6	4.65	0.38	8.54e-6	Sudden cardiac arrest;
TGCT	cis	rs523522	0.602	rs7132474	chr12:120866996	A/C	cg12219531	chr12:120966889	COQ5	0.72	4.88	0.4	3.18e-6	High light scatter reticulocyte count;
TGCT	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg24675658	chr1:53192096	ZYG11B	-0.71	-7.72	-0.57	3.38e-12	Monocyte count;
TGCT	cis	rs7172809	0.548	rs11856513	chr15:77471105	A/C	cg22256960	chr15:77711686	NA	0.49	4.44	0.37	1.95e-5	Glucose homeostasis traits;
TGCT	cis	rs6121246	0.567	rs2889488	chr20:30185758	G/A	cg13852791	chr20:30311386	BCL2L1	0.69	4.65	0.39	8.44e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg10802521	chr3:52805072	NEK4	-0.78	-10.0	-0.67	1.26e-17	Bipolar disorder;
TGCT	cis	rs36051895	0.559	rs72701682	chr9:5208025	A/G	cg02405213	chr9:5042618	JAK2	-0.63	-7.47	-0.56	1.25e-11	Pediatric autoimmune diseases;
TGCT	cis	rs2797160	0.875	rs12527010	chr6:125991507	A/G	cg05901451	chr6:126070800	HEY2	0.79	7.42	0.55	1.65e-11	Endometrial cancer;
TGCT	trans	rs1005277	0.522	rs289643	chr10:37941494	T/G	cg17830980	chr10:43048298	ZNF37B	-0.65	-7.09	-0.54	9.18e-11	Extrinsic epigenetic age acceleration;
TGCT	cis	rs8062405	0.754	rs62034323	chr16:28536473	C/T	cg09754948	chr16:28834200	ATXN2L	0.58	4.57	0.38	1.14e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs6831352	0.918	rs35662508	chr4:100050974	C/G	cg12011299	chr4:100065546	ADH4	-0.41	-4.92	-0.4	2.72e-6	Alcohol dependence;
TGCT	cis	rs600231	0.665	rs2846861	chr11:65222305	A/G	cg17120908	chr11:65337727	SSSCA1	-0.51	-4.71	-0.39	6.59e-6	Bone mineral density;
TGCT	cis	rs9928842	0.824	rs12924999	chr16:75262425	T/G	cg09066997	chr16:75300724	BCAR1	0.28	5.01	0.41	1.85e-6	Alcoholic chronic pancreatitis;
TGCT	cis	rs478304	0.934	rs570954	chr11:65498261	A/G	cg17480646	chr11:65405466	SIPA1	0.43	5.35	0.43	4.18e-7	Acne (severe);
TGCT	cis	rs975752	0.867	rs4919440	chr10:102014919	C/T	cg04750910	chr10:102416409	NA	0.73	4.48	0.37	1.69e-5	Schizophrenia;
TGCT	cis	rs17376456	0.877	rs9314092	chr5:93326362	A/G	cg21475434	chr5:93447410	FAM172A	0.66	4.97	0.41	2.2e-6	Diabetic retinopathy;
TGCT	cis	rs617219	0.698	rs7706045	chr5:78507910	T/G	cg05890484	chr5:78407552	BHMT	0.38	5.2	0.42	8.14e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg18305652	chr10:134549665	INPP5A	0.34	5.75	0.46	6.43e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs539096	0.671	rs513862	chr1:44114405	A/T	cg12908607	chr1:44402522	ARTN	-0.55	-5.9	-0.47	3.25e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs12136530	0.625	rs4912086	chr1:19730181	A/G	cg24875000	chr1:19041556	PAX7	-0.25	-4.47	-0.37	1.72e-5	Lead levels in blood;
TGCT	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.53	-6.58	-0.51	1.18e-9	Longevity;Endometriosis;
TGCT	cis	rs1568889	0.838	rs11030206	chr11:28099747	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.92	11.34	0.71	7.08e-21	Bipolar disorder;
TGCT	cis	rs73198271	0.640	rs7838012	chr8:8656630	A/G	cg06671706	chr8:8559999	CLDN23	-0.36	-4.52	-0.38	1.42e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs73815153	0.744	rs10479600	chr5:180459653	G/A	cg00299286	chr5:180478185	BTNL9	0.87	4.98	0.41	2.08e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
TGCT	cis	rs10851411	0.789	rs28886308	chr15:42770032	A/G	cg23803468	chr15:43513504	EPB42	0.23	4.53	0.38	1.36e-5	Glucose homeostasis traits;
TGCT	cis	rs6500602	0.702	rs9929475	chr16:4540885	C/T	cg08645402	chr16:4508243	NA	-0.17	-4.66	-0.39	8.09e-6	Schizophrenia;
TGCT	cis	rs8077889	0.956	rs55768269	chr17:41888997	C/T	cg26893861	chr17:41843967	DUSP3	1.1	12.5	0.75	1.08e-23	Triglycerides;
TGCT	cis	rs4654899	0.865	rs61779065	chr1:21356474	A/T	cg01072550	chr1:21505969	NA	-0.46	-6.95	-0.53	1.88e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs10056811	0.556	rs57441318	chr5:74379675	T/A	cg19683494	chr5:74908142	NA	0.58	5.17	0.42	9.04e-7	Coronary artery disease;
TGCT	cis	rs12048904	0.595	rs10493937	chr1:101342650	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.72	-7.67	-0.57	4.42e-12	Multiple sclerosis;
TGCT	cis	rs4850410	0.581	rs12997637	chr2:197909347	T/G	cg19149314	chr2:197065128	HECW2	0.23	4.47	0.37	1.77e-5	Interferon alpha levels in systemic lupus erythematosus;
TGCT	cis	rs3845702	0.736	rs72960664	chr2:180832672	C/T	cg01881094	chr2:180872142	CWC22	1.04	6.58	0.51	1.16e-9	Schizophrenia;
TGCT	cis	rs9467773	0.620	rs2494694	chr6:26619328	A/T	cg05738196	chr6:26577821	NA	0.87	11.3	0.71	8.47e-21	Intelligence (multi-trait analysis);
TGCT	cis	rs4824093	0.535	rs73443931	chr22:50291603	G/A	cg14114931	chr22:50943910	LMF2	0.37	4.58	0.38	1.11e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs9787249	0.957	rs7548120	chr1:40204424	A/T	cg19912559	chr1:40204330	PPIE	0.49	5.7	0.46	8.41e-8	Blood protein levels;
TGCT	cis	rs17376456	0.825	rs10476590	chr5:93244884	A/T	cg21475434	chr5:93447410	FAM172A	0.71	4.91	0.4	2.86e-6	Diabetic retinopathy;
TGCT	trans	rs1814175	0.817	rs10839465	chr11:49981554	C/A	cg03929089	chr4:120376271	NA	-0.72	-8.53	-0.61	4.24e-14	Height;
TGCT	cis	rs7726839	0.507	rs72703100	chr5:614291	C/T	cg09021430	chr5:549028	NA	-0.46	-6.07	-0.48	1.42e-8	Obesity-related traits;
TGCT	cis	rs9467773	0.565	rs4343916	chr6:26522675	A/T	cg09904177	chr6:26538194	HMGN4	0.5	4.76	0.39	5.25e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs12210905	0.920	rs12191414	chr6:27278634	C/G	cg08851530	chr6:28072375	NA	1.29	5.26	0.43	6.03e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs4654899	0.802	rs12123910	chr1:21233316	C/T	cg01072550	chr1:21505969	NA	-0.46	-6.94	-0.53	1.96e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs11190604	1.000	rs10883499	chr10:102232188	T/A	cg16342193	chr10:102329863	NA	-0.4	-5.31	-0.43	4.85e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg12311346	chr5:56204834	C5orf35	0.57	6.09	0.48	1.28e-8	Initial pursuit acceleration;
TGCT	cis	rs7192750	0.519	rs2008675	chr16:71995980	A/C	cg06353428	chr16:71660113	MARVELD3	0.76	6.53	0.51	1.53e-9	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs929354	1.000	rs1182377	chr7:157048403	T/C	cg05182265	chr7:156933206	UBE3C	0.32	6.63	0.51	9.08e-10	Body mass index;
TGCT	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg11890956	chr21:40555474	PSMG1	-0.68	-6.6	-0.51	1.09e-9	Menarche (age at onset);
TGCT	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg24549020	chr5:56110836	MAP3K1	0.67	5.78	0.46	5.74e-8	Initial pursuit acceleration;
TGCT	cis	rs34638657	0.732	rs62045962	chr16:82200604	T/C	cg09439754	chr16:82129088	HSD17B2	-0.24	-4.63	-0.38	9.27e-6	Lung adenocarcinoma;
TGCT	cis	rs7027203	0.964	rs6479512	chr9:96556985	G/A	cg14598338	chr9:96623480	NA	0.6	8.72	0.62	1.51e-14	DNA methylation (variation);
TGCT	cis	rs9399137	0.507	rs6923512	chr6:135335268	A/G	cg24558204	chr6:135376177	HBS1L	-0.46	-4.65	-0.39	8.3e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
TGCT	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg26118208	chr10:134322334	NA	0.26	5.21	0.42	7.56e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs7246657	0.943	rs2891699	chr19:37920237	A/G	cg18154014	chr19:37997991	ZNF793	0.73	5.38	0.44	3.53e-7	Coronary artery calcification;
TGCT	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9368481	0.761	rs3931464	chr6:26939856	C/A	cg26531700	chr6:26746687	NA	0.61	5.65	0.45	1.06e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs151997	1.000	rs27249	chr5:50232678	A/G	cg06027927	chr5:50259733	NA	0.47	4.8	0.4	4.41e-6	Callous-unemotional behaviour;
TGCT	cis	rs526231	0.575	rs12652973	chr5:102306322	G/A	cg23492399	chr5:102201601	PAM	-0.53	-4.56	-0.38	1.23e-5	Primary biliary cholangitis;
TGCT	cis	rs1348850	0.872	rs4893959	chr2:178400204	G/A	cg22681709	chr2:178499509	PDE11A	-0.38	-4.73	-0.39	6.12e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs9814567	1.000	rs6785027	chr3:134211649	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.93	9.4	0.64	3.66e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs236907	0.859	rs34320898	chr1:171759139	G/C	cg20598894	chr1:171756153	METTL13	-0.2	-4.54	-0.38	1.31e-5	Mean platelet volume;
TGCT	cis	rs9527	0.640	rs6584541	chr10:104929124	A/G	cg15744005	chr10:104629667	AS3MT	-0.4	-4.63	-0.38	9.04e-6	Arsenic metabolism;
TGCT	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	7.43	0.55	1.56e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7267979	1.000	rs2482943	chr20:25380593	G/A	cg03522245	chr20:25566470	NINL	-0.64	-7.05	-0.53	1.12e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2204008	0.811	rs11525004	chr12:38333807	T/A	cg13010199	chr12:38710504	ALG10B	0.59	4.53	0.38	1.37e-5	Bladder cancer;
TGCT	cis	rs7666738	0.861	rs5010991	chr4:98972179	A/G	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7017914	0.905	rs1908034	chr8:71922554	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.55	-5.1	-0.42	1.24e-6	Bone mineral density;
TGCT	cis	rs986417	0.901	rs1884098	chr14:61038944	A/T	cg18240143	chr14:60952599	C14orf39	0.94	5.09	0.42	1.29e-6	Gut microbiota (bacterial taxa);
TGCT	cis	rs2404602	0.716	rs17363713	chr15:76746128	G/C	cg26408565	chr15:76604113	ETFA	-0.4	-5.26	-0.43	6.23e-7	Blood metabolite levels;
TGCT	cis	rs909674	0.818	rs5750833	chr22:39843091	C/A	cg24399712	chr22:39784796	NA	-1.04	-11.0	-0.7	4.62e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs6815814	0.904	rs7664239	chr4:38786304	T/C	cg02016764	chr4:38805732	TLR1	-0.28	-4.59	-0.38	1.06e-5	Breast cancer;
TGCT	cis	rs4455778	0.659	rs4917196	chr7:49021759	C/T	cg26309511	chr7:48887640	NA	-0.43	-5.07	-0.41	1.4e-6	Lung cancer in never smokers;
TGCT	cis	rs7681440	0.904	rs2301134	chr4:90758945	A/G	cg14346243	chr4:90757452	SNCA	-0.59	-5.74	-0.46	6.87e-8	Dementia with Lewy bodies;
TGCT	cis	rs9814567	1.000	rs4498009	chr3:134198008	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.97	-9.24	-0.64	8.89e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs35000415	0.938	rs12531711	chr7:128617466	A/G	cg06242719	chr7:129414860	MIR183;MIR96	-0.31	-4.52	-0.38	1.4e-5	Systemic lupus erythematosus;
TGCT	cis	rs76935404	1.000	rs76935404	chr19:41419294	C/T	cg19493303	chr19:41414353	NA	0.42	5.11	0.42	1.17e-6	nicotine metabolite ratio in current smokers;
TGCT	cis	rs12188164	0.965	rs1056465	chr5:442438	T/A	cg26850624	chr5:429559	AHRR	-0.2	-4.84	-0.4	3.78e-6	Cystic fibrosis severity;
TGCT	cis	rs7830933	0.955	rs1550279	chr8:23600854	C/G	cg04349084	chr8:23602677	NA	0.24	4.88	0.4	3.24e-6	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
TGCT	cis	rs7666738	0.606	rs10006454	chr4:99080361	G/A	cg17366294	chr4:99064904	C4orf37	0.57	5.34	0.43	4.31e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9814567	1.000	rs1874883	chr3:134205071	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.99	-9.97	-0.67	1.5e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs7666738	0.830	rs28618180	chr4:98912184	A/C	cg18180107	chr4:99064573	C4orf37	0.53	4.99	0.41	1.98e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2562456	0.792	rs2562398	chr19:21722949	A/G	cg25650185	chr19:21324782	ZNF431	0.64	5.7	0.46	8.3e-8	Pain;
TGCT	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg13695892	chr22:41940480	POLR3H	-0.81	-7.54	-0.56	8.75e-12	Vitiligo;
TGCT	cis	rs7917772	0.503	rs7896841	chr10:104294665	C/T	cg05855489	chr10:104503620	C10orf26	-0.58	-5.06	-0.41	1.47e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs55794721	0.509	rs4649085	chr1:25778832	G/A	cg00786635	chr1:25594202	NA	0.54	5.78	0.46	5.67e-8	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs9811920	0.809	rs793464	chr3:99626028	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.46	-5.2	-0.42	7.88e-7	Axial length;
TGCT	cis	rs6933660	0.800	rs6930557	chr6:151755806	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.94	-10.66	-0.69	3.05e-19	Menarche (age at onset);
TGCT	cis	rs7267979	0.966	rs4815425	chr20:25398876	G/C	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6674176	0.628	rs3828146	chr1:44428715	C/T	cg12908607	chr1:44402522	ARTN	-0.67	-8.15	-0.59	3.4e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs826838	0.967	rs11168985	chr12:39045983	A/C	cg13010199	chr12:38710504	ALG10B	-0.68	-5.16	-0.42	9.31e-7	Heart rate;
TGCT	cis	rs3733585	0.664	rs17245436	chr4:9958169	A/G	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.7	-0.57	3.71e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs2204008	0.538	rs11514000	chr12:38067706	A/G	cg26384229	chr12:38710491	ALG10B	0.59	5.06	0.41	1.47e-6	Bladder cancer;
TGCT	cis	rs9814567	0.964	rs4974480	chr3:134178562	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.99	-9.92	-0.67	2.01e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs4888262	0.526	rs4404098	chr16:74570050	G/A	cg01733217	chr16:74700730	RFWD3	0.71	7.11	0.54	8.09e-11	Testicular germ cell tumor;
TGCT	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg09060608	chr5:178986726	RUFY1	0.63	7.96	0.58	9.3e-13	Lung cancer;
TGCT	cis	rs1322512	0.959	rs1744375	chr6:152944464	C/T	cg03415253	chr6:152958462	SYNE1	-0.57	-4.98	-0.41	2.05e-6	Tonometry;
TGCT	cis	rs12541335	0.639	rs68063696	chr8:22153236	A/G	cg26039829	chr8:22132926	PIWIL2	0.26	4.73	0.39	5.98e-6	Hypertriglyceridemia;
TGCT	cis	rs17376456	0.569	rs68122392	chr5:93077807	A/T	cg21475434	chr5:93447410	FAM172A	0.61	4.95	0.41	2.35e-6	Diabetic retinopathy;
TGCT	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg21226059	chr5:178986404	RUFY1	0.57	6.46	0.5	2.12e-9	Lung cancer;
TGCT	cis	rs2066819	1.000	rs11575234	chr12:56744276	C/G	cg26714650	chr12:56694279	CS	-1.44	-7.47	-0.56	1.26e-11	Psoriasis vulgaris;
TGCT	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg07507251	chr3:52567010	NT5DC2	0.47	6.6	0.51	1.05e-9	Bipolar disorder;
TGCT	cis	rs3820928	1.000	rs7561378	chr2:227772248	T/C	cg11843606	chr2:227700838	RHBDD1	-0.54	-4.82	-0.4	4.12e-6	Pulmonary function;
TGCT	cis	rs2228479	0.850	rs12596934	chr16:89841605	T/G	cg06558623	chr16:89946397	TCF25	0.45	4.52	0.38	1.42e-5	Skin colour saturation;
TGCT	cis	rs3772130	0.962	rs1920320	chr3:121547527	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.72	0.39	6.25e-6	Cognitive performance;
TGCT	cis	rs910316	1.000	rs876403	chr14:75602834	A/T	cg11812906	chr14:75593930	NEK9	0.73	7.1	0.54	8.42e-11	Height;
TGCT	cis	rs7666738	0.819	rs13120307	chr4:99036100	A/C	cg18180107	chr4:99064573	C4orf37	0.59	5.37	0.43	3.73e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs17221829	0.733	rs1962259	chr11:89380637	G/C	cg02982614	chr11:89391479	FOLH1B	-0.27	-4.85	-0.4	3.63e-6	Anxiety in major depressive disorder;
TGCT	cis	rs6714710	0.603	rs11691494	chr2:98419726	T/A	cg26665480	chr2:98280029	ACTR1B	0.66	6.24	0.49	6.33e-9	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs7424096	0.582	rs7600245	chr2:37220614	A/C	cg14987922	chr2:37194071	STRN	0.52	4.53	0.38	1.37e-5	High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs12257961	0.549	rs1955342	chr10:15377871	A/G	cg10616319	chr10:15468812	NA	-0.25	-4.56	-0.38	1.2e-5	Selective IgA deficiency;
TGCT	cis	rs826838	1.000	rs11183196	chr12:38685915	G/T	cg13010199	chr12:38710504	ALG10B	0.82	6.65	0.51	8.46e-10	Heart rate;
TGCT	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg03188948	chr7:1209495	NA	0.52	5.4	0.44	3.29e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7267979	1.000	rs2424712	chr20:25416942	T/C	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg12963246	chr6:28129442	ZNF389	0.52	5.01	0.41	1.85e-6	Depression;
TGCT	cis	rs12477438	0.501	rs6708878	chr2:99801564	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	14.89	0.8	2.21e-29	Chronic sinus infection;
TGCT	cis	rs7584330	0.554	rs6740834	chr2:238423442	T/C	cg08992911	chr2:238395768	MLPH	0.76	5.32	0.43	4.77e-7	Prostate cancer;
TGCT	cis	rs2637266	1.000	rs2637268	chr10:78332213	G/T	cg18941641	chr10:78392320	NA	0.39	4.97	0.41	2.16e-6	Pulmonary function;
TGCT	cis	rs644799	0.511	rs1016030	chr11:95472693	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.6	5.86	0.47	3.96e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg11301795	chr4:187892539	NA	-0.34	-4.9	-0.4	2.97e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1372520	0.748	rs1471484	chr4:90754313	C/T	cg01966878	chr4:90757139	SNCA	-0.3	-4.62	-0.38	9.66e-6	Neuroticism;
TGCT	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg13607699	chr17:42295918	UBTF	0.59	5.45	0.44	2.61e-7	Total body bone mineral density;
TGCT	cis	rs1018836	0.537	rs13251501	chr8:91458796	G/A	cg16814680	chr8:91681699	NA	-0.76	-6.99	-0.53	1.5e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10883723	0.810	rs7094366	chr10:104274730	C/G	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs9549367	0.789	rs9549365	chr13:113907391	C/T	cg18105134	chr13:113819100	PROZ	0.35	5.89	0.47	3.45e-8	Platelet distribution width;
TGCT	cis	rs6840360	0.593	rs4696106	chr4:152606818	A/G	cg22705602	chr4:152727874	NA	-0.32	-5.27	-0.43	5.96e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2404602	0.692	rs34287706	chr15:76942402	A/C	cg22467129	chr15:76604101	ETFA	-0.45	-5.11	-0.42	1.18e-6	Blood metabolite levels;
TGCT	cis	rs17152411	1.000	rs1065301	chr10:126616038	A/G	cg07906193	chr10:126599966	NA	0.41	5.12	0.42	1.12e-6	Height;
TGCT	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	6.75	0.52	5.02e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs600231	0.706	rs1111934	chr11:65329392	A/G	cg13974409	chr11:65292307	SCYL1	0.5	4.91	0.4	2.78e-6	Bone mineral density;
TGCT	cis	rs9790314	0.586	rs11713185	chr3:161111357	C/G	cg03342759	chr3:160939853	NMD3	-0.55	-5.7	-0.46	8.15e-8	Morning vs. evening chronotype;
TGCT	cis	rs2486288	0.656	rs9921035	chr15:45546660	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.41	-4.95	-0.41	2.36e-6	Glomerular filtration rate;
TGCT	cis	rs35000415	0.506	rs34288126	chr7:128735438	G/A	cg06242719	chr7:129414860	MIR183;MIR96	-0.32	-4.66	-0.39	7.91e-6	Systemic lupus erythematosus;
TGCT	cis	rs1055129	0.655	rs8067076	chr17:73837142	G/T	cg08125733	chr17:73851984	WBP2	-0.52	-4.68	-0.39	7.42e-6	White matter hyperintensity burden;
TGCT	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg16325326	chr1:53192061	ZYG11B	0.56	6.12	0.48	1.15e-8	Monocyte count;
TGCT	cis	rs10782582	0.609	rs1796815	chr1:76396793	T/G	cg10523679	chr1:76189770	ACADM	-0.55	-4.94	-0.41	2.5e-6	Daytime sleep phenotypes;
TGCT	cis	rs231513	0.954	rs231508	chr17:41967583	G/A	cg26893861	chr17:41843967	DUSP3	-0.71	-5.25	-0.43	6.26e-7	Cognitive function;
TGCT	cis	rs2204008	0.580	rs1315373	chr12:38179114	T/G	cg26384229	chr12:38710491	ALG10B	-0.58	-5.09	-0.42	1.28e-6	Bladder cancer;
TGCT	cis	rs2224391	0.628	rs766340	chr6:5243521	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-1.04	-6.69	-0.51	6.87e-10	Height;
TGCT	cis	rs13242816	1.000	rs17138714	chr7:116114274	C/T	cg02799643	chr7:116139180	CAV2	-0.43	-5.22	-0.42	7.45e-7	P wave duration;
TGCT	cis	rs7833790	0.724	rs4739627	chr8:82734657	A/G	cg06027949	chr8:82754900	SNX16	-0.65	-5.03	-0.41	1.69e-6	Diastolic blood pressure;
TGCT	cis	rs2288884	1.000	rs11673286	chr19:52540318	C/T	cg15405931	chr19:52693188	PPP2R1A	-0.69	-4.6	-0.38	1.03e-5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg06618935	chr21:46677482	NA	-0.37	-5.56	-0.45	1.58e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7726839	0.555	rs4541696	chr5:581053	A/G	cg09021430	chr5:549028	NA	-0.46	-8.99	-0.63	3.47e-15	Obesity-related traits;
TGCT	cis	rs1403694	0.515	rs1648722	chr3:186448989	C/T	cg12454167	chr3:186435060	KNG1	0.46	7.19	0.54	5.47e-11	Blood protein levels;
TGCT	cis	rs9325144	0.510	rs6582599	chr12:38715965	T/G	cg26384229	chr12:38710491	ALG10B	0.64	6.0	0.47	2.03e-8	Morning vs. evening chronotype;
TGCT	cis	rs7027203	0.538	rs10125195	chr9:96523224	T/C	cg13679303	chr9:96623674	NA	-0.53	-7.48	-0.56	1.18e-11	DNA methylation (variation);
TGCT	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg21548813	chr6:291882	DUSP22	-0.63	-6.65	-0.51	8.55e-10	Menopause (age at onset);
TGCT	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg16414030	chr3:133502952	NA	-0.5	-7.12	-0.54	7.86e-11	Iron status biomarkers;
TGCT	cis	rs912057	0.833	rs1294426	chr6:6744477	T/C	cg06612196	chr6:6737390	NA	0.37	4.88	0.4	3.17e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs17376456	0.877	rs35075119	chr5:93385457	T/C	cg25358565	chr5:93447407	FAM172A	0.92	8.38	0.6	9.58e-14	Diabetic retinopathy;
TGCT	cis	rs9650657	0.711	rs35091929	chr8:10693492	T/C	cg27411982	chr8:10470053	RP1L1	-0.24	-4.96	-0.41	2.24e-6	Neuroticism;
TGCT	cis	rs7666738	0.830	rs6831925	chr4:98947401	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9308731	0.966	rs6753785	chr2:111923630	T/G	cg04202892	chr2:111875749	ACOXL	0.44	4.88	0.4	3.18e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs1150668	0.796	rs213236	chr6:28324397	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.49	-4.68	-0.39	7.38e-6	Pubertal anthropometrics;
TGCT	cis	rs2235649	0.551	rs1742454	chr16:1939378	G/T	cg02432467	chr16:1963432	HS3ST6	-0.31	-4.89	-0.4	3.12e-6	Blood metabolite levels;
TGCT	trans	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg21659725	chr3:3221576	CRBN	-0.7	-7.98	-0.58	8.35e-13	Body mass index;
TGCT	cis	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg04013166	chr16:89971882	TCF25	0.33	4.64	0.38	8.86e-6	Skin colour saturation;
TGCT	cis	rs6570726	0.791	rs446362	chr6:145878716	G/T	cg13319975	chr6:146136371	FBXO30	-0.51	-4.6	-0.38	1.01e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs78487399	0.808	rs10180005	chr2:43737465	C/G	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.76	4.68	0.39	7.27e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs1894292	0.527	rs1997332	chr4:74374174	C/T	cg05868023	chr4:75230803	EREG	-0.56	-5.05	-0.41	1.56e-6	Prostate cancer;
TGCT	cis	rs3818285	0.679	rs612155	chr10:111630731	C/G	cg00817464	chr10:111662876	XPNPEP1	0.32	5.7	0.46	8.35e-8	Superior crus of antihelix expression;
TGCT	cis	rs478607	0.915	rs521793	chr11:64482947	G/C	cg19395706	chr11:64412079	NRXN2	-0.47	-5.02	-0.41	1.73e-6	Urate levels;
TGCT	cis	rs74233809	1.000	rs11191607	chr10:104959188	G/T	cg05855489	chr10:104503620	C10orf26	0.82	4.7	0.39	6.66e-6	Birth weight;
TGCT	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg11494091	chr17:61959527	GH2	0.61	14.8	0.8	3.65e-29	Prudent dietary pattern;
TGCT	cis	rs2115630	0.645	rs6496284	chr15:85178270	A/G	cg17173187	chr15:85201210	NMB	-0.46	-5.53	-0.44	1.82e-7	P wave terminal force;
TGCT	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg20891283	chr12:69753455	YEATS4	0.91	10.33	0.68	1.96e-18	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs2380220	0.510	rs9387562	chr6:96057006	G/T	cg04719120	chr6:96025338	MANEA	0.74	5.55	0.45	1.67e-7	Behavioural disinhibition (generation interaction);
TGCT	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg14820908	chr5:178986412	RUFY1	-0.59	-6.43	-0.5	2.52e-9	Lung cancer;
TGCT	cis	rs12450688	1	rs12450688	chr17:38144229	G/A	cg17467752	chr17:38218738	THRA	-0.53	-5.33	-0.43	4.45e-7	Sum eosinophil basophil counts;
TGCT	cis	rs7607369	0.618	rs62193298	chr2:219655211	T/G	cg02176678	chr2:219576539	TTLL4	-0.47	-6.0	-0.47	2.02e-8	Red blood cell count;Amyotrophic lateral sclerosis;
TGCT	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg23708337	chr7:1209742	NA	0.56	5.08	0.42	1.34e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs853679	0.567	rs16894091	chr6:28390137	A/T	cg18815343	chr6:28367644	ZSCAN12	0.5	4.61	0.38	9.72e-6	Depression;
TGCT	cis	rs1801251	0.644	rs283473	chr2:233654847	A/G	cg08000102	chr2:233561755	GIGYF2	0.61	6.89	0.53	2.54e-10	Coronary artery disease;
TGCT	cis	rs1568889	0.667	rs16917914	chr11:28459909	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.66	5.48	0.44	2.3e-7	Bipolar disorder;
TGCT	cis	rs4076764	0.958	rs6691127	chr1:163384831	T/C	cg24596788	chr1:163392923	NA	-0.17	-5.1	-0.42	1.23e-6	Motion sickness;
TGCT	cis	rs12575480	0.672	rs74048171	chr11:2093603	C/A	cg15541987	chr11:2077307	NA	-0.37	-4.47	-0.37	1.71e-5	Pursuit maintenance gain;
TGCT	cis	rs7119	0.623	rs11637932	chr15:77847353	T/G	cg27398640	chr15:77910606	LINGO1	-0.28	-5.11	-0.42	1.21e-6	Type 2 diabetes;
TGCT	cis	rs9611565	0.592	rs4481089	chr22:41980892	T/C	cg06481639	chr22:41940642	POLR3H	-0.62	-5.26	-0.43	6.21e-7	Vitiligo;
TGCT	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg08048268	chr3:133502702	NA	0.64	9.82	0.66	3.42e-17	Iron status biomarkers;
TGCT	trans	rs1814175	0.817	rs28594987	chr11:50045181	C/T	cg03929089	chr4:120376271	NA	-0.72	-8.55	-0.61	3.8e-14	Height;
TGCT	cis	rs9368481	0.761	rs3931464	chr6:26939856	C/A	cg02458000	chr6:26745757	NA	0.52	4.61	0.38	9.87e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12681288	0.676	rs1562921	chr8:1021986	G/T	cg08872321	chr8:1308229	NA	-0.24	-4.45	-0.37	1.86e-5	Schizophrenia;
TGCT	cis	rs4862750	0.914	rs10027250	chr4:187873460	T/C	cg10295955	chr4:187884368	NA	-0.94	-13.14	-0.76	3.07e-25	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2070488	0.965	rs2284820	chr3:38562579	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.83	-8.45	-0.6	6.78e-14	Electrocardiographic conduction measures;
TGCT	cis	rs933688	0.759	rs1423593	chr5:90752351	T/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	8.63	0.61	2.51e-14	Smoking behavior;
TGCT	cis	rs3617	0.625	rs2071042	chr3:52864584	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.49	-4.77	-0.39	5.04e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	trans	rs80264589	1	rs80264589	chr6:26927602	G/A	cg20516262	chr7:155325649	CNPY1	0.63	7.11	0.54	7.99e-11	Lung cancer;Intelligence (multi-trait analysis);
TGCT	cis	rs4664308	0.806	rs4665162	chr2:161060184	A/G	cg03641300	chr2:160917029	PLA2R1	-0.27	-6.83	-0.52	3.31e-10	Idiopathic membranous nephropathy;
TGCT	cis	rs9467711	0.790	rs34107459	chr6:26328353	T/C	cg16898833	chr6:26189333	HIST1H4D	1.27	5.72	0.46	7.64e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs854765	0.583	rs4925130	chr17:17807858	G/A	cg09796270	chr17:17721594	SREBF1	0.23	4.57	0.38	1.14e-5	Total body bone mineral density;
TGCT	cis	rs3806843	0.576	rs246017	chr5:140335060	C/T	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs6840360	0.608	rs6831644	chr4:152283746	A/G	cg17479576	chr4:152424074	FAM160A1	-0.45	-4.72	-0.39	6.27e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg13206674	chr6:150067644	NUP43	0.52	4.46	0.37	1.78e-5	Lung cancer;
TGCT	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg23708337	chr7:1209742	NA	0.6	5.57	0.45	1.53e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1008375	0.933	rs10939757	chr4:17694125	T/C	cg18681998	chr4:17616180	MED28	0.78	7.27	0.55	3.58e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4851254	0.660	rs1821830	chr2:100680279	C/T	cg22139774	chr2:100720529	AFF3	-0.45	-4.91	-0.4	2.75e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7818382	1.000	rs7818382	chr8:96054000	C/T	cg16049864	chr8:95962084	TP53INP1	-0.54	-5.91	-0.47	3.03e-8	Alzheimer's disease (late onset);
TGCT	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.94	7.92	0.58	1.17e-12	Platelet count;
TGCT	cis	rs3008870	1.000	rs2985825	chr1:67412822	T/G	cg08660285	chr1:67390436	MIER1;WDR78	1.1	11.91	0.73	2.83e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs4727027	0.899	rs6464942	chr7:148826368	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	4.58	0.38	1.13e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs7666738	0.791	rs2865953	chr4:99040319	C/T	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	6.13	0.48	1.06e-8	Bipolar disorder;
TGCT	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10464366	0.746	rs6945547	chr7:39145389	C/G	cg18850127	chr7:39170497	POU6F2	0.28	5.93	0.47	2.76e-8	IgG glycosylation;
TGCT	cis	rs6543140	0.964	rs11886793	chr2:103072220	T/G	cg09003973	chr2:102972529	NA	0.55	4.67	0.39	7.71e-6	Blood protein levels;
TGCT	cis	rs28595532	0.920	rs116799007	chr4:119763562	A/G	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs514406	0.505	rs269289	chr1:53167151	A/C	cg24675658	chr1:53192096	ZYG11B	-0.75	-8.4	-0.6	8.59e-14	Monocyte count;
TGCT	cis	rs12477438	0.520	rs2632283	chr2:99776000	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	10.3	0.68	2.42e-18	Chronic sinus infection;
TGCT	cis	rs6964587	0.967	rs34040612	chr7:91798916	G/T	cg22709100	chr7:91322751	NA	0.29	4.74	0.39	5.78e-6	Breast cancer;
TGCT	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg04287289	chr16:89883240	FANCA	0.68	6.91	0.53	2.27e-10	Vitiligo;
TGCT	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg11494091	chr17:61959527	GH2	0.61	14.49	0.79	1.92e-28	Prudent dietary pattern;
TGCT	cis	rs8037137	0.915	rs3826033	chr15:91548601	G/A	cg22570213	chr15:91497863	RCCD1	0.52	4.84	0.4	3.84e-6	Platelet count;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
TGCT	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg24829409	chr8:58192753	C8orf71	-0.59	-4.97	-0.41	2.17e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs796364	0.806	rs203767	chr2:200902411	G/A	cg17644776	chr2:200775616	C2orf69	-0.33	-5.0	-0.41	1.91e-6	Schizophrenia;
TGCT	cis	rs2204008	0.744	rs11181337	chr12:38322083	C/A	cg26384229	chr12:38710491	ALG10B	0.77	6.85	0.52	3.04e-10	Bladder cancer;
TGCT	cis	rs67311347	1.000	rs67680017	chr3:40533164	C/T	cg02782426	chr3:40428986	ENTPD3	0.42	4.44	0.37	1.99e-5	Renal cell carcinoma;
TGCT	cis	rs941408	1.000	rs1640274	chr19:2807375	G/A	cg06609049	chr19:2785107	THOP1	0.79	6.52	0.51	1.61e-9	Total cholesterol levels;
TGCT	cis	rs7586879	0.638	rs13035244	chr2:25134009	T/C	cg01884057	chr2:25150051	NA	0.36	7.1	0.54	8.63e-11	Body mass index;
TGCT	cis	rs6831352	0.918	rs2213035	chr4:100064233	G/A	cg12011299	chr4:100065546	ADH4	-0.42	-4.98	-0.41	2.06e-6	Alcohol dependence;
TGCT	cis	rs826838	0.967	rs11183577	chr12:38781887	A/G	cg26384229	chr12:38710491	ALG10B	1.08	10.86	0.7	1.01e-19	Heart rate;
TGCT	cis	rs2013441	1.000	rs2703810	chr17:20113715	C/T	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.61	-0.38	9.96e-6	Obesity-related traits;
TGCT	cis	rs1245541	0.934	rs921361	chr10:73867454	C/T	cg09661010	chr10:73848153	SPOCK2	-0.38	-4.53	-0.38	1.34e-5	Insulin-like growth factors;
TGCT	cis	rs3087591	0.960	rs4795593	chr17:29613600	G/C	cg24425628	chr17:29625626	OMG;NF1	-0.48	-7.43	-0.56	1.52e-11	Hip circumference;
TGCT	cis	rs1843834	0.611	rs1058360	chr2:225449242	A/T	cg12698349	chr2:225449008	CUL3	0.78	6.41	0.5	2.77e-9	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs7100689	0.577	rs1340385	chr10:82058851	G/A	cg01528321	chr10:82214614	TSPAN14	0.69	6.72	0.52	5.76e-10	Post bronchodilator FEV1;
TGCT	cis	rs9300255	0.664	rs28372579	chr12:123881176	A/G	cg00376283	chr12:123451042	ABCB9	-0.65	-4.58	-0.38	1.1e-5	Neutrophil percentage of white cells;
TGCT	cis	rs2074585	0.839	rs11638780	chr15:91041896	G/T	cg22089800	chr15:90895588	ZNF774	-0.76	-7.77	-0.57	2.55e-12	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
TGCT	cis	rs7615952	0.551	rs12695470	chr3:125635718	C/A	cg05084668	chr3:125655381	ALG1L	-0.63	-4.49	-0.37	1.58e-5	Blood pressure (smoking interaction);
TGCT	cis	rs13191038	1	rs13191038	chr6:28482917	T/C	cg10876282	chr6:28092338	ZSCAN16	0.86	4.47	0.37	1.72e-5	Urinary tract infection frequency;
TGCT	cis	rs1577917	1.000	rs10455455	chr6:86670214	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-5.36	-0.43	3.86e-7	Response to antipsychotic treatment;
TGCT	cis	rs263156	0.967	rs190522	chr6:142879060	T/A	cg18419694	chr6:143832440	FUCA2	-0.38	-4.53	-0.38	1.36e-5	Ear morphology;Lobe size;Lobe attachment;
TGCT	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg04267008	chr7:1944627	MAD1L1	-0.38	-5.12	-0.42	1.12e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs9611519	0.857	rs4820434	chr22:41637119	G/T	cg06634786	chr22:41940651	POLR3H	-0.57	-5.21	-0.42	7.5e-7	Neuroticism;
TGCT	cis	rs7572733	0.534	rs1518361	chr2:198812874	A/G	cg00792783	chr2:198669748	PLCL1	0.57	5.23	0.43	6.99e-7	Dermatomyositis;
TGCT	cis	rs9560113	0.922	rs4773377	chr13:112174152	G/C	cg14154082	chr13:112174009	NA	0.34	4.58	0.38	1.09e-5	Menarche (age at onset);
TGCT	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.0	0.41	1.89e-6	Menopause (age at onset);
TGCT	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg25703541	chr22:24373054	LOC391322	-0.82	-8.53	-0.61	4.22e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs17601876	0.814	rs17523527	chr15:51554032	C/T	cg19946085	chr15:51559439	CYP19A1	-0.32	-4.82	-0.4	4.06e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs4851266	0.966	rs13017207	chr2:100841235	G/A	cg07810366	chr2:100720526	AFF3	-0.38	-5.43	-0.44	2.81e-7	Educational attainment;
TGCT	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg18538332	chr22:24372958	LOC391322	-0.87	-9.91	-0.66	2.08e-17	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg06618935	chr21:46677482	NA	0.41	5.2	0.42	7.93e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6964587	1.000	rs6964587	chr7:91630620	G/T	cg22709100	chr7:91322751	NA	0.27	4.48	0.37	1.68e-5	Breast cancer;
TGCT	cis	rs2180341	0.781	rs7760652	chr6:127572096	A/G	cg24812749	chr6:127587940	RNF146	0.79	6.6	0.51	1.09e-9	Breast cancer;
TGCT	cis	rs1783925	1.000	rs1783925	chr11:125304009	C/T	cg03464685	chr11:125439445	EI24	0.59	4.94	0.41	2.49e-6	Formal thought disorder in schizophrenia;
TGCT	cis	rs7552404	1.000	rs11161510	chr1:76210289	A/G	cg10523679	chr1:76189770	ACADM	-0.91	-9.9	-0.66	2.26e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9926296	0.572	rs8047581	chr16:89884502	C/T	cg27121462	chr16:89883253	FANCA	0.59	5.77	0.46	6.09e-8	Vitiligo;
TGCT	cis	rs72781680	0.716	rs2712068	chr2:23984000	A/G	cg08917208	chr2:24149416	ATAD2B	0.75	5.04	0.41	1.59e-6	Lymphocyte counts;
TGCT	cis	rs950169	0.881	rs4081123	chr15:84956235	A/G	cg17173187	chr15:85201210	NMB	0.58	5.93	0.47	2.77e-8	Schizophrenia;
TGCT	cis	rs2730245	0.505	rs1188956	chr7:158690576	G/A	cg24397884	chr7:158709396	WDR60	0.39	5.1	0.42	1.23e-6	Height;
TGCT	cis	rs13082711	0.522	rs569960	chr3:27329540	C/T	cg02860705	chr3:27208620	NA	0.34	5.58	0.45	1.43e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg20637647	chr7:64974828	NA	-0.92	-5.09	-0.42	1.26e-6	Diabetic kidney disease;
TGCT	cis	rs7582180	0.614	rs4149518	chr2:101013649	A/G	cg08017756	chr2:100939284	LONRF2	-0.3	-4.73	-0.39	6.02e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7647973	0.588	rs9883000	chr3:49667691	A/G	cg05785598	chr3:49045655	WDR6	0.39	4.67	0.39	7.55e-6	Menarche (age at onset);
TGCT	cis	rs5769765	0.658	rs2157536	chr22:50190180	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.94	-8.64	-0.61	2.38e-14	Schizophrenia;
TGCT	cis	rs739496	0.615	rs649406	chr12:112126065	T/C	cg10833066	chr12:111807467	FAM109A	0.36	5.06	0.41	1.46e-6	Platelet count;
TGCT	cis	rs7267979	0.966	rs2387885	chr20:25415224	G/A	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9427116	0.502	rs9426827	chr1:154589965	T/C	cg17218026	chr1:154582156	ADAR	0.31	7.97	0.58	8.71e-13	Blood protein levels;
TGCT	cis	rs682748	0.846	rs12657901	chr5:17162704	A/G	cg23987134	chr5:17158319	LOC285696	-0.22	-5.37	-0.43	3.82e-7	Hippocampal atrophy;
TGCT	cis	rs7824557	0.628	rs7820301	chr8:11228672	G/A	cg21775007	chr8:11205619	TDH	0.74	7.49	0.56	1.1e-11	Retinal vascular caliber;
TGCT	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg06618935	chr21:46677482	NA	-0.34	-5.32	-0.43	4.78e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs933688	0.938	rs12110065	chr5:90718474	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.99	8.17	0.59	3.05e-13	Smoking behavior;
TGCT	cis	rs9295536	0.620	rs6901879	chr6:22137547	T/C	cg25792714	chr6:21666554	FLJ22536	-0.54	-4.87	-0.4	3.29e-6	Neuroblastoma;
TGCT	cis	rs7267979	0.549	rs11698185	chr20:25181998	T/C	cg14121845	chr20:25566513	NINL	0.42	4.45	0.37	1.85e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg22963979	chr7:1858916	MAD1L1	-0.36	-5.62	-0.45	1.21e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs2032447	0.670	rs198801	chr6:26139741	T/C	cg03264133	chr6:25882463	NA	0.5	4.53	0.38	1.39e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs933688	1.000	rs12654787	chr5:90713259	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.02	8.35	0.6	1.17e-13	Smoking behavior;
TGCT	cis	rs66573146	0.831	rs67665838	chr4:7064870	G/A	cg02503808	chr4:7069936	GRPEL1	-0.88	-4.54	-0.38	1.31e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs2797160	0.651	rs1268067	chr6:126036621	T/C	cg05901451	chr6:126070800	HEY2	0.75	6.71	0.52	6.16e-10	Endometrial cancer;
TGCT	cis	rs2677744	0.626	rs2001216	chr15:91498130	T/C	cg22570213	chr15:91497863	RCCD1	0.38	4.61	0.38	9.98e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs56104184	0.775	rs73061695	chr19:49399988	T/C	cg21252483	chr19:49399788	TULP2	-0.42	-5.89	-0.47	3.47e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs36051895	0.659	rs1575285	chr9:5267440	A/G	cg02405213	chr9:5042618	JAK2	-0.61	-7.53	-0.56	9.03e-12	Pediatric autoimmune diseases;
TGCT	cis	rs9467773	1.000	rs767471	chr6:26557854	C/T	cg26531700	chr6:26746687	NA	0.49	4.73	0.39	6.06e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7100689	0.646	rs6585967	chr10:82139791	A/G	cg01528321	chr10:82214614	TSPAN14	-0.81	-8.55	-0.61	3.8e-14	Post bronchodilator FEV1;
TGCT	cis	rs4808199	1.000	rs17288409	chr19:19504167	T/C	cg03709012	chr19:19516395	GATAD2A	0.97	7.52	0.56	9.52e-12	Nonalcoholic fatty liver disease;
TGCT	cis	rs35306767	0.761	rs11253559	chr10:1044809	T/C	cg18964960	chr10:1102726	WDR37	0.78	5.46	0.44	2.45e-7	Eosinophil percentage of granulocytes;
TGCT	cis	rs11122272	0.735	rs2739513	chr1:231515201	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-6.96	-0.53	1.78e-10	Hemoglobin concentration;
TGCT	cis	rs7474896	0.609	rs11011336	chr10:37985316	A/G	cg25427524	chr10:38739819	LOC399744	-0.31	-4.86	-0.4	3.52e-6	Obesity (extreme);
TGCT	cis	rs10789491	1.000	rs7547522	chr1:47179918	C/G	cg15501359	chr1:47185051	KIAA0494	0.81	8.34	0.6	1.19e-13	Response to hepatitis C treatment;
TGCT	cis	rs13191362	0.688	rs73035006	chr6:162997083	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs9611565	0.512	rs9607842	chr22:42192722	G/A	cg13695892	chr22:41940480	POLR3H	-0.83	-7.85	-0.58	1.69e-12	Vitiligo;
TGCT	cis	rs6840360	0.550	rs62327267	chr4:152518753	G/T	cg17479576	chr4:152424074	FAM160A1	-0.73	-7.94	-0.58	1.03e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs6952809	0.532	rs6953297	chr7:2440874	C/G	cg23289794	chr7:2394357	EIF3B	-0.83	-7.0	-0.53	1.44e-10	Multiple sclerosis;
TGCT	cis	rs9296092	0.517	rs62405895	chr6:33471969	G/T	cg13560919	chr6:33536144	NA	-0.22	-4.49	-0.37	1.6e-5	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs7824557	0.606	rs1047950	chr8:11185096	G/C	cg21775007	chr8:11205619	TDH	0.69	6.62	0.51	9.52e-10	Retinal vascular caliber;
TGCT	cis	rs66573146	0.831	rs56081162	chr4:6989718	C/T	cg05069807	chr4:6945702	TBC1D14	0.31	4.83	0.4	3.91e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs8180040	0.932	rs62248599	chr3:47516728	G/A	cg27129171	chr3:47204927	SETD2	-0.65	-7.68	-0.57	4.2e-12	Colorectal cancer;
TGCT	cis	rs28595532	0.748	rs72670249	chr4:119336823	G/T	cg11846333	chr4:119757529	SEC24D	0.72	4.51	0.38	1.48e-5	Cannabis dependence symptom count;
TGCT	cis	rs832540	0.656	rs2408597	chr5:56098632	G/A	cg24531977	chr5:56204891	C5orf35	-0.51	-5.13	-0.42	1.08e-6	Coronary artery disease;
TGCT	cis	rs17345786	0.798	rs9817043	chr3:101281852	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.45	-10.63	-0.69	3.76e-19	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs13177918	0.677	rs13161156	chr5:149822586	A/G	cg14059543	chr5:149831962	NA	-0.71	-9.46	-0.65	2.58e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs2354432	0.556	rs57388899	chr1:146773422	T/C	cg25205988	chr1:146714368	CHD1L	-1.18	-7.03	-0.53	1.24e-10	Mitochondrial DNA levels;
TGCT	cis	rs4242434	0.927	rs720746	chr8:22471399	T/C	cg21658235	chr8:22456391	C8orf58	0.43	4.5	0.37	1.54e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs881375	0.678	rs10760130	chr9:123701990	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	4.93	0.4	2.56e-6	Rheumatoid arthritis;
TGCT	cis	rs10510102	0.872	rs12246728	chr10:123726133	C/T	cg23691251	chr10:123688108	ATE1	-0.59	-4.7	-0.39	6.75e-6	Breast cancer;
TGCT	trans	rs11250098	0.583	rs36030755	chr8:10816771	G/C	cg06636001	chr8:8085503	FLJ10661	-0.78	-6.96	-0.53	1.77e-10	Morning vs. evening chronotype;
TGCT	cis	rs79349575	0.783	rs12603969	chr17:47034419	A/G	cg26022315	chr17:47021804	SNF8	0.47	4.61	0.38	9.94e-6	Type 2 diabetes;
TGCT	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg13695892	chr22:41940480	POLR3H	-0.92	-9.33	-0.64	5.22e-16	Vitiligo;
TGCT	cis	rs2933343	0.679	rs789229	chr3:128602526	C/T	cg11901034	chr3:128598214	ACAD9	-0.68	-6.63	-0.51	9.16e-10	IgG glycosylation;
TGCT	cis	rs7953249	0.618	rs7954331	chr12:121398657	G/T	cg02403541	chr12:121454288	C12orf43	-0.65	-5.5	-0.44	2.07e-7	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs28595532	0.841	rs115987912	chr4:119737085	C/T	cg21605333	chr4:119757512	SEC24D	1.61	8.95	0.63	4.36e-15	Cannabis dependence symptom count;
TGCT	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.72	-5.71	-0.46	7.86e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs4663866	0.901	rs34040298	chr2:239191607	T/C	cg17283117	chr2:239148619	HES6	1.01	4.66	0.39	8.09e-6	Irritable bowel syndrome;
TGCT	cis	rs4372836	0.505	rs6710082	chr2:28989977	A/C	cg09522027	chr2:28974177	PPP1CB	-0.73	-7.07	-0.54	9.78e-11	Body mass index;
TGCT	cis	rs78487399	0.808	rs7556744	chr2:43672795	C/T	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	-0.72	-4.62	-0.38	9.53e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg05457628	chr5:178986728	RUFY1	0.53	5.85	0.47	4.03e-8	Lung cancer;
TGCT	cis	rs981844	0.848	rs72731652	chr4:154641123	A/T	cg14289246	chr4:154710475	SFRP2	1.01	8.19	0.59	2.76e-13	Response to statins (LDL cholesterol change);
TGCT	cis	rs9486719	0.947	rs2499801	chr6:96854594	G/A	cg06623918	chr6:96969491	KIAA0776	0.98	8.23	0.59	2.13e-13	Migraine;Coronary artery disease;
TGCT	cis	rs11122272	0.735	rs2250719	chr1:231486208	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-6.88	-0.53	2.66e-10	Hemoglobin concentration;
TGCT	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg09323728	chr8:95962352	TP53INP1	-0.52	-6.6	-0.51	1.05e-9	Type 2 diabetes;
TGCT	cis	rs75686122	0.892	rs17805990	chr8:104534025	T/C	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs926938	0.618	rs360617	chr1:115404099	G/A	cg12756093	chr1:115239321	AMPD1	0.4	5.91	0.47	3.1e-8	Autism;
TGCT	cis	rs2303745	0.589	rs751599	chr19:17396549	A/G	cg02221750	chr19:17393354	ANKLE1	-0.48	-6.23	-0.49	6.76e-9	Systemic lupus erythematosus;
TGCT	trans	rs10435719	0.899	rs11250177	chr8:11799099	G/A	cg15556689	chr8:8085844	FLJ10661	0.75	7.07	0.54	9.74e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs644148	0.785	rs117048220	chr19:44965555	G/A	cg15540054	chr19:45004280	ZNF180	0.59	5.34	0.43	4.35e-7	Personality dimensions;
TGCT	cis	rs2486288	0.656	rs2413772	chr15:45549862	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.72	-7.45	-0.56	1.41e-11	Glomerular filtration rate;
TGCT	trans	rs28735056	0.875	rs4239346	chr18:77641226	A/G	cg05926928	chr17:57297772	GDPD1	0.68	7.27	0.55	3.61e-11	Schizophrenia;
TGCT	cis	rs17221829	0.645	rs4753227	chr11:89369102	C/T	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.63	-0.38	9.04e-6	Anxiety in major depressive disorder;
TGCT	cis	rs782590	0.967	rs4290693	chr2:55799991	C/G	cg03859395	chr2:55845619	SMEK2	0.91	11.18	0.71	1.71e-20	Metabolic syndrome;
TGCT	cis	rs739496	0.947	rs28362508	chr12:111884415	T/C	cg10833066	chr12:111807467	FAM109A	0.35	4.75	0.39	5.49e-6	Platelet count;
TGCT	trans	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.82	-8.52	-0.61	4.53e-14	Body mass index;
TGCT	cis	rs9810089	0.802	rs833861	chr3:136231067	T/A	cg12473912	chr3:136751656	NA	0.33	4.79	0.4	4.64e-6	Gestational age at birth (child effect);
TGCT	cis	rs17221829	0.589	rs7930747	chr11:89377160	A/G	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.63	-0.38	9.04e-6	Anxiety in major depressive disorder;
TGCT	cis	rs17384381	1.000	rs12758768	chr1:85835206	C/T	cg16011679	chr1:85725395	C1orf52	0.86	6.78	0.52	4.3e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs60154123	0.730	rs11119455	chr1:210457762	C/T	cg22029157	chr1:209979665	IRF6	0.6	4.46	0.37	1.81e-5	Coronary artery disease;
TGCT	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	5.14	0.42	1.04e-6	Alzheimer's disease;
TGCT	cis	rs9443645	0.901	rs10943612	chr6:79698380	C/T	cg09184832	chr6:79620586	NA	-0.48	-5.34	-0.43	4.21e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs13124904	chr4:98856973	T/C	cg18180107	chr4:99064573	C4orf37	0.55	5.14	0.42	1.03e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs71435601	0.628	rs529697	chr2:21387948	G/T	cg25035485	chr2:21266500	APOB	0.51	4.48	0.37	1.64e-5	Cholesterol, total;
TGCT	cis	rs861020	0.563	rs12046618	chr1:210043135	C/T	cg05527609	chr1:210001259	C1orf107	0.94	7.34	0.55	2.5e-11	Orofacial clefts;
TGCT	cis	rs6121246	0.559	rs6119650	chr20:30258480	C/A	cg13852791	chr20:30311386	BCL2L1	0.81	7.61	0.56	5.85e-12	Mean corpuscular hemoglobin;
TGCT	cis	rs259282	0.602	rs194589	chr19:33144621	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.81	7.96	0.58	9.26e-13	Schizophrenia;
TGCT	cis	rs79349575	0.811	rs1057897	chr17:47005509	T/G	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.52	-0.38	1.44e-5	Type 2 diabetes;
TGCT	cis	rs1371867	0.846	rs1660317	chr8:101333252	G/T	cg06002616	chr8:101225028	SPAG1	-0.56	-6.58	-0.51	1.2e-9	Atrioventricular conduction;
TGCT	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	6.18	0.49	8.58e-9	Bipolar disorder;
TGCT	cis	rs9473924	0.954	rs9463653	chr6:50835180	A/G	cg14470998	chr6:50812995	TFAP2B	0.61	4.48	0.37	1.7e-5	Body mass index;
TGCT	cis	rs6840360	0.571	rs11726892	chr4:152555106	A/G	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.0	-0.58	7.69e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.93	7.44	0.56	1.44e-11	Platelet count;
TGCT	cis	rs6089829	0.851	rs10854168	chr20:61669550	A/G	cg03213289	chr20:61660250	NA	0.72	9.45	0.65	2.69e-16	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg05368731	chr17:41323189	NBR1	1.05	11.93	0.73	2.59e-22	Menopause (age at onset);
TGCT	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.6	-4.9	-0.4	2.93e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs11190604	1.000	rs2495754	chr10:102324812	C/T	cg16342193	chr10:102329863	NA	-0.4	-5.08	-0.42	1.32e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs1472147	1.000	rs4323418	chr7:128506970	C/T	cg00260937	chr7:128520193	KCP	-0.39	-6.01	-0.47	1.92e-8	Calcium levels;
TGCT	cis	rs12049351	0.774	rs12039754	chr1:229644896	G/A	cg12130225	chr1:229698885	NA	0.38	4.46	0.37	1.82e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs854765	0.547	rs2955380	chr17:17944349	A/G	cg09796270	chr17:17721594	SREBF1	-0.24	-4.7	-0.39	6.87e-6	Total body bone mineral density;
TGCT	cis	rs896854	0.684	rs10099941	chr8:95987008	C/T	cg16049864	chr8:95962084	TP53INP1	-0.7	-9.94	-0.67	1.76e-17	Type 2 diabetes;
TGCT	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg01416388	chr22:39784598	NA	0.72	7.4	0.55	1.78e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs2832191	0.716	rs2297252	chr21:30377104	G/A	cg24692254	chr21:30365293	RNF160	0.97	11.36	0.71	6.01e-21	Dental caries;
TGCT	cis	rs7267979	0.844	rs6050477	chr20:25221547	C/T	cg21995068	chr20:25989032	LOC100134868	0.39	4.81	0.4	4.35e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs610932	0.517	rs668287	chr11:59974629	G/T	cg18570331	chr11:60101691	MS4A6E	0.52	4.84	0.4	3.79e-6	Alzheimer's disease;
TGCT	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg12756686	chr19:29218302	NA	0.76	6.52	0.51	1.6e-9	Methadone dose in opioid dependence;
TGCT	cis	rs2456568	0.802	rs10765640	chr11:93636462	C/T	cg26875233	chr11:93583750	C11orf90	-0.48	-6.47	-0.5	2.07e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs3617	0.573	rs62253582	chr3:52928333	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	0.49	4.67	0.39	7.65e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4494114	1.000	rs4388668	chr1:39360730	A/T	cg25970120	chr1:39325951	RRAGC	-0.6	-6.32	-0.49	4.21e-9	Blood protein levels;
TGCT	cis	rs25422	0.887	rs9481844	chr6:118990941	G/A	cg07617317	chr6:118971624	C6orf204	0.44	4.7	0.39	6.74e-6	Renal cell carcinoma;
TGCT	cis	rs74233809	1.000	rs11191514	chr10:104773364	C/T	cg05855489	chr10:104503620	C10orf26	0.74	4.45	0.37	1.87e-5	Birth weight;
TGCT	cis	rs2639990	1.000	rs2639990	chr18:72915551	T/C	cg18449964	chr18:72917101	ZADH2	0.94	6.32	0.49	4.19e-9	Vascular endothelial growth factor levels;
TGCT	cis	rs36051895	0.632	rs1360063	chr9:5167649	A/G	cg02405213	chr9:5042618	JAK2	-0.72	-9.42	-0.65	3.18e-16	Pediatric autoimmune diseases;
TGCT	cis	rs9914544	0.689	rs1634423	chr17:18844736	C/T	cg26306683	chr17:18585705	ZNF286B	0.56	5.23	0.42	7.08e-7	Educational attainment (years of education);
TGCT	cis	rs3784262	0.757	rs74655564	chr15:58325512	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.58	-8.99	-0.63	3.42e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	trans	rs6740731	0.518	rs34586719	chr2:145295647	C/T	cg19463199	chr3:197401858	MIR922;KIAA0226	0.38	6.77	0.52	4.64e-10	Coronary artery disease;
TGCT	cis	rs7098414	0.511	rs12262228	chr10:82160425	C/T	cg00277334	chr10:82204260	NA	-0.38	-4.98	-0.41	2.08e-6	Post bronchodilator FEV1;
TGCT	cis	rs2242116	0.796	rs2290546	chr3:46965197	C/G	cg27129171	chr3:47204927	SETD2	0.66	6.34	0.49	3.88e-9	Birth weight;
TGCT	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.61	5.06	0.41	1.5e-6	Tonsillectomy;
TGCT	cis	rs3820068	0.705	rs74054769	chr1:15860147	A/C	cg05660106	chr1:15850417	CASP9	1.15	13.74	0.78	1.14e-26	Systolic blood pressure;
TGCT	cis	rs4664308	0.935	rs17216980	chr2:160960932	G/A	cg03641300	chr2:160917029	PLA2R1	-0.28	-6.88	-0.53	2.57e-10	Idiopathic membranous nephropathy;
TGCT	cis	rs3799378	0.579	rs9348715	chr6:26375642	C/G	cg05738196	chr6:26577821	NA	-0.53	-5.05	-0.41	1.55e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs12477438	0.501	rs13000731	chr2:99795231	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	10.3	0.68	2.42e-18	Chronic sinus infection;
TGCT	cis	rs807669	0.772	rs809901	chr22:19228736	C/T	cg02655711	chr22:19163373	SLC25A1	0.34	7.43	0.55	1.58e-11	Metabolite levels;
TGCT	cis	rs4595586	0.545	rs6580888	chr12:39369704	C/T	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs1018836	0.923	rs13262354	chr8:91635731	G/A	cg16814680	chr8:91681699	NA	-0.91	-9.92	-0.67	1.98e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs11514810	1.000	rs9648620	chr7:1427980	T/C	cg24899294	chr7:1481343	MICALL2	-0.41	-5.69	-0.46	8.5e-8	Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder;
TGCT	cis	rs9611565	0.649	rs6002480	chr22:42176917	A/T	cg06634786	chr22:41940651	POLR3H	-0.77	-7.17	-0.54	6.02e-11	Vitiligo;
TGCT	cis	rs4704846	1.000	rs6555849	chr5:156529647	A/G	cg12943317	chr5:156479607	HAVCR1	-0.34	-4.75	-0.39	5.43e-6	Blood protein levels;
TGCT	cis	rs7845219	0.539	rs713113	chr8:95877787	C/T	cg16049864	chr8:95962084	TP53INP1	0.54	6.17	0.48	8.74e-9	Type 2 diabetes;
TGCT	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg23758822	chr17:41437982	NA	0.72	6.81	0.52	3.77e-10	Menopause (age at onset);
TGCT	cis	rs28595532	1.000	rs75497896	chr4:119636703	T/C	cg21605333	chr4:119757512	SEC24D	1.36	7.24	0.55	4.12e-11	Cannabis dependence symptom count;
TGCT	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg27170947	chr2:26402098	FAM59B	-0.4	-4.63	-0.38	8.93e-6	Gut microbiome composition (summer);
TGCT	cis	rs514406	0.621	rs928452	chr1:53195926	G/C	cg16325326	chr1:53192061	ZYG11B	-0.89	-13.12	-0.76	3.31e-25	Monocyte count;
TGCT	cis	rs9372498	0.536	rs9320660	chr6:118956827	A/T	cg07617317	chr6:118971624	C6orf204	0.48	5.08	0.42	1.32e-6	Diastolic blood pressure;
TGCT	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs752092	0.894	rs8036083	chr15:101767822	T/G	cg19997662	chr15:101784653	CHSY1	-0.27	-4.85	-0.4	3.62e-6	Corneal structure;
TGCT	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg17554472	chr22:41940697	POLR3H	0.47	4.89	0.4	3.06e-6	Vitiligo;
TGCT	cis	rs9650657	0.504	rs10108347	chr8:11033517	G/C	cg21775007	chr8:11205619	TDH	-0.49	-4.56	-0.38	1.19e-5	Neuroticism;
TGCT	cis	rs763014	0.833	rs916415	chr16:632115	G/A	cg09263875	chr16:632152	PIGQ	0.3	6.4	0.5	2.88e-9	Height;
TGCT	cis	rs12935418	0.616	rs62054239	chr16:81000184	G/T	cg07676361	chr16:80966860	NA	-0.35	-4.56	-0.38	1.19e-5	Mean corpuscular volume;
TGCT	cis	rs1577917	0.958	rs34994386	chr6:86524135	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-5.21	-0.42	7.64e-7	Response to antipsychotic treatment;
TGCT	cis	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg15556689	chr8:8085844	FLJ10661	0.74	7.02	0.53	1.27e-10	Mood instability;
TGCT	cis	rs910316	1.000	rs12879542	chr14:75507525	C/T	cg08847533	chr14:75593920	NEK9	0.96	10.6	0.69	4.36e-19	Height;
TGCT	cis	rs854765	0.624	rs11657423	chr17:17728574	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.69	-6.71	-0.52	6.32e-10	Total body bone mineral density;
TGCT	cis	rs5769765	0.955	rs7511159	chr22:50307896	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.39	5.52	0.44	1.93e-7	Schizophrenia;
TGCT	cis	rs3731896	0.706	rs11886864	chr2:220156531	A/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.71	4.45	0.37	1.87e-5	Educational attainment;
TGCT	trans	rs1005277	0.522	rs289645	chr10:37943642	T/C	cg17830980	chr10:43048298	ZNF37B	-0.65	-6.94	-0.53	1.96e-10	Extrinsic epigenetic age acceleration;
TGCT	cis	rs9611565	0.512	rs6519289	chr22:42170432	A/C	cg03806693	chr22:41940476	POLR3H	1.02	10.49	0.69	7.92e-19	Vitiligo;
TGCT	cis	rs13326165	0.760	rs34523877	chr3:52375711	T/C	cg27565382	chr3:53032988	SFMBT1	0.37	4.9	0.4	2.97e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs7605378	1.000	rs769957	chr2:200695524	A/C	cg23649088	chr2:200775458	C2orf69	0.34	5.53	0.44	1.84e-7	Osteoporosis;
TGCT	cis	rs9859260	0.744	rs3933	chr3:195784997	C/T	cg22891161	chr3:195456627	MUC20	0.23	4.64	0.38	8.64e-6	Mean corpuscular volume;
TGCT	cis	rs13191362	0.507	rs2803051	chr6:163034979	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.61	-5.85	-0.46	4.17e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs12188164	1.000	rs12188164	chr5:428236	C/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.41	-4.77	-0.39	5.03e-6	Cystic fibrosis severity;
TGCT	cis	rs2455799	0.634	rs1584326	chr3:15903951	G/A	cg16303742	chr3:15540471	COLQ	-0.24	-4.64	-0.38	8.68e-6	Mean platelet volume;
TGCT	cis	rs2404602	0.647	rs11072616	chr15:76985269	T/C	cg23625390	chr15:77176239	SCAPER	-0.37	-4.73	-0.39	5.88e-6	Blood metabolite levels;
TGCT	cis	rs524281	0.861	rs10896081	chr11:65880354	A/T	cg00563793	chr11:65837595	PACS1	0.53	4.58	0.38	1.12e-5	Electroencephalogram traits;
TGCT	cis	rs394563	0.591	rs11964335	chr6:149658101	A/T	cg03678062	chr6:149772716	ZC3H12D	0.38	4.83	0.4	3.94e-6	Dupuytren's disease;
TGCT	cis	rs17433780	0.897	rs12142922	chr1:89489915	A/G	cg09516651	chr1:89888402	LOC400759	0.26	4.48	0.37	1.67e-5	Carotid intima media thickness;
TGCT	cis	rs9733	0.519	rs72704603	chr1:150707992	C/T	cg04414720	chr1:150670196	GOLPH3L	0.38	5.0	0.41	1.88e-6	Tonsillectomy;
TGCT	cis	rs8064299	0.934	rs895692	chr17:72766252	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.78	7.84	0.58	1.77e-12	Monocyte count;
TGCT	cis	rs2180341	0.855	rs4308584	chr6:127714874	A/G	cg24812749	chr6:127587940	RNF146	0.79	6.49	0.5	1.9e-9	Breast cancer;
TGCT	cis	rs7772486	0.720	rs702320	chr6:146006654	G/A	cg13319975	chr6:146136371	FBXO30	0.52	4.68	0.39	7.31e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs736408	0.608	rs4687657	chr3:52852538	G/T	cg10802521	chr3:52805072	NEK4	-0.64	-6.51	-0.5	1.69e-9	Bipolar disorder;
TGCT	trans	rs877282	0.853	rs10904545	chr10:757100	G/A	cg22713356	chr15:30763199	NA	1.13	8.3	0.6	1.52e-13	Uric acid levels;
TGCT	cis	rs3774830	0.743	rs11728680	chr4:5462247	A/G	cg26943120	chr4:5472116	STK32B	0.23	5.16	0.42	9.66e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs1865760	0.865	rs4478388	chr6:25953633	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.64	6.31	0.49	4.56e-9	Height;
TGCT	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.51	5.23	0.42	7.05e-7	Lymphocyte counts;
TGCT	cis	rs9435341	0.965	rs3108680	chr1:107572997	T/C	cg09367891	chr1:107599246	PRMT6	0.64	5.6	0.45	1.29e-7	Facial morphology (factor 21, depth of nasal alae);
TGCT	cis	rs1113500	0.814	rs12039712	chr1:108641199	A/G	cg22161131	chr1:109420278	GPSM2	0.5	4.6	0.38	1.04e-5	Growth-regulated protein alpha levels;
TGCT	cis	rs617219	0.596	rs2131977	chr5:78613916	G/C	cg23987322	chr5:78407566	BHMT	-0.36	-4.69	-0.39	7.01e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs782590	0.620	rs7596377	chr2:55888612	T/A	cg03859395	chr2:55845619	SMEK2	-0.75	-6.87	-0.52	2.78e-10	Metabolic syndrome;
TGCT	cis	rs9916302	0.904	rs6503506	chr17:37524653	C/A	cg15445000	chr17:37608096	MED1	-0.33	-4.71	-0.39	6.46e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7949030	0.626	rs7930896	chr11:62325272	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.6	8.46	0.6	6.37e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg17178900	chr1:205818956	PM20D1	0.42	4.7	0.39	6.72e-6	Menarche (age at onset);
TGCT	cis	rs644799	0.965	rs10831426	chr11:95505888	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	8.46	0.6	6.27e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7772486	0.692	rs1577916	chr6:146069789	G/A	cg23711669	chr6:146136114	FBXO30	-0.97	-11.03	-0.7	4.03e-20	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2836974	0.545	rs3167757	chr21:40714478	C/T	cg17971929	chr21:40555470	PSMG1	0.6	5.51	0.44	1.97e-7	Cognitive function;
TGCT	cis	rs988712	0.516	rs6484320	chr11:27703188	T/A	cg10635145	chr11:27742435	BDNF	0.43	6.14	0.48	1.04e-8	Obesity;
TGCT	cis	rs6582630	0.519	rs10880194	chr12:38302836	G/A	cg13010199	chr12:38710504	ALG10B	0.58	4.54	0.38	1.3e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs1008375	0.932	rs4698629	chr4:17608884	C/G	cg18681998	chr4:17616180	MED28	0.73	4.95	0.41	2.4e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6988636	0.710	rs62521805	chr8:124159200	C/T	cg27053337	chr8:124217698	FAM83A	0.67	5.12	0.42	1.11e-6	Urinary uromodulin levels;
TGCT	cis	rs10791097	0.765	rs7943757	chr11:130716157	C/T	cg12179176	chr11:130786555	SNX19	0.63	6.55	0.51	1.39e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs57590327	0.504	rs4856348	chr3:81502923	T/G	cg07356753	chr3:81810745	GBE1	0.58	4.89	0.4	3.06e-6	Extraversion;
TGCT	cis	rs9611565	0.921	rs8137373	chr22:41729216	A/G	cg13695892	chr22:41940480	POLR3H	0.76	7.25	0.55	3.83e-11	Vitiligo;
TGCT	cis	rs28595532	0.844	rs115573749	chr4:119756848	T/A	cg14228332	chr4:119757509	SEC24D	1.29	6.0	0.47	1.98e-8	Cannabis dependence symptom count;
TGCT	cis	rs10893109	0.934	rs7130744	chr11:123801600	A/C	cg14126608	chr11:122846540	NA	-0.3	-4.51	-0.38	1.46e-5	Facial morphology (factor 13, vertical position of alar curvature relative to upper lip);
TGCT	cis	rs11105298	0.891	rs10858869	chr12:89857611	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.7	-5.02	-0.41	1.79e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg03188948	chr7:1209495	NA	0.68	5.8	0.46	5.09e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs17401966	0.809	rs12406943	chr1:10308545	T/C	cg19773385	chr1:10388646	KIF1B	-0.2	-4.5	-0.37	1.54e-5	Hepatocellular carcinoma;
TGCT	cis	rs7666738	0.753	rs2865957	chr4:99040725	G/A	cg17366294	chr4:99064904	C4orf37	0.73	7.49	0.56	1.11e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9394169	0.514	rs1886355	chr6:33776877	C/T	cg00334056	chr6:33755658	LEMD2	-0.24	-4.55	-0.38	1.28e-5	Essential tremor;
TGCT	cis	rs9913156	0.793	rs55782417	chr17:4562845	G/A	cg19197139	chr17:4613644	ARRB2	0.86	7.9	0.58	1.32e-12	Lymphocyte counts;
TGCT	cis	rs7513165	0.935	rs4951319	chr1:204162230	A/G	cg04791601	chr1:204159016	NA	0.24	5.02	0.41	1.77e-6	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
TGCT	cis	rs1670533	1.000	rs1670534	chr4:1087265	T/C	cg27284194	chr4:1044797	NA	0.68	5.95	0.47	2.59e-8	Recombination rate (females);
TGCT	cis	rs6964587	0.967	rs12538325	chr7:91757479	A/G	cg22709100	chr7:91322751	NA	0.28	4.58	0.38	1.1e-5	Breast cancer;
TGCT	cis	rs2721811	0.738	rs1544366	chr7:24758248	A/G	cg17569154	chr7:24781545	DFNA5	0.21	4.54	0.38	1.32e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9646954	0.542	rs4149513	chr2:101022726	C/T	cg08017756	chr2:100939284	LONRF2	-0.3	-4.73	-0.39	5.95e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs727505	0.954	rs2170352	chr7:124605584	G/A	cg23710748	chr7:124431027	NA	-0.26	-4.55	-0.38	1.27e-5	Lewy body disease;
TGCT	cis	rs6693567	0.507	rs9436120	chr1:150473084	T/C	cg09579323	chr1:150459698	TARS2	0.53	4.63	0.38	9.01e-6	Migraine;
TGCT	cis	rs9811920	0.535	rs1610509	chr3:99474327	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.38	-4.63	-0.38	9.01e-6	Axial length;
TGCT	cis	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg02380750	chr20:61661411	NA	0.33	5.96	0.47	2.4e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg11644478	chr21:40555479	PSMG1	1.02	10.86	0.7	1.05e-19	Cognitive function;
TGCT	cis	rs611744	0.647	rs628206	chr8:109247873	A/G	cg21045802	chr8:109455806	TTC35	0.72	7.28	0.55	3.32e-11	Dupuytren's disease;
TGCT	cis	rs7726839	0.540	rs12520279	chr5:657291	T/C	cg16624210	chr5:671434	TPPP	0.41	4.6	0.38	1.02e-5	Obesity-related traits;
TGCT	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg20203395	chr5:56204925	C5orf35	0.51	4.73	0.39	5.91e-6	Initial pursuit acceleration;
TGCT	cis	rs7439150	0.954	rs2059502	chr4:155493319	C/T	cg22130008	chr4:155548532	NA	0.5	6.14	0.48	1.05e-8	Fibrinogen levels;
TGCT	cis	rs2404602	0.655	rs34748201	chr15:77221530	G/T	cg22467129	chr15:76604101	ETFA	-0.5	-5.65	-0.45	1.06e-7	Blood metabolite levels;
TGCT	cis	rs7267979	1.000	rs4815411	chr20:25350223	A/G	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6674176	0.935	rs4314918	chr1:44377503	G/A	cg13606994	chr1:44402422	ARTN	-0.46	-4.71	-0.39	6.45e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs7666738	0.830	rs13149346	chr4:99009933	C/T	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12950390	0.893	rs4794110	chr17:45847230	A/G	cg24803719	chr17:45855879	NA	-0.41	-4.55	-0.38	1.25e-5	IgG glycosylation;
TGCT	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg23719950	chr11:63933701	MACROD1	-0.72	-5.97	-0.47	2.28e-8	Mean platelet volume;
TGCT	cis	rs7089973	0.872	rs10490908	chr10:116616162	T/C	cg03647239	chr10:116582469	FAM160B1	0.52	4.64	0.38	8.75e-6	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs7091068	0.615	rs11187609	chr10:95467031	A/C	cg20715218	chr10:95462985	C10orf4	0.51	4.94	0.41	2.45e-6	Urinary tract infection frequency;
TGCT	cis	rs17376456	0.877	rs9314101	chr5:93461593	A/T	cg21475434	chr5:93447410	FAM172A	0.59	4.66	0.39	8.09e-6	Diabetic retinopathy;
TGCT	cis	rs2439831	0.681	rs524527	chr15:43599116	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	-1.08	-8.94	-0.63	4.46e-15	Lung cancer in ever smokers;
TGCT	cis	rs6684514	0.506	rs3762281	chr1:156304782	A/G	cg16558208	chr1:156270281	VHLL	0.27	4.89	0.4	3.06e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs7513165	0.611	rs34729972	chr1:204159178	A/G	cg04791601	chr1:204159016	NA	0.24	4.43	0.37	2.01e-5	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
TGCT	cis	rs10782582	0.593	rs11163967	chr1:76154185	T/C	cg22875332	chr1:76189707	ACADM	-0.55	-6.35	-0.5	3.77e-9	Daytime sleep phenotypes;
TGCT	cis	rs1046896	0.514	rs9894705	chr17:80823758	A/C	cg03160526	chr17:80928410	B3GNTL1	-0.33	-4.59	-0.38	1.07e-5	Glycated hemoglobin levels;
TGCT	cis	rs7714584	1.000	rs6862814	chr5:150245259	G/A	cg22134413	chr5:150180641	NA	0.83	6.53	0.51	1.54e-9	Crohn's disease;
TGCT	cis	rs7020830	0.931	rs7034554	chr9:37081301	A/G	cg14235030	chr9:37121269	ZCCHC7	0.4	4.47	0.37	1.76e-5	Schizophrenia;
TGCT	cis	rs6867032	0.958	rs4505990	chr5:2015811	A/G	cg26168224	chr5:2018326	NA	0.43	7.96	0.58	9.31e-13	Gut microbiome composition (winter);
TGCT	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg06618935	chr21:46677482	NA	-0.37	-5.64	-0.45	1.1e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2153535	0.541	rs9505456	chr6:8479001	T/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg07424592	chr7:64974309	NA	1.4	8.42	0.6	7.87e-14	Diabetic kidney disease;
TGCT	cis	rs10876993	0.890	rs1082502	chr12:58035706	C/T	cg15848620	chr12:58087721	OS9	-0.72	-5.86	-0.47	3.87e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs7586879	0.559	rs13387729	chr2:25076126	A/G	cg01884057	chr2:25150051	NA	0.3	5.61	0.45	1.26e-7	Body mass index;
TGCT	cis	rs3741404	0.895	rs1860368	chr11:63994692	T/C	cg03236948	chr11:63997492	DNAJC4	-0.39	-4.93	-0.4	2.6e-6	Platelet count;
TGCT	cis	rs4383453	0.539	rs56276445	chr3:123098242	C/A	cg04890266	chr3:123102914	ADCY5	-0.5	-8.3	-0.6	1.48e-13	Gestational age at birth (maternal effect);
TGCT	cis	rs9913156	0.707	rs9902000	chr17:4582426	A/C	cg19197139	chr17:4613644	ARRB2	-0.82	-7.88	-0.58	1.42e-12	Lymphocyte counts;
TGCT	cis	rs8179	0.593	rs73232024	chr7:92277315	G/A	cg15732164	chr7:92237376	CDK6	-0.29	-5.06	-0.41	1.46e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
TGCT	cis	rs7224685	0.569	rs8066580	chr17:3996494	T/C	cg09580393	chr17:4869866	SPAG7	-0.38	-4.48	-0.37	1.64e-5	Type 2 diabetes;
TGCT	cis	rs12711979	0.513	rs7566217	chr2:3851381	A/C	cg17052675	chr2:3827356	NA	-0.26	-4.48	-0.37	1.7e-5	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs478304	0.934	rs603645	chr11:65533000	A/C	cg17480646	chr11:65405466	SIPA1	0.43	5.35	0.43	4.01e-7	Acne (severe);
TGCT	cis	rs7107174	0.688	rs10899501	chr11:78131408	C/T	cg12700464	chr11:78128424	GAB2	-0.67	-4.46	-0.37	1.83e-5	Testicular germ cell tumor;
TGCT	cis	rs6964587	0.967	rs10231350	chr7:91808499	G/T	cg22709100	chr7:91322751	NA	0.29	4.69	0.39	7.08e-6	Breast cancer;
TGCT	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg07507251	chr3:52567010	NT5DC2	0.47	6.95	0.53	1.88e-10	Bipolar disorder;
TGCT	cis	rs3008870	0.959	rs3008852	chr1:67383416	G/A	cg08660285	chr1:67390436	MIER1;WDR78	1.1	12.08	0.74	1.11e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg03709012	chr19:19516395	GATAD2A	-0.66	-5.7	-0.46	8.46e-8	Tonsillectomy;
TGCT	cis	rs76878669	0.515	rs12576299	chr11:66132286	T/C	cg18002602	chr11:66138449	SLC29A2	0.54	6.62	0.51	9.76e-10	Educational attainment (years of education);
TGCT	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg10802521	chr3:52805072	NEK4	-0.72	-9.1	-0.63	1.91e-15	Bipolar disorder;
TGCT	cis	rs4478858	0.735	rs4494186	chr1:31857847	G/A	cg00250761	chr1:31883323	NA	0.24	4.45	0.37	1.91e-5	Alcohol dependence;
TGCT	cis	rs9640161	0.750	rs17173617	chr7:150038023	G/C	cg17279839	chr7:150038598	RARRES2	0.45	4.91	0.4	2.83e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs4917300	0.743	rs34292923	chr8:143094726	G/C	cg08115556	chr8:142137922	DENND3	0.25	4.5	0.37	1.52e-5	Amyotrophic lateral sclerosis;
TGCT	cis	rs12479064	0.604	rs11893359	chr2:99954608	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-4.96	-0.41	2.29e-6	Chronic sinus infection;
TGCT	cis	rs9894429	0.621	rs9747119	chr17:79607017	A/G	cg21028142	chr17:79581711	NPLOC4	0.29	5.95	0.47	2.56e-8	Eye color traits;
TGCT	cis	rs3087591	0.960	rs12942479	chr17:29461912	T/A	cg24425628	chr17:29625626	OMG;NF1	0.47	7.3	0.55	3.03e-11	Hip circumference;
TGCT	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg20276088	chr3:133502917	NA	-0.24	-5.06	-0.41	1.5e-6	Iron status biomarkers;
TGCT	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.67	-0.39	7.73e-6	Prudent dietary pattern;
TGCT	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg03806693	chr22:41940476	POLR3H	-1.13	-13.26	-0.77	1.59e-25	Vitiligo;
TGCT	cis	rs6977660	0.714	rs1468287	chr7:19784210	T/A	cg05791153	chr7:19748676	TWISTNB	0.84	4.86	0.4	3.49e-6	Thyroid stimulating hormone;
TGCT	cis	rs3740393	0.562	rs11191393	chr10:104527430	C/G	cg05855489	chr10:104503620	C10orf26	-0.77	-6.34	-0.49	3.94e-9	Microalbuminuria;
TGCT	cis	rs9325144	0.534	rs1973293	chr12:38679575	C/T	cg13010199	chr12:38710504	ALG10B	0.53	4.72	0.39	6.36e-6	Morning vs. evening chronotype;
TGCT	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg04772025	chr11:68637568	NA	0.61	6.53	0.51	1.51e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg27121462	chr16:89883253	FANCA	0.77	8.39	0.6	8.98e-14	Vitiligo;
TGCT	cis	rs12220238	0.818	rs16931294	chr10:75999169	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.92	7.91	0.58	1.2e-12	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs4727027	0.834	rs7811446	chr7:148773226	G/T	cg23583168	chr7:148888333	NA	-0.69	-8.67	-0.61	2.04e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg06108461	chr20:60628389	TAF4	-0.36	-4.44	-0.37	1.96e-5	Obesity-related traits;
TGCT	cis	rs7267979	1.000	rs2257496	chr20:25279315	A/G	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10782582	0.593	rs11801414	chr1:76124517	G/A	cg10523679	chr1:76189770	ACADM	-0.7	-7.51	-0.56	9.94e-12	Daytime sleep phenotypes;
TGCT	cis	rs6835098	0.961	rs2078475	chr4:174098226	A/C	cg08422745	chr4:174089978	GALNT7	0.89	9.06	0.63	2.41e-15	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs60871478	0.898	rs62432225	chr7:789433	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.49	4.68	0.39	7.47e-6	Cerebrospinal P-tau181p levels;
TGCT	trans	rs7618501	0.699	rs2777888	chr3:49898000	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.93	10.31	0.68	2.22e-18	Intelligence (multi-trait analysis);
TGCT	cis	rs3820928	0.605	rs6718767	chr2:227800776	A/G	cg11843606	chr2:227700838	RHBDD1	-0.51	-4.82	-0.4	4.1e-6	Pulmonary function;
TGCT	cis	rs4788570	0.584	rs6499528	chr16:71672762	T/C	cg06353428	chr16:71660113	MARVELD3	1.54	12.33	0.74	2.73e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg24578937	chr1:2090814	PRKCZ	0.26	6.52	0.51	1.63e-9	Height;
TGCT	trans	rs9650657	0.513	rs4314618	chr8:10816772	A/G	cg15556689	chr8:8085844	FLJ10661	-0.93	-9.85	-0.66	2.99e-17	Neuroticism;
TGCT	cis	rs12477438	0.520	rs6741773	chr2:99738962	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	12.85	0.76	1.49e-24	Chronic sinus infection;
TGCT	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg07061783	chr6:25882402	NA	-0.42	-4.51	-0.38	1.51e-5	Blood metabolite levels;
TGCT	cis	rs1215050	0.791	rs165244	chr4:98687889	C/T	cg05340658	chr4:99064831	C4orf37	0.45	5.57	0.45	1.48e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs62244186	0.541	rs62244226	chr3:44831831	G/A	cg04389838	chr3:44770851	ZNF501	-0.37	-4.77	-0.39	4.99e-6	Depressive symptoms;
TGCT	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-5.1	-0.42	1.23e-6	Electroencephalogram traits;
TGCT	cis	rs1062177	0.756	rs2964587	chr5:151119972	C/T	cg12924095	chr5:151150029	G3BP1	-0.34	-4.97	-0.41	2.17e-6	Preschool internalizing problems;
TGCT	cis	rs9346649	0.630	rs4708641	chr6:168491416	G/A	cg02770688	chr6:168491649	NA	0.34	6.05	0.48	1.6e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
TGCT	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.71	0.39	6.53e-6	Prudent dietary pattern;
TGCT	cis	rs66573146	0.572	rs67750430	chr4:6957266	T/G	cg00086871	chr4:6988644	TBC1D14	0.88	4.62	0.38	9.39e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs6121246	0.609	rs6060627	chr20:30262159	C/T	cg13852791	chr20:30311386	BCL2L1	0.8	7.55	0.56	8e-12	Mean corpuscular hemoglobin;
TGCT	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg13395646	chr4:1353034	KIAA1530	-0.55	-7.57	-0.56	7.56e-12	Obesity-related traits;
TGCT	cis	rs514406	0.505	rs440871	chr1:53173052	C/T	cg01802117	chr1:53393560	SCP2	-0.38	-4.44	-0.37	1.98e-5	Monocyte count;
TGCT	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg16423285	chr20:60520624	NA	-0.6	-6.41	-0.5	2.76e-9	Body mass index;
TGCT	cis	rs939658	0.626	rs11636901	chr15:79446292	T/C	cg17916960	chr15:79447300	NA	-0.44	-6.1	-0.48	1.28e-8	Refractive error;
TGCT	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg19626725	chr5:178986131	RUFY1	0.49	6.08	0.48	1.38e-8	Lung cancer;
TGCT	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg09359103	chr1:154839909	KCNN3	-0.72	-15.03	-0.8	1.01e-29	Prostate cancer;
TGCT	cis	rs11077773	1.000	rs11077773	chr17:73060073	C/T	cg27626185	chr17:73056755	KCTD2	0.64	5.57	0.45	1.47e-7	Information processing speed;
TGCT	cis	rs3820068	0.603	rs6429769	chr1:15968610	C/G	cg05660106	chr1:15850417	CASP9	0.79	7.91	0.58	1.23e-12	Systolic blood pressure;
TGCT	cis	rs7523050	0.643	rs12736534	chr1:109399934	T/C	cg08274380	chr1:109419600	GPSM2	1.3	6.39	0.5	2.99e-9	Fat distribution (HIV);
TGCT	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg11494091	chr17:61959527	GH2	0.61	14.81	0.8	3.37e-29	Prudent dietary pattern;
TGCT	cis	rs344364	0.511	rs1742469	chr16:1950244	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.45	-5.08	-0.42	1.35e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs651907	0.588	rs1672380	chr3:101633171	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.5	4.79	0.4	4.65e-6	Colorectal cancer;
TGCT	cis	rs78487399	0.808	rs17030845	chr2:43687879	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-5.19	-0.42	8.37e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs765787	0.530	rs11636410	chr15:45535913	A/C	cg24006582	chr15:45444508	DUOX1	0.25	5.53	0.44	1.8e-7	Uric acid levels;
TGCT	cis	rs7666738	0.830	rs34135615	chr4:99001325	C/T	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9902453	0.817	rs4294865	chr17:28205736	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	6.12	0.48	1.15e-8	Coffee consumption (cups per day);
TGCT	cis	rs7000551	0.646	rs2979302	chr8:22359156	G/A	cg12081754	chr8:22256438	SLC39A14	0.28	4.6	0.38	1.04e-5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs7772486	0.622	rs1292333	chr6:145982344	C/T	cg13319975	chr6:146136371	FBXO30	0.52	4.8	0.4	4.54e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9291683	0.588	rs6857693	chr4:10018435	G/A	cg00071950	chr4:10020882	SLC2A9	0.75	10.33	0.68	2.04e-18	Bone mineral density;
TGCT	cis	rs2439831	0.867	rs2412778	chr15:43660982	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	6.61	0.51	1e-9	Lung cancer in ever smokers;
TGCT	cis	rs12519773	0.501	rs10428523	chr5:92536365	G/A	cg04854328	chr5:92914828	FLJ42709	-0.3	-4.58	-0.38	1.12e-5	Migraine;
TGCT	cis	rs6740322	0.793	rs13414908	chr2:43546658	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.42	-6.85	-0.52	3.13e-10	Coronary artery disease;
TGCT	cis	rs9972944	0.756	rs6504349	chr17:63764140	G/A	cg07283582	chr17:63770753	CCDC46	-0.26	-5.3	-0.43	5.02e-7	Total body bone mineral density;
TGCT	cis	rs7267979	0.868	rs6138550	chr20:25223430	C/T	cg16686733	chr20:25566563	NINL	0.59	6.06	0.48	1.53e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs208515	0.556	rs12206707	chr6:66697182	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.93	10.33	0.68	1.96e-18	Exhaled nitric oxide levels;
TGCT	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg14773178	chr5:1868261	NA	0.3	5.12	0.42	1.12e-6	Cardiovascular disease risk factors;
TGCT	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg08280861	chr8:58055591	NA	0.32	4.49	0.37	1.63e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs6430585	0.528	rs75667274	chr2:136682486	C/T	cg07169764	chr2:136633963	MCM6	1.24	12.13	0.74	8.21e-23	Corneal structure;
TGCT	cis	rs42648	0.623	rs194505	chr7:89841307	G/A	cg25739043	chr7:89950458	NA	-0.53	-4.92	-0.4	2.68e-6	Homocysteine levels;
TGCT	cis	rs1541995	1.000	rs4984609	chr15:96349079	G/A	cg00882281	chr15:96346592	NA	0.29	4.8	0.4	4.46e-6	Photic sneeze reflex;
TGCT	cis	rs992157	0.965	rs13427681	chr2:219167563	G/C	cg00012203	chr2:219082015	ARPC2	0.78	8.4	0.6	8.9e-14	Colorectal cancer;
TGCT	cis	rs11098499	0.754	rs10213267	chr4:120239074	A/G	cg09307838	chr4:120376055	NA	0.61	5.91	0.47	3.14e-8	Corneal astigmatism;
TGCT	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg06481639	chr22:41940642	POLR3H	-0.74	-6.74	-0.52	5.38e-10	Vitiligo;
TGCT	cis	rs3091242	0.900	rs35345536	chr1:25766488	A/G	cg10117171	chr1:25599238	RHD	-0.33	-5.44	-0.44	2.77e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs617219	0.671	rs13165414	chr5:78548873	C/T	cg05890484	chr5:78407552	BHMT	0.34	4.63	0.38	9.24e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs1784581	0.599	rs1789992	chr6:162401854	A/G	cg17173639	chr6:162384350	PARK2	-0.46	-8.02	-0.58	6.6e-13	Itch intensity from mosquito bite;
TGCT	cis	rs1975974	0.511	rs112710683	chr17:21741695	C/A	cg18423549	chr17:21743878	NA	-0.69	-6.64	-0.51	8.59e-10	Psoriasis;
TGCT	cis	rs9926296	0.656	rs7191144	chr16:89823393	C/T	cg27121462	chr16:89883253	FANCA	0.5	4.62	0.38	9.49e-6	Vitiligo;
TGCT	cis	rs796364	0.760	rs56225698	chr2:200910653	A/C	cg17644776	chr2:200775616	C2orf69	-0.33	-5.0	-0.41	1.91e-6	Schizophrenia;
TGCT	cis	rs9527	0.830	rs10883790	chr10:104640955	A/C	cg15744005	chr10:104629667	AS3MT	-0.51	-6.04	-0.48	1.63e-8	Arsenic metabolism;
TGCT	cis	rs4851254	0.660	rs60697219	chr2:100699507	G/A	cg22139774	chr2:100720529	AFF3	-0.43	-4.76	-0.39	5.4e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7617773	0.823	rs9839447	chr3:48194667	T/C	cg11946769	chr3:48343235	NME6	-0.61	-5.45	-0.44	2.6e-7	Coronary artery disease;
TGCT	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.18	0.49	8.32e-9	Electroencephalogram traits;
TGCT	cis	rs877282	0.842	rs35117541	chr10:764683	C/T	cg17470449	chr10:769945	NA	0.37	5.59	0.45	1.37e-7	Uric acid levels;
TGCT	cis	rs2235642	0.859	rs9927529	chr16:1619488	C/T	cg10465839	chr16:1584050	IFT140;TMEM204	-0.32	-4.92	-0.4	2.68e-6	Coronary artery disease;
TGCT	cis	rs903263	0.965	rs10874428	chr1:84560010	G/A	cg09664975	chr1:84543551	PRKACB	0.49	4.6	0.38	1.01e-5	Breast cancer (male);
TGCT	cis	rs7412746	0.658	rs10305704	chr1:150804429	A/C	cg04414720	chr1:150670196	GOLPH3L	0.38	4.69	0.39	7.01e-6	Melanoma;
TGCT	cis	rs1577917	0.958	rs36053156	chr6:86575509	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.42	-0.44	3.02e-7	Response to antipsychotic treatment;
TGCT	cis	rs7584330	0.666	rs937386	chr2:238364039	C/T	cg14458575	chr2:238380390	NA	0.59	8.82	0.62	8.92e-15	Prostate cancer;
TGCT	cis	rs208520	0.874	rs208485	chr6:66925654	T/C	cg07460842	chr6:66804631	NA	-0.94	-9.3	-0.64	6.32e-16	Exhaled nitric oxide output;
TGCT	cis	rs9942416	0.660	rs41534344	chr5:74997832	T/C	cg02573091	chr5:74908125	NA	0.38	4.51	0.38	1.47e-5	Age-related disease endophenotypes;
TGCT	cis	rs9818758	0.607	rs34326553	chr3:49134429	A/G	cg07636037	chr3:49044803	WDR6	-1.04	-5.16	-0.42	9.65e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs2404602	0.684	rs1011083	chr15:77007527	C/T	cg23625390	chr15:77176239	SCAPER	-0.38	-4.82	-0.4	4.05e-6	Blood metabolite levels;
TGCT	cis	rs9653442	0.564	rs11123809	chr2:100758137	C/T	cg22139774	chr2:100720529	AFF3	-0.36	-5.62	-0.45	1.21e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs3796352	1.000	rs3097417	chr3:53088601	C/G	cg27565382	chr3:53032988	SFMBT1	-0.42	-4.69	-0.39	7.17e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs2204008	0.754	rs11181643	chr12:38380553	G/A	cg13010199	chr12:38710504	ALG10B	0.59	4.64	0.38	8.86e-6	Bladder cancer;
TGCT	cis	rs6669072	0.739	rs3843305	chr1:91243376	G/A	cg08895590	chr1:91227319	NA	-0.35	-4.65	-0.39	8.28e-6	Cognitive function;
TGCT	cis	rs9902453	0.904	rs55633288	chr17:28368196	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.81	-7.67	-0.57	4.37e-12	Coffee consumption (cups per day);
TGCT	cis	rs12893668	0.638	rs11851616	chr14:104065600	G/A	cg26031613	chr14:104095156	KLC1	-0.55	-4.64	-0.38	8.81e-6	Reticulocyte count;
TGCT	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg06873352	chr17:61820015	STRADA	-0.58	-6.46	-0.5	2.16e-9	Prudent dietary pattern;
TGCT	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.84	7.5	0.56	1.08e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7226408	0.857	rs1365511	chr18:34425998	G/T	cg06757138	chr18:34340585	FHOD3	0.26	5.05	0.41	1.56e-6	Obesity-related traits;
TGCT	cis	rs7178572	1.000	rs7178572	chr15:77747190	A/G	cg15453836	chr15:77711506	NA	-0.4	-4.59	-0.38	1.07e-5	Type 2 diabetes;
TGCT	cis	rs2180341	0.576	rs2057224	chr6:127624414	C/G	cg27446573	chr6:127587934	RNF146	0.65	5.79	0.46	5.52e-8	Breast cancer;
TGCT	cis	rs7072216	0.763	rs6584205	chr10:100173806	C/T	cg26618903	chr10:100175079	PYROXD2	-0.4	-4.49	-0.37	1.64e-5	Metabolite levels;
TGCT	cis	rs2948294	0.545	rs11776397	chr8:8115161	C/T	cg15462221	chr8:8086144	FLJ10661	-0.6	-5.1	-0.42	1.23e-6	Red cell distribution width;
TGCT	cis	rs3796352	1.000	rs75217232	chr3:53132373	A/C	cg15956490	chr3:53032818	SFMBT1	0.54	6.37	0.5	3.42e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs11190604	1.000	rs11190541	chr10:102203071	A/G	cg23241863	chr10:102295624	HIF1AN	0.62	4.87	0.4	3.27e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs483180	0.512	rs597308	chr1:120214953	G/A	cg19096424	chr1:120255104	PHGDH	0.56	5.26	0.43	6.1e-7	Macular telangiectasia type 2;
TGCT	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg18230493	chr5:56204884	C5orf35	-0.68	-5.92	-0.47	2.92e-8	Initial pursuit acceleration;
TGCT	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg06618935	chr21:46677482	NA	-0.37	-5.81	-0.46	5.06e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs4929949	0.688	rs10769905	chr11:8441716	C/T	cg14521421	chr11:8862019	ST5	0.31	4.66	0.39	8.03e-6	Body mass index;
TGCT	cis	rs9653442	0.527	rs12712064	chr2:100756548	C/T	cg22139774	chr2:100720529	AFF3	-0.36	-5.56	-0.45	1.55e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs9296092	0.517	rs9461876	chr6:33516657	C/T	cg13560919	chr6:33536144	NA	-0.2	-4.63	-0.38	9.08e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs3784262	0.528	rs4553566	chr15:58336319	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.43	-6.38	-0.5	3.14e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs7809950	0.723	rs62483634	chr7:106878516	G/A	cg23024343	chr7:107201750	COG5	-0.44	-6.26	-0.49	5.66e-9	Coronary artery disease;
TGCT	cis	rs1113500	0.527	rs1777482	chr1:108611374	C/G	cg22161131	chr1:109420278	GPSM2	-0.51	-4.52	-0.38	1.43e-5	Growth-regulated protein alpha levels;
TGCT	cis	rs7822232	1.000	rs7822232	chr8:145145687	A/C	cg06239191	chr8:145163136	KIAA1875	-0.62	-5.71	-0.46	7.88e-8	Blood metabolite levels;
TGCT	cis	rs1215050	0.755	rs2952911	chr4:98850666	T/C	cg17366294	chr4:99064904	C4orf37	-0.57	-6.12	-0.48	1.13e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs908922	0.651	rs6671924	chr1:152485830	T/C	cg20991723	chr1:152506922	NA	0.47	6.64	0.51	8.74e-10	Hair morphology;
TGCT	cis	rs13191362	1.000	rs34653853	chr6:163114362	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.99	8.17	0.59	3.08e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs6591182	0.504	rs7130955	chr11:65372580	C/T	cg12758867	chr11:65354231	EHBP1L1	0.25	4.88	0.4	3.19e-6	Non-alcoholic fatty liver disease histology (lobular);
TGCT	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg11366901	chr6:160182831	ACAT2	0.96	6.28	0.49	5.21e-9	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg26818010	chr10:134567672	INPP5A	-0.38	-5.19	-0.42	8.5e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs6558530	0.932	rs7842425	chr8:1706041	G/T	cg09410841	chr8:1729607	CLN8	0.85	9.29	0.64	6.66e-16	Systolic blood pressure;
TGCT	cis	rs858239	0.537	rs2286272	chr7:23224367	T/C	cg05602783	chr7:23145260	KLHL7	-0.71	-5.55	-0.45	1.68e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	5.19	0.42	8.51e-7	Tonsillectomy;
TGCT	cis	rs67311347	0.577	rs1880763	chr3:40283255	C/T	cg13683864	chr3:40499215	RPL14	0.79	7.49	0.56	1.12e-11	Renal cell carcinoma;
TGCT	cis	rs2730260	0.500	rs73169244	chr7:158887293	T/C	cg27122614	chr7:157913741	PTPRN2	0.42	4.47	0.37	1.74e-5	Myopia (pathological);
TGCT	cis	rs2299587	0.560	rs3913555	chr8:17781810	A/C	cg01800426	chr8:17659068	MTUS1	-0.64	-5.52	-0.44	1.91e-7	Economic and political preferences;
TGCT	cis	rs4478858	0.735	rs12126725	chr1:31805853	G/T	cg07478791	chr1:31886160	SERINC2	-0.51	-4.95	-0.41	2.33e-6	Alcohol dependence;
TGCT	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg11494091	chr17:61959527	GH2	0.6	14.54	0.79	1.46e-28	Prudent dietary pattern;
TGCT	cis	rs7824557	0.525	rs12682349	chr8:11245303	C/G	cg21775007	chr8:11205619	TDH	0.72	7.39	0.55	1.94e-11	Retinal vascular caliber;
TGCT	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg00024416	chr22:24240387	NA	0.25	4.74	0.39	5.74e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs11098499	0.954	rs3890049	chr4:120326283	T/A	cg09307838	chr4:120376055	NA	0.68	6.53	0.51	1.54e-9	Corneal astigmatism;
TGCT	cis	rs2354432	0.546	rs7539416	chr1:146881586	C/T	cg25205988	chr1:146714368	CHD1L	1.21	7.72	0.57	3.34e-12	Mitochondrial DNA levels;
TGCT	cis	rs301043	0.697	rs2596779	chr12:95845962	A/G	cg07805603	chr12:95869602	METAP2	0.33	4.5	0.37	1.52e-5	Immature fraction of reticulocytes;
TGCT	cis	rs3749237	1.000	rs4768	chr3:49758764	A/G	cg03060546	chr3:49711283	APEH	0.74	7.6	0.56	6.37e-12	Resting heart rate;
TGCT	cis	rs6542838	0.580	rs1607256	chr2:99543444	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.55	-5.25	-0.43	6.43e-7	Fear of minor pain;
TGCT	cis	rs1580019	0.537	rs7804609	chr7:32558094	A/C	cg07520158	chr7:32535189	LSM5;AVL9	0.56	4.86	0.4	3.42e-6	Cognitive ability;
TGCT	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg03264133	chr6:25882463	NA	-0.9	-8.74	-0.62	1.39e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs28485415	chr4:99060340	G/A	cg17366294	chr4:99064904	C4orf37	0.73	7.45	0.56	1.4e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg18230493	chr5:56204884	C5orf35	0.86	6.85	0.52	3.07e-10	Initial pursuit acceleration;
TGCT	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	5.23	0.43	6.92e-7	Menopause (age at onset);
TGCT	cis	rs2469997	0.748	rs2470019	chr8:120362558	T/C	cg00681363	chr8:120844660	TAF2	0.69	4.48	0.37	1.64e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs10032931	0.962	rs1385671	chr4:96455967	C/T	cg03008707	chr4:96468962	UNC5C	-0.34	-4.78	-0.39	4.79e-6	Optic nerve measurement (cup-to-disc ratio);
TGCT	cis	rs611744	0.839	rs638238	chr8:109169152	A/G	cg21045802	chr8:109455806	TTC35	0.69	6.06	0.48	1.51e-8	Dupuytren's disease;
TGCT	cis	rs2549003	1.000	rs2070723	chr5:131823187	A/G	cg21138405	chr5:131827807	IRF1	0.18	4.58	0.38	1.11e-5	Asthma (sex interaction);
TGCT	cis	rs11107903	1.000	rs12372152	chr12:95520064	A/G	cg10621809	chr12:95840313	NA	0.68	5.04	0.41	1.57e-6	Coronary artery disease;
TGCT	cis	rs10510102	0.688	rs74570569	chr10:123704862	G/A	cg23691251	chr10:123688108	ATE1	-0.58	-4.58	-0.38	1.11e-5	Breast cancer;
TGCT	cis	rs2594989	0.943	rs2454502	chr3:11499331	T/C	cg00170343	chr3:11313890	ATG7	0.69	5.12	0.42	1.16e-6	Circulating chemerin levels;
TGCT	cis	rs4888262	0.604	rs12935075	chr16:74676033	A/T	cg01733217	chr16:74700730	RFWD3	0.73	7.26	0.55	3.68e-11	Testicular germ cell tumor;
TGCT	cis	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg07424592	chr7:64974309	NA	1.36	8.15	0.59	3.36e-13	Diabetic kidney disease;
TGCT	cis	rs4699052	0.826	rs17033498	chr4:104179961	C/G	cg16532752	chr4:104119610	CENPE	-0.56	-5.09	-0.42	1.28e-6	Testicular germ cell tumor;
TGCT	cis	rs950169	0.922	rs11635505	chr15:85097034	A/C	cg11189052	chr15:85197271	WDR73	-0.77	-6.42	-0.5	2.68e-9	Schizophrenia;
TGCT	cis	rs6840360	0.554	rs6849111	chr4:152708874	T/C	cg17479576	chr4:152424074	FAM160A1	-0.51	-5.22	-0.42	7.21e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7267979	0.933	rs2424708	chr20:25281398	C/T	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs8033133	0.836	rs11634716	chr15:25306646	C/T	cg14481604	chr15:25334117	SNORD116-22	0.23	4.73	0.39	5.93e-6	Blood osmolality (transformed sodium);
TGCT	cis	rs16958440	0.609	rs75911383	chr18:44716011	C/T	cg17192377	chr18:44677553	HDHD2	0.63	4.7	0.39	6.74e-6	Sitting height ratio;
TGCT	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg26513180	chr16:89883248	FANCA	1.06	14.66	0.8	7.38e-29	Vitiligo;
TGCT	cis	rs10949834	0.504	rs12539781	chr7:73568425	C/T	cg07137043	chr7:73588983	EIF4H	-0.72	-5.58	-0.45	1.45e-7	Verbal memory performance (residualized delayed recall change);
TGCT	cis	rs3806843	0.576	rs246005	chr5:140339884	A/C	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7027203	0.759	rs10761282	chr9:96586175	G/A	cg13679303	chr9:96623674	NA	-0.65	-10.05	-0.67	9.45e-18	DNA methylation (variation);
TGCT	cis	rs12765878	1.000	rs61277100	chr10:105643352	A/G	cg11005552	chr10:105648138	OBFC1	0.44	7.6	0.56	6.24e-12	Coronary artery disease;
TGCT	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg13607699	chr17:42295918	UBTF	-0.84	-7.55	-0.56	8.34e-12	Total body bone mineral density;
TGCT	cis	rs7772486	0.594	rs6901864	chr6:146023050	C/A	cg05347473	chr6:146136440	FBXO30	-0.52	-4.81	-0.4	4.26e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7226408	0.842	rs17652345	chr18:34391493	T/C	cg06757138	chr18:34340585	FHOD3	0.26	4.79	0.4	4.62e-6	Obesity-related traits;
TGCT	cis	rs12950390	0.853	rs8071192	chr17:45856141	A/G	cg03474202	chr17:45855739	NA	-0.44	-4.51	-0.38	1.5e-5	IgG glycosylation;
TGCT	cis	rs7681440	0.904	rs7680761	chr4:90763510	A/T	cg26578617	chr4:90757533	SNCA	-0.49	-5.1	-0.42	1.26e-6	Dementia with Lewy bodies;
TGCT	cis	rs367943	0.966	rs348945	chr5:112822889	C/T	cg12552261	chr5:112820674	MCC	-0.24	-4.91	-0.4	2.81e-6	Type 2 diabetes;
TGCT	cis	rs11112613	0.713	rs73184081	chr12:105951745	C/T	cg03607813	chr12:105948248	NA	0.47	5.72	0.46	7.49e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	cis	rs524023	0.874	rs519090	chr11:64456240	G/C	cg19395706	chr11:64412079	NRXN2	-0.36	-4.44	-0.37	1.96e-5	Urate levels in obese individuals;
TGCT	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg00814883	chr7:100076585	TSC22D4	-0.52	-5.14	-0.42	1.06e-6	Lung function (FEV1/FVC);
TGCT	cis	rs9653442	0.675	rs12995420	chr2:100652578	T/C	cg07810366	chr2:100720526	AFF3	-0.4	-6.59	-0.51	1.14e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs799165	1.000	rs799166	chr7:73051932	C/G	cg14087351	chr7:73037990	MLXIPL	-0.6	-4.44	-0.37	1.99e-5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
TGCT	cis	rs9467773	0.620	rs2451738	chr6:26618459	A/T	cg26531700	chr6:26746687	NA	-0.53	-5.14	-0.42	1.04e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg08280861	chr8:58055591	NA	0.39	4.86	0.4	3.45e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7264396	0.790	rs1040695	chr20:34244829	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.28	-4.68	-0.39	7.38e-6	Total cholesterol levels;
TGCT	cis	rs34014631	0.901	rs80213387	chr10:103717673	G/A	cg22630918	chr10:102748988	C10orf2	0.42	4.78	0.39	4.86e-6	Coronary artery calcification;
TGCT	cis	rs4563143	0.514	rs73029076	chr19:29292032	G/T	cg12756686	chr19:29218302	NA	0.67	5.16	0.42	9.34e-7	Methadone dose in opioid dependence;
TGCT	cis	rs2486288	0.656	rs11854365	chr15:45558083	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.45	-5.34	-0.43	4.26e-7	Glomerular filtration rate;
TGCT	cis	rs2153535	0.580	rs2183112	chr6:8528212	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.55e-8	Motion sickness;
TGCT	cis	rs36051895	0.695	rs10974922	chr9:5028813	C/T	cg02405213	chr9:5042618	JAK2	-0.83	-12.17	-0.74	6.58e-23	Pediatric autoimmune diseases;
TGCT	cis	rs62244186	0.714	rs2293600	chr3:44599103	G/T	cg04389838	chr3:44770851	ZNF501	0.42	5.7	0.46	8.29e-8	Depressive symptoms;
TGCT	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg20891283	chr12:69753455	YEATS4	0.9	10.24	0.68	3.28e-18	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs2485376	0.842	rs7077329	chr10:104161967	T/C	cg26089160	chr10:104170217	PSD	-0.52	-5.13	-0.42	1.09e-6	QT interval;
TGCT	trans	rs17685	0.753	rs1639617	chr7:75701728	A/G	cg19862616	chr7:65841803	NCRNA00174	0.51	8.59	0.61	3.07e-14	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs3820928	0.874	rs10189579	chr2:227864876	A/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-4.63	-0.38	9.03e-6	Pulmonary function;
TGCT	cis	rs6582630	0.502	rs7311700	chr12:38463232	T/A	cg26384229	chr12:38710491	ALG10B	0.88	8.04	0.59	5.98e-13	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg24549020	chr5:56110836	MAP3K1	0.67	5.78	0.46	5.74e-8	Initial pursuit acceleration;
TGCT	cis	rs933688	1.000	rs332531	chr5:90790451	G/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.94	8.24	0.59	2.07e-13	Smoking behavior;
TGCT	cis	rs9733	0.596	rs6669369	chr1:150695892	C/T	cg09365446	chr1:150670422	GOLPH3L	0.3	4.52	0.38	1.4e-5	Tonsillectomy;
TGCT	cis	rs854765	0.583	rs4925123	chr17:17784374	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.74	-7.86	-0.58	1.61e-12	Total body bone mineral density;
TGCT	trans	rs11722228	0.508	rs3796825	chr4:10092879	T/A	cg26043149	chr18:55253948	FECH	1.16	11.23	0.71	1.26e-20	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg25703541	chr22:24373054	LOC391322	0.84	7.14	0.54	6.85e-11	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs7953249	0.807	rs2393775	chr12:121424574	G/A	cg02403541	chr12:121454288	C12orf43	-0.53	-4.56	-0.38	1.23e-5	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
TGCT	trans	rs10203711	0.933	rs4994754	chr2:239567218	A/G	cg16021909	chr1:248021091	TRIM58	-0.66	-6.66	-0.51	7.94e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10465746	0.967	rs11163868	chr1:84397013	T/G	cg10977910	chr1:84465055	TTLL7	0.63	6.25	0.49	5.95e-9	Obesity-related traits;
TGCT	cis	rs7246657	0.943	rs7252099	chr19:37933780	G/A	cg18154014	chr19:37997991	ZNF793	0.95	6.52	0.51	1.58e-9	Coronary artery calcification;
TGCT	cis	rs912057	0.526	rs737449	chr6:6733729	A/G	cg06612196	chr6:6737390	NA	-0.47	-6.82	-0.52	3.61e-10	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs9486719	1.000	rs12208884	chr6:96885572	G/A	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.86	-0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs7216064	1.000	rs62084213	chr17:65842016	A/G	cg12091567	chr17:66097778	LOC651250	-0.83	-6.49	-0.5	1.9e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs10256972	0.721	rs10435145	chr7:1065988	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.46	-5.46	-0.44	2.52e-7	Longevity;Endometriosis;
TGCT	cis	rs9467773	1.000	rs6456734	chr6:26566965	G/T	cg09904177	chr6:26538194	HMGN4	0.69	6.84	0.52	3.23e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs7312933	0.585	rs7969814	chr12:42669657	C/G	cg19980929	chr12:42632907	YAF2	0.41	5.81	0.46	4.91e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs858239	0.600	rs6461690	chr7:23135534	A/G	cg05602783	chr7:23145260	KLHL7	-0.6	-4.99	-0.41	2.02e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.31	0.43	4.9e-7	Prudent dietary pattern;
TGCT	cis	rs7586879	1.000	rs11683212	chr2:25120196	T/C	cg01884057	chr2:25150051	NA	0.28	5.03	0.41	1.69e-6	Body mass index;
TGCT	cis	rs7772486	0.790	rs9497424	chr6:146225271	C/A	cg05347473	chr6:146136440	FBXO30	-0.5	-4.87	-0.4	3.29e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg23758822	chr17:41437982	NA	0.62	6.36	0.5	3.6e-9	Menopause (age at onset);
TGCT	cis	rs7731657	0.537	rs10478953	chr5:130185380	A/C	cg08523029	chr5:130500466	HINT1	0.55	4.54	0.38	1.32e-5	Fasting plasma glucose;
TGCT	cis	rs4886920	0.666	rs4595767	chr15:78083715	A/G	cg25212270	chr15:78015279	NA	-0.23	-4.86	-0.4	3.45e-6	Neuroticism;
TGCT	trans	rs10506458	0.915	rs12423078	chr12:63397529	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.47	-7.58	-0.56	6.97e-12	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs2014572	0.967	rs10411941	chr19:57762886	C/T	cg24459738	chr19:57751996	ZNF805	-0.58	-5.7	-0.46	8.38e-8	Hyperactive-impulsive symptoms;
TGCT	trans	rs561341	0.609	rs4795659	chr17:30187139	C/G	cg20587970	chr11:113659929	NA	0.66	8.12	0.59	3.98e-13	Hip circumference adjusted for BMI;
TGCT	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg02975922	chr3:195473998	MUC4	-0.24	-5.39	-0.44	3.4e-7	Pancreatic cancer;
TGCT	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg01577475	chr2:114033581	PAX8;LOC440839	-0.45	-4.8	-0.4	4.55e-6	Lymphocyte counts;
TGCT	cis	rs11822910	1.000	rs11822910	chr11:57195917	G/A	cg00522883	chr11:57194120	SLC43A3	0.36	4.61	0.38	9.93e-6	Platelet distribution width;
TGCT	cis	rs6831352	0.877	rs2602890	chr4:100043179	C/T	cg12011299	chr4:100065546	ADH4	0.42	4.99	0.41	2e-6	Alcohol dependence;
TGCT	cis	rs10744422	0.925	rs2880678	chr12:123317099	C/T	cg25930673	chr12:123319894	HIP1R	-0.85	-5.01	-0.41	1.86e-6	Schizophrenia;
TGCT	cis	rs804280	0.504	rs2645457	chr8:11614112	T/G	cg26752888	chr8:11627280	NEIL2	0.72	6.13	0.48	1.06e-8	Myopia (pathological);
TGCT	cis	rs11190604	0.767	rs10786590	chr10:102164604	T/C	cg16005271	chr10:102321736	NA	0.45	4.74	0.39	5.87e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg26531700	chr6:26746687	NA	-0.54	-4.87	-0.4	3.36e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6570726	0.935	rs387965	chr6:145869366	A/G	cg23711669	chr6:146136114	FBXO30	0.72	6.97	0.53	1.68e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11096990	0.656	rs2123027	chr4:39291113	C/T	cg20847110	chr4:39482781	LOC401127	-0.16	-4.51	-0.38	1.48e-5	Cognitive function;
TGCT	cis	rs709400	0.628	rs10150072	chr14:103977605	C/T	cg26031613	chr14:104095156	KLC1	0.86	9.54	0.65	1.61e-16	Body mass index;
TGCT	cis	rs2228479	0.681	rs4287569	chr16:89957815	A/G	cg06558623	chr16:89946397	TCF25	0.39	4.85	0.4	3.56e-6	Skin colour saturation;
TGCT	cis	rs6738485	0.507	rs66569888	chr2:106886967	G/A	cg16099169	chr2:106886729	NA	-0.42	-4.7	-0.39	6.89e-6	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
TGCT	cis	rs12477438	0.798	rs10198293	chr2:99602929	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-5.87	-0.47	3.74e-8	Chronic sinus infection;
TGCT	cis	rs2439831	1.000	rs2439831	chr15:43784475	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	8.01	0.58	7.16e-13	Lung cancer in ever smokers;
TGCT	cis	rs28595532	0.920	rs114037572	chr4:119735609	T/G	cg21605333	chr4:119757512	SEC24D	1.66	8.33	0.6	1.28e-13	Cannabis dependence symptom count;
TGCT	cis	rs7940866	0.801	rs2113928	chr11:130835975	A/G	cg05962950	chr11:130786565	SNX19	0.76	7.3	0.55	2.95e-11	Schizophrenia;
TGCT	cis	rs6988636	1.000	rs58741168	chr8:124191852	G/A	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs6964587	0.626	rs404	chr7:91544316	G/T	cg17063962	chr7:91808500	NA	-0.77	-7.32	-0.55	2.77e-11	Breast cancer;
TGCT	cis	rs9388451	0.874	rs7739566	chr6:126094757	A/T	cg05901451	chr6:126070800	HEY2	-1.02	-15.06	-0.8	8.78e-30	Brugada syndrome;
TGCT	cis	rs28595532	0.925	rs116785973	chr4:119611350	G/A	cg11846333	chr4:119757529	SEC24D	0.92	5.01	0.41	1.85e-6	Cannabis dependence symptom count;
TGCT	cis	rs36051895	0.623	rs1120679	chr9:5248073	C/G	cg02405213	chr9:5042618	JAK2	-0.72	-9.57	-0.65	1.37e-16	Pediatric autoimmune diseases;
TGCT	cis	rs2544523	0.511	rs2544536	chr2:15906854	T/C	cg26669897	chr2:15909070	NA	0.38	4.97	0.41	2.2e-6	Asthma or chronic obstructive pulmonary disease;
TGCT	cis	rs7267979	1.000	rs6050598	chr20:25397257	C/G	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9583531	0.509	rs12184676	chr13:111396484	A/G	cg24331049	chr13:111365604	ING1	-0.83	-5.63	-0.45	1.14e-7	Coronary artery disease;
TGCT	cis	rs7267979	0.966	rs2261698	chr20:25259910	A/G	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7474896	0.583	rs7071147	chr10:38003376	T/C	cg13720705	chr10:37990370	NA	0.34	4.9	0.4	2.9e-6	Obesity (extreme);
TGCT	cis	rs7940866	0.801	rs10894296	chr11:130840433	T/G	cg05962950	chr11:130786565	SNX19	0.73	7.14	0.54	6.88e-11	Schizophrenia;
TGCT	cis	rs7666738	0.830	rs17027225	chr4:99028564	C/T	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8180040	0.627	rs58956475	chr3:47224615	G/C	cg27129171	chr3:47204927	SETD2	-0.7	-8.33	-0.6	1.26e-13	Colorectal cancer;
TGCT	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg23302884	chr18:44338147	ST8SIA5	-0.41	-4.68	-0.39	7.26e-6	Personality dimensions;
TGCT	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg07092213	chr7:1199455	ZFAND2A	-0.48	-5.53	-0.44	1.83e-7	Longevity;Endometriosis;
TGCT	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-6.74	-0.52	5.26e-10	Alzheimer's disease;
TGCT	cis	rs2637266	0.703	rs1660907	chr10:78494859	A/C	cg18941641	chr10:78392320	NA	0.42	4.99	0.41	2.01e-6	Pulmonary function;
TGCT	cis	rs7923609	0.811	rs7899657	chr10:65323265	G/A	cg08743896	chr10:65200160	JMJD1C	0.32	4.46	0.37	1.82e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7681440	0.874	rs1372525	chr4:90776165	G/A	cg26578617	chr4:90757533	SNCA	-0.44	-4.54	-0.38	1.31e-5	Dementia with Lewy bodies;
TGCT	cis	rs698813	0.674	rs6544752	chr2:44499049	G/A	cg00619915	chr2:44497795	NA	-0.23	-5.32	-0.43	4.74e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
TGCT	cis	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg18188782	chr20:61659543	NA	0.44	5.37	0.43	3.73e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2153535	0.580	rs962590	chr6:8450899	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.76	0.46	6.39e-8	Motion sickness;
TGCT	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg05552183	chr6:42928497	GNMT	0.52	4.57	0.38	1.16e-5	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs6912958	0.781	rs2325064	chr6:88224467	G/A	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.91	-0.4	2.78e-6	Monocyte percentage of white cells;
TGCT	cis	rs6095298	0.595	rs752421	chr20:47435039	G/A	cg12307787	chr20:48099359	KCNB1	0.43	4.53	0.38	1.37e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg11644478	chr21:40555479	PSMG1	1.02	10.59	0.69	4.75e-19	Cognitive function;
TGCT	cis	rs7824557	0.564	rs1435275	chr8:11235735	T/C	cg21775007	chr8:11205619	TDH	-0.65	-6.4	-0.5	2.95e-9	Retinal vascular caliber;
TGCT	cis	rs2153535	0.580	rs7763190	chr6:8484197	G/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs1018836	0.923	rs2187982	chr8:91556317	G/T	cg16814680	chr8:91681699	NA	-0.87	-9.88	-0.66	2.41e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg13395646	chr4:1353034	KIAA1530	-0.39	-4.98	-0.41	2.13e-6	Obesity-related traits;
TGCT	cis	rs67478160	0.625	rs7141473	chr14:104316055	A/C	cg26031613	chr14:104095156	KLC1	0.67	6.91	0.53	2.23e-10	Schizophrenia;
TGCT	cis	rs6879260	0.963	rs11748619	chr5:179727399	C/G	cg02891314	chr5:179741120	GFPT2	-0.39	-6.43	-0.5	2.46e-9	Height;
TGCT	cis	rs981844	0.921	rs2606336	chr4:154656792	C/T	cg14289246	chr4:154710475	SFRP2	1.01	8.46	0.6	6.31e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs60154123	0.505	rs77990373	chr1:210041111	T/C	cg04352962	chr1:209979756	IRF6	0.69	4.73	0.39	6.04e-6	Coronary artery disease;
TGCT	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg10253484	chr15:75165896	SCAMP2	-0.6	-5.54	-0.45	1.74e-7	Breast cancer;
TGCT	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg10150615	chr22:24372951	LOC391322	-0.81	-8.99	-0.63	3.41e-15	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs11031096	0.769	rs12803541	chr11:4208906	G/A	cg08557956	chr11:4115526	RRM1	0.49	4.65	0.39	8.43e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs9611565	0.614	rs4822053	chr22:42212936	C/A	cg13695892	chr22:41940480	POLR3H	-0.77	-7.18	-0.54	5.51e-11	Vitiligo;
TGCT	cis	rs3847687	1.000	rs11061290	chr12:131518747	C/T	cg13586425	chr12:131519906	GPR133	-0.33	-4.96	-0.41	2.29e-6	Longevity;
TGCT	cis	rs7914558	0.966	rs10786745	chr10:104956827	A/G	cg15744005	chr10:104629667	AS3MT	-0.4	-4.85	-0.4	3.57e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs6901004	0.803	rs1040903	chr6:111470153	A/C	cg15721981	chr6:111408429	SLC16A10	-0.54	-4.7	-0.39	6.77e-6	Blood metabolite levels;
TGCT	cis	rs561341	0.739	rs8070554	chr17:30216868	A/T	cg13647721	chr17:30228624	UTP6	-0.61	-4.8	-0.4	4.39e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg04944784	chr2:26401820	FAM59B	0.72	5.92	0.47	2.93e-8	Gut microbiome composition (summer);
TGCT	cis	rs2594989	1.000	rs2594993	chr3:11360744	C/T	cg00170343	chr3:11313890	ATG7	0.66	4.87	0.4	3.39e-6	Circulating chemerin levels;
TGCT	cis	rs6674176	0.660	rs12726706	chr1:44399942	G/A	cg13606994	chr1:44402422	ARTN	-0.49	-5.39	-0.44	3.36e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs929354	0.742	rs886677	chr7:157003782	T/A	cg05182265	chr7:156933206	UBE3C	-0.39	-8.77	-0.62	1.19e-14	Body mass index;
TGCT	cis	rs77861329	1.000	rs352150	chr3:52209995	A/G	cg08692210	chr3:52188851	WDR51A	0.94	4.83	0.4	3.91e-6	Macrophage inflammatory protein 1b levels;
TGCT	cis	rs704	0.523	rs11080054	chr17:26645991	G/A	cg10342447	chr17:26645325	TMEM97	-0.62	-6.26	-0.49	5.78e-9	Osteoprotegerin levels;
TGCT	trans	rs561341	0.830	rs7218801	chr17:30217778	A/G	cg20587970	chr11:113659929	NA	0.8	9.45	0.65	2.65e-16	Hip circumference adjusted for BMI;
TGCT	cis	rs916888	0.738	rs199515	chr17:44856641	C/G	cg01570182	chr17:44337453	NA	-0.97	-8.53	-0.61	4.19e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs35306767	0.953	rs12762973	chr10:960761	C/G	cg26597838	chr10:835615	NA	0.67	9.17	0.64	1.29e-15	Eosinophil percentage of granulocytes;
TGCT	cis	rs6558174	0.965	rs2009212	chr8:22491496	G/A	cg03733263	chr8:22462867	KIAA1967	0.67	5.35	0.43	4.11e-7	Breast cancer;
TGCT	cis	rs4803468	1.000	rs284655	chr19:41928765	C/T	cg09537434	chr19:41945824	ATP5SL	-0.92	-10.57	-0.69	5.19e-19	Height;
TGCT	cis	rs58904263	1	rs58904263	chr20:30401406	A/AG	cg18721089	chr20:30220636	NA	-0.42	-4.64	-0.38	8.8e-6	Monocyte count;
TGCT	cis	rs9467773	0.620	rs2101582	chr6:26622734	C/T	cg09904177	chr6:26538194	HMGN4	0.65	6.35	0.5	3.74e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs5769707	0.967	rs5769698	chr22:49997706	A/G	cg10356904	chr22:49881777	NA	-0.25	-5.05	-0.41	1.54e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs7666738	0.830	rs7663924	chr4:99037679	A/G	cg05340658	chr4:99064831	C4orf37	-0.48	-5.45	-0.44	2.66e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3008870	0.651	rs2815376	chr1:67508531	G/A	cg02640540	chr1:67518911	SLC35D1	0.59	5.58	0.45	1.41e-7	Lymphocyte percentage of white cells;
TGCT	trans	rs3780486	0.846	rs10813954	chr9:33137596	A/C	cg04842962	chr6:43655489	MRPS18A	1.24	15.76	0.82	2.18e-31	IgG glycosylation;
TGCT	cis	rs4727027	0.901	rs11760293	chr7:148811725	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	4.6	0.38	1.04e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs13217239	0.646	rs4269366	chr6:27016413	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.41	4.58	0.38	1.14e-5	Schizophrenia;
TGCT	cis	rs8177253	0.509	rs6762415	chr3:133478557	T/G	cg08439880	chr3:133502540	NA	-0.31	-5.03	-0.41	1.68e-6	Iron status biomarkers;
TGCT	cis	rs6882076	0.884	rs7717984	chr5:156369171	A/G	cg12943317	chr5:156479607	HAVCR1	0.3	5.54	0.45	1.74e-7	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
TGCT	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.49	4.64	0.38	8.69e-6	Prudent dietary pattern;
TGCT	cis	rs13108904	0.604	rs13103860	chr4:1320120	G/A	cg00684032	chr4:1343700	KIAA1530	0.26	5.71	0.46	7.76e-8	Obesity-related traits;
TGCT	cis	rs4595586	0.545	rs61939643	chr12:39378460	G/A	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs2562456	0.833	rs8106025	chr19:21634724	A/C	cg01304269	chr19:21688519	ZNF429	-0.6	-4.89	-0.4	3.07e-6	Pain;
TGCT	cis	rs12580194	0.593	rs73118998	chr12:55736659	T/C	cg10672482	chr12:55725839	OR6C3	-0.51	-4.51	-0.38	1.46e-5	Cancer;
TGCT	cis	rs636291	0.517	rs672606	chr1:10526144	G/A	cg17425144	chr1:10567563	PEX14	0.53	7.35	0.55	2.37e-11	Prostate cancer;
TGCT	cis	rs4911259	0.552	rs2014837	chr20:31461082	C/T	cg13636640	chr20:31349939	DNMT3B	0.88	9.38	0.64	4.01e-16	Inflammatory bowel disease;
TGCT	cis	rs2692947	0.727	rs1657502	chr2:96795608	A/C	cg05933789	chr2:97190408	NA	0.15	4.45	0.37	1.91e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs864745	0.967	rs1513272	chr7:28200097	C/T	cg23620719	chr7:28220237	JAZF1	-0.48	-4.45	-0.37	1.92e-5	Crohn's disease;Type 2 diabetes;
TGCT	cis	rs7611238	0.560	rs6801007	chr3:195102447	A/T	cg27323046	chr3:195102265	ACAP2	-0.36	-4.91	-0.4	2.78e-6	Body mass index;
TGCT	cis	rs1008375	1.000	rs7661631	chr4:17679751	T/C	cg16339924	chr4:17578868	LAP3	-0.59	-4.97	-0.41	2.13e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg25703541	chr22:24373054	LOC391322	0.82	6.94	0.53	1.89e-10	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs7635838	0.654	rs164101	chr3:11281082	G/A	cg00170343	chr3:11313890	ATG7	0.68	6.46	0.5	2.19e-9	HDL cholesterol;
TGCT	cis	rs57221529	0.766	rs72703026	chr5:572383	G/A	cg20362242	chr5:692897	TPPP	0.51	4.56	0.38	1.21e-5	Lung disease severity in cystic fibrosis;
TGCT	cis	rs7809950	0.678	rs17154040	chr7:107005246	C/T	cg23024343	chr7:107201750	COG5	0.43	5.85	0.47	4.12e-8	Coronary artery disease;
TGCT	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg00149659	chr3:10157352	C3orf10	1.17	7.24	0.55	4.13e-11	Alzheimer's disease;
TGCT	cis	rs5758659	0.714	rs6002626	chr22:42517989	C/G	cg15557168	chr22:42548783	NA	0.17	4.48	0.37	1.66e-5	Cognitive function;
TGCT	cis	rs6500602	0.702	rs6500606	chr16:4502514	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.28	-5.16	-0.42	9.51e-7	Schizophrenia;
TGCT	cis	rs713587	0.713	rs11125884	chr2:25239264	C/T	cg01884057	chr2:25150051	NA	0.38	7.82	0.57	1.95e-12	Body mass index in non-asthmatics;
TGCT	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg06112835	chr11:68658793	MRPL21	-0.45	-7.62	-0.56	5.68e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	trans	rs561341	0.739	rs7213369	chr17:30211878	G/A	cg20587970	chr11:113659929	NA	0.65	8.95	0.63	4.33e-15	Hip circumference adjusted for BMI;
TGCT	cis	rs2841233	0.692	rs2028416	chr14:105348552	C/T	cg03469805	chr14:105330648	KIAA0284	-0.45	-5.05	-0.41	1.55e-6	IgG glycosylation;
TGCT	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg13732083	chr21:47605072	C21orf56	0.35	4.69	0.39	7.17e-6	Testicular germ cell tumor;
TGCT	cis	rs2806561	0.704	rs2868573	chr1:23508253	C/G	cg12483005	chr1:23474871	LUZP1	0.37	4.76	0.39	5.23e-6	Height;
TGCT	cis	rs13191362	1.000	rs4260737	chr6:163137746	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.17	9.35	0.64	4.74e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs1023500	0.505	rs134874	chr22:42661144	A/G	cg15557168	chr22:42548783	NA	-0.22	-5.17	-0.42	9.3e-7	Schizophrenia;
TGCT	cis	rs78487399	0.808	rs78886764	chr2:43653499	C/A	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.74	4.46	0.37	1.79e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg10047753	chr17:41438598	NA	0.95	9.54	0.65	1.61e-16	Menopause (age at onset);
TGCT	cis	rs3806843	0.576	rs246064	chr5:140324309	C/G	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs10193935	0.901	rs12622153	chr2:42598386	C/A	cg27598129	chr2:42591480	NA	-0.4	-5.44	-0.44	2.71e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4074961	0.604	rs4411102	chr1:38063424	C/G	cg17933807	chr1:38061675	GNL2	0.96	11.14	0.71	2.11e-20	Axial length;
TGCT	cis	rs6896969	0.504	rs10472332	chr5:40368373	T/G	cg01087697	chr5:40835557	RPL37	0.53	4.83	0.4	3.95e-6	Multiple sclerosis;
TGCT	cis	rs7246657	0.722	rs2927747	chr19:38159530	C/T	cg18154014	chr19:37997991	ZNF793	-0.67	-4.69	-0.39	6.96e-6	Coronary artery calcification;
TGCT	cis	rs539096	0.723	rs530373	chr1:44070032	C/T	cg12908607	chr1:44402522	ARTN	0.45	4.66	0.39	8.02e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2216164	1.000	rs7968411	chr12:68561575	G/A	cg17065850	chr12:67807625	NA	0.24	4.47	0.37	1.73e-5	Alopecia areata;
TGCT	cis	rs10782582	0.609	rs5745553	chr1:76379135	A/T	cg10523679	chr1:76189770	ACADM	-0.57	-5.22	-0.42	7.19e-7	Daytime sleep phenotypes;
TGCT	cis	rs1372520	0.577	rs2737021	chr4:90739992	T/A	cg15133208	chr4:90757351	SNCA	-0.52	-5.96	-0.47	2.45e-8	Neuroticism;
TGCT	cis	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg20637647	chr7:64974828	NA	1.0	5.59	0.45	1.4e-7	Diabetic kidney disease;
TGCT	cis	rs17401966	0.838	rs11579365	chr1:10470846	G/T	cg19773385	chr1:10388646	KIF1B	-0.22	-5.17	-0.42	9.17e-7	Hepatocellular carcinoma;
TGCT	cis	rs2847281	0.764	rs2847277	chr18:12778032	G/T	cg23598886	chr18:12777645	NA	0.36	4.54	0.38	1.3e-5	C-reactive protein levels;Esophageal cancer (squamous cell);
TGCT	cis	rs10131894	0.575	rs8006147	chr14:75430033	G/A	cg06637938	chr14:75390232	RPS6KL1	0.55	4.83	0.4	3.97e-6	Coronary artery disease;
TGCT	cis	rs2242116	0.932	rs1531137	chr3:46943028	T/C	cg23352942	chr3:46931381	PTH1R	-0.37	-5.81	-0.46	5.02e-8	Birth weight;
TGCT	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg13206674	chr6:150067644	NUP43	0.52	4.46	0.37	1.78e-5	Lung cancer;
TGCT	cis	rs4499344	0.730	rs614370	chr19:33106390	T/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	8.74	0.62	1.36e-14	Mean platelet volume;
TGCT	cis	rs6088580	0.624	rs6120645	chr20:33025171	C/T	cg06115741	chr20:33292138	TP53INP2	0.55	4.82	0.4	4.15e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg22857025	chr5:266934	NA	-0.32	-6.53	-0.51	1.5e-9	Breast cancer;
TGCT	cis	rs4689388	0.926	rs9998835	chr4:6293237	C/G	cg14416269	chr4:6271139	WFS1	0.37	4.9	0.4	2.95e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs2637266	0.875	rs2395409	chr10:78381004	A/G	cg18941641	chr10:78392320	NA	0.43	5.57	0.45	1.49e-7	Pulmonary function;
TGCT	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg03264133	chr6:25882463	NA	-0.64	-7.2	-0.54	4.97e-11	Blood metabolite levels;
TGCT	cis	rs7666738	0.830	rs28769113	chr4:98950371	T/G	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg03806693	chr22:41940476	POLR3H	-1.14	-13.38	-0.77	8.05e-26	Vitiligo;
TGCT	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg02725872	chr8:58115012	NA	-0.37	-4.99	-0.41	1.99e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9503598	0.714	rs7758776	chr6:3452245	C/T	cg00476032	chr6:3446245	SLC22A23	0.2	5.95	0.47	2.5e-8	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
TGCT	cis	rs3796352	1.000	rs71301814	chr3:53117663	G/A	cg07884673	chr3:53033167	SFMBT1	0.57	5.86	0.47	3.94e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg24399712	chr22:39784796	NA	-1.07	-13.49	-0.77	4.49e-26	Intelligence (multi-trait analysis);
TGCT	cis	rs2777491	0.574	rs11858812	chr15:41731550	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.94	-17.34	-0.84	6.15e-35	Ulcerative colitis;
TGCT	cis	rs13418410	0.539	rs11677468	chr2:33839053	T/C	cg04131969	chr2:33951647	MYADML	-0.78	-7.46	-0.56	1.31e-11	Non-response to antidepressants and depression;
TGCT	cis	rs7312933	0.558	rs1796394	chr12:42826359	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.58	-5.69	-0.46	8.61e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs6540559	0.546	rs59435160	chr1:210030730	C/A	cg23283495	chr1:209979779	IRF6	0.73	5.64	0.45	1.07e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs13188771	0.633	rs350506	chr5:100874283	C/T	cg18665594	chr5:101119420	NA	0.44	4.46	0.37	1.83e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs9303401	0.580	rs12946396	chr17:57164195	T/A	cg25039879	chr17:56429692	SUPT4H1	0.55	4.9	0.4	2.93e-6	Cognitive test performance;
TGCT	cis	rs7666738	0.830	rs17550735	chr4:99014076	T/G	cg17366294	chr4:99064904	C4orf37	0.68	7.04	0.53	1.17e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs644799	0.710	rs10765771	chr11:95521044	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.28	0.6	1.63e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.31	-4.82	-0.4	4.12e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7714584	1.000	rs73284126	chr5:150261307	G/A	cg22134413	chr5:150180641	NA	0.78	6.12	0.48	1.16e-8	Crohn's disease;
TGCT	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.46	4.9	0.4	2.98e-6	Lymphocyte counts;
TGCT	cis	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg22963979	chr7:1858916	MAD1L1	-0.37	-5.58	-0.45	1.42e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs28595532	0.920	rs56389935	chr4:119683571	G/A	cg14228332	chr4:119757509	SEC24D	1.05	5.39	0.44	3.45e-7	Cannabis dependence symptom count;
TGCT	cis	rs6542838	0.702	rs6739176	chr2:99536846	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.57	-5.44	-0.44	2.74e-7	Fear of minor pain;
TGCT	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg04944784	chr2:26401820	FAM59B	0.76	6.24	0.49	6.46e-9	Gut microbiome composition (summer);
TGCT	cis	rs9303401	0.573	rs34717648	chr17:56886624	T/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs7666738	0.830	rs28618180	chr4:98912184	A/C	cg05340658	chr4:99064831	C4orf37	0.54	6.51	0.5	1.7e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg23758822	chr17:41437982	NA	0.72	6.81	0.52	3.83e-10	Menopause (age at onset);
TGCT	cis	rs12142240	0.659	rs72677602	chr1:46837487	G/A	cg14993813	chr1:46806288	NSUN4	-0.57	-4.72	-0.39	6.32e-6	Menopause (age at onset);
TGCT	cis	rs854765	0.693	rs4924823	chr17:17764502	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.74	-7.65	-0.57	4.87e-12	Total body bone mineral density;
TGCT	cis	rs6121246	0.528	rs6060252	chr20:30191084	A/G	cg21427119	chr20:30132790	HM13	-0.42	-6.17	-0.48	8.75e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg13732083	chr21:47605072	C21orf56	0.34	4.52	0.38	1.44e-5	Testicular germ cell tumor;
TGCT	cis	rs7772486	0.754	rs702324	chr6:146008793	A/G	cg13319975	chr6:146136371	FBXO30	0.54	4.81	0.4	4.29e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1691799	0.899	rs1168307	chr12:66739539	A/G	cg16791601	chr12:66731901	HELB	-0.28	-6.17	-0.48	8.87e-9	White blood cell count (basophil);
TGCT	cis	rs600550	0.926	rs675655	chr11:60020874	G/C	cg18570331	chr11:60101691	MS4A6E	0.52	4.48	0.37	1.67e-5	Lipoprotein-associated phospholipase A2 activity and mass;
TGCT	cis	rs9549367	0.826	rs1885688	chr13:113894236	G/T	cg18105134	chr13:113819100	PROZ	-0.35	-5.89	-0.47	3.46e-8	Platelet distribution width;
TGCT	cis	rs7216064	0.532	rs3890640	chr17:66053028	C/T	cg12091567	chr17:66097778	LOC651250	1.17	9.62	0.65	1.04e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs9787249	0.915	rs58589165	chr1:40213670	A/T	cg20968010	chr1:40505947	CAP1	-0.53	-5.0	-0.41	1.91e-6	Blood protein levels;
TGCT	cis	rs4786125	0.581	rs1967404	chr16:6921483	G/A	cg03623568	chr16:6915990	A2BP1	-0.45	-6.68	-0.51	7.28e-10	Heart rate variability traits (SDNN);
TGCT	cis	rs4332037	0.539	rs11762545	chr7:2060775	C/T	cg25834613	chr7:1915315	MAD1L1	-0.51	-4.99	-0.41	1.95e-6	Bipolar disorder;
TGCT	cis	rs7812088	0.901	rs73169679	chr7:150953855	C/T	cg03289901	chr7:150933506	CHPF2	0.36	4.62	0.38	9.61e-6	Bone mineral density;
TGCT	cis	rs2688608	0.592	rs7909544	chr10:75484004	G/C	cg04320760	chr10:75533139	FUT11	-0.4	-6.25	-0.49	6.11e-9	Inflammatory bowel disease;
TGCT	cis	rs28595532	0.844	rs80188901	chr4:119500014	C/T	cg14228332	chr4:119757509	SEC24D	1.04	5.37	0.43	3.8e-7	Cannabis dependence symptom count;
TGCT	cis	rs1895302	0.634	rs4867917	chr5:169538188	C/T	cg23221885	chr5:170171749	NA	0.29	4.64	0.38	8.87e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs);
TGCT	cis	rs11696501	0.694	rs6094184	chr20:44256575	G/A	cg11783356	chr20:44313418	WFDC10B	-0.32	-4.63	-0.38	9.25e-6	Brain structure;
TGCT	trans	rs1814175	0.791	rs1722023	chr11:49908136	G/C	cg03929089	chr4:120376271	NA	-0.71	-8.09	-0.59	4.74e-13	Height;
TGCT	cis	rs72781680	0.716	rs2712061	chr2:24026411	G/A	cg08917208	chr2:24149416	ATAD2B	0.79	4.94	0.41	2.51e-6	Lymphocyte counts;
TGCT	cis	rs2742417	0.603	rs2673075	chr3:45778288	C/A	cg04837898	chr3:45731254	SACM1L	-0.67	-7.3	-0.55	3.06e-11	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs6121246	0.697	rs45557936	chr20:30226690	G/A	cg13852791	chr20:30311386	BCL2L1	0.74	4.84	0.4	3.77e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs10197940	0.510	rs7557092	chr2:152423459	T/A	cg19508488	chr2:152266495	RIF1	0.63	5.69	0.46	8.47e-8	Lung cancer;
TGCT	cis	rs4722166	0.630	rs4722169	chr7:22785419	C/T	cg26061582	chr7:22766209	IL6	0.57	7.31	0.55	2.85e-11	Lung cancer;
TGCT	cis	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg06636001	chr8:8085503	FLJ10661	-0.64	-5.75	-0.46	6.46e-8	Mood instability;
TGCT	cis	rs2760061	0.819	rs1745416	chr1:228204497	G/A	cg18477163	chr1:228402036	OBSCN	0.34	7.22	0.54	4.65e-11	Diastolic blood pressure;
TGCT	cis	rs12142240	0.698	rs17361833	chr1:46828700	A/G	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs3770081	1.000	rs3770087	chr2:86267068	T/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.18	-4.81	-0.4	4.33e-6	Facial emotion recognition (sad faces);
TGCT	cis	rs9486719	1.000	rs926276	chr6:96868735	C/T	cg06623918	chr6:96969491	KIAA0776	0.97	9.2	0.64	1.06e-15	Migraine;Coronary artery disease;
TGCT	cis	rs4455778	0.580	rs4437600	chr7:49090274	G/A	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs2404602	0.692	rs12911902	chr15:77053575	T/C	cg22467129	chr15:76604101	ETFA	-0.45	-5.11	-0.42	1.18e-6	Blood metabolite levels;
TGCT	cis	rs2455799	0.573	rs2455836	chr3:15754538	A/G	cg16303742	chr3:15540471	COLQ	-0.25	-4.69	-0.39	7.09e-6	Mean platelet volume;
TGCT	cis	rs17376456	0.877	rs28418572	chr5:93144161	A/C	cg21475434	chr5:93447410	FAM172A	0.6	4.58	0.38	1.13e-5	Diabetic retinopathy;
TGCT	cis	rs12042938	0.600	rs1094655	chr1:231774362	A/G	cg04892437	chr1:231737901	TSNAX-DISC1	0.46	4.79	0.4	4.68e-6	Neuranatomic and neurocognitive phenotypes;
TGCT	cis	rs7666738	0.830	rs6843777	chr4:98866635	T/A	cg18180107	chr4:99064573	C4orf37	0.55	5.13	0.42	1.09e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs854765	0.964	rs854813	chr17:18003845	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.65	-6.31	-0.49	4.57e-9	Total body bone mineral density;
TGCT	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg21016266	chr12:122356598	WDR66	0.54	6.64	0.51	8.76e-10	Mean corpuscular volume;
TGCT	cis	rs11148252	0.595	rs9526974	chr13:53251040	C/G	cg00495681	chr13:53174319	NA	0.67	6.59	0.51	1.13e-9	Lewy body disease;
TGCT	cis	rs7412746	0.658	rs6657388	chr1:150748786	A/G	cg04414720	chr1:150670196	GOLPH3L	0.38	4.73	0.39	6.04e-6	Melanoma;
TGCT	cis	rs1008375	1.000	rs10011865	chr4:17645710	G/A	cg18681998	chr4:17616180	MED28	1.01	11.89	0.73	3.17e-22	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9303401	0.659	rs17222621	chr17:56695923	C/T	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs9902453	0.904	rs9894893	chr17:28270350	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.87	8.26	0.6	1.9e-13	Coffee consumption (cups per day);
TGCT	cis	rs6138458	1.000	rs4273288	chr20:24900873	G/A	cg26195577	chr20:24973756	C20orf3	-1.2	-12.04	-0.73	1.35e-22	Blood protein levels;
TGCT	cis	rs4455778	0.580	rs7808387	chr7:49125122	T/C	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg20276088	chr3:133502917	NA	-0.24	-5.05	-0.41	1.53e-6	Iron status biomarkers;
TGCT	cis	rs7727544	0.716	rs72793278	chr5:131561372	C/A	cg24060327	chr5:131705240	SLC22A5	-0.54	-5.1	-0.42	1.22e-6	Blood metabolite levels;
TGCT	cis	rs7178572	0.568	rs7177533	chr15:77387923	C/T	cg22256960	chr15:77711686	NA	-0.84	-8.34	-0.6	1.23e-13	Type 2 diabetes;
TGCT	cis	rs1799949	0.931	rs9891977	chr17:41437398	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.46	4.9	0.4	2.91e-6	Menopause (age at onset);
TGCT	cis	rs1801251	1.000	rs283476	chr2:233650168	A/G	cg08000102	chr2:233561755	GIGYF2	0.65	6.45	0.5	2.28e-9	Coronary artery disease;
TGCT	cis	rs1757171	0.534	rs2797793	chr6:37477262	C/T	cg25019722	chr6:37503610	NA	0.42	6.02	0.48	1.87e-8	Cognitive performance;
TGCT	cis	rs12887734	0.524	rs4906363	chr14:104210239	G/A	cg26031613	chr14:104095156	KLC1	-0.71	-6.14	-0.48	1.04e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs75686122	0.892	rs17806929	chr8:104571608	C/T	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs9914988	0.887	rs4795456	chr17:27072463	G/A	cg20469991	chr17:27169893	C17orf63	-0.73	-5.11	-0.42	1.17e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs7086627	0.515	rs11202963	chr10:82210392	A/G	cg00277334	chr10:82204260	NA	-0.54	-8.46	-0.61	6.23e-14	Post bronchodilator FEV1;
TGCT	cis	rs56104184	0.615	rs73061693	chr19:49399941	C/A	cg15549821	chr19:49342101	PLEKHA4	-0.73	-9.15	-0.63	1.47e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs7914558	1.000	rs1890184	chr10:104748459	A/C	cg04362960	chr10:104952993	NT5C2	0.62	5.51	0.44	2.03e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs8103278	1.000	rs725660	chr19:46262286	C/A	cg14061069	chr19:46274453	DMPK	-0.44	-6.34	-0.49	3.86e-9	Coronary artery disease;
TGCT	cis	rs7943203	0.525	rs920679	chr11:108038477	C/T	cg04873221	chr11:107992290	ACAT1	0.64	4.72	0.39	6.23e-6	Red blood cell count;Mean corpuscular volume;
TGCT	cis	rs3924048	0.574	rs11121928	chr1:12615888	C/G	cg00291366	chr1:12616550	NA	0.32	5.05	0.41	1.54e-6	Optic cup area;
TGCT	cis	rs2243480	1.000	rs160637	chr7:65584318	C/T	cg18252515	chr7:66147081	NA	-1.24	-8.1	-0.59	4.35e-13	Diabetic kidney disease;
TGCT	cis	rs12477438	0.798	rs6736064	chr2:99658201	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-5.87	-0.47	3.74e-8	Chronic sinus infection;
TGCT	cis	rs2594989	0.943	rs6784861	chr3:11465568	T/C	cg00170343	chr3:11313890	ATG7	0.72	5.37	0.43	3.8e-7	Circulating chemerin levels;
TGCT	cis	rs17270561	1.000	rs17270561	chr6:25820439	A/C	cg17042849	chr6:26104293	HIST1H4C	0.82	5.59	0.45	1.39e-7	Iron status biomarkers;
TGCT	cis	rs4246215	1	rs4246215	chr11:61564299	G/T	cg19610905	chr11:61596333	FADS2	-1.07	-11.4	-0.72	5.06e-21	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);Platelet count;Inflammatory bowel disease;Trans fatty acid levels;Crohn's disease;Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);Red blood cell fatty acid levels;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);
TGCT	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg06238570	chr21:40685208	BRWD1	-0.8	-9.12	-0.63	1.7e-15	Cognitive function;
TGCT	trans	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg27523141	chr10:43048294	ZNF37B	0.73	8.42	0.6	7.92e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.15	0.42	1e-6	Menopause (age at onset);
TGCT	cis	rs7666738	0.830	rs10440379	chr4:98902822	G/T	cg18180107	chr4:99064573	C4orf37	0.53	4.81	0.4	4.23e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs709400	0.663	rs9671911	chr14:103967343	T/C	cg26031613	chr14:104095156	KLC1	0.84	9.5	0.65	2.08e-16	Body mass index;
TGCT	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg11494091	chr17:61959527	GH2	0.41	6.97	0.53	1.67e-10	Height;
TGCT	cis	rs2688608	0.901	rs2675671	chr10:75632760	C/T	cg19442545	chr10:75533431	FUT11	-0.29	-4.75	-0.39	5.46e-6	Inflammatory bowel disease;
TGCT	cis	rs10501293	0.703	rs4561205	chr11:42988504	A/T	cg03447554	chr11:43094025	NA	0.44	6.45	0.5	2.25e-9	Cognitive performance;
TGCT	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.69	-6.97	-0.53	1.64e-10	Prostate cancer;
TGCT	cis	rs7666738	0.830	rs35939134	chr4:98980311	A/G	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg22166914	chr1:53195759	ZYG11B	-0.39	-6.57	-0.51	1.22e-9	Monocyte count;
TGCT	cis	rs709400	0.930	rs61996717	chr14:104048571	T/C	cg26031613	chr14:104095156	KLC1	1.17	16.1	0.82	3.56e-32	Body mass index;
TGCT	cis	rs896854	0.738	rs509594	chr8:95967156	C/G	cg13393036	chr8:95962371	TP53INP1	0.56	6.85	0.52	2.99e-10	Type 2 diabetes;
TGCT	cis	rs12900413	0.603	rs2882678	chr15:90299542	A/G	cg24249390	chr15:90295951	MESP1	-0.29	-5.03	-0.41	1.7e-6	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg11965913	chr1:205819406	PM20D1	0.52	7.21	0.54	4.73e-11	Menarche (age at onset);
TGCT	cis	rs6964587	0.872	rs57969083	chr7:91665627	A/T	cg22709100	chr7:91322751	NA	0.28	4.51	0.38	1.49e-5	Breast cancer;
TGCT	cis	rs4727027	0.870	rs11525060	chr7:148801091	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	4.68	0.39	7.53e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs7429990	0.965	rs7651237	chr3:48105528	A/G	cg11946769	chr3:48343235	NME6	-0.61	-4.7	-0.39	6.69e-6	Educational attainment (years of education);
TGCT	cis	rs7017914	0.905	rs2732116	chr8:71929327	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.56	-5.11	-0.42	1.21e-6	Bone mineral density;
TGCT	cis	rs1891275	0.515	rs7093728	chr10:93443617	C/T	cg07889827	chr10:93443413	NA	-0.33	-6.99	-0.53	1.53e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs67311347	1.000	rs2168111	chr3:40395325	T/G	cg13683864	chr3:40499215	RPL14	-1.02	-10.8	-0.7	1.43e-19	Renal cell carcinoma;
TGCT	cis	rs4455778	0.580	rs4273799	chr7:49079809	T/C	cg26309511	chr7:48887640	NA	0.5	6.47	0.5	2.03e-9	Lung cancer in never smokers;
TGCT	cis	rs910316	0.967	rs8013444	chr14:75661981	A/G	cg08847533	chr14:75593920	NEK9	-0.93	-9.92	-0.67	1.95e-17	Height;
TGCT	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg23708337	chr7:1209742	NA	0.6	5.57	0.45	1.53e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs3540	0.513	rs2589963	chr15:90922675	A/G	cg22089800	chr15:90895588	ZNF774	0.82	9.04	0.63	2.61e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs7100689	0.622	rs2994389	chr10:82062257	C/G	cg01528321	chr10:82214614	TSPAN14	0.75	7.46	0.56	1.32e-11	Post bronchodilator FEV1;
TGCT	cis	rs4780401	0.609	rs12927966	chr16:11814562	C/T	cg01061890	chr16:11836724	TXNDC11	-0.6	-5.82	-0.46	4.74e-8	Rheumatoid arthritis;
TGCT	cis	rs2147959	0.941	rs10916317	chr1:228645063	A/G	cg22700015	chr1:228743131	NA	-0.57	-4.5	-0.37	1.55e-5	Adult asthma;
TGCT	cis	rs3796352	1.000	rs75217232	chr3:53132373	A/C	cg27565382	chr3:53032988	SFMBT1	0.4	4.44	0.37	1.94e-5	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.63	-5.5	-0.44	2.06e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs57221529	0.709	rs72707024	chr5:667915	G/A	cg16624210	chr5:671434	TPPP	0.42	4.71	0.39	6.61e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs950027	0.549	rs9920634	chr15:45596546	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.72	-7.4	-0.55	1.76e-11	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg03517284	chr6:25882590	NA	0.5	4.58	0.38	1.12e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs9921338	0.961	rs7202814	chr16:11389774	C/T	cg00044050	chr16:11439710	C16orf75	-0.96	-6.92	-0.53	2.16e-10	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs35160687	0.842	rs10200526	chr2:86527599	G/A	cg03171300	chr2:86307199	POLR1A	0.32	5.57	0.45	1.48e-7	Night sleep phenotypes;
TGCT	cis	rs2153535	0.601	rs1737581	chr6:8539138	A/G	cg07606381	chr6:8435919	SLC35B3	0.55	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs2688608	0.901	rs2675671	chr10:75632760	C/T	cg04320760	chr10:75533139	FUT11	-0.3	-4.7	-0.39	6.79e-6	Inflammatory bowel disease;
TGCT	cis	rs2439831	1.000	rs690002	chr15:43729349	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.8	5.7	0.46	8.33e-8	Lung cancer in ever smokers;
TGCT	cis	rs6701037	0.566	rs4344281	chr1:175135376	C/T	cg00321850	chr1:175162397	KIAA0040	0.38	5.02	0.41	1.71e-6	Alcohol dependence;
TGCT	cis	rs8077889	1.000	rs2079005	chr17:41865627	T/G	cg26893861	chr17:41843967	DUSP3	1.08	13.1	0.76	3.73e-25	Triglycerides;
TGCT	cis	rs62244186	0.659	rs9850129	chr3:44532047	C/T	cg25151919	chr3:44754333	ZNF502	-0.39	-4.58	-0.38	1.12e-5	Depressive symptoms;
TGCT	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.52	-5.13	-0.42	1.09e-6	Bipolar disorder;
TGCT	cis	rs6866344	0.697	rs11749438	chr5:178131245	C/T	cg03877680	chr5:178157825	ZNF354A	0.73	5.93	0.47	2.85e-8	Neutrophil percentage of white cells;
TGCT	cis	rs114540395	0.925	rs12244100	chr10:103379397	T/C	cg18276125	chr10:102749041	C10orf2	0.39	4.68	0.39	7.31e-6	Schizophrenia;
TGCT	cis	rs2439831	0.867	rs8039638	chr15:43634405	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	8.65	0.61	2.26e-14	Lung cancer in ever smokers;
TGCT	cis	rs13217239	0.646	rs2142685	chr6:27054497	C/T	cg15659132	chr6:26577336	NA	-0.56	-5.55	-0.45	1.62e-7	Schizophrenia;
TGCT	trans	rs629535	0.508	rs56207225	chr8:70146628	C/A	cg21567404	chr3:27674614	NA	-0.52	-7.76	-0.57	2.74e-12	Dupuytren's disease;
TGCT	cis	rs2549003	0.811	rs10035166	chr5:131823927	C/T	cg21138405	chr5:131827807	IRF1	-0.19	-4.75	-0.39	5.55e-6	Asthma (sex interaction);
TGCT	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg18876405	chr7:65276391	NA	0.31	4.8	0.4	4.53e-6	Aortic root size;
TGCT	cis	rs854765	0.654	rs9911281	chr17:17762457	G/C	cg04398451	chr17:18023971	MYO15A	0.29	4.57	0.38	1.15e-5	Total body bone mineral density;
TGCT	cis	rs12579753	0.789	rs35448307	chr12:82165817	A/G	cg07988820	chr12:82153109	PPFIA2	-0.69	-7.77	-0.57	2.56e-12	Resting heart rate;
TGCT	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg05368731	chr17:41323189	NBR1	1.2	14.48	0.79	1.98e-28	Menopause (age at onset);
TGCT	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	trans	rs17685	0.712	rs7778735	chr7:75770237	T/C	cg19862616	chr7:65841803	NCRNA00174	0.52	9.01	0.63	3.02e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs28595532	0.844	rs115411027	chr4:119490685	T/C	cg11846333	chr4:119757529	SEC24D	0.93	5.08	0.42	1.32e-6	Cannabis dependence symptom count;
TGCT	cis	rs13188771	0.690	rs352055	chr5:100871666	A/T	cg18665594	chr5:101119420	NA	0.45	4.5	0.37	1.56e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs10114408	0.959	rs10761304	chr9:96656982	A/G	cg13679303	chr9:96623674	NA	-0.36	-4.65	-0.39	8.37e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs6429082	0.749	rs291362	chr1:235686690	T/A	cg26050004	chr1:235667680	B3GALNT2	0.64	5.99	0.47	2.13e-8	Adiposity;
TGCT	trans	rs561341	0.800	rs7209766	chr17:30234848	T/A	cg20587970	chr11:113659929	NA	-0.68	-9.45	-0.65	2.75e-16	Hip circumference adjusted for BMI;
TGCT	trans	rs1814175	0.615	rs12417290	chr11:49876951	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.45	-11.09	-0.71	2.8e-20	Height;
TGCT	cis	rs6922269	0.748	rs6902664	chr6:151252917	A/G	cg21950534	chr6:152128483	ESR1	-0.52	-4.55	-0.38	1.24e-5	Coronary heart disease;
TGCT	cis	rs7249142	0.549	rs1858846	chr19:19281187	T/G	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.56	5.55	0.45	1.66e-7	IgG glycosylation;
TGCT	cis	rs17718580	0.826	rs72679533	chr14:50996692	G/T	cg04730355	chr14:51134070	SAV1	1.0	5.61	0.45	1.24e-7	Cognitive performance;
TGCT	cis	rs4285028	0.699	rs1574115	chr3:121469225	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.99	-7.86	-0.58	1.55e-12	Multiple sclerosis;
TGCT	cis	rs2663905	0.611	rs2663924	chr15:81392903	T/G	cg18837035	chr15:81426597	C15orf26	-0.55	-4.77	-0.39	5.15e-6	QT interval (drug interaction);
TGCT	cis	rs5769707	1.000	rs5769707	chr22:50013402	G/T	cg20744362	chr22:50050164	C22orf34	0.27	4.48	0.37	1.67e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs9486719	0.948	rs2472881	chr6:96862562	C/T	cg06623918	chr6:96969491	KIAA0776	1.01	8.86	0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg18230493	chr5:56204884	C5orf35	-0.51	-4.48	-0.37	1.7e-5	Initial pursuit acceleration;
TGCT	cis	rs9928842	0.664	rs7205074	chr16:75220009	A/C	cg09066997	chr16:75300724	BCAR1	-0.23	-4.77	-0.39	5.14e-6	Alcoholic chronic pancreatitis;
TGCT	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg03806693	chr22:41940476	POLR3H	-1.16	-13.37	-0.77	8.59e-26	Vitiligo;
TGCT	cis	rs2075371	0.933	rs1833474	chr7:133958240	A/G	cg11752832	chr7:134001865	SLC35B4	0.68	5.89	0.47	3.32e-8	Mean platelet volume;
TGCT	cis	rs6430585	0.528	rs660002	chr2:136723504	C/T	cg07169764	chr2:136633963	MCM6	1.22	11.95	0.73	2.26e-22	Corneal structure;
TGCT	cis	rs912057	0.526	rs201061	chr6:6730512	C/T	cg06612196	chr6:6737390	NA	-0.49	-7.19	-0.54	5.25e-11	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs6840360	0.967	rs7695162	chr4:152510541	G/A	cg17479576	chr4:152424074	FAM160A1	-0.43	-4.54	-0.38	1.29e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs13082711	1.000	rs73050029	chr3:27514760	C/A	cg02860705	chr3:27208620	NA	0.34	4.77	0.39	5.18e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs7528684	0.648	rs7546623	chr1:157761419	C/T	cg17134153	chr1:157670328	FCRL3	-0.27	-4.86	-0.4	3.51e-6	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;
TGCT	cis	rs67311347	0.713	rs9861194	chr3:40309225	C/T	cg13683864	chr3:40499215	RPL14	-0.87	-8.51	-0.61	4.77e-14	Renal cell carcinoma;
TGCT	cis	rs7726839	0.574	rs12517345	chr5:628294	G/A	cg16624210	chr5:671434	TPPP	0.42	4.68	0.39	7.38e-6	Obesity-related traits;
TGCT	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.68	5.62	0.45	1.18e-7	Tonsillectomy;
TGCT	cis	rs751728	0.965	rs4713681	chr6:33754817	T/C	cg00334056	chr6:33755658	LEMD2	-0.26	-4.69	-0.39	7.12e-6	Crohn's disease;
TGCT	cis	rs9790314	0.871	rs336561	chr3:161125305	C/T	cg03342759	chr3:160939853	NMD3	-0.49	-5.13	-0.42	1.08e-6	Morning vs. evening chronotype;
TGCT	cis	rs4664308	0.967	rs17831329	chr2:160915819	T/C	cg03641300	chr2:160917029	PLA2R1	-0.26	-6.46	-0.5	2.13e-9	Idiopathic membranous nephropathy;
TGCT	cis	rs13108904	0.604	rs13103860	chr4:1320120	G/A	cg03303774	chr4:1407052	NA	0.37	5.98	0.47	2.26e-8	Obesity-related traits;
TGCT	cis	rs6988636	1.000	rs60362869	chr8:124189971	A/G	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs1215050	0.743	rs6532692	chr4:98648005	C/A	cg17366294	chr4:99064904	C4orf37	-0.52	-5.51	-0.44	1.97e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs144345632	1	rs144345632	chr6:96886894	T/TA	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.21	-0.42	7.61e-7	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs11690935	0.632	rs11690807	chr2:172628120	G/A	cg13550731	chr2:172543902	DYNC1I2	0.68	6.0	0.47	2.02e-8	Schizophrenia;
TGCT	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg12963246	chr6:28129442	ZNF389	0.48	4.74	0.39	5.69e-6	Depression;
TGCT	cis	rs78456975	0.550	rs111467480	chr2:1569154	A/G	cg01028140	chr2:1542097	TPO	-0.34	-5.22	-0.42	7.31e-7	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs62064224	0.606	rs61390192	chr17:30837447	C/T	cg18200150	chr17:30822561	MYO1D	0.51	6.66	0.51	7.87e-10	Schizophrenia;
TGCT	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg03517284	chr6:25882590	NA	-0.66	-5.82	-0.46	4.67e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg08439880	chr3:133502540	NA	-0.31	-5.91	-0.47	3.08e-8	Iron status biomarkers;
TGCT	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg00475322	chr7:917719	C7orf20	0.47	6.04	0.48	1.68e-8	Perceived unattractiveness to mosquitoes;
TGCT	cis	rs9640161	0.871	rs56156367	chr7:150047201	A/T	cg10018233	chr7:150070692	REPIN1	0.31	4.52	0.38	1.42e-5	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs950169	0.922	rs2033284	chr15:84946273	C/T	cg12863693	chr15:85201151	NMB	0.45	4.93	0.41	2.55e-6	Schizophrenia;
TGCT	cis	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg25427524	chr10:38739819	LOC399744	-0.4	-8.2	-0.59	2.5e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.5	5.64	0.45	1.11e-7	Lymphocyte counts;
TGCT	cis	rs7192750	0.586	rs2018384	chr16:71940825	T/C	cg06353428	chr16:71660113	MARVELD3	0.83	7.25	0.55	3.86e-11	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs2180341	0.618	rs12199451	chr6:127597780	C/G	cg27446573	chr6:127587934	RNF146	0.63	5.58	0.45	1.42e-7	Breast cancer;
TGCT	cis	rs9309473	0.660	rs17349321	chr2:73643753	C/T	cg07208825	chr2:73871855	ALMS1P	0.25	4.54	0.38	1.33e-5	Metabolite levels;
TGCT	cis	rs10782582	0.609	rs112431348	chr1:76275571	A/G	cg03433033	chr1:76189801	ACADM	-0.5	-4.95	-0.41	2.39e-6	Daytime sleep phenotypes;
TGCT	cis	rs7666738	0.800	rs12163918	chr4:98835794	T/C	cg05340658	chr4:99064831	C4orf37	0.53	6.18	0.49	8.5e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9611565	0.512	rs9611667	chr22:42187015	C/T	cg06634786	chr22:41940651	POLR3H	-0.84	-7.83	-0.57	1.91e-12	Vitiligo;
TGCT	cis	rs3849570	0.695	rs62265411	chr3:81573660	T/C	cg07356753	chr3:81810745	GBE1	-0.61	-5.1	-0.42	1.24e-6	Waist circumference;Body mass index;
TGCT	cis	rs7119	0.689	rs11630926	chr15:77819582	T/C	cg27398640	chr15:77910606	LINGO1	-0.25	-4.55	-0.38	1.27e-5	Type 2 diabetes;
TGCT	cis	rs9816784	0.566	rs11720913	chr3:195832560	T/C	cg14488913	chr3:195402182	SDHAP2	-0.35	-4.47	-0.37	1.71e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs4891159	0.790	rs72973773	chr18:74115176	T/C	cg24786174	chr18:74118243	ZNF516	-0.62	-9.4	-0.65	3.56e-16	Longevity;
TGCT	cis	rs10838532	0.591	rs11038743	chr11:46029826	T/A	cg10516359	chr11:45827763	SLC35C1	-0.38	-4.45	-0.37	1.92e-5	Axial length;
TGCT	cis	rs12142240	0.698	rs41294456	chr1:46809782	T/C	cg14993813	chr1:46806288	NSUN4	-0.58	-4.81	-0.4	4.34e-6	Menopause (age at onset);
TGCT	cis	rs12478296	0.581	rs4973645	chr2:242993577	T/C	cg06360820	chr2:242988706	NA	-0.8	-5.22	-0.42	7.18e-7	Obesity-related traits;
TGCT	cis	rs9916302	0.904	rs4795355	chr17:37427382	C/T	cg07936489	chr17:37558343	FBXL20	-0.62	-4.91	-0.4	2.77e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg13206674	chr6:150067644	NUP43	0.52	4.51	0.38	1.5e-5	Lung cancer;
TGCT	cis	rs17345786	1.000	rs58907984	chr3:101305170	T/G	cg12386194	chr3:101231763	SENP7	0.59	5.39	0.44	3.43e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4253772	0.513	rs6008597	chr22:46703904	A/C	cg24881330	chr22:46731750	TRMU	1.04	5.41	0.44	3.12e-7	LDL cholesterol;Cholesterol, total;
TGCT	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg21548813	chr6:291882	DUSP22	0.67	7.24	0.55	4.14e-11	Menopause (age at onset);
TGCT	cis	rs73110464	0.609	rs4919752	chr12:53359229	G/C	cg05393297	chr12:53359155	NA	-0.79	-8.5	-0.61	5.05e-14	Cancer (pleiotropy);
TGCT	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg03709012	chr19:19516395	GATAD2A	0.75	6.16	0.48	9.21e-9	Tonsillectomy;
TGCT	cis	rs4788570	0.615	rs7206470	chr16:71668800	G/A	cg06353428	chr16:71660113	MARVELD3	1.55	12.46	0.75	1.33e-23	Intelligence (multi-trait analysis);
TGCT	trans	rs208520	0.690	rs207112	chr6:66792092	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-10.77	-0.7	1.66e-19	Exhaled nitric oxide output;
TGCT	cis	rs2456568	0.771	rs2102333	chr11:93634749	G/A	cg17595323	chr11:93583763	C11orf90	-0.47	-6.44	-0.5	2.38e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg11890956	chr21:40555474	PSMG1	1.12	12.59	0.75	6.25e-24	Cognitive function;
TGCT	cis	rs916888	0.821	rs199513	chr17:44856932	A/G	cg01570182	chr17:44337453	NA	-0.88	-8.06	-0.59	5.56e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7178572	0.568	rs1125617	chr15:77532711	A/G	cg15453836	chr15:77711506	NA	-0.42	-4.79	-0.4	4.68e-6	Type 2 diabetes;
TGCT	cis	rs9926296	0.632	rs2011925	chr16:89814064	T/G	cg27121462	chr16:89883253	FANCA	0.58	5.29	0.43	5.29e-7	Vitiligo;
TGCT	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg05368731	chr17:41323189	NBR1	1.2	14.2	0.79	9.05e-28	Menopause (age at onset);
TGCT	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.05	8.68	0.61	1.9e-14	Platelet count;
TGCT	cis	rs28595532	1.000	rs11938970	chr4:119660152	A/G	cg21605333	chr4:119757512	SEC24D	1.35	7.72	0.57	3.38e-12	Cannabis dependence symptom count;
TGCT	cis	rs1801251	1.000	rs283471	chr2:233656627	G/A	cg25237894	chr2:233734115	C2orf82	0.27	4.68	0.39	7.35e-6	Coronary artery disease;
TGCT	cis	rs394563	0.775	rs420430	chr6:149785539	T/G	cg03678062	chr6:149772716	ZC3H12D	-0.36	-4.45	-0.37	1.87e-5	Dupuytren's disease;
TGCT	cis	rs10465746	0.933	rs2224990	chr1:84436275	C/A	cg10977910	chr1:84465055	TTLL7	0.63	6.23	0.49	6.49e-9	Obesity-related traits;
TGCT	cis	rs7818688	0.697	rs58282276	chr8:95985391	G/A	cg16049864	chr8:95962084	TP53INP1	0.54	4.64	0.38	8.87e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs78461346	0.610	rs111617764	chr17:80468182	A/G	cg15014069	chr17:80540666	FOXK2	0.38	4.63	0.38	9.19e-6	3-hydroxypropylmercapturic acid levels in smokers;
TGCT	cis	rs9653442	0.628	rs12474386	chr2:100857017	G/A	cg22139774	chr2:100720529	AFF3	-0.39	-6.41	-0.5	2.73e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs1008375	0.932	rs13127157	chr4:17618049	A/G	cg16339924	chr4:17578868	LAP3	-0.71	-5.7	-0.46	8.27e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1865760	0.865	rs4478388	chr6:25953633	A/G	cg16482183	chr6:26056742	HIST1H1C	0.53	4.88	0.4	3.14e-6	Height;
TGCT	cis	rs9549260	0.753	rs61963264	chr13:41154792	G/A	cg21288729	chr13:41239152	FOXO1	0.68	4.75	0.39	5.58e-6	Red blood cell count;
TGCT	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.55	4.92	0.4	2.74e-6	Prudent dietary pattern;
TGCT	cis	rs3772130	1.000	rs34086988	chr3:121352745	G/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.55	4.95	0.41	2.35e-6	Cognitive performance;
TGCT	cis	rs2836950	0.805	rs2836961	chr21:40627020	A/C	cg06238570	chr21:40685208	BRWD1	-0.57	-5.68	-0.45	9.16e-8	Menarche (age at onset);
TGCT	cis	rs9303401	0.538	rs35454383	chr17:56475599	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.59	5.62	0.45	1.18e-7	Cognitive test performance;
TGCT	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg10802521	chr3:52805072	NEK4	-0.78	-10.0	-0.67	1.26e-17	Electroencephalogram traits;
TGCT	cis	rs6121246	0.559	rs6058468	chr20:30406448	C/A	cg13852791	chr20:30311386	BCL2L1	0.79	7.34	0.55	2.42e-11	Mean corpuscular hemoglobin;
TGCT	cis	rs6933660	0.745	rs6912830	chr6:151743629	A/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.87	-9.56	-0.65	1.45e-16	Menarche (age at onset);
TGCT	cis	rs6840360	0.571	rs4696098	chr4:152489053	C/T	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.0	-0.58	7.69e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs7635838	0.617	rs2122031	chr3:11314143	G/A	cg00170343	chr3:11313890	ATG7	0.61	5.98	0.47	2.16e-8	HDL cholesterol;
TGCT	cis	rs3099143	1.000	rs7178759	chr15:77143513	A/G	cg21673338	chr15:77095150	SCAPER	0.51	5.03	0.41	1.65e-6	Recalcitrant atopic dermatitis;
TGCT	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	5.11	0.42	1.18e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs17345786	1.000	rs3804778	chr3:101294572	C/T	cg12386194	chr3:101231763	SENP7	0.59	5.39	0.44	3.43e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg03388025	chr16:89894329	SPIRE2	0.48	8.34	0.6	1.21e-13	Vitiligo;
TGCT	cis	rs3733631	1.000	rs3796951	chr4:104628158	A/T	cg24090629	chr4:104641072	TACR3	0.73	5.81	0.46	4.96e-8	Menarche (age at onset);
TGCT	trans	rs11098499	0.954	rs12510138	chr4:120423935	C/G	cg25214090	chr10:38739885	LOC399744	0.38	6.65	0.51	8.51e-10	Corneal astigmatism;
TGCT	cis	rs12477438	0.501	rs6542868	chr2:99782848	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.75	7.25	0.55	3.92e-11	Chronic sinus infection;
TGCT	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg04287289	chr16:89883240	FANCA	0.95	12.12	0.74	8.63e-23	Vitiligo;
TGCT	cis	rs1153858	0.945	rs16943246	chr15:45720597	G/A	cg14582100	chr15:45693742	SPATA5L1	0.45	5.1	0.42	1.22e-6	Homoarginine levels;
TGCT	cis	rs1005277	0.505	rs10827836	chr10:38215441	A/G	cg13531842	chr10:38383804	ZNF37A	0.39	4.58	0.38	1.12e-5	Extrinsic epigenetic age acceleration;
TGCT	cis	rs72781680	0.904	rs72796340	chr2:24143622	T/A	cg08917208	chr2:24149416	ATAD2B	0.73	4.51	0.38	1.48e-5	Lymphocyte counts;
TGCT	cis	rs7208859	0.673	rs11658435	chr17:29228561	A/G	cg18442181	chr17:29233375	C17orf42	-0.78	-4.61	-0.38	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7824557	0.547	rs6601570	chr8:11079367	G/A	cg27411982	chr8:10470053	RP1L1	-0.22	-4.55	-0.38	1.26e-5	Retinal vascular caliber;
TGCT	cis	rs3540	0.597	rs3743409	chr15:91045539	T/A	cg22089800	chr15:90895588	ZNF774	-0.76	-7.77	-0.57	2.55e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs2243480	0.708	rs13242216	chr7:65898277	T/C	cg18252515	chr7:66147081	NA	-1.18	-7.56	-0.56	7.99e-12	Diabetic kidney disease;
TGCT	cis	rs6845621	0.901	rs1452552	chr4:18919979	G/A	cg12196642	chr4:18937545	NA	-0.24	-4.45	-0.37	1.91e-5	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
TGCT	cis	rs2290402	0.536	rs12509561	chr4:850701	C/T	cg06416060	chr4:1402434	NA	0.32	4.43	0.37	2.01e-5	Type 2 diabetes;
TGCT	cis	rs1005224	0.963	rs2302592	chr14:76129287	C/G	cg04684003	chr14:76127793	TTLL5;C14orf1	0.61	5.68	0.45	9.22e-8	Large artery stroke;
TGCT	cis	rs6909279	0.678	rs9479056	chr6:151848899	C/A	cg10883421	chr6:151773342	RMND1;C6orf211	-0.49	-4.44	-0.37	1.95e-5	Bone mineral density;
TGCT	cis	rs4304924	0.500	rs12585725	chr13:79220899	C/A	cg05295671	chr13:79234353	RNF219	0.78	6.17	0.48	8.8e-9	Large artery stroke;
TGCT	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg13607699	chr17:42295918	UBTF	-0.56	-5.49	-0.44	2.21e-7	Total body bone mineral density;
TGCT	cis	rs7267979	1.000	rs2500436	chr20:25406366	G/C	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.87	0.47	3.73e-8	Alzheimer's disease;
TGCT	cis	rs1292048	1	rs1292048	chr17:57955071	A/G	cg16369400	chr17:58041258	RNFT1	0.23	4.47	0.37	1.72e-5	Red cell distribution width;
TGCT	cis	rs17741873	0.836	rs4745723	chr10:75603338	T/C	cg07699608	chr10:75541558	CHCHD1	0.71	4.82	0.4	4.03e-6	Paclitaxel disposition in epithelial ovarian cancer;
TGCT	cis	rs9902453	0.791	rs7219163	chr17:28210703	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.9	8.62	0.61	2.66e-14	Coffee consumption (cups per day);
TGCT	cis	rs2594989	0.887	rs9850117	chr3:11571991	C/T	cg00170343	chr3:11313890	ATG7	-0.68	-4.91	-0.4	2.8e-6	Circulating chemerin levels;
TGCT	cis	rs17345786	0.861	rs79181492	chr3:101216021	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.4	-8.36	-0.6	1.09e-13	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6554196	0.606	rs7663318	chr4:55538880	T/C	cg22722822	chr4:54931066	CHIC2	0.59	4.98	0.41	2.09e-6	Monocyte count;
TGCT	cis	rs17401966	0.931	rs4846213	chr1:10399178	A/G	cg19773385	chr1:10388646	KIF1B	-0.24	-5.5	-0.44	2.03e-7	Hepatocellular carcinoma;
TGCT	cis	rs2486288	0.586	rs12909625	chr15:45572053	C/A	cg14582100	chr15:45693742	SPATA5L1	-0.47	-5.38	-0.44	3.57e-7	Glomerular filtration rate;
TGCT	cis	rs2201728	0.967	rs6532814	chr4:100173968	T/C	cg07219303	chr4:100140905	ADH6	-0.35	-5.21	-0.42	7.63e-7	Cardiac Troponin-T levels;
TGCT	cis	rs704	0.605	rs2071379	chr17:26695832	A/G	cg10342447	chr17:26645325	TMEM97	-0.61	-6.18	-0.49	8.64e-9	Osteoprotegerin levels;
TGCT	cis	rs2070433	0.706	rs2268524	chr21:47838700	C/T	cg04277056	chr21:48021941	S100B	0.31	4.48	0.37	1.67e-5	Lymphocyte counts;
TGCT	cis	rs894734	0.535	rs2366143	chr12:54323256	G/A	cg17708016	chr12:54321992	NA	0.66	5.53	0.44	1.81e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
TGCT	cis	rs2243480	0.901	rs778732	chr7:65822360	C/T	cg18252515	chr7:66147081	NA	-1.11	-6.62	-0.51	9.81e-10	Diabetic kidney disease;
TGCT	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.63	5.12	0.42	1.11e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7666738	0.819	rs13139560	chr4:99081188	C/T	cg17366294	chr4:99064904	C4orf37	0.71	5.48	0.44	2.27e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1371867	0.555	rs2861348	chr8:101285074	A/G	cg06636551	chr8:101224915	SPAG1	-0.43	-5.95	-0.47	2.58e-8	Atrioventricular conduction;
TGCT	cis	rs7267979	1.000	rs6050562	chr20:25336186	C/G	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2997447	0.653	rs56134135	chr1:26440718	A/T	cg03844060	chr1:26490628	NA	0.28	4.55	0.38	1.27e-5	QRS complex (12-leadsum);
TGCT	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg06873352	chr17:61820015	STRADA	0.58	6.36	0.5	3.51e-9	Prudent dietary pattern;
TGCT	cis	rs11677370	0.561	rs13015012	chr2:3821252	C/G	cg17052675	chr2:3827356	NA	0.45	8.02	0.58	6.66e-13	Type 2 diabetes;
TGCT	cis	rs8180040	0.545	rs9311403	chr3:47138878	T/C	cg27129171	chr3:47204927	SETD2	0.7	8.55	0.61	3.75e-14	Colorectal cancer;
TGCT	cis	rs4595586	0.545	rs6580895	chr12:39372011	C/T	cg10518543	chr12:38710700	ALG10B	-0.54	-4.44	-0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs587847	0.737	rs4368128	chr15:37677359	G/T	cg00216138	chr15:37171175	LOC145845	0.31	4.45	0.37	1.91e-5	Intraocular pressure;
TGCT	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg11941060	chr3:133502564	NA	-0.26	-5.43	-0.44	2.88e-7	Iron status biomarkers;
TGCT	cis	rs7666738	0.519	rs13136069	chr4:98819568	C/T	cg17366294	chr4:99064904	C4orf37	0.65	5.96	0.47	2.39e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11711311	0.869	rs1026364	chr3:113370010	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.71	-6.11	-0.48	1.21e-8	IgG glycosylation;
TGCT	cis	rs9921222	0.585	rs7195617	chr16:376781	A/G	cg00101154	chr16:420108	MRPL28	0.53	5.67	0.45	9.45e-8	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs7017914	0.967	rs34558600	chr8:71586152	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.03	-0.41	1.69e-6	Bone mineral density;
TGCT	cis	rs2229238	0.911	rs4639752	chr1:154508974	T/A	cg13067139	chr1:155221277	FAM189B	0.2	4.51	0.38	1.47e-5	Coronary heart disease;
TGCT	cis	rs12971120	0.891	rs3794955	chr18:72174827	C/T	cg25817165	chr18:72167213	CNDP2	-0.27	-4.65	-0.39	8.37e-6	Refractive error;
TGCT	cis	rs7666738	0.570	rs1869351	chr4:99077286	T/C	cg18180107	chr4:99064573	C4orf37	0.51	4.56	0.38	1.21e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3020333	1.000	rs3020332	chr6:152008924	C/T	cg22157087	chr6:152012887	ESR1	0.19	4.61	0.38	9.97e-6	Total body bone mineral density;
TGCT	cis	rs1857353	1.000	rs2040079	chr1:75906421	G/T	cg11838876	chr1:75668600	SLC44A5	-0.51	-4.81	-0.4	4.23e-6	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs151997	0.962	rs27475	chr5:50180439	A/C	cg06027927	chr5:50259733	NA	0.46	4.61	0.38	9.69e-6	Callous-unemotional behaviour;
TGCT	cis	rs35306767	0.953	rs10904581	chr10:964685	A/T	cg26597838	chr10:835615	NA	0.63	9.1	0.63	1.93e-15	Eosinophil percentage of granulocytes;
TGCT	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg25767906	chr1:53392781	SCP2	-0.63	-7.64	-0.57	5e-12	Monocyte count;
TGCT	cis	rs12148488	0.763	rs2304902	chr15:75340727	G/T	cg10253484	chr15:75165896	SCAMP2	-0.57	-4.93	-0.41	2.53e-6	Caffeine consumption;
TGCT	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs4595586	0.545	rs12809435	chr12:39404341	C/T	cg10518543	chr12:38710700	ALG10B	-0.54	-4.44	-0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs35771425	0.509	rs3120782	chr1:211419700	A/T	cg26515805	chr1:211431828	RCOR3	-0.44	-4.78	-0.39	4.87e-6	Educational attainment (years of education);
TGCT	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg11941060	chr3:133502564	NA	-0.26	-5.27	-0.43	5.95e-7	Iron status biomarkers;
TGCT	cis	rs1775715	0.513	rs2808089	chr10:32145112	A/T	cg14930904	chr10:32216787	ARHGAP12	0.53	5.1	0.42	1.22e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg13695892	chr22:41940480	POLR3H	-0.9	-9.03	-0.63	2.7e-15	Vitiligo;
TGCT	cis	rs7552404	0.924	rs2173378	chr1:76201992	G/T	cg03433033	chr1:76189801	ACADM	0.77	9.25	0.64	8.26e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs28735056	1.000	rs3826576	chr18:77633976	G/A	cg20368463	chr18:77673604	PQLC1	-0.44	-5.51	-0.44	1.99e-7	Schizophrenia;
TGCT	cis	rs5769765	0.954	rs6009900	chr22:50236610	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.12	-12.25	-0.74	4.22e-23	Schizophrenia;
TGCT	cis	rs611744	0.967	rs597649	chr8:109187718	T/G	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg02380750	chr20:61661411	NA	0.34	6.02	0.48	1.86e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg08859206	chr1:53392774	SCP2	-0.43	-6.71	-0.52	6.09e-10	Monocyte count;
TGCT	cis	rs67311347	1.000	rs4973898	chr3:40459532	A/G	cg13683864	chr3:40499215	RPL14	1.01	10.31	0.68	2.27e-18	Renal cell carcinoma;
TGCT	cis	rs6964587	0.967	rs6974827	chr7:91772945	C/T	cg17063962	chr7:91808500	NA	0.93	10.08	0.67	8.03e-18	Breast cancer;
TGCT	cis	rs9534288	0.797	rs6561278	chr13:46572937	T/C	cg15192986	chr13:46630673	CPB2	-0.53	-7.62	-0.56	5.82e-12	Blood protein levels;
TGCT	cis	rs57590327	0.555	rs7634258	chr3:81799100	T/C	cg07356753	chr3:81810745	GBE1	-0.77	-7.2	-0.54	5.1e-11	Extraversion;
TGCT	cis	rs2645424	0.635	rs62495697	chr8:11709007	G/A	cg18999641	chr8:11876646	NA	0.22	4.54	0.38	1.31e-5	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
TGCT	cis	rs67311347	1.000	rs7642906	chr3:40492633	G/A	cg13683864	chr3:40499215	RPL14	1.07	10.74	0.69	1.99e-19	Renal cell carcinoma;
TGCT	cis	rs7666738	0.830	rs10009206	chr4:99056900	A/C	cg05340658	chr4:99064831	C4orf37	-0.51	-5.78	-0.46	5.78e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3087591	0.960	rs2952999	chr17:29509801	G/T	cg24425628	chr17:29625626	OMG;NF1	0.47	7.11	0.54	8e-11	Hip circumference;
TGCT	cis	rs1348850	0.914	rs2364854	chr2:178378452	T/A	cg22681709	chr2:178499509	PDE11A	-0.35	-4.67	-0.39	7.69e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs7917772	0.532	rs10748829	chr10:104527244	G/A	cg05855489	chr10:104503620	C10orf26	0.66	5.24	0.43	6.74e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7674212	1.000	rs7674212	chr4:103988899	G/T	cg16532752	chr4:104119610	CENPE	-0.53	-5.03	-0.41	1.7e-6	Type 2 diabetes;
TGCT	cis	rs16866061	1.000	rs72974267	chr2:225454209	T/C	cg12698349	chr2:225449008	CUL3	1.02	9.8	0.66	3.83e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	cis	rs67311347	1.000	rs6599094	chr3:40399593	A/G	cg17264618	chr3:40429014	ENTPD3	0.31	4.65	0.39	8.38e-6	Renal cell carcinoma;
TGCT	cis	rs4622507	0.688	rs4784464	chr16:55073590	T/C	cg27642062	chr16:55513148	MMP2	-0.65	-4.68	-0.39	7.52e-6	Social communication problems;
TGCT	cis	rs9303401	0.614	rs34678056	chr17:57177549	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.64	5.87	0.47	3.79e-8	Cognitive test performance;
TGCT	cis	rs7219021	0.705	rs999475	chr17:46988044	C/T	cg26022315	chr17:47021804	SNF8	-0.54	-4.65	-0.39	8.2e-6	Schizophrenia or bipolar disorder;
TGCT	cis	rs7086627	0.515	rs10887900	chr10:82210265	A/G	cg01528321	chr10:82214614	TSPAN14	0.61	5.74	0.46	6.72e-8	Post bronchodilator FEV1;
TGCT	cis	rs11190604	1.000	rs1106565	chr10:102211613	T/C	cg23241863	chr10:102295624	HIF1AN	0.62	4.87	0.4	3.27e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2404602	0.692	rs59088060	chr15:76859974	T/C	cg22467129	chr15:76604101	ETFA	-0.47	-5.43	-0.44	2.87e-7	Blood metabolite levels;
TGCT	cis	rs10751667	1.000	rs7396798	chr11:970510	G/T	cg06064525	chr11:970664	AP2A2	-0.33	-6.51	-0.5	1.71e-9	Alzheimer's disease (late onset);
TGCT	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg17345569	chr6:42928274	GNMT	-0.48	-4.96	-0.41	2.29e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs56036086	1.000	rs73187249	chr22:50634526	G/A	cg01548456	chr22:50352384	NA	0.37	4.82	0.4	4.17e-6	Platelet count;Plateletcrit;
TGCT	cis	rs11247915	0.600	rs72649360	chr1:26662904	C/T	cg23732845	chr1:26663426	AIM1L	-0.38	-4.8	-0.4	4.4e-6	Obesity-related traits;
TGCT	cis	rs6840360	0.550	rs62327349	chr4:152627230	G/C	cg17479576	chr4:152424074	FAM160A1	-0.66	-6.63	-0.51	9.17e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg11764359	chr7:65958608	NA	0.58	5.31	0.43	4.91e-7	Aortic root size;
TGCT	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.42	4.65	0.39	8.34e-6	Lymphocyte counts;
TGCT	cis	rs36051895	0.589	rs10283734	chr9:5217139	A/T	cg02405213	chr9:5042618	JAK2	-0.72	-9.36	-0.64	4.53e-16	Pediatric autoimmune diseases;
TGCT	cis	rs35883536	0.647	rs1335765	chr1:101048612	A/T	cg10298815	chr1:101004474	GPR88	-0.25	-4.5	-0.37	1.54e-5	Monocyte count;
TGCT	cis	rs2120019	0.567	rs8029351	chr15:75177237	A/C	cg09165964	chr15:75287851	SCAMP5	-0.88	-7.07	-0.54	9.73e-11	Blood trace element (Zn levels);
TGCT	cis	rs896854	0.738	rs509594	chr8:95967156	C/G	cg16049864	chr8:95962084	TP53INP1	0.65	7.67	0.57	4.37e-12	Type 2 diabetes;
TGCT	cis	rs4273100	0.749	rs7221299	chr17:19250679	G/A	cg01534423	chr17:18965556	NA	0.9	5.1	0.42	1.22e-6	Schizophrenia;
TGCT	cis	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg08564027	chr20:61660810	NA	0.38	6.77	0.52	4.65e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7698623	0.850	rs4693195	chr4:88798211	G/A	cg27387453	chr4:88533842	DSPP	-0.6	-4.53	-0.38	1.37e-5	Cardiovascular disease risk factors;
TGCT	cis	rs9291683	0.595	rs11722930	chr4:10035454	G/A	cg00071950	chr4:10020882	SLC2A9	0.68	8.84	0.62	7.71e-15	Bone mineral density;
TGCT	cis	rs9388451	0.903	rs9388446	chr6:126064920	T/A	cg05901451	chr6:126070800	HEY2	-1.01	-13.78	-0.78	9.03e-27	Brugada syndrome;
TGCT	cis	rs2762353	0.603	rs9393670	chr6:25789061	A/G	cg03517284	chr6:25882590	NA	0.54	5.44	0.44	2.77e-7	Blood metabolite levels;
TGCT	cis	rs2730245	0.527	rs2036582	chr7:158701708	A/T	cg11984989	chr7:158649758	WDR60	0.91	7.29	0.55	3.16e-11	Height;
TGCT	cis	rs11190604	1.000	rs7085439	chr10:102210100	C/T	cg23241863	chr10:102295624	HIF1AN	0.62	4.87	0.4	3.27e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs3741404	0.620	rs12787945	chr11:63977546	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.79	8.19	0.59	2.77e-13	Platelet count;
TGCT	cis	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg18252515	chr7:66147081	NA	1.22	7.33	0.55	2.53e-11	Diabetic kidney disease;
TGCT	cis	rs13256369	0.802	rs11995449	chr8:8559898	G/A	cg17143192	chr8:8559678	CLDN23	0.53	4.82	0.4	4.03e-6	Obesity-related traits;
TGCT	cis	rs7959452	0.535	rs7133487	chr12:69774377	G/A	cg14784868	chr12:69753453	YEATS4	0.83	8.96	0.63	4.14e-15	Blood protein levels;
TGCT	cis	rs4699052	0.963	rs6533078	chr4:104212156	C/T	cg16532752	chr4:104119610	CENPE	-0.56	-5.1	-0.42	1.26e-6	Testicular germ cell tumor;
TGCT	cis	rs8103278	1.000	rs8109951	chr19:46289503	C/T	cg14061069	chr19:46274453	DMPK	-0.43	-6.19	-0.49	8.07e-9	Coronary artery disease;
TGCT	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg07507251	chr3:52567010	NT5DC2	0.47	6.64	0.51	8.85e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs7582180	0.627	rs4407265	chr2:101005846	C/G	cg14675211	chr2:100938903	LONRF2	0.47	4.56	0.38	1.22e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs9914988	0.943	rs11651867	chr17:27147248	T/G	cg20469991	chr17:27169893	C17orf63	-0.72	-5.09	-0.42	1.28e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg04632378	chr13:21900426	NA	0.43	5.04	0.41	1.6e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg21963583	chr11:68658836	MRPL21	0.36	6.04	0.48	1.7e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs910316	0.810	rs77939209	chr14:75670070	A/G	cg23033748	chr14:75592666	NEK9	-0.26	-4.49	-0.37	1.6e-5	Height;
TGCT	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.22	-5.51	-0.44	1.98e-7	Birth weight;
TGCT	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.7	-5.52	-0.44	1.92e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs908922	0.676	rs12116609	chr1:152497685	C/T	cg20991723	chr1:152506922	NA	0.46	6.28	0.49	5.26e-9	Hair morphology;
TGCT	cis	rs7617773	0.815	rs6793150	chr3:48351560	G/A	cg11946769	chr3:48343235	NME6	0.82	7.09	0.54	9.1e-11	Coronary artery disease;
TGCT	cis	rs6598955	0.671	rs3924325	chr1:26616320	T/C	cg04990556	chr1:26633338	UBXN11	0.64	4.91	0.4	2.78e-6	Obesity-related traits;
TGCT	cis	rs6912958	0.582	rs242285	chr6:88070743	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.44	5.83	0.46	4.53e-8	Monocyte percentage of white cells;
TGCT	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg05754148	chr16:3507555	NAT15	0.43	5.14	0.42	1.02e-6	Tuberculosis;
TGCT	cis	rs6089829	0.643	rs6011545	chr20:61660038	G/A	cg18188782	chr20:61659543	NA	0.41	4.45	0.37	1.91e-5	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7223966	1.000	rs8069687	chr17:61883023	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.58	-4.63	-0.38	8.91e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs11674184	0.516	rs72772088	chr2:11742458	A/G	cg07314298	chr2:11723111	GREB1	-0.38	-6.85	-0.52	3.13e-10	Endometriosis;
TGCT	cis	rs244731	0.959	rs6872021	chr5:176610012	G/A	cg06060754	chr5:176797920	RGS14	-0.44	-6.2	-0.49	7.79e-9	Urate levels in lean individuals;
TGCT	cis	rs11190604	1.000	rs10883511	chr10:102299407	A/G	cg23241863	chr10:102295624	HIF1AN	0.72	5.33	0.43	4.47e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs12478296	0.901	rs9653611	chr2:243006956	C/G	cg06360820	chr2:242988706	NA	-0.62	-5.23	-0.43	6.93e-7	Obesity-related traits;
TGCT	cis	rs9914988	0.887	rs4795463	chr17:27146389	G/C	cg20469991	chr17:27169893	C17orf63	-0.72	-5.09	-0.42	1.28e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	trans	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.8	8.32	0.6	1.31e-13	Body mass index;
TGCT	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg03517284	chr6:25882590	NA	-0.62	-6.45	-0.5	2.23e-9	Blood metabolite levels;
TGCT	cis	rs13256369	1.000	rs4841017	chr8:8577093	A/G	cg17143192	chr8:8559678	CLDN23	0.62	5.83	0.46	4.47e-8	Obesity-related traits;
TGCT	cis	rs4689388	0.791	rs1046317	chr4:6304242	T/C	cg25554036	chr4:6271136	WFS1	0.54	6.41	0.5	2.79e-9	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs8078723	0.866	rs7502514	chr17:38188844	A/G	cg17467752	chr17:38218738	THRA	-0.63	-6.18	-0.49	8.61e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs35306767	0.903	rs11253495	chr10:937064	C/T	cg20503657	chr10:835505	NA	0.73	9.92	0.67	1.92e-17	Eosinophil percentage of granulocytes;
TGCT	trans	rs1908814	0.510	rs57655799	chr8:11782417	A/C	cg15556689	chr8:8085844	FLJ10661	0.8	7.57	0.56	7.56e-12	Neuroticism;
TGCT	cis	rs4455778	0.665	rs3925006	chr7:49068450	G/C	cg26309511	chr7:48887640	NA	0.47	5.33	0.43	4.56e-7	Lung cancer in never smokers;
TGCT	cis	rs7267979	1.000	rs2258884	chr20:25279539	C/T	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs707040	0.961	rs2882047	chr2:155235000	G/T	cg18104148	chr2:154337490	NA	0.19	4.56	0.38	1.2e-5	Sudden cardiac arrest;
TGCT	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg06753367	chr22:24256600	NA	-0.24	-4.5	-0.37	1.56e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg13397359	chr6:42928475	GNMT	0.73	6.54	0.51	1.45e-9	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs3749237	0.595	rs4855861	chr3:49525962	G/T	cg07636037	chr3:49044803	WDR6	0.63	6.07	0.48	1.47e-8	Resting heart rate;
TGCT	cis	rs11031096	0.678	rs12292724	chr11:4176671	T/A	cg18678763	chr11:4115507	RRM1	-0.44	-5.75	-0.46	6.48e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg06873352	chr17:61820015	STRADA	0.58	6.37	0.5	3.32e-9	Prudent dietary pattern;
TGCT	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs514406	0.758	rs532242	chr1:53308665	C/G	cg08859206	chr1:53392774	SCP2	-0.42	-6.22	-0.49	7.06e-9	Monocyte count;
TGCT	cis	rs4285028	0.747	rs1920299	chr3:121593769	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.74	6.3	0.49	4.77e-9	Multiple sclerosis;
TGCT	cis	rs861020	0.606	rs4844903	chr1:210006267	C/T	cg05527609	chr1:210001259	C1orf107	0.86	7.54	0.56	8.69e-12	Orofacial clefts;
TGCT	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg03452623	chr4:187889614	NA	-0.37	-5.53	-0.44	1.84e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg14983838	chr19:29218262	NA	0.83	6.85	0.52	3.07e-10	Methadone dose in opioid dependence;
TGCT	cis	rs2354432	0.607	rs2353999	chr1:146830686	T/C	cg25205988	chr1:146714368	CHD1L	-1.37	-6.13	-0.48	1.1e-8	Mitochondrial DNA levels;
TGCT	cis	rs6938	0.534	rs12907898	chr15:75207872	C/T	cg09165964	chr15:75287851	SCAMP5	0.54	5.07	0.41	1.39e-6	Breast cancer;
TGCT	cis	rs6964587	1.000	rs10274756	chr7:91740796	G/A	cg17063962	chr7:91808500	NA	0.87	9.34	0.64	4.87e-16	Breast cancer;
TGCT	cis	rs73001065	0.688	rs59148799	chr19:19484008	A/G	cg03709012	chr19:19516395	GATAD2A	0.88	4.69	0.39	7.11e-6	LDL cholesterol;
TGCT	trans	rs208520	0.661	rs6937856	chr6:66867468	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-10.43	-0.68	1.13e-18	Exhaled nitric oxide output;
TGCT	cis	rs10193935	0.901	rs72798529	chr2:42537471	C/T	cg27598129	chr2:42591480	NA	-0.4	-5.51	-0.44	1.98e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs208520	1.000	rs12209225	chr6:66996443	G/T	cg07460842	chr6:66804631	NA	0.8	6.98	0.53	1.61e-10	Exhaled nitric oxide output;
TGCT	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.7	0.52	6.47e-10	Bipolar disorder;
TGCT	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg02725872	chr8:58115012	NA	-0.41	-5.38	-0.44	3.5e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg23302884	chr18:44338147	ST8SIA5	-0.4	-4.57	-0.38	1.18e-5	Personality dimensions;
TGCT	cis	rs714052	0.518	rs13234378	chr7:73026151	A/T	cg14087351	chr7:73037990	MLXIPL	-0.81	-5.58	-0.45	1.47e-7	Hypertriglyceridemia;Triglycerides;
TGCT	cis	rs9910055	0.529	rs228746	chr17:42173752	T/C	cg13607699	chr17:42295918	UBTF	-0.63	-5.14	-0.42	1.04e-6	Total body bone mineral density;
TGCT	cis	rs9383153	0.793	rs9358090	chr6:16348728	G/A	cg06493612	chr6:15502050	JARID2	0.62	4.92	0.4	2.74e-6	Gambling;
TGCT	trans	rs7618501	0.699	rs2681780	chr3:49897830	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.93	10.31	0.68	2.22e-18	Intelligence (multi-trait analysis);
TGCT	cis	rs1990950	0.692	rs10054988	chr5:156859483	T/G	cg25387487	chr5:157003181	ADAM19	0.31	4.78	0.39	4.78e-6	Lung function (FEV1/FVC);
TGCT	cis	rs10114408	0.959	rs10821258	chr9:96657324	C/T	cg13679303	chr9:96623674	NA	-0.36	-4.62	-0.38	9.52e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs16958440	0.867	rs10083937	chr18:44695602	A/G	cg17192377	chr18:44677553	HDHD2	0.63	4.7	0.39	6.74e-6	Sitting height ratio;
TGCT	cis	rs611744	0.967	rs598022	chr8:109187759	C/T	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs11696501	0.694	rs1487325	chr20:44258989	A/G	cg11783356	chr20:44313418	WFDC10B	0.32	4.63	0.38	9.25e-6	Brain structure;
TGCT	cis	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg16624210	chr5:671434	TPPP	0.42	4.68	0.39	7.38e-6	Obesity-related traits;
TGCT	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.48	-0.37	1.66e-5	Bipolar disorder;
TGCT	cis	rs600231	0.665	rs12790095	chr11:65326086	T/G	cg17120908	chr11:65337727	SSSCA1	-0.52	-4.79	-0.39	4.76e-6	Bone mineral density;
TGCT	cis	rs7666738	0.830	rs4699590	chr4:98974030	A/C	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs854765	0.547	rs4368210	chr17:17896090	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.78	-8.1	-0.59	4.3e-13	Total body bone mineral density;
TGCT	cis	rs11190604	1.000	rs10883492	chr10:102206089	G/A	cg16342193	chr10:102329863	NA	-0.4	-5.31	-0.43	4.85e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9638182	0.673	rs13233571	chr7:72971231	C/T	cg14087351	chr7:73037990	MLXIPL	-0.65	-4.88	-0.4	3.18e-6	Triglycerides;
TGCT	cis	rs394563	0.591	rs237016	chr6:149744859	T/C	cg03678062	chr6:149772716	ZC3H12D	-0.36	-4.55	-0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs1062177	1.000	rs6890099	chr5:151151962	A/G	cg12924095	chr5:151150029	G3BP1	0.35	5.09	0.42	1.31e-6	Preschool internalizing problems;
TGCT	cis	rs11935103	0.636	rs1470752	chr4:187296170	T/C	cg16785698	chr4:186456103	PDLIM3	0.44	4.47	0.37	1.74e-5	Response to citalopram treatment;
TGCT	cis	rs6435862	0.636	rs717548	chr2:215676905	G/A	cg04004882	chr2:215674386	BARD1	-0.75	-6.65	-0.51	8.39e-10	Neuroblastoma (high-risk);
TGCT	cis	rs2235642	0.821	rs8051895	chr16:1602811	A/G	cg07639376	chr16:1584516	IFT140;TMEM204	-0.33	-5.85	-0.46	4.15e-8	Coronary artery disease;
TGCT	cis	rs7820838	0.510	rs6468120	chr8:32402094	T/C	cg22651812	chr8:32095135	NRG1	-0.22	-4.56	-0.38	1.21e-5	Post bronchodilator FEV1/FVC ratio in COPD;Lung cancer;
TGCT	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg15242686	chr22:24348715	GSTTP1	-0.42	-5.68	-0.45	9.1e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg12963246	chr6:28129442	ZNF389	0.52	5.01	0.41	1.85e-6	Depression;
TGCT	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	5.73	0.46	7.09e-8	Height;
TGCT	cis	rs739496	0.653	rs7956676	chr12:112191139	A/G	cg10833066	chr12:111807467	FAM109A	0.35	5.18	0.42	8.83e-7	Platelet count;
TGCT	cis	rs1156327	0.510	rs4617845	chr16:19325209	A/G	cg02978544	chr16:19716338	NA	-0.42	-4.46	-0.37	1.82e-5	Periodontal disease-related phenotypes;
TGCT	cis	rs1372520	0.684	rs2583963	chr4:90727088	C/T	cg26578617	chr4:90757533	SNCA	-0.52	-4.44	-0.37	1.99e-5	Neuroticism;
TGCT	cis	rs3772130	0.775	rs6781857	chr3:121560721	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.62	0.38	9.48e-6	Cognitive performance;
TGCT	cis	rs250677	0.687	rs250671	chr5:148446523	T/C	cg18129178	chr5:148520854	ABLIM3	-0.43	-6.29	-0.49	5.05e-9	Breast cancer;
TGCT	cis	rs6866344	0.570	rs11740283	chr5:178136440	T/C	cg10224037	chr5:178157518	ZNF354A	0.98	9.45	0.65	2.77e-16	Neutrophil percentage of white cells;
TGCT	cis	rs11955175	0.717	rs41271053	chr5:40835393	A/C	cg17351974	chr5:40835760	RPL37	0.87	5.92	0.47	2.98e-8	Bipolar disorder and schizophrenia;
TGCT	cis	rs12510870	0.634	rs12510629	chr4:74380330	G/A	cg05868023	chr4:75230803	EREG	-0.55	-4.7	-0.39	6.84e-6	Iris color (b* coordinate);
TGCT	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg13665807	chr20:60559372	TAF4	0.47	5.04	0.41	1.62e-6	Body mass index;
TGCT	cis	rs7924176	0.521	rs10824137	chr10:76033154	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.47	4.57	0.38	1.15e-5	Primary tooth development (time to first tooth eruption);Permanent tooth development;Primary tooth development (number of teeth);
TGCT	cis	rs2115630	0.691	rs61322921	chr15:85163638	T/C	cg17173187	chr15:85201210	NMB	-0.47	-5.85	-0.47	4.06e-8	P wave terminal force;
TGCT	cis	rs2439831	0.867	rs2251844	chr15:43836478	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.97	7.38	0.55	2.03e-11	Lung cancer in ever smokers;
TGCT	cis	rs6429082	0.755	rs291372	chr1:235694106	G/C	cg26050004	chr1:235667680	B3GALNT2	0.64	5.79	0.46	5.53e-8	Adiposity;
TGCT	cis	rs67311347	1.000	rs17078511	chr3:40396254	A/G	cg13683864	chr3:40499215	RPL14	-1.1	-11.79	-0.73	5.64e-22	Renal cell carcinoma;
TGCT	cis	rs6752107	0.967	rs10203952	chr2:234153366	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.21	5.0	0.41	1.87e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs8103278	1.000	rs7256192	chr19:46338492	G/A	cg14061069	chr19:46274453	DMPK	-0.44	-6.29	-0.49	4.97e-9	Coronary artery disease;
TGCT	cis	rs2050392	1.000	rs2183176	chr10:30698544	C/T	cg13289132	chr10:30722225	MAP3K8	0.37	4.71	0.39	6.64e-6	Inflammatory bowel disease;
TGCT	cis	rs7772486	0.875	rs2748483	chr6:146335560	A/T	cg23711669	chr6:146136114	FBXO30	-0.83	-9.07	-0.63	2.2e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2228479	0.867	rs12930056	chr16:89946649	C/A	cg06558623	chr16:89946397	TCF25	0.56	6.83	0.52	3.38e-10	Skin colour saturation;
TGCT	cis	rs7000551	0.725	rs4871998	chr8:22308150	A/T	cg12081754	chr8:22256438	SLC39A14	0.3	5.0	0.41	1.93e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs17102423	0.826	rs10873180	chr14:65604361	A/G	cg11161011	chr14:65562177	MAX	0.49	6.85	0.52	3.13e-10	Obesity-related traits;
TGCT	cis	rs2429030	0.901	rs2245565	chr10:70759180	T/G	cg12938159	chr10:71332776	NEUROG3	-0.36	-4.48	-0.37	1.68e-5	Schizophrenia;
TGCT	cis	rs2836950	0.565	rs2836934	chr21:40564885	A/C	cg11890956	chr21:40555474	PSMG1	-0.68	-6.78	-0.52	4.39e-10	Menarche (age at onset);
TGCT	cis	rs2070488	0.804	rs13059256	chr3:38504315	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	7.9	0.58	1.3e-12	Electrocardiographic conduction measures;
TGCT	cis	rs61884328	0.852	rs61897782	chr11:47150177	G/A	cg13308137	chr11:47528955	CUGBP1	0.38	4.47	0.37	1.76e-5	Total body bone mineral density (age over 60);
TGCT	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg03709012	chr19:19516395	GATAD2A	0.75	6.24	0.49	6.45e-9	Tonsillectomy;
TGCT	cis	rs7072216	0.691	rs3829853	chr10:100171174	A/G	cg26618903	chr10:100175079	PYROXD2	-0.4	-4.49	-0.37	1.64e-5	Metabolite levels;
TGCT	cis	rs344364	0.511	rs1657132	chr16:1949924	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.45	-5.08	-0.42	1.35e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs36051895	0.603	rs10123980	chr9:5130363	T/C	cg02405213	chr9:5042618	JAK2	-0.76	-10.6	-0.69	4.38e-19	Pediatric autoimmune diseases;
TGCT	cis	rs7666738	0.830	rs10011009	chr4:98981749	G/A	cg18180107	chr4:99064573	C4orf37	0.53	4.89	0.4	3.01e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7552404	0.727	rs11161626	chr1:76260837	C/T	cg10523679	chr1:76189770	ACADM	0.73	6.77	0.52	4.67e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs5769765	0.658	rs2157536	chr22:50190180	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.32	4.51	0.38	1.49e-5	Schizophrenia;
TGCT	cis	rs6121246	0.528	rs6060252	chr20:30191084	A/G	cg18721089	chr20:30220636	NA	-0.63	-6.88	-0.53	2.67e-10	Mean corpuscular hemoglobin;
TGCT	cis	rs4929949	0.902	rs61875898	chr11:8627224	C/A	cg14521421	chr11:8862019	ST5	-0.3	-4.62	-0.38	9.42e-6	Body mass index;
TGCT	cis	rs8067545	1.000	rs9891739	chr17:19942177	C/T	cg13482628	chr17:19912719	NA	0.54	4.73	0.39	5.94e-6	Schizophrenia;
TGCT	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg04317338	chr11:64019027	PLCB3	0.77	6.43	0.5	2.48e-9	Mean platelet volume;
TGCT	cis	rs7707921	0.522	rs10070637	chr5:81490608	A/G	cg15871215	chr5:81402204	ATG10	0.25	4.97	0.41	2.22e-6	Breast cancer;
TGCT	cis	rs6671200	0.831	rs79662819	chr1:95619804	C/T	cg20701556	chr1:95698924	RWDD3	0.57	4.49	0.37	1.62e-5	Stearic acid (18:0) levels;
TGCT	cis	rs28735056	0.967	rs11662248	chr18:77619009	C/T	cg20368463	chr18:77673604	PQLC1	-0.44	-5.42	-0.44	2.99e-7	Schizophrenia;
TGCT	cis	rs34783982	0.748	rs12438134	chr15:89487518	T/A	cg26213453	chr15:89455860	MFGE8	0.34	4.64	0.38	8.87e-6	Squamous cell lung carcinoma;
TGCT	cis	rs12478296	1.000	rs56387669	chr2:243043889	T/C	cg06360820	chr2:242988706	NA	-0.61	-4.66	-0.39	8.13e-6	Obesity-related traits;
TGCT	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs17345786	1.000	rs3804775	chr3:101306507	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.45	-9.64	-0.65	9.35e-17	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1334894	0.792	rs56318292	chr6:35531163	C/T	cg24281267	chr6:35479648	TULP1	-0.43	-4.47	-0.37	1.78e-5	Coronary artery disease;
TGCT	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg23758822	chr17:41437982	NA	0.72	6.91	0.53	2.23e-10	Menopause (age at onset);
TGCT	cis	rs6582630	0.519	rs1607882	chr12:38361657	G/A	cg26384229	chr12:38710491	ALG10B	0.76	6.86	0.52	2.86e-10	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs1215050	0.740	rs783945	chr4:99014394	G/A	cg17366294	chr4:99064904	C4orf37	-0.54	-5.86	-0.47	3.98e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs6582630	0.560	rs11504462	chr12:38440379	G/A	cg26384229	chr12:38710491	ALG10B	-0.54	-4.81	-0.4	4.32e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs6060960	0.502	rs6089110	chr20:30486907	A/T	cg06102403	chr20:30458708	TTLL9;DUSP15	0.41	5.11	0.42	1.18e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
TGCT	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg22891161	chr3:195456627	MUC20	-0.24	-5.58	-0.45	1.45e-7	Pancreatic cancer;
TGCT	cis	rs7826238	0.601	rs2979206	chr8:8345581	G/C	cg06636001	chr8:8085503	FLJ10661	0.64	5.96	0.47	2.41e-8	Systolic blood pressure;
TGCT	cis	rs1348850	0.567	rs2222711	chr2:178534110	G/T	cg22681709	chr2:178499509	PDE11A	-0.47	-6.01	-0.47	1.94e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs806215	0.547	rs765971	chr7:127420642	C/T	cg11539674	chr7:127291444	SND1	-0.36	-4.6	-0.38	1.02e-5	Type 2 diabetes;
TGCT	cis	rs2070488	0.965	rs3762788	chr3:38493852	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	9.66	0.66	8.59e-17	Electrocardiographic conduction measures;
TGCT	cis	rs698813	0.642	rs1837702	chr2:44492444	T/A	cg00619915	chr2:44497795	NA	-0.24	-5.51	-0.44	1.99e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
TGCT	cis	rs10423674	0.526	rs11085241	chr19:18828546	G/A	cg20185461	chr19:18899082	COMP	-0.53	-5.03	-0.41	1.68e-6	Menarche (age at onset);
TGCT	cis	rs10510102	0.872	rs12265369	chr10:123727970	A/T	cg23691251	chr10:123688108	ATE1	-0.59	-4.7	-0.39	6.75e-6	Breast cancer;
TGCT	cis	rs1801251	0.963	rs7591176	chr2:233581803	C/A	cg08000102	chr2:233561755	GIGYF2	0.64	6.5	0.5	1.75e-9	Coronary artery disease;
TGCT	cis	rs17473412	1.000	rs76499408	chr5:122711035	G/A	cg15125798	chr5:122621645	NA	-0.57	-5.13	-0.42	1.08e-6	Total body bone mineral density;
TGCT	cis	rs7666738	0.609	rs28833816	chr4:98868866	T/C	cg18180107	chr4:99064573	C4orf37	0.54	4.54	0.38	1.32e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1532993	0.518	rs11097567	chr4:98597987	T/C	cg05340658	chr4:99064831	C4orf37	-0.38	-4.49	-0.37	1.59e-5	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9534288	0.912	rs2404732	chr13:46618611	C/A	cg15192986	chr13:46630673	CPB2	-0.49	-6.18	-0.49	8.64e-9	Blood protein levels;
TGCT	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg20007245	chr22:24372913	LOC391322	0.7	6.93	0.53	2.09e-10	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9583531	0.760	rs1887200	chr13:111393137	A/C	cg24331049	chr13:111365604	ING1	-0.67	-4.88	-0.4	3.21e-6	Coronary artery disease;
TGCT	cis	rs6089584	0.526	rs6061965	chr20:60607858	A/C	cg13770153	chr20:60521292	NA	-0.41	-5.23	-0.43	6.91e-7	Body mass index;
TGCT	cis	rs1580019	0.587	rs6968990	chr7:32552159	C/T	cg06627557	chr7:32535165	LSM5;AVL9	-1.17	-14.08	-0.78	1.71e-27	Cognitive ability;
TGCT	cis	rs62244186	0.566	rs55852922	chr3:44826188	A/G	cg25151919	chr3:44754333	ZNF502	-0.47	-5.44	-0.44	2.78e-7	Depressive symptoms;
TGCT	cis	rs7267979	0.934	rs2261753	chr20:25262291	G/A	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs12477438	0.798	rs6542848	chr2:99573732	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-6.21	-0.49	7.35e-9	Chronic sinus infection;
TGCT	cis	rs7208859	0.573	rs8078182	chr17:29149664	C/T	cg13385521	chr17:29058706	SUZ12P	0.74	4.5	0.37	1.56e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs12188164	0.965	rs72717435	chr5:448202	G/A	cg26850624	chr5:429559	AHRR	-0.2	-4.77	-0.39	5.02e-6	Cystic fibrosis severity;
TGCT	cis	rs12477438	0.520	rs6717729	chr2:99756941	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.12	17.23	0.84	1.05e-34	Chronic sinus infection;
TGCT	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg04287289	chr16:89883240	FANCA	0.93	11.59	0.72	1.71e-21	Vitiligo;
TGCT	cis	rs6121246	0.529	rs6060296	chr20:30198480	T/C	cg21427119	chr20:30132790	HM13	-0.39	-5.61	-0.45	1.25e-7	Mean corpuscular hemoglobin;
TGCT	cis	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg25427524	chr10:38739819	LOC399744	-0.4	-8.23	-0.59	2.17e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs28735056	0.933	rs56181785	chr18:77633629	G/A	cg20368463	chr18:77673604	PQLC1	-0.45	-5.58	-0.45	1.47e-7	Schizophrenia;
TGCT	cis	rs2439831	0.681	rs511673	chr15:43618863	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.02	8.69	0.62	1.84e-14	Lung cancer in ever smokers;
TGCT	cis	rs11098499	0.691	rs9996494	chr4:120238880	C/A	cg09307838	chr4:120376055	NA	0.63	6.14	0.48	1.01e-8	Corneal astigmatism;
TGCT	cis	rs7089973	0.604	rs58587374	chr10:116597572	A/G	cg03647239	chr10:116582469	FAM160B1	0.59	5.74	0.46	6.72e-8	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs1334894	1.000	rs72913427	chr6:35581803	G/C	cg24281267	chr6:35479648	TULP1	-0.43	-4.69	-0.39	7.09e-6	Coronary artery disease;
TGCT	cis	rs2115630	0.967	rs11073702	chr15:85310071	G/A	cg17173187	chr15:85201210	NMB	-0.39	-4.76	-0.39	5.4e-6	P wave terminal force;
TGCT	cis	rs909674	0.865	rs5757682	chr22:39848259	T/G	cg11247378	chr22:39784982	NA	-0.72	-8.67	-0.61	2.01e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs765787	0.530	rs11636018	chr15:45539137	T/C	cg24006582	chr15:45444508	DUOX1	-0.25	-5.54	-0.45	1.76e-7	Uric acid levels;
TGCT	cis	rs9660180	0.620	rs34298494	chr1:1663402	A/C	cg27541892	chr1:1571801	CDK11B	-0.42	-5.55	-0.45	1.65e-7	Body mass index;
TGCT	cis	rs514406	0.505	rs7543239	chr1:53162416	A/G	cg16325326	chr1:53192061	ZYG11B	0.85	11.54	0.72	2.24e-21	Monocyte count;
TGCT	cis	rs9902453	0.900	rs9910970	chr17:28478329	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	6.9	0.53	2.37e-10	Coffee consumption (cups per day);
TGCT	cis	rs7666738	0.830	rs7669407	chr4:98750251	G/A	cg17366294	chr4:99064904	C4orf37	0.65	6.78	0.52	4.31e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6598955	0.671	rs11579630	chr1:26612297	C/A	cg04990556	chr1:26633338	UBXN11	0.64	4.91	0.4	2.78e-6	Obesity-related traits;
TGCT	cis	rs6665290	0.870	rs1045289	chr1:227178713	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.01	-20.94	-0.88	1.57e-42	Myeloid white cell count;
TGCT	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg21724239	chr8:58056113	NA	0.38	5.14	0.42	1.02e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs116095464	0.558	rs73029475	chr5:206969	T/C	cg12570787	chr5:219185	SDHA;CCDC127	0.7	4.65	0.39	8.29e-6	Breast cancer;
TGCT	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg24399712	chr22:39784796	NA	-1.0	-12.1	-0.74	9.99e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs2153535	0.563	rs1737585	chr6:8536594	A/G	cg07606381	chr6:8435919	SLC35B3	-0.53	-4.96	-0.41	2.27e-6	Motion sickness;
TGCT	cis	rs2721195	0.845	rs756627	chr8:145737286	G/A	cg17328964	chr8:145687451	CYHR1	-0.44	-6.04	-0.48	1.62e-8	Age at first birth;
TGCT	cis	rs7953508	0.506	rs768775	chr12:93968197	T/C	cg18151635	chr12:93972918	NA	-0.19	-4.52	-0.38	1.41e-5	Pubertal anthropometrics;
TGCT	cis	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg18252515	chr7:66147081	NA	1.2	7.83	0.58	1.89e-12	Diabetic kidney disease;
TGCT	cis	rs2242116	1.000	rs1138518	chr3:46944274	T/C	cg23352942	chr3:46931381	PTH1R	-0.33	-4.81	-0.4	4.35e-6	Birth weight;
TGCT	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	5.17	0.42	9.23e-7	Electroencephalogram traits;
TGCT	trans	rs208520	1.000	rs208529	chr6:66957549	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.87	-8.1	-0.59	4.41e-13	Exhaled nitric oxide output;
TGCT	cis	rs77633900	0.614	rs2439984	chr15:76923917	T/C	cg21673338	chr15:77095150	SCAPER	-0.49	-4.73	-0.39	6.11e-6	Non-glioblastoma glioma;Glioma;
TGCT	cis	rs8031584	0.678	rs4779790	chr15:31164595	T/C	cg08109568	chr15:31115862	NA	-0.38	-5.03	-0.41	1.67e-6	Huntington's disease progression;
TGCT	cis	rs3771570	1.000	rs62193256	chr2:242362168	C/T	cg21155796	chr2:242212141	HDLBP	0.94	6.69	0.51	6.97e-10	Prostate cancer;
TGCT	cis	rs2072499	0.750	rs72708291	chr1:156177285	A/T	cg24450063	chr1:156163899	SLC25A44	1.09	10.11	0.67	6.85e-18	Testicular germ cell tumor;
TGCT	cis	rs6964587	1.000	rs34548928	chr7:91668365	G/A	cg17063962	chr7:91808500	NA	0.88	9.65	0.66	8.73e-17	Breast cancer;
TGCT	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg05368731	chr17:41323189	NBR1	1.08	11.0	0.7	4.76e-20	Menopause (age at onset);
TGCT	cis	rs617219	0.698	rs72764988	chr5:78533584	G/C	cg09550809	chr5:78407562	BHMT	0.4	5.49	0.44	2.19e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs804280	0.662	rs804283	chr8:11611043	G/A	cg26752888	chr8:11627280	NEIL2	-0.69	-5.46	-0.44	2.53e-7	Myopia (pathological);
TGCT	cis	rs13191362	1.000	rs13209100	chr6:163159350	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.64	5.62	0.45	1.22e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs6671200	1.000	rs35143903	chr1:95622527	C/T	cg26537280	chr1:95699037	RWDD3	0.69	5.46	0.44	2.47e-7	Stearic acid (18:0) levels;
TGCT	trans	rs1908814	0.516	rs13281077	chr8:11794814	C/T	cg15556689	chr8:8085844	FLJ10661	0.75	7.26	0.55	3.66e-11	Neuroticism;
TGCT	cis	rs477895	1.000	rs1047206	chr11:64089216	C/G	cg23719950	chr11:63933701	MACROD1	-0.59	-4.6	-0.38	1.01e-5	Mean platelet volume;
TGCT	cis	rs2439831	0.850	rs12101756	chr15:44053887	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	5.91	0.47	3.05e-8	Lung cancer in ever smokers;
TGCT	cis	rs2153535	0.580	rs1319169	chr6:8464456	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs9902453	0.967	rs8072664	chr17:28333385	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.74	-6.59	-0.51	1.12e-9	Coffee consumption (cups per day);
TGCT	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg24250549	chr1:154909240	PMVK	0.55	5.27	0.43	5.92e-7	Prostate cancer;
TGCT	cis	rs2458413	0.935	rs2514667	chr8:105358590	C/T	cg13045555	chr8:105342365	NA	0.42	6.91	0.53	2.22e-10	Paget's disease;
TGCT	cis	rs7264396	0.676	rs6060730	chr20:34558503	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.04	-0.41	1.58e-6	Total cholesterol levels;
TGCT	cis	rs7399018	1.000	rs7399018	chr12:51610365	C/T	cg25754956	chr12:51612065	POU6F1	-0.77	-7.03	-0.53	1.19e-10	Cisplatin-induced ototoxicity;
TGCT	cis	rs7439150	0.955	rs57292098	chr4:155481006	C/T	cg22130008	chr4:155548532	NA	-0.44	-5.59	-0.45	1.36e-7	Fibrinogen levels;
TGCT	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg06618935	chr21:46677482	NA	-0.36	-5.61	-0.45	1.25e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2243480	1.000	rs160644	chr7:65558186	C/T	cg07424592	chr7:64974309	NA	1.26	8.11	0.59	4.17e-13	Diabetic kidney disease;
TGCT	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg11764359	chr7:65958608	NA	0.61	5.54	0.45	1.76e-7	Aortic root size;
TGCT	cis	rs796364	0.662	rs11687313	chr2:201146399	G/A	cg17644776	chr2:200775616	C2orf69	-0.37	-5.05	-0.41	1.54e-6	Schizophrenia;
TGCT	cis	rs12887734	0.569	rs66953418	chr14:104271470	G/A	cg26031613	chr14:104095156	KLC1	-0.71	-6.2	-0.49	7.82e-9	Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg08219700	chr8:58056026	NA	0.29	4.5	0.37	1.54e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7584330	0.737	rs13397017	chr2:238361241	G/A	cg14458575	chr2:238380390	NA	0.51	8.09	0.59	4.69e-13	Prostate cancer;
TGCT	cis	rs67311347	1.000	rs4246666	chr3:40407670	C/T	cg17264618	chr3:40429014	ENTPD3	0.32	4.76	0.39	5.36e-6	Renal cell carcinoma;
TGCT	cis	rs73110464	0.609	rs727266	chr12:53356411	C/T	cg05393297	chr12:53359155	NA	-0.79	-8.43	-0.6	7.2e-14	Cancer (pleiotropy);
TGCT	cis	rs60871478	0.636	rs10245785	chr7:894422	T/C	cg00475322	chr7:917719	C7orf20	0.5	4.87	0.4	3.37e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs2760061	0.626	rs2796057	chr1:228124414	G/C	cg18477163	chr1:228402036	OBSCN	-0.32	-6.37	-0.5	3.31e-9	Diastolic blood pressure;
TGCT	cis	rs7954584	0.531	rs6486781	chr12:122318985	A/C	cg10207240	chr12:122356781	WDR66	0.33	4.51	0.38	1.46e-5	Mean corpuscular volume;
TGCT	cis	rs9916302	0.706	rs6503521	chr17:37715551	A/C	cg07936489	chr17:37558343	FBXL20	0.81	6.02	0.48	1.85e-8	Glomerular filtration rate (creatinine);
TGCT	cis	rs17712049	1.000	rs17712049	chr7:48266195	A/G	cg16849860	chr7:48352531	ABCA13	-0.32	-4.93	-0.4	2.57e-6	Refractive astigmatism;
TGCT	cis	rs453301	0.568	rs13281377	chr8:8811564	C/T	cg15556689	chr8:8085844	FLJ10661	0.7	5.68	0.45	9.28e-8	Joint mobility (Beighton score);
TGCT	cis	rs3733585	0.699	rs4339211	chr4:9947658	C/T	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.42	-0.55	1.62e-11	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs4509693	1.000	rs4917908	chr10:102502674	G/C	cg24127310	chr10:102502104	NA	0.7	5.86	0.47	3.84e-8	Alzheimer's disease;
TGCT	trans	rs1814175	0.708	rs10839464	chr11:49981386	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.67	-0.69	2.92e-19	Height;
TGCT	cis	rs9611565	0.559	rs5751160	chr22:42175695	A/G	cg03806693	chr22:41940476	POLR3H	1.02	10.49	0.69	7.92e-19	Vitiligo;
TGCT	cis	rs17221829	0.673	rs4491227	chr11:89403759	G/A	cg02982614	chr11:89391479	FOLH1B	-0.28	-4.67	-0.39	7.81e-6	Anxiety in major depressive disorder;
TGCT	cis	rs68170813	0.559	rs74898466	chr7:107053998	C/A	cg02696742	chr7:106810147	HBP1	-0.7	-5.68	-0.45	8.91e-8	Coronary artery disease;
TGCT	cis	rs8031584	0.678	rs798086	chr15:31129211	C/G	cg08704250	chr15:31115839	NA	0.45	6.56	0.51	1.3e-9	Huntington's disease progression;
TGCT	cis	rs8017423	0.586	rs2896134	chr14:90831293	G/A	cg04374321	chr14:90722782	PSMC1	-0.58	-5.74	-0.46	6.9e-8	Mortality in heart failure;
TGCT	cis	rs13256369	0.851	rs13254997	chr8:8563753	G/C	cg06671706	chr8:8559999	CLDN23	0.34	4.53	0.38	1.38e-5	Obesity-related traits;
TGCT	cis	rs6754311	0.731	rs2322660	chr2:136557319	A/G	cg07169764	chr2:136633963	MCM6	0.61	5.59	0.45	1.35e-7	Mosquito bite size;
TGCT	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg06715136	chr7:158046025	PTPRN2	0.39	5.69	0.45	8.71e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2463822	1.000	rs2513749	chr11:62105391	C/T	cg06239285	chr11:62104954	ASRGL1	0.93	6.71	0.52	6.27e-10	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs6952808	0.542	rs10243920	chr7:1950385	G/A	cg04267008	chr7:1944627	MAD1L1	-0.36	-4.6	-0.38	1.03e-5	Bipolar disorder and schizophrenia;
TGCT	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg26516362	chr5:178986906	RUFY1	0.44	4.93	0.4	2.57e-6	Lung cancer;
TGCT	cis	rs6088590	0.965	rs6120727	chr20:33374102	T/C	cg06115741	chr20:33292138	TP53INP2	0.66	5.51	0.44	2.01e-7	Coronary artery disease;
TGCT	cis	rs4242434	0.819	rs55776566	chr8:22469492	T/C	cg03733263	chr8:22462867	KIAA1967	1.08	17.0	0.84	3.37e-34	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs155076	1.000	rs261430	chr13:21865242	C/T	cg11317459	chr13:21872234	NA	-1.32	-10.89	-0.7	8.4e-20	White matter hyperintensity burden;
TGCT	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg11764359	chr7:65958608	NA	-0.6	-5.32	-0.43	4.68e-7	Aortic root size;
TGCT	cis	rs9611519	0.929	rs4820425	chr22:41431342	C/A	cg13695892	chr22:41940480	POLR3H	-0.55	-4.66	-0.39	8.05e-6	Neuroticism;
TGCT	cis	rs3796352	0.667	rs9831977	chr3:52854140	T/G	cg07884673	chr3:53033167	SFMBT1	0.61	4.98	0.41	2.07e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs4808199	1.000	rs12972397	chr19:19562349	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.7	5.07	0.41	1.41e-6	Nonalcoholic fatty liver disease;
TGCT	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg22535103	chr8:58192502	C8orf71	-0.43	-5.28	-0.43	5.64e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs12477438	0.765	rs6754843	chr2:99680485	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-4.88	-0.4	3.17e-6	Chronic sinus infection;
TGCT	cis	rs137699	0.652	rs137707	chr22:39751401	T/C	cg05872129	chr22:39784769	NA	-0.73	-5.62	-0.45	1.2e-7	IgG glycosylation;
TGCT	cis	rs941873	0.803	rs5015119	chr10:81101609	G/C	cg09469691	chr10:81107165	PPIF	0.53	5.29	0.43	5.38e-7	Height;
TGCT	cis	rs7744392	0.557	rs9296148	chr6:35337467	G/A	cg06087101	chr6:35551932	FKBP5	0.61	4.56	0.38	1.21e-5	Cataracts in type 2 diabetes;
TGCT	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg24578937	chr1:2090814	PRKCZ	0.26	6.95	0.53	1.8e-10	Height;
TGCT	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg09359103	chr1:154839909	KCNN3	-0.67	-13.37	-0.77	8.58e-26	Prostate cancer;
TGCT	cis	rs9467773	0.620	rs1490488	chr6:26614808	T/C	cg09904177	chr6:26538194	HMGN4	0.66	6.3	0.49	4.64e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7209700	0.742	rs7217710	chr17:45370582	C/T	cg21624342	chr17:45890973	OSBPL7	-0.2	-5.37	-0.43	3.71e-7	IgG glycosylation;
TGCT	cis	rs9303401	0.580	rs34076823	chr17:57114497	C/G	cg25039879	chr17:56429692	SUPT4H1	0.57	5.14	0.42	1.03e-6	Cognitive test performance;
TGCT	cis	rs9902453	0.935	rs4310926	chr17:28433275	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.82	7.98	0.58	8.56e-13	Coffee consumption (cups per day);
TGCT	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg13877915	chr19:58951672	ZNF132	0.89	11.16	0.71	1.92e-20	Uric acid clearance;
TGCT	cis	rs116095464	0.558	rs34629844	chr5:200829	A/G	cg12570787	chr5:219185	SDHA;CCDC127	0.72	4.62	0.38	9.36e-6	Breast cancer;
TGCT	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg04414720	chr1:150670196	GOLPH3L	0.39	5.04	0.41	1.58e-6	Tonsillectomy;
TGCT	cis	rs6981523	0.553	rs11783045	chr8:11056175	A/G	cg21775007	chr8:11205619	TDH	-0.48	-4.46	-0.37	1.81e-5	Neuroticism;
TGCT	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg06221963	chr1:154839813	KCNN3	-0.71	-11.67	-0.72	1.1e-21	Prostate cancer;
TGCT	cis	rs56104184	0.775	rs55737338	chr19:49403141	A/G	cg21252483	chr19:49399788	TULP2	-0.42	-5.89	-0.47	3.47e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg22029157	chr1:209979665	IRF6	0.76	6.32	0.49	4.37e-9	Cleft lip with or without cleft palate;
TGCT	cis	rs4889855	0.614	rs7221663	chr17:78484166	T/C	cg16591659	chr17:78472290	NA	-0.35	-5.57	-0.45	1.48e-7	Fractional excretion of uric acid;
TGCT	cis	rs12780845	0.540	rs7096079	chr10:17180675	A/C	cg01003015	chr10:17271136	VIM	-0.58	-5.4	-0.44	3.26e-7	Homocysteine levels;
TGCT	cis	rs7811142	1.000	rs6972167	chr7:100080013	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	9.42	0.65	3.26e-16	Platelet count;
TGCT	cis	rs6545883	0.794	rs12053388	chr2:61532320	G/A	cg15711740	chr2:61764176	XPO1	0.55	4.59	0.38	1.06e-5	Tuberculosis;
TGCT	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg08280861	chr8:58055591	NA	0.4	5.57	0.45	1.49e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7226408	0.857	rs17567681	chr18:34481867	A/C	cg06757138	chr18:34340585	FHOD3	-0.24	-4.66	-0.39	8.12e-6	Obesity-related traits;
TGCT	cis	rs4845570	0.834	rs13376155	chr1:151721270	A/G	cg07092448	chr1:151763213	TDRKH	-1.03	-7.53	-0.56	8.99e-12	Coronary artery disease;
TGCT	cis	rs9611565	0.559	rs132768	chr22:42013523	C/A	cg06634786	chr22:41940651	POLR3H	0.89	8.56	0.61	3.56e-14	Vitiligo;
TGCT	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg23131131	chr22:24373011	LOC391322	-0.81	-8.74	-0.62	1.33e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs11209002	0.614	rs10732837	chr1:67573120	A/G	cg02640540	chr1:67518911	SLC35D1	0.59	4.97	0.41	2.18e-6	Crohn's disease;
TGCT	cis	rs2692947	0.526	rs58719199	chr2:96578247	G/A	cg23100626	chr2:96804247	ASTL	0.38	4.61	0.38	9.79e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs1499614	0.831	rs3800822	chr7:66147149	A/G	cg18252515	chr7:66147081	NA	1.26	7.95	0.58	9.71e-13	Gout;
TGCT	cis	rs7937682	0.889	rs1789361	chr11:111485334	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.04	-11.23	-0.71	1.28e-20	Primary sclerosing cholangitis;
TGCT	cis	rs3096299	0.738	rs9929606	chr16:89527537	C/T	cg06640241	chr16:89574553	SPG7	0.71	7.13	0.54	7.22e-11	Multiple myeloma (IgH translocation);
TGCT	cis	rs7100689	0.784	rs10749578	chr10:82139115	A/G	cg01528321	chr10:82214614	TSPAN14	-0.89	-8.97	-0.63	3.94e-15	Post bronchodilator FEV1;
TGCT	cis	rs11085466	1.000	rs4399664	chr19:21778026	C/T	cg02997983	chr19:21646781	NA	-0.6	-4.6	-0.38	1.03e-5	Colorectal or endometrial cancer;
TGCT	cis	rs7267979	0.966	rs2257461	chr20:25265554	A/G	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2153535	0.563	rs3117071	chr6:8537908	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.67	0.45	9.45e-8	Motion sickness;
TGCT	cis	rs1218582	0.741	rs11264291	chr1:154914797	C/T	cg16680214	chr1:154839983	KCNN3	-0.36	-7.44	-0.56	1.42e-11	Prostate cancer;
TGCT	cis	rs1552244	0.765	rs17050675	chr3:10027686	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.83	5.71	0.46	7.72e-8	Alzheimer's disease;
TGCT	cis	rs9993613	0.756	rs60145670	chr4:73448172	T/C	cg15102770	chr4:73434591	ADAMTS3	0.5	4.49	0.37	1.59e-5	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs17345786	0.906	rs55710435	chr3:101180330	G/A	cg12386194	chr3:101231763	SENP7	0.65	6.39	0.5	3.06e-9	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg15556689	chr8:8085844	FLJ10661	0.86	8.37	0.6	1.05e-13	Retinal vascular caliber;
TGCT	cis	rs941408	0.890	rs1640269	chr19:2793194	A/C	cg06609049	chr19:2785107	THOP1	0.81	7.49	0.56	1.13e-11	Total cholesterol levels;
TGCT	cis	rs16910800	0.638	rs12273883	chr11:23164569	C/G	cg20040320	chr11:23191996	NA	0.52	4.51	0.38	1.48e-5	Cancer;
TGCT	cis	rs17030434	1.000	rs75418383	chr4:154719084	A/G	cg14289246	chr4:154710475	SFRP2	-0.91	-7.2	-0.54	5.18e-11	Electrocardiographic conduction measures;
TGCT	cis	rs35306767	0.855	rs12781100	chr10:838636	C/T	cg20503657	chr10:835505	NA	0.78	11.43	0.72	4.26e-21	Eosinophil percentage of granulocytes;
TGCT	cis	rs13191362	0.935	rs34009353	chr6:163007668	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.57	4.94	0.41	2.45e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7772486	0.790	rs2485632	chr6:146193228	A/G	cg05347473	chr6:146136440	FBXO30	0.54	4.98	0.41	2.05e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7666738	0.830	rs10021044	chr4:99002488	A/T	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7772486	0.875	rs1330939	chr6:146308518	T/A	cg23711669	chr6:146136114	FBXO30	0.84	8.85	0.62	7.33e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg24549020	chr5:56110836	MAP3K1	0.67	5.78	0.46	5.74e-8	Initial pursuit acceleration;
TGCT	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg25036284	chr2:26402008	FAM59B	-0.57	-4.97	-0.41	2.15e-6	Gut microbiome composition (summer);
TGCT	cis	rs9303401	0.592	rs66583824	chr17:56639853	C/T	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs2239547	0.657	rs2071040	chr3:52864860	A/G	cg10802521	chr3:52805072	NEK4	-0.64	-6.04	-0.48	1.64e-8	Schizophrenia;
TGCT	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg20607798	chr8:58055168	NA	0.45	4.68	0.39	7.52e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7615952	0.932	rs13321217	chr3:125631771	G/A	cg05084668	chr3:125655381	ALG1L	-0.68	-5.6	-0.45	1.33e-7	Blood pressure (smoking interaction);
TGCT	cis	rs3741151	1.000	rs75007932	chr11:73080336	G/A	cg17517138	chr11:73019481	ARHGEF17	0.94	4.71	0.39	6.45e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
TGCT	cis	rs250677	0.522	rs12520924	chr5:148349149	C/T	cg18129178	chr5:148520854	ABLIM3	0.41	5.06	0.41	1.46e-6	Breast cancer;
TGCT	cis	rs589448	0.535	rs12423794	chr12:69713018	G/A	cg11871910	chr12:69753446	YEATS4	0.68	7.13	0.54	7.33e-11	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs6988636	0.792	rs62521803	chr8:124152970	A/C	cg27053337	chr8:124217698	FAM83A	0.78	5.42	0.44	3.01e-7	Urinary uromodulin levels;
TGCT	cis	rs9807989	0.729	rs10170583	chr2:102974764	G/A	cg09003973	chr2:102972529	NA	0.67	6.03	0.48	1.75e-8	Asthma;
TGCT	cis	rs12579753	0.597	rs2244802	chr12:82153749	C/G	cg07988820	chr12:82153109	PPFIA2	0.48	5.37	0.43	3.82e-7	Resting heart rate;
TGCT	cis	rs10875595	0.836	rs62378923	chr5:140656398	C/T	cg24830062	chr5:140700576	TAF7	-0.6	-5.07	-0.41	1.42e-6	Pulmonary function decline;
TGCT	cis	rs7666738	0.830	rs10031190	chr4:98908683	C/A	cg05340658	chr4:99064831	C4orf37	0.54	6.39	0.5	3.04e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4780401	0.588	rs7205167	chr16:11791057	A/T	cg01061890	chr16:11836724	TXNDC11	-0.45	-4.47	-0.37	1.76e-5	Rheumatoid arthritis;
TGCT	cis	rs9868809	0.881	rs13076269	chr3:48675925	T/C	cg00383909	chr3:49044727	WDR6	0.93	4.92	0.4	2.68e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs9611565	0.921	rs761366	chr22:41744022	C/G	cg06481639	chr22:41940642	POLR3H	-0.58	-5.2	-0.42	8.04e-7	Vitiligo;
TGCT	cis	rs12477438	0.520	rs11685759	chr2:99766217	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.89	9.05	0.63	2.42e-15	Chronic sinus infection;
TGCT	cis	rs2354432	0.505	rs4424556	chr1:146863973	G/C	cg25205988	chr1:146714368	CHD1L	1.32	5.88	0.47	3.62e-8	Mitochondrial DNA levels;
TGCT	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg19748678	chr4:122722346	EXOSC9	0.89	8.94	0.63	4.53e-15	Type 2 diabetes;
TGCT	cis	rs7647973	1.000	rs892974	chr3:49398514	C/A	cg07636037	chr3:49044803	WDR6	0.72	5.76	0.46	6.38e-8	Menarche (age at onset);
TGCT	cis	rs1577917	0.959	rs16876540	chr6:86612519	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.18	-0.42	8.73e-7	Response to antipsychotic treatment;
TGCT	cis	rs9443189	0.570	rs523465	chr6:76330434	G/C	cg01950844	chr6:76311363	SENP6	0.99	6.27	0.49	5.49e-9	Prostate cancer;
TGCT	cis	rs2404602	0.735	rs11857015	chr15:76649390	T/C	cg26408565	chr15:76604113	ETFA	0.38	4.47	0.37	1.72e-5	Blood metabolite levels;
TGCT	cis	rs35883536	0.647	rs10875313	chr1:101043057	T/C	cg06223162	chr1:101003688	GPR88	-0.42	-7.93	-0.58	1.1e-12	Monocyte count;
TGCT	cis	rs7959452	0.527	rs4761157	chr12:69780907	A/G	cg14784868	chr12:69753453	YEATS4	0.83	8.96	0.63	4.14e-15	Blood protein levels;
TGCT	cis	rs4704846	0.821	rs35521254	chr5:156526629	T/C	cg12943317	chr5:156479607	HAVCR1	-0.3	-4.48	-0.37	1.7e-5	Blood protein levels;
TGCT	cis	rs4824093	0.610	rs77128035	chr22:50241024	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.07	-6.52	-0.51	1.61e-9	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs6674176	0.611	rs3120802	chr1:44386305	C/T	cg12908607	chr1:44402522	ARTN	-0.71	-4.55	-0.38	1.28e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs7043114	0.525	rs10761153	chr9:95130769	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-5.58	-0.45	1.42e-7	Height;
TGCT	cis	rs9611565	0.559	rs7290991	chr22:41964361	C/G	cg03806693	chr22:41940476	POLR3H	-1.08	-11.36	-0.71	6.34e-21	Vitiligo;
TGCT	cis	rs2050392	0.517	rs2489847	chr10:30743673	G/A	cg18806716	chr10:30721971	MAP3K8	-0.47	-5.56	-0.45	1.61e-7	Inflammatory bowel disease;
TGCT	cis	rs617219	0.698	rs10055956	chr5:78479678	G/A	cg23987322	chr5:78407566	BHMT	0.37	4.97	0.41	2.18e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs922182	0.535	rs28729238	chr15:64195152	T/G	cg02919090	chr15:64263738	DAPK2	0.34	5.94	0.47	2.67e-8	Blood protein levels;
TGCT	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg13866156	chr1:1669148	SLC35E2	-0.24	-5.87	-0.47	3.74e-8	Body mass index;
TGCT	cis	rs9368481	0.645	rs10456350	chr6:26975581	A/C	cg26531700	chr6:26746687	NA	0.56	5.03	0.41	1.67e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7539409	0.651	rs969724	chr1:84300712	T/G	cg10977910	chr1:84465055	TTLL7	0.96	5.87	0.47	3.76e-8	Alzheimer's disease;
TGCT	cis	rs968451	0.547	rs738331	chr22:39714216	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.88	11.02	0.7	4.09e-20	Primary biliary cholangitis;
TGCT	trans	rs2727020	0.701	rs7949044	chr11:49597334	C/T	cg15704280	chr7:45808275	SEPT13	-0.64	-6.74	-0.52	5.26e-10	Coronary artery disease;
TGCT	cis	rs10883723	0.810	rs2296589	chr10:104248106	T/A	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs12142240	0.698	rs966907	chr1:46817125	C/G	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs1406084	0.636	rs3910688	chr2:154717147	A/T	cg25703346	chr2:154729189	GALNT13	0.77	4.6	0.38	1.03e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1008375	0.932	rs12500912	chr4:17603318	C/T	cg16339924	chr4:17578868	LAP3	0.76	6.09	0.48	1.28e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7772486	0.720	rs6901888	chr6:146023144	A/G	cg23711669	chr6:146136114	FBXO30	-0.95	-11.14	-0.71	2.17e-20	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1372520	0.684	rs2619341	chr4:90741773	A/G	cg15133208	chr4:90757351	SNCA	-0.49	-5.69	-0.45	8.67e-8	Neuroticism;
TGCT	cis	rs13217239	0.646	rs4269366	chr6:27016413	C/T	cg02458000	chr6:26745757	NA	0.49	4.45	0.37	1.92e-5	Schizophrenia;
TGCT	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg13395646	chr4:1353034	KIAA1530	-0.39	-5.21	-0.42	7.7300000000000005e-07	Obesity-related traits;
TGCT	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg11845111	chr2:191398756	TMEM194B	0.38	5.81	0.46	5.02e-8	Pulse pressure;
TGCT	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg00149659	chr3:10157352	C3orf10	0.91	5.89	0.47	3.32e-8	Alzheimer's disease;
TGCT	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9611565	0.532	rs4401299	chr22:42156517	A/G	cg03806693	chr22:41940476	POLR3H	0.91	8.69	0.62	1.82e-14	Vitiligo;
TGCT	cis	rs9916302	0.707	rs11078903	chr17:37631924	G/A	cg07936489	chr17:37558343	FBXL20	-0.61	-4.79	-0.39	4.73e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs11779988	0.528	rs208029	chr8:17840987	A/C	cg01800426	chr8:17659068	MTUS1	-0.57	-4.54	-0.38	1.32e-5	Breast cancer;
TGCT	cis	rs13177918	0.677	rs13181401	chr5:149822596	T/C	cg14059543	chr5:149831962	NA	-0.71	-9.45	-0.65	2.77e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs35306767	0.579	rs7091502	chr10:1154979	C/T	cg26597838	chr10:835615	NA	0.52	5.51	0.44	1.96e-7	Eosinophil percentage of granulocytes;
TGCT	cis	rs4285028	0.747	rs7623901	chr3:121529011	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.95	8.29	0.6	1.55e-13	Multiple sclerosis;
TGCT	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg24549020	chr5:56110836	MAP3K1	0.66	5.79	0.46	5.56e-8	Initial pursuit acceleration;
TGCT	cis	rs7044106	0.762	rs10760115	chr9:123476952	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.61	6.35	0.5	3.69e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs2050392	0.624	rs303449	chr10:30726845	G/A	cg13289132	chr10:30722225	MAP3K8	-0.46	-5.57	-0.45	1.47e-7	Inflammatory bowel disease;
TGCT	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg20007245	chr22:24372913	LOC391322	-0.73	-6.83	-0.52	3.37e-10	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7582180	0.614	rs6737217	chr2:101006267	T/G	cg14675211	chr2:100938903	LONRF2	0.49	4.7	0.39	6.74e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9556958	0.588	rs9556964	chr13:99159306	T/C	cg07423050	chr13:99094983	FARP1	-0.25	-4.8	-0.4	4.41e-6	Educational attainment (years of education);
TGCT	cis	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg06636001	chr8:8085503	FLJ10661	0.68	5.98	0.47	2.17e-8	Mood instability;
TGCT	cis	rs11190604	1.000	rs11190613	chr10:102313997	C/T	cg16342193	chr10:102329863	NA	0.39	4.95	0.41	2.37e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs6665290	0.669	rs3795446	chr1:227180981	C/T	cg10327440	chr1:227177885	CDC42BPA	0.88	14.4	0.79	3.14e-28	Myeloid white cell count;
TGCT	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.94	7.92	0.58	1.17e-12	Platelet count;
TGCT	cis	rs8072100	0.837	rs8070463	chr17:45768836	A/G	cg10024583	chr17:45772800	TBKBP1	0.4	4.5	0.37	1.55e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs8014204	0.836	rs8021280	chr14:75290018	C/G	cg06637938	chr14:75390232	RPS6KL1	0.7	6.74	0.52	5.37e-10	Caffeine consumption;
TGCT	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg20891283	chr12:69753455	YEATS4	0.91	10.33	0.68	1.96e-18	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs10779751	0.666	rs77270747	chr1:11214584	A/C	cg08854313	chr1:11322531	MTOR	-0.8	-6.61	-0.51	9.98e-10	Body mass index;
TGCT	cis	rs6750047	0.678	rs4670811	chr2:38277376	C/A	cg07380506	chr2:38303506	CYP1B1	0.58	5.02	0.41	1.74e-6	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs7662987	0.517	rs2602883	chr4:100040914	A/T	cg12011299	chr4:100065546	ADH4	0.4	4.77	0.39	5.18e-6	Smoking initiation;
TGCT	cis	rs2760061	0.784	rs1745414	chr1:228212159	T/A	cg02753203	chr1:228287806	NA	0.32	6.26	0.49	5.64e-9	Diastolic blood pressure;
TGCT	cis	rs12048904	0.533	rs1590580	chr1:101292668	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.87	7.69	0.57	3.82e-12	Multiple sclerosis;
TGCT	cis	rs6088580	0.634	rs2424992	chr20:33012060	C/T	cg06115741	chr20:33292138	TP53INP2	0.55	4.82	0.4	4.15e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs3902035	0.964	rs62424000	chr6:119014557	G/A	cg07617317	chr6:118971624	C6orf204	0.43	5.01	0.41	1.79e-6	QT interval;
TGCT	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg26513180	chr16:89883248	FANCA	0.81	8.35	0.6	1.17e-13	Vitiligo;
TGCT	cis	rs801193	0.569	rs2659892	chr7:66200305	A/G	cg11764359	chr7:65958608	NA	0.54	4.79	0.4	4.68e-6	Aortic root size;
TGCT	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.54	4.88	0.4	3.18e-6	Prudent dietary pattern;
TGCT	cis	rs10751667	0.621	rs11246345	chr11:934924	T/C	cg06064525	chr11:970664	AP2A2	-0.35	-8.09	-0.59	4.54e-13	Alzheimer's disease (late onset);
TGCT	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg16325326	chr1:53192061	ZYG11B	0.6	6.94	0.53	1.98e-10	Monocyte count;
TGCT	cis	rs10986311	0.752	rs3780208	chr9:127084594	G/A	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.21	-5.23	-0.43	6.84e-7	Vitiligo;
TGCT	cis	rs6121246	0.821	rs6119718	chr20:30331074	A/G	cg13852791	chr20:30311386	BCL2L1	0.8	6.12	0.48	1.15e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs9916302	0.904	rs1619021	chr17:37739274	G/A	cg07936489	chr17:37558343	FBXL20	-0.59	-4.49	-0.37	1.59e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs2361710	0.611	rs12451471	chr17:78102517	C/T	cg06718696	chr17:78121285	EIF4A3	0.57	4.56	0.38	1.22e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
TGCT	cis	rs9611565	0.649	rs79005	chr22:41835544	G/A	cg06634786	chr22:41940651	POLR3H	0.87	8.08	0.59	4.79e-13	Vitiligo;
TGCT	cis	rs72945132	0.882	rs4261311	chr11:70132902	C/T	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs317689	0.702	rs544696	chr12:69749939	T/C	cg19645103	chr12:69753606	YEATS4	-0.63	-5.26	-0.43	6.09e-7	Response to diuretic therapy;
TGCT	trans	rs9388451	0.626	rs1268074	chr6:126107791	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.79	-9.1	-0.63	1.88e-15	Brugada syndrome;
TGCT	cis	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg20637647	chr7:64974828	NA	-0.9	-5.31	-0.43	4.87e-7	Diabetic kidney disease;
TGCT	cis	rs709400	0.526	rs8017780	chr14:103987305	C/A	cg26031613	chr14:104095156	KLC1	0.72	5.77	0.46	5.85e-8	Body mass index;
TGCT	cis	rs12911832	0.958	rs12912003	chr15:58986001	A/T	cg05156742	chr15:59063176	FAM63B	0.54	5.11	0.42	1.19e-6	Schizophrenia;
TGCT	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg08509172	chr19:19383838	TM6SF2	-0.35	-4.54	-0.38	1.32e-5	Tonsillectomy;
TGCT	cis	rs909674	0.865	rs5757684	chr22:39851584	G/A	cg01416388	chr22:39784598	NA	-0.66	-5.99	-0.47	2.09e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs854765	0.618	rs8066982	chr17:17851377	T/C	cg09796270	chr17:17721594	SREBF1	0.23	4.45	0.37	1.92e-5	Total body bone mineral density;
TGCT	cis	rs9807989	0.811	rs4485585	chr2:102970759	T/C	cg09003973	chr2:102972529	NA	0.64	5.7	0.46	8.28e-8	Asthma;
TGCT	cis	rs7714584	1.000	rs3906527	chr5:150266392	T/A	cg22134413	chr5:150180641	NA	0.78	6.12	0.48	1.16e-8	Crohn's disease;
TGCT	cis	rs939658	0.805	rs4778924	chr15:79443363	T/C	cg17916960	chr15:79447300	NA	-0.49	-7.41	-0.55	1.73e-11	Refractive error;
TGCT	cis	rs4900538	0.855	rs12590993	chr14:102844064	A/G	cg18135206	chr14:102964638	TECPR2	-0.2	-4.49	-0.37	1.62e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs12200560	0.505	rs4240555	chr6:97076274	T/C	cg06623918	chr6:96969491	KIAA0776	0.59	5.03	0.41	1.71e-6	Coronary heart disease;
TGCT	cis	rs9486715	0.838	rs9386576	chr6:96954717	C/T	cg18709589	chr6:96969512	KIAA0776	0.82	8.01	0.58	7.14e-13	Headache;
TGCT	cis	rs422249	0.512	rs174554	chr11:61579463	A/G	cg19610905	chr11:61596333	FADS2	-1.07	-12.03	-0.73	1.43e-22	Trans fatty acid levels;
TGCT	trans	rs66573146	0.803	rs59809420	chr4:6969928	G/T	cg07817883	chr1:32538562	TMEM39B	1.63	8.24	0.59	2.04e-13	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs1403694	0.734	rs266723	chr3:186447047	A/C	cg12454167	chr3:186435060	KNG1	0.44	7.05	0.53	1.09e-10	Blood protein levels;
TGCT	cis	rs344364	0.511	rs2917519	chr16:1950479	C/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.45	-5.11	-0.42	1.17e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs36051895	0.589	rs6476947	chr9:5204279	A/G	cg02405213	chr9:5042618	JAK2	-0.74	-9.28	-0.64	7.07e-16	Pediatric autoimmune diseases;
TGCT	cis	rs11190604	1.000	rs11190592	chr10:102291059	T/C	cg16342193	chr10:102329863	NA	-0.42	-5.37	-0.43	3.74e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs523522	0.962	rs55848094	chr12:120966659	G/A	cg12219531	chr12:120966889	COQ5	0.83	7.27	0.55	3.46e-11	High light scatter reticulocyte count;
TGCT	cis	rs11143230	1.000	rs62564005	chr9:74888383	A/T	cg02514559	chr9:74675332	C9orf57	-0.22	-4.56	-0.38	1.22e-5	Suicidal ideation;
TGCT	cis	rs6028335	0.502	rs6028235	chr20:37608550	A/G	cg27552599	chr20:37590471	DHX35	0.37	4.67	0.39	7.57e-6	Alcohol and nicotine co-dependence;
TGCT	cis	rs9393692	0.905	rs9393694	chr6:26279296	T/C	cg05868516	chr6:26286170	HIST1H4H	0.56	5.35	0.43	4.01e-7	Educational attainment;
TGCT	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	5.02	0.41	1.78e-6	Prudent dietary pattern;
TGCT	trans	rs57221529	0.766	rs72703065	chr5:588123	C/A	cg25482853	chr8:67687455	SGK3	1.2	10.12	0.67	6.42e-18	Lung disease severity in cystic fibrosis;
TGCT	cis	rs614226	1.000	rs614226	chr12:120974510	C/T	cg01236616	chr12:121019343	POP5	-1.26	-13.2	-0.76	2.23e-25	Type 1 diabetes nephropathy;
TGCT	cis	rs2456568	0.802	rs1574515	chr11:93629643	T/C	cg16099599	chr11:93583650	C11orf90	-0.4	-5.06	-0.41	1.49e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs78487399	0.710	rs6544665	chr2:43729212	G/A	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.74	4.49	0.37	1.59e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs4727027	0.866	rs2373438	chr7:148780287	C/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.54	5.04	0.41	1.57e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs2486288	0.656	rs11639420	chr15:45559268	A/C	cg14582100	chr15:45693742	SPATA5L1	-0.45	-5.46	-0.44	2.51e-7	Glomerular filtration rate;
TGCT	cis	rs2243480	1.000	rs1618893	chr7:66096119	C/T	cg18252515	chr7:66147081	NA	-1.17	-6.86	-0.52	2.91e-10	Diabetic kidney disease;
TGCT	cis	rs561341	0.629	rs7216107	chr17:30224419	G/A	cg13647721	chr17:30228624	UTP6	0.58	5.13	0.42	1.07e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.89	6.55	0.51	1.39e-9	Gut microbiome composition (summer);
TGCT	cis	rs6582630	0.519	rs8189549	chr12:38245752	A/G	cg13010199	chr12:38710504	ALG10B	0.64	5.01	0.41	1.85e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs13126513	0.510	rs10516445	chr4:100524679	C/G	cg05468953	chr4:100565104	NA	0.43	6.04	0.48	1.64e-8	Metabolite levels (MHPG);
TGCT	cis	rs9807989	0.839	rs10204837	chr2:102977730	C/A	cg09003973	chr2:102972529	NA	0.67	6.03	0.48	1.75e-8	Asthma;
TGCT	cis	rs9357506	1.000	rs12055715	chr6:46308436	A/G	cg21115430	chr6:46460003	NA	0.26	5.22	0.42	7.34e-7	Body mass index;
TGCT	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs3770081	1.000	rs76081054	chr2:86285037	T/G	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.17	-4.56	-0.38	1.21e-5	Facial emotion recognition (sad faces);
TGCT	cis	rs7412746	0.658	rs11204739	chr1:150865760	A/G	cg09365446	chr1:150670422	GOLPH3L	0.33	4.73	0.39	6.05e-6	Melanoma;
TGCT	cis	rs7267979	1.000	rs10966	chr20:25282944	A/G	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.13	14.76	0.8	4.39e-29	Height;
TGCT	cis	rs6582630	0.599	rs4882313	chr12:38454011	G/A	cg26384229	chr12:38710491	ALG10B	-0.54	-4.79	-0.4	4.57e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs1971762	0.521	rs5009146	chr12:54089297	A/C	cg16917193	chr12:54089295	NA	1.33	17.67	0.85	1.11e-35	Height;
TGCT	cis	rs9467711	0.790	rs35942569	chr6:26339131	A/G	cg02458000	chr6:26745757	NA	-0.99	-4.44	-0.37	2e-5	Autism spectrum disorder or schizophrenia;
TGCT	trans	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	1.03	13.16	0.76	2.65e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg04944784	chr2:26401820	FAM59B	0.7	5.91	0.47	3.11e-8	Gut microbiome composition (summer);
TGCT	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg13395646	chr4:1353034	KIAA1530	-0.4	-5.0	-0.41	1.93e-6	Obesity-related traits;
TGCT	cis	rs10927875	0.662	rs698893	chr1:16302982	C/T	cg22431228	chr1:16359049	CLCNKA	-0.27	-5.62	-0.45	1.17e-7	Dilated cardiomyopathy;
TGCT	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg13695892	chr22:41940480	POLR3H	0.9	8.66	0.61	2.17e-14	Vitiligo;
TGCT	cis	rs734999	0.572	rs4310388	chr1:2507415	G/T	cg18854424	chr1:2615690	NA	0.43	4.85	0.4	3.61e-6	Ulcerative colitis;
TGCT	cis	rs1334894	1.000	rs72911397	chr6:35525821	A/G	cg24281267	chr6:35479648	TULP1	-0.43	-4.54	-0.38	1.34e-5	Coronary artery disease;
TGCT	cis	rs4689388	0.890	rs4688991	chr4:6302220	C/G	cg25554036	chr4:6271136	WFS1	0.56	7.96	0.58	9.38e-13	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.1	0.42	1.24e-6	Menopause (age at onset);
TGCT	cis	rs501916	1.000	rs3743276	chr15:48055119	C/T	cg16110827	chr15:48056943	SEMA6D	0.17	5.15	0.42	9.79e-7	Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs3820068	0.544	rs7551750	chr1:16035008	T/C	cg05660106	chr1:15850417	CASP9	0.67	6.48	0.5	1.96e-9	Systolic blood pressure;
TGCT	cis	rs1008375	1.000	rs13148861	chr4:17688338	G/A	cg10189774	chr4:17578691	LAP3	-0.61	-5.18	-0.42	8.77e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs453301	0.564	rs28649568	chr8:8959671	T/G	cg06636001	chr8:8085503	FLJ10661	-0.67	-5.44	-0.44	2.71e-7	Joint mobility (Beighton score);
TGCT	cis	rs854765	0.547	rs2955384	chr17:17939573	C/T	cg04398451	chr17:18023971	MYO15A	-0.3	-4.85	-0.4	3.64e-6	Total body bone mineral density;
TGCT	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg10047753	chr17:41438598	NA	0.84	7.61	0.56	5.9e-12	Menopause (age at onset);
TGCT	cis	rs62244186	0.541	rs9859879	chr3:44840166	G/A	cg15687855	chr3:44754131	ZNF502	-0.53	-6.73	-0.52	5.64e-10	Depressive symptoms;
TGCT	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg22166914	chr1:53195759	ZYG11B	-0.42	-7.46	-0.56	1.33e-11	Monocyte count;
TGCT	cis	rs6733011	0.581	rs4851162	chr2:99466659	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-4.51	-0.38	1.46e-5	Bipolar disorder;
TGCT	cis	rs7945705	0.936	rs978636	chr11:8836596	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.41	4.51	0.38	1.47e-5	Hemoglobin concentration;
TGCT	cis	rs2758596	1.000	rs2758617	chr1:156160693	A/G	cg24450063	chr1:156163899	SLC25A44	0.8	4.65	0.39	8.25e-6	Paclitaxel disposition in epithelial ovarian cancer;
TGCT	cis	rs4499344	0.535	rs7260509	chr19:33121595	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.62	5.76	0.46	6.37e-8	Mean platelet volume;
TGCT	cis	rs9522267	0.535	rs9522290	chr13:112233130	A/G	cg10483660	chr13:112241077	NA	-0.27	-4.61	-0.38	9.78e-6	Hepatitis;
TGCT	cis	rs35306767	0.716	rs34487581	chr10:897201	G/A	cg26597838	chr10:835615	NA	0.8	12.11	0.74	9.26e-23	Eosinophil percentage of granulocytes;
TGCT	cis	rs4803468	1.000	rs10853751	chr19:41903220	G/A	cg09537434	chr19:41945824	ATP5SL	-0.89	-10.04	-0.67	9.93e-18	Height;
TGCT	cis	rs593982	1.000	rs74638829	chr11:65495571	C/T	cg08755490	chr11:65554678	OVOL1	-1.47	-10.68	-0.69	2.87e-19	Atopic dermatitis;
TGCT	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg20887711	chr4:1340912	KIAA1530	-0.65	-5.74	-0.46	6.9e-8	Obesity-related traits;
TGCT	cis	rs11112613	0.713	rs4015312	chr12:105948757	A/G	cg03607813	chr12:105948248	NA	0.51	5.74	0.46	6.75e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	cis	rs6088580	0.634	rs4142007	chr20:32990050	G/T	cg06115741	chr20:33292138	TP53INP2	-0.53	-4.67	-0.39	7.83e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs11098499	0.909	rs35165976	chr4:120325630	G/A	cg09307838	chr4:120376055	NA	0.68	6.53	0.51	1.54e-9	Corneal astigmatism;
TGCT	cis	rs9291683	0.609	rs4622999	chr4:10003395	C/G	cg00071950	chr4:10020882	SLC2A9	0.71	9.36	0.64	4.43e-16	Bone mineral density;
TGCT	trans	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg17470723	chr8:74884337	TCEB1	0.71	6.77	0.52	4.48e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg07424592	chr7:64974309	NA	1.4	8.42	0.6	7.87e-14	Diabetic kidney disease;
TGCT	cis	rs910316	1.000	rs7145159	chr14:75583268	A/G	cg23033748	chr14:75592666	NEK9	0.28	4.76	0.39	5.41e-6	Height;
TGCT	cis	rs6121246	0.821	rs3181073	chr20:30307199	A/C	cg18721089	chr20:30220636	NA	0.42	4.65	0.39	8.2e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs6495367	0.966	rs745029	chr15:79381779	C/T	cg17916960	chr15:79447300	NA	0.37	5.28	0.43	5.56e-7	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs7010267	0.642	rs11992136	chr8:120003727	C/G	cg17171407	chr8:119960777	TNFRSF11B	0.32	6.05	0.48	1.62e-8	Total body bone mineral density (age 45-60);
TGCT	cis	rs11924390	0.800	rs1648698	chr3:186449582	G/C	cg12454167	chr3:186435060	KNG1	0.46	7.19	0.54	5.47e-11	Adiponectin levels;
TGCT	trans	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg17830980	chr10:43048298	ZNF37B	-0.84	-10.46	-0.68	9.38e-19	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2177596	0.549	rs4592846	chr2:227948866	G/A	cg11843606	chr2:227700838	RHBDD1	-0.53	-4.61	-0.38	9.85e-6	Body mass index;
TGCT	cis	rs950169	0.580	rs11633762	chr15:85187152	T/C	cg12863693	chr15:85201151	NMB	0.46	5.51	0.44	2.02e-7	Schizophrenia;
TGCT	cis	rs7666738	0.830	rs10005120	chr4:99038200	A/G	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4253772	0.515	rs6007891	chr22:46756833	C/T	cg09491104	chr22:46646882	C22orf40	-0.59	-4.49	-0.37	1.59e-5	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs4372836	0.504	rs7597048	chr2:29066756	A/G	cg09522027	chr2:28974177	PPP1CB	0.5	5.16	0.42	9.51e-7	Body mass index;
TGCT	cis	rs9296092	0.538	rs7761268	chr6:33519300	C/T	cg13560919	chr6:33536144	NA	-0.21	-4.75	-0.39	5.5e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs8078723	1.000	rs4795415	chr17:38157995	C/T	cg17467752	chr17:38218738	THRA	0.55	5.34	0.43	4.24e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs9436747	0.615	rs6691346	chr1:66046397	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.56	5.03	0.41	1.69e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs2820315	1.000	rs2494114	chr1:201801011	C/G	cg12730843	chr1:201915899	LMOD1	-0.27	-4.81	-0.4	4.22e-6	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
TGCT	cis	rs739496	0.615	rs2285727	chr12:112093078	G/T	cg10833066	chr12:111807467	FAM109A	0.36	5.06	0.41	1.46e-6	Platelet count;
TGCT	cis	rs7572733	0.514	rs770659	chr2:198669754	G/C	cg00792783	chr2:198669748	PLCL1	0.56	5.08	0.42	1.35e-6	Dermatomyositis;
TGCT	cis	rs2153535	0.580	rs2327058	chr6:8447018	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.76	0.46	6.39e-8	Motion sickness;
TGCT	cis	rs8103278	1.000	rs725660	chr19:46262286	C/A	cg11657440	chr19:46296263	DMWD	-0.54	-5.15	-0.42	1.01e-6	Coronary artery disease;
TGCT	cis	rs17433780	0.808	rs12125301	chr1:89508501	G/A	cg09516651	chr1:89888402	LOC400759	0.26	4.94	0.41	2.48e-6	Carotid intima media thickness;
TGCT	cis	rs9311474	0.713	rs352168	chr3:52237970	C/T	cg10802521	chr3:52805072	NEK4	-0.59	-6.49	-0.5	1.88e-9	Electroencephalogram traits;
TGCT	cis	rs801193	0.569	rs11761542	chr7:66218196	G/A	cg11764359	chr7:65958608	NA	0.54	4.79	0.4	4.68e-6	Aortic root size;
TGCT	cis	rs13188771	0.527	rs408727	chr5:100877888	T/C	cg10455971	chr5:101119566	NA	0.44	4.44	0.37	1.95e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs921968	0.612	rs10189479	chr2:219287276	C/A	cg02176678	chr2:219576539	TTLL4	-0.43	-6.33	-0.49	4.18e-9	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs3806843	0.545	rs251375	chr5:140252960	T/G	cg09824255	chr5:140014002	CD14	-0.26	-4.54	-0.38	1.3e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs13191362	1.000	rs35911566	chr6:162994154	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.68	5.32	0.43	4.73e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg06640241	chr16:89574553	SPG7	0.83	9.52	0.65	1.81e-16	Multiple myeloma (IgH translocation);
TGCT	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg01570182	chr17:44337453	NA	1.08	9.48	0.65	2.25e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs1670533	1.000	rs34956924	chr4:1047270	T/C	cg27284194	chr4:1044797	NA	0.68	5.75	0.46	6.41e-8	Recombination rate (females);
TGCT	cis	rs7586879	0.828	rs11675013	chr2:25107208	G/A	cg01884057	chr2:25150051	NA	0.26	4.67	0.39	7.85e-6	Body mass index;
TGCT	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg02725872	chr8:58115012	NA	-0.41	-4.94	-0.41	2.47e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs3741404	1.000	rs11603042	chr11:64003843	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.87	9.44	0.65	2.9e-16	Platelet count;
TGCT	cis	rs9486719	1.000	rs11153018	chr6:96956137	G/A	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.21	-0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs7312933	0.584	rs7974654	chr12:42630466	C/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.54	5.16	0.42	9.61e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs1061377	1.000	rs28465556	chr4:39121189	T/G	cg24403649	chr4:39172243	NA	0.18	4.44	0.37	1.99e-5	Uric acid levels;
TGCT	cis	rs7552404	1.000	rs6672180	chr1:76123973	C/G	cg10523679	chr1:76189770	ACADM	0.93	10.32	0.68	2.12e-18	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2456568	0.741	rs2102332	chr11:93635281	G/T	cg17595323	chr11:93583763	C11orf90	-0.47	-6.44	-0.5	2.38e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs2440129	0.611	rs10852889	chr17:6900845	C/T	cg21237687	chr17:6899380	ALOX12	0.53	5.91	0.47	3.05e-8	Tonsillectomy;
TGCT	cis	rs17162190	0.569	rs3122646	chr1:26829071	A/G	cg02450742	chr1:26856648	RPS6KA1	-0.54	-4.46	-0.37	1.79e-5	Mean corpuscular volume;
TGCT	cis	rs4389656	0.857	rs5001282	chr5:6757668	T/C	cg10857441	chr5:6722123	POLS	-0.21	-4.6	-0.38	1.03e-5	Coronary artery disease;
TGCT	cis	rs7223966	1.000	rs8075061	chr17:61804723	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	4.68	0.39	7.5e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs1670533	1.000	rs11725984	chr4:1087338	C/T	cg20887711	chr4:1340912	KIAA1530	0.66	5.33	0.43	4.49e-7	Recombination rate (females);
TGCT	cis	rs9633740	0.773	rs7080009	chr10:82269461	T/C	cg01528321	chr10:82214614	TSPAN14	1.03	8.28	0.6	1.66e-13	Post bronchodilator FEV1;
TGCT	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg23131131	chr22:24373011	LOC391322	-0.58	-5.66	-0.45	1e-7	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs3761847	0.593	rs10985140	chr9:123822837	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.43	4.52	0.38	1.42e-5	Rheumatoid arthritis;
TGCT	cis	rs10782582	0.593	rs115291524	chr1:76141811	A/G	cg22875332	chr1:76189707	ACADM	-0.54	-6.17	-0.48	8.76e-9	Daytime sleep phenotypes;
TGCT	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg23719950	chr11:63933701	MACROD1	-0.71	-5.93	-0.47	2.77e-8	Mean platelet volume;
TGCT	cis	rs344364	0.511	rs1742464	chr16:1947335	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	0.45	5.08	0.42	1.35e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg26516362	chr5:178986906	RUFY1	-0.43	-4.71	-0.39	6.55e-6	Lung cancer;
TGCT	cis	rs3820068	0.603	rs16851884	chr1:15961871	A/G	cg05660106	chr1:15850417	CASP9	0.83	8.19	0.59	2.78e-13	Systolic blood pressure;
TGCT	cis	rs9517320	0.534	rs4772088	chr13:99138270	T/G	cg07423050	chr13:99094983	FARP1	-0.29	-5.62	-0.45	1.17e-7	Longevity;
TGCT	cis	rs4746818	0.818	rs10823302	chr10:70895418	G/T	cg11621586	chr10:70884670	VPS26A	1.21	10.66	0.69	3.17e-19	Left atrial antero-posterior diameter;
TGCT	cis	rs7949030	0.622	rs34894392	chr11:62374821	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.69	8.75	0.62	1.27e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7017914	0.840	rs1481804	chr8:71969430	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.63	-5.74	-0.46	6.9e-8	Bone mineral density;
TGCT	cis	rs7432375	0.966	rs7618871	chr3:136400420	G/T	cg12473912	chr3:136751656	NA	-0.34	-4.93	-0.41	2.55e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12580194	0.593	rs61957933	chr12:55744710	T/G	cg10672482	chr12:55725839	OR6C3	-0.52	-4.66	-0.39	8.13e-6	Cancer;
TGCT	cis	rs11252926	0.537	rs6560836	chr10:444997	C/T	cg20256804	chr10:444983	DIP2C	-0.22	-4.61	-0.38	1.01e-5	Psychosis in Alzheimer's disease;
TGCT	cis	rs7772486	0.686	rs2142983	chr6:146069701	G/C	cg05347473	chr6:146136440	FBXO30	-0.49	-4.52	-0.38	1.42e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg16680214	chr1:154839983	KCNN3	-0.36	-7.26	-0.55	3.81e-11	Prostate cancer;
TGCT	cis	rs9467711	0.606	rs9366653	chr6:26354247	G/A	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg19318889	chr4:1322082	MAEA	0.19	4.94	0.41	2.42e-6	Longevity;
TGCT	cis	rs1371867	0.846	rs924057	chr8:101266157	A/G	cg06636551	chr8:101224915	SPAG1	0.43	5.95	0.47	2.58e-8	Atrioventricular conduction;
TGCT	cis	rs16866061	1.000	rs4674916	chr2:225365635	C/A	cg12698349	chr2:225449008	CUL3	1.0	10.02	0.67	1.14e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg12310025	chr6:25882481	NA	-0.59	-6.04	-0.48	1.65e-8	Blood metabolite levels;
TGCT	cis	rs4851254	0.660	rs77023845	chr2:100712346	G/A	cg07810366	chr2:100720526	AFF3	-0.45	-4.72	-0.39	6.35e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9902453	0.845	rs72823935	chr17:28008595	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	7.18	0.54	5.76e-11	Coffee consumption (cups per day);
TGCT	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg27535305	chr1:53392650	SCP2	-0.28	-5.61	-0.45	1.28e-7	Monocyte count;
TGCT	cis	rs17253792	0.818	rs78393484	chr14:56065802	T/C	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs4455778	0.580	rs10229899	chr7:49110363	C/T	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs35160687	0.871	rs11127028	chr2:86537509	A/T	cg04877910	chr2:85804641	VAMP8	0.34	4.51	0.38	1.49e-5	Night sleep phenotypes;
TGCT	cis	rs9790314	0.905	rs6441370	chr3:160993754	C/T	cg03342759	chr3:160939853	NMD3	-0.42	-4.51	-0.38	1.5e-5	Morning vs. evening chronotype;
TGCT	trans	rs3822625	0.541	rs112793966	chr5:56204118	C/T	cg25190722	chr1:3801660	DFFB	0.56	6.67	0.51	7.53e-10	Breast cancer (early onset);
TGCT	cis	rs2115630	1.000	rs2115630	chr15:85364516	C/T	cg17173187	chr15:85201210	NMB	-0.4	-4.84	-0.4	3.82e-6	P wave terminal force;
TGCT	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg03806693	chr22:41940476	POLR3H	1.16	13.52	0.77	3.78e-26	Vitiligo;
TGCT	cis	rs8102476	0.905	rs7250689	chr19:38753625	C/T	cg14131526	chr19:38747285	PPP1R14A	0.53	4.63	0.38	8.93e-6	Prostate cancer;Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs10507380	0.824	rs77605840	chr13:27921658	G/A	cg25543773	chr13:27185723	WASF3	0.34	4.83	0.4	3.97e-6	Electrocardiographic traits;
TGCT	cis	rs6964587	0.869	rs2374519	chr7:91541481	T/C	cg17063962	chr7:91808500	NA	-0.86	-9.28	-0.64	6.82e-16	Breast cancer;
TGCT	cis	rs2235649	0.552	rs7203361	chr16:1963085	G/A	cg02432467	chr16:1963432	HS3ST6	-0.31	-4.63	-0.38	9.07e-6	Blood metabolite levels;
TGCT	cis	rs7959452	0.718	rs10878963	chr12:69717166	T/G	cg11871910	chr12:69753446	YEATS4	0.59	5.83	0.46	4.59e-8	Blood protein levels;
TGCT	trans	rs1814175	0.817	rs10769617	chr11:49810421	G/A	cg03929089	chr4:120376271	NA	-0.72	-8.26	-0.6	1.84e-13	Height;
TGCT	cis	rs1865760	0.865	rs10946800	chr6:25957773	C/T	cg16482183	chr6:26056742	HIST1H1C	0.52	4.84	0.4	3.78e-6	Height;
TGCT	cis	rs8141529	0.509	rs12628211	chr22:29239250	T/C	cg02153584	chr22:29168773	CCDC117	0.62	5.05	0.41	1.57e-6	Lymphocyte counts;
TGCT	cis	rs10193935	1.000	rs57883795	chr2:42387926	C/T	cg27598129	chr2:42591480	NA	-0.4	-5.05	-0.41	1.52e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6545883	0.965	rs7591345	chr2:61729641	T/A	cg15711740	chr2:61764176	XPO1	-0.55	-5.01	-0.41	1.85e-6	Tuberculosis;
TGCT	cis	rs17376456	1.000	rs9968749	chr5:93509559	A/G	cg21475434	chr5:93447410	FAM172A	0.62	4.5	0.37	1.54e-5	Diabetic retinopathy;
TGCT	cis	rs12142240	0.659	rs1984491	chr1:46858607	T/G	cg00530320	chr1:46809349	NSUN4	0.29	5.79	0.46	5.34e-8	Menopause (age at onset);
TGCT	cis	rs7824557	0.620	rs6996368	chr8:11182704	G/A	cg21775007	chr8:11205619	TDH	0.63	6.14	0.48	1.02e-8	Retinal vascular caliber;
TGCT	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg02725872	chr8:58115012	NA	-0.38	-5.16	-0.42	9.32e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6964587	0.810	rs408	chr7:91556284	A/G	cg17063962	chr7:91808500	NA	-0.89	-9.52	-0.65	1.81e-16	Breast cancer;
TGCT	cis	rs483180	0.512	rs1163251	chr1:120209755	T/C	cg19096424	chr1:120255104	PHGDH	-0.57	-5.45	-0.44	2.62e-7	Macular telangiectasia type 2;
TGCT	cis	rs13256369	0.826	rs7846050	chr8:8575669	A/G	cg18904891	chr8:8559673	CLDN23	0.6	5.49	0.44	2.19e-7	Obesity-related traits;
TGCT	cis	rs78487399	0.908	rs77888770	chr2:43787107	T/C	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.67	4.52	0.38	1.41e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs9325144	0.534	rs6582538	chr12:38629997	A/C	cg26384229	chr12:38710491	ALG10B	-0.65	-6.03	-0.48	1.74e-8	Morning vs. evening chronotype;
TGCT	cis	rs2657888	0.628	rs2638334	chr12:56882528	A/C	cg23002907	chr12:56915593	RBMS2	0.4	5.26	0.43	6.06e-7	Adiponectin levels;
TGCT	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7829975	0.606	rs7837026	chr8:8801692	T/C	cg06636001	chr8:8085503	FLJ10661	-0.83	-7.29	-0.55	3.26e-11	Mood instability;
TGCT	cis	rs6495122	0.532	rs2472304	chr15:75044238	G/A	cg13906792	chr15:75199810	C15orf17	-0.22	-4.71	-0.39	6.64e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
TGCT	cis	rs9611565	0.512	rs2050031	chr22:42152266	A/G	cg06634786	chr22:41940651	POLR3H	0.86	8.01	0.58	7.16e-13	Vitiligo;
TGCT	cis	rs2797160	1.000	rs1832979	chr6:125997436	A/G	cg05901451	chr6:126070800	HEY2	-0.73	-6.5	-0.5	1.73e-9	Endometrial cancer;
TGCT	cis	rs9494142	0.592	rs1547247	chr6:135390836	C/T	cg24558204	chr6:135376177	HBS1L	0.49	4.69	0.39	7.05e-6	Lymphocyte counts;Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs736801	0.538	rs2548998	chr5:131832514	G/A	cg00255919	chr5:131827918	IRF1	-0.2	-4.5	-0.37	1.57e-5	Breast cancer;Mosquito bite size;
TGCT	cis	rs2439831	0.850	rs28696802	chr15:44140395	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	6.2	0.49	7.73e-9	Lung cancer in ever smokers;
TGCT	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg25036284	chr2:26402008	FAM59B	0.65	5.19	0.42	8.36e-7	Gut microbiome composition (summer);
TGCT	cis	rs4319547	0.956	rs10744275	chr12:123048618	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.69	-5.5	-0.44	2.05e-7	Body mass index;
TGCT	cis	rs9393692	0.905	rs34916901	chr6:26286149	G/T	cg05868516	chr6:26286170	HIST1H4H	0.63	5.9	0.47	3.18e-8	Educational attainment;
TGCT	cis	rs523522	0.962	rs10774549	chr12:120891172	C/T	cg12219531	chr12:120966889	COQ5	0.79	6.99	0.53	1.47e-10	High light scatter reticulocyte count;
TGCT	cis	rs10875595	0.779	rs1363451	chr5:140658138	G/A	cg24830062	chr5:140700576	TAF7	-0.6	-5.07	-0.41	1.42e-6	Pulmonary function decline;
TGCT	cis	rs1801251	1.000	rs67013068	chr2:233608253	G/C	cg08000102	chr2:233561755	GIGYF2	0.63	6.49	0.5	1.88e-9	Coronary artery disease;
TGCT	cis	rs6700896	0.522	rs4655583	chr1:66155407	C/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.63	4.84	0.4	3.78e-6	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs7255045	0.788	rs2290688	chr19:12958697	T/C	cg23899408	chr19:12877188	HOOK2	-0.63	-5.3	-0.43	5.11e-7	Mean corpuscular volume;
TGCT	cis	rs9399135	0.527	rs61738492	chr6:135282771	G/A	cg24558204	chr6:135376177	HBS1L	0.46	4.67	0.39	7.71e-6	Red blood cell count;
TGCT	cis	rs921968	0.541	rs1863704	chr2:219562675	C/T	cg02176678	chr2:219576539	TTLL4	-0.5	-7.05	-0.54	1.09e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs941408	0.515	rs1736193	chr19:2785273	G/C	cg17333051	chr19:2783644	SGTA	0.42	5.11	0.42	1.2e-6	Total cholesterol levels;
TGCT	cis	rs453301	0.606	rs6601279	chr8:8908231	G/A	cg06636001	chr8:8085503	FLJ10661	-0.71	-5.8	-0.46	5.19e-8	Joint mobility (Beighton score);
TGCT	cis	rs5769765	0.728	rs6520064	chr22:50294469	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.11	-12.1	-0.74	9.56e-23	Schizophrenia;
TGCT	cis	rs9467773	0.620	rs9467810	chr6:26608261	A/C	cg11502198	chr6:26597334	ABT1	0.54	4.95	0.41	2.41e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2191566	0.845	rs7258517	chr19:44535999	G/T	cg03039196	chr19:44506973	ZNF230	0.56	4.76	0.39	5.38e-6	Acute lymphoblastic leukemia (childhood);
TGCT	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs611744	0.781	rs656406	chr8:109173843	G/A	cg21045802	chr8:109455806	TTC35	0.69	6.06	0.48	1.51e-8	Dupuytren's disease;
TGCT	cis	rs1348850	0.789	rs2197611	chr2:178369036	G/C	cg22681709	chr2:178499509	PDE11A	-0.35	-4.55	-0.38	1.27e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg13393036	chr8:95962371	TP53INP1	-0.63	-8.6	-0.61	2.94e-14	Type 2 diabetes;
TGCT	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg11062466	chr8:58055876	NA	0.43	4.52	0.38	1.45e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs8180040	1.000	rs295442	chr3:47335881	A/C	cg27129171	chr3:47204927	SETD2	0.72	8.98	0.63	3.59e-15	Colorectal cancer;
TGCT	cis	rs694739	0.930	rs574087	chr11:64102948	A/G	cg02228329	chr11:64053129	BAD;GPR137	0.78	7.83	0.58	1.86e-12	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg03732007	chr1:2071316	PRKCZ	0.28	6.63	0.51	9.05e-10	Height;
TGCT	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg18876405	chr7:65276391	NA	-0.36	-5.41	-0.44	3.12e-7	Aortic root size;
TGCT	cis	rs12188164	0.965	rs11744539	chr5:451425	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.4	-4.71	-0.39	6.42e-6	Cystic fibrosis severity;
TGCT	cis	rs707040	0.921	rs2037662	chr2:155231121	T/C	cg18104148	chr2:154337490	NA	0.19	4.63	0.38	9.05e-6	Sudden cardiac arrest;
TGCT	cis	rs6964587	1.000	rs733957	chr7:91707197	C/T	cg22709100	chr7:91322751	NA	0.28	4.56	0.38	1.19e-5	Breast cancer;
TGCT	cis	rs6840360	0.642	rs7682770	chr4:152390413	A/C	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.82e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs664172	1	rs664172	chr15:78862762	G/A	cg24631222	chr15:78858424	CHRNA5	0.86	6.45	0.5	2.3e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs9372498	0.536	rs7356947	chr6:118767920	A/G	cg07617317	chr6:118971624	C6orf204	0.5	5.39	0.44	3.37e-7	Diastolic blood pressure;
TGCT	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg04267008	chr7:1944627	MAD1L1	-0.36	-4.68	-0.39	7.34e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs2014572	0.967	rs11667407	chr19:57763122	C/T	cg24459738	chr19:57751996	ZNF805	-0.58	-5.7	-0.46	8.38e-8	Hyperactive-impulsive symptoms;
TGCT	cis	rs67311347	0.869	rs9832311	chr3:40381322	A/T	cg17264618	chr3:40429014	ENTPD3	0.32	4.63	0.38	9.1e-6	Renal cell carcinoma;
TGCT	trans	rs3780486	1.000	rs10813957	chr9:33153527	G/T	cg04842962	chr6:43655489	MRPS18A	1.27	11.2	0.71	1.52e-20	IgG glycosylation;
TGCT	cis	rs909674	0.818	rs5750833	chr22:39843091	C/A	cg11247378	chr22:39784982	NA	-0.71	-8.48	-0.61	5.76e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs7666738	0.830	rs36047842	chr4:99004902	C/A	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.06	-9.57	-0.65	1.41e-16	Platelet count;
TGCT	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg11494091	chr17:61959527	GH2	0.61	14.81	0.8	3.37e-29	Prudent dietary pattern;
TGCT	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg00149659	chr3:10157352	C3orf10	0.73	4.72	0.39	6.3e-6	Alzheimer's disease;
TGCT	cis	rs739401	0.527	rs423236	chr11:3065916	C/T	cg05729581	chr11:3078854	CARS	-0.57	-5.27	-0.43	5.81e-7	Longevity;
TGCT	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.89	-6.4	-0.5	2.85e-9	Gut microbiome composition (summer);
TGCT	cis	rs28595532	0.920	rs116739193	chr4:119771024	G/A	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs523522	0.962	rs4767904	chr12:120930798	T/G	cg27279351	chr12:120934652	DYNLL1	0.76	6.59	0.51	1.15e-9	High light scatter reticulocyte count;
TGCT	cis	rs7822232	0.908	rs56138570	chr8:145142206	G/A	cg26272248	chr8:145163034	KIAA1875	-0.49	-4.81	-0.4	4.24e-6	Blood metabolite levels;
TGCT	cis	rs7811142	0.945	rs6974282	chr7:100098295	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	7.77	0.57	2.61e-12	Platelet count;
TGCT	cis	rs6500602	0.855	rs2304631	chr16:4475868	A/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.43	5.29	0.43	5.42e-7	Schizophrenia;
TGCT	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg03806693	chr22:41940476	POLR3H	1.15	13.16	0.76	2.69e-25	Vitiligo;
TGCT	cis	rs1395	1.000	rs6717980	chr2:27452784	T/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.51	6.68	0.51	7.27e-10	Blood metabolite levels;
TGCT	cis	rs4363385	0.507	rs6587710	chr1:152870716	A/G	cg07796016	chr1:152779584	LCE1C	-0.45	-5.09	-0.42	1.32e-6	Inflammatory skin disease;
TGCT	cis	rs10927875	0.541	rs761759	chr1:16342350	A/T	cg21385522	chr1:16154831	NA	0.46	4.85	0.4	3.64e-6	Dilated cardiomyopathy;
TGCT	trans	rs9388451	0.626	rs2875881	chr6:126072853	C/G	cg05039488	chr6:79577232	IRAK1BP1	-0.87	-9.71	-0.66	6.39e-17	Brugada syndrome;
TGCT	cis	rs9943465	0.539	rs34862546	chr10:131990793	C/G	cg00179795	chr10:131695114	EBF3	-0.35	-4.45	-0.37	1.87e-5	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs7809950	0.861	rs10264412	chr7:107183877	G/A	cg23024343	chr7:107201750	COG5	-0.48	-6.95	-0.53	1.82e-10	Coronary artery disease;
TGCT	trans	rs797680	0.856	rs10874759	chr1:93630172	G/A	cg27528825	chr2:159282178	CCDC148	-0.35	-6.78	-0.52	4.33e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs66573146	1.000	rs59683609	chr4:6964910	C/G	cg01220768	chr4:7056774	TADA2B	0.35	4.63	0.38	8.96e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg20276088	chr3:133502917	NA	-0.28	-5.88	-0.47	3.56e-8	Iron status biomarkers;
TGCT	cis	rs1997103	0.822	rs10273426	chr7:55417857	G/A	cg17469321	chr7:55412551	NA	0.61	5.91	0.47	3.03e-8	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs903263	0.965	rs6689844	chr1:84592019	G/A	cg09664975	chr1:84543551	PRKACB	0.49	4.55	0.38	1.27e-5	Breast cancer (male);
TGCT	cis	rs651907	0.535	rs1460097	chr3:101497569	C/T	cg12386194	chr3:101231763	SENP7	0.47	4.7	0.39	6.87e-6	Colorectal cancer;
TGCT	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg07167872	chr1:205819463	PM20D1	0.6	7.82	0.57	2.02e-12	Menarche (age at onset);
TGCT	cis	rs6987853	0.966	rs2084709	chr8:42423190	A/G	cg20539142	chr8:42623718	CHRNA6	-0.21	-5.11	-0.42	1.21e-6	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs250677	0.652	rs250675	chr5:148438565	A/C	cg18129178	chr5:148520854	ABLIM3	0.42	5.46	0.44	2.51e-7	Breast cancer;
TGCT	cis	rs9902453	0.904	rs7219456	chr17:28374112	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.81	-7.67	-0.57	4.37e-12	Coffee consumption (cups per day);
TGCT	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg21862992	chr11:68658383	NA	0.46	6.38	0.5	3.26e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs4808199	0.895	rs6511036	chr19:19582651	A/G	cg03709012	chr19:19516395	GATAD2A	1.0	7.8	0.57	2.23e-12	Nonalcoholic fatty liver disease;
TGCT	cis	rs4689388	0.926	rs4234730	chr4:6296343	A/G	cg25554036	chr4:6271136	WFS1	0.54	7.32	0.55	2.66e-11	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs7582180	0.629	rs11682557	chr2:100948008	C/A	cg08017756	chr2:100939284	LONRF2	-0.29	-4.62	-0.38	9.47e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10791097	0.694	rs2155752	chr11:130755998	C/T	cg14779329	chr11:130786720	SNX19	0.29	4.94	0.41	2.45e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs308403	0.640	rs34518478	chr4:123719999	T/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.66	5.7	0.46	8.18e-8	Blood protein levels;
TGCT	cis	rs1215050	0.791	rs2865943	chr4:98778449	C/T	cg05340658	chr4:99064831	C4orf37	0.44	5.51	0.44	2.01e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg21226059	chr5:178986404	RUFY1	-0.55	-6.37	-0.5	3.4e-9	Lung cancer;
TGCT	cis	rs9527	0.615	rs7073295	chr10:104672233	A/G	cg15744005	chr10:104629667	AS3MT	-0.45	-5.31	-0.43	4.9e-7	Arsenic metabolism;
TGCT	cis	rs11098499	0.955	rs1511015	chr4:120170473	A/C	cg24670566	chr4:120433619	PDE5A	0.23	4.58	0.38	1.13e-5	Corneal astigmatism;
TGCT	cis	rs12142240	0.698	rs17361936	chr1:46862893	C/T	cg00530320	chr1:46809349	NSUN4	0.29	5.79	0.46	5.34e-8	Menopause (age at onset);
TGCT	cis	rs8013055	0.846	rs8003942	chr14:105971670	A/G	cg23356831	chr14:105996513	TMEM121	0.41	6.33	0.49	4.01e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs12134133	1.000	rs2782854	chr1:207462714	A/G	cg02152968	chr1:207494213	CD55	0.57	4.47	0.37	1.74e-5	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs7647973	0.667	rs9869256	chr3:49624095	T/G	cg03060546	chr3:49711283	APEH	0.62	4.83	0.4	4e-6	Menarche (age at onset);
TGCT	cis	rs138249	0.867	rs138226	chr22:50556787	A/G	cg24864161	chr22:50528282	MOV10L1	0.47	5.02	0.41	1.77e-6	Gestational age at birth in labor-initiated deliveries (child effect);
TGCT	cis	rs11190604	0.697	rs10748795	chr10:102194818	A/T	cg23241863	chr10:102295624	HIF1AN	-0.66	-4.9	-0.4	2.98e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs72615157	0.634	rs11762932	chr7:99792666	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	-0.67	-5.33	-0.43	4.45e-7	Lung function (FEV1/FVC);
TGCT	cis	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg13531842	chr10:38383804	ZNF37A	-0.39	-4.64	-0.38	8.78e-6	Extrinsic epigenetic age acceleration;
TGCT	cis	rs854765	1.000	rs854765	chr17:18012730	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-6.45	-0.5	2.27e-9	Total body bone mineral density;
TGCT	cis	rs2742417	1.000	rs2742422	chr3:45732820	G/A	cg04837898	chr3:45731254	SACM1L	-0.55	-5.68	-0.45	9.14e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg00343986	chr7:65444356	GUSB	0.2	4.5	0.37	1.57e-5	Aortic root size;
TGCT	cis	rs2692947	0.631	rs2312954	chr2:96772447	C/T	cg05933789	chr2:97190408	NA	-0.16	-4.74	-0.39	5.75e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs7267979	1.000	rs1888997	chr20:25298988	G/A	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs6762477	0.748	rs11711407	chr3:50225029	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.75	-7.79	-0.57	2.37e-12	Menarche (age at onset);
TGCT	cis	rs2354432	0.607	rs9661159	chr1:146757923	G/A	cg25205988	chr1:146714368	CHD1L	-1.34	-6.07	-0.48	1.44e-8	Mitochondrial DNA levels;
TGCT	cis	rs62244186	0.566	rs3762636	chr3:44854563	A/G	cg10263370	chr3:44754102	ZNF502	-0.45	-5.47	-0.44	2.36e-7	Depressive symptoms;
TGCT	cis	rs10875746	0.855	rs10875729	chr12:48426726	A/G	cg20731937	chr12:48336164	NA	0.67	5.15	0.42	9.92e-7	Longevity (90 years and older);
TGCT	cis	rs7119	0.717	rs11630916	chr15:77821331	G/A	cg27398640	chr15:77910606	LINGO1	-0.25	-4.61	-0.38	9.7e-6	Type 2 diabetes;
TGCT	cis	rs4690686	0.500	rs7657249	chr4:177275198	A/G	cg17059388	chr4:177262070	NA	0.29	4.59	0.38	1.09e-5	Essential tremor;
TGCT	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7513165	0.935	rs7538038	chr1:204161026	C/T	cg04791601	chr1:204159016	NA	-0.27	-5.25	-0.43	6.42e-7	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
TGCT	cis	rs2153535	0.580	rs9406159	chr6:8464859	C/G	cg07606381	chr6:8435919	SLC35B3	0.55	5.16	0.42	9.35e-7	Motion sickness;
TGCT	cis	rs295140	0.605	rs159320	chr2:201187775	A/G	cg23649088	chr2:200775458	C2orf69	0.28	4.55	0.38	1.25e-5	QT interval;
TGCT	cis	rs68170813	0.652	rs117775624	chr7:107124113	C/T	cg02696742	chr7:106810147	HBP1	-0.65	-4.93	-0.4	2.55e-6	Coronary artery disease;
TGCT	cis	rs2046867	0.818	rs9814945	chr3:72803590	C/T	cg25664220	chr3:72788482	NA	-0.54	-6.8	-0.52	3.92e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs3125734	0.633	rs3765002	chr10:64006124	G/T	cg09941381	chr10:64027924	RTKN2	-0.37	-5.58	-0.45	1.46e-7	Rheumatoid arthritis;
TGCT	cis	rs910316	1.000	rs7303	chr14:75520065	T/C	cg23033748	chr14:75592666	NEK9	0.28	4.68	0.39	7.29e-6	Height;
TGCT	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg01341218	chr17:43662625	NA	-1.11	-9.34	-0.64	5.11e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs9527	0.544	rs11191549	chr10:104846797	C/T	cg04362960	chr10:104952993	NT5C2	0.67	5.76	0.46	6.28e-8	Arsenic metabolism;
TGCT	cis	rs854765	0.647	rs1008136	chr17:18027142	C/G	cg04398451	chr17:18023971	MYO15A	-0.39	-6.7	-0.52	6.51e-10	Total body bone mineral density;
TGCT	cis	rs12220238	1.000	rs11000894	chr10:75906598	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.06	0.54	1.05e-10	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs34638657	0.732	rs12595971	chr16:82200309	T/C	cg09439754	chr16:82129088	HSD17B2	-0.24	-4.63	-0.38	9.27e-6	Lung adenocarcinoma;
TGCT	cis	rs7666738	0.830	rs7673880	chr4:99057262	A/G	cg18180107	chr4:99064573	C4orf37	0.54	4.86	0.4	3.54e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs61990749	0.597	rs12896026	chr14:78244436	A/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.64	4.5	0.37	1.54e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs6563842	0.563	rs9603786	chr13:41316364	G/A	cg21288729	chr13:41239152	FOXO1	0.95	9.36	0.64	4.52e-16	Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
TGCT	cis	rs6933660	0.720	rs6936936	chr6:151753395	A/G	cg17179660	chr6:151773299	C6orf211;RMND1	-0.53	-4.81	-0.4	4.28e-6	Menarche (age at onset);
TGCT	cis	rs9467773	1.000	rs6910899	chr6:26524339	A/G	cg15659132	chr6:26577336	NA	0.86	12.21	0.74	5.3e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs7552404	0.727	rs5745433	chr1:76333163	T/G	cg03433033	chr1:76189801	ACADM	0.59	5.95	0.47	2.53e-8	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs10501293	0.746	rs4578378	chr11:43031293	C/T	cg03447554	chr11:43094025	NA	0.44	6.29	0.49	5.05e-9	Cognitive performance;
TGCT	cis	rs5760092	0.755	rs6003959	chr22:24264395	C/T	cg10150615	chr22:24372951	LOC391322	0.86	7.67	0.57	4.36e-12	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs910316	1.000	rs10143132	chr14:75525850	G/A	cg08847533	chr14:75593920	NEK9	0.96	10.6	0.69	4.3e-19	Height;
TGCT	cis	rs2658782	0.547	rs3020052	chr11:93055184	C/G	cg15737290	chr11:93063684	CCDC67	1.06	11.42	0.72	4.37e-21	Pulmonary function decline;
TGCT	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg10295955	chr4:187884368	NA	-0.97	-14.61	-0.8	1e-28	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs950027	0.596	rs2467865	chr15:45638307	T/C	cg14582100	chr15:45693742	SPATA5L1	0.47	6.02	0.48	1.8e-8	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs1371867	0.875	rs1962901	chr8:101326428	A/G	cg06002616	chr8:101225028	SPAG1	-0.53	-6.21	-0.49	7.16e-9	Atrioventricular conduction;
TGCT	cis	rs12765878	0.580	rs11191833	chr10:105619678	G/A	cg11005552	chr10:105648138	OBFC1	-0.39	-6.06	-0.48	1.54e-8	Coronary artery disease;
TGCT	cis	rs12477438	0.798	rs1993230	chr2:99686079	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-8.52	-0.61	4.5e-14	Chronic sinus infection;
TGCT	cis	rs55883249	1.000	rs17362902	chr2:9768564	C/T	cg23886495	chr2:9695866	ADAM17	-0.74	-4.53	-0.38	1.37e-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs9467773	0.620	rs9461276	chr6:26595168	T/C	cg26531700	chr6:26746687	NA	0.5	4.65	0.39	8.29e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7937682	0.847	rs583032	chr11:111432757	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.99	-10.25	-0.68	3.19e-18	Primary sclerosing cholangitis;
TGCT	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg03609598	chr5:56110824	MAP3K1	-0.58	-4.7	-0.39	6.72e-6	Initial pursuit acceleration;
TGCT	cis	rs9916302	0.904	rs10852933	chr17:37698194	G/T	cg15445000	chr17:37608096	MED1	0.31	4.5	0.37	1.53e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs4595586	0.870	rs2388172	chr12:39290539	A/G	cg10518543	chr12:38710700	ALG10B	0.47	4.6	0.38	1.01e-5	Morning vs. evening chronotype;
TGCT	cis	rs1580019	0.587	rs9638880	chr7:32552401	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.58	4.94	0.41	2.43e-6	Cognitive ability;
TGCT	cis	rs6867032	0.958	rs9312970	chr5:2002415	C/A	cg26168224	chr5:2018326	NA	-0.39	-6.05	-0.48	1.56e-8	Gut microbiome composition (winter);
TGCT	cis	rs2404602	0.569	rs283793	chr15:76774752	G/A	cg22467129	chr15:76604101	ETFA	-0.46	-4.71	-0.39	6.53e-6	Blood metabolite levels;
TGCT	cis	rs9814567	0.929	rs2241556	chr3:134183312	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.97	9.51	0.65	1.89e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs10426930	0.607	rs877287	chr19:5041989	G/A	cg09001777	chr19:5851504	FUT3	0.2	4.57	0.38	1.14e-5	Monocyte percentage of white cells;
TGCT	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg04414720	chr1:150670196	GOLPH3L	0.39	5.11	0.42	1.19e-6	Tonsillectomy;
TGCT	cis	rs7772486	0.686	rs9497380	chr6:145955305	T/C	cg23711669	chr6:146136114	FBXO30	0.84	9.17	0.64	1.25e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2835872	0.932	rs73222345	chr21:39036569	G/A	cg20424643	chr21:39039972	KCNJ6	0.25	5.41	0.44	3.16e-7	Electroencephalographic traits in alcoholism;
TGCT	cis	rs3099143	1.000	rs4886832	chr15:77121196	G/A	cg21673338	chr15:77095150	SCAPER	0.51	4.88	0.4	3.17e-6	Recalcitrant atopic dermatitis;
TGCT	cis	rs1887596	0.639	rs11149445	chr13:27162727	A/G	cg01312412	chr13:27282625	NA	0.32	5.72	0.46	7.42e-8	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg21963583	chr11:68658836	MRPL21	0.36	6.17	0.48	9.01e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg13393036	chr8:95962371	TP53INP1	-0.63	-8.52	-0.61	4.43e-14	Type 2 diabetes;
TGCT	cis	rs727505	1.000	rs722560	chr7:124488035	T/C	cg23710748	chr7:124431027	NA	-0.26	-4.49	-0.37	1.6e-5	Lewy body disease;
TGCT	cis	rs2073300	1.000	rs6137982	chr20:23468892	T/A	cg09953122	chr20:23471693	CST8	-0.68	-4.7	-0.39	6.92e-6	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs7666738	0.546	rs10007424	chr4:98885450	C/T	cg17366294	chr4:99064904	C4orf37	0.67	6.0	0.47	2e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6598955	0.670	rs6676619	chr1:26539035	T/G	cg04990556	chr1:26633338	UBXN11	-0.89	-11.24	-0.71	1.2e-20	Obesity-related traits;
TGCT	cis	rs7666738	0.830	rs1025203	chr4:99023073	G/A	cg18180107	chr4:99064573	C4orf37	0.54	4.8	0.4	4.53e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2404602	0.631	rs9646213	chr15:76807672	G/C	cg22467129	chr15:76604101	ETFA	-0.56	-6.57	-0.51	1.28e-9	Blood metabolite levels;
TGCT	cis	rs13191362	1.000	rs13191362	chr6:163033350	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.8	6.91	0.53	2.2e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7226408	0.857	rs11081970	chr18:34484766	C/T	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs910316	0.763	rs175450	chr14:75590340	G/A	cg08847533	chr14:75593920	NEK9	-0.85	-8.58	-0.61	3.22e-14	Height;
TGCT	cis	rs523522	0.962	rs4767902	chr12:120910004	C/T	cg12219531	chr12:120966889	COQ5	0.83	7.33	0.55	2.6e-11	High light scatter reticulocyte count;
TGCT	cis	rs9393777	0.528	rs35982103	chr6:27243134	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.59	-5.17	-0.42	9.21e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs854765	0.583	rs8078105	chr17:17853782	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	7.69	0.57	3.98e-12	Total body bone mineral density;
TGCT	cis	rs28595532	0.920	rs55649377	chr4:119752745	T/A	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs28595532	0.841	rs115725150	chr4:119768647	T/A	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs7267979	1.000	rs6050590	chr20:25384994	G/A	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4242434	0.927	rs2272718	chr8:22457388	G/A	cg03733263	chr8:22462867	KIAA1967	1.16	19.41	0.87	2.12e-39	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs644148	0.803	rs2686771	chr19:44999494	T/C	cg15540054	chr19:45004280	ZNF180	-0.65	-5.33	-0.43	4.48e-7	Personality dimensions;
TGCT	cis	rs7264396	0.790	rs2295355	chr20:34252654	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.25	-0.43	6.33e-7	Total cholesterol levels;
TGCT	cis	rs2836633	0.929	rs2836602	chr21:40039169	A/T	cg12884169	chr21:40033163	ERG	-0.44	-4.8	-0.4	4.56e-6	Coronary artery disease;
TGCT	cis	rs4642101	1.000	rs7650482	chr3:12841804	A/G	cg05775895	chr3:12838266	CAND2	0.54	5.16	0.42	9.56e-7	QRS complex (12-leadsum);
TGCT	cis	rs1538970	0.962	rs2153608	chr1:45813941	C/T	cg05343316	chr1:45956843	TESK2	-0.67	-5.07	-0.41	1.39e-6	Platelet count;
TGCT	cis	rs9796	0.700	rs2305656	chr15:41279519	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.51	-6.46	-0.5	2.16e-9	Menopause (age at onset);
TGCT	cis	rs263156	0.967	rs263105	chr6:142876920	T/A	cg18419694	chr6:143832440	FUCA2	-0.38	-4.53	-0.38	1.36e-5	Ear morphology;Lobe size;Lobe attachment;
TGCT	cis	rs9916302	0.904	rs7221875	chr17:37543328	G/A	cg15445000	chr17:37608096	MED1	-0.33	-4.71	-0.39	6.46e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.49	-4.76	-0.39	5.34e-6	Bipolar disorder;
TGCT	cis	rs7524258	0.934	rs6689453	chr1:7288384	C/T	cg07173049	chr1:7289937	CAMTA1	0.27	4.44	0.37	1.97e-5	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs7666738	0.830	rs7657982	chr4:99044015	G/A	cg17366294	chr4:99064904	C4orf37	0.72	7.4	0.55	1.76e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9296092	0.500	rs9469503	chr6:33527234	G/T	cg13560919	chr6:33536144	NA	-0.23	-5.06	-0.41	1.49e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs6690583	0.623	rs12037219	chr1:85505951	G/A	cg20280350	chr1:85513789	MCOLN3	-0.71	-4.53	-0.38	1.38e-5	Serum sulfate level;
TGCT	cis	rs4074961	0.669	rs6687545	chr1:38071195	C/T	cg17933807	chr1:38061675	GNL2	0.96	11.42	0.72	4.35e-21	Axial length;
TGCT	cis	rs2228479	0.614	rs1137042	chr16:89975638	A/G	cg06558623	chr16:89946397	TCF25	0.38	4.58	0.38	1.12e-5	Skin colour saturation;
TGCT	cis	rs8180040	0.903	rs6791842	chr3:47279810	T/C	cg27129171	chr3:47204927	SETD2	0.7	8.64	0.61	2.35e-14	Colorectal cancer;
TGCT	cis	rs6964587	1.000	rs12531366	chr7:91683849	C/G	cg22709100	chr7:91322751	NA	0.29	4.92	0.4	2.71e-6	Breast cancer;
TGCT	cis	rs78487399	0.908	rs12471686	chr2:43831083	T/C	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.66	4.67	0.39	7.66e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs1865760	0.865	rs9467651	chr6:25958257	C/G	cg17042849	chr6:26104293	HIST1H4C	-0.52	-4.78	-0.39	4.88e-6	Height;
TGCT	cis	rs478607	0.831	rs3825074	chr11:64415767	G/A	cg19395706	chr11:64412079	NRXN2	0.48	4.84	0.4	3.8e-6	Urate levels;
TGCT	cis	rs3782455	1.000	rs117470230	chr12:114403053	G/C	cg23502203	chr12:113549970	RASAL1	-0.55	-4.92	-0.4	2.7e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs2455799	0.613	rs12491914	chr3:15808672	A/C	cg16303742	chr3:15540471	COLQ	-0.25	-4.74	-0.39	5.76e-6	Mean platelet volume;
TGCT	cis	rs10791097	1.000	rs10791097	chr11:130718630	G/T	cg05962950	chr11:130786565	SNX19	-0.74	-7.04	-0.53	1.15e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	trans	rs10435719	0.753	rs9694940	chr8:11789858	G/C	cg15556689	chr8:8085844	FLJ10661	0.74	7.04	0.53	1.17e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs4851254	0.961	rs13011181	chr2:100732446	T/C	cg22139774	chr2:100720529	AFF3	-0.4	-4.74	-0.39	5.7e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs5760092	0.755	rs5760096	chr22:24247310	A/G	cg04234412	chr22:24373322	LOC391322	-0.85	-8.55	-0.61	3.95e-14	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	trans	rs4919669	0.546	rs4919656	chr10:104282861	G/A	cg19053889	chr7:1098703	C7orf50;GPR146	0.51	6.78	0.52	4.25e-10	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs6988636	0.710	rs17315999	chr8:124153763	A/G	cg23067535	chr8:124195133	FAM83A	-0.37	-4.59	-0.38	1.07e-5	Urinary uromodulin levels;
TGCT	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg03351412	chr1:154909251	PMVK	-0.52	-4.85	-0.4	3.55e-6	Prostate cancer;
TGCT	cis	rs2239547	0.657	rs2072391	chr3:52862200	C/T	cg10802521	chr3:52805072	NEK4	-0.62	-5.85	-0.47	4.1e-8	Schizophrenia;
TGCT	cis	rs950169	0.526	rs698620	chr15:85177208	G/A	cg11189052	chr15:85197271	WDR73	-0.73	-7.16	-0.54	6.16e-11	Schizophrenia;
TGCT	cis	rs7618915	0.501	rs55678971	chr3:52717229	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	5.6	0.45	1.31e-7	Bipolar disorder;
TGCT	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg08683831	chr4:1404607	NA	-0.46	-4.43	-0.37	2.01e-5	Obesity-related traits;
TGCT	trans	rs1814175	0.669	rs12416837	chr11:49669761	G/T	cg03929089	chr4:120376271	NA	-0.6	-7.01	-0.53	1.34e-10	Height;
TGCT	cis	rs2742417	1.000	rs2742420	chr3:45732237	A/G	cg04837898	chr3:45731254	SACM1L	-0.55	-5.67	-0.45	9.39e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs8072100	1.000	rs7210738	chr17:45757598	G/A	cg08085267	chr17:45401833	C17orf57	0.47	5.13	0.42	1.07e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs3015497	0.789	rs923908	chr14:51123595	C/T	cg04730355	chr14:51134070	SAV1	-0.66	-6.46	-0.5	2.19e-9	Mean platelet volume;
TGCT	cis	rs600231	0.651	rs2846862	chr11:65219790	A/G	cg17120908	chr11:65337727	SSSCA1	-0.52	-4.68	-0.39	7.41e-6	Bone mineral density;
TGCT	cis	rs2120019	1.000	rs7175720	chr15:75348962	C/G	cg11632617	chr15:75315747	PPCDC	0.33	4.77	0.39	5.14e-6	Blood trace element (Zn levels);
TGCT	cis	rs3026101	0.671	rs8067917	chr17:5278307	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.47	4.57	0.38	1.18e-5	Body mass index;
TGCT	cis	rs7267979	0.868	rs6107019	chr20:25233985	C/T	cg03522245	chr20:25566470	NINL	0.6	6.58	0.51	1.21e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs250677	0.652	rs250670	chr5:148446646	G/T	cg18129178	chr5:148520854	ABLIM3	-0.43	-6.29	-0.49	5.05e-9	Breast cancer;
TGCT	cis	rs2115630	0.645	rs1107179	chr15:85198362	A/C	cg17173187	chr15:85201210	NMB	0.47	5.71	0.46	7.96e-8	P wave terminal force;
TGCT	cis	rs1008375	0.966	rs6839660	chr4:17667987	C/T	cg10189774	chr4:17578691	LAP3	0.51	4.7	0.39	6.71e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs11098499	0.954	rs3733524	chr4:120423729	T/C	cg09307838	chr4:120376055	NA	0.67	6.3	0.49	4.63e-9	Corneal astigmatism;
TGCT	cis	rs4689592	0.503	rs4689064	chr4:7055603	A/G	cg02503808	chr4:7069936	GRPEL1	-0.96	-8.24	-0.59	2.12e-13	Monocyte percentage of white cells;
TGCT	cis	rs1843834	0.539	rs1494109	chr2:225441833	G/A	cg22455342	chr2:225449267	CUL3	1.04	10.75	0.69	1.87e-19	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs7246657	0.722	rs13744	chr19:38077912	C/T	cg18154014	chr19:37997991	ZNF793	0.69	4.63	0.38	9.25e-6	Coronary artery calcification;
TGCT	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7666738	0.962	rs4699605	chr4:99064379	A/G	cg18180107	chr4:99064573	C4orf37	0.55	4.48	0.37	1.64e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs17376456	0.877	rs7728736	chr5:93404277	C/T	cg21475434	chr5:93447410	FAM172A	0.59	4.66	0.39	8.09e-6	Diabetic retinopathy;
TGCT	cis	rs2075371	0.829	rs11770521	chr7:133936251	A/C	cg11752832	chr7:134001865	SLC35B4	0.66	5.51	0.44	1.95e-7	Mean platelet volume;
TGCT	cis	rs2067615	0.524	rs754184	chr12:107117521	A/G	cg15890332	chr12:107067104	RFX4	0.26	5.3	0.43	5.03e-7	Heart rate;
TGCT	cis	rs7843479	0.601	rs3824338	chr8:21864540	A/C	cg17168535	chr8:21777572	XPO7	0.8	8.05	0.59	5.9e-13	Mean corpuscular volume;
TGCT	cis	rs1062177	1.000	rs12518722	chr5:151231460	A/G	cg00977110	chr5:151150581	G3BP1	0.4	4.5	0.38	1.51e-5	Preschool internalizing problems;
TGCT	cis	rs9486715	0.793	rs2499777	chr6:97013814	T/C	cg18709589	chr6:96969512	KIAA0776	-0.86	-8.45	-0.6	6.73e-14	Headache;
TGCT	cis	rs588177	0.522	rs34358026	chr11:64015422	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.84	7.09	0.54	9.2e-11	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg08280861	chr8:58055591	NA	0.36	4.98	0.41	2.08e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4700695	0.841	rs784276	chr5:65317332	A/T	cg21114390	chr5:65439923	SFRS12	0.6	4.53	0.38	1.36e-5	Facial morphology (factor 19);
TGCT	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg05234568	chr11:5960015	NA	0.57	6.13	0.48	1.06e-8	DNA methylation (variation);
TGCT	cis	rs10782582	0.586	rs1796813	chr1:76400403	G/A	cg10523679	chr1:76189770	ACADM	-0.56	-5.04	-0.41	1.6e-6	Daytime sleep phenotypes;
TGCT	cis	rs4499344	0.604	rs259275	chr19:33159693	A/G	cg26639809	chr19:33781782	NA	0.22	4.47	0.37	1.75e-5	Mean platelet volume;
TGCT	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	5.69	0.45	8.72e-8	Alzheimer's disease;
TGCT	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg13395646	chr4:1353034	KIAA1530	-0.39	-4.96	-0.41	2.3e-6	Obesity-related traits;
TGCT	cis	rs6748734	1.000	rs4675860	chr2:241840417	A/G	cg04034577	chr2:241836375	C2orf54	-0.4	-6.35	-0.5	3.72e-9	Urinary metabolites;
TGCT	cis	rs9303401	0.625	rs34963822	chr17:56988424	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.61	6.16	0.48	9.11e-9	Cognitive test performance;
TGCT	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg03517284	chr6:25882590	NA	-0.65	-5.74	-0.46	6.73e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.753	rs6826709	chr4:98714553	C/G	cg05340658	chr4:99064831	C4orf37	0.49	5.71	0.46	7.99e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6969780	0.722	rs983185	chr7:27188607	G/A	cg06942814	chr7:27170819	HOXA4	-0.4	-4.45	-0.37	1.92e-5	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.7	0.52	6.47e-10	Bipolar disorder;
TGCT	cis	rs2832191	0.967	rs2832216	chr21:30521921	C/T	cg24692254	chr21:30365293	RNF160	0.82	9.12	0.63	1.67e-15	Dental caries;
TGCT	cis	rs7267979	0.932	rs6115215	chr20:25562500	C/T	cg03522245	chr20:25566470	NINL	0.6	6.46	0.5	2.14e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs981844	0.683	rs1037647	chr4:154737991	A/G	cg14289246	chr4:154710475	SFRP2	-1.0	-9.32	-0.64	5.46e-16	Response to statins (LDL cholesterol change);
TGCT	cis	rs7777484	0.534	rs2533888	chr7:2831083	T/C	cg25467336	chr7:2757616	NA	-0.25	-4.64	-0.38	8.88e-6	Height;
TGCT	cis	rs644799	1.000	rs543530	chr11:95545170	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	8.74	0.62	1.39e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7772486	0.875	rs932522	chr6:146374026	A/G	cg23711669	chr6:146136114	FBXO30	-0.9	-9.98	-0.67	1.41e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.07	0.82	4.17e-32	Prudent dietary pattern;
TGCT	cis	rs4478858	0.647	rs11581476	chr1:31717675	C/T	cg07478791	chr1:31886160	SERINC2	-0.48	-4.6	-0.38	1.03e-5	Alcohol dependence;
TGCT	cis	rs9443645	0.869	rs6913028	chr6:79513590	C/T	cg09184832	chr6:79620586	NA	-0.46	-5.01	-0.41	1.83e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg06028808	chr11:68637592	NA	0.51	6.54	0.51	1.48e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7428	0.545	rs7572750	chr2:85552186	C/A	cg24342717	chr2:85555507	TGOLN2	-0.49	-7.83	-0.58	1.88e-12	Ear protrusion;
TGCT	cis	rs597539	0.552	rs10792006	chr11:68722306	T/C	cg21963583	chr11:68658836	MRPL21	-0.25	-4.56	-0.38	1.2e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs2404602	1.000	rs12441433	chr15:76816015	G/A	cg26408565	chr15:76604113	ETFA	-0.41	-5.3	-0.43	5.13e-7	Blood metabolite levels;
TGCT	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg22168489	chr12:122356033	WDR66	0.23	5.52	0.44	1.91e-7	Mean corpuscular volume;
TGCT	cis	rs60871478	0.947	rs62432862	chr7:807719	G/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.46	4.6	0.38	1.04e-5	Cerebrospinal P-tau181p levels;
TGCT	cis	rs10883723	0.773	rs11191313	chr10:104278618	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.79	7.79	0.57	2.25e-12	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs61935443	0.832	rs11107768	chr12:95274182	A/T	cg21533806	chr12:95267307	NA	-0.52	-4.64	-0.38	8.68e-6	Schizophrenia;
TGCT	cis	rs6490294	0.898	rs4767202	chr12:112354075	T/C	cg10833066	chr12:111807467	FAM109A	0.39	5.65	0.45	1.03e-7	Mean platelet volume;
TGCT	cis	rs9677476	0.863	rs3731775	chr2:232063578	G/A	cg07929768	chr2:232055508	NA	0.31	4.49	0.37	1.61e-5	Food antigen IgG levels;
TGCT	cis	rs6089584	1.000	rs6089585	chr20:60564395	G/A	cg13770153	chr20:60521292	NA	-0.44	-5.69	-0.46	8.52e-8	Body mass index;
TGCT	cis	rs614226	1.000	rs563920	chr12:121017439	A/G	cg01236616	chr12:121019343	POP5	1.29	14.01	0.78	2.51e-27	Type 1 diabetes nephropathy;
TGCT	trans	rs9929218	0.551	rs2296405	chr16:68721470	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.63	-8.27	-0.6	1.74e-13	Colorectal cancer;
TGCT	cis	rs56235845	0.694	rs11949401	chr5:176765989	A/G	cg06060754	chr5:176797920	RGS14	0.4	6.33	0.49	3.99e-9	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs9902453	0.934	rs4427857	chr17:28457989	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	6.9	0.53	2.37e-10	Coffee consumption (cups per day);
TGCT	cis	rs7666738	0.830	rs4699589	chr4:98973889	A/G	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg09174653	chr7:1063357	C7orf50;MIR339	-0.22	-4.44	-0.37	2e-5	Longevity;Endometriosis;
TGCT	cis	rs7705042	0.686	rs62381975	chr5:141513018	G/A	cg07392085	chr5:141489673	NDFIP1	-0.34	-4.54	-0.38	1.34e-5	Asthma;
TGCT	cis	rs2033711	0.870	rs1051500	chr19:58944402	A/G	cg04608855	chr19:58913158	NA	0.58	5.74	0.46	6.86e-8	Uric acid clearance;
TGCT	trans	rs561341	1.000	rs4795670	chr17:30244839	T/C	cg20587970	chr11:113659929	NA	-0.97	-12.13	-0.74	8.27e-23	Hip circumference adjusted for BMI;
TGCT	cis	rs13177918	0.677	rs4841	chr5:149826526	C/T	cg14059543	chr5:149831962	NA	-0.71	-9.35	-0.64	4.68e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs7677751	0.537	rs6554164	chr4:55106695	T/C	cg17187183	chr4:55093834	PDGFRA	0.35	4.48	0.37	1.64e-5	Corneal astigmatism;
TGCT	cis	rs600231	0.651	rs2846862	chr11:65219790	A/G	cg21890820	chr11:65308645	LTBP3	0.38	4.7	0.39	6.92e-6	Bone mineral density;
TGCT	cis	rs10875746	0.669	rs11168510	chr12:48685555	A/G	cg20731937	chr12:48336164	NA	0.59	4.49	0.37	1.61e-5	Longevity (90 years and older);
TGCT	cis	rs17401966	0.931	rs61778401	chr1:10426474	G/A	cg19773385	chr1:10388646	KIF1B	-0.24	-5.5	-0.44	2.03e-7	Hepatocellular carcinoma;
TGCT	cis	rs854765	0.551	rs56886154	chr17:17831473	C/A	cg09796270	chr17:17721594	SREBF1	0.27	5.55	0.45	1.69e-7	Total body bone mineral density;
TGCT	cis	rs10089	1.000	rs4836360	chr5:127458161	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	8.17	0.59	2.99e-13	Ileal carcinoids;
TGCT	cis	rs6088590	0.687	rs6088580	chr20:33285053	G/C	cg08999081	chr20:33150536	PIGU	0.27	5.01	0.41	1.81e-6	Coronary artery disease;
TGCT	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg27121462	chr16:89883253	FANCA	0.81	8.9	0.62	5.56e-15	Vitiligo;
TGCT	cis	rs4845570	1.000	rs3811415	chr1:151763767	C/T	cg07092448	chr1:151763213	TDRKH	-1.12	-8.62	-0.61	2.64e-14	Coronary artery disease;
TGCT	cis	rs2486288	0.656	rs1060896	chr15:45554267	C/A	cg14582100	chr15:45693742	SPATA5L1	-0.44	-5.28	-0.43	5.62e-7	Glomerular filtration rate;
TGCT	cis	rs8016982	0.633	rs55822231	chr14:81708677	C/T	cg01989461	chr14:81687754	GTF2A1	0.84	8.66	0.61	2.06e-14	Schizophrenia;
TGCT	cis	rs858239	0.539	rs6955969	chr7:23186699	C/T	cg05602783	chr7:23145260	KLHL7	-0.6	-4.74	-0.39	5.86e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs644799	0.525	rs3016206	chr11:95536724	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.8	8.76	0.62	1.21e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs6867913	0.709	rs2338874	chr5:141466926	G/A	cg01169021	chr5:140792918	PCDHGA4;PCDHGA6;PCDHGA9;PCDHGA1;PCDHGA8;PCDHGA5;PCDHGB1;PCDHGA10;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGB6;PCDHGA7;PCDHGB2;PCDHGB5;PCDHGB3	-0.41	-5.09	-0.42	1.31e-6	Asthma;
TGCT	cis	rs9303401	0.615	rs7502342	chr17:56922629	C/A	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs3096299	0.967	rs2965830	chr16:89460290	T/C	cg06640241	chr16:89574553	SPG7	0.66	6.32	0.49	4.33e-9	Multiple myeloma (IgH translocation);
TGCT	cis	rs1048238	0.846	rs945420	chr1:16345208	G/A	cg22431228	chr1:16359049	CLCNKA	-0.29	-6.2	-0.49	7.76e-9	Systolic blood pressure;
TGCT	cis	rs11190604	1.000	rs11190601	chr10:102296730	A/G	cg23241863	chr10:102295624	HIF1AN	0.67	5.12	0.42	1.12e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs1158570	0.773	rs6984963	chr8:131332096	A/G	cg16277922	chr8:131349729	ASAP1	0.48	7.2	0.54	5.06e-11	Platelet count;
TGCT	cis	rs7267979	0.966	rs6050611	chr20:25414419	A/G	cg14121845	chr20:25566513	NINL	0.48	5.06	0.41	1.45e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11761231	1.000	rs11761231	chr7:131370039	A/G	cg23399222	chr7:130417715	KLF14	0.24	4.52	0.38	1.42e-5	Rheumatoid arthritis;
TGCT	cis	rs6450176	1.000	rs4588541	chr5:53300640	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.53	-5.1	-0.42	1.23e-6	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs62244186	0.541	rs3804583	chr3:44884647	G/T	cg02073558	chr3:44770973	ZNF501	0.7	6.99	0.53	1.49e-10	Depressive symptoms;
TGCT	cis	rs4746059	0.516	rs4747080	chr10:72466545	A/G	cg03087610	chr10:71892362	AIFM2	0.54	4.78	0.39	4.85e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1577917	1.000	rs12213740	chr6:86656733	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.22	-0.42	7.27e-7	Response to antipsychotic treatment;
TGCT	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg08439880	chr3:133502540	NA	-0.28	-5.15	-0.42	9.73e-7	Iron status biomarkers;
TGCT	cis	rs7044106	0.791	rs7036196	chr9:123479457	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	6.99	0.53	1.48e-10	Hip circumference adjusted for BMI;
TGCT	cis	rs12210905	1.000	rs1102557	chr6:27149794	C/A	cg08851530	chr6:28072375	NA	-1.12	-5.43	-0.44	2.82e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg13607699	chr17:42295918	UBTF	0.6	5.48	0.44	2.23e-7	Total body bone mineral density;
TGCT	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg00738919	chr7:1100172	C7orf50	0.47	4.47	0.37	1.72e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs4718428	0.705	rs11028	chr7:66276217	T/C	cg18252515	chr7:66147081	NA	-0.59	-4.51	-0.38	1.47e-5	Corneal structure;
TGCT	cis	rs910316	1.000	rs10136948	chr14:75511075	C/T	cg23033748	chr14:75592666	NEK9	0.27	4.57	0.38	1.16e-5	Height;
TGCT	cis	rs910316	0.763	rs175450	chr14:75590340	G/A	cg11812906	chr14:75593930	NEK9	-0.63	-5.81	-0.46	4.98e-8	Height;
TGCT	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	5.57	0.45	1.52e-7	Height;
TGCT	cis	rs10504229	0.679	rs16921677	chr8:58052431	T/C	cg08280861	chr8:58055591	NA	0.36	5.14	0.42	1.03e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2469997	0.925	rs2470005	chr8:120358483	T/G	cg00681363	chr8:120844660	TAF2	0.69	4.48	0.37	1.64e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg05590025	chr7:65112418	INTS4L2	-0.76	-4.44	-0.37	1.96e-5	Diabetic kidney disease;
TGCT	cis	rs1008375	1.000	rs55939327	chr4:17642937	T/A	cg10189774	chr4:17578691	LAP3	0.57	5.15	0.42	9.95e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg03303774	chr4:1407052	NA	0.29	4.5	0.37	1.52e-5	Obesity-related traits;
TGCT	cis	rs7119	0.651	rs12915057	chr15:77847745	C/A	cg27398640	chr15:77910606	LINGO1	-0.28	-5.11	-0.42	1.21e-6	Type 2 diabetes;
TGCT	cis	rs6688613	0.959	rs112416021	chr1:166944745	T/C	cg07049167	chr1:166818506	POGK	0.22	4.55	0.38	1.28e-5	Refractive astigmatism;
TGCT	cis	rs2013441	1.000	rs2703810	chr17:20113715	C/T	cg18979559	chr17:20280153	CCDC144C	-0.44	-4.61	-0.38	9.78e-6	Obesity-related traits;
TGCT	cis	rs7552404	1.000	rs7552404	chr1:76135946	A/G	cg03433033	chr1:76189801	ACADM	0.84	10.07	0.67	8.62e-18	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9388451	0.839	rs9401845	chr6:126104118	A/G	cg05901451	chr6:126070800	HEY2	-1.0	-14.45	-0.79	2.37e-28	Brugada syndrome;
TGCT	cis	rs854765	0.547	rs8069811	chr17:17922280	G/A	cg04398451	chr17:18023971	MYO15A	-0.31	-5.05	-0.41	1.56e-6	Total body bone mineral density;
TGCT	cis	rs5769765	1.000	rs5769760	chr22:50259696	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	1.11	11.71	0.72	8.52e-22	Schizophrenia;
TGCT	trans	rs117132860	0.661	rs10224957	chr7:17117288	T/C	cg25519926	chr7:130132360	MEST;MESTIT1	0.95	6.72	0.52	5.93e-10	Cutaneous squamous cell carcinoma;
TGCT	cis	rs2836974	0.800	rs73221174	chr21:40540939	T/C	cg11644478	chr21:40555479	PSMG1	1.01	10.35	0.68	1.81e-18	Cognitive function;
TGCT	cis	rs4788570	0.584	rs11862723	chr16:71704222	T/C	cg06353428	chr16:71660113	MARVELD3	1.56	12.54	0.75	8.54e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs514406	0.536	rs878957	chr1:53197559	C/T	cg08859206	chr1:53392774	SCP2	0.38	5.39	0.44	3.49e-7	Monocyte count;
TGCT	trans	rs2688608	0.869	rs2250140	chr10:75612881	T/C	cg13918328	chr10:52500089	ASAH2B	0.68	6.95	0.53	1.87e-10	Inflammatory bowel disease;
TGCT	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg18654377	chr3:49208889	KLHDC8B	-0.47	-6.21	-0.49	7.35e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs7916697	0.947	rs1900004	chr10:70000881	C/T	cg18338521	chr10:69995036	NA	-0.28	-4.47	-0.37	1.75e-5	Optic disc area;
TGCT	cis	rs7677751	0.708	rs6554160	chr4:55077549	T/A	cg17187183	chr4:55093834	PDGFRA	0.48	6.31	0.49	4.41e-9	Corneal astigmatism;
TGCT	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg08645402	chr16:4508243	NA	0.2	5.01	0.41	1.86e-6	Schizophrenia;
TGCT	cis	rs6681544	0.544	rs3790912	chr1:82377091	C/T	cg04226724	chr1:82268649	LPHN2	0.47	4.87	0.4	3.28e-6	Metabolite levels  (X-11787);
TGCT	cis	rs35306767	0.903	rs35957139	chr10:884889	C/T	cg26597838	chr10:835615	NA	0.8	12.11	0.74	9.26e-23	Eosinophil percentage of granulocytes;
TGCT	cis	rs11214589	0.774	rs7107223	chr11:113255574	A/T	cg14159747	chr11:113255604	NA	0.36	4.52	0.38	1.41e-5	Neuroticism;
TGCT	cis	rs2730260	0.537	rs73169239	chr7:158884305	C/A	cg09066883	chr7:157932951	PTPRN2	0.42	4.66	0.39	8.09e-6	Myopia (pathological);
TGCT	cis	rs9640161	0.789	rs28432021	chr7:150046235	G/C	cg10018233	chr7:150070692	REPIN1	0.31	4.55	0.38	1.25e-5	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs6542838	0.588	rs4851174	chr2:99530113	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.53	-4.99	-0.41	2.01e-6	Fear of minor pain;
TGCT	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg01416388	chr22:39784598	NA	-0.61	-6.26	-0.49	5.88e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg15242686	chr22:24348715	GSTTP1	0.42	5.62	0.45	1.22e-7	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs4730250	0.707	rs1981696	chr7:106794100	C/T	cg02696742	chr7:106810147	HBP1	0.71	5.67	0.45	9.61e-8	Osteoarthritis;
TGCT	cis	rs68170813	0.559	rs1018946	chr7:106851754	T/C	cg02696742	chr7:106810147	HBP1	-0.69	-5.61	-0.45	1.27e-7	Coronary artery disease;
TGCT	cis	rs904251	0.965	rs1317563	chr6:37451854	G/T	cg08126542	chr6:37504118	NA	-0.36	-4.76	-0.39	5.3e-6	Cognitive performance;
TGCT	cis	rs7000551	0.663	rs7827118	chr8:22334669	T/G	cg12081754	chr8:22256438	SLC39A14	0.28	4.5	0.37	1.54e-5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs2013441	1.000	rs3850784	chr17:20185030	A/G	cg18979559	chr17:20280153	CCDC144C	-0.45	-4.67	-0.39	7.61e-6	Obesity-related traits;
TGCT	cis	rs10746514	0.833	rs10864720	chr1:232271232	C/T	cg09506761	chr1:232265262	NA	-0.52	-5.41	-0.44	3.16e-7	Response to statin therapy;
TGCT	cis	rs72781680	1.000	rs72781680	chr2:24238928	C/T	cg08917208	chr2:24149416	ATAD2B	0.83	5.08	0.42	1.35e-6	Lymphocyte counts;
TGCT	cis	rs6684514	0.961	rs12126696	chr1:156241348	C/T	cg20302342	chr1:156215951	PAQR6	0.36	4.75	0.39	5.6e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs16854884	0.770	rs4450810	chr3:143809091	C/A	cg06585982	chr3:143692056	C3orf58	0.57	4.49	0.37	1.63e-5	Economic and political preferences (feminism/equality);
TGCT	cis	rs394563	0.591	rs11155641	chr6:149648595	G/A	cg03678062	chr6:149772716	ZC3H12D	0.38	4.83	0.4	3.99e-6	Dupuytren's disease;
TGCT	cis	rs10507380	0.824	rs75922600	chr13:27914656	C/T	cg25543773	chr13:27185723	WASF3	0.34	4.83	0.4	3.97e-6	Electrocardiographic traits;
TGCT	cis	rs595982	0.527	rs35023389	chr19:49377873	G/A	cg17863274	chr19:49399704	TULP2	-0.55	-7.9	-0.58	1.31e-12	Red cell distribution width;
TGCT	cis	rs12908161	0.650	rs182517	chr15:85389631	G/A	cg11189052	chr15:85197271	WDR73	0.64	5.16	0.42	9.65e-7	Schizophrenia;
TGCT	cis	rs3733585	0.746	rs4318650	chr4:10016868	T/C	cg11266682	chr4:10021025	SLC2A9	0.69	9.1	0.63	1.93e-15	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs1008375	0.966	rs2315645	chr4:17579678	G/C	cg16339924	chr4:17578868	LAP3	0.8	6.96	0.53	1.73e-10	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2594989	0.673	rs62245959	chr3:11601797	G/T	cg00170343	chr3:11313890	ATG7	-0.71	-4.91	-0.4	2.87e-6	Circulating chemerin levels;
TGCT	cis	rs764284	0.506	rs9379980	chr6:27306518	C/T	cg02458000	chr6:26745757	NA	-0.48	-4.49	-0.37	1.6e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2153535	0.505	rs1335629	chr6:8491863	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs6964587	0.934	rs7793861	chr7:91742728	C/G	cg17063962	chr7:91808500	NA	0.87	9.34	0.64	4.87e-16	Breast cancer;
TGCT	cis	rs826838	0.585	rs4363678	chr12:38624514	G/A	cg26384229	chr12:38710491	ALG10B	0.56	5.11	0.42	1.21e-6	Heart rate;
TGCT	cis	rs7666738	0.830	rs4699595	chr4:99012827	A/G	cg05340658	chr4:99064831	C4orf37	0.48	5.43	0.44	2.92e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7119	0.717	rs12904212	chr15:77815833	C/A	cg27398640	chr15:77910606	LINGO1	-0.25	-4.6	-0.38	1.05e-5	Type 2 diabetes;
TGCT	cis	rs6582630	0.555	rs7978749	chr12:38527141	G/T	cg26384229	chr12:38710491	ALG10B	0.85	7.74	0.57	3.08e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs7666738	0.710	rs7674407	chr4:98838522	A/G	cg05340658	chr4:99064831	C4orf37	0.53	6.17	0.48	8.71e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1448094	0.533	rs2169572	chr12:86170370	G/T	cg02569458	chr12:86230093	RASSF9	-0.39	-4.58	-0.38	1.14e-5	Major depressive disorder;
TGCT	cis	rs1577917	0.917	rs1584273	chr6:86524577	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-5.53	-0.44	1.82e-7	Response to antipsychotic treatment;
TGCT	cis	rs11785400	1.000	rs13266249	chr8:143732433	A/C	cg24634471	chr8:143751801	JRK	0.54	5.85	0.46	4.19e-8	Schizophrenia;
TGCT	trans	rs1814175	0.654	rs7482446	chr11:49779020	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.38	-7.76	-0.57	2.75e-12	Height;
TGCT	cis	rs7659604	1.000	rs7659943	chr4:122665560	C/T	cg19748678	chr4:122722346	EXOSC9	0.53	5.01	0.41	1.82e-6	Type 2 diabetes;
TGCT	cis	rs7666738	0.570	rs1921415	chr4:99093804	C/T	cg18180107	chr4:99064573	C4orf37	0.53	4.75	0.39	5.61e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11098499	0.909	rs35111518	chr4:120440682	A/G	cg09307838	chr4:120376055	NA	0.69	6.53	0.51	1.49e-9	Corneal astigmatism;
TGCT	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.72	5.14	0.42	1.06e-6	Platelet count;
TGCT	cis	rs11098499	0.588	rs2389874	chr4:120554991	A/G	cg09307838	chr4:120376055	NA	-0.57	-5.35	-0.43	4.16e-7	Corneal astigmatism;
TGCT	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg10295955	chr4:187884368	NA	-0.97	-14.62	-0.8	9.35e-29	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2898681	0.519	rs6554057	chr4:53730147	A/T	cg00791764	chr4:53727839	RASL11B	0.54	4.58	0.38	1.1e-5	Optic nerve measurement (cup area);
TGCT	cis	rs198851	0.736	rs198846	chr6:26107463	A/G	cg11837274	chr6:26034134	HIST1H2AB	0.71	4.55	0.38	1.28e-5	Red cell distribution width;High light scatter reticulocyte percentage of red cells;Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs698813	0.604	rs2340814	chr2:44490977	C/T	cg00619915	chr2:44497795	NA	-0.24	-5.5	-0.44	2.05e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
TGCT	cis	rs7191439	0.858	rs6500489	chr16:88772046	T/C	cg27087555	chr16:88793112	FAM38A	-0.6	-6.37	-0.5	3.36e-9	Plateletcrit;
TGCT	cis	rs2172802	0.659	rs2343251	chr4:62492671	C/A	cg04118610	chr4:62707027	LPHN3	0.43	4.66	0.39	8.13e-6	Partial epilepsies;
TGCT	cis	rs3858526	1.000	rs10838909	chr11:5960490	G/A	cg13902645	chr11:5959945	NA	-0.44	-4.72	-0.39	6.39e-6	DNA methylation (variation);
TGCT	cis	rs17253792	0.822	rs28681420	chr14:56088403	G/T	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg13397359	chr6:42928475	GNMT	0.84	8.18	0.59	2.89e-13	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs763121	0.819	rs4560233	chr22:38982442	A/T	cg06022373	chr22:39101656	GTPBP1	0.77	7.39	0.55	1.94e-11	Menopause (age at onset);
TGCT	cis	rs7726839	0.574	rs11134149	chr5:637277	A/G	cg16624210	chr5:671434	TPPP	0.38	4.63	0.38	9.02e-6	Obesity-related traits;
TGCT	cis	rs17221829	0.931	rs35892874	chr11:89452677	C/T	cg02982614	chr11:89391479	FOLH1B	-0.29	-4.95	-0.41	2.4e-6	Anxiety in major depressive disorder;
TGCT	cis	rs7666738	0.753	rs28390295	chr4:99028497	C/A	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9291683	0.588	rs3756237	chr4:10013378	G/A	cg02734326	chr4:10020555	SLC2A9	0.38	4.56	0.38	1.22e-5	Bone mineral density;
TGCT	cis	rs12477438	0.765	rs10193039	chr2:99692373	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-5.45	-0.44	2.61e-7	Chronic sinus infection;
TGCT	cis	rs28735056	0.967	rs56071379	chr18:77647406	G/A	cg20368463	chr18:77673604	PQLC1	-0.45	-5.54	-0.45	1.75e-7	Schizophrenia;
TGCT	cis	rs6570726	0.935	rs367643	chr6:145859602	A/C	cg23711669	chr6:146136114	FBXO30	0.71	7.03	0.53	1.25e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1801251	1.000	rs1801251	chr2:233633460	G/A	cg08000102	chr2:233561755	GIGYF2	0.64	6.56	0.51	1.34e-9	Coronary artery disease;
TGCT	trans	rs12339966	0.581	rs62529408	chr9:11331268	T/G	cg03488587	chr11:64876988	C11orf2	0.31	6.62	0.51	9.51e-10	Systolic blood pressure;
TGCT	cis	rs933688	0.938	rs6866923	chr5:90669352	A/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.08	10.13	0.67	6.16e-18	Smoking behavior;
TGCT	cis	rs2933343	0.859	rs789247	chr3:128580585	C/A	cg11901034	chr3:128598214	ACAD9	-0.62	-5.16	-0.42	9.47e-7	IgG glycosylation;
TGCT	trans	rs11082438	1.000	rs11082438	chr18:42865210	G/T	cg11883238	chr10:62676418	RHOBTB1	-0.7	-6.8	-0.52	4.03e-10	Follicular lymphoma;
TGCT	cis	rs9409154	0.823	rs7467175	chr9:118109239	C/T	cg14094498	chr9:119000864	PAPPA	0.26	4.76	0.39	5.32e-6	Visceral adipose tissue adjusted for BMI;
TGCT	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.91	0.4	2.75e-6	Electroencephalogram traits;
TGCT	cis	rs62064224	0.553	rs6505297	chr17:30765767	A/G	cg18200150	chr17:30822561	MYO1D	0.44	5.27	0.43	5.73e-7	Schizophrenia;
TGCT	cis	rs858239	0.600	rs7788821	chr7:23133645	A/T	cg05602783	chr7:23145260	KLHL7	-0.58	-4.85	-0.4	3.68e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs35146811	0.695	rs1727132	chr7:99812297	T/C	cg22906224	chr7:99728672	NA	-0.49	-4.45	-0.37	1.88e-5	Coronary artery disease;
TGCT	cis	rs6912958	0.781	rs6916732	chr6:88259225	C/T	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.91	-0.4	2.78e-6	Monocyte percentage of white cells;
TGCT	cis	rs4273100	1.000	rs4273100	chr17:19153417	T/C	cg01534423	chr17:18965556	NA	0.92	5.56	0.45	1.55e-7	Schizophrenia;
TGCT	cis	rs763121	0.853	rs7289855	chr22:39042221	G/T	cg06022373	chr22:39101656	GTPBP1	0.76	7.22	0.54	4.54e-11	Menopause (age at onset);
TGCT	cis	rs853679	0.515	rs4580862	chr6:28367663	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.56	-5.27	-0.43	5.78e-7	Depression;
TGCT	cis	rs1692580	0.807	rs12138597	chr1:2189477	T/C	cg21194808	chr1:2205498	SKI	0.29	5.78	0.46	5.71e-8	Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs6832209	chr4:98994120	A/G	cg18180107	chr4:99064573	C4orf37	0.51	4.68	0.39	7.37e-6	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs17471911	0.708	rs10466169	chr10:100772791	C/T	cg03484267	chr2:207988651	KLF7	-0.52	-6.7	-0.52	6.49e-10	Neuroticism;
TGCT	cis	rs3816788	0.792	rs13257744	chr8:21872853	T/C	cg17168535	chr8:21777572	XPO7	0.77	7.65	0.57	4.88e-12	Lung cancer in ever smokers;
TGCT	cis	rs9811216	1.000	rs9868000	chr3:169510789	G/A	cg08193579	chr3:169529701	LRRC34	0.29	4.48	0.37	1.68e-5	Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;
TGCT	cis	rs11644362	0.966	rs11645507	chr16:12992570	C/A	cg06890432	chr16:12997467	SHISA9	-0.61	-6.55	-0.51	1.41e-9	Positive affect;Subjective well-being;
TGCT	cis	rs2120019	0.938	rs5020842	chr15:75322310	T/C	cg09165964	chr15:75287851	SCAMP5	-1.2	-10.21	-0.68	3.83e-18	Blood trace element (Zn levels);
TGCT	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs208520	1.000	rs208521	chr6:66953625	C/T	cg07460842	chr6:66804631	NA	-0.83	-7.52	-0.56	9.8e-12	Exhaled nitric oxide output;
TGCT	cis	rs12220238	1.000	rs10824076	chr10:75886956	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.91	7.98	0.58	8.43e-13	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs7267979	1.000	rs10966	chr20:25282944	A/G	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2816062	0.813	rs2816050	chr1:18894432	A/G	cg18795169	chr1:18902165	NA	-0.6	-14.18	-0.79	1.04e-27	Urate levels in lean individuals;
TGCT	trans	rs1814175	0.765	rs1722003	chr11:49895896	G/A	cg03929089	chr4:120376271	NA	-0.72	-8.15	-0.59	3.33e-13	Height;
TGCT	cis	rs7666738	0.830	rs10028692	chr4:98962585	C/T	cg17366294	chr4:99064904	C4orf37	0.74	7.56	0.56	7.89e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12908161	1.000	rs17600551	chr15:85319258	A/G	cg17173187	chr15:85201210	NMB	0.57	6.4	0.5	2.89e-9	Schizophrenia;
TGCT	cis	rs9388451	0.626	rs2875881	chr6:126072853	C/G	cg05901451	chr6:126070800	HEY2	-1.04	-13.0	-0.76	6.65e-25	Brugada syndrome;
TGCT	cis	rs11671005	0.735	rs3826682	chr19:58918748	C/T	cg13877915	chr19:58951672	ZNF132	0.63	4.92	0.4	2.74e-6	Mean platelet volume;
TGCT	cis	rs1355223	0.583	rs1549789	chr11:34867947	G/A	cg24088639	chr11:34937564	PDHX;APIP	-0.5	-4.51	-0.38	1.45e-5	Systemic lupus erythematosus and Systemic sclerosis;
TGCT	cis	rs11690935	0.655	rs17614941	chr2:172541378	A/G	cg13550731	chr2:172543902	DYNC1I2	0.73	6.37	0.5	3.29e-9	Schizophrenia;
TGCT	cis	rs16971465	0.850	rs62053226	chr16:73022013	C/T	cg01557791	chr16:72042693	DHODH	0.91	4.54	0.38	1.29e-5	Schizophrenia;
TGCT	cis	rs10791097	0.690	rs12286234	chr11:130730528	T/C	cg14779329	chr11:130786720	SNX19	0.25	4.44	0.37	1.96e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs2692947	0.759	rs2692937	chr2:96751871	G/A	cg23100626	chr2:96804247	ASTL	0.4	4.75	0.39	5.55e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.87	0.4	3.31e-6	Hemoglobin concentration;
TGCT	cis	rs7568458	0.846	rs10179195	chr2:85762761	A/G	cg02493740	chr2:85810744	VAMP5	-0.27	-4.97	-0.41	2.2e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs1008375	0.966	rs4698619	chr4:17580955	G/A	cg16339924	chr4:17578868	LAP3	0.8	6.96	0.53	1.73e-10	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs3733585	0.805	rs882222	chr4:9981294	G/A	cg11266682	chr4:10021025	SLC2A9	0.62	8.63	0.61	2.51e-14	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg13206674	chr6:150067644	NUP43	0.52	4.51	0.38	1.5e-5	Lung cancer;
TGCT	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.01	0.41	1.86e-6	Prudent dietary pattern;
TGCT	cis	rs11249608	0.548	rs6867208	chr5:178455575	G/A	cg21905437	chr5:178450457	ZNF879	0.43	4.5	0.37	1.53e-5	Pubertal anthropometrics;
TGCT	cis	rs427394	0.659	rs274717	chr5:6721067	C/T	cg10857441	chr5:6722123	POLS	0.28	5.86	0.47	3.82e-8	Menopause (age at onset);
TGCT	cis	rs1857353	1.000	rs1857354	chr1:75902948	C/T	cg11838876	chr1:75668600	SLC44A5	-0.51	-4.81	-0.4	4.23e-6	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs17401966	0.867	rs7546364	chr1:10418815	G/A	cg19773385	chr1:10388646	KIF1B	-0.23	-5.38	-0.44	3.57e-7	Hepatocellular carcinoma;
TGCT	cis	rs1801251	1.000	rs2592105	chr2:233645968	C/G	cg08000102	chr2:233561755	GIGYF2	0.64	6.56	0.51	1.34e-9	Coronary artery disease;
TGCT	cis	rs8017423	1.000	rs2183189	chr14:90670057	A/G	cg04374321	chr14:90722782	PSMC1	0.77	7.95	0.58	9.78e-13	Mortality in heart failure;
TGCT	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg26818010	chr10:134567672	INPP5A	-0.35	-4.76	-0.39	5.21e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs7617773	0.780	rs11714944	chr3:48366971	C/A	cg11946769	chr3:48343235	NME6	0.8	6.91	0.53	2.26e-10	Coronary artery disease;
TGCT	cis	rs2486288	0.656	rs1706770	chr15:45575062	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.84	-9.07	-0.63	2.28e-15	Glomerular filtration rate;
TGCT	cis	rs2050392	0.517	rs687036	chr10:30761249	G/A	cg18806716	chr10:30721971	MAP3K8	-0.55	-6.7	-0.52	6.64e-10	Inflammatory bowel disease;
TGCT	cis	rs7119167	0.813	rs7101831	chr11:73106690	T/C	cg17517138	chr11:73019481	ARHGEF17	0.57	4.44	0.37	2e-5	Blood protein levels;
TGCT	cis	rs644799	0.965	rs2508713	chr11:95547927	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	8.74	0.62	1.39e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.71	-0.39	6.54e-6	Prudent dietary pattern;
TGCT	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg03264133	chr6:25882463	NA	-0.49	-5.11	-0.42	1.17e-6	Height;
TGCT	cis	rs12579753	1.000	rs34894912	chr12:82228721	A/G	cg07988820	chr12:82153109	PPFIA2	-0.6	-6.48	-0.5	1.91e-9	Resting heart rate;
TGCT	cis	rs9296092	0.522	rs62405955	chr6:33527176	T/C	cg13560919	chr6:33536144	NA	-0.23	-5.06	-0.41	1.49e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg17264618	chr3:40429014	ENTPD3	0.32	4.57	0.38	1.18e-5	Renal cell carcinoma;
TGCT	cis	rs7226408	0.948	rs17567496	chr18:34355579	T/G	cg06757138	chr18:34340585	FHOD3	0.29	4.91	0.4	2.76e-6	Obesity-related traits;
TGCT	cis	rs11671005	0.735	rs35652377	chr19:58929200	A/C	cg13877915	chr19:58951672	ZNF132	0.63	4.99	0.41	1.95e-6	Mean platelet volume;
TGCT	cis	rs4242434	0.597	rs4066629	chr8:22529073	A/C	cg03733263	chr8:22462867	KIAA1967	-1.03	-14.31	-0.79	4.99e-28	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs559406	0.501	rs2542167	chr18:12795849	A/T	cg23598886	chr18:12777645	NA	0.35	4.44	0.37	1.97e-5	Psoriasis;
TGCT	cis	rs9911578	1.000	rs2643119	chr17:56827760	G/T	cg05425664	chr17:57184151	TRIM37	-0.63	-6.26	-0.49	5.86e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs2549003	1.000	rs2070726	chr5:131821738	C/A	cg00255919	chr5:131827918	IRF1	0.2	4.65	0.39	8.22e-6	Asthma (sex interaction);
TGCT	cis	rs3020736	0.500	rs5996109	chr22:42493098	A/G	cg05082376	chr22:42548792	NA	0.23	5.43	0.44	2.83e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg27425262	chr2:113953981	PSD4;LOC440839	-0.48	-7.03	-0.53	1.25e-10	Lymphocyte counts;
TGCT	cis	rs13217239	0.572	rs9379958	chr6:27066163	A/C	cg26531700	chr6:26746687	NA	-0.7	-6.84	-0.52	3.25e-10	Schizophrenia;
TGCT	cis	rs3749237	1.000	rs11130214	chr3:49735746	C/G	cg03060546	chr3:49711283	APEH	-0.74	-7.7	-0.57	3.78e-12	Resting heart rate;
TGCT	trans	rs797680	0.856	rs797672	chr1:93702119	A/T	cg27528825	chr2:159282178	CCDC148	0.35	6.88	0.53	2.65e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs6570726	0.935	rs386344	chr6:145855622	A/G	cg23711669	chr6:146136114	FBXO30	0.73	7.42	0.55	1.64e-11	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs910187	0.591	rs13041142	chr20:45788979	C/T	cg27589058	chr20:45804311	EYA2	-0.37	-6.97	-0.53	1.67e-10	Migraine;
TGCT	cis	rs12693043	0.727	rs2163236	chr2:175431707	C/G	cg11778734	chr2:175439522	WIPF1	-0.37	-4.75	-0.39	5.51e-6	Urate levels (BMI interaction);
TGCT	cis	rs12134133	0.688	rs6540875	chr1:207395031	C/T	cg02152968	chr1:207494213	CD55	0.69	4.75	0.39	5.46e-6	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs67311347	0.876	rs13068097	chr3:40504424	T/A	cg17264618	chr3:40429014	ENTPD3	-0.33	-4.85	-0.4	3.66e-6	Renal cell carcinoma;
TGCT	cis	rs2115630	1.000	rs1030863	chr15:85282635	C/T	cg17173187	chr15:85201210	NMB	-0.39	-4.76	-0.39	5.4e-6	P wave terminal force;
TGCT	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-5.1	-0.42	1.23e-6	Bipolar disorder;
TGCT	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg26118208	chr10:134322334	NA	0.26	5.1	0.42	1.22e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs17253792	0.822	rs112308750	chr14:56080073	G/A	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs7818688	0.697	rs10504939	chr8:95983354	C/G	cg16049864	chr8:95962084	TP53INP1	0.54	4.64	0.38	8.87e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs6570726	0.755	rs2092296	chr6:145893684	A/C	cg23711669	chr6:146136114	FBXO30	0.86	9.54	0.65	1.64e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs367615	0.591	rs4530812	chr5:108858587	A/C	cg17395555	chr5:108820864	NA	-0.27	-4.83	-0.4	3.88e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs6988636	1.000	rs57165742	chr8:124184559	G/A	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg23758822	chr17:41437982	NA	0.72	6.81	0.52	3.77e-10	Menopause (age at onset);
TGCT	cis	rs1348850	0.914	rs3902850	chr2:178315899	G/A	cg22681709	chr2:178499509	PDE11A	-0.35	-4.57	-0.38	1.18e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs1865760	0.566	rs2032449	chr6:26026599	G/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.77	7.44	0.56	1.47e-11	Height;
TGCT	cis	rs9393777	0.528	rs7745603	chr6:27090404	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.54	-5.27	-0.43	5.73e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs17539620	0.624	rs62432740	chr6:154836054	C/T	cg20019720	chr6:154832845	CNKSR3	0.57	5.02	0.41	1.72e-6	Lipoprotein (a) levels;
TGCT	cis	rs1008375	1.000	rs9291659	chr4:17662360	A/C	cg16339924	chr4:17578868	LAP3	0.56	4.86	0.4	3.51e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs12477438	0.748	rs6712773	chr2:99585781	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-6.1	-0.48	1.22e-8	Chronic sinus infection;
TGCT	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg27121462	chr16:89883253	FANCA	0.78	8.52	0.61	4.65e-14	Vitiligo;
TGCT	cis	rs921968	0.608	rs678814	chr2:219359287	T/C	cg02176678	chr2:219576539	TTLL4	0.44	6.33	0.49	4.17e-9	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs751728	0.648	rs6922275	chr6:33749739	G/A	cg13859433	chr6:33739653	LEMD2	-0.32	-5.67	-0.45	9.47e-8	Crohn's disease;
TGCT	cis	rs67311347	0.955	rs60554147	chr3:40472503	T/C	cg17264618	chr3:40429014	ENTPD3	0.32	4.67	0.39	7.68e-6	Renal cell carcinoma;
TGCT	cis	rs1670533	1.000	rs6836350	chr4:1069973	C/T	cg27284194	chr4:1044797	NA	0.7	6.11	0.48	1.17e-8	Recombination rate (females);
TGCT	cis	rs7258465	1.000	rs8103622	chr19:18572834	C/T	cg22489759	chr19:18572700	ELL	0.2	4.46	0.37	1.81e-5	Breast cancer;
TGCT	cis	rs35306767	0.761	rs11253558	chr10:1043983	T/C	cg20503657	chr10:835505	NA	0.61	6.71	0.52	6.11e-10	Eosinophil percentage of granulocytes;
TGCT	cis	rs7731657	0.537	rs10520092	chr5:130202197	C/T	cg08523029	chr5:130500466	HINT1	0.55	4.63	0.38	8.92e-6	Fasting plasma glucose;
TGCT	cis	rs10782582	0.609	rs5745347	chr1:76274520	C/T	cg03433033	chr1:76189801	ACADM	0.48	4.86	0.4	3.48e-6	Daytime sleep phenotypes;
TGCT	cis	rs2228479	0.850	rs62054609	chr16:89816569	C/A	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs17376456	0.877	rs10060462	chr5:93455073	C/T	cg25358565	chr5:93447407	FAM172A	0.93	8.37	0.6	1.04e-13	Diabetic retinopathy;
TGCT	cis	rs9929218	0.551	rs4783663	chr16:68720271	T/C	cg01251360	chr16:68772225	CDH1	-0.26	-4.59	-0.38	1.05e-5	Colorectal cancer;
TGCT	cis	rs2233152	0.572	rs10411008	chr19:41297241	T/C	cg11601297	chr19:41224147	ITPKC;ADCK4	0.49	4.73	0.39	5.94e-6	Kawasaki disease;
TGCT	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg21724239	chr8:58056113	NA	0.39	5.24	0.43	6.73e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2760061	0.505	rs708109	chr1:228190657	C/T	cg02753203	chr1:228287806	NA	0.39	7.63	0.57	5.36e-12	Diastolic blood pressure;
TGCT	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	5.8	0.46	5.19e-8	Alzheimer's disease;
TGCT	cis	rs6421571	0.565	rs10892263	chr11:118587319	T/C	cg19308663	chr11:118741387	NA	0.25	4.48	0.37	1.66e-5	Primary biliary cholangitis;
TGCT	cis	rs2469997	0.925	rs2470010	chr8:120359532	T/C	cg00681363	chr8:120844660	TAF2	0.69	4.48	0.37	1.64e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg13695892	chr22:41940480	POLR3H	0.89	8.48	0.61	5.62e-14	Vitiligo;
TGCT	cis	rs9399135	0.967	rs1590975	chr6:135352088	C/T	cg24558204	chr6:135376177	HBS1L	0.48	4.79	0.4	4.67e-6	Red blood cell count;
TGCT	cis	rs9362426	0.943	rs1884320	chr6:88089160	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.41	-4.45	-0.37	1.86e-5	Depressive episodes in bipolar disorder;
TGCT	trans	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg13615516	chr5:77269221	NA	0.69	8.53	0.61	4.28e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs6988636	0.534	rs62521775	chr8:124109949	A/G	cg27053337	chr8:124217698	FAM83A	0.55	4.82	0.4	4.2e-6	Urinary uromodulin levels;
TGCT	cis	rs11098499	0.865	rs28634456	chr4:120375778	A/G	cg09307838	chr4:120376055	NA	0.68	6.53	0.51	1.54e-9	Corneal astigmatism;
TGCT	cis	rs1008375	0.966	rs10939755	chr4:17693755	T/C	cg18681998	chr4:17616180	MED28	0.77	7.32	0.55	2.7e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs425277	1.000	rs262657	chr1:2088577	G/A	cg24578937	chr1:2090814	PRKCZ	0.32	7.86	0.58	1.56e-12	Height;
TGCT	cis	rs4722166	0.597	rs1554606	chr7:22768707	T/G	cg13104385	chr7:22767384	IL6	0.23	4.99	0.41	2.03e-6	Lung cancer;
TGCT	cis	rs6754311	0.517	rs1469995	chr2:136542559	G/A	cg07169764	chr2:136633963	MCM6	0.89	7.81	0.57	2.05e-12	Mosquito bite size;
TGCT	cis	rs881375	0.902	rs2900180	chr9:123706382	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.44	4.72	0.39	6.28e-6	Rheumatoid arthritis;
TGCT	cis	rs911555	0.570	rs942862	chr14:104022124	G/C	cg26031613	chr14:104095156	KLC1	0.6	5.4	0.44	3.22e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs4631830	0.869	rs4131357	chr10:51537292	C/A	cg10326726	chr10:51549505	MSMB	-0.25	-5.27	-0.43	5.73e-7	Prostate-specific antigen levels;
TGCT	cis	rs10426930	0.621	rs10409229	chr19:5009545	C/T	cg09001777	chr19:5851504	FUT3	0.24	4.6	0.38	1.03e-5	Monocyte percentage of white cells;
TGCT	cis	rs751728	1.000	rs2296747	chr6:33744882	C/G	cg13859433	chr6:33739653	LEMD2	-0.4	-7.16	-0.54	6.37e-11	Crohn's disease;
TGCT	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg12963246	chr6:28129442	ZNF389	0.52	5.1	0.42	1.23e-6	Depression;
TGCT	cis	rs7267979	1.000	rs2482919	chr20:25299756	T/C	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2204008	0.619	rs11178987	chr12:38201258	C/T	cg26384229	chr12:38710491	ALG10B	-0.58	-5.09	-0.42	1.28e-6	Bladder cancer;
TGCT	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg08280861	chr8:58055591	NA	0.4	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg13695892	chr22:41940480	POLR3H	0.93	9.1	0.63	1.88e-15	Vitiligo;
TGCT	cis	rs9341808	0.935	rs4706113	chr6:80839315	C/T	cg08355045	chr6:80787529	NA	0.28	4.89	0.4	3.04e-6	Sitting height ratio;
TGCT	cis	rs7178572	0.568	rs12912050	chr15:77689423	C/T	cg15453836	chr15:77711506	NA	-0.42	-4.78	-0.39	4.92e-6	Type 2 diabetes;
TGCT	cis	rs4253772	0.591	rs11705624	chr22:46685380	C/T	cg24881330	chr22:46731750	TRMU	1.04	5.38	0.44	3.54e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs2204008	0.687	rs1733404	chr12:38123395	G/T	cg26384229	chr12:38710491	ALG10B	-0.85	-7.68	-0.57	4.21e-12	Bladder cancer;
TGCT	cis	rs3733585	0.699	rs7694997	chr4:9947811	A/G	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.45	-0.5	2.22e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs858239	0.633	rs858300	chr7:23244631	A/G	cg05407003	chr7:23246146	NA	-0.29	-4.59	-0.38	1.07e-5	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs3820068	0.705	rs57971278	chr1:15838604	G/A	cg05660106	chr1:15850417	CASP9	1.13	13.41	0.77	6.7e-26	Systolic blood pressure;
TGCT	cis	rs950169	0.920	rs17300048	chr15:84749477	C/T	cg17173187	chr15:85201210	NMB	0.47	5.23	0.42	7.11e-7	Schizophrenia;
TGCT	cis	rs10984561	0.881	rs73540236	chr9:122252550	T/C	cg14242995	chr9:122249943	NA	0.73	5.96	0.47	2.46e-8	Pulmonary function decline;
TGCT	cis	rs11190604	0.767	rs10883483	chr10:102174244	T/C	cg16005271	chr10:102321736	NA	0.45	4.74	0.39	5.87e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs4319547	0.915	rs7314638	chr12:122983460	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.66	-5.32	-0.43	4.71e-7	Body mass index;
TGCT	cis	rs1976403	0.633	rs1697422	chr1:21821897	T/C	cg17800788	chr1:21766015	NBPF3	0.25	4.77	0.39	4.98e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.21	4.51	0.38	1.46e-5	Eosinophil percentage of white cells;
TGCT	cis	rs12200560	0.505	rs211174	chr6:97071120	C/T	cg06623918	chr6:96969491	KIAA0776	0.59	5.02	0.41	1.76e-6	Coronary heart disease;
TGCT	cis	rs7744392	0.557	rs9470007	chr6:35349739	C/T	cg06087101	chr6:35551932	FKBP5	-0.61	-4.56	-0.38	1.21e-5	Cataracts in type 2 diabetes;
TGCT	cis	rs10992471	0.603	rs10820968	chr9:95106443	A/G	cg14631576	chr9:95140430	CENPP	-0.31	-4.68	-0.39	7.5e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs11867934	0.724	rs4985746	chr17:17098213	G/A	cg26176665	chr17:16994978	MPRIP	0.27	4.88	0.4	3.24e-6	Diabetic retinopathy;
TGCT	cis	rs9467773	0.620	rs9295701	chr6:26627508	T/C	cg02458000	chr6:26745757	NA	0.53	5.02	0.41	1.76e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9653442	0.835	rs1561230	chr2:100746642	C/T	cg07810366	chr2:100720526	AFF3	0.47	7.78	0.57	2.45e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs13108904	0.846	rs9631805	chr4:1283035	T/C	cg00684032	chr4:1343700	KIAA1530	-0.22	-4.47	-0.37	1.76e-5	Obesity-related traits;
TGCT	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg16325326	chr1:53192061	ZYG11B	0.63	7.34	0.55	2.51e-11	Monocyte count;
TGCT	cis	rs4689592	0.523	rs4256224	chr4:7074583	T/C	cg02503808	chr4:7069936	GRPEL1	1.01	9.62	0.65	1.08e-16	Monocyte percentage of white cells;
TGCT	cis	rs1534166	1.000	rs1534166	chr3:133537067	C/T	cg16414030	chr3:133502952	NA	-0.42	-4.96	-0.41	2.3e-6	Alcohol consumption (transferrin glycosylation);
TGCT	cis	rs1075232	0.677	rs72714666	chr15:31492226	T/C	cg01030201	chr15:31746330	NA	-0.87	-4.63	-0.38	9.12e-6	Survival in colorectal cancer (non-distant metastatic);
TGCT	cis	rs2120019	0.935	rs34835684	chr15:75331805	T/G	cg17294928	chr15:75287854	SCAMP5	-0.78	-6.12	-0.48	1.14e-8	Blood trace element (Zn levels);
TGCT	cis	rs2439831	0.681	rs484029	chr15:43619560	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	6.63	0.51	9.35e-10	Lung cancer in ever smokers;
TGCT	cis	rs9457247	0.515	rs1951459	chr6:167402536	G/A	cg23791538	chr6:167370224	RNASET2	0.61	6.0	0.47	2.06e-8	Crohn's disease;
TGCT	cis	rs9584850	0.794	rs9630321	chr13:99106979	C/G	cg15168958	chr13:99100528	FARP1	-0.24	-4.53	-0.38	1.34e-5	Neuroticism;
TGCT	trans	rs2727020	0.656	rs7925524	chr11:49437542	G/A	cg15704280	chr7:45808275	SEPT13	-0.65	-6.64	-0.51	8.97e-10	Coronary artery disease;
TGCT	cis	rs1577917	0.876	rs12201992	chr6:86618219	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.54	-0.45	1.73e-7	Response to antipsychotic treatment;
TGCT	cis	rs17376456	0.877	rs2290937	chr5:93356515	A/T	cg25358565	chr5:93447407	FAM172A	1.01	8.01	0.58	6.99e-13	Diabetic retinopathy;
TGCT	cis	rs7552404	0.889	rs380075	chr1:76106961	T/A	cg10523679	chr1:76189770	ACADM	-0.92	-10.1	-0.67	7.29e-18	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9443645	0.901	rs1984195	chr6:79657391	G/A	cg05283184	chr6:79620031	NA	-0.21	-4.71	-0.39	6.61e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg22857025	chr5:266934	NA	-0.31	-6.32	-0.49	4.33e-9	Breast cancer;
TGCT	cis	rs806215	1.000	rs806215	chr7:127237312	T/C	cg25922125	chr7:127225783	GCC1	-0.57	-6.04	-0.48	1.64e-8	Type 2 diabetes;
TGCT	cis	rs4478858	0.735	rs2889730	chr1:31827159	C/T	cg07478791	chr1:31886160	SERINC2	-0.51	-4.94	-0.41	2.46e-6	Alcohol dependence;
TGCT	cis	rs12908161	0.959	rs1051168	chr15:85200520	G/T	cg11189052	chr15:85197271	WDR73	0.75	6.14	0.48	1.04e-8	Schizophrenia;
TGCT	cis	rs9486715	0.838	rs9320127	chr6:96865358	G/A	cg18709589	chr6:96969512	KIAA0776	0.79	7.77	0.57	2.5e-12	Headache;
TGCT	cis	rs7100689	0.646	rs10736347	chr10:82134465	G/A	cg01528321	chr10:82214614	TSPAN14	0.8	7.72	0.57	3.42e-12	Post bronchodilator FEV1;
TGCT	cis	rs6570726	0.791	rs9403730	chr6:145907233	C/T	cg13319975	chr6:146136371	FBXO30	-0.5	-4.51	-0.38	1.48e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs41307935	0.818	rs35576939	chr1:27274095	A/G	cg23921621	chr1:27994728	IFI6	-0.43	-4.61	-0.38	9.92e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs36051895	0.632	rs10115962	chr9:5140841	T/C	cg02405213	chr9:5042618	JAK2	-0.74	-10.39	-0.68	1.4e-18	Pediatric autoimmune diseases;
TGCT	cis	rs8177253	0.633	rs10935073	chr3:133439184	T/C	cg16414030	chr3:133502952	NA	-0.51	-7.13	-0.54	7.28e-11	Iron status biomarkers;
TGCT	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg03351412	chr1:154909251	PMVK	0.54	5.02	0.41	1.72e-6	Prostate cancer;
TGCT	cis	rs6089829	0.962	rs3746747	chr20:61667631	T/C	cg08564027	chr20:61660810	NA	0.37	6.67	0.51	7.47e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs6570726	0.791	rs9497357	chr6:145912888	G/A	cg13319975	chr6:146136371	FBXO30	-0.51	-4.48	-0.37	1.71e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg20362242	chr5:692897	TPPP	0.5	4.88	0.4	3.21e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs77741769	0.571	rs12580949	chr12:121298164	A/G	cg02419362	chr12:121203948	SPPL3	0.19	4.5	0.37	1.58e-5	Mean corpuscular volume;
TGCT	cis	rs4332037	0.539	rs11772627	chr7:2109821	G/C	cg25834613	chr7:1915315	MAD1L1	-0.52	-5.07	-0.41	1.41e-6	Bipolar disorder;
TGCT	cis	rs11671005	0.693	rs11668821	chr19:58955813	G/A	cg13877915	chr19:58951672	ZNF132	0.62	4.89	0.4	3.06e-6	Mean platelet volume;
TGCT	cis	rs6424115	0.830	rs1130321	chr1:24200524	C/T	cg15997130	chr1:24165203	NA	0.85	9.25	0.64	8.02e-16	Immature fraction of reticulocytes;
TGCT	cis	rs9611565	0.694	rs79008	chr22:41850500	C/T	cg17554472	chr22:41940697	POLR3H	-0.48	-4.94	-0.41	2.52e-6	Vitiligo;
TGCT	cis	rs9611565	0.512	rs5751145	chr22:42133552	C/T	cg17554472	chr22:41940697	POLR3H	0.46	4.72	0.39	6.36e-6	Vitiligo;
TGCT	cis	rs7113874	0.569	rs1446463	chr11:8566329	G/A	cg14521421	chr11:8862019	ST5	0.29	4.68	0.39	7.52e-6	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs2016266	0.819	rs4758965	chr12:53662735	C/T	cg16917193	chr12:54089295	NA	0.64	5.35	0.43	4.04e-7	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs2952156	1.000	rs2934971	chr17:37854507	G/T	cg19468946	chr17:37922297	IKZF3	-0.18	-4.47	-0.37	1.72e-5	Asthma;
TGCT	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg13732083	chr21:47605072	C21orf56	-0.35	-4.76	-0.39	5.38e-6	Testicular germ cell tumor;
TGCT	cis	rs9291683	0.509	rs10939671	chr4:10050815	T/C	cg11266682	chr4:10021025	SLC2A9	0.61	7.73	0.57	3.25e-12	Bone mineral density;
TGCT	cis	rs7772486	0.790	rs4435956	chr6:146232403	G/C	cg05347473	chr6:146136440	FBXO30	-0.51	-4.95	-0.41	2.32e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7267979	0.899	rs6115213	chr20:25550372	G/A	cg03522245	chr20:25566470	NINL	0.6	6.46	0.5	2.14e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9916302	0.904	rs12452880	chr17:37591149	G/C	cg07936489	chr17:37558343	FBXL20	-0.61	-4.81	-0.4	4.27e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs2370759	1.000	rs16933225	chr10:32599464	C/T	cg01819863	chr10:32635814	EPC1	0.96	9.09	0.63	1.96e-15	Sexual dysfunction (female);
TGCT	cis	rs7267979	0.816	rs8115257	chr20:25207931	A/G	cg03522245	chr20:25566470	NINL	0.53	5.3	0.43	5.05e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg11494091	chr17:61959527	GH2	-0.59	-15.93	-0.82	8.56e-32	Prudent dietary pattern;
TGCT	cis	rs6840360	1.000	rs6841783	chr4:152598876	C/G	cg17479576	chr4:152424074	FAM160A1	-0.5	-5.4	-0.44	3.26e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs698813	0.637	rs7579841	chr2:44498887	T/A	cg00619915	chr2:44497795	NA	-0.24	-5.52	-0.44	1.91e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
TGCT	cis	rs78487399	0.710	rs80147536	chr2:43698028	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.39	-4.52	-0.38	1.42e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg16590910	chr6:42928470	GNMT	-0.49	-4.52	-0.38	1.4e-5	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs904251	0.698	rs2646926	chr6:37424988	G/A	cg25019722	chr6:37503610	NA	-0.4	-4.75	-0.39	5.48e-6	Cognitive performance;
TGCT	cis	rs61935443	0.720	rs10859784	chr12:95288926	G/A	cg21533806	chr12:95267307	NA	0.55	4.83	0.4	3.88e-6	Schizophrenia;
TGCT	cis	rs7523273	0.526	rs12132968	chr1:207884292	T/C	cg22525895	chr1:207977042	MIR29B2	0.35	5.73	0.46	7.22e-8	Schizophrenia;
TGCT	cis	rs10791323	0.582	rs2851120	chr11:133708065	A/G	cg03690763	chr11:133734501	NA	-0.31	-4.88	-0.4	3.18e-6	Childhood ear infection;
TGCT	trans	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg13565492	chr6:43139072	SRF	-0.81	-7.71	-0.57	3.45e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs362272	0.545	rs2749782	chr4:3339761	A/G	cg06533319	chr4:3265114	C4orf44	-0.26	-5.38	-0.44	3.51e-7	Serum sulfate level;
TGCT	cis	rs9682041	1.000	rs15709	chr3:170110529	T/A	cg07589077	chr3:170072950	NA	0.3	4.54	0.38	1.3e-5	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs9581857	0.579	rs76657892	chr13:27997604	A/G	cg22138327	chr13:27999177	GTF3A	0.81	5.74	0.46	6.97e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg07870213	chr5:140052090	DND1	0.61	7.51	0.56	9.93e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	trans	rs877282	0.583	rs12358255	chr10:828626	C/T	cg22713356	chr15:30763199	NA	0.89	6.71	0.52	6.26e-10	Uric acid levels;
TGCT	cis	rs9814567	0.806	rs7648616	chr3:134318074	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.76	-7.11	-0.54	8.15e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.54	-4.78	-0.39	4.9100000000000004e-06	Prudent dietary pattern;
TGCT	cis	rs9549367	0.713	rs3024776	chr13:113827075	A/G	cg09473364	chr13:112927190	NA	0.3	4.53	0.38	1.35e-5	Platelet distribution width;
TGCT	cis	rs4746818	1.000	rs4746817	chr10:70882515	T/C	cg11621586	chr10:70884670	VPS26A	1.12	7.84	0.58	1.73e-12	Left atrial antero-posterior diameter;
TGCT	cis	rs939574	1.000	rs45488900	chr2:220116509	G/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.05	6.46	0.5	2.12e-9	Platelet distribution width;
TGCT	cis	rs7726839	0.540	rs72703092	chr5:599269	G/A	cg16624210	chr5:671434	TPPP	0.44	4.85	0.4	3.68e-6	Obesity-related traits;
TGCT	trans	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg27523141	chr10:43048294	ZNF37B	0.73	8.58	0.61	3.32e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs72627509	0.680	rs12648788	chr4:57717475	A/T	cg26694713	chr4:57773883	REST	0.76	6.03	0.48	1.75e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs651907	0.557	rs62284198	chr3:101474699	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	4.68	0.39	7.44e-6	Colorectal cancer;
TGCT	cis	rs739401	0.611	rs417957	chr11:3046231	A/G	cg05729581	chr11:3078854	CARS	-0.56	-5.22	-0.42	7.36e-7	Longevity;
TGCT	cis	rs2803122	0.502	rs1329731	chr9:19234908	C/T	cg13469590	chr9:19229767	NA	-0.48	-4.51	-0.38	1.48e-5	Pulse pressure;
TGCT	cis	rs1395	0.634	rs72817542	chr2:27526681	C/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.62	7.95	0.58	1e-12	Blood metabolite levels;
TGCT	cis	rs55882075	0.967	rs62404346	chr5:179141391	A/C	cg14593053	chr5:179126677	CANX	0.45	4.76	0.39	5.28e-6	Monocyte percentage of white cells;
TGCT	trans	rs208520	1.000	rs72884033	chr6:66995747	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.84	7.59	0.56	6.69e-12	Exhaled nitric oxide output;
TGCT	cis	rs735396	0.965	rs2257962	chr12:121445808	T/C	cg02403541	chr12:121454288	C12orf43	0.66	6.38	0.5	3.2e-9	N-glycan levels;
TGCT	cis	rs3845702	0.877	rs12693216	chr2:180839793	T/A	cg01881094	chr2:180872142	CWC22	-0.68	-6.06	-0.48	1.51e-8	Schizophrenia;
TGCT	cis	rs7267979	0.966	rs6037097	chr20:25347221	C/T	cg14121845	chr20:25566513	NINL	0.5	5.3	0.43	5.23e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.08	0.48	1.37e-8	Bipolar disorder;
TGCT	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg27454412	chr7:1067447	C7orf50	0.59	4.63	0.38	8.92e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1371867	0.846	rs1788206	chr8:101306966	A/G	cg06002616	chr8:101225028	SPAG1	-0.56	-6.58	-0.51	1.2e-9	Atrioventricular conduction;
TGCT	cis	rs2204008	0.807	rs11182461	chr12:38539288	T/C	cg26384229	chr12:38710491	ALG10B	0.89	8.13	0.59	3.76e-13	Bladder cancer;
TGCT	cis	rs10927875	0.518	rs1763597	chr1:16343297	C/T	cg22431228	chr1:16359049	CLCNKA	-0.29	-6.07	-0.48	1.42e-8	Dilated cardiomyopathy;
TGCT	cis	rs3087591	1.000	rs2051507	chr17:29700101	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.48	-7.28	-0.55	3.31e-11	Hip circumference;
TGCT	cis	rs6450176	0.909	rs12659966	chr5:53292892	C/G	ch.5.1024479R	chr5:53302184	ARL15	0.49	4.67	0.39	7.77e-6	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg00343986	chr7:65444356	GUSB	0.2	4.65	0.39	8.47e-6	Aortic root size;
TGCT	cis	rs9926296	0.581	rs12598477	chr16:89902482	T/C	cg08627397	chr16:89984028	MC1R	-0.34	-5.43	-0.44	2.79e-7	Vitiligo;
TGCT	cis	rs2290416	0.688	rs62522171	chr8:144690832	C/A	cg16316162	chr8:144660157	NAPRT1	0.68	4.48	0.37	1.71e-5	Attention deficit hyperactivity disorder;
TGCT	cis	rs7666738	0.830	rs6827516	chr4:98971740	T/C	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg10150615	chr22:24372951	LOC391322	-0.96	-11.9	-0.73	2.98e-22	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs422249	0.547	rs174533	chr11:61549025	G/A	cg19610905	chr11:61596333	FADS2	-1.05	-10.42	-0.68	1.18e-18	Trans fatty acid levels;
TGCT	cis	rs12579753	0.917	rs7138895	chr12:82203280	T/G	cg07988820	chr12:82153109	PPFIA2	-0.59	-6.19	-0.49	7.93e-9	Resting heart rate;
TGCT	cis	rs7772486	0.875	rs2777477	chr6:146305491	A/G	cg05347473	chr6:146136440	FBXO30	0.52	4.92	0.4	2.7e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7824557	0.602	rs7815463	chr8:11210983	A/G	cg21775007	chr8:11205619	TDH	0.73	7.03	0.53	1.23e-10	Retinal vascular caliber;
TGCT	cis	rs77633900	0.614	rs2439989	chr15:76883862	G/C	cg21673338	chr15:77095150	SCAPER	-0.52	-4.83	-0.4	3.88e-6	Non-glioblastoma glioma;Glioma;
TGCT	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg08859206	chr1:53392774	SCP2	-0.47	-7.31	-0.55	2.92e-11	Monocyte count;
TGCT	cis	rs2153535	0.580	rs1928184	chr6:8532108	T/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.55e-8	Motion sickness;
TGCT	cis	rs67311347	1.000	rs11539046	chr3:40503809	G/A	cg13683864	chr3:40499215	RPL14	1.17	13.19	0.76	2.34e-25	Renal cell carcinoma;
TGCT	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	6.95	0.53	1.86e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs28374715	0.532	rs11854820	chr15:41676526	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.93	-16.21	-0.82	2.08e-32	Ulcerative colitis;
TGCT	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg09517075	chr8:22133004	PIWIL2	-0.24	-4.92	-0.4	2.72e-6	Hypertriglyceridemia;
TGCT	cis	rs597480	0.892	rs680498	chr11:85447611	C/T	cg11817631	chr11:85522609	SYTL2	0.51	5.09	0.42	1.29e-6	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);
TGCT	cis	rs9302065	0.681	rs9524903	chr13:95963565	A/G	cg24476569	chr13:95954382	ABCC4	-0.45	-6.44	-0.5	2.43e-9	Blood metabolite levels;
TGCT	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg27170947	chr2:26402098	FAM59B	-0.4	-4.55	-0.38	1.25e-5	Gut microbiome composition (summer);
TGCT	cis	rs6952809	0.532	rs6952152	chr7:2440912	G/A	cg23289794	chr7:2394357	EIF3B	-0.84	-7.21	-0.54	4.72e-11	Multiple sclerosis;
TGCT	cis	rs2439831	0.681	rs28594657	chr15:43588888	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.92	5.27	0.43	5.83e-7	Lung cancer in ever smokers;
TGCT	cis	rs4631830	0.863	rs2926494	chr10:51517356	T/C	cg10326726	chr10:51549505	MSMB	-0.25	-4.99	-0.41	2.01e-6	Prostate-specific antigen levels;
TGCT	cis	rs4924935	1.000	rs35341640	chr17:18818228	G/A	cg26378065	chr17:18585709	ZNF286B	-0.56	-4.72	-0.39	6.38e-6	Pancreatic cancer;
TGCT	cis	rs12477438	0.520	rs6542865	chr2:99764521	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	13.05	0.76	4.93e-25	Chronic sinus infection;
TGCT	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg03609598	chr5:56110824	MAP3K1	-0.58	-4.7	-0.39	6.72e-6	Initial pursuit acceleration;
TGCT	cis	rs79349575	0.783	rs55771415	chr17:46999937	C/T	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.51	-0.38	1.48e-5	Type 2 diabetes;
TGCT	cis	rs12681287	0.673	rs4464946	chr8:87326259	G/A	cg27223183	chr8:87520930	FAM82B	-0.92	-6.97	-0.53	1.7e-10	Caudate activity during reward;
TGCT	cis	rs1268083	0.546	rs9398785	chr6:126057748	A/G	cg05901451	chr6:126070800	HEY2	-0.78	-7.25	-0.55	4e-11	Migraine;
TGCT	cis	rs7804356	1.000	rs12532395	chr7:26841702	G/A	cg03456212	chr7:26904342	SKAP2	-0.61	-4.7	-0.39	6.82e-6	Type 1 diabetes;
TGCT	cis	rs1552244	0.882	rs13100734	chr3:10022878	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	5.54	0.45	1.71e-7	Alzheimer's disease;
TGCT	cis	rs35306767	0.903	rs61830933	chr10:934195	G/A	cg20503657	chr10:835505	NA	0.8	11.88	0.73	3.41e-22	Eosinophil percentage of granulocytes;
TGCT	cis	rs13191362	1.000	rs35383933	chr6:163002869	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs3771570	1.000	rs3771570	chr2:242382864	C/T	cg21155796	chr2:242212141	HDLBP	0.93	6.6	0.51	1.08e-9	Prostate cancer;
TGCT	cis	rs908922	0.676	rs11581947	chr1:152482587	G/A	cg20991723	chr1:152506922	NA	0.47	6.65	0.51	8.33e-10	Hair morphology;
TGCT	cis	rs4730250	0.707	rs257373	chr7:106798290	G/A	cg02696742	chr7:106810147	HBP1	-0.73	-6.04	-0.48	1.63e-8	Osteoarthritis;
TGCT	cis	rs6722750	1.000	rs6722750	chr2:64381259	T/G	cg22352474	chr2:64371530	PELI1	0.58	4.97	0.41	2.14e-6	Neuroticism;
TGCT	cis	rs13272623	0.502	rs268627	chr8:71561041	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.61	-5.12	-0.42	1.12e-6	IgG glycosylation;
TGCT	cis	rs739496	0.579	rs12322899	chr12:112288202	A/G	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs637571	0.522	rs679581	chr11:65746653	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.67	6.58	0.51	1.18e-9	Eosinophil percentage of white cells;
TGCT	cis	rs9467773	0.967	rs7753565	chr6:26560012	A/G	cg05738196	chr6:26577821	NA	0.91	13.19	0.76	2.28e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs6938	0.534	rs4886636	chr15:75196176	G/A	cg10253484	chr15:75165896	SCAMP2	-0.55	-5.1	-0.42	1.22e-6	Breast cancer;
TGCT	cis	rs2842992	0.789	rs10945635	chr6:160214487	C/A	cg11366901	chr6:160182831	ACAT2	1.06	7.17	0.54	5.89e-11	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs7584330	0.868	rs13408361	chr2:238382899	A/G	cg16989719	chr2:238392110	NA	-0.26	-4.48	-0.37	1.7e-5	Prostate cancer;
TGCT	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg12419862	chr22:24373484	LOC391322	-0.81	-8.64	-0.61	2.33e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs611744	0.901	rs2348801	chr8:109167337	C/T	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	4.93	0.4	2.63e-6	Menopause (age at onset);
TGCT	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg06873352	chr17:61820015	STRADA	0.56	6.22	0.49	7.1e-9	Prudent dietary pattern;
TGCT	cis	rs7208859	0.673	rs73263776	chr17:29211331	G/C	cg18442181	chr17:29233375	C17orf42	-0.78	-4.61	-0.38	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs394563	0.622	rs237024	chr6:149721965	T/C	cg03678062	chr6:149772716	ZC3H12D	-0.38	-4.82	-0.4	4.12e-6	Dupuytren's disease;
TGCT	cis	rs2153535	0.580	rs9328486	chr6:8528008	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.55e-8	Motion sickness;
TGCT	cis	rs12477438	1.000	rs6732980	chr2:99921613	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.97	-8.78	-0.62	1.12e-14	Chronic sinus infection;
TGCT	cis	rs9611565	0.512	rs1983576	chr22:42166486	G/A	cg17554472	chr22:41940697	POLR3H	0.46	4.8	0.4	4.46e-6	Vitiligo;
TGCT	cis	rs832540	0.656	rs6862118	chr5:56106474	G/A	cg24531977	chr5:56204891	C5orf35	-0.55	-5.47	-0.44	2.37e-7	Coronary artery disease;
TGCT	cis	rs13108904	0.846	rs9631804	chr4:1283032	A/T	cg00684032	chr4:1343700	KIAA1530	-0.22	-4.47	-0.37	1.76e-5	Obesity-related traits;
TGCT	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg17554472	chr22:41940697	POLR3H	-0.5	-5.37	-0.43	3.72e-7	Vitiligo;
TGCT	cis	rs13326165	0.511	rs1011063	chr3:52506848	A/G	cg07884673	chr3:53033167	SFMBT1	0.39	4.87	0.4	3.39e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs62244186	0.711	rs6778410	chr3:44743993	C/T	cg15687855	chr3:44754131	ZNF502	-0.48	-5.93	-0.47	2.83e-8	Depressive symptoms;
TGCT	cis	rs6582630	0.519	rs11181998	chr12:38439970	C/A	cg26384229	chr12:38710491	ALG10B	0.84	7.7	0.57	3.77e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs926938	0.520	rs4140445	chr1:115291978	T/C	cg12756093	chr1:115239321	AMPD1	-0.41	-4.93	-0.4	2.62e-6	Autism;
TGCT	cis	rs9581857	0.556	rs9579085	chr13:28041039	G/A	cg22138327	chr13:27999177	GTF3A	0.73	5.7	0.46	8.09e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs73198271	0.653	rs10099808	chr8:8659873	A/G	cg06671706	chr8:8559999	CLDN23	0.36	4.62	0.38	9.5e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs832540	0.603	rs6870175	chr5:56093371	A/G	cg12311346	chr5:56204834	C5orf35	-0.49	-5.13	-0.42	1.08e-6	Coronary artery disease;
TGCT	cis	rs1008375	1.000	rs1558377	chr4:17650758	A/G	cg10189774	chr4:17578691	LAP3	0.6	5.29	0.43	5.23e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1371867	0.875	rs1660319	chr8:101337530	A/G	cg00191853	chr8:101177733	SPAG1	-0.23	-4.73	-0.39	6.08e-6	Atrioventricular conduction;
TGCT	cis	rs1577917	0.876	rs11752223	chr6:86573394	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.47	-0.44	2.33e-7	Response to antipsychotic treatment;
TGCT	cis	rs2299587	0.521	rs3739406	chr8:17739538	T/C	cg01800426	chr8:17659068	MTUS1	-0.56	-4.99	-0.41	1.97e-6	Economic and political preferences;
TGCT	cis	rs35146811	0.735	rs1727133	chr7:99812870	C/T	cg00553149	chr7:99775558	STAG3;GPC2	-0.31	-4.61	-0.38	9.75e-6	Coronary artery disease;
TGCT	cis	rs3087591	0.960	rs34941185	chr17:29425587	G/A	cg24425628	chr17:29625626	OMG;NF1	0.47	7.16	0.54	6.19e-11	Hip circumference;
TGCT	cis	rs12049351	0.774	rs12138176	chr1:229657902	G/A	cg12130225	chr1:229698885	NA	0.38	4.59	0.38	1.09e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs7599312	0.534	rs6751692	chr2:213408120	C/T	cg16329650	chr2:213403929	ERBB4	1.08	16.09	0.82	3.86e-32	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7772486	0.754	rs6921073	chr6:146144377	G/A	cg05347473	chr6:146136440	FBXO30	0.5	4.72	0.39	6.35e-6	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg27523141	chr10:43048294	ZNF37B	0.71	8.31	0.6	1.4e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2302464	1.000	rs11944132	chr4:15725914	C/T	cg18497811	chr4:14860861	NA	-0.48	-4.47	-0.37	1.76e-5	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs3772130	0.962	rs6784571	chr3:121539991	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.72	0.39	6.25e-6	Cognitive performance;
TGCT	cis	rs17122693	0.710	rs77598393	chr14:51159342	T/G	cg04730355	chr14:51134070	SAV1	1.22	9.45	0.65	2.75e-16	Cognitive performance;
TGCT	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	8.55	0.61	3.84e-14	Platelet count;
TGCT	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg06481639	chr22:41940642	POLR3H	-0.74	-6.74	-0.52	5.38e-10	Vitiligo;
TGCT	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg08219700	chr8:58056026	NA	0.29	4.45	0.37	1.91e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs6121246	0.697	rs45557936	chr20:30226690	G/A	cg18721089	chr20:30220636	NA	-0.53	-5.43	-0.44	2.86e-7	Mean corpuscular hemoglobin;
TGCT	cis	rs2180341	0.843	rs4895821	chr6:127572761	T/A	cg24812749	chr6:127587940	RNF146	0.93	7.35	0.55	2.36e-11	Breast cancer;
TGCT	cis	rs909002	0.811	rs11575883	chr1:32085485	G/A	cg11573219	chr1:32083031	HCRTR1	-0.49	-6.39	-0.5	3.06e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs1158570	0.835	rs6470816	chr8:131349715	C/T	cg16277922	chr8:131349729	ASAP1	-0.6	-10.42	-0.68	1.19e-18	Platelet count;
TGCT	cis	rs28595532	1.000	rs56225646	chr4:119651217	T/C	cg11846333	chr4:119757529	SEC24D	0.92	4.59	0.38	1.07e-5	Cannabis dependence symptom count;
TGCT	cis	rs26868	0.690	rs26835	chr16:2237549	C/T	cg02248941	chr16:2239361	CASKIN1	0.17	4.58	0.38	1.1e-5	Height;
TGCT	cis	rs35000415	0.745	rs117944677	chr7:128698185	A/T	cg06242719	chr7:129414860	MIR183;MIR96	-0.34	-4.67	-0.39	7.58e-6	Systemic lupus erythematosus;
TGCT	trans	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg20587970	chr11:113659929	NA	-1.03	-10.98	-0.7	5.21e-20	Hip circumference adjusted for BMI;
TGCT	cis	rs3733585	0.674	rs7375643	chr4:9955239	A/G	cg11266682	chr4:10021025	SLC2A9	-0.62	-8.62	-0.61	2.56e-14	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs1018836	0.923	rs13268594	chr8:91588545	G/T	cg16814680	chr8:91681699	NA	-0.85	-8.84	-0.62	7.73e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs28595532	0.764	rs56359736	chr4:119769689	G/A	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs11971779	0.941	rs74299967	chr7:139043769	G/T	cg07862535	chr7:139043722	LUC7L2	0.79	5.85	0.46	4.16e-8	Diisocyanate-induced asthma;
TGCT	cis	rs67311347	0.956	rs4974029	chr3:40521318	C/G	cg17264618	chr3:40429014	ENTPD3	0.33	4.75	0.39	5.53e-6	Renal cell carcinoma;
TGCT	cis	rs6076065	0.548	rs6048740	chr20:23325047	G/A	cg11657817	chr20:23433608	CST11	0.28	5.03	0.41	1.67e-6	Facial morphology (factor 15, philtrum width);
TGCT	cis	rs782590	0.935	rs782606	chr2:55886602	T/C	cg18811423	chr2:55921094	PNPT1	0.65	6.74	0.52	5.25e-10	Metabolic syndrome;
TGCT	cis	rs210138	1.000	rs210144	chr6:33547430	G/A	cg24505687	chr6:33548425	BAK1	0.53	6.11	0.48	1.16e-8	Testicular germ cell tumor;
TGCT	cis	rs7103648	0.838	rs2293576	chr11:47434986	A/G	cg20307385	chr11:47447363	PSMC3	-0.98	-11.23	-0.71	1.31e-20	Diastolic blood pressure;Systolic blood pressure;
TGCT	cis	rs9611565	0.546	rs739134	chr22:42089623	T/C	cg17554472	chr22:41940697	POLR3H	0.5	5.36	0.43	3.92e-7	Vitiligo;
TGCT	cis	rs7511006	1.000	rs7511006	chr22:50676259	T/C	cg16473166	chr22:50639996	SELO	0.61	5.99	0.47	2.15e-8	Obesity-related traits;
TGCT	cis	rs904251	0.523	rs9349039	chr6:37480392	A/G	cg25019722	chr6:37503610	NA	-0.54	-7.82	-0.57	1.92e-12	Cognitive performance;
TGCT	cis	rs13256369	0.950	rs1522839	chr8:8580453	C/T	cg17143192	chr8:8559678	CLDN23	0.63	5.6	0.45	1.34e-7	Obesity-related traits;
TGCT	cis	rs17221829	0.733	rs11018681	chr11:89364443	C/T	cg02982614	chr11:89391479	FOLH1B	-0.28	-4.87	-0.4	3.35e-6	Anxiety in major depressive disorder;
TGCT	cis	rs1580019	0.885	rs1610141	chr7:32498435	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.85	7.95	0.58	9.92e-13	Cognitive ability;
TGCT	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg07343612	chr16:622815	PIGQ	-0.42	-8.4	-0.6	8.47e-14	Height;
TGCT	trans	rs941408	1.000	rs941406	chr19:2803623	A/G	cg22153745	chr1:153894579	GATAD2B	-0.77	-7.96	-0.58	9.1e-13	Total cholesterol levels;
TGCT	cis	rs9985766	0.958	rs10022936	chr4:150988778	T/C	cg05926478	chr4:151174724	DCLK2	-0.24	-4.64	-0.38	8.63e-6	Coronary artery disease;Myocardial infarction;
TGCT	cis	rs72781680	0.898	rs72780125	chr2:24000145	T/C	cg08917208	chr2:24149416	ATAD2B	0.93	5.84	0.46	4.22e-8	Lymphocyte counts;
TGCT	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9677476	1.000	rs9677476	chr2:232126290	C/T	cg07929768	chr2:232055508	NA	-0.3	-4.48	-0.37	1.71e-5	Food antigen IgG levels;
TGCT	cis	rs9916302	0.904	rs1966916	chr17:37425238	T/G	cg15445000	chr17:37608096	MED1	0.32	4.69	0.39	7.11e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs4654899	0.758	rs6689852	chr1:21341051	T/C	cg01072550	chr1:21505969	NA	-0.55	-8.93	-0.63	4.73e-15	Superior frontal gyrus grey matter volume;
TGCT	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	5.23	0.43	6.92e-7	Menopause (age at onset);
TGCT	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg21963583	chr11:68658836	MRPL21	0.36	6.1	0.48	1.25e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg11494091	chr17:61959527	GH2	0.6	14.54	0.79	1.46e-28	Prudent dietary pattern;
TGCT	cis	rs60871478	0.636	rs12532761	chr7:905229	C/T	cg15782153	chr7:917662	C7orf20	0.57	5.12	0.42	1.14e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs7586879	0.575	rs6721750	chr2:25128719	A/G	cg01884057	chr2:25150051	NA	0.35	6.9	0.53	2.39e-10	Body mass index;
TGCT	cis	rs7772486	0.817	rs12198065	chr6:146385286	G/C	cg23711669	chr6:146136114	FBXO30	0.91	9.95	0.67	1.67e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2549003	1.000	rs2548997	chr5:131835395	C/T	cg00255919	chr5:131827918	IRF1	-0.22	-5.3	-0.43	5.07e-7	Asthma (sex interaction);
TGCT	cis	rs4499344	0.730	rs406470	chr19:33104472	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.83	8.63	0.61	2.53e-14	Mean platelet volume;
TGCT	cis	rs11105298	0.891	rs10858852	chr12:89833338	T/C	cg00757033	chr12:89920650	WDR51B	0.34	5.36	0.43	4e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs1008375	1.000	rs2058338	chr4:17678600	A/G	cg10189774	chr4:17578691	LAP3	-0.64	-6.07	-0.48	1.44e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2153535	0.580	rs1414350	chr6:8472331	C/T	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs35883536	1.000	rs2297716	chr1:101092526	G/C	cg06223162	chr1:101003688	GPR88	0.29	4.56	0.38	1.19e-5	Monocyte count;
TGCT	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg03709012	chr19:19516395	GATAD2A	0.75	6.51	0.5	1.71e-9	Tonsillectomy;
TGCT	cis	rs77861329	0.920	rs9860982	chr3:52096432	T/C	cg08692210	chr3:52188851	WDR51A	0.96	4.5	0.37	1.54e-5	Macrophage inflammatory protein 1b levels;
TGCT	cis	rs9911578	0.900	rs7214335	chr17:57158840	G/A	cg05425664	chr17:57184151	TRIM37	-0.64	-6.28	-0.49	5.3300000000000004e-09	Intelligence (multi-trait analysis);
TGCT	trans	rs10506458	1.000	rs73128794	chr12:63445313	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.47	-7.62	-0.56	5.8e-12	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs6714710	0.603	rs2305143	chr2:98413781	C/T	cg26665480	chr2:98280029	ACTR1B	0.66	6.24	0.49	6.33e-9	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs8017423	0.967	rs2151748	chr14:90694897	G/C	cg04374321	chr14:90722782	PSMC1	0.78	8.11	0.59	4.21e-13	Mortality in heart failure;
TGCT	cis	rs763121	1.000	rs1946990	chr22:38912771	C/T	cg06022373	chr22:39101656	GTPBP1	-0.77	-7.79	-0.57	2.26e-12	Menopause (age at onset);
TGCT	cis	rs2468186	0.554	rs2450066	chr8:120096807	A/C	cg02248809	chr8:120845432	TAF2	-0.45	-4.83	-0.4	3.99e-6	Osteoprotegerin levels;
TGCT	cis	rs6570726	0.791	rs4332001	chr6:145934841	T/C	cg13319975	chr6:146136371	FBXO30	-0.51	-4.49	-0.37	1.59e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg07424592	chr7:64974309	NA	-1.31	-7.72	-0.57	3.33e-12	Diabetic kidney disease;
TGCT	cis	rs826838	0.967	rs1684411	chr12:39128494	C/T	cg13010199	chr12:38710504	ALG10B	-0.59	-4.66	-0.39	8.16e-6	Heart rate;
TGCT	cis	rs2637266	1.000	rs2395394	chr10:78360679	G/C	cg18941641	chr10:78392320	NA	0.39	4.88	0.4	3.24e-6	Pulmonary function;
TGCT	cis	rs78545713	0.881	rs74608402	chr6:26240474	C/T	cg12260798	chr6:26240519	HIST1H4F	-0.64	-4.65	-0.39	8.25e-6	Iron status biomarkers (total iron binding capacity);
TGCT	cis	rs950169	0.810	rs62029594	chr15:84955252	T/C	cg11189052	chr15:85197271	WDR73	0.81	6.22	0.49	6.89e-9	Schizophrenia;
TGCT	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg04287289	chr16:89883240	FANCA	0.94	11.98	0.73	1.9e-22	Vitiligo;
TGCT	cis	rs3772130	0.962	rs4311252	chr3:121514161	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.53	4.83	0.4	3.94e-6	Cognitive performance;
TGCT	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg13393036	chr8:95962371	TP53INP1	-0.65	-8.97	-0.63	3.91e-15	Type 2 diabetes;
TGCT	cis	rs9898058	0.545	rs75764946	chr17:47782865	G/T	cg10517230	chr17:48661425	CACNA1G	0.47	4.5	0.37	1.53e-5	Milk allergy;
TGCT	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg03517284	chr6:25882590	NA	-0.62	-6.45	-0.5	2.24e-9	Blood metabolite levels;
TGCT	cis	rs2549003	1.000	rs2549003	chr5:131829297	A/G	cg02551604	chr5:131831745	NA	-0.9	-12.28	-0.74	3.61e-23	Asthma (sex interaction);
TGCT	cis	rs28595532	0.920	rs114414928	chr4:119728188	T/C	cg14228332	chr4:119757509	SEC24D	1.32	6.38	0.5	3.2e-9	Cannabis dependence symptom count;
TGCT	cis	rs694739	1.000	rs646153	chr11:64089588	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.8	7.9	0.58	1.26e-12	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs9534288	0.797	rs7990095	chr13:46587262	G/C	cg15192986	chr13:46630673	CPB2	-0.53	-7.62	-0.56	5.82e-12	Blood protein levels;
TGCT	cis	rs7647973	0.506	rs11920251	chr3:49356671	C/T	cg03060546	chr3:49711283	APEH	0.66	6.51	0.5	1.71e-9	Menarche (age at onset);
TGCT	cis	rs13191362	0.935	rs7763118	chr6:162954720	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.65	5.18	0.42	8.81e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs6125597	0.967	rs6063378	chr20:47866411	C/T	cg11220565	chr20:47934802	NA	-0.3	-4.6	-0.38	1.02e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs12615966	0.929	rs9941698	chr2:105384717	G/A	cg16465502	chr2:105461796	NA	0.78	5.03	0.41	1.66e-6	Pancreatic cancer;
TGCT	cis	rs7412746	0.658	rs72704685	chr1:150897687	C/G	cg04414720	chr1:150670196	GOLPH3L	0.37	4.46	0.37	1.81e-5	Melanoma;
TGCT	cis	rs3772130	0.923	rs13090798	chr3:121482768	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.72	0.39	6.25e-6	Cognitive performance;
TGCT	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg13665807	chr20:60559372	TAF4	-0.51	-5.25	-0.43	6.34e-7	Body mass index;
TGCT	cis	rs11098499	0.954	rs9993199	chr4:120392873	A/G	cg09307838	chr4:120376055	NA	-0.69	-6.57	-0.51	1.22e-9	Corneal astigmatism;
TGCT	cis	rs10782582	0.609	rs11588643	chr1:76255613	A/G	cg03433033	chr1:76189801	ACADM	-0.5	-4.95	-0.41	2.39e-6	Daytime sleep phenotypes;
TGCT	cis	rs4246949	0.597	rs4625397	chr10:125519383	A/G	cg12769705	chr10:125521557	CPXM2	-0.43	-4.53	-0.38	1.36e-5	Ulcerative colitis;
TGCT	cis	rs1056107	0.931	rs10118422	chr9:114998396	A/G	cg02332936	chr9:115140584	NA	-0.25	-4.44	-0.37	1.96e-5	Colorectal cancer;
TGCT	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7086627	0.515	rs7077373	chr10:82211615	C/T	cg00277334	chr10:82204260	NA	-0.54	-8.46	-0.61	6.23e-14	Post bronchodilator FEV1;
TGCT	cis	rs4595586	0.545	rs2388179	chr12:39364036	T/A	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	trans	rs1496653	0.602	rs35156003	chr3:23425738	C/T	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs921968	0.612	rs4674323	chr2:219517088	T/C	cg02176678	chr2:219576539	TTLL4	0.38	5.47	0.44	2.34e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs7226408	0.857	rs72887072	chr18:34499453	T/C	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs7666738	0.830	rs13328042	chr4:99055406	A/G	cg05340658	chr4:99064831	C4orf37	0.52	5.79	0.46	5.32e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs17376456	0.825	rs28705226	chr5:93233135	T/C	cg25358565	chr5:93447407	FAM172A	1.01	8.13	0.59	3.77e-13	Diabetic retinopathy;
TGCT	cis	rs6088580	0.634	rs1205344	chr20:32918298	G/A	cg08999081	chr20:33150536	PIGU	-0.25	-4.99	-0.41	2e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.51	5.51	0.44	2.02e-7	Lymphocyte counts;
TGCT	cis	rs3087591	0.922	rs2905879	chr17:29545431	T/A	cg24425628	chr17:29625626	OMG;NF1	0.46	7.17	0.54	6.02e-11	Hip circumference;
TGCT	cis	rs4242434	0.819	rs1059592	chr8:22477778	G/A	cg03733263	chr8:22462867	KIAA1967	1.06	16.11	0.82	3.45e-32	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg19723775	chr5:179050963	HNRNPH1	0.48	4.58	0.38	1.13e-5	Lung cancer;
TGCT	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs651907	0.535	rs13065944	chr3:101473088	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.33	-6.78	-0.52	4.35e-10	Colorectal cancer;
TGCT	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs36051895	0.589	rs16922779	chr9:5200127	G/A	cg02405213	chr9:5042618	JAK2	-0.75	-9.79	-0.66	4.03e-17	Pediatric autoimmune diseases;
TGCT	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg08859206	chr1:53392774	SCP2	0.41	6.25	0.49	6.12e-9	Monocyte count;
TGCT	cis	rs3892630	0.588	rs12610342	chr19:33250690	C/T	cg22980127	chr19:33182716	NUDT19	0.75	6.12	0.48	1.14e-8	Red blood cell traits;
TGCT	cis	rs2013441	1.000	rs17686839	chr17:20039171	A/G	cg23224458	chr17:20280056	CCDC144C	0.38	4.61	0.38	9.96e-6	Obesity-related traits;
TGCT	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg11494091	chr17:61959527	GH2	0.61	14.81	0.8	3.37e-29	Prudent dietary pattern;
TGCT	cis	rs2115630	1.000	rs7183401	chr15:85371944	G/T	cg11189052	chr15:85197271	WDR73	-0.67	-6.53	-0.51	1.56e-9	P wave terminal force;
TGCT	cis	rs7647973	1.000	rs13322887	chr3:49555583	G/A	cg07636037	chr3:49044803	WDR6	-0.65	-5.35	-0.43	4.01e-7	Menarche (age at onset);
TGCT	cis	rs13064447	0.845	rs11128610	chr3:12761123	G/T	cg20675869	chr3:12750130	NA	-0.2	-4.99	-0.41	2.03e-6	Major depression and alcohol dependence;
TGCT	cis	rs2456568	0.802	rs1506656	chr11:93639813	G/A	cg17595323	chr11:93583763	C11orf90	-0.46	-6.23	-0.49	6.52e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs886126	0.650	rs4766566	chr12:111706877	C/T	cg10833066	chr12:111807467	FAM109A	0.37	6.55	0.51	1.37e-9	Coronary heart disease;
TGCT	cis	rs17473412	1.000	rs17473412	chr5:122697431	C/T	cg15125798	chr5:122621645	NA	-0.57	-5.0	-0.41	1.89e-6	Total body bone mineral density;
TGCT	cis	rs904251	0.523	rs2797794	chr6:37480604	T/C	cg01843034	chr6:37503916	NA	-0.55	-7.33	-0.55	2.54e-11	Cognitive performance;
TGCT	cis	rs7552404	0.696	rs10518521	chr1:76461214	G/A	cg03433033	chr1:76189801	ACADM	0.73	6.74	0.52	5.45e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9318086	0.935	rs9553083	chr13:24441525	C/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.68	-6.77	-0.52	4.61e-10	Myopia (pathological);
TGCT	cis	rs9993613	0.875	rs16848284	chr4:73476901	T/C	cg15102770	chr4:73434591	ADAMTS3	0.54	4.96	0.41	2.26e-6	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs2204008	0.701	rs3898237	chr12:38219714	A/G	cg13010199	chr12:38710504	ALG10B	0.62	4.96	0.41	2.32e-6	Bladder cancer;
TGCT	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg27121462	chr16:89883253	FANCA	0.79	8.71	0.62	1.62e-14	Vitiligo;
TGCT	cis	rs9913156	0.748	rs55959711	chr17:4562581	C/A	cg19197139	chr17:4613644	ARRB2	0.86	7.9	0.58	1.32e-12	Lymphocyte counts;
TGCT	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg12310025	chr6:25882481	NA	-1.02	-11.72	-0.73	8.08e-22	Uric acid levels;
TGCT	cis	rs9894429	0.752	rs6565610	chr17:79592652	A/G	cg18240062	chr17:79603768	NPLOC4	0.84	9.67	0.66	8.03e-17	Eye color traits;
TGCT	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg00343986	chr7:65444356	GUSB	0.24	5.25	0.43	6.3e-7	Aortic root size;
TGCT	cis	rs477895	0.838	rs11607007	chr11:64007976	C/T	cg04317338	chr11:64019027	PLCB3	0.82	7.02	0.53	1.3e-10	Mean platelet volume;
TGCT	cis	rs151997	0.853	rs6882235	chr5:50260139	T/C	cg06027927	chr5:50259733	NA	0.57	5.94	0.47	2.72e-8	Callous-unemotional behaviour;
TGCT	cis	rs7772486	0.790	rs2485632	chr6:146193228	A/G	cg23711669	chr6:146136114	FBXO30	0.95	10.8	0.7	1.44e-19	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4689388	0.926	rs5018647	chr4:6292799	A/C	cg25554036	chr4:6271136	WFS1	0.54	7.37	0.55	2.11e-11	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs11191270	0.554	rs11191265	chr10:104102118	G/A	cg15320455	chr10:103880129	LDB1	0.86	5.39	0.44	3.48e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7178572	0.568	rs4886515	chr15:77686886	G/A	cg15453836	chr15:77711506	NA	-0.42	-4.78	-0.39	4.92e-6	Type 2 diabetes;
TGCT	cis	rs5760092	0.755	rs5760096	chr22:24247310	A/G	cg12419862	chr22:24373484	LOC391322	-0.75	-6.97	-0.53	1.66e-10	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg18867708	chr6:26865862	GUSBL1	-0.38	-5.03	-0.41	1.65e-6	Autism spectrum disorder or schizophrenia;
TGCT	trans	rs72634030	0.702	rs3026105	chr17:5281758	C/T	cg08933409	chr10:42672859	NA	0.88	6.65	0.51	8.16e-10	Rheumatoid arthritis;
TGCT	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs28595532	0.841	rs114465037	chr4:119778165	A/G	cg14228332	chr4:119757509	SEC24D	1.26	7.08	0.54	9.26e-11	Cannabis dependence symptom count;
TGCT	cis	rs62244186	0.711	rs6778410	chr3:44743993	C/T	cg21672276	chr3:44754072	ZNF502	-0.49	-5.68	-0.45	8.97e-8	Depressive symptoms;
TGCT	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg24675658	chr1:53192096	ZYG11B	0.7	7.98	0.58	8.42e-13	Monocyte count;
TGCT	cis	rs250677	0.522	rs4705301	chr5:148354902	C/G	cg18129178	chr5:148520854	ABLIM3	-0.35	-4.5	-0.37	1.53e-5	Breast cancer;
TGCT	cis	rs2204008	0.617	rs11831608	chr12:38210687	C/T	cg26384229	chr12:38710491	ALG10B	-0.6	-5.2	-0.42	7.91e-7	Bladder cancer;
TGCT	cis	rs17681684	0.565	rs12150149	chr17:9764039	A/C	cg15743799	chr17:9805578	RCVRN	0.25	5.41	0.44	3.16e-7	GIP levels in response to oral glucose tolerance test (fasting);
TGCT	cis	rs3749237	1.000	rs3749237	chr3:49770032	C/T	cg07636037	chr3:49044803	WDR6	0.64	5.63	0.45	1.13e-7	Resting heart rate;
TGCT	cis	rs6543140	0.964	rs62154972	chr2:103048738	G/A	cg09003973	chr2:102972529	NA	0.6	4.98	0.41	2.12e-6	Blood protein levels;
TGCT	cis	rs7267979	1.000	rs2424712	chr20:25416942	T/C	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7193541	0.640	rs4072222	chr16:74706736	A/C	cg01733217	chr16:74700730	RFWD3	0.98	12.91	0.76	1.1e-24	Multiple myeloma;
TGCT	cis	rs66573146	1.000	rs6812391	chr4:6963893	G/A	cg01220768	chr4:7056774	TADA2B	0.35	4.63	0.38	8.96e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs1057239	0.739	rs1014554	chr1:175133626	A/G	cg08873628	chr1:175162347	KIAA0040	0.48	4.57	0.38	1.15e-5	Diastolic blood pressure;
TGCT	cis	rs13242816	1.000	rs35595472	chr7:116122306	G/A	cg16553024	chr7:116138462	CAV2	-0.44	-4.59	-0.38	1.05e-5	P wave duration;
TGCT	cis	rs477895	0.838	rs72922039	chr11:64013116	A/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.84	7.01	0.53	1.38e-10	Mean platelet volume;
TGCT	trans	rs4948418	0.579	rs10994321	chr10:62135206	G/A	cg03916014	chr16:1722352	CRAMP1L	0.45	6.84	0.52	3.16e-10	Bipolar disorder;
TGCT	cis	rs709400	0.628	rs2010281	chr14:103862322	G/A	cg12935359	chr14:103987150	CKB	-0.36	-5.38	-0.43	3.63e-7	Body mass index;
TGCT	cis	rs909674	0.818	rs7364148	chr22:39842165	T/C	cg05872129	chr22:39784769	NA	-0.98	-9.55	-0.65	1.54e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs7781977	0.669	rs7791218	chr7:50353627	G/A	cg01139861	chr7:50343298	IKZF1	0.5	5.93	0.47	2.78e-8	IgG glycosylation;
TGCT	cis	rs8077889	1.000	rs2066725	chr17:41891473	A/G	cg26893861	chr17:41843967	DUSP3	1.08	12.8	0.75	1.98e-24	Triglycerides;
TGCT	cis	rs10782582	0.609	rs5745410	chr1:76314356	C/A	cg03433033	chr1:76189801	ACADM	-0.5	-4.98	-0.41	2.11e-6	Daytime sleep phenotypes;
TGCT	cis	rs7926906	0.875	rs2213084	chr11:90518158	G/A	cg22332266	chr11:89956777	CHORDC1	-0.42	-4.48	-0.37	1.7e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs9457247	0.967	rs387733	chr6:167409771	C/T	cg23791538	chr6:167370224	RNASET2	0.5	5.14	0.42	1.02e-6	Crohn's disease;
TGCT	cis	rs2862064	1.000	rs1354163	chr5:156420703	C/T	cg12943317	chr5:156479607	HAVCR1	-0.44	-5.47	-0.44	2.35e-7	Platelet count;
TGCT	cis	rs7666738	0.822	rs6815312	chr4:99058220	T/C	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.44e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1205863	0.749	rs1205888	chr6:11948183	T/A	cg07106625	chr6:11870215	NA	0.51	5.05	0.41	1.51e-6	Disc degeneration (lumbar);
TGCT	cis	rs7000551	0.675	rs2469758	chr8:22363032	C/T	cg12081754	chr8:22256438	SLC39A14	0.29	4.74	0.39	5.67e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs9902453	0.904	rs6505148	chr17:28289818	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.82	7.63	0.57	5.3e-12	Coffee consumption (cups per day);
TGCT	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg00080972	chr5:178986291	RUFY1	0.51	5.96	0.47	2.45e-8	Lung cancer;
TGCT	cis	rs13326165	0.760	rs67248391	chr3:52412006	A/T	cg07884673	chr3:53033167	SFMBT1	0.39	4.69	0.39	7e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs16958440	0.867	rs80006910	chr18:44696382	C/G	cg17192377	chr18:44677553	HDHD2	0.63	4.7	0.39	6.74e-6	Sitting height ratio;
TGCT	cis	rs3806843	0.735	rs6849	chr5:140086191	G/T	cg19875535	chr5:140030758	IK	-0.37	-6.23	-0.49	6.51e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7089973	0.872	rs17092497	chr10:116612628	G/A	cg03647239	chr10:116582469	FAM160B1	0.52	4.64	0.38	8.75e-6	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs7044106	0.791	rs735109	chr9:123488879	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	4.82	0.4	4.12e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	16.05	0.82	4.59e-32	Prudent dietary pattern;
TGCT	cis	rs7412746	0.611	rs111905669	chr1:150777565	T/C	cg09365446	chr1:150670422	GOLPH3L	0.37	5.33	0.43	4.48e-7	Melanoma;
TGCT	cis	rs6138458	0.701	rs6050255	chr20:25007089	A/G	cg26195577	chr20:24973756	C20orf3	1.02	9.23	0.64	8.94e-16	Blood protein levels;
TGCT	cis	rs6714710	0.603	rs895438	chr2:98382886	G/A	cg26665480	chr2:98280029	ACTR1B	0.73	6.86	0.52	2.93e-10	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg10150615	chr22:24372951	LOC391322	-1.01	-13.09	-0.76	3.96e-25	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg04287289	chr16:89883240	FANCA	0.93	11.56	0.72	2.07e-21	Vitiligo;
TGCT	trans	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.8	-8.32	-0.6	1.31e-13	Body mass index;
TGCT	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg01341218	chr17:43662625	NA	-1.11	-9.34	-0.64	5.11e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs9972944	0.783	rs9972942	chr17:63771007	A/G	cg07283582	chr17:63770753	CCDC46	0.25	5.09	0.42	1.27e-6	Total body bone mineral density;
TGCT	cis	rs7666738	0.791	rs13128640	chr4:99003918	A/C	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs992157	0.835	rs4674283	chr2:219144254	G/A	cg00012203	chr2:219082015	ARPC2	-0.79	-7.87	-0.58	1.48e-12	Colorectal cancer;
TGCT	cis	rs9902453	1.000	rs4075623	chr17:28386526	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-6.56	-0.51	1.3e-9	Coffee consumption (cups per day);
TGCT	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg09436375	chr6:42928200	GNMT	0.38	5.07	0.41	1.42e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs4746818	1.000	rs6480384	chr10:70890757	C/T	cg04149295	chr10:70884716	VPS26A	0.79	5.4	0.44	3.22e-7	Left atrial antero-posterior diameter;
TGCT	cis	rs1865760	0.865	rs9467647	chr6:25957642	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.64	6.29	0.49	4.91e-9	Height;
TGCT	cis	rs10791097	0.748	rs2282579	chr11:130735482	C/T	cg12179176	chr11:130786555	SNX19	0.81	9.83	0.66	3.29e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg06481639	chr22:41940642	POLR3H	-0.73	-6.64	-0.51	8.91e-10	Vitiligo;
TGCT	cis	rs4478858	0.698	rs6655946	chr1:31805728	G/A	cg07478791	chr1:31886160	SERINC2	-0.47	-4.54	-0.38	1.32e-5	Alcohol dependence;
TGCT	cis	rs9911578	0.835	rs1990008	chr17:56459408	C/G	cg12560992	chr17:57184187	TRIM37	-0.74	-8.29	-0.6	1.62e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.68	-6.7	-0.52	6.44e-10	Prostate cancer;
TGCT	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg23708337	chr7:1209742	NA	0.64	5.94	0.47	2.63e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs35883536	0.545	rs115017855	chr1:101101830	T/A	cg06223162	chr1:101003688	GPR88	0.32	5.34	0.43	4.31e-7	Monocyte count;
TGCT	cis	rs4319547	0.774	rs7959238	chr12:123131498	A/T	cg23029597	chr12:123009494	RSRC2	-0.27	-4.73	-0.39	6.11e-6	Body mass index;
TGCT	cis	rs7914558	0.933	rs10786729	chr10:104719378	A/G	cg04362960	chr10:104952993	NT5C2	0.6	5.38	0.44	3.56e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs9926296	0.682	rs467357	chr16:89717397	A/G	cg27121462	chr16:89883253	FANCA	-0.55	-5.0	-0.41	1.93e-6	Vitiligo;
TGCT	cis	rs8013055	0.846	rs35590487	chr14:105989599	C/T	cg19700328	chr14:106028568	NA	-0.47	-4.9	-0.4	2.91e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg11494091	chr17:61959527	GH2	0.59	13.79	0.78	8.61e-27	Prudent dietary pattern;
TGCT	cis	rs1994135	0.647	rs11052745	chr12:33695999	G/T	cg06521331	chr12:34319734	NA	-0.3	-4.69	-0.39	6.97e-6	Resting heart rate;
TGCT	cis	rs748404	0.578	rs2278856	chr15:43631356	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.48	5.0	0.41	1.93e-6	Lung cancer;
TGCT	cis	rs931127	0.554	rs11227261	chr11:65462843	C/G	cg27068330	chr11:65405492	SIPA1	-0.58	-5.16	-0.42	9.58e-7	Systemic lupus erythematosus;
TGCT	cis	rs6582630	0.502	rs7312212	chr12:38274760	T/G	cg13010199	chr12:38710504	ALG10B	0.59	4.59	0.38	1.08e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs9303542	0.625	rs6504340	chr17:46617019	A/G	cg25032089	chr17:46643351	HOXB3	-0.51	-5.66	-0.45	9.85e-8	Ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs2645424	0.604	rs9644756	chr8:11715100	A/T	cg18999641	chr8:11876646	NA	0.23	5.0	0.41	1.88e-6	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
TGCT	cis	rs7959452	0.535	rs7308481	chr12:69659299	A/G	cg20891283	chr12:69753455	YEATS4	0.66	6.37	0.5	3.41e-9	Blood protein levels;
TGCT	cis	rs61990749	0.597	rs2267758	chr14:78147429	T/C	cg23188588	chr14:78226832	SNW1;C14orf178	-0.67	-4.73	-0.39	6.09e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs1406084	0.636	rs1444686	chr2:154727135	C/T	cg25703346	chr2:154729189	GALNT13	0.77	4.6	0.38	1.03e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2439831	1.000	rs2245790	chr15:43744457	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.8	5.7	0.46	8.33e-8	Lung cancer in ever smokers;
TGCT	cis	rs4972806	0.849	rs1542180	chr2:177028767	C/T	cg13092806	chr2:177043255	NA	0.56	4.97	0.41	2.13e-6	IgG glycosylation;
TGCT	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	5.71	0.46	8.05e-8	Alzheimer's disease;
TGCT	cis	rs2637266	0.739	rs2579768	chr10:78415481	A/G	cg18941641	chr10:78392320	NA	0.39	4.56	0.38	1.2e-5	Pulmonary function;
TGCT	cis	rs9549367	0.713	rs3024757	chr13:113823186	G/T	cg18105134	chr13:113819100	PROZ	-0.47	-7.74	-0.57	3.05e-12	Platelet distribution width;
TGCT	cis	rs7513165	0.867	rs4951318	chr1:204161513	G/C	cg12731349	chr1:204159619	KISS1	0.49	5.62	0.45	1.19e-7	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
TGCT	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.63	-6.47	-0.5	2.08e-9	Prostate cancer;
TGCT	cis	rs7937682	0.632	rs10789850	chr11:111750829	C/T	cg09085632	chr11:111637200	PPP2R1B	0.81	7.16	0.54	6.3e-11	Primary sclerosing cholangitis;
TGCT	cis	rs11671005	0.693	rs34023391	chr19:58913368	G/A	cg13877915	chr19:58951672	ZNF132	0.66	4.9	0.4	2.94e-6	Mean platelet volume;
TGCT	cis	rs733175	0.904	rs3775944	chr4:10019974	G/T	cg11266682	chr4:10021025	SLC2A9	0.5	4.57	0.38	1.14e-5	Psychosis and Alzheimer's disease;
TGCT	cis	rs929596	0.958	rs17862873	chr2:234646722	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.34	-4.83	-0.4	3.95e-6	Total bilirubin levels in HIV-1 infection;
TGCT	trans	rs1814175	0.765	rs11493326	chr11:50018063	T/C	cg03929089	chr4:120376271	NA	-0.71	-8.08	-0.59	4.79e-13	Height;
TGCT	cis	rs7246657	0.722	rs2909105	chr19:38167906	A/G	cg03611452	chr19:38183253	ZNF781	-0.57	-4.79	-0.39	4.72e-6	Coronary artery calcification;
TGCT	cis	rs7147624	1.000	rs7160390	chr14:66052460	G/A	cg03016385	chr14:66212404	NA	-0.49	-7.08	-0.54	9.33e-11	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs12600856	1	rs12600856	chr17:38163295	T/C	cg17467752	chr17:38218738	THRA	0.54	5.22	0.42	7.25e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.53	-6.52	-0.51	1.59e-9	Longevity;Endometriosis;
TGCT	cis	rs7666738	0.830	rs60411337	chr4:99046617	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs62244186	0.541	rs3804583	chr3:44884647	G/T	cg04389838	chr3:44770851	ZNF501	-0.37	-4.76	-0.39	5.27e-6	Depressive symptoms;
TGCT	cis	rs61990749	0.597	rs2267759	chr14:78147615	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.63	-4.62	-0.38	9.34e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs2996428	0.667	rs7511793	chr1:3744249	A/G	cg13057898	chr1:3703894	LRRC47	0.22	4.68	0.39	7.24e-6	Red cell distribution width;
TGCT	cis	rs9611565	0.592	rs12484254	chr22:41962003	T/A	cg06634786	chr22:41940651	POLR3H	-0.88	-8.25	-0.6	1.98e-13	Vitiligo;
TGCT	cis	rs9549260	0.755	rs9532579	chr13:41243458	T/C	cg21288729	chr13:41239152	FOXO1	1.01	10.56	0.69	5.52e-19	Red blood cell count;
TGCT	cis	rs36051895	0.695	rs11794708	chr9:5023441	G/A	cg02405213	chr9:5042618	JAK2	-0.75	-10.05	-0.67	9.54e-18	Pediatric autoimmune diseases;
TGCT	cis	rs1499614	0.803	rs1796229	chr7:66119661	G/A	cg18252515	chr7:66147081	NA	-1.26	-7.95	-0.58	9.71e-13	Gout;
TGCT	cis	rs7264396	0.733	rs6058305	chr20:34310757	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.27	-5.05	-0.41	1.54e-6	Total cholesterol levels;
TGCT	cis	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg18252515	chr7:66147081	NA	1.2	7.83	0.58	1.89e-12	Diabetic kidney disease;
TGCT	cis	rs7267979	0.966	rs2424715	chr20:25420077	A/G	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6684514	1.000	rs6684514	chr1:156255456	G/A	cg20302342	chr1:156215951	PAQR6	0.34	4.6	0.38	1.01e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs77861329	1.000	rs1237830	chr3:52202820	T/C	cg08692210	chr3:52188851	WDR51A	0.93	4.79	0.4	4.61e-6	Macrophage inflammatory protein 1b levels;
TGCT	cis	rs12048904	0.619	rs10875346	chr1:101328083	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.69	5.64	0.45	1.1e-7	Multiple sclerosis;
TGCT	cis	rs9653442	0.545	rs11900482	chr2:100758709	G/C	cg07810366	chr2:100720526	AFF3	-0.35	-5.06	-0.41	1.48e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	trans	rs7726839	0.561	rs72703046	chr5:580129	T/C	cg11887960	chr12:57824829	NA	0.96	8.01	0.58	7.22e-13	Obesity-related traits;
TGCT	cis	rs2070488	0.965	rs7640050	chr3:38525864	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.88	8.99	0.63	3.5e-15	Electrocardiographic conduction measures;
TGCT	cis	rs6450176	0.638	rs1542167	chr5:53305742	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.83	-6.16	-0.48	9.32e-9	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg16497277	chr3:49208875	KLHDC8B	-0.49	-4.48	-0.37	1.68e-5	Parkinson's disease;
TGCT	cis	rs2050392	0.590	rs17547917	chr10:30718303	G/A	cg18806716	chr10:30721971	MAP3K8	-0.7	-9.39	-0.64	3.84e-16	Inflammatory bowel disease;
TGCT	cis	rs17401966	0.931	rs746881	chr1:10346810	C/T	cg19773385	chr1:10388646	KIF1B	0.2	4.61	0.38	9.88e-6	Hepatocellular carcinoma;
TGCT	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.75	0.46	6.49e-8	Height;
TGCT	cis	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg07424592	chr7:64974309	NA	1.33	7.68	0.57	4.1e-12	Diabetic kidney disease;
TGCT	cis	rs5760092	0.755	rs11090298	chr22:24262061	G/A	cg15242686	chr22:24348715	GSTTP1	-0.5	-5.8	-0.46	5.24e-8	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg07507251	chr3:52567010	NT5DC2	0.47	6.64	0.51	8.85e-10	Bipolar disorder;
TGCT	cis	rs76878669	0.561	rs55998145	chr11:66152586	A/G	cg18002602	chr11:66138449	SLC29A2	0.53	6.49	0.5	1.84e-9	Educational attainment (years of education);
TGCT	cis	rs7582180	0.663	rs1114595	chr2:100960072	T/A	cg14675211	chr2:100938903	LONRF2	0.47	4.57	0.38	1.16e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg04267008	chr7:1944627	MAD1L1	-0.41	-5.39	-0.44	3.35e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs9902453	0.845	rs7222842	chr17:28246943	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.81	7.28	0.55	3.32e-11	Coffee consumption (cups per day);
TGCT	cis	rs9486715	0.867	rs4131519	chr6:96964939	G/A	cg06623918	chr6:96969491	KIAA0776	1.08	14.42	0.79	2.72e-28	Headache;
TGCT	cis	rs9549367	0.713	rs556990	chr13:113845059	T/C	cg09473364	chr13:112927190	NA	0.29	4.64	0.38	8.73e-6	Platelet distribution width;
TGCT	cis	rs7829975	0.623	rs10092965	chr8:8373485	A/G	cg08975724	chr8:8085496	FLJ10661	0.58	5.42	0.44	2.99e-7	Mood instability;
TGCT	cis	rs365132	0.818	rs6879982	chr5:176351330	A/T	cg16631384	chr5:176070735	EIF4E1B	-0.15	-4.64	-0.38	8.83e-6	Menarche and menopause (age at onset);Menopause (age at onset);
TGCT	cis	rs12971120	0.891	rs3764510	chr18:72166846	A/G	cg25817165	chr18:72167213	CNDP2	-0.29	-4.98	-0.41	2.05e-6	Refractive error;
TGCT	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.71	5.14	0.42	1.02e-6	Platelet count;
TGCT	cis	rs12477438	0.520	rs11689265	chr2:99799267	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.9	9.33	0.64	5.15e-16	Chronic sinus infection;
TGCT	cis	rs11711311	0.955	rs2124105	chr3:113406003	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.79	-7.05	-0.54	1.09e-10	IgG glycosylation;
TGCT	cis	rs926938	0.765	rs1884296	chr1:115235716	A/C	cg12756093	chr1:115239321	AMPD1	-0.42	-6.1	-0.48	1.24e-8	Autism;
TGCT	cis	rs10972341	0.967	rs10972348	chr9:35148203	C/G	cg00812861	chr9:35114699	KIAA1539	0.34	5.24	0.43	6.82e-7	Weight;
TGCT	cis	rs4642101	0.597	rs9865624	chr3:12822786	T/A	cg05775895	chr3:12838266	CAND2	0.8	9.07	0.63	2.18e-15	QRS complex (12-leadsum);
TGCT	trans	rs2727020	0.704	rs4144700	chr11:49370834	C/A	cg15704280	chr7:45808275	SEPT13	-0.74	-8.45	-0.6	6.53e-14	Coronary artery disease;
TGCT	cis	rs6484504	0.532	rs7116443	chr11:31283170	T/C	cg14844989	chr11:31128820	NA	-0.24	-4.72	-0.39	6.34e-6	Red blood cell count;
TGCT	cis	rs7772486	0.754	rs1055212	chr6:146058315	A/T	cg23711669	chr6:146136114	FBXO30	-0.95	-10.87	-0.7	9.46e-20	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7582180	0.629	rs11686842	chr2:100956139	C/T	cg08017756	chr2:100939284	LONRF2	-0.3	-4.87	-0.4	3.27e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs57920188	0.585	rs6696138	chr1:4073575	G/A	cg20703997	chr1:4087676	NA	0.47	5.8	0.46	5.14e-8	Interleukin-17 levels;
TGCT	trans	rs2727020	0.521	rs11040377	chr11:49474346	T/C	cg03929089	chr4:120376271	NA	-0.64	-7.26	-0.55	3.71e-11	Coronary artery disease;
TGCT	cis	rs10197940	0.638	rs2288193	chr2:152348842	T/A	cg06191203	chr2:152266755	RIF1	-0.79	-7.38	-0.55	1.98e-11	Lung cancer;
TGCT	cis	rs9534288	0.699	rs2146886	chr13:46646711	C/T	cg15192986	chr13:46630673	CPB2	-0.53	-6.61	-0.51	1.03e-9	Blood protein levels;
TGCT	cis	rs3091242	0.933	rs3093584	chr1:25668714	T/C	cg09222892	chr1:25734099	RHCE	0.45	7.27	0.55	3.47e-11	Erythrocyte sedimentation rate;
TGCT	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg06896619	chr17:61851486	DDX42;CCDC47	0.48	4.63	0.38	9.08e-6	Prudent dietary pattern;
TGCT	cis	rs68170813	0.559	rs3801959	chr7:106955666	A/G	cg02696742	chr7:106810147	HBP1	-0.69	-5.81	-0.46	4.85e-8	Coronary artery disease;
TGCT	cis	rs765787	0.530	rs7167731	chr15:45510900	T/C	cg24006582	chr15:45444508	DUOX1	0.25	5.35	0.43	4.11e-7	Uric acid levels;
TGCT	cis	rs17712049	0.656	rs7795227	chr7:48198036	A/C	cg16849860	chr7:48352531	ABCA13	0.27	5.05	0.41	1.51e-6	Refractive astigmatism;
TGCT	trans	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg25206134	chr2:45395956	NA	1.1	9.34	0.64	5.11e-16	Bipolar disorder;
TGCT	cis	rs9467773	0.626	rs6935803	chr6:26350495	A/G	cg15659132	chr6:26577336	NA	-0.55	-5.68	-0.45	9.13e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9807989	0.507	rs7605284	chr2:103044175	T/G	cg03938978	chr2:103052716	IL18RAP	0.27	5.41	0.44	3.17e-7	Asthma;
TGCT	cis	rs7552167	0.636	rs4090311	chr1:24513768	G/A	cg01960748	chr1:24522592	NA	-0.42	-4.83	-0.4	3.99e-6	Psoriasis vulgaris;
TGCT	cis	rs2933343	0.951	rs789220	chr3:128592135	A/G	cg11901034	chr3:128598214	ACAD9	0.63	5.12	0.42	1.15e-6	IgG glycosylation;
TGCT	cis	rs9443645	0.901	rs4421161	chr6:79564219	A/G	cg09184832	chr6:79620586	NA	0.47	5.24	0.43	6.69e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs12464483	0.591	rs4952170	chr2:30885429	G/A	cg12454169	chr2:30669597	LCLAT1	0.5	5.35	0.43	4.07e-7	Pre-treatment pain in head and neck squamous cell carcinoma;
TGCT	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg22963979	chr7:1858916	MAD1L1	-0.4	-6.38	-0.5	3.12e-9	Bipolar disorder and schizophrenia;
TGCT	cis	rs13392177	0.684	rs11695527	chr2:219068103	A/G	cg00012203	chr2:219082015	ARPC2	0.76	7.61	0.56	6.04e-12	Pyoderma gangrenosum in inflammatory bowel disease;
TGCT	cis	rs9649213	0.519	rs3735258	chr7:97866291	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.77	-6.78	-0.52	4.41e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7674212	0.570	rs2069274	chr4:104020781	C/G	cg16532752	chr4:104119610	CENPE	-0.56	-5.2	-0.42	8.01e-7	Type 2 diabetes;
TGCT	cis	rs1461503	0.966	rs7944630	chr11:122838844	G/A	cg27398637	chr11:122830231	C11orf63	-0.43	-5.31	-0.43	5e-7	Menarche (age at onset);
TGCT	cis	rs7226408	0.842	rs72885229	chr18:34406352	T/C	cg06757138	chr18:34340585	FHOD3	0.26	4.79	0.4	4.62e-6	Obesity-related traits;
TGCT	cis	rs4727443	0.866	rs35228488	chr7:99617852	G/C	cg13334819	chr7:99746414	C7orf59	0.56	4.71	0.39	6.63e-6	Interstitial lung disease;
TGCT	cis	rs28595532	0.920	rs55794497	chr4:119764664	A/G	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs7296418	0.885	rs1727305	chr12:123633382	T/C	cg05973401	chr12:123451056	ABCB9	0.54	4.47	0.37	1.71e-5	Platelet count;
TGCT	cis	rs733175	0.855	rs10023068	chr4:10004832	C/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-4.59	-0.38	1.09e-5	Psychosis and Alzheimer's disease;
TGCT	cis	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg25427524	chr10:38739819	LOC399744	-0.4	-8.23	-0.59	2.17e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs881375	0.678	rs7037195	chr9:123684000	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	5.18	0.42	8.53e-7	Rheumatoid arthritis;
TGCT	cis	rs778371	0.697	rs2344611	chr2:233581937	A/G	cg08000102	chr2:233561755	GIGYF2	0.69	7.85	0.58	1.69e-12	Schizophrenia;
TGCT	cis	rs10464366	0.746	rs12670510	chr7:39142146	A/G	cg15212455	chr7:39170539	POU6F2	0.26	5.62	0.45	1.19e-7	IgG glycosylation;
TGCT	cis	rs8013055	0.796	rs4075105	chr14:106000231	C/T	cg23356831	chr14:105996513	TMEM121	0.34	5.31	0.43	4.91e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs7607369	0.637	rs3888879	chr2:219290676	C/T	cg02176678	chr2:219576539	TTLL4	-0.49	-6.29	-0.49	4.85e-9	Red blood cell count;Amyotrophic lateral sclerosis;
TGCT	cis	rs10746514	0.833	rs2026302	chr1:232264047	A/G	cg09506761	chr1:232265262	NA	-0.49	-4.99	-0.41	2.01e-6	Response to statin therapy;
TGCT	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	14.32	0.79	4.83e-28	Prudent dietary pattern;
TGCT	cis	rs4746059	0.516	rs12358019	chr10:72470176	C/T	cg03087610	chr10:71892362	AIFM2	-0.51	-4.5	-0.37	1.54e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs950169	0.580	rs62021208	chr15:85196244	G/A	cg17173187	chr15:85201210	NMB	0.59	6.75	0.52	5.05e-10	Schizophrenia;
TGCT	cis	rs1153858	0.943	rs12439575	chr15:45684816	T/G	cg26924012	chr15:45694286	SPATA5L1	1.09	15.16	0.81	5.15e-30	Homoarginine levels;
TGCT	cis	rs9303401	0.659	rs35539277	chr17:56853833	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs1167827	1.000	rs1167827	chr7:75163169	A/G	cg04681579	chr7:75027559	TRIM73;TRIM74	-0.41	-4.82	-0.4	4.19e-6	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs6598955	0.617	rs11247883	chr1:26576247	T/G	cg04990556	chr1:26633338	UBXN11	0.62	4.73	0.39	6.12e-6	Obesity-related traits;
TGCT	cis	rs3772130	1.000	rs35988617	chr3:121432902	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.54	4.85	0.4	3.66e-6	Cognitive performance;
TGCT	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg03517284	chr6:25882590	NA	-0.64	-5.74	-0.46	6.84e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs644799	1.000	rs560854	chr11:95584905	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.47	4.46	0.37	1.85e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7772486	0.686	rs6570705	chr6:145961201	C/T	cg05347473	chr6:146136440	FBXO30	0.48	4.53	0.38	1.38e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs12765878	0.580	rs10786772	chr10:105610326	A/G	cg11005552	chr10:105648138	OBFC1	0.38	5.98	0.47	2.17e-8	Coronary artery disease;
TGCT	trans	rs1499614	1.000	rs2707840	chr7:66158015	C/T	cg07424592	chr7:64974309	NA	1.35	8.05	0.59	5.72e-13	Gout;
TGCT	cis	rs826838	1.000	rs1719848	chr12:39085586	A/G	cg26384229	chr12:38710491	ALG10B	-0.85	-8.09	-0.59	4.68e-13	Heart rate;
TGCT	cis	rs56114371	0.530	rs9348774	chr6:27688930	C/T	cg10876282	chr6:28092338	ZSCAN16	0.64	5.29	0.43	5.39e-7	Breast cancer;
TGCT	cis	rs7412746	0.658	rs11582281	chr1:150826831	T/C	cg09365446	chr1:150670422	GOLPH3L	0.35	4.98	0.41	2.11e-6	Melanoma;
TGCT	cis	rs2479724	0.840	rs6925777	chr6:41750822	C/T	cg08135965	chr6:41755394	TOMM6	-0.49	-4.77	-0.39	5e-6	Menarche (age at onset);
TGCT	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	8.55	0.61	3.84e-14	Platelet count;
TGCT	cis	rs933688	1.000	rs2059207	chr5:90731931	C/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.88	8.2	0.59	2.51e-13	Smoking behavior;
TGCT	cis	rs17401966	0.838	rs12737239	chr1:10323973	C/G	cg19773385	chr1:10388646	KIF1B	-0.2	-4.5	-0.37	1.54e-5	Hepatocellular carcinoma;
TGCT	cis	rs17030434	1.000	rs75083896	chr4:154719082	A/G	cg14289246	chr4:154710475	SFRP2	-0.91	-7.2	-0.54	5.18e-11	Electrocardiographic conduction measures;
TGCT	cis	rs7772486	0.686	rs857879	chr6:145974043	C/A	cg23711669	chr6:146136114	FBXO30	-0.83	-8.98	-0.63	3.75e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9814567	1.000	rs9989967	chr3:134238964	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.92	-9.2	-0.64	1.11e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs7017914	0.905	rs3110246	chr8:71934613	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-4.97	-0.41	2.16e-6	Bone mineral density;
TGCT	cis	rs17345786	0.906	rs72946021	chr3:101250008	T/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.85	8.66	0.61	2.16e-14	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7826238	0.720	rs12546760	chr8:8374836	A/G	cg08975724	chr8:8085496	FLJ10661	-0.57	-5.25	-0.43	6.53e-7	Systolic blood pressure;
TGCT	cis	rs7666738	0.830	rs11727653	chr4:99001774	T/C	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11083475	0.714	rs1471432	chr19:39260282	G/A	cg17759274	chr19:39260954	NA	0.34	4.55	0.38	1.28e-5	Heart rate;
TGCT	cis	rs4891159	0.548	rs690414	chr18:74117840	T/C	cg24786174	chr18:74118243	ZNF516	0.71	15.66	0.82	3.6e-31	Longevity;
TGCT	cis	rs2075165	0.870	rs12128955	chr1:156243821	C/T	cg16558208	chr1:156270281	VHLL	0.27	4.74	0.39	5.65e-6	Tonsillectomy;
TGCT	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg12310025	chr6:25882481	NA	-0.62	-6.42	-0.5	2.62e-9	Blood metabolite levels;
TGCT	cis	rs2932538	1.000	rs2932538	chr1:113216543	A/G	cg22162597	chr1:113214053	CAPZA1	-0.28	-6.31	-0.49	4.46e-9	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg06618935	chr21:46677482	NA	-0.38	-4.97	-0.41	2.22e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg10152585	chr3:50297680	NA	0.49	4.47	0.37	1.77e-5	Resting heart rate;
TGCT	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg25036284	chr2:26402008	FAM59B	-0.55	-4.58	-0.38	1.14e-5	Gut microbiome composition (summer);
TGCT	cis	rs17102423	0.826	rs10873181	chr14:65604459	A/C	cg11161011	chr14:65562177	MAX	-0.49	-6.78	-0.52	4.38e-10	Obesity-related traits;
TGCT	cis	rs7119038	0.865	rs10892299	chr11:118726843	C/T	cg19308663	chr11:118741387	NA	0.31	5.86	0.47	3.87e-8	Sjögren's syndrome;
TGCT	cis	rs2115630	0.967	rs11073731	chr15:85355113	C/A	cg17173187	chr15:85201210	NMB	-0.39	-4.79	-0.39	4.76e-6	P wave terminal force;
TGCT	cis	rs35146811	0.735	rs1636978	chr7:99813912	G/A	cg22906224	chr7:99728672	NA	-0.5	-4.51	-0.38	1.48e-5	Coronary artery disease;
TGCT	cis	rs7246657	0.722	rs968073	chr19:38192021	G/A	cg03611452	chr19:38183253	ZNF781	-0.56	-4.63	-0.38	8.97e-6	Coronary artery calcification;
TGCT	cis	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg08045932	chr20:61659980	NA	0.48	9.28	0.64	7.07e-16	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7582180	0.629	rs4851296	chr2:100949570	T/C	cg14675211	chr2:100938903	LONRF2	0.53	5.16	0.42	9.36e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg05785598	chr3:49045655	WDR6	0.37	4.83	0.4	3.97e-6	Parkinson's disease;
TGCT	cis	rs7959452	0.590	rs11177619	chr12:69758871	G/A	cg14784868	chr12:69753453	YEATS4	0.83	8.85	0.62	7.59e-15	Blood protein levels;
TGCT	cis	rs9467711	0.651	rs13206443	chr6:26119245	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.57	-4.54	-0.38	1.33e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7095607	0.967	rs7095603	chr10:69957340	G/A	cg18986048	chr10:69913749	MYPN	0.46	4.93	0.41	2.54e-6	Lung function (FVC);
TGCT	cis	rs1903068	0.853	rs73236111	chr4:56019068	A/C	cg16572876	chr4:56024045	NA	0.44	4.8	0.4	4.5e-6	Endometriosis;
TGCT	cis	rs362272	0.524	rs2857982	chr4:3358665	G/A	cg18352616	chr4:3374830	RGS12	0.23	4.54	0.38	1.31e-5	Serum sulfate level;
TGCT	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg17554472	chr22:41940697	POLR3H	0.43	4.79	0.39	4.73e-6	Vitiligo;
TGCT	cis	rs1903068	0.853	rs28838369	chr4:56007249	A/G	cg01777861	chr4:56023843	NA	0.55	6.18	0.49	8.58e-9	Endometriosis;
TGCT	cis	rs10489202	0.657	rs201541	chr1:167992344	T/A	cg24449463	chr1:168025552	DCAF6	-0.61	-7.19	-0.54	5.24e-11	Schizophrenia;
TGCT	cis	rs9372498	0.536	rs9489460	chr6:118925754	C/T	cg07617317	chr6:118971624	C6orf204	0.48	5.08	0.42	1.32e-6	Diastolic blood pressure;
TGCT	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg15242686	chr22:24348715	GSTTP1	0.44	5.88	0.47	3.64e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2762353	0.574	rs9467574	chr6:25705718	C/G	cg07061783	chr6:25882402	NA	0.72	7.17	0.54	5.98e-11	Blood metabolite levels;
TGCT	cis	rs2580764	0.566	rs2920878	chr2:55296415	C/T	cg09592903	chr2:55203963	RTN4	0.25	5.79	0.46	5.55e-8	Mean platelet volume;
TGCT	cis	rs12188164	1.000	rs56104584	chr5:437542	T/C	cg26850624	chr5:429559	AHRR	-0.2	-4.82	-0.4	4.05e-6	Cystic fibrosis severity;
TGCT	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg22618164	chr12:122356400	WDR66	0.69	6.52	0.51	1.6e-9	Mean corpuscular volume;
TGCT	cis	rs344364	0.511	rs2982449	chr16:1947878	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.45	-5.08	-0.42	1.35e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs6598955	0.724	rs3924934	chr1:26644079	A/G	cg04990556	chr1:26633338	UBXN11	-0.92	-11.21	-0.71	1.46e-20	Obesity-related traits;
TGCT	cis	rs12210905	0.920	rs9348759	chr6:27290888	C/T	cg08851530	chr6:28072375	NA	1.29	5.45	0.44	2.65e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs35160687	0.871	rs2278105	chr2:86466516	A/G	cg12542933	chr2:85804724	VAMP8	0.4	4.77	0.39	5.15e-6	Night sleep phenotypes;
TGCT	cis	rs11190604	1.000	rs6584379	chr10:102224490	G/A	cg23241863	chr10:102295624	HIF1AN	0.62	4.87	0.4	3.27e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg20887711	chr4:1340912	KIAA1530	0.6	5.38	0.44	3.5e-7	Longevity;
TGCT	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg11062466	chr8:58055876	NA	0.38	4.62	0.38	9.5e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs28712821	0.930	rs11940694	chr4:39414993	C/T	cg12062995	chr4:39368212	RFC1	-0.4	-4.8	-0.4	4.41e-6	Alcohol consumption;
TGCT	cis	rs394563	0.726	rs6906384	chr6:149664540	G/A	cg11245181	chr6:149772854	ZC3H12D	0.29	4.84	0.4	3.77e-6	Dupuytren's disease;
TGCT	cis	rs11122272	0.735	rs2808596	chr1:231530723	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-6.34	-0.49	3.83e-9	Hemoglobin concentration;
TGCT	trans	rs6069325	0.529	rs6069323	chr20:54139209	C/G	cg26869512	chr4:8389770	ACOX3	0.47	6.92	0.53	2.12e-10	Motion sickness;
TGCT	cis	rs3806843	1.000	rs2240695	chr5:140168151	G/T	cg19875535	chr5:140030758	IK	0.37	6.34	0.49	3.89e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7772486	0.790	rs10223507	chr6:146285204	C/A	cg23711669	chr6:146136114	FBXO30	-0.87	-9.97	-0.67	1.5e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7666738	0.546	rs10026181	chr4:98814118	C/T	cg18180107	chr4:99064573	C4orf37	-0.57	-4.83	-0.4	3.9e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs78487399	0.808	rs74600494	chr2:43743491	C/T	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.78	4.84	0.4	3.8e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	trans	rs12599106	0.629	rs1391904	chr16:34548934	C/T	cg03395511	chr6:291903	DUSP22	-0.65	-6.78	-0.52	4.28e-10	Menopause (age at onset);
TGCT	cis	rs1008375	1.000	rs7671752	chr4:17661398	C/T	cg18681998	chr4:17616180	MED28	0.96	11.17	0.71	1.81e-20	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg18110333	chr6:292329	DUSP22	-0.72	-7.63	-0.57	5.43e-12	Menopause (age at onset);
TGCT	cis	rs62244186	0.545	rs7640654	chr3:44763037	A/C	cg04389838	chr3:44770851	ZNF501	-0.37	-4.83	-0.4	4.02e-6	Depressive symptoms;
TGCT	cis	rs6754311	0.773	rs666407	chr2:136640233	A/G	cg07169764	chr2:136633963	MCM6	0.64	6.0	0.47	1.99e-8	Mosquito bite size;
TGCT	cis	rs12188164	1.000	rs12188678	chr5:428231	T/C	cg26850624	chr5:429559	AHRR	-0.2	-4.69	-0.39	7.1e-6	Cystic fibrosis severity;
TGCT	cis	rs4700695	0.545	rs253275	chr5:65509809	A/G	cg21114390	chr5:65439923	SFRS12	-0.81	-7.72	-0.57	3.39e-12	Facial morphology (factor 19);
TGCT	cis	rs7927771	0.864	rs2053979	chr11:47439444	A/G	cg10139015	chr11:47448256	PSMC3	0.52	4.46	0.37	1.78e-5	Subjective well-being;
TGCT	cis	rs908922	0.676	rs4845443	chr1:152507156	C/T	cg20991723	chr1:152506922	NA	0.46	6.3	0.49	4.77e-9	Hair morphology;
TGCT	cis	rs514406	0.505	rs374662	chr1:53164549	C/A	cg25767906	chr1:53392781	SCP2	-0.45	-4.85	-0.4	3.59e-6	Monocyte count;
TGCT	cis	rs72700829	0.531	rs12070288	chr1:151009984	C/G	cg00666978	chr1:150947442	LASS2	0.89	4.64	0.38	8.54e-6	Schizophrenia;
TGCT	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg23131131	chr22:24373011	LOC391322	-0.67	-7.05	-0.53	1.11e-10	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg06636001	chr8:8085503	FLJ10661	0.77	7.52	0.56	9.75e-12	Mood instability;
TGCT	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.5	4.61	0.38	9.7e-6	Prudent dietary pattern;
TGCT	cis	rs2013441	0.931	rs12937827	chr17:20033202	G/C	cg23224458	chr17:20280056	CCDC144C	0.38	4.61	0.38	9.96e-6	Obesity-related traits;
TGCT	cis	rs1153858	1.000	rs7171577	chr15:45627979	G/A	cg26924012	chr15:45694286	SPATA5L1	1.07	14.56	0.79	1.32e-28	Homoarginine levels;
TGCT	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg12310025	chr6:25882481	NA	-0.62	-6.42	-0.5	2.63e-9	Blood metabolite levels;
TGCT	cis	rs2013441	1.000	rs9915059	chr17:20177104	G/T	cg18979559	chr17:20280153	CCDC144C	-0.48	-4.69	-0.39	7.09e-6	Obesity-related traits;
TGCT	cis	rs8077577	0.836	rs58441148	chr17:18106498	T/A	cg09161412	chr17:18057145	MYO15A	-0.64	-5.22	-0.42	7.2e-7	Obesity-related traits;
TGCT	cis	rs6500602	0.627	rs934929	chr16:4587789	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.4	-7.18	-0.54	5.64e-11	Schizophrenia;
TGCT	cis	rs295140	0.506	rs295136	chr2:201141002	G/C	cg23649088	chr2:200775458	C2orf69	0.28	4.59	0.38	1.06e-5	QT interval;
TGCT	cis	rs12477438	0.520	rs2171359	chr2:99795360	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	17.43	0.84	3.73e-35	Chronic sinus infection;
TGCT	cis	rs2180341	1.000	rs6569486	chr6:127708424	A/C	cg24812749	chr6:127587940	RNF146	0.99	7.63	0.57	5.24e-12	Breast cancer;
TGCT	cis	rs7818688	0.697	rs58314911	chr8:95985111	G/A	cg16049864	chr8:95962084	TP53INP1	0.54	4.64	0.38	8.87e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs6076065	0.748	rs999068	chr20:23376483	G/A	cg11657817	chr20:23433608	CST11	0.31	5.42	0.44	3.02e-7	Facial morphology (factor 15, philtrum width);
TGCT	cis	rs916888	0.610	rs199442	chr17:44820122	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.64	4.95	0.41	2.39e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs763121	0.962	rs1980455	chr22:38925719	A/C	cg06022373	chr22:39101656	GTPBP1	0.75	7.53	0.56	9.08e-12	Menopause (age at onset);
TGCT	cis	rs7666738	0.830	rs10516426	chr4:99035827	A/G	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg00343986	chr7:65444356	GUSB	0.23	5.13	0.42	1.08e-6	Aortic root size;
TGCT	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg23758822	chr17:41437982	NA	0.69	6.36	0.5	3.54e-9	Menopause (age at onset);
TGCT	cis	rs9512730	0.553	rs6491213	chr13:28049822	T/C	cg04070771	chr13:27998621	GTF3A	0.52	4.57	0.38	1.18e-5	Schizophrenia;
TGCT	cis	rs62380364	0.558	rs34319	chr5:88023349	A/T	cg22951263	chr5:87985283	NA	-0.54	-5.78	-0.46	5.76e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs34172651	0.517	rs12920774	chr16:24830750	T/C	cg06028605	chr16:24865363	SLC5A11	0.41	4.47	0.37	1.76e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7552404	0.731	rs10873787	chr1:76367797	G/A	cg10523679	chr1:76189770	ACADM	0.85	7.54	0.56	8.71e-12	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2025751	0.692	rs9474103	chr6:51696869	A/G	cg23457901	chr6:52402140	TRAM2	-0.22	-4.45	-0.37	1.85e-5	Intraocular pressure;
TGCT	cis	rs546131	0.642	rs568529	chr11:34842506	C/A	cg06937548	chr11:34938143	PDHX;APIP	0.51	4.51	0.38	1.46e-5	Lung disease severity in cystic fibrosis;
TGCT	cis	rs7264396	0.690	rs2425180	chr20:34447160	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.04	-0.41	1.58e-6	Total cholesterol levels;
TGCT	cis	rs6933660	0.720	rs6914656	chr6:151753421	C/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.64	6.4	0.5	2.87e-9	Menarche (age at onset);
TGCT	cis	rs2013441	1.000	rs2034109	chr17:20196633	C/T	cg23224458	chr17:20280056	CCDC144C	-0.42	-4.91	-0.4	2.82e-6	Obesity-related traits;
TGCT	cis	rs9929218	0.551	rs3785135	chr16:68728976	A/C	cg01251360	chr16:68772225	CDH1	0.27	5.25	0.43	6.5e-7	Colorectal cancer;
TGCT	cis	rs4755351	0.553	rs11032157	chr11:33158566	A/G	cg14646457	chr11:33280348	HIPK3	-0.91	-4.85	-0.4	3.55e-6	Lung cancer in ever smokers;
TGCT	cis	rs9733	0.818	rs12403609	chr1:150676485	T/C	cg13175981	chr1:150552382	MCL1	0.43	4.78	0.39	4.77e-6	Tonsillectomy;
TGCT	cis	rs3091242	0.809	rs660129	chr1:25727438	C/T	cg09222892	chr1:25734099	RHCE	-0.44	-7.09	-0.54	9.15e-11	Erythrocyte sedimentation rate;
TGCT	cis	rs11098499	0.863	rs11723090	chr4:120490592	T/C	cg09307838	chr4:120376055	NA	0.68	6.47	0.5	2.02e-9	Corneal astigmatism;
TGCT	cis	rs9653442	0.545	rs11123814	chr2:100767082	A/G	cg22139774	chr2:100720529	AFF3	-0.34	-5.4	-0.44	3.21e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs614226	0.935	rs77955762	chr12:121009948	T/C	cg01236616	chr12:121019343	POP5	-1.29	-12.97	-0.76	7.75e-25	Type 1 diabetes nephropathy;
TGCT	cis	rs9486719	0.948	rs2472906	chr6:96875318	G/T	cg18709589	chr6:96969512	KIAA0776	0.71	5.21	0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs5769765	0.908	rs9616376	chr22:50310829	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.43	6.08	0.48	1.35e-8	Schizophrenia;
TGCT	cis	rs7568458	0.811	rs3755014	chr2:85764006	C/T	cg02493740	chr2:85810744	VAMP5	-0.29	-5.46	-0.44	2.47e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg01448562	chr3:133502909	NA	0.26	4.91	0.4	2.81e-6	Iron status biomarkers;
TGCT	cis	rs9372498	0.908	rs17080082	chr6:118700137	C/T	cg21191810	chr6:118973309	C6orf204	-0.5	-4.61	-0.38	9.92e-6	Diastolic blood pressure;
TGCT	trans	rs11722228	0.508	rs3756227	chr4:10087995	C/A	cg26043149	chr18:55253948	FECH	1.12	11.04	0.7	3.79e-20	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.67	-0.39	7.73e-6	Prudent dietary pattern;
TGCT	cis	rs9467711	0.516	rs1177441	chr6:25859413	A/G	cg12310025	chr6:25882481	NA	-0.72	-4.77	-0.39	5.17e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	8.16	0.59	3.19e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9814567	1.000	rs7371896	chr3:134249769	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.95	-9.55	-0.65	1.56e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.0	7.42	0.55	1.64e-11	Gut microbiome composition (summer);
TGCT	cis	rs66887589	0.934	rs41464847	chr4:120532401	A/G	cg24670566	chr4:120433619	PDE5A	-0.24	-4.48	-0.37	1.67e-5	Diastolic blood pressure;
TGCT	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg18876405	chr7:65276391	NA	0.36	5.41	0.44	3.12e-7	Aortic root size;
TGCT	cis	rs6087990	0.836	rs2424909	chr20:31361861	T/C	cg13636640	chr20:31349939	DNMT3B	1.08	14.21	0.79	8.84e-28	Ulcerative colitis;
TGCT	cis	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg02380750	chr20:61661411	NA	0.34	6.02	0.48	1.86e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs11648796	0.765	rs61112891	chr16:783156	G/C	cg00908189	chr16:619842	PIGQ	0.65	4.79	0.39	4.75e-6	Height;
TGCT	cis	rs9467711	0.932	rs11966360	chr6:26316982	A/G	cg16898833	chr6:26189333	HIST1H4D	1.0	5.47	0.44	2.34e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7172809	0.599	rs2012756	chr15:77745301	G/C	cg22256960	chr15:77711686	NA	-0.51	-4.86	-0.4	3.47e-6	Glucose homeostasis traits;
TGCT	cis	rs6669384	0.774	rs4844622	chr1:208034329	C/T	cg22525895	chr1:207977042	MIR29B2	-0.39	-5.45	-0.44	2.57e-7	Immune response to measles vaccine (measles-specific neutralising antibody titre);
TGCT	trans	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg17830980	chr10:43048298	ZNF37B	-0.87	-11.3	-0.71	8.5e-21	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2735413	0.564	rs8051817	chr16:78121254	C/T	cg09132178	chr16:78079569	NA	0.35	4.51	0.38	1.47e-5	Systolic blood pressure (alcohol consumption interaction);
TGCT	cis	rs2420915	0.841	rs2254455	chr10:122872517	G/A	cg23234726	chr10:122735589	NA	-0.32	-4.48	-0.37	1.67e-5	Fibrinogen levels;
TGCT	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg09222892	chr1:25734099	RHCE	0.42	6.78	0.52	4.33e-10	Erythrocyte sedimentation rate;
TGCT	cis	rs394563	0.726	rs366905	chr6:149735097	T/A	cg03678062	chr6:149772716	ZC3H12D	-0.39	-4.83	-0.4	4.02e-6	Dupuytren's disease;
TGCT	cis	rs4478858	0.735	rs10914360	chr1:31817476	G/A	cg07478791	chr1:31886160	SERINC2	-0.47	-4.54	-0.38	1.32e-5	Alcohol dependence;
TGCT	cis	rs10779751	0.734	rs1194820	chr1:11129259	A/C	cg08854313	chr1:11322531	MTOR	0.84	8.29	0.6	1.55e-13	Body mass index;
TGCT	trans	rs10802346	0.515	rs1113270	chr1:246423217	A/G	cg13514129	chr1:39547527	MACF1	1.02	9.4	0.65	3.68e-16	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs12908161	1.000	rs12903134	chr15:85337699	T/A	cg11189052	chr15:85197271	WDR73	0.71	5.87	0.47	3.68e-8	Schizophrenia;
TGCT	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg20607798	chr8:58055168	NA	0.58	4.89	0.4	3.11e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7917772	0.582	rs12779854	chr10:104358474	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-5.46	-0.44	2.51e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9486719	1.000	rs2499809	chr6:96870110	C/T	cg06623918	chr6:96969491	KIAA0776	1.01	8.86	0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs10876993	0.890	rs774888	chr12:58036506	A/G	cg15848620	chr12:58087721	OS9	-0.72	-5.78	-0.46	5.57e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs992157	0.764	rs2382827	chr2:219184387	G/A	cg00012203	chr2:219082015	ARPC2	0.7	6.59	0.51	1.11e-9	Colorectal cancer;
TGCT	cis	rs2663905	0.706	rs2683260	chr15:81385552	A/C	cg27045999	chr15:81426544	C15orf26	-0.64	-5.78	-0.46	5.63e-8	QT interval (drug interaction);
TGCT	trans	rs1814175	0.817	rs2866545	chr11:49630824	A/C	cg03929089	chr4:120376271	NA	-0.74	-8.69	-0.62	1.75e-14	Height;
TGCT	cis	rs12477438	0.748	rs6712773	chr2:99585781	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-8.52	-0.61	4.5e-14	Chronic sinus infection;
TGCT	cis	rs9916302	0.904	rs587343	chr17:37440603	C/T	cg07936489	chr17:37558343	FBXL20	0.6	4.75	0.39	5.45e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs12220898	0.679	rs4838485	chr10:50484825	T/A	cg09603381	chr10:49954066	WDFY4	0.38	4.45	0.37	1.88e-5	Inflammatory biomarkers;
TGCT	cis	rs36051895	0.558	rs7038687	chr9:5134065	C/T	cg02405213	chr9:5042618	JAK2	0.79	11.01	0.7	4.46e-20	Pediatric autoimmune diseases;
TGCT	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	6.11	0.48	1.17e-8	Alzheimer's disease;
TGCT	cis	rs17030434	0.871	rs6847648	chr4:154729700	G/A	cg14289246	chr4:154710475	SFRP2	-0.9	-7.56	-0.56	7.62e-12	Electrocardiographic conduction measures;
TGCT	cis	rs72843506	0.722	rs79590067	chr17:20107414	G/A	cg18979559	chr17:20280153	CCDC144C	-0.64	-4.84	-0.4	3.71e-6	Schizophrenia;
TGCT	cis	rs9913156	0.802	rs4538065	chr17:4566015	G/A	cg19197139	chr17:4613644	ARRB2	-0.87	-8.05	-0.59	5.79e-13	Lymphocyte counts;
TGCT	trans	rs877282	0.898	rs34490091	chr10:765800	A/C	cg22713356	chr15:30763199	NA	1.2	9.39	0.64	3.76e-16	Uric acid levels;
TGCT	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg23758822	chr17:41437982	NA	0.72	6.99	0.53	1.47e-10	Menopause (age at onset);
TGCT	cis	rs2580764	0.540	rs2920893	chr2:55270629	C/T	cg09592903	chr2:55203963	RTN4	0.27	6.06	0.48	1.51e-8	Mean platelet volume;
TGCT	cis	rs709400	0.628	rs6575984	chr14:103876454	A/G	cg12935359	chr14:103987150	CKB	0.34	5.19	0.42	8.36e-7	Body mass index;
TGCT	cis	rs12148488	0.738	rs4886417	chr15:75330159	T/G	cg09165964	chr15:75287851	SCAMP5	0.52	4.56	0.38	1.21e-5	Caffeine consumption;
TGCT	cis	rs11122272	0.735	rs2739515	chr1:231514681	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.14	-0.54	6.86e-11	Hemoglobin concentration;
TGCT	trans	rs9650657	0.535	rs7011756	chr8:11019578	C/G	cg06636001	chr8:8085503	FLJ10661	-0.8	-7.48	-0.56	1.18e-11	Neuroticism;
TGCT	cis	rs208520	0.770	rs1342960	chr6:66883514	T/C	cg07460842	chr6:66804631	NA	-0.9	-9.36	-0.64	4.37e-16	Exhaled nitric oxide output;
TGCT	cis	rs2178146	0.535	rs4843946	chr16:86445827	A/G	cg11165158	chr16:86613094	FOXL1	-0.36	-4.92	-0.4	2.71e-6	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Esophageal adenocarcinoma;
TGCT	cis	rs13326165	0.715	rs11716017	chr3:52380991	C/T	cg07884673	chr3:53033167	SFMBT1	0.38	4.65	0.39	8.36e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs12142240	0.698	rs66847432	chr1:46832013	G/A	cg14993813	chr1:46806288	NSUN4	-0.58	-4.8	-0.4	4.46e-6	Menopause (age at onset);
TGCT	cis	rs3820928	0.845	rs13415319	chr2:227878936	G/C	cg11843606	chr2:227700838	RHBDD1	-0.52	-4.58	-0.38	1.13e-5	Pulmonary function;
TGCT	cis	rs425277	0.583	rs925905	chr1:2044037	T/C	cg24578937	chr1:2090814	PRKCZ	-0.24	-5.84	-0.46	4.38e-8	Height;
TGCT	cis	rs12464483	0.524	rs1901906	chr2:30884576	A/G	cg12454169	chr2:30669597	LCLAT1	-0.45	-4.88	-0.4	3.17e-6	Pre-treatment pain in head and neck squamous cell carcinoma;
TGCT	cis	rs2191566	1.000	rs7256908	chr19:44528898	C/T	cg03039196	chr19:44506973	ZNF230	0.57	4.91	0.4	2.87e-6	Acute lymphoblastic leukemia (childhood);
TGCT	cis	rs2204008	0.837	rs7308714	chr12:38274307	T/C	cg26384229	chr12:38710491	ALG10B	0.86	7.48	0.56	1.19e-11	Bladder cancer;
TGCT	trans	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg13565492	chr6:43139072	SRF	-0.82	-7.72	-0.57	3.43e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	trans	rs6920965	0.583	rs9388456	chr6:126147197	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.6	-6.71	-0.52	6.23e-10	High light scatter reticulocyte count;
TGCT	cis	rs12477438	0.765	rs7591992	chr2:99668954	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-4.62	-0.38	9.47e-6	Chronic sinus infection;
TGCT	trans	rs1814175	0.817	rs11518158	chr11:49985633	G/T	cg03929089	chr4:120376271	NA	-0.72	-8.53	-0.61	4.25e-14	Height;
TGCT	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	5.98	0.47	2.23e-8	Alzheimer's disease;
TGCT	cis	rs9858542	0.903	rs35999162	chr3:49597230	C/G	cg03060546	chr3:49711283	APEH	-0.61	-5.37	-0.43	3.78e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs950169	0.580	rs36126054	chr15:85177723	T/G	cg17173187	chr15:85201210	NMB	0.62	7.09	0.54	8.99e-11	Schizophrenia;
TGCT	cis	rs4319547	0.688	rs10847415	chr12:123144293	T/C	cg23029597	chr12:123009494	RSRC2	-0.3	-5.14	-0.42	1.02e-6	Body mass index;
TGCT	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.53	-5.09	-0.42	1.31e-6	Longevity;Endometriosis;
TGCT	cis	rs8056742	0.730	rs62048415	chr16:85063709	G/A	cg00229868	chr16:85520891	NA	0.4	5.45	0.44	2.65e-7	Amyotrophic lateral sclerosis;
TGCT	cis	rs3784262	0.565	rs2642632	chr15:58308254	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.38	-5.43	-0.44	2.8e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs13256369	0.851	rs11249889	chr8:8564992	G/T	cg17143192	chr8:8559678	CLDN23	0.57	5.35	0.43	4.09e-7	Obesity-related traits;
TGCT	cis	rs2463822	0.925	rs6863	chr11:62160725	G/T	cg06239285	chr11:62104954	ASRGL1	-0.8	-5.2	-0.42	8.1e-7	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs1865760	0.566	rs9295686	chr6:26081983	G/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.78	7.49	0.56	1.15e-11	Height;
TGCT	cis	rs3008870	1.000	rs2985824	chr1:67410171	C/T	cg11518657	chr1:67396239	MIER1	-0.53	-4.63	-0.38	9.2e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg27535305	chr1:53392650	SCP2	-0.26	-5.25	-0.43	6.37e-7	Monocyte count;
TGCT	cis	rs1499614	0.901	rs3936	chr7:66126489	C/T	cg18252515	chr7:66147081	NA	-1.26	-7.95	-0.58	9.71e-13	Gout;
TGCT	cis	rs9611565	0.573	rs9306355	chr22:42111896	A/T	cg06481639	chr22:41940642	POLR3H	0.56	4.87	0.4	3.39e-6	Vitiligo;
TGCT	cis	rs6570726	0.935	rs376991	chr6:145828073	G/C	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs12477438	0.520	rs7605843	chr2:99811894	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	8.83	0.62	8.31e-15	Chronic sinus infection;
TGCT	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg07507251	chr3:52567010	NT5DC2	0.47	6.64	0.51	8.85e-10	Bipolar disorder;
TGCT	cis	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg04013166	chr16:89971882	TCF25	0.33	4.64	0.38	8.86e-6	Skin colour saturation;
TGCT	trans	rs4919669	0.546	rs4919652	chr10:104274157	A/C	cg19053889	chr7:1098703	C7orf50;GPR146	-0.51	-6.78	-0.52	4.25e-10	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	trans	rs9388451	0.805	rs1028481	chr6:126106573	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.72	-8.04	-0.59	6.03e-13	Brugada syndrome;
TGCT	cis	rs7917772	0.582	rs7907417	chr10:104370662	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-5.36	-0.43	3.84e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9549260	0.755	rs9577091	chr13:41227865	G/A	cg21288729	chr13:41239152	FOXO1	1.01	10.71	0.69	2.36e-19	Red blood cell count;
TGCT	cis	rs6840360	0.642	rs1470280	chr4:152431770	C/T	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.82e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs910316	1.000	rs7145159	chr14:75583268	A/G	cg11812906	chr14:75593930	NEK9	0.74	7.28	0.55	3.42e-11	Height;
TGCT	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.67	5.58	0.45	1.43e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs909002	0.889	rs1061392	chr1:32118160	C/A	cg11573219	chr1:32083031	HCRTR1	-0.48	-5.92	-0.47	2.92e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs28485415	chr4:99060340	G/A	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.44e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7586879	0.575	rs6712981	chr2:25126230	A/G	cg01884057	chr2:25150051	NA	0.35	6.9	0.53	2.39e-10	Body mass index;
TGCT	cis	rs6674176	0.551	rs2242637	chr1:44401384	A/G	cg12908607	chr1:44402522	ARTN	-0.69	-4.6	-0.38	1.03e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs3008870	1.000	rs2985794	chr1:67425311	T/G	cg03991309	chr1:68237761	GNG12	0.27	4.53	0.38	1.36e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs1045714	0.836	rs56246161	chr7:2644679	G/A	cg17215154	chr7:2644645	IQCE	0.26	4.57	0.38	1.18e-5	Urate levels in lean individuals;
TGCT	cis	rs55962025	0.804	rs362268	chr4:3242148	C/G	cg06533319	chr4:3265114	C4orf44	0.23	4.53	0.38	1.34e-5	Parental longevity (mother's age at death);
TGCT	trans	rs17685	0.884	rs3823882	chr7:75631913	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.47	-7.26	-0.55	3.81e-11	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs3960554	0.569	rs11973658	chr7:75882026	A/C	cg19105122	chr7:75896889	SRRM3	0.62	5.32	0.43	4.78e-7	Eotaxin levels;
TGCT	cis	rs9640161	0.830	rs3757423	chr7:150067714	A/G	cg10018233	chr7:150070692	REPIN1	-0.41	-6.8	-0.52	3.84e-10	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs7246657	0.882	rs10422667	chr19:37937876	T/C	cg18154014	chr19:37997991	ZNF793	0.94	6.56	0.51	1.3e-9	Coronary artery calcification;
TGCT	trans	rs8073060	0.927	rs7502331	chr17:33868858	A/G	cg19694781	chr19:47549865	TMEM160	0.43	7.85	0.58	1.71e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs611744	0.507	rs2121900	chr8:109333542	T/C	cg21045802	chr8:109455806	TTC35	0.76	7.76	0.57	2.7e-12	Dupuytren's disease;
TGCT	cis	rs7666738	0.830	rs62318472	chr4:98926030	G/A	cg18180107	chr4:99064573	C4orf37	0.55	4.98	0.41	2.05e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs67072384	0.786	rs60497375	chr11:72452645	A/G	cg03713592	chr11:72463424	ARAP1	-0.93	-4.66	-0.39	7.89e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs11785400	0.701	rs9297968	chr8:143723009	A/G	cg24634471	chr8:143751801	JRK	0.53	5.24	0.43	6.7e-7	Schizophrenia;
TGCT	cis	rs7806994	1	rs7806994	chr7:56139505	A/T	cg23942717	chr7:56437746	NA	0.48	4.99	0.41	1.99e-6	PR interval in Tripanosoma cruzi seropositivity;
TGCT	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.53	-5.1	-0.42	1.26e-6	Prudent dietary pattern;
TGCT	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg10150615	chr22:24372951	LOC391322	-0.96	-11.46	-0.72	3.58e-21	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2404602	0.692	rs12595586	chr15:77172210	A/G	cg26408565	chr15:76604113	ETFA	-0.36	-4.52	-0.38	1.41e-5	Blood metabolite levels;
TGCT	cis	rs71597109	0.568	rs11940179	chr4:102727577	C/T	cg14855874	chr4:102712397	BANK1	0.41	4.72	0.39	6.16e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs1865760	0.964	rs1324084	chr6:25915134	C/T	cg16482183	chr6:26056742	HIST1H1C	0.52	4.6	0.38	1.04e-5	Height;
TGCT	cis	rs7044106	0.734	rs1981020	chr9:123388464	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	4.57	0.38	1.14e-5	Hip circumference adjusted for BMI;
TGCT	trans	rs941408	1.000	rs1736179	chr19:2795516	T/A	cg19676328	chr12:49525230	TUBA1B	-0.76	-7.65	-0.57	4.74e-12	Total cholesterol levels;
TGCT	cis	rs9837602	0.507	rs793452	chr3:99529523	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.57	-6.61	-0.51	9.98e-10	Breast cancer;
TGCT	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg21862992	chr11:68658383	NA	0.44	6.07	0.48	1.42e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs12479064	0.724	rs10496336	chr2:99996165	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.57	-4.47	-0.37	1.71e-5	Chronic sinus infection;
TGCT	cis	rs13177918	0.626	rs67026795	chr5:149831660	T/C	cg14059543	chr5:149831962	NA	-0.68	-9.02	-0.63	2.93e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg18538332	chr22:24372958	LOC391322	0.75	6.21	0.49	7.22e-9	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs910316	0.687	rs11627442	chr14:75669649	A/G	cg11812906	chr14:75593930	NEK9	-0.55	-4.74	-0.39	5.72e-6	Height;
TGCT	trans	rs629535	0.783	rs510632	chr8:70034570	A/G	cg21567404	chr3:27674614	NA	0.58	9.18	0.64	1.22e-15	Dupuytren's disease;
TGCT	cis	rs9611519	1.000	rs5758267	chr22:41619350	A/T	cg13695892	chr22:41940480	POLR3H	0.52	4.79	0.39	4.74e-6	Neuroticism;
TGCT	cis	rs7772486	0.713	rs1986729	chr6:146194831	G/A	cg13319975	chr6:146136371	FBXO30	-0.54	-4.81	-0.4	4.27e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6964587	1.000	rs6944591	chr7:91642714	T/C	cg17063962	chr7:91808500	NA	0.91	9.99	0.67	1.32e-17	Breast cancer;
TGCT	cis	rs651907	0.535	rs9830943	chr3:101428899	T/G	cg12386194	chr3:101231763	SENP7	0.48	4.6	0.38	1.04e-5	Colorectal cancer;
TGCT	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg04944784	chr2:26401820	FAM59B	-0.72	-5.92	-0.47	2.93e-8	Gut microbiome composition (summer);
TGCT	cis	rs6964587	0.967	rs12535601	chr7:91718346	A/G	cg17063962	chr7:91808500	NA	0.86	9.47	0.65	2.39e-16	Breast cancer;
TGCT	cis	rs939574	0.790	rs72955452	chr2:220101783	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.03	4.62	0.38	9.29e-6	Platelet distribution width;
TGCT	cis	rs4788570	0.566	rs72795864	chr16:71483497	C/G	cg06353428	chr16:71660113	MARVELD3	-1.33	-7.91	-0.58	1.24e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs12681288	0.782	rs6559213	chr8:1030923	A/G	cg04851639	chr8:1020857	NA	-0.36	-6.16	-0.48	9.23e-9	Schizophrenia;
TGCT	cis	rs4499344	0.730	rs410616	chr19:33106109	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	8.74	0.62	1.36e-14	Mean platelet volume;
TGCT	cis	rs7662987	0.517	rs1154405	chr4:100008750	G/A	cg12011299	chr4:100065546	ADH4	0.4	4.76	0.39	5.33e-6	Smoking initiation;
TGCT	cis	rs7914558	1.000	rs7094843	chr10:104806654	A/C	cg04362960	chr10:104952993	NT5C2	0.61	5.46	0.44	2.44e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs8020441	0.945	rs72681670	chr14:51169272	C/T	cg04730355	chr14:51134070	SAV1	0.75	6.28	0.49	5.1e-9	Cognitive performance;
TGCT	cis	rs6545883	0.965	rs3771258	chr2:61764140	C/T	cg15711740	chr2:61764176	XPO1	-0.57	-5.23	-0.43	6.89e-7	Tuberculosis;
TGCT	cis	rs6087771	0.851	rs6087775	chr20:30325765	G/A	cg13852791	chr20:30311386	BCL2L1	0.84	8.15	0.59	3.38e-13	Subcortical brain region volumes;Putamen volume;
TGCT	cis	rs3820068	0.705	rs4645992	chr1:15849742	G/T	cg05660106	chr1:15850417	CASP9	1.13	13.14	0.76	3.06e-25	Systolic blood pressure;
TGCT	cis	rs7666738	0.830	rs7657982	chr4:99044015	G/A	cg18180107	chr4:99064573	C4orf37	0.56	5.17	0.42	8.97e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7772486	0.790	rs2253654	chr6:146199445	T/C	cg05347473	chr6:146136440	FBXO30	0.54	5.06	0.41	1.47e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3935685	0.874	rs55858810	chr15:78004230	G/T	cg25212270	chr15:78015279	NA	0.26	5.57	0.45	1.48e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2243480	1.000	rs313831	chr7:65551226	C/T	cg07424592	chr7:64974309	NA	1.26	8.11	0.59	4.17e-13	Diabetic kidney disease;
TGCT	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg24675658	chr1:53192096	ZYG11B	-0.89	-11.35	-0.71	6.62e-21	Monocyte count;
TGCT	cis	rs4478858	0.735	rs11583123	chr1:31751772	T/C	cg00250761	chr1:31883323	NA	-0.26	-4.55	-0.38	1.28e-5	Alcohol dependence;
TGCT	cis	rs2439831	0.850	rs28564774	chr15:44125475	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.9	6.3	0.49	4.62e-9	Lung cancer in ever smokers;
TGCT	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg26119090	chr2:26468346	HADHA;HADHB	0.97	7.19	0.54	5.48e-11	Gut microbiome composition (summer);
TGCT	cis	rs4891159	0.548	rs660342	chr18:74130896	C/G	cg24786174	chr18:74118243	ZNF516	0.67	13.58	0.77	2.65e-26	Longevity;
TGCT	cis	rs1395	0.922	rs13404327	chr2:27519153	G/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.47	6.24	0.49	6.46e-9	Blood metabolite levels;
TGCT	cis	rs12367572	1.000	rs7295923	chr12:45269284	C/T	cg04608330	chr12:45269318	NELL2	-0.65	-6.63	-0.51	9.33e-10	Gut microbiome composition (summer);
TGCT	cis	rs6484504	0.576	rs286649	chr11:31230468	C/T	cg14844989	chr11:31128820	NA	-0.23	-4.51	-0.38	1.47e-5	Red blood cell count;
TGCT	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg03806693	chr22:41940476	POLR3H	1.02	11.36	0.71	6.13e-21	Vitiligo;
TGCT	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg01448562	chr3:133502909	NA	0.34	6.94	0.53	1.95e-10	Iron status biomarkers;
TGCT	cis	rs11785400	0.793	rs10956992	chr8:143736235	A/C	cg10596483	chr8:143751796	JRK	0.55	5.47	0.44	2.41e-7	Schizophrenia;
TGCT	cis	rs67460515	0.567	rs34691229	chr3:160876897	G/T	cg03342759	chr3:160939853	NMD3	-0.45	-4.53	-0.38	1.38e-5	Parkinson's disease;
TGCT	cis	rs7924176	0.521	rs61863363	chr10:76140251	C/T	cg19889307	chr10:75911429	ADK;AP3M1	-0.46	-4.48	-0.37	1.65e-5	Primary tooth development (time to first tooth eruption);Permanent tooth development;Primary tooth development (number of teeth);
TGCT	cis	rs6671200	0.573	rs3738171	chr1:95699594	A/G	cg06440946	chr1:95699313	RWDD3	-0.65	-5.43	-0.44	2.89e-7	Stearic acid (18:0) levels;
TGCT	cis	rs2235642	0.893	rs2076442	chr16:1591112	G/T	cg10465839	chr16:1584050	IFT140;TMEM204	-0.32	-5.22	-0.42	7.17e-7	Coronary artery disease;
TGCT	cis	rs17376456	0.877	rs9314099	chr5:93447375	T/C	cg25358565	chr5:93447407	FAM172A	0.92	8.38	0.6	9.58e-14	Diabetic retinopathy;
TGCT	cis	rs9549260	0.755	rs58919811	chr13:41226485	A/C	cg21288729	chr13:41239152	FOXO1	0.99	10.42	0.68	1.22e-18	Red blood cell count;
TGCT	trans	rs10435719	0.509	rs13248956	chr8:11789768	C/A	cg15556689	chr8:8085844	FLJ10661	0.73	6.89	0.53	2.55e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs9902453	0.730	rs4583306	chr17:28538715	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-5.59	-0.45	1.4e-7	Coffee consumption (cups per day);
TGCT	cis	rs12220238	1.000	rs10824113	chr10:75969018	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.91	7.77	0.57	2.63e-12	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs2153535	0.580	rs7741456	chr6:8452424	G/A	cg07606381	chr6:8435919	SLC35B3	0.53	5.02	0.41	1.79e-6	Motion sickness;
TGCT	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg16680214	chr1:154839983	KCNN3	0.27	5.08	0.41	1.37e-6	Prostate cancer;
TGCT	cis	rs981844	0.714	rs2405202	chr4:154705132	A/G	cg14289246	chr4:154710475	SFRP2	-0.92	-8.41	-0.6	8.38e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs4566357	0.964	rs2396443	chr2:227921208	A/G	cg11843606	chr2:227700838	RHBDD1	-0.58	-5.31	-0.43	4.92e-7	Coronary artery disease;
TGCT	cis	rs3820928	1.000	rs9288617	chr2:227762815	G/C	cg11843606	chr2:227700838	RHBDD1	-0.53	-4.68	-0.39	7.31e-6	Pulmonary function;
TGCT	cis	rs9611565	0.512	rs5751147	chr22:42139054	G/A	cg17554472	chr22:41940697	POLR3H	0.46	4.72	0.39	6.36e-6	Vitiligo;
TGCT	cis	rs2404602	0.647	rs11072628	chr15:77107761	C/A	cg22467129	chr15:76604101	ETFA	0.48	4.7	0.39	6.7e-6	Blood metabolite levels;
TGCT	cis	rs3099143	0.901	rs76101229	chr15:77134975	C/T	cg21673338	chr15:77095150	SCAPER	-0.49	-4.49	-0.37	1.59e-5	Recalcitrant atopic dermatitis;
TGCT	cis	rs9811920	0.809	rs1387647	chr3:99826942	T/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.44	-4.81	-0.4	4.25e-6	Axial length;
TGCT	cis	rs1843834	0.858	rs2047136	chr2:225511361	A/T	cg22455342	chr2:225449267	CUL3	0.76	7.77	0.57	2.6e-12	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs3617	0.572	rs2256332	chr3:52855865	A/G	cg10802521	chr3:52805072	NEK4	0.6	6.95	0.53	1.88e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs62244186	0.566	rs55901755	chr3:44834707	C/T	cg11003573	chr3:44754125	ZNF502	-0.47	-5.44	-0.44	2.75e-7	Depressive symptoms;
TGCT	cis	rs986417	1.000	rs1254322	chr14:60906976	G/A	cg27398547	chr14:60952738	C14orf39	-1.42	-8.68	-0.61	1.89e-14	Gut microbiota (bacterial taxa);
TGCT	cis	rs2594989	0.673	rs9855241	chr3:11602910	C/T	cg00170343	chr3:11313890	ATG7	-0.69	-4.87	-0.4	3.28e-6	Circulating chemerin levels;
TGCT	cis	rs7647973	0.593	rs9870755	chr3:49809841	A/G	cg03060546	chr3:49711283	APEH	0.61	5.36	0.43	3.96e-7	Menarche (age at onset);
TGCT	cis	rs7647973	0.626	rs1586827	chr3:49671224	T/C	cg05785598	chr3:49045655	WDR6	0.42	5.24	0.43	6.67e-7	Menarche (age at onset);
TGCT	cis	rs2302464	1.000	rs16892272	chr4:15728079	C/G	cg18497811	chr4:14860861	NA	-0.49	-4.5	-0.37	1.57e-5	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs854765	0.547	rs7209003	chr17:17907393	T/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.78	8.3	0.6	1.53e-13	Total body bone mineral density;
TGCT	cis	rs6570726	0.755	rs451699	chr6:145830594	C/G	cg05347473	chr6:146136440	FBXO30	0.53	4.95	0.41	2.4e-6	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.8	-8.32	-0.6	1.31e-13	Body mass index;
TGCT	cis	rs1865760	0.865	rs1541987	chr6:25950397	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.62	-6.12	-0.48	1.12e-8	Height;
TGCT	cis	rs7267979	1.000	rs448396	chr20:25440269	G/A	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg06558623	chr16:89946397	TCF25	0.5	5.92	0.47	2.91e-8	Skin colour saturation;
TGCT	cis	rs992157	0.735	rs13393821	chr2:219076742	C/G	cg00012203	chr2:219082015	ARPC2	0.81	10.19	0.68	4.34e-18	Colorectal cancer;
TGCT	cis	rs7255045	0.752	rs11085822	chr19:12985576	A/G	cg06537894	chr19:12978706	MAST1	-0.49	-4.47	-0.37	1.73e-5	Mean corpuscular volume;
TGCT	cis	rs6460942	0.915	rs7809263	chr7:12450589	C/G	cg06484146	chr7:12443880	VWDE	-0.57	-5.52	-0.44	1.92e-7	Coronary artery disease;
TGCT	cis	rs7666738	0.546	rs28590002	chr4:98722642	C/T	cg05340658	chr4:99064831	C4orf37	0.51	5.68	0.45	9.1e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs854765	0.547	rs2955380	chr17:17944349	A/G	cg04398451	chr17:18023971	MYO15A	0.33	5.28	0.43	5.67e-7	Total body bone mineral density;
TGCT	cis	rs933688	0.818	rs10052492	chr5:90759930	T/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.98	9.34	0.64	4.9e-16	Smoking behavior;
TGCT	cis	rs9549260	0.753	rs9532563	chr13:41160270	T/C	cg21288729	chr13:41239152	FOXO1	0.69	4.85	0.4	3.56e-6	Red blood cell count;
TGCT	cis	rs910316	0.967	rs1071989	chr14:75564659	G/T	cg11812906	chr14:75593930	NEK9	0.74	7.25	0.55	3.9e-11	Height;
TGCT	cis	rs644799	0.965	rs10831425	chr11:95500628	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	11.41	0.72	4.75e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7095607	0.785	rs10997959	chr10:69916909	G/C	cg18986048	chr10:69913749	MYPN	0.42	4.77	0.39	5.13e-6	Lung function (FVC);
TGCT	cis	rs7937682	0.921	rs7130753	chr11:111470567	C/T	cg09085632	chr11:111637200	PPP2R1B	0.92	8.2	0.59	2.5e-13	Primary sclerosing cholangitis;
TGCT	cis	rs6987853	0.933	rs2974352	chr8:42408483	C/T	cg20539142	chr8:42623718	CHRNA6	-0.19	-4.63	-0.38	9.21e-6	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs12136530	0.806	rs7522676	chr1:19762660	T/C	cg18923740	chr1:19971790	NBL1	0.35	4.57	0.38	1.16e-5	Lead levels in blood;
TGCT	cis	rs7845219	0.544	rs7015841	chr8:95920193	A/C	cg16049864	chr8:95962084	TP53INP1	-0.48	-5.3	-0.43	5.23e-7	Type 2 diabetes;
TGCT	cis	rs9993613	0.875	rs4694125	chr4:73491873	G/A	cg15102770	chr4:73434591	ADAMTS3	0.51	4.7	0.39	6.79e-6	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs9325144	0.624	rs10783333	chr12:39118931	A/T	cg13010199	chr12:38710504	ALG10B	0.53	4.72	0.39	6.22e-6	Morning vs. evening chronotype;
TGCT	cis	rs12497850	0.931	rs7621015	chr3:49016056	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.42	-5.41	-0.44	3.09e-7	Parkinson's disease;
TGCT	cis	rs2075371	0.933	rs1868785	chr7:133945855	G/C	cg11752832	chr7:134001865	SLC35B4	0.7	6.0	0.47	2.04e-8	Mean platelet volume;
TGCT	cis	rs2006933	0.959	rs16964203	chr17:26582710	A/C	cg03094083	chr17:26864469	FOXN1	0.23	4.53	0.38	1.34e-5	Amyotrophic lateral sclerosis;
TGCT	cis	rs6500602	0.627	rs9934267	chr16:4534366	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	7.4	0.55	1.78e-11	Schizophrenia;
TGCT	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg22535103	chr8:58192502	C8orf71	-0.41	-5.24	-0.43	6.7e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs593982	0.925	rs603509	chr11:65507605	C/T	cg08755490	chr11:65554678	OVOL1	-1.19	-11.29	-0.71	9.28e-21	Atopic dermatitis;
TGCT	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg22920501	chr2:26401640	FAM59B	0.81	6.36	0.5	3.52e-9	Gut microbiome composition (summer);
TGCT	cis	rs34734847	1.000	rs35360964	chr12:121156290	T/C	cg21892295	chr12:121157589	UNC119B	-0.23	-5.63	-0.45	1.14e-7	Mean corpuscular volume;
TGCT	cis	rs11809207	0.723	rs57653638	chr1:26524401	A/G	cg03844060	chr1:26490628	NA	0.25	4.62	0.38	9.44e-6	Height;
TGCT	cis	rs11098499	0.908	rs9995234	chr4:120321827	A/G	cg09307838	chr4:120376055	NA	0.67	6.39	0.5	3.05e-9	Corneal astigmatism;
TGCT	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.33	-5.2	-0.42	7.9e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs5769765	0.773	rs138834	chr22:50180497	A/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.12	-9.53	-0.65	1.73e-16	Schizophrenia;
TGCT	cis	rs4234284	0.556	rs9968173	chr3:126965437	G/A	cg26312807	chr3:127057048	NA	-0.5	-4.6	-0.38	1.03e-5	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
TGCT	cis	rs425277	0.606	rs3128339	chr1:2046938	G/T	cg24578937	chr1:2090814	PRKCZ	-0.25	-5.99	-0.47	2.14e-8	Height;
TGCT	cis	rs62244186	0.659	rs9850129	chr3:44532047	C/T	cg10263370	chr3:44754102	ZNF502	-0.4	-4.8	-0.4	4.4e-6	Depressive symptoms;
TGCT	cis	rs2980439	0.525	rs2945238	chr8:8170136	A/C	cg06636001	chr8:8085503	FLJ10661	0.72	6.33	0.49	4.14e-9	Neuroticism;
TGCT	cis	rs9913156	0.793	rs72835642	chr17:4573407	T/C	cg00122941	chr17:4613640	ARRB2	0.88	7.51	0.56	1.03e-11	Lymphocyte counts;
TGCT	cis	rs854765	0.927	rs12943914	chr17:17980671	A/G	cg04398451	chr17:18023971	MYO15A	-0.3	-4.72	-0.39	6.28e-6	Total body bone mineral density;
TGCT	cis	rs3806843	0.576	rs246045	chr5:140329884	C/T	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7707921	0.752	rs2897554	chr5:81276241	C/T	cg15871215	chr5:81402204	ATG10	0.29	5.07	0.41	1.39e-6	Breast cancer;
TGCT	trans	rs4262150	0.544	rs17549488	chr5:151917354	C/A	cg26032021	chr14:54804413	NA	0.39	6.64	0.51	8.72e-10	Bipolar disorder and schizophrenia;
TGCT	cis	rs2017387	0.572	rs157546	chr19:50525126	G/A	cg19230443	chr19:49950584	PIH1D1	-0.29	-4.69	-0.39	7.22e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
TGCT	cis	rs17384381	0.859	rs12724823	chr1:85906385	G/T	cg16011679	chr1:85725395	C1orf52	0.84	6.87	0.52	2.83e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6450176	1.000	rs6886510	chr5:53303127	A/G	ch.5.1024479R	chr5:53302184	ARL15	0.55	5.37	0.43	3.68e-7	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs10782582	0.609	rs5745469	chr1:76347394	G/A	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.52	4.53	0.38	1.37e-5	Daytime sleep phenotypes;
TGCT	cis	rs9534288	0.797	rs2404728	chr13:46581862	T/C	cg15192986	chr13:46630673	CPB2	-0.53	-7.62	-0.56	5.82e-12	Blood protein levels;
TGCT	cis	rs858239	0.670	rs6967526	chr7:23159241	C/A	cg05602783	chr7:23145260	KLHL7	-0.59	-4.94	-0.41	2.42e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg26116260	chr4:7069785	GRPEL1	1.0	9.12	0.63	1.72e-15	Monocyte percentage of white cells;
TGCT	cis	rs9419702	0.568	rs10782366	chr10:133557866	G/A	cg20568497	chr10:133558893	NA	0.47	5.04	0.41	1.63e-6	Survival in rectal cancer;
TGCT	cis	rs6430585	0.697	rs1050115	chr2:136511817	A/G	cg07169764	chr2:136633963	MCM6	1.2	11.43	0.72	4.14e-21	Corneal structure;
TGCT	cis	rs8017423	0.866	rs10184	chr14:90744672	G/A	cg04374321	chr14:90722782	PSMC1	-0.73	-6.84	-0.52	3.15e-10	Mortality in heart failure;
TGCT	cis	rs17387100	0.901	rs55808189	chr4:15983246	T/C	cg14577840	chr4:16257979	FLJ39653	0.5	4.85	0.4	3.56e-6	Suicide attempts in depression or bipolar disorder;
TGCT	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg15921436	chr17:44337874	NA	0.59	8.18	0.59	2.85e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs9467711	0.790	rs13198716	chr6:26582035	A/G	cg12315302	chr6:26189340	HIST1H4D	-0.99	-4.44	-0.37	1.93e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2836633	1.000	rs2836631	chr21:40065906	G/T	cg05519781	chr21:40033154	ERG	-0.55	-5.44	-0.44	2.74e-7	Coronary artery disease;
TGCT	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg01585852	chr22:24235823	MIF	-0.22	-4.68	-0.39	7.49e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	5.11	0.42	1.18e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs1577917	0.958	rs34230196	chr6:86526022	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-5.53	-0.44	1.82e-7	Response to antipsychotic treatment;
TGCT	cis	rs7772486	0.875	rs864390	chr6:146315035	G/T	cg23711669	chr6:146136114	FBXO30	0.82	8.84	0.62	7.71e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg19318889	chr4:1322082	MAEA	0.27	6.56	0.51	1.3e-9	Longevity;
TGCT	cis	rs9916302	0.706	rs801418	chr17:37457982	G/C	cg07936489	chr17:37558343	FBXL20	0.84	6.23	0.49	6.68e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs7552404	0.924	rs1251075	chr1:76190569	C/G	cg22875332	chr1:76189707	ACADM	0.73	9.16	0.64	1.34e-15	Blood metabolite levels;Acylcarnitine levels;
TGCT	trans	rs6561151	0.957	rs7995004	chr13:44478820	C/T	cg12856521	chr11:46389249	DGKZ	0.69	7.75	0.57	2.8e-12	Crohn's disease;
TGCT	cis	rs854624	0.892	rs1608206	chr17:34336836	G/A	cg02022384	chr17:34097390	MMP28	0.49	4.55	0.38	1.28e-5	Blood protein levels;
TGCT	cis	rs9902453	0.967	rs3813034	chr17:28524804	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	6.39	0.5	3.03e-9	Coffee consumption (cups per day);
TGCT	cis	rs7267979	0.586	rs1007707	chr20:25190598	A/G	cg03522245	chr20:25566470	NINL	0.5	5.24	0.43	6.66e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3751972	0.911	rs1157502	chr17:26250109	G/T	cg02948944	chr17:26242737	NA	0.51	7.15	0.54	6.43e-11	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs9443645	0.901	rs9343856	chr6:79678211	G/A	cg09184832	chr6:79620586	NA	-0.49	-5.29	-0.43	5.3e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs3752962	0.569	rs3803806	chr17:1940713	T/C	cg24156229	chr17:1948635	NA	-0.37	-7.07	-0.54	9.83e-11	Itch intensity from mosquito bite;
TGCT	cis	rs763121	0.853	rs6001175	chr22:39018334	T/C	cg06022373	chr22:39101656	GTPBP1	0.81	8.26	0.6	1.84e-13	Menopause (age at onset);
TGCT	cis	rs651907	0.535	rs13065944	chr3:101473088	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.87	10.21	0.68	3.89e-18	Colorectal cancer;
TGCT	cis	rs6690583	0.623	rs2083283	chr1:85439996	C/A	cg20280350	chr1:85513789	MCOLN3	-0.67	-4.5	-0.37	1.52e-5	Serum sulfate level;
TGCT	cis	rs7089973	0.604	rs7895830	chr10:116625776	A/G	cg03647239	chr10:116582469	FAM160B1	0.59	5.61	0.45	1.26e-7	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs9517320	0.534	rs4771306	chr13:99143661	T/C	cg07423050	chr13:99094983	FARP1	-0.29	-5.74	-0.46	6.86e-8	Longevity;
TGCT	cis	rs6746896	1.000	rs4619651	chr2:97416153	G/A	cg26085987	chr2:97230376	NA	0.19	4.66	0.39	8.17e-6	Bipolar disorder;
TGCT	cis	rs9929218	0.953	rs3114411	chr16:68734591	G/T	cg01251360	chr16:68772225	CDH1	-0.31	-4.44	-0.37	1.96e-5	Colorectal cancer;
TGCT	cis	rs62244186	0.659	rs4682745	chr3:44508967	T/C	cg10263370	chr3:44754102	ZNF502	-0.39	-4.8	-0.4	4.41e-6	Depressive symptoms;
TGCT	cis	rs2692947	0.727	rs893173	chr2:96789787	T/C	cg23100626	chr2:96804247	ASTL	0.43	5.24	0.43	6.58e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs7513165	0.611	rs34729972	chr1:204159178	A/G	cg12731349	chr1:204159619	KISS1	0.54	5.87	0.47	3.77e-8	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
TGCT	cis	rs1008375	0.898	rs4698623	chr4:17594702	T/C	cg18681998	chr4:17616180	MED28	1.0	10.06	0.67	8.8e-18	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7017914	0.967	rs13254801	chr8:71688984	T/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.53	-4.98	-0.41	2.09e-6	Bone mineral density;
TGCT	cis	rs4642101	0.855	rs9836128	chr3:12845426	G/C	cg05775895	chr3:12838266	CAND2	0.73	7.24	0.55	4.1e-11	QRS complex (12-leadsum);
TGCT	cis	rs6969780	0.722	rs3823764	chr7:27187753	C/T	cg22997113	chr7:27170241	HOXA4	-0.44	-4.6	-0.38	1.05e-5	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs7100689	0.646	rs12253992	chr10:82158710	G/A	cg01528321	chr10:82214614	TSPAN14	0.73	7.73	0.57	3.25e-12	Post bronchodilator FEV1;
TGCT	cis	rs4711350	1.000	rs2395401	chr6:33759471	T/C	cg18005901	chr6:33739558	LEMD2	-0.55	-5.89	-0.47	3.38e-8	Schizophrenia;
TGCT	cis	rs240764	0.658	rs4840148	chr6:101182500	G/A	cg09795085	chr6:101329169	ASCC3	-0.51	-4.51	-0.38	1.48e-5	Neuroticism;
TGCT	cis	rs7267979	0.789	rs4815429	chr20:25521611	T/C	cg14121845	chr20:25566513	NINL	-0.46	-4.76	-0.39	5.36e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9399135	0.967	rs4451151	chr6:135310546	C/T	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.36e-6	Red blood cell count;
TGCT	cis	rs2456568	0.771	rs2102333	chr11:93634749	G/A	cg26875233	chr11:93583750	C11orf90	-0.48	-6.47	-0.5	2.07e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	5.05	0.41	1.51e-6	Menopause (age at onset);
TGCT	cis	rs1971762	0.504	rs1843318	chr12:53958077	C/T	cg16917193	chr12:54089295	NA	1.02	10.34	0.68	1.87e-18	Height;
TGCT	cis	rs2153535	0.601	rs7741024	chr6:8530313	T/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.01	0.41	1.86e-6	Motion sickness;
TGCT	cis	rs1129187	0.805	rs1053538	chr6:42903763	C/G	cg02353165	chr6:42928485	GNMT	0.69	6.07	0.48	1.43e-8	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg26116260	chr4:7069785	GRPEL1	-1.07	-10.78	-0.7	1.56e-19	Monocyte percentage of white cells;
TGCT	cis	rs8020441	0.541	rs67447434	chr14:51156101	G/A	cg04730355	chr14:51134070	SAV1	1.23	9.65	0.66	8.78e-17	Cognitive performance;
TGCT	cis	rs3771570	0.901	rs4675969	chr2:242217627	C/T	cg21155796	chr2:242212141	HDLBP	0.85	6.47	0.5	2.05e-9	Prostate cancer;
TGCT	cis	rs66561647	0.563	rs4733580	chr8:128932677	G/A	cg05480350	chr8:128972681	MIR1205;PVT1	0.22	4.6	0.38	1.01e-5	Hemoglobin concentration;
TGCT	cis	rs3540	1.000	rs7173724	chr15:91036855	A/G	cg22089800	chr15:90895588	ZNF774	0.78	7.92	0.58	1.15e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs9926296	0.712	rs2434872	chr16:89716915	C/G	cg27121462	chr16:89883253	FANCA	-0.55	-5.0	-0.41	1.93e-6	Vitiligo;
TGCT	cis	rs10875746	0.903	rs10875735	chr12:48463806	T/C	cg20731937	chr12:48336164	NA	0.62	4.95	0.41	2.36e-6	Longevity (90 years and older);
TGCT	cis	rs78456975	0.527	rs11884165	chr2:1561052	A/G	cg12573674	chr2:1569213	NA	-0.45	-4.76	-0.39	5.37e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs55794721	0.543	rs1293260	chr1:25709104	C/G	cg09222892	chr1:25734099	RHCE	-0.42	-6.69	-0.51	6.94e-10	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg17971929	chr21:40555470	PSMG1	-0.92	-8.25	-0.6	1.98e-13	Cognitive function;
TGCT	cis	rs10791323	0.628	rs2853117	chr11:133705266	T/G	cg15485101	chr11:133734466	NA	0.4	5.08	0.42	1.34e-6	Childhood ear infection;
TGCT	cis	rs3809566	0.654	rs4775606	chr15:63327605	A/G	cg08198488	chr15:63333792	TPM1	-0.35	-5.37	-0.43	3.81e-7	Platelet count;
TGCT	trans	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg13615516	chr5:77269221	NA	0.67	8.36	0.6	1.09e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2354432	0.556	rs2883319	chr1:146838177	A/G	cg25205988	chr1:146714368	CHD1L	-1.35	-5.81	-0.46	4.96e-8	Mitochondrial DNA levels;
TGCT	cis	rs7223966	1.000	rs1877316	chr17:61766880	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	4.61	0.38	1e-5	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs9916302	0.861	rs2338801	chr17:37490780	G/T	cg15445000	chr17:37608096	MED1	-0.33	-4.71	-0.39	6.46e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs11250097	0.506	rs13281992	chr8:11309294	C/T	cg01383082	chr8:11323474	FAM167A	0.33	4.92	0.4	2.73e-6	Neuroticism;
TGCT	cis	rs11676348	0.935	rs2230054	chr2:219000310	C/T	cg00012203	chr2:219082015	ARPC2	-0.5	-4.45	-0.37	1.88e-5	Ulcerative colitis;
TGCT	cis	rs9611565	0.879	rs5758307	chr22:41750219	A/G	cg06481639	chr22:41940642	POLR3H	-0.57	-4.93	-0.4	2.61e-6	Vitiligo;
TGCT	cis	rs7809950	0.817	rs2237671	chr7:107131528	A/T	cg23024343	chr7:107201750	COG5	-0.45	-6.69	-0.51	6.9e-10	Coronary artery disease;
TGCT	cis	rs1729951	0.575	rs1682357	chr3:136692009	G/A	cg21827317	chr3:136751795	NA	0.4	5.61	0.45	1.28e-7	Neuroticism;
TGCT	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg06238570	chr21:40685208	BRWD1	-0.62	-6.42	-0.5	2.58e-9	Menarche (age at onset);
TGCT	cis	rs137699	1.000	rs137699	chr22:39748854	A/G	cg11247378	chr22:39784982	NA	-0.44	-4.71	-0.39	6.48e-6	IgG glycosylation;
TGCT	cis	rs4689388	0.824	rs4467645	chr4:6294305	C/T	cg14416269	chr4:6271139	WFS1	0.37	4.9	0.4	2.95e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs9916302	0.904	rs679995	chr17:37441679	A/T	cg07936489	chr17:37558343	FBXL20	0.6	4.75	0.39	5.45e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs447921	0.773	rs11077821	chr17:74455579	C/T	cg09812376	chr17:74270190	QRICH2	-0.45	-4.5	-0.37	1.53e-5	Mitochondrial DNA levels;
TGCT	cis	rs7107174	0.681	rs881337	chr11:78128335	G/C	cg12700464	chr11:78128424	GAB2	-0.67	-4.46	-0.37	1.83e-5	Testicular germ cell tumor;
TGCT	cis	rs9325144	0.556	rs34565156	chr12:39028239	G/A	cg10518543	chr12:38710700	ALG10B	-0.51	-4.84	-0.4	3.83e-6	Morning vs. evening chronotype;
TGCT	cis	rs10791323	0.569	rs10791335	chr11:133739571	A/T	cg03690763	chr11:133734501	NA	-0.28	-4.76	-0.39	5.32e-6	Childhood ear infection;
TGCT	cis	rs6582630	0.519	rs12582285	chr12:38298753	C/T	cg26384229	chr12:38710491	ALG10B	0.8	7.04	0.53	1.17e-10	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs2228638	0.816	rs2269094	chr10:33528486	T/C	cg08604594	chr10:33798231	NA	-0.38	-4.81	-0.4	4.23e-6	Tetralogy of Fallot;
TGCT	cis	rs288326	0.561	rs17703779	chr2:183895919	C/T	cg09997497	chr2:183902928	NCKAP1	1.11	4.95	0.41	2.38e-6	Blood protein levels;
TGCT	cis	rs853679	0.527	rs213228	chr6:28331252	A/C	cg18815343	chr6:28367644	ZSCAN12	-0.5	-5.01	-0.41	1.81e-6	Depression;
TGCT	cis	rs9372498	0.536	rs72952733	chr6:118834452	A/G	cg07617317	chr6:118971624	C6orf204	0.51	5.42	0.44	3e-7	Diastolic blood pressure;
TGCT	cis	rs3771570	0.901	rs35496488	chr2:242434316	G/A	cg21155796	chr2:242212141	HDLBP	0.92	6.63	0.51	9.25e-10	Prostate cancer;
TGCT	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg21724239	chr8:58056113	NA	0.39	4.59	0.38	1.07e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs4820539	1.000	rs885964	chr22:23461003	G/C	cg21100191	chr22:23484243	RTDR1	0.91	10.67	0.69	2.9e-19	Bone mineral density;
TGCT	cis	rs858239	0.537	rs10279691	chr7:23228387	A/G	cg05602783	chr7:23145260	KLHL7	-0.71	-5.5	-0.44	2.12e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs2120019	1.000	rs7162900	chr15:75368017	T/C	cg17294928	chr15:75287854	SCAMP5	-0.85	-6.5	-0.5	1.78e-9	Blood trace element (Zn levels);
TGCT	cis	rs2797160	1.000	rs1739348	chr6:126014573	T/C	cg05901451	chr6:126070800	HEY2	0.73	6.29	0.49	5.01e-9	Endometrial cancer;
TGCT	cis	rs2760061	0.626	rs591582	chr1:228117360	C/A	cg18477163	chr1:228402036	OBSCN	-0.32	-6.35	-0.5	3.71e-9	Diastolic blood pressure;
TGCT	cis	rs6088580	0.634	rs6059779	chr20:32950325	C/T	cg06115741	chr20:33292138	TP53INP2	-0.55	-4.8	-0.4	4.5e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs739496	0.579	rs12319315	chr12:112341019	A/C	cg10833066	chr12:111807467	FAM109A	0.38	4.94	0.41	2.51e-6	Platelet count;
TGCT	cis	rs1519814	0.616	rs28885745	chr8:121012458	T/C	cg22335954	chr8:121166405	COL14A1	-0.36	-4.52	-0.38	1.44e-5	Breast cancer;
TGCT	trans	rs8073060	0.586	rs225256	chr17:33955756	C/T	cg19694781	chr19:47549865	TMEM160	-0.6	-13.37	-0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs12497850	1.000	rs6788650	chr3:48749543	T/C	cg07636037	chr3:49044803	WDR6	0.92	10.34	0.68	1.91e-18	Parkinson's disease;
TGCT	cis	rs9322193	0.884	rs11155675	chr6:150064019	T/C	cg13206674	chr6:150067644	NUP43	0.52	4.51	0.38	1.46e-5	Lung cancer;
TGCT	cis	rs9291683	0.679	rs3756225	chr4:10094133	G/C	cg11266682	chr4:10021025	SLC2A9	-0.51	-6.16	-0.48	9.39e-9	Bone mineral density;
TGCT	cis	rs950776	0.518	rs4886572	chr15:78837452	A/G	cg06917634	chr15:78832804	PSMA4	-0.93	-9.08	-0.63	2.07e-15	Sudden cardiac arrest;
TGCT	cis	rs2677744	0.719	rs2106673	chr15:91452595	A/G	cg22570213	chr15:91497863	RCCD1	0.39	4.52	0.38	1.41e-5	Attention deficit hyperactivity disorder;
TGCT	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg18230493	chr5:56204884	C5orf35	-0.68	-5.92	-0.47	2.92e-8	Initial pursuit acceleration;
TGCT	cis	rs478607	1.000	rs478607	chr11:64478063	A/G	cg19395706	chr11:64412079	NRXN2	0.47	5.08	0.41	1.35e-6	Urate levels;
TGCT	trans	rs3780486	0.505	rs10813958	chr9:33165985	A/G	cg04842962	chr6:43655489	MRPS18A	0.81	8.89	0.62	6.14e-15	IgG glycosylation;
TGCT	cis	rs11030122	0.660	rs10835248	chr11:3910328	G/A	cg18678763	chr11:4115507	RRM1	-0.35	-4.45	-0.37	1.85e-5	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs10488031	0.557	rs71539815	chr7:37111356	C/T	cg06458904	chr7:36312573	EEPD1	0.58	4.8	0.4	4.49e-6	QT interval;
TGCT	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg11764359	chr7:65958608	NA	0.61	5.53	0.44	1.79e-7	Aortic root size;
TGCT	cis	rs7552404	0.731	rs5745458	chr1:76345429	G/A	cg03433033	chr1:76189801	ACADM	-0.76	-7.76	-0.57	2.66e-12	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg20203395	chr5:56204925	C5orf35	-0.58	-4.94	-0.41	2.45e-6	Initial pursuit acceleration;
TGCT	cis	rs3733585	0.699	rs4621431	chr4:9947590	C/T	cg11266682	chr4:10021025	SLC2A9	-0.62	-8.11	-0.59	4.09e-13	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs9611519	0.780	rs2235849	chr22:41653540	T/G	cg13695892	chr22:41940480	POLR3H	-0.62	-5.83	-0.46	4.54e-8	Neuroticism;
TGCT	cis	rs7000551	0.715	rs7828610	chr8:22307326	C/T	cg12081754	chr8:22256438	SLC39A14	0.33	5.48	0.44	2.26e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs7178572	0.568	rs8037561	chr15:77680462	A/G	cg22256960	chr15:77711686	NA	-0.88	-9.16	-0.64	1.32e-15	Type 2 diabetes;
TGCT	cis	rs9611565	0.918	rs4822024	chr22:41757647	G/A	cg03806693	chr22:41940476	POLR3H	-1.13	-12.32	-0.74	2.89e-23	Vitiligo;
TGCT	cis	rs4927850	0.666	rs4927853	chr3:195752053	G/C	cg12923728	chr3:195709715	SDHAP1	-0.37	-6.5	-0.5	1.78e-9	Pancreatic cancer;
TGCT	cis	rs4711350	0.862	rs688209	chr6:33700376	G/T	cg18005901	chr6:33739558	LEMD2	-0.45	-4.81	-0.4	4.3e-6	Schizophrenia;
TGCT	cis	rs78707713	0.560	rs61848397	chr10:71225584	C/A	cg14388049	chr10:71211838	TSPAN15	-0.39	-4.68	-0.39	7.52e-6	Venous thromboembolism;
TGCT	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg10560079	chr2:191398806	TMEM194B	0.37	5.33	0.43	4.5e-7	Pulse pressure;
TGCT	cis	rs1499614	1.000	rs2707828	chr7:66171377	G/A	cg18252515	chr7:66147081	NA	-1.26	-7.95	-0.58	9.71e-13	Gout;
TGCT	trans	rs854624	0.681	rs79694259	chr17:34328890	C/T	cg25044186	chr6:170494475	NA	0.75	6.73	0.52	5.7e-10	Blood protein levels;
TGCT	cis	rs317689	0.718	rs645026	chr12:69757931	G/A	cg14784868	chr12:69753453	YEATS4	0.55	4.68	0.39	7.24e-6	Response to diuretic therapy;
TGCT	cis	rs7843479	0.965	rs11785657	chr8:21859485	G/A	cg17168535	chr8:21777572	XPO7	0.64	5.82	0.46	4.81e-8	Mean corpuscular volume;
TGCT	cis	rs921968	0.643	rs484085	chr2:219396684	C/T	cg02176678	chr2:219576539	TTLL4	0.44	6.33	0.49	4.17e-9	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs7523273	0.505	rs35438924	chr1:207881489	T/G	cg22525895	chr1:207977042	MIR29B2	0.29	4.48	0.37	1.69e-5	Schizophrenia;
TGCT	cis	rs17293817	0.650	rs12778422	chr10:1413776	A/G	cg05483559	chr10:1416597	ADARB2	0.25	4.45	0.37	1.89e-5	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs3772130	0.962	rs6791046	chr3:121394707	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.55	4.98	0.41	2.09e-6	Cognitive performance;
TGCT	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg24549020	chr5:56110836	MAP3K1	0.67	5.78	0.46	5.74e-8	Initial pursuit acceleration;
TGCT	cis	rs1372520	0.684	rs10008964	chr4:90744721	G/A	cg15133208	chr4:90757351	SNCA	-0.49	-5.69	-0.45	8.67e-8	Neuroticism;
TGCT	cis	rs4149423	1.000	rs4149423	chr2:108916044	A/G	cg25838818	chr2:108905173	SULT1C2	-0.42	-7.16	-0.54	6.16e-11	Lobe size;
TGCT	cis	rs6840360	0.642	rs2724567	chr4:152351160	C/T	cg17479576	chr4:152424074	FAM160A1	0.57	6.07	0.48	1.46e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg16680214	chr1:154839983	KCNN3	-0.36	-7.33	-0.55	2.59e-11	Prostate cancer;
TGCT	cis	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg02503808	chr4:7069936	GRPEL1	1.0	9.53	0.65	1.77e-16	Monocyte percentage of white cells;
TGCT	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg04414720	chr1:150670196	GOLPH3L	0.39	5.04	0.41	1.59e-6	Tonsillectomy;
TGCT	cis	rs7147624	1.000	rs2411354	chr14:66062132	T/C	cg03016385	chr14:66212404	NA	-0.49	-7.08	-0.54	9.33e-11	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs7772486	0.806	rs2253648	chr6:146199296	G/A	cg05347473	chr6:146136440	FBXO30	0.55	5.21	0.42	7.53e-7	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg06636001	chr8:8085503	FLJ10661	-0.77	-7.05	-0.53	1.11e-10	Retinal vascular caliber;
TGCT	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg03609598	chr5:56110824	MAP3K1	-0.56	-4.57	-0.38	1.14e-5	Initial pursuit acceleration;
TGCT	cis	rs7940866	0.834	rs7939417	chr11:130853832	T/A	cg05962950	chr11:130786565	SNX19	0.71	6.9	0.53	2.33e-10	Schizophrenia;
TGCT	cis	rs1568889	1.000	rs11603799	chr11:28196488	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.81	8.17	0.59	3.04e-13	Bipolar disorder;
TGCT	cis	rs1453308	0.938	rs1453307	chr2:237186698	G/A	cg19324714	chr2:237145437	ASB18	0.57	5.08	0.41	1.37e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs2153535	0.580	rs5001322	chr6:8451608	A/G	cg07606381	chr6:8435919	SLC35B3	0.53	5.02	0.41	1.79e-6	Motion sickness;
TGCT	cis	rs68170813	0.559	rs77829121	chr7:106968470	A/G	cg02696742	chr7:106810147	HBP1	-0.7	-5.85	-0.47	4.03e-8	Coronary artery disease;
TGCT	cis	rs8016982	0.963	rs2099108	chr14:81675420	C/G	cg01989461	chr14:81687754	GTF2A1	0.62	5.27	0.43	5.83e-7	Schizophrenia;
TGCT	cis	rs2836974	0.800	rs73221174	chr21:40540939	T/C	cg17971929	chr21:40555470	PSMG1	0.93	8.54	0.61	3.97e-14	Cognitive function;
TGCT	cis	rs2820315	0.964	rs2820311	chr1:201841476	A/G	cg12730843	chr1:201915899	LMOD1	-0.26	-4.71	-0.39	6.53e-6	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
TGCT	cis	rs36051895	0.589	rs16922786	chr9:5200714	A/G	cg02405213	chr9:5042618	JAK2	-0.73	-9.54	-0.65	1.67e-16	Pediatric autoimmune diseases;
TGCT	cis	rs6089584	0.893	rs6089305	chr20:60571817	T/C	cg13770153	chr20:60521292	NA	-0.54	-7.28	-0.55	3.32e-11	Body mass index;
TGCT	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg21724239	chr8:58056113	NA	0.42	5.04	0.41	1.59e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1215050	0.791	rs260890	chr4:98741698	A/G	cg05340658	chr4:99064831	C4orf37	0.42	5.14	0.42	1.04e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7647973	1.000	rs3905330	chr3:49550774	A/G	cg07636037	chr3:49044803	WDR6	0.6	4.96	0.41	2.22e-6	Menarche (age at onset);
TGCT	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg24829409	chr8:58192753	C8orf71	-0.54	-4.69	-0.39	7.17e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg12310025	chr6:25882481	NA	-0.62	-6.42	-0.5	2.62e-9	Blood metabolite levels;
TGCT	cis	rs1670533	1.000	rs4690215	chr4:1054619	G/C	cg27284194	chr4:1044797	NA	0.67	5.79	0.46	5.37e-8	Recombination rate (females);
TGCT	cis	rs79976124	0.879	rs12214948	chr6:66633603	G/A	cg07460842	chr6:66804631	NA	0.57	5.18	0.42	8.76e-7	Type 2 diabetes;
TGCT	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg17971929	chr21:40555470	PSMG1	0.97	9.52	0.65	1.86e-16	Cognitive function;
TGCT	cis	rs9457247	1.000	rs1819333	chr6:167373547	G/T	cg23791538	chr6:167370224	RNASET2	-0.51	-5.12	-0.42	1.15e-6	Crohn's disease;
TGCT	cis	rs1468333	0.724	rs7726580	chr5:137608666	A/G	cg27119451	chr5:137514611	BRD8;KIF20A	-0.46	-4.45	-0.37	1.91e-5	Resting heart rate;
TGCT	cis	rs11894932	0.848	rs6711099	chr2:99232873	C/T	cg27446566	chr2:99952965	EIF5B;TXNDC9	0.67	4.57	0.38	1.16e-5	Left ventricular obstructive tract defect (inherited effect);
TGCT	cis	rs826838	1.000	rs7299124	chr12:39002661	T/C	cg26384229	chr12:38710491	ALG10B	1.04	10.21	0.68	4.01e-18	Heart rate;
TGCT	cis	rs4722166	0.597	rs2069845	chr7:22770149	G/A	cg26061582	chr7:22766209	IL6	0.58	7.53	0.56	8.97e-12	Lung cancer;
TGCT	cis	rs1865760	0.613	rs2071300	chr6:25914572	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.62	6.63	0.51	9.14e-10	Height;
TGCT	cis	rs514406	0.607	rs6696940	chr1:53203427	C/T	cg22166914	chr1:53195759	ZYG11B	-0.49	-9.15	-0.63	1.43e-15	Monocyte count;
TGCT	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg27454412	chr7:1067447	C7orf50	0.6	4.72	0.39	6.32e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	trans	rs561341	1.000	rs510264	chr17:30323414	A/G	cg20587970	chr11:113659929	NA	-1.04	-12.57	-0.75	6.97e-24	Hip circumference adjusted for BMI;
TGCT	cis	rs707040	1.000	rs707040	chr2:155226677	C/T	cg18104148	chr2:154337490	NA	0.18	4.44	0.37	1.95e-5	Sudden cardiac arrest;
TGCT	cis	rs11650494	0.908	rs9907478	chr17:47395729	C/T	cg08112188	chr17:47440006	ZNF652	0.98	5.33	0.43	4.57e-7	Prostate cancer;
TGCT	cis	rs11190604	0.767	rs77769532	chr10:102193646	T/C	cg16342193	chr10:102329863	NA	-0.41	-5.2	-0.42	8.01e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7819412	0.745	rs28591576	chr8:11080675	C/T	cg21775007	chr8:11205619	TDH	-0.56	-5.15	-0.42	9.93e-7	Triglycerides;
TGCT	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg03188948	chr7:1209495	NA	0.68	5.8	0.46	5.09e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.51	-4.82	-0.4	4.16e-6	Bipolar disorder;
TGCT	cis	rs2013441	0.711	rs1682297	chr17:20384920	C/T	cg23224458	chr17:20280056	CCDC144C	0.38	4.66	0.39	8.02e-6	Obesity-related traits;
TGCT	cis	rs12765878	1.000	rs7100920	chr10:105640978	A/G	cg11005552	chr10:105648138	OBFC1	-0.4	-6.95	-0.53	1.88e-10	Coronary artery disease;
TGCT	cis	rs56235845	0.694	rs6876677	chr5:176755342	T/C	cg06060754	chr5:176797920	RGS14	0.39	6.22	0.49	7.05e-9	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs6495122	0.651	rs11636952	chr15:75114322	T/C	cg10253484	chr15:75165896	SCAMP2	-0.66	-5.62	-0.45	1.19e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
TGCT	cis	rs6545883	0.929	rs1209434	chr2:61672958	G/A	cg15711740	chr2:61764176	XPO1	-0.51	-4.57	-0.38	1.15e-5	Tuberculosis;
TGCT	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg14893161	chr1:205819251	PM20D1	-0.47	-5.17	-0.42	9.03e-7	Parkinson's disease;
TGCT	cis	rs6988636	1.000	rs4282551	chr8:124185916	G/A	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs17387100	1.000	rs73230286	chr4:15993149	A/C	cg13480465	chr4:16795757	LDB2	-0.41	-4.66	-0.39	8e-6	Suicide attempts in depression or bipolar disorder;
TGCT	cis	rs73198271	0.729	rs11786474	chr8:8605492	T/C	ch.8.214553F	chr8:8189620	PRAGMIN	-0.27	-4.7	-0.39	6.66e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs546131	0.928	rs552171	chr11:34830709	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.58	5.06	0.41	1.46e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs7267979	1.000	rs6050629	chr20:25430680	G/A	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9303401	0.659	rs17822807	chr17:56687190	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs9217	0.841	rs56226499	chr17:7398223	C/T	cg17892169	chr17:7452644	TNFSF12;TNFSF12-TNFSF13	-0.23	-4.44	-0.37	1.99e-5	Height;
TGCT	cis	rs4824093	0.610	rs73443923	chr22:50285348	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.46	4.52	0.38	1.4e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs1629083	0.905	rs17121882	chr11:118081468	C/T	cg16594165	chr11:118135105	MPZL2	-0.33	-4.59	-0.38	1.09e-5	Lung cancer;
TGCT	cis	rs860554	0.640	rs2268150	chr1:201257838	G/A	cg01022117	chr1:201258280	PKP1	-0.36	-6.91	-0.53	2.27e-10	Panic disorder;
TGCT	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg00684032	chr4:1343700	KIAA1530	0.23	4.93	0.4	2.58e-6	Obesity-related traits;
TGCT	cis	rs7017914	0.967	rs10448014	chr8:71688165	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.53	-4.98	-0.41	2.09e-6	Bone mineral density;
TGCT	cis	rs2243480	1.000	rs316307	chr7:65570171	C/T	cg20637647	chr7:64974828	NA	0.86	4.93	0.4	2.58e-6	Diabetic kidney disease;
TGCT	cis	rs3096299	0.658	rs34590044	chr16:89543157	A/C	cg08392591	chr16:89556376	ANKRD11	0.56	5.33	0.43	4.39e-7	Multiple myeloma (IgH translocation);
TGCT	cis	rs57994353	0.760	rs4413892	chr9:139330158	G/A	cg13741927	chr9:139327495	INPP5E	-0.27	-6.41	-0.5	2.72e-9	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs9916302	0.851	rs11078907	chr17:37662954	C/T	cg07936489	chr17:37558343	FBXL20	-0.62	-4.91	-0.4	2.85e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs12497850	0.863	rs4974084	chr3:48939080	G/A	cg07636037	chr3:49044803	WDR6	0.95	9.97	0.67	1.53e-17	Parkinson's disease;
TGCT	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg20607798	chr8:58055168	NA	0.5	4.66	0.39	8.04e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9916302	0.904	rs602282	chr17:37433021	C/T	cg15445000	chr17:37608096	MED1	0.33	4.81	0.4	4.3e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.63	0.38	9.2e-6	Prudent dietary pattern;
TGCT	cis	rs35883536	0.967	rs2783689	chr1:101092411	C/G	cg06223162	chr1:101003688	GPR88	-0.3	-4.96	-0.41	2.28e-6	Monocyte count;
TGCT	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.5	-4.8	-0.4	4.55e-6	Prudent dietary pattern;
TGCT	cis	rs17221829	0.733	rs12281810	chr11:89409595	C/T	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.44	-0.37	1.96e-5	Anxiety in major depressive disorder;
TGCT	cis	rs3784262	0.669	rs4646609	chr15:58274989	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.41	-5.82	-0.46	4.72e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs3749237	1.000	rs11710675	chr3:49751900	C/A	cg07636037	chr3:49044803	WDR6	0.63	5.5	0.44	2.08e-7	Resting heart rate;
TGCT	cis	rs2268241	0.938	rs9974603	chr21:34776300	C/A	cg14850771	chr21:34775459	IFNGR2	0.63	5.34	0.43	4.3e-7	Obesity-related traits;
TGCT	cis	rs2836633	0.929	rs11702165	chr21:40035313	C/T	cg05519781	chr21:40033154	ERG	0.7	6.95	0.53	1.86e-10	Coronary artery disease;
TGCT	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.93	7.44	0.56	1.44e-11	Platelet count;
TGCT	cis	rs9303401	0.614	rs2007993	chr17:56590643	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs1018836	0.786	rs7016220	chr8:91606848	A/G	cg16814680	chr8:91681699	NA	-0.71	-7.25	-0.55	3.89e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs3820068	0.608	rs10927831	chr1:16028373	T/G	cg17385448	chr1:15911702	AGMAT	0.34	4.78	0.39	4.97e-6	Systolic blood pressure;
TGCT	cis	rs2439831	0.867	rs2412779	chr15:43655927	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	8.65	0.61	2.26e-14	Lung cancer in ever smokers;
TGCT	cis	rs1371867	0.846	rs1788199	chr8:101292854	A/G	cg00191853	chr8:101177733	SPAG1	-0.22	-4.47	-0.37	1.75e-5	Atrioventricular conduction;
TGCT	cis	rs17293817	0.588	rs17221652	chr10:1416472	C/G	cg05336292	chr10:466338	DIP2C	-0.19	-4.46	-0.37	1.83e-5	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg23758822	chr17:41437982	NA	0.72	6.96	0.53	1.79e-10	Menopause (age at onset);
TGCT	trans	rs2727020	0.617	rs7102702	chr11:49401125	T/G	cg15704280	chr7:45808275	SEPT13	-0.65	-6.71	-0.52	6.25e-10	Coronary artery disease;
TGCT	cis	rs67311347	0.544	rs6769627	chr3:40327845	G/A	cg13683864	chr3:40499215	RPL14	-0.77	-7.15	-0.54	6.65e-11	Renal cell carcinoma;
TGCT	cis	rs9457247	1.000	rs408918	chr6:167399282	G/T	cg23791538	chr6:167370224	RNASET2	-0.49	-4.92	-0.4	2.7e-6	Crohn's disease;
TGCT	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7267979	1.000	rs2387881	chr20:25378172	A/G	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7258465	1.000	rs3810429	chr19:18543270	G/T	cg06462663	chr19:18546047	ISYNA1	0.2	4.54	0.38	1.33e-5	Breast cancer;
TGCT	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg26354017	chr1:205819088	PM20D1	0.58	7.1	0.54	8.46e-11	Menarche (age at onset);
TGCT	cis	rs9457247	0.967	rs1590257	chr6:167377782	G/T	cg23791538	chr6:167370224	RNASET2	0.5	4.98	0.41	2.06e-6	Crohn's disease;
TGCT	cis	rs595982	0.527	rs55670257	chr19:49382654	G/A	cg21252483	chr19:49399788	TULP2	-0.46	-7.03	-0.53	1.25e-10	Red cell distribution width;
TGCT	cis	rs6582630	0.538	rs7971292	chr12:38498151	A/G	cg26384229	chr12:38710491	ALG10B	-0.55	-4.91	-0.4	2.86e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs1008375	0.932	rs11941874	chr4:17666416	C/T	cg16339924	chr4:17578868	LAP3	-0.6	-4.91	-0.4	2.76e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg09365446	chr1:150670422	GOLPH3L	0.31	4.64	0.38	8.7e-6	Tonsillectomy;
TGCT	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg20607798	chr8:58055168	NA	0.5	4.66	0.39	8.04e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs319204	1.000	rs319232	chr5:146241598	C/T	cg25021259	chr5:146258546	PPP2R2B	0.36	4.53	0.38	1.37e-5	Schizophrenia;
TGCT	cis	rs11577318	0.853	rs11247913	chr1:26648551	G/C	cg12733254	chr1:26682999	NA	-0.21	-4.51	-0.38	1.46e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs7666738	0.830	rs17484890	chr4:99013778	T/C	cg17366294	chr4:99064904	C4orf37	0.67	6.97	0.53	1.69e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7731657	0.537	rs10073388	chr5:130188080	C/T	cg08523029	chr5:130500466	HINT1	-0.55	-4.57	-0.38	1.15e-5	Fasting plasma glucose;
TGCT	cis	rs3858526	0.920	rs11039548	chr11:5930283	G/A	cg13902645	chr11:5959945	NA	-0.44	-4.8	-0.4	4.54e-6	DNA methylation (variation);
TGCT	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg13683864	chr3:40499215	RPL14	-1.19	-13.2	-0.76	2.17e-25	Renal cell carcinoma;
TGCT	cis	rs8111998	0.826	rs4932774	chr19:22766593	G/T	cg19914732	chr19:22715077	NA	-0.56	-4.51	-0.38	1.46e-5	Corneal structure;
TGCT	cis	rs4629710	0.592	rs13206776	chr6:131576679	T/G	cg12606694	chr6:131520996	AKAP7	0.4	4.74	0.39	5.82e-6	Multiple myeloma (IgH translocation);
TGCT	cis	rs986417	1.000	rs1254254	chr14:60831146	G/A	cg27398547	chr14:60952738	C14orf39	-1.36	-8.75	-0.62	1.28e-14	Gut microbiota (bacterial taxa);
TGCT	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg22920501	chr2:26401640	FAM59B	-0.73	-6.44	-0.5	2.36e-9	Gut microbiome composition (summer);
TGCT	cis	rs4919044	0.808	rs835277	chr10:94809677	T/C	cg05127821	chr10:94822908	CYP26C1	-0.74	-4.83	-0.4	3.95e-6	Coronary artery disease;
TGCT	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg24060327	chr5:131705240	SLC22A5	0.6	6.19	0.49	7.99e-9	Acylcarnitine levels;
TGCT	cis	rs79149102	0.579	rs12591175	chr15:75356073	C/T	cg09165964	chr15:75287851	SCAMP5	-1.15	-6.31	-0.49	4.4e-9	Lung cancer;
TGCT	cis	rs7666738	0.753	rs7698541	chr4:98986351	T/A	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.46	-6.68	-0.51	7.22e-10	Alzheimer's disease;
TGCT	cis	rs17102423	0.594	rs1256417	chr14:65563678	C/T	cg11161011	chr14:65562177	MAX	-0.47	-6.42	-0.5	2.57e-9	Obesity-related traits;
TGCT	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg22535103	chr8:58192502	C8orf71	-0.42	-4.72	-0.39	6.22e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6831352	0.760	rs1311616	chr4:100012303	T/G	cg12011299	chr4:100065546	ADH4	0.4	4.76	0.39	5.33e-6	Alcohol dependence;
TGCT	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg16423285	chr20:60520624	NA	-0.6	-6.41	-0.5	2.76e-9	Body mass index;
TGCT	cis	rs16867321	0.950	rs4667228	chr2:181498824	T/A	cg23363182	chr2:181467187	NA	-0.38	-5.55	-0.45	1.62e-7	Obesity;
TGCT	cis	rs9660180	0.836	rs12038134	chr1:1703865	T/A	cg17747265	chr1:1875780	NA	-0.38	-7.18	-0.54	5.62e-11	Body mass index;
TGCT	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg11644478	chr21:40555479	PSMG1	-0.52	-4.84	-0.4	3.83e-6	Menarche (age at onset);
TGCT	cis	rs1797885	0.546	rs2454421	chr3:12601105	C/T	cg05775895	chr3:12838266	CAND2	0.5	4.86	0.4	3.41e-6	Immature fraction of reticulocytes;
TGCT	cis	rs6570726	0.935	rs430561	chr6:145813140	C/T	cg23711669	chr6:146136114	FBXO30	0.73	6.89	0.53	2.55e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs13191362	0.935	rs116735807	chr6:163010615	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs10206020	0.885	rs6720797	chr2:1574340	T/C	cg01028140	chr2:1542097	TPO	-0.28	-4.51	-0.38	1.47e-5	IgG glycosylation;
TGCT	cis	rs2455799	0.573	rs2470539	chr3:15717844	C/T	cg16303742	chr3:15540471	COLQ	-0.24	-4.81	-0.4	4.24e-6	Mean platelet volume;
TGCT	cis	rs1865760	0.929	rs9467646	chr6:25957408	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.65	6.2	0.49	7.73e-9	Height;
TGCT	cis	rs854765	0.583	rs950966	chr17:17783748	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.74	-7.98	-0.58	8.43e-13	Total body bone mineral density;
TGCT	cis	rs7312933	0.703	rs2406567	chr12:42551479	G/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	4.99	0.41	1.99e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs7666738	0.830	rs4699601	chr4:99034429	G/A	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6570726	0.755	rs2092297	chr6:145893765	A/G	cg05347473	chr6:146136440	FBXO30	0.52	4.95	0.41	2.33e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs644799	0.965	rs549695	chr11:95617788	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.74	7.66	0.57	4.71e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs11792861	0.816	rs7027263	chr9:111699569	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.53	5.0	0.41	1.88e-6	Menarche (age at onset);
TGCT	cis	rs9527	0.545	rs7915816	chr10:104881750	A/G	cg15744005	chr10:104629667	AS3MT	-0.43	-4.9	-0.4	2.89e-6	Arsenic metabolism;
TGCT	cis	rs858239	0.539	rs10280815	chr7:23188370	A/C	cg05602783	chr7:23145260	KLHL7	-0.62	-5.03	-0.41	1.67e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs986417	0.748	rs10142927	chr14:61041956	A/G	cg27398547	chr14:60952738	C14orf39	1.42	10.64	0.69	3.42e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs7568458	0.709	rs11895401	chr2:85753847	C/T	cg17127132	chr2:85788382	GGCX	0.51	4.73	0.39	5.89e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg08048268	chr3:133502702	NA	-0.66	-9.85	-0.66	2.89e-17	Iron status biomarkers;
TGCT	cis	rs1878931	0.501	rs9635563	chr16:3416940	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.76	7.12	0.54	7.59e-11	Body mass index (adult);
TGCT	cis	rs7552404	0.924	rs67757078	chr1:76169456	G/A	cg22875332	chr1:76189707	ACADM	0.78	9.74	0.66	5.53e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9905704	0.647	rs9898048	chr17:57108543	C/T	cg05425664	chr17:57184151	TRIM37	-0.68	-5.61	-0.45	1.25e-7	Testicular germ cell tumor;
TGCT	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg00343986	chr7:65444356	GUSB	0.23	5.14	0.42	1.06e-6	Aortic root size;
TGCT	cis	rs6939532	0.522	rs9366652	chr6:26354219	C/G	cg05738196	chr6:26577821	NA	-0.52	-5.02	-0.41	1.73e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg20203395	chr5:56204925	C5orf35	-0.55	-4.89	-0.4	3.03e-6	Coronary artery disease;
TGCT	cis	rs7772486	0.754	rs1415747	chr6:146077249	A/G	cg23711669	chr6:146136114	FBXO30	0.93	10.78	0.7	1.61e-19	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs651907	0.557	rs11914318	chr3:101453858	C/T	cg12386194	chr3:101231763	SENP7	0.48	4.63	0.38	9.23e-6	Colorectal cancer;
TGCT	cis	rs9611565	0.512	rs2899347	chr22:42158204	T/C	cg13695892	chr22:41940480	POLR3H	0.87	8.24	0.59	2.06e-13	Vitiligo;
TGCT	cis	rs4776059	1.000	rs3751614	chr15:52901638	T/C	cg25063058	chr15:52860530	ARPP19	0.52	4.73	0.39	6.01e-6	Schizophrenia;
TGCT	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs13177918	0.559	rs12109637	chr5:149834718	G/T	cg14059543	chr5:149831962	NA	-0.62	-7.91	-0.58	1.19e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs950880	0.560	rs6733174	chr2:102929012	T/C	cg09003973	chr2:102972529	NA	-0.53	-4.69	-0.39	7.02e-6	Serum protein levels (sST2);
TGCT	cis	rs12497850	0.864	rs4521268	chr3:49137904	G/T	cg06212747	chr3:49208901	KLHDC8B	0.6	5.44	0.44	2.75e-7	Parkinson's disease;
TGCT	cis	rs7267979	0.966	rs2500433	chr20:25296335	A/G	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7666738	0.830	rs11942114	chr4:99066261	C/G	cg18180107	chr4:99064573	C4orf37	0.56	5.08	0.41	1.37e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10791097	0.694	rs4456262	chr11:130755813	C/T	cg12179176	chr11:130786555	SNX19	-0.84	-5.99	-0.47	2.07e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs4888262	0.545	rs7195499	chr16:74693973	C/G	cg01733217	chr16:74700730	RFWD3	0.73	7.3	0.55	3.08e-11	Testicular germ cell tumor;
TGCT	trans	rs1814175	0.817	rs28502006	chr11:50049930	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.26	-0.55	3.77e-11	Height;
TGCT	cis	rs7172809	0.573	rs17383078	chr15:77484746	C/T	cg22256960	chr15:77711686	NA	-0.49	-4.63	-0.38	9.01e-6	Glucose homeostasis traits;
TGCT	cis	rs155076	1.000	rs567166	chr13:21837519	T/C	cg11317459	chr13:21872234	NA	-1.42	-12.02	-0.73	1.53e-22	White matter hyperintensity burden;
TGCT	cis	rs7681440	0.904	rs2870029	chr4:90772057	G/T	cg14346243	chr4:90757452	SNCA	-0.57	-5.5	-0.44	2.04e-7	Dementia with Lewy bodies;
TGCT	cis	rs2554380	0.943	rs11636516	chr15:84361773	A/T	cg14598478	chr15:84363061	ADAMTSL3	-0.41	-4.46	-0.37	1.84e-5	Height;
TGCT	cis	rs62229266	0.682	rs11700546	chr21:37371139	A/C	cg08632701	chr21:37451849	NA	-0.15	-4.6	-0.38	1.03e-5	Mitral valve prolapse;
TGCT	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.7	-0.39	6.79e-6	Prudent dietary pattern;
TGCT	cis	rs1256061	0.630	rs1256030	chr14:64747170	A/G	cg21174375	chr14:64681225	SYNE2	0.21	4.5	0.37	1.55e-5	Hemoglobin concentration;Red blood cell count;Hematocrit;
TGCT	cis	rs6598955	0.670	rs6598942	chr1:26531034	C/T	cg01614726	chr1:26633154	UBXN11	0.48	4.52	0.38	1.44e-5	Obesity-related traits;
TGCT	cis	rs986417	1.000	rs6573313	chr14:60961299	A/G	cg27398547	chr14:60952738	C14orf39	1.49	10.81	0.7	1.38e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs6570726	0.935	rs384806	chr6:145814889	C/G	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg10117171	chr1:25599238	RHD	0.32	5.27	0.43	5.82e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg16680214	chr1:154839983	KCNN3	-0.36	-7.35	-0.55	2.36e-11	Prostate cancer;
TGCT	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.49	-4.76	-0.39	5.34e-6	Bipolar disorder;
TGCT	cis	rs3770081	1.000	rs1036554	chr2:86236099	G/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.1	-4.5	-0.37	1.52e-5	Facial emotion recognition (sad faces);
TGCT	cis	rs7248779	0.512	rs3848635	chr19:2410332	T/C	cg22729335	chr19:2427816	TIMM13	1.13	13.34	0.77	9.83e-26	Cortisol levels (saliva);
TGCT	cis	rs796364	0.760	rs56285751	chr2:200919836	C/T	cg17644776	chr2:200775616	C2orf69	-0.33	-5.0	-0.41	1.91e-6	Schizophrenia;
TGCT	cis	rs12902680	0.739	rs1402118	chr15:46392288	T/C	cg13605988	chr15:45421612	DUOX1;DUOXA1	0.32	4.45	0.37	1.87e-5	Neuroticism;
TGCT	cis	rs4076764	0.957	rs4443867	chr1:163434917	T/C	cg24596788	chr1:163392923	NA	-0.17	-4.75	-0.39	5.46e-6	Motion sickness;
TGCT	cis	rs4077468	1.000	rs4077469	chr1:205914885	C/T	cg24503407	chr1:205819492	PM20D1	-0.39	-4.59	-0.38	1.07e-5	Cystic fibrosis-related diabetes;
TGCT	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg18735214	chr6:43276756	CRIP3	-0.55	-4.83	-0.4	3.94e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs9733	0.596	rs17606613	chr1:150683015	C/T	cg09365446	chr1:150670422	GOLPH3L	0.3	4.52	0.38	1.4e-5	Tonsillectomy;
TGCT	cis	rs7584330	0.737	rs12469894	chr2:238365528	T/C	cg14458575	chr2:238380390	NA	0.51	8.14	0.59	3.53e-13	Prostate cancer;
TGCT	cis	rs151997	1.000	rs152854	chr5:50223206	G/A	cg06027927	chr5:50259733	NA	-0.48	-4.84	-0.4	3.72e-6	Callous-unemotional behaviour;
TGCT	cis	rs17401966	0.838	rs12132134	chr1:10378428	A/G	cg19773385	chr1:10388646	KIF1B	-0.24	-5.38	-0.44	3.56e-7	Hepatocellular carcinoma;
TGCT	cis	rs8054556	0.740	rs3924855	chr16:29954955	A/G	cg26859862	chr16:30389551	SEPT1	-0.56	-4.9	-0.4	2.91e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2230307	0.536	rs834164	chr1:100603948	A/C	cg24955406	chr1:100503596	HIAT1	-0.71	-4.75	-0.39	5.44e-6	Carotid intima media thickness;
TGCT	cis	rs931608	0.640	rs2082478	chr19:22539848	G/A	cg15554505	chr19:22123728	NA	-0.63	-4.57	-0.38	1.18e-5	Dental caries;Response to statins (LDL cholesterol change);
TGCT	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg22968622	chr17:43663579	NA	1.05	10.05	0.67	9.4e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs6964587	0.773	rs10488514	chr7:91951842	C/A	cg17063962	chr7:91808500	NA	0.84	8.33	0.6	1.29e-13	Breast cancer;
TGCT	cis	rs131777	0.547	rs131753	chr22:51022862	A/G	cg25309564	chr22:51001381	C22orf41	0.55	5.22	0.42	7.17e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs6693567	0.565	rs696617	chr1:150376311	G/T	cg09579323	chr1:150459698	TARS2	0.52	4.64	0.38	8.63e-6	Migraine;
TGCT	cis	rs7246657	0.941	rs67293224	chr19:37803248	C/T	cg18154014	chr19:37997991	ZNF793	0.91	6.29	0.49	5.01e-9	Coronary artery calcification;
TGCT	cis	rs1857353	1.000	rs1858631	chr1:75886523	G/C	cg11838876	chr1:75668600	SLC44A5	-0.51	-4.81	-0.4	4.23e-6	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs7772486	0.654	rs6928007	chr6:146074941	G/A	cg23711669	chr6:146136114	FBXO30	-0.88	-9.63	-0.65	1.01e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs12510870	0.599	rs1590116	chr4:74389830	A/C	cg05868023	chr4:75230803	EREG	0.56	5.07	0.41	1.42e-6	Iris color (b* coordinate);
TGCT	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg20607798	chr8:58055168	NA	0.45	4.66	0.39	7.88e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1847202	0.859	rs13079651	chr3:72922181	C/T	cg25664220	chr3:72788482	NA	-0.37	-4.79	-0.4	4.63e-6	Motion sickness;
TGCT	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg01448562	chr3:133502909	NA	-0.34	-6.9	-0.53	2.37e-10	Iron status biomarkers;
TGCT	cis	rs9372498	0.536	rs62424175	chr6:118797381	T/A	cg21191810	chr6:118973309	C6orf204	-0.37	-4.76	-0.39	5.36e-6	Diastolic blood pressure;
TGCT	cis	rs74544699	0.609	rs72855280	chr4:74835131	C/A	cg16072462	chr4:74847758	PF4	0.71	4.82	0.4	4.05e-6	Growth-regulated protein alpha levels;
TGCT	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.08	15.31	0.81	2.29e-30	Prudent dietary pattern;
TGCT	cis	rs1008375	1.000	rs10939738	chr4:17604295	G/C	cg16339924	chr4:17578868	LAP3	0.64	5.22	0.42	7.4e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs981844	0.696	rs17030349	chr4:154636039	C/T	cg14289246	chr4:154710475	SFRP2	0.94	7.38	0.55	1.99e-11	Response to statins (LDL cholesterol change);
TGCT	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.46	4.58	0.38	1.14e-5	Lymphocyte counts;
TGCT	cis	rs2070488	0.695	rs6599201	chr3:38476614	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.8	7.96	0.58	9.4e-13	Electrocardiographic conduction measures;
TGCT	cis	rs9379774	0.623	rs1876373	chr6:25442684	G/C	cg13320114	chr6:26216906	HIST1H2AE;HIST1H2BG	0.75	4.72	0.39	6.15e-6	Coronary artery disease;
TGCT	cis	rs7267979	0.738	rs2892409	chr20:25638138	C/T	cg21995068	chr20:25989032	LOC100134868	-0.44	-5.42	-0.44	2.94e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs644799	0.625	rs1255177	chr11:95471495	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.5	4.8	0.4	4.53e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs1008375	1.000	rs10939744	chr4:17664473	G/T	cg16339924	chr4:17578868	LAP3	0.55	4.73	0.39	5.96e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs838147	0.537	rs603985	chr19:49207257	T/C	cg04599840	chr19:48886497	KDELR1	0.22	4.58	0.38	1.14e-5	Dietary macronutrient intake;
TGCT	cis	rs4727027	0.754	rs917124	chr7:148851213	C/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.55	4.52	0.38	1.42e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs7959452	0.530	rs12811632	chr12:69755003	G/A	cg14784868	chr12:69753453	YEATS4	0.83	8.84	0.62	7.84e-15	Blood protein levels;
TGCT	cis	rs533581	0.873	rs555191	chr16:88978850	C/T	cg16701003	chr16:89028210	CBFA2T3	0.36	4.86	0.4	3.53e-6	Social autistic-like traits;
TGCT	trans	rs2727020	0.595	rs10769583	chr11:49483193	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.36	-6.9	-0.53	2.36e-10	Coronary artery disease;
TGCT	cis	rs11874712	0.527	rs4257298	chr18:43689353	C/A	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.49	4.86	0.4	3.47e-6	Migraine - clinic-based;
TGCT	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg15921436	chr17:44337874	NA	0.59	8.18	0.59	2.85e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2249625	0.526	rs17781511	chr6:72845455	C/T	cg24401219	chr6:72892597	RIMS1	0.57	4.46	0.37	1.84e-5	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
TGCT	cis	rs74233809	0.710	rs4147157	chr10:104536360	G/A	cg05855489	chr10:104503620	C10orf26	0.81	4.57	0.38	1.15e-5	Birth weight;
TGCT	cis	rs250677	0.958	rs36078	chr5:148430567	G/A	cg18129178	chr5:148520854	ABLIM3	-0.42	-5.79	-0.46	5.4e-8	Breast cancer;
TGCT	cis	rs2749592	0.513	rs9417249	chr10:37837155	C/T	cg25427524	chr10:38739819	LOC399744	0.3	5.16	0.42	9.41e-7	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs9929218	0.551	rs2296405	chr16:68721470	C/T	cg01251360	chr16:68772225	CDH1	0.25	4.63	0.38	8.9e-6	Colorectal cancer;
TGCT	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg16325326	chr1:53192061	ZYG11B	0.59	7.1	0.54	8.48e-11	Monocyte count;
TGCT	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg00908189	chr16:619842	PIGQ	0.87	10.65	0.69	3.27e-19	Height;
TGCT	cis	rs79349575	0.783	rs4793992	chr17:47008207	A/G	cg26022315	chr17:47021804	SNF8	0.47	4.61	0.38	9.8200000000000008e-06	Type 2 diabetes;
TGCT	cis	rs4595586	0.545	rs3858554	chr12:39381460	C/T	cg26963002	chr12:38532352	NA	0.54	4.48	0.37	1.66e-5	Morning vs. evening chronotype;
TGCT	cis	rs7523050	0.643	rs17563938	chr1:109401654	C/T	cg08274380	chr1:109419600	GPSM2	1.3	6.39	0.5	2.99e-9	Fat distribution (HIV);
TGCT	cis	rs6429082	0.755	rs291367	chr1:235690800	G/A	cg26050004	chr1:235667680	B3GALNT2	0.65	6.07	0.48	1.44e-8	Adiposity;
TGCT	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg12311346	chr5:56204834	C5orf35	0.57	6.13	0.48	1.07e-8	Initial pursuit acceleration;
TGCT	cis	rs2945232	1	rs2945232	chr8:8098038	T/C	cg06636001	chr8:8085503	FLJ10661	0.9	9.11	0.63	1.82e-15	Schizophrenia;
TGCT	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg13699009	chr12:122356056	WDR66	0.28	5.45	0.44	2.55e-7	Mean corpuscular volume;
TGCT	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg22166914	chr1:53195759	ZYG11B	-0.42	-7.46	-0.56	1.33e-11	Monocyte count;
TGCT	cis	rs17221829	0.764	rs7931085	chr11:89386197	C/T	cg02982614	chr11:89391479	FOLH1B	-0.25	-4.46	-0.37	1.8e-5	Anxiety in major depressive disorder;
TGCT	cis	rs61990749	0.597	rs4903643	chr14:78254791	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.6	4.45	0.37	1.88e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs7914558	0.966	rs10786727	chr10:104698523	G/A	cg15744005	chr10:104629667	AS3MT	-0.41	-5.11	-0.42	1.16e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs4919694	0.572	rs72846714	chr10:104878454	G/A	cg04362960	chr10:104952993	NT5C2	0.99	7.01	0.53	1.36e-10	Arsenic metabolism;
TGCT	cis	rs6840360	0.593	rs2175409	chr4:152701656	A/G	cg22705602	chr4:152727874	NA	-0.35	-6.01	-0.47	1.95e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9549367	0.713	rs2146750	chr13:113822530	A/G	cg18105134	chr13:113819100	PROZ	0.38	5.91	0.47	3.05e-8	Platelet distribution width;
TGCT	cis	rs644799	0.710	rs666398	chr11:95551136	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.79	8.64	0.61	2.36e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs13256369	0.755	rs12680167	chr8:8562467	A/G	cg17143192	chr8:8559678	CLDN23	0.56	5.23	0.43	7.03e-7	Obesity-related traits;
TGCT	cis	rs6815814	0.950	rs11722813	chr4:38810769	C/T	cg02016764	chr4:38805732	TLR1	-0.39	-6.05	-0.48	1.61e-8	Breast cancer;
TGCT	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg11890956	chr21:40555474	PSMG1	1.1	12.36	0.74	2.27e-23	Cognitive function;
TGCT	cis	rs4930561	0.714	rs7126326	chr11:67947275	T/G	cg04465784	chr11:67976953	SUV420H1	-0.38	-5.47	-0.44	2.37e-7	Breast cancer in childhood cancer survivors;IgG glycosylation;
TGCT	cis	rs7666738	0.830	rs1365458	chr4:98950961	C/T	cg18180107	chr4:99064573	C4orf37	0.59	5.29	0.43	5.35e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7246657	0.943	rs8111782	chr19:37867904	A/G	cg18154014	chr19:37997991	ZNF793	1.0	6.69	0.52	6.81e-10	Coronary artery calcification;
TGCT	cis	rs2180341	0.960	rs3756996	chr6:127664258	G/C	cg27446573	chr6:127587934	RNF146	1.19	10.56	0.69	5.48e-19	Breast cancer;
TGCT	cis	rs1008375	0.932	rs13134570	chr4:17692863	C/T	cg18681998	chr4:17616180	MED28	-0.83	-7.8	-0.57	2.22e-12	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.48	-4.44	-0.37	1.93e-5	Prudent dietary pattern;
TGCT	cis	rs7587476	0.601	rs17489363	chr2:215674341	A/G	cg04004882	chr2:215674386	BARD1	-0.65	-5.13	-0.42	1.09e-6	Neuroblastoma;
TGCT	cis	rs7681440	0.904	rs28403500	chr4:90769729	T/G	cg01966878	chr4:90757139	SNCA	-0.25	-4.53	-0.38	1.39e-5	Dementia with Lewy bodies;
TGCT	cis	rs3845702	1.000	rs3768837	chr2:180835792	T/A	cg01881094	chr2:180872142	CWC22	-0.68	-6.06	-0.48	1.51e-8	Schizophrenia;
TGCT	cis	rs617219	0.726	rs7717669	chr5:78452983	A/C	cg09550809	chr5:78407562	BHMT	0.39	5.46	0.44	2.54e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs80282103	0.618	rs11250264	chr10:1151723	A/C	cg18964960	chr10:1102726	WDR37	0.98	4.57	0.38	1.15e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs1395	1.000	rs4665958	chr2:27443196	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.51	6.73	0.52	5.6e-10	Blood metabolite levels;
TGCT	cis	rs73001065	0.636	rs10415849	chr19:19505087	C/T	cg03709012	chr19:19516395	GATAD2A	0.86	4.58	0.38	1.12e-5	LDL cholesterol;
TGCT	cis	rs9653442	0.675	rs1115910	chr2:100647872	A/G	cg07810366	chr2:100720526	AFF3	-0.4	-6.54	-0.51	1.43e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs2115630	0.818	rs7176522	chr15:85215383	C/G	cg12863693	chr15:85201151	NMB	-0.33	-4.45	-0.37	1.88e-5	P wave terminal force;
TGCT	cis	rs6964587	0.967	rs2188153	chr7:91595117	G/T	cg17063962	chr7:91808500	NA	0.91	9.99	0.67	1.32e-17	Breast cancer;
TGCT	cis	rs10510102	0.872	rs7907815	chr10:123725466	G/T	cg23691251	chr10:123688108	ATE1	-0.59	-4.64	-0.38	8.68e-6	Breast cancer;
TGCT	trans	rs1973993	0.967	rs6679458	chr1:96946253	G/T	cg10631902	chr5:14652156	NA	0.29	6.73	0.52	5.57e-10	Weight;
TGCT	cis	rs9733	0.519	rs10788792	chr1:150638572	T/G	cg09365446	chr1:150670422	GOLPH3L	0.31	4.64	0.38	8.7e-6	Tonsillectomy;
TGCT	cis	rs7547997	0.685	rs11264965	chr1:158352400	T/G	cg03528325	chr1:158223921	CD1A	0.33	4.56	0.38	1.22e-5	QRS duration;
TGCT	cis	rs28595532	0.920	rs114213539	chr4:119758794	G/C	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs1448094	0.534	rs11613070	chr12:86167544	T/A	cg02569458	chr12:86230093	RASSF9	0.38	4.49	0.37	1.61e-5	Major depressive disorder;
TGCT	cis	rs9972944	0.756	rs6504352	chr17:63765287	C/T	cg07283582	chr17:63770753	CCDC46	-0.26	-5.31	-0.43	4.9e-7	Total body bone mineral density;
TGCT	trans	rs459571	0.959	rs465535	chr9:136910905	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.75	-8.02	-0.58	6.93e-13	Platelet distribution width;
TGCT	cis	rs67478160	0.643	rs8004408	chr14:104203938	G/A	cg26031613	chr14:104095156	KLC1	-0.63	-6.36	-0.5	3.45e-9	Schizophrenia;
TGCT	cis	rs66573146	1.000	rs6812771	chr4:6964048	G/A	cg00086871	chr4:6988644	TBC1D14	0.98	4.57	0.38	1.16e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg03388025	chr16:89894329	SPIRE2	-0.53	-9.4	-0.65	3.5e-16	Vitiligo;
TGCT	cis	rs478304	0.654	rs6591185	chr11:65455742	A/G	cg17480646	chr11:65405466	SIPA1	-0.61	-8.27	-0.6	1.79e-13	Acne (severe);
TGCT	cis	rs860295	0.500	rs12032631	chr1:155995080	G/A	cg05700447	chr1:155978627	NA	-0.19	-4.66	-0.39	8.09e-6	Body mass index;
TGCT	cis	rs2832191	0.671	rs2409332	chr21:30512779	G/A	cg24692254	chr21:30365293	RNF160	-0.61	-5.41	-0.44	3.08e-7	Dental caries;
TGCT	cis	rs9399135	0.967	rs13199205	chr6:135286505	T/C	cg24558204	chr6:135376177	HBS1L	0.48	4.75	0.39	5.48e-6	Red blood cell count;
TGCT	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg11764359	chr7:65958608	NA	0.61	5.53	0.44	1.84e-7	Aortic root size;
TGCT	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg05368731	chr17:41323189	NBR1	1.17	13.8	0.78	7.84e-27	Menopause (age at onset);
TGCT	cis	rs5769765	0.865	rs9616369	chr22:50304591	A/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.39	5.61	0.45	1.24e-7	Schizophrenia;
TGCT	cis	rs7246657	0.722	rs10403173	chr19:38078680	G/A	cg18154014	chr19:37997991	ZNF793	0.69	4.63	0.38	9.25e-6	Coronary artery calcification;
TGCT	cis	rs3820068	0.655	rs72645823	chr1:15887442	C/T	cg05660106	chr1:15850417	CASP9	1.17	14.8	0.8	3.47e-29	Systolic blood pressure;
TGCT	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg25036284	chr2:26402008	FAM59B	0.53	4.71	0.39	6.48e-6	Gut microbiome composition (summer);
TGCT	cis	rs2535633	0.631	rs11915851	chr3:53096047	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.51	-4.92	-0.4	2.73e-6	Body mass index;
TGCT	cis	rs6714710	0.603	rs34503448	chr2:98587288	A/G	cg26665480	chr2:98280029	ACTR1B	0.66	6.26	0.49	5.84e-9	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg23758822	chr17:41437982	NA	0.76	7.12	0.54	7.84e-11	Menopause (age at onset);
TGCT	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.55	5.21	0.42	7.61e-7	Menarche (age at onset);
TGCT	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg02725872	chr8:58115012	NA	-0.38	-5.16	-0.42	9.32e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs523522	0.962	rs3213565	chr12:120992401	C/T	cg12219531	chr12:120966889	COQ5	0.83	7.27	0.55	3.46e-11	High light scatter reticulocyte count;
TGCT	cis	rs28595532	0.920	rs114653217	chr4:119769216	G/A	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs4242434	0.892	rs4872527	chr8:22496048	G/A	cg03733263	chr8:22462867	KIAA1967	1.16	17.73	0.85	8.57e-36	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs2236918	0.687	rs851778	chr1:242037110	A/G	cg04158730	chr1:242011433	EXO1	0.56	5.16	0.42	9.57e-7	Menopause (age at onset);
TGCT	cis	rs2075371	1.000	rs1862050	chr7:133980999	T/C	cg11752832	chr7:134001865	SLC35B4	0.7	6.53	0.51	1.51e-9	Mean platelet volume;
TGCT	cis	rs1801251	1.000	rs283468	chr2:233658309	C/T	cg25237894	chr2:233734115	C2orf82	0.27	4.68	0.39	7.35e-6	Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs6532720	chr4:99043781	C/T	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs208520	0.690	rs4618506	chr6:66756889	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-10.76	-0.69	1.76e-19	Exhaled nitric oxide output;
TGCT	cis	rs7772486	0.764	rs9399569	chr6:146242942	C/T	cg23711669	chr6:146136114	FBXO30	-0.85	-9.7	-0.66	6.73e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6987853	0.830	rs4737048	chr8:42359035	G/T	cg20539142	chr8:42623718	CHRNA6	0.19	4.52	0.38	1.44e-5	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg24531977	chr5:56204891	C5orf35	-0.76	-7.34	-0.55	2.45e-11	Initial pursuit acceleration;
TGCT	cis	rs28374715	0.617	rs16971735	chr15:41563970	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.63	-8.21	-0.59	2.43e-13	Ulcerative colitis;
TGCT	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg00343986	chr7:65444356	GUSB	-0.21	-5.32	-0.43	4.59e-7	Calcium levels;
TGCT	cis	rs2439831	0.850	rs28595038	chr15:44044859	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	5.91	0.47	3.05e-8	Lung cancer in ever smokers;
TGCT	cis	rs7635838	0.654	rs346086	chr3:11272932	G/T	cg00170343	chr3:11313890	ATG7	0.66	6.18	0.49	8.61e-9	HDL cholesterol;
TGCT	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg19723775	chr5:179050963	HNRNPH1	0.53	5.29	0.43	5.31e-7	Lung cancer;
TGCT	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg27286337	chr10:134555280	INPP5A	0.41	5.11	0.42	1.2e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs4378999	0.660	rs7433217	chr3:50987194	G/A	ch.3.1075622R	chr3:50010873	RBM6	-0.36	-4.56	-0.38	1.23e-5	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
TGCT	cis	rs473651	0.935	rs1103770	chr2:239339281	G/C	cg18131467	chr2:239335373	ASB1	0.95	9.87	0.66	2.62e-17	Multiple system atrophy;
TGCT	cis	rs9467773	0.550	rs9379874	chr6:26440429	A/T	cg05738196	chr6:26577821	NA	-0.52	-5.49	-0.44	2.18e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7582180	0.614	rs3748930	chr2:101010082	G/C	cg14675211	chr2:100938903	LONRF2	0.5	4.82	0.4	4.16e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6121246	0.909	rs6060821	chr20:30294034	C/T	cg13852791	chr20:30311386	BCL2L1	0.78	5.8	0.46	5.15e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg03452623	chr4:187889614	NA	0.41	5.8	0.46	5.14e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3796352	0.571	rs11713926	chr3:53155072	C/T	cg15956490	chr3:53032818	SFMBT1	0.53	6.22	0.49	6.87e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs832540	1.000	rs252913	chr5:56195846	C/T	cg12311346	chr5:56204834	C5orf35	0.46	4.85	0.4	3.66e-6	Coronary artery disease;
TGCT	cis	rs9372253	1.000	rs7740028	chr6:110719180	A/G	cg00083206	chr6:110721305	DDO	-0.44	-6.67	-0.51	7.55e-10	Platelet distribution width;
TGCT	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10492972	0.523	rs12746471	chr1:10475011	A/G	cg19773385	chr1:10388646	KIF1B	-0.21	-4.8	-0.4	4.49e-6	Multiple sclerosis;
TGCT	cis	rs7666738	0.830	rs10470893	chr4:99038756	C/T	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12477438	0.834	rs1563107	chr2:99701276	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.64	5.49	0.44	2.18e-7	Chronic sinus infection;
TGCT	cis	rs4699052	1.000	rs7661702	chr4:104140129	C/G	cg16532752	chr4:104119610	CENPE	-0.58	-5.59	-0.45	1.4e-7	Testicular germ cell tumor;
TGCT	cis	rs2299587	0.554	rs3913558	chr8:17747909	T/G	cg01800426	chr8:17659068	MTUS1	-0.58	-5.12	-0.42	1.16e-6	Economic and political preferences;
TGCT	cis	rs28595532	0.920	rs116366070	chr4:119764180	A/T	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	trans	rs877282	0.838	rs11253373	chr10:774857	A/G	cg22713356	chr15:30763199	NA	1.12	9.83	0.66	3.23e-17	Uric acid levels;
TGCT	cis	rs11718455	0.920	rs34909426	chr3:44000472	G/A	cg08738300	chr3:44038990	NA	0.83	6.19	0.49	8.13e-9	Coronary artery disease;
TGCT	cis	rs5769707	0.874	rs9616714	chr22:50050859	G/A	cg10356904	chr22:49881777	NA	-0.23	-4.66	-0.39	7.88e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs10276381	0.786	rs10272155	chr7:28246989	A/G	cg23620719	chr7:28220237	JAZF1	0.93	5.69	0.46	8.65e-8	Crohn's disease;
TGCT	cis	rs727563	0.636	rs2413653	chr22:42106996	T/C	cg17554472	chr22:41940697	POLR3H	0.47	5.04	0.41	1.63e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2271316	0.587	rs11078659	chr17:6903944	G/A	cg05215272	chr17:6899095	ALOX12	0.45	5.38	0.44	3.57e-7	Blood metabolite levels;
TGCT	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg05368731	chr17:41323189	NBR1	1.19	13.98	0.78	2.93e-27	Menopause (age at onset);
TGCT	cis	rs9326248	1.000	rs585849	chr11:117069061	A/G	cg16524733	chr11:117070046	TAGLN	0.33	4.73	0.39	5.9e-6	Blood protein levels;
TGCT	cis	rs9486719	1.000	rs11752584	chr6:96884952	C/A	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.86	-0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs9303401	0.921	rs34102441	chr17:56877414	A/G	cg12560992	chr17:57184187	TRIM37	0.54	5.61	0.45	1.26e-7	Cognitive test performance;
TGCT	cis	rs4563143	0.502	rs73029061	chr19:29283980	T/A	cg04546413	chr19:29218101	NA	0.86	7.0	0.53	1.45e-10	Methadone dose in opioid dependence;
TGCT	cis	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg07424592	chr7:64974309	NA	1.31	8.14	0.59	3.55e-13	Diabetic kidney disease;
TGCT	cis	rs9549367	0.673	rs575453	chr13:113837871	C/A	cg18105134	chr13:113819100	PROZ	0.46	8.58	0.61	3.25e-14	Platelet distribution width;
TGCT	cis	rs6964587	1.000	rs11982047	chr7:91705274	G/A	cg22709100	chr7:91322751	NA	0.27	4.46	0.37	1.84e-5	Breast cancer;
TGCT	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg24829409	chr8:58192753	C8orf71	-0.57	-4.72	-0.39	6.14e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg18735214	chr6:43276756	CRIP3	-0.56	-4.89	-0.4	3.05e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs4665630	0.522	rs2551351	chr2:23914065	C/T	cg08063864	chr2:24346004	PFN4;LOC375190	-1.22	-5.82	-0.46	4.81e-8	Hypertension;
TGCT	cis	rs2657888	1.000	rs7309685	chr12:56935413	A/G	cg23932658	chr12:57637574	STAC3	-0.52	-4.83	-0.4	3.91e-6	Adiponectin levels;
TGCT	cis	rs7539409	0.833	rs2057083	chr1:84269942	T/G	cg10977910	chr1:84465055	TTLL7	0.91	5.13	0.42	1.08e-6	Alzheimer's disease;
TGCT	cis	rs8051431	0.876	rs4788591	chr16:72020323	A/G	cg06353428	chr16:71660113	MARVELD3	0.56	4.47	0.37	1.73e-5	LDL cholesterol levels;
TGCT	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.8	6.14	0.48	1.02e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	trans	rs1814175	0.616	rs4881723	chr11:49788566	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.45	-11.32	-0.71	7.95e-21	Height;
TGCT	trans	rs1814175	0.817	rs7927373	chr11:49957640	A/C	cg03929089	chr4:120376271	NA	-0.72	-8.53	-0.61	4.24e-14	Height;
TGCT	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg12311346	chr5:56204834	C5orf35	-0.67	-6.77	-0.52	4.59e-10	Initial pursuit acceleration;
TGCT	cis	rs751728	1.000	rs6920075	chr6:33731797	C/T	cg13859433	chr6:33739653	LEMD2	-0.39	-7.42	-0.55	1.65e-11	Crohn's disease;
TGCT	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	5.53	0.44	1.8e-7	Alzheimer's disease;
TGCT	cis	rs73198271	0.920	rs11783112	chr8:8606193	C/T	ch.8.214553F	chr8:8189620	PRAGMIN	-0.27	-4.73	-0.39	5.95e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs17384381	0.953	rs12717763	chr1:85808164	A/T	cg16011679	chr1:85725395	C1orf52	0.81	6.36	0.5	3.47e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1008375	0.931	rs10008337	chr4:17593849	G/C	cg18681998	chr4:17616180	MED28	1.0	10.01	0.67	1.2e-17	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6882076	1.000	rs7724832	chr5:156381370	C/T	cg12943317	chr5:156479607	HAVCR1	-0.32	-5.6	-0.45	1.33e-7	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
TGCT	cis	rs2153535	0.601	rs2015281	chr6:8539673	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.67	0.45	9.45e-8	Motion sickness;
TGCT	cis	rs6570726	0.620	rs12201226	chr6:145913419	A/T	cg05347473	chr6:146136440	FBXO30	0.62	5.7	0.46	8.22e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7267979	0.966	rs2145126	chr20:25263648	G/A	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3820068	0.581	rs6669417	chr1:15922371	G/T	cg05660106	chr1:15850417	CASP9	0.79	8.54	0.61	4.01e-14	Systolic blood pressure;
TGCT	cis	rs60871478	1.000	rs9195	chr7:825786	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	-0.48	-4.75	-0.39	5.5e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	6.13	0.48	1.06e-8	Bipolar disorder;
TGCT	cis	rs9457247	0.967	rs2769355	chr6:167380493	G/A	cg25258033	chr6:167368657	RNASET2	-0.18	-4.49	-0.37	1.63e-5	Crohn's disease;
TGCT	cis	rs9549367	0.789	rs7338235	chr13:113888687	T/C	cg00898013	chr13:113819073	PROZ	-0.38	-4.66	-0.39	8.1e-6	Platelet distribution width;
TGCT	cis	rs7647973	0.560	rs77473999	chr3:49777660	T/C	cg03060546	chr3:49711283	APEH	-0.61	-5.14	-0.42	1.03e-6	Menarche (age at onset);
TGCT	cis	rs9611565	0.559	rs5758412	chr22:42080803	T/A	cg17554472	chr22:41940697	POLR3H	0.49	5.22	0.42	7.4e-7	Vitiligo;
TGCT	cis	rs2070488	0.965	rs1984312	chr3:38538466	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.88	-9.19	-0.64	1.13e-15	Electrocardiographic conduction measures;
TGCT	cis	rs6088580	0.634	rs4911418	chr20:32994257	G/A	cg08999081	chr20:33150536	PIGU	-0.29	-5.65	-0.45	1.02e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.91	7.44	0.56	1.45e-11	Platelet count;
TGCT	cis	rs6088580	0.634	rs6059878	chr20:33087166	A/T	cg06115741	chr20:33292138	TP53INP2	0.54	4.63	0.38	9.06e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs2013441	1.000	rs9325894	chr17:20197101	T/C	cg18979559	chr17:20280153	CCDC144C	-0.49	-5.04	-0.41	1.59e-6	Obesity-related traits;
TGCT	cis	rs11053548	0.602	rs11053554	chr12:10175667	G/A	cg24820250	chr12:10084936	CLEC2A	0.25	4.51	0.38	1.49e-5	Systolic blood pressure in sickle cell anemia;
TGCT	cis	rs59104589	0.959	rs60624480	chr2:242297118	G/A	cg21155796	chr2:242212141	HDLBP	0.55	4.75	0.39	5.56e-6	Fibrinogen levels;
TGCT	cis	rs6835098	0.962	rs4377567	chr4:174083590	C/G	cg08422745	chr4:174089978	GALNT7	0.91	10.78	0.7	1.59e-19	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	4.93	0.4	2.63e-6	Menopause (age at onset);
TGCT	cis	rs66573146	1.000	rs28729690	chr4:6962061	C/T	cg01220768	chr4:7056774	TADA2B	0.35	4.63	0.38	8.96e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs62064224	0.905	rs9891969	chr17:30627085	C/T	cg18200150	chr17:30822561	MYO1D	0.45	5.83	0.46	4.57e-8	Schizophrenia;
TGCT	cis	rs801193	0.569	rs2707847	chr7:66202871	C/G	cg11764359	chr7:65958608	NA	0.54	4.79	0.4	4.68e-6	Aortic root size;
TGCT	cis	rs2688608	0.592	rs7909544	chr10:75484004	G/C	cg23231163	chr10:75533350	FUT11	-0.28	-4.68	-0.39	7.4e-6	Inflammatory bowel disease;
TGCT	cis	rs9291683	0.551	rs62295971	chr4:9978142	G/A	cg11266682	chr4:10021025	SLC2A9	0.62	8.63	0.61	2.51e-14	Bone mineral density;
TGCT	cis	rs6582630	0.638	rs1829584	chr12:38526299	G/T	cg26384229	chr12:38710491	ALG10B	-0.55	-4.89	-0.4	3.05e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs11534004	0.515	rs12533776	chr7:113689001	T/C	cg21852992	chr7:112726869	GPR85	-0.35	-5.05	-0.41	1.53e-6	Schizophrenia;
TGCT	cis	rs2730260	0.537	rs73169238	chr7:158883818	G/A	cg09066883	chr7:157932951	PTPRN2	0.42	4.66	0.39	8.09e-6	Myopia (pathological);
TGCT	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.49	-4.76	-0.39	5.34e-6	Bipolar disorder;
TGCT	cis	rs7147624	1.000	rs4902408	chr14:66111901	A/T	cg03016385	chr14:66212404	NA	-0.48	-7.04	-0.53	1.17e-10	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs8062405	0.824	rs4788085	chr16:28535003	A/G	cg09754948	chr16:28834200	ATXN2L	0.63	5.01	0.41	1.79e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	trans	rs208520	0.526	rs7771233	chr6:66819784	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-12.42	-0.74	1.68e-23	Exhaled nitric oxide output;
TGCT	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.31	-4.82	-0.4	4.12e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs11252926	0.528	rs11252090	chr10:436547	C/T	cg20256804	chr10:444983	DIP2C	0.21	4.66	0.39	8e-6	Psychosis in Alzheimer's disease;
TGCT	cis	rs11252926	0.550	rs10904148	chr10:454551	G/T	cg20256804	chr10:444983	DIP2C	-0.22	-4.73	-0.39	6.02e-6	Psychosis in Alzheimer's disease;
TGCT	cis	rs62402013	1	rs62402013	chr6:26915000	A/G	cg26531700	chr6:26746687	NA	0.69	6.41	0.5	2.71e-9	Schizophrenia;
TGCT	cis	rs7267979	1.000	rs2500418	chr20:25382268	C/T	cg16686733	chr20:25566563	NINL	-0.59	-6.05	-0.48	1.57e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg13397359	chr6:42928475	GNMT	0.67	5.92	0.47	2.89e-8	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs4986172	0.539	rs3744760	chr17:43195981	C/T	cg10701640	chr17:43249399	NA	-0.39	-4.84	-0.4	3.84e-6	Height;
TGCT	cis	rs688020	1.000	rs688020	chr7:4228553	C/T	cg23797551	chr7:4243526	SDK1	-0.24	-4.45	-0.37	1.89e-5	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;
TGCT	cis	rs7769051	0.711	rs9493435	chr6:133088205	A/G	cg22852734	chr6:133119734	C6orf192	1.14	6.78	0.52	4.32e-10	Type 2 diabetes nephropathy;
TGCT	cis	rs7666738	0.830	rs4699580	chr4:98930673	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8016982	0.963	rs7149672	chr14:81657336	A/G	cg01989461	chr14:81687754	GTF2A1	0.56	4.52	0.38	1.45e-5	Schizophrenia;
TGCT	cis	rs12477438	0.748	rs7558239	chr2:99640581	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-6.1	-0.48	1.22e-8	Chronic sinus infection;
TGCT	cis	rs9926296	0.572	rs8046872	chr16:89841552	T/C	cg08627397	chr16:89984028	MC1R	-0.29	-4.57	-0.38	1.15e-5	Vitiligo;
TGCT	cis	rs804280	0.565	rs2645453	chr8:11622001	G/A	cg26752888	chr8:11627280	NEIL2	-0.52	-4.76	-0.39	5.29e-6	Myopia (pathological);
TGCT	cis	rs11779988	0.545	rs397096	chr8:17798848	C/G	cg01800426	chr8:17659068	MTUS1	0.61	5.04	0.41	1.57e-6	Breast cancer;
TGCT	cis	rs2486288	0.656	rs12440356	chr15:45567529	T/C	cg26924012	chr15:45694286	SPATA5L1	0.82	8.09	0.59	4.62e-13	Glomerular filtration rate;
TGCT	cis	rs7681440	0.869	rs894280	chr4:90760883	C/T	cg14346243	chr4:90757452	SNCA	-0.57	-5.62	-0.45	1.19e-7	Dementia with Lewy bodies;
TGCT	cis	rs17376456	0.569	rs10476520	chr5:93058290	A/C	cg21475434	chr5:93447410	FAM172A	0.6	4.9	0.4	2.92e-6	Diabetic retinopathy;
TGCT	cis	rs6545883	0.965	rs2305155	chr2:61729258	A/G	cg15711740	chr2:61764176	XPO1	-0.51	-4.6	-0.38	1.03e-5	Tuberculosis;
TGCT	cis	rs77972916	0.505	rs6727824	chr2:43528377	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.39	-5.68	-0.45	9.24e-8	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs6558530	0.692	rs10105317	chr8:1701432	G/A	cg09410841	chr8:1729607	CLN8	0.72	6.49	0.5	1.87e-9	Systolic blood pressure;
TGCT	cis	rs478304	0.718	rs61744384	chr11:65387378	T/A	cg27068330	chr11:65405492	SIPA1	-0.87	-8.89	-0.62	5.88e-15	Acne (severe);
TGCT	cis	rs7909074	0.651	rs10900127	chr10:45390103	C/A	cg05187965	chr10:45406764	TMEM72	-0.24	-4.78	-0.39	4.97e-6	Mean corpuscular volume;
TGCT	cis	rs7659604	0.521	rs13130789	chr4:122690166	G/A	cg19748678	chr4:122722346	EXOSC9	-0.56	-5.56	-0.45	1.61e-7	Type 2 diabetes;
TGCT	cis	rs4366490	0.848	rs1939757	chr11:62903823	T/A	cg21002970	chr11:62369079	MTA2	0.87	4.67	0.39	7.78e-6	Conotruncal heart defects;
TGCT	cis	rs617219	0.698	rs72764988	chr5:78533584	G/C	cg23514016	chr5:78407564	BHMT	0.34	5.09	0.42	1.29e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs6912958	0.874	rs9294381	chr6:88152681	A/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.6	-5.84	-0.46	4.27e-8	Monocyte percentage of white cells;
TGCT	cis	rs12220238	0.908	rs11000893	chr10:75905996	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.06	0.54	1.05e-10	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs4973397	0.810	rs12993290	chr2:232279687	G/A	cg09339159	chr2:232260559	B3GNT7	0.57	4.79	0.4	4.69e-6	Anti-saccade response;
TGCT	cis	rs2456568	0.900	rs1518571	chr11:93667420	C/A	cg17595323	chr11:93583763	C11orf90	-0.46	-5.86	-0.47	3.87e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs4788570	0.566	rs72795867	chr16:71484465	A/G	cg06353428	chr16:71660113	MARVELD3	-1.33	-7.9	-0.58	1.28e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs2594989	0.943	rs2606737	chr3:11398654	A/G	cg00170343	chr3:11313890	ATG7	0.66	5.08	0.42	1.34e-6	Circulating chemerin levels;
TGCT	cis	rs6901250	0.569	rs686708	chr6:117091683	A/G	cg12892004	chr6:117198278	RFX6	0.37	4.77	0.39	5.09e-6	C-reactive protein levels;
TGCT	cis	rs6540559	0.605	rs3753518	chr1:209977964	G/C	cg23283495	chr1:209979779	IRF6	0.65	5.04	0.41	1.63e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs9581857	0.685	rs9319367	chr13:28042197	T/C	cg22138327	chr13:27999177	GTF3A	0.72	4.62	0.38	9.33e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	trans	rs11722228	0.522	rs62286604	chr4:10131161	A/G	cg26043149	chr18:55253948	FECH	1.24	13.96	0.78	3.39e-27	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs12478296	0.685	rs35577962	chr2:242993575	A/G	cg06360820	chr2:242988706	NA	-0.61	-4.68	-0.39	7.26e-6	Obesity-related traits;
TGCT	trans	rs941408	1.000	rs1736181	chr19:2797703	C/T	cg22153745	chr1:153894579	GATAD2B	-0.65	-7.1	-0.54	8.37e-11	Total cholesterol levels;
TGCT	cis	rs2980439	0.557	rs2976876	chr8:8318850	T/C	cg15556689	chr8:8085844	FLJ10661	0.7	6.4	0.5	2.85e-9	Neuroticism;
TGCT	cis	rs7772486	0.623	rs9485021	chr6:146068797	A/G	cg05347473	chr6:146136440	FBXO30	-0.49	-4.52	-0.38	1.42e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1371867	0.875	rs1788187	chr8:101336099	A/G	cg06636551	chr8:101224915	SPAG1	-0.42	-5.65	-0.45	1.06e-7	Atrioventricular conduction;
TGCT	cis	rs751728	0.717	rs3763260	chr6:33774070	C/T	cg13859433	chr6:33739653	LEMD2	-0.38	-6.72	-0.52	5.77e-10	Crohn's disease;
TGCT	cis	rs42648	0.738	rs10248104	chr7:89895262	C/T	cg25739043	chr7:89950458	NA	-0.52	-4.68	-0.39	7.51e-6	Homocysteine levels;
TGCT	cis	rs763121	0.925	rs4821815	chr22:39105707	G/A	cg06022373	chr22:39101656	GTPBP1	0.76	7.85	0.58	1.7e-12	Menopause (age at onset);
TGCT	cis	rs3771570	1.000	rs62193204	chr2:242315443	A/G	cg21155796	chr2:242212141	HDLBP	0.94	6.69	0.51	6.9e-10	Prostate cancer;
TGCT	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	4.98	0.41	2.08e-6	Prudent dietary pattern;
TGCT	cis	rs546131	0.928	rs553789	chr11:34827579	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.54	4.78	0.39	4.93e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs2025751	0.666	rs10214608	chr6:51686253	C/T	cg23457901	chr6:52402140	TRAM2	-0.22	-4.52	-0.38	1.43e-5	Intraocular pressure;
TGCT	cis	rs5769765	0.954	rs910799	chr22:50278568	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.42	-6.36	-0.5	3.59e-9	Schizophrenia;
TGCT	cis	rs9952991	0.566	rs579052	chr18:12858610	T/C	cg23598886	chr18:12777645	NA	0.57	5.05	0.41	1.51e-6	Inflammatory skin disease;
TGCT	cis	rs637571	0.522	rs503524	chr11:65751764	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.21	4.45	0.37	1.9e-5	Eosinophil percentage of white cells;
TGCT	cis	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg20637647	chr7:64974828	NA	0.91	5.37	0.43	3.74e-7	Diabetic kidney disease;
TGCT	cis	rs7959452	0.868	rs10784774	chr12:69737879	C/T	cg20891283	chr12:69753455	YEATS4	-0.62	-6.24	-0.49	6.24e-9	Blood protein levels;
TGCT	cis	rs7659604	0.628	rs3828485	chr4:122722368	G/A	cg20573242	chr4:122745356	CCNA2	0.64	5.72	0.46	7.42e-8	Type 2 diabetes;
TGCT	cis	rs72945132	0.882	rs12295111	chr11:70131882	C/A	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs910316	1.000	rs4903279	chr14:75546583	C/T	cg08847533	chr14:75593920	NEK9	0.96	10.6	0.69	4.3e-19	Height;
TGCT	cis	rs3091242	0.900	rs1883427	chr1:25744468	C/T	cg00786635	chr1:25594202	NA	0.61	6.42	0.5	2.57e-9	Erythrocyte sedimentation rate;
TGCT	cis	rs56104184	0.775	rs117744769	chr19:49402686	G/T	cg21252483	chr19:49399788	TULP2	-0.42	-5.89	-0.47	3.47e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs5750830	0.620	rs1007337	chr22:39781585	C/T	cg02038168	chr22:39784481	NA	-0.72	-5.96	-0.47	2.45e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7662987	0.517	rs1453874	chr4:100022724	G/A	cg12011299	chr4:100065546	ADH4	0.4	4.82	0.4	4.07e-6	Smoking initiation;
TGCT	cis	rs2730260	0.578	rs56375711	chr7:158854935	G/A	cg27122614	chr7:157913741	PTPRN2	0.45	4.55	0.38	1.24e-5	Myopia (pathological);
TGCT	cis	rs4822044	0.568	rs1883370	chr22:42143740	C/A	cg06634786	chr22:41940651	POLR3H	0.83	7.8	0.57	2.19e-12	Cannabis dependence symptom count;
TGCT	cis	rs28595532	0.920	rs115046587	chr4:119779604	T/C	cg21605333	chr4:119757512	SEC24D	1.53	8.87	0.62	6.71e-15	Cannabis dependence symptom count;
TGCT	cis	rs9435341	0.762	rs3861909	chr1:107544176	A/G	cg09367891	chr1:107599246	PRMT6	-0.68	-5.8	-0.46	5.16e-8	Facial morphology (factor 21, depth of nasal alae);
TGCT	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg23708337	chr7:1209742	NA	0.44	4.87	0.4	3.27e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	trans	rs1814175	0.817	rs1794162	chr11:49899506	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.04	-0.53	1.16e-10	Height;
TGCT	cis	rs478304	0.903	rs495961	chr11:65540886	C/T	cg17480646	chr11:65405466	SIPA1	0.43	5.35	0.43	4.01e-7	Acne (severe);
TGCT	cis	rs7943191	0.810	rs7942154	chr11:62337163	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.53	6.24	0.49	6.4e-9	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs7772486	0.719	rs702317	chr6:146005010	C/T	cg13319975	chr6:146136371	FBXO30	0.52	4.68	0.39	7.31e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs637571	0.510	rs3892696	chr11:65582341	G/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.66	-5.74	-0.46	7.01e-8	Eosinophil percentage of white cells;
TGCT	cis	rs10193935	0.901	rs6733464	chr2:42563597	A/G	cg27598129	chr2:42591480	NA	-0.41	-5.66	-0.45	1e-7	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs4332037	0.802	rs12113633	chr7:1932936	G/A	cg25206134	chr2:45395956	NA	1.1	9.34	0.64	5.11e-16	Bipolar disorder;
TGCT	trans	rs7618501	0.699	rs1062633	chr3:49924940	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.89	9.73	0.66	5.74e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg01802117	chr1:53393560	SCP2	-0.45	-5.45	-0.44	2.57e-7	Monocyte count;
TGCT	cis	rs11690935	0.851	rs7581072	chr2:172859849	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.9	-8.09	-0.59	4.7e-13	Schizophrenia;
TGCT	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg18876405	chr7:65276391	NA	-0.36	-5.41	-0.44	3.12e-7	Aortic root size;
TGCT	cis	rs7402982	0.647	rs34038360	chr15:99201573	A/C	cg03437748	chr15:99193247	IGF1R	0.48	4.84	0.4	3.79e-6	Birth weight;
TGCT	cis	rs7727544	0.678	rs7735891	chr5:131597005	C/T	cg24060327	chr5:131705240	SLC22A5	-0.54	-5.29	-0.43	5.45e-7	Blood metabolite levels;
TGCT	cis	rs4273100	0.512	rs7502682	chr17:19295450	G/T	cg01534423	chr17:18965556	NA	-0.75	-7.83	-0.58	1.83e-12	Schizophrenia;
TGCT	cis	rs10782582	0.632	rs77099976	chr1:76240524	T/C	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.51	4.59	0.38	1.06e-5	Daytime sleep phenotypes;
TGCT	cis	rs9611519	0.894	rs13053242	chr22:41459486	G/A	cg03806693	chr22:41940476	POLR3H	-0.67	-6.05	-0.48	1.57e-8	Neuroticism;
TGCT	cis	rs10832963	0.686	rs11024743	chr11:18653712	A/G	cg09201001	chr11:18656081	SPTY2D1	1.04	11.77	0.73	6.2e-22	Breast cancer;
TGCT	cis	rs10256972	0.626	rs62433138	chr7:1050877	T/C	cg00431813	chr7:1051703	C7orf50	-0.26	-5.81	-0.46	5.03e-8	Longevity;Endometriosis;
TGCT	cis	rs12681287	0.752	rs1436628	chr8:87313345	C/G	cg27223183	chr8:87520930	FAM82B	0.83	6.32	0.49	4.32e-9	Caudate activity during reward;
TGCT	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6978712	1.000	rs55921267	chr7:127148361	A/T	cg01017541	chr7:127776461	NA	0.76	4.6	0.38	1.01e-5	Medication adherence in chronic diseases;
TGCT	cis	rs13217239	0.574	rs9366680	chr6:27006123	A/T	cg26531700	chr6:26746687	NA	0.68	6.91	0.53	2.29e-10	Schizophrenia;
TGCT	cis	rs877529	0.605	rs139412	chr22:39553003	A/G	cg18708252	chr22:39545030	CBX7	0.37	5.46	0.44	2.52e-7	Multiple myeloma;
TGCT	cis	rs11574514	1.000	rs117447021	chr16:67669455	G/A	cg00545966	chr16:67701244	C16orf86;C16orf48	0.72	4.45	0.37	1.87e-5	Crohn's disease;
TGCT	cis	rs17345786	0.906	rs12638137	chr3:101150964	C/T	cg12386194	chr3:101231763	SENP7	0.65	6.39	0.5	3.06e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9633740	0.545	rs2343306	chr10:82230146	A/G	cg01528321	chr10:82214614	TSPAN14	-0.9	-6.37	-0.5	3.39e-9	Post bronchodilator FEV1;
TGCT	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg06634786	chr22:41940651	POLR3H	0.94	8.87	0.62	6.61e-15	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs7246657	0.943	rs7408563	chr19:37808585	G/C	cg18154014	chr19:37997991	ZNF793	0.91	6.09	0.48	1.29e-8	Coronary artery calcification;
TGCT	cis	rs7829975	0.500	rs7841082	chr8:8168987	C/T	cg06636001	chr8:8085503	FLJ10661	-0.6	-5.25	-0.43	6.52e-7	Mood instability;
TGCT	cis	rs9972944	0.676	rs9303489	chr17:63784817	T/C	cg07283582	chr17:63770753	CCDC46	0.25	4.72	0.39	6.22e-6	Total body bone mineral density;
TGCT	cis	rs4455778	0.659	rs11185626	chr7:49042022	C/T	cg26309511	chr7:48887640	NA	0.42	4.98	0.41	2.08e-6	Lung cancer in never smokers;
TGCT	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg27454412	chr7:1067447	C7orf50	0.6	4.72	0.39	6.32e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9467711	0.659	rs3823158	chr6:26463271	T/A	cg16898833	chr6:26189333	HIST1H4D	1.26	5.95	0.47	2.59e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6500602	0.679	rs736685	chr16:4508606	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.3	5.5	0.44	2.08e-7	Schizophrenia;
TGCT	cis	rs7010267	0.568	rs2220189	chr8:120007708	C/G	cg17171407	chr8:119960777	TNFRSF11B	0.28	5.15	0.42	9.93e-7	Total body bone mineral density (age 45-60);
TGCT	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg27535305	chr1:53392650	SCP2	-0.29	-6.1	-0.48	1.27e-8	Monocyte count;
TGCT	cis	rs8051431	0.876	rs1559399	chr16:72011261	A/G	cg06353428	chr16:71660113	MARVELD3	0.58	4.96	0.41	2.28e-6	LDL cholesterol levels;
TGCT	cis	rs11785400	0.793	rs7459963	chr8:143737129	C/T	cg24634471	chr8:143751801	JRK	0.57	5.7	0.46	8.4e-8	Schizophrenia;
TGCT	cis	rs10465746	0.714	rs12141272	chr1:84434517	C/T	cg10977910	chr1:84465055	TTLL7	0.69	7.04	0.53	1.14e-10	Obesity-related traits;
TGCT	cis	rs7267979	0.773	rs6132821	chr20:25226192	A/G	cg14121845	chr20:25566513	NINL	0.49	4.96	0.41	2.24e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs854765	0.856	rs2955382	chr17:17947710	C/T	cg09796270	chr17:17721594	SREBF1	-0.27	-5.34	-0.43	4.31e-7	Total body bone mineral density;
TGCT	cis	rs7020830	0.898	rs997318	chr9:37364094	C/T	cg14294708	chr9:37120828	ZCCHC7	1.16	16.05	0.82	4.79e-32	Schizophrenia;
TGCT	cis	rs4077515	0.870	rs10781510	chr9:139279173	G/A	cg13741927	chr9:139327495	INPP5E	-0.2	-4.67	-0.39	7.59e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs4523957	0.548	rs11869619	chr17:2066150	G/C	cg16513277	chr17:2031491	SMG6	-0.21	-4.58	-0.38	1.09e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs3764628	0.925	rs752981	chr19:18774790	G/T	cg20098710	chr19:19640075	YJEFN3	-0.45	-4.85	-0.4	3.62e-6	Orofacial clefts;
TGCT	cis	rs5750830	0.594	rs6001568	chr22:39775786	G/A	cg01416388	chr22:39784598	NA	-0.59	-5.85	-0.47	4.11e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs6570726	0.935	rs408768	chr6:145871735	A/G	cg23711669	chr6:146136114	FBXO30	0.71	7.03	0.53	1.25e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs711245	0.573	rs3770796	chr2:36799515	T/C	cg15105969	chr2:36825350	FEZ2	0.58	5.27	0.43	5.88e-7	Height;
TGCT	cis	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg03213289	chr20:61660250	NA	0.68	9.99	0.67	1.36e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs864643	0.812	rs1513218	chr3:39545588	C/T	cg14968361	chr3:39543547	MOBP	-0.44	-4.52	-0.38	1.41e-5	Attention deficit hyperactivity disorder;
TGCT	cis	rs2470135	1	rs2470135	chr15:43995789	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.45	4.56	0.38	1.22e-5	Diastolic blood pressure;
TGCT	cis	rs6089584	0.821	rs4925332	chr20:60604639	C/T	cg06108461	chr20:60628389	TAF4	-0.65	-9.83	-0.66	3.35e-17	Body mass index;
TGCT	cis	rs3820928	0.874	rs13430941	chr2:227904447	G/A	cg11843606	chr2:227700838	RHBDD1	-0.53	-4.77	-0.39	5.14e-6	Pulmonary function;
TGCT	trans	rs1005277	0.505	rs200939	chr10:38139483	T/C	cg17830980	chr10:43048298	ZNF37B	-0.72	-8.22	-0.59	2.33e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2832191	1.000	rs8131214	chr21:30483386	T/G	cg24692254	chr21:30365293	RNF160	-0.79	-7.92	-0.58	1.17e-12	Dental caries;
TGCT	cis	rs7666738	0.830	rs2098934	chr4:98992403	A/G	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs453301	0.653	rs1045529	chr8:8890098	A/G	cg06636001	chr8:8085503	FLJ10661	-0.79	-7.3	-0.55	3.08e-11	Joint mobility (Beighton score);
TGCT	cis	rs4700695	0.686	rs251710	chr5:65347357	G/C	cg21114390	chr5:65439923	SFRS12	0.61	4.51	0.38	1.46e-5	Facial morphology (factor 19);
TGCT	cis	rs3806843	0.576	rs246064	chr5:140324309	C/G	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs1030877	1.000	rs1030877	chr2:105910513	G/A	cg02079111	chr2:105885981	TGFBRAP1	0.2	5.93	0.47	2.75e-8	Obesity-related traits;
TGCT	cis	rs854765	0.583	rs11650890	chr17:17790882	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.74	-7.98	-0.58	8.43e-13	Total body bone mineral density;
TGCT	cis	rs6714788	0.523	rs6542905	chr2:100654707	C/G	cg07810366	chr2:100720526	AFF3	-0.36	-5.07	-0.41	1.43e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg03060546	chr3:49711283	APEH	0.53	5.14	0.42	1.05e-6	Menarche (age at onset);
TGCT	cis	rs11191419	1	rs11191419	chr10:104612335	T/A	cg04362960	chr10:104952993	NT5C2	0.55	4.74	0.39	5.7e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs3806843	0.735	rs801189	chr5:140063091	A/G	cg19875535	chr5:140030758	IK	-0.36	-6.15	-0.48	9.57e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7681440	0.904	rs28507349	chr4:90767063	G/A	cg26578617	chr4:90757533	SNCA	-0.47	-4.87	-0.4	3.34e-6	Dementia with Lewy bodies;
TGCT	cis	rs2180341	0.960	rs7773484	chr6:127670779	T/C	cg27446573	chr6:127587934	RNF146	1.21	10.87	0.7	9.57e-20	Breast cancer;
TGCT	cis	rs13177918	0.578	rs35919198	chr5:149831991	A/T	cg14059543	chr5:149831962	NA	-0.69	-9.12	-0.63	1.68e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	trans	rs1814175	0.645	rs28447324	chr11:50046629	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.67	-0.69	2.92e-19	Height;
TGCT	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg20891558	chr2:74357851	NA	0.59	7.39	0.55	1.93e-11	Gestational age at birth (maternal effect);
TGCT	cis	rs7666738	0.830	rs1426666	chr4:99030887	A/G	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10465746	0.780	rs2389649	chr1:84379449	C/T	cg10977910	chr1:84465055	TTLL7	0.66	6.61	0.51	1.01e-9	Obesity-related traits;
TGCT	cis	rs9650657	0.771	rs4840516	chr8:10667335	C/G	cg27411982	chr8:10470053	RP1L1	0.22	4.97	0.41	2.14e-6	Neuroticism;
TGCT	cis	rs7937682	1.000	rs7937682	chr11:111579939	C/G	cg09085632	chr11:111637200	PPP2R1B	-1.01	-9.96	-0.67	1.61e-17	Primary sclerosing cholangitis;
TGCT	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg06212747	chr3:49208901	KLHDC8B	0.6	5.43	0.44	2.8e-7	Parkinson's disease;
TGCT	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg00814883	chr7:100076585	TSC22D4	-0.9	-9.56	-0.65	1.5e-16	Platelet count;
TGCT	cis	rs1949733	0.959	rs2688242	chr4:8429943	T/G	cg13073564	chr4:8508604	NA	-0.48	-5.14	-0.42	1.02e-6	Response to antineoplastic agents;
TGCT	cis	rs7772486	0.790	rs6926657	chr6:146255794	G/A	cg23711669	chr6:146136114	FBXO30	-0.87	-9.9	-0.66	2.24e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2153535	0.580	rs6597334	chr6:8504779	C/T	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs250677	0.687	rs3095947	chr5:148436728	T/C	cg18129178	chr5:148520854	ABLIM3	-0.43	-6.29	-0.49	5.05e-9	Breast cancer;
TGCT	cis	rs2762353	0.935	rs3757131	chr6:25783909	C/T	cg03517284	chr6:25882590	NA	0.5	5.23	0.42	7.13e-7	Blood metabolite levels;
TGCT	cis	rs7956193	0.530	rs1293781	chr12:113463665	A/T	cg04001726	chr12:112547043	NAA25	-0.45	-4.49	-0.37	1.58e-5	Visceral adipose tissue adjusted for BMI;
TGCT	cis	rs7833790	0.660	rs7839178	chr8:82763479	A/G	cg27398817	chr8:82754497	SNX16	0.69	5.52	0.44	1.9e-7	Diastolic blood pressure;
TGCT	cis	rs748404	0.578	rs552701	chr15:43613810	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	4.82	0.4	4.07e-6	Lung cancer;
TGCT	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg01341218	chr17:43662625	NA	1.12	9.2	0.64	1.06e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs11098499	0.661	rs10015965	chr4:120268237	A/G	cg09307838	chr4:120376055	NA	0.56	5.57	0.45	1.51e-7	Corneal astigmatism;
TGCT	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg26354017	chr1:205819088	PM20D1	0.57	7.01	0.53	1.33e-10	Menarche (age at onset);
TGCT	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg14983838	chr19:29218262	NA	0.83	6.81	0.52	3.8e-10	Methadone dose in opioid dependence;
TGCT	cis	rs11190604	1.000	rs3750630	chr10:102275780	A/G	cg16342193	chr10:102329863	NA	-0.42	-5.37	-0.43	3.72e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs1865760	0.566	rs9379821	chr6:26054268	A/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.78	7.49	0.56	1.1e-11	Height;
TGCT	cis	rs2842992	0.915	rs2758321	chr6:160071611	C/G	cg11366901	chr6:160182831	ACAT2	0.96	6.29	0.49	5.04e-9	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs9653442	0.545	rs1821827	chr2:100764717	T/C	cg22139774	chr2:100720529	AFF3	-0.38	-5.98	-0.47	2.19e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs11971779	0.793	rs9632774	chr7:139137562	C/T	cg07862535	chr7:139043722	LUC7L2	0.63	4.65	0.39	8.25e-6	Diisocyanate-induced asthma;
TGCT	cis	rs903263	0.582	rs11163898	chr1:84547271	C/T	cg09664975	chr1:84543551	PRKACB	0.5	4.87	0.4	3.39e-6	Breast cancer (male);
TGCT	cis	rs7267979	1.000	rs2500448	chr20:25404027	A/C	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7267979	0.873	rs6037062	chr20:25202892	G/A	cg14121845	chr20:25566513	NINL	0.45	5.01	0.41	1.81e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2730245	0.545	rs2788472	chr7:158649304	T/C	cg11984989	chr7:158649758	WDR60	1.04	9.33	0.64	5.3e-16	Height;
TGCT	cis	rs7909670	0.716	rs10906245	chr10:12928438	T/C	cg23097415	chr10:13391488	SEPHS1	0.49	4.62	0.38	9.32e-6	Height;
TGCT	cis	rs6912958	0.547	rs451089	chr6:88041859	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.41	4.81	0.4	4.22e-6	Monocyte percentage of white cells;
TGCT	cis	rs875971	0.577	rs34888281	chr7:65585771	C/T	cg00343986	chr7:65444356	GUSB	-0.23	-4.9	-0.4	2.87e-6	Aortic root size;
TGCT	cis	rs854765	0.654	rs9911281	chr17:17762457	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.74	-7.65	-0.57	4.87e-12	Total body bone mineral density;
TGCT	cis	rs2677744	0.626	rs12915155	chr15:91490894	G/T	cg23684204	chr15:91497937	RCCD1	0.36	5.37	0.43	3.79e-7	Attention deficit hyperactivity disorder;
TGCT	cis	rs1008375	0.966	rs6825133	chr4:17577776	C/T	cg18681998	chr4:17616180	MED28	0.94	9.56	0.65	1.44e-16	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9534288	0.730	rs7985754	chr13:46581287	G/A	cg15192986	chr13:46630673	CPB2	-0.53	-7.62	-0.56	5.82e-12	Blood protein levels;
TGCT	cis	rs453301	0.507	rs2929306	chr8:9084909	C/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-5.06	-0.41	1.46e-6	Joint mobility (Beighton score);
TGCT	cis	rs981844	0.857	rs72731698	chr4:154716353	T/C	cg14289246	chr4:154710475	SFRP2	1.05	8.88	0.62	6.23e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs2739330	0.615	rs2858911	chr22:24297195	G/T	cg23131131	chr22:24373011	LOC391322	-0.81	-9.08	-0.63	2.09e-15	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg17971929	chr21:40555470	PSMG1	0.95	9.07	0.63	2.19e-15	Cognitive function;
TGCT	cis	rs2816958	0.803	rs2737685	chr1:200093351	C/T	cg07971716	chr1:199773294	NA	0.46	4.52	0.38	1.45e-5	Ulcerative colitis;Inflammatory bowel disease;
TGCT	cis	rs2050392	0.624	rs2489842	chr10:30721991	T/C	cg18806716	chr10:30721971	MAP3K8	-0.7	-9.39	-0.64	3.84e-16	Inflammatory bowel disease;
TGCT	cis	rs1997103	0.911	rs11238361	chr7:55395981	A/G	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.63	6.79	0.52	4.17e-10	Height;
TGCT	trans	rs4332037	0.950	rs11771828	chr7:1941003	T/C	cg10840412	chr1:235813424	GNG4	1.04	8.16	0.59	3.22e-13	Bipolar disorder;
TGCT	cis	rs35146811	0.586	rs12705067	chr7:99594726	T/C	cg13334819	chr7:99746414	C7orf59	-0.65	-5.76	-0.46	6.21e-8	Coronary artery disease;
TGCT	cis	rs3027009	0.881	rs3026942	chr1:159131857	A/G	cg24432768	chr1:158149974	CD1D	-0.48	-4.62	-0.38	9.29e-6	Lean body mass and age at menarche (combined);
TGCT	cis	rs8014204	0.570	rs7147721	chr14:75186010	A/G	cg06637938	chr14:75390232	RPS6KL1	0.74	7.31	0.55	2.81e-11	Caffeine consumption;
TGCT	cis	rs4803468	0.967	rs3786553	chr19:41902746	T/G	cg09537434	chr19:41945824	ATP5SL	-0.91	-10.71	-0.69	2.37e-19	Height;
TGCT	cis	rs35146811	0.735	rs6465766	chr7:99785671	A/G	cg00553149	chr7:99775558	STAG3;GPC2	0.31	4.61	0.38	9.75e-6	Coronary artery disease;
TGCT	cis	rs7552404	0.590	rs1565717	chr1:76320441	T/C	cg10523679	chr1:76189770	ACADM	-0.67	-6.36	-0.5	3.5e-9	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs986417	0.818	rs1010051	chr14:61002988	G/C	cg27398547	chr14:60952738	C14orf39	1.49	10.43	0.68	1.12e-18	Gut microbiota (bacterial taxa);
TGCT	cis	rs2439831	0.867	rs2447211	chr15:43936351	G/A	cg19166733	chr15:44192098	FRMD5	-0.24	-4.89	-0.4	3.08e-6	Lung cancer in ever smokers;
TGCT	cis	rs7949030	0.591	rs11231156	chr11:62366454	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.64	9.48	0.65	2.35e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1609391	0.561	rs9817967	chr3:136629490	G/A	cg15507776	chr3:136538369	TMEM22	0.66	6.84	0.52	3.27e-10	Neuroticism;
TGCT	cis	rs7528684	0.902	rs2210912	chr1:157668701	A/C	cg17134153	chr1:157670328	FCRL3	-0.25	-4.73	-0.39	5.9e-6	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;
TGCT	cis	rs950169	0.595	rs11631921	chr15:85143277	G/A	cg11189052	chr15:85197271	WDR73	0.86	7.28	0.55	3.31e-11	Schizophrenia;
TGCT	cis	rs2777491	0.957	rs3743038	chr15:41694743	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.75	-10.81	-0.7	1.35e-19	Ulcerative colitis;
TGCT	cis	rs3015497	0.616	rs4901043	chr14:51083594	C/T	cg04730355	chr14:51134070	SAV1	0.62	5.98	0.47	2.23e-8	Mean platelet volume;
TGCT	cis	rs60871478	0.898	rs35928069	chr7:823067	G/C	cg15782153	chr7:917662	C7orf20	-0.51	-4.58	-0.38	1.1e-5	Cerebrospinal P-tau181p levels;
TGCT	cis	rs2153535	0.601	rs1855768	chr6:8472969	T/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs1538970	0.961	rs4660854	chr1:45854087	A/T	cg05343316	chr1:45956843	TESK2	0.69	5.25	0.43	6.49e-7	Platelet count;
TGCT	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.62	-8.8	-0.62	9.71e-15	Longevity;Endometriosis;
TGCT	cis	rs9894429	0.621	rs7502337	chr17:79588470	T/C	cg18240062	chr17:79603768	NPLOC4	0.56	4.94	0.41	2.5e-6	Eye color traits;
TGCT	cis	rs228437	0.586	rs2207421	chr6:134913417	A/C	cg09872934	chr6:134495829	SGK1	0.55	4.75	0.39	5.62e-6	Melanoma;
TGCT	cis	rs7582180	0.629	rs7597615	chr2:100954828	T/C	cg08017756	chr2:100939284	LONRF2	-0.3	-4.87	-0.4	3.27e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1023500	0.551	rs2859438	chr22:42466980	A/T	cg15557168	chr22:42548783	NA	-0.22	-5.58	-0.45	1.47e-7	Schizophrenia;
TGCT	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg24549020	chr5:56110836	MAP3K1	0.67	5.78	0.46	5.74e-8	Initial pursuit acceleration;
TGCT	cis	rs6500602	0.653	rs4786487	chr16:4440397	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.3	-4.9	-0.4	2.91e-6	Schizophrenia;
TGCT	cis	rs2486288	0.656	rs11632920	chr15:45551264	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.46	-5.57	-0.45	1.51e-7	Glomerular filtration rate;
TGCT	cis	rs2228479	0.702	rs62052710	chr16:89854893	C/T	cg06558623	chr16:89946397	TCF25	0.47	4.58	0.38	1.14e-5	Skin colour saturation;
TGCT	cis	rs78487399	0.808	rs7573500	chr2:43685625	C/T	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.74	4.77	0.39	5.16e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs2468186	0.710	rs2450063	chr8:120097576	G/A	cg02248809	chr8:120845432	TAF2	-0.43	-4.55	-0.38	1.27e-5	Osteoprotegerin levels;
TGCT	cis	rs12210905	0.920	rs77380818	chr6:27305498	G/A	cg08851530	chr6:28072375	NA	1.32	5.79	0.46	5.48e-8	Hip circumference adjusted for BMI;
TGCT	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg24250549	chr1:154909240	PMVK	0.55	5.34	0.43	4.31e-7	Prostate cancer;
TGCT	cis	rs2721195	0.816	rs4251689	chr8:145741130	C/T	cg15320075	chr8:145703422	NA	0.7	7.03	0.53	1.2e-10	Age at first birth;
TGCT	cis	rs1577917	1.000	rs7760207	chr6:86721700	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.22	-0.42	7.27e-7	Response to antipsychotic treatment;
TGCT	cis	rs12989701	1.000	rs13004848	chr2:127887560	C/T	cg08168897	chr2:127865431	BIN1	-0.59	-5.76	-0.46	6.14e-8	Alzheimer's disease (late onset);
TGCT	cis	rs950776	0.518	rs1979907	chr15:78842239	T/C	cg06917634	chr15:78832804	PSMA4	-0.95	-9.52	-0.65	1.81e-16	Sudden cardiac arrest;
TGCT	cis	rs9527	0.662	rs4919687	chr10:104595248	G/A	cg04362960	chr10:104952993	NT5C2	0.62	5.39	0.44	3.37e-7	Arsenic metabolism;
TGCT	cis	rs5769707	0.632	rs5770601	chr22:50021903	A/G	cg05373962	chr22:49881684	NA	-0.3	-5.02	-0.41	1.78e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.64	0.51	8.85e-10	Electroencephalogram traits;
TGCT	cis	rs4878497	0.544	rs3205166	chr9:32459450	G/T	cg14213824	chr9:33265091	SUGT1P1;BAG1;CHMP5	-0.47	-4.55	-0.38	1.24e-5	Inflammatory skin disease;
TGCT	cis	rs1371867	0.846	rs1660338	chr8:101242757	C/G	cg06636551	chr8:101224915	SPAG1	-0.44	-6.11	-0.48	1.19e-8	Atrioventricular conduction;
TGCT	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg16049864	chr8:95962084	TP53INP1	-0.75	-10.48	-0.69	8.55e-19	Type 2 diabetes;
TGCT	cis	rs6866344	0.697	rs72812613	chr5:178135257	G/A	cg03877680	chr5:178157825	ZNF354A	0.75	6.02	0.48	1.79e-8	Neutrophil percentage of white cells;
TGCT	cis	rs6665290	0.935	rs12403236	chr1:227196502	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.0	-20.65	-0.88	6.07e-42	Myeloid white cell count;
TGCT	cis	rs7267979	0.899	rs442834	chr20:25458096	A/G	cg16686733	chr20:25566563	NINL	0.56	5.69	0.46	8.49e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs79349575	0.783	rs55771415	chr17:46999937	C/T	cg07967210	chr17:47022446	SNF8	0.44	6.12	0.48	1.13e-8	Type 2 diabetes;
TGCT	cis	rs6598955	0.585	rs12138111	chr1:26590432	G/A	cg04990556	chr1:26633338	UBXN11	0.64	4.91	0.4	2.78e-6	Obesity-related traits;
TGCT	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg13732083	chr21:47605072	C21orf56	0.34	4.52	0.38	1.44e-5	Testicular germ cell tumor;
TGCT	cis	rs12367572	1.000	rs12822444	chr12:45276677	G/A	cg04608330	chr12:45269318	NELL2	-0.65	-6.63	-0.51	9.33e-10	Gut microbiome composition (summer);
TGCT	cis	rs10832169	0.967	rs11023065	chr11:14068729	C/G	cg04547675	chr11:13986162	SPON1	0.51	4.51	0.38	1.49e-5	Blood protein levels;
TGCT	cis	rs7312933	0.531	rs2708059	chr12:42851008	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.56	-5.53	-0.44	1.8e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	trans	rs7819412	0.668	rs4841507	chr8:11046394	C/G	cg15556689	chr8:8085844	FLJ10661	-0.81	-7.6	-0.56	6.26e-12	Triglycerides;
TGCT	cis	rs1867631	0.876	rs10889637	chr1:67097465	C/T	cg13052034	chr1:66999238	SGIP1	0.57	4.75	0.39	5.53e-6	Menopause (age at onset);
TGCT	cis	rs9810089	0.749	rs664088	chr3:136036986	T/C	cg12473912	chr3:136751656	NA	0.35	4.99	0.41	2.01e-6	Gestational age at birth (child effect);
TGCT	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg11890956	chr21:40555474	PSMG1	1.12	12.59	0.75	6.25e-24	Cognitive function;
TGCT	cis	rs244731	1.000	rs244731	chr5:176539679	C/T	cg06060754	chr5:176797920	RGS14	0.39	5.45	0.44	2.56e-7	Urate levels in lean individuals;
TGCT	cis	rs7909074	0.966	rs4245614	chr10:45397007	C/T	cg05187965	chr10:45406764	TMEM72	-0.24	-5.07	-0.41	1.42e-6	Mean corpuscular volume;
TGCT	cis	rs3935685	0.874	rs36058724	chr15:78006745	C/A	cg03457338	chr15:78040120	NA	-0.22	-5.74	-0.46	6.9e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7819412	0.837	rs17724467	chr8:10975682	C/G	cg21775007	chr8:11205619	TDH	-0.52	-4.99	-0.41	1.98e-6	Triglycerides;
TGCT	cis	rs3772130	0.962	rs35679661	chr3:121484763	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.72	0.39	6.25e-6	Cognitive performance;
TGCT	cis	rs2841277	0.741	rs9672139	chr14:105408182	T/G	cg21017887	chr14:105400489	NA	0.34	4.87	0.4	3.36e-6	Rheumatoid arthritis;
TGCT	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6570726	0.764	rs76635693	chr6:145834070	T/C	cg23711669	chr6:146136114	FBXO30	0.89	9.72	0.66	6.02e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg02953382	chr22:24373134	LOC391322	-0.77	-7.9	-0.58	1.27e-12	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	trans	rs931812	0.895	rs965625	chr8:101909749	T/C	cg20993868	chr7:22813445	NA	0.4	8.94	0.63	4.62e-15	Attention deficit hyperactivity disorder and conduct disorder;
TGCT	trans	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.88	9.92	0.67	1.95e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs854765	0.583	rs4534911	chr17:17852330	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.76	7.88	0.58	1.41e-12	Total body bone mineral density;
TGCT	cis	rs1153858	1.000	rs7181167	chr15:45686236	C/G	cg26924012	chr15:45694286	SPATA5L1	1.09	15.16	0.81	5.15e-30	Homoarginine levels;
TGCT	trans	rs11992162	0.597	rs7824564	chr8:11780180	A/G	cg15556689	chr8:8085844	FLJ10661	-0.79	-6.77	-0.52	4.69e-10	Monocyte count;
TGCT	cis	rs1933488	1.000	rs1442744	chr6:153441733	G/C	cg24028809	chr6:153414101	RGS17	0.2	4.5	0.38	1.51e-5	Prostate cancer;
TGCT	trans	rs9364554	0.506	rs3125055	chr6:160736787	A/T	cg26000619	chr19:2251067	AMH	-0.86	-6.66	-0.51	7.77e-10	Prostate cancer (SNP x SNP interaction);Prostate cancer;
TGCT	cis	rs6459788	0.502	rs9692347	chr7:157232659	C/T	cg06271696	chr7:157225062	NA	-0.35	-6.37	-0.5	3.36e-9	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs137699	1.000	rs2413588	chr22:39755175	A/G	cg11247378	chr22:39784982	NA	-0.46	-5.09	-0.42	1.28e-6	IgG glycosylation;
TGCT	cis	rs4727027	0.933	rs757738	chr7:148872351	T/G	cg23583168	chr7:148888333	NA	-0.75	-9.84	-0.66	3.1e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	trans	rs931812	0.757	rs4734015	chr8:101909258	C/G	cg20993868	chr7:22813445	NA	0.33	6.77	0.52	4.48e-10	Attention deficit hyperactivity disorder and conduct disorder;
TGCT	cis	rs7264396	0.635	rs6058344	chr20:34475038	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.04	-0.41	1.58e-6	Total cholesterol levels;
TGCT	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg22920501	chr2:26401640	FAM59B	-0.79	-6.36	-0.5	3.58e-9	Gut microbiome composition (summer);
TGCT	cis	rs11031096	0.542	rs7924984	chr11:3974588	C/T	cg08557956	chr11:4115526	RRM1	-0.52	-4.72	-0.39	6.28e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs1580019	0.587	rs7805311	chr7:32558302	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-1.1	-14.09	-0.78	1.65e-27	Cognitive ability;
TGCT	cis	rs174601	0.833	rs174541	chr11:61565908	T/C	cg01500311	chr11:61656094	FADS3	-0.31	-5.16	-0.42	9.37e-7	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
TGCT	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg22535103	chr8:58192502	C8orf71	-0.37	-4.73	-0.39	6.08e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs921968	0.608	rs832817	chr2:219358603	C/T	cg02176678	chr2:219576539	TTLL4	0.44	6.33	0.49	4.17e-9	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.99	11.05	0.7	3.51e-20	Height;
TGCT	cis	rs12220238	0.915	rs11000987	chr10:76073265	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.9	6.28	0.49	5.18e-9	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg27121462	chr16:89883253	FANCA	0.83	9.35	0.64	4.78e-16	Vitiligo;
TGCT	cis	rs644799	0.603	rs1255180	chr11:95472134	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.5	4.8	0.4	4.53e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7674212	0.507	rs223413	chr4:103732866	A/G	cg16532752	chr4:104119610	CENPE	0.61	5.1	0.42	1.26e-6	Type 2 diabetes;
TGCT	cis	rs7216064	1.000	rs6504542	chr17:65836642	T/C	cg12091567	chr17:66097778	LOC651250	-0.87	-6.85	-0.52	3.1e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs35306767	0.903	rs35968821	chr10:910225	A/G	cg20503657	chr10:835505	NA	0.74	10.3	0.68	2.41e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg08048268	chr3:133502702	NA	-0.67	-10.27	-0.68	2.75e-18	Iron status biomarkers;
TGCT	cis	rs2299587	0.689	rs12546237	chr8:17797055	A/G	cg01800426	chr8:17659068	MTUS1	-0.65	-5.68	-0.45	9.22e-8	Economic and political preferences;
TGCT	cis	rs35306767	0.953	rs34405399	chr10:981015	G/A	cg18964960	chr10:1102726	WDR37	0.56	4.58	0.38	1.12e-5	Eosinophil percentage of granulocytes;
TGCT	cis	rs910316	1.000	rs12435391	chr14:75601737	A/G	cg11812906	chr14:75593930	NEK9	0.73	7.18	0.54	5.79e-11	Height;
TGCT	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg24846343	chr22:24311635	DDTL	0.23	5.74	0.46	6.85e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs909674	0.734	rs5757675	chr22:39838892	G/T	cg05872129	chr22:39784769	NA	-0.98	-9.83	-0.66	3.19e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs986417	1.000	rs1268621	chr14:60921571	G/A	cg27398547	chr14:60952738	C14orf39	-1.39	-10.61	-0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs929354	0.713	rs3802130	chr7:156965237	A/G	cg05182265	chr7:156933206	UBE3C	-0.39	-8.79	-0.62	1.03e-14	Body mass index;
TGCT	cis	rs7017914	0.837	rs2639952	chr8:71925730	T/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.56	-5.11	-0.42	1.21e-6	Bone mineral density;
TGCT	cis	rs35146811	0.735	rs1061230	chr7:99807265	G/A	cg04778012	chr7:99775508	STAG3;GPC2	-0.35	-4.93	-0.41	2.55e-6	Coronary artery disease;
TGCT	cis	rs6893807	0.778	rs35991856	chr5:87968347	C/A	cg24804195	chr5:87968844	LOC645323	0.77	4.58	0.38	1.11e-5	Body mass index;
TGCT	cis	rs10782582	0.593	rs79552201	chr1:76215497	A/T	cg22875332	chr1:76189707	ACADM	-0.49	-5.39	-0.44	3.35e-7	Daytime sleep phenotypes;
TGCT	cis	rs1865760	0.566	rs1971509	chr6:26085777	T/C	cg17042849	chr6:26104293	HIST1H4C	-0.63	-5.47	-0.44	2.43e-7	Height;
TGCT	cis	rs12681288	0.862	rs935821	chr8:1022455	G/A	cg08872321	chr8:1308229	NA	-0.25	-4.67	-0.39	7.63e-6	Schizophrenia;
TGCT	cis	rs6840360	1.000	rs1896883	chr4:152595373	C/T	cg17479576	chr4:152424074	FAM160A1	0.51	5.46	0.44	2.5e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2692947	0.644	rs772178	chr2:96963684	C/T	cg22654517	chr2:96458247	NA	-0.21	-4.75	-0.39	5.54e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.98	10.69	0.69	2.69e-19	Height;
TGCT	cis	rs6964587	1.000	rs10281556	chr7:91660053	C/T	cg22709100	chr7:91322751	NA	-0.27	-4.5	-0.37	1.55e-5	Breast cancer;
TGCT	trans	rs9951602	0.512	rs4799245	chr18:76653397	T/C	cg02800362	chr5:177631904	HNRNPAB	1.14	12.9	0.76	1.17e-24	Obesity-related traits;
TGCT	cis	rs1801251	1.000	rs2044449	chr2:233718808	G/A	cg08000102	chr2:233561755	GIGYF2	-0.63	-6.41	-0.5	2.72e-9	Coronary artery disease;
TGCT	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg16325326	chr1:53192061	ZYG11B	0.59	6.41	0.5	2.81e-9	Monocyte count;
TGCT	cis	rs62244186	0.535	rs59726036	chr3:44850074	G/T	cg10263370	chr3:44754102	ZNF502	-0.47	-5.47	-0.44	2.4e-7	Depressive symptoms;
TGCT	cis	rs9409154	1.000	rs9408867	chr9:118209531	T/A	cg14094498	chr9:119000864	PAPPA	0.23	4.59	0.38	1.05e-5	Visceral adipose tissue adjusted for BMI;
TGCT	cis	rs7666738	0.680	rs11726233	chr4:99079773	G/A	cg17366294	chr4:99064904	C4orf37	0.68	6.58	0.51	1.19e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2235642	0.893	rs2143285	chr16:1593171	A/G	cg00463982	chr16:1583984	IFT140;TMEM204	-0.28	-4.72	-0.39	6.2e-6	Coronary artery disease;
TGCT	cis	rs7611238	0.583	rs58178384	chr3:195130096	G/A	cg27323046	chr3:195102265	ACAP2	0.36	4.89	0.4	3.1e-6	Body mass index;
TGCT	cis	rs3935685	0.874	rs36058724	chr15:78006745	C/A	cg25212270	chr15:78015279	NA	0.26	5.45	0.44	2.64e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9611565	0.546	rs5758430	chr22:42109844	G/T	cg17554472	chr22:41940697	POLR3H	0.48	5.17	0.42	9e-7	Vitiligo;
TGCT	cis	rs1577917	1.000	rs7756203	chr6:86627707	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.54	-0.45	1.73e-7	Response to antipsychotic treatment;
TGCT	cis	rs7772486	0.521	rs9485017	chr6:146023326	C/T	cg23711669	chr6:146136114	FBXO30	0.68	6.38	0.5	3.21e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9393692	0.627	rs1059486	chr6:26200083	A/G	cg05868516	chr6:26286170	HIST1H4H	0.52	5.18	0.42	8.72e-7	Educational attainment;
TGCT	cis	rs35306767	0.761	rs12359796	chr10:1021479	G/C	cg18964960	chr10:1102726	WDR37	0.74	5.25	0.43	6.39e-7	Eosinophil percentage of granulocytes;
TGCT	cis	rs3125734	0.660	rs10733769	chr10:63974255	G/T	cg19640130	chr10:64028056	RTKN2	-0.41	-5.19	-0.42	8.51e-7	Rheumatoid arthritis;
TGCT	cis	rs6500602	0.855	rs1139652	chr16:4476089	T/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.44	5.42	0.44	3.01e-7	Schizophrenia;
TGCT	cis	rs7208859	0.573	rs216442	chr17:28931197	T/G	cg13385521	chr17:29058706	SUZ12P	0.81	4.87	0.4	3.39e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs1692580	0.840	rs263526	chr1:2173504	T/C	cg21194808	chr1:2205498	SKI	0.3	5.69	0.46	8.51e-8	Coronary artery disease;
TGCT	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg05368731	chr17:41323189	NBR1	1.21	14.63	0.8	8.89e-29	Menopause (age at onset);
TGCT	cis	rs9660992	0.573	rs1172159	chr1:205207512	T/C	cg00857998	chr1:205179979	DSTYK	0.51	4.68	0.39	7.34e-6	Mean corpuscular volume;Mean platelet volume;
TGCT	cis	rs7095607	0.813	rs10997973	chr10:69930054	T/C	cg18986048	chr10:69913749	MYPN	0.44	5.02	0.41	1.72e-6	Lung function (FVC);
TGCT	cis	rs71636778	0.509	rs34976021	chr1:27298564	C/A	cg23921621	chr1:27994728	IFI6	-0.43	-4.66	-0.39	8.14e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
TGCT	cis	rs9914988	0.943	rs34693224	chr17:27079555	C/T	cg20469991	chr17:27169893	C17orf63	-0.72	-5.04	-0.41	1.58e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg25767906	chr1:53392781	SCP2	0.6	7.21	0.54	4.89e-11	Monocyte count;
TGCT	cis	rs3749237	0.964	rs62260719	chr3:49852419	G/A	cg07636037	chr3:49044803	WDR6	0.61	5.36	0.43	3.9e-7	Resting heart rate;
TGCT	cis	rs1580019	0.885	rs3801331	chr7:32497039	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.85	-7.93	-0.58	1.08e-12	Cognitive ability;
TGCT	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg11494091	chr17:61959527	GH2	0.61	14.81	0.8	3.37e-29	Prudent dietary pattern;
TGCT	cis	rs11785400	0.762	rs4401833	chr8:143739731	A/T	cg24634471	chr8:143751801	JRK	0.55	5.51	0.44	1.99e-7	Schizophrenia;
TGCT	cis	rs9372253	0.678	rs9487392	chr6:110708626	C/T	cg00083206	chr6:110721305	DDO	0.38	5.51	0.44	1.94e-7	Platelet distribution width;
TGCT	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg06640241	chr16:89574553	SPG7	0.77	8.57	0.61	3.4e-14	Multiple myeloma (IgH translocation);
TGCT	cis	rs7178572	0.568	rs11072643	chr15:77415508	T/A	cg22256960	chr15:77711686	NA	0.85	8.6	0.61	2.85e-14	Type 2 diabetes;
TGCT	cis	rs4072705	0.615	rs6478666	chr9:127249343	C/G	cg13476313	chr9:127244764	NR5A1	-0.3	-5.01	-0.41	1.81e-6	Menarche (age at onset);
TGCT	cis	rs797680	0.964	rs624131	chr1:93683210	A/G	cg17826107	chr1:92977322	EVI5	0.24	5.3	0.43	5.16e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	trans	rs9951602	0.512	rs4799249	chr18:76654370	A/G	cg02800362	chr5:177631904	HNRNPAB	1.13	12.84	0.76	1.57e-24	Obesity-related traits;
TGCT	cis	rs9916302	0.904	rs11869109	chr17:37518205	G/T	cg07936489	chr17:37558343	FBXL20	0.65	5.09	0.42	1.3e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs2204008	0.714	rs11520135	chr12:38114863	C/T	cg13010199	chr12:38710504	ALG10B	0.65	5.19	0.42	8.26e-7	Bladder cancer;
TGCT	cis	rs6964587	1.000	rs6976122	chr7:91610962	T/C	cg22709100	chr7:91322751	NA	0.27	4.48	0.37	1.68e-5	Breast cancer;
TGCT	cis	rs7267979	0.966	rs416745	chr20:25438868	T/C	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7772486	0.817	rs2144477	chr6:146406248	C/T	cg13319975	chr6:146136371	FBXO30	-0.51	-4.48	-0.37	1.69e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9436747	0.680	rs1171268	chr1:65996166	G/T	cg14976592	chr1:65886160	LEPROT;LEPR	-0.5	-4.69	-0.39	7.14e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs12762955	0.507	rs7070724	chr10:1040138	C/T	cg26597838	chr10:835615	NA	-0.49	-6.41	-0.5	2.76e-9	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs10114408	0.959	rs57222595	chr9:96663077	G/A	cg13679303	chr9:96623674	NA	-0.36	-4.66	-0.39	8e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs904251	0.772	rs2252920	chr6:37418327	A/G	cg08126542	chr6:37504118	NA	-0.39	-4.49	-0.37	1.6e-5	Cognitive performance;
TGCT	cis	rs13242816	1.000	rs56298491	chr7:116116687	C/T	cg16553024	chr7:116138462	CAV2	-0.45	-4.75	-0.39	5.64e-6	P wave duration;
TGCT	cis	rs9818758	0.607	rs9311439	chr3:49310408	A/G	cg00383909	chr3:49044727	WDR6	1.28	6.57	0.51	1.23e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs1552244	0.554	rs6762702	chr3:10055789	G/A	cg00149659	chr3:10157352	C3orf10	0.69	4.99	0.41	2.03e-6	Alzheimer's disease;
TGCT	cis	rs6977940	0.818	rs73033457	chr7:2899235	C/A	cg19731401	chr7:2775893	GNA12	0.37	4.49	0.37	1.61e-5	White matter integrity;
TGCT	cis	rs4803468	1.000	rs55986560	chr19:41939835	C/T	cg09537434	chr19:41945824	ATP5SL	0.92	10.44	0.68	1.1e-18	Height;
TGCT	trans	rs17685	0.753	rs1574107	chr7:75685047	A/C	cg19862616	chr7:65841803	NCRNA00174	0.5	8.31	0.6	1.45e-13	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs9399135	0.967	rs2297338	chr6:135375762	G/A	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.21e-6	Red blood cell count;
TGCT	cis	rs9341808	0.591	rs6454147	chr6:80916328	G/A	cg08355045	chr6:80787529	NA	0.31	5.17	0.42	9e-7	Sitting height ratio;
TGCT	trans	rs4332037	0.851	rs73050128	chr7:1961882	C/A	cg10840412	chr1:235813424	GNG4	1.05	8.44	0.6	7.18e-14	Bipolar disorder;
TGCT	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg04944784	chr2:26401820	FAM59B	-0.7	-6.49	-0.5	1.89e-9	Gut microbiome composition (summer);
TGCT	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	8.16	0.59	3.1400000000000003e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs2197308	0.765	rs11182481	chr12:37926019	T/C	cg13010199	chr12:38710504	ALG10B	0.63	5.2	0.42	7.87e-7	Morning vs. evening chronotype;
TGCT	cis	rs11190604	1.000	rs4604805	chr10:102261409	C/G	cg16342193	chr10:102329863	NA	-0.4	-5.17	-0.42	9.14e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs3820928	0.874	rs2276593	chr2:227898434	A/G	cg11843606	chr2:227700838	RHBDD1	0.52	4.62	0.38	9.37e-6	Pulmonary function;
TGCT	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg04234412	chr22:24373322	LOC391322	-0.91	-10.46	-0.68	9.75e-19	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2180341	0.574	rs13192350	chr6:127677762	G/T	cg27446573	chr6:127587934	RNF146	0.67	5.92	0.47	2.88e-8	Breast cancer;
TGCT	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg08439880	chr3:133502540	NA	-0.32	-5.89	-0.47	3.39e-8	Iron status biomarkers;
TGCT	cis	rs6912958	0.678	rs9450733	chr6:88250081	C/T	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.91	-0.4	2.78e-6	Monocyte percentage of white cells;
TGCT	cis	rs11031096	0.655	rs56172516	chr11:4182004	G/T	cg18678763	chr11:4115507	RRM1	-0.44	-5.75	-0.46	6.48e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs7772486	0.713	rs2328704	chr6:146020494	T/C	cg23711669	chr6:146136114	FBXO30	-0.81	-8.65	-0.61	2.25e-14	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7017914	0.934	rs62530772	chr8:71601541	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.03	-0.41	1.69e-6	Bone mineral density;
TGCT	cis	rs7662987	0.517	rs2602881	chr4:100040695	A/G	cg12011299	chr4:100065546	ADH4	0.39	4.81	0.4	4.36e-6	Smoking initiation;
TGCT	cis	rs6693567	0.565	rs1260457	chr1:150347374	G/A	cg09579323	chr1:150459698	TARS2	0.54	4.79	0.4	4.59e-6	Migraine;
TGCT	cis	rs6809651	0.524	rs6444105	chr3:185811301	C/T	cg00760338	chr3:185826511	ETV5	-0.78	-6.56	-0.51	1.32e-9	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
TGCT	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs35883536	0.513	rs4907910	chr1:101013277	T/A	cg06223162	chr1:101003688	GPR88	0.42	8.13	0.59	3.84e-13	Monocyte count;
TGCT	cis	rs6840360	0.642	rs2053566	chr4:152445831	A/C	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.82e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg08280861	chr8:58055591	NA	0.51	5.73	0.46	7.17e-8	Developmental language disorder (linguistic errors);
TGCT	cis	rs902774	0.554	rs4919749	chr12:53358034	C/T	cg16329197	chr12:53359506	NA	-0.52	-7.63	-0.57	5.32e-12	Prostate cancer;
TGCT	cis	rs12369635	1.000	rs9645723	chr12:129554501	C/T	cg01909103	chr12:129572610	TMEM132D	-0.64	-4.63	-0.38	9.16e-6	Schizophrenia (inflammation and infection response interaction);
TGCT	cis	rs1008375	1.000	rs56308330	chr4:17643050	G/A	cg16339924	chr4:17578868	LAP3	0.61	5.19	0.42	8.41e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg00814883	chr7:100076585	TSC22D4	-0.9	-9.56	-0.65	1.5e-16	Platelet count;
TGCT	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg11366901	chr6:160182831	ACAT2	0.79	5.81	0.46	4.92e-8	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs3812831	0.629	rs7318527	chr13:114946956	C/T	cg15513719	chr13:114904418	NA	0.38	4.68	0.39	7.53e-6	Schizophrenia;
TGCT	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg24675658	chr1:53192096	ZYG11B	0.9	12.17	0.74	6.61e-23	Monocyte count;
TGCT	cis	rs6061231	0.798	rs2427308	chr20:60969451	C/T	cg24112000	chr20:60950667	NA	-0.4	-5.06	-0.41	1.44e-6	Colorectal cancer;
TGCT	cis	rs7246657	0.943	rs10417503	chr19:37842735	T/C	cg18154014	chr19:37997991	ZNF793	0.97	6.49	0.5	1.82e-9	Coronary artery calcification;
TGCT	cis	rs3087591	0.919	rs2952993	chr17:29539998	G/A	cg24425628	chr17:29625626	OMG;NF1	0.42	6.22	0.49	7.06e-9	Hip circumference;
TGCT	cis	rs9436747	0.680	rs2154381	chr1:65995701	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	-0.49	-4.52	-0.38	1.42e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs2469997	1.000	rs2447183	chr8:120352978	A/G	cg00681363	chr8:120844660	TAF2	0.65	4.52	0.38	1.45e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs62380364	0.602	rs588282	chr5:88032651	G/T	cg24804195	chr5:87968844	LOC645323	-0.59	-5.9	-0.47	3.31e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2440129	0.611	rs1042357	chr17:6905061	T/G	cg19536664	chr17:6899085	ALOX12	0.39	6.1	0.48	1.23e-8	Tonsillectomy;
TGCT	cis	rs4595586	0.967	rs1400280	chr12:39241240	A/G	cg10518543	chr12:38710700	ALG10B	-0.52	-5.37	-0.43	3.7e-7	Morning vs. evening chronotype;
TGCT	cis	rs707040	1.000	rs6760854	chr2:155235144	C/T	cg18104148	chr2:154337490	NA	0.19	4.56	0.38	1.2e-5	Sudden cardiac arrest;
TGCT	cis	rs7666738	0.822	rs979946	chr4:98921235	C/A	cg18180107	chr4:99064573	C4orf37	0.56	5.13	0.42	1.08e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7598759	0.527	rs7571691	chr2:232369401	C/T	cg19187155	chr2:232395269	NMUR1	0.47	5.43	0.44	2.91e-7	Noise-induced hearing loss;
TGCT	cis	rs16958440	0.867	rs28578518	chr18:44687548	A/C	cg17192377	chr18:44677553	HDHD2	0.63	4.7	0.39	6.74e-6	Sitting height ratio;
TGCT	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg27425262	chr2:113953981	PSD4;LOC440839	-0.53	-8.24	-0.59	2.08e-13	Lymphocyte counts;
TGCT	cis	rs10114408	0.959	rs1933675	chr9:96655212	C/T	cg13679303	chr9:96623674	NA	-0.36	-4.69	-0.39	7e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg21724239	chr8:58056113	NA	0.4	5.01	0.41	1.8e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs57590327	0.503	rs9874464	chr3:81505488	C/G	cg07356753	chr3:81810745	GBE1	-0.59	-5.03	-0.41	1.67e-6	Extraversion;
TGCT	cis	rs6665290	0.904	rs2297416	chr1:227172935	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.0	-19.47	-0.87	1.62e-39	Myeloid white cell count;
TGCT	cis	rs55823223	0.646	rs74410877	chr17:73832384	C/T	cg10935138	chr17:73851978	WBP2	0.91	5.54	0.45	1.72e-7	Psoriasis;
TGCT	cis	rs2688608	0.592	rs12253429	chr10:75496161	C/G	cg04320760	chr10:75533139	FUT11	-0.4	-6.25	-0.49	6.11e-9	Inflammatory bowel disease;
TGCT	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg06238570	chr21:40685208	BRWD1	0.67	5.95	0.47	2.5e-8	Cognitive function;
TGCT	cis	rs13217239	0.646	rs12209886	chr6:26984757	G/A	cg02458000	chr6:26745757	NA	0.5	4.61	0.38	9.84e-6	Schizophrenia;
TGCT	cis	rs9300255	0.602	rs1727315	chr12:123638930	A/G	cg00376283	chr12:123451042	ABCB9	-0.67	-5.27	-0.43	5.78e-7	Neutrophil percentage of white cells;
TGCT	cis	rs1348850	0.958	rs11684320	chr2:178456346	T/C	cg22681709	chr2:178499509	PDE11A	-0.4	-4.97	-0.41	2.18e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs7772486	0.875	rs11155452	chr6:146424631	C/T	cg05347473	chr6:146136440	FBXO30	0.56	5.22	0.42	7.31e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3749237	0.615	rs11130202	chr3:49566715	C/T	cg07636037	chr3:49044803	WDR6	0.64	6.11	0.48	1.18e-8	Resting heart rate;
TGCT	cis	rs6964587	0.655	rs6465351	chr7:91773213	T/C	cg17063962	chr7:91808500	NA	0.74	6.94	0.53	1.93e-10	Breast cancer;
TGCT	cis	rs7107174	0.581	rs11237485	chr11:78126011	G/A	cg12700464	chr11:78128424	GAB2	-0.66	-4.45	-0.37	1.9e-5	Testicular germ cell tumor;
TGCT	cis	rs2739330	0.964	rs2739338	chr22:24297130	T/C	cg12419862	chr22:24373484	LOC391322	-0.8	-8.67	-0.61	1.97e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	trans	rs1864729	1.000	rs2439702	chr8:98272647	C/T	cg08679828	chr8:102218111	ZNF706	-1.09	-7.6	-0.56	6.34e-12	Estradiol plasma levels (breast cancer);
TGCT	cis	rs7940866	0.834	rs1594821	chr11:130835883	C/T	cg12179176	chr11:130786555	SNX19	0.66	6.07	0.48	1.46e-8	Schizophrenia;
TGCT	cis	rs17376456	0.825	rs67328989	chr5:93243133	T/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.74	4.89	0.4	3.12e-6	Diabetic retinopathy;
TGCT	cis	rs4499344	0.633	rs411328	chr19:33140178	T/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.83	8.96	0.63	4.15e-15	Mean platelet volume;
TGCT	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg06873352	chr17:61820015	STRADA	0.55	6.13	0.48	1.09e-8	Prudent dietary pattern;
TGCT	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg06873352	chr17:61820015	STRADA	-0.53	-5.99	-0.47	2.14e-8	Prudent dietary pattern;
TGCT	cis	rs939574	1.000	rs6712442	chr2:220117333	T/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-1.05	-6.46	-0.5	2.12e-9	Platelet distribution width;
TGCT	cis	rs8180040	1.000	rs11130127	chr3:47398793	C/G	cg27129171	chr3:47204927	SETD2	-0.7	-8.63	-0.61	2.53e-14	Colorectal cancer;
TGCT	cis	rs858239	0.602	rs6953996	chr7:23175946	A/G	cg05602783	chr7:23145260	KLHL7	-0.67	-5.71	-0.46	8.04e-8	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs74233809	1.000	rs12219027	chr10:104811203	T/C	cg05855489	chr10:104503620	C10orf26	0.76	4.53	0.38	1.36e-5	Birth weight;
TGCT	cis	rs13256369	1.000	rs13256369	chr8:8577379	T/C	cg17143192	chr8:8559678	CLDN23	0.62	5.87	0.47	3.67e-8	Obesity-related traits;
TGCT	trans	rs1814175	0.817	rs4084376	chr11:49831160	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.35	-0.55	2.38e-11	Height;
TGCT	cis	rs926938	0.563	rs360652	chr1:115445478	C/T	cg12756093	chr1:115239321	AMPD1	0.4	6.33	0.49	4.02e-9	Autism;
TGCT	cis	rs7611238	0.560	rs9855453	chr3:195067232	G/A	cg27323046	chr3:195102265	ACAP2	0.35	4.82	0.4	4.11e-6	Body mass index;
TGCT	cis	rs7178572	0.568	rs28584877	chr15:77599003	C/A	cg15453836	chr15:77711506	NA	0.42	4.79	0.4	4.68e-6	Type 2 diabetes;
TGCT	cis	rs116095464	0.558	rs7703803	chr5:292311	A/G	cg22857025	chr5:266934	NA	-0.34	-6.64	-0.51	8.6e-10	Breast cancer;
TGCT	cis	rs9467773	0.587	rs10946813	chr6:26345141	A/G	cg05738196	chr6:26577821	NA	0.62	6.59	0.51	1.12e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs8180040	1.000	rs7613282	chr3:47389409	C/T	cg27129171	chr3:47204927	SETD2	-0.7	-8.63	-0.61	2.53e-14	Colorectal cancer;
TGCT	trans	rs7618501	0.521	rs868891	chr3:49949071	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.79	8.11	0.59	4.13e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs4919694	1.000	rs4917379	chr10:104752831	A/T	cg04362960	chr10:104952993	NT5C2	1.07	7.07	0.54	9.73e-11	Arsenic metabolism;
TGCT	cis	rs17108533	0.588	rs12886330	chr14:71301048	G/A	cg23900759	chr14:71108106	TTC9	-1.14	-4.61	-0.38	9.92e-6	Response to antipsychotic treatment in schizophrenia (reasoning);
TGCT	cis	rs9325144	0.752	rs12300353	chr12:39154492	G/C	cg26384229	chr12:38710491	ALG10B	-0.64	-6.04	-0.48	1.67e-8	Morning vs. evening chronotype;
TGCT	cis	rs3796352	1.000	rs34244302	chr3:53102236	C/G	cg07884673	chr3:53033167	SFMBT1	0.59	6.05	0.48	1.6e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs9868809	0.772	rs34096717	chr3:48719453	A/C	cg00383909	chr3:49044727	WDR6	1.04	5.88	0.47	3.6e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs57920188	0.703	rs10915642	chr1:4089244	T/C	cg20703997	chr1:4087676	NA	0.49	6.12	0.48	1.11e-8	Interleukin-17 levels;
TGCT	cis	rs7246657	0.722	rs10402671	chr19:38117086	C/T	cg03611452	chr19:38183253	ZNF781	0.58	4.64	0.38	8.62e-6	Coronary artery calcification;
TGCT	cis	rs2458413	0.771	rs7010076	chr8:105342827	C/G	cg13045555	chr8:105342365	NA	-0.4	-6.46	-0.5	2.11e-9	Paget's disease;
TGCT	cis	rs6121246	0.512	rs45443696	chr20:30311396	A/C	cg13852791	chr20:30311386	BCL2L1	0.83	8.0	0.58	7.45e-13	Mean corpuscular hemoglobin;
TGCT	cis	rs769267	0.792	rs4808961	chr19:19577215	C/G	cg08509172	chr19:19383838	TM6SF2	-0.34	-4.47	-0.37	1.76e-5	Tonsillectomy;
TGCT	cis	rs7824557	0.843	rs2736375	chr8:11115749	C/T	cg21775007	chr8:11205619	TDH	-0.5	-4.83	-0.4	3.9e-6	Retinal vascular caliber;
TGCT	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg27121462	chr16:89883253	FANCA	0.83	9.3	0.64	6.14e-16	Vitiligo;
TGCT	cis	rs9341808	0.667	rs6938280	chr6:80897782	G/A	cg08355045	chr6:80787529	NA	0.3	5.09	0.42	1.27e-6	Sitting height ratio;
TGCT	cis	rs6700896	0.500	rs6700421	chr1:66082135	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.59	4.56	0.38	1.22e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs308403	0.600	rs13135445	chr4:123664457	C/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.67	6.55	0.51	1.4e-9	Blood protein levels;
TGCT	cis	rs7223966	1.000	rs11658175	chr17:61923838	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	4.68	0.39	7.5e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg20607798	chr8:58055168	NA	0.61	5.16	0.42	9.38e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs12971120	0.891	rs4891558	chr18:72170359	A/G	cg26446133	chr18:72167187	CNDP2	-0.35	-6.06	-0.48	1.51e-8	Refractive error;
TGCT	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	5.51	0.44	2.02e-7	Alzheimer's disease;
TGCT	cis	rs3784262	0.967	rs35511675	chr15:58266978	T/A	cg12031962	chr15:58353849	ALDH1A2	-0.49	-7.7	-0.57	3.78e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs60843830	1.000	rs57542652	chr2:228088	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.77	7.58	0.56	6.95e-12	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs3947	0.906	rs709822	chr8:11702313	C/G	cg02840367	chr8:11660030	FDFT1	1.0	8.13	0.59	3.82e-13	Blood protein levels;
TGCT	cis	rs2296887	0.841	rs10883717	chr10:103967590	A/G	cg26089160	chr10:104170217	PSD	-0.56	-4.97	-0.41	2.18e-6	Parkinson's disease;
TGCT	cis	rs7119	0.717	rs7176307	chr15:77816684	G/C	cg27398640	chr15:77910606	LINGO1	-0.25	-4.6	-0.38	1.05e-5	Type 2 diabetes;
TGCT	cis	rs9303401	0.614	rs2240719	chr17:56582477	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.71	6.78	0.52	4.45e-10	Cognitive test performance;
TGCT	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg16325326	chr1:53192061	ZYG11B	0.65	7.94	0.58	1.05e-12	Monocyte count;
TGCT	cis	rs765787	0.530	rs11639403	chr15:45538350	A/G	cg24006582	chr15:45444508	DUOX1	-0.25	-5.54	-0.45	1.76e-7	Uric acid levels;
TGCT	cis	rs709400	0.603	rs2296486	chr14:104003070	A/G	cg26031613	chr14:104095156	KLC1	0.89	9.8	0.66	3.77e-17	Body mass index;
TGCT	cis	rs13082711	0.522	rs820617	chr3:27335510	T/C	cg02860705	chr3:27208620	NA	0.33	5.45	0.44	2.62e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg03806693	chr22:41940476	POLR3H	-1.15	-13.24	-0.77	1.73e-25	Vitiligo;
TGCT	cis	rs79349575	0.729	rs62075824	chr17:46986679	A/G	cg07967210	chr17:47022446	SNF8	0.43	6.06	0.48	1.54e-8	Type 2 diabetes;
TGCT	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg03709012	chr19:19516395	GATAD2A	0.67	5.72	0.46	7.56e-8	Tonsillectomy;
TGCT	cis	rs12210905	1.000	rs114337870	chr6:27254937	A/C	cg08851530	chr6:28072375	NA	1.29	5.49	0.44	2.19e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs1555895	0.568	rs4097329	chr10:844839	T/C	cg02193355	chr10:851439	NA	0.22	4.71	0.39	6.6e-6	Survival in rectal cancer;
TGCT	cis	rs17001868	0.568	rs760700	chr22:40800071	C/T	cg07138101	chr22:40742427	ADSL	-0.74	-5.71	-0.46	8.01e-8	Mammographic density (dense area);
TGCT	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg20276088	chr3:133502917	NA	0.26	5.39	0.44	3.44e-7	Iron status biomarkers;
TGCT	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg17178900	chr1:205818956	PM20D1	0.58	7.21	0.54	4.81e-11	Menarche (age at onset);
TGCT	cis	rs35934224	0.783	rs34462686	chr22:19859917	A/G	cg11182965	chr22:19864308	TXNRD2	-0.38	-5.28	-0.43	5.71e-7	Glaucoma (primary open-angle);
TGCT	cis	rs17376456	0.825	rs17372615	chr5:93124768	C/T	cg21475434	chr5:93447410	FAM172A	0.63	4.92	0.4	2.72e-6	Diabetic retinopathy;
TGCT	cis	rs739496	0.579	rs3752631	chr12:112376157	A/G	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs6540559	0.673	rs17015309	chr1:210007218	C/T	cg22029157	chr1:209979665	IRF6	0.71	5.09	0.42	1.3e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs7193541	0.684	rs4888264	chr16:74681632	T/G	cg01733217	chr16:74700730	RFWD3	0.99	13.32	0.77	1.14e-25	Multiple myeloma;
TGCT	cis	rs35160687	0.901	rs12472676	chr2:86510815	T/C	cg12542933	chr2:85804724	VAMP8	0.39	4.69	0.39	7.08e-6	Night sleep phenotypes;
TGCT	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg22618164	chr12:122356400	WDR66	0.7	6.91	0.53	2.23e-10	Mean corpuscular volume;
TGCT	trans	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg21659725	chr3:3221576	CRBN	-0.67	-7.53	-0.56	9.05e-12	Body mass index;
TGCT	cis	rs68170813	0.559	rs3815148	chr7:106938420	G/T	cg02696742	chr7:106810147	HBP1	0.69	5.95	0.47	2.61e-8	Coronary artery disease;
TGCT	cis	rs826838	1.000	rs10875991	chr12:39108886	G/C	cg26384229	chr12:38710491	ALG10B	1.06	10.35	0.68	1.82e-18	Heart rate;
TGCT	cis	rs13188771	0.651	rs12523298	chr5:100903067	T/A	cg18665594	chr5:101119420	NA	0.44	4.47	0.37	1.74e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs916888	0.697	rs199516	chr17:44856485	C/T	cg16520312	chr17:43971471	MAPT;LOC100128977	0.59	5.17	0.42	8.98e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7824557	0.564	rs13268126	chr8:11230574	G/A	cg21775007	chr8:11205619	TDH	-0.64	-6.2	-0.49	7.66e-9	Retinal vascular caliber;
TGCT	cis	rs4689388	0.926	rs9998519	chr4:6292909	C/T	cg25554036	chr4:6271136	WFS1	0.54	7.37	0.55	2.11e-11	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs1362404	0.648	rs7193742	chr16:51991794	G/A	cg03955530	chr16:52681474	NA	0.31	4.55	0.38	1.24e-5	Gut microbiota (bacterial taxa);
TGCT	cis	rs10540	1.000	rs12801148	chr11:511707	T/G	cg03934478	chr11:495069	RNH1	0.32	4.82	0.4	4.16e-6	Body mass index;
TGCT	cis	rs2742417	0.603	rs2742457	chr3:45767487	G/A	cg04837898	chr3:45731254	SACM1L	-0.66	-7.09	-0.54	9.07e-11	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs7666738	0.861	rs10018654	chr4:99002226	A/G	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg11644478	chr21:40555479	PSMG1	1.03	11.02	0.7	4.14e-20	Cognitive function;
TGCT	cis	rs4642101	0.640	rs7629354	chr3:12827746	T/G	cg05775895	chr3:12838266	CAND2	0.66	7.03	0.53	1.21e-10	QRS complex (12-leadsum);
TGCT	cis	rs9611519	0.894	rs4821998	chr22:41468273	C/G	cg03806693	chr22:41940476	POLR3H	-0.66	-5.98	-0.47	2.25e-8	Neuroticism;
TGCT	cis	rs17539620	0.624	rs117591255	chr6:154839118	G/A	cg20019720	chr6:154832845	CNKSR3	0.57	4.99	0.41	2.02e-6	Lipoprotein (a) levels;
TGCT	cis	rs7654585	0.704	rs10212993	chr4:25937476	T/A	cg10409131	chr4:25915609	C4orf52	0.75	6.41	0.5	2.78e-9	Obesity-related traits;
TGCT	cis	rs433598	0.894	rs395501	chr16:20683296	C/T	cg16616769	chr16:19727142	IQCK;C16orf88	-0.2	-4.58	-0.38	1.1e-5	Schizophrenia;
TGCT	cis	rs367615	0.704	rs11747622	chr5:108844720	G/A	cg17395555	chr5:108820864	NA	0.31	5.86	0.47	3.94e-8	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs7552404	1.000	rs4559448	chr1:76203456	A/G	cg22875332	chr1:76189707	ACADM	0.77	9.42	0.65	3.17e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs3820068	0.655	rs11587521	chr1:15839206	T/C	cg05660106	chr1:15850417	CASP9	1.15	13.74	0.78	1.14e-26	Systolic blood pressure;
TGCT	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.72	5.19	0.42	8.33e-7	Platelet count;
TGCT	cis	rs9348729	1	rs9348729	chr6:26664268	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.63	-5.84	-0.46	4.22e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg03213289	chr20:61660250	NA	0.68	9.9	0.66	2.25e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs910316	1.000	rs175449	chr14:75590846	A/T	cg11812906	chr14:75593930	NEK9	-0.73	-7.13	-0.54	7.35e-11	Height;
TGCT	cis	rs7542091	0.739	rs10863793	chr1:210037420	G/A	cg22029157	chr1:209979665	IRF6	0.58	5.57	0.45	1.5e-7	Monobrow;
TGCT	cis	rs10464366	0.571	rs13233049	chr7:39187536	C/T	cg18850127	chr7:39170497	POU6F2	0.33	7.18	0.54	5.5e-11	IgG glycosylation;
TGCT	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg08280861	chr8:58055591	NA	0.52	5.97	0.47	2.35e-8	Developmental language disorder (linguistic errors);
TGCT	cis	rs2762353	0.603	rs12201071	chr6:25778055	C/T	cg12310025	chr6:25882481	NA	0.48	4.68	0.39	7.3e-6	Blood metabolite levels;
TGCT	trans	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.87	-9.4	-0.65	3.62e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg05368731	chr17:41323189	NBR1	1.19	13.97	0.78	3.22e-27	Menopause (age at onset);
TGCT	trans	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg21659725	chr3:3221576	CRBN	-0.7	-7.98	-0.58	8.35e-13	Body mass index;
TGCT	cis	rs854765	0.583	rs10048206	chr17:17866897	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	7.69	0.57	3.98e-12	Total body bone mineral density;
TGCT	cis	rs739401	0.611	rs3782069	chr11:3033275	G/A	cg05729581	chr11:3078854	CARS	-0.55	-5.24	-0.43	6.76e-7	Longevity;
TGCT	cis	rs2228479	0.618	rs62052174	chr16:89950901	G/A	cg04013166	chr16:89971882	TCF25	0.32	4.46	0.37	1.84e-5	Skin colour saturation;
TGCT	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg00684032	chr4:1343700	KIAA1530	0.22	4.83	0.4	3.99e-6	Obesity-related traits;
TGCT	cis	rs9372498	0.536	rs9481808	chr6:118784571	G/A	cg21191810	chr6:118973309	C6orf204	-0.37	-4.77	-0.39	5.03e-6	Diastolic blood pressure;
TGCT	cis	rs2439831	0.850	rs28524541	chr15:44124831	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.44	0.37	1.99e-5	Lung cancer in ever smokers;
TGCT	cis	rs7523273	0.925	rs12132780	chr1:207999605	C/T	cg22525895	chr1:207977042	MIR29B2	-0.48	-8.57	-0.61	3.42e-14	Schizophrenia;
TGCT	cis	rs941873	0.805	rs10762860	chr10:81117794	C/G	cg09469691	chr10:81107165	PPIF	0.54	5.37	0.43	3.75e-7	Height;
TGCT	cis	rs7226408	0.857	rs17652513	chr18:34483319	C/T	cg06757138	chr18:34340585	FHOD3	0.26	5.24	0.43	6.63e-7	Obesity-related traits;
TGCT	cis	rs13177918	0.677	rs2070844	chr5:149823785	G/A	cg14059543	chr5:149831962	NA	-0.71	-9.45	-0.65	2.77e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg10802521	chr3:52805072	NEK4	-0.78	-10.0	-0.67	1.26e-17	Bipolar disorder;
TGCT	cis	rs698813	0.674	rs4952707	chr2:44500683	G/C	cg00619915	chr2:44497795	NA	-0.22	-4.91	-0.4	2.79e-6	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
TGCT	cis	rs35146811	0.520	rs1015538	chr7:99626035	A/G	cg13334819	chr7:99746414	C7orf59	0.61	5.68	0.45	8.98e-8	Coronary artery disease;
TGCT	cis	rs35160687	0.842	rs10200526	chr2:86527599	G/A	cg12542933	chr2:85804724	VAMP8	0.41	4.9	0.4	2.97e-6	Night sleep phenotypes;
TGCT	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs322662	1.000	rs322662	chr3:25356873	A/G	cg23683962	chr3:24549503	NA	0.18	4.45	0.37	1.9e-5	Calcium levels;
TGCT	cis	rs651907	0.535	rs11919389	chr3:101424458	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	5.0	0.41	1.91e-6	Colorectal cancer;
TGCT	cis	rs6933660	0.512	rs13198669	chr6:151799924	A/G	cg03627880	chr6:151815985	C6orf97	0.72	6.84	0.52	3.29e-10	Menarche (age at onset);
TGCT	cis	rs6840360	0.571	rs875668	chr4:152525661	C/T	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.0	-0.58	7.69e-13	Intelligence (multi-trait analysis);
TGCT	trans	rs9859260	0.744	rs492288	chr3:195784210	C/T	cg17074656	chr11:63784126	MACROD1	0.52	6.67	0.51	7.49e-10	Mean corpuscular volume;
TGCT	cis	rs6977660	0.507	rs72591450	chr7:19775480	A/G	cg05791153	chr7:19748676	TWISTNB	1.01	6.63	0.51	9.26e-10	Thyroid stimulating hormone;
TGCT	cis	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg20637647	chr7:64974828	NA	0.89	4.99	0.41	2.01e-6	Diabetic kidney disease;
TGCT	cis	rs4851254	0.660	rs35869550	chr2:100684578	T/A	cg07810366	chr2:100720526	AFF3	-0.49	-5.22	-0.42	7.36e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7264396	0.790	rs2425083	chr20:34300456	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.3	-5.31	-0.43	4.96e-7	Total cholesterol levels;
TGCT	cis	rs9921338	0.961	rs6498185	chr16:11444726	C/T	cg00044050	chr16:11439710	C16orf75	-0.71	-5.47	-0.44	2.43e-7	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs362272	0.505	rs3129310	chr4:3301388	T/G	cg22655196	chr4:3374909	RGS12	0.24	4.69	0.39	7.07e-6	Serum sulfate level;
TGCT	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg13206674	chr6:150067644	NUP43	0.52	4.51	0.38	1.5e-5	Lung cancer;
TGCT	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg00149659	chr3:10157352	C3orf10	1.13	7.41	0.55	1.72e-11	Alzheimer's disease;
TGCT	cis	rs8031584	0.958	rs11629793	chr15:31238423	G/A	cg08704250	chr15:31115839	NA	-0.36	-4.96	-0.41	2.29e-6	Huntington's disease progression;
TGCT	cis	rs7208859	0.673	rs9894876	chr17:29182020	G/A	cg14008862	chr17:28927542	LRRC37B2	0.72	4.66	0.39	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	trans	rs941408	1.000	rs1736181	chr19:2797703	C/T	cg19676328	chr12:49525230	TUBA1B	-0.77	-7.68	-0.57	4.09e-12	Total cholesterol levels;
TGCT	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg16325326	chr1:53192061	ZYG11B	-0.71	-8.81	-0.62	9.22e-15	Monocyte count;
TGCT	cis	rs6845621	0.901	rs207294	chr4:18918758	C/A	cg12196642	chr4:18937545	NA	-0.24	-4.45	-0.37	1.91e-5	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
TGCT	cis	rs12681287	0.640	rs2953516	chr8:87332545	C/T	cg27223183	chr8:87520930	FAM82B	-0.94	-7.06	-0.54	1.02e-10	Caudate activity during reward;
TGCT	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg16414030	chr3:133502952	NA	-0.61	-9.47	-0.65	2.44e-16	Iron status biomarkers;
TGCT	cis	rs72945132	0.619	rs61887436	chr11:70243337	C/T	cg00319359	chr11:70116639	PPFIA1	1.01	7.03	0.53	1.21e-10	Coronary artery disease;
TGCT	cis	rs10206020	0.836	rs10202105	chr2:1553301	C/T	cg01028140	chr2:1542097	TPO	-0.34	-4.86	-0.4	3.54e-6	IgG glycosylation;
TGCT	cis	rs78487399	0.808	rs13417883	chr2:43700154	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-5.45	-0.44	2.63e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs4654899	0.833	rs10127757	chr1:21490045	A/G	cg01072550	chr1:21505969	NA	-0.48	-7.14	-0.54	7.03e-11	Superior frontal gyrus grey matter volume;
TGCT	cis	rs17725255	0.636	rs1205222	chr20:18131766	T/G	cg02706653	chr20:17208584	PCSK2	0.6	4.48	0.37	1.65e-5	Anorexia nervosa;
TGCT	cis	rs904251	0.797	rs1757181	chr6:37485728	A/G	cg01843034	chr6:37503916	NA	0.49	6.01	0.47	1.91e-8	Cognitive performance;
TGCT	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	6.23	0.49	6.56e-9	Bipolar disorder;
TGCT	cis	rs6714788	0.565	rs9308833	chr2:100662618	C/T	cg22139774	chr2:100720529	AFF3	-0.41	-6.58	-0.51	1.19e-9	Intelligence (multi-trait analysis);
TGCT	trans	rs877282	0.853	rs7083589	chr10:754494	G/A	cg22713356	chr15:30763199	NA	1.07	8.27	0.6	1.75e-13	Uric acid levels;
TGCT	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg02353165	chr6:42928485	GNMT	0.94	9.64	0.65	9.69e-17	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs9311474	1.000	rs9311474	chr3:52338852	T/C	cg07507251	chr3:52567010	NT5DC2	0.46	6.21	0.49	7.16e-9	Electroencephalogram traits;
TGCT	cis	rs9383153	1.000	rs2237223	chr6:16329741	G/A	cg20052079	chr6:15504923	JARID2	0.92	5.01	0.41	1.82e-6	Gambling;
TGCT	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg19318889	chr4:1322082	MAEA	0.27	6.66	0.51	7.93e-10	Longevity;
TGCT	cis	rs67460515	0.892	rs1478566	chr3:161030335	A/T	cg03342759	chr3:160939853	NMD3	-0.49	-5.31	-0.43	4.98e-7	Parkinson's disease;
TGCT	cis	rs1857353	1.000	rs79777526	chr1:75909485	T/C	cg11838876	chr1:75668600	SLC44A5	-0.51	-4.81	-0.4	4.23e-6	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs10927875	0.501	rs61782229	chr1:16220118	G/A	cg21385522	chr1:16154831	NA	-0.94	-9.41	-0.65	3.36e-16	Dilated cardiomyopathy;
TGCT	cis	rs2562456	0.516	rs56072098	chr19:21651960	G/T	cg01304269	chr19:21688519	ZNF429	-0.56	-4.7	-0.39	6.71e-6	Pain;
TGCT	cis	rs910316	1.000	rs12897094	chr14:75579416	C/T	cg23033748	chr14:75592666	NEK9	0.28	4.72	0.39	6.22e-6	Height;
TGCT	cis	rs9811920	0.609	rs4244713	chr3:99679584	T/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.62	6.98	0.53	1.6e-10	Axial length;
TGCT	cis	rs2692947	0.702	rs2312955	chr2:96777168	T/G	cg22654517	chr2:96458247	NA	-0.21	-4.58	-0.38	1.11e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs2456568	0.570	rs1827932	chr11:93663319	A/T	cg26875233	chr11:93583750	C11orf90	-0.42	-5.04	-0.41	1.59e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs3806843	0.576	rs246008	chr5:140338485	C/T	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7937682	0.889	rs10789844	chr11:111579109	A/T	cg09085632	chr11:111637200	PPP2R1B	-1.12	-12.65	-0.75	4.62e-24	Primary sclerosing cholangitis;
TGCT	cis	rs12188164	0.965	rs11744539	chr5:451425	C/T	cg26850624	chr5:429559	AHRR	-0.2	-4.84	-0.4	3.78e-6	Cystic fibrosis severity;
TGCT	cis	rs981844	0.743	rs17371461	chr4:154759220	C/T	cg14289246	chr4:154710475	SFRP2	1.01	8.89	0.62	5.85e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg05665937	chr4:1216051	CTBP1	0.25	4.68	0.39	7.33e-6	Obesity-related traits;
TGCT	cis	rs250677	1.000	rs190378	chr5:148434275	G/T	cg23229984	chr5:148520753	ABLIM3	0.21	4.96	0.41	2.22e-6	Breast cancer;
TGCT	cis	rs7027203	0.828	rs4744287	chr9:96585567	A/G	cg13679303	chr9:96623674	NA	0.66	10.69	0.69	2.63e-19	DNA methylation (variation);
TGCT	cis	rs11098499	0.954	rs6849171	chr4:120409549	G/A	cg09307838	chr4:120376055	NA	0.72	7.08	0.54	9.22e-11	Corneal astigmatism;
TGCT	cis	rs9549367	0.789	rs34448227	chr13:113884754	A/C	cg00898013	chr13:113819073	PROZ	-0.39	-4.79	-0.4	4.67e-6	Platelet distribution width;
TGCT	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg11965913	chr1:205819406	PM20D1	0.61	9.92	0.67	2e-17	Menarche (age at onset);
TGCT	cis	rs7659604	1.000	rs28532673	chr4:122664323	A/G	cg19748678	chr4:122722346	EXOSC9	-0.57	-5.49	-0.44	2.15e-7	Type 2 diabetes;
TGCT	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg11644478	chr21:40555479	PSMG1	-0.53	-4.57	-0.38	1.17e-5	Cognitive function;
TGCT	cis	rs595982	0.527	rs55706579	chr19:49382969	G/A	cg17863274	chr19:49399704	TULP2	-0.55	-7.89	-0.58	1.32e-12	Red cell distribution width;
TGCT	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg08280861	chr8:58055591	NA	0.39	4.76	0.39	5.35e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs76935404	0.811	rs12150973	chr19:41434524	T/C	cg19493303	chr19:41414353	NA	0.38	4.55	0.38	1.25e-5	nicotine metabolite ratio in current smokers;
TGCT	trans	rs57221529	0.766	rs56278696	chr5:582669	A/G	cg11887960	chr12:57824829	NA	1.14	9.3	0.64	6.29e-16	Lung disease severity in cystic fibrosis;
TGCT	cis	rs909685	0.538	rs5757596	chr22:39668961	G/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.74	8.41	0.6	8.05e-14	Rheumatoid arthritis;
TGCT	cis	rs13424612	0.864	rs4854071	chr2:240885050	C/T	cg26363272	chr2:240904871	NDUFA10	0.29	4.99	0.41	1.96e-6	Odorant perception (isobutyraldehyde);
TGCT	cis	rs4372836	0.729	rs4132617	chr2:29031312	C/A	cg09522027	chr2:28974177	PPP1CB	-0.69	-7.27	-0.55	3.54e-11	Body mass index;
TGCT	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7267979	1.000	rs4815407	chr20:25341478	G/C	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs796364	0.806	rs1509832	chr2:200874443	G/T	cg17644776	chr2:200775616	C2orf69	0.33	5.0	0.41	1.91e-6	Schizophrenia;
TGCT	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg06112835	chr11:68658793	MRPL21	0.47	8.14	0.59	3.49e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7666738	0.723	rs35327100	chr4:98977788	C/A	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4319547	1.000	rs6489157	chr12:123101673	C/G	cg23029597	chr12:123009494	RSRC2	0.29	4.75	0.39	5.43e-6	Body mass index;
TGCT	cis	rs11711311	1.000	rs12631232	chr3:113497386	C/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.73	-6.63	-0.51	9.38e-10	IgG glycosylation;
TGCT	cis	rs9398235	0.929	rs4945861	chr6:110728429	C/T	cg00083206	chr6:110721305	DDO	0.47	4.78	0.39	4.92e-6	Systemic lupus erythematosus;
TGCT	cis	rs4516970	0.826	rs59246098	chr6:160149462	C/CA	cg25736982	chr6:160182554	ACAT2	0.7	6.49	0.5	1.88e-9	Iron status biomarkers;
TGCT	cis	rs4689388	0.853	rs1079216	chr4:6282473	T/C	cg25554036	chr4:6271136	WFS1	0.57	7.77	0.57	2.63e-12	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs7208859	0.623	rs216433	chr17:28921860	T/C	cg19761014	chr17:28927070	LRRC37B2	0.56	4.81	0.4	4.32e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7666738	0.712	rs11731393	chr4:98859070	G/C	cg17366294	chr4:99064904	C4orf37	0.7	5.2	0.42	8.14e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9913156	0.793	rs8074545	chr17:4567337	C/G	cg19197139	chr17:4613644	ARRB2	-0.87	-8.05	-0.59	5.79e-13	Lymphocyte counts;
TGCT	cis	rs17068510	0.572	rs11777171	chr8:3875443	C/T	cg25338036	chr8:3047536	CSMD1	-0.46	-4.88	-0.4	3.19e-6	Cerebrospinal fluid clusterin levels;
TGCT	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.59	-6.01	-0.47	1.92e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7216064	1.000	rs8081517	chr17:65845697	A/T	cg12091567	chr17:66097778	LOC651250	-0.87	-6.85	-0.52	3.1e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs7666738	0.753	rs35146453	chr4:98902278	A/G	cg17366294	chr4:99064904	C4orf37	0.67	6.83	0.52	3.3e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7975161	1.000	rs7975161	chr12:104645405	C/T	cg25273343	chr12:104657179	TXNRD1	0.32	4.88	0.4	3.2e-6	Toenail selenium levels;
TGCT	cis	rs9534288	0.789	rs4942470	chr13:46636652	A/G	cg15192986	chr13:46630673	CPB2	-0.51	-6.19	-0.49	8.15e-9	Blood protein levels;
TGCT	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg07870213	chr5:140052090	DND1	-0.62	-7.4	-0.55	1.84e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs6121246	0.520	rs6060425	chr20:30224355	C/T	cg21427119	chr20:30132790	HM13	-0.37	-4.95	-0.41	2.4e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs9952991	0.883	rs2847293	chr18:12782448	A/T	cg23598886	chr18:12777645	NA	0.62	5.78	0.46	5.63e-8	Inflammatory skin disease;
TGCT	cis	rs739496	0.579	rs7956495	chr12:112295693	T/G	cg10833066	chr12:111807467	FAM109A	0.38	5.4	0.44	3.24e-7	Platelet count;
TGCT	cis	rs910316	1.000	rs3742780	chr14:75505008	G/C	cg23033748	chr14:75592666	NEK9	0.28	4.68	0.39	7.32e-6	Height;
TGCT	cis	rs7089973	0.872	rs41284358	chr10:116622339	A/G	cg03647239	chr10:116582469	FAM160B1	0.52	4.62	0.38	9.32e-6	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs7937682	0.889	rs567859	chr11:111486738	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.05	-11.36	-0.71	6.21e-21	Primary sclerosing cholangitis;
TGCT	cis	rs13191362	1.000	rs67646369	chr6:163003233	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7119038	0.818	rs2155433	chr11:118612921	G/A	cg19308663	chr11:118741387	NA	0.24	4.79	0.4	4.65e-6	Sjögren's syndrome;
TGCT	cis	rs28785552	0.931	rs10406850	chr19:53240807	A/C	cg04754360	chr19:53238445	ZNF611	-0.63	-5.05	-0.41	1.57e-6	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs6809651	0.524	rs4686730	chr3:185805993	C/T	cg00760338	chr3:185826511	ETV5	-0.77	-6.32	-0.49	4.23e-9	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
TGCT	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg00343986	chr7:65444356	GUSB	-0.23	-5.13	-0.42	1.07e-6	Aortic root size;
TGCT	cis	rs11190604	0.767	rs872290	chr10:102198879	G/A	cg23241863	chr10:102295624	HIF1AN	0.64	4.8	0.4	4.42e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7666738	0.791	rs62318907	chr4:99037120	C/T	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10262624	0.528	rs722294	chr7:23746585	A/C	cg09690326	chr7:23720549	C7orf46	0.43	4.47	0.37	1.76e-5	Schizophrenia;
TGCT	cis	rs7714584	1.000	rs1896707	chr5:150245129	C/T	cg22134413	chr5:150180641	NA	0.8	6.27	0.49	5.47e-9	Crohn's disease;
TGCT	cis	rs4148883	0.689	rs2602861	chr4:100030896	C/T	cg12011299	chr4:100065546	ADH4	0.38	5.74	0.46	6.75e-8	Alcohol dependence;
TGCT	cis	rs763014	0.931	rs1981483	chr16:630665	G/A	cg27436995	chr16:743998	FBXL16	-0.45	-4.82	-0.4	4.17e-6	Height;
TGCT	cis	rs7829975	0.557	rs7816427	chr8:8545884	T/C	cg06636001	chr8:8085503	FLJ10661	-0.6	-5.18	-0.42	8.83e-7	Mood instability;
TGCT	cis	rs2180341	0.538	rs11556354	chr6:127664661	G/A	cg24812749	chr6:127587940	RNF146	0.62	5.41	0.44	3.13e-7	Breast cancer;
TGCT	cis	rs4664308	0.935	rs4292050	chr2:160940899	G/T	cg03641300	chr2:160917029	PLA2R1	-0.27	-6.58	-0.51	1.2e-9	Idiopathic membranous nephropathy;
TGCT	cis	rs1670533	1.000	rs2290410	chr4:1052078	A/T	cg20887711	chr4:1340912	KIAA1530	0.7	5.33	0.43	4.53e-7	Recombination rate (females);
TGCT	cis	rs933688	1.000	rs889213	chr5:90682151	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.02	8.42	0.6	7.91e-14	Smoking behavior;
TGCT	cis	rs114540395	0.925	rs77449307	chr10:103385599	A/C	cg03300883	chr10:102748874	C10orf2	0.42	4.58	0.38	1.13e-5	Schizophrenia;
TGCT	trans	rs12339966	0.653	rs4740488	chr9:11277303	C/G	cg07173112	chr1:1114698	TTLL10	-0.33	-6.69	-0.51	6.89e-10	Systolic blood pressure;
TGCT	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	9.52	0.65	1.86e-16	Platelet count;
TGCT	cis	rs2204008	0.774	rs11520273	chr12:38354075	A/T	cg26384229	chr12:38710491	ALG10B	0.79	6.98	0.53	1.61e-10	Bladder cancer;
TGCT	cis	rs7843479	0.870	rs1809498	chr8:21836384	C/G	cg17168535	chr8:21777572	XPO7	-0.61	-5.52	-0.44	1.94e-7	Mean corpuscular volume;
TGCT	cis	rs7829975	0.514	rs2920991	chr8:8259117	T/A	cg15556689	chr8:8085844	FLJ10661	0.73	6.64	0.51	8.65e-10	Mood instability;
TGCT	cis	rs1008375	0.966	rs3796812	chr4:17582051	G/A	cg18681998	chr4:17616180	MED28	0.88	9.22	0.64	9.770000000000001e-16	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1403694	1.000	rs2689197	chr3:186438346	C/T	cg12454167	chr3:186435060	KNG1	0.42	7.37	0.55	2.15e-11	Blood protein levels;
TGCT	cis	rs12971120	0.947	rs8083001	chr18:72165058	A/G	cg25817165	chr18:72167213	CNDP2	-0.29	-5.42	-0.44	3.02e-7	Refractive error;
TGCT	cis	rs1205863	1.000	rs1205861	chr6:11943295	T/G	cg07106625	chr6:11870215	NA	0.51	5.05	0.41	1.51e-6	Disc degeneration (lumbar);
TGCT	cis	rs9830388	0.528	rs7645209	chr3:23482138	A/T	cg25382821	chr3:23496403	UBE2E2	-0.26	-4.62	-0.38	9.44e-6	RR interval (tricyclic/tetracyclic antidepressant use interaction);
TGCT	cis	rs501916	1.000	rs501916	chr15:48053229	C/A	cg16110827	chr15:48056943	SEMA6D	-0.17	-5.15	-0.42	9.79e-7	Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs6121246	0.529	rs6060174	chr20:30183538	G/A	cg13852791	chr20:30311386	BCL2L1	0.69	4.54	0.38	1.33e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg03517284	chr6:25882590	NA	-0.62	-6.45	-0.5	2.23e-9	Blood metabolite levels;
TGCT	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg23708337	chr7:1209742	NA	0.42	4.84	0.4	3.76e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9467773	0.620	rs2504592	chr6:26640951	C/G	cg05738196	chr6:26577821	NA	0.87	10.75	0.69	1.87e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs3806843	0.576	rs246002	chr5:140341104	A/G	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2760061	0.626	rs635563	chr1:228136834	C/T	cg18477163	chr1:228402036	OBSCN	-0.32	-6.42	-0.5	2.58e-9	Diastolic blood pressure;
TGCT	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg18305652	chr10:134549665	INPP5A	0.33	5.59	0.45	1.37e-7	Migraine;
TGCT	cis	rs13191362	0.507	rs2846535	chr6:163034019	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.61	-5.85	-0.46	4.17e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs10465746	0.967	rs12118434	chr1:84328629	C/T	cg10977910	chr1:84465055	TTLL7	0.6	6.07	0.48	1.47e-8	Obesity-related traits;
TGCT	cis	rs807669	0.548	rs9605957	chr22:19187375	G/A	cg02655711	chr22:19163373	SLC25A1	0.29	5.69	0.46	8.54e-8	Metabolite levels;
TGCT	cis	rs881375	0.934	rs1468671	chr9:123657502	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.38	4.52	0.38	1.43e-5	Rheumatoid arthritis;
TGCT	cis	rs2235642	0.893	rs2076445	chr16:1592266	A/T	cg08296037	chr16:1584118	IFT140;TMEM204	-0.31	-5.49	-0.44	2.2e-7	Coronary artery disease;
TGCT	cis	rs11779988	0.545	rs208058	chr8:17820433	G/A	cg01800426	chr8:17659068	MTUS1	-0.65	-4.9	-0.4	2.91e-6	Breast cancer;
TGCT	cis	rs35000415	0.873	rs13246321	chr7:128701331	T/C	cg06242719	chr7:129414860	MIR183;MIR96	-0.34	-4.67	-0.39	7.58e-6	Systemic lupus erythematosus;
TGCT	cis	rs514406	0.861	rs11206026	chr1:53281708	G/A	cg22166914	chr1:53195759	ZYG11B	0.41	7.27	0.55	3.5e-11	Monocyte count;
TGCT	cis	rs6582630	0.502	rs11514371	chr12:38306306	G/C	cg13010199	chr12:38710504	ALG10B	0.58	4.54	0.38	1.3e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs1580019	0.563	rs2392071	chr7:32572536	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.16	14.73	0.8	5.31e-29	Cognitive ability;
TGCT	cis	rs2197308	0.765	rs2387436	chr12:37935337	C/T	cg26384229	chr12:38710491	ALG10B	-0.7	-6.15	-0.48	9.71e-9	Morning vs. evening chronotype;
TGCT	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg22535103	chr8:58192502	C8orf71	-0.41	-5.22	-0.42	7.16e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs28595532	0.920	rs114575045	chr4:119739794	A/G	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs892864	0.685	rs6873360	chr5:127734030	T/C	cg01939274	chr5:127874478	FBN2	0.91	4.52	0.38	1.44e-5	Multiple system atrophy;
TGCT	cis	rs7267979	0.903	rs6107015	chr20:25216764	G/A	cg14121845	chr20:25566513	NINL	0.5	5.51	0.44	1.98e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6840360	0.681	rs4519779	chr4:152301185	G/A	cg17479576	chr4:152424074	FAM160A1	-0.56	-6.11	-0.48	1.21e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9381040	0.610	rs9357345	chr6:41025118	G/C	cg03526776	chr6:41159608	TREML2	0.27	5.29	0.43	5.37e-7	Alzheimer's disease (late onset);
TGCT	cis	rs6582630	0.519	rs4294627	chr12:38293982	C/T	cg13010199	chr12:38710504	ALG10B	0.58	4.54	0.38	1.3e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs4788570	0.625	rs2247603	chr16:71609364	G/A	cg06353428	chr16:71660113	MARVELD3	-1.45	-12.16	-0.74	6.98e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs9457247	1.000	rs439237	chr6:167391392	A/G	cg23791538	chr6:167370224	RNASET2	-0.5	-4.98	-0.41	2.08e-6	Crohn's disease;
TGCT	cis	rs9399135	0.622	rs3817776	chr6:135256756	C/T	cg22676075	chr6:135203613	NA	-0.48	-4.99	-0.41	2.03e-6	Red blood cell count;
TGCT	cis	rs2458413	0.563	rs2458419	chr8:105337141	G/C	cg13045555	chr8:105342365	NA	-0.39	-6.6	-0.51	1.05e-9	Paget's disease;
TGCT	trans	rs66573146	0.808	rs56268690	chr4:6923887	C/T	cg07817883	chr1:32538562	TMEM39B	1.31	7.04	0.53	1.19e-10	Granulocyte percentage of myeloid white cells;
TGCT	trans	rs1814175	0.626	rs1722008	chr11:49897676	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.12	-0.54	7.87e-11	Height;
TGCT	cis	rs524023	0.958	rs12802649	chr11:64359627	C/T	cg07733098	chr11:64478343	NRXN2	0.31	4.64	0.38	8.82e-6	Urate levels in obese individuals;
TGCT	cis	rs933688	1.000	rs332531	chr5:90790451	G/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.89	7.88	0.58	1.46e-12	Smoking behavior;
TGCT	cis	rs1008375	0.932	rs6814465	chr4:17659034	C/T	cg18681998	chr4:17616180	MED28	0.98	10.79	0.7	1.49e-19	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9467711	0.606	rs9358937	chr6:26374274	C/G	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9383153	1.000	rs7749925	chr6:16340776	C/G	cg06493612	chr6:15502050	JARID2	-0.65	-5.46	-0.44	2.47e-7	Gambling;
TGCT	cis	rs7937682	0.883	rs1789358	chr11:111474116	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.07	-11.45	-0.72	3.83e-21	Primary sclerosing cholangitis;
TGCT	cis	rs1372520	0.873	rs2737026	chr4:90779823	A/G	cg15133208	chr4:90757351	SNCA	-0.53	-6.26	-0.49	5.76e-9	Neuroticism;
TGCT	cis	rs6964587	1.000	rs11981461	chr7:91692662	A/G	cg17063962	chr7:91808500	NA	0.88	9.65	0.66	8.73e-17	Breast cancer;
TGCT	cis	rs7824557	0.650	rs2572406	chr8:11092252	C/G	cg21775007	chr8:11205619	TDH	0.47	4.44	0.37	1.94e-5	Retinal vascular caliber;
TGCT	cis	rs4523957	0.584	rs7219557	chr17:2086200	G/A	cg16513277	chr17:2031491	SMG6	-0.22	-4.96	-0.41	2.28e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9549367	0.865	rs9549366	chr13:113907644	G/A	cg18105134	chr13:113819100	PROZ	-0.35	-5.94	-0.47	2.68e-8	Platelet distribution width;
TGCT	cis	rs968451	0.906	rs12628367	chr22:39717104	A/C	cg17798944	chr22:39715225	SNORD43;RPL3	0.84	8.54	0.61	4.02e-14	Primary biliary cholangitis;
TGCT	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg20573242	chr4:122745356	CCNA2	0.64	5.62	0.45	1.22e-7	Type 2 diabetes;
TGCT	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	5.7	0.46	8.33e-8	Height;
TGCT	cis	rs7552404	1.000	rs6672180	chr1:76123973	C/G	cg03433033	chr1:76189801	ACADM	0.85	10.21	0.68	3.81e-18	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs6770219	0.516	rs11925189	chr3:186138413	T/A	cg20306810	chr3:186501757	SNORD2;EIF4A2	0.73	4.45	0.37	1.89e-5	Cerebrospinal T-tau levels;
TGCT	cis	rs911555	0.755	rs8014013	chr14:103937372	A/G	cg23461800	chr14:103021989	NA	-0.35	-4.61	-0.38	9.72e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg11494091	chr17:61959527	GH2	0.42	7.39	0.55	1.86e-11	Height;
TGCT	cis	rs8031584	0.918	rs35784593	chr15:31254588	G/A	cg08704250	chr15:31115839	NA	-0.35	-4.94	-0.41	2.47e-6	Huntington's disease progression;
TGCT	cis	rs7617773	0.817	rs9311421	chr3:48293078	G/A	cg11946769	chr3:48343235	NME6	0.76	6.66	0.51	7.89e-10	Coronary artery disease;
TGCT	cis	rs1878931	0.501	rs42329	chr16:3425524	G/A	cg05754148	chr16:3507555	NAT15	0.33	4.67	0.39	7.61e-6	Body mass index (adult);
TGCT	cis	rs9611565	0.512	rs5751148	chr22:42139078	A/G	cg06634786	chr22:41940651	POLR3H	0.87	8.12	0.59	3.86e-13	Vitiligo;
TGCT	cis	rs7829975	0.501	rs4840353	chr8:8580570	A/G	cg17143192	chr8:8559678	CLDN23	-0.48	-4.81	-0.4	4.29e-6	Mood instability;
TGCT	cis	rs10504229	0.861	rs60346509	chr8:58196050	G/T	cg21724239	chr8:58056113	NA	0.38	4.76	0.39	5.41e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs877282	0.853	rs12777155	chr10:754731	G/C	cg17470449	chr10:769945	NA	0.32	4.91	0.4	2.76e-6	Uric acid levels;
TGCT	cis	rs7267979	1.000	rs6115182	chr20:25410259	G/A	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs793571	0.502	rs421829	chr15:59079902	G/C	cg05156742	chr15:59063176	FAM63B	0.56	5.26	0.43	6.22e-7	Schizophrenia;
TGCT	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg13395646	chr4:1353034	KIAA1530	-0.35	-4.58	-0.38	1.11e-5	Obesity-related traits;
TGCT	cis	rs2980439	0.783	rs2955587	chr8:8098079	A/G	cg15462221	chr8:8086144	FLJ10661	-0.57	-5.29	-0.43	5.23e-7	Neuroticism;
TGCT	cis	rs11190604	0.697	rs12355942	chr10:102201320	T/C	cg16342193	chr10:102329863	NA	0.39	5.16	0.42	9.7e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7666738	0.830	rs13139024	chr4:99020700	C/T	cg05340658	chr4:99064831	C4orf37	0.48	5.43	0.44	2.92e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12477438	0.798	rs6705583	chr2:99602625	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-8.66	-0.61	2.13e-14	Chronic sinus infection;
TGCT	cis	rs2115536	1.000	rs2115540	chr15:80190308	A/G	cg00225070	chr15:80189496	MTHFS	0.61	5.53	0.44	1.82e-7	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs9911578	1.000	rs7207693	chr17:57016525	C/T	cg12560992	chr17:57184187	TRIM37	0.76	9.21	0.64	1.03e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs826838	1.000	rs7315028	chr12:38710523	G/A	cg13010199	chr12:38710504	ALG10B	0.82	6.8	0.52	3.99e-10	Heart rate;
TGCT	cis	rs798766	1.000	rs798756	chr4:1707447	T/C	cg05874882	chr4:1763078	NA	-0.38	-5.2	-0.42	7.93e-7	Bladder cancer;Urinary bladder cancer;
TGCT	cis	rs5769707	0.605	rs9616702	chr22:50025938	A/G	cg05373962	chr22:49881684	NA	-0.31	-5.24	-0.43	6.74e-7	Monocyte count;Monocyte percentage of white cells;
TGCT	trans	rs524675	0.581	rs79446337	chr4:13956492	G/A	cg02315626	chr17:27188560	MIR451;MIR144	0.42	6.87	0.53	2.82e-10	Amyotrophic lateral sclerosis in C9orf72 mutation negative individuals;
TGCT	cis	rs6540559	0.546	rs75308488	chr1:210030639	T/C	cg22029157	chr1:209979665	IRF6	0.78	5.69	0.46	8.55e-8	Cleft lip with or without cleft palate;
TGCT	cis	rs9811920	0.809	rs793443	chr3:99573547	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.43	4.89	0.4	3.05e-6	Axial length;
TGCT	cis	rs611744	0.647	rs2848620	chr8:109249551	G/T	cg21045802	chr8:109455806	TTC35	0.72	7.28	0.55	3.32e-11	Dupuytren's disease;
TGCT	cis	rs10782582	0.593	rs74968421	chr1:76233496	T/C	cg22875332	chr1:76189707	ACADM	-0.45	-4.98	-0.41	2.06e-6	Daytime sleep phenotypes;
TGCT	cis	rs11671005	0.779	rs55875034	chr19:58983558	T/G	cg07764513	chr19:58919909	ZNF584	-0.71	-4.59	-0.38	1.06e-5	Mean platelet volume;
TGCT	cis	rs8031584	0.706	rs2177670	chr15:31157751	G/T	cg08109568	chr15:31115862	NA	-0.38	-5.03	-0.41	1.67e-6	Huntington's disease progression;
TGCT	cis	rs642803	1.000	rs642803	chr11:65560620	C/T	cg27068330	chr11:65405492	SIPA1	0.56	4.97	0.41	2.19e-6	Urate levels;
TGCT	cis	rs8028182	0.636	rs8029112	chr15:75808972	T/C	cg20655648	chr15:75932815	IMP3	0.6	4.65	0.38	8.54e-6	Sudden cardiac arrest;
TGCT	cis	rs4294134	0.608	rs11767012	chr7:135246747	T/C	cg08396481	chr7:135194601	CNOT4	-0.62	-4.81	-0.4	4.25e-6	Paget's disease;
TGCT	cis	rs2729354	0.729	rs2848634	chr11:57252328	G/A	cg24343310	chr11:57249947	NA	0.28	4.59	0.38	1.05e-5	Blood protein levels;
TGCT	trans	rs1973993	0.691	rs11165623	chr1:96893000	G/A	cg10631902	chr5:14652156	NA	0.4	10.7	0.69	2.56e-19	Weight;
TGCT	cis	rs7937682	0.855	rs490897	chr11:111487914	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.1	-11.94	-0.73	2.41e-22	Primary sclerosing cholangitis;
TGCT	cis	rs954108	0.772	rs1592058	chr13:29369519	C/G	cg11788234	chr13:29393811	NA	-0.39	-4.72	-0.39	6.26e-6	Obesity-related traits;
TGCT	cis	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg03213289	chr20:61660250	NA	0.68	9.99	0.67	1.36e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs950776	0.745	rs3743075	chr15:78909452	T/C	cg06917634	chr15:78832804	PSMA4	-0.58	-4.64	-0.38	8.84e-6	Sudden cardiac arrest;
TGCT	cis	rs2702888	0.503	rs2702931	chr8:6758979	A/C	cg26795848	chr8:6756730	NA	-0.31	-6.18	-0.49	8.38e-9	Blood pressure;
TGCT	cis	rs6500602	0.627	rs841231	chr16:4583147	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.4	-7.15	-0.54	6.75e-11	Schizophrenia;
TGCT	cis	rs5769707	0.837	rs5770599	chr22:50019981	C/G	cg20744362	chr22:50050164	C22orf34	0.29	4.54	0.38	1.29e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs9906944	0.707	rs4794020	chr17:47111399	C/T	cg20966754	chr17:47091339	IGF2BP1	-0.45	-5.17	-0.42	9.27e-7	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs3772130	0.962	rs11719093	chr3:121487686	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.74	0.39	5.87e-6	Cognitive performance;
TGCT	cis	rs11785400	1.000	rs7459630	chr8:143738585	A/C	cg10596483	chr8:143751796	JRK	0.57	6.12	0.48	1.12e-8	Schizophrenia;
TGCT	cis	rs7819412	0.623	rs7833435	chr8:10801137	A/G	cg27411982	chr8:10470053	RP1L1	-0.24	-4.93	-0.4	2.62e-6	Triglycerides;
TGCT	cis	rs3809863	0.602	rs6504833	chr17:45396087	A/G	cg08085267	chr17:45401833	C17orf57	-0.67	-7.87	-0.58	1.5e-12	Glaucoma (primary open-angle);
TGCT	cis	rs3849570	1.000	rs4411908	chr3:81802418	A/C	cg07356753	chr3:81810745	GBE1	-0.72	-6.23	-0.49	6.58e-9	Waist circumference;Body mass index;
TGCT	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.9	7.25	0.55	3.93e-11	Platelet count;
TGCT	cis	rs10751667	0.643	rs7396951	chr11:927355	G/A	cg06064525	chr11:970664	AP2A2	-0.35	-8.09	-0.59	4.54e-13	Alzheimer's disease (late onset);
TGCT	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.64	-6.41	-0.5	2.72e-9	Prostate cancer;
TGCT	cis	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg15556689	chr8:8085844	FLJ10661	0.7	6.54	0.51	1.47e-9	Joint mobility (Beighton score);
TGCT	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	-0.65	-6.33	-0.49	4.13e-9	Initial pursuit acceleration;
TGCT	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg09033563	chr22:24373618	LOC391322	-0.48	-4.65	-0.39	8.35e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs8031584	0.958	rs35256769	chr15:31237776	G/A	cg08704250	chr15:31115839	NA	-0.36	-4.96	-0.41	2.29e-6	Huntington's disease progression;
TGCT	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg03517284	chr6:25882590	NA	0.52	4.73	0.39	6.01e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2066819	1.000	rs2695788	chr12:56697110	G/A	cg26714650	chr12:56694279	CS	1.51	8.1	0.59	4.38e-13	Psoriasis vulgaris;
TGCT	cis	rs6504663	0.558	rs11871603	chr17:48559037	T/G	cg03168497	chr17:48586147	MYCBPAP	0.46	4.9	0.4	2.98e-6	Visceral fat;
TGCT	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg26116260	chr4:7069785	GRPEL1	1.13	11.15	0.71	1.99e-20	Monocyte percentage of white cells;
TGCT	cis	rs7666738	0.893	rs11729640	chr4:99052699	C/T	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2290402	0.536	rs3775127	chr4:886061	G/A	cg23332689	chr4:987652	IDUA;SLC26A1	0.33	5.0	0.41	1.94e-6	Type 2 diabetes;
TGCT	cis	rs7914558	1.000	rs10883837	chr10:104896486	G/A	cg15744005	chr10:104629667	AS3MT	-0.42	-5.24	-0.43	6.69e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg27535305	chr1:53392650	SCP2	0.26	5.13	0.42	1.09e-6	Monocyte count;
TGCT	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg26516362	chr5:178986906	RUFY1	-0.43	-4.76	-0.39	5.21e-6	Lung cancer;
TGCT	cis	rs790110	1.000	rs790130	chr3:122384661	C/G	cg07366462	chr3:123162899	ADCY5	0.42	4.71	0.39	6.54e-6	Acoustic startle blink response;
TGCT	cis	rs10193935	0.901	rs13429697	chr2:42529818	C/T	cg27598129	chr2:42591480	NA	-0.41	-5.65	-0.45	1.04e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7226408	0.857	rs3747896	chr18:34647323	T/G	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs612683	0.735	rs10493923	chr1:100930254	A/G	cg06223162	chr1:101003688	GPR88	-0.31	-4.89	-0.4	3.09e-6	Breast cancer;
TGCT	cis	rs2354432	0.607	rs7545467	chr1:146746248	A/G	cg25205988	chr1:146714368	CHD1L	-1.34	-6.07	-0.48	1.44e-8	Mitochondrial DNA levels;
TGCT	cis	rs9527	0.590	rs7074395	chr10:104844928	A/C	cg15744005	chr10:104629667	AS3MT	0.4	4.63	0.38	9.04e-6	Arsenic metabolism;
TGCT	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg06618935	chr21:46677482	NA	-0.37	-5.81	-0.46	5.06e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7662987	0.517	rs1377689	chr4:100021787	A/G	cg12011299	chr4:100065546	ADH4	0.4	4.82	0.4	4.07e-6	Smoking initiation;
TGCT	cis	rs7772486	0.641	rs2748489	chr6:146331287	T/G	cg23711669	chr6:146136114	FBXO30	0.68	6.39	0.5	3e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4822044	0.561	rs132781	chr22:42046122	T/G	cg13695892	chr22:41940480	POLR3H	0.86	7.84	0.58	1.77e-12	Cannabis dependence symptom count;
TGCT	cis	rs9527	0.830	rs3740392	chr10:104636855	T/C	cg15744005	chr10:104629667	AS3MT	-0.49	-5.59	-0.45	1.38e-7	Arsenic metabolism;
TGCT	cis	rs7010267	0.773	rs13439134	chr8:119918868	G/C	cg17171407	chr8:119960777	TNFRSF11B	-0.28	-4.97	-0.41	2.2e-6	Total body bone mineral density (age 45-60);
TGCT	cis	rs2050392	0.965	rs2265368	chr10:30690289	G/C	cg18806716	chr10:30721971	MAP3K8	-0.44	-5.17	-0.42	9.28e-7	Inflammatory bowel disease;
TGCT	cis	rs7909074	1.000	rs7079573	chr10:45400406	G/A	cg04218760	chr10:45406644	TMEM72	-0.27	-5.31	-0.43	4.88e-7	Mean corpuscular volume;
TGCT	cis	rs9549367	0.789	rs7338235	chr13:113888687	T/C	cg18105134	chr13:113819100	PROZ	-0.33	-5.37	-0.43	3.79e-7	Platelet distribution width;
TGCT	cis	rs9467711	0.745	rs9467714	chr6:26340785	C/T	cg02458000	chr6:26745757	NA	-0.96	-4.76	-0.39	5.19e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs739496	0.615	rs7136874	chr12:112113658	C/T	cg10833066	chr12:111807467	FAM109A	0.35	5.18	0.42	8.89e-7	Platelet count;
TGCT	cis	rs7666738	0.515	rs10015315	chr4:98700137	A/G	cg05340658	chr4:99064831	C4orf37	0.5	5.57	0.45	1.5e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11098499	0.954	rs66506550	chr4:120371445	T/A	cg09307838	chr4:120376055	NA	0.68	6.53	0.51	1.54e-9	Corneal astigmatism;
TGCT	cis	rs986417	0.892	rs8017336	chr14:60798682	G/A	cg27398547	chr14:60952738	C14orf39	-1.55	-6.83	-0.52	3.44e-10	Gut microbiota (bacterial taxa);
TGCT	cis	rs12142240	0.698	rs17361819	chr1:46828109	A/G	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs7258465	1.000	rs10164323	chr19:18569492	C/T	cg06462663	chr19:18546047	ISYNA1	0.2	4.63	0.38	9.01e-6	Breast cancer;
TGCT	trans	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg21659725	chr3:3221576	CRBN	-0.73	-8.48	-0.61	5.64e-14	Intelligence (multi-trait analysis);
TGCT	trans	rs17685	0.753	rs10251863	chr7:75790192	T/C	cg19862616	chr7:65841803	NCRNA00174	0.51	8.88	0.62	6.28e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs6754311	0.597	rs6760329	chr2:136544752	A/G	cg07169764	chr2:136633963	MCM6	-0.71	-6.47	-0.5	2.09e-9	Mosquito bite size;
TGCT	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg18305652	chr10:134549665	INPP5A	-0.31	-5.66	-0.45	9.81e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg19010396	chr19:19431384	KIAA0892;SF4	-0.54	-4.51	-0.38	1.5e-5	Tonsillectomy;
TGCT	cis	rs7809950	0.678	rs7803151	chr7:106934246	G/A	cg23024343	chr7:107201750	COG5	-0.43	-5.88	-0.47	3.51e-8	Coronary artery disease;
TGCT	cis	rs17221829	0.733	rs12363392	chr11:89370598	T/C	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.63	-0.38	9.04e-6	Anxiety in major depressive disorder;
TGCT	trans	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg23505145	chr19:12996616	KLF1	-0.79	-8.13	-0.59	3.84e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs10751667	0.666	rs7950967	chr11:955638	G/A	cg06064525	chr11:970664	AP2A2	-0.35	-8.22	-0.59	2.29e-13	Alzheimer's disease (late onset);
TGCT	cis	rs1008375	0.932	rs2302394	chr4:17641188	A/G	cg10189774	chr4:17578691	LAP3	0.53	4.6	0.38	1.04e-5	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs611744	0.647	rs1448150	chr8:109276161	T/C	cg21045802	chr8:109455806	TTC35	0.72	7.39	0.55	1.94e-11	Dupuytren's disease;
TGCT	cis	rs10484885	0.878	rs72921916	chr6:90555990	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.47	-4.58	-0.38	1.11e-5	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs939658	0.805	rs8035606	chr15:79420245	C/T	cg17916960	chr15:79447300	NA	-0.5	-7.7	-0.57	3.74e-12	Refractive error;
TGCT	cis	rs2777491	0.874	rs7161772	chr15:41611066	A/T	cg18705301	chr15:41695430	NDUFAF1	-0.76	-10.72	-0.69	2.3e-19	Ulcerative colitis;
TGCT	cis	rs2050392	0.767	rs10763786	chr10:30693567	G/C	cg13289132	chr10:30722225	MAP3K8	0.42	5.12	0.42	1.12e-6	Inflammatory bowel disease;
TGCT	cis	rs11252926	0.574	rs4881254	chr10:453567	C/T	cg18196295	chr10:418757	DIP2C	0.29	4.73	0.39	5.91e-6	Psychosis in Alzheimer's disease;
TGCT	cis	rs10489202	0.608	rs4657733	chr1:168086434	G/A	cg24449463	chr1:168025552	DCAF6	-0.54	-5.39	-0.44	3.37e-7	Schizophrenia;
TGCT	cis	rs7726839	0.507	rs60068988	chr5:597668	T/C	cg09021430	chr5:549028	NA	-0.43	-5.77	-0.46	5.99e-8	Obesity-related traits;
TGCT	cis	rs3091242	0.967	rs3091240	chr1:25676935	G/T	cg00786635	chr1:25594202	NA	0.6	6.25	0.49	6.14e-9	Erythrocyte sedimentation rate;
TGCT	cis	rs6840360	0.615	rs12647616	chr4:152607662	G/A	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.13	-0.48	1.07e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7647973	0.626	rs2329021	chr3:49679072	G/A	cg03034192	chr3:50606346	HEMK1;C3orf18	0.36	4.75	0.39	5.61e-6	Menarche (age at onset);
TGCT	cis	rs4073582	0.595	rs801739	chr11:65922589	A/G	cg16950941	chr11:66035639	RAB1B	0.55	5.27	0.43	5.9e-7	Gout;
TGCT	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg18654377	chr3:49208889	KLHDC8B	0.37	4.91	0.4	2.78e-6	Menarche (age at onset);
TGCT	cis	rs17401966	0.838	rs1013952	chr1:10319247	G/A	cg19773385	chr1:10388646	KIF1B	-0.2	-4.5	-0.37	1.54e-5	Hepatocellular carcinoma;
TGCT	cis	rs2404602	0.716	rs2164101	chr15:76749117	A/G	cg22467129	chr15:76604101	ETFA	-0.57	-6.83	-0.52	3.31e-10	Blood metabolite levels;
TGCT	cis	rs9660180	0.836	rs12038134	chr1:1703865	T/A	cg13866156	chr1:1669148	SLC35E2	-0.24	-5.86	-0.47	4e-8	Body mass index;
TGCT	cis	rs7674212	0.539	rs6821617	chr4:104128410	G/A	cg16532752	chr4:104119610	CENPE	-0.6	-5.46	-0.44	2.51e-7	Type 2 diabetes;
TGCT	cis	rs2180341	0.781	rs7742161	chr6:127571676	T/C	cg24812749	chr6:127587940	RNF146	0.79	6.6	0.51	1.09e-9	Breast cancer;
TGCT	cis	rs28595532	0.920	rs115878132	chr4:119756239	T/A	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs928736	0.557	rs2834083	chr21:34436973	A/G	cg04836472	chr21:34405997	NA	0.46	5.62	0.45	1.19e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs4304924	0.500	rs7339081	chr13:79235501	A/G	cg07926092	chr13:79233506	RNF219	0.71	5.42	0.44	3.05e-7	Large artery stroke;
TGCT	cis	rs8014204	0.935	rs10141438	chr14:75354600	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.75	-7.25	-0.55	4e-11	Caffeine consumption;
TGCT	cis	rs72627509	0.951	rs6554401	chr4:57825336	C/G	cg26694713	chr4:57773883	REST	0.73	6.46	0.5	2.17e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs2046867	0.908	rs62251600	chr3:72778545	C/T	cg25664220	chr3:72788482	NA	-0.56	-7.02	-0.53	1.28e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs752590	1.000	rs752590	chr2:113972945	A/G	cg27425262	chr2:113953981	PSD4;LOC440839	0.4	4.52	0.38	1.43e-5	Mucinous ovarian carcinoma;
TGCT	cis	rs727505	0.954	rs1014163	chr7:124443604	G/A	cg23710748	chr7:124431027	NA	-0.27	-4.71	-0.39	6.53e-6	Lewy body disease;
TGCT	cis	rs6540559	0.611	rs6540563	chr1:210019858	C/G	cg21951975	chr1:209979733	IRF6	0.64	4.82	0.4	4.12e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs35000415	0.688	rs59110799	chr7:128716007	G/T	cg06242719	chr7:129414860	MIR183;MIR96	-0.3	-4.56	-0.38	1.19e-5	Systemic lupus erythematosus;
TGCT	cis	rs921968	0.541	rs12987171	chr2:219327030	G/C	cg02176678	chr2:219576539	TTLL4	0.47	6.72	0.52	5.75e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs2239547	0.522	rs6792578	chr3:53004604	G/A	cg10802521	chr3:52805072	NEK4	-0.59	-5.41	-0.44	3.08e-7	Schizophrenia;
TGCT	cis	rs8072100	0.935	rs78551919	chr17:45626002	A/C	cg08085267	chr17:45401833	C17orf57	0.48	5.3	0.43	5.03e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg11644478	chr21:40555479	PSMG1	1.03	11.02	0.7	4.14e-20	Cognitive function;
TGCT	cis	rs2463822	0.583	rs72919462	chr11:62035663	G/A	cg06239285	chr11:62104954	ASRGL1	-0.91	-5.83	-0.46	4.41e-8	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs12291225	0.639	rs61883858	chr11:14294708	C/T	cg19336497	chr11:14380999	RRAS2	-0.38	-5.9	-0.47	3.23e-8	Sense of smell;
TGCT	cis	rs2233152	0.656	rs2287691	chr19:41286163	C/G	cg11601297	chr19:41224147	ITPKC;ADCK4	0.53	4.86	0.4	3.46e-6	Kawasaki disease;
TGCT	cis	rs12188164	0.930	rs11743825	chr5:475463	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.41	-4.74	-0.39	5.66e-6	Cystic fibrosis severity;
TGCT	cis	rs11249608	0.548	rs7704565	chr5:178473923	G/C	cg23951258	chr5:178450506	ZNF879	0.44	4.5	0.37	1.57e-5	Pubertal anthropometrics;
TGCT	cis	rs8070740	0.898	rs4790770	chr17:5324893	A/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.49	4.88	0.4	3.15e-6	Menopause (age at onset);
TGCT	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg21862992	chr11:68658383	NA	0.46	6.52	0.51	1.6e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs68170813	0.559	rs76208112	chr7:106964222	C/T	cg02696742	chr7:106810147	HBP1	-0.68	-5.52	-0.44	1.9e-7	Coronary artery disease;
TGCT	cis	rs4788570	0.566	rs61171207	chr16:71504798	C/T	cg06353428	chr16:71660113	MARVELD3	-1.19	-7.71	-0.57	3.49e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7017914	0.967	rs6993170	chr8:71693519	A/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.53	-4.98	-0.41	2.1e-6	Bone mineral density;
TGCT	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.84	7.5	0.56	1.08e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2456568	1.000	rs2456568	chr11:93691332	A/T	cg26875233	chr11:93583750	C11orf90	-0.44	-5.63	-0.45	1.12e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs9902453	1.000	rs7222308	chr17:28277041	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	7.0	0.53	1.44e-10	Coffee consumption (cups per day);
TGCT	cis	rs3806843	0.576	rs155360	chr5:140309016	C/T	cg07102913	chr5:140593443	PCDHB13	-0.49	-4.88	-0.4	3.24e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg01448562	chr3:133502909	NA	-0.33	-6.58	-0.51	1.16e-9	Iron status biomarkers;
TGCT	cis	rs2153535	0.580	rs4960433	chr6:8523697	A/G	cg23788917	chr6:8435910	SLC35B3	0.64	5.93	0.47	2.86e-8	Motion sickness;
TGCT	cis	rs7772486	0.686	rs857880	chr6:145971115	T/C	cg23711669	chr6:146136114	FBXO30	-0.86	-9.6	-0.65	1.2e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7552404	1.000	rs11161515	chr1:76212559	C/T	cg03433033	chr1:76189801	ACADM	0.81	9.52	0.65	1.84e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7223966	0.961	rs17631783	chr17:61687600	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.56	-4.51	-0.38	1.49e-5	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs3820068	0.580	rs12082523	chr1:16005792	A/G	cg05660106	chr1:15850417	CASP9	-0.65	-6.31	-0.49	4.39e-9	Systolic blood pressure;
TGCT	cis	rs6912958	0.781	rs4334949	chr6:88290150	G/A	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.91	-0.4	2.78e-6	Monocyte percentage of white cells;
TGCT	cis	rs2836950	0.501	rs2836985	chr21:40701169	A/G	cg17971929	chr21:40555470	PSMG1	-0.51	-4.48	-0.37	1.7e-5	Menarche (age at onset);
TGCT	cis	rs7635838	0.565	rs347594	chr3:11249528	C/T	cg00170343	chr3:11313890	ATG7	0.59	5.5	0.44	2.05e-7	HDL cholesterol;
TGCT	cis	rs1371867	0.875	rs1788178	chr8:101332518	A/C	cg06636551	chr8:101224915	SPAG1	-0.48	-6.52	-0.51	1.62e-9	Atrioventricular conduction;
TGCT	cis	rs6121246	0.529	rs58757492	chr20:30181425	G/A	cg18721089	chr20:30220636	NA	-0.63	-6.86	-0.52	2.95e-10	Mean corpuscular hemoglobin;
TGCT	cis	rs7178424	0.742	rs2414755	chr15:62172429	C/T	cg00456672	chr15:62358751	C2CD4A	-0.3	-4.7	-0.39	6.79e-6	Height;
TGCT	cis	rs3806843	1.000	rs2879089	chr5:140191893	A/T	cg19875535	chr5:140030758	IK	0.35	5.85	0.47	4.01e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs1371867	0.846	rs1660326	chr8:101290447	G/A	cg00191853	chr8:101177733	SPAG1	-0.22	-4.51	-0.38	1.48e-5	Atrioventricular conduction;
TGCT	cis	rs7772486	0.738	rs75288066	chr6:146319386	C/A	cg05347473	chr6:146136440	FBXO30	0.55	5.06	0.41	1.5e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs55794721	0.509	rs6699896	chr1:25762902	A/T	cg10117171	chr1:25599238	RHD	-0.34	-5.5	-0.44	2.05e-7	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs7726839	0.574	rs12517345	chr5:628294	G/A	cg09021430	chr5:549028	NA	-0.38	-5.11	-0.42	1.21e-6	Obesity-related traits;
TGCT	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg03188948	chr7:1209495	NA	0.65	5.5	0.44	2.07e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9325144	0.647	rs1875609	chr12:39018259	C/T	cg26384229	chr12:38710491	ALG10B	-0.6	-5.76	-0.46	6.3e-8	Morning vs. evening chronotype;
TGCT	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg03303774	chr4:1407052	NA	0.31	4.87	0.4	3.31e-6	Obesity-related traits;
TGCT	cis	rs9486715	1.000	rs9486715	chr6:97059769	A/C	cg18709589	chr6:96969512	KIAA0776	-0.83	-7.92	-0.58	1.13e-12	Headache;
TGCT	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg00814883	chr7:100076585	TSC22D4	-0.89	-9.26	-0.64	7.79e-16	Platelet count;
TGCT	cis	rs13217239	0.646	rs6456767	chr6:27070543	C/T	cg15659132	chr6:26577336	NA	-0.55	-5.37	-0.43	3.7e-7	Schizophrenia;
TGCT	trans	rs1814175	0.754	rs10839453	chr11:49955815	A/T	cg03929089	chr4:120376271	NA	-0.73	-8.42	-0.6	7.65e-14	Height;
TGCT	cis	rs1008375	0.966	rs7658240	chr4:17588950	A/G	cg10189774	chr4:17578691	LAP3	-0.61	-5.29	-0.43	5.43e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg18402987	chr7:1209562	NA	0.76	6.39	0.5	3e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs797680	0.856	rs637646	chr1:93716383	A/C	cg17826107	chr1:92977322	EVI5	0.24	5.29	0.43	5.47e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg11141652	chr22:24348549	GSTTP1	0.33	4.6	0.38	1.05e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg21285383	chr16:89894308	SPIRE2	0.46	7.34	0.55	2.41e-11	Vitiligo;
TGCT	cis	rs7226408	0.857	rs72894317	chr18:34706241	A/G	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs367615	0.704	rs17161885	chr5:108852642	A/G	cg17395555	chr5:108820864	NA	0.31	5.73	0.46	7.24e-8	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs227917	1.000	rs227917	chr7:23646317	C/A	cg12601843	chr7:23510954	IGF2BP3	0.59	4.53	0.38	1.38e-5	Common carotid intima-media thickness in HIV negative individuals;
TGCT	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg06618935	chr21:46677482	NA	-0.36	-5.2	-0.42	8.1e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs3916	1.000	rs2014355	chr12:121175524	A/G	cg21892295	chr12:121157589	UNC119B	-0.22	-4.44	-0.37	1.95e-5	Urinary metabolites (H-NMR features);
TGCT	cis	rs4076764	1.000	rs12740984	chr1:163422151	A/G	cg24596788	chr1:163392923	NA	0.16	4.49	0.37	1.6e-5	Motion sickness;
TGCT	cis	rs875971	1.000	rs1167612	chr7:65567976	C/A	cg11764359	chr7:65958608	NA	-0.57	-5.02	-0.41	1.76e-6	Aortic root size;
TGCT	cis	rs631288	0.793	rs11239952	chr1:146715204	A/G	cg25205988	chr1:146714368	CHD1L	1.26	6.08	0.48	1.35e-8	PR interval in Tripanosoma cruzi seropositivity;
TGCT	cis	rs17221829	0.645	rs11018705	chr11:89382700	T/G	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.63	-0.38	9.04e-6	Anxiety in major depressive disorder;
TGCT	cis	rs2486288	0.656	rs1706770	chr15:45575062	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.43	-5.11	-0.42	1.18e-6	Glomerular filtration rate;
TGCT	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg03264133	chr6:25882463	NA	-0.61	-6.51	-0.5	1.69e-9	Blood metabolite levels;
TGCT	cis	rs6831352	0.918	rs7670638	chr4:100059807	G/C	cg12011299	chr4:100065546	ADH4	-0.41	-4.97	-0.41	2.21e-6	Alcohol dependence;
TGCT	trans	rs208520	0.690	rs10944872	chr6:66708239	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	11.22	0.71	1.34e-20	Exhaled nitric oxide output;
TGCT	cis	rs7918232	0.941	rs6482598	chr10:27426375	T/C	cg14442939	chr10:27389572	ANKRD26	0.72	5.35	0.43	4.16e-7	Breast cancer;
TGCT	trans	rs34421088	0.560	rs2248315	chr8:11397086	T/A	cg15556689	chr8:8085844	FLJ10661	-0.75	-7.08	-0.54	9.46e-11	Neuroticism;
TGCT	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg13699009	chr12:122356056	WDR66	0.3	6.53	0.51	1.51e-9	Mean corpuscular volume;
TGCT	cis	rs72945132	0.882	rs17160762	chr11:70134766	A/G	cg00319359	chr11:70116639	PPFIA1	-0.99	-6.85	-0.52	3.07e-10	Coronary artery disease;
TGCT	cis	rs2463822	0.669	rs72919480	chr11:62043133	G/A	cg06239285	chr11:62104954	ASRGL1	-0.87	-5.04	-0.41	1.6e-6	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs478304	0.934	rs610037	chr11:65546857	A/C	cg27068330	chr11:65405492	SIPA1	0.72	7.12	0.54	7.68e-11	Acne (severe);
TGCT	cis	rs739496	0.947	rs1029388	chr12:111926901	A/G	cg10833066	chr12:111807467	FAM109A	0.33	5.0	0.41	1.88e-6	Platelet count;
TGCT	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg21016266	chr12:122356598	WDR66	-0.47	-6.47	-0.5	2.07e-9	Mean corpuscular volume;
TGCT	cis	rs9393777	0.513	rs7754159	chr6:26620312	G/A	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.48	-4.59	-0.38	1.06e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs11997175	0.846	rs6999445	chr8:33732693	G/A	ch.8.33884649F	chr8:33765107	NA	0.32	4.74	0.39	5.66e-6	Body mass index;
TGCT	cis	rs9467773	1.000	rs3736782	chr6:26505403	C/A	cg09904177	chr6:26538194	HMGN4	0.65	6.53	0.51	1.5e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg09177884	chr7:1199841	ZFAND2A	-0.72	-5.71	-0.46	7.86e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2594989	0.895	rs2594980	chr3:11381387	C/T	cg00170343	chr3:11313890	ATG7	0.66	5.26	0.43	6.16e-7	Circulating chemerin levels;
TGCT	cis	rs694739	1.000	rs11231757	chr11:64106317	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.78	7.75	0.57	2.92e-12	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs6964587	0.967	rs2282969	chr7:91583772	T/C	cg17063962	chr7:91808500	NA	-0.91	-9.99	-0.67	1.32e-17	Breast cancer;
TGCT	cis	rs17767294	0.708	rs72847379	chr6:27873090	G/A	cg08851530	chr6:28072375	NA	1.57	7.27	0.55	3.59e-11	Parkinson's disease;
TGCT	cis	rs4638749	0.588	rs13401731	chr2:108885340	C/T	cg25838818	chr2:108905173	SULT1C2	-0.33	-5.0	-0.41	1.93e-6	Blood pressure;
TGCT	cis	rs2242116	0.932	rs1531137	chr3:46943028	T/C	cg02527881	chr3:46936655	PTH1R	-0.3	-5.77	-0.46	5.91e-8	Birth weight;
TGCT	cis	rs1163251	0.756	rs539799	chr1:120208472	C/T	cg19096424	chr1:120255104	PHGDH	0.62	6.19	0.49	8.01e-9	Blood metabolite levels;
TGCT	cis	rs2456568	0.802	rs1395386	chr11:93639331	A/G	cg14065697	chr11:93583672	C11orf90	0.38	4.81	0.4	4.33e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg15556689	chr8:8085844	FLJ10661	-0.67	-6.08	-0.48	1.36e-8	Mood instability;
TGCT	cis	rs11578508	0.508	rs1204677	chr1:208050972	A/G	cg22525895	chr1:207977042	MIR29B2	0.33	5.16	0.42	9.39e-7	Heart rate;
TGCT	cis	rs2180341	0.961	rs9375501	chr6:127652539	C/T	cg27446573	chr6:127587934	RNF146	1.12	10.11	0.67	6.87e-18	Breast cancer;
TGCT	cis	rs10114408	0.921	rs1320545	chr9:96655555	A/G	cg13679303	chr9:96623674	NA	-0.36	-4.69	-0.39	7e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	trans	rs877282	0.945	rs12782447	chr10:771870	C/T	cg22713356	chr15:30763199	NA	1.11	9.55	0.65	1.55e-16	Uric acid levels;
TGCT	cis	rs7772486	0.632	rs9386128	chr6:146049053	G/A	cg23711669	chr6:146136114	FBXO30	-0.88	-9.78	-0.66	4.22e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs17001868	0.568	rs17001846	chr22:40744053	A/G	cg07138101	chr22:40742427	ADSL	0.73	5.5	0.44	2.12e-7	Mammographic density (dense area);
TGCT	cis	rs6424115	0.965	rs2502986	chr1:24135292	G/T	cg15997130	chr1:24165203	NA	0.91	10.39	0.68	1.4e-18	Immature fraction of reticulocytes;
TGCT	cis	rs10779751	0.690	rs2791659	chr1:11126569	C/A	cg08854313	chr1:11322531	MTOR	0.82	7.04	0.53	1.19e-10	Body mass index;
TGCT	cis	rs2933343	0.533	rs11915889	chr3:128700866	A/C	cg11901034	chr3:128598214	ACAD9	-0.57	-5.29	-0.43	5.34e-7	IgG glycosylation;
TGCT	trans	rs8073060	0.586	rs6505486	chr17:33996776	G/A	cg19694781	chr19:47549865	TMEM160	-0.6	-13.37	-0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs6582630	0.502	rs11520276	chr12:38359216	C/T	cg13010199	chr12:38710504	ALG10B	0.58	4.52	0.38	1.41e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg15595755	chr5:1867978	NA	0.47	5.47	0.44	2.39e-7	Cardiovascular disease risk factors;
TGCT	cis	rs9952991	0.527	rs2847259	chr18:12775821	A/C	cg23544223	chr18:12777786	NA	0.41	4.64	0.38	8.89e-6	Inflammatory skin disease;
TGCT	cis	rs7246657	0.722	rs3101746	chr19:38146400	T/A	cg18154014	chr19:37997991	ZNF793	-0.67	-4.69	-0.39	6.96e-6	Coronary artery calcification;
TGCT	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.15	0.82	2.71e-32	Prudent dietary pattern;
TGCT	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg11764359	chr7:65958608	NA	0.48	4.51	0.38	1.5e-5	Aortic root size;
TGCT	trans	rs17685	0.725	rs7795291	chr7:75725206	C/A	cg19862616	chr7:65841803	NCRNA00174	0.51	8.3	0.6	1.51e-13	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-5.79	-0.46	5.39e-8	Alzheimer's disease;
TGCT	cis	rs78366141	0.649	rs7666372	chr4:89687531	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	1.26	5.58	0.45	1.43e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
TGCT	cis	rs10791323	0.569	rs1119852	chr11:133743022	C/A	cg03690763	chr11:133734501	NA	-0.3	-5.16	-0.42	9.36e-7	Childhood ear infection;
TGCT	cis	rs12497850	0.931	rs10780033	chr3:48891275	T/C	cg06212747	chr3:49208901	KLHDC8B	0.62	5.83	0.46	4.42e-8	Parkinson's disease;
TGCT	cis	rs682748	1.000	rs617089	chr5:17146347	C/T	cg23987134	chr5:17158319	LOC285696	-0.23	-5.33	-0.43	4.46e-7	Hippocampal atrophy;
TGCT	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs77948430	0.655	rs77793842	chr8:13157188	A/C	cg25598624	chr8:12235727	FAM66A	0.31	4.59	0.38	1.08e-5	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs2455826	0.500	rs2455852	chr3:15688688	C/T	cg16303742	chr3:15540471	COLQ	-0.23	-4.54	-0.38	1.33e-5	Inflammatory skin disease;
TGCT	cis	rs9894429	0.716	rs7405578	chr17:79588306	C/A	cg21984481	chr17:79567631	NPLOC4	-0.26	-4.9	-0.4	2.98e-6	Eye color traits;
TGCT	cis	rs933688	1.000	rs1964292	chr5:90743608	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.96	8.25	0.6	1.91e-13	Smoking behavior;
TGCT	cis	rs12477438	0.798	rs1453562	chr2:99615850	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-5.87	-0.47	3.74e-8	Chronic sinus infection;
TGCT	cis	rs8017423	0.647	rs12589952	chr14:90821364	T/C	cg04374321	chr14:90722782	PSMC1	-0.54	-5.41	-0.44	3.13e-7	Mortality in heart failure;
TGCT	cis	rs28595532	0.920	rs114963870	chr4:119758099	T/C	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg06238570	chr21:40685208	BRWD1	0.69	6.41	0.5	2.71e-9	Cognitive function;
TGCT	cis	rs12762955	0.507	rs7070724	chr10:1040138	C/T	cg20503657	chr10:835505	NA	-0.44	-5.62	-0.45	1.17e-7	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs2013441	1.000	rs2703818	chr17:20119976	T/A	cg18979559	chr17:20280153	CCDC144C	-0.44	-4.61	-0.38	9.78e-6	Obesity-related traits;
TGCT	cis	rs3540	0.553	rs12592611	chr15:91004093	C/T	cg22089800	chr15:90895588	ZNF774	0.76	7.96	0.58	9.24e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs1577917	0.958	rs3900313	chr6:86537154	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-5.53	-0.44	1.82e-7	Response to antipsychotic treatment;
TGCT	cis	rs10782582	0.593	rs6675076	chr1:76118503	A/C	cg22875332	chr1:76189707	ACADM	-0.54	-6.26	-0.49	5.65e-9	Daytime sleep phenotypes;
TGCT	cis	rs62380364	0.613	rs254781	chr5:88000636	C/T	cg22951263	chr5:87985283	NA	-0.61	-6.46	-0.5	2.13e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs4851254	0.660	rs10209201	chr2:100672808	C/T	cg22139774	chr2:100720529	AFF3	-0.45	-4.91	-0.4	2.75e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs12188164	1.000	rs56104584	chr5:437542	T/C	cg21144161	chr5:423903	AHRR	0.26	4.94	0.41	2.49e-6	Cystic fibrosis severity;
TGCT	cis	rs2354432	0.556	rs7525622	chr1:146774116	G/A	cg25205988	chr1:146714368	CHD1L	-1.34	-6.07	-0.48	1.44e-8	Mitochondrial DNA levels;
TGCT	cis	rs4319547	0.656	rs28730465	chr12:122863864	A/C	cg08088222	chr12:122070432	ORAI1	-0.25	-4.49	-0.37	1.58e-5	Body mass index;
TGCT	cis	rs7236492	0.688	rs77069608	chr18:77186319	C/T	cg15644404	chr18:77186268	NFATC1	-0.35	-4.67	-0.39	7.83e-6	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs6486730	1.000	rs6486730	chr12:129275027	C/T	cg09035930	chr12:129282057	SLC15A4	0.39	5.86	0.47	3.84e-8	Systemic lupus erythematosus;
TGCT	cis	rs10791323	0.569	rs10750542	chr11:133713436	T/C	cg03690763	chr11:133734501	NA	-0.31	-4.92	-0.4	2.73e-6	Childhood ear infection;
TGCT	cis	rs910316	1.000	rs11159117	chr14:75584867	C/T	cg11812906	chr14:75593930	NEK9	0.75	7.54	0.56	8.47e-12	Height;
TGCT	cis	rs6952809	0.532	rs10272548	chr7:2439467	G/A	cg23289794	chr7:2394357	EIF3B	-0.84	-7.21	-0.54	4.72e-11	Multiple sclerosis;
TGCT	trans	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg13615516	chr5:77269221	NA	0.68	8.54	0.61	3.97e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9357506	1.000	rs9381440	chr6:46308778	G/A	cg21115430	chr6:46460003	NA	-0.26	-5.17	-0.42	9.2e-7	Body mass index;
TGCT	cis	rs1865760	0.865	rs1541987	chr6:25950397	A/G	cg16482183	chr6:26056742	HIST1H1C	-0.52	-4.89	-0.4	3.04e-6	Height;
TGCT	cis	rs35306767	0.903	rs10904577	chr10:922077	A/G	cg26597838	chr10:835615	NA	0.75	10.54	0.69	6.3e-19	Eosinophil percentage of granulocytes;
TGCT	cis	rs2204008	0.902	rs11520218	chr12:38223227	G/A	cg13010199	chr12:38710504	ALG10B	0.62	4.87	0.4	3.26e-6	Bladder cancer;
TGCT	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg23708337	chr7:1209742	NA	0.51	4.46	0.37	1.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs4372836	0.796	rs7580078	chr2:28997001	G/C	cg09522027	chr2:28974177	PPP1CB	-0.71	-5.9	-0.47	3.18e-8	Body mass index;
TGCT	cis	rs713587	0.713	rs1982200	chr2:25205427	C/T	cg15423357	chr2:25149977	NA	-0.58	-5.9	-0.47	3.16e-8	Body mass index in non-asthmatics;
TGCT	cis	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg22857025	chr5:266934	NA	-0.34	-6.7	-0.52	6.65e-10	Breast cancer;
TGCT	cis	rs4372836	0.729	rs4638745	chr2:29093803	A/G	cg09522027	chr2:28974177	PPP1CB	0.67	6.91	0.53	2.24e-10	Body mass index;
TGCT	cis	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg22857025	chr5:266934	NA	-0.33	-6.57	-0.51	1.22e-9	Breast cancer;
TGCT	cis	rs617219	0.671	rs1062326	chr5:78617534	A/C	cg05890484	chr5:78407552	BHMT	-0.37	-4.95	-0.41	2.4e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs11792861	0.591	rs4978763	chr9:111728067	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	7.34	0.55	2.4e-11	Menarche (age at onset);
TGCT	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg12311346	chr5:56204834	C5orf35	-0.77	-7.11	-0.54	8.24e-11	Type 2 diabetes;
TGCT	cis	rs713587	0.713	rs1077492	chr2:25286435	C/T	cg15423357	chr2:25149977	NA	-0.6	-6.12	-0.48	1.15e-8	Body mass index in non-asthmatics;
TGCT	cis	rs6570726	0.846	rs1935616	chr6:145943512	C/T	cg13319975	chr6:146136371	FBXO30	-0.5	-4.49	-0.37	1.63e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4730250	0.654	rs12705405	chr7:106792517	C/T	cg02696742	chr7:106810147	HBP1	0.72	5.89	0.47	3.44e-8	Osteoarthritis;
TGCT	cis	rs11098499	0.863	rs10004484	chr4:120442428	C/T	cg09307838	chr4:120376055	NA	0.71	6.96	0.53	1.71e-10	Corneal astigmatism;
TGCT	cis	rs2580764	0.540	rs10174838	chr2:55241216	A/T	cg09592903	chr2:55203963	RTN4	-0.27	-5.92	-0.47	3e-8	Mean platelet volume;
TGCT	cis	rs1023500	0.573	rs133380	chr22:42468910	C/T	cg05082376	chr22:42548792	NA	-0.23	-5.59	-0.45	1.4e-7	Schizophrenia;
TGCT	cis	rs56804039	0.524	rs6991161	chr8:8405994	C/T	cg14215082	chr8:9055850	NA	-0.45	-4.65	-0.39	8.38e-6	Cervical cancer;
TGCT	cis	rs11718455	0.960	rs13082990	chr3:44005172	T/C	cg08738300	chr3:44038990	NA	0.85	6.34	0.49	3.94e-9	Coronary artery disease;
TGCT	cis	rs7246657	1.000	rs1529957	chr19:37739801	A/G	cg24025825	chr19:37761650	NA	-0.25	-4.53	-0.38	1.34e-5	Coronary artery calcification;
TGCT	cis	rs35146811	0.660	rs3779046	chr7:99779243	A/G	cg13334819	chr7:99746414	C7orf59	-0.74	-6.31	-0.49	4.4e-9	Coronary artery disease;
TGCT	cis	rs3099143	1.000	rs3110381	chr15:77099665	A/T	cg21673338	chr15:77095150	SCAPER	-0.52	-4.99	-0.41	2.01e-6	Recalcitrant atopic dermatitis;
TGCT	cis	rs853679	0.527	rs853693	chr6:28282648	C/T	cg13525197	chr6:28411240	ZSCAN23	-0.46	-4.66	-0.39	8.1e-6	Depression;
TGCT	cis	rs10883723	0.737	rs11191312	chr10:104278601	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.79	7.79	0.57	2.25e-12	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg10150615	chr22:24372951	LOC391322	-1.0	-12.91	-0.76	1.1e-24	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	trans	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg15556689	chr8:8085844	FLJ10661	-0.81	-8.5	-0.61	5.1e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs1348850	0.958	rs4893941	chr2:178269531	A/T	cg22681709	chr2:178499509	PDE11A	-0.35	-4.6	-0.38	1.03e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs2019872	0.543	rs216175	chr17:2167690	A/C	cg24156229	chr17:1948635	NA	0.37	4.55	0.38	1.26e-5	Schizophrenia;
TGCT	trans	rs3780486	0.846	rs4584234	chr9:33147479	G/A	cg20290983	chr6:43655470	MRPS18A	1.14	13.92	0.78	4.12e-27	IgG glycosylation;
TGCT	cis	rs6141769	0.542	rs6058833	chr20:31316767	T/G	cg13636640	chr20:31349939	DNMT3B	-0.52	-4.54	-0.38	1.34e-5	Subjective well-being;
TGCT	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	5.68	0.45	9.24e-8	Height;
TGCT	cis	rs34014631	0.786	rs76228295	chr10:103685231	A/C	cg22630918	chr10:102748988	C10orf2	0.42	4.78	0.39	4.86e-6	Coronary artery calcification;
TGCT	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.49	5.37	0.43	3.75e-7	Lymphocyte counts;
TGCT	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg13695892	chr22:41940480	POLR3H	0.92	9.08	0.63	2.08e-15	Vitiligo;
TGCT	cis	rs9399135	0.967	rs7750300	chr6:135350950	C/G	cg24558204	chr6:135376177	HBS1L	0.49	5.0	0.41	1.88e-6	Red blood cell count;
TGCT	cis	rs11167764	0.895	rs7734160	chr5:141473144	G/T	cg08523384	chr5:141488047	NDFIP1	-0.24	-4.91	-0.4	2.85e-6	Crohn's disease;
TGCT	cis	rs6740322	0.895	rs9309098	chr2:43554972	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.41	6.86	0.52	2.87e-10	Coronary artery disease;
TGCT	cis	rs2851682	0.706	rs2727270	chr11:61603237	C/T	cg20584555	chr11:61717780	BEST1	-0.35	-4.45	-0.37	1.87e-5	Gestational age at birth (child effect);Trans fatty acid levels;
TGCT	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg01802117	chr1:53393560	SCP2	0.44	5.35	0.43	4.14e-7	Monocyte count;
TGCT	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg13397359	chr6:42928475	GNMT	0.67	5.93	0.47	2.84e-8	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs2692947	0.673	rs4907299	chr2:96780122	G/T	cg05933789	chr2:97190408	NA	0.17	4.66	0.39	7.93e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg23708337	chr7:1209742	NA	0.51	4.46	0.37	1.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	trans	rs561341	0.714	rs7218466	chr17:30263314	A/G	cg20587970	chr11:113659929	NA	-0.83	-7.97	-0.58	8.86e-13	Hip circumference adjusted for BMI;
TGCT	cis	rs1401999	1.000	rs3805108	chr3:183691650	T/C	cg01324343	chr3:183735012	ABCC5	0.82	10.97	0.7	5.41e-20	Anterior chamber depth;
TGCT	cis	rs11673344	0.543	rs1818748	chr19:37556318	T/C	cg08039142	chr19:36980659	ZNF566	0.48	4.47	0.37	1.75e-5	Obesity-related traits;
TGCT	cis	rs394563	0.591	rs237019	chr6:149727064	G/A	cg03678062	chr6:149772716	ZC3H12D	-0.38	-4.74	-0.39	5.83e-6	Dupuytren's disease;
TGCT	cis	rs9457247	0.967	rs2757054	chr6:167380501	A/G	cg25258033	chr6:167368657	RNASET2	-0.18	-4.49	-0.37	1.63e-5	Crohn's disease;
TGCT	cis	rs68170813	0.559	rs1002935	chr7:106832361	G/A	cg02696742	chr7:106810147	HBP1	-0.72	-6.05	-0.48	1.56e-8	Coronary artery disease;
TGCT	cis	rs6867032	1.000	rs4398675	chr5:2015816	G/A	cg26168224	chr5:2018326	NA	0.43	7.96	0.58	9.31e-13	Gut microbiome composition (winter);
TGCT	cis	rs3091242	0.933	rs7541095	chr1:25761291	T/C	cg10117171	chr1:25599238	RHD	-0.32	-5.18	-0.42	8.61e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg00343986	chr7:65444356	GUSB	0.26	6.14	0.48	1.02e-8	Calcium levels;
TGCT	cis	rs78487399	0.908	rs55640722	chr2:43846040	A/T	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.65	4.58	0.38	1.12e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	trans	rs62103177	0.810	rs62103192	chr18:77629050	A/T	cg05926928	chr17:57297772	GDPD1	1.22	11.16	0.71	1.85e-20	Opioid sensitivity;
TGCT	cis	rs9916302	0.904	rs4357971	chr17:37717280	C/T	cg15445000	chr17:37608096	MED1	0.31	4.5	0.37	1.53e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg17719053	chr1:75198211	TYW3;CRYZ	-0.48	-5.12	-0.42	1.15e-6	Resistin levels;
TGCT	trans	rs459571	1.000	rs467387	chr9:136907005	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.71	-7.47	-0.56	1.26e-11	Platelet distribution width;
TGCT	cis	rs2084898	1.000	rs569044	chr11:119999191	A/G	cg00437969	chr11:120009135	TRIM29	0.4	4.66	0.39	7.89e-6	Stroke (pediatric);
TGCT	cis	rs10875746	0.951	rs8804	chr12:48541757	A/G	cg20731937	chr12:48336164	NA	0.63	5.19	0.42	8.18e-7	Longevity (90 years and older);
TGCT	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg12963246	chr6:28129442	ZNF389	0.49	4.82	0.4	4.15e-6	Depression;
TGCT	cis	rs9733	0.503	rs7556451	chr1:150913142	A/G	cg04414720	chr1:150670196	GOLPH3L	0.37	4.46	0.37	1.81e-5	Tonsillectomy;
TGCT	cis	rs2404602	0.536	rs1587381	chr15:76769620	G/A	cg26408565	chr15:76604113	ETFA	-0.37	-4.99	-0.41	2.03e-6	Blood metabolite levels;
TGCT	cis	rs3749237	0.595	rs1568661	chr3:49520958	A/G	cg07636037	chr3:49044803	WDR6	0.63	5.9	0.47	3.22e-8	Resting heart rate;
TGCT	cis	rs6701037	0.625	rs72719370	chr1:175128536	G/C	cg00321850	chr1:175162397	KIAA0040	-0.42	-5.83	-0.46	4.61e-8	Alcohol dependence;
TGCT	cis	rs1878931	0.531	rs9635548	chr16:3417156	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.76	7.12	0.54	7.59e-11	Body mass index (adult);
TGCT	cis	rs3820928	0.967	rs4675114	chr2:227768362	C/T	cg11843606	chr2:227700838	RHBDD1	-0.51	-4.5	-0.37	1.52e-5	Pulmonary function;
TGCT	cis	rs9894429	0.690	rs12949956	chr17:79542813	C/T	cg21028142	chr17:79581711	NPLOC4	-0.3	-6.96	-0.53	1.79e-10	Eye color traits;
TGCT	cis	rs1532993	0.518	rs12502451	chr4:98602932	C/T	cg05340658	chr4:99064831	C4orf37	-0.42	-5.02	-0.41	1.72e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg03213289	chr20:61660250	NA	0.68	9.9	0.66	2.25e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	8.99	0.63	3.48e-15	Platelet count;
TGCT	cis	rs6570726	0.902	rs4895678	chr6:145935510	C/T	cg23711669	chr6:146136114	FBXO30	0.65	5.95	0.47	2.53e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7193541	0.826	rs56143602	chr16:74694692	T/C	cg01733217	chr16:74700730	RFWD3	0.81	7.76	0.57	2.74e-12	Multiple myeloma;
TGCT	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.75	5.41	0.44	3.09e-7	Platelet count;
TGCT	cis	rs3125734	0.633	rs7088891	chr10:64034019	G/T	cg05499367	chr10:63213510	TMEM26	-0.33	-4.52	-0.38	1.45e-5	Rheumatoid arthritis;
TGCT	trans	rs4332037	0.539	rs56180486	chr7:2050747	C/T	cg10840412	chr1:235813424	GNG4	0.96	6.89	0.53	2.47e-10	Bipolar disorder;
TGCT	cis	rs7089973	0.584	rs4752255	chr10:116576790	C/T	cg03647239	chr10:116582469	FAM160B1	0.6	5.5	0.44	2.03e-7	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs453301	0.658	rs9329175	chr8:8866661	C/T	cg06636001	chr8:8085503	FLJ10661	-0.64	-5.42	-0.44	2.93e-7	Joint mobility (Beighton score);
TGCT	cis	rs587847	0.540	rs635200	chr15:37662390	T/G	cg16890051	chr15:37175029	LOC145845	-0.37	-4.44	-0.37	1.95e-5	Intraocular pressure;
TGCT	cis	rs6988636	0.584	rs73337885	chr8:124116300	A/G	cg27053337	chr8:124217698	FAM83A	0.56	4.9	0.4	2.88e-6	Urinary uromodulin levels;
TGCT	cis	rs7829975	0.533	rs13274028	chr8:8729193	A/C	cg15556689	chr8:8085844	FLJ10661	0.78	7.58	0.56	6.92e-12	Mood instability;
TGCT	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg22168489	chr12:122356033	WDR66	0.22	4.9	0.4	2.97e-6	Mean corpuscular volume;
TGCT	cis	rs2153535	0.580	rs1932279	chr6:8473653	T/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs8014204	0.935	rs8010840	chr14:75355203	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.75	-7.25	-0.55	4e-11	Caffeine consumption;
TGCT	cis	rs13424612	1.000	rs4854058	chr2:240923677	C/A	cg26363272	chr2:240904871	NDUFA10	0.29	4.85	0.4	3.55e-6	Odorant perception (isobutyraldehyde);
TGCT	cis	rs7659604	0.689	rs4283687	chr4:122663460	A/G	cg19748678	chr4:122722346	EXOSC9	0.54	4.6	0.38	1.05e-5	Type 2 diabetes;
TGCT	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg22963979	chr7:1858916	MAD1L1	-0.36	-5.53	-0.44	1.84e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs4780401	0.609	rs35649585	chr16:11813899	G/A	cg01061890	chr16:11836724	TXNDC11	-0.6	-5.82	-0.46	4.74e-8	Rheumatoid arthritis;
TGCT	cis	rs28595532	0.844	rs115202072	chr4:119732458	C/T	cg21605333	chr4:119757512	SEC24D	1.66	8.33	0.6	1.28e-13	Cannabis dependence symptom count;
TGCT	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg17264618	chr3:40429014	ENTPD3	0.34	4.94	0.41	2.52e-6	Renal cell carcinoma;
TGCT	cis	rs12477438	0.520	rs13031919	chr2:99848932	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.98	11.89	0.73	3.21e-22	Chronic sinus infection;
TGCT	cis	rs12579753	0.879	rs11115009	chr12:82165409	G/T	cg21231944	chr12:82153410	PPFIA2	0.34	4.62	0.38	9.52e-6	Resting heart rate;
TGCT	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs651907	0.557	rs11924013	chr3:101366698	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.91	11.18	0.71	1.7e-20	Colorectal cancer;
TGCT	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg09060608	chr5:178986726	RUFY1	-0.62	-7.74	-0.57	3.01e-12	Lung cancer;
TGCT	cis	rs10875595	0.836	rs10067231	chr5:140673429	C/T	cg24830062	chr5:140700576	TAF7	-0.61	-5.14	-0.42	1.04e-6	Pulmonary function decline;
TGCT	cis	rs6570726	0.905	rs388728	chr6:145816419	T/C	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7027203	0.576	rs7848045	chr9:96551824	G/A	cg14396892	chr9:96623032	NA	0.22	4.51	0.38	1.51e-5	DNA methylation (variation);
TGCT	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg12963246	chr6:28129442	ZNF389	-0.49	-4.72	-0.39	6.15e-6	Depression;
TGCT	cis	rs12530845	1.000	rs60179239	chr7:135333028	A/G	cg23117316	chr7:135346802	PL-5283	-0.51	-4.83	-0.4	3.98e-6	Red blood cell traits;
TGCT	cis	rs42648	0.869	rs3810891	chr7:89908851	A/G	cg25739043	chr7:89950458	NA	-0.73	-7.29	-0.55	3.15e-11	Homocysteine levels;
TGCT	cis	rs3008870	0.755	rs2815374	chr1:67507387	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.8	7.94	0.58	1.06e-12	Lymphocyte percentage of white cells;
TGCT	cis	rs12541335	0.615	rs4872464	chr8:22153381	G/A	cg09517075	chr8:22133004	PIWIL2	0.24	4.57	0.38	1.18e-5	Hypertriglyceridemia;
TGCT	cis	rs2730245	1.000	rs6965685	chr7:158726462	C/T	cg11984989	chr7:158649758	WDR60	0.98	8.74	0.62	1.33e-14	Height;
TGCT	cis	rs3749237	0.964	rs1799843	chr3:49849723	G/A	cg10152585	chr3:50297680	NA	0.51	4.84	0.4	3.79e-6	Resting heart rate;
TGCT	cis	rs12908161	1.000	rs11638290	chr15:85227636	C/T	cg12863693	chr15:85201151	NMB	0.46	5.53	0.44	1.79e-7	Schizophrenia;
TGCT	trans	rs4332037	0.851	rs10268609	chr7:1962163	A/C	cg22232500	chr2:134024266	NCKAP5	0.84	6.66	0.51	8.03e-10	Bipolar disorder;
TGCT	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg24531977	chr5:56204891	C5orf35	-0.76	-7.66	-0.57	4.53e-12	Initial pursuit acceleration;
TGCT	cis	rs892961	1.000	rs1110638	chr17:75400690	T/C	cg05865280	chr17:75406074	SEPT9	0.26	6.09	0.48	1.29e-8	Airflow obstruction;
TGCT	cis	rs11249608	0.548	rs6867208	chr5:178455575	G/A	cg23951258	chr5:178450506	ZNF879	0.45	4.61	0.38	9.7e-6	Pubertal anthropometrics;
TGCT	cis	rs7666738	0.830	rs969048	chr4:98988921	T/C	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs853679	0.550	rs1150689	chr6:28165099	T/C	cg12963246	chr6:28129442	ZNF389	0.48	4.74	0.39	5.69e-6	Depression;
TGCT	cis	rs11785400	1.000	rs3735999	chr8:143746069	T/C	cg24634471	chr8:143751801	JRK	0.55	5.92	0.47	2.93e-8	Schizophrenia;
TGCT	cis	rs514406	0.607	rs1930305	chr1:53195481	G/T	cg08859206	chr1:53392774	SCP2	0.34	4.82	0.4	4.1e-6	Monocyte count;
TGCT	cis	rs11574514	1.000	rs79631436	chr16:67728369	T/A	cg11238564	chr16:67218787	KIAA0895L;EXOC3L	0.71	4.54	0.38	1.33e-5	Crohn's disease;
TGCT	cis	rs2439831	0.681	rs484029	chr15:43619560	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.02	8.69	0.62	1.84e-14	Lung cancer in ever smokers;
TGCT	cis	rs3764400	0.567	rs1979897	chr17:46309546	C/T	cg02340556	chr17:46797764	NA	0.42	4.51	0.38	1.46e-5	Body mass index;
TGCT	cis	rs11249608	0.548	rs10479520	chr5:178451447	C/A	cg01312482	chr5:178451176	ZNF879	-0.56	-5.5	-0.44	2.09e-7	Pubertal anthropometrics;
TGCT	cis	rs911555	0.723	rs2273701	chr14:103923225	G/T	cg23461800	chr14:103021989	NA	-0.35	-4.56	-0.38	1.23e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs74233809	1.000	rs79082900	chr10:104877302	T/C	cg05855489	chr10:104503620	C10orf26	0.84	4.47	0.37	1.71e-5	Birth weight;
TGCT	cis	rs1568889	0.838	rs11030265	chr11:28296168	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.93	10.99	0.7	4.8e-20	Bipolar disorder;
TGCT	cis	rs7312933	0.558	rs61926593	chr12:42818912	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.54	5.14	0.42	1.06e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg18252515	chr7:66147081	NA	-1.17	-7.49	-0.56	1.13e-11	Diabetic kidney disease;
TGCT	trans	rs3808502	0.563	rs12549144	chr8:11422861	C/G	cg15556689	chr8:8085844	FLJ10661	0.8	7.37	0.55	2.09e-11	Neuroticism;
TGCT	cis	rs1949733	0.628	rs2688231	chr4:8490981	G/A	cg13073564	chr4:8508604	NA	-0.45	-5.09	-0.42	1.32e-6	Response to antineoplastic agents;
TGCT	cis	rs7772486	0.846	rs9373482	chr6:146363123	A/C	cg05347473	chr6:146136440	FBXO30	0.57	5.51	0.44	2.02e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9916302	0.904	rs12452509	chr17:37574722	G/A	cg07936489	chr17:37558343	FBXL20	-0.65	-4.98	-0.41	2.11e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs4900538	0.819	rs72698591	chr14:102838896	G/A	cg18135206	chr14:102964638	TECPR2	-0.2	-4.76	-0.39	5.3e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs586688	0.625	rs567337	chr1:201652979	G/A	cg07139329	chr1:201708558	NAV1	-0.51	-5.18	-0.42	8.82e-7	Obesity-related traits;
TGCT	cis	rs3733606	0.775	rs66514314	chr4:6827238	C/T	cg18375902	chr4:7764949	AFAP1;LOC84740	0.26	4.58	0.38	1.13e-5	Platelet count;
TGCT	cis	rs9868809	0.881	rs2310996	chr3:48671834	T/C	cg00383909	chr3:49044727	WDR6	0.82	4.5	0.37	1.55e-5	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs7937682	0.889	rs559482	chr11:111497902	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.09	-11.3	-0.71	8.63e-21	Primary sclerosing cholangitis;
TGCT	cis	rs2404602	0.692	rs4360890	chr15:77173295	G/A	cg22467129	chr15:76604101	ETFA	-0.47	-5.39	-0.44	3.44e-7	Blood metabolite levels;
TGCT	cis	rs7666738	0.830	rs6532701	chr4:98745134	C/T	cg17366294	chr4:99064904	C4orf37	0.65	6.75	0.52	5.05e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9388451	0.839	rs10457469	chr6:126083658	G/A	cg05901451	chr6:126070800	HEY2	-1.02	-15.06	-0.8	8.77e-30	Brugada syndrome;
TGCT	cis	rs208520	1.000	rs72882100	chr6:66981495	G/C	cg07460842	chr6:66804631	NA	0.78	6.82	0.52	3.61e-10	Exhaled nitric oxide output;
TGCT	cis	rs6543140	0.964	rs2310301	chr2:103072935	C/T	cg09003973	chr2:102972529	NA	0.55	4.67	0.39	7.71e-6	Blood protein levels;
TGCT	cis	rs13326165	0.715	rs66462821	chr3:52390555	C/T	cg27565382	chr3:53032988	SFMBT1	0.37	4.93	0.41	2.55e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs3818285	0.959	rs492943	chr10:111629030	A/T	cg00817464	chr10:111662876	XPNPEP1	0.28	4.48	0.37	1.67e-5	Superior crus of antihelix expression;
TGCT	cis	rs1865760	0.566	rs7772312	chr6:26049616	G/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.78	7.49	0.56	1.1e-11	Height;
TGCT	cis	rs889312	0.500	rs252920	chr5:56148741	C/A	cg12311346	chr5:56204834	C5orf35	-0.47	-5.03	-0.41	1.7e-6	Breast cancer;Breast cancer (early onset);
TGCT	cis	rs4523957	0.651	rs8082485	chr17:2060407	A/G	cg16513277	chr17:2031491	SMG6	-0.2	-4.64	-0.38	8.83e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs3733585	0.699	rs12498956	chr4:9950705	G/T	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.46	-0.56	1.29e-11	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs6121246	0.567	rs6058187	chr20:30190923	T/C	cg13852791	chr20:30311386	BCL2L1	0.69	4.54	0.38	1.33e-5	Mean corpuscular hemoglobin;
TGCT	trans	rs797680	0.856	rs602204	chr1:93727579	A/G	cg27528825	chr2:159282178	CCDC148	0.35	6.88	0.53	2.65e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs2820315	1.000	rs2494115	chr1:201832864	G/C	cg12730843	chr1:201915899	LMOD1	-0.27	-4.8	-0.4	4.44e-6	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
TGCT	cis	rs9467711	0.606	rs2073527	chr6:26374978	T/C	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg13695892	chr22:41940480	POLR3H	-0.91	-8.67	-0.61	1.97e-14	Vitiligo;
TGCT	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg23302884	chr18:44338147	ST8SIA5	0.47	5.47	0.44	2.43e-7	Personality dimensions;
TGCT	cis	rs9467773	0.620	rs2451744	chr6:26633463	G/T	cg11502198	chr6:26597334	ABT1	0.54	4.97	0.41	2.14e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4319547	0.741	rs4758663	chr12:122939483	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.62	-5.02	-0.41	1.72e-6	Body mass index;
TGCT	trans	rs877282	0.945	rs17293517	chr10:778770	C/T	cg22713356	chr15:30763199	NA	1.16	10.26	0.68	3.01e-18	Uric acid levels;
TGCT	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.38	-4.76	-0.39	5.31e-6	Parkinson's disease;
TGCT	cis	rs2562456	1.000	rs2359155	chr19:21671869	C/A	cg25650185	chr19:21324782	ZNF431	0.58	4.96	0.41	2.31e-6	Pain;
TGCT	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.7	6.33	0.49	4.02e-9	Tonsillectomy;
TGCT	cis	rs3858526	0.874	rs10838879	chr11:5950169	C/T	cg05234568	chr11:5960015	NA	-0.48	-4.77	-0.39	5.08e-6	DNA methylation (variation);
TGCT	cis	rs734999	0.566	rs12748729	chr1:2558740	C/T	cg18854424	chr1:2615690	NA	-0.45	-5.15	-0.42	1e-6	Ulcerative colitis;
TGCT	cis	rs9311474	0.652	rs614288	chr3:52220203	T/C	cg07507251	chr3:52567010	NT5DC2	0.35	4.56	0.38	1.19e-5	Electroencephalogram traits;
TGCT	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.59	-5.54	-0.45	1.7e-7	Bipolar disorder;
TGCT	cis	rs754133	0.963	rs12319419	chr12:54420776	G/C	cg16264616	chr12:54390824	NA	0.32	4.81	0.4	4.26e-6	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;
TGCT	cis	rs6450176	0.625	rs3776726	chr5:53290052	T/A	ch.5.1024479R	chr5:53302184	ARL15	-0.69	-5.58	-0.45	1.45e-7	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs12134133	1.000	rs61822674	chr1:207436723	T/C	cg02152968	chr1:207494213	CD55	0.61	4.66	0.39	7.94e-6	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	trans	rs9859260	0.744	rs539816	chr3:195784076	T/A	cg17074656	chr11:63784126	MACROD1	0.52	6.67	0.51	7.49e-10	Mean corpuscular volume;
TGCT	cis	rs13256369	0.802	rs13280101	chr8:8562773	G/A	cg06671706	chr8:8559999	CLDN23	0.34	4.52	0.38	1.4e-5	Obesity-related traits;
TGCT	cis	rs3796352	1.000	rs35174175	chr3:53041509	T/C	cg15956490	chr3:53032818	SFMBT1	0.62	6.82	0.52	3.6e-10	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs797680	0.856	rs682514	chr1:93719430	A/C	cg17826107	chr1:92977322	EVI5	0.24	5.29	0.43	5.47e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs11948739	0.576	rs11242051	chr5:130261276	G/A	cg08523029	chr5:130500466	HINT1	0.58	4.75	0.39	5.41e-6	Pediatric bone mineral content (hip);
TGCT	cis	rs2019216	0.502	rs1842113	chr17:21872137	G/A	cg22648282	chr17:21454238	C17orf51	-0.56	-5.48	-0.44	2.25e-7	Pelvic organ prolapse;
TGCT	cis	rs992157	0.932	rs4672884	chr2:219182481	G/A	cg00012203	chr2:219082015	ARPC2	-0.7	-7.0	-0.53	1.39e-10	Colorectal cancer;
TGCT	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.6	4.95	0.41	2.39e-6	Tonsillectomy;
TGCT	cis	rs2980439	0.818	rs2948300	chr8:8106508	C/T	cg15556689	chr8:8085844	FLJ10661	0.88	8.8	0.62	9.78e-15	Neuroticism;
TGCT	cis	rs9467773	1.000	rs6940188	chr6:26562029	G/C	cg05738196	chr6:26577821	NA	0.91	13.19	0.76	2.28e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg02725872	chr8:58115012	NA	-0.4	-4.86	-0.4	3.44e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6570726	0.935	rs446242	chr6:145843866	A/G	cg23711669	chr6:146136114	FBXO30	0.66	6.39	0.5	3.08e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6430585	0.528	rs111682961	chr2:136653848	C/T	cg07169764	chr2:136633963	MCM6	1.25	12.39	0.74	1.91e-23	Corneal structure;
TGCT	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg08280861	chr8:58055591	NA	0.4	4.73	0.39	5.97e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs861020	1.000	rs595918	chr1:209966843	A/G	cg05527609	chr1:210001259	C1orf107	0.9	7.62	0.56	5.54e-12	Orofacial clefts;
TGCT	cis	rs6815814	0.950	rs5743566	chr4:38805942	G/C	cg02016764	chr4:38805732	TLR1	-0.35	-5.65	-0.45	1.04e-7	Breast cancer;
TGCT	cis	rs12142240	0.698	rs72886907	chr1:46814265	C/T	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.4e-6	Menopause (age at onset);
TGCT	cis	rs9911578	0.933	rs2531725	chr17:56517962	G/A	cg05425664	chr17:57184151	TRIM37	-0.62	-6.16	-0.48	9.42e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg00024416	chr22:24240387	NA	0.33	5.64	0.45	1.09e-7	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg06634786	chr22:41940651	POLR3H	0.9	8.62	0.61	2.67e-14	Vitiligo;
TGCT	cis	rs2842992	0.672	rs7738253	chr6:160193917	G/T	cg11366901	chr6:160182831	ACAT2	0.98	6.47	0.5	2e-9	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs7937682	0.824	rs11213962	chr11:111506027	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.1	-11.55	-0.72	2.11e-21	Primary sclerosing cholangitis;
TGCT	cis	rs6688613	0.649	rs2280995	chr1:166846069	A/G	cg07049167	chr1:166818506	POGK	0.25	5.23	0.43	6.88e-7	Refractive astigmatism;
TGCT	cis	rs7647973	1.000	rs6785045	chr3:49435243	G/C	cg05785598	chr3:49045655	WDR6	-0.4	-4.67	-0.39	7.57e-6	Menarche (age at onset);
TGCT	cis	rs35306767	0.903	rs11253485	chr10:919362	C/T	cg20503657	chr10:835505	NA	0.74	10.3	0.68	2.41e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg07507251	chr3:52567010	NT5DC2	0.49	7.22	0.54	4.7e-11	Electroencephalogram traits;
TGCT	cis	rs1865760	0.713	rs7766342	chr6:25990674	C/A	cg16482183	chr6:26056742	HIST1H1C	0.54	4.77	0.39	5.15e-6	Height;
TGCT	trans	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg23505145	chr19:12996616	KLF1	-0.84	-8.83	-0.62	8.17e-15	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs6570726	0.935	rs12663211	chr6:145818427	G/A	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1801251	1.000	rs71421663	chr2:233619131	A/G	cg25237894	chr2:233734115	C2orf82	0.33	5.95	0.47	2.53e-8	Coronary artery disease;
TGCT	cis	rs6912958	0.781	rs2284908	chr6:88194500	A/G	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.92	-0.4	2.67e-6	Monocyte percentage of white cells;
TGCT	cis	rs11718455	1.000	rs3856744	chr3:44045812	T/C	cg08738300	chr3:44038990	NA	0.82	5.68	0.45	9.03e-8	Coronary artery disease;
TGCT	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg17178900	chr1:205818956	PM20D1	-0.53	-6.55	-0.51	1.39e-9	Monocyte percentage of white cells;
TGCT	cis	rs6540559	0.546	rs57315825	chr1:210030197	C/T	cg12034118	chr1:209979487	IRF6	0.67	4.74	0.39	5.85e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs6089584	0.927	rs2281734	chr20:60582401	C/A	cg13770153	chr20:60521292	NA	-0.54	-7.35	-0.55	2.36e-11	Body mass index;
TGCT	cis	rs4727027	0.933	rs12667123	chr7:148850621	G/A	cg23583168	chr7:148888333	NA	-0.77	-10.1	-0.67	7.35e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	trans	rs3780486	0.505	rs10758188	chr9:33123386	C/T	cg20290983	chr6:43655470	MRPS18A	-0.78	-8.21	-0.59	2.38e-13	IgG glycosylation;
TGCT	cis	rs6940638	0.688	rs7764984	chr6:27034181	A/G	cg15659132	chr6:26577336	NA	-0.56	-4.99	-0.41	1.97e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs66573146	1.000	rs7675281	chr4:7002120	C/T	cg01220768	chr4:7056774	TADA2B	0.41	4.88	0.4	3.16e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs56104184	0.775	rs56149557	chr19:49401384	C/A	cg15549821	chr19:49342101	PLEKHA4	-0.73	-9.15	-0.63	1.47e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs7681440	0.869	rs7680557	chr4:90763360	C/A	cg20003494	chr4:90757398	SNCA	-0.63	-6.09	-0.48	1.3e-8	Dementia with Lewy bodies;
TGCT	cis	rs9611565	0.802	rs4822028	chr22:41789408	A/G	cg17554472	chr22:41940697	POLR3H	-0.42	-4.56	-0.38	1.19e-5	Vitiligo;
TGCT	cis	rs9398235	0.929	rs4945860	chr6:110728383	A/G	cg19196401	chr6:110721138	DDO	0.49	4.62	0.38	9.53e-6	Systemic lupus erythematosus;
TGCT	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg19774624	chr17:42201019	HDAC5	-0.84	-8.44	-0.6	7.03e-14	Total body bone mineral density;
TGCT	cis	rs9650657	0.571	rs4240673	chr8:10787612	T/C	cg27411982	chr8:10470053	RP1L1	-0.23	-4.93	-0.4	2.56e-6	Neuroticism;
TGCT	cis	rs6912958	0.754	rs2268994	chr6:88185386	A/T	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-5.02	-0.41	1.72e-6	Monocyte percentage of white cells;
TGCT	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg27436995	chr16:743998	FBXL16	-0.47	-5.12	-0.42	1.15e-6	Height;
TGCT	cis	rs3777722	0.688	rs2757045	chr6:167350963	C/T	cg06783166	chr6:167814257	NA	-0.28	-4.48	-0.37	1.67e-5	Spontaneous preterm birth (preterm birth);
TGCT	cis	rs801193	0.967	rs3800823	chr7:66147110	C/A	cg00343986	chr7:65444356	GUSB	-0.21	-4.59	-0.38	1.06e-5	Aortic root size;
TGCT	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.41	7.48	0.56	1.16e-11	Schizophrenia;
TGCT	trans	rs2727020	0.521	rs10839299	chr11:49573981	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.42	-8.32	-0.6	1.37e-13	Coronary artery disease;
TGCT	cis	rs12682352	0.652	rs1567398	chr8:8726804	A/C	cg17143192	chr8:8559678	CLDN23	-0.47	-4.95	-0.41	2.39e-6	Neuroticism;
TGCT	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg05025164	chr4:1340916	KIAA1530	0.51	4.48	0.37	1.65e-5	Longevity;
TGCT	cis	rs60154123	0.730	rs12403947	chr1:210456524	A/G	cg04352962	chr1:209979756	IRF6	-0.65	-4.74	-0.39	5.67e-6	Coronary artery disease;
TGCT	cis	rs2204008	0.870	rs12369578	chr12:38444227	C/T	cg13010199	chr12:38710504	ALG10B	0.56	4.44	0.37	2e-5	Bladder cancer;
TGCT	cis	rs17376456	0.825	rs10054903	chr5:93281491	C/A	cg21475434	chr5:93447410	FAM172A	0.65	4.47	0.37	1.72e-5	Diabetic retinopathy;
TGCT	cis	rs9611565	0.512	rs7291736	chr22:42124874	C/A	cg03806693	chr22:41940476	POLR3H	1.08	11.99	0.73	1.84e-22	Vitiligo;
TGCT	cis	rs9549260	0.564	rs4245402	chr13:41287540	C/T	cg21288729	chr13:41239152	FOXO1	0.94	9.06	0.63	2.41e-15	Red blood cell count;
TGCT	cis	rs478304	0.651	rs7110576	chr11:65512057	T/G	cg17480646	chr11:65405466	SIPA1	-0.57	-6.93	-0.53	2.03e-10	Acne (severe);
TGCT	cis	rs72634258	0.519	rs2071984	chr1:7928656	C/T	cg26816564	chr1:7831052	VAMP3	0.62	4.99	0.41	1.98e-6	Inflammatory bowel disease;
TGCT	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg20203395	chr5:56204925	C5orf35	-0.75	-5.9	-0.47	3.19e-8	Initial pursuit acceleration;
TGCT	cis	rs28595532	0.920	rs114544767	chr4:119728364	T/C	cg14228332	chr4:119757509	SEC24D	1.32	6.38	0.5	3.2e-9	Cannabis dependence symptom count;
TGCT	cis	rs11190604	0.767	rs7090150	chr10:102173446	G/T	cg16342193	chr10:102329863	NA	-0.39	-5.05	-0.41	1.54e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9303401	0.659	rs7225896	chr17:56637337	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs6121246	0.954	rs6060978	chr20:30416893	G/A	cg13852791	chr20:30311386	BCL2L1	0.76	5.65	0.45	1.06e-7	Mean corpuscular hemoglobin;
TGCT	cis	rs3813359	0.614	rs12202999	chr6:130751454	A/G	cg25049486	chr6:130544510	SAMD3	0.37	4.48	0.37	1.66e-5	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs9297145	0.565	rs7794690	chr7:98764768	G/A	cg05967295	chr7:98741636	SMURF1	-0.66	-8.35	-0.6	1.13e-13	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs11779988	0.545	rs375203	chr8:17769054	T/A	cg01800426	chr8:17659068	MTUS1	-0.73	-5.71	-0.46	7.76e-8	Breast cancer;
TGCT	cis	rs7100689	0.784	rs7089058	chr10:82071263	T/C	cg01528321	chr10:82214614	TSPAN14	0.8	8.0	0.58	7.5e-13	Post bronchodilator FEV1;
TGCT	cis	rs2063714	0.532	rs2063713	chr6:157196299	G/T	cg23222435	chr6:157204239	ARID1B	-0.46	-7.45	-0.56	1.38e-11	Sitting height ratio;
TGCT	cis	rs7714584	1.000	rs11747065	chr5:150295486	C/T	cg22134413	chr5:150180641	NA	1.01	7.24	0.55	4.17e-11	Crohn's disease;
TGCT	trans	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg17470723	chr8:74884337	TCEB1	0.71	6.77	0.52	4.48e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2832191	0.647	rs11170	chr21:30378090	C/T	cg08807101	chr21:30365312	RNF160	0.6	5.88	0.47	3.5e-8	Dental caries;
TGCT	cis	rs1062177	0.756	rs2964592	chr5:151115688	A/G	cg12924095	chr5:151150029	G3BP1	-0.33	-4.75	-0.39	5.62e-6	Preschool internalizing problems;
TGCT	cis	rs6840360	0.967	rs4383600	chr4:152694383	T/C	cg22705602	chr4:152727874	NA	-0.24	-4.55	-0.38	1.24e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs12188164	0.686	rs72711367	chr5:418494	A/G	cg22025206	chr5:502436	SLC9A3	-0.26	-4.59	-0.38	1.06e-5	Cystic fibrosis severity;
TGCT	cis	rs981844	0.712	rs6535957	chr4:154749862	C/A	cg14289246	chr4:154710475	SFRP2	-0.99	-9.12	-0.63	1.65e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs7246657	0.943	rs7253091	chr19:37967214	C/T	cg18154014	chr19:37997991	ZNF793	0.73	5.33	0.43	4.4e-7	Coronary artery calcification;
TGCT	cis	rs1865760	0.865	rs10946800	chr6:25957773	C/T	cg17042849	chr6:26104293	HIST1H4C	-0.52	-4.78	-0.39	4.88e-6	Height;
TGCT	cis	rs3796352	0.571	rs11713926	chr3:53155072	C/T	cg07884673	chr3:53033167	SFMBT1	0.56	6.14	0.48	1.04e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs12220238	1.000	rs12220238	chr10:75952670	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.28	0.55	3.4e-11	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg18188782	chr20:61659543	NA	0.44	5.38	0.43	3.6e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs12110303	1	rs12110303	chr5:90662839	G/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	9.14	0.63	1.53e-15	Breast cancer;
TGCT	cis	rs10992471	0.603	rs7033979	chr9:95223980	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.62	-5.74	-0.46	6.79e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs2456568	0.778	rs2456563	chr11:93678675	C/T	cg17595323	chr11:93583763	C11orf90	-0.4	-5.12	-0.42	1.13e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs11153730	0.503	rs445099	chr6:118618252	T/C	cg21191810	chr6:118973309	C6orf204	0.27	4.55	0.38	1.27e-5	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
TGCT	cis	rs9894429	0.634	rs11655346	chr17:79572399	A/G	cg21028142	chr17:79581711	NPLOC4	-0.29	-5.95	-0.47	2.56e-8	Eye color traits;
TGCT	cis	rs7412746	0.634	rs12409208	chr1:150860055	A/G	cg09365446	chr1:150670422	GOLPH3L	0.35	5.0	0.41	1.87e-6	Melanoma;
TGCT	trans	rs8073060	0.544	rs225258	chr17:33956883	C/T	cg19694781	chr19:47549865	TMEM160	-0.62	-14.07	-0.78	1.86e-27	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs7829975	0.523	rs9644774	chr8:8559832	G/A	cg15556689	chr8:8085844	FLJ10661	-0.54	-4.55	-0.38	1.27e-5	Mood instability;
TGCT	cis	rs6599388	1.000	rs6599388	chr4:939087	C/T	cg17500754	chr4:1581635	NA	0.33	4.68	0.39	7.49e-6	Parkinson's disease;
TGCT	cis	rs644799	1.000	rs514170	chr11:95556696	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.82	8.63	0.61	2.52e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs6880778	0.505	rs6891952	chr5:40400885	C/T	cg01087697	chr5:40835557	RPL37	0.54	4.93	0.4	2.6e-6	Inflammatory bowel disease;
TGCT	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.35	-4.46	-0.37	1.84e-5	Total body bone mineral density;
TGCT	cis	rs7809950	0.678	rs982447	chr7:106973534	T/C	cg23024343	chr7:107201750	COG5	-0.42	-5.67	-0.45	9.29e-8	Coronary artery disease;
TGCT	cis	rs67073037	0.955	rs4371318	chr2:29156360	T/C	cg09522027	chr2:28974177	PPP1CB	0.57	4.49	0.37	1.59e-5	Breast cancer;Breast cancer (estrogen-receptor negative);
TGCT	trans	rs3780486	0.801	rs3780495	chr9:33125942	A/C	cg20290983	chr6:43655470	MRPS18A	1.19	14.71	0.8	5.8e-29	IgG glycosylation;
TGCT	cis	rs1997103	1.000	rs10224446	chr7:55413147	C/G	cg17469321	chr7:55412551	NA	0.65	6.75	0.52	5.08e-10	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.31	0.43	4.9e-7	Prudent dietary pattern;
TGCT	cis	rs2032447	0.677	rs199737	chr6:25933538	A/T	cg12310025	chr6:25882481	NA	-0.75	-6.87	-0.52	2.79e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg21724239	chr8:58056113	NA	0.38	5.14	0.42	1.02e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9926296	0.632	rs7206546	chr16:89799079	C/T	cg27121462	chr16:89883253	FANCA	-0.53	-5.01	-0.41	1.87e-6	Vitiligo;
TGCT	cis	rs35306767	0.633	rs17221491	chr10:1065191	A/G	cg26597838	chr10:835615	NA	0.57	6.32	0.49	4.34e-9	Eosinophil percentage of granulocytes;
TGCT	cis	rs10791323	0.546	rs55801927	chr11:133713094	A/C	cg15485101	chr11:133734466	NA	0.39	5.18	0.42	8.85e-7	Childhood ear infection;
TGCT	trans	rs7698623	0.850	rs7676119	chr4:88780778	G/A	cg01186725	chr1:53905612	FLJ40434	-0.48	-6.63	-0.51	9.21e-10	Cardiovascular disease risk factors;
TGCT	cis	rs11741688	0.557	rs6898923	chr5:178330559	C/T	cg08270223	chr5:178322770	ZFP2	-0.37	-5.49	-0.44	2.14e-7	Sleep duration;
TGCT	cis	rs12580194	0.957	rs12579451	chr12:55694116	C/T	cg20672549	chr12:56432144	IKZF4	0.29	4.61	0.38	9.79e-6	Cancer;
TGCT	cis	rs497273	0.553	rs508595	chr12:121198891	C/G	cg02419362	chr12:121203948	SPPL3	0.19	4.52	0.38	1.43e-5	Systemic lupus erythematosus;
TGCT	cis	rs6570726	0.875	rs416243	chr6:145868081	A/T	cg05347473	chr6:146136440	FBXO30	0.49	4.54	0.38	1.29e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg07507251	chr3:52567010	NT5DC2	0.42	5.89	0.47	3.41e-8	Bipolar disorder;
TGCT	cis	rs77106637	0.932	rs2886599	chr11:72721271	C/A	cg03713592	chr11:72463424	ARAP1	0.81	5.14	0.42	1.05e-6	Type 2 diabetes;
TGCT	cis	rs10876993	0.715	rs2169987	chr12:58012111	G/A	cg15848620	chr12:58087721	OS9	0.68	4.93	0.4	2.6e-6	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs11785400	0.793	rs4736367	chr8:143742477	G/A	cg24634471	chr8:143751801	JRK	0.55	5.51	0.44	1.99e-7	Schizophrenia;
TGCT	cis	rs2242116	0.796	rs4683297	chr3:46973673	T/C	cg23352942	chr3:46931381	PTH1R	0.31	4.53	0.38	1.36e-5	Birth weight;
TGCT	cis	rs6912958	0.631	rs9450704	chr6:88182704	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.54	-5.23	-0.43	7.03e-7	Monocyte percentage of white cells;
TGCT	cis	rs10832963	1.000	rs10128711	chr11:18632984	A/G	cg09201001	chr11:18656081	SPTY2D1	1.02	11.0	0.7	4.62e-20	Breast cancer;
TGCT	cis	rs6674176	0.660	rs3791112	chr1:44379248	T/G	cg12908607	chr1:44402522	ARTN	-0.72	-9.08	-0.63	2.12e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg22920501	chr2:26401640	FAM59B	-0.7	-6.22	-0.49	6.98e-9	Gut microbiome composition (summer);
TGCT	cis	rs6688613	0.685	rs10918600	chr1:166919342	C/T	cg07049167	chr1:166818506	POGK	-0.24	-5.09	-0.42	1.31e-6	Refractive astigmatism;
TGCT	cis	rs1008375	1.000	rs7694020	chr4:17682597	C/T	cg10189774	chr4:17578691	LAP3	0.55	5.22	0.42	7.45e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs3733585	0.781	rs13103690	chr4:9972778	T/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.92	-0.58	1.15e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs1784581	0.588	rs1784606	chr6:162405992	A/T	cg17173639	chr6:162384350	PARK2	-0.39	-6.68	-0.51	7.2e-10	Itch intensity from mosquito bite;
TGCT	cis	rs832540	0.864	rs252908	chr5:56120686	T/C	cg24531977	chr5:56204891	C5orf35	-0.52	-5.39	-0.44	3.44e-7	Coronary artery disease;
TGCT	cis	rs2120019	0.938	rs2120020	chr15:75316845	T/C	cg11632617	chr15:75315747	PPCDC	-0.3	-4.44	-0.37	1.95e-5	Blood trace element (Zn levels);
TGCT	cis	rs62244186	0.606	rs6798590	chr3:44556861	T/A	cg11003573	chr3:44754125	ZNF502	-0.41	-4.51	-0.38	1.51e-5	Depressive symptoms;
TGCT	cis	rs9300255	0.602	rs1617434	chr12:123649486	A/G	cg00376283	chr12:123451042	ABCB9	0.72	4.96	0.41	2.29e-6	Neutrophil percentage of white cells;
TGCT	cis	rs7674212	0.865	rs1481279	chr4:103977938	A/T	cg16532752	chr4:104119610	CENPE	0.5	4.55	0.38	1.26e-5	Type 2 diabetes;
TGCT	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.97	10.44	0.68	1.06e-18	Intelligence (multi-trait analysis);
TGCT	cis	rs9926296	0.744	rs164747	chr16:89708680	T/G	cg04287289	chr16:89883240	FANCA	-0.51	-4.81	-0.4	4.28e-6	Vitiligo;
TGCT	cis	rs3026101	0.671	rs1143206	chr17:5284698	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	4.68	0.39	7.51e-6	Body mass index;
TGCT	cis	rs10986311	0.775	rs11791153	chr9:127166457	C/G	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.2	-4.57	-0.38	1.17e-5	Vitiligo;
TGCT	cis	rs9341808	0.718	rs9443734	chr6:80820293	C/T	cg08355045	chr6:80787529	NA	0.32	5.83	0.46	4.48e-8	Sitting height ratio;
TGCT	cis	rs7267979	1.000	rs2856	chr20:25433536	T/C	cg03522245	chr20:25566470	NINL	0.62	6.56	0.51	1.34e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2486288	0.656	rs12904150	chr15:45547605	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.46	-5.59	-0.45	1.38e-7	Glomerular filtration rate;
TGCT	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg19010396	chr19:19431384	KIAA0892;SF4	0.54	4.47	0.37	1.77e-5	Tonsillectomy;
TGCT	cis	rs2204008	0.775	rs3900361	chr12:38238936	A/G	cg13010199	chr12:38710504	ALG10B	-0.59	-4.54	-0.38	1.29e-5	Bladder cancer;
TGCT	cis	rs908922	0.676	rs7531317	chr1:152528439	A/C	cg20991723	chr1:152506922	NA	0.44	5.96	0.47	2.44e-8	Hair morphology;
TGCT	cis	rs2153535	0.580	rs1932283	chr6:8477661	C/T	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg22168489	chr12:122356033	WDR66	-0.24	-5.98	-0.47	2.26e-8	Mean corpuscular volume;
TGCT	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg18876405	chr7:65276391	NA	-0.36	-5.41	-0.44	3.17e-7	Aortic root size;
TGCT	cis	rs910316	1.000	rs10146482	chr14:75574087	C/T	cg11812906	chr14:75593930	NEK9	0.74	7.44	0.56	1.43e-11	Height;
TGCT	cis	rs9611565	0.918	rs4822024	chr22:41757647	G/A	cg13695892	chr22:41940480	POLR3H	-0.89	-8.37	-0.6	1.03e-13	Vitiligo;
TGCT	cis	rs12210905	0.688	rs72845025	chr6:27524443	G/C	cg08851530	chr6:28072375	NA	1.34	6.29	0.49	5.02e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs7223966	1.000	rs7211213	chr17:61769456	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	5.05	0.41	1.51e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs1532993	0.518	rs877376	chr4:98625497	A/G	cg05340658	chr4:99064831	C4orf37	-0.41	-4.96	-0.41	2.3e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs12701220	0.894	rs10257744	chr7:1045612	C/T	cg27454412	chr7:1067447	C7orf50	-0.48	-4.47	-0.37	1.75e-5	Bronchopulmonary dysplasia;
TGCT	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg17554472	chr22:41940697	POLR3H	-0.49	-5.06	-0.41	1.46e-6	Vitiligo;
TGCT	cis	rs7666738	0.830	rs13101766	chr4:98957696	C/A	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1775715	0.677	rs2799034	chr10:32175896	A/G	cg14930904	chr10:32216787	ARHGAP12	0.52	5.07	0.41	1.39e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs7267979	0.844	rs4815413	chr20:25359229	G/T	cg14121845	chr20:25566513	NINL	-0.45	-4.6	-0.38	1.02e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs71435601	0.628	rs1367120	chr2:21386304	T/C	cg25035485	chr2:21266500	APOB	0.51	4.48	0.37	1.64e-5	Cholesterol, total;
TGCT	cis	rs4699052	1.000	rs6533059	chr4:104133376	T/G	cg16532752	chr4:104119610	CENPE	-0.6	-5.61	-0.45	1.28e-7	Testicular germ cell tumor;
TGCT	cis	rs360798	0.512	rs2430388	chr2:63106784	T/C	cg17519650	chr2:63277830	OTX1	0.62	5.64	0.45	1.09e-7	Coronary artery disease;
TGCT	cis	rs67311347	1.000	rs2305521	chr3:40429183	A/G	cg13683864	chr3:40499215	RPL14	-1.05	-11.13	-0.71	2.2e-20	Renal cell carcinoma;
TGCT	cis	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg18876405	chr7:65276391	NA	0.41	6.26	0.49	5.83e-9	Aortic root size;
TGCT	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg06481639	chr22:41940642	POLR3H	0.59	5.38	0.44	3.56e-7	Vitiligo;
TGCT	cis	rs9393777	0.778	rs67457459	chr6:27198343	T/G	cg10876282	chr6:28092338	ZSCAN16	0.71	4.62	0.38	9.6e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7772486	0.754	rs702304	chr6:145990797	A/G	cg23711669	chr6:146136114	FBXO30	-0.93	-10.56	-0.69	5.5e-19	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6952808	0.542	rs10243920	chr7:1950385	G/A	cg22963979	chr7:1858916	MAD1L1	-0.38	-5.8	-0.46	5.26e-8	Bipolar disorder and schizophrenia;
TGCT	cis	rs2380220	0.606	rs9488080	chr6:96006973	A/G	cg04719120	chr6:96025338	MANEA	0.62	4.94	0.41	2.44e-6	Behavioural disinhibition (generation interaction);
TGCT	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg03609598	chr5:56110824	MAP3K1	-0.56	-4.57	-0.38	1.14e-5	Initial pursuit acceleration;
TGCT	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.07	0.82	4.17e-32	Prudent dietary pattern;
TGCT	cis	rs7666738	0.579	rs7672718	chr4:98645122	A/G	cg18180107	chr4:99064573	C4orf37	0.53	4.74	0.39	5.77e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2439831	0.850	rs2439832	chr15:43779686	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	5.22	0.42	7.24e-7	Lung cancer in ever smokers;
TGCT	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg21963583	chr11:68658836	MRPL21	0.35	5.8	0.46	5.09e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs10504229	1.000	rs76270388	chr8:58195605	T/A	cg08280861	chr8:58055591	NA	0.36	4.61	0.38	9.98e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2549003	1.000	rs2070725	chr5:131821788	C/T	cg02551604	chr5:131831745	NA	-0.9	-12.1	-0.74	9.75e-23	Asthma (sex interaction);
TGCT	cis	rs7246657	0.943	rs13343502	chr19:37962292	C/T	cg18154014	chr19:37997991	ZNF793	0.95	6.52	0.51	1.58e-9	Coronary artery calcification;
TGCT	cis	rs12210905	0.688	rs9393814	chr6:27372978	C/T	cg08851530	chr6:28072375	NA	1.33	5.85	0.47	4.08e-8	Hip circumference adjusted for BMI;
TGCT	cis	rs1572072	0.593	rs3814787	chr13:24152370	G/C	cg06150803	chr13:24144257	TNFRSF19	0.41	4.89	0.4	3.01e-6	Nasopharyngeal carcinoma;
TGCT	cis	rs11122272	0.735	rs2024878	chr1:231528415	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.61	5.82	0.46	4.71e-8	Hemoglobin concentration;
TGCT	trans	rs62103177	1.000	rs62103177	chr18:77624479	G/A	cg05926928	chr17:57297772	GDPD1	1.22	11.16	0.71	1.85e-20	Opioid sensitivity;
TGCT	cis	rs35883536	0.647	rs1995142	chr1:101041174	G/A	cg06223162	chr1:101003688	GPR88	0.42	7.96	0.58	9.22e-13	Monocyte count;
TGCT	trans	rs561341	0.941	rs2470236	chr17:30304940	G/C	cg20587970	chr11:113659929	NA	-1.05	-12.74	-0.75	2.84e-24	Hip circumference adjusted for BMI;
TGCT	cis	rs709400	0.628	rs12889639	chr14:103860206	G/A	cg26031613	chr14:104095156	KLC1	-0.83	-9.22	-0.64	9.94e-16	Body mass index;
TGCT	trans	rs1974653	0.672	rs2904565	chr22:20091628	C/T	cg08822737	chr17:71088851	SLC39A11	-0.93	-7.61	-0.56	5.97e-12	Schizophrenia;
TGCT	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg13695892	chr22:41940480	POLR3H	-0.79	-7.55	-0.56	8.2e-12	Vitiligo;
TGCT	cis	rs35306767	0.953	rs12354639	chr10:963681	G/A	cg18964960	chr10:1102726	WDR37	0.57	4.55	0.38	1.27e-5	Eosinophil percentage of granulocytes;
TGCT	cis	rs12541335	0.692	rs2290274	chr8:22214374	C/T	cg18135555	chr8:22132992	PIWIL2	0.3	6.07	0.48	1.41e-8	Hypertriglyceridemia;
TGCT	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg18876405	chr7:65276391	NA	0.43	6.91	0.53	2.26e-10	Aortic root size;
TGCT	cis	rs6088590	1.000	rs6119524	chr20:33373813	C/T	cg24642439	chr20:33292090	TP53INP2	0.69	6.13	0.48	1.09e-8	Coronary artery disease;
TGCT	cis	rs35306767	0.761	rs12770173	chr10:1027108	A/C	cg26597838	chr10:835615	NA	0.58	6.55	0.51	1.35e-9	Eosinophil percentage of granulocytes;
TGCT	cis	rs11514810	1.000	rs11514810	chr7:1428476	C/T	cg24899294	chr7:1481343	MICALL2	-0.39	-5.5	-0.44	2.04e-7	Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder;
TGCT	cis	rs7611238	0.560	rs7622180	chr3:195003633	A/T	cg27323046	chr3:195102265	ACAP2	-0.37	-4.99	-0.41	1.96e-6	Body mass index;
TGCT	cis	rs858239	0.539	rs57864591	chr7:23184424	T/A	cg05602783	chr7:23145260	KLHL7	-0.62	-5.03	-0.41	1.67e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs12142240	0.698	rs17357628	chr1:46808462	A/G	cg00530320	chr1:46809349	NSUN4	0.29	5.88	0.47	3.63e-8	Menopause (age at onset);
TGCT	cis	rs4253772	0.591	rs7286155	chr22:46714735	A/G	cg24881330	chr22:46731750	TRMU	1.04	5.41	0.44	3.12e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs28595532	0.841	rs17258907	chr4:119769905	A/G	cg14228332	chr4:119757509	SEC24D	1.3	6.62	0.51	9.62e-10	Cannabis dependence symptom count;
TGCT	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg03806693	chr22:41940476	POLR3H	-1.11	-12.56	-0.75	7.44e-24	Vitiligo;
TGCT	cis	rs314370	0.951	rs12666989	chr7:100486754	G/C	cg10426581	chr7:100472382	SRRT	1.0	10.93	0.7	6.98e-20	Resting heart rate;
TGCT	cis	rs7236492	0.688	rs76247824	chr18:77186287	G/A	cg15644404	chr18:77186268	NFATC1	-0.35	-4.67	-0.39	7.83e-6	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs854765	0.583	rs5002487	chr17:17832460	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.74	7.89	0.58	1.36e-12	Total body bone mineral density;
TGCT	cis	rs9993613	1.000	rs753944	chr4:73449917	T/C	cg15102770	chr4:73434591	ADAMTS3	-0.5	-4.58	-0.38	1.09e-5	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs9911578	0.835	rs2301867	chr17:56480074	T/A	cg05425664	chr17:57184151	TRIM37	0.61	5.73	0.46	7.03e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs1865760	0.555	rs2051541	chr6:25945211	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.66	-7.59	-0.56	6.5e-12	Height;
TGCT	cis	rs826838	0.967	rs826858	chr12:39116731	A/G	cg13010199	chr12:38710504	ALG10B	-0.64	-5.07	-0.41	1.39e-6	Heart rate;
TGCT	cis	rs1215050	0.740	rs783963	chr4:98989070	A/G	cg17366294	chr4:99064904	C4orf37	0.54	5.6	0.45	1.3e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9303401	0.659	rs8074016	chr17:56840587	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs2354432	0.891	rs2165743	chr1:146690319	C/T	cg25205988	chr1:146714368	CHD1L	1.24	7.08	0.54	9.53e-11	Mitochondrial DNA levels;
TGCT	cis	rs926938	0.584	rs6689326	chr1:115369112	T/A	cg12756093	chr1:115239321	AMPD1	-0.41	-6.02	-0.48	1.79e-8	Autism;
TGCT	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg18402987	chr7:1209562	NA	0.56	5.06	0.41	1.47e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg22166914	chr1:53195759	ZYG11B	0.32	5.25	0.43	6.28e-7	Monocyte count;
TGCT	cis	rs208520	0.909	rs62414636	chr6:67015723	T/G	cg07460842	chr6:66804631	NA	0.69	5.72	0.46	7.53e-8	Exhaled nitric oxide output;
TGCT	cis	rs9911578	0.935	rs2567912	chr17:56731270	T/C	cg05425664	chr17:57184151	TRIM37	-0.64	-6.48	-0.5	1.99e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs832540	0.966	rs252925	chr5:56203773	G/A	cg24531977	chr5:56204891	C5orf35	-0.54	-5.39	-0.44	3.45e-7	Coronary artery disease;
TGCT	cis	rs644799	0.544	rs56298021	chr11:95545113	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.56	5.71	0.46	7.98e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs67311347	1.000	rs7612015	chr3:40399974	A/C	cg17264618	chr3:40429014	ENTPD3	0.31	4.65	0.39	8.38e-6	Renal cell carcinoma;
TGCT	cis	rs9486715	0.867	rs9373833	chr6:96904998	A/G	cg18709589	chr6:96969512	KIAA0776	-0.77	-7.64	-0.57	4.99e-12	Headache;
TGCT	cis	rs4906332	0.570	rs7140558	chr14:104018651	A/G	cg26031613	chr14:104095156	KLC1	-0.65	-5.19	-0.42	8.4e-7	Coronary artery disease;
TGCT	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg18402987	chr7:1209562	NA	0.65	5.32	0.43	4.65e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs8033133	0.602	rs12438531	chr15:25323876	A/C	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	-0.24	-4.82	-0.4	4.2e-6	Blood osmolality (transformed sodium);
TGCT	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs5769707	0.681	rs4622843	chr22:50036916	T/G	cg05373962	chr22:49881684	NA	-0.31	-5.31	-0.43	5e-7	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs45509595	0.841	rs200485	chr6:27775697	G/C	cg08798685	chr6:27730294	NA	-0.33	-4.53	-0.38	1.34e-5	Breast cancer;
TGCT	cis	rs6840360	0.642	rs1372977	chr4:152452398	G/A	cg17479576	chr4:152424074	FAM160A1	-0.59	-6.29	-0.49	4.87e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs910316	0.737	rs175424	chr14:75626257	T/C	cg08847533	chr14:75593920	NEK9	-0.83	-8.23	-0.59	2.13e-13	Height;
TGCT	trans	rs2469997	0.925	rs2470032	chr8:120371299	A/G	cg01792902	chr3:178864926	PIK3CA	0.83	6.77	0.52	4.49e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs10946940	0.930	rs10807029	chr6:27573463	G/A	cg10876282	chr6:28092338	ZSCAN16	-0.46	-4.73	-0.39	5.93e-6	Systemic lupus erythematosus;
TGCT	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.64	0.51	8.85e-10	Bipolar disorder;
TGCT	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg11644478	chr21:40555479	PSMG1	0.92	8.18	0.59	2.86e-13	Cognitive function;
TGCT	cis	rs12908161	1.000	rs12912388	chr15:85344550	T/A	cg11189052	chr15:85197271	WDR73	0.71	5.87	0.47	3.68e-8	Schizophrenia;
TGCT	cis	rs1953600	0.818	rs2152546	chr10:81906384	G/T	cg04850286	chr10:81895943	PLAC9	-0.4	-4.91	-0.4	2.85e-6	Sarcoidosis;
TGCT	cis	rs2070488	0.965	rs2051215	chr3:38560345	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.82	-8.21	-0.59	2.46e-13	Electrocardiographic conduction measures;
TGCT	cis	rs669446	0.562	rs304303	chr1:44178070	T/G	cg12908607	chr1:44402522	ARTN	-0.55	-5.73	-0.46	7.35e-8	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs6964587	0.839	rs12536702	chr7:91471576	G/C	cg17063962	chr7:91808500	NA	0.82	8.48	0.61	5.69e-14	Breast cancer;
TGCT	cis	rs210138	0.832	rs375555	chr6:33557741	T/C	cg24505687	chr6:33548425	BAK1	0.46	4.87	0.4	3.38e-6	Testicular germ cell tumor;
TGCT	cis	rs6669384	0.774	rs4844621	chr1:208030303	A/G	cg22525895	chr1:207977042	MIR29B2	-0.44	-6.65	-0.51	8.33e-10	Immune response to measles vaccine (measles-specific neutralising antibody titre);
TGCT	cis	rs7607369	0.680	rs533760	chr2:219381405	T/C	cg02176678	chr2:219576539	TTLL4	0.48	6.78	0.52	4.32e-10	Red blood cell count;Amyotrophic lateral sclerosis;
TGCT	cis	rs11690462	0.963	rs7603413	chr2:26561117	C/A	cg04726446	chr2:26624865	C2orf39	0.44	4.72	0.39	6.34e-6	Coronary artery disease;
TGCT	cis	rs4149423	1.000	rs4149420	chr2:108913090	G/T	cg25838818	chr2:108905173	SULT1C2	-0.42	-6.91	-0.53	2.22e-10	Lobe size;
TGCT	cis	rs35883536	0.647	rs2809790	chr1:101040461	C/T	cg10298815	chr1:101004474	GPR88	0.24	4.51	0.38	1.47e-5	Monocyte count;
TGCT	cis	rs7666738	0.830	rs7659420	chr4:98878714	G/C	cg05340658	chr4:99064831	C4orf37	0.54	6.13	0.48	1.06e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs561341	0.700	rs6505266	chr17:30225813	G/A	cg13647721	chr17:30228624	UTP6	0.6	5.32	0.43	4.72e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs6484504	0.600	rs208063	chr11:31159777	C/T	cg26647111	chr11:31128758	NA	-0.33	-4.62	-0.38	9.66e-6	Red blood cell count;
TGCT	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg15921436	chr17:44337874	NA	0.56	7.75	0.57	2.88e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs12477438	0.539	rs720228	chr2:99704547	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	12.81	0.75	1.89e-24	Chronic sinus infection;
TGCT	cis	rs2204008	0.685	rs4556621	chr12:38187236	C/A	cg26384229	chr12:38710491	ALG10B	0.85	7.48	0.56	1.21e-11	Bladder cancer;
TGCT	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg12756686	chr19:29218302	NA	0.77	6.61	0.51	1.01e-9	Methadone dose in opioid dependence;
TGCT	cis	rs11118844	0.843	rs11118847	chr1:221922614	A/G	cg04222084	chr1:221915650	DUSP10	-0.78	-5.42	-0.44	2.99e-7	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
TGCT	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.38	5.06	0.41	1.47e-6	Lymphocyte counts;
TGCT	cis	rs7666738	0.716	rs6814353	chr4:99074202	A/G	cg17366294	chr4:99064904	C4orf37	0.73	7.16	0.54	6.13e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2288884	0.943	rs11671792	chr19:52581683	A/T	cg15405931	chr19:52693188	PPP2R1A	-0.7	-4.57	-0.38	1.16e-5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs9611565	0.504	rs5758452	chr22:42144927	G/A	cg13695892	chr22:41940480	POLR3H	0.8	7.65	0.57	4.87e-12	Vitiligo;
TGCT	cis	rs6840360	0.901	rs1561915	chr4:152479724	G/A	cg17479576	chr4:152424074	FAM160A1	-0.54	-6.09	-0.48	1.31e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9902453	0.904	rs55866125	chr17:28312993	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.84	7.92	0.58	1.17e-12	Coffee consumption (cups per day);
TGCT	cis	rs2594989	0.895	rs2442789	chr3:11540188	C/T	cg00170343	chr3:11313890	ATG7	0.64	4.74	0.39	5.78e-6	Circulating chemerin levels;
TGCT	cis	rs35146811	0.735	rs1637001	chr7:99808151	G/A	cg00553149	chr7:99775558	STAG3;GPC2	-0.31	-4.61	-0.38	9.75e-6	Coronary artery disease;
TGCT	cis	rs950027	0.787	rs1547487	chr15:45723983	A/G	cg26924012	chr15:45694286	SPATA5L1	0.66	7.08	0.54	9.38e-11	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs7586879	0.964	rs13412941	chr2:25102709	C/T	cg01884057	chr2:25150051	NA	0.26	4.58	0.38	1.13e-5	Body mass index;
TGCT	cis	rs317689	0.702	rs544696	chr12:69749939	T/C	cg20891283	chr12:69753455	YEATS4	0.67	5.88	0.47	3.62e-8	Response to diuretic therapy;
TGCT	trans	rs1814175	0.817	rs10839401	chr11:49876144	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.35	-0.55	2.38e-11	Height;
TGCT	cis	rs617219	0.671	rs2220839	chr5:78603510	T/A	cg23987322	chr5:78407566	BHMT	-0.35	-4.75	-0.39	5.49e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs7760949	0.963	rs9349840	chr6:13903809	G/A	cg27413430	chr6:13925136	RNF182	0.51	4.78	0.39	4.79e-6	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs8072100	0.701	rs8075566	chr17:45771037	G/A	cg08085267	chr17:45401833	C17orf57	-0.43	-4.82	-0.4	4.04e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs7914558	0.966	rs4917997	chr10:104945213	A/G	cg04362960	chr10:104952993	NT5C2	0.61	5.47	0.44	2.42e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs709400	0.526	rs11622835	chr14:103967504	G/A	cg12935359	chr14:103987150	CKB	-0.48	-6.32	-0.49	4.2e-9	Body mass index;
TGCT	cis	rs9325144	0.723	rs3887436	chr12:39189526	A/C	cg10518543	chr12:38710700	ALG10B	-0.5	-4.65	-0.39	8.28e-6	Morning vs. evening chronotype;
TGCT	cis	rs7584330	0.554	rs79213383	chr2:238426890	A/G	cg08992911	chr2:238395768	MLPH	0.7	4.72	0.39	6.32e-6	Prostate cancer;
TGCT	cis	rs2404602	0.692	rs57178708	chr15:76904069	T/C	cg22467129	chr15:76604101	ETFA	-0.44	-4.98	-0.41	2.08e-6	Blood metabolite levels;
TGCT	cis	rs9660180	0.620	rs34298494	chr1:1663402	A/C	cg13866156	chr1:1669148	SLC35E2	0.24	5.5	0.44	2.03e-7	Body mass index;
TGCT	cis	rs6087990	0.735	rs4911261	chr20:31391360	A/G	cg13636640	chr20:31349939	DNMT3B	0.95	12.3	0.74	3.25e-23	Ulcerative colitis;
TGCT	cis	rs7100689	0.646	rs1047952	chr10:82126808	C/G	cg01528321	chr10:82214614	TSPAN14	0.8	7.76	0.57	2.7e-12	Post bronchodilator FEV1;
TGCT	cis	rs1153858	1.000	rs1554521	chr15:45664189	A/T	cg26924012	chr15:45694286	SPATA5L1	-1.1	-14.88	-0.8	2.26e-29	Homoarginine levels;
TGCT	cis	rs11640734	0.619	rs2293586	chr16:89962394	A/G	cg06558623	chr16:89946397	TCF25	0.41	4.82	0.4	4.15e-6	Interleukin-17 levels;
TGCT	cis	rs11247915	0.583	rs66569416	chr1:26659737	C/G	cg23732845	chr1:26663426	AIM1L	-0.34	-4.44	-0.37	1.95e-5	Obesity-related traits;
TGCT	cis	rs2278034	0.578	rs881753	chr3:195606770	C/T	cg01181863	chr3:195395398	SDHAP2	0.36	5.12	0.42	1.11e-6	Bronchopulmonary dysplasia;
TGCT	cis	rs2836950	0.501	rs2836980	chr21:40687618	G/T	cg11890956	chr21:40555474	PSMG1	-0.66	-6.24	-0.49	6.47e-9	Menarche (age at onset);
TGCT	cis	rs9486715	0.867	rs12207471	chr6:96963782	A/G	cg18709589	chr6:96969512	KIAA0776	0.82	8.01	0.58	7.14e-13	Headache;
TGCT	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	5.93	0.47	2.76e-8	Alzheimer's disease;
TGCT	cis	rs9486715	0.838	rs9486275	chr6:96901187	C/T	cg06623918	chr6:96969491	KIAA0776	1.11	16.62	0.83	2.35e-33	Headache;
TGCT	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg04944784	chr2:26401820	FAM59B	0.77	6.37	0.5	3.27e-9	Gut microbiome composition (summer);
TGCT	cis	rs7552404	1.000	rs7548962	chr1:76139266	G/A	cg22875332	chr1:76189707	ACADM	0.79	9.77	0.66	4.68e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs4767364	0.848	rs10774649	chr12:112539516	A/G	cg10833066	chr12:111807467	FAM109A	0.34	5.22	0.42	7.39e-7	Oral cavity and pharyngeal cancer;
TGCT	cis	rs478304	0.651	rs11227279	chr11:65495211	G/A	cg17480646	chr11:65405466	SIPA1	-0.57	-6.92	-0.53	2.1e-10	Acne (severe);
TGCT	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.0	-7.42	-0.55	1.64e-11	Gut microbiome composition (summer);
TGCT	cis	rs7086627	0.515	rs11202957	chr10:82209592	A/G	cg01528321	chr10:82214614	TSPAN14	0.65	6.21	0.49	7.21e-9	Post bronchodilator FEV1;
TGCT	cis	rs7312933	0.645	rs12049942	chr12:42587052	G/A	cg19980929	chr12:42632907	YAF2	0.47	6.46	0.5	2.13e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg10802521	chr3:52805072	NEK4	-0.78	-10.01	-0.67	1.22e-17	Bipolar disorder;
TGCT	cis	rs1483890	0.723	rs6549207	chr3:69412018	T/G	cg22125112	chr3:69402811	FRMD4B	0.29	4.74	0.39	5.85e-6	Resting heart rate;
TGCT	cis	rs9921192	0.872	rs12930815	chr16:4348635	C/T	cg00021532	chr16:4324280	TFAP4	0.83	9.35	0.64	4.71e-16	Prostate-specific antigen levels;
TGCT	cis	rs12477438	0.501	rs6753063	chr2:99801469	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	13.05	0.76	4.93e-25	Chronic sinus infection;
TGCT	cis	rs7666738	0.791	rs11729596	chr4:99045461	A/G	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2147959	0.630	rs10753449	chr1:228672526	A/G	cg22700015	chr1:228743131	NA	-0.61	-4.7	-0.39	6.82e-6	Adult asthma;
TGCT	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.56	5.0	0.41	1.91e-6	Prudent dietary pattern;
TGCT	cis	rs12497850	0.931	rs13315711	chr3:48986399	A/T	cg07636037	chr3:49044803	WDR6	0.96	10.39	0.68	1.45e-18	Parkinson's disease;
TGCT	cis	rs2637266	0.818	rs7894799	chr10:78392012	T/C	cg18941641	chr10:78392320	NA	0.43	5.58	0.45	1.46e-7	Pulmonary function;
TGCT	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.71	5.14	0.42	1.02e-6	Platelet count;
TGCT	cis	rs7216064	1.000	rs6504543	chr17:65837659	T/C	cg12091567	chr17:66097778	LOC651250	-0.84	-6.8	-0.52	4.01e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs7246657	0.722	rs4802051	chr19:38072328	C/A	cg18154014	chr19:37997991	ZNF793	0.69	4.67	0.39	7.74e-6	Coronary artery calcification;
TGCT	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg26039829	chr8:22132926	PIWIL2	0.27	5.07	0.41	1.39e-6	Hypertriglyceridemia;
TGCT	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg08736216	chr1:53307985	ZYG11A	-0.29	-5.7	-0.46	8.08e-8	Monocyte count;
TGCT	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg00149659	chr3:10157352	C3orf10	1.17	7.24	0.55	4.13e-11	Alzheimer's disease;
TGCT	cis	rs826838	1.000	rs826888	chr12:39104719	C/G	cg13010199	chr12:38710504	ALG10B	-0.62	-5.03	-0.41	1.7e-6	Heart rate;
TGCT	cis	rs478304	0.651	rs4930313	chr11:65500428	C/T	cg10518572	chr11:65560635	OVOL1	-0.24	-4.68	-0.39	7.53e-6	Acne (severe);
TGCT	cis	rs854765	0.647	rs854767	chr17:18018263	A/C	cg04398451	chr17:18023971	MYO15A	0.38	6.63	0.51	9.43e-10	Total body bone mineral density;
TGCT	cis	rs67072384	1.000	rs7125722	chr11:72449716	G/A	cg03713592	chr11:72463424	ARAP1	-0.93	-4.66	-0.39	7.89e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs4689388	0.890	rs4481292	chr4:6298375	C/T	cg00701064	chr4:6280414	WFS1	0.44	5.77	0.46	5.96e-8	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg03806693	chr22:41940476	POLR3H	1.16	13.01	0.76	6.19e-25	Vitiligo;
TGCT	cis	rs11690935	0.610	rs3770458	chr2:172651287	C/T	cg13550731	chr2:172543902	DYNC1I2	0.69	6.04	0.48	1.69e-8	Schizophrenia;
TGCT	cis	rs7824557	0.736	rs35392635	chr8:11164349	G/C	cg21775007	chr8:11205619	TDH	0.58	5.46	0.44	2.46e-7	Retinal vascular caliber;
TGCT	cis	rs56399783	0.901	rs757788	chr7:2836433	A/G	cg19731401	chr7:2775893	GNA12	0.35	4.73	0.39	5.94e-6	Childhood ear infection;
TGCT	cis	rs7959452	0.590	rs7968629	chr12:69782857	G/A	cg20891283	chr12:69753455	YEATS4	0.83	8.7	0.62	1.68e-14	Blood protein levels;
TGCT	cis	rs4499344	0.556	rs259243	chr19:33144726	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.82	8.2	0.59	2.58e-13	Mean platelet volume;
TGCT	cis	rs7208859	0.562	rs11650923	chr17:29008167	G/A	cg13385521	chr17:29058706	SUZ12P	0.75	4.51	0.38	1.5e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs8051431	0.876	rs9927968	chr16:72021767	T/C	cg06353428	chr16:71660113	MARVELD3	0.59	4.56	0.38	1.23e-5	LDL cholesterol levels;
TGCT	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg22166914	chr1:53195759	ZYG11B	0.4	6.66	0.51	8.01e-10	Monocyte count;
TGCT	cis	rs12540874	0.522	rs4947641	chr7:50489038	C/T	cg18232548	chr7:50535776	DDC	-0.37	-6.42	-0.5	2.68e-9	Systemic sclerosis;
TGCT	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg23221052	chr5:179740743	GFPT2	-0.36	-5.75	-0.46	6.7e-8	Height;
TGCT	cis	rs77741769	0.571	rs3883901	chr12:121256520	A/G	cg02419362	chr12:121203948	SPPL3	0.19	4.49	0.37	1.63e-5	Mean corpuscular volume;
TGCT	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg03452623	chr4:187889614	NA	-0.34	-4.94	-0.41	2.46e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs75686122	0.892	rs17234011	chr8:104634925	A/G	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg02725872	chr8:58115012	NA	-0.38	-5.16	-0.42	9.32e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6964587	0.740	rs2020360	chr7:91439506	G/C	cg17063962	chr7:91808500	NA	0.82	8.45	0.6	6.54e-14	Breast cancer;
TGCT	cis	rs2242116	0.743	rs11719795	chr3:46951935	T/C	cg27129171	chr3:47204927	SETD2	0.58	5.46	0.44	2.5e-7	Birth weight;
TGCT	trans	rs1814175	0.817	rs6486044	chr11:49982718	C/T	cg15704280	chr7:45808275	SEPT13	-0.73	-8.48	-0.61	5.58e-14	Height;
TGCT	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.62	5.25	0.43	6.3e-7	Tonsillectomy;
TGCT	cis	rs2153535	0.580	rs2327062	chr6:8453858	G/A	cg07606381	chr6:8435919	SLC35B3	0.53	5.02	0.41	1.79e-6	Motion sickness;
TGCT	cis	rs4478858	0.775	rs12139418	chr1:31706352	T/C	cg00250761	chr1:31883323	NA	-0.3	-5.52	-0.44	1.88e-7	Alcohol dependence;
TGCT	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg03517284	chr6:25882590	NA	-0.64	-5.76	-0.46	6.3e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs6088580	0.634	rs62212172	chr20:32987705	G/A	cg08999081	chr20:33150536	PIGU	-0.28	-5.51	-0.44	1.96e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.62	-5.11	-0.42	1.17e-6	Tonsillectomy;
TGCT	cis	rs10206020	0.885	rs13411553	chr2:1574018	A/G	cg12573674	chr2:1569213	NA	-0.45	-5.12	-0.42	1.14e-6	IgG glycosylation;
TGCT	cis	rs910316	1.000	rs10142626	chr14:75555636	A/T	cg08847533	chr14:75593920	NEK9	0.96	10.9	0.7	8.37e-20	Height;
TGCT	cis	rs2486288	0.656	rs7162022	chr15:45565253	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.72	-6.91	-0.53	2.3e-10	Glomerular filtration rate;
TGCT	cis	rs2847281	0.761	rs641085	chr18:12824930	A/T	cg23598886	chr18:12777645	NA	0.39	4.75	0.39	5.61e-6	C-reactive protein levels;Esophageal cancer (squamous cell);
TGCT	cis	rs10931896	0.531	rs295117	chr2:201146828	C/T	cg23649088	chr2:200775458	C2orf69	0.39	6.35	0.5	3.65e-9	Systolic blood pressure;
TGCT	cis	rs4253772	0.514	rs11704878	chr22:46714664	C/T	cg24881330	chr22:46731750	TRMU	1.04	5.38	0.44	3.54e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg11644478	chr21:40555479	PSMG1	-0.52	-4.64	-0.38	8.56e-6	Cognitive function;
TGCT	cis	rs3809566	0.559	rs4775605	chr15:63324048	C/G	cg00520135	chr15:63333846	TPM1	-0.4	-5.0	-0.41	1.95e-6	Platelet count;
TGCT	cis	rs394563	0.559	rs7752555	chr6:149671116	A/G	cg16235748	chr6:149772707	ZC3H12D	0.44	5.06	0.41	1.47e-6	Dupuytren's disease;
TGCT	cis	rs12039431	0.788	rs11749	chr1:38023316	C/T	cg17933807	chr1:38061675	GNL2	-0.8	-7.8	-0.57	2.15e-12	Epithelial ovarian cancer;
TGCT	cis	rs3733585	0.699	rs62294332	chr4:9959989	T/C	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.7	-0.57	3.69e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs6969780	0.545	rs983184	chr7:27188379	C/T	cg04317399	chr7:27170313	HOXA4	-0.44	-5.04	-0.41	1.64e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs3617	0.573	rs4687680	chr3:52907372	G/A	cg10802521	chr3:52805072	NEK4	-0.54	-5.99	-0.47	2.09e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6964587	1.000	rs10243241	chr7:91705696	A/G	cg17063962	chr7:91808500	NA	0.88	9.65	0.66	8.73e-17	Breast cancer;
TGCT	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg04944784	chr2:26401820	FAM59B	-0.75	-5.38	-0.43	3.64e-7	Gut microbiome composition (summer);
TGCT	cis	rs4478858	0.735	rs7556340	chr1:31788453	A/T	cg00250761	chr1:31883323	NA	-0.27	-4.82	-0.4	4.15e-6	Alcohol dependence;
TGCT	cis	rs1153858	0.723	rs1719238	chr15:45594766	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.47	-5.08	-0.42	1.34e-6	Homoarginine levels;
TGCT	cis	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg22857025	chr5:266934	NA	-0.34	-6.7	-0.52	6.65e-10	Breast cancer;
TGCT	cis	rs6089584	1.000	rs6089584	chr20:60564086	G/C	cg13770153	chr20:60521292	NA	-0.44	-5.69	-0.46	8.52e-8	Body mass index;
TGCT	cis	rs8063761	0.640	rs4785760	chr16:90051438	G/A	cg08547343	chr16:90038815	CENPBD1;AFG3L1	0.68	6.63	0.51	9.15e-10	Squamous cell carcinoma;
TGCT	cis	rs1008375	1.000	rs13119927	chr4:17691640	G/A	cg18681998	chr4:17616180	MED28	-0.78	-7.29	-0.55	3.26e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs910316	1.000	rs12590452	chr14:75548756	T/C	cg23033748	chr14:75592666	NEK9	0.27	4.57	0.38	1.16e-5	Height;
TGCT	cis	rs6667605	0.527	rs12046118	chr1:2540343	A/C	cg18854424	chr1:2615690	NA	0.46	5.36	0.43	4e-7	Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg18402987	chr7:1209562	NA	0.37	4.58	0.38	1.1e-5	Longevity;Endometriosis;
TGCT	cis	rs7954584	0.520	rs1169094	chr12:122465535	A/G	cg22168489	chr12:122356033	WDR66	-0.19	-4.52	-0.38	1.42e-5	Mean corpuscular volume;
TGCT	cis	rs2594989	0.943	rs2454499	chr3:11500531	T/C	cg26283222	chr3:11613257	VGLL4	-0.21	-4.49	-0.37	1.58e-5	Circulating chemerin levels;
TGCT	cis	rs66486766	1	rs66486766	chr15:84806060	G/A	cg11189052	chr15:85197271	WDR73	0.78	6.39	0.5	3.08e-9	Bipolar disorder lithium response (categorical) or schizophrenia;
TGCT	cis	rs4790312	0.513	rs12451211	chr17:1965542	A/G	cg24156229	chr17:1948635	NA	0.34	5.99	0.47	2.09e-8	Left atrial antero-posterior diameter;
TGCT	cis	rs11696845	0.626	rs6073537	chr20:43378270	A/G	cg09357268	chr20:43379437	KCNK15	-0.24	-4.53	-0.38	1.36e-5	Obesity-related traits;
TGCT	cis	rs11190604	1.000	rs12354411	chr10:102294537	G/A	cg23241863	chr10:102295624	HIF1AN	0.67	5.12	0.42	1.12e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.71	0.39	6.53e-6	Prudent dietary pattern;
TGCT	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.61	0.38	9.85e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs12908161	0.959	rs17598603	chr15:85200211	C/G	cg11189052	chr15:85197271	WDR73	-0.73	-6.2	-0.49	7.8e-9	Schizophrenia;
TGCT	cis	rs11098499	0.644	rs7693919	chr4:120540571	G/A	cg09307838	chr4:120376055	NA	0.62	5.86	0.47	3.86e-8	Corneal astigmatism;
TGCT	cis	rs4494114	0.967	rs9438980	chr1:39355371	A/G	cg25970120	chr1:39325951	RRAGC	-0.6	-6.25	-0.49	6.18e-9	Blood protein levels;
TGCT	cis	rs2075371	1.000	rs2544221	chr7:133993014	G/C	cg11752832	chr7:134001865	SLC35B4	0.71	6.38	0.5	3.21e-9	Mean platelet volume;
TGCT	cis	rs3806843	1.000	rs10050455	chr5:140204650	A/G	cg19875535	chr5:140030758	IK	0.37	6.16	0.48	9.55e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9399135	0.967	rs9376077	chr6:135299713	C/G	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.33e-6	Red blood cell count;
TGCT	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg11905131	chr22:24372483	LOC391322	-0.95	-11.07	-0.7	3.16e-20	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg09359103	chr1:154839909	KCNN3	-0.66	-12.3	-0.74	3.3e-23	Prostate cancer;
TGCT	cis	rs7568458	0.846	rs6743030	chr2:85763520	C/T	cg02493740	chr2:85810744	VAMP5	-0.27	-4.97	-0.41	2.2e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs3008870	1.000	rs2985797	chr1:67431499	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.12	-11.45	-0.72	3.77e-21	Lymphocyte percentage of white cells;
TGCT	cis	rs4889911	0.544	rs2650254	chr17:77833655	A/G	cg00646381	chr17:77835854	NA	0.45	6.48	0.5	1.99e-9	Electroencephalogram traits;
TGCT	cis	rs7926906	0.643	rs4320920	chr11:90530211	A/G	cg26138821	chr11:89956704	CHORDC1	-0.47	-4.77	-0.39	5.18e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7216064	1.000	rs2365764	chr17:65857714	G/A	cg12091567	chr17:66097778	LOC651250	-0.83	-6.49	-0.5	1.9e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs17331151	0.505	rs35225119	chr3:52623465	A/T	cg07884673	chr3:53033167	SFMBT1	0.78	5.72	0.46	7.67e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs4253772	0.591	rs8135363	chr22:46651713	T/C	cg09491104	chr22:46646882	C22orf40	-0.62	-6.49	-0.5	1.87e-9	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs4383453	0.539	rs55762427	chr3:123098421	A/G	cg04890266	chr3:123102914	ADCY5	-0.49	-8.3	-0.6	1.5e-13	Gestational age at birth (maternal effect);
TGCT	cis	rs7727544	0.735	rs274557	chr5:131721204	T/C	cg24060327	chr5:131705240	SLC22A5	0.58	6.45	0.5	2.23e-9	Blood metabolite levels;
TGCT	cis	rs1629083	0.935	rs2368238	chr11:118091761	T/G	cg16594165	chr11:118135105	MPZL2	-0.33	-4.7	-0.39	6.73e-6	Lung cancer;
TGCT	cis	rs9300255	0.602	rs1051431	chr12:123645803	G/A	cg00376283	chr12:123451042	ABCB9	0.73	5.64	0.45	1.09e-7	Neutrophil percentage of white cells;
TGCT	cis	rs9611565	0.765	rs727563	chr22:41867377	C/T	cg06634786	chr22:41940651	POLR3H	0.81	7.78	0.57	2.42e-12	Vitiligo;
TGCT	cis	rs933688	0.938	rs6866923	chr5:90669352	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	9.32	0.64	5.44e-16	Smoking behavior;
TGCT	cis	rs11191270	0.590	rs12569901	chr10:104025410	C/G	cg15320455	chr10:103880129	LDB1	0.85	5.39	0.44	3.36e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs4900538	0.787	rs11704	chr14:102808655	C/G	cg18135206	chr14:102964638	TECPR2	0.19	4.53	0.38	1.37e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs7829975	0.684	rs546603	chr8:8595838	T/G	cg15556689	chr8:8085844	FLJ10661	-0.64	-5.47	-0.44	2.39e-7	Mood instability;
TGCT	cis	rs57221529	0.825	rs72703051	chr5:582997	G/A	cg09021430	chr5:549028	NA	-0.41	-5.24	-0.43	6.79e-7	Lung disease severity in cystic fibrosis;
TGCT	trans	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.87	9.66	0.66	8.25e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs13136930	chr4:98937933	A/T	cg18180107	chr4:99064573	C4orf37	0.57	5.17	0.42	8.93e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9611565	0.506	rs1984839	chr22:41685937	G/C	cg06634786	chr22:41940651	POLR3H	-0.63	-5.7	-0.46	8.4e-8	Vitiligo;
TGCT	cis	rs250677	0.687	rs2963485	chr5:148452043	A/G	cg18129178	chr5:148520854	ABLIM3	0.43	6.16	0.48	9.37e-9	Breast cancer;
TGCT	cis	rs950169	0.579	rs881983	chr15:84647308	C/T	cg11189052	chr15:85197271	WDR73	0.63	4.9	0.4	2.94e-6	Schizophrenia;
TGCT	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.8	6.47	0.5	2.06e-9	Mean platelet volume;
TGCT	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg03806693	chr22:41940476	POLR3H	-1.02	-11.5	-0.72	2.83e-21	Vitiligo;
TGCT	cis	rs9790314	0.586	rs1811483	chr3:161130900	A/G	cg03342759	chr3:160939853	NMD3	-0.55	-5.69	-0.45	8.73e-8	Morning vs. evening chronotype;
TGCT	cis	rs853679	0.567	rs6905380	chr6:28374902	A/G	cg18815343	chr6:28367644	ZSCAN12	-0.48	-4.45	-0.37	1.88e-5	Depression;
TGCT	cis	rs6845621	0.901	rs4697202	chr4:18920624	A/G	cg12196642	chr4:18937545	NA	-0.25	-4.44	-0.37	1.97e-5	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
TGCT	cis	rs6964587	1.000	rs7811873	chr7:91751120	G/A	cg22709100	chr7:91322751	NA	0.29	4.69	0.39	6.98e-6	Breast cancer;
TGCT	cis	rs617219	0.737	rs2166343	chr5:78484060	A/G	cg09550809	chr5:78407562	BHMT	0.41	5.75	0.46	6.45e-8	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs7943203	1.000	rs7943063	chr11:108336907	G/T	cg04873221	chr11:107992290	ACAT1	-0.49	-4.63	-0.38	9.02e-6	Red blood cell count;Mean corpuscular volume;
TGCT	cis	rs68170813	0.617	rs17486	chr7:107112890	C/T	cg02696742	chr7:106810147	HBP1	-0.64	-4.84	-0.4	3.8e-6	Coronary artery disease;
TGCT	cis	rs2730245	0.527	rs842702	chr7:158696814	C/T	cg11984989	chr7:158649758	WDR60	1.01	7.85	0.58	1.65e-12	Height;
TGCT	cis	rs7666738	0.830	rs11932887	chr4:99072965	C/G	cg18180107	chr4:99064573	C4orf37	0.6	5.35	0.43	4e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2404602	0.684	rs11854850	chr15:76844571	C/T	cg23625390	chr15:77176239	SCAPER	-0.37	-4.64	-0.38	8.72e-6	Blood metabolite levels;
TGCT	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg04944784	chr2:26401820	FAM59B	0.75	6.09	0.48	1.29e-8	Gut microbiome composition (summer);
TGCT	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.5	-4.72	-0.39	6.33e-6	Prudent dietary pattern;
TGCT	cis	rs11190604	1.000	rs2495741	chr10:102331795	A/G	cg23241863	chr10:102295624	HIF1AN	0.69	5.12	0.42	1.15e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs554111	0.613	rs3816455	chr1:21191430	A/G	cg01072550	chr1:21505969	NA	0.34	5.22	0.42	7.27e-7	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs8177253	0.665	rs12493887	chr3:133440737	T/C	cg01448562	chr3:133502909	NA	-0.28	-5.27	-0.43	5.8e-7	Iron status biomarkers;
TGCT	cis	rs17253792	0.822	rs10483650	chr14:56145312	A/G	cg01858014	chr14:56050164	KTN1	-0.35	-4.62	-0.38	9.37e-6	Putamen volume;
TGCT	cis	rs16854884	0.586	rs4527375	chr3:143735515	A/T	cg06585982	chr3:143692056	C3orf58	-0.56	-4.74	-0.39	5.87e-6	Economic and political preferences (feminism/equality);
TGCT	cis	rs8077577	0.895	rs10048161	chr17:18082796	C/G	cg09161412	chr17:18057145	MYO15A	-0.66	-5.36	-0.43	3.94e-7	Obesity-related traits;
TGCT	cis	rs13326165	0.760	rs67834575	chr3:52411929	T/A	cg07884673	chr3:53033167	SFMBT1	0.39	4.69	0.39	7e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs7666738	0.546	rs28444809	chr4:98916934	C/T	cg05340658	chr4:99064831	C4orf37	0.6	6.62	0.51	9.9e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9611519	0.780	rs9611527	chr22:41644428	G/A	cg13695892	chr22:41940480	POLR3H	-0.65	-6.09	-0.48	1.3e-8	Neuroticism;
TGCT	cis	rs986417	0.892	rs55695351	chr14:60796565	G/T	cg27398547	chr14:60952738	C14orf39	-1.56	-6.75	-0.52	5.13e-10	Gut microbiota (bacterial taxa);
TGCT	cis	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg20637647	chr7:64974828	NA	1.0	5.59	0.45	1.4e-7	Diabetic kidney disease;
TGCT	cis	rs7917772	0.582	rs10748826	chr10:104354804	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	5.36	0.43	3.84e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs4824093	0.610	rs2208023	chr22:50249983	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.47	4.86	0.4	3.55e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs2070488	0.965	rs9829192	chr3:38569463	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.83	-8.45	-0.6	6.78e-14	Electrocardiographic conduction measures;
TGCT	cis	rs7523273	0.606	rs2724398	chr1:207993699	A/G	cg22525895	chr1:207977042	MIR29B2	-0.52	-8.85	-0.62	7.34e-15	Schizophrenia;
TGCT	cis	rs1215050	0.765	rs644839	chr4:98716357	C/A	cg17366294	chr4:99064904	C4orf37	0.52	5.61	0.45	1.27e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	trans	rs10435719	0.805	rs13269417	chr8:11791962	C/T	cg15556689	chr8:8085844	FLJ10661	0.75	7.26	0.55	3.66e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs72899043	0.800	rs1942032	chr18:35337574	C/T	cg10209886	chr18:34833563	BRUNOL4	0.46	4.72	0.39	6.38e-6	Neuroticism;
TGCT	cis	rs72945132	0.882	rs7940090	chr11:70227824	C/G	cg00319359	chr11:70116639	PPFIA1	1.03	7.86	0.58	1.59e-12	Coronary artery disease;
TGCT	cis	rs66573146	0.901	rs55882710	chr4:7030704	G/A	cg01220768	chr4:7056774	TADA2B	0.39	4.89	0.4	3.05e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs7572733	0.555	rs700671	chr2:198690001	T/C	cg00792783	chr2:198669748	PLCL1	0.56	5.08	0.42	1.35e-6	Dermatomyositis;
TGCT	cis	rs986417	1.000	rs10136642	chr14:60946098	G/C	cg27398547	chr14:60952738	C14orf39	1.39	10.61	0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs909674	0.865	rs5757683	chr22:39850174	G/A	cg01416388	chr22:39784598	NA	-0.68	-6.21	-0.49	7.5e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs4746818	0.579	rs79229724	chr10:70953872	C/T	cg11621586	chr10:70884670	VPS26A	-1.23	-5.0	-0.41	1.94e-6	Left atrial antero-posterior diameter;
TGCT	cis	rs7208859	0.573	rs7223803	chr17:29077193	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs2070488	0.775	rs13072731	chr3:38533335	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.76	7.39	0.55	1.93e-11	Electrocardiographic conduction measures;
TGCT	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg00149659	chr3:10157352	C3orf10	0.95	6.09	0.48	1.32e-8	Alzheimer's disease;
TGCT	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg23758822	chr17:41437982	NA	0.72	6.81	0.52	3.77e-10	Menopause (age at onset);
TGCT	cis	rs6693567	0.565	rs7544900	chr1:150262333	A/C	cg09579323	chr1:150459698	TARS2	-0.53	-4.81	-0.4	4.38e-6	Migraine;
TGCT	cis	rs6840360	0.571	rs6833814	chr4:152539679	A/G	cg17479576	chr4:152424074	FAM160A1	-0.71	-7.72	-0.57	3.41e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs7267979	0.966	rs2261794	chr20:25263062	T/G	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs72700829	0.593	rs77209899	chr1:150992019	G/A	cg00666978	chr1:150947442	LASS2	0.9	4.62	0.38	9.37e-6	Schizophrenia;
TGCT	cis	rs7567389	0.785	rs4150474	chr2:128033327	C/A	cg09760422	chr2:128146352	NA	-0.34	-4.46	-0.37	1.81e-5	Self-rated health;
TGCT	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.54	5.28	0.43	5.5e-7	Menarche (age at onset);
TGCT	cis	rs478607	0.834	rs2666560	chr11:64480308	C/T	cg19395706	chr11:64412079	NRXN2	-0.47	-5.02	-0.41	1.73e-6	Urate levels;
TGCT	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg10819733	chr22:24237672	NA	-0.3	-4.74	-0.39	5.76e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1670533	1.000	rs7679432	chr4:1050521	G/A	cg27284194	chr4:1044797	NA	0.68	5.87	0.47	3.76e-8	Recombination rate (females);
TGCT	cis	rs981844	1.000	rs2606328	chr4:154653864	C/T	cg14289246	chr4:154710475	SFRP2	0.99	8.39	0.6	9.39e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs10465746	0.967	rs28445286	chr1:84430483	A/G	cg10977910	chr1:84465055	TTLL7	0.63	6.27	0.49	5.38e-9	Obesity-related traits;
TGCT	cis	rs1541995	0.824	rs71396827	chr15:96243636	C/G	cg00882281	chr15:96346592	NA	0.3	4.85	0.4	3.7e-6	Photic sneeze reflex;
TGCT	cis	rs2658782	0.951	rs117384439	chr11:93111478	T/G	cg18152523	chr11:93063302	CCDC67	0.67	5.33	0.43	4.44e-7	Pulmonary function decline;
TGCT	cis	rs79349575	0.594	rs62078375	chr17:47034974	A/G	cg26022315	chr17:47021804	SNF8	0.46	4.48	0.37	1.7e-5	Type 2 diabetes;
TGCT	trans	rs12655019	0.920	rs16886497	chr5:56220714	T/C	cg25190722	chr1:3801660	DFFB	0.67	7.44	0.56	1.48e-11	Breast cancer (early onset);
TGCT	cis	rs7666738	0.606	rs4577589	chr4:99087858	A/G	cg17366294	chr4:99064904	C4orf37	0.57	5.34	0.43	4.31e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10782582	0.593	rs77733234	chr1:76101655	A/T	cg03433033	chr1:76189801	ACADM	-0.61	-7.24	-0.55	4.07e-11	Daytime sleep phenotypes;
TGCT	cis	rs422249	0.512	rs174576	chr11:61603510	C/A	cg20584555	chr11:61717780	BEST1	-0.23	-4.47	-0.37	1.74e-5	Trans fatty acid levels;
TGCT	cis	rs9473924	0.542	rs2857506	chr6:50800308	C/T	cg14470998	chr6:50812995	TFAP2B	1.37	8.51	0.61	4.67e-14	Body mass index;
TGCT	cis	rs12477438	0.765	rs17708262	chr2:99696313	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.58	-5.07	-0.41	1.4e-6	Chronic sinus infection;
TGCT	cis	rs7552404	0.691	rs61770550	chr1:76366966	C/T	cg22875332	chr1:76189707	ACADM	0.7	6.84	0.52	3.26e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9915657	0.966	rs8071725	chr17:70128726	C/T	cg06234051	chr17:70120541	SOX9	-0.28	-5.54	-0.45	1.72e-7	Thyroid hormone levels;
TGCT	cis	rs9372498	0.505	rs62424204	chr6:118861642	G/A	cg07617317	chr6:118971624	C6orf204	0.52	5.55	0.45	1.69e-7	Diastolic blood pressure;
TGCT	cis	rs926938	0.527	rs58658580	chr1:115539726	A/G	cg12756093	chr1:115239321	AMPD1	0.34	5.02	0.41	1.74e-6	Autism;
TGCT	cis	rs174551	1	rs174551	chr11:61573684	T/C	cg19610905	chr11:61596333	FADS2	-1.07	-12.03	-0.73	1.43e-22	LDL cholesterol;
TGCT	cis	rs4733781	0.509	rs1158570	chr8:131331073	C/T	cg16277922	chr8:131349729	ASAP1	-0.51	-8.42	-0.6	7.66e-14	Tuberculosis;
TGCT	cis	rs11098499	0.954	rs11729521	chr4:120416788	T/C	cg09307838	chr4:120376055	NA	0.69	6.64	0.51	8.97e-10	Corneal astigmatism;
TGCT	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg25767906	chr1:53392781	SCP2	-0.51	-6.22	-0.49	6.83e-9	Monocyte count;
TGCT	cis	rs4460629	0.742	rs7368345	chr1:155080090	C/T	cg23973274	chr1:155060172	NA	0.24	4.65	0.39	8.33e-6	Serum magnesium levels;
TGCT	cis	rs4951018	0.821	rs7529037	chr1:205637501	C/G	cg14893161	chr1:205819251	PM20D1	-0.37	-4.9	-0.4	2.99e-6	Prostate-specific antigen levels;
TGCT	cis	rs11098499	0.604	rs12642411	chr4:120580525	T/C	cg09307838	chr4:120376055	NA	0.65	6.25	0.49	5.95e-9	Corneal astigmatism;
TGCT	cis	rs7567389	0.583	rs11683427	chr2:127956543	A/G	cg09760422	chr2:128146352	NA	0.36	4.58	0.38	1.1e-5	Self-rated health;
TGCT	cis	rs13064411	0.735	rs6778800	chr3:113149236	A/G	cg10517650	chr3:113235015	CCDC52	-0.35	-4.69	-0.39	7.18e-6	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs10832963	1.000	rs10832956	chr11:18645668	A/G	cg09201001	chr11:18656081	SPTY2D1	1.01	11.4	0.72	4.91e-21	Breast cancer;
TGCT	cis	rs1865760	0.929	rs1436307	chr6:25939723	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.66	6.2	0.49	7.8e-9	Height;
TGCT	cis	rs459571	0.959	rs2520099	chr9:136918139	T/C	cg14405625	chr9:136855902	VAV2	-0.31	-4.53	-0.38	1.36e-5	Platelet distribution width;
TGCT	cis	rs2760061	0.624	rs10442629	chr1:228191070	T/A	cg02753203	chr1:228287806	NA	0.38	7.31	0.55	2.94e-11	Diastolic blood pressure;
TGCT	cis	rs7178572	0.568	rs12913233	chr15:77543297	C/T	cg22256960	chr15:77711686	NA	-0.86	-8.69	-0.62	1.77e-14	Type 2 diabetes;
TGCT	cis	rs3027234	0.727	rs74659626	chr17:8199143	G/A	cg08322244	chr17:8066669	VAMP2	-0.56	-5.22	-0.42	7.34e-7	Telomere length;
TGCT	cis	rs7264396	0.747	rs6058291	chr20:34247769	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.25	-0.43	6.33e-7	Total cholesterol levels;
TGCT	cis	rs5769707	0.967	rs2071904	chr22:50034477	C/T	cg05373962	chr22:49881684	NA	-0.31	-6.42	-0.5	2.6e-9	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	9.52	0.65	1.86e-16	Platelet count;
TGCT	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg05025164	chr4:1340916	KIAA1530	0.8	6.98	0.53	1.62e-10	Longevity;
TGCT	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg00814883	chr7:100076585	TSC22D4	-0.85	-8.62	-0.61	2.62e-14	Platelet count;
TGCT	cis	rs425277	0.561	rs11584491	chr1:2042543	A/G	cg24578937	chr1:2090814	PRKCZ	-0.24	-5.62	-0.45	1.19e-7	Height;
TGCT	cis	rs7829975	0.623	rs10092965	chr8:8373485	A/G	cg06636001	chr8:8085503	FLJ10661	0.81	7.9	0.58	1.27e-12	Mood instability;
TGCT	cis	rs208520	0.690	rs1563929	chr6:66702108	G/A	cg07460842	chr6:66804631	NA	0.96	10.29	0.68	2.52e-18	Exhaled nitric oxide output;
TGCT	cis	rs922182	0.617	rs28737203	chr15:64241169	C/T	cg02919090	chr15:64263738	DAPK2	0.37	7.01	0.53	1.33e-10	Blood protein levels;
TGCT	cis	rs9467773	1.000	rs6925703	chr6:26521589	G/A	cg26531700	chr6:26746687	NA	0.47	4.57	0.38	1.14e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7772486	0.875	rs7767660	chr6:146436550	T/C	cg05347473	chr6:146136440	FBXO30	0.54	5.01	0.41	1.86e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg22168489	chr12:122356033	WDR66	0.22	4.76	0.39	5.27e-6	Mean corpuscular volume;
TGCT	cis	rs12971120	0.891	rs4891557	chr18:72170299	C/T	cg25817165	chr18:72167213	CNDP2	-0.29	-5.11	-0.42	1.16e-6	Refractive error;
TGCT	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.62	5.22	0.42	7.25e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs236907	0.859	rs10489252	chr1:171748145	A/T	cg20598894	chr1:171756153	METTL13	-0.19	-4.47	-0.37	1.72e-5	Mean platelet volume;
TGCT	cis	rs425277	0.917	rs12410859	chr1:2038732	C/T	cg24578937	chr1:2090814	PRKCZ	0.29	6.55	0.51	1.38e-9	Height;
TGCT	cis	rs1801251	1.000	rs9653383	chr2:233670380	A/C	cg25237894	chr2:233734115	C2orf82	-0.33	-5.95	-0.47	2.53e-8	Coronary artery disease;
TGCT	cis	rs2404602	0.716	rs12437627	chr15:76845050	T/C	cg26408565	chr15:76604113	ETFA	-0.4	-5.23	-0.43	6.98e-7	Blood metabolite levels;
TGCT	cis	rs7246657	0.679	rs12461113	chr19:38083188	G/A	cg03611452	chr19:38183253	ZNF781	0.58	4.64	0.38	8.62e-6	Coronary artery calcification;
TGCT	cis	rs854765	0.647	rs7211714	chr17:17986955	A/G	cg04398451	chr17:18023971	MYO15A	-0.36	-6.31	-0.49	4.49e-9	Total body bone mineral density;
TGCT	cis	rs644799	0.965	rs10831426	chr11:95505888	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	10.82	0.7	1.31e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs35306767	0.715	rs17221456	chr10:1037234	T/C	cg18964960	chr10:1102726	WDR37	0.78	5.45	0.44	2.58e-7	Eosinophil percentage of granulocytes;
TGCT	cis	rs6424115	0.657	rs519202	chr1:24045820	C/T	cg15997130	chr1:24165203	NA	0.69	6.17	0.48	8.77e-9	Immature fraction of reticulocytes;
TGCT	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg22920501	chr2:26401640	FAM59B	-0.72	-6.38	-0.5	3.19e-9	Gut microbiome composition (summer);
TGCT	cis	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg02380750	chr20:61661411	NA	0.34	6.02	0.48	1.86e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	6.14	0.48	1.03e-8	Bipolar disorder;
TGCT	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg10802521	chr3:52805072	NEK4	-0.7	-8.55	-0.61	3.79e-14	Bipolar disorder;
TGCT	cis	rs8017423	0.967	rs28424204	chr14:90705669	G/C	cg04374321	chr14:90722782	PSMC1	0.77	8.05	0.59	5.68e-13	Mortality in heart failure;
TGCT	trans	rs4650994	0.935	rs2811290	chr1:178572978	C/T	cg05059571	chr16:84539110	KIAA1609	0.39	7.01	0.53	1.33e-10	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.38	5.06	0.41	1.47e-6	Lymphocyte counts;
TGCT	cis	rs1775715	0.707	rs2065443	chr10:32164236	C/G	cg14930904	chr10:32216787	ARHGAP12	0.52	5.07	0.41	1.39e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs9916302	0.706	rs57933226	chr17:37412829	C/T	cg07936489	chr17:37558343	FBXL20	-0.88	-6.37	-0.5	3.43e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs7647973	0.667	rs4241405	chr3:49642027	C/T	cg05785598	chr3:49045655	WDR6	0.41	4.66	0.39	8.03e-6	Menarche (age at onset);
TGCT	cis	rs6977660	0.714	rs10249635	chr7:19787090	A/G	cg07541023	chr7:19748670	TWISTNB	0.85	4.72	0.39	6.16e-6	Thyroid stimulating hormone;
TGCT	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.48	-0.37	1.66e-5	Bipolar disorder;
TGCT	cis	rs6500602	0.679	rs736685	chr16:4508606	T/C	cg08645402	chr16:4508243	NA	0.17	4.72	0.39	6.27e-6	Schizophrenia;
TGCT	cis	rs3091242	0.967	rs665372	chr1:25719235	A/C	cg23205692	chr1:25664452	TMEM50A	0.5	5.18	0.42	8.85e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs10823500	0.545	rs7082562	chr10:71945684	A/G	cg04118878	chr10:71993077	PPA1	0.48	4.84	0.4	3.84e-6	Blood protein levels;
TGCT	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg06634786	chr22:41940651	POLR3H	-0.85	-8.04	-0.59	6.2e-13	Vitiligo;
TGCT	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg11764359	chr7:65958608	NA	-0.54	-4.96	-0.41	2.27e-6	Aortic root size;
TGCT	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg11764359	chr7:65958608	NA	-0.55	-4.89	-0.4	3.11e-6	Aortic root size;
TGCT	cis	rs916888	0.610	rs199444	chr17:44818276	T/C	cg01570182	chr17:44337453	NA	0.83	7.93	0.58	1.09e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs854624	0.901	rs1734960	chr17:34336348	A/G	cg02022384	chr17:34097390	MMP28	0.5	4.67	0.39	7.74e-6	Blood protein levels;
TGCT	cis	rs4727443	0.866	rs2897075	chr7:99630342	C/T	cg13334819	chr7:99746414	C7orf59	0.56	4.71	0.39	6.63e-6	Interstitial lung disease;
TGCT	trans	rs2288327	0.557	rs60488846	chr2:179357842	C/T	cg18634211	chr1:26737262	LIN28	0.91	6.86	0.52	2.86e-10	Atrial fibrillation;
TGCT	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg18876405	chr7:65276391	NA	-0.36	-5.41	-0.44	3.12e-7	Aortic root size;
TGCT	cis	rs1158570	0.814	rs7839523	chr8:131281826	G/T	cg16277922	chr8:131349729	ASAP1	0.47	6.98	0.53	1.59e-10	Platelet count;
TGCT	cis	rs57920188	0.585	rs12126679	chr1:4072921	C/T	cg20703997	chr1:4087676	NA	0.47	5.8	0.46	5.14e-8	Interleukin-17 levels;
TGCT	cis	rs9467773	0.620	rs2498351	chr6:26659642	C/T	cg05738196	chr6:26577821	NA	0.88	10.63	0.69	3.68e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg16325326	chr1:53192061	ZYG11B	-0.58	-6.44	-0.5	2.36e-9	Monocyte count;
TGCT	cis	rs2204008	0.715	rs12368462	chr12:38336116	C/G	cg26384229	chr12:38710491	ALG10B	0.83	7.27	0.55	3.51e-11	Bladder cancer;
TGCT	cis	rs8064299	0.967	rs7420	chr17:72765215	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	-0.73	-7.51	-0.56	1.02e-11	Monocyte count;
TGCT	cis	rs478304	0.593	rs2236682	chr11:65480090	G/T	cg17480646	chr11:65405466	SIPA1	-0.59	-6.88	-0.53	2.63e-10	Acne (severe);
TGCT	cis	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg08564027	chr20:61660810	NA	0.37	6.85	0.52	3.1e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg13695892	chr22:41940480	POLR3H	-0.91	-9.07	-0.63	2.18e-15	Vitiligo;
TGCT	cis	rs7193541	0.662	rs8063458	chr16:74469121	G/T	cg01733217	chr16:74700730	RFWD3	-0.71	-7.33	-0.55	2.58e-11	Multiple myeloma;
TGCT	cis	rs6684514	1.000	rs12132794	chr1:156281020	C/G	cg20302342	chr1:156215951	PAQR6	-0.35	-4.74	-0.39	5.77e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs10782582	0.609	rs76260657	chr1:76338017	C/T	cg03433033	chr1:76189801	ACADM	-0.5	-4.98	-0.41	2.11e-6	Daytime sleep phenotypes;
TGCT	cis	rs12908161	1.000	rs17601029	chr15:85347709	A/G	cg17173187	chr15:85201210	NMB	0.56	6.26	0.49	5.79e-9	Schizophrenia;
TGCT	cis	rs739401	0.572	rs384490	chr11:3078885	A/C	cg05729581	chr11:3078854	CARS	-0.55	-5.02	-0.41	1.71e-6	Longevity;
TGCT	cis	rs7208859	0.623	rs9896603	chr17:29078512	C/G	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7100689	0.784	rs7082705	chr10:82170856	C/T	cg01528321	chr10:82214614	TSPAN14	-0.95	-9.99	-0.67	1.36e-17	Post bronchodilator FEV1;
TGCT	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg08280861	chr8:58055591	NA	0.42	4.82	0.4	4.15e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1971762	0.762	rs4759282	chr12:54072435	C/A	cg22997177	chr12:54070527	ATP5G2	-0.34	-4.54	-0.38	1.32e-5	Height;
TGCT	cis	rs12701220	0.894	rs8591	chr7:1036799	C/T	cg27454412	chr7:1067447	C7orf50	-0.48	-4.61	-0.38	9.67e-6	Bronchopulmonary dysplasia;
TGCT	cis	rs9650657	0.645	rs4841407	chr8:10516185	G/A	cg27411982	chr8:10470053	RP1L1	-0.23	-4.93	-0.4	2.62e-6	Neuroticism;
TGCT	cis	rs7582180	0.629	rs893416	chr2:100957443	G/A	cg08017756	chr2:100939284	LONRF2	-0.3	-4.87	-0.4	3.27e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg03188948	chr7:1209495	NA	0.59	4.82	0.4	4.06e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg18230493	chr5:56204884	C5orf35	-0.67	-5.88	-0.47	3.5e-8	Initial pursuit acceleration;
TGCT	cis	rs9362426	0.708	rs4707365	chr6:88100912	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.43	4.81	0.4	4.34e-6	Depressive episodes in bipolar disorder;
TGCT	cis	rs7647973	0.626	rs11720705	chr3:49753788	A/G	cg03060546	chr3:49711283	APEH	0.63	5.63	0.45	1.12e-7	Menarche (age at onset);
TGCT	cis	rs6074578	0.597	rs7353361	chr20:134400	G/A	cg16931068	chr20:139680	DEFB127	0.27	4.49	0.37	1.59e-5	Hirschsprung disease;
TGCT	cis	rs28595532	0.920	rs115673173	chr4:119755321	C/T	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs7258465	0.965	rs2561043	chr19:18622683	A/T	cg06462663	chr19:18546047	ISYNA1	0.2	4.67	0.39	7.74e-6	Breast cancer;
TGCT	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg09263875	chr16:632152	PIGQ	0.31	6.88	0.53	2.58e-10	Height;
TGCT	cis	rs739496	0.579	rs7133881	chr12:112378768	A/C	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs36051895	0.623	rs7027871	chr9:5236822	C/G	cg02405213	chr9:5042618	JAK2	0.64	6.89	0.53	2.5e-10	Pediatric autoimmune diseases;
TGCT	cis	rs4808199	0.895	rs2285628	chr19:19467996	T/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.71	5.56	0.45	1.59e-7	Nonalcoholic fatty liver disease;
TGCT	cis	rs9467711	1.000	rs1883215	chr6:26314233	G/C	cg26531700	chr6:26746687	NA	-1.08	-5.74	-0.46	7.01e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4747241	1.000	rs4746112	chr10:74042995	G/A	cg09661010	chr10:73848153	SPOCK2	0.4	4.46	0.37	1.8e-5	Heschl's gyrus morphology;
TGCT	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg13206674	chr6:150067644	NUP43	0.52	4.51	0.38	1.5e-5	Lung cancer;
TGCT	cis	rs539096	0.602	rs2970610	chr1:44097530	T/C	cg12908607	chr1:44402522	ARTN	-0.42	-4.7	-0.39	6.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs11122272	0.735	rs2256908	chr1:231506557	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.14	-0.54	6.86e-11	Hemoglobin concentration;
TGCT	cis	rs2075371	0.611	rs62462979	chr7:134019379	G/T	cg11752832	chr7:134001865	SLC35B4	0.63	5.22	0.42	7.24e-7	Mean platelet volume;
TGCT	cis	rs3784262	0.607	rs4646576	chr15:58338998	A/T	cg12031962	chr15:58353849	ALDH1A2	-0.54	-8.34	-0.6	1.2e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs6088580	0.634	rs4142007	chr20:32990050	G/T	cg08999081	chr20:33150536	PIGU	-0.28	-5.51	-0.44	1.96e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	7.34	0.55	2.49e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9653442	0.545	rs11681966	chr2:100759457	A/C	cg22139774	chr2:100720529	AFF3	0.38	5.96	0.47	2.43e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs7647973	0.826	rs9834535	chr3:49378797	A/T	cg05785598	chr3:49045655	WDR6	0.38	4.5	0.37	1.56e-5	Menarche (age at onset);
TGCT	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg10802521	chr3:52805072	NEK4	-0.73	-8.95	-0.63	4.37e-15	Electroencephalogram traits;
TGCT	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg08509172	chr19:19383838	TM6SF2	-0.34	-4.48	-0.37	1.71e-5	Tonsillectomy;
TGCT	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg22920501	chr2:26401640	FAM59B	0.8	6.34	0.5	3.8e-9	Gut microbiome composition (summer);
TGCT	cis	rs7809950	0.953	rs28687365	chr7:107106712	A/C	cg23024343	chr7:107201750	COG5	-0.33	-5.34	-0.43	4.25e-7	Coronary artery disease;
TGCT	cis	rs12497850	0.897	rs9850134	chr3:48957147	A/G	cg05785598	chr3:49045655	WDR6	0.36	4.75	0.39	5.46e-6	Parkinson's disease;
TGCT	cis	rs7659604	0.643	rs6839054	chr4:122663628	C/T	cg19748678	chr4:122722346	EXOSC9	0.59	5.13	0.42	1.07e-6	Type 2 diabetes;
TGCT	cis	rs3859192	0.561	rs12451547	chr17:38181168	T/C	cg17467752	chr17:38218738	THRA	-0.52	-4.59	-0.38	1.09e-5	White blood cell count;
TGCT	cis	rs4642101	0.765	rs9871991	chr3:12827525	C/A	cg05775895	chr3:12838266	CAND2	0.79	9.0	0.63	3.36e-15	QRS complex (12-leadsum);
TGCT	cis	rs367943	0.871	rs348938	chr5:112825032	C/A	cg12552261	chr5:112820674	MCC	-0.22	-4.7	-0.39	6.84e-6	Type 2 diabetes;
TGCT	cis	rs3733585	0.699	rs13328050	chr4:9951120	G/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-7.05	-0.54	1.08e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs9611565	0.592	rs1811113	chr22:42073134	C/T	cg13695892	chr22:41940480	POLR3H	0.89	8.6	0.61	2.92e-14	Vitiligo;
TGCT	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg20007245	chr22:24372913	LOC391322	-0.77	-8.37	-0.6	1.03e-13	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs13394619	0.655	rs7578132	chr2:11718858	C/T	cg07314298	chr2:11723111	GREB1	-0.27	-4.56	-0.38	1.21e-5	Endometriosis;
TGCT	cis	rs5769707	0.967	rs739241	chr22:50052921	G/A	cg20744362	chr22:50050164	C22orf34	0.28	4.54	0.38	1.32e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg02463440	chr8:22132932	PIWIL2	0.26	5.2	0.42	7.85e-7	Hypertriglyceridemia;
TGCT	cis	rs7927771	0.800	rs35996350	chr11:47389223	A/G	cg21462715	chr11:47870315	NUP160	0.58	4.74	0.39	5.68e-6	Subjective well-being;
TGCT	cis	rs6912958	0.559	rs446851	chr6:88043640	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.47	6.33	0.49	4.08e-9	Monocyte percentage of white cells;
TGCT	cis	rs7044106	0.500	rs56725168	chr9:123492576	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	7.99	0.58	8.05e-13	Hip circumference adjusted for BMI;
TGCT	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg04944784	chr2:26401820	FAM59B	-0.67	-6.16	-0.48	9.54e-9	Gut microbiome composition (summer);
TGCT	cis	rs12421382	0.543	rs10890996	chr11:109328421	A/G	cg27471124	chr11:109292789	C11orf87	-0.49	-6.22	-0.49	7.04e-9	Schizophrenia;
TGCT	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg27454412	chr7:1067447	C7orf50	0.6	4.7	0.39	6.76e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg07061783	chr6:25882402	NA	-0.46	-4.9	-0.4	2.94e-6	Blood metabolite levels;
TGCT	cis	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg20637647	chr7:64974828	NA	-0.9	-5.31	-0.43	4.87e-7	Diabetic kidney disease;
TGCT	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg24531977	chr5:56204891	C5orf35	0.7	7.44	0.56	1.47e-11	Initial pursuit acceleration;
TGCT	cis	rs2439831	0.764	rs2447193	chr15:43929733	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	6.61	0.51	1.03e-9	Lung cancer in ever smokers;
TGCT	cis	rs9527	0.590	rs10883818	chr10:104759586	A/G	cg04362960	chr10:104952993	NT5C2	0.68	5.7	0.46	8.14e-8	Arsenic metabolism;
TGCT	cis	rs7582180	0.629	rs11678148	chr2:100966950	A/T	cg14675211	chr2:100938903	LONRF2	0.5	4.78	0.39	4.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6681544	0.544	rs3790904	chr1:82382517	G/T	cg04226724	chr1:82268649	LPHN2	0.47	4.95	0.41	2.33e-6	Metabolite levels  (X-11787);
TGCT	cis	rs9308731	0.563	rs6760053	chr2:111932997	C/G	cg04202892	chr2:111875749	ACOXL	0.44	4.88	0.4	3.2e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs10751667	0.961	rs10902263	chr11:992691	A/C	cg06064525	chr11:970664	AP2A2	0.27	5.4	0.44	3.34e-7	Alzheimer's disease (late onset);
TGCT	cis	rs59107033	0.559	rs62262396	chr3:123105491	A/G	cg04890266	chr3:123102914	ADCY5	-0.48	-7.84	-0.58	1.81e-12	Lymphocyte counts;
TGCT	cis	rs1008375	1.000	rs2286771	chr4:17643848	G/A	cg10189774	chr4:17578691	LAP3	0.57	5.15	0.42	9.95e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs28595532	0.688	rs116053430	chr4:119731375	G/A	cg21605333	chr4:119757512	SEC24D	1.66	8.33	0.6	1.28e-13	Cannabis dependence symptom count;
TGCT	cis	rs4663969	0.873	rs759174	chr2:234668245	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.26	-4.45	-0.37	1.86e-5	Total bilirubin levels in HIV-1 infection;
TGCT	cis	rs9611565	0.879	rs2235845	chr22:41729294	T/G	cg17554472	chr22:41940697	POLR3H	-0.39	-4.49	-0.37	1.58e-5	Vitiligo;
TGCT	cis	rs916888	0.821	rs199506	chr17:44859031	A/G	cg16520312	chr17:43971471	MAPT;LOC100128977	0.57	4.86	0.4	3.45e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs644799	0.664	rs603625	chr11:95554283	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.79	8.64	0.61	2.36e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs10174077	0.874	rs6750342	chr2:152485754	A/G	cg06191203	chr2:152266755	RIF1	-0.71	-6.76	-0.52	4.93e-10	Squamous cell lung carcinoma;
TGCT	cis	rs12579753	0.830	rs12825476	chr12:82238350	G/A	cg07988820	chr12:82153109	PPFIA2	-0.6	-6.48	-0.5	1.91e-9	Resting heart rate;
TGCT	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg00814883	chr7:100076585	TSC22D4	-0.91	-8.03	-0.58	6.36e-13	Platelet count;
TGCT	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	0.5	4.85	0.4	3.68e-6	Bipolar disorder;
TGCT	cis	rs904251	0.600	rs12211110	chr6:37466232	A/G	cg01843034	chr6:37503916	NA	-0.48	-5.99	-0.47	2.11e-8	Cognitive performance;
TGCT	cis	rs4924935	0.887	rs2428380	chr17:18843089	C/A	cg26378065	chr17:18585709	ZNF286B	-0.56	-4.59	-0.38	1.05e-5	Pancreatic cancer;
TGCT	cis	rs17376456	0.569	rs2045021	chr5:93224222	G/A	cg21475434	chr5:93447410	FAM172A	-0.69	-5.2	-0.42	7.83e-7	Diabetic retinopathy;
TGCT	trans	rs1864729	0.688	rs2567768	chr8:98303151	G/A	cg08679828	chr8:102218111	ZNF706	-1.06	-7.16	-0.54	6.21e-11	Estradiol plasma levels (breast cancer);
TGCT	cis	rs12220898	0.749	rs11101075	chr10:50485110	G/T	cg09603381	chr10:49954066	WDFY4	0.38	4.45	0.37	1.88e-5	Inflammatory biomarkers;
TGCT	cis	rs9486719	1.000	rs3906199	chr6:97049899	C/A	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.32	-0.6	1.32e-13	Migraine;Coronary artery disease;
TGCT	cis	rs10858047	0.883	rs6658815	chr1:115209050	T/C	cg12756093	chr1:115239321	AMPD1	-0.47	-4.96	-0.41	2.27e-6	Autism;
TGCT	cis	rs9581857	0.547	rs9579095	chr13:28082555	C/T	cg22138327	chr13:27999177	GTF3A	0.73	4.54	0.38	1.34e-5	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg04414720	chr1:150670196	GOLPH3L	0.39	5.04	0.41	1.59e-6	Tonsillectomy;
TGCT	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg02725872	chr8:58115012	NA	-0.4	-4.78	-0.39	4.78e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9912789	0.744	rs9893755	chr17:79187432	C/T	cg14413466	chr17:79170920	AZI1	0.25	4.45	0.37	1.9e-5	Frontotemporal dementia;
TGCT	trans	rs208520	1.000	rs12190773	chr6:66968194	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	8.21	0.59	2.37e-13	Exhaled nitric oxide output;
TGCT	cis	rs344364	0.511	rs2982453	chr16:1949520	G/A	cg26617929	chr16:1858877	NA	-0.27	-4.9	-0.4	2.99e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs4788570	0.697	rs11075904	chr16:71816899	G/A	cg06353428	chr16:71660113	MARVELD3	1.53	12.59	0.75	6.48e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs9788721	0.836	rs2656065	chr15:78750549	G/A	cg18825076	chr15:78729989	IREB2	-0.32	-5.12	-0.42	1.15e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
TGCT	cis	rs4499344	0.920	rs2868149	chr19:33086096	C/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.73	-6.6	-0.51	1.07e-9	Mean platelet volume;
TGCT	cis	rs9634489	0.502	rs1328048	chr13:97119528	A/G	cg11411106	chr13:97107445	HS6ST3	0.27	4.72	0.39	6.26e-6	Body mass index;
TGCT	cis	rs3809863	0.602	rs6504833	chr17:45396087	A/G	cg25173405	chr17:45401733	C17orf57	-0.42	-4.6	-0.38	1.04e-5	Glaucoma (primary open-angle);
TGCT	cis	rs1461503	0.900	rs7102462	chr11:122828767	C/G	cg27398637	chr11:122830231	C11orf63	-0.41	-4.77	-0.39	5.14e-6	Menarche (age at onset);
TGCT	cis	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg08975724	chr8:8085496	FLJ10661	0.56	4.89	0.4	3.03e-6	Mood instability;
TGCT	cis	rs1348850	0.558	rs4337505	chr2:178529714	A/T	cg22681709	chr2:178499509	PDE11A	-0.46	-5.89	-0.47	3.46e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs250677	0.522	rs10040598	chr5:148365720	C/A	cg18129178	chr5:148520854	ABLIM3	0.36	4.69	0.39	7.23e-6	Breast cancer;
TGCT	cis	rs10823500	0.523	rs12774848	chr10:71932436	T/C	cg04118878	chr10:71993077	PPA1	0.6	5.11	0.42	1.21e-6	Blood protein levels;
TGCT	cis	rs6969780	0.915	rs12666926	chr7:27189561	A/G	cg04321618	chr7:27170880	HOXA4	-0.52	-4.5	-0.38	1.51e-5	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs7772486	0.875	rs2748482	chr6:146336532	T/C	cg13319975	chr6:146136371	FBXO30	-0.51	-4.56	-0.38	1.23e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs853679	0.546	rs200953	chr6:27837267	T/C	cg01031101	chr6:28227091	NKAPL	-0.49	-4.63	-0.38	9.05e-6	Depression;
TGCT	trans	rs4332037	0.826	rs4721188	chr7:1953615	G/A	cg10840412	chr1:235813424	GNG4	-1.02	-8.17	-0.59	3.04e-13	Bipolar disorder;
TGCT	cis	rs28595532	0.920	rs56104443	chr4:119752052	G/A	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs9467711	0.606	rs2073529	chr6:26375159	C/T	cg16898833	chr6:26189333	HIST1H4D	-1.09	-5.27	-0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2239547	0.522	rs2336669	chr3:52994138	C/T	cg10802521	chr3:52805072	NEK4	0.61	5.9	0.47	3.2e-8	Schizophrenia;
TGCT	trans	rs1908814	0.516	rs10113062	chr8:11793249	A/G	cg15556689	chr8:8085844	FLJ10661	0.75	7.26	0.55	3.66e-11	Neuroticism;
TGCT	cis	rs7607369	0.566	rs55658481	chr2:219284215	G/A	cg02176678	chr2:219576539	TTLL4	-0.48	-6.1	-0.48	1.23e-8	Red blood cell count;Amyotrophic lateral sclerosis;
TGCT	cis	rs7666738	0.678	rs7670805	chr4:99008763	A/G	cg05340658	chr4:99064831	C4orf37	0.48	5.5	0.44	2.09e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6500602	0.727	rs11076836	chr16:4569331	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.32	5.97	0.47	2.35e-8	Schizophrenia;
TGCT	cis	rs3784262	0.565	rs2899613	chr15:58347260	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.38	-5.57	-0.45	1.53e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs11098499	0.866	rs12374352	chr4:120281977	C/T	cg09307838	chr4:120376055	NA	0.58	5.76	0.46	6.16e-8	Corneal astigmatism;
TGCT	cis	rs911555	0.755	rs8014013	chr14:103937372	A/G	cg12935359	chr14:103987150	CKB	0.33	4.51	0.38	1.46e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs1903068	0.719	rs1350545	chr4:56004454	C/T	cg09978860	chr4:56023921	NA	0.53	5.63	0.45	1.14e-7	Endometriosis;
TGCT	cis	rs9814567	1.000	rs9869981	chr3:134248801	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.95	-9.55	-0.65	1.56e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs9858542	0.953	rs11719996	chr3:49525958	T/C	cg03060546	chr3:49711283	APEH	-0.61	-5.37	-0.43	3.78e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs17401966	0.894	rs61778406	chr1:10435816	G/A	cg19773385	chr1:10388646	KIF1B	-0.24	-5.45	-0.44	2.57e-7	Hepatocellular carcinoma;
TGCT	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg02353165	chr6:42928485	GNMT	0.97	9.95	0.67	1.66e-17	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg24399712	chr22:39784796	NA	-0.93	-11.33	-0.71	7.31e-21	Intelligence (multi-trait analysis);
TGCT	cis	rs9814567	1.000	rs4309773	chr3:134277301	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.92	-8.81	-0.62	9.26e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg11905131	chr22:24372483	LOC391322	-0.95	-11.07	-0.7	3.22e-20	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs425277	1.000	rs196128	chr1:2078444	T/G	cg03732007	chr1:2071316	PRKCZ	0.26	5.44	0.44	2.77e-7	Height;
TGCT	cis	rs7824557	0.568	rs35747588	chr8:11206627	C/G	cg21775007	chr8:11205619	TDH	0.73	7.01	0.53	1.32e-10	Retinal vascular caliber;
TGCT	cis	rs10031466	0.935	rs902909	chr4:189021465	A/G	cg04086012	chr4:189060900	TRIML1	0.2	4.48	0.37	1.7e-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg27588902	chr6:42928151	GNMT	-0.56	-6.8	-0.52	4.02e-10	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs1997103	1.000	rs10278894	chr7:55404748	A/G	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs6582630	0.537	rs10785436	chr12:38461040	G/C	cg26384229	chr12:38710491	ALG10B	0.82	7.5	0.56	1.07e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs8072100	1.000	rs4375701	chr17:45712218	C/T	cg08085267	chr17:45401833	C17orf57	-0.47	-5.13	-0.42	1.07e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs711245	0.573	rs3770796	chr2:36799515	T/C	cg10546459	chr2:36825355	FEZ2	0.57	5.18	0.42	8.89e-7	Height;
TGCT	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg11890956	chr21:40555474	PSMG1	-0.77	-7.01	-0.53	1.33e-10	Cognitive function;
TGCT	cis	rs9443189	0.570	rs567903	chr6:76327851	C/T	cg01950844	chr6:76311363	SENP6	1.01	6.06	0.48	1.54e-8	Prostate cancer;
TGCT	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg00814883	chr7:100076585	TSC22D4	-0.9	-9.56	-0.65	1.5e-16	Platelet count;
TGCT	cis	rs736408	0.581	rs3617	chr3:52833805	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	5.14	0.42	1.06e-6	Bipolar disorder;
TGCT	cis	rs1018836	0.886	rs4734246	chr8:91569028	A/C	cg16814680	chr8:91681699	NA	-0.9	-9.91	-0.66	2.06e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7246657	0.606	rs2972439	chr19:38212581	T/C	cg18154014	chr19:37997991	ZNF793	-0.72	-5.06	-0.41	1.48e-6	Coronary artery calcification;
TGCT	cis	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg06636001	chr8:8085503	FLJ10661	0.76	7.26	0.55	3.71e-11	Mood instability;
TGCT	cis	rs11031096	0.711	rs10835723	chr11:4207566	G/C	cg18678763	chr11:4115507	RRM1	-0.45	-5.84	-0.46	4.31e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs910316	0.712	rs175074	chr14:75504454	G/A	cg11812906	chr14:75593930	NEK9	-0.58	-5.52	-0.44	1.92e-7	Height;
TGCT	cis	rs12762955	0.561	rs1904671	chr10:1014603	G/A	cg18964960	chr10:1102726	WDR37	-0.65	-5.81	-0.46	4.9e-8	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs7809950	0.773	rs2237668	chr7:107050209	A/G	cg23024343	chr7:107201750	COG5	-0.48	-6.33	-0.49	4.11e-9	Coronary artery disease;
TGCT	cis	rs2302045	1.000	rs113807377	chr2:242052354	T/C	cg04553960	chr2:241721320	KIF1A	-0.7	-4.68	-0.39	7.4e-6	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio);
TGCT	cis	rs12049351	0.774	rs12140727	chr1:229626891	C/G	cg12130225	chr1:229698885	NA	-0.39	-4.59	-0.38	1.06e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs11931598	0.513	rs3857170	chr4:7003366	A/T	cg02503808	chr4:7069936	GRPEL1	0.52	4.79	0.4	4.64e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs939574	0.512	rs2276638	chr2:220145286	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.78	5.54	0.45	1.71e-7	Platelet distribution width;
TGCT	cis	rs2963155	0.518	rs865482	chr5:142640317	C/A	cg17617527	chr5:142782415	NR3C1	0.85	6.31	0.49	4.45e-9	Breast cancer;
TGCT	cis	rs9611565	0.592	rs5751139	chr22:42099981	G/C	cg13695892	chr22:41940480	POLR3H	0.88	8.63	0.61	2.45e-14	Vitiligo;
TGCT	cis	rs9467773	0.595	rs2451736	chr6:26620544	G/A	cg15659132	chr6:26577336	NA	0.84	10.91	0.7	7.83e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs2862064	0.929	rs2088917	chr5:156432215	A/G	cg12943317	chr5:156479607	HAVCR1	-0.45	-5.77	-0.46	5.83e-8	Platelet count;
TGCT	cis	rs8016982	0.674	rs1951615	chr14:81671762	G/A	cg01989461	chr14:81687754	GTF2A1	0.81	8.45	0.6	6.73e-14	Schizophrenia;
TGCT	cis	rs17221829	0.692	rs55823055	chr11:89388744	G/A	cg02982614	chr11:89391479	FOLH1B	-0.25	-4.46	-0.37	1.8e-5	Anxiety in major depressive disorder;
TGCT	cis	rs4880487	0.505	rs883660	chr10:1206834	A/G	cg03183215	chr10:1252341	ADARB2	-0.24	-4.73	-0.39	5.99e-6	Migraine;
TGCT	cis	rs9549260	0.816	rs964901	chr13:41248698	C/T	cg21288729	chr13:41239152	FOXO1	0.97	9.92	0.67	1.94e-17	Red blood cell count;
TGCT	cis	rs7666738	0.962	rs11728816	chr4:98951767	C/T	cg17366294	chr4:99064904	C4orf37	0.8	7.2	0.54	5.04e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12142240	0.698	rs1053628	chr1:46827769	C/T	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs17473412	0.784	rs116765405	chr5:122702576	A/G	cg15125798	chr5:122621645	NA	-0.57	-4.83	-0.4	3.88e-6	Total body bone mineral density;
TGCT	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg06028808	chr11:68637592	NA	0.51	6.62	0.51	9.55e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	trans	rs56341938	0.656	rs1420472	chr3:168776326	A/C	cg07302051	chr16:51671357	NA	-0.36	-6.67	-0.51	7.7e-10	Lung function (FEV1/FVC);
TGCT	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg16590910	chr6:42928470	GNMT	-0.49	-4.55	-0.38	1.24e-5	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs751728	0.717	rs3763258	chr6:33773744	A/G	cg00334056	chr6:33755658	LEMD2	-0.27	-4.88	-0.4	3.13e-6	Crohn's disease;
TGCT	cis	rs9435341	0.965	rs55924375	chr1:107566690	C/A	cg09367891	chr1:107599246	PRMT6	0.62	5.4	0.44	3.22e-7	Facial morphology (factor 21, depth of nasal alae);
TGCT	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg07167872	chr1:205819463	PM20D1	0.59	7.3	0.55	3.02e-11	Menarche (age at onset);
TGCT	cis	rs6867032	1.000	rs4413568	chr5:2016894	A/G	cg26168224	chr5:2018326	NA	0.43	8.0	0.58	7.57e-13	Gut microbiome composition (winter);
TGCT	cis	rs6088580	0.634	rs1890000	chr20:32968312	G/T	cg08999081	chr20:33150536	PIGU	-0.29	-5.65	-0.45	1.02e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.2	0.42	8.14e-7	Menopause (age at onset);
TGCT	cis	rs3806843	0.518	rs2569188	chr5:140008419	G/A	cg19875535	chr5:140030758	IK	-0.33	-5.26	-0.43	6.05e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg22963979	chr7:1858916	MAD1L1	-0.32	-4.78	-0.39	4.9e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs7267979	1.000	rs6037095	chr20:25335687	A/G	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2288884	1.000	rs17835749	chr19:52578695	C/G	cg15405931	chr19:52693188	PPP2R1A	-0.69	-4.5	-0.37	1.56e-5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs651907	0.535	rs12631513	chr3:101517476	A/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.86	10.4	0.68	1.35e-18	Colorectal cancer;
TGCT	cis	rs7666738	0.680	rs11097613	chr4:99079991	G/T	cg18180107	chr4:99064573	C4orf37	0.58	5.15	0.42	9.95e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs16921914	0.565	rs286650	chr11:31230207	T/C	cg14844989	chr11:31128820	NA	-0.23	-4.51	-0.38	1.47e-5	Bone mineral density (spine);
TGCT	cis	rs853679	0.546	rs200981	chr6:27833174	A/G	cg01031101	chr6:28227091	NKAPL	-0.49	-4.66	-0.39	8.09e-6	Depression;
TGCT	cis	rs12950390	0.853	rs12450733	chr17:45855404	A/G	cg24803719	chr17:45855879	NA	-0.47	-4.72	-0.39	6.14e-6	IgG glycosylation;
TGCT	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg10802521	chr3:52805072	NEK4	-0.71	-8.79	-0.62	1.04e-14	Bipolar disorder;
TGCT	cis	rs11264213	0.901	rs581459	chr1:36375110	C/T	cg07093915	chr1:36184400	C1orf216	0.68	4.56	0.38	1.21e-5	Schizophrenia;
TGCT	cis	rs17108533	0.588	rs12880297	chr14:71300055	A/T	cg23900759	chr14:71108106	TTC9	-1.13	-4.56	-0.38	1.19e-5	Response to antipsychotic treatment in schizophrenia (reasoning);
TGCT	cis	rs3087591	1.000	rs2040791	chr17:29627297	G/C	cg24425628	chr17:29625626	OMG;NF1	-0.47	-7.51	-0.56	1.01e-11	Hip circumference;
TGCT	cis	rs76889437	0.701	rs12987764	chr2:48961338	A/T	cg25061755	chr2:48808114	STON1-GTF2A1L;STON1	0.17	4.49	0.37	1.63e-5	Facial morphology (factor 19);
TGCT	cis	rs7677751	0.767	rs890205	chr4:55063373	C/A	cg17187183	chr4:55093834	PDGFRA	0.48	6.38	0.5	3.27e-9	Corneal astigmatism;
TGCT	cis	rs950027	0.620	rs35861938	chr15:45637343	T/C	cg26924012	chr15:45694286	SPATA5L1	0.79	8.86	0.62	6.92e-15	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs7267979	1.000	rs2258066	chr20:25271326	C/T	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg25703541	chr22:24373054	LOC391322	0.94	11.43	0.72	4.18e-21	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9906944	0.707	rs3816272	chr17:47120467	A/G	cg07075026	chr17:47091521	IGF2BP1	-0.43	-4.6	-0.38	1.03e-5	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs4689592	0.583	rs6823154	chr4:7078145	C/T	cg25660036	chr4:7070649	GRPEL1	-0.57	-4.96	-0.41	2.25e-6	Monocyte percentage of white cells;
TGCT	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg13395646	chr4:1353034	KIAA1530	-0.39	-4.83	-0.4	4.01e-6	Longevity;
TGCT	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg19318889	chr4:1322082	MAEA	-0.2	-4.91	-0.4	2.8e-6	Obesity-related traits;
TGCT	cis	rs7267979	1.000	rs6050562	chr20:25336186	C/G	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9357506	0.935	rs1867015	chr6:46321089	T/G	cg21115430	chr6:46460003	NA	-0.24	-4.76	-0.39	5.19e-6	Body mass index;
TGCT	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg23758822	chr17:41437982	NA	0.72	6.81	0.52	3.83e-10	Menopause (age at onset);
TGCT	cis	rs6740731	0.518	rs12996668	chr2:145298273	T/C	cg07679370	chr2:145795797	NA	0.28	5.4	0.44	3.34e-7	Coronary artery disease;
TGCT	cis	rs7727544	0.594	rs10479000	chr5:131607402	T/C	cg24060327	chr5:131705240	SLC22A5	-0.54	-5.26	-0.43	6.24e-7	Blood metabolite levels;
TGCT	cis	rs7828089	0.561	rs13266541	chr8:22266135	G/A	cg12081754	chr8:22256438	SLC39A14	0.31	4.49	0.37	1.59e-5	Verbal declarative memory;
TGCT	cis	rs2964802	0.505	rs13164697	chr5:10831212	C/T	cg14521931	chr5:10832172	NA	-0.27	-4.59	-0.38	1.06e-5	Major depressive disorder;Recurrent major depressive disorder;
TGCT	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg08859206	chr1:53392774	SCP2	-0.41	-6.12	-0.48	1.11e-8	Monocyte count;
TGCT	cis	rs3820928	1.000	rs6752707	chr2:227766822	C/G	cg11843606	chr2:227700838	RHBDD1	-0.51	-4.49	-0.37	1.6e-5	Pulmonary function;
TGCT	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg17971929	chr21:40555470	PSMG1	0.98	9.58	0.65	1.3e-16	Cognitive function;
TGCT	cis	rs7727544	0.548	rs35696821	chr5:131508017	C/T	cg24060327	chr5:131705240	SLC22A5	-0.45	-4.47	-0.37	1.73e-5	Blood metabolite levels;
TGCT	cis	rs2832191	0.755	rs2832193	chr21:30493589	T/C	cg08807101	chr21:30365312	RNF160	-0.63	-5.79	-0.46	5.53e-8	Dental caries;
TGCT	cis	rs3733585	0.664	rs28602527	chr4:9958327	G/A	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.7	-0.57	3.69e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg16405210	chr4:1374714	KIAA1530	-0.21	-4.51	-0.38	1.48e-5	Obesity-related traits;
TGCT	cis	rs11122272	0.701	rs2749702	chr1:231523808	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-6.94	-0.53	1.98e-10	Hemoglobin concentration;
TGCT	cis	rs3806843	0.966	rs6891559	chr5:140145206	G/A	cg19875535	chr5:140030758	IK	0.37	6.23	0.49	6.53e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9467603	1.000	rs6939997	chr6:25821224	C/T	cg16898833	chr6:26189333	HIST1H4D	1.18	5.6	0.45	1.33e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs240764	0.578	rs9322216	chr6:101251720	A/C	cg21058520	chr6:100914733	NA	0.35	4.54	0.38	1.33e-5	Neuroticism;
TGCT	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg17345569	chr6:42928274	GNMT	-0.48	-5.01	-0.41	1.87e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs6582630	0.502	rs11504451	chr12:38425294	G/A	cg26384229	chr12:38710491	ALG10B	0.85	7.59	0.56	6.74e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs523522	0.923	rs3916065	chr12:120934624	A/C	cg12219531	chr12:120966889	COQ5	0.83	7.27	0.55	3.46e-11	High light scatter reticulocyte count;
TGCT	cis	rs9527	0.571	rs7096249	chr10:104618524	G/A	cg04362960	chr10:104952993	NT5C2	0.55	4.73	0.39	5.91e-6	Arsenic metabolism;
TGCT	cis	rs7172809	0.573	rs55994208	chr15:77525296	C/T	cg22256960	chr15:77711686	NA	-0.49	-4.62	-0.38	9.51e-6	Glucose homeostasis traits;
TGCT	cis	rs7017914	0.905	rs3110247	chr8:71934887	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-4.97	-0.41	2.16e-6	Bone mineral density;
TGCT	cis	rs67311347	1.000	rs9829800	chr3:40443927	T/C	cg13683864	chr3:40499215	RPL14	-1.04	-10.79	-0.7	1.54e-19	Renal cell carcinoma;
TGCT	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg08736216	chr1:53307985	ZYG11A	-0.3	-5.94	-0.47	2.72e-8	Monocyte count;
TGCT	cis	rs6032067	0.516	rs16989916	chr20:43899514	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.38	-5.96	-0.47	2.38e-8	Blood protein levels;
TGCT	cis	rs9467773	0.967	rs6924865	chr6:26521353	A/G	cg15659132	chr6:26577336	NA	0.86	12.21	0.74	5.3e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs981844	1.000	rs72731670	chr4:154662471	C/T	cg14289246	chr4:154710475	SFRP2	1.01	8.46	0.6	6.31e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs929596	0.793	rs2741046	chr2:234580249	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.29	-4.58	-0.38	1.11e-5	Total bilirubin levels in HIV-1 infection;
TGCT	cis	rs4455778	0.501	rs10227306	chr7:49048026	A/G	cg26309511	chr7:48887640	NA	0.51	6.66	0.51	7.85e-10	Lung cancer in never smokers;
TGCT	cis	rs8180040	0.701	rs13066214	chr3:47033937	C/T	cg27129171	chr3:47204927	SETD2	0.74	9.74	0.66	5.36e-17	Colorectal cancer;
TGCT	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs9910055	0.530	rs8072954	chr17:42294722	G/A	cg19774624	chr17:42201019	HDAC5	-0.7	-7.47	-0.56	1.24e-11	Total body bone mineral density;
TGCT	cis	rs6558174	0.802	rs6558170	chr8:22487388	C/G	cg03733263	chr8:22462867	KIAA1967	0.6	4.8	0.4	4.41e-6	Breast cancer;
TGCT	cis	rs60843830	1.000	rs57542652	chr2:228088	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.73	6.74	0.52	5.3e-10	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs13177918	0.677	rs3797622	chr5:149827098	G/A	cg14059543	chr5:149831962	NA	-0.71	-9.3	-0.64	6.32e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs7809950	1.000	rs2293658	chr7:107270567	C/T	cg23024343	chr7:107201750	COG5	-0.36	-6.02	-0.48	1.83e-8	Coronary artery disease;
TGCT	cis	rs2439831	0.850	rs16965120	chr15:44100342	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	6.27	0.49	5.48e-9	Lung cancer in ever smokers;
TGCT	cis	rs1107366	0.593	rs12635766	chr3:125930021	T/C	cg01346077	chr3:125931526	NA	0.4	6.52	0.51	1.62e-9	Metabolite levels;
TGCT	cis	rs739496	0.615	rs668774	chr12:112169652	G/C	cg10833066	chr12:111807467	FAM109A	0.35	5.18	0.42	8.83e-7	Platelet count;
TGCT	cis	rs11030122	0.660	rs10835247	chr11:3910306	G/A	cg18678763	chr11:4115507	RRM1	-0.35	-4.45	-0.37	1.85e-5	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs4919669	0.668	rs4244354	chr10:104426177	G/A	cg05855489	chr10:104503620	C10orf26	0.86	4.63	0.38	9.05e-6	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg11764359	chr7:65958608	NA	-0.61	-5.51	-0.44	1.96e-7	Aortic root size;
TGCT	cis	rs4595586	0.545	rs12810822	chr12:39391807	T/A	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs7647973	1.000	rs7619789	chr3:49476263	T/C	cg05785598	chr3:49045655	WDR6	0.37	4.52	0.38	1.42e-5	Menarche (age at onset);
TGCT	cis	rs9486719	1.000	rs13208422	chr6:96892119	C/T	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.21	-0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs13242816	1.000	rs13233553	chr7:116182232	C/G	cg02799643	chr7:116139180	CAV2	-0.43	-5.29	-0.43	5.24e-7	P wave duration;
TGCT	cis	rs4144743	0.941	rs7222617	chr17:45324080	G/T	cg18085866	chr17:45331354	ITGB3	-0.72	-4.8	-0.4	4.39e-6	Body mass index;
TGCT	cis	rs933688	1.000	rs332531	chr5:90790451	G/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.07	10.06	0.67	9.13e-18	Smoking behavior;
TGCT	cis	rs9796	0.870	rs12910027	chr15:41283817	A/T	cg18705301	chr15:41695430	NDUFAF1	0.43	5.52	0.44	1.9e-7	Menopause (age at onset);
TGCT	cis	rs4595586	0.545	rs12812750	chr12:39363258	C/T	cg10518543	chr12:38710700	ALG10B	0.54	4.45	0.37	1.92e-5	Morning vs. evening chronotype;
TGCT	cis	rs7224685	0.569	rs67005107	chr17:3991943	A/G	cg09580393	chr17:4869866	SPAG7	-0.37	-4.49	-0.37	1.62e-5	Type 2 diabetes;
TGCT	cis	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg18252515	chr7:66147081	NA	-1.13	-6.81	-0.52	3.7e-10	Diabetic kidney disease;
TGCT	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.18	0.49	8.32e-9	Bipolar disorder;
TGCT	cis	rs17253792	0.822	rs2274075	chr14:56096731	A/G	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs7010267	0.596	rs13262276	chr8:120033918	A/T	cg17171407	chr8:119960777	TNFRSF11B	0.26	4.59	0.38	1.06e-5	Total body bone mineral density (age 45-60);
TGCT	cis	rs782590	0.935	rs2627779	chr2:55892356	A/G	cg18811423	chr2:55921094	PNPT1	0.63	6.36	0.5	3.48e-9	Metabolic syndrome;
TGCT	cis	rs7267979	0.844	rs8184820	chr20:25250577	C/T	cg14121845	chr20:25566513	NINL	-0.49	-4.96	-0.41	2.24e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg13393036	chr8:95962371	TP53INP1	-0.63	-8.66	-0.61	2.14e-14	Type 2 diabetes;
TGCT	cis	rs61884328	0.733	rs61897855	chr11:47231040	C/T	cg13308137	chr11:47528955	CUGBP1	0.38	4.56	0.38	1.23e-5	Total body bone mineral density (age over 60);
TGCT	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg09323728	chr8:95962352	TP53INP1	-0.53	-6.88	-0.53	2.67e-10	Type 2 diabetes;
TGCT	cis	rs17253792	0.822	rs77033617	chr14:56129746	T/A	cg01858014	chr14:56050164	KTN1	-0.35	-4.65	-0.39	8.23e-6	Putamen volume;
TGCT	cis	rs910316	1.000	rs4903275	chr14:75512509	C/T	cg08847533	chr14:75593920	NEK9	0.96	10.6	0.69	4.36e-19	Height;
TGCT	cis	rs1008375	1.000	rs6811887	chr4:17640858	C/T	cg10189774	chr4:17578691	LAP3	0.56	5.04	0.41	1.57e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs12477438	0.700	rs12467679	chr2:99654449	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-8.52	-0.61	4.5e-14	Chronic sinus infection;
TGCT	cis	rs12477438	0.798	rs4850894	chr2:99629396	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-6.1	-0.48	1.22e-8	Chronic sinus infection;
TGCT	cis	rs6121246	0.567	rs6058187	chr20:30190923	T/C	cg18721089	chr20:30220636	NA	-0.63	-6.88	-0.53	2.67e-10	Mean corpuscular hemoglobin;
TGCT	cis	rs290268	0.838	rs290987	chr9:93563267	T/A	cg02608019	chr9:93564028	SYK	0.44	4.44	0.37	1.94e-5	Platelet count;
TGCT	cis	rs7772486	0.846	rs1331636	chr6:146338826	T/C	cg05347473	chr6:146136440	FBXO30	0.56	5.29	0.43	5.34e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2046867	0.908	rs2679208	chr3:72787440	G/A	cg25664220	chr3:72788482	NA	0.53	6.81	0.52	3.8e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs28595532	0.668	rs58467651	chr4:119349011	T/G	cg11846333	chr4:119757529	SEC24D	0.76	4.57	0.38	1.17e-5	Cannabis dependence symptom count;
TGCT	cis	rs2072499	0.966	rs11587860	chr1:156156951	G/C	cg25208724	chr1:156163844	SLC25A44	1.11	15.72	0.82	2.62e-31	Testicular germ cell tumor;
TGCT	cis	rs6089829	0.962	rs57684920	chr20:61662639	G/A	cg18188782	chr20:61659543	NA	-0.44	-5.19	-0.42	8.51e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs644799	0.710	rs3017756	chr11:95537358	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.79	8.65	0.61	2.18e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9733	0.596	rs6681990	chr1:150695929	A/G	cg04414720	chr1:150670196	GOLPH3L	0.37	4.91	0.4	2.76e-6	Tonsillectomy;
TGCT	cis	rs4273100	0.646	rs6587216	chr17:19224397	G/C	cg03910582	chr17:19030146	GRAPL	-0.46	-5.09	-0.42	1.31e-6	Schizophrenia;
TGCT	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg06221963	chr1:154839813	KCNN3	-0.76	-13.06	-0.76	4.81e-25	Prostate cancer;
TGCT	cis	rs9916302	0.904	rs9892055	chr17:37510402	C/T	cg07936489	chr17:37558343	FBXL20	0.65	5.08	0.41	1.36e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs16867321	0.570	rs73025489	chr2:181548425	A/G	cg12875548	chr2:181044332	NA	-0.35	-4.53	-0.38	1.34e-5	Obesity;
TGCT	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg08280861	chr8:58055591	NA	0.4	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs6570726	0.764	rs9403733	chr6:145912311	A/C	cg23711669	chr6:146136114	FBXO30	0.89	9.62	0.65	1.06e-16	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg17952111	chr19:54960355	LENG8	0.84	6.99	0.53	1.53e-10	Lung disease severity in cystic fibrosis;
TGCT	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg20007245	chr22:24372913	LOC391322	-0.71	-7.07	-0.54	1.01e-10	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs854765	0.893	rs712265	chr17:18008447	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.65	-6.31	-0.49	4.57e-9	Total body bone mineral density;
TGCT	cis	rs908922	0.923	rs11205010	chr1:152457964	C/T	cg20991723	chr1:152506922	NA	0.47	5.96	0.47	2.39e-8	Hair morphology;
TGCT	cis	rs514406	0.525	rs269291	chr1:53189297	C/T	cg24675658	chr1:53192096	ZYG11B	-0.87	-10.96	-0.7	5.93e-20	Monocyte count;
TGCT	cis	rs10986311	0.862	rs912353	chr9:127119356	A/C	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.2	4.75	0.39	5.64e-6	Vitiligo;
TGCT	cis	rs3864277	0.510	rs31478	chr5:131423475	T/C	cg24060327	chr5:131705240	SLC22A5	-0.43	-4.55	-0.38	1.25e-5	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs9581857	0.685	rs9319368	chr13:28042275	T/G	cg22138327	chr13:27999177	GTF3A	0.72	4.6	0.38	1.03e-5	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs7772486	0.790	rs2253307	chr6:146196181	T/G	cg13319975	chr6:146136371	FBXO30	-0.51	-4.46	-0.37	1.83e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9393777	0.588	rs11967935	chr6:26560672	A/C	cg05738196	chr6:26577821	NA	-0.63	-4.49	-0.37	1.59e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs2282802	0.685	rs1347143	chr5:139669386	A/G	cg01081189	chr5:139537190	NA	-0.28	-5.04	-0.41	1.59e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1525293	0.509	rs10257424	chr7:70502669	T/C	cg21135135	chr7:70597687	WBSCR17	-0.61	-5.63	-0.45	1.17e-7	Colonoscopy-negative controls vs population controls;Major depressive disorder;
TGCT	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg13607699	chr17:42295918	UBTF	0.57	5.08	0.41	1.38e-6	Total body bone mineral density;
TGCT	cis	rs2688608	0.967	rs9971040	chr10:75661162	G/C	cg23231163	chr10:75533350	FUT11	-0.27	-4.74	-0.39	5.8e-6	Inflammatory bowel disease;
TGCT	cis	rs11190604	1.000	rs3750629	chr10:102275727	A/G	cg16342193	chr10:102329863	NA	-0.41	-5.34	-0.43	4.33e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7020830	0.898	rs13284651	chr9:37222681	G/T	cg14294708	chr9:37120828	ZCCHC7	-1.24	-14.09	-0.78	1.68e-27	Schizophrenia;
TGCT	cis	rs11105298	0.891	rs4842653	chr12:89834113	C/T	cg00757033	chr12:89920650	WDR51B	0.34	5.36	0.43	4e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg07424592	chr7:64974309	NA	-1.31	-7.72	-0.57	3.33e-12	Diabetic kidney disease;
TGCT	cis	rs7584330	0.666	rs60671275	chr2:238374318	C/A	cg14458575	chr2:238380390	NA	0.6	9.06	0.63	2.41e-15	Prostate cancer;
TGCT	cis	rs9457247	0.967	rs402191	chr6:167405553	T/C	cg23791538	chr6:167370224	RNASET2	-0.49	-4.96	-0.41	2.26e-6	Crohn's disease;
TGCT	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs11997175	0.574	rs58858314	chr8:33658221	T/C	ch.8.33884649F	chr8:33765107	NA	0.28	4.54	0.38	1.33e-5	Body mass index;
TGCT	cis	rs7659604	0.605	rs1396080	chr4:122740454	T/G	cg19748678	chr4:122722346	EXOSC9	0.81	8.3	0.6	1.46e-13	Type 2 diabetes;
TGCT	cis	rs12210905	1.000	rs5030958	chr6:27214257	G/C	cg08851530	chr6:28072375	NA	1.05	5.07	0.41	1.42e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs1348850	0.872	rs4893825	chr2:178298687	A/G	cg22681709	chr2:178499509	PDE11A	-0.37	-4.79	-0.4	4.67e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs2120019	1.000	rs35736167	chr15:75332002	T/G	cg17294928	chr15:75287854	SCAMP5	-0.78	-6.12	-0.48	1.14e-8	Blood trace element (Zn levels);
TGCT	cis	rs6665290	0.901	rs61834005	chr1:227202789	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.93	-16.71	-0.83	1.49e-33	Myeloid white cell count;
TGCT	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs4372836	0.602	rs11685682	chr2:29056801	T/A	cg09522027	chr2:28974177	PPP1CB	0.65	6.59	0.51	1.12e-9	Body mass index;
TGCT	cis	rs2933343	1.000	rs789237	chr3:128636961	A/C	cg11901034	chr3:128598214	ACAD9	-0.58	-4.96	-0.41	2.31e-6	IgG glycosylation;
TGCT	cis	rs4713118	0.911	rs9295746	chr6:27730064	T/C	cg20933634	chr6:27740509	NA	0.34	4.75	0.39	5.58e-6	Parkinson's disease;
TGCT	cis	rs9611565	0.879	rs5758311	chr22:41759375	G/T	cg02107564	chr22:41488750	EP300	-0.54	-4.44	-0.37	1.95e-5	Vitiligo;
TGCT	cis	rs17253792	0.822	rs10483645	chr14:56103766	G/T	cg01858014	chr14:56050164	KTN1	-0.35	-4.5	-0.37	1.53e-5	Putamen volume;
TGCT	cis	rs7226408	0.857	rs11661504	chr18:34518724	A/T	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg11941060	chr3:133502564	NA	-0.29	-6.16	-0.48	9.45e-9	Iron status biomarkers;
TGCT	cis	rs4845570	1.000	rs6659705	chr1:151769750	T/C	cg07092448	chr1:151763213	TDRKH	-1.16	-9.41	-0.65	3.38e-16	Coronary artery disease;
TGCT	cis	rs6921919	0.583	rs16894021	chr6:28345026	C/A	cg18815343	chr6:28367644	ZSCAN12	-0.56	-5.33	-0.43	4.48e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6918586	0.658	rs198837	chr6:26113398	A/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.7	6.65	0.51	8.44e-10	Schizophrenia;
TGCT	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg24829409	chr8:58192753	C8orf71	-0.51	-5.05	-0.41	1.55e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs908922	0.651	rs1885531	chr1:152480233	T/G	cg20991723	chr1:152506922	NA	0.48	6.55	0.51	1.39e-9	Hair morphology;
TGCT	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg08280861	chr8:58055591	NA	0.39	4.86	0.4	3.45e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2204008	0.869	rs34438288	chr12:38211582	G/T	cg13010199	chr12:38710504	ALG10B	0.62	4.96	0.41	2.32e-6	Bladder cancer;
TGCT	trans	rs7819412	0.538	rs4523214	chr8:10970773	T/A	cg06636001	chr8:8085503	FLJ10661	-0.74	-6.84	-0.52	3.17e-10	Triglycerides;
TGCT	cis	rs2228479	0.702	rs12599561	chr16:89894358	C/G	cg06558623	chr16:89946397	TCF25	0.55	4.79	0.4	4.69e-6	Skin colour saturation;
TGCT	cis	rs12615966	0.790	rs72830459	chr2:105387628	T/G	cg16465502	chr2:105461796	NA	0.78	4.98	0.41	2.11e-6	Pancreatic cancer;
TGCT	trans	rs1814175	0.817	rs7947526	chr11:49983654	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.36	-7.14	-0.54	6.88e-11	Height;
TGCT	cis	rs11783469	0.524	rs2235116	chr8:23337410	C/T	cg00472375	chr8:23315376	ENTPD4	-0.66	-5.13	-0.42	1.09e-6	Reticulocyte count;
TGCT	cis	rs546131	0.890	rs496558	chr11:34826425	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.54	4.78	0.39	4.9100000000000004e-06	Lung disease severity in cystic fibrosis;
TGCT	cis	rs62244186	0.659	rs6441844	chr3:44503579	C/T	cg15687855	chr3:44754131	ZNF502	-0.44	-5.11	-0.42	1.17e-6	Depressive symptoms;
TGCT	cis	rs3091242	0.804	rs631133	chr1:25724146	T/C	cg00786635	chr1:25594202	NA	0.56	5.63	0.45	1.12e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs9916302	0.904	rs34363096	chr17:37594294	G/A	cg07936489	chr17:37558343	FBXL20	-0.61	-4.82	-0.4	4.16e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs6598955	0.671	rs11247893	chr1:26597086	A/C	cg04990556	chr1:26633338	UBXN11	-0.66	-5.08	-0.41	1.38e-6	Obesity-related traits;
TGCT	cis	rs2456568	0.803	rs10831141	chr11:93640728	C/T	cg17595323	chr11:93583763	C11orf90	-0.46	-6.15	-0.48	9.78e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs9486719	0.895	rs3734239	chr6:96996244	A/G	cg18709589	chr6:96969512	KIAA0776	-0.76	-5.32	-0.43	4.63e-7	Migraine;Coronary artery disease;
TGCT	cis	rs6860806	0.507	rs2631362	chr5:131707293	A/G	cg24060327	chr5:131705240	SLC22A5	0.76	8.14	0.59	3.46e-13	Breast cancer;
TGCT	cis	rs3733585	0.699	rs2018643	chr4:9947121	C/T	cg11266682	chr4:10021025	SLC2A9	0.57	7.23	0.54	4.26e-11	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs8180040	0.835	rs6780013	chr3:47452118	G/A	cg27129171	chr3:47204927	SETD2	-0.54	-5.86	-0.47	4e-8	Colorectal cancer;
TGCT	cis	rs7674212	0.531	rs7665026	chr4:103936648	T/C	cg16532752	chr4:104119610	CENPE	-0.6	-5.29	-0.43	5.33e-7	Type 2 diabetes;
TGCT	cis	rs6728642	0.908	rs10203833	chr2:98017363	G/A	cg26665480	chr2:98280029	ACTR1B	-0.95	-5.34	-0.43	4.21e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	cis	rs1018836	0.892	rs5005585	chr8:91581975	A/G	cg16814680	chr8:91681699	NA	-0.78	-8.24	-0.6	2.02e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1941184	0.500	rs55779595	chr18:29015187	C/T	cg14871544	chr18:29027885	DSG3	0.44	4.63	0.38	9.18e-6	Parkinson's disease (age of onset);
TGCT	cis	rs6500602	0.674	rs8051695	chr16:4536621	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.39	6.86	0.52	2.91e-10	Schizophrenia;
TGCT	cis	rs9611565	0.802	rs9611577	chr22:41793090	T/G	cg17554472	chr22:41940697	POLR3H	-0.42	-4.56	-0.38	1.19e-5	Vitiligo;
TGCT	cis	rs4566357	0.930	rs6436647	chr2:227922958	G/C	cg11843606	chr2:227700838	RHBDD1	-0.58	-5.31	-0.43	4.92e-7	Coronary artery disease;
TGCT	cis	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg07424592	chr7:64974309	NA	1.4	8.42	0.6	7.87e-14	Diabetic kidney disease;
TGCT	cis	rs7937682	0.883	rs517982	chr11:111462687	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.98	-9.83	-0.66	3.23e-17	Primary sclerosing cholangitis;
TGCT	trans	rs10506458	0.834	rs12426860	chr12:63387948	C/T	cg22491629	chr6:157744540	C6orf35	-0.99	-8.5	-0.61	5.08e-14	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs6969780	0.524	rs12530948	chr7:27201258	C/G	cg04321618	chr7:27170880	HOXA4	-0.58	-4.87	-0.4	3.35e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg03303774	chr4:1407052	NA	0.3	4.74	0.39	5.79e-6	Obesity-related traits;
TGCT	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg06238570	chr21:40685208	BRWD1	0.69	6.45	0.5	2.28e-9	Cognitive function;
TGCT	cis	rs1538970	1.000	rs7417107	chr1:45831915	G/C	cg05343316	chr1:45956843	TESK2	0.64	5.13	0.42	1.08e-6	Platelet count;
TGCT	cis	rs7027203	0.828	rs10821229	chr9:96595136	A/C	cg14598338	chr9:96623480	NA	-0.61	-9.54	-0.65	1.68e-16	DNA methylation (variation);
TGCT	cis	rs478304	0.593	rs4645933	chr11:65485120	C/T	cg17480646	chr11:65405466	SIPA1	-0.59	-5.25	-0.43	6.26e-7	Acne (severe);
TGCT	cis	rs1461503	0.966	rs10892936	chr11:122841720	G/A	cg27398637	chr11:122830231	C11orf63	-0.42	-5.25	-0.43	6.48e-7	Menarche (age at onset);
TGCT	cis	rs10804591	0.848	rs6782700	chr3:129309147	G/C	cg07730360	chr3:128845626	NA	-0.19	-4.45	-0.37	1.91e-5	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Hip circumference adjusted for BMI;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9467773	1.000	rs6940053	chr6:26562122	C/T	cg05738196	chr6:26577821	NA	0.91	13.19	0.76	2.28e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs2469997	1.000	rs2447163	chr8:120373249	G/A	cg00681363	chr8:120844660	TAF2	0.69	4.48	0.37	1.64e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs9916302	0.904	rs9898170	chr17:37510092	T/C	cg15445000	chr17:37608096	MED1	-0.35	-5.05	-0.41	1.53e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg18876405	chr7:65276391	NA	-0.33	-4.99	-0.41	1.98e-6	Aortic root size;
TGCT	cis	rs17345786	1.000	rs997739	chr3:101313940	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.44	-9.59	-0.65	1.25e-16	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11578119	0.689	rs12145296	chr1:170389515	C/T	cg09767346	chr1:170501363	GORAB	-0.57	-4.65	-0.39	8.41e-6	Male-pattern baldness;
TGCT	cis	rs36051895	0.632	rs10815167	chr9:5150058	A/G	cg02405213	chr9:5042618	JAK2	-0.75	-9.81	-0.66	3.74e-17	Pediatric autoimmune diseases;
TGCT	cis	rs4654899	0.802	rs6426648	chr1:21179527	A/G	cg01072550	chr1:21505969	NA	-0.46	-6.91	-0.53	2.3e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs4478858	0.735	rs12126725	chr1:31805853	G/T	cg00250761	chr1:31883323	NA	-0.28	-4.96	-0.41	2.32e-6	Alcohol dependence;
TGCT	trans	rs208520	0.690	rs12192851	chr6:66705862	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	11.22	0.71	1.34e-20	Exhaled nitric oxide output;
TGCT	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg05368731	chr17:41323189	NBR1	1.2	14.48	0.79	1.98e-28	Menopause (age at onset);
TGCT	cis	rs12142240	0.698	rs1135459	chr1:46815930	C/T	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg00343986	chr7:65444356	GUSB	-0.2	-4.51	-0.38	1.51e-5	Aortic root size;
TGCT	cis	rs1801251	1.000	rs35212961	chr2:233582762	C/T	cg08000102	chr2:233561755	GIGYF2	0.63	6.51	0.5	1.72e-9	Coronary artery disease;
TGCT	cis	rs11098499	0.865	rs4507344	chr4:120307485	C/A	cg09307838	chr4:120376055	NA	0.65	6.39	0.5	3.02e-9	Corneal astigmatism;
TGCT	cis	rs7772486	0.720	rs1890171	chr6:146072114	T/C	cg13319975	chr6:146136371	FBXO30	0.56	4.93	0.4	2.56e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7804356	1.000	rs28733208	chr7:26830825	G/A	cg03456212	chr7:26904342	SKAP2	-0.63	-4.88	-0.4	3.19e-6	Type 1 diabetes;
TGCT	cis	rs3796352	0.892	rs58515094	chr3:52995575	C/T	cg15956490	chr3:53032818	SFMBT1	0.59	6.04	0.48	1.65e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs2708977	0.698	rs772160	chr2:97039666	C/A	cg14837825	chr2:96917567	TMEM127	0.3	4.44	0.37	1.93e-5	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	trans	rs1864982	0.892	rs560150	chr5:146314104	G/A	cg14363954	chr9:139437479	NOTCH1	0.41	6.65	0.51	8.27e-10	Alcohol dependence;
TGCT	cis	rs155076	1.000	rs261423	chr13:21852331	A/C	cg11317459	chr13:21872234	NA	-1.42	-12.26	-0.74	4.07e-23	White matter hyperintensity burden;
TGCT	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg08280861	chr8:58055591	NA	0.39	4.86	0.4	3.45e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg18402987	chr7:1209562	NA	0.48	4.79	0.39	4.72e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs10838532	0.506	rs11038739	chr11:46017895	A/T	cg10516359	chr11:45827763	SLC35C1	-0.42	-4.77	-0.39	5.18e-6	Axial length;
TGCT	cis	rs9534288	0.912	rs9526135	chr13:46624992	G/C	cg15192986	chr13:46630673	CPB2	-0.49	-6.18	-0.49	8.64e-9	Blood protein levels;
TGCT	cis	rs2075371	0.611	rs1862045	chr7:134023412	A/G	cg11752832	chr7:134001865	SLC35B4	0.66	5.37	0.43	3.71e-7	Mean platelet volume;
TGCT	cis	rs74417235	0.610	rs35212808	chr5:154057808	A/G	cg08754654	chr5:154026448	NA	0.58	5.53	0.44	1.84e-7	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
TGCT	cis	rs3749237	0.595	rs7637999	chr3:49535115	C/T	cg07636037	chr3:49044803	WDR6	0.63	6.07	0.48	1.47e-8	Resting heart rate;
TGCT	cis	rs4699052	0.739	rs6855777	chr4:104242364	C/T	cg16532752	chr4:104119610	CENPE	0.5	4.97	0.41	2.18e-6	Testicular germ cell tumor;
TGCT	cis	rs7178572	0.568	rs4886866	chr15:77696166	A/T	cg22256960	chr15:77711686	NA	-0.87	-8.97	-0.63	3.84e-15	Type 2 diabetes;
TGCT	cis	rs1008375	0.900	rs7658447	chr4:17579415	T/C	cg16339924	chr4:17578868	LAP3	0.83	7.06	0.54	1.04e-10	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7809950	1.000	rs2712191	chr7:107182724	C/G	cg23024343	chr7:107201750	COG5	-0.35	-5.43	-0.44	2.88e-7	Coronary artery disease;
TGCT	cis	rs988712	0.672	rs925947	chr11:27667367	G/T	cg10635145	chr11:27742435	BDNF	-0.38	-5.25	-0.43	6.38e-7	Obesity;
TGCT	cis	rs9430161	0.611	rs2095920	chr1:11033457	T/A	cg27631724	chr1:11040367	C1orf127	0.53	6.05	0.48	1.58e-8	Ewing sarcoma;
TGCT	cis	rs3806843	0.735	rs2530241	chr5:140054485	C/T	cg19875535	chr5:140030758	IK	-0.37	-6.25	-0.49	6.12e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs11122272	0.735	rs2790884	chr1:231531932	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-6.56	-0.51	1.3e-9	Hemoglobin concentration;
TGCT	cis	rs7169223	0.653	rs12905740	chr15:79082364	C/T	cg21242079	chr15:79101063	ADAMTS7	-0.32	-5.29	-0.43	5.38e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
TGCT	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg08736216	chr1:53307985	ZYG11A	0.25	4.93	0.4	2.59e-6	Monocyte count;
TGCT	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg12311346	chr5:56204834	C5orf35	-0.67	-6.82	-0.52	3.63e-10	Initial pursuit acceleration;
TGCT	cis	rs854765	0.624	rs11657130	chr17:17733826	T/C	cg09796270	chr17:17721594	SREBF1	-0.27	-5.19	-0.42	8.39e-7	Total body bone mineral density;
TGCT	cis	rs35160687	0.901	rs12472390	chr2:86475083	T/C	cg03171300	chr2:86307199	POLR1A	0.32	5.53	0.44	1.83e-7	Night sleep phenotypes;
TGCT	cis	rs17102423	0.963	rs11626496	chr14:65600981	C/G	cg11161011	chr14:65562177	MAX	-0.5	-6.93	-0.53	2.04e-10	Obesity-related traits;
TGCT	cis	rs17102423	0.964	rs8015330	chr14:65602183	C/T	cg11161011	chr14:65562177	MAX	-0.49	-6.7	-0.52	6.46e-10	Obesity-related traits;
TGCT	cis	rs6921919	0.583	rs35599905	chr6:28379663	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.54	-5.25	-0.43	6.29e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg14159672	chr1:205819179	PM20D1	0.59	6.91	0.53	2.23e-10	Menarche (age at onset);
TGCT	cis	rs3809863	0.602	rs2317677	chr17:45393407	G/A	cg08085267	chr17:45401833	C17orf57	-0.66	-7.62	-0.56	5.77e-12	Glaucoma (primary open-angle);
TGCT	cis	rs12544026	0.581	rs520880	chr8:102860827	C/T	cg01952226	chr8:102507382	GRHL2	0.27	4.54	0.38	1.31e-5	Major depression and alcohol dependence;
TGCT	cis	rs2235642	1.000	rs2235642	chr16:1584866	T/C	cg11375102	chr16:1583810	IFT140;TMEM204	-0.3	-5.35	-0.43	4.01e-7	Coronary artery disease;
TGCT	cis	rs9486719	1.000	rs2472888	chr6:96865501	T/C	cg18709589	chr6:96969512	KIAA0776	0.71	5.21	0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg12000995	chr2:27665139	KRTCAP3	-0.35	-4.44	-0.37	1.97e-5	Total body bone mineral density;
TGCT	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.67	-0.39	7.73e-6	Prudent dietary pattern;
TGCT	cis	rs2120019	1.000	rs12185102	chr15:75352201	G/A	cg09165964	chr15:75287851	SCAMP5	-1.18	-10.44	-0.68	1.07e-18	Blood trace element (Zn levels);
TGCT	cis	rs7666738	0.791	rs11730069	chr4:98945772	A/G	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9640161	0.750	rs59211922	chr7:150023790	T/G	cg10018233	chr7:150070692	REPIN1	0.32	4.63	0.38	9.08e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs6882076	1.000	rs1501908	chr5:156398169	C/G	cg12943317	chr5:156479607	HAVCR1	0.29	5.57	0.45	1.5e-7	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
TGCT	cis	rs6088590	0.561	rs6059918	chr20:33150503	C/T	cg06115741	chr20:33292138	TP53INP2	0.53	4.69	0.39	7.07e-6	Coronary artery disease;
TGCT	cis	rs617219	0.596	rs2131977	chr5:78613916	G/C	cg23514016	chr5:78407564	BHMT	-0.33	-4.97	-0.41	2.17e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	trans	rs731174	0.592	rs11264093	chr1:38194156	G/A	cg19725343	chr19:51830960	IGLON5	-0.63	-7.18	-0.54	5.57e-11	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs611744	0.967	rs666821	chr8:109204313	T/A	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg06481639	chr22:41940642	POLR3H	0.71	6.26	0.49	5.75e-9	Vitiligo;
TGCT	cis	rs7216064	0.953	rs75231441	chr17:65885485	A/G	cg12091567	chr17:66097778	LOC651250	-0.83	-6.48	-0.5	1.92e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.93	11.77	0.73	6.11e-22	Subjective well-being;
TGCT	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg24060327	chr5:131705240	SLC22A5	-0.58	-5.88	-0.47	3.48e-8	Breast cancer;
TGCT	cis	rs7809950	1.000	rs7782057	chr7:107098877	T/A	cg23024343	chr7:107201750	COG5	-0.33	-5.27	-0.43	5.81e-7	Coronary artery disease;
TGCT	cis	rs17376456	0.825	rs66564678	chr5:93165894	C/T	cg21475434	chr5:93447410	FAM172A	0.66	4.85	0.4	3.58e-6	Diabetic retinopathy;
TGCT	cis	rs6563842	0.563	rs4575411	chr13:41277794	C/G	cg21288729	chr13:41239152	FOXO1	0.93	9.23	0.64	8.96e-16	Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
TGCT	cis	rs9948	0.529	rs62152773	chr2:97448073	T/C	cg01990225	chr2:97406019	LMAN2L	-0.88	-4.81	-0.4	4.37e-6	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs9814567	1.000	rs7611611	chr3:134307877	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.91	-8.83	-0.62	8.17e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg15921436	chr17:44337874	NA	0.59	8.06	0.59	5.55e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs10876993	0.928	rs10877008	chr12:58103592	A/G	cg15848620	chr12:58087721	OS9	-0.72	-5.98	-0.47	2.25e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs7618915	1.000	rs3852064	chr3:52349412	G/T	cg07507251	chr3:52567010	NT5DC2	0.45	6.02	0.48	1.83e-8	Bipolar disorder;
TGCT	cis	rs6545883	0.965	rs778752	chr2:61776902	C/G	cg15711740	chr2:61764176	XPO1	-0.58	-5.36	-0.43	3.92e-7	Tuberculosis;
TGCT	cis	rs4803468	0.967	rs4802116	chr19:41905540	C/T	cg09537434	chr19:41945824	ATP5SL	-0.89	-10.04	-0.67	9.93e-18	Height;
TGCT	cis	rs9303401	0.615	rs7502342	chr17:56922629	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs1372520	0.684	rs1442144	chr4:90736113	T/C	cg15133208	chr4:90757351	SNCA	-0.53	-6.29	-0.49	4.94e-9	Neuroticism;
TGCT	cis	rs12142240	0.698	rs9661240	chr1:46827050	G/A	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs3087591	0.639	rs2854333	chr17:29713300	T/C	cg24425628	chr17:29625626	OMG;NF1	0.41	6.06	0.48	1.48e-8	Hip circumference;
TGCT	trans	rs1496653	0.602	rs35105861	chr3:23529047	A/G	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg15782153	chr7:917662	C7orf20	0.49	5.74	0.46	6.99e-8	Perceived unattractiveness to mosquitoes;
TGCT	cis	rs2013441	0.896	rs1812934	chr17:20030960	A/T	cg23224458	chr17:20280056	CCDC144C	-0.35	-4.44	-0.37	1.95e-5	Obesity-related traits;
TGCT	cis	rs2153535	0.580	rs7341206	chr6:8470489	T/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs7681440	0.904	rs7671549	chr4:90771147	T/A	cg20003494	chr4:90757398	SNCA	-0.59	-5.52	-0.44	1.9e-7	Dementia with Lewy bodies;
TGCT	cis	rs9611565	0.694	rs5758389	chr22:41941749	T/C	cg06481639	chr22:41940642	POLR3H	-0.64	-5.89	-0.47	3.42e-8	Vitiligo;
TGCT	trans	rs11764590	0.950	rs62444919	chr7:2109499	C/T	cg25206134	chr2:45395956	NA	0.94	6.93	0.53	2e-10	Neuroticism;
TGCT	cis	rs1008375	0.931	rs6813374	chr4:17649494	T/C	cg18681998	chr4:17616180	MED28	1.06	12.43	0.74	1.57e-23	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9916302	0.904	rs12952384	chr17:37669536	T/C	cg07936489	chr17:37558343	FBXL20	-0.62	-4.88	-0.4	3.2e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs67073037	0.911	rs12477538	chr2:29171288	C/T	cg09522027	chr2:28974177	PPP1CB	0.57	4.49	0.37	1.59e-5	Breast cancer;Breast cancer (estrogen-receptor negative);
TGCT	cis	rs11671005	0.735	rs34511020	chr19:58921296	A/G	cg13877915	chr19:58951672	ZNF132	0.63	4.99	0.41	1.99e-6	Mean platelet volume;
TGCT	cis	rs10760123	1	rs10760123	chr9:123650534	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.39	4.53	0.38	1.35e-5	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs9611565	0.649	rs9623450	chr22:42175231	G/A	cg06481639	chr22:41940642	POLR3H	0.53	4.54	0.38	1.29e-5	Vitiligo;
TGCT	cis	rs11148252	0.967	rs11620062	chr13:52994026	T/G	cg00495681	chr13:53174319	NA	0.5	5.08	0.42	1.34e-6	Lewy body disease;
TGCT	cis	rs28595532	0.920	rs115271785	chr4:119735748	A/T	cg14228332	chr4:119757509	SEC24D	1.31	7.06	0.54	1.06e-10	Cannabis dependence symptom count;
TGCT	cis	rs9858542	0.953	rs9858280	chr3:49597737	T/C	cg03060546	chr3:49711283	APEH	-0.61	-5.37	-0.43	3.78e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs10782582	0.593	rs12129523	chr1:76129223	C/A	cg22875332	chr1:76189707	ACADM	-0.54	-6.21	-0.49	7.36e-9	Daytime sleep phenotypes;
TGCT	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.36	0.55	2.25e-11	Prudent dietary pattern;
TGCT	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg19318889	chr4:1322082	MAEA	-0.2	-5.1	-0.42	1.24e-6	Obesity-related traits;
TGCT	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.67	-0.39	7.73e-6	Prudent dietary pattern;
TGCT	cis	rs7020830	1.000	rs7020830	chr9:37085184	A/T	cg14294708	chr9:37120828	ZCCHC7	1.2	18.29	0.85	5.19e-37	Schizophrenia;
TGCT	cis	rs1420338	0.869	rs1362452	chr7:34170519	G/A	cg01275685	chr7:34179230	BMPER	-0.25	-4.57	-0.38	1.16e-5	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg18230493	chr5:56204884	C5orf35	-0.68	-5.92	-0.47	2.92e-8	Initial pursuit acceleration;
TGCT	cis	rs62244186	0.545	rs725866	chr3:44765533	A/G	cg15687855	chr3:44754131	ZNF502	-0.52	-6.31	-0.49	4.59e-9	Depressive symptoms;
TGCT	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg21963583	chr11:68658836	MRPL21	0.37	6.08	0.48	1.39e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9372253	1.000	rs9374170	chr6:110712991	A/G	cg13266496	chr6:110720918	DDO	-0.45	-5.5	-0.44	2.11e-7	Platelet distribution width;
TGCT	cis	rs9810089	0.843	rs518972	chr3:136039268	C/A	cg12473912	chr3:136751656	NA	0.36	5.15	0.42	9.88e-7	Gestational age at birth (child effect);
TGCT	cis	rs7647973	1.000	rs8897	chr3:49460407	A/G	cg07636037	chr3:49044803	WDR6	0.63	5.39	0.44	3.48e-7	Menarche (age at onset);
TGCT	cis	rs10791097	0.667	rs2155358	chr11:130740357	T/C	cg05962950	chr11:130786565	SNX19	0.92	11.55	0.72	2.13e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs6141769	0.518	rs6058847	chr20:31324135	C/T	cg13636640	chr20:31349939	DNMT3B	-0.51	-4.6	-0.38	1.04e-5	Subjective well-being;
TGCT	cis	rs79349575	0.691	rs11079847	chr17:47037024	A/T	cg07967210	chr17:47022446	SNF8	-0.42	-5.35	-0.43	4.03e-7	Type 2 diabetes;
TGCT	cis	rs12519773	0.502	rs67862943	chr5:92529268	G/A	cg04854328	chr5:92914828	FLJ42709	-0.3	-4.55	-0.38	1.24e-5	Migraine;
TGCT	cis	rs11098499	0.908	rs2017057	chr4:120257711	A/G	cg09307838	chr4:120376055	NA	0.63	5.89	0.47	3.41e-8	Corneal astigmatism;
TGCT	cis	rs4148883	0.628	rs34195655	chr4:100073795	C/T	cg12011299	chr4:100065546	ADH4	0.38	5.72	0.46	7.71e-8	Alcohol dependence;
TGCT	cis	rs910316	0.967	rs2268619	chr14:75640354	C/G	cg08847533	chr14:75593920	NEK9	-0.93	-9.55	-0.65	1.59e-16	Height;
TGCT	cis	rs988712	0.705	rs4923461	chr11:27656910	A/G	cg10635145	chr11:27742435	BDNF	-0.38	-5.23	-0.43	7e-7	Obesity;
TGCT	cis	rs9638182	0.623	rs13246490	chr7:72992350	C/T	cg14087351	chr7:73037990	MLXIPL	-0.64	-5.01	-0.41	1.83e-6	Triglycerides;
TGCT	cis	rs7017914	0.934	rs10504479	chr8:71577515	T/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.53	-4.9	-0.4	2.87e-6	Bone mineral density;
TGCT	cis	rs6733011	0.578	rs10169003	chr2:99508866	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.52	5.2	0.42	8.07e-7	Bipolar disorder;
TGCT	cis	rs453301	0.653	rs11784393	chr8:8903134	C/T	cg15556689	chr8:8085844	FLJ10661	0.88	7.98	0.58	8.36e-13	Joint mobility (Beighton score);
TGCT	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	16.1	0.82	3.69e-32	Prudent dietary pattern;
TGCT	cis	rs6088580	0.634	rs6088488	chr20:32992631	T/C	cg08999081	chr20:33150536	PIGU	-0.29	-5.65	-0.45	1.02e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs2153535	0.601	rs2327059	chr6:8447071	A/G	cg07606381	chr6:8435919	SLC35B3	0.53	5.02	0.41	1.79e-6	Motion sickness;
TGCT	cis	rs2075371	0.830	rs12669960	chr7:133931782	A/G	cg11752832	chr7:134001865	SLC35B4	0.63	5.16	0.42	9.38e-7	Mean platelet volume;
TGCT	cis	rs151997	0.630	rs26064	chr5:50217806	T/C	cg06027927	chr5:50259733	NA	0.56	5.64	0.45	1.11e-7	Callous-unemotional behaviour;
TGCT	cis	rs1056107	0.931	rs4979089	chr9:114999096	C/T	cg02332936	chr9:115140584	NA	-0.25	-4.44	-0.37	1.96e-5	Colorectal cancer;
TGCT	cis	rs10927875	0.518	rs945416	chr1:16344402	G/A	cg21385522	chr1:16154831	NA	0.47	4.85	0.4	3.57e-6	Dilated cardiomyopathy;
TGCT	cis	rs7809950	0.817	rs3779495	chr7:107250260	G/A	cg23024343	chr7:107201750	COG5	0.43	6.16	0.48	9.49e-9	Coronary artery disease;
TGCT	cis	rs9467711	0.790	rs45527431	chr6:26599509	A/G	cg12315302	chr6:26189340	HIST1H4D	0.99	4.44	0.37	1.93e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6754311	0.509	rs10188066	chr2:136539513	G/A	cg07169764	chr2:136633963	MCM6	-0.71	-6.41	-0.5	2.69e-9	Mosquito bite size;
TGCT	cis	rs1635	0.655	rs723475	chr6:28304841	G/T	cg15743358	chr6:28303923	ZNF323	1.29	6.5	0.5	1.73e-9	Schizophrenia;
TGCT	cis	rs9549367	0.774	rs9549364	chr13:113903745	T/C	cg18105134	chr13:113819100	PROZ	-0.34	-5.58	-0.45	1.41e-7	Platelet distribution width;
TGCT	cis	rs7614311	0.731	rs17401592	chr3:63954490	A/G	cg22134162	chr3:63841271	THOC7	-0.45	-5.73	-0.46	7.3e-8	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs9527	0.590	rs12246739	chr10:104787019	A/C	cg04362960	chr10:104952993	NT5C2	-0.64	-5.18	-0.42	8.55e-7	Arsenic metabolism;
TGCT	cis	rs11098499	0.865	rs4001305	chr4:120359236	G/T	cg09307838	chr4:120376055	NA	0.71	6.98	0.53	1.57e-10	Corneal astigmatism;
TGCT	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.08	0.48	1.37e-8	Bipolar disorder;
TGCT	cis	rs1371867	0.846	rs1788167	chr8:101319996	C/T	cg06002616	chr8:101225028	SPAG1	-0.53	-6.21	-0.49	7.16e-9	Atrioventricular conduction;
TGCT	cis	rs612683	0.599	rs2809823	chr1:101003762	C/A	cg06223162	chr1:101003688	GPR88	0.43	8.81	0.62	9.45e-15	Breast cancer;
TGCT	cis	rs9894429	0.738	rs8077038	chr17:79577127	T/G	cg21984481	chr17:79567631	NPLOC4	0.26	4.9	0.4	2.91e-6	Eye color traits;
TGCT	cis	rs1971762	0.527	rs784568	chr12:53927554	C/A	cg16917193	chr12:54089295	NA	-1.05	-10.82	-0.7	1.27e-19	Height;
TGCT	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg11644478	chr21:40555479	PSMG1	0.99	10.5	0.69	7.73e-19	Cognitive function;
TGCT	cis	rs9325144	0.647	rs12822023	chr12:39097964	T/C	cg10518543	chr12:38710700	ALG10B	-0.49	-4.58	-0.38	1.11e-5	Morning vs. evening chronotype;
TGCT	cis	rs986417	0.901	rs8020867	chr14:61093246	A/T	cg27398547	chr14:60952738	C14orf39	1.48	8.31	0.6	1.44e-13	Gut microbiota (bacterial taxa);
TGCT	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg13395646	chr4:1353034	KIAA1530	-0.43	-4.89	-0.4	3.08e-6	Longevity;
TGCT	cis	rs71636778	0.509	rs11807824	chr1:27270338	A/C	cg23921621	chr1:27994728	IFI6	-0.43	-4.61	-0.38	9.92e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
TGCT	cis	rs4836694	0.574	rs3780712	chr9:132943082	A/G	cg05251000	chr9:132935664	FREQ	0.53	5.84	0.46	4.35e-8	Alzheimer's disease (cognitive decline);
TGCT	cis	rs40363	0.645	rs1690449	chr16:3520893	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.64	-4.6	-0.38	1.04e-5	Tuberculosis;
TGCT	cis	rs9486719	1.000	rs12190508	chr6:96898269	T/C	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.86	-0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs12220898	0.584	rs10857455	chr10:50474712	A/T	cg06072769	chr10:50146962	WDFY4	0.36	4.67	0.39	7.64e-6	Inflammatory biomarkers;
TGCT	cis	rs6545883	0.931	rs778765	chr2:61786385	A/T	cg15711740	chr2:61764176	XPO1	-0.57	-5.1	-0.42	1.22e-6	Tuberculosis;
TGCT	cis	rs4149178	0.656	rs3734683	chr6:43316023	A/G	cg12269535	chr6:43142014	SRF	0.61	5.14	0.42	1.02e-6	Urate levels;
TGCT	cis	rs11585357	0.947	rs11585118	chr1:17605774	C/A	cg08277548	chr1:17600880	PADI3	-0.97	-9.95	-0.67	1.7e-17	Hair shape;
TGCT	cis	rs9811920	0.683	rs4928230	chr3:99661963	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.4	4.88	0.4	3.17e-6	Axial length;
TGCT	cis	rs12134133	0.962	rs6682586	chr1:207416467	A/C	cg02152968	chr1:207494213	CD55	0.61	4.74	0.39	5.83e-6	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs9467773	0.620	rs2504600	chr6:26648334	C/A	cg26531700	chr6:26746687	NA	0.51	4.61	0.38	9.86e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs8050907	0.744	rs13330957	chr16:4525330	G/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.53	4.57	0.38	1.15e-5	Obesity-related traits;
TGCT	cis	rs12477438	0.765	rs72957180	chr2:99694452	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-8.52	-0.61	4.5e-14	Chronic sinus infection;
TGCT	cis	rs3780378	0.870	rs7034878	chr9:5058991	G/T	cg02405213	chr9:5042618	JAK2	0.54	6.87	0.53	2.75e-10	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	trans	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg11887960	chr12:57824829	NA	1.1	9.44	0.65	2.89e-16	Lung disease severity in cystic fibrosis;
TGCT	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg19318889	chr4:1322082	MAEA	0.27	6.66	0.51	8.13e-10	Longevity;
TGCT	cis	rs1059312	0.778	rs4760594	chr12:129296865	T/A	cg09035930	chr12:129282057	SLC15A4	0.55	10.73	0.69	2.06e-19	Systemic lupus erythematosus;
TGCT	cis	rs9906944	0.933	rs4794018	chr17:47093398	T/C	cg07075026	chr17:47091521	IGF2BP1	-0.45	-4.87	-0.4	3.33e-6	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs11673344	0.504	rs11666786	chr19:37624849	C/T	cg08039142	chr19:36980659	ZNF566	0.51	4.62	0.38	9.29e-6	Obesity-related traits;
TGCT	cis	rs7772486	0.790	rs7753092	chr6:146248863	C/T	cg23711669	chr6:146136114	FBXO30	-0.88	-10.27	-0.68	2.84e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9297145	0.761	rs62473005	chr7:98742510	G/C	cg05967295	chr7:98741636	SMURF1	1.01	12.87	0.76	1.33e-24	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs3849570	0.555	rs9968070	chr3:82010368	G/A	cg07356753	chr3:81810745	GBE1	-0.62	-5.38	-0.44	3.5e-7	Waist circumference;Body mass index;
TGCT	cis	rs7954584	0.546	rs10840630	chr12:122352445	C/T	cg21171335	chr12:122356390	WDR66	0.7	7.02	0.53	1.25e-10	Mean corpuscular volume;
TGCT	cis	rs73001065	1.000	rs73001065	chr19:19460541	G/C	cg03709012	chr19:19516395	GATAD2A	1.08	5.01	0.41	1.83e-6	LDL cholesterol;
TGCT	cis	rs7208859	0.673	rs73265612	chr17:29225983	A/G	cg18442181	chr17:29233375	C17orf42	-0.78	-4.61	-0.38	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs10901296	0.588	rs12003046	chr9:133741626	T/C	cg01000188	chr9:133769184	QRFP	0.33	4.57	0.38	1.18e-5	Bilirubin levels;
TGCT	cis	rs6860806	0.507	rs273912	chr5:131661349	A/C	cg24060327	chr5:131705240	SLC22A5	0.8	7.9	0.58	1.3e-12	Breast cancer;
TGCT	cis	rs7666738	0.716	rs9994641	chr4:99101605	C/T	cg18180107	chr4:99064573	C4orf37	0.52	4.66	0.39	8.01e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2458413	0.669	rs12681140	chr8:105346112	A/C	cg04554929	chr8:105342491	NA	0.6	9.37	0.64	4.33e-16	Paget's disease;
TGCT	cis	rs7027203	0.797	rs3996254	chr9:96591239	A/G	cg14396892	chr9:96623032	NA	-0.26	-5.46	-0.44	2.51e-7	DNA methylation (variation);
TGCT	cis	rs832540	0.931	rs832534	chr5:56213672	G/A	cg12311346	chr5:56204834	C5orf35	-0.47	-4.97	-0.41	2.15e-6	Coronary artery disease;
TGCT	cis	rs416603	0.967	rs11644184	chr16:11365104	G/A	cg00044050	chr16:11439710	C16orf75	-0.82	-8.44	-0.6	6.82e-14	Type 1 diabetes;
TGCT	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg06481639	chr22:41940642	POLR3H	-0.6	-5.23	-0.43	6.98e-7	Vitiligo;
TGCT	cis	rs4273100	0.607	rs1043809	chr17:19239432	C/T	cg01534423	chr17:18965556	NA	-0.79	-7.19	-0.54	5.25e-11	Schizophrenia;
TGCT	cis	rs796364	0.806	rs79156935	chr2:200913822	T/G	cg17644776	chr2:200775616	C2orf69	-0.33	-5.0	-0.41	1.91e-6	Schizophrenia;
TGCT	cis	rs1215050	0.740	rs783936	chr4:98928628	G/T	cg17366294	chr4:99064904	C4orf37	-0.57	-6.12	-0.48	1.12e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs514406	0.505	rs436363	chr1:53172163	T/C	cg22166914	chr1:53195759	ZYG11B	0.45	7.74	0.57	3.05e-12	Monocyte count;
TGCT	cis	rs11673344	0.542	rs826331	chr19:37498262	G/A	cg08039142	chr19:36980659	ZNF566	0.56	5.35	0.43	4.02e-7	Obesity-related traits;
TGCT	cis	rs1371867	0.846	rs1660346	chr8:101312497	A/G	cg06636551	chr8:101224915	SPAG1	-0.48	-6.52	-0.51	1.62e-9	Atrioventricular conduction;
TGCT	cis	rs9790314	0.791	rs6809256	chr3:161026513	G/A	cg03342759	chr3:160939853	NMD3	-0.51	-5.66	-0.45	9.96e-8	Morning vs. evening chronotype;
TGCT	cis	rs3796352	0.667	rs3755805	chr3:52866299	G/A	cg15956490	chr3:53032818	SFMBT1	0.57	5.25	0.43	6.25e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs9393777	0.513	rs9368447	chr6:26646674	A/C	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.53	-4.88	-0.4	3.19e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9915657	0.803	rs12449851	chr17:70099002	C/T	cg06234051	chr17:70120541	SOX9	0.26	5.41	0.44	3.14e-7	Thyroid hormone levels;
TGCT	cis	rs17784882	0.521	rs11713693	chr3:47074906	T/C	cg27129171	chr3:47204927	SETD2	-0.67	-7.68	-0.57	4.15e-12	QT interval;
TGCT	cis	rs9611565	0.592	rs80477	chr22:42001183	C/T	cg06481639	chr22:41940642	POLR3H	0.62	5.29	0.43	5.4e-7	Vitiligo;
TGCT	cis	rs9818758	0.607	rs13077498	chr3:49313978	C/T	cg00383909	chr3:49044727	WDR6	1.28	6.57	0.51	1.23e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs9952991	0.941	rs7237497	chr18:12777325	T/C	cg23598886	chr18:12777645	NA	0.62	5.9	0.47	3.25e-8	Inflammatory skin disease;
TGCT	cis	rs28595532	0.920	rs115437723	chr4:119741828	C/T	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs9914988	0.887	rs4795464	chr17:27146497	G/C	cg20469991	chr17:27169893	C17orf63	-0.72	-5.09	-0.42	1.28e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs7208859	0.623	rs3794796	chr17:29130880	G/C	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.66e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7959452	0.562	rs10878975	chr12:69782044	G/C	cg14784868	chr12:69753453	YEATS4	0.83	8.96	0.63	4.14e-15	Blood protein levels;
TGCT	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg03452623	chr4:187889614	NA	0.37	5.63	0.45	1.16e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs17473412	0.864	rs13436337	chr5:122681230	G/C	cg15125798	chr5:122621645	NA	-0.55	-5.01	-0.41	1.84e-6	Total body bone mineral density;
TGCT	cis	rs66573146	1.000	rs73088528	chr4:6967747	G/C	cg00086871	chr4:6988644	TBC1D14	0.98	4.57	0.38	1.16e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs941408	1.000	rs941410	chr19:2787329	G/A	cg06609049	chr19:2785107	THOP1	0.84	8.47	0.61	6.01e-14	Total cholesterol levels;
TGCT	cis	rs12681288	0.894	rs66739903	chr8:1010492	C/A	cg04851639	chr8:1020857	NA	-0.32	-5.32	-0.43	4.59e-7	Schizophrenia;
TGCT	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg15921436	chr17:44337874	NA	0.56	7.75	0.57	2.88e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs12643440	0.538	rs6834807	chr4:17138244	T/C	cg22650099	chr4:17144496	NA	-0.46	-4.66	-0.39	8.14e-6	Metabolite levels (Pyroglutamine);
TGCT	cis	rs9581857	0.547	rs9581871	chr13:28085767	G/A	cg22138327	chr13:27999177	GTF3A	0.73	4.54	0.38	1.34e-5	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs1552244	0.832	rs67145301	chr3:10197314	G/A	cg00149659	chr3:10157352	C3orf10	1.05	5.81	0.46	4.95e-8	Alzheimer's disease;
TGCT	cis	rs9303401	0.538	rs8078280	chr17:56473132	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.69	6.56	0.51	1.3e-9	Cognitive test performance;
TGCT	cis	rs587847	0.708	rs28588437	chr15:37632513	G/T	cg00216138	chr15:37171175	LOC145845	0.32	4.74	0.39	5.71e-6	Intraocular pressure;
TGCT	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	14.88	0.8	2.36e-29	Height;
TGCT	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg13866156	chr1:1669148	SLC35E2	-0.21	-5.12	-0.42	1.13e-6	Body mass index;
TGCT	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg21285383	chr16:89894308	SPIRE2	0.45	7.13	0.54	7.2e-11	Vitiligo;
TGCT	cis	rs3540	1.000	rs3540	chr15:91045408	G/A	cg22089800	chr15:90895588	ZNF774	0.79	7.8	0.57	2.17e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs17767294	0.708	rs77689085	chr6:28072536	G/A	cg08851530	chr6:28072375	NA	1.56	7.21	0.54	4.9e-11	Parkinson's disease;
TGCT	cis	rs12908161	1.000	rs12908161	chr15:85207825	A/G	cg11189052	chr15:85197271	WDR73	0.75	6.3	0.49	4.8e-9	Schizophrenia;
TGCT	cis	rs3820928	0.874	rs10933165	chr2:227883648	C/G	cg11843606	chr2:227700838	RHBDD1	0.54	5.02	0.41	1.72e-6	Pulmonary function;
TGCT	cis	rs9733	0.519	rs7511673	chr1:150707636	A/T	cg04414720	chr1:150670196	GOLPH3L	0.37	4.91	0.4	2.76e-6	Tonsillectomy;
TGCT	cis	rs16867321	0.671	rs4667318	chr2:181516693	G/A	cg23363182	chr2:181467187	NA	-0.44	-4.59	-0.38	1.09e-5	Obesity;
TGCT	cis	rs2066819	1.000	rs79824801	chr12:56728137	T/C	cg26714650	chr12:56694279	CS	-1.36	-6.06	-0.48	1.54e-8	Psoriasis vulgaris;
TGCT	cis	rs6534347	0.551	rs1398553	chr4:123548068	A/G	cg10583651	chr4:123538969	IL21	-0.31	-4.51	-0.38	1.49e-5	Type 1 diabetes;
TGCT	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg10802521	chr3:52805072	NEK4	-0.72	-8.98	-0.63	3.75e-15	Bipolar disorder;
TGCT	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs6490294	0.904	rs11066112	chr12:112416586	C/T	cg10833066	chr12:111807467	FAM109A	0.35	5.13	0.42	1.09e-6	Mean platelet volume;
TGCT	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg06618935	chr21:46677482	NA	-0.37	-5.58	-0.45	1.41e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs1372520	0.745	rs2736994	chr4:90784528	A/G	cg15133208	chr4:90757351	SNCA	-0.48	-5.48	-0.44	2.28e-7	Neuroticism;
TGCT	cis	rs981844	0.683	rs1037655	chr4:154750408	A/G	cg14289246	chr4:154710475	SFRP2	-0.99	-9.12	-0.63	1.65e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs6558530	0.666	rs7005699	chr8:1700620	A/T	cg09410841	chr8:1729607	CLN8	0.72	6.49	0.5	1.87e-9	Systolic blood pressure;
TGCT	cis	rs7772486	0.686	rs2072911	chr6:146056801	G/A	cg23711669	chr6:146136114	FBXO30	-0.87	-9.51	-0.65	1.94e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs950776	0.518	rs952216	chr15:78819202	C/T	cg06917634	chr15:78832804	PSMA4	0.95	9.52	0.65	1.81e-16	Sudden cardiac arrest;
TGCT	cis	rs4319547	0.586	rs7956480	chr12:122817507	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.6	-4.58	-0.38	1.11e-5	Body mass index;
TGCT	cis	rs9467711	0.606	rs9366656	chr6:26434630	T/C	cg16898833	chr6:26189333	HIST1H4D	1.12	5.36	0.43	3.91e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4237845	0.735	rs11172375	chr12:58291574	G/C	cg02175503	chr12:58329896	NA	0.52	4.86	0.4	3.52e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs34638657	0.732	rs7205534	chr16:82201618	C/T	cg09439754	chr16:82129088	HSD17B2	-0.24	-4.72	-0.39	6.21e-6	Lung adenocarcinoma;
TGCT	cis	rs9393777	1.000	rs9393777	chr6:26942027	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.58	-4.63	-0.38	9.02e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.784	rs4699602	chr4:99034903	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.84	0.46	4.24e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs617219	0.765	rs10053349	chr5:78475423	T/C	cg05890484	chr5:78407552	BHMT	0.38	5.23	0.42	7.13e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs9467773	1.000	rs6932156	chr6:26571506	T/G	cg15659132	chr6:26577336	NA	0.88	12.27	0.74	3.83e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs3820928	1.000	rs10193404	chr2:227777757	A/G	cg11843606	chr2:227700838	RHBDD1	-0.53	-4.73	-0.39	5.89e-6	Pulmonary function;
TGCT	cis	rs7666738	0.791	rs11097610	chr4:99011795	C/G	cg17366294	chr4:99064904	C4orf37	0.66	6.63	0.51	9.33e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9788682	0.747	rs2568485	chr15:78752114	C/T	cg24631222	chr15:78858424	CHRNA5	-0.61	-4.55	-0.38	1.25e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs344364	0.511	rs62040571	chr16:1948514	C/G	cg26617929	chr16:1858877	NA	-0.27	-4.9	-0.4	2.99e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs9467773	0.596	rs3001369	chr6:26670969	C/T	cg02458000	chr6:26745757	NA	0.56	4.83	0.4	3.89e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg17178900	chr1:205818956	PM20D1	0.58	7.13	0.54	7.41e-11	Menarche (age at onset);
TGCT	cis	rs763014	0.932	rs7204439	chr16:661335	T/C	cg27436995	chr16:743998	FBXL16	-0.44	-4.81	-0.4	4.32e-6	Height;
TGCT	cis	rs9291683	0.588	rs3756238	chr4:10013202	C/T	cg11266682	chr4:10021025	SLC2A9	0.73	11.04	0.7	3.63e-20	Bone mineral density;
TGCT	cis	rs6690583	0.524	rs12029690	chr1:85452867	C/G	cg20280350	chr1:85513789	MCOLN3	-0.74	-5.11	-0.42	1.2e-6	Serum sulfate level;
TGCT	cis	rs4595586	0.545	rs11615700	chr12:39365104	A/G	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs4711350	0.765	rs6921772	chr6:33749686	A/G	cg18005901	chr6:33739558	LEMD2	-0.59	-6.65	-0.51	8.34e-10	Schizophrenia;
TGCT	cis	rs7216064	0.553	rs62084690	chr17:66035411	A/G	cg12091567	chr17:66097778	LOC651250	0.8	6.67	0.51	7.53e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.42	-4.89	-0.4	3.08e-6	Longevity;Endometriosis;
TGCT	cis	rs6061231	0.631	rs2427317	chr20:60975725	C/T	cg24112000	chr20:60950667	NA	-0.35	-4.91	-0.4	2.77e-6	Colorectal cancer;
TGCT	cis	rs2278034	0.502	rs3747672	chr3:195612034	T/C	cg01181863	chr3:195395398	SDHAP2	-0.34	-4.75	-0.39	5.5e-6	Bronchopulmonary dysplasia;
TGCT	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg13732083	chr21:47605072	C21orf56	0.34	4.74	0.39	5.86e-6	Testicular germ cell tumor;
TGCT	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg06618935	chr21:46677482	NA	-0.37	-5.81	-0.46	5.06e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2486012	0.655	rs2906598	chr1:44372290	C/G	cg12908607	chr1:44402522	ARTN	0.71	5.86	0.47	3.87e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs79057730	0.528	rs6965219	chr7:821807	C/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.63	5.13	0.42	1.09e-6	Initial pursuit acceleration;
TGCT	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg02725872	chr8:58115012	NA	-0.41	-5.42	-0.44	3.01e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg11494091	chr17:61959527	GH2	0.43	7.51	0.56	9.88e-12	Height;
TGCT	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg05368731	chr17:41323189	NBR1	1.2	14.38	0.79	3.45e-28	Menopause (age at onset);
TGCT	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg06481639	chr22:41940642	POLR3H	0.6	5.48	0.44	2.23e-7	Vitiligo;
TGCT	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg26354017	chr1:205819088	PM20D1	-0.55	-6.82	-0.52	3.49e-10	Monocyte percentage of white cells;
TGCT	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg20887711	chr4:1340912	KIAA1530	0.52	4.49	0.37	1.62e-5	Longevity;
TGCT	cis	rs881375	0.935	rs7034390	chr9:123646488	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	5.49	0.44	2.19e-7	Rheumatoid arthritis;
TGCT	cis	rs10489525	0.599	rs7526323	chr1:115604241	G/A	cg12756093	chr1:115239321	AMPD1	-0.4	-5.49	-0.44	2.19e-7	Autism;
TGCT	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg06618935	chr21:46677482	NA	0.38	5.76	0.46	6.27e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg06873352	chr17:61820015	STRADA	0.55	6.13	0.48	1.09e-8	Prudent dietary pattern;
TGCT	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg20007245	chr22:24372913	LOC391322	-0.74	-7.49	-0.56	1.11e-11	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2361718	0.500	rs4889818	chr17:78085228	A/G	cg09238746	chr17:78121135	EIF4A3	-1.03	-9.67	-0.66	8.14e-17	Yeast infection;
TGCT	cis	rs10435719	0.902	rs7006538	chr8:11804982	A/G	cg02840367	chr8:11660030	FDFT1	-0.52	-4.48	-0.37	1.7e-5	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs7772486	0.720	rs6901888	chr6:146023144	A/G	cg13319975	chr6:146136371	FBXO30	0.53	4.8	0.4	4.49e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs112591243	0.685	rs113059032	chr21:47751646	C/T	cg10657630	chr21:48055338	PRMT2	1.06	5.76	0.46	6.29e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg24549020	chr5:56110836	MAP3K1	-0.67	-4.85	-0.4	3.66e-6	Initial pursuit acceleration;
TGCT	cis	rs1577917	1.000	rs1337844	chr6:86677273	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.16	-0.42	9.39e-7	Response to antipsychotic treatment;
TGCT	cis	rs4886920	0.537	rs6495247	chr15:78069431	C/T	cg03457338	chr15:78040120	NA	-0.21	-5.23	-0.43	6.96e-7	Neuroticism;
TGCT	cis	rs7267979	1.000	rs2257991	chr20:25270339	C/T	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs752092	1.000	rs8033360	chr15:101778710	C/A	cg19997662	chr15:101784653	CHSY1	-0.31	-5.81	-0.46	4.9e-8	Corneal structure;
TGCT	cis	rs9948	0.786	rs62156233	chr2:97434061	C/G	cg01990225	chr2:97406019	LMAN2L	-0.79	-4.98	-0.41	2.12e-6	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg26338869	chr17:61819248	STRADA	0.53	5.19	0.42	8.45e-7	Prudent dietary pattern;
TGCT	cis	rs904251	0.523	rs1757191	chr6:37482871	C/T	cg01843034	chr6:37503916	NA	-0.54	-7.32	-0.55	2.76e-11	Cognitive performance;
TGCT	cis	rs896854	0.715	rs12548874	chr8:95935164	A/C	cg09323728	chr8:95962352	TP53INP1	0.49	5.82	0.46	4.79e-8	Type 2 diabetes;
TGCT	cis	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg25427524	chr10:38739819	LOC399744	-0.39	-8.04	-0.59	5.95e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs10769945	0.592	rs1635155	chr11:1972919	G/T	cg18032502	chr11:1949113	TNNT3	-0.25	-4.82	-0.4	4.06e-6	DNA methylation (variation);
TGCT	trans	rs6561151	0.681	rs17462017	chr13:44472235	C/T	cg12856521	chr11:46389249	DGKZ	0.77	7.12	0.54	7.74e-11	Crohn's disease;
TGCT	trans	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg27523141	chr10:43048294	ZNF37B	0.73	8.39	0.6	9.23e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg13732083	chr21:47605072	C21orf56	-0.35	-4.51	-0.38	1.5e-5	Testicular germ cell tumor;
TGCT	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg13395646	chr4:1353034	KIAA1530	-0.36	-4.57	-0.38	1.14e-5	Obesity-related traits;
TGCT	cis	rs11577318	0.579	rs35456934	chr1:26686864	G/A	cg14210634	chr1:25870291	LDLRAP1	0.54	4.73	0.39	6.06e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs11122272	0.735	rs2491407	chr1:231518928	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.13	-0.54	7.33e-11	Hemoglobin concentration;
TGCT	cis	rs2820315	0.867	rs2820318	chr1:201878620	T/C	cg12730843	chr1:201915899	LMOD1	-0.28	-5.13	-0.42	1.07e-6	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
TGCT	cis	rs1568889	1.000	rs7937778	chr11:28104605	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	8.86	0.62	7.07e-15	Bipolar disorder;
TGCT	cis	rs7666738	0.618	rs10856932	chr4:98819992	C/T	cg05340658	chr4:99064831	C4orf37	0.51	6.03	0.48	1.76e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7085104	0.700	rs6163	chr10:104596924	C/A	cg05855489	chr10:104503620	C10orf26	0.54	4.88	0.4	3.15e-6	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs7296418	0.961	rs10848428	chr12:123572495	C/T	cg00376283	chr12:123451042	ABCB9	0.82	7.46	0.56	1.33e-11	Platelet count;
TGCT	cis	rs1461503	0.932	rs10892934	chr11:122837950	C/T	cg27398637	chr11:122830231	C11orf63	-0.43	-5.32	-0.43	4.69e-7	Menarche (age at onset);
TGCT	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg05368731	chr17:41323189	NBR1	1.2	14.48	0.79	1.98e-28	Menopause (age at onset);
TGCT	cis	rs892961	0.932	rs7216155	chr17:75405155	C/G	cg05865280	chr17:75406074	SEPT9	0.29	6.76	0.52	4.91e-10	Airflow obstruction;
TGCT	trans	rs1814175	0.817	rs4881627	chr11:49953955	C/A	cg03929089	chr4:120376271	NA	-0.72	-8.53	-0.61	4.24e-14	Height;
TGCT	cis	rs2153535	0.563	rs1737586	chr6:8535897	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.63	0.45	1.14e-7	Motion sickness;
TGCT	cis	rs17376456	0.569	rs11135394	chr5:93187135	C/T	cg21475434	chr5:93447410	FAM172A	-0.64	-5.89	-0.47	3.35e-8	Diabetic retinopathy;
TGCT	cis	rs12477438	0.798	rs1349778	chr2:99645011	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-8.31	-0.6	1.43e-13	Chronic sinus infection;
TGCT	cis	rs9302001	0.881	rs9516481	chr13:95469560	C/T	cg07483244	chr13:95358924	NA	0.36	4.7	0.39	6.89e-6	Panic disorder;
TGCT	cis	rs4727027	0.704	rs12704071	chr7:148904795	C/T	cg23583168	chr7:148888333	NA	-0.83	-10.88	-0.7	8.98e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs4077515	0.934	rs78428995	chr9:139281847	T/C	cg13741927	chr9:139327495	INPP5E	-0.2	-4.6	-0.38	1.01e-5	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs9682041	0.808	rs9880558	chr3:170067771	A/G	cg07589077	chr3:170072950	NA	-0.32	-5.28	-0.43	5.69e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs1635	0.655	rs10484542	chr6:28309753	C/T	cg15743358	chr6:28303923	ZNF323	-0.85	-4.57	-0.38	1.17e-5	Schizophrenia;
TGCT	cis	rs28374715	0.681	rs7162231	chr15:41591859	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.9	-14.62	-0.8	9.13e-29	Ulcerative colitis;
TGCT	cis	rs3806843	0.576	rs251373	chr5:140252615	C/T	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	0.43	5.17	0.42	8.91e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg08280861	chr8:58055591	NA	0.39	4.64	0.38	8.72e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9677476	0.517	rs2368563	chr2:232058493	A/G	cg07929768	chr2:232055508	NA	0.3	4.83	0.4	4.01e-6	Food antigen IgG levels;
TGCT	cis	rs12681288	0.550	rs59004371	chr8:962393	T/C	cg04851639	chr8:1020857	NA	-0.3	-5.08	-0.41	1.36e-6	Schizophrenia;
TGCT	cis	rs981844	1.000	rs56331473	chr4:154668052	C/A	cg14289246	chr4:154710475	SFRP2	1.01	8.67	0.61	2.02e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs612683	0.524	rs11166456	chr1:100925633	C/T	cg06223162	chr1:101003688	GPR88	0.3	4.93	0.41	2.53e-6	Breast cancer;
TGCT	cis	rs7523273	0.606	rs12401619	chr1:207976276	G/C	cg22525895	chr1:207977042	MIR29B2	-0.53	-9.07	-0.63	2.17e-15	Schizophrenia;
TGCT	cis	rs6570726	0.791	rs436156	chr6:145874873	A/G	cg23711669	chr6:146136114	FBXO30	0.89	9.93	0.67	1.82e-17	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.46	-6.7	-0.52	6.41e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs9394169	0.536	rs3998115	chr6:33784833	G/C	cg00334056	chr6:33755658	LEMD2	-0.28	-4.9	-0.4	2.97e-6	Essential tremor;
TGCT	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg23708337	chr7:1209742	NA	0.51	4.46	0.37	1.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	trans	rs17685	0.697	rs2302437	chr7:75677016	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.52	-8.84	-0.62	7.72e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs7180079	0.620	rs6494487	chr15:64998248	T/A	cg03791955	chr15:65024147	NA	0.28	5.45	0.44	2.61e-7	Monocyte count;
TGCT	cis	rs2033711	0.837	rs3764535	chr19:58929052	G/A	cg04608855	chr19:58913158	NA	0.58	5.69	0.46	8.64e-8	Uric acid clearance;
TGCT	cis	rs3008870	1.000	rs12044278	chr1:67460977	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-1.1	-11.8	-0.73	5.15e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs7017914	0.905	rs3110244	chr8:71933197	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	0.52	4.74	0.39	5.73e-6	Bone mineral density;
TGCT	cis	rs1784581	0.802	rs9365355	chr6:162414604	A/G	cg17173639	chr6:162384350	PARK2	0.42	7.3	0.55	3.02e-11	Itch intensity from mosquito bite;
TGCT	cis	rs3125734	0.633	rs6479804	chr10:64048327	T/C	cg19640130	chr10:64028056	RTKN2	-0.38	-4.79	-0.39	4.73e-6	Rheumatoid arthritis;
TGCT	cis	rs6725041	0.819	rs13420153	chr2:213083191	C/G	cg20637307	chr2:213403960	ERBB4	-0.51	-4.48	-0.37	1.68e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs9814567	0.806	rs6799543	chr3:134216139	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.96	-9.19	-0.64	1.16e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg26513180	chr16:89883248	FANCA	1.06	14.53	0.79	1.56e-28	Vitiligo;
TGCT	cis	rs903263	0.965	rs7515264	chr1:84599832	C/T	cg09664975	chr1:84543551	PRKACB	0.5	4.74	0.39	5.73e-6	Breast cancer (male);
TGCT	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg11890956	chr21:40555474	PSMG1	-0.78	-7.27	-0.55	3.48e-11	Cognitive function;
TGCT	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg13770153	chr20:60521292	NA	-0.54	-7.12	-0.54	7.73e-11	Body mass index;
TGCT	cis	rs801193	0.967	rs3800823	chr7:66147110	C/A	cg18876405	chr7:65276391	NA	-0.38	-5.83	-0.46	4.44e-8	Aortic root size;
TGCT	cis	rs763121	0.853	rs138713	chr22:39142615	T/C	cg06022373	chr22:39101656	GTPBP1	0.69	6.39	0.5	3.1e-9	Menopause (age at onset);
TGCT	cis	rs2932538	0.961	rs3013441	chr1:113192605	C/T	cg22728128	chr1:112299491	DDX20;C1orf183	-0.25	-4.72	-0.39	6.22e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs9527	0.590	rs10883818	chr10:104759586	A/G	cg15744005	chr10:104629667	AS3MT	-0.44	-5.11	-0.42	1.18e-6	Arsenic metabolism;
TGCT	cis	rs3820928	1.000	rs2396433	chr2:227772502	A/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-4.82	-0.4	4.12e-6	Pulmonary function;
TGCT	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg08509172	chr19:19383838	TM6SF2	-0.34	-4.48	-0.37	1.71e-5	Tonsillectomy;
TGCT	cis	rs3749237	0.555	rs7637665	chr3:49552295	T/C	cg02487422	chr3:49467188	NICN1	0.57	5.84	0.46	4.26e-8	Resting heart rate;
TGCT	cis	rs8062405	0.690	rs6498089	chr16:28629300	C/T	cg09754948	chr16:28834200	ATXN2L	-0.59	-4.78	-0.39	4.82e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs6088580	0.634	rs4911152	chr20:32955024	T/C	cg06115741	chr20:33292138	TP53INP2	-0.55	-4.8	-0.4	4.5e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs6429082	0.764	rs291369	chr1:235691913	T/C	cg26050004	chr1:235667680	B3GALNT2	0.6	5.25	0.43	6.36e-7	Adiposity;
TGCT	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-6.74	-0.52	5.26e-10	Alzheimer's disease;
TGCT	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.18	0.49	8.32e-9	Electroencephalogram traits;
TGCT	cis	rs12048904	0.595	rs2295280	chr1:101342497	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.63	6.07	0.48	1.42e-8	Multiple sclerosis;
TGCT	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg18402987	chr7:1209562	NA	0.65	5.32	0.43	4.65e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs35934224	0.783	rs7285948	chr22:19861127	T/C	cg11182965	chr22:19864308	TXNRD2	-0.38	-5.3	-0.43	5.04e-7	Glaucoma (primary open-angle);
TGCT	cis	rs709400	0.628	rs11623470	chr14:104004810	T/A	cg12935359	chr14:103987150	CKB	-0.38	-5.67	-0.45	9.37e-8	Body mass index;
TGCT	cis	rs739496	0.542	rs10849937	chr12:111792427	A/G	cg10833066	chr12:111807467	FAM109A	0.45	7.67	0.57	4.32e-12	Platelet count;
TGCT	cis	rs9911578	0.935	rs117819974	chr17:57002324	C/T	cg12560992	chr17:57184187	TRIM37	0.76	9.21	0.64	1.03e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs6570726	0.935	rs585292	chr6:145862228	T/C	cg05347473	chr6:146136440	FBXO30	0.49	4.54	0.38	1.29e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs250677	0.522	rs10042466	chr5:148393634	T/C	cg18129178	chr5:148520854	ABLIM3	-0.36	-4.62	-0.38	9.43e-6	Breast cancer;
TGCT	cis	rs1568889	0.838	rs10835283	chr11:28214985	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.91	9.94	0.67	1.75e-17	Bipolar disorder;
TGCT	cis	rs9611565	0.512	rs5758436	chr22:42124265	C/T	cg03806693	chr22:41940476	POLR3H	1.08	11.99	0.73	1.84e-22	Vitiligo;
TGCT	cis	rs4819052	1.000	rs2297284	chr21:46705345	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.97	7.57	0.56	7.23e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs1371867	0.817	rs1660315	chr8:101332956	G/A	cg00191853	chr8:101177733	SPAG1	-0.22	-4.47	-0.37	1.75e-5	Atrioventricular conduction;
TGCT	cis	rs4664308	0.935	rs4665148	chr2:160917901	A/G	cg03641300	chr2:160917029	PLA2R1	-0.27	-6.58	-0.51	1.2e-9	Idiopathic membranous nephropathy;
TGCT	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs12134245	0.776	rs12125947	chr1:91990487	T/C	cg25838465	chr1:92012736	NA	-0.42	-6.6	-0.51	1.09e-9	Breast cancer;
TGCT	cis	rs12477438	0.520	rs11890338	chr2:99767868	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	17.43	0.84	3.73e-35	Chronic sinus infection;
TGCT	cis	rs71435601	0.574	rs528113	chr2:21382624	G/T	cg25035485	chr2:21266500	APOB	0.51	4.48	0.37	1.64e-5	Cholesterol, total;
TGCT	cis	rs1865721	0.656	rs724765	chr18:73139794	A/G	cg26385618	chr18:73139727	C18orf62	-0.23	-4.5	-0.37	1.55e-5	Intelligence;
TGCT	cis	rs13191362	1.000	rs35383933	chr6:163002869	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7095607	0.785	rs3956957	chr10:69919445	A/T	cg18986048	chr10:69913749	MYPN	0.41	4.48	0.37	1.66e-5	Lung function (FVC);
TGCT	cis	rs9894429	0.608	rs7406219	chr17:79609410	G/T	cg18240062	chr17:79603768	NPLOC4	0.56	4.92	0.4	2.67e-6	Eye color traits;
TGCT	cis	rs6429082	0.818	rs291391	chr1:235649955	A/G	cg26050004	chr1:235667680	B3GALNT2	0.62	5.58	0.45	1.43e-7	Adiposity;
TGCT	cis	rs7940866	0.834	rs7939417	chr11:130853832	T/A	cg12179176	chr11:130786555	SNX19	0.61	5.88	0.47	3.59e-8	Schizophrenia;
TGCT	cis	rs2019216	0.500	rs12946184	chr17:21944675	A/C	cg22648282	chr17:21454238	C17orf51	-0.58	-4.95	-0.41	2.37e-6	Pelvic organ prolapse;
TGCT	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.52	-4.9	-0.4	2.9e-6	Bipolar disorder;
TGCT	cis	rs10089	1.000	rs62373701	chr5:127416294	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.81	7.57	0.56	7.27e-12	Ileal carcinoids;
TGCT	cis	rs2404602	0.684	rs8029283	chr15:76837140	A/G	cg23625390	chr15:77176239	SCAPER	-0.38	-4.68	-0.39	7.3e-6	Blood metabolite levels;
TGCT	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.33	-5.12	-0.42	1.12e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg20607798	chr8:58055168	NA	0.45	4.6	0.38	1.05e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs6460942	0.841	rs17443848	chr7:12443688	A/G	cg06484146	chr7:12443880	VWDE	-0.54	-5.76	-0.46	6.25e-8	Coronary artery disease;
TGCT	cis	rs11718455	0.767	rs11708363	chr3:43966585	G/A	cg08738300	chr3:44038990	NA	0.75	5.71	0.46	7.9e-8	Coronary artery disease;
TGCT	cis	rs35883536	0.514	rs4908062	chr1:101013211	T/C	cg10298815	chr1:101004474	GPR88	0.24	4.6	0.38	1.01e-5	Monocyte count;
TGCT	cis	rs478607	0.915	rs61884449	chr11:64485193	C/T	cg19395706	chr11:64412079	NRXN2	0.54	5.67	0.45	9.56e-8	Urate levels;
TGCT	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg23758822	chr17:41437982	NA	0.72	6.81	0.52	3.77e-10	Menopause (age at onset);
TGCT	cis	rs2404602	0.735	rs11635463	chr15:76762986	C/T	cg22467129	chr15:76604101	ETFA	0.48	5.11	0.42	1.16e-6	Blood metabolite levels;
TGCT	cis	rs902774	0.515	rs2363635	chr12:53354622	T/C	cg25025879	chr12:53359317	NA	-0.45	-5.01	-0.41	1.82e-6	Prostate cancer;
TGCT	cis	rs13191362	1.000	rs34725898	chr6:163127302	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.16	9.92	0.67	1.96e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs11711311	0.911	rs28577577	chr3:113447276	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.78	-7.13	-0.54	7.14e-11	IgG glycosylation;
TGCT	cis	rs5769765	0.913	rs4824111	chr22:50284305	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	1.18	13.09	0.76	4.1e-25	Schizophrenia;
TGCT	cis	rs17376456	0.825	rs74825443	chr5:93254973	T/C	cg21475434	chr5:93447410	FAM172A	0.65	4.5	0.37	1.57e-5	Diabetic retinopathy;
TGCT	cis	rs6582630	0.519	rs12578283	chr12:38325349	A/T	cg13010199	chr12:38710504	ALG10B	0.58	4.55	0.38	1.26e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg20637647	chr7:64974828	NA	-0.9	-5.31	-0.43	4.87e-7	Diabetic kidney disease;
TGCT	cis	rs3008870	1.000	rs7511948	chr1:67430427	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.1	11.8	0.73	5.15e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs769267	0.965	rs2965198	chr19:19473030	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.68	-5.57	-0.45	1.51e-7	Tonsillectomy;
TGCT	cis	rs9549260	0.785	rs6563842	chr13:41244297	G/T	cg21288729	chr13:41239152	FOXO1	1.0	10.25	0.68	3.06e-18	Red blood cell count;
TGCT	cis	rs5760092	0.755	rs3884794	chr22:24251766	C/A	cg00024416	chr22:24240387	NA	-0.34	-5.91	-0.47	3.02e-8	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs8180040	0.620	rs11715121	chr3:47072621	T/A	cg27129171	chr3:47204927	SETD2	-0.71	-8.51	-0.61	4.8e-14	Colorectal cancer;
TGCT	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg18876405	chr7:65276391	NA	-0.34	-5.08	-0.41	1.38e-6	Aortic root size;
TGCT	cis	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg13531842	chr10:38383804	ZNF37A	-0.38	-4.51	-0.38	1.49e-5	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7843479	0.601	rs7220	chr8:21863290	G/A	cg17168535	chr8:21777572	XPO7	0.8	8.16	0.59	3.19e-13	Mean corpuscular volume;
TGCT	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg21171335	chr12:122356390	WDR66	0.7	6.99	0.53	1.46e-10	Mean corpuscular volume;
TGCT	cis	rs6076065	0.594	rs6048755	chr20:23337233	A/G	cg11657817	chr20:23433608	CST11	0.31	5.35	0.43	4.06e-7	Facial morphology (factor 15, philtrum width);
TGCT	cis	rs2721195	0.549	rs2958492	chr8:145919126	C/T	cg15320075	chr8:145703422	NA	0.49	4.61	0.38	9.86e-6	Age at first birth;
TGCT	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg02725872	chr8:58115012	NA	-0.4	-4.86	-0.4	3.52e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2594989	0.565	rs62245958	chr3:11601493	C/G	cg00170343	chr3:11313890	ATG7	-0.64	-4.8	-0.4	4.57e-6	Circulating chemerin levels;
TGCT	cis	rs7666738	0.791	rs13127542	chr4:98949159	C/T	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs56309584	0.523	rs3027172	chr17:8055723	A/G	cg08322244	chr17:8066669	VAMP2	-0.52	-4.71	-0.39	6.61e-6	Initial pursuit acceleration;
TGCT	cis	rs1150668	0.796	rs1052215	chr6:28348158	T/G	cg19488431	chr6:28601329	NA	-0.2	-4.52	-0.38	1.42e-5	Pubertal anthropometrics;
TGCT	cis	rs9807989	0.765	rs6751967	chr2:102967413	T/C	cg09003973	chr2:102972529	NA	0.64	5.7	0.46	8.28e-8	Asthma;
TGCT	cis	rs78487399	0.808	rs6544666	chr2:43732234	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-4.82	-0.4	4.03e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs1055129	0.655	rs3744006	chr17:73838816	G/A	cg08125733	chr17:73851984	WBP2	0.58	5.12	0.42	1.12e-6	White matter hyperintensity burden;
TGCT	cis	rs651907	0.535	rs12633089	chr3:101528763	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.31	-6.52	-0.51	1.56e-9	Colorectal cancer;
TGCT	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.94	7.92	0.58	1.17e-12	Platelet count;
TGCT	cis	rs1949733	0.848	rs2255501	chr4:8475014	G/A	cg11789530	chr4:8429930	ACOX3	-0.58	-5.19	-0.42	8.5e-7	Response to antineoplastic agents;
TGCT	cis	rs3824867	0.920	rs7130693	chr11:47452321	T/C	cg20307385	chr11:47447363	PSMC3	-0.69	-5.86	-0.47	3.99e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.35	-4.46	-0.37	1.84e-5	Menopause (age at onset);
TGCT	cis	rs12479064	0.724	rs2309618	chr2:99974473	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.57	-4.47	-0.37	1.71e-5	Chronic sinus infection;
TGCT	cis	rs6701037	0.566	rs729675	chr1:175136946	T/C	cg00321850	chr1:175162397	KIAA0040	0.38	5.04	0.41	1.61e-6	Alcohol dependence;
TGCT	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.51	-4.49	-0.37	1.62e-5	Prudent dietary pattern;
TGCT	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	8.01	0.58	7.13e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs4654899	0.643	rs12123092	chr1:21067001	A/G	cg01072550	chr1:21505969	NA	0.44	6.88	0.53	2.68e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs902774	0.554	rs4919749	chr12:53358034	C/T	cg14581129	chr12:53358946	NA	-0.56	-6.32	-0.49	4.32e-9	Prostate cancer;
TGCT	trans	rs10506458	0.834	rs73125186	chr12:63373400	C/T	cg22491629	chr6:157744540	C6orf35	-0.96	-8.25	-0.6	2.01e-13	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs709400	0.633	rs3783395	chr14:103895020	T/C	cg12935359	chr14:103987150	CKB	-0.35	-5.28	-0.43	5.66e-7	Body mass index;
TGCT	cis	rs10191773	0.535	rs11685514	chr2:113100014	C/T	cg07905836	chr2:113190072	RGPD8;RGPD5	0.47	5.03	0.41	1.67e-6	Yeast infection;
TGCT	cis	rs9397585	0.626	rs6932847	chr6:153448307	G/A	cg24028809	chr6:153414101	RGS17	0.22	4.66	0.39	8.15e-6	Body mass index;
TGCT	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg22968622	chr17:43663579	NA	0.98	9.28	0.64	7.03e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg03806693	chr22:41940476	POLR3H	1.12	13.0	0.76	6.57e-25	Vitiligo;
TGCT	trans	rs629535	0.679	rs62511660	chr8:70157089	G/A	cg21567404	chr3:27674614	NA	-0.51	-7.72	-0.57	3.4e-12	Dupuytren's disease;
TGCT	cis	rs72945132	0.882	rs56368190	chr11:70204328	T/G	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs9653442	0.545	rs13415465	chr2:100764004	T/G	cg22139774	chr2:100720529	AFF3	-0.36	-5.72	-0.46	7.68e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg06640241	chr16:89574553	SPG7	0.75	8.35	0.6	1.12e-13	Multiple myeloma (IgH translocation);
TGCT	cis	rs6912958	0.781	rs9444504	chr6:88181046	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-5.18	-0.42	8.55e-7	Monocyte percentage of white cells;
TGCT	cis	rs3824867	0.881	rs4752829	chr11:47396654	G/A	cg20307385	chr11:47447363	PSMC3	-0.65	-5.44	-0.44	2.73e-7	Mean corpuscular hemoglobin;
TGCT	cis	rs4654899	0.897	rs10916856	chr1:21082074	A/C	cg01072550	chr1:21505969	NA	-0.49	-7.93	-0.58	1.12e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.61	0.38	9.85e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs3617	0.573	rs6795646	chr3:52922621	C/T	cg10802521	chr3:52805072	NEK4	0.56	6.23	0.49	6.81e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7192750	0.562	rs9889011	chr16:71987816	T/A	cg06353428	chr16:71660113	MARVELD3	0.74	6.6	0.51	1.09e-9	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs7819412	0.618	rs34772085	chr8:10964906	C/T	cg12940923	chr8:10282607	MSRA	-0.18	-4.5	-0.37	1.55e-5	Triglycerides;
TGCT	cis	rs9858542	1.000	rs2172252	chr3:49678307	A/T	cg03060546	chr3:49711283	APEH	-0.67	-6.09	-0.48	1.28e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs832540	0.629	rs10461616	chr5:56080347	T/C	cg24531977	chr5:56204891	C5orf35	-0.5	-5.08	-0.42	1.34e-6	Coronary artery disease;
TGCT	cis	rs2033711	0.936	rs893185	chr19:58989495	A/C	cg13877915	chr19:58951672	ZNF132	0.82	8.77	0.62	1.17e-14	Uric acid clearance;
TGCT	cis	rs7226408	0.894	rs72885212	chr18:34399131	G/A	cg06757138	chr18:34340585	FHOD3	0.26	4.79	0.4	4.62e-6	Obesity-related traits;
TGCT	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg11871910	chr12:69753446	YEATS4	0.89	10.53	0.69	6.39e-19	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs929354	0.772	rs7778193	chr7:156980087	C/T	cg05182265	chr7:156933206	UBE3C	-0.39	-8.79	-0.62	1.03e-14	Body mass index;
TGCT	cis	rs25422	0.878	rs55894300	chr6:118982076	T/A	cg07617317	chr6:118971624	C6orf204	0.49	5.15	0.42	9.91e-7	Renal cell carcinoma;
TGCT	trans	rs1814175	0.791	rs10769625	chr11:49869887	G/A	cg15704280	chr7:45808275	SEPT13	-0.72	-8.14	-0.59	3.61e-13	Height;
TGCT	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-5.09	-0.42	1.29e-6	Electroencephalogram traits;
TGCT	cis	rs634534	0.562	rs661335	chr11:65754061	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.65	6.38	0.5	3.14e-9	Sum eosinophil basophil counts;Eosinophil counts;
TGCT	cis	rs11030122	0.702	rs7128762	chr11:3943277	C/G	cg18678763	chr11:4115507	RRM1	-0.49	-6.14	-0.48	1.01e-8	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	5.24	0.43	6.6e-7	Height;
TGCT	cis	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg20637647	chr7:64974828	NA	0.9	5.31	0.43	4.87e-7	Diabetic kidney disease;
TGCT	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg06238570	chr21:40685208	BRWD1	0.61	5.06	0.41	1.46e-6	Cognitive function;
TGCT	cis	rs1563304	1	rs1563304	chr17:44874453	C/T	cg15921436	chr17:44337874	NA	0.46	5.28	0.43	5.65e-7	Neuroticism;
TGCT	cis	rs700651	0.789	rs10497812	chr2:198911245	A/G	cg00792783	chr2:198669748	PLCL1	-0.6	-5.2	-0.42	8.05e-7	Intracranial aneurysm;
TGCT	cis	rs9291683	0.526	rs12506122	chr4:10033538	C/A	cg00071950	chr4:10020882	SLC2A9	0.6	6.93	0.53	2.08e-10	Bone mineral density;
TGCT	cis	rs7264396	0.836	rs6058282	chr20:34212590	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-4.82	-0.4	4.17e-6	Total cholesterol levels;
TGCT	cis	rs138249	0.966	rs138238	chr22:50563140	T/C	cg24864161	chr22:50528282	MOV10L1	0.47	4.78	0.39	4.9100000000000004e-06	Gestational age at birth in labor-initiated deliveries (child effect);
TGCT	cis	rs34779708	0.931	rs17591135	chr10:35465190	T/A	cg03585969	chr10:35415529	CREM	0.43	4.52	0.38	1.4e-5	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs1692580	0.807	rs4648628	chr1:2203490	C/T	cg24578937	chr1:2090814	PRKCZ	0.21	4.58	0.38	1.13e-5	Coronary artery disease;
TGCT	cis	rs896854	0.625	rs4735336	chr8:95973410	A/C	cg09323728	chr8:95962352	TP53INP1	0.48	6.18	0.49	8.33e-9	Type 2 diabetes;
TGCT	cis	rs453301	0.686	rs6601280	chr8:8909236	A/T	cg15556689	chr8:8085844	FLJ10661	0.66	5.67	0.45	9.32e-8	Joint mobility (Beighton score);
TGCT	cis	rs42648	0.837	rs6970750	chr7:89938191	G/A	cg25739043	chr7:89950458	NA	-0.71	-7.18	-0.54	5.5e-11	Homocysteine levels;
TGCT	cis	rs1008375	1.000	rs6846238	chr4:17629939	A/G	cg10189774	chr4:17578691	LAP3	0.59	5.13	0.42	1.06e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9911578	0.933	rs11868348	chr17:57179238	C/T	cg05425664	chr17:57184151	TRIM37	-0.68	-6.9	-0.53	2.4e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs1865760	0.566	rs9467663	chr6:26021456	C/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.8	7.57	0.56	7.45e-12	Height;
TGCT	cis	rs11190604	0.513	rs2489003	chr10:102360855	A/G	cg16342193	chr10:102329863	NA	-0.46	-5.15	-0.42	1.02e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs875971	1.000	rs1144895	chr7:65541307	C/G	cg11764359	chr7:65958608	NA	-0.56	-4.7	-0.39	6.74e-6	Aortic root size;
TGCT	cis	rs4494114	0.967	rs11211566	chr1:39354700	G/C	cg25970120	chr1:39325951	RRAGC	-0.6	-6.19	-0.49	8.1e-9	Blood protein levels;
TGCT	cis	rs10946940	0.965	rs6456799	chr6:27573536	A/G	cg10876282	chr6:28092338	ZSCAN16	-0.46	-4.73	-0.39	5.93e-6	Systemic lupus erythematosus;
TGCT	cis	rs7429990	0.965	rs2882668	chr3:47980306	A/G	cg11946769	chr3:48343235	NME6	0.53	4.48	0.37	1.65e-5	Educational attainment (years of education);
TGCT	cis	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg07424592	chr7:64974309	NA	1.4	8.42	0.6	7.87e-14	Diabetic kidney disease;
TGCT	cis	rs922182	0.557	rs730589	chr15:64194173	G/T	cg02919090	chr15:64263738	DAPK2	0.33	5.92	0.47	2.97e-8	Blood protein levels;
TGCT	trans	rs2469997	1.000	rs2447172	chr8:120360863	A/T	cg01792902	chr3:178864926	PIK3CA	0.83	6.77	0.52	4.49e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs13256369	0.756	rs13280759	chr8:8562995	G/T	cg06671706	chr8:8559999	CLDN23	0.34	4.52	0.38	1.4e-5	Obesity-related traits;
TGCT	cis	rs2120019	1.000	rs12324912	chr15:75361006	G/A	cg17294928	chr15:75287854	SCAMP5	-0.84	-6.34	-0.5	3.8e-9	Blood trace element (Zn levels);
TGCT	cis	rs7666738	0.830	rs13129479	chr4:98987860	T/C	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs826838	1.000	rs1843881	chr12:38733706	A/G	cg13010199	chr12:38710504	ALG10B	-0.8	-6.55	-0.51	1.37e-9	Heart rate;
TGCT	trans	rs9985766	1.000	rs9968348	chr4:151022142	G/A	cg02993991	chr19:4064177	ZBTB7A	0.57	6.7	0.52	6.59e-10	Coronary artery disease;Myocardial infarction;
TGCT	cis	rs832540	0.966	rs252925	chr5:56203773	G/A	cg12311346	chr5:56204834	C5orf35	-0.49	-5.24	-0.43	6.72e-7	Coronary artery disease;
TGCT	cis	rs11673344	0.504	rs4806407	chr19:37588751	A/G	cg08039142	chr19:36980659	ZNF566	-0.53	-4.84	-0.4	3.84e-6	Obesity-related traits;
TGCT	cis	rs231513	0.822	rs53907	chr17:41950810	C/A	cg26893861	chr17:41843967	DUSP3	-0.8	-5.9	-0.47	3.3e-8	Cognitive function;
TGCT	cis	rs854765	0.724	rs62072049	chr17:17906520	T/C	cg09796270	chr17:17721594	SREBF1	0.27	5.4	0.44	3.22e-7	Total body bone mineral density;
TGCT	cis	rs7772486	0.597	rs2246132	chr6:146182515	C/G	cg05347473	chr6:146136440	FBXO30	0.66	6.24	0.49	6.34e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs910316	0.967	rs4899550	chr14:75647666	C/T	cg23033748	chr14:75592666	NEK9	-0.29	-4.93	-0.41	2.55e-6	Height;
TGCT	cis	rs727505	0.754	rs56012154	chr7:124781250	A/G	cg23710748	chr7:124431027	NA	-0.25	-4.44	-0.37	1.97e-5	Lewy body disease;
TGCT	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg22683308	chr4:1340831	KIAA1530	-0.59	-5.69	-0.46	8.47e-8	Longevity;
TGCT	cis	rs3125734	0.582	rs7904465	chr10:64002393	G/A	cg05499367	chr10:63213510	TMEM26	-0.33	-4.44	-0.37	1.96e-5	Rheumatoid arthritis;
TGCT	cis	rs1341267	0.529	rs6492720	chr13:95256305	T/C	cg18412871	chr13:95254051	GPR180	-0.62	-5.45	-0.44	2.58e-7	Triglyceride levels;
TGCT	cis	rs6429082	0.791	rs291394	chr1:235651682	A/G	cg26050004	chr1:235667680	B3GALNT2	0.59	5.26	0.43	6.02e-7	Adiposity;
TGCT	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg17971929	chr21:40555470	PSMG1	0.7	6.39	0.5	2.97e-9	Cognitive function;
TGCT	cis	rs739496	0.579	rs12313385	chr12:112292147	C/G	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs78487399	0.808	rs13431070	chr2:43721954	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.44	5.77	0.46	6.09e-8	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs7617773	0.780	rs34946886	chr3:48338487	A/G	cg11946769	chr3:48343235	NME6	0.82	7.06	0.54	1.03e-10	Coronary artery disease;
TGCT	cis	rs317689	0.690	rs10878946	chr12:69642315	C/T	cg14784868	chr12:69753453	YEATS4	0.54	4.5	0.37	1.56e-5	Response to diuretic therapy;
TGCT	cis	rs546131	0.928	rs550313	chr11:34830919	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.58	5.12	0.42	1.16e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs2932538	0.922	rs112363416	chr1:113107543	T/C	cg22162597	chr1:113214053	CAPZA1	0.28	5.83	0.46	4.4e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs208515	0.525	rs10498841	chr6:66663706	C/T	cg07460842	chr6:66804631	NA	0.85	8.73	0.62	1.41e-14	Exhaled nitric oxide levels;
TGCT	cis	rs7666738	0.830	rs1593572	chr4:98979322	A/G	cg17366294	chr4:99064904	C4orf37	-0.63	-6.32	-0.49	4.34e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7819412	0.502	rs4840548	chr8:10992883	C/T	cg21775007	chr8:11205619	TDH	-0.56	-4.95	-0.41	2.34e-6	Triglycerides;
TGCT	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg26039829	chr8:22132926	PIWIL2	0.27	5.13	0.42	1.1e-6	Hypertriglyceridemia;
TGCT	cis	rs4253772	0.530	rs6008774	chr22:46755298	C/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.64	4.8	0.4	4.57e-6	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs2562456	1.000	rs2562456	chr19:21666210	A/G	cg25650185	chr19:21324782	ZNF431	-0.56	-4.83	-0.4	4.02e-6	Pain;
TGCT	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg11301795	chr4:187892539	NA	0.31	4.76	0.39	5.32e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg20999797	chr1:1681921	NA	-0.18	-4.81	-0.4	4.38e-6	Body mass index;
TGCT	cis	rs73058052	0.597	rs7251877	chr19:50097547	A/G	cg09250473	chr19:50168907	IRF3;BCL2L12	0.65	5.22	0.42	7.33e-7	Fibrinogen levels;
TGCT	cis	rs2742417	1.000	rs2673057	chr3:45735730	A/T	cg04837898	chr3:45731254	SACM1L	-0.55	-5.68	-0.45	9.14e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs2334880	0.678	rs12918320	chr16:71463602	A/G	cg06353428	chr16:71660113	MARVELD3	-1.16	-7.18	-0.54	5.59e-11	Malaria;
TGCT	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg10802521	chr3:52805072	NEK4	-0.71	-8.79	-0.62	1.04e-14	Bipolar disorder;
TGCT	cis	rs9916302	0.706	rs11657153	chr17:37699729	A/G	cg07936489	chr17:37558343	FBXL20	-0.84	-6.16	-0.48	9.13e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs2439831	0.681	rs528517	chr15:43612925	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.02	8.69	0.62	1.84e-14	Lung cancer in ever smokers;
TGCT	cis	rs3935685	0.874	rs12911718	chr15:78004325	G/A	cg03457338	chr15:78040120	NA	-0.22	-5.73	-0.46	7.26e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9341808	0.714	rs9448911	chr6:80913859	A/G	cg08355045	chr6:80787529	NA	0.31	5.1	0.42	1.26e-6	Sitting height ratio;
TGCT	cis	rs13242816	1.000	rs7809755	chr7:116110732	C/T	cg02799643	chr7:116139180	CAV2	-0.48	-5.52	-0.44	1.87e-7	P wave duration;
TGCT	cis	rs8017423	0.967	rs12589808	chr14:90719236	C/T	cg04374321	chr14:90722782	PSMC1	-0.74	-7.35	-0.55	2.38e-11	Mortality in heart failure;
TGCT	cis	rs5769707	0.967	rs5770585	chr22:50007874	G/A	cg05373962	chr22:49881684	NA	-0.3	-6.19	-0.49	8.01e-9	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs9399135	0.967	rs13218642	chr6:135309940	A/G	cg24558204	chr6:135376177	HBS1L	0.48	4.75	0.39	5.5e-6	Red blood cell count;
TGCT	cis	rs9527	0.590	rs3781282	chr10:104852419	C/T	cg04362960	chr10:104952993	NT5C2	-0.72	-6.18	-0.49	8.27e-9	Arsenic metabolism;
TGCT	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.75	5.41	0.44	3.09e-7	Platelet count;
TGCT	cis	rs904251	0.525	rs12200378	chr6:37425304	A/G	cg25019722	chr6:37503610	NA	-0.48	-6.96	-0.53	1.72e-10	Cognitive performance;
TGCT	cis	rs2455799	0.573	rs2062824	chr3:15757901	T/C	cg16303742	chr3:15540471	COLQ	-0.26	-5.08	-0.41	1.37e-6	Mean platelet volume;
TGCT	cis	rs4285028	0.948	rs7615571	chr3:121665950	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.77	-6.5	-0.5	1.78e-9	Multiple sclerosis;
TGCT	cis	rs611744	0.669	rs13251024	chr8:109258333	T/C	cg21045802	chr8:109455806	TTC35	0.72	7.28	0.55	3.32e-11	Dupuytren's disease;
TGCT	cis	rs9611565	0.921	rs5751081	chr22:41742788	A/T	cg13695892	chr22:41940480	POLR3H	-0.72	-7.37	-0.55	2.15e-11	Vitiligo;
TGCT	cis	rs17345786	0.953	rs78645744	chr3:101327789	T/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.57	4.85	0.4	3.59e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs617219	0.726	rs955897	chr5:78431486	A/C	cg23987322	chr5:78407566	BHMT	0.35	4.56	0.38	1.22e-5	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs36051895	0.695	rs10123976	chr9:4997333	A/T	cg02405213	chr9:5042618	JAK2	-0.73	-9.48	-0.65	2.27e-16	Pediatric autoimmune diseases;
TGCT	cis	rs1577917	1.000	rs34622557	chr6:86630852	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.22	-0.42	7.27e-7	Response to antipsychotic treatment;
TGCT	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg03806693	chr22:41940476	POLR3H	1.13	12.99	0.76	6.98e-25	Vitiligo;
TGCT	cis	rs4766566	0.590	rs3809283	chr12:111707754	A/T	cg10833066	chr12:111807467	FAM109A	0.33	4.65	0.39	8.5e-6	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
TGCT	cis	rs137603	0.933	rs137591	chr22:39685450	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	-0.54	-5.02	-0.41	1.78e-6	Primary biliary cholangitis;
TGCT	cis	rs2074585	0.647	rs2589961	chr15:90916840	G/A	cg22089800	chr15:90895588	ZNF774	0.82	9.04	0.63	2.58e-15	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
TGCT	cis	rs1670533	1.000	rs6852850	chr4:1052857	C/G	cg27284194	chr4:1044797	NA	0.67	5.77	0.46	5.9e-8	Recombination rate (females);
TGCT	cis	rs2840044	1.000	rs8073935	chr17:33985849	C/T	cg05299278	chr17:33885742	SLFN14	0.22	4.98	0.41	2.07e-6	Response to radiotherapy in cancer (late toxicity);
TGCT	cis	rs9457247	0.534	rs9366078	chr6:167399512	A/G	cg23791538	chr6:167370224	RNASET2	0.61	6.02	0.48	1.85e-8	Crohn's disease;
TGCT	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.6	-4.96	-0.41	2.26e-6	Tonsillectomy;
TGCT	cis	rs79349575	0.715	rs999474	chr17:46987665	G/A	cg07967210	chr17:47022446	SNF8	-0.41	-5.44	-0.44	2.69e-7	Type 2 diabetes;
TGCT	cis	rs7027203	0.595	rs4308796	chr9:96570165	G/A	cg14598338	chr9:96623480	NA	0.52	7.48	0.56	1.16e-11	DNA methylation (variation);
TGCT	cis	rs6582630	0.555	rs7305352	chr12:38473800	T/C	cg13010199	chr12:38710504	ALG10B	0.64	5.09	0.42	1.27e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs6565180	0.888	rs11150586	chr16:30420851	T/C	cg17640201	chr16:30407289	ZNF48	0.92	8.66	0.61	2.06e-14	Tonsillectomy;
TGCT	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg26338869	chr17:61819248	STRADA	-0.53	-4.94	-0.41	2.48e-6	Prudent dietary pattern;
TGCT	cis	rs1153858	1.000	rs2668747	chr15:45617216	T/C	cg14582100	chr15:45693742	SPATA5L1	0.46	5.44	0.44	2.73e-7	Homoarginine levels;
TGCT	cis	rs13096760	1	rs13096760	chr3:49476806	T/C	cg02487422	chr3:49467188	NICN1	0.61	6.29	0.49	5.08e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.99	6.93	0.53	2.02e-10	Platelet count;
TGCT	cis	rs4285028	0.699	rs7637495	chr3:121573850	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.78	-6.72	-0.52	5.95e-10	Multiple sclerosis;
TGCT	cis	rs7267979	0.744	rs6050463	chr20:25208990	G/A	cg16686733	chr20:25566563	NINL	0.48	4.51	0.38	1.5e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs8078723	0.738	rs4065321	chr17:38143548	C/T	cg17467752	chr17:38218738	THRA	-0.53	-5.37	-0.43	3.69e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs1322512	0.677	rs2695251	chr6:152927101	T/C	cg03415253	chr6:152958462	SYNE1	-0.55	-5.2	-0.42	8.12e-7	Tonometry;
TGCT	trans	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg21659725	chr3:3221576	CRBN	-0.98	-15.33	-0.81	2.1000000000000002e-30	Intelligence (multi-trait analysis);
TGCT	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.54	-5.1	-0.42	1.22e-6	Electroencephalogram traits;
TGCT	cis	rs711245	0.637	rs6729495	chr2:36834192	T/A	cg15105969	chr2:36825350	FEZ2	0.62	6.06	0.48	1.49e-8	Height;
TGCT	cis	rs931127	0.747	rs11820062	chr11:65429936	T/C	cg27068330	chr11:65405492	SIPA1	-0.62	-6.12	-0.48	1.16e-8	Systemic lupus erythematosus;
TGCT	cis	rs1577917	0.771	rs2475790	chr6:86368068	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.58	-0.45	1.43e-7	Response to antipsychotic treatment;
TGCT	cis	rs72949976	0.646	rs11681232	chr2:214033002	G/A	cg08319019	chr2:214017104	IKZF2	0.87	8.64	0.61	2.37e-14	Lung cancer;Squamous cell lung carcinoma;
TGCT	cis	rs3812831	0.599	rs428636	chr13:114927133	T/C	cg06611532	chr13:114900021	NA	0.35	6.39	0.5	3.1e-9	Schizophrenia;
TGCT	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	5.61	0.45	1.27e-7	Alzheimer's disease;
TGCT	cis	rs7208859	0.623	rs1054400	chr17:29109954	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	4.83	0.4	3.98e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs889312	0.500	rs252906	chr5:56119190	G/T	cg12311346	chr5:56204834	C5orf35	-0.45	-4.87	-0.4	3.28e-6	Breast cancer;Breast cancer (early onset);
TGCT	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg13683864	chr3:40499215	RPL14	1.12	11.95	0.73	2.27e-22	Renal cell carcinoma;
TGCT	cis	rs7772486	0.905	rs9373486	chr6:146446024	C/G	cg23711669	chr6:146136114	FBXO30	-0.86	-9.69	-0.66	7.19e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg12311346	chr5:56204834	C5orf35	0.58	6.19	0.49	7.92e-9	Initial pursuit acceleration;
TGCT	cis	rs921968	0.541	rs585185	chr2:219457741	G/A	cg02176678	chr2:219576539	TTLL4	0.48	6.78	0.52	4.32e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs4851266	0.966	rs13018640	chr2:100821545	T/C	cg22139774	chr2:100720529	AFF3	-0.36	-5.4	-0.44	3.26e-7	Educational attainment;
TGCT	cis	rs7010267	0.623	rs13254554	chr8:120010805	T/C	cg17171407	chr8:119960777	TNFRSF11B	0.27	4.94	0.41	2.49e-6	Total body bone mineral density (age 45-60);
TGCT	cis	rs11098499	0.863	rs1552095	chr4:120460306	A/G	cg09307838	chr4:120376055	NA	0.71	6.69	0.52	6.71e-10	Corneal astigmatism;
TGCT	cis	rs2204008	0.837	rs12581130	chr12:38319387	A/G	cg26384229	chr12:38710491	ALG10B	0.79	6.97	0.53	1.67e-10	Bladder cancer;
TGCT	cis	rs9486715	0.838	rs6928442	chr6:96870118	A/G	cg06623918	chr6:96969491	KIAA0776	1.11	16.62	0.83	2.35e-33	Headache;
TGCT	cis	rs7666738	1.000	rs880473	chr4:98922596	C/T	cg05340658	chr4:99064831	C4orf37	0.51	5.0	0.41	1.88e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs74233809	1.000	rs2297787	chr10:104680137	T/A	cg05855489	chr10:104503620	C10orf26	0.77	4.49	0.37	1.61e-5	Birth weight;
TGCT	cis	rs6089829	0.888	rs4809467	chr20:61671688	A/G	cg08045932	chr20:61659980	NA	0.5	8.69	0.62	1.75e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7399018	0.739	rs7953955	chr12:51608467	A/G	cg25754956	chr12:51612065	POU6F1	0.96	10.38	0.68	1.47e-18	Cisplatin-induced ototoxicity;
TGCT	cis	rs3806843	1.000	rs2240694	chr5:140183058	G/A	cg19875535	chr5:140030758	IK	0.37	6.34	0.49	3.89e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs6840360	0.615	rs4696268	chr4:152464723	G/A	cg17479576	chr4:152424074	FAM160A1	-0.72	-7.98	-0.58	8.25e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs7940866	0.801	rs10894300	chr11:130845943	A/G	cg12179176	chr11:130786555	SNX19	0.62	5.95	0.47	2.57e-8	Schizophrenia;
TGCT	cis	rs13177918	0.677	rs13161417	chr5:149822500	G/C	cg14059543	chr5:149831962	NA	-0.71	-9.46	-0.65	2.58e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs735396	0.731	rs1182933	chr12:121454622	C/T	cg15155738	chr12:121454335	C12orf43	0.54	4.74	0.39	5.81e-6	N-glycan levels;
TGCT	cis	rs11148252	0.574	rs9536247	chr13:53279542	T/C	cg02158880	chr13:53174818	NA	0.4	4.84	0.4	3.7e-6	Lewy body disease;
TGCT	cis	rs8177253	0.665	rs4525863	chr3:133436136	C/A	cg08048268	chr3:133502702	NA	-0.54	-7.11	-0.54	8.1e-11	Iron status biomarkers;
TGCT	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg21724239	chr8:58056113	NA	0.47	5.05	0.41	1.54e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7666738	0.791	rs2903142	chr4:99040071	C/T	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9644630	0.672	rs12542081	chr8:19317786	G/T	cg06699216	chr8:19333253	CSGALNACT1	-0.27	-4.77	-0.39	5.04e-6	Oropharynx cancer;
TGCT	cis	rs4499344	0.805	rs12978075	chr19:33067852	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.7	-6.18	-0.49	8.37e-9	Mean platelet volume;
TGCT	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg11494091	chr17:61959527	GH2	0.61	14.8	0.8	3.65e-29	Prudent dietary pattern;
TGCT	cis	rs6762	0.748	rs7936838	chr11:839093	G/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.47	-4.65	-0.39	8.32e-6	Mean platelet volume;
TGCT	cis	rs6088580	0.634	rs6141471	chr20:33006730	A/G	cg06115741	chr20:33292138	TP53INP2	-0.55	-4.81	-0.4	4.28e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg06481639	chr22:41940642	POLR3H	-0.69	-5.92	-0.47	2.95e-8	Vitiligo;
TGCT	cis	rs7267979	1.000	rs2259873	chr20:25280781	A/G	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs709400	0.663	rs1028613	chr14:103888324	G/A	cg26031613	chr14:104095156	KLC1	0.86	9.43	0.65	2.96e-16	Body mass index;
TGCT	cis	rs11792861	0.816	rs11790105	chr9:111731785	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.53	4.9	0.4	2.93e-6	Menarche (age at onset);
TGCT	cis	rs910316	0.699	rs175039	chr14:75468950	G/C	cg11812906	chr14:75593930	NEK9	-0.59	-5.59	-0.45	1.37e-7	Height;
TGCT	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg11247378	chr22:39784982	NA	-0.74	-9.64	-0.65	9.38e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs8176704	0.702	rs11244086	chr9:136191787	A/G	cg14012599	chr9:136805113	VAV2	0.33	4.6	0.38	1.01e-5	Coagulation factor levels;Low vWF levels;
TGCT	cis	rs10504229	1.000	rs59275611	chr8:58195191	G/A	cg22535103	chr8:58192502	C8orf71	-0.39	-4.6	-0.38	1.01e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7552404	0.883	rs7513363	chr1:76143443	A/G	cg22875332	chr1:76189707	ACADM	0.78	9.74	0.66	5.53e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs13256369	1.000	rs9329166	chr8:8576655	C/T	cg18904891	chr8:8559673	CLDN23	0.63	6.12	0.48	1.13e-8	Obesity-related traits;
TGCT	cis	rs2463822	1.000	rs7481995	chr11:62129312	G/C	cg23876832	chr11:62092739	NA	0.64	4.72	0.39	6.28e-6	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs9486715	1.000	rs11153082	chr6:97059666	A/G	cg18709589	chr6:96969512	KIAA0776	-0.81	-7.71	-0.57	3.5e-12	Headache;
TGCT	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.54	4.7	0.39	6.81e-6	Prudent dietary pattern;
TGCT	cis	rs4820539	0.966	rs5751587	chr22:23470090	G/A	cg21100191	chr22:23484243	RTDR1	0.89	10.61	0.69	4.23e-19	Bone mineral density;
TGCT	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg18735214	chr6:43276756	CRIP3	-0.56	-4.84	-0.4	3.76e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs1505368	0.532	rs2888093	chr2:213328348	G/A	cg16329650	chr2:213403929	ERBB4	0.84	9.7	0.66	6.76e-17	Symmetrical dimethylarginine levels;
TGCT	cis	rs2204008	0.805	rs3863360	chr12:37966432	C/T	cg26384229	chr12:38710491	ALG10B	0.85	7.77	0.57	2.56e-12	Bladder cancer;
TGCT	cis	rs6700896	0.500	rs6690625	chr1:66077590	T/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.63	5.01	0.41	1.81e-6	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs2230307	0.536	rs561119	chr1:100603891	G/A	cg24955406	chr1:100503596	HIAT1	-0.73	-4.96	-0.41	2.27e-6	Carotid intima media thickness;
TGCT	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg06112835	chr11:68658793	MRPL21	0.5	8.47	0.61	5.89e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9611565	0.546	rs5758430	chr22:42109844	G/T	cg06634786	chr22:41940651	POLR3H	0.89	9.09	0.63	1.96e-15	Vitiligo;
TGCT	cis	rs9682041	0.825	rs6785326	chr3:170095145	T/C	cg11886554	chr3:170076028	SKIL	0.83	6.42	0.5	2.66e-9	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs9653442	0.835	rs7565967	chr2:100744683	G/T	cg22139774	chr2:100720529	AFF3	-0.44	-7.6	-0.56	6.3e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs11096990	0.613	rs6840578	chr4:39208616	A/G	cg20847110	chr4:39482781	LOC401127	0.16	4.53	0.38	1.36e-5	Cognitive function;
TGCT	cis	rs7000551	0.751	rs2443494	chr8:22372262	C/G	cg12081754	chr8:22256438	SLC39A14	0.3	4.87	0.4	3.26e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg18538332	chr22:24372958	LOC391322	-0.87	-9.98	-0.67	1.39e-17	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7208859	0.623	rs11658945	chr17:29122509	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs12478296	0.792	rs3924263	chr2:243005167	A/C	cg06360820	chr2:242988706	NA	-0.64	-5.35	-0.43	4.15e-7	Obesity-related traits;
TGCT	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.51	5.71	0.46	7.95e-8	Lymphocyte counts;
TGCT	trans	rs7819412	0.806	rs2409689	chr8:10932868	A/G	cg06636001	chr8:8085503	FLJ10661	-0.77	-7.06	-0.54	1.06e-10	Triglycerides;
TGCT	cis	rs1577917	1.000	rs12209127	chr6:86724427	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.13	-0.42	1.07e-6	Response to antipsychotic treatment;
TGCT	cis	rs11690935	0.959	rs6722757	chr2:172591963	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.18	-12.51	-0.75	9.78e-24	Schizophrenia;
TGCT	cis	rs1577917	0.958	rs13219504	chr6:86556917	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-5.25	-0.43	6.3e-7	Response to antipsychotic treatment;
TGCT	cis	rs4665630	0.522	rs114382704	chr2:23951810	G/T	cg08063864	chr2:24346004	PFN4;LOC375190	1.19	5.14	0.42	1.06e-6	Hypertension;
TGCT	cis	rs9394169	0.533	rs4713675	chr6:33718418	C/T	cg13859433	chr6:33739653	LEMD2	-0.31	-5.19	-0.42	8.5e-7	Essential tremor;
TGCT	cis	rs634534	0.561	rs613924	chr11:65769295	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.65	6.42	0.5	2.59e-9	Sum eosinophil basophil counts;Eosinophil counts;
TGCT	cis	rs2115630	0.902	rs8023276	chr15:85219638	C/T	cg17173187	chr15:85201210	NMB	-0.41	-5.2	-0.42	7.89e-7	P wave terminal force;
TGCT	cis	rs12136530	0.774	rs12092284	chr1:19778323	C/T	cg18923740	chr1:19971790	NBL1	0.37	4.55	0.38	1.27e-5	Lead levels in blood;
TGCT	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg08736216	chr1:53307985	ZYG11A	-0.25	-4.68	-0.39	7.33e-6	Monocyte count;
TGCT	cis	rs6500602	0.627	rs709632	chr16:4587811	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.4	-7.18	-0.54	5.64e-11	Schizophrenia;
TGCT	cis	rs7659604	0.702	rs61217486	chr4:122693973	T/C	cg06713675	chr4:122721982	EXOSC9	-0.57	-7.77	-0.57	2.59e-12	Type 2 diabetes;
TGCT	cis	rs72781680	0.716	rs6718631	chr2:24036086	A/G	cg08917208	chr2:24149416	ATAD2B	-0.78	-4.85	-0.4	3.62e-6	Lymphocyte counts;
TGCT	cis	rs2299587	0.560	rs7814692	chr8:17780157	G/A	cg01800426	chr8:17659068	MTUS1	-0.71	-6.02	-0.48	1.8e-8	Economic and political preferences;
TGCT	cis	rs1153858	1.000	rs1890565	chr15:45663299	T/C	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.62e-8	Homoarginine levels;
TGCT	cis	rs17376456	1.000	rs17376456	chr5:93557702	C/T	cg25358565	chr5:93447407	FAM172A	-0.94	-7.79	-0.57	2.26e-12	Diabetic retinopathy;
TGCT	cis	rs7666738	0.546	rs6827131	chr4:98744810	C/G	cg05340658	chr4:99064831	C4orf37	0.52	5.76	0.46	6.27e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2535633	0.820	rs7626551	chr3:52938092	C/G	cg11645453	chr3:52864694	ITIH4	-0.28	-5.37	-0.43	3.77e-7	Body mass index;
TGCT	cis	rs3806843	1.000	rs10073974	chr5:140165231	T/C	cg19875535	chr5:140030758	IK	0.37	6.34	0.49	3.89e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs5167	0.566	rs35080293	chr19:45496624	T/G	cg09555818	chr19:45449301	APOC2	0.24	4.83	0.4	3.96e-6	Blood protein levels;
TGCT	cis	rs6940638	0.956	rs10946899	chr6:27023694	T/A	cg05738196	chr6:26577821	NA	-0.5	-4.5	-0.37	1.52e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs28595532	0.920	rs116305850	chr4:119779892	A/G	cg21605333	chr4:119757512	SEC24D	1.53	8.87	0.62	6.71e-15	Cannabis dependence symptom count;
TGCT	cis	rs10858047	0.883	rs12039811	chr1:115107550	T/C	cg12756093	chr1:115239321	AMPD1	0.47	4.96	0.41	2.27e-6	Autism;
TGCT	cis	rs9952991	0.883	rs2542147	chr18:12775851	G/T	cg23544223	chr18:12777786	NA	0.63	6.02	0.48	1.85e-8	Inflammatory skin disease;
TGCT	cis	rs17376456	0.825	rs1470150	chr5:93138654	C/T	cg21475434	chr5:93447410	FAM172A	-0.63	-5.27	-0.43	5.89e-7	Diabetic retinopathy;
TGCT	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg00149659	chr3:10157352	C3orf10	1.17	7.24	0.55	4.13e-11	Alzheimer's disease;
TGCT	cis	rs2242116	0.743	rs11719795	chr3:46951935	T/C	cg02527881	chr3:46936655	PTH1R	-0.28	-5.05	-0.41	1.55e-6	Birth weight;
TGCT	cis	rs7917772	0.636	rs4418737	chr10:104525123	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.56	-4.59	-0.38	1.07e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs4478858	0.735	rs3806255	chr1:31791578	A/G	cg07478791	chr1:31886160	SERINC2	-0.51	-4.94	-0.41	2.47e-6	Alcohol dependence;
TGCT	cis	rs9653442	0.545	rs13415465	chr2:100764004	T/G	cg07810366	chr2:100720526	AFF3	-0.36	-5.31	-0.43	4.89e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs7818688	0.697	rs112076731	chr8:95978121	C/G	cg16049864	chr8:95962084	TP53INP1	0.54	4.64	0.38	8.87e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs425277	0.585	rs364677	chr1:2071765	A/G	cg24578937	chr1:2090814	PRKCZ	-0.25	-6.39	-0.5	2.97e-9	Height;
TGCT	cis	rs7027203	0.828	rs10821229	chr9:96595136	A/C	cg14396892	chr9:96623032	NA	-0.26	-5.46	-0.44	2.51e-7	DNA methylation (variation);
TGCT	cis	rs9611565	0.649	rs4822050	chr22:42177453	C/G	cg06481639	chr22:41940642	POLR3H	-0.55	-4.71	-0.39	6.54e-6	Vitiligo;
TGCT	cis	rs11958404	0.858	rs72818142	chr5:157474934	C/T	cg05962755	chr5:157440814	NA	0.35	4.48	0.37	1.65e-5	IgG glycosylation;
TGCT	cis	rs9291683	0.588	rs6844329	chr4:10018544	T/C	cg11266682	chr4:10021025	SLC2A9	0.73	10.98	0.7	5.33e-20	Bone mineral density;
TGCT	cis	rs9910055	0.529	rs228748	chr17:42174390	G/A	cg13607699	chr17:42295918	UBTF	-0.63	-5.26	-0.43	6.1e-7	Total body bone mineral density;
TGCT	cis	rs17102423	0.788	rs61987428	chr14:65606156	T/C	cg11161011	chr14:65562177	MAX	-0.46	-6.06	-0.48	1.51e-8	Obesity-related traits;
TGCT	cis	rs3733585	0.673	rs116046986	chr4:9957794	A/G	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.71	-0.57	3.55e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs9467773	0.620	rs2451737	chr6:26619041	T/C	cg15659132	chr6:26577336	NA	0.84	10.91	0.7	7.83e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs7772486	0.720	rs6931553	chr6:146112348	T/C	cg13319975	chr6:146136371	FBXO30	0.58	5.24	0.43	6.75e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7666738	0.716	rs11097615	chr4:99092773	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.65	0.45	1.04e-7	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs1499614	1.000	rs2659903	chr7:66180931	G/A	cg07424592	chr7:64974309	NA	1.35	8.11	0.59	4.14e-13	Gout;
TGCT	cis	rs5769765	0.908	rs4824109	chr22:50271460	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	-0.41	-6.13	-0.48	1.08e-8	Schizophrenia;
TGCT	cis	rs858239	0.796	rs433395	chr7:23401955	G/T	cg05602783	chr7:23145260	KLHL7	-0.58	-4.75	-0.39	5.45e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs7027203	0.797	rs57882762	chr9:96580825	T/G	cg14396892	chr9:96623032	NA	-0.3	-6.26	-0.49	5.85e-9	DNA methylation (variation);
TGCT	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg27454412	chr7:1067447	C7orf50	0.58	4.54	0.38	1.3e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs6690583	0.623	rs61768853	chr1:85455707	T/C	cg20280350	chr1:85513789	MCOLN3	-0.74	-5.11	-0.42	1.2e-6	Serum sulfate level;
TGCT	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg10862848	chr6:42927986	GNMT	-0.38	-4.72	-0.39	6.35e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs7267979	0.966	rs3827014	chr20:25371559	C/T	cg14121845	chr20:25566513	NINL	-0.5	-5.34	-0.43	4.25e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg18305652	chr10:134549665	INPP5A	0.31	5.3	0.43	5.01e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs6121246	0.909	rs6087778	chr20:30354142	G/A	cg18721089	chr20:30220636	NA	-0.43	-4.75	-0.39	5.54e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs7020830	0.858	rs1492714	chr9:37141259	T/C	cg14294708	chr9:37120828	ZCCHC7	1.31	20.37	0.88	2.24e-41	Schizophrenia;
TGCT	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg26338869	chr17:61819248	STRADA	-0.53	-4.87	-0.4	3.29e-6	Prudent dietary pattern;
TGCT	cis	rs7584330	0.737	rs10445707	chr2:238368751	A/G	cg14458575	chr2:238380390	NA	0.51	8.25	0.6	1.91e-13	Prostate cancer;
TGCT	cis	rs4455778	0.580	rs4268080	chr7:49117682	A/G	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs7727544	0.606	rs11950562	chr5:131652529	A/C	cg14196790	chr5:131705035	SLC22A5	0.35	4.83	0.4	3.96e-6	Blood metabolite levels;
TGCT	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg11644478	chr21:40555479	PSMG1	1.02	11.05	0.7	3.46e-20	Cognitive function;
TGCT	cis	rs7014346	0.740	rs4871788	chr8:128421785	G/A	cg04263511	chr8:128962092	PVT1	-0.33	-4.71	-0.39	6.51e-6	Colorectal cancer;
TGCT	cis	rs7085104	0.660	rs7902804	chr10:104585405	A/T	cg15744005	chr10:104629667	AS3MT	-0.42	-5.2	-0.42	8.04e-7	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs17376456	0.877	rs13156865	chr5:93390908	C/A	cg25358565	chr5:93447407	FAM172A	0.92	8.38	0.6	9.58e-14	Diabetic retinopathy;
TGCT	cis	rs6430585	0.528	rs309151	chr2:136661150	C/T	cg07169764	chr2:136633963	MCM6	1.25	12.39	0.74	1.91e-23	Corneal structure;
TGCT	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg19723775	chr5:179050963	HNRNPH1	0.55	5.5	0.44	2.07e-7	Lung cancer;
TGCT	cis	rs6138458	1.000	rs6138458	chr20:24973769	C/T	cg26195577	chr20:24973756	C20orf3	1.22	12.1	0.74	9.98e-23	Blood protein levels;
TGCT	cis	rs6582630	0.502	rs11520276	chr12:38359216	C/T	cg26384229	chr12:38710491	ALG10B	0.83	7.23	0.54	4.33e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg07061783	chr6:25882402	NA	-0.84	-8.78	-0.62	1.1e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs1372520	0.684	rs356162	chr4:90697157	T/C	cg15133208	chr4:90757351	SNCA	0.47	5.58	0.45	1.43e-7	Neuroticism;
TGCT	cis	rs7176093	0.665	rs17581281	chr15:86386197	C/T	cg22461649	chr15:86468928	NA	-0.31	-5.28	-0.43	5.54e-7	Aging traits;
TGCT	cis	rs10509586	0.522	rs1475274	chr10:91698909	A/G	cg25278353	chr10:91717815	NA	0.43	5.13	0.42	1.08e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
TGCT	cis	rs7216064	0.953	rs58141639	chr17:65864902	C/T	cg12091567	chr17:66097778	LOC651250	-0.83	-6.49	-0.5	1.9e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs9914988	0.832	rs34901720	chr17:27179518	A/G	cg20469991	chr17:27169893	C17orf63	-0.72	-4.8	-0.4	4.45e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs9911578	0.904	rs7209253	chr17:56908987	C/T	cg12560992	chr17:57184187	TRIM37	0.76	9.21	0.64	1.03e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs250677	1.000	rs36080	chr5:148430451	A/G	cg23229984	chr5:148520753	ABLIM3	0.21	4.97	0.41	2.18e-6	Breast cancer;
TGCT	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg18867708	chr6:26865862	GUSBL1	-0.39	-5.16	-0.42	9.66e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2243480	0.901	rs778730	chr7:65823325	T/A	cg07424592	chr7:64974309	NA	1.27	7.29	0.55	3.13e-11	Diabetic kidney disease;
TGCT	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg21963583	chr11:68658836	MRPL21	0.36	6.01	0.47	1.94e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7552404	0.731	rs12078299	chr1:76365764	T/A	cg03433033	chr1:76189801	ACADM	0.74	7.01	0.53	1.34e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9911578	0.835	rs10853006	chr17:56489076	G/A	cg05425664	chr17:57184151	TRIM37	0.61	5.68	0.45	9.14e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg05896524	chr21:47604654	C21orf56	0.45	4.72	0.39	6.2e-6	Testicular germ cell tumor;
TGCT	cis	rs11031096	0.502	rs4910875	chr11:4047855	C/G	cg18678763	chr11:4115507	RRM1	-0.5	-6.18	-0.49	8.41e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs9486719	1.000	rs2472882	chr6:96863474	C/T	cg06623918	chr6:96969491	KIAA0776	1.01	8.86	0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs11690935	0.959	rs2292815	chr2:172586651	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.19	-12.78	-0.75	2.24e-24	Schizophrenia;
TGCT	cis	rs1403694	0.695	rs3806689	chr3:186435077	A/G	cg12454167	chr3:186435060	KNG1	0.51	8.67	0.61	1.95e-14	Blood protein levels;
TGCT	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.96	7.8	0.57	2.16e-12	Platelet count;
TGCT	trans	rs1973993	0.691	rs553785	chr1:96895325	G/A	cg10631902	chr5:14652156	NA	0.4	10.92	0.7	7.19e-20	Weight;
TGCT	cis	rs12579753	0.917	rs6539580	chr12:82184765	T/C	cg07988820	chr12:82153109	PPFIA2	-0.59	-6.19	-0.49	7.93e-9	Resting heart rate;
TGCT	cis	rs2486288	0.656	rs8024620	chr15:45574329	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.8	-8.41	-0.6	8.03e-14	Glomerular filtration rate;
TGCT	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg08219700	chr8:58056026	NA	0.3	4.55	0.38	1.25e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.85	-9.0	-0.63	3.25e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg23172400	chr8:95962367	TP53INP1	-0.39	-6.52	-0.51	1.59e-9	Type 2 diabetes;
TGCT	cis	rs9787249	0.957	rs12239844	chr1:40217258	T/C	cg20968010	chr1:40505947	CAP1	-0.52	-4.91	-0.4	2.79e-6	Blood protein levels;
TGCT	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg03806693	chr22:41940476	POLR3H	-1.13	-12.67	-0.75	4.12e-24	Vitiligo;
TGCT	cis	rs10779751	0.770	rs2275527	chr1:11190646	A/G	cg08854313	chr1:11322531	MTOR	0.82	6.59	0.51	1.11e-9	Body mass index;
TGCT	cis	rs7169223	0.653	rs8042170	chr15:79096599	G/A	cg21242079	chr15:79101063	ADAMTS7	0.3	4.99	0.41	1.98e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
TGCT	trans	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg13565492	chr6:43139072	SRF	-0.75	-7.01	-0.53	1.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2072499	0.865	rs2758608	chr1:156202860	A/T	cg25208724	chr1:156163844	SLC25A44	0.97	10.22	0.68	3.76e-18	Testicular germ cell tumor;
TGCT	cis	rs60871478	0.636	rs73045423	chr7:893952	G/A	cg15782153	chr7:917662	C7orf20	0.54	4.92	0.4	2.74e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs11105298	0.786	rs10858867	chr12:89851166	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.7	-5.02	-0.41	1.79e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs7666738	0.962	rs17550217	chr4:98999699	T/A	cg05340658	chr4:99064831	C4orf37	0.46	4.59	0.38	1.09e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7914558	0.966	rs10786745	chr10:104956827	A/G	cg04362960	chr10:104952993	NT5C2	0.62	5.53	0.44	1.8e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg00908189	chr16:619842	PIGQ	0.85	10.4	0.68	1.33e-18	Height;
TGCT	cis	rs7647973	0.593	rs58339610	chr3:49845006	T/A	cg03034192	chr3:50606346	HEMK1;C3orf18	-0.36	-4.83	-0.4	3.96e-6	Menarche (age at onset);
TGCT	cis	rs7829975	0.540	rs2976909	chr8:8346690	C/T	cg15556689	chr8:8085844	FLJ10661	-0.53	-5.14	-0.42	1.05e-6	Mood instability;
TGCT	cis	rs10992471	0.603	rs10118939	chr9:95293641	C/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.6	-5.63	-0.45	1.13e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs42648	0.869	rs2027965	chr7:89912513	C/T	cg25739043	chr7:89950458	NA	-0.73	-7.31	-0.55	2.87e-11	Homocysteine levels;
TGCT	cis	rs838147	0.537	rs504963	chr19:49208865	G/A	cg13540341	chr19:49222985	MAMSTR	-0.38	-5.0	-0.41	1.9e-6	Dietary macronutrient intake;
TGCT	cis	rs12220898	0.749	rs4310533	chr10:50482625	C/G	cg06072769	chr10:50146962	WDFY4	0.39	5.1	0.42	1.23e-6	Inflammatory biomarkers;
TGCT	cis	rs478304	0.718	rs61744384	chr11:65387378	T/A	cg17480646	chr11:65405466	SIPA1	-0.5	-6.09	-0.48	1.3e-8	Acne (severe);
TGCT	cis	rs74233809	1.000	rs10883806	chr10:104713076	C/T	cg05855489	chr10:104503620	C10orf26	0.74	4.45	0.37	1.87e-5	Birth weight;
TGCT	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg27170947	chr2:26402098	FAM59B	-0.39	-4.46	-0.37	1.8e-5	Gut microbiome composition (summer);
TGCT	cis	rs1453308	0.935	rs11692300	chr2:237179958	C/T	cg19324714	chr2:237145437	ASB18	0.56	5.0	0.41	1.91e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs931608	1.000	rs11085534	chr19:22613229	A/G	cg15554505	chr19:22123728	NA	0.55	4.54	0.38	1.32e-5	Dental caries;Response to statins (LDL cholesterol change);
TGCT	cis	rs12477438	0.798	rs17708218	chr2:99696284	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-6.33	-0.49	4.01e-9	Chronic sinus infection;
TGCT	cis	rs2404602	0.646	rs3764245	chr15:77223176	G/C	cg23625390	chr15:77176239	SCAPER	0.39	4.96	0.41	2.24e-6	Blood metabolite levels;
TGCT	cis	rs79057730	0.599	rs79272827	chr7:807015	C/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.65	6.11	0.48	1.17e-8	Initial pursuit acceleration;
TGCT	cis	rs1150668	0.796	rs1052215	chr6:28348158	T/G	cg13525197	chr6:28411240	ZSCAN23	0.5	4.87	0.4	3.34e-6	Pubertal anthropometrics;
TGCT	cis	rs7772486	0.875	rs2224121	chr6:146343214	G/A	cg23711669	chr6:146136114	FBXO30	0.86	9.23	0.64	9.36e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3796352	0.764	rs11714902	chr3:53101544	G/C	cg27565382	chr3:53032988	SFMBT1	0.44	4.63	0.38	8.99e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs6543140	0.929	rs11465700	chr2:103057668	G/A	cg09003973	chr2:102972529	NA	0.54	4.61	0.38	9.8200000000000008e-06	Blood protein levels;
TGCT	cis	rs7772486	0.875	rs1331639	chr6:146431869	A/G	cg05347473	chr6:146136440	FBXO30	-0.54	-5.01	-0.41	1.86e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2549003	1.000	rs2070727	chr5:131820275	C/A	cg00255919	chr5:131827918	IRF1	0.2	4.7	0.39	6.92e-6	Asthma (sex interaction);
TGCT	cis	rs6683273	0.775	rs12567387	chr1:3226949	T/C	cg17435683	chr1:3230609	PRDM16	-0.4	-4.53	-0.38	1.35e-5	QRS duration;
TGCT	cis	rs11997175	0.574	rs4446694	chr8:33654978	A/G	ch.8.33884649F	chr8:33765107	NA	0.28	4.54	0.38	1.33e-5	Body mass index;
TGCT	cis	rs11599315	1.000	rs11599315	chr10:1343017	C/T	cg27336068	chr10:1336103	ADARB2	-0.36	-5.29	-0.43	5.43e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	cis	rs611744	0.934	rs1452021	chr8:109207886	A/G	cg21045802	chr8:109455806	TTC35	0.52	4.72	0.39	6.21e-6	Dupuytren's disease;
TGCT	cis	rs7308134	0.766	rs7966806	chr12:1988167	T/C	cg09189752	chr12:2113749	DCP1B	-0.58	-4.54	-0.38	1.29e-5	QRS duration in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4325129	1.000	rs6677055	chr1:159462452	G/T	cg07417683	chr1:159440267	NA	-0.45	-4.63	-0.38	9.16e-6	Obesity-related traits;
TGCT	cis	rs11677370	0.928	rs4849989	chr2:3814727	A/G	cg17052675	chr2:3827356	NA	-0.27	-4.71	-0.39	6.51e-6	Type 2 diabetes;
TGCT	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg06238570	chr21:40685208	BRWD1	-0.61	-6.34	-0.49	3.97e-9	Menarche (age at onset);
TGCT	cis	rs7267979	0.932	rs2387891	chr20:25470328	C/G	cg16686733	chr20:25566563	NINL	0.56	5.69	0.46	8.49e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7582180	0.764	rs4851293	chr2:100925106	A/T	cg14675211	chr2:100938903	LONRF2	0.51	4.93	0.4	2.61e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10883723	0.810	rs13287	chr10:104240438	A/G	cg05855489	chr10:104503620	C10orf26	-0.58	-5.05	-0.41	1.56e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs1371867	0.875	rs1619759	chr8:101337560	T/C	cg00191853	chr8:101177733	SPAG1	-0.23	-4.54	-0.38	1.3e-5	Atrioventricular conduction;
TGCT	cis	rs77741769	0.529	rs3213572	chr12:121205078	A/G	cg02419362	chr12:121203948	SPPL3	-0.19	-4.49	-0.37	1.63e-5	Mean corpuscular volume;
TGCT	cis	rs2224391	0.628	rs2753224	chr6:5244864	G/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.98	-6.21	-0.49	7.43e-9	Height;
TGCT	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.36	0.55	2.25e-11	Prudent dietary pattern;
TGCT	cis	rs10466239	0.730	rs2946992	chr10:43854279	T/C	cg08951903	chr10:44070173	ZNF239	0.83	4.85	0.4	3.7e-6	Telomere length;
TGCT	cis	rs8037137	0.915	rs60290423	chr15:91529452	T/C	cg23684204	chr15:91497937	RCCD1	0.4	4.68	0.39	7.32e-6	Platelet count;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
TGCT	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg03188948	chr7:1209495	NA	0.48	5.97	0.47	2.3e-8	Longevity;Endometriosis;
TGCT	cis	rs2075371	0.931	rs1646697	chr7:133999930	G/A	cg11752832	chr7:134001865	SLC35B4	0.7	6.44	0.5	2.41e-9	Mean platelet volume;
TGCT	cis	rs6988636	0.818	rs73339658	chr8:124173007	A/G	cg27053337	chr8:124217698	FAM83A	0.67	5.02	0.41	1.79e-6	Urinary uromodulin levels;
TGCT	cis	rs5769765	0.671	rs138833	chr22:50178917	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.32	4.59	0.38	1.09e-5	Schizophrenia;
TGCT	cis	rs931127	0.719	rs2127507	chr11:65454430	A/G	cg27068330	chr11:65405492	SIPA1	-0.63	-6.32	-0.49	4.26e-9	Systemic lupus erythematosus;
TGCT	cis	rs11673344	0.542	rs2562598	chr19:37516220	T/C	cg08039142	chr19:36980659	ZNF566	0.51	4.8	0.4	4.53e-6	Obesity-related traits;
TGCT	cis	rs7017914	0.967	rs3954897	chr8:71635955	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.03	-0.41	1.69e-6	Bone mineral density;
TGCT	cis	rs10779751	0.770	rs2015818	chr1:11170743	G/A	cg08854313	chr1:11322531	MTOR	0.81	7.89	0.58	1.37e-12	Body mass index;
TGCT	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	8.55	0.61	3.84e-14	Platelet count;
TGCT	cis	rs4237845	0.761	rs11172378	chr12:58298161	C/T	cg02175503	chr12:58329896	NA	0.49	4.69	0.39	7.02e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10992471	0.603	rs7045572	chr9:95137964	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.61	-5.59	-0.45	1.36e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs3125734	0.633	rs4979773	chr10:63967731	G/C	cg05499367	chr10:63213510	TMEM26	-0.35	-4.85	-0.4	3.7e-6	Rheumatoid arthritis;
TGCT	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg04025307	chr7:1156635	C7orf50	0.21	5.15	0.42	9.79e-7	Longevity;Endometriosis;
TGCT	cis	rs7044106	0.762	rs10491783	chr9:123450155	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	6.34	0.49	3.94e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs9910055	0.659	rs112114764	chr17:42201041	G/T	cg19774624	chr17:42201019	HDAC5	0.89	11.12	0.71	2.32e-20	Total body bone mineral density;
TGCT	cis	rs644799	0.526	rs534973	chr11:95633624	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.51	4.93	0.41	2.53e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs12638540	0.543	rs12487678	chr3:32603358	A/C	cg11605617	chr3:32612461	DYNC1LI1	0.77	5.08	0.42	1.34e-6	Mortality in heart failure;
TGCT	cis	rs13191362	0.507	rs1954806	chr6:163051858	G/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.59	-5.62	-0.45	1.18e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs174601	0.833	rs174541	chr11:61565908	T/C	cg19610905	chr11:61596333	FADS2	-1.1	-11.4	-0.72	4.93e-21	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
TGCT	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.07	0.82	4.17e-32	Prudent dietary pattern;
TGCT	cis	rs6901250	0.851	rs607372	chr6:117155929	A/G	cg12892004	chr6:117198278	RFX6	-0.54	-6.65	-0.51	8.24e-10	C-reactive protein levels;
TGCT	cis	rs611744	0.934	rs609102	chr8:109227406	A/G	cg21045802	chr8:109455806	TTC35	0.52	4.72	0.39	6.21e-6	Dupuytren's disease;
TGCT	cis	rs1215050	0.740	rs6854802	chr4:99065480	A/C	cg17366294	chr4:99064904	C4orf37	0.58	6.15	0.48	9.93e-9	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg07507251	chr3:52567010	NT5DC2	0.47	6.64	0.51	8.85e-10	Bipolar disorder;
TGCT	cis	rs10779751	1.000	rs1135172	chr1:11301714	C/T	cg08854313	chr1:11322531	MTOR	-0.97	-10.22	-0.68	3.79e-18	Body mass index;
TGCT	cis	rs57590327	0.503	rs12638997	chr3:81844912	A/G	cg07356753	chr3:81810745	GBE1	-0.67	-6.15	-0.48	9.91e-9	Extraversion;
TGCT	cis	rs78545713	1.000	rs78545713	chr6:26248840	A/G	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.7	-4.44	-0.37	1.93e-5	Iron status biomarkers (total iron binding capacity);
TGCT	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg22535103	chr8:58192502	C8orf71	-0.41	-4.81	-0.4	4.27e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs228437	0.507	rs382498	chr6:134907441	T/C	cg09872934	chr6:134495829	SGK1	0.51	4.61	0.38	1e-5	Melanoma;
TGCT	cis	rs727505	0.521	rs66787780	chr7:124791849	G/A	cg23710748	chr7:124431027	NA	-0.26	-4.51	-0.38	1.47e-5	Lewy body disease;
TGCT	cis	rs2762353	0.902	rs3799344	chr6:25786993	C/T	cg03264133	chr6:25882463	NA	0.47	4.9	0.4	2.91e-6	Blood metabolite levels;
TGCT	cis	rs9467773	0.620	rs2451738	chr6:26618459	A/T	cg11502198	chr6:26597334	ABT1	-0.52	-4.91	-0.4	2.75e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs35306767	0.903	rs765867	chr10:869901	G/T	cg26597838	chr10:835615	NA	0.71	10.12	0.67	6.47e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs10883723	0.810	rs3781289	chr10:104244991	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs12210905	0.688	rs79018549	chr6:27513460	G/A	cg08851530	chr6:28072375	NA	1.34	6.29	0.49	5.02e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs9467711	1.000	rs6939799	chr6:26328366	G/A	cg16898833	chr6:26189333	HIST1H4D	1.04	5.51	0.44	1.97e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg20007245	chr22:24372913	LOC391322	-0.77	-8.15	-0.59	3.28e-13	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg23131131	chr22:24373011	LOC391322	-0.8	-8.69	-0.62	1.78e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs3540	0.533	rs7495080	chr15:91056681	G/A	cg22089800	chr15:90895588	ZNF774	-0.74	-7.56	-0.56	7.83e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	trans	rs7618501	0.521	rs11712056	chr3:49914397	T/C	cg21659725	chr3:3221576	CRBN	0.72	8.19	0.59	2.73e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg24675658	chr1:53192096	ZYG11B	-0.84	-10.27	-0.68	2.8e-18	Monocyte count;
TGCT	cis	rs933688	1.000	rs11959525	chr5:90703840	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.98	8.52	0.61	4.61e-14	Smoking behavior;
TGCT	cis	rs7432375	0.610	rs7633629	chr3:136517028	T/A	cg15507776	chr3:136538369	TMEM22	0.55	5.64	0.45	1.1e-7	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6921919	0.583	rs9468367	chr6:28360246	C/A	cg18815343	chr6:28367644	ZSCAN12	-0.56	-5.32	-0.43	4.76e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7178572	0.962	rs1022172	chr15:77793359	A/G	cg22256960	chr15:77711686	NA	-0.92	-10.57	-0.69	5.1e-19	Type 2 diabetes;
TGCT	cis	rs9486715	0.838	rs7770889	chr6:96858453	C/T	cg06623918	chr6:96969491	KIAA0776	-1.09	-14.0	-0.78	2.69e-27	Headache;
TGCT	cis	rs8084125	0.832	rs62105178	chr18:74950635	C/T	cg05528293	chr18:74961138	GALR1	0.52	5.18	0.42	8.65e-7	Obesity-related traits;
TGCT	cis	rs10791097	0.694	rs7125622	chr11:130743388	T/C	cg14779329	chr11:130786720	SNX19	0.28	4.82	0.4	4.09e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.93	-6.89	-0.53	2.52e-10	Gut microbiome composition (summer);
TGCT	cis	rs6570726	0.935	rs407721	chr6:145871354	A/C	cg23711669	chr6:146136114	FBXO30	0.71	7.03	0.53	1.25e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1153858	1.000	rs2453541	chr15:45645378	G/A	cg26924012	chr15:45694286	SPATA5L1	0.99	12.23	0.74	4.74e-23	Homoarginine levels;
TGCT	cis	rs17401966	0.838	rs6541089	chr1:10402785	A/G	cg19773385	chr1:10388646	KIF1B	-0.23	-5.38	-0.44	3.57e-7	Hepatocellular carcinoma;
TGCT	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg19626725	chr5:178986131	RUFY1	0.46	5.96	0.47	2.38e-8	Lung cancer;
TGCT	cis	rs210138	1.000	rs210138	chr6:33542538	C/T	cg24505687	chr6:33548425	BAK1	-0.53	-6.13	-0.48	1.06e-8	Testicular germ cell tumor;
TGCT	cis	rs7226408	0.857	rs7233017	chr18:34529710	C/T	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs2072499	0.966	rs2853641	chr1:156181770	A/G	cg24450063	chr1:156163899	SLC25A44	1.17	17.12	0.84	1.84e-34	Testicular germ cell tumor;
TGCT	cis	rs7772486	0.790	rs7753833	chr6:146161432	C/A	cg23711669	chr6:146136114	FBXO30	0.91	10.4	0.68	1.38e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1499614	1.000	rs1882655	chr7:66147057	T/C	cg18252515	chr7:66147081	NA	1.26	7.95	0.58	9.71e-13	Gout;
TGCT	cis	rs6866344	0.697	rs62392831	chr5:178134365	A/G	cg10224037	chr5:178157518	ZNF354A	0.95	8.47	0.61	6.06e-14	Neutrophil percentage of white cells;
TGCT	cis	rs208520	0.690	rs1580430	chr6:66715162	T/A	cg07460842	chr6:66804631	NA	0.96	10.21	0.68	3.9e-18	Exhaled nitric oxide output;
TGCT	cis	rs617219	0.671	rs2607144	chr5:78556798	G/T	cg05890484	chr5:78407552	BHMT	0.4	5.27	0.43	5.84e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs7666738	0.830	rs11935588	chr4:98979862	A/G	cg18180107	chr4:99064573	C4orf37	-0.57	-5.11	-0.42	1.19e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9640161	0.789	rs2159234	chr7:150020422	A/T	cg10018233	chr7:150070692	REPIN1	0.32	4.63	0.38	8.98e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs2228479	0.867	rs75110337	chr16:89962635	C/A	cg06558623	chr16:89946397	TCF25	0.57	6.89	0.53	2.56e-10	Skin colour saturation;
TGCT	cis	rs2072499	0.833	rs2251636	chr1:156202809	G/C	cg06970220	chr1:156163860	SLC25A44	0.66	6.01	0.47	1.92e-8	Testicular germ cell tumor;
TGCT	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg04154034	chr17:28927549	LRRC37B2	0.74	4.56	0.38	1.22e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs36093844	0.898	rs80079882	chr11:85590955	T/C	cg25872744	chr11:85566296	CCDC83	-0.52	-4.73	-0.39	6.09e-6	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
TGCT	cis	rs904251	0.504	rs1757188	chr6:37483808	A/G	cg25019722	chr6:37503610	NA	-0.51	-7.96	-0.58	9.09e-13	Cognitive performance;
TGCT	cis	rs2074585	0.646	rs2589964	chr15:90922757	A/G	cg22089800	chr15:90895588	ZNF774	0.82	9.04	0.63	2.61e-15	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
TGCT	cis	rs12367572	1.000	rs7304472	chr12:45262324	A/G	cg04608330	chr12:45269318	NELL2	-0.64	-6.56	-0.51	1.33e-9	Gut microbiome composition (summer);
TGCT	cis	rs9467773	0.511	rs11755443	chr6:26891603	T/C	cg26531700	chr6:26746687	NA	0.85	8.37	0.6	1.01e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg10560079	chr2:191398806	TMEM194B	0.37	5.33	0.43	4.5e-7	Pulse pressure;
TGCT	cis	rs2594989	0.943	rs62245870	chr3:11439838	G/A	cg00170343	chr3:11313890	ATG7	0.66	4.99	0.41	1.96e-6	Circulating chemerin levels;
TGCT	cis	rs9611565	0.546	rs5758426	chr22:42098763	T/G	cg13695892	chr22:41940480	POLR3H	0.85	8.19	0.59	2.72e-13	Vitiligo;
TGCT	cis	rs2243480	1.000	rs1638734	chr7:66097539	A/C	cg18252515	chr7:66147081	NA	-1.23	-7.53	-0.56	9.12e-12	Diabetic kidney disease;
TGCT	cis	rs1729951	0.575	rs1682356	chr3:136692037	T/C	cg12473912	chr3:136751656	NA	0.39	6.18	0.49	8.36e-9	Neuroticism;
TGCT	cis	rs13256369	0.789	rs13282500	chr8:8568489	A/T	cg18904891	chr8:8559673	CLDN23	0.6	5.51	0.44	1.99e-7	Obesity-related traits;
TGCT	cis	rs13256369	0.802	rs11249884	chr8:8561552	C/T	cg17143192	chr8:8559678	CLDN23	-0.54	-5.14	-0.42	1.04e-6	Obesity-related traits;
TGCT	cis	rs7267979	1.000	rs13038834	chr20:25441433	C/T	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6840360	0.667	rs9994482	chr4:152391230	T/C	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.82e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7119	0.651	rs12917431	chr15:77850184	C/G	cg27398640	chr15:77910606	LINGO1	-0.27	-5.15	-0.42	1.01e-6	Type 2 diabetes;
TGCT	cis	rs6684514	1.000	rs6679145	chr1:156256000	T/C	cg20302342	chr1:156215951	PAQR6	0.34	4.6	0.38	1.01e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs2019216	0.500	rs2169916	chr17:21884670	G/C	cg22648282	chr17:21454238	C17orf51	-0.55	-5.09	-0.42	1.3e-6	Pelvic organ prolapse;
TGCT	cis	rs854765	0.927	rs12943914	chr17:17980671	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.64	6.23	0.49	6.59e-9	Total body bone mineral density;
TGCT	trans	rs12191082	0.878	rs2021916	chr6:46914521	G/T	cg15621338	chr7:128577916	IRF5	-1.05	-7.13	-0.54	7.15e-11	Mean platelet volume;
TGCT	cis	rs929354	0.713	rs3802129	chr7:156965297	G/A	cg05182265	chr7:156933206	UBE3C	-0.39	-8.79	-0.62	1.03e-14	Body mass index;
TGCT	cis	rs7208859	0.673	rs61348930	chr17:29221763	C/T	cg14008862	chr17:28927542	LRRC37B2	0.72	4.66	0.39	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg15242686	chr22:24348715	GSTTP1	0.42	5.41	0.44	3.07e-7	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2013441	0.932	rs3850785	chr17:20185248	A/G	cg18979559	chr17:20280153	CCDC144C	-0.45	-4.67	-0.39	7.61e-6	Obesity-related traits;
TGCT	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7617773	0.780	rs13085251	chr3:48340045	C/T	cg11946769	chr3:48343235	NME6	0.82	7.06	0.54	1.03e-10	Coronary artery disease;
TGCT	cis	rs6598955	0.724	rs6656716	chr1:26563105	G/A	cg04990556	chr1:26633338	UBXN11	-0.91	-12.03	-0.73	1.46e-22	Obesity-related traits;
TGCT	cis	rs28785552	0.897	rs7259466	chr19:53239369	G/A	cg10871876	chr19:53194124	ZNF83	0.6	8.78	0.62	1.07e-14	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs11578119	0.898	rs10919405	chr1:170417755	A/G	cg09767346	chr1:170501363	GORAB	0.71	5.69	0.46	8.66e-8	Male-pattern baldness;
TGCT	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg20607798	chr8:58055168	NA	0.58	4.67	0.39	7.56e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7095607	0.813	rs10997963	chr10:69921903	A/G	cg18986048	chr10:69913749	MYPN	-0.47	-5.49	-0.44	2.2e-7	Lung function (FVC);
TGCT	cis	rs7524258	0.868	rs1304711	chr1:7270320	G/T	cg07173049	chr1:7289937	CAMTA1	-0.29	-4.89	-0.4	3.1e-6	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs78707713	0.560	rs61848436	chr10:71247714	C/T	cg12610070	chr10:71211762	TSPAN15	-0.63	-7.48	-0.56	1.2e-11	Venous thromboembolism;
TGCT	cis	rs587847	0.540	rs601024	chr15:37683048	A/G	cg16890051	chr15:37175029	LOC145845	-0.37	-4.44	-0.37	1.95e-5	Intraocular pressure;
TGCT	cis	rs17376456	0.597	rs6869110	chr5:93355531	G/A	cg25358565	chr5:93447407	FAM172A	-0.63	-6.03	-0.48	1.79e-8	Diabetic retinopathy;
TGCT	cis	rs6582630	0.519	rs7294300	chr12:38277359	C/A	cg13010199	chr12:38710504	ALG10B	0.64	4.97	0.41	2.15e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs9911578	0.967	rs57869245	chr17:57106630	A/G	cg05425664	chr17:57184151	TRIM37	0.64	6.49	0.5	1.84e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs57545798	0.500	rs36094016	chr15:100643420	T/C	cg04622200	chr15:100654734	ADAMTS17	0.33	5.59	0.45	1.38e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2230307	0.656	rs644835	chr1:100543962	A/G	cg24955406	chr1:100503596	HIAT1	0.81	4.87	0.4	3.32e-6	Carotid intima media thickness;
TGCT	cis	rs7954584	0.616	rs10743185	chr12:122356435	G/A	cg22168489	chr12:122356033	WDR66	0.23	5.55	0.45	1.63e-7	Mean corpuscular volume;
TGCT	cis	rs11239930	0.538	rs618575	chr1:146552308	A/C	cg00044796	chr1:146552390	NA	-0.34	-4.46	-0.37	1.84e-5	AIDS progression;
TGCT	cis	rs9534288	0.797	rs9534276	chr13:46574317	T/G	cg15192986	chr13:46630673	CPB2	-0.53	-7.62	-0.56	5.82e-12	Blood protein levels;
TGCT	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg07507251	chr3:52567010	NT5DC2	0.49	7.17	0.54	6.03e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs422249	0.613	rs174465	chr11:61658800	C/T	cg19610905	chr11:61596333	FADS2	0.63	5.53	0.44	1.83e-7	Trans fatty acid levels;
TGCT	cis	rs17331151	0.573	rs2240916	chr3:52859212	T/A	cg11137980	chr3:52469226	SEMA3G	0.27	4.83	0.4	3.98e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs7100689	0.556	rs10788541	chr10:82016530	T/G	cg01528321	chr10:82214614	TSPAN14	0.71	6.72	0.52	6.03e-10	Post bronchodilator FEV1;
TGCT	cis	rs10488031	0.557	rs34616132	chr7:37085259	A/T	cg06458904	chr7:36312573	EEPD1	0.56	4.7	0.39	6.79e-6	QT interval;
TGCT	cis	rs208520	0.731	rs12206488	chr6:66999917	G/T	cg07460842	chr6:66804631	NA	0.78	6.57	0.51	1.25e-9	Exhaled nitric oxide output;
TGCT	cis	rs5769707	0.967	rs739241	chr22:50052921	G/A	cg10356904	chr22:49881777	NA	-0.23	-4.6	-0.38	1.02e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	trans	rs941408	1.000	rs1736180	chr19:2796021	C/T	cg22153745	chr1:153894579	GATAD2B	-0.62	-6.82	-0.52	3.54e-10	Total cholesterol levels;
TGCT	cis	rs6570726	0.791	rs425999	chr6:145819370	C/A	cg23711669	chr6:146136114	FBXO30	0.89	9.72	0.66	6.02e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg10802521	chr3:52805072	NEK4	-0.78	-10.01	-0.67	1.23e-17	Electroencephalogram traits;
TGCT	cis	rs7072216	0.763	rs3814142	chr10:100171104	C/G	cg26618903	chr10:100175079	PYROXD2	-0.4	-4.49	-0.37	1.64e-5	Metabolite levels;
TGCT	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-5.79	-0.46	5.39e-8	Alzheimer's disease;
TGCT	cis	rs9325144	0.534	rs1843866	chr12:38703160	G/T	cg26384229	chr12:38710491	ALG10B	0.68	6.27	0.49	5.35e-9	Morning vs. evening chronotype;
TGCT	cis	rs7267979	0.932	rs424487	chr20:25468131	C/G	cg03522245	chr20:25566470	NINL	0.6	6.46	0.5	2.14e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4443100	0.670	rs13054331	chr22:23407063	G/A	cg14186256	chr22:23484241	RTDR1	0.57	4.47	0.37	1.76e-5	Serum parathyroid hormone levels;
TGCT	cis	rs7666738	0.830	rs6855393	chr4:99056534	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.79	0.46	5.32e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg25427524	chr10:38739819	LOC399744	-0.39	-8.05	-0.59	5.9e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs68170813	0.652	rs17482494	chr7:107168487	T/C	cg02696742	chr7:106810147	HBP1	-0.58	-4.47	-0.37	1.74e-5	Coronary artery disease;
TGCT	cis	rs80033912	0.713	rs7629936	chr3:49836707	G/A	cg03060546	chr3:49711283	APEH	0.67	6.21	0.49	7.21e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs11122272	0.735	rs2790880	chr1:231534259	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-6.32	-0.49	4.29e-9	Hemoglobin concentration;
TGCT	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.43	-4.56	-0.38	1.22e-5	Blood metabolite levels;
TGCT	cis	rs9467773	0.967	rs1535276	chr6:26520941	T/C	cg15659132	chr6:26577336	NA	0.86	12.21	0.74	5.3e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs9581857	0.585	rs9581875	chr13:28099678	A/G	cg22138327	chr13:27999177	GTF3A	0.72	4.75	0.39	5.45e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs7666738	0.716	rs35195511	chr4:98859660	G/A	cg17366294	chr4:99064904	C4orf37	0.7	7.27	0.55	3.62e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12048904	0.619	rs3737581	chr1:101341083	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.67	5.23	0.43	7.03e-7	Multiple sclerosis;
TGCT	trans	rs1496653	0.602	rs35152860	chr3:23595594	G/T	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs7647973	1.000	rs11719762	chr3:49409002	G/C	cg07690219	chr3:49449608	TCTA;RHOA	-0.56	-4.6	-0.38	1.02e-5	Menarche (age at onset);
TGCT	cis	rs7647973	0.554	rs13096480	chr3:49658084	A/G	cg03060546	chr3:49711283	APEH	0.63	5.63	0.45	1.12e-7	Menarche (age at onset);
TGCT	cis	rs72717009	0.825	rs9427397	chr1:161476204	C/T	cg23840854	chr1:161414152	NA	-0.98	-5.87	-0.47	3.79e-8	Rheumatoid arthritis;
TGCT	cis	rs2832191	0.740	rs2853830	chr21:30416824	A/G	cg08807101	chr21:30365312	RNF160	0.65	6.11	0.48	1.19e-8	Dental caries;
TGCT	cis	rs6426558	0.537	rs56219094	chr1:227340191	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.58	-6.95	-0.53	1.88e-10	Neutrophil percentage of white cells;
TGCT	cis	rs7829975	0.542	rs7844374	chr8:8798684	A/G	cg15556689	chr8:8085844	FLJ10661	-0.71	-6.16	-0.48	9.13e-9	Mood instability;
TGCT	cis	rs7267979	0.932	rs417130	chr20:25458320	T/C	cg14121845	chr20:25566513	NINL	0.49	5.36	0.43	3.83e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg02463440	chr8:22132932	PIWIL2	0.26	5.14	0.42	1.05e-6	Hypertriglyceridemia;
TGCT	cis	rs9467773	0.584	rs1021372	chr6:26632444	T/C	cg11502198	chr6:26597334	ABT1	0.54	4.97	0.41	2.14e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs12286929	0.767	rs2507906	chr11:115009670	A/C	cg04017736	chr11:115827165	NA	0.19	4.44	0.37	1.99e-5	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs1215050	0.791	rs983187	chr4:98816350	A/T	cg17366294	chr4:99064904	C4orf37	0.56	6.05	0.48	1.57e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9911578	0.967	rs11079354	chr17:56594460	G/A	cg05425664	chr17:57184151	TRIM37	0.63	6.26	0.49	5.86e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7833790	0.777	rs1005850	chr8:82692255	G/A	cg17211192	chr8:82754475	SNX16	-1.04	-8.46	-0.6	6.42e-14	Diastolic blood pressure;
TGCT	cis	rs12368653	0.666	rs701007	chr12:58113416	C/A	cg12615879	chr12:58013172	SLC26A10	0.48	5.8	0.46	5.2e-8	Multiple sclerosis;
TGCT	trans	rs77457752	0.690	rs12349396	chr9:13912144	T/C	cg23609682	chr1:3070786	PRDM16	0.51	7.14	0.54	6.89e-11	Breast cancer;
TGCT	cis	rs17331151	0.573	rs13080929	chr3:52885112	A/C	cg27565382	chr3:53032988	SFMBT1	0.46	5.66	0.45	9.93e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs6490294	0.659	rs737280	chr12:112194976	T/C	cg10833066	chr12:111807467	FAM109A	0.32	4.96	0.41	2.25e-6	Mean platelet volume;
TGCT	cis	rs6460942	0.915	rs6965564	chr7:12306013	C/T	cg06484146	chr7:12443880	VWDE	-0.43	-4.6	-0.38	1.04e-5	Coronary artery disease;
TGCT	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg06634786	chr22:41940651	POLR3H	-0.88	-8.54	-0.61	3.98e-14	Vitiligo;
TGCT	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.59	4.87	0.4	3.29e-6	Tonsillectomy;
TGCT	cis	rs12291225	0.535	rs11023203	chr11:14409815	G/A	cg19336497	chr11:14380999	RRAS2	-0.32	-4.91	-0.4	2.82e-6	Sense of smell;
TGCT	trans	rs208520	1.000	rs12195505	chr6:66986279	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.83	7.46	0.56	1.31e-11	Exhaled nitric oxide output;
TGCT	cis	rs7809950	1.000	rs2520264	chr7:107179344	T/C	cg23024343	chr7:107201750	COG5	-0.35	-5.54	-0.45	1.72e-7	Coronary artery disease;
TGCT	cis	rs7103648	1.000	rs10838709	chr11:47447346	C/T	cg20307385	chr11:47447363	PSMC3	1.04	12.68	0.75	3.91e-24	Diastolic blood pressure;Systolic blood pressure;
TGCT	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg13206674	chr6:150067644	NUP43	0.56	4.68	0.39	7.37e-6	Lung cancer;
TGCT	cis	rs7095607	0.813	rs4746732	chr10:69931881	C/T	cg18986048	chr10:69913749	MYPN	0.46	5.24	0.43	6.63e-7	Lung function (FVC);
TGCT	cis	rs317689	0.702	rs544696	chr12:69749939	T/C	cg14784868	chr12:69753453	YEATS4	0.67	5.99	0.47	2.1e-8	Response to diuretic therapy;
TGCT	trans	rs208520	0.739	rs1935894	chr6:66891434	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-10.21	-0.68	4.02e-18	Exhaled nitric oxide output;
TGCT	cis	rs11711311	0.911	rs13321446	chr3:113522544	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.76	-6.89	-0.53	2.46e-10	IgG glycosylation;
TGCT	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-8.64	-0.61	2.39e-14	Platelet count;
TGCT	cis	rs4891159	0.548	rs617823	chr18:74120233	A/G	cg24786174	chr18:74118243	ZNF516	0.69	14.59	0.8	1.08e-28	Longevity;
TGCT	cis	rs17102423	0.530	rs4902357	chr14:65542067	C/G	cg11161011	chr14:65562177	MAX	-0.47	-6.48	-0.5	1.95e-9	Obesity-related traits;
TGCT	cis	rs10782582	0.609	rs1498311	chr1:76254726	A/C	cg05598546	chr1:76251766	SNORD45C;RABGGTB	-0.54	-4.79	-0.4	4.69e-6	Daytime sleep phenotypes;
TGCT	cis	rs1865760	0.865	rs9467648	chr6:25957933	T/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.64	6.29	0.49	4.91e-9	Height;
TGCT	cis	rs151997	1.000	rs152803	chr5:50212120	C/T	cg06027927	chr5:50259733	NA	0.47	4.83	0.4	3.9e-6	Callous-unemotional behaviour;
TGCT	cis	rs2354432	0.607	rs7553584	chr1:146693429	A/G	cg25205988	chr1:146714368	CHD1L	-1.33	-6.35	-0.5	3.68e-9	Mitochondrial DNA levels;
TGCT	cis	rs10206020	0.836	rs10202105	chr2:1553301	C/T	cg12573674	chr2:1569213	NA	-0.48	-4.83	-0.4	3.96e-6	IgG glycosylation;
TGCT	cis	rs9291683	0.609	rs7678012	chr4:9993772	T/C	cg11266682	chr4:10021025	SLC2A9	0.67	9.24	0.64	8.89e-16	Bone mineral density;
TGCT	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg06238570	chr21:40685208	BRWD1	0.8	9.09	0.63	1.95e-15	Cognitive function;
TGCT	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg09263875	chr16:632152	PIGQ	0.31	6.89	0.53	2.52e-10	Height;
TGCT	cis	rs1878931	0.501	rs28735976	chr16:3418419	G/A	cg05754148	chr16:3507555	NAT15	-0.33	-4.46	-0.37	1.82e-5	Body mass index (adult);
TGCT	cis	rs524281	0.861	rs2177054	chr11:65944612	C/A	cg00563793	chr11:65837595	PACS1	0.56	4.72	0.39	6.28e-6	Electroencephalogram traits;
TGCT	cis	rs36093844	0.904	rs7113656	chr11:85594739	T/C	cg25872744	chr11:85566296	CCDC83	-0.41	-4.54	-0.38	1.31e-5	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
TGCT	cis	rs61931739	0.500	rs11519123	chr12:34436478	A/G	cg06521331	chr12:34319734	NA	-0.29	-4.59	-0.38	1.07e-5	Morning vs. evening chronotype;
TGCT	cis	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg18252515	chr7:66147081	NA	-1.2	-7.83	-0.58	1.89e-12	Diabetic kidney disease;
TGCT	cis	rs2832191	0.740	rs2832175	chr21:30475606	A/G	cg08807101	chr21:30365312	RNF160	-0.66	-6.04	-0.48	1.63e-8	Dental caries;
TGCT	cis	rs6582630	0.519	rs11495373	chr12:38275470	T/C	cg26384229	chr12:38710491	ALG10B	0.86	7.44	0.56	1.46e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs7666738	0.822	rs28512427	chr4:98919029	G/A	cg18180107	chr4:99064573	C4orf37	0.55	5.02	0.41	1.78e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28595532	0.841	rs115907265	chr4:119730593	G/A	cg14228332	chr4:119757509	SEC24D	1.32	6.38	0.5	3.2e-9	Cannabis dependence symptom count;
TGCT	cis	rs7208859	0.623	rs7214570	chr17:29147164	A/G	cg13385521	chr17:29058706	SUZ12P	0.75	4.85	0.4	3.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs11874712	1.000	rs1800636	chr18:43670420	C/T	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	5.23	0.42	7.11e-7	Migraine - clinic-based;
TGCT	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg24531977	chr5:56204891	C5orf35	-0.76	-7.66	-0.57	4.53e-12	Initial pursuit acceleration;
TGCT	cis	rs7258465	1.000	rs4595905	chr19:18547305	T/A	cg06462663	chr19:18546047	ISYNA1	0.2	4.54	0.38	1.33e-5	Breast cancer;
TGCT	trans	rs17685	0.736	rs4732594	chr7:75753273	T/C	cg19862616	chr7:65841803	NCRNA00174	0.52	9.01	0.63	3.02e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs2549003	1.000	rs7734334	chr5:131815004	C/A	cg02551604	chr5:131831745	NA	-0.89	-11.77	-0.73	6.36e-22	Asthma (sex interaction);
TGCT	cis	rs3847687	0.901	rs12370258	chr12:131527301	G/T	cg25772418	chr12:131519998	GPR133	-0.26	-4.46	-0.37	1.83e-5	Longevity;
TGCT	cis	rs2463822	1.000	rs115395195	chr11:62100353	G/A	cg06239285	chr11:62104954	ASRGL1	-0.95	-6.56	-0.51	1.33e-9	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs137699	1.000	rs137703	chr22:39750241	A/G	cg11247378	chr22:39784982	NA	-0.44	-4.71	-0.39	6.48e-6	IgG glycosylation;
TGCT	cis	rs782590	0.608	rs10207590	chr2:55921782	G/C	cg03859395	chr2:55845619	SMEK2	-0.74	-7.9	-0.58	1.26e-12	Metabolic syndrome;
TGCT	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg04234412	chr22:24373322	LOC391322	-0.92	-10.92	-0.7	7.14e-20	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs3935685	0.874	rs11072662	chr15:77999436	A/G	cg03457338	chr15:78040120	NA	-0.22	-5.55	-0.45	1.64e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg09359103	chr1:154839909	KCNN3	-0.67	-12.46	-0.75	1.35e-23	Prostate cancer;
TGCT	cis	rs9611565	0.512	rs5751148	chr22:42139078	A/G	cg17554472	chr22:41940697	POLR3H	0.46	4.72	0.39	6.36e-6	Vitiligo;
TGCT	cis	rs62244186	0.520	rs9311361	chr3:44796132	T/G	cg04389838	chr3:44770851	ZNF501	-0.37	-4.83	-0.4	3.94e-6	Depressive symptoms;
TGCT	cis	rs741677	0.702	rs9893847	chr17:489043	C/G	cg15660573	chr17:549704	VPS53	-0.32	-4.47	-0.37	1.76e-5	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
TGCT	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg05368731	chr17:41323189	NBR1	1.19	13.98	0.78	2.93e-27	Menopause (age at onset);
TGCT	cis	rs1577917	0.666	rs6454471	chr6:86214456	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.59	5.15	0.42	1.01e-6	Response to antipsychotic treatment;
TGCT	cis	rs838147	0.507	rs1704773	chr19:49209566	A/G	cg00822241	chr19:49201468	FUT2	0.28	4.54	0.38	1.32e-5	Dietary macronutrient intake;
TGCT	cis	rs7659604	0.537	rs6815973	chr4:122663430	A/T	cg06713675	chr4:122721982	EXOSC9	0.59	7.09	0.54	9.18e-11	Type 2 diabetes;
TGCT	cis	rs72781680	0.851	rs12612830	chr2:24134599	C/T	cg08917208	chr2:24149416	ATAD2B	0.73	4.51	0.38	1.48e-5	Lymphocyte counts;
TGCT	cis	rs4788570	0.615	rs11075894	chr16:71690030	C/T	cg06353428	chr16:71660113	MARVELD3	1.55	12.51	0.75	9.87e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs644799	0.672	rs11021347	chr11:95653494	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	6.67	0.51	7.5e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs35306767	0.903	rs10904577	chr10:922077	A/G	cg20503657	chr10:835505	NA	0.74	10.3	0.68	2.41e-18	Eosinophil percentage of granulocytes;
TGCT	trans	rs2727020	0.729	rs588458	chr11:49214048	C/A	cg03929089	chr4:120376271	NA	0.65	6.99	0.53	1.47e-10	Coronary artery disease;
TGCT	cis	rs6969780	0.545	rs983184	chr7:27188379	C/T	cg07317062	chr7:27170388	HOXA4	-0.44	-4.62	-0.38	9.57e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs3096299	0.667	rs2965947	chr16:89518670	T/C	cg06640241	chr16:89574553	SPG7	0.77	8.52	0.61	4.55e-14	Multiple myeloma (IgH translocation);
TGCT	cis	rs2243480	1.000	rs781157	chr7:65478311	G/A	cg20637647	chr7:64974828	NA	1.0	5.59	0.45	1.4e-7	Diabetic kidney disease;
TGCT	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg22168489	chr12:122356033	WDR66	-0.22	-5.19	-0.42	8.32e-7	Mean corpuscular volume;
TGCT	cis	rs12701220	0.817	rs1058727	chr7:1087095	A/G	cg07217954	chr7:1067459	C7orf50	-0.45	-4.5	-0.37	1.53e-5	Bronchopulmonary dysplasia;
TGCT	cis	rs2013441	1.000	rs2703817	chr17:20119677	A/C	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.63	-0.38	9.19e-6	Obesity-related traits;
TGCT	cis	rs2486288	0.656	rs7167146	chr15:45571386	A/G	cg26924012	chr15:45694286	SPATA5L1	0.76	7.78	0.57	2.38e-12	Glomerular filtration rate;
TGCT	cis	rs3091242	0.781	rs71652378	chr1:25721457	G/C	cg10117171	chr1:25599238	RHD	-0.36	-5.77	-0.46	5.98e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs2562456	0.917	rs6511256	chr19:21693315	G/T	cg25650185	chr19:21324782	ZNF431	0.61	5.38	0.43	3.6e-7	Pain;
TGCT	cis	rs4722166	0.630	rs6461667	chr7:22796743	A/G	cg05265849	chr7:22767390	IL6	0.23	4.75	0.39	5.51e-6	Lung cancer;
TGCT	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg22920501	chr2:26401640	FAM59B	-0.74	-6.4	-0.5	2.86e-9	Gut microbiome composition (summer);
TGCT	cis	rs7267979	0.866	rs6138609	chr20:25570985	T/A	cg16686733	chr20:25566563	NINL	0.56	5.56	0.45	1.59e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs854765	0.647	rs854763	chr17:18010095	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.7	7.22	0.54	4.53e-11	Total body bone mineral density;
TGCT	cis	rs854765	0.551	rs12600546	chr17:17867614	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	7.69	0.57	3.98e-12	Total body bone mineral density;
TGCT	cis	rs11650494	0.908	rs73324308	chr17:47405338	T/G	cg08112188	chr17:47440006	ZNF652	1.04	5.34	0.43	4.3e-7	Prostate cancer;
TGCT	cis	rs13191362	1.000	rs68045643	chr6:163029709	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.56	4.64	0.38	8.87e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs67311347	0.544	rs6787516	chr3:40355616	C/T	cg13683864	chr3:40499215	RPL14	-0.84	-7.85	-0.58	1.71e-12	Renal cell carcinoma;
TGCT	cis	rs826838	0.935	rs1843639	chr12:39178919	C/A	cg26384229	chr12:38710491	ALG10B	1.0	8.98	0.63	3.56e-15	Heart rate;
TGCT	cis	rs9486719	0.948	rs2472904	chr6:96874962	T/G	cg18709589	chr6:96969512	KIAA0776	0.71	5.21	0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs3806843	0.576	rs550475	chr5:140273528	G/C	cg09824255	chr5:140014002	CD14	0.27	4.74	0.39	5.73e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs8180040	1.000	rs295458	chr3:47385585	C/A	cg27129171	chr3:47204927	SETD2	0.69	8.73	0.62	1.47e-14	Colorectal cancer;
TGCT	cis	rs981844	1.000	rs17299041	chr4:154673127	T/C	cg14289246	chr4:154710475	SFRP2	1.01	8.67	0.61	2.02e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs6993813	0.620	rs7016585	chr8:120030098	C/A	cg17171407	chr8:119960777	TNFRSF11B	0.26	4.66	0.39	8.02e-6	Bone mineral density (hip);
TGCT	cis	rs6570726	0.935	rs371744	chr6:145841024	C/T	cg23711669	chr6:146136114	FBXO30	0.7	6.46	0.5	2.12e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4938534	0.559	rs1944919	chr11:111259876	A/C	cg24049888	chr11:111250129	POU2AF1	0.34	5.8	0.46	5.27e-8	Primary biliary cholangitis;
TGCT	cis	rs5769765	0.646	rs9616205	chr22:50309915	A/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.15	-9.85	-0.66	2.93e-17	Schizophrenia;
TGCT	cis	rs601339	0.877	rs2649991	chr12:123179461	A/G	cg11919336	chr12:123188078	GPR109A	0.64	7.86	0.58	1.61e-12	Adiponectin levels;
TGCT	cis	rs727563	0.594	rs132807	chr22:42071584	T/C	cg06634786	chr22:41940651	POLR3H	0.9	8.74	0.62	1.34e-14	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs3862435	0.706	rs2589947	chr15:90949177	G/A	cg14166756	chr15:90894880	ZNF774	-0.28	-4.61	-0.38	9.95e-6	Response to exercise (triglyceride level interaction);
TGCT	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg25036284	chr2:26402008	FAM59B	-0.54	-4.7	-0.39	6.93e-6	Gut microbiome composition (summer);
TGCT	cis	rs858239	0.698	rs858295	chr7:23245569	A/G	cg05602783	chr7:23145260	KLHL7	-0.63	-5.21	-0.42	7.52e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs9894429	1.000	rs3935543	chr17:79579874	T/C	cg21028142	chr17:79581711	NPLOC4	0.29	6.81	0.52	3.83e-10	Eye color traits;
TGCT	cis	rs9372253	1.000	rs2235989	chr6:110714584	A/T	cg13266496	chr6:110720918	DDO	-0.45	-5.55	-0.45	1.64e-7	Platelet distribution width;
TGCT	cis	rs910187	0.641	rs3186647	chr20:45817067	T/C	cg27589058	chr20:45804311	EYA2	-0.35	-7.6	-0.56	6.23e-12	Migraine;
TGCT	cis	rs2013441	1.000	rs2703787	chr17:20158665	A/G	cg18979559	chr17:20280153	CCDC144C	-0.45	-4.67	-0.39	7.61e-6	Obesity-related traits;
TGCT	cis	rs2204008	0.604	rs11172718	chr12:38069819	T/C	cg26384229	chr12:38710491	ALG10B	0.85	7.77	0.57	2.56e-12	Bladder cancer;
TGCT	cis	rs9467773	1.000	rs9467796	chr6:26568411	A/G	cg09904177	chr6:26538194	HMGN4	0.69	6.84	0.52	3.23e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs2762353	0.902	rs3799344	chr6:25786993	C/T	cg03517284	chr6:25882590	NA	0.47	4.76	0.39	5.38e-6	Blood metabolite levels;
TGCT	cis	rs3091242	0.933	rs35148262	chr1:25766623	A/G	cg23205692	chr1:25664452	TMEM50A	0.48	5.0	0.41	1.92e-6	Erythrocyte sedimentation rate;
TGCT	cis	rs9790314	0.875	rs55688744	chr3:160944222	G/A	cg03342759	chr3:160939853	NMD3	-0.51	-5.73	-0.46	7.05e-8	Morning vs. evening chronotype;
TGCT	cis	rs9383153	1.000	rs9383153	chr6:16343056	A/G	cg14009473	chr6:15502099	JARID2	0.59	4.86	0.4	3.43e-6	Gambling;
TGCT	cis	rs7523273	0.565	rs2025374	chr1:207887536	A/G	cg22525895	chr1:207977042	MIR29B2	-0.35	-5.83	-0.46	4.47e-8	Schizophrenia;
TGCT	cis	rs9972944	0.756	rs2024273	chr17:63768972	A/G	cg07283582	chr17:63770753	CCDC46	-0.26	-5.27	-0.43	5.91e-7	Total body bone mineral density;
TGCT	cis	rs8017423	0.935	rs2236403	chr14:90736325	C/T	cg04374321	chr14:90722782	PSMC1	-0.75	-7.31	-0.55	2.88e-11	Mortality in heart failure;
TGCT	cis	rs6921919	0.583	rs6899389	chr6:28381140	C/A	cg18815343	chr6:28367644	ZSCAN12	-0.54	-5.25	-0.43	6.29e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1167827	1.000	rs1167827	chr7:75163169	A/G	cg08200252	chr7:75115859	POM121C	0.35	5.45	0.44	2.66e-7	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs6912958	0.702	rs6906769	chr6:88235949	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-5.06	-0.41	1.45e-6	Monocyte percentage of white cells;
TGCT	cis	rs7647973	1.000	rs7619789	chr3:49476263	T/C	cg07690219	chr3:49449608	TCTA;RHOA	-0.53	-4.45	-0.37	1.87e-5	Menarche (age at onset);
TGCT	cis	rs7223966	0.960	rs113155878	chr17:61706560	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	4.76	0.39	5.39e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs9811920	0.535	rs704572	chr3:99482314	G/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.39	4.69	0.39	7.22e-6	Axial length;
TGCT	cis	rs6977660	0.562	rs2189566	chr7:19768960	G/A	cg05791153	chr7:19748676	TWISTNB	1.03	6.95	0.53	1.88e-10	Thyroid stimulating hormone;
TGCT	cis	rs7213347	0.555	rs2760751	chr17:2028106	A/G	cg20777128	chr17:1945076	DPH1;OVCA2	-0.56	-4.9	-0.4	2.89e-6	Total body bone mineral density;
TGCT	cis	rs9467603	0.925	rs13199775	chr6:25828782	A/T	cg16898833	chr6:26189333	HIST1H4D	1.21	5.94	0.47	2.64e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9486715	0.867	rs1855533	chr6:97050265	T/C	cg18709589	chr6:96969512	KIAA0776	-0.84	-8.23	-0.59	2.19e-13	Headache;
TGCT	cis	rs1580019	0.587	rs6972365	chr7:32548931	T/A	cg07520158	chr7:32535189	LSM5;AVL9	0.58	4.96	0.41	2.25e-6	Cognitive ability;
TGCT	cis	rs3771570	0.901	rs56129392	chr2:242242439	C/T	cg21155796	chr2:242212141	HDLBP	0.98	6.68	0.51	7.29e-10	Prostate cancer;
TGCT	cis	rs11955175	0.850	rs111959286	chr5:40704141	A/T	cg17351974	chr5:40835760	RPL37	0.82	5.28	0.43	5.68e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs62244186	0.659	rs1806579	chr3:44509281	T/C	cg10108389	chr3:44770937	ZNF501	-0.48	-4.94	-0.41	2.48e-6	Depressive symptoms;
TGCT	cis	rs2933343	1.000	rs2929859	chr3:128608341	T/G	cg11901034	chr3:128598214	ACAD9	-0.65	-5.13	-0.42	1.09e-6	IgG glycosylation;
TGCT	cis	rs3806843	0.576	rs246006	chr5:140339228	G/A	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7552404	0.627	rs12127049	chr1:76353248	G/A	cg22875332	chr1:76189707	ACADM	0.69	6.91	0.53	2.24e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg23758822	chr17:41437982	NA	0.7	6.6	0.51	1.1e-9	Menopause (age at onset);
TGCT	cis	rs2153535	0.541	rs1414353	chr6:8485642	C/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	trans	rs208515	0.525	rs10944869	chr6:66687576	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.93	10.3	0.68	2.34e-18	Exhaled nitric oxide levels;
TGCT	cis	rs4786125	0.804	rs6500850	chr16:6896389	A/T	cg03623568	chr16:6915990	A2BP1	-0.33	-4.73	-0.39	5.95e-6	Heart rate variability traits (SDNN);
TGCT	cis	rs78487399	0.808	rs6726643	chr2:43753746	A/C	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.76	4.68	0.39	7.27e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs12681288	0.748	rs7000148	chr8:1016383	G/C	cg21347738	chr8:1310380	NA	-0.22	-4.59	-0.38	1.08e-5	Schizophrenia;
TGCT	cis	rs11627546	0.615	rs1958084	chr14:70366045	A/G	cg10496350	chr14:71275911	MAP3K9	-0.89	-4.5	-0.37	1.52e-5	Red blood cell traits;
TGCT	cis	rs6095298	0.595	rs4809728	chr20:47440220	C/G	cg12307787	chr20:48099359	KCNB1	0.44	4.65	0.39	8.52e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-8.0	-0.58	7.56e-13	Platelet count;
TGCT	cis	rs7959452	0.535	rs4761228	chr12:69682327	G/A	cg11871910	chr12:69753446	YEATS4	0.62	6.23	0.49	6.65e-9	Blood protein levels;
TGCT	cis	rs10464366	0.957	rs12667577	chr7:39095133	T/G	cg18850127	chr7:39170497	POU6F2	0.21	4.49	0.37	1.62e-5	IgG glycosylation;
TGCT	cis	rs67311347	0.544	rs6787516	chr3:40355616	C/T	cg17264618	chr3:40429014	ENTPD3	0.3	4.48	0.37	1.69e-5	Renal cell carcinoma;
TGCT	cis	rs4888262	0.545	rs4072450	chr16:74666634	G/C	cg01733217	chr16:74700730	RFWD3	0.73	7.26	0.55	3.77e-11	Testicular germ cell tumor;
TGCT	cis	rs7666738	0.830	rs1593572	chr4:98979322	A/G	cg05340658	chr4:99064831	C4orf37	-0.45	-5.05	-0.41	1.54e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9527	0.614	rs11191589	chr10:104930382	T/C	cg15744005	chr10:104629667	AS3MT	-0.4	-4.59	-0.38	1.08e-5	Arsenic metabolism;
TGCT	cis	rs2239547	0.521	rs9682464	chr3:52888485	C/T	cg11645453	chr3:52864694	ITIH4	0.35	5.77	0.46	5.97e-8	Schizophrenia;
TGCT	cis	rs453301	0.686	rs10217044	chr8:8894752	A/G	cg15556689	chr8:8085844	FLJ10661	-0.61	-5.23	-0.42	7.1e-7	Joint mobility (Beighton score);
TGCT	cis	rs1552244	0.554	rs6800204	chr3:9995404	A/G	cg00149659	chr3:10157352	C3orf10	0.66	4.89	0.4	3.04e-6	Alzheimer's disease;
TGCT	cis	rs6964587	0.967	rs10953063	chr7:91576958	A/G	cg17063962	chr7:91808500	NA	-0.91	-9.99	-0.67	1.32e-17	Breast cancer;
TGCT	cis	rs904251	0.523	rs914348	chr6:37484729	G/A	cg01843034	chr6:37503916	NA	-0.53	-7.08	-0.54	9.58e-11	Cognitive performance;
TGCT	cis	rs3733585	0.673	rs4292333	chr4:9953871	G/A	cg11266682	chr4:10021025	SLC2A9	-0.57	-7.6	-0.56	6.21e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7927771	0.832	rs10769258	chr11:47391039	C/T	cg21462715	chr11:47870315	NUP160	-0.58	-4.74	-0.39	5.68e-6	Subjective well-being;
TGCT	cis	rs3820068	0.581	rs72645888	chr1:15929922	C/A	cg05660106	chr1:15850417	CASP9	0.82	8.02	0.58	6.63e-13	Systolic blood pressure;
TGCT	cis	rs9894429	0.789	rs7213849	chr17:79567610	C/T	cg21028142	chr17:79581711	NPLOC4	-0.3	-7.03	-0.53	1.2e-10	Eye color traits;
TGCT	cis	rs13256369	0.865	rs13282523	chr8:8577293	C/G	cg18904891	chr8:8559673	CLDN23	0.58	5.29	0.43	5.44e-7	Obesity-related traits;
TGCT	cis	rs2242194	0.816	rs6671688	chr1:154994265	T/C	cg06221963	chr1:154839813	KCNN3	-0.49	-6.17	-0.48	9e-9	Schizophrenia;
TGCT	cis	rs8084125	0.765	rs62105165	chr18:74944464	A/G	cg05528293	chr18:74961138	GALR1	0.49	4.84	0.4	3.74e-6	Obesity-related traits;
TGCT	cis	rs909674	0.775	rs8138462	chr22:39839670	G/C	cg05872129	chr22:39784769	NA	-0.98	-9.83	-0.66	3.19e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs13242816	1.000	rs35184471	chr7:116133246	G/A	cg02799643	chr7:116139180	CAV2	-0.46	-5.53	-0.44	1.78e-7	P wave duration;
TGCT	cis	rs926938	0.520	rs6671984	chr1:115257521	C/T	cg12756093	chr1:115239321	AMPD1	-0.41	-5.4	-0.44	3.21e-7	Autism;
TGCT	cis	rs9303401	0.659	rs7210432	chr17:56668170	C/T	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs9393692	0.905	rs1125000	chr6:26287256	C/T	cg13736514	chr6:26305472	NA	-0.37	-5.33	-0.43	4.48e-7	Educational attainment;
TGCT	cis	rs9733	0.596	rs11586422	chr1:150679358	C/T	cg09365446	chr1:150670422	GOLPH3L	0.3	4.52	0.38	1.4e-5	Tonsillectomy;
TGCT	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg06558623	chr16:89946397	TCF25	0.51	6.5	0.5	1.75e-9	Skin colour saturation;
TGCT	cis	rs2120019	0.638	rs34492112	chr15:75294917	G/A	cg17294928	chr15:75287854	SCAMP5	0.94	9.07	0.63	2.2e-15	Blood trace element (Zn levels);
TGCT	cis	rs2963155	0.518	rs862489	chr5:142634355	T/C	cg17617527	chr5:142782415	NR3C1	0.85	6.29	0.49	4.9e-9	Breast cancer;
TGCT	trans	rs4824093	0.535	rs73441802	chr22:50273916	G/A	cg09872104	chr7:134855509	C7orf49	-1.0	-8.27	-0.6	1.77e-13	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs7647973	1.000	rs2140270	chr3:49439440	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.59	-4.72	-0.39	6.19e-6	Menarche (age at onset);
TGCT	cis	rs79349575	0.783	rs62075839	chr17:46996434	G/C	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.51	-0.38	1.48e-5	Type 2 diabetes;
TGCT	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg07507251	chr3:52567010	NT5DC2	0.51	7.63	0.57	5.29e-12	Bipolar disorder;
TGCT	cis	rs6582630	0.555	rs10880607	chr12:38508184	A/G	cg26384229	chr12:38710491	ALG10B	0.89	8.14	0.59	3.55e-13	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs782590	0.774	rs782637	chr2:55894247	T/C	cg18811423	chr2:55921094	PNPT1	0.65	6.76	0.52	4.79e-10	Metabolic syndrome;
TGCT	cis	rs2204008	0.837	rs10876019	chr12:37985477	C/T	cg26384229	chr12:38710491	ALG10B	0.86	7.77	0.57	2.55e-12	Bladder cancer;
TGCT	cis	rs7681440	0.904	rs3756063	chr4:90757394	G/C	cg26578617	chr4:90757533	SNCA	-0.48	-4.96	-0.41	2.31e-6	Dementia with Lewy bodies;
TGCT	cis	rs142483589	1	rs142483589	chr9:139320323	CCG/C	cg13741927	chr9:139327495	INPP5E	-0.27	-6.26	-0.49	5.64e-9	White blood cell count;
TGCT	cis	rs56104184	0.830	rs28556985	chr19:49351149	C/T	cg17863274	chr19:49399704	TULP2	-0.51	-6.28	-0.49	5.21e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs8068544	0.818	rs75771390	chr17:40194054	A/G	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.08	-5.02	-0.41	1.75e-6	Reticulocyte fraction of red cells;Reticulocyte count;
TGCT	cis	rs62244186	0.659	rs56231820	chr3:44530329	C/T	cg10108389	chr3:44770937	ZNF501	-0.47	-4.89	-0.4	3.12e-6	Depressive symptoms;
TGCT	cis	rs453301	0.686	rs3989373	chr8:8911308	G/T	cg15556689	chr8:8085844	FLJ10661	-0.61	-5.07	-0.41	1.42e-6	Joint mobility (Beighton score);
TGCT	cis	rs7666738	0.830	rs72882693	chr4:98960804	T/A	cg17366294	chr4:99064904	C4orf37	0.74	7.56	0.56	7.89e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4919044	0.756	rs2486686	chr10:94778511	G/T	cg05127821	chr10:94822908	CYP26C1	-0.77	-5.03	-0.41	1.71e-6	Coronary artery disease;
TGCT	cis	rs7226408	0.901	rs17652935	chr18:34756530	T/A	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.46	-6.7	-0.52	6.44e-10	Alzheimer's disease;
TGCT	cis	rs7647973	1.000	rs62259933	chr3:49469703	G/A	cg05785598	chr3:49045655	WDR6	-0.38	-4.5	-0.37	1.57e-5	Menarche (age at onset);
TGCT	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg06618935	chr21:46677482	NA	-0.38	-4.97	-0.41	2.22e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2072499	0.966	rs11587860	chr1:156156951	G/C	cg06970220	chr1:156163860	SLC25A44	0.6	5.1	0.42	1.22e-6	Testicular germ cell tumor;
TGCT	cis	rs35306767	0.953	rs1106064	chr10:957211	G/A	cg20503657	chr10:835505	NA	0.68	9.49	0.65	2.12e-16	Eosinophil percentage of granulocytes;
TGCT	cis	rs826838	0.806	rs826873	chr12:39121305	G/A	cg26384229	chr12:38710491	ALG10B	-0.86	-7.76	-0.57	2.68e-12	Heart rate;
TGCT	cis	rs12497850	0.931	rs6446205	chr3:49035211	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.42	-5.46	-0.44	2.5e-7	Parkinson's disease;
TGCT	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg11494091	chr17:61959527	GH2	0.43	7.3	0.55	3.05e-11	Height;
TGCT	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg18402987	chr7:1209562	NA	0.75	6.35	0.5	3.67e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs765787	0.530	rs4444275	chr15:45535347	T/C	cg24006582	chr15:45444508	DUOX1	-0.25	-5.54	-0.45	1.76e-7	Uric acid levels;
TGCT	cis	rs7675861	1.000	rs7675861	chr4:5849821	T/C	cg14241509	chr4:6196512	JAKMIP1	0.25	4.48	0.37	1.69e-5	Dysphagia;
TGCT	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg23982607	chr1:1823379	GNB1	-0.55	-8.49	-0.61	5.45e-14	Body mass index;
TGCT	cis	rs9611519	0.929	rs12484477	chr22:41429084	G/A	cg13695892	chr22:41940480	POLR3H	-0.53	-4.62	-0.38	9.54e-6	Neuroticism;
TGCT	cis	rs6964587	1.000	rs9690208	chr7:91735613	T/A	cg22709100	chr7:91322751	NA	0.28	4.61	0.38	9.79e-6	Breast cancer;
TGCT	cis	rs453301	0.686	rs11787026	chr8:8902371	A/T	cg15556689	chr8:8085844	FLJ10661	0.67	5.46	0.44	2.46e-7	Joint mobility (Beighton score);
TGCT	cis	rs1843834	0.539	rs6739735	chr2:225405253	A/G	cg22455342	chr2:225449267	CUL3	-1.02	-10.66	-0.69	3.16e-19	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs6570726	0.791	rs10457788	chr6:145921136	T/A	cg23711669	chr6:146136114	FBXO30	0.89	9.62	0.65	1.06e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6089829	0.851	rs6089827	chr20:61668845	C/T	cg08564027	chr20:61660810	NA	0.36	6.47	0.5	2.07e-9	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs79349575	0.783	rs59270107	chr17:47026185	A/T	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.52	-0.38	1.44e-5	Type 2 diabetes;
TGCT	cis	rs11785400	0.793	rs1056012	chr8:143740167	A/G	cg10596483	chr8:143751796	JRK	0.55	5.48	0.44	2.29e-7	Schizophrenia;
TGCT	cis	rs3091242	0.933	rs1534954	chr1:25761924	A/T	cg10117171	chr1:25599238	RHD	-0.33	-5.43	-0.44	2.81e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs910187	0.624	rs6018311	chr20:45792634	A/G	cg27589058	chr20:45804311	EYA2	-0.36	-6.87	-0.53	2.72e-10	Migraine;
TGCT	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.59	4.74	0.39	5.85e-6	Tonsillectomy;
TGCT	cis	rs9916302	0.904	rs7208274	chr17:37513796	C/T	cg15445000	chr17:37608096	MED1	-0.33	-4.71	-0.39	6.46e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs6088580	0.634	rs1890002	chr20:32919219	A/G	cg06115741	chr20:33292138	TP53INP2	-0.54	-4.74	-0.39	5.7e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs11190604	1.000	rs11190540	chr10:102202629	A/G	cg16342193	chr10:102329863	NA	-0.4	-5.31	-0.43	4.85e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs12971120	0.891	rs3794955	chr18:72174827	C/T	cg26446133	chr18:72167187	CNDP2	-0.35	-5.89	-0.47	3.42e-8	Refractive error;
TGCT	cis	rs950169	0.656	rs11632395	chr15:85145793	C/A	cg11189052	chr15:85197271	WDR73	0.81	6.94	0.53	1.94e-10	Schizophrenia;
TGCT	cis	rs9399135	0.967	rs34546690	chr6:135369709	T/C	cg24558204	chr6:135376177	HBS1L	0.46	4.55	0.38	1.24e-5	Red blood cell count;
TGCT	cis	rs42648	0.596	rs194524	chr7:89861832	G/A	cg25739043	chr7:89950458	NA	-0.52	-5.0	-0.41	1.88e-6	Homocysteine levels;
TGCT	cis	rs7771547	0.508	rs1570368	chr6:36437136	C/G	cg07856975	chr6:36356162	ETV7	0.21	4.74	0.39	5.86e-6	Platelet distribution width;
TGCT	cis	rs1525293	0.507	rs12698980	chr7:70508532	G/A	cg21135135	chr7:70597687	WBSCR17	0.6	5.8	0.46	5.12e-8	Colonoscopy-negative controls vs population controls;Major depressive disorder;
TGCT	cis	rs9658691	0.920	rs72809352	chr10:90742624	A/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.79	-5.7	-0.46	8.11e-8	Mosquito bite size;
TGCT	cis	rs7769051	1.000	rs9493438	chr6:133098349	T/C	cg22852734	chr6:133119734	C6orf192	1.22	7.01	0.53	1.38e-10	Type 2 diabetes nephropathy;
TGCT	cis	rs11143230	1.000	rs17628494	chr9:74889167	C/T	cg02514559	chr9:74675332	C9orf57	-0.22	-4.45	-0.37	1.88e-5	Suicidal ideation;
TGCT	cis	rs11112613	0.653	rs941101	chr12:105937098	T/G	cg03607813	chr12:105948248	NA	0.47	5.32	0.43	4.62e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	cis	rs314370	0.951	rs12667888	chr7:100474289	T/C	cg10426581	chr7:100472382	SRRT	1.0	10.93	0.7	6.98e-20	Resting heart rate;
TGCT	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg24799795	chr11:5959658	NA	-0.35	-4.66	-0.39	8.16e-6	DNA methylation (variation);
TGCT	cis	rs7914558	0.966	rs10786725	chr10:104682357	T/C	cg15744005	chr10:104629667	AS3MT	-0.41	-5.11	-0.42	1.16e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs7666738	0.830	rs6823718	chr4:99063202	C/T	cg05340658	chr4:99064831	C4orf37	0.52	5.79	0.46	5.32e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4886920	0.662	rs4322626	chr15:78105835	A/G	cg25212270	chr15:78015279	NA	-0.29	-4.63	-0.38	8.97e-6	Neuroticism;
TGCT	cis	rs950169	0.614	rs12911536	chr15:84673030	G/T	cg11189052	chr15:85197271	WDR73	0.67	5.19	0.42	8.46e-7	Schizophrenia;
TGCT	cis	rs9926296	0.632	rs4785717	chr16:89801133	A/G	cg26513180	chr16:89883248	FANCA	0.71	6.86	0.52	2.86e-10	Vitiligo;
TGCT	cis	rs10114408	0.959	rs7048848	chr9:96664058	C/T	cg13679303	chr9:96623674	NA	-0.36	-4.66	-0.39	8e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg02725872	chr8:58115012	NA	-0.41	-5.42	-0.44	3.01e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg11644478	chr21:40555479	PSMG1	-0.58	-5.1	-0.42	1.23e-6	Cognitive function;
TGCT	cis	rs68092024	0.704	rs704576	chr3:99487154	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.5	5.94	0.47	2.64e-8	Cleft lip with or without cleft palate;
TGCT	cis	rs9902453	0.934	rs7223645	chr17:28491029	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	6.39	0.5	3.03e-9	Coffee consumption (cups per day);
TGCT	cis	rs11874712	1.000	rs2298787	chr18:43669980	T/C	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	5.23	0.42	7.11e-7	Migraine - clinic-based;
TGCT	cis	rs1976403	0.659	rs10799699	chr1:21820961	C/T	cg17800788	chr1:21766015	NBPF3	0.24	4.51	0.38	1.46e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs17376456	0.877	rs10062711	chr5:93348659	G/A	cg25358565	chr5:93447407	FAM172A	0.92	8.37	0.6	1.05e-13	Diabetic retinopathy;
TGCT	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg06634786	chr22:41940651	POLR3H	0.84	8.04	0.59	5.97e-13	Vitiligo;
TGCT	cis	rs7412746	0.658	rs72704685	chr1:150897687	C/G	cg09365446	chr1:150670422	GOLPH3L	0.34	4.71	0.39	6.58e-6	Melanoma;
TGCT	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.6	-6.01	-0.48	1.91e-8	Bipolar disorder;
TGCT	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg22166914	chr1:53195759	ZYG11B	-0.39	-6.46	-0.5	2.18e-9	Monocyte count;
TGCT	cis	rs854765	0.647	rs712268	chr17:18025744	C/G	cg04398451	chr17:18023971	MYO15A	-0.39	-6.89	-0.53	2.53e-10	Total body bone mineral density;
TGCT	cis	rs1215050	0.791	rs1215055	chr4:98865454	C/T	cg17366294	chr4:99064904	C4orf37	-0.57	-6.12	-0.48	1.13e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2274273	0.564	rs10140164	chr14:55406123	A/G	cg01923255	chr14:55878535	KIAA0831	0.52	4.44	0.37	1.99e-5	Protein biomarker;
TGCT	cis	rs17133449	0.718	rs1901635	chr10:4751773	C/T	cg04530666	chr10:3759553	NA	-0.29	-4.87	-0.4	3.33e-6	Major depressive disorder;
TGCT	cis	rs7267979	0.966	rs4813557	chr20:25292545	C/T	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9911578	1.000	rs1057068	chr17:56598439	T/C	cg05425664	chr17:57184151	TRIM37	0.62	6.23	0.49	6.62e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs2242073	1.000	rs2242073	chr2:208994045	A/C	cg18579327	chr2:208395557	CREB1	0.58	4.48	0.37	1.67e-5	Attention deficit hyperactivity disorder;
TGCT	cis	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg03213289	chr20:61660250	NA	0.68	9.99	0.67	1.36e-17	Prostate cancer (SNP x SNP interaction);
TGCT	trans	rs7698623	0.717	rs4147245	chr4:88779237	A/C	cg01186725	chr1:53905612	FLJ40434	-0.48	-6.63	-0.51	9.21e-10	Cardiovascular disease risk factors;
TGCT	cis	rs17725255	0.516	rs1205213	chr20:18122278	G/A	cg02706653	chr20:17208584	PCSK2	0.56	4.49	0.37	1.59e-5	Anorexia nervosa;
TGCT	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg04944784	chr2:26401820	FAM59B	-0.67	-6.16	-0.48	9.54e-9	Gut microbiome composition (summer);
TGCT	cis	rs57590327	0.679	rs35754586	chr3:81601765	T/C	cg07356753	chr3:81810745	GBE1	-0.55	-4.54	-0.38	1.3e-5	Extraversion;
TGCT	cis	rs6840360	0.642	rs4696089	chr4:152395733	A/G	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.82e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7267979	1.000	rs6115146	chr20:25304507	G/A	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs12136530	0.577	rs4912002	chr1:19793402	G/T	cg00755546	chr1:19971792	NBL1	0.38	4.83	0.4	3.87e-6	Lead levels in blood;
TGCT	cis	rs13064411	0.866	rs35278902	chr3:113239021	A/G	cg18753928	chr3:113234510	CCDC52	-0.68	-4.74	-0.39	5.8e-6	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs6076065	0.748	rs6048784	chr20:23382652	A/T	cg11657817	chr20:23433608	CST11	0.31	5.42	0.44	3.02e-7	Facial morphology (factor 15, philtrum width);
TGCT	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg16414030	chr3:133502952	NA	-0.62	-9.73	-0.66	5.69e-17	Iron status biomarkers;
TGCT	cis	rs9911578	0.935	rs304261	chr17:56813782	A/G	cg05425664	chr17:57184151	TRIM37	-0.63	-6.26	-0.49	5.86e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs896854	0.654	rs1453377	chr8:95969947	C/T	cg09323728	chr8:95962352	TP53INP1	-0.51	-6.45	-0.5	2.23e-9	Type 2 diabetes;
TGCT	cis	rs9296092	0.538	rs9469486	chr6:33516849	G/A	cg13560919	chr6:33536144	NA	-0.21	-4.74	-0.39	5.87e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs7169223	0.653	rs3971703	chr15:79092481	G/C	cg03762349	chr15:79060523	ADAMTS7	-0.24	-4.76	-0.39	5.39e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
TGCT	cis	rs7246657	0.943	rs10424574	chr19:37838393	A/G	cg18154014	chr19:37997991	ZNF793	0.97	6.49	0.5	1.82e-9	Coronary artery calcification;
TGCT	cis	rs4906332	0.899	rs12888042	chr14:103891709	G/A	cg26031613	chr14:104095156	KLC1	-0.54	-4.82	-0.4	4.04e-6	Coronary artery disease;
TGCT	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg05368731	chr17:41323189	NBR1	1.21	14.63	0.8	8.89e-29	Menopause (age at onset);
TGCT	cis	rs3749237	0.595	rs4855864	chr3:49521974	C/T	cg03060546	chr3:49711283	APEH	0.77	8.86	0.62	6.92e-15	Resting heart rate;
TGCT	cis	rs12477438	0.798	rs2309524	chr2:99659510	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-5.87	-0.47	3.74e-8	Chronic sinus infection;
TGCT	cis	rs7633770	0.805	rs11130098	chr3:46661926	A/G	cg11219411	chr3:46661640	NA	-0.36	-5.34	-0.43	4.22e-7	Coronary artery disease;
TGCT	cis	rs7917772	0.582	rs12784963	chr10:104336986	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-5.46	-0.44	2.51e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg22968622	chr17:43663579	NA	-0.99	-9.47	-0.65	2.39e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2862064	1.000	rs6867207	chr5:156450106	G/A	cg12943317	chr5:156479607	HAVCR1	-0.45	-5.77	-0.46	6.03e-8	Platelet count;
TGCT	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9527	1.000	rs12416687	chr10:104629011	T/C	cg15744005	chr10:104629667	AS3MT	-0.52	-6.06	-0.48	1.52e-8	Arsenic metabolism;
TGCT	cis	rs11112613	0.775	rs7959699	chr12:105959848	C/A	cg03607813	chr12:105948248	NA	0.46	5.58	0.45	1.46e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	cis	rs11578119	0.933	rs12145961	chr1:170497526	C/G	cg09767346	chr1:170501363	GORAB	0.64	5.09	0.42	1.3e-6	Male-pattern baldness;
TGCT	cis	rs11785400	1.000	rs6997670	chr8:143737915	G/A	cg10596483	chr8:143751796	JRK	0.56	6.05	0.48	1.61e-8	Schizophrenia;
TGCT	cis	rs9638182	0.725	rs2074755	chr7:72877166	C/T	cg14087351	chr7:73037990	MLXIPL	0.6	4.97	0.41	2.18e-6	Triglycerides;
TGCT	trans	rs629535	0.821	rs650267	chr8:70029160	C/T	cg21567404	chr3:27674614	NA	0.58	9.18	0.64	1.22e-15	Dupuytren's disease;
TGCT	cis	rs7819412	0.807	rs6991930	chr8:10963288	G/C	cg21775007	chr8:11205619	TDH	-0.52	-5.06	-0.41	1.46e-6	Triglycerides;
TGCT	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.52	-5.68	-0.45	9.09e-8	Longevity;Endometriosis;
TGCT	trans	rs6561151	0.957	rs1373904	chr13:44475398	A/G	cg12856521	chr11:46389249	DGKZ	0.69	7.75	0.57	2.8e-12	Crohn's disease;
TGCT	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg10150615	chr22:24372951	LOC391322	-0.96	-11.77	-0.73	6.04e-22	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9674544	0.757	rs3744085	chr17:47131901	A/G	cg20966754	chr17:47091339	IGF2BP1	-0.42	-4.46	-0.37	1.81e-5	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
TGCT	cis	rs2197308	0.740	rs10880619	chr12:37922720	T/C	cg26384229	chr12:38710491	ALG10B	0.89	7.98	0.58	8.43e-13	Morning vs. evening chronotype;
TGCT	cis	rs939658	1.000	rs12439908	chr15:79456381	T/C	cg17916960	chr15:79447300	NA	0.54	8.64	0.61	2.42e-14	Refractive error;
TGCT	trans	rs28595532	0.748	rs55949457	chr4:119336174	A/G	cg26518628	chr1:97050305	NA	-0.56	-6.79	-0.52	4.19e-10	Cannabis dependence symptom count;
TGCT	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg17911788	chr17:44343683	NA	-0.62	-6.7	-0.52	6.65e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs9611565	0.559	rs9611619	chr22:41986714	C/T	cg17554472	chr22:41940697	POLR3H	-0.52	-5.37	-0.43	3.79e-7	Vitiligo;
TGCT	cis	rs7267979	0.668	rs2387977	chr20:25599776	C/T	cg16686733	chr20:25566563	NINL	-0.47	-4.83	-0.4	3.98e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs12902680	0.739	rs28851955	chr15:46416283	A/C	cg13605988	chr15:45421612	DUOX1;DUOXA1	0.33	4.62	0.38	9.28e-6	Neuroticism;
TGCT	cis	rs6089584	0.507	rs28545731	chr20:60634102	C/T	cg06108461	chr20:60628389	TAF4	-0.46	-5.72	-0.46	7.61e-8	Body mass index;
TGCT	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg23758822	chr17:41437982	NA	0.71	6.75	0.52	5.16e-10	Menopause (age at onset);
TGCT	cis	rs1865760	0.613	rs9379805	chr6:25938764	T/A	cg12310025	chr6:25882481	NA	-0.53	-5.34	-0.43	4.24e-7	Height;
TGCT	cis	rs1843834	0.898	rs2014887	chr2:225520082	A/G	cg22455342	chr2:225449267	CUL3	0.74	7.25	0.55	3.9e-11	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs12410462	0.502	rs78101727	chr1:227732069	C/T	cg23173402	chr1:227635558	NA	0.77	4.95	0.41	2.37e-6	Major depressive disorder;
TGCT	cis	rs1371867	0.810	rs1692004	chr8:101247320	T/C	cg06636551	chr8:101224915	SPAG1	0.49	6.63	0.51	9.15e-10	Atrioventricular conduction;
TGCT	cis	rs4820539	0.641	rs5759602	chr22:23489362	C/T	cg21100191	chr22:23484243	RTDR1	-0.8	-8.95	-0.63	4.31e-15	Bone mineral density;
TGCT	cis	rs9611519	0.531	rs1967708	chr22:41444444	G/C	cg03806693	chr22:41940476	POLR3H	-0.59	-5.48	-0.44	2.22e-7	Neuroticism;
TGCT	cis	rs4727027	0.933	rs6464940	chr7:148826309	G/T	cg23583168	chr7:148888333	NA	-0.72	-9.18	-0.64	1.18e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.7	-0.39	6.79e-6	Prudent dietary pattern;
TGCT	cis	rs4319547	0.737	rs4758646	chr12:122946507	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.66	-5.33	-0.43	4.48e-7	Body mass index;
TGCT	cis	rs7714584	1.000	rs4958426	chr5:150278346	A/C	cg22134413	chr5:150180641	NA	1.14	8.32	0.6	1.33e-13	Crohn's disease;
TGCT	cis	rs992157	0.835	rs11677953	chr2:219121663	G/A	cg00012203	chr2:219082015	ARPC2	-0.78	-7.64	-0.57	5.16e-12	Colorectal cancer;
TGCT	cis	rs2201728	1.000	rs12510722	chr4:100147101	A/G	cg07219303	chr4:100140905	ADH6	-0.35	-5.22	-0.42	7.29e-7	Cardiac Troponin-T levels;
TGCT	cis	rs7666738	0.830	rs6532719	chr4:99043691	A/G	cg17366294	chr4:99064904	C4orf37	0.73	7.49	0.56	1.11e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2147959	0.824	rs10916313	chr1:228625882	C/G	cg22700015	chr1:228743131	NA	-0.57	-4.53	-0.38	1.35e-5	Adult asthma;
TGCT	cis	rs732765	0.909	rs709887	chr14:75369379	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.65	-5.51	-0.44	1.99e-7	Non-small cell lung cancer;
TGCT	cis	rs6939532	0.522	rs4712981	chr6:26361430	C/T	cg05738196	chr6:26577821	NA	-0.53	-5.03	-0.41	1.68e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7324557	0.684	rs9510871	chr13:24384852	C/T	cg16602799	chr13:25254742	ATP12A	0.57	4.45	0.37	1.93e-5	Visceral adipose tissue adjusted for BMI;
TGCT	cis	rs7264396	0.790	rs6579255	chr20:34219496	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.28	-4.67	-0.39	7.62e-6	Total cholesterol levels;
TGCT	cis	rs5750830	0.597	rs4821889	chr22:39777254	T/C	cg02038168	chr22:39784481	NA	-0.68	-6.13	-0.48	1.05e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg09263875	chr16:632152	PIGQ	0.31	6.88	0.53	2.65e-10	Height;
TGCT	cis	rs7666738	0.830	rs1111541	chr4:99033860	A/G	cg17366294	chr4:99064904	C4orf37	-0.69	-6.87	-0.52	2.79e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs939574	0.512	rs10194278	chr2:220138408	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.78	5.63	0.45	1.14e-7	Platelet distribution width;
TGCT	cis	rs6879260	0.928	rs11739624	chr5:179727290	T/C	cg02891314	chr5:179741120	GFPT2	-0.39	-6.43	-0.5	2.46e-9	Height;
TGCT	cis	rs6570726	0.935	rs366621	chr6:145861275	A/G	cg05347473	chr6:146136440	FBXO30	0.49	4.51	0.38	1.49e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7666738	0.830	rs60411337	chr4:99046617	T/C	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6701037	0.512	rs4650716	chr1:175128711	C/A	cg00321850	chr1:175162397	KIAA0040	0.38	5.04	0.41	1.61e-6	Alcohol dependence;
TGCT	cis	rs6076065	0.630	rs2424559	chr20:23430519	A/G	cg11657817	chr20:23433608	CST11	0.34	6.15	0.48	9.6e-9	Facial morphology (factor 15, philtrum width);
TGCT	cis	rs709400	0.628	rs4906321	chr14:103878882	C/T	cg26031613	chr14:104095156	KLC1	0.71	8.07	0.59	5.23e-13	Body mass index;
TGCT	cis	rs4727027	0.933	rs28767030	chr7:148825918	T/G	cg23583168	chr7:148888333	NA	-0.72	-9.18	-0.64	1.18e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7582180	0.629	rs36103184	chr2:100942634	G/A	cg08017756	chr2:100939284	LONRF2	-0.3	-4.87	-0.4	3.27e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs12579753	0.879	rs11615729	chr12:82128318	T/A	cg21231944	chr12:82153410	PPFIA2	-0.36	-4.7	-0.39	6.72e-6	Resting heart rate;
TGCT	cis	rs7772486	0.846	rs7755440	chr6:146375906	T/C	cg23711669	chr6:146136114	FBXO30	0.91	9.95	0.67	1.67e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10746514	0.813	rs9724918	chr1:232248087	C/T	cg09506761	chr1:232265262	NA	0.46	4.71	0.39	6.41e-6	Response to statin therapy;
TGCT	cis	rs981844	0.696	rs7695605	chr4:154635436	C/G	cg14289246	chr4:154710475	SFRP2	0.9	6.89	0.53	2.45e-10	Response to statins (LDL cholesterol change);
TGCT	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg22920501	chr2:26401640	FAM59B	-0.79	-6.31	-0.49	4.58e-9	Gut microbiome composition (summer);
TGCT	trans	rs2688608	0.934	rs2675679	chr10:75658581	C/T	cg13918328	chr10:52500089	ASAH2B	0.65	6.73	0.52	5.7e-10	Inflammatory bowel disease;
TGCT	cis	rs4788570	0.615	rs7195059	chr16:71718366	C/T	cg06353428	chr16:71660113	MARVELD3	1.56	12.54	0.75	8.54e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs7267979	0.844	rs2424703	chr20:25270124	G/A	cg03522245	chr20:25566470	NINL	0.55	5.55	0.45	1.68e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2070488	0.775	rs1073506	chr3:38566235	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.68	-6.68	-0.51	7.13e-10	Electrocardiographic conduction measures;
TGCT	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg04944784	chr2:26401820	FAM59B	-0.8	-6.76	-0.52	4.91e-10	Gut microbiome composition (summer);
TGCT	cis	rs2228479	0.850	rs11640336	chr16:89941153	T/C	cg06558623	chr16:89946397	TCF25	0.59	6.77	0.52	4.66e-10	Skin colour saturation;
TGCT	cis	rs5769707	0.740	rs79946167	chr22:50017556	G/A	cg05373962	chr22:49881684	NA	-0.24	-4.68	-0.39	7.44e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs9916302	0.904	rs9904334	chr17:37468336	G/A	cg07936489	chr17:37558343	FBXL20	0.65	5.08	0.41	1.36e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs6074578	0.679	rs6086162	chr20:136025	C/T	cg16931068	chr20:139680	DEFB127	0.3	5.28	0.43	5.62e-7	Hirschsprung disease;
TGCT	cis	rs8103278	0.507	rs7260651	chr19:46260245	G/A	cg11657440	chr19:46296263	DMWD	0.74	7.75	0.57	2.84e-12	Coronary artery disease;
TGCT	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg03188948	chr7:1209495	NA	0.68	5.8	0.46	5.09e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs4478858	0.735	rs12134484	chr1:31823741	G/A	cg07478791	chr1:31886160	SERINC2	-0.51	-4.95	-0.41	2.33e-6	Alcohol dependence;
TGCT	cis	rs11626933	1.000	rs11626016	chr14:90747979	C/T	cg14092571	chr14:90743983	NA	-0.3	-6.18	-0.48	8.66e-9	Gut microbiota (bacterial taxa);
TGCT	cis	rs644799	1.000	rs1944074	chr11:95511445	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	11.08	0.71	2.9e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs17376456	0.877	rs10476598	chr5:93367281	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.67	-4.85	-0.4	3.66e-6	Diabetic retinopathy;
TGCT	cis	rs9611519	0.929	rs9611465	chr22:41426139	G/A	cg03806693	chr22:41940476	POLR3H	-0.7	-6.22	-0.49	6.88e-9	Neuroticism;
TGCT	cis	rs2235642	0.826	rs8048410	chr16:1614097	A/G	cg11375102	chr16:1583810	IFT140;TMEM204	-0.31	-5.21	-0.42	7.72e-7	Coronary artery disease;
TGCT	cis	rs250677	0.687	rs250678	chr5:148434830	C/T	cg18129178	chr5:148520854	ABLIM3	-0.43	-6.29	-0.49	5.05e-9	Breast cancer;
TGCT	trans	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg06636001	chr8:8085503	FLJ10661	0.75	7.04	0.53	1.14e-10	Retinal vascular caliber;
TGCT	cis	rs9393692	0.905	rs7450556	chr6:26299900	C/T	cg05868516	chr6:26286170	HIST1H4H	0.63	5.93	0.47	2.76e-8	Educational attainment;
TGCT	trans	rs1974653	0.672	rs9606248	chr22:20087539	A/G	cg08822737	chr17:71088851	SLC39A11	-0.93	-7.61	-0.56	5.97e-12	Schizophrenia;
TGCT	cis	rs12134245	0.776	rs12137878	chr1:91973210	G/T	cg07090678	chr1:91966139	CDC7	0.37	5.05	0.41	1.56e-6	Breast cancer;
TGCT	cis	rs922182	0.578	rs4776266	chr15:64236175	T/G	cg02919090	chr15:64263738	DAPK2	-0.33	-6.14	-0.48	1.05e-8	Blood protein levels;
TGCT	cis	rs2033711	0.755	rs4801587	chr19:58936679	C/A	cg13877915	chr19:58951672	ZNF132	0.88	11.14	0.71	2.09e-20	Uric acid clearance;
TGCT	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg18876405	chr7:65276391	NA	-0.33	-4.99	-0.41	1.97e-6	Aortic root size;
TGCT	cis	rs9611519	1.000	rs3818003	chr22:41609690	C/T	cg13695892	chr22:41940480	POLR3H	-0.51	-4.71	-0.39	6.49e-6	Neuroticism;
TGCT	cis	rs7666738	0.791	rs6851549	chr4:99029827	G/A	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2439831	0.867	rs2584702	chr15:43684914	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	8.12	0.59	4.02e-13	Lung cancer in ever smokers;
TGCT	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg13395646	chr4:1353034	KIAA1530	-0.47	-6.15	-0.48	9.8e-9	Obesity-related traits;
TGCT	cis	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg20637647	chr7:64974828	NA	-0.91	-5.01	-0.41	1.82e-6	Diabetic kidney disease;
TGCT	cis	rs42648	0.869	rs10234301	chr7:89918278	T/C	cg25739043	chr7:89950458	NA	-0.75	-7.35	-0.55	2.29e-11	Homocysteine levels;
TGCT	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs3806843	0.521	rs192231	chr5:140248539	C/T	cg09824255	chr5:140014002	CD14	-0.26	-4.64	-0.38	8.65e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7772486	0.846	rs6908063	chr6:146403618	T/C	cg23711669	chr6:146136114	FBXO30	0.89	9.47	0.65	2.36e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2013441	0.931	rs4925089	chr17:20064784	A/T	cg23224458	chr17:20280056	CCDC144C	0.38	4.61	0.38	9.96e-6	Obesity-related traits;
TGCT	cis	rs7216064	1.000	rs8079754	chr17:65887896	A/G	cg12091567	chr17:66097778	LOC651250	-0.84	-6.58	-0.51	1.18e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs71435601	0.506	rs547235	chr2:21384682	A/G	cg25035485	chr2:21266500	APOB	0.51	4.48	0.37	1.64e-5	Cholesterol, total;
TGCT	cis	rs782590	0.967	rs2627759	chr2:55853341	T/C	cg18811423	chr2:55921094	PNPT1	0.67	7.1	0.54	8.63e-11	Metabolic syndrome;
TGCT	cis	rs112217694	1.000	rs78289308	chr4:104643796	A/T	cg24090629	chr4:104641072	TACR3	-1.0	-5.19	-0.42	8.44e-7	Menarche (age at onset);
TGCT	cis	rs10510102	0.808	rs12253007	chr10:123698875	G/A	cg23691251	chr10:123688108	ATE1	-0.58	-4.58	-0.38	1.11e-5	Breast cancer;
TGCT	cis	rs3540	0.513	rs12905756	chr15:90924047	C/T	cg22089800	chr15:90895588	ZNF774	0.82	9.04	0.63	2.61e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	trans	rs7618501	0.699	rs2681781	chr3:49898273	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.91	10.04	0.67	1.04e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs3733585	0.673	rs7434391	chr4:9967682	C/G	cg00071950	chr4:10020882	SLC2A9	-0.57	-6.83	-0.52	3.47e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs56114371	0.777	rs200483	chr6:27774824	C/T	cg10876282	chr6:28092338	ZSCAN16	0.76	4.53	0.38	1.35e-5	Breast cancer;
TGCT	cis	rs7666738	0.830	rs9995370	chr4:98732145	T/G	cg17366294	chr4:99064904	C4orf37	0.65	6.78	0.52	4.31e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7236492	0.572	rs112024357	chr18:77175610	T/C	cg15644404	chr18:77186268	NFATC1	-0.43	-4.5	-0.37	1.57e-5	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs7119038	0.818	rs6589685	chr11:118612197	T/C	cg19308663	chr11:118741387	NA	0.22	4.56	0.38	1.22e-5	Sjögren's syndrome;
TGCT	cis	rs2067615	0.579	rs3782709	chr12:107205753	A/G	cg15890332	chr12:107067104	RFX4	0.23	4.44	0.37	1.98e-5	Heart rate;
TGCT	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-8.44	-0.6	6.87e-14	Platelet count;
TGCT	cis	rs137699	0.652	rs2413589	chr22:39755689	C/T	cg11247378	chr22:39784982	NA	0.51	5.62	0.45	1.22e-7	IgG glycosylation;
TGCT	cis	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg08975724	chr8:8085496	FLJ10661	0.56	4.91	0.4	2.85e-6	Mood instability;
TGCT	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg11062466	chr8:58055876	NA	0.42	4.49	0.37	1.61e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs3741489	1.000	rs4758889	chr12:133475533	C/T	cg08320014	chr12:133707169	ZNF10	-1.3	-4.52	-0.38	1.41e-5	Cognitive function;
TGCT	cis	rs1218582	0.596	rs906595	chr1:154822907	C/T	cg16680214	chr1:154839983	KCNN3	-0.26	-4.91	-0.4	2.8e-6	Prostate cancer;
TGCT	cis	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg00071950	chr4:10020882	SLC2A9	0.46	4.87	0.4	3.26e-6	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7975161	0.630	rs6539131	chr12:104644697	A/G	cg25273343	chr12:104657179	TXNRD1	-0.47	-5.85	-0.46	4.13e-8	Toenail selenium levels;
TGCT	cis	rs7944584	0.655	rs2856653	chr11:47361084	T/C	cg20307385	chr11:47447363	PSMC3	-0.79	-7.99	-0.58	8.1e-13	Fasting blood glucose;Fasting blood glucose (BMI interaction);
TGCT	cis	rs6700896	0.500	rs11208692	chr1:66107946	A/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.58	4.53	0.38	1.35e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs1008375	1.000	rs10939750	chr4:17692422	C/G	cg18681998	chr4:17616180	MED28	0.77	7.32	0.55	2.7e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1372520	0.567	rs2619349	chr4:90746646	G/T	cg15133208	chr4:90757351	SNCA	-0.5	-5.86	-0.47	4e-8	Neuroticism;
TGCT	cis	rs10411936	1.000	rs10411936	chr19:16548375	C/T	cg14704714	chr19:15740395	CYP4F8	-0.26	-4.59	-0.38	1.06e-5	White blood cell count;Multiple sclerosis;
TGCT	cis	rs1775715	0.707	rs2778669	chr10:32161541	C/T	cg14930904	chr10:32216787	ARHGAP12	0.54	5.3	0.43	5.12e-7	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs6701037	0.566	rs1014555	chr1:175134249	C/T	cg00321850	chr1:175162397	KIAA0040	0.38	5.04	0.41	1.61e-6	Alcohol dependence;
TGCT	cis	rs56104184	0.887	rs4801778	chr19:49370609	G/T	cg21252483	chr19:49399788	TULP2	-0.33	-5.2	-0.42	7.94e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs4072705	0.967	rs4076333	chr9:127385609	A/G	cg13476313	chr9:127244764	NR5A1	0.28	4.66	0.39	7.99e-6	Menarche (age at onset);
TGCT	cis	rs968451	0.865	rs12627761	chr22:39724137	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	-0.87	-8.73	-0.62	1.46e-14	Primary biliary cholangitis;
TGCT	cis	rs12950390	0.853	rs17773010	chr17:45858297	C/T	cg06532163	chr17:45867833	NA	0.37	5.89	0.47	3.46e-8	IgG glycosylation;
TGCT	cis	rs67311347	1.000	rs4246666	chr3:40407670	C/T	cg13683864	chr3:40499215	RPL14	-1.04	-10.79	-0.7	1.54e-19	Renal cell carcinoma;
TGCT	cis	rs73110464	0.505	rs2682296	chr12:53308265	G/A	cg25025879	chr12:53359317	NA	-0.39	-5.08	-0.42	1.35e-6	Cancer (pleiotropy);
TGCT	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg16405210	chr4:1374714	KIAA1530	0.24	4.52	0.38	1.41e-5	Longevity;
TGCT	cis	rs4499344	0.521	rs1862214	chr19:33035849	C/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.65	5.68	0.45	9.08e-8	Mean platelet volume;
TGCT	cis	rs7216064	0.861	rs73352810	chr17:65875184	G/A	cg12091567	chr17:66097778	LOC651250	-0.87	-6.85	-0.52	3.1e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg11644478	chr21:40555479	PSMG1	-0.54	-4.89	-0.4	3.02e-6	Menarche (age at onset);
TGCT	cis	rs9311474	0.575	rs4434138	chr3:52556890	A/G	cg10802521	chr3:52805072	NEK4	-0.72	-8.65	-0.61	2.18e-14	Electroencephalogram traits;
TGCT	cis	rs7267979	0.844	rs6107017	chr20:25232300	A/G	cg03522245	chr20:25566470	NINL	0.57	5.67	0.45	9.54e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg17775962	chr7:1200435	ZFAND2A	0.28	4.84	0.4	3.78e-6	Longevity;Endometriosis;
TGCT	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg11494091	chr17:61959527	GH2	0.6	13.05	0.76	5.09e-25	Prudent dietary pattern;
TGCT	cis	rs9928842	0.823	rs4888365	chr16:75282247	A/G	cg09066997	chr16:75300724	BCAR1	0.27	4.72	0.39	6.16e-6	Alcoholic chronic pancreatitis;
TGCT	cis	rs9534288	0.797	rs2094246	chr13:46602163	C/T	cg15192986	chr13:46630673	CPB2	-0.52	-7.53	-0.56	9.22e-12	Blood protein levels;
TGCT	cis	rs473651	0.692	rs579511	chr2:239334914	C/G	cg08773314	chr2:239334832	ASB1	0.48	8.09	0.59	4.68e-13	Multiple system atrophy;
TGCT	cis	rs9303542	0.625	rs4239209	chr17:46574317	T/A	cg25032089	chr17:46643351	HOXB3	-0.51	-5.59	-0.45	1.35e-7	Ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs9291683	0.679	rs13137795	chr4:10051506	G/A	cg11266682	chr4:10021025	SLC2A9	0.65	8.7	0.62	1.74e-14	Bone mineral density;
TGCT	cis	rs9291683	0.679	rs3756225	chr4:10094133	G/C	cg00071950	chr4:10020882	SLC2A9	-0.51	-5.68	-0.45	9.25e-8	Bone mineral density;
TGCT	cis	rs8031584	0.651	rs28664821	chr15:31172323	G/A	cg14829155	chr15:31115871	NA	0.34	4.49	0.37	1.63e-5	Huntington's disease progression;
TGCT	cis	rs7264396	0.635	rs2425166	chr20:34439391	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.04	-0.41	1.58e-6	Total cholesterol levels;
TGCT	cis	rs9372498	0.572	rs62422230	chr6:118959436	T/C	cg07617317	chr6:118971624	C6orf204	0.47	4.95	0.41	2.33e-6	Diastolic blood pressure;
TGCT	cis	rs35146811	0.771	rs6465762	chr7:99620554	G/A	cg13334819	chr7:99746414	C7orf59	-0.82	-7.38	-0.55	2.05e-11	Coronary artery disease;
TGCT	cis	rs9467711	0.659	rs35433030	chr6:26529890	G/A	cg16898833	chr6:26189333	HIST1H4D	1.25	5.86	0.47	3.88e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	9.52	0.65	1.86e-16	Platelet count;
TGCT	cis	rs6534347	0.613	rs6848834	chr4:123509713	T/G	cg10583651	chr4:123538969	IL21	-0.32	-4.49	-0.37	1.63e-5	Type 1 diabetes;
TGCT	cis	rs2070488	1.000	rs1002676	chr3:38444932	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.88	-9.55	-0.65	1.58e-16	Electrocardiographic conduction measures;
TGCT	cis	rs2439831	1.000	rs2245908	chr15:43731454	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.01	8.37	0.6	1.02e-13	Lung cancer in ever smokers;
TGCT	cis	rs9383153	1.000	rs2073518	chr6:16332730	T/C	cg20052079	chr6:15504923	JARID2	0.96	5.6	0.45	1.31e-7	Gambling;
TGCT	cis	rs7267979	0.714	rs3787082	chr20:25235736	A/T	cg03522245	chr20:25566470	NINL	0.48	4.59	0.38	1.06e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs7615952	0.736	rs11921945	chr3:125643719	A/G	cg07211511	chr3:129823064	LOC729375	-0.47	-7.89	-0.58	1.37e-12	Blood pressure (smoking interaction);
TGCT	trans	rs208520	0.690	rs12208310	chr6:66730108	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	11.06	0.7	3.28e-20	Exhaled nitric oxide output;
TGCT	cis	rs6570726	0.791	rs370654	chr6:145879005	C/G	cg23711669	chr6:146136114	FBXO30	0.89	9.93	0.67	1.82e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg11644478	chr21:40555479	PSMG1	-0.62	-5.84	-0.46	4.38e-8	Cognitive function;
TGCT	cis	rs1401999	1.000	rs939338	chr3:183704068	A/G	cg01324343	chr3:183735012	ABCC5	-0.82	-10.58	-0.69	4.84e-19	Anterior chamber depth;
TGCT	cis	rs7829975	0.660	rs10093926	chr8:8549020	A/C	cg15556689	chr8:8085844	FLJ10661	-0.71	-6.29	-0.49	4.97e-9	Mood instability;
TGCT	cis	rs2688608	0.530	rs71507081	chr10:75493136	G/A	cg04320760	chr10:75533139	FUT11	-0.4	-6.25	-0.49	6.11e-9	Inflammatory bowel disease;
TGCT	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg00814883	chr7:100076585	TSC22D4	-0.9	-9.56	-0.65	1.5e-16	Platelet count;
TGCT	cis	rs6933660	0.683	rs8180642	chr6:151756612	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.9	-9.68	-0.66	7.45e-17	Menarche (age at onset);
TGCT	cis	rs2404602	0.536	rs11072599	chr15:76774508	T/C	cg26408565	chr15:76604113	ETFA	-0.37	-4.97	-0.41	2.13e-6	Blood metabolite levels;
TGCT	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg23758822	chr17:41437982	NA	0.67	6.77	0.52	4.65e-10	Menopause (age at onset);
TGCT	cis	rs17122693	1.000	rs3759588	chr14:51062357	G/A	cg04730355	chr14:51134070	SAV1	1.21	8.51	0.61	4.69e-14	Cognitive performance;
TGCT	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg27535305	chr1:53392650	SCP2	-0.27	-5.29	-0.43	5.24e-7	Monocyte count;
TGCT	cis	rs9911578	1.000	rs8071280	chr17:57010225	T/C	cg05425664	chr17:57184151	TRIM37	-0.62	-6.18	-0.49	8.33e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs17433780	0.808	rs1074541	chr1:89509499	A/G	cg09516651	chr1:89888402	LOC400759	0.26	4.94	0.41	2.48e-6	Carotid intima media thickness;
TGCT	cis	rs739496	0.615	rs630616	chr12:112158966	T/C	cg10833066	chr12:111807467	FAM109A	0.37	4.79	0.39	4.76e-6	Platelet count;
TGCT	trans	rs12001652	0.579	rs12001843	chr9:14018558	C/G	cg16456503	chr16:67943052	PSKH1	0.43	6.62	0.51	9.91e-10	Carotid plaque burden;
TGCT	cis	rs7635838	0.859	rs34621655	chr3:11530121	T/C	cg00170343	chr3:11313890	ATG7	0.71	6.74	0.52	5.41e-10	HDL cholesterol;
TGCT	cis	rs7635838	0.722	rs2594982	chr3:11379958	C/T	cg00170343	chr3:11313890	ATG7	0.62	6.09	0.48	1.28e-8	HDL cholesterol;
TGCT	cis	rs7659604	0.539	rs11098645	chr4:122729251	G/A	cg06713675	chr4:122721982	EXOSC9	-0.69	-9.69	-0.66	7.11e-17	Type 2 diabetes;
TGCT	cis	rs9297145	0.585	rs17147666	chr7:98781457	A/C	cg05967295	chr7:98741636	SMURF1	-0.68	-8.35	-0.6	1.12e-13	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs10779751	0.922	rs2746638	chr1:11278125	T/C	cg08854313	chr1:11322531	MTOR	0.96	8.74	0.62	1.37e-14	Body mass index;
TGCT	cis	rs9486715	0.867	rs9373907	chr6:96981189	G/A	cg18709589	chr6:96969512	KIAA0776	0.78	7.61	0.56	6.08e-12	Headache;
TGCT	cis	rs10984561	1.000	rs57411773	chr9:122252587	T/A	cg14242995	chr9:122249943	NA	0.73	5.96	0.47	2.46e-8	Pulmonary function decline;
TGCT	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.31	-4.76	-0.39	5.36e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs12477438	0.520	rs1133978	chr2:99741964	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	10.3	0.68	2.42e-18	Chronic sinus infection;
TGCT	cis	rs7824557	0.564	rs2736294	chr8:11234626	T/C	cg21775007	chr8:11205619	TDH	-0.65	-6.4	-0.5	2.97e-9	Retinal vascular caliber;
TGCT	cis	rs1018836	0.628	rs35816262	chr8:91511017	C/G	cg16814680	chr8:91681699	NA	-0.84	-8.45	-0.6	6.52e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2070488	0.736	rs2070988	chr3:38437835	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.73	6.03	0.48	1.73e-8	Electrocardiographic conduction measures;
TGCT	cis	rs911555	0.546	rs28798508	chr14:104068970	T/C	cg26031613	chr14:104095156	KLC1	0.61	5.6	0.45	1.34e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs36051895	0.530	rs7036833	chr9:5226484	G/A	cg02405213	chr9:5042618	JAK2	-0.66	-8.18	-0.59	2.88e-13	Pediatric autoimmune diseases;
TGCT	cis	rs1670533	1.000	rs688785	chr4:1082707	G/C	cg20887711	chr4:1340912	KIAA1530	0.68	5.33	0.43	4.53e-7	Recombination rate (females);
TGCT	cis	rs1008375	1.000	rs114490726	chr4:17680898	T/C	cg10189774	chr4:17578691	LAP3	0.56	5.25	0.43	6.39e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10832963	1.000	rs11024739	chr11:18645843	A/C	cg09201001	chr11:18656081	SPTY2D1	-1.04	-11.69	-0.72	9.87e-22	Breast cancer;
TGCT	cis	rs896854	0.654	rs2011566	chr8:95971921	G/A	cg13393036	chr8:95962371	TP53INP1	-0.59	-8.06	-0.59	5.59e-13	Type 2 diabetes;
TGCT	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.31	0.43	4.9e-7	Prudent dietary pattern;
TGCT	cis	rs7833790	0.963	rs7836040	chr8:82698328	G/A	cg17211192	chr8:82754475	SNX16	-1.05	-8.28	-0.6	1.63e-13	Diastolic blood pressure;
TGCT	cis	rs74233809	1.000	rs11191560	chr10:104869038	A/G	cg05855489	chr10:104503620	C10orf26	0.84	4.47	0.37	1.71e-5	Birth weight;
TGCT	cis	rs61990749	0.597	rs4632066	chr14:78247282	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.61	-4.52	-0.38	1.43e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs6424115	0.594	rs7519640	chr1:24069637	G/C	cg15997130	chr1:24165203	NA	0.62	6.36	0.5	3.5e-9	Immature fraction of reticulocytes;
TGCT	cis	rs1116547	0.684	rs2091804	chr5:112578507	A/G	cg04138046	chr5:112608004	MCC	-0.46	-4.65	-0.39	8.46e-6	Cerebral amyloid angiopathy;
TGCT	cis	rs796364	0.806	rs4673634	chr2:200863349	A/C	cg17644776	chr2:200775616	C2orf69	0.33	5.0	0.41	1.91e-6	Schizophrenia;
TGCT	cis	rs1971762	0.527	rs4759211	chr12:53930945	T/C	cg16917193	chr12:54089295	NA	1.02	10.39	0.68	1.44e-18	Height;
TGCT	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg10802521	chr3:52805072	NEK4	-0.71	-8.79	-0.62	1.04e-14	Bipolar disorder;
TGCT	cis	rs9467773	1.000	rs9393731	chr6:26529374	C/T	cg09904177	chr6:26538194	HMGN4	0.65	6.53	0.51	1.53e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg23758822	chr17:41437982	NA	0.68	6.76	0.52	4.84e-10	Menopause (age at onset);
TGCT	cis	rs7829975	0.557	rs7816427	chr8:8545884	T/C	cg17143192	chr8:8559678	CLDN23	-0.52	-5.29	-0.43	5.45e-7	Mood instability;
TGCT	cis	rs7772486	0.754	rs9497419	chr6:146142609	T/C	cg23711669	chr6:146136114	FBXO30	0.9	10.15	0.67	5.45e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7220711	1.000	rs12602349	chr17:41792236	T/C	cg26893861	chr17:41843967	DUSP3	0.5	4.49	0.37	1.63e-5	Bone mineral density (spine);Bone mineral density (hip);
TGCT	cis	rs6977955	1.000	rs4722762	chr7:28178262	G/T	cg23620719	chr7:28220237	JAZF1	0.64	4.82	0.4	4.13e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs13191362	1.000	rs73016459	chr6:163066323	C/A	cg21926612	chr6:163149169	PACRG;PARK2	1.06	8.12	0.59	3.96e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7552404	1.000	rs4559448	chr1:76203456	A/G	cg10523679	chr1:76189770	ACADM	0.9	9.71	0.66	6.5e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs35771425	0.642	rs3767380	chr1:211452845	A/G	cg25617285	chr1:211431773	RCOR3	-0.48	-5.48	-0.44	2.27e-7	Educational attainment (years of education);
TGCT	cis	rs5769765	0.908	rs138880	chr22:50218611	A/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.06	-11.49	-0.72	2.94e-21	Schizophrenia;
TGCT	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg11301795	chr4:187892539	NA	-0.3	-4.48	-0.37	1.69e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs35306767	0.953	rs12259338	chr10:969377	C/T	cg26597838	chr10:835615	NA	0.63	9.0	0.63	3.31e-15	Eosinophil percentage of granulocytes;
TGCT	cis	rs9929218	0.953	rs12930910	chr16:68762520	A/G	cg01251360	chr16:68772225	CDH1	0.29	4.95	0.41	2.34e-6	Colorectal cancer;
TGCT	cis	rs6500602	0.647	rs4785967	chr16:4523208	G/A	cg08645402	chr16:4508243	NA	0.18	4.99	0.41	1.98e-6	Schizophrenia;
TGCT	cis	rs9303542	0.694	rs8071207	chr17:46584016	T/C	cg25032089	chr17:46643351	HOXB3	-0.52	-5.82	-0.46	4.61e-8	Ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs208515	0.525	rs1351866	chr6:66696969	A/G	cg07460842	chr6:66804631	NA	0.88	9.36	0.64	4.39e-16	Exhaled nitric oxide levels;
TGCT	cis	rs4733781	1.000	rs2033059	chr8:131271216	A/G	cg16277922	chr8:131349729	ASAP1	-0.44	-5.56	-0.45	1.55e-7	Tuberculosis;
TGCT	cis	rs7552404	0.924	rs7535991	chr1:76162624	C/T	cg03433033	chr1:76189801	ACADM	0.82	9.89	0.66	2.31e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7647973	1.000	rs13096474	chr3:49443081	C/T	cg05785598	chr3:49045655	WDR6	-0.39	-4.75	-0.39	5.56e-6	Menarche (age at onset);
TGCT	cis	rs8180040	0.676	rs1108301	chr3:47029426	G/A	cg27129171	chr3:47204927	SETD2	-0.72	-8.83	-0.62	8.21e-15	Colorectal cancer;
TGCT	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.44	4.66	0.39	7.86e-6	Lymphocyte counts;
TGCT	cis	rs7552404	1.000	rs1498315	chr1:76159225	G/A	cg22875332	chr1:76189707	ACADM	0.79	9.77	0.66	4.68e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs75686122	0.892	rs80350345	chr8:104608845	G/A	cg04852977	chr8:104510831	NA	0.59	4.45	0.37	1.92e-5	Cocaine dependence;
TGCT	cis	rs16867321	0.671	rs1544848	chr2:181487422	A/G	cg23363182	chr2:181467187	NA	-0.47	-4.85	-0.4	3.65e-6	Obesity;
TGCT	cis	rs1153858	0.725	rs74572151	chr15:45647526	T/G	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.62e-8	Homoarginine levels;
TGCT	cis	rs62064224	0.589	rs4523973	chr17:30809455	G/A	cg18200150	chr17:30822561	MYO1D	0.42	4.99	0.41	2.02e-6	Schizophrenia;
TGCT	cis	rs3749237	0.595	rs7637999	chr3:49535115	C/T	cg02487422	chr3:49467188	NICN1	0.61	6.29	0.49	5.08e-9	Resting heart rate;
TGCT	cis	rs17122693	0.748	rs72679598	chr14:51107157	C/G	cg04730355	chr14:51134070	SAV1	1.33	10.78	0.7	1.59e-19	Cognitive performance;
TGCT	cis	rs10186029	0.676	rs10932465	chr2:213968389	T/C	cg08319019	chr2:214017104	IKZF2	0.63	5.79	0.46	5.4e-8	Systemic sclerosis;
TGCT	cis	rs12762955	0.561	rs10752022	chr10:1043798	C/T	cg20503657	chr10:835505	NA	-0.4	-5.21	-0.42	7.61e-7	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs881375	0.967	rs758959	chr9:123676699	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.44	4.78	0.39	4.84e-6	Rheumatoid arthritis;
TGCT	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg08045932	chr20:61659980	NA	0.47	8.93	0.63	4.84e-15	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs4494114	0.967	rs9438986	chr1:39369652	T/G	cg25970120	chr1:39325951	RRAGC	-0.6	-6.32	-0.49	4.21e-9	Blood protein levels;
TGCT	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg24846343	chr22:24311635	DDTL	-0.23	-5.85	-0.46	4.19e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs10540	0.730	rs61876338	chr11:493730	A/G	cg03934478	chr11:495069	RNH1	0.36	5.88	0.47	3.58e-8	Body mass index;
TGCT	cis	rs9393692	0.905	rs4412192	chr6:26290377	A/G	cg05868516	chr6:26286170	HIST1H4H	-0.56	-5.35	-0.43	4.01e-7	Educational attainment;
TGCT	cis	rs9952991	0.941	rs7237497	chr18:12777325	T/C	cg24737193	chr18:12778029	NA	0.54	6.03	0.48	1.76e-8	Inflammatory skin disease;
TGCT	cis	rs6964587	1.000	rs7797369	chr7:91570615	C/A	cg17063962	chr7:91808500	NA	-0.9	-9.67	-0.66	7.91e-17	Breast cancer;
TGCT	cis	rs394563	0.726	rs6922130	chr6:149672375	C/G	cg03678062	chr6:149772716	ZC3H12D	0.41	5.3	0.43	5.09e-7	Dupuytren's disease;
TGCT	cis	rs3784262	0.904	rs4646620	chr15:58258241	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.49	-7.59	-0.56	6.66e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs2439831	0.850	rs28476182	chr15:44139643	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	6.2	0.49	7.73e-9	Lung cancer in ever smokers;
TGCT	cis	rs42648	0.869	rs42617	chr7:89952046	T/A	cg25739043	chr7:89950458	NA	-0.68	-6.84	-0.52	3.2e-10	Homocysteine levels;
TGCT	cis	rs3733585	0.579	rs4235356	chr4:10123106	G/C	cg11266682	chr4:10021025	SLC2A9	-0.55	-6.41	-0.5	2.69e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs1801251	1.000	rs7558609	chr2:233700379	C/T	cg25237894	chr2:233734115	C2orf82	0.33	5.98	0.47	2.18e-8	Coronary artery disease;
TGCT	cis	rs9325144	0.505	rs7955162	chr12:38711658	G/A	cg13010199	chr12:38710504	ALG10B	0.66	5.16	0.42	9.36e-7	Morning vs. evening chronotype;
TGCT	cis	rs881375	0.715	rs7858209	chr9:123645760	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	5.31	0.43	4.79e-7	Rheumatoid arthritis;
TGCT	cis	rs8072100	0.790	rs1962307	chr17:45707871	A/G	cg10024583	chr17:45772800	TBKBP1	0.48	4.86	0.4	3.53e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs4742903	0.967	rs2274725	chr9:106864570	C/T	cg21169611	chr9:106856078	SMC2	0.49	4.6	0.38	1.03e-5	High-grade serous ovarian cancer;Breast cancer;
TGCT	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg05368731	chr17:41323189	NBR1	1.12	11.33	0.71	7.16e-21	Menopause (age at onset);
TGCT	cis	rs9467773	0.587	rs3208733	chr6:26414425	C/T	cg05738196	chr6:26577821	NA	-0.52	-5.52	-0.44	1.89e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2230307	0.518	rs2810425	chr1:100665072	G/C	cg24955406	chr1:100503596	HIAT1	-0.7	-4.72	-0.39	6.32e-6	Carotid intima media thickness;
TGCT	cis	rs4929949	0.752	rs4758067	chr11:8493429	C/T	cg12906748	chr11:8954576	C11orf16	0.34	4.52	0.38	1.43e-5	Body mass index;
TGCT	cis	rs916888	0.821	rs199509	chr17:44858728	G/A	cg16520312	chr17:43971471	MAPT;LOC100128977	0.57	4.86	0.4	3.45e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	6.76	0.52	4.71e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs861020	1.000	rs12134698	chr1:209987801	C/A	cg05527609	chr1:210001259	C1orf107	-0.91	-7.4	-0.55	1.84e-11	Orofacial clefts;
TGCT	cis	rs12497850	0.805	rs11130176	chr3:48844077	A/G	cg06212747	chr3:49208901	KLHDC8B	0.62	5.83	0.46	4.42e-8	Parkinson's disease;
TGCT	cis	rs8180040	0.967	rs4858890	chr3:47405456	A/G	cg27129171	chr3:47204927	SETD2	-0.68	-7.94	-0.58	1.01e-12	Colorectal cancer;
TGCT	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg07507251	chr3:52567010	NT5DC2	0.47	6.74	0.52	5.28e-10	Electroencephalogram traits;
TGCT	cis	rs2657888	0.899	rs7300877	chr12:56933233	C/A	cg23002907	chr12:56915593	RBMS2	0.44	6.14	0.48	1.03e-8	Adiponectin levels;
TGCT	cis	rs7666738	0.830	rs10028505	chr4:98962310	C/A	cg17366294	chr4:99064904	C4orf37	0.74	7.56	0.56	7.89e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6546537	1.000	rs6727435	chr2:69864236	C/A	cg10773587	chr2:69614142	GFPT1	-0.71	-6.21	-0.49	7.48e-9	Serum thyroid-stimulating hormone levels;
TGCT	cis	rs910316	1.000	rs9805979	chr14:75566209	G/A	cg11812906	chr14:75593930	NEK9	0.74	7.25	0.55	3.9e-11	Height;
TGCT	cis	rs3784262	0.967	rs12910752	chr15:58314679	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.52	-7.93	-0.58	1.1e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs11249608	0.548	rs2132672	chr5:178457742	A/C	cg23951258	chr5:178450506	ZNF879	0.44	4.56	0.38	1.22e-5	Pubertal anthropometrics;
TGCT	cis	rs13401104	0.587	rs7569760	chr2:237145713	A/C	cg19324714	chr2:237145437	ASB18	0.48	5.03	0.41	1.67e-6	Educational attainment;
TGCT	cis	rs950169	0.845	rs4502182	chr15:84923520	A/G	cg12863693	chr15:85201151	NMB	0.41	4.5	0.38	1.51e-5	Schizophrenia;
TGCT	cis	rs79349575	0.716	rs46522	chr17:46988597	C/T	cg07967210	chr17:47022446	SNF8	0.44	6.21	0.49	7.17e-9	Type 2 diabetes;
TGCT	cis	rs873946	0.689	rs2803993	chr10:134550606	T/C	cg27286337	chr10:134555280	INPP5A	0.44	5.4	0.44	3.27e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs9486719	0.690	rs2092094	chr6:96844123	G/C	cg06623918	chr6:96969491	KIAA0776	0.93	7.08	0.54	9.59e-11	Migraine;Coronary artery disease;
TGCT	cis	rs6598955	0.572	rs6598951	chr1:26592714	G/T	cg04990556	chr1:26633338	UBXN11	0.64	4.91	0.4	2.78e-6	Obesity-related traits;
TGCT	cis	rs7000551	0.715	rs2469745	chr8:22343464	C/T	cg12081754	chr8:22256438	SLC39A14	0.31	5.09	0.42	1.29e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs9467603	1.000	rs13201341	chr6:25822661	C/T	cg16898833	chr6:26189333	HIST1H4D	1.38	6.09	0.48	1.31e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9399401	0.667	rs6903424	chr6:142699948	A/C	cg04461802	chr6:142623433	GPR126	0.46	4.66	0.39	8.04e-6	Chronic obstructive pulmonary disease;
TGCT	cis	rs6088590	1.000	rs10048849	chr20:33419680	C/T	cg24642439	chr20:33292090	TP53INP2	0.68	5.92	0.47	2.93e-8	Coronary artery disease;
TGCT	cis	rs473651	0.692	rs579511	chr2:239334914	C/G	cg21699342	chr2:239360505	ASB1	0.19	5.43	0.44	2.87e-7	Multiple system atrophy;
TGCT	cis	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg08975724	chr8:8085496	FLJ10661	0.53	4.76	0.39	5.29e-6	Mood instability;
TGCT	cis	rs7267979	0.844	rs869358	chr20:25374674	A/G	cg16686733	chr20:25566563	NINL	-0.52	-4.93	-0.4	2.61e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs55794721	0.509	rs11249248	chr1:25753051	T/C	cg09222892	chr1:25734099	RHCE	-0.43	-7.1	-0.54	8.54e-11	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg12311346	chr5:56204834	C5orf35	-0.67	-6.78	-0.52	4.3e-10	Initial pursuit acceleration;
TGCT	cis	rs910187	0.624	rs6066219	chr20:45793967	A/T	cg27589058	chr20:45804311	EYA2	-0.34	-6.81	-0.52	3.81e-10	Migraine;
TGCT	cis	rs77972916	0.505	rs34247383	chr2:43532780	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.38	-5.49	-0.44	2.18e-7	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs8014252	0.803	rs73282127	chr14:70986413	T/C	cg11204974	chr14:71022665	NA	-0.53	-4.46	-0.37	1.79e-5	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
TGCT	cis	rs7714584	1.000	rs10463307	chr5:150254620	C/T	cg22134413	chr5:150180641	NA	0.89	6.87	0.53	2.72e-10	Crohn's disease;
TGCT	cis	rs7804356	1.000	rs3801844	chr7:26829759	C/T	cg03456212	chr7:26904342	SKAP2	0.63	4.83	0.4	3.98e-6	Type 1 diabetes;
TGCT	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg17178900	chr1:205818956	PM20D1	0.6	7.63	0.57	5.3e-12	Menarche (age at onset);
TGCT	cis	rs858239	0.600	rs10266123	chr7:23136487	G/C	cg05602783	chr7:23145260	KLHL7	-0.71	-5.95	-0.47	2.52e-8	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs9393692	1.000	rs9393692	chr6:26276650	A/G	cg00631329	chr6:26305371	NA	-0.45	-6.9	-0.53	2.42e-10	Educational attainment;
TGCT	cis	rs6500602	0.826	rs11076830	chr16:4460049	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.43	6.7	0.52	6.4e-10	Schizophrenia;
TGCT	cis	rs12148488	0.738	rs4886417	chr15:75330159	T/G	cg10253484	chr15:75165896	SCAMP2	-0.57	-4.95	-0.41	2.4e-6	Caffeine consumption;
TGCT	cis	rs586688	1.000	rs492563	chr1:201631471	C/T	cg07139329	chr1:201708558	NAV1	-0.45	-4.67	-0.39	7.6e-6	Obesity-related traits;
TGCT	cis	rs11764590	0.950	rs62444919	chr7:2109499	C/T	cg25834613	chr7:1915315	MAD1L1	-0.52	-5.04	-0.41	1.64e-6	Neuroticism;
TGCT	cis	rs13223928	0.621	rs10228451	chr7:3150859	C/G	cg19214707	chr7:3157722	NA	0.48	6.98	0.53	1.56e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
TGCT	cis	rs9486719	0.947	rs9398072	chr6:96911304	T/C	cg18709589	chr6:96969512	KIAA0776	0.73	5.75	0.46	6.45e-8	Migraine;Coronary artery disease;
TGCT	cis	rs8031584	0.781	rs4779498	chr15:31177476	C/T	cg08109568	chr15:31115862	NA	-0.4	-5.25	-0.43	6.5e-7	Huntington's disease progression;
TGCT	cis	rs12142240	0.698	rs6667861	chr1:46815749	T/C	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg16624210	chr5:671434	TPPP	0.42	4.68	0.39	7.38e-6	Obesity-related traits;
TGCT	cis	rs12701220	0.894	rs12701348	chr7:1039457	C/T	cg07217954	chr7:1067459	C7orf50	-0.46	-4.65	-0.39	8.34e-6	Bronchopulmonary dysplasia;
TGCT	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg04267008	chr7:1944627	MAD1L1	-0.4	-5.4	-0.44	3.25e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs12579753	1.000	rs11115015	chr12:82174543	T/C	cg07988820	chr12:82153109	PPFIA2	-0.65	-6.79	-0.52	4.09e-10	Resting heart rate;
TGCT	cis	rs62244186	0.659	rs9835270	chr3:44553722	G/A	cg10108389	chr3:44770937	ZNF501	-0.47	-4.64	-0.38	8.9e-6	Depressive symptoms;
TGCT	cis	rs9467711	0.651	rs55912630	chr6:25866935	T/C	cg16898833	chr6:26189333	HIST1H4D	1.34	6.07	0.48	1.47e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9372253	1.000	rs7740028	chr6:110719180	A/G	cg19196401	chr6:110721138	DDO	-0.52	-7.56	-0.56	7.8e-12	Platelet distribution width;
TGCT	cis	rs4843747	0.749	rs13333619	chr16:88072076	C/T	cg06915872	chr16:87998081	BANP	-0.3	-4.52	-0.38	1.44e-5	Menopause (age at onset);
TGCT	cis	rs7666738	0.830	rs4699594	chr4:98980775	T/C	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7666738	0.830	rs13138920	chr4:99020786	A/G	cg17366294	chr4:99064904	C4orf37	0.68	7.04	0.53	1.17e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs447921	0.768	rs34546420	chr17:74459602	C/A	cg09812376	chr17:74270190	QRICH2	-0.46	-4.54	-0.38	1.3e-5	Mitochondrial DNA levels;
TGCT	trans	rs11785693	0.909	rs62489557	chr8:4968371	A/G	cg21607066	chr6:79787807	PHIP	0.91	6.8	0.52	3.93e-10	Neuroticism (multi-trait analysis);Neuroticism;
TGCT	cis	rs2302045	1.000	rs2302052	chr2:242063448	G/A	cg04553960	chr2:241721320	KIF1A	-0.69	-4.74	-0.39	5.8e-6	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio);
TGCT	cis	rs7666738	0.830	rs991168	chr4:98928293	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9916302	0.800	rs8081220	chr17:37473157	A/C	cg15445000	chr17:37608096	MED1	-0.35	-5.05	-0.41	1.53e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs6671200	1.000	rs71654417	chr1:95661200	G/A	cg26537280	chr1:95699037	RWDD3	0.68	5.49	0.44	2.15e-7	Stearic acid (18:0) levels;
TGCT	cis	rs9914988	0.943	rs59461345	chr17:27151852	G/T	cg20469991	chr17:27169893	C17orf63	-0.72	-5.09	-0.42	1.28e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs931127	0.719	rs11227259	chr11:65459404	T/C	cg17480646	chr11:65405466	SIPA1	-0.43	-5.74	-0.46	6.76e-8	Systemic lupus erythematosus;
TGCT	cis	rs7666738	0.830	rs7678557	chr4:99057329	A/G	cg17366294	chr4:99064904	C4orf37	0.73	7.45	0.56	1.4e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg08859206	chr1:53392774	SCP2	0.35	5.04	0.41	1.62e-6	Monocyte count;
TGCT	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg21963583	chr11:68658836	MRPL21	0.35	5.8	0.46	5.09e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs826838	0.967	rs1352122	chr12:39130885	G/A	cg26384229	chr12:38710491	ALG10B	-0.86	-7.7	-0.57	3.65e-12	Heart rate;
TGCT	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg06418219	chr1:154948305	SHC1;CKS1B	-0.69	-7.06	-0.54	1.07e-10	Prostate cancer;
TGCT	cis	rs71007656	1	rs71007656	chr10:37970845	CGGCTG/C	cg25427524	chr10:38739819	LOC399744	-0.33	-6.48	-0.5	1.99e-9	Extrinsic epigenetic age acceleration;
TGCT	cis	rs6459804	0.527	rs60688149	chr7:157533159	G/A	cg11757124	chr7:157526947	PTPRN2	-0.46	-5.36	-0.43	3.87e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs9467773	0.596	rs2451751	chr6:26646714	T/C	cg09904177	chr6:26538194	HMGN4	0.68	6.27	0.49	5.41e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs11122272	0.701	rs11582413	chr1:231530098	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-6.34	-0.49	3.83e-9	Hemoglobin concentration;
TGCT	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.25	-4.47	-0.37	1.75e-5	Total body bone mineral density;
TGCT	trans	rs561341	0.941	rs112569713	chr17:30271738	C/T	cg20587970	chr11:113659929	NA	-1.03	-10.98	-0.7	5.21e-20	Hip circumference adjusted for BMI;
TGCT	cis	rs1062177	0.756	rs2915827	chr5:151119705	T/A	cg12924095	chr5:151150029	G3BP1	-0.34	-4.97	-0.41	2.17e-6	Preschool internalizing problems;
TGCT	cis	rs17001868	0.568	rs9611312	chr22:40734790	T/C	cg07138101	chr22:40742427	ADSL	0.73	5.38	0.44	3.57e-7	Mammographic density (dense area);
TGCT	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.96	-8.31	-0.6	1.43e-13	Platelet count;
TGCT	cis	rs12484776	0.786	rs6001794	chr22:40529415	A/C	cg07138101	chr22:40742427	ADSL	-0.6	-4.84	-0.4	3.73e-6	Uterine fibroids;
TGCT	cis	rs7833790	0.929	rs10958048	chr8:82792914	C/T	cg27398817	chr8:82754497	SNX16	0.74	5.19	0.42	8.37e-7	Diastolic blood pressure;
TGCT	cis	rs6840360	0.615	rs4696290	chr4:152631472	A/G	cg17479576	chr4:152424074	FAM160A1	-0.53	-5.33	-0.43	4.47e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7552404	0.924	rs3818855	chr1:76198785	C/T	cg22875332	chr1:76189707	ACADM	0.76	9.36	0.64	4.49e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7666738	0.830	rs62318472	chr4:98926030	G/A	cg17366294	chr4:99064904	C4orf37	0.72	7.39	0.55	1.87e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9388451	0.559	rs1777210	chr6:126098916	T/G	cg05901451	chr6:126070800	HEY2	-0.94	-11.89	-0.73	3.1e-22	Brugada syndrome;
TGCT	cis	rs6714788	0.565	rs9308833	chr2:100662618	C/T	cg07810366	chr2:100720526	AFF3	-0.36	-5.28	-0.43	5.55e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs6558530	0.897	rs7838456	chr8:1707591	T/G	cg09410841	chr8:1729607	CLN8	0.92	10.2	0.68	4.08e-18	Systolic blood pressure;
TGCT	cis	rs4711350	1.000	rs10947436	chr6:33739960	A/G	cg00334056	chr6:33755658	LEMD2	-0.29	-4.63	-0.38	9.08e-6	Schizophrenia;
TGCT	cis	rs2777491	0.522	rs7173571	chr15:41712807	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.5	-7.0	-0.53	1.46e-10	Ulcerative colitis;
TGCT	cis	rs2235642	0.787	rs2235646	chr16:1601287	A/G	cg07341220	chr16:1583899	IFT140;TMEM204	-0.31	-4.88	-0.4	3.26e-6	Coronary artery disease;
TGCT	cis	rs9486719	0.857	rs13208321	chr6:96860354	C/T	cg18709589	chr6:96969512	KIAA0776	-0.69	-5.59	-0.45	1.38e-7	Migraine;Coronary artery disease;
TGCT	cis	rs2404618	0.587	rs6994849	chr8:1492839	G/T	cg13402656	chr8:1511478	DLGAP2	0.36	6.29	0.49	5.03e-9	Lung cancer;
TGCT	cis	rs1483890	0.642	rs9825849	chr3:69404575	C/T	cg22125112	chr3:69402811	FRMD4B	0.28	4.57	0.38	1.18e-5	Resting heart rate;
TGCT	cis	rs12497850	0.931	rs11920534	chr3:48937761	G/T	cg18654377	chr3:49208889	KLHDC8B	-0.42	-5.52	-0.44	1.93e-7	Parkinson's disease;
TGCT	cis	rs3784262	1.000	rs7170896	chr15:58252393	T/A	cg12031962	chr15:58353849	ALDH1A2	-0.5	-7.79	-0.57	2.28e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs17293817	0.625	rs10794748	chr10:1421516	A/G	cg19299265	chr10:1975631	NA	-0.26	-4.5	-0.37	1.55e-5	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	trans	rs9951602	0.512	rs9953258	chr18:76651199	A/C	cg02800362	chr5:177631904	HNRNPAB	1.15	13.03	0.76	5.64e-25	Obesity-related traits;
TGCT	cis	rs6952808	0.636	rs60605830	chr7:1949198	A/G	cg22963979	chr7:1858916	MAD1L1	-0.36	-5.49	-0.44	2.18e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs33794	0.588	rs28295	chr3:45252249	G/A	cg18645101	chr3:44551900	NA	0.51	4.55	0.38	1.26e-5	Lung function (forced expiratory volume in 1 second);
TGCT	cis	rs17270561	1.000	rs12200962	chr6:25828986	T/C	cg15022984	chr6:26056706	HIST1H1C	-0.73	-4.6	-0.38	1.02e-5	Iron status biomarkers;
TGCT	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg21724239	chr8:58056113	NA	0.4	5.07	0.41	1.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs765787	0.530	rs1706831	chr15:45516230	T/C	cg24006582	chr15:45444508	DUOX1	-0.26	-5.62	-0.45	1.19e-7	Uric acid levels;
TGCT	cis	rs9883204	1.000	rs35841686	chr3:123087916	T/A	cg04890266	chr3:123102914	ADCY5	0.34	4.74	0.39	5.7e-6	Birth weight;
TGCT	cis	rs4803468	1.000	rs166925	chr19:41926098	T/C	cg09537434	chr19:41945824	ATP5SL	-0.92	-10.57	-0.69	5.19e-19	Height;
TGCT	cis	rs9611565	0.559	rs6002408	chr22:41967870	C/T	cg03806693	chr22:41940476	POLR3H	-1.07	-11.03	-0.7	4e-20	Vitiligo;
TGCT	cis	rs595982	0.559	rs4802516	chr19:49366170	T/C	cg21252483	chr19:49399788	TULP2	-0.42	-6.39	-0.5	3.02e-9	Red cell distribution width;
TGCT	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg26354017	chr1:205819088	PM20D1	0.55	6.55	0.51	1.4e-9	Menarche (age at onset);
TGCT	cis	rs9682041	0.627	rs4955722	chr3:170102959	G/T	cg11886554	chr3:170076028	SKIL	0.62	4.82	0.4	4.11e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg11764359	chr7:65958608	NA	-0.57	-5.25	-0.43	6.43e-7	Aortic root size;
TGCT	cis	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg18252515	chr7:66147081	NA	-1.17	-7.49	-0.56	1.13e-11	Diabetic kidney disease;
TGCT	trans	rs916888	0.647	rs199523	chr17:44848517	C/A	cg10053473	chr17:62856997	LRRC37A3	0.4	6.73	0.52	5.74e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs1499614	1.000	rs2707832	chr7:66136549	C/T	cg18252515	chr7:66147081	NA	-1.26	-7.95	-0.58	9.71e-13	Gout;
TGCT	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg05368731	chr17:41323189	NBR1	1.16	13.7	0.78	1.41e-26	Menopause (age at onset);
TGCT	cis	rs7698623	1.000	rs7698623	chr4:88755828	A/G	cg02735620	chr4:88950514	PKD2	-0.44	-4.6	-0.38	1.02e-5	Cardiovascular disease risk factors;
TGCT	cis	rs3091242	0.967	rs3091240	chr1:25676935	G/T	cg09222892	chr1:25734099	RHCE	-0.42	-6.69	-0.52	6.75e-10	Erythrocyte sedimentation rate;
TGCT	cis	rs6121246	0.567	rs6060295	chr20:30198473	C/T	cg21427119	chr20:30132790	HM13	-0.43	-6.17	-0.48	8.86e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs8013055	1.000	rs8013055	chr14:105990620	T/A	cg19700328	chr14:106028568	NA	-0.48	-4.93	-0.4	2.62e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs427394	0.659	rs274675	chr5:6755319	C/T	cg10857441	chr5:6722123	POLS	-0.32	-6.94	-0.53	1.95e-10	Menopause (age at onset);
TGCT	cis	rs1692580	0.777	rs7547453	chr1:2195117	C/T	cg21194808	chr1:2205498	SKI	0.29	5.59	0.45	1.38e-7	Coronary artery disease;
TGCT	cis	rs9549367	0.865	rs3861721	chr13:113906308	C/T	cg18105134	chr13:113819100	PROZ	-0.34	-5.58	-0.45	1.41e-7	Platelet distribution width;
TGCT	cis	rs910187	1.000	rs4555399	chr20:45837896	G/A	cg27589058	chr20:45804311	EYA2	-0.32	-5.86	-0.47	3.86e-8	Migraine;
TGCT	cis	rs2404602	0.692	rs34478400	chr15:76923510	C/T	cg22467129	chr15:76604101	ETFA	-0.44	-4.98	-0.41	2.07e-6	Blood metabolite levels;
TGCT	trans	rs1814175	0.817	rs4881627	chr11:49953955	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.36	-7.14	-0.54	6.88e-11	Height;
TGCT	cis	rs9650657	0.585	rs4841401	chr8:10489592	C/G	cg27411982	chr8:10470053	RP1L1	-0.23	-4.89	-0.4	3.03e-6	Neuroticism;
TGCT	cis	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg18252515	chr7:66147081	NA	-1.31	-8.18	-0.59	2.87e-13	Diabetic kidney disease;
TGCT	cis	rs4237845	0.844	rs4630335	chr12:58302258	A/G	cg02175503	chr12:58329896	NA	0.58	5.92	0.47	3e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs72615157	0.634	rs11762932	chr7:99792666	C/T	cg00814883	chr7:100076585	TSC22D4	0.56	5.44	0.44	2.69e-7	Lung function (FEV1/FVC);
TGCT	cis	rs240764	0.658	rs2132168	chr6:101178491	G/A	cg09795085	chr6:101329169	ASCC3	-0.51	-4.51	-0.38	1.48e-5	Neuroticism;
TGCT	trans	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg27523141	chr10:43048294	ZNF37B	0.73	8.58	0.61	3.32e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs3617	0.573	rs9880978	chr3:52923251	C/G	cg10802521	chr3:52805072	NEK4	-0.59	-6.71	-0.52	6.06e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs11122272	0.766	rs2808608	chr1:231543175	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-6.71	-0.52	6.09e-10	Hemoglobin concentration;
TGCT	cis	rs6089584	0.528	rs881994	chr20:60623931	G/A	cg13770153	chr20:60521292	NA	-0.43	-5.09	-0.42	1.3e-6	Body mass index;
TGCT	cis	rs9902453	1.000	rs4465649	chr17:28394747	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.76	-6.7	-0.52	6.38e-10	Coffee consumption (cups per day);
TGCT	cis	rs1903068	0.925	rs1551642	chr4:55994210	T/C	cg01777861	chr4:56023843	NA	0.56	6.43	0.5	2.54e-9	Endometriosis;
TGCT	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-5.1	-0.42	1.23e-6	Bipolar disorder;
TGCT	trans	rs3780486	0.846	rs7865745	chr9:33140976	A/G	cg20290983	chr6:43655470	MRPS18A	-1.11	-14.0	-0.78	2.68e-27	IgG glycosylation;
TGCT	cis	rs12950390	0.853	rs4794107	chr17:45843159	T/G	cg24803719	chr17:45855879	NA	-0.47	-4.75	-0.39	5.6e-6	IgG glycosylation;
TGCT	cis	rs7267979	1.000	rs2424716	chr20:25423538	G/A	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs950776	0.714	rs472054	chr15:78887994	A/G	cg06917634	chr15:78832804	PSMA4	-0.65	-5.33	-0.43	4.48e-7	Sudden cardiac arrest;
TGCT	cis	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg07424592	chr7:64974309	NA	1.36	8.15	0.59	3.36e-13	Diabetic kidney disease;
TGCT	cis	rs12188164	0.686	rs72711365	chr5:416672	G/A	cg22025206	chr5:502436	SLC9A3	-0.26	-4.69	-0.39	7.2e-6	Cystic fibrosis severity;
TGCT	cis	rs904251	0.523	rs1776454	chr6:37482099	C/T	cg01843034	chr6:37503916	NA	-0.56	-7.56	-0.56	7.84e-12	Cognitive performance;
TGCT	cis	rs3733585	0.699	rs13328050	chr4:9951120	G/T	cg00071950	chr4:10020882	SLC2A9	-0.54	-6.44	-0.5	2.34e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs12477438	0.501	rs1133977	chr2:99741984	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.9	-10.02	-0.67	1.14e-17	Chronic sinus infection;
TGCT	cis	rs739496	0.744	rs10849951	chr12:111910912	G/A	cg10833066	chr12:111807467	FAM109A	0.36	5.58	0.45	1.44e-7	Platelet count;
TGCT	cis	rs10779751	0.734	rs2486920	chr1:11125050	T/C	cg08854313	chr1:11322531	MTOR	0.82	7.04	0.53	1.19e-10	Body mass index;
TGCT	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg23758822	chr17:41437982	NA	0.72	6.96	0.53	1.76e-10	Menopause (age at onset);
TGCT	cis	rs9914988	0.619	rs12451955	chr17:27314224	A/G	cg17523868	chr17:27313033	SEZ6	-0.56	-4.76	-0.39	5.23e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs67072384	0.901	rs2886366	chr11:72455207	G/C	cg03713592	chr11:72463424	ARAP1	-0.93	-4.66	-0.39	7.89e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs1865760	0.588	rs9467658	chr6:26010881	T/G	cg16482183	chr6:26056742	HIST1H1C	0.57	4.95	0.41	2.32e-6	Height;
TGCT	cis	rs422249	0.547	rs174537	chr11:61552680	G/T	cg01500311	chr11:61656094	FADS3	-0.34	-5.72	-0.46	7.53e-8	Trans fatty acid levels;
TGCT	cis	rs6429082	0.702	rs10802797	chr1:235705673	A/G	cg26050004	chr1:235667680	B3GALNT2	0.52	4.5	0.37	1.55e-5	Adiposity;
TGCT	cis	rs950169	0.887	rs35986397	chr15:84955107	G/A	cg17173187	chr15:85201210	NMB	0.57	5.74	0.46	7.02e-8	Schizophrenia;
TGCT	cis	rs56104184	0.779	rs17206686	chr19:49356317	A/G	cg17863274	chr19:49399704	TULP2	-0.4	-4.77	-0.39	5.16e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs12497850	0.931	rs9311434	chr3:48884147	T/C	cg18654377	chr3:49208889	KLHDC8B	-0.41	-5.49	-0.44	2.15e-7	Parkinson's disease;
TGCT	cis	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg25427524	chr10:38739819	LOC399744	-0.4	-8.2	-0.59	2.5e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7726839	0.540	rs58599998	chr5:596087	A/G	cg16624210	chr5:671434	TPPP	0.44	4.85	0.4	3.68e-6	Obesity-related traits;
TGCT	cis	rs62244186	0.545	rs9284880	chr3:44759389	C/T	cg21672276	chr3:44754072	ZNF502	-0.54	-6.25	-0.49	5.94e-9	Depressive symptoms;
TGCT	cis	rs9814567	1.000	rs6787371	chr3:134254991	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.95	-9.55	-0.65	1.56e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs36051895	0.623	rs7035456	chr9:5261440	G/A	cg02405213	chr9:5042618	JAK2	-0.69	-9.16	-0.64	1.34e-15	Pediatric autoimmune diseases;
TGCT	cis	rs3733585	0.673	rs7376505	chr4:9952744	C/A	cg00071950	chr4:10020882	SLC2A9	-0.55	-6.58	-0.51	1.21e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs2645424	0.762	rs2294139	chr8:11705442	G/T	cg12568669	chr8:11666485	FDFT1	-0.34	-4.54	-0.38	1.31e-5	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
TGCT	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg19729930	chr2:74357872	NA	-0.53	-6.03	-0.48	1.75e-8	Gestational age at birth (maternal effect);
TGCT	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg00343986	chr7:65444356	GUSB	0.24	5.26	0.43	6.13e-7	Aortic root size;
TGCT	cis	rs62244186	0.714	rs2293600	chr3:44599103	G/T	cg21672276	chr3:44754072	ZNF502	0.43	4.83	0.4	3.91e-6	Depressive symptoms;
TGCT	cis	rs9443645	0.901	rs6454092	chr6:79701972	G/A	cg09184832	chr6:79620586	NA	-0.48	-5.34	-0.43	4.21e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9467711	0.606	rs1978	chr6:26377573	A/T	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs910316	1.000	rs2098297	chr14:75619118	G/T	cg23033748	chr14:75592666	NEK9	-0.28	-4.64	-0.38	8.62e-6	Height;
TGCT	cis	rs79349575	0.749	rs2546491	chr17:46977916	A/G	cg26022315	chr17:47021804	SNF8	0.49	4.89	0.4	3.04e-6	Type 2 diabetes;
TGCT	cis	rs2070433	0.800	rs2073380	chr21:47863757	A/C	cg12379764	chr21:47803548	PCNT	0.54	4.67	0.39	7.77e-6	Lymphocyte counts;
TGCT	cis	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg16624210	chr5:671434	TPPP	0.42	4.49	0.37	1.64e-5	Lung disease severity in cystic fibrosis;
TGCT	cis	rs9611565	0.765	rs727563	chr22:41867377	C/T	cg06481639	chr22:41940642	POLR3H	0.59	5.13	0.42	1.08e-6	Vitiligo;
TGCT	cis	rs2645424	0.639	rs35581201	chr8:11706834	T/C	cg16012489	chr8:11489852	NA	0.19	4.68	0.39	7.28e-6	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
TGCT	cis	rs10782582	0.609	rs5745394	chr1:76311731	G/A	cg03433033	chr1:76189801	ACADM	-0.5	-4.98	-0.41	2.11e-6	Daytime sleep phenotypes;
TGCT	cis	rs6840360	0.582	rs6813735	chr4:152326990	T/G	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.35	-0.5	3.68e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg12923728	chr3:195709715	SDHAP1	-0.36	-7.57	-0.56	7.39e-12	Pancreatic cancer;
TGCT	cis	rs3806843	0.750	rs2563285	chr5:140126137	T/C	cg19875535	chr5:140030758	IK	-0.34	-5.68	-0.45	9.12e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9807989	0.524	rs6543126	chr2:103027104	G/A	cg03938978	chr2:103052716	IL18RAP	0.27	5.41	0.44	3.17e-7	Asthma;
TGCT	cis	rs12497850	0.931	rs13316620	chr3:49045355	T/C	cg05785598	chr3:49045655	WDR6	0.36	4.8	0.4	4.48e-6	Parkinson's disease;
TGCT	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg08280861	chr8:58055591	NA	0.4	4.73	0.39	5.97e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs8031584	0.918	rs3817498	chr15:31268781	T/C	cg08704250	chr15:31115839	NA	-0.35	-4.69	-0.39	6.97e-6	Huntington's disease progression;
TGCT	cis	rs1371867	0.846	rs1660323	chr8:101278724	T/A	cg06002616	chr8:101225028	SPAG1	-0.57	-6.77	-0.52	4.48e-10	Atrioventricular conduction;
TGCT	cis	rs9916302	0.706	rs903507	chr17:37726423	A/G	cg07936489	chr17:37558343	FBXL20	-0.84	-6.16	-0.48	9.13e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs10206020	0.842	rs7609325	chr2:1574718	G/A	cg01028140	chr2:1542097	TPO	-0.28	-4.51	-0.38	1.47e-5	IgG glycosylation;
TGCT	cis	rs9549367	0.789	rs2287253	chr13:113891075	G/A	cg18105134	chr13:113819100	PROZ	0.35	5.58	0.45	1.44e-7	Platelet distribution width;
TGCT	cis	rs35883536	0.565	rs2809813	chr1:101032003	A/C	cg06223162	chr1:101003688	GPR88	0.42	8.14	0.59	3.53e-13	Monocyte count;
TGCT	cis	rs9443645	0.901	rs7742034	chr6:79737106	A/G	cg09184832	chr6:79620586	NA	-0.48	-5.34	-0.43	4.21e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg07507251	chr3:52567010	NT5DC2	0.47	6.64	0.51	8.85e-10	Electroencephalogram traits;
TGCT	trans	rs1814175	0.645	rs28445479	chr11:50047999	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.84	-0.7	1.13e-19	Height;
TGCT	cis	rs72945132	0.823	rs12292240	chr11:70152612	T/C	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs74233809	0.551	rs3740393	chr10:104636655	C/G	cg05855489	chr10:104503620	C10orf26	0.75	5.48	0.44	2.31e-7	Birth weight;
TGCT	cis	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg18252515	chr7:66147081	NA	1.22	7.33	0.55	2.53e-11	Diabetic kidney disease;
TGCT	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.94	7.92	0.58	1.17e-12	Platelet count;
TGCT	cis	rs10207060	0.778	rs6543581	chr2:240702308	C/T	cg07506560	chr2:240697449	NA	-0.58	-7.14	-0.54	6.82e-11	Obesity-related traits;
TGCT	cis	rs6977660	0.714	rs12700075	chr7:19791476	G/T	cg07541023	chr7:19748670	TWISTNB	0.85	4.84	0.4	3.74e-6	Thyroid stimulating hormone;
TGCT	cis	rs2346177	0.542	rs6718875	chr2:46687982	G/T	cg26688816	chr2:46740690	ATP6V1E2	-0.42	-4.51	-0.38	1.49e-5	HDL cholesterol;
TGCT	cis	rs7914558	0.966	rs10748839	chr10:104953547	A/G	cg15744005	chr10:104629667	AS3MT	-0.4	-4.85	-0.4	3.57e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs4455778	0.538	rs13236051	chr7:49097829	T/C	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg23574427	chr4:122746245	BBS7;CCNA2	-0.34	-5.31	-0.43	4.82e-7	Type 2 diabetes;
TGCT	cis	rs10464366	0.544	rs12701697	chr7:39182165	C/T	cg15212455	chr7:39170539	POU6F2	0.3	6.73	0.52	5.66e-10	IgG glycosylation;
TGCT	cis	rs1245541	0.562	rs3780949	chr10:73886307	C/T	cg09661010	chr10:73848153	SPOCK2	-0.37	-4.53	-0.38	1.39e-5	Insulin-like growth factors;
TGCT	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg11235426	chr6:292522	DUSP22	-0.67	-6.82	-0.52	3.53e-10	Menopause (age at onset);
TGCT	cis	rs9443645	0.901	rs9352675	chr6:79612800	G/A	cg09184832	chr6:79620586	NA	-0.49	-5.29	-0.43	5.29e-7	Intelligence (multi-trait analysis);
TGCT	trans	rs877282	1.000	rs12763443	chr10:771941	G/A	cg22713356	chr15:30763199	NA	1.14	10.05	0.67	9.58e-18	Uric acid levels;
TGCT	cis	rs1348850	0.632	rs13008857	chr2:178514468	G/A	cg22681709	chr2:178499509	PDE11A	-0.51	-6.37	-0.5	3.35e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs9611565	0.512	rs139561	chr22:42195410	C/T	cg06634786	chr22:41940651	POLR3H	0.83	8.01	0.58	7.07e-13	Vitiligo;
TGCT	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	5.38	0.44	3.58e-7	Alzheimer's disease;
TGCT	cis	rs2197308	0.740	rs11182251	chr12:37919611	C/T	cg26384229	chr12:38710491	ALG10B	-0.7	-6.15	-0.48	9.71e-9	Morning vs. evening chronotype;
TGCT	cis	rs7772486	0.603	rs2223411	chr6:146028767	T/C	cg05347473	chr6:146136440	FBXO30	-0.65	-6.11	-0.48	1.17e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs208520	1.000	rs12193077	chr6:66989548	C/T	cg07460842	chr6:66804631	NA	0.78	6.82	0.52	3.61e-10	Exhaled nitric oxide output;
TGCT	cis	rs68170813	0.559	rs80212020	chr7:106957596	C/T	cg02696742	chr7:106810147	HBP1	-0.69	-5.81	-0.46	4.85e-8	Coronary artery disease;
TGCT	cis	rs9467711	0.516	rs1165184	chr6:25836257	C/G	cg12310025	chr6:25882481	NA	-0.71	-4.8	-0.4	4.43e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs11024102	0.962	rs12575487	chr11:17019317	C/T	cg15378786	chr11:17036137	PLEKHA7	0.49	4.57	0.38	1.18e-5	Glaucoma (primary angle closure);
TGCT	cis	rs11190604	0.767	rs10883489	chr10:102194532	T/C	cg16005271	chr10:102321736	NA	0.46	4.68	0.39	7.39e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs748404	0.660	rs2467738	chr15:43739936	T/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	4.81	0.4	4.37e-6	Lung cancer;
TGCT	cis	rs4478858	0.611	rs10914338	chr1:31733782	T/A	cg07478791	chr1:31886160	SERINC2	-0.52	-5.02	-0.41	1.73e-6	Alcohol dependence;
TGCT	cis	rs806215	0.950	rs3757793	chr7:127225780	G/A	cg25922125	chr7:127225783	GCC1	-0.61	-6.3	-0.49	4.71e-9	Type 2 diabetes;
TGCT	cis	rs11718455	0.960	rs13081767	chr3:44004468	T/C	cg08738300	chr3:44038990	NA	0.86	6.55	0.51	1.4e-9	Coronary artery disease;
TGCT	cis	rs9859260	0.710	rs419068	chr3:195782176	C/T	cg22891161	chr3:195456627	MUC20	0.23	4.6	0.38	1.04e-5	Mean corpuscular volume;
TGCT	cis	rs7412746	0.611	rs16827671	chr1:150738759	T/C	cg04414720	chr1:150670196	GOLPH3L	0.36	4.44	0.37	1.97e-5	Melanoma;
TGCT	cis	rs6988636	1.000	rs7002332	chr8:124185442	G/C	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs7552404	0.924	rs12136754	chr1:76230232	C/A	cg03433033	chr1:76189801	ACADM	0.8	9.43	0.65	3.01e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs896854	0.517	rs1011795	chr8:95951073	G/A	cg09323728	chr8:95962352	TP53INP1	-0.43	-4.85	-0.4	3.68e-6	Type 2 diabetes;
TGCT	cis	rs6558530	0.640	rs7844748	chr8:1702343	C/T	cg09410841	chr8:1729607	CLN8	-0.72	-6.56	-0.51	1.31e-9	Systolic blood pressure;
TGCT	cis	rs9467711	0.516	rs523383	chr6:25869848	A/G	cg03264133	chr6:25882463	NA	-0.71	-4.84	-0.4	3.73e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1997103	1.000	rs6951294	chr7:55400835	C/T	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs35306767	0.855	rs12761180	chr10:872086	C/T	cg20503657	chr10:835505	NA	0.77	11.34	0.71	6.95e-21	Eosinophil percentage of granulocytes;
TGCT	cis	rs908922	1.000	rs1199150	chr1:152455602	T/C	cg20991723	chr1:152506922	NA	0.4	5.0	0.41	1.88e-6	Hair morphology;
TGCT	cis	rs360798	0.512	rs2058566	chr2:63179076	C/T	cg17519650	chr2:63277830	OTX1	0.55	4.72	0.39	6.23e-6	Coronary artery disease;
TGCT	cis	rs10986311	0.775	rs10818957	chr9:127152585	C/T	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.21	-4.94	-0.41	2.47e-6	Vitiligo;
TGCT	cis	rs4820539	0.934	rs3788351	chr22:23469181	T/C	cg14186256	chr22:23484241	RTDR1	0.97	12.13	0.74	8.32e-23	Bone mineral density;
TGCT	trans	rs208520	0.690	rs2208442	chr6:66867004	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-10.43	-0.68	1.13e-18	Exhaled nitric oxide output;
TGCT	trans	rs1814175	0.935	rs11040465	chr11:49689323	C/T	cg03929089	chr4:120376271	NA	-0.62	-7.03	-0.53	1.23e-10	Height;
TGCT	cis	rs6840360	0.571	rs1473305	chr4:152511721	T/G	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.0	-0.58	7.69e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs732765	0.689	rs8019690	chr14:75135142	A/T	cg06637938	chr14:75390232	RPS6KL1	-0.57	-4.95	-0.41	2.4e-6	Non-small cell lung cancer;
TGCT	cis	rs3749237	0.595	rs2878298	chr3:49406080	T/C	cg03060546	chr3:49711283	APEH	0.77	8.86	0.62	7.06e-15	Resting heart rate;
TGCT	cis	rs539096	0.697	rs11210887	chr1:44076019	G/A	cg12908607	chr1:44402522	ARTN	-0.41	-4.52	-0.38	1.41e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs11696845	0.626	rs1111032	chr20:43378770	A/G	cg09357268	chr20:43379437	KCNK15	0.24	4.53	0.38	1.36e-5	Obesity-related traits;
TGCT	cis	rs6089584	0.816	rs4134440	chr20:60624296	A/G	cg13770153	chr20:60521292	NA	-0.62	-7.94	-0.58	1.02e-12	Body mass index;
TGCT	cis	rs1018836	0.892	rs13267237	chr8:91550820	T/C	cg16814680	chr8:91681699	NA	-0.78	-8.29	-0.6	1.62e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1577917	1.000	rs12196411	chr6:86779762	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.43	-0.44	2.86e-7	Response to antipsychotic treatment;
TGCT	cis	rs7223966	0.883	rs2955250	chr17:61959740	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	5.25	0.43	6.52e-7	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs7914558	1.000	rs7081075	chr10:104929191	C/T	cg15744005	chr10:104629667	AS3MT	-0.39	-4.75	-0.39	5.53e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs6558530	0.730	rs13256424	chr8:1725004	G/A	cg09410841	chr8:1729607	CLN8	0.87	10.26	0.68	2.88e-18	Systolic blood pressure;
TGCT	cis	rs2439831	0.850	rs11856795	chr15:44160582	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	6.2	0.49	7.73e-9	Lung cancer in ever smokers;
TGCT	cis	rs2073300	1.000	rs2073300	chr20:23471681	T/G	cg09953122	chr20:23471693	CST8	-0.69	-4.54	-0.38	1.3e-5	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	trans	rs1814175	0.904	rs1846289	chr11:49620253	G/A	cg03929089	chr4:120376271	NA	-0.65	-7.44	-0.56	1.46e-11	Height;
TGCT	trans	rs208520	0.837	rs208467	chr6:66914837	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.95	-9.95	-0.67	1.64e-17	Exhaled nitric oxide output;
TGCT	cis	rs4805272	0.512	rs66830923	chr19:29321277	C/T	cg04546413	chr19:29218101	NA	0.72	4.97	0.41	2.16e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
TGCT	cis	rs9341808	0.754	rs9341810	chr6:80974838	G/A	cg08355045	chr6:80787529	NA	0.29	4.98	0.41	2.04e-6	Sitting height ratio;
TGCT	cis	rs6952808	0.635	rs6952727	chr7:1947958	A/G	cg04267008	chr7:1944627	MAD1L1	-0.37	-4.88	-0.4	3.25e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs8077889	0.871	rs11079838	chr17:41898971	G/A	cg26893861	chr17:41843967	DUSP3	1.09	13.08	0.76	4.26e-25	Triglycerides;
TGCT	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg05785598	chr3:49045655	WDR6	0.36	4.86	0.4	3.41e-6	Menarche (age at onset);
TGCT	cis	rs7760949	0.888	rs1966191	chr6:13911961	A/C	cg27413430	chr6:13925136	RNF182	0.6	5.72	0.46	7.69e-8	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs41271951	0.518	rs12145630	chr1:150263832	A/G	cg18798344	chr1:149336151	NA	0.56	4.5	0.37	1.52e-5	Blood protein levels;
TGCT	cis	rs782590	0.837	rs782585	chr2:55922930	C/T	cg18811423	chr2:55921094	PNPT1	0.73	8.32	0.6	1.37e-13	Metabolic syndrome;
TGCT	cis	rs17102423	0.594	rs1271582	chr14:65564703	T/G	cg11161011	chr14:65562177	MAX	-0.47	-6.42	-0.5	2.65e-9	Obesity-related traits;
TGCT	trans	rs7824557	0.547	rs2409749	chr8:11078949	G/A	cg06636001	chr8:8085503	FLJ10661	-0.75	-6.69	-0.51	6.69e-10	Retinal vascular caliber;
TGCT	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg13395646	chr4:1353034	KIAA1530	-0.36	-4.78	-0.39	4.85e-6	Obesity-related traits;
TGCT	cis	rs4808199	0.895	rs4808194	chr19:19435680	T/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.63	4.56	0.38	1.23e-5	Nonalcoholic fatty liver disease;
TGCT	cis	rs9611565	0.729	rs12165508	chr22:41819960	T/C	cg13695892	chr22:41940480	POLR3H	0.86	8.55	0.61	3.95e-14	Vitiligo;
TGCT	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.37	4.74	0.39	5.71e-6	Total body bone mineral density;
TGCT	cis	rs1045714	0.895	rs2293405	chr7:2644607	G/T	cg17215154	chr7:2644645	IQCE	0.28	4.92	0.4	2.75e-6	Urate levels in lean individuals;
TGCT	cis	rs2629540	0.889	rs4962402	chr10:126459114	T/G	cg08799069	chr10:126477246	METTL10	-0.3	-4.5	-0.37	1.54e-5	Cocaine dependence;
TGCT	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.14	0.42	1.06e-6	Prudent dietary pattern;
TGCT	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.81	-8.37	-0.6	1.02e-13	Prudent dietary pattern;
TGCT	cis	rs908922	0.676	rs4240883	chr1:152526260	C/T	cg20991723	chr1:152506922	NA	0.44	5.99	0.47	2.14e-8	Hair morphology;
TGCT	trans	rs208520	0.690	rs3843513	chr6:66836797	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-10.43	-0.68	1.13e-18	Exhaled nitric oxide output;
TGCT	trans	rs1814175	0.617	rs6486020	chr11:49769149	T/G	cg11707556	chr5:10655725	ANKRD33B	-0.46	-11.72	-0.72	8.37e-22	Height;
TGCT	cis	rs864745	0.967	rs849133	chr7:28192280	C/T	cg23620719	chr7:28220237	JAZF1	-0.49	-4.57	-0.38	1.15e-5	Crohn's disease;Type 2 diabetes;
TGCT	cis	rs3845702	0.736	rs72962575	chr2:180862133	C/G	cg01881094	chr2:180872142	CWC22	1.06	6.66	0.51	8.12e-10	Schizophrenia;
TGCT	cis	rs67072384	0.892	rs7104664	chr11:72444450	C/T	cg03713592	chr11:72463424	ARAP1	-0.9	-4.63	-0.38	9.26e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs7178572	1.000	rs8034133	chr15:77763712	C/G	cg22256960	chr15:77711686	NA	-0.95	-10.89	-0.7	8.57e-20	Type 2 diabetes;
TGCT	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg11247378	chr22:39784982	NA	-0.73	-9.43	-0.65	3.06e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs6671200	0.920	rs7555236	chr1:95631314	G/A	cg20701556	chr1:95698924	RWDD3	0.65	5.58	0.45	1.43e-7	Stearic acid (18:0) levels;
TGCT	trans	rs4332037	0.901	rs7791299	chr7:1935598	T/C	cg25206134	chr2:45395956	NA	0.95	7.92	0.58	1.16e-12	Bipolar disorder;
TGCT	cis	rs694739	0.536	rs671976	chr11:64046029	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.57	5.04	0.41	1.59e-6	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs295140	1.000	rs67190025	chr2:201172086	C/T	cg04283868	chr2:201171347	SPATS2L	0.63	6.43	0.5	2.46e-9	QT interval;
TGCT	cis	rs11955175	1.000	rs11955175	chr5:40626753	C/T	cg17351974	chr5:40835760	RPL37	-0.78	-5.02	-0.41	1.78e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs4733781	0.871	rs12549794	chr8:131214247	T/C	cg16277922	chr8:131349729	ASAP1	0.38	5.04	0.41	1.6e-6	Tuberculosis;
TGCT	cis	rs1538970	0.739	rs4660863	chr1:45955868	T/C	cg05343316	chr1:45956843	TESK2	0.81	6.64	0.51	8.93e-10	Platelet count;
TGCT	cis	rs7666738	0.830	rs28417577	chr4:99053007	T/C	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1334894	1.000	rs72921231	chr6:35589637	T/C	cg24281267	chr6:35479648	TULP1	-0.44	-4.73	-0.39	5.95e-6	Coronary artery disease;
TGCT	cis	rs7914558	1.000	rs4917380	chr10:104775335	C/G	cg15744005	chr10:104629667	AS3MT	-0.4	-4.97	-0.41	2.21e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs2334880	0.587	rs8058188	chr16:71675136	G/A	cg00732059	chr16:71740210	PHLPP2	0.3	5.29	0.43	5.45e-7	Malaria;
TGCT	cis	rs72627509	0.951	rs72606404	chr4:57841213	G/C	cg26694713	chr4:57773883	REST	0.76	6.6	0.51	1.09e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs7727544	0.606	rs17622208	chr5:131717050	G/A	cg14196790	chr5:131705035	SLC22A5	0.35	4.81	0.4	4.37e-6	Blood metabolite levels;
TGCT	cis	rs8016982	0.657	rs11625861	chr14:81735001	C/T	cg01989461	chr14:81687754	GTF2A1	-0.81	-8.48	-0.61	5.58e-14	Schizophrenia;
TGCT	cis	rs4980532	1	rs4980532	chr11:63680719	C/T	cg12527260	chr11:63683744	RCOR2	0.37	4.44	0.37	1.96e-5	Pulse pressure;
TGCT	trans	rs208520	1.000	rs208523	chr6:66954195	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.88	-8.21	-0.59	2.37e-13	Exhaled nitric oxide output;
TGCT	cis	rs7772486	0.701	rs697056	chr6:146003897	C/T	cg13319975	chr6:146136371	FBXO30	0.52	4.68	0.39	7.31e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg24531977	chr5:56204891	C5orf35	-0.68	-7.13	-0.54	7.4e-11	Initial pursuit acceleration;
TGCT	cis	rs754133	0.507	rs10876531	chr12:54443718	A/C	cg16264616	chr12:54390824	NA	0.39	5.49	0.44	2.13e-7	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;
TGCT	cis	rs796364	0.806	rs34381014	chr2:200916403	C/T	cg17644776	chr2:200775616	C2orf69	-0.33	-5.0	-0.41	1.91e-6	Schizophrenia;
TGCT	cis	rs11671005	0.735	rs11668420	chr19:58937836	G/A	cg13877915	chr19:58951672	ZNF132	0.64	5.12	0.42	1.13e-6	Mean platelet volume;
TGCT	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg21017887	chr14:105400489	NA	0.29	4.47	0.37	1.77e-5	Rheumatoid arthritis;
TGCT	cis	rs8070740	0.898	rs9895440	chr17:5325643	C/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.49	4.88	0.4	3.15e-6	Menopause (age at onset);
TGCT	trans	rs62103177	0.810	rs62103175	chr18:77622467	C/T	cg05926928	chr17:57297772	GDPD1	1.22	11.16	0.71	1.85e-20	Opioid sensitivity;
TGCT	cis	rs950169	0.887	rs35986397	chr15:84955107	G/A	cg11189052	chr15:85197271	WDR73	0.8	6.1	0.48	1.25e-8	Schizophrenia;
TGCT	cis	rs8017423	0.872	rs7492857	chr14:90684867	T/G	cg04374321	chr14:90722782	PSMC1	-0.76	-7.73	-0.57	3.19e-12	Mortality in heart failure;
TGCT	cis	rs3784262	0.647	rs2414529	chr15:58317094	G/T	cg12031962	chr15:58353849	ALDH1A2	-0.44	-6.31	-0.49	4.52e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs6121246	0.567	rs6060249	chr20:30190944	G/A	cg18721089	chr20:30220636	NA	-0.63	-6.88	-0.53	2.67e-10	Mean corpuscular hemoglobin;
TGCT	cis	rs8141529	0.732	rs2239815	chr22:29192670	C/T	cg02153584	chr22:29168773	CCDC117	-0.56	-4.95	-0.41	2.34e-6	Lymphocyte counts;
TGCT	cis	rs904251	0.965	rs1317563	chr6:37451854	G/T	cg25019722	chr6:37503610	NA	-0.43	-5.77	-0.46	5.97e-8	Cognitive performance;
TGCT	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg18402987	chr7:1209562	NA	0.78	6.64	0.51	8.96e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1541995	1.000	rs34524501	chr15:96289064	T/A	cg00882281	chr15:96346592	NA	0.28	4.58	0.38	1.11e-5	Photic sneeze reflex;
TGCT	cis	rs17221829	0.965	rs3881252	chr11:89445186	G/A	cg02982614	chr11:89391479	FOLH1B	-0.29	-5.09	-0.42	1.3e-6	Anxiety in major depressive disorder;
TGCT	cis	rs111803315	1.000	rs112879614	chr14:60001681	A/G	cg22995959	chr14:59931024	GPR135	0.66	4.8	0.4	4.39e-6	Schizophrenia;
TGCT	cis	rs713587	0.713	rs1077492	chr2:25286435	C/T	cg01884057	chr2:25150051	NA	-0.39	-8.01	-0.58	7.24e-13	Body mass index in non-asthmatics;
TGCT	cis	rs28785552	0.765	rs28850924	chr19:53234323	T/G	cg10871876	chr19:53194124	ZNF83	0.57	7.92	0.58	1.13e-12	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs3733585	0.699	rs7435196	chr4:9967556	A/C	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.7	-0.52	6.63e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs6987853	0.933	rs2923434	chr8:42422307	A/G	cg20539142	chr8:42623718	CHRNA6	-0.21	-5.11	-0.42	1.18e-6	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs11096990	0.574	rs34070258	chr4:39189752	T/C	cg20847110	chr4:39482781	LOC401127	0.16	4.52	0.38	1.42e-5	Cognitive function;
TGCT	cis	rs7666738	0.791	rs17549003	chr4:98969132	A/C	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2050392	0.762	rs306587	chr10:30722908	G/C	cg13289132	chr10:30722225	MAP3K8	-0.4	-4.81	-0.4	4.21e-6	Inflammatory bowel disease;
TGCT	cis	rs4566357	0.576	rs10187255	chr2:227913442	T/A	cg11843606	chr2:227700838	RHBDD1	-0.55	-5.17	-0.42	8.9e-7	Coronary artery disease;
TGCT	cis	rs637571	0.780	rs677029	chr11:65683531	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.53	5.41	0.44	3.08e-7	Eosinophil percentage of white cells;
TGCT	cis	rs2228479	0.850	rs11639925	chr16:89908250	C/T	cg06558623	chr16:89946397	TCF25	0.55	4.86	0.4	3.55e-6	Skin colour saturation;
TGCT	cis	rs7191439	0.584	rs7193436	chr16:88748736	T/C	cg27087555	chr16:88793112	FAM38A	-0.47	-4.72	-0.39	6.29e-6	Plateletcrit;
TGCT	cis	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg17366294	chr4:99064904	C4orf37	0.71	6.76	0.52	4.93e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs35883536	0.528	rs1577511	chr1:101030859	G/A	cg10298815	chr1:101004474	GPR88	0.25	4.68	0.39	7.46e-6	Monocyte count;
TGCT	cis	rs2050392	0.624	rs303450	chr10:30725337	C/A	cg13289132	chr10:30722225	MAP3K8	-0.46	-5.57	-0.45	1.47e-7	Inflammatory bowel disease;
TGCT	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg18230493	chr5:56204884	C5orf35	-0.66	-5.65	-0.45	1.05e-7	Initial pursuit acceleration;
TGCT	cis	rs2982552	0.773	rs11155808	chr6:152056050	C/A	cg22157087	chr6:152012887	ESR1	0.21	5.17	0.42	8.93e-7	Bone properties (heel);
TGCT	cis	rs8072100	0.744	rs34537623	chr17:45530203	A/G	cg08085267	chr17:45401833	C17orf57	-0.46	-5.07	-0.41	1.4e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs523522	0.962	rs10849758	chr12:120971149	C/T	cg12219531	chr12:120966889	COQ5	0.83	7.27	0.55	3.46e-11	High light scatter reticulocyte count;
TGCT	cis	rs7666738	0.830	rs1426663	chr4:98990092	T/G	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9534288	0.783	rs1126366	chr13:46633148	C/G	cg15192986	chr13:46630673	CPB2	-0.5	-6.23	-0.49	6.66e-9	Blood protein levels;
TGCT	cis	rs6089584	1.000	rs6089591	chr20:60570548	A/C	cg16423285	chr20:60520624	NA	-0.55	-5.88	-0.47	3.5e-8	Body mass index;
TGCT	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	trans	rs8073060	0.504	rs225271	chr17:33969836	C/T	cg19694781	chr19:47549865	TMEM160	-0.6	-13.37	-0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs4654899	0.680	rs4654879	chr1:21186378	G/A	cg01072550	chr1:21505969	NA	0.55	8.93	0.63	4.85e-15	Superior frontal gyrus grey matter volume;
TGCT	cis	rs7582180	0.739	rs11123824	chr2:100924029	G/A	cg14675211	chr2:100938903	LONRF2	0.51	4.93	0.4	2.61e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.72	5.19	0.42	8.33e-7	Platelet count;
TGCT	cis	rs7474896	0.583	rs11011341	chr10:37998500	G/A	cg13720705	chr10:37990370	NA	0.33	4.91	0.4	2.86e-6	Obesity (extreme);
TGCT	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.54	-5.11	-0.42	1.19e-6	Prudent dietary pattern;
TGCT	cis	rs7267979	0.789	rs6083810	chr20:25329759	T/A	cg13486641	chr20:25479848	NINL	0.16	4.57	0.38	1.17e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg03517284	chr6:25882590	NA	-0.62	-5.73	-0.46	7.06e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg03517284	chr6:25882590	NA	-0.52	-5.29	-0.43	5.3e-7	Blood metabolite levels;
TGCT	cis	rs12519773	0.526	rs6897863	chr5:92512481	A/C	cg04854328	chr5:92914828	FLJ42709	-0.3	-4.65	-0.39	8.32e-6	Migraine;
TGCT	cis	rs7095607	0.606	rs4746735	chr10:69950502	A/C	cg18986048	chr10:69913749	MYPN	-0.54	-5.57	-0.45	1.49e-7	Lung function (FVC);
TGCT	cis	rs10927875	0.929	rs4661674	chr1:16296039	A/G	cg21385522	chr1:16154831	NA	-0.76	-8.31	-0.6	1.44e-13	Dilated cardiomyopathy;
TGCT	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg11764359	chr7:65958608	NA	-0.58	-5.42	-0.44	2.92e-7	Aortic root size;
TGCT	cis	rs394563	0.559	rs13219868	chr6:149686518	T/G	cg03678062	chr6:149772716	ZC3H12D	0.38	4.8	0.4	4.4e-6	Dupuytren's disease;
TGCT	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg09359103	chr1:154839909	KCNN3	-0.67	-12.43	-0.74	1.54e-23	Prostate cancer;
TGCT	cis	rs523522	0.962	rs7136951	chr12:120941927	C/T	cg12219531	chr12:120966889	COQ5	0.83	7.27	0.55	3.46e-11	High light scatter reticulocyte count;
TGCT	cis	rs4654899	0.965	rs7525620	chr1:21458392	G/A	cg01072550	chr1:21505969	NA	-0.5	-8.07	-0.59	5.13e-13	Superior frontal gyrus grey matter volume;
TGCT	cis	rs72945132	0.882	rs7942613	chr11:70210675	C/T	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs35771425	0.572	rs34552796	chr1:211422229	C/T	cg26515805	chr1:211431828	RCOR3	-0.46	-4.78	-0.39	4.85e-6	Educational attainment (years of education);
TGCT	cis	rs12971120	0.891	rs11151961	chr18:72177340	C/T	cg25817165	chr18:72167213	CNDP2	-0.27	-4.65	-0.39	8.37e-6	Refractive error;
TGCT	trans	rs1005277	0.505	rs7099777	chr10:38183569	A/C	cg17830980	chr10:43048298	ZNF37B	0.74	8.59	0.61	3.11e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg07167872	chr1:205819463	PM20D1	0.58	7.5	0.56	1.09e-11	Menarche (age at onset);
TGCT	cis	rs7432375	0.933	rs55970317	chr3:136353193	T/G	cg12473912	chr3:136751656	NA	0.34	4.93	0.41	2.55e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs3806843	0.868	rs2531349	chr5:140120953	G/A	cg19875535	chr5:140030758	IK	-0.36	-5.9	-0.47	3.18e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9814567	0.806	rs4519744	chr3:134321523	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.76	-7.11	-0.54	8.15e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs736801	0.964	rs17622656	chr5:131820997	A/G	cg02551604	chr5:131831745	NA	-0.57	-4.71	-0.39	6.65e-6	Breast cancer;Mosquito bite size;
TGCT	cis	rs42648	0.869	rs10266179	chr7:89909982	C/T	cg25739043	chr7:89950458	NA	-0.67	-6.71	-0.52	6.23e-10	Homocysteine levels;
TGCT	cis	rs9638182	0.614	rs13234157	chr7:72971728	C/A	cg14087351	chr7:73037990	MLXIPL	-0.65	-4.88	-0.4	3.18e-6	Triglycerides;
TGCT	cis	rs9911578	1.000	rs6503887	chr17:56993320	T/C	cg12560992	chr17:57184187	TRIM37	0.76	9.21	0.64	1.03e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs1215050	1.000	rs1215050	chr4:98849826	A/G	cg17366294	chr4:99064904	C4orf37	-0.51	-5.08	-0.42	1.34e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.08	0.48	1.37e-8	Bipolar disorder;
TGCT	cis	rs16866061	1.000	rs11688397	chr2:225393173	C/T	cg12698349	chr2:225449008	CUL3	1.0	9.83	0.66	3.23e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	cis	rs3008870	1.000	rs35365746	chr1:67438900	G/A	cg11518657	chr1:67396239	MIER1	-0.54	-4.61	-0.38	9.72e-6	Lymphocyte percentage of white cells;
TGCT	trans	rs2760061	0.819	rs708115	chr1:228198046	C/T	cg16006296	chr10:38738647	LOC399744	-0.31	-7.08	-0.54	9.57e-11	Diastolic blood pressure;
TGCT	cis	rs9291683	0.588	rs3756238	chr4:10013202	C/T	cg02734326	chr4:10020555	SLC2A9	0.38	4.56	0.38	1.22e-5	Bone mineral density;
TGCT	cis	rs79349575	0.783	rs11079844	chr17:47028334	G/A	cg26022315	chr17:47021804	SNF8	0.49	4.9	0.4	2.94e-6	Type 2 diabetes;
TGCT	cis	rs11118844	0.843	rs4589119	chr1:221915967	G/A	cg04222084	chr1:221915650	DUSP10	-0.85	-5.95	-0.47	2.54e-8	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
TGCT	cis	rs6138458	0.961	rs11700073	chr20:24975215	C/G	cg26195577	chr20:24973756	C20orf3	1.22	12.1	0.74	9.98e-23	Blood protein levels;
TGCT	cis	rs849210	0.517	rs2080419	chr2:206208049	T/C	cg11793701	chr2:206547163	NRP2	-0.57	-4.54	-0.38	1.31e-5	Tonsillectomy;
TGCT	cis	rs12950390	0.853	rs56387656	chr17:45860189	C/G	cg24803719	chr17:45855879	NA	-0.49	-5.03	-0.41	1.64e-6	IgG glycosylation;
TGCT	cis	rs12477438	0.765	rs56167745	chr2:99600478	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.79	-7.94	-0.58	1.06e-12	Chronic sinus infection;
TGCT	cis	rs709400	0.633	rs1951391	chr14:103898313	T/C	cg12935359	chr14:103987150	CKB	-0.35	-5.28	-0.43	5.66e-7	Body mass index;
TGCT	cis	rs9359856	0.510	rs4235839	chr6:90472410	A/G	cg13799429	chr6:90582589	CASP8AP2	0.45	4.66	0.39	7.9e-6	Bipolar disorder;
TGCT	cis	rs11190604	1.000	rs2298075	chr10:102247408	C/A	cg23241863	chr10:102295624	HIF1AN	0.63	4.95	0.41	2.41e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs4273100	0.573	rs4924783	chr17:19253981	A/G	cg03910582	chr17:19030146	GRAPL	-0.52	-6.78	-0.52	4.27e-10	Schizophrenia;
TGCT	cis	rs6912958	0.535	rs448580	chr6:88040399	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.39	4.53	0.38	1.36e-5	Monocyte percentage of white cells;
TGCT	cis	rs1018836	0.663	rs3950221	chr8:91478108	G/A	cg16814680	chr8:91681699	NA	-0.86	-8.78	-0.62	1.09e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7647973	0.925	rs4955439	chr3:49245645	G/T	cg05785598	chr3:49045655	WDR6	-0.39	-4.7	-0.39	6.74e-6	Menarche (age at onset);
TGCT	cis	rs7829975	0.533	rs35900578	chr8:8719513	G/A	cg08975724	chr8:8085496	FLJ10661	0.58	5.1	0.42	1.23e-6	Mood instability;
TGCT	cis	rs858239	0.896	rs1637193	chr7:23260251	G/T	cg05602783	chr7:23145260	KLHL7	-0.55	-4.5	-0.37	1.52e-5	Cerebrospinal fluid biomarker levels;
TGCT	trans	rs9859260	0.744	rs492349	chr3:195784192	G/A	cg17074656	chr11:63784126	MACROD1	0.52	6.67	0.51	7.49e-10	Mean corpuscular volume;
TGCT	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg22166914	chr1:53195759	ZYG11B	0.43	7.58	0.56	6.9e-12	Monocyte count;
TGCT	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg08509172	chr19:19383838	TM6SF2	-0.34	-4.48	-0.37	1.71e-5	Tonsillectomy;
TGCT	cis	rs2948294	0.588	rs7011221	chr8:8114246	C/T	cg15556689	chr8:8085844	FLJ10661	0.78	6.72	0.52	5.79e-10	Red cell distribution width;
TGCT	cis	rs2404602	0.536	rs7163946	chr15:76766049	C/G	cg22467129	chr15:76604101	ETFA	-0.48	-5.9	-0.47	3.27e-8	Blood metabolite levels;
TGCT	cis	rs1801251	1.000	rs1947105	chr2:233721455	A/G	cg25237894	chr2:233734115	C2orf82	0.33	5.94	0.47	2.73e-8	Coronary artery disease;
TGCT	cis	rs4699052	0.662	rs1400363	chr4:104250722	A/C	cg16532752	chr4:104119610	CENPE	-0.49	-4.79	-0.4	4.66e-6	Testicular germ cell tumor;
TGCT	cis	rs5769765	0.671	rs138832	chr22:50178082	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.32	4.61	0.38	9.79e-6	Schizophrenia;
TGCT	cis	rs734999	0.505	rs60687045	chr1:2539603	G/A	cg18854424	chr1:2615690	NA	0.41	4.58	0.38	1.13e-5	Ulcerative colitis;
TGCT	cis	rs3820068	0.581	rs1547033	chr1:15918988	T/C	cg05660106	chr1:15850417	CASP9	0.81	8.15	0.59	3.31e-13	Systolic blood pressure;
TGCT	cis	rs854765	0.693	rs35451946	chr17:17764061	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.75	-7.78	-0.57	2.42e-12	Total body bone mineral density;
TGCT	cis	rs3784262	0.669	rs4646635	chr15:58252277	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.42	-6.17	-0.48	8.91e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs6087990	0.899	rs1333469	chr20:31361249	C/T	cg13636640	chr20:31349939	DNMT3B	1.08	14.21	0.79	8.84e-28	Ulcerative colitis;
TGCT	cis	rs739496	0.527	rs16941703	chr12:112318734	C/T	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs916888	0.610	rs142167	chr17:44795234	C/T	cg01570182	chr17:44337453	NA	-0.79	-7.6	-0.56	6.34e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs910316	1.000	rs12588240	chr14:75612083	C/A	cg08847533	chr14:75593920	NEK9	0.96	10.86	0.7	1.05e-19	Height;
TGCT	cis	rs11250098	0.562	rs6987134	chr8:10804906	T/C	cg16664915	chr8:10907788	XKR6	-0.29	-4.5	-0.37	1.52e-5	Morning vs. evening chronotype;
TGCT	cis	rs7236492	0.572	rs34712138	chr18:77179833	G/A	cg15644404	chr18:77186268	NFATC1	-0.43	-4.5	-0.37	1.57e-5	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs9486719	0.857	rs4265039	chr6:96878929	T/C	cg06623918	chr6:96969491	KIAA0776	1.04	11.3	0.71	8.72e-21	Migraine;Coronary artery disease;
TGCT	cis	rs4631830	0.832	rs2337711	chr10:51504604	C/T	cg10326726	chr10:51549505	MSMB	0.25	4.75	0.39	5.5e-6	Prostate-specific antigen levels;
TGCT	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg06873352	chr17:61820015	STRADA	0.55	6.1	0.48	1.26e-8	Prudent dietary pattern;
TGCT	cis	rs428668	0.523	rs10060607	chr5:150679304	A/C	cg11125805	chr5:150678162	SLC36A3	0.32	7.87	0.58	1.49e-12	Skin aging (microtopography measurement);
TGCT	cis	rs59107033	0.517	rs67946200	chr3:123124824	G/C	cg04890266	chr3:123102914	ADCY5	-0.37	-5.59	-0.45	1.39e-7	Lymphocyte counts;
TGCT	cis	rs9372498	0.505	rs4416700	chr6:118975461	G/C	cg07617317	chr6:118971624	C6orf204	0.49	5.15	0.42	9.91e-7	Diastolic blood pressure;
TGCT	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1568079	0.516	rs1571424	chr10:125220311	G/A	cg14250450	chr10:124578544	NA	-0.34	-4.71	-0.39	6.57e-6	Body mass index;
TGCT	cis	rs62103177	1.000	rs62103177	chr18:77624479	G/A	cg12964065	chr18:77638022	KCNG2	0.37	4.76	0.39	5.4e-6	Opioid sensitivity;
TGCT	cis	rs3020736	0.500	rs28791586	chr22:42500483	A/G	cg15557168	chr22:42548783	NA	0.22	5.58	0.45	1.47e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6893807	1.000	rs13163336	chr5:87943710	C/A	cg24804195	chr5:87968844	LOC645323	0.74	5.2	0.42	8.09e-7	Body mass index;
TGCT	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg18402987	chr7:1209562	NA	0.47	4.71	0.39	6.41e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs853679	0.546	rs200953	chr6:27837267	T/C	cg08798685	chr6:27730294	NA	-0.35	-4.76	-0.39	5.4e-6	Depression;
TGCT	cis	rs1691799	0.899	rs1168357	chr12:66749879	T/C	cg16791601	chr12:66731901	HELB	-0.29	-6.17	-0.48	8.77e-9	White blood cell count (basophil);
TGCT	cis	rs3960554	0.597	rs3807880	chr7:75864208	T/C	cg19105122	chr7:75896889	SRRM3	0.57	4.68	0.39	7.27e-6	Eotaxin levels;
TGCT	cis	rs2594989	0.831	rs7651886	chr3:11572728	A/G	cg00170343	chr3:11313890	ATG7	0.64	4.77	0.39	5.18e-6	Circulating chemerin levels;
TGCT	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg25036284	chr2:26402008	FAM59B	-0.57	-4.97	-0.41	2.15e-6	Gut microbiome composition (summer);
TGCT	cis	rs6450176	1.000	rs60492935	chr5:53306240	G/T	ch.5.1024479R	chr5:53302184	ARL15	-0.49	-4.6	-0.38	1.03e-5	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs60843830	1.000	rs2290911	chr2:224919	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.77	7.62	0.56	5.62e-12	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.54	-5.34	-0.43	4.2e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg02725872	chr8:58115012	NA	-0.38	-5.16	-0.42	9.32e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7208859	0.673	rs216435	chr17:28922737	G/T	cg19761014	chr17:28927070	LRRC37B2	0.56	4.81	0.4	4.32e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs12188164	0.965	rs41282625	chr5:475626	C/G	cg21144161	chr5:423903	AHRR	0.25	4.64	0.38	8.55e-6	Cystic fibrosis severity;
TGCT	cis	rs6754311	0.731	rs687670	chr2:136740900	T/C	cg07169764	chr2:136633963	MCM6	0.62	5.76	0.46	6.23e-8	Mosquito bite size;
TGCT	cis	rs909674	0.865	rs5757683	chr22:39850174	G/A	cg02038168	chr22:39784481	NA	-0.69	-5.3	-0.43	5.12e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs7568458	0.663	rs699664	chr2:85780536	A/G	cg02493740	chr2:85810744	VAMP5	0.3	6.33	0.49	4.15e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg12310025	chr6:25882481	NA	-0.55	-5.58	-0.45	1.41e-7	Blood metabolite levels;
TGCT	cis	rs739496	0.579	rs10849982	chr12:112335539	G/A	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs13217239	0.646	rs4583981	chr6:26992023	G/T	cg26531700	chr6:26746687	NA	0.69	6.94	0.53	1.9e-10	Schizophrenia;
TGCT	cis	rs7027203	0.964	rs7854075	chr9:96571211	G/A	cg14396892	chr9:96623032	NA	0.26	4.93	0.4	2.62e-6	DNA methylation (variation);
TGCT	cis	rs9443645	0.901	rs2174743	chr6:79591805	G/A	cg05283184	chr6:79620031	NA	-0.21	-4.68	-0.39	7.33e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9486715	1.000	rs6899647	chr6:97065661	A/G	cg18709589	chr6:96969512	KIAA0776	-0.77	-7.12	-0.54	7.74e-11	Headache;
TGCT	cis	rs4851266	0.966	rs10496345	chr2:100817619	T/G	cg07810366	chr2:100720526	AFF3	-0.4	-5.75	-0.46	6.53e-8	Educational attainment;
TGCT	cis	rs713587	0.626	rs62140636	chr2:25233811	T/C	cg15423357	chr2:25149977	NA	-0.57	-5.77	-0.46	5.89e-8	Body mass index in non-asthmatics;
TGCT	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg03806693	chr22:41940476	POLR3H	1.11	12.05	0.73	1.3e-22	Vitiligo;
TGCT	trans	rs4942242	1.000	rs7331003	chr13:44230253	C/T	cg19169023	chr15:41853346	TYRO3	-0.33	-6.64	-0.51	9.02e-10	Response to tocilizumab in rheumatoid arthritis;
TGCT	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	trans	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg23505145	chr19:12996616	KLF1	0.79	8.07	0.59	5.16e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs13082711	0.595	rs6783818	chr3:27361988	C/G	cg02860705	chr3:27208620	NA	0.46	6.97	0.53	1.69e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs10744422	1.000	rs2135014	chr12:123333065	C/T	cg25930673	chr12:123319894	HIP1R	-0.86	-5.02	-0.41	1.72e-6	Schizophrenia;
TGCT	trans	rs2624839	0.704	rs14321	chr3:50226151	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.79	-7.17	-0.54	5.8200000000000003e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs4720575	0.868	rs7779776	chr7:47092914	C/G	cg00036614	chr7:47093842	NA	-0.22	-5.41	-0.44	3.06e-7	Angiotensin-converting enzyme inhibitor intolerance;
TGCT	cis	rs314370	0.573	rs221005	chr7:100401433	A/G	cg10426581	chr7:100472382	SRRT	0.72	7.3	0.55	3.02e-11	Resting heart rate;
TGCT	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg14893161	chr1:205819251	PM20D1	0.4	5.06	0.41	1.49e-6	Menarche (age at onset);
TGCT	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg07507251	chr3:52567010	NT5DC2	0.5	7.27	0.55	3.57e-11	Bipolar disorder;
TGCT	cis	rs10779751	1.000	rs4845856	chr1:11274547	T/C	cg08854313	chr1:11322531	MTOR	0.91	9.86	0.66	2.71e-17	Body mass index;
TGCT	cis	rs2033711	0.840	rs4801590	chr19:58961813	G/C	cg12042659	chr19:58951599	ZNF132	0.51	4.56	0.38	1.23e-5	Uric acid clearance;
TGCT	cis	rs732765	0.734	rs35461658	chr14:75207264	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.55	-4.48	-0.37	1.71e-5	Non-small cell lung cancer;
TGCT	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg17911788	chr17:44343683	NA	-0.67	-7.15	-0.54	6.59e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs6500602	0.701	rs4785968	chr16:4535307	T/A	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.26	4.73	0.39	6.13e-6	Schizophrenia;
TGCT	cis	rs6591182	0.504	rs7130955	chr11:65372580	C/T	cg27068330	chr11:65405492	SIPA1	-0.95	-10.69	-0.69	2.62e-19	Non-alcoholic fatty liver disease histology (lobular);
TGCT	cis	rs6496044	0.526	rs4291869	chr15:86054523	G/A	cg13263323	chr15:86062960	AKAP13	-0.24	-5.26	-0.43	6.02e-7	Interstitial lung disease;
TGCT	cis	rs9303401	0.527	rs2116450	chr17:56745561	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.53	5.05	0.41	1.55e-6	Cognitive test performance;
TGCT	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg24549020	chr5:56110836	MAP3K1	0.67	5.67	0.45	9.57e-8	Initial pursuit acceleration;
TGCT	cis	rs7949030	0.591	rs35156678	chr11:62369881	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.7	8.89	0.62	5.98e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2075371	0.611	rs13235296	chr7:134019192	A/G	cg11752832	chr7:134001865	SLC35B4	-0.64	-5.3	-0.43	5.22e-7	Mean platelet volume;
TGCT	cis	rs7681440	0.904	rs1442153	chr4:90775719	T/G	cg26578617	chr4:90757533	SNCA	-0.44	-4.54	-0.38	1.31e-5	Dementia with Lewy bodies;
TGCT	cis	rs2730245	0.550	rs10258339	chr7:158670243	T/C	cg24397884	chr7:158709396	WDR60	0.37	4.76	0.39	5.39e-6	Height;
TGCT	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg03188948	chr7:1209495	NA	0.48	5.15	0.42	9.85e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9303401	0.659	rs34818467	chr17:56643109	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.58	-5.92	-0.47	2.91e-8	Cognitive test performance;
TGCT	cis	rs10782582	0.609	rs5745331	chr1:76273313	A/G	cg10523679	chr1:76189770	ACADM	-0.58	-5.38	-0.43	3.6e-7	Daytime sleep phenotypes;
TGCT	cis	rs3774830	0.714	rs55816120	chr4:5463350	C/T	cg26943120	chr4:5472116	STK32B	0.22	4.82	0.4	4.15e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9300255	0.602	rs2851438	chr12:123643689	T/C	cg00376283	chr12:123451042	ABCB9	0.73	5.64	0.45	1.09e-7	Neutrophil percentage of white cells;
TGCT	cis	rs16958440	0.867	rs28587821	chr18:44687906	G/A	cg17192377	chr18:44677553	HDHD2	0.63	4.7	0.39	6.74e-6	Sitting height ratio;
TGCT	cis	rs7100689	0.784	rs1972370	chr10:82127180	A/G	cg01528321	chr10:82214614	TSPAN14	0.88	8.48	0.61	5.61e-14	Post bronchodilator FEV1;
TGCT	cis	rs11955175	1.000	rs73080591	chr5:40634687	T/C	cg17351974	chr5:40835760	RPL37	0.76	4.75	0.39	5.46e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs3849570	0.925	rs7641973	chr3:81910489	G/A	cg07356753	chr3:81810745	GBE1	-0.74	-6.77	-0.52	4.57e-10	Waist circumference;Body mass index;
TGCT	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs8077889	1.000	rs4793035	chr17:41887753	C/T	cg26893861	chr17:41843967	DUSP3	1.1	12.5	0.75	1.08e-23	Triglycerides;
TGCT	cis	rs614226	0.935	rs7137953	chr12:120894685	C/T	cg01236616	chr12:121019343	POP5	-1.23	-12.24	-0.74	4.57e-23	Type 1 diabetes nephropathy;
TGCT	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg01416388	chr22:39784598	NA	-0.72	-7.15	-0.54	6.43e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs10089	1.000	rs4836368	chr5:127486330	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	7.37	0.55	2.14e-11	Ileal carcinoids;
TGCT	cis	rs9972944	0.756	rs7223214	chr17:63761473	C/T	cg07283582	chr17:63770753	CCDC46	-0.26	-5.15	-0.42	9.85e-7	Total body bone mineral density;
TGCT	cis	rs3733585	0.781	rs57250714	chr4:9984529	C/T	cg11266682	chr4:10021025	SLC2A9	0.58	7.78	0.57	2.46e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	6.26	0.49	5.69e-9	Alzheimer's disease;
TGCT	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg01570182	chr17:44337453	NA	1.07	9.81	0.66	3.57e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs921968	0.679	rs7607369	chr2:219279097	A/G	cg02176678	chr2:219576539	TTLL4	0.39	5.69	0.46	8.61e-8	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs6570726	0.764	rs9403733	chr6:145912311	A/C	cg13319975	chr6:146136371	FBXO30	-0.54	-4.77	-0.39	5.1e-6	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs6048205	0.649	rs6036144	chr20:22531652	A/G	cg03955683	chr17:77216577	HRNBP3	0.9	8.03	0.58	6.57e-13	Fasting blood glucose (BMI interaction);Fasting blood glucose;
TGCT	cis	rs539096	0.830	rs11580074	chr1:44024484	A/G	cg12908607	chr1:44402522	ARTN	-0.51	-5.28	-0.43	5.57e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9611565	0.569	rs6002328	chr22:41710034	T/C	cg03806693	chr22:41940476	POLR3H	-0.75	-7.26	-0.55	3.78e-11	Vitiligo;
TGCT	cis	rs8037137	1.000	rs8037137	chr15:91506637	T/C	cg22570213	chr15:91497863	RCCD1	0.5	4.79	0.39	4.74e-6	Platelet count;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
TGCT	cis	rs11098499	0.863	rs3775858	chr4:120486028	A/G	cg09307838	chr4:120376055	NA	0.74	7.34	0.55	2.49e-11	Corneal astigmatism;
TGCT	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg25036284	chr2:26402008	FAM59B	-0.58	-4.61	-0.38	1.01e-5	Gut microbiome composition (summer);
TGCT	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg06481639	chr22:41940642	POLR3H	-0.74	-6.74	-0.52	5.38e-10	Vitiligo;
TGCT	cis	rs4455778	0.580	rs4917032	chr7:49111505	T/G	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	trans	rs10802346	0.545	rs1770003	chr1:246408356	A/G	cg13514129	chr1:39547527	MACF1	0.96	8.76	0.62	1.21e-14	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs7267979	1.000	rs2259956	chr20:25282433	A/G	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3733585	0.699	rs1122142	chr4:9947548	G/C	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.42	-0.55	1.62e-11	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs66569888	0.754	rs6719028	chr2:106895212	T/C	cg15412446	chr2:106886593	NA	0.46	5.07	0.41	1.42e-6	Facial morphology (factor 23);
TGCT	cis	rs11771526	0.901	rs62457494	chr7:32312299	T/G	cg27532318	chr7:32358331	NA	0.57	4.49	0.37	1.61e-5	Body mass index;
TGCT	cis	rs67478160	0.643	rs12880821	chr14:104276049	C/T	cg26031613	chr14:104095156	KLC1	-0.63	-6.42	-0.5	2.64e-9	Schizophrenia;
TGCT	trans	rs901683	0.702	rs78757497	chr10:46161918	T/C	cg18828137	chr12:52968145	KRT74	-0.61	-6.84	-0.52	3.21e-10	Red blood cell traits;Mean corpuscular volume;
TGCT	cis	rs4478858	0.735	rs1566961	chr1:31772450	G/A	cg07478791	chr1:31886160	SERINC2	-0.52	-5.03	-0.41	1.67e-6	Alcohol dependence;
TGCT	cis	rs26868	0.742	rs26848	chr16:2263516	A/G	cg26873644	chr16:2260806	C16orf79	-0.23	-4.8	-0.4	4.45e-6	Height;
TGCT	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg23982607	chr1:1823379	GNB1	-0.56	-8.48	-0.61	5.65e-14	Body mass index;
TGCT	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg19748678	chr4:122722346	EXOSC9	0.89	8.89	0.62	5.91e-15	Type 2 diabetes;
TGCT	cis	rs478304	0.530	rs11568300	chr11:65425167	C/G	cg17480646	chr11:65405466	SIPA1	-0.63	-8.35	-0.6	1.14e-13	Acne (severe);
TGCT	cis	rs2658782	0.826	rs2925355	chr11:93090887	T/C	cg18152523	chr11:93063302	CCDC67	-0.67	-5.19	-0.42	8.29e-7	Pulmonary function decline;
TGCT	cis	rs36051895	0.623	rs10283473	chr9:5244708	C/A	cg02405213	chr9:5042618	JAK2	-0.7	-8.33	-0.6	1.29e-13	Pediatric autoimmune diseases;
TGCT	cis	rs7552404	0.855	rs385897	chr1:76106962	T/C	cg03433033	chr1:76189801	ACADM	-0.84	-10.07	-0.67	8.46e-18	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs13217239	0.646	rs12523820	chr6:27001502	A/G	cg02458000	chr6:26745757	NA	0.5	4.61	0.38	1e-5	Schizophrenia;
TGCT	cis	rs6977660	0.714	rs12700075	chr7:19791476	G/T	cg05791153	chr7:19748676	TWISTNB	0.88	5.05	0.41	1.52e-6	Thyroid stimulating hormone;
TGCT	cis	rs12142240	0.698	rs41293285	chr1:46808426	C/T	cg14993813	chr1:46806288	NSUN4	-0.58	-4.81	-0.4	4.34e-6	Menopause (age at onset);
TGCT	cis	rs11080466	1.000	rs12455026	chr18:10899386	A/T	cg02393756	chr18:9912783	VAPA	0.26	4.71	0.39	6.66e-6	Non-small cell lung cancer;
TGCT	cis	rs2455799	0.613	rs2470549	chr3:15737698	T/C	cg16303742	chr3:15540471	COLQ	-0.26	-4.87	-0.4	3.26e-6	Mean platelet volume;
TGCT	cis	rs3784262	0.631	rs4646625	chr15:58256296	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.42	-6.11	-0.48	1.19e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs798766	1.000	rs1665366	chr4:1728381	A/G	cg05874882	chr4:1763078	NA	0.36	4.87	0.4	3.39e-6	Bladder cancer;Urinary bladder cancer;
TGCT	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.46	0.56	1.3e-11	Prudent dietary pattern;
TGCT	cis	rs10540	1.000	rs61877760	chr11:506596	C/T	cg03934478	chr11:495069	RNH1	0.35	5.77	0.46	6.03e-8	Body mass index;
TGCT	cis	rs10782582	0.609	rs1689270	chr1:76390937	A/G	cg10523679	chr1:76189770	ACADM	-0.54	-4.89	-0.4	3.03e-6	Daytime sleep phenotypes;
TGCT	cis	rs77741769	0.571	rs11065292	chr12:121289155	T/C	cg02419362	chr12:121203948	SPPL3	0.19	4.52	0.38	1.43e-5	Mean corpuscular volume;
TGCT	cis	rs763121	0.853	rs4821812	chr22:39075235	G/C	cg06022373	chr22:39101656	GTPBP1	0.74	7.31	0.55	2.94e-11	Menopause (age at onset);
TGCT	cis	rs68170813	0.559	rs1989814	chr7:107045076	A/G	cg02696742	chr7:106810147	HBP1	-0.68	-5.44	-0.44	2.69e-7	Coronary artery disease;
TGCT	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg11764359	chr7:65958608	NA	0.56	4.81	0.4	4.32e-6	Aortic root size;
TGCT	cis	rs13256369	0.901	rs12681298	chr8:8566235	A/G	cg17143192	chr8:8559678	CLDN23	-0.58	-5.51	-0.44	1.94e-7	Obesity-related traits;
TGCT	cis	rs1670533	0.872	rs10017931	chr4:1060747	G/A	cg20887711	chr4:1340912	KIAA1530	0.7	5.54	0.45	1.69e-7	Recombination rate (females);
TGCT	cis	rs992157	0.932	rs10194082	chr2:219188577	C/T	cg00012203	chr2:219082015	ARPC2	0.69	6.89	0.53	2.46e-10	Colorectal cancer;
TGCT	cis	rs10823500	0.748	rs12355080	chr10:71963608	G/A	cg04118878	chr10:71993077	PPA1	0.59	5.43	0.44	2.84e-7	Blood protein levels;
TGCT	cis	rs7927592	0.731	rs643609	chr11:68241833	A/G	cg16797656	chr11:68205561	LRP5	0.26	4.46	0.37	1.79e-5	Total body bone mineral density;
TGCT	cis	rs1670533	1.000	rs6599279	chr4:1058833	G/A	cg20887711	chr4:1340912	KIAA1530	0.69	5.48	0.44	2.32e-7	Recombination rate (females);
TGCT	cis	rs2439831	0.867	rs2255042	chr15:43834318	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.97	-7.38	-0.55	2.03e-11	Lung cancer in ever smokers;
TGCT	cis	rs2016266	0.855	rs4759086	chr12:53666713	A/G	cg16917193	chr12:54089295	NA	0.67	5.1	0.42	1.24e-6	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs6988636	1.000	rs59834873	chr8:124188824	G/T	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs6582630	0.537	rs12823925	chr12:38409323	C/T	cg13010199	chr12:38710504	ALG10B	0.61	4.86	0.4	3.44e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs711245	0.573	rs7570763	chr2:36800589	A/C	cg09467607	chr2:36825704	FEZ2	-0.33	-4.82	-0.4	4.15e-6	Height;
TGCT	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg13695892	chr22:41940480	POLR3H	0.91	9.11	0.63	1.79e-15	Vitiligo;
TGCT	trans	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg17470723	chr8:74884337	TCEB1	0.71	6.77	0.52	4.48e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs12908161	1.000	rs62019469	chr15:85321220	T/C	cg11189052	chr15:85197271	WDR73	0.71	5.85	0.47	4.04e-8	Schizophrenia;
TGCT	cis	rs752010	0.574	rs12130138	chr1:42117792	A/C	cg06885757	chr1:42089581	HIVEP3	0.24	4.48	0.37	1.69e-5	Lupus nephritis in systemic lupus erythematosus;
TGCT	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.87	8.55	0.61	3.91e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs3845702	0.935	rs6433822	chr2:180840422	G/C	cg01881094	chr2:180872142	CWC22	-0.66	-5.84	-0.46	4.29e-8	Schizophrenia;
TGCT	cis	rs796364	0.755	rs203762	chr2:200905136	C/A	cg17644776	chr2:200775616	C2orf69	-0.33	-5.0	-0.41	1.91e-6	Schizophrenia;
TGCT	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg05368731	chr17:41323189	NBR1	1.16	13.7	0.78	1.41e-26	Menopause (age at onset);
TGCT	cis	rs9296092	0.538	rs62407565	chr6:33535739	A/G	cg13560919	chr6:33536144	NA	-0.23	-5.04	-0.41	1.58e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg01448562	chr3:133502909	NA	-0.38	-7.63	-0.56	5.52e-12	Iron status biomarkers;
TGCT	cis	rs9638182	1.000	rs11974409	chr7:72989390	A/G	cg14087351	chr7:73037990	MLXIPL	-0.56	-4.73	-0.39	5.97e-6	Triglycerides;
TGCT	cis	rs12579753	0.879	rs11115009	chr12:82165409	G/T	cg07988820	chr12:82153109	PPFIA2	0.69	7.77	0.57	2.56e-12	Resting heart rate;
TGCT	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg22433210	chr17:43662623	NA	0.98	7.07	0.54	1.02e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs3733585	0.699	rs6815001	chr4:9958662	G/C	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.67	-0.51	7.44e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs6087990	0.735	rs2424928	chr20:31388636	T/C	cg13636640	chr20:31349939	DNMT3B	0.97	12.84	0.76	1.63e-24	Ulcerative colitis;
TGCT	cis	rs6684514	1.000	rs3806409	chr1:156252291	A/G	cg20302342	chr1:156215951	PAQR6	0.34	4.6	0.38	1.01e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs11235843	0.636	rs1464908	chr11:73402679	A/C	cg18195628	chr11:73498948	MRPL48	-0.64	-4.52	-0.38	1.42e-5	Hand grip strength;
TGCT	cis	rs12474538	0.654	rs12615259	chr2:69509617	T/C	cg24886176	chr2:70142158	MXD1	0.71	4.48	0.37	1.67e-5	Breast cancer;
TGCT	cis	rs10114408	0.959	rs3949454	chr9:96644242	G/T	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs9467711	0.606	rs9393708	chr6:26362643	C/T	cg10795676	chr6:26370623	BTN3A2	0.45	4.71	0.39	6.5e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs259282	0.646	rs34182086	chr19:33125823	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.64	5.91	0.47	3.14e-8	Schizophrenia;
TGCT	cis	rs11711311	1.000	rs2566968	chr3:113474154	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.72	-6.74	-0.52	5.36e-10	IgG glycosylation;
TGCT	trans	rs3822625	0.541	rs10042998	chr5:56205299	A/G	cg25190722	chr1:3801660	DFFB	0.54	6.63	0.51	9.27e-10	Breast cancer (early onset);
TGCT	cis	rs6754311	0.731	rs7569057	chr2:136583958	A/C	cg07169764	chr2:136633963	MCM6	0.65	6.1	0.48	1.27e-8	Mosquito bite size;
TGCT	cis	rs9910055	0.529	rs615070	chr17:42176591	A/G	cg19774624	chr17:42201019	HDAC5	-0.7	-6.8	-0.52	3.88e-10	Total body bone mineral density;
TGCT	cis	rs2486288	0.656	rs8039352	chr15:45551790	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.46	-5.54	-0.45	1.75e-7	Glomerular filtration rate;
TGCT	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg06873352	chr17:61820015	STRADA	0.56	6.22	0.49	7.1e-9	Prudent dietary pattern;
TGCT	cis	rs28830936	0.528	rs11630242	chr15:42124643	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.18	-4.89	-0.4	3.12e-6	Diastolic blood pressure;
TGCT	cis	rs16866061	0.855	rs11687736	chr2:225405122	A/T	cg12698349	chr2:225449008	CUL3	1.0	9.83	0.66	3.23e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	trans	rs7726839	0.540	rs11739847	chr5:609661	G/A	cg25482853	chr8:67687455	SGK3	1.24	10.04	0.67	1.04e-17	Obesity-related traits;
TGCT	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg26513180	chr16:89883248	FANCA	1.03	14.05	0.78	2.1e-27	Vitiligo;
TGCT	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg27454412	chr7:1067447	C7orf50	0.6	4.72	0.39	6.32e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs492146	0.765	rs316131	chr6:52848149	A/G	cg06706454	chr6:52930286	FBXO9	-0.53	-4.95	-0.41	2.37e-6	Epilepsy (remission after treatment);
TGCT	cis	rs806215	1.000	rs2106186	chr7:127241352	G/C	cg25922125	chr7:127225783	GCC1	0.59	5.99	0.47	2.15e-8	Type 2 diabetes;
TGCT	cis	rs765787	0.530	rs11854689	chr15:45516052	A/G	cg24006582	chr15:45444508	DUOX1	-0.26	-5.62	-0.45	1.19e-7	Uric acid levels;
TGCT	cis	rs2288884	0.943	rs11084132	chr19:52514580	C/T	cg13540795	chr19:52551618	ZNF432	-0.56	-4.72	-0.39	6.33e-6	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs6141769	0.542	rs6058846	chr20:31324035	A/C	cg13636640	chr20:31349939	DNMT3B	-0.52	-4.55	-0.38	1.26e-5	Subjective well-being;
TGCT	cis	rs7917772	0.503	rs7078435	chr10:104304766	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	8.33	0.6	1.3e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg21644426	chr2:191273491	MFSD6	0.62	6.15	0.48	9.57e-9	Pulse pressure;
TGCT	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs9457247	0.534	rs12055488	chr6:167379570	A/G	cg23791538	chr6:167370224	RNASET2	0.6	5.72	0.46	7.37e-8	Crohn's disease;
TGCT	cis	rs9467773	0.620	rs2494716	chr6:26662736	T/C	cg02458000	chr6:26745757	NA	0.51	4.59	0.38	1.08e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs10851411	0.779	rs57502147	chr15:42718749	T/C	cg23803468	chr15:43513504	EPB42	0.26	5.04	0.41	1.58e-6	Glucose homeostasis traits;
TGCT	cis	rs9457247	1.000	rs436707	chr6:167388843	T/C	cg25258033	chr6:167368657	RNASET2	0.18	4.49	0.37	1.63e-5	Crohn's disease;
TGCT	cis	rs4851254	0.550	rs13402289	chr2:100659389	C/T	cg22139774	chr2:100720529	AFF3	-0.46	-5.13	-0.42	1.08e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg08280861	chr8:58055591	NA	0.52	5.97	0.47	2.35e-8	Developmental language disorder (linguistic errors);
TGCT	cis	rs9787249	0.957	rs7548120	chr1:40204424	A/T	cg24920358	chr1:40204285	PPIE	0.57	10.56	0.69	5.57e-19	Blood protein levels;
TGCT	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	5.13	0.42	1.11e-6	Electroencephalogram traits;
TGCT	cis	rs7249142	0.549	rs10854012	chr19:19295719	C/T	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.53	5.26	0.43	6e-7	IgG glycosylation;
TGCT	trans	rs797680	0.753	rs11164881	chr1:93658989	C/A	cg27528825	chr2:159282178	CCDC148	-0.35	-6.82	-0.52	3.53e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs7647973	1.000	rs9860055	chr3:49506900	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.57	-4.56	-0.38	1.21e-5	Menarche (age at onset);
TGCT	trans	rs9329221	0.621	rs12156350	chr8:10268516	T/G	cg15556689	chr8:8085844	FLJ10661	-0.75	-6.78	-0.52	4.39e-10	Neuroticism;
TGCT	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg06028808	chr11:68637592	NA	0.54	6.92	0.53	2.19e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg23758822	chr17:41437982	NA	0.66	6.44	0.5	2.36e-9	Menopause (age at onset);
TGCT	cis	rs208520	0.690	rs851458	chr6:66813279	T/G	cg07460842	chr6:66804631	NA	-0.93	-9.66	-0.66	8.29e-17	Exhaled nitric oxide output;
TGCT	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg03352830	chr11:487213	PTDSS2	0.26	4.46	0.37	1.8e-5	Body mass index;
TGCT	cis	rs4699052	0.625	rs1850321	chr4:104252765	T/C	cg16532752	chr4:104119610	CENPE	-0.5	-4.92	-0.4	2.71e-6	Testicular germ cell tumor;
TGCT	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.0	-7.42	-0.55	1.64e-11	Gut microbiome composition (summer);
TGCT	cis	rs950169	0.580	rs2271431	chr15:85189464	A/C	cg17173187	chr15:85201210	NMB	0.59	6.63	0.51	9.1e-10	Schizophrenia;
TGCT	cis	rs74233809	1.000	rs76752100	chr10:104794086	G/T	cg05855489	chr10:104503620	C10orf26	0.76	4.53	0.38	1.36e-5	Birth weight;
TGCT	cis	rs3820928	0.874	rs13393902	chr2:227880554	A/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-4.94	-0.41	2.51e-6	Pulmonary function;
TGCT	cis	rs9341808	0.667	rs2476826	chr6:80876064	C/T	cg08355045	chr6:80787529	NA	0.3	5.03	0.41	1.65e-6	Sitting height ratio;
TGCT	cis	rs7267979	0.966	rs4815414	chr20:25361701	A/G	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs240764	0.658	rs4840147	chr6:101182323	T/C	cg09795085	chr6:101329169	ASCC3	-0.51	-4.51	-0.38	1.48e-5	Neuroticism;
TGCT	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg13770153	chr20:60521292	NA	-0.61	-8.66	-0.61	2.06e-14	Obesity-related traits;
TGCT	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg24531977	chr5:56204891	C5orf35	-0.77	-7.61	-0.56	5.83e-12	Initial pursuit acceleration;
TGCT	cis	rs7412746	0.634	rs7521592	chr1:150821691	A/C	cg09365446	chr1:150670422	GOLPH3L	0.35	5.04	0.41	1.62e-6	Melanoma;
TGCT	cis	rs28785552	0.897	rs34244888	chr19:53242228	T/A	cg22067481	chr19:53234126	ZNF611	-0.49	-7.39	-0.55	1.93e-11	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg20637647	chr7:64974828	NA	0.89	4.91	0.4	2.76e-6	Diabetic kidney disease;
TGCT	cis	rs17826219	0.706	rs57698184	chr17:29064918	T/C	cg14008862	chr17:28927542	LRRC37B2	0.76	4.52	0.38	1.42e-5	Body mass index;
TGCT	cis	rs1801251	1.000	rs991873	chr2:233711046	A/G	cg08000102	chr2:233561755	GIGYF2	-0.63	-6.46	-0.5	2.2e-9	Coronary artery disease;
TGCT	cis	rs2204008	0.626	rs11520260	chr12:38330092	C/T	cg13010199	chr12:38710504	ALG10B	0.58	4.55	0.38	1.26e-5	Bladder cancer;
TGCT	cis	rs2663905	0.611	rs1509560	chr15:81391713	T/G	cg09888468	chr15:81410853	NA	-0.64	-5.49	-0.44	2.16e-7	QT interval (drug interaction);
TGCT	cis	rs6582630	0.555	rs10880544	chr12:38473464	G/C	cg26384229	chr12:38710491	ALG10B	0.83	7.6	0.56	6.18e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs4478858	0.684	rs10798839	chr1:31731758	C/G	cg07478791	chr1:31886160	SERINC2	-0.49	-4.91	-0.4	2.82e-6	Alcohol dependence;
TGCT	cis	rs7588746	0.544	rs2163548	chr2:201226862	C/G	cg17644776	chr2:200775616	C2orf69	-0.35	-4.87	-0.4	3.33e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	cis	rs250677	0.958	rs43147	chr5:148417103	C/G	cg23229984	chr5:148520753	ABLIM3	-0.21	-4.92	-0.4	2.64e-6	Breast cancer;
TGCT	cis	rs7267979	1.000	rs3002702	chr20:25268920	T/C	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6545883	1.000	rs6742276	chr2:61768745	G/A	cg15711740	chr2:61764176	XPO1	-0.57	-5.29	-0.43	5.32e-7	Tuberculosis;
TGCT	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg12667521	chr19:29218732	NA	0.53	5.63	0.45	1.16e-7	Methadone dose in opioid dependence;
TGCT	cis	rs7582180	0.652	rs11675901	chr2:100951189	G/A	cg14675211	chr2:100938903	LONRF2	0.5	4.76	0.39	5.35e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10992471	0.729	rs2181585	chr9:95551830	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.56	-5.25	-0.43	6.46e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs798766	0.859	rs798727	chr4:1685137	C/T	cg05874882	chr4:1763078	NA	-0.34	-4.68	-0.39	7.52e-6	Bladder cancer;Urinary bladder cancer;
TGCT	cis	rs11249608	0.548	rs11951738	chr5:178491228	G/A	cg23951258	chr5:178450506	ZNF879	0.45	4.63	0.38	9.16e-6	Pubertal anthropometrics;
TGCT	cis	rs7829975	0.617	rs4841072	chr8:8791253	C/A	cg15556689	chr8:8085844	FLJ10661	-0.64	-5.81	-0.46	5.02e-8	Mood instability;
TGCT	cis	rs7847628	0.765	rs7026635	chr9:123550027	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.53	-4.96	-0.41	2.24e-6	Birth weight;
TGCT	cis	rs868036	0.718	rs4776982	chr15:68114974	C/T	cg05925327	chr15:68127851	NA	0.51	5.04	0.41	1.63e-6	Restless legs syndrome;
TGCT	cis	rs1990950	0.692	rs6556027	chr5:156860377	G/A	cg25387487	chr5:157003181	ADAM19	0.29	4.53	0.38	1.37e-5	Lung function (FEV1/FVC);
TGCT	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg22535103	chr8:58192502	C8orf71	-0.38	-4.88	-0.4	3.25e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.46	-6.7	-0.52	6.44e-10	Alzheimer's disease;
TGCT	trans	rs11671005	0.504	rs7257669	chr19:59064939	T/C	cg22037779	chr5:139682734	PFDN1	-0.85	-6.86	-0.52	2.89e-10	Mean platelet volume;
TGCT	cis	rs9517320	0.534	rs61971163	chr13:99188883	G/A	cg20487152	chr13:99095054	FARP1	-0.24	-4.44	-0.37	1.93e-5	Longevity;
TGCT	cis	rs10193935	1.000	rs10171023	chr2:42407093	G/C	cg27598129	chr2:42591480	NA	-0.39	-5.14	-0.42	1.05e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7010267	0.935	rs6469789	chr8:119960661	C/G	cg17171407	chr8:119960777	TNFRSF11B	0.33	6.18	0.49	8.29e-9	Total body bone mineral density (age 45-60);
TGCT	cis	rs1577917	0.958	rs12207374	chr6:86656645	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.54	-0.45	1.73e-7	Response to antipsychotic treatment;
TGCT	cis	rs7582180	0.629	rs11688285	chr2:100948054	A/C	cg08017756	chr2:100939284	LONRF2	-0.29	-4.63	-0.38	9.13e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs3849570	0.514	rs4389498	chr3:82015395	G/A	cg07356753	chr3:81810745	GBE1	-0.62	-5.41	-0.44	3.17e-7	Waist circumference;Body mass index;
TGCT	cis	rs2692947	0.727	rs749457	chr2:96795944	A/G	cg22654517	chr2:96458247	NA	0.22	4.83	0.4	4e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg05368731	chr17:41323189	NBR1	1.02	11.18	0.71	1.73e-20	Menopause (age at onset);
TGCT	cis	rs8008002	1.000	rs8007975	chr14:75865544	G/A	cg20011974	chr14:75469661	EIF2B2	-0.5	-4.48	-0.37	1.65e-5	Response to paliperidone in schizophrenia (positive Marder score);
TGCT	cis	rs644799	0.544	rs525087	chr11:95632266	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.49	4.83	0.4	3.9e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs7678567	chr4:99057346	A/G	cg05340658	chr4:99064831	C4orf37	0.52	5.79	0.46	5.32e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.8	9.07	0.63	2.27e-15	Menarche (age at onset);
TGCT	cis	rs72781680	1.000	rs72796351	chr2:24158425	T/C	cg08917208	chr2:24149416	ATAD2B	0.73	4.51	0.38	1.48e-5	Lymphocyte counts;
TGCT	cis	rs11096990	0.613	rs4974995	chr4:39218123	C/T	cg20847110	chr4:39482781	LOC401127	-0.16	-4.49	-0.37	1.64e-5	Cognitive function;
TGCT	cis	rs4654899	0.643	rs2053981	chr1:21227083	G/A	cg01072550	chr1:21505969	NA	-0.54	-8.87	-0.62	6.73e-15	Superior frontal gyrus grey matter volume;
TGCT	cis	rs1467026	0.563	rs12629928	chr3:12811796	C/T	cg05775895	chr3:12838266	CAND2	0.72	7.41	0.55	1.73e-11	P wave duration;
TGCT	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg21548813	chr6:291882	DUSP22	-0.71	-7.52	-0.56	9.59e-12	Menopause (age at onset);
TGCT	cis	rs6964587	0.967	rs10429103	chr7:91598443	T/A	cg22709100	chr7:91322751	NA	0.27	4.48	0.37	1.68e-5	Breast cancer;
TGCT	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg18305652	chr10:134549665	INPP5A	0.35	5.69	0.45	8.83e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg24060327	chr5:131705240	SLC22A5	-0.74	-7.82	-0.57	1.96e-12	Breast cancer;
TGCT	cis	rs4727027	0.704	rs12537763	chr7:148903984	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.52	4.73	0.39	6.1e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg15242686	chr22:24348715	GSTTP1	-0.53	-6.37	-0.5	3.34e-9	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg04267008	chr7:1944627	MAD1L1	-0.35	-4.68	-0.39	7.46e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs9650657	0.530	rs6982381	chr8:10952500	A/T	cg21775007	chr8:11205619	TDH	-0.55	-5.28	-0.43	5.55e-7	Neuroticism;
TGCT	cis	rs10984561	0.881	rs58300957	chr9:122252793	C/T	cg14242995	chr9:122249943	NA	0.73	5.96	0.47	2.46e-8	Pulmonary function decline;
TGCT	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg00814883	chr7:100076585	TSC22D4	-0.9	-9.56	-0.65	1.5e-16	Platelet count;
TGCT	cis	rs2239815	0.515	rs5762848	chr22:29236308	A/G	cg02153584	chr22:29168773	CCDC117	0.67	4.57	0.38	1.17e-5	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
TGCT	cis	rs1865760	0.865	rs6929805	chr6:25950834	T/A	cg16482183	chr6:26056742	HIST1H1C	0.53	4.88	0.4	3.14e-6	Height;
TGCT	cis	rs8177253	0.530	rs8177177	chr3:133463195	A/G	cg16262614	chr3:133464971	TF	0.36	4.67	0.39	7.69e-6	Iron status biomarkers;
TGCT	cis	rs12477438	0.798	rs896886	chr2:99652713	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.66	5.87	0.47	3.77e-8	Chronic sinus infection;
TGCT	cis	rs7635838	0.587	rs1992910	chr3:11311942	C/T	cg00170343	chr3:11313890	ATG7	0.61	5.98	0.47	2.16e-8	HDL cholesterol;
TGCT	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg23708337	chr7:1209742	NA	0.44	4.99	0.41	2e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2735413	0.564	rs6564508	chr16:78116575	T/C	cg09132178	chr16:78079569	NA	0.35	4.51	0.38	1.47e-5	Systolic blood pressure (alcohol consumption interaction);
TGCT	cis	rs12478296	1.000	rs55742408	chr2:243041077	G/A	cg06360820	chr2:242988706	NA	-0.59	-4.52	-0.38	1.45e-5	Obesity-related traits;
TGCT	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.29	-4.49	-0.37	1.64e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2224391	0.628	rs2753233	chr6:5250982	T/G	cg09085698	chr6:5261316	LYRM4;FARS2	-1.04	-6.69	-0.51	6.87e-10	Height;
TGCT	cis	rs35146811	0.538	rs3823642	chr7:99796072	T/C	cg22906224	chr7:99728672	NA	0.49	4.45	0.37	1.88e-5	Coronary artery disease;
TGCT	cis	rs2760061	0.599	rs849903	chr1:228137659	T/C	cg02753203	chr1:228287806	NA	-0.34	-6.48	-0.5	1.93e-9	Diastolic blood pressure;
TGCT	trans	rs35851103	0.600	rs4841662	chr8:11843758	A/G	cg06636001	chr8:8085503	FLJ10661	-0.75	-7.34	-0.55	2.41e-11	Neuroticism;
TGCT	trans	rs2832077	0.527	rs2832116	chr21:30228368	C/A	cg14791747	chr16:20752902	THUMPD1	1.09	12.67	0.75	4.09e-24	Cognitive test performance;
TGCT	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	8.0	0.58	7.67e-13	Platelet count;
TGCT	cis	rs7095607	0.606	rs7084233	chr10:69958343	T/C	cg18986048	chr10:69913749	MYPN	0.57	5.92	0.47	2.89e-8	Lung function (FVC);
TGCT	cis	rs858239	0.704	rs466240	chr7:23338774	C/T	cg00469287	chr7:23338798	C7orf30	-0.42	-4.49	-0.37	1.6e-5	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs9560113	0.573	rs61955236	chr13:112242861	G/A	cg10483660	chr13:112241077	NA	0.36	5.51	0.44	1.97e-7	Menarche (age at onset);
TGCT	cis	rs1568889	1.000	rs34667360	chr11:28055650	T/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.85	9.04	0.63	2.64e-15	Bipolar disorder;
TGCT	cis	rs1018836	0.892	rs10105142	chr8:91547420	C/T	cg16814680	chr8:91681699	NA	-0.68	-7.82	-0.57	1.97e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7945705	0.935	rs2653567	chr11:8889630	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.46	-5.31	-0.43	4.98e-7	Hemoglobin concentration;
TGCT	cis	rs941873	0.772	rs7086293	chr10:81103247	T/C	cg09469691	chr10:81107165	PPIF	0.54	5.4	0.44	3.23e-7	Height;
TGCT	cis	rs62244186	0.683	rs6766334	chr3:44567065	T/C	cg15687855	chr3:44754131	ZNF502	-0.45	-5.36	-0.43	3.94e-7	Depressive symptoms;
TGCT	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg21724239	chr8:58056113	NA	0.48	5.12	0.42	1.11e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs79349575	0.783	rs11079844	chr17:47028334	G/A	cg07967210	chr17:47022446	SNF8	0.44	6.13	0.48	1.1e-8	Type 2 diabetes;
TGCT	cis	rs6570726	0.764	rs9403731	chr6:145907937	G/A	cg05347473	chr6:146136440	FBXO30	0.51	4.74	0.39	5.8e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11971779	0.878	rs4732378	chr7:139120395	C/T	cg07862535	chr7:139043722	LUC7L2	0.78	5.7	0.46	8.32e-8	Diisocyanate-induced asthma;
TGCT	trans	rs797680	0.964	rs1932314	chr1:93638400	G/A	cg27528825	chr2:159282178	CCDC148	-0.35	-6.68	-0.51	7.13e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs7187223	0.826	rs2317972	chr16:82467476	G/A	cg03212183	chr16:81565917	CMIP	0.25	4.49	0.37	1.62e-5	Non-word repetition;
TGCT	cis	rs10791097	0.694	rs2236711	chr11:130739284	G/A	cg12179176	chr11:130786555	SNX19	0.84	10.17	0.67	4.95e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9911578	1.000	rs9901114	chr17:56575208	G/A	cg05425664	chr17:57184151	TRIM37	0.59	5.8	0.46	5.07e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs35160687	0.901	rs6714362	chr2:86476588	A/G	cg12542933	chr2:85804724	VAMP8	-0.4	-4.78	-0.39	4.86e-6	Night sleep phenotypes;
TGCT	cis	rs7772486	0.776	rs2265467	chr6:146218339	T/A	cg05347473	chr6:146136440	FBXO30	0.53	5.23	0.43	6.96e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10992471	0.729	rs1022844	chr9:95553464	A/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.56	-5.2	-0.42	8.06e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs9473924	0.542	rs9473954	chr6:50928547	G/A	cg14470998	chr6:50812995	TFAP2B	1.37	7.34	0.55	2.4e-11	Body mass index;
TGCT	cis	rs2067615	0.524	rs10778504	chr12:107120424	C/T	cg15890332	chr12:107067104	RFX4	0.28	5.53	0.44	1.82e-7	Heart rate;
TGCT	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg13732083	chr21:47605072	C21orf56	0.35	4.47	0.37	1.77e-5	Testicular germ cell tumor;
TGCT	trans	rs797680	0.820	rs11164879	chr1:93655522	G/A	cg27528825	chr2:159282178	CCDC148	-0.35	-6.82	-0.52	3.53e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs7267979	0.903	rs6050482	chr20:25226327	C/T	cg14121845	chr20:25566513	NINL	0.48	5.22	0.42	7.27e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3849570	0.673	rs13068700	chr3:81975817	G/C	cg07356753	chr3:81810745	GBE1	-0.73	-6.87	-0.53	2.74e-10	Waist circumference;Body mass index;
TGCT	cis	rs9325144	0.560	rs12424821	chr12:38649951	C/T	cg26384229	chr12:38710491	ALG10B	-0.66	-6.0	-0.47	2.06e-8	Morning vs. evening chronotype;
TGCT	cis	rs908922	0.676	rs478926	chr1:152511533	G/T	cg20991723	chr1:152506922	NA	0.46	6.18	0.48	8.66e-9	Hair morphology;
TGCT	cis	rs4689388	0.581	rs11727100	chr4:6281458	A/C	cg14416269	chr4:6271139	WFS1	0.47	5.6	0.45	1.32e-7	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs7772486	0.754	rs9390358	chr6:146145678	C/T	cg05347473	chr6:146136440	FBXO30	0.53	4.99	0.41	2.02e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs422249	0.512	rs1535	chr11:61597972	A/G	cg19610905	chr11:61596333	FADS2	-1.06	-11.49	-0.72	2.97e-21	Trans fatty acid levels;
TGCT	cis	rs4478858	0.684	rs7515988	chr1:31731061	C/T	cg00250761	chr1:31883323	NA	0.25	4.44	0.37	1.98e-5	Alcohol dependence;
TGCT	cis	rs4733781	0.583	rs1340022	chr8:131334465	T/C	cg16277922	chr8:131349729	ASAP1	0.47	7.3	0.55	3e-11	Tuberculosis;
TGCT	cis	rs514406	0.893	rs6588446	chr1:53425260	G/A	cg24675658	chr1:53192096	ZYG11B	0.69	7.85	0.58	1.64e-12	Monocyte count;
TGCT	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.05	8.69	0.62	1.83e-14	Platelet count;
TGCT	cis	rs3087591	0.960	rs2905797	chr17:29537458	G/C	cg24425628	chr17:29625626	OMG;NF1	0.42	6.22	0.49	7.06e-9	Hip circumference;
TGCT	cis	rs3741404	0.584	rs645461	chr11:63893694	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.78	-7.74	-0.57	2.98e-12	Platelet count;
TGCT	cis	rs17376456	0.877	rs10052428	chr5:93476530	T/C	cg25358565	chr5:93447407	FAM172A	0.92	8.23	0.59	2.17e-13	Diabetic retinopathy;
TGCT	cis	rs7208859	0.623	rs80355557	chr17:29154421	C/T	cg14008862	chr17:28927542	LRRC37B2	0.75	5.1	0.42	1.26e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs17376456	0.825	rs17372725	chr5:93135588	C/A	cg21475434	chr5:93447410	FAM172A	0.61	4.82	0.4	4.11e-6	Diabetic retinopathy;
TGCT	cis	rs9457247	0.902	rs366938	chr6:167403538	T/C	cg23791538	chr6:167370224	RNASET2	-0.49	-4.96	-0.41	2.26e-6	Crohn's disease;
TGCT	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg06221963	chr1:154839813	KCNN3	-0.75	-12.65	-0.75	4.66e-24	Prostate cancer;
TGCT	cis	rs4319547	0.695	rs10734915	chr12:122873408	A/C	cg05707623	chr12:122985044	ZCCHC8	-0.61	-4.74	-0.39	5.7e-6	Body mass index;
TGCT	cis	rs1552244	0.832	rs66597916	chr3:10195407	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.1	6.25	0.49	6.06e-9	Alzheimer's disease;
TGCT	cis	rs6835098	0.692	rs6822683	chr4:174063974	G/A	cg08422745	chr4:174089978	GALNT7	-0.8	-9.03	-0.63	2.7e-15	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs11190604	0.806	rs76835764	chr10:102193612	C/T	cg23241863	chr10:102295624	HIF1AN	0.65	4.89	0.4	3e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.74	-7.71	-0.57	3.59e-12	Prudent dietary pattern;
TGCT	cis	rs826838	0.967	rs34496261	chr12:39023829	G/A	cg13010199	chr12:38710504	ALG10B	0.83	6.91	0.53	2.21e-10	Heart rate;
TGCT	cis	rs7091068	0.721	rs618951	chr10:95404967	A/G	cg20715218	chr10:95462985	C10orf4	-0.54	-5.15	-0.42	9.95e-7	Urinary tract infection frequency;
TGCT	cis	rs2180341	0.782	rs6912552	chr6:127722946	C/G	cg24812749	chr6:127587940	RNF146	-0.62	-4.92	-0.4	2.7e-6	Breast cancer;
TGCT	cis	rs8103278	1.000	rs9676288	chr19:46292060	G/T	cg11657440	chr19:46296263	DMWD	-0.59	-5.72	-0.46	7.41e-8	Coronary artery disease;
TGCT	cis	rs12477438	0.834	rs10179043	chr2:99687490	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-8.47	-0.61	6.04e-14	Chronic sinus infection;
TGCT	cis	rs7178572	0.568	rs1602925	chr15:77685857	T/C	cg22256960	chr15:77711686	NA	-0.88	-9.16	-0.64	1.32e-15	Type 2 diabetes;
TGCT	cis	rs2204008	0.837	rs10876019	chr12:37985477	C/T	cg13010199	chr12:38710504	ALG10B	0.65	5.29	0.43	5.47e-7	Bladder cancer;
TGCT	cis	rs9549260	0.848	rs966968	chr13:41248037	C/T	cg21288729	chr13:41239152	FOXO1	-1.01	-10.52	-0.69	7e-19	Red blood cell count;
TGCT	cis	rs7568458	0.870	rs6757263	chr2:85803542	A/G	cg02493740	chr2:85810744	VAMP5	-0.27	-4.83	-0.4	3.93e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg03806693	chr22:41940476	POLR3H	-0.99	-10.42	-0.68	1.22e-18	Vitiligo;
TGCT	cis	rs17681684	0.565	rs62066044	chr17:9762454	G/A	cg15743799	chr17:9805578	RCVRN	-0.28	-6.0	-0.47	1.99e-8	GIP levels in response to oral glucose tolerance test (fasting);
TGCT	cis	rs2153535	0.580	rs1932283	chr6:8477661	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs60843830	0.661	rs11674477	chr2:105822	C/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.56	4.89	0.4	3.11e-6	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs9389248	0.690	rs1028314	chr6:135255710	A/C	cg24558204	chr6:135376177	HBS1L	-0.47	-4.87	-0.4	3.3e-6	High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg04267008	chr7:1944627	MAD1L1	-0.35	-4.7	-0.39	6.89e-6	Schizophrenia;
TGCT	cis	rs1941023	0.503	rs10750936	chr11:60144180	G/A	cg08716584	chr11:60157161	MS4A7	-0.34	-4.84	-0.4	3.81e-6	Congenital heart disease (maternal effect);
TGCT	cis	rs6088580	0.634	rs6058070	chr20:33103521	G/C	cg06115741	chr20:33292138	TP53INP2	0.53	4.65	0.39	8.41e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs9383153	1.000	rs2073518	chr6:16332730	T/C	cg10975897	chr6:15504844	JARID2	0.84	5.05	0.41	1.54e-6	Gambling;
TGCT	cis	rs6500602	0.701	rs6500614	chr16:4573938	A/G	cg08645402	chr16:4508243	NA	0.2	4.85	0.4	3.55e-6	Schizophrenia;
TGCT	cis	rs240764	0.631	rs9322174	chr6:101204193	G/C	cg21058520	chr6:100914733	NA	0.34	4.44	0.37	2e-5	Neuroticism;
TGCT	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg00149659	chr3:10157352	C3orf10	0.91	5.89	0.47	3.32e-8	Alzheimer's disease;
TGCT	cis	rs1008375	1.000	rs28552744	chr4:17620165	A/G	cg18681998	chr4:17616180	MED28	1.01	11.3	0.71	8.54e-21	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1580019	0.922	rs59938271	chr7:32484844	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.9	8.65	0.61	2.27e-14	Cognitive ability;
TGCT	cis	rs13191362	1.000	rs34591938	chr6:163087003	C/G	cg21926612	chr6:163149169	PACRG;PARK2	1.17	9.52	0.65	1.89e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs9291683	0.597	rs11722989	chr4:10126139	A/G	cg00071950	chr4:10020882	SLC2A9	-0.45	-4.94	-0.41	2.49e-6	Bone mineral density;
TGCT	cis	rs713587	0.967	rs713586	chr2:25158008	A/G	cg15423357	chr2:25149977	NA	0.63	6.43	0.5	2.52e-9	Body mass index in non-asthmatics;
TGCT	cis	rs11578119	0.898	rs4399219	chr1:170382776	C/T	cg09767346	chr1:170501363	GORAB	-0.72	-5.72	-0.46	7.52e-8	Male-pattern baldness;
TGCT	trans	rs28735056	1.000	rs3826576	chr18:77633976	G/A	cg05926928	chr17:57297772	GDPD1	-0.7	-7.56	-0.56	7.89e-12	Schizophrenia;
TGCT	cis	rs6964587	0.869	rs13237856	chr7:91551788	G/A	cg17063962	chr7:91808500	NA	-0.86	-9.28	-0.64	6.82e-16	Breast cancer;
TGCT	cis	rs7178572	0.633	rs12907746	chr15:77843326	A/G	cg22256960	chr15:77711686	NA	-0.82	-7.51	-0.56	1.03e-11	Type 2 diabetes;
TGCT	cis	rs56104184	0.723	rs116909499	chr19:49407733	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.73	-9.15	-0.63	1.47e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs317689	0.690	rs570256	chr12:69662929	A/T	cg14784868	chr12:69753453	YEATS4	0.53	4.51	0.38	1.5e-5	Response to diuretic therapy;
TGCT	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg16325326	chr1:53192061	ZYG11B	0.6	6.77	0.52	4.62e-10	Monocyte count;
TGCT	cis	rs7584330	0.868	rs7571898	chr2:238383028	T/C	cg16989719	chr2:238392110	NA	-0.26	-4.48	-0.37	1.7e-5	Prostate cancer;
TGCT	cis	rs826838	1.000	rs10880963	chr12:38748408	T/C	cg26384229	chr12:38710491	ALG10B	1.08	10.82	0.7	1.3e-19	Heart rate;
TGCT	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg00343986	chr7:65444356	GUSB	0.23	4.97	0.41	2.14e-6	Aortic root size;
TGCT	cis	rs7659604	0.702	rs61217486	chr4:122693973	T/C	cg19748678	chr4:122722346	EXOSC9	0.83	8.84	0.62	8.1e-15	Type 2 diabetes;
TGCT	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg08975724	chr8:8085496	FLJ10661	0.58	5.4	0.44	3.29e-7	Neuroticism;
TGCT	cis	rs2172802	1.000	rs35550109	chr4:62462234	A/G	cg04118610	chr4:62707027	LPHN3	0.4	4.65	0.39	8.47e-6	Partial epilepsies;
TGCT	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.02	0.53	1.3e-10	Prudent dietary pattern;
TGCT	cis	rs2354432	0.546	rs11240030	chr1:146882616	G/A	cg25205988	chr1:146714368	CHD1L	1.16	7.68	0.57	4.11e-12	Mitochondrial DNA levels;
TGCT	trans	rs7819412	0.511	rs2898290	chr8:11433909	T/C	cg15556689	chr8:8085844	FLJ10661	-0.77	-7.2	-0.54	5.08e-11	Triglycerides;
TGCT	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg26818010	chr10:134567672	INPP5A	-0.38	-5.19	-0.42	8.5e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	trans	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg17470723	chr8:74884337	TCEB1	0.72	6.94	0.53	1.91e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs950169	0.887	rs220333	chr15:85091133	C/T	cg12863693	chr15:85201151	NMB	0.4	4.47	0.37	1.73e-5	Schizophrenia;
TGCT	cis	rs6460942	0.915	rs72584550	chr7:12304990	G/A	cg06484146	chr7:12443880	VWDE	-0.43	-4.63	-0.38	8.94e-6	Coronary artery disease;
TGCT	cis	rs3213545	0.700	rs2260445	chr12:121468863	C/A	cg02403541	chr12:121454288	C12orf43	0.7	7.86	0.58	1.63e-12	Subjective well-being;Cardiovascular disease risk factors;
TGCT	cis	rs1453308	1.000	rs4663645	chr2:237185631	A/T	cg19324714	chr2:237145437	ASB18	0.57	5.08	0.41	1.37e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg22433210	chr17:43662623	NA	0.94	7.95	0.58	9.69e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2032447	0.530	rs9356996	chr6:26008487	C/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.72	7.09	0.54	8.81e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs4780401	0.527	rs4780402	chr16:11839809	C/T	cg01061890	chr16:11836724	TXNDC11	-0.48	-4.48	-0.37	1.65e-5	Rheumatoid arthritis;
TGCT	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg21862992	chr11:68658383	NA	0.46	6.26	0.49	5.67e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs514406	0.505	rs269286	chr1:53169018	C/T	cg16325326	chr1:53192061	ZYG11B	-0.82	-10.87	-0.7	9.63e-20	Monocyte count;
TGCT	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg22920501	chr2:26401640	FAM59B	-0.74	-6.4	-0.5	2.86e-9	Gut microbiome composition (summer);
TGCT	cis	rs6579837	1.000	rs6579837	chr5:150434894	G/T	cg11901248	chr5:149866502	NA	-0.59	-4.63	-0.38	8.93e-6	Sjögren's syndrome;
TGCT	cis	rs12950390	0.814	rs4794099	chr17:45838358	T/C	cg24803719	chr17:45855879	NA	-0.47	-4.75	-0.39	5.6e-6	IgG glycosylation;
TGCT	cis	rs9948	0.786	rs62156234	chr2:97436292	C/G	cg01990225	chr2:97406019	LMAN2L	-0.88	-4.81	-0.4	4.37e-6	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs6688613	0.694	rs3820387	chr1:166820284	A/T	cg07049167	chr1:166818506	POGK	0.24	5.15	0.42	9.86e-7	Refractive astigmatism;
TGCT	cis	rs7647973	1.000	rs6805609	chr3:49471522	C/G	cg06212747	chr3:49208901	KLHDC8B	-0.71	-5.41	-0.44	3.07e-7	Menarche (age at onset);
TGCT	cis	rs6490294	0.659	rs11066028	chr12:112245170	A/C	cg10833066	chr12:111807467	FAM109A	0.33	5.27	0.43	5.76e-7	Mean platelet volume;
TGCT	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg27170947	chr2:26402098	FAM59B	-0.4	-4.63	-0.38	8.93e-6	Gut microbiome composition (summer);
TGCT	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.5	5.42	0.44	2.93e-7	Lymphocyte counts;
TGCT	cis	rs6964587	1.000	rs28735847	chr7:91592755	T/C	cg17063962	chr7:91808500	NA	0.91	9.99	0.67	1.32e-17	Breast cancer;
TGCT	cis	rs9926296	0.744	rs164749	chr16:89708224	A/C	cg04287289	chr16:89883240	FANCA	-0.45	-4.45	-0.37	1.9e-5	Vitiligo;
TGCT	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg21171335	chr12:122356390	WDR66	0.65	7.12	0.54	7.51e-11	Mean corpuscular volume;
TGCT	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	5.54	0.45	1.71e-7	Height;
TGCT	trans	rs9951602	0.512	rs9946138	chr18:76654608	A/G	cg02800362	chr5:177631904	HNRNPAB	1.14	12.55	0.75	7.84e-24	Obesity-related traits;
TGCT	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.04	0.41	1.59e-6	Prudent dietary pattern;
TGCT	cis	rs35306767	0.904	rs35667562	chr10:950630	G/A	cg26597838	chr10:835615	NA	0.82	12.45	0.75	1.39e-23	Eosinophil percentage of granulocytes;
TGCT	cis	rs10479542	0.896	rs10078712	chr5:178978805	C/T	cg14820908	chr5:178986412	RUFY1	-0.45	-4.5	-0.37	1.54e-5	Lung cancer;
TGCT	cis	rs9788721	0.806	rs4887056	chr15:78734585	A/G	cg18825076	chr15:78729989	IREB2	-0.33	-5.22	-0.42	7.38e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
TGCT	cis	rs7267979	0.586	rs1007708	chr20:25190959	C/T	cg14121845	chr20:25566513	NINL	0.46	4.85	0.4	3.61e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.9	7.36	0.55	2.22e-11	Platelet count;
TGCT	cis	rs9682041	0.660	rs13089256	chr3:170113601	G/A	cg11886554	chr3:170076028	SKIL	0.62	4.85	0.4	3.59e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs7769051	0.711	rs9493436	chr6:133088275	T/C	cg22852734	chr6:133119734	C6orf192	1.18	6.54	0.51	1.46e-9	Type 2 diabetes nephropathy;
TGCT	cis	rs3806933	0.500	rs10491423	chr5:110453977	C/A	cg04022379	chr5:110408740	TSLP	0.6	6.36	0.5	3.53e-9	Eosinophilic esophagitis;
TGCT	cis	rs6987853	0.901	rs2974344	chr8:42400732	T/G	cg20539142	chr8:42623718	CHRNA6	-0.19	-4.58	-0.38	1.11e-5	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs709400	0.526	rs11622473	chr14:103979762	G/A	cg26031613	chr14:104095156	KLC1	0.74	6.0	0.47	2.03e-8	Body mass index;
TGCT	cis	rs9902453	0.808	rs1986555	chr17:28014448	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	7.18	0.54	5.76e-11	Coffee consumption (cups per day);
TGCT	cis	rs295140	0.507	rs4673814	chr2:201108133	G/A	cg23649088	chr2:200775458	C2orf69	-0.32	-5.38	-0.43	3.62e-7	QT interval;
TGCT	cis	rs7772486	0.727	rs6941429	chr6:145952283	G/A	cg23711669	chr6:146136114	FBXO30	0.92	10.45	0.68	1.03e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2249625	0.523	rs1969530	chr6:72861276	A/C	cg24401219	chr6:72892597	RIMS1	-0.54	-4.7	-0.39	6.92e-6	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
TGCT	cis	rs7178572	0.568	rs4886862	chr15:77652368	T/C	cg15453836	chr15:77711506	NA	-0.42	-4.79	-0.4	4.68e-6	Type 2 diabetes;
TGCT	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg03188948	chr7:1209495	NA	0.45	5.76	0.46	6.15e-8	Longevity;Endometriosis;
TGCT	cis	rs709400	0.628	rs6575984	chr14:103876454	A/G	cg26031613	chr14:104095156	KLC1	-0.83	-9.19	-0.64	1.17e-15	Body mass index;
TGCT	cis	rs6921919	0.583	rs9461458	chr6:28355875	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.56	-5.32	-0.43	4.76e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9402673	0.517	rs978036	chr6:135342903	C/T	cg24558204	chr6:135376177	HBS1L	0.5	5.0	0.41	1.89e-6	Reticulocyte count;High light scatter reticulocyte count;
TGCT	trans	rs7618501	0.521	rs3774759	chr3:49939120	G/T	cg21659725	chr3:3221576	CRBN	0.68	7.77	0.57	2.53e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs868036	0.681	rs3784718	chr15:68098004	C/T	cg05925327	chr15:68127851	NA	-0.5	-4.85	-0.4	3.57e-6	Restless legs syndrome;
TGCT	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg07507251	chr3:52567010	NT5DC2	-0.47	-6.64	-0.51	8.85e-10	Electroencephalogram traits;
TGCT	cis	rs3749237	0.595	rs10865955	chr3:49499829	G/A	cg07636037	chr3:49044803	WDR6	0.63	6.07	0.48	1.47e-8	Resting heart rate;
TGCT	cis	rs875971	1.000	rs1167411	chr7:65539264	C/G	cg18876405	chr7:65276391	NA	-0.35	-5.19	-0.42	8.26e-7	Aortic root size;
TGCT	cis	rs7267979	1.000	rs2259926	chr20:25281733	T/C	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg03517284	chr6:25882590	NA	-0.62	-6.51	-0.5	1.7e-9	Blood metabolite levels;
TGCT	cis	rs12927205	0.510	rs7185601	chr16:72035082	A/G	cg06353428	chr16:71660113	MARVELD3	0.88	4.85	0.4	3.64e-6	Cholesterol, total;LDL cholesterol;
TGCT	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg00149659	chr3:10157352	C3orf10	0.94	6.02	0.48	1.82e-8	Alzheimer's disease;
TGCT	cis	rs13223928	0.621	rs4722440	chr7:3155901	C/T	cg19214707	chr7:3157722	NA	0.46	6.97	0.53	1.7e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
TGCT	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg19774624	chr17:42201019	HDAC5	-0.87	-10.69	-0.69	2.7e-19	Total body bone mineral density;
TGCT	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg03388025	chr16:89894329	SPIRE2	0.48	8.08	0.59	4.79e-13	Vitiligo;
TGCT	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs9653442	0.564	rs4851253	chr2:100762786	T/G	cg07810366	chr2:100720526	AFF3	-0.37	-5.49	-0.44	2.16e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs7772486	0.902	rs2777480	chr6:146309983	T/A	cg23711669	chr6:146136114	FBXO30	0.77	7.93	0.58	1.08e-12	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs79057730	0.599	rs6944167	chr7:826274	G/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.64	5.28	0.43	5.51e-7	Initial pursuit acceleration;
TGCT	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg12310025	chr6:25882481	NA	0.52	4.72	0.39	6.18e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg23708337	chr7:1209742	NA	0.43	4.91	0.4	2.84e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2153535	0.541	rs1414353	chr6:8485642	C/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs7267979	1.000	rs6083804	chr20:25317060	A/G	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3617	0.591	rs11918800	chr3:52868145	G/A	cg11645453	chr3:52864694	ITIH4	-0.29	-5.71	-0.46	7.84e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.53	0.38	1.35e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2535633	0.631	rs2581819	chr3:53016552	C/A	cg05573699	chr3:52720067	GNL3;PBRM1	0.55	5.24	0.43	6.68e-7	Body mass index;
TGCT	cis	rs6684514	1.000	rs2273833	chr1:156233189	C/T	cg16558208	chr1:156270281	VHLL	0.48	9.29	0.64	6.47e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs9325144	0.624	rs10783330	chr12:39114084	A/G	cg10518543	chr12:38710700	ALG10B	-0.51	-4.68	-0.39	7.43e-6	Morning vs. evening chronotype;
TGCT	cis	rs2239547	0.657	rs2276817	chr3:52860936	C/T	cg10802521	chr3:52805072	NEK4	-0.62	-5.85	-0.47	4.1e-8	Schizophrenia;
TGCT	cis	rs6460942	0.841	rs17444203	chr7:12461864	C/G	cg06484146	chr7:12443880	VWDE	0.53	5.59	0.45	1.36e-7	Coronary artery disease;
TGCT	cis	rs9858542	1.000	rs13316695	chr3:49684917	C/G	cg03060546	chr3:49711283	APEH	-0.67	-6.09	-0.48	1.28e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs78487399	0.808	rs7567535	chr2:43668261	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.24	-0.43	6.79e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg10047753	chr17:41438598	NA	0.84	7.61	0.56	5.9e-12	Menopause (age at onset);
TGCT	cis	rs59197085	0.551	rs58518485	chr7:128437731	G/A	cg00260937	chr7:128520193	KCP	0.45	4.66	0.39	7.95e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
TGCT	cis	rs5769707	0.609	rs2007024	chr22:49988815	C/T	cg06623630	chr22:50017776	C22orf34	-0.25	-4.45	-0.37	1.91e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg10802521	chr3:52805072	NEK4	-0.71	-8.79	-0.62	1.04e-14	Bipolar disorder;
TGCT	cis	rs782590	0.818	rs2627782	chr2:55825352	A/G	cg03859395	chr2:55845619	SMEK2	0.84	10.09	0.67	7.69e-18	Metabolic syndrome;
TGCT	cis	rs2013441	1.000	rs17759959	chr17:20024095	A/G	cg23224458	chr17:20280056	CCDC144C	0.4	4.82	0.4	4.1e-6	Obesity-related traits;
TGCT	cis	rs13217239	0.572	rs9379958	chr6:27066163	A/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.42	-4.61	-0.38	9.71e-6	Schizophrenia;
TGCT	cis	rs68170813	0.559	rs3801958	chr7:106961139	C/T	cg02696742	chr7:106810147	HBP1	-0.71	-5.83	-0.46	4.43e-8	Coronary artery disease;
TGCT	cis	rs7937682	0.921	rs10891280	chr11:111433609	A/T	cg09085632	chr11:111637200	PPP2R1B	0.87	7.31	0.55	2.9e-11	Primary sclerosing cholangitis;
TGCT	cis	rs708547	0.735	rs1277280	chr4:57866872	T/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.55	-5.03	-0.41	1.71e-6	Response to bleomycin (chromatid breaks);
TGCT	cis	rs10791097	0.608	rs12363140	chr11:130744268	A/C	cg14779329	chr11:130786720	SNX19	0.28	4.82	0.4	4.09e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs4727027	0.704	rs2888600	chr7:148908562	C/T	cg23583168	chr7:148888333	NA	-0.85	-10.95	-0.7	6.08e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs9972944	0.902	rs10512503	chr17:63772066	G/A	cg07283582	chr17:63770753	CCDC46	0.27	5.27	0.43	5.91e-7	Total body bone mineral density;
TGCT	cis	rs910316	1.000	rs11845639	chr14:75570293	C/T	cg23033748	chr14:75592666	NEK9	0.28	4.72	0.39	6.22e-6	Height;
TGCT	trans	rs4332037	0.901	rs7791299	chr7:1935598	T/C	cg10840412	chr1:235813424	GNG4	0.89	6.9	0.53	2.37e-10	Bipolar disorder;
TGCT	cis	rs7412746	0.658	rs11581757	chr1:150892244	A/G	cg04414720	chr1:150670196	GOLPH3L	0.37	4.5	0.37	1.53e-5	Melanoma;
TGCT	cis	rs12210905	0.688	rs72845028	chr6:27528408	T/C	cg08851530	chr6:28072375	NA	1.34	6.29	0.49	5.02e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs73198271	0.960	rs73198288	chr8:8613940	G/A	ch.8.214553F	chr8:8189620	PRAGMIN	-0.27	-4.79	-0.39	4.72e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs2013441	1.000	rs2080673	chr17:20062395	C/A	cg18979559	chr17:20280153	CCDC144C	0.44	4.61	0.38	9.78e-6	Obesity-related traits;
TGCT	cis	rs2463822	0.669	rs72919484	chr11:62043430	T/C	cg06239285	chr11:62104954	ASRGL1	-0.87	-5.04	-0.41	1.6e-6	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs60154123	0.505	rs1319435	chr1:210047618	C/T	cg22029157	chr1:209979665	IRF6	-0.74	-5.2	-0.42	7.83e-7	Coronary artery disease;
TGCT	cis	rs2290402	0.536	rs4690204	chr4:881195	C/T	cg11315544	chr4:1222440	CTBP1	0.26	4.46	0.37	1.84e-5	Type 2 diabetes;
TGCT	cis	rs174601	0.861	rs174580	chr11:61606642	A/G	cg20584555	chr11:61717780	BEST1	-0.23	-4.45	-0.37	1.88e-5	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
TGCT	cis	rs2303745	0.589	rs10401700	chr19:17397700	A/C	cg04248312	chr19:17393744	ANKLE1	-0.32	-5.44	-0.44	2.69e-7	Systemic lupus erythematosus;
TGCT	cis	rs12681287	0.640	rs7007855	chr8:87429491	T/G	cg27223183	chr8:87520930	FAM82B	0.89	6.43	0.5	2.54e-9	Caudate activity during reward;
TGCT	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg13770153	chr20:60521292	NA	-0.54	-7.12	-0.54	7.73e-11	Body mass index;
TGCT	cis	rs7666738	0.830	rs11941844	chr4:99042722	A/T	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3008870	1.000	rs4620509	chr1:67449941	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.1	-11.8	-0.73	5.15e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs950169	0.922	rs11633075	chr15:85113972	C/A	cg11189052	chr15:85197271	WDR73	0.77	6.44	0.5	2.34e-9	Schizophrenia;
TGCT	cis	rs4727027	0.645	rs12704072	chr7:148904888	G/A	cg23583168	chr7:148888333	NA	-0.82	-10.48	-0.69	8.54e-19	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs1472147	0.503	rs73238122	chr7:128433977	G/T	cg00260937	chr7:128520193	KCP	0.43	4.94	0.41	2.43e-6	Calcium levels;
TGCT	cis	rs10080237	0.564	rs2490232	chr6:80814802	C/T	cg08355045	chr6:80787529	NA	-0.34	-5.98	-0.47	2.17e-8	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
TGCT	cis	rs1215050	0.740	rs1084777	chr4:99017542	C/T	cg17366294	chr4:99064904	C4orf37	-0.54	-5.86	-0.47	3.98e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs11249608	0.636	rs13361077	chr5:178449174	G/C	cg01312482	chr5:178451176	ZNF879	-0.58	-5.77	-0.46	5.94e-8	Pubertal anthropometrics;
TGCT	cis	rs7647973	0.961	rs6778080	chr3:49317338	C/T	cg07636037	chr3:49044803	WDR6	-0.65	-5.26	-0.43	6.13e-7	Menarche (age at onset);
TGCT	trans	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-1.03	-13.16	-0.76	2.65e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg03213289	chr20:61660250	NA	0.68	9.9	0.66	2.25e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg11764359	chr7:65958608	NA	0.54	4.66	0.39	7.88e-6	Aortic root size;
TGCT	cis	rs17433780	0.964	rs12121223	chr1:89481583	C/T	cg09516651	chr1:89888402	LOC400759	0.3	5.26	0.43	6.05e-7	Carotid intima media thickness;
TGCT	cis	rs60843830	1.000	rs60484953	chr2:221560	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.76	7.26	0.55	3.8e-11	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs11249608	0.548	rs2047354	chr5:178455247	T/C	cg23951258	chr5:178450506	ZNF879	0.45	4.61	0.38	9.7e-6	Pubertal anthropometrics;
TGCT	cis	rs1059312	1.000	rs12814773	chr12:129280786	C/T	cg09035930	chr12:129282057	SLC15A4	0.59	11.76	0.73	6.45e-22	Systemic lupus erythematosus;
TGCT	cis	rs9972944	0.756	rs2318869	chr17:63767736	C/G	cg07283582	chr17:63770753	CCDC46	-0.26	-5.27	-0.43	5.91e-7	Total body bone mineral density;
TGCT	cis	rs8016982	0.610	rs2371570	chr14:81709686	C/T	cg01989461	chr14:81687754	GTF2A1	0.78	7.8	0.57	2.21e-12	Schizophrenia;
TGCT	cis	rs1801251	1.000	rs283486	chr2:233644223	A/G	cg25237894	chr2:233734115	C2orf82	0.33	6.05	0.48	1.57e-8	Coronary artery disease;
TGCT	cis	rs8017423	0.904	rs2149647	chr14:90769539	C/T	cg04374321	chr14:90722782	PSMC1	-0.73	-6.71	-0.52	6.06e-10	Mortality in heart failure;
TGCT	cis	rs7666738	0.830	rs62321569	chr4:98984250	T/A	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12908161	0.959	rs34784022	chr15:85231906	T/C	cg11189052	chr15:85197271	WDR73	0.75	6.3	0.49	4.8e-9	Schizophrenia;
TGCT	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg00149659	chr3:10157352	C3orf10	1.2	7.56	0.56	7.9e-12	Alzheimer's disease;
TGCT	cis	rs9527	0.830	rs11191440	chr10:104641511	G/A	cg15744005	chr10:104629667	AS3MT	-0.51	-6.04	-0.48	1.63e-8	Arsenic metabolism;
TGCT	cis	rs2735413	0.564	rs8059851	chr16:78118332	A/G	cg09132178	chr16:78079569	NA	0.35	4.51	0.38	1.47e-5	Systolic blood pressure (alcohol consumption interaction);
TGCT	cis	rs6964587	0.869	rs401	chr7:91527945	T/G	cg17063962	chr7:91808500	NA	-0.86	-9.28	-0.64	6.82e-16	Breast cancer;
TGCT	cis	rs453301	0.606	rs7462373	chr8:8899318	G/C	cg15556689	chr8:8085844	FLJ10661	-0.65	-5.43	-0.44	2.91e-7	Joint mobility (Beighton score);
TGCT	cis	rs1580019	0.961	rs11765387	chr7:32494790	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.79	7.42	0.55	1.63e-11	Cognitive ability;
TGCT	cis	rs2806561	0.704	rs588387	chr1:23523689	A/G	cg12483005	chr1:23474871	LUZP1	0.42	5.41	0.44	3.15e-7	Height;
TGCT	cis	rs896854	0.654	rs16893776	chr8:95973604	C/T	cg23172400	chr8:95962367	TP53INP1	-0.38	-6.46	-0.5	2.21e-9	Type 2 diabetes;
TGCT	cis	rs7805747	1.000	rs6464165	chr7:151413124	T/C	cg17611936	chr7:151411526	PRKAG2	0.54	6.91	0.53	2.29e-10	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
TGCT	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg24531977	chr5:56204891	C5orf35	0.64	6.57	0.51	1.28e-9	Initial pursuit acceleration;
TGCT	cis	rs11578119	0.866	rs17350305	chr1:170377200	C/G	cg09767346	chr1:170501363	GORAB	-0.66	-5.24	-0.43	6.6e-7	Male-pattern baldness;
TGCT	cis	rs11190604	1.000	rs4919472	chr10:102315864	T/A	cg23241863	chr10:102295624	HIF1AN	0.68	5.18	0.42	8.89e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2920503	1.000	rs2920503	chr3:12324230	C/T	cg23514324	chr3:12329213	PPARG	0.62	5.71	0.46	7.76e-8	LDL cholesterol;
TGCT	cis	rs4566357	1.000	rs3820926	chr2:227926621	G/T	cg11843606	chr2:227700838	RHBDD1	-0.5	-4.49	-0.37	1.59e-5	Coronary artery disease;
TGCT	cis	rs2046867	0.818	rs6786469	chr3:72873809	A/G	cg25664220	chr3:72788482	NA	-0.55	-6.29	-0.49	5.01e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs651907	0.535	rs35799195	chr3:101521927	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.86	10.4	0.68	1.35e-18	Colorectal cancer;
TGCT	cis	rs9399401	0.667	rs11759653	chr6:142720354	G/A	cg03128060	chr6:142623767	GPR126	0.37	4.47	0.37	1.77e-5	Chronic obstructive pulmonary disease;
TGCT	cis	rs7000551	0.581	rs2293145	chr8:22262654	A/T	cg12081754	chr8:22256438	SLC39A14	0.34	5.1	0.42	1.21e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs10876993	0.806	rs1689598	chr12:58050500	G/C	cg15848620	chr12:58087721	OS9	-0.72	-5.82	-0.46	4.71e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs4455778	0.580	rs4524741	chr7:49105138	A/C	cg26309511	chr7:48887640	NA	0.48	5.96	0.47	2.44e-8	Lung cancer in never smokers;
TGCT	cis	rs6121246	0.567	rs6060247	chr20:30190720	C/G	cg21427119	chr20:30132790	HM13	-0.43	-6.28	-0.49	5.3e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs4294134	0.580	rs11760731	chr7:135244179	C/T	cg08396481	chr7:135194601	CNOT4	-0.62	-4.81	-0.4	4.25e-6	Paget's disease;
TGCT	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs35306767	0.715	rs12772979	chr10:1034412	C/T	cg26597838	chr10:835615	NA	0.63	7.0	0.53	1.45e-10	Eosinophil percentage of granulocytes;
TGCT	cis	rs6570726	0.905	rs430248	chr6:145874104	A/G	cg05347473	chr6:146136440	FBXO30	0.49	4.54	0.38	1.29e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9650657	0.504	rs10093053	chr8:11037187	T/C	cg21775007	chr8:11205619	TDH	-0.5	-4.61	-0.38	9.88e-6	Neuroticism;
TGCT	cis	rs174479	0.647	rs174454	chr11:61650747	A/G	cg01500311	chr11:61656094	FADS3	-0.3	-5.31	-0.43	4.93e-7	Sphingolipid levels;
TGCT	cis	rs1403694	0.695	rs3774291	chr3:186433471	C/T	cg12454167	chr3:186435060	KNG1	0.51	8.67	0.61	1.95e-14	Blood protein levels;
TGCT	cis	rs587847	0.737	rs4923745	chr15:37665497	G/C	cg00216138	chr15:37171175	LOC145845	0.31	4.45	0.37	1.91e-5	Intraocular pressure;
TGCT	cis	rs11677370	0.603	rs10174064	chr2:3849806	C/T	cg17052675	chr2:3827356	NA	-0.42	-7.13	-0.54	7.31e-11	Type 2 diabetes;
TGCT	cis	rs7666738	0.830	rs13119995	chr4:99026790	T/C	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7312933	0.558	rs4768411	chr12:42855390	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.56	-5.5	-0.44	2.06e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs2742417	1.000	rs2673035	chr3:45753665	C/G	cg04837898	chr3:45731254	SACM1L	-0.55	-5.82	-0.46	4.69e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs904251	0.861	rs1757171	chr6:37487044	T/C	cg25019722	chr6:37503610	NA	-0.51	-6.87	-0.53	2.74e-10	Cognitive performance;
TGCT	cis	rs9926296	0.656	rs2376881	chr16:89827011	C/G	cg26513180	chr16:89883248	FANCA	0.71	6.99	0.53	1.53e-10	Vitiligo;
TGCT	cis	rs73001065	0.636	rs8182472	chr19:19539891	A/G	cg03709012	chr19:19516395	GATAD2A	0.92	5.0	0.41	1.88e-6	LDL cholesterol;
TGCT	cis	rs6901004	0.803	rs2757571	chr6:111511124	T/G	cg15721981	chr6:111408429	SLC16A10	-0.53	-4.64	-0.38	8.82e-6	Blood metabolite levels;
TGCT	cis	rs2737273	0.884	rs7873822	chr9:35726821	G/T	cg12717594	chr9:36037454	RECK	-0.54	-4.52	-0.38	1.43e-5	Platelet distribution width;
TGCT	trans	rs9388451	0.903	rs9388446	chr6:126064920	T/A	cg05039488	chr6:79577232	IRAK1BP1	-0.75	-8.32	-0.6	1.33e-13	Brugada syndrome;
TGCT	cis	rs67311347	0.955	rs4973999	chr3:40460383	G/A	cg17264618	chr3:40429014	ENTPD3	0.32	4.76	0.39	5.36e-6	Renal cell carcinoma;
TGCT	cis	rs1018836	0.923	rs4734269	chr8:91635474	G/C	cg16814680	chr8:91681699	NA	-0.86	-8.92	-0.63	5.07e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs854765	0.547	rs9897761	chr17:17912011	A/T	cg09796270	chr17:17721594	SREBF1	0.25	5.03	0.41	1.65e-6	Total body bone mineral density;
TGCT	cis	rs17068510	0.688	rs77547210	chr8:3865814	A/T	cg25338036	chr8:3047536	CSMD1	-0.44	-4.59	-0.38	1.05e-5	Cerebrospinal fluid clusterin levels;
TGCT	cis	rs17376456	0.504	rs7702649	chr5:93065149	C/A	cg21475434	chr5:93447410	FAM172A	0.61	4.95	0.41	2.35e-6	Diabetic retinopathy;
TGCT	cis	rs1538970	0.962	rs3219463	chr1:45806432	C/T	cg05343316	chr1:45956843	TESK2	0.63	4.92	0.4	2.64e-6	Platelet count;
TGCT	cis	rs4975709	0.544	rs4975748	chr5:1866025	G/A	cg07747251	chr5:1868357	NA	0.41	6.07	0.48	1.47e-8	Cardiovascular disease risk factors;
TGCT	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg03188948	chr7:1209495	NA	0.44	5.79	0.46	5.51e-8	Longevity;Endometriosis;
TGCT	cis	rs2120019	0.938	rs59094290	chr15:75308561	G/T	cg17294928	chr15:75287854	SCAMP5	-0.83	-6.36	-0.5	3.45e-9	Blood trace element (Zn levels);
TGCT	cis	rs7819412	0.522	rs10101329	chr8:10990672	C/T	cg21775007	chr8:11205619	TDH	-0.6	-5.26	-0.43	5.99e-7	Triglycerides;
TGCT	cis	rs9814567	1.000	rs11928499	chr3:134232350	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.96	9.11	0.63	1.79e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs7582180	0.764	rs10180423	chr2:100919012	C/G	cg08017756	chr2:100939284	LONRF2	-0.32	-5.31	-0.43	4.89e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs62321564	chr4:98976496	C/G	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10876993	0.928	rs10877001	chr12:58083077	T/C	cg15848620	chr12:58087721	OS9	0.72	5.94	0.47	2.73e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg08645402	chr16:4508243	NA	0.2	4.97	0.41	2.21e-6	Schizophrenia;
TGCT	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg18876405	chr7:65276391	NA	-0.36	-5.71	-0.46	7.96e-8	Aortic root size;
TGCT	cis	rs7267979	1.000	rs6083809	chr20:25329309	A/G	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2811893	0.967	rs232869	chr1:59119135	C/A	cg26196860	chr1:59745563	NA	0.24	4.44	0.37	1.96e-5	Diabetic retinopathy;
TGCT	cis	rs2188554	0.958	rs10487367	chr7:117081480	G/T	cg08576598	chr7:116962626	WNT2	-0.4	-4.92	-0.4	2.65e-6	Esophageal adenocarcinoma;
TGCT	trans	rs62103177	0.733	rs62096747	chr18:77619568	A/G	cg05926928	chr17:57297772	GDPD1	1.22	11.16	0.71	1.85e-20	Opioid sensitivity;
TGCT	cis	rs55882075	0.808	rs6867806	chr5:179179585	C/G	cg14593053	chr5:179126677	CANX	0.48	5.25	0.43	6.37e-7	Monocyte percentage of white cells;
TGCT	cis	rs7617773	0.780	rs6793239	chr3:48351618	G/T	cg11946769	chr3:48343235	NME6	0.82	7.09	0.54	9.1e-11	Coronary artery disease;
TGCT	cis	rs1894292	0.527	rs2071097	chr4:74369298	G/A	cg05868023	chr4:75230803	EREG	-0.52	-4.64	-0.38	8.72e-6	Prostate cancer;
TGCT	cis	rs2574985	0.530	rs2144862	chr10:52260398	A/G	cg12753529	chr10:51525504	NA	-0.23	-4.59	-0.38	1.06e-5	Subjective well-being;
TGCT	cis	rs473651	0.935	rs559579	chr2:239339501	G/C	cg08773314	chr2:239334832	ASB1	0.45	6.39	0.5	3.05e-9	Multiple system atrophy;
TGCT	cis	rs2688608	0.592	rs7076585	chr10:75503692	T/C	cg04320760	chr10:75533139	FUT11	-0.4	-6.06	-0.48	1.49e-8	Inflammatory bowel disease;
TGCT	cis	rs4808199	0.895	rs4808194	chr19:19435680	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.69	5.33	0.43	4.49e-7	Nonalcoholic fatty liver disease;
TGCT	cis	rs11673344	0.523	rs2562594	chr19:37514685	G/A	cg08039142	chr19:36980659	ZNF566	0.5	4.72	0.39	6.26e-6	Obesity-related traits;
TGCT	cis	rs9467773	0.526	rs3734536	chr6:26365346	C/G	cg05738196	chr6:26577821	NA	-0.61	-6.45	-0.5	2.25e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs1568657	1.000	rs1568657	chr15:83726179	A/G	cg12240358	chr15:83619523	HOMER2	-0.27	-4.56	-0.38	1.19e-5	Kawasaki disease;
TGCT	cis	rs3820928	1.000	rs7592387	chr2:227777095	A/G	cg11843606	chr2:227700838	RHBDD1	-0.53	-4.73	-0.39	5.89e-6	Pulmonary function;
TGCT	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg03732007	chr1:2071316	PRKCZ	0.28	6.63	0.51	9.05e-10	Height;
TGCT	cis	rs3091242	0.933	rs34933589	chr1:25788198	T/C	cg09222892	chr1:25734099	RHCE	0.42	6.83	0.52	3.33e-10	Erythrocyte sedimentation rate;
TGCT	cis	rs763121	0.853	rs2413547	chr22:39107338	A/G	cg06022373	chr22:39101656	GTPBP1	0.74	7.07	0.54	9.75e-11	Menopause (age at onset);
TGCT	cis	rs42648	0.935	rs42627	chr7:89961876	C/T	cg25739043	chr7:89950458	NA	-0.71	-7.0	-0.53	1.46e-10	Homocysteine levels;
TGCT	cis	rs9916302	0.851	rs7225096	chr17:37664443	T/C	cg07936489	chr17:37558343	FBXL20	-0.62	-4.91	-0.4	2.85e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs3617	0.539	rs11130331	chr3:52956918	G/A	cg10802521	chr3:52805072	NEK4	0.57	6.56	0.51	1.34e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg25767906	chr1:53392781	SCP2	0.49	5.52	0.44	1.87e-7	Monocyte count;
TGCT	cis	rs1801251	0.963	rs35395584	chr2:233573698	G/C	cg25237894	chr2:233734115	C2orf82	0.32	5.78	0.46	5.59e-8	Coronary artery disease;
TGCT	cis	rs727563	0.635	rs2899348	chr22:42164516	C/G	cg17554472	chr22:41940697	POLR3H	0.46	4.8	0.4	4.46e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs11122272	0.735	rs2808601	chr1:231536571	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-6.18	-0.49	8.48e-9	Hemoglobin concentration;
TGCT	cis	rs16910800	0.731	rs59333536	chr11:23191649	G/A	cg20040320	chr11:23191996	NA	-0.51	-4.47	-0.37	1.71e-5	Cancer;
TGCT	cis	rs250677	1.000	rs36069	chr5:148417253	G/C	cg23229984	chr5:148520753	ABLIM3	0.2	4.88	0.4	3.13e-6	Breast cancer;
TGCT	cis	rs2760061	0.598	rs632832	chr1:228121838	G/T	cg02753203	chr1:228287806	NA	-0.34	-6.63	-0.51	9.15e-10	Diastolic blood pressure;
TGCT	cis	rs896854	0.684	rs10098778	chr8:95992020	C/T	cg13393036	chr8:95962371	TP53INP1	-0.58	-7.98	-0.58	8.59e-13	Type 2 diabetes;
TGCT	cis	rs2153535	0.580	rs4365970	chr6:8453813	C/T	cg23788917	chr6:8435910	SLC35B3	-0.57	-5.17	-0.42	9.27e-7	Motion sickness;
TGCT	cis	rs2455799	0.613	rs7642876	chr3:15883094	A/G	cg16303742	chr3:15540471	COLQ	-0.25	-4.8	-0.4	4.53e-6	Mean platelet volume;
TGCT	cis	rs11718455	0.767	rs4682924	chr3:43992760	G/A	cg08738300	chr3:44038990	NA	0.75	5.71	0.46	7.9e-8	Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs2903150	chr4:99027184	T/C	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6690583	0.623	rs1371141	chr1:85455372	C/A	cg20280350	chr1:85513789	MCOLN3	-0.74	-5.11	-0.42	1.2e-6	Serum sulfate level;
TGCT	cis	rs4888262	0.508	rs4462623	chr16:74692426	C/T	cg01733217	chr16:74700730	RFWD3	0.73	7.27	0.55	3.62e-11	Testicular germ cell tumor;
TGCT	cis	rs4780355	0.918	rs243318	chr16:11358018	G/A	cg00044050	chr16:11439710	C16orf75	0.54	4.77	0.39	5.01e-6	Crohn's disease and psoriasis;
TGCT	cis	rs1538970	0.962	rs9429160	chr1:45827968	G/T	cg05343316	chr1:45956843	TESK2	0.64	5.06	0.41	1.47e-6	Platelet count;
TGCT	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2153535	0.580	rs4960421	chr6:8459292	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs13191362	1.000	rs73008453	chr6:163013384	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs62244186	0.659	rs12108134	chr3:44543030	A/G	cg02073558	chr3:44770973	ZNF501	-0.62	-5.88	-0.47	3.6e-8	Depressive symptoms;
TGCT	cis	rs12220238	0.722	rs6480742	chr10:76398466	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.63	4.89	0.4	3.02e-6	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs13242816	1.000	rs73206052	chr7:116117056	G/T	cg02799643	chr7:116139180	CAV2	-0.46	-4.65	-0.39	8.23e-6	P wave duration;
TGCT	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg21724239	chr8:58056113	NA	0.33	4.54	0.38	1.31e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs910316	1.000	rs28626045	chr14:75589195	G/C	cg11812906	chr14:75593930	NEK9	0.74	7.43	0.55	1.56e-11	Height;
TGCT	cis	rs9372498	0.536	rs62422220	chr6:118923731	G/A	cg21191810	chr6:118973309	C6orf204	-0.39	-5.13	-0.42	1.07e-6	Diastolic blood pressure;
TGCT	cis	rs35146811	0.735	rs1727138	chr7:99815247	A/G	cg00553149	chr7:99775558	STAG3;GPC2	-0.31	-4.61	-0.38	9.75e-6	Coronary artery disease;
TGCT	cis	rs6964587	0.967	rs7783414	chr7:91785957	C/T	cg22709100	chr7:91322751	NA	0.28	4.5	0.37	1.54e-5	Breast cancer;
TGCT	trans	rs7698623	0.717	rs1982624	chr4:88790847	A/G	cg01186725	chr1:53905612	FLJ40434	-0.48	-6.63	-0.51	9.21e-10	Cardiovascular disease risk factors;
TGCT	cis	rs1048238	0.506	rs848212	chr1:16263452	A/G	cg21385522	chr1:16154831	NA	-0.61	-6.78	-0.52	4.39e-10	Systolic blood pressure;
TGCT	cis	rs7208859	0.573	rs73267872	chr17:29067207	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	4.87	0.4	3.36e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg03060546	chr3:49711283	APEH	0.7	7.25	0.55	4.01e-11	Resting heart rate;
TGCT	cis	rs3087591	0.960	rs9898664	chr17:29567152	T/C	cg24425628	chr17:29625626	OMG;NF1	-0.48	-7.43	-0.56	1.53e-11	Hip circumference;
TGCT	cis	rs12478296	0.786	rs6721704	chr2:242994923	A/G	cg06360820	chr2:242988706	NA	-0.63	-5.43	-0.44	2.86e-7	Obesity-related traits;
TGCT	cis	rs17001868	0.568	rs9611329	chr22:40792038	G/T	cg07138101	chr22:40742427	ADSL	0.73	5.6	0.45	1.34e-7	Mammographic density (dense area);
TGCT	cis	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg20637647	chr7:64974828	NA	0.94	5.17	0.42	9.06e-7	Diabetic kidney disease;
TGCT	cis	rs6665290	0.904	rs10495273	chr1:227183359	T/G	cg10327440	chr1:227177885	CDC42BPA	-0.99	-20.27	-0.88	3.54e-41	Myeloid white cell count;
TGCT	cis	rs2070433	0.752	rs60290737	chr21:47837630	C/A	cg04277056	chr21:48021941	S100B	0.31	4.48	0.37	1.67e-5	Lymphocyte counts;
TGCT	cis	rs3754214	0.823	rs496203	chr1:150270025	A/G	cg09579323	chr1:150459698	TARS2	-0.5	-4.52	-0.38	1.43e-5	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs739496	0.947	rs6490162	chr12:111941120	T/C	cg10833066	chr12:111807467	FAM109A	0.37	5.38	0.44	3.53e-7	Platelet count;
TGCT	cis	rs3008870	1.000	rs4620509	chr1:67449941	A/G	cg11518657	chr1:67396239	MIER1	-0.54	-4.61	-0.38	9.72e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg04944784	chr2:26401820	FAM59B	-0.68	-6.13	-0.48	1.1e-8	Gut microbiome composition (summer);
TGCT	cis	rs644799	1.000	rs544119	chr11:95538624	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	10.57	0.69	5.17e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs2346177	0.519	rs13003074	chr2:46671420	A/T	cg26688816	chr2:46740690	ATP6V1E2	0.44	4.77	0.39	5.08e-6	HDL cholesterol;
TGCT	cis	rs7666738	0.830	rs10007872	chr4:99001904	T/C	cg17366294	chr4:99064904	C4orf37	0.68	6.96	0.53	1.75e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	5.3	0.43	5.06e-7	Height;
TGCT	cis	rs950169	0.881	rs4842852	chr15:84941961	A/G	cg12863693	chr15:85201151	NMB	0.45	4.96	0.41	2.28e-6	Schizophrenia;
TGCT	cis	rs2820315	0.838	rs2819347	chr1:201884288	C/G	cg12730843	chr1:201915899	LMOD1	-0.27	-4.9	-0.4	2.94e-6	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
TGCT	cis	rs2274273	0.623	rs1187881	chr14:55489197	G/A	cg01923255	chr14:55878535	KIAA0831	-0.58	-4.94	-0.41	2.51e-6	Protein biomarker;
TGCT	cis	rs981844	0.813	rs72731678	chr4:154671476	T/C	cg14289246	chr4:154710475	SFRP2	1.01	8.67	0.61	2.02e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs7147624	0.572	rs72714491	chr14:66024580	T/A	cg03016385	chr14:66212404	NA	0.61	7.04	0.53	1.16e-10	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	trans	rs853356	1.000	rs853385	chr6:14182741	G/A	cg14262035	chr17:42019790	PPY	0.51	6.72	0.52	5.86e-10	Height;
TGCT	cis	rs2463822	1.000	rs2246920	chr11:62104937	T/G	cg23876832	chr11:62092739	NA	0.67	4.91	0.4	2.82e-6	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs854765	0.547	rs2955378	chr17:17930253	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.78	8.1	0.59	4.3e-13	Total body bone mineral density;
TGCT	cis	rs13008689	0.875	rs12616139	chr2:8522651	C/T	cg26785157	chr2:7987059	NA	0.21	4.85	0.4	3.7e-6	Longevity;
TGCT	cis	rs2688608	0.592	rs10762560	chr10:75495405	T/G	cg19442545	chr10:75533431	FUT11	-0.37	-5.77	-0.46	5.89e-8	Inflammatory bowel disease;
TGCT	cis	rs7617773	0.780	rs9846818	chr3:48375685	C/T	cg11946769	chr3:48343235	NME6	0.74	6.81	0.52	3.67e-10	Coronary artery disease;
TGCT	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg03188948	chr7:1209495	NA	0.44	5.76	0.46	6.32e-8	Longevity;Endometriosis;
TGCT	cis	rs4919694	1.000	rs12257941	chr10:104833161	C/T	cg04362960	chr10:104952993	NT5C2	1.07	7.2	0.54	5.11e-11	Arsenic metabolism;
TGCT	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg03517284	chr6:25882590	NA	0.89	9.12	0.63	1.72e-15	Blood metabolite levels;
TGCT	cis	rs2013441	0.965	rs1544421	chr17:20114217	T/C	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.61	-0.38	9.96e-6	Obesity-related traits;
TGCT	trans	rs9951602	0.541	rs7243702	chr18:76645637	G/A	cg02800362	chr5:177631904	HNRNPAB	1.14	13.02	0.76	6.04e-25	Obesity-related traits;
TGCT	cis	rs922182	0.633	rs12592702	chr15:64271882	C/T	cg02919090	chr15:64263738	DAPK2	-0.3	-5.37	-0.43	3.82e-7	Blood protein levels;
TGCT	cis	rs4654899	0.865	rs72975078	chr1:21476196	A/G	cg01072550	chr1:21505969	NA	-0.47	-6.92	-0.53	2.16e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs57221529	0.713	rs56328416	chr5:591138	G/A	cg09021430	chr5:549028	NA	-0.38	-5.12	-0.42	1.14e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs986417	0.892	rs78026410	chr14:60801142	G/A	cg27398547	chr14:60952738	C14orf39	-1.55	-6.83	-0.52	3.44e-10	Gut microbiota (bacterial taxa);
TGCT	cis	rs6831352	0.918	rs13138294	chr4:100062675	T/G	cg12011299	chr4:100065546	ADH4	-0.41	-4.97	-0.41	2.21e-6	Alcohol dependence;
TGCT	cis	rs2075371	1.000	rs1862051	chr7:133981021	G/A	cg11752832	chr7:134001865	SLC35B4	0.69	6.32	0.49	4.19e-9	Mean platelet volume;
TGCT	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg24549020	chr5:56110836	MAP3K1	0.67	5.67	0.45	9.58e-8	Initial pursuit acceleration;
TGCT	cis	rs2730245	1.000	rs2527199	chr7:158737113	G/A	cg24397884	chr7:158709396	WDR60	-0.4	-5.3	-0.43	5.05e-7	Height;
TGCT	cis	rs4499344	0.657	rs7250123	chr19:33054463	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.72	-6.04	-0.48	1.67e-8	Mean platelet volume;
TGCT	cis	rs617219	0.726	rs7717669	chr5:78452983	A/C	cg05890484	chr5:78407552	BHMT	0.37	5.03	0.41	1.7e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs368755101	1	rs368755101	chr2:100762215	AG/A	cg22139774	chr2:100720529	AFF3	-0.36	-5.47	-0.44	2.36e-7	Plateletcrit;Red blood cell count;
TGCT	cis	rs1348850	0.914	rs6710575	chr2:178377311	C/T	cg22681709	chr2:178499509	PDE11A	-0.35	-4.55	-0.38	1.27e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs10791097	0.642	rs7107568	chr11:130779668	T/C	cg12179176	chr11:130786555	SNX19	0.85	10.3	0.68	2.3e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs3806933	0.522	rs13186912	chr5:110456704	A/T	cg04022379	chr5:110408740	TSLP	-0.59	-6.16	-0.48	9.28e-9	Eosinophilic esophagitis;
TGCT	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg18230493	chr5:56204884	C5orf35	-0.68	-5.93	-0.47	2.85e-8	Initial pursuit acceleration;
TGCT	cis	rs8050907	0.744	rs78538387	chr16:4523167	G/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.53	4.57	0.38	1.15e-5	Obesity-related traits;
TGCT	cis	rs8014204	0.544	rs2286913	chr14:75386576	G/A	cg06637938	chr14:75390232	RPS6KL1	0.93	9.89	0.66	2.35e-17	Caffeine consumption;
TGCT	cis	rs2797160	0.684	rs1832937	chr6:125985934	A/G	cg10911889	chr6:126070802	HEY2	-0.51	-4.62	-0.38	9.32e-6	Endometrial cancer;
TGCT	cis	rs9399135	0.967	rs9373122	chr6:135373534	G/A	cg24558204	chr6:135376177	HBS1L	0.46	4.55	0.38	1.24e-5	Red blood cell count;
TGCT	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg22105103	chr4:187893119	NA	0.32	4.54	0.38	1.31e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2295359	0.892	rs11209004	chr1:67613932	G/A	cg03340356	chr1:67600835	NA	0.39	4.65	0.39	8.22e-6	Psoriasis;
TGCT	cis	rs12045440	0.525	rs1472565	chr1:19755030	T/C	cg24875000	chr1:19041556	PAX7	0.25	5.6	0.45	1.29e-7	Thyroid volume;
TGCT	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg06634786	chr22:41940651	POLR3H	0.89	8.45	0.6	6.78e-14	Vitiligo;
TGCT	cis	rs9611565	0.694	rs9611591	chr22:41830212	G/A	cg03806693	chr22:41940476	POLR3H	1.03	11.3	0.71	8.46e-21	Vitiligo;
TGCT	cis	rs4972806	0.775	rs2857534	chr2:177035676	G/T	cg14324370	chr2:177042789	NA	0.71	6.56	0.51	1.33e-9	IgG glycosylation;
TGCT	cis	rs6866344	0.570	rs1071882	chr5:178136040	C/T	cg10224037	chr5:178157518	ZNF354A	0.97	9.36	0.64	4.38e-16	Neutrophil percentage of white cells;
TGCT	cis	rs7584330	0.554	rs13405619	chr2:238445661	C/T	cg08992911	chr2:238395768	MLPH	0.64	4.49	0.37	1.63e-5	Prostate cancer;
TGCT	cis	rs9303401	0.659	rs34382037	chr17:56643550	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs13256369	0.851	rs13256611	chr8:8564341	G/A	cg18904891	chr8:8559673	CLDN23	0.59	5.46	0.44	2.54e-7	Obesity-related traits;
TGCT	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg01448562	chr3:133502909	NA	-0.26	-5.06	-0.41	1.49e-6	Iron status biomarkers;
TGCT	cis	rs9486715	0.929	rs2025044	chr6:97067028	A/G	cg18709589	chr6:96969512	KIAA0776	-0.79	-7.18	-0.54	5.76e-11	Headache;
TGCT	cis	rs6988636	0.534	rs4489325	chr8:124105254	G/A	cg27053337	chr8:124217698	FAM83A	0.54	4.68	0.39	7.34e-6	Urinary uromodulin levels;
TGCT	cis	rs78545713	1.000	rs16891484	chr6:26242930	G/A	cg12260798	chr6:26240519	HIST1H4F	-0.51	-4.68	-0.39	7.29e-6	Iron status biomarkers (total iron binding capacity);
TGCT	cis	rs62283056	0.512	rs4568307	chr4:6284965	A/G	cg14416269	chr4:6271139	WFS1	0.41	5.13	0.42	1.1e-6	Cisplatin-induced ototoxicity;
TGCT	cis	rs7917772	0.582	rs10786695	chr10:104368756	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	5.36	0.43	3.84e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1153858	1.000	rs56806728	chr15:45637814	A/G	cg14582100	chr15:45693742	SPATA5L1	0.48	5.7	0.46	8.17e-8	Homoarginine levels;
TGCT	cis	rs4700695	0.925	rs6449799	chr5:65394476	A/G	cg21114390	chr5:65439923	SFRS12	-0.57	-4.49	-0.37	1.59e-5	Facial morphology (factor 19);
TGCT	cis	rs6940638	0.956	rs13207365	chr6:27030980	T/C	cg26531700	chr6:26746687	NA	-0.6	-4.63	-0.38	9.25e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs13082711	1.000	rs13082711	chr3:27537909	T/C	cg02860705	chr3:27208620	NA	0.33	4.56	0.38	1.19e-5	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs2729354	1.000	rs2649662	chr11:57352562	G/T	cg24343310	chr11:57249947	NA	-0.28	-4.71	-0.39	6.66e-6	Blood protein levels;
TGCT	cis	rs308403	0.509	rs1849431	chr4:123674762	G/A	cg10495464	chr4:123653540	BBS12;LOC729338	0.82	11.78	0.73	5.72e-22	Blood protein levels;
TGCT	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg22920501	chr2:26401640	FAM59B	0.81	6.36	0.5	3.52e-9	Gut microbiome composition (summer);
TGCT	cis	rs1322512	0.760	rs2695252	chr6:152926834	C/T	cg03415253	chr6:152958462	SYNE1	-0.55	-5.2	-0.42	8.12e-7	Tonometry;
TGCT	cis	rs36051895	0.623	rs6476957	chr9:5261324	A/G	cg02405213	chr9:5042618	JAK2	-0.7	-9.4	-0.65	3.55e-16	Pediatric autoimmune diseases;
TGCT	cis	rs9467773	0.595	rs2172007	chr6:26639777	A/C	cg02458000	chr6:26745757	NA	0.65	6.34	0.49	3.92e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs6964587	1.000	rs12531366	chr7:91683849	C/G	cg17063962	chr7:91808500	NA	0.89	9.93	0.67	1.84e-17	Breast cancer;
TGCT	cis	rs1865760	0.566	rs9366634	chr6:26072396	C/G	cg17042849	chr6:26104293	HIST1H4C	-0.63	-5.48	-0.44	2.31e-7	Height;
TGCT	cis	rs2710642	0.927	rs1468748	chr2:63204611	C/T	cg17519650	chr2:63277830	OTX1	0.68	6.27	0.49	5.41e-9	LDL cholesterol levels;LDL cholesterol;
TGCT	cis	rs950776	0.752	rs7182583	chr15:78899210	G/C	cg06917634	chr15:78832804	PSMA4	0.65	5.26	0.43	6.03e-7	Sudden cardiac arrest;
TGCT	cis	rs4819852	0.958	rs2240716	chr22:19969696	C/T	cg07821417	chr22:19972146	ARVCF	0.21	5.37	0.43	3.81e-7	Pulse pressure;
TGCT	cis	rs9503598	0.778	rs10155771	chr6:3465930	G/A	cg00476032	chr6:3446245	SLC22A23	0.17	4.87	0.4	3.35e-6	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
TGCT	cis	rs1784581	0.894	rs1790000	chr6:162388707	A/G	cg17173639	chr6:162384350	PARK2	0.49	9.49	0.65	2.15e-16	Itch intensity from mosquito bite;
TGCT	cis	rs6558530	0.666	rs4242539	chr8:1694236	A/G	cg09410841	chr8:1729607	CLN8	0.66	5.85	0.46	4.12e-8	Systolic blood pressure;
TGCT	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg13877915	chr19:58951672	ZNF132	0.89	11.16	0.71	1.92e-20	Uric acid clearance;
TGCT	cis	rs9527	0.590	rs10883830	chr10:104851285	G/A	cg15744005	chr10:104629667	AS3MT	-0.42	-4.84	-0.4	3.82e-6	Arsenic metabolism;
TGCT	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg03188948	chr7:1209495	NA	0.45	5.86	0.47	3.93e-8	Longevity;Endometriosis;
TGCT	cis	rs59482735	1	rs59482735	chr9:123643426	T/TAA	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	4.77	0.39	5.05e-6	Prostate-specific antigen levels;
TGCT	trans	rs10953454	1.000	rs34508498	chr7:104480657	C/T	cg04208666	chr6:19734707	NA	-0.57	-6.89	-0.53	2.52e-10	Obesity;
TGCT	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.18	0.49	8.32e-9	Bipolar disorder;
TGCT	cis	rs5769765	1.000	rs5769760	chr22:50259696	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.4	-6.01	-0.47	1.96e-8	Schizophrenia;
TGCT	cis	rs7439150	0.954	rs72679197	chr4:155475159	G/A	cg22130008	chr4:155548532	NA	-0.43	-5.38	-0.44	3.5e-7	Fibrinogen levels;
TGCT	cis	rs854765	0.663	rs1052299	chr17:17750419	A/G	cg09796270	chr17:17721594	SREBF1	-0.3	-5.85	-0.46	4.18e-8	Total body bone mineral density;
TGCT	cis	rs6095298	0.595	rs6095320	chr20:47446595	A/G	cg12307787	chr20:48099359	KCNB1	0.44	4.67	0.39	7.75e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2688608	0.592	rs10762563	chr10:75524802	C/A	cg15838173	chr10:75533400	FUT11	-0.3	-4.94	-0.41	2.5e-6	Inflammatory bowel disease;
TGCT	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg23248424	chr5:179741104	GFPT2	-0.38	-7.07	-0.54	9.78e-11	Height;
TGCT	cis	rs10949834	0.540	rs810552	chr7:73489298	A/G	cg07137043	chr7:73588983	EIF4H	0.51	4.86	0.4	3.45e-6	Verbal memory performance (residualized delayed recall change);
TGCT	cis	rs7523050	0.643	rs35520362	chr1:109419841	C/T	cg08274380	chr1:109419600	GPSM2	1.35	6.86	0.52	2.89e-10	Fat distribution (HIV);
TGCT	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	16.07	0.82	4.16e-32	Prudent dietary pattern;
TGCT	cis	rs9467773	0.587	rs10946812	chr6:26344975	G/C	cg05738196	chr6:26577821	NA	-0.62	-6.55	-0.51	1.38e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg16228356	chr17:43848958	NA	-0.26	-4.62	-0.38	9.47e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2535633	0.631	rs6799185	chr3:53101580	C/T	cg11645453	chr3:52864694	ITIH4	0.28	5.07	0.41	1.41e-6	Body mass index;
TGCT	cis	rs13126513	0.519	rs7659550	chr4:100554402	G/T	cg05468953	chr4:100565104	NA	0.42	5.68	0.45	9.27e-8	Metabolite levels (MHPG);
TGCT	cis	rs1843834	0.574	rs6436499	chr2:225456551	A/T	cg12698349	chr2:225449008	CUL3	0.76	6.39	0.5	3.11e-9	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs1153858	1.000	rs12437887	chr15:45669094	G/A	cg26924012	chr15:45694286	SPATA5L1	1.09	15.08	0.8	7.99e-30	Homoarginine levels;
TGCT	cis	rs11785400	0.793	rs4430071	chr8:143737680	T/C	cg24634471	chr8:143751801	JRK	0.55	5.51	0.44	1.99e-7	Schizophrenia;
TGCT	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg26513180	chr16:89883248	FANCA	1.07	14.96	0.8	1.48e-29	Vitiligo;
TGCT	trans	rs2624839	0.630	rs2624841	chr3:50198415	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.81	7.51	0.56	1.02e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs921968	0.643	rs4674320	chr2:219510768	A/G	cg02176678	chr2:219576539	TTLL4	0.38	5.47	0.44	2.34e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs727563	0.594	rs132807	chr22:42071584	T/C	cg03806693	chr22:41940476	POLR3H	1.08	11.79	0.73	5.53e-22	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs11105298	0.891	rs11105287	chr12:89829470	C/T	cg00757033	chr12:89920650	WDR51B	0.31	4.92	0.4	2.72e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs1451375	0.794	rs11238134	chr7:50542927	A/C	cg18232548	chr7:50535776	DDC	-0.34	-5.16	-0.42	9.39e-7	Malaria;
TGCT	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg18538332	chr22:24372958	LOC391322	-1.02	-13.19	-0.76	2.24e-25	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9926296	0.546	rs9935541	chr16:89905925	G/C	cg08627397	chr16:89984028	MC1R	-0.34	-5.48	-0.44	2.25e-7	Vitiligo;
TGCT	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg17328964	chr8:145687451	CYHR1	0.51	8.05	0.59	5.62e-13	Age at first birth;
TGCT	cis	rs763121	0.853	rs6001214	chr22:39149155	C/T	cg06022373	chr22:39101656	GTPBP1	0.78	7.26	0.55	3.69e-11	Menopause (age at onset);
TGCT	cis	rs1215050	0.776	rs1627946	chr4:98844416	G/A	cg17366294	chr4:99064904	C4orf37	-0.57	-6.13	-0.48	1.08e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	trans	rs9985766	1.000	rs28397206	chr4:151022898	A/G	cg02993991	chr19:4064177	ZBTB7A	0.57	6.7	0.52	6.59e-10	Coronary artery disease;Myocardial infarction;
TGCT	cis	rs7945705	0.875	rs2568065	chr11:8889648	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.44	-5.09	-0.42	1.28e-6	Hemoglobin concentration;
TGCT	cis	rs9486719	1.000	rs4839837	chr6:96908706	G/A	cg18709589	chr6:96969512	KIAA0776	0.66	5.35	0.43	4.12e-7	Migraine;Coronary artery disease;
TGCT	cis	rs8072100	0.811	rs1912483	chr17:45443494	A/G	cg08085267	chr17:45401833	C17orf57	-0.49	-5.59	-0.45	1.4e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs2153535	0.601	rs1928183	chr6:8530018	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.55e-8	Motion sickness;
TGCT	cis	rs739401	0.611	rs2239900	chr11:3030992	C/T	cg25174290	chr11:3078921	CARS	0.47	4.73	0.39	6.07e-6	Longevity;
TGCT	cis	rs2439831	0.850	rs9944216	chr15:44160773	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.94	-6.36	-0.5	3.57e-9	Lung cancer in ever smokers;
TGCT	cis	rs7772486	0.686	rs702314	chr6:146003510	G/A	cg23711669	chr6:146136114	FBXO30	-0.85	-9.2	-0.64	1.08e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs5760092	0.842	rs5751763	chr22:24247793	T/C	cg04234412	chr22:24373322	LOC391322	-0.92	-8.21	-0.59	2.49e-13	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs453301	0.658	rs6986044	chr8:8874786	G/C	cg06636001	chr8:8085503	FLJ10661	-0.66	-5.44	-0.44	2.69e-7	Joint mobility (Beighton score);
TGCT	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg18402987	chr7:1209562	NA	0.7	5.67	0.45	9.66e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs41271951	0.512	rs12070256	chr1:151070090	C/T	cg00666978	chr1:150947442	LASS2	0.89	4.64	0.38	8.54e-6	Blood protein levels;
TGCT	cis	rs921968	0.541	rs664514	chr2:219329819	A/G	cg02176678	chr2:219576539	TTLL4	0.47	6.72	0.52	5.75e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs739496	0.793	rs655107	chr12:111996557	T/C	cg10833066	chr12:111807467	FAM109A	0.37	5.2	0.42	8.01e-7	Platelet count;
TGCT	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	5.93	0.47	2.8e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7523050	0.643	rs12752417	chr1:109400639	A/C	cg08274380	chr1:109419600	GPSM2	-1.27	-6.37	-0.5	3.32e-9	Fat distribution (HIV);
TGCT	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg21862992	chr11:68658383	NA	0.46	6.26	0.49	5.67e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs56104184	0.775	rs73061694	chr19:49399978	T/C	cg21252483	chr19:49399788	TULP2	-0.42	-5.89	-0.47	3.47e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs6912958	0.631	rs9450704	chr6:88182704	G/C	cg06598631	chr6:88300029	RARS2;ORC3L	-0.53	-4.85	-0.4	3.69e-6	Monocyte percentage of white cells;
TGCT	cis	rs1801251	1.000	rs4517962	chr2:233578337	T/C	cg25237894	chr2:233734115	C2orf82	0.31	5.51	0.44	1.96e-7	Coronary artery disease;
TGCT	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg00343986	chr7:65444356	GUSB	0.26	6.11	0.48	1.18e-8	Calcium levels;
TGCT	cis	rs17331151	0.573	rs77223362	chr3:52865125	G/A	cg11137980	chr3:52469226	SEMA3G	0.29	5.14	0.42	1.04e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs12368653	0.641	rs12826708	chr12:58058373	G/A	cg12615879	chr12:58013172	SLC26A10	0.47	5.46	0.44	2.49e-7	Multiple sclerosis;
TGCT	cis	rs3824867	0.879	rs4752837	chr11:47465955	G/A	cg20307385	chr11:47447363	PSMC3	0.7	6.03	0.48	1.71e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs4851266	1.000	rs12991254	chr2:100817933	T/C	cg22139774	chr2:100720529	AFF3	-0.38	-5.6	-0.45	1.33e-7	Educational attainment;
TGCT	cis	rs8014204	1.000	rs4553560	chr14:75334199	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.77	-7.49	-0.56	1.14e-11	Caffeine consumption;
TGCT	cis	rs9682041	0.597	rs62295834	chr3:170075701	G/A	cg07589077	chr3:170072950	NA	0.28	4.85	0.4	3.55e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs4295623	0.559	rs4841600	chr8:11688148	T/C	cg21775007	chr8:11205619	TDH	0.57	5.01	0.41	1.84e-6	Morning vs. evening chronotype;
TGCT	cis	rs910316	1.000	rs175492	chr14:75545220	A/C	cg23033748	chr14:75592666	NEK9	0.28	4.9	0.4	2.96e-6	Height;
TGCT	cis	rs9916302	0.706	rs8075737	chr17:37727316	C/T	cg15445000	chr17:37608096	MED1	-0.35	-4.84	-0.4	3.8e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg17554472	chr22:41940697	POLR3H	0.48	4.95	0.41	2.39e-6	Vitiligo;
TGCT	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg04267008	chr7:1944627	MAD1L1	-0.41	-5.4	-0.44	3.34e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs889312	0.500	rs702691	chr5:56114526	T/G	cg24531977	chr5:56204891	C5orf35	-0.52	-5.39	-0.44	3.44e-7	Breast cancer;Breast cancer (early onset);
TGCT	cis	rs77861329	1.000	rs17051977	chr3:52182944	A/G	cg08692210	chr3:52188851	WDR51A	0.83	4.64	0.38	8.71e-6	Macrophage inflammatory protein 1b levels;
TGCT	cis	rs72615157	0.716	rs75779608	chr7:99768957	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.68	5.24	0.43	6.71e-7	Lung function (FEV1/FVC);
TGCT	cis	rs9486719	0.895	rs3798294	chr6:97049587	G/A	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.32	-0.6	1.32e-13	Migraine;Coronary artery disease;
TGCT	cis	rs6835098	0.887	rs12644699	chr4:174142874	A/G	cg08422745	chr4:174089978	GALNT7	0.88	10.07	0.67	8.46e-18	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs6088590	1.000	rs12626122	chr20:33425800	A/G	cg08999081	chr20:33150536	PIGU	0.26	4.45	0.37	1.87e-5	Coronary artery disease;
TGCT	cis	rs4285028	0.948	rs2877560	chr3:121699238	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.77	-6.5	-0.5	1.78e-9	Multiple sclerosis;
TGCT	cis	rs10170846	0.800	rs10194743	chr2:223518151	A/G	cg25565276	chr2:223520875	FARSB	0.57	4.72	0.39	6.18e-6	Schizophrenia (inflammation and infection response interaction);
TGCT	cis	rs9325144	0.555	rs2387843	chr12:38711203	T/C	cg26384229	chr12:38710491	ALG10B	0.68	6.28	0.49	5.18e-9	Morning vs. evening chronotype;
TGCT	cis	rs7523273	1.000	rs1142469	chr1:207965427	G/A	cg22525895	chr1:207977042	MIR29B2	-0.48	-8.57	-0.61	3.53e-14	Schizophrenia;
TGCT	cis	rs2230307	0.536	rs2784173	chr1:100639752	A/G	cg24955406	chr1:100503596	HIAT1	-0.76	-5.21	-0.42	7.5e-7	Carotid intima media thickness;
TGCT	cis	rs3820928	1.000	rs11686072	chr2:227777493	A/T	cg11843606	chr2:227700838	RHBDD1	-0.53	-4.73	-0.39	5.89e-6	Pulmonary function;
TGCT	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.33	0.43	4.5e-7	Prudent dietary pattern;
TGCT	trans	rs7613875	0.580	rs3774745	chr3:50204745	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.79	-8.22	-0.59	2.36e-13	Body mass index;
TGCT	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg05552183	chr6:42928497	GNMT	0.52	4.55	0.38	1.25e-5	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs4822044	0.560	rs7284839	chr22:42010902	C/T	cg03806693	chr22:41940476	POLR3H	1.07	11.4	0.72	4.95e-21	Cannabis dependence symptom count;
TGCT	cis	rs8017423	1.000	rs4904644	chr14:90665689	A/G	cg04374321	chr14:90722782	PSMC1	-0.77	-7.89	-0.58	1.34e-12	Mortality in heart failure;
TGCT	cis	rs9467773	0.572	rs13213953	chr6:26594534	T/A	cg02458000	chr6:26745757	NA	0.71	7.06	0.54	1.07e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs57221529	0.709	rs72703090	chr5:598314	C/T	cg20362242	chr5:692897	TPPP	0.53	4.56	0.38	1.22e-5	Lung disease severity in cystic fibrosis;
TGCT	cis	rs11690935	0.885	rs6750058	chr2:172786909	G/T	cg13550731	chr2:172543902	DYNC1I2	-0.92	-8.29	-0.6	1.5700000000000001e-13	Schizophrenia;
TGCT	cis	rs6459788	0.720	rs11974772	chr7:157250645	G/A	cg03453431	chr7:157225567	NA	-0.4	-5.97	-0.47	2.35e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs9308731	0.644	rs1837366	chr2:111874629	C/T	cg04202892	chr2:111875749	ACOXL	0.54	6.22	0.49	6.96e-9	Chronic lymphocytic leukemia;
TGCT	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg05215272	chr17:6899095	ALOX12	-0.5	-6.13	-0.48	1.07e-8	Tonsillectomy;
TGCT	cis	rs9393777	0.764	rs35565446	chr6:27145341	C/T	cg16898833	chr6:26189333	HIST1H4D	1.3	5.86	0.47	3.92e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg23708337	chr7:1209742	NA	0.6	5.57	0.45	1.53e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1008375	0.932	rs11934968	chr4:17667766	A/G	cg16339924	chr4:17578868	LAP3	0.56	4.53	0.38	1.37e-5	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.29	-4.49	-0.37	1.64e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9902453	0.817	rs880749	chr17:28059970	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-7.27	-0.55	3.59e-11	Coffee consumption (cups per day);
TGCT	cis	rs4925386	1.000	rs2151512	chr20:60913495	T/C	cg06026331	chr20:60912101	LAMA5	-0.29	-5.37	-0.43	3.71e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg16414030	chr3:133502952	NA	-0.61	-9.68	-0.66	7.39e-17	Iron status biomarkers;
TGCT	cis	rs8013055	0.846	rs10151805	chr14:105974781	T/C	cg25008857	chr14:105974488	NA	0.27	4.65	0.39	8.35e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs13082711	0.522	rs578501	chr3:27344963	A/G	cg02860705	chr3:27208620	NA	0.34	5.58	0.45	1.43e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	trans	rs1814175	0.817	rs28525029	chr11:50045815	A/G	cg03929089	chr4:120376271	NA	-0.72	-8.55	-0.61	3.8e-14	Height;
TGCT	cis	rs56235845	0.694	rs6876677	chr5:176755342	T/C	cg17509989	chr5:176798049	RGS14	0.54	7.47	0.56	1.25e-11	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs7829975	0.755	rs3789849	chr8:8687054	G/C	cg15556689	chr8:8085844	FLJ10661	0.67	5.97	0.47	2.33e-8	Mood instability;
TGCT	cis	rs9911578	0.835	rs9788975	chr17:56460800	G/A	cg05425664	chr17:57184151	TRIM37	0.57	5.19	0.42	8.24e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs910316	0.737	rs175043	chr14:75471803	G/A	cg08847533	chr14:75593920	NEK9	-0.84	-8.92	-0.63	5.19e-15	Height;
TGCT	cis	rs11190604	1.000	rs7088827	chr10:102303865	C/G	cg16342193	chr10:102329863	NA	-0.4	-4.89	-0.4	3.08e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg05552183	chr6:42928497	GNMT	0.52	4.57	0.38	1.17e-5	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	6.75	0.52	5.02e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg17971929	chr21:40555470	PSMG1	0.97	9.73	0.66	5.86e-17	Cognitive function;
TGCT	cis	rs9916302	0.808	rs12943928	chr17:37611330	G/A	cg15445000	chr17:37608096	MED1	0.31	4.59	0.38	1.06e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs7552167	0.925	rs4489498	chr1:24512055	A/G	cg01960748	chr1:24522592	NA	0.44	5.01	0.41	1.83e-6	Psoriasis vulgaris;
TGCT	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg22920501	chr2:26401640	FAM59B	-0.8	-6.27	-0.49	5.4e-9	Gut microbiome composition (summer);
TGCT	cis	rs4722166	0.597	rs2069845	chr7:22770149	G/A	cg13104385	chr7:22767384	IL6	0.23	4.91	0.4	2.79e-6	Lung cancer;
TGCT	cis	rs4629710	0.592	rs11759793	chr6:131546384	G/A	cg12606694	chr6:131520996	AKAP7	0.39	4.63	0.38	9.14e-6	Multiple myeloma (IgH translocation);
TGCT	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg04546413	chr19:29218101	NA	0.86	6.96	0.53	1.7e-10	Methadone dose in opioid dependence;
TGCT	cis	rs9325144	0.555	rs4882358	chr12:38726640	A/G	cg26384229	chr12:38710491	ALG10B	0.65	6.06	0.48	1.55e-8	Morning vs. evening chronotype;
TGCT	cis	rs9611565	0.649	rs139553	chr22:42187199	A/G	cg06481639	chr22:41940642	POLR3H	0.57	4.82	0.4	4.18e-6	Vitiligo;
TGCT	cis	rs7119	0.931	rs11630540	chr15:77833625	G/A	cg27398640	chr15:77910606	LINGO1	-0.25	-4.73	-0.39	5.96e-6	Type 2 diabetes;
TGCT	cis	rs1059312	0.966	rs12368452	chr12:129277164	C/A	cg09035930	chr12:129282057	SLC15A4	0.6	11.86	0.73	3.65e-22	Systemic lupus erythematosus;
TGCT	cis	rs7666738	0.830	rs28522896	chr4:99008243	C/T	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3020736	0.500	rs6002604	chr22:42493081	A/T	cg15557168	chr22:42548783	NA	0.22	5.58	0.45	1.47e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6722750	0.933	rs12999721	chr2:64407710	C/T	cg22352474	chr2:64371530	PELI1	0.53	4.8	0.4	4.49e-6	Neuroticism;
TGCT	cis	rs6088590	1.000	rs28542147	chr20:33376323	G/A	cg24642439	chr20:33292090	TP53INP2	0.69	6.13	0.48	1.09e-8	Coronary artery disease;
TGCT	cis	rs12681287	0.640	rs13269259	chr8:87470453	G/A	cg27223183	chr8:87520930	FAM82B	-0.89	-6.43	-0.5	2.54e-9	Caudate activity during reward;
TGCT	cis	rs10782582	0.609	rs11588643	chr1:76255613	A/G	cg10523679	chr1:76189770	ACADM	-0.58	-5.38	-0.43	3.6e-7	Daytime sleep phenotypes;
TGCT	cis	rs9611565	0.879	rs5758307	chr22:41750219	A/G	cg03806693	chr22:41940476	POLR3H	-1.02	-11.0	-0.7	4.75e-20	Vitiligo;
TGCT	cis	rs3806843	0.576	rs246062	chr5:140324580	T/A	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2456568	0.564	rs6483270	chr11:93624380	C/T	cg17595323	chr11:93583763	C11orf90	-0.49	-6.48	-0.5	1.95e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg27211696	chr2:191398769	TMEM194B	0.28	5.16	0.42	9.36e-7	Pulse pressure;
TGCT	cis	rs1801251	1.000	rs3817311	chr2:233612557	C/T	cg08000102	chr2:233561755	GIGYF2	0.64	6.56	0.51	1.34e-9	Coronary artery disease;
TGCT	cis	rs12210905	1.000	rs72843644	chr6:27211601	A/C	cg08851530	chr6:28072375	NA	1.05	5.07	0.41	1.42e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs1008375	0.900	rs6851783	chr4:17578469	A/G	cg18681998	chr4:17616180	MED28	0.83	7.51	0.56	1.02e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1784581	0.706	rs9346895	chr6:162431168	T/C	cg17173639	chr6:162384350	PARK2	0.42	7.38	0.55	2.03e-11	Itch intensity from mosquito bite;
TGCT	cis	rs3902035	0.964	rs62423993	chr6:119010967	C/T	cg07617317	chr6:118971624	C6orf204	0.43	5.01	0.41	1.79e-6	QT interval;
TGCT	cis	rs7312933	0.531	rs2406674	chr12:42720150	T/C	cg19980929	chr12:42632907	YAF2	-0.41	-5.76	-0.46	6.3e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg01570182	chr17:44337453	NA	1.07	9.81	0.66	3.57e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.62	6.11	0.48	1.2e-8	Sum eosinophil basophil counts;Eosinophil counts;
TGCT	cis	rs7949030	0.688	rs2849031	chr11:62365665	G/A	cg22862634	chr11:62369728	EML3;MTA2	-0.68	-8.7	-0.62	1.69e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7772486	0.790	rs2249147	chr6:146184999	T/C	cg23711669	chr6:146136114	FBXO30	0.93	10.57	0.69	5.33e-19	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2153535	0.580	rs718502	chr6:8527400	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.49e-8	Motion sickness;
TGCT	cis	rs11931598	0.783	rs28385900	chr4:7050836	C/T	cg02503808	chr4:7069936	GRPEL1	0.58	5.35	0.43	4.14e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs17376456	0.825	rs17372057	chr5:93071916	C/A	cg25358565	chr5:93447407	FAM172A	0.91	8.26	0.6	1.88e-13	Diabetic retinopathy;
TGCT	trans	rs561341	1.000	rs537166	chr17:30326827	C/T	cg20587970	chr11:113659929	NA	-1.05	-13.02	-0.76	5.98e-25	Hip circumference adjusted for BMI;
TGCT	cis	rs968451	0.526	rs137594	chr22:39691221	G/A	cg17798944	chr22:39715225	SNORD43;RPL3	-0.54	-4.64	-0.38	8.7e-6	Primary biliary cholangitis;
TGCT	cis	rs6674176	0.932	rs12410334	chr1:44442521	A/C	cg13606994	chr1:44402422	ARTN	-0.47	-4.7	-0.39	6.93e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs1153858	1.000	rs1049503	chr15:45653707	T/C	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.62e-8	Homoarginine levels;
TGCT	cis	rs57221529	0.766	rs72703065	chr5:588123	C/A	cg09021430	chr5:549028	NA	-0.37	-4.98	-0.41	2.07e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs593982	0.843	rs565267	chr11:65473597	T/C	cg08755490	chr11:65554678	OVOL1	1.27	6.79	0.52	4.05e-10	Atopic dermatitis;
TGCT	cis	rs1008375	0.931	rs6449309	chr4:17573208	C/T	cg16339924	chr4:17578868	LAP3	0.84	7.48	0.56	1.16e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2723064	0.516	rs17849707	chr2:65298839	A/G	cg05010058	chr2:65284262	CEP68	0.47	4.48	0.37	1.67e-5	Atrial fibrillation;
TGCT	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	5.02	0.41	1.78e-6	Prudent dietary pattern;
TGCT	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg23302884	chr18:44338147	ST8SIA5	-0.4	-4.52	-0.38	1.45e-5	Personality dimensions;
TGCT	cis	rs3087591	0.919	rs2018624	chr17:29560777	T/G	cg24425628	chr17:29625626	OMG;NF1	-0.49	-7.65	-0.57	4.82e-12	Hip circumference;
TGCT	cis	rs1475911	0.708	rs56185023	chr21:43521538	T/C	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.27	-5.33	-0.43	4.5e-7	IgG glycosylation;
TGCT	cis	rs9611565	0.592	rs8779	chr22:42070276	T/C	cg06634786	chr22:41940651	POLR3H	0.9	8.74	0.62	1.34e-14	Vitiligo;
TGCT	cis	rs2832191	0.692	rs2254872	chr21:30414724	C/T	cg08807101	chr21:30365312	RNF160	0.64	6.01	0.47	1.96e-8	Dental caries;
TGCT	cis	rs3809566	1.000	rs4775610	chr15:63332057	C/T	cg08198488	chr15:63333792	TPM1	0.36	5.37	0.43	3.8e-7	Platelet count;
TGCT	cis	rs2933343	0.729	rs1680780	chr3:128612659	G/C	cg11901034	chr3:128598214	ACAD9	-0.68	-6.72	-0.52	6.01e-10	IgG glycosylation;
TGCT	cis	rs2688608	0.592	rs2306328	chr10:75579510	C/T	cg23231163	chr10:75533350	FUT11	-0.27	-4.64	-0.38	8.56e-6	Inflammatory bowel disease;
TGCT	cis	rs7666738	0.830	rs4699598	chr4:99019158	C/T	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.33e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs782590	0.935	rs782652	chr2:55862775	C/A	cg03859395	chr2:55845619	SMEK2	0.91	10.87	0.7	9.92e-20	Metabolic syndrome;
TGCT	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg12310025	chr6:25882481	NA	0.51	4.62	0.38	9.56e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg16624210	chr5:671434	TPPP	0.4	4.59	0.38	1.07e-5	Obesity-related traits;
TGCT	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg06212747	chr3:49208901	KLHDC8B	0.65	6.23	0.49	6.68e-9	Menarche (age at onset);
TGCT	cis	rs3540	0.554	rs4244879	chr15:91066915	C/T	cg22089800	chr15:90895588	ZNF774	-0.75	-7.66	-0.57	4.62e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs7582180	0.663	rs10199518	chr2:100946041	G/A	cg14675211	chr2:100938903	LONRF2	0.47	4.57	0.38	1.16e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	0.48	6.76	0.52	4.82e-10	Alzheimer's disease;
TGCT	cis	rs3774830	1.000	rs3774830	chr4:5440083	A/G	cg26943120	chr4:5472116	STK32B	-0.22	-4.87	-0.4	3.33e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	trans	rs2727020	0.595	rs7924311	chr11:49507573	G/A	cg03929089	chr4:120376271	NA	-0.76	-9.15	-0.63	1.43e-15	Coronary artery disease;
TGCT	cis	rs7772486	0.790	rs2247429	chr6:146217769	T/C	cg05347473	chr6:146136440	FBXO30	0.53	5.08	0.42	1.35e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2013441	1.000	rs4924808	chr17:20026548	C/T	cg18979559	chr17:20280153	CCDC144C	-0.42	-4.46	-0.37	1.83e-5	Obesity-related traits;
TGCT	trans	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.96	12.05	0.73	1.29e-22	Intelligence (multi-trait analysis);
TGCT	cis	rs10419226	0.625	rs12980154	chr19:18770119	C/T	cg14292368	chr19:18793705	CRTC1	-0.49	-5.42	-0.44	2.98e-7	Barrett's esophagus;Esophageal adenocarcinoma;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs7772486	0.623	rs9485021	chr6:146068797	A/G	cg23711669	chr6:146136114	FBXO30	-0.88	-9.63	-0.65	1.01e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs853679	0.527	rs9468333	chr6:28271198	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.46	-4.8	-0.4	4.46e-6	Depression;
TGCT	cis	rs909674	0.818	rs5757678	chr22:39843409	A/G	cg11247378	chr22:39784982	NA	0.7	8.55	0.61	3.76e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg00343986	chr7:65444356	GUSB	-0.23	-5.16	-0.42	9.66e-7	Aortic root size;
TGCT	cis	rs6570726	0.967	rs450973	chr6:145863065	C/A	cg23711669	chr6:146136114	FBXO30	0.7	6.48	0.5	1.9e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1035144	0.546	rs2215981	chr14:81444967	G/A	cg06600135	chr14:81408086	NA	-0.48	-4.54	-0.38	1.29e-5	Male sexual orientation;
TGCT	cis	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg25660036	chr4:7070649	GRPEL1	-0.69	-5.98	-0.47	2.21e-8	Monocyte percentage of white cells;
TGCT	cis	rs1334894	1.000	rs7754668	chr6:35590092	G/A	cg24281267	chr6:35479648	TULP1	-0.44	-4.73	-0.39	5.95e-6	Coronary artery disease;
TGCT	cis	rs644799	0.965	rs598876	chr11:95560853	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	8.74	0.62	1.37e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg21016266	chr12:122356598	WDR66	-0.54	-7.02	-0.53	1.26e-10	Mean corpuscular volume;
TGCT	cis	rs478304	0.651	rs948494	chr11:65552118	G/A	cg27068330	chr11:65405492	SIPA1	-0.95	-9.42	-0.65	3.25e-16	Acne (severe);
TGCT	cis	rs2293052	0.762	rs549098	chr12:117754327	G/A	cg02962597	chr12:117799749	NOS1	0.27	4.87	0.4	3.36e-6	Schizophrenia;
TGCT	cis	rs2228479	0.619	rs78001663	chr16:89896331	C/A	cg06558623	chr16:89946397	TCF25	0.55	4.77	0.39	5.13e-6	Skin colour saturation;
TGCT	cis	rs2486012	0.737	rs11210928	chr1:44268219	C/T	cg12908607	chr1:44402522	ARTN	-0.72	-5.69	-0.45	8.81e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg02725872	chr8:58115012	NA	-0.38	-4.99	-0.41	1.98e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6088590	1.000	rs6120705	chr20:33313740	T/C	cg24642439	chr20:33292090	TP53INP2	0.69	6.17	0.48	8.94e-9	Coronary artery disease;
TGCT	cis	rs3751972	0.590	rs8067428	chr17:26267997	A/G	cg02948944	chr17:26242737	NA	0.45	5.54	0.45	1.73e-7	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg09263875	chr16:632152	PIGQ	0.31	6.98	0.53	1.55e-10	Height;
TGCT	cis	rs9549367	0.713	rs3024761	chr13:113824090	C/G	cg18105134	chr13:113819100	PROZ	0.47	8.28	0.6	1.71e-13	Platelet distribution width;
TGCT	cis	rs7044106	0.690	rs10739569	chr9:123361027	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	5.76	0.46	6.27e-8	Hip circumference adjusted for BMI;
TGCT	cis	rs11112613	0.775	rs10778413	chr12:105962118	G/A	cg03607813	chr12:105948248	NA	0.47	5.74	0.46	6.71e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	cis	rs10838634	1.000	rs4500447	chr11:46776093	A/G	cg18332754	chr11:46939436	LRP4	0.84	4.54	0.38	1.29e-5	Schizophrenia;
TGCT	cis	rs734999	0.545	rs12749591	chr1:2563250	G/T	cg18854424	chr1:2615690	NA	-0.5	-5.95	-0.47	2.54e-8	Ulcerative colitis;
TGCT	cis	rs12142240	0.698	rs72679807	chr1:46846490	G/A	cg00530320	chr1:46809349	NSUN4	0.29	5.79	0.46	5.34e-8	Menopause (age at onset);
TGCT	cis	rs7714584	1.000	rs9324660	chr5:150257054	C/G	cg22134413	chr5:150180641	NA	0.83	6.53	0.51	1.54e-9	Crohn's disease;
TGCT	cis	rs79349575	0.783	rs62075818	chr17:46982327	T/A	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.44	-0.37	1.95e-5	Type 2 diabetes;
TGCT	cis	rs3771570	1.000	rs4675811	chr2:242402062	A/T	cg21155796	chr2:242212141	HDLBP	0.89	6.85	0.52	3.11e-10	Prostate cancer;
TGCT	cis	rs12142240	0.698	rs10158130	chr1:46822600	T/C	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs9527	0.830	rs11191442	chr10:104643596	T/A	cg15744005	chr10:104629667	AS3MT	-0.5	-6.0	-0.47	1.98e-8	Arsenic metabolism;
TGCT	cis	rs6089829	0.962	rs2314131	chr20:61665225	A/G	cg03213289	chr20:61660250	NA	0.59	6.97	0.53	1.7e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1372520	0.684	rs1837891	chr4:90736131	C/G	cg01966878	chr4:90757139	SNCA	0.31	4.81	0.4	4.3e-6	Neuroticism;
TGCT	cis	rs9303401	0.659	rs12944971	chr17:56988801	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.61	6.16	0.48	9.11e-9	Cognitive test performance;
TGCT	cis	rs2153535	0.541	rs9328477	chr6:8519109	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.55e-8	Motion sickness;
TGCT	cis	rs9357506	1.000	rs62402365	chr6:46318800	G/T	cg21115430	chr6:46460003	NA	-0.24	-4.76	-0.39	5.19e-6	Body mass index;
TGCT	cis	rs9303401	0.573	rs34717648	chr17:56886624	T/A	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs11722228	1.000	rs6825187	chr4:9915325	T/C	cg11266682	chr4:10021025	SLC2A9	-0.48	-5.38	-0.44	3.55e-7	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs796364	0.662	rs11688415	chr2:201143409	C/T	cg17644776	chr2:200775616	C2orf69	0.37	5.05	0.41	1.54e-6	Schizophrenia;
TGCT	cis	rs7772486	0.875	rs9390377	chr6:146386932	G/A	cg23711669	chr6:146136114	FBXO30	0.91	9.95	0.67	1.67e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1577917	0.739	rs6922	chr6:86205323	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.59	5.15	0.42	1.01e-6	Response to antipsychotic treatment;
TGCT	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg17747265	chr1:1875780	NA	-0.42	-8.11	-0.59	4.15e-13	Body mass index;
TGCT	cis	rs1348850	0.914	rs12612857	chr2:178467144	A/G	cg22681709	chr2:178499509	PDE11A	-0.43	-5.2	-0.42	8e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs12935418	0.583	rs7206625	chr16:80964433	G/A	cg07676361	chr16:80966860	NA	-0.35	-4.66	-0.39	8.02e-6	Mean corpuscular volume;
TGCT	cis	rs9916302	0.904	rs11078897	chr17:37415870	C/T	cg15445000	chr17:37608096	MED1	0.33	4.84	0.4	3.8e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg06060754	chr5:176797920	RGS14	-0.59	-10.59	-0.69	4.56e-19	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs9902453	0.935	rs9911794	chr17:28349466	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-6.56	-0.51	1.3e-9	Coffee consumption (cups per day);
TGCT	cis	rs1018836	0.632	rs7002775	chr8:91476765	C/T	cg16814680	chr8:91681699	NA	0.77	8.01	0.58	7.13e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2721195	0.967	rs1985022	chr8:145684031	C/T	cg17328964	chr8:145687451	CYHR1	-0.53	-8.06	-0.59	5.36e-13	Age at first birth;
TGCT	cis	rs17133449	0.718	rs7923564	chr10:4753292	G/A	cg04530666	chr10:3759553	NA	-0.28	-4.68	-0.39	7.48e-6	Major depressive disorder;
TGCT	cis	rs137699	0.959	rs5757631	chr22:39755953	T/C	cg05872129	chr22:39784769	NA	-0.56	-4.85	-0.4	3.64e-6	IgG glycosylation;
TGCT	cis	rs9341808	0.718	rs9352803	chr6:80864667	G/T	cg08355045	chr6:80787529	NA	0.31	5.53	0.44	1.79e-7	Sitting height ratio;
TGCT	cis	rs9902453	0.765	rs8079209	chr17:28186773	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.88	8.7	0.62	1.65e-14	Coffee consumption (cups per day);
TGCT	trans	rs62103177	0.713	rs3744886	chr18:77659561	G/T	cg05926928	chr17:57297772	GDPD1	1.21	11.0	0.7	4.67e-20	Opioid sensitivity;
TGCT	cis	rs752010	0.619	rs7539238	chr1:42113572	A/C	cg06885757	chr1:42089581	HIVEP3	0.29	5.07	0.41	1.41e-6	Lupus nephritis in systemic lupus erythematosus;
TGCT	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	16.07	0.82	4.16e-32	Prudent dietary pattern;
TGCT	cis	rs7772486	0.902	rs1125462	chr6:146417832	A/G	cg23711669	chr6:146136114	FBXO30	0.79	8.32	0.6	1.37e-13	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg12667521	chr19:29218732	NA	0.53	5.64	0.45	1.07e-7	Methadone dose in opioid dependence;
TGCT	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg22963979	chr7:1858916	MAD1L1	-0.34	-5.41	-0.44	3.05e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs7255045	0.752	rs55730975	chr19:12973039	G/A	cg06537894	chr19:12978706	MAST1	-0.49	-4.48	-0.37	1.69e-5	Mean corpuscular volume;
TGCT	cis	rs10178094	0.669	rs7595982	chr2:161332385	T/G	cg03641300	chr2:160917029	PLA2R1	-0.22	-4.77	-0.39	5.05e-6	White blood cell count;
TGCT	cis	rs3749237	0.595	rs2878298	chr3:49406080	T/C	cg07636037	chr3:49044803	WDR6	0.63	6.04	0.48	1.67e-8	Resting heart rate;
TGCT	cis	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg09021430	chr5:549028	NA	-0.37	-5.35	-0.43	4.16e-7	Lung disease severity in cystic fibrosis;
TGCT	cis	rs9581857	0.579	rs2780341	chr13:27996401	C/T	cg22138327	chr13:27999177	GTF3A	-0.83	-5.75	-0.46	6.62e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs71435601	0.574	rs547239	chr2:21384686	T/A	cg25035485	chr2:21266500	APOB	0.51	4.48	0.37	1.64e-5	Cholesterol, total;
TGCT	cis	rs611744	0.935	rs679077	chr8:109244742	G/T	cg21045802	chr8:109455806	TTC35	0.5	4.57	0.38	1.18e-5	Dupuytren's disease;
TGCT	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg06221963	chr1:154839813	KCNN3	-0.75	-12.65	-0.75	4.66e-24	Prostate cancer;
TGCT	cis	rs6088590	0.930	rs6120723	chr20:33364655	C/T	cg06115741	chr20:33292138	TP53INP2	0.67	5.6	0.45	1.34e-7	Coronary artery disease;
TGCT	cis	rs9527	0.830	rs11191442	chr10:104643596	T/A	cg04362960	chr10:104952993	NT5C2	0.61	4.96	0.41	2.26e-6	Arsenic metabolism;
TGCT	cis	rs17741873	0.779	rs10509346	chr10:75596014	A/G	cg07699608	chr10:75541558	CHCHD1	-0.72	-5.15	-0.42	1.02e-6	Paclitaxel disposition in epithelial ovarian cancer;
TGCT	cis	rs1371867	0.846	rs2047249	chr8:101234126	A/G	cg06636551	chr8:101224915	SPAG1	0.4	5.03	0.41	1.66e-6	Atrioventricular conduction;
TGCT	cis	rs7175404	0.536	rs79719082	chr15:94038436	A/G	cg08478250	chr15:93957936	NA	0.36	4.77	0.39	5.11e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs2180341	1.000	rs6569479	chr6:127606588	A/G	cg24812749	chr6:127587940	RNF146	0.91	6.98	0.53	1.56e-10	Breast cancer;
TGCT	cis	rs6087990	0.865	rs6058859	chr20:31335157	A/G	cg13636640	chr20:31349939	DNMT3B	1.01	14.09	0.78	1.66e-27	Ulcerative colitis;
TGCT	cis	rs12136530	0.744	rs12090885	chr1:19779781	G/A	cg18923740	chr1:19971790	NBL1	0.38	4.65	0.39	8.48e-6	Lead levels in blood;
TGCT	cis	rs9394841	0.692	rs34073739	chr6:41829970	A/G	cg08135965	chr6:41755394	TOMM6	0.52	4.82	0.4	4.13e-6	Mean corpuscular hemoglobin;Red cell distribution width;
TGCT	cis	rs9611565	0.512	rs6002474	chr22:42168181	A/G	cg06481639	chr22:41940642	POLR3H	0.69	6.05	0.48	1.59e-8	Vitiligo;
TGCT	cis	rs727479	0.502	rs10046	chr15:51502986	G/A	cg19946085	chr15:51559439	CYP19A1	-0.31	-4.53	-0.38	1.39e-5	Estradiol levels;
TGCT	cis	rs17253792	0.822	rs80321745	chr14:56162947	T/A	cg01858014	chr14:56050164	KTN1	-0.35	-4.47	-0.37	1.73e-5	Putamen volume;
TGCT	cis	rs9611565	0.512	rs5751148	chr22:42139078	A/G	cg13695892	chr22:41940480	POLR3H	0.89	8.43	0.6	7.37e-14	Vitiligo;
TGCT	cis	rs10992471	0.603	rs10761160	chr9:95208701	A/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.6	-5.67	-0.45	9.42e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs4383453	0.520	rs6790286	chr3:123103037	G/A	cg04890266	chr3:123102914	ADCY5	-0.49	-7.91	-0.58	1.23e-12	Gestational age at birth (maternal effect);
TGCT	cis	rs12681288	0.644	rs2600494	chr8:1025517	C/T	cg04851639	chr8:1020857	NA	-0.36	-6.82	-0.52	3.56e-10	Schizophrenia;
TGCT	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg08219700	chr8:58056026	NA	0.3	4.53	0.38	1.35e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs4900538	0.855	rs12587464	chr14:102886561	G/C	cg18135206	chr14:102964638	TECPR2	-0.2	-4.57	-0.38	1.18e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs4654899	0.643	rs12145181	chr1:21086046	C/A	cg01072550	chr1:21505969	NA	-0.54	-8.85	-0.62	7.34e-15	Superior frontal gyrus grey matter volume;
TGCT	cis	rs4786125	0.665	rs8060329	chr16:6908864	G/A	cg03623568	chr16:6915990	A2BP1	-0.41	-6.06	-0.48	1.5e-8	Heart rate variability traits (SDNN);
TGCT	cis	rs6088590	0.930	rs6087618	chr20:33288407	C/T	cg06115741	chr20:33292138	TP53INP2	0.66	5.62	0.45	1.19e-7	Coronary artery disease;
TGCT	cis	rs12600635	0.564	rs80068883	chr17:17107854	C/T	cg16928487	chr17:17741425	SREBF1	0.38	4.94	0.41	2.46e-6	IgG glycosylation;
TGCT	cis	rs35160687	0.901	rs12622200	chr2:86498595	A/G	cg12542933	chr2:85804724	VAMP8	-0.39	-4.7	-0.39	6.7e-6	Night sleep phenotypes;
TGCT	cis	rs8072100	0.840	rs9912311	chr17:45547132	T/C	cg08085267	chr17:45401833	C17orf57	-0.46	-5.07	-0.41	1.39e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs2342371	0.848	rs12632592	chr3:196219365	G/A	cg15048948	chr3:196158458	UBXN7	0.53	4.49	0.37	1.6e-5	Fat distribution (HIV);
TGCT	cis	rs4794202	0.629	rs16948662	chr17:45913847	C/A	cg02219949	chr17:45927392	SP6	0.42	4.52	0.38	1.4e-5	Alzheimer's disease (cognitive decline);
TGCT	cis	rs2115630	0.691	rs61322921	chr15:85163638	T/C	cg12863693	chr15:85201151	NMB	-0.4	-5.42	-0.44	2.96e-7	P wave terminal force;
TGCT	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10992471	0.603	rs12336884	chr9:95234183	A/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.62	-5.79	-0.46	5.39e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs6688613	1.000	rs1327866	chr1:166952910	C/T	cg07049167	chr1:166818506	POGK	-0.22	-4.63	-0.38	8.97e-6	Refractive astigmatism;
TGCT	cis	rs909002	0.849	rs871634	chr1:32093167	G/C	cg11573219	chr1:32083031	HCRTR1	-0.46	-5.93	-0.47	2.77e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs4788570	0.625	rs4788810	chr16:71621637	C/T	cg06353428	chr16:71660113	MARVELD3	-1.46	-12.42	-0.74	1.67e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs10876993	0.890	rs1689584	chr12:58081478	G/A	cg15848620	chr12:58087721	OS9	-0.72	-5.98	-0.47	2.25e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs12188164	1.000	rs72717412	chr5:429381	C/T	cg26850624	chr5:429559	AHRR	-0.2	-4.81	-0.4	4.22e-6	Cystic fibrosis severity;
TGCT	cis	rs1998418	0.599	rs7086834	chr10:126357963	C/A	cg03585084	chr10:126284563	LHPP	-0.27	-5.07	-0.41	1.4e-6	Mean platelet volume;
TGCT	cis	rs9389248	0.690	rs728030	chr6:135246294	G/T	cg24558204	chr6:135376177	HBS1L	-0.47	-4.8	-0.4	4.41e-6	High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs12220238	0.822	rs73286281	chr10:76083337	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.88	5.98	0.47	2.22e-8	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs2120019	0.567	rs68036747	chr15:75203200	A/C	cg09165964	chr15:75287851	SCAMP5	-0.89	-6.78	-0.52	4.42e-10	Blood trace element (Zn levels);
TGCT	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg06221963	chr1:154839813	KCNN3	-0.76	-13.04	-0.76	5.27e-25	Prostate cancer;
TGCT	cis	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg20637647	chr7:64974828	NA	0.94	5.17	0.42	9.06e-7	Diabetic kidney disease;
TGCT	cis	rs651907	0.557	rs3094297	chr3:101399260	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.31	-6.76	-0.52	4.83e-10	Colorectal cancer;
TGCT	cis	rs9611519	0.894	rs9623320	chr22:41478482	G/A	cg03806693	chr22:41940476	POLR3H	-0.65	-5.91	-0.47	3.04e-8	Neuroticism;
TGCT	cis	rs9914544	1.000	rs9916245	chr17:18766825	C/G	cg26306683	chr17:18585705	ZNF286B	0.57	5.08	0.41	1.36e-6	Educational attainment (years of education);
TGCT	cis	rs6671200	1.000	rs6671200	chr1:95697529	A/C	cg26537280	chr1:95699037	RWDD3	-0.7	-5.55	-0.45	1.62e-7	Stearic acid (18:0) levels;
TGCT	cis	rs739401	0.611	rs2071104	chr11:3036933	G/T	cg25174290	chr11:3078921	CARS	0.47	4.68	0.39	7.52e-6	Longevity;
TGCT	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg22105103	chr4:187893119	NA	0.35	4.89	0.4	3.02e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7681440	0.904	rs7680761	chr4:90763510	A/T	cg14346243	chr4:90757452	SNCA	-0.59	-5.74	-0.46	6.82e-8	Dementia with Lewy bodies;
TGCT	cis	rs12220238	1.000	rs10824129	chr10:76008855	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.92	7.91	0.58	1.21e-12	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs9300255	0.602	rs2510885	chr12:123614813	G/C	cg00376283	chr12:123451042	ABCB9	0.71	5.61	0.45	1.26e-7	Neutrophil percentage of white cells;
TGCT	cis	rs263156	0.770	rs263121	chr6:142894300	T/C	cg18419694	chr6:143832440	FUCA2	-0.39	-4.46	-0.37	1.81e-5	Ear morphology;Lobe size;Lobe attachment;
TGCT	cis	rs3741151	1.000	rs79778136	chr11:73041339	T/C	cg17517138	chr11:73019481	ARHGEF17	0.97	4.76	0.39	5.22e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
TGCT	cis	rs7264396	0.790	rs2425160	chr20:34425968	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.28	-4.83	-0.4	3.89e-6	Total cholesterol levels;
TGCT	cis	rs617219	0.597	rs10474581	chr5:78578884	G/A	cg09550809	chr5:78407562	BHMT	-0.4	-5.49	-0.44	2.19e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs796364	1.000	rs281783	chr2:200751582	G/A	cg17644776	chr2:200775616	C2orf69	0.31	4.83	0.4	3.99e-6	Schizophrenia;
TGCT	cis	rs40363	0.729	rs6501176	chr16:3522197	A/G	cg21433313	chr16:3507492	NAT15	-0.36	-4.94	-0.41	2.5e-6	Tuberculosis;
TGCT	cis	rs1865760	0.613	rs7749342	chr6:25920265	T/C	cg03264133	chr6:25882463	NA	-0.46	-4.72	-0.39	6.36e-6	Height;
TGCT	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.18	-0.49	8.51e-9	Alzheimer's disease;
TGCT	cis	rs13191362	1.000	rs60719662	chr6:163006643	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.57	4.94	0.41	2.45e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs36051895	0.664	rs17425819	chr9:5114773	C/T	cg02405213	chr9:5042618	JAK2	-0.69	-8.88	-0.62	6.38e-15	Pediatric autoimmune diseases;
TGCT	cis	rs9467711	0.606	rs28360517	chr6:26602453	A/G	cg16898833	chr6:26189333	HIST1H4D	1.02	5.25	0.43	6.32e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7833790	0.553	rs9693128	chr8:82706128	A/G	cg06027949	chr8:82754900	SNX16	-0.68	-5.6	-0.45	1.31e-7	Diastolic blood pressure;
TGCT	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg09359103	chr1:154839909	KCNN3	-0.64	-12.27	-0.74	3.87e-23	Prostate cancer;
TGCT	cis	rs3818285	0.556	rs944966	chr10:111658334	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.29	-4.97	-0.41	2.14e-6	Superior crus of antihelix expression;
TGCT	cis	rs12681287	0.547	rs13249177	chr8:87513034	A/G	cg19078186	chr8:87526527	CPNE3	-0.37	-4.57	-0.38	1.15e-5	Caudate activity during reward;
TGCT	cis	rs9611519	0.780	rs3171692	chr22:41642212	C/T	cg13695892	chr22:41940480	POLR3H	-0.61	-5.61	-0.45	1.24e-7	Neuroticism;
TGCT	cis	rs3749237	0.595	rs6797765	chr3:49423976	A/G	cg03060546	chr3:49711283	APEH	0.77	8.87	0.62	6.79e-15	Resting heart rate;
TGCT	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg12963246	chr6:28129442	ZNF389	0.52	5.01	0.41	1.85e-6	Depression;
TGCT	cis	rs904251	0.797	rs1776460	chr6:37485484	A/G	cg08126542	chr6:37504118	NA	-0.4	-5.41	-0.44	3.12e-7	Cognitive performance;
TGCT	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg06238570	chr21:40685208	BRWD1	0.7	6.45	0.5	2.3e-9	Cognitive function;
TGCT	cis	rs10875595	0.836	rs10062604	chr5:140661932	T/C	cg20560182	chr5:140700478	TAF7	-0.66	-5.06	-0.41	1.49e-6	Pulmonary function decline;
TGCT	cis	rs1395	0.677	rs113353646	chr2:27492674	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.69	9.17	0.64	1.29e-15	Blood metabolite levels;
TGCT	cis	rs2236918	0.687	rs1776136	chr1:242026845	G/A	cg04158730	chr1:242011433	EXO1	0.56	5.36	0.43	3.88e-7	Menopause (age at onset);
TGCT	cis	rs7568458	0.905	rs59877521	chr2:85759494	C/T	cg02493740	chr2:85810744	VAMP5	-0.27	-4.86	-0.4	3.53e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg20362242	chr5:692897	TPPP	0.5	4.88	0.4	3.21e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.15	0.82	2.71e-32	Prudent dietary pattern;
TGCT	cis	rs1941023	0.584	rs2014121	chr11:60156297	T/C	cg08716584	chr11:60157161	MS4A7	-0.35	-5.29	-0.43	5.3e-7	Congenital heart disease (maternal effect);
TGCT	trans	rs524675	0.581	rs473124	chr4:13956897	A/G	cg02315626	chr17:27188560	MIR451;MIR144	0.42	6.87	0.53	2.82e-10	Amyotrophic lateral sclerosis in C9orf72 mutation negative individuals;
TGCT	trans	rs916888	0.647	rs199523	chr17:44848517	C/A	cg01341218	chr17:43662625	NA	-0.86	-7.5	-0.56	1.06e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs10875746	0.551	rs2054903	chr12:48724493	C/T	cg20731937	chr12:48336164	NA	0.55	5.04	0.41	1.6e-6	Longevity (90 years and older);
TGCT	cis	rs9393692	0.905	rs6916289	chr6:26289122	A/T	cg13736514	chr6:26305472	NA	-0.37	-5.42	-0.44	3.01e-7	Educational attainment;
TGCT	cis	rs709400	0.663	rs3783402	chr14:103967929	C/G	cg26031613	chr14:104095156	KLC1	0.84	9.5	0.65	2.08e-16	Body mass index;
TGCT	cis	rs939658	0.805	rs59104559	chr15:79438784	A/G	cg17916960	chr15:79447300	NA	-0.49	-7.41	-0.55	1.73e-11	Refractive error;
TGCT	cis	rs75059851	0.756	rs11223648	chr11:133840412	C/T	cg14047540	chr11:133829660	NA	-0.57	-5.69	-0.45	8.72e-8	Schizophrenia;
TGCT	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.2	0.42	8.14e-7	Menopause (age at onset);
TGCT	cis	rs4595586	0.967	rs56149694	chr12:39263771	T/C	cg10518543	chr12:38710700	ALG10B	-0.51	-5.09	-0.42	1.31e-6	Morning vs. evening chronotype;
TGCT	cis	rs7909074	1.000	rs6593447	chr10:45400235	G/A	cg05187965	chr10:45406764	TMEM72	-0.24	-5.02	-0.41	1.73e-6	Mean corpuscular volume;
TGCT	cis	rs231513	0.954	rs170766	chr17:41963407	C/G	cg26893861	chr17:41843967	DUSP3	-0.71	-5.21	-0.42	7.57e-7	Cognitive function;
TGCT	cis	rs7542091	0.635	rs7550733	chr1:210044968	G/A	cg21951975	chr1:209979733	IRF6	0.6	6.11	0.48	1.18e-8	Monobrow;
TGCT	cis	rs7727544	0.735	rs273913	chr5:131661156	A/G	cg24060327	chr5:131705240	SLC22A5	-0.43	-4.45	-0.37	1.92e-5	Blood metabolite levels;
TGCT	cis	rs7666738	0.830	rs28795113	chr4:98951331	A/G	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg11764359	chr7:65958608	NA	0.54	5.02	0.41	1.73e-6	Aortic root size;
TGCT	cis	rs9303401	0.659	rs11079358	chr17:56920949	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs59698941	0.943	rs66628697	chr5:132252561	C/T	cg27099455	chr5:132201840	GDF9;UQCRQ	0.37	4.47	0.37	1.74e-5	Apolipoprotein A-IV levels;
TGCT	cis	rs7312933	0.558	rs1669886	chr12:42838240	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.58	-5.7	-0.46	8.41e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs2243480	1.000	rs316307	chr7:65570171	C/T	cg07424592	chr7:64974309	NA	1.25	7.49	0.56	1.15e-11	Diabetic kidney disease;
TGCT	cis	rs3820068	0.705	rs4646103	chr1:15819827	T/A	cg05660106	chr1:15850417	CASP9	1.15	14.12	0.79	1.41e-27	Systolic blood pressure;
TGCT	cis	rs35146811	0.700	rs858513	chr7:99825558	G/A	cg00553149	chr7:99775558	STAG3;GPC2	-0.32	-4.81	-0.4	4.28e-6	Coronary artery disease;
TGCT	cis	rs12477438	0.520	rs2516830	chr2:99773702	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.75	7.25	0.55	3.92e-11	Chronic sinus infection;
TGCT	cis	rs3820928	1.000	rs10197757	chr2:227763244	A/C	cg11843606	chr2:227700838	RHBDD1	-0.53	-4.69	-0.39	7.22e-6	Pulmonary function;
TGCT	cis	rs832540	0.669	rs832539	chr5:56199386	A/C	cg12311346	chr5:56204834	C5orf35	-0.61	-6.24	-0.49	6.33e-9	Coronary artery disease;
TGCT	cis	rs933688	1.000	rs2059208	chr5:90732065	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.0	9.76	0.66	4.82e-17	Smoking behavior;
TGCT	cis	rs875971	0.965	rs697968	chr7:65535033	G/A	cg11764359	chr7:65958608	NA	-0.56	-4.7	-0.39	6.74e-6	Aortic root size;
TGCT	cis	rs56399783	0.901	rs73049362	chr7:2826822	G/A	cg19731401	chr7:2775893	GNA12	0.37	5.15	0.42	1e-6	Childhood ear infection;
TGCT	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg04267008	chr7:1944627	MAD1L1	-0.36	-4.88	-0.4	3.23e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs9467773	1.000	rs9357010	chr6:26527945	C/G	cg15659132	chr6:26577336	NA	0.85	12.22	0.74	5.02e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg16325326	chr1:53192061	ZYG11B	-0.57	-6.39	-0.5	2.97e-9	Monocyte count;
TGCT	cis	rs916888	0.610	rs199529	chr17:44837217	A/C	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.56	-4.9	-0.4	2.93e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs9399135	0.507	rs2072825	chr6:135253451	A/G	cg22676075	chr6:135203613	NA	-0.51	-5.11	-0.42	1.17e-6	Red blood cell count;
TGCT	cis	rs6540559	0.673	rs7550857	chr1:209956542	C/A	cg22029157	chr1:209979665	IRF6	0.76	5.58	0.45	1.41e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs4268898	0.760	rs11676939	chr2:24479057	C/T	cg02683114	chr2:24398427	C2orf84	0.2	4.98	0.41	2.1e-6	Asthma;
TGCT	cis	rs922182	0.554	rs9972387	chr15:64191485	A/G	cg02919090	chr15:64263738	DAPK2	0.33	5.94	0.47	2.71e-8	Blood protein levels;
TGCT	cis	rs7267979	0.844	rs35735333	chr20:25337205	T/G	cg03522245	chr20:25566470	NINL	-0.55	-5.55	-0.45	1.68e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs651907	0.557	rs11925001	chr3:101373966	C/T	cg12386194	chr3:101231763	SENP7	0.53	5.13	0.42	1.08e-6	Colorectal cancer;
TGCT	cis	rs9467773	0.620	rs1490488	chr6:26614808	T/C	cg02458000	chr6:26745757	NA	0.55	5.29	0.43	5.31e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7917772	0.560	rs4919664	chr10:104363408	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	5.36	0.43	3.84e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs6435161	0.762	rs933969	chr2:203499720	G/A	cg18429434	chr2:203499731	FAM117B	0.53	5.19	0.42	8.43e-7	Total cholesterol levels;
TGCT	cis	rs12762955	0.507	rs10737004	chr10:1039019	T/C	cg20503657	chr10:835505	NA	-0.42	-5.47	-0.44	2.42e-7	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs3015497	0.789	rs1389652	chr14:51125240	T/C	cg04730355	chr14:51134070	SAV1	-0.6	-5.81	-0.46	5.04e-8	Mean platelet volume;
TGCT	cis	rs4242434	0.819	rs720745	chr8:22471147	G/T	cg03733263	chr8:22462867	KIAA1967	1.08	17.0	0.84	3.37e-34	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg22535103	chr8:58192502	C8orf71	-0.39	-4.69	-0.39	7.13e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs981844	0.961	rs62325084	chr4:154662603	C/T	cg14289246	chr4:154710475	SFRP2	1.01	8.46	0.6	6.31e-14	Response to statins (LDL cholesterol change);
TGCT	trans	rs17471911	0.708	rs80240449	chr10:100754725	T/C	cg03484267	chr2:207988651	KLF7	-0.53	-6.79	-0.52	4.24e-10	Neuroticism;
TGCT	cis	rs11098499	0.562	rs58583086	chr4:120556362	A/G	cg09307838	chr4:120376055	NA	-0.57	-5.45	-0.44	2.59e-7	Corneal astigmatism;
TGCT	cis	rs3741404	0.620	rs2236648	chr11:63964657	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.79	8.1	0.59	4.29e-13	Platelet count;
TGCT	cis	rs765787	0.530	rs4775832	chr15:45534828	A/G	cg24006582	chr15:45444508	DUOX1	-0.25	-5.53	-0.44	1.82e-7	Uric acid levels;
TGCT	cis	rs7192750	0.562	rs152838	chr16:72105702	C/T	cg06353428	chr16:71660113	MARVELD3	1.03	5.31	0.43	4.93e-7	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs694739	0.796	rs479777	chr11:64107477	A/G	cg23796481	chr11:64053134	BAD;GPR137	0.55	5.47	0.44	2.41e-7	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs6061231	0.755	rs11699160	chr20:60958651	T/C	cg24112000	chr20:60950667	NA	-0.34	-5.07	-0.41	1.38e-6	Colorectal cancer;
TGCT	cis	rs2239547	0.657	rs3755803	chr3:52866157	C/G	cg11645453	chr3:52864694	ITIH4	0.35	5.75	0.46	6.41e-8	Schizophrenia;
TGCT	cis	rs9549367	0.713	rs3024747	chr13:113821787	C/G	cg00898013	chr13:113819073	PROZ	-0.53	-6.74	-0.52	5.25e-10	Platelet distribution width;
TGCT	cis	rs903263	0.841	rs1874070	chr1:84599276	T/C	cg09664975	chr1:84543551	PRKACB	0.5	4.74	0.39	5.69e-6	Breast cancer (male);
TGCT	cis	rs55794721	0.509	rs2982358	chr1:25745204	G/T	cg00786635	chr1:25594202	NA	0.58	6.07	0.48	1.43e-8	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs2797160	0.547	rs10872298	chr6:125956348	A/C	cg05901451	chr6:126070800	HEY2	-0.62	-5.17	-0.42	9.25e-7	Endometrial cancer;
TGCT	cis	rs7172809	0.573	rs3784787	chr15:77681010	T/C	cg22256960	chr15:77711686	NA	-0.5	-4.74	-0.39	5.82e-6	Glucose homeostasis traits;
TGCT	cis	rs9549367	0.789	rs6577031	chr13:113878182	T/C	cg00898013	chr13:113819073	PROZ	0.41	5.19	0.42	8.21e-7	Platelet distribution width;
TGCT	cis	rs9640161	0.742	rs11767726	chr7:150018096	A/C	cg17279839	chr7:150038598	RARRES2	-0.43	-4.55	-0.38	1.28e-5	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs2075165	0.870	rs9943105	chr1:156245245	T/C	cg16558208	chr1:156270281	VHLL	0.27	4.83	0.4	3.87e-6	Tonsillectomy;
TGCT	cis	rs1023500	0.551	rs2854837	chr22:42458481	G/A	cg05082376	chr22:42548792	NA	-0.22	-5.31	-0.43	4.85e-7	Schizophrenia;
TGCT	cis	rs7255045	0.788	rs8110185	chr19:12959827	T/A	cg23899408	chr19:12877188	HOOK2	-0.61	-4.99	-0.41	1.97e-6	Mean corpuscular volume;
TGCT	cis	rs2228479	0.867	rs62056110	chr16:89946388	A/C	cg06558623	chr16:89946397	TCF25	0.56	6.83	0.52	3.38e-10	Skin colour saturation;
TGCT	cis	rs3733585	0.631	rs4697707	chr4:10119787	G/T	cg11266682	chr4:10021025	SLC2A9	-0.55	-6.35	-0.5	3.78e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7586879	0.681	rs28836469	chr2:25117215	A/G	cg15423357	chr2:25149977	NA	0.5	4.89	0.4	3.06e-6	Body mass index;
TGCT	cis	rs1865760	0.892	rs2328903	chr6:25935765	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.64	6.15	0.48	9.9e-9	Height;
TGCT	cis	rs4788570	0.584	rs11075898	chr16:71705215	T/C	cg06353428	chr16:71660113	MARVELD3	1.56	12.54	0.75	8.54e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs6840360	0.615	rs113052419	chr4:152473008	T/C	cg17479576	chr4:152424074	FAM160A1	-0.72	-7.75	-0.57	2.8e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs2933343	0.729	rs1683816	chr3:128651195	G/T	cg11901034	chr3:128598214	ACAD9	0.65	6.29	0.49	5.07e-9	IgG glycosylation;
TGCT	cis	rs7226408	0.857	rs55895201	chr18:34478630	G/A	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs939574	0.722	rs72955435	chr2:220087354	A/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.11	5.34	0.43	4.31e-7	Platelet distribution width;
TGCT	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.7	6.31	0.49	4.41e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg21963583	chr11:68658836	MRPL21	0.36	6.17	0.48	9.01e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs4851266	1.000	rs11695383	chr2:100826098	G/T	cg22139774	chr2:100720529	AFF3	-0.35	-5.19	-0.42	8.51e-7	Educational attainment;
TGCT	cis	rs17270561	0.779	rs17271767	chr6:25886921	C/T	cg16482183	chr6:26056742	HIST1H1C	0.89	6.63	0.51	9.23e-10	Iron status biomarkers;
TGCT	cis	rs709400	0.526	rs11622473	chr14:103979762	G/A	cg12935359	chr14:103987150	CKB	-0.49	-6.55	-0.51	1.37e-9	Body mass index;
TGCT	cis	rs2629540	0.824	rs1552345	chr10:126477406	A/G	cg08799069	chr10:126477246	METTL10	-0.31	-4.68	-0.39	7.26e-6	Cocaine dependence;
TGCT	cis	rs763121	0.744	rs5757140	chr22:38957013	T/C	cg06022373	chr22:39101656	GTPBP1	0.81	7.86	0.58	1.58e-12	Menopause (age at onset);
TGCT	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg04317338	chr11:64019027	PLCB3	0.8	6.61	0.51	1.01e-9	Mean platelet volume;
TGCT	cis	rs1971762	0.545	rs7297461	chr12:54047178	A/T	cg16917193	chr12:54089295	NA	1.08	11.48	0.72	3.21e-21	Height;
TGCT	cis	rs3796352	0.667	rs34860124	chr3:52857778	T/A	cg15956490	chr3:53032818	SFMBT1	0.55	4.9	0.4	2.93e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg07424592	chr7:64974309	NA	1.27	7.84	0.58	1.8e-12	Diabetic kidney disease;
TGCT	cis	rs62244186	0.516	rs11922470	chr3:44777795	C/T	cg02073558	chr3:44770973	ZNF501	0.96	10.79	0.7	1.5e-19	Depressive symptoms;
TGCT	cis	rs11190604	1.000	rs11190555	chr10:102209160	A/G	cg23241863	chr10:102295624	HIF1AN	0.62	4.87	0.4	3.27e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs6906287	0.647	rs6569015	chr6:118686344	C/T	cg21191810	chr6:118973309	C6orf204	0.26	4.46	0.37	1.85e-5	Electrocardiographic conduction measures;
TGCT	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg18876405	chr7:65276391	NA	0.33	4.97	0.41	2.14e-6	Aortic root size;
TGCT	cis	rs7085104	0.660	rs3781286	chr10:104595719	C/T	cg15744005	chr10:104629667	AS3MT	-0.43	-5.48	-0.44	2.26e-7	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs2658782	0.789	rs2658773	chr11:93126914	A/G	cg18152523	chr11:93063302	CCDC67	-0.58	-4.6	-0.38	1.03e-5	Pulmonary function decline;
TGCT	cis	rs9534288	0.699	rs1409432	chr13:46668302	C/T	cg15192986	chr13:46630673	CPB2	-0.49	-6.05	-0.48	1.62e-8	Blood protein levels;
TGCT	trans	rs2440129	0.963	rs12325805	chr17:6912219	T/G	cg18731024	chr5:2998264	NA	0.83	6.74	0.52	5.4e-10	Tonsillectomy;
TGCT	trans	rs3780486	0.505	rs1411609	chr9:33137303	C/T	cg20290983	chr6:43655470	MRPS18A	0.79	8.48	0.61	5.68e-14	IgG glycosylation;
TGCT	cis	rs2730260	0.537	rs73169233	chr7:158882201	C/T	cg27122614	chr7:157913741	PTPRN2	0.42	4.47	0.37	1.74e-5	Myopia (pathological);
TGCT	cis	rs2797160	1.000	rs1578794	chr6:126015469	T/C	cg05901451	chr6:126070800	HEY2	0.73	6.29	0.49	5.01e-9	Endometrial cancer;
TGCT	cis	rs17401966	0.931	rs11585794	chr1:10443867	G/A	cg19773385	chr1:10388646	KIF1B	-0.24	-5.49	-0.44	2.16e-7	Hepatocellular carcinoma;
TGCT	cis	rs3091242	0.933	rs7541095	chr1:25761291	T/C	cg23205692	chr1:25664452	TMEM50A	0.47	4.89	0.4	3.04e-6	Erythrocyte sedimentation rate;
TGCT	cis	rs453301	0.686	rs28482034	chr8:8869664	G/A	cg00184457	chr8:8946301	NA	-0.27	-4.92	-0.4	2.72e-6	Joint mobility (Beighton score);
TGCT	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg06112835	chr11:68658793	MRPL21	0.5	8.25	0.6	1.92e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9807989	0.839	rs10206753	chr2:102968362	T/C	cg09003973	chr2:102972529	NA	0.64	5.7	0.46	8.28e-8	Asthma;
TGCT	cis	rs6831352	0.918	rs13127153	chr4:100058121	C/T	cg12011299	chr4:100065546	ADH4	-0.41	-4.96	-0.41	2.29e-6	Alcohol dependence;
TGCT	cis	rs58688157	0.883	rs34793529	chr11:575800	T/G	cg16486109	chr11:613632	IRF7	0.33	4.73	0.39	6.05e-6	Systemic lupus erythematosus;
TGCT	cis	rs74054849	0.541	rs12094673	chr1:15914820	T/C	cg05660106	chr1:15850417	CASP9	0.93	5.88	0.47	3.61e-8	Alcoholic chronic pancreatitis;
TGCT	cis	rs9902453	0.817	rs1038089	chr17:28178724	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	7.18	0.54	5.62e-11	Coffee consumption (cups per day);
TGCT	cis	rs739496	0.744	rs848130	chr12:112009831	G/A	cg10833066	chr12:111807467	FAM109A	0.37	5.38	0.44	3.53e-7	Platelet count;
TGCT	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.51	-4.85	-0.4	3.62e-6	Bipolar disorder;
TGCT	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9399135	0.967	rs12661423	chr6:135349570	C/T	cg24558204	chr6:135376177	HBS1L	0.48	4.93	0.4	2.62e-6	Red blood cell count;
TGCT	cis	rs763121	0.626	rs5757236	chr22:39073824	T/C	cg06022373	chr22:39101656	GTPBP1	0.77	7.46	0.56	1.35e-11	Menopause (age at onset);
TGCT	cis	rs12532214	0.617	rs73673328	chr7:3149140	G/C	cg19214707	chr7:3157722	NA	-0.4	-4.88	-0.4	3.17e-6	Itch intensity from mosquito bite;
TGCT	cis	rs2224391	0.534	rs2773308	chr6:5246833	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-1.04	-6.69	-0.51	6.87e-10	Height;
TGCT	cis	rs8017423	0.935	rs3783838	chr14:90733012	A/G	cg04374321	chr14:90722782	PSMC1	-0.75	-7.24	-0.54	4.19e-11	Mortality in heart failure;
TGCT	cis	rs9486719	0.947	rs6916232	chr6:96985959	A/T	cg18709589	chr6:96969512	KIAA0776	0.72	5.28	0.43	5.64e-7	Migraine;Coronary artery disease;
TGCT	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg18402987	chr7:1209562	NA	0.48	4.79	0.39	4.72e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2688608	0.592	rs7909802	chr10:75484186	G/C	cg23231163	chr10:75533350	FUT11	-0.28	-4.68	-0.39	7.4e-6	Inflammatory bowel disease;
TGCT	cis	rs8002180	0.921	rs4771910	chr13:95929888	C/T	cg24476569	chr13:95954382	ABCC4	-0.39	-4.82	-0.4	4.05e-6	Blood metabolite levels;
TGCT	trans	rs1005277	0.505	rs1208689	chr10:38097775	C/G	cg17830980	chr10:43048298	ZNF37B	-0.72	-8.22	-0.59	2.27e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7959452	0.640	rs4761233	chr12:69722880	T/C	cg11871910	chr12:69753446	YEATS4	0.63	6.42	0.5	2.69e-9	Blood protein levels;
TGCT	cis	rs9911578	1.000	rs9898916	chr17:57048660	C/T	cg12560992	chr17:57184187	TRIM37	0.76	9.29	0.64	6.74e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs9393692	0.875	rs6939589	chr6:26289203	C/T	cg05868516	chr6:26286170	HIST1H4H	-0.63	-5.88	-0.47	3.5e-8	Educational attainment;
TGCT	cis	rs854765	0.547	rs4584886	chr17:17896205	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.78	8.07	0.59	5.28e-13	Total body bone mineral density;
TGCT	trans	rs4650994	0.623	rs7534394	chr1:178622760	G/A	cg05059571	chr16:84539110	KIAA1609	0.41	7.14	0.54	7.07e-11	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.62	-5.25	-0.43	6.3e-7	Tonsillectomy;
TGCT	cis	rs11098499	0.562	rs13101722	chr4:120555975	C/A	cg09307838	chr4:120376055	NA	-0.57	-5.3	-0.43	5.13e-7	Corneal astigmatism;
TGCT	cis	rs6688613	1.000	rs6699159	chr1:166946072	T/C	cg07049167	chr1:166818506	POGK	0.21	4.53	0.38	1.36e-5	Refractive astigmatism;
TGCT	cis	rs1552244	0.832	rs61056817	chr3:10027641	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.43	-6.29	-0.49	4.94e-9	Alzheimer's disease;
TGCT	cis	rs6087990	0.735	rs910083	chr20:31378690	A/C	cg13636640	chr20:31349939	DNMT3B	0.98	12.93	0.76	9.81e-25	Ulcerative colitis;
TGCT	cis	rs9467773	0.583	rs2498380	chr6:26643996	C/G	cg09904177	chr6:26538194	HMGN4	-0.66	-6.27	-0.49	5.38e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs62244186	0.659	rs9835270	chr3:44553722	G/A	cg25151919	chr3:44754333	ZNF502	-0.43	-4.94	-0.41	2.43e-6	Depressive symptoms;
TGCT	cis	rs6725041	0.819	rs939224	chr2:213089095	T/C	cg16329650	chr2:213403929	ERBB4	-0.53	-4.52	-0.38	1.44e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs12497850	0.931	rs7643368	chr3:48992855	T/G	cg05785598	chr3:49045655	WDR6	0.37	4.83	0.4	3.98e-6	Parkinson's disease;
TGCT	cis	rs7731657	0.537	rs987024	chr5:130337029	T/G	cg08523029	chr5:130500466	HINT1	-0.61	-5.08	-0.42	1.34e-6	Fasting plasma glucose;
TGCT	cis	rs9660992	0.674	rs1151785	chr1:205232299	C/T	cg00857998	chr1:205179979	DSTYK	0.52	4.56	0.38	1.19e-5	Mean corpuscular volume;Mean platelet volume;
TGCT	cis	rs6988636	1.000	rs61422480	chr8:124188940	C/A	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg08280861	chr8:58055591	NA	0.4	4.73	0.39	5.97e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6076065	0.707	rs12349	chr20:23352480	A/G	cg11657817	chr20:23433608	CST11	0.31	5.47	0.44	2.42e-7	Facial morphology (factor 15, philtrum width);
TGCT	cis	rs9905704	0.647	rs2108435	chr17:57102133	T/C	cg05425664	chr17:57184151	TRIM37	0.66	5.67	0.45	9.61e-8	Testicular germ cell tumor;
TGCT	cis	rs2996428	0.667	rs17412654	chr1:3758493	T/C	cg17848003	chr1:3704513	LRRC47	0.19	5.14	0.42	1.04e-6	Red cell distribution width;
TGCT	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg25036284	chr2:26402008	FAM59B	-0.57	-4.97	-0.41	2.15e-6	Gut microbiome composition (summer);
TGCT	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg27286337	chr10:134555280	INPP5A	0.39	4.73	0.39	6.02e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs6754311	0.773	rs1435576	chr2:136641882	A/T	cg07169764	chr2:136633963	MCM6	0.65	5.95	0.47	2.53e-8	Mosquito bite size;
TGCT	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg11644478	chr21:40555479	PSMG1	1.03	11.12	0.71	2.32e-20	Cognitive function;
TGCT	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg11062466	chr8:58055876	NA	0.38	4.56	0.38	1.23e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs259282	0.524	rs731674	chr19:33132395	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.62	5.81	0.46	4.86e-8	Schizophrenia;
TGCT	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg10802521	chr3:52805072	NEK4	-0.71	-8.79	-0.62	1.04e-14	Bipolar disorder;
TGCT	cis	rs739496	0.579	rs16941759	chr12:112367921	A/G	cg10833066	chr12:111807467	FAM109A	-0.39	-5.45	-0.44	2.61e-7	Platelet count;
TGCT	cis	rs35160687	0.842	rs7593440	chr2:86550657	T/C	cg03171300	chr2:86307199	POLR1A	-0.27	-4.81	-0.4	4.34e-6	Night sleep phenotypes;
TGCT	cis	rs6831352	0.918	rs4699712	chr4:100060490	A/T	cg12011299	chr4:100065546	ADH4	-0.43	-5.07	-0.41	1.38e-6	Alcohol dependence;
TGCT	cis	rs7085104	0.700	rs10883785	chr10:104603588	A/G	cg05855489	chr10:104503620	C10orf26	0.54	4.88	0.4	3.15e-6	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs12291225	0.637	rs8570	chr11:14300759	C/G	cg19336497	chr11:14380999	RRAS2	-0.38	-5.9	-0.47	3.23e-8	Sense of smell;
TGCT	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg08219700	chr8:58056026	NA	0.29	4.5	0.37	1.54e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2301436	0.512	rs6925969	chr6:167501738	C/A	cg07741184	chr6:167504864	NA	0.27	5.35	0.43	4.13e-7	Crohn's disease;
TGCT	cis	rs6752107	1.000	rs35300242	chr2:234168790	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.19	4.6	0.38	1.04e-5	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.7	0.52	6.47e-10	Bipolar disorder;
TGCT	trans	rs4719841	0.662	rs9639523	chr7:25991977	A/C	cg22329286	chr11:46761054	F2	0.3	6.75	0.52	5.02e-10	Triglyceride levels;
TGCT	cis	rs12048904	0.533	rs1590580	chr1:101292668	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.7	5.67	0.45	9.63e-8	Multiple sclerosis;
TGCT	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg11890956	chr21:40555474	PSMG1	1.11	12.39	0.74	1.95e-23	Cognitive function;
TGCT	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg11890956	chr21:40555474	PSMG1	1.06	11.97	0.73	2.05e-22	Cognitive function;
TGCT	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg13206674	chr6:150067644	NUP43	0.53	4.56	0.38	1.23e-5	Lung cancer;
TGCT	trans	rs1496653	0.602	rs71322183	chr3:23438121	T/C	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs4273100	0.646	rs2296981	chr17:19213335	C/G	cg03910582	chr17:19030146	GRAPL	-0.46	-5.09	-0.42	1.31e-6	Schizophrenia;
TGCT	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg27454412	chr7:1067447	C7orf50	0.62	4.67	0.39	7.67e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs10876993	0.890	rs1689597	chr12:58051886	G/A	cg15848620	chr12:58087721	OS9	-0.72	-5.82	-0.46	4.71e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs1971762	0.730	rs12830769	chr12:54087705	G/A	cg16917193	chr12:54089295	NA	0.6	4.5	0.37	1.54e-5	Height;
TGCT	cis	rs2276314	1.000	rs4799835	chr18:33571268	G/A	cg05985134	chr18:33552581	C18orf21	0.56	4.85	0.4	3.67e-6	Endometriosis;Drug-induced torsades de pointes;
TGCT	cis	rs9611565	0.918	rs4820438	chr22:41767135	C/T	cg17554472	chr22:41940697	POLR3H	-0.44	-4.47	-0.37	1.75e-5	Vitiligo;
TGCT	cis	rs3796352	1.000	rs11710292	chr3:53117798	T/C	cg07884673	chr3:53033167	SFMBT1	0.53	5.23	0.43	6.94e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs57590327	0.679	rs35942842	chr3:81588362	G/A	cg07356753	chr3:81810745	GBE1	-0.55	-4.54	-0.38	1.3e-5	Extraversion;
TGCT	cis	rs6815814	1.000	rs11722836	chr4:38811529	T/A	cg02016764	chr4:38805732	TLR1	-0.36	-5.71	-0.46	7.91e-8	Breast cancer;
TGCT	cis	rs1008375	0.800	rs35463363	chr4:17613423	G/T	cg18681998	chr4:17616180	MED28	0.98	9.34	0.64	5.05e-16	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4478858	0.735	rs6676682	chr1:31809816	C/T	cg07478791	chr1:31886160	SERINC2	-0.51	-4.95	-0.41	2.33e-6	Alcohol dependence;
TGCT	cis	rs7666738	0.830	rs60994860	chr4:99046753	G/A	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9611565	0.918	rs6002351	chr22:41757223	C/T	cg13695892	chr22:41940480	POLR3H	-0.85	-8.45	-0.6	6.59e-14	Vitiligo;
TGCT	cis	rs4820539	1.000	rs916584	chr22:23469433	A/G	cg21100191	chr22:23484243	RTDR1	0.89	10.51	0.69	7.38e-19	Bone mineral density;
TGCT	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg02725872	chr8:58115012	NA	-0.39	-5.15	-0.42	1.01e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg24531977	chr5:56204891	C5orf35	-0.76	-7.66	-0.57	4.53e-12	Initial pursuit acceleration;
TGCT	cis	rs7945705	0.738	rs11042067	chr11:8815453	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.41	-4.57	-0.38	1.16e-5	Hemoglobin concentration;
TGCT	cis	rs2243480	0.614	rs34032527	chr7:65565141	C/G	cg07424592	chr7:64974309	NA	1.26	8.11	0.59	4.17e-13	Diabetic kidney disease;
TGCT	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg23034840	chr1:205782522	SLC41A1	-0.67	-6.6	-0.51	1.07e-9	Monocyte percentage of white cells;
TGCT	cis	rs79349575	0.783	rs4793996	chr17:47019597	T/C	cg07967210	chr17:47022446	SNF8	0.44	6.13	0.48	1.1e-8	Type 2 diabetes;
TGCT	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg08280861	chr8:58055591	NA	0.36	4.93	0.4	2.61e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4499344	0.730	rs380320	chr19:33105904	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	8.84	0.62	7.71e-15	Mean platelet volume;
TGCT	cis	rs2271400	1.000	rs2271400	chr8:56791244	C/T	cg08417620	chr8:56013556	XKR4	-0.34	-4.49	-0.37	1.61e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;
TGCT	cis	rs13256369	0.590	rs10113115	chr8:8559588	A/G	cg17143192	chr8:8559678	CLDN23	0.49	4.44	0.37	1.97e-5	Obesity-related traits;
TGCT	cis	rs3027009	0.881	rs3026955	chr1:159144034	C/A	cg27303699	chr1:158224869	CD1A	-0.4	-4.59	-0.38	1.07e-5	Lean body mass and age at menarche (combined);
TGCT	cis	rs6570726	0.967	rs1396648	chr6:145785248	C/A	cg23711669	chr6:146136114	FBXO30	-0.68	-6.24	-0.49	6.2e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7698623	1.000	rs4693882	chr4:88752045	G/T	cg02735620	chr4:88950514	PKD2	0.4	4.83	0.4	3.96e-6	Cardiovascular disease risk factors;
TGCT	cis	rs644799	0.672	rs11021307	chr11:95501407	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.8	8.99	0.63	3.39e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	trans	rs797680	0.856	rs4847235	chr1:93627727	T/C	cg27528825	chr2:159282178	CCDC148	-0.35	-6.78	-0.52	4.27e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs6964587	1.000	rs733957	chr7:91707197	C/T	cg17063962	chr7:91808500	NA	0.88	9.65	0.66	8.73e-17	Breast cancer;
TGCT	cis	rs28735056	0.565	rs12957336	chr18:77716889	A/G	cg20368463	chr18:77673604	PQLC1	-0.46	-5.43	-0.44	2.83e-7	Schizophrenia;
TGCT	cis	rs7246657	0.943	rs10414904	chr19:37830088	G/A	cg03233940	chr19:37894644	NA	-0.34	-4.53	-0.38	1.34e-5	Coronary artery calcification;
TGCT	cis	rs6424115	0.830	rs2503000	chr1:24197898	C/G	cg15997130	chr1:24165203	NA	0.86	9.53	0.65	1.76e-16	Immature fraction of reticulocytes;
TGCT	cis	rs9549260	0.564	rs12184871	chr13:41291928	C/A	cg21288729	chr13:41239152	FOXO1	0.93	8.81	0.62	9.38e-15	Red blood cell count;
TGCT	cis	rs586688	1.000	rs1267121	chr1:201644262	C/A	cg05779441	chr1:201574716	NA	0.29	4.54	0.38	1.31e-5	Obesity-related traits;
TGCT	cis	rs7949030	0.626	rs1061093	chr11:62334908	G/C	cg13298116	chr11:62369859	EML3;MTA2	0.64	9.42	0.65	3.17e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs12220898	0.749	rs2377978	chr10:50476193	C/A	cg06072769	chr10:50146962	WDFY4	0.36	4.67	0.39	7.64e-6	Inflammatory biomarkers;
TGCT	cis	rs4788570	0.697	rs9635524	chr16:71804956	C/G	cg06353428	chr16:71660113	MARVELD3	1.53	12.59	0.75	6.48e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs3892630	0.878	rs7246451	chr19:33209614	C/G	cg22980127	chr19:33182716	NUDT19	0.7	5.1	0.42	1.25e-6	Red blood cell traits;
TGCT	cis	rs10032931	0.717	rs970689	chr4:96460537	A/G	cg03008707	chr4:96468962	UNC5C	-0.35	-4.71	-0.39	6.44e-6	Optic nerve measurement (cup-to-disc ratio);
TGCT	trans	rs17685	0.753	rs1859791	chr7:75786043	T/C	cg19862616	chr7:65841803	NCRNA00174	0.52	9.01	0.63	3.02e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs12693043	0.790	rs2033310	chr2:175409060	A/C	cg11778734	chr2:175439522	WIPF1	-0.37	-4.85	-0.4	3.6e-6	Urate levels (BMI interaction);
TGCT	trans	rs2760061	0.819	rs3094913	chr1:228206980	T/C	cg16006296	chr10:38738647	LOC399744	-0.31	-7.12	-0.54	7.75e-11	Diastolic blood pressure;
TGCT	cis	rs12510870	0.599	rs7676884	chr4:74449747	C/T	cg05868023	chr4:75230803	EREG	-0.54	-4.76	-0.39	5.33e-6	Iris color (b* coordinate);
TGCT	cis	rs7605378	0.964	rs2689763	chr2:200689555	G/A	cg23649088	chr2:200775458	C2orf69	0.35	5.83	0.46	4.53e-8	Osteoporosis;
TGCT	cis	rs514406	0.607	rs1930305	chr1:53195481	G/T	cg24675658	chr1:53192096	ZYG11B	0.84	10.45	0.68	1.03e-18	Monocyte count;
TGCT	cis	rs8056742	0.558	rs71386881	chr16:85005907	G/T	cg00229868	chr16:85520891	NA	0.37	4.64	0.38	8.75e-6	Amyotrophic lateral sclerosis;
TGCT	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	6.13	0.48	1.06e-8	Bipolar disorder;
TGCT	cis	rs4074961	0.565	rs4415526	chr1:38071728	T/C	cg17933807	chr1:38061675	GNL2	1.09	16.57	0.83	3.19e-33	Axial length;
TGCT	cis	rs9383153	1.000	rs2237223	chr6:16329741	G/A	cg14009473	chr6:15502099	JARID2	0.67	5.16	0.42	9.52e-7	Gambling;
TGCT	cis	rs1901167	0.908	rs14190	chr5:40982977	A/G	cg02441090	chr5:41871058	OXCT1	-0.31	-4.61	-0.38	9.86e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs7524258	0.868	rs10779678	chr1:7300573	A/G	cg07173049	chr1:7289937	CAMTA1	0.29	4.8	0.4	4.42e-6	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs6876348	0.598	rs2526252	chr5:128310259	C/G	cg25555059	chr5:128301488	SLC27A6	-0.28	-4.73	-0.39	5.94e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3820068	0.871	rs74539603	chr1:15809601	C/T	cg05660106	chr1:15850417	CASP9	1.13	11.01	0.7	4.37e-20	Systolic blood pressure;
TGCT	cis	rs2180341	0.618	rs6683	chr6:127610021	G/A	cg24812749	chr6:127587940	RNF146	0.63	5.33	0.43	4.51e-7	Breast cancer;
TGCT	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg27588902	chr6:42928151	GNMT	-0.5	-5.96	-0.47	2.49e-8	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs793571	0.523	rs12439457	chr15:58982390	T/C	cg05156742	chr15:59063176	FAM63B	0.49	4.51	0.38	1.45e-5	Schizophrenia;
TGCT	cis	rs3780378	0.875	rs7869668	chr9:5069837	G/A	cg02405213	chr9:5042618	JAK2	-0.63	-8.83	-0.62	8.54e-15	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs7666738	0.830	rs7679299	chr4:99057620	C/A	cg05340658	chr4:99064831	C4orf37	0.52	5.79	0.46	5.32e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7727544	0.606	rs17622208	chr5:131717050	G/A	cg24060327	chr5:131705240	SLC22A5	-0.52	-5.57	-0.45	1.52e-7	Blood metabolite levels;
TGCT	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg22433210	chr17:43662623	NA	1.04	7.37	0.55	2.07e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg08280861	chr8:58055591	NA	0.42	4.82	0.4	4.15e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7819412	0.538	rs4523214	chr8:10970773	T/A	cg27411982	chr8:10470053	RP1L1	-0.24	-5.32	-0.43	4.72e-7	Triglycerides;
TGCT	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg07507251	chr3:52567010	NT5DC2	0.47	6.7	0.52	6.47e-10	Bipolar disorder;
TGCT	cis	rs3733631	1.000	rs28650409	chr4:104628577	C/T	cg24090629	chr4:104641072	TACR3	-0.73	-5.81	-0.46	4.96e-8	Menarche (age at onset);
TGCT	cis	rs367615	0.704	rs7704824	chr5:108850278	A/G	cg17395555	chr5:108820864	NA	0.3	5.75	0.46	6.64e-8	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs12579753	0.956	rs7309624	chr12:82204266	C/A	cg07988820	chr12:82153109	PPFIA2	-0.65	-6.79	-0.52	4.09e-10	Resting heart rate;
TGCT	cis	rs78487399	0.808	rs17030925	chr2:43713808	A/C	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.76	4.69	0.39	7.06e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg22920501	chr2:26401640	FAM59B	0.81	6.36	0.5	3.52e-9	Gut microbiome composition (summer);
TGCT	cis	rs185694	0.652	rs1296549	chr13:30892055	A/T	cg07600127	chr13:30881527	KATNAL1	0.6	5.54	0.45	1.7e-7	Antineutrophil cytoplasmic antibody-associated vasculitis;
TGCT	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg12419862	chr22:24373484	LOC391322	-0.78	-7.5	-0.56	1.05e-11	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg22963979	chr7:1858916	MAD1L1	0.47	7.94	0.58	1.04e-12	Bipolar disorder and schizophrenia;
TGCT	cis	rs360798	0.512	rs2710637	chr2:63173450	G/A	cg17519650	chr2:63277830	OTX1	0.63	5.77	0.46	6.01e-8	Coronary artery disease;
TGCT	cis	rs8078723	0.677	rs11658328	chr17:38149236	T/C	cg17467752	chr17:38218738	THRA	-0.53	-5.37	-0.43	3.8e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs13191362	0.507	rs2023015	chr6:163060528	A/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.6	-5.48	-0.44	2.25e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	trans	rs1814175	0.645	rs1818895	chr11:50031523	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.84	-0.7	1.13e-19	Height;
TGCT	cis	rs11190604	1.000	rs10883501	chr10:102238326	A/G	cg23241863	chr10:102295624	HIF1AN	0.63	4.95	0.41	2.41e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9486719	1.000	rs12193732	chr6:96942609	G/A	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.86	-0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	trans	rs7618501	1.000	rs695238	chr3:49869158	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	1.03	13.16	0.76	2.65e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs7172809	0.524	rs4886852	chr15:77417173	A/T	cg22256960	chr15:77711686	NA	-0.47	-4.46	-0.37	1.83e-5	Glucose homeostasis traits;
TGCT	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg17911788	chr17:44343683	NA	-0.67	-7.15	-0.54	6.59e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs11098499	0.588	rs6534149	chr4:120559292	T/G	cg09307838	chr4:120376055	NA	-0.58	-5.38	-0.43	3.62e-7	Corneal astigmatism;
TGCT	cis	rs4803468	0.904	rs60781668	chr19:41944842	A/T	cg09537434	chr19:41945824	ATP5SL	0.91	10.21	0.68	3.82e-18	Height;
TGCT	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg13206674	chr6:150067644	NUP43	0.52	4.54	0.38	1.32e-5	Lung cancer;
TGCT	cis	rs6424115	0.708	rs13551	chr1:24180962	T/C	cg15997130	chr1:24165203	NA	-0.7	-7.02	-0.53	1.26e-10	Immature fraction of reticulocytes;
TGCT	cis	rs72945132	0.882	rs67244582	chr11:70122009	G/A	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs9486719	1.000	rs12212614	chr6:97036466	T/G	cg18709589	chr6:96969512	KIAA0776	-0.74	-5.21	-0.42	7.5e-7	Migraine;Coronary artery disease;
TGCT	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg24399712	chr22:39784796	NA	0.95	11.16	0.71	1.93e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs1800469	1.000	rs1549933	chr19:41871142	A/G	cg09537434	chr19:41945824	ATP5SL	-0.58	-5.26	-0.43	6.17e-7	Colorectal cancer;
TGCT	cis	rs514406	0.505	rs6688064	chr1:53165609	C/T	cg22166914	chr1:53195759	ZYG11B	0.44	7.66	0.57	4.64e-12	Monocyte count;
TGCT	cis	rs1208285	0.964	rs9389106	chr6:134150456	C/T	cg01805282	chr6:133563764	EYA4	0.4	4.44	0.37	2e-5	Infantile hypertrophic pyloric stenosis;
TGCT	cis	rs231513	0.638	rs79139991	chr17:42010359	C/T	cg26893861	chr17:41843967	DUSP3	0.82	5.03	0.41	1.67e-6	Cognitive function;
TGCT	cis	rs9549367	0.737	rs71446680	chr13:113894846	C/T	cg18105134	chr13:113819100	PROZ	-0.34	-5.58	-0.45	1.41e-7	Platelet distribution width;
TGCT	cis	rs34172651	0.517	rs189919	chr16:24737741	G/A	cg06028605	chr16:24865363	SLC5A11	-0.42	-4.53	-0.38	1.37e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs3806843	0.735	rs778595	chr5:140036681	G/A	cg19875535	chr5:140030758	IK	-0.37	-6.25	-0.49	6.12e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.0	7.42	0.55	1.64e-11	Gut microbiome composition (summer);
TGCT	cis	rs7175404	0.591	rs75029049	chr15:94061120	C/T	cg18324227	chr15:93584571	NA	0.49	4.56	0.38	1.2e-5	Attention deficit hyperactivity disorder;
TGCT	cis	rs7528684	0.768	rs6675393	chr1:157734907	C/T	cg17134153	chr1:157670328	FCRL3	-0.28	-4.95	-0.41	2.37e-6	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;
TGCT	cis	rs13242816	1.000	rs12706090	chr7:116104045	A/G	cg02799643	chr7:116139180	CAV2	0.45	5.37	0.43	3.77e-7	P wave duration;
TGCT	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg26513180	chr16:89883248	FANCA	1.07	14.96	0.8	1.48e-29	Vitiligo;
TGCT	cis	rs1857353	1.000	rs80337562	chr1:75878243	A/T	cg11838876	chr1:75668600	SLC44A5	-0.47	-4.56	-0.38	1.2e-5	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs4786125	0.636	rs8062299	chr16:6902722	T/C	cg03623568	chr16:6915990	A2BP1	-0.42	-6.12	-0.48	1.13e-8	Heart rate variability traits (SDNN);
TGCT	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg13628971	chr7:2884303	GNA12	0.58	4.61	0.38	1e-5	Height;
TGCT	cis	rs6987853	0.966	rs1947297	chr8:42453023	A/G	cg20539142	chr8:42623718	CHRNA6	-0.2	-5.0	-0.41	1.95e-6	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg22764044	chr5:178986830	RUFY1	-0.49	-5.61	-0.45	1.23e-7	Lung cancer;
TGCT	cis	rs7044106	0.762	rs1547267	chr9:123408736	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	4.75	0.39	5.55e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs7552404	0.627	rs12127049	chr1:76353248	G/A	cg10523679	chr1:76189770	ACADM	0.84	7.63	0.57	5.26e-12	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg10150615	chr22:24372951	LOC391322	-1.01	-13.12	-0.76	3.43e-25	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2677744	0.534	rs6496739	chr15:91494430	C/T	cg22570213	chr15:91497863	RCCD1	0.42	5.08	0.41	1.37e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs6426558	0.537	rs2813969	chr1:227404082	T/C	cg10327440	chr1:227177885	CDC42BPA	0.59	6.81	0.52	3.72e-10	Neutrophil percentage of white cells;
TGCT	cis	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg03213289	chr20:61660250	NA	0.68	9.99	0.67	1.36e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs75686122	0.655	rs74969771	chr8:104636083	C/T	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs7260538	0.509	rs10420194	chr19:41529781	A/T	cg27089200	chr19:41531976	NA	0.52	6.7	0.52	6.45e-10	DDT metabolite (p,p'-DDE levels);
TGCT	cis	rs2982552	0.873	rs3020308	chr6:152068685	A/G	cg22157087	chr6:152012887	ESR1	0.2	4.77	0.39	5e-6	Bone properties (heel);
TGCT	cis	rs1775715	0.737	rs2799012	chr10:32103077	C/T	cg14930904	chr10:32216787	ARHGAP12	0.52	5.07	0.41	1.38e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs2067615	0.524	rs10778499	chr12:107068387	C/T	cg15890332	chr12:107067104	RFX4	0.29	5.77	0.46	5.9e-8	Heart rate;
TGCT	cis	rs6831352	0.918	rs13112733	chr4:100050319	A/T	cg12011299	chr4:100065546	ADH4	-0.41	-4.92	-0.4	2.72e-6	Alcohol dependence;
TGCT	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg06108461	chr20:60628389	TAF4	0.39	4.8	0.4	4.51e-6	Obesity-related traits;
TGCT	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.49	-7.0	-0.53	1.4e-10	Alzheimer's disease;
TGCT	cis	rs3806843	1.000	rs10066278	chr5:140156318	A/C	cg19875535	chr5:140030758	IK	0.37	6.23	0.49	6.53e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs6815814	0.950	rs56357984	chr4:38806462	G/A	cg02016764	chr4:38805732	TLR1	-0.34	-5.27	-0.43	5.82e-7	Breast cancer;
TGCT	cis	rs1801251	1.000	rs2674839	chr2:233669040	G/C	cg25237894	chr2:233734115	C2orf82	0.33	5.95	0.47	2.53e-8	Coronary artery disease;
TGCT	cis	rs2228479	0.850	rs11644804	chr16:89976224	G/A	cg06558623	chr16:89946397	TCF25	0.56	6.55	0.51	1.4e-9	Skin colour saturation;
TGCT	cis	rs6728642	0.808	rs113319086	chr2:97633267	G/C	cg26665480	chr2:98280029	ACTR1B	-0.96	-5.36	-0.43	3.91e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	cis	rs7027203	0.828	rs10761287	chr9:96609150	A/G	cg14598338	chr9:96623480	NA	-0.61	-9.54	-0.65	1.68e-16	DNA methylation (variation);
TGCT	cis	rs593982	0.688	rs55971008	chr11:65395860	G/A	cg08755490	chr11:65554678	OVOL1	-1.06	-5.22	-0.42	7.44e-7	Atopic dermatitis;
TGCT	trans	rs3780486	0.757	rs10121987	chr9:33119818	A/G	cg04842962	chr6:43655489	MRPS18A	1.23	15.13	0.81	6e-30	IgG glycosylation;
TGCT	cis	rs6671200	0.790	rs259357	chr1:95711478	G/T	cg26537280	chr1:95699037	RWDD3	-0.7	-5.55	-0.45	1.62e-7	Stearic acid (18:0) levels;
TGCT	cis	rs1061377	1.000	rs7655122	chr4:39122016	A/G	cg24403649	chr4:39172243	NA	0.18	4.44	0.37	1.99e-5	Uric acid levels;
TGCT	cis	rs9467773	0.583	rs2498380	chr6:26643996	C/G	cg02458000	chr6:26745757	NA	-0.55	-5.3	-0.43	5.12e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2153535	0.580	rs6938071	chr6:8464845	A/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.67	0.45	9.42e-8	Motion sickness;
TGCT	cis	rs7208859	0.623	rs426434	chr17:28925353	C/T	cg04154034	chr17:28927549	LRRC37B2	0.86	4.95	0.41	2.35e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs265548	0.646	rs36692	chr19:17906839	C/T	cg03316864	chr19:17906309	B3GNT3	0.44	5.24	0.43	6.81e-7	Tumor biomarkers;
TGCT	cis	rs1472147	1.000	rs4323418	chr7:128506970	C/T	cg05395852	chr7:128750384	NA	-0.17	-5.45	-0.44	2.62e-7	Calcium levels;
TGCT	trans	rs8073060	0.586	rs2523114	chr17:34023762	G/A	cg19694781	chr19:47549865	TMEM160	-0.6	-13.37	-0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs910187	0.678	rs8115769	chr20:45813704	A/C	cg27589058	chr20:45804311	EYA2	-0.35	-7.6	-0.56	6.23e-12	Migraine;
TGCT	cis	rs10927875	0.550	rs12121918	chr1:16183556	C/A	cg21385522	chr1:16154831	NA	-0.91	-9.29	-0.64	6.69e-16	Dilated cardiomyopathy;
TGCT	cis	rs4851266	0.898	rs12614880	chr2:100849341	A/G	cg07810366	chr2:100720526	AFF3	-0.34	-4.6	-0.38	1.05e-5	Educational attainment;
TGCT	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg23758822	chr17:41437982	NA	0.69	6.37	0.5	3.34e-9	Menopause (age at onset);
TGCT	cis	rs1903068	0.657	rs2239702	chr4:55992139	C/T	cg09978860	chr4:56023921	NA	0.52	5.29	0.43	5.46e-7	Endometriosis;
TGCT	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs12908161	0.959	rs61074241	chr15:85333396	C/T	cg11189052	chr15:85197271	WDR73	0.71	5.83	0.46	4.42e-8	Schizophrenia;
TGCT	cis	rs12210905	1.000	rs12209456	chr6:27085225	C/T	cg08851530	chr6:28072375	NA	1.21	5.58	0.45	1.43e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs7267979	1.000	rs6115191	chr20:25440478	C/T	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs13394619	0.775	rs10165819	chr2:11722102	A/T	cg07314298	chr2:11723111	GREB1	-0.29	-4.98	-0.41	2.09e-6	Endometriosis;
TGCT	cis	rs9814567	0.752	rs4318591	chr3:134328333	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-6.41	-0.5	2.8e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg18876405	chr7:65276391	NA	-0.33	-5.05	-0.41	1.52e-6	Aortic root size;
TGCT	cis	rs17122693	0.551	rs2934683	chr14:51058511	C/T	cg04730355	chr14:51134070	SAV1	1.19	12.02	0.73	1.56e-22	Cognitive performance;
TGCT	cis	rs17152411	1.000	rs12569940	chr10:126592684	T/C	cg07906193	chr10:126599966	NA	0.42	5.16	0.42	9.36e-7	Height;
TGCT	cis	rs9517320	1.000	rs7994160	chr13:99132749	C/A	cg07423050	chr13:99094983	FARP1	0.23	4.58	0.38	1.11e-5	Longevity;
TGCT	cis	rs7267979	0.933	rs2261109	chr20:25259200	T/C	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs28595532	0.920	rs56303276	chr4:119723514	C/T	cg14228332	chr4:119757509	SEC24D	1.38	6.91	0.53	2.21e-10	Cannabis dependence symptom count;
TGCT	cis	rs7208859	0.524	rs57670615	chr17:29069498	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	4.87	0.4	3.36e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs981844	0.601	rs1337	chr4:154631587	C/G	cg14289246	chr4:154710475	SFRP2	1.05	8.41	0.6	8.3e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs7666738	0.830	rs11725095	chr4:99009711	T/A	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6912958	0.781	rs7742965	chr6:88278196	T/C	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.91	-0.4	2.78e-6	Monocyte percentage of white cells;
TGCT	cis	rs854765	0.663	rs12941550	chr17:17753828	C/A	cg09796270	chr17:17721594	SREBF1	-0.26	-4.88	-0.4	3.13e-6	Total body bone mineral density;
TGCT	cis	rs7681440	0.874	rs1442154	chr4:90775761	C/G	cg14346243	chr4:90757452	SNCA	-0.56	-5.47	-0.44	2.41e-7	Dementia with Lewy bodies;
TGCT	cis	rs2014572	0.967	rs10418480	chr19:57755055	C/T	cg24459738	chr19:57751996	ZNF805	-0.54	-5.4	-0.44	3.21e-7	Hyperactive-impulsive symptoms;
TGCT	trans	rs7819412	0.668	rs2409694	chr8:10946861	T/G	cg15556689	chr8:8085844	FLJ10661	-0.78	-6.86	-0.52	2.91e-10	Triglycerides;
TGCT	cis	rs3091242	0.933	rs35530120	chr1:25785451	A/G	cg10117171	chr1:25599238	RHD	0.3	4.79	0.39	4.76e-6	Erythrocyte sedimentation rate;
TGCT	trans	rs10506458	0.834	rs17738403	chr12:63389200	A/G	cg22491629	chr6:157744540	C6orf35	-0.99	-8.5	-0.61	5.08e-14	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.1	0.54	8.35e-11	Prudent dietary pattern;
TGCT	cis	rs208515	0.525	rs10944863	chr6:66676238	C/T	cg07460842	chr6:66804631	NA	0.87	9.16	0.64	1.32e-15	Exhaled nitric oxide levels;
TGCT	cis	rs4073582	0.595	rs801737	chr11:65928193	T/C	cg16950941	chr11:66035639	RAB1B	0.55	5.42	0.44	2.94e-7	Gout;
TGCT	cis	rs62244186	0.659	rs9855433	chr3:44468065	C/A	cg04389838	chr3:44770851	ZNF501	-0.41	-5.47	-0.44	2.33e-7	Depressive symptoms;
TGCT	trans	rs1974653	0.672	rs75967927	chr22:20068496	C/T	cg08822737	chr17:71088851	SLC39A11	-0.93	-7.61	-0.56	5.97e-12	Schizophrenia;
TGCT	cis	rs8026198	0.568	rs58712247	chr15:42616288	C/CA	cg20584732	chr15:42349694	NA	0.45	4.53	0.38	1.39e-5	Fibrinogen levels;
TGCT	cis	rs6964587	1.000	rs10270598	chr7:91700827	T/C	cg17063962	chr7:91808500	NA	0.88	9.65	0.66	8.73e-17	Breast cancer;
TGCT	cis	rs76419734	1.000	rs11726094	chr4:106773387	G/T	cg24545054	chr4:106630052	GSTCD;INTS12	1.09	4.45	0.37	1.9e-5	Post bronchodilator FEV1;
TGCT	cis	rs941408	1.000	rs941406	chr19:2803623	A/G	cg06609049	chr19:2785107	THOP1	0.85	7.34	0.55	2.49e-11	Total cholesterol levels;
TGCT	cis	rs3099143	1.000	rs1114717	chr15:77086078	A/G	cg21673338	chr15:77095150	SCAPER	0.51	5.12	0.42	1.11e-6	Recalcitrant atopic dermatitis;
TGCT	cis	rs992157	0.835	rs13005100	chr2:219151767	C/T	cg00012203	chr2:219082015	ARPC2	-0.8	-7.98	-0.58	8.26e-13	Colorectal cancer;
TGCT	trans	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg27523141	chr10:43048294	ZNF37B	0.74	8.61	0.61	2.7e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7681440	0.874	rs1442151	chr4:90775491	T/A	cg26578617	chr4:90757533	SNCA	-0.44	-4.54	-0.38	1.31e-5	Dementia with Lewy bodies;
TGCT	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg11644478	chr21:40555479	PSMG1	1.03	11.02	0.7	4.14e-20	Cognitive function;
TGCT	cis	rs7937682	0.710	rs674230	chr11:111437887	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.98	-10.12	-0.67	6.37e-18	Primary sclerosing cholangitis;
TGCT	cis	rs35306767	0.903	rs12769002	chr10:927666	C/G	cg26597838	chr10:835615	NA	-0.85	-12.57	-0.75	7.33e-24	Eosinophil percentage of granulocytes;
TGCT	cis	rs35146811	0.735	rs2272345	chr7:99797031	C/G	cg22906224	chr7:99728672	NA	0.49	4.45	0.37	1.88e-5	Coronary artery disease;
TGCT	cis	rs7552404	0.731	rs11588578	chr1:76400539	T/G	cg03433033	chr1:76189801	ACADM	0.75	7.14	0.54	6.77e-11	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs13191362	1.000	rs35092540	chr6:163090778	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.99	8.05	0.59	5.69e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs9916302	0.605	rs2879258	chr17:37399379	G/T	cg07936489	chr17:37558343	FBXL20	-0.86	-6.14	-0.48	1.02e-8	Glomerular filtration rate (creatinine);
TGCT	cis	rs7666738	0.830	rs6854902	chr4:99033416	T/G	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7666738	0.830	rs62318503	chr4:98935479	T/C	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs919433	0.680	rs2605039	chr2:198362851	C/A	cg00792783	chr2:198669748	PLCL1	0.52	4.77	0.39	4.99e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs9443645	0.901	rs55755815	chr6:79607121	G/T	cg05283184	chr6:79620031	NA	-0.21	-4.71	-0.39	6.61e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7584330	0.666	rs72620816	chr2:238353604	C/T	cg14458575	chr2:238380390	NA	0.55	8.09	0.59	4.56e-13	Prostate cancer;
TGCT	cis	rs12497850	0.931	rs6791542	chr3:48787219	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.41	-5.49	-0.44	2.15e-7	Parkinson's disease;
TGCT	cis	rs80282103	0.764	rs12247779	chr10:1107957	T/G	cg08668510	chr10:1095578	IDI1	1.07	5.3	0.43	5.01e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs4654899	0.802	rs6685306	chr1:21219050	C/T	cg01072550	chr1:21505969	NA	-0.46	-6.94	-0.53	1.96e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg17971929	chr21:40555470	PSMG1	-0.5	-4.55	-0.38	1.25e-5	Menarche (age at onset);
TGCT	cis	rs11098499	0.954	rs13133522	chr4:120324424	A/T	cg09307838	chr4:120376055	NA	0.68	6.53	0.51	1.54e-9	Corneal astigmatism;
TGCT	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.73	-4.58	-0.38	1.11e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs12142240	0.698	rs17357676	chr1:46812444	A/G	cg00530320	chr1:46809349	NSUN4	0.29	5.84	0.46	4.33e-8	Menopause (age at onset);
TGCT	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg24531977	chr5:56204891	C5orf35	-0.76	-7.66	-0.57	4.53e-12	Initial pursuit acceleration;
TGCT	trans	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg20587970	chr11:113659929	NA	-1.03	-10.98	-0.7	5.21e-20	Hip circumference adjusted for BMI;
TGCT	cis	rs10871290	1.000	rs10871290	chr16:74472696	C/T	cg01733217	chr16:74700730	RFWD3	-0.52	-4.77	-0.39	5.01e-6	Breast cancer;
TGCT	trans	rs77457752	0.690	rs17224436	chr9:13912875	C/T	cg12973904	chr7:149457885	NA	-0.5	-7.47	-0.56	1.24e-11	Breast cancer;
TGCT	cis	rs77972916	0.517	rs17406126	chr2:43546632	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.4	-4.69	-0.39	7.07e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs2115630	0.818	rs7176522	chr15:85215383	C/G	cg12501888	chr15:85177176	SCAND2	-0.47	-4.44	-0.37	1.96e-5	P wave terminal force;
TGCT	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg13395646	chr4:1353034	KIAA1530	-0.39	-5.19	-0.42	8.46e-7	Obesity-related traits;
TGCT	cis	rs9611565	0.729	rs505533	chr22:41864216	A/C	cg17554472	chr22:41940697	POLR3H	0.46	5.0	0.41	1.89e-6	Vitiligo;
TGCT	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	5.23	0.43	6.92e-7	Menopause (age at onset);
TGCT	cis	rs7772486	0.655	rs2142981	chr6:146071695	G/C	cg23711669	chr6:146136114	FBXO30	-0.97	-11.03	-0.7	4.03e-20	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-5.79	-0.46	5.39e-8	Alzheimer's disease;
TGCT	cis	rs9611565	0.921	rs3927	chr22:41722864	A/G	cg17554472	chr22:41940697	POLR3H	-0.42	-4.7	-0.39	6.85e-6	Vitiligo;
TGCT	cis	rs3806843	0.735	rs801188	chr5:140066916	G/T	cg19875535	chr5:140030758	IK	-0.37	-6.25	-0.49	6.12e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs651907	0.557	rs36002990	chr3:101437862	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.33	-6.78	-0.52	4.35e-10	Colorectal cancer;
TGCT	cis	rs3617	0.625	rs11719137	chr3:52876389	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.48	-4.53	-0.38	1.35e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg27425262	chr2:113953981	PSD4;LOC440839	-0.52	-8.2	-0.59	2.52e-13	Lymphocyte counts;
TGCT	cis	rs67311347	1.000	rs12633431	chr3:40505740	C/T	cg17264618	chr3:40429014	ENTPD3	-0.32	-4.64	-0.38	8.57e-6	Renal cell carcinoma;
TGCT	cis	rs79349575	0.783	rs62078372	chr17:47028989	T/C	cg26022315	chr17:47021804	SNF8	0.49	4.9	0.4	2.94e-6	Type 2 diabetes;
TGCT	cis	rs66573146	1.000	rs66712119	chr4:6965428	A/T	cg01220768	chr4:7056774	TADA2B	0.35	4.63	0.38	8.96e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs7267979	1.000	rs6083804	chr20:25317060	A/G	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4819052	0.851	rs7275468	chr21:46656499	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	6.32	0.49	4.3e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9611565	0.879	rs5758307	chr22:41750219	A/G	cg02107564	chr22:41488750	EP300	-0.56	-4.54	-0.38	1.29e-5	Vitiligo;
TGCT	cis	rs727563	0.635	rs5758444	chr22:42133921	T/A	cg06634786	chr22:41940651	POLR3H	0.87	8.12	0.59	3.86e-13	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs9467773	0.620	rs1027203	chr6:26639332	G/C	cg05738196	chr6:26577821	NA	0.86	10.49	0.69	8.31e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg03517284	chr6:25882590	NA	-0.94	-9.09	-0.63	1.98e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs546131	0.642	rs508062	chr11:34843820	C/G	cg06937548	chr11:34938143	PDHX;APIP	0.54	4.75	0.39	5.54e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg09033563	chr22:24373618	LOC391322	-0.48	-4.71	-0.39	6.57e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs12908161	1.000	rs62019469	chr15:85321220	T/C	cg12863693	chr15:85201151	NMB	0.43	5.12	0.42	1.15e-6	Schizophrenia;
TGCT	cis	rs7072216	0.763	rs2147901	chr10:100165496	A/C	cg26618903	chr10:100175079	PYROXD2	0.4	4.51	0.38	1.49e-5	Metabolite levels;
TGCT	cis	rs1153858	0.832	rs1145078	chr15:45682277	C/T	cg14582100	chr15:45693742	SPATA5L1	0.48	5.68	0.45	9.02e-8	Homoarginine levels;
TGCT	cis	rs13191362	1.000	rs35575481	chr6:163007746	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs2806561	0.704	rs6680974	chr1:23376233	A/G	cg12483005	chr1:23474871	LUZP1	0.38	4.76	0.39	5.34e-6	Height;
TGCT	cis	rs11172134	0.508	rs1800181	chr12:57578288	C/T	cg19258868	chr12:57585184	LRP1	-0.32	-6.09	-0.48	1.32e-8	Urate levels in overweight individuals;
TGCT	cis	rs7584330	0.554	rs7587496	chr2:238387632	A/G	cg14458575	chr2:238380390	NA	0.58	5.05	0.41	1.53e-6	Prostate cancer;
TGCT	cis	rs9467773	0.587	rs3208733	chr6:26414425	C/T	cg15659132	chr6:26577336	NA	-0.43	-4.52	-0.38	1.45e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs10782582	0.609	rs1630302	chr1:76412090	A/T	cg10523679	chr1:76189770	ACADM	-0.57	-5.14	-0.42	1.04e-6	Daytime sleep phenotypes;
TGCT	cis	rs10751667	0.666	rs7395402	chr11:950293	A/G	cg06064525	chr11:970664	AP2A2	0.34	7.82	0.57	2.02e-12	Alzheimer's disease (late onset);
TGCT	cis	rs644799	0.623	rs17207890	chr11:95490754	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	7.47	0.56	1.27e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs17376456	0.825	rs10056879	chr5:93282218	C/A	cg25358565	chr5:93447407	FAM172A	1.01	6.35	0.5	3.72e-9	Diabetic retinopathy;
TGCT	cis	rs6570726	0.846	rs870491	chr6:145933390	T/G	cg05347473	chr6:146136440	FBXO30	0.5	4.61	0.38	9.8200000000000008e-06	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg13695892	chr22:41940480	POLR3H	-0.91	-9.07	-0.63	2.18e-15	Vitiligo;
TGCT	cis	rs2440129	0.632	rs13396	chr17:6905624	T/C	cg19536664	chr17:6899085	ALOX12	0.39	6.1	0.48	1.23e-8	Tonsillectomy;
TGCT	trans	rs2688608	0.592	rs2306328	chr10:75579510	C/T	cg13918328	chr10:52500089	ASAH2B	0.7	7.07	0.54	9.81e-11	Inflammatory bowel disease;
TGCT	cis	rs4972806	0.849	rs2071581	chr2:177026148	G/T	cg13092806	chr2:177043255	NA	0.56	4.85	0.4	3.6e-6	IgG glycosylation;
TGCT	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg22433210	chr17:43662623	NA	1.04	7.25	0.55	3.96e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2692947	0.673	rs2692894	chr2:96784934	T/G	cg23100626	chr2:96804247	ASTL	-0.44	-5.21	-0.42	7.78e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs7267979	0.932	rs2387891	chr20:25470328	C/G	cg14121845	chr20:25566513	NINL	0.49	5.36	0.43	3.83e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9467773	1.000	rs10946835	chr6:26533757	C/T	cg05738196	chr6:26577821	NA	0.88	12.5	0.75	1.03e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs7412746	0.658	rs6658066	chr1:150918937	T/G	cg09365446	chr1:150670422	GOLPH3L	0.34	4.71	0.39	6.58e-6	Melanoma;
TGCT	cis	rs9318086	0.712	rs12875437	chr13:24453956	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.77	8.25	0.6	1.99e-13	Myopia (pathological);
TGCT	cis	rs10484885	0.824	rs72921954	chr6:90586656	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.47	-4.58	-0.38	1.11e-5	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg13699009	chr12:122356056	WDR66	0.29	6.56	0.51	1.32e-9	Mean corpuscular volume;
TGCT	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.04	0.53	1.16e-10	Prudent dietary pattern;
TGCT	cis	rs9486719	1.000	rs12197411	chr6:97039621	G/A	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.32	-0.6	1.32e-13	Migraine;Coronary artery disease;
TGCT	cis	rs16866061	0.515	rs1027340	chr2:225370554	C/A	cg12698349	chr2:225449008	CUL3	1.12	15.51	0.81	8.08e-31	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	cis	rs28595532	0.920	rs115500312	chr4:119752551	G/A	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs11249608	0.548	rs11951738	chr5:178491228	G/A	cg21905437	chr5:178450457	ZNF879	0.45	4.64	0.38	8.87e-6	Pubertal anthropometrics;
TGCT	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	6.06	0.48	1.52e-8	Alzheimer's disease;
TGCT	cis	rs7666738	0.830	rs7664051	chr4:98766970	C/G	cg18180107	chr4:99064573	C4orf37	0.53	5.07	0.41	1.38e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6912958	0.559	rs446851	chr6:88043640	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.4	4.7	0.39	6.83e-6	Monocyte percentage of white cells;
TGCT	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg24250549	chr1:154909240	PMVK	0.55	5.18	0.42	8.74e-7	Prostate cancer;
TGCT	cis	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg18188782	chr20:61659543	NA	0.44	5.38	0.43	3.6e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9811920	0.809	rs4928150	chr3:99685991	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.44	-4.83	-0.4	3.88e-6	Axial length;
TGCT	cis	rs7208859	0.673	rs73263981	chr17:28920502	A/G	cg19761014	chr17:28927070	LRRC37B2	0.56	4.81	0.4	4.32e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs11190604	0.767	rs10883478	chr10:102162852	C/T	cg16005271	chr10:102321736	NA	0.45	4.74	0.39	5.87e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg06636001	chr8:8085503	FLJ10661	0.65	5.8	0.46	5.26e-8	Mood instability;
TGCT	cis	rs904251	0.523	rs1757191	chr6:37482871	C/T	cg25019722	chr6:37503610	NA	-0.52	-7.9	-0.58	1.28e-12	Cognitive performance;
TGCT	cis	rs1011108	1.000	rs1011108	chr2:26782621	A/G	cg18742855	chr2:26800399	C2orf70	-0.26	-5.77	-0.46	6.07e-8	Periodontal microbiota;
TGCT	cis	rs7621025	0.500	rs12629000	chr3:136643571	T/A	cg15507776	chr3:136538369	TMEM22	0.67	6.26	0.49	5.69e-9	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
TGCT	cis	rs9486719	0.843	rs3860230	chr6:97036560	T/A	cg06623918	chr6:96969491	KIAA0776	-1.03	-10.2	-0.68	4.18e-18	Migraine;Coronary artery disease;
TGCT	cis	rs7017914	0.905	rs3110249	chr8:71935545	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.55	-5.03	-0.41	1.68e-6	Bone mineral density;
TGCT	cis	rs16958440	0.867	rs117060920	chr18:44709035	G/A	cg17192377	chr18:44677553	HDHD2	0.65	4.64	0.38	8.62e-6	Sitting height ratio;
TGCT	cis	rs60154123	0.505	rs7540237	chr1:210053325	C/T	cg22029157	chr1:209979665	IRF6	0.76	5.52	0.44	1.89e-7	Coronary artery disease;
TGCT	cis	rs1124376	0.688	rs11715447	chr3:20140129	A/C	cg05072819	chr3:20081367	KAT2B	0.81	5.51	0.44	2.02e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs7103648	0.669	rs7131262	chr11:47836302	T/A	cg20307385	chr11:47447363	PSMC3	0.77	7.37	0.55	2.1e-11	Diastolic blood pressure;Systolic blood pressure;
TGCT	cis	rs910316	0.967	rs4903293	chr14:75656568	A/G	cg08847533	chr14:75593920	NEK9	-0.91	-9.71	-0.66	6.33e-17	Height;
TGCT	trans	rs9859260	0.710	rs366268	chr3:195782177	A/G	cg17074656	chr11:63784126	MACROD1	0.52	6.67	0.51	7.49e-10	Mean corpuscular volume;
TGCT	cis	rs12477438	0.798	rs9308816	chr2:99637230	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.68	-5.84	-0.46	4.27e-8	Chronic sinus infection;
TGCT	cis	rs992157	0.764	rs62183964	chr2:219186592	G/A	cg00012203	chr2:219082015	ARPC2	0.7	6.58	0.51	1.16e-9	Colorectal cancer;
TGCT	cis	rs1334894	1.000	rs2294807	chr6:35555110	C/T	cg24281267	chr6:35479648	TULP1	-0.43	-4.47	-0.37	1.78e-5	Coronary artery disease;
TGCT	cis	rs7914558	0.932	rs4307650	chr10:104959852	C/A	cg05855489	chr10:104503620	C10orf26	0.52	4.59	0.38	1.06e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs10744422	0.562	rs10847775	chr12:123298221	G/A	cg18912006	chr12:123335444	HIP1R	0.56	4.78	0.39	4.84e-6	Schizophrenia;
TGCT	cis	rs9303401	0.661	rs9902820	chr17:56637545	A/C	cg12560992	chr17:57184187	TRIM37	0.6	6.5	0.5	1.74e-9	Cognitive test performance;
TGCT	cis	rs12220898	0.679	rs4582889	chr10:50475014	A/C	cg09603381	chr10:49954066	WDFY4	0.38	4.45	0.37	1.85e-5	Inflammatory biomarkers;
TGCT	cis	rs11578119	0.806	rs12409985	chr1:170377564	G/A	cg09767346	chr1:170501363	GORAB	0.72	5.78	0.46	5.76e-8	Male-pattern baldness;
TGCT	cis	rs10791097	0.739	rs4936120	chr11:130723452	G/A	cg05962950	chr11:130786565	SNX19	0.83	9.85	0.66	2.99e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs908922	0.651	rs4240886	chr1:152530396	A/T	cg20991723	chr1:152506922	NA	-0.45	-6.05	-0.48	1.6e-8	Hair morphology;
TGCT	trans	rs9951602	0.512	rs9304070	chr18:76654890	A/C	cg02800362	chr5:177631904	HNRNPAB	1.1	12.7	0.75	3.48e-24	Obesity-related traits;
TGCT	cis	rs11249608	0.548	rs17078988	chr5:178459283	A/G	cg23951258	chr5:178450506	ZNF879	0.43	4.53	0.38	1.37e-5	Pubertal anthropometrics;
TGCT	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg23758822	chr17:41437982	NA	0.73	6.74	0.52	5.43e-10	Menopause (age at onset);
TGCT	cis	rs9486719	0.948	rs11152952	chr6:96894303	A/G	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.21	-0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg03303774	chr4:1407052	NA	0.31	4.93	0.4	2.58e-6	Obesity-related traits;
TGCT	cis	rs208520	0.690	rs6932475	chr6:66863155	G/A	cg07460842	chr6:66804631	NA	-0.92	-9.58	-0.65	1.29e-16	Exhaled nitric oxide output;
TGCT	cis	rs9814567	1.000	rs4368544	chr3:134300014	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.95	8.76	0.62	1.21e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs138229	0.506	rs138233	chr22:50559953	G/A	cg08875078	chr22:50639485	SELO	0.56	4.59	0.38	1.07e-5	Behavioural disinhibition (generation interaction);
TGCT	cis	rs2224391	0.590	rs72813693	chr6:5273464	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-1.0	-5.18	-0.42	8.9e-7	Height;
TGCT	cis	rs10504229	0.679	rs7840100	chr8:58036662	T/G	cg08280861	chr8:58055591	NA	0.35	4.98	0.41	2.11e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs62064224	0.791	rs2344977	chr17:30720573	C/G	cg18200150	chr17:30822561	MYO1D	0.62	8.41	0.6	8.08e-14	Schizophrenia;
TGCT	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg08280861	chr8:58055591	NA	0.36	4.98	0.41	2.1e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7474896	0.583	rs10827817	chr10:37997974	A/G	cg13720705	chr10:37990370	NA	0.31	4.72	0.39	6.33e-6	Obesity (extreme);
TGCT	cis	rs9527	0.590	rs12246739	chr10:104787019	A/C	cg15744005	chr10:104629667	AS3MT	0.47	5.35	0.43	4.16e-7	Arsenic metabolism;
TGCT	cis	rs9916302	0.904	rs8077104	chr17:37530510	A/G	cg15445000	chr17:37608096	MED1	-0.33	-4.71	-0.39	6.46e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs11677370	0.603	rs10198219	chr2:3854600	T/C	cg17052675	chr2:3827356	NA	-0.43	-6.92	-0.53	2.15e-10	Type 2 diabetes;
TGCT	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	6.73	0.52	5.61e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg10207240	chr12:122356781	WDR66	0.34	4.65	0.39	8.21e-6	Mean corpuscular volume;
TGCT	cis	rs7666738	0.830	rs13138059	chr4:99050430	A/G	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs62380364	0.870	rs4145738	chr5:88150289	G/A	cg22951263	chr5:87985283	NA	-0.48	-4.62	-0.38	9.39e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9916302	0.904	rs7503069	chr17:37697128	C/G	cg15445000	chr17:37608096	MED1	0.31	4.5	0.37	1.53e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs2120019	0.938	rs8033925	chr15:75311959	A/G	cg17294928	chr15:75287854	SCAMP5	-0.79	-6.27	-0.49	5.46e-9	Blood trace element (Zn levels);
TGCT	cis	rs9467773	1.000	rs1535277	chr6:26567802	G/T	cg26531700	chr6:26746687	NA	0.5	4.85	0.4	3.64e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1971762	0.762	rs7312853	chr12:54073597	C/G	cg16917193	chr12:54089295	NA	-0.6	-4.85	-0.4	3.7e-6	Height;
TGCT	cis	rs9393692	1.000	rs3999544	chr6:26285867	C/T	cg00631329	chr6:26305371	NA	-0.46	-6.82	-0.52	3.51e-10	Educational attainment;
TGCT	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg26354017	chr1:205819088	PM20D1	0.67	9.29	0.64	6.74e-16	Menarche (age at onset);
TGCT	cis	rs6076065	0.748	rs6137933	chr20:23383103	A/T	cg11657817	chr20:23433608	CST11	0.31	5.42	0.44	3.02e-7	Facial morphology (factor 15, philtrum width);
TGCT	cis	rs9810089	0.900	rs11915629	chr3:136139730	C/G	cg12473912	chr3:136751656	NA	0.35	5.1	0.42	1.22e-6	Gestational age at birth (child effect);
TGCT	cis	rs2204008	0.837	rs11180821	chr12:38242843	A/G	cg26384229	chr12:38710491	ALG10B	0.84	7.28	0.55	3.29e-11	Bladder cancer;
TGCT	cis	rs3806843	1.000	rs6891995	chr5:140172008	A/G	cg19875535	chr5:140030758	IK	0.37	6.34	0.49	3.89e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs11671005	0.735	rs11668789	chr19:58928309	C/T	cg13877915	chr19:58951672	ZNF132	0.63	4.99	0.41	1.95e-6	Mean platelet volume;
TGCT	cis	rs4319547	0.661	rs7398014	chr12:122943980	T/C	cg23029597	chr12:123009494	RSRC2	-0.28	-4.52	-0.38	1.41e-5	Body mass index;
TGCT	cis	rs877282	0.891	rs34652870	chr10:772218	T/C	cg17470449	chr10:769945	NA	0.31	4.8	0.4	4.44e-6	Uric acid levels;
TGCT	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg03264133	chr6:25882463	NA	-0.6	-5.61	-0.45	1.23e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs66573146	1.000	rs28384174	chr4:6961107	G/T	cg00086871	chr4:6988644	TBC1D14	0.98	4.57	0.38	1.16e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs6088590	1.000	rs6119524	chr20:33373813	C/T	cg06115741	chr20:33292138	TP53INP2	0.66	5.51	0.44	2.01e-7	Coronary artery disease;
TGCT	cis	rs12711979	0.765	rs10208316	chr2:3827630	T/C	cg17052675	chr2:3827356	NA	-0.4	-7.89	-0.58	1.34e-12	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg11247378	chr22:39784982	NA	-0.75	-10.35	-0.68	1.8e-18	Intelligence (multi-trait analysis);
TGCT	cis	rs12497850	0.897	rs7432989	chr3:49105136	A/G	cg07636037	chr3:49044803	WDR6	0.97	10.64	0.69	3.45e-19	Parkinson's disease;
TGCT	cis	rs9512730	0.553	rs9507904	chr13:28049506	C/T	cg04070771	chr13:27998621	GTF3A	0.52	4.57	0.38	1.18e-5	Schizophrenia;
TGCT	cis	rs17376456	0.877	rs7736620	chr5:93305762	C/T	cg21475434	chr5:93447410	FAM172A	0.65	4.85	0.4	3.58e-6	Diabetic retinopathy;
TGCT	cis	rs4506170	1.000	rs16902104	chr8:128340908	A/G	cg07795030	chr8:128802207	NA	0.2	4.54	0.38	1.3e-5	Prostate cancer;
TGCT	cis	rs6831352	0.819	rs1230155	chr4:99989259	C/T	cg12011299	chr4:100065546	ADH4	0.38	5.07	0.41	1.43e-6	Alcohol dependence;
TGCT	cis	rs9913156	0.793	rs11655166	chr17:4559302	T/A	cg23387401	chr17:4582204	PELP1	-0.31	-4.62	-0.38	9.38e-6	Lymphocyte counts;
TGCT	cis	rs2594989	0.831	rs7620624	chr3:11476270	C/G	cg00170343	chr3:11313890	ATG7	0.74	5.52	0.44	1.9e-7	Circulating chemerin levels;
TGCT	cis	rs586688	0.625	rs510576	chr1:201654962	G/T	cg07139329	chr1:201708558	NAV1	-0.52	-5.32	-0.43	4.74e-7	Obesity-related traits;
TGCT	cis	rs7599312	0.553	rs6710653	chr2:213404893	A/G	cg20637307	chr2:213403960	ERBB4	0.91	11.8	0.73	5.21e-22	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs172166	0.652	rs476167	chr6:28065888	T/C	cg10876282	chr6:28092338	ZSCAN16	0.51	4.79	0.39	4.75e-6	Cardiac Troponin-T levels;
TGCT	cis	rs7226408	0.857	rs72890545	chr18:34603292	C/G	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs3733585	0.566	rs35955619	chr4:9918986	T/A	cg00071950	chr4:10020882	SLC2A9	-0.47	-5.05	-0.41	1.53e-6	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs785422	0.867	rs785429	chr15:30188232	C/T	cg10584986	chr15:29825929	FAM189A1	0.36	4.68	0.39	7.35e-6	Corneal structure;
TGCT	cis	rs7617773	0.817	rs6787500	chr3:48299439	T/C	cg11946769	chr3:48343235	NME6	0.74	7.03	0.53	1.21e-10	Coronary artery disease;
TGCT	cis	rs7599312	0.534	rs7607363	chr2:213402705	A/G	cg20637307	chr2:213403960	ERBB4	0.91	11.8	0.73	5.21e-22	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs4888262	0.564	rs6564147	chr16:74622586	G/A	cg01733217	chr16:74700730	RFWD3	0.74	7.42	0.55	1.6e-11	Testicular germ cell tumor;
TGCT	cis	rs11785400	0.762	rs2280880	chr8:143721929	C/A	cg24634471	chr8:143751801	JRK	0.53	5.07	0.41	1.42e-6	Schizophrenia;
TGCT	cis	rs2816062	1.000	rs2816062	chr1:18903902	G/A	cg18795169	chr1:18902165	NA	-0.57	-12.35	-0.74	2.43e-23	Urate levels in lean individuals;
TGCT	cis	rs3027009	0.881	rs3026955	chr1:159144034	C/A	cg18972751	chr1:158261555	CD1C	-0.46	-4.81	-0.4	4.27e-6	Lean body mass and age at menarche (combined);
TGCT	cis	rs3008870	0.916	rs2025608	chr1:67422550	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.1	11.8	0.73	5.15e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs35264875	1.000	rs72928636	chr11:68848386	C/T	cg02660097	chr11:68866761	NA	0.32	4.96	0.41	2.3e-6	Blond vs. brown hair color;
TGCT	cis	rs6460942	0.915	rs7803051	chr7:12306904	A/T	cg06484146	chr7:12443880	VWDE	-0.45	-4.68	-0.39	7.41e-6	Coronary artery disease;
TGCT	cis	rs6964587	0.839	rs9656002	chr7:91475007	A/G	cg17063962	chr7:91808500	NA	-0.87	-8.86	-0.62	6.91e-15	Breast cancer;
TGCT	cis	rs7826238	0.524	rs2921055	chr8:8319342	C/A	cg08975724	chr8:8085496	FLJ10661	0.6	5.45	0.44	2.59e-7	Systolic blood pressure;
TGCT	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg10802521	chr3:52805072	NEK4	-0.78	-10.0	-0.67	1.26e-17	Bipolar disorder;
TGCT	cis	rs1050631	1.000	rs1785919	chr18:33691964	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.51	4.98	0.41	2.07e-6	Esophageal squamous cell cancer (length of survival);
TGCT	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg27454412	chr7:1067447	C7orf50	0.58	4.51	0.38	1.48e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9611519	0.542	rs8139770	chr22:41416181	C/T	cg13695892	chr22:41940480	POLR3H	-0.54	-5.07	-0.41	1.42e-6	Neuroticism;
TGCT	cis	rs9357506	1.000	rs6940858	chr6:46305042	A/G	cg21115430	chr6:46460003	NA	-0.26	-5.16	-0.42	9.37e-7	Body mass index;
TGCT	cis	rs9952991	0.941	rs45450798	chr18:12792940	C/G	cg24737193	chr18:12778029	NA	-0.51	-5.35	-0.43	4.04e-7	Inflammatory skin disease;
TGCT	cis	rs5769707	0.967	rs9616713	chr22:50049109	G/A	cg20744362	chr22:50050164	C22orf34	0.29	4.76	0.39	5.41e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs1048238	0.506	rs698890	chr1:16267371	C/G	cg21385522	chr1:16154831	NA	-0.61	-6.85	-0.52	3.07e-10	Systolic blood pressure;
TGCT	cis	rs362272	0.545	rs2748447	chr4:3337831	G/A	cg22655196	chr4:3374909	RGS12	0.22	4.52	0.38	1.43e-5	Serum sulfate level;
TGCT	cis	rs727563	0.648	rs6002406	chr22:41965237	A/T	cg06481639	chr22:41940642	POLR3H	-0.72	-6.25	-0.49	6.08e-9	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs57221529	0.766	rs4527146	chr5:555236	A/G	cg09021430	chr5:549028	NA	-0.41	-5.53	-0.44	1.81e-7	Lung disease severity in cystic fibrosis;
TGCT	cis	rs7964899	0.611	rs4237951	chr12:14624574	A/C	cg10925082	chr12:15114703	ARHGDIB	-0.22	-4.51	-0.38	1.5e-5	Educational attainment (years of education);
TGCT	cis	rs9303401	0.659	rs12602389	chr17:56779778	G/A	cg25039879	chr17:56429692	SUPT4H1	0.52	4.62	0.38	9.48e-6	Cognitive test performance;
TGCT	cis	rs7223966	1.000	rs8077265	chr17:61732727	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	4.96	0.41	2.3e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs854765	0.583	rs11650890	chr17:17790882	C/T	cg09796270	chr17:17721594	SREBF1	-0.27	-5.5	-0.44	2.04e-7	Total body bone mineral density;
TGCT	cis	rs2458413	0.542	rs2458412	chr8:105363901	C/G	cg04554929	chr8:105342491	NA	0.48	5.76	0.46	6.13e-8	Paget's disease;
TGCT	cis	rs611744	0.967	rs627019	chr8:109222544	G/A	cg21045802	chr8:109455806	TTC35	0.52	4.72	0.39	6.21e-6	Dupuytren's disease;
TGCT	cis	rs7666738	0.830	rs17026973	chr4:98680041	T/A	cg05340658	chr4:99064831	C4orf37	0.46	5.42	0.44	3.01e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs644799	1.000	rs546809	chr11:95579938	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	8.19	0.59	2.72e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs3099143	1.000	rs4583202	chr15:77161676	G/A	cg21673338	chr15:77095150	SCAPER	0.54	5.15	0.42	1.01e-6	Recalcitrant atopic dermatitis;
TGCT	trans	rs901683	0.702	rs78757497	chr10:46161918	T/C	cg03236627	chr11:44786104	TSPAN18	-0.58	-6.69	-0.51	6.68e-10	Red blood cell traits;Mean corpuscular volume;
TGCT	cis	rs7769051	0.711	rs9493437	chr6:133088405	A/T	cg22852734	chr6:133119734	C6orf192	1.18	6.54	0.51	1.46e-9	Type 2 diabetes nephropathy;
TGCT	cis	rs6840360	0.615	rs72728179	chr4:152477877	A/G	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.03	-0.58	6.46e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs7312933	0.703	rs10880264	chr12:42586535	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.56	5.18	0.42	8.7e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs35264875	0.851	rs72930611	chr11:68863659	G/T	cg02660097	chr11:68866761	NA	0.32	4.61	0.38	9.94e-6	Blond vs. brown hair color;
TGCT	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	7.12	0.54	7.55e-11	Platelet count;
TGCT	cis	rs17253792	0.822	rs77676035	chr14:56096229	G/A	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs7772486	0.754	rs12199362	chr6:146118225	A/G	cg23711669	chr6:146136114	FBXO30	0.93	10.49	0.69	8.22e-19	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs62244186	0.659	rs1806579	chr3:44509281	T/C	cg04389838	chr3:44770851	ZNF501	-0.41	-5.7	-0.46	8.29e-8	Depressive symptoms;
TGCT	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg13385521	chr17:29058706	SUZ12P	-0.71	-4.62	-0.38	9.65e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg11247378	chr22:39784982	NA	0.73	10.24	0.68	3.26e-18	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	5.16	0.42	9.48e-7	Menopause (age at onset);
TGCT	cis	rs17376456	0.877	rs2085960	chr5:93399934	A/G	cg25358565	chr5:93447407	FAM172A	0.92	8.38	0.6	9.58e-14	Diabetic retinopathy;
TGCT	cis	rs79149102	0.579	rs9673012	chr15:75293737	C/T	cg09165964	chr15:75287851	SCAMP5	-1.04	-5.71	-0.46	7.93e-8	Lung cancer;
TGCT	cis	rs2797160	1.000	rs2747722	chr6:126009629	A/G	cg05901451	chr6:126070800	HEY2	0.72	6.11	0.48	1.18e-8	Endometrial cancer;
TGCT	cis	rs3806843	1.000	rs4451093	chr5:140158542	A/G	cg19875535	chr5:140030758	IK	-0.36	-6.19	-0.49	7.89e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs3741404	0.931	rs594942	chr11:64006292	T/C	cg01727686	chr11:63997306	NUDT22;DNAJC4	-0.22	-4.6	-0.38	1.01e-5	Platelet count;
TGCT	cis	rs7824557	0.628	rs11250129	chr8:11202154	G/A	cg21775007	chr8:11205619	TDH	0.69	6.81	0.52	3.8e-10	Retinal vascular caliber;
TGCT	cis	rs3008870	0.920	rs1925413	chr1:67417101	T/C	cg03991309	chr1:68237761	GNG12	0.27	4.57	0.38	1.18e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs7582180	0.563	rs4851304	chr2:100963871	C/T	cg14675211	chr2:100938903	LONRF2	0.5	4.78	0.39	4.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs3087591	0.683	rs2525564	chr17:29652531	A/G	cg24425628	chr17:29625626	OMG;NF1	0.39	5.74	0.46	6.74e-8	Hip circumference;
TGCT	cis	rs910316	0.967	rs4903285	chr14:75609268	A/T	cg11812906	chr14:75593930	NEK9	0.74	7.37	0.55	2.12e-11	Height;
TGCT	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg05368731	chr17:41323189	NBR1	1.16	13.44	0.77	5.72e-26	Menopause (age at onset);
TGCT	cis	rs763014	0.898	rs1981484	chr16:630710	A/G	cg07343612	chr16:622815	PIGQ	-0.41	-7.87	-0.58	1.52e-12	Height;
TGCT	cis	rs7523273	0.565	rs2796234	chr1:207900695	T/A	cg22525895	chr1:207977042	MIR29B2	-0.33	-5.31	-0.43	4.83e-7	Schizophrenia;
TGCT	cis	rs6740322	0.748	rs13420649	chr2:43463637	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.39	-6.08	-0.48	1.36e-8	Coronary artery disease;
TGCT	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg05785598	chr3:49045655	WDR6	0.36	4.87	0.4	3.27e-6	Menarche (age at onset);
TGCT	cis	rs1113500	0.575	rs1781067	chr1:108568011	C/T	cg22161131	chr1:109420278	GPSM2	0.56	5.39	0.44	3.48e-7	Growth-regulated protein alpha levels;
TGCT	cis	rs11809207	0.501	rs3762460	chr1:26495550	A/G	cg24519413	chr1:26490540	NA	0.22	4.58	0.38	1.13e-5	Height;
TGCT	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg17345569	chr6:42928274	GNMT	-0.47	-4.8	-0.4	4.47e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs9902453	0.967	rs8067576	chr17:28444254	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	6.56	0.51	1.32e-9	Coffee consumption (cups per day);
TGCT	cis	rs6880778	0.505	rs7445978	chr5:40381056	A/T	cg01087697	chr5:40835557	RPL37	0.55	5.1	0.42	1.22e-6	Inflammatory bowel disease;
TGCT	cis	rs2594989	0.943	rs2454500	chr3:11500103	C/T	cg00170343	chr3:11313890	ATG7	0.69	5.12	0.42	1.16e-6	Circulating chemerin levels;
TGCT	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg02187348	chr16:89574699	SPG7	0.62	6.64	0.51	8.59e-10	Multiple myeloma (IgH translocation);
TGCT	cis	rs3540	0.533	rs12916560	chr15:91056259	A/C	cg22089800	chr15:90895588	ZNF774	-0.76	-7.96	-0.58	9.11e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs3008870	0.755	rs1024229	chr1:67512903	G/T	cg02640540	chr1:67518911	SLC35D1	0.65	5.79	0.46	5.46e-8	Lymphocyte percentage of white cells;
TGCT	cis	rs2742417	1.000	rs2742373	chr3:45784046	C/G	cg04837898	chr3:45731254	SACM1L	-0.53	-5.53	-0.45	1.78e-7	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs7909074	1.000	rs10751360	chr10:45396971	G/A	cg04218760	chr10:45406644	TMEM72	-0.27	-5.33	-0.43	4.38e-7	Mean corpuscular volume;
TGCT	cis	rs4713118	0.629	rs203890	chr6:28022248	T/C	cg12963246	chr6:28129442	ZNF389	0.45	4.55	0.38	1.27e-5	Parkinson's disease;
TGCT	cis	rs3772130	0.962	rs13061326	chr3:121493125	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.72	0.39	6.25e-6	Cognitive performance;
TGCT	cis	rs9309473	0.519	rs2421586	chr2:73899719	C/T	cg20560298	chr2:73613845	ALMS1	0.41	4.51	0.38	1.46e-5	Metabolite levels;
TGCT	cis	rs9436747	0.641	rs1938486	chr1:66047125	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.56	5.03	0.41	1.69e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs7267979	0.527	rs6076369	chr20:25576783	G/A	cg03522245	chr20:25566470	NINL	-0.44	-4.53	-0.38	1.35e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4372836	0.504	rs6730321	chr2:29004299	T/C	cg09522027	chr2:28974177	PPP1CB	-0.56	-5.75	-0.46	6.58e-8	Body mass index;
TGCT	cis	rs6964587	0.839	rs10236107	chr7:91485461	G/A	cg17063962	chr7:91808500	NA	-0.85	-8.94	-0.63	4.52e-15	Breast cancer;
TGCT	cis	rs868036	0.645	rs4776987	chr15:68123915	A/T	cg05925327	chr15:68127851	NA	0.57	5.65	0.45	1.05e-7	Restless legs syndrome;
TGCT	cis	rs6088580	0.624	rs6120645	chr20:33025171	C/T	cg24642439	chr20:33292090	TP53INP2	0.49	4.5	0.37	1.55e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs7666738	0.830	rs3846444	chr4:99032888	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11785400	1.000	rs4297023	chr8:143733307	C/A	cg24634471	chr8:143751801	JRK	0.56	6.12	0.48	1.13e-8	Schizophrenia;
TGCT	cis	rs10782582	0.593	rs11163904	chr1:76121208	A/G	cg22875332	chr1:76189707	ACADM	0.54	6.27	0.49	5.35e-9	Daytime sleep phenotypes;
TGCT	cis	rs1534166	0.647	rs9876158	chr3:133508300	T/C	cg08048268	chr3:133502702	NA	0.45	5.58	0.45	1.44e-7	Alcohol consumption (transferrin glycosylation);
TGCT	cis	rs2760061	0.603	rs697761	chr1:228192397	G/A	cg02753203	chr1:228287806	NA	0.38	7.5	0.56	1.04e-11	Diastolic blood pressure;
TGCT	cis	rs11030122	0.673	rs10835474	chr11:4020819	G/T	cg18678763	chr11:4115507	RRM1	-0.49	-6.04	-0.48	1.66e-8	Mean platelet volume;Platelet distribution width;
TGCT	trans	rs208520	0.633	rs79679034	chr6:66701724	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	10.58	0.69	5e-19	Exhaled nitric oxide output;
TGCT	cis	rs425277	0.539	rs3107142	chr1:2044542	T/C	cg24578937	chr1:2090814	PRKCZ	-0.24	-5.67	-0.45	9.32e-8	Height;
TGCT	cis	rs57221529	0.766	rs12521051	chr5:560440	A/G	cg09021430	chr5:549028	NA	0.41	5.69	0.46	8.58e-8	Lung disease severity in cystic fibrosis;
TGCT	cis	rs7647973	1.000	rs6446275	chr3:49466871	A/G	cg07636037	chr3:49044803	WDR6	-0.7	-5.73	-0.46	7.08e-8	Menarche (age at onset);
TGCT	trans	rs4650994	0.544	rs4132058	chr1:178505557	A/C	cg05059571	chr16:84539110	KIAA1609	-0.55	-11.43	-0.72	4.08e-21	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg18305652	chr10:134549665	INPP5A	0.33	5.55	0.45	1.65e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs7917772	0.510	rs2001389	chr10:104375258	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	5.36	0.43	3.84e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.98	10.7	0.69	2.55e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs9611565	0.765	rs132915	chr22:41805782	T/C	cg13695892	chr22:41940480	POLR3H	0.8	8.01	0.58	7.2e-13	Vitiligo;
TGCT	cis	rs731174	0.797	rs510208	chr1:38147166	A/G	cg03714163	chr1:38157357	CDCA8;C1orf109	-0.43	-4.45	-0.37	1.89e-5	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7178572	0.568	rs3743479	chr15:77406396	A/G	cg22256960	chr15:77711686	NA	0.85	8.61	0.61	2.75e-14	Type 2 diabetes;
TGCT	cis	rs896854	0.548	rs574183	chr8:95973816	A/G	cg09323728	chr8:95962352	TP53INP1	0.43	5.04	0.41	1.59e-6	Type 2 diabetes;
TGCT	cis	rs7819412	0.669	rs28630509	chr8:10997039	A/G	cg03192020	chr8:11204681	TDH	-0.52	-4.5	-0.37	1.53e-5	Triglycerides;
TGCT	cis	rs17443541	0.507	rs6755597	chr2:200451440	A/G	cg00055341	chr2:200446845	NA	-0.31	-4.45	-0.37	1.89e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs477895	0.568	rs34838337	chr11:63870892	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.67	5.61	0.45	1.23e-7	Mean platelet volume;
TGCT	cis	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg07424592	chr7:64974309	NA	1.31	8.14	0.59	3.55e-13	Diabetic kidney disease;
TGCT	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg20891283	chr12:69753455	YEATS4	0.9	10.36	0.68	1.69e-18	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs992157	0.835	rs2271543	chr2:219142491	C/T	cg00012203	chr2:219082015	ARPC2	-0.79	-7.87	-0.58	1.48e-12	Colorectal cancer;
TGCT	cis	rs11577318	0.579	rs11548246	chr1:26697166	G/A	cg14210634	chr1:25870291	LDLRAP1	0.53	4.61	0.38	9.8e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs1348850	0.874	rs6742951	chr2:178340766	G/C	cg22681709	chr2:178499509	PDE11A	-0.38	-4.54	-0.38	1.31e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs17253792	0.822	rs117050012	chr14:56038729	G/T	cg01858014	chr14:56050164	KTN1	-0.36	-4.57	-0.38	1.15e-5	Putamen volume;
TGCT	cis	rs12908161	1.000	rs11637142	chr15:85295927	A/G	cg12863693	chr15:85201151	NMB	0.42	4.97	0.41	2.21e-6	Schizophrenia;
TGCT	cis	rs35306767	0.714	rs11250228	chr10:1074887	A/G	cg20503657	chr10:835505	NA	0.49	5.66	0.45	9.87e-8	Eosinophil percentage of granulocytes;
TGCT	cis	rs9486715	1.000	rs9386670	chr6:97060688	C/A	cg06623918	chr6:96969491	KIAA0776	-1.12	-13.69	-0.78	1.45e-26	Headache;
TGCT	cis	rs2486288	0.656	rs11632419	chr15:45557456	C/A	cg14582100	chr15:45693742	SPATA5L1	-0.45	-5.34	-0.43	4.26e-7	Glomerular filtration rate;
TGCT	cis	rs13082711	0.596	rs683503	chr3:27348094	C/T	cg02860705	chr3:27208620	NA	0.34	5.36	0.43	3.99e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs6087771	0.650	rs6060395	chr20:30219823	G/C	cg18721089	chr20:30220636	NA	-0.43	-5.45	-0.44	2.6e-7	Subcortical brain region volumes;Putamen volume;
TGCT	cis	rs2239547	0.522	rs2581815	chr3:52982159	C/G	cg10802521	chr3:52805072	NEK4	-0.64	-6.17	-0.48	9.06e-9	Schizophrenia;
TGCT	trans	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg21659725	chr3:3221576	CRBN	-0.65	-7.16	-0.54	6.39e-11	Body mass index;
TGCT	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg23758822	chr17:41437982	NA	0.68	6.73	0.52	5.6e-10	Menopause (age at onset);
TGCT	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg04944784	chr2:26401820	FAM59B	-0.68	-6.13	-0.48	1.1e-8	Gut microbiome composition (summer);
TGCT	cis	rs2404602	0.647	rs11072618	chr15:77019342	A/G	cg22467129	chr15:76604101	ETFA	0.47	4.7	0.39	6.84e-6	Blood metabolite levels;
TGCT	cis	rs4237845	0.591	rs4760344	chr12:58320783	A/T	cg02175503	chr12:58329896	NA	0.68	6.5	0.5	1.79e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs6933660	0.800	rs6930557	chr6:151755806	G/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.55	5.2	0.42	7.82e-7	Menarche (age at onset);
TGCT	cis	rs514406	0.607	rs1930305	chr1:53195481	G/T	cg16325326	chr1:53192061	ZYG11B	-0.89	-13.12	-0.76	3.31e-25	Monocyte count;
TGCT	cis	rs9653442	0.863	rs10865035	chr2:100835734	A/G	cg07810366	chr2:100720526	AFF3	-0.45	-7.72	-0.57	3.4e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs35934224	0.783	rs7286104	chr22:19861226	T/C	cg11182965	chr22:19864308	TXNRD2	-0.38	-5.3	-0.43	5.04e-7	Glaucoma (primary open-angle);
TGCT	cis	rs17539620	0.624	rs74551216	chr6:154840524	T/C	cg20019720	chr6:154832845	CNKSR3	0.56	4.75	0.39	5.48e-6	Lipoprotein (a) levels;
TGCT	cis	rs909674	0.818	rs5750830	chr22:39840828	C/A	cg05872129	chr22:39784769	NA	-0.99	-9.84	-0.66	3.06e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs7017914	0.967	rs6991329	chr8:71593425	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.03	-0.41	1.69e-6	Bone mineral density;
TGCT	cis	rs9902453	0.765	rs2628185	chr17:28070107	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.84	-8.4	-0.6	8.88e-14	Coffee consumption (cups per day);
TGCT	cis	rs1008375	0.900	rs1003413	chr4:17582442	C/T	cg10189774	chr4:17578691	LAP3	-0.61	-5.17	-0.42	9.19e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	trans	rs7618501	1.000	rs7374183	chr3:49785133	G/A	cg21659725	chr3:3221576	CRBN	-0.98	-15.33	-0.81	2.1000000000000002e-30	Intelligence (multi-trait analysis);
TGCT	trans	rs12655019	0.920	rs12654125	chr5:56215753	G/A	cg25190722	chr1:3801660	DFFB	0.62	7.17	0.54	5.87e-11	Breast cancer (early onset);
TGCT	cis	rs4523957	0.560	rs1994884	chr17:2084008	G/A	cg16513277	chr17:2031491	SMG6	-0.2	-4.64	-0.38	8.83e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs7772486	0.754	rs702319	chr6:146006117	T/C	cg23711669	chr6:146136114	FBXO30	-0.93	-10.83	-0.7	1.24e-19	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs587847	0.597	rs17445101	chr15:37713464	G/A	cg00216138	chr15:37171175	LOC145845	0.31	4.56	0.38	1.2e-5	Intraocular pressure;
TGCT	cis	rs2124969	0.562	rs6750639	chr2:161066862	T/C	cg03641300	chr2:160917029	PLA2R1	-0.19	-4.49	-0.37	1.62e-5	Waist circumference adjusted for body mass index;
TGCT	cis	rs67311347	1.000	rs9822909	chr3:40457084	G/T	cg13683864	chr3:40499215	RPL14	-1.16	-13.32	-0.77	1.14e-25	Renal cell carcinoma;
TGCT	cis	rs1023500	0.573	rs2413666	chr22:42459622	C/T	cg05082376	chr22:42548792	NA	-0.23	-5.41	-0.44	3.14e-7	Schizophrenia;
TGCT	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg03396347	chr1:1875803	NA	-0.36	-6.48	-0.5	1.93e-9	Body mass index;
TGCT	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg13695892	chr22:41940480	POLR3H	0.92	9.06	0.63	2.36e-15	Vitiligo;
TGCT	cis	rs7819412	0.618	rs13276836	chr8:10981003	A/C	cg21775007	chr8:11205619	TDH	-0.53	-4.91	-0.4	2.79e-6	Triglycerides;
TGCT	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg08859206	chr1:53392774	SCP2	0.42	6.43	0.5	2.54e-9	Monocyte count;
TGCT	cis	rs9534288	0.797	rs7989351	chr13:46534080	C/A	cg15192986	chr13:46630673	CPB2	-0.52	-7.28	-0.55	3.34e-11	Blood protein levels;
TGCT	cis	rs79349575	0.783	rs62078372	chr17:47028989	T/C	cg07967210	chr17:47022446	SNF8	0.44	6.13	0.48	1.1e-8	Type 2 diabetes;
TGCT	cis	rs1023500	0.505	rs134878	chr22:42663874	A/G	cg15557168	chr22:42548783	NA	-0.22	-5.17	-0.42	9.3e-7	Schizophrenia;
TGCT	cis	rs8014252	0.711	rs58069917	chr14:71043557	C/T	cg11204974	chr14:71022665	NA	-0.54	-4.44	-0.37	2e-5	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
TGCT	cis	rs6089584	0.816	rs4134440	chr20:60624296	A/G	cg13665807	chr20:60559372	TAF4	-0.53	-5.41	-0.44	3.06e-7	Body mass index;
TGCT	cis	rs1008375	0.900	rs4698622	chr4:17589557	C/T	cg18681998	chr4:17616180	MED28	0.84	7.69	0.57	3.9e-12	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6681544	0.544	rs6690951	chr1:82384961	G/A	cg04226724	chr1:82268649	LPHN2	0.47	4.97	0.41	2.19e-6	Metabolite levels  (X-11787);
TGCT	cis	rs9902453	0.967	rs4994355	chr17:28386284	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-6.56	-0.51	1.3e-9	Coffee consumption (cups per day);
TGCT	cis	rs9527	0.637	rs12219247	chr10:104613361	A/G	cg15744005	chr10:104629667	AS3MT	-0.51	-6.51	-0.5	1.7e-9	Arsenic metabolism;
TGCT	cis	rs7659604	0.540	rs11724322	chr4:122697850	A/T	cg19748678	chr4:122722346	EXOSC9	-0.58	-5.85	-0.47	4.04e-8	Type 2 diabetes;
TGCT	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg25036284	chr2:26402008	FAM59B	0.65	5.19	0.42	8.36e-7	Gut microbiome composition (summer);
TGCT	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg22891161	chr3:195456627	MUC20	-0.23	-5.38	-0.44	3.53e-7	Pancreatic cancer;
TGCT	cis	rs4713118	0.568	rs9468213	chr6:27706180	G/A	cg10876282	chr6:28092338	ZSCAN16	0.5	5.12	0.42	1.12e-6	Parkinson's disease;
TGCT	cis	rs2862064	0.932	rs6870977	chr5:156446249	T/C	cg12943317	chr5:156479607	HAVCR1	-0.45	-5.71	-0.46	7.96e-8	Platelet count;
TGCT	cis	rs7267979	0.903	rs6132819	chr20:25218618	C/G	cg16686733	chr20:25566563	NINL	0.59	6.06	0.48	1.53e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9914544	0.505	rs7503678	chr17:18776020	A/T	cg26378065	chr17:18585709	ZNF286B	0.53	4.63	0.38	9.06e-6	Educational attainment (years of education);
TGCT	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg27535305	chr1:53392650	SCP2	-0.24	-4.49	-0.37	1.64e-5	Monocyte count;
TGCT	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg23708337	chr7:1209742	NA	0.75	6.88	0.53	2.66e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7666738	0.578	rs1989109	chr4:98881246	T/A	cg17366294	chr4:99064904	C4orf37	0.74	7.62	0.56	5.55e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6964587	1.000	rs2285333	chr7:91667692	T/G	cg22709100	chr7:91322751	NA	0.28	4.56	0.38	1.19e-5	Breast cancer;
TGCT	cis	rs3213545	0.700	rs10849829	chr12:121470256	A/G	cg15155738	chr12:121454335	C12orf43	-0.46	-4.54	-0.38	1.31e-5	Subjective well-being;Cardiovascular disease risk factors;
TGCT	cis	rs9443189	0.526	rs6902898	chr6:76201856	G/A	cg01950844	chr6:76311363	SENP6	0.92	5.57	0.45	1.48e-7	Prostate cancer;
TGCT	cis	rs7703051	0.520	rs13354746	chr5:74619132	C/T	cg19683494	chr5:74908142	NA	0.75	7.54	0.56	8.78e-12	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
TGCT	cis	rs7552404	0.731	rs11161845	chr1:76367559	T/C	cg10523679	chr1:76189770	ACADM	0.85	7.54	0.56	8.71e-12	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs561341	0.623	rs4795665	chr17:30233657	C/T	cg13647721	chr17:30228624	UTP6	0.61	4.71	0.39	6.65e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs11792861	0.926	rs2271878	chr9:111868885	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.48	4.48	0.37	1.66e-5	Menarche (age at onset);
TGCT	cis	rs611744	0.967	rs2597654	chr8:109221090	A/G	cg21045802	chr8:109455806	TTC35	0.52	4.72	0.39	6.21e-6	Dupuytren's disease;
TGCT	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg04944784	chr2:26401820	FAM59B	-0.78	-6.56	-0.51	1.34e-9	Gut microbiome composition (summer);
TGCT	cis	rs59107033	0.559	rs58531872	chr3:123105640	C/G	cg04890266	chr3:123102914	ADCY5	-0.48	-7.84	-0.58	1.81e-12	Lymphocyte counts;
TGCT	trans	rs877282	0.797	rs11253329	chr10:753200	A/T	cg22713356	chr15:30763199	NA	1.07	8.27	0.6	1.75e-13	Uric acid levels;
TGCT	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.52	-5.85	-0.47	4.02e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs739496	0.615	rs4646778	chr12:112235783	C/A	cg10833066	chr12:111807467	FAM109A	0.4	5.17	0.42	9.17e-7	Platelet count;
TGCT	cis	rs2242116	1.000	rs2168443	chr3:46947087	A/T	cg02527881	chr3:46936655	PTH1R	0.33	6.35	0.5	3.63e-9	Birth weight;
TGCT	cis	rs7621025	0.630	rs1681818	chr3:136473673	A/G	cg15507776	chr3:136538369	TMEM22	-0.5	-4.56	-0.38	1.22e-5	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
TGCT	cis	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg18252515	chr7:66147081	NA	-1.17	-7.17	-0.54	5.94e-11	Diabetic kidney disease;
TGCT	cis	rs4478858	0.735	rs6425736	chr1:31784376	T/A	cg07478791	chr1:31886160	SERINC2	-0.52	-5.03	-0.41	1.67e-6	Alcohol dependence;
TGCT	cis	rs4938534	0.716	rs7947717	chr11:111289738	T/C	cg24049888	chr11:111250129	POU2AF1	-0.25	-4.44	-0.37	1.98e-5	Primary biliary cholangitis;
TGCT	cis	rs7394190	0.748	rs2292307	chr10:75549916	C/A	cg07699608	chr10:75541558	CHCHD1	0.79	5.45	0.44	2.63e-7	Incident atrial fibrillation;
TGCT	cis	rs74233809	0.534	rs284844	chr10:104554529	A/G	cg05855489	chr10:104503620	C10orf26	-0.76	-5.24	-0.43	6.78e-7	Birth weight;
TGCT	cis	rs453301	0.624	rs6987558	chr8:8862521	C/G	cg15556689	chr8:8085844	FLJ10661	0.73	6.43	0.5	2.47e-9	Joint mobility (Beighton score);
TGCT	cis	rs17881320	0.510	rs6503699	chr17:40554261	C/G	cg05878104	chr17:40932452	WNK4	0.9	5.93	0.47	2.76e-8	Atopic dermatitis;
TGCT	cis	rs4631830	0.832	rs2843554	chr10:51523861	G/T	cg10326726	chr10:51549505	MSMB	-0.24	-4.9	-0.4	2.96e-6	Prostate-specific antigen levels;
TGCT	cis	rs7666738	0.830	rs1115616	chr4:99006603	A/C	cg05340658	chr4:99064831	C4orf37	0.49	5.51	0.44	1.97e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4727027	0.736	rs12704084	chr7:148915050	C/G	cg23583168	chr7:148888333	NA	-0.81	-10.36	-0.68	1.73e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.4	-4.76	-0.39	5.31e-6	Longevity;Endometriosis;
TGCT	cis	rs7216064	1.000	rs6504549	chr17:65888784	A/G	cg12091567	chr17:66097778	LOC651250	-0.84	-6.8	-0.52	4.01e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs28595532	0.920	rs116428408	chr4:119758514	G/C	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs7575217	0.767	rs13386749	chr2:101746592	C/T	cg12737833	chr2:101500543	NPAS2	0.28	4.58	0.38	1.09e-5	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
TGCT	cis	rs13394619	1.000	rs2358040	chr2:11731774	G/T	cg07314298	chr2:11723111	GREB1	0.29	5.27	0.43	5.95e-7	Endometriosis;
TGCT	cis	rs6815814	0.950	rs66979032	chr4:38814700	A/G	cg02016764	chr4:38805732	TLR1	-0.34	-5.4	-0.44	3.26e-7	Breast cancer;
TGCT	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg04944784	chr2:26401820	FAM59B	-0.68	-6.13	-0.48	1.1e-8	Gut microbiome composition (summer);
TGCT	cis	rs6546537	1.000	rs4852868	chr2:69831636	C/T	cg10773587	chr2:69614142	GFPT1	-0.64	-6.07	-0.48	1.41e-8	Serum thyroid-stimulating hormone levels;
TGCT	cis	rs6598955	0.724	rs869683	chr1:26570993	T/A	cg04990556	chr1:26633338	UBXN11	-0.91	-11.99	-0.73	1.8e-22	Obesity-related traits;
TGCT	trans	rs2108225	0.900	rs2395930	chr7:107451677	T/C	cg14662119	chr1:153950267	JTB	0.66	6.67	0.51	7.48e-10	Ulcerative colitis;
TGCT	cis	rs28785552	0.931	rs8112235	chr19:53239010	C/G	cg22067481	chr19:53234126	ZNF611	-0.48	-6.78	-0.52	4.27e-10	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs10751667	0.961	rs7395303	chr11:986221	T/A	cg06064525	chr11:970664	AP2A2	-0.32	-6.43	-0.5	2.45e-9	Alzheimer's disease (late onset);
TGCT	cis	rs7666738	0.830	rs11944855	chr4:99068258	G/A	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.44e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3733585	0.699	rs10001964	chr4:9959275	C/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.58	-0.51	1.2e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs13188771	0.690	rs350556	chr5:100860279	A/G	cg10455971	chr5:101119566	NA	-0.43	-4.53	-0.38	1.38e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs36051895	0.530	rs4142064	chr9:5221818	C/T	cg02405213	chr9:5042618	JAK2	-0.63	-7.46	-0.56	1.29e-11	Pediatric autoimmune diseases;
TGCT	cis	rs11671007	1	rs11671007	chr19:2893405	A/G	cg08634464	chr19:2901147	ZNF57	-1.62	-6.91	-0.53	2.2e-10	Daytime sleep phenotypes;
TGCT	cis	rs1372520	0.567	rs2619349	chr4:90746646	G/T	cg01966878	chr4:90757139	SNCA	-0.3	-4.76	-0.39	5.2e-6	Neuroticism;
TGCT	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg04013166	chr16:89971882	TCF25	0.32	4.46	0.37	1.84e-5	Skin colour saturation;
TGCT	cis	rs57994353	0.540	rs12379380	chr9:139279981	C/T	cg13741927	chr9:139327495	INPP5E	-0.21	-4.57	-0.38	1.15e-5	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs1552244	0.832	rs73024575	chr3:10198200	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.1	6.25	0.49	6.06e-9	Alzheimer's disease;
TGCT	cis	rs77633900	0.614	rs2439991	chr15:76877227	A/G	cg21673338	chr15:77095150	SCAPER	-0.51	-4.7	-0.39	6.69e-6	Non-glioblastoma glioma;Glioma;
TGCT	cis	rs2153535	0.601	rs2327091	chr6:8540369	G/A	cg07606381	chr6:8435919	SLC35B3	0.55	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs28595532	0.920	rs115006522	chr4:119732499	A/G	cg21605333	chr4:119757512	SEC24D	1.66	8.33	0.6	1.28e-13	Cannabis dependence symptom count;
TGCT	cis	rs2742417	0.603	rs2742448	chr3:45764246	C/T	cg04837898	chr3:45731254	SACM1L	0.64	6.79	0.52	4.13e-10	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs2239547	0.523	rs6803486	chr3:53098209	T/A	cg11645453	chr3:52864694	ITIH4	0.3	4.83	0.4	3.88e-6	Schizophrenia;
TGCT	cis	rs7582180	0.764	rs11683121	chr2:100920705	C/T	cg08017756	chr2:100939284	LONRF2	-0.32	-5.31	-0.43	4.89e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7674212	0.507	rs223471	chr4:103698786	G/C	cg16532752	chr4:104119610	CENPE	-0.6	-5.07	-0.41	1.42e-6	Type 2 diabetes;
TGCT	cis	rs6976053	0.846	rs314375	chr7:100457344	G/A	cg05669210	chr7:100450634	SLC12A9	0.51	4.45	0.37	1.87e-5	Plasminogen activator inhibitor type 1 levels (PAI-1);
TGCT	cis	rs1348850	0.837	rs12619074	chr2:178472336	G/A	cg22681709	chr2:178499509	PDE11A	-0.48	-5.4	-0.44	3.2e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	trans	rs7726839	0.540	rs72705097	chr5:655067	G/A	cg25482853	chr8:67687455	SGK3	1.2	10.13	0.67	6.02e-18	Obesity-related traits;
TGCT	trans	rs561341	1.000	rs8064843	chr17:30245744	A/G	cg20587970	chr11:113659929	NA	-0.96	-12.13	-0.74	8.3300000000000006e-23	Hip circumference adjusted for BMI;
TGCT	cis	rs10992471	0.603	rs1535755	chr9:95202031	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.6	-5.67	-0.45	9.42e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs1577917	1.000	rs12201735	chr6:86656939	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.54	-0.45	1.73e-7	Response to antipsychotic treatment;
TGCT	trans	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.88	9.71	0.66	6.38e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs12142240	0.698	rs6429599	chr1:46827871	G/A	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg23758822	chr17:41437982	NA	0.69	6.37	0.5	3.34e-9	Menopause (age at onset);
TGCT	cis	rs12286929	0.736	rs11215397	chr11:115044076	G/A	cg04017736	chr11:115827165	NA	-0.19	-4.47	-0.37	1.71e-5	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs500492	0.542	rs2573148	chr16:1073372	C/T	cg01366354	chr16:1075121	NA	0.35	5.18	0.42	8.52e-7	Polycystic ovary syndrome;
TGCT	cis	rs9914544	0.545	rs7212905	chr17:18774271	A/G	cg26378065	chr17:18585709	ZNF286B	0.51	4.73	0.39	5.96e-6	Educational attainment (years of education);
TGCT	cis	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg06636001	chr8:8085503	FLJ10661	0.65	5.73	0.46	7.34e-8	Mood instability;
TGCT	cis	rs6746896	0.959	rs56351161	chr2:97373817	G/A	cg26085987	chr2:97230376	NA	0.19	4.71	0.39	6.5e-6	Bipolar disorder;
TGCT	cis	rs35883536	0.565	rs2809813	chr1:101032003	A/C	cg10298815	chr1:101004474	GPR88	0.25	4.69	0.39	7.06e-6	Monocyte count;
TGCT	cis	rs860295	0.557	rs915181	chr1:155914772	C/T	cg05700447	chr1:155978627	NA	0.21	4.44	0.37	1.97e-5	Body mass index;
TGCT	cis	rs922182	0.617	rs28621460	chr15:64240232	C/T	cg02919090	chr15:64263738	DAPK2	0.37	7.01	0.53	1.35e-10	Blood protein levels;
TGCT	cis	rs9381040	0.610	rs2268195	chr6:41024340	G/A	cg03526776	chr6:41159608	TREML2	0.27	5.29	0.43	5.37e-7	Alzheimer's disease (late onset);
TGCT	cis	rs7940866	0.903	rs10791109	chr11:130850377	A/C	cg12179176	chr11:130786555	SNX19	0.52	5.06	0.41	1.46e-6	Schizophrenia;
TGCT	cis	rs2369473	1	rs2369473	chr1:160210727	C/A	cg07195126	chr1:160370843	VANGL2	0.58	5.11	0.42	1.17e-6	Squamous cell lung carcinoma;
TGCT	cis	rs9952991	0.566	rs487273	chr18:12853458	T/G	cg23544223	chr18:12777786	NA	0.55	4.88	0.4	3.22e-6	Inflammatory skin disease;
TGCT	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.08	0.48	1.37e-8	Bipolar disorder;
TGCT	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.46	4.47	0.37	1.75e-5	Cerebrospinal P-tau181p levels;
TGCT	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg09033563	chr22:24373618	LOC391322	0.49	4.79	0.4	4.64e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9467773	1.000	rs9467782	chr6:26542773	G/A	cg15659132	chr6:26577336	NA	0.86	12.21	0.74	5.3e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs7940866	0.874	rs1433979	chr11:130871617	G/A	cg05962950	chr11:130786565	SNX19	0.6	6.06	0.48	1.52e-8	Schizophrenia;
TGCT	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg20607798	chr8:58055168	NA	0.44	4.6	0.38	1.04e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs8014204	0.541	rs35591392	chr14:75157713	G/T	cg06637938	chr14:75390232	RPS6KL1	0.64	5.87	0.47	3.74e-8	Caffeine consumption;
TGCT	cis	rs7937682	0.632	rs1045282	chr11:111754574	A/C	cg09085632	chr11:111637200	PPP2R1B	0.84	7.27	0.55	3.45e-11	Primary sclerosing cholangitis;
TGCT	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9296092	0.521	rs56332659	chr6:33537887	T/C	cg13560919	chr6:33536144	NA	-0.21	-4.71	-0.39	6.66e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs523522	0.962	rs2393590	chr12:120913900	G/A	cg27279351	chr12:120934652	DYNLL1	0.76	6.58	0.51	1.19e-9	High light scatter reticulocyte count;
TGCT	trans	rs8073060	0.660	rs58266733	chr17:34003812	A/T	cg19694781	chr19:47549865	TMEM160	-0.6	-13.37	-0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	trans	rs1387416	1.000	rs9352077	chr6:74890635	C/T	cg19320816	chr6:26087776	HFE	-0.54	-6.66	-0.51	8.1e-10	Acute graft versus host disease in bone marrow transplantation (donor effect);
TGCT	cis	rs11252926	0.502	rs7072510	chr10:455596	C/T	cg13477178	chr10:375248	DIP2C	-0.24	-4.57	-0.38	1.14e-5	Psychosis in Alzheimer's disease;
TGCT	trans	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg11887960	chr12:57824829	NA	1.1	9.44	0.65	2.89e-16	Lung disease severity in cystic fibrosis;
TGCT	cis	rs4372836	0.964	rs2045884	chr2:28964355	C/T	cg09522027	chr2:28974177	PPP1CB	-0.54	-4.6	-0.38	1.04e-5	Body mass index;
TGCT	cis	rs6545883	0.868	rs6748003	chr2:61806700	T/G	cg15711740	chr2:61764176	XPO1	-0.59	-5.7	-0.46	8.42e-8	Tuberculosis;
TGCT	cis	rs6598955	0.671	rs10902732	chr1:26606174	A/C	cg04990556	chr1:26633338	UBXN11	0.66	5.0	0.41	1.88e-6	Obesity-related traits;
TGCT	cis	rs344364	0.511	rs337284	chr16:1954799	A/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.47	-5.43	-0.44	2.8e-7	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg02725872	chr8:58115012	NA	-0.38	-5.16	-0.42	9.32e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6882076	0.961	rs4704827	chr5:156392089	T/C	cg12943317	chr5:156479607	HAVCR1	-0.31	-6.09	-0.48	1.31e-8	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
TGCT	cis	rs11785400	1.000	rs4736365	chr8:143742197	A/G	cg10596483	chr8:143751796	JRK	0.56	6.05	0.48	1.61e-8	Schizophrenia;
TGCT	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg05665937	chr4:1216051	CTBP1	0.24	4.61	0.38	1e-5	Obesity-related traits;
TGCT	cis	rs62064224	0.902	rs17732573	chr17:30627664	C/T	cg18200150	chr17:30822561	MYO1D	-0.45	-5.94	-0.47	2.7e-8	Schizophrenia;
TGCT	cis	rs11190604	0.767	rs7392696	chr10:102182141	G/A	cg16342193	chr10:102329863	NA	-0.4	-5.02	-0.41	1.74e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9325144	0.647	rs35254764	chr12:39102928	T/C	cg26384229	chr12:38710491	ALG10B	-0.57	-5.29	-0.43	5.23e-7	Morning vs. evening chronotype;
TGCT	cis	rs593982	0.920	rs488170	chr11:65481544	T/C	cg08755490	chr11:65554678	OVOL1	1.34	8.14	0.59	3.53e-13	Atopic dermatitis;
TGCT	cis	rs7937612	1.000	rs9633950	chr11:120248249	T/G	cg24566217	chr11:120254723	ARHGEF12	-0.29	-4.58	-0.38	1.1e-5	Intraocular pressure;
TGCT	cis	rs7772486	0.743	rs62433835	chr6:146032688	C/G	cg05347473	chr6:146136440	FBXO30	-0.5	-4.75	-0.39	5.58e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11122272	0.706	rs2749710	chr1:231535112	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.69	6.9	0.53	2.38e-10	Hemoglobin concentration;
TGCT	cis	rs9906944	0.545	rs1994969	chr17:47080431	G/T	cg07075026	chr17:47091521	IGF2BP1	-0.43	-4.6	-0.38	1.03e-5	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg13395646	chr4:1353034	KIAA1530	-0.36	-4.61	-0.38	9.75e-6	Obesity-related traits;
TGCT	cis	rs2832191	0.692	rs2776240	chr21:30310639	C/T	cg24692254	chr21:30365293	RNF160	0.92	10.49	0.69	8.31e-19	Dental caries;
TGCT	cis	rs28493229	0.708	rs78084428	chr19:41160097	G/A	cg11601297	chr19:41224147	ITPKC;ADCK4	0.57	5.15	0.42	9.78e-7	Kawasaki disease;
TGCT	cis	rs7014346	0.767	rs11784983	chr8:128421348	A/G	cg04263511	chr8:128962092	PVT1	-0.31	-4.55	-0.38	1.25e-5	Colorectal cancer;
TGCT	cis	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg13531842	chr10:38383804	ZNF37A	0.39	4.58	0.38	1.13e-5	Extrinsic epigenetic age acceleration;
TGCT	cis	rs8177253	0.665	rs6774822	chr3:133442012	G/T	cg01448562	chr3:133502909	NA	-0.28	-5.27	-0.43	5.8e-7	Iron status biomarkers;
TGCT	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg07167872	chr1:205819463	PM20D1	0.41	4.77	0.39	4.98e-6	Menarche (age at onset);
TGCT	cis	rs3741404	0.895	rs2429455	chr11:63995302	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.89	9.91	0.66	2.06e-17	Platelet count;
TGCT	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg16405210	chr4:1374714	KIAA1530	-0.25	-4.5	-0.37	1.54e-5	Longevity;
TGCT	cis	rs593982	0.920	rs76925283	chr11:65548108	C/T	cg08755490	chr11:65554678	OVOL1	-1.49	-10.9	-0.7	8.17e-20	Atopic dermatitis;
TGCT	cis	rs7605378	1.000	rs7577763	chr2:200681753	C/T	cg17644776	chr2:200775616	C2orf69	0.29	5.51	0.44	1.94e-7	Osteoporosis;
TGCT	cis	rs931608	0.640	rs4932758	chr19:22540094	G/A	cg23859931	chr19:22123797	NA	-0.64	-4.8	-0.4	4.43e-6	Dental caries;Response to statins (LDL cholesterol change);
TGCT	cis	rs10088262	0.527	rs3911939	chr8:124793744	T/G	cg20713898	chr8:124780851	FAM91A1	-0.75	-5.46	-0.44	2.45e-7	Pancreatic cancer;
TGCT	cis	rs1215050	0.740	rs804051	chr4:98935935	A/T	cg17366294	chr4:99064904	C4orf37	-0.57	-6.12	-0.48	1.12e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	trans	rs2727020	0.619	rs1164665	chr11:49295630	T/C	cg11707556	chr5:10655725	ANKRD33B	0.38	6.8	0.52	3.89e-10	Coronary artery disease;
TGCT	cis	rs10992471	0.605	rs7872375	chr9:95064843	C/G	cg14631576	chr9:95140430	CENPP	-0.28	-4.65	-0.39	8.23e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs1008375	0.932	rs13127157	chr4:17618049	A/G	cg10189774	chr4:17578691	LAP3	-0.62	-5.21	-0.42	7.77e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs950776	0.593	rs481134	chr15:78877563	C/T	cg06917634	chr15:78832804	PSMA4	0.66	5.35	0.43	4.17e-7	Sudden cardiac arrest;
TGCT	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg11764359	chr7:65958608	NA	-0.57	-5.12	-0.42	1.12e-6	Aortic root size;
TGCT	cis	rs514406	0.505	rs835609	chr1:53170494	T/C	cg08859206	chr1:53392774	SCP2	-0.35	-4.89	-0.4	3.1e-6	Monocyte count;
TGCT	cis	rs57994353	0.759	rs35873563	chr9:139324029	C/T	cg13741927	chr9:139327495	INPP5E	-0.27	-6.02	-0.48	1.83e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs17253792	0.822	rs76055105	chr14:56069127	A/G	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs595982	0.517	rs4801779	chr19:49406651	T/G	cg15549821	chr19:49342101	PLEKHA4	-0.4	-5.48	-0.44	2.32e-7	Red cell distribution width;
TGCT	cis	rs9611565	0.559	rs4822049	chr22:41993496	G/A	cg06481639	chr22:41940642	POLR3H	-0.75	-6.47	-0.5	2.1e-9	Vitiligo;
TGCT	cis	rs514406	0.861	rs35581164	chr1:53271373	C/G	cg08736216	chr1:53307985	ZYG11A	-0.25	-4.86	-0.4	3.42e-6	Monocyte count;
TGCT	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.54	-0.38	1.33e-5	Bipolar disorder;
TGCT	cis	rs4824093	0.610	rs7410534	chr22:50289925	C/T	cg20569369	chr22:51173646	NA	0.29	4.76	0.39	5.26e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs7552404	0.690	rs7549863	chr1:76327923	T/C	cg10523679	chr1:76189770	ACADM	-0.67	-6.27	-0.49	5.47e-9	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs6831352	0.801	rs2602897	chr4:100046293	A/T	cg12011299	chr4:100065546	ADH4	0.41	4.92	0.4	2.72e-6	Alcohol dependence;
TGCT	cis	rs9790314	0.846	rs4856714	chr3:160961824	T/C	cg03342759	chr3:160939853	NMD3	-0.51	-5.66	-0.45	9.96e-8	Morning vs. evening chronotype;
TGCT	cis	rs12477438	0.715	rs7586608	chr2:99558017	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-7.31	-0.55	2.9100000000000002e-11	Chronic sinus infection;
TGCT	cis	rs11585357	0.895	rs72633803	chr1:17616758	G/A	cg08277548	chr1:17600880	PADI3	-0.96	-9.72	-0.66	5.97e-17	Hair shape;
TGCT	cis	rs10193935	0.901	rs2286702	chr2:42555473	C/T	cg27598129	chr2:42591480	NA	-0.41	-5.68	-0.45	9.25e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2204008	0.775	rs11182513	chr12:38560252	G/C	cg26384229	chr12:38710491	ALG10B	0.89	8.1	0.59	4.28e-13	Bladder cancer;
TGCT	cis	rs7659604	0.540	rs10004284	chr4:122699222	A/T	cg06713675	chr4:122721982	EXOSC9	0.36	4.52	0.38	1.42e-5	Type 2 diabetes;
TGCT	cis	rs10779751	0.770	rs11121695	chr1:11229515	G/A	cg08854313	chr1:11322531	MTOR	-0.84	-6.81	-0.52	3.82e-10	Body mass index;
TGCT	cis	rs6565180	1.000	rs11863150	chr16:30385503	C/T	cg17640201	chr16:30407289	ZNF48	0.93	9.48	0.65	2.33e-16	Tonsillectomy;
TGCT	cis	rs1056107	0.931	rs7864927	chr9:115003993	C/T	cg02332936	chr9:115140584	NA	-0.25	-4.44	-0.37	1.96e-5	Colorectal cancer;
TGCT	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg13395646	chr4:1353034	KIAA1530	0.47	6.15	0.48	9.8e-9	Obesity-related traits;
TGCT	cis	rs523522	0.962	rs9788155	chr12:120938408	G/A	cg12219531	chr12:120966889	COQ5	0.83	7.27	0.55	3.46e-11	High light scatter reticulocyte count;
TGCT	cis	rs1723838	0.510	rs17132534	chr11:73691774	A/G	cg26954736	chr11:73693896	UCP2	-1.37	-6.3	-0.49	4.64e-9	Obesity-related traits;
TGCT	cis	rs12541335	0.639	rs68063696	chr8:22153236	A/G	cg02788857	chr8:22132959	PIWIL2	0.26	4.57	0.38	1.16e-5	Hypertriglyceridemia;
TGCT	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg21724239	chr8:58056113	NA	0.5	5.43	0.44	2.83e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7772486	0.641	rs9390370	chr6:146357569	C/T	cg23711669	chr6:146136114	FBXO30	0.68	6.55	0.51	1.39e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs13082711	0.640	rs35903173	chr3:27287751	T/C	cg02860705	chr3:27208620	NA	0.55	8.42	0.6	7.68e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs797680	0.786	rs6694508	chr1:93842023	A/C	cg17826107	chr1:92977322	EVI5	-0.24	-5.63	-0.45	1.13e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg20607798	chr8:58055168	NA	0.58	4.67	0.39	7.56e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6921919	0.583	rs4642462	chr6:28389251	G/C	cg18815343	chr6:28367644	ZSCAN12	-0.54	-5.24	-0.43	6.83e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6912958	0.754	rs7762864	chr6:88236213	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-5.06	-0.41	1.45e-6	Monocyte percentage of white cells;
TGCT	cis	rs6840360	0.593	rs1429558	chr4:152685406	A/T	cg17479576	chr4:152424074	FAM160A1	-0.52	-5.16	-0.42	9.49e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.07	0.48	1.47e-8	Bipolar disorder;
TGCT	cis	rs2549003	1.000	rs9282762	chr5:131822055	T/C	cg02551604	chr5:131831745	NA	-0.9	-12.1	-0.74	9.75e-23	Asthma (sex interaction);
TGCT	cis	rs3096299	0.719	rs2965818	chr16:89510494	A/G	cg08392591	chr16:89556376	ANKRD11	0.63	6.08	0.48	1.38e-8	Multiple myeloma (IgH translocation);
TGCT	cis	rs3096299	0.566	rs4129126	chr16:89561475	A/C	cg02244288	chr16:89573955	SPG7	-0.32	-4.56	-0.38	1.22e-5	Multiple myeloma (IgH translocation);
TGCT	cis	rs4699052	0.590	rs4698892	chr4:104261271	C/G	cg16532752	chr4:104119610	CENPE	-0.51	-5.01	-0.41	1.8e-6	Testicular germ cell tumor;
TGCT	cis	rs8017423	0.565	rs4904681	chr14:90835566	A/T	cg04374321	chr14:90722782	PSMC1	-0.55	-5.26	-0.43	6.23e-7	Mortality in heart failure;
TGCT	cis	rs12134133	1.000	rs11580387	chr1:207418408	A/G	cg02152968	chr1:207494213	CD55	0.61	4.83	0.4	3.92e-6	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs9527	0.544	rs11191549	chr10:104846797	C/T	cg15744005	chr10:104629667	AS3MT	-0.42	-4.84	-0.4	3.82e-6	Arsenic metabolism;
TGCT	trans	rs1005277	0.522	rs1208684	chr10:38093936	G/A	cg17830980	chr10:43048298	ZNF37B	-0.65	-7.49	-0.56	1.11e-11	Extrinsic epigenetic age acceleration;
TGCT	cis	rs12681287	0.640	rs13253296	chr8:87448245	C/T	cg27223183	chr8:87520930	FAM82B	-0.89	-6.43	-0.5	2.54e-9	Caudate activity during reward;
TGCT	trans	rs8073060	0.586	rs7212488	chr17:33993476	A/T	cg19694781	chr19:47549865	TMEM160	-0.62	-14.07	-0.78	1.86e-27	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	trans	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg23505145	chr19:12996616	KLF1	0.78	8.06	0.59	5.54e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs17826219	0.714	rs11650821	chr17:28968150	T/C	cg13385521	chr17:29058706	SUZ12P	0.81	4.87	0.4	3.39e-6	Body mass index;
TGCT	cis	rs3741404	0.665	rs594461	chr11:63872543	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	7.52	0.56	9.8e-12	Platelet count;
TGCT	cis	rs9527	0.545	rs10218853	chr10:104796787	A/C	cg04362960	chr10:104952993	NT5C2	0.68	5.73	0.46	7.14e-8	Arsenic metabolism;
TGCT	cis	rs10504229	1.000	rs76270388	chr8:58195605	T/A	cg21724239	chr8:58056113	NA	0.38	4.76	0.39	5.41e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2439831	0.681	rs484846	chr15:43600803	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.02	8.69	0.62	1.84e-14	Lung cancer in ever smokers;
TGCT	cis	rs11676348	0.755	rs1008562	chr2:219026972	G/C	cg00012203	chr2:219082015	ARPC2	0.53	4.89	0.4	3.01e-6	Ulcerative colitis;
TGCT	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg04234412	chr22:24373322	LOC391322	-0.94	-11.56	-0.72	2.03e-21	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9399137	0.507	rs11753673	chr6:135316476	T/C	cg24558204	chr6:135376177	HBS1L	0.47	4.78	0.39	4.95e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
TGCT	cis	rs4975616	0.836	rs421629	chr5:1320136	G/A	cg07493874	chr5:1342172	CLPTM1L	-0.28	-6.59	-0.51	1.15e-9	Lung cancer;
TGCT	cis	rs2688608	1.000	rs2675680	chr10:75658864	T/C	cg19442545	chr10:75533431	FUT11	-0.3	-4.8	-0.4	4.49e-6	Inflammatory bowel disease;
TGCT	cis	rs7568458	0.684	rs7608074	chr2:85809703	T/G	cg02493740	chr2:85810744	VAMP5	-0.31	-5.74	-0.46	6.97e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs6490294	0.904	rs12306814	chr12:112403813	T/C	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Mean platelet volume;
TGCT	cis	rs9969804	0.782	rs912262	chr9:95525557	C/T	cg13940029	chr9:95239186	CENPP;ASPN	0.17	4.58	0.38	1.11e-5	Height;
TGCT	cis	rs2071303	0.836	rs198835	chr6:26113994	T/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.72	-6.87	-0.53	2.76e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs6547741	1.000	rs1528402	chr2:27857517	G/A	cg27432699	chr2:27873401	GPN1	0.18	4.63	0.38	9.05e-6	Oral cavity cancer;
TGCT	cis	rs6554196	0.686	rs723585	chr4:55503194	A/G	cg02821500	chr4:54931072	CHIC2	0.46	4.44	0.37	1.95e-5	Monocyte count;
TGCT	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg12310025	chr6:25882481	NA	-0.59	-6.04	-0.48	1.65e-8	Blood metabolite levels;
TGCT	cis	rs9325144	0.532	rs12812406	chr12:38719802	G/A	cg26384229	chr12:38710491	ALG10B	-0.63	-5.91	-0.47	3.03e-8	Morning vs. evening chronotype;
TGCT	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg03264133	chr6:25882463	NA	-0.51	-5.36	-0.43	3.84e-7	Blood metabolite levels;
TGCT	cis	rs7216064	1.000	rs12600941	chr17:65918807	A/G	cg12091567	chr17:66097778	LOC651250	-0.78	-5.57	-0.45	1.51e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs7666738	0.830	rs13118945	chr4:98968586	T/G	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12142240	0.698	rs67276232	chr1:46825484	T/G	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs4494114	1.000	rs12037982	chr1:39358600	G/A	cg25970120	chr1:39325951	RRAGC	-0.6	-6.17	-0.48	8.89e-9	Blood protein levels;
TGCT	cis	rs1153858	0.943	rs12439575	chr15:45684816	T/G	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.62e-8	Homoarginine levels;
TGCT	cis	rs6450176	1.000	rs6450176	chr5:53298025	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.53	-5.11	-0.42	1.17e-6	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.55	-5.37	-0.43	3.68e-7	Longevity;Endometriosis;
TGCT	cis	rs4149178	0.656	rs3734683	chr6:43316023	A/G	cg07522644	chr6:43142093	SRF	0.7	4.99	0.41	1.96e-6	Urate levels;
TGCT	cis	rs231513	0.911	rs231527	chr17:41951228	T/C	cg26893861	chr17:41843967	DUSP3	-0.87	-6.27	-0.49	5.58e-9	Cognitive function;
TGCT	cis	rs13217239	0.646	rs10946888	chr6:26951678	A/G	cg05738196	chr6:26577821	NA	0.49	4.67	0.39	7.73e-6	Schizophrenia;
TGCT	cis	rs10992471	0.603	rs10114912	chr9:95307863	C/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.6	-5.68	-0.45	9.01e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg08564027	chr20:61660810	NA	0.38	7.08	0.54	9.36e-11	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs13191362	1.000	rs13209728	chr6:162997533	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.57	4.94	0.41	2.45e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs492146	0.765	rs316133	chr6:52847551	C/G	cg06706454	chr6:52930286	FBXO9	-0.5	-4.7	-0.39	6.83e-6	Epilepsy (remission after treatment);
TGCT	cis	rs1153858	1.000	rs7167900	chr15:45639471	A/G	cg14582100	chr15:45693742	SPATA5L1	0.48	5.7	0.46	8.17e-8	Homoarginine levels;
TGCT	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2657888	0.965	rs2657905	chr12:56935402	T/A	cg23002907	chr12:56915593	RBMS2	0.44	6.15	0.48	9.65e-9	Adiponectin levels;
TGCT	cis	rs7809950	1.000	rs2894475	chr7:107262558	A/T	cg23024343	chr7:107201750	COG5	-0.32	-5.0	-0.41	1.93e-6	Coronary artery disease;
TGCT	cis	rs62244186	0.659	rs56231820	chr3:44530329	C/T	cg21672276	chr3:44754072	ZNF502	-0.41	-4.63	-0.38	9.03e-6	Depressive symptoms;
TGCT	cis	rs6977940	0.512	rs6461600	chr7:2816537	C/T	cg19731401	chr7:2775893	GNA12	0.32	4.57	0.38	1.15e-5	White matter integrity;
TGCT	cis	rs3008870	0.755	rs2815362	chr1:67496803	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.82	8.67	0.61	1.95e-14	Lymphocyte percentage of white cells;
TGCT	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg21963583	chr11:68658836	MRPL21	0.36	6.17	0.48	9.01e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9913156	0.748	rs72835619	chr17:4557285	G/A	cg19197139	chr17:4613644	ARRB2	0.86	7.9	0.58	1.32e-12	Lymphocyte counts;
TGCT	cis	rs7226408	0.802	rs72885272	chr18:34437656	A/C	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs12902680	0.739	rs1607719	chr15:46419008	G/A	cg13605988	chr15:45421612	DUOX1;DUOXA1	0.33	4.62	0.38	9.28e-6	Neuroticism;
TGCT	cis	rs7412746	0.611	rs10888394	chr1:150749913	C/T	cg04414720	chr1:150670196	GOLPH3L	0.38	4.73	0.39	6.04e-6	Melanoma;
TGCT	cis	rs739401	0.572	rs404629	chr11:3077025	A/G	cg05729581	chr11:3078854	CARS	-0.58	-5.31	-0.43	4.93e-7	Longevity;
TGCT	cis	rs10875595	0.836	rs1363450	chr5:140658363	A/T	cg20560182	chr5:140700478	TAF7	0.64	4.92	0.4	2.64e-6	Pulmonary function decline;
TGCT	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-5.79	-0.46	5.39e-8	Alzheimer's disease;
TGCT	cis	rs1580019	0.587	rs7806113	chr7:32553084	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.57	4.98	0.41	2.05e-6	Cognitive ability;
TGCT	cis	rs3820928	1.000	rs2163041	chr2:227772480	T/C	cg11843606	chr2:227700838	RHBDD1	-0.54	-4.82	-0.4	4.12e-6	Pulmonary function;
TGCT	cis	rs262150	0.625	rs55974535	chr7:158769145	C/G	cg01219135	chr7:158766336	NA	-0.51	-5.34	-0.43	4.25e-7	Facial morphology (factor 20);
TGCT	cis	rs12210905	0.610	rs72845033	chr6:27546262	C/T	cg08851530	chr6:28072375	NA	1.34	6.29	0.49	5.02e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs7772486	0.875	rs9403768	chr6:146406458	A/C	cg13319975	chr6:146136371	FBXO30	-0.52	-4.6	-0.38	1.04e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7617773	0.539	rs2017859	chr3:48382261	G/A	cg11946769	chr3:48343235	NME6	0.55	4.6	0.38	1.02e-5	Coronary artery disease;
TGCT	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg11905131	chr22:24372483	LOC391322	0.87	10.19	0.68	4.43e-18	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9467773	0.933	rs2024970	chr6:26497520	T/A	cg05738196	chr6:26577821	NA	0.72	7.91	0.58	1.25e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs4654899	0.931	rs935917	chr1:21167102	A/T	cg01072550	chr1:21505969	NA	-0.5	-7.75	-0.57	2.84e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs7091068	0.659	rs10732241	chr10:95468573	T/C	cg20715218	chr10:95462985	C10orf4	0.55	5.18	0.42	8.59e-7	Urinary tract infection frequency;
TGCT	cis	rs67478160	0.643	rs8003653	chr14:104298836	A/G	cg26031613	chr14:104095156	KLC1	-0.63	-6.53	-0.51	1.56e-9	Schizophrenia;
TGCT	cis	rs9303401	0.614	rs12950028	chr17:56510140	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.58	6.1	0.48	1.23e-8	Cognitive test performance;
TGCT	cis	rs1372520	0.684	rs2583978	chr4:90750326	A/C	cg01966878	chr4:90757139	SNCA	-0.3	-4.76	-0.39	5.2e-6	Neuroticism;
TGCT	cis	rs10465746	0.780	rs11163866	chr1:84367123	A/G	cg10977910	chr1:84465055	TTLL7	0.66	6.56	0.51	1.31e-9	Obesity-related traits;
TGCT	cis	rs9303401	0.614	rs34843288	chr17:57103140	T/C	cg25039879	chr17:56429692	SUPT4H1	0.55	4.93	0.4	2.63e-6	Cognitive test performance;
TGCT	cis	rs17345786	1.000	rs7641261	chr3:101279006	C/T	cg12386194	chr3:101231763	SENP7	0.59	5.45	0.44	2.64e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9921338	0.924	rs72773831	chr16:11412927	G/A	cg00044050	chr16:11439710	C16orf75	-0.93	-6.96	-0.53	1.7e-10	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs4851266	0.966	rs11689199	chr2:100820421	A/G	cg07810366	chr2:100720526	AFF3	-0.4	-5.74	-0.46	6.97e-8	Educational attainment;
TGCT	cis	rs9611565	0.921	rs5751080	chr22:41736267	A/G	cg17554472	chr22:41940697	POLR3H	-0.4	-4.58	-0.38	1.11e-5	Vitiligo;
TGCT	cis	rs6500602	0.929	rs6500603	chr16:4497537	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.29	4.81	0.4	4.37e-6	Schizophrenia;
TGCT	cis	rs9291683	0.575	rs3756223	chr4:10105797	C/T	cg00071950	chr4:10020882	SLC2A9	0.45	4.52	0.38	1.44e-5	Bone mineral density;
TGCT	cis	rs10114408	0.959	rs7874271	chr9:96638818	C/A	cg13679303	chr9:96623674	NA	-0.36	-4.69	-0.39	6.98e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs1538970	0.816	rs61788356	chr1:46006675	C/T	cg05343316	chr1:45956843	TESK2	0.7	5.48	0.44	2.29e-7	Platelet count;
TGCT	cis	rs67311347	1.000	rs66841330	chr3:40531123	G/A	cg13683864	chr3:40499215	RPL14	-1.19	-12.73	-0.75	2.99e-24	Renal cell carcinoma;
TGCT	cis	rs751728	1.000	rs4713684	chr6:33766488	T/C	cg13859433	chr6:33739653	LEMD2	-0.39	-6.99	-0.53	1.51e-10	Crohn's disease;
TGCT	cis	rs10489202	0.608	rs6657019	chr1:168079669	T/C	cg24449463	chr1:168025552	DCAF6	-0.49	-5.06	-0.41	1.45e-6	Schizophrenia;
TGCT	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg15242686	chr22:24348715	GSTTP1	0.43	5.85	0.47	4.12e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs11920354	0.513	rs62248910	chr3:47302036	G/A	cg27129171	chr3:47204927	SETD2	-0.67	-5.08	-0.41	1.38e-6	Granulocyte count;Sum neutrophil eosinophil counts;
TGCT	cis	rs6693567	0.545	rs7553647	chr1:150472666	C/T	cg09579323	chr1:150459698	TARS2	0.53	4.63	0.38	9.01e-6	Migraine;
TGCT	cis	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg22857025	chr5:266934	NA	-0.32	-6.58	-0.51	1.18e-9	Breast cancer;
TGCT	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs4642101	0.824	rs9825233	chr3:12843368	A/G	cg05775895	chr3:12838266	CAND2	-0.72	-7.15	-0.54	6.58e-11	QRS complex (12-leadsum);
TGCT	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.08	0.48	1.37e-8	Bipolar disorder;
TGCT	cis	rs3087591	0.708	rs10438801	chr17:29693785	G/A	cg24425628	chr17:29625626	OMG;NF1	0.39	5.66	0.45	1.01e-7	Hip circumference;
TGCT	cis	rs9677476	0.516	rs6749	chr2:232035429	G/A	cg27665808	chr2:232055229	NA	0.35	4.43	0.37	2.01e-5	Food antigen IgG levels;
TGCT	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	15.94	0.82	8.5e-32	Prudent dietary pattern;
TGCT	cis	rs734999	0.505	rs10797439	chr1:2540364	G/A	cg18854424	chr1:2615690	NA	0.46	5.36	0.43	4e-7	Ulcerative colitis;
TGCT	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg04156016	chr5:1868137	NA	0.35	5.08	0.42	1.33e-6	Cardiovascular disease risk factors;
TGCT	cis	rs17030434	0.906	rs4145339	chr4:154710481	C/T	cg14289246	chr4:154710475	SFRP2	-0.99	-7.77	-0.57	2.51e-12	Electrocardiographic conduction measures;
TGCT	trans	rs11671005	0.504	rs2305119	chr19:59067623	C/T	cg22037779	chr5:139682734	PFDN1	-0.86	-6.8	-0.52	4.03e-10	Mean platelet volume;
TGCT	cis	rs7666738	0.546	rs10018080	chr4:98758436	C/A	cg17366294	chr4:99064904	C4orf37	0.62	5.77	0.46	6.03e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7659604	1.000	rs7689714	chr4:122665943	T/A	cg19748678	chr4:122722346	EXOSC9	0.55	5.31	0.43	4.92e-7	Type 2 diabetes;
TGCT	cis	rs727563	0.608	rs2076200	chr22:41985956	G/T	cg03806693	chr22:41940476	POLR3H	-1.11	-11.64	-0.72	1.26e-21	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs3733585	0.699	rs57574512	chr4:9960182	T/C	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.7	-0.57	3.69e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs67311347	1.000	rs9874499	chr3:40441908	C/T	cg17264618	chr3:40429014	ENTPD3	0.33	4.73	0.39	5.89e-6	Renal cell carcinoma;
TGCT	cis	rs68170813	0.641	rs74451547	chr7:107078435	A/C	cg02696742	chr7:106810147	HBP1	-0.65	-5.15	-0.42	1.01e-6	Coronary artery disease;
TGCT	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg25036284	chr2:26402008	FAM59B	-0.56	-4.88	-0.4	3.2e-6	Gut microbiome composition (summer);
TGCT	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg24846343	chr22:24311635	DDTL	0.25	6.26	0.49	5.83e-9	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1538970	0.924	rs2088100	chr1:45877575	C/T	cg05343316	chr1:45956843	TESK2	0.72	5.53	0.44	1.82e-7	Platelet count;
TGCT	cis	rs9372253	1.000	rs9384740	chr6:110716207	G/A	cg13266496	chr6:110720918	DDO	-0.46	-5.68	-0.45	8.89e-8	Platelet distribution width;
TGCT	cis	rs1008375	1.000	rs10011865	chr4:17645710	G/A	cg16339924	chr4:17578868	LAP3	0.63	5.33	0.43	4.49e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6681544	0.544	rs6696876	chr1:82392040	C/T	cg04226724	chr1:82268649	LPHN2	0.48	5.06	0.41	1.5e-6	Metabolite levels  (X-11787);
TGCT	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.94	7.92	0.58	1.17e-12	Platelet count;
TGCT	cis	rs694739	0.628	rs475032	chr11:64140737	G/C	cg02228329	chr11:64053129	BAD;GPR137	-0.7	-6.8	-0.52	4.02e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs72945132	1.000	rs7938912	chr11:70114885	C/T	cg00319359	chr11:70116639	PPFIA1	0.98	7.07	0.54	9.95e-11	Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs34313689	chr4:99013689	T/C	cg17366294	chr4:99064904	C4orf37	0.68	7.04	0.53	1.17e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs13126513	0.519	rs12641768	chr4:100558594	C/A	cg05468953	chr4:100565104	NA	0.4	5.61	0.45	1.26e-7	Metabolite levels (MHPG);
TGCT	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg00149659	chr3:10157352	C3orf10	0.79	4.96	0.41	2.27e-6	Alzheimer's disease;
TGCT	cis	rs9486719	0.895	rs34051754	chr6:97007754	A/T	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.32	-0.6	1.32e-13	Migraine;Coronary artery disease;
TGCT	cis	rs13064447	0.967	rs9861125	chr3:12765012	G/A	cg20675869	chr3:12750130	NA	-0.19	-4.67	-0.39	7.75e-6	Major depression and alcohol dependence;
TGCT	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	4.56	0.38	1.21e-5	Height;
TGCT	cis	rs758747	0.531	rs8058233	chr16:3638809	G/A	cg07396092	chr16:3662230	BTBD12	0.57	4.88	0.4	3.16e-6	Body mass index;
TGCT	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs9634489	0.502	rs431500	chr13:97102003	C/T	cg11411106	chr13:97107445	HS6ST3	0.26	4.63	0.38	8.92e-6	Body mass index;
TGCT	cis	rs4499344	0.633	rs259246	chr19:33146154	G/C	cg26639809	chr19:33781782	NA	0.22	4.63	0.38	9.01e-6	Mean platelet volume;
TGCT	cis	rs2239547	0.603	rs4687698	chr3:53097108	C/T	cg10802521	chr3:52805072	NEK4	-0.57	-5.24	-0.43	6.68e-7	Schizophrenia;
TGCT	cis	rs7666738	0.830	rs11938686	chr4:98964470	A/G	cg17366294	chr4:99064904	C4orf37	0.73	7.48	0.56	1.18e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1348850	0.632	rs13009207	chr2:178501632	A/G	cg22681709	chr2:178499509	PDE11A	-0.54	-6.63	-0.51	9.22e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs66561647	0.853	rs66824612	chr8:128967819	C/T	cg05480350	chr8:128972681	MIR1205;PVT1	0.22	4.48	0.37	1.71e-5	Hemoglobin concentration;
TGCT	trans	rs10504390	0.656	rs79616747	chr8:66546593	C/A	cg26037026	chr7:1641922	NA	-0.64	-6.84	-0.52	3.29e-10	IgG glycosylation;
TGCT	cis	rs319204	0.761	rs319156	chr5:146304946	T/C	cg25021259	chr5:146258546	PPP2R2B	0.39	4.69	0.39	7.23e-6	Schizophrenia;
TGCT	cis	rs7666738	0.830	rs10012003	chr4:99064881	A/G	cg17366294	chr4:99064904	C4orf37	0.73	7.45	0.56	1.37e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7727544	0.660	rs274563	chr5:131717859	C/A	cg24060327	chr5:131705240	SLC22A5	0.61	6.7	0.52	6.54e-10	Blood metabolite levels;
TGCT	cis	rs1580019	0.587	rs10951338	chr7:32560089	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.57	4.86	0.4	3.43e-6	Cognitive ability;
TGCT	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg04414720	chr1:150670196	GOLPH3L	0.39	5.04	0.41	1.58e-6	Tonsillectomy;
TGCT	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.5	-4.68	-0.39	7.46e-6	Longevity;Endometriosis;
TGCT	cis	rs7100689	0.556	rs6585971	chr10:82145057	G/C	cg01528321	chr10:82214614	TSPAN14	0.78	7.86	0.58	1.56e-12	Post bronchodilator FEV1;
TGCT	cis	rs259282	0.524	rs11878322	chr19:33122886	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.59	5.49	0.44	2.13e-7	Schizophrenia;
TGCT	cis	rs2116941	1.000	rs7250265	chr19:10339818	G/C	cg01850179	chr19:10340795	S1PR2	-0.75	-10.01	-0.67	1.21e-17	Pulse pressure;
TGCT	cis	rs6076065	0.748	rs2295239	chr20:23387550	C/T	cg11657817	chr20:23433608	CST11	0.31	5.42	0.44	3.02e-7	Facial morphology (factor 15, philtrum width);
TGCT	cis	rs9911578	0.934	rs58092632	chr17:57111101	T/C	cg12560992	chr17:57184187	TRIM37	-0.79	-9.55	-0.65	1.52e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs2013441	0.901	rs2526474	chr17:20137134	C/T	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.63	-0.38	9.19e-6	Obesity-related traits;
TGCT	cis	rs7605378	1.000	rs2346662	chr2:200679158	C/T	cg17644776	chr2:200775616	C2orf69	0.25	5.05	0.41	1.52e-6	Osteoporosis;
TGCT	cis	rs2303745	0.622	rs1864113	chr19:17393504	G/C	cg04248312	chr19:17393744	ANKLE1	-0.34	-5.7	-0.46	8.29e-8	Systemic lupus erythematosus;
TGCT	cis	rs2075371	0.966	rs2544224	chr7:133995832	A/G	cg11752832	chr7:134001865	SLC35B4	0.7	6.44	0.5	2.41e-9	Mean platelet volume;
TGCT	cis	rs1023500	0.505	rs134887	chr22:42674239	A/G	cg15557168	chr22:42548783	NA	-0.21	-4.99	-0.41	2.03e-6	Schizophrenia;
TGCT	cis	rs28595532	0.920	rs28797314	chr4:119783044	A/G	cg00700008	chr4:120138107	USP53	0.49	4.48	0.37	1.71e-5	Cannabis dependence symptom count;
TGCT	cis	rs9311474	0.652	rs614288	chr3:52220203	T/C	cg10802521	chr3:52805072	NEK4	-0.56	-6.12	-0.48	1.11e-8	Electroencephalogram traits;
TGCT	cis	rs7412746	0.658	rs7526489	chr1:150726238	C/T	cg09365446	chr1:150670422	GOLPH3L	0.33	4.78	0.39	4.8e-6	Melanoma;
TGCT	cis	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.71	-5.48	-0.44	2.29e-7	Lung cancer in ever smokers;
TGCT	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg11764359	chr7:65958608	NA	0.59	5.28	0.43	5.64e-7	Aortic root size;
TGCT	cis	rs12210905	1.000	rs9393803	chr6:27257714	A/G	cg08851530	chr6:28072375	NA	1.29	5.49	0.44	2.19e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs7681440	0.933	rs10005233	chr4:90743331	C/T	cg14346243	chr4:90757452	SNCA	-0.57	-5.55	-0.45	1.66e-7	Dementia with Lewy bodies;
TGCT	cis	rs1403694	0.515	rs1656925	chr3:186449123	T/C	cg12454167	chr3:186435060	KNG1	0.46	7.19	0.54	5.47e-11	Blood protein levels;
TGCT	cis	rs151997	0.925	rs26087	chr5:50172911	G/A	cg06027927	chr5:50259733	NA	0.46	4.63	0.38	9.01e-6	Callous-unemotional behaviour;
TGCT	cis	rs7126328	1	rs7126328	chr11:120244577	C/T	cg24566217	chr11:120254723	ARHGEF12	-0.29	-4.62	-0.38	9.51e-6	Intraocular pressure;
TGCT	cis	rs986417	1.000	rs1950904	chr14:60964954	G/C	cg27398547	chr14:60952738	C14orf39	1.49	10.81	0.7	1.38e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs9972944	0.756	rs9907996	chr17:63754889	C/T	cg07283582	chr17:63770753	CCDC46	-0.26	-5.09	-0.42	1.27e-6	Total body bone mineral density;
TGCT	cis	rs7772486	0.754	rs9386134	chr6:146145508	G/A	cg23711669	chr6:146136114	FBXO30	0.94	10.97	0.7	5.5e-20	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs57590327	0.503	rs12497231	chr3:81519291	A/G	cg07356753	chr3:81810745	GBE1	0.58	4.89	0.4	3.06e-6	Extraversion;
TGCT	cis	rs11711311	0.955	rs34458493	chr3:113396473	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.76	-6.88	-0.53	2.6200000000000003e-10	IgG glycosylation;
TGCT	cis	rs752010	0.806	rs11210500	chr1:42089737	A/G	cg06885757	chr1:42089581	HIVEP3	0.25	4.56	0.38	1.23e-5	Lupus nephritis in systemic lupus erythematosus;
TGCT	cis	rs3091242	0.967	rs1053438	chr1:25687901	T/C	cg09222892	chr1:25734099	RHCE	0.44	7.13	0.54	7.46e-11	Erythrocyte sedimentation rate;
TGCT	cis	rs6427508	1	rs6427508	chr1:160238857	T/C	cg07195126	chr1:160370843	VANGL2	0.51	4.67	0.39	7.58e-6	Breast size;
TGCT	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg03709012	chr19:19516395	GATAD2A	0.75	6.16	0.48	9.21e-9	Tonsillectomy;
TGCT	cis	rs9303401	0.527	rs34835800	chr17:56764990	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.53	5.05	0.41	1.55e-6	Cognitive test performance;
TGCT	cis	rs8020441	0.786	rs59498790	chr14:51167929	T/A	cg04730355	chr14:51134070	SAV1	0.75	6.1	0.48	1.25e-8	Cognitive performance;
TGCT	cis	rs9291683	0.546	rs4575994	chr4:9997979	G/A	cg00071950	chr4:10020882	SLC2A9	0.6	6.77	0.52	4.6e-10	Bone mineral density;
TGCT	cis	rs7267979	0.586	rs1473695	chr20:25186965	A/G	cg14121845	chr20:25566513	NINL	0.45	4.86	0.4	3.51e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs12682352	0.652	rs1567398	chr8:8726804	A/C	cg08975724	chr8:8085496	FLJ10661	-0.6	-5.76	-0.46	6.15e-8	Neuroticism;
TGCT	cis	rs9796	0.621	rs28737302	chr15:41469943	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.52	-7.17	-0.54	5.94e-11	Menopause (age at onset);
TGCT	cis	rs7267979	0.933	rs11699203	chr20:25435169	G/C	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3806843	0.576	rs246024	chr5:140333952	C/T	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs13082711	0.522	rs7651661	chr3:27362773	G/C	cg02860705	chr3:27208620	NA	0.29	4.85	0.4	3.67e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs7412746	0.658	rs6660845	chr1:150841066	G/A	cg09365446	chr1:150670422	GOLPH3L	0.35	4.98	0.41	2.11e-6	Melanoma;
TGCT	cis	rs13064447	0.817	rs73022951	chr3:12767557	G/A	cg20675869	chr3:12750130	NA	-0.2	-5.03	-0.41	1.65e-6	Major depression and alcohol dependence;
TGCT	cis	rs7178572	0.568	rs1565757	chr15:77657682	C/T	cg15453836	chr15:77711506	NA	-0.42	-4.79	-0.4	4.68e-6	Type 2 diabetes;
TGCT	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg06634786	chr22:41940651	POLR3H	-0.88	-8.54	-0.61	3.98e-14	Vitiligo;
TGCT	cis	rs28595532	0.920	rs115214765	chr4:119728167	C/T	cg14228332	chr4:119757509	SEC24D	1.32	6.38	0.5	3.2e-9	Cannabis dependence symptom count;
TGCT	cis	rs1372520	0.684	rs2583968	chr4:90745395	C/G	cg20003494	chr4:90757398	SNCA	-0.63	-5.06	-0.41	1.48e-6	Neuroticism;
TGCT	cis	rs986417	0.748	rs4400969	chr14:61013298	A/C	cg27398547	chr14:60952738	C14orf39	1.42	8.85	0.62	7.44e-15	Gut microbiota (bacterial taxa);
TGCT	cis	rs644799	1.000	rs557079	chr11:95530125	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	10.57	0.69	5.17e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9549260	0.755	rs2755214	chr13:41149345	T/G	cg21288729	chr13:41239152	FOXO1	1.0	10.34	0.68	1.84e-18	Red blood cell count;
TGCT	cis	rs7611238	0.560	rs7641810	chr3:195055633	G/C	cg27323046	chr3:195102265	ACAP2	0.35	4.75	0.39	5.5e-6	Body mass index;
TGCT	cis	rs1371867	0.875	rs1660319	chr8:101337530	A/G	cg06002616	chr8:101225028	SPAG1	-0.54	-6.29	-0.49	4.88e-9	Atrioventricular conduction;
TGCT	cis	rs9926296	0.632	rs1800286	chr16:89869761	T/C	cg03388025	chr16:89894329	SPIRE2	0.34	4.67	0.39	7.57e-6	Vitiligo;
TGCT	cis	rs12220238	0.915	rs10824197	chr10:76282793	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.89	5.7	0.46	8.36e-8	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg10802521	chr3:52805072	NEK4	-0.71	-8.79	-0.62	1.04e-14	Bipolar disorder;
TGCT	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg03188948	chr7:1209495	NA	0.42	5.65	0.45	1.03e-7	Longevity;Endometriosis;
TGCT	cis	rs28595532	0.920	rs115673173	chr4:119755321	C/T	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg16325326	chr1:53192061	ZYG11B	-0.71	-8.81	-0.62	9.22e-15	Monocyte count;
TGCT	cis	rs9921338	0.961	rs11074958	chr16:11397079	C/T	cg00044050	chr16:11439710	C16orf75	-0.97	-7.1	-0.54	8.61e-11	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs2235642	0.859	rs12599207	chr16:1606445	A/G	cg10465839	chr16:1584050	IFT140;TMEM204	-0.3	-4.93	-0.41	2.53e-6	Coronary artery disease;
TGCT	cis	rs35306767	0.903	rs11253494	chr10:937047	C/T	cg26597838	chr10:835615	NA	0.75	10.54	0.69	6.3e-19	Eosinophil percentage of granulocytes;
TGCT	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.31	-4.76	-0.39	5.36e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7959452	0.590	rs10878974	chr12:69781528	C/G	cg20891283	chr12:69753455	YEATS4	0.83	8.7	0.62	1.68e-14	Blood protein levels;
TGCT	cis	rs6835098	0.539	rs1383628	chr4:174194453	C/T	cg08422745	chr4:174089978	GALNT7	-0.59	-5.97	-0.47	2.31e-8	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs6977660	0.714	rs10276518	chr7:19781325	C/A	cg07541023	chr7:19748670	TWISTNB	0.87	4.92	0.4	2.74e-6	Thyroid stimulating hormone;
TGCT	cis	rs28374715	0.617	rs16971733	chr15:41562030	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.65	-8.7	-0.62	1.71e-14	Ulcerative colitis;
TGCT	cis	rs2658782	0.593	rs2243410	chr11:93255519	T/G	cg15737290	chr11:93063684	CCDC67	0.63	4.71	0.39	6.59e-6	Pulmonary function decline;
TGCT	cis	rs7666738	0.515	rs28615369	chr4:98896858	C/T	cg05340658	chr4:99064831	C4orf37	0.56	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7010267	0.935	rs6415470	chr8:119955111	G/A	cg17171407	chr8:119960777	TNFRSF11B	0.33	6.18	0.49	8.29e-9	Total body bone mineral density (age 45-60);
TGCT	cis	rs2688608	0.839	rs2633311	chr10:75598099	C/T	cg19442545	chr10:75533431	FUT11	0.31	4.53	0.38	1.35e-5	Inflammatory bowel disease;
TGCT	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	5.11	0.42	1.18e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs907683	0.559	rs11685408	chr2:220291474	T/C	cg15015639	chr2:220282977	DES	0.4	5.11	0.42	1.18e-6	Resting heart rate;
TGCT	cis	rs763014	0.966	rs4144003	chr16:645968	C/T	cg09263875	chr16:632152	PIGQ	0.31	6.91	0.53	2.22e-10	Height;
TGCT	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg04267008	chr7:1944627	MAD1L1	-0.41	-5.45	-0.44	2.65e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs7465272	0.530	rs10103161	chr8:143738571	A/G	cg24634471	chr8:143751801	JRK	0.56	5.58	0.45	1.46e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs67311347	0.502	rs3924444	chr3:40576061	T/C	cg13683864	chr3:40499215	RPL14	-0.64	-5.89	-0.47	3.44e-8	Renal cell carcinoma;
TGCT	cis	rs763014	0.966	rs4144003	chr16:645968	C/T	cg07343612	chr16:622815	PIGQ	-0.41	-8.1	-0.59	4.34e-13	Height;
TGCT	cis	rs2456568	0.835	rs1518578	chr11:93656854	G/T	cg14065697	chr11:93583672	C11orf90	-0.39	-4.63	-0.38	9.22e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs6665290	0.904	rs6664955	chr1:227183434	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.98	-19.78	-0.87	3.72e-40	Myeloid white cell count;
TGCT	cis	rs3818285	1.000	rs10787218	chr10:111621456	A/C	cg00817464	chr10:111662876	XPNPEP1	-0.29	-4.5	-0.37	1.53e-5	Superior crus of antihelix expression;
TGCT	cis	rs79349575	0.749	rs1057902	chr17:47005588	C/T	cg07967210	chr17:47022446	SNF8	0.44	6.09	0.48	1.33e-8	Type 2 diabetes;
TGCT	cis	rs2952156	0.684	rs11658786	chr17:37815899	G/A	cg00129232	chr17:37814104	STARD3	-0.22	-4.48	-0.37	1.68e-5	Asthma;
TGCT	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg17178900	chr1:205818956	PM20D1	0.41	4.56	0.38	1.19e-5	Menarche (age at onset);
TGCT	cis	rs11250098	0.567	rs4326350	chr8:10763655	C/G	cg21775007	chr8:11205619	TDH	0.49	4.52	0.38	1.44e-5	Morning vs. evening chronotype;
TGCT	cis	rs2456568	0.741	rs9633811	chr11:93628327	A/G	cg14065697	chr11:93583672	C11orf90	0.38	4.82	0.4	4.06e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg09704166	chr2:114031854	PAX8;LOC440839	-0.34	-4.96	-0.41	2.29e-6	Lymphocyte counts;
TGCT	cis	rs6964587	0.626	rs2188841	chr7:91522641	A/G	cg17063962	chr7:91808500	NA	-0.76	-7.15	-0.54	6.42e-11	Breast cancer;
TGCT	cis	rs6500602	0.964	rs2896893	chr16:4478559	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.3	5.09	0.42	1.28e-6	Schizophrenia;
TGCT	cis	rs12711979	0.509	rs10195596	chr2:3824222	T/G	cg17052675	chr2:3827356	NA	-0.55	-12.72	-0.75	3.04e-24	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs8180040	0.701	rs12491473	chr3:46989904	G/A	cg27129171	chr3:47204927	SETD2	-0.71	-8.9	-0.62	5.58e-15	Colorectal cancer;
TGCT	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg03303774	chr4:1407052	NA	0.32	4.74	0.39	5.74e-6	Obesity-related traits;
TGCT	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg08975724	chr8:8085496	FLJ10661	0.58	5.22	0.42	7.33e-7	Systolic blood pressure;
TGCT	cis	rs4851313	0.527	rs10183150	chr2:100939117	A/G	cg08017756	chr2:100939284	LONRF2	-0.3	-4.92	-0.4	2.7e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2688608	0.592	rs7908825	chr10:75554541	C/G	cg19442545	chr10:75533431	FUT11	0.36	5.7	0.46	8.36e-8	Inflammatory bowel disease;
TGCT	cis	rs13191362	0.507	rs2510207	chr6:163086592	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.66	-5.89	-0.47	3.46e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs554111	0.656	rs17450813	chr1:21264308	T/C	cg01072550	chr1:21505969	NA	0.35	5.33	0.43	4.38e-7	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs709400	1.000	rs55885592	chr14:104126024	C/T	cg26031613	chr14:104095156	KLC1	1.14	17.16	0.84	1.53e-34	Body mass index;
TGCT	cis	rs9948	0.786	rs62152774	chr2:97448377	A/G	cg01990225	chr2:97406019	LMAN2L	-0.88	-4.81	-0.4	4.37e-6	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg08280861	chr8:58055591	NA	0.32	4.46	0.37	1.83e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg04944784	chr2:26401820	FAM59B	-0.68	-6.13	-0.48	1.1e-8	Gut microbiome composition (summer);
TGCT	cis	rs6993813	0.590	rs10955919	chr8:120020918	C/G	cg17171407	chr8:119960777	TNFRSF11B	0.26	4.66	0.39	8.02e-6	Bone mineral density (hip);
TGCT	cis	rs422249	0.511	rs102274	chr11:61557826	T/C	cg19610905	chr11:61596333	FADS2	-1.04	-10.88	-0.7	8.91e-20	Trans fatty acid levels;
TGCT	cis	rs2013441	1.000	rs2165897	chr17:20209721	T/C	cg23224458	chr17:20280056	CCDC144C	-0.41	-4.88	-0.4	3.25e-6	Obesity-related traits;
TGCT	cis	rs6714710	0.580	rs35564270	chr2:98602165	A/G	cg26665480	chr2:98280029	ACTR1B	0.63	6.01	0.47	1.92e-8	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs2201841	0.960	rs10889676	chr1:67722567	C/A	cg25131922	chr1:68698529	GPR177	0.43	4.58	0.38	1.1e-5	Ulcerative colitis;Psoriasis;Crohn's disease;
TGCT	cis	rs3087591	0.573	rs731758	chr17:29723000	C/G	cg24425628	chr17:29625626	OMG;NF1	0.37	5.36	0.43	3.96e-7	Hip circumference;
TGCT	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg03806693	chr22:41940476	POLR3H	-1.13	-13.26	-0.77	1.59e-25	Vitiligo;
TGCT	cis	rs12220898	0.748	rs10776550	chr10:50472901	A/G	cg06072769	chr10:50146962	WDFY4	0.35	4.63	0.38	9.25e-6	Inflammatory biomarkers;
TGCT	cis	rs7000551	0.689	rs10110254	chr8:22309551	G/T	cg12081754	chr8:22256438	SLC39A14	0.3	4.93	0.4	2.55e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg18402987	chr7:1209562	NA	0.39	5.03	0.41	1.64e-6	Longevity;Endometriosis;
TGCT	cis	rs9868809	0.656	rs73078362	chr3:48703917	G/C	cg00383909	chr3:49044727	WDR6	1.3	6.21	0.49	7.36e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs12142240	0.667	rs12062	chr1:46830447	G/T	cg00530320	chr1:46809349	NSUN4	-0.3	-6.22	-0.49	7.07e-9	Menopause (age at onset);
TGCT	cis	rs7474896	0.583	rs34185758	chr10:37990854	T/C	cg25427524	chr10:38739819	LOC399744	-0.33	-4.99	-0.41	2.03e-6	Obesity (extreme);
TGCT	cis	rs8081692	1	rs8081692	chr17:38154595	A/G	cg17467752	chr17:38218738	THRA	0.54	5.17	0.42	8.96e-7	Neutrophil count;
TGCT	cis	rs3091242	0.806	rs35189848	chr1:25788422	A/G	cg10117171	chr1:25599238	RHD	0.32	5.16	0.42	9.43e-7	Erythrocyte sedimentation rate;
TGCT	cis	rs425277	1.000	rs262647	chr1:2095699	C/T	cg24578937	chr1:2090814	PRKCZ	0.32	8.19	0.59	2.64e-13	Height;
TGCT	trans	rs62103177	0.733	rs62103193	chr18:77629217	C/T	cg05926928	chr17:57297772	GDPD1	1.22	11.16	0.71	1.85e-20	Opioid sensitivity;
TGCT	cis	rs4638749	1.000	rs10209928	chr2:108863898	C/T	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.69	-0.39	6.95e-6	Blood pressure;
TGCT	cis	rs10504229	0.520	rs55967509	chr8:57992448	A/G	cg08280861	chr8:58055591	NA	0.34	4.69	0.39	7.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs977747	0.872	rs743270	chr1:47675536	G/C	cg03885399	chr1:47691550	TAL1	-0.42	-5.48	-0.44	2.26e-7	Body mass index;
TGCT	cis	rs11203032	0.831	rs2211599	chr10:90929547	G/A	cg16672925	chr10:90967113	CH25H	0.73	4.5	0.37	1.55e-5	Heart failure;
TGCT	cis	rs7666738	0.677	rs13120306	chr4:99036099	A/T	cg18180107	chr4:99064573	C4orf37	0.59	5.37	0.43	3.73e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7809950	0.817	rs2712224	chr7:107181235	C/A	cg23024343	chr7:107201750	COG5	-0.48	-6.95	-0.53	1.82e-10	Coronary artery disease;
TGCT	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg26338869	chr17:61819248	STRADA	-0.55	-5.08	-0.42	1.34e-6	Prudent dietary pattern;
TGCT	cis	rs7647973	0.626	rs11720705	chr3:49753788	A/G	cg03034192	chr3:50606346	HEMK1;C3orf18	0.36	4.75	0.39	5.61e-6	Menarche (age at onset);
TGCT	cis	rs17681684	0.565	rs12150476	chr17:9763876	A/C	cg15743799	chr17:9805578	RCVRN	-0.27	-5.89	-0.47	3.45e-8	GIP levels in response to oral glucose tolerance test (fasting);
TGCT	cis	rs2153535	0.580	rs9379206	chr6:8458021	C/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs9921338	0.924	rs7204628	chr16:11444572	A/C	cg00044050	chr16:11439710	C16orf75	-0.89	-6.8	-0.52	3.88e-10	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs11690935	0.959	rs12185567	chr2:172560729	A/C	cg13550731	chr2:172543902	DYNC1I2	1.21	13.07	0.76	4.43e-25	Schizophrenia;
TGCT	cis	rs1348850	0.632	rs12467363	chr2:178502512	C/T	cg22681709	chr2:178499509	PDE11A	-0.53	-6.64	-0.51	8.93e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs28785552	0.589	rs7257371	chr19:53243910	A/G	cg04754360	chr19:53238445	ZNF611	-0.61	-4.86	-0.4	3.52e-6	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs74054849	0.850	rs41270277	chr1:15960364	G/A	cg05660106	chr1:15850417	CASP9	0.86	4.48	0.37	1.68e-5	Alcoholic chronic pancreatitis;
TGCT	cis	rs7940866	0.770	rs10750456	chr11:130819634	A/G	cg05962950	chr11:130786565	SNX19	0.74	7.27	0.55	3.54e-11	Schizophrenia;
TGCT	cis	rs148387471	1	rs148387471	chr3:127057551	ATAG/A	cg25436886	chr3:127056972	NA	-0.53	-4.86	-0.4	3.51e-6	Interleukin-10 levels;Interleukin-13 levels;
TGCT	cis	rs6674176	0.628	rs2240447	chr1:44415415	C/T	cg12908607	chr1:44402522	ARTN	-0.68	-8.19	-0.59	2.7e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs7599312	0.534	rs10182996	chr2:213404834	T/C	cg20637307	chr2:213403960	ERBB4	0.91	11.8	0.73	5.21e-22	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs6770219	0.516	rs6444126	chr3:186138608	T/C	cg20306810	chr3:186501757	SNORD2;EIF4A2	0.73	4.45	0.37	1.89e-5	Cerebrospinal T-tau levels;
TGCT	cis	rs6671200	0.915	rs34266846	chr1:95739748	G/A	cg03123541	chr1:95699097	RWDD3	1.0	6.44	0.5	2.43e-9	Stearic acid (18:0) levels;
TGCT	cis	rs10992471	0.651	rs10124058	chr9:95522882	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.58	-5.48	-0.44	2.27e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs16866061	1.000	rs72974238	chr2:225432470	C/A	cg12698349	chr2:225449008	CUL3	1.0	9.83	0.66	3.23e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg05368731	chr17:41323189	NBR1	1.16	13.44	0.77	5.72e-26	Menopause (age at onset);
TGCT	cis	rs9858542	0.953	rs11710037	chr3:49675334	C/G	cg03060546	chr3:49711283	APEH	-0.64	-5.7	-0.46	8.18e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg13395646	chr4:1353034	KIAA1530	-0.39	-4.97	-0.41	2.2e-6	Obesity-related traits;
TGCT	cis	rs11190604	1.000	rs7079136	chr10:102292709	T/C	cg16342193	chr10:102329863	NA	-0.42	-5.37	-0.43	3.74e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.8	5.52	0.44	1.89e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7208859	0.573	rs55661352	chr17:29045628	A/G	cg13385521	chr17:29058706	SUZ12P	0.79	4.75	0.39	5.57e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs2404602	0.692	rs58889902	chr15:77173070	A/C	cg26408565	chr15:76604113	ETFA	-0.36	-4.52	-0.38	1.41e-5	Blood metabolite levels;
TGCT	cis	rs2836950	0.565	rs3171465	chr21:40552307	A/G	cg17971929	chr21:40555470	PSMG1	-0.52	-4.57	-0.38	1.18e-5	Menarche (age at onset);
TGCT	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg23708337	chr7:1209742	NA	0.43	4.96	0.41	2.23e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7267979	1.000	rs6037086	chr20:25306338	A/G	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs858239	0.600	rs13438179	chr7:23143851	T/C	cg05602783	chr7:23145260	KLHL7	-0.68	-5.75	-0.46	6.69e-8	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs9486719	0.857	rs3798293	chr6:97033370	A/G	cg18709589	chr6:96969512	KIAA0776	-0.75	-5.88	-0.47	3.64e-8	Migraine;Coronary artery disease;
TGCT	cis	rs10883723	0.810	rs7094751	chr10:104274818	G/A	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	trans	rs208520	0.526	rs9294682	chr6:66795159	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.09	-16.9	-0.84	5.6e-34	Exhaled nitric oxide output;
TGCT	cis	rs7267979	1.000	rs6115191	chr20:25440478	C/T	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs600231	0.706	rs10896016	chr11:65335705	C/T	cg21890820	chr11:65308645	LTBP3	-0.37	-4.9	-0.4	2.91e-6	Bone mineral density;
TGCT	cis	rs346785	0.692	rs4789273	chr17:74286082	A/G	cg09812376	chr17:74270190	QRICH2	0.32	4.99	0.41	1.99e-6	White matter hyperintensities in ischemic stroke;
TGCT	cis	rs2456568	0.548	rs4402256	chr11:93660803	T/C	cg26875233	chr11:93583750	C11orf90	-0.43	-5.4	-0.44	3.25e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs9911578	1.000	rs304296	chr17:56834229	G/T	cg12560992	chr17:57184187	TRIM37	0.76	9.34	0.64	4.88e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs7809950	1.000	rs987391	chr7:107100794	C/G	cg23024343	chr7:107201750	COG5	-0.34	-5.43	-0.44	2.92e-7	Coronary artery disease;
TGCT	cis	rs6840360	0.530	rs11946622	chr4:152486018	C/T	cg17479576	chr4:152424074	FAM160A1	-0.68	-7.3	-0.55	3.07e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs789859	0.869	rs1773225	chr3:194403578	A/G	cg21106136	chr3:194405973	FAM43A	-0.39	-5.72	-0.46	7.55e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
TGCT	cis	rs2688608	0.592	rs11814282	chr10:75490217	T/C	cg19442545	chr10:75533431	FUT11	-0.37	-5.77	-0.46	5.89e-8	Inflammatory bowel disease;
TGCT	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg21951975	chr1:209979733	IRF6	0.7	6.01	0.47	1.92e-8	Cleft lip with or without cleft palate;
TGCT	cis	rs7017914	0.934	rs7830550	chr8:71570431	C/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.49	-4.57	-0.38	1.17e-5	Bone mineral density;
TGCT	cis	rs477895	0.713	rs12575642	chr11:63979643	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.79	6.65	0.51	8.31e-10	Mean platelet volume;
TGCT	cis	rs12908161	1.000	rs60957376	chr15:85280792	T/G	cg12863693	chr15:85201151	NMB	0.42	4.99	0.41	2.03e-6	Schizophrenia;
TGCT	cis	rs4372836	0.504	rs7601720	chr2:29032478	G/A	cg09522027	chr2:28974177	PPP1CB	-0.55	-5.59	-0.45	1.34e-7	Body mass index;
TGCT	trans	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg27523141	chr10:43048294	ZNF37B	0.7	8.15	0.59	3.36e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7666738	0.830	rs969048	chr4:98988921	T/C	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7647973	1.000	rs10865956	chr3:49581559	C/A	cg05785598	chr3:49045655	WDR6	0.38	4.6	0.38	1.02e-5	Menarche (age at onset);
TGCT	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.63	-6.23	-0.49	6.56e-9	Bipolar disorder;
TGCT	cis	rs1008375	1.000	rs6449323	chr4:17683916	A/T	cg16339924	chr4:17578868	LAP3	0.54	4.5	0.37	1.55e-5	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs13256369	0.851	rs13256611	chr8:8564341	G/A	cg06671706	chr8:8559999	CLDN23	0.34	4.53	0.38	1.38e-5	Obesity-related traits;
TGCT	cis	rs877282	0.853	rs7069720	chr10:754487	A/G	cg17470449	chr10:769945	NA	0.32	4.91	0.4	2.76e-6	Uric acid levels;
TGCT	cis	rs9611565	0.592	rs4822044	chr22:41979668	G/C	cg06634786	chr22:41940651	POLR3H	-0.89	-8.27	-0.6	1.71e-13	Vitiligo;
TGCT	cis	rs7394190	0.748	rs3843939	chr10:75578948	T/C	cg07699608	chr10:75541558	CHCHD1	0.79	4.95	0.41	2.42e-6	Incident atrial fibrillation;
TGCT	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg04772025	chr11:68637568	NA	0.59	6.69	0.52	6.73e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs6918586	0.658	rs198826	chr6:26121153	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.68	6.46	0.5	2.18e-9	Schizophrenia;
TGCT	cis	rs78487399	0.808	rs78108161	chr2:43663848	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.27	-0.43	5.74e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg10862848	chr6:42927986	GNMT	-0.39	-4.7	-0.39	6.86e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs9467711	1.000	rs6908156	chr6:26322861	C/T	cg26531700	chr6:26746687	NA	-0.94	-5.09	-0.42	1.28e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs826838	1.000	rs11183160	chr12:38676702	T/C	cg13010199	chr12:38710504	ALG10B	0.78	6.16	0.48	9.25e-9	Heart rate;
TGCT	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg26338869	chr17:61819248	STRADA	-0.55	-5.03	-0.41	1.65e-6	Prudent dietary pattern;
TGCT	trans	rs7819412	0.805	rs2409710	chr8:10979821	A/G	cg06636001	chr8:8085503	FLJ10661	-0.75	-7.16	-0.54	6.28e-11	Triglycerides;
TGCT	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9894429	0.690	rs12949956	chr17:79542813	C/T	cg21984481	chr17:79567631	NPLOC4	0.26	4.83	0.4	3.98e-6	Eye color traits;
TGCT	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.91	7.43	0.55	1.55e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2334880	0.641	rs12325234	chr16:71459628	A/T	cg06353428	chr16:71660113	MARVELD3	-1.14	-7.12	-0.54	7.54e-11	Malaria;
TGCT	cis	rs916888	0.779	rs430685	chr17:44859148	T/C	cg16520312	chr17:43971471	MAPT;LOC100128977	0.57	4.86	0.4	3.45e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg03161606	chr19:29218774	NA	0.59	5.69	0.45	8.74e-8	Methadone dose in opioid dependence;
TGCT	cis	rs13217239	0.646	rs11756275	chr6:27007113	A/C	cg15659132	chr6:26577336	NA	-0.52	-5.16	-0.42	9.5e-7	Schizophrenia;
TGCT	cis	rs8017423	1.000	rs8017423	chr14:90679910	A/G	cg04374321	chr14:90722782	PSMC1	0.74	7.67	0.57	4.41e-12	Mortality in heart failure;
TGCT	cis	rs3847687	1.000	rs10848269	chr12:131518622	A/G	cg25772418	chr12:131519998	GPR133	-0.31	-5.51	-0.44	1.95e-7	Longevity;
TGCT	cis	rs10883723	0.810	rs7069356	chr10:104254359	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs2836974	0.565	rs34304022	chr21:40579619	G/A	cg17971929	chr21:40555470	PSMG1	0.67	4.59	0.38	1.06e-5	Cognitive function;
TGCT	cis	rs9913156	0.670	rs9894225	chr17:4546559	A/G	cg19197139	chr17:4613644	ARRB2	-0.8	-7.68	-0.57	4.19e-12	Lymphocyte counts;
TGCT	cis	rs9300255	0.602	rs2682431	chr12:123703226	T/A	cg00376283	chr12:123451042	ABCB9	0.73	5.67	0.45	9.46e-8	Neutrophil percentage of white cells;
TGCT	cis	rs2228479	0.764	rs35518096	chr16:89961140	C/A	cg06558623	chr16:89946397	TCF25	0.5	6.04	0.48	1.68e-8	Skin colour saturation;
TGCT	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	5.59	0.45	1.39e-7	Alzheimer's disease;
TGCT	cis	rs9393692	1.000	rs3999544	chr6:26285867	C/T	cg13736514	chr6:26305472	NA	-0.43	-6.28	-0.49	5.32e-9	Educational attainment;
TGCT	cis	rs11098499	0.863	rs6853998	chr4:120475860	C/A	cg09307838	chr4:120376055	NA	0.72	6.9	0.53	2.41e-10	Corneal astigmatism;
TGCT	cis	rs10782582	0.609	rs1630587	chr1:76399787	T/C	cg22875332	chr1:76189707	ACADM	-0.45	-4.53	-0.38	1.34e-5	Daytime sleep phenotypes;
TGCT	cis	rs7582180	0.629	rs13004216	chr2:100945402	G/A	cg14675211	chr2:100938903	LONRF2	0.5	4.78	0.39	4.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs710216	0.957	rs12041787	chr1:43432275	G/C	cg03128534	chr1:43423976	SLC2A1	0.6	4.6	0.38	1.01e-5	Red cell distribution width;
TGCT	cis	rs4478037	0.822	rs3924695	chr3:33122085	C/T	cg19404215	chr3:33155277	CRTAP	1.03	5.38	0.44	3.56e-7	Major depressive disorder;
TGCT	cis	rs16958440	0.867	rs79395141	chr18:44695680	A/G	cg17192377	chr18:44677553	HDHD2	0.63	4.7	0.39	6.74e-6	Sitting height ratio;
TGCT	cis	rs2996428	0.629	rs12135894	chr1:3728061	C/T	cg17848003	chr1:3704513	LRRC47	0.17	4.63	0.38	9.05e-6	Red cell distribution width;
TGCT	cis	rs2836950	0.565	rs2836934	chr21:40564885	A/C	cg06238570	chr21:40685208	BRWD1	-0.62	-6.55	-0.51	1.4e-9	Menarche (age at onset);
TGCT	cis	rs7666738	0.791	rs11097610	chr4:99011795	C/G	cg05340658	chr4:99064831	C4orf37	0.47	5.23	0.43	6.96e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12142240	0.738	rs41293275	chr1:46806429	A/T	cg14993813	chr1:46806288	NSUN4	-0.58	-4.78	-0.39	4.78e-6	Menopause (age at onset);
TGCT	cis	rs941408	1.000	rs759068	chr19:2792566	G/A	cg06609049	chr19:2785107	THOP1	0.8	7.95	0.58	9.77e-13	Total cholesterol levels;
TGCT	cis	rs9674544	0.646	rs6504594	chr17:47142697	C/A	cg07075026	chr17:47091521	IGF2BP1	-0.41	-4.57	-0.38	1.18e-5	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
TGCT	cis	rs2580764	0.565	rs2044291	chr2:55247954	A/G	cg09592903	chr2:55203963	RTN4	-0.27	-6.05	-0.48	1.59e-8	Mean platelet volume;
TGCT	cis	rs858239	0.899	rs2268745	chr7:23317600	G/A	cg05602783	chr7:23145260	KLHL7	-0.66	-5.31	-0.43	4.92e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs7246657	0.525	rs10410594	chr19:37477758	C/T	cg18154014	chr19:37997991	ZNF793	0.73	4.58	0.38	1.11e-5	Coronary artery calcification;
TGCT	cis	rs4886920	0.563	rs4442775	chr15:78079120	T/C	cg03457338	chr15:78040120	NA	0.18	4.51	0.38	1.48e-5	Neuroticism;
TGCT	cis	rs2153535	0.580	rs5001130	chr6:8442298	G/A	cg07606381	chr6:8435919	SLC35B3	0.57	5.25	0.43	6.46e-7	Motion sickness;
TGCT	cis	rs10089	0.953	rs6875982	chr5:127529197	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.79	7.54	0.56	8.56e-12	Ileal carcinoids;
TGCT	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.42	-5.11	-0.42	1.16e-6	Alzheimer's disease;
TGCT	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg03517284	chr6:25882590	NA	-0.63	-5.77	-0.46	5.91e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg24829409	chr8:58192753	C8orf71	-0.59	-4.97	-0.41	2.17e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9633740	1.000	rs7922621	chr10:82251544	C/A	cg01528321	chr10:82214614	TSPAN14	1.0	8.33	0.6	1.25e-13	Post bronchodilator FEV1;
TGCT	cis	rs631288	0.557	rs894470	chr1:146671947	A/G	cg25205988	chr1:146714368	CHD1L	1.33	5.42	0.44	2.97e-7	PR interval in Tripanosoma cruzi seropositivity;
TGCT	cis	rs77633900	0.614	rs2459360	chr15:76868664	C/T	cg21673338	chr15:77095150	SCAPER	-0.51	-4.81	-0.4	4.22e-6	Non-glioblastoma glioma;Glioma;
TGCT	cis	rs6840360	0.593	rs11723227	chr4:152689717	G/A	cg22705602	chr4:152727874	NA	-0.35	-5.94	-0.47	2.62e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs17376456	0.877	rs10057605	chr5:93443950	T/G	cg25358565	chr5:93447407	FAM172A	0.93	8.37	0.6	1.04e-13	Diabetic retinopathy;
TGCT	cis	rs11514810	1.000	rs57444112	chr7:1430892	T/C	cg24899294	chr7:1481343	MICALL2	-0.47	-5.84	-0.46	4.24e-8	Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder;
TGCT	cis	rs7568458	0.840	rs2886722	chr2:85742297	C/T	cg17127132	chr2:85788382	GGCX	-0.66	-6.12	-0.48	1.14e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs8051431	0.544	rs2878492	chr16:71981113	A/T	cg06353428	chr16:71660113	MARVELD3	0.75	6.74	0.52	5.43e-10	LDL cholesterol levels;
TGCT	cis	rs11874712	1.000	rs3765636	chr18:43653660	G/T	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.54	5.28	0.43	5.47e-7	Migraine - clinic-based;
TGCT	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg01341218	chr17:43662625	NA	0.86	7.52	0.56	9.73e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs4746818	1.000	rs10998614	chr10:70923347	G/T	cg04149295	chr10:70884716	VPS26A	0.79	5.44	0.44	2.79e-7	Left atrial antero-posterior diameter;
TGCT	cis	rs28595532	0.920	rs114314373	chr4:119639128	G/A	cg21605333	chr4:119757512	SEC24D	1.36	7.24	0.55	4.12e-11	Cannabis dependence symptom count;
TGCT	cis	rs2688608	0.617	rs6480709	chr10:75479125	T/C	cg23231163	chr10:75533350	FUT11	-0.29	-4.87	-0.4	3.37e-6	Inflammatory bowel disease;
TGCT	cis	rs4478858	0.743	rs11578422	chr1:31707298	C/T	cg00250761	chr1:31883323	NA	-0.3	-5.42	-0.44	2.94e-7	Alcohol dependence;
TGCT	cis	rs11864453	0.679	rs2303285	chr16:72124495	A/C	cg14768367	chr16:72042858	DHODH	0.52	5.21	0.42	7.61e-7	Fibrinogen levels;
TGCT	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.0	0.41	1.89e-6	Menopause (age at onset);
TGCT	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg11890956	chr21:40555474	PSMG1	1.12	12.59	0.75	6.25e-24	Cognitive function;
TGCT	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg12311346	chr5:56204834	C5orf35	-0.67	-6.82	-0.52	3.63e-10	Initial pursuit acceleration;
TGCT	cis	rs1801251	1.000	rs13004406	chr2:233584557	A/T	cg25237894	chr2:233734115	C2orf82	-0.31	-5.52	-0.44	1.93e-7	Coronary artery disease;
TGCT	trans	rs9388451	0.626	rs1935983	chr6:126068914	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.87	-9.71	-0.66	6.39e-17	Brugada syndrome;
TGCT	cis	rs3008870	1.000	rs4655663	chr1:67430103	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.07	10.99	0.7	5.04e-20	Lymphocyte percentage of white cells;
TGCT	cis	rs9300255	0.739	rs1969354	chr12:123741776	T/C	cg00376283	chr12:123451042	ABCB9	0.72	5.54	0.45	1.76e-7	Neutrophil percentage of white cells;
TGCT	cis	rs1800682	0.528	rs3903454	chr10:90743434	A/T	cg03111039	chr10:90751583	FAS;ACTA2	0.62	8.76	0.62	1.23e-14	Chronic lymphocytic leukemia;
TGCT	cis	rs11167764	1.000	rs7722567	chr5:141483178	C/T	cg02659431	chr5:141694439	SPRY4	-0.22	-4.72	-0.39	6.33e-6	Crohn's disease;
TGCT	cis	rs12413816	0.517	rs4750400	chr10:13765923	A/G	cg16485048	chr10:13749193	FRMD4A	0.23	4.59	0.38	1.07e-5	Red cell distribution width;
TGCT	cis	rs2456568	0.503	rs11020603	chr11:93667439	A/G	cg17595323	chr11:93583763	C11orf90	0.47	5.91	0.47	3.08e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs10876993	0.890	rs10783844	chr12:58098425	A/C	cg15848620	chr12:58087721	OS9	-0.72	-5.98	-0.47	2.25e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs2070488	0.775	rs7649984	chr3:38570221	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.64	-5.68	-0.45	9.01e-8	Electrocardiographic conduction measures;
TGCT	cis	rs2549003	1.000	rs9282761	chr5:131822224	T/C	cg21138405	chr5:131827807	IRF1	0.19	4.79	0.39	4.76e-6	Asthma (sex interaction);
TGCT	cis	rs7216064	1.000	rs8082512	chr17:65837059	T/C	cg12091567	chr17:66097778	LOC651250	-0.83	-6.49	-0.5	1.9e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs67311347	1.000	rs9860162	chr3:40403875	C/T	cg17264618	chr3:40429014	ENTPD3	0.31	4.59	0.38	1.09e-5	Renal cell carcinoma;
TGCT	cis	rs7819412	0.715	rs35223712	chr8:11043926	C/T	cg21775007	chr8:11205619	TDH	-0.51	-4.65	-0.39	8.35e-6	Triglycerides;
TGCT	cis	rs240764	0.794	rs4840133	chr6:100914717	C/T	cg21058520	chr6:100914733	NA	0.39	4.73	0.39	5.93e-6	Neuroticism;
TGCT	cis	rs2404602	0.735	rs11637490	chr15:76759565	A/G	cg22467129	chr15:76604101	ETFA	0.48	5.06	0.41	1.5e-6	Blood metabolite levels;
TGCT	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg13607699	chr17:42295918	UBTF	0.84	7.76	0.57	2.72e-12	Total body bone mineral density;
TGCT	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg13206674	chr6:150067644	NUP43	0.52	4.51	0.38	1.5e-5	Lung cancer;
TGCT	cis	rs8073060	0.521	rs225254	chr17:33953384	G/A	cg05299278	chr17:33885742	SLFN14	0.23	5.09	0.42	1.28e-6	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs3820068	0.608	rs9660255	chr1:16031891	T/G	cg05660106	chr1:15850417	CASP9	0.64	5.99	0.47	2.09e-8	Systolic blood pressure;
TGCT	cis	rs35146811	0.844	rs2070215	chr7:99696797	T/C	cg13334819	chr7:99746414	C7orf59	-0.76	-6.38	-0.5	3.17e-9	Coronary artery disease;
TGCT	cis	rs9653442	0.527	rs10176782	chr2:100782827	C/A	cg22139774	chr2:100720529	AFF3	-0.36	-5.69	-0.46	8.67e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs10193935	0.901	rs17029344	chr2:42444287	T/C	cg27598129	chr2:42591480	NA	-0.39	-5.16	-0.42	9.46e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg10117171	chr1:25599238	RHD	-0.36	-5.72	-0.46	7.56e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs56104184	0.775	rs55756106	chr19:49403055	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.73	-9.15	-0.63	1.47e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs8014204	0.587	rs6574201	chr14:75387256	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.9	-9.51	-0.65	1.92e-16	Caffeine consumption;
TGCT	cis	rs3806843	0.771	rs2563336	chr5:140107199	A/G	cg19875535	chr5:140030758	IK	-0.36	-6.1	-0.48	1.23e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs6684514	1.000	rs12139321	chr1:156230429	A/G	cg20302342	chr1:156215951	PAQR6	0.37	4.72	0.39	6.38e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs11118844	0.843	rs4601596	chr1:221914458	C/T	cg04222084	chr1:221915650	DUSP10	-0.88	-5.95	-0.47	2.59e-8	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
TGCT	cis	rs1635	0.826	rs115041649	chr6:28274653	G/C	cg15743358	chr6:28303923	ZNF323	-1.34	-5.96	-0.47	2.44e-8	Schizophrenia;
TGCT	cis	rs7666738	0.830	rs4443293	chr4:99063120	G/A	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.44e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg21724239	chr8:58056113	NA	0.42	5.04	0.41	1.59e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg07138768	chr7:917805	C7orf20	0.44	5.81	0.46	4.98e-8	Perceived unattractiveness to mosquitoes;
TGCT	cis	rs11585357	0.842	rs72633804	chr1:17617024	T/C	cg08277548	chr1:17600880	PADI3	-0.96	-9.72	-0.66	5.97e-17	Hair shape;
TGCT	cis	rs1667284	1.000	rs1667284	chr18:29226208	C/T	cg15259973	chr18:29078565	DSG2	-0.5	-4.78	-0.39	4.86e-6	Problematic alcohol use in trauma-exposed individuals;
TGCT	cis	rs6598955	0.671	rs6658935	chr1:26568912	G/A	cg04990556	chr1:26633338	UBXN11	0.64	5.11	0.42	1.19e-6	Obesity-related traits;
TGCT	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg22535103	chr8:58192502	C8orf71	-0.41	-4.81	-0.4	4.27e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs11690935	0.959	rs10803863	chr2:172535337	T/C	cg13550731	chr2:172543902	DYNC1I2	1.2	12.8	0.75	2.01e-24	Schizophrenia;
TGCT	cis	rs72615157	0.634	rs7789890	chr7:99800559	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.64	5.1	0.42	1.26e-6	Lung function (FEV1/FVC);
TGCT	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg03388025	chr16:89894329	SPIRE2	0.48	8.07	0.59	5.2e-13	Vitiligo;
TGCT	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg02546618	chr19:19431379	KIAA0892;SF4	-0.62	-5.2	-0.42	8.07e-7	Tonsillectomy;
TGCT	cis	rs548987	0.507	rs3757132	chr6:25832691	C/T	cg12310025	chr6:25882481	NA	-0.57	-4.67	-0.39	7.69e-6	Homocysteine levels;
TGCT	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg24675658	chr1:53192096	ZYG11B	-0.69	-8.16	-0.59	3.23e-13	Monocyte count;
TGCT	cis	rs11669910	1	rs11669910	chr19:45741333	A/T	cg20198684	chr19:45742032	NA	0.3	5.46	0.44	2.53e-7	Sum eosinophil basophil counts;
TGCT	cis	rs7937682	0.640	rs587010	chr11:111425658	C/A	cg09085632	chr11:111637200	PPP2R1B	-0.8	-8.33	-0.6	1.3e-13	Primary sclerosing cholangitis;
TGCT	cis	rs6540559	0.673	rs6694552	chr1:209976459	A/C	cg21951975	chr1:209979733	IRF6	0.69	5.42	0.44	2.99e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs3892630	0.878	rs8112955	chr19:33191192	C/T	cg22980127	chr19:33182716	NUDT19	0.7	5.18	0.42	8.9e-7	Red blood cell traits;
TGCT	cis	rs992157	0.798	rs1017698	chr2:219170525	A/G	cg00012203	chr2:219082015	ARPC2	-0.76	-7.6	-0.56	6.17e-12	Colorectal cancer;
TGCT	cis	rs3796352	1.000	rs71301804	chr3:53073314	C/A	cg07884673	chr3:53033167	SFMBT1	0.6	6.24	0.49	6.25e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg24675658	chr1:53192096	ZYG11B	0.88	11.74	0.73	7.52e-22	Monocyte count;
TGCT	cis	rs12579753	0.917	rs12366599	chr12:82212112	C/T	cg21231944	chr12:82153410	PPFIA2	-0.33	-4.45	-0.37	1.88e-5	Resting heart rate;
TGCT	cis	rs6969780	0.915	rs4722659	chr7:27166750	C/T	cg04321618	chr7:27170880	HOXA4	-0.5	-4.81	-0.4	4.35e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs514406	0.698	rs11206043	chr1:53402552	C/T	cg01802117	chr1:53393560	SCP2	-0.44	-5.45	-0.44	2.55e-7	Monocyte count;
TGCT	cis	rs9467773	0.620	rs2494716	chr6:26662736	T/C	cg05738196	chr6:26577821	NA	0.88	10.63	0.69	3.68e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs950776	0.518	rs12594391	chr15:78816240	A/G	cg06917634	chr15:78832804	PSMA4	0.96	9.71	0.66	6.43e-17	Sudden cardiac arrest;
TGCT	cis	rs12620999	0.887	rs6723783	chr2:237963572	C/A	cg23555395	chr2:238036564	NA	0.29	4.95	0.41	2.35e-6	Systemic lupus erythematosus;
TGCT	cis	rs7267979	0.966	rs2257233	chr20:25265984	A/C	cg14121845	chr20:25566513	NINL	-0.5	-5.25	-0.43	6.34e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs12048904	0.505	rs11166508	chr1:101233511	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.75	-6.69	-0.52	6.77e-10	Multiple sclerosis;
TGCT	cis	rs3749237	0.557	rs7631908	chr3:49425707	T/G	cg03060546	chr3:49711283	APEH	0.77	8.87	0.62	6.79e-15	Resting heart rate;
TGCT	cis	rs7586879	0.639	rs4077678	chr2:25122840	C/G	cg15423357	chr2:25149977	NA	0.5	4.89	0.4	3.06e-6	Body mass index;
TGCT	cis	rs4478858	0.654	rs113490486	chr1:31712863	C/G	cg00250761	chr1:31883323	NA	-0.27	-4.89	-0.4	3.11e-6	Alcohol dependence;
TGCT	cis	rs6121246	0.697	rs6060446	chr20:30231637	T/C	cg21427119	chr20:30132790	HM13	-0.37	-5.19	-0.42	8.51e-7	Mean corpuscular hemoglobin;
TGCT	cis	rs7666738	0.830	rs7696686	chr4:98938445	T/C	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7943203	0.568	rs179110	chr11:108254999	T/C	cg04873221	chr11:107992290	ACAT1	-0.59	-5.0	-0.41	1.87e-6	Red blood cell count;Mean corpuscular volume;
TGCT	cis	rs13191362	0.938	rs35211042	chr6:162998703	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.68	5.79	0.46	5.33e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg01341218	chr17:43662625	NA	0.81	7.07	0.54	9.95e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg07138768	chr7:917805	C7orf20	-0.37	-4.77	-0.39	5.12e-6	Perceived unattractiveness to mosquitoes;
TGCT	cis	rs9972944	0.729	rs2024275	chr17:63768913	C/T	cg07283582	chr17:63770753	CCDC46	-0.26	-5.27	-0.43	5.91e-7	Total body bone mineral density;
TGCT	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg09436375	chr6:42928200	GNMT	-0.4	-5.19	-0.42	8.34e-7	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs17433780	0.857	rs12140979	chr1:89467242	C/G	cg09516651	chr1:89888402	LOC400759	0.32	5.89	0.47	3.35e-8	Carotid intima media thickness;
TGCT	cis	rs2439831	0.681	rs1095386	chr15:43609509	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	6.63	0.51	9.35e-10	Lung cancer in ever smokers;
TGCT	cis	rs3008870	0.958	rs34367328	chr1:67445321	T/C	cg11518657	chr1:67396239	MIER1	-0.54	-4.61	-0.38	9.72e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs933688	1.000	rs10073657	chr5:90689749	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.95	8.81	0.62	9.38e-15	Smoking behavior;
TGCT	cis	rs7100689	0.577	rs9420349	chr10:82031160	T/C	cg01528321	chr10:82214614	TSPAN14	0.7	6.87	0.52	2.78e-10	Post bronchodilator FEV1;
TGCT	cis	rs10791097	0.694	rs10791100	chr11:130738946	T/A	cg14779329	chr11:130786720	SNX19	0.28	4.82	0.4	4.09e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.25	4.47	0.37	1.75e-5	Total body bone mineral density;
TGCT	cis	rs3008870	0.755	rs4655662	chr1:67416432	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.79	8.31	0.6	1.44e-13	Lymphocyte percentage of white cells;
TGCT	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg13607699	chr17:42295918	UBTF	0.79	7.3	0.55	2.99e-11	Total body bone mineral density;
TGCT	cis	rs2013441	1.000	rs2526480	chr17:20130074	A/G	cg18979559	chr17:20280153	CCDC144C	0.48	4.84	0.4	3.75e-6	Obesity-related traits;
TGCT	cis	rs8013055	0.846	rs8003942	chr14:105971670	A/G	cg25008857	chr14:105974488	NA	0.27	4.65	0.39	8.35e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs9372498	0.536	rs62422221	chr6:118925581	T/C	cg07617317	chr6:118971624	C6orf204	0.47	4.95	0.41	2.33e-6	Diastolic blood pressure;
TGCT	cis	rs763121	0.853	rs2413544	chr22:39059404	A/C	cg06022373	chr22:39101656	GTPBP1	0.77	7.51	0.56	9.9e-12	Menopause (age at onset);
TGCT	cis	rs117533700	1.000	rs117122405	chr19:13116436	G/A	cg14678774	chr19:12978360	MAST1	-0.87	-4.44	-0.37	1.94e-5	Monocyte count;
TGCT	trans	rs1814175	0.791	rs10769625	chr11:49869887	G/A	cg03929089	chr4:120376271	NA	-0.72	-8.26	-0.6	1.84e-13	Height;
TGCT	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/A	cg03388025	chr16:89894329	SPIRE2	0.49	7.48	0.56	1.2e-11	Vitiligo;
TGCT	cis	rs75059851	0.756	rs73036081	chr11:133840156	C/T	cg14047540	chr11:133829660	NA	-0.57	-5.69	-0.45	8.72e-8	Schizophrenia;
TGCT	cis	rs4455778	0.519	rs10227532	chr7:49048208	A/G	cg26309511	chr7:48887640	NA	0.51	6.66	0.51	7.85e-10	Lung cancer in never smokers;
TGCT	cis	rs1008375	1.000	rs6449323	chr4:17683916	A/T	cg10189774	chr4:17578691	LAP3	0.55	4.87	0.4	3.37e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs17221829	0.599	rs7112871	chr11:89404829	G/A	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.44	-0.37	1.93e-5	Anxiety in major depressive disorder;
TGCT	trans	rs11722228	0.549	rs62288521	chr4:10099772	G/A	cg26043149	chr18:55253948	FECH	1.16	11.2	0.71	1.55e-20	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs4319547	0.956	rs9988963	chr12:122991478	C/G	cg23029597	chr12:123009494	RSRC2	-0.32	-5.13	-0.42	1.09e-6	Body mass index;
TGCT	cis	rs7264396	0.790	rs6060562	chr20:34282053	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.3	-5.31	-0.43	4.87e-7	Total cholesterol levels;
TGCT	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg06873352	chr17:61820015	STRADA	0.56	6.19	0.49	8.27e-9	Prudent dietary pattern;
TGCT	cis	rs739496	0.894	rs10849947	chr12:111864684	T/C	cg10833066	chr12:111807467	FAM109A	0.36	5.51	0.44	2.01e-7	Platelet count;
TGCT	cis	rs78545713	0.892	rs11751286	chr6:26241361	C/G	cg12260798	chr6:26240519	HIST1H4F	-0.51	-4.68	-0.39	7.29e-6	Iron status biomarkers (total iron binding capacity);
TGCT	cis	rs7677751	0.537	rs964259	chr4:55057222	C/G	cg17187183	chr4:55093834	PDGFRA	0.42	5.28	0.43	5.49e-7	Corneal astigmatism;
TGCT	cis	rs782590	0.620	rs7596377	chr2:55888612	T/A	cg18811423	chr2:55921094	PNPT1	-0.61	-5.57	-0.45	1.5e-7	Metabolic syndrome;
TGCT	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.77	-7.48	-0.56	1.17e-11	Prudent dietary pattern;
TGCT	cis	rs77633900	0.614	rs203753	chr15:76946195	A/T	cg21673338	chr15:77095150	SCAPER	-0.52	-4.92	-0.4	2.72e-6	Non-glioblastoma glioma;Glioma;
TGCT	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg21226059	chr5:178986404	RUFY1	0.46	5.03	0.41	1.66e-6	Lung cancer;
TGCT	cis	rs9467711	0.659	rs34246779	chr6:26549212	G/A	cg16898833	chr6:26189333	HIST1H4D	1.25	5.86	0.47	3.88e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs3820068	0.580	rs12760698	chr1:16009814	G/A	cg17385448	chr1:15911702	AGMAT	0.34	4.69	0.39	7.06e-6	Systolic blood pressure;
TGCT	cis	rs11651000	0.625	rs11079786	chr17:45805916	A/G	cg24803719	chr17:45855879	NA	0.45	5.04	0.41	1.6e-6	IgG glycosylation;
TGCT	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg13395646	chr4:1353034	KIAA1530	-0.39	-4.97	-0.41	2.2e-6	Obesity-related traits;
TGCT	cis	rs4796354	0.639	rs4796558	chr17:6696984	A/C	cg04115740	chr17:6690948	FBXO39	0.25	4.45	0.37	1.86e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9467773	0.620	rs2451732	chr6:26622904	A/T	cg02458000	chr6:26745757	NA	-0.56	-5.06	-0.41	1.45e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6831352	0.703	rs2602854	chr4:100028651	C/T	cg12011299	chr4:100065546	ADH4	0.39	5.2	0.42	8.04e-7	Alcohol dependence;
TGCT	cis	rs909674	0.690	rs5750823	chr22:39829973	C/T	cg11247378	chr22:39784982	NA	-0.73	-8.55	-0.61	3.78e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs7666738	0.830	rs34870112	chr4:99045815	T/G	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg14784868	chr12:69753453	YEATS4	0.9	10.55	0.69	5.67e-19	Cerebrospinal fluid biomarker levels;
TGCT	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg21548813	chr6:291882	DUSP22	-0.73	-7.58	-0.56	6.89e-12	Menopause (age at onset);
TGCT	cis	rs478304	0.593	rs6591188	chr11:65467953	T/C	cg27068330	chr11:65405492	SIPA1	-1.01	-11.31	-0.71	8.13e-21	Acne (severe);
TGCT	cis	rs9611565	0.879	rs5758307	chr22:41750219	A/G	cg06634786	chr22:41940651	POLR3H	-0.8	-7.58	-0.56	7.14e-12	Vitiligo;
TGCT	cis	rs2070488	0.775	rs11926767	chr3:38527913	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.69	-6.13	-0.48	1.09e-8	Electrocardiographic conduction measures;
TGCT	cis	rs7394579	1	rs7394579	chr11:61581450	A/G	cg01500311	chr11:61656094	FADS3	-0.28	-4.47	-0.37	1.75e-5	Red cell distribution width;Mean platelet volume;
TGCT	cis	rs7635838	0.654	rs346083	chr3:11280017	T/C	cg00170343	chr3:11313890	ATG7	0.66	6.26	0.49	5.67e-9	HDL cholesterol;
TGCT	cis	rs9399135	0.967	rs6569990	chr6:135365818	C/T	cg24558204	chr6:135376177	HBS1L	0.46	4.55	0.38	1.24e-5	Red blood cell count;
TGCT	cis	rs9308731	0.965	rs6758181	chr2:111886914	C/T	cg04202892	chr2:111875749	ACOXL	0.44	4.63	0.38	9.09e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs28595532	1.000	rs114682099	chr4:119702004	C/T	cg21605333	chr4:119757512	SEC24D	1.41	7.28	0.55	3.45e-11	Cannabis dependence symptom count;
TGCT	cis	rs10791097	0.690	rs12286234	chr11:130730528	T/C	cg12179176	chr11:130786555	SNX19	0.73	8.6	0.61	2.98e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9527	0.590	rs1807298	chr10:104870218	G/A	cg15744005	chr10:104629667	AS3MT	-0.43	-4.9	-0.4	2.89e-6	Arsenic metabolism;
TGCT	cis	rs9916302	0.595	rs4795371	chr17:37636695	T/G	cg07936489	chr17:37558343	FBXL20	-0.61	-4.85	-0.4	3.6e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7772486	0.846	rs1854901	chr6:146325685	T/C	cg23711669	chr6:146136114	FBXO30	0.84	9.12	0.63	1.72e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs13217239	0.646	rs11756275	chr6:27007113	A/C	cg26531700	chr6:26746687	NA	-0.68	-6.71	-0.52	6.07e-10	Schizophrenia;
TGCT	cis	rs7943191	0.805	rs12226821	chr11:62369018	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.6	5.98	0.47	2.24e-8	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs3008870	0.920	rs3008865	chr1:67402838	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.1	11.97	0.73	2.07e-22	Lymphocyte percentage of white cells;
TGCT	trans	rs1814175	0.817	rs1851858	chr11:49855638	G/A	cg15704280	chr7:45808275	SEPT13	-0.72	-8.14	-0.59	3.61e-13	Height;
TGCT	cis	rs950169	0.887	rs62029593	chr15:84955180	A/G	cg12863693	chr15:85201151	NMB	0.45	4.96	0.41	2.28e-6	Schizophrenia;
TGCT	cis	rs2153535	0.601	rs4960414	chr6:8438541	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.58	0.45	1.42e-7	Motion sickness;
TGCT	cis	rs514406	0.621	rs928452	chr1:53195926	G/C	cg22166914	chr1:53195759	ZYG11B	-0.5	-9.42	-0.65	3.19e-16	Monocyte count;
TGCT	cis	rs9611565	0.559	rs12483860	chr22:41961916	C/T	cg03806693	chr22:41940476	POLR3H	-1.08	-11.36	-0.71	6.34e-21	Vitiligo;
TGCT	cis	rs9916302	0.904	rs634365	chr17:37436966	C/T	cg15445000	chr17:37608096	MED1	0.31	4.68	0.39	7.45e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg24531977	chr5:56204891	C5orf35	-0.75	-7.31	-0.55	2.87e-11	Initial pursuit acceleration;
TGCT	cis	rs13086611	1	rs13086611	chr3:49385417	A/T	cg03060546	chr3:49711283	APEH	-0.65	-5.65	-0.45	1.04e-7	Educational attainment;
TGCT	cis	rs1371867	0.810	rs2919470	chr8:101233301	C/A	cg00191853	chr8:101177733	SPAG1	0.25	4.96	0.41	2.24e-6	Atrioventricular conduction;
TGCT	cis	rs11648796	0.680	rs11248946	chr16:768597	A/G	cg27144592	chr16:783916	NARFL	0.4	5.48	0.44	2.3e-7	Height;
TGCT	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg13770153	chr20:60521292	NA	-0.63	-7.95	-0.58	9.71e-13	Body mass index;
TGCT	cis	rs59698941	0.550	rs11748063	chr5:132200943	C/T	cg21474247	chr5:131268130	NA	0.31	4.77	0.39	5.01e-6	Apolipoprotein A-IV levels;
TGCT	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg24531977	chr5:56204891	C5orf35	-0.74	-7.14	-0.54	7.06e-11	Initial pursuit acceleration;
TGCT	cis	rs916888	0.610	rs199446	chr17:44813169	G/A	cg15921436	chr17:44337874	NA	-0.41	-6.27	-0.49	5.47e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg19748678	chr4:122722346	EXOSC9	0.89	8.94	0.63	4.53e-15	Type 2 diabetes;
TGCT	cis	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg20637647	chr7:64974828	NA	0.9	5.31	0.43	4.87e-7	Diabetic kidney disease;
TGCT	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg24399712	chr22:39784796	NA	-1.06	-12.58	-0.75	6.72e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs9916302	0.904	rs2061342	chr17:37405657	T/G	cg07936489	chr17:37558343	FBXL20	-0.65	-5.24	-0.43	6.62e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs9921338	0.961	rs57579443	chr16:11442997	G/C	cg00044050	chr16:11439710	C16orf75	-0.91	-7.1	-0.54	8.47e-11	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs4822044	0.560	rs7284839	chr22:42010902	C/T	cg13695892	chr22:41940480	POLR3H	0.88	8.46	0.6	6.38e-14	Cannabis dependence symptom count;
TGCT	cis	rs7618915	0.547	rs11719685	chr3:52676065	C/T	cg07507251	chr3:52567010	NT5DC2	0.48	6.73	0.52	5.48e-10	Bipolar disorder;
TGCT	cis	rs4700695	0.668	rs166180	chr5:65499225	C/T	cg21114390	chr5:65439923	SFRS12	-0.81	-7.72	-0.57	3.34e-12	Facial morphology (factor 19);
TGCT	cis	rs4321325	0.668	rs56346774	chr2:127932551	G/A	cg09760422	chr2:128146352	NA	0.44	4.47	0.37	1.76e-5	Protein C levels;
TGCT	cis	rs6866344	0.697	rs11739893	chr5:178127837	G/A	cg03877680	chr5:178157825	ZNF354A	0.72	5.61	0.45	1.27e-7	Neutrophil percentage of white cells;
TGCT	cis	rs259282	0.574	rs4805780	chr19:33114406	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.5	4.56	0.38	1.2e-5	Schizophrenia;
TGCT	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg01802117	chr1:53393560	SCP2	0.49	6.02	0.48	1.86e-8	Monocyte count;
TGCT	cis	rs36051895	0.695	rs11794778	chr9:5023794	G/T	cg02405213	chr9:5042618	JAK2	-0.77	-10.45	-0.68	1e-18	Pediatric autoimmune diseases;
TGCT	cis	rs42648	0.935	rs42624	chr7:89957541	C/G	cg25739043	chr7:89950458	NA	-0.75	-7.61	-0.56	5.9e-12	Homocysteine levels;
TGCT	cis	rs2439831	0.681	rs825739	chr15:43592428	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	6.39	0.5	3.1e-9	Lung cancer in ever smokers;
TGCT	cis	rs6674176	0.628	rs4660759	chr1:44432500	C/G	cg13606994	chr1:44402422	ARTN	-0.47	-5.08	-0.41	1.37e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs6840360	0.550	rs7683134	chr4:152503362	A/C	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.0	-0.58	7.69e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs2197308	0.619	rs4002730	chr12:37876400	T/C	cg13010199	chr12:38710504	ALG10B	0.67	5.38	0.44	3.57e-7	Morning vs. evening chronotype;
TGCT	cis	rs10492096	0.947	rs10849482	chr12:6635274	G/A	cg00459232	chr12:6309025	CD9	0.36	4.47	0.37	1.77e-5	Hip geometry;
TGCT	cis	rs1348850	0.914	rs4893823	chr2:178285811	C/T	cg22681709	chr2:178499509	PDE11A	0.35	4.56	0.38	1.2e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs9457247	0.967	rs385460	chr6:167403888	A/T	cg23791538	chr6:167370224	RNASET2	-0.49	-4.96	-0.41	2.26e-6	Crohn's disease;
TGCT	trans	rs7726839	0.561	rs72703046	chr5:580129	T/C	cg25482853	chr8:67687455	SGK3	1.05	9.29	0.64	6.67e-16	Obesity-related traits;
TGCT	cis	rs711830	0.965	rs6755777	chr2:177043226	T/G	cg13092806	chr2:177043255	NA	0.77	6.12	0.48	1.14e-8	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
TGCT	cis	rs651907	0.557	rs7629753	chr3:101371922	C/T	cg12386194	chr3:101231763	SENP7	-0.48	-4.72	-0.39	6.28e-6	Colorectal cancer;
TGCT	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg25767906	chr1:53392781	SCP2	-0.61	-7.2	-0.54	5.02e-11	Monocyte count;
TGCT	cis	rs526231	0.543	rs7709726	chr5:102327463	A/G	cg23492399	chr5:102201601	PAM	0.51	4.47	0.37	1.78e-5	Primary biliary cholangitis;
TGCT	cis	rs74417235	0.517	rs13179034	chr5:154059487	C/A	cg08754654	chr5:154026448	NA	0.58	5.53	0.44	1.84e-7	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
TGCT	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1941023	0.503	rs894591	chr11:60132647	T/C	cg08716584	chr11:60157161	MS4A7	-0.31	-4.53	-0.38	1.34e-5	Congenital heart disease (maternal effect);
TGCT	cis	rs832540	0.629	rs3309	chr5:56092779	A/T	cg24531977	chr5:56204891	C5orf35	0.52	4.99	0.41	1.97e-6	Coronary artery disease;
TGCT	cis	rs2197308	0.631	rs4882308	chr12:38446252	G/C	cg26384229	chr12:38710491	ALG10B	-0.54	-4.81	-0.4	4.32e-6	Morning vs. evening chronotype;
TGCT	cis	rs1371867	0.875	rs1788176	chr8:101332112	A/G	cg06636551	chr8:101224915	SPAG1	-0.48	-6.52	-0.51	1.62e-9	Atrioventricular conduction;
TGCT	cis	rs3733585	0.699	rs6449174	chr4:9966422	C/T	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.5	-0.56	1.05e-11	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.7	6.33	0.49	4.02e-9	Tonsillectomy;
TGCT	cis	rs682748	0.846	rs6859179	chr5:17141484	C/G	cg23987134	chr5:17158319	LOC285696	-0.21	-5.19	-0.42	8.4e-7	Hippocampal atrophy;
TGCT	cis	rs10114408	0.959	rs10821246	chr9:96645759	A/T	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs881375	0.678	rs10118357	chr9:123680068	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	5.77	0.46	5.87e-8	Rheumatoid arthritis;
TGCT	cis	rs7829975	0.811	rs7011229	chr8:8543324	T/C	cg15556689	chr8:8085844	FLJ10661	-0.69	-6.07	-0.48	1.46e-8	Mood instability;
TGCT	cis	rs910316	1.000	rs3742773	chr14:75579643	A/G	cg23033748	chr14:75592666	NEK9	0.28	4.72	0.39	6.22e-6	Height;
TGCT	cis	rs12908161	0.960	rs11633450	chr15:85307287	C/T	cg11189052	chr15:85197271	WDR73	0.71	5.21	0.42	7.63e-7	Schizophrenia;
TGCT	cis	rs116161686	0.521	rs701941	chr1:210439529	G/A	cg22029157	chr1:209979665	IRF6	0.62	4.46	0.37	1.79e-5	Coronary artery disease;
TGCT	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.85	7.0	0.53	1.44e-10	Platelet count;
TGCT	cis	rs10423674	0.526	rs11668545	chr19:18829529	C/T	cg20185461	chr19:18899082	COMP	-0.5	-4.73	-0.39	6.09e-6	Menarche (age at onset);
TGCT	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg21724239	chr8:58056113	NA	0.42	5.04	0.41	1.59e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg27454412	chr7:1067447	C7orf50	0.52	4.57	0.38	1.16e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1401999	1.000	rs2313217	chr3:183635997	A/G	cg01324343	chr3:183735012	ABCC5	0.85	11.48	0.72	3.16e-21	Anterior chamber depth;
TGCT	cis	rs3820928	0.874	rs3752895	chr2:227886773	A/G	cg11843606	chr2:227700838	RHBDD1	-0.51	-4.71	-0.39	6.63e-6	Pulmonary function;
TGCT	cis	rs2718812	0.792	rs3772680	chr3:133371807	A/G	cg08048268	chr3:133502702	NA	-0.38	-4.73	-0.39	6.03e-6	Iron status biomarkers;
TGCT	cis	rs9303401	0.659	rs62083410	chr17:56964386	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs7760949	0.963	rs4142889	chr6:13918461	T/A	cg27413430	chr6:13925136	RNF182	0.61	5.8	0.46	5.08e-8	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg08509172	chr19:19383838	TM6SF2	-0.35	-4.59	-0.38	1.08e-5	Tonsillectomy;
TGCT	cis	rs9435341	0.965	rs1762485	chr1:107625056	C/T	cg09367891	chr1:107599246	PRMT6	-0.61	-5.2	-0.42	8.08e-7	Facial morphology (factor 21, depth of nasal alae);
TGCT	cis	rs12048904	0.541	rs6699536	chr1:101276544	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.87	7.77	0.57	2.6e-12	Multiple sclerosis;
TGCT	cis	rs854765	0.547	rs7224047	chr17:17932931	G/A	cg04398451	chr17:18023971	MYO15A	-0.32	-5.15	-0.42	1.01e-6	Total body bone mineral density;
TGCT	cis	rs4851254	0.660	rs56037757	chr2:100690130	A/G	cg07810366	chr2:100720526	AFF3	-0.49	-5.22	-0.42	7.36e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs11252926	0.550	rs10904148	chr10:454551	G/T	cg18196295	chr10:418757	DIP2C	0.28	4.45	0.37	1.92e-5	Psychosis in Alzheimer's disease;
TGCT	cis	rs35306767	0.855	rs35666723	chr10:867346	A/G	cg26597838	chr10:835615	NA	0.8	12.0	0.73	1.67e-22	Eosinophil percentage of granulocytes;
TGCT	cis	rs7940866	0.903	rs7942900	chr11:130839244	G/A	cg12179176	chr11:130786555	SNX19	0.53	5.05	0.41	1.56e-6	Schizophrenia;
TGCT	cis	rs17376456	0.569	rs6556839	chr5:93206292	T/C	cg21475434	chr5:93447410	FAM172A	-0.7	-5.15	-0.42	1.02e-6	Diabetic retinopathy;
TGCT	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.46	-6.43	-0.5	2.53e-9	Alzheimer's disease;
TGCT	cis	rs1371867	0.875	rs1660344	chr8:101324659	A/G	cg06002616	chr8:101225028	SPAG1	-0.56	-6.58	-0.51	1.2e-9	Atrioventricular conduction;
TGCT	cis	rs2439831	0.867	rs12443102	chr15:43932103	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	6.37	0.5	3.3e-9	Lung cancer in ever smokers;
TGCT	cis	rs1153858	1.000	rs12441971	chr15:45671957	A/T	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.62e-8	Homoarginine levels;
TGCT	cis	rs3091242	0.933	rs11249251	chr1:25770188	C/G	cg23205692	chr1:25664452	TMEM50A	0.47	4.97	0.41	2.22e-6	Erythrocyte sedimentation rate;
TGCT	cis	rs66573146	1.000	rs59683609	chr4:6964910	C/G	cg00086871	chr4:6988644	TBC1D14	0.98	4.57	0.38	1.16e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs35883536	0.566	rs10783141	chr1:101043897	G/A	cg10298815	chr1:101004474	GPR88	-0.25	-4.7	-0.39	6.67e-6	Monocyte count;
TGCT	cis	rs3091242	0.836	rs34997029	chr1:25783823	A/G	cg23205692	chr1:25664452	TMEM50A	-0.47	-4.95	-0.41	2.32e-6	Erythrocyte sedimentation rate;
TGCT	cis	rs6032067	0.673	rs36019441	chr20:43892401	G/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.45	-6.37	-0.5	3.36e-9	Blood protein levels;
TGCT	cis	rs317689	0.513	rs317678	chr12:69692166	C/G	cg11871910	chr12:69753446	YEATS4	0.63	6.11	0.48	1.18e-8	Response to diuretic therapy;
TGCT	cis	rs769267	0.929	rs2905424	chr19:19473445	T/C	cg03709012	chr19:19516395	GATAD2A	-0.78	-6.42	-0.5	2.58e-9	Tonsillectomy;
TGCT	cis	rs2295359	1.000	rs11209006	chr1:67619259	T/G	cg12940439	chr1:67600707	NA	0.56	6.04	0.48	1.63e-8	Psoriasis;
TGCT	cis	rs36051895	0.659	rs59225790	chr9:5042757	G/A	cg02405213	chr9:5042618	JAK2	-0.72	-9.64	-0.65	9.46e-17	Pediatric autoimmune diseases;
TGCT	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg11062466	chr8:58055876	NA	0.38	4.62	0.38	9.5e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs950169	0.545	rs4842841	chr15:84641125	G/A	cg11189052	chr15:85197271	WDR73	0.58	4.65	0.39	8.49e-6	Schizophrenia;
TGCT	cis	rs2070488	0.804	rs35463537	chr3:38498248	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	7.9	0.58	1.3e-12	Electrocardiographic conduction measures;
TGCT	cis	rs9393777	0.513	rs6936555	chr6:26640886	C/T	cg15659132	chr6:26577336	NA	-0.77	-5.48	-0.44	2.26e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7809950	0.862	rs2299421	chr7:106946195	C/G	cg23024343	chr7:107201750	COG5	-0.3	-4.74	-0.39	5.82e-6	Coronary artery disease;
TGCT	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	7.32	0.55	2.74e-11	Platelet count;
TGCT	cis	rs2197308	0.626	rs6581156	chr12:37858731	C/A	cg26384229	chr12:38710491	ALG10B	-0.67	-6.02	-0.48	1.82e-8	Morning vs. evening chronotype;
TGCT	cis	rs17376456	0.825	rs17372649	chr5:93126096	C/G	cg21475434	chr5:93447410	FAM172A	0.63	4.77	0.39	5.03e-6	Diabetic retinopathy;
TGCT	cis	rs2153535	0.601	rs6906170	chr6:8543128	T/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.63	0.45	1.14e-7	Motion sickness;
TGCT	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	0.63	6.72	0.52	5.88e-10	Prostate cancer;
TGCT	cis	rs6570726	0.791	rs6570694	chr6:145911204	C/G	cg05347473	chr6:146136440	FBXO30	0.51	4.75	0.39	5.42e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4727027	0.680	rs6464941	chr7:148826352	A/G	cg23583168	chr7:148888333	NA	-0.66	-7.38	-0.55	2e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs17741873	0.779	rs12573092	chr10:75600016	A/G	cg07699608	chr10:75541558	CHCHD1	0.7	4.88	0.4	3.23e-6	Paclitaxel disposition in epithelial ovarian cancer;
TGCT	cis	rs1729951	0.575	rs1654926	chr3:136709924	G/A	cg21827317	chr3:136751795	NA	0.41	5.79	0.46	5.43e-8	Neuroticism;
TGCT	cis	rs4918072	0.917	rs12571879	chr10:105663346	G/A	cg11005552	chr10:105648138	OBFC1	0.41	5.4	0.44	3.29e-7	Coronary artery disease;
TGCT	cis	rs6671200	1.000	rs76064624	chr1:95661033	A/G	cg03123541	chr1:95699097	RWDD3	0.87	6.17	0.48	8.81e-9	Stearic acid (18:0) levels;
TGCT	cis	rs2204008	0.811	rs8189445	chr12:38276295	T/C	cg26384229	chr12:38710491	ALG10B	0.86	7.48	0.56	1.19e-11	Bladder cancer;
TGCT	cis	rs67311347	0.713	rs114569261	chr3:40314580	G/A	cg13683864	chr3:40499215	RPL14	-0.89	-8.71	-0.62	1.65e-14	Renal cell carcinoma;
TGCT	cis	rs6500602	0.563	rs917305	chr16:4440593	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.41	5.1	0.42	1.23e-6	Schizophrenia;
TGCT	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg20607798	chr8:58055168	NA	0.6	4.95	0.41	2.39e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7666738	0.830	rs6846229	chr4:99016546	C/T	cg05340658	chr4:99064831	C4orf37	0.48	5.43	0.44	2.92e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1797081	0.646	rs7090256	chr10:16851949	T/G	cg23933602	chr10:16859644	RSU1	0.82	8.57	0.61	3.41e-14	Platelet distribution width;
TGCT	cis	rs9393777	0.513	rs9393739	chr6:26646966	T/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.59	-4.66	-0.39	8.03e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1153858	1.000	rs4271549	chr15:45652730	G/A	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.62e-8	Homoarginine levels;
TGCT	cis	rs12477438	0.605	rs4585080	chr2:99557327	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.83	-8.22	-0.59	2.29e-13	Chronic sinus infection;
TGCT	cis	rs12477438	0.572	rs10170063	chr2:99655639	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-4.88	-0.4	3.17e-6	Chronic sinus infection;
TGCT	cis	rs7236492	0.748	rs11663658	chr18:77197555	T/C	cg15644404	chr18:77186268	NFATC1	-0.35	-4.76	-0.39	5.22e-6	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg08736216	chr1:53307985	ZYG11A	0.26	4.95	0.41	2.32e-6	Monocyte count;
TGCT	cis	rs6484504	0.532	rs7116443	chr11:31283170	T/C	cg26647111	chr11:31128758	NA	-0.35	-4.85	-0.4	3.69e-6	Red blood cell count;
TGCT	cis	rs7772486	0.790	rs1133832	chr6:146205604	C/T	cg23711669	chr6:146136114	FBXO30	-0.86	-9.77	-0.66	4.48e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3960554	0.808	rs78587454	chr7:75688672	G/A	cg17325771	chr7:75508891	RHBDD2	-0.54	-4.63	-0.38	8.97e-6	Eotaxin levels;
TGCT	cis	rs11031096	0.542	rs11828337	chr11:3976974	T/G	cg18678763	chr11:4115507	RRM1	-0.41	-5.09	-0.42	1.27e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs7635838	0.650	rs1375206	chr3:11339117	C/G	cg00170343	chr3:11313890	ATG7	0.62	6.09	0.48	1.28e-8	HDL cholesterol;
TGCT	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg12310025	chr6:25882481	NA	0.69	7.5	0.56	1.07e-11	Blood metabolite levels;
TGCT	cis	rs858239	0.601	rs6948469	chr7:23174766	G/T	cg05602783	chr7:23145260	KLHL7	-0.63	-5.28	-0.43	5.64e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs9818758	0.607	rs34566463	chr3:49245077	T/C	cg00383909	chr3:49044727	WDR6	1.28	6.57	0.51	1.23e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs5167	0.781	rs11672748	chr19:45490192	A/G	cg09555818	chr19:45449301	APOC2	0.23	5.02	0.41	1.78e-6	Blood protein levels;
TGCT	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg20276088	chr3:133502917	NA	0.25	5.27	0.43	5.97e-7	Iron status biomarkers;
TGCT	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	5.53	0.44	1.81e-7	Height;
TGCT	cis	rs1577917	0.917	rs4707226	chr6:86527828	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-5.53	-0.44	1.82e-7	Response to antipsychotic treatment;
TGCT	cis	rs10504229	0.593	rs74760806	chr8:58024785	C/T	cg08280861	chr8:58055591	NA	0.36	5.16	0.42	9.31e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6912958	0.781	rs13193380	chr6:88297057	G/T	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.91	-0.4	2.78e-6	Monocyte percentage of white cells;
TGCT	cis	rs739496	0.579	rs4766705	chr12:112333660	C/A	cg10833066	chr12:111807467	FAM109A	0.38	5.61	0.45	1.24e-7	Platelet count;
TGCT	cis	rs6582630	0.502	rs8186661	chr12:38380781	G/A	cg13010199	chr12:38710504	ALG10B	0.6	4.74	0.39	5.76e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs9926296	0.607	rs2079672	chr16:89884917	A/G	cg26513180	chr16:89883248	FANCA	-0.75	-7.52	-0.56	9.5e-12	Vitiligo;
TGCT	cis	rs4566357	1.000	rs2251223	chr2:227914975	T/G	cg11843606	chr2:227700838	RHBDD1	-0.58	-5.34	-0.43	4.26e-7	Coronary artery disease;
TGCT	cis	rs7172809	0.573	rs17468413	chr15:77544510	T/A	cg22256960	chr15:77711686	NA	-0.48	-4.6	-0.38	1.02e-5	Glucose homeostasis traits;
TGCT	cis	rs9486719	0.947	rs2472893	chr6:96870048	G/C	cg18709589	chr6:96969512	KIAA0776	0.71	5.21	0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs2594989	0.943	rs346073	chr3:11298181	G/A	cg00170343	chr3:11313890	ATG7	0.64	4.65	0.39	8.23e-6	Circulating chemerin levels;
TGCT	cis	rs10779751	0.922	rs2295079	chr1:11322565	C/G	cg08854313	chr1:11322531	MTOR	0.93	10.56	0.69	5.37e-19	Body mass index;
TGCT	cis	rs10876993	0.680	rs2277322	chr12:58009202	T/C	cg15848620	chr12:58087721	OS9	0.68	4.97	0.41	2.21e-6	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs986417	1.000	rs1116854	chr14:60917496	C/A	cg27398547	chr14:60952738	C14orf39	-1.39	-10.61	-0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs7666738	0.753	rs1527520	chr4:98929164	A/G	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12908161	0.683	rs12903256	chr15:85308141	G/T	cg17173187	chr15:85201210	NMB	0.39	4.6	0.38	1.01e-5	Schizophrenia;
TGCT	cis	rs9300255	0.596	rs7304782	chr12:123719444	A/G	cg00376283	chr12:123451042	ABCB9	-0.7	-5.9	-0.47	3.3e-8	Neutrophil percentage of white cells;
TGCT	cis	rs896854	0.552	rs2515236	chr8:95934907	A/G	cg16049864	chr8:95962084	TP53INP1	0.61	7.04	0.53	1.18e-10	Type 2 diabetes;
TGCT	cis	rs6088590	1.000	rs6087623	chr20:33317662	C/G	cg06115741	chr20:33292138	TP53INP2	0.67	5.61	0.45	1.24e-7	Coronary artery disease;
TGCT	cis	rs10089	1.000	rs10060390	chr5:127452947	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	7.41	0.55	1.72e-11	Ileal carcinoids;
TGCT	cis	rs2153535	0.601	rs4960414	chr6:8438541	A/G	cg07606381	chr6:8435919	SLC35B3	0.57	5.25	0.43	6.46e-7	Motion sickness;
TGCT	cis	rs4820539	0.708	rs5751591	chr22:23489042	G/A	cg21100191	chr22:23484243	RTDR1	0.8	8.8	0.62	1e-14	Bone mineral density;
TGCT	cis	rs2562456	0.583	rs4809144	chr19:21772730	C/T	cg13978929	chr19:21580086	ZNF493	-0.56	-4.72	-0.39	6.29e-6	Pain;
TGCT	cis	rs933688	1.000	rs2839728	chr5:90727412	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	10.12	0.67	6.32e-18	Smoking behavior;
TGCT	cis	rs1153858	1.000	rs1346266	chr15:45694516	G/T	cg14582100	chr15:45693742	SPATA5L1	0.48	5.69	0.46	8.56e-8	Homoarginine levels;
TGCT	cis	rs5769707	0.967	rs739241	chr22:50052921	G/A	cg05373962	chr22:49881684	NA	-0.32	-6.66	-0.51	7.86e-10	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs1568889	1.000	rs2354427	chr11:28049623	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	8.86	0.62	7.07e-15	Bipolar disorder;
TGCT	cis	rs1008375	1.000	rs10939747	chr4:17691166	C/A	cg18681998	chr4:17616180	MED28	0.79	7.53	0.56	9.23e-12	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs11098499	0.599	rs3864142	chr4:120266191	A/T	cg09307838	chr4:120376055	NA	0.56	5.49	0.44	2.18e-7	Corneal astigmatism;
TGCT	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.45	0.56	1.42e-11	Prudent dietary pattern;
TGCT	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg16325326	chr1:53192061	ZYG11B	0.6	6.97	0.53	1.68e-10	Monocyte count;
TGCT	cis	rs4808199	0.947	rs7250658	chr19:19571100	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.72	5.15	0.42	9.94e-7	Nonalcoholic fatty liver disease;
TGCT	cis	rs3820928	0.904	rs2894623	chr2:227766112	T/C	cg11843606	chr2:227700838	RHBDD1	-0.51	-4.49	-0.37	1.59e-5	Pulmonary function;
TGCT	cis	rs7828089	0.519	rs2443500	chr8:22352342	C/T	cg12081754	chr8:22256438	SLC39A14	0.29	4.5	0.37	1.55e-5	Verbal declarative memory;
TGCT	cis	rs9486719	0.895	rs12190520	chr6:96928620	A/C	cg18709589	chr6:96969512	KIAA0776	-0.72	-5.24	-0.43	6.58e-7	Migraine;Coronary artery disease;
TGCT	trans	rs77457752	0.690	rs12335400	chr9:13912195	A/G	cg18948646	chr4:83674694	SCD5;MIR575	0.55	6.62	0.51	9.75e-10	Breast cancer;
TGCT	cis	rs981844	0.603	rs13132437	chr4:154748006	T/G	cg14289246	chr4:154710475	SFRP2	-0.99	-9.05	-0.63	2.54e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg12310025	chr6:25882481	NA	0.79	8.09	0.59	4.59e-13	Blood metabolite levels;
TGCT	cis	rs11785400	1.000	rs4266629	chr8:143736635	A/G	cg24634471	chr8:143751801	JRK	0.56	6.12	0.48	1.16e-8	Schizophrenia;
TGCT	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg03188948	chr7:1209495	NA	0.64	5.38	0.43	3.61e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9297145	0.761	rs12534399	chr7:98746401	A/G	cg05967295	chr7:98741636	SMURF1	1.01	12.87	0.76	1.33e-24	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs10791097	0.694	rs61910787	chr11:130744473	G/A	cg05962950	chr11:130786565	SNX19	0.92	11.55	0.72	2.13e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9486715	0.867	rs4438964	chr6:96917563	T/G	cg06623918	chr6:96969491	KIAA0776	1.1	15.31	0.81	2.34e-30	Headache;
TGCT	trans	rs1814175	0.935	rs11040465	chr11:49689323	C/T	cg15704280	chr7:45808275	SEPT13	-0.61	-6.69	-0.51	6.8e-10	Height;
TGCT	cis	rs2932538	0.961	rs6690292	chr1:113188419	C/T	cg22162597	chr1:113214053	CAPZA1	-0.26	-5.82	-0.46	4.83e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs12681287	0.640	rs7841690	chr8:87365359	T/C	cg27223183	chr8:87520930	FAM82B	0.9	6.71	0.52	6.12e-10	Caudate activity during reward;
TGCT	cis	rs9646954	0.542	rs11674830	chr2:101024735	A/G	cg08017756	chr2:100939284	LONRF2	-0.29	-4.57	-0.38	1.15e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs17384381	0.834	rs12130380	chr1:85901309	T/C	cg16011679	chr1:85725395	C1orf52	0.82	6.71	0.52	6.25e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6684514	1.000	rs12040868	chr1:156284803	G/T	cg20302342	chr1:156215951	PAQR6	0.35	4.74	0.39	5.77e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs6964587	0.732	rs12539523	chr7:91710836	G/A	cg22709100	chr7:91322751	NA	0.27	4.46	0.37	1.84e-5	Breast cancer;
TGCT	cis	rs7172809	0.524	rs74025105	chr15:77572357	G/A	cg22256960	chr15:77711686	NA	-0.48	-4.67	-0.39	7.76e-6	Glucose homeostasis traits;
TGCT	cis	rs4689388	0.750	rs12642481	chr4:6301058	G/A	cg14416269	chr4:6271139	WFS1	0.48	5.91	0.47	3.02e-8	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs9653442	0.564	rs13013594	chr2:100784190	A/G	cg07810366	chr2:100720526	AFF3	-0.36	-5.26	-0.43	6.14e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs6840360	1.000	rs749982	chr4:152601353	A/G	cg17479576	chr4:152424074	FAM160A1	-0.52	-5.66	-0.45	9.86e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.0	7.42	0.55	1.64e-11	Gut microbiome composition (summer);
TGCT	cis	rs7937682	0.883	rs512669	chr11:111467893	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.98	-9.83	-0.66	3.23e-17	Primary sclerosing cholangitis;
TGCT	cis	rs6669919	0.967	rs11119752	chr1:211675765	A/G	cg26515805	chr1:211431828	RCOR3	-0.38	-4.49	-0.37	1.6e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7000551	0.725	rs2449349	chr8:22383284	A/G	cg12081754	chr8:22256438	SLC39A14	0.28	4.51	0.38	1.46e-5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs4711350	0.862	rs602399	chr6:33713779	C/T	cg18005901	chr6:33739558	LEMD2	0.57	5.9	0.47	3.23e-8	Schizophrenia;
TGCT	cis	rs10883723	0.738	rs3781290	chr10:104244948	G/C	cg05855489	chr10:104503620	C10orf26	-0.58	-5.07	-0.41	1.42e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs854765	0.547	rs9894138	chr17:17964345	G/A	cg09796270	chr17:17721594	SREBF1	-0.27	-5.23	-0.42	7.04e-7	Total body bone mineral density;
TGCT	cis	rs709400	0.663	rs3783402	chr14:103967929	C/G	cg12935359	chr14:103987150	CKB	-0.36	-5.64	-0.45	1.11e-7	Body mass index;
TGCT	cis	rs17122693	0.539	rs72681610	chr14:51117773	T/C	cg04730355	chr14:51134070	SAV1	1.04	6.32	0.49	4.38e-9	Cognitive performance;
TGCT	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.3	-4.7	-0.39	6.73e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2997447	0.846	rs61775425	chr1:26405634	A/T	cg03844060	chr1:26490628	NA	0.28	4.57	0.38	1.17e-5	QRS complex (12-leadsum);
TGCT	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg18876405	chr7:65276391	NA	0.32	4.87	0.4	3.29e-6	Aortic root size;
TGCT	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.61	-5.09	-0.42	1.3e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg03517284	chr6:25882590	NA	-0.81	-8.33	-0.6	1.24e-13	Blood metabolite levels;
TGCT	cis	rs12510870	0.599	rs2008288	chr4:74447800	A/G	cg05868023	chr4:75230803	EREG	-0.54	-4.76	-0.39	5.33e-6	Iris color (b* coordinate);
TGCT	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg10047753	chr17:41438598	NA	0.68	6.16	0.48	9.22e-9	Menopause (age at onset);
TGCT	cis	rs10089	1.000	rs1864922	chr5:127420700	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.8	7.64	0.57	5.24e-12	Ileal carcinoids;
TGCT	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg10802521	chr3:52805072	NEK4	-0.78	-10.0	-0.67	1.25e-17	Bipolar disorder;
TGCT	trans	rs7618501	0.933	rs6809431	chr3:49804119	A/G	cg21659725	chr3:3221576	CRBN	0.98	15.33	0.81	2.1000000000000002e-30	Intelligence (multi-trait analysis);
TGCT	cis	rs8017423	0.647	rs12587362	chr14:90821227	G/T	cg04374321	chr14:90722782	PSMC1	-0.54	-5.41	-0.44	3.13e-7	Mortality in heart failure;
TGCT	cis	rs11969893	0.850	rs9791284	chr6:101353886	G/A	cg12253828	chr6:101329408	ASCC3	1.45	5.99	0.47	2.15e-8	Economic and political preferences (immigration/crime);
TGCT	cis	rs138249	1.000	rs138244	chr22:50565367	C/T	cg24864161	chr22:50528282	MOV10L1	0.46	4.75	0.39	5.48e-6	Gestational age at birth in labor-initiated deliveries (child effect);
TGCT	cis	rs899997	1.000	rs12899940	chr15:79001699	A/G	cg04896959	chr15:78267971	NA	-0.33	-4.94	-0.41	2.44e-6	Coronary artery disease or large artery stroke;
TGCT	cis	rs9467773	1.000	rs2208331	chr6:26507319	A/G	cg05738196	chr6:26577821	NA	0.88	12.49	0.75	1.09e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs9993613	0.875	rs1842660	chr4:73479875	A/C	cg15102770	chr4:73434591	ADAMTS3	0.52	4.89	0.4	3.07e-6	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2880765	0.835	rs7178991	chr15:86050944	G/C	cg13263323	chr15:86062960	AKAP13	-0.22	-4.88	-0.4	3.14e-6	Coronary artery disease;
TGCT	cis	rs9902453	0.704	rs2617874	chr17:28085172	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	7.42	0.55	1.64e-11	Coffee consumption (cups per day);
TGCT	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg06238570	chr21:40685208	BRWD1	-0.62	-6.35	-0.5	3.74e-9	Menarche (age at onset);
TGCT	cis	rs56104184	0.775	rs117744769	chr19:49402686	G/T	cg15549821	chr19:49342101	PLEKHA4	-0.73	-9.15	-0.63	1.47e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs929596	0.785	rs34352510	chr2:234650562	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.34	-5.41	-0.44	3.11e-7	Total bilirubin levels in HIV-1 infection;
TGCT	cis	rs3770081	1.000	rs6724025	chr2:86200835	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.24	-4.98	-0.41	2.07e-6	Facial emotion recognition (sad faces);
TGCT	cis	rs1005224	1.000	rs1158282	chr14:76172916	C/G	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.59	-5.23	-0.42	7.08e-7	Large artery stroke;
TGCT	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-8.44	-0.6	6.87e-14	Platelet count;
TGCT	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg06873352	chr17:61820015	STRADA	0.56	6.22	0.49	6.93e-9	Prudent dietary pattern;
TGCT	cis	rs17122693	0.748	rs1009292	chr14:51143683	A/T	cg04730355	chr14:51134070	SAV1	1.33	12.04	0.73	1.37e-22	Cognitive performance;
TGCT	cis	rs4727027	0.522	rs6956736	chr7:148893472	G/C	cg23583168	chr7:148888333	NA	-0.74	-7.8	-0.57	2.15e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg27286337	chr10:134555280	INPP5A	0.41	5.24	0.43	6.65e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs56104184	0.775	rs3760785	chr19:49403178	G/T	cg21252483	chr19:49399788	TULP2	-0.42	-5.83	-0.46	4.55e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs28595532	0.920	rs55985953	chr4:119764971	T/A	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs10089	0.953	rs3805615	chr5:127519049	A/G	cg19767477	chr5:127420684	SLC12A2	-0.44	-4.56	-0.38	1.2e-5	Ileal carcinoids;
TGCT	cis	rs2295359	0.892	rs4655686	chr1:67638004	T/A	cg12940439	chr1:67600707	NA	0.58	5.91	0.47	3.09e-8	Psoriasis;
TGCT	cis	rs10782582	0.609	rs1796815	chr1:76396793	T/G	cg03433033	chr1:76189801	ACADM	-0.5	-4.9	-0.4	2.9e-6	Daytime sleep phenotypes;
TGCT	cis	rs9653442	0.593	rs4851273	chr2:100848321	A/G	cg07810366	chr2:100720526	AFF3	-0.38	-5.55	-0.45	1.63e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs4919694	0.611	rs7091462	chr10:104948615	C/T	cg04362960	chr10:104952993	NT5C2	0.97	6.81	0.52	3.82e-10	Arsenic metabolism;
TGCT	cis	rs1669338	0.588	rs3864050	chr3:3186769	T/C	cg16797762	chr3:3221439	CRBN	-0.89	-5.67	-0.45	9.6e-8	White matter integrity;
TGCT	cis	rs12477438	0.520	rs2964969	chr2:99782811	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	17.43	0.84	3.73e-35	Chronic sinus infection;
TGCT	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg12311346	chr5:56204834	C5orf35	-0.67	-6.82	-0.52	3.63e-10	Initial pursuit acceleration;
TGCT	cis	rs7909074	1.000	rs6593447	chr10:45400235	G/A	cg04218760	chr10:45406644	TMEM72	-0.27	-5.31	-0.43	4.88e-7	Mean corpuscular volume;
TGCT	cis	rs57994353	0.566	rs10870160	chr9:139312996	C/T	cg13741927	chr9:139327495	INPP5E	-0.24	-5.65	-0.45	1.02e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs758129	0.501	rs2529927	chr15:89877527	G/A	cg24365117	chr15:89879190	POLG	0.34	4.64	0.38	8.68e-6	Schizophrenia;
TGCT	cis	rs6920965	0.507	rs7754833	chr6:126190894	A/G	cg05901451	chr6:126070800	HEY2	-0.67	-6.53	-0.51	1.51e-9	High light scatter reticulocyte count;
TGCT	cis	rs73198271	1.000	rs4841031	chr8:8607395	G/A	ch.8.214553F	chr8:8189620	PRAGMIN	-0.27	-4.57	-0.38	1.17e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg16325326	chr1:53192061	ZYG11B	-0.6	-6.74	-0.52	5.43e-10	Monocyte count;
TGCT	cis	rs709400	0.859	rs7154948	chr14:104022944	C/T	cg26031613	chr14:104095156	KLC1	1.17	15.98	0.82	6.61e-32	Body mass index;
TGCT	cis	rs394563	0.559	rs7752555	chr6:149671116	A/G	cg03678062	chr6:149772716	ZC3H12D	0.38	4.83	0.4	3.94e-6	Dupuytren's disease;
TGCT	cis	rs10197940	0.550	rs77233070	chr2:152416477	G/A	cg19508488	chr2:152266495	RIF1	0.65	5.69	0.45	8.81e-8	Lung cancer;
TGCT	cis	rs74233809	1.000	rs5011520	chr10:104697516	G/A	cg05855489	chr10:104503620	C10orf26	0.74	4.45	0.37	1.87e-5	Birth weight;
TGCT	cis	rs13191362	0.507	rs2849525	chr6:163126652	A/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.59	-5.75	-0.46	6.6e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7809950	0.678	rs77395658	chr7:107000651	G/A	cg23024343	chr7:107201750	COG5	-0.43	-5.85	-0.47	4.12e-8	Coronary artery disease;
TGCT	cis	rs2836950	0.501	rs4818018	chr21:40694072	C/T	cg06238570	chr21:40685208	BRWD1	-0.62	-6.32	-0.49	4.19e-9	Menarche (age at onset);
TGCT	trans	rs561341	0.700	rs6505266	chr17:30225813	G/A	cg20587970	chr11:113659929	NA	-0.59	-8.98	-0.63	3.73e-15	Hip circumference adjusted for BMI;
TGCT	cis	rs7843479	0.601	rs878873	chr8:21834581	T/C	cg17168535	chr8:21777572	XPO7	0.8	8.11	0.59	4.09e-13	Mean corpuscular volume;
TGCT	cis	rs6545883	0.862	rs11691734	chr2:61702466	C/T	cg15711740	chr2:61764176	XPO1	-0.53	-4.74	-0.39	5.82e-6	Tuberculosis;
TGCT	trans	rs1814175	0.817	rs10769617	chr11:49810421	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.35	-0.55	2.38e-11	Height;
TGCT	cis	rs7223966	1.000	rs8080211	chr17:61729882	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	4.51	0.38	1.49e-5	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs807669	0.835	rs698423	chr22:19197896	T/C	cg02655711	chr22:19163373	SLC25A1	0.39	8.65	0.61	2.23e-14	Metabolite levels;
TGCT	cis	rs10504229	0.813	rs6999878	chr8:58197243	C/G	cg22535103	chr8:58192502	C8orf71	-0.39	-4.94	-0.41	2.47e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg04944784	chr2:26401820	FAM59B	-0.7	-6.49	-0.5	1.89e-9	Gut microbiome composition (summer);
TGCT	cis	rs6988636	1.000	rs16898095	chr8:124193523	T/C	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs62064224	0.589	rs9903650	chr17:30689370	T/A	cg18200150	chr17:30822561	MYO1D	0.39	4.7	0.39	6.77e-6	Schizophrenia;
TGCT	cis	rs17473412	0.784	rs115433169	chr5:122702575	A/T	cg15125798	chr5:122621645	NA	-0.57	-4.83	-0.4	3.88e-6	Total body bone mineral density;
TGCT	cis	rs7412746	0.611	rs111842513	chr1:150712926	G/A	cg09365446	chr1:150670422	GOLPH3L	0.3	4.53	0.38	1.37e-5	Melanoma;
TGCT	cis	rs806215	1.000	rs806219	chr7:127240094	A/C	cg25922125	chr7:127225783	GCC1	0.55	5.66	0.45	9.96e-8	Type 2 diabetes;
TGCT	cis	rs3796352	1.000	rs4478072	chr3:53106125	G/T	cg15956490	chr3:53032818	SFMBT1	0.57	6.59	0.51	1.13e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs1475911	1.000	rs1475911	chr21:43513480	A/C	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.28	-5.12	-0.42	1.15e-6	IgG glycosylation;
TGCT	cis	rs1461503	0.932	rs10790542	chr11:122838243	C/T	cg27398637	chr11:122830231	C11orf63	-0.43	-5.32	-0.43	4.69e-7	Menarche (age at onset);
TGCT	cis	rs921968	0.541	rs3770213	chr2:219508372	A/T	cg02176678	chr2:219576539	TTLL4	-0.5	-6.98	-0.53	1.59e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs9467773	1.000	rs6903973	chr6:26499942	C/A	cg05738196	chr6:26577821	NA	0.87	12.41	0.74	1.7e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs7663924	chr4:99037679	A/G	cg18180107	chr4:99064573	C4orf37	-0.55	-5.12	-0.42	1.15e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10493773	1.000	rs2274738	chr1:86119898	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.37	-4.69	-0.39	7.01e-6	Urate levels in overweight individuals;
TGCT	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg05665937	chr4:1216051	CTBP1	0.24	4.73	0.39	6.09e-6	Obesity-related traits;
TGCT	cis	rs7949030	0.626	rs7943191	chr11:62328551	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.64	9.42	0.65	3.17e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs116095464	0.558	rs10056628	chr5:279512	G/A	cg22857025	chr5:266934	NA	-0.35	-6.87	-0.53	2.7e-10	Breast cancer;
TGCT	cis	rs28595532	1.000	rs41455648	chr4:119718030	A/G	cg11846333	chr4:119757529	SEC24D	0.92	4.81	0.4	4.21e-6	Cannabis dependence symptom count;
TGCT	cis	rs1153858	1.000	rs2467864	chr15:45641098	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.49	-5.88	-0.47	3.51e-8	Homoarginine levels;
TGCT	cis	rs9325144	0.581	rs2653758	chr12:38946233	G/T	cg26384229	chr12:38710491	ALG10B	-0.61	-6.21	-0.49	7.5e-9	Morning vs. evening chronotype;
TGCT	cis	rs765787	0.530	rs12323957	chr15:45490773	C/T	cg24006582	chr15:45444508	DUOX1	0.25	5.33	0.43	4.48e-7	Uric acid levels;
TGCT	cis	rs3892630	0.818	rs80137870	chr19:33182750	C/T	cg22980127	chr19:33182716	NUDT19	0.72	5.11	0.42	1.16e-6	Red blood cell traits;
TGCT	cis	rs7659604	1.000	rs6823488	chr4:122664819	A/G	cg06713675	chr4:122721982	EXOSC9	-0.38	-4.66	-0.39	7.88e-6	Type 2 diabetes;
TGCT	cis	rs4654899	1.000	rs6426659	chr1:21361302	G/A	cg01072550	chr1:21505969	NA	-0.49	-7.87	-0.58	1.47e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs6088580	0.634	rs6087577	chr20:32955423	C/T	cg06115741	chr20:33292138	TP53INP2	0.51	4.53	0.38	1.35e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs12477438	0.765	rs62154638	chr2:99639584	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-7.6	-0.56	6.47e-12	Chronic sinus infection;
TGCT	cis	rs7666738	0.830	rs10021709	chr4:99030587	G/A	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9291683	0.620	rs717615	chr4:10104670	C/T	cg11266682	chr4:10021025	SLC2A9	0.48	5.65	0.45	1.04e-7	Bone mineral density;
TGCT	cis	rs1784581	0.651	rs1784593	chr6:162386096	A/T	cg17173639	chr6:162384350	PARK2	-0.47	-8.09	-0.59	4.55e-13	Itch intensity from mosquito bite;
TGCT	cis	rs13401104	0.680	rs72620813	chr2:237146225	C/T	cg19324714	chr2:237145437	ASB18	0.48	5.05	0.41	1.57e-6	Educational attainment;
TGCT	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg00024416	chr22:24240387	NA	0.25	4.74	0.39	5.74e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.51	-5.0	-0.41	1.92e-6	Bipolar disorder;
TGCT	cis	rs13191362	0.507	rs1954810	chr6:163061749	C/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.61	-5.52	-0.44	1.91e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7666738	0.830	rs3907021	chr4:99038668	C/T	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg11644478	chr21:40555479	PSMG1	-0.53	-4.57	-0.38	1.17e-5	Cognitive function;
TGCT	cis	rs7267979	0.565	rs6107060	chr20:25592476	C/G	cg03522245	chr20:25566470	NINL	0.44	4.71	0.39	6.4e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg08219700	chr8:58056026	NA	0.38	4.69	0.39	6.95e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6540559	0.605	rs3753518	chr1:209977964	G/C	cg04352962	chr1:209979756	IRF6	0.65	4.6	0.38	1.05e-5	Cleft lip with or without cleft palate;
TGCT	cis	rs2440129	0.611	rs1042357	chr17:6905061	T/G	cg05215272	chr17:6899095	ALOX12	0.57	6.79	0.52	4.04e-10	Tonsillectomy;
TGCT	cis	rs9583531	0.714	rs79483970	chr13:111342298	G/A	cg15747390	chr13:111297551	CARS2	0.86	5.86	0.47	3.9e-8	Coronary artery disease;
TGCT	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg11764359	chr7:65958608	NA	-0.57	-5.2	-0.42	8.06e-7	Aortic root size;
TGCT	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg22963979	chr7:1858916	MAD1L1	-0.38	-5.89	-0.47	3.35e-8	Bipolar disorder and schizophrenia;
TGCT	cis	rs921968	0.509	rs7571743	chr2:219352572	C/T	cg02176678	chr2:219576539	TTLL4	0.48	6.78	0.52	4.32e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg26818010	chr10:134567672	INPP5A	-0.35	-4.77	-0.39	5.13e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs11247915	0.540	rs72649368	chr1:26675018	G/T	cg23732845	chr1:26663426	AIM1L	-0.37	-4.66	-0.39	8.11e-6	Obesity-related traits;
TGCT	cis	rs11190604	1.000	rs4919472	chr10:102315864	T/A	cg16342193	chr10:102329863	NA	-0.39	-4.95	-0.41	2.35e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs28595532	0.920	rs116607127	chr4:119731072	T/C	cg14228332	chr4:119757509	SEC24D	1.32	6.38	0.5	3.2e-9	Cannabis dependence symptom count;
TGCT	cis	rs9457247	0.534	rs4710154	chr6:167394634	A/T	cg23791538	chr6:167370224	RNASET2	0.63	6.27	0.49	5.55e-9	Crohn's disease;
TGCT	cis	rs6762477	0.748	rs11714286	chr3:50185508	G/A	cg15335139	chr3:50242325	SLC38A3	-0.26	-4.83	-0.4	3.94e-6	Menarche (age at onset);
TGCT	cis	rs244731	0.920	rs244707	chr5:176555636	A/T	cg16006841	chr5:176797999	RGS14	0.53	6.5	0.5	1.76e-9	Urate levels in lean individuals;
TGCT	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg03452623	chr4:187889614	NA	-0.34	-4.94	-0.41	2.46e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs858239	0.539	rs4294098	chr7:23185995	G/A	cg05602783	chr7:23145260	KLHL7	-0.62	-5.03	-0.41	1.67e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs9308731	0.583	rs6726007	chr2:111932122	A/T	cg04202892	chr2:111875749	ACOXL	0.46	5.14	0.42	1.02e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs6684514	1.000	rs12117947	chr1:156244058	A/T	cg16558208	chr1:156270281	VHLL	0.46	9.38	0.64	3.92e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs2729354	0.768	rs2729384	chr11:57258617	T/C	cg24343310	chr11:57249947	NA	0.29	4.65	0.39	8.49e-6	Blood protein levels;
TGCT	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6964587	1.000	rs13230588	chr7:91615427	C/A	cg22709100	chr7:91322751	NA	0.27	4.48	0.37	1.68e-5	Breast cancer;
TGCT	cis	rs6074578	0.679	rs6086352	chr20:140695	C/T	cg16931068	chr20:139680	DEFB127	-0.28	-4.85	-0.4	3.62e-6	Hirschsprung disease;
TGCT	cis	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg20637647	chr7:64974828	NA	0.99	5.54	0.45	1.71e-7	Diabetic kidney disease;
TGCT	cis	rs7208859	0.673	rs999797	chr17:29159329	G/A	cg14008862	chr17:28927542	LRRC37B2	0.72	4.67	0.39	7.77e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs9560113	0.550	rs1163632	chr13:112231530	T/C	cg10483660	chr13:112241077	NA	-0.31	-4.9	-0.4	2.91e-6	Menarche (age at onset);
TGCT	cis	rs35306767	0.953	rs10904581	chr10:964685	A/T	cg20503657	chr10:835505	NA	0.65	9.54	0.65	1.66e-16	Eosinophil percentage of granulocytes;
TGCT	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg05985448	chr10:134359359	INPP5A	0.23	5.03	0.41	1.68e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg06873352	chr17:61820015	STRADA	0.58	6.37	0.5	3.32e-9	Prudent dietary pattern;
TGCT	cis	rs9790314	0.846	rs9834659	chr3:160980947	A/C	cg03342759	chr3:160939853	NMD3	-0.51	-5.66	-0.45	9.96e-8	Morning vs. evening chronotype;
TGCT	cis	rs3785574	0.650	rs7406102	chr17:62004749	G/A	cg11494091	chr17:61959527	GH2	-0.44	-7.54	-0.56	8.47e-12	Height;
TGCT	cis	rs10992471	0.580	rs7852698	chr9:95396409	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-4.65	-0.39	8.53e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg07343612	chr16:622815	PIGQ	-0.42	-8.4	-0.6	8.47e-14	Height;
TGCT	cis	rs7208859	0.623	rs55638872	chr17:29149552	G/C	cg14008862	chr17:28927542	LRRC37B2	0.8	4.73	0.39	6.11e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7010267	0.570	rs2326192	chr8:120028855	C/G	cg17171407	chr8:119960777	TNFRSF11B	0.26	4.59	0.38	1.06e-5	Total body bone mineral density (age 45-60);
TGCT	cis	rs259282	0.628	rs35946544	chr19:33109983	C/T	cg26639809	chr19:33781782	NA	0.24	4.79	0.4	4.7e-6	Schizophrenia;
TGCT	cis	rs7666738	0.830	rs34412187	chr4:99010454	A/G	cg17366294	chr4:99064904	C4orf37	0.68	7.04	0.53	1.17e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4455778	0.724	rs993871	chr7:48993937	C/T	cg26309511	chr7:48887640	NA	0.5	6.13	0.48	1.07e-8	Lung cancer in never smokers;
TGCT	cis	rs1577917	0.876	rs66986937	chr6:86532191	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.46	-0.44	2.47e-7	Response to antipsychotic treatment;
TGCT	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	7.16	0.54	6.12e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs79057730	0.527	rs34519158	chr7:811114	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.74	5.59	0.45	1.36e-7	Initial pursuit acceleration;
TGCT	cis	rs2072499	0.900	rs2248080	chr1:156195971	T/A	cg25208724	chr1:156163844	SLC25A44	1.11	12.68	0.75	3.79e-24	Testicular germ cell tumor;
TGCT	cis	rs9436747	0.641	rs11208676	chr1:66048123	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.53	4.72	0.39	6.28e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs7945705	0.747	rs1123936	chr11:9003306	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.45	-4.95	-0.41	2.38e-6	Hemoglobin concentration;
TGCT	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg24829409	chr8:58192753	C8orf71	-0.59	-4.97	-0.41	2.17e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs12541335	0.507	rs9644047	chr8:22158670	T/A	cg02463440	chr8:22132932	PIWIL2	0.25	4.82	0.4	4.18e-6	Hypertriglyceridemia;
TGCT	cis	rs9788682	0.624	rs518425	chr15:78883813	A/G	cg24631222	chr15:78858424	CHRNA5	0.61	4.8	0.4	4.48e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg11764359	chr7:65958608	NA	-0.55	-5.08	-0.42	1.34e-6	Aortic root size;
TGCT	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg19723775	chr5:179050963	HNRNPH1	0.59	5.85	0.46	4.19e-8	Lung cancer;
TGCT	cis	rs7000551	0.505	rs13258195	chr8:22227271	A/G	cg12081754	chr8:22256438	SLC39A14	-0.38	-5.68	-0.45	8.99e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs6977940	0.730	rs11766514	chr7:2896271	C/T	cg19731401	chr7:2775893	GNA12	0.37	4.44	0.37	1.98e-5	White matter integrity;
TGCT	cis	rs447921	0.861	rs36119142	chr17:74454336	T/G	cg09812376	chr17:74270190	QRICH2	-0.45	-4.65	-0.39	8.4e-6	Mitochondrial DNA levels;
TGCT	cis	rs6061231	0.561	rs67072353	chr20:60940702	G/A	cg24112000	chr20:60950667	NA	-0.4	-4.71	-0.39	6.44e-6	Colorectal cancer;
TGCT	cis	rs7107174	0.688	rs881361	chr11:78128047	C/G	cg12700464	chr11:78128424	GAB2	-0.67	-4.46	-0.37	1.83e-5	Testicular germ cell tumor;
TGCT	cis	rs12497850	0.931	rs4072859	chr3:49032205	G/C	cg06212747	chr3:49208901	KLHDC8B	0.61	5.51	0.44	1.95e-7	Parkinson's disease;
TGCT	cis	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg25427524	chr10:38739819	LOC399744	-0.4	-8.2	-0.59	2.5e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs1577917	1.000	rs35385043	chr6:86648546	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.05	-0.41	1.57e-6	Response to antipsychotic treatment;
TGCT	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg04155289	chr7:94953770	PON1	0.36	6.06	0.48	1.51e-8	Paraoxonase activity;
TGCT	cis	rs1008375	0.931	rs2315558	chr4:17674558	C/A	cg10189774	chr4:17578691	LAP3	0.57	5.25	0.43	6.37e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9467773	0.649	rs2145318	chr6:26496603	T/A	cg15659132	chr6:26577336	NA	0.64	6.98	0.53	1.59e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs2204008	0.652	rs11513964	chr12:37998214	C/G	cg13010199	chr12:38710504	ALG10B	0.65	5.22	0.42	7.4e-7	Bladder cancer;
TGCT	cis	rs1005277	0.522	rs289645	chr10:37943642	T/C	cg25427524	chr10:38739819	LOC399744	-0.36	-7.18	-0.54	5.79e-11	Extrinsic epigenetic age acceleration;
TGCT	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg21963583	chr11:68658836	MRPL21	0.36	6.17	0.48	9.01e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs11676348	0.846	rs7594532	chr2:219008000	T/C	cg00012203	chr2:219082015	ARPC2	-0.52	-4.99	-0.41	1.99e-6	Ulcerative colitis;
TGCT	cis	rs13040088	0.872	rs2295481	chr20:61574727	C/T	cg23096297	chr20:61557774	DIDO1	1.18	9.71	0.66	6.5e-17	Menopause (age at onset);
TGCT	cis	rs9393692	0.645	rs28446029	chr6:26305801	C/G	cg13736514	chr6:26305472	NA	-0.45	-6.67	-0.51	7.52e-10	Educational attainment;
TGCT	cis	rs11809207	1.000	rs11247867	chr1:26517891	C/T	cg03844060	chr1:26490628	NA	0.25	4.62	0.38	9.44e-6	Height;
TGCT	cis	rs74181299	0.892	rs2249105	chr2:65287896	C/T	cg05010058	chr2:65284262	CEP68	-0.42	-4.79	-0.4	4.66e-6	Pulse pressure;
TGCT	cis	rs7267979	0.899	rs2179459	chr20:25456141	C/A	cg16686733	chr20:25566563	NINL	0.52	5.24	0.43	6.64e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6460942	0.908	rs967126	chr7:12237300	G/C	cg06484146	chr7:12443880	VWDE	-0.54	-4.76	-0.39	5.21e-6	Coronary artery disease;
TGCT	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg09060608	chr5:178986726	RUFY1	0.58	6.88	0.53	2.61e-10	Lung cancer;
TGCT	cis	rs12220238	1.000	rs111704178	chr10:75957251	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.78	0.57	2.42e-12	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs9787249	0.957	rs7547787	chr1:40220806	C/T	cg24920358	chr1:40204285	PPIE	0.58	10.68	0.69	2.74e-19	Blood protein levels;
TGCT	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg06873352	chr17:61820015	STRADA	0.58	6.37	0.5	3.32e-9	Prudent dietary pattern;
TGCT	cis	rs11718455	0.960	rs13059547	chr3:44004492	G/A	cg08738300	chr3:44038990	NA	0.86	6.55	0.51	1.4e-9	Coronary artery disease;
TGCT	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg22920501	chr2:26401640	FAM59B	0.81	6.36	0.5	3.52e-9	Gut microbiome composition (summer);
TGCT	cis	rs8067545	0.750	rs4925069	chr17:19953531	C/G	cg13482628	chr17:19912719	NA	0.53	4.58	0.38	1.1e-5	Schizophrenia;
TGCT	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	6.06	0.48	1.51e-8	Mean platelet volume;
TGCT	trans	rs208520	0.661	rs1100950	chr6:66827285	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-10.56	-0.69	5.53e-19	Exhaled nitric oxide output;
TGCT	cis	rs72781680	0.716	rs7564732	chr2:24034178	C/T	cg08917208	chr2:24149416	ATAD2B	0.81	5.13	0.42	1.1e-6	Lymphocyte counts;
TGCT	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg06238570	chr21:40685208	BRWD1	-0.61	-6.35	-0.5	3.7e-9	Menarche (age at onset);
TGCT	cis	rs79387448	0.745	rs72995652	chr2:103171651	C/A	cg09003973	chr2:102972529	NA	0.95	6.15	0.48	9.95e-9	Gut microbiota (bacterial taxa);
TGCT	cis	rs459571	0.959	rs2073818	chr9:136918662	C/A	cg13789015	chr9:136890014	NCRNA00094	0.39	6.83	0.52	3.45e-10	Platelet distribution width;
TGCT	cis	rs2153535	0.601	rs4140584	chr6:8540614	C/G	cg07606381	chr6:8435919	SLC35B3	-0.54	-4.97	-0.41	2.22e-6	Motion sickness;
TGCT	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg24060327	chr5:131705240	SLC22A5	0.72	8.0	0.58	7.65e-13	Breast cancer;
TGCT	cis	rs5769765	0.542	rs5769751	chr22:50242733	T/G	cg02269571	chr22:50332266	NA	0.35	4.57	0.38	1.18e-5	Schizophrenia;
TGCT	cis	rs651907	0.535	rs13094911	chr3:101519021	T/C	cg12386194	chr3:101231763	SENP7	0.48	4.81	0.4	4.36e-6	Colorectal cancer;
TGCT	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg25036284	chr2:26402008	FAM59B	-0.56	-4.88	-0.4	3.2e-6	Gut microbiome composition (summer);
TGCT	cis	rs644148	0.902	rs12982159	chr19:44964300	C/T	cg15540054	chr19:45004280	ZNF180	-0.56	-5.12	-0.42	1.12e-6	Personality dimensions;
TGCT	cis	rs2439831	0.850	rs16950562	chr15:44036364	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	5.91	0.47	3.05e-8	Lung cancer in ever smokers;
TGCT	cis	rs11190604	0.767	rs7076606	chr10:102192267	T/C	cg16342193	chr10:102329863	NA	-0.38	-5.0	-0.41	1.93e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs832540	0.931	rs832399	chr5:56222358	A/T	cg24531977	chr5:56204891	C5orf35	-0.54	-5.51	-0.44	2.02e-7	Coronary artery disease;
TGCT	cis	rs1008375	0.898	rs61047804	chr4:17593965	G/A	cg18681998	chr4:17616180	MED28	1.0	10.01	0.67	1.2e-17	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4851266	0.898	rs13010010	chr2:100852734	C/T	cg07810366	chr2:100720526	AFF3	-0.38	-5.39	-0.44	3.48e-7	Educational attainment;
TGCT	cis	rs2721195	0.614	rs12719778	chr8:145879883	T/C	cg15857475	chr8:145742913	RECQL4;LRRC14	0.93	9.9	0.66	2.19e-17	Age at first birth;
TGCT	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2777491	0.507	rs11854081	chr15:41646398	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.93	-15.88	-0.82	1.15e-31	Ulcerative colitis;
TGCT	cis	rs72781680	1.000	rs72796327	chr2:24140372	T/C	cg08917208	chr2:24149416	ATAD2B	0.8	4.94	0.41	2.47e-6	Lymphocyte counts;
TGCT	cis	rs7119	0.717	rs12916642	chr15:77818426	G/T	cg27398640	chr15:77910606	LINGO1	-0.26	-4.66	-0.39	7.98e-6	Type 2 diabetes;
TGCT	cis	rs514406	0.505	rs395169	chr1:53174071	G/A	cg01802117	chr1:53393560	SCP2	-0.39	-4.6	-0.38	1.02e-5	Monocyte count;
TGCT	cis	rs9318086	0.663	rs2312295	chr13:24457744	A/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.81	9.02	0.63	2.85e-15	Myopia (pathological);
TGCT	cis	rs7666738	0.753	rs35194639	chr4:99053819	G/C	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs478304	0.934	rs669742	chr11:65501291	C/T	cg17480646	chr11:65405466	SIPA1	0.43	5.35	0.43	4.18e-7	Acne (severe);
TGCT	cis	rs858239	0.600	rs2072368	chr7:23146112	C/T	cg05602783	chr7:23145260	KLHL7	-0.67	-5.7	-0.46	8.23e-8	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs7119038	0.629	rs11216995	chr11:118603526	G/A	cg19308663	chr11:118741387	NA	0.23	4.49	0.37	1.62e-5	Sjögren's syndrome;
TGCT	cis	rs6076065	0.513	rs13037787	chr20:23425811	C/T	cg11657817	chr20:23433608	CST11	0.29	4.75	0.39	5.44e-6	Facial morphology (factor 15, philtrum width);
TGCT	cis	rs9914988	0.943	rs4313850	chr17:27080768	T/C	cg20469991	chr17:27169893	C17orf63	-0.72	-5.01	-0.41	1.8e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs9916302	0.904	rs2024073	chr17:37471330	T/G	cg15445000	chr17:37608096	MED1	-0.33	-4.71	-0.39	6.46e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs250677	0.687	rs250672	chr5:148446110	A/G	cg23229984	chr5:148520753	ABLIM3	0.21	4.89	0.4	3.11e-6	Breast cancer;
TGCT	cis	rs6500602	0.727	rs11076837	chr16:4569440	C/T	cg08645402	chr16:4508243	NA	0.18	5.18	0.42	8.72e-7	Schizophrenia;
TGCT	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg12310025	chr6:25882481	NA	0.66	5.99	0.47	2.11e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7654585	0.886	rs1466281	chr4:25936665	G/A	cg10409131	chr4:25915609	C4orf52	0.71	6.64	0.51	8.9e-10	Obesity-related traits;
TGCT	cis	rs12368653	1.000	rs12368653	chr12:58133256	A/G	cg12615879	chr12:58013172	SLC26A10	-0.47	-5.8	-0.46	5.07e-8	Multiple sclerosis;
TGCT	cis	rs6546537	1.000	rs2048256	chr2:69847357	G/C	cg10773587	chr2:69614142	GFPT1	-0.71	-6.21	-0.49	7.16e-9	Serum thyroid-stimulating hormone levels;
TGCT	cis	rs16958440	0.867	rs75901436	chr18:44689644	C/T	cg17192377	chr18:44677553	HDHD2	0.63	4.7	0.39	6.74e-6	Sitting height ratio;
TGCT	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg03709012	chr19:19516395	GATAD2A	0.75	6.51	0.5	1.71e-9	Tonsillectomy;
TGCT	cis	rs78487399	0.808	rs75135247	chr2:43699399	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.39	-4.52	-0.38	1.42e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs4304924	0.500	rs2281856	chr13:79207644	C/T	cg01819759	chr13:79234251	RNF219	-0.78	-6.66	-0.51	8.13e-10	Large artery stroke;
TGCT	cis	rs886126	0.950	rs6490029	chr12:111698457	G/A	cg10833066	chr12:111807467	FAM109A	0.35	5.45	0.44	2.59e-7	Coronary heart disease;
TGCT	cis	rs910316	1.000	rs1043674	chr14:75549370	T/C	cg08847533	chr14:75593920	NEK9	0.96	10.9	0.7	8.37e-20	Height;
TGCT	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg22535103	chr8:58192502	C8orf71	-0.46	-5.16	-0.42	9.68e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7833790	0.750	rs10108955	chr8:82690644	C/T	cg17211192	chr8:82754475	SNX16	-1.04	-8.46	-0.6	6.42e-14	Diastolic blood pressure;
TGCT	cis	rs6088580	0.634	rs6088471	chr20:32932643	C/A	cg08999081	chr20:33150536	PIGU	-0.26	-4.98	-0.41	2.06e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.91	0.4	2.75e-6	Electroencephalogram traits;
TGCT	cis	rs10927875	0.518	rs732286	chr1:16344360	A/G	cg21385522	chr1:16154831	NA	0.47	4.85	0.4	3.57e-6	Dilated cardiomyopathy;
TGCT	cis	rs6500602	0.673	rs4786513	chr16:4576423	T/C	cg08645402	chr16:4508243	NA	0.22	5.58	0.45	1.43e-7	Schizophrenia;
TGCT	cis	rs765787	0.530	rs12442533	chr15:45529631	G/C	cg24006582	chr15:45444508	DUOX1	0.24	5.3	0.43	5.17e-7	Uric acid levels;
TGCT	cis	rs7681440	0.904	rs6816469	chr4:90772885	G/C	cg20003494	chr4:90757398	SNCA	-0.59	-5.52	-0.44	1.9e-7	Dementia with Lewy bodies;
TGCT	cis	rs4622507	0.819	rs4784455	chr16:55054810	T/A	cg04853843	chr16:55358461	IRX6	-0.54	-4.93	-0.4	2.59e-6	Social communication problems;
TGCT	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg01341218	chr17:43662625	NA	-1.11	-9.34	-0.64	5.11e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs1775715	0.707	rs1541261	chr10:32179523	G/A	cg14930904	chr10:32216787	ARHGAP12	0.53	5.03	0.41	1.66e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs6866344	0.697	rs62392833	chr5:178135452	T/A	cg03877680	chr5:178157825	ZNF354A	0.74	5.98	0.47	2.16e-8	Neutrophil percentage of white cells;
TGCT	cis	rs1008375	0.966	rs3775925	chr4:17588437	A/G	cg18681998	chr4:17616180	MED28	0.94	9.56	0.65	1.44e-16	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg03264133	chr6:25882463	NA	0.5	4.58	0.38	1.13e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs67478160	0.643	rs12434686	chr14:104316033	C/T	cg26031613	chr14:104095156	KLC1	0.67	6.93	0.53	2e-10	Schizophrenia;
TGCT	cis	rs694739	0.628	rs508168	chr11:64135435	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.64	6.62	0.51	9.49e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs2180341	0.781	rs877102	chr6:127587086	T/C	cg27446573	chr6:127587934	RNF146	0.91	8.5	0.61	5.12e-14	Breast cancer;
TGCT	cis	rs11711311	0.736	rs13320940	chr3:113400954	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.69	-6.08	-0.48	1.37e-8	IgG glycosylation;
TGCT	cis	rs4700695	0.841	rs433773	chr5:65309609	G/C	cg21114390	chr5:65439923	SFRS12	0.6	4.47	0.37	1.71e-5	Facial morphology (factor 19);
TGCT	cis	rs6754311	0.731	rs12615624	chr2:136721603	A/G	cg07169764	chr2:136633963	MCM6	0.69	6.43	0.5	2.49e-9	Mosquito bite size;
TGCT	cis	rs2594989	0.943	rs2443713	chr3:11537540	T/G	cg00170343	chr3:11313890	ATG7	0.65	4.66	0.39	8e-6	Circulating chemerin levels;
TGCT	cis	rs7666738	0.830	rs62318471	chr4:98925848	G/A	cg05340658	chr4:99064831	C4orf37	0.52	5.85	0.46	4.16e-8	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs1814175	0.817	rs10839358	chr11:49770972	G/A	cg03929089	chr4:120376271	NA	-0.69	-8.17	-0.59	3.03e-13	Height;
TGCT	cis	rs5167	0.566	rs60876330	chr19:45488133	C/T	cg09555818	chr19:45449301	APOC2	0.23	4.52	0.38	1.45e-5	Blood protein levels;
TGCT	cis	rs67311347	0.955	rs73078170	chr3:40483947	C/T	cg13409248	chr3:40428643	ENTPD3	0.59	4.62	0.38	9.58e-6	Renal cell carcinoma;
TGCT	cis	rs10779751	0.734	rs2748877	chr1:11129437	T/C	cg08854313	chr1:11322531	MTOR	0.82	7.04	0.53	1.19e-10	Body mass index;
TGCT	cis	rs6063312	0.667	rs9679994	chr20:47281853	T/C	cg18078177	chr20:47281410	PREX1	0.39	4.98	0.41	2.05e-6	Tonometry;
TGCT	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg16414030	chr3:133502952	NA	-0.61	-9.65	-0.66	8.74e-17	Iron status biomarkers;
TGCT	cis	rs28595532	0.920	rs56252481	chr4:119754023	C/T	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs854765	0.619	rs4561528	chr17:17979099	C/T	cg09796270	chr17:17721594	SREBF1	0.23	4.63	0.38	9e-6	Total body bone mineral density;
TGCT	cis	rs9796	0.689	rs692511	chr15:41446252	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.53	-6.88	-0.53	2.57e-10	Menopause (age at onset);
TGCT	cis	rs1729951	0.575	rs2163896	chr3:136691177	G/A	cg21827317	chr3:136751795	NA	0.4	5.61	0.45	1.28e-7	Neuroticism;
TGCT	cis	rs34014631	1.000	rs75905271	chr10:103686236	T/C	cg22630918	chr10:102748988	C10orf2	0.42	4.78	0.39	4.86e-6	Coronary artery calcification;
TGCT	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg03161606	chr19:29218774	NA	0.6	5.79	0.46	5.33e-8	Methadone dose in opioid dependence;
TGCT	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/C	cg07636037	chr3:49044803	WDR6	0.92	10.34	0.68	1.91e-18	Parkinson's disease;
TGCT	cis	rs4663866	1.000	rs13026475	chr2:239178455	T/C	cg17283117	chr2:239148619	HES6	0.98	4.52	0.38	1.42e-5	Irritable bowel syndrome;
TGCT	cis	rs4786125	0.706	rs8062094	chr16:6902585	A/G	cg03623568	chr16:6915990	A2BP1	-0.44	-6.4	-0.5	2.85e-9	Heart rate variability traits (SDNN);
TGCT	cis	rs7027203	0.717	rs7869328	chr9:96588782	A/G	cg14396892	chr9:96623032	NA	-0.28	-5.86	-0.47	3.9e-8	DNA methylation (variation);
TGCT	cis	rs7043114	0.544	rs4302908	chr9:95321641	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.53	-5.25	-0.43	6.27e-7	Height;
TGCT	cis	rs514406	0.505	rs269289	chr1:53167151	A/C	cg16325326	chr1:53192061	ZYG11B	0.83	11.14	0.71	2.12e-20	Monocyte count;
TGCT	cis	rs6728642	0.708	rs115507803	chr2:97752054	T/C	cg26665480	chr2:98280029	ACTR1B	-0.96	-5.36	-0.43	3.91e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	cis	rs6088590	0.735	rs2273684	chr20:33529766	G/T	cg08999081	chr20:33150536	PIGU	-0.25	-4.59	-0.38	1.07e-5	Coronary artery disease;
TGCT	cis	rs2302045	1.000	rs2270044	chr2:242056924	A/G	cg04553960	chr2:241721320	KIF1A	-0.75	-4.76	-0.39	5.19e-6	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio);
TGCT	cis	rs644799	0.544	rs1150360	chr11:95512060	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.55	5.67	0.45	9.5e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs3015497	0.626	rs7150204	chr14:51137355	T/C	cg04730355	chr14:51134070	SAV1	-0.61	-5.84	-0.46	4.22e-8	Mean platelet volume;
TGCT	cis	rs6665290	0.901	rs61834001	chr1:227197411	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.99	-20.13	-0.88	6.85e-41	Myeloid white cell count;
TGCT	cis	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg20637647	chr7:64974828	NA	0.94	5.17	0.42	9.06e-7	Diabetic kidney disease;
TGCT	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.51	-4.96	-0.41	2.24e-6	Prudent dietary pattern;
TGCT	cis	rs501916	0.833	rs59184310	chr15:48050205	A/T	cg16110827	chr15:48056943	SEMA6D	-0.17	-4.77	-0.39	5.12e-6	Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs28595532	0.541	rs114463740	chr4:119763329	C/T	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs3087591	0.959	rs8076441	chr17:29405878	C/T	cg24425628	chr17:29625626	OMG;NF1	-0.5	-7.54	-0.56	8.86e-12	Hip circumference;
TGCT	cis	rs2637266	1.000	rs12258924	chr10:78364758	G/A	cg18941641	chr10:78392320	NA	0.39	4.88	0.4	3.24e-6	Pulmonary function;
TGCT	cis	rs6095298	0.574	rs4428070	chr20:47457735	C/A	cg12307787	chr20:48099359	KCNB1	0.42	4.54	0.38	1.32e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs3741151	1.000	rs76764824	chr11:73073580	C/T	cg17517138	chr11:73019481	ARHGEF17	0.94	4.71	0.39	6.45e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
TGCT	cis	rs9611565	0.921	rs2235846	chr22:41741042	G/C	cg06634786	chr22:41940651	POLR3H	-0.63	-6.01	-0.47	1.93e-8	Vitiligo;
TGCT	cis	rs4149178	0.656	rs9472032	chr6:43294041	C/A	cg12269535	chr6:43142014	SRF	0.58	4.84	0.4	3.72e-6	Urate levels;
TGCT	cis	rs12142240	0.698	rs66575205	chr1:46814092	T/G	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg18876405	chr7:65276391	NA	-0.4	-6.12	-0.48	1.11e-8	Aortic root size;
TGCT	cis	rs12049351	0.774	rs4925455	chr1:229623665	T/A	cg12130225	chr1:229698885	NA	0.39	4.59	0.38	1.06e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs9527	0.590	rs1935323	chr10:104877035	T/C	cg15744005	chr10:104629667	AS3MT	-0.41	-4.8	-0.4	4.46e-6	Arsenic metabolism;
TGCT	cis	rs4478858	0.647	rs12752761	chr1:31710888	T/C	cg00250761	chr1:31883323	NA	-0.27	-4.89	-0.4	3.11e-6	Alcohol dependence;
TGCT	cis	rs1865760	1.000	rs7770139	chr6:25925823	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.65	6.21	0.49	7.42e-9	Height;
TGCT	cis	rs7662987	0.517	rs2851277	chr4:100022910	G/T	cg12011299	chr4:100065546	ADH4	0.4	4.82	0.4	4.07e-6	Smoking initiation;
TGCT	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.35	0.55	2.28e-11	Prudent dietary pattern;
TGCT	cis	rs12421382	1.000	rs12421382	chr11:109378071	C/T	cg16359550	chr11:109292809	C11orf87	0.52	5.61	0.45	1.27e-7	Schizophrenia;
TGCT	cis	rs2708977	0.933	rs2708976	chr2:97184532	C/G	cg01950434	chr2:97203154	ARID5A	-0.69	-6.34	-0.49	3.87e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs72945132	0.882	rs17160753	chr11:70131462	A/G	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs9926296	0.632	rs9935559	chr16:89800529	C/T	cg27121462	chr16:89883253	FANCA	-0.54	-5.06	-0.41	1.45e-6	Vitiligo;
TGCT	cis	rs10782582	0.593	rs6673786	chr1:76149637	C/T	cg10523679	chr1:76189770	ACADM	-0.69	-7.16	-0.54	6.4e-11	Daytime sleep phenotypes;
TGCT	cis	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg06558623	chr16:89946397	TCF25	0.53	6.59	0.51	1.14e-9	Skin colour saturation;
TGCT	cis	rs1008375	0.797	rs6843530	chr4:17593605	G/T	cg16339924	chr4:17578868	LAP3	0.81	6.69	0.52	6.75e-10	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs13401104	0.587	rs62190972	chr2:237145164	T/C	cg19324714	chr2:237145437	ASB18	0.48	5.03	0.41	1.67e-6	Educational attainment;
TGCT	cis	rs9393777	0.513	rs9379893	chr6:26584668	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.52	4.73	0.39	6.06e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg07424592	chr7:64974309	NA	1.39	8.27	0.6	1.78e-13	Diabetic kidney disease;
TGCT	cis	rs587847	0.737	rs2124972	chr15:37681973	C/T	cg00216138	chr15:37171175	LOC145845	0.31	4.45	0.37	1.91e-5	Intraocular pressure;
TGCT	cis	rs12497850	0.931	rs7636057	chr3:48992582	C/T	cg07636037	chr3:49044803	WDR6	0.96	10.39	0.68	1.45e-18	Parkinson's disease;
TGCT	cis	rs12530845	1.000	rs6979439	chr7:135329004	A/G	cg23117316	chr7:135346802	PL-5283	-0.51	-4.83	-0.4	3.98e-6	Red blood cell traits;
TGCT	cis	rs7428	1.000	rs7428	chr2:85545490	C/T	cg24342717	chr2:85555507	TGOLN2	0.39	6.41	0.5	2.72e-9	Ear protrusion;
TGCT	cis	rs9583531	0.527	rs3818496	chr13:111358488	G/A	cg24331049	chr13:111365604	ING1	0.74	7.18	0.54	5.77e-11	Coronary artery disease;
TGCT	cis	rs478304	0.903	rs12293022	chr11:65531698	C/T	cg27068330	chr11:65405492	SIPA1	0.74	7.41	0.55	1.67e-11	Acne (severe);
TGCT	cis	rs1062177	0.906	rs2964573	chr5:151160122	A/T	cg12924095	chr5:151150029	G3BP1	0.35	5.09	0.42	1.31e-6	Preschool internalizing problems;
TGCT	cis	rs6088580	0.634	rs6059824	chr20:33014543	T/C	cg08999081	chr20:33150536	PIGU	0.28	5.52	0.44	1.89e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs295140	0.656	rs3769472	chr2:201193373	G/A	cg04283868	chr2:201171347	SPATS2L	0.6	5.81	0.46	4.83e-8	QT interval;
TGCT	cis	rs7666738	0.546	rs6827131	chr4:98744810	C/G	cg18180107	chr4:99064573	C4orf37	0.54	4.78	0.39	4.93e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg03351412	chr1:154909251	PMVK	0.53	4.93	0.4	2.6e-6	Prostate cancer;
TGCT	cis	rs939658	0.805	rs12902831	chr15:79433171	G/A	cg17916960	chr15:79447300	NA	-0.49	-7.41	-0.55	1.73e-11	Refractive error;
TGCT	cis	rs9467773	0.626	rs6935803	chr6:26350495	A/G	cg05738196	chr6:26577821	NA	-0.63	-6.77	-0.52	4.5e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs2439831	0.867	rs2447211	chr15:43936351	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	4.95	0.41	2.38e-6	Lung cancer in ever smokers;
TGCT	cis	rs6840360	0.558	rs11735310	chr4:152287922	T/C	cg17479576	chr4:152424074	FAM160A1	-0.45	-4.72	-0.39	6.27e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs12478296	0.892	rs60545379	chr2:243034390	A/T	cg06360820	chr2:242988706	NA	-0.58	-4.47	-0.37	1.76e-5	Obesity-related traits;
TGCT	cis	rs11785400	0.793	rs7017851	chr8:143722038	G/T	cg10596483	chr8:143751796	JRK	0.53	5.09	0.42	1.28e-6	Schizophrenia;
TGCT	cis	rs9660180	0.780	rs12038111	chr1:1703849	T/C	cg13866156	chr1:1669148	SLC35E2	-0.24	-5.86	-0.47	4e-8	Body mass index;
TGCT	cis	rs9549260	0.564	rs4941989	chr13:41299687	T/C	cg21288729	chr13:41239152	FOXO1	0.94	9.08	0.63	2.07e-15	Red blood cell count;
TGCT	cis	rs8030485	0.690	rs9920235	chr15:79384021	C/T	cg17916960	chr15:79447300	NA	0.36	5.02	0.41	1.74e-6	Left ventricle wall thickness;
TGCT	cis	rs6840360	0.615	rs4696097	chr4:152479765	C/T	cg17479576	chr4:152424074	FAM160A1	0.7	7.49	0.56	1.14e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.03	0.48	1.79e-8	Bipolar disorder;
TGCT	cis	rs2153535	0.580	rs1335641	chr6:8487860	G/T	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs2730260	0.537	rs3793224	chr7:158876573	G/A	cg27122614	chr7:157913741	PTPRN2	0.42	4.47	0.37	1.74e-5	Myopia (pathological);
TGCT	cis	rs904251	0.523	rs2797798	chr6:37481437	C/T	cg01843034	chr6:37503916	NA	-0.56	-7.56	-0.56	7.84e-12	Cognitive performance;
TGCT	cis	rs4072705	0.605	rs10986358	chr9:127294185	A/C	cg13476313	chr9:127244764	NR5A1	0.32	4.73	0.39	6.08e-6	Menarche (age at onset);
TGCT	cis	rs2535633	0.631	rs2581819	chr3:53016552	C/A	cg10802521	chr3:52805072	NEK4	0.55	5.88	0.47	3.48e-8	Body mass index;
TGCT	cis	rs6598541	0.505	rs2137680	chr15:99312741	A/G	cg18742785	chr15:100270048	LYSMD4	-0.26	-4.55	-0.38	1.25e-5	Urate levels;
TGCT	cis	rs12477438	0.520	rs4851188	chr2:99745898	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	14.89	0.8	2.21e-29	Chronic sinus infection;
TGCT	cis	rs425277	0.561	rs925906	chr1:2044054	A/C	cg03732007	chr1:2071316	PRKCZ	-0.26	-5.96	-0.47	2.48e-8	Height;
TGCT	cis	rs1669338	0.588	rs4685612	chr3:3209242	G/T	cg16797762	chr3:3221439	CRBN	-0.95	-5.68	-0.45	9.17e-8	White matter integrity;
TGCT	trans	rs1814175	0.588	rs10839463	chr11:49971643	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.67	-0.69	2.92e-19	Height;
TGCT	cis	rs7412746	0.588	rs10305664	chr1:150839686	A/C	cg09365446	chr1:150670422	GOLPH3L	0.35	4.98	0.41	2.11e-6	Melanoma;
TGCT	cis	rs732765	0.648	rs8019391	chr14:75409682	T/C	cg06637938	chr14:75390232	RPS6KL1	0.65	5.76	0.46	6.11e-8	Non-small cell lung cancer;
TGCT	cis	rs9393692	0.645	rs766406	chr6:26319588	G/T	cg13736514	chr6:26305472	NA	-0.47	-6.9	-0.53	2.34e-10	Educational attainment;
TGCT	cis	rs4595586	0.545	rs925828	chr12:39364222	A/G	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs986417	0.786	rs1254273	chr14:60843581	C/A	cg27398547	chr14:60952738	C14orf39	-1.37	-8.31	-0.6	1.44e-13	Gut microbiota (bacterial taxa);
TGCT	cis	rs2439831	0.850	rs7163245	chr15:43671294	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	8.65	0.61	2.26e-14	Lung cancer in ever smokers;
TGCT	cis	rs3733585	0.673	rs4495037	chr4:9954050	C/G	cg11266682	chr4:10021025	SLC2A9	-0.57	-7.6	-0.56	6.21e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7959452	0.868	rs10784774	chr12:69737879	C/T	cg11871910	chr12:69753446	YEATS4	-0.68	-7.39	-0.55	1.93e-11	Blood protein levels;
TGCT	cis	rs1008375	1.000	rs2315560	chr4:17677305	C/G	cg10189774	chr4:17578691	LAP3	0.53	5.05	0.41	1.52e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6988636	1.000	rs7002021	chr8:124185250	G/A	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs8177253	0.511	rs9830001	chr3:133433470	A/G	cg16414030	chr3:133502952	NA	0.44	5.8	0.46	5.09e-8	Iron status biomarkers;
TGCT	cis	rs7017914	0.905	rs4074909	chr8:71955827	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	0.55	5.11	0.42	1.17e-6	Bone mineral density;
TGCT	trans	rs797680	0.856	rs10874762	chr1:93639101	T/G	cg27528825	chr2:159282178	CCDC148	-0.35	-6.83	-0.52	3.39e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg20999797	chr1:1681921	NA	0.19	4.87	0.4	3.26e-6	Body mass index;
TGCT	cis	rs453301	0.653	rs1045529	chr8:8890098	A/G	cg15556689	chr8:8085844	FLJ10661	-0.78	-7.27	-0.55	3.52e-11	Joint mobility (Beighton score);
TGCT	cis	rs2013441	1.000	rs2703804	chr17:20107195	T/C	cg18979559	chr17:20280153	CCDC144C	-0.44	-4.61	-0.38	9.78e-6	Obesity-related traits;
TGCT	cis	rs1200821	0.535	rs1208783	chr10:37767467	A/G	cg25427524	chr10:38739819	LOC399744	-0.29	-5.26	-0.43	5.99e-7	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs6815814	0.950	rs73236632	chr4:38836071	G/A	cg02016764	chr4:38805732	TLR1	-0.33	-4.95	-0.41	2.39e-6	Breast cancer;
TGCT	cis	rs929354	0.772	rs1182365	chr7:157017255	A/T	cg05182265	chr7:156933206	UBE3C	0.4	9.08	0.63	2.11e-15	Body mass index;
TGCT	cis	rs7833790	0.777	rs10958042	chr8:82678393	G/T	cg27398817	chr8:82754497	SNX16	-0.82	-5.97	-0.47	2.29e-8	Diastolic blood pressure;
TGCT	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg20607798	chr8:58055168	NA	0.61	5.16	0.42	9.38e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7552404	1.000	rs942270	chr1:76177332	G/A	cg22875332	chr1:76189707	ACADM	0.78	9.59	0.65	1.27e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs35306767	0.903	rs7074642	chr10:878359	A/G	cg26597838	chr10:835615	NA	0.71	10.12	0.67	6.47e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs57590327	0.628	rs34439726	chr3:81667241	C/T	cg07356753	chr3:81810745	GBE1	-0.61	-4.95	-0.41	2.37e-6	Extraversion;
TGCT	cis	rs6964587	0.967	rs17164315	chr7:91659150	C/G	cg22709100	chr7:91322751	NA	0.27	4.48	0.37	1.68e-5	Breast cancer;
TGCT	cis	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg02380750	chr20:61661411	NA	0.34	6.02	0.48	1.86e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1800795	0.652	rs7802307	chr7:22766433	T/A	cg26061582	chr7:22766209	IL6	0.46	5.91	0.47	3.14e-8	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
TGCT	cis	rs3812049	0.826	rs2409110	chr5:127433047	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	5.87	0.47	3.81e-8	Lymphocyte counts;Red cell distribution width;
TGCT	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.72	-0.39	6.15e-6	Prudent dietary pattern;
TGCT	cis	rs6570726	1.000	rs444564	chr6:145859795	G/C	cg05347473	chr6:146136440	FBXO30	0.5	4.46	0.37	1.82e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs79976124	0.837	rs74327235	chr6:66648353	T/A	cg07460842	chr6:66804631	NA	0.58	5.29	0.43	5.33e-7	Type 2 diabetes;
TGCT	cis	rs4711350	0.906	rs943463	chr6:33719877	A/G	cg18005901	chr6:33739558	LEMD2	-0.46	-5.04	-0.41	1.62e-6	Schizophrenia;
TGCT	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg05368731	chr17:41323189	NBR1	1.2	14.2	0.79	8.98e-28	Menopause (age at onset);
TGCT	cis	rs6665290	0.904	rs3738729	chr1:227191227	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.0	-20.5	-0.88	1.18e-41	Myeloid white cell count;
TGCT	cis	rs2019216	0.542	rs2221893	chr17:21930012	A/G	cg22648282	chr17:21454238	C17orf51	-0.59	-5.89	-0.47	3.46e-8	Pelvic organ prolapse;
TGCT	cis	rs3776081	0.600	rs17708682	chr5:149529999	C/T	cg18424208	chr5:149546337	CDX1	-0.25	-4.6	-0.38	1.01e-5	Blood protein levels;
TGCT	cis	rs4332037	0.586	rs62442944	chr7:2015047	T/G	cg25834613	chr7:1915315	MAD1L1	-0.47	-4.51	-0.38	1.48e-5	Bipolar disorder;
TGCT	cis	rs7607369	0.714	rs55900247	chr2:219618708	T/C	cg02176678	chr2:219576539	TTLL4	-0.5	-6.48	-0.5	1.92e-9	Red blood cell count;Amyotrophic lateral sclerosis;
TGCT	cis	rs9916302	0.706	rs9891892	chr17:37479856	A/C	cg07936489	chr17:37558343	FBXL20	0.87	6.27	0.49	5.47e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs3806843	0.576	rs246024	chr5:140333952	C/T	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs60411337	chr4:99046617	T/C	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8062405	0.789	rs1968752	chr16:28631585	G/T	cg09754948	chr16:28834200	ATXN2L	0.55	4.47	0.37	1.71e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs4689388	0.889	rs10026334	chr4:6294607	G/A	cg14416269	chr4:6271139	WFS1	0.37	4.9	0.4	2.95e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg22618164	chr12:122356400	WDR66	0.69	6.32	0.49	4.32e-9	Mean corpuscular volume;
TGCT	cis	rs11626933	1.000	rs7149083	chr14:90754006	G/A	cg14092571	chr14:90743983	NA	-0.29	-6.02	-0.48	1.86e-8	Gut microbiota (bacterial taxa);
TGCT	cis	rs600231	0.706	rs1111934	chr11:65329392	A/G	cg21890820	chr11:65308645	LTBP3	0.39	5.11	0.42	1.19e-6	Bone mineral density;
TGCT	cis	rs6988636	1.000	rs13260318	chr8:124190165	C/G	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs10464366	0.544	rs1525799	chr7:39153131	C/G	cg15212455	chr7:39170539	POU6F2	-0.3	-6.55	-0.51	1.38e-9	IgG glycosylation;
TGCT	cis	rs910316	0.935	rs3742771	chr14:75599647	A/G	cg08847533	chr14:75593920	NEK9	0.92	9.91	0.66	2.1e-17	Height;
TGCT	cis	rs796364	0.906	rs1658810	chr2:200816382	C/T	cg23649088	chr2:200775458	C2orf69	0.34	4.54	0.38	1.31e-5	Schizophrenia;
TGCT	cis	rs10465746	0.967	rs12757632	chr1:84416408	T/C	cg10977910	chr1:84465055	TTLL7	0.66	6.57	0.51	1.27e-9	Obesity-related traits;
TGCT	cis	rs7940866	0.903	rs7942900	chr11:130839244	G/A	cg05962950	chr11:130786565	SNX19	0.67	6.57	0.51	1.26e-9	Schizophrenia;
TGCT	cis	rs6964587	0.967	rs10246036	chr7:91558523	G/A	cg17063962	chr7:91808500	NA	-0.9	-9.67	-0.66	7.91e-17	Breast cancer;
TGCT	cis	rs1005277	0.505	rs200910	chr10:38108176	C/T	cg13531842	chr10:38383804	ZNF37A	-0.39	-4.58	-0.38	1.1e-5	Extrinsic epigenetic age acceleration;
TGCT	trans	rs561341	1.000	rs56362439	chr17:30253140	T/A	cg20587970	chr11:113659929	NA	-0.91	-10.05	-0.67	9.52e-18	Hip circumference adjusted for BMI;
TGCT	cis	rs7666738	0.830	rs4443293	chr4:99063120	G/A	cg17366294	chr4:99064904	C4orf37	0.73	7.45	0.56	1.4e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9581857	0.579	rs3759434	chr13:27997700	A/C	cg01674679	chr13:27998804	GTF3A	-0.66	-4.6	-0.38	1.01e-5	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs1577917	0.958	rs2084294	chr6:86565943	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.29	-0.43	5.34e-7	Response to antipsychotic treatment;
TGCT	cis	rs7267979	0.966	rs6037103	chr20:25369095	A/G	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10411936	1.000	rs7256818	chr19:16558766	C/A	cg19006008	chr19:16999768	F2RL3	-0.27	-4.65	-0.39	8.23e-6	White blood cell count;Multiple sclerosis;
TGCT	cis	rs6840360	0.615	rs2120098	chr4:152457180	T/A	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.03	-0.58	6.46e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs11577318	0.853	rs4333841	chr1:26631927	T/C	cg04990556	chr1:26633338	UBXN11	-0.63	-5.83	-0.46	4.58e-8	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs6988636	1.000	rs13261021	chr8:124190239	G/A	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs9536318	0.673	rs7984541	chr13:53510729	T/C	cg08567279	chr13:53313529	LECT1	-0.49	-4.47	-0.37	1.73e-5	Airflow obstruction;
TGCT	cis	rs6088590	1.000	rs6087623	chr20:33317662	C/G	cg24642439	chr20:33292090	TP53INP2	0.69	6.17	0.48	8.94e-9	Coronary artery disease;
TGCT	cis	rs9911578	0.933	rs2632508	chr17:56533235	G/A	cg05425664	chr17:57184151	TRIM37	-0.63	-6.21	-0.49	7.48e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs62244186	0.714	rs2293600	chr3:44599103	G/T	cg11003573	chr3:44754125	ZNF502	0.41	4.64	0.38	8.86e-6	Depressive symptoms;
TGCT	cis	rs8078723	0.966	rs7021	chr17:38153875	T/A	cg17467752	chr17:38218738	THRA	0.55	5.34	0.43	4.24e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs17534004	1.000	rs34538248	chr13:31468796	A/C	cg13251181	chr13:31481184	C13orf33	0.38	4.67	0.39	7.64e-6	3-hydroxypropylmercapturic acid levels in smokers;
TGCT	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg11764359	chr7:65958608	NA	0.58	5.31	0.43	4.91e-7	Aortic root size;
TGCT	cis	rs9650657	0.538	rs6984496	chr8:10796093	G/T	cg27411982	chr8:10470053	RP1L1	-0.23	-4.68	-0.39	7.46e-6	Neuroticism;
TGCT	cis	rs1878931	0.582	rs27238	chr16:3441223	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.76	-6.45	-0.5	2.3e-9	Body mass index (adult);
TGCT	cis	rs9300255	0.544	rs1790123	chr12:123659542	C/T	cg00376283	chr12:123451042	ABCB9	0.73	5.06	0.41	1.49e-6	Neutrophil percentage of white cells;
TGCT	cis	rs7246657	0.722	rs968073	chr19:38192021	G/A	cg18154014	chr19:37997991	ZNF793	-0.72	-5.06	-0.41	1.48e-6	Coronary artery calcification;
TGCT	cis	rs2299587	0.623	rs7816738	chr8:17768482	A/G	cg01800426	chr8:17659068	MTUS1	-0.67	-5.67	-0.45	9.6e-8	Economic and political preferences;
TGCT	cis	rs9611519	0.754	rs4820435	chr22:41652846	G/T	cg13695892	chr22:41940480	POLR3H	-0.67	-6.44	-0.5	2.34e-9	Neuroticism;
TGCT	cis	rs7043114	0.525	rs10116241	chr9:95240546	T/C	cg14631576	chr9:95140430	CENPP	-0.28	-4.52	-0.38	1.44e-5	Height;
TGCT	cis	rs17473412	0.825	rs2115170	chr5:122663496	G/A	cg15125798	chr5:122621645	NA	-0.61	-5.58	-0.45	1.45e-7	Total body bone mineral density;
TGCT	cis	rs116095464	0.558	rs28636067	chr5:199415	G/A	cg22857025	chr5:266934	NA	-0.35	-6.4	-0.5	2.95e-9	Breast cancer;
TGCT	cis	rs7542091	0.704	rs4133950	chr1:210044393	C/G	cg21951975	chr1:209979733	IRF6	0.6	6.1	0.48	1.24e-8	Monobrow;
TGCT	cis	rs10851411	0.706	rs7169521	chr15:42715944	C/T	cg23803468	chr15:43513504	EPB42	-0.26	-5.09	-0.42	1.29e-6	Glucose homeostasis traits;
TGCT	cis	rs1670533	1.000	rs1670533	chr4:1078187	G/A	cg27284194	chr4:1044797	NA	0.68	5.84	0.46	4.28e-8	Recombination rate (females);
TGCT	cis	rs829418	0.582	rs747662	chr1:21947218	C/G	cg04260293	chr1:22924330	EPHA8	0.43	4.6	0.38	1.03e-5	Neurocognitive impairment in HIV-1 infection (continuous);
TGCT	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg01448562	chr3:133502909	NA	-0.26	-5.06	-0.41	1.49e-6	Iron status biomarkers;
TGCT	cis	rs6940116	1	rs6940116	chr6:27708732	A/G	cg20933634	chr6:27740509	NA	0.44	5.07	0.41	1.38e-6	Intelligence (multi-trait analysis);Autism spectrum disorder or schizophrenia;
TGCT	cis	rs172166	0.538	rs1150686	chr6:28161271	T/G	cg13525197	chr6:28411240	ZSCAN23	-0.48	-4.71	-0.39	6.43e-6	Cardiac Troponin-T levels;
TGCT	cis	rs6121246	0.560	rs6088854	chr20:30225357	G/A	cg18721089	chr20:30220636	NA	-0.55	-5.15	-0.42	9.93e-7	Mean corpuscular hemoglobin;
TGCT	cis	rs12142240	0.628	rs56126529	chr1:46808860	C/T	cg00530320	chr1:46809349	NSUN4	0.29	5.88	0.47	3.63e-8	Menopause (age at onset);
TGCT	cis	rs9436747	0.618	rs1171266	chr1:66003824	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	-0.54	-5.02	-0.41	1.75e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg22963979	chr7:1858916	MAD1L1	-0.39	-6.41	-0.5	2.79e-9	Bipolar disorder and schizophrenia;
TGCT	cis	rs9807989	0.839	rs10182710	chr2:102981306	A/G	cg09003973	chr2:102972529	NA	0.67	6.03	0.48	1.75e-8	Asthma;
TGCT	cis	rs31872	0.520	rs246053	chr5:140326290	T/A	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Visceral adipose tissue adjusted for BMI;
TGCT	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg20203395	chr5:56204925	C5orf35	0.53	4.92	0.4	2.67e-6	Initial pursuit acceleration;
TGCT	cis	rs9308731	0.644	rs3789068	chr2:111909247	A/G	cg04202892	chr2:111875749	ACOXL	0.55	6.47	0.5	2.1e-9	Chronic lymphocytic leukemia;
TGCT	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.54	-0.38	1.33e-5	Bipolar disorder;
TGCT	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg14159672	chr1:205819179	PM20D1	0.63	8.04	0.59	5.93e-13	Menarche (age at onset);
TGCT	cis	rs7267979	0.549	rs11698185	chr20:25181998	T/C	cg16686733	chr20:25566563	NINL	0.51	5.17	0.42	9.1e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7940866	0.804	rs3910267	chr11:130810282	C/T	cg05962950	chr11:130786565	SNX19	0.67	6.68	0.51	7.1e-10	Schizophrenia;
TGCT	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg13206674	chr6:150067644	NUP43	0.53	4.65	0.39	8.3e-6	Lung cancer;
TGCT	cis	rs57920188	0.585	rs4077389	chr1:4070616	C/T	cg20703997	chr1:4087676	NA	0.47	5.84	0.46	4.38e-8	Interleukin-17 levels;
TGCT	cis	rs9486719	1.000	rs12214469	chr6:97019471	G/T	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.0	-0.41	1.9e-6	Migraine;Coronary artery disease;
TGCT	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg03395511	chr6:291903	DUSP22	-0.65	-6.76	-0.52	4.84e-10	Menopause (age at onset);
TGCT	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.5	-4.81	-0.4	4.26e-6	Bipolar disorder;
TGCT	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.69	-7.06	-0.54	1.07e-10	Prostate cancer;
TGCT	cis	rs28785552	0.796	rs8112908	chr19:53248041	C/T	cg10871876	chr19:53194124	ZNF83	0.49	6.9	0.53	2.41e-10	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs7772486	0.817	rs9386145	chr6:146363519	A/T	cg23711669	chr6:146136114	FBXO30	0.87	9.53	0.65	1.75e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg24060327	chr5:131705240	SLC22A5	0.78	8.46	0.61	6.22e-14	Breast cancer;
TGCT	cis	rs11148252	0.574	rs61958118	chr13:53170226	C/T	cg02158880	chr13:53174818	NA	0.41	4.77	0.39	5.05e-6	Lewy body disease;
TGCT	cis	rs1865760	0.515	rs2003208	chr6:25940719	G/C	cg12310025	chr6:25882481	NA	-0.53	-5.34	-0.43	4.24e-7	Height;
TGCT	cis	rs12579753	1.000	rs2400979	chr12:82197353	T/C	cg07988820	chr12:82153109	PPFIA2	-0.65	-6.79	-0.52	4.09e-10	Resting heart rate;
TGCT	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg08736216	chr1:53307985	ZYG11A	-0.3	-6.08	-0.48	1.37e-8	Monocyte count;
TGCT	cis	rs6933660	0.512	rs9383905	chr6:151804296	C/T	cg03627880	chr6:151815985	C6orf97	-0.69	-6.49	-0.5	1.81e-9	Menarche (age at onset);
TGCT	cis	rs9443645	0.901	rs56057971	chr6:79607182	G/A	cg09184832	chr6:79620586	NA	-0.48	-5.17	-0.42	9.23e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7568458	0.709	rs2028898	chr2:85777270	G/A	cg17127132	chr2:85788382	GGCX	0.52	4.63	0.38	9.25e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs644799	0.710	rs10831433	chr11:95519787	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.83	9.58	0.65	1.31e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg17178900	chr1:205818956	PM20D1	0.59	7.53	0.56	9.04e-12	Menarche (age at onset);
TGCT	trans	rs7618501	0.521	rs11709573	chr3:49956628	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.79	8.11	0.59	4.13e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs6545883	0.791	rs4672445	chr2:61655008	T/C	cg15711740	chr2:61764176	XPO1	0.55	4.99	0.41	1.96e-6	Tuberculosis;
TGCT	cis	rs5769707	0.967	rs763126	chr22:49988574	G/T	cg05373962	chr22:49881684	NA	0.3	6.15	0.48	9.63e-9	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs7666738	0.687	rs6830176	chr4:99093955	G/C	cg18180107	chr4:99064573	C4orf37	0.54	4.76	0.39	5.29e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg00814883	chr7:100076585	TSC22D4	-0.85	-8.62	-0.61	2.62e-14	Platelet count;
TGCT	cis	rs7208859	0.673	rs73263785	chr17:29214808	C/T	cg18442181	chr17:29233375	C17orf42	-0.78	-4.61	-0.38	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg10047753	chr17:41438598	NA	0.96	9.64	0.65	9.37e-17	Menopause (age at onset);
TGCT	cis	rs7635838	0.827	rs4273358	chr3:11415160	T/G	cg00170343	chr3:11313890	ATG7	0.63	5.9	0.47	3.21e-8	HDL cholesterol;
TGCT	cis	rs992157	0.835	rs2292550	chr2:219140288	G/C	cg00012203	chr2:219082015	ARPC2	-0.78	-7.64	-0.57	5.16e-12	Colorectal cancer;
TGCT	cis	rs295140	0.706	rs1347551	chr2:201186572	C/T	cg04283868	chr2:201171347	SPATS2L	0.64	6.33	0.49	4.07e-9	QT interval;
TGCT	cis	rs12776158	0.901	rs35355528	chr10:71216268	A/G	cg12610070	chr10:71211762	TSPAN15	-0.55	-4.83	-0.4	3.87e-6	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg07424592	chr7:64974309	NA	-1.31	-7.72	-0.57	3.33e-12	Diabetic kidney disease;
TGCT	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.77	-7.06	-0.54	1.05e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs3733585	0.673	rs4314284	chr4:9956096	C/T	cg11266682	chr4:10021025	SLC2A9	-0.6	-8.05	-0.59	5.71e-13	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg06618935	chr21:46677482	NA	0.33	5.41	0.44	3.09e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6500602	1.000	rs11647946	chr16:4462836	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.3	5.12	0.42	1.12e-6	Schizophrenia;
TGCT	cis	rs8179	0.700	rs42044	chr7:92250140	T/G	cg15732164	chr7:92237376	CDK6	-0.28	-4.8	-0.4	4.49e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
TGCT	trans	rs12339966	0.653	rs1489176	chr9:11276970	C/G	cg07173112	chr1:1114698	TTLL10	-0.33	-6.69	-0.51	6.89e-10	Systolic blood pressure;
TGCT	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg06238570	chr21:40685208	BRWD1	0.69	6.43	0.5	2.55e-9	Cognitive function;
TGCT	cis	rs950776	0.593	rs621849	chr15:78872861	G/A	cg06917634	chr15:78832804	PSMA4	-0.65	-5.32	-0.43	4.65e-7	Sudden cardiac arrest;
TGCT	cis	rs4654899	0.758	rs4457549	chr1:21487231	A/G	cg01072550	chr1:21505969	NA	0.58	9.65	0.65	9.14e-17	Superior frontal gyrus grey matter volume;
TGCT	cis	rs911555	0.692	rs60235428	chr14:103904350	T/C	cg23461800	chr14:103021989	NA	-0.35	-4.56	-0.38	1.23e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs3806843	1.000	rs10223116	chr5:140192643	C/T	cg19875535	chr5:140030758	IK	0.35	5.77	0.46	5.86e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9457247	0.871	rs1811121	chr6:167403539	T/C	cg23791538	chr6:167370224	RNASET2	-0.49	-4.96	-0.41	2.26e-6	Crohn's disease;
TGCT	cis	rs9341808	0.718	rs10943696	chr6:80901272	C/G	cg08355045	chr6:80787529	NA	0.32	5.6	0.45	1.29e-7	Sitting height ratio;
TGCT	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg16049864	chr8:95962084	TP53INP1	-0.76	-10.83	-0.7	1.24e-19	Type 2 diabetes;
TGCT	cis	rs12497850	1.000	rs6788650	chr3:48749543	T/C	cg18654377	chr3:49208889	KLHDC8B	-0.44	-6.06	-0.48	1.52e-8	Parkinson's disease;
TGCT	cis	rs72781680	0.784	rs72798406	chr2:24180144	T/C	cg08917208	chr2:24149416	ATAD2B	0.77	4.77	0.39	5.02e-6	Lymphocyte counts;
TGCT	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6138458	0.626	rs6132789	chr20:25012809	C/T	cg26195577	chr20:24973756	C20orf3	-0.99	-9.24	-0.64	8.46e-16	Blood protein levels;
TGCT	cis	rs6690583	0.697	rs10782537	chr1:85484473	C/T	cg22153463	chr1:85462885	MCOLN2	-0.71	-5.37	-0.43	3.75e-7	Serum sulfate level;
TGCT	trans	rs4650994	0.525	rs2224811	chr1:178544323	C/T	cg05059571	chr16:84539110	KIAA1609	0.52	10.34	0.68	1.86e-18	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs73198271	0.694	rs114184516	chr8:8647082	A/G	cg15556689	chr8:8085844	FLJ10661	-0.6	-4.46	-0.37	1.8e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs1784581	0.894	rs1626020	chr6:162383379	G/A	cg17173639	chr6:162384350	PARK2	-0.5	-9.26	-0.64	7.99e-16	Itch intensity from mosquito bite;
TGCT	cis	rs228437	0.586	rs6935311	chr6:134911038	C/T	cg09872934	chr6:134495829	SGK1	-0.51	-4.44	-0.37	1.98e-5	Melanoma;
TGCT	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg14784868	chr12:69753453	YEATS4	0.9	10.55	0.69	5.67e-19	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs7091068	0.616	rs7093903	chr10:95484010	C/T	cg20715218	chr10:95462985	C10orf4	-0.53	-4.93	-0.4	2.59e-6	Urinary tract infection frequency;
TGCT	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg10047753	chr17:41438598	NA	0.96	9.86	0.66	2.71e-17	Menopause (age at onset);
TGCT	cis	rs9611565	0.592	rs6519270	chr22:42078666	A/G	cg13695892	chr22:41940480	POLR3H	0.85	8.19	0.59	2.72e-13	Vitiligo;
TGCT	cis	rs13040088	1.000	rs10854167	chr20:61533039	G/C	cg23096297	chr20:61557774	DIDO1	1.17	9.71	0.66	6.25e-17	Menopause (age at onset);
TGCT	cis	rs9527	0.571	rs7096249	chr10:104618524	G/A	cg15744005	chr10:104629667	AS3MT	-0.5	-6.39	-0.5	3.12e-9	Arsenic metabolism;
TGCT	trans	rs7618501	0.521	rs7615206	chr3:49937505	T/C	cg21659725	chr3:3221576	CRBN	0.68	7.77	0.57	2.53e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs17184557	0.957	rs1036837	chr18:67150897	G/T	cg03647455	chr18:67872746	RTTN	0.58	4.52	0.38	1.43e-5	Osteoporosis-related phenotypes;
TGCT	cis	rs2295359	0.892	rs56920441	chr1:67652012	A/G	cg08029281	chr1:67600428	NA	0.4	4.68	0.39	7.49e-6	Psoriasis;
TGCT	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg06873352	chr17:61820015	STRADA	0.55	6.1	0.48	1.26e-8	Prudent dietary pattern;
TGCT	cis	rs10425738	0.536	rs10426903	chr19:41417719	T/C	cg21111256	chr19:41386507	CYP2A7	-0.38	-4.75	-0.39	5.55e-6	nicotine metabolite ratio in current smokers;Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
TGCT	cis	rs734999	0.933	rs4648648	chr1:2512452	G/A	cg18854424	chr1:2615690	NA	0.46	5.85	0.47	4.1e-8	Ulcerative colitis;
TGCT	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg16325326	chr1:53192061	ZYG11B	-0.84	-11.96	-0.73	2.15e-22	Monocyte count;
TGCT	cis	rs6992820	0.933	rs35193637	chr8:56741274	A/C	cg06880721	chr8:56792545	LYN	-0.55	-4.71	-0.39	6.4e-6	Mean platelet volume;
TGCT	cis	rs9291683	0.552	rs10939655	chr4:10014642	A/T	cg02734326	chr4:10020555	SLC2A9	0.38	4.56	0.38	1.22e-5	Bone mineral density;
TGCT	cis	rs910316	0.935	rs175076	chr14:75505486	A/G	cg08847533	chr14:75593920	NEK9	-0.93	-10.19	-0.67	4.44e-18	Height;
TGCT	trans	rs4650994	0.507	rs12405456	chr1:178512331	T/G	cg05059571	chr16:84539110	KIAA1609	-0.55	-11.45	-0.72	3.74e-21	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs6815814	0.799	rs11466640	chr4:38778903	A/G	cg02016764	chr4:38805732	TLR1	0.36	5.57	0.45	1.5e-7	Breast cancer;
TGCT	cis	rs912057	0.833	rs1024245	chr6:6743319	A/G	cg06612196	chr6:6737390	NA	0.37	4.88	0.4	3.17e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs12136530	0.593	rs881247	chr1:19733320	A/G	cg24875000	chr1:19041556	PAX7	-0.26	-4.62	-0.38	9.56e-6	Lead levels in blood;
TGCT	cis	rs59197085	0.636	rs4728138	chr7:128468105	A/G	cg00260937	chr7:128520193	KCP	0.47	4.95	0.41	2.36e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
TGCT	cis	rs6076065	0.707	rs1419007	chr20:23336895	T/C	cg11657817	chr20:23433608	CST11	0.31	5.35	0.43	4.12e-7	Facial morphology (factor 15, philtrum width);
TGCT	cis	rs2239547	0.618	rs4687658	chr3:52860366	C/G	cg10802521	chr3:52805072	NEK4	-0.62	-5.85	-0.47	4.1e-8	Schizophrenia;
TGCT	cis	rs7412746	0.597	rs868751	chr1:150669414	T/G	cg09365446	chr1:150670422	GOLPH3L	0.31	4.64	0.38	8.7e-6	Melanoma;
TGCT	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2439831	0.867	rs689616	chr15:43761901	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.8	5.7	0.46	8.33e-8	Lung cancer in ever smokers;
TGCT	cis	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg02380750	chr20:61661411	NA	0.34	6.02	0.48	1.86e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2760061	0.784	rs708116	chr1:228198196	C/A	cg02753203	chr1:228287806	NA	0.31	5.94	0.47	2.62e-8	Diastolic blood pressure;
TGCT	cis	rs3733585	0.631	rs4697924	chr4:10124239	A/G	cg11266682	chr4:10021025	SLC2A9	-0.51	-5.79	-0.46	5.34e-8	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs425277	0.539	rs3107142	chr1:2044542	T/C	cg03732007	chr1:2071316	PRKCZ	-0.26	-5.75	-0.46	6.6e-8	Height;
TGCT	cis	rs6570726	0.791	rs11155426	chr6:145817130	T/C	cg23711669	chr6:146136114	FBXO30	0.89	9.72	0.66	6.02e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg24549020	chr5:56110836	MAP3K1	0.67	5.78	0.46	5.74e-8	Initial pursuit acceleration;
TGCT	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg18402987	chr7:1209562	NA	0.47	4.69	0.39	7.03e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs4820539	0.966	rs5759594	chr22:23470660	G/A	cg14186256	chr22:23484241	RTDR1	0.99	12.58	0.75	6.81e-24	Bone mineral density;
TGCT	cis	rs3796352	1.000	rs11714876	chr3:53101640	C/G	cg07884673	chr3:53033167	SFMBT1	-0.6	-6.23	-0.49	6.77e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs4664308	0.935	rs58354887	chr2:160927112	C/T	cg03641300	chr2:160917029	PLA2R1	-0.27	-6.71	-0.52	6.31e-10	Idiopathic membranous nephropathy;
TGCT	trans	rs459571	0.959	rs460888	chr9:136913123	C/G	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.77	-8.29	-0.6	1.58e-13	Platelet distribution width;
TGCT	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg24549020	chr5:56110836	MAP3K1	0.67	5.78	0.46	5.74e-8	Initial pursuit acceleration;
TGCT	trans	rs7618501	0.669	rs2230590	chr3:49936102	T/C	cg21659725	chr3:3221576	CRBN	0.78	9.49	0.65	2.13e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs6879260	0.963	rs11738924	chr5:179727308	A/G	cg23221052	chr5:179740743	GFPT2	-0.33	-5.09	-0.42	1.27e-6	Height;
TGCT	cis	rs6570726	0.846	rs4896824	chr6:145927048	C/T	cg05347473	chr6:146136440	FBXO30	0.5	4.59	0.38	1.07e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs478222	0.930	rs510107	chr2:25319471	G/A	cg15423357	chr2:25149977	NA	-0.46	-4.46	-0.37	1.83e-5	Type 1 diabetes;
TGCT	cis	rs2836974	0.897	rs2836923	chr21:40524236	T/C	cg06238570	chr21:40685208	BRWD1	0.71	6.39	0.5	3.04e-9	Cognitive function;
TGCT	cis	rs17712049	0.908	rs62447155	chr7:48201162	A/G	cg16849860	chr7:48352531	ABCA13	0.32	5.26	0.43	6.19e-7	Refractive astigmatism;
TGCT	cis	rs12765878	0.603	rs10883944	chr10:105651657	G/T	cg04788957	chr10:105438008	SH3PXD2A	0.28	4.45	0.37	1.91e-5	Coronary artery disease;
TGCT	cis	rs2455799	0.593	rs2062823	chr3:15732256	G/T	cg16303742	chr3:15540471	COLQ	-0.25	-4.72	-0.39	6.27e-6	Mean platelet volume;
TGCT	trans	rs7819412	0.660	rs7462931	chr8:10910343	G/C	cg15556689	chr8:8085844	FLJ10661	-0.72	-6.88	-0.53	2.66e-10	Triglycerides;
TGCT	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg13732083	chr21:47605072	C21orf56	0.35	4.69	0.39	7.17e-6	Testicular germ cell tumor;
TGCT	cis	rs17376456	0.877	rs7728736	chr5:93404277	C/T	cg25358565	chr5:93447407	FAM172A	0.92	8.38	0.6	9.58e-14	Diabetic retinopathy;
TGCT	cis	rs2933343	0.729	rs789224	chr3:128598231	A/C	cg11901034	chr3:128598214	ACAD9	-0.64	-6.11	-0.48	1.16e-8	IgG glycosylation;
TGCT	cis	rs9911578	0.967	rs12938821	chr17:56959422	T/C	cg05425664	chr17:57184151	TRIM37	-0.62	-6.18	-0.49	8.33e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs4319547	0.508	rs10846826	chr12:122894987	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.63	-4.94	-0.41	2.46e-6	Body mass index;
TGCT	cis	rs7666738	0.830	rs6853266	chr4:99047528	G/T	cg18180107	chr4:99064573	C4orf37	0.58	5.24	0.43	6.75e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg11494091	chr17:61959527	GH2	0.6	14.51	0.79	1.71e-28	Prudent dietary pattern;
TGCT	trans	rs877282	0.682	rs2265092	chr10:780293	C/T	cg22713356	chr15:30763199	NA	-0.93	-8.86	-0.62	6.95e-15	Uric acid levels;
TGCT	cis	rs2742234	0.955	rs1800861	chr10:43613843	G/T	cg02780029	chr10:43622663	RET	-0.25	-4.89	-0.4	3.05e-6	Hirschsprung disease;
TGCT	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg11062466	chr8:58055876	NA	0.38	4.62	0.38	9.5e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs12681287	0.752	rs10956786	chr8:87301237	T/C	cg27223183	chr8:87520930	FAM82B	-0.82	-5.86	-0.47	3.98e-8	Caudate activity during reward;
TGCT	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.49	-6.64	-0.51	8.8e-10	Alzheimer's disease;
TGCT	cis	rs7918232	0.882	rs10829190	chr10:27409555	C/T	cg14442939	chr10:27389572	ANKRD26	0.72	5.23	0.43	6.85e-7	Breast cancer;
TGCT	cis	rs7107174	0.901	rs11237487	chr11:78126754	G/C	cg12700464	chr11:78128424	GAB2	-0.66	-4.45	-0.37	1.9e-5	Testicular germ cell tumor;
TGCT	cis	rs28735056	0.591	rs62101204	chr18:77712832	G/A	cg20368463	chr18:77673604	PQLC1	0.52	6.11	0.48	1.2e-8	Schizophrenia;
TGCT	cis	rs644799	0.710	rs564480	chr11:95561741	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	8.39	0.6	9.37e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs72843506	0.722	rs9901484	chr17:20132894	G/A	cg18979559	chr17:20280153	CCDC144C	-0.65	-4.89	-0.4	3.07e-6	Schizophrenia;
TGCT	cis	rs912057	0.901	rs744056	chr6:6733540	A/G	cg06612196	chr6:6737390	NA	0.37	4.51	0.38	1.51e-5	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	trans	rs28735056	0.563	rs12968139	chr18:77685520	A/G	cg05926928	chr17:57297772	GDPD1	-0.68	-6.75	-0.52	5.1e-10	Schizophrenia;
TGCT	cis	rs317689	0.600	rs478188	chr12:69639215	A/G	cg14784868	chr12:69753453	YEATS4	0.55	4.56	0.38	1.21e-5	Response to diuretic therapy;
TGCT	cis	rs2404602	0.647	rs12898810	chr15:76904738	T/C	cg22467129	chr15:76604101	ETFA	0.47	4.61	0.38	9.77e-6	Blood metabolite levels;
TGCT	cis	rs910187	0.641	rs6124966	chr20:45813099	T/G	cg27589058	chr20:45804311	EYA2	-0.33	-7.21	-0.54	4.72e-11	Migraine;
TGCT	cis	rs7666738	0.830	rs3846445	chr4:99032939	T/A	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs7615952	0.799	rs13315434	chr3:125641394	T/G	cg07211511	chr3:129823064	LOC729375	-0.46	-7.9	-0.58	1.26e-12	Blood pressure (smoking interaction);
TGCT	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg22920501	chr2:26401640	FAM59B	0.81	6.36	0.5	3.52e-9	Gut microbiome composition (summer);
TGCT	cis	rs929354	0.605	rs7806314	chr7:156946903	A/T	cg05182265	chr7:156933206	UBE3C	-0.39	-8.98	-0.63	3.72e-15	Body mass index;
TGCT	cis	rs3008870	1.000	rs6673462	chr1:67461857	A/C	cg08660285	chr1:67390436	MIER1;WDR78	-1.1	-11.8	-0.73	5.15e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs2010099	0.759	rs78365741	chr3:124294281	A/C	cg17170942	chr3:124452405	UMPS	-0.41	-4.67	-0.39	7.7e-6	Thyroid peroxidase antibody levels;
TGCT	cis	rs9388451	0.531	rs9375414	chr6:126154475	G/A	cg05901451	chr6:126070800	HEY2	-0.74	-7.69	-0.57	3.97e-12	Brugada syndrome;
TGCT	cis	rs151997	0.924	rs32480	chr5:50208099	G/A	cg06027927	chr5:50259733	NA	0.47	4.76	0.39	5.2e-6	Callous-unemotional behaviour;
TGCT	cis	rs7246657	0.943	rs28402338	chr19:37833923	G/A	cg18154014	chr19:37997991	ZNF793	0.97	6.49	0.5	1.82e-9	Coronary artery calcification;
TGCT	cis	rs17221829	0.703	rs10830336	chr11:89406461	G/A	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.44	-0.37	1.99e-5	Anxiety in major depressive disorder;
TGCT	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg06481639	chr22:41940642	POLR3H	-0.69	-5.97	-0.47	2.33e-8	Vitiligo;
TGCT	cis	rs7432375	0.583	rs1609391	chr3:136615268	G/A	cg12473912	chr3:136751656	NA	0.32	4.53	0.38	1.35e-5	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2880765	0.835	rs4280192	chr15:86043020	G/A	cg13263323	chr15:86062960	AKAP13	-0.23	-4.82	-0.4	4.1e-6	Coronary artery disease;
TGCT	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg12963246	chr6:28129442	ZNF389	0.51	5.02	0.41	1.73e-6	Depression;
TGCT	cis	rs11190604	1.000	rs10786598	chr10:102291579	G/A	cg16342193	chr10:102329863	NA	-0.42	-5.37	-0.43	3.74e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs514406	0.584	rs7524702	chr1:53197830	G/A	cg01802117	chr1:53393560	SCP2	0.42	4.92	0.4	2.64e-6	Monocyte count;
TGCT	trans	rs1499614	1.000	rs2707832	chr7:66136549	C/T	cg07424592	chr7:64974309	NA	1.35	8.11	0.59	4.14e-13	Gout;
TGCT	cis	rs7236492	0.683	rs59828426	chr18:77204397	T/C	cg15644404	chr18:77186268	NFATC1	-0.35	-5.6	-0.45	1.32e-7	Inflammatory bowel disease;Crohn's disease;
TGCT	trans	rs4332037	0.950	rs7807014	chr7:1939021	T/C	cg25206134	chr2:45395956	NA	1.1	9.34	0.64	5.11e-16	Bipolar disorder;
TGCT	cis	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg20637647	chr7:64974828	NA	0.9	5.29	0.43	5.42e-7	Diabetic kidney disease;
TGCT	cis	rs2820315	1.000	rs1517810	chr1:201850057	T/C	cg12730843	chr1:201915899	LMOD1	-0.27	-4.79	-0.4	4.6e-6	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
TGCT	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg18538332	chr22:24372958	LOC391322	1.01	13.15	0.76	2.86e-25	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg00814883	chr7:100076585	TSC22D4	-0.89	-9.26	-0.64	7.79e-16	Platelet count;
TGCT	cis	rs231513	0.954	rs231493	chr17:41976998	G/C	cg26893861	chr17:41843967	DUSP3	-0.71	-5.33	-0.43	4.45e-7	Cognitive function;
TGCT	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.7	-0.39	6.79e-6	Prudent dietary pattern;
TGCT	cis	rs9325144	0.723	rs10161183	chr12:39182087	T/C	cg26384229	chr12:38710491	ALG10B	-0.61	-5.67	-0.45	9.5e-8	Morning vs. evening chronotype;
TGCT	cis	rs6570726	0.791	rs4335004	chr6:145904764	G/A	cg23711669	chr6:146136114	FBXO30	0.89	9.85	0.66	2.95e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs556990	0.570	rs5960	chr13:113801737	C/T	cg00619561	chr13:112980676	NA	0.31	4.95	0.41	2.34e-6	Blood protein levels;
TGCT	cis	rs11718455	1.000	rs9858826	chr3:44031412	C/T	cg08738300	chr3:44038990	NA	-0.85	-6.49	-0.5	1.87e-9	Coronary artery disease;
TGCT	cis	rs4689388	0.890	rs6838400	chr4:6295427	C/G	cg00701064	chr4:6280414	WFS1	0.37	4.7	0.39	6.72e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs2688608	0.839	rs2633311	chr10:75598099	C/T	cg04320760	chr10:75533139	FUT11	0.31	4.46	0.37	1.78e-5	Inflammatory bowel disease;
TGCT	cis	rs2354432	0.556	rs2353984	chr1:146813358	C/T	cg25205988	chr1:146714368	CHD1L	1.33	6.22	0.49	7.07e-9	Mitochondrial DNA levels;
TGCT	trans	rs4332037	0.539	rs55790766	chr7:2021248	C/T	cg25206134	chr2:45395956	NA	0.97	7.33	0.55	2.6e-11	Bipolar disorder;
TGCT	cis	rs4642101	0.561	rs6766744	chr3:12801843	C/T	cg05775895	chr3:12838266	CAND2	0.5	4.85	0.4	3.69e-6	QRS complex (12-leadsum);
TGCT	cis	rs35306767	0.903	rs11253462	chr10:889323	T/G	cg20503657	chr10:835505	NA	0.7	9.83	0.66	3.22e-17	Eosinophil percentage of granulocytes;
TGCT	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg17971929	chr21:40555470	PSMG1	-0.69	-5.94	-0.47	2.63e-8	Cognitive function;
TGCT	cis	rs1670533	1.000	rs935972	chr4:1045171	A/G	cg19318889	chr4:1322082	MAEA	0.22	4.61	0.38	9.86e-6	Recombination rate (females);
TGCT	cis	rs2404602	0.622	rs2003344	chr15:76632301	T/C	cg22467129	chr15:76604101	ETFA	0.49	4.88	0.4	3.23e-6	Blood metabolite levels;
TGCT	cis	rs614226	0.744	rs787832	chr12:120986801	A/G	cg01236616	chr12:121019343	POP5	1.26	13.2	0.76	2.23e-25	Type 1 diabetes nephropathy;
TGCT	cis	rs7547997	0.654	rs10158210	chr1:158311985	A/G	cg03528325	chr1:158223921	CD1A	0.33	4.81	0.4	4.38e-6	QRS duration;
TGCT	cis	rs10207060	1.000	rs10207060	chr2:240687289	A/C	cg07506560	chr2:240697449	NA	0.58	7.42	0.55	1.65e-11	Obesity-related traits;
TGCT	cis	rs3806843	0.735	rs2530242	chr5:140053351	G/C	cg19875535	chr5:140030758	IK	-0.37	-6.25	-0.49	6.12e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg27286337	chr10:134555280	INPP5A	-0.46	-5.46	-0.44	2.47e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs9911578	1.000	rs4398153	chr17:56968181	T/C	cg12560992	chr17:57184187	TRIM37	-0.76	-9.21	-0.64	1.03e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs826838	1.000	rs55828987	chr12:39056421	A/C	cg26384229	chr12:38710491	ALG10B	1.01	9.58	0.65	1.31e-16	Heart rate;
TGCT	cis	rs453301	0.686	rs11785634	chr8:8892597	G/T	cg15556689	chr8:8085844	FLJ10661	-0.62	-5.24	-0.43	6.69e-7	Joint mobility (Beighton score);
TGCT	cis	rs7267979	0.844	rs6076343	chr20:25376663	C/T	cg16686733	chr20:25566563	NINL	-0.52	-4.93	-0.4	2.61e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs700590	0.723	rs304161	chr5:88134310	A/G	cg22951263	chr5:87985283	NA	0.56	5.4	0.44	3.22e-7	Educational attainment (years of education);
TGCT	cis	rs10504229	0.724	rs72649117	chr8:58037639	A/G	cg08280861	chr8:58055591	NA	0.35	5.07	0.41	1.43e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9556958	0.708	rs4772092	chr13:99166614	A/G	cg15168958	chr13:99100528	FARP1	0.22	5.01	0.41	1.8e-6	Educational attainment (years of education);
TGCT	cis	rs644799	1.000	rs617999	chr11:95589935	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.31	0.6	1.38e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs6448317	1.000	rs11938296	chr4:24938861	A/G	cg21108841	chr4:24914750	CCDC149	-0.65	-4.95	-0.41	2.33e-6	Heschl's gyrus morphology;
TGCT	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg11062466	chr8:58055876	NA	0.38	4.62	0.38	9.5e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.34	0.55	2.43e-11	Prudent dietary pattern;
TGCT	cis	rs9985766	1.000	rs10027662	chr4:151034358	C/T	cg05926478	chr4:151174724	DCLK2	-0.27	-4.81	-0.4	4.35e-6	Coronary artery disease;Myocardial infarction;
TGCT	cis	rs3741404	0.620	rs12787945	chr11:63977546	G/A	cg00022866	chr11:64108440	CCDC88B	0.24	4.54	0.38	1.29e-5	Platelet count;
TGCT	cis	rs11935103	0.610	rs9998003	chr4:187293933	A/G	cg16785698	chr4:186456103	PDLIM3	0.44	4.62	0.38	9.55e-6	Response to citalopram treatment;
TGCT	cis	rs2832191	1.000	rs2832184	chr21:30483265	C/T	cg24692254	chr21:30365293	RNF160	-0.83	-8.72	-0.62	1.56e-14	Dental caries;
TGCT	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg17554472	chr22:41940697	POLR3H	-0.49	-5.27	-0.43	5.9e-7	Vitiligo;
TGCT	cis	rs700651	0.786	rs58224025	chr2:198821988	G/A	cg00792783	chr2:198669748	PLCL1	0.57	5.23	0.43	6.99e-7	Intracranial aneurysm;
TGCT	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg07507251	chr3:52567010	NT5DC2	-0.51	-7.05	-0.54	1.09e-10	Bipolar disorder;
TGCT	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg09060608	chr5:178986726	RUFY1	-0.56	-6.66	-0.51	7.9e-10	Lung cancer;
TGCT	cis	rs1475911	0.947	rs67055914	chr21:43510427	T/C	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.25	-4.7	-0.39	6.87e-6	IgG glycosylation;
TGCT	cis	rs7917772	0.503	rs11191328	chr10:104305185	C/T	cg05855489	chr10:104503620	C10orf26	-0.58	-5.02	-0.41	1.73e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs10992471	0.756	rs3758229	chr9:95078852	G/T	cg14631576	chr9:95140430	CENPP	-0.28	-4.55	-0.38	1.27e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg08859206	chr1:53392774	SCP2	-0.43	-6.29	-0.49	5.07e-9	Monocyte count;
TGCT	trans	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg11887960	chr12:57824829	NA	1.17	9.7	0.66	6.57e-17	Lung disease severity in cystic fibrosis;
TGCT	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg12310025	chr6:25882481	NA	0.65	5.85	0.47	4.03e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2806561	0.704	rs663942	chr1:23522476	G/A	cg12483005	chr1:23474871	LUZP1	0.42	5.41	0.44	3.15e-7	Height;
TGCT	cis	rs3008870	1.000	rs2815357	chr1:67491854	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.01	0.7	4.47e-20	Lymphocyte percentage of white cells;
TGCT	cis	rs3771570	1.000	rs62193221	chr2:242354632	T/C	cg21155796	chr2:242212141	HDLBP	0.94	6.69	0.51	6.97e-10	Prostate cancer;
TGCT	cis	rs8017423	0.607	rs12885664	chr14:90845697	T/C	cg04374321	chr14:90722782	PSMC1	-0.51	-4.7	-0.39	6.87e-6	Mortality in heart failure;
TGCT	cis	rs2153535	0.504	rs5001323	chr6:8451605	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.76	0.46	6.15e-8	Motion sickness;
TGCT	cis	rs9911578	1.000	rs2611782	chr17:56717956	T/C	cg12560992	chr17:57184187	TRIM37	0.75	9.21	0.64	1.04e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs981844	1.000	rs2405430	chr4:154658391	A/G	cg14289246	chr4:154710475	SFRP2	1.01	8.46	0.6	6.31e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs73058052	0.935	rs3745473	chr19:50086626	T/C	cg14048834	chr19:49990801	RPL13AP5;RPL13A	-0.58	-4.55	-0.38	1.26e-5	Fibrinogen levels;
TGCT	cis	rs59197085	0.636	rs4487676	chr7:128469362	G/A	cg00260937	chr7:128520193	KCP	0.46	4.82	0.4	4.15e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
TGCT	cis	rs36051895	0.659	rs12348771	chr9:5083634	T/C	cg02405213	chr9:5042618	JAK2	-0.78	-10.36	-0.68	1.65e-18	Pediatric autoimmune diseases;
TGCT	cis	rs7646507	1.000	rs6445088	chr3:172495722	A/G	cg10532262	chr3:172428426	NCEH1	0.97	4.9	0.4	2.89e-6	Obesity-related traits;
TGCT	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	8.55	0.61	3.84e-14	Platelet count;
TGCT	cis	rs7772486	0.558	rs2142978	chr6:146012061	T/C	cg13319975	chr6:146136371	FBXO30	0.68	6.18	0.49	8.39e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7937682	0.564	rs10891277	chr11:111373103	A/G	cg09085632	chr11:111637200	PPP2R1B	0.55	4.89	0.4	3.09e-6	Primary sclerosing cholangitis;
TGCT	cis	rs6988636	1.000	rs57322232	chr8:124193532	A/G	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs2288278	0.502	rs62065847	chr17:46593125	C/T	cg25032089	chr17:46643351	HOXB3	-0.41	-4.77	-0.39	5.17e-6	Hand grip strength;
TGCT	cis	rs894734	0.535	rs2366144	chr12:54324069	G/T	cg17708016	chr12:54321992	NA	0.61	5.4	0.44	3.32e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
TGCT	cis	rs2243480	0.901	rs778732	chr7:65822360	C/T	cg07424592	chr7:64974309	NA	1.24	7.18	0.54	5.75e-11	Diabetic kidney disease;
TGCT	cis	rs7937682	0.632	rs11603779	chr11:111781047	A/C	cg09085632	chr11:111637200	PPP2R1B	0.84	7.34	0.55	2.4e-11	Primary sclerosing cholangitis;
TGCT	cis	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg08045932	chr20:61659980	NA	0.48	9.28	0.64	7.07e-16	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9467711	0.722	rs13201782	chr6:26651053	T/A	cg16898833	chr6:26189333	HIST1H4D	1.37	6.2	0.49	7.83e-9	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7772486	0.754	rs1415746	chr6:146077107	A/G	cg23711669	chr6:146136114	FBXO30	-0.95	-11.1	-0.71	2.6e-20	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7267979	0.932	rs417130	chr20:25458320	T/C	cg16686733	chr20:25566563	NINL	0.56	5.69	0.46	8.49e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6594499	0.500	rs10491424	chr5:110453806	T/C	cg04022379	chr5:110408740	TSLP	0.59	6.39	0.5	3.04e-9	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs6967414	0.786	rs6463578	chr7:6753050	C/A	cg00387323	chr7:6746715	ZNF12	0.76	4.65	0.39	8.21e-6	Hematocrit;Hemoglobin concentration;
TGCT	cis	rs877529	0.625	rs714013	chr22:39533272	A/G	cg18708252	chr22:39545030	CBX7	-0.38	-5.61	-0.45	1.28e-7	Multiple myeloma;
TGCT	cis	rs2180341	0.782	rs6569490	chr6:127729615	C/T	cg24812749	chr6:127587940	RNF146	0.76	6.22	0.49	7.07e-9	Breast cancer;
TGCT	cis	rs7617773	0.963	rs6771787	chr3:48194242	C/T	cg11946769	chr3:48343235	NME6	-0.59	-5.25	-0.43	6.49e-7	Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs9999200	chr4:99030690	A/C	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9611565	1.000	rs9611565	chr22:41767486	T/C	cg03806693	chr22:41940476	POLR3H	-0.91	-9.45	-0.65	2.78e-16	Vitiligo;
TGCT	cis	rs2549003	0.966	rs10072571	chr5:131816711	A/C	cg02551604	chr5:131831745	NA	-0.89	-11.77	-0.73	6.36e-22	Asthma (sex interaction);
TGCT	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg10802521	chr3:52805072	NEK4	-0.73	-8.95	-0.63	4.37e-15	Electroencephalogram traits;
TGCT	cis	rs7772486	0.790	rs3924498	chr6:146233338	A/T	cg05347473	chr6:146136440	FBXO30	-0.52	-5.03	-0.41	1.67e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1023500	0.573	rs1807494	chr22:42474138	C/G	cg05082376	chr22:42548792	NA	0.23	5.43	0.44	2.83e-7	Schizophrenia;
TGCT	cis	rs2956278	0.717	rs2929748	chr12:84682837	A/G	cg25678815	chr12:85673915	ALX1	-0.54	-4.86	-0.4	3.48e-6	Depressive symptoms;Depressive symptoms (multi-trait analysis);
TGCT	cis	rs919433	0.713	rs6714697	chr2:198484486	C/T	cg00792783	chr2:198669748	PLCL1	0.5	4.67	0.39	7.84e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg07167872	chr1:205819463	PM20D1	0.57	7.24	0.55	4.11e-11	Menarche (age at onset);
TGCT	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg19318889	chr4:1322082	MAEA	-0.25	-6.29	-0.49	4.89e-9	Longevity;
TGCT	cis	rs10197940	0.532	rs13425170	chr2:152387112	A/C	cg06191203	chr2:152266755	RIF1	-0.71	-6.35	-0.5	3.72e-9	Lung cancer;
TGCT	cis	rs9300255	0.544	rs10772995	chr12:123671761	T/C	cg00376283	chr12:123451042	ABCB9	0.73	5.69	0.46	8.5e-8	Neutrophil percentage of white cells;
TGCT	cis	rs2439831	0.681	rs825740	chr15:43592408	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	7.99	0.58	7.86e-13	Lung cancer in ever smokers;
TGCT	cis	rs7677751	0.767	rs6554158	chr4:55066077	G/A	cg17187183	chr4:55093834	PDGFRA	0.48	6.45	0.5	2.26e-9	Corneal astigmatism;
TGCT	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg03188948	chr7:1209495	NA	0.65	5.5	0.44	2.07e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9527	0.615	rs10883811	chr10:104727279	A/G	cg15744005	chr10:104629667	AS3MT	-0.44	-5.19	-0.42	8.3e-7	Arsenic metabolism;
TGCT	cis	rs2594989	0.943	rs2454509	chr3:11489653	C/T	cg26283222	chr3:11613257	VGLL4	0.21	4.46	0.37	1.84e-5	Circulating chemerin levels;
TGCT	cis	rs6860806	0.507	rs272854	chr5:131688017	C/T	cg24060327	chr5:131705240	SLC22A5	-0.75	-8.12	-0.59	3.87e-13	Breast cancer;
TGCT	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs6570726	0.935	rs365658	chr6:145844588	C/T	cg23711669	chr6:146136114	FBXO30	0.69	6.69	0.51	7.01e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11809207	1.000	rs4659412	chr1:26518470	C/T	cg03844060	chr1:26490628	NA	0.25	4.62	0.38	9.44e-6	Height;
TGCT	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg10047753	chr17:41438598	NA	0.96	9.6	0.65	1.16e-16	Menopause (age at onset);
TGCT	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg01448562	chr3:133502909	NA	-0.33	-6.62	-0.51	9.75e-10	Iron status biomarkers;
TGCT	cis	rs6565180	0.962	rs6565183	chr16:30382755	T/C	cg17640201	chr16:30407289	ZNF48	-0.9	-9.03	-0.63	2.81e-15	Tonsillectomy;
TGCT	cis	rs9914544	1.000	rs8066385	chr17:18761133	C/T	cg26306683	chr17:18585705	ZNF286B	0.57	5.08	0.41	1.36e-6	Educational attainment (years of education);
TGCT	cis	rs7267979	1.000	rs2297497	chr20:25297909	C/T	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs155076	1.000	rs261369	chr13:21868420	C/A	cg14456004	chr13:21872349	NA	-1.18	-10.05	-0.67	9.55e-18	White matter hyperintensity burden;
TGCT	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg12310025	chr6:25882481	NA	-0.61	-5.42	-0.44	3.04e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs6831352	0.918	rs17817359	chr4:100054197	G/T	cg12011299	chr4:100065546	ADH4	-0.4	-4.88	-0.4	3.26e-6	Alcohol dependence;
TGCT	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg04317338	chr11:64019027	PLCB3	-0.77	-6.95	-0.53	1.81e-10	Mean platelet volume;
TGCT	cis	rs523522	0.962	rs7488320	chr12:120981630	G/T	cg27279351	chr12:120934652	DYNLL1	0.76	6.59	0.51	1.15e-9	High light scatter reticulocyte count;
TGCT	cis	rs1385374	0.858	rs11059927	chr12:129294333	T/C	cg09035930	chr12:129282057	SLC15A4	-0.55	-4.76	-0.39	5.27e-6	Systemic lupus erythematosus;
TGCT	cis	rs10197940	0.578	rs6718372	chr2:152345871	C/G	cg06191203	chr2:152266755	RIF1	-0.61	-5.14	-0.42	1.03e-6	Lung cancer;
TGCT	cis	rs2486288	0.656	rs6493145	chr15:45573862	G/T	cg14582100	chr15:45693742	SPATA5L1	-0.45	-5.33	-0.43	4.53e-7	Glomerular filtration rate;
TGCT	cis	rs35146811	0.735	rs1043915	chr7:99799845	T/A	cg13334819	chr7:99746414	C7orf59	-0.71	-5.83	-0.46	4.56e-8	Coronary artery disease;
TGCT	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg22166914	chr1:53195759	ZYG11B	-0.36	-6.11	-0.48	1.22e-8	Monocyte count;
TGCT	cis	rs4499344	0.693	rs382416	chr19:33107938	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.72	-7.25	-0.55	4.02e-11	Mean platelet volume;
TGCT	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	5.46	0.44	2.5e-7	Alzheimer's disease;
TGCT	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg06873352	chr17:61820015	STRADA	-0.55	-6.07	-0.48	1.43e-8	Prudent dietary pattern;
TGCT	cis	rs2120019	1.000	rs7168680	chr15:75369212	G/A	cg09165964	chr15:75287851	SCAMP5	-1.07	-8.58	-0.61	3.34e-14	Blood trace element (Zn levels);
TGCT	cis	rs17376456	0.569	rs6879620	chr5:93119893	G/A	cg21475434	chr5:93447410	FAM172A	-0.6	-4.9	-0.4	2.92e-6	Diabetic retinopathy;
TGCT	cis	rs35934224	0.783	rs13056219	chr22:19860846	C/T	cg11182965	chr22:19864308	TXNRD2	-0.38	-5.06	-0.41	1.47e-6	Glaucoma (primary open-angle);
TGCT	cis	rs12210905	0.541	rs56099947	chr6:27490937	G/T	cg08851530	chr6:28072375	NA	1.34	6.29	0.49	5.02e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs4294134	0.608	rs13233394	chr7:135243240	T/C	cg08396481	chr7:135194601	CNOT4	-0.62	-4.81	-0.4	4.25e-6	Paget's disease;
TGCT	cis	rs9906944	0.707	rs729003	chr17:47117775	C/T	cg07075026	chr17:47091521	IGF2BP1	-0.43	-4.6	-0.38	1.03e-5	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs644148	0.967	rs2686778	chr19:44972257	G/A	cg15540054	chr19:45004280	ZNF180	-0.59	-5.21	-0.42	7.8e-7	Personality dimensions;
TGCT	cis	rs9790314	0.846	rs9815222	chr3:160994897	C/T	cg03342759	chr3:160939853	NMD3	-0.51	-5.66	-0.45	9.96e-8	Morning vs. evening chronotype;
TGCT	cis	rs4788570	0.697	rs4788559	chr16:71848959	T/C	cg06353428	chr16:71660113	MARVELD3	1.53	12.59	0.75	6.48e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg00684032	chr4:1343700	KIAA1530	0.24	5.03	0.41	1.66e-6	Obesity-related traits;
TGCT	cis	rs7552404	0.961	rs211710	chr1:76109038	G/A	cg10523679	chr1:76189770	ACADM	-0.92	-10.05	-0.67	9.78e-18	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2204008	0.528	rs11503820	chr12:38395379	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-4.54	-0.38	1.32e-5	Bladder cancer;
TGCT	cis	rs453301	0.606	rs6981060	chr8:8908235	C/A	cg08975724	chr8:8085496	FLJ10661	-0.58	-4.75	-0.39	5.63e-6	Joint mobility (Beighton score);
TGCT	cis	rs533581	0.844	rs548591	chr16:88974516	A/G	cg16701003	chr16:89028210	CBFA2T3	0.34	4.76	0.39	5.2e-6	Social autistic-like traits;
TGCT	cis	rs425277	1.000	rs385039	chr1:2077409	C/T	cg03732007	chr1:2071316	PRKCZ	-0.26	-5.55	-0.45	1.67e-7	Height;
TGCT	cis	rs7666738	0.800	rs11941885	chr4:99072921	A/C	cg05340658	chr4:99064831	C4orf37	0.55	6.22	0.49	7.09e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6714710	0.603	rs17488897	chr2:98365164	G/C	cg26665480	chr2:98280029	ACTR1B	0.69	6.52	0.51	1.61e-9	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg18876405	chr7:65276391	NA	0.32	4.89	0.4	3.12e-6	Aortic root size;
TGCT	cis	rs112217694	1.000	rs17249363	chr4:104657689	A/G	cg24090629	chr4:104641072	TACR3	-1.01	-4.96	-0.41	2.29e-6	Menarche (age at onset);
TGCT	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	5.11	0.42	1.18e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg13395646	chr4:1353034	KIAA1530	-0.59	-8.0	-0.58	7.57e-13	Obesity-related traits;
TGCT	cis	rs9787249	0.957	rs12074147	chr1:40203722	T/C	cg20968010	chr1:40505947	CAP1	-0.53	-4.96	-0.41	2.3e-6	Blood protein levels;
TGCT	cis	rs732765	0.734	rs7153812	chr14:75173490	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.57	-4.97	-0.41	2.2e-6	Non-small cell lung cancer;
TGCT	cis	rs860295	0.580	rs10908483	chr1:155866834	C/T	cg05700447	chr1:155978627	NA	0.22	4.6	0.38	1.02e-5	Body mass index;
TGCT	cis	rs7017914	0.934	rs7006615	chr8:71639807	T/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.03	-0.41	1.69e-6	Bone mineral density;
TGCT	cis	rs4925386	0.802	rs6142735	chr20:60918087	G/C	cg06026331	chr20:60912101	LAMA5	0.41	6.87	0.52	2.82e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs7949030	0.626	rs35587183	chr11:62318656	C/T	cg11742103	chr11:62369870	EML3;MTA2	0.55	6.35	0.5	3.69e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs881375	0.678	rs1930782	chr9:123687905	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	4.97	0.41	2.18e-6	Rheumatoid arthritis;
TGCT	cis	rs7267979	0.932	rs4280527	chr20:25544014	A/G	cg16686733	chr20:25566563	NINL	0.55	5.46	0.44	2.46e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3125734	0.633	rs3902162	chr10:64041817	C/T	cg09941381	chr10:64027924	RTKN2	-0.33	-4.92	-0.4	2.65e-6	Rheumatoid arthritis;
TGCT	cis	rs9910055	0.529	rs2523161	chr17:42179405	C/T	cg19774624	chr17:42201019	HDAC5	0.73	7.1	0.54	8.3e-11	Total body bone mineral density;
TGCT	cis	rs587847	0.708	rs11073240	chr15:37634216	G/A	cg00216138	chr15:37171175	LOC145845	0.32	4.74	0.39	5.71e-6	Intraocular pressure;
TGCT	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg06028808	chr11:68637592	NA	0.55	6.9	0.53	2.37e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-8.64	-0.61	2.39e-14	Platelet count;
TGCT	cis	rs9443645	0.901	rs13191068	chr6:79714867	T/C	cg09184832	chr6:79620586	NA	-0.48	-5.34	-0.43	4.21e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg03303774	chr4:1407052	NA	0.3	4.78	0.39	4.8e-6	Obesity-related traits;
TGCT	cis	rs13256369	1.000	rs10103769	chr8:8573036	G/T	cg18904891	chr8:8559673	CLDN23	0.62	5.67	0.45	9.47e-8	Obesity-related traits;
TGCT	cis	rs79149102	0.579	rs7173218	chr15:75315328	A/G	cg09165964	chr15:75287851	SCAMP5	-1.05	-5.73	-0.46	7.26e-8	Lung cancer;
TGCT	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	7.24	0.55	4.17e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7428	0.545	rs17026212	chr2:85551696	T/G	cg24342717	chr2:85555507	TGOLN2	-0.48	-8.29	-0.6	1.6e-13	Ear protrusion;
TGCT	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg11366901	chr6:160182831	ACAT2	1.03	6.98	0.53	1.59e-10	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs1008375	0.966	rs10489036	chr4:17697687	A/G	cg10189774	chr4:17578691	LAP3	0.57	4.86	0.4	3.41e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs17764205	0.713	rs17696611	chr19:3259171	C/A	cg18738857	chr19:3606974	TBXA2R	-0.76	-4.6	-0.38	1.01e-5	Bipolar disorder and schizophrenia;
TGCT	cis	rs2594989	0.887	rs9985349	chr3:11591200	T/G	cg00170343	chr3:11313890	ATG7	-0.69	-5.1	-0.42	1.22e-6	Circulating chemerin levels;
TGCT	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg12310025	chr6:25882481	NA	-0.54	-5.6	-0.45	1.31e-7	Height;
TGCT	cis	rs2235642	0.893	rs2143285	chr16:1593171	A/G	cg10465839	chr16:1584050	IFT140;TMEM204	-0.3	-4.95	-0.41	2.35e-6	Coronary artery disease;
TGCT	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg27535305	chr1:53392650	SCP2	-0.28	-5.42	-0.44	2.93e-7	Monocyte count;
TGCT	cis	rs5760092	0.755	rs5760096	chr22:24247310	A/G	cg25703541	chr22:24373054	LOC391322	-0.71	-6.41	-0.5	2.72e-9	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs9926296	0.542	rs12599531	chr16:89909401	C/T	cg04287289	chr16:89883240	FANCA	-0.68	-6.38	-0.5	3.23e-9	Vitiligo;
TGCT	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg27454412	chr7:1067447	C7orf50	0.57	4.48	0.37	1.71e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs62244186	0.566	rs3762636	chr3:44854563	A/G	cg25151919	chr3:44754333	ZNF502	-0.47	-5.58	-0.45	1.46e-7	Depressive symptoms;
TGCT	cis	rs2997447	0.846	rs12071062	chr1:26412199	T/G	cg03844060	chr1:26490628	NA	0.28	4.57	0.38	1.16e-5	QRS complex (12-leadsum);
TGCT	cis	rs2839186	0.632	rs17176110	chr21:47706535	C/A	cg12516959	chr21:47718080	NA	-0.3	-4.49	-0.37	1.58e-5	Testicular germ cell tumor;
TGCT	cis	rs2303745	0.589	rs10401700	chr19:17397700	A/C	cg02221750	chr19:17393354	ANKLE1	-0.48	-6.22	-0.49	6.97e-9	Systemic lupus erythematosus;
TGCT	trans	rs3780486	0.813	rs3780488	chr9:33133812	T/C	cg20290983	chr6:43655470	MRPS18A	1.19	14.84	0.8	2.81e-29	IgG glycosylation;
TGCT	cis	rs12477438	0.798	rs2084987	chr2:99587885	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-8.52	-0.61	4.5e-14	Chronic sinus infection;
TGCT	cis	rs12477438	0.765	rs56167745	chr2:99600478	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.56	-4.86	-0.4	3.51e-6	Chronic sinus infection;
TGCT	cis	rs3806843	1.000	rs3756342	chr5:140165624	G/A	cg19875535	chr5:140030758	IK	0.37	6.34	0.49	3.89e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg26513180	chr16:89883248	FANCA	1.05	14.79	0.8	3.68e-29	Vitiligo;
TGCT	cis	rs12134245	0.747	rs17501512	chr1:92012481	C/G	cg02896835	chr1:92012615	NA	0.29	4.81	0.4	4.22e-6	Breast cancer;
TGCT	cis	rs9611565	0.614	rs4822053	chr22:42212936	C/A	cg17554472	chr22:41940697	POLR3H	-0.45	-4.76	-0.39	5.32e-6	Vitiligo;
TGCT	cis	rs950027	0.620	rs1153855	chr15:45660758	C/G	cg14582100	chr15:45693742	SPATA5L1	0.47	6.02	0.48	1.8e-8	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg11764359	chr7:65958608	NA	-0.55	-4.87	-0.4	3.3e-6	Aortic root size;
TGCT	cis	rs9807841	0.670	rs2360942	chr19:10780802	G/A	cg17848348	chr19:10766748	ILF3	-0.4	-4.58	-0.38	1.12e-5	Inflammatory skin disease;
TGCT	cis	rs2046867	0.818	rs6789061	chr3:72888690	C/T	cg25664220	chr3:72788482	NA	-0.57	-6.33	-0.49	4.08e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs8017423	0.967	rs11628812	chr14:90713720	G/T	cg04374321	chr14:90722782	PSMC1	-0.77	-8.03	-0.58	6.42e-13	Mortality in heart failure;
TGCT	cis	rs7586673	0.893	rs889925	chr2:161971597	T/C	cg22496339	chr2:162101262	NA	0.53	4.81	0.4	4.27e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs17601876	0.807	rs12910259	chr15:51555049	G/A	cg19946085	chr15:51559439	CYP19A1	-0.32	-4.84	-0.4	3.84e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	trans	rs4942242	0.763	rs7327129	chr13:44233014	T/C	cg19169023	chr15:41853346	TYRO3	-0.35	-6.7	-0.52	6.53e-10	Response to tocilizumab in rheumatoid arthritis;
TGCT	cis	rs9325144	0.554	rs7960616	chr12:39096664	T/A	cg10518543	chr12:38710700	ALG10B	-0.49	-4.58	-0.38	1.11e-5	Morning vs. evening chronotype;
TGCT	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg05985448	chr10:134359359	INPP5A	-0.19	-4.58	-0.38	1.13e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs9341808	0.527	rs7453746	chr6:80810013	T/G	cg08355045	chr6:80787529	NA	0.33	5.84	0.46	4.34e-8	Sitting height ratio;
TGCT	cis	rs6665290	0.901	rs12410103	chr1:227197408	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.99	-20.13	-0.88	6.85e-41	Myeloid white cell count;
TGCT	cis	rs35883536	0.647	rs2050474	chr1:101082131	G/C	cg06223162	chr1:101003688	GPR88	-0.41	-7.28	-0.55	3.38e-11	Monocyte count;
TGCT	cis	rs11690935	0.885	rs10202823	chr2:172780132	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.92	-8.36	-0.6	1.11e-13	Schizophrenia;
TGCT	cis	rs57590327	0.555	rs6795133	chr3:81756267	A/G	cg07356753	chr3:81810745	GBE1	-0.77	-7.2	-0.54	5.2e-11	Extraversion;
TGCT	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.31	-4.82	-0.4	4.12e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7528684	0.779	rs1537949	chr1:157701249	T/C	cg17134153	chr1:157670328	FCRL3	-0.26	-4.66	-0.39	8.17e-6	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;
TGCT	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg10047753	chr17:41438598	NA	0.96	9.6	0.65	1.16e-16	Menopause (age at onset);
TGCT	cis	rs17152411	1.000	rs7082846	chr10:126593310	C/A	cg07906193	chr10:126599966	NA	0.42	5.28	0.43	5.6e-7	Height;
TGCT	cis	rs6424115	0.679	rs2076345	chr1:24083494	C/T	cg15997130	chr1:24165203	NA	-0.67	-6.3	-0.49	4.75e-9	Immature fraction of reticulocytes;
TGCT	cis	rs7731657	0.537	rs7709977	chr5:130367086	A/T	cg08523029	chr5:130500466	HINT1	-0.61	-5.08	-0.42	1.34e-6	Fasting plasma glucose;
TGCT	cis	rs9379945	1	rs9379945	chr6:26907831	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.57	-4.71	-0.39	6.51e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10876993	0.890	rs1092472	chr12:58036688	G/T	cg15848620	chr12:58087721	OS9	-0.72	-5.78	-0.46	5.57e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs7666738	0.830	rs11097605	chr4:98985167	T/C	cg05340658	chr4:99064831	C4orf37	0.5	5.84	0.46	4.35e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs17443541	0.507	rs6726848	chr2:200451027	G/A	cg00055341	chr2:200446845	NA	-0.31	-4.45	-0.37	1.89e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs4273100	0.607	rs8072587	chr17:19211073	C/G	cg01534423	chr17:18965556	NA	-0.78	-7.04	-0.53	1.16e-10	Schizophrenia;
TGCT	trans	rs877282	0.898	rs11253338	chr10:759559	C/T	cg22713356	chr15:30763199	NA	1.0	7.29	0.55	3.23e-11	Uric acid levels;
TGCT	cis	rs12908161	0.959	rs3748376	chr15:85328352	C/T	cg17173187	chr15:85201210	NMB	0.55	6.15	0.48	9.95e-9	Schizophrenia;
TGCT	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2072499	0.898	rs2736609	chr1:156202640	C/T	cg24450063	chr1:156163899	SLC25A44	1.05	11.04	0.7	3.74e-20	Testicular germ cell tumor;
TGCT	cis	rs1577917	0.958	rs10944137	chr6:86454314	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.43	-0.44	2.81e-7	Response to antipsychotic treatment;
TGCT	cis	rs2777491	1.000	rs7168177	chr15:41715585	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.75	-11.01	-0.7	4.47e-20	Ulcerative colitis;
TGCT	cis	rs7666738	0.791	rs10013680	chr4:99023030	G/C	cg05340658	chr4:99064831	C4orf37	0.51	5.6	0.45	1.33e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6088580	0.634	rs4911419	chr20:32995873	G/A	cg06115741	chr20:33292138	TP53INP2	-0.55	-4.81	-0.4	4.28e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	6.11	0.48	1.2e-8	Alzheimer's disease;
TGCT	cis	rs911555	0.926	rs2756121	chr14:103989581	T/A	cg12935359	chr14:103987150	CKB	0.38	5.35	0.43	4.18e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9911578	0.835	rs723991	chr17:56482039	G/A	cg12560992	chr17:57184187	TRIM37	-0.77	-8.97	-0.63	3.76e-15	Intelligence (multi-trait analysis);
TGCT	trans	rs17685	0.725	rs2302436	chr7:75676988	A/T	cg19862616	chr7:65841803	NCRNA00174	-0.5	-8.42	-0.6	7.75e-14	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs68170813	0.559	rs12535081	chr7:106979291	C/T	cg02696742	chr7:106810147	HBP1	-0.73	-6.07	-0.48	1.42e-8	Coronary artery disease;
TGCT	cis	rs6500602	0.727	rs11076837	chr16:4569440	C/T	cg09549813	chr16:4587862	C16orf5	-0.28	-4.46	-0.37	1.78e-5	Schizophrenia;
TGCT	cis	rs2404602	0.684	rs57682236	chr15:76868478	G/A	cg22467129	chr15:76604101	ETFA	0.47	4.61	0.38	9.77e-6	Blood metabolite levels;
TGCT	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg07167872	chr1:205819463	PM20D1	0.57	7.29	0.55	3.14e-11	Menarche (age at onset);
TGCT	cis	rs4919044	0.599	rs10882124	chr10:94665826	A/G	cg05127821	chr10:94822908	CYP26C1	-0.76	-4.54	-0.38	1.32e-5	Coronary artery disease;
TGCT	cis	rs896854	0.654	rs13274945	chr8:95986626	C/T	cg09323728	chr8:95962352	TP53INP1	-0.49	-6.32	-0.49	4.22e-9	Type 2 diabetes;
TGCT	cis	rs904251	0.828	rs2797803	chr6:37487340	T/C	cg08126542	chr6:37504118	NA	-0.44	-5.94	-0.47	2.73e-8	Cognitive performance;
TGCT	cis	rs77106637	0.932	rs7109082	chr11:72707441	A/C	cg03713592	chr11:72463424	ARAP1	0.84	5.48	0.44	2.26e-7	Type 2 diabetes;
TGCT	cis	rs3008870	0.755	rs2755254	chr1:67470855	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.82	8.51	0.61	4.75e-14	Lymphocyte percentage of white cells;
TGCT	cis	rs2180341	1.000	rs13218061	chr6:127653758	G/A	cg24812749	chr6:127587940	RNF146	0.98	7.64	0.57	5.06e-12	Breast cancer;
TGCT	cis	rs1580019	0.587	rs7805311	chr7:32558302	A/G	cg07520158	chr7:32535189	LSM5;AVL9	-0.57	-5.05	-0.41	1.52e-6	Cognitive ability;
TGCT	cis	rs4642101	0.824	rs11717013	chr3:12843862	A/C	cg05775895	chr3:12838266	CAND2	0.73	7.24	0.55	4.1e-11	QRS complex (12-leadsum);
TGCT	cis	rs6121246	0.609	rs2376998	chr20:30340663	T/C	cg10886678	chr20:30946050	ASXL1	-0.52	-4.44	-0.37	1.97e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs782590	0.738	rs4312532	chr2:55812061	A/G	cg18811423	chr2:55921094	PNPT1	-0.62	-6.29	-0.49	4.93e-9	Metabolic syndrome;
TGCT	trans	rs6089829	0.851	rs6089827	chr20:61668845	C/T	cg13615516	chr5:77269221	NA	0.72	9.08	0.63	2.05e-15	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs4389656	0.806	rs71600238	chr5:6763238	T/C	cg12187999	chr5:6845652	NA	-0.33	-4.49	-0.37	1.59e-5	Coronary artery disease;
TGCT	cis	rs61774743	0.521	rs60144015	chr1:41845246	C/A	cg01193554	chr1:41846683	NA	-0.41	-5.01	-0.41	1.86e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg13607699	chr17:42295918	UBTF	0.59	5.44	0.44	2.67e-7	Total body bone mineral density;
TGCT	cis	rs1865760	1.000	rs9358893	chr6:25921761	A/G	cg16482183	chr6:26056742	HIST1H1C	0.51	4.59	0.38	1.06e-5	Height;
TGCT	cis	rs12220238	1.000	rs10824125	chr10:75997498	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.92	7.84	0.58	1.79e-12	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs11098499	0.909	rs1546504	chr4:120241179	C/T	cg09307838	chr4:120376055	NA	0.62	5.87	0.47	3.66e-8	Corneal astigmatism;
TGCT	cis	rs6687430	0.526	rs12127400	chr1:10613660	C/T	cg17425144	chr1:10567563	PEX14	0.51	5.95	0.47	2.54e-8	Hand grip strength;
TGCT	cis	rs2742417	0.904	rs2251021	chr3:45796657	A/G	cg04837898	chr3:45731254	SACM1L	0.49	4.96	0.41	2.23e-6	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	6.98	0.53	1.55e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs17345786	0.511	rs13061565	chr3:101392270	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.03	0.41	1.65e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg06873352	chr17:61820015	STRADA	0.58	6.37	0.5	3.32e-9	Prudent dietary pattern;
TGCT	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg18402987	chr7:1209562	NA	0.81	6.94	0.53	1.9e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs11098499	0.754	rs878376	chr4:120237702	G/A	cg09307838	chr4:120376055	NA	0.58	5.49	0.44	2.15e-7	Corneal astigmatism;
TGCT	cis	rs778371	0.659	rs2289911	chr2:233704252	A/G	cg08000102	chr2:233561755	GIGYF2	-0.67	-7.64	-0.57	5.21e-12	Schizophrenia;
TGCT	cis	rs6840360	0.642	rs2709815	chr4:152363772	T/C	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.83e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs9517320	0.515	rs61969456	chr13:99174799	C/G	cg20487152	chr13:99095054	FARP1	-0.24	-4.54	-0.38	1.29e-5	Longevity;
TGCT	cis	rs6460942	1.000	rs112794590	chr7:12319426	G/A	cg06484146	chr7:12443880	VWDE	-0.54	-4.55	-0.38	1.26e-5	Coronary artery disease;
TGCT	cis	rs9397585	0.502	rs6557273	chr6:153443159	A/G	cg24028809	chr6:153414101	RGS17	0.22	4.66	0.39	8.15e-6	Body mass index;
TGCT	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg16423285	chr20:60520624	NA	0.77	9.31	0.64	5.84e-16	Obesity-related traits;
TGCT	cis	rs11098499	0.955	rs7684942	chr4:120162201	C/T	cg24670566	chr4:120433619	PDE5A	0.23	4.45	0.37	1.89e-5	Corneal astigmatism;
TGCT	cis	rs10114408	0.959	rs10821255	chr9:96656549	A/C	cg13679303	chr9:96623674	NA	-0.36	-4.69	-0.39	7e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs9372253	0.967	rs9400379	chr6:110713783	A/G	cg01119278	chr6:110721349	DDO	-0.33	-5.4	-0.44	3.34e-7	Platelet distribution width;
TGCT	cis	rs13256369	0.851	rs13258283	chr8:8563630	T/C	cg06671706	chr8:8559999	CLDN23	0.34	4.53	0.38	1.38e-5	Obesity-related traits;
TGCT	cis	rs1008375	1.000	rs555	chr4:17625658	A/G	cg10189774	chr4:17578691	LAP3	0.59	5.28	0.43	5.68e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs62244186	0.748	rs13319803	chr3:44635461	G/A	cg25151919	chr3:44754333	ZNF502	-0.41	-4.74	-0.39	5.87e-6	Depressive symptoms;
TGCT	cis	rs1797081	0.967	rs811912	chr10:16859618	G/C	cg23933602	chr10:16859644	RSU1	1.04	13.14	0.76	3.06e-25	Platelet distribution width;
TGCT	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg03303774	chr4:1407052	NA	0.31	4.93	0.41	2.54e-6	Obesity-related traits;
TGCT	cis	rs734999	0.505	rs10910107	chr1:2539181	C/T	cg18854424	chr1:2615690	NA	0.46	5.36	0.43	4e-7	Ulcerative colitis;
TGCT	cis	rs2795502	1.000	rs1852959	chr10:43359636	T/C	cg20628663	chr10:43360327	NA	0.45	6.35	0.5	3.67e-9	Blood protein levels;
TGCT	cis	rs17345786	0.906	rs55710435	chr3:101180330	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.4	-8.36	-0.6	1.09e-13	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg12963246	chr6:28129442	ZNF389	0.52	5.1	0.42	1.23e-6	Depression;
TGCT	cis	rs7364180	0.582	rs139568	chr22:42210985	C/T	cg13695892	chr22:41940480	POLR3H	0.55	5.52	0.44	1.88e-7	Alzheimer's disease biomarkers;
TGCT	cis	rs9467773	1.000	rs10484442	chr6:26555879	A/G	cg09904177	chr6:26538194	HMGN4	0.68	6.77	0.52	4.62e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg11890956	chr21:40555474	PSMG1	1.04	10.14	0.67	5.79e-18	Cognitive function;
TGCT	cis	rs6831352	0.734	rs3100630	chr4:100031715	T/A	cg12011299	chr4:100065546	ADH4	0.39	5.2	0.42	8.04e-7	Alcohol dependence;
TGCT	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.44	-5.16	-0.42	9.7e-7	Longevity;Endometriosis;
TGCT	cis	rs9660180	0.967	rs12040325	chr1:1702436	G/A	cg13866156	chr1:1669148	SLC35E2	-0.24	-5.86	-0.47	3.84e-8	Body mass index;
TGCT	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg15691649	chr6:25882328	NA	-0.35	-4.55	-0.38	1.25e-5	Blood metabolite levels;
TGCT	cis	rs727563	0.636	rs2187795	chr22:42092225	C/A	cg06481639	chr22:41940642	POLR3H	0.73	6.57	0.51	1.27e-9	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs10883723	0.773	rs2296587	chr10:104245588	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.78	7.43	0.56	1.54e-11	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs1862618	0.641	rs170733	chr5:56249251	A/G	cg24531977	chr5:56204891	C5orf35	0.69	7.25	0.55	4e-11	Initial pursuit acceleration;
TGCT	cis	rs9611565	0.512	rs139560	chr22:42194962	A/G	cg03806693	chr22:41940476	POLR3H	-0.97	-9.87	-0.66	2.66e-17	Vitiligo;
TGCT	cis	rs6141769	0.542	rs6119939	chr20:31315153	T/C	cg13636640	chr20:31349939	DNMT3B	-0.52	-4.54	-0.38	1.34e-5	Subjective well-being;
TGCT	cis	rs710216	0.917	rs900834	chr1:43412343	A/G	cg03128534	chr1:43423976	SLC2A1	-0.61	-4.46	-0.37	1.81e-5	Red cell distribution width;
TGCT	cis	rs7666738	0.830	rs11731478	chr4:99001686	A/G	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs367615	0.731	rs58241713	chr5:108853664	G/A	cg17395555	chr5:108820864	NA	0.3	5.59	0.45	1.38e-7	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs10779751	0.960	rs2076657	chr1:11318763	C/G	cg08854313	chr1:11322531	MTOR	0.94	10.5	0.69	7.65e-19	Body mass index;
TGCT	cis	rs9650657	0.513	rs4314618	chr8:10816772	A/G	cg21775007	chr8:11205619	TDH	-0.53	-5.03	-0.41	1.65e-6	Neuroticism;
TGCT	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg02725872	chr8:58115012	NA	-0.38	-5.16	-0.42	9.32e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9811920	0.609	rs13317017	chr3:99665521	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.59	6.77	0.52	4.51e-10	Axial length;
TGCT	cis	rs9443645	0.803	rs12195716	chr6:79535412	T/C	cg09184832	chr6:79620586	NA	-0.46	-4.99	-0.41	1.97e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs67311347	1.000	rs11129876	chr3:40401636	C/T	cg13683864	chr3:40499215	RPL14	1.01	10.48	0.69	8.65e-19	Renal cell carcinoma;
TGCT	cis	rs68170813	0.559	rs11764448	chr7:106924928	A/G	cg02696742	chr7:106810147	HBP1	-0.69	-5.81	-0.46	4.85e-8	Coronary artery disease;
TGCT	cis	rs8037137	0.731	rs78029804	chr15:91538920	C/T	cg22570213	chr15:91497863	RCCD1	0.51	4.77	0.39	5.13e-6	Platelet count;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
TGCT	cis	rs926938	0.584	rs1286558	chr1:115357587	C/T	cg12756093	chr1:115239321	AMPD1	0.41	6.08	0.48	1.36e-8	Autism;
TGCT	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg21285383	chr16:89894308	SPIRE2	-0.47	-7.46	-0.56	1.3e-11	Vitiligo;
TGCT	cis	rs2404602	0.716	rs56351018	chr15:76824591	T/C	cg22467129	chr15:76604101	ETFA	-0.56	-6.65	-0.51	8.35e-10	Blood metabolite levels;
TGCT	cis	rs1775715	1.000	rs1251363	chr10:32328526	G/C	cg14930904	chr10:32216787	ARHGAP12	-0.5	-4.64	-0.38	8.69e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	trans	rs8073060	0.544	rs225246	chr17:33944773	T/C	cg19694781	chr19:47549865	TMEM160	-0.6	-13.04	-0.76	5.29e-25	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs9640161	0.702	rs11765692	chr7:150026567	C/T	cg10018233	chr7:150070692	REPIN1	0.32	4.68	0.39	7.4e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs17767294	0.612	rs9461425	chr6:27919688	G/A	cg08851530	chr6:28072375	NA	0.78	4.84	0.4	3.79e-6	Parkinson's disease;
TGCT	cis	rs11711311	0.955	rs7617313	chr3:113391740	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.78	-6.77	-0.52	4.53e-10	IgG glycosylation;
TGCT	cis	rs1801251	1.000	rs67013068	chr2:233608253	G/C	cg25237894	chr2:233734115	C2orf82	0.32	5.88	0.47	3.5e-8	Coronary artery disease;
TGCT	cis	rs3733631	0.843	rs10019555	chr4:104615281	G/A	cg24090629	chr4:104641072	TACR3	-0.73	-5.72	-0.46	7.65e-8	Menarche (age at onset);
TGCT	cis	rs17152411	0.843	rs7904691	chr10:126582927	G/T	cg07906193	chr10:126599966	NA	0.43	5.25	0.43	6.46e-7	Height;
TGCT	trans	rs3780486	0.846	rs10971419	chr9:33124161	T/C	cg04842962	chr6:43655489	MRPS18A	1.22	16.02	0.82	5.54e-32	IgG glycosylation;
TGCT	cis	rs1348850	0.632	rs10167783	chr2:178519041	G/A	cg22681709	chr2:178499509	PDE11A	-0.5	-6.08	-0.48	1.39e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs2191566	0.691	rs59086054	chr19:44549096	C/A	cg03039196	chr19:44506973	ZNF230	0.53	4.47	0.37	1.78e-5	Acute lymphoblastic leukemia (childhood);
TGCT	cis	rs7924176	0.601	rs1874152	chr10:75836119	C/T	cg19889307	chr10:75911429	ADK;AP3M1	-0.52	-4.92	-0.4	2.65e-6	Primary tooth development (time to first tooth eruption);Permanent tooth development;Primary tooth development (number of teeth);
TGCT	cis	rs2228479	0.557	rs57071566	chr16:89889327	T/G	cg06558623	chr16:89946397	TCF25	0.55	4.79	0.4	4.69e-6	Skin colour saturation;
TGCT	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg11494091	chr17:61959527	GH2	0.6	14.54	0.79	1.46e-28	Prudent dietary pattern;
TGCT	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.18	0.49	8.32e-9	Bipolar disorder;
TGCT	cis	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg12570787	chr5:219185	SDHA;CCDC127	0.66	4.48	0.37	1.64e-5	Breast cancer;
TGCT	cis	rs73416724	0.544	rs732691	chr6:43240390	C/T	cg24109273	chr6:43484729	YIPF3;POLR1C	0.86	4.7	0.39	6.75e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs3806843	0.607	rs246044	chr5:140330656	C/T	cg07102913	chr5:140593443	PCDHB13	-0.46	-4.65	-0.39	8.2e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg03609598	chr5:56110824	MAP3K1	-0.56	-4.57	-0.38	1.14e-5	Initial pursuit acceleration;
TGCT	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg16325326	chr1:53192061	ZYG11B	-0.85	-11.92	-0.73	2.62e-22	Monocyte count;
TGCT	cis	rs2243480	0.708	rs13242216	chr7:65898277	T/C	cg20637647	chr7:64974828	NA	0.91	5.33	0.43	4.55e-7	Diabetic kidney disease;
TGCT	cis	rs7216064	1.000	rs12452511	chr17:65832576	A/G	cg12091567	chr17:66097778	LOC651250	-0.81	-5.99	-0.47	2.07e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg08736216	chr1:53307985	ZYG11A	-0.3	-5.99	-0.47	2.09e-8	Monocyte count;
TGCT	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg00814883	chr7:100076585	TSC22D4	-0.85	-8.62	-0.61	2.62e-14	Platelet count;
TGCT	cis	rs7917772	0.503	rs11191328	chr10:104305185	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.72	0.62	1.54e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg18230493	chr5:56204884	C5orf35	0.76	5.67	0.45	9.71e-8	Initial pursuit acceleration;
TGCT	cis	rs12220238	1.000	rs7909915	chr10:75960942	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.91	7.77	0.57	2.63e-12	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs789859	1.000	rs789859	chr3:194405888	G/T	cg21106136	chr3:194405973	FAM43A	-0.36	-5.26	-0.43	6.12e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
TGCT	cis	rs877282	0.898	rs11253350	chr10:765968	G/A	cg17470449	chr10:769945	NA	0.37	5.59	0.45	1.37e-7	Uric acid levels;
TGCT	cis	rs6684514	1.000	rs12117903	chr1:156311165	G/T	cg16558208	chr1:156270281	VHLL	0.48	9.61	0.65	1.13e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg08564027	chr20:61660810	NA	0.37	6.85	0.52	3.1e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9916302	0.904	rs6503519	chr17:37706578	A/G	cg07936489	chr17:37558343	FBXL20	-0.61	-4.87	-0.4	3.29e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs1023500	0.551	rs133371	chr22:42465574	G/A	cg15557168	chr22:42548783	NA	-0.22	-5.54	-0.45	1.76e-7	Schizophrenia;
TGCT	cis	rs3540	0.512	rs8033595	chr15:91083353	G/A	cg22089800	chr15:90895588	ZNF774	-0.76	-7.91	-0.58	1.22e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	trans	rs11722228	0.549	rs73212863	chr4:10104173	C/T	cg26043149	chr18:55253948	FECH	1.18	11.39	0.72	5.19e-21	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs61612642	0.590	rs6931028	chr6:42193064	A/T	cg01092361	chr6:42185687	MRPS10	0.98	7.15	0.54	6.56e-11	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
TGCT	cis	rs1005224	0.819	rs10147492	chr14:76155309	T/G	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.67	-5.96	-0.47	2.45e-8	Large artery stroke;
TGCT	cis	rs9902453	1.000	rs8065059	chr17:28417376	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.74	-6.52	-0.51	1.63e-9	Coffee consumption (cups per day);
TGCT	cis	rs6540559	0.546	rs7551944	chr1:210029430	G/C	cg04352962	chr1:209979756	IRF6	0.69	4.71	0.39	6.51e-6	Cleft lip with or without cleft palate;
TGCT	trans	rs9951602	0.512	rs9958497	chr18:76655296	G/C	cg02800362	chr5:177631904	HNRNPAB	1.13	12.84	0.76	1.57e-24	Obesity-related traits;
TGCT	cis	rs9814567	0.806	rs4074523	chr3:134325657	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-7.21	-0.54	4.85e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs9814567	0.752	rs4605591	chr3:134328361	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-6.41	-0.5	2.8e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	trans	rs208520	0.633	rs7738469	chr6:66807446	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-10.77	-0.7	1.66e-19	Exhaled nitric oxide output;
TGCT	cis	rs7010267	0.570	rs6469804	chr8:120044829	G/A	cg17171407	chr8:119960777	TNFRSF11B	0.25	4.49	0.37	1.59e-5	Total body bone mineral density (age 45-60);
TGCT	cis	rs7666738	0.830	rs60007031	chr4:98824753	G/C	cg17366294	chr4:99064904	C4orf37	0.7	7.45	0.56	1.42e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.47	-0.5	2.01e-9	Alzheimer's disease;
TGCT	cis	rs2239785	0.959	rs129423	chr22:36657329	A/G	cg15716373	chr22:36655542	APOL1	-0.43	-4.96	-0.41	2.28e-6	Glomerulosclerosis;
TGCT	cis	rs2549003	0.966	rs10213701	chr5:131824064	T/A	cg02551604	chr5:131831745	NA	-0.86	-10.87	-0.7	9.47e-20	Asthma (sex interaction);
TGCT	cis	rs9916302	0.904	rs650106	chr17:37451559	A/G	cg15445000	chr17:37608096	MED1	-0.31	-4.59	-0.38	1.06e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs7949030	0.591	rs35880596	chr11:62369884	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.64	9.36	0.64	4.48e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7267979	1.000	rs397119	chr20:25440187	C/A	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6121246	0.529	rs6060142	chr20:30178028	A/G	cg21427119	chr20:30132790	HM13	-0.39	-5.73	-0.46	7.06e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs7809950	0.530	rs34021916	chr7:106817901	A/G	cg23024343	chr7:107201750	COG5	-0.37	-5.2	-0.42	8.08e-7	Coronary artery disease;
TGCT	cis	rs17376456	0.825	rs13165400	chr5:93091427	G/A	cg25358565	chr5:93447407	FAM172A	0.89	7.39	0.55	1.89e-11	Diabetic retinopathy;
TGCT	cis	rs7119038	0.818	rs11217033	chr11:118673706	T/C	cg19308663	chr11:118741387	NA	0.31	6.43	0.5	2.56e-9	Sjögren's syndrome;
TGCT	cis	rs1371867	0.846	rs1788204	chr8:101303936	C/T	cg06002616	chr8:101225028	SPAG1	-0.56	-6.58	-0.51	1.2e-9	Atrioventricular conduction;
TGCT	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg13683864	chr3:40499215	RPL14	-1.18	-13.68	-0.78	1.54e-26	Renal cell carcinoma;
TGCT	cis	rs7301826	0.966	rs10734980	chr12:131294626	T/C	cg14921827	chr12:131289118	STX2	0.15	4.5	0.37	1.52e-5	Plasma plasminogen activator levels;
TGCT	cis	rs3752962	0.630	rs11870150	chr17:1948601	C/T	cg24156229	chr17:1948635	NA	-0.39	-7.52	-0.56	9.43e-12	Itch intensity from mosquito bite;
TGCT	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg03160526	chr17:80928410	B3GNTL1	0.33	4.68	0.39	7.4e-6	Glycated hemoglobin levels;
TGCT	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg17054783	chr10:134559939	INPP5A	0.24	4.61	0.38	9.88e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs9677476	0.818	rs28678038	chr2:232063997	A/T	cg07929768	chr2:232055508	NA	0.31	4.49	0.37	1.61e-5	Food antigen IgG levels;
TGCT	cis	rs9303401	0.659	rs11495824	chr17:56918882	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg11366901	chr6:160182831	ACAT2	1.03	6.92	0.53	2.14e-10	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs10858047	0.883	rs4839384	chr1:115101171	G/A	cg12756093	chr1:115239321	AMPD1	0.46	4.66	0.39	8.09e-6	Autism;
TGCT	cis	rs9902453	0.967	rs12450441	chr17:28495021	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	6.39	0.5	3.03e-9	Coffee consumption (cups per day);
TGCT	cis	rs9467711	0.659	rs35304979	chr6:26356347	C/A	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7267979	0.932	rs4280527	chr20:25544014	A/G	cg03522245	chr20:25566470	NINL	0.59	6.22	0.49	6.95e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs933688	1.000	rs12654787	chr5:90713259	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.96	8.06	0.59	5.53e-13	Smoking behavior;
TGCT	cis	rs17331151	0.573	rs4687556	chr3:52890475	T/C	cg07884673	chr3:53033167	SFMBT1	-0.5	-5.77	-0.46	5.86e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs826838	0.809	rs11169666	chr12:39211300	T/C	cg13010199	chr12:38710504	ALG10B	0.73	5.8	0.46	5.2100000000000003e-08	Heart rate;
TGCT	cis	rs6570726	0.791	rs6570692	chr6:145904401	T/A	cg13319975	chr6:146136371	FBXO30	-0.5	-4.51	-0.38	1.48e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10986311	0.832	rs9695388	chr9:127141727	C/A	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.2	-5.02	-0.41	1.76e-6	Vitiligo;
TGCT	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg07157834	chr1:205819609	PM20D1	0.43	6.84	0.52	3.26e-10	Menarche (age at onset);
TGCT	cis	rs4700695	0.719	rs27586	chr5:65445873	G/A	cg21114390	chr5:65439923	SFRS12	-0.84	-7.45	-0.56	1.35e-11	Facial morphology (factor 19);
TGCT	cis	rs3806843	0.735	rs801183	chr5:140091115	C/T	cg19875535	chr5:140030758	IK	0.35	5.95	0.47	2.55e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs28595532	1.000	rs28595532	chr4:119716950	A/C	cg11846333	chr4:119757529	SEC24D	0.83	4.62	0.38	9.65e-6	Cannabis dependence symptom count;
TGCT	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg24549020	chr5:56110836	MAP3K1	0.7	5.97	0.47	2.34e-8	Initial pursuit acceleration;
TGCT	cis	rs12712073	0.837	rs11692867	chr2:100759477	G/A	cg22139774	chr2:100720529	AFF3	-0.38	-5.88	-0.47	3.51e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9467711	0.606	rs12174623	chr6:26373086	C/T	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs3820928	0.874	rs10176882	chr2:227896432	A/T	cg11843606	chr2:227700838	RHBDD1	-0.5	-4.7	-0.39	6.8e-6	Pulmonary function;
TGCT	cis	rs1903068	0.853	rs17773240	chr4:55999781	T/C	cg09978860	chr4:56023921	NA	0.57	6.47	0.5	2.1e-9	Endometriosis;
TGCT	cis	rs11190604	1.000	rs7073586	chr10:102307671	A/G	cg23241863	chr10:102295624	HIF1AN	0.82	5.84	0.46	4.38e-8	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9682041	0.877	rs6804688	chr3:170071191	T/G	cg07589077	chr3:170072950	NA	0.29	5.15	0.42	1e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs709400	0.663	rs1022736	chr14:103998423	G/C	cg12935359	chr14:103987150	CKB	-0.37	-5.54	-0.45	1.73e-7	Body mass index;
TGCT	cis	rs9985766	1.000	rs28887006	chr4:151013718	T/C	cg05926478	chr4:151174724	DCLK2	-0.25	-4.91	-0.4	2.82e-6	Coronary artery disease;Myocardial infarction;
TGCT	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg11644478	chr21:40555479	PSMG1	1.0	10.6	0.69	4.32e-19	Cognitive function;
TGCT	cis	rs1949733	0.701	rs2688222	chr4:8473735	C/A	cg11789530	chr4:8429930	ACOX3	0.55	4.87	0.4	3.27e-6	Response to antineoplastic agents;
TGCT	cis	rs10493773	0.775	rs12564080	chr1:86196586	A/C	cg17807903	chr1:86174739	ZNHIT6	-0.43	-6.17	-0.48	8.98e-9	Urate levels in overweight individuals;
TGCT	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg19318889	chr4:1322082	MAEA	-0.2	-4.83	-0.4	4.02e-6	Obesity-related traits;
TGCT	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg00080972	chr5:178986291	RUFY1	-0.53	-6.54	-0.51	1.47e-9	Lung cancer;
TGCT	cis	rs7607369	0.782	rs639913	chr2:219365971	A/C	cg02176678	chr2:219576539	TTLL4	0.48	6.78	0.52	4.32e-10	Red blood cell count;Amyotrophic lateral sclerosis;
TGCT	cis	rs9303401	0.614	rs34900851	chr17:56566399	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.77	0.52	4.6e-10	Cognitive test performance;
TGCT	cis	rs6121246	0.567	rs6060260	chr20:30192907	C/T	cg13852791	chr20:30311386	BCL2L1	0.69	4.54	0.38	1.33e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs77633900	0.614	rs2930681	chr15:76995150	G/A	cg21673338	chr15:77095150	SCAPER	-0.51	-5.12	-0.42	1.11e-6	Non-glioblastoma glioma;Glioma;
TGCT	cis	rs4722166	0.630	rs2091115	chr7:22810166	G/T	cg26061582	chr7:22766209	IL6	0.46	6.12	0.48	1.14e-8	Lung cancer;
TGCT	cis	rs916888	0.531	rs183211	chr17:44788310	G/A	cg15921436	chr17:44337874	NA	0.41	6.31	0.49	4.55e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2073300	1.000	rs6048803	chr20:23438889	A/G	cg09953122	chr20:23471693	CST8	-0.62	-4.59	-0.38	1.08e-5	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs9807989	0.507	rs6734762	chr2:103062926	C/T	cg03938978	chr2:103052716	IL18RAP	0.27	5.34	0.43	4.19e-7	Asthma;
TGCT	cis	rs9858542	1.000	rs1131095	chr3:49714225	T/C	cg03060546	chr3:49711283	APEH	-0.67	-6.09	-0.48	1.28e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs5760092	0.842	rs5760103	chr22:24248781	A/G	cg20007245	chr22:24372913	LOC391322	-0.78	-6.29	-0.49	4.98e-9	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs6988636	1.000	rs16898086	chr8:124190445	A/G	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs6748734	1.000	rs11898716	chr2:241828311	A/G	cg04034577	chr2:241836375	C2orf54	-0.41	-6.36	-0.5	3.5e-9	Urinary metabolites;
TGCT	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg08736216	chr1:53307985	ZYG11A	-0.31	-4.72	-0.39	6.23e-6	Monocyte count;
TGCT	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg22433210	chr17:43662623	NA	1.01	7.37	0.55	2.14e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs6964587	1.000	rs7455444	chr7:91639313	C/T	cg17063962	chr7:91808500	NA	0.91	9.99	0.67	1.32e-17	Breast cancer;
TGCT	cis	rs651907	0.557	rs35117343	chr3:101445126	A/G	cg12386194	chr3:101231763	SENP7	0.48	4.63	0.38	9.23e-6	Colorectal cancer;
TGCT	cis	rs228437	0.507	rs228440	chr6:134899380	A/G	cg09872934	chr6:134495829	SGK1	0.51	4.63	0.38	9.17e-6	Melanoma;
TGCT	cis	rs904251	0.772	rs1224127	chr6:37417556	G/A	cg08126542	chr6:37504118	NA	-0.4	-4.68	-0.39	7.39e-6	Cognitive performance;
TGCT	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	6.23	0.49	6.56e-9	Bipolar disorder;
TGCT	cis	rs28595532	0.920	rs56212415	chr4:119737731	C/T	cg11846333	chr4:119757529	SEC24D	0.93	4.44	0.37	2e-5	Cannabis dependence symptom count;
TGCT	cis	rs2307449	0.964	rs758130	chr15:89873797	A/G	cg24365117	chr15:89879190	POLG	0.35	4.93	0.41	2.54e-6	Menopause (age at onset);
TGCT	cis	rs28595532	0.920	rs114916728	chr4:119776886	G/A	cg14228332	chr4:119757509	SEC24D	1.26	7.08	0.54	9.26e-11	Cannabis dependence symptom count;
TGCT	cis	rs4563143	0.514	rs73029076	chr19:29292032	G/T	cg14983838	chr19:29218262	NA	0.71	5.19	0.42	8.21e-7	Methadone dose in opioid dependence;
TGCT	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.66	-6.91	-0.53	2.3e-10	Longevity;Endometriosis;
TGCT	cis	rs704	0.605	rs2071379	chr17:26695832	A/G	cg10494684	chr17:26645200	TMEM97	-0.46	-5.09	-0.42	1.3e-6	Osteoprotegerin levels;
TGCT	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg03388025	chr16:89894329	SPIRE2	0.53	9.46	0.65	2.57e-16	Vitiligo;
TGCT	cis	rs66573146	1.000	rs6812391	chr4:6963893	G/A	cg05069807	chr4:6945702	TBC1D14	0.31	4.6	0.38	1.03e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs6502955	1.000	rs6502955	chr17:6344127	C/G	cg25288085	chr17:6347142	FAM64A	-0.63	-5.28	-0.43	5.65e-7	Life satisfaction;
TGCT	cis	rs4253772	0.591	rs6008365	chr22:46652929	G/A	cg09491104	chr22:46646882	C22orf40	-0.62	-6.49	-0.5	1.87e-9	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs1008375	0.898	rs7670500	chr4:17586957	A/G	cg16339924	chr4:17578868	LAP3	0.8	6.96	0.53	1.73e-10	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	5.24	0.43	6.73e-7	Menopause (age at onset);
TGCT	cis	rs9902453	0.817	rs3115089	chr17:28031881	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.76	6.84	0.52	3.17e-10	Coffee consumption (cups per day);
TGCT	cis	rs2235642	0.893	rs8051295	chr16:1588087	A/G	cg10465839	chr16:1584050	IFT140;TMEM204	-0.31	-5.09	-0.42	1.28e-6	Coronary artery disease;
TGCT	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg04546413	chr19:29218101	NA	0.84	6.82	0.52	3.52e-10	Methadone dose in opioid dependence;
TGCT	cis	rs62244186	0.545	rs7640654	chr3:44763037	A/C	cg11003573	chr3:44754125	ZNF502	-0.45	-5.08	-0.42	1.32e-6	Depressive symptoms;
TGCT	cis	rs796364	0.616	rs1523818	chr2:200684704	G/T	cg17644776	chr2:200775616	C2orf69	0.31	4.59	0.38	1.07e-5	Schizophrenia;
TGCT	cis	rs11578119	0.843	rs113019901	chr1:170543775	T/C	cg09767346	chr1:170501363	GORAB	0.59	4.66	0.39	8.03e-6	Male-pattern baldness;
TGCT	cis	rs1865760	0.625	rs9393681	chr6:26008260	A/G	cg16482183	chr6:26056742	HIST1H1C	0.55	4.75	0.39	5.58e-6	Height;
TGCT	cis	rs28595532	0.764	rs56359736	chr4:119769689	G/A	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs595982	0.527	rs35023389	chr19:49377873	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.66	-7.99	-0.58	7.91e-13	Red cell distribution width;
TGCT	trans	rs1814175	0.817	rs28679516	chr11:50055998	G/A	cg03929089	chr4:120376271	NA	-0.72	-8.55	-0.61	3.8e-14	Height;
TGCT	cis	rs12210905	0.925	rs858989	chr6:27179373	T/A	cg08851530	chr6:28072375	NA	-0.99	-4.79	-0.4	4.65e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs611744	0.967	rs662714	chr8:109221659	C/A	cg21045802	chr8:109455806	TTC35	0.52	4.72	0.39	6.21e-6	Dupuytren's disease;
TGCT	cis	rs57221529	0.655	rs11948381	chr5:568413	A/T	cg09021430	chr5:549028	NA	-0.42	-5.71	-0.46	7.91e-8	Lung disease severity in cystic fibrosis;
TGCT	cis	rs62380364	0.719	rs56947091	chr5:88160354	C/T	cg22951263	chr5:87985283	NA	-0.51	-5.06	-0.41	1.47e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs539096	0.872	rs2004899	chr1:44045465	A/G	cg12908607	chr1:44402522	ARTN	-0.49	-4.96	-0.41	2.24e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg00814883	chr7:100076585	TSC22D4	-0.92	-9.76	-0.66	4.73e-17	Platelet count;
TGCT	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg18876405	chr7:65276391	NA	-0.34	-5.19	-0.42	8.37e-7	Aortic root size;
TGCT	cis	rs9467711	0.606	rs34550936	chr6:26361985	A/G	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs17253792	0.822	rs80328469	chr14:56067701	G/A	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs617791	0.569	rs11227370	chr11:65747693	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.5	4.54	0.38	1.31e-5	Breast cancer;
TGCT	cis	rs1355223	0.583	rs2116085	chr11:34884001	C/A	cg11058730	chr11:34937778	PDHX;APIP	0.8	8.94	0.63	4.53e-15	Systemic lupus erythematosus and Systemic sclerosis;
TGCT	cis	rs73001065	0.792	rs17216588	chr19:19664077	C/T	cg03709012	chr19:19516395	GATAD2A	1.0	4.66	0.39	8.05e-6	LDL cholesterol;
TGCT	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg11890956	chr21:40555474	PSMG1	1.03	10.96	0.7	5.74e-20	Cognitive function;
TGCT	cis	rs864643	0.898	rs1473864	chr3:39541194	C/A	cg14968361	chr3:39543547	MOBP	-0.46	-4.48	-0.37	1.65e-5	Attention deficit hyperactivity disorder;
TGCT	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg07092213	chr7:1199455	ZFAND2A	-0.5	-5.85	-0.47	4.11e-8	Longevity;Endometriosis;
TGCT	cis	rs2952156	0.920	rs2934956	chr17:37830447	T/A	cg20243544	chr17:37824526	PNMT	0.51	4.47	0.37	1.73e-5	Asthma;
TGCT	cis	rs9894429	1.000	rs9748176	chr17:79584043	C/G	cg21028142	chr17:79581711	NPLOC4	0.29	6.74	0.52	5.33e-10	Eye color traits;
TGCT	cis	rs1568889	1.000	rs12803655	chr11:28060785	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	8.86	0.62	7.07e-15	Bipolar disorder;
TGCT	cis	rs2204008	0.580	rs11174421	chr12:38105138	A/G	cg13010199	chr12:38710504	ALG10B	0.56	4.7	0.39	6.73e-6	Bladder cancer;
TGCT	cis	rs9467773	0.534	rs34453863	chr6:26628005	T/C	cg02458000	chr6:26745757	NA	0.73	7.42	0.55	1.59e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs78487399	0.710	rs79625619	chr2:43594483	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.06	-0.41	1.47e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs9467773	0.620	rs2504566	chr6:26660488	G/C	cg11502198	chr6:26597334	ABT1	0.55	4.89	0.4	3.05e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs13177918	0.677	rs13177951	chr5:149825939	C/T	cg14059543	chr5:149831962	NA	-0.71	-9.45	-0.65	2.77e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs7582180	0.629	rs34745556	chr2:100942506	A/G	cg14675211	chr2:100938903	LONRF2	0.51	4.95	0.41	2.32e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs910316	0.967	rs35446981	chr14:75637351	A/T	cg11812906	chr14:75593930	NEK9	-0.73	-7.21	-0.54	4.87e-11	Height;
TGCT	cis	rs11673344	0.562	rs7257320	chr19:37571835	C/T	cg08039142	chr19:36980659	ZNF566	0.5	4.6	0.38	1.01e-5	Obesity-related traits;
TGCT	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg11764359	chr7:65958608	NA	-0.55	-5.08	-0.42	1.34e-6	Aortic root size;
TGCT	cis	rs1372520	0.684	rs10008964	chr4:90744721	G/A	cg20003494	chr4:90757398	SNCA	-0.63	-5.06	-0.41	1.48e-6	Neuroticism;
TGCT	cis	rs9303401	0.625	rs34963822	chr17:56988424	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.68	6.48	0.5	1.94e-9	Cognitive test performance;
TGCT	cis	rs9611519	0.780	rs2235849	chr22:41653540	T/G	cg03806693	chr22:41940476	POLR3H	-0.71	-6.7	-0.52	6.48e-10	Neuroticism;
TGCT	cis	rs9583531	0.600	rs7984468	chr13:111362093	C/A	cg24331049	chr13:111365604	ING1	0.76	7.31	0.55	2.95e-11	Coronary artery disease;
TGCT	cis	rs13326165	0.760	rs57441156	chr3:52354242	C/G	cg07884673	chr3:53033167	SFMBT1	0.39	4.69	0.39	7e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs9611519	0.780	rs5751071	chr22:41656332	G/A	cg06634786	chr22:41940651	POLR3H	-0.55	-5.04	-0.41	1.59e-6	Neuroticism;
TGCT	cis	rs9993613	0.875	rs10938030	chr4:73454720	A/G	cg15102770	chr4:73434591	ADAMTS3	-0.52	-4.7	-0.39	6.76e-6	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs12477438	0.765	rs4374423	chr2:99662348	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-4.62	-0.38	9.47e-6	Chronic sinus infection;
TGCT	cis	rs11098499	0.569	rs55845118	chr4:120290913	T/C	cg09307838	chr4:120376055	NA	0.58	5.75	0.46	6.63e-8	Corneal astigmatism;
TGCT	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7959452	0.558	rs1478464	chr12:69779789	G/C	cg20891283	chr12:69753455	YEATS4	0.84	8.7	0.62	1.65e-14	Blood protein levels;
TGCT	cis	rs11648796	0.757	rs763206	chr16:770103	C/G	cg07343612	chr16:622815	PIGQ	-0.36	-5.13	-0.42	1.09e-6	Height;
TGCT	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg06028808	chr11:68637592	NA	0.52	6.84	0.52	3.18e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg18230493	chr5:56204884	C5orf35	-0.68	-5.92	-0.47	2.92e-8	Initial pursuit acceleration;
TGCT	cis	rs2153535	0.580	rs7761937	chr6:8459434	A/T	cg23788917	chr6:8435910	SLC35B3	0.66	5.97	0.47	2.28e-8	Motion sickness;
TGCT	cis	rs10833905	0.648	rs1529347	chr11:23036524	A/C	cg06387204	chr11:22647648	FANCF	0.58	5.31	0.43	4.97e-7	Sudden cardiac arrest;
TGCT	cis	rs9399135	0.967	rs6915770	chr6:135369214	G/A	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.21e-6	Red blood cell count;
TGCT	cis	rs9972944	0.756	rs7222190	chr17:63764953	T/C	cg07283582	chr17:63770753	CCDC46	-0.26	-5.3	-0.43	5.02e-7	Total body bone mineral density;
TGCT	trans	rs17685	0.712	rs28456330	chr7:75810542	A/G	cg19862616	chr7:65841803	NCRNA00174	0.49	8.36	0.6	1.09e-13	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg22168489	chr12:122356033	WDR66	-0.22	-4.9	-0.4	2.97e-6	Mean corpuscular volume;
TGCT	cis	rs78487399	0.808	rs998768	chr2:43711523	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.68	-0.45	9.11e-8	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.48	-0.37	1.66e-5	Bipolar disorder;
TGCT	trans	rs1814175	0.616	rs10769644	chr11:49987676	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.67	-0.69	2.92e-19	Height;
TGCT	cis	rs9486719	0.741	rs2499799	chr6:96851676	T/C	cg06623918	chr6:96969491	KIAA0776	0.9	6.7	0.52	6.67e-10	Migraine;Coronary artery disease;
TGCT	trans	rs3857536	0.544	rs208453	chr6:66906841	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.74	-7.75	-0.57	2.85e-12	Blood trace element (Cu levels);
TGCT	cis	rs877282	0.945	rs10904554	chr10:786768	T/C	cg17470449	chr10:769945	NA	0.3	4.71	0.39	6.53e-6	Uric acid levels;
TGCT	trans	rs7618501	1.000	rs7372725	chr3:49790544	C/A	cg21659725	chr3:3221576	CRBN	-0.98	-15.33	-0.81	2.1000000000000002e-30	Intelligence (multi-trait analysis);
TGCT	cis	rs11779988	0.545	rs427168	chr8:17784829	G/A	cg01800426	chr8:17659068	MTUS1	-0.7	-5.46	-0.44	2.5e-7	Breast cancer;
TGCT	cis	rs7819412	0.775	rs4545055	chr8:10935366	T/C	cg21775007	chr8:11205619	TDH	-0.5	-4.61	-0.38	9.74e-6	Triglycerides;
TGCT	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg18305652	chr10:134549665	INPP5A	0.31	5.07	0.41	1.42e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs4713118	0.513	rs149975	chr6:27986340	G/A	cg10876282	chr6:28092338	ZSCAN16	0.49	4.49	0.37	1.6e-5	Parkinson's disease;
TGCT	trans	rs1814175	0.630	rs1722019	chr11:49904102	G/A	cg03929089	chr4:120376271	NA	-0.59	-6.76	-0.52	4.86e-10	Height;
TGCT	trans	rs7615952	0.932	rs13314869	chr3:125644669	G/A	cg07211511	chr3:129823064	LOC729375	-0.48	-8.02	-0.58	6.91e-13	Blood pressure (smoking interaction);
TGCT	cis	rs9467711	0.651	rs16891264	chr6:26072445	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.59	4.63	0.38	9.26e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9527	0.518	rs12776863	chr10:104641679	T/C	cg15744005	chr10:104629667	AS3MT	-0.62	-4.99	-0.41	1.96e-6	Arsenic metabolism;
TGCT	cis	rs1577917	0.958	rs1591437	chr6:86525305	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.23	-0.43	7.01e-7	Response to antipsychotic treatment;
TGCT	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg15242686	chr22:24348715	GSTTP1	0.44	5.95	0.47	2.53e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs4849845	0.637	rs4077564	chr2:121004241	C/T	cg24070213	chr2:121070622	NA	0.34	4.52	0.38	1.41e-5	Mean platelet volume;
TGCT	cis	rs916888	0.610	rs199436	chr17:44789285	C/T	cg01570182	chr17:44337453	NA	-0.77	-7.7	-0.57	3.69e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7246657	0.653	rs28701616	chr19:37681098	G/A	cg24025825	chr19:37761650	NA	-0.32	-5.08	-0.42	1.35e-6	Coronary artery calcification;
TGCT	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg03264133	chr6:25882463	NA	-0.68	-7.52	-0.56	9.75e-12	Blood metabolite levels;
TGCT	cis	rs3020333	0.875	rs3020336	chr6:152013760	G/T	cg22157087	chr6:152012887	ESR1	0.19	4.51	0.38	1.5e-5	Total body bone mineral density;
TGCT	cis	rs11030122	0.661	rs4910877	chr11:4062153	A/G	cg18678763	chr11:4115507	RRM1	-0.46	-5.62	-0.45	1.22e-7	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs7575217	0.740	rs12468712	chr2:101746066	A/T	cg12737833	chr2:101500543	NPAS2	0.28	4.58	0.38	1.09e-5	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
TGCT	cis	rs78487399	0.808	rs76851696	chr2:43746062	T/C	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.76	4.68	0.39	7.27e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs9911578	0.867	rs72628394	chr17:57121313	C/T	cg12560992	chr17:57184187	TRIM37	-0.79	-9.86	-0.66	2.77e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs644799	0.965	rs687529	chr11:95545587	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	8.74	0.62	1.39e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9467773	1.000	rs10214634	chr6:26564582	T/A	cg15659132	chr6:26577336	NA	0.9	13.19	0.76	2.26e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs2738048	0.545	rs2738046	chr8:6823542	C/A	cg24860332	chr8:6827800	DEFA10P	-0.42	-6.08	-0.48	1.36e-8	IgA nephropathy;
TGCT	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg03188948	chr7:1209495	NA	0.66	5.67	0.45	9.65e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg23131131	chr22:24373011	LOC391322	-0.84	-9.26	-0.64	7.95e-16	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs344364	0.511	rs2917519	chr16:1950479	C/A	cg26617929	chr16:1858877	NA	-0.27	-4.75	-0.39	5.6e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg04025307	chr7:1156635	C7orf50	-0.21	-4.73	-0.39	5.95e-6	Longevity;Endometriosis;
TGCT	cis	rs12220238	0.908	rs10824124	chr10:75997360	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.92	7.84	0.58	1.79e-12	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs6540559	0.546	rs75308488	chr1:210030639	T/C	cg04352962	chr1:209979756	IRF6	0.68	4.63	0.38	8.97e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs10851411	0.733	rs2899051	chr15:42786160	T/C	cg23803468	chr15:43513504	EPB42	0.27	5.09	0.42	1.27e-6	Glucose homeostasis traits;
TGCT	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg26338869	chr17:61819248	STRADA	-0.55	-5.08	-0.41	1.37e-6	Prudent dietary pattern;
TGCT	cis	rs7917772	0.619	rs2801050	chr10:104509393	T/A	cg05855489	chr10:104503620	C10orf26	-0.66	-5.19	-0.42	8.45e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg16497277	chr3:49208875	KLHDC8B	-0.53	-5.13	-0.42	1.08e-6	Menarche (age at onset);
TGCT	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg07298985	chr8:22133076	PIWIL2	0.33	5.28	0.43	5.7e-7	Hypertriglyceridemia;
TGCT	cis	rs739496	0.579	rs73426362	chr12:112380470	G/C	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs7666738	0.830	rs34273190	chr4:99004568	C/T	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs860295	0.580	rs867550	chr1:155880391	T/C	cg13795986	chr1:155880507	RIT1	0.38	4.61	0.38	9.9e-6	Body mass index;
TGCT	cis	rs7267979	1.000	rs6083844	chr20:25386832	C/T	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg18252515	chr7:66147081	NA	-1.13	-6.81	-0.52	3.7e-10	Diabetic kidney disease;
TGCT	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.47	0.56	1.28e-11	Prudent dietary pattern;
TGCT	cis	rs7829975	0.871	rs572307	chr8:8578811	T/C	cg06636001	chr8:8085503	FLJ10661	-0.6	-5.01	-0.41	1.84e-6	Mood instability;
TGCT	cis	rs854765	0.927	rs4925138	chr17:17992793	T/G	cg09796270	chr17:17721594	SREBF1	-0.26	-5.08	-0.42	1.35e-6	Total body bone mineral density;
TGCT	cis	rs35771425	0.518	rs1055565	chr1:211605697	G/A	cg25617285	chr1:211431773	RCOR3	-0.5	-6.09	-0.48	1.29e-8	Educational attainment (years of education);
TGCT	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg12963246	chr6:28129442	ZNF389	0.53	5.09	0.42	1.27e-6	Depression;
TGCT	cis	rs35146811	0.883	rs4134903	chr7:99711040	G/A	cg13334819	chr7:99746414	C7orf59	-0.81	-6.92	-0.53	2.13e-10	Coronary artery disease;
TGCT	cis	rs924712	0.522	rs7750012	chr6:54702643	C/T	cg04690482	chr6:54711388	FAM83B	0.32	4.48	0.37	1.64e-5	Breast cancer;
TGCT	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.69	-6.95	-0.53	1.82e-10	Prostate cancer;
TGCT	cis	rs1008375	0.932	rs11935124	chr4:17668200	G/A	cg16339924	chr4:17578868	LAP3	-0.58	-4.81	-0.4	4.28e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg11764359	chr7:65958608	NA	0.58	5.34	0.43	4.22e-7	Aortic root size;
TGCT	cis	rs1075232	1.000	rs67634762	chr15:31748055	G/T	cg01030201	chr15:31746330	NA	-1.03	-5.45	-0.44	2.6e-7	Survival in colorectal cancer (non-distant metastatic);
TGCT	cis	rs6089584	0.526	rs6061965	chr20:60607858	A/C	cg06108461	chr20:60628389	TAF4	-0.39	-4.98	-0.41	2.05e-6	Body mass index;
TGCT	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg04267008	chr7:1944627	MAD1L1	-0.4	-5.33	-0.43	4.39e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs79349575	0.783	rs832410	chr17:46972865	C/T	cg07967210	chr17:47022446	SNF8	0.44	5.9	0.47	3.17e-8	Type 2 diabetes;
TGCT	cis	rs7507204	0.530	rs4807470	chr19:3443470	A/T	cg08380311	chr19:3435252	NFIC	1.18	16.39	0.83	7.76e-33	Height;
TGCT	cis	rs9303401	0.538	rs12603174	chr17:56489279	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.75	6.73	0.52	5.58e-10	Cognitive test performance;
TGCT	cis	rs12765878	0.565	rs11191818	chr10:105591779	A/C	cg07956775	chr10:105212289	CALHM2	-0.3	-4.52	-0.38	1.42e-5	Coronary artery disease;
TGCT	cis	rs6558530	0.653	rs7001282	chr8:1700188	A/C	cg09410841	chr8:1729607	CLN8	0.72	6.48	0.5	1.98e-9	Systolic blood pressure;
TGCT	cis	rs10490913	1.000	rs1473141	chr10:120143158	A/G	cg23160142	chr10:120154512	NA	-0.3	-4.45	-0.37	1.92e-5	Cancer;
TGCT	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.68	5.73	0.46	7.3e-8	Tonsillectomy;
TGCT	cis	rs9921338	0.961	rs11545336	chr16:11439496	G/A	cg00044050	chr16:11439710	C16orf75	-0.82	-6.15	-0.48	9.71e-9	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs4689388	0.926	rs5018647	chr4:6292799	A/C	cg00701064	chr4:6280414	WFS1	0.37	4.72	0.39	6.3e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs769267	0.965	rs10419245	chr19:19383755	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.71	6.34	0.49	3.86e-9	Tonsillectomy;
TGCT	cis	rs9814567	1.000	rs1498718	chr3:134205920	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.93	-9.27	-0.64	7.51e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs617219	0.698	rs12189248	chr5:78517143	A/G	cg23514016	chr5:78407564	BHMT	-0.36	-5.52	-0.44	1.85e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs6725041	0.819	rs10196229	chr2:213081987	C/T	cg16329650	chr2:213403929	ERBB4	-0.54	-4.61	-0.38	9.88e-6	QT interval (ambient particulate matter interaction);
TGCT	cis	rs9303401	0.659	rs61291849	chr17:56909867	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	trans	rs9329221	0.711	rs55864141	chr8:9807022	T/C	cg15556689	chr8:8085844	FLJ10661	-0.81	-7.5	-0.56	1.07e-11	Neuroticism;
TGCT	cis	rs12477438	0.798	rs13414153	chr2:99624748	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.56	-4.86	-0.4	3.51e-6	Chronic sinus infection;
TGCT	cis	rs4820539	0.966	rs2267001	chr22:23456696	T/C	cg21100191	chr22:23484243	RTDR1	0.95	11.35	0.71	6.7e-21	Bone mineral density;
TGCT	cis	rs9611565	0.512	rs5758465	chr22:42175314	T/C	cg17554472	chr22:41940697	POLR3H	0.46	4.8	0.4	4.46e-6	Vitiligo;
TGCT	cis	rs2120019	0.935	rs12591119	chr15:75355944	A/G	cg11632617	chr15:75315747	PPCDC	-0.33	-4.59	-0.38	1.07e-5	Blood trace element (Zn levels);
TGCT	cis	rs2469997	0.925	rs2470001	chr8:120356402	C/T	cg00681363	chr8:120844660	TAF2	0.74	4.87	0.4	3.3e-6	Hypertension (SNP x SNP interaction);
TGCT	cis	rs6582630	0.555	rs2197308	chr12:38281261	A/G	cg26384229	chr12:38710491	ALG10B	-0.54	-4.7	-0.39	6.68e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs9296092	0.500	rs35150558	chr6:33519612	T/A	cg13560919	chr6:33536144	NA	-0.21	-4.75	-0.39	5.5e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs11671005	0.695	rs11673069	chr19:58934918	C/G	cg13877915	chr19:58951672	ZNF132	0.65	5.14	0.42	1.04e-6	Mean platelet volume;
TGCT	cis	rs6088580	0.601	rs6059872	chr20:33082775	C/A	cg06115741	chr20:33292138	TP53INP2	0.54	4.63	0.38	9.06e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs11098499	0.604	rs10022185	chr4:120571765	C/G	cg09307838	chr4:120376055	NA	0.65	6.3	0.49	4.68e-9	Corneal astigmatism;
TGCT	cis	rs793571	0.502	rs387812	chr15:59074786	T/C	cg05156742	chr15:59063176	FAM63B	0.56	5.26	0.43	6.22e-7	Schizophrenia;
TGCT	cis	rs7659604	0.502	rs4516738	chr4:122669177	T/C	cg19748678	chr4:122722346	EXOSC9	-0.48	-4.76	-0.39	5.32e-6	Type 2 diabetes;
TGCT	cis	rs9393692	0.875	rs9393690	chr6:26271713	A/T	cg05868516	chr6:26286170	HIST1H4H	0.63	5.94	0.47	2.72e-8	Educational attainment;
TGCT	cis	rs7178424	0.742	rs12915825	chr15:62175636	A/G	cg00456672	chr15:62358751	C2CD4A	-0.31	-4.73	-0.39	6e-6	Height;
TGCT	cis	rs2806561	0.578	rs6702719	chr1:23302576	T/C	cg12483005	chr1:23474871	LUZP1	0.39	4.99	0.41	2.03e-6	Height;
TGCT	cis	rs10769945	0.500	rs217203	chr11:1972456	G/C	cg06679296	chr11:1949032	TNNT3	-0.25	-4.57	-0.38	1.16e-5	DNA methylation (variation);
TGCT	cis	rs2204008	0.744	rs11495519	chr12:38060546	C/A	cg26384229	chr12:38710491	ALG10B	0.86	7.77	0.57	2.55e-12	Bladder cancer;
TGCT	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg10150615	chr22:24372951	LOC391322	-0.98	-12.41	-0.74	1.75e-23	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7917772	0.503	rs7100753	chr10:104300979	C/T	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	trans	rs629535	0.590	rs56200825	chr8:70123450	G/A	cg21567404	chr3:27674614	NA	-0.54	-8.15	-0.59	3.45e-13	Dupuytren's disease;
TGCT	cis	rs6450176	1.000	rs59061738	chr5:53296557	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.53	-5.12	-0.42	1.15e-6	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs67311347	0.955	rs2085114	chr3:40497437	T/A	cg13409248	chr3:40428643	ENTPD3	0.56	4.45	0.37	1.91e-5	Renal cell carcinoma;
TGCT	cis	rs4478858	0.735	rs11576621	chr1:31795460	A/G	cg07478791	chr1:31886160	SERINC2	-0.51	-4.94	-0.41	2.47e-6	Alcohol dependence;
TGCT	cis	rs7552404	0.924	rs67757078	chr1:76169456	G/A	cg03433033	chr1:76189801	ACADM	0.82	9.89	0.66	2.31e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg06115741	chr20:33292138	TP53INP2	-0.62	-5.25	-0.43	6.27e-7	Coronary artery disease;
TGCT	cis	rs6570726	0.935	rs110289	chr6:145865176	C/G	cg23711669	chr6:146136114	FBXO30	0.71	7.03	0.53	1.25e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs151997	0.537	rs11746939	chr5:50268856	G/A	cg06027927	chr5:50259733	NA	0.54	5.44	0.44	2.76e-7	Callous-unemotional behaviour;
TGCT	cis	rs7666738	0.546	rs7679681	chr4:98882221	A/G	cg17366294	chr4:99064904	C4orf37	0.67	5.94	0.47	2.64e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7659604	0.540	rs28672860	chr4:122705051	G/A	cg06713675	chr4:122721982	EXOSC9	0.39	4.73	0.39	5.99e-6	Type 2 diabetes;
TGCT	cis	rs2657888	0.542	rs7131699	chr12:56933162	T/C	cg23002907	chr12:56915593	RBMS2	0.43	6.31	0.49	4.47e-9	Adiponectin levels;
TGCT	cis	rs9902453	0.904	rs8078638	chr17:28290358	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.81	7.51	0.56	9.93e-12	Coffee consumption (cups per day);
TGCT	cis	rs8072100	0.840	rs9900360	chr17:45491979	C/T	cg08085267	chr17:45401833	C17orf57	-0.51	-5.71	-0.46	8.04e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	trans	rs1814175	0.715	rs7479622	chr11:49673340	T/G	cg03929089	chr4:120376271	NA	-0.63	-7.05	-0.53	1.1e-10	Height;
TGCT	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg11764359	chr7:65958608	NA	0.61	5.54	0.45	1.76e-7	Aortic root size;
TGCT	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg06896619	chr17:61851486	DDX42;CCDC47	-0.51	-4.96	-0.41	2.24e-6	Prudent dietary pattern;
TGCT	cis	rs1372520	0.684	rs184810	chr4:90697979	T/C	cg01966878	chr4:90757139	SNCA	0.3	4.82	0.4	4.11e-6	Neuroticism;
TGCT	cis	rs8180040	0.620	rs9844122	chr3:47108330	C/T	cg27129171	chr3:47204927	SETD2	0.71	8.55	0.61	3.9e-14	Colorectal cancer;
TGCT	cis	rs137699	1.000	rs137703	chr22:39750241	A/G	cg24399712	chr22:39784796	NA	-0.66	-5.73	-0.46	7.3e-8	IgG glycosylation;
TGCT	cis	rs11577318	0.853	rs4526602	chr1:26648034	C/T	cg04990556	chr1:26633338	UBXN11	-0.6	-4.96	-0.41	2.28e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs826838	0.678	rs11182781	chr12:38610178	C/T	cg13010199	chr12:38710504	ALG10B	0.66	5.18	0.42	8.76e-7	Heart rate;
TGCT	cis	rs10883723	0.810	rs7079810	chr10:104243883	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	8.36	0.6	1.1e-13	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs2658782	0.738	rs2605628	chr11:93261560	C/A	cg15737290	chr11:93063684	CCDC67	0.7	5.24	0.43	6.55e-7	Pulmonary function decline;
TGCT	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	7.15	0.54	6.65e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs360798	0.532	rs2421816	chr2:63075033	C/A	cg17519650	chr2:63277830	OTX1	0.64	5.56	0.45	1.55e-7	Coronary artery disease;
TGCT	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg13628971	chr7:2884303	GNA12	0.54	4.53	0.38	1.36e-5	Height;
TGCT	cis	rs28595532	0.920	rs115683389	chr4:119735557	T/G	cg14228332	chr4:119757509	SEC24D	1.32	6.38	0.5	3.2e-9	Cannabis dependence symptom count;
TGCT	cis	rs9372253	1.000	rs9374170	chr6:110712991	A/G	cg01119278	chr6:110721349	DDO	-0.34	-5.45	-0.44	2.55e-7	Platelet distribution width;
TGCT	trans	rs9951602	0.512	rs58352488	chr18:76651113	T/A	cg02800362	chr5:177631904	HNRNPAB	1.15	13.03	0.76	5.64e-25	Obesity-related traits;
TGCT	cis	rs10489202	0.632	rs203779	chr1:167877647	T/G	cg24449463	chr1:168025552	DCAF6	-0.58	-6.88	-0.53	2.57e-10	Schizophrenia;
TGCT	cis	rs10031466	0.967	rs12647135	chr4:189011174	A/C	cg05865660	chr4:189158066	NA	0.21	4.48	0.37	1.68e-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs12681287	0.888	rs2976201	chr8:87335937	T/C	cg27223183	chr8:87520930	FAM82B	-0.84	-6.5	-0.5	1.79e-9	Caudate activity during reward;
TGCT	cis	rs4494114	1.000	rs6675245	chr1:39356820	T/A	cg25970120	chr1:39325951	RRAGC	-0.6	-6.17	-0.48	8.89e-9	Blood protein levels;
TGCT	cis	rs36051895	0.623	rs7025005	chr9:5261794	T/C	cg02405213	chr9:5042618	JAK2	-0.7	-9.15	-0.63	1.44e-15	Pediatric autoimmune diseases;
TGCT	cis	rs6671200	0.607	rs2296308	chr1:95709939	G/T	cg03123541	chr1:95699097	RWDD3	0.64	6.03	0.48	1.71e-8	Stearic acid (18:0) levels;
TGCT	cis	rs6684514	1.000	rs2270291	chr1:156244992	G/C	cg16558208	chr1:156270281	VHLL	0.46	9.38	0.64	3.92e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs854765	0.583	rs11869536	chr17:17826528	T/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.74	7.69	0.57	3.91e-12	Total body bone mineral density;
TGCT	cis	rs10464366	1.000	rs10464366	chr7:39121500	A/T	cg18850127	chr7:39170497	POU6F2	-0.23	-5.0	-0.41	1.9e-6	IgG glycosylation;
TGCT	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	4.99	0.41	1.98e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6740322	1.000	rs6740322	chr2:43561929	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.38	-5.37	-0.43	3.66e-7	Coronary artery disease;
TGCT	cis	rs7104764	0.957	rs7116130	chr11:244129	C/T	cg18336825	chr11:236787	PSMD13;SIRT3	1.07	11.19	0.71	1.61e-20	Menarche (age at onset);
TGCT	cis	rs2549003	1.000	rs9282762	chr5:131822055	T/C	cg00255919	chr5:131827918	IRF1	0.2	4.65	0.39	8.22e-6	Asthma (sex interaction);
TGCT	cis	rs11997175	0.846	rs7388664	chr8:33768773	T/G	ch.8.33884649F	chr8:33765107	NA	0.32	4.75	0.39	5.51e-6	Body mass index;
TGCT	cis	rs9527	0.662	rs4919686	chr10:104592249	A/C	cg04362960	chr10:104952993	NT5C2	0.63	5.31	0.43	4.84e-7	Arsenic metabolism;
TGCT	cis	rs11098499	0.775	rs67281037	chr4:120281157	G/C	cg09307838	chr4:120376055	NA	0.58	5.76	0.46	6.16e-8	Corneal astigmatism;
TGCT	cis	rs854765	0.547	rs2955353	chr17:17948979	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.79	-8.27	-0.6	1.76e-13	Total body bone mineral density;
TGCT	cis	rs2594989	0.943	rs2442769	chr3:11491086	A/G	cg00170343	chr3:11313890	ATG7	-0.66	-4.48	-0.37	1.67e-5	Circulating chemerin levels;
TGCT	cis	rs7805747	1.000	rs7805747	chr7:151407801	G/A	cg17611936	chr7:151411526	PRKAG2	0.52	6.64	0.51	8.61e-10	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
TGCT	cis	rs7666738	0.962	rs4699596	chr4:99012924	C/T	cg17366294	chr4:99064904	C4orf37	0.74	6.87	0.53	2.76e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs59197085	0.636	rs4731517	chr7:128458649	A/C	cg00260937	chr7:128520193	KCP	-0.47	-4.98	-0.41	2.1e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
TGCT	cis	rs2797780	1.000	rs2797779	chr6:37508585	C/T	cg00985040	chr6:37553208	NA	0.24	4.72	0.39	6.35e-6	Systemic lupus erythematosus;
TGCT	cis	rs877282	0.891	rs11595385	chr10:800539	A/G	cg17470449	chr10:769945	NA	0.31	4.64	0.38	8.88e-6	Uric acid levels;
TGCT	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.03	7.66	0.57	4.67e-12	Gut microbiome composition (summer);
TGCT	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.65	-6.77	-0.52	4.52e-10	Prostate cancer;
TGCT	cis	rs597480	0.892	rs556669	chr11:85436394	T/C	cg11817631	chr11:85522609	SYTL2	-0.47	-4.66	-0.39	8.18e-6	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);
TGCT	cis	rs1670533	1.000	rs7673898	chr4:1056569	C/A	cg27284194	chr4:1044797	NA	0.67	5.79	0.46	5.37e-8	Recombination rate (females);
TGCT	cis	rs921968	0.541	rs562510	chr2:219443001	A/C	cg02176678	chr2:219576539	TTLL4	0.48	6.78	0.52	4.32e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs7666738	0.830	rs7662114	chr4:99019985	A/G	cg18180107	chr4:99064573	C4orf37	0.54	5.03	0.41	1.7e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6770219	0.516	rs7646885	chr3:186134686	T/C	cg20306810	chr3:186501757	SNORD2;EIF4A2	0.73	4.45	0.37	1.89e-5	Cerebrospinal T-tau levels;
TGCT	cis	rs8062405	0.573	rs11645306	chr16:28983936	G/C	cg01117621	chr16:28073818	GSG1L	-0.37	-4.69	-0.39	7.05e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs13217239	0.646	rs10946898	chr6:27003884	T/C	cg05738196	chr6:26577821	NA	0.49	4.75	0.39	5.45e-6	Schizophrenia;
TGCT	cis	rs595982	0.517	rs10404905	chr19:49406175	A/T	cg21252483	chr19:49399788	TULP2	0.31	5.33	0.43	4.55e-7	Red cell distribution width;
TGCT	cis	rs137699	0.958	rs137705	chr22:39751394	T/C	cg24399712	chr22:39784796	NA	-0.63	-5.44	-0.44	2.76e-7	IgG glycosylation;
TGCT	cis	rs9296092	0.538	rs62405953	chr6:33524760	C/T	cg13560919	chr6:33536144	NA	-0.22	-4.93	-0.41	2.54e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg16680214	chr1:154839983	KCNN3	-0.36	-7.67	-0.57	4.44e-12	Prostate cancer;
TGCT	cis	rs11785400	1.000	rs3735999	chr8:143746069	T/C	cg10596483	chr8:143751796	JRK	0.55	5.82	0.46	4.69e-8	Schizophrenia;
TGCT	trans	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg13615516	chr5:77269221	NA	0.67	8.36	0.6	1.09e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs924607	0.898	rs905193	chr5:635095	T/C	cg18765565	chr5:669397	TPPP	0.58	6.07	0.48	1.45e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs7681440	0.904	rs28403500	chr4:90769729	T/G	cg20003494	chr4:90757398	SNCA	-0.6	-5.76	-0.46	6.3e-8	Dementia with Lewy bodies;
TGCT	cis	rs11190604	0.945	rs2495746	chr10:102328270	T/C	cg16342193	chr10:102329863	NA	-0.42	-5.39	-0.44	3.47e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs3784262	0.669	rs7178598	chr15:58309016	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.43	-6.27	-0.49	5.49e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	trans	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg21659725	chr3:3221576	CRBN	-0.76	-9.03	-0.63	2.74e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs7715806	0.500	rs72633985	chr5:75006384	A/G	cg19683494	chr5:74908142	NA	0.57	5.02	0.41	1.76e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs2012796	1.000	rs11621378	chr14:81814426	T/A	cg02996355	chr14:81879375	NA	0.51	4.81	0.4	4.35e-6	Night sleep phenotypes;
TGCT	cis	rs112217694	1.000	rs17196104	chr4:104657246	G/T	cg24090629	chr4:104641072	TACR3	-1.01	-4.96	-0.41	2.29e-6	Menarche (age at onset);
TGCT	cis	rs6987853	0.933	rs2974353	chr8:42409165	A/C	cg20539142	chr8:42623718	CHRNA6	-0.19	-4.63	-0.38	9.21e-6	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs858239	0.712	rs199650	chr7:23367189	C/T	cg05602783	chr7:23145260	KLHL7	0.53	4.48	0.37	1.7e-5	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs2439831	0.867	rs933941	chr15:43632226	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	8.65	0.61	2.26e-14	Lung cancer in ever smokers;
TGCT	cis	rs2066819	1.000	rs17118409	chr12:56630764	G/A	cg26714650	chr12:56694279	CS	-1.42	-5.7	-0.46	8.43e-8	Psoriasis vulgaris;
TGCT	cis	rs4950928	0.823	rs4950882	chr1:203164848	A/G	cg17014757	chr1:203156097	CHI3L1	-0.38	-4.68	-0.39	7.54e-6	YKL-40 levels;
TGCT	cis	rs6582630	0.555	rs35284307	chr12:38509999	T/G	cg13010199	chr12:38710504	ALG10B	0.6	4.88	0.4	3.15e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs13191362	0.935	rs73008456	chr6:163013697	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs34526934	0.608	rs7591820	chr2:177028144	G/T	cg14324370	chr2:177042789	NA	-0.9	-8.57	-0.61	3.41e-14	Obstructive sleep apnea trait (apnea hypopnea index);
TGCT	cis	rs9910055	0.571	rs10208	chr17:42300278	C/T	cg19774624	chr17:42201019	HDAC5	-0.65	-6.44	-0.5	2.36e-9	Total body bone mineral density;
TGCT	cis	rs806215	0.526	rs2058457	chr7:127493657	A/T	cg11539674	chr7:127291444	SND1	-0.36	-4.65	-0.39	8.46e-6	Type 2 diabetes;
TGCT	cis	rs6912958	0.781	rs985764	chr6:88215206	G/A	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.91	-0.4	2.78e-6	Monocyte percentage of white cells;
TGCT	cis	rs7429990	0.932	rs6766641	chr3:48145224	G/A	cg11946769	chr3:48343235	NME6	-0.56	-4.52	-0.38	1.42e-5	Educational attainment (years of education);
TGCT	cis	rs6088590	1.000	rs2295353	chr20:33356511	C/T	cg24642439	chr20:33292090	TP53INP2	0.7	6.22	0.49	7.12e-9	Coronary artery disease;
TGCT	cis	rs2980439	0.525	rs2980508	chr8:8171732	C/T	cg15556689	chr8:8085844	FLJ10661	0.62	5.52	0.44	1.89e-7	Neuroticism;
TGCT	cis	rs739401	0.588	rs10219272	chr11:3020789	G/A	cg05729581	chr11:3078854	CARS	-0.53	-4.92	-0.4	2.69e-6	Longevity;
TGCT	cis	rs11614913	0.509	rs12300425	chr12:54395082	G/T	cg27482031	chr12:54402697	HOXC8	-0.57	-5.15	-0.42	9.83e-7	Waist circumference adjusted for body mass index;
TGCT	cis	rs17376456	0.877	rs12374488	chr5:93481407	A/G	cg25358565	chr5:93447407	FAM172A	0.97	8.32	0.6	1.34e-13	Diabetic retinopathy;
TGCT	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg04414720	chr1:150670196	GOLPH3L	0.39	5.04	0.41	1.59e-6	Tonsillectomy;
TGCT	cis	rs4822044	0.617	rs13054514	chr22:42130383	A/G	cg13695892	chr22:41940480	POLR3H	0.84	7.96	0.58	9.2e-13	Cannabis dependence symptom count;
TGCT	cis	rs7582180	0.629	rs6731549	chr2:100939937	T/G	cg14675211	chr2:100938903	LONRF2	0.51	4.95	0.41	2.32e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2228479	0.702	rs3819574	chr16:89826630	G/A	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg11494091	chr17:61959527	GH2	-0.39	-6.61	-0.51	1.01e-9	Height;
TGCT	cis	rs3096299	0.685	rs3803682	chr16:89544636	C/T	cg02187348	chr16:89574699	SPG7	0.61	6.56	0.51	1.32e-9	Multiple myeloma (IgH translocation);
TGCT	cis	rs9467711	1.000	rs6903015	chr6:26322526	A/G	cg02458000	chr6:26745757	NA	-1.05	-5.8	-0.46	5.29e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12780845	0.522	rs10795457	chr10:17230150	A/G	cg01003015	chr10:17271136	VIM	-0.49	-4.46	-0.37	1.8e-5	Homocysteine levels;
TGCT	cis	rs11711311	0.955	rs67550112	chr3:113401988	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.81	-7.28	-0.55	3.35e-11	IgG glycosylation;
TGCT	cis	rs11118844	0.739	rs10863653	chr1:221943926	T/C	cg04222084	chr1:221915650	DUSP10	-0.78	-5.41	-0.44	3.1e-7	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
TGCT	cis	rs7937682	0.961	rs7106104	chr11:111635655	T/C	cg09085632	chr11:111637200	PPP2R1B	1.16	11.46	0.72	3.59e-21	Primary sclerosing cholangitis;
TGCT	cis	rs4727027	0.901	rs4727017	chr7:148822062	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	4.58	0.38	1.13e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs12931792	0.846	rs9924308	chr16:30154740	C/T	cg17640201	chr16:30407289	ZNF48	-0.61	-5.59	-0.45	1.38e-7	Tonsillectomy;
TGCT	cis	rs6964587	1.000	rs34043009	chr7:91578447	T/C	cg22709100	chr7:91322751	NA	-0.27	-4.48	-0.37	1.68e-5	Breast cancer;
TGCT	cis	rs7666738	0.830	rs4699594	chr4:98980775	T/C	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg21724239	chr8:58056113	NA	0.37	4.95	0.41	2.38e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs734999	0.545	rs12752515	chr1:2564465	T/C	cg18854424	chr1:2615690	NA	-0.45	-5.15	-0.42	1e-6	Ulcerative colitis;
TGCT	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg11890956	chr21:40555474	PSMG1	-0.66	-6.4	-0.5	2.94e-9	Menarche (age at onset);
TGCT	cis	rs10493773	0.609	rs6689168	chr1:86174232	G/T	cg17807903	chr1:86174739	ZNHIT6	-0.52	-8.15	-0.59	3.45e-13	Urate levels in overweight individuals;
TGCT	cis	rs709400	1.000	rs709400	chr14:104149475	A/G	cg26031613	chr14:104095156	KLC1	1.13	16.3	0.83	1.26e-32	Body mass index;
TGCT	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg22168489	chr12:122356033	WDR66	0.22	4.78	0.39	4.96e-6	Mean corpuscular volume;
TGCT	cis	rs9388451	0.626	rs1343115	chr6:126069817	C/G	cg10911889	chr6:126070802	HEY2	0.5	4.69	0.39	7.17e-6	Brugada syndrome;
TGCT	cis	rs1153858	1.000	rs4775906	chr15:45638294	C/T	cg26924012	chr15:45694286	SPATA5L1	1.07	14.56	0.79	1.32e-28	Homoarginine levels;
TGCT	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.51	-4.96	-0.41	2.24e-6	Prudent dietary pattern;
TGCT	trans	rs66573146	0.808	rs73202120	chr4:7005588	A/G	cg07817883	chr1:32538562	TMEM39B	1.31	7.05	0.53	1.08e-10	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs1784581	0.546	rs1954917	chr6:162447490	C/T	cg17173639	chr6:162384350	PARK2	0.44	6.1	0.48	1.26e-8	Itch intensity from mosquito bite;
TGCT	cis	rs832540	0.512	rs33320	chr5:56206529	C/T	cg24531977	chr5:56204891	C5orf35	-0.55	-5.31	-0.43	4.93e-7	Coronary artery disease;
TGCT	cis	rs7178572	0.568	rs28584877	chr15:77599003	C/A	cg22256960	chr15:77711686	NA	0.85	8.73	0.62	1.4e-14	Type 2 diabetes;
TGCT	cis	rs7635838	0.892	rs754015	chr3:11493945	T/C	cg00170343	chr3:11313890	ATG7	0.66	6.0	0.47	2.03e-8	HDL cholesterol;
TGCT	cis	rs6582630	0.593	rs7299329	chr12:38447943	G/C	cg13010199	chr12:38710504	ALG10B	0.59	4.75	0.39	5.61e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs986417	0.818	rs8008804	chr14:61082357	A/T	cg27398547	chr14:60952738	C14orf39	1.41	8.43	0.6	7.41e-14	Gut microbiota (bacterial taxa);
TGCT	cis	rs6964587	0.935	rs28412174	chr7:91577245	T/G	cg17063962	chr7:91808500	NA	-0.91	-9.99	-0.67	1.32e-17	Breast cancer;
TGCT	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg03351412	chr1:154909251	PMVK	0.52	4.8	0.4	4.51e-6	Prostate cancer;
TGCT	cis	rs2120019	1.000	rs12903201	chr15:75370776	A/C	cg11632617	chr15:75315747	PPCDC	-0.33	-4.78	-0.39	4.82e-6	Blood trace element (Zn levels);
TGCT	cis	rs2862064	1.000	rs905211	chr5:156447218	A/T	cg12943317	chr5:156479607	HAVCR1	-0.39	-5.26	-0.43	6.24e-7	Platelet count;
TGCT	cis	rs11167764	0.895	rs7734160	chr5:141473144	G/T	cg23435118	chr5:141488016	NDFIP1	-0.28	-4.58	-0.38	1.1e-5	Crohn's disease;
TGCT	cis	rs732765	0.648	rs8185	chr14:75408789	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.65	-4.86	-0.4	3.42e-6	Non-small cell lung cancer;
TGCT	cis	rs7552404	0.696	rs67487205	chr1:76373756	T/C	cg22875332	chr1:76189707	ACADM	0.69	6.67	0.51	7.46e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg22920501	chr2:26401640	FAM59B	-0.73	-6.44	-0.5	2.35e-9	Gut microbiome composition (summer);
TGCT	cis	rs7267979	0.933	rs2258728	chr20:25276343	G/A	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7586879	0.593	rs11689543	chr2:25130440	A/T	cg01884057	chr2:25150051	NA	0.35	6.87	0.53	2.76e-10	Body mass index;
TGCT	cis	rs4780401	0.609	rs8055247	chr16:11827543	G/A	cg01061890	chr16:11836724	TXNDC11	-0.6	-5.71	-0.46	7.73e-8	Rheumatoid arthritis;
TGCT	cis	rs67478160	0.619	rs12878682	chr14:104233627	G/C	cg26031613	chr14:104095156	KLC1	-0.63	-6.57	-0.51	1.25e-9	Schizophrenia;
TGCT	cis	rs13064411	0.696	rs7631082	chr3:113208913	C/G	cg18753928	chr3:113234510	CCDC52	-0.7	-5.75	-0.46	6.6e-8	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs67311347	0.955	rs9821036	chr3:40379007	A/G	cg17264618	chr3:40429014	ENTPD3	0.32	4.63	0.38	9.1e-6	Renal cell carcinoma;
TGCT	cis	rs4851254	0.660	rs4851244	chr2:100671449	C/T	cg22139774	chr2:100720529	AFF3	0.45	4.91	0.4	2.75e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1997103	0.863	rs4480062	chr7:55401299	T/C	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg13683864	chr3:40499215	RPL14	-1.19	-13.2	-0.76	2.17e-25	Renal cell carcinoma;
TGCT	cis	rs3833788	1	rs3833788	chr12:121151062	CTCTCTTG/C	cg21892295	chr12:121157589	UNC119B	-0.24	-5.71	-0.46	7.99e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs2832077	0.506	rs10222093	chr21:30163518	T/C	cg24692254	chr21:30365293	RNF160	-0.59	-5.22	-0.42	7.35e-7	Cognitive test performance;
TGCT	cis	rs2204008	0.837	rs1842599	chr12:37986081	G/A	cg26384229	chr12:38710491	ALG10B	-0.7	-6.12	-0.48	1.11e-8	Bladder cancer;
TGCT	cis	rs12762955	0.687	rs4880470	chr10:1077480	G/A	cg18964960	chr10:1102726	WDR37	-0.68	-6.05	-0.48	1.58e-8	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs2841277	0.708	rs2582533	chr14:105398787	G/C	cg21017887	chr14:105400489	NA	0.38	5.17	0.42	9.06e-7	Rheumatoid arthritis;
TGCT	cis	rs473651	0.935	rs474478	chr2:239335473	C/T	cg08773314	chr2:239334832	ASB1	0.47	7.96	0.58	9.43e-13	Multiple system atrophy;
TGCT	cis	rs3784262	0.692	rs12914388	chr15:58283843	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.42	-5.96	-0.47	2.43e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.0	7.42	0.55	1.64e-11	Gut microbiome composition (summer);
TGCT	cis	rs7208859	0.623	rs59029591	chr17:29235746	A/C	cg14008862	chr17:28927542	LRRC37B2	0.72	4.66	0.39	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs3784262	0.528	rs4144005	chr15:58330094	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.42	-6.28	-0.49	5.09e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs79724016	0.546	rs78410207	chr1:42112627	A/G	cg14093106	chr1:42503579	NA	-0.63	-4.57	-0.38	1.18e-5	Breast cancer;
TGCT	cis	rs7666738	0.830	rs2903152	chr4:99067992	A/G	cg05340658	chr4:99064831	C4orf37	0.52	5.79	0.46	5.32e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2204008	0.774	rs11615665	chr12:38328162	T/A	cg26384229	chr12:38710491	ALG10B	0.83	7.27	0.55	3.51e-11	Bladder cancer;
TGCT	cis	rs7674212	0.540	rs2720469	chr4:104086484	C/T	cg16532752	chr4:104119610	CENPE	-0.61	-5.67	-0.45	9.45e-8	Type 2 diabetes;
TGCT	cis	rs11585357	0.793	rs11587669	chr1:17616259	C/T	cg08277548	chr1:17600880	PADI3	-0.96	-9.72	-0.66	5.97e-17	Hair shape;
TGCT	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg13732083	chr21:47605072	C21orf56	0.37	4.69	0.39	7.07e-6	Testicular germ cell tumor;
TGCT	cis	rs7914558	0.966	rs2297786	chr10:104679978	C/T	cg04362960	chr10:104952993	NT5C2	0.58	5.15	0.42	9.77e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs700590	0.532	rs17558396	chr5:88102281	T/G	cg22951263	chr5:87985283	NA	-0.52	-5.3	-0.43	5.2e-7	Educational attainment (years of education);
TGCT	cis	rs775227	0.574	rs60279293	chr3:113096087	T/G	cg18753928	chr3:113234510	CCDC52	-0.65	-4.77	-0.39	5.12e-6	Dental caries;
TGCT	cis	rs17376456	0.825	rs7715562	chr5:93222034	C/T	cg21475434	chr5:93447410	FAM172A	-0.63	-4.61	-0.38	9.98e-6	Diabetic retinopathy;
TGCT	cis	rs28395178	1	rs28395178	chr15:78850558	G/A	cg24631222	chr15:78858424	CHRNA5	0.97	7.48	0.56	1.17e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs651907	0.557	rs3806653	chr3:101396972	T/C	cg12386194	chr3:101231763	SENP7	0.53	5.13	0.42	1.08e-6	Colorectal cancer;
TGCT	cis	rs4144743	0.938	rs35069360	chr17:45321270	C/T	cg18085866	chr17:45331354	ITGB3	-0.72	-4.85	-0.4	3.61e-6	Body mass index;
TGCT	cis	rs2730245	0.550	rs2788478	chr7:158672619	A/G	cg11984989	chr7:158649758	WDR60	1.02	9.51	0.65	1.95e-16	Height;
TGCT	cis	rs9532580	0.553	rs9549250	chr13:41225229	T/G	cg21288729	chr13:41239152	FOXO1	1.02	10.33	0.68	1.95e-18	Mean corpuscular hemoglobin;
TGCT	cis	rs2153535	0.505	rs9405395	chr6:8468622	T/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.8	0.46	5.19e-8	Motion sickness;
TGCT	cis	rs11578119	0.898	rs12141076	chr1:170379310	T/G	cg09767346	chr1:170501363	GORAB	0.74	5.87	0.47	3.81e-8	Male-pattern baldness;
TGCT	cis	rs4654899	0.727	rs11805169	chr1:21156862	A/T	cg01072550	chr1:21505969	NA	0.47	6.95	0.53	1.85e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs11741688	0.557	rs10043579	chr5:178330174	C/T	cg08270223	chr5:178322770	ZFP2	-0.37	-5.49	-0.44	2.14e-7	Sleep duration;
TGCT	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg12310025	chr6:25882481	NA	0.53	5.5	0.44	2.03e-7	Blood metabolite levels;
TGCT	cis	rs6459788	0.693	rs35146559	chr7:157238557	G/A	cg03453431	chr7:157225567	NA	-0.4	-5.8	-0.46	5.3e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs12464483	0.524	rs2593470	chr2:30887402	G/T	cg17749961	chr2:30669863	LCLAT1	0.59	4.58	0.38	1.12e-5	Pre-treatment pain in head and neck squamous cell carcinoma;
TGCT	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg12963246	chr6:28129442	ZNF389	0.53	5.09	0.42	1.27e-6	Depression;
TGCT	cis	rs3008870	0.920	rs2755253	chr1:67470843	C/T	cg11518657	chr1:67396239	MIER1	0.53	4.61	0.38	9.89e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg12311346	chr5:56204834	C5orf35	-0.83	-7.48	-0.56	1.18e-11	Initial pursuit acceleration;
TGCT	cis	rs2816062	0.747	rs2816049	chr1:18893768	A/G	cg18795169	chr1:18902165	NA	-0.6	-14.18	-0.79	1.01e-27	Urate levels in lean individuals;
TGCT	cis	rs68170813	0.559	rs4730232	chr7:106942382	G/C	cg02696742	chr7:106810147	HBP1	-0.69	-5.81	-0.46	4.85e-8	Coronary artery disease;
TGCT	cis	rs12497850	0.863	rs4974084	chr3:48939080	G/A	cg18654377	chr3:49208889	KLHDC8B	-0.41	-5.28	-0.43	5.62e-7	Parkinson's disease;
TGCT	cis	rs950169	0.845	rs4502182	chr15:84923520	A/G	cg17173187	chr15:85201210	NMB	0.54	5.55	0.45	1.67e-7	Schizophrenia;
TGCT	cis	rs9911578	1.000	rs2055779	chr17:57030561	A/G	cg05425664	chr17:57184151	TRIM37	-0.62	-6.18	-0.49	8.33e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs60994860	chr4:99046753	G/A	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11112613	0.713	rs73184082	chr12:105951748	T/C	cg03607813	chr12:105948248	NA	0.47	5.72	0.46	7.49e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	cis	rs7804356	1.000	rs6964094	chr7:26834380	C/G	cg03456212	chr7:26904342	SKAP2	-0.62	-4.76	-0.39	5.4e-6	Type 1 diabetes;
TGCT	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.93	7.44	0.56	1.44e-11	Platelet count;
TGCT	cis	rs7647973	0.516	rs4955419	chr3:49200692	T/A	cg07636037	chr3:49044803	WDR6	0.86	8.97	0.63	3.83e-15	Menarche (age at onset);
TGCT	cis	rs6540559	0.673	rs17015361	chr1:210018901	C/G	cg21951975	chr1:209979733	IRF6	0.63	4.76	0.39	5.36e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs6733011	0.628	rs981602	chr2:99464275	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.5	-4.95	-0.41	2.33e-6	Bipolar disorder;
TGCT	cis	rs2836974	0.653	rs8130556	chr21:40516872	C/T	cg11890956	chr21:40555474	PSMG1	1.11	11.82	0.73	4.61e-22	Cognitive function;
TGCT	cis	rs1981331	0.609	rs7282611	chr21:48043297	C/A	cg17243659	chr21:48055224	PRMT2	1.26	6.43	0.5	2.45e-9	Cerebrospinal fluid t-tau:AB1-42 ratio;
TGCT	cis	rs116975820	0.698	rs11181503	chr12:42827697	A/G	cg19980929	chr12:42632907	YAF2	0.61	4.88	0.4	3.14e-6	PR interval in Tripanosoma cruzi seropositivity;
TGCT	cis	rs826838	0.967	rs826876	chr12:39123843	T/C	cg13010199	chr12:38710504	ALG10B	-0.64	-5.07	-0.41	1.39e-6	Heart rate;
TGCT	cis	rs6714710	0.603	rs10432626	chr2:98561153	C/A	cg26665480	chr2:98280029	ACTR1B	0.63	5.98	0.47	2.19e-8	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs459571	0.959	rs456205	chr9:136911146	G/A	cg14405625	chr9:136855902	VAV2	-0.32	-4.72	-0.39	6.15e-6	Platelet distribution width;
TGCT	cis	rs912057	0.671	rs1294433	chr6:6745163	G/A	cg06612196	chr6:6737390	NA	0.47	6.77	0.52	4.57e-10	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs11190604	0.767	rs35508946	chr10:102191156	A/G	cg16342193	chr10:102329863	NA	-0.38	-5.0	-0.41	1.93e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2235642	0.750	rs2755185	chr16:1645827	A/G	cg08296037	chr16:1584118	IFT140;TMEM204	-0.28	-4.89	-0.4	3.09e-6	Coronary artery disease;
TGCT	cis	rs763121	0.925	rs1056661	chr22:39080245	A/G	cg06022373	chr22:39101656	GTPBP1	0.7	6.86	0.52	2.83e-10	Menopause (age at onset);
TGCT	cis	rs6665290	0.868	rs2183836	chr1:227199404	A/T	cg10327440	chr1:227177885	CDC42BPA	-0.95	-16.62	-0.83	2.46e-33	Myeloid white cell count;
TGCT	cis	rs11018874	0.597	rs4268468	chr11:89886284	C/T	cg14505434	chr11:89522851	NA	0.42	4.65	0.39	8.44e-6	White blood cell types;
TGCT	cis	rs4851254	0.660	rs4851250	chr2:100729293	T/C	cg04109781	chr2:100722022	AFF3	0.49	4.73	0.39	5.95e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs28374715	0.783	rs11630656	chr15:41570909	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.89	-13.95	-0.78	3.49e-27	Ulcerative colitis;
TGCT	cis	rs8056742	0.730	rs12929714	chr16:85093357	C/T	cg00229868	chr16:85520891	NA	0.39	4.97	0.41	2.19e-6	Amyotrophic lateral sclerosis;
TGCT	cis	rs67460515	0.926	rs66508859	chr3:160946351	C/T	cg03342759	chr3:160939853	NMD3	-0.5	-5.42	-0.44	2.99e-7	Parkinson's disease;
TGCT	cis	rs9911578	1.000	rs9898626	chr17:56698219	C/G	cg12560992	chr17:57184187	TRIM37	0.75	9.21	0.64	1.04e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs34014631	0.688	rs17770716	chr10:103574362	C/G	cg22630918	chr10:102748988	C10orf2	0.34	4.7	0.39	6.89e-6	Coronary artery calcification;
TGCT	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg22920501	chr2:26401640	FAM59B	-0.73	-6.44	-0.5	2.36e-9	Gut microbiome composition (summer);
TGCT	cis	rs4654899	0.802	rs115818417	chr1:21200411	C/T	cg01072550	chr1:21505969	NA	-0.46	-6.94	-0.53	1.96e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg25036284	chr2:26402008	FAM59B	0.65	5.19	0.42	8.36e-7	Gut microbiome composition (summer);
TGCT	cis	rs155076	1.000	rs598754	chr13:21845010	C/A	cg14456004	chr13:21872349	NA	-1.32	-10.82	-0.7	1.25e-19	White matter hyperintensity burden;
TGCT	cis	rs7617773	0.780	rs4130522	chr3:48352313	G/A	cg11946769	chr3:48343235	NME6	0.82	7.09	0.54	9.1e-11	Coronary artery disease;
TGCT	trans	rs561341	0.714	rs547473	chr17:30297560	T/G	cg20587970	chr11:113659929	NA	-1.03	-10.98	-0.7	5.21e-20	Hip circumference adjusted for BMI;
TGCT	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg22433210	chr17:43662623	NA	0.94	7.94	0.58	1.05e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs4700695	0.719	rs27587	chr5:65444163	C/T	cg21114390	chr5:65439923	SFRS12	-0.84	-7.45	-0.56	1.35e-11	Facial morphology (factor 19);
TGCT	cis	rs12421382	0.507	rs11600810	chr11:109356443	G/A	cg27471124	chr11:109292789	C11orf87	0.53	6.33	0.49	4.06e-9	Schizophrenia;
TGCT	cis	rs62064224	0.902	rs17732573	chr17:30627664	C/T	cg09324608	chr17:30823087	MYO1D	-0.21	-4.57	-0.38	1.17e-5	Schizophrenia;
TGCT	cis	rs9399135	0.967	rs4896125	chr6:135342569	C/T	cg24558204	chr6:135376177	HBS1L	0.5	5.0	0.41	1.89e-6	Red blood cell count;
TGCT	trans	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg27523141	chr10:43048294	ZNF37B	0.7	8.15	0.59	3.36e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs1801251	1.000	rs13008942	chr2:233594875	G/A	cg08000102	chr2:233561755	GIGYF2	0.64	6.53	0.51	1.53e-9	Coronary artery disease;
TGCT	cis	rs7772486	0.790	rs2253768	chr6:146199922	A/G	cg05347473	chr6:146136440	FBXO30	0.54	4.99	0.41	1.96e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs765787	0.530	rs12904331	chr15:45518293	C/T	cg24006582	chr15:45444508	DUOX1	0.25	5.33	0.43	4.46e-7	Uric acid levels;
TGCT	cis	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg18252515	chr7:66147081	NA	-1.21	-7.89	-0.58	1.36e-12	Diabetic kidney disease;
TGCT	cis	rs73198271	1.000	rs73198279	chr8:8608504	A/G	ch.8.214553F	chr8:8189620	PRAGMIN	-0.27	-4.57	-0.38	1.17e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs17001868	0.568	rs10854729	chr22:40750612	T/C	cg07138101	chr22:40742427	ADSL	0.71	5.41	0.44	3.08e-7	Mammographic density (dense area);
TGCT	cis	rs6752107	0.901	rs10187752	chr2:234146550	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.19	4.58	0.38	1.1e-5	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs2404602	0.647	rs12903331	chr15:77168268	C/G	cg23625390	chr15:77176239	SCAPER	-0.38	-4.96	-0.41	2.22e-6	Blood metabolite levels;
TGCT	cis	rs55823223	0.646	rs55868394	chr17:73851113	C/A	cg23806715	chr17:73775811	H3F3B	0.76	5.16	0.42	9.43e-7	Psoriasis;
TGCT	cis	rs2677744	1.000	rs1266483	chr15:91462406	A/G	cg22288577	chr15:91498497	RCCD1	0.48	4.88	0.4	3.16e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs4654899	0.929	rs7515845	chr1:21314455	G/A	cg01072550	chr1:21505969	NA	-0.5	-7.94	-0.58	1.04e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs2299587	0.560	rs11996792	chr8:17781012	C/G	cg01800426	chr8:17659068	MTUS1	-0.65	-5.63	-0.45	1.14e-7	Economic and political preferences;
TGCT	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg12310025	chr6:25882481	NA	0.52	5.42	0.44	2.98e-7	Blood metabolite levels;
TGCT	trans	rs17684571	0.938	rs13192037	chr6:56554272	C/A	cg14229071	chr15:89282588	NA	0.52	6.63	0.51	9.28e-10	Schizophrenia;
TGCT	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg19774624	chr17:42201019	HDAC5	0.83	8.52	0.61	4.64e-14	Total body bone mineral density;
TGCT	cis	rs6500602	0.701	rs11643057	chr16:4544505	C/T	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.26	4.73	0.39	5.95e-6	Schizophrenia;
TGCT	cis	rs17221829	0.733	rs11600011	chr11:89407980	T/C	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.44	-0.37	1.96e-5	Anxiety in major depressive disorder;
TGCT	cis	rs11249608	0.548	rs12152869	chr5:178462520	A/G	cg21905437	chr5:178450457	ZNF879	0.44	4.55	0.38	1.25e-5	Pubertal anthropometrics;
TGCT	cis	rs7221109	0.560	rs2253717	chr17:38868236	G/A	cg07480653	chr17:39868082	GAST	-0.23	-5.02	-0.41	1.77e-6	Type 1 diabetes;
TGCT	cis	rs5417	0.689	rs55868524	chr17:7170665	G/A	cg25256661	chr17:7137939	DVL2	-0.66	-6.67	-0.51	7.41e-10	Diastolic blood pressure;
TGCT	cis	rs881375	1.000	rs6478486	chr9:123655329	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	5.34	0.43	4.31e-7	Rheumatoid arthritis;
TGCT	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg03517284	chr6:25882590	NA	0.65	5.87	0.47	3.78e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs17767294	0.708	rs115736281	chr6:27842888	G/A	cg08851530	chr6:28072375	NA	1.58	6.9	0.53	2.39e-10	Parkinson's disease;
TGCT	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2204008	0.837	rs11514225	chr12:38076270	G/A	cg13010199	chr12:38710504	ALG10B	0.65	5.24	0.43	6.69e-7	Bladder cancer;
TGCT	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.06	14.7	0.8	5.95e-29	Prudent dietary pattern;
TGCT	cis	rs7568458	0.684	rs67988001	chr2:85787123	C/T	cg02493740	chr2:85810744	VAMP5	-0.28	-5.36	-0.43	3.98e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs8032315	0.895	rs4932370	chr15:91404705	A/G	cg05180856	chr15:91428056	FES	-0.25	-4.61	-0.38	9.88e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg12963246	chr6:28129442	ZNF389	0.48	4.79	0.4	4.58e-6	Parkinson's disease;
TGCT	cis	rs1403694	0.695	rs1050274	chr3:186435370	G/A	cg12454167	chr3:186435060	KNG1	0.51	8.67	0.61	1.95e-14	Blood protein levels;
TGCT	cis	rs713587	0.520	rs522806	chr2:25316584	C/A	cg15423357	chr2:25149977	NA	-0.46	-4.46	-0.37	1.83e-5	Body mass index in non-asthmatics;
TGCT	cis	rs3806843	0.607	rs246060	chr5:140324749	T/C	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs1018836	0.923	rs7812970	chr8:91541229	G/A	cg16814680	chr8:91681699	NA	-0.86	-9.52	-0.65	1.84e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1670533	1.000	rs62294756	chr4:1097676	G/A	cg20887711	chr4:1340912	KIAA1530	-0.68	-5.47	-0.44	2.33e-7	Recombination rate (females);
TGCT	cis	rs12681287	0.547	rs6985066	chr8:87526439	A/C	cg27223183	chr8:87520930	FAM82B	-0.96	-7.03	-0.53	1.21e-10	Caudate activity during reward;
TGCT	cis	rs3733585	0.605	rs4235355	chr4:10123078	C/A	cg00071950	chr4:10020882	SLC2A9	-0.51	-5.28	-0.43	5.62e-7	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs4409675	0.576	rs11247706	chr1:28213983	G/C	cg23691781	chr1:28212827	C1orf38	0.26	5.32	0.43	4.68e-7	Corneal astigmatism;
TGCT	cis	rs28595532	0.748	rs66615663	chr4:119336701	C/T	cg21605333	chr4:119757512	SEC24D	0.85	5.43	0.44	2.84e-7	Cannabis dependence symptom count;
TGCT	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg24846343	chr22:24311635	DDTL	0.21	5.22	0.42	7.18e-7	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs3806843	0.576	rs405192	chr5:140324710	T/G	cg07102913	chr5:140593443	PCDHB13	-0.46	-4.65	-0.39	8.2e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs137699	0.604	rs137702	chr22:39750158	T/C	cg24399712	chr22:39784796	NA	-0.82	-6.6	-0.51	1.07e-9	IgG glycosylation;
TGCT	cis	rs56104184	0.775	rs56317021	chr19:49395960	C/T	cg21252483	chr19:49399788	TULP2	-0.42	-5.89	-0.47	3.47e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg11764359	chr7:65958608	NA	0.62	5.53	0.44	1.82e-7	Aortic root size;
TGCT	cis	rs12959333	0.772	rs12961128	chr18:33306492	C/G	cg18885387	chr18:32820922	ZNF397	0.95	4.44	0.37	1.97e-5	Post bronchodilator FEV1;
TGCT	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg06212747	chr3:49208901	KLHDC8B	0.61	5.36	0.43	3.88e-7	Parkinson's disease;
TGCT	cis	rs13102973	0.720	rs4473702	chr4:135851159	C/G	cg14419869	chr4:135874104	NA	0.26	4.47	0.37	1.75e-5	Subjective well-being;
TGCT	cis	rs9467711	1.000	rs9467713	chr6:26338128	T/C	cg26531700	chr6:26746687	NA	-0.94	-5.63	-0.45	1.16e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12210905	0.688	rs72845005	chr6:27492378	T/G	cg08851530	chr6:28072375	NA	1.34	6.29	0.49	5.02e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs7824557	0.628	rs7815802	chr8:11190647	G/C	cg21775007	chr8:11205619	TDH	0.7	6.86	0.52	2.93e-10	Retinal vascular caliber;
TGCT	cis	rs62380364	0.701	rs304138	chr5:88169567	A/G	cg22951263	chr5:87985283	NA	0.5	5.02	0.41	1.79e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9926296	0.593	rs6500456	chr16:89888341	T/C	cg03388025	chr16:89894329	SPIRE2	0.32	4.72	0.39	6.19e-6	Vitiligo;
TGCT	cis	rs6714788	0.565	rs7599083	chr2:100658077	G/A	cg22139774	chr2:100720529	AFF3	-0.41	-6.53	-0.51	1.56e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs28374715	0.662	rs513280	chr15:41482800	T/C	cg18705301	chr15:41695430	NDUFAF1	0.75	11.19	0.71	1.6e-20	Ulcerative colitis;
TGCT	trans	rs4650994	0.525	rs4993304	chr1:178535144	A/G	cg05059571	chr16:84539110	KIAA1609	-0.54	-11.11	-0.71	2.47e-20	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	0.53	4.83	0.4	3.95e-6	Bipolar disorder;
TGCT	cis	rs9911578	0.967	rs12944948	chr17:56951474	A/G	cg05425664	chr17:57184151	TRIM37	-0.62	-6.18	-0.49	8.33e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs4253772	0.638	rs6007845	chr22:46718417	A/T	cg24881330	chr22:46731750	TRMU	-0.94	-6.36	-0.5	3.54e-9	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs1865760	1.000	rs6910174	chr6:25904414	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.65	6.24	0.49	6.27e-9	Height;
TGCT	cis	rs4144743	1.000	rs10438781	chr17:45323819	A/G	cg18085866	chr17:45331354	ITGB3	-0.72	-4.8	-0.4	4.39e-6	Body mass index;
TGCT	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg04317338	chr11:64019027	PLCB3	0.78	6.46	0.5	2.17e-9	Mean platelet volume;
TGCT	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg09359103	chr1:154839909	KCNN3	-0.66	-12.15	-0.74	7.27e-23	Prostate cancer;
TGCT	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg19761014	chr17:28927070	LRRC37B2	0.55	4.77	0.39	5.12e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	trans	rs62103177	0.789	rs7242289	chr18:77603291	C/T	cg05926928	chr17:57297772	GDPD1	1.22	11.62	0.72	1.41e-21	Opioid sensitivity;
TGCT	cis	rs7917772	0.636	rs10786708	chr10:104526245	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	4.6	0.38	1.03e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	trans	rs1814175	0.754	rs28593359	chr11:50042357	C/T	cg15704280	chr7:45808275	SEPT13	-0.72	-8.47	-0.61	6.02e-14	Height;
TGCT	cis	rs2046867	0.774	rs62249873	chr3:72907115	G/A	cg25664220	chr3:72788482	NA	-0.55	-7.01	-0.53	1.33e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9916302	0.706	rs7208252	chr17:37584368	A/G	cg07936489	chr17:37558343	FBXL20	-0.87	-6.27	-0.49	5.47e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs798766	1.000	rs1374469	chr4:1724799	C/T	cg05874882	chr4:1763078	NA	-0.39	-5.17	-0.42	8.91e-7	Bladder cancer;Urinary bladder cancer;
TGCT	cis	rs8042680	0.554	rs59278520	chr15:91514707	G/A	cg23684204	chr15:91497937	RCCD1	0.36	4.67	0.39	7.75e-6	Type 2 diabetes;
TGCT	cis	rs2692947	0.673	rs584811	chr2:97069879	A/G	cg23100626	chr2:96804247	ASTL	-0.43	-5.51	-0.44	1.99e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs10791323	0.593	rs10791329	chr11:133716356	T/C	cg03690763	chr11:133734501	NA	-0.32	-4.75	-0.39	5.48e-6	Childhood ear infection;
TGCT	trans	rs7618501	0.902	rs7645061	chr3:49868842	C/T	cg21659725	chr3:3221576	CRBN	0.98	15.33	0.81	2.1000000000000002e-30	Intelligence (multi-trait analysis);
TGCT	cis	rs4455778	0.580	rs6952050	chr7:49116354	A/C	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs9611565	0.559	rs6002408	chr22:41967870	C/T	cg06634786	chr22:41940651	POLR3H	-0.88	-8.32	-0.6	1.36e-13	Vitiligo;
TGCT	cis	rs7666738	0.712	rs11731393	chr4:98859070	G/C	cg24818145	chr4:99064322	C4orf37	0.62	4.46	0.37	1.85e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7659604	0.539	rs11098645	chr4:122729251	G/A	cg19748678	chr4:122722346	EXOSC9	0.9	9.34	0.64	4.9e-16	Type 2 diabetes;
TGCT	cis	rs244731	0.959	rs6556307	chr5:176641434	C/T	cg06060754	chr5:176797920	RGS14	0.44	6.15	0.48	9.81e-9	Urate levels in lean individuals;
TGCT	cis	rs9549367	0.789	rs9549711	chr13:113900557	C/T	cg18105134	chr13:113819100	PROZ	-0.34	-5.58	-0.45	1.41e-7	Platelet distribution width;
TGCT	cis	rs3741404	0.560	rs7938819	chr11:63910116	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.78	-7.75	-0.57	2.8e-12	Platelet count;
TGCT	cis	rs7666738	0.830	rs3911282	chr4:99037602	T/A	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3008870	1.000	rs12132068	chr1:67451924	G/T	cg11518657	chr1:67396239	MIER1	-0.53	-4.6	-0.38	1.04e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs2075371	1.000	rs2075372	chr7:133984432	C/T	cg11752832	chr7:134001865	SLC35B4	0.69	6.32	0.49	4.19e-9	Mean platelet volume;
TGCT	trans	rs2727020	0.595	rs10839286	chr11:49497063	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.36	-7.03	-0.53	1.25e-10	Coronary artery disease;
TGCT	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg07167872	chr1:205819463	PM20D1	0.43	4.96	0.41	2.3e-6	Menarche (age at onset);
TGCT	cis	rs7586879	0.964	rs4077680	chr2:25122942	A/G	cg01884057	chr2:25150051	NA	0.28	5.03	0.41	1.69e-6	Body mass index;
TGCT	cis	rs7666738	0.830	rs11725095	chr4:99009711	T/A	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2933343	0.649	rs728839	chr3:128589359	A/G	cg11901034	chr3:128598214	ACAD9	-0.64	-6.11	-0.48	1.16e-8	IgG glycosylation;
TGCT	cis	rs9383153	1.000	rs2073518	chr6:16332730	T/C	cg14009473	chr6:15502099	JARID2	0.68	5.73	0.46	7.12e-8	Gambling;
TGCT	cis	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg20637647	chr7:64974828	NA	0.89	4.99	0.41	2.01e-6	Diabetic kidney disease;
TGCT	cis	rs595982	0.546	rs10401443	chr19:49402059	C/A	cg21252483	chr19:49399788	TULP2	-0.29	-5.12	-0.42	1.13e-6	Red cell distribution width;
TGCT	trans	rs3780486	0.505	rs959749	chr9:33147858	T/C	cg04842962	chr6:43655489	MRPS18A	0.8	8.57	0.61	3.51e-14	IgG glycosylation;
TGCT	cis	rs4713118	0.955	rs9468200	chr6:27683063	T/A	cg10876282	chr6:28092338	ZSCAN16	0.5	4.62	0.38	9.35e-6	Parkinson's disease;
TGCT	cis	rs854765	0.624	rs9891957	chr17:17744439	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.7	-6.64	-0.51	8.69e-10	Total body bone mineral density;
TGCT	trans	rs4650994	1.000	rs10913570	chr1:178523126	A/C	cg05059571	chr16:84539110	KIAA1609	-0.43	-8.0	-0.58	7.66e-13	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs910316	1.000	rs12590452	chr14:75548756	T/C	cg11812906	chr14:75593930	NEK9	0.74	7.38	0.55	1.97e-11	Height;
TGCT	cis	rs2851682	0.572	rs174570	chr11:61597212	C/T	cg19610905	chr11:61596333	FADS2	-0.79	-4.55	-0.38	1.26e-5	Gestational age at birth (child effect);Trans fatty acid levels;
TGCT	cis	rs2797160	0.967	rs2226158	chr6:125995467	C/T	cg05901451	chr6:126070800	HEY2	-0.72	-6.76	-0.52	4.77e-10	Endometrial cancer;
TGCT	cis	rs1541995	0.824	rs28670798	chr15:96248345	T/C	cg00882281	chr15:96346592	NA	0.3	4.85	0.4	3.7e-6	Photic sneeze reflex;
TGCT	cis	rs3087591	1.000	rs2953015	chr17:29495341	A/G	cg24425628	chr17:29625626	OMG;NF1	0.45	6.95	0.53	1.84e-10	Hip circumference;
TGCT	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg05368731	chr17:41323189	NBR1	1.2	14.59	0.79	1.08e-28	Menopause (age at onset);
TGCT	cis	rs1371867	0.875	rs1788169	chr8:101326314	C/T	cg06636551	chr8:101224915	SPAG1	-0.48	-6.52	-0.51	1.62e-9	Atrioventricular conduction;
TGCT	cis	rs600231	0.542	rs34527830	chr11:65240863	G/A	cg17120908	chr11:65337727	SSSCA1	-0.57	-4.45	-0.37	1.9e-5	Bone mineral density;
TGCT	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg01238044	chr22:24384105	GSTT1	-0.5	-4.65	-0.39	8.32e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs12893668	0.703	rs4906337	chr14:104040414	C/A	cg26031613	chr14:104095156	KLC1	-0.54	-4.44	-0.37	1.97e-5	Reticulocyte count;
TGCT	cis	rs1577917	1.000	rs13217384	chr6:86720000	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.56	-4.77	-0.39	5.06e-6	Response to antipsychotic treatment;
TGCT	cis	rs2066819	1.000	rs2066818	chr12:56753822	C/A	cg26714650	chr12:56694279	CS	-1.36	-5.89	-0.47	3.4e-8	Psoriasis vulgaris;
TGCT	cis	rs9467711	1.000	rs9467701	chr6:26312170	G/C	cg03264133	chr6:25882463	NA	-0.82	-4.48	-0.37	1.65e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2191566	0.881	rs1996408	chr19:44532732	G/A	cg03039196	chr19:44506973	ZNF230	0.55	4.76	0.39	5.24e-6	Acute lymphoblastic leukemia (childhood);
TGCT	cis	rs838147	0.508	rs507711	chr19:49208564	C/T	cg04599840	chr19:48886497	KDELR1	0.23	4.75	0.39	5.54e-6	Dietary macronutrient intake;
TGCT	cis	rs6912958	0.712	rs7772561	chr6:88331299	A/G	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.98	-0.41	2.06e-6	Monocyte percentage of white cells;
TGCT	cis	rs8067545	1.000	rs1860302	chr17:19914399	T/A	cg13482628	chr17:19912719	NA	0.55	4.83	0.4	3.98e-6	Schizophrenia;
TGCT	cis	rs4076764	0.914	rs4638099	chr1:163365521	A/G	cg24596788	chr1:163392923	NA	0.17	4.79	0.39	4.75e-6	Motion sickness;
TGCT	cis	rs6570726	0.935	rs7757387	chr6:145816726	G/T	cg23711669	chr6:146136114	FBXO30	0.7	6.6	0.51	1.09e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6987853	0.931	rs2923399	chr8:42439509	G/A	cg20539142	chr8:42623718	CHRNA6	-0.2	-4.82	-0.4	4.2e-6	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs3821902	0.646	rs17344570	chr3:64014239	A/C	cg22134162	chr3:63841271	THOC7	0.32	4.85	0.4	3.64e-6	Breast cancer;
TGCT	cis	rs12580194	1.000	rs4262806	chr12:55711562	T/A	cg20672549	chr12:56432144	IKZF4	0.26	4.69	0.39	7.12e-6	Cancer;
TGCT	cis	rs6674176	0.597	rs12127737	chr1:44402565	G/A	cg13606994	chr1:44402422	ARTN	-0.5	-5.47	-0.44	2.36e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg16680214	chr1:154839983	KCNN3	-0.42	-9.25	-0.64	8.37e-16	Prostate cancer;
TGCT	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg16325326	chr1:53192061	ZYG11B	0.57	6.36	0.5	3.5e-9	Monocyte count;
TGCT	cis	rs3820928	0.810	rs10175929	chr2:227858609	T/C	cg11843606	chr2:227700838	RHBDD1	-0.52	-4.63	-0.38	9.03e-6	Pulmonary function;
TGCT	cis	rs17345786	0.911	rs10936707	chr3:101324063	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.44	-9.59	-0.65	1.25e-16	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7666738	0.830	rs6811940	chr4:98777898	G/A	cg17366294	chr4:99064904	C4orf37	0.65	6.79	0.52	4.13e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6882046	0.513	rs35148765	chr5:88046158	C/A	cg22951263	chr5:87985283	NA	-0.55	-5.91	-0.47	3.09e-8	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs9911578	1.000	rs7215808	chr17:56940742	G/C	cg05425664	chr17:57184151	TRIM37	-0.62	-6.18	-0.49	8.33e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs2303745	0.544	rs6512181	chr19:17399213	T/G	cg04248312	chr19:17393744	ANKLE1	-0.34	-5.57	-0.45	1.54e-7	Systemic lupus erythematosus;
TGCT	trans	rs6089829	0.962	rs1116450	chr20:61658210	T/C	cg13615516	chr5:77269221	NA	0.68	8.54	0.61	3.97e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2276314	0.857	rs4799408	chr18:33588982	C/T	cg19628046	chr18:33552617	C18orf21	-0.51	-4.47	-0.37	1.74e-5	Endometriosis;Drug-induced torsades de pointes;
TGCT	cis	rs2153535	0.607	rs9502722	chr6:8541483	C/T	cg07606381	chr6:8435919	SLC35B3	0.56	5.16	0.42	9.46e-7	Motion sickness;
TGCT	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg03188948	chr7:1209495	NA	0.68	5.8	0.46	5.09e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1577917	0.917	rs35038582	chr6:86721305	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.22	-0.42	7.27e-7	Response to antipsychotic treatment;
TGCT	cis	rs7666738	0.791	rs11097601	chr4:98960103	C/T	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs2970818	0.831	rs2909381	chr12:4606527	T/C	cg04106436	chr12:8665373	CLEC4D	0.35	6.83	0.52	3.33e-10	Phosphorus levels;
TGCT	cis	rs394563	0.591	rs11155641	chr6:149648595	G/A	cg16235748	chr6:149772707	ZC3H12D	0.44	5.14	0.42	1.05e-6	Dupuytren's disease;
TGCT	trans	rs561341	1.000	rs498391	chr17:30328704	G/A	cg20587970	chr11:113659929	NA	-1.05	-12.8	-0.75	2.04e-24	Hip circumference adjusted for BMI;
TGCT	cis	rs8180040	0.966	rs878659	chr3:47500662	G/A	cg27129171	chr3:47204927	SETD2	0.66	8.01	0.58	7.07e-13	Colorectal cancer;
TGCT	trans	rs57221529	0.825	rs72703051	chr5:582997	G/A	cg11887960	chr12:57824829	NA	1.17	8.86	0.62	7.09e-15	Lung disease severity in cystic fibrosis;
TGCT	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg03264133	chr6:25882463	NA	-0.64	-6.81	-0.52	3.66e-10	Blood metabolite levels;
TGCT	cis	rs7666738	0.962	rs2865986	chr4:99067907	A/G	cg17366294	chr4:99064904	C4orf37	0.73	6.51	0.5	1.72e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2980439	0.783	rs2955587	chr8:8098079	A/G	cg06636001	chr8:8085503	FLJ10661	0.87	8.77	0.62	1.18e-14	Neuroticism;
TGCT	cis	rs17102423	0.723	rs11158573	chr14:65579370	A/G	cg11161011	chr14:65562177	MAX	-0.53	-7.18	-0.54	5.74e-11	Obesity-related traits;
TGCT	cis	rs1682825	0.790	rs73812277	chr3:10751837	C/A	cg23512531	chr3:10780469	NA	0.64	4.55	0.38	1.24e-5	Economic and political preferences (feminism/equality);
TGCT	cis	rs9357506	1.000	rs6910478	chr6:46307341	A/T	cg21115430	chr6:46460003	NA	-0.26	-5.17	-0.42	9.2e-7	Body mass index;
TGCT	trans	rs7618501	0.501	rs35275715	chr3:49959148	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.83	8.58	0.61	3.34e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs514406	0.698	rs1672913	chr1:53408326	A/T	cg08736216	chr1:53307985	ZYG11A	-0.23	-4.56	-0.38	1.19e-5	Monocyte count;
TGCT	cis	rs3008870	0.755	rs2815368	chr1:67500778	C/T	cg11518657	chr1:67396239	MIER1	0.47	4.61	0.38	9.68e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs4237845	0.742	rs6650219	chr12:58289100	T/C	cg02175503	chr12:58329896	NA	0.52	5.49	0.44	2.17e-7	Intelligence (multi-trait analysis);
TGCT	trans	rs7824557	0.518	rs11250094	chr8:10802001	G/C	cg15556689	chr8:8085844	FLJ10661	-0.82	-7.42	-0.55	1.62e-11	Retinal vascular caliber;
TGCT	cis	rs4654899	0.758	rs1609558	chr1:21525228	C/T	cg01072550	chr1:21505969	NA	0.57	9.6	0.65	1.15e-16	Superior frontal gyrus grey matter volume;
TGCT	cis	rs28595532	0.920	rs115485705	chr4:119733286	G/C	cg21605333	chr4:119757512	SEC24D	1.66	8.33	0.6	1.28e-13	Cannabis dependence symptom count;
TGCT	cis	rs1580019	0.813	rs2044839	chr7:32500805	A/C	cg06627557	chr7:32535165	LSM5;AVL9	0.88	8.48	0.61	5.7e-14	Cognitive ability;
TGCT	cis	rs4757319	0.656	rs10832404	chr11:15347481	A/G	cg26427818	chr11:15093613	NA	-0.37	-4.56	-0.38	1.2e-5	Breast cancer;
TGCT	cis	rs9611565	0.559	rs132771	chr22:42025350	A/G	cg06481639	chr22:41940642	POLR3H	0.73	6.47	0.5	2.04e-9	Vitiligo;
TGCT	cis	rs10782582	0.593	rs17848068	chr1:76190216	G/A	cg03433033	chr1:76189801	ACADM	-0.58	-6.58	-0.51	1.18e-9	Daytime sleep phenotypes;
TGCT	cis	rs453301	0.686	rs6601280	chr8:8909236	A/T	cg08975724	chr8:8085496	FLJ10661	0.58	5.07	0.41	1.38e-6	Joint mobility (Beighton score);
TGCT	cis	rs1401999	0.510	rs3749438	chr3:183705184	G/A	cg01324343	chr3:183735012	ABCC5	0.49	5.24	0.43	6.68e-7	Anterior chamber depth;
TGCT	cis	rs7666738	0.830	rs4292342	chr4:98959870	A/T	cg05340658	chr4:99064831	C4orf37	0.52	6.01	0.47	1.93e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12477438	0.765	rs7591992	chr2:99668954	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-7.6	-0.56	6.47e-12	Chronic sinus infection;
TGCT	cis	rs826838	0.967	rs11169387	chr12:39145737	C/T	cg13010199	chr12:38710504	ALG10B	0.82	6.67	0.51	7.41e-10	Heart rate;
TGCT	cis	rs881375	0.678	rs10760125	chr9:123662590	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	5.31	0.43	4.92e-7	Rheumatoid arthritis;
TGCT	cis	rs10782582	0.593	rs1412717	chr1:76125471	C/T	cg03433033	chr1:76189801	ACADM	-0.63	-7.25	-0.55	3.83e-11	Daytime sleep phenotypes;
TGCT	cis	rs1008375	0.932	rs6835077	chr4:17653285	A/T	cg10189774	chr4:17578691	LAP3	0.55	4.83	0.4	3.89e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1862618	0.525	rs2662019	chr5:56263104	A/G	cg18230493	chr5:56204884	C5orf35	0.65	5.07	0.41	1.41e-6	Initial pursuit acceleration;
TGCT	cis	rs3008870	1.000	rs3008871	chr1:67419089	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.06	-10.8	-0.7	1.47e-19	Lymphocyte percentage of white cells;
TGCT	cis	rs877282	0.838	rs34912955	chr10:772222	T/C	cg17470449	chr10:769945	NA	0.31	4.8	0.4	4.44e-6	Uric acid levels;
TGCT	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg24578937	chr1:2090814	PRKCZ	-0.24	-5.88	-0.47	3.51e-8	Height;
TGCT	cis	rs2293052	0.697	rs553715	chr12:117753856	G/T	cg02962597	chr12:117799749	NOS1	0.27	4.65	0.39	8.28e-6	Schizophrenia;
TGCT	cis	rs838147	0.563	rs281379	chr19:49214274	C/T	cg13540341	chr19:49222985	MAMSTR	-0.36	-4.64	-0.38	8.64e-6	Dietary macronutrient intake;
TGCT	cis	rs651907	0.557	rs1056579	chr3:101397877	T/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.91	10.9	0.7	8.24e-20	Colorectal cancer;
TGCT	cis	rs17221829	0.668	rs12364732	chr11:89374054	T/G	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.63	-0.38	9.04e-6	Anxiety in major depressive disorder;
TGCT	cis	rs595982	0.559	rs17206714	chr19:49362001	T/A	cg17863274	chr19:49399704	TULP2	-0.48	-6.9	-0.53	2.38e-10	Red cell distribution width;
TGCT	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg06238570	chr21:40685208	BRWD1	0.69	6.41	0.5	2.71e-9	Cognitive function;
TGCT	cis	rs9549260	0.755	rs4943798	chr13:41202948	T/C	cg21288729	chr13:41239152	FOXO1	0.97	10.16	0.67	5.23e-18	Red blood cell count;
TGCT	cis	rs5167	0.566	rs2075620	chr19:45480037	C/T	cg09555818	chr19:45449301	APOC2	-0.23	-4.62	-0.38	9.53e-6	Blood protein levels;
TGCT	cis	rs1008375	0.931	rs3796814	chr4:17602033	G/C	cg10189774	chr4:17578691	LAP3	0.57	4.9	0.4	2.93e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9527	0.590	rs12415388	chr10:104796345	T/C	cg04362960	chr10:104952993	NT5C2	0.65	5.59	0.45	1.36e-7	Arsenic metabolism;
TGCT	cis	rs6424115	0.931	rs11800561	chr1:24164398	T/G	cg15997130	chr1:24165203	NA	0.9	9.86	0.66	2.77e-17	Immature fraction of reticulocytes;
TGCT	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	8.55	0.61	3.84e-14	Platelet count;
TGCT	cis	rs1865760	0.928	rs9295673	chr6:25912094	T/G	cg16482183	chr6:26056742	HIST1H1C	0.52	4.58	0.38	1.14e-5	Height;
TGCT	cis	rs1150668	0.799	rs7206	chr6:28201138	A/G	cg11262757	chr6:27280423	POM121L2	0.45	4.44	0.37	1.94e-5	Pubertal anthropometrics;
TGCT	cis	rs3731896	0.898	rs72955485	chr2:220152103	C/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.72	4.66	0.39	7.89e-6	Educational attainment;
TGCT	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg05457628	chr5:178986728	RUFY1	-0.44	-4.91	-0.4	2.84e-6	Lung cancer;
TGCT	cis	rs2486288	0.656	rs7171312	chr15:45570225	C/G	cg26924012	chr15:45694286	SPATA5L1	-0.78	-7.55	-0.56	8e-12	Glomerular filtration rate;
TGCT	cis	rs2932538	0.922	rs7535636	chr1:113101799	C/T	cg22162597	chr1:113214053	CAPZA1	-0.27	-5.98	-0.47	2.24e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs2239547	0.521	rs9682464	chr3:52888485	C/T	cg10802521	chr3:52805072	NEK4	-0.65	-6.14	-0.48	1.02e-8	Schizophrenia;
TGCT	cis	rs4494114	0.967	rs6660891	chr1:39319009	C/T	cg25970120	chr1:39325951	RRAGC	-0.6	-6.28	-0.49	5.09e-9	Blood protein levels;
TGCT	cis	rs12620999	0.941	rs62183343	chr2:237979163	T/C	cg23555395	chr2:238036564	NA	0.27	4.76	0.39	5.28e-6	Systemic lupus erythematosus;
TGCT	cis	rs992157	0.700	rs10165153	chr2:219159629	T/C	cg00012203	chr2:219082015	ARPC2	0.81	8.08	0.59	4.97e-13	Colorectal cancer;
TGCT	cis	rs6430585	0.528	rs79826902	chr2:136670419	G/A	cg07169764	chr2:136633963	MCM6	1.25	12.39	0.74	1.91e-23	Corneal structure;
TGCT	cis	rs362272	0.524	rs2749781	chr4:3346617	T/C	cg18352616	chr4:3374830	RGS12	0.26	5.25	0.43	6.33e-7	Serum sulfate level;
TGCT	cis	rs12477438	0.798	rs6705583	chr2:99602625	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.67	-5.89	-0.47	3.39e-8	Chronic sinus infection;
TGCT	cis	rs1903068	0.853	rs12505096	chr4:56006102	C/A	cg09978860	chr4:56023921	NA	0.58	6.22	0.49	6.84e-9	Endometriosis;
TGCT	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg18402987	chr7:1209562	NA	0.52	4.76	0.39	5.3e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs4253772	0.513	rs6008700	chr22:46722560	C/T	cg26492175	chr22:47022658	GRAMD4	0.19	4.5	0.37	1.54e-5	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs7945705	0.967	rs1569408	chr11:8909732	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.42	4.7	0.39	6.86e-6	Hemoglobin concentration;
TGCT	cis	rs7647973	0.925	rs9881860	chr3:49352522	A/T	cg06212747	chr3:49208901	KLHDC8B	0.6	4.71	0.39	6.63e-6	Menarche (age at onset);
TGCT	trans	rs9929218	0.551	rs2296409	chr16:68713730	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.62	8.2	0.59	2.51e-13	Colorectal cancer;
TGCT	cis	rs911555	0.755	rs17841064	chr14:103900609	A/G	cg12935359	chr14:103987150	CKB	-0.33	-4.47	-0.37	1.76e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs2742234	0.910	rs2505511	chr10:43641029	T/A	cg02780029	chr10:43622663	RET	-0.26	-5.09	-0.42	1.28e-6	Hirschsprung disease;
TGCT	cis	rs68170813	0.652	rs7784906	chr7:107148386	C/T	cg02696742	chr7:106810147	HBP1	-0.58	-4.47	-0.37	1.74e-5	Coronary artery disease;
TGCT	cis	rs1045529	0.524	rs34251783	chr8:8891376	T/C	cg00184457	chr8:8946301	NA	-0.26	-4.94	-0.41	2.45e-6	Myopia;Myopia (pathological);
TGCT	cis	rs4555082	0.834	rs2735819	chr14:105713449	C/T	cg01266790	chr14:105781312	PACS2	0.55	4.51	0.38	1.49e-5	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs2692947	0.702	rs2312955	chr2:96777168	T/G	cg23100626	chr2:96804247	ASTL	-0.42	-5.0	-0.41	1.92e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.91	7.44	0.56	1.45e-11	Platelet count;
TGCT	cis	rs7542091	1.000	rs7542091	chr1:210031948	G/C	cg22029157	chr1:209979665	IRF6	0.57	5.64	0.45	1.1e-7	Monobrow;
TGCT	cis	rs12142240	0.731	rs6681857	chr1:46850124	T/C	cg00530320	chr1:46809349	NSUN4	0.29	5.83	0.46	4.57e-8	Menopause (age at onset);
TGCT	cis	rs933688	1.000	rs933688	chr5:90762748	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.06	10.58	0.69	4.94e-19	Smoking behavior;
TGCT	cis	rs4285028	0.948	rs34566912	chr3:121679626	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.77	-6.55	-0.51	1.35e-9	Multiple sclerosis;
TGCT	cis	rs10540	1.000	rs61876339	chr11:495283	T/C	cg03934478	chr11:495069	RNH1	0.35	5.82	0.46	4.66e-8	Body mass index;
TGCT	cis	rs60154123	0.505	rs2206043	chr1:210042983	G/A	cg22029157	chr1:209979665	IRF6	0.79	5.78	0.46	5.6e-8	Coronary artery disease;
TGCT	cis	rs13064411	0.696	rs2087129	chr3:113142769	T/A	cg10517650	chr3:113235015	CCDC52	-0.35	-4.69	-0.39	7.18e-6	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs904251	0.523	rs2776870	chr6:37481364	C/A	cg08126542	chr6:37504118	NA	-0.44	-6.51	-0.5	1.71e-9	Cognitive performance;
TGCT	cis	rs6840360	0.550	rs6816471	chr4:152494869	A/G	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.0	-0.58	7.69e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg02975922	chr3:195473998	MUC4	-0.24	-5.47	-0.44	2.4e-7	Pancreatic cancer;
TGCT	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.71	-0.39	6.54e-6	Prudent dietary pattern;
TGCT	cis	rs11586313	0.507	rs2339385	chr1:152859594	C/G	cg07796016	chr1:152779584	LCE1C	-0.41	-4.56	-0.38	1.2e-5	Vitamin D levels;
TGCT	cis	rs3008870	0.959	rs56707923	chr1:67388016	T/C	cg03991309	chr1:68237761	GNG12	0.27	4.56	0.38	1.23e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs9902453	0.904	rs4528633	chr17:28356136	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.81	-7.67	-0.57	4.37e-12	Coffee consumption (cups per day);
TGCT	cis	rs60154123	0.505	rs76101197	chr1:210044089	T/C	cg21951975	chr1:209979733	IRF6	0.69	5.18	0.42	8.74e-7	Coronary artery disease;
TGCT	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg25036284	chr2:26402008	FAM59B	-0.54	-4.7	-0.39	6.93e-6	Gut microbiome composition (summer);
TGCT	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	8.0	0.58	7.67e-13	Platelet count;
TGCT	cis	rs9926296	0.643	rs2159114	chr16:89831841	A/G	cg26513180	chr16:89883248	FANCA	0.72	7.02	0.53	1.3e-10	Vitiligo;
TGCT	cis	rs1538970	0.851	rs2055145	chr1:45926495	C/G	cg05343316	chr1:45956843	TESK2	0.81	6.81	0.52	3.79e-10	Platelet count;
TGCT	cis	rs11122272	0.735	rs2474623	chr1:231513993	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.14	-0.54	6.86e-11	Hemoglobin concentration;
TGCT	cis	rs2795502	0.873	rs2077626	chr10:43410962	A/G	cg20628663	chr10:43360327	NA	0.36	5.47	0.44	2.33e-7	Blood protein levels;
TGCT	cis	rs7100689	0.646	rs1340375	chr10:82129039	C/T	cg01528321	chr10:82214614	TSPAN14	0.8	7.76	0.57	2.7e-12	Post bronchodilator FEV1;
TGCT	cis	rs9788721	0.614	rs951984	chr15:78720915	T/A	cg18825076	chr15:78729989	IREB2	-0.33	-4.88	-0.4	3.13e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
TGCT	cis	rs986417	1.000	rs1474999	chr14:60905920	T/C	cg27398547	chr14:60952738	C14orf39	-1.39	-10.61	-0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg15921436	chr17:44337874	NA	0.58	8.15	0.59	3.34e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7944584	0.551	rs12224672	chr11:47500400	C/T	cg20307385	chr11:47447363	PSMC3	0.9	8.5	0.61	5.08e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
TGCT	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.73	-0.39	5.93e-6	Prudent dietary pattern;
TGCT	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg27541892	chr1:1571801	CDK11B	-0.4	-5.3	-0.43	5.09e-7	Body mass index;
TGCT	cis	rs7714584	1.000	rs10051924	chr5:150226639	T/C	cg22134413	chr5:150180641	NA	0.87	6.89	0.53	2.52e-10	Crohn's disease;
TGCT	cis	rs28595532	0.668	rs56410164	chr4:119331625	A/G	cg21605333	chr4:119757512	SEC24D	0.87	5.49	0.44	2.14e-7	Cannabis dependence symptom count;
TGCT	cis	rs9611565	0.512	rs139562	chr22:42196684	G/C	cg06634786	chr22:41940651	POLR3H	-0.81	-7.49	-0.56	1.1e-11	Vitiligo;
TGCT	cis	rs362272	0.524	rs7435601	chr4:3369645	A/G	cg22655196	chr4:3374909	RGS12	0.22	4.6	0.38	1.03e-5	Serum sulfate level;
TGCT	cis	rs9926296	0.744	rs164747	chr16:89708680	T/G	cg27121462	chr16:89883253	FANCA	-0.5	-4.61	-0.38	9.76e-6	Vitiligo;
TGCT	cis	rs250677	0.687	rs250667	chr5:148455134	A/G	cg23229984	chr5:148520753	ABLIM3	-0.22	-4.95	-0.41	2.38e-6	Breast cancer;
TGCT	trans	rs7819412	0.511	rs10108511	chr8:11435516	T/C	cg15556689	chr8:8085844	FLJ10661	-0.78	-7.4	-0.55	1.79e-11	Triglycerides;
TGCT	cis	rs9653442	0.900	rs1160544	chr2:100832218	A/C	cg07810366	chr2:100720526	AFF3	-0.39	-5.97	-0.47	2.3e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs17376456	0.597	rs1031423	chr5:93276883	A/G	cg21475434	chr5:93447410	FAM172A	-0.64	-6.0	-0.47	1.99e-8	Diabetic retinopathy;
TGCT	cis	rs72945132	0.882	rs67822447	chr11:70230972	G/T	cg00319359	chr11:70116639	PPFIA1	1.04	7.94	0.58	1.03e-12	Coronary artery disease;
TGCT	cis	rs3813567	0.759	rs12595350	chr15:78953464	G/A	cg24631222	chr15:78858424	CHRNA5	0.68	4.72	0.39	6.35e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
TGCT	trans	rs561341	0.556	rs118032208	chr17:30395634	T/C	cg20587970	chr11:113659929	NA	-0.98	-8.12	-0.59	3.87e-13	Hip circumference adjusted for BMI;
TGCT	cis	rs2963155	0.518	rs853177	chr5:142635460	A/G	cg17617527	chr5:142782415	NR3C1	0.83	6.17	0.48	8.99e-9	Breast cancer;
TGCT	cis	rs17270561	0.578	rs76182885	chr6:25904085	G/C	cg16482183	chr6:26056742	HIST1H1C	0.94	7.33	0.55	2.58e-11	Iron status biomarkers;
TGCT	cis	rs28595532	0.688	rs116566508	chr4:119619195	G/A	cg14228332	chr4:119757509	SEC24D	1.0	5.76	0.46	6.22e-8	Cannabis dependence symptom count;
TGCT	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg06112835	chr11:68658793	MRPL21	0.47	8.03	0.59	6.25e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9443189	0.570	rs72884926	chr6:76266208	T/C	cg01950844	chr6:76311363	SENP6	0.95	5.82	0.46	4.69e-8	Prostate cancer;
TGCT	cis	rs11098499	0.730	rs78971550	chr4:120281041	C/T	cg09307838	chr4:120376055	NA	0.56	5.41	0.44	3.18e-7	Corneal astigmatism;
TGCT	cis	rs739496	0.579	rs73426310	chr12:112342410	A/G	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs4704846	1.000	rs919744	chr5:156531254	G/C	cg12943317	chr5:156479607	HAVCR1	-0.34	-4.75	-0.39	5.43e-6	Blood protein levels;
TGCT	cis	rs2239547	0.657	rs3755803	chr3:52866157	C/G	cg10802521	chr3:52805072	NEK4	-0.63	-5.99	-0.47	2.16e-8	Schizophrenia;
TGCT	cis	rs35146811	0.735	rs1727139	chr7:99815367	C/T	cg04778012	chr7:99775508	STAG3;GPC2	-0.35	-4.93	-0.41	2.55e-6	Coronary artery disease;
TGCT	cis	rs782590	0.837	rs782584	chr2:55921116	C/G	cg18811423	chr2:55921094	PNPT1	-0.73	-8.31	-0.6	1.38e-13	Metabolic syndrome;
TGCT	trans	rs7824557	0.564	rs2572395	chr8:11235360	A/C	cg15556689	chr8:8085844	FLJ10661	-0.76	-6.96	-0.53	1.75e-10	Retinal vascular caliber;
TGCT	cis	rs2033711	0.870	rs4801583	chr19:58918405	A/G	cg12042659	chr19:58951599	ZNF132	0.51	4.67	0.39	7.69e-6	Uric acid clearance;
TGCT	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg23708337	chr7:1209742	NA	0.51	4.46	0.37	1.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs17122693	0.551	rs2934685	chr14:51050865	C/G	cg04730355	chr14:51134070	SAV1	1.2	12.06	0.73	1.23e-22	Cognitive performance;
TGCT	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg14827481	chr10:134361889	INPP5A	0.3	4.82	0.4	4.18e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs8020441	0.891	rs61362797	chr14:51167752	A/T	cg04730355	chr14:51134070	SAV1	0.71	5.77	0.46	5.92e-8	Cognitive performance;
TGCT	cis	rs3771570	1.000	rs55634485	chr2:242268994	T/C	cg21155796	chr2:242212141	HDLBP	0.98	6.68	0.51	7.29e-10	Prostate cancer;
TGCT	cis	rs250677	0.687	rs36044	chr5:148441128	T/C	cg23229984	chr5:148520753	ABLIM3	0.21	4.89	0.4	3.11e-6	Breast cancer;
TGCT	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg03452623	chr4:187889614	NA	-0.37	-5.55	-0.45	1.63e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs896854	0.684	rs10099941	chr8:95987008	C/T	cg13393036	chr8:95962371	TP53INP1	-0.58	-7.97	-0.58	8.83e-13	Type 2 diabetes;
TGCT	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg23758822	chr17:41437982	NA	0.7	6.6	0.51	1.1e-9	Menopause (age at onset);
TGCT	cis	rs12142240	0.698	rs67276232	chr1:46825484	T/G	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs4455778	0.580	rs4492325	chr7:49096154	G/A	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	trans	rs208520	0.634	rs3909071	chr6:66836947	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-10.43	-0.68	1.15e-18	Exhaled nitric oxide output;
TGCT	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.91	7.47	0.56	1.26e-11	Platelet count;
TGCT	cis	rs7949030	0.591	rs12049914	chr11:62369436	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.61	8.75	0.62	1.29e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs3935685	0.934	rs61331678	chr15:77995949	G/C	cg03457338	chr15:78040120	NA	-0.22	-5.17	-0.42	9.25e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg06481639	chr22:41940642	POLR3H	0.75	6.64	0.51	8.81e-10	Vitiligo;
TGCT	cis	rs2933343	1.000	rs1683778	chr3:128644595	A/G	cg11901034	chr3:128598214	ACAD9	-0.63	-5.13	-0.42	1.08e-6	IgG glycosylation;
TGCT	cis	rs6570726	0.935	rs449377	chr6:145852437	C/G	cg23711669	chr6:146136114	FBXO30	0.69	7.04	0.53	1.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg18188782	chr20:61659543	NA	0.46	5.49	0.44	2.13e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs68170813	0.652	rs17403088	chr7:107111373	C/A	cg02696742	chr7:106810147	HBP1	-0.64	-4.84	-0.4	3.8e-6	Coronary artery disease;
TGCT	cis	rs17345786	0.953	rs78645744	chr3:101327789	T/A	cg12386194	chr3:101231763	SENP7	0.61	5.66	0.45	9.91e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs13217239	0.646	rs4269366	chr6:27016413	C/T	cg15659132	chr6:26577336	NA	0.54	5.34	0.43	4.32e-7	Schizophrenia;
TGCT	cis	rs3733585	0.699	rs6844316	chr4:9958977	A/G	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.7	-0.57	3.69e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs72843506	0.722	rs74658636	chr17:20197982	A/G	cg18979559	chr17:20280153	CCDC144C	-0.65	-4.86	-0.4	3.54e-6	Schizophrenia;
TGCT	cis	rs2180341	0.814	rs6905553	chr6:127727407	A/G	cg27446573	chr6:127587934	RNF146	0.88	8.07	0.59	5.22e-13	Breast cancer;
TGCT	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg03934478	chr11:495069	RNH1	0.36	5.98	0.47	2.19e-8	Body mass index;
TGCT	cis	rs7666738	0.830	rs10022389	chr4:99022229	T/C	cg18180107	chr4:99064573	C4orf37	0.54	5.03	0.41	1.7e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	5.11	0.42	1.18e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg20607798	chr8:58055168	NA	0.61	5.16	0.42	9.38e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg13531842	chr10:38383804	ZNF37A	-0.39	-4.66	-0.39	8.06e-6	Extrinsic epigenetic age acceleration;
TGCT	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg26513180	chr16:89883248	FANCA	1.06	14.89	0.8	2.22e-29	Vitiligo;
TGCT	cis	rs28595532	0.920	rs116231457	chr4:119762396	A/C	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg07507251	chr3:52567010	NT5DC2	0.47	6.75	0.52	5.11e-10	Bipolar disorder;
TGCT	cis	rs4727027	0.866	rs1358062	chr7:148783743	T/C	cg23583168	chr7:148888333	NA	-0.69	-8.76	-0.62	1.23e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg14008862	chr17:28927542	LRRC37B2	0.69	4.46	0.37	1.84e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7666738	0.830	rs1813972	chr4:98886828	C/A	cg05340658	chr4:99064831	C4orf37	0.52	6.02	0.48	1.81e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12142240	1.000	rs12146051	chr1:46742952	G/C	cg00530320	chr1:46809349	NSUN4	0.25	4.92	0.4	2.68e-6	Menopause (age at onset);
TGCT	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg25767906	chr1:53392781	SCP2	0.46	5.11	0.42	1.19e-6	Monocyte count;
TGCT	cis	rs13082711	0.522	rs551621	chr3:27336325	G/C	cg02860705	chr3:27208620	NA	0.33	5.45	0.44	2.62e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg18876405	chr7:65276391	NA	0.31	4.79	0.4	4.58e-6	Aortic root size;
TGCT	cis	rs6061231	0.544	rs2427314	chr20:60973666	C/T	cg15674680	chr20:60982522	CABLES2	0.72	6.16	0.48	9.26e-9	Colorectal cancer;
TGCT	cis	rs1633360	1	rs1633360	chr12:58108052	C/T	cg15848620	chr12:58087721	OS9	-0.58	-4.89	-0.4	3.12e-6	Rheumatoid arthritis;
TGCT	cis	rs3902035	1.000	rs3902035	chr6:119000232	T/C	cg07617317	chr6:118971624	C6orf204	0.48	5.52	0.44	1.87e-7	QT interval;
TGCT	cis	rs2745967	0.505	rs607952	chr1:208053785	T/C	cg22525895	chr1:207977042	MIR29B2	0.37	5.65	0.45	1.02e-7	Resting heart rate;
TGCT	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg16680214	chr1:154839983	KCNN3	-0.36	-7.26	-0.55	3.81e-11	Prostate cancer;
TGCT	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg11764359	chr7:65958608	NA	0.61	5.54	0.45	1.76e-7	Aortic root size;
TGCT	cis	rs950776	0.518	rs12910289	chr15:78822065	T/G	cg06917634	chr15:78832804	PSMA4	0.95	9.52	0.65	1.81e-16	Sudden cardiac arrest;
TGCT	cis	rs344364	0.511	rs2917515	chr16:1945271	G/C	cg26617929	chr16:1858877	NA	-0.27	-4.9	-0.4	2.99e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs2469997	1.000	rs2447178	chr8:120356188	C/T	cg00681363	chr8:120844660	TAF2	0.65	4.52	0.38	1.45e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs28595532	0.920	rs116149978	chr4:119761069	A/C	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs2255336	0.938	rs1478310	chr12:10534878	C/T	cg16084090	chr12:10586130	KLRC2	0.27	4.45	0.37	1.9e-5	Blood protein levels;
TGCT	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg23758822	chr17:41437982	NA	0.79	7.6	0.56	6.31e-12	Menopause (age at onset);
TGCT	cis	rs7267979	1.000	rs2257496	chr20:25279315	A/G	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3806843	0.518	rs173471	chr5:140335226	A/G	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs295137	0.798	rs295142	chr2:201211716	C/T	cg23649088	chr2:200775458	C2orf69	-0.28	-4.67	-0.39	7.68e-6	Asthma (bronchodilator response);
TGCT	cis	rs11077998	0.933	rs3736204	chr17:80530279	C/T	cg10255544	chr17:80519551	FOXK2	0.23	4.44	0.37	1.97e-5	Reticulocyte fraction of red cells;
TGCT	cis	rs17253792	0.822	rs45501402	chr14:56140115	C/T	cg01858014	chr14:56050164	KTN1	-0.35	-4.62	-0.38	9.37e-6	Putamen volume;
TGCT	cis	rs17473412	0.787	rs10069343	chr5:122705535	C/T	cg15125798	chr5:122621645	NA	-0.57	-5.15	-0.42	9.93e-7	Total body bone mineral density;
TGCT	trans	rs1814175	0.781	rs11040681	chr11:49981654	G/T	cg03929089	chr4:120376271	NA	-0.72	-8.53	-0.61	4.24e-14	Height;
TGCT	cis	rs829883	0.738	rs249846	chr12:98868739	T/C	cg25150519	chr12:98850993	NA	0.64	7.83	0.58	1.84e-12	Colorectal adenoma (advanced);
TGCT	cis	rs62064224	0.791	rs2344977	chr17:30720573	C/G	cg25809561	chr17:30822961	MYO1D	0.32	5.42	0.44	3.01e-7	Schizophrenia;
TGCT	cis	rs4711350	0.765	rs1318691	chr6:33761884	G/A	cg18005901	chr6:33739558	LEMD2	-0.58	-6.48	-0.5	1.96e-9	Schizophrenia;
TGCT	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg17911788	chr17:44343683	NA	-0.67	-7.15	-0.54	6.59e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2180341	0.920	rs1073932	chr6:127682009	G/T	cg24812749	chr6:127587940	RNF146	0.93	7.4	0.55	1.83e-11	Breast cancer;
TGCT	cis	rs66573146	0.803	rs59742225	chr4:6969942	C/T	cg00086871	chr4:6988644	TBC1D14	0.98	4.57	0.38	1.16e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	8.99	0.63	3.48e-15	Platelet count;
TGCT	cis	rs17767294	0.708	rs72847377	chr6:27866189	C/T	cg08851530	chr6:28072375	NA	1.57	7.27	0.55	3.59e-11	Parkinson's disease;
TGCT	cis	rs7845219	0.544	rs2123647	chr8:95931782	A/G	cg16049864	chr8:95962084	TP53INP1	0.46	5.06	0.41	1.47e-6	Type 2 diabetes;
TGCT	cis	rs1878931	0.507	rs8054222	chr16:3413477	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.62	-4.89	-0.4	3.1e-6	Body mass index (adult);
TGCT	cis	rs1692580	0.777	rs7547453	chr1:2195117	C/T	cg24578937	chr1:2090814	PRKCZ	0.2	4.56	0.38	1.22e-5	Coronary artery disease;
TGCT	cis	rs317689	0.690	rs317646	chr12:69657145	A/G	cg14784868	chr12:69753453	YEATS4	-0.53	-4.51	-0.38	1.5e-5	Response to diuretic therapy;
TGCT	cis	rs10782582	0.609	rs11161848	chr1:76367722	A/G	cg03433033	chr1:76189801	ACADM	-0.5	-4.91	-0.4	2.81e-6	Daytime sleep phenotypes;
TGCT	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg11890956	chr21:40555474	PSMG1	1.13	12.1	0.74	1e-22	Cognitive function;
TGCT	cis	rs66561647	0.563	rs4733580	chr8:128932677	G/A	cg11792826	chr8:129160931	MIR1208	0.23	5.07	0.41	1.4e-6	Hemoglobin concentration;
TGCT	cis	rs9388451	0.868	rs1268083	chr6:126049040	T/C	cg05901451	chr6:126070800	HEY2	1.01	12.85	0.76	1.47e-24	Brugada syndrome;
TGCT	cis	rs75686122	0.892	rs76423444	chr8:104714028	G/A	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs13256369	1.000	rs10095733	chr8:8574646	A/G	cg18904891	chr8:8559673	CLDN23	0.64	5.89	0.47	3.36e-8	Obesity-related traits;
TGCT	cis	rs28595532	0.920	rs115860303	chr4:119734526	T/C	cg21605333	chr4:119757512	SEC24D	1.66	8.33	0.6	1.28e-13	Cannabis dependence symptom count;
TGCT	cis	rs7731657	0.537	rs2189504	chr5:130298900	C/A	cg08523029	chr5:130500466	HINT1	-0.58	-4.84	-0.4	3.8e-6	Fasting plasma glucose;
TGCT	trans	rs208520	0.661	rs1776361	chr6:66822270	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.97	-10.47	-0.69	9.18e-19	Exhaled nitric oxide output;
TGCT	cis	rs9868809	0.881	rs57334642	chr3:48666795	C/T	cg00383909	chr3:49044727	WDR6	0.97	5.08	0.42	1.34e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs3125734	0.572	rs7896627	chr10:64046354	T/G	cg19640130	chr10:64028056	RTKN2	-0.38	-4.79	-0.39	4.73e-6	Rheumatoid arthritis;
TGCT	cis	rs8017423	0.967	rs4900030	chr14:90689813	T/A	cg04374321	chr14:90722782	PSMC1	0.77	8.03	0.58	6.42e-13	Mortality in heart failure;
TGCT	cis	rs2153535	0.580	rs9505450	chr6:8469902	C/T	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs1348850	0.914	rs4893938	chr2:178250095	T/C	cg22681709	chr2:178499509	PDE11A	-0.35	-4.57	-0.38	1.15e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs12762955	0.507	rs10737004	chr10:1039019	T/C	cg26597838	chr10:835615	NA	-0.48	-6.43	-0.5	2.45e-9	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs12893668	0.572	rs4900590	chr14:104146421	C/T	cg26031613	chr14:104095156	KLC1	-0.59	-5.05	-0.41	1.51e-6	Reticulocyte count;
TGCT	cis	rs8017423	0.935	rs11624295	chr14:90695612	T/G	cg04374321	chr14:90722782	PSMC1	0.77	8.05	0.59	5.68e-13	Mortality in heart failure;
TGCT	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg22968622	chr17:43663579	NA	1.28	12.17	0.74	6.65e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs1008375	1.000	rs7661631	chr4:17679751	T/C	cg10189774	chr4:17578691	LAP3	-0.53	-4.69	-0.39	7.14e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs78487399	0.908	rs75664918	chr2:43839090	T/G	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.64	4.63	0.38	8.92e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs303386	0.501	rs6703819	chr1:99574494	T/C	cg03593336	chr1:99471295	LPPR5	0.26	5.33	0.43	4.4e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors);Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin);
TGCT	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg24829409	chr8:58192753	C8orf71	-0.54	-5.03	-0.41	1.68e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7829975	0.658	rs2409096	chr8:8692477	T/C	cg08975724	chr8:8085496	FLJ10661	0.56	5.04	0.41	1.57e-6	Mood instability;
TGCT	cis	rs77880822	0.562	rs6078405	chr20:1247246	T/C	cg23117778	chr20:1206693	RAD21L1	0.7	4.51	0.38	1.48e-5	Angiotensin-converting enzyme inhibitor intolerance;
TGCT	cis	rs2293052	0.757	rs567581	chr12:117757512	C/T	cg02962597	chr12:117799749	NOS1	0.26	4.56	0.38	1.21e-5	Schizophrenia;
TGCT	cis	rs7523273	0.565	rs12733108	chr1:207887210	C/T	cg22525895	chr1:207977042	MIR29B2	0.35	5.75	0.46	6.66e-8	Schizophrenia;
TGCT	cis	rs7914558	1.000	rs7067970	chr10:104913870	C/T	cg15744005	chr10:104629667	AS3MT	-0.42	-5.24	-0.43	6.69e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs9868809	0.772	rs9841602	chr3:48713570	A/G	cg00383909	chr3:49044727	WDR6	0.88	5.29	0.43	5.32e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs2204008	0.837	rs11180821	chr12:38242843	A/G	cg13010199	chr12:38710504	ALG10B	0.6	4.64	0.38	8.72e-6	Bladder cancer;
TGCT	cis	rs881375	1.000	rs881375	chr9:123652898	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	5.5	0.44	2.03e-7	Rheumatoid arthritis;
TGCT	cis	rs2721195	0.967	rs11777703	chr8:145703508	G/A	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.86	-9.53	-0.65	1.75e-16	Age at first birth;
TGCT	cis	rs727563	0.638	rs5996058	chr22:42141452	A/G	cg03806693	chr22:41940476	POLR3H	1.04	10.94	0.7	6.42e-20	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs4319547	0.695	rs11057797	chr12:122860732	G/A	cg08088222	chr12:122070432	ORAI1	-0.25	-4.49	-0.37	1.58e-5	Body mass index;
TGCT	cis	rs950776	0.518	rs2292117	chr15:78834689	C/T	cg06917634	chr15:78832804	PSMA4	0.95	9.52	0.65	1.81e-16	Sudden cardiac arrest;
TGCT	cis	rs7524258	0.903	rs4908450	chr1:7292756	T/C	cg07173049	chr1:7289937	CAMTA1	0.32	5.31	0.43	4.88e-7	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.51	-4.96	-0.41	2.24e-6	Prudent dietary pattern;
TGCT	cis	rs1018836	0.886	rs10956750	chr8:91621704	G/C	cg16814680	chr8:91681699	NA	-0.86	-9.19	-0.64	1.12e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	trans	rs2288327	0.557	rs7577862	chr2:179352857	G/A	cg14011486	chr1:26737247	LIN28	1.03	7.28	0.55	3.41e-11	Atrial fibrillation;
TGCT	cis	rs669446	0.533	rs3791041	chr1:44202991	A/G	cg12908607	chr1:44402522	ARTN	-0.61	-6.99	-0.53	1.52e-10	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs921968	0.541	rs647990	chr2:219441428	T/C	cg02176678	chr2:219576539	TTLL4	0.48	6.78	0.52	4.32e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs10484885	0.571	rs17708151	chr6:90632293	T/C	cg10278699	chr6:90661155	BACH2	0.31	4.51	0.38	1.49e-5	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs12477438	0.520	rs6542863	chr2:99725138	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	13.05	0.76	4.93e-25	Chronic sinus infection;
TGCT	cis	rs682748	0.901	rs999990	chr5:17122228	C/T	cg23987134	chr5:17158319	LOC285696	-0.19	-4.48	-0.37	1.66e-5	Hippocampal atrophy;
TGCT	cis	rs7246657	0.943	rs2303131	chr19:37936025	G/A	cg18154014	chr19:37997991	ZNF793	0.95	6.63	0.51	9.39e-10	Coronary artery calcification;
TGCT	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg22105103	chr4:187893119	NA	0.35	4.89	0.4	3.02e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs17401966	0.867	rs6696056	chr1:10305992	C/A	cg19773385	chr1:10388646	KIF1B	-0.2	-4.5	-0.37	1.54e-5	Hepatocellular carcinoma;
TGCT	cis	rs7017914	0.967	rs1348535	chr8:71662741	A/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.05	-0.41	1.56e-6	Bone mineral density;
TGCT	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg21285383	chr16:89894308	SPIRE2	-0.44	-6.82	-0.52	3.48e-10	Vitiligo;
TGCT	cis	rs12681288	0.823	rs4735974	chr8:1000218	T/G	cg04851639	chr8:1020857	NA	-0.36	-6.43	-0.5	2.55e-9	Schizophrenia;
TGCT	cis	rs3916	0.911	rs34673751	chr12:121171891	G/A	cg21892295	chr12:121157589	UNC119B	-0.22	-4.45	-0.37	1.89e-5	Urinary metabolites (H-NMR features);
TGCT	cis	rs34245846	0.769	rs12729486	chr1:154827366	T/C	cg06418219	chr1:154948305	SHC1;CKS1B	0.73	5.86	0.47	3.83e-8	Atrial fibrillation;
TGCT	cis	rs3784262	0.740	rs1372369	chr15:58294381	T/G	cg12031962	chr15:58353849	ALDH1A2	-0.43	-6.3	-0.49	4.77e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg06212747	chr3:49208901	KLHDC8B	0.6	5.44	0.44	2.75e-7	Parkinson's disease;
TGCT	cis	rs7833790	0.724	rs6473310	chr8:82707981	A/G	cg27398817	chr8:82754497	SNX16	-0.73	-6.03	-0.48	1.75e-8	Diastolic blood pressure;
TGCT	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	6.23	0.49	6.56e-9	Bipolar disorder;
TGCT	cis	rs4478037	0.822	rs9868526	chr3:33124269	A/G	cg19404215	chr3:33155277	CRTAP	-0.98	-5.13	-0.42	1.1e-6	Major depressive disorder;
TGCT	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg02725872	chr8:58115012	NA	0.36	5.0	0.41	1.94e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7666738	0.830	rs2865979	chr4:99027137	T/C	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs832540	0.931	rs33319	chr5:56206675	C/A	cg12311346	chr5:56204834	C5orf35	-0.48	-5.14	-0.42	1.06e-6	Coronary artery disease;
TGCT	cis	rs6882046	0.513	rs616391	chr5:88038845	C/T	cg22951263	chr5:87985283	NA	-0.55	-5.9	-0.47	3.27e-8	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs7727544	0.507	rs11741341	chr5:131570218	A/G	cg24060327	chr5:131705240	SLC22A5	-0.58	-6.04	-0.48	1.64e-8	Blood metabolite levels;
TGCT	cis	rs8180040	0.681	rs9818382	chr3:47193034	C/T	cg27129171	chr3:47204927	SETD2	0.71	8.5	0.61	5.06e-14	Colorectal cancer;
TGCT	cis	rs1403694	0.966	rs1648715	chr3:186439618	A/G	cg12454167	chr3:186435060	KNG1	0.42	7.32	0.55	2.77e-11	Blood protein levels;
TGCT	cis	rs6430585	0.583	rs60253740	chr2:136571852	G/T	cg07169764	chr2:136633963	MCM6	1.18	10.93	0.7	6.96e-20	Corneal structure;
TGCT	cis	rs11190604	1.000	rs9420797	chr10:102331147	C/T	cg16342193	chr10:102329863	NA	-0.41	-5.21	-0.42	7.71e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs35883536	0.647	rs10875314	chr1:101043207	G/C	cg10298815	chr1:101004474	GPR88	-0.25	-4.73	-0.39	6.03e-6	Monocyte count;
TGCT	cis	rs4906332	1.000	rs911549	chr14:103984537	T/C	cg26031613	chr14:104095156	KLC1	0.6	5.33	0.43	4.56e-7	Coronary artery disease;
TGCT	cis	rs986417	0.540	rs10144415	chr14:61112667	G/C	cg18240143	chr14:60952599	C14orf39	0.93	4.64	0.38	8.58e-6	Gut microbiota (bacterial taxa);
TGCT	cis	rs68170813	0.559	rs6963917	chr7:106953427	T/G	cg02696742	chr7:106810147	HBP1	-0.69	-5.81	-0.46	4.85e-8	Coronary artery disease;
TGCT	cis	rs2180341	0.576	rs2057224	chr6:127624414	C/G	cg24812749	chr6:127587940	RNF146	0.63	5.33	0.43	4.51e-7	Breast cancer;
TGCT	cis	rs7432375	0.609	rs835637	chr3:136673157	A/T	cg15507776	chr3:136538369	TMEM22	0.5	5.1	0.42	1.24e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs910316	0.836	rs6574212	chr14:75671659	G/A	cg08847533	chr14:75593920	NEK9	-0.87	-9.53	-0.65	1.7e-16	Height;
TGCT	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg03188948	chr7:1209495	NA	0.45	5.85	0.47	4.04e-8	Longevity;Endometriosis;
TGCT	cis	rs13394619	0.935	rs6746291	chr2:11728381	T/C	cg07314298	chr2:11723111	GREB1	-0.3	-5.39	-0.44	3.45e-7	Endometriosis;
TGCT	cis	rs9486719	0.656	rs4839826	chr6:96853616	A/G	cg18709589	chr6:96969512	KIAA0776	-0.65	-4.81	-0.4	4.36e-6	Migraine;Coronary artery disease;
TGCT	cis	rs12210905	0.614	rs72845006	chr6:27492958	G/A	cg08851530	chr6:28072375	NA	1.34	6.29	0.49	5.02e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs4654899	0.680	rs3125160	chr1:21127803	G/C	cg01072550	chr1:21505969	NA	0.55	8.83	0.62	8.24e-15	Superior frontal gyrus grey matter volume;
TGCT	cis	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg20637647	chr7:64974828	NA	-0.9	-5.31	-0.43	4.87e-7	Diabetic kidney disease;
TGCT	cis	rs6089584	0.528	rs4925334	chr20:60626769	C/T	cg06108461	chr20:60628389	TAF4	-0.43	-5.2	-0.42	7.98e-7	Body mass index;
TGCT	cis	rs35306767	0.953	rs10904581	chr10:964685	A/T	cg18964960	chr10:1102726	WDR37	0.57	4.55	0.38	1.27e-5	Eosinophil percentage of granulocytes;
TGCT	cis	rs7611238	0.560	rs12054333	chr3:195032122	G/A	cg27323046	chr3:195102265	ACAP2	0.36	4.9	0.4	2.93e-6	Body mass index;
TGCT	cis	rs17068510	0.572	rs66819405	chr8:3882298	C/T	cg25338036	chr8:3047536	CSMD1	-0.46	-4.87	-0.4	3.28e-6	Cerebrospinal fluid clusterin levels;
TGCT	cis	rs4665630	0.614	rs2712105	chr2:23901353	A/G	cg08063864	chr2:24346004	PFN4;LOC375190	-1.13	-5.4	-0.44	3.29e-7	Hypertension;
TGCT	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg03609598	chr5:56110824	MAP3K1	-0.58	-4.7	-0.39	6.72e-6	Initial pursuit acceleration;
TGCT	cis	rs11118844	0.744	rs6655994	chr1:221933888	A/G	cg04222084	chr1:221915650	DUSP10	-0.81	-5.34	-0.43	4.19e-7	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
TGCT	cis	rs10193935	0.901	rs62142599	chr2:42548935	G/A	cg27598129	chr2:42591480	NA	-0.39	-5.45	-0.44	2.59e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs854765	0.623	rs9893690	chr17:17753846	A/T	cg04398451	chr17:18023971	MYO15A	0.31	4.68	0.39	7.4e-6	Total body bone mineral density;
TGCT	cis	rs11098499	0.645	rs78422072	chr4:120281042	C/T	cg09307838	chr4:120376055	NA	0.56	5.41	0.44	3.18e-7	Corneal astigmatism;
TGCT	cis	rs478304	0.654	rs7947604	chr11:65442059	G/C	cg27068330	chr11:65405492	SIPA1	-1.01	-11.26	-0.71	1.09e-20	Acne (severe);
TGCT	cis	rs4455778	0.659	rs11185620	chr7:49025869	C/A	cg26309511	chr7:48887640	NA	-0.44	-5.22	-0.42	7.26e-7	Lung cancer in never smokers;
TGCT	cis	rs9430161	0.579	rs10864486	chr1:11040979	A/G	cg27631724	chr1:11040367	C1orf127	0.55	6.46	0.5	2.16e-9	Ewing sarcoma;
TGCT	cis	rs7647973	0.961	rs4955430	chr3:49378088	G/A	cg05785598	chr3:49045655	WDR6	0.39	4.62	0.38	9.58e-6	Menarche (age at onset);
TGCT	cis	rs7394190	0.748	rs2075641	chr10:75562108	G/A	cg07699608	chr10:75541558	CHCHD1	0.79	5.44	0.44	2.72e-7	Incident atrial fibrillation;
TGCT	cis	rs6582630	0.537	rs7310749	chr12:38400472	C/T	cg26384229	chr12:38710491	ALG10B	0.83	7.39	0.55	1.92e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs2455799	0.553	rs12495958	chr3:15941439	G/T	cg16303742	chr3:15540471	COLQ	-0.24	-4.53	-0.38	1.36e-5	Mean platelet volume;
TGCT	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg24675658	chr1:53192096	ZYG11B	-0.7	-7.91	-0.58	1.22e-12	Monocyte count;
TGCT	trans	rs13064411	0.542	rs2399477	chr3:113222998	A/G	cg00307254	chr3:126706825	PLXNA1	0.34	6.78	0.52	4.36e-10	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg17554472	chr22:41940697	POLR3H	-0.51	-5.26	-0.43	6.08e-7	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs1385374	0.841	rs11059929	chr12:129296893	G/A	cg09035930	chr12:129282057	SLC15A4	-0.55	-4.48	-0.37	1.67e-5	Systemic lupus erythematosus;
TGCT	cis	rs7267979	1.000	rs6050559	chr20:25329915	A/G	cg03522245	chr20:25566470	NINL	0.63	6.79	0.52	4.05e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs941408	1.000	rs1640273	chr19:2803227	C/T	cg22153745	chr1:153894579	GATAD2B	-0.62	-6.69	-0.51	6.82e-10	Total cholesterol levels;
TGCT	cis	rs12220898	0.749	rs11101076	chr10:50486539	G/A	cg09603381	chr10:49954066	WDFY4	0.38	4.45	0.37	1.88e-5	Inflammatory biomarkers;
TGCT	cis	rs6967414	0.579	rs11980762	chr7:6756878	G/A	cg00387323	chr7:6746715	ZNF12	0.76	4.65	0.39	8.23e-6	Hematocrit;Hemoglobin concentration;
TGCT	cis	rs8077889	0.672	rs2106764	chr17:41852717	T/A	cg26893861	chr17:41843967	DUSP3	1.14	20.46	0.88	1.46e-41	Triglycerides;
TGCT	cis	rs7824557	0.628	rs7005469	chr8:11194457	G/A	cg21775007	chr8:11205619	TDH	0.7	6.86	0.52	2.93e-10	Retinal vascular caliber;
TGCT	cis	rs2948294	0.545	rs11776397	chr8:8115161	C/T	cg06636001	chr8:8085503	FLJ10661	0.82	7.16	0.54	6.3e-11	Red cell distribution width;
TGCT	cis	rs6987853	0.933	rs55881007	chr8:42367290	A/G	cg20539142	chr8:42623718	CHRNA6	0.19	4.46	0.37	1.83e-5	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg00149659	chr3:10157352	C3orf10	-0.97	-6.25	-0.49	5.95e-9	Alzheimer's disease;
TGCT	cis	rs7226408	0.948	rs72883571	chr18:34382245	T/G	cg06757138	chr18:34340585	FHOD3	0.26	4.79	0.4	4.62e-6	Obesity-related traits;
TGCT	cis	rs6964587	0.758	rs35963176	chr7:91617115	C/T	cg17063962	chr7:91808500	NA	0.76	6.18	0.49	8.37e-9	Breast cancer;
TGCT	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg23302884	chr18:44338147	ST8SIA5	-0.4	-4.61	-0.38	9.88e-6	Personality dimensions;
TGCT	cis	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg13531842	chr10:38383804	ZNF37A	-0.39	-4.64	-0.38	8.78e-6	Extrinsic epigenetic age acceleration;
TGCT	cis	rs832540	0.902	rs194059	chr5:56197416	G/A	cg12311346	chr5:56204834	C5orf35	-0.49	-5.16	-0.42	9.56e-7	Coronary artery disease;
TGCT	cis	rs568617	0.767	rs2231884	chr11:65656564	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.69	5.96	0.47	2.45e-8	Crohn's disease;
TGCT	cis	rs17270561	0.723	rs12213243	chr6:25890108	C/T	cg17042849	chr6:26104293	HIST1H4C	-0.76	-5.36	-0.43	3.98e-7	Iron status biomarkers;
TGCT	cis	rs7027203	0.595	rs4308796	chr9:96570165	G/A	cg14396892	chr9:96623032	NA	0.23	4.58	0.38	1.13e-5	DNA methylation (variation);
TGCT	cis	rs9308731	0.623	rs2241842	chr2:111879415	A/G	cg04202892	chr2:111875749	ACOXL	0.54	6.25	0.49	6.18e-9	Chronic lymphocytic leukemia;
TGCT	cis	rs1990950	0.716	rs6868374	chr5:156832202	G/A	cg25387487	chr5:157003181	ADAM19	0.32	4.94	0.41	2.46e-6	Lung function (FEV1/FVC);
TGCT	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	5.32	0.43	4.73e-7	Bipolar disorder;
TGCT	cis	rs4689388	0.856	rs3200	chr4:6304878	C/T	cg14416269	chr4:6271139	WFS1	0.41	5.5	0.44	2.08e-7	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs12893668	0.514	rs3212090	chr14:104168863	C/T	cg26031613	chr14:104095156	KLC1	-0.59	-5.0	-0.41	1.94e-6	Reticulocyte count;
TGCT	cis	rs9527	0.615	rs7096452	chr10:104736563	G/A	cg15744005	chr10:104629667	AS3MT	-0.44	-5.19	-0.42	8.3e-7	Arsenic metabolism;
TGCT	cis	rs7949030	0.725	rs12808829	chr11:62378660	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.7	8.79	0.62	1.02e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs4074961	0.505	rs4653306	chr1:38065390	C/T	cg11397548	chr1:38022522	DNALI1	0.41	4.67	0.39	7.69e-6	Axial length;
TGCT	cis	rs2066819	0.892	rs2066807	chr12:56740682	C/G	cg26714650	chr12:56694279	CS	-1.36	-5.95	-0.47	2.56e-8	Psoriasis vulgaris;
TGCT	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg03188948	chr7:1209495	NA	0.59	4.82	0.4	4.06e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs12142240	0.583	rs5013330	chr1:46815154	G/A	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs6570726	0.846	rs870491	chr6:145933390	T/G	cg13319975	chr6:146136371	FBXO30	-0.51	-4.49	-0.37	1.59e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg10295955	chr4:187884368	NA	-1.02	-15.84	-0.82	1.42e-31	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7666738	0.830	rs6854703	chr4:98977586	A/T	cg05340658	chr4:99064831	C4orf37	0.5	5.84	0.46	4.35e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9467773	0.620	rs2504592	chr6:26640951	C/G	cg09904177	chr6:26538194	HMGN4	0.68	6.36	0.5	3.55e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs2180341	0.960	rs9398842	chr6:127674662	T/C	cg24812749	chr6:127587940	RNF146	0.93	7.4	0.55	1.83e-11	Breast cancer;
TGCT	cis	rs1334894	1.000	rs72913405	chr6:35530062	C/T	cg24281267	chr6:35479648	TULP1	-0.43	-4.47	-0.37	1.78e-5	Coronary artery disease;
TGCT	cis	rs9303401	0.614	rs3887355	chr17:56538639	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.61	6.17	0.48	8.95e-9	Cognitive test performance;
TGCT	cis	rs1008375	0.574	rs7670135	chr4:17566221	G/T	cg18681998	chr4:17616180	MED28	0.75	7.15	0.54	6.68e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6032067	0.636	rs7272597	chr20:43908869	T/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.47	-7.24	-0.54	4.21e-11	Blood protein levels;
TGCT	cis	rs6998277	0.830	rs12543046	chr8:103603809	A/G	cg10187029	chr8:103597600	NA	-0.55	-8.75	-0.62	1.31e-14	Migraine;
TGCT	trans	rs1814175	0.791	rs1722023	chr11:49908136	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.36	-7.05	-0.53	1.13e-10	Height;
TGCT	cis	rs2658782	0.901	rs11604909	chr11:93218355	C/G	cg26827247	chr11:93063208	CCDC67	-0.56	-4.51	-0.38	1.51e-5	Pulmonary function decline;
TGCT	cis	rs7142881	0.756	rs4981135	chr14:32332071	C/T	cg19615721	chr14:32671389	NA	0.51	4.46	0.37	1.85e-5	Response to iloperidone treatment (QT prolongation);
TGCT	cis	rs9952991	0.941	rs8096138	chr18:12808140	C/G	cg23598886	chr18:12777645	NA	-0.62	-5.57	-0.45	1.5e-7	Inflammatory skin disease;
TGCT	cis	rs7010267	0.902	rs10505348	chr8:119972696	A/G	cg17171407	chr8:119960777	TNFRSF11B	0.33	6.18	0.49	8.48e-9	Total body bone mineral density (age 45-60);
TGCT	cis	rs1799949	0.965	rs4792989	chr17:41437552	T/C	cg05368731	chr17:41323189	NBR1	1.11	11.95	0.73	2.23e-22	Menopause (age at onset);
TGCT	cis	rs35417517	1	rs35417517	chr7:91772730	CG/C	cg17063962	chr7:91808500	NA	0.93	10.08	0.67	8.03e-18	Breast cancer;
TGCT	cis	rs13188771	0.578	rs17137390	chr5:100918526	C/T	cg05545777	chr5:101119128	NA	0.5	4.47	0.37	1.76e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs7937682	0.889	rs541198	chr11:111475340	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.06	-11.27	-0.71	1.04e-20	Primary sclerosing cholangitis;
TGCT	cis	rs9633740	0.578	rs11185951	chr10:82301536	G/C	cg01528321	chr10:82214614	TSPAN14	-0.87	-5.57	-0.45	1.51e-7	Post bronchodilator FEV1;
TGCT	cis	rs7113874	0.569	rs10769915	chr11:8597449	C/G	cg14521421	chr11:8862019	ST5	0.28	4.44	0.37	1.96e-5	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs909674	0.775	rs8138462	chr22:39839670	G/C	cg02038168	chr22:39784481	NA	-0.71	-5.56	-0.45	1.55e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	trans	rs10506458	0.834	rs55966529	chr12:63384114	A/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.46	-7.24	-0.55	4.04e-11	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs807669	0.807	rs712948	chr22:19206499	A/G	cg02655711	chr22:19163373	SLC25A1	0.41	9.45	0.65	2.75e-16	Metabolite levels;
TGCT	cis	rs13256369	0.802	rs12541520	chr8:8564146	G/T	cg06671706	chr8:8559999	CLDN23	0.34	4.53	0.38	1.38e-5	Obesity-related traits;
TGCT	cis	rs8072100	0.875	rs62073966	chr17:45600013	T/A	cg08085267	chr17:45401833	C17orf57	0.48	5.31	0.43	4.86e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs3862030	0.503	rs6584506	chr10:104254428	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
TGCT	cis	rs9303542	0.625	rs8064626	chr17:46567851	G/A	cg25032089	chr17:46643351	HOXB3	0.57	5.75	0.46	6.47e-8	Ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs7772486	0.875	rs2777476	chr6:146345024	A/G	cg05347473	chr6:146136440	FBXO30	0.53	4.98	0.41	2.11e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs694739	0.894	rs887314	chr11:64053157	T/G	cg23796481	chr11:64053134	BAD;GPR137	0.66	6.88	0.53	2.67e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs6725041	0.819	rs1521644	chr2:213091246	A/G	cg16329650	chr2:213403929	ERBB4	-0.53	-4.58	-0.38	1.12e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg18402987	chr7:1209562	NA	0.74	6.19	0.49	7.92e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg03264133	chr6:25882463	NA	-0.61	-6.51	-0.5	1.68e-9	Blood metabolite levels;
TGCT	cis	rs9581857	0.547	rs9579087	chr13:28059780	G/A	cg22138327	chr13:27999177	GTF3A	0.73	4.55	0.38	1.25e-5	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs12510870	0.599	rs7667019	chr4:74453035	C/T	cg05868023	chr4:75230803	EREG	-0.55	-4.74	-0.39	5.71e-6	Iris color (b* coordinate);
TGCT	cis	rs8016982	0.633	rs8015423	chr14:81719357	C/T	cg01989461	chr14:81687754	GTF2A1	0.76	7.5	0.56	1.08e-11	Schizophrenia;
TGCT	cis	rs13082711	0.554	rs1494422	chr3:27375190	T/C	cg02860705	chr3:27208620	NA	-0.36	-5.39	-0.44	3.43e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs1215050	0.904	rs2903153	chr4:99057457	C/T	cg05340658	chr4:99064831	C4orf37	0.42	5.03	0.41	1.65e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs11170631	0.504	rs10128880	chr12:53927783	T/C	cg16917193	chr12:54089295	NA	1.02	10.39	0.68	1.44e-18	Height;
TGCT	cis	rs6693567	0.545	rs1260385	chr1:150316385	G/A	cg09579323	chr1:150459698	TARS2	0.54	4.79	0.4	4.59e-6	Migraine;
TGCT	cis	rs11098499	0.954	rs12505469	chr4:120249585	C/T	cg09307838	chr4:120376055	NA	0.63	5.89	0.47	3.41e-8	Corneal astigmatism;
TGCT	cis	rs2204008	0.658	rs12371956	chr12:38298010	A/T	cg26384229	chr12:38710491	ALG10B	0.8	7.04	0.53	1.17e-10	Bladder cancer;
TGCT	cis	rs2201728	1.000	rs2201728	chr4:100163873	G/A	cg07219303	chr4:100140905	ADH6	-0.35	-5.2	-0.42	8.15e-7	Cardiac Troponin-T levels;
TGCT	cis	rs611744	0.967	rs613644	chr8:109188994	G/A	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs148803332	1	rs148803332	chr17:65958250	CAAAAGAAA/C	cg12091567	chr17:66097778	LOC651250	0.88	6.66	0.51	7.92e-10	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;
TGCT	cis	rs3780378	0.875	rs7032785	chr9:5042046	C/T	cg02405213	chr9:5042618	JAK2	-0.59	-7.69	-0.57	3.87e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg00738919	chr7:1100172	C7orf50	0.47	4.53	0.38	1.37e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2299587	0.554	rs3913558	chr8:17747909	T/G	cg04898035	chr8:17640624	MTUS1	-0.21	-4.7	-0.39	6.92e-6	Economic and political preferences;
TGCT	cis	rs250677	0.522	rs2895837	chr5:148357535	C/T	cg18129178	chr5:148520854	ABLIM3	0.35	4.58	0.38	1.12e-5	Breast cancer;
TGCT	cis	rs10751667	0.961	rs6597953	chr11:991099	G/A	cg06064525	chr11:970664	AP2A2	-0.3	-6.06	-0.48	1.51e-8	Alzheimer's disease (late onset);
TGCT	cis	rs12549902	0.897	rs12549294	chr8:41506380	A/G	cg21772509	chr8:41503840	NKX6-3	0.89	10.58	0.69	4.81e-19	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
TGCT	cis	rs6901250	0.851	rs339362	chr6:117165370	A/C	cg12892004	chr6:117198278	RFX6	-0.55	-6.76	-0.52	4.74e-10	C-reactive protein levels;
TGCT	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg11764359	chr7:65958608	NA	0.61	5.53	0.44	1.84e-7	Aortic root size;
TGCT	cis	rs7584330	0.736	rs6431541	chr2:238376190	A/T	cg14458575	chr2:238380390	NA	0.49	7.83	0.58	1.89e-12	Prostate cancer;
TGCT	cis	rs6089584	0.927	rs2281734	chr20:60582401	C/A	cg13665807	chr20:60559372	TAF4	-0.42	-4.52	-0.38	1.43e-5	Body mass index;
TGCT	cis	rs11209185	0.509	rs9436790	chr1:68447044	G/A	cg22082780	chr1:68452167	NA	0.31	4.7	0.39	6.73e-6	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs9296661	0.522	rs1326570	chr6:51665597	C/T	cg20180370	chr6:50691003	TFAP2D	0.46	4.55	0.38	1.27e-5	Weight loss (gastric bypass surgery);
TGCT	cis	rs1198430	0.925	rs1767148	chr1:23765472	A/G	cg19827787	chr1:23763612	ASAP3	0.44	4.71	0.39	6.55e-6	Total cholesterol levels;
TGCT	cis	rs6598955	0.671	rs12139514	chr1:26575939	G/A	cg04990556	chr1:26633338	UBXN11	0.62	4.73	0.39	6.12e-6	Obesity-related traits;
TGCT	cis	rs60843830	1.000	rs58461606	chr2:267367	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.72	7.19	0.54	5.25e-11	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs17376456	0.825	rs10052662	chr5:93271385	A/G	cg21475434	chr5:93447410	FAM172A	0.65	4.47	0.37	1.72e-5	Diabetic retinopathy;
TGCT	cis	rs10927875	0.632	rs2013745	chr1:16126676	G/A	cg21385522	chr1:16154831	NA	-0.96	-15.34	-0.81	1.96e-30	Dilated cardiomyopathy;
TGCT	cis	rs1055129	0.655	rs7223416	chr17:73836162	C/G	cg08125733	chr17:73851984	WBP2	0.56	5.09	0.42	1.28e-6	White matter hyperintensity burden;
TGCT	cis	rs7017914	0.967	rs3098867	chr8:71916871	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.57	-5.31	-0.43	4.8e-7	Bone mineral density;
TGCT	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg18230493	chr5:56204884	C5orf35	-0.68	-5.85	-0.46	4.13e-8	Initial pursuit acceleration;
TGCT	cis	rs2535633	0.588	rs2564930	chr3:53017307	T/C	cg11645453	chr3:52864694	ITIH4	-0.27	-4.96	-0.41	2.25e-6	Body mass index;
TGCT	cis	rs7017914	0.967	rs35295900	chr8:71642061	G/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.03	-0.41	1.69e-6	Bone mineral density;
TGCT	cis	rs2485376	1.000	rs3781295	chr10:104140602	G/A	cg26089160	chr10:104170217	PSD	0.48	4.52	0.38	1.44e-5	QT interval;
TGCT	cis	rs12134133	1.000	rs11584921	chr1:207441975	A/G	cg02152968	chr1:207494213	CD55	0.62	4.67	0.39	7.71e-6	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg06481639	chr22:41940642	POLR3H	-0.73	-6.64	-0.51	8.91e-10	Vitiligo;
TGCT	cis	rs2204008	0.806	rs3922574	chr12:38329069	C/T	cg26384229	chr12:38710491	ALG10B	0.83	7.27	0.55	3.51e-11	Bladder cancer;
TGCT	cis	rs2153535	0.547	rs9502720	chr6:8541362	C/A	cg07606381	chr6:8435919	SLC35B3	0.56	5.16	0.42	9.46e-7	Motion sickness;
TGCT	cis	rs2458413	0.669	rs12681140	chr8:105346112	A/C	cg23108931	chr8:105342351	NA	0.35	6.24	0.49	6.25e-9	Paget's disease;
TGCT	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.0	-7.42	-0.55	1.64e-11	Gut microbiome composition (summer);
TGCT	cis	rs910316	1.000	rs10140851	chr14:75512612	G/A	cg08847533	chr14:75593920	NEK9	0.96	10.6	0.69	4.36e-19	Height;
TGCT	cis	rs12220898	0.749	rs2377975	chr10:50481421	A/G	cg06072769	chr10:50146962	WDFY4	0.38	4.98	0.41	2.07e-6	Inflammatory biomarkers;
TGCT	cis	rs28595532	0.920	rs112097820	chr4:119746532	G/A	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs896854	0.625	rs4735335	chr8:95973327	G/C	cg16049864	chr8:95962084	TP53INP1	-0.75	-10.48	-0.69	8.55e-19	Type 2 diabetes;
TGCT	cis	rs3820068	0.581	rs72645864	chr1:15921153	C/T	cg05660106	chr1:15850417	CASP9	0.84	8.27	0.6	1.8e-13	Systolic blood pressure;
TGCT	cis	rs1580019	0.510	rs4723162	chr7:32543804	C/A	cg07520158	chr7:32535189	LSM5;AVL9	0.58	4.96	0.41	2.28e-6	Cognitive ability;
TGCT	cis	rs13191362	1.000	rs34619021	chr6:163029767	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.66	5.11	0.42	1.18e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs17125944	0.505	rs3783447	chr14:53191647	G/A	cg00686598	chr14:53173677	PSMC6	1.19	6.34	0.49	3.96e-9	Alzheimer's disease (late onset);
TGCT	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg09060608	chr5:178986726	RUFY1	-0.49	-5.53	-0.44	1.83e-7	Lung cancer;
TGCT	cis	rs10782582	0.609	rs1770889	chr1:76401166	A/G	cg22875332	chr1:76189707	ACADM	-0.45	-4.53	-0.38	1.34e-5	Daytime sleep phenotypes;
TGCT	cis	rs61990749	0.597	rs176971	chr14:78191599	T/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.67	4.73	0.39	6.09e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs2933343	0.729	rs1680794	chr3:128620390	A/G	cg11901034	chr3:128598214	ACAD9	-0.63	-6.06	-0.48	1.54e-8	IgG glycosylation;
TGCT	cis	rs11098499	0.955	rs11931312	chr4:120159023	T/C	cg24670566	chr4:120433619	PDE5A	0.23	4.45	0.37	1.89e-5	Corneal astigmatism;
TGCT	cis	rs4372836	1.000	rs11127188	chr2:28972852	G/A	cg09522027	chr2:28974177	PPP1CB	-0.58	-5.07	-0.41	1.42e-6	Body mass index;
TGCT	cis	rs12989701	0.877	rs13029812	chr2:127872622	A/G	cg08168897	chr2:127865431	BIN1	0.5	5.34	0.43	4.28e-7	Alzheimer's disease (late onset);
TGCT	cis	rs10782582	0.609	rs111914775	chr1:76319036	C/T	cg10523679	chr1:76189770	ACADM	-0.59	-5.42	-0.44	2.94e-7	Daytime sleep phenotypes;
TGCT	cis	rs17401966	1.000	rs11578788	chr1:10422958	A/G	cg19773385	chr1:10388646	KIF1B	-0.21	-4.5	-0.37	1.57e-5	Hepatocellular carcinoma;
TGCT	cis	rs1372520	0.684	rs2737010	chr4:90746466	G/A	cg01966878	chr4:90757139	SNCA	-0.3	-4.76	-0.39	5.2e-6	Neuroticism;
TGCT	trans	rs9295123	0.898	rs1382785	chr6:160573407	C/T	cg22927510	chr22:50968328	TYMP	-0.51	-6.82	-0.52	3.63e-10	Blood protein levels;
TGCT	cis	rs9486719	0.948	rs6920913	chr6:96874297	A/G	cg06623918	chr6:96969491	KIAA0776	0.98	9.49	0.65	2.2e-16	Migraine;Coronary artery disease;
TGCT	cis	rs34734847	0.965	rs2005455	chr12:121128699	A/G	cg21892295	chr12:121157589	UNC119B	-0.23	-5.49	-0.44	2.13e-7	Mean corpuscular volume;
TGCT	cis	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg25427524	chr10:38739819	LOC399744	-0.39	-8.05	-0.59	5.9e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.45	-6.01	-0.47	1.91e-8	Alzheimer's disease;
TGCT	cis	rs1975974	0.935	rs67979358	chr17:21723834	G/C	cg18423549	chr17:21743878	NA	-0.49	-4.76	-0.39	5.3e-6	Psoriasis;
TGCT	cis	rs8103278	0.860	rs11669073	chr19:46324880	C/T	cg14061069	chr19:46274453	DMPK	-0.44	-6.14	-0.48	1.04e-8	Coronary artery disease;
TGCT	trans	rs1499614	0.901	rs3936	chr7:66126489	C/T	cg07424592	chr7:64974309	NA	1.35	8.11	0.59	4.14e-13	Gout;
TGCT	cis	rs55692411	0.537	rs7648652	chr3:50135412	A/C	cg14019146	chr3:50243930	SLC38A3	-0.22	-4.6	-0.38	1.01e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs6901004	0.803	rs1022092	chr6:111427286	G/A	cg15721981	chr6:111408429	SLC16A10	-0.52	-4.53	-0.38	1.35e-5	Blood metabolite levels;
TGCT	cis	rs7201929	1.000	rs8061877	chr16:28856819	C/T	cg09754948	chr16:28834200	ATXN2L	-0.61	-4.76	-0.39	5.21e-6	QT interval;
TGCT	cis	rs3091242	0.967	rs3091240	chr1:25676935	G/T	cg10117171	chr1:25599238	RHD	-0.36	-5.85	-0.46	4.18e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2795502	0.938	rs2744085	chr10:43341976	C/T	cg20628663	chr10:43360327	NA	0.45	6.42	0.5	2.61e-9	Blood protein levels;
TGCT	cis	rs4622507	0.773	rs36054803	chr16:55054817	C/T	cg04853843	chr16:55358461	IRX6	-0.54	-4.97	-0.41	2.22e-6	Social communication problems;
TGCT	cis	rs9638182	0.667	rs13240065	chr7:73015369	G/A	cg14087351	chr7:73037990	MLXIPL	-0.68	-5.21	-0.42	7.48e-7	Triglycerides;
TGCT	cis	rs7829975	0.606	rs7819827	chr8:8797055	G/C	cg15556689	chr8:8085844	FLJ10661	-0.69	-6.14	-0.48	1.01e-8	Mood instability;
TGCT	cis	rs7666738	0.753	rs2903143	chr4:99040480	C/T	cg05340658	chr4:99064831	C4orf37	0.52	5.94	0.47	2.68e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7611238	0.583	rs4677844	chr3:195155338	C/G	cg27323046	chr3:195102265	ACAP2	0.33	4.44	0.37	1.96e-5	Body mass index;
TGCT	cis	rs11203032	0.831	rs11203009	chr10:90927163	G/A	cg16672925	chr10:90967113	CH25H	0.73	4.5	0.37	1.55e-5	Heart failure;
TGCT	cis	rs2657888	1.000	rs7310284	chr12:56935652	A/G	cg23932658	chr12:57637574	STAC3	0.54	5.03	0.41	1.67e-6	Adiponectin levels;
TGCT	cis	rs7772486	0.597	rs2246132	chr6:146182515	C/G	cg13319975	chr6:146136371	FBXO30	-0.68	-6.24	-0.49	6.44e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs12579753	0.810	rs1343934	chr12:82123112	G/A	cg07988820	chr12:82153109	PPFIA2	-0.68	-7.49	-0.56	1.1e-11	Resting heart rate;
TGCT	cis	rs17068510	0.572	rs67885938	chr8:3877995	G/C	cg25338036	chr8:3047536	CSMD1	-0.46	-4.87	-0.4	3.28e-6	Cerebrospinal fluid clusterin levels;
TGCT	cis	rs651907	0.535	rs35810977	chr3:101531380	G/A	cg12386194	chr3:101231763	SENP7	0.46	4.52	0.38	1.43e-5	Colorectal cancer;
TGCT	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg06238570	chr21:40685208	BRWD1	-0.8	-8.38	-0.6	9.46e-14	Cognitive function;
TGCT	cis	rs644799	0.710	rs519511	chr11:95538270	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	8.5	0.61	5.03e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7020830	0.825	rs66684257	chr9:37199087	G/T	cg14294708	chr9:37120828	ZCCHC7	1.17	16.59	0.83	2.84e-33	Schizophrenia;
TGCT	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg13770153	chr20:60521292	NA	-0.62	-7.76	-0.57	2.73e-12	Body mass index;
TGCT	cis	rs7833790	0.724	rs6473311	chr8:82726682	G/A	cg17211192	chr8:82754475	SNX16	-0.95	-8.83	-0.62	8.45e-15	Diastolic blood pressure;
TGCT	cis	rs826838	0.967	rs1352123	chr12:39130992	T/C	cg26384229	chr12:38710491	ALG10B	-0.86	-7.7	-0.57	3.65e-12	Heart rate;
TGCT	cis	rs4888262	0.545	rs8052923	chr16:74680105	C/T	cg01733217	chr16:74700730	RFWD3	0.76	7.58	0.56	7.1e-12	Testicular germ cell tumor;
TGCT	cis	rs7681440	0.904	rs7672979	chr4:90767873	A/G	cg20003494	chr4:90757398	SNCA	-0.62	-5.93	-0.47	2.74e-8	Dementia with Lewy bodies;
TGCT	cis	rs7429990	0.901	rs9825114	chr3:48138082	A/G	cg11946769	chr3:48343235	NME6	-0.56	-4.52	-0.38	1.42e-5	Educational attainment (years of education);
TGCT	cis	rs7949030	0.626	rs7124057	chr11:62334096	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.71	9.07	0.63	2.23e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1050631	1.000	rs1789514	chr18:33692654	T/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.51	4.99	0.41	2.03e-6	Esophageal squamous cell cancer (length of survival);
TGCT	cis	rs9473924	0.580	rs68118663	chr6:50815367	C/T	cg14470998	chr6:50812995	TFAP2B	1.35	8.5	0.61	5.05e-14	Body mass index;
TGCT	cis	rs2072499	0.898	rs2758609	chr1:156202868	G/A	cg24450063	chr1:156163899	SLC25A44	1.05	11.04	0.7	3.74e-20	Testicular germ cell tumor;
TGCT	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg26338869	chr17:61819248	STRADA	-0.52	-4.85	-0.4	3.6e-6	Prudent dietary pattern;
TGCT	cis	rs10197940	0.648	rs7587301	chr2:152347600	A/G	cg19508488	chr2:152266495	RIF1	0.59	4.99	0.41	2.03e-6	Lung cancer;
TGCT	cis	rs9814567	0.964	rs9815894	chr3:134282796	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.94	-9.18	-0.64	1.2e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs3733585	0.638	rs6449155	chr4:9956547	T/G	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.7	-0.52	6.62e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs9303401	0.592	rs12936771	chr17:56725052	T/C	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs713587	0.520	rs530951	chr2:25307005	C/T	cg01884057	chr2:25150051	NA	-0.26	-4.87	-0.4	3.36e-6	Body mass index in non-asthmatics;
TGCT	cis	rs7172809	0.573	rs59831220	chr15:77455246	A/G	cg22256960	chr15:77711686	NA	-0.48	-4.63	-0.38	9.17e-6	Glucose homeostasis traits;
TGCT	cis	rs344364	0.511	rs2982449	chr16:1947878	C/G	cg26617929	chr16:1858877	NA	-0.27	-4.9	-0.4	2.99e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs854765	0.583	rs6502619	chr17:17779704	C/G	cg09796270	chr17:17721594	SREBF1	-0.27	-5.5	-0.44	2.04e-7	Total body bone mineral density;
TGCT	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg22535103	chr8:58192502	C8orf71	-0.35	-4.69	-0.39	7.04e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg08509172	chr19:19383838	TM6SF2	-0.34	-4.52	-0.38	1.4e-5	Tonsillectomy;
TGCT	cis	rs7568458	0.846	rs6743030	chr2:85763520	C/T	cg17127132	chr2:85788382	GGCX	0.63	5.94	0.47	2.65e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs9467711	0.606	rs9379900	chr6:26603811	A/C	cg16898833	chr6:26189333	HIST1H4D	1.02	5.25	0.43	6.32e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9549367	0.713	rs9549356	chr13:113851633	A/G	cg09473364	chr13:112927190	NA	-0.3	-4.6	-0.38	1.01e-5	Platelet distribution width;
TGCT	cis	rs35883536	0.647	rs10875316	chr1:101044150	G/A	cg06223162	chr1:101003688	GPR88	-0.41	-7.55	-0.56	7.99e-12	Monocyte count;
TGCT	cis	rs896854	0.540	rs2011567	chr8:95971920	G/A	cg23172400	chr8:95962367	TP53INP1	-0.39	-6.53	-0.51	1.52e-9	Type 2 diabetes;
TGCT	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg07507251	chr3:52567010	NT5DC2	0.48	6.76	0.52	4.7e-10	Bipolar disorder;
TGCT	cis	rs1055129	0.537	rs1135640	chr17:73949540	C/G	cg08125733	chr17:73851984	WBP2	-0.55	-5.23	-0.43	6.94e-7	White matter hyperintensity burden;
TGCT	cis	rs763121	0.889	rs4820335	chr22:38935927	C/G	cg06022373	chr22:39101656	GTPBP1	-0.7	-6.82	-0.52	3.58e-10	Menopause (age at onset);
TGCT	cis	rs9486719	0.857	rs3798293	chr6:97033370	A/G	cg06623918	chr6:96969491	KIAA0776	-1.03	-9.64	-0.65	9.66e-17	Migraine;Coronary artery disease;
TGCT	cis	rs9811920	0.535	rs792835	chr3:99476295	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.39	4.6	0.38	1.04e-5	Axial length;
TGCT	cis	rs2932538	0.961	rs10745332	chr1:113189053	G/A	cg22162597	chr1:113214053	CAPZA1	-0.27	-5.98	-0.47	2.24e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs1997103	1.000	rs1997098	chr7:55405594	G/T	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs11249608	0.548	rs6601007	chr5:178455796	G/C	cg01312482	chr5:178451176	ZNF879	-0.48	-4.77	-0.39	5.15e-6	Pubertal anthropometrics;
TGCT	cis	rs854765	0.583	rs8065563	chr17:17782404	A/G	cg09796270	chr17:17721594	SREBF1	0.28	5.61	0.45	1.28e-7	Total body bone mineral density;
TGCT	cis	rs12681287	0.547	rs7459877	chr8:87505660	G/A	cg19078186	chr8:87526527	CPNE3	-0.37	-4.57	-0.38	1.15e-5	Caudate activity during reward;
TGCT	cis	rs6728642	1.000	rs60608738	chr2:97608085	G/A	cg26665480	chr2:98280029	ACTR1B	-0.91	-5.37	-0.43	3.77e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	cis	rs13191362	1.000	rs35126854	chr6:163012443	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.68	5.79	0.46	5.33e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.15	0.82	2.71e-32	Prudent dietary pattern;
TGCT	cis	rs9910055	0.615	rs189049	chr17:42197213	A/C	cg13607699	chr17:42295918	UBTF	-0.55	-5.1	-0.42	1.24e-6	Total body bone mineral density;
TGCT	cis	rs8077577	0.945	rs62073649	chr17:18080522	T/C	cg09161412	chr17:18057145	MYO15A	-0.66	-5.36	-0.43	3.94e-7	Obesity-related traits;
TGCT	cis	rs11190604	0.767	rs11190520	chr10:102175309	T/C	cg16342193	chr10:102329863	NA	-0.4	-5.06	-0.41	1.5e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	4.88	0.4	3.2e-6	Menopause (age at onset);
TGCT	cis	rs9948	0.786	rs62156226	chr2:97417108	G/A	cg01990225	chr2:97406019	LMAN2L	-0.88	-4.81	-0.4	4.37e-6	Erectile dysfunction and prostate cancer treatment;
TGCT	trans	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg21659725	chr3:3221576	CRBN	-0.7	-7.76	-0.57	2.66e-12	Body mass index;
TGCT	cis	rs2216164	1.000	rs2041864	chr12:68538489	C/T	cg17065850	chr12:67807625	NA	0.23	4.44	0.37	1.93e-5	Alopecia areata;
TGCT	cis	rs2204008	0.720	rs11181343	chr12:38323616	G/T	cg13010199	chr12:38710504	ALG10B	0.59	4.59	0.38	1.07e-5	Bladder cancer;
TGCT	cis	rs7119	0.717	rs62009069	chr15:77817877	T/G	cg27398640	chr15:77910606	LINGO1	-0.25	-4.6	-0.38	1.05e-5	Type 2 diabetes;
TGCT	cis	rs1371867	0.817	rs7846076	chr8:101327629	A/G	cg00191853	chr8:101177733	SPAG1	-0.23	-4.76	-0.39	5.2e-6	Atrioventricular conduction;
TGCT	cis	rs3091242	0.866	rs11249249	chr1:25758134	A/G	cg09222892	chr1:25734099	RHCE	-0.42	-6.74	-0.52	5.38e-10	Erythrocyte sedimentation rate;
TGCT	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg17971929	chr21:40555470	PSMG1	-0.98	-9.43	-0.65	3.07e-16	Cognitive function;
TGCT	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg22535103	chr8:58192502	C8orf71	-0.42	-4.72	-0.39	6.22e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2456568	0.508	rs1607403	chr11:93660514	A/G	cg17595323	chr11:93583763	C11orf90	-0.42	-5.26	-0.43	6.2e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs28374715	0.532	rs316606	chr15:41772202	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.93	-17.19	-0.84	1.29e-34	Ulcerative colitis;
TGCT	trans	rs10809457	0.596	rs2015995	chr9:11559202	G/A	cg07726222	chr16:2125875	TSC2	0.22	6.64	0.51	8.77e-10	Palmitic acid (16:0) levels;
TGCT	cis	rs11650494	0.808	rs76366926	chr17:47396628	T/C	cg08112188	chr17:47440006	ZNF652	1.04	5.35	0.43	4.09e-7	Prostate cancer;
TGCT	cis	rs2070488	0.930	rs2370840	chr3:38529825	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.93	9.8	0.66	3.77e-17	Electrocardiographic conduction measures;
TGCT	cis	rs4819052	0.765	rs2838827	chr21:46656146	C/T	cg06618935	chr21:46677482	NA	-0.36	-5.48	-0.44	2.23e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs5757676	0.858	rs6001585	chr22:39812986	G/T	cg11247378	chr22:39784982	NA	-0.71	-7.51	-0.56	1e-11	IgG glycosylation;
TGCT	cis	rs7772486	0.754	rs9373476	chr6:146139741	C/G	cg05347473	chr6:146136440	FBXO30	0.55	5.16	0.42	9.53e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1205863	1.000	rs1205872	chr6:11945143	T/C	cg07106625	chr6:11870215	NA	0.51	5.05	0.41	1.51e-6	Disc degeneration (lumbar);
TGCT	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg18305652	chr10:134549665	INPP5A	0.35	5.72	0.46	7.3900000000000007e-08	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs6988636	1.000	rs13260318	chr8:124190165	C/G	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.52	-4.9	-0.4	2.9e-6	Bipolar disorder;
TGCT	cis	rs317865	0.609	rs73234660	chr4:16221047	G/C	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.78	5.15	0.42	1.01e-6	Kidney disease (early stage) in type 1 diabetes;
TGCT	cis	rs3806843	0.576	rs246037	chr5:140331846	C/T	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9308731	0.966	rs4849442	chr2:111934219	C/T	cg04202892	chr2:111875749	ACOXL	0.44	4.75	0.39	5.45e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs3820068	0.603	rs17448778	chr1:15985306	A/G	cg05660106	chr1:15850417	CASP9	0.8	8.04	0.59	5.97e-13	Systolic blood pressure;
TGCT	cis	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs76419734	0.558	rs17035939	chr4:106526544	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.82	4.66	0.39	7.91e-6	Post bronchodilator FEV1;
TGCT	cis	rs6728642	0.831	rs10496325	chr2:97683329	C/T	cg26665480	chr2:98280029	ACTR1B	0.91	5.85	0.46	4.19e-8	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	cis	rs7208859	0.623	rs56018041	chr17:29059985	G/A	cg13385521	chr17:29058706	SUZ12P	0.79	4.77	0.39	5.16e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs1153858	1.000	rs1153858	chr15:45652703	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.99	-11.84	-0.73	4.26e-22	Homoarginine levels;
TGCT	trans	rs797680	0.856	rs693737	chr1:93724924	G/A	cg27528825	chr2:159282178	CCDC148	0.35	6.88	0.53	2.65e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7659604	0.605	rs1507994	chr4:122749541	C/T	cg06713675	chr4:122721982	EXOSC9	-0.62	-8.45	-0.6	6.5e-14	Type 2 diabetes;
TGCT	cis	rs12135062	0.851	rs2651926	chr1:3101820	C/T	cg25382214	chr1:3105252	PRDM16	-0.3	-5.28	-0.43	5.56e-7	Migraine;
TGCT	cis	rs9921338	0.887	rs6498183	chr16:11430908	C/T	cg00044050	chr16:11439710	C16orf75	-0.88	-6.75	-0.52	5.08e-10	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs4455778	0.500	rs10224270	chr7:49041354	T/C	cg26309511	chr7:48887640	NA	0.51	6.66	0.51	7.85e-10	Lung cancer in never smokers;
TGCT	cis	rs6582630	0.519	rs1851121	chr12:38389467	T/C	cg26384229	chr12:38710491	ALG10B	0.83	7.26	0.55	3.72e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs2046867	0.908	rs62251649	chr3:72809610	A/C	cg25664220	chr3:72788482	NA	-0.52	-6.66	-0.51	8.07e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7178572	0.568	rs12911371	chr15:77689050	C/T	cg15453836	chr15:77711506	NA	-0.42	-4.78	-0.39	4.92e-6	Type 2 diabetes;
TGCT	cis	rs12497850	0.931	rs13315711	chr3:48986399	A/T	cg18654377	chr3:49208889	KLHDC8B	-0.42	-5.41	-0.44	3.09e-7	Parkinson's disease;
TGCT	cis	rs1372520	0.684	rs3113355	chr4:90745345	A/T	cg20003494	chr4:90757398	SNCA	-0.63	-5.06	-0.41	1.48e-6	Neuroticism;
TGCT	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg22920501	chr2:26401640	FAM59B	-0.8	-6.34	-0.5	3.8e-9	Gut microbiome composition (summer);
TGCT	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg03188948	chr7:1209495	NA	0.59	4.82	0.4	4.06e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.64	7.0	0.53	1.43e-10	Blood metabolite levels;
TGCT	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg01802117	chr1:53393560	SCP2	0.43	5.12	0.42	1.14e-6	Monocyte count;
TGCT	cis	rs595982	0.527	rs73061659	chr19:49373556	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.69	-9.16	-0.64	1.35e-15	Red cell distribution width;
TGCT	cis	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg20637647	chr7:64974828	NA	0.89	4.95	0.41	2.37e-6	Diabetic kidney disease;
TGCT	cis	rs10754283	0.935	rs1934046	chr1:90119290	A/T	cg03145924	chr1:90228473	NA	0.4	4.52	0.38	1.4e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	6.75	0.52	5.02e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs1153858	0.943	rs1145079	chr15:45681761	T/C	cg26924012	chr15:45694286	SPATA5L1	0.99	12.23	0.74	4.74e-23	Homoarginine levels;
TGCT	cis	rs9633740	0.947	rs1878036	chr10:82280137	T/G	cg01528321	chr10:82214614	TSPAN14	1.01	8.15	0.59	3.39e-13	Post bronchodilator FEV1;
TGCT	cis	rs76473307	1.000	rs79375984	chr20:57399869	T/C	cg06163629	chr20:57414884	GNASAS;GNAS	-0.67	-4.58	-0.38	1.13e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs6460942	0.822	rs13340498	chr7:12233877	G/T	cg06484146	chr7:12443880	VWDE	-0.54	-4.76	-0.39	5.21e-6	Coronary artery disease;
TGCT	cis	rs1552244	0.554	rs6762702	chr3:10055789	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.33	-4.95	-0.41	2.39e-6	Alzheimer's disease;
TGCT	cis	rs7659604	0.702	rs6815790	chr4:122695385	A/C	cg06713675	chr4:122721982	EXOSC9	-0.56	-7.41	-0.55	1.72e-11	Type 2 diabetes;
TGCT	cis	rs9549367	0.713	rs11620600	chr13:113829090	G/A	cg18105134	chr13:113819100	PROZ	-0.47	-8.24	-0.59	2.05e-13	Platelet distribution width;
TGCT	cis	rs11745493	0.609	rs1392436	chr5:122835138	A/G	cg15125798	chr5:122621645	NA	-0.48	-4.5	-0.37	1.54e-5	Total body bone mineral density;
TGCT	cis	rs12142240	0.698	rs68112720	chr1:46813888	T/C	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs651907	0.557	rs13099674	chr3:101489629	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.32	-6.66	-0.51	7.93e-10	Colorectal cancer;
TGCT	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg10802521	chr3:52805072	NEK4	-0.71	-8.81	-0.62	9.29e-15	Bipolar disorder;
TGCT	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg23708337	chr7:1209742	NA	0.51	4.46	0.37	1.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1215050	0.765	rs181521	chr4:98745728	A/C	cg05340658	chr4:99064831	C4orf37	0.44	5.52	0.44	1.85e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	trans	rs4332037	0.624	rs11764337	chr7:1892309	A/G	cg25206134	chr2:45395956	NA	-0.82	-7.28	-0.55	3.4e-11	Bipolar disorder;
TGCT	cis	rs2204008	0.807	rs8186948	chr12:38325101	C/G	cg26384229	chr12:38710491	ALG10B	0.79	6.98	0.53	1.61e-10	Bladder cancer;
TGCT	cis	rs734999	0.588	rs745367	chr1:2524457	T/C	cg18854424	chr1:2615690	NA	0.5	5.78	0.46	5.64e-8	Ulcerative colitis;
TGCT	cis	rs55823223	0.503	rs9906971	chr17:73848477	A/G	cg10935138	chr17:73851978	WBP2	0.82	7.59	0.56	6.81e-12	Psoriasis;
TGCT	cis	rs1994135	0.549	rs2218650	chr12:33734783	A/G	cg06521331	chr12:34319734	NA	-0.34	-5.38	-0.43	3.62e-7	Resting heart rate;
TGCT	cis	rs6831352	0.918	rs2602895	chr4:100045840	C/T	cg12011299	chr4:100065546	ADH4	0.41	4.92	0.4	2.72e-6	Alcohol dependence;
TGCT	cis	rs7267979	0.966	rs3827014	chr20:25371559	C/T	cg16686733	chr20:25566563	NINL	-0.59	-5.87	-0.47	3.75e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9926296	0.712	rs258330	chr16:89729574	T/G	cg27121462	chr16:89883253	FANCA	-0.54	-5.01	-0.41	1.83e-6	Vitiligo;
TGCT	cis	rs2486288	0.656	rs11629859	chr15:45547121	T/G	cg14582100	chr15:45693742	SPATA5L1	-0.44	-5.02	-0.41	1.78e-6	Glomerular filtration rate;
TGCT	cis	rs1865760	0.532	rs2794719	chr6:26088890	T/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.82	7.71	0.57	3.6e-12	Height;
TGCT	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	5.8	0.46	5.19e-8	Alzheimer's disease;
TGCT	cis	rs7772486	0.790	rs2265917	chr6:146212285	A/G	cg23711669	chr6:146136114	FBXO30	0.89	10.16	0.67	5.28e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9549367	0.762	rs9549694	chr13:113870510	G/A	cg18105134	chr13:113819100	PROZ	-0.36	-6.06	-0.48	1.51e-8	Platelet distribution width;
TGCT	cis	rs7727544	0.716	rs4594848	chr5:131586598	C/A	cg21474247	chr5:131268130	NA	0.32	4.71	0.39	6.41e-6	Blood metabolite levels;
TGCT	cis	rs1865760	0.865	rs9467648	chr6:25957933	T/A	cg17042849	chr6:26104293	HIST1H4C	-0.52	-4.78	-0.39	4.88e-6	Height;
TGCT	cis	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg08975724	chr8:8085496	FLJ10661	0.53	4.74	0.39	5.88e-6	Mood instability;
TGCT	cis	rs10791323	0.604	rs2723598	chr11:133711652	G/A	cg15485101	chr11:133734466	NA	0.39	5.12	0.42	1.15e-6	Childhood ear infection;
TGCT	cis	rs6582630	0.519	rs8186881	chr12:38310285	A/G	cg26384229	chr12:38710491	ALG10B	0.82	7.23	0.54	4.32e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs514406	0.584	rs7524702	chr1:53197830	G/A	cg16325326	chr1:53192061	ZYG11B	-0.89	-13.12	-0.76	3.38e-25	Monocyte count;
TGCT	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg19748678	chr4:122722346	EXOSC9	0.89	8.94	0.63	4.53e-15	Type 2 diabetes;
TGCT	cis	rs651907	0.557	rs1031710	chr3:101463895	C/T	cg12386194	chr3:101231763	SENP7	0.48	4.63	0.38	9.23e-6	Colorectal cancer;
TGCT	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	7.12	0.54	7.55e-11	Platelet count;
TGCT	cis	rs1691799	0.867	rs1039056	chr12:66760391	C/T	cg16791601	chr12:66731901	HELB	-0.28	-6.03	-0.48	1.74e-8	White blood cell count (basophil);
TGCT	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg20573242	chr4:122745356	CCNA2	0.62	5.48	0.44	2.24e-7	Type 2 diabetes;
TGCT	cis	rs4730250	0.707	rs78472146	chr7:106967491	C/A	cg02696742	chr7:106810147	HBP1	-0.68	-5.64	-0.45	1.09e-7	Osteoarthritis;
TGCT	cis	rs6570726	0.791	rs392612	chr6:145881586	C/G	cg23711669	chr6:146136114	FBXO30	-0.89	-9.93	-0.67	1.82e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2594989	0.832	rs13325556	chr3:11566961	T/G	cg00170343	chr3:11313890	ATG7	-0.69	-5.0	-0.41	1.95e-6	Circulating chemerin levels;
TGCT	cis	rs6952808	0.771	rs10265944	chr7:1918337	C/T	cg22963979	chr7:1858916	MAD1L1	-0.37	-5.81	-0.46	5.05e-8	Bipolar disorder and schizophrenia;
TGCT	cis	rs2130392	1.000	rs873686	chr4:185638876	A/G	cg14471096	chr4:185570637	CCDC111;CASP3	-0.49	-4.48	-0.37	1.68e-5	Kawasaki disease;
TGCT	cis	rs9527	0.567	rs6584539	chr10:104879402	G/C	cg04362960	chr10:104952993	NT5C2	0.7	5.88	0.47	3.57e-8	Arsenic metabolism;
TGCT	cis	rs644799	1.000	rs534497	chr11:95562868	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	10.52	0.69	6.94e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs2708977	0.666	rs17685664	chr2:97315570	C/T	cg01950434	chr2:97203154	ARID5A	0.62	5.46	0.44	2.54e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs1406084	0.526	rs895050	chr2:154729785	A/C	cg25703346	chr2:154729189	GALNT13	0.89	4.68	0.39	7.28e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9914988	0.943	rs11658884	chr17:27132742	A/G	cg20469991	chr17:27169893	C17orf63	0.72	5.09	0.42	1.28e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs7655441	0.750	rs11561687	chr4:80909951	A/C	cg02241357	chr4:80885279	ANTXR2	-0.23	-4.52	-0.38	1.45e-5	Neutrophil percentage of white cells;
TGCT	cis	rs941873	0.772	rs7920127	chr10:81122914	T/C	cg09469691	chr10:81107165	PPIF	0.54	5.38	0.43	3.64e-7	Height;
TGCT	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg00080972	chr5:178986291	RUFY1	-0.57	-7.17	-0.54	5.98e-11	Lung cancer;
TGCT	cis	rs3771570	0.901	rs62190407	chr2:242405772	G/A	cg21155796	chr2:242212141	HDLBP	0.89	6.82	0.52	3.55e-10	Prostate cancer;
TGCT	cis	rs7043114	0.525	rs6479417	chr9:95064562	G/C	cg14311495	chr9:95764742	FGD3	-0.22	-4.44	-0.37	1.95e-5	Height;
TGCT	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg21433313	chr16:3507492	NAT15	0.38	5.06	0.41	1.5e-6	Tuberculosis;
TGCT	cis	rs6570726	0.791	rs4335004	chr6:145904764	G/A	cg05347473	chr6:146136440	FBXO30	0.54	5.12	0.42	1.14e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7940866	0.903	rs2324316	chr11:130872353	G/T	cg12179176	chr11:130786555	SNX19	0.56	5.27	0.43	5.82e-7	Schizophrenia;
TGCT	cis	rs9560113	1.000	rs4773383	chr13:112177764	C/T	cg14154082	chr13:112174009	NA	0.37	5.07	0.41	1.42e-6	Menarche (age at onset);
TGCT	trans	rs7819412	0.775	rs34094119	chr8:10935898	A/G	cg15556689	chr8:8085844	FLJ10661	-0.84	-8.16	-0.59	3.12e-13	Triglycerides;
TGCT	cis	rs4285028	0.747	rs12496318	chr3:121561500	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.97	7.59	0.56	6.59e-12	Multiple sclerosis;
TGCT	cis	rs12762955	0.608	rs7922760	chr10:1156815	G/C	cg26597838	chr10:835615	NA	-0.41	-5.08	-0.42	1.34e-6	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg12570787	chr5:219185	SDHA;CCDC127	0.65	4.46	0.37	1.83e-5	Breast cancer;
TGCT	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg03188948	chr7:1209495	NA	0.77	6.26	0.49	5.77e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs6121246	0.567	rs6087700	chr20:30217560	A/G	cg13852791	chr20:30311386	BCL2L1	0.7	4.58	0.38	1.1e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs926938	0.618	rs904292	chr1:115358421	C/T	cg12756093	chr1:115239321	AMPD1	0.42	5.97	0.47	2.28e-8	Autism;
TGCT	cis	rs2084881	0.521	rs1022088	chr17:46579790	T/A	cg25032089	chr17:46643351	HOXB3	-0.38	-4.46	-0.37	1.83e-5	Ovarian cancer;
TGCT	cis	rs909674	0.662	rs2899318	chr22:39837625	A/G	cg24399712	chr22:39784796	NA	-1.05	-10.84	-0.7	1.14e-19	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	trans	rs8073060	0.586	rs4796104	chr17:34046832	T/C	cg19694781	chr19:47549865	TMEM160	0.6	13.37	0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs7937612	1.000	rs2305008	chr11:120319064	A/C	cg24566217	chr11:120254723	ARHGEF12	-0.29	-4.68	-0.39	7.39e-6	Intraocular pressure;
TGCT	cis	rs9486719	1.000	rs11152959	chr6:96900272	C/T	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.21	-0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs6964587	1.000	rs2299240	chr7:91654618	A/G	cg17063962	chr7:91808500	NA	0.92	10.17	0.67	4.92e-18	Breast cancer;
TGCT	cis	rs3733585	0.637	rs6850684	chr4:9964380	G/T	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.54	-0.56	8.83e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg08280861	chr8:58055591	NA	0.49	5.26	0.43	6.19e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs208520	0.526	rs6455072	chr6:66797215	A/G	cg07460842	chr6:66804631	NA	-1.08	-15.99	-0.82	6.47e-32	Exhaled nitric oxide output;
TGCT	cis	rs62103177	0.564	rs1715230	chr18:77848002	C/T	cg07235805	chr18:78004237	PARD6G	0.52	5.12	0.42	1.13e-6	Opioid sensitivity;
TGCT	cis	rs9649213	0.614	rs2240348	chr7:97984077	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.93	-8.76	-0.62	1.24e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg12963246	chr6:28129442	ZNF389	0.52	5.01	0.41	1.85e-6	Parkinson's disease;
TGCT	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg27286337	chr10:134555280	INPP5A	0.45	5.3	0.43	5.05e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs4851254	0.660	rs74340261	chr2:100696827	C/T	cg22139774	chr2:100720529	AFF3	-0.43	-4.76	-0.39	5.4e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs344364	0.511	rs1742462	chr16:1946062	A/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.45	-5.08	-0.42	1.35e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs7524258	0.868	rs2157499	chr1:7271472	C/T	cg07173049	chr1:7289937	CAMTA1	0.29	4.74	0.39	5.74e-6	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	trans	rs3774749	0.565	rs2518795	chr3:50208819	C/T	cg21659725	chr3:3221576	CRBN	0.66	6.99	0.53	1.48e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs9926296	0.586	rs1800359	chr16:89805261	A/G	cg03388025	chr16:89894329	SPIRE2	0.33	4.84	0.4	3.83e-6	Vitiligo;
TGCT	cis	rs11190604	1.000	rs9420785	chr10:102240451	C/G	cg23241863	chr10:102295624	HIF1AN	0.64	5.04	0.41	1.59e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7829975	0.902	rs485107	chr8:8581408	C/G	cg15556689	chr8:8085844	FLJ10661	-0.66	-5.77	-0.46	6.03e-8	Mood instability;
TGCT	cis	rs2933343	1.000	rs789213	chr3:128616359	C/G	cg11901034	chr3:128598214	ACAD9	0.65	5.45	0.44	2.59e-7	IgG glycosylation;
TGCT	cis	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg20637647	chr7:64974828	NA	-0.88	-4.89	-0.4	3.06e-6	Diabetic kidney disease;
TGCT	cis	rs2147959	0.883	rs7529055	chr1:228636824	T/G	cg22700015	chr1:228743131	NA	-0.57	-4.5	-0.37	1.55e-5	Adult asthma;
TGCT	cis	rs1371867	0.875	rs1788184	chr8:101335106	A/G	cg00191853	chr8:101177733	SPAG1	-0.23	-4.76	-0.39	5.2e-6	Atrioventricular conduction;
TGCT	cis	rs3091242	0.933	rs35403885	chr1:25784551	G/A	cg09222892	chr1:25734099	RHCE	0.42	7.15	0.54	6.72e-11	Erythrocyte sedimentation rate;
TGCT	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg21280719	chr6:42927975	GNMT	-0.37	-4.59	-0.38	1.07e-5	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs2153535	0.623	rs6597338	chr6:8533508	A/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.55e-8	Motion sickness;
TGCT	cis	rs3772130	0.560	rs7649585	chr3:121562300	G/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.6	5.54	0.45	1.76e-7	Cognitive performance;
TGCT	cis	rs8063761	0.589	rs4238833	chr16:90050689	G/T	cg08547343	chr16:90038815	CENPBD1;AFG3L1	0.68	6.71	0.52	6.1e-10	Squamous cell carcinoma;
TGCT	cis	rs71435601	0.628	rs1367119	chr2:21386375	A/G	cg25035485	chr2:21266500	APOB	0.51	4.48	0.37	1.64e-5	Cholesterol, total;
TGCT	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg10047753	chr17:41438598	NA	0.77	7.44	0.56	1.43e-11	Menopause (age at onset);
TGCT	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg08439880	chr3:133502540	NA	-0.31	-5.88	-0.47	3.57e-8	Iron status biomarkers;
TGCT	cis	rs7937682	0.814	rs1619652	chr11:111469757	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.02	-10.37	-0.68	1.58e-18	Primary sclerosing cholangitis;
TGCT	cis	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg22857025	chr5:266934	NA	-0.34	-6.7	-0.52	6.65e-10	Breast cancer;
TGCT	cis	rs1056107	0.572	rs10981396	chr9:115170273	G/T	cg02332936	chr9:115140584	NA	0.26	4.44	0.37	1.95e-5	Colorectal cancer;
TGCT	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg01802117	chr1:53393560	SCP2	-0.42	-5.06	-0.41	1.44e-6	Monocyte count;
TGCT	cis	rs55882075	0.634	rs11249657	chr5:179111637	G/C	cg14593053	chr5:179126677	CANX	0.46	4.49	0.37	1.63e-5	Monocyte percentage of white cells;
TGCT	cis	rs8177179	0.967	rs4994581	chr3:133437563	T/C	cg24879335	chr3:133465180	TF	0.35	4.73	0.39	5.96e-6	Iron status biomarkers (transferrin levels);
TGCT	cis	rs28374715	0.532	rs28703570	chr15:41679492	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.94	-16.61	-0.83	2.59e-33	Ulcerative colitis;
TGCT	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg20887711	chr4:1340912	KIAA1530	0.57	4.94	0.41	2.48e-6	Longevity;
TGCT	cis	rs595982	0.501	rs112370206	chr19:49396623	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.41	-5.3	-0.43	5.08e-7	Red cell distribution width;
TGCT	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg24846343	chr22:24311635	DDTL	0.23	5.67	0.45	9.48e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	trans	rs4650994	0.816	rs2761470	chr1:178596033	G/C	cg05059571	chr16:84539110	KIAA1609	0.41	7.51	0.56	1e-11	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs7647973	0.626	rs9870858	chr3:49769071	C/T	cg03060546	chr3:49711283	APEH	0.63	5.63	0.45	1.12e-7	Menarche (age at onset);
TGCT	cis	rs7432375	0.610	rs4420814	chr3:136513282	T/C	cg15507776	chr3:136538369	TMEM22	0.55	5.64	0.45	1.1e-7	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2692947	0.537	rs11164049	chr2:96345518	C/T	cg22654517	chr2:96458247	NA	0.2	4.45	0.37	1.9e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs6988636	0.710	rs62521805	chr8:124159200	C/T	cg23067535	chr8:124195133	FAM83A	-0.35	-4.71	-0.39	6.44e-6	Urinary uromodulin levels;
TGCT	cis	rs72945132	0.882	rs57810426	chr11:70230030	G/A	cg00319359	chr11:70116639	PPFIA1	1.04	7.94	0.58	1.03e-12	Coronary artery disease;
TGCT	cis	rs10791097	0.690	rs12286234	chr11:130730528	T/C	cg05962950	chr11:130786565	SNX19	0.8	9.66	0.66	8.34e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg06481639	chr22:41940642	POLR3H	-0.72	-6.29	-0.49	4.98e-9	Vitiligo;
TGCT	cis	rs17384381	1.000	rs12140170	chr1:85849723	G/A	cg16011679	chr1:85725395	C1orf52	0.85	6.61	0.51	1.02e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6089584	0.830	rs4925331	chr20:60580174	T/C	cg16423285	chr20:60520624	NA	-0.62	-6.86	-0.52	2.86e-10	Body mass index;
TGCT	cis	rs3820068	0.734	rs6674806	chr1:15902656	A/G	cg05660106	chr1:15850417	CASP9	1.16	14.57	0.79	1.25e-28	Systolic blood pressure;
TGCT	cis	rs9611565	0.580	rs5758449	chr22:42140160	C/T	cg06634786	chr22:41940651	POLR3H	0.79	7.29	0.55	3.13e-11	Vitiligo;
TGCT	trans	rs3790455	0.610	rs3790458	chr1:156459699	A/T	cg16443977	chr5:115884994	SEMA6A	0.41	7.18	0.54	5.72e-11	Migraine;
TGCT	cis	rs9993613	1.000	rs2366302	chr4:73450550	T/C	cg15102770	chr4:73434591	ADAMTS3	-0.5	-4.58	-0.38	1.09e-5	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs711245	0.670	rs7560321	chr2:36822318	C/G	cg09467607	chr2:36825704	FEZ2	-0.36	-5.56	-0.45	1.58e-7	Height;
TGCT	cis	rs16958440	0.867	rs80106524	chr18:44676639	G/A	cg17192377	chr18:44677553	HDHD2	0.61	4.85	0.4	3.65e-6	Sitting height ratio;
TGCT	cis	rs13217239	0.646	rs12527111	chr6:27006475	C/T	cg15659132	chr6:26577336	NA	0.54	5.44	0.44	2.78e-7	Schizophrenia;
TGCT	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg11644478	chr21:40555479	PSMG1	0.98	10.28	0.68	2.68e-18	Cognitive function;
TGCT	cis	rs9462846	0.691	rs67059212	chr6:42913269	T/G	cg02353165	chr6:42928485	GNMT	0.73	5.66	0.45	1e-7	Blood protein levels;
TGCT	cis	rs651907	0.557	rs11712748	chr3:101383562	G/A	cg12386194	chr3:101231763	SENP7	0.51	5.04	0.41	1.61e-6	Colorectal cancer;
TGCT	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg21724239	chr8:58056113	NA	0.48	5.12	0.42	1.11e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4851266	0.966	rs11689199	chr2:100820421	A/G	cg22139774	chr2:100720529	AFF3	-0.36	-5.36	-0.43	3.91e-7	Educational attainment;
TGCT	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg03303774	chr4:1407052	NA	0.31	4.93	0.4	2.58e-6	Obesity-related traits;
TGCT	cis	rs9653442	0.564	rs4851256	chr2:100775045	A/G	cg07810366	chr2:100720526	AFF3	-0.34	-5.13	-0.42	1.09e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs2354432	0.607	rs4314933	chr1:146821386	T/C	cg25205988	chr1:146714368	CHD1L	1.32	6.18	0.49	8.5e-9	Mitochondrial DNA levels;
TGCT	cis	rs8072100	0.688	rs12602134	chr17:45582136	C/G	cg08085267	chr17:45401833	C17orf57	0.46	4.99	0.41	2.01e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs3812831	0.654	rs6560933	chr13:114937294	A/G	cg08824895	chr13:115047677	UPF3A	-0.47	-4.88	-0.4	3.18e-6	Schizophrenia;
TGCT	cis	rs9650657	0.571	rs11783247	chr8:10788875	C/T	cg27411982	chr8:10470053	RP1L1	-0.23	-4.82	-0.4	4.08e-6	Neuroticism;
TGCT	cis	rs9650657	0.648	rs6601512	chr8:10585596	G/A	cg16664915	chr8:10907788	XKR6	-0.3	-4.61	-0.38	9.67e-6	Neuroticism;
TGCT	cis	rs9326248	0.953	rs488962	chr11:117072525	C/T	cg26566898	chr11:117069891	TAGLN	-0.36	-5.01	-0.41	1.8e-6	Blood protein levels;
TGCT	cis	rs1801251	0.778	rs709933	chr2:233733144	G/A	cg08000102	chr2:233561755	GIGYF2	-0.44	-4.53	-0.38	1.39e-5	Coronary artery disease;
TGCT	cis	rs7582180	0.764	rs13001423	chr2:100925340	A/G	cg08017756	chr2:100939284	LONRF2	-0.32	-5.31	-0.43	4.86e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2456568	0.709	rs7942444	chr11:93637160	G/A	cg26875233	chr11:93583750	C11orf90	0.45	5.66	0.45	9.87e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg00343986	chr7:65444356	GUSB	0.25	5.81	0.46	4.88e-8	Aortic root size;
TGCT	cis	rs77861329	1.000	rs183029	chr3:52209884	A/G	cg08692210	chr3:52188851	WDR51A	0.97	5.08	0.42	1.34e-6	Macrophage inflammatory protein 1b levels;
TGCT	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.93	-5.43	-0.44	2.89e-7	Alzheimer's disease;
TGCT	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg06618935	chr21:46677482	NA	-0.37	-5.81	-0.46	5.06e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2204008	0.747	rs11514040	chr12:38201040	G/A	cg13010199	chr12:38710504	ALG10B	0.65	5.14	0.42	1.03e-6	Bladder cancer;
TGCT	cis	rs67311347	0.956	rs7640228	chr3:40516190	G/A	cg13683864	chr3:40499215	RPL14	1.18	13.19	0.76	2.28e-25	Renal cell carcinoma;
TGCT	cis	rs526231	0.783	rs28158	chr5:102595892	C/G	cg05225461	chr5:102596755	C5orf30	0.22	4.49	0.37	1.64e-5	Primary biliary cholangitis;
TGCT	cis	rs6490294	0.583	rs1005902	chr12:112667675	G/T	cg10833066	chr12:111807467	FAM109A	-0.34	-5.22	-0.42	7.39e-7	Mean platelet volume;
TGCT	cis	rs854765	0.964	rs854764	chr17:18011750	A/G	cg09796270	chr17:17721594	SREBF1	-0.27	-5.53	-0.45	1.78e-7	Total body bone mineral density;
TGCT	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.65	-6.6	-0.51	1.05e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs137603	0.602	rs9611146	chr22:39718120	G/T	cg01093212	chr22:39715156	SNORD43;RPL3	-0.5	-4.7	-0.39	6.73e-6	Primary biliary cholangitis;
TGCT	cis	rs2153535	0.580	rs1577468	chr6:8444266	C/A	cg07606381	chr6:8435919	SLC35B3	0.57	5.25	0.43	6.46e-7	Motion sickness;
TGCT	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg11062466	chr8:58055876	NA	0.38	4.5	0.37	1.56e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs4930561	0.714	rs10896300	chr11:67953772	C/T	cg04465784	chr11:67976953	SUV420H1	0.4	5.53	0.44	1.79e-7	Breast cancer in childhood cancer survivors;IgG glycosylation;
TGCT	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	0.69	6.98	0.53	1.61e-10	Prostate cancer;
TGCT	cis	rs7666738	0.830	rs13133619	chr4:99067312	C/G	cg05340658	chr4:99064831	C4orf37	-0.53	-5.98	-0.47	2.23e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2072499	0.750	rs72708291	chr1:156177285	A/T	cg25208724	chr1:156163844	SLC25A44	0.98	8.96	0.63	4e-15	Testicular germ cell tumor;
TGCT	cis	rs11209185	0.509	rs9326078	chr1:68452388	A/G	cg22082780	chr1:68452167	NA	0.32	5.07	0.41	1.39e-6	Itch intensity from mosquito bite adjusted by bite size;
TGCT	trans	rs28735056	0.904	rs12953738	chr18:77627877	A/G	cg05926928	chr17:57297772	GDPD1	0.65	6.74	0.52	5.44e-10	Schizophrenia;
TGCT	cis	rs6964587	0.692	rs10236483	chr7:91797296	A/C	cg17063962	chr7:91808500	NA	0.74	6.94	0.53	1.93e-10	Breast cancer;
TGCT	cis	rs950169	0.580	rs11635597	chr15:85165699	C/T	cg12863693	chr15:85201151	NMB	0.44	5.25	0.43	6.32e-7	Schizophrenia;
TGCT	cis	rs9527	0.590	rs2148200	chr10:104879847	C/A	cg04362960	chr10:104952993	NT5C2	0.7	5.88	0.47	3.57e-8	Arsenic metabolism;
TGCT	cis	rs9733	0.596	rs72702585	chr1:150696427	G/A	cg04414720	chr1:150670196	GOLPH3L	0.37	4.91	0.4	2.76e-6	Tonsillectomy;
TGCT	cis	rs3087591	0.920	rs7225014	chr17:29572973	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.47	-7.26	-0.55	3.82e-11	Hip circumference;
TGCT	cis	rs9549367	0.789	rs9577218	chr13:113894911	A/G	cg00898013	chr13:113819073	PROZ	-0.43	-5.55	-0.45	1.68e-7	Platelet distribution width;
TGCT	cis	rs308403	0.568	rs13135778	chr4:123664446	G/A	cg10495464	chr4:123653540	BBS12;LOC729338	0.7	6.51	0.5	1.66e-9	Blood protein levels;
TGCT	cis	rs909674	0.690	rs5750823	chr22:39829973	C/T	cg02038168	chr22:39784481	NA	-0.74	-5.67	-0.45	9.63e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs2455799	0.613	rs4467435	chr3:15791671	A/G	cg16303742	chr3:15540471	COLQ	-0.25	-4.88	-0.4	3.18e-6	Mean platelet volume;
TGCT	cis	rs1801251	1.000	rs283474	chr2:233654627	A/G	cg08000102	chr2:233561755	GIGYF2	0.64	6.38	0.5	3.2e-9	Coronary artery disease;
TGCT	cis	rs210152	0.531	rs4713634	chr6:33514708	T/C	cg16739976	chr6:34101401	GRM4	-0.63	-5.2	-0.42	8e-7	Schizophrenia;
TGCT	cis	rs79349575	0.721	rs2291725	chr17:47039132	T/C	cg07967210	chr17:47022446	SNF8	0.45	6.15	0.48	9.7e-9	Type 2 diabetes;
TGCT	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg10047753	chr17:41438598	NA	0.81	6.37	0.5	3.42e-9	Menopause (age at onset);
TGCT	cis	rs6500596	0.570	rs8055628	chr16:4447477	G/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.39	4.93	0.41	2.55e-6	Schizophrenia;
TGCT	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg23708337	chr7:1209742	NA	0.64	5.94	0.47	2.63e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9929218	0.954	rs12928043	chr16:68828885	G/A	cg03880890	chr16:69439245	NA	-0.23	-4.62	-0.38	9.31e-6	Colorectal cancer;
TGCT	cis	rs2032447	0.677	rs199737	chr6:25933538	A/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.86	8.27	0.6	1.72e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs12477438	0.715	rs7586608	chr2:99558017	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-4.51	-0.38	1.46e-5	Chronic sinus infection;
TGCT	cis	rs7845219	0.525	rs3019175	chr8:95949013	G/A	cg09323728	chr8:95962352	TP53INP1	-0.4	-4.56	-0.38	1.23e-5	Type 2 diabetes;
TGCT	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs12368653	0.534	rs923828	chr12:58015494	G/A	cg12615879	chr12:58013172	SLC26A10	0.6	6.78	0.52	4.26e-10	Multiple sclerosis;
TGCT	cis	rs11874712	1.000	rs11874712	chr18:43688576	C/A	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	5.09	0.42	1.29e-6	Migraine - clinic-based;
TGCT	cis	rs9436747	0.567	rs10889564	chr1:66053488	C/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.53	4.68	0.39	7.45e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.96	7.8	0.57	2.16e-12	Platelet count;
TGCT	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg15691649	chr6:25882328	NA	0.33	4.44	0.37	1.99e-5	Blood metabolite levels;
TGCT	cis	rs4242434	0.536	rs1871900	chr8:22481449	A/G	cg03733263	chr8:22462867	KIAA1967	0.91	11.75	0.73	6.81e-22	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs7666738	0.830	rs7659593	chr4:98934823	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9486719	0.947	rs2472908	chr6:96875998	A/T	cg18709589	chr6:96969512	KIAA0776	0.71	5.2	0.42	8.13e-7	Migraine;Coronary artery disease;
TGCT	trans	rs916888	0.647	rs199524	chr17:44848438	G/T	cg22968622	chr17:43663579	NA	-1.05	-10.06	-0.67	8.89e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs16921914	0.565	rs286650	chr11:31230207	T/C	cg26647111	chr11:31128758	NA	-0.34	-4.73	-0.39	5.88e-6	Bone mineral density (spine);
TGCT	cis	rs7635838	0.892	rs7644968	chr3:11489493	C/T	cg00170343	chr3:11313890	ATG7	0.64	6.08	0.48	1.38e-8	HDL cholesterol;
TGCT	cis	rs7020830	0.858	rs7856690	chr9:37127545	A/T	cg14294708	chr9:37120828	ZCCHC7	1.17	16.08	0.82	3.91e-32	Schizophrenia;
TGCT	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg02725872	chr8:58115012	NA	-0.4	-4.85	-0.4	3.61e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs57590327	0.555	rs3772909	chr3:81707264	T/C	cg07356753	chr3:81810745	GBE1	-0.78	-7.07	-0.54	1.01e-10	Extraversion;
TGCT	cis	rs7772486	0.720	rs4896837	chr6:146014168	C/T	cg23711669	chr6:146136114	FBXO30	-0.93	-10.83	-0.7	1.24e-19	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.86	9.38	0.64	3.95e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs9638182	0.725	rs75229905	chr7:72895946	T/C	cg14087351	chr7:73037990	MLXIPL	-0.61	-4.81	-0.4	4.34e-6	Triglycerides;
TGCT	cis	rs9296092	0.517	rs113111213	chr6:33520790	A/G	cg13560919	chr6:33536144	NA	-0.21	-4.75	-0.39	5.5e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg07061783	chr6:25882402	NA	-0.58	-5.62	-0.45	1.21e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs4706831	0.647	rs9350847	chr6:80889017	C/T	cg08355045	chr6:80787529	NA	0.29	5.03	0.41	1.66e-6	Joint mobility (Beighton score);
TGCT	cis	rs1865760	0.566	rs9358902	chr6:26058570	C/G	cg17042849	chr6:26104293	HIST1H4C	-0.62	-5.41	-0.44	3.18e-7	Height;
TGCT	cis	rs9527	0.551	rs28606370	chr10:104670832	C/A	cg15744005	chr10:104629667	AS3MT	-0.43	-5.38	-0.44	3.54e-7	Arsenic metabolism;
TGCT	cis	rs72843506	0.591	rs117720402	chr17:20347611	C/T	cg18979559	chr17:20280153	CCDC144C	-0.65	-4.78	-0.39	4.96e-6	Schizophrenia;
TGCT	cis	rs1729951	0.575	rs16844326	chr3:136678385	G/C	cg21827317	chr3:136751795	NA	0.4	5.61	0.45	1.28e-7	Neuroticism;
TGCT	cis	rs9682041	0.688	rs7621787	chr3:170146862	T/A	cg11886554	chr3:170076028	SKIL	0.95	6.87	0.52	2.8e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg19010396	chr19:19431384	KIAA0892;SF4	-0.54	-4.54	-0.38	1.3e-5	Tonsillectomy;
TGCT	cis	rs17253792	0.822	rs78820104	chr14:56068854	C/T	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs6815814	0.861	rs10012017	chr4:38784633	G/T	cg02016764	chr4:38805732	TLR1	-0.27	-4.46	-0.37	1.78e-5	Breast cancer;
TGCT	cis	rs3862260	0.509	rs2281493	chr1:120162787	T/C	cg16322792	chr1:120165303	ZNF697	0.35	8.36	0.6	1.07e-13	Systemic lupus erythematosus;
TGCT	cis	rs57590327	0.503	rs6776737	chr3:81513729	T/C	cg07356753	chr3:81810745	GBE1	0.58	4.89	0.4	3.06e-6	Extraversion;
TGCT	cis	rs651907	0.535	rs11714444	chr3:101513682	G/A	cg12386194	chr3:101231763	SENP7	0.48	4.81	0.4	4.36e-6	Colorectal cancer;
TGCT	cis	rs9291683	0.632	rs7679916	chr4:10042160	C/T	cg00071950	chr4:10020882	SLC2A9	0.68	8.74	0.62	1.38e-14	Bone mineral density;
TGCT	cis	rs7772486	0.754	rs4896832	chr6:145964151	G/A	cg23711669	chr6:146136114	FBXO30	0.88	9.78	0.66	4.39e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg06481639	chr22:41940642	POLR3H	0.72	6.4	0.5	2.96e-9	Vitiligo;
TGCT	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg00149659	chr3:10157352	C3orf10	1.18	7.44	0.56	1.44e-11	Alzheimer's disease;
TGCT	cis	rs950169	0.922	rs11633534	chr15:85124642	C/T	cg11189052	chr15:85197271	WDR73	0.78	6.44	0.5	2.42e-9	Schizophrenia;
TGCT	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg20607798	chr8:58055168	NA	0.62	5.19	0.42	8.32e-7	Developmental language disorder (linguistic errors);
TGCT	trans	rs561341	0.825	rs2008368	chr17:30347397	T/C	cg20587970	chr11:113659929	NA	-1.06	-13.47	-0.77	4.88e-26	Hip circumference adjusted for BMI;
TGCT	cis	rs28595532	0.841	rs56388366	chr4:119769242	A/G	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg22891161	chr3:195456627	MUC20	-0.21	-4.65	-0.39	8.3e-6	Pancreatic cancer;
TGCT	cis	rs854765	0.583	rs4925126	chr17:17798633	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	7.53	0.56	9.12e-12	Total body bone mineral density;
TGCT	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg18538332	chr22:24372958	LOC391322	0.87	10.04	0.67	1.04e-17	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7542091	0.506	rs992976	chr1:210066658	A/T	cg21951975	chr1:209979733	IRF6	-0.53	-5.24	-0.43	6.58e-7	Monobrow;
TGCT	cis	rs2404602	0.655	rs34748201	chr15:77221530	G/T	cg26408565	chr15:76604113	ETFA	-0.37	-4.63	-0.38	9.04e-6	Blood metabolite levels;
TGCT	cis	rs11741688	0.557	rs6600994	chr5:178336005	T/A	cg09339527	chr5:178322752	ZFP2	-0.29	-4.85	-0.4	3.57e-6	Sleep duration;
TGCT	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg11235426	chr6:292522	DUSP22	-0.69	-6.94	-0.53	1.93e-10	Menopause (age at onset);
TGCT	cis	rs7945705	0.747	rs1980429	chr11:9010474	C/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.44	-4.78	-0.39	4.95e-6	Hemoglobin concentration;
TGCT	cis	rs6912958	0.781	rs6940150	chr6:88287114	T/C	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.91	-0.4	2.78e-6	Monocyte percentage of white cells;
TGCT	cis	rs734999	0.588	rs3748817	chr1:2525665	T/C	cg18854424	chr1:2615690	NA	0.5	5.78	0.46	5.64e-8	Ulcerative colitis;
TGCT	cis	rs4699052	0.963	rs11097801	chr4:104150323	A/G	cg16532752	chr4:104119610	CENPE	-0.59	-5.58	-0.45	1.41e-7	Testicular germ cell tumor;
TGCT	cis	rs7010267	0.687	rs13264791	chr8:120013090	A/G	cg17171407	chr8:119960777	TNFRSF11B	0.29	5.4	0.44	3.25e-7	Total body bone mineral density (age 45-60);
TGCT	cis	rs9796	0.561	rs7173086	chr15:41509288	A/T	cg18705301	chr15:41695430	NDUFAF1	-0.5	-6.78	-0.52	4.32e-10	Menopause (age at onset);
TGCT	cis	rs6089584	0.861	rs2180302	chr20:60576369	A/G	cg23262073	chr20:60523788	NA	-0.31	-4.63	-0.38	8.99e-6	Body mass index;
TGCT	cis	rs9611565	0.694	rs5758389	chr22:41941749	T/C	cg13695892	chr22:41940480	POLR3H	-0.86	-9.05	-0.63	2.46e-15	Vitiligo;
TGCT	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg24675658	chr1:53192096	ZYG11B	0.7	7.98	0.58	8.59e-13	Monocyte count;
TGCT	cis	rs10540	1.000	rs35874808	chr11:506442	G/T	cg03934478	chr11:495069	RNH1	0.35	5.77	0.46	6.03e-8	Body mass index;
TGCT	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg25036284	chr2:26402008	FAM59B	-0.61	-4.9	-0.4	2.92e-6	Gut microbiome composition (summer);
TGCT	cis	rs8103278	0.507	rs3745802	chr19:46271177	G/T	cg14061069	chr19:46274453	DMPK	0.62	10.71	0.69	2.44e-19	Coronary artery disease;
TGCT	cis	rs9291683	0.546	rs13146686	chr4:10034933	A/G	cg00071950	chr4:10020882	SLC2A9	0.58	6.08	0.48	1.39e-8	Bone mineral density;
TGCT	cis	rs4654899	0.571	rs1888759	chr1:21065167	G/A	cg01072550	chr1:21505969	NA	-0.52	-8.59	-0.61	3.04e-14	Superior frontal gyrus grey matter volume;
TGCT	cis	rs7552404	1.000	rs6593585	chr1:76140273	G/A	cg10523679	chr1:76189770	ACADM	0.91	9.92	0.67	2.01e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7662987	0.517	rs2602865	chr4:100034841	T/C	cg12011299	chr4:100065546	ADH4	0.39	4.81	0.4	4.36e-6	Smoking initiation;
TGCT	cis	rs3125734	0.633	rs3902162	chr10:64041817	C/T	cg19640130	chr10:64028056	RTKN2	-0.38	-4.82	-0.4	4.15e-6	Rheumatoid arthritis;
TGCT	cis	rs7178572	0.568	rs1823100	chr15:77402744	C/T	cg22256960	chr15:77711686	NA	-0.86	-8.84	-0.62	8.05e-15	Type 2 diabetes;
TGCT	cis	rs9611565	0.512	rs768414	chr22:42135751	T/C	cg13695892	chr22:41940480	POLR3H	0.89	8.43	0.6	7.37e-14	Vitiligo;
TGCT	cis	rs12477438	0.735	rs12474477	chr2:99690408	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-8.47	-0.61	5.8e-14	Chronic sinus infection;
TGCT	cis	rs921968	0.541	rs12619347	chr2:219419935	T/C	cg02176678	chr2:219576539	TTLL4	-0.49	-6.94	-0.53	1.95e-10	Mean corpuscular hemoglobin concentration;
TGCT	trans	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg27523141	chr10:43048294	ZNF37B	0.73	8.5	0.61	5.19e-14	Extrinsic epigenetic age acceleration;
TGCT	trans	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.88	-9.5	-0.65	2.02e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg06618935	chr21:46677482	NA	-0.37	-5.81	-0.46	5.06e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg23172400	chr8:95962367	TP53INP1	-0.4	-6.65	-0.51	8.46e-10	Type 2 diabetes;
TGCT	cis	rs7582180	0.590	rs11123828	chr2:100960918	T/G	cg08017756	chr2:100939284	LONRF2	-0.3	-4.86	-0.4	3.52e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2721195	0.719	rs4925812	chr8:145808035	C/T	cg15320075	chr8:145703422	NA	0.75	7.27	0.55	3.62e-11	Age at first birth;
TGCT	cis	rs7666738	0.791	rs10856933	chr4:98958542	C/A	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6714710	0.580	rs13032265	chr2:98409565	T/C	cg26665480	chr2:98280029	ACTR1B	0.66	6.24	0.49	6.33e-9	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs1775715	1.000	rs1251355	chr10:32290146	C/G	cg14930904	chr10:32216787	ARHGAP12	0.51	4.77	0.39	5.14e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs9419702	0.568	rs10782366	chr10:133557866	G/A	cg04492858	chr10:133558786	NA	0.57	5.92	0.47	2.89e-8	Survival in rectal cancer;
TGCT	cis	rs7945705	1.000	rs4910062	chr11:8862188	A/C	cg21881798	chr11:8931708	C11orf17;ST5	0.41	4.56	0.38	1.23e-5	Hemoglobin concentration;
TGCT	cis	rs9549367	0.756	rs9603814	chr13:113900782	C/T	cg00898013	chr13:113819073	PROZ	0.4	5.07	0.41	1.39e-6	Platelet distribution width;
TGCT	cis	rs9393692	0.645	rs9467703	chr6:26318903	A/G	cg00631329	chr6:26305371	NA	-0.47	-6.94	-0.53	1.89e-10	Educational attainment;
TGCT	cis	rs4660261	0.561	rs11210934	chr1:44369435	G/A	cg13606994	chr1:44402422	ARTN	-0.42	-4.61	-0.38	1e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs9486719	1.000	rs4262195	chr6:96929475	T/C	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.77	-0.62	1.18e-14	Migraine;Coronary artery disease;
TGCT	cis	rs2739330	0.615	rs2858911	chr22:24297195	G/T	cg20007245	chr22:24372913	LOC391322	-0.65	-6.44	-0.5	2.34e-9	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2836633	1.000	rs2836634	chr21:40068230	T/A	cg05519781	chr21:40033154	ERG	0.56	5.47	0.44	2.36e-7	Coronary artery disease;
TGCT	cis	rs7524258	0.868	rs7538921	chr1:7267007	T/C	cg07173049	chr1:7289937	CAMTA1	0.31	5.29	0.43	5.39e-7	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs1153858	1.000	rs7179743	chr15:45638331	G/C	cg26924012	chr15:45694286	SPATA5L1	1.07	14.56	0.79	1.32e-28	Homoarginine levels;
TGCT	cis	rs9611565	0.512	rs964899	chr22:42142386	G/A	cg03806693	chr22:41940476	POLR3H	0.99	9.96	0.67	1.57e-17	Vitiligo;
TGCT	cis	rs3764400	0.567	rs12946208	chr17:46312129	G/A	cg02340556	chr17:46797764	NA	0.42	4.51	0.38	1.46e-5	Body mass index;
TGCT	cis	rs9814567	1.000	rs9289475	chr3:134236459	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.92	-8.81	-0.62	9.26e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs1691799	0.867	rs1168332	chr12:66761548	C/T	cg16791601	chr12:66731901	HELB	-0.28	-6.03	-0.48	1.74e-8	White blood cell count (basophil);
TGCT	cis	rs2242116	0.727	rs6442040	chr3:46963035	C/A	cg23352942	chr3:46931381	PTH1R	-0.33	-4.91	-0.4	2.81e-6	Birth weight;
TGCT	cis	rs2718812	0.766	rs11924101	chr3:133394478	T/G	cg16414030	chr3:133502952	NA	-0.4	-5.2	-0.42	8.03e-7	Iron status biomarkers;
TGCT	cis	rs2439831	0.681	rs540388	chr15:43606494	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.02	8.51	0.61	4.91e-14	Lung cancer in ever smokers;
TGCT	cis	rs7666738	0.830	rs34870112	chr4:99045815	T/G	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs208520	0.690	rs3899423	chr6:66835285	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-10.43	-0.68	1.13e-18	Exhaled nitric oxide output;
TGCT	cis	rs7904368	0.707	rs12253979	chr10:16853415	T/C	cg14835575	chr10:16859367	RSU1	0.71	7.37	0.55	2.16e-11	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
TGCT	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg18402987	chr7:1209562	NA	0.74	6.21	0.49	7.23e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1371867	0.875	rs7830342	chr8:101327738	T/A	cg06636551	chr8:101224915	SPAG1	-0.42	-5.65	-0.45	1.06e-7	Atrioventricular conduction;
TGCT	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg11644478	chr21:40555479	PSMG1	1.02	10.86	0.7	1.05e-19	Cognitive function;
TGCT	cis	rs7659604	1.000	rs72678650	chr4:122666000	A/G	cg19748678	chr4:122722346	EXOSC9	0.55	5.31	0.43	4.92e-7	Type 2 diabetes;
TGCT	cis	rs6901250	0.589	rs684023	chr6:117092308	T/C	cg12892004	chr6:117198278	RFX6	0.38	4.81	0.4	4.38e-6	C-reactive protein levels;
TGCT	cis	rs9388451	0.536	rs34725880	chr6:126155237	A/G	cg05901451	chr6:126070800	HEY2	-0.73	-7.57	-0.56	7.38e-12	Brugada syndrome;
TGCT	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg18230493	chr5:56204884	C5orf35	0.86	6.85	0.52	3.07e-10	Initial pursuit acceleration;
TGCT	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg24829409	chr8:58192753	C8orf71	-0.64	-5.31	-0.43	4.89e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs611744	0.625	rs4735055	chr8:109286642	G/A	cg21045802	chr8:109455806	TTC35	0.76	7.97	0.58	8.77e-13	Dupuytren's disease;
TGCT	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg02725872	chr8:58115012	NA	-0.36	-4.78	-0.39	4.93e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9467773	1.000	rs2224380	chr6:26553943	G/A	cg26531700	chr6:26746687	NA	0.48	4.72	0.39	6.37e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2235642	0.859	rs9927529	chr16:1619488	C/T	cg07341220	chr16:1583899	IFT140;TMEM204	-0.31	-4.51	-0.38	1.46e-5	Coronary artery disease;
TGCT	cis	rs78707713	0.560	rs61848397	chr10:71225584	C/A	cg12610070	chr10:71211762	TSPAN15	-0.62	-7.37	-0.55	2.14e-11	Venous thromboembolism;
TGCT	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg16228356	chr17:43848958	NA	-0.26	-4.53	-0.38	1.37e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs60871478	1.000	rs34260834	chr7:822958	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.48	4.66	0.39	7.91e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs2120019	0.567	rs8037152	chr15:75156996	A/T	cg09165964	chr15:75287851	SCAMP5	-0.83	-6.46	-0.5	2.12e-9	Blood trace element (Zn levels);
TGCT	cis	rs1371867	0.817	rs1788179	chr8:101333345	A/G	cg06636551	chr8:101224915	SPAG1	-0.48	-6.52	-0.51	1.62e-9	Atrioventricular conduction;
TGCT	cis	rs6121246	0.909	rs6088962	chr20:30268184	C/T	cg13852791	chr20:30311386	BCL2L1	0.68	4.79	0.4	4.6e-6	Mean corpuscular hemoglobin;
TGCT	trans	rs7618501	0.699	rs2777888	chr3:49898000	A/G	cg21659725	chr3:3221576	CRBN	0.79	9.28	0.64	6.9e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs7312933	0.584	rs6582395	chr12:42700141	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.57	5.31	0.43	4.8e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg10047753	chr17:41438598	NA	0.95	9.0	0.63	3.2e-15	Menopause (age at onset);
TGCT	cis	rs9467773	1.000	rs2255070	chr6:26501777	C/G	cg05738196	chr6:26577821	NA	0.87	12.23	0.74	4.65e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs2153535	0.580	rs9328478	chr6:8519183	A/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.01	0.41	1.86e-6	Motion sickness;
TGCT	cis	rs8017423	0.935	rs2149653	chr14:90669333	G/A	cg04374321	chr14:90722782	PSMC1	0.77	7.95	0.58	9.78e-13	Mortality in heart failure;
TGCT	cis	rs2228479	0.867	rs34272502	chr16:89949000	G/C	cg04013166	chr16:89971882	TCF25	0.32	4.46	0.37	1.84e-5	Skin colour saturation;
TGCT	cis	rs17102423	0.594	rs10151162	chr14:65566695	T/C	cg11161011	chr14:65562177	MAX	-0.46	-6.3	-0.49	4.84e-9	Obesity-related traits;
TGCT	cis	rs367943	0.966	rs348924	chr5:112817930	T/G	cg12552261	chr5:112820674	MCC	-0.24	-4.91	-0.4	2.81e-6	Type 2 diabetes;
TGCT	cis	rs12971120	0.947	rs7241558	chr18:72169267	A/T	cg26446133	chr18:72167187	CNDP2	-0.4	-7.77	-0.57	2.58e-12	Refractive error;
TGCT	trans	rs1814175	0.817	rs7929173	chr11:49944007	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.12	-0.54	7.75e-11	Height;
TGCT	cis	rs13427251	0.903	rs6746402	chr2:100150443	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.51	-4.51	-0.38	1.49e-5	Chronic sinus infection;
TGCT	cis	rs3770081	0.793	rs60719866	chr2:86284378	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.17	-4.56	-0.38	1.21e-5	Facial emotion recognition (sad faces);
TGCT	cis	rs4478858	0.735	rs6679365	chr1:31787866	A/C	cg07478791	chr1:31886160	SERINC2	0.52	5.03	0.41	1.67e-6	Alcohol dependence;
TGCT	cis	rs933688	0.818	rs10052492	chr5:90759930	T/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.06	10.58	0.69	4.94e-19	Smoking behavior;
TGCT	cis	rs2072499	0.966	rs6427307	chr1:156190083	A/G	cg24450063	chr1:156163899	SLC25A44	1.14	16.5	0.83	4.43e-33	Testicular germ cell tumor;
TGCT	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	5.06	0.41	1.46e-6	Menopause (age at onset);
TGCT	cis	rs2692947	0.727	rs749457	chr2:96795944	A/G	cg23100626	chr2:96804247	ASTL	0.41	5.06	0.41	1.46e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs4321325	0.536	rs10198483	chr2:127934102	G/A	cg09760422	chr2:128146352	NA	0.44	4.81	0.4	4.31e-6	Protein C levels;
TGCT	trans	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.82	8.52	0.61	4.53e-14	Body mass index;
TGCT	cis	rs7677751	0.806	rs1800813	chr4:55094467	G/A	cg17187183	chr4:55093834	PDGFRA	0.56	7.08	0.54	9.52e-11	Corneal astigmatism;
TGCT	trans	rs797680	0.856	rs12030549	chr1:93669218	T/C	cg27528825	chr2:159282178	CCDC148	-0.35	-6.8	-0.52	3.95e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs1801251	0.964	rs7589201	chr2:233724536	A/G	cg08000102	chr2:233561755	GIGYF2	-0.63	-6.36	-0.5	3.57e-9	Coronary artery disease;
TGCT	cis	rs1670533	1.000	rs11735663	chr4:1051845	C/T	cg27284194	chr4:1044797	NA	0.68	5.8	0.46	5.11e-8	Recombination rate (females);
TGCT	cis	rs10789491	1.000	rs1440487	chr1:47167075	C/T	cg15501359	chr1:47185051	KIAA0494	-0.81	-8.17	-0.59	2.99e-13	Response to hepatitis C treatment;
TGCT	cis	rs644799	0.687	rs3748252	chr11:95519195	A/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.8	-8.74	-0.62	1.4e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs4253772	0.591	rs6008545	chr22:46686375	C/T	cg24881330	chr22:46731750	TRMU	0.93	6.08	0.48	1.36e-8	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg21724239	chr8:58056113	NA	0.39	5.29	0.43	5.44e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs3087591	0.919	rs2285892	chr17:29553485	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.48	-7.42	-0.55	1.64e-11	Hip circumference;
TGCT	cis	rs2404602	0.669	rs9788684	chr15:77194838	A/T	cg22467129	chr15:76604101	ETFA	-0.48	-5.45	-0.44	2.56e-7	Blood metabolite levels;
TGCT	cis	rs950169	0.580	rs62021208	chr15:85196244	G/A	cg11189052	chr15:85197271	WDR73	0.76	6.33	0.49	4.04e-9	Schizophrenia;
TGCT	cis	rs778371	0.723	rs12993791	chr2:233690082	C/T	cg08000102	chr2:233561755	GIGYF2	-0.69	-7.77	-0.57	2.62e-12	Schizophrenia;
TGCT	cis	rs1403694	0.515	rs1648699	chr3:186449890	G/C	cg12454167	chr3:186435060	KNG1	0.46	7.19	0.54	5.47e-11	Blood protein levels;
TGCT	cis	rs137699	0.652	rs137706	chr22:39751400	T/G	cg05872129	chr22:39784769	NA	-0.73	-5.62	-0.45	1.2e-7	IgG glycosylation;
TGCT	cis	rs4689388	0.926	rs3821940	chr4:6286711	C/A	cg00701064	chr4:6280414	WFS1	0.45	5.98	0.47	2.18e-8	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs4455778	0.580	rs56068416	chr7:49083226	T/C	cg26309511	chr7:48887640	NA	0.5	6.47	0.5	2.03e-9	Lung cancer in never smokers;
TGCT	cis	rs916888	0.821	rs199504	chr17:44861003	C/T	cg01570182	chr17:44337453	NA	-1.01	-9.11	-0.63	1.74e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs17221829	0.616	rs75627051	chr11:89360903	C/T	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.65	-0.39	8.43e-6	Anxiety in major depressive disorder;
TGCT	cis	rs2033711	0.902	rs4801589	chr19:58953398	C/G	cg13877915	chr19:58951672	ZNF132	0.92	11.82	0.73	4.64e-22	Uric acid clearance;
TGCT	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg13397359	chr6:42928475	GNMT	0.72	6.48	0.5	1.93e-9	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs6570726	0.846	rs6919684	chr6:145883801	A/G	cg23711669	chr6:146136114	FBXO30	0.84	8.89	0.62	6.14e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs422249	0.512	rs174568	chr11:61593816	C/T	cg01500311	chr11:61656094	FADS3	-0.3	-5.25	-0.43	6.42e-7	Trans fatty acid levels;
TGCT	cis	rs7824557	0.602	rs35807737	chr8:11204411	C/G	cg21775007	chr8:11205619	TDH	0.72	7.02	0.53	1.27e-10	Retinal vascular caliber;
TGCT	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg00149659	chr3:10157352	C3orf10	0.93	6.0	0.47	2.05e-8	Alzheimer's disease;
TGCT	cis	rs1008375	0.866	rs12233712	chr4:17570063	T/A	cg10189774	chr4:17578691	LAP3	0.57	5.08	0.41	1.36e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs12200560	0.505	rs211163	chr6:97067654	A/G	cg06623918	chr6:96969491	KIAA0776	0.57	4.83	0.4	3.93e-6	Coronary heart disease;
TGCT	trans	rs17206232	0.534	rs6877731	chr5:64695717	C/T	cg17738841	chr2:31094363	NA	0.7	6.95	0.53	1.85e-10	Schizophrenia;
TGCT	cis	rs593982	0.688	rs3897552	chr11:65560880	C/T	cg08755490	chr11:65554678	OVOL1	-1.24	-8.42	-0.6	8e-14	Atopic dermatitis;
TGCT	cis	rs2251381	0.750	rs2251087	chr21:30527999	C/T	cg08807101	chr21:30365312	RNF160	0.53	4.65	0.39	8.51e-6	Selective IgA deficiency;
TGCT	cis	rs3924048	0.547	rs72642661	chr1:12612873	C/G	cg00291366	chr1:12616550	NA	0.35	5.38	0.44	3.55e-7	Optic cup area;
TGCT	cis	rs3733585	0.673	rs10000983	chr4:9951606	T/C	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.5	-0.56	1.04e-11	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs6964587	0.900	rs4279	chr7:91764128	C/A	cg22709100	chr7:91322751	NA	0.29	4.55	0.38	1.26e-5	Breast cancer;
TGCT	cis	rs4975616	0.804	rs381949	chr5:1322468	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.29	-4.55	-0.38	1.28e-5	Lung cancer;
TGCT	cis	rs6598955	0.543	rs79778574	chr1:26538482	A/G	cg04990556	chr1:26633338	UBXN11	0.82	7.9	0.58	1.31e-12	Obesity-related traits;
TGCT	cis	rs11997175	0.819	rs6415400	chr8:33783714	C/T	ch.8.33884649F	chr8:33765107	NA	0.34	5.33	0.43	4.57e-7	Body mass index;
TGCT	cis	rs62244186	0.535	rs59726036	chr3:44850074	G/T	cg25151919	chr3:44754333	ZNF502	-0.44	-4.94	-0.41	2.48e-6	Depressive symptoms;
TGCT	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg11366901	chr6:160182831	ACAT2	0.79	5.81	0.46	4.92e-8	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs919433	0.679	rs6757669	chr2:198530355	C/T	cg00792783	chr2:198669748	PLCL1	0.55	4.93	0.4	2.56e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs727505	1.000	rs3925331	chr7:124446137	C/G	cg23710748	chr7:124431027	NA	-0.27	-4.59	-0.38	1.09e-5	Lewy body disease;
TGCT	cis	rs12950390	0.853	rs4794107	chr17:45843159	T/G	cg06532163	chr17:45867833	NA	0.34	5.31	0.43	4.82e-7	IgG glycosylation;
TGCT	cis	rs7246657	0.943	rs713256	chr19:37865365	C/T	cg18154014	chr19:37997991	ZNF793	1.0	6.69	0.52	6.81e-10	Coronary artery calcification;
TGCT	cis	rs11098499	0.754	rs66900435	chr4:120249425	C/A	cg09307838	chr4:120376055	NA	0.61	5.91	0.47	3.14e-8	Corneal astigmatism;
TGCT	cis	rs1775715	0.707	rs2799024	chr10:32166922	A/G	cg14930904	chr10:32216787	ARHGAP12	0.53	5.03	0.41	1.66e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg18876405	chr7:65276391	NA	-0.32	-4.92	-0.4	2.72e-6	Aortic root size;
TGCT	cis	rs28595532	0.748	rs72670258	chr4:119391660	A/T	cg11846333	chr4:119757529	SEC24D	0.69	4.51	0.38	1.48e-5	Cannabis dependence symptom count;
TGCT	cis	rs28712821	0.930	rs11940694	chr4:39414993	C/T	cg16714752	chr4:39368184	RFC1	-0.36	-4.83	-0.4	3.94e-6	Alcohol consumption;
TGCT	cis	rs17376456	0.877	rs10476597	chr5:93367172	C/T	cg25358565	chr5:93447407	FAM172A	-1.02	-8.64	-0.61	2.31e-14	Diabetic retinopathy;
TGCT	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg11764359	chr7:65958608	NA	-0.56	-5.06	-0.41	1.45e-6	Aortic root size;
TGCT	cis	rs9549367	0.713	rs3024747	chr13:113821787	C/G	cg18105134	chr13:113819100	PROZ	-0.47	-8.21	-0.59	2.49e-13	Platelet distribution width;
TGCT	cis	rs346785	0.692	rs9900514	chr17:74285595	T/C	cg09812376	chr17:74270190	QRICH2	-0.37	-5.55	-0.45	1.65e-7	White matter hyperintensities in ischemic stroke;
TGCT	cis	rs2996428	0.601	rs10909804	chr1:3770929	A/G	cg13057898	chr1:3703894	LRRC47	-0.21	-4.64	-0.38	8.81e-6	Red cell distribution width;
TGCT	cis	rs6087990	0.669	rs2424929	chr20:31389518	A/G	cg13636640	chr20:31349939	DNMT3B	0.97	12.84	0.76	1.63e-24	Ulcerative colitis;
TGCT	cis	rs6087990	0.899	rs1003521	chr20:31366598	T/C	cg13636640	chr20:31349939	DNMT3B	1.08	14.22	0.79	8.35e-28	Ulcerative colitis;
TGCT	cis	rs2549003	1.000	rs2070731	chr5:131819798	T/C	cg02551604	chr5:131831745	NA	-0.83	-10.59	-0.69	4.58e-19	Asthma (sex interaction);
TGCT	cis	rs2594989	0.616	rs6442255	chr3:11474492	A/G	cg00170343	chr3:11313890	ATG7	0.74	5.52	0.44	1.9e-7	Circulating chemerin levels;
TGCT	cis	rs9677476	0.516	rs1549339	chr2:231982826	G/A	cg07929768	chr2:232055508	NA	0.34	5.23	0.43	7.03e-7	Food antigen IgG levels;
TGCT	cis	rs7523050	0.730	rs12726126	chr1:109436128	A/G	cg08274380	chr1:109419600	GPSM2	1.35	6.86	0.52	2.89e-10	Fat distribution (HIV);
TGCT	cis	rs9921338	0.887	rs13330151	chr16:11402399	C/T	cg00044050	chr16:11439710	C16orf75	-0.97	-6.94	-0.53	1.94e-10	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs1153858	1.000	rs59889118	chr15:45618730	G/A	cg26924012	chr15:45694286	SPATA5L1	1.07	14.11	0.79	1.45e-27	Homoarginine levels;
TGCT	cis	rs9911578	0.867	rs72628394	chr17:57121313	C/T	cg05425664	chr17:57184151	TRIM37	0.63	6.3	0.49	4.61e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7590720	1.000	rs7590720	chr2:216898658	A/G	cg12620499	chr2:216877984	MREG	-0.91	-9.87	-0.66	2.65e-17	Alcohol dependence;
TGCT	cis	rs57244997	1.000	rs73026551	chr6:162393642	A/C	cg17173639	chr6:162384350	PARK2	-0.51	-5.43	-0.44	2.8e-7	Mosquito bite size;
TGCT	cis	rs2050392	0.590	rs2065723	chr10:30720462	A/T	cg18806716	chr10:30721971	MAP3K8	-0.7	-9.39	-0.64	3.84e-16	Inflammatory bowel disease;
TGCT	cis	rs9443189	0.762	rs2647417	chr6:76435943	A/G	cg01950844	chr6:76311363	SENP6	-0.69	-4.73	-0.39	6e-6	Prostate cancer;
TGCT	cis	rs7666738	0.830	rs1426670	chr4:98923572	A/G	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs16892673	0.731	rs9458295	chr6:161937558	G/A	cg23498925	chr13:52952113	THSD1	0.43	6.71	0.52	6.2e-10	Aging;
TGCT	cis	rs1887596	0.705	rs12875211	chr13:27269900	G/A	cg01312412	chr13:27282625	NA	0.3	5.34	0.43	4.23e-7	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs7937682	0.562	rs7938620	chr11:111366844	G/A	cg09085632	chr11:111637200	PPP2R1B	0.69	6.53	0.51	1.49e-9	Primary sclerosing cholangitis;
TGCT	cis	rs9457247	0.646	rs239934	chr6:167412048	G/A	cg23791538	chr6:167370224	RNASET2	-0.51	-5.08	-0.42	1.33e-6	Crohn's disease;
TGCT	cis	rs13064411	0.735	rs6438158	chr3:113217290	C/T	cg18753928	chr3:113234510	CCDC52	-0.7	-5.75	-0.46	6.6e-8	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs10788264	0.569	rs3901289	chr10:124027433	T/C	cg09507567	chr10:124027408	NA	0.45	6.82	0.52	3.52e-10	Total body bone mineral density;
TGCT	cis	rs916888	0.821	rs70600	chr17:44860021	C/T	cg17911788	chr17:44343683	NA	-0.59	-6.13	-0.48	1.09e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	trans	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg20587970	chr11:113659929	NA	-1.04	-12.57	-0.75	6.97e-24	Hip circumference adjusted for BMI;
TGCT	cis	rs11172134	0.508	rs1800177	chr12:57567180	G/T	cg19258868	chr12:57585184	LRP1	-0.32	-6.0	-0.47	2.05e-8	Urate levels in overweight individuals;
TGCT	cis	rs35306767	0.903	rs1341741	chr10:888073	A/G	cg20503657	chr10:835505	NA	0.7	9.83	0.66	3.22e-17	Eosinophil percentage of granulocytes;
TGCT	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	5.58	0.45	1.45e-7	Alzheimer's disease;
TGCT	cis	rs9916302	0.706	rs1874226	chr17:37729031	C/T	cg07936489	chr17:37558343	FBXL20	0.84	6.16	0.48	9.13e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs10782582	0.609	rs12138898	chr1:76375183	G/T	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.54	4.64	0.38	8.55e-6	Daytime sleep phenotypes;
TGCT	cis	rs6835098	0.962	rs4419455	chr4:174083622	C/T	cg08422745	chr4:174089978	GALNT7	0.91	10.41	0.68	1.31e-18	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs2046867	0.628	rs61159664	chr3:72916958	C/G	cg25664220	chr3:72788482	NA	-0.43	-5.86	-0.47	3.9e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs12477438	0.520	rs2632276	chr2:99779655	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	16.69	0.83	1.7e-33	Chronic sinus infection;
TGCT	cis	rs362272	0.505	rs60208975	chr4:3364530	A/G	cg18352616	chr4:3374830	RGS12	0.25	5.23	0.42	7.13e-7	Serum sulfate level;
TGCT	cis	rs2760061	0.569	rs621631	chr1:228114728	A/G	cg18477163	chr1:228402036	OBSCN	-0.31	-6.27	-0.49	5.55e-9	Diastolic blood pressure;
TGCT	cis	rs9790314	0.586	rs34727114	chr3:161138929	A/C	cg03342759	chr3:160939853	NMD3	-0.53	-5.3	-0.43	5.21e-7	Morning vs. evening chronotype;
TGCT	cis	rs288326	0.561	rs77227040	chr2:183894166	T/C	cg09997497	chr2:183902928	NCKAP1	1.11	4.95	0.41	2.38e-6	Blood protein levels;
TGCT	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.71	6.36	0.5	3.53e-9	Tonsillectomy;
TGCT	cis	rs6866344	0.697	rs58549512	chr5:178133204	C/T	cg03877680	chr5:178157825	ZNF354A	0.75	6.1	0.48	1.25e-8	Neutrophil percentage of white cells;
TGCT	cis	rs79149102	0.579	rs7179097	chr15:75279240	T/G	cg09165964	chr15:75287851	SCAMP5	-1.06	-5.96	-0.47	2.39e-8	Lung cancer;
TGCT	cis	rs13217239	0.585	rs114919438	chr6:26963792	T/C	cg05738196	chr6:26577821	NA	-0.54	-5.21	-0.42	7.65e-7	Schizophrenia;
TGCT	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg11494091	chr17:61959527	GH2	0.61	14.49	0.79	1.92e-28	Prudent dietary pattern;
TGCT	cis	rs7027203	0.797	rs4744294	chr9:96612114	C/G	cg14396892	chr9:96623032	NA	-0.26	-5.47	-0.44	2.35e-7	DNA methylation (variation);
TGCT	cis	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg08627397	chr16:89984028	MC1R	0.29	4.47	0.37	1.73e-5	Vitiligo;
TGCT	cis	rs4750440	0.637	rs2457859	chr10:14032099	T/G	cg05755354	chr10:14372596	FRMD4A	0.3	4.77	0.39	5.1e-6	Adiponectin levels;
TGCT	cis	rs10791097	0.694	rs876641	chr11:130752040	A/C	cg12179176	chr11:130786555	SNX19	0.82	10.15	0.67	5.45e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg06873352	chr17:61820015	STRADA	0.58	6.37	0.5	3.32e-9	Prudent dietary pattern;
TGCT	cis	rs9611565	0.649	rs2064189	chr22:42127999	A/G	cg03806693	chr22:41940476	POLR3H	0.97	9.86	0.66	2.81e-17	Vitiligo;
TGCT	trans	rs7819412	0.745	rs7017567	chr8:10933699	T/A	cg15556689	chr8:8085844	FLJ10661	-0.81	-7.77	-0.57	2.53e-12	Triglycerides;
TGCT	cis	rs7666738	0.830	rs921523	chr4:98841659	C/T	cg05340658	chr4:99064831	C4orf37	0.45	5.01	0.41	1.87e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7772486	0.875	rs6934467	chr6:146410529	G/T	cg13319975	chr6:146136371	FBXO30	-0.51	-4.56	-0.38	1.23e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs5769765	0.955	rs7511159	chr22:50307896	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.11	-10.99	-0.7	4.95e-20	Schizophrenia;
TGCT	trans	rs1814175	0.817	rs28594987	chr11:50045181	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.26	-0.55	3.77e-11	Height;
TGCT	cis	rs9788682	1.000	rs34138960	chr15:78831668	A/G	cg06917634	chr15:78832804	PSMA4	-0.7	-4.86	-0.4	3.47e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs10858047	0.883	rs6537842	chr1:115204467	C/T	cg12756093	chr1:115239321	AMPD1	-0.47	-4.96	-0.41	2.27e-6	Autism;
TGCT	cis	rs7208859	0.623	rs73269916	chr17:29096326	A/G	cg13385521	chr17:29058706	SUZ12P	0.82	4.89	0.4	3e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7666738	0.830	rs991168	chr4:98928293	T/C	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7412746	0.611	rs6660084	chr1:150748803	T/C	cg04414720	chr1:150670196	GOLPH3L	0.38	4.73	0.39	6.04e-6	Melanoma;
TGCT	cis	rs7412746	0.611	rs11204748	chr1:150927369	G/T	cg04414720	chr1:150670196	GOLPH3L	0.37	4.46	0.37	1.81e-5	Melanoma;
TGCT	cis	rs6088580	0.561	rs3761147	chr20:32996689	G/T	cg06115741	chr20:33292138	TP53INP2	-0.55	-4.81	-0.4	4.28e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs6840360	0.692	rs4479686	chr4:152399324	C/T	cg17479576	chr4:152424074	FAM160A1	-0.52	-5.23	-0.43	6.86e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs4820539	1.000	rs5759596	chr22:23475750	G/A	cg14186256	chr22:23484241	RTDR1	0.98	12.77	0.75	2.31e-24	Bone mineral density;
TGCT	cis	rs61990749	0.597	rs4632066	chr14:78247282	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	-0.64	-4.5	-0.37	1.54e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs9611565	0.694	rs5758411	chr22:42079734	G/A	cg06481639	chr22:41940642	POLR3H	0.58	4.95	0.41	2.34e-6	Vitiligo;
TGCT	cis	rs840163	0.512	rs4759035	chr12:57255135	A/G	cg20779414	chr12:57505882	STAT6	0.44	4.85	0.4	3.64e-6	Alzheimer's disease (survival time);
TGCT	cis	rs1971762	0.602	rs4759283	chr12:54079243	C/T	cg16917193	chr12:54089295	NA	1.37	17.65	0.85	1.25e-35	Height;
TGCT	cis	rs2235642	1.000	rs2076438	chr16:1584618	T/C	cg10465839	chr16:1584050	IFT140;TMEM204	-0.3	-5.09	-0.42	1.31e-6	Coronary artery disease;
TGCT	cis	rs35883536	0.967	rs2297713	chr1:101092766	T/G	cg06223162	chr1:101003688	GPR88	0.29	4.56	0.38	1.19e-5	Monocyte count;
TGCT	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg05368731	chr17:41323189	NBR1	1.21	14.63	0.8	8.89e-29	Menopause (age at onset);
TGCT	cis	rs2072499	0.966	rs2253677	chr1:156171296	C/G	cg24450063	chr1:156163899	SLC25A44	-1.2	-18.21	-0.85	7.43e-37	Testicular germ cell tumor;
TGCT	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg22535103	chr8:58192502	C8orf71	-0.42	-4.72	-0.39	6.22e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs632111	0.519	rs281380	chr19:49214470	A/G	cg13540341	chr19:49222985	MAMSTR	0.46	6.92	0.53	2.11e-10	Serum lipase activity;
TGCT	cis	rs7744392	0.557	rs7739752	chr6:35339035	C/T	cg06087101	chr6:35551932	FKBP5	0.61	4.56	0.38	1.21e-5	Cataracts in type 2 diabetes;
TGCT	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg22683308	chr4:1340831	KIAA1530	-0.63	-5.81	-0.46	4.97e-8	Longevity;
TGCT	cis	rs1153858	1.000	rs9783731	chr15:45642884	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.48	-5.7	-0.46	8.17e-8	Homoarginine levels;
TGCT	cis	rs3820928	1.000	rs10167422	chr2:227777554	G/A	cg11843606	chr2:227700838	RHBDD1	-0.53	-4.73	-0.39	5.89e-6	Pulmonary function;
TGCT	cis	rs2594989	0.943	rs4365605	chr3:11452793	G/A	cg00170343	chr3:11313890	ATG7	0.67	5.12	0.42	1.13e-6	Circulating chemerin levels;
TGCT	cis	rs5769707	0.935	rs5770594	chr22:50018497	G/A	cg10356904	chr22:49881777	NA	-0.22	-4.52	-0.38	1.4e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs765787	0.530	rs4775819	chr15:45525966	C/T	cg24006582	chr15:45444508	DUOX1	-0.24	-5.33	-0.43	4.54e-7	Uric acid levels;
TGCT	cis	rs9810089	0.777	rs2688601	chr3:136252601	G/A	cg12473912	chr3:136751656	NA	0.35	4.79	0.4	4.67e-6	Gestational age at birth (child effect);
TGCT	cis	rs2932538	0.922	rs6698030	chr1:113138318	G/A	cg22162597	chr1:113214053	CAPZA1	0.28	5.83	0.46	4.4e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	8.3	0.6	1.49e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg26338869	chr17:61819248	STRADA	-0.53	-4.87	-0.4	3.29e-6	Prudent dietary pattern;
TGCT	cis	rs10489525	0.599	rs11102879	chr1:115603504	C/T	cg12756093	chr1:115239321	AMPD1	-0.41	-5.51	-0.44	1.96e-7	Autism;
TGCT	cis	rs68170813	0.559	rs75672288	chr7:107031549	G/C	cg02696742	chr7:106810147	HBP1	-0.68	-5.44	-0.44	2.69e-7	Coronary artery disease;
TGCT	cis	rs9467711	0.606	rs9379852	chr6:26357278	A/G	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1857353	1.000	rs12408190	chr1:75889179	G/C	cg11838876	chr1:75668600	SLC44A5	-0.51	-4.81	-0.4	4.23e-6	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs6671200	1.000	rs6671200	chr1:95697529	A/C	cg20701556	chr1:95698924	RWDD3	-0.67	-5.63	-0.45	1.13e-7	Stearic acid (18:0) levels;
TGCT	cis	rs59197085	0.636	rs3734974	chr7:128461720	C/T	cg00260937	chr7:128520193	KCP	0.44	4.71	0.39	6.42e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
TGCT	cis	rs13256369	0.802	rs12681326	chr8:8566389	G/A	cg06671706	chr8:8559999	CLDN23	0.34	4.6	0.38	1.03e-5	Obesity-related traits;
TGCT	cis	rs1056107	0.898	rs1831118	chr9:115002832	G/C	cg02332936	chr9:115140584	NA	-0.25	-4.44	-0.37	1.96e-5	Colorectal cancer;
TGCT	cis	rs77741769	0.571	rs12822123	chr12:121298644	C/T	cg02419362	chr12:121203948	SPPL3	0.19	4.49	0.37	1.63e-5	Mean corpuscular volume;
TGCT	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	15.87	0.82	1.19e-31	Prudent dietary pattern;
TGCT	cis	rs6912958	0.559	rs451829	chr6:88041919	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.48	6.35	0.5	3.65e-9	Monocyte percentage of white cells;
TGCT	cis	rs2153535	0.580	rs1410766	chr6:8525360	T/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.01	0.41	1.86e-6	Motion sickness;
TGCT	cis	rs12497850	0.931	rs1134591	chr3:48972892	C/T	cg06212747	chr3:49208901	KLHDC8B	0.65	5.74	0.46	6.75e-8	Parkinson's disease;
TGCT	cis	rs3771570	0.901	rs4075818	chr2:242432142	T/C	cg21155796	chr2:242212141	HDLBP	0.93	6.71	0.52	6.12e-10	Prostate cancer;
TGCT	trans	rs7819412	0.511	rs2898290	chr8:11433909	T/C	cg06636001	chr8:8085503	FLJ10661	-0.79	-7.27	-0.55	3.49e-11	Triglycerides;
TGCT	cis	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg20637647	chr7:64974828	NA	0.89	4.95	0.41	2.37e-6	Diabetic kidney disease;
TGCT	cis	rs1799899	0.572	rs8177220	chr3:133473625	A/C	cg18342939	chr3:134203408	ANAPC13;CEP63	-0.55	-5.3	-0.43	5.23e-7	Alcohol consumption (transferrin glycosylation);
TGCT	cis	rs3806843	0.897	rs2531338	chr5:140136957	A/T	cg19875535	chr5:140030758	IK	-0.36	-6.09	-0.48	1.32e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs67478160	0.654	rs1535097	chr14:104216649	C/T	cg26031613	chr14:104095156	KLC1	-0.63	-6.53	-0.51	1.56e-9	Schizophrenia;
TGCT	cis	rs68170813	0.559	rs78888729	chr7:106940957	G/C	cg02696742	chr7:106810147	HBP1	-0.69	-5.81	-0.46	4.85e-8	Coronary artery disease;
TGCT	cis	rs17376456	0.597	rs11135401	chr5:93365716	G/A	cg25358565	chr5:93447407	FAM172A	-0.62	-5.89	-0.47	3.45e-8	Diabetic retinopathy;
TGCT	cis	rs9926296	0.562	rs4785725	chr16:89893243	A/G	cg03388025	chr16:89894329	SPIRE2	0.35	5.28	0.43	5.66e-7	Vitiligo;
TGCT	cis	rs12935418	0.616	rs11864367	chr16:81001779	A/T	cg07676361	chr16:80966860	NA	-0.35	-4.56	-0.38	1.19e-5	Mean corpuscular volume;
TGCT	cis	rs12510870	0.634	rs1590115	chr4:74389749	T/A	cg05868023	chr4:75230803	EREG	0.53	4.73	0.39	6.01e-6	Iris color (b* coordinate);
TGCT	cis	rs10791323	0.569	rs2282601	chr11:133712594	C/G	cg03690763	chr11:133734501	NA	-0.31	-4.82	-0.4	4.08e-6	Childhood ear infection;
TGCT	cis	rs986417	0.901	rs4901989	chr14:61014743	G/C	cg27398547	chr14:60952738	C14orf39	1.42	8.85	0.62	7.44e-15	Gut microbiota (bacterial taxa);
TGCT	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	6.75	0.52	5.02e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs35934224	0.504	rs10372	chr22:19837298	G/A	cg11182965	chr22:19864308	TXNRD2	-0.36	-4.59	-0.38	1.09e-5	Glaucoma (primary open-angle);
TGCT	cis	rs3125734	0.608	rs7094950	chr10:64019744	T/C	cg05499367	chr10:63213510	TMEM26	-0.33	-4.46	-0.37	1.84e-5	Rheumatoid arthritis;
TGCT	cis	rs317689	0.684	rs315125	chr12:69758884	C/T	cg14784868	chr12:69753453	YEATS4	0.55	4.68	0.39	7.24e-6	Response to diuretic therapy;
TGCT	cis	rs12681287	0.517	rs68008113	chr8:87520894	C/A	cg27223183	chr8:87520930	FAM82B	-0.96	-7.08	-0.54	9.31e-11	Caudate activity during reward;
TGCT	cis	rs1322512	0.920	rs1407487	chr6:152945846	T/C	cg03415253	chr6:152958462	SYNE1	-0.57	-4.99	-0.41	2e-6	Tonometry;
TGCT	cis	rs208520	1.000	rs208520	chr6:66952828	G/T	cg07460842	chr6:66804631	NA	-0.85	-7.74	-0.57	3.03e-12	Exhaled nitric oxide output;
TGCT	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg22535103	chr8:58192502	C8orf71	-0.42	-4.79	-0.4	4.7e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1577917	0.816	rs9353349	chr6:86707725	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.65	5.21	0.42	7.61e-7	Response to antipsychotic treatment;
TGCT	cis	rs10089	0.953	rs6875982	chr5:127529197	A/C	cg19767477	chr5:127420684	SLC12A2	-0.44	-4.63	-0.38	8.98e-6	Ileal carcinoids;
TGCT	cis	rs17826219	0.706	rs9893922	chr17:29068425	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	4.87	0.4	3.36e-6	Body mass index;
TGCT	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg13944838	chr5:179740914	GFPT2	-0.4	-6.4	-0.5	2.96e-9	Height;
TGCT	cis	rs2456568	0.803	rs10831142	chr11:93640781	A/G	cg26875233	chr11:93583750	C11orf90	0.48	6.45	0.5	2.3e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.9	7.29	0.55	3.18e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2742417	0.603	rs2064062	chr3:45761115	G/C	cg04837898	chr3:45731254	SACM1L	-0.66	-7.02	-0.53	1.27e-10	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs67311347	1.000	rs12630072	chr3:40517190	T/G	cg13683864	chr3:40499215	RPL14	-1.2	-13.3	-0.77	1.27e-25	Renal cell carcinoma;
TGCT	cis	rs4780355	0.776	rs9936459	chr16:11437779	C/T	cg00044050	chr16:11439710	C16orf75	-0.73	-6.85	-0.52	3.03e-10	Crohn's disease and psoriasis;
TGCT	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-8.64	-0.61	2.39e-14	Platelet count;
TGCT	cis	rs1568889	1.000	rs7931847	chr11:28175245	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.84	8.91	0.62	5.44e-15	Bipolar disorder;
TGCT	cis	rs9297145	0.673	rs62473003	chr7:98725660	A/G	cg05967295	chr7:98741636	SMURF1	1.0	12.46	0.75	1.35e-23	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs13217239	0.646	rs12201393	chr6:26975690	C/A	cg26531700	chr6:26746687	NA	0.68	6.79	0.52	4.1e-10	Schizophrenia;
TGCT	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg07507251	chr3:52567010	NT5DC2	0.47	6.64	0.51	8.85e-10	Bipolar disorder;
TGCT	cis	rs7027203	0.538	rs2244395	chr9:96520723	A/G	cg14598338	chr9:96623480	NA	-0.49	-7.04	-0.53	1.18e-10	DNA methylation (variation);
TGCT	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg06112835	chr11:68658793	MRPL21	0.47	8.23	0.59	2.19e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9942416	0.660	rs41534344	chr5:74997832	T/C	cg19683494	chr5:74908142	NA	0.57	6.37	0.5	3.33e-9	Age-related disease endophenotypes;
TGCT	cis	rs9467773	0.595	rs2237236	chr6:26451553	A/G	cg15659132	chr6:26577336	NA	-0.43	-4.52	-0.38	1.45e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs6848404	chr4:98946750	A/G	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6121246	0.529	rs6060291	chr20:30198043	T/G	cg18721089	chr20:30220636	NA	-0.64	-6.86	-0.52	2.84e-10	Mean corpuscular hemoglobin;
TGCT	cis	rs9810089	0.758	rs12492510	chr3:136151631	G/T	cg12473912	chr3:136751656	NA	0.36	5.1	0.42	1.22e-6	Gestational age at birth (child effect);
TGCT	cis	rs601339	1.000	rs601339	chr12:123174743	A/G	cg11919336	chr12:123188078	GPR109A	0.64	7.49	0.56	1.1e-11	Adiponectin levels;
TGCT	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg16680214	chr1:154839983	KCNN3	0.43	9.51	0.65	1.94e-16	Prostate cancer;
TGCT	cis	rs453301	0.571	rs2929456	chr8:9083416	G/A	cg15556689	chr8:8085844	FLJ10661	-0.64	-6.05	-0.48	1.6e-8	Joint mobility (Beighton score);
TGCT	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg27286337	chr10:134555280	INPP5A	0.39	4.79	0.39	4.75e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs9393777	0.513	rs9379907	chr6:26654318	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.63	-5.75	-0.46	6.58e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7095607	0.935	rs12415105	chr10:69958631	G/A	cg18986048	chr10:69913749	MYPN	0.45	4.85	0.4	3.56e-6	Lung function (FVC);
TGCT	cis	rs2760061	0.717	rs708117	chr1:228199902	G/A	cg02753203	chr1:228287806	NA	0.32	6.14	0.48	1e-8	Diastolic blood pressure;
TGCT	cis	rs2019216	0.521	rs2175657	chr17:21908494	T/G	cg22648282	chr17:21454238	C17orf51	-0.61	-6.04	-0.48	1.69e-8	Pelvic organ prolapse;
TGCT	cis	rs7714584	1.000	rs11747270	chr5:150258867	C/T	cg22134413	chr5:150180641	NA	-0.78	-6.12	-0.48	1.16e-8	Crohn's disease;
TGCT	cis	rs2652822	0.509	rs8468	chr15:63434110	C/T	cg12855773	chr15:63363890	TPM1	-0.19	-5.16	-0.42	9.31e-7	Metabolic traits;
TGCT	trans	rs11722228	0.549	rs2241488	chr4:10101131	T/C	cg26043149	chr18:55253948	FECH	1.16	11.02	0.7	4.14e-20	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs9972944	1.000	rs9972944	chr17:63771079	A/G	cg07283582	chr17:63770753	CCDC46	0.28	5.89	0.47	3.36e-8	Total body bone mineral density;
TGCT	cis	rs9325144	0.723	rs1586373	chr12:39181582	G/A	cg10518543	chr12:38710700	ALG10B	-0.5	-4.65	-0.39	8.28e-6	Morning vs. evening chronotype;
TGCT	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg01448562	chr3:133502909	NA	-0.26	-5.06	-0.41	1.49e-6	Iron status biomarkers;
TGCT	cis	rs10507380	0.824	rs9507880	chr13:27915667	T/A	cg25543773	chr13:27185723	WASF3	0.34	4.83	0.4	3.97e-6	Electrocardiographic traits;
TGCT	cis	rs7208859	0.673	rs79541516	chr17:29240583	C/T	cg14008862	chr17:28927542	LRRC37B2	0.72	4.62	0.38	9.31e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs1023500	1.000	rs6002554	chr22:42339095	T/C	cg04692870	chr22:42525206	CYP2D6	-0.35	-5.2	-0.42	7.83e-7	Schizophrenia;
TGCT	cis	rs11098499	0.863	rs1155576	chr4:120450159	A/C	cg09307838	chr4:120376055	NA	0.71	6.96	0.53	1.71e-10	Corneal astigmatism;
TGCT	cis	rs3733585	0.673	rs7434391	chr4:9967682	C/G	cg11266682	chr4:10021025	SLC2A9	-0.59	-7.85	-0.58	1.7e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs2594989	1.000	rs2594986	chr3:11330964	G/A	cg00170343	chr3:11313890	ATG7	0.67	5.06	0.41	1.44e-6	Circulating chemerin levels;
TGCT	cis	rs6088580	0.634	rs6088502	chr20:33037644	A/T	cg08999081	chr20:33150536	PIGU	0.28	5.52	0.44	1.89e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs1757171	0.534	rs2797793	chr6:37477262	C/T	cg08126542	chr6:37504118	NA	0.4	5.71	0.46	7.9e-8	Cognitive performance;
TGCT	cis	rs10782582	0.609	rs56159153	chr1:76353498	T/G	cg10523679	chr1:76189770	ACADM	-0.58	-5.38	-0.43	3.6e-7	Daytime sleep phenotypes;
TGCT	trans	rs1814175	0.817	rs7929173	chr11:49944007	T/C	cg15704280	chr7:45808275	SEPT13	-0.7	-7.78	-0.57	2.45e-12	Height;
TGCT	cis	rs1577917	1.000	rs35797755	chr6:86706554	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.54	-0.45	1.73e-7	Response to antipsychotic treatment;
TGCT	cis	rs7678296	0.649	rs77896458	chr4:37237843	A/G	cg18431856	chr4:37245254	KIAA1239	0.68	4.47	0.37	1.74e-5	3-hydroxypropylmercapturic acid levels in smokers;
TGCT	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg06896619	chr17:61851486	DDX42;CCDC47	-0.53	-5.21	-0.42	7.55e-7	Prudent dietary pattern;
TGCT	cis	rs35146811	0.961	rs1880949	chr7:99722266	A/C	cg22906224	chr7:99728672	NA	-0.55	-5.05	-0.41	1.52e-6	Coronary artery disease;
TGCT	cis	rs17376456	1.000	rs17376207	chr5:93545524	C/T	cg25358565	chr5:93447407	FAM172A	-0.93	-7.58	-0.56	6.91e-12	Diabetic retinopathy;
TGCT	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg12963246	chr6:28129442	ZNF389	-0.5	-5.05	-0.41	1.53e-6	Depression;
TGCT	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4808199	0.948	rs757000	chr19:19448301	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.69	5.33	0.43	4.49e-7	Nonalcoholic fatty liver disease;
TGCT	trans	rs12339966	0.653	rs10733232	chr9:11285316	G/T	cg07173112	chr1:1114698	TTLL10	-0.34	-6.68	-0.51	7.34e-10	Systolic blood pressure;
TGCT	cis	rs10744422	1.000	rs10744422	chr12:123336789	T/C	cg25930673	chr12:123319894	HIP1R	-0.86	-5.02	-0.41	1.72e-6	Schizophrenia;
TGCT	cis	rs10883723	0.810	rs7090276	chr10:104281239	G/T	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs2692947	0.644	rs1168975	chr2:96814075	G/A	cg22654517	chr2:96458247	NA	0.23	4.86	0.4	3.42e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs9611565	0.512	rs4822052	chr22:42193741	G/A	cg17554472	chr22:41940697	POLR3H	-0.43	-4.62	-0.38	9.4e-6	Vitiligo;
TGCT	cis	rs17767294	0.708	rs72848772	chr6:27920948	C/T	cg08851530	chr6:28072375	NA	1.56	7.22	0.54	4.47e-11	Parkinson's disease;
TGCT	cis	rs6964587	0.967	rs10231496	chr7:91741132	T/C	cg22709100	chr7:91322751	NA	0.28	4.56	0.38	1.21e-5	Breast cancer;
TGCT	cis	rs17253792	0.822	rs78988988	chr14:56152404	G/A	cg01858014	chr14:56050164	KTN1	-0.35	-4.62	-0.38	9.37e-6	Putamen volume;
TGCT	cis	rs10779751	0.960	rs11121712	chr1:11320329	G/C	cg08854313	chr1:11322531	MTOR	0.94	10.47	0.69	8.87e-19	Body mass index;
TGCT	cis	rs6988636	0.792	rs62521807	chr8:124163621	T/C	cg23067535	chr8:124195133	FAM83A	-0.35	-4.75	-0.39	5.61e-6	Urinary uromodulin levels;
TGCT	cis	rs13256369	1.000	rs12547721	chr8:8570671	C/T	cg06671706	chr8:8559999	CLDN23	0.34	4.59	0.38	1.09e-5	Obesity-related traits;
TGCT	cis	rs7586879	0.828	rs1865688	chr2:25108245	C/G	cg01884057	chr2:25150051	NA	0.26	4.58	0.38	1.14e-5	Body mass index;
TGCT	cis	rs62244186	0.715	rs10212378	chr3:44667286	C/G	cg09333631	chr3:44802604	KIF15;KIAA1143	-0.41	-4.63	-0.38	8.91e-6	Depressive symptoms;
TGCT	cis	rs2046867	0.954	rs74559336	chr3:72780501	T/C	cg25664220	chr3:72788482	NA	-0.56	-6.91	-0.53	2.3e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs911263	0.961	rs28498223	chr14:68728425	C/T	cg18825221	chr14:68749962	RAD51L1	-0.3	-5.8	-0.46	5.2100000000000003e-08	Primary biliary cholangitis;
TGCT	cis	rs9942416	0.660	rs34905687	chr5:74997736	A/G	cg07671805	chr5:74907694	NA	0.44	4.47	0.37	1.73e-5	Age-related disease endophenotypes;
TGCT	cis	rs7264396	0.635	rs6060719	chr20:34546013	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.04	-0.41	1.58e-6	Total cholesterol levels;
TGCT	cis	rs6032067	0.561	rs2741502	chr20:43936265	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.41	-6.4	-0.5	2.92e-9	Blood protein levels;
TGCT	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg05665937	chr4:1216051	CTBP1	0.25	4.68	0.39	7.33e-6	Obesity-related traits;
TGCT	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg21963583	chr11:68658836	MRPL21	0.36	6.17	0.48	8.74e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg07424592	chr7:64974309	NA	1.34	8.17	0.59	3.1e-13	Diabetic kidney disease;
TGCT	cis	rs9911578	0.785	rs10853008	chr17:56993407	T/C	cg12560992	chr17:57184187	TRIM37	-0.8	-8.13	-0.59	3.72e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs7954584	0.813	rs11043288	chr12:122451187	C/T	cg22618164	chr12:122356400	WDR66	-0.53	-5.04	-0.41	1.61e-6	Mean corpuscular volume;
TGCT	cis	rs13102973	0.965	rs13142779	chr4:135872841	G/T	cg14419869	chr4:135874104	NA	0.24	4.46	0.37	1.83e-5	Subjective well-being;
TGCT	trans	rs2727020	0.823	rs7102374	chr11:49261795	G/A	cg03929089	chr4:120376271	NA	0.73	8.12	0.59	4e-13	Coronary artery disease;
TGCT	cis	rs11673344	0.504	rs7258360	chr19:37605917	C/T	cg08039142	chr19:36980659	ZNF566	0.53	4.74	0.39	5.87e-6	Obesity-related traits;
TGCT	cis	rs35883536	0.900	rs7520474	chr1:101091376	T/C	cg06223162	chr1:101003688	GPR88	-0.3	-4.99	-0.41	2e-6	Monocyte count;
TGCT	cis	rs7119	0.635	rs867916	chr15:77882860	A/G	cg27398640	chr15:77910606	LINGO1	0.31	6.17	0.48	9.04e-9	Type 2 diabetes;
TGCT	trans	rs1864729	1.000	rs2853312	chr8:98281319	T/C	cg08679828	chr8:102218111	ZNF706	-1.07	-7.43	-0.56	1.55e-11	Estradiol plasma levels (breast cancer);
TGCT	cis	rs62244186	0.683	rs6766334	chr3:44567065	T/C	cg02073558	chr3:44770973	ZNF501	0.62	5.96	0.47	2.41e-8	Depressive symptoms;
TGCT	cis	rs10865541	0.545	rs10176868	chr2:3383662	C/T	cg01472464	chr2:3383078	TTC15;TSSC1	0.24	4.5	0.37	1.55e-5	Obesity-related traits;
TGCT	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg00024416	chr22:24240387	NA	0.26	5.26	0.43	6.21e-7	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg11941060	chr3:133502564	NA	0.3	6.55	0.51	1.4e-9	Iron status biomarkers;
TGCT	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg05985448	chr10:134359359	INPP5A	0.23	4.96	0.41	2.3e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs524281	0.861	rs11227410	chr11:65873396	G/C	cg00563793	chr11:65837595	PACS1	0.55	4.62	0.38	9.44e-6	Electroencephalogram traits;
TGCT	trans	rs2727020	0.567	rs1164687	chr11:49290669	G/A	cg15704280	chr7:45808275	SEPT13	0.72	7.71	0.57	3.47e-12	Coronary artery disease;
TGCT	cis	rs631288	0.793	rs6681716	chr1:146707824	A/C	cg25205988	chr1:146714368	CHD1L	1.17	6.25	0.49	6.09e-9	PR interval in Tripanosoma cruzi seropositivity;
TGCT	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg13683864	chr3:40499215	RPL14	-1.18	-13.68	-0.78	1.54e-26	Renal cell carcinoma;
TGCT	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg27170947	chr2:26402098	FAM59B	-0.39	-4.46	-0.37	1.8e-5	Gut microbiome composition (summer);
TGCT	cis	rs11098499	0.954	rs17046116	chr4:120387259	G/A	cg09307838	chr4:120376055	NA	0.68	6.53	0.51	1.54e-9	Corneal astigmatism;
TGCT	cis	rs7267979	1.000	rs4815408	chr20:25346678	C/T	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg07424592	chr7:64974309	NA	1.27	7.84	0.58	1.8e-12	Diabetic kidney disease;
TGCT	cis	rs6977660	0.507	rs4721822	chr7:19771693	T/C	cg07541023	chr7:19748670	TWISTNB	0.98	6.43	0.5	2.48e-9	Thyroid stimulating hormone;
TGCT	cis	rs921968	0.540	rs10190250	chr2:219457731	C/T	cg02176678	chr2:219576539	TTLL4	-0.49	-6.93	-0.53	1.99e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs9399135	0.967	rs12526055	chr6:135325918	C/T	cg24558204	chr6:135376177	HBS1L	0.48	4.83	0.4	3.94e-6	Red blood cell count;
TGCT	cis	rs6061231	1.000	rs6061231	chr20:60956917	C/A	cg24112000	chr20:60950667	NA	-0.36	-5.12	-0.42	1.11e-6	Colorectal cancer;
TGCT	cis	rs10501293	0.917	rs10768914	chr11:43102263	G/A	cg03447554	chr11:43094025	NA	-0.47	-6.58	-0.51	1.2e-9	Cognitive performance;
TGCT	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg06221963	chr1:154839813	KCNN3	-0.79	-15.15	-0.81	5.4e-30	Prostate cancer;
TGCT	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg16405210	chr4:1374714	KIAA1530	-0.26	-4.59	-0.38	1.06e-5	Longevity;
TGCT	cis	rs910316	0.875	rs12588099	chr14:75594462	A/T	cg23033748	chr14:75592666	NEK9	0.29	4.9	0.4	2.94e-6	Height;
TGCT	cis	rs35934224	0.891	rs8141451	chr22:19870036	C/G	cg11182965	chr22:19864308	TXNRD2	-0.38	-5.34	-0.43	4.3e-7	Glaucoma (primary open-angle);
TGCT	cis	rs1801251	1.000	rs7592717	chr2:233577038	G/A	cg08000102	chr2:233561755	GIGYF2	0.66	6.84	0.52	3.29e-10	Coronary artery disease;
TGCT	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.46	0.56	1.3e-11	Prudent dietary pattern;
TGCT	cis	rs2486288	0.656	rs11629858	chr15:45547114	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.44	-5.02	-0.41	1.78e-6	Glomerular filtration rate;
TGCT	cis	rs6740322	0.748	rs6756625	chr2:43489313	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.37	6.46	0.5	2.18e-9	Coronary artery disease;
TGCT	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.63	-5.13	-0.42	1.07e-6	Tonsillectomy;
TGCT	cis	rs4986172	0.726	rs12051846	chr17:43226887	A/G	cg10701640	chr17:43249399	NA	0.55	6.58	0.51	1.18e-9	Height;
TGCT	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg10802521	chr3:52805072	NEK4	-0.71	-8.79	-0.62	1.04e-14	Bipolar disorder;
TGCT	cis	rs7914558	1.000	rs10509757	chr10:104752960	C/T	cg15744005	chr10:104629667	AS3MT	-0.41	-5.06	-0.41	1.47e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs72845660	0.513	rs72845694	chr10:104169733	C/T	cg26089160	chr10:104170217	PSD	0.51	5.08	0.41	1.37e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs28595532	0.841	rs115851302	chr4:119776504	C/T	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs6666258	0.924	rs34292822	chr1:154812400	G/C	cg06418219	chr1:154948305	SHC1;CKS1B	0.65	5.22	0.42	7.23e-7	Atrial fibrillation;
TGCT	cis	rs1865760	0.508	rs9379820	chr6:26049924	T/C	cg16482183	chr6:26056742	HIST1H1C	0.58	4.98	0.41	2.12e-6	Height;
TGCT	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	5.23	0.43	6.92e-7	Menopause (age at onset);
TGCT	cis	rs9894429	0.646	rs7217415	chr17:79618252	G/A	cg18240062	chr17:79603768	NPLOC4	0.54	4.63	0.38	9.22e-6	Eye color traits;
TGCT	cis	rs5769765	0.908	rs2319464	chr22:50265777	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	1.11	11.76	0.73	6.5e-22	Schizophrenia;
TGCT	cis	rs9911578	1.000	rs437732	chr17:56675861	A/C	cg05425664	chr17:57184151	TRIM37	-0.63	-6.3	-0.49	4.84e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg25036284	chr2:26402008	FAM59B	-0.62	-5.06	-0.41	1.47e-6	Gut microbiome composition (summer);
TGCT	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg03404566	chr17:6899310	ALOX12	-0.43	-4.85	-0.4	3.56e-6	Tonsillectomy;
TGCT	trans	rs1496653	0.602	rs35657558	chr3:23384808	T/C	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs7772486	0.875	rs56181683	chr6:146286620	A/G	cg23711669	chr6:146136114	FBXO30	-0.84	-9.06	-0.63	2.3e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7088591	0.614	rs16911550	chr10:59758506	T/C	cg07264682	chr10:60082823	NA	0.35	4.52	0.38	1.42e-5	Blood pressure;
TGCT	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg13206674	chr6:150067644	NUP43	0.52	4.62	0.38	9.53e-6	Lung cancer;
TGCT	cis	rs4242434	0.672	rs3758042	chr8:22486951	T/C	cg03733263	chr8:22462867	KIAA1967	0.98	13.14	0.76	2.97e-25	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs9297145	1.000	rs9297145	chr7:98759117	A/C	cg05967295	chr7:98741636	SMURF1	1.02	16.5	0.83	4.56e-33	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg10819733	chr22:24237672	NA	-0.29	-4.84	-0.4	3.85e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1878931	0.501	rs4785934	chr16:3419934	G/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.76	7.12	0.54	7.59e-11	Body mass index (adult);
TGCT	cis	rs6671200	0.573	rs3820345	chr1:95713175	C/T	cg26537280	chr1:95699037	RWDD3	-0.51	-4.9	-0.4	2.94e-6	Stearic acid (18:0) levels;
TGCT	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg04944784	chr2:26401820	FAM59B	0.8	5.67	0.45	9.45e-8	Gut microbiome composition (summer);
TGCT	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg11644478	chr21:40555479	PSMG1	-0.53	-4.55	-0.38	1.28e-5	Cognitive function;
TGCT	cis	rs9379850	0.527	rs9393704	chr6:26358775	T/C	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Intelligence (multi-trait analysis);
TGCT	trans	rs3780486	0.522	rs10217770	chr9:33146393	C/A	cg04842962	chr6:43655489	MRPS18A	0.78	8.41	0.6	8.28e-14	IgG glycosylation;
TGCT	cis	rs1784581	0.500	rs9355379	chr6:162421466	C/T	cg17173639	chr6:162384350	PARK2	0.37	4.77	0.39	5.16e-6	Itch intensity from mosquito bite;
TGCT	cis	rs7909074	0.966	rs4948645	chr10:45391481	A/G	cg04218760	chr10:45406644	TMEM72	-0.26	-5.23	-0.43	6.89e-7	Mean corpuscular volume;
TGCT	cis	rs7267979	1.000	rs2474777	chr20:25272633	A/G	cg16686733	chr20:25566563	NINL	0.59	6.03	0.48	1.71e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9818758	0.607	rs55873331	chr3:49597055	C/T	cg07636037	chr3:49044803	WDR6	-0.98	-4.72	-0.39	6.18e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs4851254	0.920	rs11123808	chr2:100750750	A/C	cg04109781	chr2:100722022	AFF3	0.45	4.8	0.4	4.51e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2239547	0.603	rs9870898	chr3:53092375	A/G	cg10802521	chr3:52805072	NEK4	-0.57	-5.22	-0.42	7.38e-7	Schizophrenia;
TGCT	trans	rs941408	1.000	rs1736176	chr19:2790394	G/A	cg19676328	chr12:49525230	TUBA1B	-0.68	-6.62	-0.51	9.9e-10	Total cholesterol levels;
TGCT	cis	rs6854137	0.524	rs9991075	chr4:169701090	A/G	cg20607169	chr4:169750834	PALLD	0.21	4.45	0.37	1.91e-5	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs11585357	0.895	rs72633814	chr1:17626456	T/C	cg08277548	chr1:17600880	PADI3	-0.95	-9.6	-0.65	1.15e-16	Hair shape;
TGCT	cis	rs7120118	0.517	rs12221497	chr11:47280653	G/A	cg13308137	chr11:47528955	CUGBP1	0.33	5.19	0.42	8.16e-7	HDL cholesterol;
TGCT	cis	rs62244186	0.627	rs3935212	chr3:44460954	G/A	cg02073558	chr3:44770973	ZNF501	0.59	5.75	0.46	6.53e-8	Depressive symptoms;
TGCT	cis	rs938554	0.513	rs4529048	chr4:9997112	G/T	cg02734326	chr4:10020555	SLC2A9	0.58	4.77	0.39	5.11e-6	Blood metabolite levels;
TGCT	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.97	-8.51	-0.61	4.86e-14	Platelet count;
TGCT	cis	rs17384381	0.906	rs2300639	chr1:85823676	T/A	cg16011679	chr1:85725395	C1orf52	0.85	6.6	0.51	1.1e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs17376456	0.569	rs68122392	chr5:93077807	A/T	cg25358565	chr5:93447407	FAM172A	0.74	6.42	0.5	2.66e-9	Diabetic retinopathy;
TGCT	cis	rs4919044	0.808	rs835271	chr10:94791678	C/T	cg05127821	chr10:94822908	CYP26C1	-0.74	-4.83	-0.4	3.95e-6	Coronary artery disease;
TGCT	cis	rs10875746	0.859	rs4760680	chr12:48466697	G/T	cg20731937	chr12:48336164	NA	0.62	4.95	0.41	2.36e-6	Longevity (90 years and older);
TGCT	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg20887711	chr4:1340912	KIAA1530	0.54	4.76	0.39	5.33e-6	Longevity;
TGCT	cis	rs700590	0.723	rs304160	chr5:88135462	T/C	cg22951263	chr5:87985283	NA	0.56	5.4	0.44	3.22e-7	Educational attainment (years of education);
TGCT	cis	rs7586879	0.964	rs11688665	chr2:25121168	G/T	cg01884057	chr2:25150051	NA	0.27	4.84	0.4	3.75e-6	Body mass index;
TGCT	cis	rs4746818	1.000	rs7071904	chr10:70903005	C/T	cg04149295	chr10:70884716	VPS26A	0.79	5.39	0.44	3.47e-7	Left atrial antero-posterior diameter;
TGCT	cis	rs10114408	0.959	rs1933673	chr9:96655010	A/T	cg13679303	chr9:96623674	NA	-0.36	-4.69	-0.39	7e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs2404602	0.735	rs4886798	chr15:76673226	A/G	cg26408565	chr15:76604113	ETFA	-0.39	-4.53	-0.38	1.35e-5	Blood metabolite levels;
TGCT	cis	rs9611565	0.500	rs10775759	chr22:42088158	T/C	cg03806693	chr22:41940476	POLR3H	1.06	11.74	0.73	7.15e-22	Vitiligo;
TGCT	cis	rs3087591	0.708	rs2285894	chr17:29654876	T/A	cg24425628	chr17:29625626	OMG;NF1	0.39	5.46	0.44	2.45e-7	Hip circumference;
TGCT	cis	rs4851254	0.660	rs4851244	chr2:100671449	C/T	cg07810366	chr2:100720526	AFF3	0.49	5.22	0.42	7.36e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs11690462	0.963	rs17529423	chr2:26583506	A/C	cg11525280	chr2:26624667	C2orf39	0.35	4.47	0.37	1.73e-5	Coronary artery disease;
TGCT	cis	rs4704846	1.000	rs919747	chr5:156531330	A/G	cg12943317	chr5:156479607	HAVCR1	-0.34	-4.75	-0.39	5.43e-6	Blood protein levels;
TGCT	cis	rs17270561	0.514	rs10946805	chr6:26077891	C/T	cg17042849	chr6:26104293	HIST1H4C	-0.85	-5.98	-0.47	2.2e-8	Iron status biomarkers;
TGCT	cis	rs4654899	0.965	rs2873424	chr1:21500701	C/A	cg01072550	chr1:21505969	NA	-0.51	-8.23	-0.59	2.18e-13	Superior frontal gyrus grey matter volume;
TGCT	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.7	6.33	0.49	4.02e-9	Tonsillectomy;
TGCT	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg11890956	chr21:40555474	PSMG1	1.09	11.98	0.73	1.95e-22	Cognitive function;
TGCT	cis	rs9419702	0.526	rs9419637	chr10:133548059	T/C	cg23460707	chr10:133558971	NA	0.44	4.9	0.4	2.96e-6	Survival in rectal cancer;
TGCT	cis	rs28595532	0.920	rs114683212	chr4:119760209	A/G	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs4690686	0.500	rs7667671	chr4:177275599	T/C	cg17059388	chr4:177262070	NA	0.29	4.59	0.38	1.09e-5	Essential tremor;
TGCT	cis	rs66561647	0.719	rs7812386	chr8:128937609	C/A	cg11792826	chr8:129160931	MIR1208	0.22	5.15	0.42	1.01e-6	Hemoglobin concentration;
TGCT	cis	rs9611565	0.512	rs2899349	chr22:42164660	T/C	cg06481639	chr22:41940642	POLR3H	0.69	6.05	0.48	1.59e-8	Vitiligo;
TGCT	cis	rs9381040	0.626	rs2272986	chr6:41037778	C/T	cg03526776	chr6:41159608	TREML2	0.27	5.34	0.43	4.21e-7	Alzheimer's disease (late onset);
TGCT	cis	rs2463822	0.925	rs2513075	chr11:62102408	C/T	cg06239285	chr11:62104954	ASRGL1	0.93	6.71	0.52	6.27e-10	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs9462846	0.691	rs9462853	chr6:42910666	T/C	cg13397359	chr6:42928475	GNMT	0.58	4.52	0.38	1.41e-5	Blood protein levels;
TGCT	cis	rs4499344	0.555	rs7250741	chr19:33033231	T/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.68	-5.73	-0.46	7.27e-8	Mean platelet volume;
TGCT	cis	rs9486719	0.843	rs2499792	chr6:96846264	A/C	cg06623918	chr6:96969491	KIAA0776	0.93	7.08	0.54	9.59e-11	Migraine;Coronary artery disease;
TGCT	cis	rs6912958	0.781	rs9450738	chr6:88267314	A/G	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.91	-0.4	2.78e-6	Monocyte percentage of white cells;
TGCT	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg25036284	chr2:26402008	FAM59B	-0.65	-5.27	-0.43	5.77e-7	Gut microbiome composition (summer);
TGCT	cis	rs9611565	0.512	rs139561	chr22:42195410	C/T	cg17554472	chr22:41940697	POLR3H	0.43	4.56	0.38	1.22e-5	Vitiligo;
TGCT	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg18538332	chr22:24372958	LOC391322	-0.85	-9.96	-0.67	1.61e-17	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs17164851	0.636	rs17164847	chr7:130003458	A/G	cg01390574	chr7:129425451	NA	-0.65	-4.47	-0.37	1.74e-5	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg11247378	chr22:39784982	NA	-0.74	-10.33	-0.68	1.98e-18	Intelligence (multi-trait analysis);
TGCT	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs9733	0.536	rs10888385	chr1:150574302	T/C	cg13175981	chr1:150552382	MCL1	0.55	6.33	0.49	4.15e-9	Tonsillectomy;
TGCT	cis	rs4808199	0.947	rs10401193	chr19:19591066	A/G	cg03709012	chr19:19516395	GATAD2A	1.0	7.85	0.58	1.69e-12	Nonalcoholic fatty liver disease;
TGCT	cis	rs9916302	0.904	rs8079355	chr17:37473018	G/A	cg15445000	chr17:37608096	MED1	-0.33	-4.71	-0.39	6.46e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg20607798	chr8:58055168	NA	0.5	4.66	0.39	8.04e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs17376456	0.542	rs1982439	chr5:93160560	C/G	cg21475434	chr5:93447410	FAM172A	-0.63	-4.96	-0.41	2.23e-6	Diabetic retinopathy;
TGCT	cis	rs1878931	0.696	rs35175748	chr16:3445427	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.98	12.26	0.74	4.06e-23	Body mass index (adult);
TGCT	trans	rs57221529	0.766	rs72704799	chr5:551457	C/G	cg11887960	chr12:57824829	NA	1.12	8.48	0.61	5.72e-14	Lung disease severity in cystic fibrosis;
TGCT	cis	rs1008375	1.000	rs2315561	chr4:17679695	C/T	cg16339924	chr4:17578868	LAP3	0.56	4.8	0.4	4.43e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg05368731	chr17:41323189	NBR1	1.2	14.48	0.79	1.98e-28	Menopause (age at onset);
TGCT	cis	rs2180341	0.883	rs7760748	chr6:127690062	C/T	cg24812749	chr6:127587940	RNF146	0.92	7.43	0.55	1.55e-11	Breast cancer;
TGCT	cis	rs350251	0.899	rs350274	chr16:12233259	G/C	cg02910054	chr16:12241554	SNX29	0.33	4.57	0.38	1.18e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7584330	0.868	rs13408361	chr2:238382899	A/G	cg14458575	chr2:238380390	NA	0.5	7.89	0.58	1.35e-12	Prostate cancer;
TGCT	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg12311346	chr5:56204834	C5orf35	-0.82	-7.71	-0.57	3.54e-12	Initial pursuit acceleration;
TGCT	cis	rs2576037	0.566	rs2437854	chr18:44557613	T/C	cg23302884	chr18:44338147	ST8SIA5	0.43	5.02	0.41	1.77e-6	Personality dimensions;
TGCT	cis	rs12510870	0.566	rs28696705	chr4:74426954	C/G	cg05868023	chr4:75230803	EREG	0.54	4.89	0.4	3.07e-6	Iris color (b* coordinate);
TGCT	cis	rs7927771	0.770	rs11039203	chr11:47384597	A/G	cg21462715	chr11:47870315	NUP160	0.57	4.63	0.38	9.08e-6	Subjective well-being;
TGCT	cis	rs2797160	1.000	rs9401843	chr6:126004124	T/C	cg05901451	chr6:126070800	HEY2	-0.74	-6.3	-0.49	4.62e-9	Endometrial cancer;
TGCT	cis	rs950880	0.560	rs12712141	chr2:102953067	A/G	cg09003973	chr2:102972529	NA	-0.51	-4.5	-0.37	1.54e-5	Serum protein levels (sST2);
TGCT	cis	rs73110464	0.505	rs2638503	chr12:53307369	C/G	cg05393297	chr12:53359155	NA	-0.43	-4.87	-0.4	3.36e-6	Cancer (pleiotropy);
TGCT	cis	rs2735413	0.564	rs78898310	chr16:78115510	T/C	cg09132178	chr16:78079569	NA	0.37	4.7	0.39	6.84e-6	Systolic blood pressure (alcohol consumption interaction);
TGCT	cis	rs2440129	0.611	rs2292352	chr17:6902887	A/G	cg03407747	chr17:6899364	ALOX12	0.52	5.67	0.45	9.41e-8	Tonsillectomy;
TGCT	cis	rs1153858	1.000	rs1365610	chr15:45694610	C/T	cg26924012	chr15:45694286	SPATA5L1	1.09	15.16	0.81	5.15e-30	Homoarginine levels;
TGCT	cis	rs7208859	0.673	rs11652409	chr17:29182707	T/A	cg18442181	chr17:29233375	C17orf42	-0.79	-4.78	-0.39	4.95e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs4808199	1.000	rs7258508	chr19:19475469	T/C	cg03709012	chr19:19516395	GATAD2A	1.0	8.01	0.58	7.11e-13	Nonalcoholic fatty liver disease;
TGCT	cis	rs10782582	0.609	rs80059220	chr1:76279112	G/T	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.52	4.54	0.38	1.31e-5	Daytime sleep phenotypes;
TGCT	cis	rs4819852	0.958	rs2238787	chr22:19976406	G/A	cg07821417	chr22:19972146	ARVCF	0.19	4.79	0.4	4.7e-6	Pulse pressure;
TGCT	cis	rs9911578	0.967	rs6503890	chr17:57064167	A/G	cg05425664	chr17:57184151	TRIM37	-0.62	-6.14	-0.48	1.03e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7010267	0.773	rs72680380	chr8:119932741	T/A	cg17171407	chr8:119960777	TNFRSF11B	-0.29	-5.06	-0.41	1.44e-6	Total body bone mineral density (age 45-60);
TGCT	cis	rs2479724	0.792	rs7739064	chr6:41834037	C/A	cg08135965	chr6:41755394	TOMM6	0.46	4.48	0.37	1.7e-5	Menarche (age at onset);
TGCT	cis	rs1420338	0.967	rs2192874	chr7:34144916	G/A	cg01275685	chr7:34179230	BMPER	-0.25	-4.69	-0.39	7.03e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs1205863	1.000	rs1205891	chr6:11948621	C/A	cg07106625	chr6:11870215	NA	0.51	5.05	0.41	1.51e-6	Disc degeneration (lumbar);
TGCT	cis	rs6074578	0.535	rs6077293	chr20:138620	A/C	cg16931068	chr20:139680	DEFB127	0.27	4.47	0.37	1.75e-5	Hirschsprung disease;
TGCT	cis	rs6598955	0.671	rs11247910	chr1:26645666	G/A	cg04990556	chr1:26633338	UBXN11	0.64	4.55	0.38	1.27e-5	Obesity-related traits;
TGCT	cis	rs13064411	0.735	rs7636128	chr3:113133701	A/T	cg10517650	chr3:113235015	CCDC52	-0.35	-4.69	-0.39	7.18e-6	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs6598955	0.724	rs12757113	chr1:26597144	C/T	cg04990556	chr1:26633338	UBXN11	-0.87	-10.54	-0.69	6.11e-19	Obesity-related traits;
TGCT	cis	rs2797160	1.000	rs77678056	chr6:126019738	A/G	cg05901451	chr6:126070800	HEY2	0.73	6.29	0.49	4.85e-9	Endometrial cancer;
TGCT	cis	rs1532993	0.518	rs1983166	chr4:98583178	A/G	cg05340658	chr4:99064831	C4orf37	0.41	4.77	0.39	5.05e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs155076	1.000	rs261369	chr13:21868420	C/A	cg11317459	chr13:21872234	NA	-1.29	-11.56	-0.72	2.03e-21	White matter hyperintensity burden;
TGCT	cis	rs4819052	0.840	rs914217	chr21:46698299	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.99	8.08	0.59	4.92e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs1372520	0.766	rs2583961	chr4:90779758	A/G	cg20003494	chr4:90757398	SNCA	-0.65	-5.22	-0.42	7.45e-7	Neuroticism;
TGCT	cis	rs492146	0.935	rs316139	chr6:52846372	G/T	cg06706454	chr6:52930286	FBXO9	-0.47	-4.54	-0.38	1.32e-5	Epilepsy (remission after treatment);
TGCT	cis	rs7208859	0.673	rs73263981	chr17:28920502	A/G	cg04154034	chr17:28927549	LRRC37B2	0.79	4.8	0.4	4.54e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs9394841	0.810	rs3218097	chr6:41905275	G/A	cg08135965	chr6:41755394	TOMM6	0.56	5.35	0.43	4.05e-7	Mean corpuscular hemoglobin;Red cell distribution width;
TGCT	trans	rs208520	1.000	rs12189683	chr6:66977716	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.83	-7.46	-0.56	1.31e-11	Exhaled nitric oxide output;
TGCT	cis	rs2859741	1.000	rs2859741	chr1:37509352	C/T	cg09363841	chr1:37513479	NA	-0.19	-4.49	-0.37	1.63e-5	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
TGCT	cis	rs763121	0.819	rs138700	chr22:39129999	A/G	cg06022373	chr22:39101656	GTPBP1	0.77	7.17	0.54	6e-11	Menopause (age at onset);
TGCT	cis	rs7236492	0.748	rs11664153	chr18:77195813	G/A	cg15644404	chr18:77186268	NFATC1	-0.35	-4.67	-0.39	7.83e-6	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg13665807	chr20:60559372	TAF4	-0.46	-5.0	-0.41	1.92e-6	Body mass index;
TGCT	cis	rs10986311	0.775	rs4574	chr9:127177161	A/G	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.19	-4.64	-0.38	8.78e-6	Vitiligo;
TGCT	cis	rs9393692	0.905	rs9358919	chr6:26287862	C/T	cg00631329	chr6:26305371	NA	-0.41	-6.08	-0.48	1.34e-8	Educational attainment;
TGCT	cis	rs10791323	0.569	rs2156679	chr11:133742304	C/T	cg15485101	chr11:133734466	NA	0.37	5.42	0.44	3e-7	Childhood ear infection;
TGCT	cis	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg02503808	chr4:7069936	GRPEL1	0.98	9.23	0.64	9.22e-16	Monocyte percentage of white cells;
TGCT	cis	rs72945132	0.678	rs12786421	chr11:70235314	G/C	cg00319359	chr11:70116639	PPFIA1	0.99	7.17	0.54	5.79e-11	Coronary artery disease;
TGCT	cis	rs6964587	1.000	rs756647	chr7:91586389	A/G	cg22709100	chr7:91322751	NA	0.27	4.48	0.37	1.68e-5	Breast cancer;
TGCT	cis	rs1865760	0.929	rs1816546	chr6:25938252	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.66	6.2	0.49	7.8e-9	Height;
TGCT	cis	rs813218	0.584	rs793469	chr3:99537305	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	5.29	0.43	5.28e-7	Orofacial clefts;
TGCT	cis	rs9952991	1.000	rs9952991	chr18:12780464	G/A	cg24737193	chr18:12778029	NA	0.51	5.73	0.46	7.31e-8	Inflammatory skin disease;
TGCT	cis	rs9916302	0.904	rs4795359	chr17:37573146	C/T	cg07936489	chr17:37558343	FBXL20	-0.65	-4.98	-0.41	2.11e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs73110464	0.505	rs2682296	chr12:53308265	G/A	cg16329197	chr12:53359506	NA	-0.32	-4.78	-0.39	4.86e-6	Cancer (pleiotropy);
TGCT	cis	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg20637647	chr7:64974828	NA	0.92	5.36	0.43	3.87e-7	Diabetic kidney disease;
TGCT	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	4.92	0.4	2.75e-6	Menopause (age at onset);
TGCT	trans	rs1496653	0.602	rs71322174	chr3:23409907	C/T	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs12477438	0.798	rs6712338	chr2:99585457	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-5.87	-0.47	3.74e-8	Chronic sinus infection;
TGCT	cis	rs7845219	0.544	rs9643350	chr8:95917276	C/A	cg16049864	chr8:95962084	TP53INP1	-0.46	-5.12	-0.42	1.11e-6	Type 2 diabetes;
TGCT	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg11494091	chr17:61959527	GH2	0.61	14.83	0.8	2.95e-29	Prudent dietary pattern;
TGCT	cis	rs10057188	1.000	rs10060400	chr5:77874205	G/A	cg06873401	chr5:77792105	LHFPL2	-0.22	-4.46	-0.37	1.79e-5	Pulse pressure;
TGCT	cis	rs7178572	1.000	rs34591043	chr15:77713586	A/G	cg15453836	chr15:77711506	NA	-0.4	-4.56	-0.38	1.22e-5	Type 2 diabetes;
TGCT	cis	rs12188164	0.965	rs1056465	chr5:442438	T/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.4	-4.71	-0.39	6.42e-6	Cystic fibrosis severity;
TGCT	cis	rs3733585	0.631	rs3822236	chr4:10119961	T/G	cg11266682	chr4:10021025	SLC2A9	-0.55	-6.35	-0.5	3.78e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7772486	0.764	rs7745696	chr6:146162829	T/C	cg05347473	chr6:146136440	FBXO30	0.51	4.77	0.39	5.02e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs739401	0.572	rs12276060	chr11:3015572	A/T	cg05729581	chr11:3078854	CARS	-0.6	-5.43	-0.44	2.79e-7	Longevity;
TGCT	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg12923728	chr3:195709715	SDHAP1	-0.36	-7.57	-0.56	7.39e-12	Pancreatic cancer;
TGCT	cis	rs9362426	1.000	rs9294377	chr6:88084839	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.46	5.19	0.42	8.5e-7	Depressive episodes in bipolar disorder;
TGCT	cis	rs62283056	1.000	rs62283056	chr4:6276630	G/C	cg25554036	chr4:6271136	WFS1	-0.44	-4.78	-0.39	4.93e-6	Cisplatin-induced ototoxicity;
TGCT	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg27170947	chr2:26402098	FAM59B	-0.39	-4.46	-0.37	1.8e-5	Gut microbiome composition (summer);
TGCT	cis	rs765787	0.530	rs2413775	chr15:45544288	T/A	cg24006582	chr15:45444508	DUOX1	-0.27	-5.85	-0.46	4.18e-8	Uric acid levels;
TGCT	cis	rs2840044	0.534	rs321596	chr17:33885736	C/T	cg05299278	chr17:33885742	SLFN14	-0.23	-5.12	-0.42	1.13e-6	Response to radiotherapy in cancer (late toxicity);
TGCT	cis	rs4788815	0.532	rs59709630	chr16:71978608	G/T	cg06353428	chr16:71660113	MARVELD3	0.78	7.05	0.53	1.12e-10	Metabolite levels;
TGCT	trans	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg17470723	chr8:74884337	TCEB1	0.72	6.94	0.53	1.91e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	5.02	0.41	1.78e-6	Prudent dietary pattern;
TGCT	cis	rs933688	0.938	rs1477348	chr5:90707823	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.02	8.35	0.6	1.17e-13	Smoking behavior;
TGCT	cis	rs7635838	0.892	rs3942925	chr3:11442921	T/C	cg00170343	chr3:11313890	ATG7	0.64	6.15	0.48	9.88e-9	HDL cholesterol;
TGCT	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg03396347	chr1:1875803	NA	-0.36	-6.48	-0.5	1.97e-9	Body mass index;
TGCT	cis	rs4819052	0.765	rs2838868	chr21:46714641	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.89	-7.89	-0.58	1.39e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs35306767	0.761	rs12770173	chr10:1027108	A/C	cg20503657	chr10:835505	NA	0.59	6.67	0.51	7.75e-10	Eosinophil percentage of granulocytes;
TGCT	cis	rs9325144	0.505	rs1906262	chr12:38653605	A/G	cg13010199	chr12:38710504	ALG10B	0.58	5.2	0.42	8.08e-7	Morning vs. evening chronotype;
TGCT	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.92	7.32	0.55	2.79e-11	Platelet count;
TGCT	cis	rs9952991	1.000	rs9952991	chr18:12780464	G/A	cg23598886	chr18:12777645	NA	0.6	5.58	0.45	1.41e-7	Inflammatory skin disease;
TGCT	cis	rs2486288	0.656	rs2413771	chr15:45553140	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.48	-5.77	-0.46	5.91e-8	Glomerular filtration rate;
TGCT	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.11	13.91	0.78	4.47e-27	Height;
TGCT	cis	rs3806843	0.576	rs246032	chr5:140332547	C/A	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7402982	0.625	rs7179841	chr15:99204652	C/T	cg03437748	chr15:99193247	IGF1R	0.46	4.62	0.38	9.38e-6	Birth weight;
TGCT	cis	rs8063761	1.000	rs8063761	chr16:90027626	A/T	cg08547343	chr16:90038815	CENPBD1;AFG3L1	0.58	5.34	0.43	4.19e-7	Squamous cell carcinoma;
TGCT	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.46	0.56	1.3e-11	Prudent dietary pattern;
TGCT	cis	rs1005224	0.895	rs6574252	chr14:76141834	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.61	-5.59	-0.45	1.36e-7	Large artery stroke;
TGCT	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs62244186	0.659	rs9835270	chr3:44553722	G/A	cg04389838	chr3:44770851	ZNF501	-0.43	-5.67	-0.45	9.4e-8	Depressive symptoms;
TGCT	cis	rs10883723	0.962	rs1056739	chr10:104236542	T/C	cg05855489	chr10:104503620	C10orf26	-0.55	-4.68	-0.39	7.42e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs5769707	0.967	rs2187891	chr22:49994094	C/T	cg20744362	chr22:50050164	C22orf34	0.27	4.58	0.38	1.09e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs7552404	1.000	rs12091720	chr1:76186949	G/A	cg03433033	chr1:76189801	ACADM	0.82	9.68	0.66	7.51e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs6684514	1.000	rs10908499	chr1:156279176	G/C	cg20302342	chr1:156215951	PAQR6	0.36	4.77	0.39	5.1e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs6921919	0.559	rs13210866	chr6:28383842	G/A	cg18815343	chr6:28367644	ZSCAN12	-0.54	-5.25	-0.43	6.29e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2980439	0.517	rs17594065	chr8:8105405	T/C	cg06636001	chr8:8085503	FLJ10661	-0.61	-5.33	-0.43	4.51e-7	Neuroticism;
TGCT	cis	rs6964587	0.967	rs6980247	chr7:91594228	T/A	cg17063962	chr7:91808500	NA	0.91	9.97	0.67	1.53e-17	Breast cancer;
TGCT	cis	rs77669868	0.929	rs3782002	chr11:114070563	A/T	cg01914181	chr11:114070210	ZBTB16	0.33	5.73	0.46	7.25e-8	Monocyte percentage of white cells;
TGCT	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg20203395	chr5:56204925	C5orf35	0.53	4.92	0.4	2.67e-6	Initial pursuit acceleration;
TGCT	trans	rs7618501	0.521	rs2352984	chr3:49948728	T/C	cg21659725	chr3:3221576	CRBN	0.71	8.01	0.58	6.98e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs854765	0.964	rs12943202	chr17:17994332	T/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.63	-5.96	-0.47	2.46e-8	Total body bone mineral density;
TGCT	cis	rs1784581	0.802	rs2156747	chr6:162430000	C/G	cg17173639	chr6:162384350	PARK2	-0.41	-7.34	-0.55	2.52e-11	Itch intensity from mosquito bite;
TGCT	cis	rs9467711	1.000	rs9467708	chr6:26327956	T/C	cg16898833	chr6:26189333	HIST1H4D	1.04	5.51	0.44	1.97e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs514406	0.548	rs6670871	chr1:53212082	A/C	cg01802117	chr1:53393560	SCP2	0.44	5.14	0.42	1.05e-6	Monocyte count;
TGCT	cis	rs79149102	0.579	rs74025863	chr15:75284161	T/C	cg09165964	chr15:75287851	SCAMP5	-1.07	-5.89	-0.47	3.42e-8	Lung cancer;
TGCT	cis	rs4654899	0.644	rs6669077	chr1:21290520	A/C	cg01072550	chr1:21505969	NA	-0.56	-9.13	-0.63	1.61e-15	Superior frontal gyrus grey matter volume;
TGCT	cis	rs9611565	0.512	rs139566	chr22:42199277	A/G	cg06481639	chr22:41940642	POLR3H	-0.69	-5.92	-0.47	2.91e-8	Vitiligo;
TGCT	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg07061783	chr6:25882402	NA	0.72	7.44	0.56	1.44e-11	Blood metabolite levels;
TGCT	cis	rs7586879	0.681	rs28836469	chr2:25117215	A/G	cg01884057	chr2:25150051	NA	0.35	6.9	0.53	2.39e-10	Body mass index;
TGCT	cis	rs2730260	0.537	rs55662704	chr7:158864184	T/C	cg27122614	chr7:157913741	PTPRN2	0.43	4.46	0.37	1.81e-5	Myopia (pathological);
TGCT	cis	rs9393692	0.875	rs2142703	chr6:26289605	A/G	cg05868516	chr6:26286170	HIST1H4H	0.63	5.91	0.47	3.02e-8	Educational attainment;
TGCT	cis	rs2120019	1.000	rs12898259	chr15:75369780	G/A	cg09165964	chr15:75287851	SCAMP5	-1.07	-8.58	-0.61	3.34e-14	Blood trace element (Zn levels);
TGCT	cis	rs2439831	0.850	rs7174208	chr15:44052682	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	5.91	0.47	3.05e-8	Lung cancer in ever smokers;
TGCT	cis	rs7020830	0.931	rs1388978	chr9:37144062	G/T	cg14294708	chr9:37120828	ZCCHC7	1.18	15.98	0.82	6.73e-32	Schizophrenia;
TGCT	cis	rs13326165	0.760	rs28481563	chr3:52417638	T/C	cg07884673	chr3:53033167	SFMBT1	0.4	4.86	0.4	3.45e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg15691649	chr6:25882328	NA	-0.45	-5.51	-0.44	1.97e-7	Blood metabolite levels;
TGCT	cis	rs6952808	0.626	rs57633152	chr7:2042547	C/G	cg22963979	chr7:1858916	MAD1L1	-0.39	-5.95	-0.47	2.5e-8	Bipolar disorder and schizophrenia;
TGCT	cis	rs8056742	0.642	rs67300532	chr16:85029995	C/A	cg00229868	chr16:85520891	NA	0.37	4.64	0.38	8.75e-6	Amyotrophic lateral sclerosis;
TGCT	cis	rs11792861	0.926	rs7870597	chr9:111871864	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.48	4.48	0.37	1.66e-5	Menarche (age at onset);
TGCT	cis	rs4253772	0.550	rs739164	chr22:46684558	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.7	-5.27	-0.43	5.83e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs9372498	0.536	rs9489457	chr6:118920285	C/T	cg21191810	chr6:118973309	C6orf204	-0.39	-5.13	-0.42	1.07e-6	Diastolic blood pressure;
TGCT	cis	rs17376456	0.877	rs9314092	chr5:93326362	A/G	cg25358565	chr5:93447407	FAM172A	0.98	8.59	0.61	3.14e-14	Diabetic retinopathy;
TGCT	cis	rs2594989	0.831	rs13324245	chr3:11570769	T/G	cg26283222	chr3:11613257	VGLL4	0.21	4.49	0.37	1.62e-5	Circulating chemerin levels;
TGCT	cis	rs4455778	0.580	rs4270911	chr7:49112131	T/A	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg06108461	chr20:60628389	TAF4	-0.69	-10.77	-0.7	1.71e-19	Body mass index;
TGCT	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg21724239	chr8:58056113	NA	0.39	5.28	0.43	5.67e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg17264618	chr3:40429014	ENTPD3	0.34	4.81	0.4	4.34e-6	Renal cell carcinoma;
TGCT	cis	rs896854	0.654	rs10104909	chr8:95977973	C/T	cg23172400	chr8:95962367	TP53INP1	-0.36	-6.14	-0.48	1.05e-8	Type 2 diabetes;
TGCT	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg14784868	chr12:69753453	YEATS4	0.83	8.96	0.63	4.14e-15	Blood protein levels;
TGCT	cis	rs2066819	1.000	rs59295315	chr12:56708576	G/A	cg26714650	chr12:56694279	CS	-1.36	-6.06	-0.48	1.54e-8	Psoriasis vulgaris;
TGCT	cis	rs17152411	1.000	rs7914110	chr10:126599886	C/G	cg07906193	chr10:126599966	NA	0.41	5.03	0.41	1.71e-6	Height;
TGCT	cis	rs9921192	0.967	rs233956	chr16:4332858	C/T	cg00021532	chr16:4324280	TFAP4	0.82	9.12	0.63	1.66e-15	Prostate-specific antigen levels;
TGCT	cis	rs933688	1.000	rs60513756	chr5:90727692	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.96	8.27	0.6	1.74e-13	Smoking behavior;
TGCT	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.38	4.67	0.39	7.61e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs10927875	0.800	rs1627145	chr1:16328116	C/T	cg22431228	chr1:16359049	CLCNKA	-0.25	-4.8	-0.4	4.39e-6	Dilated cardiomyopathy;
TGCT	cis	rs62103177	0.584	rs9956207	chr18:77968392	A/G	cg07235805	chr18:78004237	PARD6G	-0.51	-5.1	-0.42	1.25e-6	Opioid sensitivity;
TGCT	cis	rs8078723	0.674	rs9303284	chr17:38205793	C/T	cg17467752	chr17:38218738	THRA	-0.73	-7.17	-0.54	6.03e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs3796352	0.667	rs3755805	chr3:52866299	G/A	cg07884673	chr3:53033167	SFMBT1	0.62	5.35	0.43	4.16e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs3008870	0.583	rs2815369	chr1:67500894	T/C	cg11518657	chr1:67396239	MIER1	0.61	4.81	0.4	4.26e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg00684032	chr4:1343700	KIAA1530	0.22	4.9	0.4	2.93e-6	Obesity-related traits;
TGCT	cis	rs10197940	0.624	rs6724796	chr2:152412813	C/T	cg06191203	chr2:152266755	RIF1	-0.75	-7.03	-0.53	1.21e-10	Lung cancer;
TGCT	cis	rs4906332	0.966	rs4906331	chr14:103971374	C/T	cg26031613	chr14:104095156	KLC1	-0.54	-4.66	-0.39	8.15e-6	Coronary artery disease;
TGCT	cis	rs9467711	0.606	rs2073530	chr6:26375243	T/C	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4595586	0.546	rs2056159	chr12:39270417	C/G	cg13010199	chr12:38710504	ALG10B	0.62	4.86	0.4	3.45e-6	Morning vs. evening chronotype;
TGCT	trans	rs1864729	0.748	rs2635138	chr8:98301418	A/G	cg08679828	chr8:102218111	ZNF706	1.04	6.94	0.53	1.9e-10	Estradiol plasma levels (breast cancer);
TGCT	cis	rs637571	0.510	rs4930320	chr11:65576788	C/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.67	-6.01	-0.48	1.9e-8	Eosinophil percentage of white cells;
TGCT	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg23758822	chr17:41437982	NA	0.72	6.84	0.52	3.18e-10	Menopause (age at onset);
TGCT	cis	rs2742234	0.910	rs2503866	chr10:43646261	T/A	cg02780029	chr10:43622663	RET	-0.26	-5.05	-0.41	1.57e-6	Hirschsprung disease;
TGCT	cis	rs1580019	0.587	rs7806113	chr7:32553084	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.11	14.04	0.78	2.14e-27	Cognitive ability;
TGCT	cis	rs4319547	0.774	rs7959238	chr12:123131498	A/T	cg05707623	chr12:122985044	ZCCHC8	-0.65	-5.52	-0.44	1.89e-7	Body mass index;
TGCT	cis	rs7681440	0.904	rs28415623	chr4:90767110	C/T	cg20003494	chr4:90757398	SNCA	-0.62	-5.93	-0.47	2.74e-8	Dementia with Lewy bodies;
TGCT	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg03609598	chr5:56110824	MAP3K1	-0.58	-4.7	-0.39	6.72e-6	Initial pursuit acceleration;
TGCT	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg12311346	chr5:56204834	C5orf35	-0.67	-6.78	-0.52	4.34e-10	Initial pursuit acceleration;
TGCT	cis	rs6088580	0.634	rs6142153	chr20:32968747	C/G	cg06115741	chr20:33292138	TP53INP2	-0.53	-4.67	-0.39	7.83e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7772486	0.790	rs2265474	chr6:146182092	G/A	cg13319975	chr6:146136371	FBXO30	-0.54	-4.89	-0.4	3.07e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9948	0.786	rs62156230	chr2:97424915	A/G	cg01990225	chr2:97406019	LMAN2L	-0.8	-5.02	-0.41	1.74e-6	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs1034435	0.723	rs713946	chr22:48891376	T/C	cg05992904	chr22:48892994	FAM19A5	-0.34	-4.64	-0.38	8.54e-6	Late-onset Alzheimer's disease;
TGCT	cis	rs13326165	0.715	rs34908451	chr3:52385115	C/T	cg07884673	chr3:53033167	SFMBT1	0.39	4.69	0.39	7e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs7192750	0.586	rs13329779	chr16:71943940	T/C	cg06353428	chr16:71660113	MARVELD3	0.82	7.26	0.55	3.82e-11	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs2677744	0.688	rs6496737	chr15:91455618	C/T	cg23684204	chr15:91497937	RCCD1	0.33	4.81	0.4	4.32e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs1843834	0.931	rs10170573	chr2:225552916	A/G	cg22455342	chr2:225449267	CUL3	0.75	7.37	0.55	2.15e-11	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs9926296	0.656	rs2376881	chr16:89827011	C/G	cg03388025	chr16:89894329	SPIRE2	0.31	4.57	0.38	1.18e-5	Vitiligo;
TGCT	cis	rs9926296	0.557	rs11076618	chr16:89807705	T/C	cg03388025	chr16:89894329	SPIRE2	0.33	4.78	0.39	4.85e-6	Vitiligo;
TGCT	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.61	0.38	9.85e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs8013055	0.699	rs66798104	chr14:105987782	C/G	cg19700328	chr14:106028568	NA	-0.53	-5.79	-0.46	5.38e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs10875746	0.951	rs10875756	chr12:48562304	C/T	cg20731937	chr12:48336164	NA	0.62	4.94	0.41	2.46e-6	Longevity (90 years and older);
TGCT	cis	rs10504229	0.817	rs60646469	chr8:58195348	T/C	cg24829409	chr8:58192753	C8orf71	-0.53	-4.57	-0.38	1.18e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7809950	1.000	rs2520269	chr7:107191327	T/C	cg23024343	chr7:107201750	COG5	-0.35	-5.47	-0.44	2.36e-7	Coronary artery disease;
TGCT	cis	rs7224685	0.569	rs12452393	chr17:3985427	G/A	cg09580393	chr17:4869866	SPAG7	-0.39	-4.5	-0.37	1.56e-5	Type 2 diabetes;
TGCT	cis	rs1887596	0.607	rs9553870	chr13:27170716	G/A	cg01312412	chr13:27282625	NA	0.32	5.74	0.46	6.84e-8	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs11190604	1.000	rs11190602	chr10:102297256	T/C	cg16342193	chr10:102329863	NA	-0.41	-5.11	-0.42	1.18e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs13191362	1.000	rs34138336	chr6:163144929	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.0	7.73	0.57	3.24e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg02953382	chr22:24373134	LOC391322	-0.79	-8.35	-0.6	1.15e-13	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs67311347	1.000	rs7628796	chr3:40507332	G/A	cg13683864	chr3:40499215	RPL14	1.17	13.19	0.76	2.34e-25	Renal cell carcinoma;
TGCT	cis	rs775227	0.574	rs13067967	chr3:113265215	C/G	cg18753928	chr3:113234510	CCDC52	-0.66	-4.49	-0.37	1.64e-5	Dental caries;
TGCT	cis	rs9443645	0.901	rs9359354	chr6:79590385	A/G	cg05283184	chr6:79620031	NA	-0.21	-4.71	-0.39	6.61e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs12681287	0.640	rs10098356	chr8:87442667	A/G	cg27223183	chr8:87520930	FAM82B	0.89	6.43	0.5	2.54e-9	Caudate activity during reward;
TGCT	cis	rs2650000	0.798	rs2701175	chr12:121391671	C/A	cg02403541	chr12:121454288	C12orf43	-0.62	-5.3	-0.43	5.11e-7	Metabolic traits;LDL cholesterol;
TGCT	cis	rs6748734	0.894	rs4675869	chr2:241827696	A/G	cg04034577	chr2:241836375	C2orf54	-0.4	-6.32	-0.49	4.22e-9	Urinary metabolites;
TGCT	cis	rs501916	0.796	rs55961203	chr15:48050518	G/T	cg16110827	chr15:48056943	SEMA6D	-0.17	-4.73	-0.39	5.93e-6	Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs12762955	0.519	rs10795306	chr10:1019138	A/T	cg18964960	chr10:1102726	WDR37	-0.69	-6.19	-0.49	8.21e-9	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.61	0.38	9.85e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs394563	0.591	rs6570963	chr6:149691355	T/G	cg11245181	chr6:149772854	ZC3H12D	0.28	4.48	0.37	1.7e-5	Dupuytren's disease;
TGCT	cis	rs10089	0.951	rs736969	chr5:127466347	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	7.43	0.56	1.53e-11	Ileal carcinoids;
TGCT	cis	rs6570726	0.557	rs403956	chr6:145829956	T/C	cg05347473	chr6:146136440	FBXO30	0.62	5.72	0.46	7.48e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs17767294	0.708	rs72845060	chr6:27648935	G/A	cg08851530	chr6:28072375	NA	1.55	6.56	0.51	1.32e-9	Parkinson's disease;
TGCT	cis	rs7666738	0.830	rs6831588	chr4:98977356	T/G	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9911578	0.803	rs8069033	chr17:57131581	T/A	cg12560992	chr17:57184187	TRIM37	-0.78	-9.67	-0.66	7.8e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs644799	1.000	rs11021319	chr11:95523123	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	10.57	0.69	5.17e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs208520	0.690	rs851468	chr6:66825875	G/A	cg07460842	chr6:66804631	NA	-0.95	-9.88	-0.66	2.43e-17	Exhaled nitric oxide output;
TGCT	cis	rs8177179	0.967	rs10935085	chr3:133459735	C/T	cg24879335	chr3:133465180	TF	0.36	4.86	0.4	3.46e-6	Iron status biomarkers (transferrin levels);
TGCT	cis	rs57590327	0.503	rs6802480	chr3:81906671	G/A	cg07356753	chr3:81810745	GBE1	-0.7	-6.42	-0.5	2.68e-9	Extraversion;
TGCT	cis	rs7959452	0.590	rs7968629	chr12:69782857	G/A	cg11871910	chr12:69753446	YEATS4	0.82	8.95	0.63	4.38e-15	Blood protein levels;
TGCT	cis	rs524281	0.861	rs10896080	chr11:65876796	G/A	cg00563793	chr11:65837595	PACS1	0.54	4.55	0.38	1.24e-5	Electroencephalogram traits;
TGCT	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg01341218	chr17:43662625	NA	0.83	7.32	0.55	2.77e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs8008002	0.930	rs8007827	chr14:75865458	G/T	cg20011974	chr14:75469661	EIF2B2	-0.5	-4.48	-0.37	1.65e-5	Response to paliperidone in schizophrenia (positive Marder score);
TGCT	cis	rs6684514	1.000	rs12041164	chr1:156279811	G/A	cg16558208	chr1:156270281	VHLL	0.48	9.61	0.65	1.13e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs9318086	0.578	rs2077709	chr13:24476073	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.83	-9.34	-0.64	4.98e-16	Myopia (pathological);
TGCT	cis	rs8103278	0.507	rs522769	chr19:46284520	G/A	cg14061069	chr19:46274453	DMPK	0.61	10.51	0.69	7.14e-19	Coronary artery disease;
TGCT	cis	rs5771242	0.518	rs6010216	chr22:50679471	C/T	cg16473166	chr22:50639996	SELO	0.63	5.29	0.43	5.24e-7	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
TGCT	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg06558623	chr16:89946397	TCF25	0.56	6.83	0.52	3.38e-10	Skin colour saturation;
TGCT	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg06634786	chr22:41940651	POLR3H	0.89	8.55	0.61	3.83e-14	Vitiligo;
TGCT	cis	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg25427524	chr10:38739819	LOC399744	-0.37	-7.42	-0.55	1.6e-11	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs9814567	1.000	rs13059720	chr3:134242021	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.96	9.11	0.63	1.79e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs1475911	0.708	rs11701371	chr21:43523972	C/G	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.26	-5.23	-0.43	6.91e-7	IgG glycosylation;
TGCT	cis	rs1538970	0.924	rs3790582	chr1:45887288	T/C	cg05343316	chr1:45956843	TESK2	0.77	6.2	0.49	7.66e-9	Platelet count;
TGCT	cis	rs68092024	0.704	rs792832	chr3:99474862	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.51	6.19	0.49	8.23e-9	Cleft lip with or without cleft palate;
TGCT	trans	rs3780486	0.846	rs10971420	chr9:33125000	T/C	cg20290983	chr6:43655470	MRPS18A	1.18	14.81	0.8	3.33e-29	IgG glycosylation;
TGCT	trans	rs7618501	0.699	rs6446187	chr3:49907111	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.9	9.84	0.66	3.04e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs9436747	0.641	rs4655519	chr1:66039919	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.54	5.11	0.42	1.17e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs80282103	0.867	rs17155821	chr10:1071701	A/G	cg18964960	chr10:1102726	WDR37	1.08	4.63	0.38	9.23e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg23758822	chr17:41437982	NA	0.72	6.81	0.52	3.83e-10	Menopause (age at onset);
TGCT	cis	rs11122272	0.735	rs2486727	chr1:231539245	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-6.28	-0.49	5.32e-9	Hemoglobin concentration;
TGCT	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.01	8.32	0.6	1.34e-13	Platelet count;
TGCT	trans	rs1814175	0.817	rs1319547	chr11:49916705	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.36	-7.05	-0.53	1.13e-10	Height;
TGCT	cis	rs7681440	0.904	rs7671549	chr4:90771147	T/A	cg26578617	chr4:90757533	SNCA	-0.46	-4.73	-0.39	6.01e-6	Dementia with Lewy bodies;
TGCT	cis	rs2816062	0.813	rs2816057	chr1:18902257	G/C	cg18795169	chr1:18902165	NA	-0.6	-13.83	-0.78	6.99e-27	Urate levels in lean individuals;
TGCT	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg18230493	chr5:56204884	C5orf35	-0.67	-5.76	-0.46	6.2e-8	Initial pursuit acceleration;
TGCT	cis	rs9653442	0.522	rs4851274	chr2:100870862	T/C	cg07810366	chr2:100720526	AFF3	-0.38	-5.71	-0.46	7.81e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs12118280	1.000	rs12118280	chr1:108738780	T/C	cg11967332	chr1:108735228	SLC25A24	0.39	5.41	0.44	3.15e-7	Myeloid white cell count;
TGCT	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg03452623	chr4:187889614	NA	-0.38	-5.84	-0.46	4.25e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6540559	0.611	rs17015226	chr1:209970096	C/G	cg04352962	chr1:209979756	IRF6	0.68	4.79	0.4	4.64e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.84	0.46	4.39e-8	Height;
TGCT	cis	rs13326165	0.760	rs11706001	chr3:52372128	T/A	cg27565382	chr3:53032988	SFMBT1	0.37	4.91	0.4	2.84e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs904251	0.525	rs12200378	chr6:37425304	A/G	cg08126542	chr6:37504118	NA	-0.41	-5.73	-0.46	7.35e-8	Cognitive performance;
TGCT	cis	rs7666738	0.927	rs11736876	chr4:98987206	A/G	cg05340658	chr4:99064831	C4orf37	0.49	4.88	0.4	3.14e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6688613	0.694	rs11576455	chr1:166811970	G/A	cg07049167	chr1:166818506	POGK	0.24	4.87	0.4	3.34e-6	Refractive astigmatism;
TGCT	cis	rs62244186	0.632	rs1402751	chr3:44594030	C/A	cg25151919	chr3:44754333	ZNF502	-0.42	-4.91	-0.4	2.81e-6	Depressive symptoms;
TGCT	cis	rs6840360	1.000	rs751014	chr4:152601902	G/A	cg17479576	chr4:152424074	FAM160A1	-0.52	-5.66	-0.45	9.86e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs9914988	0.943	rs4794838	chr17:27131095	T/C	cg20469991	chr17:27169893	C17orf63	-0.72	-5.09	-0.42	1.29e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg03709012	chr19:19516395	GATAD2A	0.75	6.16	0.48	9.21e-9	Tonsillectomy;
TGCT	cis	rs909341	0.909	rs6122158	chr20:62363096	G/A	cg14758556	chr20:62440591	NA	0.3	4.53	0.38	1.38e-5	Atopic dermatitis;
TGCT	cis	rs924607	1.000	rs4045344	chr5:595870	G/T	cg04476341	chr5:669733	TPPP	-0.25	-4.49	-0.37	1.64e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs6912958	1.000	rs9294380	chr6:88152667	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.36	-4.55	-0.38	1.28e-5	Monocyte percentage of white cells;
TGCT	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg15242686	chr22:24348715	GSTTP1	0.44	5.87	0.47	3.81e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs3812831	0.654	rs367312	chr13:114930195	G/A	cg08824895	chr13:115047677	UPF3A	0.48	5.14	0.42	1.02e-6	Schizophrenia;
TGCT	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg22968622	chr17:43663579	NA	-1.24	-11.32	-0.71	7.53e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg12570787	chr5:219185	SDHA;CCDC127	0.65	4.46	0.37	1.83e-5	Breast cancer;
TGCT	cis	rs3733585	0.664	rs28602527	chr4:9958327	G/A	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.67	-0.51	7.44e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs4972806	0.814	rs2113560	chr2:177030986	T/C	cg13092806	chr2:177043255	NA	0.56	4.81	0.4	4.33e-6	IgG glycosylation;
TGCT	cis	rs6964587	1.000	rs58965837	chr7:91585258	T/A	cg22709100	chr7:91322751	NA	0.27	4.48	0.37	1.68e-5	Breast cancer;
TGCT	cis	rs6790105	1	rs6790105	chr3:49393409	C/T	cg07636037	chr3:49044803	WDR6	0.66	5.33	0.43	4.45e-7	Childhood ear infection;
TGCT	cis	rs3796352	1.000	rs35507120	chr3:53053924	C/T	cg07884673	chr3:53033167	SFMBT1	0.64	6.39	0.5	3.03e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs79349575	0.783	rs2088139	chr17:47000110	C/T	cg26022315	chr17:47021804	SNF8	0.48	4.8	0.4	4.52e-6	Type 2 diabetes;
TGCT	cis	rs7017914	0.870	rs3098877	chr8:71936446	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-4.97	-0.41	2.16e-6	Bone mineral density;
TGCT	cis	rs59698941	0.550	rs11748737	chr5:132201070	C/T	cg21474247	chr5:131268130	NA	0.31	4.77	0.39	5.01e-6	Apolipoprotein A-IV levels;
TGCT	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg11764359	chr7:65958608	NA	-0.56	-5.06	-0.41	1.45e-6	Aortic root size;
TGCT	cis	rs3617	0.539	rs4687687	chr3:52948332	A/G	cg11645453	chr3:52864694	ITIH4	-0.27	-5.32	-0.43	4.74e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs28595532	0.920	rs17259173	chr4:119777232	T/C	cg11846333	chr4:119757529	SEC24D	0.92	4.64	0.38	8.74e-6	Cannabis dependence symptom count;
TGCT	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.68	6.05	0.48	1.57e-8	Tonsillectomy;
TGCT	cis	rs2832191	0.967	rs1999321	chr21:30530233	A/C	cg24692254	chr21:30365293	RNF160	0.75	7.4	0.55	1.78e-11	Dental caries;
TGCT	cis	rs3858526	0.883	rs11039686	chr11:5948725	T/C	cg05234568	chr11:5960015	NA	-0.47	-4.56	-0.38	1.21e-5	DNA methylation (variation);
TGCT	cis	rs3617	0.522	rs6773650	chr3:52897095	A/T	cg10802521	chr3:52805072	NEK4	-0.56	-6.36	-0.5	3.6e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2629540	0.889	rs4962696	chr10:126445630	A/G	cg08799069	chr10:126477246	METTL10	-0.31	-4.7	-0.39	6.75e-6	Cocaine dependence;
TGCT	cis	rs13191362	0.938	rs13192618	chr6:163132822	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.07	8.83	0.62	8.46e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7267979	1.000	rs2258201	chr20:25272490	G/C	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11711311	0.712	rs3773684	chr3:113334488	A/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.62	5.11	0.42	1.16e-6	IgG glycosylation;
TGCT	cis	rs651907	0.557	rs3864012	chr3:101397623	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.24	0.43	6.66e-7	Colorectal cancer;
TGCT	cis	rs7940866	0.803	rs10894307	chr11:130876350	G/A	cg12179176	chr11:130786555	SNX19	0.58	5.5	0.44	2.04e-7	Schizophrenia;
TGCT	cis	rs35306767	0.623	rs36051896	chr10:1155747	T/C	cg20503657	chr10:835505	NA	0.54	5.8	0.46	5.25e-8	Eosinophil percentage of granulocytes;
TGCT	cis	rs41271951	0.512	rs6664387	chr1:151021509	A/G	cg00666978	chr1:150947442	LASS2	0.89	4.64	0.38	8.54e-6	Blood protein levels;
TGCT	cis	rs6752107	0.936	rs6431660	chr2:234167234	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.2	4.79	0.39	4.74e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg21862992	chr11:68658383	NA	0.48	6.35	0.5	3.63e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs425277	0.628	rs3107147	chr1:2048729	G/A	cg03732007	chr1:2071316	PRKCZ	-0.26	-5.9	-0.47	3.17e-8	Height;
TGCT	cis	rs2637266	0.967	rs7900230	chr10:78366879	A/G	cg18941641	chr10:78392320	NA	0.39	4.88	0.4	3.24e-6	Pulmonary function;
TGCT	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg27454412	chr7:1067447	C7orf50	0.6	4.7	0.39	6.76e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg23758822	chr17:41437982	NA	0.69	6.37	0.5	3.34e-9	Menopause (age at onset);
TGCT	cis	rs921968	0.542	rs588182	chr2:219412335	C/A	cg02176678	chr2:219576539	TTLL4	0.48	6.86	0.52	2.94e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs9660992	0.573	rs4400674	chr1:205218425	A/C	cg00857998	chr1:205179979	DSTYK	-0.5	-4.67	-0.39	7.78e-6	Mean corpuscular volume;Mean platelet volume;
TGCT	cis	rs10256972	0.694	rs7784701	chr7:1003041	A/G	cg07930192	chr7:1003750	NA	0.3	4.72	0.39	6.33e-6	Longevity;Endometriosis;
TGCT	cis	rs9467773	1.000	rs767471	chr6:26557854	C/T	cg05738196	chr6:26577821	NA	0.91	13.19	0.76	2.28e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs734999	0.545	rs4648565	chr1:2570023	A/G	cg18854424	chr1:2615690	NA	-0.45	-5.15	-0.42	1e-6	Ulcerative colitis;
TGCT	cis	rs9467773	0.935	rs1884947	chr6:26553273	G/T	cg02458000	chr6:26745757	NA	0.59	5.92	0.47	2.93e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2153535	0.580	rs1932282	chr6:8477330	G/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	trans	rs2727020	0.636	rs10839275	chr11:49438962	T/A	cg03929089	chr4:120376271	NA	-0.74	-8.55	-0.61	3.78e-14	Coronary artery disease;
TGCT	cis	rs7617773	0.746	rs7619865	chr3:48370580	G/A	cg11946769	chr3:48343235	NME6	0.73	6.76	0.52	4.71e-10	Coronary artery disease;
TGCT	cis	rs2439831	0.717	rs2447198	chr15:43895118	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.97	6.69	0.52	6.74e-10	Lung cancer in ever smokers;
TGCT	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg20607798	chr8:58055168	NA	0.5	4.66	0.39	8.04e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7829975	0.811	rs7011229	chr8:8543324	T/C	cg08975724	chr8:8085496	FLJ10661	-0.53	-4.58	-0.38	1.11e-5	Mood instability;
TGCT	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg08048268	chr3:133502702	NA	-0.66	-9.83	-0.66	3.36e-17	Iron status biomarkers;
TGCT	cis	rs4689388	0.926	rs10012946	chr4:6293350	C/T	cg25554036	chr4:6271136	WFS1	-0.55	-6.98	-0.53	1.54e-10	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs9549367	0.789	rs8001506	chr13:113867153	A/C	cg00898013	chr13:113819073	PROZ	-0.41	-5.32	-0.43	4.59e-7	Platelet distribution width;
TGCT	cis	rs9796	0.654	rs2947489	chr15:41459576	T/A	cg18705301	chr15:41695430	NDUFAF1	0.54	7.22	0.54	4.66e-11	Menopause (age at onset);
TGCT	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg26039829	chr8:22132926	PIWIL2	0.27	5.18	0.42	8.83e-7	Hypertriglyceridemia;
TGCT	cis	rs4242434	0.819	rs6999893	chr8:22465427	T/C	cg03733263	chr8:22462867	KIAA1967	1.08	17.46	0.84	3.22e-35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs713587	0.719	rs4665736	chr2:25187599	C/T	cg01884057	chr2:25150051	NA	-0.38	-7.8	-0.57	2.16e-12	Body mass index in non-asthmatics;
TGCT	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg11644478	chr21:40555479	PSMG1	-0.6	-4.98	-0.41	2.05e-6	Cognitive function;
TGCT	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg11941060	chr3:133502564	NA	-0.29	-6.16	-0.48	9.17e-9	Iron status biomarkers;
TGCT	cis	rs12780845	0.540	rs10490959	chr10:17230836	A/T	cg01003015	chr10:17271136	VIM	-0.49	-4.46	-0.37	1.82e-5	Homocysteine levels;
TGCT	cis	rs12579753	1.000	rs11115047	chr12:82232773	C/G	cg07988820	chr12:82153109	PPFIA2	-0.6	-6.48	-0.5	1.91e-9	Resting heart rate;
TGCT	cis	rs4073582	0.595	rs801731	chr11:65938446	G/C	cg16950941	chr11:66035639	RAB1B	0.55	5.42	0.44	2.94e-7	Gout;
TGCT	cis	rs9326248	1.000	rs7946257	chr11:117053165	A/G	cg16524733	chr11:117070046	TAGLN	0.32	4.56	0.38	1.23e-5	Blood protein levels;
TGCT	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg08736216	chr1:53307985	ZYG11A	-0.28	-5.38	-0.44	3.57e-7	Monocyte count;
TGCT	cis	rs992157	0.835	rs7559416	chr2:219150211	A/G	cg00012203	chr2:219082015	ARPC2	-0.77	-7.64	-0.57	5.1e-12	Colorectal cancer;
TGCT	cis	rs7208859	0.623	rs78071511	chr17:29128154	C/T	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs11122272	0.705	rs1416914	chr1:231533196	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.74	-7.35	-0.55	2.3e-11	Hemoglobin concentration;
TGCT	cis	rs4786125	0.626	rs6500859	chr16:6914358	A/T	cg03623568	chr16:6915990	A2BP1	-0.39	-5.83	-0.46	4.41e-8	Heart rate variability traits (SDNN);
TGCT	cis	rs2486012	0.737	rs6670344	chr1:44269208	A/G	cg12908607	chr1:44402522	ARTN	-0.71	-5.54	-0.45	1.75e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs16957091	0.647	rs28613047	chr15:43176165	G/A	cg17935677	chr15:44119062	WDR76	0.52	4.71	0.39	6.44e-6	MGMT methylation in smokers;
TGCT	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg11890956	chr21:40555474	PSMG1	-0.79	-7.72	-0.57	3.29e-12	Cognitive function;
TGCT	cis	rs35306767	0.855	rs61830900	chr10:871481	C/G	cg20503657	chr10:835505	NA	0.77	11.34	0.71	6.95e-21	Eosinophil percentage of granulocytes;
TGCT	cis	rs2072499	0.838	rs2758619	chr1:156162559	A/G	cg24450063	chr1:156163899	SLC25A44	1.19	17.21	0.84	1.15e-34	Testicular germ cell tumor;
TGCT	cis	rs611744	0.901	rs639746	chr8:109234825	T/C	cg21045802	chr8:109455806	TTC35	0.52	4.72	0.39	6.21e-6	Dupuytren's disease;
TGCT	cis	rs7208859	0.573	rs11654035	chr17:29136426	T/C	cg14008862	chr17:28927542	LRRC37B2	0.77	4.61	0.38	9.76e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs28595532	0.920	rs114581578	chr4:119756404	C/T	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs9296092	0.538	rs5000098	chr6:33519231	T/G	cg13560919	chr6:33536144	NA	-0.21	-4.75	-0.39	5.5e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg18402987	chr7:1209562	NA	0.48	4.79	0.39	4.72e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg17971929	chr21:40555470	PSMG1	0.98	9.57	0.65	1.43e-16	Cognitive function;
TGCT	cis	rs959260	0.528	rs9909443	chr17:73308346	C/T	cg14668889	chr17:73230827	NUP85	0.21	4.49	0.37	1.61e-5	Systemic lupus erythematosus;
TGCT	cis	rs1949733	1.000	rs3103071	chr4:8508579	C/G	cg11789530	chr4:8429930	ACOX3	-0.63	-5.82	-0.46	4.82e-8	Response to antineoplastic agents;
TGCT	cis	rs259282	0.524	rs731674	chr19:33132395	A/G	cg26639809	chr19:33781782	NA	0.21	4.45	0.37	1.93e-5	Schizophrenia;
TGCT	cis	rs7923609	0.783	rs7100409	chr10:65330195	T/A	cg08743896	chr10:65200160	JMJD1C	0.32	4.46	0.37	1.82e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs16939607	0.908	rs6997505	chr8:79004739	C/A	cg21244580	chr8:79934476	NA	0.47	4.71	0.39	6.52e-6	White blood cell count;
TGCT	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg01577475	chr2:114033581	PAX8;LOC440839	-0.45	-4.93	-0.41	2.54e-6	Lymphocyte counts;
TGCT	cis	rs1865760	0.865	rs1115920	chr6:25954027	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.64	6.29	0.49	4.91e-9	Height;
TGCT	cis	rs12049351	0.774	rs2381108	chr1:229637881	T/G	cg12130225	chr1:229698885	NA	0.39	4.59	0.38	1.06e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs910316	0.967	rs4899550	chr14:75647666	C/T	cg08847533	chr14:75593920	NEK9	-0.91	-9.96	-0.67	1.56e-17	Height;
TGCT	cis	rs72781680	0.898	rs72780188	chr2:24006065	G/A	cg08917208	chr2:24149416	ATAD2B	0.81	5.01	0.41	1.8e-6	Lymphocyte counts;
TGCT	cis	rs9443645	0.901	rs9361460	chr6:79589467	C/G	cg05283184	chr6:79620031	NA	-0.22	-4.98	-0.41	2.11e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7474896	0.537	rs598857	chr10:38302926	A/G	cg13720705	chr10:37990370	NA	-0.35	-4.73	-0.39	5.99e-6	Obesity (extreme);
TGCT	cis	rs1894292	0.527	rs4267703	chr4:74375921	T/C	cg05868023	chr4:75230803	EREG	0.56	5.05	0.41	1.56e-6	Prostate cancer;
TGCT	cis	rs477895	0.838	rs11605738	chr11:64013406	G/A	cg04317338	chr11:64019027	PLCB3	0.81	6.9	0.53	2.35e-10	Mean platelet volume;
TGCT	cis	rs9916302	0.904	rs11867312	chr17:37597748	C/T	cg07936489	chr17:37558343	FBXL20	-0.61	-4.82	-0.4	4.16e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs2688608	0.530	rs71507081	chr10:75493136	G/A	cg23231163	chr10:75533350	FUT11	-0.28	-4.68	-0.39	7.4e-6	Inflammatory bowel disease;
TGCT	trans	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-1.03	-13.16	-0.76	2.65e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs7246657	0.765	rs7247259	chr19:37851090	T/C	cg03233940	chr19:37894644	NA	-0.34	-4.49	-0.37	1.59e-5	Coronary artery calcification;
TGCT	cis	rs1949733	1.000	rs2140337	chr4:8502112	A/G	cg11789530	chr4:8429930	ACOX3	0.64	5.95	0.47	2.52e-8	Response to antineoplastic agents;
TGCT	cis	rs10057188	1.000	rs6886783	chr5:77843876	C/T	cg06873401	chr5:77792105	LHFPL2	-0.25	-4.93	-0.41	2.53e-6	Pulse pressure;
TGCT	cis	rs13191362	1.000	rs13218900	chr6:163081638	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.91	6.97	0.53	1.69e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg11890956	chr21:40555474	PSMG1	-0.76	-7.45	-0.56	1.36e-11	Cognitive function;
TGCT	cis	rs68170813	0.559	rs74774133	chr7:106941449	T/C	cg02696742	chr7:106810147	HBP1	-0.69	-5.81	-0.46	4.85e-8	Coronary artery disease;
TGCT	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg16325326	chr1:53192061	ZYG11B	0.73	9.0	0.63	3.34e-15	Monocyte count;
TGCT	cis	rs34779708	0.897	rs9787566	chr10:35279455	T/A	cg04310649	chr10:35416472	CREM	-0.51	-4.55	-0.38	1.24e-5	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs4664308	0.905	rs7567781	chr2:160999537	A/G	cg03641300	chr2:160917029	PLA2R1	-0.27	-6.74	-0.52	5.42e-10	Idiopathic membranous nephropathy;
TGCT	cis	rs34014631	1.000	rs116564386	chr10:103583355	T/C	cg22630918	chr10:102748988	C10orf2	0.43	4.83	0.4	3.98e-6	Coronary artery calcification;
TGCT	cis	rs3020333	0.846	rs3020335	chr6:152013223	G/T	cg22157087	chr6:152012887	ESR1	0.19	4.58	0.38	1.1e-5	Total body bone mineral density;
TGCT	cis	rs7845219	0.525	rs7820818	chr8:95919231	G/A	cg16049864	chr8:95962084	TP53INP1	-0.51	-5.45	-0.44	2.56e-7	Type 2 diabetes;
TGCT	cis	rs2239547	0.522	rs2710345	chr3:52976075	T/C	cg10802521	chr3:52805072	NEK4	0.64	6.1	0.48	1.24e-8	Schizophrenia;
TGCT	trans	rs10506458	0.915	rs12426308	chr12:63405778	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.47	-7.52	-0.56	9.68e-12	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs2235642	0.928	rs1057610	chr16:1605537	T/C	cg08296037	chr16:1584118	IFT140;TMEM204	-0.31	-5.47	-0.44	2.39e-7	Coronary artery disease;
TGCT	cis	rs9640161	0.830	rs3757424	chr7:150067679	C/A	cg10018233	chr7:150070692	REPIN1	0.4	6.51	0.5	1.68e-9	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs2820315	0.867	rs2820317	chr1:201878537	G/C	cg12730843	chr1:201915899	LMOD1	-0.28	-5.13	-0.42	1.07e-6	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
TGCT	cis	rs910316	0.967	rs175432	chr14:75615246	C/G	cg11812906	chr14:75593930	NEK9	-0.76	-7.27	-0.55	3.45e-11	Height;
TGCT	cis	rs8077889	0.917	rs6503479	chr17:41917003	A/G	cg26893861	chr17:41843967	DUSP3	1.1	12.37	0.74	2.15e-23	Triglycerides;
TGCT	cis	rs12510870	0.599	rs7676870	chr4:74449722	C/T	cg05868023	chr4:75230803	EREG	-0.54	-4.76	-0.39	5.33e-6	Iris color (b* coordinate);
TGCT	cis	rs9467773	0.620	rs2504571	chr6:26643435	C/T	cg15659132	chr6:26577336	NA	0.85	10.79	0.7	1.54e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs28595532	0.920	rs116105567	chr4:119746204	C/T	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs62380364	0.565	rs617944	chr5:88057915	T/C	cg24804195	chr5:87968844	LOC645323	-0.55	-5.34	-0.43	4.23e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7666738	0.830	rs115712871	chr4:98954535	A/T	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs236907	0.814	rs6695933	chr1:171774239	A/C	cg20598894	chr1:171756153	METTL13	-0.2	-4.59	-0.38	1.07e-5	Mean platelet volume;
TGCT	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-5.1	-0.42	1.23e-6	Electroencephalogram traits;
TGCT	cis	rs55823223	0.702	rs3785437	chr17:73906222	G/T	cg10935138	chr17:73851978	WBP2	1.02	6.29	0.49	5.06e-9	Psoriasis;
TGCT	cis	rs17102423	0.731	rs10143198	chr14:65555471	C/T	cg11161011	chr14:65562177	MAX	-0.43	-5.91	-0.47	3.04e-8	Obesity-related traits;
TGCT	cis	rs11577318	0.579	rs11247934	chr1:26695758	A/T	cg15090202	chr1:26687087	NA	0.58	4.43	0.37	2.01e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs2439831	0.681	rs540031	chr15:43608855	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	6.75	0.52	4.98e-10	Lung cancer in ever smokers;
TGCT	cis	rs61990749	0.597	rs117131659	chr14:78131126	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.61	-4.45	-0.37	1.89e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.61	5.06	0.41	1.5e-6	Tonsillectomy;
TGCT	cis	rs13256369	1.000	rs883648	chr8:8569521	A/G	cg06671706	chr8:8559999	CLDN23	0.34	4.57	0.38	1.18e-5	Obesity-related traits;
TGCT	cis	rs28595532	0.920	rs115860482	chr4:119759546	A/G	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs62380364	0.727	rs304137	chr5:88169652	A/G	cg22951263	chr5:87985283	NA	0.5	5.02	0.41	1.79e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg03303774	chr4:1407052	NA	-0.32	-4.88	-0.4	3.21e-6	Obesity-related traits;
TGCT	cis	rs2242194	0.816	rs2242193	chr1:154995503	A/G	cg24348479	chr1:155007323	DCST1;DCST2	-0.27	-5.72	-0.46	7.46e-8	Schizophrenia;
TGCT	cis	rs6754311	0.589	rs11681659	chr2:136820960	C/T	cg07169764	chr2:136633963	MCM6	-0.56	-5.5	-0.44	2.08e-7	Mosquito bite size;
TGCT	cis	rs9457247	1.000	rs376574	chr6:167389956	A/T	cg23791538	chr6:167370224	RNASET2	-0.5	-4.98	-0.41	2.08e-6	Crohn's disease;
TGCT	cis	rs28595532	0.920	rs116739193	chr4:119771024	G/A	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs13177918	0.626	rs13170300	chr5:149829311	G/A	cg14059543	chr5:149831962	NA	-0.69	-9.27	-0.64	7.32e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs35883536	0.935	rs1577510	chr1:101114295	G/A	cg06223162	chr1:101003688	GPR88	-0.29	-4.79	-0.4	4.61e-6	Monocyte count;
TGCT	cis	rs9911578	1.000	rs302848	chr17:56686454	C/T	cg12560992	chr17:57184187	TRIM37	0.74	9.71	0.66	6.46e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs5769707	0.609	rs135861	chr22:49998118	A/G	cg05373962	chr22:49881684	NA	-0.3	-5.16	-0.42	9.59e-7	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs2070488	0.775	rs6599207	chr3:38554901	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.73	-7.01	-0.53	1.37e-10	Electrocardiographic conduction measures;
TGCT	cis	rs752092	0.894	rs8043243	chr15:101771453	C/T	cg25114630	chr15:101792522	CHSY1	0.49	4.47	0.37	1.74e-5	Corneal structure;
TGCT	cis	rs9611519	0.780	rs9611527	chr22:41644428	G/A	cg06634786	chr22:41940651	POLR3H	-0.58	-5.32	-0.43	4.77e-7	Neuroticism;
TGCT	cis	rs3008870	0.755	rs2815364	chr1:67498384	C/T	cg11518657	chr1:67396239	MIER1	0.47	4.61	0.38	9.68e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs4664308	1.000	rs10929965	chr2:160906931	C/T	cg03641300	chr2:160917029	PLA2R1	0.26	6.53	0.51	1.49e-9	Idiopathic membranous nephropathy;
TGCT	cis	rs35160687	0.640	rs13015186	chr2:86485578	A/G	cg03171300	chr2:86307199	POLR1A	0.32	5.35	0.43	4.05e-7	Night sleep phenotypes;
TGCT	cis	rs3806843	0.547	rs246065	chr5:140323638	A/G	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9916302	0.904	rs8079303	chr17:37530755	G/C	cg07936489	chr17:37558343	FBXL20	0.65	5.08	0.41	1.36e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs2721195	0.845	rs2721150	chr8:145724973	C/G	cg15320075	chr8:145703422	NA	0.7	6.8	0.52	3.84e-10	Age at first birth;
TGCT	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg03396347	chr1:1875803	NA	-0.38	-6.89	-0.53	2.45e-10	Body mass index;
TGCT	cis	rs7216064	0.589	rs8072723	chr17:66056970	T/A	cg12091567	chr17:66097778	LOC651250	1.17	9.62	0.65	1.04e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs2832191	0.791	rs7283853	chr21:30498515	G/A	cg08807101	chr21:30365312	RNF160	-0.62	-5.8	-0.46	5.14e-8	Dental caries;
TGCT	cis	rs45535039	0.506	rs2511856	chr11:119144148	A/C	cg16724696	chr11:118992527	HINFP	-0.68	-6.0	-0.47	2.06e-8	Plateletcrit;
TGCT	cis	rs8070740	0.786	rs8067738	chr17:5328661	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.49	4.49	0.37	1.63e-5	Menopause (age at onset);
TGCT	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg17345569	chr6:42928274	GNMT	-0.43	-4.43	-0.37	2.01e-5	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs9436747	0.641	rs10493379	chr1:66045927	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.58	5.22	0.42	7.22e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs739496	0.512	rs6489793	chr12:112249884	T/G	cg10833066	chr12:111807467	FAM109A	0.38	5.67	0.45	9.69e-8	Platelet count;
TGCT	cis	rs11783469	0.524	rs17089281	chr8:23335151	T/C	cg00472375	chr8:23315376	ENTPD4	0.67	5.08	0.41	1.37e-6	Reticulocyte count;
TGCT	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.54	-4.89	-0.4	3.1e-6	Menarche (age at onset);
TGCT	cis	rs9325144	0.554	rs7960616	chr12:39096664	T/A	cg26384229	chr12:38710491	ALG10B	-0.55	-5.16	-0.42	9.52e-7	Morning vs. evening chronotype;
TGCT	cis	rs12477438	0.700	rs12467679	chr2:99654449	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-5.87	-0.47	3.74e-8	Chronic sinus infection;
TGCT	cis	rs6740322	1.000	rs4128209	chr2:43554729	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.38	-6.32	-0.49	4.21e-9	Coronary artery disease;
TGCT	cis	rs10464366	0.544	rs12668821	chr7:39167846	T/A	cg15212455	chr7:39170539	POU6F2	0.3	6.63	0.51	9.08e-10	IgG glycosylation;
TGCT	cis	rs910187	0.678	rs3818008	chr20:45816488	C/T	cg27589058	chr20:45804311	EYA2	-0.35	-7.58	-0.56	7.14e-12	Migraine;
TGCT	cis	rs2153535	0.580	rs9393025	chr6:8490618	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs17102423	0.594	rs1270074	chr14:65564856	T/C	cg11161011	chr14:65562177	MAX	-0.47	-6.42	-0.5	2.65e-9	Obesity-related traits;
TGCT	cis	rs896854	0.738	rs527234	chr8:95963798	C/G	cg16049864	chr8:95962084	TP53INP1	0.63	7.6	0.56	6.45e-12	Type 2 diabetes;
TGCT	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-5.1	-0.42	1.23e-6	Bipolar disorder;
TGCT	cis	rs9486719	1.000	rs12208124	chr6:97027942	C/T	cg06623918	chr6:96969491	KIAA0776	-0.99	-8.05	-0.59	5.65e-13	Migraine;Coronary artery disease;
TGCT	cis	rs7714584	1.000	rs11167520	chr5:150265639	T/C	cg22134413	chr5:150180641	NA	0.78	6.12	0.48	1.16e-8	Crohn's disease;
TGCT	cis	rs3784262	1.000	rs3784262	chr15:58253106	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.49	-7.67	-0.57	4.27e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs909002	0.800	rs7549590	chr1:32109849	G/A	cg11573219	chr1:32083031	HCRTR1	-0.42	-5.41	-0.44	3.18e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1395	0.848	rs6716850	chr2:27525350	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.49	6.41	0.5	2.71e-9	Blood metabolite levels;
TGCT	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg11905131	chr22:24372483	LOC391322	0.66	5.2	0.42	7.88e-7	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg13395646	chr4:1353034	KIAA1530	-0.55	-7.57	-0.56	7.56e-12	Obesity-related traits;
TGCT	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg00484396	chr16:3507460	NAT15	0.43	6.52	0.51	1.62e-9	Tuberculosis;
TGCT	cis	rs1577917	1.000	rs791856	chr6:86681841	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.64	5.1	0.42	1.22e-6	Response to antipsychotic treatment;
TGCT	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg18110333	chr6:292329	DUSP22	-0.72	-7.63	-0.57	5.43e-12	Menopause (age at onset);
TGCT	cis	rs4478858	0.698	rs6669381	chr1:31833506	A/G	cg07478791	chr1:31886160	SERINC2	-0.51	-4.93	-0.41	2.55e-6	Alcohol dependence;
TGCT	cis	rs7772486	0.686	rs1011596	chr6:146076433	A/G	cg13319975	chr6:146136371	FBXO30	-0.53	-4.65	-0.39	8.25e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6912958	0.781	rs9450723	chr6:88226641	C/T	cg06598631	chr6:88300029	RARS2;ORC3L	0.5	4.65	0.39	8.23e-6	Monocyte percentage of white cells;
TGCT	cis	rs2013441	1.000	rs34089239	chr17:20057959	G/T	cg23224458	chr17:20280056	CCDC144C	0.38	4.61	0.38	9.96e-6	Obesity-related traits;
TGCT	cis	rs10872587	0.657	rs11155459	chr6:146578751	A/G	cg05347473	chr6:146136440	FBXO30	-0.6	-4.68	-0.39	7.54e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs12540874	0.698	rs10899736	chr7:50546925	C/T	cg18232548	chr7:50535776	DDC	-0.37	-6.77	-0.52	4.49e-10	Systemic sclerosis;
TGCT	cis	rs1245541	0.595	rs1668155	chr10:73858139	T/C	cg10983208	chr10:73848320	SPOCK2	-0.26	-4.45	-0.37	1.88e-5	Insulin-like growth factors;
TGCT	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg00475322	chr7:917719	C7orf20	0.55	7.95	0.58	9.94e-13	Perceived unattractiveness to mosquitoes;
TGCT	cis	rs7681440	0.904	rs12331318	chr4:90770255	A/G	cg20003494	chr4:90757398	SNCA	-0.61	-5.75	-0.46	6.58e-8	Dementia with Lewy bodies;
TGCT	cis	rs2153535	0.504	rs9405393	chr6:8467432	G/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs36051895	0.632	rs12001334	chr9:5152604	C/A	cg02405213	chr9:5042618	JAK2	-0.75	-9.81	-0.66	3.66e-17	Pediatric autoimmune diseases;
TGCT	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg12311346	chr5:56204834	C5orf35	-0.66	-6.37	-0.5	3.3e-9	Initial pursuit acceleration;
TGCT	cis	rs7845219	0.539	rs713113	chr8:95877787	C/T	cg13393036	chr8:95962371	TP53INP1	0.49	5.95	0.47	2.55e-8	Type 2 diabetes;
TGCT	cis	rs6598955	0.543	rs60433268	chr1:26548055	A/C	cg04990556	chr1:26633338	UBXN11	0.8	7.3	0.55	3.01e-11	Obesity-related traits;
TGCT	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2120019	1.000	rs60425110	chr15:75333000	T/A	cg09165964	chr15:75287851	SCAMP5	-1.14	-10.22	-0.68	3.76e-18	Blood trace element (Zn levels);
TGCT	cis	rs6666258	1.000	rs13376333	chr1:154814353	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.59	-4.83	-0.4	3.97e-6	Atrial fibrillation;
TGCT	cis	rs62064224	0.614	rs4794921	chr17:30742310	C/T	cg18200150	chr17:30822561	MYO1D	0.39	4.71	0.39	6.52e-6	Schizophrenia;
TGCT	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg08736216	chr1:53307985	ZYG11A	0.25	4.93	0.4	2.59e-6	Monocyte count;
TGCT	cis	rs6589563	0.737	rs57200947	chr11:116623674	C/T	cg01124546	chr11:117515332	DSCAML1	-0.44	-4.77	-0.39	5.18e-6	Eosinophil counts;
TGCT	cis	rs6088580	0.634	rs3736762	chr20:33037336	C/T	cg08999081	chr20:33150536	PIGU	0.29	5.67	0.45	9.68e-8	Glomerular filtration rate (creatinine);
TGCT	cis	rs9467773	0.572	rs13213953	chr6:26594534	T/A	cg05738196	chr6:26577821	NA	0.87	10.44	0.68	1.08e-18	Intelligence (multi-trait analysis);
TGCT	cis	rs319204	0.843	rs319160	chr5:146300571	T/C	cg25021259	chr5:146258546	PPP2R2B	0.37	4.59	0.38	1.06e-5	Schizophrenia;
TGCT	cis	rs28595532	0.844	rs115202072	chr4:119732458	C/T	cg14228332	chr4:119757509	SEC24D	1.32	6.38	0.5	3.2e-9	Cannabis dependence symptom count;
TGCT	cis	rs36051895	0.632	rs7036536	chr9:5181610	T/C	cg02405213	chr9:5042618	JAK2	-0.76	-10.76	-0.69	1.8e-19	Pediatric autoimmune diseases;
TGCT	cis	rs9902453	0.817	rs67206808	chr17:28190096	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	7.15	0.54	6.65e-11	Coffee consumption (cups per day);
TGCT	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg27454412	chr7:1067447	C7orf50	0.6	4.7	0.39	6.76e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2153535	0.623	rs2152346	chr6:8454652	A/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs4919694	1.000	rs78214351	chr10:104822688	A/G	cg04362960	chr10:104952993	NT5C2	1.07	7.09	0.54	8.9e-11	Arsenic metabolism;
TGCT	cis	rs6141769	0.542	rs28536730	chr20:31301954	A/C	cg13636640	chr20:31349939	DNMT3B	-0.51	-4.48	-0.37	1.68e-5	Subjective well-being;
TGCT	cis	rs1775715	0.737	rs2799031	chr10:32173168	C/T	cg14930904	chr10:32216787	ARHGAP12	0.54	5.3	0.43	5.12e-7	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs514406	0.861	rs11206026	chr1:53281708	G/A	cg08859206	chr1:53392774	SCP2	-0.38	-5.68	-0.45	8.95e-8	Monocyte count;
TGCT	cis	rs478304	0.651	rs948493	chr11:65552154	C/T	cg17480646	chr11:65405466	SIPA1	-0.55	-6.45	-0.5	2.25e-9	Acne (severe);
TGCT	cis	rs9611519	1.000	rs5758264	chr22:41616284	T/G	cg03806693	chr22:41940476	POLR3H	-0.66	-6.3	-0.49	4.65e-9	Neuroticism;
TGCT	cis	rs7296418	0.961	rs10773921	chr12:123541606	C/T	cg00376283	chr12:123451042	ABCB9	0.81	7.38	0.55	2.03e-11	Platelet count;
TGCT	cis	rs71636778	0.509	rs12752711	chr1:27250258	G/C	cg23921621	chr1:27994728	IFI6	-0.43	-4.61	-0.38	9.95e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
TGCT	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg16325326	chr1:53192061	ZYG11B	0.5	5.56	0.45	1.56e-7	Monocyte count;
TGCT	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	6.75	0.52	5.18e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9611565	0.512	rs7291736	chr22:42124874	C/A	cg13695892	chr22:41940480	POLR3H	0.88	8.63	0.61	2.45e-14	Vitiligo;
TGCT	cis	rs931127	0.502	rs1466462	chr11:65419364	C/G	cg27068330	chr11:65405492	SIPA1	1.01	11.9	0.73	3.05e-22	Systemic lupus erythematosus;
TGCT	cis	rs9611565	0.592	rs5996038	chr22:41965300	T/C	cg17554472	chr22:41940697	POLR3H	-0.48	-4.94	-0.41	2.47e-6	Vitiligo;
TGCT	cis	rs9916302	0.784	rs4795382	chr17:37700860	A/G	cg07936489	chr17:37558343	FBXL20	-0.61	-4.87	-0.4	3.29e-6	Glomerular filtration rate (creatinine);
TGCT	trans	rs551517	0.541	rs575638	chr9:113639333	C/T	cg18410444	chr5:89825535	LYSMD3	0.67	6.77	0.52	4.49e-10	Post bronchodilator FEV1 in COPD;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
TGCT	cis	rs6901250	1.000	rs6924002	chr6:117114223	A/T	cg12892004	chr6:117198278	RFX6	0.46	5.23	0.43	6.85e-7	C-reactive protein levels;
TGCT	trans	rs4650994	1.000	rs4354501	chr1:178524596	T/C	cg05059571	chr16:84539110	KIAA1609	-0.41	-7.67	-0.57	4.37e-12	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs9916302	0.898	rs8072297	chr17:37478048	A/T	cg15445000	chr17:37608096	MED1	-0.33	-4.61	-0.38	9.9e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7582180	0.614	rs4340543	chr2:101005511	G/A	cg08017756	chr2:100939284	LONRF2	-0.3	-4.77	-0.39	5.16e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs12220898	0.679	rs10776555	chr10:50484995	A/G	cg06072769	chr10:50146962	WDFY4	0.38	5.07	0.41	1.38e-6	Inflammatory biomarkers;
TGCT	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg06634786	chr22:41940651	POLR3H	-0.88	-8.54	-0.61	3.98e-14	Vitiligo;
TGCT	cis	rs9916302	0.752	rs676882	chr17:37433424	A/T	cg07936489	chr17:37558343	FBXL20	0.94	6.14	0.48	1.02e-8	Glomerular filtration rate (creatinine);
TGCT	cis	rs7226408	0.842	rs72883593	chr18:34390840	G/A	cg06757138	chr18:34340585	FHOD3	0.26	4.79	0.4	4.62e-6	Obesity-related traits;
TGCT	cis	rs7917772	0.582	rs11191352	chr10:104372244	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	5.36	0.43	3.84e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs3820068	0.581	rs74054797	chr1:15926217	G/A	cg05660106	chr1:15850417	CASP9	0.82	8.02	0.58	6.63e-13	Systolic blood pressure;
TGCT	cis	rs909674	0.865	rs5757683	chr22:39850174	G/A	cg24399712	chr22:39784796	NA	-1.05	-11.23	-0.71	1.25e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs4888262	0.526	rs8055803	chr16:74615190	A/G	cg01733217	chr16:74700730	RFWD3	0.75	7.54	0.56	8.8e-12	Testicular germ cell tumor;
TGCT	cis	rs12681288	0.862	rs2600487	chr8:1016903	C/T	cg21347738	chr8:1310380	NA	-0.22	-4.44	-0.37	1.93e-5	Schizophrenia;
TGCT	cis	rs7014346	0.767	rs12678562	chr8:128422488	A/G	cg04263511	chr8:128962092	PVT1	-0.31	-4.5	-0.37	1.54e-5	Colorectal cancer;
TGCT	trans	rs2469997	1.000	rs2469998	chr8:120354022	G/A	cg01792902	chr3:178864926	PIK3CA	0.78	6.66	0.51	7.93e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs12142240	0.698	rs72677585	chr1:46812374	T/C	cg14993813	chr1:46806288	NSUN4	-0.58	-4.79	-0.4	4.68e-6	Menopause (age at onset);
TGCT	cis	rs77741769	0.529	rs909053	chr12:121237668	G/A	cg02419362	chr12:121203948	SPPL3	0.19	4.49	0.37	1.63e-5	Mean corpuscular volume;
TGCT	cis	rs910316	0.763	rs175435	chr14:75612025	A/G	cg11812906	chr14:75593930	NEK9	0.63	5.82	0.46	4.69e-8	Height;
TGCT	cis	rs2439831	0.867	rs935901	chr15:43651256	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	5.28	0.43	5.66e-7	Lung cancer in ever smokers;
TGCT	cis	rs611744	0.538	rs13257548	chr8:109273185	G/A	cg21045802	chr8:109455806	TTC35	0.82	8.65	0.61	2.19e-14	Dupuytren's disease;
TGCT	trans	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg27523141	chr10:43048294	ZNF37B	0.73	8.58	0.61	3.32e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs1153858	1.000	rs1554521	chr15:45664189	A/T	cg14582100	chr15:45693742	SPATA5L1	-0.51	-5.99	-0.47	2.12e-8	Homoarginine levels;
TGCT	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg09365446	chr1:150670422	GOLPH3L	0.31	4.71	0.39	6.57e-6	Tonsillectomy;
TGCT	cis	rs9990333	0.562	rs55970879	chr3:195821966	G/A	cg14488913	chr3:195402182	SDHAP2	-0.36	-4.6	-0.38	1.03e-5	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);
TGCT	cis	rs4808199	0.948	rs7250368	chr19:19452763	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.69	5.48	0.44	2.24e-7	Nonalcoholic fatty liver disease;
TGCT	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg18876405	chr7:65276391	NA	-0.32	-4.92	-0.4	2.72e-6	Aortic root size;
TGCT	cis	rs1034435	0.755	rs6007869	chr22:48894213	A/G	cg05992904	chr22:48892994	FAM19A5	-0.33	-4.53	-0.38	1.37e-5	Late-onset Alzheimer's disease;
TGCT	cis	rs7523273	0.597	rs4844620	chr1:207980901	C/T	cg22525895	chr1:207977042	MIR29B2	-0.44	-6.28	-0.49	5.18e-9	Schizophrenia;
TGCT	cis	rs7523050	0.730	rs11102650	chr1:109464228	C/G	cg08274380	chr1:109419600	GPSM2	1.27	6.86	0.52	2.9e-10	Fat distribution (HIV);
TGCT	cis	rs35306767	0.903	rs11253488	chr10:922482	G/C	cg26597838	chr10:835615	NA	0.75	10.54	0.69	6.3e-19	Eosinophil percentage of granulocytes;
TGCT	cis	rs9393777	0.720	rs56874662	chr6:26985607	C/A	cg16898833	chr6:26189333	HIST1H4D	0.97	5.95	0.47	2.6e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs4325129	1.000	rs12133664	chr1:159460890	C/T	cg20944283	chr1:159172620	CADM3	-0.28	-4.44	-0.37	1.96e-5	Obesity-related traits;
TGCT	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	8.55	0.61	3.84e-14	Platelet count;
TGCT	cis	rs2242116	0.760	rs4682845	chr3:46955404	G/C	cg23352942	chr3:46931381	PTH1R	-0.34	-4.97	-0.41	2.19e-6	Birth weight;
TGCT	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	6.23	0.49	6.56e-9	Bipolar disorder;
TGCT	cis	rs7666738	0.719	rs4699323	chr4:98967484	G/A	cg17366294	chr4:99064904	C4orf37	0.69	4.96	0.41	2.23e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6976053	0.818	rs13241786	chr7:100486656	T/G	cg03880458	chr7:100306854	NA	0.17	4.51	0.38	1.47e-5	Plasminogen activator inhibitor type 1 levels (PAI-1);
TGCT	cis	rs17030434	1.000	rs12651051	chr4:154722114	A/G	cg14289246	chr4:154710475	SFRP2	-0.91	-7.2	-0.54	5.18e-11	Electrocardiographic conduction measures;
TGCT	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg25036284	chr2:26402008	FAM59B	-0.57	-4.99	-0.41	2e-6	Gut microbiome composition (summer);
TGCT	cis	rs651907	0.535	rs11711903	chr3:101500748	C/G	cg11279151	chr3:101281821	RG9MTD1	-0.29	-6.22	-0.49	6.91e-9	Colorectal cancer;
TGCT	cis	rs7552404	1.000	rs11161521	chr1:76216330	T/C	cg22875332	chr1:76189707	ACADM	0.76	9.2	0.64	1.1e-15	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9527	0.590	rs10883829	chr10:104840635	T/C	cg04362960	chr10:104952993	NT5C2	0.66	5.55	0.45	1.62e-7	Arsenic metabolism;
TGCT	cis	rs763014	0.966	rs7198877	chr16:661439	A/G	cg27436995	chr16:743998	FBXL16	-0.45	-4.92	-0.4	2.64e-6	Height;
TGCT	cis	rs72843506	0.722	rs9908032	chr17:20108184	C/G	cg18979559	chr17:20280153	CCDC144C	-0.65	-4.89	-0.4	3.07e-6	Schizophrenia;
TGCT	cis	rs13064411	0.696	rs7622740	chr3:113206771	G/A	cg18753928	chr3:113234510	CCDC52	-0.69	-5.57	-0.45	1.47e-7	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs1577917	1.000	rs6923148	chr6:86767786	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.67	5.5	0.44	2.05e-7	Response to antipsychotic treatment;
TGCT	cis	rs2439831	0.867	rs11856184	chr15:43919162	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	4.95	0.41	2.38e-6	Lung cancer in ever smokers;
TGCT	cis	rs7089973	0.604	rs11196937	chr10:116589500	G/C	cg03647239	chr10:116582469	FAM160B1	0.59	5.75	0.46	6.46e-8	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs13217239	0.646	rs12523820	chr6:27001502	A/G	cg26531700	chr6:26746687	NA	0.68	6.86	0.52	2.83e-10	Schizophrenia;
TGCT	cis	rs78456975	1.000	rs72776252	chr2:1525599	G/A	cg01028140	chr2:1542097	TPO	-0.36	-4.63	-0.38	9.02e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs6921919	0.515	rs1558205	chr6:28382262	A/C	cg18815343	chr6:28367644	ZSCAN12	0.47	4.8	0.4	4.5e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs951366	0.677	rs1775140	chr1:205672107	C/A	cg07157834	chr1:205819609	PM20D1	0.44	6.76	0.52	4.71e-10	Menarche (age at onset);
TGCT	cis	rs7635838	0.892	rs6442252	chr3:11451416	T/C	cg00170343	chr3:11313890	ATG7	0.65	6.15	0.48	9.98e-9	HDL cholesterol;
TGCT	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.01	8.32	0.6	1.34e-13	Platelet count;
TGCT	cis	rs524281	0.861	rs7941469	chr11:65900152	A/G	cg00563793	chr11:65837595	PACS1	-0.55	-4.58	-0.38	1.13e-5	Electroencephalogram traits;
TGCT	cis	rs6570726	0.791	rs7755253	chr6:145858893	C/G	cg23711669	chr6:146136114	FBXO30	0.89	9.93	0.67	1.82e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs13064411	0.696	rs1552432	chr3:113225660	G/C	cg10517650	chr3:113235015	CCDC52	-0.32	-4.45	-0.37	1.85e-5	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs208520	0.690	rs207102	chr6:66795671	G/A	cg07460842	chr6:66804631	NA	-0.94	-9.86	-0.66	2.74e-17	Exhaled nitric oxide output;
TGCT	cis	rs1865760	0.593	rs2097273	chr6:25941310	A/C	cg03517284	chr6:25882590	NA	-0.48	-4.79	-0.4	4.65e-6	Height;
TGCT	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs5769765	0.908	rs138867	chr22:50207703	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.34	-5.04	-0.41	1.63e-6	Schizophrenia;
TGCT	cis	rs9872999	1	rs9872999	chr3:133457514	C/T	cg24879335	chr3:133465180	TF	0.36	4.86	0.4	3.46e-6	Iron status biomarkers;
TGCT	cis	rs9916302	0.904	rs9944411	chr17:37483599	T/C	cg07936489	chr17:37558343	FBXL20	0.63	4.91	0.4	2.83e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7095607	0.538	rs2255136	chr10:69921733	T/A	cg18986048	chr10:69913749	MYPN	0.61	6.45	0.5	2.3e-9	Lung function (FVC);
TGCT	cis	rs1577917	0.771	rs2783171	chr6:86382765	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.63	5.58	0.45	1.43e-7	Response to antipsychotic treatment;
TGCT	cis	rs17102423	0.755	rs7143495	chr14:65546361	C/T	cg11161011	chr14:65562177	MAX	0.55	7.66	0.57	4.63e-12	Obesity-related traits;
TGCT	cis	rs62103177	0.608	rs8088089	chr18:77832154	A/G	cg07235805	chr18:78004237	PARD6G	-0.51	-4.98	-0.41	2.11e-6	Opioid sensitivity;
TGCT	cis	rs453301	0.657	rs36056437	chr8:8792865	T/G	cg15556689	chr8:8085844	FLJ10661	-0.64	-5.4	-0.44	3.31e-7	Joint mobility (Beighton score);
TGCT	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.5	-5.98	-0.47	2.18e-8	Longevity;Endometriosis;
TGCT	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg22508957	chr16:3507546	NAT15	-0.53	-6.17	-0.48	8.69e-9	Tuberculosis;
TGCT	cis	rs9611565	0.512	rs6002474	chr22:42168181	A/G	cg06634786	chr22:41940651	POLR3H	0.85	8.15	0.59	3.41e-13	Vitiligo;
TGCT	cis	rs3771570	0.792	rs4675970	chr2:242200406	G/A	cg21155796	chr2:242212141	HDLBP	0.86	6.43	0.5	2.53e-9	Prostate cancer;
TGCT	cis	rs7020830	0.898	rs7857936	chr9:37078491	T/C	cg14294708	chr9:37120828	ZCCHC7	1.21	17.76	0.85	7.18e-36	Schizophrenia;
TGCT	cis	rs9303401	0.659	rs34878689	chr17:56694330	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg22963979	chr7:1858916	MAD1L1	-0.34	-5.21	-0.42	7.6e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs6582630	0.555	rs11182429	chr12:38526679	A/C	cg26384229	chr12:38710491	ALG10B	0.85	7.84	0.58	1.81e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg07424592	chr7:64974309	NA	-1.27	-7.84	-0.58	1.8e-12	Diabetic kidney disease;
TGCT	trans	rs7698623	0.702	rs4693884	chr4:88770229	C/T	cg01186725	chr1:53905612	FLJ40434	0.48	6.63	0.51	9.21e-10	Cardiovascular disease risk factors;
TGCT	cis	rs10114408	0.877	rs10992946	chr9:96642327	C/T	cg13679303	chr9:96623674	NA	-0.35	-4.45	-0.37	1.85e-5	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs17443541	0.516	rs971324	chr2:200450386	A/G	cg00055341	chr2:200446845	NA	-0.37	-4.53	-0.38	1.35e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs11696501	0.739	rs6104249	chr20:44250487	C/G	cg11783356	chr20:44313418	WFDC10B	0.35	4.99	0.41	1.97e-6	Brain structure;
TGCT	cis	rs908922	0.676	rs2181172	chr1:152491794	A/G	cg20991723	chr1:152506922	NA	0.46	6.28	0.49	5.16e-9	Hair morphology;
TGCT	cis	rs9916302	0.768	rs11078900	chr17:37614641	C/T	cg07936489	chr17:37558343	FBXL20	-0.62	-4.91	-0.4	2.85e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs9913156	0.793	rs55682338	chr17:4582183	G/A	cg19197139	chr17:4613644	ARRB2	0.84	7.9	0.58	1.25e-12	Lymphocyte counts;
TGCT	cis	rs6500602	0.673	rs4786512	chr16:4573040	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.44	7.88	0.58	1.4e-12	Schizophrenia;
TGCT	cis	rs4629710	0.592	rs9492868	chr6:131542238	A/C	cg12606694	chr6:131520996	AKAP7	0.39	4.63	0.38	9.14e-6	Multiple myeloma (IgH translocation);
TGCT	cis	rs1372520	0.577	rs2737028	chr4:90717016	A/G	cg15133208	chr4:90757351	SNCA	-0.53	-6.14	-0.48	1.02e-8	Neuroticism;
TGCT	cis	rs797680	0.821	rs7551485	chr1:93751280	G/A	cg17826107	chr1:92977322	EVI5	0.23	5.11	0.42	1.2e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs7582180	0.764	rs4635546	chr2:100921125	G/A	cg08017756	chr2:100939284	LONRF2	-0.32	-5.26	-0.43	6.1e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9911578	0.933	rs11868348	chr17:57179238	C/T	cg12560992	chr17:57184187	TRIM37	0.79	9.71	0.66	6.56e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs9811920	0.515	rs792836	chr3:99476384	G/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.39	4.6	0.38	1.04e-5	Axial length;
TGCT	cis	rs6121246	0.909	rs6058463	chr20:30385192	C/T	cg18721089	chr20:30220636	NA	-0.43	-4.75	-0.39	5.54e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs9787249	0.957	rs7518431	chr1:40214944	C/T	cg20968010	chr1:40505947	CAP1	0.48	4.55	0.38	1.24e-5	Blood protein levels;
TGCT	cis	rs9611519	0.780	rs1535048	chr22:41684093	C/T	cg03806693	chr22:41940476	POLR3H	-0.8	-7.66	-0.57	4.62e-12	Neuroticism;
TGCT	trans	rs9388451	0.868	rs1268083	chr6:126049040	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.76	8.09	0.59	4.66e-13	Brugada syndrome;
TGCT	cis	rs7044106	0.791	rs10760116	chr9:123494681	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	4.79	0.4	4.57e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs6879260	0.963	rs11748619	chr5:179727399	C/G	cg23248424	chr5:179741104	GFPT2	-0.35	-6.32	-0.49	4.31e-9	Height;
TGCT	cis	rs308403	0.568	rs13138520	chr4:123675483	C/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.7	6.48	0.5	1.9e-9	Blood protein levels;
TGCT	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.61	5.06	0.41	1.5e-6	Tonsillectomy;
TGCT	cis	rs6912958	0.781	rs9444504	chr6:88181046	A/C	cg06598631	chr6:88300029	RARS2;ORC3L	-0.52	-4.83	-0.4	3.92e-6	Monocyte percentage of white cells;
TGCT	cis	rs13326165	0.760	rs11711934	chr3:52358117	T/C	cg27565382	chr3:53032988	SFMBT1	0.37	4.9	0.4	2.97e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs5769707	0.839	rs73176988	chr22:49989649	G/T	cg05373962	chr22:49881684	NA	-0.3	-6.12	-0.48	1.12e-8	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs6975373	0.643	rs12540089	chr7:4446121	C/A	cg10785373	chr7:4456119	NA	0.61	6.45	0.5	2.21e-9	Borderline personality disorder;
TGCT	cis	rs2658782	0.756	rs3019223	chr11:93084182	G/A	cg18152523	chr11:93063302	CCDC67	-0.67	-5.19	-0.42	8.29e-7	Pulmonary function decline;
TGCT	cis	rs910316	1.000	rs175512	chr14:75523382	T/C	cg11812906	chr14:75593930	NEK9	-0.73	-7.08	-0.54	9.26e-11	Height;
TGCT	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg24578937	chr1:2090814	PRKCZ	0.26	6.95	0.53	1.8e-10	Height;
TGCT	cis	rs28489187	0.558	rs2474123	chr1:85827452	C/T	cg16011679	chr1:85725395	C1orf52	0.49	4.5	0.37	1.57e-5	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
TGCT	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg02187348	chr16:89574699	SPG7	0.46	4.52	0.38	1.45e-5	Multiple myeloma (IgH translocation);
TGCT	cis	rs7267979	1.000	rs11087521	chr20:25440648	G/A	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs938554	0.513	rs3733588	chr4:9997303	A/G	cg00071950	chr4:10020882	SLC2A9	-0.59	-5.84	-0.46	4.4e-8	Blood metabolite levels;
TGCT	cis	rs6570726	0.935	rs419847	chr6:145827278	A/G	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7586879	0.616	rs13410999	chr2:25097939	T/C	cg15423357	chr2:25149977	NA	0.46	4.47	0.37	1.72e-5	Body mass index;
TGCT	cis	rs9788721	1.000	rs10519203	chr15:78814046	C/T	cg18825076	chr15:78729989	IREB2	0.31	4.62	0.38	9.56e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
TGCT	cis	rs7914558	0.966	rs10786727	chr10:104698523	G/A	cg04362960	chr10:104952993	NT5C2	0.58	5.15	0.42	9.77e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs4148883	0.645	rs1154404	chr4:100009004	A/T	cg12011299	chr4:100065546	ADH4	0.39	5.85	0.47	4.01e-8	Alcohol dependence;
TGCT	cis	rs6582630	0.502	rs4385963	chr12:38295264	G/A	cg26384229	chr12:38710491	ALG10B	0.8	7.04	0.53	1.17e-10	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs10089	1.000	rs10057122	chr5:127512063	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.79	7.63	0.57	5.42e-12	Ileal carcinoids;
TGCT	cis	rs6671200	0.607	rs2147587	chr1:95714884	G/A	cg20701556	chr1:95698924	RWDD3	-0.52	-5.34	-0.43	4.26e-7	Stearic acid (18:0) levels;
TGCT	cis	rs73198271	0.653	rs3827811	chr8:8659038	C/T	cg06671706	chr8:8559999	CLDN23	-0.35	-4.59	-0.38	1.08e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs9926296	0.557	rs11076618	chr16:89807705	T/C	cg27121462	chr16:89883253	FANCA	0.55	5.05	0.41	1.57e-6	Vitiligo;
TGCT	cis	rs7085104	0.684	rs7092690	chr10:104609365	T/C	cg15744005	chr10:104629667	AS3MT	-0.45	-5.8	-0.46	5.2e-8	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs1005224	0.853	rs61980778	chr14:76151532	C/T	cg25116370	chr14:76127843	TTLL5;C14orf1	0.54	4.72	0.39	6.23e-6	Large artery stroke;
TGCT	cis	rs28785552	0.536	rs7260576	chr19:53248626	G/T	cg22067481	chr19:53234126	ZNF611	-0.44	-5.92	-0.47	2.99e-8	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs6840360	0.642	rs1470281	chr4:152431552	A/G	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.82e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs11864453	0.578	rs2072141	chr16:72133211	G/A	cg14768367	chr16:72042858	DHODH	0.52	5.27	0.43	5.78e-7	Fibrinogen levels;
TGCT	cis	rs6793245	0.960	rs12053903	chr3:38593393	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.49	-4.71	-0.39	6.45e-6	QT interval;
TGCT	cis	rs9443645	0.901	rs9352667	chr6:79572296	A/G	cg09184832	chr6:79620586	NA	0.49	5.29	0.43	5.3e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7726839	0.540	rs7434	chr5:660804	A/G	cg09021430	chr5:549028	NA	0.38	5.32	0.43	4.74e-7	Obesity-related traits;
TGCT	cis	rs7666738	0.791	rs11735105	chr4:98937357	C/T	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.15	0.82	2.71e-32	Prudent dietary pattern;
TGCT	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	5.8	0.46	5.19e-8	Alzheimer's disease;
TGCT	cis	rs250677	0.522	rs12523526	chr5:148349107	A/C	cg18129178	chr5:148520854	ABLIM3	0.38	4.75	0.39	5.62e-6	Breast cancer;
TGCT	cis	rs3885907	0.542	rs9670531	chr13:31321069	A/G	cg22282089	chr13:30686841	NA	-0.21	-4.49	-0.37	1.59e-5	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU);
TGCT	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg01516881	chr6:292596	DUSP22	-0.79	-8.23	-0.59	2.24e-13	Menopause (age at onset);
TGCT	cis	rs12477438	0.520	rs6708576	chr2:99801308	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	8.52	0.61	4.42e-14	Chronic sinus infection;
TGCT	cis	rs9611565	0.512	rs139561	chr22:42195410	C/T	cg03806693	chr22:41940476	POLR3H	0.98	10.13	0.67	6e-18	Vitiligo;
TGCT	cis	rs8067545	1.000	rs2108979	chr17:19928566	G/A	cg13482628	chr17:19912719	NA	0.53	4.48	0.37	1.66e-5	Schizophrenia;
TGCT	cis	rs7584330	0.955	rs58643200	chr2:238389855	A/G	cg14458575	chr2:238380390	NA	0.48	7.42	0.55	1.66e-11	Prostate cancer;
TGCT	cis	rs2040771	0.872	rs12485084	chr22:19162326	A/G	cg02655711	chr22:19163373	SLC25A1	0.24	4.58	0.38	1.11e-5	Metabolite levels (small molecules and protein measures);
TGCT	cis	rs7914558	1.000	rs943036	chr10:104836047	T/C	cg04362960	chr10:104952993	NT5C2	0.6	5.32	0.43	4.64e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs17030434	0.953	rs76442373	chr4:154694783	G/A	cg14289246	chr4:154710475	SFRP2	-0.95	-7.48	-0.56	1.18e-11	Electrocardiographic conduction measures;
TGCT	cis	rs1757171	0.534	rs2797793	chr6:37477262	C/T	cg01843034	chr6:37503916	NA	0.47	6.05	0.48	1.55e-8	Cognitive performance;
TGCT	cis	rs7822232	0.908	rs6558295	chr8:145139522	C/G	cg14631276	chr8:145163102	KIAA1875	-0.56	-5.05	-0.41	1.55e-6	Blood metabolite levels;
TGCT	cis	rs1215050	0.791	rs260889	chr4:98742340	A/G	cg05340658	chr4:99064831	C4orf37	0.44	5.52	0.44	1.85e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs908922	0.676	rs12129646	chr1:152518816	C/T	cg20991723	chr1:152506922	NA	0.44	5.99	0.47	2.13e-8	Hair morphology;
TGCT	cis	rs2289681	0.583	rs2289674	chr17:42953409	A/G	cg15193461	chr17:42977049	CCDC103;EFTUD2	-0.68	-5.75	-0.46	6.44e-8	Cognitive function;
TGCT	cis	rs709400	1.000	rs6593	chr14:104163282	G/A	cg26031613	chr14:104095156	KLC1	1.13	17.11	0.84	1.95e-34	Body mass index;
TGCT	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.28	4.92	0.4	2.73e-6	Schizophrenia;
TGCT	cis	rs9911578	1.000	rs12936058	chr17:57017420	T/C	cg12560992	chr17:57184187	TRIM37	0.76	9.21	0.64	1.03e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs42648	1.000	rs42656	chr7:89981636	A/G	cg25739043	chr7:89950458	NA	-0.67	-6.71	-0.52	6.07e-10	Homocysteine levels;
TGCT	cis	rs2228479	0.850	rs11649162	chr16:89807131	C/A	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs10479542	0.683	rs7380706	chr5:178961872	C/T	cg09060608	chr5:178986726	RUFY1	0.42	4.7	0.39	6.83e-6	Lung cancer;
TGCT	cis	rs1008375	1.000	rs10939743	chr4:17662731	G/A	cg10189774	chr4:17578691	LAP3	0.54	5.0	0.41	1.89e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs17331151	0.573	rs28552648	chr3:52865593	G/A	cg12962167	chr3:53033115	SFMBT1	0.44	4.96	0.41	2.28e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs3749237	0.964	rs35210174	chr3:49812606	C/T	cg10152585	chr3:50297680	NA	0.5	4.65	0.39	8.38e-6	Resting heart rate;
TGCT	cis	rs56104184	0.775	rs17272707	chr19:49404535	T/G	cg15549821	chr19:49342101	PLEKHA4	-0.73	-9.15	-0.63	1.47e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs3091242	0.933	rs10903129	chr1:25768937	A/G	cg09222892	chr1:25734099	RHCE	-0.42	-7.15	-0.54	6.67e-11	Erythrocyte sedimentation rate;
TGCT	cis	rs9467773	0.620	rs2494696	chr6:26620894	A/G	cg02458000	chr6:26745757	NA	0.55	5.25	0.43	6.28e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg17971929	chr21:40555470	PSMG1	-0.69	-6.0	-0.47	1.97e-8	Cognitive function;
TGCT	cis	rs10254284	0.921	rs2391591	chr7:28157664	G/T	cg23620719	chr7:28220237	JAZF1	-0.55	-4.85	-0.4	3.67e-6	Lymphocyte percentage of white cells;Systemic lupus erythematosus;
TGCT	cis	rs6714710	0.603	rs4311104	chr2:98424802	A/G	cg26665480	chr2:98280029	ACTR1B	0.66	6.24	0.49	6.33e-9	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs477895	1.000	rs66968227	chr11:64070930	T/C	cg04317338	chr11:64019027	PLCB3	0.68	5.33	0.43	4.39e-7	Mean platelet volume;
TGCT	cis	rs734999	0.588	rs60520190	chr1:2533706	G/A	cg18854424	chr1:2615690	NA	0.44	5.1	0.42	1.22e-6	Ulcerative colitis;
TGCT	cis	rs6725041	0.819	rs1521644	chr2:213091246	A/G	cg20637307	chr2:213403960	ERBB4	-0.52	-4.6	-0.38	1.02e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg00814883	chr7:100076585	TSC22D4	-0.92	-9.76	-0.66	4.73e-17	Platelet count;
TGCT	cis	rs10779751	1.000	rs12032364	chr1:11286872	G/T	cg08854313	chr1:11322531	MTOR	0.96	8.74	0.62	1.37e-14	Body mass index;
TGCT	trans	rs7819412	0.774	rs34208825	chr8:11014616	T/G	cg15556689	chr8:8085844	FLJ10661	-0.83	-7.48	-0.56	1.18e-11	Triglycerides;
TGCT	cis	rs5769765	0.908	rs9627788	chr22:50300438	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.08	-10.42	-0.68	1.19e-18	Schizophrenia;
TGCT	cis	rs2050392	0.928	rs6481677	chr10:30701816	A/G	cg18806716	chr10:30721971	MAP3K8	-0.45	-5.32	-0.43	4.66e-7	Inflammatory bowel disease;
TGCT	cis	rs28595532	0.920	rs114080496	chr4:119726372	C/T	cg21605333	chr4:119757512	SEC24D	1.72	8.96	0.63	3.99e-15	Cannabis dependence symptom count;
TGCT	cis	rs9303401	0.659	rs35103007	chr17:56900738	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs2721195	0.845	rs1063739	chr8:145729727	C/A	cg15320075	chr8:145703422	NA	0.68	6.6	0.51	1.05e-9	Age at first birth;
TGCT	cis	rs9948	0.529	rs62156208	chr2:97383686	A/G	cg01990225	chr2:97406019	LMAN2L	-1.01	-5.13	-0.42	1.08e-6	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg22857025	chr5:266934	NA	-0.34	-6.7	-0.52	6.65e-10	Breast cancer;
TGCT	cis	rs67478160	0.643	rs2024667	chr14:104211529	T/G	cg26031613	chr14:104095156	KLC1	-0.63	-6.53	-0.51	1.56e-9	Schizophrenia;
TGCT	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg17747265	chr1:1875780	NA	-0.38	-7.18	-0.54	5.67e-11	Body mass index;
TGCT	cis	rs17268829	1.000	rs10273041	chr7:94087489	C/T	cg06439941	chr7:93550756	GNG11	-0.24	-4.49	-0.37	1.62e-5	Breast cancer;
TGCT	cis	rs7516138	1.000	rs4240895	chr1:9713386	C/T	cg26573321	chr1:9711663	PIK3CD	0.37	4.48	0.37	1.71e-5	Monocyte count;
TGCT	cis	rs2115630	0.645	rs3825877	chr15:85174631	G/A	cg17173187	chr15:85201210	NMB	-0.48	-5.78	-0.46	5.69e-8	P wave terminal force;
TGCT	cis	rs427394	0.802	rs274718	chr5:6720988	G/T	cg10857441	chr5:6722123	POLS	-0.33	-8.05	-0.59	5.7e-13	Menopause (age at onset);
TGCT	cis	rs2562456	0.754	rs55771551	chr19:21746380	C/T	cg01304269	chr19:21688519	ZNF429	0.58	4.73	0.39	5.93e-6	Pain;
TGCT	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg21724239	chr8:58056113	NA	0.33	4.54	0.38	1.31e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7209700	0.821	rs2292863	chr17:45369130	C/G	cg21624342	chr17:45890973	OSBPL7	0.19	5.09	0.42	1.32e-6	IgG glycosylation;
TGCT	cis	rs3806843	1.000	rs991918	chr5:140194858	C/T	cg19875535	chr5:140030758	IK	0.35	5.71	0.46	7.94e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs936229	0.813	rs72730503	chr15:75086386	G/A	cg10253484	chr15:75165896	SCAMP2	-0.63	-4.95	-0.41	2.33e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
TGCT	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.31	-4.76	-0.39	5.36e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	trans	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg17470723	chr8:74884337	TCEB1	0.74	6.95	0.53	1.86e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9467773	0.649	rs2145318	chr6:26496603	T/A	cg05738196	chr6:26577821	NA	0.73	8.21	0.59	2.39e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs11105298	0.786	rs3803128	chr12:89860319	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.7	-5.02	-0.41	1.79e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs67311347	1.000	rs67680017	chr3:40533164	C/T	cg13409248	chr3:40428643	ENTPD3	0.61	4.61	0.38	9.7e-6	Renal cell carcinoma;
TGCT	cis	rs17712049	0.908	rs73694364	chr7:48200348	C/T	cg16849860	chr7:48352531	ABCA13	0.32	5.26	0.43	6.19e-7	Refractive astigmatism;
TGCT	cis	rs4325129	1.000	rs67371748	chr1:159489964	T/C	cg20944283	chr1:159172620	CADM3	-0.29	-4.48	-0.37	1.65e-5	Obesity-related traits;
TGCT	cis	rs28595532	0.920	rs56117870	chr4:119766583	T/C	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg00814883	chr7:100076585	TSC22D4	-0.59	-5.7	-0.46	8.45e-8	Lung function (FEV1/FVC);
TGCT	cis	rs6669919	0.967	rs6678844	chr1:211674774	G/T	cg26515805	chr1:211431828	RCOR3	-0.39	-4.51	-0.38	1.5e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs17473412	0.804	rs9327295	chr5:122742602	G/T	cg15125798	chr5:122621645	NA	0.57	5.04	0.41	1.64e-6	Total body bone mineral density;
TGCT	cis	rs3784262	0.740	rs33960206	chr15:58288731	C/G	cg12031962	chr15:58353849	ALDH1A2	-0.42	-5.95	-0.47	2.58e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs3091242	0.967	rs1053438	chr1:25687901	T/C	cg10117171	chr1:25599238	RHD	0.35	5.73	0.46	7.31e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs3796352	1.000	rs2336540	chr3:52974589	G/A	cg07884673	chr3:53033167	SFMBT1	0.6	5.53	0.44	1.82e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs13191362	0.938	rs35760705	chr6:163020637	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.57	4.91	0.4	2.85e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs4886920	0.601	rs12901558	chr15:78076379	G/A	cg03457338	chr15:78040120	NA	0.18	4.51	0.38	1.48e-5	Neuroticism;
TGCT	cis	rs112217694	1.000	rs7665931	chr4:104660682	C/T	cg24090629	chr4:104641072	TACR3	-0.88	-4.79	-0.39	4.73e-6	Menarche (age at onset);
TGCT	cis	rs6540559	0.546	rs735693	chr1:210033988	A/C	cg21951975	chr1:209979733	IRF6	0.76	5.93	0.47	2.83e-8	Cleft lip with or without cleft palate;
TGCT	cis	rs2033711	0.902	rs4801589	chr19:58953398	C/G	cg12042659	chr19:58951599	ZNF132	0.51	4.54	0.38	1.29e-5	Uric acid clearance;
TGCT	cis	rs7017914	0.875	rs3098871	chr8:71930415	C/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.56	-5.11	-0.42	1.19e-6	Bone mineral density;
TGCT	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg24531977	chr5:56204891	C5orf35	-0.64	-6.36	-0.5	3.51e-9	Coronary artery disease;
TGCT	cis	rs9467773	0.836	rs1977198	chr6:26466225	A/C	cg09904177	chr6:26538194	HMGN4	0.55	4.94	0.41	2.46e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs17253792	0.571	rs112129578	chr14:56028415	T/C	cg01858014	chr14:56050164	KTN1	-0.36	-4.54	-0.38	1.33e-5	Putamen volume;
TGCT	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs6964587	1.000	rs12539231	chr7:91634963	G/A	cg22709100	chr7:91322751	NA	0.27	4.48	0.37	1.68e-5	Breast cancer;
TGCT	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.6	0.51	1.05e-9	Bipolar disorder;
TGCT	cis	rs1580019	0.563	rs13225132	chr7:32800975	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.13	13.5	0.77	4.23e-26	Cognitive ability;
TGCT	cis	rs2243480	1.000	rs160644	chr7:65558186	C/T	cg20637647	chr7:64974828	NA	0.88	5.34	0.43	4.19e-7	Diabetic kidney disease;
TGCT	cis	rs1008375	1.000	rs11737138	chr4:17657986	G/A	cg18681998	chr4:17616180	MED28	1.01	11.89	0.73	3.17e-22	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2469997	1.000	rs2470006	chr8:120358591	G/C	cg00681363	chr8:120844660	TAF2	0.69	4.48	0.37	1.64e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs936229	0.861	rs11634474	chr15:75116184	C/G	cg10253484	chr15:75165896	SCAMP2	-0.66	-5.34	-0.43	4.28e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
TGCT	cis	rs4242434	0.819	rs7826059	chr8:22512068	T/C	cg03733263	chr8:22462867	KIAA1967	-1.1	-15.66	-0.81	3.7e-31	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs9926296	0.656	rs4522419	chr16:89853307	T/C	cg27121462	chr16:89883253	FANCA	0.6	5.66	0.45	1.02e-7	Vitiligo;
TGCT	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	5.23	0.43	6.92e-7	Menopause (age at onset);
TGCT	cis	rs778371	0.788	rs4973569	chr2:233767037	A/G	cg08000102	chr2:233561755	GIGYF2	-0.55	-5.46	-0.44	2.53e-7	Schizophrenia;
TGCT	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg25767906	chr1:53392781	SCP2	-0.57	-6.88	-0.53	2.61e-10	Monocyte count;
TGCT	cis	rs9486715	0.867	rs4438964	chr6:96917563	T/G	cg18709589	chr6:96969512	KIAA0776	0.82	8.02	0.58	6.9e-13	Headache;
TGCT	trans	rs1814175	0.817	rs4084376	chr11:49831160	T/C	cg15704280	chr7:45808275	SEPT13	-0.72	-8.14	-0.59	3.61e-13	Height;
TGCT	cis	rs992157	0.661	rs10171839	chr2:219051314	C/T	cg00012203	chr2:219082015	ARPC2	0.82	9.83	0.66	3.27e-17	Colorectal cancer;
TGCT	cis	rs2019216	0.500	rs11651446	chr17:21967129	C/T	cg22648282	chr17:21454238	C17orf51	-0.54	-4.49	-0.37	1.62e-5	Pelvic organ prolapse;
TGCT	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg11764359	chr7:65958608	NA	-0.54	-4.85	-0.4	3.67e-6	Aortic root size;
TGCT	cis	rs2115630	0.846	rs8024538	chr15:85368419	A/T	cg11189052	chr15:85197271	WDR73	-0.59	-5.33	-0.43	4.54e-7	P wave terminal force;
TGCT	cis	rs2072499	0.868	rs2758600	chr1:156195205	C/T	cg24450063	chr1:156163899	SLC25A44	1.18	13.63	0.77	1.99e-26	Testicular germ cell tumor;
TGCT	cis	rs3733585	0.699	rs7657340	chr4:9966772	A/T	cg00071950	chr4:10020882	SLC2A9	-0.57	-6.85	-0.52	3.12e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg02038168	chr22:39784481	NA	-0.76	-6.36	-0.5	3.47e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs9640161	0.750	rs73170185	chr7:150030191	C/A	cg10018233	chr7:150070692	REPIN1	0.32	4.62	0.38	9.41e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg09365446	chr1:150670422	GOLPH3L	0.3	4.59	0.38	1.05e-5	Tonsillectomy;
TGCT	cis	rs7772486	0.743	rs1292339	chr6:145967086	C/T	cg05347473	chr6:146136440	FBXO30	-0.51	-4.78	-0.39	4.84e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg06238570	chr21:40685208	BRWD1	-0.82	-8.76	-0.62	1.19e-14	Cognitive function;
TGCT	cis	rs12034598	1.000	rs11118166	chr1:207781995	A/G	cg06640374	chr1:207250784	PFKFB2	0.3	4.48	0.37	1.69e-5	Inflammatory biomarkers;
TGCT	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg08736216	chr1:53307985	ZYG11A	-0.25	-4.86	-0.4	3.48e-6	Monocyte count;
TGCT	cis	rs1511802	0.666	rs2292424	chr4:187120625	G/A	cg19358738	chr4:186734530	SORBS2	0.17	4.44	0.37	1.95e-5	Blood protein levels;
TGCT	cis	rs12971120	0.838	rs747176	chr18:72154931	G/A	cg25817165	chr18:72167213	CNDP2	-0.3	-5.34	-0.43	4.26e-7	Refractive error;
TGCT	cis	rs7772486	0.641	rs9390374	chr6:146368175	A/T	cg05347473	chr6:146136440	FBXO30	0.58	5.56	0.45	1.57e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs17102423	0.623	rs2898862	chr14:65612144	G/A	cg11161011	chr14:65562177	MAX	-0.41	-5.54	-0.45	1.77e-7	Obesity-related traits;
TGCT	cis	rs1055129	0.516	rs7218498	chr17:73931847	C/G	cg10935138	chr17:73851978	WBP2	0.53	4.67	0.39	7.58e-6	White matter hyperintensity burden;
TGCT	cis	rs4711350	0.954	rs11751943	chr6:33729718	G/C	cg18005901	chr6:33739558	LEMD2	-0.57	-5.79	-0.46	5.31e-8	Schizophrenia;
TGCT	cis	rs7246657	0.943	rs2112923	chr19:37940327	C/T	cg18154014	chr19:37997991	ZNF793	0.73	5.38	0.44	3.53e-7	Coronary artery calcification;
TGCT	cis	rs7213347	0.579	rs8072532	chr17:2045273	G/A	cg22033759	chr17:1182267	TUSC5	-0.23	-4.65	-0.39	8.4e-6	Total body bone mineral density;
TGCT	cis	rs1878931	0.520	rs2015640	chr16:3465018	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.73	-5.47	-0.44	2.36e-7	Body mass index (adult);
TGCT	cis	rs10788575	0.805	rs12569998	chr10:89674157	A/C	cg03166508	chr10:89453226	PAPSS2	0.31	4.71	0.39	6.55e-6	Type 2 diabetes;
TGCT	trans	rs7613875	0.580	rs3774745	chr3:50204745	C/T	cg21659725	chr3:3221576	CRBN	-0.7	-7.99	-0.58	8.03e-13	Body mass index;
TGCT	trans	rs66573146	0.803	rs60228659	chr4:7031704	G/A	cg07817883	chr1:32538562	TMEM39B	1.66	8.05	0.59	5.84e-13	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs7772486	0.790	rs2249386	chr6:146186611	G/A	cg13319975	chr6:146136371	FBXO30	-0.54	-4.81	-0.4	4.35e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg14851468	chr5:179071604	C5orf60	-0.23	-4.82	-0.4	4.17e-6	Lung cancer;
TGCT	cis	rs9788682	0.894	rs4461039	chr15:78817447	A/T	cg24631222	chr15:78858424	CHRNA5	-0.92	-8.06	-0.59	5.54e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg23758822	chr17:41437982	NA	0.72	6.81	0.52	3.77e-10	Menopause (age at onset);
TGCT	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg26338869	chr17:61819248	STRADA	-0.55	-5.03	-0.41	1.65e-6	Prudent dietary pattern;
TGCT	cis	rs10089	0.903	rs6862701	chr5:127391249	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	6.93	0.53	2e-10	Ileal carcinoids;
TGCT	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg05665937	chr4:1216051	CTBP1	0.22	4.51	0.38	1.47e-5	Obesity-related traits;
TGCT	cis	rs7647973	1.000	rs62259933	chr3:49469703	G/A	cg07636037	chr3:49044803	WDR6	-0.7	-5.73	-0.46	7.08e-8	Menarche (age at onset);
TGCT	cis	rs1865760	0.865	rs9393677	chr6:25945815	G/A	cg17042849	chr6:26104293	HIST1H4C	-0.52	-4.78	-0.39	4.97e-6	Height;
TGCT	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg06618935	chr21:46677482	NA	-0.36	-5.04	-0.41	1.59e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs3125734	0.582	rs7904465	chr10:64002393	G/A	cg09941381	chr10:64027924	RTKN2	-0.37	-5.59	-0.45	1.41e-7	Rheumatoid arthritis;
TGCT	cis	rs922182	0.967	rs34772505	chr15:64276772	C/T	cg02919090	chr15:64263738	DAPK2	0.3	5.51	0.44	1.96e-7	Blood protein levels;
TGCT	cis	rs4711336	1.000	rs4711336	chr6:33659046	A/G	cg14003231	chr6:33640908	ITPR3	-0.31	-4.97	-0.41	2.2e-6	Height;
TGCT	cis	rs916888	0.647	rs199524	chr17:44848438	G/T	cg16520312	chr17:43971471	MAPT;LOC100128977	0.48	4.67	0.39	7.86e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2729354	0.903	rs2729371	chr11:57321322	A/G	cg24343310	chr11:57249947	NA	0.3	4.96	0.41	2.28e-6	Blood protein levels;
TGCT	cis	rs4901869	0.966	rs9972206	chr14:59336095	A/G	cg02291164	chr14:59296302	NA	0.24	4.7	0.39	6.73e-6	Panic disorder;
TGCT	cis	rs11676348	0.755	rs62183956	chr2:219046122	C/T	cg00012203	chr2:219082015	ARPC2	0.6	5.73	0.46	7.33e-8	Ulcerative colitis;
TGCT	cis	rs4851254	0.961	rs13011181	chr2:100732446	T/C	cg07810366	chr2:100720526	AFF3	-0.42	-4.79	-0.4	4.68e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs138229	0.506	rs138233	chr22:50559953	G/A	cg16473166	chr22:50639996	SELO	0.58	4.76	0.39	5.34e-6	Behavioural disinhibition (generation interaction);
TGCT	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs17376456	0.825	rs10075217	chr5:93176774	C/G	cg25358565	chr5:93447407	FAM172A	0.99	7.46	0.56	1.29e-11	Diabetic retinopathy;
TGCT	cis	rs2840044	0.963	rs225247	chr17:33944590	T/A	cg05299278	chr17:33885742	SLFN14	0.23	5.07	0.41	1.38e-6	Response to radiotherapy in cancer (late toxicity);
TGCT	cis	rs7940866	0.903	rs10791109	chr11:130850377	A/C	cg05962950	chr11:130786565	SNX19	0.64	6.37	0.5	3.32e-9	Schizophrenia;
TGCT	cis	rs3809566	0.632	rs9806533	chr15:63328298	A/G	cg00520135	chr15:63333846	TPM1	-0.4	-4.9	-0.4	2.95e-6	Platelet count;
TGCT	cis	rs4820539	1.000	rs4822358	chr22:23474795	A/G	cg14186256	chr22:23484241	RTDR1	0.99	12.54	0.75	8.46e-24	Bone mineral density;
TGCT	cis	rs17473412	0.804	rs6595441	chr5:122724446	A/G	cg15125798	chr5:122621645	NA	-0.57	-5.15	-0.42	9.93e-7	Total body bone mineral density;
TGCT	cis	rs7829975	0.582	rs6982832	chr8:8792217	A/C	cg00184457	chr8:8946301	NA	-0.23	-4.44	-0.37	2e-5	Mood instability;
TGCT	cis	rs367615	0.959	rs17161951	chr5:108930590	A/G	cg17395555	chr5:108820864	NA	-0.28	-4.49	-0.37	1.59e-5	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs36051895	0.632	rs12343038	chr9:5178579	A/G	cg02405213	chr9:5042618	JAK2	0.74	10.54	0.69	6.32e-19	Pediatric autoimmune diseases;
TGCT	cis	rs492146	0.765	rs670960	chr6:52843796	A/G	cg06706454	chr6:52930286	FBXO9	-0.51	-4.66	-0.39	8.12e-6	Epilepsy (remission after treatment);
TGCT	cis	rs9660992	0.573	rs7368327	chr1:205214792	C/T	cg00857998	chr1:205179979	DSTYK	0.51	4.68	0.39	7.34e-6	Mean corpuscular volume;Mean platelet volume;
TGCT	cis	rs9814567	1.000	rs2370641	chr3:134222161	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.95	-9.62	-0.65	1.04e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs9926296	0.744	rs154657	chr16:89708096	A/G	cg04287289	chr16:89883240	FANCA	0.5	4.79	0.39	4.73e-6	Vitiligo;
TGCT	cis	rs4654899	0.758	rs6426667	chr1:21396216	C/A	cg01072550	chr1:21505969	NA	-0.56	-9.08	-0.63	2.14e-15	Superior frontal gyrus grey matter volume;
TGCT	cis	rs6912958	0.559	rs242270	chr6:88062190	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.41	-5.31	-0.43	4.94e-7	Monocyte percentage of white cells;
TGCT	cis	rs7809950	0.723	rs2237662	chr7:106874065	C/G	cg23024343	chr7:107201750	COG5	-0.41	-5.62	-0.45	1.17e-7	Coronary artery disease;
TGCT	trans	rs1814175	0.647	rs2903409	chr11:49953612	C/G	cg15704280	chr7:45808275	SEPT13	-0.63	-7.35	-0.55	2.28e-11	Height;
TGCT	cis	rs4689388	0.926	rs5018648	chr4:6292818	C/G	cg25554036	chr4:6271136	WFS1	-0.54	-7.56	-0.56	7.66e-12	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg11941060	chr3:133502564	NA	0.25	5.24	0.43	6.58e-7	Iron status biomarkers;
TGCT	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg02353165	chr6:42928485	GNMT	0.95	9.72	0.66	5.91e-17	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs8017423	0.967	rs7155315	chr14:90700787	G/A	cg04374321	chr14:90722782	PSMC1	0.77	8.05	0.59	5.68e-13	Mortality in heart failure;
TGCT	cis	rs12220238	1.000	rs10824103	chr10:75949415	A/T	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.06	0.54	1.05e-10	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.72	-6.47	-0.5	2.04e-9	Tonsillectomy;
TGCT	cis	rs2760061	0.603	rs697762	chr1:228192410	G/A	cg02753203	chr1:228287806	NA	0.33	6.31	0.49	4.41e-9	Diastolic blood pressure;
TGCT	cis	rs7523273	0.565	rs2796250	chr1:207903654	T/C	cg22525895	chr1:207977042	MIR29B2	-0.33	-5.33	-0.43	4.38e-7	Schizophrenia;
TGCT	cis	rs367615	0.704	rs60538082	chr5:108829101	A/G	cg17395555	chr5:108820864	NA	0.31	5.92	0.47	2.9e-8	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs2842992	0.915	rs1322427	chr6:160075454	C/A	cg11366901	chr6:160182831	ACAT2	1.02	6.67	0.51	7.59e-10	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs9372498	0.908	rs72967581	chr6:118699329	G/A	cg18833306	chr6:118973337	C6orf204	-0.61	-4.81	-0.4	4.28e-6	Diastolic blood pressure;
TGCT	cis	rs587847	0.737	rs1520958	chr15:37658456	C/G	cg00216138	chr15:37171175	LOC145845	-0.31	-4.45	-0.37	1.91e-5	Intraocular pressure;
TGCT	cis	rs10992471	0.729	rs13284038	chr9:95555488	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.58	-5.32	-0.43	4.62e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs2153535	0.580	rs9393021	chr6:8466123	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs9926296	0.656	rs7191144	chr16:89823393	C/T	cg26513180	chr16:89883248	FANCA	0.7	6.76	0.52	4.86e-10	Vitiligo;
TGCT	cis	rs13188771	0.775	rs67015325	chr5:100870217	C/T	cg18665594	chr5:101119420	NA	0.47	4.57	0.38	1.14e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs9467711	0.790	rs17598658	chr6:26175866	A/C	cg16898833	chr6:26189333	HIST1H4D	1.44	6.24	0.49	6.22e-9	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4654899	1.000	rs6681064	chr1:21339644	A/G	cg01072550	chr1:21505969	NA	-0.5	-7.97	-0.58	8.84e-13	Superior frontal gyrus grey matter volume;
TGCT	cis	rs854765	0.624	rs7359509	chr17:17741875	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.69	-6.67	-0.51	7.5e-10	Total body bone mineral density;
TGCT	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg12963246	chr6:28129442	ZNF389	0.52	5.1	0.42	1.23e-6	Depression;
TGCT	cis	rs75686122	0.892	rs1895900	chr8:104602709	C/T	cg04852977	chr8:104510831	NA	0.59	4.45	0.37	1.92e-5	Cocaine dependence;
TGCT	cis	rs9393777	0.513	rs7754159	chr6:26620312	G/A	cg15659132	chr6:26577336	NA	-0.72	-5.29	-0.43	5.24e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1857353	0.908	rs3845362	chr1:75885158	A/G	cg11838876	chr1:75668600	SLC44A5	-0.46	-4.5	-0.37	1.54e-5	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs2370759	1.000	rs2769241	chr10:32556229	T/C	cg01819863	chr10:32635814	EPC1	-1.01	-9.82	-0.66	3.44e-17	Sexual dysfunction (female);
TGCT	cis	rs12971120	0.891	rs2303463	chr18:72168608	G/A	cg26446133	chr18:72167187	CNDP2	-0.36	-6.11	-0.48	1.2e-8	Refractive error;
TGCT	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.31	0.43	4.9e-7	Prudent dietary pattern;
TGCT	cis	rs78487399	0.808	rs72865267	chr2:43726328	T/C	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.74	4.49	0.37	1.59e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/A	cg26513180	chr16:89883248	FANCA	0.85	8.19	0.59	2.75e-13	Vitiligo;
TGCT	cis	rs1577917	0.917	rs2218594	chr6:86543766	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.47	-0.44	2.33e-7	Response to antipsychotic treatment;
TGCT	cis	rs1395	0.710	rs2083363	chr2:27475318	G/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.62	7.72	0.57	3.38e-12	Blood metabolite levels;
TGCT	cis	rs12530845	0.524	rs7795267	chr7:135308455	C/G	cg23117316	chr7:135346802	PL-5283	-0.51	-4.52	-0.38	1.4e-5	Red blood cell traits;
TGCT	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg14784868	chr12:69753453	YEATS4	0.9	10.55	0.69	5.67e-19	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs3008870	1.000	rs1925408	chr1:67365034	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.07	11.84	0.73	4.25e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs13326165	0.760	rs498946	chr3:52434967	T/C	cg27565382	chr3:53032988	SFMBT1	0.37	5.1	0.42	1.26e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs1903068	1.000	rs73236109	chr4:56007425	C/T	cg01777861	chr4:56023843	NA	0.56	6.55	0.51	1.39e-9	Endometriosis;
TGCT	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg22891161	chr3:195456627	MUC20	-0.23	-5.38	-0.44	3.53e-7	Pancreatic cancer;
TGCT	cis	rs7552404	0.961	rs448710	chr1:76116554	T/C	cg22875332	chr1:76189707	ACADM	-0.8	-9.79	-0.66	4.2e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2072499	0.931	rs1052053	chr1:156202173	A/G	cg25208724	chr1:156163844	SLC25A44	0.96	12.24	0.74	4.45e-23	Testicular germ cell tumor;
TGCT	cis	rs11825685	1.000	rs11825685	chr11:134573810	C/T	cg26418160	chr11:134306122	NA	0.39	5.15	0.42	9.83e-7	IgG glycosylation;
TGCT	cis	rs13242816	1.000	rs35595472	chr7:116122306	G/A	cg02799643	chr7:116139180	CAV2	-0.49	-5.53	-0.45	1.78e-7	P wave duration;
TGCT	cis	rs707040	1.000	rs7566536	chr2:155237893	C/T	cg18104148	chr2:154337490	NA	0.19	4.56	0.38	1.2e-5	Sudden cardiac arrest;
TGCT	cis	rs6964587	1.000	rs11982213	chr7:91722966	A/G	cg22709100	chr7:91322751	NA	0.29	4.8	0.4	4.45e-6	Breast cancer;
TGCT	cis	rs3818285	0.679	rs2475275	chr10:111633979	C/T	cg00817464	chr10:111662876	XPNPEP1	0.32	5.57	0.45	1.51e-7	Superior crus of antihelix expression;
TGCT	cis	rs6840360	0.571	rs17275598	chr4:152568478	C/A	cg17479576	chr4:152424074	FAM160A1	-0.73	-7.95	-0.58	9.69e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs7017914	0.875	rs2639897	chr8:71920676	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.55	-5.1	-0.42	1.24e-6	Bone mineral density;
TGCT	cis	rs7666738	0.830	rs28769113	chr4:98950371	T/G	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9467711	0.516	rs1165168	chr6:25859508	A/C	cg12310025	chr6:25882481	NA	-0.72	-4.77	-0.39	5.17e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1505368	0.781	rs4673664	chr2:213277649	T/C	cg16329650	chr2:213403929	ERBB4	0.64	6.44	0.5	2.41e-9	Symmetrical dimethylarginine levels;
TGCT	cis	rs2153535	0.601	rs2327054	chr6:8443130	T/C	cg07606381	chr6:8435919	SLC35B3	0.57	5.25	0.43	6.46e-7	Motion sickness;
TGCT	cis	rs13191362	0.507	rs2849534	chr6:163144657	T/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.59	-5.28	-0.43	5.5e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg01802117	chr1:53393560	SCP2	0.43	5.12	0.42	1.14e-6	Monocyte count;
TGCT	trans	rs2469997	1.000	rs2447167	chr8:120366068	T/C	cg01792902	chr3:178864926	PIK3CA	0.83	6.77	0.52	4.49e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs7772486	0.790	rs2253307	chr6:146196181	T/G	cg23711669	chr6:146136114	FBXO30	0.95	10.8	0.7	1.44e-19	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7226408	0.857	rs72890579	chr18:34626456	A/G	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs1008375	1.000	rs56308330	chr4:17643050	G/A	cg18681998	chr4:17616180	MED28	1.0	11.88	0.73	3.32e-22	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2204008	0.805	rs7296063	chr12:37964775	T/G	cg26384229	chr12:38710491	ALG10B	0.86	7.77	0.57	2.55e-12	Bladder cancer;
TGCT	cis	rs886126	1.000	rs4766451	chr12:111670682	G/T	cg10833066	chr12:111807467	FAM109A	0.32	5.56	0.45	1.59e-7	Coronary heart disease;
TGCT	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg05368731	chr17:41323189	NBR1	1.08	11.0	0.7	4.76e-20	Menopause (age at onset);
TGCT	cis	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg18252515	chr7:66147081	NA	-1.15	-7.05	-0.53	1.1e-10	Diabetic kidney disease;
TGCT	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg20849893	chr7:64541193	NA	0.49	5.1	0.42	1.24e-6	Calcium levels;
TGCT	cis	rs4499344	0.921	rs12973855	chr19:33085395	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.7	-6.32	-0.49	4.21e-9	Mean platelet volume;
TGCT	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg04944784	chr2:26401820	FAM59B	0.77	5.18	0.42	8.59e-7	Gut microbiome composition (summer);
TGCT	cis	rs7267979	0.932	rs6115214	chr20:25557426	C/T	cg16686733	chr20:25566563	NINL	-0.55	-5.57	-0.45	1.53e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3008870	1.000	rs2065001	chr1:67486509	C/G	cg08660285	chr1:67390436	MIER1;WDR78	1.05	10.47	0.68	9.28e-19	Lymphocyte percentage of white cells;
TGCT	trans	rs7726839	0.561	rs72703044	chr5:579737	G/A	cg25482853	chr8:67687455	SGK3	1.05	9.29	0.64	6.67e-16	Obesity-related traits;
TGCT	cis	rs6460942	0.915	rs2216051	chr7:12304054	G/A	cg06484146	chr7:12443880	VWDE	-0.49	-5.17	-0.42	9.27e-7	Coronary artery disease;
TGCT	cis	rs9952991	0.528	rs612058	chr18:12850211	T/C	cg23598886	chr18:12777645	NA	0.57	5.05	0.41	1.51e-6	Inflammatory skin disease;
TGCT	cis	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg20637647	chr7:64974828	NA	1.0	5.59	0.45	1.4e-7	Diabetic kidney disease;
TGCT	cis	rs9611565	0.512	rs9611672	chr22:42209922	A/G	cg17554472	chr22:41940697	POLR3H	-0.46	-4.69	-0.39	7.09e-6	Vitiligo;
TGCT	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg03188948	chr7:1209495	NA	0.42	5.53	0.44	1.84e-7	Longevity;Endometriosis;
TGCT	cis	rs7542091	0.704	rs1108628	chr1:210041150	A/G	cg22029157	chr1:209979665	IRF6	0.65	6.3	0.49	4.63e-9	Monobrow;
TGCT	cis	rs12579753	0.872	rs34415838	chr12:82122078	T/C	cg21231944	chr12:82153410	PPFIA2	-0.34	-4.55	-0.38	1.28e-5	Resting heart rate;
TGCT	cis	rs9611565	0.559	rs132761	chr22:42004371	C/T	cg03806693	chr22:41940476	POLR3H	1.07	11.4	0.72	4.95e-21	Vitiligo;
TGCT	cis	rs12142240	0.698	rs1057534	chr1:46815880	A/C	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs1023500	0.596	rs133369	chr22:42463814	C/T	cg05082376	chr22:42548792	NA	-0.23	-5.44	-0.44	2.72e-7	Schizophrenia;
TGCT	cis	rs7772486	0.754	rs9386134	chr6:146145508	G/A	cg05347473	chr6:146136440	FBXO30	0.52	4.94	0.41	2.5e-6	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg21659725	chr3:3221576	CRBN	0.76	9.35	0.64	4.85e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs62244186	0.659	rs9873072	chr3:44516496	G/A	cg25151919	chr3:44754333	ZNF502	-0.39	-4.58	-0.38	1.12e-5	Depressive symptoms;
TGCT	cis	rs6495367	1.000	rs3851677	chr15:79380869	C/T	cg17916960	chr15:79447300	NA	0.36	5.2	0.42	8.06e-7	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs9911578	0.835	rs1476596	chr17:56485358	C/T	cg05425664	chr17:57184151	TRIM37	-0.61	-5.74	-0.46	6.98e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.791	rs10033994	chr4:98969582	C/T	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2549003	0.674	rs960757	chr5:131826310	G/A	cg21138405	chr5:131827807	IRF1	0.18	4.53	0.38	1.37e-5	Asthma (sex interaction);
TGCT	trans	rs10802346	0.545	rs6662672	chr1:246387611	A/C	cg22732515	chr19:44031385	ETHE1	0.83	6.62	0.51	9.79e-10	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg10047753	chr17:41438598	NA	0.97	9.76	0.66	4.73e-17	Menopause (age at onset);
TGCT	cis	rs6088590	0.965	rs910869	chr20:33292777	C/T	cg24642439	chr20:33292090	TP53INP2	0.7	6.41	0.5	2.75e-9	Coronary artery disease;
TGCT	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg25036284	chr2:26402008	FAM59B	-0.53	-4.53	-0.38	1.37e-5	Gut microbiome composition (summer);
TGCT	cis	rs6921919	0.583	rs6928771	chr6:28375209	T/G	cg18815343	chr6:28367644	ZSCAN12	-0.53	-5.13	-0.42	1.09e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6435862	0.593	rs34732883	chr2:215674371	C/T	cg04004882	chr2:215674386	BARD1	-0.77	-6.88	-0.53	2.66e-10	Neuroblastoma (high-risk);
TGCT	cis	rs6674176	0.611	rs3120803	chr1:44386615	A/G	cg12908607	chr1:44402522	ARTN	-0.73	-4.61	-0.38	9.87e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs2832191	0.791	rs2832199	chr21:30498501	G/A	cg24692254	chr21:30365293	RNF160	-0.89	-9.49	-0.65	2.2e-16	Dental caries;
TGCT	cis	rs1949733	0.701	rs4696828	chr4:8455604	G/A	cg11789530	chr4:8429930	ACOX3	-0.54	-5.13	-0.42	1.08e-6	Response to antineoplastic agents;
TGCT	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg08859206	chr1:53392774	SCP2	0.4	5.96	0.47	2.46e-8	Monocyte count;
TGCT	cis	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg18252515	chr7:66147081	NA	-1.19	-7.51	-0.56	1.02e-11	Diabetic kidney disease;
TGCT	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs56011263	0.687	rs11734460	chr4:705074	C/T	cg17689763	chr4:710664	PCGF3	-0.24	-7.23	-0.54	4.25e-11	White blood cell count;
TGCT	cis	rs7772486	0.875	rs2180192	chr6:146322284	T/C	cg23711669	chr6:146136114	FBXO30	0.88	9.65	0.65	9.01e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs8031584	0.678	rs35098644	chr15:31145440	A/G	cg08109568	chr15:31115862	NA	-0.38	-4.83	-0.4	3.99e-6	Huntington's disease progression;
TGCT	cis	rs317865	0.737	rs73234644	chr4:16190661	T/G	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.78	5.11	0.42	1.18e-6	Kidney disease (early stage) in type 1 diabetes;
TGCT	cis	rs11690935	0.788	rs10201053	chr2:172889558	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.03	-10.05	-0.67	9.72e-18	Schizophrenia;
TGCT	cis	rs778371	0.723	rs12105766	chr2:233617647	A/G	cg08000102	chr2:233561755	GIGYF2	0.72	8.42	0.6	7.71e-14	Schizophrenia;
TGCT	cis	rs10408945	1	rs10408945	chr19:16576991	G/T	cg14704714	chr19:15740395	CYP4F8	-0.41	-4.49	-0.37	1.6e-5	Lymphocyte counts;
TGCT	cis	rs10876993	0.890	rs1678539	chr12:58060359	A/G	cg15848620	chr12:58087721	OS9	-0.74	-5.98	-0.47	2.23e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs765787	0.530	rs28733848	chr15:45516047	C/T	cg24006582	chr15:45444508	DUOX1	-0.26	-5.62	-0.45	1.19e-7	Uric acid levels;
TGCT	cis	rs62244186	0.608	rs2888390	chr3:44511405	G/A	cg02073558	chr3:44770973	ZNF501	0.61	5.79	0.46	5.39e-8	Depressive symptoms;
TGCT	cis	rs7666738	0.716	rs11721453	chr4:99045485	G/T	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs4919669	0.668	rs4919666	chr10:104384029	G/A	cg24066601	chr6:26271455	HIST1H3G	0.66	6.81	0.52	3.7e-10	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs7772486	0.686	rs1292336	chr6:145967818	T/C	cg05347473	chr6:146136440	FBXO30	-0.47	-4.49	-0.37	1.58e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4631830	0.863	rs2843546	chr10:51518688	A/C	cg10326726	chr10:51549505	MSMB	-0.26	-5.37	-0.43	3.68e-7	Prostate-specific antigen levels;
TGCT	cis	rs2721195	0.577	rs4532636	chr8:145904423	A/C	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.95	-9.71	-0.66	6.5e-17	Age at first birth;
TGCT	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg17971929	chr21:40555470	PSMG1	0.98	9.67	0.66	8.18e-17	Cognitive function;
TGCT	cis	rs2439831	0.867	rs2920781	chr15:43924682	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	6.61	0.51	1.03e-9	Lung cancer in ever smokers;
TGCT	cis	rs11650494	0.831	rs11650886	chr17:47449193	G/A	cg08112188	chr17:47440006	ZNF652	1.04	5.31	0.43	4.85e-7	Prostate cancer;
TGCT	cis	rs12497850	0.931	rs6446205	chr3:49035211	C/T	cg06212747	chr3:49208901	KLHDC8B	0.61	5.49	0.44	2.2e-7	Parkinson's disease;
TGCT	cis	rs4689388	0.890	rs4342257	chr4:6290037	G/C	cg14416269	chr4:6271139	WFS1	0.37	4.88	0.4	3.15e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	trans	rs629535	0.590	rs62513426	chr8:70136843	T/G	cg21567404	chr3:27674614	NA	-0.52	-7.76	-0.57	2.74e-12	Dupuytren's disease;
TGCT	cis	rs9302065	0.565	rs2993586	chr13:95962578	T/C	cg24476569	chr13:95954382	ABCC4	-0.54	-8.26	-0.6	1.9e-13	Blood metabolite levels;
TGCT	cis	rs6882076	0.925	rs4704826	chr5:156392082	C/A	cg12943317	chr5:156479607	HAVCR1	-0.29	-5.6	-0.45	1.3e-7	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
TGCT	trans	rs1814175	0.781	rs12286395	chr11:49954062	C/G	cg15704280	chr7:45808275	SEPT13	-0.73	-8.48	-0.61	5.58e-14	Height;
TGCT	trans	rs3780486	0.505	rs959749	chr9:33147858	T/C	cg20290983	chr6:43655470	MRPS18A	0.77	8.33	0.6	1.28e-13	IgG glycosylation;
TGCT	trans	rs2243480	0.522	rs1638736	chr7:66092308	A/T	cg07424592	chr7:64974309	NA	1.36	8.8	0.62	1.01e-14	Diabetic kidney disease;
TGCT	cis	rs10771431	1.000	rs10771431	chr12:9380859	C/T	cg08997352	chr12:9597637	DDX12	-0.26	-5.65	-0.45	1.04e-7	Breast size;
TGCT	cis	rs875971	1.000	rs1144894	chr7:65542894	A/G	cg18876405	chr7:65276391	NA	-0.35	-5.19	-0.42	8.26e-7	Aortic root size;
TGCT	cis	rs1467026	0.584	rs11712581	chr3:12807781	T/C	cg05775895	chr3:12838266	CAND2	0.72	7.41	0.55	1.73e-11	P wave duration;
TGCT	cis	rs56235845	0.694	rs11749830	chr5:176766547	G/A	cg16006841	chr5:176797999	RGS14	0.52	7.69	0.57	3.9e-12	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs7833790	0.700	rs7834483	chr8:82704828	A/G	cg17211192	chr8:82754475	SNX16	-0.89	-7.91	-0.58	1.24e-12	Diastolic blood pressure;
TGCT	cis	rs10197940	0.662	rs13555	chr2:152333304	C/A	cg06191203	chr2:152266755	RIF1	-0.71	-6.28	-0.49	5.14e-9	Lung cancer;
TGCT	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg25036284	chr2:26402008	FAM59B	-0.56	-4.85	-0.4	3.62e-6	Gut microbiome composition (summer);
TGCT	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg22963979	chr7:1858916	MAD1L1	-0.44	-6.99	-0.53	1.5e-10	Bipolar disorder and schizophrenia;
TGCT	cis	rs72781680	0.821	rs72790329	chr2:24129277	A/G	cg08917208	chr2:24149416	ATAD2B	0.74	4.66	0.39	7.9e-6	Lymphocyte counts;
TGCT	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg12564285	chr5:131593104	PDLIM4	0.41	4.74	0.39	5.82e-6	Acylcarnitine levels;
TGCT	trans	rs2727020	0.595	rs10839286	chr11:49497063	C/A	cg15704280	chr7:45808275	SEPT13	-0.74	-8.49	-0.61	5.28e-14	Coronary artery disease;
TGCT	cis	rs6867032	1.000	rs16902321	chr5:2015148	A/G	cg26168224	chr5:2018326	NA	0.43	7.86	0.58	1.62e-12	Gut microbiome composition (winter);
TGCT	cis	rs11122272	0.735	rs2790885	chr1:231529925	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-6.34	-0.49	3.83e-9	Hemoglobin concentration;
TGCT	cis	rs7904368	0.806	rs3858182	chr10:16855094	C/T	cg14835575	chr10:16859367	RSU1	0.7	7.48	0.56	1.19e-11	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
TGCT	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg06028605	chr16:24865363	SLC5A11	0.41	4.57	0.38	1.17e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7226408	0.857	rs72890583	chr18:34627906	A/G	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs7666738	0.830	rs116103936	chr4:98954531	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1008375	0.897	rs1006723	chr4:17618524	G/A	cg18681998	chr4:17616180	MED28	1.06	11.58	0.72	1.76e-21	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	trans	rs57221529	0.766	rs12521988	chr5:556421	C/T	cg11887960	chr12:57824829	NA	1.15	9.35	0.64	4.71e-16	Lung disease severity in cystic fibrosis;
TGCT	cis	rs3125734	0.633	rs4979782	chr10:63998527	C/T	cg09941381	chr10:64027924	RTKN2	-0.37	-5.58	-0.45	1.45e-7	Rheumatoid arthritis;
TGCT	cis	rs17376456	0.877	rs10040648	chr5:93490301	G/C	cg21475434	chr5:93447410	FAM172A	0.63	4.6	0.38	1.01e-5	Diabetic retinopathy;
TGCT	cis	rs854765	0.583	rs9904163	chr17:17830553	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.74	7.73	0.57	3.18e-12	Total body bone mineral density;
TGCT	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6121246	0.954	rs6060992	chr20:30431255	G/T	cg13852791	chr20:30311386	BCL2L1	0.76	5.67	0.45	9.7e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs11098499	0.865	rs9996417	chr4:120295862	T/C	cg09307838	chr4:120376055	NA	0.66	6.46	0.5	2.15e-9	Corneal astigmatism;
TGCT	cis	rs8062405	0.824	rs7191618	chr16:28565667	C/G	cg09754948	chr16:28834200	ATXN2L	0.63	4.97	0.41	2.16e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs709400	1.000	rs61995780	chr14:104120612	A/G	cg26031613	chr14:104095156	KLC1	1.14	17.16	0.84	1.53e-34	Body mass index;
TGCT	cis	rs4660261	0.526	rs2906458	chr1:44336389	A/G	cg13606994	chr1:44402422	ARTN	0.41	4.46	0.37	1.82e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9906944	0.742	rs4073893	chr17:47118523	A/G	cg07075026	chr17:47091521	IGF2BP1	-0.43	-4.6	-0.38	1.03e-5	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs9467773	0.620	rs1027203	chr6:26639332	G/C	cg02458000	chr6:26745757	NA	0.65	6.34	0.49	3.92e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.97	-8.51	-0.61	4.86e-14	Platelet count;
TGCT	cis	rs71636778	0.509	rs60340200	chr1:27287716	A/G	cg23921621	chr1:27994728	IFI6	-0.43	-4.61	-0.38	9.92e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
TGCT	cis	rs4383453	0.539	rs56384012	chr3:123098176	G/A	cg04890266	chr3:123102914	ADCY5	-0.5	-8.3	-0.6	1.48e-13	Gestational age at birth (maternal effect);
TGCT	cis	rs6582630	0.555	rs7965311	chr12:38513307	G/A	cg26384229	chr12:38710491	ALG10B	-0.8	-7.43	-0.56	1.51e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs9814567	1.000	rs11927068	chr3:134266321	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.96	9.11	0.63	1.79e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs6882046	0.513	rs34318	chr5:88027149	G/A	cg22951263	chr5:87985283	NA	-0.54	-5.8	-0.46	5.2100000000000003e-08	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg06238570	chr21:40685208	BRWD1	0.6	5.25	0.43	6.39e-7	Cognitive function;
TGCT	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg10802521	chr3:52805072	NEK4	-0.78	-10.01	-0.67	1.22e-17	Bipolar disorder;
TGCT	cis	rs9486715	0.867	rs2475025	chr6:96988696	A/T	cg18709589	chr6:96969512	KIAA0776	-0.79	-7.84	-0.58	1.79e-12	Headache;
TGCT	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg01448562	chr3:133502909	NA	-0.26	-4.9	-0.4	2.97e-6	Iron status biomarkers;
TGCT	cis	rs7647973	0.626	rs1491985	chr3:49739507	G/C	cg05785598	chr3:49045655	WDR6	0.42	5.24	0.43	6.67e-7	Menarche (age at onset);
TGCT	cis	rs72781680	0.752	rs72796114	chr2:23906133	C/G	cg08917208	chr2:24149416	ATAD2B	1.0	5.56	0.45	1.59e-7	Lymphocyte counts;
TGCT	cis	rs208520	0.909	rs60604603	chr6:67022955	T/C	cg07460842	chr6:66804631	NA	0.69	5.72	0.46	7.53e-8	Exhaled nitric oxide output;
TGCT	cis	rs6684514	1.000	rs2241106	chr1:156218910	C/G	cg16558208	chr1:156270281	VHLL	0.46	8.4	0.6	8.73e-14	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs6582630	0.598	rs10880645	chr12:38556172	G/A	cg26384229	chr12:38710491	ALG10B	-0.53	-4.77	-0.39	5.12e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs9291683	0.530	rs11723591	chr4:9985398	T/A	cg11266682	chr4:10021025	SLC2A9	0.62	8.49	0.61	5.26e-14	Bone mineral density;
TGCT	cis	rs492146	0.765	rs316132	chr6:52847966	C/T	cg06706454	chr6:52930286	FBXO9	-0.53	-4.95	-0.41	2.37e-6	Epilepsy (remission after treatment);
TGCT	cis	rs4720575	1.000	rs6463383	chr7:47091686	A/G	cg00036614	chr7:47093842	NA	0.2	5.11	0.42	1.18e-6	Angiotensin-converting enzyme inhibitor intolerance;
TGCT	cis	rs11098499	0.618	rs6858383	chr4:120296772	T/C	cg09307838	chr4:120376055	NA	0.66	6.48	0.5	1.98e-9	Corneal astigmatism;
TGCT	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg04944784	chr2:26401820	FAM59B	0.76	6.24	0.49	6.46e-9	Gut microbiome composition (summer);
TGCT	cis	rs7681440	0.669	rs6814481	chr4:90805660	C/T	cg10208370	chr4:90758469	SNCA	-0.57	-5.33	-0.43	4.48e-7	Dementia with Lewy bodies;
TGCT	cis	rs12134133	1.000	rs6660254	chr1:207446091	C/G	cg02152968	chr1:207494213	CD55	0.6	4.53	0.38	1.36e-5	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs9291683	0.546	rs13110307	chr4:10044364	T/C	cg11266682	chr4:10021025	SLC2A9	0.6	7.52	0.56	9.49e-12	Bone mineral density;
TGCT	cis	rs7224685	0.569	rs8082483	chr17:4000849	G/A	cg09580393	chr17:4869866	SPAG7	-0.38	-4.48	-0.37	1.64e-5	Type 2 diabetes;
TGCT	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	5.71	0.46	8.05e-8	Alzheimer's disease;
TGCT	cis	rs6545883	0.931	rs12713438	chr2:61725501	G/A	cg15711740	chr2:61764176	XPO1	-0.5	-4.51	-0.38	1.46e-5	Tuberculosis;
TGCT	cis	rs13191362	1.000	rs13195226	chr6:163006421	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.68	5.79	0.46	5.33e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs511515	1	rs511515	chr6:33541507	A/G	cg07679836	chr6:33548423	BAK1	0.42	5.86	0.47	3.91e-8	Eosinophil counts;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
TGCT	cis	rs6032067	0.571	rs6017536	chr20:43907369	G/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.48	-7.23	-0.54	4.28e-11	Blood protein levels;
TGCT	cis	rs319204	0.843	rs178549	chr5:146295990	A/G	cg25021259	chr5:146258546	PPP2R2B	-0.36	-4.54	-0.38	1.29e-5	Schizophrenia;
TGCT	cis	rs7208859	0.524	rs8065744	chr17:29099449	C/T	cg13385521	chr17:29058706	SUZ12P	0.82	4.86	0.4	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7666738	0.822	rs17484018	chr4:98988960	G/A	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs72615157	0.628	rs7801070	chr7:99847147	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.61	4.72	0.39	6.31e-6	Lung function (FEV1/FVC);
TGCT	cis	rs9787249	0.957	rs11809515	chr1:40205326	C/A	cg24920358	chr1:40204285	PPIE	0.57	10.56	0.69	5.57e-19	Blood protein levels;
TGCT	cis	rs62380364	0.557	rs663046	chr5:88036486	C/T	cg22951263	chr5:87985283	NA	-0.55	-5.96	-0.47	2.46e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2033711	0.811	rs9304814	chr19:58951811	C/A	cg13877915	chr19:58951672	ZNF132	0.9	10.8	0.7	1.44e-19	Uric acid clearance;
TGCT	cis	rs9611565	0.649	rs139540	chr22:42178040	C/T	cg13695892	chr22:41940480	POLR3H	-0.85	-8.02	-0.58	6.79e-13	Vitiligo;
TGCT	cis	rs1008375	1.000	rs28693609	chr4:17645233	C/T	cg10189774	chr4:17578691	LAP3	0.58	5.26	0.43	6.24e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2075371	0.611	rs12707154	chr7:134015832	C/T	cg11752832	chr7:134001865	SLC35B4	0.63	5.07	0.41	1.41e-6	Mean platelet volume;
TGCT	cis	rs7172809	0.599	rs17472200	chr15:77783812	C/G	cg22256960	chr15:77711686	NA	-0.51	-4.86	-0.4	3.47e-6	Glucose homeostasis traits;
TGCT	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg10862848	chr6:42927986	GNMT	-0.38	-4.72	-0.39	6.35e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs950027	0.620	rs1153857	chr15:45659095	G/T	cg26924012	chr15:45694286	SPATA5L1	0.79	8.86	0.62	6.92e-15	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs2153535	0.580	rs1577466	chr6:8444192	T/C	cg07606381	chr6:8435919	SLC35B3	0.57	5.25	0.43	6.46e-7	Motion sickness;
TGCT	cis	rs4366490	0.848	rs1939758	chr11:62903612	T/C	cg21002970	chr11:62369079	MTA2	0.87	4.67	0.39	7.78e-6	Conotruncal heart defects;
TGCT	cis	rs36051895	0.632	rs12337481	chr9:5134599	T/G	cg02405213	chr9:5042618	JAK2	-0.75	-10.52	-0.69	6.97e-19	Pediatric autoimmune diseases;
TGCT	cis	rs6547741	0.874	rs58737572	chr2:27852118	A/C	cg27432699	chr2:27873401	GPN1	0.18	4.56	0.38	1.19e-5	Oral cavity cancer;
TGCT	cis	rs9818758	0.607	rs3923475	chr3:49055788	G/T	cg07636037	chr3:49044803	WDR6	-1.04	-5.16	-0.42	9.65e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs11874712	1.000	rs56181324	chr18:43678024	G/A	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	5.23	0.42	7.04e-7	Migraine - clinic-based;
TGCT	cis	rs7246657	0.943	rs10403613	chr19:37844306	C/T	cg18154014	chr19:37997991	ZNF793	0.97	6.49	0.5	1.82e-9	Coronary artery calcification;
TGCT	cis	rs9653442	0.510	rs11891046	chr2:100794402	C/G	cg07810366	chr2:100720526	AFF3	-0.35	-5.25	-0.43	6.27e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs2456568	0.805	rs2032400	chr11:93676937	G/A	cg17595323	chr11:93583763	C11orf90	-0.45	-5.91	-0.47	3.1e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs6448317	1.000	rs13105803	chr4:24940002	A/G	cg21108841	chr4:24914750	CCDC149	-0.65	-4.94	-0.41	2.51e-6	Heschl's gyrus morphology;
TGCT	cis	rs524023	0.958	rs3825016	chr11:64359286	C/T	cg07733098	chr11:64478343	NRXN2	0.31	4.66	0.39	7.9e-6	Urate levels in obese individuals;
TGCT	cis	rs655601	1.000	rs655601	chr5:180226673	G/T	cg13724780	chr5:180237085	MGAT1	-0.82	-5.6	-0.45	1.3e-7	Quantitative traits;
TGCT	trans	rs1814175	0.587	rs847628	chr11:49927064	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.51	-0.69	7.2e-19	Height;
TGCT	cis	rs13424612	0.930	rs6748327	chr2:240902511	G/A	cg26363272	chr2:240904871	NDUFA10	0.3	5.01	0.41	1.82e-6	Odorant perception (isobutyraldehyde);
TGCT	cis	rs2439831	0.541	rs12440854	chr15:43610672	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.12	7.38	0.55	1.97e-11	Lung cancer in ever smokers;
TGCT	cis	rs2456568	0.805	rs2032400	chr11:93676937	G/A	cg14065697	chr11:93583672	C11orf90	-0.37	-4.45	-0.37	1.87e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs6570726	0.791	rs436498	chr6:145876347	G/A	cg05347473	chr6:146136440	FBXO30	0.54	5.15	0.42	1.01e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1046896	0.586	rs9897951	chr17:80810662	T/C	cg03160526	chr17:80928410	B3GNTL1	0.33	4.57	0.38	1.18e-5	Glycated hemoglobin levels;
TGCT	cis	rs1008375	0.932	rs9283698	chr4:17662471	T/C	cg18681998	chr4:17616180	MED28	0.94	10.15	0.67	5.6e-18	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs11024102	1.000	rs4141194	chr11:17011176	A/C	cg15378786	chr11:17036137	PLEKHA7	-0.48	-4.51	-0.38	1.48e-5	Glaucoma (primary angle closure);
TGCT	cis	rs7044106	0.734	rs12553070	chr9:123485266	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	7.35	0.55	2.35e-11	Hip circumference adjusted for BMI;
TGCT	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg12288994	chr5:1860383	NA	0.24	4.78	0.39	4.86e-6	Cardiovascular disease risk factors;
TGCT	cis	rs2180341	0.618	rs11154398	chr6:127654281	C/A	cg27446573	chr6:127587934	RNF146	0.65	5.79	0.46	5.52e-8	Breast cancer;
TGCT	cis	rs1949733	1.000	rs3103072	chr4:8508431	C/T	cg11789530	chr4:8429930	ACOX3	-0.63	-5.74	-0.46	6.71e-8	Response to antineoplastic agents;
TGCT	cis	rs9640161	0.789	rs28432021	chr7:150046235	G/C	cg17279839	chr7:150038598	RARRES2	0.43	4.64	0.38	8.89e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs10984561	0.881	rs7031568	chr9:122253548	C/T	cg14242995	chr9:122249943	NA	0.74	6.01	0.47	1.96e-8	Pulmonary function decline;
TGCT	cis	rs4455778	0.580	rs10242641	chr7:49085748	G/A	cg26309511	chr7:48887640	NA	0.5	6.47	0.5	2.03e-9	Lung cancer in never smokers;
TGCT	cis	rs3806843	0.576	rs155358	chr5:140297032	A/T	cg07102913	chr5:140593443	PCDHB13	-0.48	-4.71	-0.39	6.57e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs6951245	0.542	rs28460147	chr7:1217192	G/A	cg18402987	chr7:1209562	NA	0.76	6.35	0.5	3.62e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.04	-9.17	-0.64	1.27e-15	Platelet count;
TGCT	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg13395646	chr4:1353034	KIAA1530	-0.5	-6.46	-0.5	2.15e-9	Obesity-related traits;
TGCT	cis	rs7772486	0.536	rs9373467	chr6:145955605	C/T	cg05347473	chr6:146136440	FBXO30	0.64	6.0	0.47	2.04e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs797680	0.789	rs35940311	chr1:93663604	G/A	cg17826107	chr1:92977322	EVI5	-0.24	-5.31	-0.43	4.9e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs7714584	0.793	rs11949375	chr5:150202980	T/C	cg22134413	chr5:150180641	NA	0.89	6.96	0.53	1.73e-10	Crohn's disease;
TGCT	cis	rs6788371	0.966	rs2059552	chr3:187318908	A/G	cg01598596	chr3:187464648	BCL6	-0.44	-4.72	-0.39	6.38e-6	Pursuit maintenance gain;
TGCT	cis	rs62244186	0.659	rs9835270	chr3:44553722	G/A	cg11003573	chr3:44754125	ZNF502	-0.42	-4.72	-0.39	6.36e-6	Depressive symptoms;
TGCT	cis	rs9443189	0.570	rs6903124	chr6:76290079	A/C	cg01950844	chr6:76311363	SENP6	0.97	6.1	0.48	1.27e-8	Prostate cancer;
TGCT	cis	rs611744	0.647	rs2597658	chr8:109256014	C/T	cg21045802	chr8:109455806	TTC35	0.7	6.74	0.52	5.23e-10	Dupuytren's disease;
TGCT	cis	rs7818688	0.697	rs78088250	chr8:95972718	G/A	cg16049864	chr8:95962084	TP53INP1	0.54	4.64	0.38	8.87e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs4689388	0.929	rs1046320	chr4:6304344	C/T	cg25554036	chr4:6271136	WFS1	0.5	6.75	0.52	5.02e-10	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs17376456	0.877	rs28575883	chr5:93346035	T/C	cg25358565	chr5:93447407	FAM172A	0.97	8.5	0.61	5.11e-14	Diabetic retinopathy;
TGCT	cis	rs9467773	0.595	rs3799379	chr6:26404694	C/T	cg05738196	chr6:26577821	NA	-0.5	-5.22	-0.42	7.31e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs10197940	0.662	rs4592848	chr2:152337822	G/A	cg06191203	chr2:152266755	RIF1	-0.77	-7.27	-0.55	3.53e-11	Lung cancer;
TGCT	cis	rs2153535	0.580	rs9505448	chr6:8459804	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs9527	0.571	rs10786715	chr10:104620735	G/C	cg15744005	chr10:104629667	AS3MT	-0.5	-6.39	-0.5	3.12e-9	Arsenic metabolism;
TGCT	cis	rs7772486	0.712	rs1292335	chr6:145967877	G/T	cg23711669	chr6:146136114	FBXO30	0.65	6.22	0.49	6.92e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1055129	0.560	rs2608880	chr17:73938957	C/T	cg10935138	chr17:73851978	WBP2	0.55	4.87	0.4	3.35e-6	White matter hyperintensity burden;
TGCT	cis	rs7113874	0.543	rs7935708	chr11:8478545	C/A	cg14521421	chr11:8862019	ST5	0.29	4.49	0.37	1.59e-5	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs11098499	0.909	rs1546502	chr4:120235898	A/G	cg09307838	chr4:120376055	NA	0.61	5.68	0.45	8.88e-8	Corneal astigmatism;
TGCT	cis	rs9902453	1.000	rs9891871	chr17:28370191	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-6.8	-0.52	3.85e-10	Coffee consumption (cups per day);
TGCT	cis	rs35264875	1.000	rs6591370	chr11:68843003	G/A	cg02660097	chr11:68866761	NA	0.32	4.87	0.4	3.4e-6	Blond vs. brown hair color;
TGCT	cis	rs7914558	1.000	rs11191542	chr10:104824324	T/A	cg15744005	chr10:104629667	AS3MT	-0.38	-4.63	-0.38	9.1e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs35306767	0.903	rs12778891	chr10:950130	T/A	cg26597838	chr10:835615	NA	0.75	10.3	0.68	2.42e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs4654899	0.643	rs1408409	chr1:21089781	T/C	cg01072550	chr1:21505969	NA	-0.54	-8.83	-0.62	8.43e-15	Superior frontal gyrus grey matter volume;
TGCT	cis	rs3806843	0.576	rs246002	chr5:140341104	A/G	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg18252515	chr7:66147081	NA	-1.13	-6.81	-0.52	3.7e-10	Diabetic kidney disease;
TGCT	cis	rs1670533	0.585	rs6827206	chr4:1065071	A/T	cg20887711	chr4:1340912	KIAA1530	0.69	5.5	0.44	2.03e-7	Recombination rate (females);
TGCT	cis	rs9911578	0.933	rs74370218	chr17:57095212	C/T	cg05425664	chr17:57184151	TRIM37	0.68	6.89	0.53	2.55e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs651907	0.557	rs35850993	chr3:101437433	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	4.68	0.39	7.44e-6	Colorectal cancer;
TGCT	cis	rs9790314	0.905	rs6774276	chr3:160941318	C/T	cg03342759	chr3:160939853	NMD3	-0.42	-4.51	-0.38	1.5e-5	Morning vs. evening chronotype;
TGCT	cis	rs7017914	0.870	rs34282253	chr8:71582366	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.03	-0.41	1.69e-6	Bone mineral density;
TGCT	cis	rs3806843	0.676	rs778594	chr5:140027304	T/C	cg19875535	chr5:140030758	IK	-0.36	-6.34	-0.49	3.84e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs12477438	0.520	rs34252185	chr2:99737646	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.06	13.26	0.77	1.59e-25	Chronic sinus infection;
TGCT	cis	rs12971120	0.891	rs11151961	chr18:72177340	C/T	cg26446133	chr18:72167187	CNDP2	-0.35	-5.89	-0.47	3.42e-8	Refractive error;
TGCT	cis	rs6921919	0.778	rs67381177	chr6:28411941	G/C	cg10876282	chr6:28092338	ZSCAN16	0.86	4.46	0.37	1.8e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2243480	1.000	rs2243480	chr7:65599196	C/T	cg18252515	chr7:66147081	NA	-1.25	-7.45	-0.56	1.37e-11	Diabetic kidney disease;
TGCT	cis	rs2404602	0.618	rs12442266	chr15:76567142	T/C	cg26408565	chr15:76604113	ETFA	-0.47	-6.49	-0.5	1.86e-9	Blood metabolite levels;
TGCT	cis	rs6540559	0.808	rs11119358	chr1:210042456	T/C	cg10074409	chr1:209979377	IRF6	0.54	4.55	0.38	1.24e-5	Cleft lip with or without cleft palate;
TGCT	cis	rs1577917	0.958	rs12202712	chr6:86578541	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.16	-0.42	9.71e-7	Response to antipsychotic treatment;
TGCT	cis	rs13191362	0.935	rs66923841	chr6:163177317	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.19	0.59	2.72e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs2241685	0.850	rs10865521	chr2:1943691	C/G	cg21862353	chr2:1801628	MYT1L	-0.48	-4.54	-0.38	1.31e-5	Attention deficit hyperactivity disorder;
TGCT	cis	rs7586879	0.616	rs6726199	chr2:25126328	G/C	cg01884057	chr2:25150051	NA	0.35	6.9	0.53	2.39e-10	Body mass index;
TGCT	cis	rs8014252	0.803	rs59233924	chr14:71050660	A/G	cg11204974	chr14:71022665	NA	-0.55	-4.54	-0.38	1.31e-5	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
TGCT	cis	rs4733781	0.871	rs7839155	chr8:131318869	G/A	cg16277922	chr8:131349729	ASAP1	0.36	4.66	0.39	7.92e-6	Tuberculosis;
TGCT	cis	rs7523273	0.925	rs6540443	chr1:208002010	T/A	cg22525895	chr1:207977042	MIR29B2	-0.49	-8.6	-0.61	2.98e-14	Schizophrenia;
TGCT	cis	rs933688	0.938	rs7708782	chr5:90718517	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.98	8.36	0.6	1.11e-13	Smoking behavior;
TGCT	cis	rs4746818	0.688	rs951718	chr10:70928044	A/G	cg04149295	chr10:70884716	VPS26A	0.79	5.44	0.44	2.79e-7	Left atrial antero-posterior diameter;
TGCT	cis	rs7829975	0.658	rs907181	chr8:8702875	T/C	cg06636001	chr8:8085503	FLJ10661	0.7	6.49	0.5	1.82e-9	Mood instability;
TGCT	cis	rs12579753	0.917	rs12316644	chr12:82205497	C/T	cg07988820	chr12:82153109	PPFIA2	0.59	6.19	0.49	7.93e-9	Resting heart rate;
TGCT	cis	rs7772486	0.655	rs2142981	chr6:146071695	G/C	cg05347473	chr6:146136440	FBXO30	-0.54	-4.95	-0.41	2.33e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg20887711	chr4:1340912	KIAA1530	0.54	4.77	0.39	5.11e-6	Longevity;
TGCT	cis	rs62209	0.752	rs11256939	chr10:11009166	T/G	cg26901096	chr10:10994189	LOC254312	0.43	6.99	0.53	1.46e-10	Alzheimer's disease (late onset);
TGCT	cis	rs587847	0.558	rs627477	chr15:37684407	T/C	cg16890051	chr15:37175029	LOC145845	-0.39	-4.57	-0.38	1.16e-5	Intraocular pressure;
TGCT	cis	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg20637647	chr7:64974828	NA	0.9	5.31	0.43	4.87e-7	Diabetic kidney disease;
TGCT	cis	rs9303401	0.659	rs3809724	chr17:57061238	G/A	cg25039879	chr17:56429692	SUPT4H1	0.54	4.72	0.39	6.33e-6	Cognitive test performance;
TGCT	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg21724239	chr8:58056113	NA	0.38	5.18	0.42	8.82e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs427394	0.659	rs274693	chr5:6734162	G/A	cg10857441	chr5:6722123	POLS	-0.28	-6.08	-0.48	1.38e-8	Menopause (age at onset);
TGCT	cis	rs10254284	0.959	rs757729	chr7:28146305	G/C	cg23620719	chr7:28220237	JAZF1	-0.55	-4.93	-0.4	2.62e-6	Lymphocyte percentage of white cells;Systemic lupus erythematosus;
TGCT	cis	rs13256369	0.951	rs13260947	chr8:8565883	A/G	cg06671706	chr8:8559999	CLDN23	0.34	4.59	0.38	1.09e-5	Obesity-related traits;
TGCT	cis	rs4654899	0.802	rs61781104	chr1:21257235	T/A	cg01072550	chr1:21505969	NA	-0.46	-6.94	-0.53	1.96e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs4975616	0.714	rs37007	chr5:1352372	G/C	cg26373071	chr5:1325741	CLPTM1L	0.18	4.84	0.4	3.79e-6	Lung cancer;
TGCT	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg11247378	chr22:39784982	NA	-0.73	-9.83	-0.66	3.22e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs1008375	1.000	rs13106338	chr4:17676871	G/T	cg16339924	chr4:17578868	LAP3	-0.61	-5.07	-0.41	1.38e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7193541	0.684	rs9929496	chr16:74668473	G/A	cg01733217	chr16:74700730	RFWD3	1.0	13.52	0.77	3.8e-26	Multiple myeloma;
TGCT	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg26531700	chr6:26746687	NA	0.51	4.52	0.38	1.44e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg20637647	chr7:64974828	NA	0.9	5.31	0.43	4.87e-7	Diabetic kidney disease;
TGCT	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg16325326	chr1:53192061	ZYG11B	-0.73	-8.95	-0.63	4.41e-15	Monocyte count;
TGCT	cis	rs727563	0.565	rs132774	chr22:42031953	C/G	cg06634786	chr22:41940651	POLR3H	-0.8	-7.63	-0.57	5.37e-12	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs7267979	0.844	rs4423675	chr20:25402778	A/G	cg03522245	chr20:25566470	NINL	-0.55	-5.55	-0.45	1.68e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs3780486	0.846	rs10813948	chr9:33121570	G/A	cg20290983	chr6:43655470	MRPS18A	1.21	15.13	0.81	5.99e-30	IgG glycosylation;
TGCT	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg13902645	chr11:5959945	NA	0.53	6.1	0.48	1.24e-8	DNA methylation (variation);
TGCT	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg09704166	chr2:114031854	PAX8;LOC440839	-0.34	-4.96	-0.41	2.29e-6	Lymphocyte counts;
TGCT	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg13342137	chr4:2252803	MXD4	0.17	4.59	0.38	1.07e-5	Obesity-related traits;
TGCT	cis	rs3617	0.539	rs9880619	chr3:52953055	G/A	cg10802521	chr3:52805072	NEK4	0.56	6.5	0.5	1.76e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7211079	0.879	rs61357240	chr17:78131775	A/G	cg09238746	chr17:78121135	EIF4A3	-0.71	-5.87	-0.47	3.73e-8	Myocardial infarction;
TGCT	cis	rs2235642	0.750	rs2859310	chr16:1656765	C/T	cg10465839	chr16:1584050	IFT140;TMEM204	0.28	4.63	0.38	9.27e-6	Coronary artery disease;
TGCT	cis	rs12497850	0.931	rs9867373	chr3:48960938	A/T	cg07636037	chr3:49044803	WDR6	0.94	10.39	0.68	1.46e-18	Parkinson's disease;
TGCT	cis	rs10782582	0.593	rs12142247	chr1:76235746	C/T	cg22875332	chr1:76189707	ACADM	-0.45	-4.93	-0.4	2.55e-6	Daytime sleep phenotypes;
TGCT	cis	rs4242434	0.757	rs4872531	chr8:22529695	A/G	cg03733263	chr8:22462867	KIAA1967	-1.04	-15.96	-0.82	7.59e-32	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs2730245	0.505	rs1188956	chr7:158690576	G/A	cg11984989	chr7:158649758	WDR60	0.99	8.9	0.62	5.65e-15	Height;
TGCT	cis	rs9611565	1.000	rs5758314	chr22:41762523	T/G	cg06634786	chr22:41940651	POLR3H	-0.65	-6.21	-0.49	7.17e-9	Vitiligo;
TGCT	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg24549020	chr5:56110836	MAP3K1	0.67	5.78	0.46	5.74e-8	Initial pursuit acceleration;
TGCT	cis	rs7731657	0.569	rs17621454	chr5:130205584	C/G	cg08523029	chr5:130500466	HINT1	0.81	5.24	0.43	6.77e-7	Fasting plasma glucose;
TGCT	cis	rs11792861	0.619	rs2289480	chr9:111705501	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.68	7.84	0.58	1.78e-12	Menarche (age at onset);
TGCT	cis	rs807669	0.869	rs1061325	chr22:19184095	T/C	cg02655711	chr22:19163373	SLC25A1	0.29	6.1	0.48	1.27e-8	Metabolite levels;
TGCT	cis	rs2456568	0.695	rs55756119	chr11:93689909	A/G	cg17595323	chr11:93583763	C11orf90	0.4	4.99	0.41	1.98e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs225245	0.791	rs7406966	chr17:34013636	A/C	cg05299278	chr17:33885742	SLFN14	0.21	4.53	0.38	1.37e-5	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs9486715	0.867	rs4598081	chr6:96975227	A/G	cg18709589	chr6:96969512	KIAA0776	0.79	7.84	0.58	1.79e-12	Headache;
TGCT	cis	rs9787249	0.957	rs6670841	chr1:40220284	C/G	cg20968010	chr1:40505947	CAP1	-0.5	-4.7	-0.39	6.72e-6	Blood protein levels;
TGCT	cis	rs2535633	0.820	rs7626551	chr3:52938092	C/G	cg05573699	chr3:52720067	GNL3;PBRM1	0.52	5.06	0.41	1.48e-6	Body mass index;
TGCT	cis	rs3809863	0.602	rs11650072	chr17:45393665	A/G	cg08085267	chr17:45401833	C17orf57	-0.61	-7.05	-0.54	1.07e-10	Glaucoma (primary open-angle);
TGCT	cis	rs7043114	0.525	rs9299404	chr9:95170338	A/G	cg13798575	chr9:95087839	CENPP;NOL8	0.53	5.44	0.44	2.73e-7	Height;
TGCT	cis	rs10504229	0.679	rs12679920	chr8:58051710	G/T	cg08219700	chr8:58056026	NA	0.29	4.45	0.37	1.91e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs1008375	1.000	rs1121089	chr4:17676476	C/A	cg18681998	chr4:17616180	MED28	0.89	10.2	0.68	4.06e-18	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7781977	0.695	rs6583437	chr7:50350267	C/T	cg01139861	chr7:50343298	IKZF1	0.49	5.9	0.47	3.22e-8	IgG glycosylation;
TGCT	cis	rs7582180	0.677	rs11694723	chr2:100878122	C/T	cg14675211	chr2:100938903	LONRF2	0.47	4.5	0.37	1.53e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7582180	0.614	rs3748930	chr2:101010082	G/C	cg08017756	chr2:100939284	LONRF2	-0.3	-4.77	-0.39	5.18e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7914558	1.000	rs1926030	chr10:104855656	T/C	cg15744005	chr10:104629667	AS3MT	-0.42	-5.24	-0.43	6.69e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs13256369	0.756	rs13282580	chr8:8562903	C/T	cg18904891	chr8:8559673	CLDN23	0.58	5.4	0.44	3.23e-7	Obesity-related traits;
TGCT	cis	rs1018836	0.545	rs4236827	chr8:91688943	A/T	cg16814680	chr8:91681699	NA	-0.95	-13.83	-0.78	6.82e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs62244186	0.520	rs9311361	chr3:44796132	T/G	cg21672276	chr3:44754072	ZNF502	-0.53	-6.12	-0.48	1.14e-8	Depressive symptoms;
TGCT	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg06618935	chr21:46677482	NA	-0.37	-5.04	-0.41	1.64e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs8032315	0.965	rs35346340	chr15:91427872	G/C	cg06330618	chr15:91428456	FES	0.19	4.68	0.39	7.42e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg26338869	chr17:61819248	STRADA	-0.57	-5.31	-0.43	4.81e-7	Prudent dietary pattern;
TGCT	cis	rs7223966	1.000	rs78172786	chr17:61847114	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	4.62	0.38	9.61e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs10464366	0.957	rs6979210	chr7:39104119	C/G	cg18850127	chr7:39170497	POU6F2	0.21	4.5	0.37	1.55e-5	IgG glycosylation;
TGCT	cis	rs3540	0.574	rs2526000	chr15:90962626	C/T	cg22089800	chr15:90895588	ZNF774	0.76	8.15	0.59	3.29e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs1865760	0.566	rs9467663	chr6:26021456	C/G	cg16482183	chr6:26056742	HIST1H1C	0.56	4.78	0.39	4.96e-6	Height;
TGCT	cis	rs617219	0.671	rs6414979	chr5:78548010	T/G	cg05890484	chr5:78407552	BHMT	0.38	5.17	0.42	9.01e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg26818010	chr10:134567672	INPP5A	-0.38	-5.19	-0.42	8.5e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs12477438	0.501	rs12619780	chr2:99707307	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	11.11	0.71	2.53e-20	Chronic sinus infection;
TGCT	cis	rs4566357	0.930	rs13424003	chr2:227926860	G/A	cg11843606	chr2:227700838	RHBDD1	-0.5	-4.49	-0.37	1.59e-5	Coronary artery disease;
TGCT	cis	rs6095298	0.574	rs67763459	chr20:47464464	C/T	cg12307787	chr20:48099359	KCNB1	0.42	4.54	0.38	1.32e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs28595532	0.841	rs114970257	chr4:119756937	G/A	cg21605333	chr4:119757512	SEC24D	1.62	7.73	0.57	3.22e-12	Cannabis dependence symptom count;
TGCT	cis	rs3924048	0.574	rs11589283	chr1:12612280	G/A	cg00291366	chr1:12616550	NA	0.32	4.87	0.4	3.34e-6	Optic cup area;
TGCT	cis	rs804280	0.525	rs1004712	chr8:11622293	C/T	cg26752888	chr8:11627280	NEIL2	-0.57	-5.31	-0.43	4.9e-7	Myopia (pathological);
TGCT	cis	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg07424592	chr7:64974309	NA	1.38	8.17	0.59	3.04e-13	Diabetic kidney disease;
TGCT	cis	rs2153535	0.580	rs7743686	chr6:8526111	A/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.01	0.41	1.86e-6	Motion sickness;
TGCT	cis	rs12477438	0.765	rs1115756	chr2:99659845	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-4.88	-0.4	3.17e-6	Chronic sinus infection;
TGCT	cis	rs7100689	0.646	rs10749573	chr10:82136839	T/A	cg01528321	chr10:82214614	TSPAN14	0.8	7.72	0.57	3.42e-12	Post bronchodilator FEV1;
TGCT	cis	rs9814567	1.000	rs62271515	chr3:134300507	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.91	-8.83	-0.62	8.17e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs7267979	1.000	rs6083856	chr20:25407585	C/T	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs5760092	0.755	rs6003959	chr22:24264395	C/T	cg15242686	chr22:24348715	GSTTP1	-0.46	-5.33	-0.43	4.42e-7	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs3741404	0.825	rs2845597	chr11:63954370	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.9	10.24	0.68	3.38e-18	Platelet count;
TGCT	cis	rs9467773	0.620	rs2494700	chr6:26631306	C/T	cg05738196	chr6:26577821	NA	0.88	11.22	0.71	1.33e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs11122272	0.735	rs2474625	chr1:231519331	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.13	-0.54	7.33e-11	Hemoglobin concentration;
TGCT	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg06108461	chr20:60628389	TAF4	-0.69	-10.64	-0.69	3.59e-19	Body mass index;
TGCT	cis	rs1372520	0.564	rs2737011	chr4:90746219	T/C	cg20003494	chr4:90757398	SNCA	-0.59	-4.63	-0.38	9.21e-6	Neuroticism;
TGCT	cis	rs16854884	0.586	rs7611326	chr3:143736374	C/T	cg06585982	chr3:143692056	C3orf58	0.57	4.61	0.38	9.92e-6	Economic and political preferences (feminism/equality);
TGCT	cis	rs12497850	0.931	rs4974079	chr3:48906469	T/G	cg07636037	chr3:49044803	WDR6	0.94	10.39	0.68	1.46e-18	Parkinson's disease;
TGCT	cis	rs67478160	0.595	rs8022783	chr14:104245573	T/C	cg26031613	chr14:104095156	KLC1	-0.64	-6.62	-0.51	9.86e-10	Schizophrenia;
TGCT	trans	rs1814175	0.712	rs9665784	chr11:50030617	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.26	-0.55	3.77e-11	Height;
TGCT	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg21724239	chr8:58056113	NA	0.52	5.53	0.44	1.8e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg02018176	chr4:1364513	KIAA1530	0.27	4.51	0.38	1.49e-5	Longevity;
TGCT	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg07061783	chr6:25882402	NA	-0.45	-4.82	-0.4	4.15e-6	Blood metabolite levels;
TGCT	cis	rs9902453	0.791	rs9904051	chr17:28244122	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.92	9.1	0.63	1.88e-15	Coffee consumption (cups per day);
TGCT	cis	rs7937612	0.965	rs11217840	chr11:120238655	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.29	-4.61	-0.38	9.95e-6	Intraocular pressure;
TGCT	cis	rs6009824	1.000	rs6009823	chr22:50086334	C/T	cg27029450	chr22:50098074	NA	0.34	4.44	0.37	1.96e-5	Natriuretic peptide levels;
TGCT	cis	rs6570726	0.791	rs6570694	chr6:145911204	C/G	cg13319975	chr6:146136371	FBXO30	-0.52	-4.68	-0.39	7.45e-6	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs7618501	0.521	rs34654589	chr3:49911449	C/G	cg21659725	chr3:3221576	CRBN	0.69	7.72	0.57	3.29e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs1801251	1.000	rs6738386	chr2:233602028	T/C	cg08000102	chr2:233561755	GIGYF2	0.64	6.45	0.5	2.22e-9	Coronary artery disease;
TGCT	cis	rs55883249	1.000	rs75139639	chr2:9763905	A/T	cg23886495	chr2:9695866	ADAM17	0.74	4.44	0.37	1.99e-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs610932	0.517	rs652303	chr11:59970047	C/T	cg18570331	chr11:60101691	MS4A6E	0.51	4.69	0.39	7.12e-6	Alzheimer's disease;
TGCT	cis	rs748404	0.631	rs560191	chr15:43767774	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	4.77	0.39	5.05e-6	Lung cancer;
TGCT	cis	rs4319547	0.774	rs7954006	chr12:123131824	A/C	cg05707623	chr12:122985044	ZCCHC8	0.65	5.53	0.44	1.79e-7	Body mass index;
TGCT	cis	rs778371	1.000	rs11535	chr2:233743532	G/C	cg08000102	chr2:233561755	GIGYF2	-0.59	-6.56	-0.51	1.29e-9	Schizophrenia;
TGCT	cis	rs2050392	0.965	rs2265371	chr10:30690840	C/T	cg18806716	chr10:30721971	MAP3K8	-0.44	-5.17	-0.42	9.28e-7	Inflammatory bowel disease;
TGCT	cis	rs12497850	0.931	rs7636057	chr3:48992582	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.42	-5.41	-0.44	3.09e-7	Parkinson's disease;
TGCT	cis	rs79349575	0.783	rs28409394	chr17:46998118	T/C	cg07967210	chr17:47022446	SNF8	0.44	6.12	0.48	1.13e-8	Type 2 diabetes;
TGCT	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg08219700	chr8:58056026	NA	0.35	6.19	0.49	8.15e-9	Developmental language disorder (linguistic errors);
TGCT	cis	rs2380220	0.576	rs4498363	chr6:96042338	A/C	cg04719120	chr6:96025338	MANEA	0.74	5.55	0.45	1.67e-7	Behavioural disinhibition (generation interaction);
TGCT	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg00343986	chr7:65444356	GUSB	0.26	6.11	0.48	1.18e-8	Aortic root size;
TGCT	cis	rs79349575	0.783	rs12603969	chr17:47034419	A/G	cg07967210	chr17:47022446	SNF8	0.44	6.15	0.48	9.98e-9	Type 2 diabetes;
TGCT	cis	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg25427524	chr10:38739819	LOC399744	-0.4	-8.1	-0.59	4.35e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7681440	0.904	rs6816736	chr4:90765746	G/A	cg26578617	chr4:90757533	SNCA	-0.47	-4.87	-0.4	3.34e-6	Dementia with Lewy bodies;
TGCT	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg17971929	chr21:40555470	PSMG1	0.7	6.4	0.5	2.88e-9	Cognitive function;
TGCT	cis	rs12908161	1.000	rs34570071	chr15:85280212	T/A	cg17173187	chr15:85201210	NMB	0.59	6.57	0.51	1.22e-9	Schizophrenia;
TGCT	cis	rs4820539	1.000	rs885965	chr22:23461425	A/G	cg14186256	chr22:23484241	RTDR1	1.03	12.73	0.75	2.94e-24	Bone mineral density;
TGCT	cis	rs6500602	0.893	rs6500596	chr16:4470027	G/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	6.31	0.49	4.45e-9	Schizophrenia;
TGCT	cis	rs3751972	0.590	rs34256002	chr17:26272308	G/C	cg02948944	chr17:26242737	NA	-0.47	-5.45	-0.44	2.57e-7	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs7666738	0.791	rs1896155	chr4:99020948	C/A	cg05340658	chr4:99064831	C4orf37	0.48	5.43	0.44	2.92e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs67311347	0.866	rs1454491	chr3:40352647	C/G	cg13683864	chr3:40499215	RPL14	-0.9	-8.63	-0.61	2.55e-14	Renal cell carcinoma;
TGCT	cis	rs2486288	0.656	rs11632651	chr15:45550838	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.46	-5.59	-0.45	1.38e-7	Glomerular filtration rate;
TGCT	cis	rs7647973	0.626	rs1586827	chr3:49671224	T/C	cg03034192	chr3:50606346	HEMK1;C3orf18	0.36	4.75	0.39	5.61e-6	Menarche (age at onset);
TGCT	cis	rs17761864	1.000	rs17761864	chr17:2171637	G/T	cg02171503	chr17:1588363	PRPF8	-0.49	-4.77	-0.39	5.06e-6	Esophageal cancer (squamous cell);
TGCT	cis	rs2842992	0.789	rs7765490	chr6:160204326	C/T	cg11366901	chr6:160182831	ACAT2	1.03	7.06	0.54	1.02e-10	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs700590	0.723	rs700587	chr5:88110084	C/T	cg22951263	chr5:87985283	NA	0.56	5.4	0.44	3.24e-7	Educational attainment (years of education);
TGCT	cis	rs7611238	0.538	rs6794216	chr3:195100658	A/G	cg27323046	chr3:195102265	ACAP2	0.39	5.17	0.42	8.93e-7	Body mass index;
TGCT	cis	rs7246657	0.722	rs35863684	chr19:38109777	C/T	cg03611452	chr19:38183253	ZNF781	0.57	4.55	0.38	1.28e-5	Coronary artery calcification;
TGCT	trans	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg23505145	chr19:12996616	KLF1	0.79	8.3	0.6	1.47e-13	Prostate cancer (SNP x SNP interaction);
TGCT	trans	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg11887960	chr12:57824829	NA	1.17	9.7	0.66	6.57e-17	Lung disease severity in cystic fibrosis;
TGCT	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg11494091	chr17:61959527	GH2	0.42	7.16	0.54	6.15e-11	Height;
TGCT	cis	rs7226408	0.857	rs8084381	chr18:34597522	G/A	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs12681288	0.676	rs935820	chr8:1022168	A/G	cg04851639	chr8:1020857	NA	-0.35	-6.3	-0.49	4.66e-9	Schizophrenia;
TGCT	cis	rs2178146	0.535	rs7195744	chr16:86454376	C/G	cg11165158	chr16:86613094	FOXL1	0.36	4.71	0.39	6.57e-6	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Esophageal adenocarcinoma;
TGCT	cis	rs752010	0.714	rs2182606	chr1:42082375	T/C	cg06885757	chr1:42089581	HIVEP3	0.25	4.45	0.37	1.92e-5	Lupus nephritis in systemic lupus erythematosus;
TGCT	cis	rs1371867	0.846	rs2919469	chr8:101233896	C/T	cg06636551	chr8:101224915	SPAG1	-0.5	-7.05	-0.53	1.12e-10	Atrioventricular conduction;
TGCT	cis	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg07424592	chr7:64974309	NA	-1.27	-7.28	-0.55	3.29e-11	Diabetic kidney disease;
TGCT	cis	rs7246657	0.722	rs16958863	chr19:38124235	A/G	cg03611452	chr19:38183253	ZNF781	0.59	4.76	0.39	5.34e-6	Coronary artery calcification;
TGCT	cis	rs2456568	0.802	rs10831136	chr11:93636860	T/C	cg16099599	chr11:93583650	C11orf90	-0.4	-4.98	-0.41	2.04e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs6750047	0.628	rs2855655	chr2:38304488	T/C	cg07380506	chr2:38303506	CYP1B1	0.68	6.46	0.5	2.13e-9	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs2820315	0.928	rs2644111	chr1:201802052	G/A	cg12730843	chr1:201915899	LMOD1	-0.26	-4.72	-0.39	6.26e-6	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
TGCT	cis	rs12908161	1.000	rs12911736	chr15:85240008	A/G	cg11189052	chr15:85197271	WDR73	0.75	6.3	0.49	4.8e-9	Schizophrenia;
TGCT	cis	rs2629540	0.847	rs12247543	chr10:126419743	G/C	cg08799069	chr10:126477246	METTL10	0.29	4.45	0.37	1.9e-5	Cocaine dependence;
TGCT	cis	rs10927875	0.691	rs1048302	chr1:16340879	T/G	cg22431228	chr1:16359049	CLCNKA	-0.25	-4.77	-0.39	5.1e-6	Dilated cardiomyopathy;
TGCT	cis	rs12533831	0.642	rs891508	chr7:150877774	A/G	cg04712895	chr7:150801789	AGAP3	-0.2	-4.85	-0.4	3.66e-6	Childhood ear infection;
TGCT	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg11301795	chr4:187892539	NA	0.34	5.13	0.42	1.09e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7226408	0.842	rs62083203	chr18:34352507	T/G	cg06757138	chr18:34340585	FHOD3	0.3	5.26	0.43	6.01e-7	Obesity-related traits;
TGCT	cis	rs9303401	0.614	rs2240719	chr17:56582477	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.63	6.36	0.5	3.54e-9	Cognitive test performance;
TGCT	cis	rs4148883	0.629	rs10009145	chr4:100047929	G/A	cg12011299	chr4:100065546	ADH4	0.4	6.08	0.48	1.4e-8	Alcohol dependence;
TGCT	cis	rs7582180	0.739	rs4851292	chr2:100924761	A/G	cg08017756	chr2:100939284	LONRF2	-0.32	-5.31	-0.43	4.86e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs3020736	0.500	rs6002605	chr22:42494335	A/G	cg05082376	chr22:42548792	NA	0.23	5.43	0.44	2.83e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7312933	0.531	rs1796380	chr12:42791543	T/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.58	-5.7	-0.46	8.41e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs10751667	1.000	rs7927156	chr11:970607	A/G	cg06064525	chr11:970664	AP2A2	-0.32	-5.95	-0.47	2.54e-8	Alzheimer's disease (late onset);
TGCT	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg12564285	chr5:131593104	PDLIM4	0.4	4.78	0.39	4.79e-6	Acylcarnitine levels;
TGCT	cis	rs11122272	0.735	rs2808595	chr1:231526238	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-6.58	-0.51	1.2e-9	Hemoglobin concentration;
TGCT	cis	rs79349575	0.783	rs17708633	chr17:47011620	C/G	cg07967210	chr17:47022446	SNF8	0.44	6.13	0.48	1.1e-8	Type 2 diabetes;
TGCT	cis	rs2798269	0.604	rs7325693	chr13:22163211	G/C	cg18095732	chr13:22033692	ZDHHC20	-0.5	-4.46	-0.37	1.83e-5	PR segment;
TGCT	cis	rs6831352	0.959	rs6848050	chr4:100053733	T/C	cg12011299	chr4:100065546	ADH4	0.41	5.16	0.42	9.55e-7	Alcohol dependence;
TGCT	cis	rs9427116	0.702	rs9427109	chr1:154609009	A/G	cg17218026	chr1:154582156	ADAR	0.28	7.02	0.53	1.3e-10	Blood protein levels;
TGCT	cis	rs1018836	0.828	rs10086462	chr8:91558089	A/G	cg16814680	chr8:91681699	NA	-0.75	-7.83	-0.58	1.82e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs73198271	0.813	rs17697237	chr8:8615874	A/C	cg06671706	chr8:8559999	CLDN23	0.36	4.64	0.38	8.8e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs12497850	1.000	rs4858798	chr3:48727112	C/T	cg06212747	chr3:49208901	KLHDC8B	0.62	5.93	0.47	2.82e-8	Parkinson's disease;
TGCT	cis	rs76473307	1.000	rs75507818	chr20:57419334	C/A	cg06163629	chr20:57414884	GNASAS;GNAS	-0.64	-4.5	-0.37	1.54e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs6840360	0.516	rs6535794	chr4:152302783	G/T	cg17479576	chr4:152424074	FAM160A1	-0.55	-5.8	-0.46	5.23e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg04025307	chr7:1156635	C7orf50	0.23	5.33	0.43	4.46e-7	Longevity;Endometriosis;
TGCT	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.98	10.67	0.69	2.97e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs2295359	0.963	rs12030867	chr1:67627620	T/C	cg12940439	chr1:67600707	NA	0.53	5.59	0.45	1.36e-7	Psoriasis;
TGCT	cis	rs11190604	0.945	rs2495746	chr10:102328270	T/C	cg23241863	chr10:102295624	HIF1AN	0.67	5.1	0.42	1.23e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs10197940	0.510	rs7602715	chr2:152421937	A/G	cg06191203	chr2:152266755	RIF1	-0.64	-5.67	-0.45	9.57e-8	Lung cancer;
TGCT	cis	rs10858047	0.883	rs975446	chr1:115187361	C/A	cg12756093	chr1:115239321	AMPD1	-0.45	-4.73	-0.39	6.09e-6	Autism;
TGCT	cis	rs9560113	0.960	rs9560102	chr13:112173825	G/A	cg14154082	chr13:112174009	NA	0.34	4.67	0.39	7.79e-6	Menarche (age at onset);
TGCT	cis	rs3820068	0.705	rs2145396	chr1:15875184	A/G	cg05660106	chr1:15850417	CASP9	1.16	14.82	0.8	3.11e-29	Systolic blood pressure;
TGCT	cis	rs1878931	0.501	rs9635563	chr16:3416940	A/G	cg22508957	chr16:3507546	NAT15	-0.38	-4.98	-0.41	2.1e-6	Body mass index (adult);
TGCT	cis	rs35934224	0.783	rs6518585	chr22:19849501	C/T	cg11182965	chr22:19864308	TXNRD2	-0.34	-4.51	-0.38	1.48e-5	Glaucoma (primary open-angle);
TGCT	cis	rs651907	0.535	rs34648996	chr3:101511202	A/G	cg12386194	chr3:101231763	SENP7	0.48	4.81	0.4	4.36e-6	Colorectal cancer;
TGCT	trans	rs17685	0.625	rs1639630	chr7:75730499	T/C	cg19862616	chr7:65841803	NCRNA00174	0.51	8.3	0.6	1.51e-13	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg10802521	chr3:52805072	NEK4	-0.73	-8.91	-0.62	5.5e-15	Bipolar disorder;
TGCT	cis	rs1865760	0.568	rs2032450	chr6:25993114	C/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.72	6.94	0.53	1.97e-10	Height;
TGCT	cis	rs61612642	0.523	rs59004693	chr6:42157392	G/A	cg01092361	chr6:42185687	MRPS10	0.98	7.06	0.54	1.04e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
TGCT	cis	rs7507204	0.723	rs62125964	chr19:3414742	C/A	cg08380311	chr19:3435252	NFIC	0.98	8.25	0.6	2e-13	Height;
TGCT	cis	rs7085104	0.700	rs3740397	chr10:104592675	G/C	cg05855489	chr10:104503620	C10orf26	0.52	4.62	0.38	9.64e-6	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs9611519	0.780	rs2235850	chr22:41657626	C/T	cg06634786	chr22:41940651	POLR3H	-0.55	-4.98	-0.41	2.04e-6	Neuroticism;
TGCT	cis	rs9486719	1.000	rs10872018	chr6:97026429	G/A	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.0	-0.41	1.9e-6	Migraine;Coronary artery disease;
TGCT	cis	rs35883536	0.647	rs12043865	chr1:101042651	G/A	cg06223162	chr1:101003688	GPR88	-0.42	-7.93	-0.58	1.1e-12	Monocyte count;
TGCT	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg20007245	chr22:24372913	LOC391322	-0.51	-4.75	-0.39	5.53e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs10789491	0.953	rs11211337	chr1:47133811	T/C	cg15501359	chr1:47185051	KIAA0494	0.84	8.52	0.61	4.48e-14	Response to hepatitis C treatment;
TGCT	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg13397359	chr6:42928475	GNMT	0.74	6.83	0.52	3.33e-10	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs2982552	1.000	rs3020307	chr6:152067244	A/C	cg22157087	chr6:152012887	ESR1	0.19	4.65	0.39	8.44e-6	Bone properties (heel);
TGCT	cis	rs4072705	0.586	rs7855247	chr9:127246644	T/C	cg13476313	chr9:127244764	NR5A1	-0.3	-5.18	-0.42	8.73e-7	Menarche (age at onset);
TGCT	cis	rs7567389	0.504	rs13030463	chr2:128188871	G/A	cg09760422	chr2:128146352	NA	0.34	4.51	0.38	1.46e-5	Self-rated health;
TGCT	cis	rs17539620	0.624	rs111868524	chr6:154839960	G/C	cg20019720	chr6:154832845	CNKSR3	0.56	4.78	0.39	4.84e-6	Lipoprotein (a) levels;
TGCT	cis	rs9394841	0.646	rs9369313	chr6:41847065	C/T	cg08135965	chr6:41755394	TOMM6	0.54	4.87	0.4	3.36e-6	Mean corpuscular hemoglobin;Red cell distribution width;
TGCT	cis	rs1453308	1.000	rs1973040	chr2:237180199	A/G	cg19324714	chr2:237145437	ASB18	0.57	5.09	0.42	1.3e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg14784868	chr12:69753453	YEATS4	0.89	10.48	0.69	8.4e-19	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs2147959	0.882	rs4653551	chr1:228627913	A/G	cg22700015	chr1:228743131	NA	0.56	4.53	0.38	1.34e-5	Adult asthma;
TGCT	cis	rs801193	0.569	rs2659893	chr7:66199993	G/A	cg11764359	chr7:65958608	NA	0.54	4.79	0.4	4.68e-6	Aortic root size;
TGCT	cis	rs9325144	0.560	rs2013804	chr12:38631079	C/T	cg13010199	chr12:38710504	ALG10B	-0.51	-4.52	-0.38	1.45e-5	Morning vs. evening chronotype;
TGCT	cis	rs4689592	0.583	rs12501362	chr4:7083563	C/T	cg25660036	chr4:7070649	GRPEL1	0.51	4.67	0.39	7.66e-6	Monocyte percentage of white cells;
TGCT	cis	rs7726839	0.540	rs72703092	chr5:599269	G/A	cg09021430	chr5:549028	NA	-0.43	-5.77	-0.46	5.99e-8	Obesity-related traits;
TGCT	cis	rs8017423	1.000	rs8011810	chr14:90685669	A/G	cg04374321	chr14:90722782	PSMC1	0.77	7.94	0.58	1.06e-12	Mortality in heart failure;
TGCT	cis	rs17221829	0.702	rs72971023	chr11:89363934	A/G	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.65	-0.39	8.43e-6	Anxiety in major depressive disorder;
TGCT	cis	rs12477438	0.765	rs62156363	chr2:99693324	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-7.6	-0.56	6.47e-12	Chronic sinus infection;
TGCT	cis	rs6840360	1.000	rs4696109	chr4:152668785	A/C	cg22705602	chr4:152727874	NA	-0.24	-4.44	-0.37	1.98e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs801193	1.000	rs2055682	chr7:66260289	A/G	cg00343986	chr7:65444356	GUSB	0.21	4.58	0.38	1.11e-5	Aortic root size;
TGCT	cis	rs11148252	0.595	rs4885117	chr13:53153027	T/C	cg00495681	chr13:53174319	NA	0.64	6.42	0.5	2.68e-9	Lewy body disease;
TGCT	cis	rs6840360	1.000	rs6535809	chr4:152592933	A/G	cg17479576	chr4:152424074	FAM160A1	-0.5	-5.41	-0.44	3.18e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg21724239	chr8:58056113	NA	0.44	4.81	0.4	4.36e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs11741688	0.597	rs6880072	chr5:178334480	G/C	cg08270223	chr5:178322770	ZFP2	-0.37	-5.49	-0.44	2.14e-7	Sleep duration;
TGCT	trans	rs114540395	0.858	rs75820490	chr10:103253308	G/A	cg10198749	chr1:39920707	MACF1	0.55	7.12	0.54	7.73e-11	Schizophrenia;
TGCT	cis	rs6539288	0.500	rs11113116	chr12:107195929	C/A	cg15890332	chr12:107067104	RFX4	0.28	5.53	0.44	1.8e-7	Total body bone mineral density;
TGCT	cis	rs62244186	0.593	rs9814298	chr3:44871899	T/A	cg02073558	chr3:44770973	ZNF501	0.71	7.03	0.53	1.19e-10	Depressive symptoms;
TGCT	cis	rs7017914	0.934	rs35109143	chr8:71577900	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.53	-4.9	-0.4	2.87e-6	Bone mineral density;
TGCT	cis	rs6671200	1.000	rs34037437	chr1:95660921	C/G	cg26537280	chr1:95699037	RWDD3	0.68	5.49	0.44	2.15e-7	Stearic acid (18:0) levels;
TGCT	cis	rs2361718	0.500	rs4889970	chr17:78096086	C/T	cg22255288	chr17:78854418	RPTOR	0.26	4.56	0.38	1.2e-5	Yeast infection;
TGCT	cis	rs7772486	0.686	rs4896827	chr6:145953338	T/A	cg13319975	chr6:146136371	FBXO30	-0.52	-4.78	-0.39	4.81e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2153535	0.580	rs1335628	chr6:8491742	A/T	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg19318889	chr4:1322082	MAEA	0.27	6.66	0.51	8.13e-10	Longevity;
TGCT	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.12	15.17	0.81	4.81e-30	Height;
TGCT	cis	rs7677751	0.848	rs4635872	chr4:55099041	C/A	cg17187183	chr4:55093834	PDGFRA	0.55	7.06	0.54	1.05e-10	Corneal astigmatism;
TGCT	trans	rs1814175	0.754	rs28663627	chr11:50048829	C/T	cg03929089	chr4:120376271	NA	-0.72	-8.55	-0.61	3.8e-14	Height;
TGCT	cis	rs9914988	0.887	rs12947735	chr17:27156866	A/T	cg20469991	chr17:27169893	C17orf63	-0.74	-5.31	-0.43	4.83e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg24675658	chr1:53192096	ZYG11B	0.89	11.87	0.73	3.58e-22	Monocyte count;
TGCT	cis	rs7917772	0.636	rs4418737	chr10:104525123	A/G	cg05855489	chr10:104503620	C10orf26	0.67	5.32	0.43	4.77e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9976767	0.608	rs3746923	chr21:43826344	C/T	cg23042151	chr21:43824109	UBASH3A	-0.23	-5.14	-0.42	1.02e-6	Type 1 diabetes;
TGCT	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg20007245	chr22:24372913	LOC391322	-0.74	-7.45	-0.56	1.38e-11	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7666738	0.791	rs7665273	chr4:98997413	C/A	cg17366294	chr4:99064904	C4orf37	0.69	7.0	0.53	1.39e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7829975	0.606	rs10112585	chr8:8795030	A/T	cg06636001	chr8:8085503	FLJ10661	-0.73	-6.58	-0.51	1.21e-9	Mood instability;
TGCT	cis	rs13242816	0.881	rs12706091	chr7:116130783	G/C	cg02799643	chr7:116139180	CAV2	-0.46	-5.53	-0.44	1.78e-7	P wave duration;
TGCT	cis	rs2075371	0.965	rs2544216	chr7:133987902	G/A	cg11752832	chr7:134001865	SLC35B4	0.69	6.32	0.49	4.25e-9	Mean platelet volume;
TGCT	trans	rs8073060	0.586	rs4795086	chr17:34042190	G/A	cg19694781	chr19:47549865	TMEM160	0.6	13.37	0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs2637266	1.000	rs7392737	chr10:78366059	C/T	cg18941641	chr10:78392320	NA	0.4	4.73	0.39	6.03e-6	Pulmonary function;
TGCT	cis	rs79387448	0.683	rs7571985	chr2:103147561	G/A	cg09003973	chr2:102972529	NA	0.98	6.36	0.5	3.57e-9	Gut microbiota (bacterial taxa);
TGCT	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg03806693	chr22:41940476	POLR3H	1.16	13.41	0.77	7.02e-26	Vitiligo;
TGCT	cis	rs4478858	0.611	rs1007012	chr1:31710068	G/A	cg00250761	chr1:31883323	NA	-0.28	-4.95	-0.41	2.42e-6	Alcohol dependence;
TGCT	cis	rs1865760	0.663	rs9348704	chr6:26000393	A/C	cg17042849	chr6:26104293	HIST1H4C	-0.6	-5.38	-0.44	3.57e-7	Height;
TGCT	cis	rs17221829	0.836	rs3931233	chr11:89451588	G/A	cg02982614	chr11:89391479	FOLH1B	-0.29	-5.09	-0.42	1.3e-6	Anxiety in major depressive disorder;
TGCT	cis	rs9902453	0.834	rs9901694	chr17:28271645	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.9	8.55	0.61	3.78e-14	Coffee consumption (cups per day);
TGCT	cis	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg20637647	chr7:64974828	NA	0.94	5.17	0.42	9.06e-7	Diabetic kidney disease;
TGCT	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.18	0.42	8.74e-7	Menopause (age at onset);
TGCT	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg21226059	chr5:178986404	RUFY1	-0.61	-7.2	-0.54	5.01e-11	Lung cancer;
TGCT	cis	rs6545883	0.826	rs777591	chr2:61417617	A/G	cg15711740	chr2:61764176	XPO1	-0.52	-4.45	-0.37	1.92e-5	Tuberculosis;
TGCT	cis	rs10791097	0.694	rs3190331	chr11:130748131	C/T	cg05962950	chr11:130786565	SNX19	-0.89	-11.3	-0.71	8.81e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs6582630	0.519	rs11182457	chr12:38538331	G/A	cg26384229	chr12:38710491	ALG10B	0.89	8.13	0.59	3.76e-13	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs1887596	0.705	rs2454917	chr13:27227881	A/G	cg01312412	chr13:27282625	NA	0.28	4.86	0.4	3.41e-6	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs17270561	0.943	rs76703022	chr6:25703529	A/C	cg17042849	chr6:26104293	HIST1H4C	-0.69	-4.48	-0.37	1.64e-5	Iron status biomarkers;
TGCT	cis	rs2180341	1.000	rs6569486	chr6:127708424	A/C	cg27446573	chr6:127587934	RNF146	1.16	10.52	0.69	6.95e-19	Breast cancer;
TGCT	cis	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg18188782	chr20:61659543	NA	0.44	5.38	0.43	3.6e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7611238	0.583	rs4677826	chr3:195049539	C/A	cg27323046	chr3:195102265	ACAP2	0.36	4.9	0.4	2.94e-6	Body mass index;
TGCT	cis	rs9676308	0.677	rs77420930	chr19:57639222	C/G	cg25972591	chr19:58627987	ZSCAN18	-0.5	-4.47	-0.37	1.73e-5	Colorectal cancer;
TGCT	cis	rs35146811	0.771	rs1060544	chr7:99613476	C/T	cg13334819	chr7:99746414	C7orf59	-0.82	-7.38	-0.55	2.05e-11	Coronary artery disease;
TGCT	cis	rs933688	1.000	rs2052553	chr5:90729906	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	8.86	0.62	7.17e-15	Smoking behavior;
TGCT	cis	rs2404602	0.583	rs12592501	chr15:76554790	C/A	cg26408565	chr15:76604113	ETFA	-0.46	-6.46	-0.5	2.15e-9	Blood metabolite levels;
TGCT	cis	rs6918586	0.615	rs198824	chr6:26122783	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.7	-6.75	-0.52	4.96e-10	Schizophrenia;
TGCT	cis	rs12681288	0.862	rs2701898	chr8:1020812	C/T	cg04851639	chr8:1020857	NA	-0.39	-7.59	-0.56	6.79e-12	Schizophrenia;
TGCT	cis	rs10037670	0.557	rs2882673	chr5:153823066	G/C	cg21964928	chr5:153872958	NA	0.26	4.7	0.39	6.68e-6	Behavioural disinhibition (generation interaction);
TGCT	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg11890956	chr21:40555474	PSMG1	-0.78	-7.64	-0.57	5.14e-12	Cognitive function;
TGCT	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg14159672	chr1:205819179	PM20D1	0.6	7.44	0.56	1.45e-11	Menarche (age at onset);
TGCT	cis	rs7953249	0.514	rs1169312	chr12:121441461	G/T	cg02403541	chr12:121454288	C12orf43	0.66	6.26	0.49	5.61e-9	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs2439831	0.867	rs3213990	chr15:43670226	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	8.65	0.61	2.26e-14	Lung cancer in ever smokers;
TGCT	cis	rs11098499	0.954	rs2389803	chr4:120393511	A/G	cg09307838	chr4:120376055	NA	-0.75	-7.0	-0.53	1.44e-10	Corneal astigmatism;
TGCT	cis	rs9660992	0.573	rs1172158	chr1:205208948	G/A	cg00857998	chr1:205179979	DSTYK	0.51	4.68	0.39	7.34e-6	Mean corpuscular volume;Mean platelet volume;
TGCT	trans	rs7618501	0.633	rs2008877	chr3:50162291	T/G	cg21659725	chr3:3221576	CRBN	-0.7	-7.98	-0.58	8.19e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs9915657	0.687	rs2216169	chr17:70110419	G/A	cg06234051	chr17:70120541	SOX9	-0.24	-5.0	-0.41	1.87e-6	Thyroid hormone levels;
TGCT	cis	rs3947	0.789	rs9009	chr8:11702006	A/T	cg02840367	chr8:11660030	FDFT1	-1.03	-8.54	-0.61	3.97e-14	Blood protein levels;
TGCT	cis	rs10242455	0.571	rs41258334	chr7:99271808	T/C	cg25640893	chr7:99214727	ZNF498	0.96	4.44	0.37	2e-5	Blood metabolite levels;
TGCT	cis	rs6504663	0.558	rs2412325	chr17:48546232	G/C	cg03168497	chr17:48586147	MYCBPAP	0.43	4.64	0.38	8.75e-6	Visceral fat;
TGCT	cis	rs3771570	1.000	rs7557535	chr2:242206555	T/C	cg21155796	chr2:242212141	HDLBP	0.94	6.69	0.51	6.9e-10	Prostate cancer;
TGCT	cis	rs8031584	0.678	rs4779496	chr15:31151054	A/G	cg14829155	chr15:31115871	NA	-0.36	-4.72	-0.39	6.14e-6	Huntington's disease progression;
TGCT	cis	rs896854	0.608	rs7004862	chr8:95876963	T/G	cg23172400	chr8:95962367	TP53INP1	-0.29	-4.49	-0.37	1.61e-5	Type 2 diabetes;
TGCT	cis	rs36051895	0.623	rs10975023	chr9:5239549	A/G	cg02405213	chr9:5042618	JAK2	0.7	8.37	0.6	1e-13	Pediatric autoimmune diseases;
TGCT	cis	rs2204008	0.747	rs11514040	chr12:38201040	G/A	cg26384229	chr12:38710491	ALG10B	0.86	7.6	0.56	6.23e-12	Bladder cancer;
TGCT	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg23131131	chr22:24373011	LOC391322	0.57	4.54	0.38	1.3e-5	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs7568458	0.704	rs10176176	chr2:85762048	A/T	cg17127132	chr2:85788382	GGCX	0.67	6.49	0.5	1.86e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs6831352	0.918	rs7689753	chr4:100055575	A/G	cg12011299	chr4:100065546	ADH4	-0.4	-4.88	-0.4	3.26e-6	Alcohol dependence;
TGCT	cis	rs806215	1.000	rs712700	chr7:127250907	T/C	cg25922125	chr7:127225783	GCC1	0.59	5.98	0.47	2.21e-8	Type 2 diabetes;
TGCT	cis	rs7267979	1.000	rs4815412	chr20:25350325	A/G	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1008375	0.932	rs6814465	chr4:17659034	C/T	cg10189774	chr4:17578691	LAP3	0.55	4.83	0.4	3.89e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6570726	0.791	rs9403734	chr6:145931459	C/G	cg23711669	chr6:146136114	FBXO30	0.89	9.63	0.65	1.01e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3733585	0.699	rs4621431	chr4:9947590	C/T	cg00071950	chr4:10020882	SLC2A9	-0.58	-6.72	-0.52	5.83e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg22968622	chr17:43663579	NA	1.0	9.72	0.66	6.16e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7027203	0.688	rs4075733	chr9:96624645	C/T	cg14598338	chr9:96623480	NA	-0.63	-10.08	-0.67	8.11e-18	DNA methylation (variation);
TGCT	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.48	-0.37	1.66e-5	Bipolar disorder;
TGCT	cis	rs6570726	0.818	rs9399555	chr6:145877554	T/C	cg05347473	chr6:146136440	FBXO30	0.52	4.87	0.4	3.37e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs12681287	0.640	rs10086340	chr8:87446789	G/T	cg27223183	chr8:87520930	FAM82B	-0.86	-6.69	-0.51	6.88e-10	Caudate activity during reward;
TGCT	cis	rs6665290	0.904	rs3795449	chr1:227181838	T/G	cg10327440	chr1:227177885	CDC42BPA	-0.98	-19.72	-0.87	4.93e-40	Myeloid white cell count;
TGCT	cis	rs6674176	0.597	rs4660262	chr1:44382524	G/A	cg12908607	chr1:44402522	ARTN	-0.76	-9.58	-0.65	1.31e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg13902645	chr11:5959945	NA	-0.47	-5.74	-0.46	6.8e-8	DNA methylation (variation);
TGCT	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	16.05	0.82	4.59e-32	Prudent dietary pattern;
TGCT	cis	rs9611565	0.918	rs2281333	chr22:41749630	T/C	cg13695892	chr22:41940480	POLR3H	-0.85	-8.51	-0.61	4.83e-14	Vitiligo;
TGCT	cis	rs9914988	0.887	rs62066838	chr17:27184533	C/T	cg20469991	chr17:27169893	C17orf63	0.69	5.05	0.41	1.51e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs6665290	0.904	rs1343743	chr1:227183125	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.98	-19.78	-0.87	3.72e-40	Myeloid white cell count;
TGCT	cis	rs11718455	0.921	rs11130020	chr3:44009459	C/T	cg08738300	chr3:44038990	NA	0.77	5.69	0.46	8.61e-8	Coronary artery disease;
TGCT	cis	rs6840360	0.901	rs1946999	chr4:152455339	T/C	cg17479576	chr4:152424074	FAM160A1	-0.55	-6.17	-0.48	8.74e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg12419862	chr22:24373484	LOC391322	-0.81	-8.51	-0.61	4.7e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs10644111	1	rs10644111	chr7:91652178	A/AAAC	cg17063962	chr7:91808500	NA	0.91	9.97	0.67	1.53e-17	Breast cancer;
TGCT	cis	rs910187	0.605	rs3787235	chr20:45803522	C/T	cg27589058	chr20:45804311	EYA2	-0.38	-8.22	-0.59	2.25e-13	Migraine;
TGCT	cis	rs11098499	0.779	rs28495013	chr4:120375831	A/C	cg09307838	chr4:120376055	NA	0.68	6.53	0.51	1.54e-9	Corneal astigmatism;
TGCT	cis	rs2797160	0.935	rs1739372	chr6:126011325	G/A	cg05901451	chr6:126070800	HEY2	0.72	6.11	0.48	1.18e-8	Endometrial cancer;
TGCT	cis	rs56235845	0.694	rs11748912	chr5:176765395	G/A	cg16006841	chr5:176797999	RGS14	0.5	7.45	0.56	1.38e-11	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs3849570	0.696	rs13092157	chr3:81875332	T/A	cg07356753	chr3:81810745	GBE1	-0.65	-5.97	-0.47	2.36e-8	Waist circumference;Body mass index;
TGCT	cis	rs172166	0.694	rs203893	chr6:28062066	C/A	cg10876282	chr6:28092338	ZSCAN16	0.51	4.79	0.39	4.75e-6	Cardiac Troponin-T levels;
TGCT	cis	rs1757171	0.542	rs3818985	chr6:37484214	G/T	cg01843034	chr6:37503916	NA	-0.53	-7.06	-0.54	1.03e-10	Cognitive performance;
TGCT	cis	rs60154123	0.505	rs77990373	chr1:210041111	T/C	cg22029157	chr1:209979665	IRF6	0.79	5.78	0.46	5.6e-8	Coronary artery disease;
TGCT	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg19318889	chr4:1322082	MAEA	0.28	6.74	0.52	5.27e-10	Longevity;
TGCT	cis	rs12477438	0.520	rs2969379	chr2:99776686	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.15	18.32	0.85	4.52e-37	Chronic sinus infection;
TGCT	cis	rs7786808	0.741	rs4909222	chr7:158228095	C/T	cg01191920	chr7:158217561	PTPRN2	0.43	6.49	0.5	1.87e-9	Obesity-related traits;
TGCT	cis	rs73198271	0.628	rs11781258	chr8:8589758	A/G	ch.8.214553F	chr8:8189620	PRAGMIN	-0.32	-5.23	-0.42	7.04e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs7674212	0.507	rs223331	chr4:103793565	T/A	cg16532752	chr4:104119610	CENPE	-0.62	-5.59	-0.45	1.41e-7	Type 2 diabetes;
TGCT	cis	rs4285028	0.948	rs12630486	chr3:121685267	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.77	-6.5	-0.5	1.78e-9	Multiple sclerosis;
TGCT	cis	rs992157	0.764	rs4423579	chr2:219185033	G/T	cg00012203	chr2:219082015	ARPC2	0.7	6.58	0.51	1.16e-9	Colorectal cancer;
TGCT	cis	rs7394190	0.688	rs3812629	chr10:75407290	G/A	cg07699608	chr10:75541558	CHCHD1	0.62	4.63	0.38	9.08e-6	Incident atrial fibrillation;
TGCT	cis	rs7605378	1.000	rs796363	chr2:200693668	T/C	cg17644776	chr2:200775616	C2orf69	0.29	5.51	0.44	1.94e-7	Osteoporosis;
TGCT	cis	rs7091068	0.518	rs4144097	chr10:95432480	A/C	cg20715218	chr10:95462985	C10orf4	0.52	5.56	0.45	1.59e-7	Urinary tract infection frequency;
TGCT	cis	rs3813567	0.759	rs12148319	chr15:78956192	A/G	cg24631222	chr15:78858424	CHRNA5	0.69	4.79	0.4	4.66e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
TGCT	cis	rs4253772	0.550	rs9615347	chr22:46728153	A/G	cg24881330	chr22:46731750	TRMU	0.96	4.79	0.4	4.65e-6	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs11673344	0.503	rs703531	chr19:37500952	A/G	cg08039142	chr19:36980659	ZNF566	0.52	4.84	0.4	3.71e-6	Obesity-related traits;
TGCT	cis	rs763014	0.865	rs710924	chr16:633353	T/C	cg27436995	chr16:743998	FBXL16	-0.46	-4.95	-0.41	2.35e-6	Height;
TGCT	cis	rs5769707	0.777	rs8141219	chr22:50044546	A/G	cg05373962	chr22:49881684	NA	-0.33	-6.09	-0.48	1.3e-8	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs2880765	0.835	rs4514633	chr15:86041017	T/G	cg13263323	chr15:86062960	AKAP13	-0.22	-4.77	-0.39	5e-6	Coronary artery disease;
TGCT	cis	rs1670533	0.932	rs4690347	chr4:1057328	A/G	cg27284194	chr4:1044797	NA	0.67	5.79	0.46	5.37e-8	Recombination rate (females);
TGCT	cis	rs9926296	0.542	rs12599531	chr16:89909401	C/T	cg08627397	chr16:89984028	MC1R	0.34	5.15	0.42	1.01e-6	Vitiligo;
TGCT	cis	rs1371867	0.846	rs1660316	chr8:101333049	T/C	cg00191853	chr8:101177733	SPAG1	-0.22	-4.47	-0.37	1.75e-5	Atrioventricular conduction;
TGCT	cis	rs72781680	0.800	rs72780112	chr2:23991182	C/T	cg08917208	chr2:24149416	ATAD2B	0.83	5.24	0.43	6.62e-7	Lymphocyte counts;
TGCT	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg08736216	chr1:53307985	ZYG11A	-0.31	-6.14	-0.48	1.03e-8	Monocyte count;
TGCT	cis	rs2115630	1.000	rs11073730	chr15:85354596	C/T	cg12501888	chr15:85177176	SCAND2	-0.48	-4.49	-0.37	1.6e-5	P wave terminal force;
TGCT	cis	rs986417	0.901	rs6573314	chr14:60972045	C/T	cg27398547	chr14:60952738	C14orf39	1.41	9.11	0.63	1.75e-15	Gut microbiota (bacterial taxa);
TGCT	cis	rs8072100	0.967	rs4794058	chr17:45597098	C/T	cg08085267	chr17:45401833	C17orf57	0.44	4.89	0.4	3.12e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs7805747	1.000	rs10480300	chr7:151406005	C/T	cg17611936	chr7:151411526	PRKAG2	0.51	6.4	0.5	2.96e-9	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
TGCT	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg11494091	chr17:61959527	GH2	0.61	14.43	0.79	2.59e-28	Prudent dietary pattern;
TGCT	cis	rs9309473	0.514	rs62149630	chr2:73581755	C/G	cg07208825	chr2:73871855	ALMS1P	0.27	5.11	0.42	1.21e-6	Metabolite levels;
TGCT	cis	rs4566357	0.615	rs2894626	chr2:227916039	T/C	cg11843606	chr2:227700838	RHBDD1	-0.54	-5.24	-0.43	6.55e-7	Coronary artery disease;
TGCT	cis	rs78487399	0.731	rs13395302	chr2:43706350	C/G	cg03762820	chr2:43823654	THADA	-0.48	-4.45	-0.37	1.88e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs12477438	1.000	rs12477438	chr2:99841085	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.97	-8.87	-0.62	6.77e-15	Chronic sinus infection;
TGCT	trans	rs7698623	0.850	rs1982623	chr4:88790777	C/G	cg01186725	chr1:53905612	FLJ40434	-0.48	-6.63	-0.51	9.21e-10	Cardiovascular disease risk factors;
TGCT	cis	rs2204008	0.689	rs1581357	chr12:38391479	C/G	cg13010199	chr12:38710504	ALG10B	0.58	4.59	0.38	1.05e-5	Bladder cancer;
TGCT	cis	rs734999	0.870	rs2147905	chr1:2482921	C/T	cg18854424	chr1:2615690	NA	-0.45	-5.6	-0.45	1.31e-7	Ulcerative colitis;
TGCT	cis	rs6940638	0.531	rs12211984	chr6:26986054	G/C	cg26531700	chr6:26746687	NA	0.68	6.79	0.52	4.1e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs7428	0.527	rs1053560	chr2:85546192	C/T	cg24342717	chr2:85555507	TGOLN2	-0.49	-8.1	-0.59	4.49e-13	Ear protrusion;
TGCT	cis	rs4389656	0.857	rs274676	chr5:6754762	T/C	cg10857441	chr5:6722123	POLS	-0.21	-4.6	-0.38	1.03e-5	Coronary artery disease;
TGCT	cis	rs7809950	1.000	rs10234355	chr7:107086517	T/G	cg23024343	chr7:107201750	COG5	-0.35	-5.6	-0.45	1.34e-7	Coronary artery disease;
TGCT	cis	rs1865760	0.566	rs10807006	chr6:26048752	C/A	cg17042849	chr6:26104293	HIST1H4C	-0.62	-5.41	-0.44	3.18e-7	Height;
TGCT	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	16.04	0.82	4.85e-32	Prudent dietary pattern;
TGCT	cis	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg15556689	chr8:8085844	FLJ10661	-0.68	-6.32	-0.49	4.37e-9	Mood instability;
TGCT	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs4149178	1.000	rs4149178	chr6:43272188	A/G	cg12572677	chr6:43398225	ABCC10	0.31	4.8	0.4	4.47e-6	Urate levels;
TGCT	cis	rs1629083	0.967	rs1715450	chr11:118128445	C/G	cg16594165	chr11:118135105	MPZL2	0.33	4.62	0.38	9.32e-6	Lung cancer;
TGCT	cis	rs910316	1.000	rs4903289	chr14:75623988	C/T	cg08847533	chr14:75593920	NEK9	-0.98	-10.79	-0.7	1.55e-19	Height;
TGCT	cis	rs7659604	0.702	rs6815790	chr4:122695385	A/C	cg23574427	chr4:122746245	BBS7;CCNA2	-0.33	-5.26	-0.43	6.17e-7	Type 2 diabetes;
TGCT	cis	rs9486719	1.000	rs12208449	chr6:96903253	A/G	cg06623918	chr6:96969491	KIAA0776	0.87	7.38	0.55	1.96e-11	Migraine;Coronary artery disease;
TGCT	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg24399712	chr22:39784796	NA	1.06	13.4	0.77	7.31e-26	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs734999	0.545	rs10752748	chr1:2544640	G/A	cg18854424	chr1:2615690	NA	0.44	5.15	0.42	1.01e-6	Ulcerative colitis;
TGCT	cis	rs7914558	0.966	rs10748836	chr10:104693917	G/A	cg15744005	chr10:104629667	AS3MT	-0.41	-5.11	-0.42	1.16e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs7666738	0.830	rs6833312	chr4:98951356	A/T	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11190604	1.000	rs10883497	chr10:102228519	A/G	cg16342193	chr10:102329863	NA	-0.39	-5.26	-0.43	6.21e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs854765	0.547	rs2955359	chr17:17946730	T/C	cg09796270	chr17:17721594	SREBF1	-0.24	-4.7	-0.39	6.8e-6	Total body bone mineral density;
TGCT	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg21226059	chr5:178986404	RUFY1	0.46	5.02	0.41	1.75e-6	Lung cancer;
TGCT	cis	rs35000415	0.683	rs71581969	chr7:128722237	C/A	cg06242719	chr7:129414860	MIR183;MIR96	-0.3	-4.58	-0.38	1.1e-5	Systemic lupus erythematosus;
TGCT	cis	rs4285028	0.948	rs1920291	chr3:121672440	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.77	-6.55	-0.51	1.35e-9	Multiple sclerosis;
TGCT	cis	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg22121687	chr7:65037720	NA	-0.78	-4.7	-0.39	6.74e-6	Diabetic kidney disease;
TGCT	cis	rs68170813	0.599	rs77878465	chr7:106890996	G/A	cg02696742	chr7:106810147	HBP1	-0.66	-5.51	-0.44	1.94e-7	Coronary artery disease;
TGCT	cis	rs11640734	0.609	rs11647746	chr16:89806343	C/A	cg27121462	chr16:89883253	FANCA	0.78	4.65	0.39	8.51e-6	Interleukin-17 levels;
TGCT	cis	rs3096299	0.503	rs4785677	chr16:89555101	A/G	cg08392591	chr16:89556376	ANKRD11	0.56	5.24	0.43	6.83e-7	Multiple myeloma (IgH translocation);
TGCT	cis	rs208520	0.690	rs10455595	chr6:66738034	T/C	cg07460842	chr6:66804631	NA	0.94	9.91	0.66	2.15e-17	Exhaled nitric oxide output;
TGCT	cis	rs12477438	0.520	rs34252185	chr2:99737646	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.89	9.0	0.63	3.26e-15	Chronic sinus infection;
TGCT	cis	rs9291683	0.546	rs6820188	chr4:10051655	C/T	cg11266682	chr4:10021025	SLC2A9	0.6	7.56	0.56	7.72e-12	Bone mineral density;
TGCT	cis	rs2299587	0.554	rs2073565	chr8:17743649	T/C	cg04898035	chr8:17640624	MTUS1	-0.2	-4.67	-0.39	7.77e-6	Economic and political preferences;
TGCT	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.71	5.14	0.42	1.02e-6	Platelet count;
TGCT	cis	rs34891900	0.507	rs738133	chr22:18205557	C/T	cg19898043	chr22:18121309	BCL2L13	0.55	4.74	0.39	5.77e-6	Sum neutrophil eosinophil counts;
TGCT	cis	rs4478858	0.735	rs10914361	chr1:31817542	T/G	cg00250761	chr1:31883323	NA	-0.28	-4.96	-0.41	2.32e-6	Alcohol dependence;
TGCT	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9788682	0.947	rs7169584	chr15:78822660	A/T	cg24631222	chr15:78858424	CHRNA5	0.93	7.96	0.58	9.55e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs7959452	0.590	rs11177628	chr12:69765421	G/A	cg20891283	chr12:69753455	YEATS4	0.83	8.61	0.61	2.8e-14	Blood protein levels;
TGCT	cis	rs2019216	0.500	rs1356483	chr17:21934029	A/C	cg22648282	chr17:21454238	C17orf51	-0.6	-5.51	-0.44	1.98e-7	Pelvic organ prolapse;
TGCT	cis	rs7208859	0.673	rs73263981	chr17:28920502	A/G	cg14008862	chr17:28927542	LRRC37B2	0.72	4.59	0.38	1.08e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs941408	0.964	rs1736194	chr19:2786397	C/G	cg06609049	chr19:2785107	THOP1	0.85	7.87	0.58	1.47e-12	Total cholesterol levels;
TGCT	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.0	7.42	0.55	1.64e-11	Gut microbiome composition (summer);
TGCT	cis	rs10782582	0.593	rs12142247	chr1:76235746	C/T	cg10523679	chr1:76189770	ACADM	-0.61	-6.13	-0.48	1.09e-8	Daytime sleep phenotypes;
TGCT	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg27121462	chr16:89883253	FANCA	-0.81	-8.83	-0.62	8.24e-15	Vitiligo;
TGCT	cis	rs6570726	0.846	rs7762536	chr6:145923145	T/C	cg13319975	chr6:146136371	FBXO30	-0.53	-4.79	-0.4	4.6e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1692580	0.840	rs262679	chr1:2169792	C/T	cg24578937	chr1:2090814	PRKCZ	0.24	5.35	0.43	4.12e-7	Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs6811940	chr4:98777898	G/A	cg05340658	chr4:99064831	C4orf37	0.49	5.75	0.46	6.46e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg05368731	chr17:41323189	NBR1	1.03	11.58	0.72	1.83e-21	Menopause (age at onset);
TGCT	cis	rs2153535	0.580	rs718503	chr6:8527463	A/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.49e-8	Motion sickness;
TGCT	cis	rs7507204	0.723	rs12982194	chr19:3411947	G/A	cg08380311	chr19:3435252	NFIC	0.97	8.2	0.59	2.59e-13	Height;
TGCT	cis	rs7843479	1.000	rs7821592	chr8:21811530	C/G	cg17168535	chr8:21777572	XPO7	0.63	5.75	0.46	6.56e-8	Mean corpuscular volume;
TGCT	cis	rs7809950	0.911	rs1015411	chr7:107135612	C/T	cg23024343	chr7:107201750	COG5	-0.35	-5.5	-0.44	2.05e-7	Coronary artery disease;
TGCT	cis	rs10779751	1.000	rs7526649	chr1:11278163	C/T	cg08854313	chr1:11322531	MTOR	0.95	8.99	0.63	3.52e-15	Body mass index;
TGCT	cis	rs1797081	1.000	rs2603807	chr10:16872797	A/G	cg23933602	chr10:16859644	RSU1	1.07	13.21	0.76	2.04e-25	Platelet distribution width;
TGCT	cis	rs72781680	1.000	rs115861480	chr2:24129464	T/A	cg08917208	chr2:24149416	ATAD2B	0.85	5.28	0.43	5.53e-7	Lymphocyte counts;
TGCT	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg01416388	chr22:39784598	NA	-0.72	-7.04	-0.53	1.18e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs7191439	0.626	rs8059794	chr16:88787388	C/T	cg27087555	chr16:88793112	FAM38A	-0.46	-5.5	-0.44	2.11e-7	Plateletcrit;
TGCT	trans	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg21659725	chr3:3221576	CRBN	0.75	8.79	0.62	1.06e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs875971	0.825	rs59466412	chr7:65565358	A/G	cg11764359	chr7:65958608	NA	-0.55	-4.7	-0.39	6.77e-6	Aortic root size;
TGCT	cis	rs60843830	1.000	rs62114544	chr2:269679	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.73	7.41	0.55	1.74e-11	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs617219	0.710	rs2255913	chr5:78562399	G/C	cg23514016	chr5:78407564	BHMT	0.32	4.87	0.4	3.38e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs896854	0.517	rs9643353	chr8:95957063	A/G	cg16049864	chr8:95962084	TP53INP1	0.54	6.01	0.48	1.9e-8	Type 2 diabetes;
TGCT	cis	rs2288278	0.601	rs60859312	chr17:46599035	C/T	cg25032089	chr17:46643351	HOXB3	-0.42	-5.01	-0.41	1.86e-6	Hand grip strength;
TGCT	cis	rs858239	0.600	rs6461691	chr7:23139345	G/A	cg05602783	chr7:23145260	KLHL7	-0.73	-6.3	-0.49	4.74e-9	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg22535103	chr8:58192502	C8orf71	-0.4	-5.06	-0.41	1.44e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.62	-8.8	-0.62	9.71e-15	Longevity;Endometriosis;
TGCT	cis	rs4653767	0.573	rs708772	chr1:226912891	A/G	cg26513734	chr1:225996982	EPHX1	0.16	4.52	0.38	1.4e-5	Parkinson's disease;
TGCT	cis	rs7647973	1.000	rs62261249	chr3:49594060	T/C	cg07636037	chr3:49044803	WDR6	-0.68	-5.5	-0.44	2.09e-7	Menarche (age at onset);
TGCT	cis	rs9902453	0.845	rs2321331	chr17:28025528	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	7.27	0.55	3.55e-11	Coffee consumption (cups per day);
TGCT	cis	rs651907	0.557	rs3094297	chr3:101399260	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.6	6.1	0.48	1.27e-8	Colorectal cancer;
TGCT	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg05368731	chr17:41323189	NBR1	1.17	13.8	0.78	7.84e-27	Menopause (age at onset);
TGCT	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.55	-5.25	-0.43	6.31e-7	Menarche (age at onset);
TGCT	cis	rs4499344	0.657	rs2868146	chr19:33050047	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.73	-6.21	-0.49	7.33e-9	Mean platelet volume;
TGCT	cis	rs7666738	0.544	rs35160902	chr4:98974690	A/T	cg17366294	chr4:99064904	C4orf37	0.69	6.93	0.53	2.03e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3087591	0.960	rs12939815	chr17:29430916	G/C	cg24425628	chr17:29625626	OMG;NF1	0.47	7.16	0.54	6.19e-11	Hip circumference;
TGCT	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg03609598	chr5:56110824	MAP3K1	-0.59	-4.78	-0.39	4.81e-6	Initial pursuit acceleration;
TGCT	cis	rs6558530	0.730	rs4875958	chr8:1721090	A/G	cg09410841	chr8:1729607	CLN8	-0.78	-8.76	-0.62	1.22e-14	Systolic blood pressure;
TGCT	cis	rs11874712	1.000	rs28699609	chr18:43674879	A/T	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	5.23	0.42	7.11e-7	Migraine - clinic-based;
TGCT	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg06634786	chr22:41940651	POLR3H	0.87	8.49	0.61	5.3e-14	Vitiligo;
TGCT	cis	rs858239	0.539	rs6965833	chr7:23192366	T/C	cg05602783	chr7:23145260	KLHL7	-0.63	-5.03	-0.41	1.67e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg22920501	chr2:26401640	FAM59B	-0.72	-6.38	-0.5	3.19e-9	Gut microbiome composition (summer);
TGCT	cis	rs651907	0.557	rs2288272	chr3:101378476	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.91	10.79	0.7	1.52e-19	Colorectal cancer;
TGCT	cis	rs7647973	1.000	rs9842132	chr3:49427933	G/A	cg07636037	chr3:49044803	WDR6	-0.72	-5.79	-0.46	5.35e-8	Menarche (age at onset);
TGCT	cis	rs12477438	0.700	rs10190421	chr2:99670711	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-8.52	-0.61	4.5e-14	Chronic sinus infection;
TGCT	cis	rs4746818	0.901	rs10740317	chr10:70937566	G/A	cg11621586	chr10:70884670	VPS26A	1.1	7.75	0.57	2.8e-12	Left atrial antero-posterior diameter;
TGCT	cis	rs4253772	0.678	rs1053332	chr22:46640179	A/G	cg09491104	chr22:46646882	C22orf40	-0.48	-4.9	-0.4	2.9e-6	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs2439831	0.850	rs68079546	chr15:44136957	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	6.2	0.49	7.73e-9	Lung cancer in ever smokers;
TGCT	cis	rs7296418	0.922	rs1727293	chr12:123648032	C/T	cg05973401	chr12:123451056	ABCB9	0.55	4.53	0.38	1.39e-5	Platelet count;
TGCT	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg04944784	chr2:26401820	FAM59B	0.63	5.85	0.46	4.13e-8	Gut microbiome composition (summer);
TGCT	cis	rs9393692	0.905	rs9393693	chr6:26277408	C/A	cg00631329	chr6:26305371	NA	-0.41	-6.09	-0.48	1.34e-8	Educational attainment;
TGCT	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg06108461	chr20:60628389	TAF4	-0.74	-10.73	-0.69	2.07e-19	Body mass index;
TGCT	cis	rs7027203	0.595	rs4308796	chr9:96570165	G/A	cg13679303	chr9:96623674	NA	0.55	7.77	0.57	2.54e-12	DNA methylation (variation);
TGCT	cis	rs9814567	1.000	rs1534025	chr3:134313304	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.95	8.76	0.62	1.21e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs7267979	0.844	rs4423675	chr20:25402778	A/G	cg16686733	chr20:25566563	NINL	-0.52	-4.93	-0.4	2.61e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6901004	0.803	rs402014	chr6:111527696	C/T	cg15721981	chr6:111408429	SLC16A10	-0.51	-4.5	-0.37	1.56e-5	Blood metabolite levels;
TGCT	cis	rs910316	1.000	rs4903284	chr14:75592483	G/C	cg23033748	chr14:75592666	NEK9	0.29	4.9	0.4	2.95e-6	Height;
TGCT	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg03517284	chr6:25882590	NA	0.68	6.25	0.49	6.06e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs78487399	0.710	rs79625619	chr2:43594483	A/T	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.73	4.48	0.37	1.65e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs7945705	0.902	rs10743095	chr11:8936984	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.47	5.29	0.43	5.36e-7	Hemoglobin concentration;
TGCT	cis	rs9372498	0.536	rs72969531	chr6:118729974	C/A	cg07617317	chr6:118971624	C6orf204	0.5	5.39	0.44	3.37e-7	Diastolic blood pressure;
TGCT	cis	rs1865760	0.827	rs9295680	chr6:25944103	T/C	cg17042849	chr6:26104293	HIST1H4C	-0.5	-4.55	-0.38	1.27e-5	Height;
TGCT	cis	rs763121	0.853	rs9610993	chr22:39042818	C/A	cg06022373	chr22:39101656	GTPBP1	0.74	7.14	0.54	7.09e-11	Menopause (age at onset);
TGCT	cis	rs9894429	1.000	rs35435780	chr17:79579602	G/T	cg18240062	chr17:79603768	NPLOC4	0.67	6.84	0.52	3.23e-10	Eye color traits;
TGCT	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.64	0.51	8.85e-10	Electroencephalogram traits;
TGCT	trans	rs11764590	0.715	rs9969125	chr7:2088460	C/T	cg25206134	chr2:45395956	NA	0.97	6.72	0.52	5.86e-10	Neuroticism;
TGCT	cis	rs611744	0.647	rs12675265	chr8:109268805	C/T	cg21045802	chr8:109455806	TTC35	0.71	7.25	0.55	4.03e-11	Dupuytren's disease;
TGCT	cis	rs6752107	1.000	rs34123137	chr2:234167881	T/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.2	4.88	0.4	3.17e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs7394190	0.748	rs11000772	chr10:75533988	T/G	cg07699608	chr10:75541558	CHCHD1	0.79	5.44	0.44	2.72e-7	Incident atrial fibrillation;
TGCT	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg12310025	chr6:25882481	NA	-0.66	-6.0	-0.47	2.02e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7582180	0.700	rs11685293	chr2:100976502	A/C	cg08017756	chr2:100939284	LONRF2	-0.3	-4.98	-0.41	2.1e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.6	-6.02	-0.48	1.84e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg22857025	chr5:266934	NA	-0.31	-6.32	-0.49	4.33e-9	Breast cancer;
TGCT	cis	rs1042445	1.000	rs1042445	chr3:186395436	C/T	cg13908232	chr3:186371902	NA	0.46	5.23	0.43	6.94e-7	Blood protein levels;
TGCT	cis	rs4319547	0.614	rs10846764	chr12:122874297	T/C	cg05707623	chr12:122985044	ZCCHC8	0.62	4.87	0.4	3.32e-6	Body mass index;
TGCT	cis	rs686320	1.000	rs72643572	chr11:65250967	A/G	cg21890820	chr11:65308645	LTBP3	0.8	5.05	0.41	1.51e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs986417	0.901	rs2351171	chr14:61000322	T/C	cg27398547	chr14:60952738	C14orf39	1.42	8.85	0.62	7.44e-15	Gut microbiota (bacterial taxa);
TGCT	cis	rs28374715	0.662	rs10851403	chr15:41466087	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.81	-11.41	-0.72	4.6e-21	Ulcerative colitis;
TGCT	cis	rs12478296	0.786	rs55876934	chr2:243033816	C/T	cg06360820	chr2:242988706	NA	-0.58	-4.47	-0.37	1.76e-5	Obesity-related traits;
TGCT	cis	rs1048238	0.506	rs56352596	chr1:16297592	G/A	cg22431228	chr1:16359049	CLCNKA	-0.23	-4.57	-0.38	1.18e-5	Systolic blood pressure;
TGCT	cis	rs11122272	0.705	rs2486731	chr1:231532511	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.67	6.5	0.5	1.74e-9	Hemoglobin concentration;
TGCT	cis	rs12368653	0.607	rs7966795	chr12:58031413	C/A	cg12615879	chr12:58013172	SLC26A10	0.59	7.2	0.54	5.18e-11	Multiple sclerosis;
TGCT	trans	rs9929218	0.551	rs3785135	chr16:68728976	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.58	-7.69	-0.57	4.02e-12	Colorectal cancer;
TGCT	cis	rs2742417	0.967	rs2742439	chr3:45744248	G/A	cg04837898	chr3:45731254	SACM1L	-0.55	-5.68	-0.45	9.22e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs7666738	0.753	rs1527520	chr4:98929164	A/G	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6138458	0.828	rs6138466	chr20:24997137	A/G	cg26195577	chr20:24973756	C20orf3	1.04	9.62	0.65	1.04e-16	Blood protein levels;
TGCT	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	7.12	0.54	7.55e-11	Platelet count;
TGCT	cis	rs9372498	0.536	rs77435770	chr6:118819467	G/A	cg07617317	chr6:118971624	C6orf204	0.46	5.08	0.41	1.36e-6	Diastolic blood pressure;
TGCT	cis	rs13256369	0.802	rs1060107	chr8:8561399	G/T	cg17143192	chr8:8559678	CLDN23	0.55	5.13	0.42	1.1e-6	Obesity-related traits;
TGCT	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.42	-4.47	-0.37	1.72e-5	Alzheimer's disease;
TGCT	cis	rs1570884	0.516	rs9526580	chr13:50164023	C/G	cg08779649	chr13:50194554	NA	-0.4	-6.38	-0.5	3.12e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
TGCT	cis	rs7044106	0.708	rs10760113	chr9:123474050	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.61	6.35	0.5	3.69e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs2948294	0.588	rs7011221	chr8:8114246	C/T	cg06636001	chr8:8085503	FLJ10661	0.82	7.11	0.54	7.94e-11	Red cell distribution width;
TGCT	cis	rs2982552	0.773	rs11155809	chr6:152056058	A/G	cg22157087	chr6:152012887	ESR1	0.21	5.17	0.42	8.93e-7	Bone properties (heel);
TGCT	trans	rs797680	0.856	rs531358	chr1:93676011	C/T	cg27528825	chr2:159282178	CCDC148	-0.35	-6.88	-0.53	2.65e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs1524927	1.000	rs12704872	chr7:96334616	T/C	cg03808172	chr7:96339361	SHFM1	0.49	5.06	0.41	1.45e-6	Total body bone mineral density;
TGCT	cis	rs922182	0.557	rs2004231	chr15:64195769	C/T	cg02919090	chr15:64263738	DAPK2	0.37	7.05	0.53	1.09e-10	Blood protein levels;
TGCT	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg15242686	chr22:24348715	GSTTP1	0.44	5.98	0.47	2.23e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9443645	0.810	rs9361482	chr6:79750385	T/C	cg09184832	chr6:79620586	NA	-0.45	-4.88	-0.4	3.19e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs56091001	0.528	rs9616387	chr22:50313219	G/A	cg02269571	chr22:50332266	NA	-0.35	-4.44	-0.37	1.97e-5	Acne (severe);
TGCT	cis	rs1865760	0.865	rs9467647	chr6:25957642	A/G	cg16482183	chr6:26056742	HIST1H1C	0.52	4.84	0.4	3.78e-6	Height;
TGCT	cis	rs2282802	0.758	rs739954	chr5:139701920	C/T	cg01081189	chr5:139537190	NA	0.25	4.53	0.38	1.37e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs17376456	0.569	rs1026279	chr5:93209581	C/A	cg21475434	chr5:93447410	FAM172A	-0.68	-5.22	-0.42	7.16e-7	Diabetic retinopathy;
TGCT	cis	rs137699	0.604	rs137702	chr22:39750158	T/C	cg05872129	chr22:39784769	NA	-0.73	-5.64	-0.45	1.1e-7	IgG glycosylation;
TGCT	cis	rs17665859	0.925	rs35475931	chr8:481500	C/G	cg17960703	chr8:356704	FBXO25	1.2	4.7	0.39	6.74e-6	Bilirubin levels;
TGCT	cis	rs2486012	0.649	rs9726489	chr1:44267668	G/C	cg12908607	chr1:44402522	ARTN	-0.71	-5.54	-0.45	1.75e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs10823500	0.604	rs10762345	chr10:71939374	A/G	cg04118878	chr10:71993077	PPA1	0.48	4.86	0.4	3.51e-6	Blood protein levels;
TGCT	cis	rs6586111	0.904	rs6586105	chr10:82372248	A/G	cg03086067	chr10:82368399	SH2D4B	-0.24	-4.7	-0.39	6.84e-6	Capecitabine sensitivity;
TGCT	cis	rs2204008	0.837	rs11611861	chr12:38357459	A/G	cg13010199	chr12:38710504	ALG10B	0.58	4.55	0.38	1.26e-5	Bladder cancer;
TGCT	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg22105103	chr4:187893119	NA	0.31	4.44	0.37	1.98e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs8072100	0.817	rs6505049	chr17:45675781	G/A	cg08085267	chr17:45401833	C17orf57	0.47	4.99	0.41	1.96e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs9611565	0.506	rs1984839	chr22:41685937	G/C	cg03806693	chr22:41940476	POLR3H	-0.81	-7.72	-0.57	3.26e-12	Vitiligo;
TGCT	cis	rs3820928	0.874	rs4675138	chr2:227884118	G/A	cg11843606	chr2:227700838	RHBDD1	-0.58	-5.35	-0.43	4e-7	Pulmonary function;
TGCT	cis	rs3749237	0.615	rs55957735	chr3:49438158	G/A	cg07636037	chr3:49044803	WDR6	0.64	6.04	0.48	1.63e-8	Resting heart rate;
TGCT	cis	rs8072100	0.869	rs4439799	chr17:45781599	C/T	cg08085267	chr17:45401833	C17orf57	-0.47	-5.51	-0.44	1.98e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg24829409	chr8:58192753	C8orf71	-0.52	-5.02	-0.41	1.73e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7312933	0.701	rs10880260	chr12:42561398	A/G	cg19980929	chr12:42632907	YAF2	0.46	6.3	0.49	4.75e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs4746818	1.000	rs7476357	chr10:70935660	G/A	cg11621586	chr10:70884670	VPS26A	1.21	10.5	0.69	7.7e-19	Left atrial antero-posterior diameter;
TGCT	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg12310025	chr6:25882481	NA	-0.55	-5.59	-0.45	1.4e-7	Blood metabolite levels;
TGCT	trans	rs1814175	0.817	rs1988416	chr11:49932324	G/A	cg15704280	chr7:45808275	SEPT13	-0.71	-8.0	-0.58	7.45e-13	Height;
TGCT	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg13695892	chr22:41940480	POLR3H	0.93	9.1	0.63	1.91e-15	Vitiligo;
TGCT	cis	rs1215050	0.740	rs10025482	chr4:99053277	T/C	cg17366294	chr4:99064904	C4orf37	0.59	6.26	0.49	5.68e-9	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs737008	1.000	rs737008	chr16:11374866	G/T	cg00044050	chr16:11439710	C16orf75	-0.7	-6.92	-0.53	2.13e-10	Obesity-related traits;
TGCT	cis	rs1395	0.922	rs4665376	chr2:27509032	T/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.47	6.18	0.49	8.53e-9	Blood metabolite levels;
TGCT	cis	rs4253772	0.591	rs73886791	chr22:46687212	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.7	5.27	0.43	5.83e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs9733	0.519	rs2184833	chr1:150675483	C/T	cg04414720	chr1:150670196	GOLPH3L	0.37	4.81	0.4	4.38e-6	Tonsillectomy;
TGCT	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	6.13	0.48	1.06e-8	Bipolar disorder;
TGCT	cis	rs6964587	0.626	rs34404183	chr7:91551249	T/C	cg17063962	chr7:91808500	NA	-0.76	-7.25	-0.55	3.94e-11	Breast cancer;
TGCT	cis	rs765787	0.530	rs11070444	chr15:45513121	T/C	cg24006582	chr15:45444508	DUOX1	0.25	5.35	0.43	4.11e-7	Uric acid levels;
TGCT	trans	rs2727020	0.729	rs10839283	chr11:49490943	T/C	cg15704280	chr7:45808275	SEPT13	0.71	7.95	0.58	9.76e-13	Coronary artery disease;
TGCT	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg13902645	chr11:5959945	NA	0.58	6.69	0.51	6.89e-10	DNA methylation (variation);
TGCT	cis	rs425277	0.606	rs3128339	chr1:2046938	G/T	cg03732007	chr1:2071316	PRKCZ	-0.28	-6.03	-0.48	1.78e-8	Height;
TGCT	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg06238570	chr21:40685208	BRWD1	-0.83	-8.85	-0.62	7.32e-15	Cognitive function;
TGCT	cis	rs6543140	0.964	rs10200081	chr2:103091556	T/C	cg09003973	chr2:102972529	NA	0.54	4.46	0.37	1.83e-5	Blood protein levels;
TGCT	cis	rs9640161	0.750	rs59211922	chr7:150023790	T/G	cg17279839	chr7:150038598	RARRES2	0.43	4.6	0.38	1.02e-5	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs9467773	0.523	rs2498399	chr6:26706544	T/C	cg15659132	chr6:26577336	NA	0.86	9.64	0.65	9.36e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs10789491	1.000	rs1545206	chr1:47185082	C/G	cg15501359	chr1:47185051	KIAA0494	0.82	8.36	0.6	1.08e-13	Response to hepatitis C treatment;
TGCT	cis	rs12134245	0.776	rs13447464	chr1:91968278	G/A	cg25838465	chr1:92012736	NA	-0.44	-7.01	-0.53	1.37e-10	Breast cancer;
TGCT	cis	rs6089584	0.606	rs2144674	chr20:60576579	G/A	cg13770153	chr20:60521292	NA	-0.41	-4.95	-0.41	2.38e-6	Body mass index;
TGCT	cis	rs9372253	1.000	rs9386894	chr6:110718853	A/G	cg19196401	chr6:110721138	DDO	-0.52	-7.57	-0.56	7.36e-12	Platelet distribution width;
TGCT	cis	rs7246657	0.722	rs1564208	chr19:38041221	A/G	cg03611452	chr19:38183253	ZNF781	0.58	4.64	0.38	8.62e-6	Coronary artery calcification;
TGCT	cis	rs8014204	0.816	rs10144023	chr14:75291531	T/C	cg06637938	chr14:75390232	RPS6KL1	0.57	5.07	0.41	1.4e-6	Caffeine consumption;
TGCT	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.36	-4.45	-0.37	1.9e-5	Total body bone mineral density;
TGCT	cis	rs8103278	1.000	rs9676288	chr19:46292060	G/T	cg14061069	chr19:46274453	DMPK	-0.43	-6.19	-0.49	8.07e-9	Coronary artery disease;
TGCT	cis	rs4891159	0.757	rs11665018	chr18:74123589	C/T	cg24786174	chr18:74118243	ZNF516	-0.61	-9.12	-0.63	1.68e-15	Longevity;
TGCT	cis	rs1426153	0.548	rs12800009	chr11:125159375	A/T	cg08311403	chr11:124735215	ROBO3	0.76	4.45	0.37	1.88e-5	Alcohol and nicotine co-dependence;
TGCT	cis	rs12900413	0.631	rs62023455	chr15:90301999	G/A	cg24249390	chr15:90295951	MESP1	-0.3	-5.2	-0.42	8.04e-7	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs9297145	0.585	rs4729521	chr7:98780520	G/T	cg05967295	chr7:98741636	SMURF1	-0.68	-8.35	-0.6	1.12e-13	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs10791097	0.547	rs3829271	chr11:130753912	T/A	cg14779329	chr11:130786720	SNX19	0.3	5.08	0.41	1.36e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	trans	rs7618501	0.966	rs13085679	chr3:49869631	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	1.03	13.16	0.76	2.7e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs11792861	0.591	rs7044275	chr9:111717138	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.66	7.62	0.56	5.71e-12	Menarche (age at onset);
TGCT	cis	rs988712	0.672	rs36029218	chr11:27648371	A/T	cg10635145	chr11:27742435	BDNF	-0.38	-5.23	-0.43	7e-7	Obesity;
TGCT	cis	rs17221829	0.703	rs10047486	chr11:89405190	A/G	cg02982614	chr11:89391479	FOLH1B	-0.28	-4.67	-0.39	7.81e-6	Anxiety in major depressive disorder;
TGCT	cis	rs4919669	0.668	rs3824756	chr10:104359350	T/C	cg05855489	chr10:104503620	C10orf26	0.71	4.69	0.39	7.18e-6	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
TGCT	cis	rs72768842	1.000	rs114878198	chr5:78939907	C/A	cg24834873	chr5:79865402	ANKRD34B	-1.16	-4.61	-0.38	9.84e-6	Post bronchodilator FEV1/FVC ratio in COPD;
TGCT	trans	rs11088226	0.681	rs2833895	chr21:33929802	G/A	cg09050820	chr6:167586206	TCP10L2	0.76	6.79	0.52	4.22e-10	Gastritis;
TGCT	cis	rs1215050	0.527	rs1214998	chr4:99042878	T/G	cg17366294	chr4:99064904	C4orf37	0.59	6.26	0.49	5.68e-9	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs10875746	0.859	rs12305647	chr12:48582961	T/C	cg20731937	chr12:48336164	NA	0.59	4.72	0.39	6.13e-6	Longevity (90 years and older);
TGCT	cis	rs9467711	0.790	rs41266839	chr6:26409890	G/C	cg16898833	chr6:26189333	HIST1H4D	1.37	6.2	0.49	7.83e-9	Autism spectrum disorder or schizophrenia;
TGCT	trans	rs4332037	0.539	rs57148375	chr7:2025001	G/C	cg10840412	chr1:235813424	GNG4	0.93	6.69	0.51	6.97e-10	Bipolar disorder;
TGCT	cis	rs2562456	0.876	rs11085465	chr19:21751790	A/G	cg25650185	chr19:21324782	ZNF431	0.66	5.85	0.46	4.18e-8	Pain;
TGCT	cis	rs7100689	0.646	rs7919380	chr10:82133380	C/T	cg01528321	chr10:82214614	TSPAN14	0.8	7.76	0.57	2.7e-12	Post bronchodilator FEV1;
TGCT	cis	rs9291683	0.509	rs998676	chr4:9948564	T/C	cg11266682	chr4:10021025	SLC2A9	-0.62	-8.51	-0.61	4.84e-14	Bone mineral density;
TGCT	cis	rs2692947	0.770	rs2579552	chr2:96737083	A/G	cg23100626	chr2:96804247	ASTL	0.4	4.75	0.39	5.55e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs950776	0.518	rs4886571	chr15:78833758	G/A	cg06917634	chr15:78832804	PSMA4	-0.95	-9.52	-0.65	1.81e-16	Sudden cardiac arrest;
TGCT	cis	rs10883723	0.810	rs6584508	chr10:104258567	A/G	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs3862260	0.509	rs3862262	chr1:120161841	G/T	cg11530693	chr1:120165357	ZNF697	0.2	4.59	0.38	1.09e-5	Systemic lupus erythematosus;
TGCT	cis	rs12497850	0.931	rs11920534	chr3:48937761	G/T	cg07636037	chr3:49044803	WDR6	0.94	10.39	0.68	1.46e-18	Parkinson's disease;
TGCT	cis	rs8077577	0.895	rs735960	chr17:18057301	G/A	cg09161412	chr17:18057145	MYO15A	-0.69	-5.57	-0.45	1.5e-7	Obesity-related traits;
TGCT	cis	rs8016982	0.662	rs7148100	chr14:81678096	A/G	cg01989461	chr14:81687754	GTF2A1	0.61	4.55	0.38	1.26e-5	Schizophrenia;
TGCT	cis	rs11098499	0.874	rs13123591	chr4:120105990	T/G	cg09307838	chr4:120376055	NA	0.5	4.64	0.38	8.86e-6	Corneal astigmatism;
TGCT	cis	rs9818758	0.607	rs80170003	chr3:48951640	T/C	cg00383909	chr3:49044727	WDR6	1.39	7.14	0.54	6.9e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs9467773	1.000	rs10946835	chr6:26533757	C/T	cg15659132	chr6:26577336	NA	0.86	12.21	0.74	5.3e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs6582630	0.519	rs11495376	chr12:38284957	A/C	cg13010199	chr12:38710504	ALG10B	0.58	4.54	0.38	1.3e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg25427524	chr10:38739819	LOC399744	-0.4	-8.2	-0.59	2.5e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg22166914	chr1:53195759	ZYG11B	-0.42	-7.46	-0.56	1.33e-11	Monocyte count;
TGCT	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg20607798	chr8:58055168	NA	0.57	4.91	0.4	2.8e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs3749237	0.595	rs4855877	chr3:49448527	T/C	cg02487422	chr3:49467188	NICN1	0.58	5.95	0.47	2.56e-8	Resting heart rate;
TGCT	cis	rs713587	0.713	rs12466350	chr2:25239969	A/G	cg01884057	chr2:25150051	NA	0.38	7.82	0.57	1.95e-12	Body mass index in non-asthmatics;
TGCT	cis	rs9660992	0.710	rs1180721	chr1:205232696	T/C	cg00857998	chr1:205179979	DSTYK	0.52	4.56	0.38	1.19e-5	Mean corpuscular volume;Mean platelet volume;
TGCT	cis	rs13242816	1.000	rs7801950	chr7:116154783	C/T	cg16553024	chr7:116138462	CAV2	-0.45	-5.27	-0.43	5.81e-7	P wave duration;
TGCT	cis	rs921968	0.541	rs2556391	chr2:219556346	T/C	cg02176678	chr2:219576539	TTLL4	-0.5	-6.95	-0.53	1.8e-10	Mean corpuscular hemoglobin concentration;
TGCT	trans	rs57221529	0.608	rs11749927	chr5:668842	C/T	cg11887960	chr12:57824829	NA	1.04	9.03	0.63	2.77e-15	Lung disease severity in cystic fibrosis;
TGCT	cis	rs1801251	1.000	rs1801251	chr2:233633460	G/A	cg25237894	chr2:233734115	C2orf82	0.33	5.95	0.47	2.53e-8	Coronary artery disease;
TGCT	cis	rs2688608	0.967	rs9971040	chr10:75661162	G/C	cg04320760	chr10:75533139	FUT11	-0.31	-4.84	-0.4	3.72e-6	Inflammatory bowel disease;
TGCT	cis	rs9894429	0.646	rs7210026	chr17:79612382	T/C	cg18240062	chr17:79603768	NPLOC4	0.56	4.9	0.4	2.95e-6	Eye color traits;
TGCT	cis	rs12579753	0.917	rs11115029	chr12:82202219	C/G	cg07988820	chr12:82153109	PPFIA2	-0.59	-6.19	-0.49	7.93e-9	Resting heart rate;
TGCT	cis	rs1372520	0.684	rs184810	chr4:90697979	T/C	cg15133208	chr4:90757351	SNCA	0.47	5.58	0.45	1.43e-7	Neuroticism;
TGCT	cis	rs6088580	0.634	rs6059835	chr20:33020141	A/G	cg08999081	chr20:33150536	PIGU	0.29	5.66	0.45	9.92e-8	Glomerular filtration rate (creatinine);
TGCT	cis	rs910187	0.678	rs6066229	chr20:45815341	A/G	cg27589058	chr20:45804311	EYA2	0.34	7.29	0.55	3.14e-11	Migraine;
TGCT	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.66	5.42	0.44	3.01e-7	Tonsillectomy;
TGCT	cis	rs4148883	0.504	rs4147544	chr4:100134514	G/T	cg12011299	chr4:100065546	ADH4	-0.32	-4.55	-0.38	1.29e-5	Alcohol dependence;
TGCT	trans	rs4819388	0.751	rs2838533	chr21:45640260	T/C	cg17383793	chr5:52405638	MOCS2	-0.72	-6.89	-0.53	2.52e-10	Celiac disease;
TGCT	cis	rs10927875	0.793	rs1763619	chr1:16326935	A/G	cg14742211	chr1:16348397	CLCNKA	0.19	4.45	0.37	1.88e-5	Dilated cardiomyopathy;
TGCT	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.43	4.84	0.4	3.75e-6	Lymphocyte counts;
TGCT	cis	rs7010267	0.935	rs4319131	chr8:119947651	A/G	cg17171407	chr8:119960777	TNFRSF11B	-0.33	-6.2	-0.49	7.72e-9	Total body bone mineral density (age 45-60);
TGCT	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg04944784	chr2:26401820	FAM59B	-0.76	-6.37	-0.5	3.34e-9	Gut microbiome composition (summer);
TGCT	cis	rs17125944	0.505	rs28568967	chr14:53223060	A/G	cg00686598	chr14:53173677	PSMC6	1.08	6.35	0.5	3.79e-9	Alzheimer's disease (late onset);
TGCT	cis	rs7312933	0.558	rs1796384	chr12:42780568	G/A	cg19980929	chr12:42632907	YAF2	-0.4	-5.66	-0.45	1e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs3796352	1.000	rs71301804	chr3:53073314	C/A	cg27565382	chr3:53032988	SFMBT1	0.43	4.62	0.38	9.64e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs737008	0.800	rs535998	chr16:11366003	G/C	cg00044050	chr16:11439710	C16orf75	-0.59	-4.56	-0.38	1.21e-5	Obesity-related traits;
TGCT	cis	rs7726839	0.540	rs4957083	chr5:659343	T/C	cg09021430	chr5:549028	NA	-0.45	-6.27	-0.49	5.56e-9	Obesity-related traits;
TGCT	cis	rs7394190	0.748	rs12573448	chr10:75504512	T/G	cg07699608	chr10:75541558	CHCHD1	0.77	4.86	0.4	3.44e-6	Incident atrial fibrillation;
TGCT	cis	rs4268898	0.686	rs2042468	chr2:24398446	A/T	cg05570707	chr2:24270316	C2orf44	0.49	4.8	0.4	4.54e-6	Asthma;
TGCT	trans	rs1974653	0.631	rs55929151	chr22:20082566	C/T	cg08822737	chr17:71088851	SLC39A11	-0.93	-7.61	-0.56	5.97e-12	Schizophrenia;
TGCT	cis	rs7582180	0.764	rs11693424	chr2:100925439	G/A	cg14675211	chr2:100938903	LONRF2	0.49	4.8	0.4	4.49e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10823500	0.748	rs2394668	chr10:71943951	G/A	cg04118878	chr10:71993077	PPA1	0.54	4.96	0.41	2.3e-6	Blood protein levels;
TGCT	cis	rs12971120	0.891	rs2278158	chr18:72178300	G/T	cg25817165	chr18:72167213	CNDP2	-0.27	-4.65	-0.39	8.37e-6	Refractive error;
TGCT	cis	rs9467773	0.550	rs4712987	chr6:26399615	A/C	cg05738196	chr6:26577821	NA	-0.49	-5.11	-0.42	1.19e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7208859	0.673	rs3764421	chr17:29167653	A/C	cg14008862	chr17:28927542	LRRC37B2	0.72	4.66	0.39	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs514406	0.505	rs425520	chr1:53179805	C/G	cg22166914	chr1:53195759	ZYG11B	0.45	8.14	0.59	3.47e-13	Monocyte count;
TGCT	cis	rs9300255	0.543	rs1260294	chr12:123560289	T/C	cg00376283	chr12:123451042	ABCB9	-0.71	-4.78	-0.39	4.9100000000000004e-06	Neutrophil percentage of white cells;
TGCT	cis	rs1990950	0.692	rs6556028	chr5:156860488	T/C	cg25387487	chr5:157003181	ADAM19	0.31	4.78	0.39	4.78e-6	Lung function (FEV1/FVC);
TGCT	cis	rs2115630	0.905	rs6496401	chr15:85297793	A/T	cg17173187	chr15:85201210	NMB	-0.39	-4.76	-0.39	5.4e-6	P wave terminal force;
TGCT	cis	rs6450176	0.556	rs111423662	chr5:53288661	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.8	-5.67	-0.45	9.46e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs2982552	0.873	rs1999807	chr6:152064199	C/G	cg22157087	chr6:152012887	ESR1	0.21	4.93	0.4	2.61e-6	Bone properties (heel);
TGCT	cis	rs2762353	0.845	rs1937130	chr6:25787554	T/A	cg03517284	chr6:25882590	NA	0.5	5.13	0.42	1.1e-6	Blood metabolite levels;
TGCT	cis	rs2288884	0.943	rs75722407	chr19:52525242	C/T	cg15405931	chr19:52693188	PPP2R1A	-0.69	-4.47	-0.37	1.77e-5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs11096990	0.819	rs4974991	chr4:39194767	T/A	ch.4.37949012R	chr4:38272617	NA	-0.38	-4.74	-0.39	5.67e-6	Cognitive function;
TGCT	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.06	-9.6	-0.65	1.15e-16	Platelet count;
TGCT	cis	rs13326165	0.709	rs6796333	chr3:52359678	T/C	cg27565382	chr3:53032988	SFMBT1	0.37	4.9	0.4	2.97e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs7666738	0.830	rs17548431	chr4:98923768	C/G	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7666738	0.830	rs116103936	chr4:98954531	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs992157	0.835	rs2045434	chr2:219144498	A/G	cg00012203	chr2:219082015	ARPC2	-0.79	-7.87	-0.58	1.48e-12	Colorectal cancer;
TGCT	cis	rs35883536	0.587	rs2809799	chr1:101036516	A/G	cg06223162	chr1:101003688	GPR88	0.43	8.31	0.6	1.45e-13	Monocyte count;
TGCT	cis	rs7605378	1.000	rs10194076	chr2:200677663	T/C	cg23649088	chr2:200775458	C2orf69	0.33	5.61	0.45	1.25e-7	Osteoporosis;
TGCT	cis	rs57920188	0.584	rs12062024	chr1:4089259	A/T	cg20703997	chr1:4087676	NA	-0.49	-6.2	-0.49	7.57e-9	Interleukin-17 levels;
TGCT	cis	rs9788721	0.836	rs72738718	chr15:78735438	G/C	cg18825076	chr15:78729989	IREB2	-0.33	-5.22	-0.42	7.38e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
TGCT	cis	rs6815814	0.950	rs11722788	chr4:38810738	C/G	cg02016764	chr4:38805732	TLR1	-0.37	-5.98	-0.47	2.2e-8	Breast cancer;
TGCT	cis	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg25427524	chr10:38739819	LOC399744	-0.38	-7.92	-0.58	1.17e-12	Extrinsic epigenetic age acceleration;
TGCT	cis	rs6674176	0.593	rs6675620	chr1:44417630	C/T	cg13606994	chr1:44402422	ARTN	-0.46	-4.95	-0.41	2.36e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs7824557	0.583	rs2263512	chr8:11233419	T/G	cg21775007	chr8:11205619	TDH	-0.66	-6.81	-0.52	3.79e-10	Retinal vascular caliber;
TGCT	cis	rs6988636	0.710	rs73339626	chr8:124142757	A/G	cg27053337	chr8:124217698	FAM83A	0.77	5.55	0.45	1.65e-7	Urinary uromodulin levels;
TGCT	cis	rs4455778	0.538	rs6965822	chr7:49123931	A/G	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs7219014	1	rs7219014	chr17:37624790	A/G	cg07936489	chr17:37558343	FBXL20	-0.6	-4.75	-0.39	5.45e-6	Urinary metabolites;
TGCT	cis	rs7772486	0.720	rs6931553	chr6:146112348	T/C	cg23711669	chr6:146136114	FBXO30	-0.93	-10.49	-0.69	8.22e-19	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2439831	1.000	rs28666488	chr15:43741090	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.8	5.7	0.46	8.33e-8	Lung cancer in ever smokers;
TGCT	cis	rs3820928	1.000	rs1835158	chr2:227763993	C/A	cg11843606	chr2:227700838	RHBDD1	-0.53	-4.68	-0.39	7.31e-6	Pulmonary function;
TGCT	cis	rs1577917	0.740	rs9353320	chr6:86244848	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.54	4.87	0.4	3.29e-6	Response to antipsychotic treatment;
TGCT	cis	rs9788682	0.948	rs34664138	chr15:78831624	T/G	cg24631222	chr15:78858424	CHRNA5	0.92	7.57	0.56	7.51e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg15691649	chr6:25882328	NA	-0.47	-5.25	-0.43	6.45e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs11642862	1.000	rs75500538	chr16:30782449	G/A	cg02466173	chr16:30829666	NA	-0.39	-4.68	-0.39	7.24e-6	Tonsillectomy;
TGCT	cis	rs6684514	1.000	rs10908494	chr1:156263097	A/G	cg16558208	chr1:156270281	VHLL	0.46	9.38	0.64	3.92e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs910316	1.000	rs12589815	chr14:75544101	C/T	cg23033748	chr14:75592666	NEK9	0.28	4.76	0.39	5.27e-6	Height;
TGCT	cis	rs7666738	0.830	rs2098934	chr4:98992403	A/G	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7772486	0.875	rs9403770	chr6:146423334	C/T	cg13319975	chr6:146136371	FBXO30	-0.51	-4.48	-0.37	1.69e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg06896619	chr17:61851486	DDX42;CCDC47	-0.51	-4.96	-0.41	2.24e-6	Prudent dietary pattern;
TGCT	cis	rs72781680	0.821	rs72796378	chr2:24167385	G/A	cg08917208	chr2:24149416	ATAD2B	0.74	4.66	0.39	7.9e-6	Lymphocyte counts;
TGCT	cis	rs921968	0.643	rs522377	chr2:219437476	T/C	cg02176678	chr2:219576539	TTLL4	0.38	5.48	0.44	2.31e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs67311347	0.544	rs2278930	chr3:40351092	C/T	cg13683864	chr3:40499215	RPL14	-0.81	-7.58	-0.56	7.14e-12	Renal cell carcinoma;
TGCT	cis	rs708547	0.957	rs1718875	chr4:57837438	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.57	-4.68	-0.39	7.48e-6	Response to bleomycin (chromatid breaks);
TGCT	cis	rs9300255	0.537	rs1716182	chr12:123686127	A/C	cg00376283	chr12:123451042	ABCB9	0.71	5.59	0.45	1.41e-7	Neutrophil percentage of white cells;
TGCT	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	8.0	0.58	7.67e-13	Platelet count;
TGCT	cis	rs7584330	0.868	rs7571898	chr2:238383028	T/C	cg08992911	chr2:238395768	MLPH	0.64	5.13	0.42	1.07e-6	Prostate cancer;
TGCT	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg08859206	chr1:53392774	SCP2	0.4	5.97	0.47	2.38e-8	Monocyte count;
TGCT	cis	rs3820068	0.581	rs72645881	chr1:15928203	C/T	cg05660106	chr1:15850417	CASP9	0.82	8.02	0.58	6.63e-13	Systolic blood pressure;
TGCT	cis	rs6570726	0.846	rs9376954	chr6:145943737	T/A	cg23711669	chr6:146136114	FBXO30	0.84	9.16	0.64	1.36e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6840360	0.967	rs1105534	chr4:152605312	C/A	cg17479576	chr4:152424074	FAM160A1	-0.47	-4.86	-0.4	3.41e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs61990749	0.597	rs117131659	chr14:78131126	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	-0.68	-4.76	-0.39	5.29e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs7192750	0.586	rs8062946	chr16:71930807	A/G	cg06353428	chr16:71660113	MARVELD3	0.83	7.32	0.55	2.74e-11	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs7523273	0.925	rs12749612	chr1:208006749	A/G	cg22525895	chr1:207977042	MIR29B2	-0.49	-8.69	-0.62	1.78e-14	Schizophrenia;
TGCT	cis	rs5769765	0.773	rs9616383	chr22:50313014	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.43	6.08	0.48	1.35e-8	Schizophrenia;
TGCT	cis	rs9447004	0.584	rs7747167	chr6:74430673	T/G	cg23004174	chr6:74404879	CD109	0.23	5.04	0.41	1.58e-6	Blood protein levels;Calcium levels;
TGCT	cis	rs367615	0.661	rs9326775	chr5:108836925	A/T	cg17395555	chr5:108820864	NA	0.31	5.86	0.47	3.94e-8	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs2326825	0.624	rs1938164	chr6:6805059	C/T	cg06501113	chr6:6534839	LOC285780	0.35	4.64	0.38	8.69e-6	Gastroesophageal reflux disease;
TGCT	cis	rs12579753	1.000	rs7306395	chr12:82175867	A/G	cg07988820	chr12:82153109	PPFIA2	-0.65	-6.79	-0.52	4.09e-10	Resting heart rate;
TGCT	cis	rs2046867	0.908	rs62251655	chr3:72821708	T/C	cg25664220	chr3:72788482	NA	-0.55	-6.92	-0.53	2.15e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2404602	0.669	rs17464903	chr15:77195486	A/G	cg22467129	chr15:76604101	ETFA	-0.47	-5.33	-0.43	4.47e-7	Blood metabolite levels;
TGCT	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg06028808	chr11:68637592	NA	0.51	6.66	0.51	7.87e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs2439831	0.867	rs12443102	chr15:43932103	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.72	4.8	0.4	4.52e-6	Lung cancer in ever smokers;
TGCT	cis	rs950169	0.580	rs62021208	chr15:85196244	G/A	cg12863693	chr15:85201151	NMB	0.46	5.51	0.44	1.97e-7	Schizophrenia;
TGCT	cis	rs765787	0.530	rs12915027	chr15:45512626	G/A	cg24006582	chr15:45444508	DUOX1	0.25	5.35	0.43	4.11e-7	Uric acid levels;
TGCT	cis	rs7611238	0.538	rs62287119	chr3:195078818	G/A	cg27323046	chr3:195102265	ACAP2	0.39	5.09	0.42	1.29e-6	Body mass index;
TGCT	cis	rs2204008	0.805	rs11180825	chr12:38242916	G/T	cg13010199	chr12:38710504	ALG10B	0.64	5.01	0.41	1.85e-6	Bladder cancer;
TGCT	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg00684032	chr4:1343700	KIAA1530	0.24	4.91	0.4	2.82e-6	Obesity-related traits;
TGCT	cis	rs12477438	0.748	rs6712773	chr2:99585781	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-5.87	-0.47	3.74e-8	Chronic sinus infection;
TGCT	cis	rs7267979	1.000	rs2257809	chr20:25266476	C/T	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs12134245	0.776	rs12125947	chr1:91990487	T/C	cg07090678	chr1:91966139	CDC7	0.34	4.72	0.39	6.29e-6	Breast cancer;
TGCT	cis	rs67311347	1.000	rs73080126	chr3:40509153	A/G	cg13683864	chr3:40499215	RPL14	-1.2	-13.3	-0.77	1.27e-25	Renal cell carcinoma;
TGCT	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg14983838	chr19:29218262	NA	0.74	6.69	0.52	6.75e-10	Methadone dose in opioid dependence;
TGCT	cis	rs11148252	0.532	rs9536190	chr13:53181044	T/C	cg00495681	chr13:53174319	NA	0.91	10.15	0.67	5.33e-18	Lewy body disease;
TGCT	cis	rs11809207	1.000	rs11247865	chr1:26517773	T/C	cg03844060	chr1:26490628	NA	0.25	4.62	0.38	9.44e-6	Height;
TGCT	cis	rs67311347	0.544	rs13098483	chr3:40342743	G/C	cg13683864	chr3:40499215	RPL14	-0.78	-7.5	-0.56	1.06e-11	Renal cell carcinoma;
TGCT	cis	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg16524733	chr11:117070046	TAGLN	0.33	4.9	0.4	2.87e-6	Blood protein levels;
TGCT	cis	rs2404618	0.504	rs2906567	chr8:1494118	C/T	cg13402656	chr8:1511478	DLGAP2	-0.36	-6.27	-0.49	5.6e-9	Lung cancer;
TGCT	cis	rs7772486	0.790	rs9376971	chr6:146259505	C/T	cg05347473	chr6:146136440	FBXO30	-0.51	-4.95	-0.41	2.32e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9868809	0.505	rs11706983	chr3:48738678	A/G	cg00383909	chr3:49044727	WDR6	1.06	6.28	0.49	5.26e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs6671200	1.000	rs6678964	chr1:95694268	C/T	cg26537280	chr1:95699037	RWDD3	0.73	6.19	0.49	8.07e-9	Stearic acid (18:0) levels;
TGCT	cis	rs7226408	0.857	rs4344828	chr18:34613339	A/G	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg15921436	chr17:44337874	NA	0.59	8.18	0.59	2.85e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs10832169	0.933	rs11023060	chr11:14064931	T/G	cg04547675	chr11:13986162	SPON1	0.51	4.51	0.38	1.49e-5	Blood protein levels;
TGCT	cis	rs7552404	1.000	rs4949875	chr1:76173080	G/A	cg03433033	chr1:76189801	ACADM	0.83	9.91	0.66	2.13e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg12311346	chr5:56204834	C5orf35	-0.63	-6.36	-0.5	3.5e-9	Initial pursuit acceleration;
TGCT	cis	rs2153535	0.580	rs2327061	chr6:8447231	G/C	cg07606381	chr6:8435919	SLC35B3	0.53	5.02	0.41	1.79e-6	Motion sickness;
TGCT	cis	rs12579753	0.879	rs11115002	chr12:82153090	C/T	cg07988820	chr12:82153109	PPFIA2	-0.66	-7.01	-0.53	1.32e-10	Resting heart rate;
TGCT	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg17971929	chr21:40555470	PSMG1	-0.72	-6.53	-0.51	1.5e-9	Cognitive function;
TGCT	cis	rs1008375	0.932	rs2302391	chr4:17660237	T/C	cg16339924	chr4:17578868	LAP3	0.65	5.31	0.43	4.8e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg02380750	chr20:61661411	NA	0.34	6.02	0.48	1.86e-8	Prostate cancer (SNP x SNP interaction);
TGCT	trans	rs804280	0.509	rs35626932	chr8:11786932	C/A	cg15556689	chr8:8085844	FLJ10661	0.77	7.03	0.53	1.22e-10	Myopia (pathological);
TGCT	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg24829409	chr8:58192753	C8orf71	-0.52	-5.02	-0.41	1.73e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs79839061	0.667	rs13104885	chr4:827368	G/C	cg07828340	chr4:882639	GAK	0.4	5.08	0.42	1.34e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs17384381	1.000	rs12123745	chr1:85884772	T/C	cg16011679	chr1:85725395	C1orf52	0.8	6.44	0.5	2.39e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg06634786	chr22:41940651	POLR3H	-0.86	-8.02	-0.58	6.88e-13	Vitiligo;
TGCT	cis	rs6840360	0.533	rs13121190	chr4:152729072	T/G	cg22705602	chr4:152727874	NA	0.37	6.56	0.51	1.3e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs4478037	0.558	rs57502645	chr3:33082174	G/A	cg19404215	chr3:33155277	CRTAP	1.09	5.31	0.43	4.86e-7	Major depressive disorder;
TGCT	cis	rs2777491	0.915	rs7178777	chr15:41634588	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.74	-10.4	-0.68	1.37e-18	Ulcerative colitis;
TGCT	cis	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg18252515	chr7:66147081	NA	-1.13	-7.39	-0.55	1.94e-11	Diabetic kidney disease;
TGCT	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg09359103	chr1:154839909	KCNN3	-0.62	-11.25	-0.71	1.15e-20	Prostate cancer;
TGCT	cis	rs9536318	0.673	rs1323113	chr13:53509475	A/C	cg08567279	chr13:53313529	LECT1	0.48	4.47	0.37	1.75e-5	Airflow obstruction;
TGCT	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg24549020	chr5:56110836	MAP3K1	0.72	6.03	0.48	1.73e-8	Initial pursuit acceleration;
TGCT	cis	rs6922617	0.786	rs79915147	chr6:41344947	G/T	cg07798131	chr6:41471673	NA	0.98	4.85	0.4	3.6e-6	Alzheimer's disease biomarkers;
TGCT	cis	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg08045932	chr20:61659980	NA	0.48	9.16	0.64	1.36e-15	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1205863	0.607	rs10947661	chr6:11934964	A/G	cg07106625	chr6:11870215	NA	-0.44	-4.64	-0.38	8.88e-6	Disc degeneration (lumbar);
TGCT	cis	rs981844	0.961	rs56288418	chr4:154668228	C/A	cg14289246	chr4:154710475	SFRP2	1.01	8.67	0.61	2.02e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg10802521	chr3:52805072	NEK4	-0.72	-9.1	-0.63	1.91e-15	Bipolar disorder;
TGCT	cis	rs7918232	0.943	rs6482593	chr10:27371437	A/G	cg14442939	chr10:27389572	ANKRD26	0.73	5.37	0.43	3.69e-7	Breast cancer;
TGCT	cis	rs644799	0.710	rs56384142	chr11:95502075	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.81	9.02	0.63	2.92e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs16958440	0.867	rs59217333	chr18:44694844	A/C	cg17192377	chr18:44677553	HDHD2	0.63	4.7	0.39	6.74e-6	Sitting height ratio;
TGCT	cis	rs9611565	0.765	rs132909	chr22:41802031	G/A	cg13695892	chr22:41940480	POLR3H	0.8	8.01	0.58	7.2e-13	Vitiligo;
TGCT	cis	rs1729951	0.575	rs361244	chr3:136697506	C/T	cg21827317	chr3:136751795	NA	0.4	5.6	0.45	1.28e-7	Neuroticism;
TGCT	cis	rs61884328	0.733	rs79044335	chr11:47200402	G/C	cg13308137	chr11:47528955	CUGBP1	0.38	4.48	0.37	1.65e-5	Total body bone mineral density (age over 60);
TGCT	trans	rs9929218	0.551	rs6499193	chr16:68727069	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.57	7.35	0.55	2.33e-11	Colorectal cancer;
TGCT	trans	rs3780486	0.846	rs12554995	chr9:33132044	A/G	cg20290983	chr6:43655470	MRPS18A	1.19	14.84	0.8	2.81e-29	IgG glycosylation;
TGCT	cis	rs1775715	0.737	rs2799018	chr10:32202069	C/T	cg14930904	chr10:32216787	ARHGAP12	0.52	5.07	0.41	1.39e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg00684032	chr4:1343700	KIAA1530	0.25	5.09	0.42	1.31e-6	Obesity-related traits;
TGCT	cis	rs2836974	0.653	rs8130556	chr21:40516872	C/T	cg06238570	chr21:40685208	BRWD1	0.71	6.51	0.5	1.71e-9	Cognitive function;
TGCT	cis	rs2997447	0.846	rs3008230	chr1:26401331	A/G	cg19633962	chr1:26362018	EXTL1	-0.64	-4.46	-0.37	1.84e-5	QRS complex (12-leadsum);
TGCT	cis	rs7236492	0.572	rs78124041	chr18:77181489	G/A	cg15644404	chr18:77186268	NFATC1	-0.43	-4.61	-0.38	9.81e-6	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs5769707	0.967	rs739248	chr22:50025205	T/C	cg05373962	chr22:49881684	NA	-0.31	-6.42	-0.5	2.6e-9	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs9296092	0.538	rs76589475	chr6:33519517	G/C	cg13560919	chr6:33536144	NA	-0.21	-4.75	-0.39	5.5e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg23758822	chr17:41437982	NA	0.72	6.96	0.53	1.76e-10	Menopause (age at onset);
TGCT	cis	rs7615952	0.932	rs13314869	chr3:125644669	G/A	cg05084668	chr3:125655381	ALG1L	-0.75	-6.07	-0.48	1.41e-8	Blood pressure (smoking interaction);
TGCT	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg21171335	chr12:122356390	WDR66	0.55	5.73	0.46	7.28e-8	Mean corpuscular volume;
TGCT	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg13206674	chr6:150067644	NUP43	0.52	4.51	0.38	1.5e-5	Lung cancer;
TGCT	cis	rs2072499	0.695	rs112223391	chr1:156156094	G/A	cg24450063	chr1:156163899	SLC25A44	1.09	9.82	0.66	3.53e-17	Testicular germ cell tumor;
TGCT	cis	rs909002	0.849	rs10914458	chr1:32096746	T/C	cg11573219	chr1:32083031	HCRTR1	-0.47	-6.08	-0.48	1.37e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs11650494	0.908	rs73324323	chr17:47420054	G/T	cg08112188	chr17:47440006	ZNF652	1.04	5.34	0.43	4.3e-7	Prostate cancer;
TGCT	cis	rs59197085	0.636	rs58320939	chr7:128462843	T/A	cg00260937	chr7:128520193	KCP	0.47	4.98	0.41	2.1e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
TGCT	cis	rs1153858	1.000	rs60476496	chr15:45713801	C/T	cg14582100	chr15:45693742	SPATA5L1	0.48	5.67	0.45	9.65e-8	Homoarginine levels;
TGCT	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg07061783	chr6:25882402	NA	-0.45	-4.82	-0.4	4.14e-6	Blood metabolite levels;
TGCT	cis	rs10782582	0.617	rs1846233	chr1:76159354	C/T	cg10523679	chr1:76189770	ACADM	-0.69	-7.19	-0.54	5.26e-11	Daytime sleep phenotypes;
TGCT	cis	rs7772486	0.790	rs2265919	chr6:146221753	A/G	cg23711669	chr6:146136114	FBXO30	0.89	10.16	0.67	5.28e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2549003	1.000	rs10214312	chr5:131821866	T/G	cg02551604	chr5:131831745	NA	-0.9	-12.1	-0.74	9.75e-23	Asthma (sex interaction);
TGCT	cis	rs6840360	0.557	rs1143036	chr4:152329404	A/G	cg17479576	chr4:152424074	FAM160A1	-0.55	-5.72	-0.46	7.48e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.37	-4.91	-0.4	2.78e-6	Menarche (age at onset);
TGCT	cis	rs7666738	0.830	rs1813642	chr4:98852225	G/A	cg05340658	chr4:99064831	C4orf37	0.52	6.03	0.48	1.78e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg07636037	chr3:49044803	WDR6	0.85	8.88	0.62	6.21e-15	Menarche (age at onset);
TGCT	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg24531977	chr5:56204891	C5orf35	0.69	7.29	0.55	3.25e-11	Initial pursuit acceleration;
TGCT	cis	rs10791097	0.694	rs12361892	chr11:130744490	T/G	cg05962950	chr11:130786565	SNX19	0.92	11.55	0.72	2.13e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs4746818	1.000	rs7909631	chr10:70918676	C/T	cg04149295	chr10:70884716	VPS26A	0.79	5.44	0.44	2.79e-7	Left atrial antero-posterior diameter;
TGCT	cis	rs7659604	0.628	rs6838153	chr4:122720999	A/G	cg06713675	chr4:122721982	EXOSC9	-0.69	-9.57	-0.65	1.4e-16	Type 2 diabetes;
TGCT	cis	rs2594989	1.000	rs2594967	chr3:11349748	T/G	cg00170343	chr3:11313890	ATG7	0.61	4.58	0.38	1.11e-5	Circulating chemerin levels;
TGCT	cis	rs425277	0.585	rs3107143	chr1:2045372	G/C	cg24578937	chr1:2090814	PRKCZ	-0.23	-5.54	-0.45	1.73e-7	Height;
TGCT	cis	rs7666738	0.830	rs890470	chr4:98923435	A/C	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10875746	0.669	rs61941006	chr12:48631133	G/A	cg20731937	chr12:48336164	NA	0.59	4.52	0.38	1.45e-5	Longevity (90 years and older);
TGCT	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg23708337	chr7:1209742	NA	0.51	4.46	0.37	1.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs17345786	0.861	rs74768235	chr3:101142821	T/C	cg12386194	chr3:101231763	SENP7	0.65	6.33	0.49	4.1e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg11890956	chr21:40555474	PSMG1	-0.73	-6.98	-0.53	1.59e-10	Menarche (age at onset);
TGCT	cis	rs9372498	0.908	rs4551203	chr6:118693502	G/A	cg21191810	chr6:118973309	C6orf204	-0.5	-4.61	-0.38	9.92e-6	Diastolic blood pressure;
TGCT	cis	rs9638182	0.725	rs13244268	chr7:72911843	T/C	cg14087351	chr7:73037990	MLXIPL	-0.61	-4.81	-0.4	4.34e-6	Triglycerides;
TGCT	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg02725872	chr8:58115012	NA	-0.4	-4.87	-0.4	3.34e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs425277	0.585	rs364677	chr1:2071765	A/G	cg03732007	chr1:2071316	PRKCZ	-0.27	-6.37	-0.5	3.37e-9	Height;
TGCT	cis	rs1941023	0.584	rs2233252	chr11:60157107	T/G	cg08716584	chr11:60157161	MS4A7	-0.35	-5.29	-0.43	5.3e-7	Congenital heart disease (maternal effect);
TGCT	cis	rs9790314	0.502	rs34972965	chr3:160984296	G/A	cg03342759	chr3:160939853	NMD3	-0.49	-5.3	-0.43	5.16e-7	Morning vs. evening chronotype;
TGCT	cis	rs911555	0.692	rs7146215	chr14:103915908	A/G	cg23461800	chr14:103021989	NA	-0.34	-4.5	-0.37	1.57e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs4822044	0.561	rs132781	chr22:42046122	T/G	cg17554472	chr22:41940697	POLR3H	0.52	5.37	0.43	3.68e-7	Cannabis dependence symptom count;
TGCT	cis	rs8180040	0.726	rs2305634	chr3:47043538	A/G	cg27129171	chr3:47204927	SETD2	-0.73	-9.67	-0.66	8.02e-17	Colorectal cancer;
TGCT	cis	rs13256369	0.851	rs13249700	chr8:8563637	C/T	cg17143192	chr8:8559678	CLDN23	0.57	5.35	0.43	4.09e-7	Obesity-related traits;
TGCT	cis	rs7523050	0.643	rs34096625	chr1:109401101	G/A	cg08274380	chr1:109419600	GPSM2	1.3	6.39	0.5	2.99e-9	Fat distribution (HIV);
TGCT	cis	rs1044826	0.692	rs176987	chr3:139233001	G/A	cg00490450	chr3:139108681	COPB2	-0.51	-4.48	-0.37	1.67e-5	Obesity-related traits;
TGCT	cis	rs9534288	0.797	rs7331069	chr13:46564609	A/T	cg15192986	chr13:46630673	CPB2	0.48	6.81	0.52	3.68e-10	Blood protein levels;
TGCT	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	7.88	0.58	1.43e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs11252926	0.550	rs10904148	chr10:454551	G/T	cg13477178	chr10:375248	DIP2C	-0.24	-4.46	-0.37	1.82e-5	Psychosis in Alzheimer's disease;
TGCT	cis	rs6964587	1.000	rs2282975	chr7:91761638	A/G	cg17063962	chr7:91808500	NA	0.87	9.26	0.64	7.83e-16	Breast cancer;
TGCT	cis	rs933688	1.000	rs9293568	chr5:90737845	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.03	8.74	0.62	1.33e-14	Smoking behavior;
TGCT	cis	rs6490294	0.607	rs2339907	chr12:112418146	C/A	cg10833066	chr12:111807467	FAM109A	0.33	5.18	0.42	8.61e-7	Mean platelet volume;
TGCT	cis	rs732765	1.000	rs732765	chr14:75365729	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.63	-5.39	-0.44	3.49e-7	Non-small cell lung cancer;
TGCT	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg23708337	chr7:1209742	NA	0.64	5.94	0.47	2.63e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs319204	0.843	rs319171	chr5:146288806	T/C	cg25021259	chr5:146258546	PPP2R2B	0.36	4.46	0.37	1.83e-5	Schizophrenia;
TGCT	cis	rs12477438	0.501	rs11123770	chr2:99825102	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	9.12	0.63	1.72e-15	Chronic sinus infection;
TGCT	trans	rs4332037	0.539	rs11763750	chr7:2080114	G/A	cg10840412	chr1:235813424	GNG4	0.94	6.76	0.52	4.78e-10	Bipolar disorder;
TGCT	cis	rs2688608	0.560	rs10128354	chr10:75470045	T/C	cg19442545	chr10:75533431	FUT11	-0.37	-5.87	-0.47	3.64e-8	Inflammatory bowel disease;
TGCT	cis	rs7223966	1.000	rs16947005	chr17:61702989	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.55	-4.75	-0.39	5.63e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs13326165	0.715	rs11707864	chr3:52392877	G/A	cg07884673	chr3:53033167	SFMBT1	0.38	4.65	0.39	8.36e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs9383153	1.000	rs9370888	chr6:16335544	A/G	cg03173502	chr6:15505345	JARID2	0.9	5.64	0.45	1.1e-7	Gambling;
TGCT	cis	rs6500602	0.674	rs8051695	chr16:4536621	T/C	cg08645402	chr16:4508243	NA	0.2	4.98	0.41	2.09e-6	Schizophrenia;
TGCT	cis	rs2862064	1.000	rs1910053	chr5:156463063	G/A	cg12943317	chr5:156479607	HAVCR1	-0.45	-5.29	-0.43	5.36e-7	Platelet count;
TGCT	cis	rs1552244	0.554	rs55847233	chr3:9991101	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.3	-4.63	-0.38	9.17e-6	Alzheimer's disease;
TGCT	cis	rs9425766	0.546	rs6691001	chr1:173819076	T/G	cg07177756	chr1:173836307	SNORD75;SNORD78;ZBTB37;SNORD76;GAS5;SNORD77;SNORD44	0.49	4.51	0.38	1.49e-5	Life satisfaction;
TGCT	cis	rs7772486	0.686	rs9403739	chr6:146015357	A/G	cg23711669	chr6:146136114	FBXO30	-0.87	-9.84	-0.66	3.1e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3812831	0.695	rs422149	chr13:114931086	T/G	cg08824895	chr13:115047677	UPF3A	0.51	4.98	0.41	2.07e-6	Schizophrenia;
TGCT	cis	rs910316	0.737	rs424120	chr14:75482828	G/T	cg08847533	chr14:75593920	NEK9	-0.84	-8.92	-0.63	5.19e-15	Height;
TGCT	cis	rs6831352	0.918	rs2851246	chr4:100046104	A/G	cg12011299	chr4:100065546	ADH4	0.4	4.88	0.4	3.26e-6	Alcohol dependence;
TGCT	cis	rs9611565	0.570	rs12159188	chr22:42121125	A/T	cg06481639	chr22:41940642	POLR3H	0.63	5.6	0.45	1.28e-7	Vitiligo;
TGCT	cis	rs35851103	0.507	rs6601649	chr8:11857317	A/G	cg20542592	chr8:11973495	FAM66D	0.54	5.02	0.41	1.78e-6	Neuroticism;
TGCT	cis	rs7216064	1.000	rs62085992	chr17:65923083	T/A	cg12091567	chr17:66097778	LOC651250	-0.81	-6.06	-0.48	1.53e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	trans	rs3824451	1.000	rs16914811	chr9:101076627	C/T	cg11574975	chr1:112058304	ADORA3	-0.44	-6.91	-0.53	2.3e-10	Schizophrenia;
TGCT	cis	rs1215050	0.704	rs783915	chr4:99023151	C/G	cg05340658	chr4:99064831	C4orf37	0.43	5.17	0.42	9.18e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7772486	0.754	rs1415747	chr6:146077249	A/G	cg13319975	chr6:146136371	FBXO30	-0.51	-4.58	-0.38	1.1e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6912958	0.712	rs6454641	chr6:88371060	T/C	cg06598631	chr6:88300029	RARS2;ORC3L	-0.52	-4.78	-0.39	4.95e-6	Monocyte percentage of white cells;
TGCT	cis	rs6988636	0.710	rs62521797	chr8:124134321	A/T	cg23067535	chr8:124195133	FAM83A	-0.41	-4.45	-0.37	1.92e-5	Urinary uromodulin levels;
TGCT	trans	rs941408	0.964	rs1736195	chr19:2786557	C/T	cg19676328	chr12:49525230	TUBA1B	-0.73	-6.74	-0.52	5.36e-10	Total cholesterol levels;
TGCT	cis	rs5769765	0.913	rs28670284	chr22:50221973	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.38	5.18	0.42	8.71e-7	Schizophrenia;
TGCT	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg02725872	chr8:58115012	NA	-0.41	-5.42	-0.44	3.01e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6912958	1.000	rs13214153	chr6:88153983	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.64	-6.36	-0.5	3.58e-9	Monocyte percentage of white cells;
TGCT	trans	rs3780486	0.846	rs10813954	chr9:33137596	A/C	cg20290983	chr6:43655470	MRPS18A	1.2	14.83	0.8	3.07e-29	IgG glycosylation;
TGCT	cis	rs151997	0.671	rs3991902	chr5:50203749	A/T	cg06027927	chr5:50259733	NA	0.56	5.64	0.45	1.11e-7	Callous-unemotional behaviour;
TGCT	cis	rs7726839	0.540	rs56325086	chr5:640728	G/A	cg09021430	chr5:549028	NA	-0.38	-5.21	-0.42	7.5e-7	Obesity-related traits;
TGCT	cis	rs12497850	0.931	rs6446205	chr3:49035211	C/T	cg07636037	chr3:49044803	WDR6	0.99	11.03	0.7	4e-20	Parkinson's disease;
TGCT	cis	rs4319547	0.695	rs11836188	chr12:122865507	T/C	cg08088222	chr12:122070432	ORAI1	-0.25	-4.5	-0.37	1.56e-5	Body mass index;
TGCT	cis	rs710216	0.917	rs710223	chr1:43411038	C/G	cg03128534	chr1:43423976	SLC2A1	0.65	4.57	0.38	1.16e-5	Red cell distribution width;
TGCT	cis	rs9303401	0.659	rs12150264	chr17:56939927	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs7772486	0.790	rs4435956	chr6:146232403	G/C	cg23711669	chr6:146136114	FBXO30	-0.87	-9.9	-0.66	2.24e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4975709	0.569	rs931509	chr5:1858821	A/T	cg15595755	chr5:1867978	NA	0.46	5.21	0.42	7.54e-7	Cardiovascular disease risk factors;
TGCT	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg03806693	chr22:41940476	POLR3H	1.14	12.75	0.75	2.57e-24	Vitiligo;
TGCT	cis	rs7086627	0.515	rs10887900	chr10:82210265	A/G	cg00277334	chr10:82204260	NA	-0.53	-8.34	-0.6	1.21e-13	Post bronchodilator FEV1;
TGCT	cis	rs6988636	0.792	rs62521807	chr8:124163621	T/C	cg22384356	chr8:124195192	FAM83A	-0.39	-4.57	-0.38	1.19e-5	Urinary uromodulin levels;
TGCT	cis	rs4713118	0.868	rs7756968	chr6:27734954	C/G	cg20933634	chr6:27740509	NA	0.34	4.79	0.4	4.67e-6	Parkinson's disease;
TGCT	cis	rs7178572	0.625	rs12904553	chr15:77845959	G/A	cg22256960	chr15:77711686	NA	-0.79	-9.06	-0.63	2.33e-15	Type 2 diabetes;
TGCT	cis	rs9972944	0.627	rs28845012	chr17:63760891	G/A	cg07283582	chr17:63770753	CCDC46	-0.26	-5.25	-0.43	6.32e-7	Total body bone mineral density;
TGCT	cis	rs9549367	0.789	rs9549718	chr13:113909822	A/G	cg18105134	chr13:113819100	PROZ	-0.34	-5.61	-0.45	1.26e-7	Platelet distribution width;
TGCT	cis	rs881375	1.000	rs1953126	chr9:123640500	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	5.63	0.45	1.17e-7	Rheumatoid arthritis;
TGCT	cis	rs1801251	1.000	rs283484	chr2:233646505	A/G	cg25237894	chr2:233734115	C2orf82	0.32	5.68	0.45	8.93e-8	Coronary artery disease;
TGCT	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.54	-0.38	1.33e-5	Bipolar disorder;
TGCT	cis	rs2982552	0.967	rs1999806	chr6:152064355	G/A	cg22157087	chr6:152012887	ESR1	0.19	4.62	0.38	9.37e-6	Bone properties (heel);
TGCT	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.77	-7.48	-0.56	1.17e-11	Prudent dietary pattern;
TGCT	cis	rs6684514	1.000	rs11264468	chr1:156274585	C/G	cg16558208	chr1:156270281	VHLL	0.46	9.38	0.64	3.92e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	trans	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg17830980	chr10:43048298	ZNF37B	-0.83	-10.65	-0.69	3.3e-19	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg17971929	chr21:40555470	PSMG1	0.98	9.67	0.66	8.18e-17	Cognitive function;
TGCT	cis	rs35146811	0.695	rs1623264	chr7:99811204	G/C	cg22906224	chr7:99728672	NA	-0.49	-4.45	-0.37	1.88e-5	Coronary artery disease;
TGCT	cis	rs2075371	0.933	rs1421482	chr7:133964383	A/G	cg11752832	chr7:134001865	SLC35B4	0.69	6.1	0.48	1.24e-8	Mean platelet volume;
TGCT	cis	rs9357506	0.967	rs75331811	chr6:46309143	T/A	cg21115430	chr6:46460003	NA	-0.26	-5.17	-0.42	9.2e-7	Body mass index;
TGCT	cis	rs7698623	0.850	rs10011586	chr4:88798921	C/T	cg02735620	chr4:88950514	PKD2	-0.44	-4.78	-0.39	4.95e-6	Cardiovascular disease risk factors;
TGCT	cis	rs3125734	0.571	rs7100401	chr10:64024417	C/G	cg19640130	chr10:64028056	RTKN2	-0.4	-5.17	-0.42	9.02e-7	Rheumatoid arthritis;
TGCT	cis	rs4664308	0.935	rs6739867	chr2:160942818	G/A	cg03641300	chr2:160917029	PLA2R1	-0.28	-6.83	-0.52	3.44e-10	Idiopathic membranous nephropathy;
TGCT	cis	rs6740322	0.748	rs13432574	chr2:43544328	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.41	-7.0	-0.53	1.42e-10	Coronary artery disease;
TGCT	cis	rs67311347	1.000	rs12638199	chr3:40475285	A/G	cg17264618	chr3:40429014	ENTPD3	0.32	4.76	0.39	5.36e-6	Renal cell carcinoma;
TGCT	cis	rs751728	1.000	rs6904991	chr6:33732262	T/G	cg13859433	chr6:33739653	LEMD2	-0.39	-7.43	-0.56	1.5e-11	Crohn's disease;
TGCT	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.7	-0.39	6.79e-6	Prudent dietary pattern;
TGCT	cis	rs13191362	1.000	rs67025553	chr6:163011552	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7267979	0.816	rs6115094	chr20:25210827	A/G	cg03522245	chr20:25566470	NINL	0.54	5.34	0.43	4.25e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg11366901	chr6:160182831	ACAT2	0.79	5.81	0.46	4.92e-8	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg00149659	chr3:10157352	C3orf10	0.96	6.1	0.48	1.26e-8	Alzheimer's disease;
TGCT	cis	rs1552244	0.554	rs17050704	chr3:10045734	T/C	cg00149659	chr3:10157352	C3orf10	0.69	4.99	0.41	2.03e-6	Alzheimer's disease;
TGCT	cis	rs6582630	0.555	rs11610015	chr12:38508856	A/G	cg13010199	chr12:38710504	ALG10B	0.56	4.55	0.38	1.25e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg02038168	chr22:39784481	NA	-0.62	-5.41	-0.44	3.19e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9814567	1.000	rs7356093	chr3:134238753	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.98	-9.89	-0.66	2.32e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	trans	rs1908814	0.516	rs13252853	chr8:11792974	T/C	cg15556689	chr8:8085844	FLJ10661	0.77	7.37	0.55	2.13e-11	Neuroticism;
TGCT	cis	rs514406	0.505	rs7543239	chr1:53162416	A/G	cg01802117	chr1:53393560	SCP2	-0.42	-4.86	-0.4	3.51e-6	Monocyte count;
TGCT	cis	rs2688608	0.592	rs10824031	chr10:75509273	C/T	cg23231163	chr10:75533350	FUT11	-0.28	-4.86	-0.4	3.51e-6	Inflammatory bowel disease;
TGCT	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg00684032	chr4:1343700	KIAA1530	-0.22	-4.68	-0.39	7.39e-6	Obesity-related traits;
TGCT	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.58	-5.78	-0.46	5.74e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2762353	0.574	rs9467570	chr6:25699283	C/A	cg07061783	chr6:25882402	NA	0.74	7.43	0.55	1.54e-11	Blood metabolite levels;
TGCT	cis	rs931127	0.666	rs7932857	chr11:65457493	A/C	cg27068330	chr11:65405492	SIPA1	-0.63	-6.32	-0.49	4.26e-9	Systemic lupus erythematosus;
TGCT	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg25767906	chr1:53392781	SCP2	-0.46	-5.19	-0.42	8.49e-7	Monocyte count;
TGCT	cis	rs8179	0.700	rs42040	chr7:92245927	C/T	cg15732164	chr7:92237376	CDK6	-0.31	-5.28	-0.43	5.56e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
TGCT	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg22920501	chr2:26401640	FAM59B	-0.8	-6.34	-0.49	3.84e-9	Gut microbiome composition (summer);
TGCT	cis	rs2072499	0.966	rs2842864	chr1:156159217	G/A	cg06970220	chr1:156163860	SLC25A44	0.72	6.3	0.49	4.62e-9	Testicular germ cell tumor;
TGCT	cis	rs7027203	0.576	rs7862149	chr9:96546778	A/G	cg14598338	chr9:96623480	NA	0.49	7.16	0.54	6.37e-11	DNA methylation (variation);
TGCT	cis	rs7772486	0.754	rs6570703	chr6:145957052	C/T	cg13319975	chr6:146136371	FBXO30	-0.5	-4.49	-0.37	1.63e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg13695892	chr22:41940480	POLR3H	-0.91	-9.07	-0.63	2.18e-15	Vitiligo;
TGCT	cis	rs7666738	0.570	rs10032272	chr4:99095601	T/C	cg17366294	chr4:99064904	C4orf37	0.55	5.09	0.42	1.29e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs79387448	0.745	rs17027442	chr2:103164948	A/G	cg09003973	chr2:102972529	NA	-0.98	-6.02	-0.48	1.86e-8	Gut microbiota (bacterial taxa);
TGCT	cis	rs11098499	0.954	rs10017543	chr4:120321420	G/A	cg09307838	chr4:120376055	NA	0.67	6.37	0.5	3.35e-9	Corneal astigmatism;
TGCT	cis	rs4919694	0.667	rs117927731	chr10:105112852	C/A	cg04362960	chr10:104952993	NT5C2	0.94	6.28	0.49	5.14e-9	Arsenic metabolism;
TGCT	cis	rs9926296	0.607	rs2079672	chr16:89884917	A/G	cg08627397	chr16:89984028	MC1R	0.3	4.79	0.4	4.65e-6	Vitiligo;
TGCT	cis	rs13217239	0.646	rs10946897	chr6:26995251	A/C	cg26531700	chr6:26746687	NA	0.68	6.86	0.52	2.83e-10	Schizophrenia;
TGCT	cis	rs6540559	0.673	rs17015218	chr1:209967915	A/G	cg21951975	chr1:209979733	IRF6	0.69	5.42	0.44	2.99e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs9549260	1.000	rs9549260	chr13:41254104	G/T	cg21288729	chr13:41239152	FOXO1	0.75	6.66	0.51	7.91e-10	Red blood cell count;
TGCT	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg09436375	chr6:42928200	GNMT	-0.4	-5.2	-0.42	8.08e-7	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs28595532	0.920	rs115118317	chr4:119736613	C/T	cg14228332	chr4:119757509	SEC24D	1.31	7.06	0.54	1.06e-10	Cannabis dependence symptom count;
TGCT	cis	rs12902680	0.739	rs12101647	chr15:46408825	G/C	cg13605988	chr15:45421612	DUOX1;DUOXA1	0.32	4.5	0.37	1.56e-5	Neuroticism;
TGCT	cis	rs3774830	0.811	rs2654501	chr4:5432416	T/C	cg26943120	chr4:5472116	STK32B	-0.21	-4.73	-0.39	6.12e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs933688	1.000	rs12656350	chr5:90751343	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.99	8.32	0.6	1.36e-13	Smoking behavior;
TGCT	cis	rs1784581	1.000	rs1784581	chr6:162401127	A/C	cg17173639	chr6:162384350	PARK2	-0.5	-9.18	-0.64	1.19e-15	Itch intensity from mosquito bite;
TGCT	cis	rs4788570	0.584	rs4788548	chr16:71655361	A/G	cg06353428	chr16:71660113	MARVELD3	1.44	11.08	0.71	2.91e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs3820068	0.608	rs12091326	chr1:16048005	A/G	cg05660106	chr1:15850417	CASP9	0.73	6.71	0.52	6.18e-10	Systolic blood pressure;
TGCT	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg07747251	chr5:1868357	NA	0.38	5.46	0.44	2.45e-7	Cardiovascular disease risk factors;
TGCT	cis	rs8103278	0.507	rs2041975	chr19:46238555	T/C	cg11657440	chr19:46296263	DMWD	0.74	7.82	0.57	1.92e-12	Coronary artery disease;
TGCT	cis	rs1838472	0.607	rs1997422	chr3:123980608	A/G	cg19008133	chr3:123124015	ADCY5	-0.18	-4.48	-0.37	1.64e-5	Schizophrenia;
TGCT	cis	rs6570726	0.764	rs9386125	chr6:145911677	C/T	cg13319975	chr6:146136371	FBXO30	-0.52	-4.68	-0.39	7.45e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9457247	0.515	rs2757039	chr6:167370353	G/T	cg23791538	chr6:167370224	RNASET2	0.64	6.13	0.48	1.07e-8	Crohn's disease;
TGCT	cis	rs7639513	0.767	rs3806661	chr3:12705855	A/G	cg23032965	chr3:12705835	RAF1	0.77	8.51	0.61	4.81e-14	Itch intensity from mosquito bite;
TGCT	cis	rs7698623	0.850	rs7678318	chr4:88768888	C/T	cg02735620	chr4:88950514	PKD2	-0.44	-4.81	-0.4	4.22e-6	Cardiovascular disease risk factors;
TGCT	cis	rs10191773	0.535	rs11123133	chr2:112965023	G/A	cg07905836	chr2:113190072	RGPD8;RGPD5	0.45	4.66	0.39	7.94e-6	Yeast infection;
TGCT	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg21280719	chr6:42927975	GNMT	-0.37	-4.54	-0.38	1.33e-5	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs9296092	0.517	rs7775914	chr6:33518110	T/C	cg13560919	chr6:33536144	NA	-0.21	-4.74	-0.39	5.87e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs651907	0.557	rs11924013	chr3:101366698	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.34	-7.25	-0.55	3.86e-11	Colorectal cancer;
TGCT	cis	rs2075371	0.829	rs35897155	chr7:134002711	G/A	cg11752832	chr7:134001865	SLC35B4	0.74	6.76	0.52	4.72e-10	Mean platelet volume;
TGCT	cis	rs4720575	1.000	rs4507670	chr7:47097526	C/T	cg00036614	chr7:47093842	NA	-0.21	-5.35	-0.43	4.03e-7	Angiotensin-converting enzyme inhibitor intolerance;
TGCT	cis	rs6882046	0.513	rs618298	chr5:88038390	A/G	cg24804195	chr5:87968844	LOC645323	-0.62	-6.17	-0.48	8.88e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs9467711	1.000	rs34569761	chr6:26334306	A/G	cg03517284	chr6:25882590	NA	-0.87	-4.68	-0.39	7.52e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.08	0.48	1.37e-8	Bipolar disorder;
TGCT	cis	rs9814567	1.000	rs2370642	chr3:134222136	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.96	-9.19	-0.64	1.16e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs4455778	0.659	rs10245633	chr7:49036606	A/G	cg26309511	chr7:48887640	NA	0.44	5.22	0.42	7.26e-7	Lung cancer in never smokers;
TGCT	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg23758822	chr17:41437982	NA	0.72	6.81	0.52	3.77e-10	Menopause (age at onset);
TGCT	cis	rs9911578	1.000	rs1631237	chr17:56734695	A/G	cg05425664	chr17:57184151	TRIM37	-0.64	-6.48	-0.5	1.99e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs910316	1.000	rs876402	chr14:75601862	C/T	cg11812906	chr14:75593930	NEK9	-0.73	-7.44	-0.56	1.45e-11	Height;
TGCT	cis	rs9308731	1.000	rs9308731	chr2:111908262	G/A	cg04202892	chr2:111875749	ACOXL	0.43	4.6	0.38	1.04e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs8141529	0.732	rs2347447	chr22:29179739	C/A	cg02153584	chr22:29168773	CCDC117	0.74	6.25	0.49	5.89e-9	Lymphocyte counts;
TGCT	cis	rs6545883	0.929	rs1186710	chr2:61688727	T/A	cg15711740	chr2:61764176	XPO1	-0.54	-4.93	-0.4	2.56e-6	Tuberculosis;
TGCT	cis	rs17767294	0.611	rs66487884	chr6:28202912	C/G	cg08851530	chr6:28072375	NA	0.87	5.04	0.41	1.58e-6	Parkinson's disease;
TGCT	cis	rs727505	1.000	rs1541416	chr7:124450345	T/C	cg23710748	chr7:124431027	NA	-0.26	-4.5	-0.37	1.54e-5	Lewy body disease;
TGCT	cis	rs6735179	0.607	rs10185594	chr2:1746661	G/A	cg20311673	chr2:1746207	PXDN	0.3	4.77	0.39	5.09e-6	Response to antipsychotic treatment;
TGCT	cis	rs1030877	0.521	rs2576747	chr2:105978676	A/T	cg02079111	chr2:105885981	TGFBRAP1	0.17	5.29	0.43	5.25e-7	Obesity-related traits;
TGCT	cis	rs7666738	0.791	rs1527516	chr4:98967937	A/C	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1008375	0.966	rs12509962	chr4:17680292	G/A	cg18681998	chr4:17616180	MED28	0.88	10.28	0.68	2.7e-18	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs36051895	0.659	rs12349508	chr9:5184222	T/G	cg02405213	chr9:5042618	JAK2	-0.71	-8.93	-0.63	4.79e-15	Pediatric autoimmune diseases;
TGCT	trans	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg17830980	chr10:43048298	ZNF37B	-0.84	-10.72	-0.69	2.25e-19	Extrinsic epigenetic age acceleration;
TGCT	cis	rs2153535	0.547	rs9505475	chr6:8542890	A/G	cg07606381	chr6:8435919	SLC35B3	0.56	5.16	0.42	9.56e-7	Motion sickness;
TGCT	cis	rs6121246	1.000	rs6121246	chr20:30433352	C/T	cg13852791	chr20:30311386	BCL2L1	0.76	5.67	0.45	9.7e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs4566357	1.000	rs4566357	chr2:227922015	C/T	cg11843606	chr2:227700838	RHBDD1	0.51	4.56	0.38	1.19e-5	Coronary artery disease;
TGCT	cis	rs3749237	0.595	rs6797765	chr3:49423976	A/G	cg07636037	chr3:49044803	WDR6	0.64	6.04	0.48	1.63e-8	Resting heart rate;
TGCT	cis	rs2945232	1	rs2945232	chr8:8098038	T/C	cg15556689	chr8:8085844	FLJ10661	0.87	8.84	0.62	7.94e-15	Schizophrenia;
TGCT	cis	rs36051895	0.623	rs10283467	chr9:5244356	C/G	cg02405213	chr9:5042618	JAK2	0.69	8.13	0.59	3.78e-13	Pediatric autoimmune diseases;
TGCT	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg03934478	chr11:495069	RNH1	0.35	5.82	0.46	4.66e-8	Body mass index;
TGCT	cis	rs9604529	0.532	rs41291213	chr13:114774991	C/T	cg13259177	chr13:114761607	RASA3	-0.29	-5.02	-0.41	1.79e-6	Response to tocilizumab in rheumatoid arthritis;
TGCT	cis	rs28595532	0.920	rs116668854	chr4:119707642	A/G	cg14228332	chr4:119757509	SEC24D	1.0	4.69	0.39	7.01e-6	Cannabis dependence symptom count;
TGCT	cis	rs35146811	0.735	rs1727140	chr7:99815399	T/A	cg22906224	chr7:99728672	NA	-0.49	-4.45	-0.37	1.88e-5	Coronary artery disease;
TGCT	cis	rs2820315	1.000	rs2820316	chr1:201811761	C/T	cg12730843	chr1:201915899	LMOD1	-0.27	-4.77	-0.39	4.98e-6	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
TGCT	cis	rs2997447	0.846	rs2997446	chr1:26388241	C/G	cg19633962	chr1:26362018	EXTL1	-0.68	-4.7	-0.39	6.68e-6	QRS complex (12-leadsum);
TGCT	cis	rs3091242	0.933	rs9645452	chr1:25668326	C/T	cg00786635	chr1:25594202	NA	-0.58	-6.02	-0.48	1.87e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs151997	0.962	rs27256	chr5:50190264	G/C	cg06027927	chr5:50259733	NA	0.47	4.83	0.4	4e-6	Callous-unemotional behaviour;
TGCT	cis	rs10876993	0.890	rs4760165	chr12:58063801	C/T	cg15848620	chr12:58087721	OS9	-0.75	-6.13	-0.48	1.09e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs17376456	1.000	rs13181660	chr5:93533658	A/G	cg25358565	chr5:93447407	FAM172A	0.96	7.95	0.58	1.01e-12	Diabetic retinopathy;
TGCT	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg25036284	chr2:26402008	FAM59B	-0.65	-5.18	-0.42	8.59e-7	Gut microbiome composition (summer);
TGCT	cis	rs1348850	0.914	rs4893957	chr2:178380409	A/G	cg22681709	chr2:178499509	PDE11A	-0.35	-4.55	-0.38	1.27e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg22535103	chr8:58192502	C8orf71	-0.42	-4.72	-0.39	6.22e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs616402	0.527	rs2274985	chr1:10573867	G/A	cg17425144	chr1:10567563	PEX14	0.55	8.08	0.59	4.81e-13	Breast size;
TGCT	cis	rs12579753	0.956	rs11115039	chr12:82217338	A/C	cg07988820	chr12:82153109	PPFIA2	-0.65	-6.81	-0.52	3.72e-10	Resting heart rate;
TGCT	cis	rs72843506	0.591	rs75925580	chr17:20115013	G/T	cg18979559	chr17:20280153	CCDC144C	-0.65	-4.89	-0.4	3.07e-6	Schizophrenia;
TGCT	cis	rs13256369	0.901	rs4841015	chr8:8567140	C/G	cg18904891	chr8:8559673	CLDN23	0.59	5.52	0.44	1.93e-7	Obesity-related traits;
TGCT	cis	rs1348850	0.872	rs10165785	chr2:178293295	C/T	cg22681709	chr2:178499509	PDE11A	-0.38	-4.83	-0.4	3.96e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs2153535	0.580	rs6905237	chr6:8471790	A/T	cg07606381	chr6:8435919	SLC35B3	0.54	5.07	0.41	1.43e-6	Motion sickness;
TGCT	cis	rs4766566	0.704	rs10849931	chr12:111753808	T/C	cg10833066	chr12:111807467	FAM109A	0.37	6.47	0.5	2.01e-9	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
TGCT	cis	rs9972944	0.729	rs12939140	chr17:63777249	T/A	cg07283582	chr17:63770753	CCDC46	0.26	5.05	0.41	1.53e-6	Total body bone mineral density;
TGCT	cis	rs3008870	1.000	rs2065000	chr1:67468124	G/C	cg03991309	chr1:68237761	GNG12	-0.28	-4.69	-0.39	6.98e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs826838	0.935	rs1719855	chr12:39127242	C/T	cg26384229	chr12:38710491	ALG10B	-0.86	-7.72	-0.57	3.37e-12	Heart rate;
TGCT	cis	rs1018836	0.923	rs7007102	chr8:91629730	T/A	cg16814680	chr8:91681699	NA	-0.85	-9.28	-0.64	7e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2836974	0.544	rs8128919	chr21:40711862	C/T	cg17971929	chr21:40555470	PSMG1	0.61	5.57	0.45	1.51e-7	Cognitive function;
TGCT	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	5.45	0.44	2.66e-7	Height;
TGCT	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg11764359	chr7:65958608	NA	-0.55	-5.08	-0.42	1.34e-6	Aortic root size;
TGCT	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs77216612	0.835	rs56692845	chr12:12887811	C/T	cg04607235	chr12:12878440	APOLD1	-0.97	-8.51	-0.61	4.81e-14	Lymphocyte counts;
TGCT	cis	rs13191362	1.000	rs68045643	chr6:163029709	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.65	5.32	0.43	4.7e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs9913156	0.793	rs55782417	chr17:4562845	G/A	cg23387401	chr17:4582204	PELP1	0.31	4.57	0.38	1.14e-5	Lymphocyte counts;
TGCT	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg10862848	chr6:42927986	GNMT	-0.38	-4.7	-0.39	6.7e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs7599312	0.534	rs2128321	chr2:213405276	G/T	cg20637307	chr2:213403960	ERBB4	0.88	11.47	0.72	3.32e-21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs3733585	0.699	rs28837683	chr4:9959808	C/T	cg11266682	chr4:10021025	SLC2A9	-0.57	-7.47	-0.56	1.23e-11	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs59107033	0.559	rs62262395	chr3:123105437	C/A	cg04890266	chr3:123102914	ADCY5	-0.49	-7.87	-0.58	1.48e-12	Lymphocyte counts;
TGCT	cis	rs9948	0.655	rs62156212	chr2:97399096	C/T	cg01990225	chr2:97406019	LMAN2L	-1.02	-5.19	-0.42	8.43e-7	Erectile dysfunction and prostate cancer treatment;
TGCT	trans	rs7726839	0.540	rs72703095	chr5:601789	T/C	cg25482853	chr8:67687455	SGK3	1.27	10.56	0.69	5.48e-19	Obesity-related traits;
TGCT	cis	rs7714584	1.000	rs1816256	chr5:150272853	T/C	cg22134413	chr5:150180641	NA	0.83	6.27	0.49	5.47e-9	Crohn's disease;
TGCT	cis	rs514406	0.763	rs9988539	chr1:53213884	T/C	cg08736216	chr1:53307985	ZYG11A	0.25	4.77	0.39	4.98e-6	Monocyte count;
TGCT	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg03264133	chr6:25882463	NA	-0.61	-6.51	-0.5	1.68e-9	Blood metabolite levels;
TGCT	trans	rs561341	1.000	rs508192	chr17:30315147	C/T	cg20587970	chr11:113659929	NA	1.02	12.02	0.73	1.52e-22	Hip circumference adjusted for BMI;
TGCT	cis	rs61990749	0.597	rs176944	chr14:78176211	G/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.63	-4.62	-0.38	9.34e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs7819412	0.595	rs10106914	chr8:10987651	T/G	cg21775007	chr8:11205619	TDH	-0.55	-5.07	-0.41	1.41e-6	Triglycerides;
TGCT	cis	rs3845702	0.866	rs3914458	chr2:180862606	A/G	cg01881094	chr2:180872142	CWC22	-0.68	-6.11	-0.48	1.16e-8	Schizophrenia;
TGCT	cis	rs17767294	0.708	rs115714358	chr6:27964332	A/C	cg08851530	chr6:28072375	NA	1.56	7.22	0.54	4.47e-11	Parkinson's disease;
TGCT	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.36	0.55	2.25e-11	Prudent dietary pattern;
TGCT	cis	rs231513	0.954	rs425135	chr17:41984517	A/C	cg26893861	chr17:41843967	DUSP3	-0.73	-5.35	-0.43	4.16e-7	Cognitive function;
TGCT	cis	rs10788264	0.561	rs7916839	chr10:124062223	C/T	cg09507567	chr10:124027408	NA	0.38	5.42	0.44	2.99e-7	Total body bone mineral density;
TGCT	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg05872129	chr22:39784769	NA	-1.02	-11.22	-0.71	1.32e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs1348850	0.634	rs1534304	chr2:178489264	C/T	cg19192590	chr2:178524533	PDE11A	0.51	4.8	0.4	4.54e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs6582630	0.502	rs10880388	chr12:38401341	A/T	cg13010199	chr12:38710504	ALG10B	0.59	4.68	0.39	7.35e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs3858526	0.959	rs10838795	chr11:5920721	A/G	cg13902645	chr11:5959945	NA	0.42	4.74	0.39	5.76e-6	DNA methylation (variation);
TGCT	cis	rs10992471	0.756	rs3758229	chr9:95078852	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.61	-6.23	-0.49	6.69e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs10089	1.000	rs2054444	chr5:127493206	A/C	cg19767477	chr5:127420684	SLC12A2	0.44	4.63	0.38	9.22e-6	Ileal carcinoids;
TGCT	cis	rs4523957	0.651	rs9895342	chr17:2081647	T/C	cg16513277	chr17:2031491	SMG6	-0.2	-4.64	-0.38	8.83e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs10504229	1.000	rs79311869	chr8:58195546	T/C	cg22535103	chr8:58192502	C8orf71	-0.39	-4.62	-0.38	9.61e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2657888	0.528	rs12304519	chr12:56874522	C/A	cg23002907	chr12:56915593	RBMS2	-0.39	-4.82	-0.4	4.05e-6	Adiponectin levels;
TGCT	cis	rs6500602	0.727	rs8051389	chr16:4570570	C/T	cg08645402	chr16:4508243	NA	0.19	5.25	0.43	6.32e-7	Schizophrenia;
TGCT	cis	rs9810089	0.676	rs526574	chr3:136103349	A/G	cg12473912	chr3:136751656	NA	0.37	5.17	0.42	8.93e-7	Gestational age at birth (child effect);
TGCT	cis	rs10193935	0.901	rs72800020	chr2:42655615	A/G	cg27598129	chr2:42591480	NA	-0.39	-5.5	-0.44	2.12e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4727027	0.866	rs12666477	chr7:148812322	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	4.6	0.38	1.04e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs910316	1.000	rs8003506	chr14:75586288	A/C	cg08847533	chr14:75593920	NEK9	-0.95	-11.03	-0.7	3.86e-20	Height;
TGCT	cis	rs317865	1.000	rs4635814	chr4:16151148	G/A	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.72	4.55	0.38	1.24e-5	Kidney disease (early stage) in type 1 diabetes;
TGCT	cis	rs858239	0.508	rs10242104	chr7:23220450	C/T	cg05602783	chr7:23145260	KLHL7	-0.7	-5.57	-0.45	1.52e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs4149423	1.000	rs12620050	chr2:108919798	G/A	cg06795125	chr2:108905320	SULT1C2	-0.46	-6.92	-0.53	2.11e-10	Lobe size;
TGCT	cis	rs8014204	0.836	rs7154256	chr14:75252587	A/G	cg06637938	chr14:75390232	RPS6KL1	0.72	6.91	0.53	2.31e-10	Caffeine consumption;
TGCT	cis	rs1215050	0.740	rs11097580	chr4:98767255	C/A	cg05340658	chr4:99064831	C4orf37	0.44	5.51	0.44	2.01e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7246657	0.943	rs10420430	chr19:37894194	C/G	cg18154014	chr19:37997991	ZNF793	0.96	6.69	0.52	6.7e-10	Coronary artery calcification;
TGCT	cis	rs4455778	0.629	rs6972830	chr7:49022339	G/A	cg26309511	chr7:48887640	NA	-0.43	-5.07	-0.41	1.4e-6	Lung cancer in never smokers;
TGCT	cis	rs3091242	0.935	rs4233043	chr1:25765483	A/G	cg23205692	chr1:25664452	TMEM50A	0.47	4.88	0.4	3.15e-6	Erythrocyte sedimentation rate;
TGCT	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.15	0.82	2.71e-32	Prudent dietary pattern;
TGCT	cis	rs1420338	0.867	rs7795950	chr7:34161715	A/G	cg01275685	chr7:34179230	BMPER	-0.26	-4.87	-0.4	3.28e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs8068544	0.818	rs7209012	chr17:40161323	C/T	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.08	-5.02	-0.41	1.75e-6	Reticulocyte fraction of red cells;Reticulocyte count;
TGCT	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg05890377	chr2:74357713	NA	0.46	5.35	0.43	4.06e-7	Gestational age at birth (maternal effect);
TGCT	cis	rs9549367	0.636	rs486407	chr13:113833499	G/A	cg00898013	chr13:113819073	PROZ	0.55	7.34	0.55	2.43e-11	Platelet distribution width;
TGCT	cis	rs9291683	0.530	rs17246501	chr4:9985710	A/C	cg00071950	chr4:10020882	SLC2A9	0.64	8.17	0.59	3.09e-13	Bone mineral density;
TGCT	cis	rs9399135	0.935	rs4273704	chr6:135297520	G/T	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.36e-6	Red blood cell count;
TGCT	cis	rs11098499	1.000	rs35643470	chr4:120184948	T/C	cg24670566	chr4:120433619	PDE5A	0.23	4.58	0.38	1.1e-5	Corneal astigmatism;
TGCT	trans	rs57221529	0.766	rs72703075	chr5:592819	C/T	cg25482853	chr8:67687455	SGK3	1.26	10.43	0.68	1.17e-18	Lung disease severity in cystic fibrosis;
TGCT	cis	rs9399135	0.967	rs1041480	chr6:135373076	G/T	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.21e-6	Red blood cell count;
TGCT	cis	rs9916302	0.851	rs612209	chr17:37442713	G/C	cg07936489	chr17:37558343	FBXL20	0.62	4.91	0.4	2.85e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs1580019	0.563	rs34201720	chr7:32568935	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.57	4.95	0.41	2.34e-6	Cognitive ability;
TGCT	cis	rs11098499	0.954	rs13151285	chr4:120314741	C/A	cg09307838	chr4:120376055	NA	0.65	6.39	0.5	3.02e-9	Corneal astigmatism;
TGCT	cis	rs6964587	0.967	rs4626516	chr7:91807153	G/C	cg22709100	chr7:91322751	NA	0.29	4.62	0.38	9.6e-6	Breast cancer;
TGCT	cis	rs425277	1.000	rs381664	chr1:2088104	A/G	cg24578937	chr1:2090814	PRKCZ	0.32	8.19	0.59	2.64e-13	Height;
TGCT	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.31	0.43	4.9e-7	Prudent dietary pattern;
TGCT	cis	rs7267979	0.932	rs6107052	chr20:25530838	G/A	cg14121845	chr20:25566513	NINL	0.49	5.36	0.43	3.83e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11112613	0.713	rs12321309	chr12:105943263	T/G	cg03607813	chr12:105948248	NA	0.47	5.45	0.44	2.59e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	cis	rs2274471	0.645	rs3824432	chr9:5091675	G/A	cg03390472	chr9:5043263	JAK2	-0.29	-4.63	-0.38	8.95e-6	Crohn's disease;
TGCT	cis	rs931127	0.719	rs11227259	chr11:65459404	T/C	cg27068330	chr11:65405492	SIPA1	-0.63	-6.32	-0.49	4.26e-9	Systemic lupus erythematosus;
TGCT	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs4654899	0.929	rs7552999	chr1:21314454	T/C	cg01072550	chr1:21505969	NA	-0.5	-7.94	-0.58	1.04e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs1375194	0.606	rs935625	chr2:33811516	C/G	cg04131969	chr2:33951647	MYADML	-0.58	-5.07	-0.41	1.41e-6	Response to antidepressants in depression;
TGCT	cis	rs61990749	0.544	rs7151211	chr14:78151901	C/A	cg23188588	chr14:78226832	SNW1;C14orf178	-0.66	-4.69	-0.39	7.04e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs6940638	0.956	rs3922717	chr6:27030924	A/G	cg16898833	chr6:26189333	HIST1H4D	0.71	5.34	0.43	4.2e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.716	rs13108535	chr4:99046324	A/G	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6977660	0.714	rs12700077	chr7:19791607	A/G	cg07541023	chr7:19748670	TWISTNB	-0.8	-4.47	-0.37	1.74e-5	Thyroid stimulating hormone;
TGCT	cis	rs2921036	0.529	rs2979192	chr8:8338147	C/T	cg08975724	chr8:8085496	FLJ10661	0.55	4.91	0.4	2.79e-6	Neuroticism;
TGCT	cis	rs2242194	0.816	rs6671688	chr1:154994265	T/C	cg06418219	chr1:154948305	SHC1;CKS1B	-0.56	-5.18	-0.42	8.76e-7	Schizophrenia;
TGCT	cis	rs3820068	0.705	rs4646092	chr1:15821673	C/T	cg05660106	chr1:15850417	CASP9	1.16	14.82	0.8	3.11e-29	Systolic blood pressure;
TGCT	trans	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg27523141	chr10:43048294	ZNF37B	0.73	8.51	0.61	4.68e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs67478160	0.609	rs6576003	chr14:104291330	C/A	cg26031613	chr14:104095156	KLC1	-0.63	-6.35	-0.5	3.78e-9	Schizophrenia;
TGCT	cis	rs2456568	0.548	rs4753113	chr11:93660974	G/A	cg17595323	chr11:93583763	C11orf90	-0.42	-5.26	-0.43	6.2e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs1059312	0.808	rs900982	chr12:129304369	G/A	cg09035930	chr12:129282057	SLC15A4	0.58	10.9	0.7	7.96e-20	Systemic lupus erythematosus;
TGCT	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg02725872	chr8:58115012	NA	-0.38	-4.99	-0.41	1.98e-6	Developmental language disorder (linguistic errors);
TGCT	trans	rs7819412	0.838	rs3021494	chr8:10983534	A/G	cg06636001	chr8:8085503	FLJ10661	-0.75	-7.09	-0.54	9.09e-11	Triglycerides;
TGCT	cis	rs910316	0.810	rs77939209	chr14:75670070	A/G	cg08847533	chr14:75593920	NEK9	-0.91	-10.07	-0.67	8.51e-18	Height;
TGCT	cis	rs936229	0.749	rs4886633	chr15:75178207	G/A	cg10253484	chr15:75165896	SCAMP2	-0.76	-6.29	-0.49	4.87e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
TGCT	cis	rs4851266	1.000	rs999052	chr2:100836106	C/T	cg07810366	chr2:100720526	AFF3	-0.39	-5.73	-0.46	7.19e-8	Educational attainment;
TGCT	cis	rs6540559	0.673	rs7511996	chr1:210018473	C/A	cg21951975	chr1:209979733	IRF6	0.63	4.76	0.39	5.36e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs7681440	0.647	rs1442136	chr4:90819026	C/T	cg10208370	chr4:90758469	SNCA	0.57	5.32	0.43	4.73e-7	Dementia with Lewy bodies;
TGCT	cis	rs13256369	0.708	rs10903310	chr8:8589687	A/C	cg17143192	chr8:8559678	CLDN23	-0.58	-4.93	-0.4	2.56e-6	Obesity-related traits;
TGCT	cis	rs66573146	1.000	rs56074877	chr4:6990374	C/T	cg05069807	chr4:6945702	TBC1D14	0.31	4.83	0.4	3.91e-6	Granulocyte percentage of myeloid white cells;
TGCT	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg22968622	chr17:43663579	NA	-1.24	-11.01	-0.7	4.49e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7260538	0.808	rs707265	chr19:41524087	A/G	cg27089200	chr19:41531976	NA	0.46	5.98	0.47	2.24e-8	DDT metabolite (p,p'-DDE levels);
TGCT	cis	rs67311347	1.000	rs11914297	chr3:40410070	T/C	cg13683864	chr3:40499215	RPL14	-1.12	-11.9	-0.73	2.94e-22	Renal cell carcinoma;
TGCT	trans	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg25482853	chr8:67687455	SGK3	1.21	10.33	0.68	2.02e-18	Lung disease severity in cystic fibrosis;
TGCT	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.48	-4.49	-0.37	1.61e-5	Bipolar disorder;
TGCT	cis	rs11249608	0.548	rs6894076	chr5:178449813	T/C	cg01312482	chr5:178451176	ZNF879	-0.56	-5.5	-0.44	2.09e-7	Pubertal anthropometrics;
TGCT	cis	rs3125734	0.671	rs3852406	chr10:64015162	T/C	cg19640130	chr10:64028056	RTKN2	-0.39	-5.12	-0.42	1.15e-6	Rheumatoid arthritis;
TGCT	cis	rs858239	0.601	rs2068459	chr7:23154313	A/C	cg05602783	chr7:23145260	KLHL7	-0.71	-6.11	-0.48	1.2e-8	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs12142240	0.698	rs41294478	chr1:46818442	G/A	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs1865760	0.566	rs9379821	chr6:26054268	A/C	cg17042849	chr6:26104293	HIST1H4C	-0.62	-5.41	-0.44	3.18e-7	Height;
TGCT	cis	rs3733585	0.699	rs6449202	chr4:9974043	T/C	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.7	-0.52	6.51e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs67478160	0.571	rs1155751	chr14:104286547	C/G	cg26031613	chr14:104095156	KLC1	-0.63	-6.37	-0.5	3.33e-9	Schizophrenia;
TGCT	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg13206674	chr6:150067644	NUP43	0.51	4.47	0.37	1.76e-5	Lung cancer;
TGCT	cis	rs4689388	0.890	rs4688991	chr4:6302220	C/G	cg14416269	chr4:6271139	WFS1	0.41	5.51	0.44	1.98e-7	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs3774830	0.869	rs11737487	chr4:5446673	G/A	cg26943120	chr4:5472116	STK32B	0.22	4.76	0.39	5.33e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg08736216	chr1:53307985	ZYG11A	0.24	4.51	0.38	1.45e-5	Monocyte count;
TGCT	cis	rs1670533	0.932	rs9992925	chr4:1050909	A/T	cg20887711	chr4:1340912	KIAA1530	0.7	5.66	0.45	9.77e-8	Recombination rate (females);
TGCT	cis	rs9457247	0.967	rs433191	chr6:167409662	T/A	cg23791538	chr6:167370224	RNASET2	-0.49	-4.96	-0.41	2.3e-6	Crohn's disease;
TGCT	cis	rs6665290	0.935	rs6704144	chr1:227201030	C/G	cg10327440	chr1:227177885	CDC42BPA	-0.95	-17.36	-0.84	5.48e-35	Myeloid white cell count;
TGCT	cis	rs1171582	0.545	rs9943397	chr10:61522319	G/A	cg23572703	chr10:62241191	NA	-0.27	-4.64	-0.38	8.55e-6	Alopecia areata;
TGCT	cis	rs7463256	0.966	rs6557643	chr8:23097802	A/G	cg14349055	chr8:23104193	CHMP7	-1.13	-17.63	-0.85	1.41e-35	Attention deficit hyperactivity disorder;
TGCT	cis	rs4722585	0.533	rs2049843	chr7:26196963	G/A	cg07876897	chr7:26191696	NFE2L3	0.4	5.44	0.44	2.75e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
TGCT	cis	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg08975724	chr8:8085496	FLJ10661	0.52	4.7	0.39	6.68e-6	Mood instability;
TGCT	cis	rs7772486	0.727	rs12190966	chr6:146146820	T/G	cg23711669	chr6:146136114	FBXO30	0.9	10.15	0.67	5.45e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4654899	0.897	rs1021077	chr1:21106016	A/G	cg01072550	chr1:21505969	NA	-0.49	-7.89	-0.58	1.37e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs514406	0.893	rs6588445	chr1:53424928	T/C	cg01802117	chr1:53393560	SCP2	0.4	4.86	0.4	3.44e-6	Monocyte count;
TGCT	cis	rs7698623	0.850	rs6821260	chr4:88787439	T/C	cg02735620	chr4:88950514	PKD2	-0.45	-4.79	-0.39	4.73e-6	Cardiovascular disease risk factors;
TGCT	cis	rs2842992	0.830	rs2842974	chr6:160159034	C/T	cg11366901	chr6:160182831	ACAT2	1.03	6.92	0.53	2.14e-10	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs7666738	0.791	rs34088022	chr4:99001508	G/T	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1055129	0.560	rs9891076	chr17:73911715	C/T	cg08125733	chr17:73851984	WBP2	0.57	5.25	0.43	6.4e-7	White matter hyperintensity burden;
TGCT	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.47	0.56	1.28e-11	Prudent dietary pattern;
TGCT	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.55	4.92	0.4	2.74e-6	Prudent dietary pattern;
TGCT	cis	rs514406	0.929	rs12145105	chr1:53340564	T/C	cg16325326	chr1:53192061	ZYG11B	0.59	6.78	0.52	4.32e-10	Monocyte count;
TGCT	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg23248424	chr5:179741104	GFPT2	-0.37	-6.97	-0.53	1.69e-10	Height;
TGCT	cis	rs9303401	0.614	rs34941454	chr17:57102742	T/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.63	5.82	0.46	4.8e-8	Cognitive test performance;
TGCT	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg08859206	chr1:53392774	SCP2	-0.42	-6.4	-0.5	2.95e-9	Monocyte count;
TGCT	cis	rs11167764	0.945	rs6878397	chr5:141474012	A/G	cg23435118	chr5:141488016	NDFIP1	-0.28	-4.58	-0.38	1.1e-5	Crohn's disease;
TGCT	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.01	0.41	1.86e-6	Prudent dietary pattern;
TGCT	cis	rs6121246	0.567	rs6120890	chr20:30207659	T/G	cg21427119	chr20:30132790	HM13	-0.39	-5.61	-0.45	1.25e-7	Mean corpuscular hemoglobin;
TGCT	cis	rs231513	0.954	rs231516	chr17:41963205	G/A	cg26893861	chr17:41843967	DUSP3	-0.71	-5.21	-0.42	7.57e-7	Cognitive function;
TGCT	cis	rs7647973	1.000	rs9871024	chr3:49554241	T/C	cg05785598	chr3:49045655	WDR6	-0.38	-4.6	-0.38	1.02e-5	Menarche (age at onset);
TGCT	cis	rs459571	0.920	rs2520094	chr9:136919985	A/T	cg14405625	chr9:136855902	VAV2	-0.33	-5.01	-0.41	1.81e-6	Platelet distribution width;
TGCT	cis	rs2456568	0.531	rs7105060	chr11:93661268	C/A	cg17595323	chr11:93583763	C11orf90	-0.42	-5.26	-0.43	6.25e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs514406	0.560	rs1889033	chr1:53211887	A/G	cg16325326	chr1:53192061	ZYG11B	-0.9	-13.21	-0.76	2.07e-25	Monocyte count;
TGCT	cis	rs35306767	0.953	rs11253520	chr10:975961	C/G	cg26597838	chr10:835615	NA	-0.38	-5.07	-0.41	1.44e-6	Eosinophil percentage of granulocytes;
TGCT	cis	rs2239547	0.522	rs9311485	chr3:52987645	T/G	cg10802521	chr3:52805072	NEK4	0.64	6.06	0.48	1.48e-8	Schizophrenia;
TGCT	cis	rs1878931	0.668	rs11643983	chr16:3438865	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.97	11.92	0.73	2.66e-22	Body mass index (adult);
TGCT	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg14820908	chr5:178986412	RUFY1	0.48	4.83	0.4	3.96e-6	Lung cancer;
TGCT	cis	rs1215050	0.605	rs10005628	chr4:98606732	A/T	cg05340658	chr4:99064831	C4orf37	0.41	4.84	0.4	3.72e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs10501293	0.746	rs7924326	chr11:43031752	A/G	cg03447554	chr11:43094025	NA	0.47	6.85	0.52	3.07e-10	Cognitive performance;
TGCT	cis	rs2153535	0.580	rs2327067	chr6:8518482	C/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.01	0.41	1.86e-6	Motion sickness;
TGCT	cis	rs4285028	0.948	rs12488334	chr3:121702526	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.77	-6.5	-0.5	1.78e-9	Multiple sclerosis;
TGCT	cis	rs7582180	0.652	rs11123830	chr2:100974747	A/G	cg14675211	chr2:100938903	LONRF2	0.49	4.65	0.39	8.21e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg04772025	chr11:68637568	NA	0.6	6.77	0.52	4.48e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9611565	0.918	rs2281333	chr22:41749630	T/C	cg03806693	chr22:41940476	POLR3H	-1.01	-10.96	-0.7	5.96e-20	Vitiligo;
TGCT	cis	rs7267979	0.714	rs2474763	chr20:25241295	A/G	cg03522245	chr20:25566470	NINL	0.48	4.59	0.38	1.06e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6424115	0.743	rs2229580	chr1:24201109	C/T	cg15997130	chr1:24165203	NA	0.85	9.25	0.64	8.02e-16	Immature fraction of reticulocytes;
TGCT	cis	rs6547741	0.844	rs55826602	chr2:27863452	A/G	cg27432699	chr2:27873401	GPN1	-0.24	-6.05	-0.48	1.57e-8	Oral cavity cancer;
TGCT	cis	rs9733	0.596	rs72702580	chr1:150691285	A/T	cg04414720	chr1:150670196	GOLPH3L	0.37	4.91	0.4	2.76e-6	Tonsillectomy;
TGCT	cis	rs2354432	1.000	rs2354432	chr1:146693229	C/T	cg25205988	chr1:146714368	CHD1L	1.33	8.46	0.6	6.33e-14	Mitochondrial DNA levels;
TGCT	cis	rs13022357	1.000	rs12692544	chr2:160082354	C/T	cg00168785	chr2:160142643	WDSUB1	0.46	4.6	0.38	1.04e-5	Sudden cardiac arrest;
TGCT	cis	rs4972806	0.776	rs2072589	chr2:177042871	C/T	cg03152288	chr2:177042942	NA	0.66	5.75	0.46	6.5e-8	IgG glycosylation;
TGCT	cis	rs208520	1.000	rs12212063	chr6:66985148	C/A	cg07460842	chr6:66804631	NA	0.75	6.49	0.5	1.86e-9	Exhaled nitric oxide output;
TGCT	cis	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg15556689	chr8:8085844	FLJ10661	0.65	5.71	0.46	7.85e-8	Mood instability;
TGCT	cis	rs9346649	0.616	rs1873337	chr6:168492160	T/G	cg02770688	chr6:168491649	NA	0.34	6.06	0.48	1.48e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
TGCT	cis	rs2204008	0.583	rs12820907	chr12:37990931	T/C	cg26384229	chr12:38710491	ALG10B	0.85	7.77	0.57	2.56e-12	Bladder cancer;
TGCT	cis	rs10131894	0.575	rs8006147	chr14:75430033	G/A	cg08847533	chr14:75593920	NEK9	0.64	5.88	0.47	3.49e-8	Coronary artery disease;
TGCT	cis	rs6754311	0.551	rs313526	chr2:136445526	C/T	cg07169764	chr2:136633963	MCM6	0.69	6.28	0.49	5.13e-9	Mosquito bite size;
TGCT	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg03188948	chr7:1209495	NA	0.45	5.83	0.46	4.45e-8	Longevity;Endometriosis;
TGCT	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.46	-5.81	-0.46	4.9e-8	Alzheimer's disease;
TGCT	cis	rs12497850	1.000	rs4858828	chr3:48724811	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.44	-6.06	-0.48	1.52e-8	Parkinson's disease;
TGCT	cis	rs8033133	0.602	rs12439159	chr15:25323874	T/C	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	-0.24	-4.82	-0.4	4.2e-6	Blood osmolality (transformed sodium);
TGCT	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg00149659	chr3:10157352	C3orf10	0.91	5.89	0.47	3.32e-8	Alzheimer's disease;
TGCT	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg24503407	chr1:205819492	PM20D1	0.58	8.13	0.59	3.84e-13	Menarche (age at onset);
TGCT	cis	rs1008375	0.966	rs11733730	chr4:17625209	G/C	cg18681998	chr4:17616180	MED28	1.08	12.13	0.74	8.24e-23	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9443645	0.869	rs9443621	chr6:79576499	A/G	cg09184832	chr6:79620586	NA	-0.48	-5.17	-0.42	9.23e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs151997	0.962	rs27612	chr5:50179120	G/A	cg06027927	chr5:50259733	NA	0.46	4.61	0.38	9.69e-6	Callous-unemotional behaviour;
TGCT	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg10253484	chr15:75165896	SCAMP2	-0.58	-5.21	-0.42	7.66e-7	Breast cancer;
TGCT	cis	rs1153858	1.000	rs60476496	chr15:45713801	C/T	cg26924012	chr15:45694286	SPATA5L1	1.1	15.34	0.81	2.01e-30	Homoarginine levels;
TGCT	cis	rs2251381	0.778	rs2245021	chr21:30546841	C/T	cg24692254	chr21:30365293	RNF160	0.74	7.43	0.56	1.52e-11	Selective IgA deficiency;
TGCT	cis	rs2456568	0.543	rs4144616	chr11:93621900	A/G	cg17595323	chr11:93583763	C11orf90	-0.48	-6.48	-0.5	1.98e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs2274273	0.745	rs748017	chr14:55542300	A/G	cg01923255	chr14:55878535	KIAA0831	0.56	4.57	0.38	1.15e-5	Protein biomarker;
TGCT	cis	rs2859741	0.967	rs592520	chr1:37513503	G/C	cg09363841	chr1:37513479	NA	-0.21	-4.91	-0.4	2.77e-6	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
TGCT	cis	rs6688613	1.000	rs17551703	chr1:166957879	T/C	cg07049167	chr1:166818506	POGK	0.21	4.52	0.38	1.43e-5	Refractive astigmatism;
TGCT	cis	rs35306767	0.903	rs12764024	chr10:922861	A/G	cg26597838	chr10:835615	NA	0.74	10.2	0.68	4.21e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs1218582	0.741	rs705094	chr1:154917314	G/A	cg09359103	chr1:154839909	KCNN3	-0.64	-11.84	-0.73	4.25e-22	Prostate cancer;
TGCT	cis	rs826838	0.586	rs10785554	chr12:38628749	T/A	cg26384229	chr12:38710491	ALG10B	0.55	5.0	0.41	1.93e-6	Heart rate;
TGCT	cis	rs2760061	0.819	rs708112	chr1:228192452	G/A	cg02753203	chr1:228287806	NA	0.3	5.71	0.46	7.95e-8	Diastolic blood pressure;
TGCT	cis	rs12220238	0.915	rs10824074	chr10:75876457	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.91	7.94	0.58	1.02e-12	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs5769765	0.862	rs56377703	chr22:50306940	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.22	-12.72	-0.75	3.08e-24	Schizophrenia;
TGCT	trans	rs1814175	0.817	rs1996982	chr11:49972619	G/T	cg03929089	chr4:120376271	NA	-0.72	-8.53	-0.61	4.24e-14	Height;
TGCT	cis	rs35306767	0.903	rs12250936	chr10:870109	C/T	cg20503657	chr10:835505	NA	0.7	9.83	0.66	3.22e-17	Eosinophil percentage of granulocytes;
TGCT	cis	rs682748	1.000	rs167213	chr5:17160112	A/G	cg23987134	chr5:17158319	LOC285696	0.23	5.35	0.43	4.18e-7	Hippocampal atrophy;
TGCT	cis	rs2404602	0.692	rs1471780	chr15:77026526	T/C	cg22467129	chr15:76604101	ETFA	-0.45	-5.11	-0.42	1.2e-6	Blood metabolite levels;
TGCT	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg10560079	chr2:191398806	TMEM194B	0.37	5.33	0.43	4.5e-7	Pulse pressure;
TGCT	cis	rs858239	0.541	rs4624924	chr7:23168843	A/C	cg05602783	chr7:23145260	KLHL7	-0.65	-5.48	-0.44	2.32e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs10089	1.000	rs1842006	chr5:127508687	G/A	cg19767477	chr5:127420684	SLC12A2	-0.44	-4.56	-0.38	1.2e-5	Ileal carcinoids;
TGCT	cis	rs6570726	0.935	rs377130	chr6:145836632	C/T	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs208520	1.000	rs208529	chr6:66957549	T/C	cg07460842	chr6:66804631	NA	-0.82	-7.44	-0.56	1.46e-11	Exhaled nitric oxide output;
TGCT	cis	rs4891159	0.584	rs690397	chr18:74117767	C/T	cg24786174	chr18:74118243	ZNF516	0.71	15.66	0.82	3.6e-31	Longevity;
TGCT	cis	rs2549003	1.000	rs9282762	chr5:131822055	T/C	cg21138405	chr5:131827807	IRF1	0.19	4.79	0.39	4.76e-6	Asthma (sex interaction);
TGCT	cis	rs2455799	0.586	rs2121736	chr3:15877165	A/G	cg12172478	chr3:16357591	RFTN1	-0.3	-4.49	-0.37	1.62e-5	Mean platelet volume;
TGCT	cis	rs10540	1.000	rs67912009	chr11:495057	G/T	cg03934478	chr11:495069	RNH1	0.33	5.42	0.44	2.93e-7	Body mass index;
TGCT	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg10047753	chr17:41438598	NA	0.97	9.99	0.67	1.37e-17	Menopause (age at onset);
TGCT	cis	rs12681288	0.782	rs2123055	chr8:1029500	T/G	cg04851639	chr8:1020857	NA	-0.35	-6.24	-0.49	6.21e-9	Schizophrenia;
TGCT	cis	rs78487399	0.908	rs60868396	chr2:43836877	T/G	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.67	4.95	0.41	2.37e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs910316	0.904	rs7156089	chr14:75645527	A/G	cg11812906	chr14:75593930	NEK9	-0.74	-7.3	-0.55	3.1e-11	Height;
TGCT	cis	rs3754214	0.823	rs494041	chr1:150270026	T/C	cg09579323	chr1:150459698	TARS2	-0.5	-4.52	-0.38	1.43e-5	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs1023500	0.573	rs133374	chr22:42465941	G/A	cg15557168	chr22:42548783	NA	-0.22	-5.54	-0.45	1.76e-7	Schizophrenia;
TGCT	cis	rs12602901	0.528	rs12941688	chr17:4985515	G/A	cg20814095	chr17:4802981	CHRNE;C17orf107	-0.53	-4.57	-0.38	1.15e-5	Blood metabolite levels;
TGCT	cis	rs9611519	0.732	rs1883826	chr22:41703428	G/A	cg03806693	chr22:41940476	POLR3H	-0.81	-7.85	-0.58	1.69e-12	Neuroticism;
TGCT	cis	rs7248779	0.512	rs12610522	chr19:2413228	C/T	cg22729335	chr19:2427816	TIMM13	1.13	13.77	0.78	9.49e-27	Cortisol levels (saliva);
TGCT	cis	rs314370	0.904	rs314373	chr7:100456595	G/A	cg10426581	chr7:100472382	SRRT	0.98	10.52	0.69	7e-19	Resting heart rate;
TGCT	cis	rs7944584	0.632	rs7116451	chr11:47322327	G/A	cg20307385	chr11:47447363	PSMC3	0.79	7.81	0.57	2.08e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
TGCT	cis	rs4660261	0.561	rs11210934	chr1:44369435	G/A	cg12908607	chr1:44402522	ARTN	-0.69	-8.61	-0.61	2.71e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs11690935	0.959	rs7586207	chr2:172671094	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.19	-12.75	-0.75	2.7e-24	Schizophrenia;
TGCT	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg06873352	chr17:61820015	STRADA	0.55	6.13	0.48	1.09e-8	Prudent dietary pattern;
TGCT	cis	rs7923452	0.938	rs753173	chr10:30778738	T/C	cg18806716	chr10:30721971	MAP3K8	0.69	6.19	0.49	7.91e-9	Itch intensity from mosquito bite;
TGCT	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg24060327	chr5:131705240	SLC22A5	-0.74	-7.91	-0.58	1.2e-12	Breast cancer;
TGCT	cis	rs6748734	0.948	rs4471886	chr2:241838622	T/C	cg04034577	chr2:241836375	C2orf54	-0.41	-6.31	-0.49	4.55e-9	Urinary metabolites;
TGCT	cis	rs8180040	0.966	rs9683033	chr3:47489820	C/T	cg27129171	chr3:47204927	SETD2	0.66	8.01	0.58	7.07e-13	Colorectal cancer;
TGCT	cis	rs7937682	0.681	rs7107378	chr11:111401840	C/A	cg09085632	chr11:111637200	PPP2R1B	0.52	4.7	0.39	6.67e-6	Primary sclerosing cholangitis;
TGCT	cis	rs727479	0.543	rs6493489	chr15:51514203	C/T	cg19946085	chr15:51559439	CYP19A1	-0.31	-4.55	-0.38	1.27e-5	Estradiol levels;
TGCT	cis	rs12477438	0.798	rs13412764	chr2:99583733	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-5.97	-0.47	2.3e-8	Chronic sinus infection;
TGCT	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.63	-0.51	9.04e-10	Alzheimer's disease;
TGCT	cis	rs1008375	1.000	rs10011865	chr4:17645710	G/A	cg10189774	chr4:17578691	LAP3	0.57	5.15	0.42	9.95e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs11122272	0.735	rs1076804	chr1:231498460	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-6.68	-0.51	7.25e-10	Hemoglobin concentration;
TGCT	cis	rs2288884	1.000	rs76768215	chr19:52572623	C/T	cg13540795	chr19:52551618	ZNF432	-0.59	-5.02	-0.41	1.79e-6	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs7523050	0.643	rs34920128	chr1:109400889	C/T	cg08274380	chr1:109419600	GPSM2	1.3	6.39	0.5	2.99e-9	Fat distribution (HIV);
TGCT	cis	rs10927875	0.722	rs6660685	chr1:16346988	A/G	cg21385522	chr1:16154831	NA	0.62	6.41	0.5	2.76e-9	Dilated cardiomyopathy;
TGCT	cis	rs11711311	1.000	rs16861312	chr3:113492402	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.79	-7.32	-0.55	2.75e-11	IgG glycosylation;
TGCT	cis	rs62103177	0.525	rs8086024	chr18:77746623	A/G	cg07235805	chr18:78004237	PARD6G	-0.48	-4.89	-0.4	3e-6	Opioid sensitivity;
TGCT	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg15691649	chr6:25882328	NA	-0.38	-4.95	-0.41	2.35e-6	Blood metabolite levels;
TGCT	cis	rs1949733	1.000	rs868105	chr4:8501030	G/T	cg13073564	chr4:8508604	NA	0.47	5.05	0.41	1.55e-6	Response to antineoplastic agents;
TGCT	cis	rs13256369	0.789	rs13282500	chr8:8568489	A/T	cg17143192	chr8:8559678	CLDN23	0.57	5.3	0.43	5.05e-7	Obesity-related traits;
TGCT	cis	rs514406	0.893	rs1242317	chr1:53414766	T/C	cg24675658	chr1:53192096	ZYG11B	-0.69	-8.05	-0.59	5.8e-13	Monocyte count;
TGCT	cis	rs10751667	0.666	rs4074231	chr11:978219	G/C	cg06064525	chr11:970664	AP2A2	-0.36	-8.28	-0.6	1.67e-13	Alzheimer's disease (late onset);
TGCT	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg08509172	chr19:19383838	TM6SF2	0.35	4.63	0.38	9.18e-6	Tonsillectomy;
TGCT	cis	rs7959452	0.719	rs57954211	chr12:69748397	C/A	cg20891283	chr12:69753455	YEATS4	0.83	8.77	0.62	1.16e-14	Blood protein levels;
TGCT	cis	rs9928842	0.712	rs8057843	chr16:75221555	T/G	cg09066997	chr16:75300724	BCAR1	0.26	4.65	0.39	8.39e-6	Alcoholic chronic pancreatitis;
TGCT	cis	rs6840360	0.642	rs2724580	chr4:152372505	A/G	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.83e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs2832191	0.967	rs1999321	chr21:30530233	A/C	cg08807101	chr21:30365312	RNF160	0.52	4.71	0.39	6.57e-6	Dental caries;
TGCT	cis	rs7089973	0.604	rs7923693	chr10:116619566	A/G	cg03647239	chr10:116582469	FAM160B1	0.59	5.61	0.45	1.26e-7	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs7666738	0.791	rs6851549	chr4:99029827	G/A	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs933688	1.000	rs10059163	chr5:90742444	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	9.69	0.66	7.22e-17	Smoking behavior;
TGCT	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	16.07	0.82	4.16e-32	Prudent dietary pattern;
TGCT	cis	rs9911578	1.000	rs2333332	chr17:56631054	A/G	cg12560992	chr17:57184187	TRIM37	-0.76	-9.34	-0.64	4.88e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg10819733	chr22:24237672	NA	0.28	4.59	0.38	1.09e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs62103177	0.673	rs4438371	chr18:77615988	C/T	cg12964065	chr18:77638022	KCNG2	0.31	4.46	0.37	1.84e-5	Opioid sensitivity;
TGCT	cis	rs6089584	0.893	rs6089305	chr20:60571817	T/C	cg16423285	chr20:60520624	NA	-0.62	-6.87	-0.53	2.75e-10	Body mass index;
TGCT	cis	rs55692468	0.652	rs10173398	chr2:153354994	G/A	cg10068330	chr2:152622650	NA	-0.32	-4.46	-0.37	1.85e-5	Intraocular pressure;
TGCT	cis	rs3845702	0.736	rs2678936	chr2:180872179	G/C	cg01881094	chr2:180872142	CWC22	1.07	6.79	0.52	4.2e-10	Schizophrenia;
TGCT	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg02038168	chr22:39784481	NA	-0.79	-6.79	-0.52	4.07e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs1005277	0.540	rs11011351	chr10:38030525	A/G	cg25427524	chr10:38739819	LOC399744	-0.33	-6.6	-0.51	1.07e-9	Extrinsic epigenetic age acceleration;
TGCT	cis	rs3862030	0.839	rs7078511	chr10:104283874	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.53	-5.15	-0.42	9.99e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
TGCT	cis	rs910316	0.763	rs175014	chr14:75456927	A/G	cg11812906	chr14:75593930	NEK9	-0.61	-5.66	-0.45	9.82e-8	Height;
TGCT	trans	rs17685	0.753	rs2286830	chr7:75693963	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.53	-9.09	-0.63	2.02e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg02018176	chr4:1364513	KIAA1530	0.3	4.86	0.4	3.52e-6	Longevity;
TGCT	cis	rs7647973	1.000	rs2140270	chr3:49439440	A/G	cg07636037	chr3:49044803	WDR6	-0.72	-5.79	-0.46	5.35e-8	Menarche (age at onset);
TGCT	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	6.18	0.49	8.58e-9	Bipolar disorder;
TGCT	cis	rs7666738	0.830	rs9998803	chr4:99002519	C/T	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs7618501	1.000	rs60205400	chr3:49800272	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	1.03	13.16	0.76	2.65e-25	Intelligence (multi-trait analysis);
TGCT	trans	rs1814175	0.817	rs11040651	chr11:49938395	G/A	cg03929089	chr4:120376271	NA	-0.71	-8.09	-0.59	4.74e-13	Height;
TGCT	cis	rs7100689	0.646	rs2095994	chr10:82127956	G/A	cg01528321	chr10:82214614	TSPAN14	0.8	7.76	0.57	2.7e-12	Post bronchodilator FEV1;
TGCT	cis	rs9486719	0.857	rs2971606	chr6:97043025	C/G	cg18709589	chr6:96969512	KIAA0776	-0.78	-6.38	-0.5	3.24e-9	Migraine;Coronary artery disease;
TGCT	cis	rs2677744	0.626	rs867468	chr15:91498127	G/A	cg23684204	chr15:91497937	RCCD1	0.39	5.92	0.47	2.91e-8	Attention deficit hyperactivity disorder;
TGCT	cis	rs2070488	0.699	rs13064938	chr3:38440237	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.81	7.71	0.57	3.52e-12	Electrocardiographic conduction measures;
TGCT	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	9.52	0.65	1.86e-16	Platelet count;
TGCT	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg21226059	chr5:178986404	RUFY1	0.46	5.02	0.41	1.77e-6	Lung cancer;
TGCT	cis	rs9733	0.593	rs10888384	chr1:150574256	C/T	cg13175981	chr1:150552382	MCL1	0.55	6.33	0.49	4.15e-9	Tonsillectomy;
TGCT	cis	rs73001065	0.818	rs12610191	chr19:19721976	C/T	cg03709012	chr19:19516395	GATAD2A	1.04	5.1	0.42	1.26e-6	LDL cholesterol;
TGCT	cis	rs8180040	0.932	rs62246474	chr3:47398130	C/T	cg27129171	chr3:47204927	SETD2	-0.7	-8.63	-0.61	2.53e-14	Colorectal cancer;
TGCT	cis	rs1008375	1.000	rs62295634	chr4:17685346	C/A	cg18681998	chr4:17616180	MED28	0.92	10.35	0.68	1.82e-18	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs11190604	1.000	rs11190556	chr10:102209223	G/A	cg23241863	chr10:102295624	HIF1AN	0.62	4.87	0.4	3.27e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg08280861	chr8:58055591	NA	0.4	4.73	0.39	5.97e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1729951	0.575	rs361248	chr3:136709066	G/A	cg12473912	chr3:136751656	NA	0.39	6.18	0.48	8.68e-9	Neuroticism;
TGCT	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg06221963	chr1:154839813	KCNN3	-0.71	-11.67	-0.72	1.1e-21	Prostate cancer;
TGCT	cis	rs9660992	0.573	rs7531256	chr1:205191202	T/G	cg00857998	chr1:205179979	DSTYK	0.51	4.68	0.39	7.34e-6	Mean corpuscular volume;Mean platelet volume;
TGCT	cis	rs2657888	0.931	rs2939312	chr12:56932554	G/A	cg23932658	chr12:57637574	STAC3	0.48	4.62	0.38	9.53e-6	Adiponectin levels;
TGCT	cis	rs9430161	0.644	rs6685766	chr1:11037051	T/C	cg27631724	chr1:11040367	C1orf127	0.54	6.28	0.49	5.3300000000000004e-09	Ewing sarcoma;
TGCT	cis	rs2580764	0.678	rs2580765	chr2:55204028	A/C	cg09592903	chr2:55203963	RTN4	0.24	5.47	0.44	2.4e-7	Mean platelet volume;
TGCT	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg06873352	chr17:61820015	STRADA	0.56	6.11	0.48	1.19e-8	Prudent dietary pattern;
TGCT	cis	rs9972944	0.902	rs10512504	chr17:63772091	C/T	cg07283582	chr17:63770753	CCDC46	0.27	5.27	0.43	5.91e-7	Total body bone mineral density;
TGCT	cis	rs12971120	0.783	rs7229256	chr18:72169129	T/A	cg25817165	chr18:72167213	CNDP2	-0.3	-5.61	-0.45	1.28e-7	Refractive error;
TGCT	cis	rs2346177	0.875	rs4413204	chr2:46647092	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.43	-4.77	-0.39	5.07e-6	HDL cholesterol;
TGCT	cis	rs9549367	0.713	rs3024756	chr13:113822950	G/C	cg00898013	chr13:113819073	PROZ	-0.55	-6.92	-0.53	2.14e-10	Platelet distribution width;
TGCT	cis	rs11031096	0.502	rs7935824	chr11:4046900	C/G	cg18678763	chr11:4115507	RRM1	-0.5	-6.2	-0.49	7.56e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs9653442	0.900	rs4851269	chr2:100830348	C/T	cg07810366	chr2:100720526	AFF3	0.4	6.01	0.48	1.9e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs9457247	0.967	rs376097	chr6:167410878	A/G	cg23791538	chr6:167370224	RNASET2	-0.49	-4.96	-0.41	2.31e-6	Crohn's disease;
TGCT	cis	rs7666738	0.830	rs4392515	chr4:98957431	A/G	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg22535103	chr8:58192502	C8orf71	-0.41	-4.81	-0.4	4.27e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs208520	0.661	rs6937856	chr6:66867468	A/G	cg07460842	chr6:66804631	NA	-0.92	-9.58	-0.65	1.29e-16	Exhaled nitric oxide output;
TGCT	cis	rs4911259	0.552	rs62208880	chr20:31463284	T/C	cg13636640	chr20:31349939	DNMT3B	-0.89	-9.83	-0.66	3.33e-17	Inflammatory bowel disease;
TGCT	cis	rs2456568	0.771	rs8181530	chr11:93638678	G/A	cg17595323	chr11:93583763	C11orf90	-0.47	-6.52	-0.51	1.58e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs2046867	0.818	rs1502758	chr3:72865126	A/G	cg25664220	chr3:72788482	NA	-0.56	-7.04	-0.53	1.16e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs523522	0.673	rs643372	chr12:121022640	C/G	cg27279351	chr12:120934652	DYNLL1	0.74	6.46	0.5	2.19e-9	High light scatter reticulocyte count;
TGCT	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs3096299	0.933	rs2965823	chr16:89454924	G/A	cg06640241	chr16:89574553	SPG7	0.66	6.49	0.5	1.86e-9	Multiple myeloma (IgH translocation);
TGCT	cis	rs7412746	0.658	rs11204723	chr1:150731618	T/C	cg04414720	chr1:150670196	GOLPH3L	0.37	4.63	0.38	9.12e-6	Melanoma;
TGCT	cis	rs13326165	0.760	rs57441156	chr3:52354242	C/G	cg27565382	chr3:53032988	SFMBT1	0.37	4.9	0.4	2.97e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs7584330	0.737	rs11886117	chr2:238361650	A/T	cg14458575	chr2:238380390	NA	0.48	7.57	0.56	7.54e-12	Prostate cancer;
TGCT	cis	rs77861329	1.000	rs171294	chr3:52203599	C/G	cg08692210	chr3:52188851	WDR51A	0.93	4.79	0.4	4.61e-6	Macrophage inflammatory protein 1b levels;
TGCT	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg13695892	chr22:41940480	POLR3H	-0.92	-9.06	-0.63	2.36e-15	Vitiligo;
TGCT	cis	rs11997175	0.574	rs4520125	chr8:33648628	C/T	ch.8.33884649F	chr8:33765107	NA	0.28	4.53	0.38	1.35e-5	Body mass index;
TGCT	cis	rs35306767	0.951	rs11253530	chr10:993729	T/C	cg26597838	chr10:835615	NA	0.62	8.25	0.6	1.94e-13	Eosinophil percentage of granulocytes;
TGCT	cis	rs4654899	0.758	rs17453044	chr1:21517361	A/G	cg01072550	chr1:21505969	NA	-0.57	-9.6	-0.65	1.15e-16	Superior frontal gyrus grey matter volume;
TGCT	cis	rs13191362	0.507	rs2849524	chr6:163127070	C/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.6	-5.61	-0.45	1.23e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs12950390	0.814	rs11659069	chr17:45834275	G/T	cg24803719	chr17:45855879	NA	-0.47	-4.75	-0.39	5.6e-6	IgG glycosylation;
TGCT	cis	rs7843479	0.601	rs4422769	chr8:21844265	A/G	cg17168535	chr8:21777572	XPO7	0.8	8.02	0.58	6.82e-13	Mean corpuscular volume;
TGCT	cis	rs6933660	0.720	rs6913515	chr6:151753470	G/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.49	4.56	0.38	1.2e-5	Menarche (age at onset);
TGCT	cis	rs7659604	0.967	rs10008348	chr4:122666987	A/C	cg19748678	chr4:122722346	EXOSC9	0.55	5.31	0.43	4.92e-7	Type 2 diabetes;
TGCT	cis	rs1570884	0.516	rs7334387	chr13:50172133	T/A	cg03651054	chr13:50194643	NA	0.33	5.28	0.43	5.66e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
TGCT	cis	rs1008375	0.966	rs2315553	chr4:17627332	T/C	cg18681998	chr4:17616180	MED28	1.08	12.13	0.74	8.24e-23	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1008375	1.000	rs10009541	chr4:17682218	C/T	cg16339924	chr4:17578868	LAP3	-0.59	-4.97	-0.41	2.13e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4660261	0.526	rs2485997	chr1:44345841	G/C	cg12908607	chr1:44402522	ARTN	-0.67	-8.24	-0.59	2.12e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs727505	0.821	rs67167896	chr7:124614127	T/C	cg23710748	chr7:124431027	NA	-0.26	-4.55	-0.38	1.27e-5	Lewy body disease;
TGCT	cis	rs228437	0.565	rs11759614	chr6:134962916	A/G	cg09872934	chr6:134495829	SGK1	0.53	4.56	0.38	1.21e-5	Melanoma;
TGCT	cis	rs7655441	1.000	rs7692932	chr4:80919178	G/A	cg02241357	chr4:80885279	ANTXR2	-0.24	-4.59	-0.38	1.07e-5	Neutrophil percentage of white cells;
TGCT	cis	rs7582180	0.627	rs6749018	chr2:101001859	G/T	cg08017756	chr2:100939284	LONRF2	-0.32	-5.37	-0.43	3.72e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1894292	0.527	rs4267704	chr4:74376022	T/C	cg05868023	chr4:75230803	EREG	0.56	5.05	0.41	1.56e-6	Prostate cancer;
TGCT	cis	rs12765878	0.580	rs11191822	chr10:105599770	T/G	cg11005552	chr10:105648138	OBFC1	-0.39	-6.05	-0.48	1.6e-8	Coronary artery disease;
TGCT	cis	rs2204008	0.774	rs12810027	chr12:38212165	A/G	cg13010199	chr12:38710504	ALG10B	0.62	4.96	0.41	2.32e-6	Bladder cancer;
TGCT	cis	rs2067615	0.579	rs10778506	chr12:107143260	T/C	cg15890332	chr12:107067104	RFX4	0.29	5.63	0.45	1.14e-7	Heart rate;
TGCT	cis	rs7772486	0.846	rs9403767	chr6:146402386	G/T	cg23711669	chr6:146136114	FBXO30	0.9	9.97	0.67	1.46e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10489525	0.599	rs17033129	chr1:115611539	C/T	cg12756093	chr1:115239321	AMPD1	-0.37	-4.95	-0.41	2.35e-6	Autism;
TGCT	cis	rs2836950	0.585	rs1029004	chr21:40615343	A/G	cg17971929	chr21:40555470	PSMG1	-0.51	-4.61	-0.38	9.97e-6	Menarche (age at onset);
TGCT	trans	rs561341	0.843	rs2028067	chr17:30239698	T/C	cg20587970	chr11:113659929	NA	-0.85	-10.92	-0.7	7.41e-20	Hip circumference adjusted for BMI;
TGCT	cis	rs8062405	0.737	rs11861132	chr16:28871860	A/G	cg09754948	chr16:28834200	ATXN2L	0.59	4.45	0.37	1.91e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs1577917	0.958	rs28442244	chr6:86701236	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.62	4.96	0.41	2.24e-6	Response to antipsychotic treatment;
TGCT	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg26818010	chr10:134567672	INPP5A	-0.37	-5.02	-0.41	1.74e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs17270561	0.779	rs78589800	chr6:25883500	C/G	cg16482183	chr6:26056742	HIST1H1C	0.89	6.63	0.51	9.23e-10	Iron status biomarkers;
TGCT	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs7091068	0.518	rs4919436	chr10:95461475	C/T	cg20715218	chr10:95462985	C10orf4	0.52	5.51	0.44	1.99e-7	Urinary tract infection frequency;
TGCT	cis	rs7772486	0.597	rs6912351	chr6:146264071	T/C	cg23711669	chr6:146136114	FBXO30	-0.74	-6.96	-0.53	1.75e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg24829409	chr8:58192753	C8orf71	-0.54	-4.99	-0.41	2.04e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9303401	0.659	rs35797125	chr17:56736547	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs10751667	0.621	rs10794353	chr11:948740	A/G	cg06064525	chr11:970664	AP2A2	-0.35	-7.92	-0.58	1.15e-12	Alzheimer's disease (late onset);
TGCT	cis	rs7772486	0.790	rs2247666	chr6:146220409	C/A	cg23711669	chr6:146136114	FBXO30	0.91	10.65	0.69	3.26e-19	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6089829	0.888	rs6011559	chr20:61675620	C/T	cg18188782	chr20:61659543	NA	-0.45	-4.86	-0.4	3.52e-6	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs6074578	0.679	rs12626088	chr20:139154	A/G	cg16931068	chr20:139680	DEFB127	0.26	4.48	0.37	1.69e-5	Hirschsprung disease;
TGCT	cis	rs117785887	0.536	rs12192366	chr6:146409990	A/G	cg06708562	chr6:146285465	SHPRH	-0.8	-4.79	-0.4	4.66e-6	Interleukin-17 levels;
TGCT	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-4.88	-0.4	3.2e-6	Bipolar disorder;
TGCT	cis	rs873946	0.564	rs2803991	chr10:134557068	A/G	cg18305652	chr10:134549665	INPP5A	0.31	5.12	0.42	1.11e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs453301	0.658	rs13271797	chr8:8885954	G/A	cg11995313	chr8:8860691	ERI1	0.54	4.73	0.39	6.09e-6	Joint mobility (Beighton score);
TGCT	cis	rs1005277	0.691	rs2474558	chr10:38486141	A/C	cg25427524	chr10:38739819	LOC399744	0.38	6.63	0.51	9.48e-10	Extrinsic epigenetic age acceleration;
TGCT	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg13397359	chr6:42928475	GNMT	0.72	6.48	0.5	1.94e-9	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs9325144	0.624	rs10783330	chr12:39114084	A/G	cg26384229	chr12:38710491	ALG10B	-0.62	-5.69	-0.46	8.48e-8	Morning vs. evening chronotype;
TGCT	cis	rs7412746	0.658	rs59024312	chr1:150909005	T/G	cg04414720	chr1:150670196	GOLPH3L	0.37	4.46	0.37	1.81e-5	Melanoma;
TGCT	cis	rs6665290	0.904	rs11586604	chr1:227183865	G/T	cg10327440	chr1:227177885	CDC42BPA	-0.99	-20.27	-0.88	3.54e-41	Myeloid white cell count;
TGCT	cis	rs72781680	1.000	rs72781667	chr2:24225667	A/G	cg08917208	chr2:24149416	ATAD2B	0.76	4.67	0.39	7.83e-6	Lymphocyte counts;
TGCT	cis	rs7260538	0.808	rs1552219	chr19:41525374	A/G	cg27089200	chr19:41531976	NA	0.45	5.88	0.47	3.63e-8	DDT metabolite (p,p'-DDE levels);
TGCT	cis	rs7582180	0.629	rs13025184	chr2:100944842	A/G	cg14675211	chr2:100938903	LONRF2	0.5	4.78	0.39	4.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2067615	0.542	rs10861654	chr12:107122896	A/G	cg15890332	chr12:107067104	RFX4	0.3	5.99	0.47	2.11e-8	Heart rate;
TGCT	cis	rs7914558	1.000	rs7911789	chr10:104756374	T/C	cg04362960	chr10:104952993	NT5C2	0.62	5.49	0.44	2.14e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs17221829	0.733	rs72971011	chr11:89358858	A/G	cg02982614	chr11:89391479	FOLH1B	-0.28	-4.87	-0.4	3.35e-6	Anxiety in major depressive disorder;
TGCT	cis	rs12142240	0.698	rs7515284	chr1:46809419	A/G	cg14993813	chr1:46806288	NSUN4	-0.58	-4.81	-0.4	4.34e-6	Menopause (age at onset);
TGCT	cis	rs1865760	0.602	rs2157050	chr6:26020431	C/T	cg17042849	chr6:26104293	HIST1H4C	-0.61	-5.13	-0.42	1.07e-6	Height;
TGCT	cis	rs78487399	0.808	rs6746610	chr2:43677253	T/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.24	-0.43	6.79e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs172166	0.694	rs188105	chr6:28071393	C/T	cg10876282	chr6:28092338	ZSCAN16	0.51	4.79	0.39	4.75e-6	Cardiac Troponin-T levels;
TGCT	cis	rs2153535	0.541	rs9392222	chr6:8467649	G/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg16680214	chr1:154839983	KCNN3	-0.36	-7.26	-0.55	3.81e-11	Prostate cancer;
TGCT	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg20007245	chr22:24372913	LOC391322	0.8	6.75	0.52	4.96e-10	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs62244186	0.659	rs12108134	chr3:44543030	A/G	cg04389838	chr3:44770851	ZNF501	0.38	4.94	0.41	2.49e-6	Depressive symptoms;
TGCT	cis	rs12776158	1.000	rs34618077	chr10:71216134	T/C	cg12610070	chr10:71211762	TSPAN15	-0.55	-4.83	-0.4	3.87e-6	Age-related hearing impairment (SNP x SNP interaction);
TGCT	cis	rs380904	1.000	rs12543128	chr8:144595042	G/A	cg22012530	chr8:144635309	GSDMD	0.47	4.89	0.4	3.03e-6	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs1865760	0.663	rs9379815	chr6:25980116	T/A	cg17042849	chr6:26104293	HIST1H4C	-0.59	-5.43	-0.44	2.91e-7	Height;
TGCT	cis	rs28595532	0.844	rs55845920	chr4:119490085	C/T	cg14228332	chr4:119757509	SEC24D	1.0	5.75	0.46	6.54e-8	Cannabis dependence symptom count;
TGCT	trans	rs9650657	0.504	rs10108347	chr8:11033517	G/C	cg15556689	chr8:8085844	FLJ10661	-0.74	-6.81	-0.52	3.65e-10	Neuroticism;
TGCT	cis	rs10892173	0.566	rs12364667	chr11:117675286	A/C	cg04064380	chr11:117688259	NA	-0.5	-4.48	-0.37	1.7e-5	Myopia;
TGCT	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg15242686	chr22:24348715	GSTTP1	-0.42	-5.64	-0.45	1.07e-7	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs13191362	0.810	rs28360533	chr6:162996742	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs644799	0.965	rs598876	chr11:95560853	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	10.52	0.69	6.75e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg08048268	chr3:133502702	NA	-0.54	-7.21	-0.54	4.93e-11	Iron status biomarkers;
TGCT	cis	rs78487399	0.908	rs6749617	chr2:43845329	A/T	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	-0.63	-4.62	-0.38	9.47e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs3809566	0.963	rs4775608	chr15:63331940	A/G	cg05507819	chr15:63340323	TPM1	0.48	4.52	0.38	1.4e-5	Platelet count;
TGCT	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg13665807	chr20:60559372	TAF4	0.47	5.04	0.41	1.62e-6	Body mass index;
TGCT	cis	rs28595532	1.000	rs17258106	chr4:119675406	C/T	cg11846333	chr4:119757529	SEC24D	-0.9	-4.94	-0.41	2.51e-6	Cannabis dependence symptom count;
TGCT	cis	rs12477438	0.520	rs4340581	chr2:99725025	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.15	18.22	0.85	7.28e-37	Chronic sinus infection;
TGCT	cis	rs6901004	0.835	rs1150079	chr6:111471425	A/T	cg15721981	chr6:111408429	SLC16A10	-0.53	-4.67	-0.39	7.84e-6	Blood metabolite levels;
TGCT	cis	rs12210905	1.000	rs72843615	chr6:27150569	C/T	cg08851530	chr6:28072375	NA	1.12	5.43	0.44	2.82e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs2702888	0.501	rs2741718	chr8:6746641	A/G	cg26795848	chr8:6756730	NA	-0.32	-6.39	-0.5	3e-9	Blood pressure;
TGCT	cis	rs2797160	0.515	rs9375409	chr6:125972798	A/G	cg05901451	chr6:126070800	HEY2	-0.63	-5.35	-0.43	4.14e-7	Endometrial cancer;
TGCT	cis	rs4319547	0.915	rs3803005	chr12:123110654	T/C	cg23029597	chr12:123009494	RSRC2	-0.3	-4.92	-0.4	2.74e-6	Body mass index;
TGCT	cis	rs7412746	0.658	rs10305711	chr1:150802996	T/C	cg09365446	chr1:150670422	GOLPH3L	0.35	5.16	0.42	9.31e-7	Melanoma;
TGCT	cis	rs6121246	0.567	rs6060297	chr20:30198560	A/G	cg18721089	chr20:30220636	NA	-0.64	-6.86	-0.52	2.84e-10	Mean corpuscular hemoglobin;
TGCT	cis	rs981844	0.857	rs62325139	chr4:154712213	C/T	cg14289246	chr4:154710475	SFRP2	1.05	9.32	0.64	5.44e-16	Response to statins (LDL cholesterol change);
TGCT	trans	rs1973993	0.967	rs1555543	chr1:96944797	A/C	cg10631902	chr5:14652156	NA	0.3	6.94	0.53	1.97e-10	Weight;
TGCT	cis	rs240764	0.631	rs6932158	chr6:101246010	T/C	cg21058520	chr6:100914733	NA	0.35	4.56	0.38	1.22e-5	Neuroticism;
TGCT	cis	rs941408	0.515	rs878893	chr19:2781325	A/G	cg17333051	chr19:2783644	SGTA	0.36	4.48	0.37	1.66e-5	Total cholesterol levels;
TGCT	cis	rs344364	0.511	rs1742395	chr16:1955965	G/A	cg26617929	chr16:1858877	NA	-0.25	-4.48	-0.37	1.69e-5	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs9303401	0.580	rs12603808	chr17:56578508	T/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.63	6.36	0.5	3.54e-9	Cognitive test performance;
TGCT	cis	rs4733781	0.901	rs4733777	chr8:131271562	C/T	cg16277922	chr8:131349729	ASAP1	0.36	4.61	0.38	9.92e-6	Tuberculosis;
TGCT	cis	rs7364180	0.582	rs139568	chr22:42210985	C/T	cg03806693	chr22:41940476	POLR3H	0.62	6.23	0.49	6.66e-9	Alzheimer's disease biomarkers;
TGCT	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg07092213	chr7:1199455	ZFAND2A	-0.45	-4.86	-0.4	3.5e-6	Longevity;Endometriosis;
TGCT	cis	rs9915657	0.870	rs34129640	chr17:70125665	A/C	cg06234051	chr17:70120541	SOX9	-0.27	-5.43	-0.44	2.88e-7	Thyroid hormone levels;
TGCT	cis	rs2996428	0.643	rs6424056	chr1:3722486	G/A	cg17848003	chr1:3704513	LRRC47	0.17	4.63	0.38	9.05e-6	Red cell distribution width;
TGCT	cis	rs8064299	0.503	rs11653346	chr17:72773333	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.59	5.5	0.44	2.09e-7	Monocyte count;
TGCT	cis	rs11671005	0.735	rs11671591	chr19:58918337	A/G	cg13877915	chr19:58951672	ZNF132	-0.69	-5.58	-0.45	1.46e-7	Mean platelet volume;
TGCT	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg18876405	chr7:65276391	NA	0.33	4.88	0.4	3.15e-6	Aortic root size;
TGCT	cis	rs778371	1.000	rs709937	chr2:233744021	A/G	cg08000102	chr2:233561755	GIGYF2	0.6	6.48	0.5	1.95e-9	Schizophrenia;
TGCT	cis	rs17102423	0.788	rs35176994	chr14:65596004	T/C	cg11161011	chr14:65562177	MAX	-0.55	-7.37	-0.55	2.09e-11	Obesity-related traits;
TGCT	cis	rs9325144	0.600	rs1817648	chr12:38733424	C/T	cg26384229	chr12:38710491	ALG10B	-0.62	-5.81	-0.46	5.06e-8	Morning vs. evening chronotype;
TGCT	cis	rs3617	0.625	rs11922961	chr3:52868610	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.48	-4.53	-0.38	1.35e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1941023	0.606	rs7946122	chr11:60172770	G/A	cg08716584	chr11:60157161	MS4A7	-0.31	-4.69	-0.39	7.18e-6	Congenital heart disease (maternal effect);
TGCT	cis	rs3617	0.532	rs9836499	chr3:52904524	G/T	cg05573699	chr3:52720067	GNL3;PBRM1	0.5	4.91	0.4	2.77e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4242434	0.892	rs11776549	chr8:22493124	C/T	cg03733263	chr8:22462867	KIAA1967	1.07	15.12	0.81	6.42e-30	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs2295359	0.824	rs4655679	chr1:67599657	A/G	cg12940439	chr1:67600707	NA	-0.63	-6.66	-0.51	7.99e-10	Psoriasis;
TGCT	cis	rs7647973	1.000	rs11928090	chr3:49604904	G/A	cg07690219	chr3:49449608	TCTA;RHOA	-0.56	-4.76	-0.39	5.24e-6	Menarche (age at onset);
TGCT	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.69	-7.06	-0.54	1.07e-10	Prostate cancer;
TGCT	cis	rs11719291	0.833	rs11715835	chr3:48770732	C/T	cg07636037	chr3:49044803	WDR6	-0.98	-5.09	-0.42	1.27e-6	Cognitive function;
TGCT	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg18876405	chr7:65276391	NA	-0.35	-5.46	-0.44	2.44e-7	Aortic root size;
TGCT	cis	rs62244186	0.566	rs55901755	chr3:44834707	C/T	cg21672276	chr3:44754072	ZNF502	-0.55	-6.31	-0.49	4.58e-9	Depressive symptoms;
TGCT	cis	rs9457247	0.508	rs7760495	chr6:167506795	C/T	cg07741184	chr6:167504864	NA	0.27	5.25	0.43	6.4e-7	Crohn's disease;
TGCT	cis	rs9916302	0.851	rs9904919	chr17:37556431	G/C	cg15445000	chr17:37608096	MED1	-0.34	-4.8	-0.4	4.43e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs3099143	1.000	rs3110378	chr15:77127983	G/A	cg21673338	chr15:77095150	SCAPER	-0.51	-4.88	-0.4	3.17e-6	Recalcitrant atopic dermatitis;
TGCT	cis	rs56104184	0.830	rs73061622	chr19:49358111	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.78	-9.12	-0.63	1.66e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs4819052	0.851	rs7279182	chr21:46656112	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.69	6.07	0.48	1.41e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6754311	0.773	rs309176	chr2:136622216	T/C	cg07169764	chr2:136633963	MCM6	-0.63	-5.88	-0.47	3.51e-8	Mosquito bite size;
TGCT	cis	rs59698941	0.550	rs12652469	chr5:132182765	A/G	cg21474247	chr5:131268130	NA	0.31	4.97	0.41	2.16e-6	Apolipoprotein A-IV levels;
TGCT	cis	rs9399135	0.967	rs9402676	chr6:135355507	C/T	cg24558204	chr6:135376177	HBS1L	0.48	4.77	0.39	5.14e-6	Red blood cell count;
TGCT	cis	rs72945132	0.714	rs115143889	chr11:70150122	G/T	cg00319359	chr11:70116639	PPFIA1	0.97	7.07	0.54	1.01e-10	Coronary artery disease;
TGCT	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.54	4.88	0.4	3.18e-6	Prudent dietary pattern;
TGCT	trans	rs1880529	0.830	rs6533687	chr4:114365275	C/T	cg19626253	chr1:15062529	KIAA1026	0.3	6.79	0.52	4.11e-10	White matter integrity (bipolar disorder risk interaction);
TGCT	cis	rs7000551	0.725	rs1075534	chr8:22374074	A/G	cg12081754	chr8:22256438	SLC39A14	0.29	4.71	0.39	6.56e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs8070128	0.583	rs7406982	chr17:17942613	C/T	cg04398451	chr17:18023971	MYO15A	-0.33	-5.28	-0.43	5.67e-7	Total body bone mineral density;
TGCT	cis	rs3741404	1.000	rs11603042	chr11:64003843	G/T	cg01727686	chr11:63997306	NUDT22;DNAJC4	0.22	4.68	0.39	7.26e-6	Platelet count;
TGCT	cis	rs548181	0.736	rs497344	chr11:125470524	T/C	cg03464685	chr11:125439445	EI24	1.14	8.16	0.59	3.1400000000000003e-13	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs2224391	0.554	rs114825667	chr6:5242618	A/T	cg09085698	chr6:5261316	LYRM4;FARS2	-1.02	-6.47	-0.5	2.04e-9	Height;
TGCT	cis	rs6903823	0.508	rs1150718	chr6:28256947	C/A	cg18815343	chr6:28367644	ZSCAN12	-0.44	-4.65	-0.39	8.28e-6	Pulmonary function;
TGCT	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg24531977	chr5:56204891	C5orf35	-0.76	-7.34	-0.55	2.45e-11	Initial pursuit acceleration;
TGCT	cis	rs12220238	1.000	rs7073432	chr10:75953350	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.06	0.54	1.05e-10	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs7714584	1.000	rs59715748	chr5:150189287	G/A	cg22134413	chr5:150180641	NA	1.13	8.18	0.59	2.91e-13	Crohn's disease;
TGCT	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	-1.05	-8.95	-0.63	4.39e-15	Platelet count;
TGCT	cis	rs4523957	0.651	rs7212342	chr17:2084305	A/G	cg16513277	chr17:2031491	SMG6	-0.2	-4.64	-0.38	8.83e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs7829975	0.511	rs1401390	chr8:8136410	C/T	cg15556689	chr8:8085844	FLJ10661	0.84	8.03	0.59	6.29e-13	Mood instability;
TGCT	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.56	-5.53	-0.45	1.77e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2765041	1	rs2765041	chr14:103991478	T/A	cg26031613	chr14:104095156	KLC1	0.56	4.67	0.39	7.74e-6	High light scatter reticulocyte count;
TGCT	cis	rs651907	0.557	rs34376498	chr3:101480156	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.33	-6.8	-0.52	3.91e-10	Colorectal cancer;
TGCT	cis	rs3784262	0.669	rs12595180	chr15:58332541	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.43	-6.19	-0.49	8.07e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	trans	rs931812	0.757	rs34988706	chr8:101907062	C/T	cg20993868	chr7:22813445	NA	0.32	6.63	0.51	9.13e-10	Attention deficit hyperactivity disorder and conduct disorder;
TGCT	cis	rs975752	0.867	rs11190444	chr10:102024352	C/T	cg04750910	chr10:102416409	NA	0.73	4.48	0.37	1.69e-5	Schizophrenia;
TGCT	cis	rs9916302	0.768	rs62077464	chr17:37656056	C/G	cg15445000	chr17:37608096	MED1	0.31	4.57	0.38	1.18e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs13191362	1.000	rs4489133	chr6:163137793	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.0	7.73	0.57	3.24e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs1513670	1.000	rs8071941	chr17:41810313	A/G	cg10758466	chr17:41974087	MPP2	-0.28	-4.55	-0.38	1.27e-5	Bone mineral density (hip);
TGCT	cis	rs7208859	0.623	rs7223404	chr17:29107363	C/T	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7772486	0.686	rs2179323	chr6:145982786	T/G	cg05347473	chr6:146136440	FBXO30	-0.48	-4.52	-0.38	1.42e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs74233809	1.000	rs11191453	chr10:104659852	T/C	cg05855489	chr10:104503620	C10orf26	0.74	4.45	0.37	1.87e-5	Birth weight;
TGCT	cis	rs9527	0.640	rs35195396	chr10:104928770	T/A	cg15744005	chr10:104629667	AS3MT	-0.4	-4.59	-0.38	1.08e-5	Arsenic metabolism;
TGCT	cis	rs7267979	0.903	rs2474766	chr20:25246153	A/G	cg03522245	chr20:25566470	NINL	0.6	6.58	0.51	1.21e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11264213	0.591	rs274728	chr1:36493420	T/C	cg27506609	chr1:36549197	TEKT2	-0.47	-5.33	-0.43	4.54e-7	Schizophrenia;
TGCT	cis	rs1048238	0.506	rs848209	chr1:16256007	T/C	cg22431228	chr1:16359049	CLCNKA	0.23	4.48	0.37	1.67e-5	Systolic blood pressure;
TGCT	cis	rs1887596	0.663	rs3794413	chr13:27250945	A/G	cg01312412	chr13:27282625	NA	0.28	4.98	0.41	2.07e-6	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs6582630	0.555	rs10880625	chr12:38526612	A/C	cg13010199	chr12:38710504	ALG10B	0.65	5.18	0.42	8.78e-7	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs7246657	0.943	rs7246993	chr19:37890154	C/T	cg18154014	chr19:37997991	ZNF793	0.95	6.63	0.51	9.39e-10	Coronary artery calcification;
TGCT	cis	rs9357506	1.000	rs6911474	chr6:46307667	G/T	cg21115430	chr6:46460003	NA	-0.26	-5.17	-0.42	9.2e-7	Body mass index;
TGCT	cis	rs7017914	0.967	rs2100908	chr8:71583310	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.03	-0.41	1.69e-6	Bone mineral density;
TGCT	cis	rs1577917	0.652	rs75593931	chr6:86719539	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.54	-0.45	1.73e-7	Response to antipsychotic treatment;
TGCT	cis	rs6964587	0.967	rs28399886	chr7:91638451	A/G	cg17063962	chr7:91808500	NA	0.91	9.99	0.67	1.32e-17	Breast cancer;
TGCT	cis	rs9303401	0.659	rs12948133	chr17:56673602	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs910316	1.000	rs12588240	chr14:75612083	C/A	cg23033748	chr14:75592666	NEK9	0.28	4.79	0.39	4.73e-6	Height;
TGCT	trans	rs28595532	0.702	rs116320061	chr4:119384600	C/T	cg26518628	chr1:97050305	NA	-0.54	-6.85	-0.52	2.98e-10	Cannabis dependence symptom count;
TGCT	cis	rs72781680	1.000	rs12617839	chr2:24166277	A/T	cg08917208	chr2:24149416	ATAD2B	0.73	4.51	0.38	1.48e-5	Lymphocyte counts;
TGCT	cis	rs11671005	0.693	rs11668757	chr19:58928299	A/T	cg13877915	chr19:58951672	ZNF132	0.63	4.99	0.41	1.95e-6	Mean platelet volume;
TGCT	cis	rs1406084	0.636	rs3843319	chr2:154717586	G/C	cg25703346	chr2:154729189	GALNT13	0.77	4.6	0.38	1.03e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2730245	0.527	rs1188974	chr7:158665748	C/T	cg11984989	chr7:158649758	WDR60	1.01	7.84	0.58	1.79e-12	Height;
TGCT	cis	rs11783469	0.522	rs11781871	chr8:23257090	C/T	cg00472375	chr8:23315376	ENTPD4	0.7	5.64	0.45	1.08e-7	Reticulocyte count;
TGCT	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg08280861	chr8:58055591	NA	0.36	4.82	0.4	4.2e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs12753569	0.720	rs4381138	chr1:76509783	G/A	cg00791851	chr1:76518896	NA	0.35	4.6	0.38	1.04e-5	Personality dimensions;
TGCT	cis	rs1997103	1.000	rs9649851	chr7:55398692	C/A	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs7809950	1.000	rs3801948	chr7:107238447	A/T	cg23024343	chr7:107201750	COG5	-0.35	-5.42	-0.44	2.94e-7	Coronary artery disease;
TGCT	cis	rs7589728	0.514	rs74426843	chr2:88459388	C/T	cg04511125	chr2:88470314	THNSL2	0.79	6.55	0.51	1.37e-9	Plasma clusterin levels;
TGCT	cis	rs2544527	0.557	rs2112101	chr2:15902679	C/T	cg26669897	chr2:15909070	NA	-0.42	-4.89	-0.4	3.08e-6	Pulmonary function (smoking interaction);Pulmonary function;
TGCT	cis	rs2224391	0.911	rs6925249	chr6:5262510	G/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.79	-6.05	-0.48	1.61e-8	Height;
TGCT	cis	rs11112613	0.713	rs17041546	chr12:105950801	G/T	cg03607813	chr12:105948248	NA	-0.52	-6.28	-0.49	5.28e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	cis	rs8177179	0.967	rs9869311	chr3:133451613	C/T	cg16262614	chr3:133464971	TF	0.35	4.72	0.39	6.28e-6	Iron status biomarkers (transferrin levels);
TGCT	cis	rs75059851	0.756	rs11223661	chr11:133851412	G/T	cg14047540	chr11:133829660	NA	-0.54	-4.97	-0.41	2.21e-6	Schizophrenia;
TGCT	cis	rs12908161	1.000	rs12911736	chr15:85240008	A/G	cg12863693	chr15:85201151	NMB	0.46	5.53	0.44	1.79e-7	Schizophrenia;
TGCT	cis	rs12477438	0.765	rs4374423	chr2:99662348	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-4.88	-0.4	3.17e-6	Chronic sinus infection;
TGCT	cis	rs2072499	0.966	rs2842882	chr1:156165342	T/G	cg24450063	chr1:156163899	SLC25A44	1.2	18.21	0.85	7.43e-37	Testicular germ cell tumor;
TGCT	cis	rs2153535	0.580	rs9406174	chr6:8516764	T/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.01	0.41	1.86e-6	Motion sickness;
TGCT	cis	rs3617	0.625	rs7652667	chr3:52866535	C/A	cg10802521	chr3:52805072	NEK4	0.62	7.17	0.54	6e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs10170846	0.530	rs56353541	chr2:223421187	G/C	cg25565276	chr2:223520875	FARSB	0.75	6.01	0.47	1.95e-8	Schizophrenia (inflammation and infection response interaction);
TGCT	cis	rs7845219	0.525	rs10956931	chr8:95930301	A/G	cg13393036	chr8:95962371	TP53INP1	-0.42	-4.89	-0.4	3.08e-6	Type 2 diabetes;
TGCT	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg05985448	chr10:134359359	INPP5A	0.22	4.83	0.4	3.89e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs829883	0.664	rs249833	chr12:98832189	T/C	cg25150519	chr12:98850993	NA	0.62	7.36	0.55	2.2e-11	Colorectal adenoma (advanced);
TGCT	cis	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg07424592	chr7:64974309	NA	1.25	8.11	0.59	4.21e-13	Diabetic kidney disease;
TGCT	cis	rs10782582	0.609	rs78748984	chr1:76340467	G/A	cg03433033	chr1:76189801	ACADM	-0.5	-4.98	-0.41	2.11e-6	Daytime sleep phenotypes;
TGCT	cis	rs13272623	0.502	rs268601	chr8:71518548	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.61	-5.16	-0.42	9.64e-7	IgG glycosylation;
TGCT	cis	rs2420915	0.841	rs7072051	chr10:122873110	A/T	cg23234726	chr10:122735589	NA	-0.39	-4.49	-0.37	1.6e-5	Fibrinogen levels;
TGCT	cis	rs7937682	0.921	rs12806479	chr11:111443192	G/C	cg09085632	chr11:111637200	PPP2R1B	0.87	7.28	0.55	3.34e-11	Primary sclerosing cholangitis;
TGCT	cis	rs9322193	0.884	rs10872648	chr6:150079835	A/G	cg13206674	chr6:150067644	NUP43	0.54	4.65	0.39	8.48e-6	Lung cancer;
TGCT	cis	rs1200821	0.559	rs9418267	chr10:37819951	A/G	cg25427524	chr10:38739819	LOC399744	0.3	5.27	0.43	5.89e-7	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs7824557	0.564	rs2736288	chr8:11228100	G/A	cg21775007	chr8:11205619	TDH	-0.65	-6.14	-0.48	1.01e-8	Retinal vascular caliber;
TGCT	cis	rs875971	1.000	rs1167411	chr7:65539264	C/G	cg11764359	chr7:65958608	NA	-0.56	-4.7	-0.39	6.74e-6	Aortic root size;
TGCT	cis	rs3806843	0.576	rs155358	chr5:140297032	A/T	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.44	-5.32	-0.43	4.6e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs344364	0.511	rs1742468	chr16:1950243	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.45	-5.08	-0.42	1.35e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs10992471	0.603	rs10992342	chr9:95212068	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.62	-5.74	-0.46	6.79e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs6450176	0.909	rs6884760	chr5:53293077	T/A	ch.5.1024479R	chr5:53302184	ARL15	-0.49	-4.59	-0.38	1.08e-5	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs314370	0.570	rs314324	chr7:100433794	C/T	cg10426581	chr7:100472382	SRRT	0.74	7.72	0.57	3.37e-12	Resting heart rate;
TGCT	cis	rs7847628	0.666	rs2031974	chr9:123527521	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	4.75	0.39	5.42e-6	Birth weight;
TGCT	cis	rs514406	0.825	rs12089511	chr1:53436427	A/T	cg08859206	chr1:53392774	SCP2	0.42	6.44	0.5	2.32e-9	Monocyte count;
TGCT	cis	rs7552404	1.000	rs7548962	chr1:76139266	G/A	cg03433033	chr1:76189801	ACADM	0.83	9.91	0.66	2.13e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2535633	0.594	rs2581789	chr3:53096230	C/T	cg10802521	chr3:52805072	NEK4	0.5	5.38	0.43	3.6e-7	Body mass index;
TGCT	cis	rs903263	0.965	rs1402694	chr1:84600513	C/T	cg09664975	chr1:84543551	PRKACB	0.5	4.74	0.39	5.73e-6	Breast cancer (male);
TGCT	cis	rs7937890	1.000	rs2970335	chr11:14325401	A/C	cg19336497	chr11:14380999	RRAS2	-0.3	-4.8	-0.4	4.4e-6	Mitochondrial DNA levels;
TGCT	cis	rs6121246	0.954	rs6089093	chr20:30421459	C/T	cg13852791	chr20:30311386	BCL2L1	0.79	5.6	0.45	1.33e-7	Mean corpuscular hemoglobin;
TGCT	cis	rs4478858	0.735	rs6425736	chr1:31784376	T/A	cg00250761	chr1:31883323	NA	-0.28	-5.01	-0.41	1.86e-6	Alcohol dependence;
TGCT	cis	rs447921	0.813	rs435892	chr17:74398505	A/T	cg09812376	chr17:74270190	QRICH2	0.46	4.6	0.38	1.01e-5	Mitochondrial DNA levels;
TGCT	cis	rs509477	0.887	rs657018	chr18:32558960	C/T	cg23791764	chr18:32556832	MAPRE2	0.77	6.54	0.51	1.42e-9	Cerebrospinal fluid AB1-42 levels;
TGCT	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg22508957	chr16:3507546	NAT15	0.47	5.3	0.43	5.1e-7	Tuberculosis;
TGCT	cis	rs3784262	1.000	rs4646593	chr15:58302467	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.5	-7.82	-0.57	1.98e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs2760061	0.784	rs708116	chr1:228198196	C/A	cg18477163	chr1:228402036	OBSCN	0.34	7.19	0.54	5.33e-11	Diastolic blood pressure;
TGCT	cis	rs9611565	0.512	rs139573	chr22:42214785	G/A	cg03806693	chr22:41940476	POLR3H	-1.04	-10.57	-0.69	5.2e-19	Vitiligo;
TGCT	cis	rs6545883	0.718	rs6715259	chr2:61851845	G/T	cg15711740	chr2:61764176	XPO1	-0.59	-5.39	-0.44	3.45e-7	Tuberculosis;
TGCT	cis	rs9814567	1.000	rs12637751	chr3:134266124	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.96	9.11	0.63	1.79e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs7959452	0.535	rs10784771	chr12:69621264	A/G	cg20891283	chr12:69753455	YEATS4	0.62	5.85	0.47	4.04e-8	Blood protein levels;
TGCT	cis	rs7017914	0.934	rs7015035	chr8:71653601	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.03	-0.41	1.69e-6	Bone mineral density;
TGCT	cis	rs6534347	0.573	rs1398554	chr4:123522569	G/A	cg10583651	chr4:123538969	IL21	-0.36	-5.27	-0.43	5.97e-7	Type 1 diabetes;
TGCT	cis	rs7937682	0.889	rs2850247	chr11:111637202	C/A	cg09085632	chr11:111637200	PPP2R1B	1.24	15.61	0.81	4.86e-31	Primary sclerosing cholangitis;
TGCT	cis	rs2455799	0.573	rs2174172	chr3:15768579	C/A	cg16303742	chr3:15540471	COLQ	-0.26	-5.02	-0.41	1.76e-6	Mean platelet volume;
TGCT	cis	rs7666738	1.000	rs1426673	chr4:98924024	G/A	cg17366294	chr4:99064904	C4orf37	0.72	6.58	0.51	1.17e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg25767906	chr1:53392781	SCP2	-0.59	-7.49	-0.56	1.12e-11	Monocyte count;
TGCT	cis	rs8180040	0.522	rs749512	chr3:47035900	C/T	cg27129171	chr3:47204927	SETD2	-0.66	-7.54	-0.56	8.87e-12	Colorectal cancer;
TGCT	cis	rs6674176	0.561	rs7161	chr1:44438974	A/G	cg13606994	chr1:44402422	ARTN	0.45	4.92	0.4	2.64e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs6901250	0.851	rs339322	chr6:117193356	T/C	cg12892004	chr6:117198278	RFX6	-0.57	-7.0	-0.53	1.46e-10	C-reactive protein levels;
TGCT	cis	rs2224391	1.000	rs2224391	chr6:5260936	A/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.75	-5.62	-0.45	1.2e-7	Height;
TGCT	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg04352962	chr1:209979756	IRF6	-0.6	-4.6	-0.38	1.03e-5	Cleft lip with or without cleft palate;
TGCT	cis	rs7772486	0.686	rs2179323	chr6:145982786	T/G	cg13319975	chr6:146136371	FBXO30	0.5	4.5	0.37	1.56e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg17554472	chr22:41940697	POLR3H	0.49	5.0	0.41	1.88e-6	Vitiligo;
TGCT	cis	rs9894429	0.538	rs9747080	chr17:79606704	A/G	cg21028142	chr17:79581711	NPLOC4	0.29	6.01	0.48	1.9e-8	Eye color traits;
TGCT	cis	rs7772486	0.875	rs6570738	chr6:146412695	G/A	cg05347473	chr6:146136440	FBXO30	0.53	5.03	0.41	1.71e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9325144	0.560	rs1843911	chr12:38676585	C/T	cg26384229	chr12:38710491	ALG10B	-0.69	-6.57	-0.51	1.26e-9	Morning vs. evening chronotype;
TGCT	cis	rs80282103	0.618	rs11250252	chr10:1124939	G/C	cg18964960	chr10:1102726	WDR37	0.99	4.44	0.37	2.01e-5	Glomerular filtration rate (creatinine);
TGCT	trans	rs62103177	0.810	rs3902996	chr18:77630571	A/G	cg05926928	chr17:57297772	GDPD1	1.22	11.16	0.71	1.85e-20	Opioid sensitivity;
TGCT	cis	rs1670533	1.000	rs10031302	chr4:1059664	G/A	cg27284194	chr4:1044797	NA	0.69	5.96	0.47	2.44e-8	Recombination rate (females);
TGCT	trans	rs1814175	0.935	rs10839317	chr11:49657228	A/C	cg15704280	chr7:45808275	SEPT13	-0.61	-6.8	-0.52	4.02e-10	Height;
TGCT	cis	rs7772486	0.558	rs2142978	chr6:146012061	T/C	cg23711669	chr6:146136114	FBXO30	-0.73	-6.84	-0.52	3.19e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3733585	0.699	rs7663097	chr4:9966791	T/C	cg00071950	chr4:10020882	SLC2A9	-0.57	-6.85	-0.52	3.12e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs12643440	0.538	rs16894428	chr4:17142974	A/G	cg22650099	chr4:17144496	NA	-0.46	-4.7	-0.39	6.79e-6	Metabolite levels (Pyroglutamine);
TGCT	trans	rs16860537	1.000	rs79583958	chr1:183229061	C/T	cg10317387	chr2:88470873	THNSL2	-0.67	-6.62	-0.51	9.68e-10	Systemic lupus erythematosus and Systemic sclerosis;
TGCT	cis	rs28735056	0.592	rs10853392	chr18:77708781	A/G	cg20368463	chr18:77673604	PQLC1	-0.47	-5.5	-0.44	2.12e-7	Schizophrenia;
TGCT	cis	rs114540395	0.858	rs77334916	chr10:103178507	T/G	cg18276125	chr10:102749041	C10orf2	0.38	4.6	0.38	1.05e-5	Schizophrenia;
TGCT	cis	rs6426558	0.515	rs7543579	chr1:227377699	A/T	cg10327440	chr1:227177885	CDC42BPA	-0.61	-7.07	-0.54	1.01e-10	Neutrophil percentage of white cells;
TGCT	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg03303774	chr4:1407052	NA	0.3	4.78	0.39	4.82e-6	Obesity-related traits;
TGCT	cis	rs79349575	0.715	rs4793997	chr17:47019672	C/A	cg07967210	chr17:47022446	SNF8	0.44	6.13	0.48	1.1e-8	Type 2 diabetes;
TGCT	cis	rs7226408	0.749	rs4539671	chr18:34435006	T/G	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs7020830	0.867	rs13301916	chr9:37361455	A/C	cg14294708	chr9:37120828	ZCCHC7	1.21	16.97	0.84	4.05e-34	Schizophrenia;
TGCT	cis	rs2153904	0.793	rs12748961	chr1:205676263	T/C	cg23034840	chr1:205782522	SLC41A1	-0.89	-5.32	-0.43	4.66e-7	Prostate-specific antigen levels;
TGCT	cis	rs17767294	0.708	rs72848753	chr6:27878269	C/G	cg08851530	chr6:28072375	NA	1.53	7.17	0.54	6.02e-11	Parkinson's disease;
TGCT	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg06634786	chr22:41940651	POLR3H	-0.88	-8.54	-0.61	3.98e-14	Vitiligo;
TGCT	cis	rs2070433	0.528	rs68063691	chr21:47759237	T/C	cg12379764	chr21:47803548	PCNT	0.65	5.61	0.45	1.24e-7	Lymphocyte counts;
TGCT	cis	rs7572733	0.515	rs700675	chr2:198700216	G/A	cg00792783	chr2:198669748	PLCL1	0.56	5.08	0.42	1.35e-6	Dermatomyositis;
TGCT	cis	rs9911578	1.000	rs7216680	chr17:56988243	G/C	cg12560992	chr17:57184187	TRIM37	0.76	9.21	0.64	1.03e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg02725872	chr8:58115012	NA	-0.38	-4.99	-0.41	1.98e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg02487422	chr3:49467188	NICN1	0.55	5.32	0.43	4.77e-7	Menarche (age at onset);
TGCT	cis	rs9346649	0.654	rs12527055	chr6:168492655	C/T	cg02770688	chr6:168491649	NA	0.32	5.61	0.45	1.26e-7	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
TGCT	cis	rs7666738	0.830	rs62318504	chr4:98935558	T/G	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9467711	1.000	rs6939978	chr6:26328462	G/C	cg02458000	chr6:26745757	NA	-1.05	-5.8	-0.46	5.29e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1865760	0.555	rs2051541	chr6:25945211	C/T	cg12310025	chr6:25882481	NA	0.49	5.16	0.42	9.4e-7	Height;
TGCT	cis	rs7617773	0.925	rs34513961	chr3:48173653	T/C	cg11946769	chr3:48343235	NME6	0.6	4.83	0.4	3.97e-6	Coronary artery disease;
TGCT	cis	rs7726839	0.540	rs12520279	chr5:657291	T/C	cg09021430	chr5:549028	NA	-0.45	-6.27	-0.49	5.56e-9	Obesity-related traits;
TGCT	cis	rs10489202	0.632	rs12410730	chr1:168069477	T/C	cg24449463	chr1:168025552	DCAF6	-0.53	-5.54	-0.45	1.75e-7	Schizophrenia;
TGCT	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg12751644	chr20:60527061	NA	-0.41	-4.66	-0.39	8.01e-6	Body mass index;
TGCT	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg06481639	chr22:41940642	POLR3H	0.8	6.85	0.52	3.08e-10	Vitiligo;
TGCT	cis	rs727505	0.607	rs67454509	chr7:124792500	A/G	cg23710748	chr7:124431027	NA	-0.26	-4.51	-0.38	1.47e-5	Lewy body disease;
TGCT	cis	rs9486715	0.867	rs3860243	chr6:96905303	T/G	cg06623918	chr6:96969491	KIAA0776	1.1	16.66	0.83	1.99e-33	Headache;
TGCT	trans	rs11992162	0.508	rs7003792	chr8:11781464	T/C	cg15556689	chr8:8085844	FLJ10661	-0.8	-6.91	-0.53	2.27e-10	Monocyte count;
TGCT	cis	rs587847	0.737	rs4924153	chr15:37666010	A/T	cg22444584	chr15:37174661	LOC145845	-0.37	-4.58	-0.38	1.09e-5	Intraocular pressure;
TGCT	cis	rs7772486	0.720	rs6570713	chr6:146075085	G/A	cg13319975	chr6:146136371	FBXO30	0.56	4.93	0.4	2.56e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs910316	0.763	rs735452	chr14:75497984	A/G	cg08847533	chr14:75593920	NEK9	-0.84	-9.19	-0.64	1.14e-15	Height;
TGCT	trans	rs1814175	0.817	rs7481230	chr11:49772235	G/A	cg15704280	chr7:45808275	SEPT13	-0.69	-8.05	-0.59	5.61e-13	Height;
TGCT	cis	rs10927875	0.619	rs12121764	chr1:16138059	A/T	cg21385522	chr1:16154831	NA	-0.73	-9.15	-0.64	1.39e-15	Dilated cardiomyopathy;
TGCT	cis	rs35306767	0.855	rs11253465	chr10:897208	A/C	cg20503657	chr10:835505	NA	0.75	10.41	0.68	1.3e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	5.8	0.46	5.19e-8	Alzheimer's disease;
TGCT	cis	rs4665630	0.522	rs2712100	chr2:23931925	A/T	cg08063864	chr2:24346004	PFN4;LOC375190	-1.23	-5.86	-0.47	3.98e-8	Hypertension;
TGCT	cis	rs250677	0.522	rs6872701	chr5:148359086	C/G	cg18129178	chr5:148520854	ABLIM3	0.36	4.69	0.39	7.23e-6	Breast cancer;
TGCT	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg06028808	chr11:68637592	NA	-0.5	-6.3	-0.49	4.65e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7267979	1.000	rs6050609	chr20:25411751	A/G	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2404602	0.692	rs7169663	chr15:77192843	A/C	cg22467129	chr15:76604101	ETFA	-0.48	-5.45	-0.44	2.58e-7	Blood metabolite levels;
TGCT	cis	rs9894429	1.000	rs9747349	chr17:79584297	C/T	cg18240062	chr17:79603768	NPLOC4	0.67	6.84	0.52	3.23e-10	Eye color traits;
TGCT	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg21724239	chr8:58056113	NA	0.47	5.05	0.41	1.54e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7726839	0.561	rs4957048	chr5:583442	G/A	cg09021430	chr5:549028	NA	-0.37	-5.23	-0.42	7.12e-7	Obesity-related traits;
TGCT	cis	rs6087990	0.748	rs4911255	chr20:31357580	A/T	cg13636640	chr20:31349939	DNMT3B	1.07	14.14	0.79	1.28e-27	Ulcerative colitis;
TGCT	cis	rs7772486	0.597	rs9386136	chr6:146158300	A/T	cg23711669	chr6:146136114	FBXO30	0.76	7.12	0.54	7.61e-11	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs637571	0.522	rs556643	chr11:65733289	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.6	5.98	0.47	2.24e-8	Eosinophil percentage of white cells;
TGCT	cis	rs11626933	1.000	rs7146724	chr14:90766092	C/T	cg14092571	chr14:90743983	NA	-0.29	-6.1	-0.48	1.26e-8	Gut microbiota (bacterial taxa);
TGCT	cis	rs5769707	0.706	rs763128	chr22:50018045	G/A	cg06623630	chr22:50017776	C22orf34	-0.27	-4.64	-0.38	8.67e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs137699	1.000	rs137699	chr22:39748854	A/G	cg24399712	chr22:39784796	NA	-0.66	-5.73	-0.46	7.3e-8	IgG glycosylation;
TGCT	cis	rs478304	0.593	rs4645927	chr11:65482827	C/T	cg17480646	chr11:65405466	SIPA1	-0.58	-6.56	-0.51	1.34e-9	Acne (severe);
TGCT	cis	rs2224391	1.000	rs2753249	chr6:5263475	T/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.75	-5.62	-0.45	1.2e-7	Height;
TGCT	cis	rs2721195	0.781	rs10110962	chr8:145780323	C/T	cg15320075	chr8:145703422	NA	0.71	7.1	0.54	8.74e-11	Age at first birth;
TGCT	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg13342137	chr4:2252803	MXD4	-0.17	-4.6	-0.38	1.05e-5	Obesity-related traits;
TGCT	cis	rs7666738	0.791	rs1426661	chr4:98874303	C/G	cg18180107	chr4:99064573	C4orf37	0.55	5.14	0.42	1.03e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7267979	0.649	rs2500406	chr20:25401862	A/C	cg03522245	chr20:25566470	NINL	-0.44	-4.52	-0.38	1.43e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs68170813	0.596	rs76888321	chr7:106945926	T/C	cg02696742	chr7:106810147	HBP1	-0.69	-5.81	-0.46	4.85e-8	Coronary artery disease;
TGCT	cis	rs11785693	0.862	rs6994323	chr8:4996786	T/A	cg26367366	chr8:4980734	NA	0.58	4.45	0.37	1.91e-5	Neuroticism (multi-trait analysis);Neuroticism;
TGCT	cis	rs12540874	0.542	rs4947581	chr7:50565967	G/A	cg18232548	chr7:50535776	DDC	-0.35	-6.01	-0.48	1.89e-8	Systemic sclerosis;
TGCT	cis	rs6570726	0.791	rs385729	chr6:145855465	T/C	cg05347473	chr6:146136440	FBXO30	0.54	5.15	0.42	1.01e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg22920501	chr2:26401640	FAM59B	0.72	5.59	0.45	1.34e-7	Gut microbiome composition (summer);
TGCT	cis	rs7714584	1.000	rs76433514	chr5:150306532	C/G	cg22134413	chr5:150180641	NA	1.04	7.44	0.56	1.48e-11	Crohn's disease;
TGCT	cis	rs1971762	0.527	rs6580952	chr12:53937452	C/T	cg16917193	chr12:54089295	NA	1.02	10.39	0.68	1.45e-18	Height;
TGCT	cis	rs8014204	0.804	rs34956813	chr14:75254167	G/A	cg06637938	chr14:75390232	RPS6KL1	0.7	6.77	0.52	4.47e-10	Caffeine consumption;
TGCT	cis	rs7819412	0.875	rs6981523	chr8:11061792	C/T	cg21775007	chr8:11205619	TDH	-0.51	-4.9	-0.4	2.95e-6	Triglycerides;
TGCT	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg03517284	chr6:25882590	NA	-0.6	-5.35	-0.43	4.13e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs28489187	0.577	rs6697083	chr1:85887775	A/T	cg16011679	chr1:85725395	C1orf52	-0.48	-4.45	-0.37	1.91e-5	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
TGCT	cis	rs9372498	0.536	rs9481825	chr6:118876092	C/T	cg21191810	chr6:118973309	C6orf204	-0.37	-4.86	-0.4	3.5e-6	Diastolic blood pressure;
TGCT	cis	rs2153535	0.504	rs9328472	chr6:8470848	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs10782582	0.609	rs5745553	chr1:76379135	A/T	cg03433033	chr1:76189801	ACADM	-0.5	-4.89	-0.4	3.09e-6	Daytime sleep phenotypes;
TGCT	cis	rs617219	0.671	rs6414979	chr5:78548010	T/G	cg09550809	chr5:78407562	BHMT	0.4	5.49	0.44	2.19e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs6840360	0.582	rs2709823	chr4:152340446	T/C	cg17479576	chr4:152424074	FAM160A1	-0.57	-5.98	-0.47	2.17e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs896854	0.812	rs12546365	chr8:95911477	T/C	cg16049864	chr8:95962084	TP53INP1	-0.7	-9.71	-0.66	6.27e-17	Type 2 diabetes;
TGCT	cis	rs35771425	0.626	rs55761812	chr1:211653935	C/T	cg10512769	chr1:211675356	NA	-0.25	-4.49	-0.37	1.59e-5	Educational attainment (years of education);
TGCT	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-5.1	-0.42	1.23e-6	Electroencephalogram traits;
TGCT	cis	rs7513165	0.932	rs11240694	chr1:204157973	C/T	cg12731349	chr1:204159619	KISS1	0.5	5.51	0.44	1.94e-7	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
TGCT	cis	rs1757171	0.542	rs1757186	chr6:37484111	A/G	cg01843034	chr6:37503916	NA	-0.54	-7.33	-0.55	2.57e-11	Cognitive performance;
TGCT	cis	rs34779708	0.898	rs4934695	chr10:35280605	C/T	cg04310649	chr10:35416472	CREM	-0.51	-4.55	-0.38	1.24e-5	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs1483890	0.723	rs6549208	chr3:69412134	T/G	cg22125112	chr3:69402811	FRMD4B	0.29	4.74	0.39	5.85e-6	Resting heart rate;
TGCT	cis	rs4711350	0.862	rs602399	chr6:33713779	C/T	cg00334056	chr6:33755658	LEMD2	0.31	4.81	0.4	4.31e-6	Schizophrenia;
TGCT	cis	rs6714710	0.603	rs11681535	chr2:98488949	G/C	cg26665480	chr2:98280029	ACTR1B	0.64	6.03	0.48	1.71e-8	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs9611565	0.918	rs4822024	chr22:41757647	G/A	cg17554472	chr22:41940697	POLR3H	-0.47	-4.79	-0.4	4.59e-6	Vitiligo;
TGCT	cis	rs7945705	0.870	rs10840142	chr11:8906078	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.42	4.7	0.39	6.86e-6	Hemoglobin concentration;
TGCT	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	6.24	0.49	6.22e-9	Mean platelet volume;
TGCT	cis	rs752010	0.746	rs11210499	chr1:42089703	C/T	cg06885757	chr1:42089581	HIVEP3	-0.25	-4.49	-0.37	1.62e-5	Lupus nephritis in systemic lupus erythematosus;
TGCT	cis	rs17376456	0.597	rs10064158	chr5:93095186	C/T	cg21475434	chr5:93447410	FAM172A	0.61	4.95	0.41	2.35e-6	Diabetic retinopathy;
TGCT	cis	rs9303401	0.659	rs62081316	chr17:56781499	C/T	cg25039879	chr17:56429692	SUPT4H1	0.52	4.62	0.38	9.48e-6	Cognitive test performance;
TGCT	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.52	-4.9	-0.4	2.9e-6	Bipolar disorder;
TGCT	cis	rs854765	0.663	rs4925120	chr17:17754633	C/T	cg04398451	chr17:18023971	MYO15A	0.29	4.52	0.38	1.44e-5	Total body bone mineral density;
TGCT	trans	rs877282	1.000	rs71494928	chr10:769134	A/G	cg22713356	chr15:30763199	NA	1.25	10.39	0.68	1.43e-18	Uric acid levels;
TGCT	cis	rs4383453	0.539	rs4677886	chr3:123100196	A/G	cg04890266	chr3:123102914	ADCY5	-0.5	-8.19	-0.59	2.68e-13	Gestational age at birth (maternal effect);
TGCT	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs3806843	0.868	rs2531342	chr5:140130612	C/T	cg19875535	chr5:140030758	IK	-0.36	-5.97	-0.47	2.32e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9325144	0.624	rs7979541	chr12:39129679	T/C	cg13010199	chr12:38710504	ALG10B	-0.52	-4.68	-0.39	7.29e-6	Morning vs. evening chronotype;
TGCT	cis	rs9443189	0.570	rs72888705	chr6:76403114	A/G	cg01950844	chr6:76311363	SENP6	1.0	6.24	0.49	6.35e-9	Prostate cancer;
TGCT	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg18402987	chr7:1209562	NA	0.39	4.99	0.41	1.97e-6	Longevity;Endometriosis;
TGCT	cis	rs832540	0.898	rs252890	chr5:56226410	T/C	cg24531977	chr5:56204891	C5orf35	-0.49	-5.03	-0.41	1.66e-6	Coronary artery disease;
TGCT	cis	rs12477438	0.520	rs6542864	chr2:99725223	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.82	0.62	8.67e-15	Chronic sinus infection;
TGCT	cis	rs35883536	0.528	rs1542837	chr1:101029768	T/C	cg10298815	chr1:101004474	GPR88	0.25	4.69	0.39	7.06e-6	Monocyte count;
TGCT	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg03388025	chr16:89894329	SPIRE2	-0.49	-8.46	-0.6	6.36e-14	Vitiligo;
TGCT	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.09	-16.13	-0.82	3.1e-32	Prudent dietary pattern;
TGCT	cis	rs7474896	0.515	rs594594	chr10:38307723	A/G	cg13720705	chr10:37990370	NA	-0.37	-4.68	-0.39	7.35e-6	Obesity (extreme);
TGCT	cis	rs12541335	0.507	rs9644047	chr8:22158670	T/A	cg18135555	chr8:22132992	PIWIL2	0.28	5.51	0.44	1.98e-7	Hypertriglyceridemia;
TGCT	cis	rs10927875	0.864	rs1976402	chr1:16143779	G/A	cg21385522	chr1:16154831	NA	-0.89	-11.09	-0.71	2.88e-20	Dilated cardiomyopathy;
TGCT	cis	rs5769707	0.837	rs5770599	chr22:50019981	C/G	cg05373962	chr22:49881684	NA	-0.27	-5.14	-0.42	1.03e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs7267979	0.932	rs6115214	chr20:25557426	C/T	cg03522245	chr20:25566470	NINL	-0.58	-6.24	-0.49	6.39e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7809950	1.000	rs7786801	chr7:107085889	C/T	cg23024343	chr7:107201750	COG5	-0.35	-5.54	-0.45	1.71e-7	Coronary artery disease;
TGCT	cis	rs7833790	0.685	rs13255262	chr8:82728024	T/G	cg27398817	chr8:82754497	SNX16	-0.67	-5.34	-0.43	4.27e-7	Diastolic blood pressure;
TGCT	cis	rs11809207	0.522	rs3762459	chr1:26494886	C/G	cg24519413	chr1:26490540	NA	0.22	4.57	0.38	1.18e-5	Height;
TGCT	cis	rs114540395	0.858	rs17767748	chr10:103285900	A/G	cg22630918	chr10:102748988	C10orf2	-0.43	-4.51	-0.38	1.46e-5	Schizophrenia;
TGCT	cis	rs7584330	0.737	rs61212490	chr2:238365230	T/C	cg14458575	chr2:238380390	NA	0.51	8.14	0.59	3.53e-13	Prostate cancer;
TGCT	cis	rs9527	0.590	rs2281877	chr10:104866062	C/T	cg04362960	chr10:104952993	NT5C2	0.7	5.88	0.47	3.57e-8	Arsenic metabolism;
TGCT	cis	rs7666738	0.830	rs13116691	chr4:98929771	A/C	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1008375	0.900	rs12650220	chr4:17595365	A/T	cg10189774	chr4:17578691	LAP3	0.69	5.85	0.47	4.09e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7829975	0.846	rs6601724	chr8:8544872	C/T	cg08975724	chr8:8085496	FLJ10661	-0.53	-4.71	-0.39	6.49e-6	Mood instability;
TGCT	cis	rs2050392	0.894	rs2480277	chr10:30703513	G/T	cg13289132	chr10:30722225	MAP3K8	0.37	4.51	0.38	1.46e-5	Inflammatory bowel disease;
TGCT	cis	rs9486719	1.000	rs4078038	chr6:96904366	A/G	cg06623918	chr6:96969491	KIAA0776	-0.99	-8.79	-0.62	1.03e-14	Migraine;Coronary artery disease;
TGCT	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg03303774	chr4:1407052	NA	-0.34	-5.43	-0.44	2.91e-7	Obesity-related traits;
TGCT	cis	rs61884328	0.852	rs57964319	chr11:47146599	C/T	cg13308137	chr11:47528955	CUGBP1	0.38	4.47	0.37	1.76e-5	Total body bone mineral density (age over 60);
TGCT	cis	rs79149102	0.579	rs12594117	chr15:75323648	C/G	cg09165964	chr15:75287851	SCAMP5	-1.07	-5.81	-0.46	4.93e-8	Lung cancer;
TGCT	cis	rs12142240	0.731	rs12385693	chr1:46818921	A/C	cg07811940	chr1:46828259	NSUN4	0.27	4.56	0.38	1.2e-5	Menopause (age at onset);
TGCT	cis	rs2067615	0.579	rs1922435	chr12:107082455	A/G	cg15890332	chr12:107067104	RFX4	0.3	5.91	0.47	3.15e-8	Heart rate;
TGCT	cis	rs1153858	1.000	rs4775895	chr15:45617957	T/A	cg26924012	chr15:45694286	SPATA5L1	1.05	13.95	0.78	3.56e-27	Homoarginine levels;
TGCT	cis	rs11792861	0.816	rs7021366	chr9:111727670	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.53	4.96	0.41	2.24e-6	Menarche (age at onset);
TGCT	cis	rs2228479	1.000	rs4257207	chr16:89947861	T/A	cg06558623	chr16:89946397	TCF25	0.57	6.46	0.5	2.15e-9	Skin colour saturation;
TGCT	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg24503407	chr1:205819492	PM20D1	0.68	11.04	0.7	3.64e-20	Menarche (age at onset);
TGCT	cis	rs2239547	0.525	rs2246556	chr3:53027983	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	0.49	4.61	0.38	9.77e-6	Schizophrenia;
TGCT	cis	rs7666738	0.791	rs28858828	chr4:98950442	C/G	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs9467711	1.000	rs6923139	chr6:26313348	C/T	cg20516262	chr7:155325649	CNPY1	0.54	6.63	0.51	9.34e-10	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg26119090	chr2:26468346	HADHA;HADHB	0.97	7.19	0.54	5.48e-11	Gut microbiome composition (summer);
TGCT	cis	rs6940638	1.000	rs12204280	chr6:27033104	T/C	cg26531700	chr6:26746687	NA	-0.6	-4.63	-0.38	9.25e-6	Intelligence (multi-trait analysis);
TGCT	trans	rs13270892	0.556	rs57487396	chr8:20469493	C/T	cg14551562	chr9:130461838	NA	-0.89	-6.75	-0.52	5.19e-10	Daytime sleep phenotypes;
TGCT	cis	rs4951018	0.821	rs7529037	chr1:205637501	C/G	cg14159672	chr1:205819179	PM20D1	-0.39	-4.59	-0.38	1.07e-5	Prostate-specific antigen levels;
TGCT	cis	rs17401966	0.931	rs3737155	chr1:10459779	G/A	cg19773385	chr1:10388646	KIF1B	-0.23	-5.42	-0.44	2.97e-7	Hepatocellular carcinoma;
TGCT	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg05985448	chr10:134359359	INPP5A	0.22	4.75	0.39	5.54e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs10927875	0.632	rs6677321	chr1:16149301	A/C	cg14742211	chr1:16348397	CLCNKA	-0.2	-4.79	-0.39	4.75e-6	Dilated cardiomyopathy;
TGCT	cis	rs1008375	0.686	rs34338142	chr4:17626174	T/A	cg10189774	chr4:17578691	LAP3	0.67	5.65	0.45	1.02e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1729951	0.575	rs1654926	chr3:136709924	G/A	cg12473912	chr3:136751656	NA	0.39	6.33	0.49	4.01e-9	Neuroticism;
TGCT	cis	rs17384381	0.953	rs12120551	chr1:85810903	T/C	cg16011679	chr1:85725395	C1orf52	0.84	6.5	0.5	1.74e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs11971779	0.680	rs10229358	chr7:139052545	C/T	cg07862535	chr7:139043722	LUC7L2	-0.57	-4.52	-0.38	1.42e-5	Diisocyanate-induced asthma;
TGCT	cis	rs2334880	0.678	rs12922830	chr16:71447270	C/T	cg06353428	chr16:71660113	MARVELD3	-0.96	-6.35	-0.5	3.66e-9	Malaria;
TGCT	cis	rs9399137	0.507	rs11154791	chr6:135379148	A/G	cg24558204	chr6:135376177	HBS1L	0.47	4.73	0.39	5.98e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
TGCT	cis	rs42648	0.748	rs10226014	chr7:89902533	C/T	cg25739043	chr7:89950458	NA	0.62	6.12	0.48	1.15e-8	Homocysteine levels;
TGCT	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg02353165	chr6:42928485	GNMT	0.95	9.5	0.65	2.01e-16	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs7731657	0.537	rs10073487	chr5:130373397	G/A	cg08523029	chr5:130500466	HINT1	-0.61	-5.08	-0.42	1.34e-6	Fasting plasma glucose;
TGCT	cis	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg02380750	chr20:61661411	NA	0.33	5.96	0.47	2.4e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs11148252	0.532	rs9536185	chr13:53179801	G/A	cg02158880	chr13:53174818	NA	0.49	5.66	0.45	9.75e-8	Lewy body disease;
TGCT	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.54	-5.11	-0.42	1.21e-6	Bipolar disorder;
TGCT	cis	rs61990749	0.597	rs176980	chr14:78198449	C/G	cg02301378	chr14:78227641	SNW1;C14orf178	-0.62	-4.58	-0.38	1.13e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg18305652	chr10:134549665	INPP5A	0.35	6.01	0.48	1.89e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs9467773	0.620	rs2101581	chr6:26622769	G/T	cg15659132	chr6:26577336	NA	0.86	11.08	0.71	3.01e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs651907	0.557	rs7645391	chr3:101361506	C/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.9	10.75	0.69	1.88e-19	Colorectal cancer;
TGCT	cis	rs3820068	0.608	rs12091326	chr1:16048005	A/G	cg17385448	chr1:15911702	AGMAT	0.36	4.76	0.39	5.21e-6	Systolic blood pressure;
TGCT	cis	rs79387448	0.564	rs77375846	chr2:103155075	T/C	cg09003973	chr2:102972529	NA	1.15	6.67	0.51	7.66e-10	Gut microbiota (bacterial taxa);
TGCT	cis	rs6582630	0.555	rs10880421	chr12:38423015	C/T	cg26384229	chr12:38710491	ALG10B	0.85	7.76	0.57	2.69e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs35883536	0.967	rs4908085	chr1:101087901	C/G	cg06223162	chr1:101003688	GPR88	0.29	4.61	0.38	9.73e-6	Monocyte count;
TGCT	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg02463440	chr8:22132932	PIWIL2	0.24	4.69	0.39	7.2e-6	Hypertriglyceridemia;
TGCT	cis	rs7727544	0.716	rs11949055	chr5:131576737	T/C	cg24060327	chr5:131705240	SLC22A5	-0.56	-5.5	-0.44	2.06e-7	Blood metabolite levels;
TGCT	cis	rs12188164	1.000	rs72717411	chr5:429124	C/G	cg26850624	chr5:429559	AHRR	-0.2	-4.81	-0.4	4.22e-6	Cystic fibrosis severity;
TGCT	cis	rs8180040	0.726	rs4682842	chr3:46982773	C/G	cg27129171	chr3:47204927	SETD2	-0.71	-8.76	-0.62	1.25e-14	Colorectal cancer;
TGCT	cis	rs9419702	0.639	rs4367873	chr10:133533485	C/T	cg20568497	chr10:133558893	NA	0.45	4.73	0.39	6e-6	Survival in rectal cancer;
TGCT	cis	rs6785206	0.892	rs6793907	chr3:128391626	A/G	cg14476212	chr3:127535191	MGLL	-0.67	-4.73	-0.39	6.02e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs13242816	1.000	rs56180538	chr7:116079711	C/T	cg02799643	chr7:116139180	CAV2	-0.44	-5.15	-0.42	9.76e-7	P wave duration;
TGCT	cis	rs6688613	1.000	rs12569084	chr1:166943352	T/C	cg07049167	chr1:166818506	POGK	0.22	4.55	0.38	1.25e-5	Refractive astigmatism;
TGCT	cis	rs7590720	0.819	rs12467676	chr2:216895736	T/G	cg12620499	chr2:216877984	MREG	0.9	10.43	0.68	1.17e-18	Alcohol dependence;
TGCT	cis	rs11105298	0.891	rs11105318	chr12:89926658	C/T	cg00757033	chr12:89920650	WDR51B	0.31	5.04	0.41	1.57e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs11249608	0.750	rs6891216	chr5:178447026	G/C	cg01312482	chr5:178451176	ZNF879	-0.55	-5.41	-0.44	3.08e-7	Pubertal anthropometrics;
TGCT	cis	rs12681288	0.550	rs7000482	chr8:958380	T/C	cg04851639	chr8:1020857	NA	-0.27	-4.45	-0.37	1.85e-5	Schizophrenia;
TGCT	cis	rs9926296	0.643	rs12596429	chr16:89841374	T/C	cg08627397	chr16:89984028	MC1R	-0.3	-4.66	-0.39	8.13e-6	Vitiligo;
TGCT	cis	rs13217239	0.646	rs10456351	chr6:26986792	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.4	4.47	0.37	1.76e-5	Schizophrenia;
TGCT	cis	rs877529	0.647	rs139395	chr22:39538433	T/C	cg18708252	chr22:39545030	CBX7	-0.35	-5.34	-0.43	4.28e-7	Multiple myeloma;
TGCT	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg00343986	chr7:65444356	GUSB	0.22	5.01	0.41	1.84e-6	Aortic root size;
TGCT	cis	rs3733346	0.590	rs6848199	chr4:940838	C/T	cg22718636	chr4:961658	DGKQ	0.46	4.47	0.37	1.77e-5	Sjögren's syndrome;
TGCT	cis	rs7246657	0.943	rs12981532	chr19:37889280	G/A	cg18154014	chr19:37997991	ZNF793	0.95	6.63	0.51	9.39e-10	Coronary artery calcification;
TGCT	cis	rs7666738	0.791	rs1896155	chr4:99020948	C/A	cg18180107	chr4:99064573	C4orf37	0.54	5.03	0.41	1.7e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3091242	0.836	rs35346083	chr1:25788425	C/A	cg00786635	chr1:25594202	NA	-0.55	-5.67	-0.45	9.46e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs7666738	0.830	rs35938349	chr4:98974998	T/C	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12142240	0.698	rs10158572	chr1:46822440	G/T	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs7917772	0.582	rs7906115	chr10:104327164	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	5.36	0.43	3.84e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs4563143	0.592	rs12151001	chr19:29283386	C/G	cg14983838	chr19:29218262	NA	0.86	7.07	0.54	9.71e-11	Methadone dose in opioid dependence;
TGCT	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.61	-5.23	-0.42	7.12e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg27454412	chr7:1067447	C7orf50	0.6	4.72	0.39	6.32e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs8179	0.648	rs42036	chr7:92241451	C/G	cg15732164	chr7:92237376	CDK6	-0.3	-5.34	-0.43	4.22e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
TGCT	cis	rs4808199	0.947	rs1465695	chr19:19588546	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.72	5.2	0.42	8.14e-7	Nonalcoholic fatty liver disease;
TGCT	cis	rs9467711	0.606	rs9348709	chr6:26360311	G/A	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7524258	0.868	rs10779678	chr1:7300573	A/G	cg04342483	chr1:7259290	CAMTA1	-0.3	-4.48	-0.37	1.7e-5	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg24531977	chr5:56204891	C5orf35	0.75	7.52	0.56	9.46e-12	Initial pursuit acceleration;
TGCT	cis	rs2486288	0.656	rs8037583	chr15:45546378	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.71	-7.39	-0.55	1.91e-11	Glomerular filtration rate;
TGCT	cis	rs7635838	0.892	rs9310381	chr3:11458466	A/G	cg00170343	chr3:11313890	ATG7	0.65	6.15	0.48	9.98e-9	HDL cholesterol;
TGCT	cis	rs2708977	0.609	rs670498	chr2:97090227	A/G	cg01950434	chr2:97203154	ARID5A	-0.61	-5.17	-0.42	9.02e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs7786808	0.615	rs4909212	chr7:158197037	G/T	cg01191920	chr7:158217561	PTPRN2	-0.41	-6.14	-0.48	1.03e-8	Obesity-related traits;
TGCT	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.94	10.14	0.67	5.79e-18	Intelligence (multi-trait analysis);
TGCT	cis	rs939574	0.858	rs2891733	chr2:220135208	A/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.06	6.67	0.51	7.65e-10	Platelet distribution width;
TGCT	cis	rs9577381	0.628	rs9577380	chr13:112575568	A/G	cg11336860	chr13:112575966	NA	-0.28	-4.45	-0.37	1.87e-5	Axial length;
TGCT	cis	rs9393777	0.513	rs9368451	chr6:26654333	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.59	-4.66	-0.39	8.03e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9467711	0.606	rs9393707	chr6:26362486	T/C	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg03303774	chr4:1407052	NA	0.28	4.57	0.38	1.16e-5	Obesity-related traits;
TGCT	cis	rs2016266	0.964	rs1110720	chr12:53682326	G/A	cg16917193	chr12:54089295	NA	0.67	5.27	0.43	5.83e-7	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs2153535	0.580	rs7775909	chr6:8477778	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs950027	0.549	rs1719250	chr15:45609773	A/G	cg26924012	chr15:45694286	SPATA5L1	0.78	8.49	0.61	5.48e-14	Response to fenofibrate (adiponectin levels);
TGCT	trans	rs10203711	1.000	rs10207724	chr2:239566705	G/C	cg16021909	chr1:248021091	TRIM58	-0.66	-6.66	-0.51	7.94e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9467773	0.620	rs1027204	chr6:26639613	T/C	cg26531700	chr6:26746687	NA	0.5	4.68	0.39	7.52e-6	Intelligence (multi-trait analysis);
TGCT	trans	rs9364554	0.506	rs3125055	chr6:160736787	A/T	cg01534613	chr7:96337050	SHFM1	0.54	6.66	0.51	8e-10	Prostate cancer (SNP x SNP interaction);Prostate cancer;
TGCT	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg03303774	chr4:1407052	NA	0.31	4.93	0.4	2.58e-6	Obesity-related traits;
TGCT	cis	rs11264213	0.901	rs72661644	chr1:36453894	G/A	cg27506609	chr1:36549197	TEKT2	0.41	4.61	0.38	9.88e-6	Schizophrenia;
TGCT	cis	rs4851266	0.933	rs6709656	chr2:100806719	A/G	cg07810366	chr2:100720526	AFF3	-0.39	-5.69	-0.46	8.49e-8	Educational attainment;
TGCT	cis	rs2658782	1.000	rs2605582	chr11:93163799	C/T	cg15737290	chr11:93063684	CCDC67	0.78	5.51	0.44	1.94e-7	Pulmonary function decline;
TGCT	cis	rs3125734	0.719	rs3852410	chr10:64037563	A/G	cg09941381	chr10:64027924	RTKN2	0.33	4.67	0.39	7.61e-6	Rheumatoid arthritis;
TGCT	cis	rs2502731	1.000	rs2502731	chr9:130976557	A/G	cg09976142	chr9:130955436	CIZ1	-0.45	-5.3	-0.43	5.21e-7	Attention deficit hyperactivity disorder;
TGCT	cis	rs2921036	0.505	rs35190619	chr8:8361823	A/C	cg06636001	chr8:8085503	FLJ10661	-0.64	-5.72	-0.46	7.43e-8	Neuroticism;
TGCT	cis	rs2338224	1.000	rs10043295	chr5:71743024	C/G	cg01187920	chr5:71015162	CARTPT	-0.53	-4.61	-0.38	9.68e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Granulocyte count;Myeloid white cell count;
TGCT	cis	rs7267979	1.000	rs6138575	chr20:25438952	G/A	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs9951602	1.000	rs9949784	chr18:76649994	A/G	cg02800362	chr5:177631904	HNRNPAB	1.02	7.23	0.54	4.4e-11	Obesity-related traits;
TGCT	cis	rs60843830	0.964	rs17713879	chr2:254215	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.7	7.03	0.53	1.22e-10	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs56104184	0.775	rs73061694	chr19:49399978	T/C	cg17863274	chr19:49399704	TULP2	-0.54	-7.43	-0.55	1.58e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs13191362	0.935	rs13193473	chr6:162966852	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.66	5.11	0.42	1.17e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs4886920	0.666	rs12591307	chr15:78081529	C/T	cg25212270	chr15:78015279	NA	-0.23	-4.86	-0.4	3.45e-6	Neuroticism;
TGCT	cis	rs10927875	0.793	rs1763619	chr1:16326935	A/G	cg21385522	chr1:16154831	NA	0.64	6.9	0.53	2.33e-10	Dilated cardiomyopathy;
TGCT	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg03934478	chr11:495069	RNH1	0.35	5.89	0.47	3.34e-8	Body mass index;
TGCT	cis	rs727505	0.721	rs67817822	chr7:124769572	A/G	cg23710748	chr7:124431027	NA	-0.25	-4.44	-0.37	1.97e-5	Lewy body disease;
TGCT	cis	rs524281	0.861	rs10791854	chr11:65963543	A/T	cg00563793	chr11:65837595	PACS1	0.53	4.67	0.39	7.6e-6	Electroencephalogram traits;
TGCT	cis	rs7937682	0.889	rs479667	chr11:111484034	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.05	-11.35	-0.71	6.63e-21	Primary sclerosing cholangitis;
TGCT	cis	rs5769765	0.704	rs138837	chr22:50180714	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.93	-8.67	-0.61	2.04e-14	Schizophrenia;
TGCT	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg16423285	chr20:60520624	NA	-0.69	-7.11	-0.54	8.23e-11	Body mass index;
TGCT	cis	rs1577917	0.761	rs117452258	chr6:86554211	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.29	-0.43	5.34e-7	Response to antipsychotic treatment;
TGCT	cis	rs72843506	0.722	rs75226250	chr17:20132317	G/A	cg18979559	chr17:20280153	CCDC144C	-0.64	-4.84	-0.4	3.71e-6	Schizophrenia;
TGCT	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7666738	0.830	rs13148324	chr4:98833616	G/A	cg05340658	chr4:99064831	C4orf37	0.53	6.18	0.49	8.5e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9303401	0.614	rs12948536	chr17:56580413	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.63	6.36	0.5	3.54e-9	Cognitive test performance;
TGCT	cis	rs78487399	0.519	rs11124929	chr2:43582103	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.4	-6.08	-0.48	1.36e-8	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	trans	rs8048207	1.000	rs4567699	chr16:61792663	C/T	cg12718502	chr12:2999424	TULP3	-0.71	-6.8	-0.52	4.01e-10	Non-small cell lung cancer;
TGCT	cis	rs1865760	0.929	rs2876693	chr6:25954434	C/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.65	6.25	0.49	6.04e-9	Height;
TGCT	cis	rs11711311	1.000	rs12736	chr3:113530211	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.76	-7.16	-0.54	6.29e-11	IgG glycosylation;
TGCT	cis	rs6484504	0.576	rs208071	chr11:31144996	C/T	cg26647111	chr11:31128758	NA	-0.33	-4.55	-0.38	1.27e-5	Red blood cell count;
TGCT	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg18305652	chr10:134549665	INPP5A	0.35	5.94	0.47	2.73e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs981844	1.000	rs1116636	chr4:154657151	C/T	cg14289246	chr4:154710475	SFRP2	1.01	8.46	0.6	6.31e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs586688	0.696	rs1256457	chr1:201659739	T/C	cg07139329	chr1:201708558	NAV1	-0.55	-5.47	-0.44	2.37e-7	Obesity-related traits;
TGCT	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg00814883	chr7:100076585	TSC22D4	-0.85	-8.62	-0.61	2.62e-14	Platelet count;
TGCT	cis	rs12484776	0.729	rs67465697	chr22:40531645	A/G	cg07138101	chr22:40742427	ADSL	0.61	4.6	0.38	1.01e-5	Uterine fibroids;
TGCT	cis	rs7178572	0.568	rs12912050	chr15:77689423	C/T	cg22256960	chr15:77711686	NA	-0.88	-9.16	-0.64	1.32e-15	Type 2 diabetes;
TGCT	cis	rs367615	0.660	rs10477972	chr5:108831951	C/A	cg17395555	chr5:108820864	NA	0.31	5.9	0.47	3.17e-8	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs7829975	0.572	rs7005000	chr8:8796602	A/G	cg15556689	chr8:8085844	FLJ10661	-0.69	-6.25	-0.49	5.93e-9	Mood instability;
TGCT	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	8.39	0.6	9.03e-14	Platelet count;
TGCT	cis	rs919433	0.647	rs1979239	chr2:198498316	T/G	cg00792783	chr2:198669748	PLCL1	0.56	5.03	0.41	1.68e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg03709012	chr19:19516395	GATAD2A	0.75	6.16	0.48	9.21e-9	Tonsillectomy;
TGCT	cis	rs7772486	0.686	rs9403741	chr6:146030548	G/A	cg23711669	chr6:146136114	FBXO30	-0.88	-9.77	-0.66	4.64e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7267979	0.966	rs454723	chr20:25438928	G/C	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6998277	0.830	rs17186961	chr8:103630028	G/A	cg10187029	chr8:103597600	NA	0.5	7.42	0.55	1.66e-11	Migraine;
TGCT	cis	rs9291683	0.588	rs13133766	chr4:10019732	C/T	cg00071950	chr4:10020882	SLC2A9	0.75	10.33	0.68	2.04e-18	Bone mineral density;
TGCT	cis	rs3087591	1.000	rs2012988	chr17:29547296	T/C	cg24425628	chr17:29625626	OMG;NF1	0.46	7.18	0.54	5.72e-11	Hip circumference;
TGCT	cis	rs7089973	0.604	rs2181563	chr10:116604344	T/C	cg03647239	chr10:116582469	FAM160B1	0.6	5.73	0.46	7.18e-8	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs2033711	0.870	rs1465789	chr19:58946056	C/T	cg13877915	chr19:58951672	ZNF132	0.9	11.15	0.71	2.05e-20	Uric acid clearance;
TGCT	cis	rs11711311	1.000	rs3732793	chr3:113442198	C/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.76	-6.84	-0.52	3.17e-10	IgG glycosylation;
TGCT	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg11366901	chr6:160182831	ACAT2	1.01	6.74	0.52	5.42e-10	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs2885056	0.783	rs73007347	chr19:10650649	C/T	cg04833646	chr19:10679720	CDKN2D	0.92	8.19	0.59	2.65e-13	Red cell distribution width;
TGCT	cis	rs986417	0.818	rs4278669	chr14:60982075	T/C	cg27398547	chr14:60952738	C14orf39	1.5	10.38	0.68	1.54e-18	Gut microbiota (bacterial taxa);
TGCT	cis	rs11107903	1.000	rs11107904	chr12:95515719	T/C	cg10621809	chr12:95840313	NA	0.67	4.52	0.38	1.41e-5	Coronary artery disease;
TGCT	cis	rs6920965	0.509	rs654213	chr6:126149127	C/T	cg05901451	chr6:126070800	HEY2	0.54	4.82	0.4	4.1e-6	High light scatter reticulocyte count;
TGCT	cis	rs35264875	0.851	rs72930631	chr11:68867835	T/C	cg02660097	chr11:68866761	NA	0.32	5.06	0.41	1.48e-6	Blond vs. brown hair color;
TGCT	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.97	7.19	0.54	5.48e-11	Gut microbiome composition (summer);
TGCT	cis	rs7811142	1.000	rs6972167	chr7:100080013	G/T	cg00814883	chr7:100076585	TSC22D4	-0.91	-9.41	-0.65	3.39e-16	Platelet count;
TGCT	cis	rs9372498	0.536	rs62421539	chr6:118730559	C/A	cg21191810	chr6:118973309	C6orf204	-0.37	-4.77	-0.39	5.03e-6	Diastolic blood pressure;
TGCT	cis	rs9611565	0.512	rs4822052	chr22:42193741	G/A	cg13695892	chr22:41940480	POLR3H	-0.83	-8.2	-0.59	2.54e-13	Vitiligo;
TGCT	cis	rs3806843	0.576	rs246063	chr5:140324492	T/A	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs921968	0.715	rs62182125	chr2:219274142	G/A	cg02176678	chr2:219576539	TTLL4	0.37	5.34	0.43	4.28e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs782590	0.559	rs12617719	chr2:55915826	G/C	cg18811423	chr2:55921094	PNPT1	-0.68	-7.6	-0.56	6.39e-12	Metabolic syndrome;
TGCT	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg13683864	chr3:40499215	RPL14	-1.18	-13.68	-0.78	1.54e-26	Renal cell carcinoma;
TGCT	trans	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg21659725	chr3:3221576	CRBN	-0.73	-8.46	-0.6	6.21e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs4689388	0.856	rs10016157	chr4:6294414	T/C	cg00701064	chr4:6280414	WFS1	0.37	4.72	0.39	6.3e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs4478858	0.735	rs1566964	chr1:31792794	C/A	cg07478791	chr1:31886160	SERINC2	-0.51	-4.94	-0.41	2.47e-6	Alcohol dependence;
TGCT	cis	rs11677203	1.000	rs12990104	chr2:12564429	G/A	cg00419568	chr2:11919532	LPIN1	-0.2	-4.55	-0.38	1.26e-5	Electroencephalogram traits;
TGCT	cis	rs8031584	0.736	rs11635775	chr15:31160640	A/G	cg08109568	chr15:31115862	NA	-0.39	-5.18	-0.42	8.86e-7	Huntington's disease progression;
TGCT	cis	rs1008375	1.000	rs555	chr4:17625658	A/G	cg18681998	chr4:17616180	MED28	1.0	11.31	0.71	8.26e-21	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9318086	0.648	rs78881146	chr13:24468704	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.83	9.04	0.63	2.62e-15	Myopia (pathological);
TGCT	cis	rs4727027	0.704	rs7787753	chr7:148901779	A/T	cg23583168	chr7:148888333	NA	-0.81	-10.92	-0.7	7.37e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	trans	rs72737821	0.714	rs17385947	chr1:98655574	C/A	cg14575559	chr19:18111766	ARRDC2	0.61	6.69	0.51	6.93e-10	Cognitive ability;Cognitive ability (multi-trait analysis);
TGCT	cis	rs67311347	1.000	rs28434528	chr3:40484893	A/G	cg13683864	chr3:40499215	RPL14	-1.04	-10.79	-0.7	1.54e-19	Renal cell carcinoma;
TGCT	cis	rs74233809	1.000	rs77602510	chr10:104682602	G/A	cg05855489	chr10:104503620	C10orf26	0.74	4.45	0.37	1.87e-5	Birth weight;
TGCT	cis	rs1964356	0.967	rs17701675	chr8:8850633	A/G	cg06636001	chr8:8085503	FLJ10661	-0.72	-6.29	-0.49	4.95e-9	Mean corpuscular volume;
TGCT	cis	rs2236918	0.710	rs2797603	chr1:242029027	T/G	cg04158730	chr1:242011433	EXO1	0.56	5.2	0.42	8.05e-7	Menopause (age at onset);
TGCT	cis	rs1023500	0.573	rs133378	chr22:42467695	G/C	cg15557168	chr22:42548783	NA	-0.23	-5.77	-0.46	6e-8	Schizophrenia;
TGCT	cis	rs6866344	0.570	rs1132338	chr5:178139442	T/G	cg10224037	chr5:178157518	ZNF354A	0.98	9.68	0.66	7.49e-17	Neutrophil percentage of white cells;
TGCT	cis	rs9486719	0.901	rs13206547	chr6:97006942	T/C	cg18709589	chr6:96969512	KIAA0776	-0.77	-5.47	-0.44	2.38e-7	Migraine;Coronary artery disease;
TGCT	cis	rs644799	1.000	rs505220	chr11:95563228	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.82	8.63	0.61	2.52e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg11764359	chr7:65958608	NA	-0.54	-4.9	-0.4	2.89e-6	Aortic root size;
TGCT	cis	rs13242816	1.000	rs62469031	chr7:116195841	A/G	cg16553024	chr7:116138462	CAV2	-0.43	-5.19	-0.42	8.16e-7	P wave duration;
TGCT	cis	rs7223966	1.000	rs8067431	chr17:61817048	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	4.57	0.38	1.16e-5	Hip circumference adjusted for BMI;Body mass index;
TGCT	trans	rs459571	0.959	rs416390	chr9:136908549	C/G	cg09836344	chr4:1243392	C4orf42;CTBP1	0.73	7.95	0.58	9.76e-13	Platelet distribution width;
TGCT	cis	rs5769765	0.955	rs9616368	chr22:50303533	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.17	-11.76	-0.73	6.61e-22	Schizophrenia;
TGCT	cis	rs1894292	0.527	rs1894293	chr4:74352022	G/A	cg05868023	chr4:75230803	EREG	0.51	4.5	0.37	1.56e-5	Prostate cancer;
TGCT	cis	rs1497406	0.744	rs924203	chr1:16511539	G/T	cg20430773	chr1:16534157	ARHGEF19	0.55	6.25	0.49	6e-9	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs10114408	0.959	rs7033563	chr9:96663499	T/C	cg13679303	chr9:96623674	NA	-0.36	-4.63	-0.38	9.04e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg00814883	chr7:100076585	TSC22D4	-0.92	-9.76	-0.66	4.73e-17	Platelet count;
TGCT	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg17554472	chr22:41940697	POLR3H	-0.47	-4.86	-0.4	3.54e-6	Vitiligo;
TGCT	cis	rs295140	0.605	rs10931893	chr2:201114652	A/G	cg23649088	chr2:200775458	C2orf69	-0.3	-5.03	-0.41	1.7e-6	QT interval;
TGCT	cis	rs1534166	0.647	rs7355929	chr3:133514190	C/T	cg08048268	chr3:133502702	NA	0.45	5.47	0.44	2.34e-7	Alcohol consumption (transferrin glycosylation);
TGCT	cis	rs9549367	0.789	rs9549361	chr13:113898329	C/T	cg00898013	chr13:113819073	PROZ	0.4	4.95	0.41	2.36e-6	Platelet distribution width;
TGCT	cis	rs9921222	0.656	rs12719801	chr16:381141	C/T	cg10349874	chr16:420996	TMEM8A;MRPL28	-0.26	-4.63	-0.38	9.21e-6	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs7567389	0.600	rs7590030	chr2:128055967	G/A	cg09760422	chr2:128146352	NA	-0.39	-5.18	-0.42	8.76e-7	Self-rated health;
TGCT	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg18402987	chr7:1209562	NA	0.78	6.64	0.51	8.96e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs763121	0.819	rs5750629	chr22:38985065	T/C	cg06022373	chr22:39101656	GTPBP1	0.81	8.26	0.6	1.84e-13	Menopause (age at onset);
TGCT	cis	rs7043114	0.507	rs6479420	chr9:95116406	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-5.56	-0.45	1.61e-7	Height;
TGCT	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg06238570	chr21:40685208	BRWD1	0.69	6.41	0.5	2.71e-9	Cognitive function;
TGCT	cis	rs6088580	0.634	rs6058051	chr20:33044862	G/A	cg06115741	chr20:33292138	TP53INP2	0.55	4.68	0.39	7.39e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs9399135	0.967	rs9389256	chr6:135331254	A/C	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.36e-6	Red blood cell count;
TGCT	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs9790314	0.846	rs6441371	chr3:161008727	C/A	cg03342759	chr3:160939853	NMD3	-0.42	-4.51	-0.38	1.5e-5	Morning vs. evening chronotype;
TGCT	cis	rs6121246	0.647	rs6088855	chr20:30225792	C/T	cg21427119	chr20:30132790	HM13	-0.35	-4.74	-0.39	5.73e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs10197940	0.578	rs2045025	chr2:152317531	T/C	cg19508488	chr2:152266495	RIF1	0.61	5.12	0.42	1.12e-6	Lung cancer;
TGCT	cis	rs909674	0.865	rs5757682	chr22:39848259	T/G	cg01416388	chr22:39784598	NA	-0.69	-6.28	-0.49	5.3e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs941873	0.868	rs7332	chr10:81114060	G/A	cg09469691	chr10:81107165	PPIF	0.64	6.53	0.51	1.5e-9	Height;
TGCT	cis	rs2932538	0.922	rs2932535	chr1:113201412	G/C	cg22162597	chr1:113214053	CAPZA1	-0.27	-5.98	-0.47	2.24e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs7255045	0.752	rs2242512	chr19:12975599	G/A	cg06537894	chr19:12978706	MAST1	-0.49	-4.48	-0.37	1.69e-5	Mean corpuscular volume;
TGCT	cis	rs35828350	1	rs35828350	chr15:85355841	G/A	cg12863693	chr15:85201151	NMB	0.41	4.92	0.4	2.65e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4409675	0.576	rs12062621	chr1:28230404	A/G	cg23691781	chr1:28212827	C1orf38	0.25	5.38	0.43	3.59e-7	Corneal astigmatism;
TGCT	cis	rs2956278	0.717	rs986802	chr12:84683978	T/C	cg25678815	chr12:85673915	ALX1	-0.53	-4.76	-0.39	5.4e-6	Depressive symptoms;Depressive symptoms (multi-trait analysis);
TGCT	trans	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg21659725	chr3:3221576	CRBN	-0.98	-15.33	-0.81	2.1000000000000002e-30	Intelligence (multi-trait analysis);
TGCT	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg10862848	chr6:42927986	GNMT	-0.4	-4.97	-0.41	2.14e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs13242816	1.000	rs7796429	chr7:116144369	T/C	cg02799643	chr7:116139180	CAV2	-0.42	-5.46	-0.44	2.45e-7	P wave duration;
TGCT	cis	rs881375	0.678	rs3761846	chr9:123689597	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.4	4.64	0.38	8.89e-6	Rheumatoid arthritis;
TGCT	cis	rs2486288	0.656	rs11631021	chr15:45556829	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.81	-8.67	-0.61	1.95e-14	Glomerular filtration rate;
TGCT	cis	rs12477438	0.765	rs12612688	chr2:99613091	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.54	-4.66	-0.39	8.04e-6	Chronic sinus infection;
TGCT	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg01802117	chr1:53393560	SCP2	0.43	5.12	0.42	1.14e-6	Monocyte count;
TGCT	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg25767906	chr1:53392781	SCP2	-0.61	-7.35	-0.55	2.37e-11	Monocyte count;
TGCT	cis	rs17473412	1.000	rs6595439	chr5:122692786	G/C	cg15125798	chr5:122621645	NA	-0.54	-4.96	-0.41	2.28e-6	Total body bone mineral density;
TGCT	cis	rs8054556	0.656	rs4420550	chr16:29938820	A/G	cg26859862	chr16:30389551	SEPT1	-0.54	-4.61	-0.38	9.9e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs694739	0.628	rs508168	chr11:64135435	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.69	6.78	0.52	4.25e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs5769707	0.872	rs5770604	chr22:50030672	G/A	cg05373962	chr22:49881684	NA	-0.29	-5.5	-0.44	2.06e-7	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs6543140	0.964	rs6761350	chr2:103030776	A/G	cg09003973	chr2:102972529	NA	0.59	4.95	0.41	2.39e-6	Blood protein levels;
TGCT	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg24829409	chr8:58192753	C8orf71	-0.59	-5.18	-0.42	8.54e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7731657	0.537	rs13355837	chr5:130360537	C/T	cg08523029	chr5:130500466	HINT1	-0.6	-4.91	-0.4	2.79e-6	Fasting plasma glucose;
TGCT	cis	rs9534288	0.659	rs9534314	chr13:46654844	A/G	cg15192986	chr13:46630673	CPB2	-0.53	-6.39	-0.5	3.01e-9	Blood protein levels;
TGCT	cis	rs7655441	1.000	rs11098957	chr4:80880510	C/T	cg02241357	chr4:80885279	ANTXR2	-0.23	-4.46	-0.37	1.81e-5	Neutrophil percentage of white cells;
TGCT	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg17345569	chr6:42928274	GNMT	0.47	5.41	0.44	3.15e-7	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs9677476	0.516	rs2303350	chr2:232030555	G/A	cg27665808	chr2:232055229	NA	0.35	4.43	0.37	2.01e-5	Food antigen IgG levels;
TGCT	cis	rs2580764	0.678	rs2255112	chr2:55200800	T/G	cg09592903	chr2:55203963	RTN4	0.24	5.4	0.44	3.33e-7	Mean platelet volume;
TGCT	cis	rs669446	0.591	rs483679	chr1:44108119	T/A	cg12908607	chr1:44402522	ARTN	-0.55	-5.9	-0.47	3.25e-8	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs12908161	0.515	rs12907646	chr15:85403496	G/A	cg11189052	chr15:85197271	WDR73	0.65	4.81	0.4	4.3e-6	Schizophrenia;
TGCT	cis	rs7666738	0.800	rs2865988	chr4:99067807	T/C	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.44e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1018836	0.700	rs10504894	chr8:91516436	G/A	cg16814680	chr8:91681699	NA	-0.8	-7.98	-0.58	8.34e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2070433	0.539	rs2070432	chr21:47957332	G/A	cg12379764	chr21:47803548	PCNT	0.52	5.17	0.42	9.2e-7	Lymphocyte counts;
TGCT	cis	rs840163	0.512	rs7954692	chr12:57259162	A/G	cg20779414	chr12:57505882	STAT6	0.44	4.85	0.4	3.64e-6	Alzheimer's disease (survival time);
TGCT	cis	rs11864453	0.647	rs7194397	chr16:72128299	C/T	cg14768367	chr16:72042858	DHODH	0.52	5.27	0.43	5.78e-7	Fibrinogen levels;
TGCT	cis	rs9987353	0.544	rs2929470	chr8:9062490	A/G	cg15556689	chr8:8085844	FLJ10661	-0.52	-5.1	-0.42	1.23e-6	Recombination measurement;
TGCT	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg06481639	chr22:41940642	POLR3H	0.73	6.49	0.5	1.83e-9	Vitiligo;
TGCT	cis	rs7208859	0.573	rs216442	chr17:28931197	T/G	cg14008862	chr17:28927542	LRRC37B2	0.88	5.32	0.43	4.75e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7937682	0.883	rs568506	chr11:111466429	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.99	-10.02	-0.67	1.16e-17	Primary sclerosing cholangitis;
TGCT	cis	rs4689388	0.926	rs1801214	chr4:6303022	C/T	cg25554036	chr4:6271136	WFS1	0.53	7.39	0.55	1.88e-11	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs11676348	0.818	rs6436031	chr2:218979259	T/C	cg00012203	chr2:219082015	ARPC2	-0.51	-4.93	-0.4	2.58e-6	Ulcerative colitis;
TGCT	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.64	0.38	8.63e-6	Prudent dietary pattern;
TGCT	cis	rs11031096	0.678	rs12222136	chr11:4180148	T/C	cg18678763	chr11:4115507	RRM1	-0.44	-5.75	-0.46	6.48e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs11650494	0.706	rs76778410	chr17:47459877	A/T	cg08112188	chr17:47440006	ZNF652	1.05	4.73	0.39	6.01e-6	Prostate cancer;
TGCT	cis	rs7017914	0.935	rs2732097	chr8:71920013	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.55	-5.1	-0.42	1.24e-6	Bone mineral density;
TGCT	cis	rs56104184	0.775	rs56149557	chr19:49401384	C/A	cg21252483	chr19:49399788	TULP2	-0.42	-5.89	-0.47	3.47e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs7208859	0.573	rs7214313	chr17:29138596	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg03303774	chr4:1407052	NA	0.3	4.74	0.39	5.73e-6	Obesity-related traits;
TGCT	cis	rs9467711	0.606	rs9393714	chr6:26373740	G/T	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs5769765	0.862	rs9616385	chr22:50313124	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.43	6.08	0.48	1.35e-8	Schizophrenia;
TGCT	cis	rs1775715	0.707	rs2808094	chr10:32133756	T/C	cg14930904	chr10:32216787	ARHGAP12	0.51	4.91	0.4	2.79e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs7582180	0.652	rs11675901	chr2:100951189	G/A	cg08017756	chr2:100939284	LONRF2	-0.3	-4.82	-0.4	4.16e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9581857	0.556	rs9581863	chr13:28040171	A/G	cg22138327	chr13:27999177	GTF3A	0.73	5.63	0.45	1.13e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg08736216	chr1:53307985	ZYG11A	-0.26	-5.16	-0.42	9.38e-7	Monocyte count;
TGCT	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg24829409	chr8:58192753	C8orf71	-0.59	-4.97	-0.41	2.17e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs793571	0.669	rs714696	chr15:58962987	C/G	cg05156742	chr15:59063176	FAM63B	0.49	4.61	0.38	9.88e-6	Schizophrenia;
TGCT	cis	rs56235845	0.694	rs12055081	chr5:176757191	C/T	cg06060754	chr5:176797920	RGS14	0.4	6.33	0.49	3.99e-9	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg05721485	chr17:44071124	MAPT	0.24	4.44	0.37	1.99e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg22857025	chr5:266934	NA	-0.31	-6.32	-0.49	4.33e-9	Breast cancer;
TGCT	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg24250549	chr1:154909240	PMVK	0.65	6.49	0.5	1.84e-9	Prostate cancer;
TGCT	cis	rs11190604	1.000	rs11190587	chr10:102266638	C/T	cg16342193	chr10:102329863	NA	-0.41	-5.18	-0.42	8.61e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs35883536	0.514	rs4908062	chr1:101013211	T/C	cg06223162	chr1:101003688	GPR88	0.42	8.13	0.59	3.84e-13	Monocyte count;
TGCT	cis	rs523522	0.923	rs1048830	chr12:120882217	G/T	cg12219531	chr12:120966889	COQ5	0.79	6.99	0.53	1.47e-10	High light scatter reticulocyte count;
TGCT	cis	rs72781680	0.898	rs112985192	chr2:24102797	G/A	cg08917208	chr2:24149416	ATAD2B	0.78	4.79	0.4	4.69e-6	Lymphocyte counts;
TGCT	cis	rs7267979	1.000	rs4813566	chr20:25386465	G/T	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7829975	0.606	rs7837026	chr8:8801692	T/C	cg15556689	chr8:8085844	FLJ10661	-0.73	-6.18	-0.49	8.44e-9	Mood instability;
TGCT	cis	rs7822232	1.000	rs7822232	chr8:145145687	A/C	cg26272248	chr8:145163034	KIAA1875	-0.37	-4.68	-0.39	7.29e-6	Blood metabolite levels;
TGCT	cis	rs9549367	0.664	rs3794419	chr13:113851874	T/C	cg00898013	chr13:113819073	PROZ	-0.52	-6.7	-0.52	6.5e-10	Platelet distribution width;
TGCT	cis	rs763121	0.853	rs5757162	chr22:38993370	C/T	cg06022373	chr22:39101656	GTPBP1	0.78	7.43	0.56	1.51e-11	Menopause (age at onset);
TGCT	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.45	-4.81	-0.4	4.31e-6	Longevity;Endometriosis;
TGCT	cis	rs2456568	0.548	rs10765647	chr11:93662459	T/C	cg17595323	chr11:93583763	C11orf90	-0.42	-5.26	-0.43	6.25e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7772486	0.790	rs6924159	chr6:146267873	A/G	cg05347473	chr6:146136440	FBXO30	-0.52	-5.03	-0.41	1.67e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.51	5.37	0.43	3.71e-7	Menopause (age at onset);
TGCT	cis	rs1505368	0.567	rs972491	chr2:213316573	A/G	cg16329650	chr2:213403929	ERBB4	-0.84	-9.76	-0.66	4.71e-17	Symmetrical dimethylarginine levels;
TGCT	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg20276088	chr3:133502917	NA	-0.25	-5.1	-0.42	1.24e-6	Iron status biomarkers;
TGCT	cis	rs10089	1.000	rs2409109	chr5:127461471	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	7.41	0.55	1.72e-11	Ileal carcinoids;
TGCT	cis	rs11696501	0.688	rs6104247	chr20:44244938	C/T	cg11783356	chr20:44313418	WFDC10B	-0.32	-4.52	-0.38	1.41e-5	Brain structure;
TGCT	cis	rs72781680	0.716	rs2712079	chr2:24082061	G/A	cg08917208	chr2:24149416	ATAD2B	0.75	4.61	0.38	9.75e-6	Lymphocyte counts;
TGCT	cis	rs1451375	1.000	rs921451	chr7:50623285	A/G	cg18232548	chr7:50535776	DDC	0.4	6.28	0.49	5.26e-9	Malaria;
TGCT	cis	rs9733	0.818	rs4970924	chr1:150633079	A/G	cg13175981	chr1:150552382	MCL1	0.43	4.79	0.4	4.61e-6	Tonsillectomy;
TGCT	cis	rs3849570	1.000	rs11711331	chr3:81819040	A/G	cg07356753	chr3:81810745	GBE1	0.84	7.65	0.57	4.85e-12	Waist circumference;Body mass index;
TGCT	cis	rs826838	1.000	rs11168217	chr12:38884278	T/C	cg13010199	chr12:38710504	ALG10B	0.78	6.59	0.51	1.14e-9	Heart rate;
TGCT	cis	rs986417	1.000	rs10130255	chr14:60944435	C/T	cg27398547	chr14:60952738	C14orf39	1.39	10.61	0.69	4.06e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs4713118	0.955	rs34752872	chr6:27683244	A/T	cg10876282	chr6:28092338	ZSCAN16	0.5	4.62	0.38	9.35e-6	Parkinson's disease;
TGCT	cis	rs10751667	0.857	rs7481221	chr11:966813	G/C	cg06064525	chr11:970664	AP2A2	-0.36	-8.22	-0.59	2.3e-13	Alzheimer's disease (late onset);
TGCT	cis	rs1395	0.778	rs12465084	chr2:27414203	G/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.64	8.78	0.62	1.1e-14	Blood metabolite levels;
TGCT	cis	rs10744422	1.000	rs2292135	chr12:123334075	G/A	cg25930673	chr12:123319894	HIP1R	-0.86	-5.02	-0.41	1.72e-6	Schizophrenia;
TGCT	cis	rs612683	0.518	rs565590	chr1:100846956	T/C	cg06223162	chr1:101003688	GPR88	0.27	4.52	0.38	1.45e-5	Breast cancer;
TGCT	cis	rs10489202	0.608	rs35059151	chr1:168079393	C/A	cg24449463	chr1:168025552	DCAF6	-0.49	-5.06	-0.41	1.49e-6	Schizophrenia;
TGCT	cis	rs6088580	0.634	rs6142164	chr20:33006597	C/T	cg08999081	chr20:33150536	PIGU	-0.28	-5.51	-0.44	1.96e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg22920501	chr2:26401640	FAM59B	0.74	5.78	0.46	5.68e-8	Gut microbiome composition (summer);
TGCT	cis	rs7926906	1.000	rs1404524	chr11:90533647	T/G	cg26138821	chr11:89956704	CHORDC1	-0.5	-5.33	-0.43	4.44e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs12458462	0.892	rs2007483	chr18:77476131	A/T	cg11879182	chr18:77439856	CTDP1	0.71	8.04	0.59	6.07e-13	Monocyte count;
TGCT	cis	rs11676348	0.811	rs13027120	chr2:219020914	C/T	cg00012203	chr2:219082015	ARPC2	0.49	4.77	0.39	5.04e-6	Ulcerative colitis;
TGCT	cis	rs1372520	0.808	rs1372518	chr4:90757294	A/C	cg14346243	chr4:90757452	SNCA	-0.64	-5.24	-0.43	6.59e-7	Neuroticism;
TGCT	cis	rs12701220	0.817	rs1058729	chr7:1087283	C/T	cg07217954	chr7:1067459	C7orf50	-0.47	-4.59	-0.38	1.08e-5	Bronchopulmonary dysplasia;
TGCT	cis	rs17490626	0.568	rs12413523	chr10:71211664	C/G	cg12610070	chr10:71211762	TSPAN15	-0.62	-7.15	-0.54	6.52e-11	Thrombosis;
TGCT	cis	rs1008375	1.000	rs17507481	chr4:17620066	A/G	cg18681998	chr4:17616180	MED28	1.07	12.0	0.73	1.7e-22	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs910316	1.000	rs11623413	chr14:75588824	C/T	cg08847533	chr14:75593920	NEK9	-0.96	-11.1	-0.71	2.62e-20	Height;
TGCT	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.7	7.42	0.55	1.61e-11	Menarche (age at onset);
TGCT	cis	rs7178572	0.524	rs7163503	chr15:77493505	C/A	cg15453836	chr15:77711506	NA	-0.44	-4.91	-0.4	2.86e-6	Type 2 diabetes;
TGCT	cis	rs12220898	0.749	rs6537520	chr10:50484107	T/C	cg09603381	chr10:49954066	WDFY4	0.38	4.45	0.37	1.88e-5	Inflammatory biomarkers;
TGCT	cis	rs3749237	0.595	rs7637999	chr3:49535115	C/T	cg03060546	chr3:49711283	APEH	0.76	8.69	0.62	1.77e-14	Resting heart rate;
TGCT	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg02038168	chr22:39784481	NA	0.65	5.58	0.45	1.46e-7	IgG glycosylation;
TGCT	cis	rs9926296	0.581	rs1108064	chr16:89894150	G/C	cg03388025	chr16:89894329	SPIRE2	0.35	5.18	0.42	8.89e-7	Vitiligo;
TGCT	trans	rs4650994	1.000	rs10798616	chr1:178515642	G/C	cg05059571	chr16:84539110	KIAA1609	-0.41	-7.67	-0.57	4.33e-12	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs3749237	0.595	rs1464568	chr3:49458266	G/A	cg02487422	chr3:49467188	NICN1	0.57	5.84	0.46	4.26e-8	Resting heart rate;
TGCT	cis	rs4889855	0.545	rs61171555	chr17:78465975	T/G	cg16591659	chr17:78472290	NA	-0.36	-5.61	-0.45	1.26e-7	Fractional excretion of uric acid;
TGCT	cis	rs7937682	0.883	rs11213941	chr11:111434094	T/C	cg09085632	chr11:111637200	PPP2R1B	0.99	9.52	0.65	1.82e-16	Primary sclerosing cholangitis;
TGCT	cis	rs9326248	0.954	rs8521	chr11:117067699	C/T	cg16524733	chr11:117070046	TAGLN	0.34	4.91	0.4	2.77e-6	Blood protein levels;
TGCT	cis	rs10782582	0.609	rs11161848	chr1:76367722	A/G	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.54	4.6	0.38	1.02e-5	Daytime sleep phenotypes;
TGCT	cis	rs6752107	0.936	rs1045100	chr2:234203597	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.21	4.71	0.39	6.47e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs6540559	0.546	rs59435160	chr1:210030730	C/A	cg04352962	chr1:209979756	IRF6	0.75	5.29	0.43	5.32e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs10751667	0.643	rs7479473	chr11:929111	C/T	cg06064525	chr11:970664	AP2A2	-0.35	-8.09	-0.59	4.54e-13	Alzheimer's disease (late onset);
TGCT	cis	rs9549367	0.826	rs2287249	chr13:113889355	A/G	cg00898013	chr13:113819073	PROZ	-0.4	-4.92	-0.4	2.7e-6	Platelet distribution width;
TGCT	cis	rs7312774	0.618	rs4964510	chr12:107357251	A/G	cg16260113	chr12:107380972	MTERFD3	1.02	5.27	0.43	5.92e-7	Severe influenza A (H1N1) infection;
TGCT	cis	rs2832191	0.632	rs1984011	chr21:30337831	T/A	cg24692254	chr21:30365293	RNF160	-1.0	-11.42	-0.72	4.34e-21	Dental caries;
TGCT	cis	rs9296661	0.765	rs927859	chr6:51668970	T/G	cg00593404	chr6:52377740	TRAM2	-0.28	-4.56	-0.38	1.19e-5	Weight loss (gastric bypass surgery);
TGCT	cis	rs4478858	0.735	rs6676354	chr1:31800746	A/T	cg07478791	chr1:31886160	SERINC2	-0.51	-4.95	-0.41	2.33e-6	Alcohol dependence;
TGCT	cis	rs2299587	0.698	rs2283113	chr8:17880243	C/A	cg08627089	chr8:17753878	FGL1	-0.28	-4.73	-0.39	5.97e-6	Economic and political preferences;
TGCT	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg13395646	chr4:1353034	KIAA1530	-0.4	-5.0	-0.41	1.93e-6	Obesity-related traits;
TGCT	cis	rs2840044	1.000	rs9900378	chr17:33911302	C/T	cg05299278	chr17:33885742	SLFN14	-0.23	-5.05	-0.41	1.53e-6	Response to radiotherapy in cancer (late toxicity);
TGCT	cis	rs11122272	0.735	rs10489611	chr1:231517854	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.13	-0.54	7.33e-11	Hemoglobin concentration;
TGCT	cis	rs9929218	0.529	rs11640736	chr16:68738324	G/T	cg01251360	chr16:68772225	CDH1	-0.25	-4.49	-0.37	1.64e-5	Colorectal cancer;
TGCT	cis	rs1008375	1.000	rs10939738	chr4:17604295	G/C	cg18681998	chr4:17616180	MED28	0.98	10.43	0.68	1.17e-18	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs950776	0.518	rs62008194	chr15:78813805	G/T	cg06917634	chr15:78832804	PSMA4	0.96	9.71	0.66	6.43e-17	Sudden cardiac arrest;
TGCT	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.89	-6.62	-0.51	9.85e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	trans	rs9379945	1	rs9379945	chr6:26907831	T/C	cg15633603	chr2:190399258	NA	0.4	6.96	0.53	1.74e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs13191362	0.872	rs35443919	chr6:163055804	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.06	8.12	0.59	3.96e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs3806843	0.606	rs251377	chr5:140255792	C/A	cg09824255	chr5:140014002	CD14	-0.26	-4.54	-0.38	1.3e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs950169	0.509	rs71395455	chr15:85153804	A/G	cg11189052	chr15:85197271	WDR73	0.78	6.71	0.52	6.11e-10	Schizophrenia;
TGCT	cis	rs6714710	0.603	rs1470483	chr2:98393894	C/T	cg26665480	chr2:98280029	ACTR1B	0.68	6.49	0.5	1.85e-9	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.05	-9.36	-0.64	4.35e-16	Platelet count;
TGCT	trans	rs561341	0.528	rs11650908	chr17:30195425	T/C	cg20587970	chr11:113659929	NA	0.58	7.41	0.55	1.68e-11	Hip circumference adjusted for BMI;
TGCT	cis	rs1568889	1.000	rs11602768	chr11:28351786	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	8.19	0.59	2.67e-13	Bipolar disorder;
TGCT	cis	rs5750830	0.594	rs6001568	chr22:39775786	G/A	cg11247378	chr22:39784982	NA	-0.65	-8.71	-0.62	1.59e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs155076	1.000	rs261407	chr13:21855213	C/A	cg14456004	chr13:21872349	NA	-1.23	-10.21	-0.68	3.9e-18	White matter hyperintensity burden;
TGCT	cis	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg09021430	chr5:549028	NA	-0.38	-5.06	-0.41	1.45e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs7552404	0.731	rs5745491	chr1:76350159	T/G	cg03433033	chr1:76189801	ACADM	-0.74	-7.5	-0.56	1.09e-11	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2797160	1.000	rs1777222	chr6:126021030	C/T	cg05901451	chr6:126070800	HEY2	0.75	6.66	0.51	8e-10	Endometrial cancer;
TGCT	cis	rs9549367	0.713	rs556990	chr13:113845059	T/C	cg18105134	chr13:113819100	PROZ	0.46	8.58	0.61	3.25e-14	Platelet distribution width;
TGCT	cis	rs9330264	0.508	rs7364869	chr1:155087188	A/G	cg23973274	chr1:155060172	NA	-0.26	-4.69	-0.39	7.1e-6	1,5-anhydroglucitol levels;
TGCT	cis	rs7267979	1.000	rs6107045	chr20:25441936	G/A	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1878931	0.615	rs6501171	chr16:3402610	T/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.91	10.37	0.68	1.63e-18	Body mass index (adult);
TGCT	cis	rs9457247	1.000	rs364451	chr6:167384756	G/A	cg25258033	chr6:167368657	RNASET2	0.2	4.82	0.4	4.03e-6	Crohn's disease;
TGCT	cis	rs2201728	0.967	rs13104485	chr4:100140823	T/A	cg07219303	chr4:100140905	ADH6	-0.35	-5.22	-0.42	7.29e-7	Cardiac Troponin-T levels;
TGCT	cis	rs4523957	0.690	rs28505924	chr17:2088838	G/C	cg16513277	chr17:2031491	SMG6	-0.2	-4.52	-0.38	1.42e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	trans	rs6762477	0.715	rs12631337	chr3:50198537	A/G	cg21659725	chr3:3221576	CRBN	-0.71	-8.05	-0.59	5.86e-13	Menarche (age at onset);
TGCT	cis	rs4988958	0.565	rs6732138	chr2:103009662	G/A	cg03938978	chr2:103052716	IL18RAP	0.27	5.41	0.44	3.17e-7	Asthma (childhood onset);
TGCT	cis	rs758129	0.578	rs1006660	chr15:89883520	T/C	cg01877814	chr15:89879097	POLG	0.31	4.46	0.37	1.8e-5	Schizophrenia;
TGCT	cis	rs9653442	0.527	rs4851258	chr2:100780830	T/C	cg22139774	chr2:100720529	AFF3	-0.36	-5.69	-0.46	8.67e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.67	-0.39	7.73e-6	Prudent dietary pattern;
TGCT	cis	rs1757171	0.542	rs3818985	chr6:37484214	G/T	cg08126542	chr6:37504118	NA	-0.42	-6.2	-0.49	7.66e-9	Cognitive performance;
TGCT	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg15242686	chr22:24348715	GSTTP1	0.49	7.39	0.55	1.88e-11	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs3806843	0.576	rs246020	chr5:140334771	G/A	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs1635	0.655	rs16893917	chr6:28269407	G/A	cg15743358	chr6:28303923	ZNF323	-1.34	-5.96	-0.47	2.44e-8	Schizophrenia;
TGCT	cis	rs265548	0.608	rs265545	chr19:17903465	C/T	cg16744531	chr19:17905626	B3GNT3	0.4	4.92	0.4	2.65e-6	Tumor biomarkers;
TGCT	cis	rs7727544	0.716	rs3844312	chr5:131582356	C/T	cg21474247	chr5:131268130	NA	0.31	4.63	0.38	8.95e-6	Blood metabolite levels;
TGCT	cis	rs6049375	1.000	rs6049375	chr20:24058407	A/G	cg14741141	chr20:24973699	C20orf3	-0.65	-4.6	-0.38	1.03e-5	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs7584330	0.910	rs6713555	chr2:238398182	A/G	cg16989719	chr2:238392110	NA	0.3	4.65	0.39	8.28e-6	Prostate cancer;
TGCT	cis	rs1534166	0.647	rs9853615	chr3:133519981	C/T	cg08048268	chr3:133502702	NA	-0.47	-5.82	-0.46	4.78e-8	Alcohol consumption (transferrin glycosylation);
TGCT	cis	rs7666738	0.830	rs11935078	chr4:99010476	T/A	cg18180107	chr4:99064573	C4orf37	0.54	5.03	0.41	1.7e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs35306767	0.715	rs11253550	chr10:1028288	C/G	cg18964960	chr10:1102726	WDR37	0.74	5.31	0.43	4.97e-7	Eosinophil percentage of granulocytes;
TGCT	cis	rs28785552	1.000	rs28785552	chr19:53234161	G/A	cg04754360	chr19:53238445	ZNF611	-0.59	-4.55	-0.38	1.26e-5	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg18252515	chr7:66147081	NA	-1.13	-6.81	-0.52	3.7e-10	Diabetic kidney disease;
TGCT	cis	rs6964587	0.869	rs7810391	chr7:91520227	G/A	cg17063962	chr7:91808500	NA	-0.86	-9.28	-0.64	6.82e-16	Breast cancer;
TGCT	cis	rs4886920	0.563	rs4886915	chr15:78075023	A/G	cg25212270	chr15:78015279	NA	-0.23	-4.87	-0.4	3.36e-6	Neuroticism;
TGCT	cis	rs2742417	0.624	rs2673029	chr3:45758867	A/G	cg04837898	chr3:45731254	SACM1L	-0.66	-7.02	-0.53	1.27e-10	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg17554472	chr22:41940697	POLR3H	-0.49	-5.27	-0.43	5.9e-7	Vitiligo;
TGCT	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg12310025	chr6:25882481	NA	-0.67	-5.84	-0.46	4.3e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs1915146	0.546	rs1715862	chr10:126856255	C/T	cg23000734	chr10:126850823	CTBP2	-0.46	-5.01	-0.41	1.8e-6	Menarche (age at onset);
TGCT	cis	rs62055045	0.722	rs62055056	chr16:71418999	G/A	cg09204302	chr16:70713462	MTSS1L	-0.31	-4.93	-0.4	2.62e-6	Schizophrenia;
TGCT	cis	rs2486012	1.000	rs61770286	chr1:44356609	A/G	cg12908607	chr1:44402522	ARTN	0.71	5.86	0.47	3.87e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg18188782	chr20:61659543	NA	0.44	5.38	0.43	3.6e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs763121	0.819	rs3747173	chr22:39069045	A/G	cg06022373	chr22:39101656	GTPBP1	0.77	7.46	0.56	1.35e-11	Menopause (age at onset);
TGCT	cis	rs3733585	0.673	rs7672947	chr4:9961368	G/C	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.7	-0.57	3.69e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs6138458	1.000	rs6114980	chr20:24974288	A/G	cg26195577	chr20:24973756	C20orf3	1.22	12.1	0.74	9.98e-23	Blood protein levels;
TGCT	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg12963246	chr6:28129442	ZNF389	0.52	5.1	0.42	1.23e-6	Parkinson's disease;
TGCT	cis	rs6426558	0.537	rs10495253	chr1:227471820	A/T	cg10327440	chr1:227177885	CDC42BPA	0.57	6.65	0.51	8.55e-10	Neutrophil percentage of white cells;
TGCT	cis	rs7809950	0.678	rs13230144	chr7:106909172	T/C	cg23024343	chr7:107201750	COG5	-0.43	-5.81	-0.46	4.86e-8	Coronary artery disease;
TGCT	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg25703541	chr22:24373054	LOC391322	-0.81	-8.44	-0.6	6.94e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg03303774	chr4:1407052	NA	0.3	4.78	0.39	4.8e-6	Obesity-related traits;
TGCT	cis	rs950169	0.922	rs62021167	chr15:85118051	T/A	cg17173187	chr15:85201210	NMB	0.47	4.95	0.41	2.39e-6	Schizophrenia;
TGCT	cis	rs11971779	0.648	rs6967836	chr7:139079944	C/G	cg07862535	chr7:139043722	LUC7L2	0.57	4.52	0.38	1.42e-5	Diisocyanate-induced asthma;
TGCT	cis	rs2549003	1.000	rs9282763	chr5:131822133	T/C	cg21138405	chr5:131827807	IRF1	0.19	4.79	0.39	4.76e-6	Asthma (sex interaction);
TGCT	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.72	0.39	6.26e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7599312	0.534	rs6751692	chr2:213408120	C/T	cg20637307	chr2:213403960	ERBB4	0.92	11.46	0.72	3.54e-21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs3087591	0.708	rs9894648	chr17:29653293	T/C	cg24425628	chr17:29625626	OMG;NF1	0.35	5.01	0.41	1.82e-6	Hip circumference;
TGCT	cis	rs28785552	0.897	rs34244888	chr19:53242228	T/A	cg04754360	chr19:53238445	ZNF611	-0.68	-5.66	-0.45	9.86e-8	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs644799	0.965	rs565771	chr11:95644179	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	8.08	0.59	4.98e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs554111	0.656	rs6685914	chr1:21362378	G/A	cg01072550	chr1:21505969	NA	0.35	5.27	0.43	5.91e-7	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg26513180	chr16:89883248	FANCA	1.07	14.96	0.8	1.48e-29	Vitiligo;
TGCT	cis	rs4499344	0.881	rs6510263	chr19:33067367	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.68	-5.95	-0.47	2.59e-8	Mean platelet volume;
TGCT	cis	rs10949834	0.715	rs710968	chr7:73497728	A/G	cg07137043	chr7:73588983	EIF4H	0.63	4.61	0.38	1.01e-5	Verbal memory performance (residualized delayed recall change);
TGCT	cis	rs7191439	0.728	rs8043637	chr16:88781125	T/C	cg27087555	chr16:88793112	FAM38A	-0.47	-5.36	-0.43	3.91e-7	Plateletcrit;
TGCT	trans	rs208520	0.874	rs208515	chr6:66945749	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-9.93	-0.67	1.84e-17	Exhaled nitric oxide output;
TGCT	cis	rs4642101	0.662	rs57411588	chr3:12820384	C/G	cg05775895	chr3:12838266	CAND2	0.92	11.11	0.71	2.53e-20	QRS complex (12-leadsum);
TGCT	cis	rs8072100	0.790	rs11079783	chr17:45686016	C/T	cg10024583	chr17:45772800	TBKBP1	-0.43	-4.47	-0.37	1.76e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg23758822	chr17:41437982	NA	0.7	6.6	0.51	1.1e-9	Menopause (age at onset);
TGCT	cis	rs3820068	0.581	rs1122386	chr1:15946877	C/T	cg05660106	chr1:15850417	CASP9	0.83	8.16	0.59	3.26e-13	Systolic blood pressure;
TGCT	cis	rs3845702	0.736	rs72960701	chr2:180851202	A/T	cg01881094	chr2:180872142	CWC22	1.03	6.55	0.51	1.35e-9	Schizophrenia;
TGCT	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.93	-5.95	-0.47	2.57e-8	Alzheimer's disease;
TGCT	cis	rs921968	0.541	rs3770214	chr2:219508988	C/T	cg02176678	chr2:219576539	TTLL4	-0.49	-6.82	-0.52	3.52e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs950169	0.922	rs12912934	chr15:85114447	C/T	cg12863693	chr15:85201151	NMB	0.39	4.44	0.37	1.99e-5	Schizophrenia;
TGCT	cis	rs7937682	0.889	rs2850247	chr11:111637202	C/A	cg19812747	chr11:111475976	SIK2	0.39	4.61	0.38	9.74e-6	Primary sclerosing cholangitis;
TGCT	cis	rs5769765	0.954	rs5770739	chr22:50268014	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	1.11	11.76	0.73	6.5e-22	Schizophrenia;
TGCT	cis	rs2239547	0.522	rs6773040	chr3:52935428	C/A	cg10802521	chr3:52805072	NEK4	0.63	5.88	0.47	3.48e-8	Schizophrenia;
TGCT	cis	rs9325144	0.505	rs826893	chr12:39100536	A/G	cg26384229	chr12:38710491	ALG10B	-0.82	-7.79	-0.57	2.28e-12	Morning vs. evening chronotype;
TGCT	cis	rs6061231	0.583	rs2427313	chr20:60970675	G/A	cg22633769	chr20:60982531	CABLES2	0.57	4.54	0.38	1.29e-5	Colorectal cancer;
TGCT	cis	rs2204008	0.775	rs11514370	chr12:38305566	G/A	cg26384229	chr12:38710491	ALG10B	0.78	6.9	0.53	2.33e-10	Bladder cancer;
TGCT	cis	rs1185460	0.967	rs1184902	chr11:118945337	A/G	cg01677386	chr11:118938358	VPS11	-0.53	-4.51	-0.38	1.47e-5	Coronary artery disease;
TGCT	cis	rs62244186	0.541	rs3804583	chr3:44884647	G/T	cg10108389	chr3:44770937	ZNF501	-0.48	-4.75	-0.39	5.45e-6	Depressive symptoms;
TGCT	cis	rs10882165	0.779	rs11596090	chr10:94909481	C/T	cg15980076	chr10:94822747	CYP26C1	0.45	4.82	0.4	4.2e-6	Refractive error;
TGCT	cis	rs9952991	0.941	rs2542150	chr18:12779763	G/C	cg23544223	chr18:12777786	NA	0.64	6.12	0.48	1.15e-8	Inflammatory skin disease;
TGCT	cis	rs782590	0.620	rs4322879	chr2:55797033	G/T	cg18811423	chr2:55921094	PNPT1	-0.63	-6.07	-0.48	1.47e-8	Metabolic syndrome;
TGCT	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg22920501	chr2:26401640	FAM59B	-0.8	-6.43	-0.5	2.55e-9	Gut microbiome composition (summer);
TGCT	cis	rs2594989	0.779	rs56053623	chr3:11592153	T/C	cg00170343	chr3:11313890	ATG7	-0.7	-5.24	-0.43	6.66e-7	Circulating chemerin levels;
TGCT	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg06873352	chr17:61820015	STRADA	0.56	6.22	0.49	7.03e-9	Prudent dietary pattern;
TGCT	trans	rs1814175	0.817	rs1390676	chr11:50056778	C/T	cg15704280	chr7:45808275	SEPT13	-0.72	-8.47	-0.61	6.02e-14	Height;
TGCT	cis	rs7772486	0.790	rs9376970	chr6:146241472	A/C	cg05347473	chr6:146136440	FBXO30	-0.51	-4.95	-0.41	2.42e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg25767906	chr1:53392781	SCP2	-0.52	-6.19	-0.49	8.06e-9	Monocyte count;
TGCT	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg22683308	chr4:1340831	KIAA1530	-0.65	-6.11	-0.48	1.19e-8	Longevity;
TGCT	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg02953382	chr22:24373134	LOC391322	-0.72	-7.08	-0.54	9.43e-11	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs263156	1.000	rs263122	chr6:142894794	T/C	cg18419694	chr6:143832440	FUCA2	-0.4	-4.66	-0.39	8.05e-6	Ear morphology;Lobe size;Lobe attachment;
TGCT	cis	rs9911578	0.967	rs11079368	chr17:57086473	C/T	cg05425664	chr17:57184151	TRIM37	0.68	6.9	0.53	2.4e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs739496	0.843	rs595529	chr12:112000648	A/T	cg10833066	chr12:111807467	FAM109A	0.37	5.2	0.42	8.01e-7	Platelet count;
TGCT	cis	rs2594989	0.887	rs7632902	chr3:11476884	T/C	cg00170343	chr3:11313890	ATG7	0.79	5.8	0.46	5.18e-8	Circulating chemerin levels;
TGCT	cis	rs9394438	0.628	rs4714079	chr6:37544439	C/T	cg00985040	chr6:37553208	NA	-0.25	-5.0	-0.41	1.94e-6	IgG glycosylation;
TGCT	cis	rs853679	0.713	rs200991	chr6:27815494	A/C	cg01031101	chr6:28227091	NKAPL	0.38	4.49	0.37	1.62e-5	Depression;
TGCT	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.71	7.56	0.56	7.98e-12	Blood metabolite levels;
TGCT	cis	rs981844	0.689	rs7666762	chr4:154684197	C/T	cg14289246	chr4:154710475	SFRP2	-0.89	-8.17	-0.59	3.09e-13	Response to statins (LDL cholesterol change);
TGCT	cis	rs79349575	0.783	rs12602746	chr17:47031741	A/C	cg07967210	chr17:47022446	SNF8	0.44	6.13	0.48	1.1e-8	Type 2 diabetes;
TGCT	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.52	4.52	0.38	1.44e-5	Prudent dietary pattern;
TGCT	cis	rs10782582	0.609	rs111914775	chr1:76319036	C/T	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.52	4.53	0.38	1.37e-5	Daytime sleep phenotypes;
TGCT	cis	rs6570726	0.791	rs414600	chr6:145879606	G/A	cg23711669	chr6:146136114	FBXO30	0.89	9.93	0.67	1.82e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs13202913	0.837	rs9397052	chr6:151779228	C/T	cg03627880	chr6:151815985	C6orf97	-0.76	-5.85	-0.47	4.05e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs17345786	0.954	rs17508319	chr3:101318903	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.44	-9.59	-0.65	1.25e-16	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9653442	0.545	rs11681227	chr2:100754997	A/G	cg07810366	chr2:100720526	AFF3	-0.36	-5.09	-0.42	1.27e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs8062405	0.789	rs28676837	chr16:28627063	C/T	cg09754948	chr16:28834200	ATXN2L	-0.58	-4.67	-0.39	7.76e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg12310025	chr6:25882481	NA	-0.51	-4.68	-0.39	7.46e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs62244186	0.659	rs1806579	chr3:44509281	T/C	cg15687855	chr3:44754131	ZNF502	-0.43	-5.24	-0.43	6.74e-7	Depressive symptoms;
TGCT	cis	rs2050392	0.767	rs1536833	chr10:30699265	C/T	cg18806716	chr10:30721971	MAP3K8	0.69	9.16	0.64	1.37e-15	Inflammatory bowel disease;
TGCT	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg04414720	chr1:150670196	GOLPH3L	0.39	5.04	0.41	1.59e-6	Tonsillectomy;
TGCT	cis	rs362272	0.505	rs3129310	chr4:3301388	T/G	cg06533319	chr4:3265114	C4orf44	-0.26	-5.12	-0.42	1.13e-6	Serum sulfate level;
TGCT	cis	rs4557202	0.509	rs12690576	chr3:160647912	G/A	cg03342759	chr3:160939853	NMD3	-0.47	-4.57	-0.38	1.17e-5	Menarche (age at onset);
TGCT	cis	rs35146811	1.000	rs35146811	chr7:99720994	A/C	cg13334819	chr7:99746414	C7orf59	-0.82	-7.34	-0.55	2.49e-11	Coronary artery disease;
TGCT	cis	rs4566357	1.000	rs2177597	chr2:227922546	C/T	cg11843606	chr2:227700838	RHBDD1	-0.58	-5.31	-0.43	4.92e-7	Coronary artery disease;
TGCT	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg16423285	chr20:60520624	NA	-0.6	-6.69	-0.51	6.91e-10	Body mass index;
TGCT	trans	rs3790455	0.610	rs3790461	chr1:156469364	A/G	cg16443977	chr5:115884994	SEMA6A	-0.38	-7.12	-0.54	7.51e-11	Migraine;
TGCT	cis	rs6684514	1.000	rs12023704	chr1:156294149	C/A	cg16558208	chr1:156270281	VHLL	0.48	9.6	0.65	1.19e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs7267979	0.789	rs4815429	chr20:25521611	T/C	cg03522245	chr20:25566470	NINL	-0.56	-5.79	-0.46	5.51e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs651907	0.935	rs2926538	chr3:101587585	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.46	4.76	0.39	5.25e-6	Colorectal cancer;
TGCT	cis	rs5850	0.602	rs1005786	chr7:23145837	G/C	cg05602783	chr7:23145260	KLHL7	-0.65	-5.8	-0.46	5.23e-8	Blood protein levels;
TGCT	cis	rs9534288	0.957	rs2404731	chr13:46618384	T/C	cg15192986	chr13:46630673	CPB2	-0.49	-6.18	-0.49	8.64e-9	Blood protein levels;
TGCT	cis	rs7772486	0.790	rs1832362	chr6:146179955	C/T	cg05347473	chr6:146136440	FBXO30	0.51	4.77	0.39	5.02e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg10117171	chr1:25599238	RHD	0.36	6.03	0.48	1.71e-8	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg27535305	chr1:53392650	SCP2	-0.28	-5.89	-0.47	3.35e-8	Monocyte count;
TGCT	cis	rs2073300	1.000	rs12625160	chr20:23442008	T/C	cg09953122	chr20:23471693	CST8	-0.64	-4.56	-0.38	1.19e-5	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg14820908	chr5:178986412	RUFY1	0.45	4.56	0.38	1.23e-5	Lung cancer;
TGCT	cis	rs6570726	0.557	rs403956	chr6:145829956	T/C	cg13319975	chr6:146136371	FBXO30	-0.65	-5.77	-0.46	5.93e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9911578	0.835	rs58647683	chr17:56483194	T/C	cg05425664	chr17:57184151	TRIM37	0.61	5.76	0.46	6.33e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs12477438	0.501	rs13008171	chr2:99743419	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	10.3	0.68	2.42e-18	Chronic sinus infection;
TGCT	cis	rs6570726	0.846	rs9376954	chr6:145943737	T/A	cg05347473	chr6:146136440	FBXO30	0.48	4.53	0.38	1.38e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg22857025	chr5:266934	NA	-0.33	-6.6	-0.51	1.1e-9	Breast cancer;
TGCT	cis	rs5751150	1	rs5751150	chr22:42153292	T/G	cg17554472	chr22:41940697	POLR3H	0.46	4.69	0.39	7.09e-6	Cannabis dependence symptom count;
TGCT	cis	rs10510102	0.872	rs12257207	chr10:123701252	C/T	cg23691251	chr10:123688108	ATE1	-0.58	-4.58	-0.38	1.11e-5	Breast cancer;
TGCT	cis	rs7647973	0.626	rs9829155	chr3:49817450	T/C	cg05785598	chr3:49045655	WDR6	-0.42	-5.24	-0.43	6.67e-7	Menarche (age at onset);
TGCT	cis	rs4319547	0.737	rs7964138	chr12:122950375	A/G	cg23029597	chr12:123009494	RSRC2	-0.28	-4.67	-0.39	7.8e-6	Body mass index;
TGCT	cis	rs9796	0.870	rs3214068	chr15:41313064	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.41	-5.41	-0.44	3.06e-7	Menopause (age at onset);
TGCT	cis	rs9467773	0.620	rs2494716	chr6:26662736	T/C	cg15659132	chr6:26577336	NA	0.87	10.72	0.69	2.19e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs7225537	0.509	rs11870035	chr17:17033397	C/T	cg26176665	chr17:16994978	MPRIP	0.25	5.9	0.47	3.22e-8	Mean platelet volume;
TGCT	cis	rs7586879	0.658	rs7563204	chr2:25125075	T/G	cg15423357	chr2:25149977	NA	0.5	4.89	0.4	3.06e-6	Body mass index;
TGCT	cis	rs7772486	0.720	rs6570713	chr6:146075085	G/A	cg05347473	chr6:146136440	FBXO30	-0.54	-4.95	-0.41	2.33e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7811142	1.000	rs6972167	chr7:100080013	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.98	8.15	0.59	3.28e-13	Platelet count;
TGCT	cis	rs10254284	0.959	rs1109483	chr7:28145031	C/T	cg23620719	chr7:28220237	JAZF1	0.54	4.94	0.41	2.52e-6	Lymphocyte percentage of white cells;Systemic lupus erythematosus;
TGCT	cis	rs908922	0.676	rs549044	chr1:152514332	C/T	cg20991723	chr1:152506922	NA	0.42	5.87	0.47	3.77e-8	Hair morphology;
TGCT	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg18876405	chr7:65276391	NA	0.36	5.41	0.44	3.12e-7	Aortic root size;
TGCT	cis	rs669446	0.561	rs516790	chr1:44081712	G/T	cg12908607	chr1:44402522	ARTN	0.55	5.9	0.47	3.25e-8	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs523522	0.847	rs11065132	chr12:120908459	C/T	cg12219531	chr12:120966889	COQ5	0.83	7.33	0.55	2.6e-11	High light scatter reticulocyte count;
TGCT	cis	rs13242816	1.000	rs56250718	chr7:116103303	A/G	cg16553024	chr7:116138462	CAV2	-0.43	-4.8	-0.4	4.41e-6	P wave duration;
TGCT	cis	rs11098499	0.909	rs73842633	chr4:120375464	G/A	cg09307838	chr4:120376055	NA	0.67	6.29	0.49	4.88e-9	Corneal astigmatism;
TGCT	cis	rs7513165	0.542	rs4951317	chr1:204161507	C/T	cg12731349	chr1:204159619	KISS1	0.45	5.36	0.43	3.91e-7	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
TGCT	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg05896524	chr21:47604654	C21orf56	0.42	4.47	0.37	1.74e-5	Testicular germ cell tumor;
TGCT	cis	rs1894292	0.527	rs6852149	chr4:74369540	C/G	cg05868023	chr4:75230803	EREG	-0.52	-4.64	-0.38	8.72e-6	Prostate cancer;
TGCT	cis	rs6964587	1.000	rs12704635	chr7:91737324	T/G	cg17063962	chr7:91808500	NA	0.88	9.59	0.65	1.22e-16	Breast cancer;
TGCT	cis	rs4319547	0.695	rs4758666	chr12:122902840	C/T	cg08088222	chr12:122070432	ORAI1	0.25	4.5	0.37	1.54e-5	Body mass index;
TGCT	cis	rs3741404	0.895	rs2429455	chr11:63995302	C/G	cg04317338	chr11:64019027	PLCB3	0.5	4.62	0.38	9.36e-6	Platelet count;
TGCT	cis	rs3806843	0.576	rs246066	chr5:140323147	T/G	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.43	-5.48	-0.44	2.27e-7	Depressive symptoms (multi-trait analysis);
TGCT	trans	rs2688608	1.000	rs2688608	chr10:75658349	G/T	cg13918328	chr10:52500089	ASAH2B	0.65	6.7	0.52	6.47e-10	Inflammatory bowel disease;
TGCT	trans	rs17685	0.672	rs1639618	chr7:75701987	T/C	cg19862616	chr7:65841803	NCRNA00174	0.52	9.01	0.63	3.02e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs6988636	1.000	rs13261021	chr8:124190239	G/A	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs829880	0.570	rs4488248	chr12:98853688	G/C	cg25150519	chr12:98850993	NA	0.64	5.76	0.46	6.2e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs240764	0.658	rs9322213	chr6:101248480	T/C	cg21058520	chr6:100914733	NA	0.35	4.53	0.38	1.36e-5	Neuroticism;
TGCT	cis	rs1153858	1.000	rs4774577	chr15:45644685	A/C	cg26924012	chr15:45694286	SPATA5L1	1.09	15.16	0.81	5.15e-30	Homoarginine levels;
TGCT	cis	rs10464366	0.560	rs11763728	chr7:39145862	C/T	cg18850127	chr7:39170497	POU6F2	0.26	5.95	0.47	2.57e-8	IgG glycosylation;
TGCT	cis	rs7119	0.635	rs59745219	chr15:77884130	A/G	cg27398640	chr15:77910606	LINGO1	0.33	6.88	0.53	2.68e-10	Type 2 diabetes;
TGCT	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.75	5.41	0.44	3.09e-7	Platelet count;
TGCT	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg03452623	chr4:187889614	NA	-0.37	-5.53	-0.44	1.84e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2013441	1.000	rs2526490	chr17:20097526	A/G	cg18979559	chr17:20280153	CCDC144C	-0.44	-4.61	-0.38	9.78e-6	Obesity-related traits;
TGCT	cis	rs4820539	0.966	rs2157709	chr22:23457420	T/C	cg21100191	chr22:23484243	RTDR1	0.95	11.4	0.72	4.85e-21	Bone mineral density;
TGCT	cis	rs9393777	0.720	rs35769282	chr6:26999908	G/C	cg16898833	chr6:26189333	HIST1H4D	0.97	5.95	0.47	2.6e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg26338869	chr17:61819248	STRADA	-0.55	-5.08	-0.42	1.34e-6	Prudent dietary pattern;
TGCT	cis	rs514406	0.584	rs7548832	chr1:53193576	A/T	cg08859206	chr1:53392774	SCP2	-0.36	-5.07	-0.41	1.38e-6	Monocyte count;
TGCT	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg17971929	chr21:40555470	PSMG1	-0.54	-4.87	-0.4	3.32e-6	Menarche (age at onset);
TGCT	cis	rs904251	0.861	rs1757173	chr6:37486952	A/C	cg08126542	chr6:37504118	NA	-0.44	-5.92	-0.47	2.96e-8	Cognitive performance;
TGCT	cis	rs17197710	0.673	rs12575296	chr11:47320985	A/G	cg13308137	chr11:47528955	CUGBP1	-0.41	-5.82	-0.46	4.71e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs6582630	0.502	rs11522899	chr12:38270637	T/C	cg13010199	chr12:38710504	ALG10B	0.64	4.97	0.41	2.15e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs4906332	1.000	rs12885762	chr14:103882200	C/A	cg26031613	chr14:104095156	KLC1	-0.51	-4.63	-0.38	9.17e-6	Coronary artery disease;
TGCT	cis	rs950169	1.000	rs35648189	chr15:84740748	T/C	cg17173187	chr15:85201210	NMB	0.47	5.23	0.42	7.11e-7	Schizophrenia;
TGCT	cis	rs11779988	0.545	rs448882	chr8:17794039	C/T	cg01800426	chr8:17659068	MTUS1	-0.68	-5.41	-0.44	3.14e-7	Breast cancer;
TGCT	cis	rs6089584	0.508	rs6061988	chr20:60626300	C/T	cg06108461	chr20:60628389	TAF4	-0.41	-4.91	-0.4	2.86e-6	Body mass index;
TGCT	cis	rs7666738	0.830	rs13149779	chr4:99010145	G/T	cg18180107	chr4:99064573	C4orf37	0.55	5.01	0.41	1.81e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2276314	1.000	rs4573997	chr18:33552568	C/T	cg19628046	chr18:33552617	C18orf21	0.53	4.5	0.37	1.53e-5	Endometriosis;Drug-induced torsades de pointes;
TGCT	cis	rs7666738	0.830	rs10470894	chr4:99039107	G/A	cg05340658	chr4:99064831	C4orf37	0.52	5.94	0.47	2.68e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1887596	0.705	rs541816	chr13:27204062	T/G	cg01312412	chr13:27282625	NA	0.28	4.98	0.41	2.05e-6	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs3806843	0.569	rs753279	chr5:140023818	A/G	cg19875535	chr5:140030758	IK	-0.28	-4.56	-0.38	1.2e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs523522	0.962	rs3742052	chr12:120966921	A/G	cg12219531	chr12:120966889	COQ5	0.83	7.27	0.55	3.46e-11	High light scatter reticulocyte count;
TGCT	cis	rs17761864	1.000	rs1466389	chr17:2096384	C/T	cg02171503	chr17:1588363	PRPF8	-0.48	-4.65	-0.39	8.34e-6	Esophageal cancer (squamous cell);
TGCT	cis	rs9291683	0.588	rs13113730	chr4:10017628	C/T	cg00071950	chr4:10020882	SLC2A9	0.75	10.33	0.68	2.04e-18	Bone mineral density;
TGCT	cis	rs6933660	0.745	rs9397405	chr6:151736084	G/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.87	-9.34	-0.64	4.97e-16	Menarche (age at onset);
TGCT	cis	rs344364	0.511	rs62040571	chr16:1948514	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.45	-5.08	-0.42	1.35e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg00786635	chr1:25594202	NA	0.55	5.75	0.46	6.46e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg11905131	chr22:24372483	LOC391322	-0.95	-11.19	-0.71	1.64e-20	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2777491	1.000	rs316613	chr15:41747598	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.75	-11.07	-0.71	3.15e-20	Ulcerative colitis;
TGCT	cis	rs7666738	0.800	rs10028921	chr4:98962630	G/T	cg18180107	chr4:99064573	C4orf37	0.57	5.11	0.42	1.16e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	5.02	0.41	1.78e-6	Prudent dietary pattern;
TGCT	trans	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg13565492	chr6:43139072	SRF	-0.82	-7.87	-0.58	1.51e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9399137	0.507	rs4594969	chr6:135285586	A/T	cg24558204	chr6:135376177	HBS1L	0.47	4.78	0.39	4.95e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
TGCT	cis	rs7513165	0.660	rs12040249	chr1:204158228	C/T	cg12731349	chr1:204159619	KISS1	0.43	4.92	0.4	2.71e-6	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
TGCT	cis	rs7552404	0.731	rs11161857	chr1:76370228	G/C	cg03433033	chr1:76189801	ACADM	0.75	7.09	0.54	8.86e-11	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs4455778	0.659	rs13312049	chr7:49023488	C/T	cg26309511	chr7:48887640	NA	-0.43	-5.07	-0.41	1.4e-6	Lung cancer in never smokers;
TGCT	cis	rs9325144	0.555	rs7968322	chr12:38792348	T/C	cg26384229	chr12:38710491	ALG10B	-0.61	-5.72	-0.46	7.51e-8	Morning vs. evening chronotype;
TGCT	cis	rs7727544	0.735	rs272875	chr5:131674888	T/C	cg14196790	chr5:131705035	SLC22A5	0.32	4.48	0.37	1.69e-5	Blood metabolite levels;
TGCT	cis	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg25427524	chr10:38739819	LOC399744	-0.41	-8.54	-0.61	4.04e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7677751	0.767	rs7676985	chr4:55064573	G/A	cg17187183	chr4:55093834	PDGFRA	0.49	6.49	0.5	1.84e-9	Corneal astigmatism;
TGCT	cis	rs36051895	0.659	rs1576271	chr9:5039652	A/C	cg02405213	chr9:5042618	JAK2	-0.78	-10.18	-0.67	4.7e-18	Pediatric autoimmune diseases;
TGCT	cis	rs2404602	0.669	rs1875885	chr15:76638081	G/A	cg22467129	chr15:76604101	ETFA	-0.57	-6.86	-0.52	2.88e-10	Blood metabolite levels;
TGCT	cis	rs7786808	0.782	rs7787923	chr7:158227312	A/G	cg01191920	chr7:158217561	PTPRN2	-0.39	-5.63	-0.45	1.13e-7	Obesity-related traits;
TGCT	trans	rs10953454	1.000	rs10227564	chr7:104491237	C/A	cg04208666	chr6:19734707	NA	-0.57	-6.84	-0.52	3.27e-10	Obesity;
TGCT	cis	rs2439831	0.867	rs2255051	chr15:43846161	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.84	5.79	0.46	5.33e-8	Lung cancer in ever smokers;
TGCT	cis	rs831571	0.519	rs13059603	chr3:63827381	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.65	5.42	0.44	2.98e-7	Type 2 diabetes;
TGCT	cis	rs80282103	0.867	rs74117668	chr10:1076620	C/T	cg15531433	chr10:1639090	ADARB2	0.41	4.5	0.37	1.52e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs854765	0.547	rs6502633	chr17:17941037	G/C	cg04398451	chr17:18023971	MYO15A	-0.33	-5.27	-0.43	5.77e-7	Total body bone mineral density;
TGCT	cis	rs11214775	0.500	rs7943062	chr11:113817286	C/T	cg20857767	chr11:113147175	NCAM1	0.44	5.2	0.42	7.88e-7	Prostate cancer;
TGCT	cis	rs912057	0.601	rs1294405	chr6:6737591	A/G	cg06612196	chr6:6737390	NA	0.49	7.33	0.55	2.58e-11	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs4478858	0.735	rs11436	chr1:31837320	T/C	cg07478791	chr1:31886160	SERINC2	-0.51	-4.93	-0.41	2.55e-6	Alcohol dependence;
TGCT	cis	rs6967414	0.786	rs6953825	chr7:6755624	A/C	cg09896999	chr7:6746977	ZNF12	-0.59	-6.54	-0.51	1.45e-9	Hematocrit;Hemoglobin concentration;
TGCT	cis	rs8062405	1.000	rs3088215	chr16:28853996	A/C	cg09754948	chr16:28834200	ATXN2L	0.59	4.45	0.37	1.91e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg11890956	chr21:40555474	PSMG1	1.12	12.23	0.74	4.65e-23	Cognitive function;
TGCT	cis	rs8017423	0.935	rs11159960	chr14:90740012	C/T	cg04374321	chr14:90722782	PSMC1	-0.75	-7.3	-0.55	2.96e-11	Mortality in heart failure;
TGCT	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg06558623	chr16:89946397	TCF25	0.49	6.18	0.49	8.5e-9	Skin colour saturation;
TGCT	cis	rs6121246	0.567	rs6060295	chr20:30198473	C/T	cg18721089	chr20:30220636	NA	-0.64	-6.86	-0.52	2.84e-10	Mean corpuscular hemoglobin;
TGCT	cis	rs908922	0.676	rs1538083	chr1:152517116	A/G	cg20991723	chr1:152506922	NA	0.45	6.11	0.48	1.18e-8	Hair morphology;
TGCT	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg11941060	chr3:133502564	NA	-0.26	-5.43	-0.44	2.88e-7	Iron status biomarkers;
TGCT	cis	rs12210905	0.688	rs72845030	chr6:27532643	A/G	cg08851530	chr6:28072375	NA	1.34	6.29	0.49	5.02e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg22166914	chr1:53195759	ZYG11B	-0.39	-6.57	-0.51	1.25e-9	Monocyte count;
TGCT	cis	rs7584330	0.554	rs76408976	chr2:238384784	C/T	cg14458575	chr2:238380390	NA	0.58	5.05	0.41	1.53e-6	Prostate cancer;
TGCT	cis	rs7940866	0.838	rs10736592	chr11:130800572	C/T	cg12179176	chr11:130786555	SNX19	0.63	6.32	0.49	4.39e-9	Schizophrenia;
TGCT	cis	rs910316	0.967	rs4903293	chr14:75656568	A/G	cg11812906	chr14:75593930	NEK9	-0.71	-6.83	-0.52	3.43e-10	Height;
TGCT	cis	rs904251	0.772	rs10692	chr6:37450914	T/C	cg25019722	chr6:37503610	NA	-0.43	-5.02	-0.41	1.73e-6	Cognitive performance;
TGCT	cis	rs9733	0.791	rs11204693	chr1:150647987	C/T	cg13175981	chr1:150552382	MCL1	0.42	4.73	0.39	5.88e-6	Tonsillectomy;
TGCT	cis	rs12477438	0.520	rs4851187	chr2:99745860	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.16	-18.76	-0.86	5.07e-38	Chronic sinus infection;
TGCT	cis	rs12701220	0.894	rs13224488	chr7:1052353	C/A	cg27454412	chr7:1067447	C7orf50	-0.48	-4.44	-0.37	1.98e-5	Bronchopulmonary dysplasia;
TGCT	cis	rs80282103	0.618	rs56004802	chr10:1159187	C/T	cg18964960	chr10:1102726	WDR37	1.06	4.57	0.38	1.15e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs10782582	0.593	rs6675212	chr1:76230829	C/A	cg22875332	chr1:76189707	ACADM	-0.45	-4.97	-0.41	2.15e-6	Daytime sleep phenotypes;
TGCT	cis	rs7258465	0.931	rs8107351	chr19:18612758	G/A	cg06462663	chr19:18546047	ISYNA1	0.2	4.67	0.39	7.74e-6	Breast cancer;
TGCT	cis	rs11025559	0.812	rs16906280	chr11:20472242	T/C	cg19653624	chr11:20408972	PRMT3	-0.63	-4.88	-0.4	3.14e-6	Pursuit maintenance gain;
TGCT	cis	rs13191362	1.000	rs73035023	chr6:163000927	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7937682	0.737	rs518294	chr11:111424716	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.8	-8.33	-0.6	1.3e-13	Primary sclerosing cholangitis;
TGCT	cis	rs7267979	1.000	rs4815407	chr20:25341478	G/C	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs7726839	0.574	rs11134149	chr5:637277	A/G	cg25482853	chr8:67687455	SGK3	1.13	10.6	0.69	4.48e-19	Obesity-related traits;
TGCT	trans	rs2469997	0.925	rs2470015	chr8:120360969	T/C	cg01792902	chr3:178864926	PIK3CA	0.83	6.77	0.52	4.49e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs13242816	0.881	rs13235183	chr7:116140149	G/T	cg16553024	chr7:116138462	CAV2	-0.44	-5.38	-0.44	3.56e-7	P wave duration;
TGCT	trans	rs1814175	0.935	rs1827017	chr11:49632592	C/G	cg03929089	chr4:120376271	NA	-0.65	-7.44	-0.56	1.46e-11	Height;
TGCT	cis	rs854765	0.583	rs8075965	chr17:17853180	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	7.69	0.57	3.98e-12	Total body bone mineral density;
TGCT	cis	rs853679	0.546	rs200948	chr6:27835272	T/C	cg01031101	chr6:28227091	NKAPL	-0.49	-4.66	-0.39	8.09e-6	Depression;
TGCT	cis	rs7267979	0.966	rs4815414	chr20:25361701	A/G	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7659604	0.539	rs72680779	chr4:122797263	C/T	cg23574427	chr4:122746245	BBS7;CCNA2	-0.35	-5.36	-0.43	3.84e-7	Type 2 diabetes;
TGCT	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg25767906	chr1:53392781	SCP2	0.48	5.55	0.45	1.62e-7	Monocyte count;
TGCT	cis	rs13191362	1.000	rs67487119	chr6:163102657	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.99	8.09	0.59	4.62e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs11098499	0.754	rs11098502	chr4:120252063	T/A	cg09307838	chr4:120376055	NA	0.61	5.91	0.47	3.14e-8	Corneal astigmatism;
TGCT	cis	rs835154	1.000	rs835154	chr5:14876569	A/G	cg14843632	chr5:14870594	ANKH	-0.42	-6.25	-0.49	6e-9	Blood metabolite levels;
TGCT	cis	rs7428	0.527	rs3184780	chr2:85549547	C/T	cg03728395	chr2:85555865	TGOLN2	-0.29	-5.09	-0.42	1.32e-6	Ear protrusion;
TGCT	cis	rs17401966	0.838	rs946501	chr1:10309580	C/G	cg19773385	chr1:10388646	KIF1B	-0.2	-4.5	-0.37	1.54e-5	Hepatocellular carcinoma;
TGCT	cis	rs12971120	0.891	rs71359051	chr18:72169723	G/A	cg25817165	chr18:72167213	CNDP2	-0.29	-5.11	-0.42	1.16e-6	Refractive error;
TGCT	cis	rs9527	0.518	rs11191530	chr10:104800044	C/T	cg15744005	chr10:104629667	AS3MT	0.55	4.63	0.38	9.04e-6	Arsenic metabolism;
TGCT	cis	rs57994353	0.598	rs72775768	chr9:139324574	C/T	cg13741927	chr9:139327495	INPP5E	-0.28	-6.65	-0.51	8.17e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs9910055	1.000	rs9895423	chr17:42285740	T/C	cg13607699	chr17:42295918	UBTF	0.87	7.48	0.56	1.16e-11	Total body bone mineral density;
TGCT	cis	rs9921338	0.923	rs17233387	chr16:11389048	C/T	cg00044050	chr16:11439710	C16orf75	-0.63	-4.52	-0.38	1.45e-5	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs208520	0.690	rs3899423	chr6:66835285	A/G	cg07460842	chr6:66804631	NA	-0.92	-9.58	-0.65	1.29e-16	Exhaled nitric oxide output;
TGCT	cis	rs4654899	0.758	rs6688147	chr1:21335894	A/G	cg01072550	chr1:21505969	NA	-0.55	-8.93	-0.63	4.73e-15	Superior frontal gyrus grey matter volume;
TGCT	cis	rs7107174	1.000	rs10793302	chr11:78040961	C/T	cg12700464	chr11:78128424	GAB2	-0.65	-4.75	-0.39	5.55e-6	Testicular germ cell tumor;
TGCT	cis	rs9325144	0.505	rs1906262	chr12:38653605	A/G	cg26384229	chr12:38710491	ALG10B	0.71	6.85	0.52	3.09e-10	Morning vs. evening chronotype;
TGCT	trans	rs2727020	0.734	rs1164664	chr11:49295542	T/G	cg11707556	chr5:10655725	ANKRD33B	0.38	6.8	0.52	3.89e-10	Coronary artery disease;
TGCT	cis	rs2288884	0.943	rs75722407	chr19:52525242	C/T	cg13540795	chr19:52551618	ZNF432	-0.56	-4.72	-0.39	6.33e-6	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs2115630	0.691	rs8040066	chr15:85176465	G/C	cg12501888	chr15:85177176	SCAND2	-0.49	-4.57	-0.38	1.14e-5	P wave terminal force;
TGCT	cis	rs4886920	0.563	rs4442775	chr15:78079120	T/C	cg25212270	chr15:78015279	NA	-0.23	-4.87	-0.4	3.36e-6	Neuroticism;
TGCT	cis	rs6988636	1.000	rs13260775	chr8:124190167	G/A	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs11098499	1.000	rs6849889	chr4:120186348	A/C	cg09307838	chr4:120376055	NA	0.52	4.73	0.39	6.12e-6	Corneal astigmatism;
TGCT	cis	rs12200560	0.505	rs211173	chr6:97070804	C/T	cg06623918	chr6:96969491	KIAA0776	0.59	5.02	0.41	1.76e-6	Coronary heart disease;
TGCT	cis	rs68170813	0.559	rs76646886	chr7:107034328	T/C	cg02696742	chr7:106810147	HBP1	-0.68	-5.44	-0.44	2.69e-7	Coronary artery disease;
TGCT	cis	rs12519773	0.576	rs55971857	chr5:92441594	A/C	cg18783429	chr5:92414398	NA	0.31	4.5	0.37	1.56e-5	Migraine;
TGCT	cis	rs1372520	0.684	rs2619341	chr4:90741773	A/G	cg14346243	chr4:90757452	SNCA	-0.67	-5.64	-0.45	1.11e-7	Neuroticism;
TGCT	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg00814883	chr7:100076585	TSC22D4	0.84	8.45	0.6	6.59e-14	Platelet count;
TGCT	cis	rs509477	0.851	rs1941751	chr18:32577017	G/A	cg23791764	chr18:32556832	MAPRE2	-0.63	-5.15	-0.42	9.82e-7	Cerebrospinal fluid AB1-42 levels;
TGCT	cis	rs514406	0.505	rs835609	chr1:53170494	T/C	cg25767906	chr1:53392781	SCP2	-0.46	-4.99	-0.41	2.03e-6	Monocyte count;
TGCT	cis	rs7818688	0.697	rs61591488	chr8:95984955	C/T	cg16049864	chr8:95962084	TP53INP1	0.54	4.64	0.38	8.87e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs12142240	0.698	rs10158236	chr1:46820896	G/T	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs8031584	0.918	rs61997140	chr15:31277312	A/G	cg08704250	chr15:31115839	NA	-0.35	-4.93	-0.4	2.6e-6	Huntington's disease progression;
TGCT	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg08219700	chr8:58056026	NA	0.3	4.57	0.38	1.14e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs10791323	0.593	rs2282604	chr11:133714672	A/G	cg15485101	chr11:133734466	NA	0.35	4.84	0.4	3.75e-6	Childhood ear infection;
TGCT	cis	rs10186029	0.680	rs1530238	chr2:213957928	G/C	cg08319019	chr2:214017104	IKZF2	0.62	5.63	0.45	1.16e-7	Systemic sclerosis;
TGCT	cis	rs9921338	0.961	rs72773834	chr16:11413293	G/A	cg00044050	chr16:11439710	C16orf75	-0.93	-6.96	-0.53	1.7e-10	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs1568889	0.838	rs3812738	chr11:28129982	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.92	11.14	0.71	2.18e-20	Bipolar disorder;
TGCT	cis	rs7829975	0.511	rs2948286	chr8:8130160	A/G	cg15556689	chr8:8085844	FLJ10661	0.82	7.77	0.57	2.59e-12	Mood instability;
TGCT	cis	rs6460942	1.000	rs79659770	chr7:12326371	T/C	cg06484146	chr7:12443880	VWDE	-0.54	-4.55	-0.38	1.26e-5	Coronary artery disease;
TGCT	cis	rs25422	0.938	rs62424176	chr6:118798602	T/C	cg21191810	chr6:118973309	C6orf204	-0.36	-4.74	-0.39	5.8e-6	Renal cell carcinoma;
TGCT	cis	rs6570726	0.846	rs6919684	chr6:145883801	A/G	cg05347473	chr6:146136440	FBXO30	0.51	4.78	0.39	4.8e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10782582	0.593	rs11163915	chr1:76130199	C/T	cg22875332	chr1:76189707	ACADM	-0.54	-6.21	-0.49	7.36e-9	Daytime sleep phenotypes;
TGCT	cis	rs6740322	1.000	rs6756736	chr2:43558743	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.38	-6.32	-0.49	4.21e-9	Coronary artery disease;
TGCT	trans	rs62103177	0.608	rs59300126	chr18:77694439	C/A	cg05926928	chr17:57297772	GDPD1	0.98	9.2	0.64	1.09e-15	Opioid sensitivity;
TGCT	cis	rs9296092	0.517	rs55683509	chr6:33471077	A/G	cg13560919	chr6:33536144	NA	-0.22	-4.49	-0.37	1.6e-5	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs10197940	0.662	rs4467261	chr2:152281391	G/C	cg06191203	chr2:152266755	RIF1	-0.71	-6.28	-0.49	5.14e-9	Lung cancer;
TGCT	cis	rs1451375	0.698	rs1839740	chr7:50646280	C/T	cg18232548	chr7:50535776	DDC	0.44	6.83	0.52	3.36e-10	Malaria;
TGCT	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg18876405	chr7:65276391	NA	0.32	4.89	0.4	3.11e-6	Aortic root size;
TGCT	cis	rs2153535	0.601	rs7738877	chr6:8542230	A/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.03	0.41	1.69e-6	Motion sickness;
TGCT	cis	rs7647973	0.626	rs4855882	chr3:49715354	G/T	cg03060546	chr3:49711283	APEH	0.63	5.33	0.43	4.5e-7	Menarche (age at onset);
TGCT	cis	rs709400	0.628	rs7146506	chr14:103924477	A/G	cg12935359	chr14:103987150	CKB	-0.35	-5.38	-0.44	3.5e-7	Body mass index;
TGCT	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg23758822	chr17:41437982	NA	0.75	7.03	0.53	1.22e-10	Menopause (age at onset);
TGCT	cis	rs3818285	0.632	rs536343	chr10:111632879	T/C	cg00817464	chr10:111662876	XPNPEP1	0.32	5.57	0.45	1.51e-7	Superior crus of antihelix expression;
TGCT	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg12963246	chr6:28129442	ZNF389	0.51	5.02	0.41	1.73e-6	Depression;
TGCT	cis	rs12579753	0.833	rs1922566	chr12:82135030	T/C	cg07988820	chr12:82153109	PPFIA2	-0.68	-7.32	-0.55	2.7e-11	Resting heart rate;
TGCT	cis	rs6554196	0.686	rs6554195	chr4:55500714	G/T	cg02821500	chr4:54931072	CHIC2	0.48	4.71	0.39	6.54e-6	Monocyte count;
TGCT	cis	rs9611565	0.592	rs5758406	chr22:42076641	A/G	cg06634786	chr22:41940651	POLR3H	0.9	9.03	0.63	2.7e-15	Vitiligo;
TGCT	cis	rs2243480	1.000	rs383402	chr7:65586653	A/C	cg07424592	chr7:64974309	NA	-1.26	-7.79	-0.57	2.25e-12	Diabetic kidney disease;
TGCT	cis	rs3008870	0.583	rs3008892	chr1:67373558	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.93	8.01	0.58	7.28e-13	Lymphocyte percentage of white cells;
TGCT	cis	rs2758596	0.850	rs2241110	chr1:156172487	A/G	cg24450063	chr1:156163899	SLC25A44	0.79	4.58	0.38	1.11e-5	Paclitaxel disposition in epithelial ovarian cancer;
TGCT	cis	rs6665290	0.935	rs17600627	chr1:227201449	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.98	-20.12	-0.87	7.08e-41	Myeloid white cell count;
TGCT	cis	rs4555082	0.794	rs2735829	chr14:105708472	C/T	cg01266790	chr14:105781312	PACS2	0.55	4.5	0.37	1.57e-5	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg16325326	chr1:53192061	ZYG11B	0.56	6.18	0.49	8.46e-9	Monocyte count;
TGCT	cis	rs17345786	0.798	rs1609159	chr3:101275902	A/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.64	6.08	0.48	1.36e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg07424592	chr7:64974309	NA	1.3	8.23	0.59	2.19e-13	Diabetic kidney disease;
TGCT	cis	rs9341808	0.700	rs12215236	chr6:80975058	A/T	cg08355045	chr6:80787529	NA	0.29	4.98	0.41	2.04e-6	Sitting height ratio;
TGCT	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg24829409	chr8:58192753	C8orf71	-0.52	-5.02	-0.41	1.73e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs12049351	0.774	rs6661924	chr1:229642740	G/T	cg12130225	chr1:229698885	NA	0.39	4.6	0.38	1.02e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs763121	0.853	rs5750664	chr22:39072769	C/T	cg06022373	chr22:39101656	GTPBP1	0.77	7.46	0.56	1.35e-11	Menopause (age at onset);
TGCT	cis	rs1129187	0.935	rs9462859	chr6:42946943	G/A	cg27588902	chr6:42928151	GNMT	-0.5	-5.92	-0.47	2.93e-8	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.01	0.41	1.86e-6	Prudent dietary pattern;
TGCT	cis	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg22857025	chr5:266934	NA	-0.31	-6.32	-0.49	4.33e-9	Breast cancer;
TGCT	cis	rs3733585	0.699	rs6815001	chr4:9958662	G/C	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.7	-0.57	3.69e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7666738	0.830	rs115279324	chr4:99042114	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.94	0.47	2.68e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs651907	0.535	rs34161138	chr3:101510388	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.31	-6.4	-0.5	2.91e-9	Colorectal cancer;
TGCT	cis	rs765787	0.530	rs4774550	chr15:45542312	C/T	cg24006582	chr15:45444508	DUOX1	-0.25	-5.54	-0.45	1.76e-7	Uric acid levels;
TGCT	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg22963979	chr7:1858916	MAD1L1	-0.36	-5.51	-0.44	2e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs35306767	0.715	rs1250891	chr10:1040159	G/C	cg20503657	chr10:835505	NA	0.62	6.9	0.53	2.4e-10	Eosinophil percentage of granulocytes;
TGCT	cis	rs71435601	0.628	rs4560142	chr2:21383717	A/G	cg25035485	chr2:21266500	APOB	-0.51	-4.48	-0.37	1.64e-5	Cholesterol, total;
TGCT	cis	rs7412746	0.658	rs7526489	chr1:150726238	C/T	cg04414720	chr1:150670196	GOLPH3L	0.37	4.57	0.38	1.15e-5	Melanoma;
TGCT	cis	rs2235642	0.750	rs2755185	chr16:1645827	A/G	cg00463982	chr16:1583984	IFT140;TMEM204	-0.27	-4.53	-0.38	1.39e-5	Coronary artery disease;
TGCT	trans	rs1814175	0.817	rs4881648	chr11:49812901	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.35	-0.55	2.38e-11	Height;
TGCT	cis	rs709400	0.930	rs2274268	chr14:104029378	C/G	cg26031613	chr14:104095156	KLC1	1.15	14.5	0.79	1.83e-28	Body mass index;
TGCT	cis	rs8050907	1.000	rs7195763	chr16:4649300	C/G	cg02183435	chr16:5121731	ALG1	-0.85	-4.44	-0.37	1.99e-5	Obesity-related traits;
TGCT	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	5.53	0.44	1.8e-7	Alzheimer's disease;
TGCT	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs2075371	0.796	rs12672752	chr7:134007382	C/T	cg11752832	chr7:134001865	SLC35B4	0.72	6.44	0.5	2.4e-9	Mean platelet volume;
TGCT	cis	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg21191810	chr6:118973309	C6orf204	-0.27	-4.5	-0.37	1.52e-5	Electrocardiographic conduction measures;
TGCT	cis	rs6840360	0.762	rs62327352	chr4:152670780	C/A	cg22705602	chr4:152727874	NA	-0.25	-4.48	-0.37	1.64e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs9653442	0.564	rs12712071	chr2:100793876	G/A	cg07810366	chr2:100720526	AFF3	-0.36	-5.22	-0.42	7.26e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs7429990	0.965	rs62260764	chr3:47990500	G/C	cg11946769	chr3:48343235	NME6	0.59	4.5	0.37	1.57e-5	Educational attainment (years of education);
TGCT	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg06238570	chr21:40685208	BRWD1	0.76	7.13	0.54	7.21e-11	Cognitive function;
TGCT	cis	rs4987668	0.786	rs4252379	chr7:142629654	A/C	cg21621906	chr7:142494914	NA	-0.87	-4.51	-0.38	1.49e-5	Cancer;
TGCT	cis	rs9430161	0.579	rs11121667	chr1:11038476	C/T	cg02454025	chr1:11042201	C1orf127	0.97	12.9	0.76	1.15e-24	Ewing sarcoma;
TGCT	cis	rs12142240	0.698	rs6690075	chr1:46819848	G/A	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs11719291	0.504	rs34571182	chr3:49209057	T/A	cg00383909	chr3:49044727	WDR6	1.28	6.68	0.51	7.04e-10	Cognitive function;
TGCT	cis	rs8180040	0.764	rs11712716	chr3:47193432	T/C	cg27129171	chr3:47204927	SETD2	0.75	9.86	0.66	2.82e-17	Colorectal cancer;
TGCT	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg22618164	chr12:122356400	WDR66	0.69	6.49	0.5	1.83e-9	Mean corpuscular volume;
TGCT	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg17971929	chr21:40555470	PSMG1	0.97	9.48	0.65	2.31e-16	Cognitive function;
TGCT	cis	rs2120019	1.000	rs1867146	chr15:75354971	C/G	cg11632617	chr15:75315747	PPCDC	-0.33	-4.59	-0.38	1.07e-5	Blood trace element (Zn levels);
TGCT	cis	rs208515	0.592	rs10944862	chr6:66674215	C/T	cg07460842	chr6:66804631	NA	0.88	9.35	0.64	4.63e-16	Exhaled nitric oxide levels;
TGCT	cis	rs6964587	0.934	rs7811328	chr7:91720931	A/T	cg17063962	chr7:91808500	NA	0.86	9.47	0.65	2.39e-16	Breast cancer;
TGCT	cis	rs13188771	0.527	rs408727	chr5:100877888	T/C	cg18665594	chr5:101119420	NA	0.44	4.49	0.37	1.62e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg15556689	chr8:8085844	FLJ10661	-0.67	-6.21	-0.49	7.49e-9	Mood instability;
TGCT	cis	rs12142240	0.698	rs17357683	chr1:46815378	C/T	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs56036086	1.000	rs56036086	chr22:50628996	G/A	cg01548456	chr22:50352384	NA	0.37	4.82	0.4	4.15e-6	Platelet count;Plateletcrit;
TGCT	cis	rs1865760	0.964	rs9379802	chr6:25933898	T/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.63	6.06	0.48	1.52e-8	Height;
TGCT	trans	rs74910095	0.786	rs11957329	chr5:62936327	G/C	cg02938449	chr2:220419364	OBSL1	0.8	6.75	0.52	4.95e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs76473307	1.000	rs77855067	chr20:57378801	G/C	cg06163629	chr20:57414884	GNASAS;GNAS	-0.7	-4.61	-0.38	1.01e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs2016266	0.859	rs56225815	chr12:53740090	C/G	cg16917193	chr12:54089295	NA	-0.7	-4.68	-0.39	7.49e-6	Bone mineral density (spine);Bone mineral density;
TGCT	cis	rs4727027	0.901	rs10952792	chr7:148760501	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	4.99	0.41	2.02e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg14159672	chr1:205819179	PM20D1	0.42	4.56	0.38	1.19e-5	Menarche (age at onset);
TGCT	cis	rs13336428	0.730	rs3946124	chr16:1525779	A/G	cg08008072	chr16:1524255	CLCN7	0.62	9.34	0.64	5.05e-16	Bone mineral density;
TGCT	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg11890956	chr21:40555474	PSMG1	1.09	11.95	0.73	2.27e-22	Cognitive function;
TGCT	cis	rs6725041	0.819	rs939226	chr2:213088846	A/G	cg20637307	chr2:213403960	ERBB4	-0.52	-4.47	-0.37	1.72e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs10992471	0.603	rs1980848	chr9:95248571	A/G	cg13798575	chr9:95087839	CENPP;NOL8	0.62	5.72	0.46	7.5e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs9929218	0.551	rs3785133	chr16:68728611	C/T	cg01251360	chr16:68772225	CDH1	-0.27	-4.92	-0.4	2.66e-6	Colorectal cancer;
TGCT	trans	rs621559	0.636	rs632866	chr1:43670624	C/A	cg19324027	chr2:74699582	MRPL53	-0.87	-6.75	-0.52	5.12e-10	Telomere length;
TGCT	cis	rs2115630	1.000	rs2115630	chr15:85364516	C/T	cg11189052	chr15:85197271	WDR73	-0.63	-5.93	-0.47	2.84e-8	P wave terminal force;
TGCT	cis	rs478304	0.651	rs78412025	chr11:65495696	T/C	cg17480646	chr11:65405466	SIPA1	-0.57	-6.98	-0.53	1.61e-10	Acne (severe);
TGCT	cis	rs7147624	0.683	rs8017258	chr14:66231017	C/G	cg03016385	chr14:66212404	NA	0.51	5.72	0.46	7.58e-8	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs427394	0.802	rs274692	chr5:6734625	C/T	cg10857441	chr5:6722123	POLS	-0.32	-7.93	-0.58	1.08e-12	Menopause (age at onset);
TGCT	cis	rs7027203	1.000	rs7854820	chr9:96526027	A/G	cg13679303	chr9:96623674	NA	0.65	10.13	0.67	6.09e-18	DNA methylation (variation);
TGCT	cis	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg18252515	chr7:66147081	NA	-1.2	-7.83	-0.58	1.89e-12	Diabetic kidney disease;
TGCT	cis	rs881375	0.631	rs2416808	chr9:123706283	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.44	4.73	0.39	6.09e-6	Rheumatoid arthritis;
TGCT	cis	rs4919694	1.000	rs76255497	chr10:104651955	T/C	cg04362960	chr10:104952993	NT5C2	1.03	6.95	0.53	1.83e-10	Arsenic metabolism;
TGCT	cis	rs4711350	0.862	rs597723	chr6:33694079	C/T	cg18005901	chr6:33739558	LEMD2	0.44	4.73	0.39	6.11e-6	Schizophrenia;
TGCT	cis	rs10788264	0.569	rs7089468	chr10:124019052	T/C	cg09507567	chr10:124027408	NA	0.39	5.89	0.47	3.35e-8	Total body bone mineral density;
TGCT	cis	rs7552404	0.731	rs61770552	chr1:76373050	T/C	cg10523679	chr1:76189770	ACADM	0.84	7.32	0.55	2.77e-11	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg07061783	chr6:25882402	NA	0.58	5.62	0.45	1.21e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs554111	0.637	rs604659	chr1:21043913	T/C	cg24117274	chr1:21945805	RAP1GAP	0.31	4.72	0.39	6.35e-6	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	-0.75	-5.93	-0.47	2.84e-8	Initial pursuit acceleration;
TGCT	cis	rs727505	0.954	rs2239532	chr7:124405676	A/C	cg23710748	chr7:124431027	NA	-0.27	-4.82	-0.4	4.05e-6	Lewy body disease;
TGCT	cis	rs11107903	1.000	rs12830164	chr12:95514233	G/T	cg10621809	chr12:95840313	NA	0.7	4.61	0.38	9.89e-6	Coronary artery disease;
TGCT	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.63	5.12	0.42	1.11e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	trans	rs629535	0.814	rs506931	chr8:70068129	T/G	cg21567404	chr3:27674614	NA	0.57	9.11	0.63	1.82e-15	Dupuytren's disease;
TGCT	cis	rs9300255	0.770	rs28683528	chr12:123845351	C/T	cg00376283	chr12:123451042	ABCB9	-0.65	-4.57	-0.38	1.17e-5	Neutrophil percentage of white cells;
TGCT	cis	rs1729951	0.575	rs1682356	chr3:136692037	T/C	cg21827317	chr3:136751795	NA	0.4	5.61	0.45	1.28e-7	Neuroticism;
TGCT	cis	rs9611519	1.000	rs5758268	chr22:41622419	A/T	cg13695892	chr22:41940480	POLR3H	-0.51	-4.68	-0.39	7.46e-6	Neuroticism;
TGCT	cis	rs909674	0.731	rs4821897	chr22:39835587	A/G	cg01416388	chr22:39784598	NA	-0.75	-6.8	-0.52	3.9e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs13217239	0.646	rs35691005	chr6:26972070	A/G	cg26531700	chr6:26746687	NA	0.68	6.79	0.52	4.1e-10	Schizophrenia;
TGCT	cis	rs7975161	0.640	rs4477504	chr12:104710465	T/C	cg25273343	chr12:104657179	TXNRD1	-0.34	-4.82	-0.4	4.16e-6	Toenail selenium levels;
TGCT	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg08736216	chr1:53307985	ZYG11A	-0.28	-5.38	-0.44	3.57e-7	Monocyte count;
TGCT	cis	rs11190604	1.000	rs2495747	chr10:102328247	C/T	cg16342193	chr10:102329863	NA	-0.42	-5.39	-0.44	3.47e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs929596	0.785	rs11695484	chr2:234654449	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.34	-5.3	-0.43	5.14e-7	Total bilirubin levels in HIV-1 infection;
TGCT	cis	rs78456975	0.527	rs10206020	chr2:1557927	A/G	cg12573674	chr2:1569213	NA	-0.45	-4.76	-0.39	5.37e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs7216064	1.000	rs62084251	chr17:65878736	G/A	cg12091567	chr17:66097778	LOC651250	-0.83	-6.49	-0.5	1.9e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs3782455	1.000	rs117171899	chr12:114403070	G/A	cg23502203	chr12:113549970	RASAL1	-0.55	-4.92	-0.4	2.7e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs853679	0.546	rs200948	chr6:27835272	T/C	cg08798685	chr6:27730294	NA	-0.34	-4.69	-0.39	7.2e-6	Depression;
TGCT	trans	rs941408	1.000	rs1736177	chr19:2791624	C/T	cg22153745	chr1:153894579	GATAD2B	-0.65	-7.5	-0.56	1.08e-11	Total cholesterol levels;
TGCT	cis	rs7959452	0.530	rs12811632	chr12:69755003	G/A	cg20891283	chr12:69753455	YEATS4	0.83	8.61	0.61	2.77e-14	Blood protein levels;
TGCT	cis	rs3008870	0.959	rs3008852	chr1:67383416	G/A	cg03991309	chr1:68237761	GNG12	0.27	4.68	0.39	7.28e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs682748	0.846	rs13187032	chr5:17135535	A/G	cg23987134	chr5:17158319	LOC285696	-0.21	-5.11	-0.42	1.17e-6	Hippocampal atrophy;
TGCT	cis	rs3617	0.573	rs9810807	chr3:52924227	C/T	cg10802521	chr3:52805072	NEK4	0.58	6.47	0.5	2.07e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1997103	0.863	rs6956287	chr7:55415107	T/C	cg17469321	chr7:55412551	NA	0.61	5.91	0.47	3.03e-8	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs11085466	1.000	rs73552468	chr19:21772097	G/A	cg01048962	chr19:21646470	NA	-0.57	-4.49	-0.37	1.63e-5	Colorectal or endometrial cancer;
TGCT	cis	rs617219	0.671	rs2220839	chr5:78603510	T/A	cg05890484	chr5:78407552	BHMT	-0.34	-4.65	-0.39	8.5e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs9611565	0.592	rs5758427	chr22:42099688	A/G	cg06481639	chr22:41940642	POLR3H	0.71	6.48	0.5	1.95e-9	Vitiligo;
TGCT	cis	rs3774830	0.714	rs7685158	chr4:5462776	C/T	cg26943120	chr4:5472116	STK32B	0.23	5.16	0.42	9.66e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6939532	0.761	rs3799378	chr6:26404374	C/T	cg05738196	chr6:26577821	NA	0.5	4.62	0.38	9.34e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg12310025	chr6:25882481	NA	-0.7	-6.44	-0.5	2.4e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs2230307	0.536	rs11166407	chr1:100637708	C/T	cg24955406	chr1:100503596	HIAT1	0.75	5.33	0.43	4.41e-7	Carotid intima media thickness;
TGCT	cis	rs7666738	0.515	rs13131874	chr4:98779183	A/G	cg05340658	chr4:99064831	C4orf37	0.52	5.73	0.46	7.24e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6095298	0.595	rs6095319	chr20:47446556	G/A	cg12307787	chr20:48099359	KCNB1	0.44	4.67	0.39	7.75e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2836633	0.929	rs764482	chr21:40033661	C/G	cg12884169	chr21:40033163	ERG	0.47	4.98	0.41	2.04e-6	Coronary artery disease;
TGCT	cis	rs2239547	0.657	rs4687672	chr3:52880543	G/A	cg11645453	chr3:52864694	ITIH4	0.35	5.88	0.47	3.57e-8	Schizophrenia;
TGCT	cis	rs7567389	0.710	rs72848618	chr2:128135325	A/C	cg09760422	chr2:128146352	NA	0.34	4.52	0.38	1.41e-5	Self-rated health;
TGCT	cis	rs13217239	0.646	rs11756275	chr6:27007113	A/C	cg05738196	chr6:26577821	NA	-0.48	-4.57	-0.38	1.14e-5	Schizophrenia;
TGCT	cis	rs12682352	0.602	rs4841044	chr8:8664940	A/G	cg08975724	chr8:8085496	FLJ10661	-0.51	-4.48	-0.37	1.68e-5	Neuroticism;
TGCT	trans	rs7615952	0.741	rs13314845	chr3:125644782	C/T	cg07211511	chr3:129823064	LOC729375	-0.48	-8.02	-0.58	6.91e-13	Blood pressure (smoking interaction);
TGCT	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg24531977	chr5:56204891	C5orf35	-0.77	-7.61	-0.56	5.83e-12	Initial pursuit acceleration;
TGCT	cis	rs7647973	0.925	rs6446256	chr3:49224210	A/G	cg07636037	chr3:49044803	WDR6	0.63	5.09	0.42	1.27e-6	Menarche (age at onset);
TGCT	cis	rs1008375	1.000	rs1008374	chr4:17683219	G/A	cg10189774	chr4:17578691	LAP3	0.52	4.87	0.4	3.28e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2147959	0.771	rs6426505	chr1:228701102	C/G	cg22700015	chr1:228743131	NA	-0.62	-5.1	-0.42	1.23e-6	Adult asthma;
TGCT	cis	rs1577917	0.771	rs4383777	chr6:86435960	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.63	5.39	0.44	3.43e-7	Response to antipsychotic treatment;
TGCT	cis	rs13242816	1.000	rs73208106	chr7:116173263	G/A	cg16553024	chr7:116138462	CAV2	-0.44	-5.26	-0.43	6.11e-7	P wave duration;
TGCT	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg16423285	chr20:60520624	NA	-0.76	-9.26	-0.64	7.88e-16	Obesity-related traits;
TGCT	cis	rs58688157	0.960	rs1061502	chr11:614318	T/C	cg16486109	chr11:613632	IRF7	0.36	5.26	0.43	6.02e-7	Systemic lupus erythematosus;
TGCT	cis	rs2996428	0.667	rs2368534	chr1:3740640	C/T	cg10555106	chr1:3691387	LOC388588	0.33	4.74	0.39	5.85e-6	Red cell distribution width;
TGCT	cis	rs13242816	1.000	rs3807995	chr7:116197976	C/T	cg02799643	chr7:116139180	CAV2	-0.43	-5.45	-0.44	2.59e-7	P wave duration;
TGCT	trans	rs931812	0.825	rs13271753	chr8:101895491	T/C	cg20993868	chr7:22813445	NA	0.42	9.03	0.63	2.75e-15	Attention deficit hyperactivity disorder and conduct disorder;
TGCT	cis	rs55794721	0.509	rs2375313	chr1:25748235	G/A	cg10117171	chr1:25599238	RHD	-0.36	-5.95	-0.47	2.58e-8	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs9527	0.590	rs6584537	chr10:104778267	C/G	cg04362960	chr10:104952993	NT5C2	0.65	5.54	0.45	1.73e-7	Arsenic metabolism;
TGCT	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs28595532	0.764	rs17259257	chr4:119778889	C/T	cg21605333	chr4:119757512	SEC24D	1.55	8.04	0.59	6.15e-13	Cannabis dependence symptom count;
TGCT	cis	rs11711311	0.712	rs11718013	chr3:113341661	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.69	-5.81	-0.46	5.03e-8	IgG glycosylation;
TGCT	cis	rs12048904	0.619	rs12239082	chr1:101330077	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.82	-8.31	-0.6	1.42e-13	Multiple sclerosis;
TGCT	cis	rs7829975	0.577	rs79495969	chr8:8545250	G/A	cg15556689	chr8:8085844	FLJ10661	-0.53	-4.5	-0.37	1.53e-5	Mood instability;
TGCT	cis	rs11578119	0.933	rs11587811	chr1:170482352	C/T	cg09767346	chr1:170501363	GORAB	0.66	5.29	0.43	5.27e-7	Male-pattern baldness;
TGCT	cis	rs6740322	0.748	rs6727631	chr2:43470408	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.4	-6.2	-0.49	7.78e-9	Coronary artery disease;
TGCT	cis	rs651907	0.967	rs694936	chr3:101587793	A/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.46	4.83	0.4	3.97e-6	Colorectal cancer;
TGCT	cis	rs11578119	0.902	rs4508077	chr1:170461981	A/G	cg09767346	chr1:170501363	GORAB	-0.68	-5.41	-0.44	3.18e-7	Male-pattern baldness;
TGCT	cis	rs459571	0.959	rs378740	chr9:136890876	C/A	cg13789015	chr9:136890014	NCRNA00094	0.39	7.2	0.54	5.07e-11	Platelet distribution width;
TGCT	cis	rs739496	0.843	rs12369009	chr12:112019799	G/T	cg10833066	chr12:111807467	FAM109A	-0.37	-5.62	-0.45	1.19e-7	Platelet count;
TGCT	cis	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg08564027	chr20:61660810	NA	-0.37	-6.57	-0.51	1.25e-9	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg03517284	chr6:25882590	NA	0.6	6.28	0.49	5.11e-9	Blood metabolite levels;
TGCT	cis	rs2115536	1.000	rs2115536	chr15:80194247	C/T	cg00225070	chr15:80189496	MTHFS	0.61	5.63	0.45	1.16e-7	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	trans	rs1496653	0.602	rs35990123	chr3:23397104	C/T	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs151997	0.671	rs27907	chr5:50193797	C/G	cg06027927	chr5:50259733	NA	0.56	5.78	0.46	5.72e-8	Callous-unemotional behaviour;
TGCT	cis	rs2046867	0.908	rs9811830	chr3:72809591	A/G	cg25664220	chr3:72788482	NA	-0.53	-6.81	-0.52	3.8e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs35146811	0.695	rs1618851	chr7:99810643	T/G	cg13334819	chr7:99746414	C7orf59	0.74	6.31	0.49	4.4e-9	Coronary artery disease;
TGCT	cis	rs4925386	0.840	rs8124907	chr20:60913127	A/G	cg06026331	chr20:60912101	LAMA5	0.37	6.37	0.5	3.35e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg11247378	chr22:39784982	NA	0.7	9.18	0.64	1.19e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs2456568	0.741	rs10831137	chr11:93636912	C/T	cg16099599	chr11:93583650	C11orf90	-0.4	-5.12	-0.42	1.14e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs926938	0.563	rs360586	chr1:115467489	A/G	cg12756093	chr1:115239321	AMPD1	0.41	6.44	0.5	2.37e-9	Autism;
TGCT	cis	rs9810089	0.903	rs7427564	chr3:136274435	G/A	cg12473912	chr3:136751656	NA	0.34	4.86	0.4	3.54e-6	Gestational age at birth (child effect);
TGCT	cis	rs4862750	0.914	rs10027250	chr4:187873460	T/C	cg03452623	chr4:187889614	NA	-0.36	-5.36	-0.43	3.84e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1865760	1.000	rs7739966	chr6:25906040	T/C	cg17042849	chr6:26104293	HIST1H4C	-0.52	-4.68	-0.39	7.33e-6	Height;
TGCT	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.71	-5.64	-0.45	1.1e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs116095464	1.000	rs28416084	chr5:217640	G/A	cg22857025	chr5:266934	NA	-0.34	-6.6	-0.51	1.09e-9	Breast cancer;
TGCT	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.75	5.41	0.44	3.09e-7	Platelet count;
TGCT	cis	rs6728642	0.908	rs13400545	chr2:97871626	A/G	cg26665480	chr2:98280029	ACTR1B	-0.97	-5.19	-0.42	8.35e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	cis	rs9399135	0.967	rs1041481	chr6:135335063	G/A	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.36e-6	Red blood cell count;
TGCT	cis	rs17197710	0.673	rs3736101	chr11:47306628	G/A	cg13308137	chr11:47528955	CUGBP1	0.4	5.38	0.44	3.58e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs35160687	0.901	rs6713456	chr2:86507653	T/A	cg03171300	chr2:86307199	POLR1A	0.3	4.93	0.4	2.61e-6	Night sleep phenotypes;
TGCT	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg00684032	chr4:1343700	KIAA1530	0.22	4.82	0.4	4.11e-6	Obesity-related traits;
TGCT	cis	rs35160687	0.901	rs12714180	chr2:86525323	G/T	cg03171300	chr2:86307199	POLR1A	0.32	5.56	0.45	1.61e-7	Night sleep phenotypes;
TGCT	cis	rs13082711	0.554	rs674798	chr3:27332302	G/T	cg02860705	chr3:27208620	NA	0.34	5.58	0.45	1.43e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs7582180	0.845	rs11683088	chr2:100920667	C/T	cg08017756	chr2:100939284	LONRF2	-0.32	-5.4	-0.44	3.2e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs67311347	0.911	rs9849224	chr3:40392562	T/C	cg17264618	chr3:40429014	ENTPD3	0.31	4.65	0.39	8.38e-6	Renal cell carcinoma;
TGCT	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg11764359	chr7:65958608	NA	0.54	4.66	0.39	7.88e-6	Aortic root size;
TGCT	cis	rs12478296	1.000	rs7420157	chr2:243005204	G/A	cg06360820	chr2:242988706	NA	-0.64	-5.35	-0.43	4.15e-7	Obesity-related traits;
TGCT	cis	rs9916302	0.904	rs612194	chr17:37442707	T/A	cg07936489	chr17:37558343	FBXL20	0.62	4.91	0.4	2.85e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs4499344	0.633	rs259229	chr19:33134425	A/G	cg26639809	chr19:33781782	NA	-0.22	-4.59	-0.38	1.08e-5	Mean platelet volume;
TGCT	cis	rs1913185	0.787	rs59850864	chr3:145829162	C/G	cg26283496	chr3:146269126	NA	0.38	4.61	0.38	9.81e-6	Obesity-related traits;
TGCT	cis	rs13202913	0.779	rs9383896	chr6:151768495	A/G	cg03627880	chr6:151815985	C6orf97	-0.73	-5.42	-0.44	2.92e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg04944784	chr2:26401820	FAM59B	-0.68	-6.13	-0.48	1.1e-8	Gut microbiome composition (summer);
TGCT	cis	rs7666738	0.791	rs13125277	chr4:99009922	T/G	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs682748	0.846	rs62347963	chr5:17133766	G/A	cg23987134	chr5:17158319	LOC285696	-0.21	-5.11	-0.42	1.17e-6	Hippocampal atrophy;
TGCT	cis	rs4820539	1.000	rs3788347	chr22:23467804	G/A	cg14186256	chr22:23484241	RTDR1	0.98	11.79	0.73	5.47e-22	Bone mineral density;
TGCT	cis	rs7095607	1.000	rs7094885	chr10:69953817	T/C	cg18986048	chr10:69913749	MYPN	0.46	4.93	0.41	2.54e-6	Lung function (FVC);
TGCT	cis	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg02380750	chr20:61661411	NA	0.34	6.02	0.48	1.86e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7000551	0.663	rs7827093	chr8:22334610	A/G	cg12081754	chr8:22256438	SLC39A14	0.3	4.97	0.41	2.16e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs6558174	0.714	rs17674754	chr8:22533388	A/G	cg03733263	chr8:22462867	KIAA1967	0.61	4.45	0.37	1.85e-5	Breast cancer;
TGCT	cis	rs9467773	0.620	rs2504571	chr6:26643435	C/T	cg02458000	chr6:26745757	NA	0.53	5.02	0.41	1.79e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg17554472	chr22:41940697	POLR3H	0.48	4.95	0.41	2.39e-6	Vitiligo;
TGCT	cis	rs4911259	0.552	rs13038881	chr20:31468113	T/C	cg13636640	chr20:31349939	DNMT3B	-0.89	-9.83	-0.66	3.33e-17	Inflammatory bowel disease;
TGCT	cis	rs2562456	0.833	rs516519	chr19:21481532	C/G	cg01304269	chr19:21688519	ZNF429	-0.55	-4.47	-0.37	1.76e-5	Pain;
TGCT	cis	rs7178572	0.633	rs907369	chr15:77843560	A/G	cg22256960	chr15:77711686	NA	-0.82	-7.51	-0.56	1.03e-11	Type 2 diabetes;
TGCT	cis	rs9291683	0.595	rs13145442	chr4:10037261	C/A	cg00071950	chr4:10020882	SLC2A9	0.68	8.83	0.62	8.22e-15	Bone mineral density;
TGCT	cis	rs6545883	0.894	rs9677047	chr2:61585295	C/G	cg15711740	chr2:61764176	XPO1	0.54	4.61	0.38	9.77e-6	Tuberculosis;
TGCT	cis	rs7267979	1.000	rs6115159	chr20:25350944	T/C	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7959452	0.535	rs7135092	chr12:69658330	T/C	cg20891283	chr12:69753455	YEATS4	0.66	6.37	0.5	3.41e-9	Blood protein levels;
TGCT	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg06873352	chr17:61820015	STRADA	0.5	5.28	0.43	5.67e-7	Prudent dietary pattern;
TGCT	cis	rs2120019	1.000	rs60425110	chr15:75333000	T/A	cg11632617	chr15:75315747	PPCDC	-0.3	-4.47	-0.37	1.71e-5	Blood trace element (Zn levels);
TGCT	cis	rs10504229	0.817	rs60646469	chr8:58195348	T/C	cg21724239	chr8:58056113	NA	0.39	4.79	0.39	4.76e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg25767906	chr1:53392781	SCP2	0.46	5.17	0.42	8.95e-7	Monocyte count;
TGCT	cis	rs854765	0.964	rs12943202	chr17:17994332	T/A	cg09796270	chr17:17721594	SREBF1	-0.26	-5.08	-0.41	1.37e-6	Total body bone mineral density;
TGCT	trans	rs4759375	0.748	rs596940	chr12:123560731	T/C	cg08426444	chr8:73164019	NA	1.17	6.72	0.52	5.74e-10	HDL cholesterol;
TGCT	cis	rs6815814	0.898	rs5743562	chr4:38806096	T/C	cg02016764	chr4:38805732	TLR1	-0.35	-5.65	-0.45	1.04e-7	Breast cancer;
TGCT	cis	rs10465746	0.935	rs35946036	chr1:84438991	A/G	cg10977910	chr1:84465055	TTLL7	0.65	6.54	0.51	1.44e-9	Obesity-related traits;
TGCT	cis	rs12142240	0.698	rs1475390	chr1:46816340	A/G	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs9611565	0.729	rs203319	chr22:41914593	C/T	cg06634786	chr22:41940651	POLR3H	-0.79	-7.87	-0.58	1.54e-12	Vitiligo;
TGCT	trans	rs7726839	0.540	rs7434	chr5:660804	A/G	cg25482853	chr8:67687455	SGK3	-1.19	-10.67	-0.69	2.93e-19	Obesity-related traits;
TGCT	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg11764359	chr7:65958608	NA	-0.58	-5.05	-0.41	1.53e-6	Aortic root size;
TGCT	cis	rs617219	0.671	rs2220839	chr5:78603510	T/A	cg23514016	chr5:78407564	BHMT	-0.31	-4.82	-0.4	4.11e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs6087990	0.735	rs2889703	chr20:31379184	C/A	cg13636640	chr20:31349939	DNMT3B	0.94	12.29	0.74	3.46e-23	Ulcerative colitis;
TGCT	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.51	-6.62	-0.51	9.58e-10	Lymphocyte counts;
TGCT	cis	rs11578119	0.933	rs12405323	chr1:170418964	G/A	cg09767346	chr1:170501363	GORAB	0.71	5.69	0.46	8.66e-8	Male-pattern baldness;
TGCT	cis	rs172166	0.538	rs149956	chr6:28036251	G/A	cg13525197	chr6:28411240	ZSCAN23	-0.46	-4.5	-0.37	1.56e-5	Cardiac Troponin-T levels;
TGCT	cis	rs1215050	0.605	rs10018404	chr4:98610830	A/C	cg05340658	chr4:99064831	C4orf37	-0.41	-4.96	-0.41	2.3e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	trans	rs931812	0.964	rs2102290	chr8:101919844	G/C	cg20993868	chr7:22813445	NA	0.35	7.72	0.57	3.35e-12	Attention deficit hyperactivity disorder and conduct disorder;
TGCT	cis	rs9368481	0.761	rs7775041	chr6:27009512	T/A	cg26531700	chr6:26746687	NA	-0.54	-4.78	-0.39	4.9100000000000004e-06	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6670062	0.536	rs1771941	chr1:247410614	G/A	cg01868367	chr1:247372405	NA	0.27	4.62	0.38	9.47e-6	Trans fatty acid levels;
TGCT	trans	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg21659725	chr3:3221576	CRBN	0.76	9.02	0.63	2.92e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs35146811	0.735	rs7811662	chr7:99792608	A/G	cg22906224	chr7:99728672	NA	0.49	4.45	0.37	1.88e-5	Coronary artery disease;
TGCT	cis	rs28595532	0.920	rs115675321	chr4:119742153	A/T	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs7647973	1.000	rs7648995	chr3:49438803	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.59	-4.72	-0.39	6.19e-6	Menarche (age at onset);
TGCT	cis	rs10984561	0.881	rs10984553	chr9:122247521	G/A	cg14242995	chr9:122249943	NA	0.75	6.41	0.5	2.7e-9	Pulmonary function decline;
TGCT	cis	rs2964802	0.505	rs6872243	chr5:10818337	C/T	cg14521931	chr5:10832172	NA	-0.28	-4.73	-0.39	6.02e-6	Major depressive disorder;Recurrent major depressive disorder;
TGCT	cis	rs13190036	1.000	rs6880798	chr5:176704457	C/T	cg18465082	chr5:176734745	MXD3	-0.35	-4.64	-0.38	8.56e-6	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
TGCT	cis	rs55665837	0.559	rs11023209	chr11:14422600	T/C	cg19336497	chr11:14380999	RRAS2	-0.33	-5.04	-0.41	1.57e-6	Vitamin D levels;
TGCT	cis	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg22857025	chr5:266934	NA	-0.33	-6.6	-0.51	1.1e-9	Breast cancer;
TGCT	cis	rs6918586	0.615	rs198841	chr6:26111671	G/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.7	-6.6	-0.51	1.07e-9	Schizophrenia;
TGCT	cis	rs6121246	0.567	rs6060262	chr20:30193071	A/C	cg13852791	chr20:30311386	BCL2L1	0.69	4.65	0.39	8.44e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs939658	0.776	rs11631411	chr15:79445816	C/T	cg17916960	chr15:79447300	NA	-0.49	-7.57	-0.56	7.2e-12	Refractive error;
TGCT	cis	rs709400	0.965	rs861534	chr14:104168701	C/T	cg26031613	chr14:104095156	KLC1	1.12	16.24	0.82	1.71e-32	Body mass index;
TGCT	cis	rs4319547	0.956	rs10773302	chr12:123043145	G/T	cg05707623	chr12:122985044	ZCCHC8	-0.69	-5.47	-0.44	2.42e-7	Body mass index;
TGCT	cis	rs240764	0.658	rs12212435	chr6:101196080	T/C	cg09795085	chr6:101329169	ASCC3	-0.51	-4.51	-0.38	1.45e-5	Neuroticism;
TGCT	cis	rs9653442	0.527	rs11690905	chr2:100761473	C/T	cg07810366	chr2:100720526	AFF3	0.36	5.31	0.43	4.89e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs380904	0.963	rs410836	chr8:144576849	A/G	cg09317036	chr8:144635547	GSDMD	0.53	4.89	0.4	3.01e-6	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg13866156	chr1:1669148	SLC35E2	-0.22	-5.22	-0.42	7.41e-7	Body mass index;
TGCT	cis	rs6121246	0.567	rs6060399	chr20:30220823	C/T	cg21427119	chr20:30132790	HM13	-0.43	-6.02	-0.48	1.86e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs3733585	0.699	rs28610447	chr4:9971517	T/C	cg11266682	chr4:10021025	SLC2A9	-0.59	-7.85	-0.58	1.63e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7647973	1.000	rs62259947	chr3:49439924	T/C	cg07636037	chr3:49044803	WDR6	-0.72	-5.72	-0.46	7.47e-8	Menarche (age at onset);
TGCT	cis	rs7027203	0.828	rs4344139	chr9:96600298	T/C	cg13679303	chr9:96623674	NA	-0.66	-10.78	-0.7	1.64e-19	DNA methylation (variation);
TGCT	cis	rs3138083	0.607	rs12376740	chr9:35639595	G/C	cg07116010	chr9:35646325	NA	0.82	10.29	0.68	2.44e-18	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);
TGCT	cis	rs36051895	0.659	rs62543863	chr9:5085417	C/T	cg02405213	chr9:5042618	JAK2	-0.78	-9.94	-0.67	1.81e-17	Pediatric autoimmune diseases;
TGCT	cis	rs7705042	0.647	rs10051379	chr5:141501662	T/G	cg07392085	chr5:141489673	NDFIP1	-0.33	-4.5	-0.37	1.55e-5	Asthma;
TGCT	cis	rs2235642	0.685	rs2667681	chr16:1653206	C/T	cg08296037	chr16:1584118	IFT140;TMEM204	-0.28	-4.94	-0.41	2.44e-6	Coronary artery disease;
TGCT	cis	rs904251	0.523	rs10807184	chr6:37483713	C/T	cg25019722	chr6:37503610	NA	-0.52	-7.86	-0.58	1.62e-12	Cognitive performance;
TGCT	cis	rs9512730	0.527	rs11619722	chr13:27998600	T/C	cg04070771	chr13:27998621	GTF3A	0.6	5.29	0.43	5.43e-7	Schizophrenia;
TGCT	trans	rs561341	0.882	rs111484028	chr17:30287701	G/A	cg20587970	chr11:113659929	NA	-1.03	-10.98	-0.7	5.21e-20	Hip circumference adjusted for BMI;
TGCT	cis	rs12908161	1.000	rs12910012	chr15:85298662	T/C	cg11189052	chr15:85197271	WDR73	0.71	5.82	0.46	4.67e-8	Schizophrenia;
TGCT	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg04944784	chr2:26401820	FAM59B	-0.7	-6.49	-0.5	1.89e-9	Gut microbiome composition (summer);
TGCT	cis	rs68170813	0.559	rs1121312	chr7:106927820	C/T	cg02696742	chr7:106810147	HBP1	-0.69	-5.81	-0.46	4.85e-8	Coronary artery disease;
TGCT	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.49	-4.77	-0.39	5.03e-6	Bipolar disorder;
TGCT	cis	rs7940866	0.903	rs11222421	chr11:130872351	A/T	cg12179176	chr11:130786555	SNX19	0.56	5.25	0.43	6.27e-7	Schizophrenia;
TGCT	cis	rs6969780	0.722	rs3823764	chr7:27187753	C/T	cg17457637	chr7:27170717	HOXA4	-0.46	-5.11	-0.42	1.19e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs66573146	0.901	rs7668802	chr4:6986236	T/A	cg05069807	chr4:6945702	TBC1D14	0.38	5.11	0.42	1.17e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg12310025	chr6:25882481	NA	-0.72	-6.63	-0.51	9.27e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs4951018	0.821	rs11240547	chr1:205632932	A/G	cg14893161	chr1:205819251	PM20D1	0.37	4.78	0.39	4.83e-6	Prostate-specific antigen levels;
TGCT	cis	rs713587	0.776	rs3731623	chr2:25163783	T/C	cg15423357	chr2:25149977	NA	0.59	5.98	0.47	2.17e-8	Body mass index in non-asthmatics;
TGCT	cis	rs17433780	0.964	rs10493821	chr1:89475135	C/T	cg09516651	chr1:89888402	LOC400759	0.31	5.56	0.45	1.59e-7	Carotid intima media thickness;
TGCT	cis	rs501916	0.932	rs483656	chr15:48055932	T/C	cg16110827	chr15:48056943	SEMA6D	-0.17	-5.15	-0.42	9.73e-7	Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs2191566	0.821	rs62119173	chr19:44518073	G/A	cg03039196	chr19:44506973	ZNF230	0.53	4.47	0.37	1.73e-5	Acute lymphoblastic leukemia (childhood);
TGCT	cis	rs7666738	0.830	rs35531558	chr4:98938217	A/G	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs981844	0.712	rs4696507	chr4:154753702	G/A	cg14289246	chr4:154710475	SFRP2	-0.98	-8.82	-0.62	8.67e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg22920501	chr2:26401640	FAM59B	-0.71	-6.17	-0.48	9.06e-9	Gut microbiome composition (summer);
TGCT	cis	rs7647973	0.710	rs6446284	chr3:49616997	A/G	cg05785598	chr3:49045655	WDR6	0.41	4.66	0.39	8.03e-6	Menarche (age at onset);
TGCT	cis	rs2239547	0.522	rs6445550	chr3:52983434	G/A	cg10802521	chr3:52805072	NEK4	-0.64	-6.13	-0.48	1.06e-8	Schizophrenia;
TGCT	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg08736216	chr1:53307985	ZYG11A	-0.25	-4.79	-0.4	4.59e-6	Monocyte count;
TGCT	cis	rs2072499	0.966	rs2253677	chr1:156171296	C/G	cg06970220	chr1:156163860	SLC25A44	-0.73	-6.46	-0.5	2.13e-9	Testicular germ cell tumor;
TGCT	cis	rs7539409	0.651	rs6696140	chr1:84317468	C/T	cg10977910	chr1:84465055	TTLL7	-0.88	-5.62	-0.45	1.19e-7	Alzheimer's disease;
TGCT	cis	rs559406	0.540	rs888267	chr18:12773838	G/A	cg23598886	chr18:12777645	NA	0.36	4.54	0.38	1.32e-5	Psoriasis;
TGCT	cis	rs2204008	0.782	rs117824012	chr12:38215517	T/C	cg13010199	chr12:38710504	ALG10B	0.62	4.96	0.41	2.32e-6	Bladder cancer;
TGCT	cis	rs2243480	1.000	rs4718317	chr7:65648901	A/G	cg18252515	chr7:66147081	NA	1.22	7.98	0.58	8.46e-13	Diabetic kidney disease;
TGCT	cis	rs67311347	1.000	rs977652	chr3:40479169	A/G	cg13683864	chr3:40499215	RPL14	-1.04	-10.79	-0.7	1.54e-19	Renal cell carcinoma;
TGCT	cis	rs1775715	0.870	rs3847415	chr10:32219456	G/T	cg14930904	chr10:32216787	ARHGAP12	0.49	4.61	0.38	9.88e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg22535103	chr8:58192502	C8orf71	-0.42	-4.79	-0.4	4.7e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9611565	0.559	rs4822049	chr22:41993496	G/A	cg03806693	chr22:41940476	POLR3H	-1.11	-11.64	-0.72	1.26e-21	Vitiligo;
TGCT	cis	rs4680	0.701	rs4646317	chr22:19952168	G/A	cg23601416	chr22:19950040	COMT	-0.38	-4.8	-0.4	4.47e-6	Blood metabolite levels;
TGCT	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg25767906	chr1:53392781	SCP2	-0.51	-5.91	-0.47	3.09e-8	Monocyte count;
TGCT	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg11247378	chr22:39784982	NA	-0.73	-9.59	-0.65	1.22e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs2066819	1.000	rs2291361	chr12:56717805	G/A	cg26714650	chr12:56694279	CS	-1.36	-6.06	-0.48	1.54e-8	Psoriasis vulgaris;
TGCT	cis	rs6088580	0.634	rs6087580	chr20:32992592	A/G	cg08999081	chr20:33150536	PIGU	-0.28	-5.4	-0.44	3.26e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg16680214	chr1:154839983	KCNN3	-0.41	-8.75	-0.62	1.29e-14	Prostate cancer;
TGCT	cis	rs12188164	1.000	rs12188678	chr5:428231	T/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.41	-4.77	-0.39	5.03e-6	Cystic fibrosis severity;
TGCT	cis	rs1552244	0.882	rs56125067	chr3:9984130	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	5.89	0.47	3.37e-8	Alzheimer's disease;
TGCT	cis	rs17376456	0.877	rs10476598	chr5:93367281	C/T	cg21475434	chr5:93447410	FAM172A	-0.66	-5.04	-0.41	1.62e-6	Diabetic retinopathy;
TGCT	cis	rs3008870	0.959	rs2985816	chr1:67387750	G/T	cg03991309	chr1:68237761	GNG12	0.27	4.56	0.38	1.23e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs739496	0.579	rs12582302	chr12:112345634	A/G	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs1480597	0.518	rs10793552	chr10:45162388	G/A	cg12063947	chr10:45878068	ALOX5	0.28	4.45	0.37	1.86e-5	Parkinson's disease;
TGCT	cis	rs2295359	0.892	rs72676058	chr1:67627681	C/A	cg12940439	chr1:67600707	NA	0.58	5.9	0.47	3.2e-8	Psoriasis;
TGCT	cis	rs7666738	0.830	rs4619898	chr4:98959646	G/A	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg01570182	chr17:44337453	NA	1.01	9.34	0.64	4.88e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg20607798	chr8:58055168	NA	0.62	5.21	0.42	7.64e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2839186	0.565	rs2839183	chr21:47687144	G/A	cg12379764	chr21:47803548	PCNT	0.5	5.6	0.45	1.33e-7	Testicular germ cell tumor;
TGCT	cis	rs7267979	1.000	rs761025	chr20:25426968	G/A	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9372498	0.536	rs62422235	chr6:118971913	G/A	cg21191810	chr6:118973309	C6orf204	-0.38	-4.85	-0.4	3.6e-6	Diastolic blood pressure;
TGCT	cis	rs10791097	0.690	rs12284540	chr11:130729772	T/C	cg05962950	chr11:130786565	SNX19	0.81	9.71	0.66	6.35e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs4273100	0.646	rs6587216	chr17:19224397	G/C	cg01534423	chr17:18965556	NA	-0.79	-6.76	-0.52	4.91e-10	Schizophrenia;
TGCT	cis	rs67311347	1.000	rs9875245	chr3:40442280	G/T	cg13409248	chr3:40428643	ENTPD3	0.57	4.53	0.38	1.37e-5	Renal cell carcinoma;
TGCT	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg22920501	chr2:26401640	FAM59B	-0.74	-6.29	-0.49	5.08e-9	Gut microbiome composition (summer);
TGCT	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.61	0.38	9.85e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs12210905	0.688	rs78285097	chr6:27374644	G/C	cg08851530	chr6:28072375	NA	1.33	5.85	0.47	4.08e-8	Hip circumference adjusted for BMI;
TGCT	trans	rs916888	0.779	rs199498	chr17:44865603	A/G	cg22968622	chr17:43663579	NA	0.96	7.81	0.57	2.08e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7208859	0.573	rs73267872	chr17:29067207	T/C	cg14008862	chr17:28927542	LRRC37B2	0.76	4.52	0.38	1.42e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs6967414	0.786	rs6953825	chr7:6755624	A/C	cg00387323	chr7:6746715	ZNF12	0.76	4.65	0.39	8.23e-6	Hematocrit;Hemoglobin concentration;
TGCT	cis	rs2242194	0.816	rs6671688	chr1:154994265	T/C	cg24348479	chr1:155007323	DCST1;DCST2	0.27	5.67	0.45	9.51e-8	Schizophrenia;
TGCT	cis	rs2688608	0.620	rs7080350	chr10:75577843	A/G	cg23231163	chr10:75533350	FUT11	0.26	4.55	0.38	1.27e-5	Inflammatory bowel disease;
TGCT	cis	rs12711979	0.509	rs13035992	chr2:3826597	G/A	cg17052675	chr2:3827356	NA	-0.55	-12.73	-0.75	2.94e-24	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs4319547	0.626	rs10744210	chr12:122931793	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.71	-5.49	-0.44	2.16e-7	Body mass index;
TGCT	cis	rs6088580	0.634	rs1205336	chr20:32926336	G/A	cg06115741	chr20:33292138	TP53INP2	-0.53	-4.7	-0.39	6.67e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7091068	0.616	rs1890657	chr10:95506087	G/A	cg20715218	chr10:95462985	C10orf4	0.52	4.62	0.38	9.33e-6	Urinary tract infection frequency;
TGCT	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg08280861	chr8:58055591	NA	0.41	4.63	0.38	8.93e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs67311347	0.577	rs11712626	chr3:40259927	G/A	cg13683864	chr3:40499215	RPL14	-0.79	-7.4	-0.55	1.83e-11	Renal cell carcinoma;
TGCT	cis	rs7565124	1.000	rs7565124	chr2:20261685	G/A	cg00462460	chr2:20212509	MATN3	-0.43	-4.64	-0.38	8.69e-6	Major depressive disorder;
TGCT	cis	rs7726839	0.578	rs10080150	chr5:593160	C/T	cg09021430	chr5:549028	NA	0.39	7.6	0.56	6.25e-12	Obesity-related traits;
TGCT	cis	rs2456568	0.548	rs7117597	chr11:93655091	A/G	cg17595323	chr11:93583763	C11orf90	-0.43	-5.54	-0.45	1.7e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs11190604	0.767	rs11190534	chr10:102190930	G/A	cg23241863	chr10:102295624	HIF1AN	0.62	4.79	0.4	4.69e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7296418	0.699	rs11608297	chr12:123826642	T/C	cg00376283	chr12:123451042	ABCB9	0.63	5.42	0.44	3.02e-7	Platelet count;
TGCT	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs4285028	0.747	rs3732407	chr3:121416623	G/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.93	-7.31	-0.55	2.85e-11	Multiple sclerosis;
TGCT	cis	rs9549260	0.564	rs4943805	chr13:41270080	A/G	cg21288729	chr13:41239152	FOXO1	0.86	8.0	0.58	7.71e-13	Red blood cell count;
TGCT	cis	rs13242816	1.000	rs56250718	chr7:116103303	A/G	cg02799643	chr7:116139180	CAV2	-0.45	-5.38	-0.44	3.5e-7	P wave duration;
TGCT	cis	rs2721195	1.000	rs11542372	chr8:145677089	G/A	cg17328964	chr8:145687451	CYHR1	0.48	6.96	0.53	1.71e-10	Age at first birth;
TGCT	cis	rs4699052	0.963	rs2061646	chr4:104183894	T/C	cg16532752	chr4:104119610	CENPE	-0.55	-4.97	-0.41	2.19e-6	Testicular germ cell tumor;
TGCT	cis	rs9611519	0.894	rs8136923	chr22:41470522	G/A	cg13695892	chr22:41940480	POLR3H	-0.54	-4.78	-0.39	4.93e-6	Neuroticism;
TGCT	cis	rs12477438	0.798	rs9679602	chr2:99577827	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.72	6.25	0.49	5.98e-9	Chronic sinus infection;
TGCT	cis	rs9467773	0.967	rs6456732	chr6:26514445	T/C	cg05738196	chr6:26577821	NA	0.88	12.5	0.75	1.03e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs4727027	0.866	rs3735311	chr7:148877737	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	4.77	0.39	5.16e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs208520	0.526	rs9351542	chr6:66788571	A/G	cg07460842	chr6:66804631	NA	-1.08	-15.95	-0.82	8.03e-32	Exhaled nitric oxide output;
TGCT	cis	rs155076	1.000	rs261432	chr13:21865915	G/C	cg11317459	chr13:21872234	NA	-1.3	-11.68	-0.72	1.02e-21	White matter hyperintensity burden;
TGCT	cis	rs1799949	0.965	rs4793237	chr17:41436595	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	4.5	0.37	1.54e-5	Menopause (age at onset);
TGCT	cis	rs7584330	0.697	rs9287620	chr2:238368730	C/T	cg14458575	chr2:238380390	NA	0.56	8.88	0.62	6.43e-15	Prostate cancer;
TGCT	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg10047753	chr17:41438598	NA	0.77	7.43	0.56	1.54e-11	Menopause (age at onset);
TGCT	trans	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.88	-9.92	-0.67	1.95e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs548987	0.529	rs9467618	chr6:25824809	C/T	cg03517284	chr6:25882590	NA	-0.55	-4.44	-0.37	1.93e-5	Homocysteine levels;
TGCT	cis	rs2295359	1.000	rs963427	chr1:67609347	A/G	cg03340356	chr1:67600835	NA	0.37	4.63	0.38	9.1e-6	Psoriasis;
TGCT	cis	rs7267979	1.000	rs2257809	chr20:25266476	C/T	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6448317	0.954	rs13139649	chr4:24922007	C/A	cg21108841	chr4:24914750	CCDC149	-0.61	-4.63	-0.38	8.9e-6	Heschl's gyrus morphology;
TGCT	cis	rs7703051	0.513	rs59014134	chr5:74589385	C/T	cg00601450	chr5:74908170	NA	0.44	4.8	0.4	4.4e-6	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
TGCT	cis	rs7552404	0.765	rs211717	chr1:76106969	G/A	cg03433033	chr1:76189801	ACADM	-0.84	-10.07	-0.67	8.46e-18	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs6121246	0.954	rs6058470	chr20:30416827	A/T	cg13852791	chr20:30311386	BCL2L1	0.8	6.12	0.48	1.15e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs826838	1.000	rs10880963	chr12:38748408	T/C	cg13010199	chr12:38710504	ALG10B	0.82	6.88	0.53	2.57e-10	Heart rate;
TGCT	cis	rs1129187	0.702	rs2296805	chr6:42928758	T/G	cg13397359	chr6:42928475	GNMT	0.58	4.8	0.4	4.39e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs950169	0.922	rs62028133	chr15:84919375	A/C	cg11189052	chr15:85197271	WDR73	0.83	6.67	0.51	7.71e-10	Schizophrenia;
TGCT	cis	rs6674176	0.542	rs3011225	chr1:44319373	G/A	cg12908607	chr1:44402522	ARTN	-0.63	-7.18	-0.54	5.58e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg24829409	chr8:58192753	C8orf71	-0.59	-4.97	-0.41	2.17e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg07507251	chr3:52567010	NT5DC2	0.47	6.75	0.52	5.11e-10	Bipolar disorder;
TGCT	cis	rs2255336	0.817	rs4764430	chr12:10517808	A/G	cg16084090	chr12:10586130	KLRC2	0.3	4.59	0.38	1.06e-5	Blood protein levels;
TGCT	cis	rs2579519	0.556	rs4907302	chr2:96217197	C/G	cg23100626	chr2:96804247	ASTL	0.41	4.71	0.39	6.59e-6	Diastolic blood pressure;
TGCT	cis	rs9611565	0.879	rs4820437	chr22:41761290	T/C	cg02107564	chr22:41488750	EP300	-0.54	-4.44	-0.37	1.95e-5	Vitiligo;
TGCT	cis	rs950027	0.620	rs1617984	chr15:45622662	A/G	cg14582100	chr15:45693742	SPATA5L1	0.48	6.06	0.48	1.48e-8	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs12479064	0.505	rs62153764	chr2:99818612	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.84	-6.7	-0.52	6.49e-10	Chronic sinus infection;
TGCT	cis	rs7226408	0.857	rs17652454	chr18:34476108	G/A	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs988712	0.705	rs1488830	chr11:27636885	A/G	cg10635145	chr11:27742435	BDNF	-0.36	-4.98	-0.41	2.1e-6	Obesity;
TGCT	cis	rs910316	0.967	rs119076	chr14:75572419	G/T	cg08847533	chr14:75593920	NEK9	-0.96	-10.44	-0.68	1.05e-18	Height;
TGCT	cis	rs13217239	0.646	rs62401067	chr6:27018101	T/A	cg26531700	chr6:26746687	NA	0.68	6.65	0.51	8.26e-10	Schizophrenia;
TGCT	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg06238570	chr21:40685208	BRWD1	-0.82	-8.79	-0.62	1.03e-14	Cognitive function;
TGCT	cis	rs4478858	0.735	rs7526095	chr1:31797581	C/T	cg00250761	chr1:31883323	NA	-0.28	-4.96	-0.41	2.32e-6	Alcohol dependence;
TGCT	cis	rs56104184	0.723	rs73063515	chr19:49407715	C/T	cg17863274	chr19:49399704	TULP2	-0.54	-7.43	-0.55	1.58e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs4372836	0.543	rs6742291	chr2:29007349	T/C	cg09522027	chr2:28974177	PPP1CB	-0.77	-7.59	-0.56	6.62e-12	Body mass index;
TGCT	cis	rs9807989	0.507	rs6743516	chr2:103036335	A/G	cg03938978	chr2:103052716	IL18RAP	0.27	5.4	0.44	3.31e-7	Asthma;
TGCT	cis	rs1949733	0.523	rs16842560	chr4:8544238	G/A	cg13073564	chr4:8508604	NA	0.5	4.94	0.41	2.46e-6	Response to antineoplastic agents;
TGCT	cis	rs7584330	0.554	rs3751111	chr2:238426953	G/T	cg08992911	chr2:238395768	MLPH	0.7	4.72	0.39	6.32e-6	Prostate cancer;
TGCT	cis	rs1150668	0.768	rs1150716	chr6:28262698	T/G	cg13525197	chr6:28411240	ZSCAN23	-0.49	-4.86	-0.4	3.52e-6	Pubertal anthropometrics;
TGCT	cis	rs9399135	0.507	rs2072825	chr6:135253451	A/G	cg24558204	chr6:135376177	HBS1L	-0.47	-4.81	-0.4	4.35e-6	Red blood cell count;
TGCT	cis	rs7617773	0.817	rs4131362	chr3:48329036	A/C	cg11946769	chr3:48343235	NME6	0.74	6.34	0.49	3.97e-9	Coronary artery disease;
TGCT	cis	rs10779751	0.734	rs1211575	chr1:11118390	G/A	cg08854313	chr1:11322531	MTOR	0.84	8.3	0.6	1.47e-13	Body mass index;
TGCT	cis	rs9914988	0.832	rs11650788	chr17:27174523	T/A	cg20469991	chr17:27169893	C17orf63	-0.69	-4.6	-0.38	1.01e-5	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs8017423	0.647	rs4904677	chr14:90819245	C/T	cg04374321	chr14:90722782	PSMC1	-0.58	-5.75	-0.46	6.5e-8	Mortality in heart failure;
TGCT	cis	rs7552404	0.883	rs77773255	chr1:76217193	G/A	cg03433033	chr1:76189801	ACADM	0.82	9.74	0.66	5.46e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7027203	1.000	rs7856374	chr9:96529791	G/A	cg14598338	chr9:96623480	NA	0.58	8.5	0.61	5.15e-14	DNA methylation (variation);
TGCT	cis	rs9296092	0.538	rs9461880	chr6:33518714	C/T	cg13560919	chr6:33536144	NA	-0.2	-4.63	-0.38	9.25e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs2075371	0.829	rs35897242	chr7:134004041	G/A	cg11752832	chr7:134001865	SLC35B4	0.74	6.69	0.51	6.91e-10	Mean platelet volume;
TGCT	cis	rs68170813	0.559	rs4730231	chr7:106942039	G/C	cg02696742	chr7:106810147	HBP1	-0.69	-5.73	-0.46	7.17e-8	Coronary artery disease;
TGCT	cis	rs644799	0.540	rs10831419	chr11:95478037	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.59	5.76	0.46	6.12e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	trans	rs1814175	0.803	rs11040451	chr11:49650639	C/T	cg03929089	chr4:120376271	NA	-0.65	-7.44	-0.56	1.46e-11	Height;
TGCT	cis	rs7617773	0.817	rs35456569	chr3:48250899	T/A	cg11946769	chr3:48343235	NME6	0.76	6.67	0.51	7.6e-10	Coronary artery disease;
TGCT	cis	rs950169	1.000	rs12916348	chr15:84765527	C/T	cg11189052	chr15:85197271	WDR73	0.69	5.91	0.47	3.07e-8	Schizophrenia;
TGCT	cis	rs3829109	0.564	rs3812578	chr9:139299673	G/C	cg13741927	chr9:139327495	INPP5E	-0.24	-5.15	-0.42	9.81e-7	Peak insulin response;Acute insulin response;
TGCT	cis	rs17376456	0.825	rs10057130	chr5:93282557	C/T	cg21475434	chr5:93447410	FAM172A	0.65	4.47	0.37	1.72e-5	Diabetic retinopathy;
TGCT	cis	rs2013441	1.000	rs2703785	chr17:20152418	C/T	cg18979559	chr17:20280153	CCDC144C	-0.45	-4.67	-0.39	7.61e-6	Obesity-related traits;
TGCT	cis	rs7666738	0.791	rs13128640	chr4:99003918	A/C	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg18538332	chr22:24372958	LOC391322	-1.0	-12.48	-0.75	1.21e-23	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs13256369	0.774	rs11777719	chr8:8581038	A/G	cg17143192	chr8:8559678	CLDN23	0.6	5.39	0.44	3.35e-7	Obesity-related traits;
TGCT	cis	rs7772486	0.686	rs9485019	chr6:146046381	C/G	cg23711669	chr6:146136114	FBXO30	-0.88	-9.77	-0.66	4.64e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg03060546	chr3:49711283	APEH	-0.52	-4.86	-0.4	3.53e-6	Menarche (age at onset);
TGCT	cis	rs28595532	0.920	rs114670456	chr4:119771202	A/G	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs12762955	0.561	rs6560863	chr10:1013535	C/A	cg26597838	chr10:835615	NA	-0.45	-6.15	-0.48	9.6e-9	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs10489202	0.632	rs203781	chr1:167880518	A/C	cg24449463	chr1:168025552	DCAF6	-0.55	-6.54	-0.51	1.43e-9	Schizophrenia;
TGCT	cis	rs7119038	0.818	rs10892286	chr11:118642085	A/C	cg19308663	chr11:118741387	NA	0.3	5.59	0.45	1.37e-7	Sjögren's syndrome;
TGCT	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg26818010	chr10:134567672	INPP5A	-0.37	-5.02	-0.41	1.74e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs908922	0.676	rs2105117	chr1:152484129	G/A	cg20991723	chr1:152506922	NA	0.47	6.55	0.51	1.4e-9	Hair morphology;
TGCT	cis	rs1941023	0.584	rs950803	chr11:60152563	A/T	cg08716584	chr11:60157161	MS4A7	0.29	4.6	0.38	1.05e-5	Congenital heart disease (maternal effect);
TGCT	cis	rs748404	0.631	rs28702649	chr15:43648629	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	4.69	0.39	7.09e-6	Lung cancer;
TGCT	cis	rs1878931	0.507	rs35214904	chr16:3410017	C/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.66	-5.18	-0.42	8.77e-7	Body mass index (adult);
TGCT	cis	rs7010267	0.596	rs67819415	chr8:120016916	A/G	cg17171407	chr8:119960777	TNFRSF11B	0.26	4.58	0.38	1.12e-5	Total body bone mineral density (age 45-60);
TGCT	cis	rs11122272	0.735	rs2808591	chr1:231523421	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-6.94	-0.53	1.98e-10	Hemoglobin concentration;
TGCT	trans	rs7819412	0.740	rs11250119	chr8:11037034	C/T	cg15556689	chr8:8085844	FLJ10661	-0.72	-6.74	-0.52	5.2e-10	Triglycerides;
TGCT	cis	rs9814567	0.806	rs7626557	chr3:134318213	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.76	-7.11	-0.54	8.15e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs2486288	0.656	rs7165039	chr15:45570413	C/G	cg14582100	chr15:45693742	SPATA5L1	-0.43	-4.86	-0.4	3.48e-6	Glomerular filtration rate;
TGCT	cis	rs9611565	0.503	rs5996062	chr22:42167464	C/G	cg13695892	chr22:41940480	POLR3H	0.85	8.06	0.59	5.4e-13	Vitiligo;
TGCT	cis	rs10875595	0.836	rs6868387	chr5:140660814	G/A	cg24830062	chr5:140700576	TAF7	-0.6	-5.07	-0.41	1.42e-6	Pulmonary function decline;
TGCT	cis	rs727505	0.721	rs55890146	chr7:124755461	A/T	cg23710748	chr7:124431027	NA	-0.26	-4.56	-0.38	1.2e-5	Lewy body disease;
TGCT	cis	rs669446	0.561	rs639929	chr1:44083874	A/G	cg12908607	chr1:44402522	ARTN	-0.55	-5.9	-0.47	3.25e-8	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs548181	0.668	rs579661	chr11:125474766	A/G	cg03464685	chr11:125439445	EI24	1.43	10.1	0.67	7.31e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg07332563	chr6:291687	DUSP22	-0.74	-7.64	-0.57	5.21e-12	Menopause (age at onset);
TGCT	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.46	-6.7	-0.52	6.44e-10	Alzheimer's disease;
TGCT	cis	rs9467773	0.873	rs9295698	chr6:26566099	T/A	cg26531700	chr6:26746687	NA	0.49	4.73	0.39	6.06e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs929354	0.713	rs7798816	chr7:156940574	A/G	cg05182265	chr7:156933206	UBE3C	-0.39	-8.98	-0.63	3.72e-15	Body mass index;
TGCT	cis	rs1903068	0.785	rs28584303	chr4:55997622	C/T	cg16572876	chr4:56024045	NA	0.44	4.94	0.41	2.47e-6	Endometriosis;
TGCT	cis	rs295140	0.546	rs295134	chr2:201110223	A/G	cg23649088	chr2:200775458	C2orf69	-0.32	-5.56	-0.45	1.55e-7	QT interval;
TGCT	cis	rs9467773	0.620	rs1027203	chr6:26639332	G/C	cg11502198	chr6:26597334	ABT1	0.51	4.61	0.38	9.7e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs514406	0.505	rs416968	chr1:53183513	A/G	cg24675658	chr1:53192096	ZYG11B	-0.79	-9.7	-0.66	6.82e-17	Monocyte count;
TGCT	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg17554472	chr22:41940697	POLR3H	-0.49	-5.27	-0.43	5.9e-7	Vitiligo;
TGCT	cis	rs17401966	0.931	rs3748577	chr1:10357406	C/T	cg19773385	chr1:10388646	KIF1B	0.21	4.65	0.39	8.25e-6	Hepatocellular carcinoma;
TGCT	cis	rs7552404	0.731	rs11161836	chr1:76354333	C/T	cg10523679	chr1:76189770	ACADM	0.83	7.47	0.56	1.28e-11	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.18	0.49	8.46e-9	Electroencephalogram traits;
TGCT	cis	rs941408	1.000	rs1736184	chr19:2810248	G/A	cg06609049	chr19:2785107	THOP1	0.81	7.55	0.56	8.21e-12	Total cholesterol levels;
TGCT	cis	rs7772486	0.875	rs11755334	chr6:146399297	T/C	cg23711669	chr6:146136114	FBXO30	0.89	9.47	0.65	2.36e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2295359	0.892	rs2064689	chr1:67653010	G/A	cg12940439	chr1:67600707	NA	0.6	6.28	0.49	5.25e-9	Psoriasis;
TGCT	cis	rs6424115	1.000	rs7514394	chr1:24100223	A/G	cg15997130	chr1:24165203	NA	-0.9	-9.38	-0.64	4.07e-16	Immature fraction of reticulocytes;
TGCT	cis	rs9486719	1.000	rs3798289	chr6:97023632	T/C	cg06623918	chr6:96969491	KIAA0776	-0.99	-8.05	-0.59	5.65e-13	Migraine;Coronary artery disease;
TGCT	cis	rs17001868	0.881	rs12484358	chr22:40774660	G/A	cg07138101	chr22:40742427	ADSL	0.69	4.65	0.39	8.38e-6	Mammographic density (dense area);
TGCT	cis	rs4906332	1.000	rs8004780	chr14:103853360	A/C	cg26031613	chr14:104095156	KLC1	-0.52	-4.65	-0.39	8.37e-6	Coronary artery disease;
TGCT	cis	rs1568889	0.877	rs34351528	chr11:28304293	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.85	8.8	0.62	9.82e-15	Bipolar disorder;
TGCT	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg17971929	chr21:40555470	PSMG1	-0.65	-5.56	-0.45	1.56e-7	Cognitive function;
TGCT	cis	rs394563	0.726	rs366905	chr6:149735097	T/A	cg16235748	chr6:149772707	ZC3H12D	-0.43	-4.89	-0.4	3.03e-6	Dupuytren's disease;
TGCT	cis	rs950776	0.518	rs12902493	chr15:78819275	C/G	cg06917634	chr15:78832804	PSMA4	0.95	9.52	0.65	1.81e-16	Sudden cardiac arrest;
TGCT	cis	rs9430161	0.645	rs12081186	chr1:11034195	T/C	cg27631724	chr1:11040367	C1orf127	0.53	6.05	0.48	1.58e-8	Ewing sarcoma;
TGCT	cis	rs11690935	0.655	rs1028127	chr2:172530036	T/C	cg13550731	chr2:172543902	DYNC1I2	0.71	6.19	0.49	8.01e-9	Schizophrenia;
TGCT	cis	rs3733585	0.598	rs28677023	chr4:9958326	C/A	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.67	-0.51	7.44e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg00814883	chr7:100076585	TSC22D4	-0.85	-8.62	-0.61	2.62e-14	Platelet count;
TGCT	cis	rs78487399	0.731	rs72790940	chr2:43768545	T/G	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.64	4.48	0.37	1.66e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs10744422	1.000	rs4993320	chr12:123338092	T/C	cg25930673	chr12:123319894	HIP1R	-0.86	-5.02	-0.41	1.72e-6	Schizophrenia;
TGCT	cis	rs295140	0.526	rs295114	chr2:201195602	C/T	cg23649088	chr2:200775458	C2orf69	0.29	4.93	0.4	2.63e-6	QT interval;
TGCT	cis	rs2299587	0.554	rs2283106	chr8:17754330	G/A	cg04898035	chr8:17640624	MTUS1	-0.21	-4.75	-0.39	5.54e-6	Economic and political preferences;
TGCT	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	6.13	0.48	1.06e-8	Bipolar disorder;
TGCT	cis	rs9517320	0.534	rs9556962	chr13:99156648	C/T	cg20487152	chr13:99095054	FARP1	-0.24	-4.64	-0.38	8.83e-6	Longevity;
TGCT	cis	rs13408808	0.679	rs6710727	chr2:168582788	A/G	cg25427580	chr2:168675357	B3GALT1	0.39	4.46	0.37	1.82e-5	Obesity-related traits;
TGCT	cis	rs10836699	0.772	rs11033996	chr11:37177868	A/G	cg18520238	chr11:36422557	PRR5L	0.17	4.44	0.37	1.94e-5	Low high density lipoprotein cholesterol levels;
TGCT	cis	rs524281	0.861	rs9736673	chr11:65924024	T/A	cg00563793	chr11:65837595	PACS1	0.58	4.92	0.4	2.66e-6	Electroencephalogram traits;
TGCT	cis	rs10489525	1.000	rs10489525	chr1:115263685	A/G	cg12756093	chr1:115239321	AMPD1	0.35	4.53	0.38	1.38e-5	Autism;
TGCT	cis	rs9527	0.615	rs11191489	chr10:104740568	C/A	cg04362960	chr10:104952993	NT5C2	0.68	5.77	0.46	5.91e-8	Arsenic metabolism;
TGCT	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg07870213	chr5:140052090	DND1	0.66	8.23	0.59	2.18e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs8103278	0.740	rs2341097	chr19:46268902	C/T	cg11657440	chr19:46296263	DMWD	-0.55	-5.4	-0.44	3.25e-7	Coronary artery disease;
TGCT	cis	rs1008375	1.000	rs4698651	chr4:17694223	A/G	cg18681998	chr4:17616180	MED28	0.78	7.27	0.55	3.58e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs3772130	1.000	rs13083794	chr3:121464928	T/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.54	4.85	0.4	3.66e-6	Cognitive performance;
TGCT	cis	rs2299587	0.689	rs6586670	chr8:17772332	A/G	cg01800426	chr8:17659068	MTUS1	-0.69	-6.01	-0.47	1.96e-8	Economic and political preferences;
TGCT	cis	rs9894429	0.789	rs9747336	chr17:79584189	C/T	cg18240062	chr17:79603768	NPLOC4	0.84	9.67	0.66	8.03e-17	Eye color traits;
TGCT	cis	rs2255336	0.608	rs7958658	chr12:10518828	C/G	cg16084090	chr12:10586130	KLRC2	0.3	4.62	0.38	9.55e-6	Blood protein levels;
TGCT	cis	rs13217239	0.646	rs2142685	chr6:27054497	C/T	cg06035815	chr6:26189597	HIST1H4D	0.44	4.53	0.38	1.39e-5	Schizophrenia;
TGCT	cis	rs58688157	0.883	rs7936397	chr11:577534	G/A	cg16486109	chr11:613632	IRF7	0.34	5.0	0.41	1.87e-6	Systemic lupus erythematosus;
TGCT	cis	rs17665859	1.000	rs17665859	chr8:445601	T/C	cg17960703	chr8:356704	FBXO25	1.48	5.62	0.45	1.22e-7	Bilirubin levels;
TGCT	cis	rs137699	0.652	rs137706	chr22:39751400	T/G	cg11247378	chr22:39784982	NA	-0.6	-5.94	-0.47	2.68e-8	IgG glycosylation;
TGCT	cis	rs775227	0.574	rs16861158	chr3:113261709	G/T	cg18753928	chr3:113234510	CCDC52	-0.66	-4.49	-0.37	1.64e-5	Dental caries;
TGCT	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg11890956	chr21:40555474	PSMG1	-0.75	-7.28	-0.55	3.44e-11	Cognitive function;
TGCT	cis	rs9916302	0.706	rs11655972	chr17:37407072	C/T	cg07936489	chr17:37558343	FBXL20	-0.82	-6.2	-0.49	7.86e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs3858526	0.920	rs11039698	chr11:5950907	C/T	cg05234568	chr11:5960015	NA	-0.48	-4.77	-0.39	5.08e-6	DNA methylation (variation);
TGCT	cis	rs2463822	0.925	rs12292586	chr11:62156312	C/T	cg06239285	chr11:62104954	ASRGL1	-0.94	-6.61	-0.51	1.03e-9	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.39	-4.57	-0.38	1.17e-5	Longevity;Endometriosis;
TGCT	cis	rs9611565	0.649	rs139553	chr22:42187199	A/G	cg17554472	chr22:41940697	POLR3H	0.45	4.66	0.39	8.18e-6	Vitiligo;
TGCT	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.36	-4.58	-0.38	1.11e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9325144	0.505	rs7955162	chr12:38711658	G/A	cg26384229	chr12:38710491	ALG10B	0.97	8.97	0.63	3.86e-15	Morning vs. evening chronotype;
TGCT	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg16680214	chr1:154839983	KCNN3	-0.42	-9.25	-0.64	8.37e-16	Prostate cancer;
TGCT	cis	rs1215050	0.791	rs783960	chr4:98893437	A/G	cg05340658	chr4:99064831	C4orf37	-0.46	-5.82	-0.46	4.74e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9733	0.596	rs1136808	chr1:150702717	G/C	cg09365446	chr1:150670422	GOLPH3L	0.3	4.52	0.38	1.4e-5	Tonsillectomy;
TGCT	cis	rs478304	0.651	rs7110576	chr11:65512057	T/G	cg27068330	chr11:65405492	SIPA1	-0.93	-9.34	-0.64	4.92e-16	Acne (severe);
TGCT	cis	rs2692947	0.696	rs2969490	chr2:96803904	A/G	cg23100626	chr2:96804247	ASTL	0.41	5.03	0.41	1.65e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs79149102	0.579	rs7174129	chr15:75305040	A/G	cg09165964	chr15:75287851	SCAMP5	-1.04	-5.71	-0.46	7.93e-8	Lung cancer;
TGCT	trans	rs1864729	0.748	rs2583509	chr8:98294151	G/A	cg08679828	chr8:102218111	ZNF706	-1.03	-6.71	-0.52	6.09e-10	Estradiol plasma levels (breast cancer);
TGCT	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg16423285	chr20:60520624	NA	-0.69	-7.11	-0.54	8.23e-11	Body mass index;
TGCT	cis	rs1348850	0.598	rs1405717	chr2:178500101	G/T	cg22681709	chr2:178499509	PDE11A	-0.52	-6.65	-0.51	8.49e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs6964587	0.967	rs6465340	chr7:91588664	G/A	cg22709100	chr7:91322751	NA	0.28	4.54	0.38	1.3e-5	Breast cancer;
TGCT	cis	rs832540	0.931	rs33319	chr5:56206675	C/A	cg24531977	chr5:56204891	C5orf35	-0.53	-5.49	-0.44	2.15e-7	Coronary artery disease;
TGCT	cis	rs12497850	0.931	rs4974082	chr3:48999323	G/A	cg07636037	chr3:49044803	WDR6	0.96	10.42	0.68	1.17e-18	Parkinson's disease;
TGCT	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg03351412	chr1:154909251	PMVK	0.54	5.02	0.41	1.72e-6	Prostate cancer;
TGCT	cis	rs7020830	0.571	rs3780335	chr9:37376587	A/G	cg14235030	chr9:37121269	ZCCHC7	-0.44	-4.78	-0.39	4.87e-6	Schizophrenia;
TGCT	trans	rs208520	1.000	rs12193077	chr6:66989548	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.83	7.46	0.56	1.31e-11	Exhaled nitric oxide output;
TGCT	cis	rs9400467	0.537	rs12192695	chr6:111453046	C/T	cg15721981	chr6:111408429	SLC16A10	0.72	4.6	0.38	1.01e-5	Blood metabolite levels;Amino acid levels;
TGCT	cis	rs1403694	0.515	rs1624569	chr3:186450069	A/G	cg12454167	chr3:186435060	KNG1	0.45	7.22	0.54	4.67e-11	Blood protein levels;
TGCT	cis	rs3125734	0.633	rs7100297	chr10:63985100	T/C	cg05499367	chr10:63213510	TMEM26	-0.33	-4.52	-0.38	1.4e-5	Rheumatoid arthritis;
TGCT	cis	rs6964587	0.692	rs2027950	chr7:91863700	C/G	cg17063962	chr7:91808500	NA	-0.73	-6.75	-0.52	5.17e-10	Breast cancer;
TGCT	cis	rs7267979	1.000	rs34645895	chr20:25368373	A/G	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg27523141	chr10:43048294	ZNF37B	0.71	8.14	0.59	3.46e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs4372836	0.553	rs6706858	chr2:28992607	C/G	cg09522027	chr2:28974177	PPP1CB	-0.73	-7.07	-0.54	9.78e-11	Body mass index;
TGCT	cis	rs7953249	0.722	rs2255531	chr12:121414915	G/A	cg02403541	chr12:121454288	C12orf43	0.6	5.1	0.42	1.23e-6	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs12681287	0.640	rs7017706	chr8:87480890	C/T	cg27223183	chr8:87520930	FAM82B	-0.89	-6.41	-0.5	2.8e-9	Caudate activity during reward;
TGCT	cis	rs1153858	1.000	rs4627277	chr15:45652768	C/A	cg26924012	chr15:45694286	SPATA5L1	1.09	15.16	0.81	5.15e-30	Homoarginine levels;
TGCT	cis	rs7208859	0.673	rs73277967	chr17:29184166	T/A	cg18442181	chr17:29233375	C17orf42	-0.78	-4.61	-0.38	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs11105298	0.891	rs10858854	chr12:89835728	C/A	cg00757033	chr12:89920650	WDR51B	0.34	5.36	0.43	4e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg06618935	chr21:46677482	NA	-0.37	-5.56	-0.45	1.58e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2346177	0.816	rs74179078	chr2:46654651	T/A	cg26688816	chr2:46740690	ATP6V1E2	-0.46	-5.18	-0.42	8.6e-7	HDL cholesterol;
TGCT	cis	rs9811920	0.809	rs4928153	chr3:99808445	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.43	4.77	0.39	5.16e-6	Axial length;
TGCT	cis	rs7959452	0.535	rs11615712	chr12:69619736	A/T	cg20891283	chr12:69753455	YEATS4	-0.59	-5.55	-0.45	1.68e-7	Blood protein levels;
TGCT	cis	rs72781680	0.752	rs72780185	chr2:24003967	G/A	cg08917208	chr2:24149416	ATAD2B	0.81	5.01	0.41	1.8e-6	Lymphocyte counts;
TGCT	cis	rs62244186	0.748	rs4682987	chr3:44674996	C/T	cg04389838	chr3:44770851	ZNF501	-0.38	-5.02	-0.41	1.75e-6	Depressive symptoms;
TGCT	cis	rs8078723	1.000	rs2227336	chr17:38174855	T/G	cg17467752	chr17:38218738	THRA	0.52	4.93	0.41	2.54e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs9400467	0.537	rs56272203	chr6:111492436	C/A	cg15721981	chr6:111408429	SLC16A10	0.69	4.5	0.37	1.56e-5	Blood metabolite levels;Amino acid levels;
TGCT	cis	rs709400	0.628	rs7155014	chr14:103863970	C/G	cg26031613	chr14:104095156	KLC1	0.81	8.8	0.62	1.01e-14	Body mass index;
TGCT	cis	rs600231	0.542	rs11227196	chr11:65234922	G/A	cg17120908	chr11:65337727	SSSCA1	-0.56	-4.45	-0.37	1.86e-5	Bone mineral density;
TGCT	cis	rs877426	0.634	rs7329801	chr13:114824560	G/A	cg16820615	chr13:114884918	RASA3	0.32	5.1	0.42	1.21e-6	Facial morphology (factor 14, intercanthal width);
TGCT	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg03188948	chr7:1209495	NA	0.45	5.85	0.47	4.04e-8	Longevity;Endometriosis;
TGCT	cis	rs6912958	0.702	rs2300909	chr6:88212100	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-5.06	-0.41	1.45e-6	Monocyte percentage of white cells;
TGCT	cis	rs2439831	0.867	rs7170489	chr15:43636651	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	6.61	0.51	1e-9	Lung cancer in ever smokers;
TGCT	cis	rs3820068	0.581	rs72645871	chr1:15926142	G/A	cg05660106	chr1:15850417	CASP9	0.82	8.02	0.58	6.63e-13	Systolic blood pressure;
TGCT	cis	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg09021430	chr5:549028	NA	-0.43	-5.66	-0.45	1.01e-7	Lung disease severity in cystic fibrosis;
TGCT	cis	rs514406	0.825	rs12089511	chr1:53436427	A/T	cg16325326	chr1:53192061	ZYG11B	-0.58	-6.63	-0.51	9.32e-10	Monocyte count;
TGCT	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg03188948	chr7:1209495	NA	0.68	5.8	0.46	5.09e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	trans	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg27523141	chr10:43048294	ZNF37B	0.74	8.66	0.61	2.13e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg08439880	chr3:133502540	NA	-0.27	-4.82	-0.4	4.05e-6	Iron status biomarkers;
TGCT	cis	rs12497850	0.931	rs6442130	chr3:48778027	A/G	cg07636037	chr3:49044803	WDR6	0.93	10.07	0.67	8.61e-18	Parkinson's disease;
TGCT	cis	rs9894429	0.738	rs8077038	chr17:79577127	T/G	cg21028142	chr17:79581711	NPLOC4	-0.3	-7.03	-0.53	1.2e-10	Eye color traits;
TGCT	cis	rs7954584	0.616	rs10743185	chr12:122356435	G/A	cg21171335	chr12:122356390	WDR66	0.59	6.19	0.49	8.15e-9	Mean corpuscular volume;
TGCT	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.65	-6.23	-0.49	6.72e-9	Menarche (age at onset);
TGCT	cis	rs2467099	0.504	rs55956362	chr17:73901294	G/T	cg10108402	chr17:73901394	MRPL38	-0.47	-4.47	-0.37	1.75e-5	Systolic blood pressure;
TGCT	cis	rs28595532	0.920	rs116821181	chr4:119734892	T/C	cg21605333	chr4:119757512	SEC24D	1.66	8.33	0.6	1.28e-13	Cannabis dependence symptom count;
TGCT	cis	rs2458413	0.543	rs2514658	chr8:105337871	G/A	cg04554929	chr8:105342491	NA	-0.61	-9.81	-0.66	3.55e-17	Paget's disease;
TGCT	cis	rs17401966	0.838	rs61775887	chr1:10284733	T/C	cg19773385	chr1:10388646	KIF1B	-0.22	-4.6	-0.38	1.02e-5	Hepatocellular carcinoma;
TGCT	cis	rs6570726	0.818	rs952405	chr6:145925952	T/C	cg23711669	chr6:146136114	FBXO30	0.83	8.64	0.61	2.4e-14	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4509693	0.943	rs10732789	chr10:102496184	T/C	cg24127310	chr10:102502104	NA	0.7	5.86	0.47	3.84e-8	Alzheimer's disease;
TGCT	cis	rs17197710	0.673	rs12576690	chr11:47321509	T/C	cg13308137	chr11:47528955	CUGBP1	0.41	5.82	0.46	4.71e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7010267	0.935	rs7463176	chr8:119957625	A/G	cg17171407	chr8:119960777	TNFRSF11B	0.33	6.18	0.49	8.29e-9	Total body bone mineral density (age 45-60);
TGCT	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	5.8	0.46	5.19e-8	Alzheimer's disease;
TGCT	cis	rs17253792	0.822	rs10129890	chr14:56040413	A/T	cg01858014	chr14:56050164	KTN1	-0.36	-4.55	-0.38	1.24e-5	Putamen volume;
TGCT	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	8.99	0.63	3.48e-15	Platelet count;
TGCT	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg08280861	chr8:58055591	NA	0.36	4.91	0.4	2.77e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs12510870	0.599	rs10019146	chr4:74453656	G/A	cg05868023	chr4:75230803	EREG	-0.55	-4.74	-0.39	5.71e-6	Iris color (b* coordinate);
TGCT	cis	rs6121246	0.559	rs6058465	chr20:30397691	G/A	cg13852791	chr20:30311386	BCL2L1	0.8	7.42	0.55	1.61e-11	Mean corpuscular hemoglobin;
TGCT	cis	rs4319547	1.000	rs4319547	chr12:123079035	A/G	cg23029597	chr12:123009494	RSRC2	-0.31	-5.01	-0.41	1.82e-6	Body mass index;
TGCT	cis	rs116095464	0.558	rs62347677	chr5:227453	A/G	cg12570787	chr5:219185	SDHA;CCDC127	0.66	4.49	0.37	1.62e-5	Breast cancer;
TGCT	cis	rs3796352	1.000	rs34933390	chr3:53006265	T/G	cg15956490	chr3:53032818	SFMBT1	0.61	6.76	0.52	4.92e-10	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs13256369	0.901	rs4841015	chr8:8567140	C/G	cg06671706	chr8:8559999	CLDN23	0.34	4.59	0.38	1.09e-5	Obesity-related traits;
TGCT	cis	rs7267979	0.932	rs424487	chr20:25468131	C/G	cg16686733	chr20:25566563	NINL	0.56	5.69	0.46	8.49e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs797680	0.789	rs797671	chr1:93700363	C/A	cg17826107	chr1:92977322	EVI5	0.24	5.29	0.43	5.47e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.5	-4.81	-0.4	4.26e-6	Bipolar disorder;
TGCT	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg04287289	chr16:89883240	FANCA	0.95	11.94	0.73	2.39e-22	Vitiligo;
TGCT	cis	rs367943	1.000	rs348946	chr5:112822814	C/T	cg12552261	chr5:112820674	MCC	-0.24	-4.91	-0.4	2.81e-6	Type 2 diabetes;
TGCT	cis	rs9733	0.650	rs9803935	chr1:150552622	T/G	cg13175981	chr1:150552382	MCL1	0.52	5.75	0.46	6.55e-8	Tonsillectomy;
TGCT	cis	rs4975616	0.804	rs457130	chr5:1336178	A/T	cg07493874	chr5:1342172	CLPTM1L	-0.27	-6.53	-0.51	1.55e-9	Lung cancer;
TGCT	cis	rs72843506	0.722	rs117096120	chr17:20167693	G/A	cg18979559	chr17:20280153	CCDC144C	-0.64	-4.82	-0.4	4.04e-6	Schizophrenia;
TGCT	cis	rs6912958	0.703	rs12207825	chr6:88098292	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.4	5.18	0.42	8.73e-7	Monocyte percentage of white cells;
TGCT	cis	rs6545883	0.965	rs766447	chr2:61735569	C/T	cg15711740	chr2:61764176	XPO1	-0.56	-5.1	-0.42	1.22e-6	Tuberculosis;
TGCT	cis	rs9549260	0.753	rs9532562	chr13:41153585	A/G	cg21288729	chr13:41239152	FOXO1	0.67	4.89	0.4	3e-6	Red blood cell count;
TGCT	cis	rs3749237	0.595	rs11130192	chr3:49467206	C/G	cg02487422	chr3:49467188	NICN1	0.61	6.29	0.49	5.08e-9	Resting heart rate;
TGCT	cis	rs9560113	0.959	rs9555803	chr13:112179560	G/T	cg14154082	chr13:112174009	NA	0.37	5.07	0.41	1.42e-6	Menarche (age at onset);
TGCT	cis	rs2730245	0.550	rs10258339	chr7:158670243	T/C	cg11984989	chr7:158649758	WDR60	1.01	8.98	0.63	3.58e-15	Height;
TGCT	cis	rs4383453	0.539	rs12636451	chr3:123102924	A/C	cg04890266	chr3:123102914	ADCY5	-0.49	-7.91	-0.58	1.23e-12	Gestational age at birth (maternal effect);
TGCT	cis	rs459571	0.876	rs2520095	chr9:136919568	A/G	cg13789015	chr9:136890014	NCRNA00094	0.39	6.83	0.52	3.45e-10	Platelet distribution width;
TGCT	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg11494091	chr17:61959527	GH2	0.61	14.34	0.79	4.3e-28	Prudent dietary pattern;
TGCT	cis	rs9303401	0.659	rs12940212	chr17:56674474	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs3849570	0.961	rs7620240	chr3:81762787	G/T	cg07356753	chr3:81810745	GBE1	-0.85	-8.16	-0.59	3.13e-13	Waist circumference;Body mass index;
TGCT	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs74544699	0.826	rs74499711	chr4:74842764	G/A	cg16072462	chr4:74847758	PF4	0.78	5.16	0.42	9.32e-7	Growth-regulated protein alpha levels;
TGCT	cis	rs2075165	0.935	rs933489	chr1:156235120	T/C	cg20302342	chr1:156215951	PAQR6	0.39	5.67	0.45	9.49e-8	Tonsillectomy;
TGCT	cis	rs7833790	0.724	rs4739627	chr8:82734657	A/G	cg27398817	chr8:82754497	SNX16	-0.67	-5.34	-0.43	4.27e-7	Diastolic blood pressure;
TGCT	cis	rs1580019	0.587	rs6972365	chr7:32548931	T/A	cg06627557	chr7:32535165	LSM5;AVL9	1.13	14.15	0.79	1.17e-27	Cognitive ability;
TGCT	cis	rs9486715	0.867	rs926277	chr6:96868837	T/A	cg18709589	chr6:96969512	KIAA0776	0.79	7.77	0.57	2.5e-12	Headache;
TGCT	cis	rs593982	0.920	rs563427	chr11:65484569	A/G	cg08755490	chr11:65554678	OVOL1	1.35	8.23	0.59	2.2e-13	Atopic dermatitis;
TGCT	cis	rs12681288	0.823	rs2701908	chr8:1003250	T/C	cg04851639	chr8:1020857	NA	-0.32	-5.39	-0.44	3.35e-7	Schizophrenia;
TGCT	cis	rs453301	0.686	rs7017868	chr8:8873293	G/A	cg00184457	chr8:8946301	NA	-0.27	-4.92	-0.4	2.72e-6	Joint mobility (Beighton score);
TGCT	cis	rs3806843	0.576	rs246030	chr5:140333154	C/G	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs1593573	chr4:98925293	T/C	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs2469997	1.000	rs2447181	chr8:120354288	T/A	cg01792902	chr3:178864926	PIK3CA	0.78	6.66	0.51	7.93e-10	Hypertension (SNP x SNP interaction);
TGCT	cis	rs9883204	0.855	rs11720108	chr3:123069058	C/T	cg04890266	chr3:123102914	ADCY5	0.37	4.99	0.41	1.98e-6	Birth weight;
TGCT	cis	rs62193398	1.000	rs62193398	chr2:202531264	T/C	cg12618251	chr2:202899058	FZD7	0.53	4.47	0.37	1.75e-5	Breast cancer;
TGCT	cis	rs295140	0.934	rs74853338	chr2:201171651	C/T	cg04283868	chr2:201171347	SPATS2L	0.63	6.43	0.5	2.46e-9	QT interval;
TGCT	cis	rs651907	0.535	rs2290859	chr3:101525625	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.32	-6.67	-0.51	7.53e-10	Colorectal cancer;
TGCT	cis	rs2204008	0.754	rs11181244	chr12:38302454	T/C	cg13010199	chr12:38710504	ALG10B	0.58	4.54	0.38	1.31e-5	Bladder cancer;
TGCT	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg24250549	chr1:154909240	PMVK	0.65	6.49	0.5	1.84e-9	Prostate cancer;
TGCT	cis	rs950169	0.920	rs2135551	chr15:84707851	A/G	cg17173187	chr15:85201210	NMB	0.47	5.22	0.42	7.36e-7	Schizophrenia;
TGCT	cis	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.67	6.69	0.51	6.95e-10	Eosinophil percentage of white cells;
TGCT	cis	rs6088590	0.931	rs12625149	chr20:33425812	A/C	cg24642439	chr20:33292090	TP53INP2	-0.68	-5.88	-0.47	3.55e-8	Coronary artery disease;
TGCT	trans	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg21659725	chr3:3221576	CRBN	0.98	15.33	0.81	2.1000000000000002e-30	Intelligence (multi-trait analysis);
TGCT	cis	rs9329221	0.509	rs3088186	chr8:10226355	C/T	cg21293242	chr8:11204541	TDH	0.43	4.45	0.37	1.88e-5	Neuroticism;
TGCT	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg00814883	chr7:100076585	TSC22D4	-0.9	-9.56	-0.65	1.5e-16	Platelet count;
TGCT	cis	rs117785887	0.536	rs10457790	chr6:146359865	A/G	cg06708562	chr6:146285465	SHPRH	-0.8	-4.81	-0.4	4.23e-6	Interleukin-17 levels;
TGCT	cis	rs13040088	0.935	rs62200158	chr20:61557906	C/T	cg23096297	chr20:61557774	DIDO1	1.17	9.71	0.66	6.25e-17	Menopause (age at onset);
TGCT	cis	rs3749237	0.595	rs885592	chr3:49497883	T/G	cg07636037	chr3:49044803	WDR6	0.63	6.07	0.48	1.47e-8	Resting heart rate;
TGCT	cis	rs910316	1.000	rs175436	chr14:75608683	C/G	cg23033748	chr14:75592666	NEK9	-0.3	-4.96	-0.41	2.26e-6	Height;
TGCT	cis	rs4820539	0.966	rs5759600	chr22:23483769	C/A	cg14186256	chr22:23484241	RTDR1	1.04	13.85	0.78	6.06e-27	Bone mineral density;
TGCT	cis	rs6752107	0.846	rs7559194	chr2:234206799	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.22	4.69	0.39	7.05e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs614226	1.000	rs616157	chr12:120925795	T/C	cg10072921	chr12:121022843	NA	0.45	4.86	0.4	3.45e-6	Type 1 diabetes nephropathy;
TGCT	cis	rs2282802	0.685	rs2337081	chr5:139642414	A/C	cg01081189	chr5:139537190	NA	0.29	5.24	0.43	6.57e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg16497277	chr3:49208875	KLHDC8B	-0.5	-4.56	-0.38	1.21e-5	Parkinson's disease;
TGCT	cis	rs4663866	1.000	rs4663868	chr2:239161091	C/T	cg17283117	chr2:239148619	HES6	0.98	4.52	0.38	1.42e-5	Irritable bowel syndrome;
TGCT	cis	rs5769765	1.000	rs5770741	chr22:50270215	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.41	-6.13	-0.48	1.08e-8	Schizophrenia;
TGCT	cis	rs10986311	0.775	rs1007185	chr9:127136644	G/C	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.19	-4.8	-0.4	4.45e-6	Vitiligo;
TGCT	cis	rs9911578	0.967	rs7503190	chr17:57184162	A/C	cg12560992	chr17:57184187	TRIM37	0.79	9.71	0.66	6.56e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs6964587	1.000	rs28927678	chr7:91715662	C/T	cg17063962	chr7:91808500	NA	0.86	9.36	0.64	4.58e-16	Breast cancer;
TGCT	cis	rs12971120	0.838	rs3794950	chr18:72182965	G/A	cg26446133	chr18:72167187	CNDP2	-0.35	-5.84	-0.46	4.22e-8	Refractive error;
TGCT	cis	rs5769765	0.913	rs28670284	chr22:50221973	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.19	-11.95	-0.73	2.3e-22	Schizophrenia;
TGCT	cis	rs858239	0.601	rs12539331	chr7:23151330	A/G	cg05602783	chr7:23145260	KLHL7	-0.71	-6.14	-0.48	1.03e-8	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs2089162	1	rs2089162	chr15:78739763	A/G	cg18825076	chr15:78729989	IREB2	-0.35	-5.31	-0.43	4.99e-7	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs2153535	0.580	rs2327056	chr6:8443305	C/T	cg07606381	chr6:8435919	SLC35B3	0.57	5.25	0.43	6.46e-7	Motion sickness;
TGCT	cis	rs68170813	0.652	rs79295036	chr7:107193669	C/A	cg02696742	chr7:106810147	HBP1	-0.59	-4.71	-0.39	6.61e-6	Coronary artery disease;
TGCT	cis	rs7474896	0.616	rs2505239	chr10:38440765	A/G	cg25427524	chr10:38739819	LOC399744	-0.35	-4.55	-0.38	1.24e-5	Obesity (extreme);
TGCT	cis	rs6860806	0.531	rs270607	chr5:131649186	A/G	cg24060327	chr5:131705240	SLC22A5	-0.72	-7.76	-0.57	2.7e-12	Breast cancer;
TGCT	cis	rs478304	0.651	rs11227279	chr11:65495211	G/A	cg27068330	chr11:65405492	SIPA1	-0.94	-9.51	-0.65	1.94e-16	Acne (severe);
TGCT	cis	rs7017914	0.967	rs7825446	chr8:71664174	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.53	-4.9	-0.4	2.87e-6	Bone mineral density;
TGCT	cis	rs6918586	0.594	rs198842	chr6:26111448	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.7	-6.6	-0.51	1.07e-9	Schizophrenia;
TGCT	cis	rs9291683	0.632	rs13137074	chr4:10042842	C/T	cg00071950	chr4:10020882	SLC2A9	0.68	8.74	0.62	1.38e-14	Bone mineral density;
TGCT	cis	rs986417	0.818	rs10148116	chr14:61101089	C/T	cg27398547	chr14:60952738	C14orf39	1.57	10.0	0.67	1.28e-17	Gut microbiota (bacterial taxa);
TGCT	cis	rs7552404	0.727	rs5745390	chr1:76306591	A/C	cg10523679	chr1:76189770	ACADM	0.74	7.08	0.54	9.41e-11	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs67073037	0.955	rs12620680	chr2:29144611	C/T	cg09522027	chr2:28974177	PPP1CB	0.57	4.49	0.37	1.59e-5	Breast cancer;Breast cancer (estrogen-receptor negative);
TGCT	cis	rs2688608	0.592	rs7923045	chr10:75487498	A/T	cg15838173	chr10:75533400	FUT11	-0.3	-4.91	-0.4	2.78e-6	Inflammatory bowel disease;
TGCT	cis	rs2721195	0.845	rs2721150	chr8:145724973	C/G	cg17328964	chr8:145687451	CYHR1	-0.38	-5.07	-0.41	1.39e-6	Age at first birth;
TGCT	cis	rs4820539	1.000	rs4822357	chr22:23473231	A/G	cg14186256	chr22:23484241	RTDR1	0.92	8.41	0.6	8.13e-14	Bone mineral density;
TGCT	cis	rs1215050	0.791	rs783959	chr4:98893476	C/T	cg05340658	chr4:99064831	C4orf37	-0.47	-5.89	-0.47	3.41e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs860295	0.502	rs2886070	chr1:155973971	G/A	cg05700447	chr1:155978627	NA	-0.19	-4.57	-0.38	1.18e-5	Body mass index;
TGCT	cis	rs7772486	0.719	rs2206141	chr6:146086192	A/G	cg13319975	chr6:146136371	FBXO30	0.58	5.29	0.43	5.27e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs12136530	0.774	rs12140338	chr1:19766430	C/G	cg18923740	chr1:19971790	NBL1	0.35	4.47	0.37	1.72e-5	Lead levels in blood;
TGCT	cis	rs6121246	0.609	rs6088997	chr20:30289824	A/G	cg18721089	chr20:30220636	NA	0.37	4.58	0.38	1.11e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs12049351	0.719	rs4925493	chr1:229623137	T/C	cg12130225	chr1:229698885	NA	0.39	4.5	0.37	1.52e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs6912958	0.781	rs2273129	chr6:88182439	T/C	cg06598631	chr6:88300029	RARS2;ORC3L	-0.53	-4.85	-0.4	3.69e-6	Monocyte percentage of white cells;
TGCT	cis	rs9399135	0.967	rs2327578	chr6:135329969	C/T	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.36e-6	Red blood cell count;
TGCT	cis	rs17376456	0.877	rs12109629	chr5:93359702	A/G	cg25358565	chr5:93447407	FAM172A	0.92	8.4	0.6	8.88e-14	Diabetic retinopathy;
TGCT	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg25767906	chr1:53392781	SCP2	-0.51	-6.22	-0.49	6.83e-9	Monocyte count;
TGCT	cis	rs7843479	0.526	rs34802507	chr8:21773853	C/T	cg17168535	chr8:21777572	XPO7	0.78	7.35	0.55	2.29e-11	Mean corpuscular volume;
TGCT	cis	rs1371867	0.817	rs1788179	chr8:101333345	A/G	cg00191853	chr8:101177733	SPAG1	-0.22	-4.47	-0.37	1.75e-5	Atrioventricular conduction;
TGCT	cis	rs4253772	0.550	rs9615913	chr22:46668515	A/T	cg09491104	chr22:46646882	C22orf40	0.67	6.71	0.52	6.33e-10	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs8017423	0.647	rs4904673	chr14:90817338	G/A	cg04374321	chr14:90722782	PSMC1	-0.58	-5.73	-0.46	7.04e-8	Mortality in heart failure;
TGCT	trans	rs66573146	0.831	rs56081162	chr4:6989718	C/T	cg07817883	chr1:32538562	TMEM39B	1.3	6.83	0.52	3.41e-10	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs586688	1.000	rs647130	chr1:201637982	A/G	cg22851694	chr1:202075546	NA	0.37	4.46	0.37	1.83e-5	Obesity-related traits;
TGCT	cis	rs28374715	0.662	rs113913466	chr15:41483100	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.81	-11.6	-0.72	1.65e-21	Ulcerative colitis;
TGCT	cis	rs4788570	0.625	rs4788813	chr16:71625572	T/C	cg06353428	chr16:71660113	MARVELD3	1.48	10.62	0.69	3.91e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs7191439	0.728	rs8056374	chr16:88790147	G/T	cg27087555	chr16:88793112	FAM38A	-0.48	-5.47	-0.44	2.41e-7	Plateletcrit;
TGCT	cis	rs7267979	0.789	rs6083841	chr20:25384564	C/T	cg03522245	chr20:25566470	NINL	-0.52	-5.25	-0.43	6.43e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.34	0.55	2.43e-11	Prudent dietary pattern;
TGCT	cis	rs7178572	0.568	rs1446312	chr15:77412189	G/C	cg22256960	chr15:77711686	NA	-0.86	-8.75	-0.62	1.27e-14	Type 2 diabetes;
TGCT	cis	rs12908161	1.000	rs34900908	chr15:85257599	G/A	cg17173187	chr15:85201210	NMB	0.59	6.77	0.52	4.55e-10	Schizophrenia;
TGCT	cis	rs9972944	0.756	rs7222229	chr17:63765025	T/G	cg07283582	chr17:63770753	CCDC46	-0.26	-5.3	-0.43	5.02e-7	Total body bone mineral density;
TGCT	cis	rs10779751	0.734	rs1034528	chr1:11249132	G/C	cg08854313	chr1:11322531	MTOR	-0.82	-6.99	-0.53	1.5e-10	Body mass index;
TGCT	cis	rs4631830	0.863	rs2249986	chr10:51521684	T/G	cg10326726	chr10:51549505	MSMB	-0.26	-5.35	-0.43	4.12e-7	Prostate-specific antigen levels;
TGCT	cis	rs10131894	0.611	rs175000	chr14:75436367	T/C	cg08847533	chr14:75593920	NEK9	-0.66	-6.29	-0.49	4.87e-9	Coronary artery disease;
TGCT	cis	rs4713118	0.516	rs6931858	chr6:28078411	A/T	cg12963246	chr6:28129442	ZNF389	0.51	4.87	0.4	3.3e-6	Parkinson's disease;
TGCT	cis	rs4664308	0.740	rs877635	chr2:160902847	A/C	cg03641300	chr2:160917029	PLA2R1	-0.26	-6.09	-0.48	1.3e-8	Idiopathic membranous nephropathy;
TGCT	cis	rs6089584	1.000	rs3787425	chr20:60559256	C/T	cg13770153	chr20:60521292	NA	-0.44	-5.62	-0.45	1.21e-7	Body mass index;
TGCT	cis	rs3749237	0.595	rs17650792	chr3:49390250	A/G	cg03060546	chr3:49711283	APEH	0.76	8.57	0.61	3.4e-14	Resting heart rate;
TGCT	cis	rs78487399	0.808	rs10169346	chr2:43741105	A/G	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.76	4.68	0.39	7.27e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs36405	1.000	rs36405	chr14:72357937	C/T	cg10066683	chr14:71515513	PCNX	-0.25	-4.7	-0.39	6.71e-6	Yang-deficiency constitution;
TGCT	cis	rs10465746	0.780	rs11163862	chr1:84355418	A/T	cg10977910	chr1:84465055	TTLL7	-0.64	-6.56	-0.51	1.29e-9	Obesity-related traits;
TGCT	cis	rs9467773	0.620	rs3800303	chr6:26598188	A/G	cg05738196	chr6:26577821	NA	0.88	11.09	0.71	2.86e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs7647973	1.000	rs62261249	chr3:49594060	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.57	-4.59	-0.38	1.08e-5	Menarche (age at onset);
TGCT	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg24829409	chr8:58192753	C8orf71	-0.59	-4.97	-0.41	2.17e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7917772	0.560	rs10786697	chr10:104378563	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.56	5.45	0.44	2.6e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs61931739	0.517	rs7958856	chr12:34294737	T/C	cg06521331	chr12:34319734	NA	-0.3	-4.55	-0.38	1.28e-5	Morning vs. evening chronotype;
TGCT	cis	rs7267979	1.000	rs6050565	chr20:25347563	A/C	cg03522245	chr20:25566470	NINL	-0.62	-6.7	-0.52	6.66e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11191270	0.554	rs11191275	chr10:104142800	C/T	cg15320455	chr10:103880129	LDB1	0.86	5.38	0.43	3.58e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs614226	0.935	rs2235222	chr12:120892193	G/C	cg10072921	chr12:121022843	NA	0.43	4.51	0.38	1.48e-5	Type 1 diabetes nephropathy;
TGCT	cis	rs72945132	0.882	rs7118156	chr11:70142922	T/C	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs7666738	0.791	rs10005118	chr4:99038196	A/C	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1843834	1.000	rs1843834	chr2:225558042	A/G	cg22455342	chr2:225449267	CUL3	0.75	7.37	0.55	2.15e-11	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs2657888	0.931	rs2939312	chr12:56932554	G/A	cg23002907	chr12:56915593	RBMS2	0.44	6.13	0.48	1.09e-8	Adiponectin levels;
TGCT	cis	rs6815814	0.950	rs11722889	chr4:38810975	C/T	cg02016764	chr4:38805732	TLR1	-0.37	-5.85	-0.47	4.08e-8	Breast cancer;
TGCT	cis	rs6728642	0.908	rs6731522	chr2:97647997	A/G	cg26665480	chr2:98280029	ACTR1B	-0.92	-6.0	-0.47	2.01e-8	Bipolar disorder lithium response (continuous) or schizophrenia;
TGCT	cis	rs10493773	0.775	rs12756013	chr1:86153532	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.43	-6.18	-0.49	8.29e-9	Urate levels in overweight individuals;
TGCT	cis	rs7246657	0.943	rs2081096	chr19:37964700	G/A	cg18154014	chr19:37997991	ZNF793	0.73	5.33	0.43	4.4e-7	Coronary artery calcification;
TGCT	cis	rs3733585	0.699	rs7699609	chr4:9961059	A/G	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.67	-0.51	7.44e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7666738	0.830	rs4699592	chr4:98974202	A/C	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs4332037	0.539	rs11772627	chr7:2109821	G/C	cg25206134	chr2:45395956	NA	0.94	6.99	0.53	1.52e-10	Bipolar disorder;
TGCT	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg08280861	chr8:58055591	NA	0.39	4.86	0.4	3.45e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7085104	0.632	rs6162	chr10:104596981	G/A	cg04362960	chr10:104952993	NT5C2	0.56	4.92	0.4	2.68e-6	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs7567389	0.564	rs10209483	chr2:128158637	C/T	cg02161262	chr2:127865248	BIN1	-0.54	-4.75	-0.39	5.56e-6	Self-rated health;
TGCT	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg14159672	chr1:205819179	PM20D1	0.71	9.63	0.65	9.76e-17	Menarche (age at onset);
TGCT	cis	rs7914558	0.966	rs12571568	chr10:104891396	C/G	cg04362960	chr10:104952993	NT5C2	0.62	5.55	0.45	1.66e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs3091242	0.933	rs932372	chr1:25755014	G/A	cg00786635	chr1:25594202	NA	0.57	6.0	0.47	2e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs3796352	1.000	rs13072818	chr3:53074263	C/T	cg27565382	chr3:53032988	SFMBT1	0.43	4.62	0.38	9.64e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	trans	rs1814175	0.645	rs1963215	chr11:49931486	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.51	-0.69	7.2e-19	Height;
TGCT	cis	rs2486288	0.656	rs2413772	chr15:45549862	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.46	-5.59	-0.45	1.39e-7	Glomerular filtration rate;
TGCT	cis	rs7584330	0.554	rs77194105	chr2:238436463	T/C	cg14458575	chr2:238380390	NA	0.43	4.55	0.38	1.25e-5	Prostate cancer;
TGCT	cis	rs786425	0.585	rs2333834	chr12:124246004	G/A	cg10461218	chr12:124144432	GTF2H3	0.22	4.67	0.39	7.73e-6	Pubertal anthropometrics;
TGCT	cis	rs28374715	0.662	rs521890	chr15:41473143	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.74	-11.02	-0.7	4.25e-20	Ulcerative colitis;
TGCT	cis	rs2535633	0.602	rs6801235	chr3:53009595	T/C	cg10802521	chr3:52805072	NEK4	-0.52	-5.52	-0.44	1.86e-7	Body mass index;
TGCT	trans	rs77457752	0.525	rs1923351	chr9:13898902	G/A	cg23609682	chr1:3070786	PRDM16	0.5	6.79	0.52	4.09e-10	Breast cancer;
TGCT	cis	rs6088590	1.000	rs6088590	chr20:33313566	T/C	cg24642439	chr20:33292090	TP53INP2	0.69	6.17	0.48	8.94e-9	Coronary artery disease;
TGCT	cis	rs7845219	0.539	rs10441538	chr8:95868608	G/A	cg16049864	chr8:95962084	TP53INP1	-0.55	-6.29	-0.49	4.98e-9	Type 2 diabetes;
TGCT	cis	rs7772486	0.790	rs9403756	chr6:146257761	C/G	cg23711669	chr6:146136114	FBXO30	-0.86	-9.95	-0.67	1.64e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10875746	0.903	rs2158516	chr12:48490834	T/A	cg20731937	chr12:48336164	NA	0.62	4.95	0.41	2.36e-6	Longevity (90 years and older);
TGCT	cis	rs4750440	0.637	rs2457859	chr10:14032099	T/G	cg25464840	chr10:14372910	FRMD4A	0.33	4.46	0.37	1.82e-5	Adiponectin levels;
TGCT	cis	rs9906944	0.707	rs9912906	chr17:47104432	A/T	cg20966754	chr17:47091339	IGF2BP1	-0.45	-5.17	-0.42	9.27e-7	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs763121	0.853	rs5757234	chr22:39072686	C/T	cg06022373	chr22:39101656	GTPBP1	0.8	8.25	0.6	1.95e-13	Menopause (age at onset);
TGCT	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg10802521	chr3:52805072	NEK4	0.75	9.17	0.64	1.26e-15	Bipolar disorder;
TGCT	cis	rs35000415	0.683	rs66872377	chr7:128722172	A/C	cg06242719	chr7:129414860	MIR183;MIR96	-0.3	-4.58	-0.38	1.1e-5	Systemic lupus erythematosus;
TGCT	cis	rs5769765	1.000	rs2319458	chr22:50236306	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.37	5.62	0.45	1.19e-7	Schizophrenia;
TGCT	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg00343986	chr7:65444356	GUSB	0.25	5.63	0.45	1.15e-7	Aortic root size;
TGCT	cis	rs2730260	0.537	rs55864635	chr7:158859744	C/T	cg12144100	chr7:157890277	PTPRN2	0.35	4.45	0.37	1.87e-5	Myopia (pathological);
TGCT	cis	rs950169	0.579	rs12912716	chr15:84664263	A/T	cg11189052	chr15:85197271	WDR73	0.65	5.06	0.41	1.45e-6	Schizophrenia;
TGCT	cis	rs6882076	0.925	rs1393207	chr5:156397540	T/A	cg12943317	chr5:156479607	HAVCR1	-0.31	-6.01	-0.48	1.9e-8	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
TGCT	cis	rs60843830	1.000	rs11553746	chr2:272203	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.73	7.41	0.55	1.74e-11	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs6500602	0.701	rs11643057	chr16:4544505	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.37	5.22	0.42	7.15e-7	Schizophrenia;
TGCT	cis	rs2932538	0.922	rs6698030	chr1:113138318	G/A	cg10983938	chr1:113465962	AFARP1;SLC16A1	0.21	4.44	0.37	1.99e-5	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs12681287	0.640	rs12550142	chr8:87471861	C/A	cg27223183	chr8:87520930	FAM82B	-0.89	-6.43	-0.5	2.54e-9	Caudate activity during reward;
TGCT	cis	rs7617773	0.925	rs7374376	chr3:48172687	T/C	cg11946769	chr3:48343235	NME6	-0.56	-4.84	-0.4	3.74e-6	Coronary artery disease;
TGCT	cis	rs7769051	0.522	rs60133731	chr6:133095818	T/C	cg22852734	chr6:133119734	C6orf192	1.16	4.48	0.37	1.67e-5	Type 2 diabetes nephropathy;
TGCT	cis	rs854765	0.505	rs2955358	chr17:17946623	A/G	cg09796270	chr17:17721594	SREBF1	-0.25	-4.77	-0.39	5.07e-6	Total body bone mineral density;
TGCT	cis	rs11874712	1.000	rs9783886	chr18:43651270	A/G	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	5.11	0.42	1.19e-6	Migraine - clinic-based;
TGCT	cis	rs9653442	0.564	rs6707067	chr2:100767232	G/A	cg22139774	chr2:100720529	AFF3	-0.35	-5.55	-0.45	1.63e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs17376456	0.877	rs10057605	chr5:93443950	T/G	cg21475434	chr5:93447410	FAM172A	0.6	4.62	0.38	9.48e-6	Diabetic retinopathy;
TGCT	cis	rs2204008	0.694	rs10880262	chr12:38328696	C/T	cg26384229	chr12:38710491	ALG10B	0.63	5.68	0.45	9.15e-8	Bladder cancer;
TGCT	cis	rs860295	0.580	rs2282301	chr1:155868625	A/G	cg05700447	chr1:155978627	NA	-0.22	-4.67	-0.39	7.64e-6	Body mass index;
TGCT	cis	rs2637266	0.703	rs846641	chr10:78524136	C/T	cg18941641	chr10:78392320	NA	0.4	4.73	0.39	5.96e-6	Pulmonary function;
TGCT	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg22433210	chr17:43662623	NA	-1.02	-7.43	-0.56	1.52e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs1552244	0.554	rs3732964	chr3:10048839	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.33	-4.95	-0.41	2.39e-6	Alzheimer's disease;
TGCT	cis	rs2832191	0.716	rs1543652	chr21:30448000	G/C	cg08807101	chr21:30365312	RNF160	0.65	6.13	0.48	1.06e-8	Dental caries;
TGCT	cis	rs66573146	0.831	rs67315413	chr4:6987910	T/C	cg00086871	chr4:6988644	TBC1D14	0.94	4.62	0.38	9.61e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs7666738	0.791	rs7660866	chr4:98961335	G/A	cg18180107	chr4:99064573	C4orf37	0.57	5.18	0.42	8.63e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11711311	1.000	rs7622403	chr3:113472434	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.76	7.09	0.54	8.84e-11	IgG glycosylation;
TGCT	cis	rs2288884	1.000	rs78543982	chr19:52550867	T/C	cg13540795	chr19:52551618	ZNF432	-0.59	-5.02	-0.41	1.79e-6	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs3809566	1.000	rs10851721	chr15:63332383	T/C	cg00520135	chr15:63333846	TPM1	-0.44	-5.46	-0.44	2.44e-7	Platelet count;
TGCT	cis	rs9457247	0.967	rs388406	chr6:167409562	A/G	cg23791538	chr6:167370224	RNASET2	-0.49	-4.96	-0.41	2.31e-6	Crohn's disease;
TGCT	cis	rs4730430	0.515	rs6943600	chr7:110132602	G/A	cg14239618	chr7:110281356	NA	0.24	4.65	0.39	8.25e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs208520	1.000	rs12190187	chr6:66973207	T/G	cg07460842	chr6:66804631	NA	0.81	7.16	0.54	6.31e-11	Exhaled nitric oxide output;
TGCT	cis	rs936229	0.813	rs2168519	chr15:75080872	T/C	cg10253484	chr15:75165896	SCAMP2	-0.67	-5.38	-0.43	3.64e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
TGCT	cis	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg22467129	chr15:76604101	ETFA	0.45	5.07	0.41	1.4e-6	Blood metabolite levels;
TGCT	cis	rs78456975	0.607	rs73909625	chr2:1541934	A/G	cg01028140	chr2:1542097	TPO	-0.36	-4.63	-0.38	9.02e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs7666738	0.830	rs7664169	chr4:99037859	C/T	cg18180107	chr4:99064573	C4orf37	-0.56	-5.15	-0.42	9.93e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9796	0.866	rs544744	chr15:41366290	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.47	-6.09	-0.48	1.34e-8	Menopause (age at onset);
TGCT	cis	rs453301	0.653	rs1045529	chr8:8890098	A/G	cg00184457	chr8:8946301	NA	-0.24	-4.45	-0.37	1.89e-5	Joint mobility (Beighton score);
TGCT	cis	rs7044106	0.762	rs1867254	chr9:123429078	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	4.56	0.38	1.21e-5	Hip circumference adjusted for BMI;
TGCT	cis	rs7666738	0.791	rs4699329	chr4:99056212	G/A	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.44e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2243480	1.000	rs58669269	chr7:65951953	T/C	cg07424592	chr7:64974309	NA	1.29	8.01	0.58	7.16e-13	Diabetic kidney disease;
TGCT	cis	rs853679	0.527	rs1997660	chr6:28269663	A/G	cg18815343	chr6:28367644	ZSCAN12	-0.46	-4.8	-0.4	4.46e-6	Depression;
TGCT	cis	rs7833790	0.660	rs7839178	chr8:82763479	A/G	cg23324259	chr8:82754387	SNX16	0.62	4.71	0.39	6.47e-6	Diastolic blood pressure;
TGCT	cis	rs2243480	1.000	rs313831	chr7:65551226	C/T	cg18252515	chr7:66147081	NA	-1.1	-7.18	-0.54	5.77e-11	Diabetic kidney disease;
TGCT	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg13395646	chr4:1353034	KIAA1530	-0.39	-5.2	-0.42	7.9e-7	Obesity-related traits;
TGCT	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs5769707	0.935	rs5770594	chr22:50018497	G/A	cg20744362	chr22:50050164	C22orf34	0.27	4.47	0.37	1.77e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs16867321	0.671	rs13429179	chr2:181492790	T/C	cg23363182	chr2:181467187	NA	-0.46	-4.75	-0.39	5.44e-6	Obesity;
TGCT	cis	rs6725041	0.547	rs4672645	chr2:213204955	C/T	cg16329650	chr2:213403929	ERBB4	-0.67	-5.89	-0.47	3.4e-8	QT interval (ambient particulate matter interaction);
TGCT	cis	rs9467773	0.596	rs3001369	chr6:26670969	C/T	cg15659132	chr6:26577336	NA	0.89	10.22	0.68	3.77e-18	Intelligence (multi-trait analysis);
TGCT	cis	rs858239	0.600	rs13438188	chr7:23144197	C/T	cg05602783	chr7:23145260	KLHL7	0.62	5.45	0.44	2.56e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs6700896	0.522	rs4655792	chr1:66159264	T/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.54	4.44	0.37	1.98e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs4566357	0.615	rs6436644	chr2:227914275	T/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-5.25	-0.43	6.53e-7	Coronary artery disease;
TGCT	cis	rs79349575	0.749	rs12601672	chr17:47006493	T/C	cg07967210	chr17:47022446	SNF8	0.44	6.13	0.48	1.1e-8	Type 2 diabetes;
TGCT	cis	rs1348850	0.914	rs10170546	chr2:178248790	C/T	cg22681709	chr2:178499509	PDE11A	-0.35	-4.57	-0.38	1.15e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs2996428	0.709	rs6667255	chr1:3711689	T/C	cg17848003	chr1:3704513	LRRC47	0.17	4.71	0.39	6.63e-6	Red cell distribution width;
TGCT	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg01802117	chr1:53393560	SCP2	0.43	5.13	0.42	1.1e-6	Monocyte count;
TGCT	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg20891283	chr12:69753455	YEATS4	0.9	10.36	0.68	1.69e-18	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs6500602	0.727	rs1477123	chr16:4560627	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.4	7.02	0.53	1.32e-10	Schizophrenia;
TGCT	cis	rs9325144	0.647	rs34311455	chr12:39060889	C/T	cg26384229	chr12:38710491	ALG10B	-0.56	-5.1	-0.42	1.25e-6	Morning vs. evening chronotype;
TGCT	cis	rs12681287	0.640	rs6471309	chr8:87387760	C/T	cg27223183	chr8:87520930	FAM82B	-0.89	-6.82	-0.52	3.58e-10	Caudate activity during reward;
TGCT	cis	rs6701037	0.681	rs1894709	chr1:175132371	G/T	cg00321850	chr1:175162397	KIAA0040	-0.42	-5.83	-0.46	4.61e-8	Alcohol dependence;
TGCT	cis	rs3125734	0.633	rs1835862	chr10:64056068	G/A	cg19640130	chr10:64028056	RTKN2	-0.38	-4.77	-0.39	5.19e-6	Rheumatoid arthritis;
TGCT	cis	rs7772486	0.790	rs9376968	chr6:146180364	T/C	cg05347473	chr6:146136440	FBXO30	0.51	4.76	0.39	5.27e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9611565	0.573	rs9306355	chr22:42111896	A/T	cg17554472	chr22:41940697	POLR3H	0.45	4.84	0.4	3.72e-6	Vitiligo;
TGCT	trans	rs941408	1.000	rs1076447	chr19:2792128	C/G	cg19676328	chr12:49525230	TUBA1B	-0.74	-7.15	-0.54	6.67e-11	Total cholesterol levels;
TGCT	cis	rs1385374	1.000	rs12311303	chr12:129301592	C/T	cg09035930	chr12:129282057	SLC15A4	-0.55	-4.76	-0.39	5.27e-6	Systemic lupus erythematosus;
TGCT	cis	rs138249	0.898	rs138227	chr22:50556815	A/G	cg24864161	chr22:50528282	MOV10L1	0.47	5.02	0.41	1.77e-6	Gestational age at birth in labor-initiated deliveries (child effect);
TGCT	cis	rs7412746	0.658	rs17660092	chr1:150797748	T/C	cg04414720	chr1:150670196	GOLPH3L	0.38	4.69	0.39	7.01e-6	Melanoma;
TGCT	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg06028605	chr16:24865363	SLC5A11	0.41	4.59	0.38	1.05e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs826838	0.967	rs11169387	chr12:39145737	C/T	cg26384229	chr12:38710491	ALG10B	1.05	9.91	0.66	2.14e-17	Heart rate;
TGCT	cis	rs7772486	0.641	rs2748489	chr6:146331287	T/G	cg13319975	chr6:146136371	FBXO30	-0.68	-6.33	-0.49	4.17e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs66561647	1.000	rs66561647	chr8:128971861	C/T	cg11792826	chr8:129160931	MIR1208	0.22	4.9	0.4	2.94e-6	Hemoglobin concentration;
TGCT	cis	rs2245008	0.774	rs253136	chr16:83979601	A/C	cg27171569	chr16:83987465	OSGIN1	-0.4	-4.59	-0.38	1.06e-5	Pursuit maintenance gain;
TGCT	cis	rs12887734	0.524	rs4906364	chr14:104214342	C/G	cg26031613	chr14:104095156	KLC1	-0.72	-6.2	-0.49	7.61e-9	Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7772486	0.720	rs4896844	chr6:146075224	T/C	cg13319975	chr6:146136371	FBXO30	0.56	4.93	0.4	2.56e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg06481639	chr22:41940642	POLR3H	-0.72	-6.52	-0.51	1.61e-9	Vitiligo;
TGCT	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg21171335	chr12:122356390	WDR66	-0.62	-6.82	-0.52	3.56e-10	Mean corpuscular volume;
TGCT	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg06634786	chr22:41940651	POLR3H	-0.89	-8.45	-0.6	6.78e-14	Vitiligo;
TGCT	cis	rs1691799	0.867	rs1168356	chr12:66750469	A/G	cg16791601	chr12:66731901	HELB	-0.27	-5.8	-0.46	5.22e-8	White blood cell count (basophil);
TGCT	cis	rs7917772	0.582	rs12411442	chr10:104349531	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	5.36	0.43	3.84e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg13665807	chr20:60559372	TAF4	-0.46	-5.0	-0.41	1.92e-6	Body mass index;
TGCT	cis	rs7666738	0.830	rs17026973	chr4:98680041	T/A	cg17366294	chr4:99064904	C4orf37	0.62	6.4	0.5	2.94e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4820539	1.000	rs2157710	chr22:23457486	C/T	cg14186256	chr22:23484241	RTDR1	0.98	12.21	0.74	5.2e-23	Bone mineral density;
TGCT	cis	rs7918232	0.607	rs1755401	chr10:27405763	A/C	cg14442939	chr10:27389572	ANKRD26	0.82	5.9	0.47	3.26e-8	Breast cancer;
TGCT	cis	rs78456975	0.782	rs13403265	chr2:1516836	A/G	cg01028140	chr2:1542097	TPO	-0.36	-4.67	-0.39	7.69e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs6448317	0.954	rs7666033	chr4:24925272	A/G	cg21108841	chr4:24914750	CCDC149	-0.61	-4.85	-0.4	3.63e-6	Heschl's gyrus morphology;
TGCT	cis	rs6430585	0.528	rs309133	chr2:136751842	A/C	cg07169764	chr2:136633963	MCM6	1.2	11.66	0.72	1.14e-21	Corneal structure;
TGCT	cis	rs6754311	0.593	rs4954279	chr2:136409073	G/A	cg07169764	chr2:136633963	MCM6	0.68	5.89	0.47	3.33e-8	Mosquito bite size;
TGCT	cis	rs858239	0.669	rs1006709	chr7:23140099	C/T	cg05602783	chr7:23145260	KLHL7	-0.63	-5.32	-0.43	4.7e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs150641967	1	rs150641967	chr19:19370340	TGACA/T	cg03709012	chr19:19516395	GATAD2A	1.05	4.86	0.4	3.45e-6	Triglyceride levels;Very low density lipoprotein cholesterol levels;Low density lipoprotein cholesterol;Total cholesterol levels;
TGCT	cis	rs10779751	0.960	rs6661859	chr1:11301063	T/C	cg08854313	chr1:11322531	MTOR	0.99	10.58	0.69	4.78e-19	Body mass index;
TGCT	cis	rs7772486	0.754	rs9497401	chr6:146051271	T/C	cg05347473	chr6:146136440	FBXO30	-0.51	-4.66	-0.39	8.17e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7819412	0.806	rs17723229	chr8:10930069	A/C	cg21775007	chr8:11205619	TDH	-0.5	-4.63	-0.38	9.11e-6	Triglycerides;
TGCT	cis	rs7666738	0.830	rs1896154	chr4:99021161	T/C	cg17366294	chr4:99064904	C4orf37	0.68	7.04	0.53	1.17e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg10802521	chr3:52805072	NEK4	-0.71	-8.79	-0.62	1.04e-14	Bipolar disorder;
TGCT	cis	rs2046867	0.862	rs6778168	chr3:72840206	T/A	cg25664220	chr3:72788482	NA	-0.52	-6.65	-0.51	8.27e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs4144743	0.877	rs7218773	chr17:45324211	C/T	cg18085866	chr17:45331354	ITGB3	-0.72	-4.8	-0.4	4.39e-6	Body mass index;
TGCT	cis	rs74233809	0.901	rs11191416	chr10:104604916	G/T	cg05855489	chr10:104503620	C10orf26	-0.81	-4.6	-0.38	1.03e-5	Birth weight;
TGCT	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg00684032	chr4:1343700	KIAA1530	-0.23	-4.94	-0.41	2.48e-6	Obesity-related traits;
TGCT	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/A	cg02609749	chr16:89786786	C16orf7;ZNF276	0.35	4.94	0.41	2.44e-6	Vitiligo;
TGCT	cis	rs713587	0.713	rs4665276	chr2:25213333	C/T	cg15423357	chr2:25149977	NA	-0.58	-5.91	-0.47	3.05e-8	Body mass index in non-asthmatics;
TGCT	cis	rs4713118	0.581	rs200504	chr6:27785820	T/C	cg10876282	chr6:28092338	ZSCAN16	0.59	4.83	0.4	3.89e-6	Parkinson's disease;
TGCT	cis	rs7429990	0.803	rs11714518	chr3:48156635	T/C	cg11946769	chr3:48343235	NME6	-0.56	-4.61	-0.38	9.72e-6	Educational attainment (years of education);
TGCT	cis	rs11650494	0.908	rs75904857	chr17:47370449	T/G	cg08112188	chr17:47440006	ZNF652	1.04	5.35	0.43	4.09e-7	Prostate cancer;
TGCT	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg16405210	chr4:1374714	KIAA1530	-0.24	-4.51	-0.38	1.49e-5	Longevity;
TGCT	cis	rs941873	0.835	rs10762859	chr10:81103370	T/A	cg09469691	chr10:81107165	PPIF	0.56	5.55	0.45	1.67e-7	Height;
TGCT	cis	rs9457247	1.000	rs386548	chr6:167385533	A/T	cg23791538	chr6:167370224	RNASET2	0.48	4.8	0.4	4.52e-6	Crohn's disease;
TGCT	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg12310025	chr6:25882481	NA	-0.53	-5.45	-0.44	2.58e-7	Blood metabolite levels;
TGCT	cis	rs9388451	0.839	rs3966775	chr6:126067655	C/A	cg05901451	chr6:126070800	HEY2	-1.04	-15.78	-0.82	1.89e-31	Brugada syndrome;
TGCT	cis	rs12477438	0.520	rs13798	chr2:99813614	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	17.06	0.84	2.55e-34	Chronic sinus infection;
TGCT	cis	rs9677476	0.955	rs9973370	chr2:232095587	A/G	cg07929768	chr2:232055508	NA	0.3	4.48	0.37	1.71e-5	Food antigen IgG levels;
TGCT	cis	rs11112613	1.000	rs11112613	chr12:106003786	A/G	cg03607813	chr12:105948248	NA	0.47	5.0	0.41	1.9e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	cis	rs7586879	0.639	rs2384058	chr2:25100328	A/G	cg01884057	chr2:25150051	NA	0.33	6.36	0.5	3.53e-9	Body mass index;
TGCT	cis	rs7568458	0.709	rs1446669	chr2:85762209	T/C	cg02493740	chr2:85810744	VAMP5	-0.29	-5.58	-0.45	1.42e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs7824557	0.564	rs2043508	chr8:11227406	G/A	cg21775007	chr8:11205619	TDH	-0.65	-6.14	-0.48	1.01e-8	Retinal vascular caliber;
TGCT	cis	rs10832963	0.924	rs10832950	chr11:18635815	A/G	cg09201001	chr11:18656081	SPTY2D1	1.05	11.63	0.72	1.34e-21	Breast cancer;
TGCT	cis	rs9926296	0.581	rs2108838	chr16:89904426	A/G	cg08627397	chr16:89984028	MC1R	-0.34	-5.43	-0.44	2.79e-7	Vitiligo;
TGCT	cis	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg03213289	chr20:61660250	NA	0.72	10.83	0.7	1.22e-19	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2836974	0.897	rs2836923	chr21:40524236	T/C	cg11644478	chr21:40555479	PSMG1	1.05	10.98	0.7	5.12e-20	Cognitive function;
TGCT	cis	rs9372253	1.000	rs9374170	chr6:110712991	A/G	cg19196401	chr6:110721138	DDO	-0.48	-7.05	-0.53	1.1e-10	Platelet distribution width;
TGCT	cis	rs514406	0.536	rs878957	chr1:53197559	C/T	cg22166914	chr1:53195759	ZYG11B	-0.46	-7.97	-0.58	8.69e-13	Monocyte count;
TGCT	cis	rs28595532	1.000	rs56000725	chr4:119637675	G/A	cg21605333	chr4:119757512	SEC24D	1.36	7.39	0.55	1.89e-11	Cannabis dependence symptom count;
TGCT	cis	rs10197940	0.624	rs4461258	chr2:152429679	A/G	cg06191203	chr2:152266755	RIF1	0.78	7.61	0.56	5.94e-12	Lung cancer;
TGCT	cis	rs6921919	0.583	rs740621	chr6:28397787	A/G	cg18815343	chr6:28367644	ZSCAN12	-0.54	-5.06	-0.41	1.48e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs79349575	0.756	rs4793605	chr17:47035869	T/C	cg27201301	chr17:47039149	GIP	0.25	4.47	0.37	1.72e-5	Type 2 diabetes;
TGCT	cis	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg18252515	chr7:66147081	NA	-1.14	-6.81	-0.52	3.76e-10	Diabetic kidney disease;
TGCT	cis	rs7178572	0.568	rs4886850	chr15:77404160	G/C	cg15453836	chr15:77711506	NA	-0.4	-4.52	-0.38	1.45e-5	Type 2 diabetes;
TGCT	cis	rs3776081	0.600	rs11167497	chr5:149533976	G/T	cg18424208	chr5:149546337	CDX1	-0.25	-4.48	-0.37	1.66e-5	Blood protein levels;
TGCT	cis	rs9443645	0.901	rs4706079	chr6:79615208	G/A	cg05283184	chr6:79620031	NA	-0.21	-4.71	-0.39	6.61e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs8179	0.553	rs42377	chr7:92243672	G/A	cg15732164	chr7:92237376	CDK6	-0.24	-4.52	-0.38	1.45e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
TGCT	cis	rs7100689	0.646	rs2994390	chr10:82074395	C/A	cg01528321	chr10:82214614	TSPAN14	0.72	7.28	0.55	3.37e-11	Post bronchodilator FEV1;
TGCT	cis	rs4242434	0.927	rs35952885	chr8:22491622	T/G	cg03733263	chr8:22462867	KIAA1967	1.14	17.32	0.84	6.76e-35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs17253792	0.822	rs75016910	chr14:56050466	C/G	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg09060608	chr5:178986726	RUFY1	0.49	5.59	0.45	1.35e-7	Lung cancer;
TGCT	cis	rs3820928	0.845	rs1917126	chr2:227840923	G/T	cg11843606	chr2:227700838	RHBDD1	-0.52	-4.58	-0.38	1.1e-5	Pulmonary function;
TGCT	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg23758822	chr17:41437982	NA	0.72	6.81	0.52	3.77e-10	Menopause (age at onset);
TGCT	cis	rs2463822	1.000	rs2463820	chr11:62112290	A/T	cg06239285	chr11:62104954	ASRGL1	0.89	5.91	0.47	3.04e-8	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs12142240	0.698	rs17361805	chr1:46813967	C/T	cg00530320	chr1:46809349	NSUN4	0.29	5.95	0.47	2.53e-8	Menopause (age at onset);
TGCT	cis	rs367943	0.901	rs171180	chr5:112817093	A/C	cg12552261	chr5:112820674	MCC	-0.24	-4.91	-0.4	2.81e-6	Type 2 diabetes;
TGCT	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg20999797	chr1:1681921	NA	-0.2	-5.09	-0.42	1.27e-6	Body mass index;
TGCT	trans	rs4332037	0.586	rs62442944	chr7:2015047	T/G	cg25206134	chr2:45395956	NA	0.97	7.33	0.55	2.6e-11	Bipolar disorder;
TGCT	cis	rs2153535	0.542	rs915354	chr6:8440357	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.56	0.45	1.55e-7	Motion sickness;
TGCT	cis	rs1541995	1.000	rs4984608	chr15:96335890	A/G	cg00882281	chr15:96346592	NA	0.28	4.53	0.38	1.39e-5	Photic sneeze reflex;
TGCT	cis	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg03213289	chr20:61660250	NA	0.69	9.79	0.66	4.07e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7746199	0.668	rs7749305	chr6:27446566	T/C	cg02458000	chr6:26745757	NA	-0.94	-4.46	-0.37	1.82e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs57590327	0.508	rs13093082	chr3:81949958	C/T	cg07356753	chr3:81810745	GBE1	-0.74	-6.82	-0.52	3.5e-10	Extraversion;
TGCT	cis	rs2204008	0.837	rs8189467	chr12:38241956	T/C	cg26384229	chr12:38710491	ALG10B	0.84	7.28	0.55	3.29e-11	Bladder cancer;
TGCT	cis	rs9467773	1.000	rs1884946	chr6:26545308	C/G	cg26531700	chr6:26746687	NA	0.47	4.56	0.38	1.19e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs11969893	0.850	rs9498414	chr6:101322976	C/T	cg12253828	chr6:101329408	ASCC3	1.08	5.14	0.42	1.06e-6	Economic and political preferences (immigration/crime);
TGCT	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.05	8.68	0.61	1.9e-14	Platelet count;
TGCT	cis	rs4252435	0.614	rs78357866	chr7:142629280	T/G	cg21621906	chr7:142494914	NA	-1.09	-4.56	-0.38	1.22e-5	Cancer;
TGCT	cis	rs12530134	1.000	rs12530134	chr6:170919470	G/A	cg16639145	chr6:170041015	WDR27	0.58	5.12	0.42	1.11e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs3796352	1.000	rs58660500	chr3:53086573	C/T	cg15956490	chr3:53032818	SFMBT1	0.6	6.78	0.52	4.31e-10	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs1670533	1.000	rs1010342	chr4:1068819	C/T	cg20887711	chr4:1340912	KIAA1530	0.64	5.16	0.42	9.64e-7	Recombination rate (females);
TGCT	cis	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg22857025	chr5:266934	NA	-0.34	-6.64	-0.51	8.6e-10	Breast cancer;
TGCT	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg20607798	chr8:58055168	NA	0.5	4.66	0.39	8.04e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7954584	0.546	rs10840630	chr12:122352445	C/T	cg13699009	chr12:122356056	WDR66	0.29	5.73	0.46	7.13e-8	Mean corpuscular volume;
TGCT	cis	rs12497850	0.931	rs4974079	chr3:48906469	T/G	cg18654377	chr3:49208889	KLHDC8B	-0.42	-5.52	-0.44	1.93e-7	Parkinson's disease;
TGCT	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg25036284	chr2:26402008	FAM59B	-0.67	-5.42	-0.44	3.04e-7	Gut microbiome composition (summer);
TGCT	cis	rs12477438	0.520	rs6756650	chr2:99801800	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	13.05	0.76	4.93e-25	Chronic sinus infection;
TGCT	cis	rs6831352	0.838	rs2851250	chr4:100044113	G/C	cg12011299	chr4:100065546	ADH4	0.43	5.02	0.41	1.71e-6	Alcohol dependence;
TGCT	cis	rs2404602	0.692	rs4886829	chr15:77091182	G/T	cg22467129	chr15:76604101	ETFA	-0.45	-5.11	-0.42	1.21e-6	Blood metabolite levels;
TGCT	cis	rs9372498	0.536	rs72952761	chr6:118866758	A/C	cg21191810	chr6:118973309	C6orf204	-0.37	-4.79	-0.39	4.73e-6	Diastolic blood pressure;
TGCT	cis	rs4786125	0.879	rs11645781	chr16:6896128	C/T	cg03623568	chr16:6915990	A2BP1	0.35	4.83	0.4	3.87e-6	Heart rate variability traits (SDNN);
TGCT	cis	rs4285028	0.699	rs1920297	chr3:121598000	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.78	-6.72	-0.52	5.95e-10	Multiple sclerosis;
TGCT	cis	rs514406	0.505	rs269290	chr1:53167027	A/T	cg01802117	chr1:53393560	SCP2	-0.42	-4.84	-0.4	3.86e-6	Monocyte count;
TGCT	cis	rs10114408	0.959	rs1890380	chr9:96665812	G/A	cg13679303	chr9:96623674	NA	-0.36	-4.63	-0.38	9.04e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs9325144	0.647	rs11169258	chr12:39113040	C/T	cg26384229	chr12:38710491	ALG10B	-0.6	-5.65	-0.45	1.03e-7	Morning vs. evening chronotype;
TGCT	cis	rs11085466	0.615	rs76695906	chr19:21766710	G/A	cg02997983	chr19:21646781	NA	-0.63	-4.53	-0.38	1.35e-5	Colorectal or endometrial cancer;
TGCT	cis	rs2832191	0.740	rs6516890	chr21:30476812	T/A	cg08807101	chr21:30365312	RNF160	0.64	6.01	0.48	1.91e-8	Dental caries;
TGCT	cis	rs11864453	0.647	rs9932062	chr16:72136055	T/C	cg14768367	chr16:72042858	DHODH	0.52	5.27	0.43	5.78e-7	Fibrinogen levels;
TGCT	trans	rs1499614	1.000	rs34250985	chr7:66161062	A/T	cg07424592	chr7:64974309	NA	1.41	8.04	0.59	6.2e-13	Gout;
TGCT	trans	rs1814175	0.817	rs28502006	chr11:50049930	T/C	cg03929089	chr4:120376271	NA	-0.72	-8.55	-0.61	3.8e-14	Height;
TGCT	cis	rs9911578	0.935	rs117819974	chr17:57002324	C/T	cg05425664	chr17:57184151	TRIM37	-0.62	-6.18	-0.49	8.33e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg25036284	chr2:26402008	FAM59B	-0.54	-4.7	-0.39	6.93e-6	Gut microbiome composition (summer);
TGCT	cis	rs910316	1.000	rs175425	chr14:75626131	T/C	cg08847533	chr14:75593920	NEK9	-0.92	-9.96	-0.67	1.6e-17	Height;
TGCT	trans	rs6762477	0.748	rs11717349	chr3:50223977	C/T	cg21659725	chr3:3221576	CRBN	-0.65	-7.35	-0.55	2.37e-11	Menarche (age at onset);
TGCT	cis	rs55823223	0.564	rs58363746	chr17:73850819	C/T	cg08125733	chr17:73851984	WBP2	0.87	8.8	0.62	1e-14	Psoriasis;
TGCT	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg11764359	chr7:65958608	NA	-0.57	-5.07	-0.41	1.4e-6	Aortic root size;
TGCT	cis	rs939574	0.790	rs79225383	chr2:220093972	C/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.04	4.8	0.4	4.54e-6	Platelet distribution width;
TGCT	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg17971929	chr21:40555470	PSMG1	0.98	9.51	0.65	1.95e-16	Cognitive function;
TGCT	cis	rs7267979	0.844	rs1555330	chr20:25232097	A/C	cg16686733	chr20:25566563	NINL	0.52	4.9	0.4	2.98e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs7819412	0.745	rs2898260	chr8:10939490	G/T	cg15556689	chr8:8085844	FLJ10661	-0.74	-7.04	-0.53	1.15e-10	Triglycerides;
TGCT	cis	rs7772486	0.641	rs67882056	chr6:146416301	T/C	cg23711669	chr6:146136114	FBXO30	0.66	6.04	0.48	1.66e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2228479	0.541	rs9806913	chr16:89953773	A/G	cg06558623	chr16:89946397	TCF25	0.42	5.09	0.42	1.29e-6	Skin colour saturation;
TGCT	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg05368731	chr17:41323189	NBR1	-1.19	-14.04	-0.78	2.15e-27	Menopause (age at onset);
TGCT	cis	rs6988636	1.000	rs13260318	chr8:124190165	C/G	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs9399135	0.967	rs4896120	chr6:135293512	C/G	cg24558204	chr6:135376177	HBS1L	0.48	4.79	0.39	4.76e-6	Red blood cell count;
TGCT	trans	rs6561151	0.957	rs2121034	chr13:44473866	G/T	cg12856521	chr11:46389249	DGKZ	0.67	7.47	0.56	1.22e-11	Crohn's disease;
TGCT	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg13665807	chr20:60559372	TAF4	0.51	5.25	0.43	6.3e-7	Body mass index;
TGCT	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg03517284	chr6:25882590	NA	0.78	8.11	0.59	4.26e-13	Blood metabolite levels;
TGCT	cis	rs4824093	0.610	rs58671506	chr22:50288983	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.48	4.93	0.41	2.53e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs864537	0.676	rs2988279	chr1:167419839	G/A	cg22356347	chr1:167427500	CD247	-0.21	-5.28	-0.43	5.51e-7	Celiac disease or Rheumatoid arthritis;Celiac disease;
TGCT	cis	rs3806843	0.608	rs155364	chr5:140346468	T/A	cg09824255	chr5:140014002	CD14	0.25	4.59	0.38	1.09e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9534288	0.843	rs4362286	chr13:46566514	G/A	cg15192986	chr13:46630673	CPB2	-0.53	-7.62	-0.56	5.82e-12	Blood protein levels;
TGCT	cis	rs4953076	0.533	rs10173126	chr2:44446492	T/C	cg04920474	chr2:44395004	PPM1B	0.6	6.07	0.48	1.43e-8	Height;
TGCT	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg11764359	chr7:65958608	NA	-0.55	-4.87	-0.4	3.3e-6	Aortic root size;
TGCT	cis	rs4478858	0.684	rs7549245	chr1:31752187	A/G	cg07478791	chr1:31886160	SERINC2	-0.49	-4.91	-0.4	2.82e-6	Alcohol dependence;
TGCT	cis	rs7103648	0.643	rs12365079	chr11:47696596	A/T	cg20307385	chr11:47447363	PSMC3	0.83	7.81	0.57	2.1e-12	Diastolic blood pressure;Systolic blood pressure;
TGCT	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs6061231	0.518	rs639836	chr20:60926223	G/A	cg24112000	chr20:60950667	NA	0.34	4.76	0.39	5.24e-6	Colorectal cancer;
TGCT	cis	rs933688	1.000	rs6867091	chr5:90734333	C/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.0	9.55	0.65	1.59e-16	Smoking behavior;
TGCT	cis	rs12134133	1.000	rs4844588	chr1:207429668	T/C	cg02152968	chr1:207494213	CD55	0.61	4.83	0.4	3.92e-6	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
TGCT	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg25036284	chr2:26402008	FAM59B	-0.57	-4.99	-0.41	2e-6	Gut microbiome composition (summer);
TGCT	cis	rs4389656	0.857	rs274715	chr5:6723429	C/T	cg10857441	chr5:6722123	POLS	0.22	4.74	0.39	5.75e-6	Coronary artery disease;
TGCT	cis	rs709400	0.663	rs1467561	chr14:103994961	T/C	cg12935359	chr14:103987150	CKB	-0.4	-6.07	-0.48	1.45e-8	Body mass index;
TGCT	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg07507251	chr3:52567010	NT5DC2	0.47	6.7	0.52	6.47e-10	Bipolar disorder;
TGCT	cis	rs734999	1.000	rs2016366	chr1:2513678	A/T	cg18854424	chr1:2615690	NA	0.44	5.33	0.43	4.46e-7	Ulcerative colitis;
TGCT	cis	rs858239	0.806	rs10268610	chr7:23274764	A/G	cg05602783	chr7:23145260	KLHL7	-0.65	-4.92	-0.4	2.64e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs1541995	0.824	rs16975550	chr15:96257703	C/A	cg00882281	chr15:96346592	NA	0.29	4.58	0.38	1.11e-5	Photic sneeze reflex;
TGCT	cis	rs7666738	0.791	rs1115615	chr4:99006614	G/A	cg05340658	chr4:99064831	C4orf37	0.49	5.51	0.44	1.97e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg06108461	chr20:60628389	TAF4	0.64	9.5	0.65	2.08e-16	Body mass index;
TGCT	cis	rs453301	0.658	rs13271797	chr8:8885954	G/A	cg06636001	chr8:8085503	FLJ10661	-0.69	-5.67	-0.45	9.36e-8	Joint mobility (Beighton score);
TGCT	cis	rs17401966	0.800	rs12725210	chr1:10416993	G/A	cg19773385	chr1:10388646	KIF1B	-0.23	-5.38	-0.44	3.57e-7	Hepatocellular carcinoma;
TGCT	cis	rs3862260	0.509	rs7552885	chr1:120164966	C/T	cg11530693	chr1:120165357	ZNF697	0.21	4.75	0.39	5.48e-6	Systemic lupus erythematosus;
TGCT	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.72	5.19	0.42	8.33e-7	Platelet count;
TGCT	cis	rs2832191	0.511	rs7278227	chr21:30482707	C/T	cg24692254	chr21:30365293	RNF160	-0.59	-5.71	-0.46	8.06e-8	Dental caries;
TGCT	cis	rs13256369	1.000	rs7843488	chr8:8576217	C/T	cg06671706	chr8:8559999	CLDN23	0.35	4.69	0.39	7e-6	Obesity-related traits;
TGCT	cis	rs2288884	0.806	rs11084142	chr19:52587917	A/G	cg13540795	chr19:52551618	ZNF432	-0.64	-5.42	-0.44	2.98e-7	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	trans	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg21659725	chr3:3221576	CRBN	-0.99	-15.57	-0.81	5.76e-31	Intelligence (multi-trait analysis);
TGCT	cis	rs35306767	0.953	rs12259801	chr10:959306	C/G	cg20503657	chr10:835505	NA	0.68	9.49	0.65	2.12e-16	Eosinophil percentage of granulocytes;
TGCT	cis	rs10791097	0.506	rs10750446	chr11:130706918	T/C	cg14779329	chr11:130786720	SNX19	-0.29	-5.01	-0.41	1.81e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs4455778	0.659	rs4538815	chr7:49024084	A/G	cg26309511	chr7:48887640	NA	-0.43	-5.07	-0.41	1.4e-6	Lung cancer in never smokers;
TGCT	cis	rs7267979	0.764	rs2474767	chr20:25246733	T/C	cg14121845	chr20:25566513	NINL	0.45	4.8	0.4	4.44e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1903068	0.819	rs10517343	chr4:56002267	T/A	cg09978860	chr4:56023921	NA	0.57	6.47	0.5	2.1e-9	Endometriosis;
TGCT	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg18876405	chr7:65276391	NA	-0.32	-4.94	-0.41	2.46e-6	Aortic root size;
TGCT	cis	rs7937682	0.632	rs12785809	chr11:111776055	T/A	cg09085632	chr11:111637200	PPP2R1B	0.84	7.34	0.55	2.4e-11	Primary sclerosing cholangitis;
TGCT	cis	rs1552244	0.543	rs28719585	chr3:10050813	T/C	cg00149659	chr3:10157352	C3orf10	0.69	4.99	0.41	2.03e-6	Alzheimer's disease;
TGCT	cis	rs875971	1.000	rs2220626	chr7:65546062	C/T	cg18876405	chr7:65276391	NA	-0.35	-5.31	-0.43	4.85e-7	Aortic root size;
TGCT	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg24846343	chr22:24311635	DDTL	0.23	5.93	0.47	2.76e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg22764044	chr5:178986830	RUFY1	-0.5	-5.78	-0.46	5.77e-8	Lung cancer;
TGCT	cis	rs6430585	0.528	rs7573555	chr2:136694905	C/T	cg07169764	chr2:136633963	MCM6	-1.19	-12.51	-0.75	1e-23	Corneal structure;
TGCT	cis	rs62007496	0.562	rs2234137	chr14:103597322	A/G	cg01937803	chr14:103605307	NA	0.64	4.9	0.4	2.9e-6	Language performance in older adults (adjusted for episodic memory);
TGCT	trans	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg23505145	chr19:12996616	KLF1	0.79	8.3	0.6	1.47e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7818688	0.697	rs11779698	chr8:95979764	C/G	cg16049864	chr8:95962084	TP53INP1	0.54	4.64	0.38	8.87e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs7119	0.651	rs8041398	chr15:77839173	A/G	cg27398640	chr15:77910606	LINGO1	-0.27	-5.12	-0.42	1.15e-6	Type 2 diabetes;
TGCT	cis	rs10507380	0.766	rs9507877	chr13:27903933	G/T	cg25543773	chr13:27185723	WASF3	0.31	4.49	0.37	1.6e-5	Electrocardiographic traits;
TGCT	cis	rs1059312	1.000	rs2291350	chr12:129283711	G/A	cg09035930	chr12:129282057	SLC15A4	0.59	11.76	0.73	6.45e-22	Systemic lupus erythematosus;
TGCT	cis	rs5167	0.566	rs2075618	chr19:45495668	G/C	cg13119609	chr19:45449297	APOC2	0.23	4.65	0.39	8.26e-6	Blood protein levels;
TGCT	cis	rs910316	1.000	rs175426	chr14:75624134	C/T	cg23033748	chr14:75592666	NEK9	-0.28	-4.75	-0.39	5.63e-6	Height;
TGCT	cis	rs72781680	0.716	rs72788284	chr2:24097539	A/G	cg08917208	chr2:24149416	ATAD2B	0.83	5.18	0.42	8.54e-7	Lymphocyte counts;
TGCT	cis	rs2204008	0.749	rs10880692	chr12:38592918	C/G	cg13010199	chr12:38710504	ALG10B	-0.68	-5.44	-0.44	2.75e-7	Bladder cancer;
TGCT	cis	rs1403694	0.515	rs822362	chr3:186453065	A/C	cg12454167	chr3:186435060	KNG1	0.44	6.91	0.53	2.24e-10	Blood protein levels;
TGCT	cis	rs3820068	0.603	rs72647128	chr1:15963908	T/C	cg05660106	chr1:15850417	CASP9	0.83	8.19	0.59	2.78e-13	Systolic blood pressure;
TGCT	cis	rs7666738	0.830	rs7678557	chr4:99057329	A/G	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.44e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6500602	0.627	rs1641866	chr16:4593040	A/C	cg08645402	chr16:4508243	NA	0.2	4.91	0.4	2.76e-6	Schizophrenia;
TGCT	cis	rs35306767	0.953	rs12357633	chr10:957246	C/T	cg26597838	chr10:835615	NA	0.75	10.39	0.68	1.43e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs9911578	0.904	rs7209253	chr17:56908987	C/T	cg05425664	chr17:57184151	TRIM37	-0.62	-6.18	-0.49	8.33e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg01448562	chr3:133502909	NA	-0.34	-7.01	-0.53	1.33e-10	Iron status biomarkers;
TGCT	trans	rs57221529	0.766	rs12519763	chr5:559145	C/T	cg11887960	chr12:57824829	NA	1.15	9.35	0.64	4.71e-16	Lung disease severity in cystic fibrosis;
TGCT	cis	rs7552404	0.691	rs61770550	chr1:76366966	C/T	cg03433033	chr1:76189801	ACADM	0.77	7.43	0.56	1.5e-11	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9372253	0.678	rs9372251	chr6:110700656	A/G	cg13266496	chr6:110720918	DDO	-0.39	-4.53	-0.38	1.37e-5	Platelet distribution width;
TGCT	cis	rs7226408	0.857	rs72887035	chr18:34474461	A/T	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg19748678	chr4:122722346	EXOSC9	0.84	8.99	0.63	3.42e-15	Type 2 diabetes;
TGCT	cis	rs17221829	0.733	rs2388105	chr11:89355317	A/G	cg02982614	chr11:89391479	FOLH1B	0.27	4.67	0.39	7.62e-6	Anxiety in major depressive disorder;
TGCT	cis	rs763121	0.853	rs5750630	chr22:38985818	A/C	cg06022373	chr22:39101656	GTPBP1	0.76	7.43	0.56	1.52e-11	Menopause (age at onset);
TGCT	cis	rs4366490	1.000	rs9665846	chr11:62907832	G/A	cg21002970	chr11:62369079	MTA2	0.87	4.69	0.39	6.98e-6	Conotruncal heart defects;
TGCT	cis	rs5167	0.566	rs934427	chr19:45478816	T/G	cg09555818	chr19:45449301	APOC2	0.23	4.58	0.38	1.13e-5	Blood protein levels;
TGCT	cis	rs8078723	0.933	rs55846942	chr17:38164470	G/A	cg17467752	chr17:38218738	THRA	0.54	5.22	0.42	7.25e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
TGCT	cis	rs2469997	1.000	rs2447176	chr8:120356892	G/A	cg00681363	chr8:120844660	TAF2	0.72	4.69	0.39	7.2e-6	Hypertension (SNP x SNP interaction);
TGCT	cis	rs28830936	0.510	rs11070349	chr15:42085017	A/C	cg17847044	chr15:42102381	MAPKBP1	-0.19	-5.28	-0.43	5.6e-7	Diastolic blood pressure;
TGCT	cis	rs524023	1.000	rs11602903	chr11:64358241	A/T	cg07733098	chr11:64478343	NRXN2	0.31	4.63	0.38	8.93e-6	Urate levels in obese individuals;
TGCT	cis	rs651907	0.557	rs2303474	chr3:101371899	G/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.91	10.64	0.69	3.59e-19	Colorectal cancer;
TGCT	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg04944784	chr2:26401820	FAM59B	-0.68	-6.13	-0.48	1.1e-8	Gut microbiome composition (summer);
TGCT	cis	rs1062177	1.000	rs62377945	chr5:151208004	C/G	cg12924095	chr5:151150029	G3BP1	0.36	5.18	0.42	8.79e-7	Preschool internalizing problems;
TGCT	cis	rs12421382	0.690	rs2716049	chr11:109609889	A/C	cg16359550	chr11:109292809	C11orf87	0.5	4.91	0.4	2.85e-6	Schizophrenia;
TGCT	trans	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg17470723	chr8:74884337	TCEB1	0.72	6.94	0.53	1.91e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1008375	0.864	rs4698196	chr4:17574735	T/C	cg18681998	chr4:17616180	MED28	0.82	7.35	0.55	2.37e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs56011263	0.687	rs4690292	chr4:703712	A/G	cg20735989	chr4:730612	PCGF3	-0.25	-5.49	-0.44	2.21e-7	White blood cell count;
TGCT	cis	rs9911578	1.000	rs4793950	chr17:56593111	T/C	cg12560992	chr17:57184187	TRIM37	-0.76	-9.34	-0.64	4.88e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs4808199	1.000	rs7258508	chr19:19475469	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.68	4.98	0.41	2.12e-6	Nonalcoholic fatty liver disease;
TGCT	cis	rs10057188	0.933	rs11948106	chr5:77894746	G/T	cg07379703	chr5:78279424	ARSB	-0.19	-4.45	-0.37	1.87e-5	Pulse pressure;
TGCT	trans	rs4332037	0.950	rs62442895	chr7:1936938	G/A	cg25206134	chr2:45395956	NA	1.1	9.34	0.64	5.11e-16	Bipolar disorder;
TGCT	cis	rs986417	0.786	rs76632048	chr14:60846934	G/A	cg27398547	chr14:60952738	C14orf39	-1.37	-8.31	-0.6	1.44e-13	Gut microbiota (bacterial taxa);
TGCT	cis	rs2197308	0.813	rs11504316	chr12:38219320	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-4.5	-0.37	1.57e-5	Morning vs. evening chronotype;
TGCT	cis	rs12220238	1.000	rs10824096	chr10:75937554	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.06	0.54	1.05e-10	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs6912958	1.000	rs6933587	chr6:88175577	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.59	-5.63	-0.45	1.15e-7	Monocyte percentage of white cells;
TGCT	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg06481639	chr22:41940642	POLR3H	-0.74	-6.53	-0.51	1.49e-9	Vitiligo;
TGCT	cis	rs4803468	1.000	rs284650	chr19:41927129	A/G	cg09537434	chr19:41945824	ATP5SL	-0.92	-10.57	-0.69	5.19e-19	Height;
TGCT	cis	rs12210905	0.688	rs12215386	chr6:27406877	G/T	cg08851530	chr6:28072375	NA	1.34	6.07	0.48	1.44e-8	Hip circumference adjusted for BMI;
TGCT	cis	rs61931739	0.534	rs10844828	chr12:34303109	C/T	cg06521331	chr12:34319734	NA	-0.35	-5.77	-0.46	5.94e-8	Morning vs. evening chronotype;
TGCT	cis	rs2677744	0.719	rs877285	chr15:91452204	A/G	cg22570213	chr15:91497863	RCCD1	0.39	4.52	0.38	1.41e-5	Attention deficit hyperactivity disorder;
TGCT	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg01802117	chr1:53393560	SCP2	-0.44	-5.52	-0.44	1.86e-7	Monocyte count;
TGCT	cis	rs3096299	0.586	rs4572400	chr16:89533516	T/A	cg08392591	chr16:89556376	ANKRD11	0.51	4.48	0.37	1.67e-5	Multiple myeloma (IgH translocation);
TGCT	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg12311346	chr5:56204834	C5orf35	-0.67	-6.82	-0.52	3.63e-10	Initial pursuit acceleration;
TGCT	cis	rs1538970	1.000	rs9326141	chr1:45828943	A/G	cg05343316	chr1:45956843	TESK2	-0.64	-4.94	-0.41	2.49e-6	Platelet count;
TGCT	cis	rs9910055	0.530	rs11652651	chr17:42302907	A/G	cg19774624	chr17:42201019	HDAC5	0.73	7.74	0.57	2.94e-12	Total body bone mineral density;
TGCT	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	6.11	0.48	1.17e-8	Alzheimer's disease;
TGCT	cis	rs10493389	0.673	rs11208758	chr1:66287200	A/G	cg08716655	chr1:66257732	PDE4B	-0.42	-4.56	-0.38	1.23e-5	Echocardiographic traits;
TGCT	cis	rs35264875	0.851	rs72930621	chr11:68866745	C/T	cg02660097	chr11:68866761	NA	0.31	4.49	0.37	1.63e-5	Blond vs. brown hair color;
TGCT	cis	rs13064411	0.696	rs869342	chr3:113226330	C/T	cg10517650	chr3:113235015	CCDC52	-0.32	-4.45	-0.37	1.85e-5	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	trans	rs3790455	0.610	rs1171561	chr1:156455898	G/A	cg16443977	chr5:115884994	SEMA6A	0.39	6.66	0.51	8.1e-10	Migraine;
TGCT	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg00786635	chr1:25594202	NA	0.57	6.0	0.47	2.02e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs3806843	0.932	rs2563269	chr5:140136468	G/T	cg19875535	chr5:140030758	IK	-0.37	-6.3	-0.49	4.75e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs1475911	1.000	rs2839465	chr21:43511232	C/T	cg19766460	chr21:43528205	UMODL1;C21orf128	0.51	7.02	0.53	1.3e-10	IgG glycosylation;
TGCT	cis	rs911555	0.755	rs55742283	chr14:103942965	A/G	cg23461800	chr14:103021989	NA	-0.35	-4.56	-0.38	1.23e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7659604	0.540	rs10024878	chr4:122665451	C/G	cg19748678	chr4:122722346	EXOSC9	-0.47	-4.59	-0.38	1.06e-5	Type 2 diabetes;
TGCT	cis	rs2862064	1.000	rs2902128	chr5:156421347	C/T	cg12943317	chr5:156479607	HAVCR1	-0.42	-5.62	-0.45	1.22e-7	Platelet count;
TGCT	cis	rs751728	0.687	rs943479	chr6:33752013	A/G	cg13859433	chr6:33739653	LEMD2	-0.33	-5.75	-0.46	6.65e-8	Crohn's disease;
TGCT	cis	rs2760061	0.819	rs708120	chr1:228207651	G/C	cg18477163	chr1:228402036	OBSCN	0.34	7.24	0.55	4.1e-11	Diastolic blood pressure;
TGCT	cis	rs12142240	0.698	rs6679898	chr1:46820589	A/C	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs57994353	0.897	rs55824202	chr9:139357273	A/T	cg13741927	chr9:139327495	INPP5E	-0.26	-5.95	-0.47	2.51e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs2847281	0.761	rs478582	chr18:12835976	T/C	cg23598886	chr18:12777645	NA	0.4	4.77	0.39	5.13e-6	C-reactive protein levels;Esophageal cancer (squamous cell);
TGCT	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg21724239	chr8:58056113	NA	0.45	6.59	0.51	1.14e-9	Developmental language disorder (linguistic errors);
TGCT	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg25036284	chr2:26402008	FAM59B	-0.61	-4.9	-0.4	2.92e-6	Gut microbiome composition (summer);
TGCT	cis	rs9910055	0.529	rs575798	chr17:42181796	A/C	cg13607699	chr17:42295918	UBTF	-0.65	-5.39	-0.44	3.34e-7	Total body bone mineral density;
TGCT	cis	rs651907	0.557	rs62284198	chr3:101474699	G/A	cg12386194	chr3:101231763	SENP7	0.49	4.69	0.39	7.17e-6	Colorectal cancer;
TGCT	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg27454412	chr7:1067447	C7orf50	0.58	4.45	0.37	1.88e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9910055	0.529	rs615070	chr17:42176591	A/G	cg13607699	chr17:42295918	UBTF	0.58	4.87	0.4	3.32e-6	Total body bone mineral density;
TGCT	cis	rs751728	0.664	rs943475	chr6:33749978	C/T	cg13859433	chr6:33739653	LEMD2	0.32	5.68	0.45	9.23e-8	Crohn's disease;
TGCT	cis	rs6671200	0.688	rs4950024	chr1:95713499	A/G	cg03123541	chr1:95699097	RWDD3	-0.81	-7.26	-0.55	3.81e-11	Stearic acid (18:0) levels;
TGCT	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg26338869	chr17:61819248	STRADA	-0.55	-4.99	-0.41	1.98e-6	Prudent dietary pattern;
TGCT	cis	rs4713118	0.666	rs2893930	chr6:27738806	T/C	cg20933634	chr6:27740509	NA	0.35	4.83	0.4	3.92e-6	Parkinson's disease;
TGCT	cis	rs9467711	1.000	rs6908156	chr6:26322861	C/T	cg03517284	chr6:25882590	NA	-0.86	-4.67	-0.39	7.69e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs739496	0.615	rs3809276	chr12:112073916	A/G	cg10833066	chr12:111807467	FAM109A	0.36	5.15	0.42	9.76e-7	Platelet count;
TGCT	cis	rs9467773	0.620	rs2494692	chr6:26615223	G/A	cg15659132	chr6:26577336	NA	0.85	10.93	0.7	7e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs986417	1.000	rs6573316	chr14:61058029	C/A	cg27398547	chr14:60952738	C14orf39	1.41	8.43	0.6	7.41e-14	Gut microbiota (bacterial taxa);
TGCT	cis	rs6500602	0.727	rs4786509	chr16:4568769	C/G	cg08645402	chr16:4508243	NA	-0.19	-5.3	-0.43	5.14e-7	Schizophrenia;
TGCT	trans	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg17830980	chr10:43048298	ZNF37B	-0.85	-10.98	-0.7	5.08e-20	Extrinsic epigenetic age acceleration;
TGCT	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg11764359	chr7:65958608	NA	-0.56	-5.06	-0.41	1.45e-6	Aortic root size;
TGCT	cis	rs231513	0.911	rs231476	chr17:41985845	A/G	cg26893861	chr17:41843967	DUSP3	-0.76	-5.44	-0.44	2.67e-7	Cognitive function;
TGCT	cis	rs67385638	1.000	rs11036474	chr11:5275178	T/C	cg12559170	chr11:5275217	HBG2	0.46	8.09	0.59	4.52e-13	Hemoglobin levels;
TGCT	cis	rs67311347	0.955	rs73078170	chr3:40483947	C/T	cg17264618	chr3:40429014	ENTPD3	0.34	4.67	0.39	7.68e-6	Renal cell carcinoma;
TGCT	cis	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg07424592	chr7:64974309	NA	1.34	8.08	0.59	4.95e-13	Diabetic kidney disease;
TGCT	cis	rs11783469	0.524	rs13250995	chr8:23329985	G/A	cg00472375	chr8:23315376	ENTPD4	0.69	5.22	0.42	7.38e-7	Reticulocyte count;
TGCT	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg11764359	chr7:65958608	NA	-0.57	-5.07	-0.41	1.4e-6	Aortic root size;
TGCT	trans	rs1814175	0.935	rs11040438	chr11:49622521	G/A	cg15704280	chr7:45808275	SEPT13	-0.61	-6.8	-0.52	4.02e-10	Height;
TGCT	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg16325326	chr1:53192061	ZYG11B	-0.84	-11.96	-0.73	2.15e-22	Monocyte count;
TGCT	cis	rs7208859	0.673	rs73265633	chr17:29236306	G/T	cg18442181	chr17:29233375	C17orf42	-0.78	-4.61	-0.38	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9291683	0.566	rs13144709	chr4:10044182	C/T	cg00071950	chr4:10020882	SLC2A9	0.57	6.47	0.5	2.01e-9	Bone mineral density;
TGCT	cis	rs6752107	0.967	rs11680130	chr2:234157258	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.21	5.0	0.41	1.87e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs11971779	0.715	rs55714903	chr7:139074590	T/C	cg07862535	chr7:139043722	LUC7L2	0.71	5.55	0.45	1.63e-7	Diisocyanate-induced asthma;
TGCT	cis	rs4372836	1.000	rs11690423	chr2:28951537	G/C	cg09522027	chr2:28974177	PPP1CB	0.59	5.14	0.42	1.03e-6	Body mass index;
TGCT	cis	rs453301	0.624	rs2288671	chr8:8860894	T/C	cg06636001	chr8:8085503	FLJ10661	0.8	7.08	0.54	9.32e-11	Joint mobility (Beighton score);
TGCT	cis	rs9611565	0.592	rs9611613	chr22:41961831	T/C	cg13695892	chr22:41940480	POLR3H	-0.87	-8.17	-0.59	2.95e-13	Vitiligo;
TGCT	trans	rs2688608	1.000	rs2675680	chr10:75658864	T/C	cg13918328	chr10:52500089	ASAH2B	0.65	6.68	0.51	7.29e-10	Inflammatory bowel disease;
TGCT	cis	rs1843834	0.539	rs6713629	chr2:225410973	A/T	cg12698349	chr2:225449008	CUL3	0.78	6.41	0.5	2.77e-9	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs10267417	0.514	rs2072184	chr7:19748883	A/G	cg07541023	chr7:19748670	TWISTNB	1.22	11.09	0.71	2.84e-20	Night sleep phenotypes;
TGCT	cis	rs7772486	0.558	rs9376965	chr6:146130055	G/A	cg13319975	chr6:146136371	FBXO30	-0.69	-6.28	-0.49	5.18e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs79349575	0.783	rs62075838	chr17:46996432	C/T	cg07967210	chr17:47022446	SNF8	0.44	6.12	0.48	1.13e-8	Type 2 diabetes;
TGCT	cis	rs7674212	0.556	rs34475639	chr4:103954851	C/T	cg16532752	chr4:104119610	CENPE	-0.59	-5.29	-0.43	5.43e-7	Type 2 diabetes;
TGCT	cis	rs907683	0.559	rs4674394	chr2:220289870	C/T	cg15015639	chr2:220282977	DES	-0.4	-4.98	-0.41	2.09e-6	Resting heart rate;
TGCT	cis	rs5167	0.789	rs204467	chr19:45491174	A/G	cg09555818	chr19:45449301	APOC2	-0.22	-4.81	-0.4	4.27e-6	Blood protein levels;
TGCT	cis	rs6121246	0.865	rs6089055	chr20:30324045	C/T	cg13852791	chr20:30311386	BCL2L1	0.7	4.84	0.4	3.79e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg04772025	chr11:68637568	NA	0.6	6.76	0.52	4.74e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs6586163	0.872	rs7082101	chr10:90741615	C/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.36	-4.47	-0.37	1.76e-5	Chronic lymphocytic leukemia;
TGCT	cis	rs2730245	0.593	rs842699	chr7:158663404	T/A	cg11984989	chr7:158649758	WDR60	1.07	9.87	0.66	2.58e-17	Height;
TGCT	cis	rs7582180	0.764	rs1967341	chr2:100924559	T/C	cg14675211	chr2:100938903	LONRF2	0.51	4.93	0.4	2.61e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9972944	0.729	rs6504348	chr17:63763049	C/T	cg07283582	chr17:63770753	CCDC46	-0.26	-5.24	-0.43	6.6e-7	Total body bone mineral density;
TGCT	cis	rs7260538	0.773	rs1552223	chr19:41525952	A/G	cg20630647	chr19:41531805	NA	-0.27	-4.44	-0.37	1.94e-5	DDT metabolite (p,p'-DDE levels);
TGCT	cis	rs16957091	0.647	rs7181859	chr15:43158239	A/G	cg17935677	chr15:44119062	WDR76	0.53	4.69	0.39	7.11e-6	MGMT methylation in smokers;
TGCT	cis	rs7666738	0.830	rs4699580	chr4:98930673	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs939574	0.790	rs72955440	chr2:220091765	A/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.11	5.34	0.43	4.31e-7	Platelet distribution width;
TGCT	cis	rs6840360	0.606	rs2724550	chr4:152358986	C/T	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.83e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs10883723	0.810	rs7092622	chr10:104249919	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs10751667	0.600	rs10794342	chr11:924904	C/T	cg06064525	chr11:970664	AP2A2	-0.35	-8.09	-0.59	4.69e-13	Alzheimer's disease (late onset);
TGCT	cis	rs806215	0.906	rs806195	chr7:127249178	A/G	cg25922125	chr7:127225783	GCC1	0.59	5.98	0.47	2.21e-8	Type 2 diabetes;
TGCT	cis	rs7010267	0.570	rs35746859	chr8:120039139	G/C	cg17171407	chr8:119960777	TNFRSF11B	0.26	4.59	0.38	1.06e-5	Total body bone mineral density (age 45-60);
TGCT	cis	rs2549003	0.934	rs2549006	chr5:131827065	A/G	cg02551604	chr5:131831745	NA	0.86	10.72	0.69	2.18e-19	Asthma (sex interaction);
TGCT	cis	rs6964587	0.610	rs4729008	chr7:91457054	G/T	cg17063962	chr7:91808500	NA	0.73	6.65	0.51	8.52e-10	Breast cancer;
TGCT	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg24531977	chr5:56204891	C5orf35	-0.77	-7.61	-0.56	5.83e-12	Initial pursuit acceleration;
TGCT	cis	rs7726839	0.540	rs12520279	chr5:657291	T/C	cg20362242	chr5:692897	TPPP	0.51	4.49	0.37	1.61e-5	Obesity-related traits;
TGCT	cis	rs6964587	1.000	rs9690208	chr7:91735613	T/A	cg17063962	chr7:91808500	NA	0.87	9.34	0.64	4.87e-16	Breast cancer;
TGCT	cis	rs12477438	0.520	rs11123766	chr2:99780915	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	13.05	0.76	4.93e-25	Chronic sinus infection;
TGCT	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg07507251	chr3:52567010	NT5DC2	0.47	6.64	0.51	8.85e-10	Bipolar disorder;
TGCT	trans	rs1814175	0.645	rs11040699	chr11:50023798	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.84	-0.7	1.13e-19	Height;
TGCT	cis	rs1784581	0.855	rs1893101	chr6:162384371	G/C	cg17173639	chr6:162384350	PARK2	-0.5	-9.31	-0.64	6.05e-16	Itch intensity from mosquito bite;
TGCT	cis	rs7017914	0.934	rs1993862	chr8:71579362	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.03	-0.41	1.69e-6	Bone mineral density;
TGCT	cis	rs12908161	0.959	rs11637728	chr15:85203392	A/T	cg12863693	chr15:85201151	NMB	0.44	5.22	0.42	7.28e-7	Schizophrenia;
TGCT	cis	rs3782455	1.000	rs117171899	chr12:114403070	G/A	cg10631684	chr12:113795897	PLBD2	-0.7	-4.61	-0.38	1e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	trans	rs1814175	0.817	rs7947526	chr11:49983654	T/C	cg15704280	chr7:45808275	SEPT13	-0.73	-8.48	-0.61	5.58e-14	Height;
TGCT	cis	rs1153858	1.000	rs28679834	chr15:45616206	C/T	cg26924012	chr15:45694286	SPATA5L1	1.04	13.01	0.76	6.06e-25	Homoarginine levels;
TGCT	cis	rs1729951	0.575	rs835641	chr3:136703474	G/T	cg12473912	chr3:136751656	NA	0.39	6.18	0.48	8.68e-9	Neuroticism;
TGCT	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg03452623	chr4:187889614	NA	-0.35	-5.26	-0.43	6e-7	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs561341	1.000	rs484175	chr17:30309041	G/A	cg20587970	chr11:113659929	NA	-1.04	-12.57	-0.75	6.97e-24	Hip circumference adjusted for BMI;
TGCT	cis	rs9527	0.662	rs743575	chr10:104594906	T/G	cg04362960	chr10:104952993	NT5C2	0.62	5.39	0.44	3.37e-7	Arsenic metabolism;
TGCT	trans	rs12623360	1.000	rs871946	chr2:116824113	A/T	cg24136780	chr7:2158430	MAD1L1	-0.62	-6.9	-0.53	2.32e-10	Urate levels (BMI interaction);
TGCT	cis	rs2456568	0.606	rs11020616	chr11:93691594	C/T	cg17595323	chr11:93583763	C11orf90	0.41	5.02	0.41	1.78e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs2688608	1.000	rs2675680	chr10:75658864	T/C	cg23231163	chr10:75533350	FUT11	-0.26	-4.67	-0.39	7.77e-6	Inflammatory bowel disease;
TGCT	cis	rs2562456	0.920	rs2650784	chr19:21666597	T/C	cg01304269	chr19:21688519	ZNF429	-0.57	-4.76	-0.39	5.32e-6	Pain;
TGCT	cis	rs7698623	0.717	rs4693193	chr4:88797992	T/C	cg02735620	chr4:88950514	PKD2	-0.44	-4.81	-0.4	4.22e-6	Cardiovascular disease risk factors;
TGCT	cis	rs7772486	0.875	rs10457794	chr6:146415608	A/G	cg23711669	chr6:146136114	FBXO30	0.91	9.95	0.67	1.67e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9308731	0.563	rs11899831	chr2:111932694	G/A	cg04202892	chr2:111875749	ACOXL	0.46	5.14	0.42	1.02e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs4808199	0.894	rs9304960	chr19:19465529	G/A	cg03709012	chr19:19516395	GATAD2A	0.81	6.32	0.49	4.32e-9	Nonalcoholic fatty liver disease;
TGCT	cis	rs11098499	1.000	rs12506395	chr4:120185094	C/T	cg24670566	chr4:120433619	PDE5A	0.23	4.58	0.38	1.1e-5	Corneal astigmatism;
TGCT	cis	rs7666738	0.830	rs10021709	chr4:99030587	G/A	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg03934478	chr11:495069	RNH1	0.35	5.89	0.47	3.34e-8	Body mass index;
TGCT	cis	rs131805	0.794	rs131813	chr22:50961169	A/G	cg25309564	chr22:51001381	C22orf41	0.56	4.86	0.4	3.55e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs394563	0.591	rs805026	chr6:149728254	G/C	cg03678062	chr6:149772716	ZC3H12D	-0.39	-4.85	-0.4	3.61e-6	Dupuytren's disease;
TGCT	cis	rs12142240	0.698	rs12385695	chr1:46819021	A/G	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs1008375	1.000	rs10019856	chr4:17615742	T/A	cg10189774	chr4:17578691	LAP3	0.65	5.6	0.45	1.34e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4972806	0.775	rs2857534	chr2:177035676	G/T	cg13092806	chr2:177043255	NA	0.55	4.79	0.4	4.58e-6	IgG glycosylation;
TGCT	cis	rs2760061	0.626	rs1636192	chr1:228124688	A/G	cg02753203	chr1:228287806	NA	-0.34	-6.63	-0.51	9.15e-10	Diastolic blood pressure;
TGCT	cis	rs4563143	0.514	rs55727361	chr19:29300415	A/T	cg12756686	chr19:29218302	NA	0.67	5.16	0.42	9.34e-7	Methadone dose in opioid dependence;
TGCT	cis	rs4788570	0.686	rs9937511	chr16:71815913	C/T	cg06353428	chr16:71660113	MARVELD3	1.53	12.59	0.75	6.48e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs921968	0.613	rs2710251	chr2:219543433	T/C	cg02176678	chr2:219576539	TTLL4	-0.33	-4.45	-0.37	1.91e-5	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs7552404	0.924	rs7535991	chr1:76162624	C/T	cg22875332	chr1:76189707	ACADM	0.78	9.74	0.66	5.53e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	trans	rs3780486	0.846	rs10113903	chr9:33122645	C/G	cg04842962	chr6:43655489	MRPS18A	-1.21	-15.02	-0.8	1.08e-29	IgG glycosylation;
TGCT	cis	rs8070128	0.601	rs8080602	chr17:17954728	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.79	-8.27	-0.6	1.76e-13	Total body bone mineral density;
TGCT	cis	rs4523957	0.651	rs1994883	chr17:2083881	T/A	cg16513277	chr17:2031491	SMG6	-0.2	-4.64	-0.38	8.83e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs2012796	0.956	rs7146802	chr14:81820515	A/G	cg02996355	chr14:81879375	NA	0.47	4.61	0.38	9.68e-6	Night sleep phenotypes;
TGCT	cis	rs9952991	0.941	rs2542150	chr18:12779763	G/C	cg23598886	chr18:12777645	NA	0.62	5.9	0.47	3.25e-8	Inflammatory skin disease;
TGCT	cis	rs7937682	0.681	rs2156580	chr11:111394328	C/G	cg09085632	chr11:111637200	PPP2R1B	0.51	4.61	0.38	1e-5	Primary sclerosing cholangitis;
TGCT	cis	rs8038465	0.638	rs12591473	chr15:73967485	A/T	cg15420318	chr15:73925796	NPTN	0.72	8.19	0.59	2.66e-13	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg06481639	chr22:41940642	POLR3H	0.74	6.48	0.5	1.97e-9	Vitiligo;
TGCT	cis	rs3782455	0.793	rs2290799	chr12:114404208	G/A	cg10631684	chr12:113795897	PLBD2	-0.7	-4.61	-0.38	1e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs950169	0.840	rs12905223	chr15:85114268	T/C	cg12863693	chr15:85201151	NMB	0.39	4.44	0.37	1.99e-5	Schizophrenia;
TGCT	cis	rs9393692	0.905	rs9357004	chr6:26303319	A/G	cg13736514	chr6:26305472	NA	-0.42	-5.9	-0.47	3.23e-8	Educational attainment;
TGCT	cis	rs3771570	1.000	rs62193202	chr2:242303717	G/A	cg21155796	chr2:242212141	HDLBP	0.94	6.69	0.51	6.9e-10	Prostate cancer;
TGCT	cis	rs9653442	0.900	rs6754937	chr2:100827720	T/G	cg07810366	chr2:100720526	AFF3	-0.4	-5.98	-0.47	2.17e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs10782582	0.586	rs5745383	chr1:76288590	G/C	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.52	4.53	0.38	1.37e-5	Daytime sleep phenotypes;
TGCT	cis	rs704	0.790	rs13469	chr17:26676135	C/T	cg10342447	chr17:26645325	TMEM97	-0.53	-5.12	-0.42	1.14e-6	Osteoprotegerin levels;
TGCT	cis	rs763121	0.853	rs4821798	chr22:39021165	T/C	cg06022373	chr22:39101656	GTPBP1	0.81	8.26	0.6	1.84e-13	Menopause (age at onset);
TGCT	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.51	5.37	0.43	3.71e-7	Menopause (age at onset);
TGCT	cis	rs8072100	0.905	rs11651766	chr17:45574931	G/T	cg10024583	chr17:45772800	TBKBP1	0.43	4.47	0.37	1.74e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs910316	0.763	rs175490	chr14:75545685	A/G	cg08847533	chr14:75593920	NEK9	0.84	8.37	0.6	1.02e-13	Height;
TGCT	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg13012494	chr21:47604986	C21orf56	0.38	4.49	0.37	1.58e-5	Testicular germ cell tumor;
TGCT	cis	rs9807989	0.524	rs6759479	chr2:103040047	A/C	cg03938978	chr2:103052716	IL18RAP	0.27	5.41	0.44	3.17e-7	Asthma;
TGCT	cis	rs9818758	0.607	rs9837625	chr3:49215966	C/T	cg00383909	chr3:49044727	WDR6	1.29	6.62	0.51	9.88e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs7926906	0.713	rs10741376	chr11:90538099	C/T	cg26138821	chr11:89956704	CHORDC1	0.45	4.46	0.37	1.79e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs797680	0.856	rs7537403	chr1:93777724	T/C	cg17826107	chr1:92977322	EVI5	-0.22	-5.05	-0.41	1.53e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs7267979	1.000	rs6037099	chr20:25356876	T/G	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs832540	0.864	rs252908	chr5:56120686	T/C	cg12311346	chr5:56204834	C5orf35	-0.47	-5.03	-0.41	1.7e-6	Coronary artery disease;
TGCT	cis	rs7412746	0.646	rs1972060	chr1:150937594	T/C	cg04414720	chr1:150670196	GOLPH3L	0.38	4.5	0.37	1.52e-5	Melanoma;
TGCT	cis	rs7916852	0.618	rs3802523	chr10:28341885	C/T	cg15286905	chr10:27530250	ACBD5	-0.64	-5.01	-0.41	1.82e-6	Glaucoma (primary open-angle);
TGCT	cis	rs7829975	0.522	rs6601689	chr8:8172283	C/T	cg15556689	chr8:8085844	FLJ10661	0.63	5.87	0.47	3.74e-8	Mood instability;
TGCT	cis	rs13188771	0.651	rs3846602	chr5:100884294	C/A	cg10455971	chr5:101119566	NA	0.44	4.45	0.37	1.87e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs6725041	0.757	rs9973677	chr2:213080994	C/T	cg20637307	chr2:213403960	ERBB4	-0.51	-4.48	-0.37	1.68e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs2404602	0.716	rs1946650	chr15:76848463	T/C	cg26408565	chr15:76604113	ETFA	-0.4	-5.23	-0.43	6.98e-7	Blood metabolite levels;
TGCT	cis	rs4081724	0.565	rs7251505	chr19:33802542	G/A	cg18823272	chr19:34111733	CHST8	0.4	4.45	0.37	1.86e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2456568	0.900	rs877340	chr11:93689292	A/T	cg14065697	chr11:93583672	C11orf90	-0.38	-4.52	-0.38	1.4e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs10875746	0.903	rs3782911	chr12:48483492	T/G	cg20731937	chr12:48336164	NA	0.62	4.95	0.41	2.36e-6	Longevity (90 years and older);
TGCT	cis	rs763121	0.853	rs8140617	chr22:38970439	A/G	cg06022373	chr22:39101656	GTPBP1	-0.72	-6.8	-0.52	3.97e-10	Menopause (age at onset);
TGCT	cis	rs6674176	0.611	rs12737898	chr1:44407401	C/G	cg12908607	chr1:44402522	ARTN	-0.69	-4.6	-0.38	1.03e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs3796352	1.000	rs113995589	chr3:53132372	A/T	cg27565382	chr3:53032988	SFMBT1	0.4	4.44	0.37	1.94e-5	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs7267979	1.000	rs2424700	chr20:25266513	A/G	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg24399712	chr22:39784796	NA	0.97	11.25	0.71	1.14e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2224391	0.628	rs2773307	chr6:5244290	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-1.04	-6.69	-0.51	6.87e-10	Height;
TGCT	cis	rs910187	0.678	rs6124967	chr20:45813624	T/C	cg27589058	chr20:45804311	EYA2	-0.35	-7.6	-0.56	6.23e-12	Migraine;
TGCT	cis	rs7312933	0.558	rs7305397	chr12:42850058	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.51	4.82	0.4	4.13e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs56235845	0.694	rs6860069	chr5:176755841	C/T	cg16006841	chr5:176797999	RGS14	0.51	7.35	0.55	2.35e-11	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg02725872	chr8:58115012	NA	-0.38	-4.76	-0.39	5.39e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2153535	0.580	rs9393023	chr6:8469994	T/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs7647973	0.626	rs6809879	chr3:49834571	A/G	cg05785598	chr3:49045655	WDR6	-0.42	-5.24	-0.43	6.67e-7	Menarche (age at onset);
TGCT	cis	rs9993613	0.808	rs16848143	chr4:73441573	C/T	cg15102770	chr4:73434591	ADAMTS3	0.51	4.59	0.38	1.07e-5	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs10984561	0.881	rs73540226	chr9:122250588	C/T	cg14242995	chr9:122249943	NA	0.73	5.96	0.47	2.46e-8	Pulmonary function decline;
TGCT	cis	rs11690935	1.000	rs1554166	chr2:172541609	G/T	cg13550731	chr2:172543902	DYNC1I2	-1.18	-12.58	-0.75	6.59e-24	Schizophrenia;
TGCT	cis	rs2120019	1.000	rs34237279	chr15:75361121	A/G	cg09165964	chr15:75287851	SCAMP5	-1.16	-9.78	-0.66	4.33e-17	Blood trace element (Zn levels);
TGCT	cis	rs8141529	0.732	rs2269577	chr22:29196757	G/C	cg02153584	chr22:29168773	CCDC117	0.71	6.08	0.48	1.41e-8	Lymphocyte counts;
TGCT	cis	rs12533831	0.654	rs2435609	chr7:150890073	C/T	cg04712895	chr7:150801789	AGAP3	-0.23	-4.73	-0.39	6.12e-6	Childhood ear infection;
TGCT	cis	rs2153535	0.541	rs6908504	chr6:8456778	A/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs7226408	0.595	rs72887010	chr18:34460257	G/A	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs2708977	1.000	rs13029764	chr2:97328874	C/T	cg01950434	chr2:97203154	ARID5A	-0.61	-5.54	-0.45	1.76e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs9894429	0.789	rs35887231	chr17:79587126	G/A	cg21984481	chr17:79567631	NPLOC4	-0.26	-4.9	-0.4	2.91e-6	Eye color traits;
TGCT	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg22968622	chr17:43663579	NA	1.25	10.99	0.7	4.93e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs9858542	0.537	rs34915642	chr3:49358646	G/A	cg08550065	chr3:50336684	HYAL3;NAT6	0.66	4.66	0.39	7.87e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs7178572	0.524	rs1473922	chr15:77656798	G/T	cg22256960	chr15:77711686	NA	-0.85	-8.73	-0.62	1.4e-14	Type 2 diabetes;
TGCT	cis	rs28595532	0.920	rs115683389	chr4:119735557	T/G	cg21605333	chr4:119757512	SEC24D	1.66	8.33	0.6	1.28e-13	Cannabis dependence symptom count;
TGCT	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg01341218	chr17:43662625	NA	-1.11	-9.34	-0.64	5.11e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs9611565	0.512	rs132767	chr22:42009520	C/T	cg03806693	chr22:41940476	POLR3H	-0.99	-9.99	-0.67	1.35e-17	Vitiligo;
TGCT	cis	rs1538970	0.961	rs7553318	chr1:45843086	A/G	cg05343316	chr1:45956843	TESK2	0.65	5.14	0.42	1.06e-6	Platelet count;
TGCT	cis	rs17376456	0.877	rs10073039	chr5:93467709	A/G	cg21475434	chr5:93447410	FAM172A	0.59	4.66	0.39	8.09e-6	Diabetic retinopathy;
TGCT	cis	rs5769707	0.681	rs8140095	chr22:50043795	A/G	cg05373962	chr22:49881684	NA	-0.31	-5.31	-0.43	4.99e-7	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs6831352	0.918	rs29001214	chr4:100051733	A/G	cg12011299	chr4:100065546	ADH4	-0.41	-4.92	-0.4	2.72e-6	Alcohol dependence;
TGCT	cis	rs7949030	1.000	rs7949030	chr11:62394881	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.56	7.85	0.58	1.69e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs3617	0.625	rs2535633	chr3:52859630	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	-0.48	-4.59	-0.38	1.08e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7666738	0.753	rs17027308	chr4:99091088	T/A	cg05340658	chr4:99064831	C4orf37	0.5	5.51	0.44	2.02e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6500602	0.727	rs4238849	chr16:4538114	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.3	5.56	0.45	1.61e-7	Schizophrenia;
TGCT	cis	rs4654899	0.758	rs7521711	chr1:21400218	A/G	cg01072550	chr1:21505969	NA	-0.56	-9.15	-0.63	1.42e-15	Superior frontal gyrus grey matter volume;
TGCT	cis	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg22121687	chr7:65037720	NA	-0.81	-5.03	-0.41	1.7e-6	Diabetic kidney disease;
TGCT	cis	rs7829975	0.511	rs1401390	chr8:8136410	C/T	cg08975724	chr8:8085496	FLJ10661	0.53	4.64	0.38	8.6e-6	Mood instability;
TGCT	cis	rs1008375	0.932	rs3846356	chr4:17614176	C/T	cg16339924	chr4:17578868	LAP3	0.74	5.88	0.47	3.64e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs3848445	1.000	rs7214411	chr17:14288990	C/T	cg05091736	chr17:14942129	NA	-0.53	-4.48	-0.37	1.7e-5	Protein quantitative trait loci;
TGCT	cis	rs2992756	1.000	rs2992756	chr1:18807339	T/C	cg05040210	chr1:18807594	KLHDC7A	-0.26	-4.46	-0.37	1.83e-5	Breast cancer;
TGCT	cis	rs116095464	1.000	rs6555160	chr5:311669	A/G	cg03604011	chr5:400201	AHRR	0.53	4.64	0.38	8.84e-6	Breast cancer;
TGCT	cis	rs9611565	0.765	rs132909	chr22:41802031	G/A	cg06481639	chr22:41940642	POLR3H	0.6	5.48	0.44	2.23e-7	Vitiligo;
TGCT	cis	rs9831754	0.856	rs9824624	chr3:78407182	G/A	cg06138941	chr3:78371609	NA	-0.48	-5.2	-0.42	7.84e-7	Calcium levels;
TGCT	cis	rs2153535	0.580	rs9328483	chr6:8521295	A/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.01	0.41	1.86e-6	Motion sickness;
TGCT	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg21548813	chr6:291882	DUSP22	-0.64	-6.74	-0.52	5.2e-10	Menopause (age at onset);
TGCT	cis	rs137603	0.562	rs470080	chr22:39712368	C/T	cg01093212	chr22:39715156	SNORD43;RPL3	-0.5	-4.84	-0.4	3.78e-6	Primary biliary cholangitis;
TGCT	trans	rs7618501	1.000	rs57648519	chr3:49813169	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	1.03	13.16	0.76	2.65e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs539096	0.566	rs3011220	chr1:44308867	A/G	cg12908607	chr1:44402522	ARTN	-0.66	-7.92	-0.58	1.18e-12	Intelligence (multi-trait analysis);
TGCT	trans	rs10506458	0.834	rs73127067	chr12:63390333	G/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.47	-7.54	-0.56	8.62e-12	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs17270561	1.000	rs12211184	chr6:25823774	G/A	cg15022984	chr6:26056706	HIST1H1C	-0.73	-4.6	-0.38	1.02e-5	Iron status biomarkers;
TGCT	cis	rs2276314	0.762	rs3826600	chr18:33609053	A/G	cg19628046	chr18:33552617	C18orf21	0.51	4.46	0.37	1.79e-5	Endometriosis;Drug-induced torsades de pointes;
TGCT	cis	rs8129326	0.805	rs9984075	chr21:35784117	T/A	cg27150370	chr21:34863940	DNAJC28	-0.47	-4.61	-0.38	9.86e-6	Cancer;
TGCT	cis	rs9297145	0.585	rs10953283	chr7:98782750	A/G	cg05967295	chr7:98741636	SMURF1	0.69	8.57	0.61	3.4e-14	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs17376456	0.825	rs6877030	chr5:93201841	C/A	cg25358565	chr5:93447407	FAM172A	0.98	7.67	0.57	4.38e-12	Diabetic retinopathy;
TGCT	cis	rs13326165	0.715	rs7643570	chr3:52373792	G/T	cg27565382	chr3:53032988	SFMBT1	0.37	4.93	0.41	2.55e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg08859206	chr1:53392774	SCP2	-0.41	-6.17	-0.48	9e-9	Monocyte count;
TGCT	cis	rs6665290	0.904	rs1045252	chr1:227181555	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.99	-20.27	-0.88	3.54e-41	Myeloid white cell count;
TGCT	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg23574427	chr4:122746245	BBS7;CCNA2	-0.35	-5.31	-0.43	4.79e-7	Type 2 diabetes;
TGCT	cis	rs7586879	0.796	rs916484	chr2:25082588	A/C	cg01884057	chr2:25150051	NA	0.26	4.59	0.38	1.08e-5	Body mass index;
TGCT	cis	rs546131	0.928	rs553789	chr11:34827579	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.65	5.91	0.47	3.14e-8	Lung disease severity in cystic fibrosis;
TGCT	cis	rs7927771	0.832	rs1542321	chr11:47379615	G/A	cg21462715	chr11:47870315	NUP160	-0.55	-4.47	-0.37	1.78e-5	Subjective well-being;
TGCT	cis	rs4843747	0.519	rs12599755	chr16:88107006	A/G	cg06915872	chr16:87998081	BANP	-0.29	-4.46	-0.37	1.81e-5	Menopause (age at onset);
TGCT	cis	rs2663905	0.706	rs2683260	chr15:81385552	A/C	cg18028999	chr15:81426610	C15orf26	-0.72	-6.43	-0.5	2.49e-9	QT interval (drug interaction);
TGCT	cis	rs7771547	0.642	rs12214285	chr6:36434679	C/T	cg07856975	chr6:36356162	ETV7	-0.2	-4.58	-0.38	1.11e-5	Platelet distribution width;
TGCT	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.72	5.19	0.42	8.33e-7	Platelet count;
TGCT	cis	rs17076896	0.786	rs61956083	chr13:19935217	C/T	cg00777926	chr13:20807375	GJB6	-0.37	-4.53	-0.38	1.36e-5	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs4631830	0.863	rs2611489	chr10:51524889	C/T	cg10326726	chr10:51549505	MSMB	-0.25	-4.84	-0.4	3.72e-6	Prostate-specific antigen levels;
TGCT	cis	rs10089	1.000	rs11957052	chr5:127524055	T/C	cg19767477	chr5:127420684	SLC12A2	-0.43	-4.55	-0.38	1.25e-5	Ileal carcinoids;
TGCT	cis	rs7772486	0.686	rs857880	chr6:145971115	T/C	cg05347473	chr6:146136440	FBXO30	-0.49	-4.59	-0.38	1.06e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs453301	0.686	rs11787026	chr8:8902371	A/T	cg06636001	chr8:8085503	FLJ10661	0.68	5.54	0.45	1.75e-7	Joint mobility (Beighton score);
TGCT	cis	rs2535633	0.631	rs2465101	chr3:52991307	A/T	cg10802521	chr3:52805072	NEK4	0.54	5.73	0.46	7.03e-8	Body mass index;
TGCT	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg27454412	chr7:1067447	C7orf50	0.61	4.75	0.39	5.6e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7020830	0.867	rs563132	chr9:37245476	A/T	cg14294708	chr9:37120828	ZCCHC7	1.12	14.94	0.8	1.71e-29	Schizophrenia;
TGCT	cis	rs1903068	0.886	rs1551644	chr4:55994266	A/T	cg16572876	chr4:56024045	NA	0.45	5.08	0.42	1.34e-6	Endometriosis;
TGCT	cis	rs7824557	0.767	rs1897951	chr8:11169854	C/T	cg21775007	chr8:11205619	TDH	0.58	5.46	0.44	2.46e-7	Retinal vascular caliber;
TGCT	cis	rs7772486	0.719	rs702317	chr6:146005010	C/T	cg23711669	chr6:146136114	FBXO30	-0.93	-10.83	-0.7	1.24e-19	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg18402987	chr7:1209562	NA	0.7	5.67	0.45	9.66e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs17253792	0.822	rs28754619	chr14:56088394	G/A	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs4746818	1.000	rs4746818	chr10:70884687	G/T	cg04149295	chr10:70884716	VPS26A	0.71	5.07	0.41	1.4e-6	Left atrial antero-posterior diameter;
TGCT	cis	rs11792861	0.926	rs72607166	chr9:111821530	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.49	4.52	0.38	1.45e-5	Menarche (age at onset);
TGCT	cis	rs877282	1.000	rs11253370	chr10:773712	G/A	cg17470449	chr10:769945	NA	0.3	4.79	0.39	4.71e-6	Uric acid levels;
TGCT	cis	rs2692947	0.727	rs893173	chr2:96789787	T/C	cg22654517	chr2:96458247	NA	0.23	4.97	0.41	2.18e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs6988636	0.892	rs58116120	chr8:124191776	T/G	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs2072499	0.966	rs2853641	chr1:156181770	A/G	cg25208724	chr1:156163844	SLC25A44	1.1	16.06	0.82	4.53e-32	Testicular germ cell tumor;
TGCT	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg13683864	chr3:40499215	RPL14	-1.19	-13.2	-0.76	2.17e-25	Renal cell carcinoma;
TGCT	cis	rs617219	0.737	rs6453431	chr5:78493873	G/C	cg05890484	chr5:78407552	BHMT	0.36	4.93	0.41	2.53e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs2235642	0.787	rs2235646	chr16:1601287	A/G	cg00463982	chr16:1583984	IFT140;TMEM204	-0.31	-5.3	-0.43	5.12e-7	Coronary artery disease;
TGCT	cis	rs78487399	0.808	rs6737882	chr2:43731908	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-4.77	-0.39	4.99e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs9916302	0.706	rs8182252	chr17:37727950	T/C	cg07936489	chr17:37558343	FBXL20	0.87	6.95	0.53	1.85e-10	Glomerular filtration rate (creatinine);
TGCT	cis	rs12497850	0.764	rs6784111	chr3:49178846	T/C	cg07636037	chr3:49044803	WDR6	0.94	9.88	0.66	2.51e-17	Parkinson's disease;
TGCT	cis	rs1158570	0.500	rs2670890	chr8:131314923	G/A	cg16277922	chr8:131349729	ASAP1	-0.46	-5.85	-0.46	4.14e-8	Platelet count;
TGCT	cis	rs3770081	1.000	rs13390702	chr2:86237935	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.17	-4.75	-0.39	5.63e-6	Facial emotion recognition (sad faces);
TGCT	cis	rs8177179	0.904	rs1130459	chr3:133465283	A/G	cg24879335	chr3:133465180	TF	0.36	4.82	0.4	4.16e-6	Iron status biomarkers (transferrin levels);
TGCT	cis	rs28374715	0.532	rs28535540	chr15:41659277	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.92	-15.84	-0.82	1.44e-31	Ulcerative colitis;
TGCT	cis	rs7674212	0.541	rs2720471	chr4:104023840	A/G	cg16532752	chr4:104119610	CENPE	-0.59	-5.13	-0.42	1.06e-6	Type 2 diabetes;
TGCT	cis	rs2120019	1.000	rs1867146	chr15:75354971	C/G	cg17294928	chr15:75287854	SCAMP5	-0.84	-6.3	-0.49	4.75e-9	Blood trace element (Zn levels);
TGCT	trans	rs4650994	1.000	rs4650994	chr1:178515312	A/G	cg05059571	chr16:84539110	KIAA1609	0.41	7.67	0.57	4.32e-12	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs763014	0.898	rs916416	chr16:632198	T/A	cg27436995	chr16:743998	FBXL16	-0.45	-4.82	-0.4	4.17e-6	Height;
TGCT	cis	rs4808199	1.000	rs4808199	chr19:19545099	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.64	4.57	0.38	1.15e-5	Nonalcoholic fatty liver disease;
TGCT	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg20203395	chr5:56204925	C5orf35	-0.59	-5.12	-0.42	1.12e-6	Initial pursuit acceleration;
TGCT	cis	rs35150201	0.818	rs7810260	chr7:135311120	G/A	cg23117316	chr7:135346802	PL-5283	-0.48	-5.21	-0.42	7.48e-7	Plateletcrit;Mean corpuscular hemoglobin;Mean platelet volume;
TGCT	cis	rs1691799	0.867	rs1168330	chr12:66763167	C/T	cg16791601	chr12:66731901	HELB	0.25	5.05	0.41	1.56e-6	White blood cell count (basophil);
TGCT	cis	rs7412746	0.658	rs6669855	chr1:150861229	C/T	cg09365446	chr1:150670422	GOLPH3L	0.35	5.03	0.41	1.68e-6	Melanoma;
TGCT	cis	rs7223966	0.921	rs2006123	chr17:61958669	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	5.32	0.43	4.68e-7	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs9611565	0.500	rs2011053	chr22:42121278	G/A	cg06481639	chr22:41940642	POLR3H	0.56	4.87	0.4	3.39e-6	Vitiligo;
TGCT	cis	rs10028773	0.515	rs9994488	chr4:120587781	C/T	cg09307838	chr4:120376055	NA	0.56	5.36	0.43	3.87e-7	Educational attainment;
TGCT	cis	rs7267979	1.000	rs6138575	chr20:25438952	G/A	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4273100	0.512	rs973650	chr17:19291785	A/G	cg01534423	chr17:18965556	NA	-0.75	-7.83	-0.58	1.83e-12	Schizophrenia;
TGCT	trans	rs7726839	0.794	rs6883536	chr5:599274	G/A	cg25482853	chr8:67687455	SGK3	0.99	7.83	0.58	1.85e-12	Obesity-related traits;
TGCT	cis	rs10197940	0.662	rs4467261	chr2:152281391	G/C	cg19508488	chr2:152266495	RIF1	0.74	6.66	0.51	7.77e-10	Lung cancer;
TGCT	cis	rs7169223	0.653	rs8042170	chr15:79096599	G/A	cg03762349	chr15:79060523	ADAMTS7	-0.25	-5.45	-0.44	2.6e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
TGCT	cis	rs7666738	0.830	rs35752787	chr4:98935202	G/A	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg03934478	chr11:495069	RNH1	-0.36	-5.57	-0.45	1.49e-7	Body mass index;
TGCT	cis	rs11718455	0.960	rs34179760	chr3:44002303	A/G	cg08738300	chr3:44038990	NA	0.85	6.41	0.5	2.72e-9	Coronary artery disease;
TGCT	cis	rs7937682	0.883	rs472465	chr11:111468962	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.99	-10.02	-0.67	1.16e-17	Primary sclerosing cholangitis;
TGCT	cis	rs9926296	0.715	rs2115401	chr16:89740609	A/G	cg27121462	chr16:89883253	FANCA	0.54	5.21	0.42	7.54e-7	Vitiligo;
TGCT	cis	rs1878931	0.555	rs27228	chr16:3431933	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.69	-5.53	-0.44	1.81e-7	Body mass index (adult);
TGCT	cis	rs7772486	0.686	rs9386131	chr6:146121608	G/A	cg05347473	chr6:146136440	FBXO30	0.47	4.48	0.37	1.7e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1577917	0.538	rs7755996	chr6:86423720	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.52	4.65	0.39	8.34e-6	Response to antipsychotic treatment;
TGCT	cis	rs9926296	0.632	rs7184315	chr16:89799373	C/G	cg26513180	chr16:89883248	FANCA	-0.69	-6.77	-0.52	4.51e-10	Vitiligo;
TGCT	cis	rs981844	0.583	rs62325060	chr4:154630501	G/A	cg14289246	chr4:154710475	SFRP2	1.02	7.78	0.57	2.45e-12	Response to statins (LDL cholesterol change);
TGCT	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg19774624	chr17:42201019	HDAC5	-0.85	-10.09	-0.67	7.79e-18	Total body bone mineral density;
TGCT	cis	rs713587	0.646	rs34697209	chr2:25127394	A/G	cg01884057	chr2:25150051	NA	0.34	6.57	0.51	1.24e-9	Body mass index in non-asthmatics;
TGCT	cis	rs644799	1.000	rs543530	chr11:95545170	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	10.57	0.69	5.17e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs74417235	0.639	rs2396994	chr5:154052750	A/T	cg08754654	chr5:154026448	NA	-0.59	-5.68	-0.45	9.04e-8	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
TGCT	cis	rs10754283	0.967	rs10922685	chr1:90118320	A/G	cg03145924	chr1:90228473	NA	-0.4	-4.51	-0.38	1.5e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg06238570	chr21:40685208	BRWD1	0.57	5.17	0.42	8.96e-7	Cognitive function;
TGCT	cis	rs13217239	0.646	rs4403259	chr6:26997617	C/T	cg26531700	chr6:26746687	NA	0.68	6.86	0.52	2.83e-10	Schizophrenia;
TGCT	cis	rs425277	0.565	rs3128293	chr1:2065339	A/G	cg12140144	chr1:2984275	FLJ42875;PRDM16	0.37	5.06	0.41	1.5e-6	Height;
TGCT	cis	rs9902453	0.765	rs2264303	chr17:28055348	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.84	-8.39	-0.6	9.14e-14	Coffee consumption (cups per day);
TGCT	cis	rs1008375	0.932	rs7697329	chr4:17657853	C/A	cg18681998	chr4:17616180	MED28	0.96	10.38	0.68	1.51e-18	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7917772	0.503	rs56219824	chr10:104302337	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	8.36	0.6	1.1e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs6582630	0.502	rs11182760	chr12:38606273	A/T	cg26384229	chr12:38710491	ALG10B	0.9	8.06	0.59	5.32e-13	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs7666738	0.673	rs35009908	chr4:99110770	G/A	cg17366294	chr4:99064904	C4orf37	0.76	6.13	0.48	1.08e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg12923728	chr3:195709715	SDHAP1	-0.36	-7.57	-0.56	7.39e-12	Pancreatic cancer;
TGCT	cis	rs10031466	0.967	rs12647135	chr4:189011174	A/C	cg04086012	chr4:189060900	TRIML1	0.22	4.9	0.4	2.89e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs1800795	0.652	rs7802307	chr7:22766433	T/A	cg13104385	chr7:22767384	IL6	0.2	4.64	0.38	8.85e-6	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
TGCT	cis	rs7567389	0.671	rs72845993	chr2:128108601	T/C	cg02161262	chr2:127865248	BIN1	0.52	4.72	0.39	6.35e-6	Self-rated health;
TGCT	cis	rs17001868	0.568	rs6001894	chr22:40779197	T/C	cg07138101	chr22:40742427	ADSL	0.71	5.36	0.43	3.92e-7	Mammographic density (dense area);
TGCT	cis	rs9430161	0.611	rs2095920	chr1:11033457	T/A	cg02454025	chr1:11042201	C1orf127	0.94	11.31	0.71	8.14e-21	Ewing sarcoma;
TGCT	cis	rs1421811	0.532	rs17540044	chr5:32692238	C/G	cg16267343	chr5:32710456	NPR3	-0.74	-6.4	-0.5	2.87e-9	Blood pressure;
TGCT	cis	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg02380750	chr20:61661411	NA	0.35	6.13	0.48	1.1e-8	Prostate cancer (SNP x SNP interaction);
TGCT	trans	rs525455	1.000	rs2580898	chr10:13102437	T/C	cg21721093	chr17:8906386	NA	0.63	6.62	0.51	9.7e-10	Platelet aggregation;
TGCT	cis	rs73001065	0.591	rs11668386	chr19:19531910	A/G	cg03709012	chr19:19516395	GATAD2A	0.9	4.9	0.4	2.99e-6	LDL cholesterol;
TGCT	cis	rs2013441	1.000	rs2526460	chr17:20086352	G/A	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.61	-0.38	9.96e-6	Obesity-related traits;
TGCT	cis	rs7666738	0.791	rs2903151	chr4:99027218	T/C	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs5769765	1.000	rs5769764	chr22:50270784	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	1.11	11.76	0.73	6.5e-22	Schizophrenia;
TGCT	trans	rs2727020	0.729	rs1164685	chr11:49293660	G/A	cg15704280	chr7:45808275	SEPT13	0.73	8.36	0.6	1.1e-13	Coronary artery disease;
TGCT	cis	rs8072100	0.934	rs9905583	chr17:45741016	C/T	cg08085267	chr17:45401833	C17orf57	-0.47	-5.13	-0.42	1.07e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs4242434	0.927	rs720746	chr8:22471399	T/C	cg03733263	chr8:22462867	KIAA1967	1.15	20.1	0.87	7.99e-41	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg13695892	chr22:41940480	POLR3H	-0.91	-8.8	-0.62	9.77e-15	Vitiligo;
TGCT	cis	rs11190604	1.000	rs4244338	chr10:102272802	A/G	cg23241863	chr10:102295624	HIF1AN	0.68	5.17	0.42	9.15e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs3806843	1.000	rs3806845	chr5:140180737	C/T	cg19875535	chr5:140030758	IK	0.36	6.09	0.48	1.33e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs9733	0.818	rs6694531	chr1:150683512	C/A	cg13175981	chr1:150552382	MCL1	0.43	4.78	0.39	4.88e-6	Tonsillectomy;
TGCT	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg14784868	chr12:69753453	YEATS4	0.89	10.48	0.69	8.4e-19	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	4.48	0.37	1.69e-5	Prudent dietary pattern;
TGCT	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg00420450	chr8:22132641	PIWIL2	0.23	4.56	0.38	1.22e-5	Hypertriglyceridemia;
TGCT	cis	rs1344694	0.548	rs12468812	chr2:216905867	C/T	cg25588852	chr2:216877276	MREG	-0.25	-4.54	-0.38	1.31e-5	Alcohol dependence;
TGCT	cis	rs9549260	0.755	rs9549241	chr13:41210041	G/A	cg21288729	chr13:41239152	FOXO1	0.99	10.47	0.69	8.86e-19	Red blood cell count;
TGCT	cis	rs7100689	0.646	rs7081889	chr10:82165427	C/A	cg01528321	chr10:82214614	TSPAN14	0.73	7.73	0.57	3.25e-12	Post bronchodilator FEV1;
TGCT	cis	rs9926296	0.681	rs12923946	chr16:89821080	C/T	cg03388025	chr16:89894329	SPIRE2	0.32	4.73	0.39	6.03e-6	Vitiligo;
TGCT	cis	rs3820928	0.967	rs16822905	chr2:227770727	G/C	cg11843606	chr2:227700838	RHBDD1	-0.53	-4.69	-0.39	7.17e-6	Pulmonary function;
TGCT	trans	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg13615516	chr5:77269221	NA	0.67	8.36	0.6	1.09e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1949733	1.000	rs1916326	chr4:8500023	G/A	cg11789530	chr4:8429930	ACOX3	-0.64	-5.95	-0.47	2.52e-8	Response to antineoplastic agents;
TGCT	trans	rs1974653	0.672	rs76584826	chr22:20068503	G/T	cg08822737	chr17:71088851	SLC39A11	-0.93	-7.61	-0.56	5.97e-12	Schizophrenia;
TGCT	cis	rs12220238	0.722	rs7073340	chr10:76402277	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.59	4.54	0.38	1.29e-5	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs12682352	0.652	rs3827806	chr8:8724276	C/T	cg08975724	chr8:8085496	FLJ10661	0.56	5.13	0.42	1.07e-6	Neuroticism;
TGCT	cis	rs7267979	0.586	rs11087505	chr20:25196520	T/A	cg14121845	chr20:25566513	NINL	0.43	4.65	0.39	8.21e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg13565492	chr6:43139072	SRF	-0.81	-7.71	-0.57	3.45e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.08	0.48	1.37e-8	Bipolar disorder;
TGCT	cis	rs2932538	0.922	rs12739994	chr1:113131159	T/C	cg22162597	chr1:113214053	CAPZA1	0.28	5.92	0.47	2.98e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs9818758	0.607	rs73074866	chr3:49626666	C/T	cg08550065	chr3:50336684	HYAL3;NAT6	1.04	5.13	0.42	1.08e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs7937682	1.000	rs12363179	chr11:111568091	G/A	cg09085632	chr11:111637200	PPP2R1B	1.04	9.55	0.65	1.58e-16	Primary sclerosing cholangitis;
TGCT	cis	rs7666738	0.822	rs11097599	chr4:98959562	T/A	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2760061	0.598	rs673726	chr1:228120173	T/C	cg18477163	chr1:228402036	OBSCN	-0.32	-6.37	-0.5	3.31e-9	Diastolic blood pressure;
TGCT	cis	rs73198271	0.583	rs11781985	chr8:8589783	C/T	cg06671706	chr8:8559999	CLDN23	0.39	4.68	0.39	7.49e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs9436747	0.739	rs1171267	chr1:66003854	T/G	cg14976592	chr1:65886160	LEPROT;LEPR	-0.5	-4.87	-0.4	3.4e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs72781680	0.716	rs2675363	chr2:24080003	G/C	cg08917208	chr2:24149416	ATAD2B	0.77	4.83	0.4	3.98e-6	Lymphocyte counts;
TGCT	cis	rs1372520	0.577	rs2737028	chr4:90717016	A/G	cg01966878	chr4:90757139	SNCA	-0.32	-4.84	-0.4	3.76e-6	Neuroticism;
TGCT	cis	rs4891159	0.513	rs35534021	chr18:74130523	G/A	cg24786174	chr18:74118243	ZNF516	0.66	12.82	0.76	1.76e-24	Longevity;
TGCT	cis	rs2197308	0.623	rs1672426	chr12:38118671	C/T	cg26384229	chr12:38710491	ALG10B	-0.58	-5.09	-0.42	1.28e-6	Morning vs. evening chronotype;
TGCT	cis	rs4595586	0.545	rs12827823	chr12:39392144	G/T	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg10802521	chr3:52805072	NEK4	-0.71	-8.79	-0.62	1.04e-14	Bipolar disorder;
TGCT	cis	rs6964587	1.000	rs6970277	chr7:91680655	T/C	cg22709100	chr7:91322751	NA	0.27	4.46	0.37	1.84e-5	Breast cancer;
TGCT	cis	rs17767294	0.614	rs72845061	chr6:27653261	G/A	cg08851530	chr6:28072375	NA	1.56	7.38	0.55	1.95e-11	Parkinson's disease;
TGCT	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs11098499	0.789	rs10212719	chr4:120254437	T/C	cg09307838	chr4:120376055	NA	0.63	6.06	0.48	1.49e-8	Corneal astigmatism;
TGCT	cis	rs1347297	0.526	rs2276617	chr2:179250397	A/G	cg03991736	chr2:179345203	MIR548N;PLEKHA3	-0.49	-4.75	-0.39	5.55e-6	Alzheimer disease and age of onset;
TGCT	cis	rs4975709	0.569	rs4975742	chr5:1858612	T/C	cg07747251	chr5:1868357	NA	0.35	4.65	0.39	8.24e-6	Cardiovascular disease risk factors;
TGCT	cis	rs4653767	0.573	rs708770	chr1:226912135	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.4	-4.46	-0.37	1.84e-5	Parkinson's disease;
TGCT	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg09436375	chr6:42928200	GNMT	-0.4	-5.18	-0.42	8.58e-7	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg12963246	chr6:28129442	ZNF389	0.51	4.97	0.41	2.19e-6	Depression;
TGCT	cis	rs2067615	0.524	rs10861645	chr12:107071130	C/T	cg15890332	chr12:107067104	RFX4	0.29	5.77	0.46	5.9e-8	Heart rate;
TGCT	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg15691649	chr6:25882328	NA	-0.35	-4.67	-0.39	7.71e-6	Blood metabolite levels;
TGCT	cis	rs3749237	0.964	rs1799843	chr3:49849723	G/A	cg03060546	chr3:49711283	APEH	0.69	7.12	0.54	7.8e-11	Resting heart rate;
TGCT	cis	rs78487399	0.614	rs77061610	chr2:43659970	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.42	-4.54	-0.38	1.34e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs4727027	0.933	rs2158633	chr7:148832652	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	4.58	0.38	1.13e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs57590327	0.555	rs13088603	chr3:81791167	A/G	cg07356753	chr3:81810745	GBE1	-0.77	-7.2	-0.54	5.1e-11	Extraversion;
TGCT	cis	rs9733	0.526	rs11204696	chr1:150658721	T/C	cg04414720	chr1:150670196	GOLPH3L	0.39	5.04	0.41	1.58e-6	Tonsillectomy;
TGCT	cis	rs12220238	1.000	rs11000936	chr10:75992383	A/T	cg19889307	chr10:75911429	ADK;AP3M1	0.91	7.98	0.58	8.43e-13	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs2070488	0.775	rs4371464	chr3:38548021	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.74	-6.94	-0.53	1.94e-10	Electrocardiographic conduction measures;
TGCT	cis	rs12477438	0.520	rs6741772	chr2:99738961	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.85	8.41	0.6	8.43e-14	Chronic sinus infection;
TGCT	cis	rs7119	0.717	rs7181283	chr15:77814544	G/A	cg27398640	chr15:77910606	LINGO1	-0.25	-4.6	-0.38	1.05e-5	Type 2 diabetes;
TGCT	cis	rs6964587	0.967	rs34040612	chr7:91798916	G/T	cg17063962	chr7:91808500	NA	0.89	9.59	0.65	1.24e-16	Breast cancer;
TGCT	cis	rs9372498	0.536	rs62422236	chr6:118972633	G/T	cg21191810	chr6:118973309	C6orf204	-0.37	-4.77	-0.39	5.15e-6	Diastolic blood pressure;
TGCT	cis	rs6582630	0.593	rs7134006	chr12:38596245	A/C	cg26384229	chr12:38710491	ALG10B	0.89	7.82	0.57	2e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs1903068	0.925	rs1551641	chr4:55993915	C/T	cg16572876	chr4:56024045	NA	0.45	5.08	0.42	1.34e-6	Endometriosis;
TGCT	cis	rs2204008	0.641	rs2387810	chr12:38368875	G/T	cg13010199	chr12:38710504	ALG10B	0.58	4.55	0.38	1.26e-5	Bladder cancer;
TGCT	cis	rs7178572	0.568	rs1493700	chr15:77629060	T/C	cg22256960	chr15:77711686	NA	-0.85	-8.73	-0.62	1.4e-14	Type 2 diabetes;
TGCT	cis	rs2758596	0.850	rs2241110	chr1:156172487	A/G	cg25208724	chr1:156163844	SLC25A44	0.83	5.04	0.41	1.61e-6	Paclitaxel disposition in epithelial ovarian cancer;
TGCT	cis	rs7647973	1.000	rs6446275	chr3:49466871	A/G	cg05785598	chr3:49045655	WDR6	-0.38	-4.5	-0.37	1.57e-5	Menarche (age at onset);
TGCT	cis	rs13202913	0.652	rs9383578	chr6:151838192	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.72	-4.93	-0.4	2.61e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs1570884	0.516	rs2094108	chr13:50171550	G/A	cg08779649	chr13:50194554	NA	0.37	5.82	0.46	4.74e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
TGCT	cis	rs9929218	0.953	rs11075696	chr16:68731365	A/G	cg01251360	chr16:68772225	CDH1	0.29	4.6	0.38	1.01e-5	Colorectal cancer;
TGCT	cis	rs67311347	1.000	rs12630072	chr3:40517190	T/G	cg13409248	chr3:40428643	ENTPD3	0.56	4.45	0.37	1.91e-5	Renal cell carcinoma;
TGCT	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg06481639	chr22:41940642	POLR3H	-0.73	-6.45	-0.5	2.27e-9	Vitiligo;
TGCT	cis	rs12142240	0.660	rs72890715	chr1:46852077	A/G	cg00530320	chr1:46809349	NSUN4	0.29	5.79	0.46	5.34e-8	Menopause (age at onset);
TGCT	cis	rs9911578	1.000	rs1472288	chr17:56910720	G/A	cg05425664	chr17:57184151	TRIM37	-0.62	-6.18	-0.49	8.33e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs57590327	0.503	rs13062741	chr3:81887124	C/T	cg07356753	chr3:81810745	GBE1	-0.69	-6.34	-0.49	3.87e-9	Extraversion;
TGCT	cis	rs7027203	0.576	rs7865043	chr9:96549004	G/T	cg13679303	chr9:96623674	NA	0.54	7.68	0.57	4.04e-12	DNA methylation (variation);
TGCT	trans	rs4650994	0.623	rs12121188	chr1:178622499	G/A	cg05059571	chr16:84539110	KIAA1609	0.41	7.14	0.54	7.07e-11	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs1395	0.778	rs60631624	chr2:27497815	T/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.62	8.02	0.58	6.76e-13	Blood metabolite levels;
TGCT	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg05368731	chr17:41323189	NBR1	1.2	14.2	0.79	8.98e-28	Menopause (age at onset);
TGCT	trans	rs62103177	0.810	rs62096745	chr18:77619135	A/G	cg05926928	chr17:57297772	GDPD1	1.22	11.16	0.71	1.85e-20	Opioid sensitivity;
TGCT	cis	rs2832191	0.671	rs68101501	chr21:30513229	G/T	cg24692254	chr21:30365293	RNF160	-0.61	-5.41	-0.44	3.08e-7	Dental caries;
TGCT	cis	rs8141529	0.778	rs9625566	chr22:29162506	G/A	cg02153584	chr22:29168773	CCDC117	0.7	6.15	0.48	9.93e-9	Lymphocyte counts;
TGCT	cis	rs11190604	1.000	rs1417823	chr10:102227886	C/T	cg23241863	chr10:102295624	HIF1AN	-0.63	-4.97	-0.41	2.2e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg22663859	chr13:21900854	NA	0.33	4.6	0.38	1.03e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	cis	rs9486719	0.843	rs3849198	chr6:97036539	C/A	cg18709589	chr6:96969512	KIAA0776	-0.74	-5.21	-0.42	7.5e-7	Migraine;Coronary artery disease;
TGCT	cis	rs6921919	0.525	rs11760133	chr6:28386739	A/T	cg18815343	chr6:28367644	ZSCAN12	-0.52	-5.01	-0.41	1.83e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4819852	0.752	rs917479	chr22:19973205	T/G	cg07821417	chr22:19972146	ARVCF	0.19	4.56	0.38	1.2e-5	Pulse pressure;
TGCT	trans	rs8073060	0.544	rs7211724	chr17:33993414	C/G	cg19694781	chr19:47549865	TMEM160	-0.62	-14.07	-0.78	1.86e-27	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs6570726	0.791	rs6900040	chr6:145893134	C/T	cg05347473	chr6:146136440	FBXO30	0.52	4.95	0.41	2.33e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6429082	0.715	rs9793740	chr1:235595590	T/C	cg26050004	chr1:235667680	B3GALNT2	-0.54	-4.77	-0.39	5.07e-6	Adiposity;
TGCT	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg10253484	chr15:75165896	SCAMP2	-0.6	-5.5	-0.44	2.06e-7	Breast cancer;
TGCT	cis	rs7772486	0.875	rs2814875	chr6:146305810	G/A	cg13319975	chr6:146136371	FBXO30	-0.52	-4.62	-0.38	9.45e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs916888	0.697	rs199516	chr17:44856485	C/T	cg17911788	chr17:44343683	NA	0.62	6.56	0.51	1.32e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs9388451	0.531	rs9321057	chr6:126156943	G/A	cg05901451	chr6:126070800	HEY2	-0.74	-7.69	-0.57	3.97e-12	Brugada syndrome;
TGCT	cis	rs1062177	1.000	rs2915878	chr5:151149662	A/G	cg00977110	chr5:151150581	G3BP1	0.4	4.62	0.38	9.43e-6	Preschool internalizing problems;
TGCT	cis	rs12579753	1.000	rs12827923	chr12:82242067	G/A	cg07988820	chr12:82153109	PPFIA2	-0.6	-6.48	-0.5	1.91e-9	Resting heart rate;
TGCT	cis	rs514406	0.505	rs427319	chr1:53178807	T/G	cg24675658	chr1:53192096	ZYG11B	-0.79	-9.71	-0.66	6.32e-17	Monocyte count;
TGCT	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg16325326	chr1:53192061	ZYG11B	-0.71	-8.82	-0.62	8.9e-15	Monocyte count;
TGCT	cis	rs1395	0.778	rs17005956	chr2:27451099	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.7	9.6	0.65	1.2e-16	Blood metabolite levels;
TGCT	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg05064044	chr6:292385	DUSP22	0.65	6.87	0.53	2.8e-10	Menopause (age at onset);
TGCT	cis	rs9486715	0.659	rs9399930	chr6:96854444	G/T	cg18709589	chr6:96969512	KIAA0776	0.69	6.15	0.48	9.69e-9	Headache;
TGCT	cis	rs7178572	0.962	rs12324627	chr15:77767539	A/G	cg15453836	chr15:77711506	NA	-0.4	-4.59	-0.38	1.07e-5	Type 2 diabetes;
TGCT	cis	rs4925386	0.681	rs2427294	chr20:60927257	G/A	cg06026331	chr20:60912101	LAMA5	0.32	4.91	0.4	2.84e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs6582630	0.537	rs8189533	chr12:38391068	A/G	cg13010199	chr12:38710504	ALG10B	0.63	4.92	0.4	2.64e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs11718455	0.960	rs35277738	chr3:44006732	T/C	cg08738300	chr3:44038990	NA	0.85	6.34	0.49	3.94e-9	Coronary artery disease;
TGCT	cis	rs35146811	0.735	rs1138417	chr7:99807146	C/G	cg13334819	chr7:99746414	C7orf59	0.74	6.62	0.51	9.79e-10	Coronary artery disease;
TGCT	cis	rs9457247	1.000	rs408087	chr6:167398952	C/T	cg23791538	chr6:167370224	RNASET2	-0.49	-4.96	-0.41	2.26e-6	Crohn's disease;
TGCT	cis	rs3087591	0.959	rs2940182	chr17:29410944	A/G	cg24425628	chr17:29625626	OMG;NF1	0.46	6.94	0.53	1.93e-10	Hip circumference;
TGCT	cis	rs669446	0.561	rs559575	chr1:44089940	A/G	cg12908607	chr1:44402522	ARTN	-0.54	-5.68	-0.45	8.9e-8	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs1775715	0.737	rs2808028	chr10:32101189	G/A	cg14930904	chr10:32216787	ARHGAP12	0.52	5.07	0.41	1.38e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs748404	0.660	rs2602141	chr15:43724646	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	4.76	0.39	5.35e-6	Lung cancer;
TGCT	cis	rs6563842	0.563	rs4941991	chr13:41335719	T/C	cg21288729	chr13:41239152	FOXO1	0.88	7.87	0.58	1.49e-12	Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
TGCT	cis	rs7178424	0.742	rs1981916	chr15:62171479	T/C	cg00456672	chr15:62358751	C2CD4A	-0.31	-4.72	-0.39	6.37e-6	Height;
TGCT	cis	rs1030877	0.960	rs3792050	chr2:105902255	T/C	cg02079111	chr2:105885981	TGFBRAP1	-0.17	-4.82	-0.4	4.19e-6	Obesity-related traits;
TGCT	cis	rs2688608	0.967	rs2688609	chr10:75658181	A/G	cg19442545	chr10:75533431	FUT11	0.29	4.62	0.38	9.62e-6	Inflammatory bowel disease;
TGCT	cis	rs727505	1.000	rs17246404	chr7:124462661	C/T	cg23710748	chr7:124431027	NA	-0.26	-4.49	-0.37	1.6e-5	Lewy body disease;
TGCT	cis	rs1670533	1.000	rs3816474	chr4:1050653	G/A	cg18657303	chr4:1051139	NA	0.32	4.9	0.4	2.9e-6	Recombination rate (females);
TGCT	cis	rs4253772	0.637	rs3087501	chr22:46647909	A/G	cg09491104	chr22:46646882	C22orf40	-0.61	-6.25	-0.49	6.14e-9	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs10992471	0.528	rs10115290	chr9:95195858	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.53	-5.12	-0.42	1.15e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs916888	0.647	rs199449	chr17:44808902	G/A	cg01570182	chr17:44337453	NA	0.83	8.07	0.59	5.19e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs8077889	0.917	rs28694735	chr17:41912144	A/G	cg26893861	chr17:41843967	DUSP3	1.11	13.43	0.77	6.22e-26	Triglycerides;
TGCT	cis	rs3806843	0.551	rs246018	chr5:140335043	T/C	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs78487399	0.710	rs7567685	chr2:43668169	G/C	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.72	4.62	0.38	9.53e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs6714710	0.580	rs6711101	chr2:98379813	G/A	cg26665480	chr2:98280029	ACTR1B	0.66	6.17	0.48	8.8e-9	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs62244186	0.659	rs62251383	chr3:44552421	A/G	cg15687855	chr3:44754131	ZNF502	-0.43	-5.17	-0.42	9.22e-7	Depressive symptoms;
TGCT	cis	rs9368481	0.761	rs4713062	chr6:26948195	A/G	cg26531700	chr6:26746687	NA	-0.58	-5.48	-0.44	2.31e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg21724239	chr8:58056113	NA	0.32	4.45	0.37	1.93e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7072216	0.763	rs2274244	chr10:100175218	A/G	cg26618903	chr10:100175079	PYROXD2	-0.4	-4.49	-0.37	1.64e-5	Metabolite levels;
TGCT	cis	rs9640161	0.830	rs3757425	chr7:150067640	A/C	cg10018233	chr7:150070692	REPIN1	0.4	6.51	0.5	1.68e-9	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs12908161	0.959	rs35557864	chr15:85331629	A/G	cg12863693	chr15:85201151	NMB	0.42	4.95	0.41	2.38e-6	Schizophrenia;
TGCT	cis	rs28595532	0.920	rs115294251	chr4:119772833	C/T	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs12950390	0.814	rs11659069	chr17:45834275	G/T	cg06532163	chr17:45867833	NA	0.34	5.31	0.43	4.82e-7	IgG glycosylation;
TGCT	cis	rs909674	0.818	rs7364148	chr22:39842165	T/C	cg01416388	chr22:39784598	NA	-0.69	-6.23	-0.49	6.78e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs4808199	0.948	rs2074300	chr19:19380996	G/T	cg03709012	chr19:19516395	GATAD2A	0.8	6.14	0.48	1.03e-8	Nonalcoholic fatty liver disease;
TGCT	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.33	-5.16	-0.42	9.32e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7647973	0.626	rs7637711	chr3:49829653	A/G	cg03060546	chr3:49711283	APEH	-0.63	-5.63	-0.45	1.12e-7	Menarche (age at onset);
TGCT	cis	rs2996428	0.667	rs10492942	chr1:3764216	C/T	cg17848003	chr1:3704513	LRRC47	0.19	5.21	0.42	7.56e-7	Red cell distribution width;
TGCT	cis	rs6088580	0.634	rs6058073	chr20:33116483	T/C	cg06115741	chr20:33292138	TP53INP2	0.54	4.63	0.38	9.06e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs1998418	0.551	rs60499622	chr10:126551228	C/T	cg03585084	chr10:126284563	LHPP	0.28	4.76	0.39	5.39e-6	Mean platelet volume;
TGCT	cis	rs11148252	0.904	rs7990581	chr13:53019433	A/G	cg00495681	chr13:53174319	NA	0.59	6.1	0.48	1.24e-8	Lewy body disease;
TGCT	cis	rs9400467	0.506	rs12192617	chr6:111490275	A/G	cg15721981	chr6:111408429	SLC16A10	0.69	4.5	0.37	1.56e-5	Blood metabolite levels;Amino acid levels;
TGCT	cis	rs28595532	0.748	rs72670258	chr4:119391660	A/T	cg21605333	chr4:119757512	SEC24D	0.82	5.41	0.44	3.15e-7	Cannabis dependence symptom count;
TGCT	cis	rs13326165	0.715	rs34355561	chr3:52383120	G/A	cg27565382	chr3:53032988	SFMBT1	0.36	4.8	0.4	4.54e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs6988636	1.000	rs58189203	chr8:124184739	G/T	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs939658	0.805	rs35602654	chr15:79417527	T/A	cg17916960	chr15:79447300	NA	-0.5	-7.7	-0.57	3.74e-12	Refractive error;
TGCT	cis	rs13190036	1.000	rs71601343	chr5:176632107	G/A	cg18465082	chr5:176734745	MXD3	0.32	4.46	0.37	1.78e-5	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
TGCT	cis	rs2456568	0.778	rs7944194	chr11:93682413	C/G	cg26875233	chr11:93583750	C11orf90	0.39	4.65	0.39	8.39e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7760949	0.963	rs1330118	chr6:13921016	C/T	cg27413430	chr6:13925136	RNF182	-0.54	-4.9	-0.4	2.97e-6	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs854765	0.616	rs8070624	chr17:17843396	G/A	cg09796270	chr17:17721594	SREBF1	0.28	5.64	0.45	1.07e-7	Total body bone mineral density;
TGCT	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg26338869	chr17:61819248	STRADA	-0.5	-4.55	-0.38	1.24e-5	Prudent dietary pattern;
TGCT	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg13628971	chr7:2884303	GNA12	0.54	4.53	0.38	1.36e-5	Height;
TGCT	cis	rs9916302	0.706	rs7212621	chr17:37527911	T/G	cg07936489	chr17:37558343	FBXL20	0.87	6.26	0.49	5.63e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs10510102	0.808	rs11200296	chr10:123731471	C/T	cg23691251	chr10:123688108	ATE1	-0.67	-4.76	-0.39	5.23e-6	Breast cancer;
TGCT	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg22433210	chr17:43662623	NA	1.06	7.29	0.55	3.2e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs644799	0.965	rs499076	chr11:95546341	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	10.57	0.69	5.17e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9653442	0.564	rs11687586	chr2:100789346	A/G	cg07810366	chr2:100720526	AFF3	-0.35	-5.26	-0.43	6e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg13342137	chr4:2252803	MXD4	0.17	4.55	0.38	1.27e-5	Obesity-related traits;
TGCT	trans	rs8073060	0.586	rs117573546	chr17:33909588	G/A	cg19694781	chr19:47549865	TMEM160	0.6	13.04	0.76	5.29e-25	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs67340775	0.541	rs200979	chr6:27852357	G/A	cg26587870	chr6:27730563	NA	-0.34	-4.62	-0.38	9.28e-6	Lung cancer in ever smokers;
TGCT	cis	rs55882075	0.722	rs10903245	chr5:179133608	T/C	cg14593053	chr5:179126677	CANX	0.47	5.28	0.43	5.7e-7	Monocyte percentage of white cells;
TGCT	cis	rs7208859	0.623	rs2035494	chr17:29130393	T/G	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs7565124	0.955	rs67500069	chr2:20269864	A/C	cg00462460	chr2:20212509	MATN3	-0.42	-4.64	-0.38	8.69e-6	Major depressive disorder;
TGCT	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg17554472	chr22:41940697	POLR3H	-0.49	-5.27	-0.43	5.9e-7	Vitiligo;
TGCT	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.71	-0.39	6.54e-6	Prudent dietary pattern;
TGCT	cis	rs7752195	0.643	rs115949281	chr6:25240214	G/A	cg16898833	chr6:26189333	HIST1H4D	1.17	5.47	0.44	2.34e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7909074	0.832	rs10793564	chr10:45386352	C/A	cg04218760	chr10:45406644	TMEM72	-0.28	-5.59	-0.45	1.38e-7	Mean corpuscular volume;
TGCT	trans	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg25482853	chr8:67687455	SGK3	1.16	10.5	0.69	7.91e-19	Lung disease severity in cystic fibrosis;
TGCT	cis	rs5769765	1.000	rs5770742	chr22:50270309	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	-0.41	-6.13	-0.48	1.08e-8	Schizophrenia;
TGCT	cis	rs35264875	0.796	rs72928657	chr11:68852336	T/C	cg02660097	chr11:68866761	NA	0.32	4.96	0.41	2.3e-6	Blond vs. brown hair color;
TGCT	cis	rs9911578	0.967	rs405684	chr17:56777148	T/C	cg05425664	chr17:57184151	TRIM37	-0.63	-6.26	-0.49	5.86e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs6964587	0.692	rs17672805	chr7:91573466	A/G	cg17063962	chr7:91808500	NA	-0.76	-7.12	-0.54	7.65e-11	Breast cancer;
TGCT	cis	rs79349575	0.811	rs12601072	chr17:46997998	T/C	cg07967210	chr17:47022446	SNF8	0.44	6.12	0.48	1.13e-8	Type 2 diabetes;
TGCT	cis	rs12541335	0.536	rs4266653	chr8:22169087	A/G	cg18135555	chr8:22132992	PIWIL2	0.28	5.8	0.46	5.25e-8	Hypertriglyceridemia;
TGCT	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg16325326	chr1:53192061	ZYG11B	0.56	6.4	0.5	2.83e-9	Monocyte count;
TGCT	cis	rs1375194	0.606	rs10188817	chr2:33815471	A/G	cg04131969	chr2:33951647	MYADML	-0.56	-4.84	-0.4	3.85e-6	Response to antidepressants in depression;
TGCT	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg06753367	chr22:24256600	NA	-0.24	-4.51	-0.38	1.5e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7917772	0.503	rs11191330	chr10:104306160	G/T	cg05855489	chr10:104503620	C10orf26	-0.6	-5.26	-0.43	6.16e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs6570726	0.902	rs973855	chr6:145781850	C/T	cg23711669	chr6:146136114	FBXO30	-0.71	-6.74	-0.52	5.36e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs77741769	0.529	rs2893876	chr12:121245158	T/C	cg02419362	chr12:121203948	SPPL3	0.19	4.49	0.37	1.63e-5	Mean corpuscular volume;
TGCT	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	5.11	0.42	1.18e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9393777	0.513	rs13190754	chr6:26587406	G/A	cg15659132	chr6:26577336	NA	-0.64	-4.82	-0.4	4.09e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs13217239	0.646	rs12527111	chr6:27006475	C/T	cg26531700	chr6:26746687	NA	0.68	6.86	0.52	2.83e-10	Schizophrenia;
TGCT	cis	rs4654899	1.000	rs6703227	chr1:21374810	A/G	cg01072550	chr1:21505969	NA	-0.49	-7.88	-0.58	1.41e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs4455778	0.580	rs56191832	chr7:49128223	C/A	cg26309511	chr7:48887640	NA	0.5	6.51	0.5	1.66e-9	Lung cancer in never smokers;
TGCT	cis	rs9611565	0.765	rs132905	chr22:41799106	C/A	cg17554472	chr22:41940697	POLR3H	0.43	4.79	0.39	4.73e-6	Vitiligo;
TGCT	trans	rs4824093	0.610	rs12106611	chr22:50242686	G/A	cg09872104	chr7:134855509	C7orf49	-0.91	-7.33	-0.55	2.66e-11	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs28595532	0.920	rs112016126	chr4:119726528	C/T	cg21605333	chr4:119757512	SEC24D	1.72	8.96	0.63	3.99e-15	Cannabis dependence symptom count;
TGCT	cis	rs6088580	0.634	rs6141471	chr20:33006730	A/G	cg08999081	chr20:33150536	PIGU	-0.29	-5.65	-0.45	1.02e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs78456975	0.506	rs6756310	chr2:1549809	A/G	cg12573674	chr2:1569213	NA	-0.49	-4.95	-0.41	2.41e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs68170813	0.605	rs4730227	chr7:106904031	G/C	cg02696742	chr7:106810147	HBP1	-0.69	-5.61	-0.45	1.27e-7	Coronary artery disease;
TGCT	cis	rs7772486	0.754	rs6570718	chr6:146088443	T/G	cg13319975	chr6:146136371	FBXO30	0.58	5.29	0.43	5.27e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7746199	0.736	rs6904596	chr6:27491299	G/A	cg08798685	chr6:27730294	NA	-0.37	-4.67	-0.39	7.76e-6	Gait speed in old age;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7647973	0.593	rs7652179	chr3:49808618	T/A	cg03060546	chr3:49711283	APEH	-0.61	-5.14	-0.42	1.04e-6	Menarche (age at onset);
TGCT	cis	rs12510870	0.729	rs10938077	chr4:74375374	A/G	cg05868023	chr4:75230803	EREG	0.56	5.05	0.41	1.56e-6	Iris color (b* coordinate);
TGCT	cis	rs78456975	0.506	rs13384333	chr2:1555531	A/C	cg12573674	chr2:1569213	NA	-0.44	-4.71	-0.39	6.64e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg13695892	chr22:41940480	POLR3H	0.93	9.1	0.63	1.88e-15	Vitiligo;
TGCT	cis	rs7552404	0.731	rs11588578	chr1:76400539	T/G	cg22875332	chr1:76189707	ACADM	0.66	6.4	0.5	2.94e-9	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs950169	0.922	rs8037078	chr15:84818871	A/G	cg12863693	chr15:85201151	NMB	-0.41	-4.47	-0.37	1.77e-5	Schizophrenia;
TGCT	trans	rs7618501	1.000	rs2247036	chr3:49882349	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	1.03	13.19	0.76	2.31e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs11098499	0.866	rs12501602	chr4:120287935	A/T	cg09307838	chr4:120376055	NA	0.58	5.77	0.46	5.97e-8	Corneal astigmatism;
TGCT	cis	rs7769051	0.522	rs11965927	chr6:133101353	T/C	cg22852734	chr6:133119734	C6orf192	1.16	4.48	0.37	1.67e-5	Type 2 diabetes nephropathy;
TGCT	cis	rs919433	0.679	rs1902249	chr2:198521356	T/C	cg00792783	chr2:198669748	PLCL1	0.55	4.88	0.4	3.24e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs2120019	0.938	rs2304903	chr15:75315778	A/G	cg17294928	chr15:75287854	SCAMP5	-0.79	-6.27	-0.49	5.46e-9	Blood trace element (Zn levels);
TGCT	cis	rs9467711	0.606	rs2072806	chr6:26385093	C/G	cg10795676	chr6:26370623	BTN3A2	-0.48	-4.78	-0.39	4.78e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs797680	0.964	rs12038699	chr1:93558818	A/G	cg17826107	chr1:92977322	EVI5	-0.22	-5.11	-0.42	1.19e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs854765	0.647	rs854791	chr17:18029857	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.7	6.99	0.53	1.52e-10	Total body bone mineral density;
TGCT	cis	rs611744	0.967	rs639059	chr8:109236119	G/A	cg21045802	chr8:109455806	TTC35	0.52	4.69	0.39	6.99e-6	Dupuytren's disease;
TGCT	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2180341	0.960	rs9375503	chr6:127677071	T/C	cg24812749	chr6:127587940	RNF146	1.01	7.62	0.56	5.59e-12	Breast cancer;
TGCT	cis	rs11578119	0.933	rs12140770	chr1:170449235	T/A	cg09767346	chr1:170501363	GORAB	0.73	5.8	0.46	5.23e-8	Male-pattern baldness;
TGCT	cis	rs896854	0.625	rs13281709	chr8:95972819	T/A	cg23172400	chr8:95962367	TP53INP1	-0.39	-6.52	-0.51	1.57e-9	Type 2 diabetes;
TGCT	cis	rs7586879	1.000	rs10175064	chr2:25117537	T/C	cg01884057	chr2:25150051	NA	0.28	5.03	0.41	1.69e-6	Body mass index;
TGCT	cis	rs7666738	0.519	rs28539191	chr4:98821552	C/T	cg05340658	chr4:99064831	C4orf37	0.55	5.96	0.47	2.42e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10804591	1.000	rs2811435	chr3:129339470	C/T	cg07730360	chr3:128845626	NA	-0.2	-4.66	-0.39	7.91e-6	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Hip circumference adjusted for BMI;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2688608	0.901	rs2664280	chr10:75617344	A/T	cg19442545	chr10:75533431	FUT11	0.32	5.07	0.41	1.42e-6	Inflammatory bowel disease;
TGCT	cis	rs7568458	0.870	rs1562323	chr2:85809711	T/C	cg17127132	chr2:85788382	GGCX	0.71	6.51	0.5	1.65e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs7267979	0.932	rs433352	chr20:25467992	C/T	cg03522245	chr20:25566470	NINL	-0.61	-6.59	-0.51	1.15e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7567389	0.600	rs11691088	chr2:128131853	A/G	cg09760422	chr2:128146352	NA	0.39	5.18	0.42	8.76e-7	Self-rated health;
TGCT	cis	rs6088580	0.634	rs4277599	chr20:33008905	A/G	cg08999081	chr20:33150536	PIGU	-0.29	-5.73	-0.46	7.34e-8	Glomerular filtration rate (creatinine);
TGCT	cis	rs2688608	0.592	rs10824032	chr10:75528130	G/A	cg04320760	chr10:75533139	FUT11	-0.38	-5.9	-0.47	3.24e-8	Inflammatory bowel disease;
TGCT	cis	rs1113500	0.541	rs6692571	chr1:108576684	G/A	cg06207961	chr1:108661230	NA	0.24	4.7	0.39	6.91e-6	Growth-regulated protein alpha levels;
TGCT	cis	rs2153535	0.563	rs1737584	chr6:8536742	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.67	0.45	9.45e-8	Motion sickness;
TGCT	cis	rs9467773	1.000	rs3736781	chr6:26505362	G/A	cg15659132	chr6:26577336	NA	0.86	12.18	0.74	6.14e-23	Intelligence (multi-trait analysis);
TGCT	trans	rs77457752	0.690	rs12352669	chr9:13911919	A/T	cg23609682	chr1:3070786	PRDM16	-0.45	-6.64	-0.51	8.66e-10	Breast cancer;
TGCT	cis	rs67072384	0.901	rs67288233	chr11:72458361	G/A	cg03713592	chr11:72463424	ARAP1	-0.93	-4.66	-0.39	7.89e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs9467711	0.606	rs9393715	chr6:26375645	G/A	cg16898833	chr6:26189333	HIST1H4D	1.1	5.3	0.43	5.16e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1153858	0.723	rs1719238	chr15:45594766	C/T	cg26924012	chr15:45694286	SPATA5L1	-1.01	-11.05	-0.7	3.45e-20	Homoarginine levels;
TGCT	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg05368731	chr17:41323189	NBR1	1.19	13.98	0.78	2.93e-27	Menopause (age at onset);
TGCT	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg04608855	chr19:58913158	NA	0.57	5.7	0.46	8.44e-8	Uric acid clearance;
TGCT	cis	rs933688	1.000	rs35712350	chr5:90679519	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.08	10.13	0.67	6.16e-18	Smoking behavior;
TGCT	cis	rs7909074	1.000	rs4948925	chr10:45392455	C/T	cg05187965	chr10:45406764	TMEM72	-0.24	-5.28	-0.43	5.7e-7	Mean corpuscular volume;
TGCT	cis	rs7474896	0.561	rs2474603	chr10:38445682	C/T	cg25427524	chr10:38739819	LOC399744	-0.35	-4.55	-0.38	1.24e-5	Obesity (extreme);
TGCT	cis	rs7959452	0.532	rs2291005	chr12:69764388	A/G	cg20891283	chr12:69753455	YEATS4	0.83	8.61	0.61	2.8e-14	Blood protein levels;
TGCT	cis	rs7772486	0.597	rs1970306	chr6:146154543	A/G	cg23711669	chr6:146136114	FBXO30	0.76	7.12	0.54	7.61e-11	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4242434	0.889	rs4592028	chr8:22449484	T/C	cg03733263	chr8:22462867	KIAA1967	1.15	18.4	0.86	2.98e-37	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs4900538	0.855	rs762105	chr14:102830175	A/G	cg18135206	chr14:102964638	TECPR2	-0.2	-4.55	-0.38	1.28e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg13770153	chr20:60521292	NA	-0.6	-7.89	-0.58	1.37e-12	Body mass index;
TGCT	cis	rs2204008	0.715	rs11525003	chr12:38332359	G/A	cg13010199	chr12:38710504	ALG10B	0.58	4.55	0.38	1.26e-5	Bladder cancer;
TGCT	cis	rs7666738	0.830	rs1426665	chr4:99027764	C/T	cg05340658	chr4:99064831	C4orf37	0.51	5.82	0.46	4.75e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3741404	0.560	rs2875748	chr11:63915537	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.77	-7.46	-0.56	1.34e-11	Platelet count;
TGCT	cis	rs763121	0.853	rs6001182	chr22:39047443	A/G	cg06022373	chr22:39101656	GTPBP1	0.77	7.46	0.56	1.35e-11	Menopause (age at onset);
TGCT	cis	rs7959452	0.558	rs1478464	chr12:69779789	G/C	cg14784868	chr12:69753453	YEATS4	0.84	8.95	0.63	4.25e-15	Blood protein levels;
TGCT	cis	rs4689592	0.503	rs11945642	chr4:7051065	G/C	cg26116260	chr4:7069785	GRPEL1	-1.02	-8.21	-0.59	2.41e-13	Monocyte percentage of white cells;
TGCT	cis	rs7917772	0.503	rs11191325	chr10:104302933	G/A	cg05855489	chr10:104503620	C10orf26	-0.58	-5.06	-0.41	1.47e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs4788570	0.655	rs7359478	chr16:71825445	A/G	cg06353428	chr16:71660113	MARVELD3	1.53	12.59	0.75	6.48e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs12701220	0.894	rs12701348	chr7:1039457	C/T	cg27454412	chr7:1067447	C7orf50	-0.46	-4.44	-0.37	1.95e-5	Bronchopulmonary dysplasia;
TGCT	cis	rs9910055	0.529	rs228764	chr17:42185469	A/G	cg19774624	chr17:42201019	HDAC5	0.75	7.12	0.54	7.85e-11	Total body bone mineral density;
TGCT	cis	rs9467773	0.620	rs2504567	chr6:26662920	C/G	cg02458000	chr6:26745757	NA	0.51	4.66	0.39	8.19e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg11890956	chr21:40555474	PSMG1	1.1	12.31	0.74	2.99e-23	Cognitive function;
TGCT	cis	rs2658782	1.000	rs2019814	chr11:93168885	A/G	cg15737290	chr11:93063684	CCDC67	0.79	5.61	0.45	1.24e-7	Pulmonary function decline;
TGCT	cis	rs2692947	0.795	rs2252697	chr2:96778190	G/C	cg05933789	chr2:97190408	NA	-0.16	-4.78	-0.39	4.79e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs1997103	1.000	rs6953494	chr7:55412157	G/A	cg17469321	chr7:55412551	NA	0.65	6.75	0.52	5.08e-10	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs11031096	0.655	rs12275634	chr11:4211754	T/G	cg18678763	chr11:4115507	RRM1	-0.45	-5.77	-0.46	6.11e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg01416388	chr22:39784598	NA	-0.72	-7.15	-0.54	6.43e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg01802117	chr1:53393560	SCP2	0.42	4.92	0.4	2.69e-6	Monocyte count;
TGCT	cis	rs8062405	0.573	rs7187575	chr16:28990101	C/T	cg01117621	chr16:28073818	GSG1L	-0.37	-4.73	-0.39	6.13e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg03709012	chr19:19516395	GATAD2A	0.74	6.07	0.48	1.44e-8	Tonsillectomy;
TGCT	cis	rs2153535	0.580	rs9328478	chr6:8519183	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.55e-8	Motion sickness;
TGCT	cis	rs7772486	0.686	rs1337841	chr6:146059487	A/G	cg13319975	chr6:146136371	FBXO30	0.52	4.73	0.39	6.06e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs700651	0.789	rs1813106	chr2:198880589	A/G	cg00792783	chr2:198669748	PLCL1	0.59	5.34	0.43	4.33e-7	Intracranial aneurysm;
TGCT	cis	rs2301573	1.000	rs2301573	chr3:129305919	A/G	cg12216435	chr3:128995479	COPG	0.38	4.66	0.39	7.98e-6	Hip circumference;
TGCT	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg08280861	chr8:58055591	NA	0.35	4.72	0.39	6.16e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs875971	1.000	rs1183245	chr7:65541185	C/T	cg11764359	chr7:65958608	NA	-0.56	-4.7	-0.39	6.74e-6	Aortic root size;
TGCT	cis	rs7940866	0.803	rs1865296	chr11:130882944	C/T	cg12179176	chr11:130786555	SNX19	-0.6	-5.82	-0.46	4.67e-8	Schizophrenia;
TGCT	cis	rs908922	0.676	rs945789	chr1:152512705	C/A	cg20991723	chr1:152506922	NA	0.46	6.18	0.48	8.66e-9	Hair morphology;
TGCT	cis	rs727563	0.638	rs5996058	chr22:42141452	A/G	cg17554472	chr22:41940697	POLR3H	0.48	5.02	0.41	1.73e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs10479542	0.806	rs4700836	chr5:178976393	A/G	cg09060608	chr5:178986726	RUFY1	0.47	5.25	0.43	6.34e-7	Lung cancer;
TGCT	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg05368731	chr17:41323189	NBR1	1.16	13.44	0.77	5.9e-26	Menopause (age at onset);
TGCT	cis	rs6598955	0.671	rs17162105	chr1:26591255	A/G	cg04990556	chr1:26633338	UBXN11	0.64	4.91	0.4	2.78e-6	Obesity-related traits;
TGCT	trans	rs66573146	0.831	rs56300156	chr4:6990813	G/C	cg07817883	chr1:32538562	TMEM39B	1.32	6.94	0.53	1.92e-10	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg00149659	chr3:10157352	C3orf10	0.78	4.99	0.41	2.04e-6	Alzheimer's disease;
TGCT	cis	rs9640161	0.789	rs10282458	chr7:150045302	C/T	cg17279839	chr7:150038598	RARRES2	0.43	4.64	0.38	8.89e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg27535305	chr1:53392650	SCP2	0.26	5.09	0.42	1.28e-6	Monocyte count;
TGCT	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.68	5.62	0.45	1.18e-7	Tonsillectomy;
TGCT	cis	rs367943	1.000	rs348960	chr5:112820651	C/A	cg12552261	chr5:112820674	MCC	0.24	4.91	0.4	2.81e-6	Type 2 diabetes;
TGCT	cis	rs74233809	1.000	rs77787671	chr10:104776205	C/T	cg05855489	chr10:104503620	C10orf26	0.76	4.53	0.38	1.36e-5	Birth weight;
TGCT	cis	rs76419734	0.614	rs17035936	chr4:106525864	T/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.82	4.66	0.39	7.91e-6	Post bronchodilator FEV1;
TGCT	cis	rs7246967	0.611	rs12978511	chr19:22819216	C/T	cg05241461	chr19:22816980	ZNF492	0.71	4.79	0.4	4.6e-6	Bronchopulmonary dysplasia;
TGCT	cis	rs7659604	1.000	rs6846232	chr4:122664805	A/G	cg19748678	chr4:122722346	EXOSC9	0.57	5.5	0.44	2.07e-7	Type 2 diabetes;
TGCT	cis	rs3617	0.652	rs7630552	chr3:52891570	G/C	cg05573699	chr3:52720067	GNL3;PBRM1	0.49	4.79	0.4	4.67e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2295359	0.892	rs4655687	chr1:67649946	C/T	cg12940439	chr1:67600707	NA	0.6	6.28	0.49	5.25e-9	Psoriasis;
TGCT	cis	rs892961	0.932	rs2170863	chr17:75415037	C/T	cg05865280	chr17:75406074	SEPT9	0.29	6.98	0.53	1.61e-10	Airflow obstruction;
TGCT	cis	rs17767294	0.708	rs72851139	chr6:28042698	G/T	cg08851530	chr6:28072375	NA	1.56	7.21	0.54	4.9e-11	Parkinson's disease;
TGCT	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.72	-6.47	-0.5	2.04e-9	Tonsillectomy;
TGCT	cis	rs7786808	0.552	rs35809824	chr7:158185067	C/T	cg01191920	chr7:158217561	PTPRN2	-0.36	-5.36	-0.43	3.86e-7	Obesity-related traits;
TGCT	cis	rs782590	0.837	rs782573	chr2:55912961	T/C	cg03859395	chr2:55845619	SMEK2	0.81	9.36	0.64	4.35e-16	Metabolic syndrome;
TGCT	trans	rs2688608	0.592	rs7909544	chr10:75484004	G/C	cg13918328	chr10:52500089	ASAH2B	0.68	6.7	0.52	6.48e-10	Inflammatory bowel disease;
TGCT	cis	rs11118844	0.843	rs12144586	chr1:221919378	A/G	cg04222084	chr1:221915650	DUSP10	-0.78	-5.42	-0.44	2.99e-7	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
TGCT	cis	rs6547741	0.816	rs10201652	chr2:27874332	A/C	cg27432699	chr2:27873401	GPN1	-0.24	-6.14	-0.48	1.04e-8	Oral cavity cancer;
TGCT	trans	rs797680	0.856	rs7512911	chr1:93715818	C/G	cg27528825	chr2:159282178	CCDC148	0.35	6.88	0.53	2.65e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs7666738	0.830	rs13125432	chr4:98961253	G/A	cg17366294	chr4:99064904	C4orf37	0.74	7.56	0.56	7.89e-12	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg05064044	chr6:292385	DUSP22	-0.71	-7.27	-0.55	3.45e-11	Menopause (age at onset);
TGCT	cis	rs66887589	0.592	rs28580295	chr4:120278873	C/T	cg09307838	chr4:120376055	NA	0.46	4.59	0.38	1.09e-5	Diastolic blood pressure;
TGCT	cis	rs3857536	0.605	rs36040831	chr6:66876588	G/A	cg07460842	chr6:66804631	NA	-0.52	-4.49	-0.37	1.6e-5	Blood trace element (Cu levels);
TGCT	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg07507251	chr3:52567010	NT5DC2	0.48	6.95	0.53	1.82e-10	Bipolar disorder;
TGCT	cis	rs35883536	0.967	rs9434126	chr1:101106981	A/G	cg06223162	chr1:101003688	GPR88	-0.29	-4.86	-0.4	3.53e-6	Monocyte count;
TGCT	cis	rs7223966	1.000	rs8066719	chr17:61825764	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	4.68	0.39	7.5e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs13336428	0.730	rs3946124	chr16:1525779	A/G	cg26690334	chr16:1524521	CLCN7	0.39	6.93	0.53	2.03e-10	Bone mineral density;
TGCT	cis	rs35934224	0.783	rs34545894	chr22:19857942	C/G	cg11182965	chr22:19864308	TXNRD2	-0.36	-5.02	-0.41	1.73e-6	Glaucoma (primary open-angle);
TGCT	trans	rs459571	0.876	rs2520095	chr9:136919568	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.79	-8.59	-0.61	3.1e-14	Platelet distribution width;
TGCT	cis	rs42648	0.837	rs3761804	chr7:89915338	C/T	cg25739043	chr7:89950458	NA	-0.59	-5.73	-0.46	7.21e-8	Homocysteine levels;
TGCT	cis	rs1215050	0.791	rs165254	chr4:98763564	C/T	cg05340658	chr4:99064831	C4orf37	0.44	5.52	0.44	1.85e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7949030	0.765	rs11553576	chr11:62378801	T/C	cg22862634	chr11:62369728	EML3;MTA2	0.69	8.69	0.62	1.83e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7264396	0.747	rs73283043	chr20:34383863	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.3	-5.25	-0.43	6.36e-7	Total cholesterol levels;
TGCT	cis	rs11190604	1.000	rs2295780	chr10:102305965	A/G	cg23241863	chr10:102295624	HIF1AN	0.67	4.88	0.4	3.22e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs10089	1.000	rs1842006	chr5:127508687	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.85	8.27	0.6	1.8e-13	Ileal carcinoids;
TGCT	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg11494091	chr17:61959527	GH2	0.61	14.81	0.8	3.37e-29	Prudent dietary pattern;
TGCT	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg18654377	chr3:49208889	KLHDC8B	-0.38	-4.78	-0.39	4.92e-6	Parkinson's disease;
TGCT	cis	rs899997	0.954	rs11856441	chr15:79030526	T/G	cg04896959	chr15:78267971	NA	0.35	5.11	0.42	1.18e-6	Coronary artery disease or large artery stroke;
TGCT	cis	rs7647973	0.961	rs62259943	chr3:49425167	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.59	-4.62	-0.38	9.36e-6	Menarche (age at onset);
TGCT	cis	rs9916302	0.904	rs4239222	chr17:37696235	A/C	cg07936489	chr17:37558343	FBXL20	0.63	4.85	0.4	3.67e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs6866344	0.570	rs1132336	chr5:178140090	C/T	cg10224037	chr5:178157518	ZNF354A	0.98	9.87	0.66	2.66e-17	Neutrophil percentage of white cells;
TGCT	cis	rs6684514	1.000	rs12038217	chr1:156248297	C/T	cg20302342	chr1:156215951	PAQR6	0.34	4.6	0.38	1.01e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs7552404	0.690	rs11161620	chr1:76255228	A/G	cg22875332	chr1:76189707	ACADM	-0.63	-6.81	-0.52	3.72e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs6845621	0.727	rs10032307	chr4:18911775	T/C	cg12196642	chr4:18937545	NA	-0.25	-4.48	-0.37	1.69e-5	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
TGCT	cis	rs317689	0.876	rs547332	chr12:69743639	C/G	cg11871910	chr12:69753446	YEATS4	0.59	5.19	0.42	8.46e-7	Response to diuretic therapy;
TGCT	cis	rs2153535	0.580	rs915351	chr6:8442793	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.58	0.45	1.42e-7	Motion sickness;
TGCT	cis	rs35146811	0.735	rs1727140	chr7:99815399	T/A	cg04778012	chr7:99775508	STAG3;GPC2	-0.35	-4.93	-0.41	2.55e-6	Coronary artery disease;
TGCT	cis	rs9435341	0.965	rs1730859	chr1:107617707	A/G	cg09367891	chr1:107599246	PRMT6	0.61	5.21	0.42	7.69e-7	Facial morphology (factor 21, depth of nasal alae);
TGCT	cis	rs4819052	0.851	rs2838867	chr21:46713092	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	6.73	0.52	5.66e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9952991	0.566	rs534911	chr18:12857335	G/A	cg23598886	chr18:12777645	NA	0.55	4.77	0.39	5.06e-6	Inflammatory skin disease;
TGCT	cis	rs514406	0.505	rs7543239	chr1:53162416	A/G	cg25767906	chr1:53392781	SCP2	-0.45	-4.85	-0.4	3.64e-6	Monocyte count;
TGCT	cis	rs11971779	0.590	rs59602547	chr7:139117023	G/A	cg07862535	chr7:139043722	LUC7L2	0.66	5.07	0.41	1.42e-6	Diisocyanate-induced asthma;
TGCT	cis	rs7615952	0.932	rs9841157	chr3:125635655	C/A	cg05084668	chr3:125655381	ALG1L	-0.63	-4.49	-0.37	1.58e-5	Blood pressure (smoking interaction);
TGCT	cis	rs28493229	0.881	rs73931345	chr19:41180347	G/A	cg11601297	chr19:41224147	ITPKC;ADCK4	0.59	5.69	0.46	8.61e-8	Kawasaki disease;
TGCT	cis	rs16854884	0.739	rs56196484	chr3:143786160	G/T	cg06585982	chr3:143692056	C3orf58	0.59	4.74	0.39	5.84e-6	Economic and political preferences (feminism/equality);
TGCT	cis	rs651907	0.535	rs35810977	chr3:101531380	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.86	10.47	0.68	9.31e-19	Colorectal cancer;
TGCT	cis	rs6448317	0.906	rs4053966	chr4:24901466	A/G	cg21108841	chr4:24914750	CCDC149	-0.66	-5.52	-0.44	1.89e-7	Heschl's gyrus morphology;
TGCT	cis	rs7267979	0.932	rs446649	chr20:25467359	A/G	cg14121845	chr20:25566513	NINL	0.51	5.7	0.46	8.26e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1499614	1.000	rs2707830	chr7:66167645	T/C	cg18252515	chr7:66147081	NA	-1.26	-7.95	-0.58	9.71e-13	Gout;
TGCT	cis	rs986417	0.901	rs7159628	chr14:61010688	A/C	cg27398547	chr14:60952738	C14orf39	1.42	8.85	0.62	7.44e-15	Gut microbiota (bacterial taxa);
TGCT	cis	rs56399783	0.901	rs11764225	chr7:2775607	G/A	cg19731401	chr7:2775893	GNA12	0.35	4.97	0.41	2.18e-6	Childhood ear infection;
TGCT	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg21017887	chr14:105400489	NA	0.38	5.42	0.44	3.03e-7	Rheumatoid arthritis;
TGCT	cis	rs910316	0.836	rs6574212	chr14:75671659	G/A	cg11812906	chr14:75593930	NEK9	-0.63	-6.15	-0.48	9.66e-9	Height;
TGCT	cis	rs9467773	1.000	rs6940053	chr6:26562122	C/T	cg09904177	chr6:26538194	HMGN4	0.66	6.6	0.51	1.05e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	5.71	0.46	8.05e-8	Alzheimer's disease;
TGCT	trans	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg11887960	chr12:57824829	NA	1.1	9.44	0.65	2.89e-16	Lung disease severity in cystic fibrosis;
TGCT	cis	rs941764	0.830	rs6575189	chr14:91840267	C/T	cg10511902	chr14:91842949	CCDC88C	0.29	4.47	0.37	1.76e-5	Breast cancer;
TGCT	cis	rs9549260	0.753	rs61963266	chr13:41171036	G/A	cg21288729	chr13:41239152	FOXO1	0.67	4.68	0.39	7.31e-6	Red blood cell count;
TGCT	cis	rs7312933	0.703	rs10880259	chr12:42558003	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	5.06	0.41	1.45e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg06634786	chr22:41940651	POLR3H	0.87	8.25	0.6	1.92e-13	Vitiligo;
TGCT	cis	rs8031584	0.723	rs711224	chr15:31127921	G/C	cg14829155	chr15:31115871	NA	0.37	4.86	0.4	3.43e-6	Huntington's disease progression;
TGCT	cis	rs453301	0.658	rs9329175	chr8:8866661	C/T	cg00184457	chr8:8946301	NA	-0.25	-4.67	-0.39	7.61e-6	Joint mobility (Beighton score);
TGCT	trans	rs6762477	0.748	rs11711407	chr3:50225029	A/G	cg21659725	chr3:3221576	CRBN	-0.66	-7.62	-0.56	5.68e-12	Menarche (age at onset);
TGCT	cis	rs5769765	0.862	rs9616384	chr22:50313082	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.24	-12.97	-0.76	7.81e-25	Schizophrenia;
TGCT	cis	rs2970818	0.831	rs2907499	chr12:4616901	G/T	cg02722637	chr12:4922070	KCNA6	-0.32	-4.59	-0.38	1.05e-5	Phosphorus levels;
TGCT	cis	rs9372498	0.536	rs72952733	chr6:118834452	A/G	cg21191810	chr6:118973309	C6orf204	-0.37	-4.8	-0.4	4.4e-6	Diastolic blood pressure;
TGCT	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	5.02	0.41	1.78e-6	Prudent dietary pattern;
TGCT	cis	rs2228479	0.557	rs2293584	chr16:89888686	C/G	cg06558623	chr16:89946397	TCF25	0.55	4.79	0.4	4.69e-6	Skin colour saturation;
TGCT	cis	rs7432375	1.000	rs6439649	chr3:136371691	G/T	cg12473912	chr3:136751656	NA	-0.34	-4.93	-0.41	2.55e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs11792861	0.816	rs17792434	chr9:111667319	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.52	4.95	0.41	2.4e-6	Menarche (age at onset);
TGCT	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg11764359	chr7:65958608	NA	0.61	5.53	0.44	1.84e-7	Aortic root size;
TGCT	cis	rs6594499	0.564	rs12518884	chr5:110452223	A/G	cg04022379	chr5:110408740	TSLP	0.6	6.19	0.49	8.11e-9	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs78487399	0.808	rs7570242	chr2:43706002	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.42	-5.56	-0.45	1.57e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg23262073	chr20:60523788	NA	0.35	5.54	0.45	1.75e-7	Obesity-related traits;
TGCT	cis	rs7681440	0.647	rs1372508	chr4:90819786	C/G	cg10208370	chr4:90758469	SNCA	0.58	5.58	0.45	1.45e-7	Dementia with Lewy bodies;
TGCT	cis	rs2729354	0.817	rs2649667	chr11:57270509	A/C	cg24343310	chr11:57249947	NA	0.28	4.6	0.38	1.03e-5	Blood protein levels;
TGCT	cis	rs9325144	0.600	rs1825807	chr12:38737007	T/C	cg26384229	chr12:38710491	ALG10B	0.62	5.66	0.45	1e-7	Morning vs. evening chronotype;
TGCT	cis	rs9443645	0.901	rs1027813	chr6:79552118	G/T	cg05283184	chr6:79620031	NA	0.2	4.67	0.39	7.71e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.679	rs1596142	chr8:58032406	G/A	cg08280861	chr8:58055591	NA	0.35	5.07	0.41	1.43e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7666738	0.830	rs1120708	chr4:98931260	G/C	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg18252515	chr7:66147081	NA	-1.31	-8.18	-0.59	2.87e-13	Diabetic kidney disease;
TGCT	cis	rs10791097	0.967	rs6590512	chr11:130717916	A/G	cg05962950	chr11:130786565	SNX19	-0.7	-7.23	-0.54	4.26e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7904368	0.951	rs7074647	chr10:16855455	T/C	cg14835575	chr10:16859367	RSU1	0.63	6.53	0.51	1.49e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
TGCT	cis	rs17387100	0.901	rs73230220	chr4:15982382	G/A	cg13480465	chr4:16795757	LDB2	-0.44	-5.08	-0.42	1.35e-6	Suicide attempts in depression or bipolar disorder;
TGCT	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg04317338	chr11:64019027	PLCB3	0.79	6.5	0.5	1.77e-9	Mean platelet volume;
TGCT	cis	rs3935685	0.874	rs35028279	chr15:78003542	T/C	cg03457338	chr15:78040120	NA	-0.22	-5.59	-0.45	1.35e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs826838	0.651	rs1843896	chr12:38612913	G/C	cg26384229	chr12:38710491	ALG10B	0.65	6.07	0.48	1.44e-8	Heart rate;
TGCT	cis	rs2692947	0.740	rs4907280	chr2:96402126	A/G	cg23100626	chr2:96804247	ASTL	0.37	4.49	0.37	1.62e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs2115630	1.000	rs7183401	chr15:85371944	G/T	cg17173187	chr15:85201210	NMB	-0.38	-4.62	-0.38	9.33e-6	P wave terminal force;
TGCT	cis	rs9916302	0.904	rs801419	chr17:37466327	A/G	cg07936489	chr17:37558343	FBXL20	0.63	4.91	0.4	2.83e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs4711350	0.862	rs570749	chr6:33710229	C/T	cg00334056	chr6:33755658	LEMD2	0.31	4.81	0.4	4.31e-6	Schizophrenia;
TGCT	cis	rs2070433	0.706	rs3788265	chr21:47833789	G/T	cg12379764	chr21:47803548	PCNT	0.63	5.32	0.43	4.64e-7	Lymphocyte counts;
TGCT	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg22535103	chr8:58192502	C8orf71	-0.42	-4.79	-0.4	4.7e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6088590	1.000	rs6088595	chr20:33358499	T/A	cg24642439	chr20:33292090	TP53INP2	0.68	6.02	0.48	1.83e-8	Coronary artery disease;
TGCT	cis	rs2013441	1.000	rs2703821	chr17:20121526	C/T	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.61	-0.38	9.96e-6	Obesity-related traits;
TGCT	cis	rs7833790	0.724	rs12676336	chr8:82771008	C/T	cg23324259	chr8:82754387	SNX16	0.62	4.71	0.39	6.47e-6	Diastolic blood pressure;
TGCT	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg27286337	chr10:134555280	INPP5A	0.45	5.32	0.43	4.64e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs12643440	0.538	rs1522080	chr4:17135354	G/C	cg22650099	chr4:17144496	NA	-0.46	-4.66	-0.39	8.14e-6	Metabolite levels (Pyroglutamine);
TGCT	trans	rs1864982	0.685	rs1368379	chr5:146213535	A/C	cg07017998	chr4:733617	PCGF3	0.28	6.88	0.53	2.68e-10	Alcohol dependence;
TGCT	cis	rs12477438	0.501	rs17759607	chr2:99737005	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	10.3	0.68	2.42e-18	Chronic sinus infection;
TGCT	cis	rs2073300	1.000	rs6106669	chr20:23460328	C/T	cg09953122	chr20:23471693	CST8	-0.66	-4.67	-0.39	7.68e-6	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs7729723	0.591	rs6890204	chr5:137818178	T/C	cg19169342	chr5:137827400	NA	0.35	4.99	0.41	1.97e-6	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);
TGCT	cis	rs7017914	0.846	rs6472561	chr8:71955183	A/T	cg23757474	chr8:71581111	LACTB2;XKR9	0.55	5.11	0.42	1.17e-6	Bone mineral density;
TGCT	cis	rs877282	0.853	rs12779017	chr10:763619	T/C	cg17470449	chr10:769945	NA	0.37	5.59	0.45	1.37e-7	Uric acid levels;
TGCT	cis	rs62244186	0.659	rs62251383	chr3:44552421	A/G	cg17546649	chr3:44802566	KIF15;KIAA1143	-0.37	-4.44	-0.37	1.99e-5	Depressive symptoms;
TGCT	cis	rs79976124	0.719	rs34488909	chr6:66637850	T/C	cg07460842	chr6:66804631	NA	0.58	5.12	0.42	1.14e-6	Type 2 diabetes;
TGCT	cis	rs7917772	0.582	rs7907760	chr10:104345197	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	5.36	0.43	3.84e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7267979	1.000	rs6037121	chr20:25428311	G/A	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7666738	0.830	rs6818045	chr4:99049374	G/A	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7226408	0.857	rs11665258	chr18:34508112	T/C	cg06757138	chr18:34340585	FHOD3	0.25	4.8	0.4	4.39e-6	Obesity-related traits;
TGCT	cis	rs35000415	0.938	rs17424602	chr7:128687940	A/G	cg06242719	chr7:129414860	MIR183;MIR96	-0.32	-4.46	-0.37	1.83e-5	Systemic lupus erythematosus;
TGCT	trans	rs2727020	0.635	rs7124266	chr11:49280857	T/G	cg15704280	chr7:45808275	SEPT13	0.73	8.06	0.59	5.51e-13	Coronary artery disease;
TGCT	cis	rs7772486	0.597	rs7746618	chr6:146281367	T/C	cg05347473	chr6:146136440	FBXO30	-0.65	-6.15	-0.48	9.86e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7010267	0.596	rs1905777	chr8:120021840	A/T	cg17171407	chr8:119960777	TNFRSF11B	0.25	4.45	0.37	1.87e-5	Total body bone mineral density (age 45-60);
TGCT	cis	rs986417	0.748	rs10147346	chr14:61083334	G/C	cg27398547	chr14:60952738	C14orf39	1.33	9.79	0.66	4e-17	Gut microbiota (bacterial taxa);
TGCT	trans	rs62103177	0.810	rs62103195	chr18:77629693	T/C	cg05926928	chr17:57297772	GDPD1	1.21	10.83	0.7	1.23e-19	Opioid sensitivity;
TGCT	cis	rs3796619	0.503	rs1466216	chr4:1071907	C/T	cg27284194	chr4:1044797	NA	-0.71	-8.06	-0.59	5.44e-13	Recombination rate (males);
TGCT	cis	rs860295	0.529	rs17385065	chr1:155976388	A/G	cg05700447	chr1:155978627	NA	-0.19	-4.75	-0.39	5.57e-6	Body mass index;
TGCT	cis	rs751728	1.000	rs3793079	chr6:33767788	T/A	cg13859433	chr6:33739653	LEMD2	-0.39	-7.23	-0.54	4.25e-11	Crohn's disease;
TGCT	cis	rs10089	0.953	rs7713860	chr5:127428789	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.8	7.74	0.57	3.04e-12	Ileal carcinoids;
TGCT	cis	rs9503598	0.714	rs11242859	chr6:3454032	G/A	cg00476032	chr6:3446245	SLC22A23	0.17	4.98	0.41	2.11e-6	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
TGCT	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg03396347	chr1:1875803	NA	-0.36	-6.48	-0.5	1.93e-9	Body mass index;
TGCT	cis	rs3935685	0.845	rs7175083	chr15:78006842	T/C	cg03457338	chr15:78040120	NA	-0.22	-5.75	-0.46	6.67e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7474896	0.583	rs7071147	chr10:38003376	T/C	cg25427524	chr10:38739819	LOC399744	-0.34	-5.47	-0.44	2.43e-7	Obesity (extreme);
TGCT	cis	rs6570726	0.791	rs2096201	chr6:145934273	C/T	cg13319975	chr6:146136371	FBXO30	-0.53	-4.75	-0.39	5.62e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg12963246	chr6:28129442	ZNF389	0.51	4.6	0.38	1.01e-5	Depression;
TGCT	cis	rs3617	0.625	rs7620690	chr3:52891707	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	0.49	4.79	0.4	4.67e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12220238	0.841	rs11001001	chr10:76097678	G/T	cg19889307	chr10:75911429	ADK;AP3M1	0.88	6.38	0.5	3.27e-9	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs7666738	0.546	rs10018080	chr4:98758436	C/A	cg05340658	chr4:99064831	C4orf37	0.52	5.76	0.46	6.27e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4746818	1.000	rs7901617	chr10:70904063	C/T	cg04149295	chr10:70884716	VPS26A	0.76	5.36	0.43	3.98e-7	Left atrial antero-posterior diameter;
TGCT	cis	rs548181	0.673	rs12288034	chr11:125570941	A/T	cg03464685	chr11:125439445	EI24	-1.42	-9.3	-0.64	6.36e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs72843506	0.722	rs9902683	chr17:20015428	G/A	cg18979559	chr17:20280153	CCDC144C	-0.64	-4.8	-0.4	4.5e-6	Schizophrenia;
TGCT	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg03264133	chr6:25882463	NA	-0.53	-5.65	-0.45	1.06e-7	Height;
TGCT	cis	rs1018836	0.828	rs10956730	chr8:91597428	T/G	cg16814680	chr8:91681699	NA	-0.69	-6.92	-0.53	2.14e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs17102423	0.964	rs868814	chr14:65584508	C/T	cg11161011	chr14:65562177	MAX	-0.46	-6.43	-0.5	2.45e-9	Obesity-related traits;
TGCT	trans	rs931812	0.858	rs4734017	chr8:101912073	C/T	cg20993868	chr7:22813445	NA	0.39	8.11	0.59	4.2e-13	Attention deficit hyperactivity disorder and conduct disorder;
TGCT	cis	rs10788575	0.950	rs79252540	chr10:89749671	G/A	cg03166508	chr10:89453226	PAPSS2	0.35	4.85	0.4	3.69e-6	Type 2 diabetes;
TGCT	cis	rs1005224	0.889	rs9323617	chr14:76158638	A/G	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.53	-4.57	-0.38	1.16e-5	Large artery stroke;
TGCT	cis	rs9549367	0.789	rs2302754	chr13:113898385	C/T	cg00898013	chr13:113819073	PROZ	0.4	4.94	0.41	2.45e-6	Platelet distribution width;
TGCT	cis	rs8072100	0.713	rs9895776	chr17:45486003	A/G	cg08085267	chr17:45401833	C17orf57	-0.52	-5.75	-0.46	6.48e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	trans	rs2727020	0.729	rs4980439	chr11:49342246	G/C	cg15704280	chr7:45808275	SEPT13	-0.69	-7.78	-0.57	2.45e-12	Coronary artery disease;
TGCT	cis	rs3774830	0.748	rs58854245	chr4:5466134	G/A	cg26943120	chr4:5472116	STK32B	0.23	5.08	0.42	1.34e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg04156016	chr5:1868137	NA	0.33	4.77	0.39	5.05e-6	Cardiovascular disease risk factors;
TGCT	cis	rs4252435	0.520	rs7797908	chr7:142641207	T/C	cg21621906	chr7:142494914	NA	-1.08	-4.53	-0.38	1.36e-5	Cancer;
TGCT	cis	rs6845621	0.727	rs13119001	chr4:18878532	T/A	cg12196642	chr4:18937545	NA	-0.24	-4.47	-0.37	1.74e-5	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
TGCT	cis	rs12220898	0.749	rs10732631	chr10:50485910	T/C	cg09603381	chr10:49954066	WDFY4	0.38	4.45	0.37	1.88e-5	Inflammatory biomarkers;
TGCT	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg08280861	chr8:58055591	NA	0.4	4.67	0.39	7.79e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7000551	0.619	rs2443506	chr8:22373383	T/C	cg12081754	chr8:22256438	SLC39A14	0.3	4.72	0.39	6.19e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs2688608	0.620	rs7098444	chr10:75580042	C/T	cg04320760	chr10:75533139	FUT11	-0.37	-5.72	-0.46	7.3900000000000007e-08	Inflammatory bowel disease;
TGCT	cis	rs651907	0.640	rs1091664	chr3:101618690	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.63	6.01	0.47	1.92e-8	Colorectal cancer;
TGCT	cis	rs7100689	0.646	rs4357632	chr10:82131783	C/T	cg01528321	chr10:82214614	TSPAN14	0.8	7.76	0.57	2.7e-12	Post bronchodilator FEV1;
TGCT	cis	rs4746818	1.000	rs4284308	chr10:70884861	C/T	cg11621586	chr10:70884670	VPS26A	1.18	10.97	0.7	5.39e-20	Left atrial antero-posterior diameter;
TGCT	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg16414030	chr3:133502952	NA	-0.61	-9.55	-0.65	1.59e-16	Iron status biomarkers;
TGCT	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg25767906	chr1:53392781	SCP2	0.46	5.18	0.42	8.88e-7	Monocyte count;
TGCT	cis	rs524281	0.861	rs6591207	chr11:65949674	A/T	cg00563793	chr11:65837595	PACS1	0.57	4.99	0.41	2.02e-6	Electroencephalogram traits;
TGCT	cis	rs7809950	0.954	rs2520242	chr7:107136320	G/T	cg23024343	chr7:107201750	COG5	0.35	5.5	0.44	2.05e-7	Coronary artery disease;
TGCT	cis	rs4699052	1.000	rs4699052	chr4:104137790	C/T	cg16532752	chr4:104119610	CENPE	-0.59	-5.56	-0.45	1.56e-7	Testicular germ cell tumor;
TGCT	cis	rs4234284	0.556	rs4679147	chr3:126955702	C/T	cg25436886	chr3:127056972	NA	-0.47	-4.58	-0.38	1.1e-5	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
TGCT	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.97	7.19	0.54	5.48e-11	Gut microbiome composition (summer);
TGCT	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-1.04	-12.56	-0.75	7.35e-24	Height;
TGCT	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg03452623	chr4:187889614	NA	-0.36	-5.49	-0.44	2.17e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg11062466	chr8:58055876	NA	0.43	4.52	0.38	1.45e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs4499344	0.633	rs259258	chr19:33152523	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.85	9.09	0.63	2.01e-15	Mean platelet volume;
TGCT	cis	rs7666738	0.546	rs10025064	chr4:98914060	A/G	cg05340658	chr4:99064831	C4orf37	0.59	6.52	0.51	1.62e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11122272	0.735	rs2790877	chr1:231535427	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-6.47	-0.5	2.07e-9	Hemoglobin concentration;
TGCT	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	5.02	0.41	1.78e-6	Prudent dietary pattern;
TGCT	cis	rs9682041	0.696	rs35177863	chr3:170090006	A/G	cg11886554	chr3:170076028	SKIL	0.6	4.76	0.39	5.35e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs11098499	0.754	rs714899	chr4:120243035	G/A	cg09307838	chr4:120376055	NA	0.61	5.91	0.47	3.14e-8	Corneal astigmatism;
TGCT	cis	rs6665290	0.835	rs7549586	chr1:227214566	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.98	-20.31	-0.88	2.98e-41	Myeloid white cell count;
TGCT	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg16325326	chr1:53192061	ZYG11B	-0.58	-6.76	-0.52	4.76e-10	Monocyte count;
TGCT	cis	rs62244186	0.545	rs725866	chr3:44765533	A/G	cg21672276	chr3:44754072	ZNF502	-0.54	-6.25	-0.49	5.94e-9	Depressive symptoms;
TGCT	cis	rs3892630	0.588	rs2287881	chr19:33333155	A/G	cg22980127	chr19:33182716	NUDT19	-0.7	-5.94	-0.47	2.72e-8	Red blood cell traits;
TGCT	cis	rs28595532	0.841	rs114965278	chr4:119743694	T/A	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.99	8.17	0.59	3.09e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7937682	1.000	rs2186839	chr11:111534442	T/G	cg09085632	chr11:111637200	PPP2R1B	-1.05	-10.05	-0.67	9.54e-18	Primary sclerosing cholangitis;
TGCT	cis	rs308447	0.522	rs309363	chr4:123658169	C/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.73	6.85	0.52	3e-10	Perceived unattractiveness to mosquitoes;
TGCT	cis	rs3764400	0.567	rs2240120	chr17:46142144	C/T	cg02340556	chr17:46797764	NA	0.41	4.47	0.37	1.72e-5	Body mass index;
TGCT	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg12042659	chr19:58951599	ZNF132	0.52	4.66	0.39	7.87e-6	Uric acid clearance;
TGCT	cis	rs3087591	0.919	rs2953004	chr17:29502723	C/T	cg24425628	chr17:29625626	OMG;NF1	0.42	6.17	0.48	8.91e-9	Hip circumference;
TGCT	cis	rs11626933	1.000	rs61989986	chr14:90739180	G/A	cg14092571	chr14:90743983	NA	-0.3	-6.23	-0.49	6.81e-9	Gut microbiota (bacterial taxa);
TGCT	cis	rs4366490	0.796	rs1939756	chr11:62904525	A/G	cg21002970	chr11:62369079	MTA2	0.87	4.67	0.39	7.78e-6	Conotruncal heart defects;
TGCT	cis	rs56804039	0.524	rs7003826	chr8:8406190	A/G	cg14215082	chr8:9055850	NA	-0.45	-4.65	-0.39	8.38e-6	Cervical cancer;
TGCT	cis	rs1018836	0.608	rs7843149	chr8:91474961	C/T	cg16814680	chr8:91681699	NA	-0.71	-7.18	-0.54	5.67e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs727563	0.520	rs132773	chr22:42031768	T/A	cg06481639	chr22:41940642	POLR3H	0.73	6.47	0.5	2.04e-9	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs9383153	1.000	rs9370888	chr6:16335544	A/G	cg14009473	chr6:15502099	JARID2	0.66	5.69	0.46	8.57e-8	Gambling;
TGCT	cis	rs3820068	0.705	rs4646075	chr1:15827461	T/C	cg05660106	chr1:15850417	CASP9	1.16	14.82	0.8	3.11e-29	Systolic blood pressure;
TGCT	cis	rs78487399	0.808	rs7573500	chr2:43685625	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-5.19	-0.42	8.37e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs2562456	0.755	rs1879234	chr19:21704479	T/G	cg01304269	chr19:21688519	ZNF429	-0.55	-4.59	-0.38	1.06e-5	Pain;
TGCT	cis	rs72945132	0.882	rs55915603	chr11:70210067	G/T	cg00319359	chr11:70116639	PPFIA1	0.97	7.07	0.54	1.01e-10	Coronary artery disease;
TGCT	cis	rs7666738	0.791	rs4699324	chr4:98967496	G/A	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg06221963	chr1:154839813	KCNN3	-0.79	-14.65	-0.8	7.83e-29	Prostate cancer;
TGCT	cis	rs854765	0.583	rs950966	chr17:17783748	A/G	cg09796270	chr17:17721594	SREBF1	-0.27	-5.5	-0.44	2.04e-7	Total body bone mineral density;
TGCT	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg19318889	chr4:1322082	MAEA	0.28	6.78	0.52	4.46e-10	Longevity;
TGCT	cis	rs7617773	1.000	rs6442108	chr3:48192959	G/C	cg11946769	chr3:48343235	NME6	-0.59	-5.33	-0.43	4.54e-7	Coronary artery disease;
TGCT	cis	rs832540	0.593	rs252912	chr5:56195792	C/T	cg24531977	chr5:56204891	C5orf35	-0.56	-5.15	-0.42	9.92e-7	Coronary artery disease;
TGCT	cis	rs9467773	1.000	rs9467779	chr6:26536687	A/T	cg26531700	chr6:26746687	NA	-0.47	-4.66	-0.39	7.93e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2469997	1.000	rs2447164	chr8:120371887	G/T	cg00681363	chr8:120844660	TAF2	0.69	4.48	0.37	1.64e-5	Hypertension (SNP x SNP interaction);
TGCT	trans	rs9388451	0.839	rs10457469	chr6:126083658	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.74	-8.38	-0.6	9.81e-14	Brugada syndrome;
TGCT	cis	rs6570726	0.935	rs414222	chr6:145850482	C/T	cg23711669	chr6:146136114	FBXO30	0.68	6.67	0.51	7.58e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9611565	0.802	rs4822028	chr22:41789408	A/G	cg13695892	chr22:41940480	POLR3H	-0.77	-7.47	-0.56	1.24e-11	Vitiligo;
TGCT	cis	rs78487399	0.808	rs6746632	chr2:43712163	T/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-5.14	-0.42	1.04e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs7647973	0.593	rs58339610	chr3:49845006	T/A	cg03060546	chr3:49711283	APEH	-0.62	-5.56	-0.45	1.59e-7	Menarche (age at onset);
TGCT	cis	rs4653767	1.000	rs708773	chr1:226920730	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.47	-5.26	-0.43	6.02e-7	Parkinson's disease;
TGCT	cis	rs2692947	0.568	rs57579941	chr2:96336253	T/C	cg23100626	chr2:96804247	ASTL	0.41	4.75	0.39	5.46e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs911555	0.755	rs34411783	chr14:103900639	G/A	cg12935359	chr14:103987150	CKB	0.34	4.53	0.38	1.35e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7772486	0.641	rs2253757	chr6:146199686	C/T	cg13319975	chr6:146136371	FBXO30	-0.66	-5.93	-0.47	2.83e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2153535	0.580	rs7450817	chr6:8481421	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs11122272	0.735	rs2808592	chr1:231523757	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-6.94	-0.53	1.98e-10	Hemoglobin concentration;
TGCT	cis	rs17780086	0.529	rs7406406	chr17:30220153	T/G	cg13647721	chr17:30228624	UTP6	0.6	5.32	0.43	4.72e-7	Height;
TGCT	cis	rs8084125	1.000	rs72978665	chr18:74953641	A/G	cg05528293	chr18:74961138	GALR1	0.52	5.16	0.42	9.72e-7	Obesity-related traits;
TGCT	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.55	-6.55	-0.51	1.37e-9	Birth weight;
TGCT	cis	rs7100689	0.646	rs11202724	chr10:82136190	T/C	cg01528321	chr10:82214614	TSPAN14	0.8	7.72	0.57	3.42e-12	Post bronchodilator FEV1;
TGCT	cis	rs5769707	0.967	rs5769698	chr22:49997706	A/G	cg05373962	chr22:49881684	NA	-0.31	-6.26	-0.49	5.87e-9	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs7829975	0.533	rs13274028	chr8:8729193	A/C	cg06636001	chr8:8085503	FLJ10661	0.69	6.29	0.49	4.95e-9	Mood instability;
TGCT	cis	rs7824557	0.628	rs11994376	chr8:11202960	G/A	cg21775007	chr8:11205619	TDH	0.69	6.81	0.52	3.8e-10	Retinal vascular caliber;
TGCT	cis	rs6558530	0.698	rs7015858	chr8:1724307	C/T	cg09410841	chr8:1729607	CLN8	0.87	9.95	0.67	1.7e-17	Systolic blood pressure;
TGCT	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg06873352	chr17:61820015	STRADA	0.58	6.42	0.5	2.65e-9	Prudent dietary pattern;
TGCT	cis	rs7552404	1.000	rs11161521	chr1:76216330	T/C	cg03433033	chr1:76189801	ACADM	0.81	9.52	0.65	1.84e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7829975	0.535	rs17683510	chr8:8500724	A/G	cg15556689	chr8:8085844	FLJ10661	0.54	5.15	0.42	1.01e-6	Mood instability;
TGCT	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.67	4.52	0.38	1.43e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2013441	1.000	rs3850783	chr17:20184501	C/T	cg23224458	chr17:20280056	CCDC144C	0.38	4.61	0.38	9.96e-6	Obesity-related traits;
TGCT	cis	rs7552404	0.731	rs10732723	chr1:76392437	C/T	cg22875332	chr1:76189707	ACADM	-0.68	-7.0	-0.53	1.41e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg17554472	chr22:41940697	POLR3H	0.49	5.16	0.42	9.72e-7	Vitiligo;
TGCT	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg12311346	chr5:56204834	C5orf35	0.83	7.78	0.57	2.41e-12	Initial pursuit acceleration;
TGCT	cis	rs2153535	0.580	rs2143356	chr6:8517675	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.55e-8	Motion sickness;
TGCT	cis	rs7085104	0.572	rs284857	chr10:104574063	C/T	cg05855489	chr10:104503620	C10orf26	-0.65	-6.52	-0.51	1.57e-9	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs5750830	0.645	rs4821890	chr22:39777523	G/A	cg05872129	chr22:39784769	NA	-0.9	-10.38	-0.68	1.51e-18	Intelligence (multi-trait analysis);
TGCT	cis	rs921968	0.541	rs7604319	chr2:219538799	A/C	cg02176678	chr2:219576539	TTLL4	-0.5	-6.93	-0.53	2.02e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs114540395	0.687	rs75269434	chr10:103473111	G/C	cg24291461	chr10:102749544	C10orf2	0.35	4.54	0.38	1.29e-5	Schizophrenia;
TGCT	cis	rs11030122	0.592	rs4910880	chr11:4084630	C/G	cg18678763	chr11:4115507	RRM1	-0.46	-5.67	-0.45	9.61e-8	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs3780378	0.967	rs7863219	chr9:5046548	A/C	cg02405213	chr9:5042618	JAK2	-0.59	-7.49	-0.56	1.13e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs698833	0.518	rs7562945	chr2:44552772	G/T	cg23552047	chr2:44669647	C2orf34	0.29	4.66	0.39	8.08e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
TGCT	cis	rs637571	0.522	rs679581	chr11:65746653	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.21	4.51	0.38	1.47e-5	Eosinophil percentage of white cells;
TGCT	cis	rs9640161	0.750	rs11538922	chr7:150035183	C/T	cg10018233	chr7:150070692	REPIN1	0.32	4.59	0.38	1.09e-5	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs2880765	0.835	rs4526974	chr15:86024284	C/T	cg13263323	chr15:86062960	AKAP13	-0.23	-4.99	-0.41	2e-6	Coronary artery disease;
TGCT	cis	rs11249608	0.789	rs6868425	chr5:178446708	A/G	cg01312482	chr5:178451176	ZNF879	-0.55	-5.41	-0.44	3.08e-7	Pubertal anthropometrics;
TGCT	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg16325326	chr1:53192061	ZYG11B	-0.7	-8.6	-0.61	2.93e-14	Monocyte count;
TGCT	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg15320075	chr8:145703422	NA	-0.73	-7.36	-0.55	2.21e-11	Age at first birth;
TGCT	cis	rs2034088	0.507	rs11650424	chr17:435896	C/T	cg04370829	chr17:406249	NA	-0.36	-4.47	-0.37	1.73e-5	Hip circumference adjusted for BMI;
TGCT	cis	rs9467711	1.000	rs6923139	chr6:26313348	C/T	cg02458000	chr6:26745757	NA	-1.05	-5.8	-0.46	5.29e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2224391	0.628	rs2773304	chr6:5242602	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-1.02	-6.56	-0.51	1.33e-9	Height;
TGCT	cis	rs10791097	0.653	rs11222362	chr11:130731425	T/C	cg12179176	chr11:130786555	SNX19	0.77	9.52	0.65	1.82e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs7666738	0.830	rs13129503	chr4:98987892	T/C	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs75059851	1.000	rs3758927	chr11:133829644	C/G	cg14047540	chr11:133829660	NA	0.49	5.07	0.41	1.38e-6	Schizophrenia;
TGCT	cis	rs1692580	0.807	rs10910036	chr1:2183754	C/G	cg21194808	chr1:2205498	SKI	0.29	5.59	0.45	1.38e-7	Coronary artery disease;
TGCT	cis	rs7104764	0.917	rs6598067	chr11:243093	T/C	cg18336825	chr11:236787	PSMD13;SIRT3	1.07	11.19	0.71	1.61e-20	Menarche (age at onset);
TGCT	cis	rs798766	1.000	rs798724	chr4:1704643	C/T	cg05874882	chr4:1763078	NA	-0.38	-5.23	-0.43	6.87e-7	Bladder cancer;Urinary bladder cancer;
TGCT	cis	rs6545883	0.965	rs10186325	chr2:61757721	G/T	cg15711740	chr2:61764176	XPO1	-0.57	-5.46	-0.44	2.51e-7	Tuberculosis;
TGCT	cis	rs74544699	1.000	rs11508014	chr4:74837510	A/G	cg16072462	chr4:74847758	PF4	0.76	4.86	0.4	3.49e-6	Growth-regulated protein alpha levels;
TGCT	cis	rs858239	0.571	rs6953020	chr7:23172132	T/C	cg05602783	chr7:23145260	KLHL7	-0.6	-4.99	-0.41	1.96e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg24675658	chr1:53192096	ZYG11B	-0.77	-9.64	-0.65	9.38e-17	Monocyte count;
TGCT	cis	rs8072100	0.870	rs10432035	chr17:45624913	G/C	cg08085267	chr17:45401833	C17orf57	0.44	4.89	0.4	3.12e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs3820928	0.874	rs4675137	chr2:227883910	G/C	cg11843606	chr2:227700838	RHBDD1	-0.54	-4.94	-0.41	2.51e-6	Pulmonary function;
TGCT	cis	rs9611565	0.729	rs203319	chr22:41914593	C/T	cg13695892	chr22:41940480	POLR3H	-0.86	-9.02	-0.63	2.98e-15	Vitiligo;
TGCT	cis	rs523522	1.000	rs1563333	chr12:120934407	C/T	cg27279351	chr12:120934652	DYNLL1	0.76	6.59	0.51	1.15e-9	High light scatter reticulocyte count;
TGCT	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.54	4.88	0.4	3.18e-6	Prudent dietary pattern;
TGCT	cis	rs12908161	1.000	rs12899981	chr15:85302373	G/A	cg11189052	chr15:85197271	WDR73	0.71	5.82	0.46	4.67e-8	Schizophrenia;
TGCT	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg11890956	chr21:40555474	PSMG1	-0.76	-7.08	-0.54	9.53e-11	Cognitive function;
TGCT	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.54	-5.17	-0.42	9.07e-7	Menarche (age at onset);
TGCT	cis	rs62244186	0.520	rs2372828	chr3:44784949	A/G	cg02073558	chr3:44770973	ZNF501	-0.73	-7.31	-0.55	2.81e-11	Depressive symptoms;
TGCT	cis	rs7772486	0.658	rs6570706	chr6:145962922	T/C	cg05347473	chr6:146136440	FBXO30	0.48	4.53	0.38	1.38e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.48	-0.37	1.66e-5	Bipolar disorder;
TGCT	cis	rs61990749	0.597	rs717683	chr14:78255453	A/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.64	4.5	0.37	1.54e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs10037055	1.000	rs6886255	chr5:176718361	A/G	cg18465082	chr5:176734745	MXD3	-0.29	-4.55	-0.38	1.28e-5	Migraine without aura;
TGCT	cis	rs1048238	0.846	rs945417	chr1:16344625	C/G	cg21385522	chr1:16154831	NA	0.43	4.52	0.38	1.43e-5	Systolic blood pressure;
TGCT	cis	rs9527	0.615	rs10883810	chr10:104727224	A/C	cg04362960	chr10:104952993	NT5C2	0.66	5.55	0.45	1.66e-7	Arsenic metabolism;
TGCT	cis	rs1008375	1.000	rs3933453	chr4:17636319	A/C	cg16339924	chr4:17578868	LAP3	0.66	5.43	0.44	2.82e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs28374715	0.681	rs28687846	chr15:41599902	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.9	-14.62	-0.8	9.13e-29	Ulcerative colitis;
TGCT	cis	rs9911578	0.935	rs9893351	chr17:57023326	G/A	cg05425664	chr17:57184151	TRIM37	-0.56	-5.42	-0.44	2.99e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7829975	0.539	rs4841012	chr8:8551710	C/A	cg17143192	chr8:8559678	CLDN23	-0.49	-4.94	-0.41	2.44e-6	Mood instability;
TGCT	cis	rs6840360	0.615	rs3828546	chr4:152679816	A/G	cg22705602	chr4:152727874	NA	-0.35	-5.94	-0.47	2.63e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg03188948	chr7:1209495	NA	0.47	6.54	0.51	1.47e-9	Longevity;Endometriosis;
TGCT	cis	rs319204	1.000	rs1380014	chr5:146235722	A/G	cg25021259	chr5:146258546	PPP2R2B	0.35	4.48	0.37	1.69e-5	Schizophrenia;
TGCT	cis	rs79387448	0.745	rs59694233	chr2:103116521	G/A	cg09003973	chr2:102972529	NA	0.85	5.61	0.45	1.25e-7	Gut microbiota (bacterial taxa);
TGCT	cis	rs12478296	1.000	rs56162244	chr2:243018690	A/G	cg06360820	chr2:242988706	NA	-0.59	-4.83	-0.4	3.89e-6	Obesity-related traits;
TGCT	cis	rs6450176	0.638	rs11746856	chr5:53291295	A/C	ch.5.1024479R	chr5:53302184	ARL15	-0.77	-5.46	-0.44	2.46e-7	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs1153858	0.945	rs7182300	chr15:45634928	G/A	cg14582100	chr15:45693742	SPATA5L1	0.48	5.7	0.46	8.17e-8	Homoarginine levels;
TGCT	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg15691649	chr6:25882328	NA	-0.56	-7.3	-0.55	3.04e-11	Urate levels;
TGCT	cis	rs2070488	0.775	rs6599211	chr3:38558830	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.71	-6.89	-0.53	2.46e-10	Electrocardiographic conduction measures;
TGCT	cis	rs9326248	0.954	rs4938349	chr11:117021923	C/T	cg26566898	chr11:117069891	TAGLN	0.33	4.52	0.38	1.41e-5	Blood protein levels;
TGCT	cis	rs3858704	0.517	rs7297186	chr12:111778178	C/T	cg10833066	chr12:111807467	FAM109A	-0.41	-8.01	-0.58	6.96e-13	Idiopathic osteonecrosis of the femoral head;
TGCT	cis	rs7246657	0.943	rs10426666	chr19:37828514	C/G	cg18154014	chr19:37997991	ZNF793	0.97	6.49	0.5	1.82e-9	Coronary artery calcification;
TGCT	cis	rs10771431	0.597	rs10843142	chr12:9357502	A/G	cg21349645	chr12:9436242	LOC642846	-0.45	-4.59	-0.38	1.08e-5	Breast size;
TGCT	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg20607798	chr8:58055168	NA	0.45	4.62	0.38	9.57e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7647973	0.516	rs4499638	chr3:49202782	C/G	cg18654377	chr3:49208889	KLHDC8B	-0.38	-4.96	-0.41	2.25e-6	Menarche (age at onset);
TGCT	cis	rs9419702	0.614	rs4897816	chr10:133533646	G/A	cg23460707	chr10:133558971	NA	0.42	4.63	0.38	9.08e-6	Survival in rectal cancer;
TGCT	cis	rs12681287	0.752	rs4641037	chr8:87268379	A/G	cg27223183	chr8:87520930	FAM82B	-0.8	-5.69	-0.46	8.66e-8	Caudate activity during reward;
TGCT	cis	rs2296887	0.841	rs7913281	chr10:104010142	A/G	cg26089160	chr10:104170217	PSD	-0.61	-5.62	-0.45	1.19e-7	Parkinson's disease;
TGCT	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg08280861	chr8:58055591	NA	0.39	4.76	0.39	5.35e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs801193	0.875	rs13227951	chr7:66213108	C/T	cg18876405	chr7:65276391	NA	-0.37	-5.75	-0.46	6.62e-8	Aortic root size;
TGCT	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.45	4.67	0.39	7.86e-6	Menopause (age at onset);
TGCT	cis	rs8050907	0.744	rs8047271	chr16:4536634	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.53	4.57	0.38	1.15e-5	Obesity-related traits;
TGCT	cis	rs1865760	0.516	rs10807007	chr6:26048931	A/C	cg16482183	chr6:26056742	HIST1H1C	0.57	5.0	0.41	1.93e-6	Height;
TGCT	cis	rs713587	0.776	rs1172294	chr2:25169200	A/G	cg01884057	chr2:25150051	NA	0.39	7.97	0.58	8.81e-13	Body mass index in non-asthmatics;
TGCT	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg03806693	chr22:41940476	POLR3H	-1.09	-11.81	-0.73	4.98e-22	Vitiligo;
TGCT	cis	rs12579753	0.879	rs12579544	chr12:82164043	A/C	cg21231944	chr12:82153410	PPFIA2	-0.34	-4.62	-0.38	9.52e-6	Resting heart rate;
TGCT	cis	rs7267979	0.816	rs6115094	chr20:25210827	A/G	cg14121845	chr20:25566513	NINL	0.46	4.68	0.39	7.51e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9303401	0.573	rs62081879	chr17:57181524	C/T	cg25039879	chr17:56429692	SUPT4H1	0.55	4.9	0.4	2.93e-6	Cognitive test performance;
TGCT	cis	rs308447	0.516	rs13142203	chr4:123679002	T/C	cg10495464	chr4:123653540	BBS12;LOC729338	0.66	6.42	0.5	2.63e-9	Perceived unattractiveness to mosquitoes;
TGCT	cis	rs3617	0.625	rs11719137	chr3:52876389	G/T	cg05573699	chr3:52720067	GNL3;PBRM1	0.49	4.77	0.39	5.04e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg09021430	chr5:549028	NA	-0.38	-5.11	-0.42	1.21e-6	Obesity-related traits;
TGCT	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg13206674	chr6:150067644	NUP43	0.52	4.51	0.38	1.5e-5	Lung cancer;
TGCT	cis	rs1670533	1.000	rs12645644	chr4:1054159	C/T	cg20887711	chr4:1340912	KIAA1530	0.6	5.06	0.41	1.48e-6	Recombination rate (females);
TGCT	cis	rs6570726	0.791	rs6923074	chr6:145893332	T/C	cg23711669	chr6:146136114	FBXO30	0.86	9.54	0.65	1.64e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11190604	1.000	rs2489039	chr10:102328036	T/A	cg23241863	chr10:102295624	HIF1AN	0.67	5.1	0.42	1.23e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7666738	0.830	rs2167892	chr4:99048503	G/C	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9653442	0.510	rs11891046	chr2:100794402	C/G	cg22139774	chr2:100720529	AFF3	-0.33	-5.24	-0.43	6.61e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs7843479	0.601	rs10109521	chr8:21829948	G/A	cg17168535	chr8:21777572	XPO7	0.8	8.11	0.59	4.09e-13	Mean corpuscular volume;
TGCT	cis	rs17345786	0.906	rs11710016	chr3:101120030	A/C	cg12386194	chr3:101231763	SENP7	-0.65	-6.39	-0.5	3.06e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs751728	0.626	rs6457741	chr6:33756026	C/T	cg13859433	chr6:33739653	LEMD2	-0.33	-5.75	-0.46	6.65e-8	Crohn's disease;
TGCT	cis	rs5769707	0.681	rs2319346	chr22:50029640	A/G	cg05373962	chr22:49881684	NA	-0.3	-5.26	-0.43	6.23e-7	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg00149659	chr3:10157352	C3orf10	1.17	7.24	0.55	4.13e-11	Alzheimer's disease;
TGCT	cis	rs617219	0.710	rs2607141	chr5:78558635	G/T	cg23514016	chr5:78407564	BHMT	0.32	4.87	0.4	3.38e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.09	-16.13	-0.82	3.1e-32	Prudent dietary pattern;
TGCT	cis	rs8017423	0.967	rs11624725	chr14:90713609	G/T	cg04374321	chr14:90722782	PSMC1	-0.72	-7.31	-0.55	2.85e-11	Mortality in heart failure;
TGCT	cis	rs9814567	0.896	rs58491661	chr3:134355189	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.84	7.7	0.57	3.76e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	trans	rs797680	0.856	rs7540025	chr1:93759228	C/T	cg27528825	chr2:159282178	CCDC148	0.34	6.71	0.52	6.19e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	trans	rs11722228	0.508	rs2241472	chr4:10085902	C/G	cg26043149	chr18:55253948	FECH	1.15	11.21	0.71	1.41e-20	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg18538332	chr22:24372958	LOC391322	-0.86	-9.78	-0.66	4.35e-17	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9300255	0.602	rs10846486	chr12:123709927	G/A	cg00376283	chr12:123451042	ABCB9	0.73	5.67	0.45	9.46e-8	Neutrophil percentage of white cells;
TGCT	cis	rs2180341	0.961	rs7774468	chr6:127592501	G/C	cg24812749	chr6:127587940	RNF146	0.99	7.72	0.57	3.33e-12	Breast cancer;
TGCT	cis	rs910316	0.763	rs4556	chr14:75476071	G/C	cg08847533	chr14:75593920	NEK9	0.83	8.89	0.62	5.99e-15	Height;
TGCT	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg06618935	chr21:46677482	NA	-0.36	-5.5	-0.44	2.06e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6424115	0.830	rs6673210	chr1:24203534	A/G	cg15997130	chr1:24165203	NA	0.85	8.93	0.63	4.81e-15	Immature fraction of reticulocytes;
TGCT	cis	rs806215	0.526	rs12668077	chr7:127476253	T/C	cg11539674	chr7:127291444	SND1	-0.36	-4.67	-0.39	7.77e-6	Type 2 diabetes;
TGCT	cis	rs10782582	0.609	rs80059220	chr1:76279112	G/T	cg10523679	chr1:76189770	ACADM	-0.58	-5.38	-0.43	3.6e-7	Daytime sleep phenotypes;
TGCT	cis	rs11650494	0.908	rs77338752	chr17:47372328	A/C	cg08112188	chr17:47440006	ZNF652	1.04	5.35	0.43	4.09e-7	Prostate cancer;
TGCT	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg07167872	chr1:205819463	PM20D1	0.68	9.92	0.67	2.01e-17	Menarche (age at onset);
TGCT	cis	rs9486719	0.843	rs2499793	chr6:96846402	A/C	cg18709589	chr6:96969512	KIAA0776	0.75	5.13	0.42	1.1e-6	Migraine;Coronary artery disease;
TGCT	cis	rs8062405	0.540	rs193628	chr16:28582142	G/T	cg09754948	chr16:28834200	ATXN2L	-0.54	-4.46	-0.37	1.82e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs7267979	1.000	rs2482937	chr20:25340786	A/G	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10751667	0.621	rs10794351	chr11:946228	C/T	cg06064525	chr11:970664	AP2A2	-0.35	-8.29	-0.6	1.6e-13	Alzheimer's disease (late onset);
TGCT	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9649213	0.614	rs3944111	chr7:98005766	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.92	-8.65	-0.61	2.22e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg11764359	chr7:65958608	NA	0.61	5.53	0.44	1.84e-7	Aortic root size;
TGCT	cis	rs74233809	1.000	rs12221335	chr10:104769392	T/A	cg05855489	chr10:104503620	C10orf26	0.74	4.45	0.37	1.87e-5	Birth weight;
TGCT	cis	rs10992471	0.756	rs7027595	chr9:95131553	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.61	-6.29	-0.49	4.96e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg11764359	chr7:65958608	NA	0.55	5.09	0.42	1.29e-6	Aortic root size;
TGCT	cis	rs7584330	0.554	rs4420668	chr2:238444793	G/A	cg08992911	chr2:238395768	MLPH	0.64	4.49	0.37	1.63e-5	Prostate cancer;
TGCT	cis	rs7178572	1.000	rs952472	chr15:77776562	A/C	cg15453836	chr15:77711506	NA	-0.4	-4.59	-0.38	1.07e-5	Type 2 diabetes;
TGCT	cis	rs2153535	0.580	rs6927589	chr6:8456632	A/G	cg23788917	chr6:8435910	SLC35B3	-0.59	-5.34	-0.43	4.23e-7	Motion sickness;
TGCT	cis	rs79349575	0.681	rs56080003	chr17:47019049	A/T	cg26022315	chr17:47021804	SNF8	0.49	4.9	0.4	2.94e-6	Type 2 diabetes;
TGCT	cis	rs6964587	1.000	rs11982047	chr7:91705274	G/A	cg17063962	chr7:91808500	NA	0.88	9.54	0.65	1.69e-16	Breast cancer;
TGCT	cis	rs12681287	0.547	rs56752411	chr8:87515156	C/T	cg27223183	chr8:87520930	FAM82B	-0.96	-7.08	-0.54	9.31e-11	Caudate activity during reward;
TGCT	cis	rs7681440	0.904	rs28777703	chr4:90769924	A/G	cg20003494	chr4:90757398	SNCA	0.57	5.39	0.44	3.41e-7	Dementia with Lewy bodies;
TGCT	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg12310025	chr6:25882481	NA	-0.55	-5.58	-0.45	1.41e-7	Blood metabolite levels;
TGCT	cis	rs17826219	0.568	rs9907834	chr17:29154013	G/A	cg14008862	chr17:28927542	LRRC37B2	0.75	5.06	0.41	1.5e-6	Body mass index;
TGCT	cis	rs2677744	1.000	rs1266489	chr15:91458485	G/A	cg23684204	chr15:91497937	RCCD1	0.34	5.09	0.42	1.28e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs4409766	0.518	rs486955	chr10:104546284	C/T	cg05855489	chr10:104503620	C10orf26	-0.76	-5.24	-0.43	6.78e-7	Hypertension;Systolic blood pressure;Diastolic blood pressure (long-term average);Body mass index;Diastolic blood pressure;Mean arterial pressure (long-term average);
TGCT	cis	rs3540	0.533	rs937793	chr15:91053583	A/G	cg22089800	chr15:90895588	ZNF774	-0.71	-7.3	-0.55	3.08e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs6088580	0.634	rs6579165	chr20:32994715	A/G	cg08999081	chr20:33150536	PIGU	-0.29	-5.65	-0.45	1.02e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs1461503	0.932	rs10892944	chr11:122843895	T/C	cg27398637	chr11:122830231	C11orf63	-0.43	-5.31	-0.43	5e-7	Menarche (age at onset);
TGCT	cis	rs1635	1.000	rs1635	chr6:28227604	C/A	cg15743358	chr6:28303923	ZNF323	-1.1	-4.55	-0.38	1.25e-5	Schizophrenia;
TGCT	trans	rs35365539	1	rs35365539	chr3:49794347	A/AC	cg21659725	chr3:3221576	CRBN	-0.98	-15.33	-0.81	2.1000000000000002e-30	Blood protein levels;
TGCT	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg16325326	chr1:53192061	ZYG11B	0.71	8.65	0.61	2.18e-14	Monocyte count;
TGCT	cis	rs8068544	0.818	rs75771390	chr17:40194054	A/G	cg13092355	chr17:39992602	KLHL10;NT5C3L	-0.95	-4.46	-0.37	1.84e-5	Reticulocyte fraction of red cells;Reticulocyte count;
TGCT	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg07507251	chr3:52567010	NT5DC2	0.47	6.7	0.52	6.47e-10	Bipolar disorder;
TGCT	cis	rs2235642	0.785	rs1057983	chr16:1660274	A/G	cg08296037	chr16:1584118	IFT140;TMEM204	-0.28	-5.02	-0.41	1.78e-6	Coronary artery disease;
TGCT	cis	rs11122272	0.701	rs971533	chr1:231522097	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-6.94	-0.53	1.98e-10	Hemoglobin concentration;
TGCT	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.0	8.11	0.59	4.07e-13	Platelet count;
TGCT	cis	rs4689388	0.581	rs4476672	chr4:6281496	A/G	cg25554036	chr4:6271136	WFS1	0.56	6.58	0.51	1.21e-9	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg12963246	chr6:28129442	ZNF389	0.52	5.1	0.42	1.23e-6	Depression;
TGCT	cis	rs8084125	0.832	rs62105178	chr18:74950635	C/T	cg15443732	chr18:74961078	GALR1	0.48	4.7	0.39	6.76e-6	Obesity-related traits;
TGCT	cis	rs11651000	0.857	rs56172120	chr17:45824904	G/A	cg06532163	chr17:45867833	NA	0.36	5.24	0.43	6.81e-7	IgG glycosylation;
TGCT	cis	rs4478858	0.647	rs10798836	chr1:31709214	C/T	cg00250761	chr1:31883323	NA	-0.27	-4.9	-0.4	2.89e-6	Alcohol dependence;
TGCT	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg21724239	chr8:58056113	NA	0.39	5.28	0.43	5.67e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7666738	0.830	rs1834647	chr4:98882915	G/A	cg17366294	chr4:99064904	C4orf37	0.71	7.28	0.55	3.33e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg02953382	chr22:24373134	LOC391322	-0.78	-8.12	-0.59	4.06e-13	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7552404	1.000	rs4646961	chr1:76217169	G/A	cg03433033	chr1:76189801	ACADM	0.81	9.52	0.65	1.84e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	6.14	0.48	1.03e-8	Bipolar disorder;
TGCT	cis	rs6969780	0.722	rs985652	chr7:27198083	A/C	cg17457637	chr7:27170717	HOXA4	-0.44	-4.74	-0.39	5.67e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs459571	0.839	rs10993895	chr9:136887726	C/T	cg14405625	chr9:136855902	VAV2	0.3	4.52	0.38	1.44e-5	Platelet distribution width;
TGCT	cis	rs7605378	0.567	rs717915	chr2:200714766	C/T	cg19045956	chr2:200819837	C2orf60;C2orf47	0.57	6.13	0.48	1.1e-8	Osteoporosis;
TGCT	cis	rs7605378	0.752	rs769960	chr2:200710706	G/T	cg23649088	chr2:200775458	C2orf69	-0.42	-7.46	-0.56	1.33e-11	Osteoporosis;
TGCT	cis	rs1865760	0.865	rs2164485	chr6:25952106	G/A	cg16482183	chr6:26056742	HIST1H1C	0.53	4.88	0.4	3.14e-6	Height;
TGCT	cis	rs7617773	0.817	rs3729577	chr3:48228994	A/C	cg11946769	chr3:48343235	NME6	0.76	6.67	0.51	7.6e-10	Coronary artery disease;
TGCT	cis	rs4285028	0.948	rs35902163	chr3:121649526	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.77	-6.5	-0.5	1.78e-9	Multiple sclerosis;
TGCT	trans	rs208520	0.706	rs851601	chr6:66893853	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-10.21	-0.68	4.02e-18	Exhaled nitric oxide output;
TGCT	cis	rs10875595	0.836	rs56756237	chr5:140678342	T/C	cg24830062	chr5:140700576	TAF7	-0.63	-5.29	-0.43	5.35e-7	Pulmonary function decline;
TGCT	cis	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg22121687	chr7:65037720	NA	-0.78	-4.7	-0.39	6.74e-6	Diabetic kidney disease;
TGCT	trans	rs551517	0.522	rs2766982	chr9:113641725	T/A	cg18410444	chr5:89825535	LYSMD3	0.66	6.66	0.51	8.12e-10	Post bronchodilator FEV1 in COPD;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
TGCT	cis	rs12477438	0.798	rs1580068	chr2:99649969	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-6.1	-0.48	1.22e-8	Chronic sinus infection;
TGCT	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg20573242	chr4:122745356	CCNA2	0.62	5.48	0.44	2.23e-7	Type 2 diabetes;
TGCT	cis	rs425277	0.565	rs61775448	chr1:2045376	A/G	cg24578937	chr1:2090814	PRKCZ	-0.23	-5.54	-0.45	1.73e-7	Height;
TGCT	cis	rs904251	0.523	rs2776920	chr6:37480605	G/A	cg25019722	chr6:37503610	NA	-0.53	-7.98	-0.58	8.18e-13	Cognitive performance;
TGCT	cis	rs2721195	0.683	rs6989368	chr8:145813457	A/G	cg15320075	chr8:145703422	NA	0.64	5.8	0.46	5.3e-8	Age at first birth;
TGCT	cis	rs11105298	0.891	rs10858903	chr12:89927972	G/A	cg00757033	chr12:89920650	WDR51B	0.3	4.65	0.39	8.21e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs7809950	1.000	rs1544336	chr7:107082415	G/C	cg23024343	chr7:107201750	COG5	-0.36	-5.64	-0.45	1.11e-7	Coronary artery disease;
TGCT	cis	rs17401966	0.838	rs2105212	chr1:10281012	T/C	cg19773385	chr1:10388646	KIF1B	-0.23	-5.03	-0.41	1.71e-6	Hepatocellular carcinoma;
TGCT	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.52	-5.81	-0.46	4.88e-8	Lymphocyte counts;
TGCT	cis	rs514406	0.825	rs12089511	chr1:53436427	A/T	cg25767906	chr1:53392781	SCP2	0.5	5.94	0.47	2.65e-8	Monocyte count;
TGCT	cis	rs9902453	0.904	rs4375718	chr17:28363642	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.84	-8.06	-0.59	5.38e-13	Coffee consumption (cups per day);
TGCT	cis	rs11105298	0.891	rs10858865	chr12:89846476	G/A	cg00757033	chr12:89920650	WDR51B	0.34	5.36	0.43	4e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs7647973	0.516	rs4955418	chr3:49200627	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.38	-4.96	-0.41	2.25e-6	Menarche (age at onset);
TGCT	cis	rs7666738	0.715	rs3857216	chr4:99032129	G/T	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs473651	0.503	rs515342	chr2:239367296	A/G	cg08773314	chr2:239334832	ASB1	-0.41	-4.87	-0.4	3.37e-6	Multiple system atrophy;
TGCT	cis	rs3862435	0.706	rs2253425	chr15:90945759	G/A	cg14166756	chr15:90894880	ZNF774	-0.28	-4.61	-0.38	9.95e-6	Response to exercise (triglyceride level interaction);
TGCT	cis	rs1975974	0.549	rs4889746	chr17:21745187	T/C	cg18423549	chr17:21743878	NA	-0.66	-6.21	-0.49	7.18e-9	Psoriasis;
TGCT	cis	rs17172199	0.908	rs75148026	chr7:43335242	G/A	cg04651707	chr7:43622869	STK17A	0.89	4.43	0.37	2.01e-5	Alzheimer's disease (cognitive decline);
TGCT	cis	rs6138458	1.000	rs227631	chr20:24913653	A/G	cg26195577	chr20:24973756	C20orf3	1.2	12.04	0.73	1.35e-22	Blood protein levels;
TGCT	trans	rs8073060	0.586	rs72829927	chr17:34049992	A/G	cg19694781	chr19:47549865	TMEM160	0.6	13.37	0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs933688	0.877	rs10474352	chr5:90732225	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	8.73	0.62	1.47e-14	Smoking behavior;
TGCT	cis	rs1801251	0.896	rs921054	chr2:233694673	G/A	cg08000102	chr2:233561755	GIGYF2	-0.57	-6.03	-0.48	1.74e-8	Coronary artery disease;
TGCT	cis	rs3540	0.960	rs11853271	chr15:91025830	C/T	cg22089800	chr15:90895588	ZNF774	0.74	7.14	0.54	6.77e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs7267979	0.966	rs8123949	chr20:25388133	C/T	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg16680214	chr1:154839983	KCNN3	-0.42	-9.45	-0.65	2.78e-16	Prostate cancer;
TGCT	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9894429	0.550	rs6565617	chr17:79612333	G/A	cg18240062	chr17:79603768	NPLOC4	0.56	4.9	0.4	2.95e-6	Eye color traits;
TGCT	cis	rs12908161	0.853	rs11633788	chr15:85305142	T/A	cg11189052	chr15:85197271	WDR73	0.64	5.89	0.47	3.32e-8	Schizophrenia;
TGCT	cis	rs8180040	0.647	rs57756484	chr3:47239333	A/G	cg27129171	chr3:47204927	SETD2	-0.7	-8.35	-0.6	1.13e-13	Colorectal cancer;
TGCT	cis	rs981844	0.740	rs6858578	chr4:154682058	G/T	cg14289246	chr4:154710475	SFRP2	-0.89	-8.12	-0.59	3.89e-13	Response to statins (LDL cholesterol change);
TGCT	cis	rs986417	1.000	rs1269984	chr14:60898138	C/G	cg27398547	chr14:60952738	C14orf39	-1.42	-8.68	-0.61	1.89e-14	Gut microbiota (bacterial taxa);
TGCT	cis	rs9383153	0.625	rs1886349	chr6:16320320	G/A	cg06493612	chr6:15502050	JARID2	0.64	4.81	0.4	4.21e-6	Gambling;
TGCT	cis	rs7582180	0.625	rs12612755	chr2:100906061	T/C	cg08017756	chr2:100939284	LONRF2	-0.28	-4.76	-0.39	5.37e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7267979	0.844	rs6115188	chr20:25432170	G/T	cg14121845	chr20:25566513	NINL	0.45	4.6	0.38	1.03e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10782582	0.609	rs1796827	chr1:76391536	A/T	cg10523679	chr1:76189770	ACADM	-0.52	-4.73	-0.39	5.94e-6	Daytime sleep phenotypes;
TGCT	cis	rs748404	0.631	rs11070399	chr15:43646347	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	4.72	0.39	6.3e-6	Lung cancer;
TGCT	cis	rs9522267	0.535	rs9522301	chr13:112236726	A/T	cg10483660	chr13:112241077	NA	-0.27	-4.61	-0.38	9.78e-6	Hepatitis;
TGCT	cis	rs11578119	0.933	rs12128573	chr1:170391126	C/T	cg09767346	chr1:170501363	GORAB	0.71	5.69	0.46	8.67e-8	Male-pattern baldness;
TGCT	cis	rs3820068	0.705	rs1800616	chr1:15832229	G/A	cg05660106	chr1:15850417	CASP9	1.16	14.41	0.79	2.88e-28	Systolic blood pressure;
TGCT	cis	rs35306767	0.903	rs11816064	chr10:931176	A/C	cg20503657	chr10:835505	NA	0.74	10.3	0.68	2.41e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs9914544	0.678	rs28374894	chr17:18761659	C/A	cg26378065	chr17:18585709	ZNF286B	0.52	4.5	0.37	1.56e-5	Educational attainment (years of education);
TGCT	cis	rs981844	1.000	rs2251997	chr4:154654067	A/G	cg14289246	chr4:154710475	SFRP2	-1.0	-8.6	-0.61	2.88e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.07	-9.63	-0.65	1.01e-16	Platelet count;
TGCT	cis	rs10790268	1	rs10790268	chr11:118729391	A/G	cg19308663	chr11:118741387	NA	-0.32	-5.88	-0.47	3.6e-8	Rheumatoid arthritis;
TGCT	cis	rs1008375	0.898	rs9998130	chr4:17593905	A/G	cg18681998	chr4:17616180	MED28	0.88	8.14	0.59	3.56e-13	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10791097	0.592	rs4936122	chr11:130734264	A/C	cg14779329	chr11:130786720	SNX19	0.29	4.91	0.4	2.77e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs231513	0.954	rs231505	chr17:41970268	A/T	cg26893861	chr17:41843967	DUSP3	0.63	4.86	0.4	3.49e-6	Cognitive function;
TGCT	cis	rs2370759	1.000	rs11594459	chr10:32561858	A/C	cg01819863	chr10:32635814	EPC1	1.01	9.98	0.67	1.45e-17	Sexual dysfunction (female);
TGCT	cis	rs514406	0.505	rs431459	chr1:53183230	T/G	cg01802117	chr1:53393560	SCP2	-0.39	-4.61	-0.38	9.88e-6	Monocyte count;
TGCT	cis	rs9291683	0.610	rs993173	chr4:10323935	T/C	cg00071950	chr4:10020882	SLC2A9	-0.46	-4.92	-0.4	2.74e-6	Bone mineral density;
TGCT	trans	rs2727020	0.729	rs588458	chr11:49214048	C/A	cg15704280	chr7:45808275	SEPT13	0.64	6.81	0.52	3.74e-10	Coronary artery disease;
TGCT	cis	rs4936891	0.645	rs74858431	chr11:123902862	T/C	cg22125253	chr11:123886957	OR10G4	0.21	4.83	0.4	3.98e-6	Male fertility;
TGCT	cis	rs9902453	0.967	rs28792710	chr17:28450015	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	5.41	0.44	3.13e-7	Coffee consumption (cups per day);
TGCT	cis	rs886126	0.585	rs7295764	chr12:111693198	G/A	cg10833066	chr12:111807467	FAM109A	0.3	4.48	0.37	1.68e-5	Coronary heart disease;
TGCT	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg16414030	chr3:133502952	NA	0.6	9.8	0.66	3.77e-17	Iron status biomarkers;
TGCT	cis	rs7572733	0.515	rs6726506	chr2:198846486	G/T	cg00792783	chr2:198669748	PLCL1	0.57	5.1	0.42	1.24e-6	Dermatomyositis;
TGCT	cis	rs7226408	0.948	rs72883572	chr18:34382334	T/A	cg06757138	chr18:34340585	FHOD3	0.26	4.79	0.4	4.62e-6	Obesity-related traits;
TGCT	cis	rs514406	0.763	rs6685599	chr1:53213172	G/A	cg08859206	chr1:53392774	SCP2	0.4	5.88	0.47	3.56e-8	Monocyte count;
TGCT	cis	rs9611565	0.649	rs2413659	chr22:42164862	A/G	cg06481639	chr22:41940642	POLR3H	0.54	4.55	0.38	1.25e-5	Vitiligo;
TGCT	cis	rs9457247	1.000	rs413232	chr6:167400972	G/A	cg23791538	chr6:167370224	RNASET2	-0.49	-4.96	-0.41	2.26e-6	Crohn's disease;
TGCT	cis	rs9913156	0.696	rs72835620	chr17:4558128	G/A	cg23387401	chr17:4582204	PELP1	0.31	4.57	0.38	1.14e-5	Lymphocyte counts;
TGCT	cis	rs62244186	0.566	rs3762636	chr3:44854563	A/G	cg04389838	chr3:44770851	ZNF501	-0.36	-4.72	-0.39	6.2e-6	Depressive symptoms;
TGCT	cis	rs13392177	0.684	rs11682371	chr2:219079513	G/A	cg00012203	chr2:219082015	ARPC2	-0.79	-8.02	-0.58	6.73e-13	Pyoderma gangrenosum in inflammatory bowel disease;
TGCT	cis	rs35306767	0.903	rs35567307	chr10:915804	G/C	cg20503657	chr10:835505	NA	0.74	10.3	0.68	2.41e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs896854	0.654	rs16893776	chr8:95973604	C/T	cg13393036	chr8:95962371	TP53INP1	-0.62	-8.41	-0.6	8.05e-14	Type 2 diabetes;
TGCT	cis	rs1467026	0.589	rs9876483	chr3:12803792	G/T	cg05775895	chr3:12838266	CAND2	0.53	5.32	0.43	4.61e-7	P wave duration;
TGCT	cis	rs2290402	0.536	rs56223707	chr4:881896	C/T	cg23332689	chr4:987652	IDUA;SLC26A1	0.33	5.0	0.41	1.94e-6	Type 2 diabetes;
TGCT	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.71	-0.39	6.54e-6	Prudent dietary pattern;
TGCT	cis	rs3784262	0.765	rs8026952	chr15:58276950	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.42	-5.94	-0.47	2.69e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs8031584	0.958	rs7168641	chr15:31235452	G/A	cg08704250	chr15:31115839	NA	-0.36	-4.96	-0.41	2.28e-6	Huntington's disease progression;
TGCT	cis	rs6484504	0.576	rs11031320	chr11:31242545	C/T	cg26647111	chr11:31128758	NA	-0.34	-4.73	-0.39	5.88e-6	Red blood cell count;
TGCT	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg27454412	chr7:1067447	C7orf50	0.57	4.48	0.37	1.71e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs17443541	0.507	rs4675698	chr2:200451350	T/C	cg00055341	chr2:200446845	NA	-0.31	-4.45	-0.37	1.89e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.71	5.14	0.42	1.02e-6	Platelet count;
TGCT	cis	rs3751972	0.681	rs986993	chr17:26187576	A/G	cg02948944	chr17:26242737	NA	0.38	5.17	0.42	9.01e-7	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.73	-0.39	5.93e-6	Prudent dietary pattern;
TGCT	cis	rs3087591	0.959	rs9893872	chr17:29571195	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.48	-7.48	-0.56	1.18e-11	Hip circumference;
TGCT	cis	rs2455799	0.559	rs1584325	chr3:15903888	G/T	cg12172478	chr3:16357591	RFTN1	-0.36	-5.3	-0.43	5.07e-7	Mean platelet volume;
TGCT	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.54	4.47	0.37	1.77e-5	Tonsillectomy;
TGCT	cis	rs11264213	0.901	rs67641270	chr1:36413329	T/C	cg07093915	chr1:36184400	C1orf216	0.65	4.47	0.37	1.77e-5	Schizophrenia;
TGCT	cis	rs55883249	1.000	rs62119428	chr2:9743332	T/C	cg23886495	chr2:9695866	ADAM17	0.81	5.0	0.41	1.93e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs709400	1.000	rs861539	chr14:104165753	G/A	cg26031613	chr14:104095156	KLC1	1.13	16.87	0.83	6.66e-34	Body mass index;
TGCT	cis	rs9393777	0.513	rs3999471	chr6:26650306	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.59	-4.66	-0.39	8.03e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7611238	0.560	rs9854941	chr3:195066926	G/A	cg27323046	chr3:195102265	ACAP2	0.35	4.82	0.4	4.11e-6	Body mass index;
TGCT	cis	rs7772486	0.875	rs2814876	chr6:146304030	C/T	cg13319975	chr6:146136371	FBXO30	-0.52	-4.62	-0.38	9.45e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7809950	1.000	rs12667527	chr7:107086969	T/C	cg23024343	chr7:107201750	COG5	-0.35	-5.42	-0.44	2.97e-7	Coronary artery disease;
TGCT	cis	rs473651	0.904	rs62196716	chr2:239356977	C/G	cg18131467	chr2:239335373	ASB1	1.01	14.86	0.8	2.56e-29	Multiple system atrophy;
TGCT	cis	rs797680	0.930	rs11164870	chr1:93552187	C/G	cg17826107	chr1:92977322	EVI5	-0.2	-4.62	-0.38	9.6e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs4808199	0.948	rs11085261	chr19:19462606	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.64	4.75	0.39	5.58e-6	Nonalcoholic fatty liver disease;
TGCT	cis	rs9325144	0.624	rs10506126	chr12:39123244	G/A	cg26384229	chr12:38710491	ALG10B	-0.62	-5.82	-0.46	4.71e-8	Morning vs. evening chronotype;
TGCT	cis	rs478304	0.637	rs11227255	chr11:65454044	C/T	cg17480646	chr11:65405466	SIPA1	-0.63	-8.47	-0.61	6.08e-14	Acne (severe);
TGCT	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg02975922	chr3:195473998	MUC4	-0.24	-5.44	-0.44	2.69e-7	Pancreatic cancer;
TGCT	cis	rs319204	1.000	rs319238	chr5:146240381	G/A	cg25021259	chr5:146258546	PPP2R2B	0.36	4.53	0.38	1.37e-5	Schizophrenia;
TGCT	cis	rs6089584	0.566	rs7274240	chr20:60622004	C/T	cg13770153	chr20:60521292	NA	-0.39	-4.65	-0.39	8.39e-6	Body mass index;
TGCT	cis	rs2456568	0.867	rs10501810	chr11:93666589	C/G	cg16099599	chr11:93583650	C11orf90	-0.4	-4.78	-0.39	4.88e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg10802521	chr3:52805072	NEK4	-0.78	-10.01	-0.67	1.22e-17	Bipolar disorder;
TGCT	cis	rs2594989	0.780	rs2443706	chr3:11550505	C/G	cg00170343	chr3:11313890	ATG7	0.64	4.67	0.39	7.71e-6	Circulating chemerin levels;
TGCT	cis	rs11098499	0.532	rs4504231	chr4:120586891	G/A	cg09307838	chr4:120376055	NA	0.62	5.92	0.47	2.89e-8	Corneal astigmatism;
TGCT	cis	rs10488031	0.557	rs34553617	chr7:37101129	G/A	cg06458904	chr7:36312573	EEPD1	0.58	4.79	0.39	4.72e-6	QT interval;
TGCT	cis	rs10791097	0.668	rs10791102	chr11:130744977	G/A	cg14779329	chr11:130786720	SNX19	0.28	4.82	0.4	4.09e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs3749237	0.595	rs11720264	chr3:49580347	C/T	cg03060546	chr3:49711283	APEH	0.76	8.69	0.62	1.77e-14	Resting heart rate;
TGCT	cis	rs60843830	1.000	rs6709534	chr2:217334	G/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.76	7.21	0.54	4.93e-11	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs1483890	0.723	rs1843046	chr3:69410614	C/A	cg22125112	chr3:69402811	FRMD4B	0.29	4.74	0.39	5.85e-6	Resting heart rate;
TGCT	cis	rs1008375	0.898	rs2079892	chr4:17577163	G/A	cg10189774	chr4:17578691	LAP3	0.64	5.61	0.45	1.28e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7258465	1.000	rs7252707	chr19:18612257	G/A	cg06462663	chr19:18546047	ISYNA1	0.21	4.66	0.39	8.13e-6	Breast cancer;
TGCT	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg04632378	chr13:21900426	NA	0.4	4.92	0.4	2.68e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	cis	rs12477438	0.501	rs13033012	chr2:99795149	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	14.89	0.8	2.21e-29	Chronic sinus infection;
TGCT	trans	rs2688608	0.780	rs2688619	chr10:75682176	A/G	cg13918328	chr10:52500089	ASAH2B	0.68	6.93	0.53	1.99e-10	Inflammatory bowel disease;
TGCT	cis	rs7582180	0.663	rs4850929	chr2:100990707	A/C	cg08017756	chr2:100939284	LONRF2	-0.31	-5.14	-0.42	1.06e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7428	0.527	rs4832164	chr2:85546932	A/C	cg24342717	chr2:85555507	TGOLN2	-0.49	-8.0	-0.58	7.48e-13	Ear protrusion;
TGCT	cis	rs4700695	0.719	rs40176	chr5:65464965	C/T	cg21114390	chr5:65439923	SFRS12	-0.82	-6.8	-0.52	4.03e-10	Facial morphology (factor 19);
TGCT	cis	rs9611565	0.512	rs9611672	chr22:42209922	A/G	cg06634786	chr22:41940651	POLR3H	-0.86	-8.01	-0.58	7.16e-13	Vitiligo;
TGCT	cis	rs6835098	1.000	rs1054496	chr4:174089080	A/G	cg08422745	chr4:174089978	GALNT7	-0.94	-10.98	-0.7	5.25e-20	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs1541995	0.824	rs2397829	chr15:96245270	C/T	cg00882281	chr15:96346592	NA	0.3	4.85	0.4	3.7e-6	Photic sneeze reflex;
TGCT	cis	rs7568458	0.783	rs1561198	chr2:85809989	C/T	cg02493740	chr2:85810744	VAMP5	-0.34	-6.24	-0.49	6.43e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs2228638	0.816	rs2269093	chr10:33528772	A/G	cg08604594	chr10:33798231	NA	-0.4	-4.8	-0.4	4.55e-6	Tetralogy of Fallot;
TGCT	cis	rs2180341	0.814	rs9321085	chr6:127735361	T/C	cg24812749	chr6:127587940	RNF146	0.76	6.22	0.49	7.07e-9	Breast cancer;
TGCT	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg14159672	chr1:205819179	PM20D1	0.72	10.27	0.68	2.85e-18	Menarche (age at onset);
TGCT	cis	rs4888262	0.526	rs13330282	chr16:74572373	C/T	cg01733217	chr16:74700730	RFWD3	0.71	7.11	0.54	8.09e-11	Testicular germ cell tumor;
TGCT	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg04267008	chr7:1944627	MAD1L1	-0.41	-5.45	-0.44	2.65e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs9733	0.519	rs1134067	chr1:150721175	G/T	cg04414720	chr1:150670196	GOLPH3L	0.4	5.21	0.42	7.77e-7	Tonsillectomy;
TGCT	cis	rs1670533	0.932	rs935968	chr4:1063187	G/T	cg20887711	chr4:1340912	KIAA1530	0.7	5.58	0.45	1.45e-7	Recombination rate (females);
TGCT	cis	rs6450176	0.625	rs67656636	chr5:53288455	C/A	ch.5.1024479R	chr5:53302184	ARL15	-0.69	-5.58	-0.45	1.45e-7	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg07636037	chr3:49044803	WDR6	0.97	10.64	0.69	3.45e-19	Parkinson's disease;
TGCT	cis	rs75686122	0.892	rs77475063	chr8:104586060	T/A	cg04852977	chr8:104510831	NA	0.59	4.45	0.37	1.92e-5	Cocaine dependence;
TGCT	trans	rs208520	1.000	rs12216109	chr6:66987488	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.83	7.46	0.56	1.31e-11	Exhaled nitric oxide output;
TGCT	cis	rs1997103	0.954	rs1997099	chr7:55405540	T/C	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs911263	0.603	rs12878627	chr14:68795149	G/A	cg18825221	chr14:68749962	RAD51L1	0.22	4.46	0.37	1.82e-5	Primary biliary cholangitis;
TGCT	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.68	5.72	0.46	7.46e-8	Tonsillectomy;
TGCT	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg20203395	chr5:56204925	C5orf35	0.79	6.24	0.49	6.41e-9	Initial pursuit acceleration;
TGCT	cis	rs4252435	0.614	rs56874942	chr7:142600954	A/T	cg09833174	chr7:143059591	FAM131B	-0.96	-4.52	-0.38	1.41e-5	Cancer;
TGCT	cis	rs2204008	0.583	rs12820907	chr12:37990931	T/C	cg13010199	chr12:38710504	ALG10B	0.61	4.89	0.4	3.05e-6	Bladder cancer;
TGCT	cis	rs12579753	0.879	rs11115002	chr12:82153090	C/T	cg21231944	chr12:82153410	PPFIA2	-0.35	-4.61	-0.38	9.96e-6	Resting heart rate;
TGCT	trans	rs9383153	1.000	rs9370888	chr6:16335544	A/G	cg18843856	chr2:121651050	GLI2	0.83	6.66	0.51	7.84e-10	Gambling;
TGCT	cis	rs9905704	0.647	rs12943705	chr17:57097047	T/C	cg05425664	chr17:57184151	TRIM37	0.68	5.61	0.45	1.25e-7	Testicular germ cell tumor;
TGCT	cis	rs10782582	0.609	rs1001160	chr1:76358591	A/C	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.52	4.54	0.38	1.31e-5	Daytime sleep phenotypes;
TGCT	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg01416388	chr22:39784598	NA	-0.72	-7.15	-0.54	6.43e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs2677744	0.962	rs1266486	chr15:91460284	T/C	cg22570213	chr15:91497863	RCCD1	0.37	4.5	0.37	1.54e-5	Attention deficit hyperactivity disorder;
TGCT	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg13770153	chr20:60521292	NA	-0.62	-7.94	-0.58	1.02e-12	Body mass index;
TGCT	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg07507251	chr3:52567010	NT5DC2	0.47	6.75	0.52	4.97e-10	Electroencephalogram traits;
TGCT	trans	rs225245	0.541	rs321613	chr17:33881718	G/A	cg19694781	chr19:47549865	TMEM160	-0.36	-6.69	-0.51	6.94e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs7829975	0.514	rs2976929	chr8:8258712	T/C	cg15556689	chr8:8085844	FLJ10661	0.73	6.64	0.51	8.65e-10	Mood instability;
TGCT	cis	rs9911578	1.000	rs2643119	chr17:56827760	G/T	cg12560992	chr17:57184187	TRIM37	0.76	9.34	0.64	4.88e-16	Intelligence (multi-trait analysis);
TGCT	trans	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg27523141	chr10:43048294	ZNF37B	0.74	8.66	0.61	2.13e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs1862618	0.525	rs2662019	chr5:56263104	A/G	cg12311346	chr5:56204834	C5orf35	0.6	5.39	0.44	3.46e-7	Initial pursuit acceleration;
TGCT	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg07217954	chr7:1067459	C7orf50	-0.49	-4.83	-0.4	3.96e-6	Bronchopulmonary dysplasia;
TGCT	cis	rs7091068	0.616	rs1409336	chr10:95479674	T/G	cg20715218	chr10:95462985	C10orf4	0.56	5.29	0.43	5.36e-7	Urinary tract infection frequency;
TGCT	cis	rs4862307	0.836	rs4643860	chr4:184997945	T/C	cg06737308	chr4:185021514	ENPP6	-0.33	-4.78	-0.39	4.92e-6	Serum dimethylarginine levels (asymmetric/symetric ratio);
TGCT	cis	rs6121246	0.609	rs6060843	chr20:30297047	G/C	cg13852791	chr20:30311386	BCL2L1	0.77	7.0	0.53	1.44e-10	Mean corpuscular hemoglobin;
TGCT	cis	rs7246657	0.722	rs8110865	chr19:38047387	G/A	cg18154014	chr19:37997991	ZNF793	0.69	4.63	0.38	9.25e-6	Coronary artery calcification;
TGCT	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg02788857	chr8:22132959	PIWIL2	0.29	5.14	0.42	1.04e-6	Hypertriglyceridemia;
TGCT	cis	rs2066819	0.818	rs703830	chr12:56701872	T/C	cg26714650	chr12:56694279	CS	1.53	8.28	0.6	1.67e-13	Psoriasis vulgaris;
TGCT	cis	rs12984174	1.000	rs403439	chr19:18142075	A/G	cg21649277	chr19:18117794	ARRDC2	-0.71	-4.64	-0.38	8.84e-6	Pulmonary function in asthmatics;
TGCT	cis	rs17401966	0.540	rs11121557	chr1:10448260	T/G	cg19773385	chr1:10388646	KIF1B	-0.22	-5.27	-0.43	5.96e-7	Hepatocellular carcinoma;
TGCT	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.18	0.49	8.32e-9	Bipolar disorder;
TGCT	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg25036284	chr2:26402008	FAM59B	0.65	5.18	0.42	8.59e-7	Gut microbiome composition (summer);
TGCT	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg06112835	chr11:68658793	MRPL21	0.47	8.32	0.6	1.32e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9467711	0.559	rs2295593	chr6:26501768	C/T	cg16898833	chr6:26189333	HIST1H4D	1.01	5.1	0.42	1.21e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1129187	0.782	rs9462860	chr6:42947013	G/C	cg27588902	chr6:42928151	GNMT	-0.57	-7.0	-0.53	1.39e-10	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs9513593	1.000	rs7331894	chr13:99852952	C/T	cg21788972	chr13:99853209	UBAC2	0.61	4.96	0.41	2.24e-6	Psoriasis;
TGCT	cis	rs2439831	1.000	rs2467740	chr15:43746792	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.01	8.37	0.6	1.02e-13	Lung cancer in ever smokers;
TGCT	cis	rs6741892	0.536	rs13024840	chr2:38895920	T/A	cg08308459	chr2:38893161	GALM	-0.7	-4.61	-0.38	9.7e-6	5-HTT brain serotonin transporter levels;
TGCT	cis	rs5769765	0.955	rs9616367	chr22:50303515	A/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.17	-11.76	-0.73	6.61e-22	Schizophrenia;
TGCT	cis	rs7267979	0.966	rs6107031	chr20:25350677	C/T	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.75	0.52	5.11e-10	Bipolar disorder;
TGCT	cis	rs4808199	0.948	rs757001	chr19:19448808	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.69	5.33	0.43	4.49e-7	Nonalcoholic fatty liver disease;
TGCT	cis	rs9611565	0.592	rs4822044	chr22:41979668	G/C	cg03806693	chr22:41940476	POLR3H	-1.1	-11.57	-0.72	1.86e-21	Vitiligo;
TGCT	cis	rs3796352	1.000	rs116616340	chr3:53132371	C/G	cg27565382	chr3:53032988	SFMBT1	0.4	4.44	0.37	1.94e-5	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs968567	0.528	rs174582	chr11:61607168	A/G	cg19610905	chr11:61596333	FADS2	-0.89	-6.8	-0.52	3.93e-10	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
TGCT	cis	rs6671200	0.688	rs4950024	chr1:95713499	A/G	cg06440946	chr1:95699313	RWDD3	-0.62	-5.3	-0.43	5.09e-7	Stearic acid (18:0) levels;
TGCT	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg09165964	chr15:75287851	SCAMP5	0.57	5.36	0.43	3.86e-7	Breast cancer;
TGCT	cis	rs8072100	0.935	rs8070759	chr17:45638760	C/T	cg08085267	chr17:45401833	C17orf57	0.42	4.6	0.38	1.01e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs11779988	0.545	rs415840	chr8:17782134	C/T	cg01800426	chr8:17659068	MTUS1	-0.67	-5.19	-0.42	8.49e-7	Breast cancer;
TGCT	cis	rs2050392	0.928	rs2250077	chr10:30702929	A/G	cg13289132	chr10:30722225	MAP3K8	-0.36	-4.47	-0.37	1.72e-5	Inflammatory bowel disease;
TGCT	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg10047753	chr17:41438598	NA	0.95	9.61	0.65	1.12e-16	Menopause (age at onset);
TGCT	cis	rs7909074	0.831	rs11239271	chr10:45376294	A/G	cg04218760	chr10:45406644	TMEM72	-0.31	-5.95	-0.47	2.52e-8	Mean corpuscular volume;
TGCT	cis	rs2235642	0.928	rs56289115	chr16:1608934	A/G	cg00463982	chr16:1583984	IFT140;TMEM204	-0.28	-4.79	-0.4	4.64e-6	Coronary artery disease;
TGCT	cis	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg20637647	chr7:64974828	NA	0.97	5.37	0.43	3.82e-7	Diabetic kidney disease;
TGCT	cis	rs6952808	0.575	rs10280993	chr7:1948096	T/C	cg22963979	chr7:1858916	MAD1L1	-0.37	-5.62	-0.45	1.22e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs7666738	0.830	rs6831925	chr4:98947401	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.94	7.92	0.58	1.17e-12	Platelet count;
TGCT	cis	rs7647973	0.961	rs11130187	chr3:49307872	T/C	cg05785598	chr3:49045655	WDR6	0.39	4.61	0.38	9.91e-6	Menarche (age at onset);
TGCT	cis	rs853679	0.550	rs1233699	chr6:28169158	A/T	cg12963246	chr6:28129442	ZNF389	0.48	4.85	0.4	3.66e-6	Depression;
TGCT	trans	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg27523141	chr10:43048294	ZNF37B	0.74	8.58	0.61	3.28e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs4843185	0.731	rs10514608	chr16:85713173	C/G	cg07795346	chr16:84800637	USP10	0.23	4.54	0.38	1.31e-5	Platelet distribution width;
TGCT	cis	rs13064411	0.696	rs1552432	chr3:113225660	G/C	cg18753928	chr3:113234510	CCDC52	-0.71	-5.78	-0.46	5.63e-8	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs67311347	1.000	rs951560	chr3:40463471	A/G	cg17264618	chr3:40429014	ENTPD3	0.32	4.76	0.39	5.36e-6	Renal cell carcinoma;
TGCT	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg20607798	chr8:58055168	NA	0.45	4.62	0.38	9.32e-6	Developmental language disorder (linguistic errors);
TGCT	trans	rs877282	0.945	rs11253390	chr10:788678	A/G	cg22713356	chr15:30763199	NA	1.16	10.26	0.68	3.01e-18	Uric acid levels;
TGCT	cis	rs727505	0.721	rs67277928	chr7:124776704	G/T	cg23710748	chr7:124431027	NA	-0.25	-4.63	-0.38	9.13e-6	Lewy body disease;
TGCT	cis	rs79387448	0.592	rs76362690	chr2:102951477	A/G	cg09003973	chr2:102972529	NA	1.4	9.44	0.65	2.87e-16	Gut microbiota (bacterial taxa);
TGCT	cis	rs9916302	0.904	rs7223331	chr17:37482930	A/G	cg07936489	chr17:37558343	FBXL20	0.65	5.08	0.41	1.36e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs3733585	0.657	rs62286568	chr4:10124889	C/T	cg11266682	chr4:10021025	SLC2A9	-0.51	-5.88	-0.47	3.61e-8	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs28830936	0.509	rs6493004	chr15:41858687	A/G	cg17847044	chr15:42102381	MAPKBP1	0.19	4.71	0.39	6.42e-6	Diastolic blood pressure;
TGCT	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg11764359	chr7:65958608	NA	-0.6	-5.32	-0.43	4.63e-7	Aortic root size;
TGCT	trans	rs3808502	0.503	rs2061830	chr8:11397457	C/G	cg06636001	chr8:8085503	FLJ10661	0.72	6.86	0.52	2.86e-10	Neuroticism;
TGCT	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg14820908	chr5:178986412	RUFY1	0.59	6.22	0.49	6.87e-9	Lung cancer;
TGCT	cis	rs1552244	0.554	rs6800204	chr3:9995404	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.32	-4.84	-0.4	3.76e-6	Alzheimer's disease;
TGCT	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg02038168	chr22:39784481	NA	0.77	6.61	0.51	1.02e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs9611565	0.559	rs6002408	chr22:41967870	C/T	cg17554472	chr22:41940697	POLR3H	-0.49	-5.08	-0.41	1.36e-6	Vitiligo;
TGCT	cis	rs9811920	0.609	rs9872871	chr3:99658702	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.59	6.77	0.52	4.51e-10	Axial length;
TGCT	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.45	-0.5	2.31e-9	Alzheimer's disease;
TGCT	cis	rs9517320	0.515	rs9556969	chr13:99195948	T/C	cg07423050	chr13:99094983	FARP1	-0.28	-5.44	-0.44	2.76e-7	Longevity;
TGCT	cis	rs244731	1.000	rs244731	chr5:176539679	C/T	cg17509989	chr5:176798049	RGS14	0.55	6.52	0.51	1.6e-9	Urate levels in lean individuals;
TGCT	cis	rs9357506	0.875	rs9395175	chr6:46315337	A/T	cg21115430	chr6:46460003	NA	-0.26	-5.16	-0.42	9.6e-7	Body mass index;
TGCT	cis	rs6964587	1.000	rs6946356	chr7:91727385	G/A	cg22709100	chr7:91322751	NA	0.29	4.8	0.4	4.45e-6	Breast cancer;
TGCT	cis	rs11252926	0.507	rs4881199	chr10:428090	C/G	cg13477178	chr10:375248	DIP2C	-0.26	-5.03	-0.41	1.65e-6	Psychosis in Alzheimer's disease;
TGCT	cis	rs9788682	0.948	rs59133824	chr15:78833450	C/A	cg06917634	chr15:78832804	PSMA4	-0.7	-4.86	-0.4	3.47e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg01341218	chr17:43662625	NA	1.09	9.23	0.64	9.27e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs709400	0.663	rs2273703	chr14:103918029	C/G	cg26031613	chr14:104095156	KLC1	0.83	9.07	0.63	2.22e-15	Body mass index;
TGCT	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg16680214	chr1:154839983	KCNN3	-0.36	-7.26	-0.55	3.81e-11	Prostate cancer;
TGCT	cis	rs9902453	0.967	rs4533341	chr17:28495672	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	6.51	0.5	1.66e-9	Coffee consumption (cups per day);
TGCT	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg27121462	chr16:89883253	FANCA	0.81	9.17	0.64	1.26e-15	Vitiligo;
TGCT	cis	rs3020736	0.500	rs5996110	chr22:42493767	A/G	cg15557168	chr22:42548783	NA	0.22	5.58	0.45	1.47e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs17152411	0.901	rs7081640	chr10:126592522	C/T	cg07906193	chr10:126599966	NA	0.32	4.59	0.38	1.09e-5	Height;
TGCT	cis	rs9467711	0.606	rs9358939	chr6:26416787	C/G	cg10795676	chr6:26370623	BTN3A2	-0.45	-4.56	-0.38	1.23e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9814567	0.806	rs4074521	chr3:134325536	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.78	7.26	0.55	3.68e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs2933343	0.601	rs1680759	chr3:128594896	C/G	cg11901034	chr3:128598214	ACAD9	-0.66	-6.11	-0.48	1.2e-8	IgG glycosylation;
TGCT	cis	rs1062177	0.855	rs6892117	chr5:151264985	C/T	cg00977110	chr5:151150581	G3BP1	-0.39	-4.45	-0.37	1.87e-5	Preschool internalizing problems;
TGCT	cis	rs4455778	0.659	rs13237643	chr7:49025116	C/T	cg26309511	chr7:48887640	NA	-0.45	-5.25	-0.43	6.39e-7	Lung cancer in never smokers;
TGCT	cis	rs62209	0.800	rs201078	chr10:11002752	A/G	cg26901096	chr10:10994189	LOC254312	0.28	4.77	0.39	5.12e-6	Alzheimer's disease (late onset);
TGCT	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg18876405	chr7:65276391	NA	-0.37	-5.58	-0.45	1.47e-7	Aortic root size;
TGCT	cis	rs7586879	1.000	rs6736711	chr2:25116456	C/T	cg01884057	chr2:25150051	NA	0.28	5.03	0.41	1.69e-6	Body mass index;
TGCT	cis	rs7843479	0.965	rs1484162	chr8:21831385	A/G	cg17168535	chr8:21777572	XPO7	0.63	5.72	0.46	7.3900000000000007e-08	Mean corpuscular volume;
TGCT	cis	rs6570726	0.791	rs7765675	chr6:145915077	A/C	cg23711669	chr6:146136114	FBXO30	0.89	9.62	0.65	1.06e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6669072	0.703	rs3843306	chr1:91288130	A/T	cg08895590	chr1:91227319	NA	0.4	5.11	0.42	1.19e-6	Cognitive function;
TGCT	cis	rs6722750	1.000	rs12475563	chr2:64384515	G/A	cg22352474	chr2:64371530	PELI1	0.6	5.26	0.43	6.15e-7	Neuroticism;
TGCT	cis	rs4808199	0.948	rs12982276	chr19:19459800	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.65	4.91	0.4	2.77e-6	Nonalcoholic fatty liver disease;
TGCT	cis	rs3796352	1.000	rs34313969	chr3:52995166	A/G	cg07884673	chr3:53033167	SFMBT1	0.6	5.53	0.44	1.82e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs3806843	0.868	rs2262573	chr5:140123627	T/A	cg19875535	chr5:140030758	IK	-0.35	-5.92	-0.47	2.89e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2346177	0.875	rs2881327	chr2:46641955	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.43	-4.84	-0.4	3.73e-6	HDL cholesterol;
TGCT	cis	rs12989701	0.825	rs4663097	chr2:127861906	C/G	cg08168897	chr2:127865431	BIN1	-0.52	-6.32	-0.49	4.3e-9	Alzheimer's disease (late onset);
TGCT	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg13409248	chr3:40428643	ENTPD3	0.57	4.53	0.38	1.37e-5	Renal cell carcinoma;
TGCT	cis	rs12579753	0.833	rs1922566	chr12:82135030	T/C	cg21231944	chr12:82153410	PPFIA2	-0.36	-4.7	-0.39	6.72e-6	Resting heart rate;
TGCT	cis	rs6570726	0.557	rs403956	chr6:145829956	T/C	cg23711669	chr6:146136114	FBXO30	0.71	6.51	0.5	1.72e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.03	0.53	1.23e-10	Prudent dietary pattern;
TGCT	cis	rs2180341	0.711	rs4371861	chr6:127568447	G/T	cg24812749	chr6:127587940	RNF146	0.65	5.96	0.47	2.45e-8	Breast cancer;
TGCT	cis	rs7909074	0.966	rs4268464	chr10:45401081	T/A	cg05187965	chr10:45406764	TMEM72	-0.23	-4.88	-0.4	3.25e-6	Mean corpuscular volume;
TGCT	cis	rs7666738	0.830	rs10009206	chr4:99056900	A/C	cg17366294	chr4:99064904	C4orf37	-0.72	-7.45	-0.56	1.39e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs74233809	1.000	rs10883808	chr10:104721126	A/T	cg05855489	chr10:104503620	C10orf26	0.74	4.45	0.37	1.87e-5	Birth weight;
TGCT	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.27	4.87	0.4	3.38e-6	Schizophrenia;
TGCT	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9549367	0.756	rs9549702	chr13:113881944	T/G	cg00898013	chr13:113819073	PROZ	-0.41	-5.21	-0.42	7.7300000000000005e-07	Platelet distribution width;
TGCT	cis	rs2549003	1.000	rs2070731	chr5:131819798	T/C	cg21138405	chr5:131827807	IRF1	0.18	4.71	0.39	6.49e-6	Asthma (sex interaction);
TGCT	cis	rs4713118	0.615	rs9348772	chr6:27656090	G/T	cg10876282	chr6:28092338	ZSCAN16	0.51	5.19	0.42	8.45e-7	Parkinson's disease;
TGCT	cis	rs6840360	0.571	rs4696275	chr4:152530981	C/T	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.0	-0.58	7.69e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs6725041	0.819	rs10172865	chr2:213089339	G/A	cg20637307	chr2:213403960	ERBB4	-0.52	-4.47	-0.37	1.72e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs17331151	0.573	rs2276818	chr3:52864635	A/G	cg11137980	chr3:52469226	SEMA3G	0.29	5.14	0.42	1.04e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs78487399	0.808	rs6757251	chr2:43734847	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-4.79	-0.4	4.67e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs2153535	0.580	rs9393022	chr6:8466588	T/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg27286337	chr10:134555280	INPP5A	0.38	4.57	0.38	1.17e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs4808199	0.947	rs2099333	chr19:19605963	C/T	cg03709012	chr19:19516395	GATAD2A	1.0	7.8	0.57	2.23e-12	Nonalcoholic fatty liver disease;
TGCT	trans	rs551517	0.541	rs576559	chr9:113642646	T/C	cg18410444	chr5:89825535	LYSMD3	0.66	6.73	0.52	5.51e-10	Post bronchodilator FEV1 in COPD;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
TGCT	cis	rs6121246	0.559	rs6087782	chr20:30391580	C/T	cg13852791	chr20:30311386	BCL2L1	0.8	7.42	0.55	1.61e-11	Mean corpuscular hemoglobin;
TGCT	cis	rs9611565	0.921	rs5751080	chr22:41736267	A/G	cg06634786	chr22:41940651	POLR3H	-0.63	-6.01	-0.47	1.93e-8	Vitiligo;
TGCT	cis	rs1107366	0.513	rs10934761	chr3:125973585	G/T	cg01346077	chr3:125931526	NA	0.32	5.3	0.43	5.03e-7	Metabolite levels;
TGCT	cis	rs12971120	1.000	rs12971120	chr18:72174023	A/G	cg25817165	chr18:72167213	CNDP2	-0.25	-4.5	-0.37	1.56e-5	Refractive error;
TGCT	cis	rs11209002	0.571	rs7531772	chr1:67555516	T/C	cg02640540	chr1:67518911	SLC35D1	0.56	4.66	0.39	8.05e-6	Crohn's disease;
TGCT	cis	rs7786808	0.653	rs7810861	chr7:158212633	G/A	cg01191920	chr7:158217561	PTPRN2	-0.38	-6.01	-0.48	1.88e-8	Obesity-related traits;
TGCT	cis	rs67311347	1.000	rs9332450	chr3:40458041	C/T	cg13683864	chr3:40499215	RPL14	1.04	10.79	0.7	1.54e-19	Renal cell carcinoma;
TGCT	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg07870213	chr5:140052090	DND1	0.67	7.91	0.58	1.22e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs778371	0.676	rs13024330	chr2:233715487	A/G	cg08000102	chr2:233561755	GIGYF2	0.67	7.67	0.57	4.47e-12	Schizophrenia;
TGCT	cis	rs6558174	0.965	rs2404655	chr8:22490209	T/C	cg03733263	chr8:22462867	KIAA1967	0.68	5.47	0.44	2.42e-7	Breast cancer;
TGCT	cis	rs11247915	0.600	rs11247920	chr1:26665478	C/T	cg01414934	chr1:26605969	SH3BGRL3	0.21	4.51	0.38	1.46e-5	Obesity-related traits;
TGCT	cis	rs79387448	0.505	rs17027327	chr2:103122513	C/A	cg09003973	chr2:102972529	NA	0.85	5.65	0.45	1.03e-7	Gut microbiota (bacterial taxa);
TGCT	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg24531977	chr5:56204891	C5orf35	0.68	7.14	0.54	6.98e-11	Initial pursuit acceleration;
TGCT	cis	rs12049351	0.774	rs6671385	chr1:229642652	C/T	cg12130225	chr1:229698885	NA	0.39	4.6	0.38	1.02e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs250677	0.687	rs250663	chr5:148453117	T/C	cg18129178	chr5:148520854	ABLIM3	-0.43	-6.29	-0.49	5.05e-9	Breast cancer;
TGCT	cis	rs3771570	1.000	rs59496049	chr2:242260756	G/C	cg21155796	chr2:242212141	HDLBP	0.93	6.82	0.52	3.63e-10	Prostate cancer;
TGCT	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg12564285	chr5:131593104	PDLIM4	0.37	4.44	0.37	1.98e-5	Acylcarnitine levels;
TGCT	cis	rs2230307	0.536	rs482466	chr1:100488177	C/T	cg24955406	chr1:100503596	HIAT1	0.72	4.62	0.38	9.34e-6	Carotid intima media thickness;
TGCT	cis	rs17384381	0.861	rs2300640	chr1:85823795	C/G	cg16011679	chr1:85725395	C1orf52	0.84	6.5	0.5	1.74e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9611565	0.546	rs739129	chr22:42118249	G/A	cg03806693	chr22:41940476	POLR3H	1.08	11.99	0.73	1.84e-22	Vitiligo;
TGCT	cis	rs4295623	0.504	rs11250160	chr8:11592717	G/A	cg21775007	chr8:11205619	TDH	-0.54	-5.04	-0.41	1.6e-6	Morning vs. evening chronotype;
TGCT	cis	rs12762955	0.561	rs11253567	chr10:1054444	A/G	cg26597838	chr10:835615	NA	0.45	6.03	0.48	1.71e-8	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs2228479	0.867	rs12930056	chr16:89946649	C/A	cg04013166	chr16:89971882	TCF25	0.32	4.46	0.37	1.84e-5	Skin colour saturation;
TGCT	cis	rs4929949	0.724	rs11041986	chr11:8582878	A/G	cg06699848	chr11:8847662	ST5	0.28	4.45	0.37	1.89e-5	Body mass index;
TGCT	cis	rs9372498	0.536	rs9489477	chr6:118946192	T/G	cg07617317	chr6:118971624	C6orf204	0.48	5.08	0.42	1.32e-6	Diastolic blood pressure;
TGCT	cis	rs7402982	0.625	rs4966011	chr15:99204006	G/A	cg03437748	chr15:99193247	IGF1R	0.46	4.56	0.38	1.2e-5	Birth weight;
TGCT	cis	rs909674	0.909	rs1557541	chr22:39851970	C/A	cg02038168	chr22:39784481	NA	-0.7	-5.32	-0.43	4.72e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs10206020	0.885	rs6746052	chr2:1576811	T/C	cg12573674	chr2:1569213	NA	-0.46	-5.2	-0.42	7.88e-7	IgG glycosylation;
TGCT	cis	rs10883723	0.810	rs2296581	chr10:104242886	G/A	cg05855489	chr10:104503620	C10orf26	-0.58	-5.06	-0.41	1.47e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs7542091	0.813	rs2049999	chr1:210031331	A/G	cg21951975	chr1:209979733	IRF6	0.52	5.35	0.43	4.11e-7	Monobrow;
TGCT	cis	rs9372498	0.505	rs72956993	chr6:118949708	A/T	cg21191810	chr6:118973309	C6orf204	-0.38	-4.97	-0.41	2.14e-6	Diastolic blood pressure;
TGCT	cis	rs9549367	0.789	rs912012	chr13:113886152	G/A	cg18105134	chr13:113819100	PROZ	-0.34	-5.45	-0.44	2.63e-7	Platelet distribution width;
TGCT	cis	rs3008870	0.959	rs2815359	chr1:67494374	T/C	cg03991309	chr1:68237761	GNG12	0.27	4.5	0.37	1.56e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs4332037	0.539	rs55993248	chr7:2071132	A/G	cg25834613	chr7:1915315	MAD1L1	-0.52	-5.11	-0.42	1.2e-6	Bipolar disorder;
TGCT	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg12042659	chr19:58951599	ZNF132	0.52	4.82	0.4	4.18e-6	Uric acid clearance;
TGCT	cis	rs13177918	0.557	rs12520101	chr5:149810923	C/T	cg14059543	chr5:149831962	NA	-0.69	-8.62	-0.61	2.65e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg21862992	chr11:68658383	NA	0.45	6.29	0.49	5.02e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9388451	0.839	rs4897155	chr6:126095144	C/A	cg10911889	chr6:126070802	HEY2	0.54	5.64	0.45	1.09e-7	Brugada syndrome;
TGCT	cis	rs2290402	0.536	rs73207790	chr4:865430	G/A	cg23332689	chr4:987652	IDUA;SLC26A1	0.32	4.97	0.41	2.18e-6	Type 2 diabetes;
TGCT	cis	rs2795502	1.000	rs2744092	chr10:43339343	T/C	cg20628663	chr10:43360327	NA	-0.44	-6.37	-0.5	3.4e-9	Blood protein levels;
TGCT	cis	rs274567	0.711	rs404771	chr5:131635092	A/T	cg24060327	chr5:131705240	SLC22A5	-0.71	-7.62	-0.56	5.58e-12	Blood metabolite levels;
TGCT	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg10802521	chr3:52805072	NEK4	-0.78	-10.0	-0.67	1.28e-17	Electroencephalogram traits;
TGCT	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.46	4.86	0.4	3.51e-6	Lymphocyte counts;
TGCT	trans	rs7618501	0.933	rs6809431	chr3:49804119	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	1.03	13.16	0.76	2.65e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs1371867	0.846	rs1660349	chr8:101319326	G/A	cg06636551	chr8:101224915	SPAG1	-0.48	-6.52	-0.51	1.62e-9	Atrioventricular conduction;
TGCT	cis	rs6701037	0.512	rs2285216	chr1:175133012	C/T	cg08873628	chr1:175162347	KIAA0040	0.48	4.57	0.38	1.15e-5	Alcohol dependence;
TGCT	cis	rs7208859	0.623	rs56095789	chr17:29060170	A/G	cg14008862	chr17:28927542	LRRC37B2	0.77	4.59	0.38	1.08e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs644799	0.710	rs473852	chr11:95568757	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	7.83	0.58	1.82e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs6598955	0.724	rs12754536	chr1:26639605	T/C	cg04990556	chr1:26633338	UBXN11	-0.91	-11.98	-0.73	1.92e-22	Obesity-related traits;
TGCT	cis	rs6754311	0.550	rs12994270	chr2:136518103	T/A	cg07169764	chr2:136633963	MCM6	-0.66	-6.11	-0.48	1.2e-8	Mosquito bite size;
TGCT	cis	rs9303401	0.659	rs7223708	chr17:56896398	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs28595532	0.920	rs115576008	chr4:119736967	T/C	cg14228332	chr4:119757509	SEC24D	1.31	7.06	0.54	1.06e-10	Cannabis dependence symptom count;
TGCT	cis	rs3749237	0.636	rs1568662	chr3:49521263	A/G	cg07636037	chr3:49044803	WDR6	0.63	6.07	0.48	1.47e-8	Resting heart rate;
TGCT	cis	rs6570726	0.935	rs368848	chr6:145855281	A/T	cg23711669	chr6:146136114	FBXO30	0.71	7.03	0.53	1.25e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs514406	0.800	rs4926930	chr1:53217335	A/G	cg08859206	chr1:53392774	SCP2	0.4	5.88	0.47	3.56e-8	Monocyte count;
TGCT	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg23221052	chr5:179740743	GFPT2	-0.35	-5.6	-0.45	1.34e-7	Height;
TGCT	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.7	-5.79	-0.46	5.35e-8	Tonsillectomy;
TGCT	cis	rs67311347	1.000	rs7642906	chr3:40492633	G/A	cg17264618	chr3:40429014	ENTPD3	-0.31	-4.52	-0.38	1.44e-5	Renal cell carcinoma;
TGCT	cis	rs7659604	0.540	rs4833769	chr4:122672970	A/C	cg19748678	chr4:122722346	EXOSC9	0.5	4.86	0.4	3.5e-6	Type 2 diabetes;
TGCT	cis	rs3862260	0.509	rs3795663	chr1:120165187	G/A	cg16322792	chr1:120165303	ZNF697	0.35	8.4	0.6	8.92e-14	Systemic lupus erythematosus;
TGCT	cis	rs1971256	0.500	rs17081284	chr6:151800796	C/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.74	-4.49	-0.37	1.63e-5	Endometriosis;
TGCT	trans	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg21659725	chr3:3221576	CRBN	-0.76	-9.03	-0.63	2.74e-15	Intelligence (multi-trait analysis);
TGCT	trans	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg21659725	chr3:3221576	CRBN	-0.7	-7.98	-0.58	8.35e-13	Body mass index;
TGCT	cis	rs6988636	1.000	rs58177772	chr8:124188067	T/C	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs7296418	0.922	rs1727293	chr12:123648032	C/T	cg00376283	chr12:123451042	ABCB9	0.83	7.59	0.56	6.61e-12	Platelet count;
TGCT	cis	rs10206020	0.921	rs72778005	chr2:1573122	C/G	cg01028140	chr2:1542097	TPO	-0.31	-4.77	-0.39	5.07e-6	IgG glycosylation;
TGCT	cis	rs7584330	0.910	rs12465081	chr2:238401784	A/G	cg08992911	chr2:238395768	MLPH	0.56	4.6	0.38	1.03e-5	Prostate cancer;
TGCT	cis	rs4595586	0.545	rs12823721	chr12:39386461	G/A	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs13315871	1.000	rs71311868	chr3:58392874	A/G	cg12435725	chr3:58293450	RPP14	-0.43	-4.47	-0.37	1.71e-5	Cholesterol, total;
TGCT	cis	rs10858047	0.943	rs9729280	chr1:115076994	G/A	cg12756093	chr1:115239321	AMPD1	0.45	4.64	0.38	8.87e-6	Autism;
TGCT	cis	rs9291683	0.632	rs7679916	chr4:10042160	C/T	cg11266682	chr4:10021025	SLC2A9	0.64	8.75	0.62	1.29e-14	Bone mineral density;
TGCT	cis	rs1635	0.655	rs60698636	chr6:28316045	A/G	cg15743358	chr6:28303923	ZNF323	-1.25	-6.08	-0.48	1.37e-8	Schizophrenia;
TGCT	trans	rs2727020	0.658	rs4980431	chr11:49350071	G/T	cg15704280	chr7:45808275	SEPT13	-0.69	-7.78	-0.57	2.45e-12	Coronary artery disease;
TGCT	trans	rs208520	0.690	rs2797693	chr6:66868985	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-10.43	-0.68	1.13e-18	Exhaled nitric oxide output;
TGCT	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg22968622	chr17:43663579	NA	-1.23	-10.98	-0.7	5.31e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs12142240	0.698	rs79490411	chr1:46813568	G/A	cg00530320	chr1:46809349	NSUN4	0.27	5.19	0.42	8.25e-7	Menopause (age at onset);
TGCT	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	16.07	0.82	4.16e-32	Prudent dietary pattern;
TGCT	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg06873352	chr17:61820015	STRADA	0.58	6.39	0.5	3.01e-9	Prudent dietary pattern;
TGCT	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg09323728	chr8:95962352	TP53INP1	-0.52	-6.6	-0.51	1.05e-9	Type 2 diabetes;
TGCT	cis	rs4654899	0.580	rs1977296	chr1:21091543	G/T	cg01072550	chr1:21505969	NA	-0.53	-8.89	-0.62	6.03e-15	Superior frontal gyrus grey matter volume;
TGCT	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg05368731	chr17:41323189	NBR1	1.16	13.44	0.77	5.72e-26	Menopause (age at onset);
TGCT	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg13206674	chr6:150067644	NUP43	0.52	4.46	0.37	1.78e-5	Lung cancer;
TGCT	cis	rs1451375	0.669	rs4512339	chr7:50646977	C/T	cg18232548	chr7:50535776	DDC	-0.46	-7.1	-0.54	8.31e-11	Malaria;
TGCT	cis	rs870825	0.616	rs2696037	chr4:185610940	C/T	cg14471096	chr4:185570637	CCDC111;CASP3	-0.67	-4.62	-0.38	9.4e-6	Blood protein levels;
TGCT	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg12963246	chr6:28129442	ZNF389	0.52	5.1	0.42	1.23e-6	Depression;
TGCT	cis	rs7267979	0.668	rs4815398	chr20:25237338	C/T	cg03522245	chr20:25566470	NINL	-0.48	-4.58	-0.38	1.12e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7017914	0.967	rs12680988	chr8:71695890	T/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.53	-4.98	-0.41	2.09e-6	Bone mineral density;
TGCT	cis	rs9443189	0.570	rs7765254	chr6:76398143	T/C	cg01950844	chr6:76311363	SENP6	1.01	6.27	0.49	5.46e-9	Prostate cancer;
TGCT	cis	rs9534288	0.797	rs7331368	chr13:46609062	G/C	cg15192986	chr13:46630673	CPB2	-0.53	-7.66	-0.57	4.65e-12	Blood protein levels;
TGCT	cis	rs7267979	1.000	rs6050617	chr20:25421648	C/T	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg23131131	chr22:24373011	LOC391322	-0.8	-8.69	-0.62	1.78e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1153858	0.943	rs11070454	chr15:45680252	C/T	cg26924012	chr15:45694286	SPATA5L1	1.09	15.16	0.81	5.15e-30	Homoarginine levels;
TGCT	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg23574427	chr4:122746245	BBS7;CCNA2	-0.34	-5.12	-0.42	1.12e-6	Type 2 diabetes;
TGCT	cis	rs739496	0.542	rs7300400	chr12:111792179	A/C	cg10833066	chr12:111807467	FAM109A	0.44	7.52	0.56	9.58e-12	Platelet count;
TGCT	cis	rs17331151	0.541	rs4687676	chr3:52890418	C/T	cg27565382	chr3:53032988	SFMBT1	-0.46	-5.85	-0.47	4.05e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	5.71	0.46	8.05e-8	Alzheimer's disease;
TGCT	cis	rs2115630	1.000	rs11854291	chr15:85363708	T/C	cg17173187	chr15:85201210	NMB	-0.4	-4.93	-0.4	2.56e-6	P wave terminal force;
TGCT	cis	rs7552404	0.656	rs11161792	chr1:76336746	C/T	cg22875332	chr1:76189707	ACADM	0.57	5.65	0.45	1.03e-7	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs10089	1.000	rs1560636	chr5:127447987	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	8.19	0.59	2.7e-13	Ileal carcinoids;
TGCT	cis	rs9534288	0.619	rs9526146	chr13:46680854	C/T	cg15192986	chr13:46630673	CPB2	-0.5	-6.0	-0.47	2.05e-8	Blood protein levels;
TGCT	cis	rs1878931	0.582	rs27239	chr16:3442140	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.76	-6.45	-0.5	2.3e-9	Body mass index (adult);
TGCT	cis	rs13343954	0.778	rs10426551	chr19:33541514	A/G	cg07624008	chr19:33672378	NA	-0.28	-4.71	-0.39	6.43e-6	Colorectal cancer;
TGCT	cis	rs1205863	0.748	rs1205860	chr6:11943271	G/A	cg07106625	chr6:11870215	NA	0.51	5.05	0.41	1.51e-6	Disc degeneration (lumbar);
TGCT	cis	rs2738459	0.500	rs2738465	chr19:11242496	G/A	cg13393778	chr19:10342129	S1PR2	-0.52	-4.5	-0.37	1.57e-5	LDL cholesterol;
TGCT	trans	rs1496653	0.602	rs35209889	chr3:23517148	G/A	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs910316	1.000	rs12889309	chr14:75593902	C/T	cg08847533	chr14:75593920	NEK9	0.96	10.86	0.7	1.05e-19	Height;
TGCT	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg06713675	chr4:122721982	EXOSC9	-0.69	-9.69	-0.66	7.11e-17	Type 2 diabetes;
TGCT	cis	rs9467773	0.572	rs13213953	chr6:26594534	T/A	cg15659132	chr6:26577336	NA	0.84	10.07	0.67	8.62e-18	Intelligence (multi-trait analysis);
TGCT	cis	rs12682352	0.602	rs6993494	chr8:8667444	C/T	cg08975724	chr8:8085496	FLJ10661	0.52	4.46	0.37	1.84e-5	Neuroticism;
TGCT	cis	rs2786098	0.577	rs12046808	chr1:197818024	G/A	cg00114966	chr1:197893920	LHX9	0.39	4.72	0.39	6.15e-6	Asthma;
TGCT	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg10411590	chr13:21900810	NA	0.38	5.06	0.41	1.48e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
TGCT	trans	rs7618501	1.000	rs6785549	chr3:49736565	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-1.04	-13.29	-0.77	1.33e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg17264618	chr3:40429014	ENTPD3	0.34	4.98	0.41	2.1e-6	Renal cell carcinoma;
TGCT	cis	rs7226408	0.802	rs72887098	chr18:34511073	C/T	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs9926296	0.546	rs9935541	chr16:89905925	G/C	cg04287289	chr16:89883240	FANCA	0.72	7.27	0.55	3.59e-11	Vitiligo;
TGCT	cis	rs9811920	0.581	rs793468	chr3:99538346	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.6	6.82	0.52	3.63e-10	Axial length;
TGCT	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg08280861	chr8:58055591	NA	0.38	4.75	0.39	5.45e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9430161	0.579	rs11121669	chr1:11039567	T/C	cg02454025	chr1:11042201	C1orf127	0.97	12.71	0.75	3.27e-24	Ewing sarcoma;
TGCT	cis	rs78487399	0.908	rs7576643	chr2:43841269	C/T	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.62	4.46	0.37	1.84e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs2932538	0.883	rs6701351	chr1:113139196	G/A	cg22162597	chr1:113214053	CAPZA1	0.25	5.6	0.45	1.34e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs7267979	1.000	rs6050564	chr20:25344231	G/A	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1555895	0.611	rs12774722	chr10:854675	G/A	cg02193355	chr10:851439	NA	0.2	4.55	0.38	1.28e-5	Survival in rectal cancer;
TGCT	cis	rs28551159	1	rs28551159	chr6:26376368	A/G	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Urinary tract infection frequency;
TGCT	cis	rs709400	0.628	rs11622320	chr14:103912194	A/T	cg26031613	chr14:104095156	KLC1	0.88	9.75	0.66	5.05e-17	Body mass index;
TGCT	cis	rs6840360	0.642	rs6845648	chr4:152376050	C/T	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.83e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.49	-6.62	-0.51	9.56e-10	Alzheimer's disease;
TGCT	cis	rs6918586	0.636	rs198816	chr6:26127184	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.66	-6.22	-0.49	7.01e-9	Schizophrenia;
TGCT	cis	rs9905704	0.647	rs12944274	chr17:57041293	C/G	cg05425664	chr17:57184151	TRIM37	0.6	4.81	0.4	4.33e-6	Testicular germ cell tumor;
TGCT	cis	rs2013441	1.000	rs2703818	chr17:20119976	T/A	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.61	-0.38	9.96e-6	Obesity-related traits;
TGCT	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	4.62	0.38	9.36e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	6.18	0.49	8.58e-9	Bipolar disorder;
TGCT	cis	rs116095464	0.558	rs62346508	chr5:203668	T/C	cg12570787	chr5:219185	SDHA;CCDC127	0.73	4.63	0.38	9.01e-6	Breast cancer;
TGCT	cis	rs7666738	0.830	rs35938349	chr4:98974998	T/C	cg05340658	chr4:99064831	C4orf37	0.5	5.72	0.46	7.3900000000000007e-08	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2439831	0.681	rs540031	chr15:43608855	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.02	8.51	0.61	4.91e-14	Lung cancer in ever smokers;
TGCT	cis	rs2639990	1.000	rs655156	chr18:72898181	T/C	cg21330207	chr18:72916311	ZADH2	0.52	4.61	0.38	9.8e-6	Vascular endothelial growth factor levels;
TGCT	cis	rs1997103	1.000	rs4628219	chr7:55410449	A/G	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs67072384	0.818	rs2291291	chr11:72466897	T/C	cg03713592	chr11:72463424	ARAP1	-0.93	-4.68	-0.39	7.3e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs3780378	0.935	rs2149560	chr9:5082106	G/T	cg02405213	chr9:5042618	JAK2	-0.62	-8.3	-0.6	1.48e-13	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg10047753	chr17:41438598	NA	0.81	7.67	0.57	4.38e-12	Menopause (age at onset);
TGCT	trans	rs1814175	0.817	rs1794162	chr11:49899506	A/C	cg15704280	chr7:45808275	SEPT13	-0.71	-8.02	-0.58	6.85e-13	Height;
TGCT	cis	rs9902453	0.933	rs1128156	chr17:28513176	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	6.39	0.5	3.03e-9	Coffee consumption (cups per day);
TGCT	cis	rs912057	0.601	rs1294411	chr6:6739034	T/C	cg06612196	chr6:6737390	NA	0.49	7.31	0.55	2.85e-11	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg18876405	chr7:65276391	NA	-0.36	-5.41	-0.44	3.12e-7	Aortic root size;
TGCT	cis	rs1215050	0.791	rs165250	chr4:98696259	G/A	cg05340658	chr4:99064831	C4orf37	0.44	5.52	0.44	1.85e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs8032315	0.965	rs7497304	chr15:91429176	G/T	cg04510874	chr15:91427884	FES	0.51	5.71	0.46	7.76e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs936229	0.651	rs12908814	chr15:75132490	C/G	cg10253484	chr15:75165896	SCAMP2	-0.52	-4.79	-0.4	4.59e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
TGCT	cis	rs2014572	0.904	rs10412465	chr19:57753931	T/C	cg24459738	chr19:57751996	ZNF805	-0.57	-5.53	-0.44	1.84e-7	Hyperactive-impulsive symptoms;
TGCT	cis	rs6969780	0.632	rs11762730	chr7:27190398	A/C	cg04317399	chr7:27170313	HOXA4	-0.37	-4.77	-0.39	5.05e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs6840360	0.615	rs72728171	chr4:152469372	C/A	cg17479576	chr4:152424074	FAM160A1	-0.71	-7.74	-0.57	2.96e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs644799	1.000	rs481630	chr11:95582447	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	10.43	0.68	1.13e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg06481639	chr22:41940642	POLR3H	-0.75	-6.67	-0.51	7.59e-10	Vitiligo;
TGCT	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg16486109	chr11:613632	IRF7	0.35	5.19	0.42	8.4e-7	Systemic lupus erythematosus;
TGCT	cis	rs346785	0.692	rs6501881	chr17:74289839	G/A	cg09812376	chr17:74270190	QRICH2	-0.36	-5.33	-0.43	4.43e-7	White matter hyperintensities in ischemic stroke;
TGCT	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs6835098	0.961	rs28709762	chr4:174099149	T/C	cg08422745	chr4:174089978	GALNT7	-0.9	-10.08	-0.67	7.91e-18	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.12	0.42	1.15e-6	Prudent dietary pattern;
TGCT	cis	rs6088590	0.931	rs6088624	chr20:33436852	T/A	cg06115741	chr20:33292138	TP53INP2	0.62	5.07	0.41	1.43e-6	Coronary artery disease;
TGCT	cis	rs881375	0.967	rs10739579	chr9:123694788	C/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	4.99	0.41	2.03e-6	Rheumatoid arthritis;
TGCT	cis	rs73198271	0.613	rs11249892	chr8:8657240	C/T	cg06671706	chr8:8559999	CLDN23	-0.36	-4.52	-0.38	1.42e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs9399135	0.967	rs4895439	chr6:135318854	A/T	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.36e-6	Red blood cell count;
TGCT	cis	rs807669	0.903	rs1771540	chr22:19173933	T/A	cg02655711	chr22:19163373	SLC25A1	0.42	9.92	0.67	1.94e-17	Metabolite levels;
TGCT	cis	rs748404	0.631	rs6493083	chr15:43637985	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.45	4.64	0.38	8.62e-6	Lung cancer;
TGCT	cis	rs6534347	0.597	rs7698404	chr4:123507053	G/C	cg10583651	chr4:123538969	IL21	-0.32	-4.49	-0.37	1.63e-5	Type 1 diabetes;
TGCT	cis	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg13531842	chr10:38383804	ZNF37A	-0.38	-4.51	-0.38	1.49e-5	Extrinsic epigenetic age acceleration;
TGCT	cis	rs11190604	1.000	rs11190587	chr10:102266638	C/T	cg23241863	chr10:102295624	HIF1AN	0.66	4.86	0.4	3.55e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9814567	1.000	rs4974493	chr3:134219993	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.96	-9.19	-0.64	1.16e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs13217239	0.646	rs10456352	chr6:26990358	A/T	cg05738196	chr6:26577821	NA	0.49	4.78	0.39	4.97e-6	Schizophrenia;
TGCT	cis	rs56036086	0.824	rs56308603	chr22:50630794	G/A	cg01548456	chr22:50352384	NA	0.37	5.26	0.43	5.98e-7	Platelet count;Plateletcrit;
TGCT	cis	rs864745	0.967	rs1708302	chr7:28198677	C/T	cg23620719	chr7:28220237	JAZF1	-0.49	-4.58	-0.38	1.11e-5	Crohn's disease;Type 2 diabetes;
TGCT	cis	rs6879260	0.963	rs11738924	chr5:179727308	A/G	cg02891314	chr5:179741120	GFPT2	-0.39	-6.43	-0.5	2.46e-9	Height;
TGCT	cis	rs10493773	0.609	rs11161660	chr1:86184066	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.52	-8.16	-0.59	3.27e-13	Urate levels in overweight individuals;
TGCT	cis	rs7586879	0.616	rs6545814	chr2:25131316	A/G	cg01884057	chr2:25150051	NA	0.34	6.56	0.51	1.3e-9	Body mass index;
TGCT	cis	rs6840360	0.593	rs6855883	chr4:152688997	A/G	cg22705602	chr4:152727874	NA	-0.35	-5.94	-0.47	2.63e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs1215050	0.682	rs6839343	chr4:98839732	G/A	cg17366294	chr4:99064904	C4orf37	0.57	5.0	0.41	1.95e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs6992820	0.967	rs7816281	chr8:56696726	G/A	cg06880721	chr8:56792545	LYN	-0.53	-4.5	-0.37	1.53e-5	Mean platelet volume;
TGCT	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg19729930	chr2:74357872	NA	0.65	9.35	0.64	4.6e-16	Gestational age at birth (maternal effect);
TGCT	cis	rs7949030	0.626	rs72927213	chr11:62351198	G/C	cg22862634	chr11:62369728	EML3;MTA2	0.7	8.89	0.62	6.15e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9677476	1.000	rs7584535	chr2:232106857	C/T	cg07929768	chr2:232055508	NA	0.3	4.48	0.37	1.71e-5	Food antigen IgG levels;
TGCT	cis	rs8077889	0.703	rs72836567	chr17:41945776	G/A	cg26893861	chr17:41843967	DUSP3	1.05	9.84	0.66	3.08e-17	Triglycerides;
TGCT	cis	rs7666738	0.830	rs11097582	chr4:98772201	G/A	cg17366294	chr4:99064904	C4orf37	0.65	6.79	0.52	4.13e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9796	0.624	rs9920619	chr15:41318845	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.47	-5.96	-0.47	2.49e-8	Menopause (age at onset);
TGCT	cis	rs191220855	1	rs191220855	chr2:200778130	A/G	cg23649088	chr2:200775458	C2orf69	-0.45	-6.15	-0.48	9.86e-9	Chickenpox;
TGCT	cis	rs9388451	0.839	rs4897157	chr6:126102981	A/T	cg05901451	chr6:126070800	HEY2	-1.0	-14.45	-0.79	2.37e-28	Brugada syndrome;
TGCT	cis	rs4803455	0.565	rs11083616	chr19:41865643	A/G	cg09537434	chr19:41945824	ATP5SL	0.51	5.01	0.41	1.85e-6	Migraine;Coronary artery disease;
TGCT	cis	rs7917772	0.503	rs7096072	chr10:104299976	C/T	cg05855489	chr10:104503620	C10orf26	-0.58	-5.06	-0.41	1.47e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg12963246	chr6:28129442	ZNF389	0.51	5.02	0.41	1.73e-6	Parkinson's disease;
TGCT	cis	rs6912958	0.559	rs107690	chr6:88069352	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.57	-0.45	1.51e-7	Monocyte percentage of white cells;
TGCT	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg22535103	chr8:58192502	C8orf71	-0.41	-5.24	-0.43	6.57e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs1580019	0.844	rs1037322	chr7:32501857	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.88	8.65	0.61	2.23e-14	Cognitive ability;
TGCT	cis	rs1568889	1.000	rs61889027	chr11:28281908	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	8.06	0.59	5.42e-13	Bipolar disorder;
TGCT	cis	rs7584330	0.910	rs6737914	chr2:238393434	A/G	cg14458575	chr2:238380390	NA	0.45	6.77	0.52	4.52e-10	Prostate cancer;
TGCT	cis	rs826838	1.000	rs826889	chr12:39101076	G/A	cg26384229	chr12:38710491	ALG10B	-0.88	-8.19	-0.59	2.72e-13	Heart rate;
TGCT	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg21226059	chr5:178986404	RUFY1	0.46	5.02	0.41	1.75e-6	Lung cancer;
TGCT	cis	rs4851266	0.898	rs10496346	chr2:100853267	A/G	cg22139774	chr2:100720529	AFF3	0.31	4.55	0.38	1.27e-5	Educational attainment;
TGCT	cis	rs10276381	0.786	rs28430601	chr7:28238811	A/G	cg23620719	chr7:28220237	JAZF1	1.01	5.39	0.44	3.36e-7	Crohn's disease;
TGCT	cis	rs3820928	0.874	rs7423610	chr2:227836262	A/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-4.58	-0.38	1.1e-5	Pulmonary function;
TGCT	cis	rs2153535	0.504	rs4493781	chr6:8473941	G/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.3e-6	Motion sickness;
TGCT	cis	rs3820068	0.581	rs16849152	chr1:15921774	A/C	cg05660106	chr1:15850417	CASP9	0.83	8.29	0.6	1.58e-13	Systolic blood pressure;
TGCT	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs116095464	0.558	rs10059907	chr5:205360	G/C	cg12570787	chr5:219185	SDHA;CCDC127	0.71	4.51	0.38	1.48e-5	Breast cancer;
TGCT	trans	rs877282	0.898	rs35743076	chr10:758991	C/T	cg22713356	chr15:30763199	NA	1.12	8.42	0.6	7.78e-14	Uric acid levels;
TGCT	cis	rs7267979	1.000	rs2500446	chr20:25339664	C/T	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg03806693	chr22:41940476	POLR3H	1.16	13.52	0.77	3.78e-26	Vitiligo;
TGCT	cis	rs11118844	0.843	rs58850477	chr1:221927229	G/A	cg04222084	chr1:221915650	DUSP10	-0.89	-6.09	-0.48	1.28e-8	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
TGCT	cis	rs1008375	0.898	rs10008445	chr4:17593978	G/T	cg16339924	chr4:17578868	LAP3	0.81	6.69	0.52	6.75e-10	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9467773	1.000	rs6940053	chr6:26562122	C/T	cg26531700	chr6:26746687	NA	0.49	4.73	0.39	6.06e-6	Intelligence (multi-trait analysis);
TGCT	trans	rs62103177	0.714	rs12607447	chr18:77605212	A/G	cg05926928	chr17:57297772	GDPD1	1.05	10.15	0.67	5.52e-18	Opioid sensitivity;
TGCT	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	16.1	0.82	3.69e-32	Prudent dietary pattern;
TGCT	cis	rs12135062	0.851	rs2651927	chr1:3101762	A/C	cg00254258	chr1:3105189	PRDM16	-0.35	-5.74	-0.46	6.91e-8	Migraine;
TGCT	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.64	-6.5	-0.5	1.79e-9	Prostate cancer;
TGCT	cis	rs1153858	1.000	rs16942000	chr15:45633003	C/T	cg14582100	chr15:45693742	SPATA5L1	0.48	5.7	0.46	8.17e-8	Homoarginine levels;
TGCT	cis	rs7178572	0.568	rs12916731	chr15:77507021	C/T	cg22256960	chr15:77711686	NA	-0.87	-8.87	-0.62	6.78e-15	Type 2 diabetes;
TGCT	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg19723775	chr5:179050963	HNRNPH1	0.51	5.18	0.42	8.81e-7	Lung cancer;
TGCT	cis	rs9616064	0.813	rs9627512	chr22:46977702	C/T	cg04500879	chr22:46327243	WNT7B	0.28	4.57	0.38	1.17e-5	Urate levels in obese individuals;
TGCT	cis	rs9926296	0.681	rs12923946	chr16:89821080	C/T	cg08627397	chr16:89984028	MC1R	-0.29	-4.59	-0.38	1.07e-5	Vitiligo;
TGCT	cis	rs79349575	0.715	rs55724082	chr17:47017879	G/A	cg26022315	chr17:47021804	SNF8	0.5	4.96	0.41	2.23e-6	Type 2 diabetes;
TGCT	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg19010396	chr19:19431384	KIAA0892;SF4	-0.56	-4.58	-0.38	1.13e-5	Tonsillectomy;
TGCT	trans	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg27523141	chr10:43048294	ZNF37B	0.74	8.66	0.61	2.13e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs10904887	0.846	rs1885396	chr10:17243351	C/T	cg01003015	chr10:17271136	VIM	-0.6	-5.46	-0.44	2.5e-7	Telomere length;
TGCT	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg03709012	chr19:19516395	GATAD2A	-0.66	-5.7	-0.46	8.46e-8	Tonsillectomy;
TGCT	cis	rs9486719	1.000	rs3798295	chr6:97052164	C/T	cg18709589	chr6:96969512	KIAA0776	-0.74	-5.21	-0.42	7.5e-7	Migraine;Coronary artery disease;
TGCT	cis	rs9916302	0.706	rs667239	chr17:37442241	A/G	cg07936489	chr17:37558343	FBXL20	0.81	5.99	0.47	2.16e-8	Glomerular filtration rate (creatinine);
TGCT	cis	rs4478858	0.735	rs7556340	chr1:31788453	A/T	cg07478791	chr1:31886160	SERINC2	-0.51	-4.93	-0.41	2.55e-6	Alcohol dependence;
TGCT	cis	rs2239547	0.603	rs17304995	chr3:53070755	A/G	cg11645453	chr3:52864694	ITIH4	0.32	5.02	0.41	1.72e-6	Schizophrenia;
TGCT	cis	rs35000415	0.938	rs13239597	chr7:128695983	C/A	cg06242719	chr7:129414860	MIR183;MIR96	-0.34	-4.67	-0.39	7.73e-6	Systemic lupus erythematosus;
TGCT	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg17345569	chr6:42928274	GNMT	-0.48	-4.91	-0.4	2.82e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg18305652	chr10:134549665	INPP5A	0.35	5.64	0.45	1.1e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs6993813	0.620	rs4546691	chr8:120025004	G/A	cg17171407	chr8:119960777	TNFRSF11B	0.26	4.66	0.39	8.02e-6	Bone mineral density (hip);
TGCT	cis	rs9467773	0.572	rs3846846	chr6:26445039	A/G	cg05738196	chr6:26577821	NA	-0.52	-5.49	-0.44	2.18e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9913156	0.793	rs7210953	chr17:4608870	C/T	cg19197139	chr17:4613644	ARRB2	0.83	7.74	0.57	3.03e-12	Lymphocyte counts;
TGCT	cis	rs8033133	0.602	rs12438531	chr15:25323876	A/C	cg14481604	chr15:25334117	SNORD116-22	-0.23	-5.17	-0.42	9.25e-7	Blood osmolality (transformed sodium);
TGCT	cis	rs7264396	0.733	rs6060515	chr20:34211779	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.28	-4.67	-0.39	7.62e-6	Total cholesterol levels;
TGCT	cis	rs7312933	0.558	rs11181507	chr12:42844763	T/A	cg19980929	chr12:42632907	YAF2	0.43	6.13	0.48	1.08e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs9733	0.544	rs72700902	chr1:150633347	C/T	cg09365446	chr1:150670422	GOLPH3L	0.31	4.64	0.38	8.7e-6	Tonsillectomy;
TGCT	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.55	4.92	0.4	2.74e-6	Prudent dietary pattern;
TGCT	cis	rs7829975	0.748	rs693109	chr8:8640172	C/A	cg15556689	chr8:8085844	FLJ10661	-0.69	-6.05	-0.48	1.62e-8	Mood instability;
TGCT	cis	rs7781977	0.644	rs10269380	chr7:50354512	G/A	cg14216940	chr7:50343131	IKZF1	0.36	4.51	0.38	1.48e-5	IgG glycosylation;
TGCT	trans	rs10435719	0.867	rs35778860	chr8:11791338	C/T	cg15556689	chr8:8085844	FLJ10661	0.75	7.26	0.55	3.66e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg04608855	chr19:58913158	NA	0.58	5.64	0.45	1.11e-7	Uric acid clearance;
TGCT	cis	rs6665290	0.904	rs1045286	chr1:227179037	A/C	cg10327440	chr1:227177885	CDC42BPA	0.91	17.25	0.84	9.67e-35	Myeloid white cell count;
TGCT	cis	rs7772486	0.790	rs80050589	chr6:146230454	T/C	cg05347473	chr6:146136440	FBXO30	-0.52	-5.03	-0.41	1.67e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7666738	0.830	rs28818218	chr4:98880575	A/C	cg05340658	chr4:99064831	C4orf37	0.54	6.13	0.48	1.06e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7542091	0.579	rs34638782	chr1:210032055	C/G	cg22029157	chr1:209979665	IRF6	0.51	4.92	0.4	2.68e-6	Monobrow;
TGCT	cis	rs1878931	0.582	rs4785933	chr16:3419741	T/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.76	6.35	0.5	3.66e-9	Body mass index (adult);
TGCT	cis	rs9467773	1.000	rs10214634	chr6:26564582	T/A	cg26531700	chr6:26746687	NA	0.49	4.73	0.39	6.06e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs709400	0.930	rs28513222	chr14:104028069	A/T	cg26031613	chr14:104095156	KLC1	1.16	15.24	0.81	3.33e-30	Body mass index;
TGCT	cis	rs2688608	0.905	rs2633300	chr10:75656647	A/C	cg04320760	chr10:75533139	FUT11	-0.3	-4.58	-0.38	1.1e-5	Inflammatory bowel disease;
TGCT	cis	rs11711311	0.866	rs13313893	chr3:113400856	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.77	-7.04	-0.53	1.16e-10	IgG glycosylation;
TGCT	cis	rs644799	0.710	rs10831429	chr11:95508524	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.29	0.6	1.54e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.12	0.42	1.15e-6	Prudent dietary pattern;
TGCT	cis	rs28595532	0.764	rs115986119	chr4:119767785	C/T	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs694739	1.000	rs694739	chr11:64097233	A/G	cg02228329	chr11:64053129	BAD;GPR137	0.79	7.87	0.58	1.54e-12	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs4711350	0.862	rs530614	chr6:33714781	G/A	cg18005901	chr6:33739558	LEMD2	0.57	5.94	0.47	2.62e-8	Schizophrenia;
TGCT	trans	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg21659725	chr3:3221576	CRBN	-0.69	-7.57	-0.56	7.35e-12	Body mass index;
TGCT	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg18538332	chr22:24372958	LOC391322	-1.01	-12.89	-0.76	1.18e-24	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1008375	0.966	rs7666888	chr4:17695722	C/T	cg18681998	chr4:17616180	MED28	0.75	7.38	0.55	2e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7191439	0.583	rs9935872	chr16:88788477	A/G	cg27087555	chr16:88793112	FAM38A	-0.43	-4.81	-0.4	4.34e-6	Plateletcrit;
TGCT	cis	rs6912958	0.559	rs242267	chr6:88061837	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.69	-7.11	-0.54	8.14e-11	Monocyte percentage of white cells;
TGCT	cis	rs6987853	0.901	rs2923429	chr8:42389743	A/G	cg20539142	chr8:42623718	CHRNA6	-0.21	-5.03	-0.41	1.69e-6	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs3806843	0.900	rs2337983	chr5:140136808	G/A	cg19875535	chr5:140030758	IK	-0.36	-6.16	-0.48	9.15e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs5769765	0.908	rs4074304	chr22:50309446	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.24	-12.96	-0.76	8.23e-25	Schizophrenia;
TGCT	trans	rs561341	0.505	rs548298	chr17:30297494	C/A	cg20587970	chr11:113659929	NA	-1.03	-10.98	-0.7	5.21e-20	Hip circumference adjusted for BMI;
TGCT	cis	rs7666738	0.830	rs13106434	chr4:98991651	T/A	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg23131131	chr22:24373011	LOC391322	-0.8	-8.64	-0.61	2.41e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs35146811	0.625	rs2906645	chr7:99817859	A/G	cg04778012	chr7:99775508	STAG3;GPC2	-0.36	-5.1	-0.42	1.22e-6	Coronary artery disease;
TGCT	cis	rs7954584	0.616	rs10743186	chr12:122356436	C/T	cg13699009	chr12:122356056	WDR66	0.32	7.33	0.55	2.6e-11	Mean corpuscular volume;
TGCT	cis	rs13242816	1.000	rs12669740	chr7:116138576	T/C	cg02799643	chr7:116139180	CAV2	-0.45	-5.85	-0.47	4.03e-8	P wave duration;
TGCT	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg12310025	chr6:25882481	NA	0.53	4.83	0.4	4.01e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs849210	0.517	rs3856509	chr2:206180836	A/G	cg11793701	chr2:206547163	NRP2	-0.54	-4.49	-0.37	1.62e-5	Tonsillectomy;
TGCT	cis	rs1372520	0.935	rs1372519	chr4:90757309	A/G	cg01966878	chr4:90757139	SNCA	-0.3	-4.59	-0.38	1.09e-5	Neuroticism;
TGCT	cis	rs2204008	0.713	rs11173567	chr12:38089375	T/C	cg26384229	chr12:38710491	ALG10B	0.85	7.65	0.57	4.91e-12	Bladder cancer;
TGCT	cis	rs7267979	0.903	rs2500400	chr20:25354705	A/G	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs34638657	0.732	rs4889477	chr16:82201302	C/T	cg09439754	chr16:82129088	HSD17B2	-0.24	-4.53	-0.38	1.37e-5	Lung adenocarcinoma;
TGCT	cis	rs2228479	0.850	rs76075456	chr16:89834270	T/C	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.99	11.35	0.71	6.6e-21	Height;
TGCT	cis	rs3026101	0.576	rs56188406	chr17:5316769	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	4.78	0.39	4.97e-6	Body mass index;
TGCT	cis	rs17767294	0.708	rs72846792	chr6:28133311	C/T	cg08851530	chr6:28072375	NA	1.47	6.82	0.52	3.64e-10	Parkinson's disease;
TGCT	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg24829409	chr8:58192753	C8orf71	-0.64	-5.31	-0.43	4.89e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg05368731	chr17:41323189	NBR1	1.08	11.0	0.7	4.76e-20	Menopause (age at onset);
TGCT	cis	rs2172802	0.570	rs2343526	chr4:62521386	T/C	cg04118610	chr4:62707027	LPHN3	0.42	4.95	0.41	2.41e-6	Partial epilepsies;
TGCT	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg14893161	chr1:205819251	PM20D1	0.51	6.98	0.53	1.54e-10	Menarche (age at onset);
TGCT	cis	rs10174077	0.874	rs10186656	chr2:152475938	T/G	cg06191203	chr2:152266755	RIF1	-0.69	-6.39	-0.5	3.05e-9	Squamous cell lung carcinoma;
TGCT	cis	rs7824557	0.628	rs6988922	chr8:11194911	A/G	cg21775007	chr8:11205619	TDH	0.7	6.86	0.52	2.93e-10	Retinal vascular caliber;
TGCT	cis	rs739496	0.579	rs12316525	chr12:112344119	T/C	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs4851254	0.618	rs35840153	chr2:100669829	A/G	cg07810366	chr2:100720526	AFF3	-0.49	-5.04	-0.41	1.61e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9457247	1.000	rs10946198	chr6:167404432	C/T	cg23791538	chr6:167370224	RNASET2	-0.49	-4.96	-0.41	2.26e-6	Crohn's disease;
TGCT	cis	rs1843834	0.721	rs1434057	chr2:225606389	T/G	cg22455342	chr2:225449267	CUL3	0.65	6.26	0.49	5.64e-9	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs4906332	0.782	rs12891288	chr14:103999750	C/T	cg26031613	chr14:104095156	KLC1	-0.58	-4.68	-0.39	7.51e-6	Coronary artery disease;
TGCT	cis	rs826838	0.900	rs11169301	chr12:39128497	C/A	cg13010199	chr12:38710504	ALG10B	0.72	5.75	0.46	6.7e-8	Heart rate;
TGCT	cis	rs9393692	0.905	rs9379838	chr6:26277133	C/T	cg00631329	chr6:26305371	NA	-0.41	-6.09	-0.48	1.34e-8	Educational attainment;
TGCT	cis	rs739496	0.615	rs7312260	chr12:112358663	T/G	cg10833066	chr12:111807467	FAM109A	0.38	5.42	0.44	2.97e-7	Platelet count;
TGCT	cis	rs7647973	0.925	rs9834003	chr3:49216472	T/C	cg05785598	chr3:49045655	WDR6	0.38	4.68	0.39	7.48e-6	Menarche (age at onset);
TGCT	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg14983838	chr19:29218262	NA	0.83	6.76	0.52	4.75e-10	Methadone dose in opioid dependence;
TGCT	cis	rs7586879	0.593	rs10198275	chr2:25130542	A/C	cg01884057	chr2:25150051	NA	0.36	7.09	0.54	8.92e-11	Body mass index;
TGCT	cis	rs751728	0.664	rs4711347	chr6:33735292	G/A	cg13859433	chr6:33739653	LEMD2	-0.32	-5.83	-0.46	4.46e-8	Crohn's disease;
TGCT	cis	rs9467773	0.620	rs2451741	chr6:26629404	A/G	cg15659132	chr6:26577336	NA	0.86	11.04	0.7	3.71e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs4523957	0.583	rs1565763	chr17:2055300	T/C	cg16513277	chr17:2031491	SMG6	-0.2	-4.64	-0.38	8.69e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs11874712	0.527	rs1866321	chr18:43698309	C/T	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.49	4.86	0.4	3.47e-6	Migraine - clinic-based;
TGCT	cis	rs7681440	0.874	rs1372523	chr4:90775923	G/A	cg26578617	chr4:90757533	SNCA	-0.44	-4.54	-0.38	1.31e-5	Dementia with Lewy bodies;
TGCT	cis	rs9650657	0.675	rs2409658	chr8:10668965	A/G	cg27411982	chr8:10470053	RP1L1	-0.22	-5.0	-0.41	1.9e-6	Neuroticism;
TGCT	cis	rs514406	0.679	rs11206006	chr1:53218380	A/G	cg01802117	chr1:53393560	SCP2	0.5	6.0	0.47	2.05e-8	Monocyte count;
TGCT	cis	rs4808199	0.947	rs751858	chr19:19602821	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.75	5.42	0.44	2.93e-7	Nonalcoholic fatty liver disease;
TGCT	cis	rs2688608	0.967	rs2633299	chr10:75656754	T/G	cg04320760	chr10:75533139	FUT11	-0.3	-4.58	-0.38	1.1e-5	Inflammatory bowel disease;
TGCT	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg09365446	chr1:150670422	GOLPH3L	0.31	4.64	0.38	8.74e-6	Tonsillectomy;
TGCT	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	6.03	0.48	1.71e-8	Mean platelet volume;
TGCT	cis	rs739496	0.649	rs666727	chr12:111989658	C/T	cg10833066	chr12:111807467	FAM109A	0.37	5.17	0.42	8.98e-7	Platelet count;
TGCT	cis	rs6693567	0.565	rs1260374	chr1:150331593	G/A	cg09579323	chr1:150459698	TARS2	0.54	4.79	0.4	4.59e-6	Migraine;
TGCT	cis	rs1865760	0.963	rs9356991	chr6:25901758	C/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.65	6.24	0.49	6.27e-9	Height;
TGCT	cis	rs8103278	0.894	rs74821481	chr19:46320041	G/T	cg11657440	chr19:46296263	DMWD	-0.6	-5.72	-0.46	7.58e-8	Coronary artery disease;
TGCT	cis	rs35883536	0.513	rs6577180	chr1:101016939	G/A	cg10298815	chr1:101004474	GPR88	0.25	4.71	0.39	6.56e-6	Monocyte count;
TGCT	cis	rs5769765	0.773	rs138834	chr22:50180497	A/C	cg26441486	chr22:50317300	CRELD2	0.31	4.67	0.39	7.63e-6	Schizophrenia;
TGCT	cis	rs6088590	1.000	rs6120708	chr20:33335526	G/A	cg06115741	chr20:33292138	TP53INP2	0.67	5.61	0.45	1.24e-7	Coronary artery disease;
TGCT	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg07507251	chr3:52567010	NT5DC2	0.45	6.12	0.48	1.13e-8	Bipolar disorder;
TGCT	cis	rs9486719	0.895	rs4486019	chr6:96883814	T/C	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.21	-0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	trans	rs208520	0.690	rs1776365	chr6:66834474	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-10.43	-0.68	1.13e-18	Exhaled nitric oxide output;
TGCT	cis	rs78487399	0.710	rs72881068	chr2:43690860	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.42	-5.56	-0.45	1.57e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs7666738	0.830	rs3907021	chr4:99038668	C/T	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs17376456	0.696	rs6860390	chr5:93494731	G/T	cg25358565	chr5:93447407	FAM172A	-0.63	-5.94	-0.47	2.74e-8	Diabetic retinopathy;
TGCT	cis	rs6088590	1.000	rs2295353	chr20:33356511	C/T	cg06115741	chr20:33292138	TP53INP2	0.67	5.6	0.45	1.34e-7	Coronary artery disease;
TGCT	cis	rs8180040	0.764	rs4082155	chr3:47125385	G/A	cg27129171	chr3:47204927	SETD2	0.74	9.79	0.66	4.15e-17	Colorectal cancer;
TGCT	cis	rs7666738	0.830	rs1426669	chr4:98945534	C/T	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2760061	0.598	rs632832	chr1:228121838	G/T	cg18477163	chr1:228402036	OBSCN	-0.32	-6.37	-0.5	3.31e-9	Diastolic blood pressure;
TGCT	cis	rs78487399	0.808	rs13414619	chr2:43699406	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.42	-5.56	-0.45	1.57e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs571497	0.697	rs62128260	chr19:7833876	T/A	cg07381814	chr19:8576031	ZNF414	-0.3	-4.57	-0.38	1.18e-5	Monocyte count;
TGCT	trans	rs1496653	0.602	rs35021696	chr3:23479478	A/C	cg02770683	chr12:57597238	LRP1	0.38	6.89	0.53	2.53e-10	Type 2 diabetes;
TGCT	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg23982607	chr1:1823379	GNB1	-0.55	-8.5	-0.61	5.16e-14	Body mass index;
TGCT	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg23708337	chr7:1209742	NA	0.51	4.46	0.37	1.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7804356	0.651	rs73061889	chr7:26799874	A/C	cg03456212	chr7:26904342	SKAP2	-0.54	-4.6	-0.38	1.04e-5	Type 1 diabetes;
TGCT	cis	rs739496	0.542	rs7399251	chr12:111802680	C/T	cg10833066	chr12:111807467	FAM109A	0.47	7.09	0.54	9.07e-11	Platelet count;
TGCT	cis	rs35160687	0.901	rs12714179	chr2:86514958	T/C	cg12542933	chr2:85804724	VAMP8	0.4	4.79	0.39	4.75e-6	Night sleep phenotypes;
TGCT	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg09222892	chr1:25734099	RHCE	-0.43	-6.92	-0.53	2.09e-10	Erythrocyte sedimentation rate;
TGCT	cis	rs2933343	0.903	rs2638846	chr3:128587163	A/T	cg11901034	chr3:128598214	ACAD9	-0.62	-5.16	-0.42	9.47e-7	IgG glycosylation;
TGCT	cis	rs28595532	0.841	rs114363775	chr4:119765587	G/A	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg25036284	chr2:26402008	FAM59B	-0.53	-4.58	-0.38	1.1e-5	Gut microbiome composition (summer);
TGCT	cis	rs7843479	0.601	rs2306645	chr8:21845428	C/T	cg17168535	chr8:21777572	XPO7	-0.8	-7.93	-0.58	1.11e-12	Mean corpuscular volume;
TGCT	cis	rs2290405	0.527	rs7663192	chr4:923947	T/C	cg04824913	chr4:887549	GAK	0.35	4.75	0.39	5.64e-6	Systemic sclerosis;
TGCT	cis	rs7769051	0.711	rs7770081	chr6:133089569	G/T	cg07930552	chr6:133119739	C6orf192	0.93	5.0	0.41	1.87e-6	Type 2 diabetes nephropathy;
TGCT	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg06221963	chr1:154839813	KCNN3	0.76	12.91	0.76	1.09e-24	Prostate cancer;
TGCT	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.61	-6.27	-0.49	5.54e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs1843834	0.539	rs10177898	chr2:225437552	C/T	cg12698349	chr2:225449008	CUL3	0.78	6.41	0.5	2.77e-9	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs10992471	0.603	rs12341817	chr9:95252152	C/T	cg14631576	chr9:95140430	CENPP	-0.31	-4.61	-0.38	9.95e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs12188164	0.965	rs11739543	chr5:443676	G/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.4	-4.71	-0.39	6.42e-6	Cystic fibrosis severity;
TGCT	cis	rs2239547	0.603	rs2276825	chr3:52886605	T/C	cg11645453	chr3:52864694	ITIH4	0.35	5.77	0.46	5.97e-8	Schizophrenia;
TGCT	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.59	-5.71	-0.46	7.79e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs4824093	0.610	rs73441787	chr22:50269646	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.11	-6.79	-0.52	4.13e-10	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs2120019	1.000	rs12185102	chr15:75352201	G/A	cg17294928	chr15:75287854	SCAMP5	-0.81	-6.21	-0.49	7.41e-9	Blood trace element (Zn levels);
TGCT	cis	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg08045932	chr20:61659980	NA	0.49	9.25	0.64	8.4e-16	Prostate cancer (SNP x SNP interaction);
TGCT	trans	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg21659725	chr3:3221576	CRBN	-0.69	-7.51	-0.56	9.95e-12	Body mass index;
TGCT	cis	rs1008375	0.902	rs12503164	chr4:17656107	C/T	cg18681998	chr4:17616180	MED28	1.01	11.89	0.73	3.17e-22	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7267979	1.000	rs6083862	chr20:25411086	A/T	cg14121845	chr20:25566513	NINL	-0.46	-4.99	-0.41	2.01e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs868036	0.609	rs3784707	chr15:68043878	A/C	cg27219399	chr15:67835830	MAP2K5	0.34	4.44	0.37	1.94e-5	Restless legs syndrome;
TGCT	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg04772025	chr11:68637568	NA	0.59	6.69	0.52	6.73e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs12908161	1.000	rs4643294	chr15:85250253	C/T	cg17173187	chr15:85201210	NMB	0.59	6.77	0.52	4.55e-10	Schizophrenia;
TGCT	cis	rs6582630	0.519	rs12578283	chr12:38325349	A/T	cg26384229	chr12:38710491	ALG10B	0.83	7.27	0.55	3.51e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs7308116	1.000	rs7311985	chr12:108236335	C/T	cg19508191	chr12:109124361	CORO1C	-0.45	-4.46	-0.37	1.84e-5	Pelvic organ prolapse (moderate/severe);
TGCT	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg22166914	chr1:53195759	ZYG11B	0.39	6.35	0.5	3.71e-9	Monocyte count;
TGCT	cis	rs1775715	0.675	rs2808085	chr10:32148599	C/T	cg14930904	chr10:32216787	ARHGAP12	0.52	5.12	0.42	1.14e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs5769707	0.837	rs5769709	chr22:50021757	C/T	cg05373962	chr22:49881684	NA	-0.28	-5.32	-0.43	4.6e-7	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs1514658	0.903	rs13119545	chr4:119273712	C/G	cg21605333	chr4:119757512	SEC24D	-0.5	-4.5	-0.37	1.56e-5	Congenital heart disease (maternal effect);
TGCT	cis	rs476633	0.708	rs28656781	chr15:41447440	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.66	-8.77	-0.62	1.18e-14	Glomerular filtration rate (creatinine);
TGCT	cis	rs72945132	0.882	rs72945194	chr11:70138621	A/G	cg00319359	chr11:70116639	PPFIA1	0.97	7.07	0.54	1.01e-10	Coronary artery disease;
TGCT	cis	rs56235845	0.694	rs11738681	chr5:176761535	A/G	cg06060754	chr5:176797920	RGS14	0.4	6.28	0.49	5.16e-9	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs4648739	0.613	rs13303201	chr1:1903712	G/T	cg03688085	chr1:1910585	KIAA1751	-0.51	-8.58	-0.61	3.25e-14	Severe influenza A (H1N1) infection;
TGCT	cis	rs6540559	0.673	rs17015224	chr1:209968918	G/A	cg04352962	chr1:209979756	IRF6	0.65	4.6	0.38	1.05e-5	Cleft lip with or without cleft palate;
TGCT	cis	rs57221529	0.608	rs11749927	chr5:668842	C/T	cg09021430	chr5:549028	NA	-0.32	-4.56	-0.38	1.21e-5	Lung disease severity in cystic fibrosis;
TGCT	cis	rs739496	0.579	rs3752630	chr12:112375990	A/C	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs9911578	1.000	rs2270097	chr17:56572070	G/A	cg05425664	chr17:57184151	TRIM37	0.6	5.83	0.46	4.54e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2439831	0.867	rs2899082	chr15:43656043	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	6.61	0.51	1e-9	Lung cancer in ever smokers;
TGCT	cis	rs7937682	0.889	rs493865	chr11:111495178	A/C	cg09085632	chr11:111637200	PPP2R1B	-1.04	-11.19	-0.71	1.57e-20	Primary sclerosing cholangitis;
TGCT	cis	rs68170813	0.523	rs11766131	chr7:107071138	T/C	cg02696742	chr7:106810147	HBP1	-0.68	-5.44	-0.44	2.69e-7	Coronary artery disease;
TGCT	cis	rs9942416	0.660	rs34905687	chr5:74997736	A/G	cg19683494	chr5:74908142	NA	0.58	6.41	0.5	2.77e-9	Age-related disease endophenotypes;
TGCT	cis	rs861020	0.630	rs656566	chr1:210006603	C/T	cg05527609	chr1:210001259	C1orf107	0.86	7.54	0.56	8.69e-12	Orofacial clefts;
TGCT	cis	rs453301	0.597	rs7001187	chr8:8792782	G/A	cg15556689	chr8:8085844	FLJ10661	-0.63	-5.36	-0.43	3.99e-7	Joint mobility (Beighton score);
TGCT	cis	rs7267979	0.966	rs2387885	chr20:25415224	G/A	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6570726	0.967	rs373527	chr6:145801861	C/T	cg23711669	chr6:146136114	FBXO30	0.66	6.08	0.48	1.37e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1552244	0.507	rs6443274	chr3:9995288	A/T	cg00149659	chr3:10157352	C3orf10	0.65	4.78	0.39	4.85e-6	Alzheimer's disease;
TGCT	cis	rs10089	0.953	rs13358455	chr5:127365786	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	6.93	0.53	2e-10	Ileal carcinoids;
TGCT	cis	rs11190604	0.767	rs7078070	chr10:102166415	A/C	cg16005271	chr10:102321736	NA	0.45	4.74	0.39	5.87e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7267979	1.000	rs6138572	chr20:25435934	G/C	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11030122	0.702	rs10835402	chr11:3990914	T/C	cg18678763	chr11:4115507	RRM1	-0.49	-6.13	-0.48	1.08e-8	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs250677	0.687	rs250664	chr5:148453823	C/T	cg23229984	chr5:148520753	ABLIM3	0.21	4.89	0.4	3.11e-6	Breast cancer;
TGCT	cis	rs2153535	0.560	rs2210798	chr6:8481522	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs7547997	0.685	rs1575172	chr1:158345279	A/G	cg03528325	chr1:158223921	CD1A	0.33	4.56	0.38	1.22e-5	QRS duration;
TGCT	trans	rs7824557	0.510	rs1435274	chr8:11235910	G/A	cg15556689	chr8:8085844	FLJ10661	-0.74	-6.69	-0.51	7.01e-10	Retinal vascular caliber;
TGCT	trans	rs208520	0.874	rs208456	chr6:66907942	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.93	-9.78	-0.66	4.3e-17	Exhaled nitric oxide output;
TGCT	cis	rs473651	0.935	rs483166	chr2:239346641	C/T	cg18131467	chr2:239335373	ASB1	-1.02	-15.09	-0.8	7.51e-30	Multiple system atrophy;
TGCT	cis	rs4555082	1.000	rs66777564	chr14:105760245	A/G	cg10792982	chr14:105748885	BRF1	0.23	4.6	0.38	1.01e-5	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs9517320	0.515	rs1107379	chr13:99198921	C/T	cg07423050	chr13:99094983	FARP1	-0.27	-5.42	-0.44	2.92e-7	Longevity;
TGCT	cis	rs11785693	0.862	rs62489554	chr8:4960685	T/C	cg26367366	chr8:4980734	NA	0.61	4.59	0.38	1.09e-5	Neuroticism (multi-trait analysis);Neuroticism;
TGCT	cis	rs478304	0.654	rs1074155	chr11:65458197	C/T	cg10518572	chr11:65560635	OVOL1	0.23	4.56	0.38	1.19e-5	Acne (severe);
TGCT	cis	rs7781977	0.554	rs7797255	chr7:50351604	C/T	cg01139861	chr7:50343298	IKZF1	-0.48	-5.69	-0.46	8.57e-8	IgG glycosylation;
TGCT	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg23034840	chr1:205782522	SLC41A1	0.5	4.53	0.38	1.39e-5	Menarche (age at onset);
TGCT	cis	rs2535633	0.602	rs2581816	chr3:53014657	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	4.45	0.37	1.89e-5	Body mass index;
TGCT	cis	rs711830	1.000	rs1562315	chr2:177045482	T/A	cg13092806	chr2:177043255	NA	0.81	6.37	0.5	3.34e-9	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
TGCT	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg03609598	chr5:56110824	MAP3K1	-0.58	-4.7	-0.39	6.72e-6	Initial pursuit acceleration;
TGCT	cis	rs35306767	0.761	rs11253559	chr10:1044809	T/C	cg26597838	chr10:835615	NA	0.6	6.63	0.51	9.45e-10	Eosinophil percentage of granulocytes;
TGCT	cis	rs7027203	1.000	rs7856374	chr9:96529791	G/A	cg13679303	chr9:96623674	NA	0.64	9.54	0.65	1.66e-16	DNA methylation (variation);
TGCT	cis	rs7772486	0.790	rs6917482	chr6:146243581	C/T	cg05347473	chr6:146136440	FBXO30	-0.51	-4.95	-0.41	2.32e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7267979	1.000	rs7268053	chr20:25328286	A/T	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs644799	1.000	rs580255	chr11:95577929	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	9.73	0.66	5.62e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs617219	0.710	rs2607141	chr5:78558635	G/T	cg23987322	chr5:78407566	BHMT	0.35	4.69	0.39	7.07e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs17102423	0.731	rs998247	chr14:65546299	C/T	cg11161011	chr14:65562177	MAX	-0.43	-5.91	-0.47	3.04e-8	Obesity-related traits;
TGCT	cis	rs56104184	0.775	rs56349331	chr19:49403009	T/A	cg15549821	chr19:49342101	PLEKHA4	-0.73	-9.15	-0.63	1.47e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs950776	0.648	rs57945453	chr15:78862845	C/T	cg06917634	chr15:78832804	PSMA4	0.68	5.48	0.44	2.24e-7	Sudden cardiac arrest;
TGCT	cis	rs7611238	0.560	rs4677832	chr3:195081244	G/A	cg27323046	chr3:195102265	ACAP2	0.37	5.01	0.41	1.86e-6	Body mass index;
TGCT	cis	rs1949733	1.000	rs1916326	chr4:8500023	G/A	cg13073564	chr4:8508604	NA	0.47	5.05	0.41	1.55e-6	Response to antineoplastic agents;
TGCT	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg02725872	chr8:58115012	NA	-0.39	-4.83	-0.4	3.99e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2290402	0.505	rs9328759	chr4:882845	C/T	cg23332689	chr4:987652	IDUA;SLC26A1	-0.32	-4.88	-0.4	3.17e-6	Type 2 diabetes;
TGCT	cis	rs2456568	0.802	rs10765640	chr11:93636462	C/T	cg16099599	chr11:93583650	C11orf90	-0.4	-4.98	-0.41	2.04e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs2692947	0.537	rs11164050	chr2:96352451	T/C	cg23100626	chr2:96804247	ASTL	0.42	4.82	0.4	4.17e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	trans	rs629535	0.547	rs62513420	chr8:70122597	G/A	cg21567404	chr3:27674614	NA	-0.53	-8.12	-0.59	3.87e-13	Dupuytren's disease;
TGCT	trans	rs7819412	1.000	rs7819412	chr8:11045161	A/G	cg15556689	chr8:8085844	FLJ10661	0.8	7.98	0.58	8.22e-13	Triglycerides;
TGCT	cis	rs3733585	0.699	rs6449159	chr4:9960498	G/A	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.67	-0.51	7.44e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7208859	0.673	rs73277984	chr17:29196133	T/C	cg18442181	chr17:29233375	C17orf42	-0.79	-4.78	-0.39	4.95e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs2980439	0.783	rs2948305	chr8:8098577	G/A	cg06636001	chr8:8085503	FLJ10661	0.88	8.82	0.62	9.02e-15	Neuroticism;
TGCT	cis	rs2074585	0.806	rs2657949	chr15:90950790	G/A	cg00487526	chr15:90818384	NA	-0.29	-4.47	-0.37	1.71e-5	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
TGCT	cis	rs7666738	0.830	rs9994346	chr4:99037986	A/G	cg18180107	chr4:99064573	C4orf37	0.56	4.74	0.39	5.73e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs55882075	1.000	rs55882075	chr5:179210115	C/G	cg14593053	chr5:179126677	CANX	0.48	5.24	0.43	6.58e-7	Monocyte percentage of white cells;
TGCT	cis	rs2180341	0.597	rs3798859	chr6:127663116	C/T	cg24812749	chr6:127587940	RNF146	0.63	5.32	0.43	4.72e-7	Breast cancer;
TGCT	cis	rs9985766	0.917	rs4459971	chr4:150991590	T/G	cg05926478	chr4:151174724	DCLK2	-0.24	-4.64	-0.38	8.63e-6	Coronary artery disease;Myocardial infarction;
TGCT	cis	rs9430161	0.579	rs79323519	chr1:11036050	T/C	cg02454025	chr1:11042201	C1orf127	0.95	10.77	0.7	1.73e-19	Ewing sarcoma;
TGCT	trans	rs2288327	0.643	rs1559908	chr2:179336347	C/T	cg14011486	chr1:26737247	LIN28	-1.07	-8.55	-0.61	3.9e-14	Atrial fibrillation;
TGCT	cis	rs9443645	0.901	rs6912683	chr6:79543492	C/A	cg09184832	chr6:79620586	NA	-0.49	-5.42	-0.44	2.96e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7552404	0.961	rs448710	chr1:76116554	T/C	cg10523679	chr1:76189770	ACADM	-0.93	-10.18	-0.67	4.69e-18	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs902774	0.515	rs2363635	chr12:53354622	T/C	cg14581129	chr12:53358946	NA	-0.56	-6.14	-0.48	1.02e-8	Prostate cancer;
TGCT	cis	rs6912958	0.781	rs7757636	chr6:88256092	T/G	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.91	-0.4	2.78e-6	Monocyte percentage of white cells;
TGCT	cis	rs727563	0.562	rs5758458	chr22:42154132	G/A	cg06634786	chr22:41940651	POLR3H	0.86	8.01	0.58	7.16e-13	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs12681287	0.927	rs2976177	chr8:87332332	A/T	cg27223183	chr8:87520930	FAM82B	-0.88	-6.82	-0.52	3.62e-10	Caudate activity during reward;
TGCT	cis	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg18252515	chr7:66147081	NA	-1.13	-6.81	-0.52	3.7e-10	Diabetic kidney disease;
TGCT	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg11366901	chr6:160182831	ACAT2	1.01	6.74	0.52	5.42e-10	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs559406	0.623	rs12971201	chr18:12830538	G/A	cg23598886	chr18:12777645	NA	0.37	4.49	0.37	1.6e-5	Psoriasis;
TGCT	cis	rs4478858	0.718	rs10914329	chr1:31688441	T/A	cg00250761	chr1:31883323	NA	0.29	4.78	0.39	4.9e-6	Alcohol dependence;
TGCT	cis	rs2371030	1.000	rs1019392	chr2:211593082	A/C	cg18417063	chr2:211583084	NA	-0.31	-4.45	-0.37	1.91e-5	Non-small cell lung cancer;
TGCT	cis	rs13191362	1.000	rs13190742	chr6:163008758	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.72	0.39	6.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	trans	rs629535	0.814	rs477200	chr8:70059584	A/G	cg21567404	chr3:27674614	NA	0.5	8.28	0.6	1.67e-13	Dupuytren's disease;
TGCT	cis	rs2180341	1.000	rs7453272	chr6:127633959	C/T	cg24812749	chr6:127587940	RNF146	-0.94	-6.5	-0.5	1.79e-9	Breast cancer;
TGCT	cis	rs78456975	1.000	rs4073861	chr2:1563611	G/A	cg01028140	chr2:1542097	TPO	-0.33	-4.54	-0.38	1.29e-5	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs78487399	0.808	rs12105786	chr2:43676433	T/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.24	-0.43	6.79e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs362272	0.524	rs13150241	chr4:3367281	A/G	cg18352616	chr4:3374830	RGS12	0.23	4.54	0.38	1.31e-5	Serum sulfate level;
TGCT	cis	rs3935685	0.934	rs61331678	chr15:77995949	G/C	cg25212270	chr15:78015279	NA	0.3	6.06	0.48	1.48e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs12682352	0.602	rs13260419	chr8:8675176	A/G	cg06636001	chr8:8085503	FLJ10661	0.6	5.07	0.41	1.41e-6	Neuroticism;
TGCT	cis	rs3008870	1.000	rs2985825	chr1:67412822	T/G	cg03991309	chr1:68237761	GNG12	0.27	4.57	0.38	1.18e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	trans	rs2727020	0.729	rs10839268	chr11:49380328	G/A	cg03929089	chr4:120376271	NA	-0.76	-8.89	-0.62	6.02e-15	Coronary artery disease;
TGCT	cis	rs11190604	1.000	rs2295776	chr10:102295629	G/T	cg23241863	chr10:102295624	HIF1AN	0.67	5.12	0.42	1.12e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs4689388	0.782	rs4262051	chr4:6281775	G/A	cg00701064	chr4:6280414	WFS1	0.39	4.79	0.4	4.7e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4786125	0.626	rs11077095	chr16:6916451	C/T	cg03623568	chr16:6915990	A2BP1	0.43	6.08	0.48	1.39e-8	Heart rate variability traits (SDNN);
TGCT	cis	rs7172809	0.573	rs11853696	chr15:77688417	C/T	cg22256960	chr15:77711686	NA	-0.5	-4.74	-0.39	5.82e-6	Glucose homeostasis traits;
TGCT	cis	rs7666738	0.830	rs7657982	chr4:99044015	G/A	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	7.99e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6089584	0.606	rs2296082	chr20:60573983	A/G	cg13770153	chr20:60521292	NA	-0.41	-4.95	-0.41	2.39e-6	Body mass index;
TGCT	cis	rs789859	0.965	rs812583	chr3:194406505	C/G	cg21106136	chr3:194405973	FAM43A	-0.38	-5.35	-0.43	4.08e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
TGCT	cis	rs6598541	0.505	rs4966025	chr15:99309542	G/A	cg18742785	chr15:100270048	LYSMD4	-0.26	-4.51	-0.38	1.49e-5	Urate levels;
TGCT	cis	rs12681287	0.673	rs2976178	chr8:87332552	C/G	cg27223183	chr8:87520930	FAM82B	-0.94	-7.06	-0.54	1.02e-10	Caudate activity during reward;
TGCT	cis	rs11785400	0.753	rs9694286	chr8:143737157	G/T	cg24634471	chr8:143751801	JRK	0.57	5.7	0.46	8.4e-8	Schizophrenia;
TGCT	cis	rs710216	0.536	rs710222	chr1:43413653	A/G	cg03128534	chr1:43423976	SLC2A1	0.68	7.15	0.54	6.65e-11	Red cell distribution width;
TGCT	cis	rs9911578	0.874	rs302865	chr17:56756977	A/G	cg05425664	chr17:57184151	TRIM37	-0.62	-6.29	-0.49	5.01e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg05368731	chr17:41323189	NBR1	0.87	8.87	0.62	6.78e-15	Menopause (age at onset);
TGCT	cis	rs7568458	0.811	rs10175792	chr2:85761654	A/G	cg02493740	chr2:85810744	VAMP5	-0.27	-5.01	-0.41	1.8e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	trans	rs7618501	0.932	rs4855850	chr3:49761571	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-1.03	-13.16	-0.76	2.65e-25	Intelligence (multi-trait analysis);
TGCT	cis	rs2677744	1.000	rs1266483	chr15:91462406	A/G	cg23684204	chr15:91497937	RCCD1	0.35	5.23	0.43	7.01e-7	Attention deficit hyperactivity disorder;
TGCT	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg11644478	chr21:40555479	PSMG1	-0.55	-4.77	-0.39	5.12e-6	Cognitive function;
TGCT	cis	rs763121	0.853	rs2076028	chr22:39150450	G/A	cg06022373	chr22:39101656	GTPBP1	0.76	7.12	0.54	7.63e-11	Menopause (age at onset);
TGCT	cis	rs7226408	0.802	rs72892528	chr18:34673014	C/T	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs8077889	0.917	rs72836556	chr17:41911824	G/T	cg26893861	chr17:41843967	DUSP3	1.09	13.16	0.76	2.68e-25	Triglycerides;
TGCT	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg08280861	chr8:58055591	NA	0.39	4.93	0.4	2.57e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9811920	0.609	rs704583	chr3:99643693	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.59	-6.77	-0.52	4.51e-10	Axial length;
TGCT	cis	rs801193	1.000	rs17566701	chr7:66193183	T/C	cg18876405	chr7:65276391	NA	0.38	5.83	0.46	4.4e-8	Aortic root size;
TGCT	cis	rs10791097	0.694	rs7107595	chr11:130758556	C/T	cg12179176	chr11:130786555	SNX19	0.83	10.44	0.68	1.05e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg07507251	chr3:52567010	NT5DC2	0.48	6.91	0.53	2.24e-10	Bipolar disorder;
TGCT	cis	rs17270561	0.666	rs4712976	chr6:25842203	C/T	cg16482183	chr6:26056742	HIST1H1C	0.58	4.45	0.37	1.89e-5	Iron status biomarkers;
TGCT	cis	rs2012796	0.872	rs59397507	chr14:81821334	A/G	cg02996355	chr14:81879375	NA	0.47	4.61	0.38	9.68e-6	Night sleep phenotypes;
TGCT	cis	rs9902453	0.845	rs3115099	chr17:28019293	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	7.27	0.55	3.55e-11	Coffee consumption (cups per day);
TGCT	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg24675658	chr1:53192096	ZYG11B	0.75	8.77	0.62	1.18e-14	Monocyte count;
TGCT	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.67	0.39	7.57e-6	Prudent dietary pattern;
TGCT	cis	rs478304	0.651	rs948493	chr11:65552154	C/T	cg27068330	chr11:65405492	SIPA1	-0.95	-9.42	-0.65	3.25e-16	Acne (severe);
TGCT	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.2	0.42	8.14e-7	Menopause (age at onset);
TGCT	cis	rs3820928	0.605	rs7560867	chr2:227780945	C/A	cg11843606	chr2:227700838	RHBDD1	-0.51	-4.83	-0.4	3.89e-6	Pulmonary function;
TGCT	cis	rs3751972	0.668	rs7218395	chr17:26241477	G/A	cg02948944	chr17:26242737	NA	0.39	5.61	0.45	1.26e-7	Fractional exhaled nitric oxide (childhood);
TGCT	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6952809	0.532	rs2023969	chr7:2449980	T/C	cg23289794	chr7:2394357	EIF3B	-0.81	-6.84	-0.52	3.19e-10	Multiple sclerosis;
TGCT	cis	rs66569888	0.710	rs67005606	chr2:106876277	T/C	cg15412446	chr2:106886593	NA	-0.41	-4.47	-0.37	1.72e-5	Facial morphology (factor 23);
TGCT	cis	rs6429082	0.755	rs291371	chr1:235693105	C/G	cg26050004	chr1:235667680	B3GALNT2	0.62	5.88	0.47	3.48e-8	Adiposity;
TGCT	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.69	-0.39	7e-6	Prudent dietary pattern;
TGCT	cis	rs6977660	0.714	rs12386623	chr7:19791875	A/G	cg05791153	chr7:19748676	TWISTNB	-0.88	-5.05	-0.41	1.52e-6	Thyroid stimulating hormone;
TGCT	cis	rs9911578	0.967	rs6503883	chr17:56917543	C/T	cg05425664	chr17:57184151	TRIM37	-0.62	-6.18	-0.49	8.33e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7586879	0.828	rs1077641	chr2:25123665	G/A	cg01884057	chr2:25150051	NA	0.27	4.81	0.4	4.36e-6	Body mass index;
TGCT	cis	rs651907	0.557	rs34624546	chr3:101374226	T/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.91	10.9	0.7	8.24e-20	Colorectal cancer;
TGCT	cis	rs3015497	0.616	rs6572678	chr14:51090115	T/G	cg04730355	chr14:51134070	SAV1	-0.64	-6.04	-0.48	1.64e-8	Mean platelet volume;
TGCT	cis	rs10782582	0.609	rs72979226	chr1:76302222	C/A	cg03433033	chr1:76189801	ACADM	-0.5	-4.98	-0.41	2.11e-6	Daytime sleep phenotypes;
TGCT	cis	rs28595532	0.920	rs112016126	chr4:119726528	C/T	cg14228332	chr4:119757509	SEC24D	1.38	6.93	0.53	2.07e-10	Cannabis dependence symptom count;
TGCT	cis	rs7617773	0.779	rs1045482	chr3:48312229	A/G	cg11946769	chr3:48343235	NME6	0.74	6.92	0.53	2.09e-10	Coronary artery disease;
TGCT	cis	rs9611565	0.568	rs5751159	chr22:42175365	G/A	cg17554472	chr22:41940697	POLR3H	0.43	4.61	0.38	9.67e-6	Vitiligo;
TGCT	cis	rs7000551	0.751	rs2461481	chr8:22382780	A/G	cg12081754	chr8:22256438	SLC39A14	-0.28	-4.44	-0.37	1.96e-5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs4072705	0.835	rs10122154	chr9:127559038	C/T	cg13476313	chr9:127244764	NR5A1	0.3	4.99	0.41	1.96e-6	Menarche (age at onset);
TGCT	cis	rs11644362	1.000	rs72782620	chr16:12987416	T/A	cg06890432	chr16:12997467	SHISA9	-0.6	-6.49	-0.5	1.88e-9	Positive affect;Subjective well-being;
TGCT	cis	rs10791097	0.694	rs1893017	chr11:130756253	C/T	cg14779329	chr11:130786720	SNX19	0.29	4.94	0.41	2.45e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs8017423	0.967	rs60548738	chr14:90724399	G/A	cg04374321	chr14:90722782	PSMC1	0.76	7.71	0.57	3.59e-12	Mortality in heart failure;
TGCT	cis	rs2404602	1.000	rs2404740	chr15:76852143	C/T	cg22467129	chr15:76604101	ETFA	-0.58	-6.68	-0.51	7.09e-10	Blood metabolite levels;
TGCT	cis	rs4285028	0.847	rs1986712	chr3:121710986	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.77	-6.44	-0.5	2.36e-9	Multiple sclerosis;
TGCT	cis	rs17539620	0.624	rs62432736	chr6:154834401	A/G	cg20019720	chr6:154832845	CNKSR3	0.56	4.75	0.39	5.5e-6	Lipoprotein (a) levels;
TGCT	cis	rs6089584	0.888	rs6061405	chr20:60617033	A/G	cg06108461	chr20:60628389	TAF4	-0.69	-10.77	-0.7	1.71e-19	Body mass index;
TGCT	trans	rs8073060	0.586	rs4796101	chr17:33998593	C/T	cg19694781	chr19:47549865	TMEM160	-0.6	-13.37	-0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs9858542	0.537	rs9864406	chr3:49352619	A/G	cg00383909	chr3:49044727	WDR6	0.69	4.78	0.39	4.84e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs6570726	0.967	rs7772286	chr6:145930423	A/T	cg23711669	chr6:146136114	FBXO30	-0.77	-7.57	-0.56	7.21e-12	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.49	-4.76	-0.39	5.34e-6	Bipolar disorder;
TGCT	cis	rs9534288	0.671	rs4942465	chr13:46562687	C/T	cg15192986	chr13:46630673	CPB2	-0.5	-7.03	-0.53	1.23e-10	Blood protein levels;
TGCT	cis	rs7647973	1.000	rs56127630	chr3:49438036	C/G	cg07636037	chr3:49044803	WDR6	-0.72	-5.79	-0.46	5.35e-8	Menarche (age at onset);
TGCT	cis	rs12049671	0.530	rs11018412	chr10:129747902	A/G	cg22891191	chr10:129706234	PTPRE	-0.34	-5.03	-0.41	1.66e-6	Response to amphetamines;
TGCT	cis	rs4820539	0.932	rs3788349	chr22:23467950	A/G	cg21100191	chr22:23484243	RTDR1	0.88	10.0	0.67	1.28e-17	Bone mineral density;
TGCT	cis	rs7659604	0.605	rs1507994	chr4:122749541	C/T	cg19748678	chr4:122722346	EXOSC9	0.8	8.14	0.59	3.52e-13	Type 2 diabetes;
TGCT	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.13	0.82	3.12e-32	Prudent dietary pattern;
TGCT	cis	rs7772486	0.754	rs702319	chr6:146006117	T/C	cg05347473	chr6:146136440	FBXO30	-0.51	-4.8	-0.4	4.44e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7666738	0.830	rs10010698	chr4:98981594	C/T	cg05340658	chr4:99064831	C4orf37	0.5	5.84	0.46	4.35e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7805747	1.000	rs10480299	chr7:151405818	A/G	cg17611936	chr7:151411526	PRKAG2	0.51	6.56	0.51	1.32e-9	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
TGCT	cis	rs9330316	0.588	rs28567471	chr2:110306425	A/G	cg25199208	chr2:109402912	CCDC138	-0.42	-4.52	-0.38	1.42e-5	Schizophrenia;
TGCT	cis	rs11578119	0.933	rs35227427	chr1:170468472	G/A	cg09767346	chr1:170501363	GORAB	0.66	5.29	0.43	5.27e-7	Male-pattern baldness;
TGCT	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.99	8.01	0.58	7.16e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9858542	1.000	rs6770670	chr3:49686682	T/C	cg03060546	chr3:49711283	APEH	-0.67	-6.09	-0.48	1.28e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs7267979	1.000	rs7020	chr20:25278600	G/A	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg17330251	chr7:94953956	PON1	-0.52	-6.93	-0.53	2.05e-10	Paraoxonase activity;
TGCT	cis	rs9926296	0.712	rs258319	chr16:89732024	A/T	cg27121462	chr16:89883253	FANCA	-0.54	-4.87	-0.4	3.38e-6	Vitiligo;
TGCT	cis	rs10927875	0.864	rs12135073	chr1:16167799	C/T	cg21385522	chr1:16154831	NA	0.77	10.36	0.68	1.69e-18	Dilated cardiomyopathy;
TGCT	cis	rs7959452	0.570	rs10878964	chr12:69720691	T/G	cg20891283	chr12:69753455	YEATS4	0.66	6.6	0.51	1.08e-9	Blood protein levels;
TGCT	cis	rs523522	0.962	rs10849753	chr12:120910813	C/T	cg27279351	chr12:120934652	DYNLL1	0.78	6.7	0.52	6.57e-10	High light scatter reticulocyte count;
TGCT	cis	rs1385374	0.858	rs3741615	chr12:129298848	G/A	cg09035930	chr12:129282057	SLC15A4	-0.55	-4.76	-0.39	5.27e-6	Systemic lupus erythematosus;
TGCT	cis	rs1577917	0.771	rs12199873	chr6:86294947	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.58	-0.45	1.43e-7	Response to antipsychotic treatment;
TGCT	cis	rs921968	0.541	rs7601872	chr2:219319885	C/G	cg02176678	chr2:219576539	TTLL4	-0.49	-7.7	-0.57	3.81e-12	Mean corpuscular hemoglobin concentration;
TGCT	trans	rs459571	0.920	rs417142	chr9:136891370	G/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.72	-7.8	-0.57	2.15e-12	Platelet distribution width;
TGCT	cis	rs1577917	1.000	rs16876529	chr6:86591202	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.16	-0.42	9.71e-7	Response to antipsychotic treatment;
TGCT	cis	rs7937682	0.924	rs495460	chr11:111504777	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.1	-11.55	-0.72	2.11e-21	Primary sclerosing cholangitis;
TGCT	cis	rs9436747	0.641	rs11208677	chr1:66048417	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.53	4.72	0.39	6.28e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
TGCT	cis	rs7178424	0.516	rs11632842	chr15:62329868	A/G	cg00456672	chr15:62358751	C2CD4A	-0.29	-4.48	-0.37	1.67e-5	Height;
TGCT	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.46	6.37	0.5	3.31e-9	Alzheimer's disease;
TGCT	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.48	-0.37	1.66e-5	Bipolar disorder;
TGCT	cis	rs9910055	0.509	rs9916444	chr17:42313512	C/G	cg13607699	chr17:42295918	UBTF	0.96	10.81	0.7	1.38e-19	Total body bone mineral density;
TGCT	cis	rs1580019	0.587	rs34488151	chr7:32548146	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.13	14.15	0.79	1.17e-27	Cognitive ability;
TGCT	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg10802521	chr3:52805072	NEK4	-0.69	-8.25	-0.6	1.98e-13	Bipolar disorder;
TGCT	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg13695892	chr22:41940480	POLR3H	-0.91	-9.07	-0.63	2.18e-15	Vitiligo;
TGCT	cis	rs3820068	0.705	rs11584209	chr1:15885041	G/T	cg05660106	chr1:15850417	CASP9	1.15	13.74	0.78	1.14e-26	Systolic blood pressure;
TGCT	cis	rs7829975	0.606	rs6601274	chr8:8799059	T/G	cg15556689	chr8:8085844	FLJ10661	-0.72	-6.22	-0.49	6.91e-9	Mood instability;
TGCT	cis	rs79349575	0.783	rs62075818	chr17:46982327	T/A	cg07967210	chr17:47022446	SNF8	0.43	6.06	0.48	1.54e-8	Type 2 diabetes;
TGCT	trans	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.8	8.32	0.6	1.31e-13	Body mass index;
TGCT	cis	rs6570726	0.764	rs1912023	chr6:145824278	C/A	cg23711669	chr6:146136114	FBXO30	0.89	9.72	0.66	6.02e-17	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs17684571	0.938	rs10498811	chr6:56561273	T/C	cg14229071	chr15:89282588	NA	0.51	6.79	0.52	4.04e-10	Schizophrenia;
TGCT	cis	rs9818758	0.607	rs80170003	chr3:48951640	T/C	cg07636037	chr3:49044803	WDR6	-1.01	-4.87	-0.4	3.34e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs2235642	0.750	rs2859310	chr16:1656765	C/T	cg07639376	chr16:1584516	IFT140;TMEM204	0.29	4.93	0.4	2.6e-6	Coronary artery disease;
TGCT	cis	rs35306767	0.903	rs11813210	chr10:919796	G/A	cg20503657	chr10:835505	NA	0.74	10.3	0.68	2.41e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs9611565	0.512	rs132767	chr22:42009520	C/T	cg06481639	chr22:41940642	POLR3H	-0.7	-6.22	-0.49	6.96e-9	Vitiligo;
TGCT	cis	rs4851266	1.000	rs6750097	chr2:100836885	T/C	cg22139774	chr2:100720529	AFF3	-0.34	-5.09	-0.42	1.28e-6	Educational attainment;
TGCT	cis	rs826838	0.967	rs1352123	chr12:39130992	T/C	cg13010199	chr12:38710504	ALG10B	-0.63	-5.06	-0.41	1.46e-6	Heart rate;
TGCT	cis	rs9467711	0.559	rs3799383	chr6:26510748	C/T	cg16898833	chr6:26189333	HIST1H4D	1.01	5.1	0.42	1.21e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs931127	0.719	rs2170082	chr11:65454795	A/G	cg17480646	chr11:65405466	SIPA1	-0.44	-5.73	-0.46	7.24e-8	Systemic lupus erythematosus;
TGCT	cis	rs17253792	0.731	rs74829671	chr14:56112759	G/C	cg01858014	chr14:56050164	KTN1	-0.35	-4.65	-0.39	8.23e-6	Putamen volume;
TGCT	cis	rs1362404	0.614	rs9925381	chr16:51959612	A/C	cg03955530	chr16:52681474	NA	0.29	4.5	0.37	1.53e-5	Gut microbiota (bacterial taxa);
TGCT	cis	rs1385374	0.698	rs2170988	chr12:129290876	A/C	cg09035930	chr12:129282057	SLC15A4	-0.55	-4.76	-0.39	5.27e-6	Systemic lupus erythematosus;
TGCT	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg25036284	chr2:26402008	FAM59B	-0.57	-4.99	-0.41	2e-6	Gut microbiome composition (summer);
TGCT	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg23708337	chr7:1209742	NA	0.63	6.03	0.48	1.78e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs6921919	0.583	rs13437294	chr6:28341535	C/A	cg18815343	chr6:28367644	ZSCAN12	-0.56	-5.37	-0.43	3.8e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4727027	0.716	rs4727020	chr7:148837317	C/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.57	4.72	0.39	6.24e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs6666258	1.000	rs11588763	chr1:154813584	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	0.61	4.96	0.41	2.26e-6	Atrial fibrillation;
TGCT	cis	rs858239	0.799	rs10279941	chr7:23370508	C/G	cg05602783	chr7:23145260	KLHL7	-0.7	-5.82	-0.46	4.83e-8	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs6674176	0.935	rs4314918	chr1:44377503	G/A	cg12908607	chr1:44402522	ARTN	-0.74	-8.71	-0.62	1.58e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs7655441	0.963	rs11543549	chr4:80909952	G/T	cg02241357	chr4:80885279	ANTXR2	-0.23	-4.52	-0.38	1.45e-5	Neutrophil percentage of white cells;
TGCT	cis	rs36051895	0.632	rs10115335	chr9:5140963	A/T	cg02405213	chr9:5042618	JAK2	-0.74	-10.39	-0.68	1.4e-18	Pediatric autoimmune diseases;
TGCT	cis	rs55794721	0.509	rs11249248	chr1:25753051	T/C	cg00786635	chr1:25594202	NA	0.57	5.96	0.47	2.4e-8	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs10791097	0.694	rs10791103	chr11:130757161	G/A	cg05962950	chr11:130786565	SNX19	0.92	11.77	0.73	6.29e-22	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs7264396	0.635	rs6058366	chr20:34512172	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.04	-0.41	1.58e-6	Total cholesterol levels;
TGCT	cis	rs981844	0.712	rs2405208	chr4:154755774	T/C	cg14289246	chr4:154710475	SFRP2	-0.96	-8.97	-0.63	3.91e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs10883723	0.810	rs3740406	chr10:104272789	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs72945132	0.882	rs56176527	chr11:70162513	A/G	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs910316	0.737	rs175049	chr14:75481368	C/T	cg08847533	chr14:75593920	NEK9	-0.84	-8.92	-0.63	5.19e-15	Height;
TGCT	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg12311346	chr5:56204834	C5orf35	-0.63	-6.36	-0.5	3.5e-9	Initial pursuit acceleration;
TGCT	cis	rs9534288	0.731	rs2404730	chr13:46617381	G/A	cg15192986	chr13:46630673	CPB2	-0.5	-7.06	-0.54	1.07e-10	Blood protein levels;
TGCT	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg03303774	chr4:1407052	NA	0.28	4.57	0.38	1.16e-5	Obesity-related traits;
TGCT	cis	rs3026101	0.671	rs1806222	chr17:5289676	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	4.57	0.38	1.16e-5	Body mass index;
TGCT	cis	rs28595532	0.841	rs114965278	chr4:119743694	T/A	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs1008375	1.000	rs13148861	chr4:17688338	G/A	cg16339924	chr4:17578868	LAP3	-0.6	-4.76	-0.39	5.25e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs13394619	0.565	rs12478958	chr2:11748037	A/G	cg07314298	chr2:11723111	GREB1	-0.29	-4.94	-0.41	2.46e-6	Endometriosis;
TGCT	cis	rs1205863	1.000	rs1205887	chr6:11948136	C/T	cg07106625	chr6:11870215	NA	0.51	5.05	0.41	1.51e-6	Disc degeneration (lumbar);
TGCT	cis	rs11096990	0.634	rs2381372	chr4:39273091	A/C	cg20847110	chr4:39482781	LOC401127	0.16	4.55	0.38	1.26e-5	Cognitive function;
TGCT	cis	rs7085104	0.572	rs284856	chr10:104574329	A/T	cg05855489	chr10:104503620	C10orf26	-0.63	-6.21	-0.49	7.3e-9	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs9303401	0.659	rs35082010	chr17:56936867	A/G	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs765787	0.530	rs11070451	chr15:45533541	T/C	cg24006582	chr15:45444508	DUOX1	-0.25	-5.53	-0.44	1.82e-7	Uric acid levels;
TGCT	cis	rs9372498	0.536	rs13437605	chr6:118899014	C/T	cg07617317	chr6:118971624	C6orf204	0.5	5.32	0.43	4.71e-7	Diastolic blood pressure;
TGCT	cis	rs9309473	0.687	rs6710659	chr2:73607510	A/G	cg20560298	chr2:73613845	ALMS1	-0.44	-4.81	-0.4	4.23e-6	Metabolite levels;
TGCT	cis	rs7267979	0.816	rs405822	chr20:25501314	A/G	cg03522245	chr20:25566470	NINL	0.56	5.79	0.46	5.51e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3099143	0.522	rs2469227	chr15:77281830	C/G	cg22256960	chr15:77711686	NA	0.71	4.49	0.37	1.58e-5	Recalcitrant atopic dermatitis;
TGCT	cis	rs9467773	0.565	rs6925047	chr6:26521435	C/G	cg09904177	chr6:26538194	HMGN4	0.5	4.76	0.39	5.25e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs57024841	0.562	rs7862602	chr9:139840471	G/T	cg00693599	chr9:139836323	FBXW5	0.22	4.79	0.4	4.62e-6	Beta-trace protein levels;
TGCT	cis	rs1865760	0.566	rs9358904	chr6:26068566	C/T	cg16482183	chr6:26056742	HIST1H1C	0.54	4.54	0.38	1.32e-5	Height;
TGCT	cis	rs548987	0.529	rs1165164	chr6:25863481	G/A	cg12310025	chr6:25882481	NA	-0.65	-5.4	-0.44	3.31e-7	Homocysteine levels;
TGCT	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg07157834	chr1:205819609	PM20D1	0.43	7.03	0.53	1.25e-10	Menarche (age at onset);
TGCT	cis	rs7267979	0.816	rs409853	chr20:25506067	T/C	cg16686733	chr20:25566563	NINL	0.52	5.05	0.41	1.52e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg04156016	chr5:1868137	NA	0.33	4.66	0.39	8.06e-6	Cardiovascular disease risk factors;
TGCT	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg09359103	chr1:154839909	KCNN3	-0.72	-14.91	-0.8	1.93e-29	Prostate cancer;
TGCT	cis	rs56235845	0.694	rs11749830	chr5:176766547	G/A	cg17509989	chr5:176798049	RGS14	0.57	7.78	0.57	2.49e-12	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs2688608	0.868	rs2688625	chr10:75631548	T/C	cg19442545	chr10:75533431	FUT11	-0.31	-5.04	-0.41	1.61e-6	Inflammatory bowel disease;
TGCT	cis	rs7760949	0.963	rs1330117	chr6:13920926	C/T	cg27413430	chr6:13925136	RNF182	0.6	5.72	0.46	7.41e-8	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg22920501	chr2:26401640	FAM59B	-0.74	-6.4	-0.5	2.86e-9	Gut microbiome composition (summer);
TGCT	cis	rs1972863	0.915	rs1972860	chr4:94579640	C/T	cg20305610	chr4:95373302	PDLIM5	-0.52	-4.55	-0.38	1.24e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs2034088	0.833	rs7219151	chr17:440497	G/A	cg06217071	chr17:408420	NA	0.35	5.27	0.43	5.75e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs9560113	1.000	rs61967684	chr13:112178026	G/C	cg14154082	chr13:112174009	NA	0.37	5.07	0.41	1.42e-6	Menarche (age at onset);
TGCT	cis	rs6840360	0.615	rs10001603	chr4:152647577	T/A	cg22705602	chr4:152727874	NA	-0.34	-5.83	-0.46	4.4e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2836950	0.545	rs11700449	chr21:40522419	A/T	cg06238570	chr21:40685208	BRWD1	-0.6	-6.19	-0.49	7.97e-9	Menarche (age at onset);
TGCT	cis	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg20637647	chr7:64974828	NA	-0.9	-5.31	-0.43	4.87e-7	Diabetic kidney disease;
TGCT	cis	rs11577318	0.796	rs4625269	chr1:26626967	C/A	cg04990556	chr1:26633338	UBXN11	-0.62	-5.76	-0.46	6.33e-8	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs7611238	0.560	rs6437471	chr3:195051895	A/G	cg27323046	chr3:195102265	ACAP2	0.36	4.81	0.4	4.35e-6	Body mass index;
TGCT	cis	rs651907	0.535	rs17412601	chr3:101499275	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	4.86	0.4	3.51e-6	Colorectal cancer;
TGCT	trans	rs17685	0.753	rs1104879	chr7:75685568	C/T	cg19862616	chr7:65841803	NCRNA00174	0.52	8.84	0.62	7.72e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs17376456	0.877	rs9885329	chr5:93380278	G/A	cg21475434	chr5:93447410	FAM172A	0.6	4.62	0.38	9.48e-6	Diabetic retinopathy;
TGCT	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg26118208	chr10:134322334	NA	0.24	4.59	0.38	1.07e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg12311346	chr5:56204834	C5orf35	-0.67	-6.86	-0.52	2.83e-10	Initial pursuit acceleration;
TGCT	cis	rs6546537	0.824	rs55864699	chr2:69803650	C/T	cg10773587	chr2:69614142	GFPT1	-0.76	-6.88	-0.53	2.6e-10	Serum thyroid-stimulating hormone levels;
TGCT	cis	rs12220238	0.915	rs11001014	chr10:76128832	A/G	cg19889307	chr10:75911429	ADK;AP3M1	-0.91	-6.27	-0.49	5.54e-9	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs9388451	0.839	rs1811852	chr6:126071575	G/C	cg05901451	chr6:126070800	HEY2	-1.04	-15.8	-0.82	1.76e-31	Brugada syndrome;
TGCT	trans	rs941408	1.000	rs759068	chr19:2792566	G/A	cg22153745	chr1:153894579	GATAD2B	-0.64	-7.26	-0.55	3.67e-11	Total cholesterol levels;
TGCT	cis	rs4478037	0.731	rs9835090	chr3:33107671	G/T	cg19404215	chr3:33155277	CRTAP	0.91	4.72	0.39	6.24e-6	Major depressive disorder;
TGCT	cis	rs7605378	1.000	rs2577852	chr2:200687248	C/T	cg23649088	chr2:200775458	C2orf69	0.35	5.83	0.46	4.53e-8	Osteoporosis;
TGCT	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg14820908	chr5:178986412	RUFY1	0.49	4.95	0.41	2.35e-6	Lung cancer;
TGCT	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	4.89	0.4	3e-6	Menopause (age at onset);
TGCT	cis	rs1801251	1.000	rs13035829	chr2:233604487	A/T	cg08000102	chr2:233561755	GIGYF2	0.64	6.45	0.5	2.22e-9	Coronary artery disease;
TGCT	cis	rs11792861	0.781	rs28361152	chr9:111727529	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.53	4.96	0.41	2.24e-6	Menarche (age at onset);
TGCT	cis	rs3796619	1.000	rs12647929	chr4:1092019	G/T	cg27284194	chr4:1044797	NA	0.47	4.57	0.38	1.17e-5	Recombination rate (males);
TGCT	cis	rs1532993	0.500	rs12509721	chr4:98554525	C/A	cg05340658	chr4:99064831	C4orf37	-0.42	-5.05	-0.41	1.57e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs2070488	0.662	rs6599203	chr3:38487802	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.66	5.14	0.42	1.02e-6	Electrocardiographic conduction measures;
TGCT	cis	rs17384381	0.834	rs11161614	chr1:85898160	A/C	cg16011679	chr1:85725395	C1orf52	0.8	6.4	0.5	2.84e-9	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs208520	0.526	rs9354366	chr6:66788559	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.09	-16.9	-0.84	5.6e-34	Exhaled nitric oxide output;
TGCT	cis	rs2292884	0.505	rs77856818	chr2:238402830	G/A	cg14458575	chr2:238380390	NA	0.56	5.13	0.42	1.08e-6	Prostate cancer;
TGCT	cis	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg20637647	chr7:64974828	NA	0.92	5.36	0.43	3.87e-7	Diabetic kidney disease;
TGCT	cis	rs7845219	0.555	rs1129152	chr8:95888307	C/T	cg16049864	chr8:95962084	TP53INP1	-0.66	-7.88	-0.58	1.43e-12	Type 2 diabetes;
TGCT	cis	rs7312933	0.501	rs3810793	chr12:42729407	C/T	cg19980929	chr12:42632907	YAF2	0.43	5.99	0.47	2.11e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs11874712	0.507	rs7239525	chr18:43654033	C/T	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.51	4.98	0.41	2.09e-6	Migraine - clinic-based;
TGCT	cis	rs223116	1.000	rs223116	chr14:23977010	A/G	cg11790074	chr14:23573850	NA	-0.25	-4.48	-0.37	1.68e-5	Resting heart rate;
TGCT	cis	rs2361718	0.631	rs2289539	chr17:78152119	T/C	cg09238746	chr17:78121135	EIF4A3	-0.77	-7.22	-0.54	4.52e-11	Yeast infection;
TGCT	cis	rs9926296	0.712	rs258319	chr16:89732024	A/T	cg01097406	chr16:89675127	NA	0.36	6.31	0.49	4.55e-9	Vitiligo;
TGCT	cis	rs9467773	0.620	rs2494701	chr6:26634432	C/T	cg15659132	chr6:26577336	NA	0.86	11.04	0.7	3.71e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs11190604	1.000	rs2489034	chr10:102319192	C/T	cg16342193	chr10:102329863	NA	-0.39	-5.0	-0.41	1.92e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs6546537	1.000	rs4286306	chr2:69885647	G/C	cg10773587	chr2:69614142	GFPT1	-0.68	-6.1	-0.48	1.27e-8	Serum thyroid-stimulating hormone levels;
TGCT	cis	rs477895	0.938	rs28395875	chr11:64024048	G/C	cg04317338	chr11:64019027	PLCB3	0.71	5.75	0.46	6.48e-8	Mean platelet volume;
TGCT	cis	rs9915657	0.773	rs9894696	chr17:70099487	C/T	cg06234051	chr17:70120541	SOX9	-0.27	-5.58	-0.45	1.44e-7	Thyroid hormone levels;
TGCT	cis	rs4906332	1.000	rs35771849	chr14:103981942	A/G	cg26031613	chr14:104095156	KLC1	-0.54	-4.67	-0.39	7.66e-6	Coronary artery disease;
TGCT	cis	rs9828933	0.577	rs832194	chr3:63857071	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	0.75	4.52	0.38	1.4e-5	Type 2 diabetes;
TGCT	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg15691649	chr6:25882328	NA	-0.47	-5.32	-0.43	4.61e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2153535	0.601	rs9505472	chr6:8538765	T/C	cg07606381	chr6:8435919	SLC35B3	0.55	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs698833	0.548	rs6721421	chr2:44535686	G/A	cg23552047	chr2:44669647	C2orf34	0.29	4.68	0.39	7.32e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
TGCT	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg18876405	chr7:65276391	NA	0.36	5.37	0.43	3.81e-7	Aortic root size;
TGCT	cis	rs877282	0.947	rs957642	chr10:773966	C/T	cg17470449	chr10:769945	NA	0.3	4.77	0.39	5.05e-6	Uric acid levels;
TGCT	cis	rs78487399	0.710	rs7590220	chr2:43702151	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-5.45	-0.44	2.63e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs11711311	1.000	rs62268168	chr3:113489447	A/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.79	-7.32	-0.55	2.75e-11	IgG glycosylation;
TGCT	cis	rs17376456	0.825	rs10078941	chr5:93279029	C/T	cg21475434	chr5:93447410	FAM172A	0.65	4.47	0.37	1.72e-5	Diabetic retinopathy;
TGCT	cis	rs3087591	0.881	rs2905804	chr17:29519995	T/C	cg24425628	chr17:29625626	OMG;NF1	0.42	6.22	0.49	7.06e-9	Hip circumference;
TGCT	cis	rs72781680	0.821	rs56064672	chr2:24156769	G/T	cg08917208	chr2:24149416	ATAD2B	0.74	4.66	0.39	7.9e-6	Lymphocyte counts;
TGCT	cis	rs4523957	0.620	rs8070272	chr17:2063117	A/G	cg16513277	chr17:2031491	SMG6	-0.2	-4.64	-0.38	8.83e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg13866156	chr1:1669148	SLC35E2	-0.21	-5.12	-0.42	1.16e-6	Body mass index;
TGCT	cis	rs17490626	0.568	rs12413525	chr10:71211721	C/A	cg12610070	chr10:71211762	TSPAN15	-0.62	-7.15	-0.54	6.52e-11	Thrombosis;
TGCT	cis	rs9467711	0.606	rs9379858	chr6:26367689	T/C	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6964587	1.000	rs35317449	chr7:91637010	G/A	cg17063962	chr7:91808500	NA	0.91	9.99	0.67	1.32e-17	Breast cancer;
TGCT	cis	rs11711311	1.000	rs9863050	chr3:113508888	C/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.76	-7.07	-0.54	1.01e-10	IgG glycosylation;
TGCT	cis	rs2120019	1.000	rs35577967	chr15:75354621	G/A	cg11632617	chr15:75315747	PPCDC	-0.33	-4.59	-0.38	1.07e-5	Blood trace element (Zn levels);
TGCT	cis	rs7945705	0.967	rs10840141	chr11:8902218	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.43	4.85	0.4	3.56e-6	Hemoglobin concentration;
TGCT	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg04234412	chr22:24373322	LOC391322	-0.91	-10.58	-0.69	4.78e-19	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9467773	0.620	rs2504565	chr6:26656890	G/A	cg15659132	chr6:26577336	NA	0.87	10.67	0.69	2.97e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs317689	0.819	rs317677	chr12:69691806	G/A	cg14784868	chr12:69753453	YEATS4	0.57	4.9	0.4	2.96e-6	Response to diuretic therapy;
TGCT	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg17554472	chr22:41940697	POLR3H	-0.5	-5.25	-0.43	6.29e-7	Vitiligo;
TGCT	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg14159672	chr1:205819179	PM20D1	0.61	7.57	0.56	7.33e-12	Menarche (age at onset);
TGCT	cis	rs4689388	0.856	rs1046314	chr4:6303955	A/G	cg00701064	chr4:6280414	WFS1	-0.43	-5.63	-0.45	1.17e-7	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs554111	0.891	rs659046	chr1:21047725	C/T	cg08890418	chr1:21044141	KIF17	-0.57	-6.26	-0.49	5.62e-9	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs6674176	0.597	rs9326136	chr1:44390392	A/G	cg12908607	chr1:44402522	ARTN	0.74	9.09	0.63	1.99e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs7412746	0.658	rs2275235	chr1:150730279	A/G	cg09365446	chr1:150670422	GOLPH3L	0.35	5.08	0.42	1.33e-6	Melanoma;
TGCT	cis	rs2180341	0.814	rs6569488	chr6:127726256	C/T	cg24812749	chr6:127587940	RNF146	0.76	6.22	0.49	7.07e-9	Breast cancer;
TGCT	cis	rs7429990	0.965	rs35012836	chr3:47711490	G/A	cg11946769	chr3:48343235	NME6	0.59	4.45	0.37	1.91e-5	Educational attainment (years of education);
TGCT	cis	rs2562456	0.833	rs552800	chr19:21484642	G/A	cg01304269	chr19:21688519	ZNF429	-0.55	-4.47	-0.37	1.76e-5	Pain;
TGCT	cis	rs7909074	1.000	rs12777258	chr10:45394961	A/G	cg04218760	chr10:45406644	TMEM72	0.27	5.54	0.45	1.76e-7	Mean corpuscular volume;
TGCT	cis	rs6500602	0.727	rs10451135	chr16:4580214	T/C	cg08645402	chr16:4508243	NA	0.19	5.3	0.43	5.14e-7	Schizophrenia;
TGCT	cis	rs2235642	0.893	rs2076440	chr16:1587322	G/A	cg10465839	chr16:1584050	IFT140;TMEM204	-0.32	-5.23	-0.43	6.98e-7	Coronary artery disease;
TGCT	cis	rs868036	0.718	rs4776985	chr15:68123021	T/G	cg05925327	chr15:68127851	NA	-0.51	-5.04	-0.41	1.63e-6	Restless legs syndrome;
TGCT	cis	rs36051895	0.623	rs2146041	chr9:5262911	A/G	cg02405213	chr9:5042618	JAK2	-0.68	-8.17	-0.59	3e-13	Pediatric autoimmune diseases;
TGCT	cis	rs9790314	0.846	rs7627528	chr3:160990878	A/G	cg03342759	chr3:160939853	NMD3	-0.51	-5.66	-0.45	9.96e-8	Morning vs. evening chronotype;
TGCT	cis	rs765787	0.530	rs1706830	chr15:45516229	G/A	cg24006582	chr15:45444508	DUOX1	-0.26	-5.62	-0.45	1.19e-7	Uric acid levels;
TGCT	trans	rs10506458	0.915	rs17738485	chr12:63394932	T/C	cg22491629	chr6:157744540	C6orf35	-0.99	-8.55	-0.61	3.94e-14	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.94	7.92	0.58	1.17e-12	Platelet count;
TGCT	cis	rs3845624	0.610	rs3027044	chr1:159181869	C/T	cg07961479	chr1:159825173	VSIG8;C1orf204	0.23	4.55	0.38	1.28e-5	Inflammatory biomarkers;
TGCT	cis	rs539096	0.918	rs519669	chr1:44075505	G/C	cg12908607	chr1:44402522	ARTN	-0.53	-5.61	-0.45	1.26e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2932538	0.922	rs3790612	chr1:113084146	G/A	cg22162597	chr1:113214053	CAPZA1	0.28	6.0	0.47	2.02e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg24675658	chr1:53192096	ZYG11B	0.75	8.79	0.62	1.05e-14	Monocyte count;
TGCT	cis	rs17270561	0.562	rs74293932	chr6:26014811	C/A	cg17691542	chr6:26056736	HIST1H1C	1.0	7.07	0.54	9.94e-11	Iron status biomarkers;
TGCT	cis	rs2066819	0.892	rs112931321	chr12:56667894	C/T	cg26714650	chr12:56694279	CS	-1.36	-6.06	-0.48	1.54e-8	Psoriasis vulgaris;
TGCT	cis	rs67073037	0.955	rs4666144	chr2:29174105	C/T	cg09522027	chr2:28974177	PPP1CB	0.58	4.62	0.38	9.63e-6	Breast cancer;Breast cancer (estrogen-receptor negative);
TGCT	cis	rs6540559	0.673	rs11803382	chr1:209986426	G/A	cg23283495	chr1:209979779	IRF6	0.65	5.04	0.41	1.63e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg09021430	chr5:549028	NA	-0.37	-5.16	-0.42	9.7e-7	Lung disease severity in cystic fibrosis;
TGCT	cis	rs4285028	0.948	rs71329247	chr3:121681523	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.77	-6.55	-0.51	1.35e-9	Multiple sclerosis;
TGCT	cis	rs2692947	0.644	rs1168970	chr2:96816606	C/T	cg23100626	chr2:96804247	ASTL	0.46	5.42	0.44	3.03e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs739496	0.579	rs80017658	chr12:112380372	G/A	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs9527	0.590	rs11191544	chr10:104827198	C/G	cg04362960	chr10:104952993	NT5C2	0.66	5.55	0.45	1.62e-7	Arsenic metabolism;
TGCT	cis	rs736408	1.000	rs2710331	chr3:52837855	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.64	0.38	8.84e-6	Bipolar disorder;
TGCT	cis	rs28595532	0.920	rs114584210	chr4:119773363	G/A	cg11846333	chr4:119757529	SEC24D	0.9	4.57	0.38	1.18e-5	Cannabis dependence symptom count;
TGCT	cis	rs988712	0.672	rs12419948	chr11:27666984	T/A	cg10635145	chr11:27742435	BDNF	-0.38	-5.25	-0.43	6.38e-7	Obesity;
TGCT	cis	rs919433	0.679	rs10166328	chr2:198511917	A/G	cg00792783	chr2:198669748	PLCL1	0.56	5.03	0.41	1.68e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs854765	0.583	rs67253360	chr17:17828973	T/C	cg09796270	chr17:17721594	SREBF1	0.24	4.77	0.39	5.16e-6	Total body bone mineral density;
TGCT	cis	rs17433780	0.897	rs12120863	chr1:89501522	T/C	cg09516651	chr1:89888402	LOC400759	0.26	4.48	0.37	1.67e-5	Carotid intima media thickness;
TGCT	cis	rs9341808	0.718	rs9343978	chr6:80971978	A/G	cg08355045	chr6:80787529	NA	0.29	4.98	0.41	2.04e-6	Sitting height ratio;
TGCT	cis	rs5769707	0.667	rs4824069	chr22:50030325	T/C	cg06623630	chr22:50017776	C22orf34	-0.27	-4.7	-0.39	6.81e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs9916302	0.904	rs600010	chr17:37433517	T/C	cg07936489	chr17:37558343	FBXL20	-0.62	-4.91	-0.4	2.77e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs62055045	0.656	rs112777805	chr16:71425165	G/C	cg09204302	chr16:70713462	MTSS1L	-0.31	-4.94	-0.41	2.51e-6	Schizophrenia;
TGCT	cis	rs7666738	0.830	rs6840766	chr4:99016260	C/G	cg18180107	chr4:99064573	C4orf37	0.54	5.03	0.41	1.7e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg11890956	chr21:40555474	PSMG1	1.14	12.22	0.74	4.93e-23	Cognitive function;
TGCT	cis	rs7428	0.527	rs4832164	chr2:85546932	A/C	cg03728395	chr2:85555865	TGOLN2	-0.31	-5.27	-0.43	5.85e-7	Ear protrusion;
TGCT	cis	rs1153858	1.000	rs66939267	chr15:45676902	T/A	cg14582100	chr15:45693742	SPATA5L1	0.49	5.73	0.46	7.14e-8	Homoarginine levels;
TGCT	cis	rs2361718	0.501	rs8065486	chr17:78138196	A/G	cg21238619	chr17:78079768	GAA	0.33	4.66	0.39	7.96e-6	Yeast infection;
TGCT	cis	rs1801251	1.000	rs7606090	chr2:233606740	T/C	cg08000102	chr2:233561755	GIGYF2	0.64	6.45	0.5	2.22e-9	Coronary artery disease;
TGCT	cis	rs2933343	0.553	rs789212	chr3:128686912	A/C	cg11901034	chr3:128598214	ACAD9	-0.56	-5.26	-0.43	6.06e-7	IgG glycosylation;
TGCT	cis	rs6089829	0.632	rs62197308	chr20:61660705	T/C	cg03213289	chr20:61660250	NA	-0.51	-5.59	-0.45	1.38e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg12419862	chr22:24373484	LOC391322	0.8	8.5	0.61	5.17e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs57590327	0.527	rs7610703	chr3:81613942	G/A	cg07356753	chr3:81810745	GBE1	-0.59	-4.96	-0.41	2.23e-6	Extraversion;
TGCT	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.67	-0.39	7.73e-6	Prudent dietary pattern;
TGCT	cis	rs12142240	0.738	rs41293277	chr1:46806550	C/T	cg14993813	chr1:46806288	NSUN4	-0.58	-4.78	-0.39	4.78e-6	Menopause (age at onset);
TGCT	cis	rs7659604	0.502	rs13108419	chr4:122687238	A/G	cg19748678	chr4:122722346	EXOSC9	-0.57	-5.58	-0.45	1.41e-7	Type 2 diabetes;
TGCT	cis	rs12216125	0.554	rs6942196	chr6:26072804	A/G	cg16482183	chr6:26056742	HIST1H1C	0.58	4.97	0.41	2.19e-6	Iron status biomarkers;
TGCT	cis	rs9443189	0.526	rs10943250	chr6:76208445	C/G	cg01950844	chr6:76311363	SENP6	0.91	5.52	0.44	1.89e-7	Prostate cancer;
TGCT	cis	rs9926296	0.712	rs2434872	chr16:89716915	C/G	cg26513180	chr16:89883248	FANCA	-0.68	-6.33	-0.49	4.16e-9	Vitiligo;
TGCT	cis	rs28595532	0.920	rs6818519	chr4:119787820	G/T	cg14228332	chr4:119757509	SEC24D	1.19	6.66	0.51	8.07e-10	Cannabis dependence symptom count;
TGCT	cis	rs1385374	0.858	rs10847698	chr12:129300222	T/C	cg09035930	chr12:129282057	SLC15A4	-0.55	-4.76	-0.39	5.27e-6	Systemic lupus erythematosus;
TGCT	cis	rs739401	0.611	rs391188	chr11:3047634	G/A	cg05729581	chr11:3078854	CARS	-0.53	-4.94	-0.41	2.51e-6	Longevity;
TGCT	cis	rs3796352	1.000	rs6445557	chr3:53083969	C/T	cg15956490	chr3:53032818	SFMBT1	-0.53	-6.27	-0.49	5.56e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg11941060	chr3:133502564	NA	-0.28	-5.58	-0.45	1.47e-7	Iron status biomarkers;
TGCT	cis	rs6964587	0.839	rs62466159	chr7:91450507	A/G	cg17063962	chr7:91808500	NA	0.83	8.41	0.6	8.35e-14	Breast cancer;
TGCT	cis	rs908922	0.887	rs4596895	chr1:152528075	T/G	cg20991723	chr1:152506922	NA	0.41	5.18	0.42	8.76e-7	Hair morphology;
TGCT	cis	rs644799	1.000	rs518919	chr11:95623313	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.83	9.35	0.64	4.64e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7044106	0.708	rs991121	chr9:123370345	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.58	6.31	0.49	4.56e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs694739	0.657	rs11231770	chr11:64140625	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.63	6.54	0.51	1.44e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs4237845	0.967	rs4553410	chr12:58301211	G/A	cg02175503	chr12:58329896	NA	0.51	5.09	0.42	1.3e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6582630	0.519	rs10880194	chr12:38302836	G/A	cg26384229	chr12:38710491	ALG10B	0.82	7.18	0.54	5.6e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs1150688	1	rs1150688	chr6:28162780	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.48	-4.71	-0.39	6.43e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6701037	0.625	rs34270511	chr1:175128543	C/T	cg00321850	chr1:175162397	KIAA0040	-0.42	-5.83	-0.46	4.61e-8	Alcohol dependence;
TGCT	cis	rs3733585	0.588	rs6449154	chr4:9956404	C/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.7	-0.52	6.62e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg24846343	chr22:24311635	DDTL	-0.22	-5.7	-0.46	8.24e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7975161	0.572	rs4964228	chr12:104572759	T/C	cg25273343	chr12:104657179	TXNRD1	-0.44	-5.8	-0.46	5.27e-8	Toenail selenium levels;
TGCT	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.7	0.52	6.47e-10	Bipolar disorder;
TGCT	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg22963979	chr7:1858916	MAD1L1	-0.47	-7.55	-0.56	8.09e-12	Bipolar disorder and schizophrenia;
TGCT	cis	rs832540	0.966	rs33321	chr5:56206073	G/T	cg12311346	chr5:56204834	C5orf35	-0.51	-5.51	-0.44	1.94e-7	Coronary artery disease;
TGCT	trans	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg17830980	chr10:43048298	ZNF37B	-0.86	-11.18	-0.71	1.68e-20	Extrinsic epigenetic age acceleration;
TGCT	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg22618164	chr12:122356400	WDR66	-0.63	-6.2	-0.49	7.55e-9	Mean corpuscular volume;
TGCT	cis	rs425277	1.000	rs1401138	chr1:2063149	C/T	cg24578937	chr1:2090814	PRKCZ	0.32	7.65	0.57	4.86e-12	Height;
TGCT	cis	rs78487399	0.808	rs7564886	chr2:43733028	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-4.84	-0.4	3.79e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs7582180	0.715	rs1866198	chr2:100917739	C/A	cg14675211	chr2:100938903	LONRF2	0.49	4.8	0.4	4.45e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs933688	1.000	rs6862125	chr5:90724598	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.08	9.5	0.65	2.02e-16	Smoking behavior;
TGCT	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6495122	0.699	rs34862454	chr15:75101530	C/T	cg10253484	chr15:75165896	SCAMP2	-0.68	-6.04	-0.48	1.63e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
TGCT	cis	rs74054849	0.717	rs74054799	chr1:15926350	C/T	cg05660106	chr1:15850417	CASP9	0.86	4.47	0.37	1.71e-5	Alcoholic chronic pancreatitis;
TGCT	cis	rs2847297	1.000	rs2847297	chr18:12797694	A/G	cg23598886	chr18:12777645	NA	-0.4	-4.73	-0.39	5.95e-6	Rheumatoid arthritis;
TGCT	cis	rs17030434	0.607	rs3747522	chr4:154644929	G/A	cg14289246	chr4:154710475	SFRP2	-0.82	-6.83	-0.52	3.3e-10	Electrocardiographic conduction measures;
TGCT	cis	rs3820068	0.603	rs7536654	chr1:15989141	C/G	cg05660106	chr1:15850417	CASP9	0.8	8.0	0.58	7.42e-13	Systolic blood pressure;
TGCT	cis	rs151317012	1	rs151317012	chr4:106806194	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	1.01	4.61	0.38	9.83e-6	Post bronchodilator FEV1;
TGCT	cis	rs9399135	0.967	rs3756799	chr6:135341011	A/G	cg24558204	chr6:135376177	HBS1L	0.49	4.84	0.4	3.77e-6	Red blood cell count;
TGCT	cis	rs11785400	0.793	rs34875149	chr8:143736131	G/A	cg10596483	chr8:143751796	JRK	0.53	5.27	0.43	5.89e-7	Schizophrenia;
TGCT	cis	rs6988636	1.000	rs10505430	chr8:124191933	A/G	cg23067535	chr8:124195133	FAM83A	0.35	5.22	0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg03188948	chr7:1209495	NA	0.48	6.91	0.53	2.31e-10	Longevity;Endometriosis;
TGCT	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	8.99	0.63	3.48e-15	Platelet count;
TGCT	cis	rs9796	0.870	rs8023345	chr15:41338348	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.41	-5.41	-0.44	3.06e-7	Menopause (age at onset);
TGCT	cis	rs11718455	0.767	rs6782500	chr3:43990260	A/G	cg08738300	chr3:44038990	NA	-0.75	-5.73	-0.46	7.13e-8	Coronary artery disease;
TGCT	cis	rs10992471	0.518	rs4743876	chr9:95512216	C/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.54	-4.58	-0.38	1.1e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	4.48	0.37	1.67e-5	Menopause (age at onset);
TGCT	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg11764359	chr7:65958608	NA	-0.55	-5.08	-0.42	1.34e-6	Aortic root size;
TGCT	cis	rs68170813	0.652	rs7807154	chr7:107161391	T/G	cg02696742	chr7:106810147	HBP1	-0.58	-4.47	-0.37	1.74e-5	Coronary artery disease;
TGCT	cis	rs6714710	0.580	rs55886305	chr2:98495661	T/G	cg26665480	chr2:98280029	ACTR1B	0.64	6.03	0.48	1.71e-8	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs6089584	0.927	rs2296081	chr20:60572663	G/T	cg06108461	chr20:60628389	TAF4	-0.58	-8.56	-0.61	3.6e-14	Body mass index;
TGCT	cis	rs7666738	0.830	rs1426668	chr4:98945585	T/A	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs289997	1.000	rs2960816	chr7:25585754	A/G	cg14064488	chr7:26331273	SNX10	-0.34	-4.74	-0.39	5.83e-6	Breast cancer;
TGCT	cis	rs7917772	0.503	rs7899576	chr10:104307504	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.8	8.21	0.59	2.44e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs950169	0.922	rs12911223	chr15:84831671	G/A	cg12863693	chr15:85201151	NMB	-0.41	-4.47	-0.37	1.77e-5	Schizophrenia;
TGCT	cis	rs9902453	0.730	rs3794808	chr17:28531793	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	5.93	0.47	2.78e-8	Coffee consumption (cups per day);
TGCT	cis	rs548181	0.736	rs540436	chr11:125512619	A/G	cg03464685	chr11:125439445	EI24	1.11	8.13	0.59	3.76e-13	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg22166914	chr1:53195759	ZYG11B	-0.42	-7.46	-0.56	1.33e-11	Monocyte count;
TGCT	cis	rs4523957	0.583	rs9889861	chr17:2041369	A/G	cg16513277	chr17:2031491	SMG6	-0.2	-4.58	-0.38	1.13e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs6748734	1.000	rs11893118	chr2:241828308	C/G	cg04034577	chr2:241836375	C2orf54	-0.42	-6.45	-0.5	2.23e-9	Urinary metabolites;
TGCT	cis	rs9467773	0.869	rs742090	chr6:26415637	A/C	cg07107628	chr6:27210934	NA	0.16	4.53	0.38	1.38e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs1670533	1.000	rs2100411	chr4:1074412	T/C	cg27284194	chr4:1044797	NA	0.68	5.84	0.46	4.28e-8	Recombination rate (females);
TGCT	cis	rs7647973	0.961	rs4955417	chr3:49298205	T/C	cg07690219	chr3:49449608	TCTA;RHOA	-0.55	-4.48	-0.37	1.68e-5	Menarche (age at onset);
TGCT	cis	rs13064411	0.542	rs9874747	chr3:113221258	G/A	cg18753928	chr3:113234510	CCDC52	-0.54	-4.58	-0.38	1.12e-5	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs3791556	1.000	rs3791568	chr2:240115701	G/A	cg03281426	chr2:240109471	HDAC4	0.28	4.46	0.37	1.82e-5	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs12950390	0.853	rs12451815	chr17:45855956	A/G	cg06532163	chr17:45867833	NA	0.34	5.32	0.43	4.73e-7	IgG glycosylation;
TGCT	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg17971929	chr21:40555470	PSMG1	0.98	9.65	0.65	9.11e-17	Cognitive function;
TGCT	cis	rs2657888	0.930	rs7312441	chr12:56941146	C/A	cg23002907	chr12:56915593	RBMS2	-0.45	-6.07	-0.48	1.44e-8	Adiponectin levels;
TGCT	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg01238044	chr22:24384105	GSTT1	-0.49	-4.5	-0.37	1.53e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg12564285	chr5:131593104	PDLIM4	0.37	4.44	0.37	1.98e-5	Acylcarnitine levels;
TGCT	cis	rs17376456	0.825	rs72786702	chr5:93254656	A/C	cg25358565	chr5:93447407	FAM172A	0.98	7.85	0.58	1.68e-12	Diabetic retinopathy;
TGCT	cis	rs281408	0.559	rs281381	chr19:49214748	C/T	cg13540341	chr19:49222985	MAMSTR	-0.44	-6.58	-0.51	1.16e-9	Urinary metabolites (H-NMR features);
TGCT	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg26118208	chr10:134322334	NA	0.27	5.21	0.42	7.65e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs7769051	0.711	rs7758531	chr6:133085302	T/C	cg07930552	chr6:133119739	C6orf192	0.9	4.67	0.39	7.86e-6	Type 2 diabetes nephropathy;
TGCT	cis	rs4851266	1.000	rs11693324	chr2:100827753	T/C	cg07810366	chr2:100720526	AFF3	-0.38	-5.44	-0.44	2.73e-7	Educational attainment;
TGCT	cis	rs6582630	0.537	rs1949610	chr12:38387838	C/T	cg13010199	chr12:38710504	ALG10B	0.59	4.64	0.38	8.86e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs9814567	0.896	rs13089566	chr3:134349710	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.84	7.7	0.57	3.76e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs6912958	0.559	rs445434	chr6:88041849	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.39	4.48	0.37	1.66e-5	Monocyte percentage of white cells;
TGCT	cis	rs7829975	0.559	rs4841025	chr8:8603160	A/G	cg06636001	chr8:8085503	FLJ10661	-0.58	-4.79	-0.39	4.72e-6	Mood instability;
TGCT	trans	rs1814175	0.817	rs11040474	chr11:49708441	G/A	cg15704280	chr7:45808275	SEPT13	-0.71	-8.23	-0.59	2.14e-13	Height;
TGCT	cis	rs523522	0.923	rs3916065	chr12:120934624	A/C	cg27279351	chr12:120934652	DYNLL1	0.76	6.59	0.51	1.15e-9	High light scatter reticulocyte count;
TGCT	cis	rs1185460	0.934	rs10892328	chr11:118942654	T/A	cg01677386	chr11:118938358	VPS11	-0.54	-4.54	-0.38	1.32e-5	Coronary artery disease;
TGCT	cis	rs9291683	0.610	rs993172	chr4:10324361	G/T	cg00071950	chr4:10020882	SLC2A9	0.45	4.77	0.39	5.03e-6	Bone mineral density;
TGCT	cis	rs4242434	0.757	rs7005025	chr8:22519815	G/T	cg03733263	chr8:22462867	KIAA1967	1.02	14.27	0.79	6.14e-28	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs7226408	0.802	rs72885298	chr18:34452064	C/G	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs651907	0.557	rs3806654	chr3:101396529	G/C	cg12386194	chr3:101231763	SENP7	0.51	5.04	0.41	1.61e-6	Colorectal cancer;
TGCT	cis	rs826838	0.904	rs1554550	chr12:39208889	G/A	cg26384229	chr12:38710491	ALG10B	0.98	8.78	0.62	1.07e-14	Heart rate;
TGCT	cis	rs7666738	0.830	rs11947578	chr4:98930462	T/G	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28595532	0.920	rs115320476	chr4:119759680	G/A	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs9549367	0.713	rs3024743	chr13:113821430	C/T	cg00898013	chr13:113819073	PROZ	-0.53	-6.77	-0.52	4.62e-10	Platelet distribution width;
TGCT	cis	rs9913156	0.793	rs9436	chr17:4574751	T/A	cg19197139	chr17:4613644	ARRB2	0.86	7.97	0.58	8.69e-13	Lymphocyte counts;
TGCT	cis	rs7264396	0.635	rs3827030	chr20:34474947	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.29	4.97	0.41	2.18e-6	Total cholesterol levels;
TGCT	cis	rs8054556	0.760	rs12598856	chr16:30029548	C/T	cg06015834	chr16:30021696	DOC2A	-0.27	-4.5	-0.37	1.56e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg17054783	chr10:134559939	INPP5A	0.24	4.83	0.4	3.92e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs7786877	0.521	rs4729607	chr7:100326744	T/A	cg20848291	chr7:100343083	ZAN	-0.52	-4.45	-0.37	1.92e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs832540	1.000	rs252914	chr5:56198150	A/C	cg24531977	chr5:56204891	C5orf35	-0.52	-5.12	-0.42	1.12e-6	Coronary artery disease;
TGCT	cis	rs2439831	1.000	rs2444250	chr15:43785051	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	5.51	0.44	1.95e-7	Lung cancer in ever smokers;
TGCT	cis	rs3806843	0.576	rs246059	chr5:140325010	G/T	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs208346	0.612	rs208356	chr7:2775825	A/T	cg11411865	chr7:2701802	TTYH3	-0.22	-5.08	-0.42	1.34e-6	Loneliness (linear analysis);
TGCT	trans	rs608114	0.793	rs688184	chr6:96378265	G/A	cg04008557	chr11:2826328	KCNQ1	-0.65	-6.82	-0.52	3.51e-10	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
TGCT	cis	rs9341808	0.718	rs9448899	chr6:80845864	G/A	cg08355045	chr6:80787529	NA	0.32	5.83	0.46	4.48e-8	Sitting height ratio;
TGCT	cis	rs9291683	0.530	rs35908990	chr4:9976105	G/A	cg11266682	chr4:10021025	SLC2A9	0.62	8.63	0.61	2.51e-14	Bone mineral density;
TGCT	cis	rs9913156	0.553	rs1045280	chr17:4622638	C/T	cg00122941	chr17:4613640	ARRB2	-0.78	-7.04	-0.53	1.14e-10	Lymphocyte counts;
TGCT	cis	rs4783244	0.864	rs8062260	chr16:82658090	G/A	cg09415485	chr16:82663111	CDH13	-0.25	-4.67	-0.39	7.77e-6	Adiponectin levels;
TGCT	cis	rs12701220	0.857	rs1057558	chr7:1062366	A/G	cg07217954	chr7:1067459	C7orf50	-0.45	-4.53	-0.38	1.39e-5	Bronchopulmonary dysplasia;
TGCT	cis	rs2549003	0.933	rs7719499	chr5:131814091	C/G	cg02551604	chr5:131831745	NA	-0.89	-11.11	-0.71	2.52e-20	Asthma (sex interaction);
TGCT	cis	rs78487399	0.808	rs74821293	chr2:43742923	T/C	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.73	4.78	0.39	4.97e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs6460942	1.000	rs2033871	chr7:12405098	C/A	cg06484146	chr7:12443880	VWDE	-0.63	-5.65	-0.45	1.04e-7	Coronary artery disease;
TGCT	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg09323728	chr8:95962352	TP53INP1	-0.55	-7.16	-0.54	6.26e-11	Type 2 diabetes;
TGCT	cis	rs9309473	0.687	rs10165862	chr2:73610743	C/T	cg20560298	chr2:73613845	ALMS1	-0.42	-4.58	-0.38	1.11e-5	Metabolite levels;
TGCT	cis	rs12477438	0.765	rs10181422	chr2:99558970	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-7.29	-0.55	3.21e-11	Chronic sinus infection;
TGCT	cis	rs911263	0.961	rs7148416	chr14:68747868	A/T	cg18825221	chr14:68749962	RAD51L1	0.27	5.44	0.44	2.71e-7	Primary biliary cholangitis;
TGCT	cis	rs1215050	0.740	rs783932	chr4:98973936	C/G	cg05340658	chr4:99064831	C4orf37	-0.43	-5.27	-0.43	5.8e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2982552	0.838	rs977533	chr6:152068874	G/A	cg22157087	chr6:152012887	ESR1	0.2	4.77	0.39	5e-6	Bone properties (heel);
TGCT	cis	rs9372498	0.536	rs62421539	chr6:118730559	C/A	cg07617317	chr6:118971624	C6orf204	0.5	5.39	0.44	3.37e-7	Diastolic blood pressure;
TGCT	cis	rs9902453	0.967	rs6505155	chr17:28372783	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-6.56	-0.51	1.3e-9	Coffee consumption (cups per day);
TGCT	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg25036284	chr2:26402008	FAM59B	0.55	4.68	0.39	7.51e-6	Gut microbiome composition (summer);
TGCT	cis	rs6674176	0.628	rs2240447	chr1:44415415	C/T	cg13606994	chr1:44402422	ARTN	-0.46	-4.98	-0.41	2.12e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs950027	0.620	rs2453533	chr15:45641225	C/A	cg14582100	chr15:45693742	SPATA5L1	0.47	6.05	0.48	1.59e-8	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs9381040	0.655	rs2268190	chr6:41030226	C/T	cg03526776	chr6:41159608	TREML2	0.27	5.27	0.43	5.78e-7	Alzheimer's disease (late onset);
TGCT	cis	rs7726839	0.526	rs55647623	chr5:567747	T/C	cg09021430	chr5:549028	NA	-0.42	-5.68	-0.45	9.25e-8	Obesity-related traits;
TGCT	cis	rs8179	0.645	rs10264916	chr7:92286376	A/G	cg15732164	chr7:92237376	CDK6	-0.28	-4.84	-0.4	3.78e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
TGCT	cis	rs9653442	0.900	rs10194635	chr2:100834217	T/A	cg07810366	chr2:100720526	AFF3	-0.4	-6.06	-0.48	1.49e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs909341	0.818	rs2259858	chr20:62346459	A/T	cg14758556	chr20:62440591	NA	0.3	4.49	0.37	1.6e-5	Atopic dermatitis;
TGCT	cis	rs6582630	0.519	rs11495700	chr12:38288240	A/G	cg13010199	chr12:38710504	ALG10B	0.61	4.77	0.39	5.11e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs7223966	0.921	rs2727300	chr17:61965398	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	4.65	0.39	8.42e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs4077515	0.967	rs4266763	chr9:139289825	C/T	cg13741927	chr9:139327495	INPP5E	0.21	5.0	0.41	1.87e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs1949733	1.000	rs1949733	chr4:8503359	C/T	cg13073564	chr4:8508604	NA	0.48	5.2	0.42	8.02e-7	Response to antineoplastic agents;
TGCT	cis	rs5769765	0.671	rs138817	chr22:50163058	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.0	-9.33	-0.64	5.41e-16	Schizophrenia;
TGCT	cis	rs700651	0.789	rs116165148	chr2:198888347	T/G	cg00792783	chr2:198669748	PLCL1	0.59	5.34	0.43	4.33e-7	Intracranial aneurysm;
TGCT	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg22920501	chr2:26401640	FAM59B	-0.79	-6.31	-0.49	4.58e-9	Gut microbiome composition (summer);
TGCT	cis	rs9303401	0.614	rs12950028	chr17:56510140	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.68	6.69	0.52	6.76e-10	Cognitive test performance;
TGCT	cis	rs1670533	0.585	rs6827206	chr4:1065071	A/T	cg27284194	chr4:1044797	NA	0.69	5.94	0.47	2.66e-8	Recombination rate (females);
TGCT	cis	rs3617	0.599	rs12487379	chr3:52895785	G/A	cg11645453	chr3:52864694	ITIH4	0.25	4.82	0.4	4.08e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7044106	0.791	rs747819	chr9:123488441	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.49	5.44	0.44	2.74e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs1395	0.922	rs13404446	chr2:27519254	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.44	5.84	0.46	4.25e-8	Blood metabolite levels;
TGCT	cis	rs9549260	0.609	rs9315780	chr13:41263960	C/T	cg21288729	chr13:41239152	FOXO1	0.9	8.44	0.6	7.07e-14	Red blood cell count;
TGCT	cis	rs7937682	0.632	rs10891297	chr11:111770150	C/T	cg09085632	chr11:111637200	PPP2R1B	0.83	7.15	0.54	6.45e-11	Primary sclerosing cholangitis;
TGCT	cis	rs4975709	1.000	rs2279588	chr5:1878021	G/A	cg14773178	chr5:1868261	NA	0.37	4.71	0.39	6.42e-6	Cardiovascular disease risk factors;
TGCT	cis	rs7666738	0.830	rs4699593	chr4:98980628	A/G	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg06634786	chr22:41940651	POLR3H	0.87	8.08	0.59	4.79e-13	Vitiligo;
TGCT	cis	rs2710642	0.779	rs360807	chr2:62926859	C/T	cg17519650	chr2:63277830	OTX1	-0.56	-4.85	-0.4	3.62e-6	LDL cholesterol levels;LDL cholesterol;
TGCT	cis	rs12950390	0.853	rs12450729	chr17:45855363	A/G	cg06532163	chr17:45867833	NA	0.37	5.86	0.47	3.9e-8	IgG glycosylation;
TGCT	cis	rs6547741	1.000	rs13026621	chr2:27807624	G/A	cg27432699	chr2:27873401	GPN1	0.18	4.65	0.38	8.53e-6	Oral cavity cancer;
TGCT	cis	rs587847	0.522	rs582122	chr15:37687805	A/T	cg16890051	chr15:37175029	LOC145845	-0.39	-4.65	-0.39	8.44e-6	Intraocular pressure;
TGCT	cis	rs9611565	0.506	rs7364221	chr22:41650190	C/A	cg03806693	chr22:41940476	POLR3H	-0.76	-7.13	-0.54	7.2e-11	Vitiligo;
TGCT	cis	rs909002	0.789	rs2139539	chr1:32117779	C/T	cg11573219	chr1:32083031	HCRTR1	-0.38	-4.89	-0.4	3.03e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs1552244	0.554	rs6786636	chr3:10045703	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.33	-4.95	-0.41	2.39e-6	Alzheimer's disease;
TGCT	cis	rs1372520	0.873	rs2583990	chr4:90771499	A/G	cg20003494	chr4:90757398	SNCA	-0.63	-5.13	-0.42	1.08e-6	Neuroticism;
TGCT	cis	rs6459788	0.720	rs6965466	chr7:157250749	G/T	cg03453431	chr7:157225567	NA	-0.37	-5.68	-0.45	9.12e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs74417235	0.684	rs7723610	chr5:154053349	A/C	cg08754654	chr5:154026448	NA	0.58	5.53	0.44	1.84e-7	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
TGCT	cis	rs250677	1.000	rs36069	chr5:148417253	G/C	cg18129178	chr5:148520854	ABLIM3	-0.43	-6.56	-0.51	1.31e-9	Breast cancer;
TGCT	cis	rs7666738	0.861	rs13139309	chr4:99020916	A/G	cg05340658	chr4:99064831	C4orf37	0.48	5.43	0.44	2.92e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10114408	0.959	rs10821254	chr9:96655855	A/G	cg13679303	chr9:96623674	NA	-0.36	-4.69	-0.39	7e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs9467711	0.651	rs2237228	chr6:26104630	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.57	-4.54	-0.38	1.33e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9682041	1.000	rs6773095	chr3:170082181	A/G	cg07589077	chr3:170072950	NA	0.31	4.7	0.39	6.94e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs13082711	0.516	rs13084067	chr3:27358935	A/T	cg02860705	chr3:27208620	NA	0.44	6.92	0.53	2.15e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs12188164	0.686	rs11741946	chr5:421403	G/A	cg26850624	chr5:429559	AHRR	-0.21	-4.93	-0.4	2.61e-6	Cystic fibrosis severity;
TGCT	cis	rs13326165	0.760	rs67248391	chr3:52412006	A/T	cg27565382	chr3:53032988	SFMBT1	0.37	4.9	0.4	2.97e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs9486719	1.000	rs6923212	chr6:97061940	A/G	cg18709589	chr6:96969512	KIAA0776	-0.73	-5.5	-0.44	2.04e-7	Migraine;Coronary artery disease;
TGCT	cis	rs806215	1.000	rs327512	chr7:127257251	G/A	cg25922125	chr7:127225783	GCC1	0.47	4.79	0.4	4.62e-6	Type 2 diabetes;
TGCT	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg11764359	chr7:65958608	NA	-0.56	-5.09	-0.42	1.31e-6	Aortic root size;
TGCT	cis	rs1801251	0.778	rs809639	chr2:233731244	C/G	cg25237894	chr2:233734115	C2orf82	0.3	5.84	0.46	4.33e-8	Coronary artery disease;
TGCT	cis	rs13191362	1.000	rs4489133	chr6:163137793	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.17	9.35	0.64	4.74e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs6964587	1.000	rs12540565	chr7:91633213	T/G	cg22709100	chr7:91322751	NA	0.27	4.48	0.37	1.68e-5	Breast cancer;
TGCT	cis	rs7809950	0.817	rs2712230	chr7:107294151	G/A	cg23024343	chr7:107201750	COG5	0.41	5.78	0.46	5.71e-8	Coronary artery disease;
TGCT	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg11062466	chr8:58055876	NA	0.34	4.67	0.39	7.73e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2439831	0.681	rs498837	chr15:43608024	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.02	8.51	0.61	4.91e-14	Lung cancer in ever smokers;
TGCT	cis	rs11574514	1.000	rs75760574	chr16:67644173	G/A	cg00545966	chr16:67701244	C16orf86;C16orf48	0.72	4.45	0.37	1.87e-5	Crohn's disease;
TGCT	cis	rs3858526	0.514	rs4595572	chr11:5864045	T/G	cg13902645	chr11:5959945	NA	-0.39	-4.57	-0.38	1.16e-5	DNA methylation (variation);
TGCT	cis	rs80282103	0.867	rs80254477	chr10:1077387	T/G	cg18964960	chr10:1102726	WDR37	1.09	4.69	0.39	7.15e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs9650657	0.530	rs6982381	chr8:10952500	A/T	cg27411982	chr8:10470053	RP1L1	-0.21	-4.59	-0.38	1.08e-5	Neuroticism;
TGCT	cis	rs17376456	0.569	rs10057664	chr5:93182274	C/T	cg21475434	chr5:93447410	FAM172A	-0.68	-5.22	-0.42	7.16e-7	Diabetic retinopathy;
TGCT	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg13695892	chr22:41940480	POLR3H	-0.78	-7.66	-0.57	4.58e-12	Vitiligo;
TGCT	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg06896619	chr17:61851486	DDX42;CCDC47	-0.51	-4.96	-0.41	2.24e-6	Prudent dietary pattern;
TGCT	cis	rs67311347	1.000	rs73076046	chr3:40447724	C/T	cg17264618	chr3:40429014	ENTPD3	0.32	4.57	0.38	1.18e-5	Renal cell carcinoma;
TGCT	cis	rs1451375	0.669	rs4469404	chr7:50647062	C/T	cg18232548	chr7:50535776	DDC	-0.46	-7.1	-0.54	8.31e-11	Malaria;
TGCT	cis	rs9906944	0.545	rs11079851	chr17:47092310	G/C	cg20966754	chr17:47091339	IGF2BP1	-0.41	-4.48	-0.37	1.65e-5	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs704	1.000	rs704	chr17:26694861	G/A	cg10342447	chr17:26645325	TMEM97	-0.49	-4.64	-0.38	8.82e-6	Osteoprotegerin levels;
TGCT	cis	rs7267979	0.868	rs6138550	chr20:25223430	C/T	cg03522245	chr20:25566470	NINL	0.6	6.58	0.51	1.21e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9467773	0.935	rs1884947	chr6:26553273	G/T	cg26531700	chr6:26746687	NA	0.67	7.07	0.54	1.02e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg19901468	chr14:105411992	AHNAK2	-0.28	-5.93	-0.47	2.77e-8	Rheumatoid arthritis;
TGCT	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg03060546	chr3:49711283	APEH	0.51	4.82	0.4	4.2e-6	Menarche (age at onset);
TGCT	cis	rs34526934	0.566	rs9141	chr2:177037970	T/C	cg14324370	chr2:177042789	NA	-0.91	-8.67	-0.61	2.03e-14	Obstructive sleep apnea trait (apnea hypopnea index);
TGCT	cis	rs986417	1.000	rs2351176	chr14:61073731	A/T	cg27398547	chr14:60952738	C14orf39	1.41	8.43	0.6	7.41e-14	Gut microbiota (bacterial taxa);
TGCT	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg11644478	chr21:40555479	PSMG1	1.04	10.72	0.69	2.25e-19	Cognitive function;
TGCT	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg03351412	chr1:154909251	PMVK	0.52	4.8	0.4	4.51e-6	Prostate cancer;
TGCT	cis	rs7267979	1.000	rs1047171	chr20:25428786	T/C	cg03522245	chr20:25566470	NINL	0.63	6.8	0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1580019	0.587	rs6968990	chr7:32552159	C/T	cg07520158	chr7:32535189	LSM5;AVL9	-0.57	-4.73	-0.39	6.04e-6	Cognitive ability;
TGCT	cis	rs10992471	0.603	rs755209	chr9:95489671	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.53	-4.58	-0.38	1.13e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	trans	rs17685	0.753	rs1637037	chr7:75692927	C/T	cg19862616	chr7:65841803	NCRNA00174	0.52	8.93	0.63	4.87e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs6582630	0.555	rs2004152	chr12:38478951	C/T	cg26384229	chr12:38710491	ALG10B	0.88	8.04	0.59	5.98e-13	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs2235642	0.859	rs12599207	chr16:1606445	A/G	cg08296037	chr16:1584118	IFT140;TMEM204	-0.3	-5.32	-0.43	4.74e-7	Coronary artery disease;
TGCT	cis	rs9611519	0.754	rs4820435	chr22:41652846	G/T	cg03806693	chr22:41940476	POLR3H	-0.77	-7.59	-0.56	6.65e-12	Neuroticism;
TGCT	cis	rs514406	0.698	rs11206043	chr1:53402552	C/T	cg25767906	chr1:53392781	SCP2	-0.59	-7.45	-0.56	1.37e-11	Monocyte count;
TGCT	cis	rs919433	0.647	rs6741205	chr2:198525997	G/C	cg00792783	chr2:198669748	PLCL1	0.55	4.88	0.4	3.24e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs854765	0.565	rs854768	chr17:18018806	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	7.37	0.55	2.15e-11	Total body bone mineral density;
TGCT	cis	rs6598955	0.640	rs6667826	chr1:26531408	T/C	cg01614726	chr1:26633154	UBXN11	0.5	4.67	0.39	7.56e-6	Obesity-related traits;
TGCT	cis	rs854765	0.583	rs7214002	chr17:17852104	G/C	cg09796270	chr17:17721594	SREBF1	0.23	4.56	0.38	1.22e-5	Total body bone mineral density;
TGCT	cis	rs67311347	1.000	rs7617989	chr3:40512463	A/G	cg13683864	chr3:40499215	RPL14	1.04	10.6	0.69	4.48e-19	Renal cell carcinoma;
TGCT	cis	rs2204008	0.683	rs7305703	chr12:38138381	T/C	cg26384229	chr12:38710491	ALG10B	0.85	7.68	0.57	4.21e-12	Bladder cancer;
TGCT	cis	rs12519773	0.549	rs11738974	chr5:92537336	G/A	cg04854328	chr5:92914828	FLJ42709	-0.3	-4.55	-0.38	1.24e-5	Migraine;
TGCT	cis	rs4689388	0.824	rs4467645	chr4:6294305	C/T	cg25554036	chr4:6271136	WFS1	0.54	7.37	0.55	2.11e-11	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs4953076	0.573	rs6726680	chr2:44406686	C/G	cg00619915	chr2:44497795	NA	-0.22	-4.9	-0.4	2.88e-6	Height;
TGCT	cis	rs2594989	1.000	rs2606761	chr3:11344427	G/A	cg00170343	chr3:11313890	ATG7	0.67	5.06	0.41	1.44e-6	Circulating chemerin levels;
TGCT	cis	rs2216164	0.901	rs10878756	chr12:68522610	T/C	cg17065850	chr12:67807625	NA	0.25	4.57	0.38	1.15e-5	Alopecia areata;
TGCT	cis	rs9467773	0.596	rs2494693	chr6:26619226	T/C	cg02458000	chr6:26745757	NA	0.55	5.25	0.43	6.28e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg22535103	chr8:58192502	C8orf71	-0.41	-5.22	-0.42	7.36e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6840360	0.615	rs7695412	chr4:152488075	A/G	cg17479576	chr4:152424074	FAM160A1	-0.72	-7.98	-0.58	8.25e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs9534288	0.659	rs2146882	chr13:46668111	A/G	cg15192986	chr13:46630673	CPB2	-0.51	-6.12	-0.48	1.16e-8	Blood protein levels;
TGCT	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg23708337	chr7:1209742	NA	0.56	5.43	0.44	2.83e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7201929	1.000	rs12920514	chr16:28835900	G/A	cg09754948	chr16:28834200	ATXN2L	-0.61	-4.55	-0.38	1.27e-5	QT interval;
TGCT	cis	rs11167764	1.000	rs13354528	chr5:141476769	C/T	cg23435118	chr5:141488016	NDFIP1	-0.27	-4.48	-0.37	1.65e-5	Crohn's disease;
TGCT	cis	rs62283056	0.512	rs1079215	chr4:6282393	A/G	cg25554036	chr4:6271136	WFS1	0.53	6.84	0.52	3.27e-10	Cisplatin-induced ototoxicity;
TGCT	cis	rs34091558	1	rs34091558	chr1:201886769	TA/T	cg12730843	chr1:201915899	LMOD1	-0.27	-4.59	-0.38	1.07e-5	Breast size;
TGCT	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg02953382	chr22:24373134	LOC391322	-0.77	-8.01	-0.58	7.12e-13	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2797160	1.000	rs926853	chr6:126021435	A/T	cg05901451	chr6:126070800	HEY2	0.73	6.29	0.49	4.92e-9	Endometrial cancer;
TGCT	cis	rs6684514	1.000	rs6800	chr1:156262653	A/C	cg16558208	chr1:156270281	VHLL	0.46	9.38	0.64	3.92e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs61897795	0.657	rs174590	chr11:61616977	G/C	cg19610905	chr11:61596333	FADS2	-0.62	-4.73	-0.39	5.88e-6	Neutrophil count;Sum basophil neutrophil counts;
TGCT	cis	rs68170813	0.523	rs12535093	chr7:107020182	C/T	cg02696742	chr7:106810147	HBP1	-0.73	-5.95	-0.47	2.6e-8	Coronary artery disease;
TGCT	cis	rs72717009	0.825	rs12746613	chr1:161467042	A/G	cg23840854	chr1:161414152	NA	1.01	6.21	0.49	7.46e-9	Rheumatoid arthritis;
TGCT	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg10802521	chr3:52805072	NEK4	-0.73	-9.23	-0.64	9.18e-16	Bipolar disorder;
TGCT	cis	rs877282	0.945	rs11253398	chr10:790012	T/C	cg17470449	chr10:769945	NA	0.3	4.82	0.4	4.14e-6	Uric acid levels;
TGCT	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg00684032	chr4:1343700	KIAA1530	-0.23	-4.98	-0.41	2.08e-6	Obesity-related traits;
TGCT	cis	rs950169	0.922	rs12911223	chr15:84831671	G/A	cg11189052	chr15:85197271	WDR73	-0.81	-6.5	-0.5	1.78e-9	Schizophrenia;
TGCT	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg03806693	chr22:41940476	POLR3H	1.13	13.66	0.78	1.74e-26	Vitiligo;
TGCT	trans	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg11887960	chr12:57824829	NA	1.1	9.51	0.65	1.98e-16	Lung disease severity in cystic fibrosis;
TGCT	cis	rs10782582	0.609	rs1796827	chr1:76391536	A/T	cg03433033	chr1:76189801	ACADM	-0.47	-4.65	-0.39	8.23e-6	Daytime sleep phenotypes;
TGCT	cis	rs7513165	0.867	rs4951318	chr1:204161513	G/C	cg04791601	chr1:204159016	NA	0.26	5.21	0.42	7.68e-7	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
TGCT	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg18230493	chr5:56204884	C5orf35	-0.68	-5.92	-0.47	2.92e-8	Initial pursuit acceleration;
TGCT	cis	rs3087591	0.853	rs2953003	chr17:29502731	T/C	cg24425628	chr17:29625626	OMG;NF1	0.45	6.95	0.53	1.84e-10	Hip circumference;
TGCT	cis	rs651907	0.535	rs35799195	chr3:101521927	A/G	cg12386194	chr3:101231763	SENP7	0.48	4.81	0.4	4.36e-6	Colorectal cancer;
TGCT	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg04234412	chr22:24373322	LOC391322	0.92	8.49	0.61	5.45e-14	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg00149659	chr3:10157352	C3orf10	0.73	4.72	0.39	6.17e-6	Alzheimer's disease;
TGCT	cis	rs896854	0.654	rs13274945	chr8:95986626	C/T	cg16049864	chr8:95962084	TP53INP1	-0.72	-10.2	-0.68	4.16e-18	Type 2 diabetes;
TGCT	cis	rs3785574	0.650	rs2070776	chr17:62007498	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.55	-4.85	-0.4	3.63e-6	Height;
TGCT	trans	rs9383153	1.000	rs2073518	chr6:16332730	T/C	cg19776793	chr17:79225974	SLC38A10	0.81	6.76	0.52	4.83e-10	Gambling;
TGCT	cis	rs9911578	1.000	rs1971659	chr17:57004787	A/G	cg12560992	chr17:57184187	TRIM37	0.76	9.21	0.64	1.03e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs12497850	1.000	rs10865952	chr3:48744484	A/G	cg06212747	chr3:49208901	KLHDC8B	0.62	5.94	0.47	2.65e-8	Parkinson's disease;
TGCT	cis	rs3540	0.960	rs6496675	chr15:90982756	C/T	cg22089800	chr15:90895588	ZNF774	0.72	6.59	0.51	1.15e-9	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs10465746	0.967	rs1570690	chr1:84377515	G/T	cg10977910	chr1:84465055	TTLL7	0.63	6.19	0.49	8.08e-9	Obesity-related traits;
TGCT	cis	rs7945705	0.747	rs11042150	chr11:9010819	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.45	-4.82	-0.4	4.11e-6	Hemoglobin concentration;
TGCT	cis	rs826838	0.935	rs1843639	chr12:39178919	C/A	cg13010199	chr12:38710504	ALG10B	0.78	6.16	0.48	9.26e-9	Heart rate;
TGCT	cis	rs6430585	0.528	rs309123	chr2:136761175	C/G	cg07169764	chr2:136633963	MCM6	1.2	11.53	0.72	2.34e-21	Corneal structure;
TGCT	cis	rs3806843	1.000	rs6579987	chr5:140183659	T/C	cg19875535	chr5:140030758	IK	0.35	5.85	0.47	4.01e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7917772	0.636	rs7088981	chr10:104520423	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.57	-4.62	-0.38	9.3e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9584850	0.834	rs7339274	chr13:99120272	A/G	cg15168958	chr13:99100528	FARP1	0.25	4.84	0.4	3.76e-6	Neuroticism;
TGCT	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg07507251	chr3:52567010	NT5DC2	0.49	7.11	0.54	8.16e-11	Bipolar disorder;
TGCT	cis	rs13064411	0.735	rs7631138	chr3:113231925	A/T	cg18753928	chr3:113234510	CCDC52	-0.7	-5.68	-0.45	9.16e-8	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	5.55	0.45	1.67e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs734999	0.588	rs11585048	chr1:2534087	C/T	cg18854424	chr1:2615690	NA	0.44	5.1	0.42	1.22e-6	Ulcerative colitis;
TGCT	cis	rs514406	0.505	rs448788	chr1:53161620	A/G	cg16325326	chr1:53192061	ZYG11B	-0.86	-11.53	-0.72	2.4e-21	Monocyte count;
TGCT	cis	rs6740322	1.000	rs11693666	chr2:43562479	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.38	6.32	0.49	4.21e-9	Coronary artery disease;
TGCT	cis	rs7044106	0.762	rs1411158	chr9:123464804	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.61	6.47	0.5	2.01e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs7772486	0.594	rs6901864	chr6:146023050	C/A	cg23711669	chr6:146136114	FBXO30	-0.96	-11.06	-0.7	3.28e-20	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1371867	0.875	rs28595052	chr8:101327553	G/A	cg06636551	chr8:101224915	SPAG1	-0.48	-6.52	-0.51	1.62e-9	Atrioventricular conduction;
TGCT	cis	rs9388451	0.807	rs1268065	chr6:126042783	G/A	cg10911889	chr6:126070802	HEY2	-0.52	-5.26	-0.43	6.17e-7	Brugada syndrome;
TGCT	cis	rs1008375	1.000	rs2058339	chr4:17678456	C/T	cg18681998	chr4:17616180	MED28	0.89	10.34	0.68	1.84e-18	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs12103	0.749	rs2649599	chr1:1305493	A/G	cg14089984	chr1:1182418	FAM132A	0.37	4.77	0.39	5.06e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs908922	0.651	rs1572534	chr1:152509689	G/A	cg20991723	chr1:152506922	NA	0.46	6.18	0.48	8.66e-9	Hair morphology;
TGCT	cis	rs2072499	0.865	rs2758608	chr1:156202860	A/T	cg06970220	chr1:156163860	SLC25A44	0.71	5.87	0.47	3.81e-8	Testicular germ cell tumor;
TGCT	cis	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.67	6.69	0.51	6.89e-10	Eosinophil percentage of white cells;
TGCT	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg22166914	chr1:53195759	ZYG11B	0.3	4.87	0.4	3.29e-6	Monocyte count;
TGCT	cis	rs78456975	0.506	rs13384333	chr2:1555531	A/C	cg01028140	chr2:1542097	TPO	-0.32	-4.86	-0.4	3.54e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs11190604	1.000	rs10883496	chr10:102221931	T/C	cg16342193	chr10:102329863	NA	-0.4	-5.31	-0.43	4.85e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9811920	0.742	rs2316263	chr3:99900096	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.4	-4.68	-0.39	7.28e-6	Axial length;
TGCT	cis	rs838147	0.537	rs504963	chr19:49208865	G/A	cg05248581	chr19:49925731	PTH2	0.42	4.55	0.38	1.28e-5	Dietary macronutrient intake;
TGCT	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg17554472	chr22:41940697	POLR3H	-0.49	-5.26	-0.43	6.14e-7	Vitiligo;
TGCT	cis	rs10751667	0.857	rs6597952	chr11:991109	C/G	cg06064525	chr11:970664	AP2A2	-0.3	-6.06	-0.48	1.51e-8	Alzheimer's disease (late onset);
TGCT	cis	rs2013441	0.786	rs4003797	chr17:20288900	T/C	cg18979559	chr17:20280153	CCDC144C	-0.44	-4.56	-0.38	1.21e-5	Obesity-related traits;
TGCT	cis	rs11190604	1.000	rs2298074	chr10:102247526	G/C	cg16342193	chr10:102329863	NA	-0.41	-5.34	-0.43	4.25e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2439831	0.867	rs2447208	chr15:43933895	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	4.95	0.41	2.38e-6	Lung cancer in ever smokers;
TGCT	cis	rs4803468	1.000	rs4803465	chr19:41918158	A/G	cg09537434	chr19:41945824	ATP5SL	0.91	10.85	0.7	1.06e-19	Height;
TGCT	cis	rs6964587	0.967	rs6974827	chr7:91772945	C/T	cg22709100	chr7:91322751	NA	0.29	4.62	0.38	9.33e-6	Breast cancer;
TGCT	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.61	5.06	0.41	1.5e-6	Tonsillectomy;
TGCT	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg06873352	chr17:61820015	STRADA	0.55	6.1	0.48	1.26e-8	Prudent dietary pattern;
TGCT	cis	rs7267979	1.000	rs6050544	chr20:25320228	T/A	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3091242	0.728	rs706845	chr1:25730713	G/A	cg10117171	chr1:25599238	RHD	-0.36	-5.73	-0.46	7.35e-8	Erythrocyte sedimentation rate;
TGCT	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg17330251	chr7:94953956	PON1	-0.45	-4.45	-0.37	1.93e-5	Yu-Zhi constitution type in type 2 diabetes;
TGCT	cis	rs7914558	0.901	rs35525740	chr10:104941112	A/T	cg15744005	chr10:104629667	AS3MT	-0.39	-4.75	-0.39	5.53e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs11190604	1.000	rs74210981	chr10:102287520	C/T	cg16342193	chr10:102329863	NA	-0.44	-5.56	-0.45	1.58e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs5769765	0.955	rs5769761	chr22:50263641	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	1.11	11.76	0.73	6.5e-22	Schizophrenia;
TGCT	cis	rs17401966	0.898	rs11582123	chr1:10303942	A/T	cg19773385	chr1:10388646	KIF1B	-0.21	-4.6	-0.38	1.02e-5	Hepatocellular carcinoma;
TGCT	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg26818010	chr10:134567672	INPP5A	-0.39	-5.51	-0.44	1.96e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs4925386	0.559	rs2427291	chr20:60921324	G/A	cg06026331	chr20:60912101	LAMA5	0.35	5.44	0.44	2.74e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs709400	0.658	rs72708874	chr14:103899251	T/G	cg26031613	chr14:104095156	KLC1	0.85	9.31	0.64	6e-16	Body mass index;
TGCT	cis	rs11190604	0.943	rs11190588	chr10:102273565	C/T	cg23241863	chr10:102295624	HIF1AN	0.67	4.89	0.4	3.03e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9926296	0.744	rs154656	chr16:89708003	T/A	cg27121462	chr16:89883253	FANCA	-0.49	-4.54	-0.38	1.31e-5	Vitiligo;
TGCT	cis	rs2463822	0.858	rs2513077	chr11:62105925	A/G	cg23876832	chr11:62092739	NA	-0.67	-5.0	-0.41	1.95e-6	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	trans	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg17830980	chr10:43048298	ZNF37B	-0.87	-11.11	-0.71	2.53e-20	Extrinsic epigenetic age acceleration;
TGCT	cis	rs3812831	0.669	rs382913	chr13:114928255	G/T	cg15513719	chr13:114904418	NA	0.38	4.64	0.38	8.57e-6	Schizophrenia;
TGCT	cis	rs12134245	0.776	rs12137878	chr1:91973210	G/T	cg02896835	chr1:92012615	NA	-0.29	-4.77	-0.39	4.98e-6	Breast cancer;
TGCT	cis	rs12530845	1.000	rs73721606	chr7:135335678	C/T	cg23117316	chr7:135346802	PL-5283	-0.51	-4.83	-0.4	3.98e-6	Red blood cell traits;
TGCT	cis	rs6964587	0.773	rs13223564	chr7:91932666	A/G	cg17063962	chr7:91808500	NA	0.83	7.96	0.58	9.29e-13	Breast cancer;
TGCT	cis	rs709400	0.930	rs10134399	chr14:104083457	G/A	cg26031613	chr14:104095156	KLC1	1.15	16.05	0.82	4.72e-32	Body mass index;
TGCT	cis	rs7586879	0.616	rs916485	chr2:25082273	T/C	cg01884057	chr2:25150051	NA	0.33	6.25	0.49	6.16e-9	Body mass index;
TGCT	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg05457628	chr5:178986728	RUFY1	0.44	4.63	0.38	9.2e-6	Lung cancer;
TGCT	cis	rs17125944	0.686	rs73304351	chr14:53375140	G/A	cg00686598	chr14:53173677	PSMC6	0.89	4.44	0.37	1.99e-5	Alzheimer's disease (late onset);
TGCT	cis	rs763121	0.853	rs2267394	chr22:39101633	T/C	cg06022373	chr22:39101656	GTPBP1	0.78	8.1	0.59	4.34e-13	Menopause (age at onset);
TGCT	cis	rs55665837	0.778	rs11023212	chr11:14431709	G/A	cg19336497	chr11:14380999	RRAS2	-0.29	-4.5	-0.37	1.53e-5	Vitamin D levels;
TGCT	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg18876405	chr7:65276391	NA	-0.33	-5.08	-0.42	1.33e-6	Aortic root size;
TGCT	cis	rs2013441	1.000	rs8079701	chr17:20216565	G/A	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.63	-0.38	9.19e-6	Obesity-related traits;
TGCT	cis	rs4555082	1.000	rs4555082	chr14:105758964	C/T	cg10792982	chr14:105748885	BRF1	0.22	4.48	0.37	1.7e-5	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs6684514	1.000	rs12118238	chr1:156235221	G/A	cg16558208	chr1:156270281	VHLL	0.47	9.2	0.64	1.1e-15	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg17775962	chr7:1200435	ZFAND2A	0.28	4.76	0.39	5.27e-6	Longevity;Endometriosis;
TGCT	cis	rs3733585	0.673	rs4447861	chr4:9953940	C/T	cg11266682	chr4:10021025	SLC2A9	-0.57	-7.6	-0.56	6.21e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs1215050	0.791	rs260893	chr4:98744785	A/C	cg17366294	chr4:99064904	C4orf37	0.52	5.61	0.45	1.27e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs12048904	0.619	rs3737581	chr1:101341083	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.86	7.41	0.55	1.68e-11	Multiple sclerosis;
TGCT	trans	rs11722228	0.549	rs73212828	chr4:10078756	C/T	cg26043149	chr18:55253948	FECH	1.15	11.28	0.71	9.49e-21	Gout;Urate levels;Serum uric acid levels;
TGCT	cis	rs11098499	1.000	rs6849889	chr4:120186348	A/C	cg24670566	chr4:120433619	PDE5A	0.23	4.65	0.39	8.5e-6	Corneal astigmatism;
TGCT	cis	rs7666738	0.830	rs34212748	chr4:99068708	G/A	cg17366294	chr4:99064904	C4orf37	0.73	7.45	0.56	1.4e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg11764359	chr7:65958608	NA	0.57	5.28	0.43	5.64e-7	Aortic root size;
TGCT	cis	rs587847	0.567	rs28875580	chr15:37764569	C/T	cg00216138	chr15:37171175	LOC145845	0.31	4.45	0.37	1.86e-5	Intraocular pressure;
TGCT	cis	rs8017423	0.935	rs11621820	chr14:90727154	C/T	cg04374321	chr14:90722782	PSMC1	0.78	7.87	0.58	1.52e-12	Mortality in heart failure;
TGCT	cis	rs1008375	1.000	rs4642241	chr4:17617111	T/C	cg10189774	chr4:17578691	LAP3	0.55	4.92	0.4	2.69e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7302981	1.000	rs7302981	chr12:50537815	A/G	cg23855989	chr12:50355821	AQP5	-0.3	-4.5	-0.38	1.52e-5	Systolic blood pressure;
TGCT	cis	rs2120019	0.608	rs4886414	chr15:75308650	C/T	cg17294928	chr15:75287854	SCAMP5	0.94	9.05	0.63	2.49e-15	Blood trace element (Zn levels);
TGCT	cis	rs7216064	0.734	rs11653507	chr17:65892064	A/T	cg12091567	chr17:66097778	LOC651250	-0.62	-5.29	-0.43	5.46e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs13102973	0.720	rs7668824	chr4:135884707	A/T	cg14419869	chr4:135874104	NA	0.26	4.56	0.38	1.2e-5	Subjective well-being;
TGCT	cis	rs2692947	0.655	rs4605406	chr2:96583735	A/C	cg13655245	chr2:97463316	CNNM4	0.15	4.53	0.38	1.37e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs28735056	1.000	rs4798923	chr18:77629373	G/A	cg20368463	chr18:77673604	PQLC1	-0.45	-5.55	-0.45	1.65e-7	Schizophrenia;
TGCT	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg22963979	chr7:1858916	MAD1L1	-0.42	-6.74	-0.52	5.22e-10	Bipolar disorder and schizophrenia;
TGCT	cis	rs7100689	0.646	rs4265545	chr10:82119271	G/T	cg01528321	chr10:82214614	TSPAN14	0.8	7.76	0.57	2.7e-12	Post bronchodilator FEV1;
TGCT	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg00080972	chr5:178986291	RUFY1	-0.44	-5.25	-0.43	6.45e-7	Lung cancer;
TGCT	cis	rs6665290	0.904	rs9727512	chr1:227185375	G/T	cg10327440	chr1:227177885	CDC42BPA	-0.98	-19.76	-0.87	4.01e-40	Myeloid white cell count;
TGCT	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg06618935	chr21:46677482	NA	-0.34	-5.26	-0.43	6.1e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs904251	0.828	rs2797803	chr6:37487340	T/C	cg25019722	chr6:37503610	NA	-0.51	-7.03	-0.53	1.24e-10	Cognitive performance;
TGCT	cis	rs9486719	1.000	rs2205755	chr6:96864704	A/G	cg18709589	chr6:96969512	KIAA0776	0.71	5.21	0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs360798	0.512	rs9973612	chr2:63019815	G/C	cg17519650	chr2:63277830	OTX1	-0.64	-5.62	-0.45	1.22e-7	Coronary artery disease;
TGCT	cis	rs12900413	0.562	rs28450767	chr15:90298228	A/G	cg24249390	chr15:90295951	MESP1	-0.29	-5.11	-0.42	1.19e-6	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs6570726	1.000	rs951143	chr6:145932576	C/T	cg23711669	chr6:146136114	FBXO30	0.7	6.41	0.5	2.81e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg03732007	chr1:2071316	PRKCZ	0.28	6.35	0.5	3.74e-9	Height;
TGCT	cis	rs1691799	0.867	rs1168309	chr12:66726439	A/G	cg16791601	chr12:66731901	HELB	0.29	6.44	0.5	2.34e-9	White blood cell count (basophil);
TGCT	cis	rs5750830	0.597	rs4821889	chr22:39777254	T/C	cg24399712	chr22:39784796	NA	-0.98	-12.63	-0.75	5.18e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs35146811	0.657	rs36019559	chr7:99814586	A/G	cg00553149	chr7:99775558	STAG3;GPC2	-0.31	-4.61	-0.38	9.75e-6	Coronary artery disease;
TGCT	cis	rs8056742	0.554	rs11647764	chr16:85079813	C/T	cg00229868	chr16:85520891	NA	-0.35	-4.86	-0.4	3.49e-6	Amyotrophic lateral sclerosis;
TGCT	cis	rs508618	0.666	rs480902	chr1:231531627	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.58	5.17	0.42	9e-7	Red blood cell count;
TGCT	cis	rs7267979	0.753	rs404148	chr20:25447931	A/G	cg21995068	chr20:25989032	LOC100134868	-0.43	-5.18	-0.42	8.85e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs10193935	0.901	rs13384404	chr2:42601147	G/T	cg27598129	chr2:42591480	NA	-0.4	-5.44	-0.44	2.71e-7	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs9329221	0.617	rs615632	chr8:9796321	C/T	cg06636001	chr8:8085503	FLJ10661	-0.77	-7.67	-0.57	4.36e-12	Neuroticism;
TGCT	cis	rs7917772	0.503	rs7915589	chr10:104299264	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs4566357	0.521	rs78411533	chr2:227910807	G/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-5.24	-0.43	6.55e-7	Coronary artery disease;
TGCT	cis	rs7666738	0.924	rs11097592	chr4:98927532	C/T	cg18180107	chr4:99064573	C4orf37	0.56	4.78	0.39	4.8e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8014204	0.781	rs10143492	chr14:75212114	G/C	cg06637938	chr14:75390232	RPS6KL1	0.54	4.83	0.4	3.97e-6	Caffeine consumption;
TGCT	cis	rs7904368	0.806	rs7900527	chr10:16857992	C/G	cg14835575	chr10:16859367	RSU1	0.71	7.55	0.56	8.2e-12	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
TGCT	cis	rs1008375	1.000	rs1121089	chr4:17676476	C/A	cg10189774	chr4:17578691	LAP3	0.53	5.0	0.41	1.91e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs826838	0.935	rs11169511	chr12:39175802	T/C	cg13010199	chr12:38710504	ALG10B	0.78	6.16	0.48	9.26e-9	Heart rate;
TGCT	cis	rs6770219	0.516	rs56368029	chr3:186140882	C/T	cg20306810	chr3:186501757	SNORD2;EIF4A2	0.73	4.46	0.37	1.81e-5	Cerebrospinal T-tau levels;
TGCT	cis	rs4654899	0.865	rs72973154	chr1:21459125	G/T	cg01072550	chr1:21505969	NA	-0.48	-7.21	-0.54	4.91e-11	Superior frontal gyrus grey matter volume;
TGCT	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg03188948	chr7:1209495	NA	0.6	4.89	0.4	3.02e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9303401	0.659	rs36109237	chr17:56653834	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs17826219	0.706	rs73271850	chr17:29142140	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Body mass index;
TGCT	cis	rs9818758	0.556	rs13086240	chr3:49001409	G/A	cg00383909	chr3:49044727	WDR6	1.26	6.52	0.51	1.58e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs6912958	0.712	rs2754260	chr6:88397666	T/C	cg06598631	chr6:88300029	RARS2;ORC3L	-0.51	-4.84	-0.4	3.73e-6	Monocyte percentage of white cells;
TGCT	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg22166914	chr1:53195759	ZYG11B	0.37	6.41	0.5	2.77e-9	Monocyte count;
TGCT	cis	rs11264213	0.591	rs1967782	chr1:36543783	C/T	cg27506609	chr1:36549197	TEKT2	-0.33	-4.88	-0.4	3.15e-6	Schizophrenia;
TGCT	cis	rs758129	0.578	rs7497468	chr15:89883147	G/T	cg24365117	chr15:89879190	POLG	-0.35	-4.89	-0.4	3.1e-6	Schizophrenia;
TGCT	cis	rs7582180	0.591	rs2241810	chr2:101011877	T/C	cg14675211	chr2:100938903	LONRF2	0.5	4.77	0.39	5.18e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs66573146	0.831	rs67602077	chr4:7024244	A/G	cg05069807	chr4:6945702	TBC1D14	0.36	5.11	0.42	1.2e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs7611238	0.560	rs4677669	chr3:195051300	C/T	cg27323046	chr3:195102265	ACAP2	0.36	4.9	0.4	2.94e-6	Body mass index;
TGCT	cis	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg12570787	chr5:219185	SDHA;CCDC127	0.66	4.49	0.37	1.62e-5	Breast cancer;
TGCT	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs362272	0.545	rs2749785	chr4:3325179	G/C	cg22655196	chr4:3374909	RGS12	0.23	4.55	0.38	1.24e-5	Serum sulfate level;
TGCT	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg23131131	chr22:24373011	LOC391322	-0.7	-7.17	-0.54	6.03e-11	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9486719	0.843	rs2499792	chr6:96846264	A/C	cg18709589	chr6:96969512	KIAA0776	0.75	5.13	0.42	1.1e-6	Migraine;Coronary artery disease;
TGCT	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.24	-4.53	-0.38	1.37e-5	Calcium levels;
TGCT	cis	rs6964587	1.000	rs13231820	chr7:91663529	A/G	cg22709100	chr7:91322751	NA	0.27	4.46	0.37	1.84e-5	Breast cancer;
TGCT	cis	rs2928148	0.522	rs11858278	chr15:41416276	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.61	-7.87	-0.58	1.52e-12	Glomerular filtration rate in non diabetics (creatinine);
TGCT	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg24503407	chr1:205819492	PM20D1	0.6	8.5	0.61	5e-14	Menarche (age at onset);
TGCT	cis	rs12510870	0.634	rs56011127	chr4:74386212	C/T	cg05868023	chr4:75230803	EREG	-0.55	-4.7	-0.39	6.84e-6	Iris color (b* coordinate);
TGCT	cis	rs9467711	0.659	rs35680819	chr6:26455814	T/C	cg16898833	chr6:26189333	HIST1H4D	1.26	5.95	0.47	2.59e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs67311347	1.000	rs4973878	chr3:40407565	C/T	cg17264618	chr3:40429014	ENTPD3	0.32	4.76	0.39	5.36e-6	Renal cell carcinoma;
TGCT	cis	rs6921919	0.583	rs34513104	chr6:28343343	G/A	cg18815343	chr6:28367644	ZSCAN12	-0.56	-5.33	-0.43	4.48e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2180341	1.000	rs2057223	chr6:127637374	T/C	cg27446573	chr6:127587934	RNF146	1.12	10.11	0.67	6.87e-18	Breast cancer;
TGCT	cis	rs4733781	0.527	rs7002892	chr8:131235135	A/T	cg16277922	chr8:131349729	ASAP1	0.39	5.52	0.44	1.92e-7	Tuberculosis;
TGCT	cis	rs651907	0.557	rs13081846	chr3:101383321	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.91	10.9	0.7	8.24e-20	Colorectal cancer;
TGCT	cis	rs7193541	0.682	rs28681530	chr16:74682496	C/T	cg01733217	chr16:74700730	RFWD3	1.0	13.51	0.77	3.91e-26	Multiple myeloma;
TGCT	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg03452623	chr4:187889614	NA	-0.36	-5.19	-0.42	8.48e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9916302	0.861	rs4795377	chr17:37669056	C/T	cg07936489	chr17:37558343	FBXL20	-0.62	-4.88	-0.4	3.2e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs6089829	0.962	rs3746747	chr20:61667631	T/C	cg08045932	chr20:61659980	NA	0.48	9.1	0.63	1.91e-15	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs6831352	0.918	rs7669636	chr4:100059312	G/A	cg12011299	chr4:100065546	ADH4	-0.4	-4.88	-0.4	3.26e-6	Alcohol dependence;
TGCT	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg00684032	chr4:1343700	KIAA1530	0.22	4.83	0.4	3.99e-6	Obesity-related traits;
TGCT	cis	rs950027	0.584	rs1145086	chr15:45654327	A/G	cg14582100	chr15:45693742	SPATA5L1	0.47	6.02	0.48	1.8e-8	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs61656020	1	rs61656020	chr16:1882221	C/G	cg26617929	chr16:1858877	NA	-0.27	-4.8	-0.4	4.42e-6	Ankle injury;
TGCT	cis	rs2120019	1.000	rs2415253	chr15:75375699	A/G	cg17294928	chr15:75287854	SCAMP5	-0.86	-6.62	-0.51	9.55e-10	Blood trace element (Zn levels);
TGCT	cis	rs11673344	0.523	rs7245520	chr19:37527318	A/G	cg08039142	chr19:36980659	ZNF566	0.49	4.5	0.37	1.57e-5	Obesity-related traits;
TGCT	cis	rs9969804	0.682	rs10761168	chr9:95505560	A/G	cg13940029	chr9:95239186	CENPP;ASPN	-0.17	-4.45	-0.37	1.92e-5	Height;
TGCT	cis	rs2050392	0.624	rs303447	chr10:30728464	T/C	cg18806716	chr10:30721971	MAP3K8	-0.7	-9.39	-0.64	3.84e-16	Inflammatory bowel disease;
TGCT	cis	rs79349575	0.783	rs9912829	chr17:46982749	G/C	cg07967210	chr17:47022446	SNF8	0.43	6.06	0.48	1.54e-8	Type 2 diabetes;
TGCT	cis	rs10984561	0.881	rs10984556	chr9:122247734	T/G	cg14242995	chr9:122249943	NA	0.75	6.41	0.5	2.7e-9	Pulmonary function decline;
TGCT	cis	rs11105298	0.786	rs10858867	chr12:89851166	C/T	cg00757033	chr12:89920650	WDR51B	0.34	5.37	0.43	3.75e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs77741769	0.571	rs869781	chr12:121340246	T/C	cg02419362	chr12:121203948	SPPL3	0.19	4.49	0.37	1.63e-5	Mean corpuscular volume;
TGCT	cis	rs10751667	0.666	rs7394427	chr11:970405	G/A	cg06064525	chr11:970664	AP2A2	-0.36	-8.28	-0.6	1.67e-13	Alzheimer's disease (late onset);
TGCT	cis	rs7945705	0.869	rs4909952	chr11:8963946	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.46	5.2	0.42	8.11e-7	Hemoglobin concentration;
TGCT	cis	rs8030485	0.756	rs2102999	chr15:79410710	C/T	cg17916960	chr15:79447300	NA	-0.35	-4.96	-0.41	2.31e-6	Left ventricle wall thickness;
TGCT	cis	rs17206232	0.534	rs72760572	chr5:64692640	T/C	cg09571848	chr5:64330935	NA	-0.31	-4.46	-0.37	1.82e-5	Schizophrenia;
TGCT	cis	rs3015497	0.789	rs8003372	chr14:51102351	G/A	cg04730355	chr14:51134070	SAV1	-0.64	-6.26	-0.49	5.8e-9	Mean platelet volume;
TGCT	cis	rs11096990	0.593	rs35552004	chr4:39172534	C/T	cg20847110	chr4:39482781	LOC401127	0.17	4.96	0.41	2.3e-6	Cognitive function;
TGCT	cis	rs7000551	0.751	rs2100291	chr8:22374551	C/T	cg12081754	chr8:22256438	SLC39A14	0.31	5.0	0.41	1.9e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs904251	0.737	rs914347	chr6:37484970	A/C	cg08126542	chr6:37504118	NA	-0.41	-5.45	-0.44	2.57e-7	Cognitive performance;
TGCT	cis	rs9611519	0.780	rs5751071	chr22:41656332	G/A	cg13695892	chr22:41940480	POLR3H	-0.65	-6.2	-0.49	7.73e-9	Neuroticism;
TGCT	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg22535103	chr8:58192502	C8orf71	-0.42	-5.39	-0.44	3.49e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs9486715	0.830	rs2255552	chr6:96999643	A/G	cg06623918	chr6:96969491	KIAA0776	-1.06	-13.63	-0.77	2.02e-26	Headache;
TGCT	cis	rs2282802	0.685	rs7737543	chr5:139646026	A/G	cg01081189	chr5:139537190	NA	0.28	5.15	0.42	9.75e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.44	4.98	0.41	2.05e-6	Lymphocyte counts;
TGCT	cis	rs2241685	0.540	rs11683007	chr2:1865262	C/G	cg21862353	chr2:1801628	MYT1L	-0.47	-4.71	-0.39	6.64e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs9790314	0.846	rs9809522	chr3:160983768	G/C	cg03342759	chr3:160939853	NMD3	-0.51	-5.66	-0.45	9.96e-8	Morning vs. evening chronotype;
TGCT	cis	rs6933660	0.646	rs9383899	chr6:151781022	G/C	cg14416726	chr6:151773293	C6orf211;RMND1	-1.05	-14.06	-0.78	1.99e-27	Menarche (age at onset);
TGCT	cis	rs1801251	1.000	rs9653383	chr2:233670380	A/C	cg08000102	chr2:233561755	GIGYF2	-0.64	-6.56	-0.51	1.34e-9	Coronary artery disease;
TGCT	cis	rs6429082	0.782	rs704705	chr1:235612320	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.57	-4.88	-0.4	3.21e-6	Adiposity;
TGCT	cis	rs11122272	0.670	rs2474632	chr1:231484361	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-6.92	-0.53	2.18e-10	Hemoglobin concentration;
TGCT	cis	rs8180040	0.934	rs62260710	chr3:47564462	C/G	cg27129171	chr3:47204927	SETD2	-0.64	-7.34	-0.55	2.41e-11	Colorectal cancer;
TGCT	cis	rs10791097	0.629	rs11222361	chr11:130731424	T/G	cg12179176	chr11:130786555	SNX19	0.77	9.52	0.65	1.82e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs4499344	0.521	rs259222	chr19:33136895	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.82	8.26	0.6	1.84e-13	Mean platelet volume;
TGCT	cis	rs7824557	0.518	rs11783749	chr8:10802055	G/A	cg27411982	chr8:10470053	RP1L1	-0.24	-5.02	-0.41	1.78e-6	Retinal vascular caliber;
TGCT	cis	rs3812049	0.737	rs1993878	chr5:127476971	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.6	5.67	0.45	9.62e-8	Lymphocyte counts;Red cell distribution width;
TGCT	cis	rs2742417	0.904	rs2373047	chr3:45747497	C/A	cg04837898	chr3:45731254	SACM1L	-0.55	-5.68	-0.45	9.22e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs6089584	0.606	rs2273989	chr20:60579138	G/A	cg06108461	chr20:60628389	TAF4	-0.4	-5.02	-0.41	1.73e-6	Body mass index;
TGCT	cis	rs611744	0.870	rs635941	chr8:109235457	G/A	cg21045802	chr8:109455806	TTC35	0.7	6.26	0.49	5.73e-9	Dupuytren's disease;
TGCT	cis	rs9902453	0.933	rs60694493	chr17:28473256	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	6.51	0.5	1.66e-9	Coffee consumption (cups per day);
TGCT	cis	rs12477438	0.520	rs6708576	chr2:99801308	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	12.84	0.76	1.57e-24	Chronic sinus infection;
TGCT	cis	rs9549367	0.789	rs9604040	chr13:113910611	A/G	cg00898013	chr13:113819073	PROZ	0.37	4.66	0.39	7.87e-6	Platelet distribution width;
TGCT	cis	rs9902453	0.808	rs4595850	chr17:28206326	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.8	7.31	0.55	2.9100000000000002e-11	Coffee consumption (cups per day);
TGCT	cis	rs7772486	0.754	rs6921073	chr6:146144377	G/A	cg23711669	chr6:146136114	FBXO30	0.9	10.15	0.67	5.45e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs5769707	0.681	rs2071902	chr22:50034538	G/C	cg05373962	chr22:49881684	NA	-0.31	-5.31	-0.43	4.99e-7	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs3008870	1.000	rs2815351	chr1:67477980	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.01	9.9	0.66	2.23e-17	Lymphocyte percentage of white cells;
TGCT	cis	rs7178572	0.568	rs11632966	chr15:77621805	A/C	cg22256960	chr15:77711686	NA	-0.85	-8.73	-0.62	1.4e-14	Type 2 diabetes;
TGCT	cis	rs2458413	1.000	rs2458413	chr8:105359432	C/T	cg13045555	chr8:105342365	NA	0.38	5.93	0.47	2.78e-8	Paget's disease;
TGCT	cis	rs28595532	0.841	rs115516095	chr4:119760096	A/C	cg14228332	chr4:119757509	SEC24D	1.3	6.62	0.51	9.62e-10	Cannabis dependence symptom count;
TGCT	cis	rs4819052	0.766	rs4819035	chr21:46645715	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	5.14	0.42	1.04e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2721811	0.593	rs2521768	chr7:24784403	C/T	cg17569154	chr7:24781545	DFNA5	0.23	4.77	0.39	5.07e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs1008375	1.000	rs7661631	chr4:17679751	T/C	cg18681998	chr4:17616180	MED28	-0.83	-8.43	-0.6	7.25e-14	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9467773	0.620	rs2451741	chr6:26629404	A/G	cg26531700	chr6:26746687	NA	0.5	4.68	0.39	7.52e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg12310025	chr6:25882481	NA	-0.62	-6.42	-0.5	2.62e-9	Blood metabolite levels;
TGCT	cis	rs2028201	1.000	rs2028201	chr2:201303010	A/C	cg04781494	chr2:202047246	CASP10	-0.25	-4.43	-0.37	2.01e-5	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
TGCT	cis	rs7772486	0.754	rs9497434	chr6:146260753	C/T	cg05347473	chr6:146136440	FBXO30	-0.52	-5.03	-0.41	1.67e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs35306767	0.909	rs12264390	chr10:959111	T/C	cg20503657	chr10:835505	NA	0.68	9.49	0.65	2.12e-16	Eosinophil percentage of granulocytes;
TGCT	cis	rs12682352	0.602	rs28399241	chr8:8663215	C/T	cg06636001	chr8:8085503	FLJ10661	0.62	5.3	0.43	5.07e-7	Neuroticism;
TGCT	cis	rs9677476	0.516	rs6755467	chr2:232044684	G/T	cg07929768	chr2:232055508	NA	-0.34	-5.38	-0.44	3.55e-7	Food antigen IgG levels;
TGCT	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg24399712	chr22:39784796	NA	-1.06	-12.44	-0.75	1.44e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs2072499	0.838	rs2758619	chr1:156162559	A/G	cg25208724	chr1:156163844	SLC25A44	1.14	16.72	0.83	1.43e-33	Testicular germ cell tumor;
TGCT	trans	rs2727020	0.636	rs11040368	chr11:49453602	C/A	cg03929089	chr4:120376271	NA	-0.77	-9.03	-0.63	2.74e-15	Coronary artery disease;
TGCT	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg03709012	chr19:19516395	GATAD2A	0.75	6.51	0.5	1.71e-9	Tonsillectomy;
TGCT	cis	rs7811142	0.945	rs34989573	chr7:100097895	C/T	cg00814883	chr7:100076585	TSC22D4	-0.89	-9.03	-0.63	2.76e-15	Platelet count;
TGCT	cis	rs12142240	0.698	rs66516678	chr1:46810112	G/T	cg00530320	chr1:46809349	NSUN4	0.29	5.88	0.47	3.63e-8	Menopause (age at onset);
TGCT	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg01802117	chr1:53393560	SCP2	0.44	5.34	0.43	4.33e-7	Monocyte count;
TGCT	cis	rs3847687	1.000	rs3847688	chr12:131525310	C/T	cg25772418	chr12:131519998	GPR133	-0.33	-6.1	-0.48	1.26e-8	Longevity;
TGCT	cis	rs9911578	1.000	rs304296	chr17:56834229	G/T	cg05425664	chr17:57184151	TRIM37	-0.63	-6.26	-0.49	5.86e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs2486012	1.000	rs1766968	chr1:44403042	T/C	cg12908607	chr1:44402522	ARTN	0.78	6.04	0.48	1.68e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs67072384	0.748	rs6592484	chr11:72464470	C/T	cg03713592	chr11:72463424	ARAP1	-0.88	-4.77	-0.39	5.04e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
TGCT	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.06	-9.57	-0.65	1.41e-16	Platelet count;
TGCT	cis	rs6570726	0.577	rs406868	chr6:145809983	C/T	cg05347473	chr6:146136440	FBXO30	0.62	5.75	0.46	6.64e-8	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs1005277	0.505	rs719569	chr10:38154415	T/G	cg17830980	chr10:43048298	ZNF37B	0.74	8.59	0.61	3.11e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs9811920	0.641	rs58704213	chr3:99690331	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.43	5.12	0.42	1.14e-6	Axial length;
TGCT	cis	rs208520	0.837	rs208488	chr6:66926902	C/T	cg07460842	chr6:66804631	NA	-0.94	-9.3	-0.64	6.32e-16	Exhaled nitric oxide output;
TGCT	cis	rs6540559	0.546	rs735694	chr1:210034029	T/C	cg23283495	chr1:209979779	IRF6	0.67	4.99	0.41	1.96e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs12681288	0.782	rs12544713	chr8:1026697	C/T	cg04851639	chr8:1020857	NA	-0.32	-5.75	-0.46	6.63e-8	Schizophrenia;
TGCT	cis	rs72781680	0.898	rs72786279	chr2:24063266	C/T	cg08917208	chr2:24149416	ATAD2B	0.78	4.79	0.4	4.69e-6	Lymphocyte counts;
TGCT	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.73	-0.39	5.93e-6	Prudent dietary pattern;
TGCT	cis	rs3011225	0.691	rs3791102	chr1:44366617	C/T	cg12908607	chr1:44402522	ARTN	-0.66	-8.12	-0.59	3.95e-13	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	-0.53	-4.5	-0.37	1.55e-5	Tonsillectomy;
TGCT	cis	rs910316	1.000	rs12889309	chr14:75593902	C/T	cg11812906	chr14:75593930	NEK9	0.74	7.37	0.55	2.12e-11	Height;
TGCT	cis	rs1008375	0.932	rs11935124	chr4:17668200	G/A	cg18681998	chr4:17616180	MED28	-0.87	-8.96	-0.63	4.13e-15	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.72	7.31	0.55	2.83e-11	Menarche (age at onset);
TGCT	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg22920501	chr2:26401640	FAM59B	-0.74	-6.4	-0.5	2.86e-9	Gut microbiome composition (summer);
TGCT	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg11890956	chr21:40555474	PSMG1	-0.76	-7.45	-0.56	1.39e-11	Cognitive function;
TGCT	cis	rs10832169	0.967	rs2178241	chr11:14072994	G/A	cg04547675	chr11:13986162	SPON1	0.51	4.51	0.38	1.49e-5	Blood protein levels;
TGCT	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg21280719	chr6:42927975	GNMT	-0.37	-4.52	-0.38	1.41e-5	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs7267979	1.000	rs2500405	chr20:25360826	A/G	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6964587	0.692	rs418	chr7:91583334	C/T	cg17063962	chr7:91808500	NA	-0.75	-7.1	-0.54	8.63e-11	Breast cancer;
TGCT	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.34	0.55	2.43e-11	Prudent dietary pattern;
TGCT	cis	rs2842992	0.714	rs2475564	chr6:160123673	A/G	cg11366901	chr6:160182831	ACAT2	0.91	6.33	0.49	4.04e-9	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg12667521	chr19:29218732	NA	0.54	5.72	0.46	7.65e-8	Methadone dose in opioid dependence;
TGCT	cis	rs10791097	0.748	rs2282579	chr11:130735482	C/T	cg14779329	chr11:130786720	SNX19	0.28	4.96	0.41	2.31e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg08439880	chr3:133502540	NA	-0.31	-5.75	-0.46	6.41e-8	Iron status biomarkers;
TGCT	cis	rs3733585	0.753	rs12500805	chr4:10017979	C/T	cg00071950	chr4:10020882	SLC2A9	0.69	8.25	0.6	1.95e-13	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs11209002	0.592	rs4655672	chr1:67553543	C/T	cg02640540	chr1:67518911	SLC35D1	0.55	4.65	0.39	8.42e-6	Crohn's disease;
TGCT	cis	rs7666738	0.830	rs6846739	chr4:99016647	G/A	cg18180107	chr4:99064573	C4orf37	0.54	5.03	0.41	1.7e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	16.05	0.82	4.59e-32	Prudent dietary pattern;
TGCT	cis	rs2229238	0.866	rs112231452	chr1:154504900	G/A	cg13067139	chr1:155221277	FAM189B	0.2	4.69	0.39	6.95e-6	Coronary heart disease;
TGCT	cis	rs4851254	0.517	rs13020141	chr2:100653842	G/A	cg07810366	chr2:100720526	AFF3	-0.46	-4.64	-0.38	8.78e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs12188164	0.965	rs56146525	chr5:442571	A/C	cg21144161	chr5:423903	AHRR	0.25	4.79	0.4	4.59e-6	Cystic fibrosis severity;
TGCT	cis	rs3820068	0.705	rs11584398	chr1:15880275	G/A	cg05660106	chr1:15850417	CASP9	1.17	14.8	0.8	3.47e-29	Systolic blood pressure;
TGCT	cis	rs10498514	1.000	rs117727667	chr14:65028278	T/A	cg25134081	chr14:64931936	AKAP5	1.13	4.63	0.38	9.22e-6	Cognitive performance;
TGCT	cis	rs6589563	0.737	rs61905086	chr11:116614863	T/C	cg01124546	chr11:117515332	DSCAML1	-0.41	-4.5	-0.37	1.55e-5	Eosinophil counts;
TGCT	cis	rs3087591	0.960	rs2905802	chr17:29520084	T/C	cg24425628	chr17:29625626	OMG;NF1	0.46	7.39	0.55	1.91e-11	Hip circumference;
TGCT	cis	rs999943	0.774	rs12212284	chr6:33640874	T/A	cg14003231	chr6:33640908	ITPR3	0.4	4.88	0.4	3.19e-6	Obesity (extreme);
TGCT	cis	rs78456975	0.527	rs4073862	chr2:1563433	A/G	cg12573674	chr2:1569213	NA	-0.45	-4.84	-0.4	3.84e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs614226	0.938	rs787824	chr12:120924638	A/G	cg01236616	chr12:121019343	POP5	-1.11	-12.2	-0.74	5.61e-23	Type 1 diabetes nephropathy;
TGCT	cis	rs7508	0.511	rs208026	chr8:17878155	A/G	cg01800426	chr8:17659068	MTUS1	-0.62	-5.08	-0.42	1.33e-6	Atrial fibrillation;
TGCT	cis	rs7017914	0.783	rs13252584	chr8:71689031	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.53	-4.98	-0.41	2.09e-6	Bone mineral density;
TGCT	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs1568889	1.000	rs7951681	chr11:28273894	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.81	7.87	0.58	1.54e-12	Bipolar disorder;
TGCT	cis	rs9303401	1.000	rs1390006	chr17:56890663	C/T	cg12560992	chr17:57184187	TRIM37	-0.54	-5.61	-0.45	1.26e-7	Cognitive test performance;
TGCT	trans	rs10504390	0.585	rs80151640	chr8:66537841	C/T	cg18118147	chr19:51128640	SYT3	-0.77	-6.85	-0.52	2.99e-10	IgG glycosylation;
TGCT	cis	rs9894429	0.682	rs7406360	chr17:79591545	G/A	cg18240062	chr17:79603768	NPLOC4	0.84	9.67	0.66	8.1e-17	Eye color traits;
TGCT	cis	rs12497850	0.864	rs4521268	chr3:49137904	G/T	cg16497277	chr3:49208875	KLHDC8B	-0.49	-4.48	-0.37	1.68e-5	Parkinson's disease;
TGCT	trans	rs4650994	0.544	rs4075631	chr1:178506594	C/A	cg05059571	chr16:84539110	KIAA1609	-0.55	-11.44	-0.72	3.86e-21	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs9383153	0.590	rs2072736	chr6:16328068	T/C	cg03173502	chr6:15505345	JARID2	0.83	4.59	0.38	1.06e-5	Gambling;
TGCT	cis	rs473651	1.000	rs473651	chr2:239335401	A/C	cg08773314	chr2:239334832	ASB1	0.47	7.96	0.58	9.43e-13	Multiple system atrophy;
TGCT	cis	rs3749237	0.964	rs7431078	chr3:49808190	G/A	cg07636037	chr3:49044803	WDR6	0.64	5.63	0.45	1.13e-7	Resting heart rate;
TGCT	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg26338869	chr17:61819248	STRADA	-0.53	-4.87	-0.4	3.29e-6	Prudent dietary pattern;
TGCT	cis	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg07424592	chr7:64974309	NA	1.4	8.42	0.6	7.87e-14	Diabetic kidney disease;
TGCT	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg05872129	chr22:39784769	NA	-1.01	-11.06	-0.7	3.4e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg17554472	chr22:41940697	POLR3H	-0.49	-5.27	-0.43	5.9e-7	Vitiligo;
TGCT	cis	rs2594989	0.779	rs2447603	chr3:11590261	T/C	cg00170343	chr3:11313890	ATG7	-0.71	-5.4	-0.44	3.26e-7	Circulating chemerin levels;
TGCT	cis	rs11122272	0.735	rs2474634	chr1:231487017	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-6.77	-0.52	4.54e-10	Hemoglobin concentration;
TGCT	cis	rs11673344	0.504	rs7245882	chr19:37580415	A/G	cg08039142	chr19:36980659	ZNF566	-0.5	-4.63	-0.38	8.95e-6	Obesity-related traits;
TGCT	cis	rs6495122	0.532	rs2470890	chr15:75047426	C/T	cg10253484	chr15:75165896	SCAMP2	-0.69	-6.0	-0.47	2.05e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
TGCT	cis	rs644799	1.000	rs2508289	chr11:95624669	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	9.93	0.67	1.91e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs1008375	0.966	rs6449313	chr4:17588320	A/G	cg10189774	chr4:17578691	LAP3	0.63	5.52	0.44	1.9e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9611565	0.729	rs203320	chr22:41913477	T/C	cg17554472	chr22:41940697	POLR3H	-0.44	-4.97	-0.41	2.15e-6	Vitiligo;
TGCT	cis	rs1868673	0.679	rs4323025	chr3:150161522	A/G	cg24290546	chr3:150134309	TSC22D2	0.24	4.53	0.38	1.37e-5	Waist circumference;
TGCT	cis	rs4862307	0.964	rs6840005	chr4:184998350	C/T	cg06737308	chr4:185021514	ENPP6	0.44	6.38	0.5	3.12e-9	Serum dimethylarginine levels (asymmetric/symetric ratio);
TGCT	cis	rs7572733	0.534	rs700667	chr2:198677508	T/C	cg00792783	chr2:198669748	PLCL1	0.56	5.08	0.42	1.35e-6	Dermatomyositis;
TGCT	cis	rs854765	0.624	rs8078756	chr17:17744725	T/C	cg04398451	chr17:18023971	MYO15A	0.32	4.76	0.39	5.24e-6	Total body bone mineral density;
TGCT	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg11644478	chr21:40555479	PSMG1	1.0	10.6	0.69	4.32e-19	Cognitive function;
TGCT	cis	rs2932538	0.922	rs12137107	chr1:113127437	A/G	cg22162597	chr1:113214053	CAPZA1	0.27	5.98	0.47	2.24e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs9549260	0.755	rs9532571	chr13:41218670	C/T	cg21288729	chr13:41239152	FOXO1	1.01	11.06	0.7	3.29e-20	Red blood cell count;
TGCT	cis	rs11107903	1.000	rs11107903	chr12:95507971	G/A	cg10621809	chr12:95840313	NA	0.7	4.61	0.38	9.89e-6	Coronary artery disease;
TGCT	cis	rs9916302	0.904	rs10432031	chr17:37397852	G/A	cg07936489	chr17:37558343	FBXL20	-0.65	-5.26	-0.43	6e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs10464366	0.544	rs9639812	chr7:39192058	C/T	cg15212455	chr7:39170539	POU6F2	0.3	6.66	0.51	8.11e-10	IgG glycosylation;
TGCT	cis	rs13191362	0.507	rs2849534	chr6:163144657	T/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.58	-5.35	-0.43	4.05e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg17345569	chr6:42928274	GNMT	-0.48	-4.95	-0.41	2.35e-6	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs453301	0.512	rs2921381	chr8:8895401	T/A	cg00184457	chr8:8946301	NA	0.24	4.54	0.38	1.32e-5	Joint mobility (Beighton score);
TGCT	cis	rs7169223	0.653	rs1564499	chr15:79084808	C/T	cg03762349	chr15:79060523	ADAMTS7	0.22	4.61	0.38	9.96e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
TGCT	cis	rs7666738	0.830	rs6532720	chr4:99043781	C/T	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs74544699	1.000	rs80127839	chr4:74837229	A/C	cg16072462	chr4:74847758	PF4	0.76	4.86	0.4	3.49e-6	Growth-regulated protein alpha levels;
TGCT	cis	rs28595532	0.764	rs115298416	chr4:119565383	C/T	cg21605333	chr4:119757512	SEC24D	1.36	7.24	0.55	4.15e-11	Cannabis dependence symptom count;
TGCT	cis	rs854765	0.583	rs9912895	chr17:17826020	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.73	-7.63	-0.57	5.33e-12	Total body bone mineral density;
TGCT	cis	rs7267979	0.903	rs6107015	chr20:25216764	G/A	cg16686733	chr20:25566563	NINL	0.59	6.04	0.48	1.64e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9640161	0.659	rs7788316	chr7:150013995	A/T	cg10018233	chr7:150070692	REPIN1	0.32	4.47	0.37	1.75e-5	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs539096	0.872	rs10890255	chr1:44031493	A/G	cg12908607	chr1:44402522	ARTN	-0.48	-4.98	-0.41	2.06e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6988636	1.000	rs13260626	chr8:124190317	C/T	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	5.48	0.44	2.25e-7	Height;
TGCT	cis	rs4711350	0.953	rs1547668	chr6:33775446	A/G	cg18005901	chr6:33739558	LEMD2	-0.53	-5.66	-0.45	9.98e-8	Schizophrenia;
TGCT	cis	rs7914558	0.966	rs7908280	chr10:104816947	C/G	cg05855489	chr10:104503620	C10orf26	0.51	4.5	0.37	1.56e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs1609391	0.543	rs9828009	chr3:136631275	C/T	cg15507776	chr3:136538369	TMEM22	0.66	6.84	0.52	3.27e-10	Neuroticism;
TGCT	cis	rs11031096	0.711	rs1348309	chr11:4202000	A/T	cg18678763	chr11:4115507	RRM1	-0.46	-6.03	-0.48	1.78e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs28599928	0.920	rs17415203	chr22:43455592	A/G	cg15811549	chr22:43485393	TTLL1	-0.93	-4.89	-0.4	3.04e-6	Breast cancer;
TGCT	cis	rs911555	0.755	rs8010247	chr14:103933556	A/G	cg23461800	chr14:103021989	NA	-0.35	-4.56	-0.38	1.23e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs3733585	0.598	rs28677023	chr4:9958326	C/A	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.7	-0.57	3.69e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs6570726	0.791	rs370112	chr6:145859853	T/G	cg13319975	chr6:146136371	FBXO30	-0.51	-4.6	-0.38	1.01e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs5769765	0.671	rs138832	chr22:50178082	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.96	-9.26	-0.64	7.87e-16	Schizophrenia;
TGCT	cis	rs35883536	0.528	rs1577511	chr1:101030859	G/A	cg06223162	chr1:101003688	GPR88	0.43	8.41	0.6	8.23e-14	Monocyte count;
TGCT	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg05985448	chr10:134359359	INPP5A	0.22	4.73	0.39	6e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs7666738	0.830	rs4699331	chr4:99059816	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.79	0.46	5.32e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg22963979	chr7:1858916	MAD1L1	-0.45	-7.41	-0.55	1.74e-11	Bipolar disorder and schizophrenia;
TGCT	cis	rs595982	0.527	rs73061658	chr19:49372376	G/C	cg17863274	chr19:49399704	TULP2	-0.47	-6.81	-0.52	3.78e-10	Red cell distribution width;
TGCT	cis	rs12762955	0.687	rs4880470	chr10:1077480	G/A	cg26597838	chr10:835615	NA	-0.4	-5.08	-0.42	1.33e-6	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs3796352	1.000	rs34244302	chr3:53102236	C/G	cg15956490	chr3:53032818	SFMBT1	0.59	6.64	0.51	8.89e-10	Immune reponse to smallpox (secreted IL-2);
TGCT	trans	rs214785	0.790	rs62192637	chr20:2260968	G/A	cg24980040	chr10:1714535	ADARB2	0.46	6.62	0.51	9.65e-10	Basal cell carcinoma;
TGCT	cis	rs587847	0.737	rs4924153	chr15:37666010	A/T	cg00216138	chr15:37171175	LOC145845	-0.32	-4.8	-0.4	4.45e-6	Intraocular pressure;
TGCT	cis	rs10207060	0.500	rs11884577	chr2:240702216	C/G	cg15726768	chr2:241314588	NA	-0.32	-4.58	-0.38	1.1e-5	Obesity-related traits;
TGCT	cis	rs9942416	0.660	rs17649055	chr5:74984269	C/T	cg19683494	chr5:74908142	NA	0.59	6.34	0.49	3.85e-9	Age-related disease endophenotypes;
TGCT	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg10802521	chr3:52805072	NEK4	-0.7	-8.54	-0.61	4.07e-14	Bipolar disorder;
TGCT	cis	rs16866061	0.962	rs16866045	chr2:225413020	G/A	cg12698349	chr2:225449008	CUL3	1.0	9.83	0.66	3.23e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg05025164	chr4:1340916	KIAA1530	0.8	6.42	0.5	2.68e-9	Longevity;
TGCT	cis	rs7027203	0.557	rs2490997	chr9:96522109	C/T	cg13679303	chr9:96623674	NA	-0.53	-7.48	-0.56	1.18e-11	DNA methylation (variation);
TGCT	cis	rs8038465	0.622	rs7182124	chr15:73915254	C/T	cg15420318	chr15:73925796	NPTN	0.68	7.35	0.55	2.28e-11	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7772486	0.790	rs9497427	chr6:146238302	T/A	cg05347473	chr6:146136440	FBXO30	-0.5	-4.85	-0.4	3.68e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs5769765	0.913	rs4824111	chr22:50284305	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.43	-6.37	-0.5	3.28e-9	Schizophrenia;
TGCT	cis	rs7975161	0.572	rs11111919	chr12:104569918	C/A	cg25273343	chr12:104657179	TXNRD1	-0.44	-5.61	-0.45	1.26e-7	Toenail selenium levels;
TGCT	cis	rs603424	0.597	rs574122	chr10:102089174	C/A	cg22671421	chr10:102507979	PAX2	0.59	4.71	0.39	6.63e-6	Phospholipid levels (plasma);Palmitic acid (16:0) levels;Palmitoleic acid (16:1n-7) levels;Mean platelet volume;Serum metabolite levels;Blood metabolite levels;Vaccenic acid (18:1n-7) levels;Metabolic traits;Coronary artery disease;Blood metabolite ratios;Glycerophospholipid levels;
TGCT	cis	rs2688608	0.620	rs7080350	chr10:75577843	A/G	cg15838173	chr10:75533400	FUT11	0.31	5.27	0.43	5.76e-7	Inflammatory bowel disease;
TGCT	cis	rs854765	0.583	rs11869536	chr17:17826528	T/A	cg09796270	chr17:17721594	SREBF1	0.24	4.7	0.39	6.83e-6	Total body bone mineral density;
TGCT	cis	rs28595532	0.920	rs115850161	chr4:119732447	T/C	cg14228332	chr4:119757509	SEC24D	1.32	6.38	0.5	3.2e-9	Cannabis dependence symptom count;
TGCT	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg12042659	chr19:58951599	ZNF132	0.52	4.67	0.39	7.67e-6	Uric acid clearance;
TGCT	trans	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.83	-8.69	-0.62	1.76e-14	Body mass index;
TGCT	cis	rs11971779	0.715	rs6943973	chr7:139029893	G/C	cg07862535	chr7:139043722	LUC7L2	0.56	4.46	0.37	1.82e-5	Diisocyanate-induced asthma;
TGCT	cis	rs453301	0.686	rs7814328	chr8:8876229	T/C	cg15556689	chr8:8085844	FLJ10661	-0.62	-5.13	-0.42	1.07e-6	Joint mobility (Beighton score);
TGCT	cis	rs11577318	0.579	rs35456934	chr1:26686864	G/A	cg15090202	chr1:26687087	NA	0.59	4.58	0.38	1.1e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	5.06	0.41	1.45e-6	Menopause (age at onset);
TGCT	cis	rs154659	0.887	rs154660	chr16:89667637	C/G	cg01710450	chr16:89662404	CPNE7	-0.39	-6.89	-0.53	2.44e-10	Tanning;
TGCT	trans	rs9329221	0.655	rs656319	chr8:9814411	A/G	cg15556689	chr8:8085844	FLJ10661	-0.75	-6.79	-0.52	4.05e-10	Neuroticism;
TGCT	cis	rs77972916	0.505	rs6736400	chr2:43500804	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.39	-5.7	-0.46	8.41e-8	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.05	0.41	1.54e-6	Prudent dietary pattern;
TGCT	cis	rs11776272	0.927	rs11135789	chr8:21878607	C/T	cg17168535	chr8:21777572	XPO7	-0.64	-5.9	-0.47	3.21e-8	Obesity-related traits;
TGCT	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.8	5.52	0.44	1.89e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs1865760	0.532	rs2006736	chr6:26086017	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.78	7.49	0.56	1.15e-11	Height;
TGCT	cis	rs17270561	0.779	rs1165200	chr6:25875212	C/T	cg17042849	chr6:26104293	HIST1H4C	0.65	4.66	0.39	7.87e-6	Iron status biomarkers;
TGCT	cis	rs9457247	0.935	rs2149093	chr6:167373045	T/C	cg25258033	chr6:167368657	RNASET2	-0.19	-4.58	-0.38	1.1e-5	Crohn's disease;
TGCT	cis	rs7264396	0.561	rs6058388	chr20:34571846	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.28	-4.94	-0.41	2.49e-6	Total cholesterol levels;
TGCT	cis	rs317689	0.718	rs160827	chr12:69770147	G/A	cg11871910	chr12:69753446	YEATS4	0.55	4.72	0.39	6.38e-6	Response to diuretic therapy;
TGCT	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg26338869	chr17:61819248	STRADA	-0.53	-4.87	-0.4	3.29e-6	Prudent dietary pattern;
TGCT	cis	rs7100689	0.577	rs2236569	chr10:82043576	G/A	cg01528321	chr10:82214614	TSPAN14	0.66	6.47	0.5	2.02e-9	Post bronchodilator FEV1;
TGCT	cis	rs7944584	0.511	rs10838731	chr11:47607135	C/T	cg20307385	chr11:47447363	PSMC3	0.88	8.62	0.61	2.57e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
TGCT	cis	rs10883723	0.962	rs1056738	chr10:104236481	G/A	cg05855489	chr10:104503620	C10orf26	-0.55	-4.68	-0.39	7.42e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg21963583	chr11:68658836	MRPL21	-0.37	-6.22	-0.49	7.08e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9814567	1.000	rs10935120	chr3:134233092	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.86	8.53	0.61	4.26e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs1568889	0.838	rs7125749	chr11:28154692	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.92	11.01	0.7	4.33e-20	Bipolar disorder;
TGCT	cis	rs7829975	0.567	rs6601273	chr8:8796519	T/G	cg06636001	chr8:8085503	FLJ10661	-0.7	-6.19	-0.49	8.23e-9	Mood instability;
TGCT	cis	rs12541335	0.639	rs4872468	chr8:22179844	G/C	cg09517075	chr8:22133004	PIWIL2	0.25	5.0	0.41	1.93e-6	Hypertriglyceridemia;
TGCT	cis	rs9915657	0.870	rs12941066	chr17:70141226	C/T	cg06234051	chr17:70120541	SOX9	-0.25	-4.92	-0.4	2.67e-6	Thyroid hormone levels;
TGCT	cis	rs6138458	1.000	rs2387362	chr20:24899906	C/T	cg26195577	chr20:24973756	C20orf3	-1.2	-12.04	-0.73	1.35e-22	Blood protein levels;
TGCT	cis	rs7953508	0.506	rs2200160	chr12:93963873	C/T	cg18151635	chr12:93972918	NA	-0.2	-4.65	-0.39	8.34e-6	Pubertal anthropometrics;
TGCT	cis	rs2012796	1.000	rs10450894	chr14:81825172	T/A	cg02996355	chr14:81879375	NA	0.47	4.61	0.38	9.68e-6	Night sleep phenotypes;
TGCT	cis	rs6088590	0.561	rs6059932	chr20:33175466	C/T	cg06115741	chr20:33292138	TP53INP2	0.51	4.47	0.37	1.76e-5	Coronary artery disease;
TGCT	cis	rs4478858	0.660	rs10798844	chr1:31819128	A/G	cg07478791	chr1:31886160	SERINC2	-0.5	-4.71	-0.39	6.56e-6	Alcohol dependence;
TGCT	cis	rs7246657	1.000	rs7247672	chr19:37743928	A/G	cg18154014	chr19:37997991	ZNF793	0.84	5.58	0.45	1.46e-7	Coronary artery calcification;
TGCT	cis	rs9303401	0.659	rs17222691	chr17:56771096	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.59	5.99	0.47	2.08e-8	Cognitive test performance;
TGCT	cis	rs1971762	0.563	rs4759285	chr12:54079513	G/T	cg16917193	chr12:54089295	NA	1.36	17.86	0.85	4.33e-36	Height;
TGCT	cis	rs7223966	1.000	rs9895920	chr17:61852719	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	4.89	0.4	3.12e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs3806843	0.966	rs11741994	chr5:140145949	G/A	cg19875535	chr5:140030758	IK	0.37	6.23	0.49	6.53e-9	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs55962025	0.883	rs82334	chr4:3225371	A/C	cg06533319	chr4:3265114	C4orf44	0.24	4.68	0.39	7.31e-6	Parental longevity (mother's age at death);
TGCT	cis	rs6540559	0.673	rs4556361	chr1:210019654	C/G	cg22029157	chr1:209979665	IRF6	-0.67	-4.95	-0.41	2.33e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg16049864	chr8:95962084	TP53INP1	-0.76	-11.14	-0.71	2.13e-20	Type 2 diabetes;
TGCT	cis	rs9303401	0.659	rs12600349	chr17:57054245	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	-0.6	-5.97	-0.47	2.36e-8	Cognitive test performance;
TGCT	cis	rs28735056	0.572	rs4799100	chr18:77640207	A/G	cg20368463	chr18:77673604	PQLC1	-0.46	-5.6	-0.45	1.31e-7	Schizophrenia;
TGCT	cis	rs2562456	0.837	rs11085462	chr19:21750251	C/G	cg25650185	chr19:21324782	ZNF431	-0.66	-5.86	-0.47	3.92e-8	Pain;
TGCT	cis	rs2486012	1.000	rs2906459	chr1:44335657	A/C	cg12908607	chr1:44402522	ARTN	-0.69	-5.57	-0.45	1.49e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9549367	0.713	rs1323315	chr13:113859658	T/C	cg00898013	chr13:113819073	PROZ	0.51	6.95	0.53	1.84e-10	Platelet distribution width;
TGCT	cis	rs7681440	0.874	rs1442151	chr4:90775491	T/A	cg20003494	chr4:90757398	SNCA	-0.56	-5.35	-0.43	4.11e-7	Dementia with Lewy bodies;
TGCT	cis	rs10858047	0.883	rs6537841	chr1:115200808	A/G	cg12756093	chr1:115239321	AMPD1	-0.47	-4.96	-0.41	2.27e-6	Autism;
TGCT	cis	rs936229	0.861	rs12441505	chr15:75107311	A/C	cg10253484	chr15:75165896	SCAMP2	-0.66	-5.34	-0.43	4.28e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
TGCT	cis	rs929596	0.785	rs17864701	chr2:234652717	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.33	-5.23	-0.42	7.05e-7	Total bilirubin levels in HIV-1 infection;
TGCT	cis	rs6909279	0.933	rs9478219	chr6:151882362	T/G	cg14416726	chr6:151773293	C6orf211;RMND1	0.53	4.64	0.38	8.58e-6	Bone mineral density;
TGCT	cis	rs2797160	1.000	rs1935773	chr6:125996475	A/G	cg05901451	chr6:126070800	HEY2	-0.73	-6.6	-0.51	1.09e-9	Endometrial cancer;
TGCT	cis	rs7091068	0.518	rs1572772	chr10:95432862	A/G	cg20715218	chr10:95462985	C10orf4	-0.5	-5.35	-0.43	4.12e-7	Urinary tract infection frequency;
TGCT	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg11644478	chr21:40555479	PSMG1	1.01	10.47	0.69	8.99e-19	Cognitive function;
TGCT	cis	rs350251	0.868	rs350278	chr16:12232402	T/C	cg01574788	chr16:12184133	SNX29	0.34	4.48	0.37	1.67e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs9325144	0.671	rs7485963	chr12:38768254	C/G	cg26384229	chr12:38710491	ALG10B	-0.62	-5.77	-0.46	5.9e-8	Morning vs. evening chronotype;
TGCT	cis	rs7772486	0.754	rs4895682	chr6:146062861	G/A	cg05347473	chr6:146136440	FBXO30	-0.53	-4.91	-0.4	2.81e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1878931	0.624	rs39728	chr16:3453076	A/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.69	5.77	0.46	6.01e-8	Body mass index (adult);
TGCT	cis	rs3760775	1.000	rs3760775	chr19:5841356	A/C	cg25387410	chr19:5844109	FUT3	0.38	5.79	0.46	5.51e-8	Vitamin B12 levels;Elevated serum carcinoembryonic antigen levels;Tumor biomarkers;
TGCT	cis	rs12681288	0.523	rs111782857	chr8:962486	T/C	cg04851639	chr8:1020857	NA	-0.3	-5.08	-0.41	1.36e-6	Schizophrenia;
TGCT	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg20607798	chr8:58055168	NA	0.49	4.56	0.38	1.23e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs68170813	0.559	rs11761181	chr7:106954879	T/C	cg02696742	chr7:106810147	HBP1	-0.69	-5.81	-0.46	4.85e-8	Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs9992639	chr4:98940400	G/T	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6921919	0.583	rs16894108	chr6:28401790	A/G	cg18815343	chr6:28367644	ZSCAN12	-0.55	-5.16	-0.42	9.34e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9611565	0.649	rs126092	chr22:42178441	A/G	cg06481639	chr22:41940642	POLR3H	0.56	4.64	0.38	8.66e-6	Vitiligo;
TGCT	cis	rs56309584	0.597	rs78296773	chr17:8167962	G/T	cg08322244	chr17:8066669	VAMP2	-0.56	-5.16	-0.42	9.58e-7	Initial pursuit acceleration;
TGCT	cis	rs2204008	0.623	rs1315348	chr12:38163044	G/A	cg26384229	chr12:38710491	ALG10B	-0.58	-5.08	-0.42	1.33e-6	Bladder cancer;
TGCT	cis	rs6141769	0.542	rs6058819	chr20:31303942	T/C	cg13636640	chr20:31349939	DNMT3B	-0.51	-4.48	-0.37	1.68e-5	Subjective well-being;
TGCT	cis	rs4631830	0.896	rs7088225	chr10:51522120	T/C	cg10326726	chr10:51549505	MSMB	0.23	4.67	0.39	7.81e-6	Prostate-specific antigen levels;
TGCT	cis	rs6988636	1.000	rs7002332	chr8:124185442	G/C	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs1395	0.778	rs11693660	chr2:27468856	T/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.7	9.35	0.64	4.81e-16	Blood metabolite levels;
TGCT	cis	rs2289583	0.544	rs6495132	chr15:75255322	C/T	cg10253484	chr15:75165896	SCAMP2	0.58	5.23	0.43	6.95e-7	Systemic lupus erythematosus;
TGCT	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg08736216	chr1:53307985	ZYG11A	-0.3	-5.99	-0.47	2.09e-8	Monocyte count;
TGCT	cis	rs35771425	0.642	rs11586974	chr1:211464115	A/G	cg25617285	chr1:211431773	RCOR3	0.47	5.39	0.44	3.44e-7	Educational attainment (years of education);
TGCT	cis	rs9911578	0.704	rs72628393	chr17:56585314	A/T	cg12560992	chr17:57184187	TRIM37	-0.76	-9.0	-0.63	3.28e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs59698941	0.527	rs7719428	chr5:132180919	C/G	cg21474247	chr5:131268130	NA	-0.31	-4.83	-0.4	3.86e-6	Apolipoprotein A-IV levels;
TGCT	cis	rs36051895	0.632	rs1571438	chr9:5140313	A/C	cg02405213	chr9:5042618	JAK2	-0.75	-10.5	-0.69	7.82e-19	Pediatric autoimmune diseases;
TGCT	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg17971929	chr21:40555470	PSMG1	-0.7	-6.6	-0.51	1.1e-9	Cognitive function;
TGCT	cis	rs4285028	0.747	rs7648340	chr3:121426188	G/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.92	-7.3	-0.55	3.03e-11	Multiple sclerosis;
TGCT	cis	rs7727544	0.606	rs72795121	chr5:131638324	T/A	cg14196790	chr5:131705035	SLC22A5	0.36	4.87	0.4	3.3e-6	Blood metabolite levels;
TGCT	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg07507251	chr3:52567010	NT5DC2	0.46	6.63	0.51	9.3e-10	Bipolar disorder;
TGCT	cis	rs61931739	0.500	rs6488209	chr12:34319309	A/G	cg06521331	chr12:34319734	NA	-0.35	-5.74	-0.46	6.71e-8	Morning vs. evening chronotype;
TGCT	cis	rs909002	0.800	rs7529064	chr1:32105192	C/A	cg11573219	chr1:32083031	HCRTR1	-0.43	-5.6	-0.45	1.33e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1552244	0.608	rs3732962	chr3:10048951	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.33	-4.95	-0.41	2.39e-6	Alzheimer's disease;
TGCT	cis	rs3849570	0.643	rs10779987	chr3:81970856	C/T	cg07356753	chr3:81810745	GBE1	-0.64	-5.62	-0.45	1.19e-7	Waist circumference;Body mass index;
TGCT	trans	rs1814175	0.817	rs10128730	chr11:50023369	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.26	-0.55	3.77e-11	Height;
TGCT	cis	rs644799	0.544	rs525087	chr11:95632266	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.49	4.98	0.41	2.08e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs6088580	0.634	rs6059867	chr20:33078103	C/T	cg06115741	chr20:33292138	TP53INP2	0.54	4.82	0.4	4.11e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg11764359	chr7:65958608	NA	-0.61	-5.51	-0.44	1.96e-7	Aortic root size;
TGCT	trans	rs7819412	0.645	rs10156356	chr8:11046209	T/C	cg15556689	chr8:8085844	FLJ10661	-0.76	-6.86	-0.52	2.97e-10	Triglycerides;
TGCT	cis	rs6880778	0.505	rs7730693	chr5:40373105	A/G	cg01087697	chr5:40835557	RPL37	0.53	4.83	0.4	3.95e-6	Inflammatory bowel disease;
TGCT	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg11644478	chr21:40555479	PSMG1	-0.61	-5.74	-0.46	6.75e-8	Cognitive function;
TGCT	cis	rs936229	0.654	rs762551	chr15:75041917	C/A	cg10253484	chr15:75165896	SCAMP2	-0.59	-5.0	-0.41	1.89e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
TGCT	cis	rs42648	0.869	rs3810890	chr7:89908833	G/T	cg25739043	chr7:89950458	NA	-0.73	-7.29	-0.55	3.15e-11	Homocysteine levels;
TGCT	cis	rs9549367	0.713	rs9549691	chr13:113861606	A/C	cg18105134	chr13:113819100	PROZ	-0.46	-8.1	-0.59	4.35e-13	Platelet distribution width;
TGCT	cis	rs6684514	0.885	rs12036837	chr1:156283895	A/C	cg16558208	chr1:156270281	VHLL	0.48	9.6	0.65	1.19e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs11874712	1.000	rs9783884	chr18:43651133	A/G	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	5.11	0.42	1.19e-6	Migraine - clinic-based;
TGCT	cis	rs2228479	0.867	rs62052168	chr16:89947203	G/A	cg06558623	chr16:89946397	TCF25	0.57	6.52	0.51	1.62e-9	Skin colour saturation;
TGCT	cis	rs6725041	0.766	rs13415721	chr2:213092242	C/T	cg20637307	chr2:213403960	ERBB4	-0.51	-4.49	-0.37	1.64e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs10114408	0.959	rs2185110	chr9:96648679	A/C	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg22963979	chr7:1858916	MAD1L1	0.44	7.04	0.53	1.17e-10	Bipolar disorder and schizophrenia;
TGCT	trans	rs2727020	0.514	rs4980444	chr11:49550764	T/A	cg15704280	chr7:45808275	SEPT13	-0.61	-6.78	-0.52	4.26e-10	Coronary artery disease;
TGCT	cis	rs2380220	0.606	rs4571572	chr6:96004823	T/C	cg04719120	chr6:96025338	MANEA	0.58	4.53	0.38	1.35e-5	Behavioural disinhibition (generation interaction);
TGCT	cis	rs7208859	0.623	rs12006	chr17:29110652	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg11764359	chr7:65958608	NA	0.54	5.02	0.41	1.73e-6	Aortic root size;
TGCT	cis	rs6582630	0.513	rs11181246	chr12:38302670	C/T	cg13010199	chr12:38710504	ALG10B	0.58	4.54	0.38	1.31e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs2242116	0.796	rs2290546	chr3:46965197	C/G	cg23352942	chr3:46931381	PTH1R	-0.32	-4.53	-0.38	1.36e-5	Birth weight;
TGCT	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg23302884	chr18:44338147	ST8SIA5	-0.4	-4.58	-0.38	1.11e-5	Personality dimensions;
TGCT	cis	rs8180040	0.966	rs922957	chr3:47422152	G/C	cg27129171	chr3:47204927	SETD2	-0.64	-7.39	-0.55	1.89e-11	Colorectal cancer;
TGCT	cis	rs6733011	0.500	rs885115	chr2:99446445	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-4.67	-0.39	7.65e-6	Bipolar disorder;
TGCT	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg14784868	chr12:69753453	YEATS4	0.9	10.6	0.69	4.47e-19	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs45430	1.000	rs364525	chr21:42745578	A/G	cg22778903	chr21:42741698	MX2	-0.3	-5.01	-0.41	1.84e-6	Melanoma;
TGCT	cis	rs7666738	0.830	rs7678567	chr4:99057346	A/G	cg17366294	chr4:99064904	C4orf37	0.73	7.45	0.56	1.4e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7666738	0.830	rs1534318	chr4:98965058	C/T	cg17366294	chr4:99064904	C4orf37	0.73	7.48	0.56	1.18e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg03303774	chr4:1407052	NA	-0.31	-4.86	-0.4	3.49e-6	Obesity-related traits;
TGCT	cis	rs6892003	0.951	rs1507805	chr5:174193309	C/T	cg06056415	chr5:174162510	NA	-0.41	-4.66	-0.39	7.99e-6	Clopidogrel active metabolite levels;
TGCT	cis	rs2799081	1	rs2799081	chr6:28270584	T/C	cg11262757	chr6:27280423	POM121L2	0.52	5.12	0.42	1.14e-6	Myopia;
TGCT	cis	rs1023500	0.596	rs5751204	chr22:42433801	C/T	cg05082376	chr22:42548792	NA	-0.22	-5.3	-0.43	5.09e-7	Schizophrenia;
TGCT	cis	rs6840360	0.571	rs11944139	chr4:152505291	T/C	cg17479576	chr4:152424074	FAM160A1	-0.72	-7.81	-0.57	2.09e-12	Intelligence (multi-trait analysis);
TGCT	trans	rs7824557	0.564	rs2736290	chr8:11234298	C/T	cg15556689	chr8:8085844	FLJ10661	-0.74	-6.68	-0.51	7.04e-10	Retinal vascular caliber;
TGCT	cis	rs9807989	0.839	rs1974675	chr2:102986375	G/A	cg09003973	chr2:102972529	NA	0.66	5.81	0.46	4.92e-8	Asthma;
TGCT	cis	rs1062177	1.000	rs2915877	chr5:151150601	C/G	cg00977110	chr5:151150581	G3BP1	0.4	4.57	0.38	1.16e-5	Preschool internalizing problems;
TGCT	cis	rs72781680	0.898	rs72788218	chr2:24090435	C/T	cg08917208	chr2:24149416	ATAD2B	0.73	4.51	0.38	1.48e-5	Lymphocyte counts;
TGCT	cis	rs10174077	0.874	rs11892439	chr2:152469858	T/A	cg19508488	chr2:152266495	RIF1	0.7	6.66	0.51	7.93e-10	Squamous cell lung carcinoma;
TGCT	cis	rs6964587	1.000	rs11772102	chr7:91558326	A/T	cg17063962	chr7:91808500	NA	-0.9	-9.67	-0.66	7.91e-17	Breast cancer;
TGCT	trans	rs10022799	0.725	rs7658246	chr4:168135377	A/T	cg08507725	chr4:8239220	SH3TC1	0.39	7.34	0.55	2.4e-11	Cognitive function;
TGCT	cis	rs9549367	0.789	rs2316442	chr13:113877487	C/T	cg18105134	chr13:113819100	PROZ	-0.33	-5.34	-0.43	4.25e-7	Platelet distribution width;
TGCT	trans	rs2760061	0.819	rs708111	chr1:228191365	G/A	cg16006296	chr10:38738647	LOC399744	-0.31	-7.24	-0.55	4.17e-11	Diastolic blood pressure;
TGCT	cis	rs2795502	0.872	rs2744062	chr10:43254789	T/A	cg20628663	chr10:43360327	NA	-0.43	-5.05	-0.41	1.51e-6	Blood protein levels;
TGCT	cis	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg07424592	chr7:64974309	NA	-1.32	-7.74	-0.57	3e-12	Diabetic kidney disease;
TGCT	cis	rs3784262	0.565	rs4646605	chr15:58287912	C/A	cg12031962	chr15:58353849	ALDH1A2	0.37	5.24	0.43	6.8e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs11098499	0.754	rs12509621	chr4:120249660	T/C	cg09307838	chr4:120376055	NA	0.61	5.91	0.47	3.14e-8	Corneal astigmatism;
TGCT	cis	rs7647973	0.626	rs35129566	chr3:49866584	T/G	cg03034192	chr3:50606346	HEMK1;C3orf18	-0.36	-4.83	-0.4	3.96e-6	Menarche (age at onset);
TGCT	cis	rs6450176	0.909	rs3776712	chr5:53304179	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.49	-4.6	-0.38	1.03e-5	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs7666738	0.546	rs34159897	chr4:98787367	T/C	cg18180107	chr4:99064573	C4orf37	0.52	4.58	0.38	1.13e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs68170813	0.559	rs6949961	chr7:106850755	G/T	cg02696742	chr7:106810147	HBP1	0.71	5.83	0.46	4.6e-8	Coronary artery disease;
TGCT	cis	rs17376456	0.877	rs34595581	chr5:93369422	G/A	cg21475434	chr5:93447410	FAM172A	0.59	4.66	0.39	8.09e-6	Diabetic retinopathy;
TGCT	cis	rs12580194	1.000	rs12580194	chr12:55696558	A/G	cg20672549	chr12:56432144	IKZF4	-0.27	-4.76	-0.39	5.35e-6	Cancer;
TGCT	cis	rs71597109	0.608	rs11931087	chr4:102727619	A/G	cg14855874	chr4:102712397	BANK1	0.41	4.7	0.39	6.66e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs1023500	0.573	rs2413666	chr22:42459622	C/T	cg15557168	chr22:42548783	NA	-0.22	-5.49	-0.44	2.17e-7	Schizophrenia;
TGCT	cis	rs7312933	0.533	rs17551006	chr12:42848738	G/C	cg19980929	chr12:42632907	YAF2	0.43	6.1	0.48	1.26e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs9814567	1.000	rs9814567	chr3:134218557	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.99	10.0	0.67	1.28e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg22920501	chr2:26401640	FAM59B	-0.73	-6.28	-0.49	5.18e-9	Gut microbiome composition (summer);
TGCT	cis	rs801193	0.569	rs881285	chr7:66119420	A/G	cg11764359	chr7:65958608	NA	-0.55	-4.87	-0.4	3.3e-6	Aortic root size;
TGCT	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	5.84	0.46	4.26e-8	Bipolar disorder;
TGCT	cis	rs1519814	0.581	rs1879150	chr8:121011233	A/T	cg22335954	chr8:121166405	COL14A1	-0.36	-4.52	-0.38	1.44e-5	Breast cancer;
TGCT	cis	rs7954584	0.710	rs10840641	chr12:122465831	G/T	cg21016266	chr12:122356598	WDR66	0.41	4.96	0.41	2.32e-6	Mean corpuscular volume;
TGCT	cis	rs7666738	0.791	rs7665273	chr4:98997413	C/A	cg18180107	chr4:99064573	C4orf37	0.53	4.84	0.4	3.72e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7662987	0.517	rs2602845	chr4:100023944	T/C	cg12011299	chr4:100065546	ADH4	0.4	4.82	0.4	4.07e-6	Smoking initiation;
TGCT	cis	rs225245	0.791	rs3890901	chr17:34011322	A/C	cg05299278	chr17:33885742	SLFN14	0.21	4.5	0.37	1.54e-5	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs9303401	1.000	rs6503882	chr17:56915761	T/C	cg12560992	chr17:57184187	TRIM37	0.54	5.68	0.45	9.06e-8	Cognitive test performance;
TGCT	cis	rs13323323	1.000	rs13323323	chr3:44333324	G/T	cg04389838	chr3:44770851	ZNF501	-0.42	-4.73	-0.39	5.94e-6	IgG glycosylation;
TGCT	cis	rs6988636	0.710	rs17315999	chr8:124153763	A/G	cg27053337	chr8:124217698	FAM83A	0.72	5.08	0.42	1.34e-6	Urinary uromodulin levels;
TGCT	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg13206674	chr6:150067644	NUP43	0.52	4.51	0.38	1.5e-5	Lung cancer;
TGCT	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg25767906	chr1:53392781	SCP2	-0.56	-6.55	-0.51	1.41e-9	Monocyte count;
TGCT	trans	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg27523141	chr10:43048294	ZNF37B	0.73	8.51	0.61	4.68e-14	Extrinsic epigenetic age acceleration;
TGCT	cis	rs10838634	1.000	rs73456126	chr11:46814785	A/G	cg18332754	chr11:46939436	LRP4	0.9	4.59	0.38	1.05e-5	Schizophrenia;
TGCT	cis	rs9486719	0.656	rs6924957	chr6:96853579	G/T	cg18709589	chr6:96969512	KIAA0776	0.64	4.52	0.38	1.41e-5	Migraine;Coronary artery disease;
TGCT	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg11890956	chr21:40555474	PSMG1	1.1	12.36	0.74	2.27e-23	Cognitive function;
TGCT	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg03806693	chr22:41940476	POLR3H	-1.14	-13.51	-0.77	4e-26	Vitiligo;
TGCT	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs8177253	0.665	rs12493887	chr3:133440737	T/C	cg08048268	chr3:133502702	NA	-0.54	-7.2	-0.54	5.06e-11	Iron status biomarkers;
TGCT	trans	rs12655019	0.920	rs74865790	chr5:56219698	T/C	cg25190722	chr1:3801660	DFFB	0.65	7.42	0.55	1.63e-11	Breast cancer (early onset);
TGCT	cis	rs7618915	1.000	rs3844291	chr3:52341215	A/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.15	0.48	9.57e-9	Bipolar disorder;
TGCT	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	8.99	0.63	3.48e-15	Platelet count;
TGCT	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg06238570	chr21:40685208	BRWD1	-0.6	-6.27	-0.49	5.47e-9	Menarche (age at onset);
TGCT	cis	rs2464469	0.654	rs2067062	chr15:58341954	T/G	cg12031962	chr15:58353849	ALDH1A2	-0.4	-5.88	-0.47	3.57e-8	Barrett's esophagus  or Esophageal adenocarcinoma;
TGCT	cis	rs5167	0.533	rs55778858	chr19:45485465	G/A	cg13119609	chr19:45449297	APOC2	0.23	4.65	0.39	8.26e-6	Blood protein levels;
TGCT	cis	rs6088580	0.634	rs6059890	chr20:33101653	G/C	cg06115741	chr20:33292138	TP53INP2	0.54	4.63	0.38	9.06e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg02503808	chr4:7069936	GRPEL1	1.0	9.66	0.66	8.38e-17	Monocyte percentage of white cells;
TGCT	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg21862992	chr11:68658383	NA	-0.43	-5.99	-0.47	2.15e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7824557	0.767	rs3808509	chr8:11163256	G/T	cg21775007	chr8:11205619	TDH	0.58	5.46	0.44	2.46e-7	Retinal vascular caliber;
TGCT	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg00149659	chr3:10157352	C3orf10	1.18	7.44	0.56	1.44e-11	Alzheimer's disease;
TGCT	cis	rs17152411	0.895	rs7079153	chr10:126587146	C/G	cg07906193	chr10:126599966	NA	0.41	5.05	0.41	1.52e-6	Height;
TGCT	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg22105103	chr4:187893119	NA	0.33	4.56	0.38	1.19e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg13206674	chr6:150067644	NUP43	0.52	4.46	0.37	1.78e-5	Lung cancer;
TGCT	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg01585852	chr22:24235823	MIF	-0.22	-4.82	-0.4	4.2e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9467711	0.790	rs13220495	chr6:26441640	C/T	cg16898833	chr6:26189333	HIST1H4D	1.37	6.2	0.49	7.83e-9	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9291683	0.530	rs10939620	chr4:9946132	C/T	cg00071950	chr4:10020882	SLC2A9	-0.64	-8.25	-0.6	2.01e-13	Bone mineral density;
TGCT	cis	rs9894429	0.646	rs7406522	chr17:79615396	G/T	cg21028142	chr17:79581711	NPLOC4	0.28	5.87	0.47	3.73e-8	Eye color traits;
TGCT	cis	rs3845702	0.733	rs12693217	chr2:180841914	T/G	cg01881094	chr2:180872142	CWC22	-1.03	-6.51	-0.5	1.72e-9	Schizophrenia;
TGCT	cis	rs9354352	0.967	rs9354351	chr6:66696271	G/A	cg07460842	chr6:66804631	NA	0.65	6.68	0.51	7.29e-10	Initial pursuit acceleration in psychotic disorders;
TGCT	cis	rs7193541	0.508	rs7188581	chr16:74672901	T/A	cg01733217	chr16:74700730	RFWD3	1.01	13.21	0.76	2.1e-25	Multiple myeloma;
TGCT	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg13206674	chr6:150067644	NUP43	0.53	4.65	0.39	8.3e-6	Lung cancer;
TGCT	cis	rs11190604	1.000	rs10883511	chr10:102299407	A/G	cg16342193	chr10:102329863	NA	-0.41	-5.12	-0.42	1.15e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs11098499	0.954	rs4577559	chr4:120404043	T/G	cg09307838	chr4:120376055	NA	0.69	6.64	0.51	8.97e-10	Corneal astigmatism;
TGCT	cis	rs7255045	0.788	rs4804737	chr19:12947938	C/T	cg23899408	chr19:12877188	HOOK2	0.54	4.47	0.37	1.75e-5	Mean corpuscular volume;
TGCT	cis	rs727505	0.954	rs1525613	chr7:124658636	A/G	cg23710748	chr7:124431027	NA	-0.26	-4.55	-0.38	1.27e-5	Lewy body disease;
TGCT	cis	rs4325129	0.651	rs4656837	chr1:159505297	C/T	cg07417683	chr1:159440267	NA	0.37	4.52	0.38	1.4e-5	Obesity-related traits;
TGCT	cis	rs7829975	0.560	rs56094035	chr8:8551622	G/A	cg17143192	chr8:8559678	CLDN23	-0.49	-4.94	-0.41	2.44e-6	Mood instability;
TGCT	cis	rs9902453	0.845	rs58606097	chr17:28020379	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	7.27	0.55	3.55e-11	Coffee consumption (cups per day);
TGCT	cis	rs9915657	0.743	rs9894720	chr17:70097607	C/T	cg06234051	chr17:70120541	SOX9	-0.23	-4.93	-0.4	2.63e-6	Thyroid hormone levels;
TGCT	cis	rs921968	0.643	rs4674319	chr2:219510320	C/T	cg02176678	chr2:219576539	TTLL4	0.37	5.29	0.43	5.24e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs1348850	0.519	rs13034781	chr2:178523550	C/A	cg22681709	chr2:178499509	PDE11A	-0.48	-6.08	-0.48	1.36e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs12479064	0.694	rs11896520	chr2:99995517	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.71	-5.81	-0.46	5.01e-8	Chronic sinus infection;
TGCT	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg22963979	chr7:1858916	MAD1L1	-0.44	-6.93	-0.53	2.01e-10	Bipolar disorder and schizophrenia;
TGCT	cis	rs10256972	0.514	rs2140578	chr7:1214003	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.64	-6.35	-0.5	3.64e-9	Longevity;Endometriosis;
TGCT	cis	rs4824093	0.610	rs2208023	chr22:50249983	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.12	-6.87	-0.52	2.83e-10	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs1670533	1.000	rs6839931	chr4:1053172	A/G	cg27284194	chr4:1044797	NA	0.67	5.77	0.46	5.9e-8	Recombination rate (females);
TGCT	cis	rs9611565	0.546	rs5758426	chr22:42098763	T/G	cg03806693	chr22:41940476	POLR3H	1.0	10.29	0.68	2.52e-18	Vitiligo;
TGCT	cis	rs3733585	0.648	rs35954357	chr4:9978758	G/C	cg11266682	chr4:10021025	SLC2A9	0.59	7.62	0.56	5.7e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7085104	0.552	rs11191414	chr10:104601565	A/T	cg04362960	chr10:104952993	NT5C2	0.56	4.92	0.4	2.68e-6	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs7959452	0.503	rs7300266	chr12:69654187	A/G	cg11871910	chr12:69753446	YEATS4	0.62	6.22	0.49	6.95e-9	Blood protein levels;
TGCT	cis	rs10514758	0.744	rs72947739	chr3:114909861	G/T	cg05943254	chr3:114009756	NA	-0.76	-4.53	-0.38	1.39e-5	Urate levels in obese individuals;
TGCT	cis	rs11792861	0.888	rs57314245	chr9:111813832	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.47	4.6	0.38	1.03e-5	Menarche (age at onset);
TGCT	cis	rs61884328	0.733	rs61897853	chr11:47217906	C/T	cg13308137	chr11:47528955	CUGBP1	0.38	4.48	0.37	1.65e-5	Total body bone mineral density (age over 60);
TGCT	cis	rs1670533	1.000	rs6812596	chr4:1069866	A/G	cg20887711	chr4:1340912	KIAA1530	0.69	5.5	0.44	2.03e-7	Recombination rate (females);
TGCT	cis	rs902774	0.554	rs4503623	chr12:53353759	T/C	cg25025879	chr12:53359317	NA	-0.44	-4.83	-0.4	3.97e-6	Prostate cancer;
TGCT	cis	rs797680	0.856	rs6685271	chr1:93634590	C/A	cg17826107	chr1:92977322	EVI5	-0.23	-5.0	-0.41	1.88e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs2645424	0.550	rs12338	chr8:11710888	G/C	cg18999641	chr8:11876646	NA	0.23	5.03	0.41	1.7e-6	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
TGCT	cis	rs7027203	0.576	rs11792101	chr9:96535470	C/T	cg14598338	chr9:96623480	NA	0.51	7.4	0.55	1.83e-11	DNA methylation (variation);
TGCT	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg24250549	chr1:154909240	PMVK	-0.6	-6.35	-0.5	3.68e-9	Prostate cancer;
TGCT	cis	rs7172809	0.643	rs75159723	chr15:77841841	A/G	cg22256960	chr15:77711686	NA	-0.48	-4.84	-0.4	3.84e-6	Glucose homeostasis traits;
TGCT	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg04944784	chr2:26401820	FAM59B	-0.8	-6.84	-0.52	3.27e-10	Gut microbiome composition (summer);
TGCT	cis	rs7584330	0.910	rs72620830	chr2:238396985	C/T	cg14458575	chr2:238380390	NA	0.5	7.15	0.54	6.63e-11	Prostate cancer;
TGCT	cis	rs28830936	0.510	rs11858843	chr15:42092915	C/A	cg17847044	chr15:42102381	MAPKBP1	-0.18	-5.14	-0.42	1.03e-6	Diastolic blood pressure;
TGCT	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg05665937	chr4:1216051	CTBP1	0.24	4.65	0.39	8.32e-6	Obesity-related traits;
TGCT	cis	rs11997175	0.574	rs4364597	chr8:33653729	G/C	ch.8.33884649F	chr8:33765107	NA	0.28	4.54	0.38	1.33e-5	Body mass index;
TGCT	cis	rs9921338	0.961	rs9936328	chr16:11438221	T/A	cg00044050	chr16:11439710	C16orf75	-0.91	-7.11	-0.54	8.19e-11	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg17264618	chr3:40429014	ENTPD3	0.32	4.57	0.38	1.18e-5	Renal cell carcinoma;
TGCT	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs4794202	0.534	rs9915028	chr17:45927491	G/T	cg02219949	chr17:45927392	SP6	0.38	4.55	0.38	1.24e-5	Alzheimer's disease (cognitive decline);
TGCT	cis	rs295140	1.000	rs295140	chr2:201160699	T/C	cg04283868	chr2:201171347	SPATS2L	-0.63	-6.28	-0.49	5.19e-9	QT interval;
TGCT	cis	rs7923452	0.938	rs34930615	chr10:30761051	G/A	cg18806716	chr10:30721971	MAP3K8	0.66	6.06	0.48	1.48e-8	Itch intensity from mosquito bite;
TGCT	cis	rs10504229	0.861	rs57314710	chr8:58196051	T/C	cg21724239	chr8:58056113	NA	0.38	4.76	0.39	5.41e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg06873352	chr17:61820015	STRADA	-0.55	-6.07	-0.48	1.43e-8	Prudent dietary pattern;
TGCT	cis	rs17122693	0.748	rs17122714	chr14:51104741	C/T	cg04730355	chr14:51134070	SAV1	1.34	12.06	0.73	1.24e-22	Cognitive performance;
TGCT	cis	rs245880	0.666	rs245894	chr7:29192686	G/C	cg17163760	chr7:29186267	CPVL	-0.41	-5.21	-0.42	7.51e-7	Warfarin maintenance dose;
TGCT	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg04546413	chr19:29218101	NA	0.73	6.49	0.5	1.87e-9	Methadone dose in opioid dependence;
TGCT	cis	rs8180040	0.966	rs11707895	chr3:47574937	G/A	cg27129171	chr3:47204927	SETD2	-0.64	-7.34	-0.55	2.41e-11	Colorectal cancer;
TGCT	cis	rs262150	0.625	rs117651953	chr7:158780563	G/A	cg01219135	chr7:158766336	NA	-0.46	-4.72	-0.39	6.19e-6	Facial morphology (factor 20);
TGCT	cis	rs3733585	0.664	rs17185870	chr4:9958214	C/A	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.7	-0.57	3.71e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs2204008	0.754	rs11181244	chr12:38302454	T/C	cg26384229	chr12:38710491	ALG10B	0.82	7.14	0.54	6.78e-11	Bladder cancer;
TGCT	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg06618935	chr21:46677482	NA	-0.37	-5.56	-0.45	1.58e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs28595532	0.920	rs114462478	chr4:119752656	T/C	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs8072100	0.754	rs8081717	chr17:45653921	T/A	cg08085267	chr17:45401833	C17orf57	0.47	5.13	0.42	1.07e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg22618164	chr12:122356400	WDR66	0.69	6.52	0.51	1.6e-9	Mean corpuscular volume;
TGCT	cis	rs3784262	0.669	rs34226780	chr15:58280168	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.41	-5.95	-0.47	2.53e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs9399137	0.507	rs11759062	chr6:135381248	A/C	cg24558204	chr6:135376177	HBS1L	0.47	4.73	0.39	5.98e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
TGCT	cis	rs832540	0.898	rs331497	chr5:56251660	G/T	cg12311346	chr5:56204834	C5orf35	0.44	4.87	0.4	3.38e-6	Coronary artery disease;
TGCT	cis	rs477895	0.568	rs12418035	chr11:63871558	G/A	cg23719950	chr11:63933701	MACROD1	-0.61	-5.24	-0.43	6.61e-7	Mean platelet volume;
TGCT	cis	rs7772486	0.686	rs1292337	chr6:145967807	A/G	cg13319975	chr6:146136371	FBXO30	0.5	4.6	0.38	1.01e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2739330	0.576	rs2858912	chr22:24297197	A/G	cg11905131	chr22:24372483	LOC391322	-0.98	-12.41	-0.74	1.79e-23	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9914988	0.565	rs34039488	chr17:27320232	G/A	cg17523868	chr17:27313033	SEZ6	-0.56	-4.77	-0.39	5.17e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs11190604	0.943	rs3750631	chr10:102279294	A/G	cg16342193	chr10:102329863	NA	-0.42	-5.37	-0.43	3.74e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg22166914	chr1:53195759	ZYG11B	-0.32	-5.22	-0.42	7.31e-7	Monocyte count;
TGCT	cis	rs826838	0.935	rs11169547	chr12:39185625	C/A	cg26384229	chr12:38710491	ALG10B	0.98	8.78	0.62	1.07e-14	Heart rate;
TGCT	cis	rs1801251	1.000	rs12987513	chr2:233622066	A/G	cg25237894	chr2:233734115	C2orf82	0.31	5.62	0.45	1.21e-7	Coronary artery disease;
TGCT	cis	rs7772486	0.790	rs2253654	chr6:146199445	T/C	cg13319975	chr6:146136371	FBXO30	-0.54	-4.81	-0.4	4.35e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs5760092	0.842	rs5751763	chr22:24247793	T/C	cg12419862	chr22:24373484	LOC391322	-0.8	-6.62	-0.51	9.91e-10	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs9303542	0.559	rs12947405	chr17:46614755	C/T	cg25032089	chr17:46643351	HOXB3	0.58	5.47	0.44	2.38e-7	Ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs2629540	0.855	rs12776722	chr10:126469833	G/A	cg08799069	chr10:126477246	METTL10	0.31	4.59	0.38	1.06e-5	Cocaine dependence;
TGCT	cis	rs7937612	1.000	rs7117321	chr11:120239051	T/C	cg24566217	chr11:120254723	ARHGEF12	-0.29	-4.7	-0.39	6.76e-6	Intraocular pressure;
TGCT	cis	rs7552404	0.727	rs7547508	chr1:76327958	A/G	cg22875332	chr1:76189707	ACADM	-0.57	-6.14	-0.48	1.05e-8	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7843479	0.544	rs7839925	chr8:21792983	G/C	cg17168535	chr8:21777572	XPO7	0.91	9.55	0.65	1.53e-16	Mean corpuscular volume;
TGCT	cis	rs35160687	0.798	rs6547674	chr2:86552919	G/T	cg03171300	chr2:86307199	POLR1A	-0.27	-4.59	-0.38	1.07e-5	Night sleep phenotypes;
TGCT	cis	rs7829975	0.667	rs1877119	chr8:8707197	C/G	cg15556689	chr8:8085844	FLJ10661	0.69	6.21	0.49	7.27e-9	Mood instability;
TGCT	cis	rs74544699	1.000	rs11574450	chr4:74847111	A/C	cg15398841	chr4:74847761	PF4	0.88	4.87	0.4	3.3e-6	Growth-regulated protein alpha levels;
TGCT	cis	rs79349575	0.783	rs62075852	chr17:47017176	T/C	cg07967210	chr17:47022446	SNF8	0.44	6.13	0.48	1.1e-8	Type 2 diabetes;
TGCT	cis	rs72634258	0.554	rs17374781	chr1:7919363	A/G	cg26816564	chr1:7831052	VAMP3	-0.64	-5.2	-0.42	7.82e-7	Inflammatory bowel disease;
TGCT	cis	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg08564027	chr20:61660810	NA	0.37	6.85	0.52	3.1e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9372498	0.505	rs9481811	chr6:118801174	T/C	cg21191810	chr6:118973309	C6orf204	-0.36	-4.74	-0.39	5.8e-6	Diastolic blood pressure;
TGCT	cis	rs2797160	0.651	rs9491503	chr6:126031682	G/A	cg05901451	chr6:126070800	HEY2	0.75	6.67	0.51	7.42e-10	Endometrial cancer;
TGCT	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg13683864	chr3:40499215	RPL14	-1.18	-13.68	-0.78	1.54e-26	Renal cell carcinoma;
TGCT	cis	rs17270561	0.723	rs12213243	chr6:25890108	C/T	cg16482183	chr6:26056742	HIST1H1C	0.9	6.76	0.52	4.9e-10	Iron status biomarkers;
TGCT	cis	rs8056742	1.000	rs16975170	chr16:85092575	C/T	cg00229868	chr16:85520891	NA	0.28	4.67	0.39	7.57e-6	Amyotrophic lateral sclerosis;
TGCT	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg24531977	chr5:56204891	C5orf35	-0.76	-7.34	-0.55	2.45e-11	Initial pursuit acceleration;
TGCT	cis	rs7586879	0.639	rs4077678	chr2:25122840	C/G	cg01884057	chr2:25150051	NA	0.35	6.9	0.53	2.39e-10	Body mass index;
TGCT	trans	rs7819412	0.537	rs2127127	chr8:11434792	C/G	cg15556689	chr8:8085844	FLJ10661	-0.75	-7.08	-0.54	9.37e-11	Triglycerides;
TGCT	cis	rs986417	1.000	rs1955699	chr14:61045989	A/G	cg27398547	chr14:60952738	C14orf39	1.49	8.69	0.62	1.81e-14	Gut microbiota (bacterial taxa);
TGCT	cis	rs259282	0.560	rs4805786	chr19:33120265	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.59	5.48	0.44	2.25e-7	Schizophrenia;
TGCT	cis	rs9325144	0.723	rs3887436	chr12:39189526	A/C	cg26384229	chr12:38710491	ALG10B	-0.61	-5.67	-0.45	9.5e-8	Morning vs. evening chronotype;
TGCT	cis	rs9549367	0.789	rs2287253	chr13:113891075	G/A	cg00898013	chr13:113819073	PROZ	0.43	5.21	0.42	7.53e-7	Platelet distribution width;
TGCT	cis	rs67073037	0.955	rs4666141	chr2:29164022	G/T	cg09522027	chr2:28974177	PPP1CB	0.57	4.49	0.37	1.59e-5	Breast cancer;Breast cancer (estrogen-receptor negative);
TGCT	cis	rs394563	0.589	rs1900300	chr6:149641627	T/C	cg11245181	chr6:149772854	ZC3H12D	0.27	4.44	0.37	1.94e-5	Dupuytren's disease;
TGCT	cis	rs6570726	0.935	rs367643	chr6:145859602	A/C	cg05347473	chr6:146136440	FBXO30	0.49	4.54	0.38	1.29e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6700896	0.500	rs11208687	chr1:66076358	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.59	4.56	0.38	1.22e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg03709012	chr19:19516395	GATAD2A	0.74	6.09	0.48	1.28e-8	Tonsillectomy;
TGCT	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs28595532	0.920	rs115500312	chr4:119752551	G/A	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs6545883	0.868	rs7574631	chr2:61825142	T/G	cg15711740	chr2:61764176	XPO1	-0.59	-5.64	-0.45	1.08e-7	Tuberculosis;
TGCT	cis	rs7617773	0.817	rs79310258	chr3:48259667	C/G	cg11946769	chr3:48343235	NME6	0.76	6.67	0.51	7.6e-10	Coronary artery disease;
TGCT	cis	rs896854	0.684	rs10098778	chr8:95992020	C/T	cg16049864	chr8:95962084	TP53INP1	-0.69	-9.84	-0.66	3.17e-17	Type 2 diabetes;
TGCT	cis	rs9486715	0.867	rs4131519	chr6:96964939	G/A	cg18709589	chr6:96969512	KIAA0776	0.79	7.53	0.56	8.99e-12	Headache;
TGCT	cis	rs2282802	0.635	rs269767	chr5:139536922	A/G	cg01081189	chr5:139537190	NA	0.3	5.62	0.45	1.2e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs362272	0.545	rs3135146	chr4:3307638	C/G	cg18352616	chr4:3374830	RGS12	-0.25	-5.03	-0.41	1.71e-6	Serum sulfate level;
TGCT	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	4.88	0.4	3.21e-6	Menopause (age at onset);
TGCT	cis	rs644799	0.710	rs12272061	chr11:95524067	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	8.5	0.61	5.03e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs17030434	0.834	rs1456399	chr4:154735242	C/T	cg14289246	chr4:154710475	SFRP2	-0.92	-7.65	-0.57	4.85e-12	Electrocardiographic conduction measures;
TGCT	cis	rs7552404	0.961	rs1061337	chr1:76227022	A/G	cg10523679	chr1:76189770	ACADM	0.91	9.53	0.65	1.77e-16	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7666738	0.800	rs7683737	chr4:99070880	A/T	cg17366294	chr4:99064904	C4orf37	0.73	7.45	0.56	1.4e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2637266	0.846	rs752006	chr10:78393136	G/T	cg18941641	chr10:78392320	NA	0.43	5.58	0.45	1.46e-7	Pulmonary function;
TGCT	cis	rs453301	0.658	rs13271797	chr8:8885954	G/A	cg00184457	chr8:8946301	NA	-0.27	-4.85	-0.4	3.69e-6	Joint mobility (Beighton score);
TGCT	cis	rs2933343	1.000	rs1680790	chr3:128625853	G/T	cg11901034	chr3:128598214	ACAD9	-0.63	-5.13	-0.42	1.08e-6	IgG glycosylation;
TGCT	cis	rs7208859	0.623	rs1054397	chr17:29110196	T/C	cg13385521	chr17:29058706	SUZ12P	0.79	4.74	0.39	5.7e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg06636001	chr8:8085503	FLJ10661	0.85	8.73	0.62	1.47e-14	Neuroticism;
TGCT	cis	rs10832963	0.847	rs4237722	chr11:18639363	T/C	cg20219074	chr11:18656078	SPTY2D1	0.95	9.01	0.63	3.04e-15	Breast cancer;
TGCT	cis	rs1218582	0.772	rs2061690	chr1:154919080	C/T	cg16680214	chr1:154839983	KCNN3	-0.37	-7.82	-0.57	2e-12	Prostate cancer;
TGCT	cis	rs7611238	0.583	rs9288744	chr3:195058837	C/T	cg27323046	chr3:195102265	ACAP2	-0.32	-4.5	-0.37	1.55e-5	Body mass index;
TGCT	cis	rs892961	0.932	rs6501954	chr17:75414398	G/C	cg05865280	chr17:75406074	SEPT9	0.28	6.71	0.52	6.16e-10	Airflow obstruction;
TGCT	cis	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg09021430	chr5:549028	NA	-0.37	-5.16	-0.42	9.7e-7	Lung disease severity in cystic fibrosis;
TGCT	cis	rs12142240	0.667	rs41293287	chr1:46808852	C/T	cg14993813	chr1:46806288	NSUN4	-0.58	-4.81	-0.4	4.34e-6	Menopause (age at onset);
TGCT	trans	rs877282	1.000	rs12219807	chr10:772870	A/C	cg22713356	chr15:30763199	NA	1.16	10.02	0.67	1.16e-17	Uric acid levels;
TGCT	cis	rs10779751	1.000	rs2300094	chr1:11266044	C/T	cg08854313	chr1:11322531	MTOR	0.92	10.28	0.68	2.6e-18	Body mass index;
TGCT	cis	rs11190604	1.000	rs2489048	chr10:102348497	G/T	cg16342193	chr10:102329863	NA	-0.43	-5.43	-0.44	2.79e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7945705	1.000	rs11603841	chr11:8834680	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.41	4.46	0.37	1.85e-5	Hemoglobin concentration;
TGCT	cis	rs763014	0.865	rs710924	chr16:633353	T/C	cg09263875	chr16:632152	PIGQ	0.3	6.35	0.5	3.63e-9	Height;
TGCT	cis	rs344364	0.518	rs1657129	chr16:1945826	G/A	cg26617929	chr16:1858877	NA	-0.27	-4.9	-0.4	2.99e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg22963979	chr7:1858916	MAD1L1	-0.39	-5.94	-0.47	2.68e-8	Bipolar disorder and schizophrenia;
TGCT	cis	rs1018836	0.632	rs1028255	chr8:91485578	A/T	cg16814680	chr8:91681699	NA	-0.79	-8.2	-0.59	2.57e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs854765	0.583	rs8070128	chr17:17804725	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.75	-8.0	-0.58	7.59e-13	Total body bone mineral density;
TGCT	cis	rs939658	0.805	rs11638004	chr15:79425765	A/C	cg17916960	chr15:79447300	NA	-0.49	-7.59	-0.56	6.76e-12	Refractive error;
TGCT	cis	rs9902453	0.765	rs2617883	chr17:28120488	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.84	-8.19	-0.59	2.73e-13	Coffee consumption (cups per day);
TGCT	cis	rs7666738	0.830	rs13147195	chr4:98893334	G/T	cg17366294	chr4:99064904	C4orf37	0.68	6.87	0.53	2.72e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7584330	0.868	rs7571898	chr2:238383028	T/C	cg14458575	chr2:238380390	NA	0.5	7.89	0.58	1.35e-12	Prostate cancer;
TGCT	cis	rs28595532	0.920	rs114792862	chr4:119759938	G/A	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs2594989	0.779	rs2437686	chr3:11588989	C/T	cg00170343	chr3:11313890	ATG7	0.65	4.93	0.4	2.61e-6	Circulating chemerin levels;
TGCT	cis	rs1018836	0.884	rs9643307	chr8:91625257	A/C	cg16814680	chr8:91681699	NA	-0.85	-9.22	-0.64	9.9e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1670533	0.932	rs4690214	chr4:1054636	T/C	cg20887711	chr4:1340912	KIAA1530	0.71	5.7	0.46	8.33e-8	Recombination rate (females);
TGCT	cis	rs911555	0.755	rs35233301	chr14:103885291	A/G	cg23461800	chr14:103021989	NA	-0.34	-4.58	-0.38	1.1e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs2730245	1.000	rs2730245	chr7:158724789	G/C	cg11984989	chr7:158649758	WDR60	-0.95	-8.47	-0.61	5.89e-14	Height;
TGCT	cis	rs9309473	0.606	rs1589576	chr2:73738804	A/G	cg07208825	chr2:73871855	ALMS1P	0.24	4.46	0.37	1.83e-5	Metabolite levels;
TGCT	cis	rs2832077	0.527	rs2142375	chr21:30223742	G/A	cg24692254	chr21:30365293	RNF160	-0.59	-5.05	-0.41	1.53e-6	Cognitive test performance;
TGCT	cis	rs12257961	0.521	rs10796281	chr10:15375605	T/G	cg10616319	chr10:15468812	NA	-0.25	-4.56	-0.38	1.2e-5	Selective IgA deficiency;
TGCT	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg06896619	chr17:61851486	DDX42;CCDC47	-0.51	-4.96	-0.41	2.24e-6	Prudent dietary pattern;
TGCT	cis	rs910316	1.000	rs9805979	chr14:75566209	G/A	cg23033748	chr14:75592666	NEK9	0.28	4.68	0.39	7.29e-6	Height;
TGCT	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.74	-0.39	5.77e-6	Prudent dietary pattern;
TGCT	cis	rs11585357	0.895	rs4625336	chr1:17630964	G/T	cg08277548	chr1:17600880	PADI3	-0.95	-9.47	-0.65	2.45e-16	Hair shape;
TGCT	trans	rs12339966	0.615	rs62529420	chr9:11336775	C/T	cg03488587	chr11:64876988	C11orf2	0.32	7.0	0.53	1.42e-10	Systolic blood pressure;
TGCT	cis	rs3796352	1.000	rs34979715	chr3:53048960	G/A	cg07884673	chr3:53033167	SFMBT1	0.64	6.39	0.5	3.03e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs35306767	0.903	rs12778891	chr10:950130	T/A	cg20503657	chr10:835505	NA	0.75	10.4	0.68	1.37e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs2072499	0.966	rs6427304	chr1:156156789	A/G	cg25208724	chr1:156163844	SLC25A44	1.11	15.72	0.82	2.62e-31	Testicular germ cell tumor;
TGCT	cis	rs9325144	0.723	rs11169535	chr12:39183494	C/T	cg10518543	chr12:38710700	ALG10B	-0.5	-4.65	-0.39	8.28e-6	Morning vs. evening chronotype;
TGCT	cis	rs1008375	0.966	rs2315645	chr4:17579678	G/C	cg18681998	chr4:17616180	MED28	0.94	9.56	0.65	1.44e-16	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6912958	0.559	rs6921504	chr6:88058972	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.68	6.88	0.53	2.68e-10	Monocyte percentage of white cells;
TGCT	cis	rs6540559	0.673	rs17015183	chr1:209948711	A/C	cg21951975	chr1:209979733	IRF6	0.69	5.38	0.43	3.58e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs6450176	1.000	rs3776703	chr5:53305259	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.49	-4.6	-0.38	1.03e-5	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs6733011	0.560	rs7579189	chr2:99464718	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.48	-4.78	-0.39	4.78e-6	Bipolar disorder;
TGCT	cis	rs13008689	0.905	rs6752907	chr2:8522010	A/C	cg21129864	chr2:9369739	ASAP2	-0.18	-4.46	-0.37	1.8e-5	Longevity;
TGCT	cis	rs12908161	0.959	rs17534709	chr15:85314397	G/C	cg12863693	chr15:85201151	NMB	0.44	5.2	0.42	7.87e-7	Schizophrenia;
TGCT	cis	rs62244186	0.711	rs6778410	chr3:44743993	C/T	cg10263370	chr3:44754102	ZNF502	-0.43	-5.29	-0.43	5.33e-7	Depressive symptoms;
TGCT	cis	rs4409675	0.576	rs6564	chr1:28212975	A/G	cg23691781	chr1:28212827	C1orf38	-0.25	-5.23	-0.43	6.9e-7	Corneal astigmatism;
TGCT	cis	rs12701220	0.894	rs12701406	chr7:1050283	G/A	cg27454412	chr7:1067447	C7orf50	-0.48	-4.44	-0.37	1.98e-5	Bronchopulmonary dysplasia;
TGCT	cis	rs7647973	1.000	rs9842132	chr3:49427933	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.59	-4.72	-0.39	6.19e-6	Menarche (age at onset);
TGCT	trans	rs6069325	0.529	rs11905021	chr20:54139226	T/C	cg26869512	chr4:8389770	ACOX3	0.47	6.92	0.53	2.12e-10	Motion sickness;
TGCT	cis	rs1372520	0.748	rs990085	chr4:90754771	A/G	cg20003494	chr4:90757398	SNCA	-0.63	-5.09	-0.42	1.3e-6	Neuroticism;
TGCT	trans	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg25482853	chr8:67687455	SGK3	1.19	10.96	0.7	5.68e-20	Lung disease severity in cystic fibrosis;
TGCT	cis	rs1887596	0.705	rs9553874	chr13:27189883	C/T	cg01312412	chr13:27282625	NA	0.31	5.52	0.44	1.9e-7	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs3087591	0.960	rs1801052	chr17:29508775	C/T	cg24425628	chr17:29625626	OMG;NF1	0.47	7.22	0.54	4.59e-11	Hip circumference;
TGCT	cis	rs13256369	1.000	rs12547721	chr8:8570671	C/T	cg18904891	chr8:8559673	CLDN23	0.59	5.52	0.44	1.93e-7	Obesity-related traits;
TGCT	cis	rs2816958	0.803	rs2737679	chr1:200088240	T/A	cg07971716	chr1:199773294	NA	0.46	4.52	0.38	1.45e-5	Ulcerative colitis;Inflammatory bowel disease;
TGCT	cis	rs7666738	0.830	rs28878289	chr4:98855181	C/T	cg17366294	chr4:99064904	C4orf37	0.7	7.27	0.55	3.62e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12477438	0.501	rs11685756	chr2:99766215	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	16.87	0.83	6.81e-34	Chronic sinus infection;
TGCT	cis	rs2851682	0.706	rs2727271	chr11:61603358	A/T	cg19610905	chr11:61596333	FADS2	-0.94	-5.04	-0.41	1.62e-6	Gestational age at birth (child effect);Trans fatty acid levels;
TGCT	cis	rs6500602	0.701	rs1362626	chr16:4549226	C/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.27	4.97	0.41	2.14e-6	Schizophrenia;
TGCT	cis	rs7666738	0.716	rs114187620	chr4:98819534	T/A	cg17366294	chr4:99064904	C4orf37	0.7	7.45	0.56	1.42e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1878931	0.615	rs4786412	chr16:3440390	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.98	12.26	0.74	3.95e-23	Body mass index (adult);
TGCT	cis	rs4478858	0.684	rs3753374	chr1:31740668	C/T	cg00250761	chr1:31883323	NA	-0.25	-4.48	-0.37	1.64e-5	Alcohol dependence;
TGCT	cis	rs6570726	0.791	rs383841	chr6:145888329	G/T	cg13319975	chr6:146136371	FBXO30	0.51	4.6	0.38	1.01e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs13064411	0.696	rs7619913	chr3:113017503	A/G	cg18753928	chr3:113234510	CCDC52	-0.71	-5.09	-0.42	1.29e-6	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg04317338	chr11:64019027	PLCB3	0.51	4.55	0.38	1.27e-5	Platelet count;
TGCT	trans	rs2760061	0.819	rs708112	chr1:228192452	G/A	cg16006296	chr10:38738647	LOC399744	-0.31	-7.24	-0.55	4.17e-11	Diastolic blood pressure;
TGCT	cis	rs2177596	0.525	rs2229814	chr2:227954599	G/A	cg11843606	chr2:227700838	RHBDD1	-0.55	-5.07	-0.41	1.44e-6	Body mass index;
TGCT	cis	rs17376456	0.825	rs10054903	chr5:93281491	C/A	cg25358565	chr5:93447407	FAM172A	1.02	8.11	0.59	4.23e-13	Diabetic retinopathy;
TGCT	cis	rs2439831	1.000	rs2245054	chr15:43751909	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.81	5.66	0.45	9.81e-8	Lung cancer in ever smokers;
TGCT	trans	rs2018683	1.000	rs160837	chr7:29012732	C/G	cg19402173	chr7:128379420	CALU	-0.73	-6.94	-0.53	1.92e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
TGCT	cis	rs7772486	0.754	rs702304	chr6:145990797	A/G	cg13319975	chr6:146136371	FBXO30	0.56	5.03	0.41	1.7e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg08280861	chr8:58055591	NA	0.39	4.76	0.39	5.35e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs3733585	0.673	rs4455410	chr4:9953297	C/T	cg00071950	chr4:10020882	SLC2A9	0.53	6.33	0.49	4.11e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg08509172	chr19:19383838	TM6SF2	-0.34	-4.48	-0.37	1.71e-5	Tonsillectomy;
TGCT	cis	rs10870270	0.500	rs9419217	chr10:133758379	A/G	cg03810717	chr10:132909213	TCERG1L	0.32	4.48	0.37	1.67e-5	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
TGCT	cis	rs2997457	1.000	rs2997457	chr1:26343112	A/G	cg16724196	chr1:26126450	SEPN1	-0.57	-4.59	-0.38	1.09e-5	Facial morphology (factor 16);
TGCT	cis	rs7192750	0.586	rs8050488	chr16:71911470	C/T	cg06353428	chr16:71660113	MARVELD3	0.83	6.97	0.53	1.65e-10	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs17173637	0.614	rs116435075	chr7:150505395	G/A	cg06746365	chr7:151468796	PRKAG2	0.28	4.44	0.37	1.93e-5	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs7666738	0.830	rs28785514	chr4:98959135	G/A	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6430585	0.583	rs79176913	chr2:136638113	C/A	cg07169764	chr2:136633963	MCM6	1.23	11.98	0.73	1.9e-22	Corneal structure;
TGCT	cis	rs1887596	0.624	rs9553857	chr13:27136589	C/A	cg01312412	chr13:27282625	NA	0.27	4.8	0.4	4.4e-6	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs6545883	0.929	rs6545873	chr2:61733012	T/C	cg15711740	chr2:61764176	XPO1	-0.55	-5.01	-0.41	1.85e-6	Tuberculosis;
TGCT	cis	rs796364	0.539	rs6738494	chr2:200697058	A/C	cg17644776	chr2:200775616	C2orf69	0.35	4.91	0.4	2.75e-6	Schizophrenia;
TGCT	cis	rs7524258	0.868	rs2157499	chr1:7271472	C/T	cg04342483	chr1:7259290	CAMTA1	-0.31	-4.44	-0.37	2e-5	Tourette's syndrome or obsessive-compulsive disorder;
TGCT	cis	rs8050907	0.744	rs8058798	chr16:4531659	C/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.53	4.57	0.38	1.15e-5	Obesity-related traits;
TGCT	cis	rs950027	0.620	rs1617984	chr15:45622662	A/G	cg26924012	chr15:45694286	SPATA5L1	0.83	9.38	0.64	4.05e-16	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs377070	0.934	rs309414	chr4:123620912	A/C	cg10495464	chr4:123653540	BBS12;LOC729338	0.54	5.23	0.43	6.92e-7	Mosquito bite size;
TGCT	cis	rs7666738	0.830	rs2865981	chr4:99031493	G/A	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1443512	0.812	rs1975472	chr12:54337083	A/G	cg17708016	chr12:54321992	NA	0.56	4.53	0.38	1.35e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
TGCT	cis	rs7513165	0.867	rs7524621	chr1:204160938	A/G	cg12731349	chr1:204159619	KISS1	-0.53	-6.15	-0.48	9.97e-9	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
TGCT	cis	rs6087990	0.731	rs2424897	chr20:31338098	A/T	cg13636640	chr20:31349939	DNMT3B	1.03	14.85	0.8	2.67e-29	Ulcerative colitis;
TGCT	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg08645402	chr16:4508243	NA	0.21	5.06	0.41	1.47e-6	Schizophrenia;
TGCT	cis	rs9467711	0.591	rs9467621	chr6:25851338	G/A	cg16898833	chr6:26189333	HIST1H4D	1.16	5.51	0.44	2.03e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12541335	0.536	rs4266653	chr8:22169087	A/G	cg02463440	chr8:22132932	PIWIL2	0.25	5.04	0.41	1.63e-6	Hypertriglyceridemia;
TGCT	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg24549020	chr5:56110836	MAP3K1	0.7	5.97	0.47	2.34e-8	Initial pursuit acceleration;
TGCT	cis	rs854765	0.663	rs3744115	chr17:17749822	G/A	cg04398451	chr17:18023971	MYO15A	0.3	4.58	0.38	1.1e-5	Total body bone mineral density;
TGCT	cis	rs9399137	0.561	rs11753985	chr6:135280438	C/T	cg24558204	chr6:135376177	HBS1L	0.47	4.78	0.39	4.95e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
TGCT	cis	rs6722750	0.846	rs13394665	chr2:64391431	A/C	cg22352474	chr2:64371530	PELI1	-0.65	-6.2	-0.49	7.78e-9	Neuroticism;
TGCT	cis	rs904251	0.861	rs1757183	chr6:37484790	C/T	cg01843034	chr6:37503916	NA	0.47	5.94	0.47	2.74e-8	Cognitive performance;
TGCT	cis	rs2760061	0.598	rs673726	chr1:228120173	T/C	cg02753203	chr1:228287806	NA	-0.34	-6.63	-0.51	9.15e-10	Diastolic blood pressure;
TGCT	cis	rs7917772	0.503	rs7078435	chr10:104304766	T/C	cg05855489	chr10:104503620	C10orf26	-0.59	-5.18	-0.42	8.7e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg06112835	chr11:68658793	MRPL21	0.49	8.17	0.59	2.97e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs11190604	0.652	rs76629555	chr10:102191417	T/C	cg16005271	chr10:102321736	NA	0.45	4.7	0.39	6.81e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9467773	0.583	rs1021373	chr6:26632457	G/A	cg02458000	chr6:26745757	NA	0.53	5.02	0.41	1.76e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.78	6.25	0.49	6.17e-9	Mean platelet volume;
TGCT	cis	rs7216064	1.000	rs3206817	chr17:65892834	A/G	cg12091567	chr17:66097778	LOC651250	-0.82	-6.24	-0.49	6.25e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs950169	0.922	rs12910334	chr15:84958318	G/A	cg11189052	chr15:85197271	WDR73	0.81	6.22	0.49	6.89e-9	Schizophrenia;
TGCT	cis	rs4665630	0.522	rs4665626	chr2:23883120	A/T	cg08063864	chr2:24346004	PFN4;LOC375190	-1.22	-5.82	-0.46	4.81e-8	Hypertension;
TGCT	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg04772025	chr11:68637568	NA	0.6	6.67	0.51	7.4e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs2549003	1.000	rs2549009	chr5:131826765	T/C	cg02551604	chr5:131831745	NA	0.86	10.72	0.69	2.18e-19	Asthma (sex interaction);
TGCT	cis	rs17253792	0.822	rs113692713	chr14:56087424	C/T	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs151997	0.962	rs28090	chr5:50177509	T/C	cg06027927	chr5:50259733	NA	0.46	4.63	0.38	9.01e-6	Callous-unemotional behaviour;
TGCT	cis	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg09021430	chr5:549028	NA	-0.39	-5.37	-0.43	3.77e-7	Obesity-related traits;
TGCT	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg18538332	chr22:24372958	LOC391322	-0.88	-10.28	-0.68	2.68e-18	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1577917	0.958	rs10944147	chr6:86550786	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-5.02	-0.41	1.74e-6	Response to antipsychotic treatment;
TGCT	cis	rs9894429	0.646	rs9904137	chr17:79613925	C/T	cg18240062	chr17:79603768	NPLOC4	0.56	4.9	0.4	2.95e-6	Eye color traits;
TGCT	cis	rs9486715	0.867	rs2499774	chr6:97006581	C/G	cg18709589	chr6:96969512	KIAA0776	-0.86	-8.41	-0.6	8.44e-14	Headache;
TGCT	cis	rs9393692	0.905	rs9393694	chr6:26279296	T/C	cg00631329	chr6:26305371	NA	-0.41	-6.09	-0.48	1.34e-8	Educational attainment;
TGCT	cis	rs1536827	0.541	rs11592589	chr10:135363657	G/A	cg14503168	chr10:134895446	NA	-0.55	-4.53	-0.38	1.36e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg00814883	chr7:100076585	TSC22D4	-0.82	-8.23	-0.59	2.14e-13	Platelet count;
TGCT	cis	rs7412746	0.634	rs12562939	chr1:150951452	A/C	cg09365446	chr1:150670422	GOLPH3L	0.35	4.88	0.4	3.17e-6	Melanoma;
TGCT	cis	rs12765878	0.756	rs6584579	chr10:105645725	A/G	cg11005552	chr10:105648138	OBFC1	-0.43	-6.97	-0.53	1.67e-10	Coronary artery disease;
TGCT	cis	rs514406	0.800	rs4926930	chr1:53217335	A/G	cg25767906	chr1:53392781	SCP2	0.48	5.36	0.43	3.95e-7	Monocyte count;
TGCT	cis	rs2594989	0.837	rs2454497	chr3:11501597	T/C	cg26283222	chr3:11613257	VGLL4	-0.21	-4.49	-0.37	1.58e-5	Circulating chemerin levels;
TGCT	cis	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg18188782	chr20:61659543	NA	0.46	5.55	0.45	1.61e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2832191	0.791	rs2832202	chr21:30501342	G/A	cg08807101	chr21:30365312	RNF160	-0.65	-6.08	-0.48	1.35e-8	Dental caries;
TGCT	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg13695892	chr22:41940480	POLR3H	0.92	9.08	0.63	2.08e-15	Vitiligo;
TGCT	cis	rs11190604	0.943	rs11190581	chr10:102243387	T/G	cg16342193	chr10:102329863	NA	-0.4	-5.34	-0.43	4.36e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs11785400	0.793	rs9297970	chr8:143723386	C/T	cg24634471	chr8:143751801	JRK	0.53	5.33	0.43	4.41e-7	Schizophrenia;
TGCT	cis	rs7044106	0.762	rs7044226	chr9:123466328	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	6.82	0.52	3.48e-10	Hip circumference adjusted for BMI;
TGCT	cis	rs61680841	0.627	rs16945457	chr15:91795758	A/C	cg16895464	chr15:91415119	FURIN	-0.7	-4.55	-0.38	1.28e-5	Age-related hearing impairment;
TGCT	cis	rs7089973	0.872	rs7923295	chr10:116625159	C/G	cg03647239	chr10:116582469	FAM160B1	-0.5	-4.44	-0.37	2e-5	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs7727544	0.716	rs11949055	chr5:131576737	T/C	cg21474247	chr5:131268130	NA	0.31	4.63	0.38	8.95e-6	Blood metabolite levels;
TGCT	trans	rs783396	0.892	rs6906338	chr6:106969995	T/A	cg27564810	chr2:201635376	AOX2P	-0.42	-6.64	-0.51	9.02e-10	Stroke;
TGCT	cis	rs17253792	0.822	rs77420254	chr14:56069646	C/T	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.98	0.41	2.05e-6	Bipolar disorder;
TGCT	cis	rs6988636	1.000	rs62521826	chr8:124186668	C/T	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg03806693	chr22:41940476	POLR3H	1.16	13.52	0.77	3.78e-26	Vitiligo;
TGCT	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg08219700	chr8:58056026	NA	0.3	4.57	0.38	1.14e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7666738	0.753	rs11932536	chr4:98930105	A/G	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10193935	0.901	rs1044562	chr2:42516884	C/G	cg27598129	chr2:42591480	NA	-0.42	-5.72	-0.46	7.48e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs59698941	0.550	rs60042615	chr5:132193220	A/G	cg21474247	chr5:131268130	NA	0.32	4.82	0.4	4.16e-6	Apolipoprotein A-IV levels;
TGCT	cis	rs7336332	0.569	rs57724994	chr13:28010389	T/C	cg22138327	chr13:27999177	GTF3A	0.68	4.99	0.41	2.01e-6	Weight;
TGCT	cis	rs56399783	0.808	rs73049331	chr7:2799911	C/T	cg19731401	chr7:2775893	GNA12	0.35	4.92	0.4	2.7e-6	Childhood ear infection;
TGCT	cis	rs7412746	0.611	rs10788794	chr1:150728676	T/C	cg04414720	chr1:150670196	GOLPH3L	0.37	4.57	0.38	1.15e-5	Melanoma;
TGCT	cis	rs12421382	0.659	rs1371331	chr11:109382578	G/A	cg16359550	chr11:109292809	C11orf87	0.4	4.5	0.37	1.54e-5	Schizophrenia;
TGCT	cis	rs1670533	0.818	rs585735	chr4:1080391	G/C	cg27284194	chr4:1044797	NA	0.68	5.84	0.46	4.28e-8	Recombination rate (females);
TGCT	cis	rs4378999	0.800	rs2609031	chr3:50857796	C/T	cg11728787	chr3:50609551	HEMK1	0.36	4.58	0.38	1.11e-5	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
TGCT	cis	rs12048904	0.619	rs10875347	chr1:101333737	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.88	8.3	0.6	1.46e-13	Multiple sclerosis;
TGCT	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg21226059	chr5:178986404	RUFY1	0.46	5.18	0.42	8.68e-7	Lung cancer;
TGCT	cis	rs7659604	0.540	rs4455438	chr4:122669550	G/A	cg19748678	chr4:122722346	EXOSC9	-0.5	-4.95	-0.41	2.37e-6	Type 2 diabetes;
TGCT	cis	rs4819052	0.679	rs2236450	chr21:46702553	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.66	6.48	0.5	1.93e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7829975	0.508	rs1594437	chr8:8825875	T/C	cg06636001	chr8:8085503	FLJ10661	0.68	5.58	0.45	1.46e-7	Mood instability;
TGCT	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg07061783	chr6:25882402	NA	-0.45	-4.82	-0.4	4.14e-6	Blood metabolite levels;
TGCT	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg13628971	chr7:2884303	GNA12	0.56	4.48	0.37	1.69e-5	Height;
TGCT	cis	rs4478858	0.698	rs7543348	chr1:31804805	A/C	cg07478791	chr1:31886160	SERINC2	-0.51	-4.95	-0.41	2.33e-6	Alcohol dependence;
TGCT	cis	rs59197085	0.636	rs3823481	chr7:128469381	G/A	cg00260937	chr7:128520193	KCP	0.46	4.82	0.4	4.15e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
TGCT	cis	rs7439150	0.738	rs72681215	chr4:155479803	C/A	cg22130008	chr4:155548532	NA	-0.44	-5.59	-0.45	1.36e-7	Fibrinogen levels;
TGCT	cis	rs1982963	0.950	rs2645738	chr14:52513202	G/A	cg10843707	chr14:52510701	NID2	-0.44	-6.81	-0.52	3.72e-10	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs41271473	0.526	rs72765760	chr1:228743222	G/A	cg10167378	chr1:228756711	NA	0.74	4.61	0.38	9.77e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg08859206	chr1:53392774	SCP2	0.4	5.96	0.47	2.46e-8	Monocyte count;
TGCT	cis	rs9300255	0.510	rs1727323	chr12:123698790	T/C	cg00376283	chr12:123451042	ABCB9	0.73	5.67	0.45	9.46e-8	Neutrophil percentage of white cells;
TGCT	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.78	0.39	4.79e-6	Prudent dietary pattern;
TGCT	cis	rs2243480	0.706	rs6460257	chr7:65196780	C/T	cg07424592	chr7:64974309	NA	0.83	5.36	0.43	3.95e-7	Diabetic kidney disease;
TGCT	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	5.08	0.41	1.37e-6	Height;
TGCT	cis	rs933688	1.000	rs332544	chr5:90778848	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.94	8.95	0.63	4.39e-15	Smoking behavior;
TGCT	cis	rs727563	0.635	rs2899348	chr22:42164516	C/G	cg03806693	chr22:41940476	POLR3H	1.02	10.49	0.69	7.92e-19	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs797680	0.856	rs7512911	chr1:93715818	C/G	cg17826107	chr1:92977322	EVI5	0.24	5.29	0.43	5.47e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs7590720	0.802	rs12694383	chr2:216915838	A/G	cg12620499	chr2:216877984	MREG	0.79	7.33	0.55	2.61e-11	Alcohol dependence;
TGCT	cis	rs6598955	0.515	rs61776655	chr1:26541430	T/C	cg01614726	chr1:26633154	UBXN11	0.49	4.67	0.39	7.59e-6	Obesity-related traits;
TGCT	cis	rs7953249	0.564	rs1183910	chr12:121420807	G/A	cg02403541	chr12:121454288	C12orf43	0.66	5.85	0.47	4.01e-8	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs9611565	0.512	rs139571	chr22:42214238	G/A	cg06481639	chr22:41940642	POLR3H	-0.69	-6.02	-0.48	1.83e-8	Vitiligo;
TGCT	cis	rs12477438	0.520	rs11123762	chr2:99727789	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	17.43	0.84	3.73e-35	Chronic sinus infection;
TGCT	cis	rs11718455	0.960	rs13065591	chr3:43996585	T/C	cg08738300	chr3:44038990	NA	0.81	6.02	0.48	1.8e-8	Coronary artery disease;
TGCT	cis	rs12950390	0.776	rs4793646	chr17:45853966	A/C	cg06532163	chr17:45867833	NA	0.37	5.87	0.47	3.74e-8	IgG glycosylation;
TGCT	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg10295955	chr4:187884368	NA	-1.02	-15.6	-0.81	5.02e-31	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2688608	0.588	rs10128205	chr10:75469648	C/G	cg15838173	chr10:75533400	FUT11	-0.32	-5.06	-0.41	1.48e-6	Inflammatory bowel disease;
TGCT	cis	rs13082711	0.522	rs594466	chr3:27362069	A/G	cg02860705	chr3:27208620	NA	-0.31	-5.17	-0.42	8.93e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs10927875	0.830	rs1763610	chr1:16335527	C/G	cg21385522	chr1:16154831	NA	-0.57	-6.18	-0.49	8.6e-9	Dilated cardiomyopathy;
TGCT	cis	rs56235845	0.694	rs36102285	chr5:176774018	C/T	cg16006841	chr5:176797999	RGS14	0.52	7.69	0.57	3.9e-12	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg16680214	chr1:154839983	KCNN3	-0.36	-7.33	-0.55	2.59e-11	Prostate cancer;
TGCT	cis	rs9650657	0.515	rs7820860	chr8:10950396	C/G	cg21775007	chr8:11205619	TDH	-0.54	-5.08	-0.41	1.37e-6	Neuroticism;
TGCT	cis	rs910316	1.000	rs12589815	chr14:75544101	C/T	cg08847533	chr14:75593920	NEK9	0.96	10.53	0.69	6.43e-19	Height;
TGCT	cis	rs9611565	0.506	rs2024567	chr22:41699206	G/C	cg13695892	chr22:41940480	POLR3H	-0.67	-6.2	-0.49	7.58e-9	Vitiligo;
TGCT	cis	rs1577917	1.000	rs12663651	chr6:86701655	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.54	-0.45	1.73e-7	Response to antipsychotic treatment;
TGCT	cis	rs2361718	0.564	rs2304844	chr17:78084507	G/C	cg09238746	chr17:78121135	EIF4A3	-0.96	-8.98	-0.63	3.64e-15	Yeast infection;
TGCT	cis	rs72781680	1.000	rs6751655	chr2:24155478	A/G	cg08917208	chr2:24149416	ATAD2B	0.8	4.94	0.41	2.47e-6	Lymphocyte counts;
TGCT	cis	rs477895	1.000	rs11600990	chr11:64082807	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	5.19	0.42	8.41e-7	Mean platelet volume;
TGCT	cis	rs5769765	0.728	rs6520064	chr22:50294469	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.4	6.02	0.48	1.81e-8	Schizophrenia;
TGCT	cis	rs11105298	0.891	rs11105310	chr12:89918677	C/A	cg00757033	chr12:89920650	WDR51B	0.32	5.13	0.42	1.11e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs9303401	0.614	rs2007993	chr17:56590643	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs9325144	0.532	rs1352121	chr12:39130696	A/G	cg13010199	chr12:38710504	ALG10B	-0.52	-4.68	-0.39	7.29e-6	Morning vs. evening chronotype;
TGCT	cis	rs1568889	0.838	rs11030187	chr11:28044391	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.92	11.42	0.72	4.31e-21	Bipolar disorder;
TGCT	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg20607798	chr8:58055168	NA	0.5	4.66	0.39	8.04e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7523273	0.597	rs2796265	chr1:207920788	A/G	cg22525895	chr1:207977042	MIR29B2	-0.44	-6.48	-0.5	1.93e-9	Schizophrenia;
TGCT	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	8.16	0.59	3.19e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs59197085	0.636	rs2270593	chr7:128456234	C/T	cg00260937	chr7:128520193	KCP	0.47	4.98	0.41	2.1e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
TGCT	cis	rs7975161	0.579	rs7962423	chr12:104710910	G/A	cg25273343	chr12:104657179	TXNRD1	-0.36	-5.0	-0.41	1.9e-6	Toenail selenium levels;
TGCT	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg00684032	chr4:1343700	KIAA1530	0.23	4.95	0.41	2.36e-6	Obesity-related traits;
TGCT	cis	rs981844	1.000	rs2263434	chr4:154658312	A/G	cg14289246	chr4:154710475	SFRP2	1.01	8.46	0.6	6.31e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs7113874	0.569	rs9737401	chr11:8595652	C/T	cg14521421	chr11:8862019	ST5	0.28	4.44	0.37	1.96e-5	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs2739330	1.000	rs2739330	chr22:24295286	T/C	cg20007245	chr22:24372913	LOC391322	-0.65	-6.45	-0.5	2.24e-9	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs75686122	0.892	rs117436056	chr8:104564376	A/G	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs9372498	0.536	rs10484286	chr6:118956447	T/C	cg21191810	chr6:118973309	C6orf204	-0.38	-4.98	-0.41	2.04e-6	Diastolic blood pressure;
TGCT	cis	rs7772486	0.686	rs857883	chr6:145969214	G/T	cg13319975	chr6:146136371	FBXO30	0.54	4.98	0.41	2.09e-6	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs629535	0.814	rs55873935	chr8:70081646	G/A	cg21567404	chr3:27674614	NA	-0.57	-8.99	-0.63	3.38e-15	Dupuytren's disease;
TGCT	cis	rs17443541	0.516	rs1450569	chr2:200443111	A/T	cg00055341	chr2:200446845	NA	-0.32	-4.47	-0.37	1.73e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.49	-5.79	-0.46	5.48e-8	Longevity;Endometriosis;
TGCT	cis	rs28595532	1.000	rs73842212	chr4:119638122	A/G	cg14228332	chr4:119757509	SEC24D	1.02	5.39	0.44	3.44e-7	Cannabis dependence symptom count;
TGCT	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg22166914	chr1:53195759	ZYG11B	0.3	4.87	0.4	3.29e-6	Monocyte count;
TGCT	cis	rs7224685	0.569	rs58357241	chr17:3996641	T/C	cg09580393	chr17:4869866	SPAG7	-0.39	-4.49	-0.37	1.62e-5	Type 2 diabetes;
TGCT	cis	rs3848445	1.000	rs7214411	chr17:14288990	C/T	cg05083273	chr17:13688564	NA	-0.63	-4.45	-0.37	1.92e-5	Protein quantitative trait loci;
TGCT	cis	rs3731896	1.000	rs3731896	chr2:220146402	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.78	5.54	0.45	1.71e-7	Educational attainment;
TGCT	cis	rs1975974	0.590	rs113830378	chr17:21744147	G/C	cg18423549	chr17:21743878	NA	-0.65	-5.7	-0.46	8.21e-8	Psoriasis;
TGCT	cis	rs7617773	1.000	rs11711766	chr3:48193170	G/C	cg11946769	chr3:48343235	NME6	-0.59	-5.25	-0.43	6.49e-7	Coronary artery disease;
TGCT	trans	rs2727020	0.755	rs652655	chr11:49251293	G/A	cg15704280	chr7:45808275	SEPT13	0.73	8.35	0.6	1.16e-13	Coronary artery disease;
TGCT	cis	rs12497850	0.931	rs9867373	chr3:48960938	A/T	cg18654377	chr3:49208889	KLHDC8B	-0.42	-5.52	-0.44	1.93e-7	Parkinson's disease;
TGCT	cis	rs142328051	1	rs142328051	chr1:44371441	T/C	cg12908607	chr1:44402522	ARTN	0.72	5.02	0.41	1.72e-6	Educational attainment (years of education);
TGCT	cis	rs17401966	0.931	rs12409754	chr1:10457540	T/C	cg19773385	chr1:10388646	KIF1B	-0.23	-5.42	-0.44	2.97e-7	Hepatocellular carcinoma;
TGCT	cis	rs13392177	0.684	rs6720105	chr2:219080718	G/A	cg00012203	chr2:219082015	ARPC2	-0.79	-8.02	-0.58	6.73e-13	Pyoderma gangrenosum in inflammatory bowel disease;
TGCT	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg11905131	chr22:24372483	LOC391322	-0.78	-8.26	-0.6	1.85e-13	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs903263	0.901	rs7512288	chr1:84599007	C/T	cg09664975	chr1:84543551	PRKACB	0.5	4.74	0.39	5.73e-6	Breast cancer (male);
TGCT	cis	rs7208859	0.623	rs9894709	chr17:29078454	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs17376456	0.877	rs55832164	chr5:93436579	C/T	cg25358565	chr5:93447407	FAM172A	0.92	8.38	0.6	9.58e-14	Diabetic retinopathy;
TGCT	cis	rs7175404	0.591	rs57153897	chr15:94057102	G/A	cg18324227	chr15:93584571	NA	0.48	4.51	0.38	1.49e-5	Attention deficit hyperactivity disorder;
TGCT	cis	rs6746896	0.959	rs72809838	chr2:97428320	G/A	cg26085987	chr2:97230376	NA	0.19	4.63	0.38	8.95e-6	Bipolar disorder;
TGCT	cis	rs1059312	0.966	rs7135968	chr12:129280066	G/A	cg09035930	chr12:129282057	SLC15A4	0.59	11.76	0.73	6.45e-22	Systemic lupus erythematosus;
TGCT	cis	rs9611565	0.649	rs5751144	chr22:42128097	A/G	cg17554472	chr22:41940697	POLR3H	-0.45	-4.84	-0.4	3.72e-6	Vitiligo;
TGCT	cis	rs7666738	0.830	rs34628820	chr4:99004764	C/T	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg06634786	chr22:41940651	POLR3H	-0.73	-6.8	-0.52	3.93e-10	Vitiligo;
TGCT	cis	rs7246657	0.943	rs2291004	chr19:37997952	C/A	cg18154014	chr19:37997991	ZNF793	0.88	5.73	0.46	7.14e-8	Coronary artery calcification;
TGCT	cis	rs1865760	0.865	rs9393678	chr6:25945819	C/T	cg16482183	chr6:26056742	HIST1H1C	0.53	4.88	0.4	3.14e-6	Height;
TGCT	trans	rs3780486	0.846	rs10971420	chr9:33125000	T/C	cg04842962	chr6:43655489	MRPS18A	1.22	16.02	0.82	5.54e-32	IgG glycosylation;
TGCT	cis	rs2120019	1.000	rs8033837	chr15:75353975	A/C	cg17294928	chr15:75287854	SCAMP5	-0.81	-6.21	-0.49	7.41e-9	Blood trace element (Zn levels);
TGCT	cis	rs6964587	0.934	rs7798973	chr7:91588360	G/A	cg17063962	chr7:91808500	NA	0.91	9.99	0.67	1.32e-17	Breast cancer;
TGCT	cis	rs644799	0.965	rs545342	chr11:95545369	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	8.74	0.62	1.39e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7095607	0.935	rs12774635	chr10:69950477	T/A	cg18986048	chr10:69913749	MYPN	0.46	4.93	0.41	2.54e-6	Lung function (FVC);
TGCT	cis	rs4074961	0.527	rs2294875	chr1:38052445	C/T	cg11397548	chr1:38022522	DNALI1	0.42	4.86	0.4	3.47e-6	Axial length;
TGCT	cis	rs7829975	0.774	rs11249893	chr8:8700851	C/T	cg06636001	chr8:8085503	FLJ10661	0.72	6.67	0.51	7.64e-10	Mood instability;
TGCT	cis	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg22857025	chr5:266934	NA	-0.31	-6.32	-0.49	4.33e-9	Breast cancer;
TGCT	cis	rs2180341	1.000	rs6569477	chr6:127589302	T/A	cg27446573	chr6:127587934	RNF146	1.13	10.12	0.67	6.64e-18	Breast cancer;
TGCT	cis	rs12142240	0.698	rs1984490	chr1:46858734	C/T	cg00530320	chr1:46809349	NSUN4	-0.29	-5.88	-0.47	3.51e-8	Menopause (age at onset);
TGCT	cis	rs826838	0.804	rs6580755	chr12:39159190	C/T	cg13010199	chr12:38710504	ALG10B	0.83	6.7	0.52	6.57e-10	Heart rate;
TGCT	cis	rs7607369	0.759	rs10179708	chr2:219390967	T/A	cg02176678	chr2:219576539	TTLL4	-0.47	-6.65	-0.51	8.44e-10	Red blood cell count;Amyotrophic lateral sclerosis;
TGCT	trans	rs208515	0.525	rs12193560	chr6:66690457	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.93	10.3	0.68	2.34e-18	Exhaled nitric oxide levels;
TGCT	cis	rs61990749	0.686	rs11159288	chr14:78216972	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	0.6	4.45	0.37	1.88e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs5769765	0.773	rs7410291	chr22:50300078	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.09	-10.56	-0.69	5.6e-19	Schizophrenia;
TGCT	cis	rs9926296	0.712	rs459920	chr16:89730827	T/C	cg21285383	chr16:89894308	SPIRE2	-0.32	-4.52	-0.38	1.42e-5	Vitiligo;
TGCT	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg03806693	chr22:41940476	POLR3H	-1.13	-13.26	-0.77	1.59e-25	Vitiligo;
TGCT	cis	rs9399135	0.967	rs2297340	chr6:135376058	T/C	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.21e-6	Red blood cell count;
TGCT	cis	rs1371867	0.875	rs28595052	chr8:101327553	G/A	cg06002616	chr8:101225028	SPAG1	-0.56	-6.58	-0.51	1.2e-9	Atrioventricular conduction;
TGCT	cis	rs782590	0.935	rs62165197	chr2:55801812	C/T	cg03859395	chr2:55845619	SMEK2	0.92	11.39	0.72	5.08e-21	Metabolic syndrome;
TGCT	cis	rs4478037	1.000	rs4074416	chr3:33161729	A/G	cg19404215	chr3:33155277	CRTAP	1.33	8.79	0.62	1.04e-14	Major depressive disorder;
TGCT	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg05368731	chr17:41323189	NBR1	1.2	14.2	0.79	8.98e-28	Menopause (age at onset);
TGCT	cis	rs394563	0.591	rs237029	chr6:149717425	A/G	cg16235748	chr6:149772707	ZC3H12D	-0.44	-4.9	-0.4	2.87e-6	Dupuytren's disease;
TGCT	cis	rs2242116	1.000	rs2168443	chr3:46947087	A/T	cg23352942	chr3:46931381	PTH1R	0.32	4.8	0.4	4.51e-6	Birth weight;
TGCT	cis	rs6840360	1.000	rs6535819	chr4:152651503	A/G	cg22705602	chr4:152727874	NA	-0.25	-4.45	-0.37	1.91e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg24531977	chr5:56204891	C5orf35	-0.74	-7.1	-0.54	8.53e-11	Initial pursuit acceleration;
TGCT	cis	rs13191362	0.938	rs35395472	chr6:163008493	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	trans	rs4650994	1.000	rs4076205	chr1:178534157	G/A	cg05059571	chr16:84539110	KIAA1609	-0.4	-7.39	-0.55	1.92e-11	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs3820068	0.532	rs72647105	chr1:15935238	C/G	cg05660106	chr1:15850417	CASP9	0.83	8.16	0.59	3.26e-13	Systolic blood pressure;
TGCT	cis	rs11190604	1.000	rs11190570	chr10:102227702	G/C	cg23241863	chr10:102295624	HIF1AN	0.62	4.87	0.4	3.27e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs6121246	0.697	rs8118150	chr20:30436088	G/A	cg18721089	chr20:30220636	NA	-0.45	-4.75	-0.39	5.43e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs10883723	0.738	rs715438	chr10:104258303	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	8.36	0.6	1.1e-13	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs3087591	0.708	rs8067440	chr17:29708155	A/T	cg24425628	chr17:29625626	OMG;NF1	0.4	5.77	0.46	5.86e-8	Hip circumference;
TGCT	cis	rs6433895	1.000	rs6759865	chr2:182017385	A/G	cg16904960	chr2:182549928	NA	0.34	4.47	0.37	1.77e-5	Lymphocyte counts;
TGCT	cis	rs11690935	0.959	rs10204622	chr2:172588982	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.18	-12.51	-0.75	9.78e-24	Schizophrenia;
TGCT	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg14820908	chr5:178986412	RUFY1	0.49	4.94	0.41	2.46e-6	Lung cancer;
TGCT	cis	rs7474896	0.537	rs1779068	chr10:38250785	G/A	cg13720705	chr10:37990370	NA	-0.34	-4.6	-0.38	1.04e-5	Obesity (extreme);
TGCT	cis	rs35146811	0.735	rs1061230	chr7:99807265	G/A	cg22906224	chr7:99728672	NA	-0.49	-4.45	-0.37	1.88e-5	Coronary artery disease;
TGCT	cis	rs9368481	0.700	rs6911401	chr6:26913214	C/G	cg26531700	chr6:26746687	NA	0.7	6.39	0.5	3.12e-9	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7819412	0.511	rs10108511	chr8:11435516	T/C	cg27411982	chr8:10470053	RP1L1	-0.21	-4.59	-0.38	1.07e-5	Triglycerides;
TGCT	cis	rs2070488	0.965	rs4679053	chr3:38523495	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.88	8.99	0.63	3.5e-15	Electrocardiographic conduction measures;
TGCT	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg11494091	chr17:61959527	GH2	0.61	14.8	0.8	3.65e-29	Prudent dietary pattern;
TGCT	cis	rs7666738	0.830	rs6853266	chr4:99047528	G/T	cg05340658	chr4:99064831	C4orf37	0.55	6.29	0.49	4.98e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9611565	0.512	rs4822052	chr22:42193741	G/A	cg06634786	chr22:41940651	POLR3H	-0.82	-8.03	-0.59	6.31e-13	Vitiligo;
TGCT	cis	rs28735056	0.587	rs8093548	chr18:77636451	G/A	cg20368463	chr18:77673604	PQLC1	-0.45	-5.52	-0.44	1.89e-7	Schizophrenia;
TGCT	cis	rs10276381	0.786	rs740261	chr7:28241276	A/G	cg23620719	chr7:28220237	JAZF1	1.0	5.39	0.44	3.36e-7	Crohn's disease;
TGCT	cis	rs7666738	0.688	rs4632667	chr4:98748299	A/G	cg24818145	chr4:99064322	C4orf37	0.62	4.67	0.39	7.82e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs5750830	0.620	rs1007337	chr22:39781585	C/T	cg01416388	chr22:39784598	NA	-0.63	-6.06	-0.48	1.52e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs6430585	0.527	rs59413285	chr2:136444185	G/T	cg07169764	chr2:136633963	MCM6	1.0	9.14	0.63	1.51e-15	Corneal structure;
TGCT	cis	rs1555895	0.576	rs7071801	chr10:854011	T/C	cg02193355	chr10:851439	NA	0.2	4.54	0.38	1.3e-5	Survival in rectal cancer;
TGCT	cis	rs4509693	0.891	rs10748797	chr10:102502173	A/C	cg24127310	chr10:102502104	NA	0.7	5.86	0.47	3.84e-8	Alzheimer's disease;
TGCT	cis	rs2046867	0.818	rs62249874	chr3:72911202	G/C	cg25664220	chr3:72788482	NA	-0.56	-7.45	-0.56	1.38e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6582630	0.573	rs12319414	chr12:38267440	T/C	cg26384229	chr12:38710491	ALG10B	-0.54	-4.7	-0.39	6.68e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs4478858	0.709	rs937786	chr1:31857869	G/A	cg00250761	chr1:31883323	NA	0.25	4.54	0.38	1.3e-5	Alcohol dependence;
TGCT	cis	rs6906287	0.647	rs67832971	chr6:118832205	C/T	cg21191810	chr6:118973309	C6orf204	0.26	4.49	0.37	1.58e-5	Electrocardiographic conduction measures;
TGCT	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg18402987	chr7:1209562	NA	0.81	6.94	0.53	1.9e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg18252515	chr7:66147081	NA	-1.31	-8.18	-0.59	2.87e-13	Diabetic kidney disease;
TGCT	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	8.39	0.6	9.03e-14	Platelet count;
TGCT	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg06618935	chr21:46677482	NA	-0.37	-5.8	-0.46	5.29e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	trans	rs208520	0.874	rs208469	chr6:66915891	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.95	-9.95	-0.67	1.64e-17	Exhaled nitric oxide output;
TGCT	cis	rs7954584	0.560	rs745327	chr12:122456524	T/C	cg13699009	chr12:122356056	WDR66	-0.23	-4.73	-0.39	5.92e-6	Mean corpuscular volume;
TGCT	cis	rs2033711	0.811	rs9304814	chr19:58951811	C/A	cg04608855	chr19:58913158	NA	0.6	5.86	0.47	3.99e-8	Uric acid clearance;
TGCT	cis	rs2370759	1.000	rs77165999	chr10:32577131	T/C	cg01819863	chr10:32635814	EPC1	1.03	10.03	0.67	1.05e-17	Sexual dysfunction (female);
TGCT	cis	rs12042938	0.507	rs1655299	chr1:231732161	C/T	cg04892437	chr1:231737901	TSNAX-DISC1	-0.42	-4.83	-0.4	3.98e-6	Neuranatomic and neurocognitive phenotypes;
TGCT	cis	rs6534347	0.573	rs11098666	chr4:123507914	A/G	cg10583651	chr4:123538969	IL21	-0.32	-4.49	-0.37	1.63e-5	Type 1 diabetes;
TGCT	cis	rs314590	1.000	rs314590	chr7:4474132	G/A	cg10785373	chr7:4456119	NA	-0.41	-4.48	-0.37	1.7e-5	Obesity-related traits;
TGCT	cis	rs908922	0.676	rs1538082	chr1:152517304	A/G	cg20991723	chr1:152506922	NA	0.45	6.11	0.48	1.18e-8	Hair morphology;
TGCT	cis	rs8177179	0.967	rs6439434	chr3:133450371	T/G	cg24879335	chr3:133465180	TF	0.37	5.02	0.41	1.72e-6	Iron status biomarkers (transferrin levels);
TGCT	cis	rs6671200	0.607	rs1927043	chr1:95667251	G/A	cg26537280	chr1:95699037	RWDD3	-0.53	-4.98	-0.41	2.1e-6	Stearic acid (18:0) levels;
TGCT	cis	rs7599312	0.517	rs10192988	chr2:213407782	T/G	cg20637307	chr2:213403960	ERBB4	0.92	11.46	0.72	3.6e-21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs11098499	0.954	rs11098526	chr4:120390359	C/T	cg09307838	chr4:120376055	NA	0.69	6.56	0.51	1.31e-9	Corneal astigmatism;
TGCT	cis	rs6831352	0.918	rs7670060	chr4:100059568	G/T	cg12011299	chr4:100065546	ADH4	-0.41	-4.96	-0.41	2.29e-6	Alcohol dependence;
TGCT	cis	rs2013441	1.000	rs2703787	chr17:20158665	A/G	cg23224458	chr17:20280056	CCDC144C	-0.38	-4.63	-0.38	9.19e-6	Obesity-related traits;
TGCT	cis	rs1865760	0.593	rs9393676	chr6:25936944	G/A	cg03264133	chr6:25882463	NA	-0.5	-5.2	-0.42	8.12e-7	Height;
TGCT	cis	rs2153535	0.580	rs1335633	chr6:8448800	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.76	0.46	6.39e-8	Motion sickness;
TGCT	cis	rs4919694	1.000	rs111622998	chr10:104953021	C/A	cg04362960	chr10:104952993	NT5C2	1.07	7.15	0.54	6.62e-11	Arsenic metabolism;
TGCT	cis	rs765787	0.530	rs2668737	chr15:45522799	C/T	cg24006582	chr15:45444508	DUOX1	-0.25	-5.53	-0.44	1.82e-7	Uric acid levels;
TGCT	cis	rs1062177	1.000	rs17804178	chr5:151197729	T/G	cg12924095	chr5:151150029	G3BP1	0.35	5.05	0.41	1.53e-6	Preschool internalizing problems;
TGCT	cis	rs2996428	0.667	rs11578581	chr1:3770642	G/A	cg13057898	chr1:3703894	LRRC47	0.21	4.64	0.38	8.81e-6	Red cell distribution width;
TGCT	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg22535103	chr8:58192502	C8orf71	-0.41	-5.24	-0.43	6.7e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2440129	0.611	rs1042357	chr17:6905061	T/G	cg03760483	chr17:6899297	ALOX12	0.48	5.5	0.44	2.11e-7	Tonsillectomy;
TGCT	cis	rs11098499	0.774	rs11098505	chr4:120284627	C/T	cg09307838	chr4:120376055	NA	0.58	5.76	0.46	6.16e-8	Corneal astigmatism;
TGCT	cis	rs6460942	0.908	rs6948654	chr7:12418546	T/A	cg06484146	chr7:12443880	VWDE	-0.62	-6.21	-0.49	7.17e-9	Coronary artery disease;
TGCT	cis	rs6032067	0.543	rs7272524	chr20:43908694	A/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.39	-6.18	-0.49	8.63e-9	Blood protein levels;
TGCT	cis	rs751728	0.664	rs4711349	chr6:33740592	C/T	cg13859433	chr6:33739653	LEMD2	-0.32	-5.6	-0.45	1.29e-7	Crohn's disease;
TGCT	cis	rs7216064	0.531	rs6504573	chr17:66015963	C/T	cg12091567	chr17:66097778	LOC651250	-0.77	-6.54	-0.51	1.48e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs4820539	0.966	rs2283803	chr22:23454881	G/A	cg14186256	chr22:23484241	RTDR1	0.92	10.78	0.7	1.6e-19	Bone mineral density;
TGCT	cis	rs7772486	0.686	rs2142983	chr6:146069701	G/C	cg23711669	chr6:146136114	FBXO30	-0.88	-9.63	-0.65	1.01e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4880487	0.888	rs10794730	chr10:1247022	C/T	cg03183215	chr10:1252341	ADARB2	-0.3	-5.77	-0.46	6.09e-8	Migraine;
TGCT	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.55	-6.86	-0.52	2.84e-10	Longevity;Endometriosis;
TGCT	cis	rs9372498	0.536	rs12333080	chr6:118845410	A/C	cg21191810	chr6:118973309	C6orf204	-0.37	-4.79	-0.39	4.73e-6	Diastolic blood pressure;
TGCT	cis	rs5769707	0.967	rs2051626	chr22:50008973	G/A	cg05373962	chr22:49881684	NA	-0.3	-6.1	-0.48	1.22e-8	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs9467773	0.620	rs9295701	chr6:26627508	T/C	cg11502198	chr6:26597334	ABT1	0.54	4.97	0.41	2.14e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg10047753	chr17:41438598	NA	0.94	9.23	0.64	9.06e-16	Menopause (age at onset);
TGCT	cis	rs9399135	0.935	rs11760000	chr6:135370496	G/A	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.28e-6	Red blood cell count;
TGCT	cis	rs9381040	0.655	rs4140578	chr6:41041829	A/G	cg03526776	chr6:41159608	TREML2	0.27	5.34	0.43	4.21e-7	Alzheimer's disease (late onset);
TGCT	cis	rs35306767	0.855	rs34318754	chr10:890714	G/A	cg26597838	chr10:835615	NA	0.8	12.11	0.74	9.26e-23	Eosinophil percentage of granulocytes;
TGCT	trans	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg13615516	chr5:77269221	NA	0.68	8.54	0.61	3.97e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs1124769	0.502	rs12911207	chr15:51069296	T/C	cg23028286	chr15:51614521	CYP19A1	0.19	4.47	0.37	1.75e-5	Cognitive performance;
TGCT	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	4.67	0.39	7.7e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs4711336	1.000	rs4711337	chr6:33659987	T/C	cg14003231	chr6:33640908	ITPR3	0.28	4.51	0.38	1.49e-5	Height;
TGCT	cis	rs939658	1.000	rs11072826	chr15:79461516	C/T	cg17916960	chr15:79447300	NA	0.52	8.43	0.6	7.56e-14	Refractive error;
TGCT	cis	rs7698623	0.717	rs4147245	chr4:88779237	A/C	cg27387453	chr4:88533842	DSPP	-0.61	-4.6	-0.38	1.03e-5	Cardiovascular disease risk factors;
TGCT	cis	rs4253772	0.550	rs715515	chr22:46720921	G/A	cg24881330	chr22:46731750	TRMU	1.04	5.38	0.44	3.54e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.54	4.86	0.4	3.47e-6	Prudent dietary pattern;
TGCT	trans	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg21659725	chr3:3221576	CRBN	-0.76	-9.03	-0.63	2.74e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg24549020	chr5:56110836	MAP3K1	0.67	5.78	0.46	5.74e-8	Initial pursuit acceleration;
TGCT	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg08859206	chr1:53392774	SCP2	0.35	5.07	0.41	1.39e-6	Monocyte count;
TGCT	cis	rs877282	0.945	rs12776447	chr10:790625	A/G	cg17470449	chr10:769945	NA	0.3	4.82	0.4	4.14e-6	Uric acid levels;
TGCT	cis	rs4242434	0.787	rs1545837	chr8:22477807	T/C	cg03733263	chr8:22462867	KIAA1967	1.04	15.21	0.81	4.06e-30	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs7904368	0.806	rs7099178	chr10:16862578	C/G	cg14835575	chr10:16859367	RSU1	0.65	6.89	0.53	2.45e-10	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
TGCT	cis	rs7917772	0.636	rs2249850	chr10:104512006	A/G	cg05855489	chr10:104503620	C10orf26	-0.66	-5.19	-0.42	8.45e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2486288	0.656	rs6493143	chr15:45570781	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.78	-7.55	-0.56	8e-12	Glomerular filtration rate;
TGCT	cis	rs644148	0.933	rs565819	chr19:44967714	A/G	cg15540054	chr19:45004280	ZNF180	0.59	5.25	0.43	6.49e-7	Personality dimensions;
TGCT	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg24503407	chr1:205819492	PM20D1	-0.55	-7.74	-0.57	3.05e-12	Menarche (age at onset);
TGCT	cis	rs2439831	1.000	rs2439850	chr15:43784854	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.01	8.19	0.59	2.67e-13	Lung cancer in ever smokers;
TGCT	cis	rs704	0.628	rs10853128	chr17:26721304	A/G	cg10342447	chr17:26645325	TMEM97	-0.46	-4.63	-0.38	9.04e-6	Osteoprotegerin levels;
TGCT	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.94	7.92	0.58	1.17e-12	Platelet count;
TGCT	trans	rs2727020	0.513	rs10839307	chr11:49609843	A/C	cg15704280	chr7:45808275	SEPT13	-0.72	-8.6	-0.61	2.91e-14	Coronary artery disease;
TGCT	cis	rs6542838	0.583	rs12712040	chr2:99513416	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.51	-4.71	-0.39	6.41e-6	Fear of minor pain;
TGCT	cis	rs8037137	0.915	rs8028409	chr15:91506422	A/T	cg22570213	chr15:91497863	RCCD1	0.52	4.87	0.4	3.29e-6	Platelet count;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
TGCT	cis	rs887829	0.569	rs10179091	chr2:234657983	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.26	-4.5	-0.37	1.56e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
TGCT	cis	rs6450176	1.000	rs3776707	chr5:53304873	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.49	-4.6	-0.38	1.03e-5	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg08975724	chr8:8085496	FLJ10661	-0.54	-5.26	-0.43	6.02e-7	Neuroticism;
TGCT	cis	rs9916302	0.851	rs11078906	chr17:37662767	C/T	cg15445000	chr17:37608096	MED1	0.31	4.59	0.38	1.06e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs7937682	0.889	rs3017767	chr11:111508098	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.1	-11.55	-0.72	2.11e-21	Primary sclerosing cholangitis;
TGCT	cis	rs9383153	0.590	rs2072736	chr6:16328068	T/C	cg10975897	chr6:15504844	JARID2	0.8	4.45	0.37	1.88e-5	Gambling;
TGCT	cis	rs586688	1.000	rs522869	chr1:201638600	A/G	cg05779441	chr1:201574716	NA	0.29	4.81	0.4	4.25e-6	Obesity-related traits;
TGCT	cis	rs651907	0.640	rs771574	chr3:101620682	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.59	5.6	0.45	1.34e-7	Colorectal cancer;
TGCT	cis	rs10464366	0.517	rs13231075	chr7:39174806	G/T	cg18850127	chr7:39170497	POU6F2	0.33	7.18	0.54	5.5e-11	IgG glycosylation;
TGCT	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	5.3	0.43	5.06e-7	Height;
TGCT	cis	rs72781680	1.000	rs56205282	chr2:24221317	C/T	cg08917208	chr2:24149416	ATAD2B	0.82	4.92	0.4	2.68e-6	Lymphocyte counts;
TGCT	cis	rs4803468	1.000	rs878083	chr19:41897688	G/A	cg09537434	chr19:41945824	ATP5SL	-0.89	-9.84	-0.66	3.15e-17	Height;
TGCT	cis	rs17443541	0.507	rs4675699	chr2:200451389	A/C	cg00055341	chr2:200446845	NA	-0.31	-4.45	-0.37	1.89e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs4919044	0.641	rs11187225	chr10:94714427	C/G	cg05127821	chr10:94822908	CYP26C1	-0.73	-4.47	-0.37	1.74e-5	Coronary artery disease;
TGCT	cis	rs1062177	0.547	rs2915818	chr5:151115290	T/A	cg00977110	chr5:151150581	G3BP1	-0.41	-4.89	-0.4	3.1e-6	Preschool internalizing problems;
TGCT	cis	rs16867321	1.000	rs1358521	chr2:181444628	T/C	cg23363182	chr2:181467187	NA	-0.39	-5.47	-0.44	2.38e-7	Obesity;
TGCT	cis	rs28595532	0.688	rs116566508	chr4:119619195	G/A	cg21605333	chr4:119757512	SEC24D	1.33	8.02	0.58	6.93e-13	Cannabis dependence symptom count;
TGCT	cis	rs67311347	1.000	rs1466236	chr3:40462162	C/T	cg13683864	chr3:40499215	RPL14	-1.04	-10.79	-0.7	1.54e-19	Renal cell carcinoma;
TGCT	cis	rs2594989	1.000	rs2594994	chr3:11339960	T/A	cg00170343	chr3:11313890	ATG7	0.67	5.06	0.41	1.44e-6	Circulating chemerin levels;
TGCT	cis	rs259282	0.519	rs259276	chr19:33160953	C/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	1.0	10.18	0.67	4.62e-18	Schizophrenia;
TGCT	cis	rs7845219	0.544	rs4570121	chr8:95917088	C/T	cg16049864	chr8:95962084	TP53INP1	-0.48	-5.3	-0.43	5.23e-7	Type 2 diabetes;
TGCT	cis	rs10032931	0.962	rs1385670	chr4:96456167	T/A	cg03008707	chr4:96468962	UNC5C	-0.33	-4.72	-0.39	6.35e-6	Optic nerve measurement (cup-to-disc ratio);
TGCT	cis	rs1348850	0.567	rs880898	chr2:178532470	C/T	cg22681709	chr2:178499509	PDE11A	-0.48	-6.02	-0.48	1.81e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs4654899	1.000	rs7521675	chr1:21424070	T/C	cg01072550	chr1:21505969	NA	-0.48	-7.71	-0.57	3.44e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs1371867	0.846	rs959022	chr8:101295992	T/A	cg06636551	chr8:101224915	SPAG1	-0.48	-6.52	-0.51	1.62e-9	Atrioventricular conduction;
TGCT	trans	rs1814175	0.715	rs1722007	chr11:49897319	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.34	-0.55	2.4e-11	Height;
TGCT	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg06675538	chr2:114033490	PAX8;LOC440839	-0.42	-4.65	-0.39	8.23e-6	Lymphocyte counts;
TGCT	cis	rs12142240	0.738	rs67545510	chr1:46806242	G/T	cg14993813	chr1:46806288	NSUN4	-0.58	-4.78	-0.39	4.78e-6	Menopause (age at onset);
TGCT	cis	rs7552404	0.924	rs1146579	chr1:76209792	C/T	cg22875332	chr1:76189707	ACADM	-0.72	-9.0	-0.63	3.21e-15	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg02380750	chr20:61661411	NA	0.35	6.1	0.48	1.25e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7085104	0.700	rs743572	chr10:104597152	A/G	cg15744005	chr10:104629667	AS3MT	-0.42	-5.28	-0.43	5.69e-7	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs180358	0.738	rs180323	chr11:116626570	A/G	cg08672956	chr11:116640933	BUD13	-0.22	-4.49	-0.37	1.6e-5	Multiple sclerosis (severity);
TGCT	cis	rs7582180	0.585	rs6736311	chr2:100950599	C/G	cg08017756	chr2:100939284	LONRF2	-0.3	-4.95	-0.41	2.34e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs8111998	0.826	rs59838183	chr19:22766434	G/A	cg19914732	chr19:22715077	NA	-0.56	-4.51	-0.38	1.46e-5	Corneal structure;
TGCT	cis	rs9549367	0.713	rs1755690	chr13:113824266	T/C	cg18105134	chr13:113819100	PROZ	0.48	8.52	0.61	4.55e-14	Platelet distribution width;
TGCT	cis	rs2153535	0.580	rs9505450	chr6:8469902	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs9300255	0.537	rs10772993	chr12:123644714	A/G	cg00376283	chr12:123451042	ABCB9	0.72	4.96	0.41	2.29e-6	Neutrophil percentage of white cells;
TGCT	cis	rs2075371	0.796	rs12154724	chr7:133943443	G/A	cg11752832	chr7:134001865	SLC35B4	0.66	5.51	0.44	1.95e-7	Mean platelet volume;
TGCT	cis	rs12643440	0.538	rs2314599	chr4:17139624	A/G	cg22650099	chr4:17144496	NA	-0.48	-4.75	-0.39	5.59e-6	Metabolite levels (Pyroglutamine);
TGCT	trans	rs10504390	0.585	rs79812520	chr8:66507615	T/C	cg07799219	chr22:43901523	MPPED1	-0.71	-6.88	-0.53	2.67e-10	IgG glycosylation;
TGCT	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.68	5.62	0.45	1.18e-7	Tonsillectomy;
TGCT	cis	rs7666738	0.830	rs10050008	chr4:99025313	T/G	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs57221529	0.709	rs72703090	chr5:598314	C/T	cg09021430	chr5:549028	NA	-0.43	-5.77	-0.46	5.99e-8	Lung disease severity in cystic fibrosis;
TGCT	cis	rs9486719	1.000	rs2499807	chr6:96864053	T/G	cg18709589	chr6:96969512	KIAA0776	0.71	5.21	0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs6688613	0.840	rs6699294	chr1:166955174	G/A	cg07049167	chr1:166818506	POGK	0.26	5.18	0.42	8.56e-7	Refractive astigmatism;
TGCT	trans	rs11088226	0.681	rs2833901	chr21:33939318	T/C	cg09050820	chr6:167586206	TCP10L2	0.79	7.04	0.53	1.13e-10	Gastritis;
TGCT	cis	rs896854	0.573	rs11996455	chr8:95853708	G/A	cg16049864	chr8:95962084	TP53INP1	-0.6	-7.11	-0.54	8.27e-11	Type 2 diabetes;
TGCT	cis	rs68170813	0.559	rs6965001	chr7:106933196	A/G	cg02696742	chr7:106810147	HBP1	-0.69	-5.81	-0.46	4.85e-8	Coronary artery disease;
TGCT	cis	rs7260538	0.808	rs2086785	chr19:41527085	T/C	cg20630647	chr19:41531805	NA	0.31	4.93	0.4	2.58e-6	DDT metabolite (p,p'-DDE levels);
TGCT	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	7.61	0.56	5.94e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs6684514	1.000	rs10908502	chr1:156300082	A/G	cg16558208	chr1:156270281	VHLL	0.48	9.6	0.65	1.19e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg23708337	chr7:1209742	NA	0.56	5.08	0.42	1.34e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9486719	1.000	rs2472886	chr6:96864876	C/T	cg18709589	chr6:96969512	KIAA0776	0.71	5.21	0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs7572733	0.515	rs11891555	chr2:198853540	G/T	cg00792783	chr2:198669748	PLCL1	0.57	5.09	0.42	1.29e-6	Dermatomyositis;
TGCT	trans	rs877282	0.898	rs11253350	chr10:765968	G/A	cg22713356	chr15:30763199	NA	1.2	9.39	0.64	3.76e-16	Uric acid levels;
TGCT	cis	rs6952808	0.636	rs73048162	chr7:1949328	T/C	cg22963979	chr7:1858916	MAD1L1	-0.36	-5.49	-0.44	2.18e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs9894429	1.000	rs11652797	chr17:79574124	A/G	cg18240062	chr17:79603768	NPLOC4	0.67	6.84	0.52	3.23e-10	Eye color traits;
TGCT	cis	rs4285028	0.580	rs1523519	chr3:121631841	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.63	-5.37	-0.43	3.74e-7	Multiple sclerosis;
TGCT	cis	rs2071303	1.000	rs2071303	chr6:26091336	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.61	-5.83	-0.46	4.55e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7336332	0.598	rs77055070	chr13:28010516	C/G	cg22138327	chr13:27999177	GTF3A	0.8	5.97	0.47	2.35e-8	Weight;
TGCT	cis	rs7523273	0.606	rs761275	chr1:207972154	A/C	cg22525895	chr1:207977042	MIR29B2	-0.52	-8.83	-0.62	8.51e-15	Schizophrenia;
TGCT	cis	rs478304	0.934	rs669742	chr11:65501291	C/T	cg27068330	chr11:65405492	SIPA1	0.75	7.39	0.55	1.93e-11	Acne (severe);
TGCT	cis	rs2228479	0.717	rs11644967	chr16:89806614	T/A	cg26513180	chr16:89883248	FANCA	0.79	4.57	0.38	1.16e-5	Skin colour saturation;
TGCT	cis	rs634534	0.622	rs624273	chr11:65712413	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.21	4.58	0.38	1.12e-5	Sum eosinophil basophil counts;Eosinophil counts;
TGCT	cis	rs11578119	0.832	rs10919376	chr1:170350049	T/G	cg09767346	chr1:170501363	GORAB	0.61	4.57	0.38	1.16e-5	Male-pattern baldness;
TGCT	cis	rs6450176	0.638	rs56220547	chr5:53287952	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.77	-5.46	-0.44	2.46e-7	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs4285028	0.747	rs3732410	chr3:121415720	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.92	-7.3	-0.55	3.03e-11	Multiple sclerosis;
TGCT	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg24549020	chr5:56110836	MAP3K1	0.75	6.06	0.48	1.52e-8	Initial pursuit acceleration;
TGCT	cis	rs338419	1.000	rs900630	chr15:60512695	C/T	cg03365496	chr15:60286384	NA	-0.4	-4.48	-0.37	1.66e-5	Blood protein levels;
TGCT	cis	rs3806843	0.576	rs251368	chr5:140241027	G/T	cg09824255	chr5:140014002	CD14	-0.27	-4.68	-0.39	7.25e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg01448562	chr3:133502909	NA	0.34	6.81	0.52	3.73e-10	Iron status biomarkers;
TGCT	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg01017244	chr2:74357527	NA	0.51	8.97	0.63	3.95e-15	Gestational age at birth (maternal effect);
TGCT	trans	rs9467711	1.000	rs34569761	chr6:26334306	A/G	cg20516262	chr7:155325649	CNPY1	0.56	6.89	0.53	2.46e-10	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs8072100	0.840	rs4968319	chr17:45464967	A/G	cg08085267	chr17:45401833	C17orf57	-0.47	-5.56	-0.45	1.57e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs12134245	0.776	rs13447464	chr1:91968278	G/A	cg07090678	chr1:91966139	CDC7	0.36	4.9	0.4	2.92e-6	Breast cancer;
TGCT	cis	rs7465272	0.515	rs34087536	chr8:143720876	G/A	cg24634471	chr8:143751801	JRK	0.53	5.11	0.42	1.18e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs611744	0.901	rs599357	chr8:109194160	T/C	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs12220238	0.822	rs10824160	chr10:76132267	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.9	6.17	0.48	9.08e-9	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs950169	1.000	rs12903820	chr15:84723820	A/G	cg17173187	chr15:85201210	NMB	0.47	5.23	0.42	7.11e-7	Schizophrenia;
TGCT	cis	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg20637647	chr7:64974828	NA	-0.92	-5.09	-0.42	1.26e-6	Diabetic kidney disease;
TGCT	cis	rs11096990	0.613	rs4974990	chr4:39193265	T/C	cg20847110	chr4:39482781	LOC401127	0.16	4.52	0.38	1.42e-5	Cognitive function;
TGCT	cis	rs1887596	0.705	rs9788361	chr13:27201814	A/G	cg01312412	chr13:27282625	NA	0.3	5.31	0.43	4.89e-7	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs2235642	0.826	rs8048410	chr16:1614097	A/G	cg08296037	chr16:1584118	IFT140;TMEM204	-0.31	-5.22	-0.42	7.31e-7	Coronary artery disease;
TGCT	cis	rs7772486	0.686	rs1011596	chr6:146076433	A/G	cg23711669	chr6:146136114	FBXO30	0.88	9.38	0.64	4.01e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4478858	0.735	rs6676682	chr1:31809816	C/T	cg00250761	chr1:31883323	NA	-0.28	-4.96	-0.41	2.32e-6	Alcohol dependence;
TGCT	cis	rs7772486	0.558	rs7753273	chr6:146066039	C/T	cg05347473	chr6:146136440	FBXO30	-0.68	-6.22	-0.49	7.01e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2797160	0.651	rs1269176	chr6:126029682	A/T	cg05901451	chr6:126070800	HEY2	-0.72	-6.47	-0.5	2.08e-9	Endometrial cancer;
TGCT	cis	rs1723838	0.826	rs1792197	chr11:73585860	G/A	cg18195628	chr11:73498948	MRPL48	0.93	4.55	0.38	1.28e-5	Obesity-related traits;
TGCT	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg11890956	chr21:40555474	PSMG1	1.1	12.16	0.74	7.11e-23	Cognitive function;
TGCT	cis	rs13242816	1.000	rs17138747	chr7:116132670	G/A	cg02799643	chr7:116139180	CAV2	-0.46	-5.53	-0.44	1.78e-7	P wave duration;
TGCT	cis	rs10791097	0.667	rs4937584	chr11:130741761	A/G	cg12179176	chr11:130786555	SNX19	0.84	10.17	0.67	4.95e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs67311347	1.000	rs1466237	chr3:40462026	C/G	cg13683864	chr3:40499215	RPL14	-1.02	-10.48	-0.69	8.69e-19	Renal cell carcinoma;
TGCT	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg10802521	chr3:52805072	NEK4	-0.71	-8.79	-0.62	1.04e-14	Bipolar disorder;
TGCT	cis	rs950027	0.620	rs1153857	chr15:45659095	G/T	cg14582100	chr15:45693742	SPATA5L1	0.47	6.02	0.48	1.8e-8	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs7666738	0.830	rs10001701	chr4:98918871	G/C	cg17366294	chr4:99064904	C4orf37	0.71	7.25	0.55	3.96e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2028201	0.900	rs2289196	chr2:201305086	A/G	cg04781494	chr2:202047246	CASP10	0.24	4.51	0.38	1.46e-5	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
TGCT	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg06238570	chr21:40685208	BRWD1	0.62	5.42	0.44	2.97e-7	Cognitive function;
TGCT	cis	rs35146811	0.735	rs1727133	chr7:99812870	C/T	cg22906224	chr7:99728672	NA	-0.49	-4.45	-0.37	1.88e-5	Coronary artery disease;
TGCT	cis	rs2739330	0.615	rs2858911	chr22:24297195	G/T	cg10150615	chr22:24372951	LOC391322	-0.97	-12.67	-0.75	4.14e-24	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs617219	0.737	rs1275103	chr5:78448105	C/G	cg23987322	chr5:78407566	BHMT	0.36	4.82	0.4	4.19e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs6430585	0.646	rs12468768	chr2:136494985	C/T	cg07169764	chr2:136633963	MCM6	1.21	11.31	0.71	8.06e-21	Corneal structure;
TGCT	cis	rs7043114	0.507	rs10761154	chr9:95144086	A/G	cg14631576	chr9:95140430	CENPP	-0.27	-4.56	-0.38	1.22e-5	Height;
TGCT	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg25036284	chr2:26402008	FAM59B	-0.54	-4.7	-0.39	6.93e-6	Gut microbiome composition (summer);
TGCT	cis	rs453301	0.686	rs10217044	chr8:8894752	A/G	cg00184457	chr8:8946301	NA	-0.26	-4.94	-0.41	2.43e-6	Joint mobility (Beighton score);
TGCT	trans	rs28595532	0.557	rs7696047	chr4:119303024	G/A	cg26518628	chr1:97050305	NA	-0.53	-7.44	-0.56	1.48e-11	Cannabis dependence symptom count;
TGCT	cis	rs2204008	0.774	rs8189620	chr12:38241621	A/G	cg13010199	chr12:38710504	ALG10B	0.64	5.01	0.41	1.85e-6	Bladder cancer;
TGCT	cis	rs4478858	0.662	rs6425735	chr1:31783945	T/C	cg00250761	chr1:31883323	NA	-0.27	-4.94	-0.41	2.43e-6	Alcohol dependence;
TGCT	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg11494091	chr17:61959527	GH2	0.61	14.8	0.8	3.65e-29	Prudent dietary pattern;
TGCT	cis	rs9640161	0.789	rs28439010	chr7:150046276	C/T	cg17279839	chr7:150038598	RARRES2	0.43	4.64	0.38	8.89e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs13064411	0.542	rs2399477	chr3:113222998	A/G	cg18753928	chr3:113234510	CCDC52	-0.56	-4.72	-0.39	6.3e-6	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs7824557	0.614	rs10503421	chr8:11221313	C/T	cg21775007	chr8:11205619	TDH	0.72	6.59	0.51	1.11e-9	Retinal vascular caliber;
TGCT	cis	rs4839421	0.934	rs12046828	chr1:111017477	C/G	cg06880108	chr1:111021908	CYMP	0.18	5.42	0.44	2.96e-7	Response to bupropion in depression;
TGCT	trans	rs877282	0.947	rs957642	chr10:773966	C/T	cg22713356	chr15:30763199	NA	1.11	9.86	0.66	2.79e-17	Uric acid levels;
TGCT	cis	rs9733	0.519	rs1336899	chr1:150678910	T/C	cg04414720	chr1:150670196	GOLPH3L	0.37	4.91	0.4	2.76e-6	Tonsillectomy;
TGCT	cis	rs1483890	1.000	rs900671	chr3:69406527	C/A	cg22125112	chr3:69402811	FRMD4B	0.27	4.52	0.38	1.45e-5	Resting heart rate;
TGCT	cis	rs1371867	0.839	rs1660313	chr8:101332712	G/A	cg06636551	chr8:101224915	SPAG1	-0.48	-6.52	-0.51	1.62e-9	Atrioventricular conduction;
TGCT	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.34	0.55	2.43e-11	Prudent dietary pattern;
TGCT	cis	rs910316	0.967	rs35446981	chr14:75637351	A/T	cg08847533	chr14:75593920	NEK9	-0.92	-9.96	-0.67	1.6e-17	Height;
TGCT	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	4.48	0.37	1.66e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg22920501	chr2:26401640	FAM59B	0.81	6.36	0.5	3.52e-9	Gut microbiome composition (summer);
TGCT	cis	rs4808199	0.793	rs12459676	chr19:19425141	A/T	cg03709012	chr19:19516395	GATAD2A	0.77	5.36	0.43	3.99e-7	Nonalcoholic fatty liver disease;
TGCT	cis	rs6121246	0.559	rs10439607	chr20:30258541	G/A	cg10886678	chr20:30946050	ASXL1	-0.52	-4.44	-0.37	1.97e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.55	4.96	0.41	2.22e-6	Prudent dietary pattern;
TGCT	cis	rs6690583	0.623	rs55721024	chr1:85454447	A/C	cg20280350	chr1:85513789	MCOLN3	-0.74	-5.11	-0.42	1.2e-6	Serum sulfate level;
TGCT	cis	rs151997	1.000	rs27247	chr5:50232299	T/C	cg06027927	chr5:50259733	NA	-0.47	-4.86	-0.4	3.47e-6	Callous-unemotional behaviour;
TGCT	trans	rs7618501	0.699	rs1317154	chr3:49910084	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.9	9.84	0.66	3.04e-17	Intelligence (multi-trait analysis);
TGCT	cis	rs612683	0.824	rs17454919	chr1:100830370	A/G	cg06223162	chr1:101003688	GPR88	0.29	4.99	0.41	1.97e-6	Breast cancer;
TGCT	cis	rs10479542	0.701	rs10479541	chr5:178981003	G/C	cg11939631	chr5:178977406	RUFY1	0.48	4.58	0.38	1.1e-5	Lung cancer;
TGCT	cis	rs17384381	1.000	rs12129502	chr1:85900727	T/C	cg16011679	chr1:85725395	C1orf52	0.82	6.67	0.51	7.53e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg04267008	chr7:1944627	MAD1L1	-0.41	-5.45	-0.44	2.65e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs4820539	1.000	rs885965	chr22:23461425	A/G	cg21100191	chr22:23484243	RTDR1	0.95	11.16	0.71	1.87e-20	Bone mineral density;
TGCT	cis	rs7412746	0.611	rs7532045	chr1:150821847	G/A	cg04414720	chr1:150670196	GOLPH3L	0.38	4.62	0.38	9.47e-6	Melanoma;
TGCT	cis	rs7666738	0.830	rs62321569	chr4:98984250	T/A	cg18180107	chr4:99064573	C4orf37	0.55	5.07	0.41	1.43e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1971762	0.583	rs11170648	chr12:54089660	C/T	cg16917193	chr12:54089295	NA	1.34	17.42	0.84	4.03e-35	Height;
TGCT	cis	rs10883723	0.773	rs2296587	chr10:104245588	G/A	cg05855489	chr10:104503620	C10orf26	-0.54	-4.44	-0.37	1.99e-5	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs911263	0.961	rs8008961	chr14:68752643	A/G	cg18825221	chr14:68749962	RAD51L1	0.28	5.33	0.43	4.4e-7	Primary biliary cholangitis;
TGCT	cis	rs9995821	0.591	rs35148853	chr4:154819521	A/G	cg00381131	chr4:154073616	TRIM2	-0.66	-4.6	-0.38	1.02e-5	facial morphology traits (multivariate analysis);
TGCT	cis	rs9993613	0.875	rs60645723	chr4:73484862	G/A	cg15102770	chr4:73434591	ADAMTS3	0.52	4.89	0.4	3.12e-6	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs57920188	0.584	rs10915654	chr1:4091419	C/A	cg20703997	chr1:4087676	NA	0.49	5.75	0.46	6.45e-8	Interleukin-17 levels;
TGCT	cis	rs35883536	0.611	rs61070860	chr1:101097628	G/A	cg06223162	chr1:101003688	GPR88	0.32	5.34	0.43	4.31e-7	Monocyte count;
TGCT	cis	rs1371867	0.875	rs1619759	chr8:101337560	T/C	cg06636551	chr8:101224915	SPAG1	-0.49	-6.59	-0.51	1.12e-9	Atrioventricular conduction;
TGCT	cis	rs9300255	0.602	rs1727317	chr12:123618942	T/C	cg00376283	chr12:123451042	ABCB9	0.72	4.96	0.41	2.31e-6	Neutrophil percentage of white cells;
TGCT	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg17554472	chr22:41940697	POLR3H	-0.49	-5.27	-0.43	5.9e-7	Vitiligo;
TGCT	cis	rs4319547	0.656	rs10846664	chr12:122823777	C/T	cg08088222	chr12:122070432	ORAI1	-0.27	-4.77	-0.39	5.11e-6	Body mass index;
TGCT	cis	rs2243480	0.522	rs778717	chr7:65848151	G/C	cg20637647	chr7:64974828	NA	0.93	5.08	0.42	1.34e-6	Diabetic kidney disease;
TGCT	cis	rs12483853	1.000	rs12483853	chr22:40539525	G/C	cg07138101	chr22:40742427	ADSL	0.77	5.5	0.44	2.12e-7	Breast cancer;
TGCT	cis	rs889312	0.500	rs185219	chr5:56136492	A/G	cg24531977	chr5:56204891	C5orf35	-0.52	-5.39	-0.44	3.44e-7	Breast cancer;Breast cancer (early onset);
TGCT	cis	rs587847	0.737	rs4924156	chr15:37688630	G/A	cg00216138	chr15:37171175	LOC145845	0.31	4.5	0.37	1.52e-5	Intraocular pressure;
TGCT	cis	rs35146811	0.659	rs863450	chr7:99821685	C/T	cg22906224	chr7:99728672	NA	-0.5	-4.51	-0.38	1.48e-5	Coronary artery disease;
TGCT	cis	rs59107033	0.607	rs62262427	chr3:123125779	A/G	cg04890266	chr3:123102914	ADCY5	-0.37	-5.59	-0.45	1.39e-7	Lymphocyte counts;
TGCT	cis	rs4722166	0.695	rs7787893	chr7:22774437	A/G	cg26061582	chr7:22766209	IL6	0.55	7.08	0.54	9.23e-11	Lung cancer;
TGCT	cis	rs2836950	0.501	rs13047518	chr21:40707307	G/A	cg06238570	chr21:40685208	BRWD1	-0.64	-6.51	-0.5	1.71e-9	Menarche (age at onset);
TGCT	cis	rs11098499	0.908	rs28499576	chr4:120386677	G/A	cg09307838	chr4:120376055	NA	0.71	6.96	0.53	1.71e-10	Corneal astigmatism;
TGCT	cis	rs61884328	0.777	rs61897776	chr11:47133419	C/G	cg13308137	chr11:47528955	CUGBP1	0.38	4.47	0.37	1.76e-5	Total body bone mineral density (age over 60);
TGCT	cis	rs4727027	0.933	rs12540094	chr7:148847178	A/G	cg23583168	chr7:148888333	NA	0.77	9.82	0.66	3.39e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs10892173	0.566	rs10892175	chr11:117674355	G/A	cg07621104	chr11:117668040	DSCAML1	0.74	8.12	0.59	3.98e-13	Myopia;
TGCT	trans	rs901683	0.702	rs73292848	chr10:46169752	T/C	cg24926042	chr12:52799999	KRT82	-0.61	-6.62	-0.51	9.55e-10	Red blood cell traits;Mean corpuscular volume;
TGCT	cis	rs12142240	0.698	rs10158130	chr1:46822600	T/C	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs6840360	0.642	rs2724571	chr4:152376795	T/C	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.83e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg12963246	chr6:28129442	ZNF389	0.52	5.1	0.42	1.23e-6	Depression;
TGCT	cis	rs644799	0.965	rs2950522	chr11:95524719	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	8.74	0.62	1.39e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7119038	0.818	rs7942535	chr11:118681464	C/T	cg19308663	chr11:118741387	NA	-0.28	-5.74	-0.46	6.95e-8	Sjögren's syndrome;
TGCT	cis	rs9457247	1.000	rs405553	chr6:167395058	A/G	cg23791538	chr6:167370224	RNASET2	-0.5	-4.98	-0.41	2.08e-6	Crohn's disease;
TGCT	cis	rs2777491	0.957	rs16971798	chr15:41657144	A/T	cg18705301	chr15:41695430	NDUFAF1	0.72	10.08	0.67	8.2e-18	Ulcerative colitis;
TGCT	cis	rs7666738	0.830	rs13130923	chr4:99046281	T/C	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.26e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg12419862	chr22:24373484	LOC391322	-0.84	-9.42	-0.65	3.27e-16	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs5769707	0.935	rs1109320	chr22:49989106	G/A	cg05373962	chr22:49881684	NA	-0.3	-6.11	-0.48	1.17e-8	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-8.64	-0.61	2.39e-14	Platelet count;
TGCT	cis	rs12210905	0.688	rs72845012	chr6:27501986	C/A	cg08851530	chr6:28072375	NA	1.34	6.29	0.49	5.02e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg15242686	chr22:24348715	GSTTP1	0.44	6.09	0.48	1.3e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9383153	1.000	rs9370887	chr6:16329258	G/C	cg23850913	chr6:15505452	JARID2	0.85	4.68	0.39	7.32e-6	Gambling;
TGCT	cis	rs748404	0.660	rs690512	chr15:43717678	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	4.75	0.39	5.51e-6	Lung cancer;
TGCT	cis	rs763014	0.966	rs7198877	chr16:661439	A/G	cg09263875	chr16:632152	PIGQ	0.31	6.76	0.52	4.93e-10	Height;
TGCT	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg10150615	chr22:24372951	LOC391322	-1.0	-13.02	-0.76	5.83e-25	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs732765	0.734	rs12891243	chr14:75208656	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.56	-4.87	-0.4	3.28e-6	Non-small cell lung cancer;
TGCT	cis	rs7830933	0.955	rs7835797	chr8:23597020	A/G	cg04349084	chr8:23602677	NA	0.24	4.88	0.4	3.24e-6	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
TGCT	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.81	7.17	0.54	5.96e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs1129187	0.702	rs2296805	chr6:42928758	T/G	cg27588902	chr6:42928151	GNMT	-0.59	-7.2	-0.54	5.01e-11	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs2797160	0.522	rs6925158	chr6:125940188	T/G	cg05901451	chr6:126070800	HEY2	-0.64	-5.37	-0.43	3.67e-7	Endometrial cancer;
TGCT	cis	rs9325144	0.647	rs11168819	chr12:39011082	C/A	cg26384229	chr12:38710491	ALG10B	-0.58	-5.49	-0.44	2.16e-7	Morning vs. evening chronotype;
TGCT	cis	rs1153858	1.000	rs1153849	chr15:45695695	G/A	cg26924012	chr15:45694286	SPATA5L1	0.99	12.38	0.74	2.11e-23	Homoarginine levels;
TGCT	cis	rs10782582	0.522	rs12125933	chr1:76130920	C/T	cg22875332	chr1:76189707	ACADM	-0.55	-6.27	-0.49	5.53e-9	Daytime sleep phenotypes;
TGCT	cis	rs12478296	1.000	rs55758933	chr2:243040289	T/C	cg06360820	chr2:242988706	NA	-0.61	-4.66	-0.39	8.13e-6	Obesity-related traits;
TGCT	cis	rs9914544	0.545	rs9898426	chr17:18794071	A/G	cg26378065	chr17:18585709	ZNF286B	0.53	4.63	0.38	9.01e-6	Educational attainment (years of education);
TGCT	cis	rs12477438	0.798	rs6716913	chr2:99580641	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-6.25	-0.49	5.98e-9	Chronic sinus infection;
TGCT	cis	rs2153535	0.580	rs6941771	chr6:8494452	T/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs62244186	0.715	rs13321717	chr3:44667455	C/A	cg15687855	chr3:44754131	ZNF502	-0.46	-5.56	-0.45	1.58e-7	Depressive symptoms;
TGCT	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg06238570	chr21:40685208	BRWD1	0.75	7.06	0.54	1.07e-10	Cognitive function;
TGCT	cis	rs8072100	0.738	rs9915222	chr17:45448615	G/T	cg08085267	chr17:45401833	C17orf57	-0.51	-5.6	-0.45	1.3e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs2544523	0.511	rs2544535	chr2:15906778	A/G	cg26669897	chr2:15909070	NA	0.38	5.06	0.41	1.48e-6	Asthma or chronic obstructive pulmonary disease;
TGCT	cis	rs28595532	0.920	rs116305850	chr4:119779892	A/G	cg11846333	chr4:119757529	SEC24D	0.92	4.64	0.38	8.74e-6	Cannabis dependence symptom count;
TGCT	cis	rs611744	0.967	rs673015	chr8:109191669	C/T	cg21045802	chr8:109455806	TTC35	0.5	4.62	0.38	9.35e-6	Dupuytren's disease;
TGCT	cis	rs12497850	0.931	rs13064911	chr3:48952385	A/G	cg07636037	chr3:49044803	WDR6	0.94	10.39	0.68	1.46e-18	Parkinson's disease;
TGCT	cis	rs2153535	0.580	rs9379216	chr6:8481235	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs881375	0.933	rs4837799	chr9:123668326	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	4.94	0.41	2.44e-6	Rheumatoid arthritis;
TGCT	trans	rs12599106	0.629	rs1391904	chr16:34548934	C/T	cg11235426	chr6:292522	DUSP22	-0.66	-6.87	-0.53	2.76e-10	Menopause (age at onset);
TGCT	trans	rs8073060	0.586	rs7213804	chr17:34010931	T/G	cg19694781	chr19:47549865	TMEM160	-0.6	-13.37	-0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	trans	rs12655019	0.920	rs1466007	chr5:56213639	A/C	cg25190722	chr1:3801660	DFFB	0.62	7.17	0.54	5.87e-11	Breast cancer (early onset);
TGCT	cis	rs9486715	0.929	rs7775721	chr6:97056979	C/T	cg18709589	chr6:96969512	KIAA0776	-0.87	-8.44	-0.6	7.09e-14	Headache;
TGCT	cis	rs4631830	0.965	rs4306255	chr10:51542444	A/G	cg10326726	chr10:51549505	MSMB	-0.25	-4.94	-0.41	2.52e-6	Prostate-specific antigen levels;
TGCT	cis	rs7914558	0.901	rs35525740	chr10:104941112	A/T	cg04362960	chr10:104952993	NT5C2	0.61	5.45	0.44	2.6e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs2115630	0.967	rs10438428	chr15:85330745	C/T	cg11189052	chr15:85197271	WDR73	-0.63	-6.19	-0.49	8.12e-9	P wave terminal force;
TGCT	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg14893161	chr1:205819251	PM20D1	0.68	11.2	0.71	1.56e-20	Menarche (age at onset);
TGCT	cis	rs66573146	1.000	rs7686186	chr4:6986094	C/T	cg01220768	chr4:7056774	TADA2B	0.39	4.91	0.4	2.77e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs28595532	0.920	rs115530096	chr4:119760512	T/G	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs907683	0.635	rs11691617	chr2:220295167	C/T	cg15015639	chr2:220282977	DES	0.37	4.72	0.39	6.3e-6	Resting heart rate;
TGCT	cis	rs514406	0.861	rs35581164	chr1:53271373	C/G	cg22166914	chr1:53195759	ZYG11B	0.41	7.23	0.54	4.29e-11	Monocyte count;
TGCT	cis	rs7772486	0.754	rs697053	chr6:145989807	T/C	cg13319975	chr6:146136371	FBXO30	0.56	5.03	0.41	1.7e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs12762955	0.561	rs1904671	chr10:1014603	G/A	cg20503657	chr10:835505	NA	-0.39	-5.04	-0.41	1.58e-6	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs2180341	0.855	rs9385422	chr6:127716457	C/T	cg27446573	chr6:127587934	RNF146	0.92	8.5	0.61	5.15e-14	Breast cancer;
TGCT	cis	rs12711979	0.509	rs10195488	chr2:3824135	T/C	cg17052675	chr2:3827356	NA	-0.55	-12.73	-0.75	2.94e-24	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs7178572	0.568	rs12916731	chr15:77507021	C/T	cg15453836	chr15:77711506	NA	-0.43	-4.82	-0.4	4.12e-6	Type 2 diabetes;
TGCT	cis	rs9814567	0.722	rs13083717	chr3:134348796	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.74	5.4	0.44	3.22e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg06896619	chr17:61851486	DDX42;CCDC47	0.51	4.96	0.41	2.24e-6	Prudent dietary pattern;
TGCT	cis	rs9914988	0.887	rs12948575	chr17:27130520	G/A	cg20469991	chr17:27169893	C17orf63	-0.72	-5.09	-0.42	1.29e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg20607798	chr8:58055168	NA	0.57	4.57	0.38	1.19e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs793571	0.544	rs1427282	chr15:58914326	C/T	cg05156742	chr15:59063176	FAM63B	0.56	5.31	0.43	4.95e-7	Schizophrenia;
TGCT	cis	rs36051895	0.664	rs3780373	chr9:5098223	T/C	cg02405213	chr9:5042618	JAK2	-0.76	-10.67	-0.69	3.05e-19	Pediatric autoimmune diseases;
TGCT	cis	rs17152411	1.000	rs733402	chr10:126594152	T/C	cg07906193	chr10:126599966	NA	0.42	5.28	0.43	5.6e-7	Height;
TGCT	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg15242686	chr22:24348715	GSTTP1	0.43	5.78	0.46	5.8e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs4824093	0.610	rs7410534	chr22:50289925	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.5	5.17	0.42	9.25e-7	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg16325326	chr1:53192061	ZYG11B	0.61	6.79	0.52	4.18e-10	Monocyte count;
TGCT	cis	rs9549260	0.709	rs9549247	chr13:41220777	G/C	cg21288729	chr13:41239152	FOXO1	0.99	10.42	0.68	1.22e-18	Red blood cell count;
TGCT	cis	rs548181	0.611	rs1293672	chr11:125461034	A/G	cg03464685	chr11:125439445	EI24	1.37	9.3	0.64	6.08e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs4654899	0.802	rs10493004	chr1:21442736	T/C	cg01072550	chr1:21505969	NA	-0.47	-7.02	-0.53	1.27e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs9660992	0.674	rs1151784	chr1:205232447	C/T	cg00857998	chr1:205179979	DSTYK	0.52	4.56	0.38	1.19e-5	Mean corpuscular volume;Mean platelet volume;
TGCT	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg04772025	chr11:68637568	NA	0.62	6.89	0.53	2.52e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg08859206	chr1:53392774	SCP2	-0.41	-6.39	-0.5	3.01e-9	Monocyte count;
TGCT	cis	rs10193935	0.901	rs59984817	chr2:42566909	C/G	cg27598129	chr2:42591480	NA	-0.41	-5.66	-0.45	1e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10197940	0.578	rs2444264	chr2:152310928	G/T	cg19508488	chr2:152266495	RIF1	-0.51	-4.47	-0.37	1.74e-5	Lung cancer;
TGCT	trans	rs28735056	0.967	rs4799092	chr18:77608203	C/G	cg05926928	chr17:57297772	GDPD1	-0.71	-7.57	-0.56	7.48e-12	Schizophrenia;
TGCT	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.51	-4.82	-0.4	4.16e-6	Bipolar disorder;
TGCT	cis	rs7714584	1.000	rs11741861	chr5:150277909	C/T	cg22134413	chr5:150180641	NA	-1.14	-8.32	-0.6	1.33e-13	Crohn's disease;
TGCT	cis	rs707040	0.881	rs7575231	chr2:155228406	G/A	cg18104148	chr2:154337490	NA	0.19	4.63	0.38	9.05e-6	Sudden cardiac arrest;
TGCT	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg18538332	chr22:24372958	LOC391322	-1.01	-12.77	-0.75	2.33e-24	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs4252435	0.614	rs4252417	chr7:142625258	G/A	cg09833174	chr7:143059591	FAM131B	-1.04	-4.97	-0.41	2.17e-6	Cancer;
TGCT	cis	rs1371867	0.846	rs1660349	chr8:101319326	G/A	cg06002616	chr8:101225028	SPAG1	-0.56	-6.58	-0.51	1.2e-9	Atrioventricular conduction;
TGCT	cis	rs9611565	0.918	rs4820438	chr22:41767135	C/T	cg13695892	chr22:41940480	POLR3H	-0.86	-8.08	-0.59	4.85e-13	Vitiligo;
TGCT	cis	rs77140172	0.677	rs28435799	chr4:89617931	G/A	cg01026744	chr4:89619053	NAP1L5;HERC3	1.28	5.48	0.44	2.32e-7	Post bronchodilator FEV1;
TGCT	cis	rs11578119	0.902	rs12138138	chr1:170420921	C/T	cg09767346	chr1:170501363	GORAB	0.71	5.65	0.45	1.04e-7	Male-pattern baldness;
TGCT	cis	rs477895	1.000	rs477895	chr11:64048912	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.66	-5.08	-0.41	1.37e-6	Mean platelet volume;
TGCT	trans	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.86	9.4	0.65	3.49e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs7100689	0.646	rs1538815	chr10:82137670	A/G	cg01528321	chr10:82214614	TSPAN14	0.8	7.72	0.57	3.42e-12	Post bronchodilator FEV1;
TGCT	cis	rs7833790	0.963	rs1451997	chr8:82774053	A/T	cg27398817	chr8:82754497	SNX16	0.84	6.3	0.49	4.81e-9	Diastolic blood pressure;
TGCT	cis	rs6704768	0.545	rs5004510	chr2:233679275	A/C	cg08000102	chr2:233561755	GIGYF2	-0.69	-7.77	-0.57	2.62e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs950169	0.580	rs36126054	chr15:85177723	T/G	cg12863693	chr15:85201151	NMB	0.46	5.56	0.45	1.6e-7	Schizophrenia;
TGCT	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg08859206	chr1:53392774	SCP2	-0.44	-6.85	-0.52	3.1e-10	Monocyte count;
TGCT	cis	rs344364	0.511	rs12599337	chr16:1946751	A/G	cg26617929	chr16:1858877	NA	0.28	4.98	0.41	2.11e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs7829975	0.502	rs7820738	chr8:8702607	C/G	cg06636001	chr8:8085503	FLJ10661	-0.74	-7.09	-0.54	9.14e-11	Mood instability;
TGCT	cis	rs9611565	0.722	rs202635	chr22:41809637	C/T	cg03806693	chr22:41940476	POLR3H	1.01	11.44	0.72	3.94e-21	Vitiligo;
TGCT	cis	rs394563	0.717	rs548848	chr6:149782009	A/G	cg16235748	chr6:149772707	ZC3H12D	-0.42	-4.67	-0.39	7.79e-6	Dupuytren's disease;
TGCT	cis	rs854765	0.693	rs4924822	chr17:17748013	A/G	cg04398451	chr17:18023971	MYO15A	0.31	4.66	0.39	7.97e-6	Total body bone mineral density;
TGCT	cis	rs2836974	0.544	rs8128919	chr21:40711862	C/T	cg11890956	chr21:40555474	PSMG1	0.78	7.85	0.58	1.65e-12	Cognitive function;
TGCT	cis	rs1062177	1.000	rs2915887	chr5:151205504	C/T	cg00977110	chr5:151150581	G3BP1	0.4	4.52	0.38	1.4e-5	Preschool internalizing problems;
TGCT	cis	rs7772486	0.754	rs9373475	chr6:146126419	C/T	cg23711669	chr6:146136114	FBXO30	0.94	10.68	0.69	2.77e-19	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6088590	0.561	rs6059918	chr20:33150503	C/T	cg08999081	chr20:33150536	PIGU	0.28	5.42	0.44	3.02e-7	Coronary artery disease;
TGCT	cis	rs704	0.628	rs2239911	chr17:26723613	G/T	cg10342447	chr17:26645325	TMEM97	-0.45	-4.46	-0.37	1.8e-5	Osteoprotegerin levels;
TGCT	cis	rs2153535	0.504	rs9405393	chr6:8467432	G/T	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg06618935	chr21:46677482	NA	-0.36	-5.61	-0.45	1.25e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs6570726	0.846	rs1935616	chr6:145943512	C/T	cg05347473	chr6:146136440	FBXO30	0.48	4.53	0.38	1.38e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9653442	0.576	rs6542921	chr2:100864498	C/A	cg22139774	chr2:100720529	AFF3	-0.39	-6.4	-0.5	2.93e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs3849570	0.615	rs35779564	chr3:81982771	G/A	cg07356753	chr3:81810745	GBE1	-0.69	-6.36	-0.5	3.55e-9	Waist circumference;Body mass index;
TGCT	cis	rs858239	0.698	rs4265084	chr7:23407240	G/C	cg05602783	chr7:23145260	KLHL7	-0.71	-5.95	-0.47	2.53e-8	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs3087591	0.821	rs12949024	chr17:29445086	A/T	cg24425628	chr17:29625626	OMG;NF1	0.49	7.37	0.55	2.15e-11	Hip circumference;
TGCT	cis	rs7089973	0.624	rs10885614	chr10:116609098	C/T	cg03647239	chr10:116582469	FAM160B1	0.59	5.74	0.46	6.72e-8	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs709400	0.663	rs3742458	chr14:103950368	A/G	cg26031613	chr14:104095156	KLC1	0.84	9.5	0.65	2.08e-16	Body mass index;
TGCT	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg09436375	chr6:42928200	GNMT	-0.4	-5.19	-0.42	8.34e-7	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs10779751	0.770	rs1148480	chr1:11172006	A/G	cg08854313	chr1:11322531	MTOR	0.83	8.02	0.58	6.7e-13	Body mass index;
TGCT	cis	rs9583531	0.600	rs4773240	chr13:111360585	G/A	cg24331049	chr13:111365604	ING1	0.76	7.31	0.55	2.95e-11	Coronary artery disease;
TGCT	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg06481639	chr22:41940642	POLR3H	-0.61	-5.49	-0.44	2.17e-7	Vitiligo;
TGCT	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg07298985	chr8:22133076	PIWIL2	0.33	5.32	0.43	4.73e-7	Hypertriglyceridemia;
TGCT	cis	rs7714584	1.000	rs73282209	chr5:150174959	G/A	cg22134413	chr5:150180641	NA	1.17	8.69	0.62	1.76e-14	Crohn's disease;
TGCT	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg06640241	chr16:89574553	SPG7	0.73	7.86	0.58	1.61e-12	Multiple myeloma (IgH translocation);
TGCT	cis	rs9611565	0.918	rs28638318	chr22:41753059	G/A	cg06481639	chr22:41940642	POLR3H	-0.72	-6.33	-0.49	4.05e-9	Vitiligo;
TGCT	cis	rs7647973	0.626	rs4855833	chr3:49657441	A/G	cg03034192	chr3:50606346	HEMK1;C3orf18	0.36	4.75	0.39	5.61e-6	Menarche (age at onset);
TGCT	cis	rs35160687	0.842	rs1863051	chr2:86559148	A/C	cg03171300	chr2:86307199	POLR1A	0.26	4.57	0.38	1.14e-5	Night sleep phenotypes;
TGCT	cis	rs6964587	0.869	rs4729010	chr7:91486751	G/A	cg17063962	chr7:91808500	NA	-0.85	-9.05	-0.63	2.54e-15	Breast cancer;
TGCT	cis	rs9894429	0.869	rs9748184	chr17:79596280	A/G	cg18240062	chr17:79603768	NPLOC4	0.69	7.22	0.54	4.67e-11	Eye color traits;
TGCT	cis	rs9486719	0.947	rs12194971	chr6:96911073	T/C	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.77	-0.62	1.18e-14	Migraine;Coronary artery disease;
TGCT	cis	rs6740322	0.748	rs6720087	chr2:43468745	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.4	6.1	0.48	1.25e-8	Coronary artery disease;
TGCT	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg13770153	chr20:60521292	NA	-0.47	-5.99	-0.47	2.13e-8	Body mass index;
TGCT	cis	rs17376456	0.877	rs17316137	chr5:93456577	C/T	cg25358565	chr5:93447407	FAM172A	0.92	8.38	0.6	9.58e-14	Diabetic retinopathy;
TGCT	cis	rs7586879	0.639	rs2033656	chr2:25100902	C/G	cg01884057	chr2:25150051	NA	0.33	6.31	0.49	4.6e-9	Body mass index;
TGCT	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg23982607	chr1:1823379	GNB1	-0.55	-8.48	-0.61	5.58e-14	Body mass index;
TGCT	cis	rs10782582	0.609	rs5745347	chr1:76274520	C/T	cg10523679	chr1:76189770	ACADM	0.57	5.29	0.43	5.27e-7	Daytime sleep phenotypes;
TGCT	cis	rs11122272	0.735	rs2808597	chr1:231532351	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-6.53	-0.51	1.55e-9	Hemoglobin concentration;
TGCT	cis	rs7715806	0.500	rs2291630	chr5:75013356	G/A	cg19683494	chr5:74908142	NA	0.56	4.86	0.4	3.41e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs3858526	0.651	rs10838713	chr11:5858434	T/C	cg13902645	chr11:5959945	NA	-0.42	-4.57	-0.38	1.18e-5	DNA methylation (variation);
TGCT	trans	rs28595532	0.623	rs56324414	chr4:119274655	A/C	cg26518628	chr1:97050305	NA	-0.6	-7.07	-0.54	1.01e-10	Cannabis dependence symptom count;
TGCT	cis	rs3008870	1.000	rs12740884	chr1:67459855	C/A	cg11518657	chr1:67396239	MIER1	-0.54	-4.61	-0.38	9.72e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs1903068	0.819	rs10517343	chr4:56002267	T/A	cg16572876	chr4:56024045	NA	0.43	4.94	0.41	2.43e-6	Endometriosis;
TGCT	cis	rs7760949	0.963	rs1571565	chr6:13907185	A/G	cg27413430	chr6:13925136	RNF182	0.5	4.71	0.39	6.62e-6	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs17331151	0.541	rs4687676	chr3:52890418	C/T	cg15956490	chr3:53032818	SFMBT1	-0.46	-5.65	-0.45	1.05e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs394563	0.589	rs1900300	chr6:149641627	T/C	cg16235748	chr6:149772707	ZC3H12D	0.43	4.98	0.41	2.05e-6	Dupuytren's disease;
TGCT	cis	rs61935443	0.720	rs11107776	chr12:95294283	T/G	cg21533806	chr12:95267307	NA	0.54	4.67	0.39	7.66e-6	Schizophrenia;
TGCT	cis	rs7666738	0.546	rs2098935	chr4:98914376	A/G	cg17366294	chr4:99064904	C4orf37	0.64	5.88	0.47	3.54e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs367943	0.644	rs348942	chr5:112824039	T/C	cg12552261	chr5:112820674	MCC	-0.23	-4.68	-0.39	7.45e-6	Type 2 diabetes;
TGCT	cis	rs4711350	1.000	rs4711350	chr6:33741716	A/G	cg13859433	chr6:33739653	LEMD2	-0.31	-4.5	-0.37	1.52e-5	Schizophrenia;
TGCT	trans	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg21659725	chr3:3221576	CRBN	-0.73	-8.48	-0.61	5.64e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs28735056	0.592	rs12455965	chr18:77688830	G/C	cg20368463	chr18:77673604	PQLC1	-0.47	-5.52	-0.44	1.86e-7	Schizophrenia;
TGCT	cis	rs7727544	0.716	rs7720230	chr5:131592405	T/G	cg24060327	chr5:131705240	SLC22A5	-0.56	-5.45	-0.44	2.62e-7	Blood metabolite levels;
TGCT	cis	rs7582180	0.676	rs11680660	chr2:100931738	G/C	cg08017756	chr2:100939284	LONRF2	-0.3	-4.98	-0.41	2.11e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs36051895	0.659	rs72701605	chr9:5062056	G/A	cg02405213	chr9:5042618	JAK2	-0.73	-9.89	-0.66	2.38e-17	Pediatric autoimmune diseases;
TGCT	cis	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg20637647	chr7:64974828	NA	-0.95	-5.3	-0.43	5.09e-7	Diabetic kidney disease;
TGCT	cis	rs921968	0.541	rs561570	chr2:219379348	T/A	cg02176678	chr2:219576539	TTLL4	0.48	6.78	0.52	4.32e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs523522	0.962	rs10849759	chr12:120994488	T/A	cg27279351	chr12:120934652	DYNLL1	0.74	6.46	0.5	2.19e-9	High light scatter reticulocyte count;
TGCT	cis	rs3096299	0.967	rs2965827	chr16:89457350	A/C	cg02187348	chr16:89574699	SPG7	-0.49	-4.53	-0.38	1.36e-5	Multiple myeloma (IgH translocation);
TGCT	cis	rs7568458	0.905	rs10187424	chr2:85794297	T/C	cg17127132	chr2:85788382	GGCX	0.73	6.97	0.53	1.64e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs6121246	0.567	rs6060295	chr20:30198473	C/T	cg13852791	chr20:30311386	BCL2L1	0.7	4.58	0.38	1.1e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs1982963	0.639	rs2749875	chr14:52503396	G/A	cg10843707	chr14:52510701	NID2	-0.36	-7.22	-0.54	4.54e-11	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1150668	0.799	rs1150707	chr6:28197605	C/T	cg11262757	chr6:27280423	POM121L2	0.45	4.44	0.37	1.94e-5	Pubertal anthropometrics;
TGCT	cis	rs4727027	0.870	rs11524138	chr7:148799125	G/A	cg23583168	chr7:148888333	NA	-0.72	-9.11	-0.63	1.8e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs2549003	1.000	rs2549009	chr5:131826765	T/C	cg21138405	chr5:131827807	IRF1	-0.18	-4.46	-0.37	1.82e-5	Asthma (sex interaction);
TGCT	cis	rs4664308	0.875	rs60908067	chr2:161004983	T/G	cg03641300	chr2:160917029	PLA2R1	-0.27	-6.74	-0.52	5.42e-10	Idiopathic membranous nephropathy;
TGCT	cis	rs62380364	0.602	rs11743441	chr5:88065637	G/T	cg22951263	chr5:87985283	NA	-0.6	-6.35	-0.5	3.73e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs2303745	0.589	rs1864115	chr19:17393327	G/C	cg02221750	chr19:17393354	ANKLE1	-0.48	-6.27	-0.49	5.46e-9	Systemic lupus erythematosus;
TGCT	trans	rs57221529	0.664	rs72704802	chr5:554211	C/T	cg11887960	chr12:57824829	NA	1.12	8.84	0.62	7.84e-15	Lung disease severity in cystic fibrosis;
TGCT	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs2204008	0.837	rs12369089	chr12:38060263	G/A	cg13010199	chr12:38710504	ALG10B	0.65	5.29	0.43	5.47e-7	Bladder cancer;
TGCT	cis	rs11190604	1.000	rs9420797	chr10:102331147	C/T	cg23241863	chr10:102295624	HIF1AN	0.69	5.21	0.42	7.71e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs7605378	0.528	rs812760	chr2:200724372	C/T	cg19045956	chr2:200819837	C2orf60;C2orf47	0.55	5.88	0.47	3.6e-8	Osteoporosis;
TGCT	cis	rs7246657	0.722	rs2927739	chr19:38149330	C/A	cg03611452	chr19:38183253	ZNF781	-0.57	-4.79	-0.39	4.72e-6	Coronary artery calcification;
TGCT	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg17971929	chr21:40555470	PSMG1	0.98	9.49	0.65	2.19e-16	Cognitive function;
TGCT	cis	rs17433780	0.836	rs17434342	chr1:89505742	C/G	cg09516651	chr1:89888402	LOC400759	-0.25	-4.66	-0.39	8.01e-6	Carotid intima media thickness;
TGCT	cis	rs4383453	0.510	rs16834219	chr3:123099470	A/G	cg04890266	chr3:123102914	ADCY5	-0.5	-8.34	-0.6	1.2e-13	Gestational age at birth (maternal effect);
TGCT	cis	rs9297145	0.678	rs62473051	chr7:98781955	C/T	cg05967295	chr7:98741636	SMURF1	0.99	12.22	0.74	4.99e-23	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs7582180	0.764	rs11682748	chr2:100925934	C/A	cg14675211	chr2:100938903	LONRF2	0.49	4.8	0.4	4.49e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7917772	0.582	rs3936017	chr10:104354424	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	5.36	0.43	3.84e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1348850	0.567	rs3770009	chr2:178536544	C/T	cg22681709	chr2:178499509	PDE11A	-0.46	-5.73	-0.46	7.14e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs78545713	1.000	rs77281308	chr6:26250029	C/T	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.71	-4.68	-0.39	7.39e-6	Iron status biomarkers (total iron binding capacity);
TGCT	cis	rs7020830	0.825	rs7036132	chr9:37317241	A/G	cg14294708	chr9:37120828	ZCCHC7	1.27	17.5	0.84	2.7e-35	Schizophrenia;
TGCT	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg08048268	chr3:133502702	NA	-0.66	-9.83	-0.66	3.36e-17	Iron status biomarkers;
TGCT	cis	rs7714584	1.000	rs60134818	chr5:150261043	A/G	cg22134413	chr5:150180641	NA	0.78	6.12	0.48	1.16e-8	Crohn's disease;
TGCT	trans	rs10506458	0.915	rs2013042	chr12:63394211	A/G	cg22491629	chr6:157744540	C6orf35	-0.96	-8.31	-0.6	1.42e-13	Hemostatic factors and hematological phenotypes;
TGCT	trans	rs1496653	0.602	rs71322202	chr3:23623852	G/A	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs5769707	0.872	rs5770604	chr22:50030672	G/A	cg20744362	chr22:50050164	C22orf34	0.29	4.61	0.38	9.85e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs13217239	0.646	rs10946897	chr6:26995251	A/C	cg15659132	chr6:26577336	NA	0.54	5.44	0.44	2.78e-7	Schizophrenia;
TGCT	cis	rs11249608	0.548	rs12152869	chr5:178462520	A/G	cg01312482	chr5:178451176	ZNF879	-0.49	-4.83	-0.4	3.96e-6	Pubertal anthropometrics;
TGCT	cis	rs9911578	0.835	rs9303398	chr17:56484257	T/C	cg12560992	chr17:57184187	TRIM37	-0.78	-9.12	-0.63	1.72e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg02038168	chr22:39784481	NA	-0.7	-5.72	-0.46	7.48e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs17253792	0.822	rs76612185	chr14:56037706	T/C	cg01858014	chr14:56050164	KTN1	-0.36	-4.57	-0.38	1.15e-5	Putamen volume;
TGCT	cis	rs7412746	0.658	rs2864869	chr1:150734655	G/A	cg09365446	chr1:150670422	GOLPH3L	0.35	5.08	0.42	1.33e-6	Melanoma;
TGCT	trans	rs561341	0.882	rs16967101	chr17:30377162	A/G	cg20587970	chr11:113659929	NA	-0.96	-12.55	-0.75	7.96e-24	Hip circumference adjusted for BMI;
TGCT	cis	rs1401999	1.000	rs1533684	chr3:183635815	A/G	cg01324343	chr3:183735012	ABCC5	0.85	11.47	0.72	3.33e-21	Anterior chamber depth;
TGCT	cis	rs6095298	0.574	rs67843835	chr20:47453760	G/A	cg12307787	chr20:48099359	KCNB1	0.42	4.51	0.38	1.51e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs13101352	chr4:98957544	C/T	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs394563	0.591	rs237028	chr6:149718650	C/T	cg03678062	chr6:149772716	ZC3H12D	-0.38	-4.74	-0.39	5.87e-6	Dupuytren's disease;
TGCT	cis	rs3772130	0.962	rs13433692	chr3:121484714	G/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.72	0.39	6.25e-6	Cognitive performance;
TGCT	cis	rs3849570	0.961	rs3772912	chr3:81698481	A/G	cg07356753	chr3:81810745	GBE1	-0.69	-6.02	-0.48	1.81e-8	Waist circumference;Body mass index;
TGCT	cis	rs7769051	1.000	rs7769051	chr6:133146796	G/T	cg22852734	chr6:133119734	C6orf192	1.29	7.34	0.55	2.44e-11	Type 2 diabetes nephropathy;
TGCT	trans	rs11250098	0.583	rs73196860	chr8:10814133	A/G	cg06636001	chr8:8085503	FLJ10661	-0.81	-7.26	-0.55	3.71e-11	Morning vs. evening chronotype;
TGCT	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg18876405	chr7:65276391	NA	0.38	5.89	0.47	3.4e-8	Calcium levels;
TGCT	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.47	-6.69	-0.51	7.01e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg07424592	chr7:64974309	NA	1.36	8.08	0.59	4.97e-13	Diabetic kidney disease;
TGCT	cis	rs9913156	0.793	rs72835643	chr17:4573612	G/A	cg23387401	chr17:4582204	PELP1	0.32	4.7	0.39	6.8e-6	Lymphocyte counts;
TGCT	cis	rs6460942	0.841	rs6968277	chr7:12443795	C/A	cg06484146	chr7:12443880	VWDE	-0.54	-5.76	-0.46	6.25e-8	Coronary artery disease;
TGCT	cis	rs765787	0.530	rs2554456	chr15:45521138	A/C	cg24006582	chr15:45444508	DUOX1	-0.25	-5.45	-0.44	2.66e-7	Uric acid levels;
TGCT	cis	rs6540559	0.673	rs17015224	chr1:209968918	G/A	cg22029157	chr1:209979665	IRF6	0.74	5.53	0.44	1.84e-7	Cleft lip with or without cleft palate;
TGCT	trans	rs13064411	0.542	rs4396864	chr3:113212562	C/T	cg00307254	chr3:126706825	PLXNA1	0.34	6.72	0.52	5.79e-10	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs7677751	0.767	rs6832597	chr4:55076237	C/A	cg17187183	chr4:55093834	PDGFRA	0.47	6.33	0.49	4.12e-9	Corneal astigmatism;
TGCT	cis	rs12893668	0.543	rs1799796	chr14:104165927	T/C	cg26031613	chr14:104095156	KLC1	-0.59	-5.0	-0.41	1.94e-6	Reticulocyte count;
TGCT	cis	rs2404602	0.735	rs11857327	chr15:76764263	G/C	cg22467129	chr15:76604101	ETFA	0.48	5.11	0.42	1.16e-6	Blood metabolite levels;
TGCT	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg17554472	chr22:41940697	POLR3H	-0.49	-5.27	-0.43	5.9e-7	Vitiligo;
TGCT	cis	rs35883536	0.631	rs2783704	chr1:101040652	T/A	cg10298815	chr1:101004474	GPR88	0.24	4.51	0.38	1.47e-5	Monocyte count;
TGCT	cis	rs9549260	0.753	rs9532578	chr13:41236407	G/A	cg21288729	chr13:41239152	FOXO1	0.68	4.75	0.39	5.58e-6	Red blood cell count;
TGCT	cis	rs9921338	0.887	rs9926136	chr16:11437275	A/G	cg00044050	chr16:11439710	C16orf75	-0.87	-6.68	-0.51	7.32e-10	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs9942416	0.660	rs17563863	chr5:74998334	G/A	cg02573091	chr5:74908125	NA	0.38	4.51	0.38	1.47e-5	Age-related disease endophenotypes;
TGCT	cis	rs12142240	0.698	rs6429599	chr1:46827871	G/A	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs35883536	0.647	rs2809795	chr1:101038345	A/G	cg06223162	chr1:101003688	GPR88	0.43	8.24	0.59	2.07e-13	Monocyte count;
TGCT	cis	rs2841277	0.509	rs11850949	chr14:105408827	A/C	cg19901468	chr14:105411992	AHNAK2	-0.27	-5.57	-0.45	1.53e-7	Rheumatoid arthritis;
TGCT	cis	rs12136530	0.593	rs12121242	chr1:19740609	G/C	cg24875000	chr1:19041556	PAX7	-0.26	-4.62	-0.38	9.56e-6	Lead levels in blood;
TGCT	cis	rs9372498	0.536	rs9489436	chr6:118873817	A/C	cg21191810	chr6:118973309	C6orf204	-0.37	-4.83	-0.4	4.03e-6	Diastolic blood pressure;
TGCT	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg08280861	chr8:58055591	NA	0.37	4.99	0.41	1.95e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7666738	0.962	rs11932892	chr4:99072967	C/T	cg17366294	chr4:99064904	C4orf37	0.85	7.29	0.55	3.19e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg27286337	chr10:134555280	INPP5A	0.39	4.68	0.39	7.36e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs4073582	0.595	rs1115508	chr11:65923149	A/G	cg16950941	chr11:66035639	RAB1B	0.53	5.08	0.42	1.34e-6	Gout;
TGCT	cis	rs12142240	0.698	rs66483119	chr1:46838389	T/C	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs4455778	0.659	rs1004168	chr7:49030320	C/A	cg26309511	chr7:48887640	NA	0.44	5.22	0.42	7.26e-7	Lung cancer in never smokers;
TGCT	cis	rs1008375	0.863	rs4590022	chr4:17614434	T/C	cg10189774	chr4:17578691	LAP3	0.65	5.49	0.44	2.22e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg17971929	chr21:40555470	PSMG1	0.91	8.16	0.59	3.18e-13	Cognitive function;
TGCT	cis	rs12368653	0.591	rs1038914	chr12:58011066	G/A	cg12615879	chr12:58013172	SLC26A10	-0.52	-6.24	-0.49	6.47e-9	Multiple sclerosis;
TGCT	cis	rs1532993	0.518	rs1993409	chr4:98635911	C/T	cg05340658	chr4:99064831	C4orf37	-0.41	-4.92	-0.4	2.72e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.61	0.38	9.85e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs367615	0.879	rs4351197	chr5:108866667	A/G	cg17395555	chr5:108820864	NA	0.31	5.01	0.41	1.85e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg08045932	chr20:61659980	NA	0.48	9.28	0.64	7.07e-16	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7811142	1.000	rs6953107	chr7:100095664	C/T	cg00814883	chr7:100076585	TSC22D4	-0.89	-9.24	-0.64	8.75e-16	Platelet count;
TGCT	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg27588902	chr6:42928151	GNMT	-0.56	-6.93	-0.53	2.08e-10	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs6570726	0.599	rs4398765	chr6:145935006	C/A	cg05347473	chr6:146136440	FBXO30	0.62	5.7	0.46	8.22e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs8141529	0.509	rs5762853	chr22:29245231	T/G	cg02153584	chr22:29168773	CCDC117	0.6	4.84	0.4	3.81e-6	Lymphocyte counts;
TGCT	cis	rs7944584	0.511	rs10838725	chr11:47557871	T/C	cg20307385	chr11:47447363	PSMC3	0.88	8.62	0.61	2.57e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
TGCT	cis	rs17253792	0.822	rs10083431	chr14:56068348	G/A	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs2440129	0.632	rs15966	chr17:6905643	T/C	cg03407747	chr17:6899364	ALOX12	0.54	5.85	0.47	4.06e-8	Tonsillectomy;
TGCT	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.31	0.43	4.95e-7	Prudent dietary pattern;
TGCT	cis	rs13191362	1.000	rs13210756	chr6:163009030	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.68	5.79	0.46	5.33e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs78487399	0.808	rs6544664	chr2:43729108	T/A	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.74	4.49	0.37	1.59e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs60843830	0.661	rs62116681	chr2:104197	A/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.62	5.52	0.44	1.92e-7	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs12765878	0.812	rs7076119	chr10:105667110	T/C	cg11005552	chr10:105648138	OBFC1	-0.44	-7.3	-0.55	3.08e-11	Coronary artery disease;
TGCT	cis	rs6088580	0.634	rs6088483	chr20:32984714	T/A	cg08999081	chr20:33150536	PIGU	-0.29	-5.65	-0.45	1.02e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs10504229	1.000	rs79311869	chr8:58195546	T/C	cg21724239	chr8:58056113	NA	0.38	4.76	0.39	5.41e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs6912958	0.712	rs7746465	chr6:88348996	T/G	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.98	-0.41	2.06e-6	Monocyte percentage of white cells;
TGCT	cis	rs6448317	0.539	rs13113895	chr4:24932077	T/C	cg21108841	chr4:24914750	CCDC149	-0.75	-7.11	-0.54	8.21e-11	Heschl's gyrus morphology;
TGCT	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg13395646	chr4:1353034	KIAA1530	-0.36	-4.77	-0.39	5.17e-6	Obesity-related traits;
TGCT	cis	rs35146811	0.735	rs2528900	chr7:99805319	A/G	cg22906224	chr7:99728672	NA	-0.49	-4.45	-0.37	1.88e-5	Coronary artery disease;
TGCT	cis	rs7000551	0.725	rs2249098	chr8:22400098	T/C	cg12081754	chr8:22256438	SLC39A14	0.28	4.69	0.39	6.95e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs9296092	0.500	rs4376348	chr6:33521097	A/G	cg13560919	chr6:33536144	NA	-0.2	-4.64	-0.38	8.68e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs7843479	0.965	rs3816786	chr8:21860425	A/T	cg17168535	chr8:21777572	XPO7	0.63	5.78	0.46	5.59e-8	Mean corpuscular volume;
TGCT	cis	rs17253792	0.822	rs78261053	chr14:56061784	C/T	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs12908161	0.959	rs3748376	chr15:85328352	C/T	cg12863693	chr15:85201151	NMB	0.42	5.01	0.41	1.81e-6	Schizophrenia;
TGCT	cis	rs13242816	1.000	rs12672717	chr7:116128270	G/A	cg16553024	chr7:116138462	CAV2	-0.45	-5.04	-0.41	1.57e-6	P wave duration;
TGCT	cis	rs35146811	0.735	rs11764176	chr7:99786964	G/T	cg04778012	chr7:99775508	STAG3;GPC2	0.35	4.93	0.41	2.55e-6	Coronary artery disease;
TGCT	cis	rs11190604	0.943	rs11190574	chr10:102234331	T/C	cg16342193	chr10:102329863	NA	-0.41	-5.3	-0.43	5.06e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs2197308	0.740	rs10880619	chr12:37922720	T/C	cg13010199	chr12:38710504	ALG10B	0.67	5.38	0.44	3.57e-7	Morning vs. evening chronotype;
TGCT	cis	rs4936891	1.000	rs7119122	chr11:123917281	A/C	cg22125253	chr11:123886957	OR10G4	0.21	4.59	0.38	1.07e-5	Male fertility;
TGCT	cis	rs2022068	0.583	rs2284020	chr22:37200835	G/A	cg26999345	chr22:37584441	C1QTNF6	0.2	4.47	0.37	1.77e-5	Pit-and-Fissure caries;
TGCT	cis	rs9921222	0.597	rs7193109	chr16:413523	T/G	cg00101154	chr16:420108	MRPL28	-0.62	-7.02	-0.53	1.27e-10	Bone mineral density (spine);Bone mineral density;
TGCT	trans	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg21659725	chr3:3221576	CRBN	-0.98	-15.33	-0.81	2.1000000000000002e-30	Intelligence (multi-trait analysis);
TGCT	cis	rs739496	0.895	rs7309325	chr12:111849515	G/T	cg10833066	chr12:111807467	FAM109A	0.36	5.33	0.43	4.55e-7	Platelet count;
TGCT	cis	rs951366	0.677	rs1775140	chr1:205672107	C/A	cg07167872	chr1:205819463	PM20D1	0.57	6.98	0.53	1.55e-10	Menarche (age at onset);
TGCT	cis	rs4319547	0.656	rs7294559	chr12:122837564	C/A	cg08088222	chr12:122070432	ORAI1	0.26	4.59	0.38	1.09e-5	Body mass index;
TGCT	cis	rs2295359	1.000	rs4655682	chr1:67610967	C/T	cg03340356	chr1:67600835	NA	0.37	4.5	0.38	1.51e-5	Psoriasis;
TGCT	cis	rs7267979	0.966	rs2482923	chr20:25308981	T/C	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs909674	0.818	rs7364148	chr22:39842165	T/C	cg02038168	chr22:39784481	NA	-0.74	-5.74	-0.46	7.01e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs2153535	0.541	rs945304	chr6:8442892	A/G	cg07606381	chr6:8435919	SLC35B3	0.57	5.25	0.43	6.46e-7	Motion sickness;
TGCT	cis	rs12902680	0.739	rs1607720	chr15:46419082	T/A	cg13605988	chr15:45421612	DUOX1;DUOXA1	0.33	4.62	0.38	9.28e-6	Neuroticism;
TGCT	cis	rs7826238	0.535	rs2979179	chr8:8320029	C/T	cg15556689	chr8:8085844	FLJ10661	0.7	6.35	0.5	3.69e-9	Systolic blood pressure;
TGCT	cis	rs6693567	0.545	rs12049177	chr1:150474337	G/A	cg09579323	chr1:150459698	TARS2	0.53	4.63	0.38	9.01e-6	Migraine;
TGCT	cis	rs12900413	0.603	rs7177841	chr15:90302117	C/A	cg24249390	chr15:90295951	MESP1	-0.3	-5.2	-0.42	8.04e-7	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs7226408	0.857	rs72887016	chr18:34464090	G/T	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg16325326	chr1:53192061	ZYG11B	0.61	6.97	0.53	1.66e-10	Monocyte count;
TGCT	cis	rs78456975	0.550	rs10197874	chr2:1545310	A/G	cg01028140	chr2:1542097	TPO	-0.34	-4.85	-0.4	3.68e-6	Placebo response in major depressive disorder (% change in symptom score);
TGCT	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1801251	1.000	rs1044480	chr2:233633736	A/G	cg08000102	chr2:233561755	GIGYF2	0.64	6.45	0.5	2.22e-9	Coronary artery disease;
TGCT	cis	rs11098499	0.779	rs10857066	chr4:120286596	C/T	cg09307838	chr4:120376055	NA	0.58	5.76	0.46	6.16e-8	Corneal astigmatism;
TGCT	cis	rs765787	0.530	rs1706832	chr15:45517173	C/T	cg24006582	chr15:45444508	DUOX1	-0.24	-5.28	-0.43	5.49e-7	Uric acid levels;
TGCT	cis	rs9640161	0.830	rs12703061	chr7:150062545	T/C	cg10018233	chr7:150070692	REPIN1	0.31	4.73	0.39	6.11e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs7772486	0.764	rs2247211	chr6:146216379	G/A	cg05347473	chr6:146136440	FBXO30	0.5	4.9	0.4	2.94e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2153535	0.580	rs9378556	chr6:8514695	A/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.01	0.41	1.86e-6	Motion sickness;
TGCT	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg10047753	chr17:41438598	NA	0.92	9.49	0.65	2.12e-16	Menopause (age at onset);
TGCT	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg17554472	chr22:41940697	POLR3H	0.48	4.97	0.41	2.16e-6	Vitiligo;
TGCT	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg04317338	chr11:64019027	PLCB3	0.78	6.46	0.5	2.17e-9	Mean platelet volume;
TGCT	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg11890956	chr21:40555474	PSMG1	-0.79	-7.77	-0.57	2.51e-12	Cognitive function;
TGCT	cis	rs7267979	0.527	rs6083891	chr20:25574272	C/G	cg03522245	chr20:25566470	NINL	-0.44	-4.59	-0.38	1.06e-5	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7216064	0.734	rs12942774	chr17:65967562	A/G	cg12091567	chr17:66097778	LOC651250	0.64	5.31	0.43	4.81e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs9902453	0.967	rs61014003	chr17:28485233	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	6.51	0.5	1.66e-9	Coffee consumption (cups per day);
TGCT	cis	rs2072499	0.966	rs2842857	chr1:156168736	T/C	cg25208724	chr1:156163844	SLC25A44	1.14	17.15	0.84	1.56e-34	Testicular germ cell tumor;
TGCT	cis	rs7246657	0.941	rs7256130	chr19:37933981	T/C	cg18154014	chr19:37997991	ZNF793	0.73	5.38	0.44	3.53e-7	Coronary artery calcification;
TGCT	cis	rs1322512	0.761	rs1631293	chr6:152939886	T/C	cg03415253	chr6:152958462	SYNE1	-0.54	-5.01	-0.41	1.83e-6	Tonometry;
TGCT	cis	rs617791	0.530	rs10791835	chr11:65750924	C/A	cg09783858	chr11:65769428	EIF1AD;BANF1	0.5	4.56	0.38	1.2e-5	Breast cancer;
TGCT	cis	rs12643440	0.538	rs2041442	chr4:17137895	C/T	cg22650099	chr4:17144496	NA	-0.46	-4.66	-0.39	8.14e-6	Metabolite levels (Pyroglutamine);
TGCT	cis	rs295140	0.605	rs3739119	chr2:201194279	C/A	cg04283868	chr2:201171347	SPATS2L	0.48	4.59	0.38	1.07e-5	QT interval;
TGCT	cis	rs62244186	0.659	rs12489887	chr3:44547124	A/T	cg25151919	chr3:44754333	ZNF502	-0.39	-4.55	-0.38	1.26e-5	Depressive symptoms;
TGCT	trans	rs9467711	1.000	rs9467708	chr6:26327956	T/C	cg20516262	chr7:155325649	CNPY1	0.54	6.63	0.51	9.34e-10	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9549367	0.713	rs9549682	chr13:113830181	C/T	cg18105134	chr13:113819100	PROZ	-0.47	-8.24	-0.59	2.05e-13	Platelet distribution width;
TGCT	cis	rs782590	0.818	rs2627765	chr2:55883317	G/T	cg03859395	chr2:55845619	SMEK2	0.81	8.13	0.59	3.82e-13	Metabolic syndrome;
TGCT	cis	rs377070	0.966	rs411043	chr4:123633221	G/C	cg10495464	chr4:123653540	BBS12;LOC729338	0.49	5.42	0.44	2.96e-7	Mosquito bite size;
TGCT	cis	rs2066819	1.000	rs808919	chr12:56647911	C/G	cg26714650	chr12:56694279	CS	1.48	8.4	0.6	8.92e-14	Psoriasis vulgaris;
TGCT	cis	rs7584330	0.657	rs10202599	chr2:238352465	A/C	cg14458575	chr2:238380390	NA	0.51	7.37	0.55	2.15e-11	Prostate cancer;
TGCT	cis	rs2243480	0.901	rs778730	chr7:65823325	T/A	cg20637647	chr7:64974828	NA	0.92	5.09	0.42	1.31e-6	Diabetic kidney disease;
TGCT	cis	rs2549003	0.811	rs10072700	chr5:131816903	A/C	cg00255919	chr5:131827918	IRF1	0.25	5.4	0.44	3.25e-7	Asthma (sex interaction);
TGCT	cis	rs36051895	0.593	rs62541903	chr9:5146952	G/C	cg02405213	chr9:5042618	JAK2	-0.7	-9.44	-0.65	2.87e-16	Pediatric autoimmune diseases;
TGCT	cis	rs12579753	0.719	rs11115060	chr12:82269624	C/T	cg07988820	chr12:82153109	PPFIA2	-0.42	-4.44	-0.37	1.97e-5	Resting heart rate;
TGCT	cis	rs950169	0.922	rs67804993	chr15:85104030	T/G	cg11189052	chr15:85197271	WDR73	0.81	6.71	0.52	6.33e-10	Schizophrenia;
TGCT	cis	rs1878931	0.559	rs2106863	chr16:3391330	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.79	7.61	0.56	5.86e-12	Body mass index (adult);
TGCT	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg11890956	chr21:40555474	PSMG1	1.12	12.59	0.75	6.25e-24	Cognitive function;
TGCT	cis	rs7246967	0.673	rs59567211	chr19:22829882	G/A	cg05241461	chr19:22816980	ZNF492	0.66	4.44	0.37	1.95e-5	Bronchopulmonary dysplasia;
TGCT	cis	rs13256369	0.756	rs13280759	chr8:8562995	G/T	cg18904891	chr8:8559673	CLDN23	0.58	5.4	0.44	3.23e-7	Obesity-related traits;
TGCT	cis	rs17384381	0.953	rs2076699	chr1:85817295	G/A	cg16011679	chr1:85725395	C1orf52	0.87	6.78	0.52	4.43e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7523273	0.564	rs7543097	chr1:207882592	T/G	cg22525895	chr1:207977042	MIR29B2	0.29	4.48	0.37	1.69e-5	Schizophrenia;
TGCT	cis	rs798766	0.723	rs3134865	chr4:1723279	T/C	cg05874882	chr4:1763078	NA	-0.36	-4.87	-0.4	3.27e-6	Bladder cancer;Urinary bladder cancer;
TGCT	cis	rs586688	0.625	rs624041	chr1:201652769	C/G	cg07139329	chr1:201708558	NAV1	-0.51	-5.18	-0.42	8.82e-7	Obesity-related traits;
TGCT	cis	rs9309473	0.615	rs62151562	chr2:73603540	T/G	cg07208825	chr2:73871855	ALMS1P	0.26	5.04	0.41	1.6e-6	Metabolite levels;
TGCT	cis	rs9921338	0.961	rs72773825	chr16:11412448	A/G	cg00044050	chr16:11439710	C16orf75	-0.93	-6.96	-0.53	1.7e-10	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs1371867	0.846	rs1660332	chr8:101309490	A/G	cg06002616	chr8:101225028	SPAG1	0.53	6.21	0.49	7.16e-9	Atrioventricular conduction;
TGCT	cis	rs7635838	0.686	rs347588	chr3:11287504	C/T	cg00170343	chr3:11313890	ATG7	0.68	6.61	0.51	1.03e-9	HDL cholesterol;
TGCT	cis	rs17331151	0.573	rs76029595	chr3:52868523	C/T	cg27565382	chr3:53032988	SFMBT1	0.47	5.96	0.47	2.42e-8	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs11122272	0.735	rs2491416	chr1:231547335	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.66	6.2	0.49	7.88e-9	Hemoglobin concentration;
TGCT	cis	rs617219	0.710	rs2255913	chr5:78562399	G/C	cg23987322	chr5:78407566	BHMT	0.35	4.69	0.39	7.07e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs17253792	0.731	rs8008528	chr14:56062052	C/T	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs7666738	0.830	rs11097600	chr4:98959564	T/G	cg18180107	chr4:99064573	C4orf37	0.55	4.98	0.41	2.05e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg01448562	chr3:133502909	NA	-0.32	-6.38	-0.5	3.17e-9	Iron status biomarkers;
TGCT	cis	rs72781680	1.000	rs72796388	chr2:24171509	A/C	cg08917208	chr2:24149416	ATAD2B	0.73	4.51	0.38	1.48e-5	Lymphocyte counts;
TGCT	cis	rs6674176	0.597	rs4031031	chr1:44393533	C/T	cg12908607	chr1:44402522	ARTN	-0.79	-9.73	-0.66	5.63e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs9393777	0.513	rs9295702	chr6:26634040	T/C	cg15659132	chr6:26577336	NA	-0.77	-5.48	-0.44	2.26e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs3749237	0.929	rs62260715	chr3:49829326	G/A	cg07636037	chr3:49044803	WDR6	0.61	5.32	0.43	4.68e-7	Resting heart rate;
TGCT	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg03709012	chr19:19516395	GATAD2A	0.7	6.0	0.47	2e-8	Tonsillectomy;
TGCT	cis	rs9814567	1.000	rs4974484	chr3:134219019	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.96	-9.19	-0.64	1.16e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg06221963	chr1:154839813	KCNN3	-0.8	-14.87	-0.8	2.38e-29	Prostate cancer;
TGCT	cis	rs1401999	0.606	rs7644687	chr3:183753353	A/G	cg01324343	chr3:183735012	ABCC5	0.75	8.76	0.62	1.25e-14	Anterior chamber depth;
TGCT	cis	rs11785400	0.793	rs4467920	chr8:143736846	C/T	cg10596483	chr8:143751796	JRK	0.54	5.44	0.44	2.7e-7	Schizophrenia;
TGCT	cis	rs4595586	0.545	rs1839402	chr12:39371615	C/T	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs2455799	0.559	rs1447645	chr3:15930342	T/C	cg12172478	chr3:16357591	RFTN1	-0.34	-4.98	-0.41	2.09e-6	Mean platelet volume;
TGCT	cis	rs2637266	0.703	rs35654095	chr10:78472016	C/T	cg18941641	chr10:78392320	NA	0.4	4.79	0.39	4.74e-6	Pulmonary function;
TGCT	cis	rs6547741	1.000	rs6706610	chr2:27778091	G/A	cg27432699	chr2:27873401	GPN1	0.18	4.66	0.39	8.09e-6	Oral cavity cancer;
TGCT	cis	rs7666738	0.962	rs4699605	chr4:99064379	A/G	cg17366294	chr4:99064904	C4orf37	0.71	6.36	0.5	3.48e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7085104	0.660	rs7902804	chr10:104585405	A/T	cg04362960	chr10:104952993	NT5C2	0.58	5.08	0.42	1.35e-6	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg06028808	chr11:68637592	NA	0.52	6.74	0.52	5.33e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	trans	rs17685	0.672	rs10952841	chr7:75778626	A/C	cg19862616	chr7:65841803	NCRNA00174	0.52	9.01	0.63	3.02e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg02038168	chr22:39784481	NA	-0.77	-6.32	-0.49	4.23e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7635838	0.819	rs904474	chr3:11524648	C/G	cg00170343	chr3:11313890	ATG7	0.69	6.67	0.51	7.44e-10	HDL cholesterol;
TGCT	cis	rs12497850	0.765	rs12487580	chr3:49182932	G/A	cg18654377	chr3:49208889	KLHDC8B	-0.38	-4.79	-0.4	4.61e-6	Parkinson's disease;
TGCT	cis	rs2594989	0.943	rs2454501	chr3:11500089	A/G	cg00170343	chr3:11313890	ATG7	0.69	5.12	0.42	1.16e-6	Circulating chemerin levels;
TGCT	cis	rs3812831	0.599	rs428637	chr13:114927139	T/G	cg08824895	chr13:115047677	UPF3A	0.46	4.45	0.37	1.86e-5	Schizophrenia;
TGCT	cis	rs3125734	0.633	rs12217669	chr10:63988456	A/G	cg05499367	chr10:63213510	TMEM26	0.33	4.49	0.37	1.63e-5	Rheumatoid arthritis;
TGCT	cis	rs7772486	0.686	rs1045820	chr6:145947080	C/T	cg13319975	chr6:146136371	FBXO30	-0.5	-4.49	-0.37	1.63e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs854765	0.624	rs12938501	chr17:17737258	A/C	cg09796270	chr17:17721594	SREBF1	-0.24	-4.52	-0.38	1.42e-5	Total body bone mineral density;
TGCT	cis	rs7833790	0.926	rs72686467	chr8:82758929	T/G	cg17211192	chr8:82754475	SNX16	1.06	8.51	0.61	4.89e-14	Diastolic blood pressure;
TGCT	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg23758822	chr17:41437982	NA	0.73	6.74	0.52	5.43e-10	Menopause (age at onset);
TGCT	cis	rs916888	0.821	rs70602	chr17:44859715	T/C	cg16520312	chr17:43971471	MAPT;LOC100128977	0.57	4.86	0.4	3.45e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs8135665	0.600	rs8142379	chr22:38450971	G/A	cg13116946	chr22:38479732	SLC16A8	0.28	5.55	0.45	1.63e-7	Advanced age-related macular degeneration;Age-related macular degeneration;
TGCT	cis	rs9911578	0.967	rs7214892	chr17:57065401	G/A	cg12560992	chr17:57184187	TRIM37	0.8	9.64	0.65	9.47e-17	Intelligence (multi-trait analysis);
TGCT	trans	rs561341	0.941	rs2428341	chr17:30317295	C/T	cg20587970	chr11:113659929	NA	-0.97	-12.38	-0.74	2.11e-23	Hip circumference adjusted for BMI;
TGCT	cis	rs7937612	1.000	rs7933086	chr11:120269308	A/G	cg24566217	chr11:120254723	ARHGEF12	0.3	5.02	0.41	1.78e-6	Intraocular pressure;
TGCT	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg06618935	chr21:46677482	NA	-0.37	-5.52	-0.44	1.87e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs10986311	0.775	rs10986324	chr9:127121825	T/C	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.19	4.72	0.39	6.23e-6	Vitiligo;
TGCT	cis	rs3733585	0.673	rs6850143	chr4:9958924	T/C	cg11266682	chr4:10021025	SLC2A9	-0.58	-7.7	-0.57	3.69e-12	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs6089584	0.566	rs11699442	chr20:60623268	A/G	cg06108461	chr20:60628389	TAF4	-0.43	-5.46	-0.44	2.46e-7	Body mass index;
TGCT	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg14983838	chr19:29218262	NA	0.7	5.18	0.42	8.85e-7	Methadone dose in opioid dependence;
TGCT	cis	rs240764	0.658	rs12210255	chr6:101187540	G/C	cg09795085	chr6:101329169	ASCC3	-0.51	-4.51	-0.38	1.45e-5	Neuroticism;
TGCT	trans	rs2727020	0.729	rs4980439	chr11:49342246	G/C	cg03929089	chr4:120376271	NA	-0.7	-7.94	-0.58	1.06e-12	Coronary artery disease;
TGCT	cis	rs9291683	0.551	rs62295971	chr4:9978142	G/A	cg00071950	chr4:10020882	SLC2A9	0.65	8.23	0.59	2.21e-13	Bone mineral density;
TGCT	cis	rs453301	0.686	rs2409120	chr8:8882571	G/C	cg15556689	chr8:8085844	FLJ10661	-0.64	-5.26	-0.43	6.24e-7	Joint mobility (Beighton score);
TGCT	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg23034840	chr1:205782522	SLC41A1	0.57	5.29	0.43	5.24e-7	Menarche (age at onset);
TGCT	cis	rs9467773	1.000	rs2393670	chr6:26535541	A/G	cg26531700	chr6:26746687	NA	0.47	4.57	0.38	1.14e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs9818758	0.607	rs10049462	chr3:49309684	C/T	cg07636037	chr3:49044803	WDR6	-1.04	-5.13	-0.42	1.09e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs2204008	0.837	rs11519926	chr12:38348992	G/A	cg13010199	chr12:38710504	ALG10B	0.6	4.74	0.39	5.87e-6	Bladder cancer;
TGCT	cis	rs9814567	1.000	rs4955555	chr3:134286427	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.94	-9.18	-0.64	1.2e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs4319547	0.915	rs7316734	chr12:123117425	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.69	-5.47	-0.44	2.39e-7	Body mass index;
TGCT	cis	rs7552404	0.883	rs2185436	chr1:76203783	A/G	cg03433033	chr1:76189801	ACADM	0.82	9.91	0.66	2.05e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs4253772	0.591	rs6520010	chr22:46721223	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.69	5.31	0.43	4.82e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs8062405	0.789	rs2106480	chr16:28537971	T/C	cg09754948	chr16:28834200	ATXN2L	0.63	5.01	0.41	1.79e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs875971	0.964	rs160635	chr7:65528918	T/C	cg11764359	chr7:65958608	NA	0.53	4.64	0.38	8.87e-6	Aortic root size;
TGCT	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg07061783	chr6:25882402	NA	-0.45	-4.82	-0.4	4.15e-6	Blood metabolite levels;
TGCT	cis	rs849210	0.517	rs10490295	chr2:206185236	G/C	cg11793701	chr2:206547163	NRP2	-0.57	-4.75	-0.39	5.62e-6	Tonsillectomy;
TGCT	cis	rs9517302	0.665	rs3752971	chr13:99097252	G/A	cg22223119	chr13:99095684	FARP1	-0.55	-6.23	-0.49	6.58e-9	Obesity-related traits;
TGCT	cis	rs4494114	1.000	rs6674910	chr1:39357157	C/T	cg25970120	chr1:39325951	RRAGC	0.6	6.28	0.49	5.26e-9	Blood protein levels;
TGCT	cis	rs34891900	0.507	rs2008085	chr22:18204316	T/G	cg19898043	chr22:18121309	BCL2L13	0.55	4.74	0.39	5.77e-6	Sum neutrophil eosinophil counts;
TGCT	cis	rs10779751	0.960	rs12739368	chr1:11288247	T/C	cg08854313	chr1:11322531	MTOR	0.96	8.74	0.62	1.37e-14	Body mass index;
TGCT	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg02725872	chr8:58115012	NA	-0.38	-5.16	-0.42	9.32e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs8050907	0.661	rs17137056	chr16:4524685	G/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.53	4.57	0.38	1.15e-5	Obesity-related traits;
TGCT	trans	rs208520	0.690	rs12202805	chr6:66703903	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-11.22	-0.71	1.34e-20	Exhaled nitric oxide output;
TGCT	cis	rs11098499	0.821	rs56155624	chr4:120291026	C/G	cg09307838	chr4:120376055	NA	0.56	5.35	0.43	4.05e-7	Corneal astigmatism;
TGCT	cis	rs13256369	0.802	rs12541520	chr8:8564146	G/T	cg17143192	chr8:8559678	CLDN23	0.57	5.35	0.43	4.09e-7	Obesity-related traits;
TGCT	cis	rs644799	0.664	rs603625	chr11:95554283	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	8.48	0.61	5.55e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs4900538	0.963	rs1190554	chr14:102918686	T/C	cg18135206	chr14:102964638	TECPR2	0.21	5.08	0.41	1.38e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs7089973	0.646	rs35453961	chr10:116638166	T/C	cg03647239	chr10:116582469	FAM160B1	0.58	5.28	0.43	5.7e-7	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs7584330	0.554	rs74832280	chr2:238426625	G/A	cg08992911	chr2:238395768	MLPH	0.7	4.72	0.39	6.32e-6	Prostate cancer;
TGCT	cis	rs1580019	0.568	rs2122633	chr7:32523870	G/T	cg06627557	chr7:32535165	LSM5;AVL9	1.02	10.57	0.69	5.23e-19	Cognitive ability;
TGCT	cis	rs478607	0.749	rs61884370	chr11:64361955	T/G	cg19395706	chr11:64412079	NRXN2	0.46	4.63	0.38	8.92e-6	Urate levels;
TGCT	cis	rs344364	0.511	rs1742467	chr16:1950187	G/T	cg26617929	chr16:1858877	NA	-0.27	-4.9	-0.4	2.99e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs2295359	0.824	rs12060309	chr1:67604219	T/C	cg12940439	chr1:67600707	NA	0.66	6.89	0.53	2.53e-10	Psoriasis;
TGCT	cis	rs11696845	0.604	rs1980577	chr20:43382112	A/G	cg25301532	chr20:43378953	KCNK15	0.46	5.11	0.42	1.17e-6	Obesity-related traits;
TGCT	cis	rs17767294	0.708	rs72847348	chr6:27801853	G/A	cg08851530	chr6:28072375	NA	1.54	7.3	0.55	3.1e-11	Parkinson's disease;
TGCT	cis	rs6967414	0.786	rs7804259	chr7:6755448	C/G	cg00387323	chr7:6746715	ZNF12	0.76	4.65	0.39	8.23e-6	Hematocrit;Hemoglobin concentration;
TGCT	cis	rs13256369	1.000	rs4841016	chr8:8572561	C/T	cg18904891	chr8:8559673	CLDN23	0.62	5.67	0.45	9.47e-8	Obesity-related traits;
TGCT	cis	rs6087771	0.642	rs6060403	chr20:30221104	C/A	cg18721089	chr20:30220636	NA	-0.42	-5.19	-0.42	8.31e-7	Subcortical brain region volumes;Putamen volume;
TGCT	cis	rs9467711	0.651	rs35506517	chr6:26044864	T/C	cg16898833	chr6:26189333	HIST1H4D	1.34	6.07	0.48	1.47e-8	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1933488	0.931	rs7750498	chr6:153424055	G/A	cg24028809	chr6:153414101	RGS17	0.21	4.67	0.39	7.69e-6	Prostate cancer;
TGCT	cis	rs3791556	1.000	rs3791558	chr2:240113255	G/A	cg03281426	chr2:240109471	HDAC4	0.28	4.46	0.37	1.82e-5	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs7552404	1.000	rs4949874	chr1:76161889	T/C	cg22875332	chr1:76189707	ACADM	0.79	9.77	0.66	4.68e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs6121246	0.954	rs73241710	chr20:30424956	G/A	cg13852791	chr20:30311386	BCL2L1	0.77	5.7	0.46	8.2e-8	Mean corpuscular hemoglobin;
TGCT	trans	rs12339966	0.653	rs7857285	chr9:11293560	C/G	cg07173112	chr1:1114698	TTLL10	-0.34	-6.94	-0.53	1.89e-10	Systolic blood pressure;
TGCT	cis	rs7833790	0.660	rs1451995	chr8:82746123	G/C	cg06027949	chr8:82754900	SNX16	0.65	5.03	0.41	1.69e-6	Diastolic blood pressure;
TGCT	cis	rs7914558	1.000	rs7914558	chr10:104775908	G/A	cg15744005	chr10:104629667	AS3MT	-0.4	-4.97	-0.41	2.21e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs7394190	0.748	rs79936644	chr10:75545117	C/T	cg07699608	chr10:75541558	CHCHD1	0.79	5.44	0.44	2.72e-7	Incident atrial fibrillation;
TGCT	cis	rs36093844	0.898	rs11234458	chr11:85591370	A/C	cg25872744	chr11:85566296	CCDC83	-0.52	-4.73	-0.39	6.09e-6	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
TGCT	cis	rs7156960	0.639	rs2360983	chr14:76727099	C/T	cg13981132	chr14:76734493	NA	-0.37	-5.43	-0.44	2.83e-7	Acute lymphoblastic leukemia (childhood);
TGCT	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg07507251	chr3:52567010	NT5DC2	-0.48	-6.95	-0.53	1.82e-10	Bipolar disorder;
TGCT	cis	rs7666738	0.830	rs17550735	chr4:99014076	T/G	cg05340658	chr4:99064831	C4orf37	0.48	5.43	0.44	2.92e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg21963583	chr11:68658836	MRPL21	0.37	6.14	0.48	1.03e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs6456156	0.792	rs10946214	chr6:167516122	G/A	cg07741184	chr6:167504864	NA	0.22	4.44	0.37	2e-5	Primary biliary cholangitis;
TGCT	cis	rs7647973	1.000	rs7644148	chr3:49545241	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.57	-4.56	-0.38	1.21e-5	Menarche (age at onset);
TGCT	cis	rs739496	0.579	rs2238152	chr12:112214459	G/T	cg10833066	chr12:111807467	FAM109A	0.36	4.67	0.39	7.74e-6	Platelet count;
TGCT	cis	rs2549003	1.000	rs2070728	chr5:131819977	C/T	cg00255919	chr5:131827918	IRF1	0.2	4.7	0.39	6.92e-6	Asthma (sex interaction);
TGCT	cis	rs7586879	0.796	rs11684619	chr2:25078859	G/A	cg01884057	chr2:25150051	NA	0.26	4.59	0.38	1.08e-5	Body mass index;
TGCT	cis	rs10883723	0.737	rs11191312	chr10:104278601	T/C	cg05855489	chr10:104503620	C10orf26	-0.6	-5.18	-0.42	8.85e-7	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs778371	0.874	rs938575	chr2:233768788	G/A	cg08000102	chr2:233561755	GIGYF2	-0.57	-5.64	-0.45	1.07e-7	Schizophrenia;
TGCT	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg16031515	chr1:205743344	RAB7L1	-0.27	-4.55	-0.38	1.28e-5	Menarche (age at onset);
TGCT	cis	rs7615952	0.932	rs13325495	chr3:125637416	T/G	cg05084668	chr3:125655381	ALG1L	-0.64	-4.55	-0.38	1.24e-5	Blood pressure (smoking interaction);
TGCT	cis	rs514406	0.679	rs11206006	chr1:53218380	A/G	cg16325326	chr1:53192061	ZYG11B	-0.59	-6.47	-0.5	2.09e-9	Monocyte count;
TGCT	cis	rs4631830	0.828	rs10763567	chr10:51538169	C/A	cg10326726	chr10:51549505	MSMB	0.23	4.69	0.39	7.23e-6	Prostate-specific antigen levels;
TGCT	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg20007245	chr22:24372913	LOC391322	-0.78	-8.46	-0.61	6.19e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7095607	0.900	rs10823155	chr10:69950196	G/A	cg18986048	chr10:69913749	MYPN	0.46	5.08	0.41	1.37e-6	Lung function (FVC);
TGCT	cis	rs7095607	0.785	rs10762190	chr10:69919905	C/A	cg18986048	chr10:69913749	MYPN	0.41	4.48	0.37	1.66e-5	Lung function (FVC);
TGCT	cis	rs9527	0.590	rs10786741	chr10:104939182	G/A	cg04362960	chr10:104952993	NT5C2	0.67	5.64	0.45	1.07e-7	Arsenic metabolism;
TGCT	cis	rs11577318	0.579	rs10794532	chr1:26694260	T/C	cg14210634	chr1:25870291	LDLRAP1	0.53	4.59	0.38	1.07e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg17911788	chr17:44343683	NA	-0.65	-6.56	-0.51	1.34e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg04317338	chr11:64019027	PLCB3	0.75	6.19	0.49	8.06e-9	Mean platelet volume;
TGCT	cis	rs2439831	0.681	rs3742969	chr15:43621947	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	6.63	0.51	9.35e-10	Lung cancer in ever smokers;
TGCT	cis	rs4746818	1.000	rs1506770	chr10:70964357	G/A	cg04149295	chr10:70884716	VPS26A	0.79	5.44	0.44	2.79e-7	Left atrial antero-posterior diameter;
TGCT	cis	rs1878931	0.501	rs37800	chr16:3423648	T/G	cg05754148	chr16:3507555	NAT15	0.33	4.61	0.38	9.98e-6	Body mass index (adult);
TGCT	cis	rs9611565	0.921	rs5751081	chr22:41742788	A/T	cg17554472	chr22:41940697	POLR3H	-0.4	-4.58	-0.38	1.11e-5	Vitiligo;
TGCT	cis	rs56399783	0.901	rs73047393	chr7:2775879	C/T	cg19731401	chr7:2775893	GNA12	0.36	5.07	0.41	1.4e-6	Childhood ear infection;
TGCT	cis	rs739496	0.579	rs1981517	chr12:112323582	A/G	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs7586879	0.828	rs13387053	chr2:25103025	G/A	cg01884057	chr2:25150051	NA	0.26	4.58	0.38	1.13e-5	Body mass index;
TGCT	cis	rs7786808	0.707	rs11770299	chr7:158228822	G/A	cg01191920	chr7:158217561	PTPRN2	-0.44	-6.64	-0.51	8.76e-10	Obesity-related traits;
TGCT	cis	rs11118844	0.793	rs10863654	chr1:221946787	G/A	cg04222084	chr1:221915650	DUSP10	-0.71	-4.99	-0.41	1.96e-6	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
TGCT	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg12311346	chr5:56204834	C5orf35	-0.7	-6.47	-0.5	2e-9	Initial pursuit acceleration;
TGCT	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg18402987	chr7:1209562	NA	0.38	4.78	0.39	4.83e-6	Longevity;Endometriosis;
TGCT	cis	rs17094222	0.504	rs11190661	chr10:102452136	C/T	cg26540559	chr10:102447443	NA	0.34	4.68	0.39	7.38e-6	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs9902453	0.868	rs11080118	chr17:28475379	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-6.54	-0.51	1.47e-9	Coffee consumption (cups per day);
TGCT	cis	rs9527	0.590	rs763914	chr10:104841587	T/C	cg15744005	chr10:104629667	AS3MT	-0.43	-4.95	-0.41	2.35e-6	Arsenic metabolism;
TGCT	cis	rs9916302	0.706	rs7208487	chr17:37543449	T/G	cg07936489	chr17:37558343	FBXL20	0.87	6.27	0.49	5.47e-9	Glomerular filtration rate (creatinine);
TGCT	cis	rs1403694	0.695	rs1523435	chr3:186436306	G/A	cg12454167	chr3:186435060	KNG1	0.51	8.67	0.61	1.95e-14	Blood protein levels;
TGCT	cis	rs3818285	0.544	rs7899805	chr10:111671177	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.32	-5.51	-0.44	2.03e-7	Superior crus of antihelix expression;
TGCT	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg02953382	chr22:24373134	LOC391322	-0.78	-8.1	-0.59	4.41e-13	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs11025559	0.773	rs16906274	chr11:20470142	T/C	cg19653624	chr11:20408972	PRMT3	-0.64	-5.11	-0.42	1.2e-6	Pursuit maintenance gain;
TGCT	cis	rs6121246	0.909	rs6060644	chr20:30265652	G/A	cg13852791	chr20:30311386	BCL2L1	0.78	5.8	0.46	5.15e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs7824557	0.547	rs6601570	chr8:11079367	G/A	cg21775007	chr8:11205619	TDH	-0.53	-4.8	-0.4	4.55e-6	Retinal vascular caliber;
TGCT	cis	rs9611519	0.565	rs8135524	chr22:41436442	T/C	cg13695892	chr22:41940480	POLR3H	-0.56	-5.19	-0.42	8.23e-7	Neuroticism;
TGCT	cis	rs73001065	0.901	rs17217098	chr19:19702384	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	1.07	4.76	0.39	5.22e-6	LDL cholesterol;
TGCT	cis	rs8180040	0.701	rs1079276	chr3:47045739	C/G	cg27129171	chr3:47204927	SETD2	0.74	9.77	0.66	4.58e-17	Colorectal cancer;
TGCT	cis	rs7267979	1.000	rs6083813	chr20:25337671	A/G	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs8030485	0.536	rs12595749	chr15:79432359	A/G	cg17916960	chr15:79447300	NA	0.4	6.1	0.48	1.24e-8	Left ventricle wall thickness;
TGCT	cis	rs6582630	0.555	rs7969922	chr12:38529491	C/T	cg26384229	chr12:38710491	ALG10B	0.85	7.74	0.57	3.08e-12	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs2038227	1	rs2038227	chr16:539140	C/A	cg06259664	chr16:537672	RAB11FIP3	0.27	5.52	0.44	1.93e-7	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs7264396	0.635	rs6119672	chr20:34479767	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.04	-0.41	1.58e-6	Total cholesterol levels;
TGCT	cis	rs9314614	0.933	rs2741098	chr8:6690276	C/T	cg27319216	chr8:6693540	XKR5	0.29	4.86	0.4	3.45e-6	IgA nephropathy;White blood cell count (basophil);
TGCT	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg11764359	chr7:65958608	NA	0.61	5.53	0.44	1.84e-7	Aortic root size;
TGCT	cis	rs4294134	0.529	rs62479497	chr7:135247070	T/C	cg08396481	chr7:135194601	CNOT4	-0.55	-4.51	-0.38	1.46e-5	Paget's disease;
TGCT	cis	rs7726839	0.794	rs10474792	chr5:600058	G/A	cg09021430	chr5:549028	NA	-0.42	-6.04	-0.48	1.66e-8	Obesity-related traits;
TGCT	cis	rs6815814	0.731	rs28532329	chr4:38771368	C/T	cg02016764	chr4:38805732	TLR1	-0.27	-4.54	-0.38	1.32e-5	Breast cancer;
TGCT	cis	rs7104764	0.957	rs1045454	chr11:204228	G/A	cg18336825	chr11:236787	PSMD13;SIRT3	-1.02	-10.55	-0.69	5.9e-19	Menarche (age at onset);
TGCT	cis	rs6693567	0.565	rs11205371	chr1:150398510	A/G	cg09579323	chr1:150459698	TARS2	0.52	4.64	0.38	8.63e-6	Migraine;
TGCT	cis	rs9362426	0.551	rs6912282	chr6:88103000	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.45	4.78	0.39	4.92e-6	Depressive episodes in bipolar disorder;
TGCT	cis	rs16867321	0.950	rs1919152	chr2:181507765	C/T	cg23363182	chr2:181467187	NA	-0.4	-5.62	-0.45	1.21e-7	Obesity;
TGCT	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg08645402	chr16:4508243	NA	0.2	5.01	0.41	1.86e-6	Schizophrenia;
TGCT	cis	rs797680	0.786	rs12406245	chr1:93860625	G/A	cg17826107	chr1:92977322	EVI5	-0.23	-5.51	-0.44	2.01e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg24549020	chr5:56110836	MAP3K1	0.67	5.78	0.46	5.74e-8	Initial pursuit acceleration;
TGCT	cis	rs12765878	0.675	rs3752946	chr10:105670849	A/T	cg11005552	chr10:105648138	OBFC1	0.36	6.11	0.48	1.21e-8	Coronary artery disease;
TGCT	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg11890956	chr21:40555474	PSMG1	1.11	12.48	0.75	1.21e-23	Cognitive function;
TGCT	cis	rs7809950	0.953	rs2520263	chr7:107179119	T/C	cg23024343	chr7:107201750	COG5	-0.35	-5.43	-0.44	2.88e-7	Coronary artery disease;
TGCT	cis	rs6089829	0.926	rs6011552	chr20:61667894	T/C	cg18188782	chr20:61659543	NA	0.44	5.37	0.43	3.73e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7523050	0.643	rs79451947	chr1:109404130	T/A	cg08274380	chr1:109419600	GPSM2	1.31	6.12	0.48	1.15e-8	Fat distribution (HIV);
TGCT	cis	rs13242816	1.000	rs35800776	chr7:116110069	C/A	cg16553024	chr7:116138462	CAV2	-0.49	-5.11	-0.42	1.17e-6	P wave duration;
TGCT	cis	rs6896969	0.510	rs6874500	chr5:40427883	G/T	cg01087697	chr5:40835557	RPL37	-0.53	-4.63	-0.38	8.91e-6	Multiple sclerosis;
TGCT	cis	rs2115630	0.645	rs6496284	chr15:85178270	A/G	cg11189052	chr15:85197271	WDR73	-0.72	-6.85	-0.52	3.12e-10	P wave terminal force;
TGCT	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg09517075	chr8:22133004	PIWIL2	0.25	4.99	0.41	2.02e-6	Hypertriglyceridemia;
TGCT	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg16325326	chr1:53192061	ZYG11B	-0.85	-11.95	-0.73	2.3e-22	Monocyte count;
TGCT	cis	rs4713118	0.824	rs9468225	chr6:27745719	T/G	cg02458000	chr6:26745757	NA	-0.56	-4.91	-0.4	2.79e-6	Parkinson's disease;
TGCT	cis	rs2180341	0.804	rs6902233	chr6:127555963	A/G	cg27446573	chr6:127587934	RNF146	1.06	8.23	0.59	2.16e-13	Breast cancer;
TGCT	cis	rs1865760	0.555	rs2051541	chr6:25945211	C/T	cg03264133	chr6:25882463	NA	0.47	5.05	0.41	1.57e-6	Height;
TGCT	cis	rs9611519	0.929	rs9611474	chr22:41434858	G/A	cg03806693	chr22:41940476	POLR3H	-0.7	-6.22	-0.49	6.88e-9	Neuroticism;
TGCT	cis	rs9303542	0.559	rs2229302	chr17:46620402	G/A	cg25032089	chr17:46643351	HOXB3	0.56	5.27	0.43	5.97e-7	Ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs9467773	0.620	rs2451744	chr6:26633463	G/T	cg15659132	chr6:26577336	NA	0.86	11.04	0.7	3.71e-20	Intelligence (multi-trait analysis);
TGCT	cis	rs2997447	0.633	rs11247848	chr1:26357667	G/A	cg19633962	chr1:26362018	EXTL1	-0.72	-4.89	-0.4	3.01e-6	QRS complex (12-leadsum);
TGCT	cis	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg18252515	chr7:66147081	NA	-1.3	-8.08	-0.59	4.84e-13	Diabetic kidney disease;
TGCT	cis	rs739496	0.843	rs621899	chr12:111984851	T/C	cg10833066	chr12:111807467	FAM109A	0.37	4.93	0.4	2.61e-6	Platelet count;
TGCT	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg01802117	chr1:53393560	SCP2	0.43	5.12	0.42	1.14e-6	Monocyte count;
TGCT	trans	rs7076096	0.505	rs71471182	chr10:87635602	A/T	cg22879689	chr7:925143	C7orf20	0.48	6.77	0.52	4.48e-10	Post-traumatic stress disorder (asjusted for relatedness);
TGCT	trans	rs1814175	0.645	rs7395438	chr11:49877379	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.45	-11.09	-0.71	2.8e-20	Height;
TGCT	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg09359103	chr1:154839909	KCNN3	-0.62	-11.25	-0.71	1.15e-20	Prostate cancer;
TGCT	cis	rs8062405	1.000	rs4451951	chr16:28836205	T/C	cg09754948	chr16:28834200	ATXN2L	0.61	4.56	0.38	1.22e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs7819412	0.539	rs11250131	chr8:11251175	C/T	cg21775007	chr8:11205619	TDH	-0.64	-7.01	-0.53	1.39e-10	Triglycerides;
TGCT	cis	rs1008375	0.933	rs4698637	chr4:17632843	A/T	cg18681998	chr4:17616180	MED28	1.01	11.13	0.71	2.22e-20	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6701037	0.748	rs10912901	chr1:175138602	G/A	cg00321850	chr1:175162397	KIAA0040	-0.41	-5.6	-0.45	1.32e-7	Alcohol dependence;
TGCT	cis	rs10791097	0.653	rs11222362	chr11:130731425	T/C	cg14779329	chr11:130786720	SNX19	0.27	4.89	0.4	3.11e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs2180341	0.814	rs9385424	chr6:127726796	A/G	cg24812749	chr6:127587940	RNF146	0.76	6.22	0.49	7.07e-9	Breast cancer;
TGCT	cis	rs11031096	0.655	rs1822288	chr11:4212478	C/T	cg08557956	chr11:4115526	RRM1	0.52	4.83	0.4	4e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs35306767	0.903	rs12250937	chr10:900209	C/T	cg26597838	chr10:835615	NA	0.76	10.71	0.69	2.41e-19	Eosinophil percentage of granulocytes;
TGCT	cis	rs8141529	0.748	rs5752826	chr22:29269808	A/G	cg02153584	chr22:29168773	CCDC117	0.63	4.87	0.4	3.3e-6	Lymphocyte counts;
TGCT	cis	rs1153858	1.000	rs11852800	chr15:45639131	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.5	-5.77	-0.46	6.02e-8	Homoarginine levels;
TGCT	cis	rs7607369	0.648	rs7582193	chr2:219652532	T/C	cg02176678	chr2:219576539	TTLL4	-0.45	-5.86	-0.47	3.89e-8	Red blood cell count;Amyotrophic lateral sclerosis;
TGCT	cis	rs12220238	1.000	rs11000930	chr10:75982982	C/G	cg19889307	chr10:75911429	ADK;AP3M1	-0.85	-5.91	-0.47	3.14e-8	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg05368731	chr17:41323189	NBR1	1.2	14.2	0.79	8.98e-28	Menopause (age at onset);
TGCT	cis	rs453301	0.652	rs2043129	chr8:8825504	C/G	cg15556689	chr8:8085844	FLJ10661	0.67	5.53	0.44	1.79e-7	Joint mobility (Beighton score);
TGCT	cis	rs136211	0.577	rs9607339	chr22:36768932	G/T	cg16924664	chr22:36878180	TXN2	0.5	4.69	0.39	7.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs763121	0.819	rs5757160	chr22:38989646	T/C	cg06022373	chr22:39101656	GTPBP1	0.81	8.26	0.6	1.84e-13	Menopause (age at onset);
TGCT	cis	rs6964587	0.626	rs4729011	chr7:91515419	G/A	cg17063962	chr7:91808500	NA	-0.76	-7.15	-0.54	6.42e-11	Breast cancer;
TGCT	cis	rs4843747	0.671	rs4075599	chr16:88107423	C/G	cg06915872	chr16:87998081	BANP	-0.3	-4.55	-0.38	1.25e-5	Menopause (age at onset);
TGCT	cis	rs7582180	0.663	rs4850930	chr2:100990955	T/C	cg14675211	chr2:100938903	LONRF2	0.48	4.6	0.38	1.01e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg11764359	chr7:65958608	NA	0.61	5.53	0.44	1.84e-7	Aortic root size;
TGCT	cis	rs17401966	0.898	rs11587495	chr1:10448999	T/C	cg19773385	chr1:10388646	KIF1B	-0.24	-5.5	-0.44	2.09e-7	Hepatocellular carcinoma;
TGCT	cis	rs7772486	0.701	rs7772717	chr6:145954854	T/C	cg23711669	chr6:146136114	FBXO30	0.92	10.45	0.68	1.03e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs478304	0.651	rs11600918	chr11:65511965	A/G	cg27068330	chr11:65405492	SIPA1	-0.94	-9.57	-0.65	1.41e-16	Acne (severe);
TGCT	cis	rs1475911	1.000	rs2839467	chr21:43513200	A/G	cg19766460	chr21:43528205	UMODL1;C21orf128	-0.53	-7.33	-0.55	2.55e-11	IgG glycosylation;
TGCT	cis	rs6882046	0.513	rs676096	chr5:88035887	C/T	cg24804195	chr5:87968844	LOC645323	-0.59	-5.9	-0.47	3.31e-8	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg15556689	chr8:8085844	FLJ10661	0.72	6.42	0.5	2.67e-9	Mood instability;
TGCT	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs12681288	0.862	rs2701899	chr8:1019581	G/A	cg08872321	chr8:1308229	NA	-0.26	-4.72	-0.39	6.15e-6	Schizophrenia;
TGCT	cis	rs986417	0.818	rs10151839	chr14:60980688	T/G	cg27398547	chr14:60952738	C14orf39	1.43	9.1	0.63	1.87e-15	Gut microbiota (bacterial taxa);
TGCT	cis	rs2658782	1.000	rs2608216	chr11:93149172	G/A	cg18152523	chr11:93063302	CCDC67	-0.69	-5.41	-0.44	3.11e-7	Pulmonary function decline;
TGCT	cis	rs10751667	0.643	rs10751669	chr11:942344	C/G	cg06064525	chr11:970664	AP2A2	0.35	8.1	0.59	4.49e-13	Alzheimer's disease (late onset);
TGCT	cis	rs2469997	0.925	rs2470018	chr8:120361655	C/T	cg00681363	chr8:120844660	TAF2	0.69	4.48	0.37	1.64e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs9788682	0.947	rs7169584	chr15:78822660	A/T	cg06917634	chr15:78832804	PSMA4	-0.7	-5.01	-0.41	1.83e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs9430161	0.579	rs7542164	chr1:11040223	G/A	cg02454025	chr1:11042201	C1orf127	0.97	12.71	0.75	3.27e-24	Ewing sarcoma;
TGCT	cis	rs2549003	1.000	rs2070728	chr5:131819977	C/T	cg02551604	chr5:131831745	NA	-0.89	-11.95	-0.73	2.33e-22	Asthma (sex interaction);
TGCT	cis	rs9467711	0.651	rs115648484	chr6:25938767	T/A	cg16898833	chr6:26189333	HIST1H4D	1.32	5.63	0.45	1.16e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12477438	0.765	rs7340412	chr2:99661148	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-4.62	-0.38	9.47e-6	Chronic sinus infection;
TGCT	cis	rs1008375	0.966	rs2872957	chr4:17651757	C/A	cg10189774	chr4:17578691	LAP3	0.6	5.29	0.43	5.23e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg12140144	chr1:2984275	FLJ42875;PRDM16	0.35	4.93	0.41	2.55e-6	Height;
TGCT	cis	rs9486719	1.000	rs12190507	chr6:96898265	T/G	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.21	-0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs6684514	1.000	rs12142808	chr1:156230546	G/A	cg20302342	chr1:156215951	PAQR6	0.37	4.72	0.39	6.38e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs2455799	0.634	rs6771390	chr3:15906637	C/G	cg16303742	chr3:15540471	COLQ	-0.24	-4.64	-0.38	8.68e-6	Mean platelet volume;
TGCT	cis	rs5769765	0.862	rs9616774	chr22:50290599	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.4	6.02	0.48	1.81e-8	Schizophrenia;
TGCT	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg00149659	chr3:10157352	C3orf10	0.73	4.72	0.39	6.17e-6	Alzheimer's disease;
TGCT	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg10150615	chr22:24372951	LOC391322	1.01	13.23	0.77	1.86e-25	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs67460515	0.892	rs4856756	chr3:160999414	G/A	cg03342759	chr3:160939853	NMD3	-0.49	-5.3	-0.43	5.16e-7	Parkinson's disease;
TGCT	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg11644478	chr21:40555479	PSMG1	0.96	9.88	0.66	2.44e-17	Cognitive function;
TGCT	cis	rs6987853	0.933	rs2923430	chr8:42391195	T/C	cg20539142	chr8:42623718	CHRNA6	-0.19	-4.55	-0.38	1.24e-5	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs71435601	0.699	rs515135	chr2:21286057	T/C	cg25035485	chr2:21266500	APOB	0.52	4.54	0.38	1.32e-5	Cholesterol, total;
TGCT	cis	rs4642101	0.662	rs4034942	chr3:12836792	C/T	cg05775895	chr3:12838266	CAND2	0.91	10.85	0.7	1.06e-19	QRS complex (12-leadsum);
TGCT	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg17054783	chr10:134559939	INPP5A	0.26	5.3	0.43	5.04e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs13191362	0.507	rs2846566	chr6:163059714	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.57	-5.28	-0.43	5.63e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs11190604	0.767	rs10883489	chr10:102194532	T/C	cg23241863	chr10:102295624	HIF1AN	0.64	4.8	0.4	4.42e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.77	6.05	0.48	1.56e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg22920501	chr2:26401640	FAM59B	-0.73	-6.28	-0.49	5.18e-9	Gut microbiome composition (summer);
TGCT	cis	rs2115630	0.936	rs6496318	chr15:85215229	C/T	cg12501888	chr15:85177176	SCAND2	-0.49	-4.77	-0.39	5.18e-6	P wave terminal force;
TGCT	cis	rs9368481	0.761	rs4713062	chr6:26948195	A/G	cg18867708	chr6:26865862	GUSBL1	-0.34	-4.56	-0.38	1.23e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs11792861	0.781	rs2297581	chr9:111755008	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.5	4.73	0.39	6.12e-6	Menarche (age at onset);
TGCT	cis	rs936229	0.861	rs7176022	chr15:75107880	G/T	cg10253484	chr15:75165896	SCAMP2	0.66	5.34	0.43	4.28e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
TGCT	cis	rs13242816	1.000	rs2191499	chr7:116138599	C/T	cg16553024	chr7:116138462	CAV2	-0.44	-5.34	-0.43	4.29e-7	P wave duration;
TGCT	cis	rs10986311	0.775	rs3758207	chr9:127132020	C/T	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.19	-4.85	-0.4	3.61e-6	Vitiligo;
TGCT	cis	rs832540	0.931	rs2662040	chr5:56246610	A/G	cg24531977	chr5:56204891	C5orf35	0.5	5.21	0.42	7.64e-7	Coronary artery disease;
TGCT	cis	rs9653442	0.648	rs11123805	chr2:100643464	A/G	cg22139774	chr2:100720529	AFF3	-0.41	-7.28	-0.55	3.3e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs2458413	0.522	rs2514657	chr8:105331215	T/C	cg13045555	chr8:105342365	NA	-0.39	-6.2	-0.49	7.83e-9	Paget's disease;
TGCT	cis	rs1395	0.885	rs7575245	chr2:27527321	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.47	6.18	0.49	8.53e-9	Blood metabolite levels;
TGCT	cis	rs1322512	1.000	rs7744697	chr6:152948986	G/A	cg03415253	chr6:152958462	SYNE1	-0.57	-4.99	-0.41	2e-6	Tonometry;
TGCT	cis	rs6569992	0.500	rs1022506	chr6:135511587	G/A	cg22676075	chr6:135203613	NA	0.75	4.64	0.38	8.82e-6	Red blood cell traits;
TGCT	cis	rs7100689	0.784	rs4934153	chr10:82191255	T/C	cg01528321	chr10:82214614	TSPAN14	0.9	9.42	0.65	3.22e-16	Post bronchodilator FEV1;
TGCT	cis	rs514406	0.621	rs928452	chr1:53195926	G/C	cg01802117	chr1:53393560	SCP2	0.42	4.92	0.4	2.69e-6	Monocyte count;
TGCT	cis	rs6088580	0.634	rs2378133	chr20:32919505	C/G	cg08999081	chr20:33150536	PIGU	-0.27	-5.19	-0.42	8.22e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg18876405	chr7:65276391	NA	0.31	4.79	0.4	4.58e-6	Aortic root size;
TGCT	cis	rs7819412	0.749	rs11991118	chr8:10939273	A/C	cg21775007	chr8:11205619	TDH	0.48	4.7	0.39	6.82e-6	Triglycerides;
TGCT	cis	rs7937682	1.000	rs11608122	chr11:111535105	C/T	cg09085632	chr11:111637200	PPP2R1B	1.03	9.46	0.65	2.53e-16	Primary sclerosing cholangitis;
TGCT	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg06873352	chr17:61820015	STRADA	0.55	5.69	0.46	8.57e-8	Prudent dietary pattern;
TGCT	cis	rs854765	0.547	rs2955370	chr17:17966945	C/T	cg04398451	chr17:18023971	MYO15A	0.34	5.46	0.44	2.48e-7	Total body bone mineral density;
TGCT	cis	rs56235845	0.694	rs9313758	chr5:176773091	T/G	cg06060754	chr5:176797920	RGS14	0.42	6.76	0.52	4.78e-10	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg03934478	chr11:495069	RNH1	0.35	5.89	0.47	3.34e-8	Body mass index;
TGCT	cis	rs3008870	1.000	rs2985824	chr1:67410171	C/T	cg03991309	chr1:68237761	GNG12	-0.26	-4.57	-0.38	1.17e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs17345786	1.000	rs58907984	chr3:101305170	T/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.86	8.79	0.62	1.01e-14	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4889855	0.530	rs4303599	chr17:78566700	C/T	cg16591659	chr17:78472290	NA	0.28	4.46	0.37	1.84e-5	Fractional excretion of uric acid;
TGCT	cis	rs9611565	0.644	rs2413652	chr22:42097238	C/T	cg06481639	chr22:41940642	POLR3H	0.58	4.95	0.41	2.34e-6	Vitiligo;
TGCT	cis	rs2898290	0.500	rs11998678	chr8:11830150	A/G	cg21775007	chr8:11205619	TDH	-0.49	-4.58	-0.38	1.13e-5	Systolic blood pressure;
TGCT	cis	rs1997103	1.000	rs2877284	chr7:55408778	A/G	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs7020830	0.898	rs2790063	chr9:37287405	G/A	cg14294708	chr9:37120828	ZCCHC7	1.16	15.22	0.81	3.78e-30	Schizophrenia;
TGCT	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg11764359	chr7:65958608	NA	-0.61	-5.52	-0.44	1.93e-7	Aortic root size;
TGCT	cis	rs2235642	0.750	rs2859310	chr16:1656765	C/T	cg11375102	chr16:1583810	IFT140;TMEM204	0.27	4.64	0.38	8.77e-6	Coronary artery disease;
TGCT	trans	rs9388451	0.874	rs3734634	chr6:126111800	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.72	-8.03	-0.58	6.54e-13	Brugada syndrome;
TGCT	trans	rs8073060	0.544	rs225283	chr17:33934912	A/G	cg19694781	chr19:47549865	TMEM160	-0.6	-13.04	-0.76	5.29e-25	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs1018836	0.544	rs10112371	chr8:91457626	C/T	cg16814680	chr8:91681699	NA	0.57	5.57	0.45	1.53e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9611519	0.929	rs9611509	chr22:41565827	A/G	cg13695892	chr22:41940480	POLR3H	-0.5	-4.51	-0.38	1.5e-5	Neuroticism;
TGCT	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg08219700	chr8:58056026	NA	0.38	4.64	0.38	8.83e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs11025559	0.812	rs10833338	chr11:20514709	A/G	cg19653624	chr11:20408972	PRMT3	-0.61	-4.74	-0.39	5.69e-6	Pursuit maintenance gain;
TGCT	cis	rs1372520	0.684	rs1442144	chr4:90736113	T/C	cg14346243	chr4:90757452	SNCA	-0.66	-5.56	-0.45	1.55e-7	Neuroticism;
TGCT	trans	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg25482853	chr8:67687455	SGK3	1.21	10.33	0.68	2.02e-18	Lung disease severity in cystic fibrosis;
TGCT	cis	rs6840360	0.571	rs7674244	chr4:152488302	T/C	cg17479576	chr4:152424074	FAM160A1	-0.73	-7.94	-0.58	1.03e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs1030877	0.557	rs2576752	chr2:105978761	A/G	cg02079111	chr2:105885981	TGFBRAP1	0.17	5.27	0.43	5.93e-7	Obesity-related traits;
TGCT	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg09359103	chr1:154839909	KCNN3	-0.67	-12.42	-0.74	1.61e-23	Prostate cancer;
TGCT	cis	rs11874712	0.688	rs12954742	chr18:43703223	C/G	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.48	4.82	0.4	4.19e-6	Migraine - clinic-based;
TGCT	cis	rs35883536	0.609	rs2647327	chr1:101041766	C/T	cg14855972	chr1:101004472	GPR88	0.23	4.44	0.37	1.97e-5	Monocyte count;
TGCT	cis	rs1497406	0.744	rs4233540	chr1:16507384	A/G	cg20430773	chr1:16534157	ARHGEF19	-0.54	-5.71	-0.46	7.75e-8	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg06238570	chr21:40685208	BRWD1	0.69	6.41	0.5	2.81e-9	Cognitive function;
TGCT	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg03609598	chr5:56110824	MAP3K1	-0.58	-4.7	-0.39	6.72e-6	Initial pursuit acceleration;
TGCT	cis	rs3733631	1.000	rs4141203	chr4:104638435	A/G	cg24090629	chr4:104641072	TACR3	-0.74	-5.8	-0.46	5.14e-8	Menarche (age at onset);
TGCT	cis	rs3008870	1.000	rs3008894	chr1:67377739	A/G	cg03991309	chr1:68237761	GNG12	0.29	4.88	0.4	3.2e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg11905131	chr22:24372483	LOC391322	-0.79	-8.45	-0.6	6.78e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	4.95	0.41	2.37e-6	Electroencephalogram traits;
TGCT	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg11062466	chr8:58055876	NA	0.45	4.83	0.4	3.91e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1008375	0.931	rs6449310	chr4:17575530	T/C	cg10189774	chr4:17578691	LAP3	0.62	5.36	0.43	3.97e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7586879	0.598	rs6724772	chr2:25128730	T/C	cg15423357	chr2:25149977	NA	0.5	4.89	0.4	3.06e-6	Body mass index;
TGCT	cis	rs2404602	0.735	rs4886495	chr15:76738959	C/T	cg22467129	chr15:76604101	ETFA	-0.43	-4.6	-0.38	1.01e-5	Blood metabolite levels;
TGCT	cis	rs6880778	0.505	rs10473189	chr5:40402692	G/C	cg01087697	chr5:40835557	RPL37	0.54	4.93	0.4	2.6e-6	Inflammatory bowel disease;
TGCT	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg23131131	chr22:24373011	LOC391322	0.67	7.07	0.54	9.88e-11	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7572733	0.534	rs1464211	chr2:198798630	G/A	cg00792783	chr2:198669748	PLCL1	0.57	5.23	0.43	6.99e-7	Dermatomyositis;
TGCT	cis	rs2180341	0.782	rs6912006	chr6:127722631	C/T	cg24812749	chr6:127587940	RNF146	0.63	5.37	0.43	3.81e-7	Breast cancer;
TGCT	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg21963583	chr11:68658836	MRPL21	0.36	6.1	0.48	1.25e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9443645	0.869	rs7756858	chr6:79619968	A/G	cg05283184	chr6:79620031	NA	-0.21	-4.63	-0.38	9.16e-6	Intelligence (multi-trait analysis);
TGCT	trans	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg21659725	chr3:3221576	CRBN	-0.7	-7.98	-0.58	8.35e-13	Body mass index;
TGCT	cis	rs9911578	0.935	rs12948039	chr17:57045184	C/T	cg12560992	chr17:57184187	TRIM37	0.73	8.7	0.62	1.69e-14	Intelligence (multi-trait analysis);
TGCT	cis	rs6831352	0.879	rs29001215	chr4:100051722	T/C	cg12011299	chr4:100065546	ADH4	-0.41	-4.92	-0.4	2.72e-6	Alcohol dependence;
TGCT	cis	rs4705962	0.918	rs6879672	chr5:132025947	A/G	cg13566430	chr5:131992455	IL13	-0.29	-4.44	-0.37	1.97e-5	Atopic dermatitis;
TGCT	cis	rs9549367	0.713	rs3024747	chr13:113821787	C/G	cg09473364	chr13:112927190	NA	-0.3	-4.44	-0.37	1.95e-5	Platelet distribution width;
TGCT	cis	rs8072100	0.782	rs28507314	chr17:45551402	C/T	cg08085267	chr17:45401833	C17orf57	-0.48	-5.23	-0.43	6.87e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg06212747	chr3:49208901	KLHDC8B	0.65	6.23	0.49	6.72e-9	Menarche (age at onset);
TGCT	cis	rs17197710	0.673	rs41310332	chr11:47348057	C/T	cg13308137	chr11:47528955	CUGBP1	0.41	5.82	0.46	4.71e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9814567	1.000	rs9876658	chr3:134179453	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.97	9.98	0.67	1.45e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs7429990	0.932	rs2361684	chr3:48152618	G/C	cg11946769	chr3:48343235	NME6	-0.56	-4.63	-0.38	9.27e-6	Educational attainment (years of education);
TGCT	cis	rs7178572	1.000	rs6495240	chr15:77766556	T/C	cg22256960	chr15:77711686	NA	-0.95	-10.89	-0.7	8.57e-20	Type 2 diabetes;
TGCT	cis	rs1448094	0.511	rs7967183	chr12:86216845	T/G	cg02569458	chr12:86230093	RASSF9	0.36	4.53	0.38	1.36e-5	Major depressive disorder;
TGCT	cis	rs1395	1.000	rs1395	chr2:27424636	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.47	-6.33	-0.49	4.08e-9	Blood metabolite levels;
TGCT	cis	rs7208859	0.623	rs77544470	chr17:28934550	C/A	cg14008862	chr17:28927542	LRRC37B2	0.88	5.32	0.43	4.75e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs35306767	0.953	rs35174953	chr10:961191	C/A	cg20503657	chr10:835505	NA	0.68	9.49	0.65	2.12e-16	Eosinophil percentage of granulocytes;
TGCT	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg24675658	chr1:53192096	ZYG11B	-0.75	-9.11	-0.63	1.78e-15	Monocyte count;
TGCT	cis	rs3540	0.883	rs6496676	chr15:90988384	A/T	cg22089800	chr15:90895588	ZNF774	0.74	6.72	0.52	5.87e-10	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs9868809	0.772	rs12107252	chr3:48691316	T/C	cg00383909	chr3:49044727	WDR6	0.9	5.42	0.44	3.05e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs9486715	0.793	rs2499777	chr6:97013814	T/C	cg06623918	chr6:96969491	KIAA0776	-1.1	-14.37	-0.79	3.55e-28	Headache;
TGCT	cis	rs28785552	0.966	rs7247272	chr19:53236331	C/T	cg04754360	chr19:53238445	ZNF611	0.58	4.73	0.39	5.89e-6	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs4808199	0.895	rs4808194	chr19:19435680	T/G	cg03709012	chr19:19516395	GATAD2A	0.81	6.32	0.49	4.32e-9	Nonalcoholic fatty liver disease;
TGCT	cis	rs9611565	0.649	rs5758442	chr22:42133060	T/C	cg03806693	chr22:41940476	POLR3H	0.93	9.08	0.63	2.06e-15	Vitiligo;
TGCT	cis	rs2982552	0.967	rs2982556	chr6:152056842	G/A	cg22157087	chr6:152012887	ESR1	0.18	4.58	0.38	1.11e-5	Bone properties (heel);
TGCT	cis	rs9796	0.835	rs28455998	chr15:41430969	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.48	-6.18	-0.49	8.55e-9	Menopause (age at onset);
TGCT	cis	rs10791097	0.694	rs6590520	chr11:130747386	C/G	cg12179176	chr11:130786555	SNX19	0.84	10.14	0.67	5.76e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs854765	0.547	rs2955377	chr17:17932818	G/A	cg04398451	chr17:18023971	MYO15A	-0.32	-5.15	-0.42	1.01e-6	Total body bone mineral density;
TGCT	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg10560079	chr2:191398806	TMEM194B	-0.36	-5.07	-0.41	1.4e-6	Pulse pressure;
TGCT	cis	rs6570726	0.526	rs9403699	chr6:145730685	G/T	cg23711669	chr6:146136114	FBXO30	0.59	5.3	0.43	5.19e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2243480	1.000	rs316307	chr7:65570171	C/T	cg18252515	chr7:66147081	NA	-1.21	-7.77	-0.57	2.59e-12	Diabetic kidney disease;
TGCT	cis	rs9291683	0.620	rs7699512	chr4:10125808	C/T	cg00071950	chr4:10020882	SLC2A9	-0.43	-4.7	-0.39	6.69e-6	Bone mineral density;
TGCT	cis	rs36051895	0.664	rs2274649	chr9:5090934	A/T	cg02405213	chr9:5042618	JAK2	-0.72	-9.52	-0.65	1.85e-16	Pediatric autoimmune diseases;
TGCT	cis	rs7681440	0.835	rs6839608	chr4:90805493	T/C	cg26578617	chr4:90757533	SNCA	-0.45	-4.63	-0.38	9.12e-6	Dementia with Lewy bodies;
TGCT	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg19723775	chr5:179050963	HNRNPH1	-0.5	-5.03	-0.41	1.67e-6	Lung cancer;
TGCT	cis	rs7829975	0.711	rs4481596	chr8:8704330	G/C	cg15556689	chr8:8085844	FLJ10661	0.75	7.1	0.54	8.38e-11	Mood instability;
TGCT	cis	rs56104184	0.578	rs7254608	chr19:49395774	G/T	cg15549821	chr19:49342101	PLEKHA4	-0.41	-5.3	-0.43	5.08e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg19318889	chr4:1322082	MAEA	-0.25	-6.46	-0.5	2.19e-9	Longevity;
TGCT	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.51	-4.82	-0.4	4.16e-6	Bipolar disorder;
TGCT	cis	rs7208859	0.623	rs11656844	chr17:29060597	G/T	cg13385521	chr17:29058706	SUZ12P	0.79	4.77	0.39	5.16e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs1048238	0.506	rs6668183	chr1:16173814	G/C	cg21385522	chr1:16154831	NA	0.61	6.99	0.53	1.53e-10	Systolic blood pressure;
TGCT	cis	rs854765	0.616	rs8076747	chr17:17853595	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	7.36	0.55	2.19e-11	Total body bone mineral density;
TGCT	cis	rs4820539	1.000	rs885964	chr22:23461003	G/C	cg14186256	chr22:23484241	RTDR1	0.98	12.14	0.74	7.67e-23	Bone mineral density;
TGCT	cis	rs8177253	0.555	rs4481157	chr3:133464684	G/A	cg08048268	chr3:133502702	NA	-0.37	-4.52	-0.38	1.43e-5	Iron status biomarkers;
TGCT	cis	rs782590	0.582	rs2627767	chr2:55926815	A/T	cg03859395	chr2:55845619	SMEK2	0.73	7.48	0.56	1.19e-11	Metabolic syndrome;
TGCT	cis	rs2677744	0.563	rs8024249	chr15:91494249	T/C	cg23684204	chr15:91497937	RCCD1	0.31	4.66	0.39	7.94e-6	Attention deficit hyperactivity disorder;
TGCT	cis	rs3087591	0.683	rs2854306	chr17:29648146	G/A	cg24425628	chr17:29625626	OMG;NF1	0.4	5.63	0.45	1.14e-7	Hip circumference;
TGCT	trans	rs12655019	0.920	rs2271202	chr5:56208541	T/C	cg25190722	chr1:3801660	DFFB	0.62	7.17	0.54	5.87e-11	Breast cancer (early onset);
TGCT	cis	rs2456568	0.867	rs4753111	chr11:93658410	A/G	cg26875233	chr11:93583750	C11orf90	-0.47	-5.83	-0.46	4.5e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs9303401	0.614	rs28651036	chr17:57080471	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.59	5.97	0.47	2.27e-8	Cognitive test performance;
TGCT	cis	rs6121246	0.529	rs56153385	chr20:30187609	C/T	cg10886678	chr20:30946050	ASXL1	-0.71	-4.8	-0.4	4.42e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs2463822	1.000	rs2513074	chr11:62100880	A/C	cg23876832	chr11:62092739	NA	0.67	4.91	0.4	2.82e-6	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs1525293	0.714	rs12698981	chr7:70508699	A/G	cg21135135	chr7:70597687	WBSCR17	0.48	4.59	0.38	1.05e-5	Colonoscopy-negative controls vs population controls;Major depressive disorder;
TGCT	cis	rs7666738	0.830	rs28444709	chr4:99028496	A/T	cg18180107	chr4:99064573	C4orf37	0.57	5.31	0.43	4.94e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7824557	0.767	rs11250127	chr8:11170209	G/A	cg21775007	chr8:11205619	TDH	0.58	5.46	0.44	2.46e-7	Retinal vascular caliber;
TGCT	cis	rs2153535	0.580	rs2143354	chr6:8517907	G/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.01	0.41	1.86e-6	Motion sickness;
TGCT	trans	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.83	-8.69	-0.62	1.76e-14	Body mass index;
TGCT	cis	rs13191362	1.000	rs67042566	chr6:163006541	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs600626	0.636	rs11236517	chr11:75452721	T/C	cg15975211	chr11:75525881	UVRAG	0.82	4.53	0.38	1.37e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
TGCT	cis	rs10089	1.000	rs4835945	chr5:127526481	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	7.35	0.55	2.37e-11	Ileal carcinoids;
TGCT	cis	rs10504229	0.679	rs16921683	chr8:58053270	T/C	cg08280861	chr8:58055591	NA	0.35	4.88	0.4	3.2e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10465746	0.905	rs1324484	chr1:84382844	T/C	cg10977910	chr1:84465055	TTLL7	0.67	6.63	0.51	9.19e-10	Obesity-related traits;
TGCT	trans	rs66573146	0.803	rs59742225	chr4:6969942	C/T	cg07817883	chr1:32538562	TMEM39B	1.56	8.31	0.6	1.45e-13	Granulocyte percentage of myeloid white cells;
TGCT	trans	rs7618501	0.699	rs11713193	chr3:49924424	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.87	9.22	0.64	9.94e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs10883723	0.810	rs2296586	chr10:104245575	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	9.22	0.64	9.86e-16	Allergic disease (asthma, hay fever or eczema);
TGCT	trans	rs2688608	0.592	rs13013	chr10:75562161	C/A	cg13918328	chr10:52500089	ASAH2B	0.69	6.89	0.53	2.56e-10	Inflammatory bowel disease;
TGCT	trans	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg13615516	chr5:77269221	NA	0.67	8.36	0.6	1.09e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs231513	0.911	rs231517	chr17:41961789	C/T	cg26893861	chr17:41843967	DUSP3	-0.73	-5.64	-0.45	1.08e-7	Cognitive function;
TGCT	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg22166914	chr1:53195759	ZYG11B	-0.39	-6.57	-0.51	1.23e-9	Monocyte count;
TGCT	cis	rs9858542	0.903	rs9875617	chr3:49634696	G/A	cg03060546	chr3:49711283	APEH	-0.63	-5.48	-0.44	2.28e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs1887596	0.624	rs9553854	chr13:27131270	T/C	cg01312412	chr13:27282625	NA	0.28	5.04	0.41	1.59e-6	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs9611565	0.512	rs45500192	chr22:42177899	A/G	cg13695892	chr22:41940480	POLR3H	-0.84	-7.96	-0.58	9.47e-13	Vitiligo;
TGCT	cis	rs1865760	0.663	rs9467656	chr6:25993559	G/A	cg16482183	chr6:26056742	HIST1H1C	0.56	5.05	0.41	1.52e-6	Height;
TGCT	cis	rs782590	0.935	rs782649	chr2:55860308	T/C	cg18811423	chr2:55921094	PNPT1	0.67	7.06	0.54	1.06e-10	Metabolic syndrome;
TGCT	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	8.99	0.63	3.48e-15	Platelet count;
TGCT	cis	rs12510870	0.599	rs12506668	chr4:74449824	T/C	cg05868023	chr4:75230803	EREG	-0.54	-4.76	-0.39	5.33e-6	Iris color (b* coordinate);
TGCT	cis	rs208520	0.690	rs12213561	chr6:66705646	T/C	cg07460842	chr6:66804631	NA	0.96	10.26	0.68	2.92e-18	Exhaled nitric oxide output;
TGCT	trans	rs9329221	0.711	rs55864141	chr8:9807022	T/C	cg06636001	chr8:8085503	FLJ10661	-0.77	-6.81	-0.52	3.74e-10	Neuroticism;
TGCT	cis	rs8064299	0.560	rs11077763	chr17:72786029	T/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.89	10.13	0.67	6.14e-18	Monocyte count;
TGCT	cis	rs17331151	0.573	rs76029595	chr3:52868523	C/T	cg12962167	chr3:53033115	SFMBT1	0.44	4.96	0.41	2.28e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs1541995	0.754	rs4984452	chr15:96233382	A/G	cg00882281	chr15:96346592	NA	-0.3	-4.84	-0.4	3.78e-6	Photic sneeze reflex;
TGCT	cis	rs174601	0.861	rs174580	chr11:61606642	A/G	cg19610905	chr11:61596333	FADS2	-0.96	-9.43	-0.65	3.08e-16	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
TGCT	cis	rs6121246	0.697	rs6087716	chr20:30229040	C/T	cg18721089	chr20:30220636	NA	-0.53	-5.43	-0.44	2.86e-7	Mean corpuscular hemoglobin;
TGCT	cis	rs42648	0.819	rs10953006	chr7:90030153	A/G	cg25739043	chr7:89950458	NA	-0.53	-4.98	-0.41	2.1e-6	Homocysteine levels;
TGCT	cis	rs10791097	0.668	rs10791102	chr11:130744977	G/A	cg05962950	chr11:130786565	SNX19	0.92	11.55	0.72	2.13e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg20891283	chr12:69753455	YEATS4	-0.9	-10.42	-0.68	1.18e-18	Cerebrospinal fluid biomarker levels;
TGCT	trans	rs1814175	0.546	rs1614397	chr11:49913384	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.36	-7.05	-0.53	1.13e-10	Height;
TGCT	trans	rs459571	0.834	rs379417	chr9:136890704	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.72	-7.83	-0.58	1.87e-12	Platelet distribution width;
TGCT	cis	rs9326248	0.954	rs521171	chr11:117064693	C/G	cg26566898	chr11:117069891	TAGLN	0.35	5.07	0.41	1.42e-6	Blood protein levels;
TGCT	cis	rs9549367	0.789	rs2025247	chr13:113882564	C/G	cg00898013	chr13:113819073	PROZ	-0.4	-4.88	-0.4	3.18e-6	Platelet distribution width;
TGCT	trans	rs2832077	0.527	rs2705690	chr21:30239245	T/A	cg14791747	chr16:20752902	THUMPD1	-1.01	-10.54	-0.69	6.23e-19	Cognitive test performance;
TGCT	cis	rs7973719	0.899	rs12424618	chr12:7344802	A/G	cg07052231	chr12:7363540	PEX5	0.37	5.58	0.45	1.43e-7	IgG glycosylation;
TGCT	cis	rs4654899	0.828	rs6668591	chr1:21066557	A/G	cg01072550	chr1:21505969	NA	-0.49	-7.7	-0.57	3.76e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs7224685	0.569	rs35578550	chr17:3996470	A/G	cg09580393	chr17:4869866	SPAG7	-0.39	-4.49	-0.37	1.62e-5	Type 2 diabetes;
TGCT	cis	rs9419702	0.538	rs9419625	chr10:133534954	T/G	cg23460707	chr10:133558971	NA	0.43	4.84	0.4	3.75e-6	Survival in rectal cancer;
TGCT	cis	rs17767294	0.614	rs72847329	chr6:27767046	T/C	cg08851530	chr6:28072375	NA	1.54	7.3	0.55	3.1e-11	Parkinson's disease;
TGCT	cis	rs2594989	0.943	rs2454499	chr3:11500531	T/C	cg00170343	chr3:11313890	ATG7	0.69	5.12	0.42	1.16e-6	Circulating chemerin levels;
TGCT	cis	rs4319547	0.656	rs2173582	chr12:122824694	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.6	-4.69	-0.39	7.14e-6	Body mass index;
TGCT	cis	rs4727443	0.866	rs6963345	chr7:99618606	G/A	cg13334819	chr7:99746414	C7orf59	0.56	4.71	0.39	6.63e-6	Interstitial lung disease;
TGCT	cis	rs6430585	0.583	rs2304371	chr2:136561557	A/G	cg07169764	chr2:136633963	MCM6	0.95	8.66	0.61	2.15e-14	Corneal structure;
TGCT	cis	rs4499344	0.633	rs259262	chr19:33153951	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.85	9.09	0.63	2.01e-15	Mean platelet volume;
TGCT	cis	rs10114408	0.959	rs12342427	chr9:96641701	A/C	cg13679303	chr9:96623674	NA	-0.36	-4.69	-0.39	6.98e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.7	-7.23	-0.54	4.37e-11	Prostate cancer;
TGCT	cis	rs7635838	0.596	rs347598	chr3:11258289	G/C	cg00170343	chr3:11313890	ATG7	0.58	5.54	0.45	1.72e-7	HDL cholesterol;
TGCT	cis	rs12762955	0.519	rs10795306	chr10:1019138	A/T	cg20503657	chr10:835505	NA	-0.4	-5.29	-0.43	5.26e-7	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs9788682	0.895	rs3813570	chr15:78832832	T/C	cg24631222	chr15:78858424	CHRNA5	0.92	7.57	0.56	7.51e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs12477438	0.520	rs13023744	chr2:99738224	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.15	18.22	0.85	7.28e-37	Chronic sinus infection;
TGCT	cis	rs12220238	0.722	rs10740440	chr10:76380366	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.59	4.54	0.38	1.29e-5	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs734999	0.545	rs4074789	chr1:2537464	A/G	cg18854424	chr1:2615690	NA	0.46	5.36	0.43	4e-7	Ulcerative colitis;
TGCT	cis	rs12368653	0.651	rs2277326	chr12:58202419	A/C	cg12615879	chr12:58013172	SLC26A10	-0.51	-6.49	-0.5	1.87e-9	Multiple sclerosis;
TGCT	cis	rs3780378	0.967	rs7037207	chr9:5043156	C/T	cg02405213	chr9:5042618	JAK2	-0.58	-7.5	-0.56	1.09e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg18252515	chr7:66147081	NA	-1.17	-7.49	-0.56	1.13e-11	Diabetic kidney disease;
TGCT	cis	rs4332037	0.539	rs62444881	chr7:2052318	C/T	cg25834613	chr7:1915315	MAD1L1	-0.52	-5.0	-0.41	1.87e-6	Bipolar disorder;
TGCT	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg15691649	chr6:25882328	NA	0.43	5.34	0.43	4.27e-7	Blood metabolite levels;
TGCT	cis	rs669446	0.591	rs586339	chr1:44137257	C/A	cg12908607	chr1:44402522	ARTN	-0.61	-6.64	-0.51	8.84e-10	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs11025559	0.812	rs10766679	chr11:20509190	T/C	cg19653624	chr11:20408972	PRMT3	-0.59	-4.7	-0.39	6.9e-6	Pursuit maintenance gain;
TGCT	cis	rs17376456	1.000	rs67150649	chr5:93292377	A/G	cg25358565	chr5:93447407	FAM172A	1.02	8.11	0.59	4.23e-13	Diabetic retinopathy;
TGCT	cis	rs4851266	1.000	rs11684761	chr2:100826871	C/A	cg07810366	chr2:100720526	AFF3	-0.38	-5.44	-0.44	2.7e-7	Educational attainment;
TGCT	cis	rs4820539	0.966	rs2157709	chr22:23457420	T/C	cg14186256	chr22:23484241	RTDR1	0.99	12.18	0.74	6.28e-23	Bone mineral density;
TGCT	cis	rs2075371	1.000	rs2544210	chr7:133971535	C/T	cg11752832	chr7:134001865	SLC35B4	0.7	6.51	0.5	1.66e-9	Mean platelet volume;
TGCT	cis	rs4727027	0.899	rs6944096	chr7:148870026	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.52	4.61	0.38	9.67e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs72945132	0.882	rs17160777	chr11:70163723	T/C	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs9928842	0.765	rs4479268	chr16:75224733	G/T	cg09066997	chr16:75300724	BCAR1	-0.27	-4.79	-0.39	4.75e-6	Alcoholic chronic pancreatitis;
TGCT	cis	rs4713118	0.868	rs10484401	chr6:27746590	A/T	cg20933634	chr6:27740509	NA	-0.36	-4.93	-0.4	2.62e-6	Parkinson's disease;
TGCT	cis	rs12765878	0.513	rs56093138	chr10:105617908	A/C	cg11005552	chr10:105648138	OBFC1	-0.36	-5.16	-0.42	9.33e-7	Coronary artery disease;
TGCT	cis	rs4372836	1.000	rs2169748	chr2:28957753	G/A	cg09522027	chr2:28974177	PPP1CB	0.54	4.61	0.38	9.87e-6	Body mass index;
TGCT	cis	rs894734	0.567	rs7138907	chr12:54324576	C/T	cg17708016	chr12:54321992	NA	0.68	5.64	0.45	1.11e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
TGCT	cis	rs2115630	1.000	rs8037423	chr15:85355494	C/T	cg11189052	chr15:85197271	WDR73	-0.64	-6.15	-0.48	9.77e-9	P wave terminal force;
TGCT	cis	rs854765	0.654	rs11078400	chr17:17757728	A/G	cg04398451	chr17:18023971	MYO15A	0.29	4.57	0.38	1.15e-5	Total body bone mineral density;
TGCT	cis	rs4746818	0.793	rs2008541	chr10:70860599	A/G	cg11621586	chr10:70884670	VPS26A	1.16	8.0	0.58	7.7e-13	Left atrial antero-posterior diameter;
TGCT	trans	rs629535	0.814	rs62513376	chr8:70086881	C/T	cg21567404	chr3:27674614	NA	-0.56	-8.82	-0.62	8.75e-15	Dupuytren's disease;
TGCT	cis	rs60154123	0.505	rs115881613	chr1:210040369	C/T	cg04352962	chr1:209979756	IRF6	0.69	4.73	0.39	6.04e-6	Coronary artery disease;
TGCT	cis	rs377070	0.903	rs309403	chr4:123616822	T/C	cg10495464	chr4:123653540	BBS12;LOC729338	0.46	5.08	0.42	1.35e-6	Mosquito bite size;
TGCT	cis	rs1185460	0.967	rs1784460	chr11:118938371	A/T	cg01677386	chr11:118938358	VPS11	0.5	4.53	0.38	1.39e-5	Coronary artery disease;
TGCT	cis	rs3784262	0.669	rs4646602	chr15:58294757	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.44	-6.31	-0.49	4.53e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs9902453	1.000	rs4795525	chr17:28388487	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-6.56	-0.51	1.3e-9	Coffee consumption (cups per day);
TGCT	cis	rs7582180	0.629	rs6731549	chr2:100939937	T/G	cg08017756	chr2:100939284	LONRF2	-0.3	-4.78	-0.39	4.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg11890956	chr21:40555474	PSMG1	-0.69	-6.63	-0.51	9.35e-10	Menarche (age at onset);
TGCT	cis	rs67311347	0.577	rs11129870	chr3:40260406	G/A	cg13683864	chr3:40499215	RPL14	-0.79	-7.4	-0.55	1.83e-11	Renal cell carcinoma;
TGCT	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg11965913	chr1:205819406	PM20D1	0.44	4.89	0.4	3.09e-6	Parkinson's disease;
TGCT	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg08280861	chr8:58055591	NA	0.46	5.33	0.43	4.45e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6087771	0.890	rs6089056	chr20:30325773	A/G	cg13852791	chr20:30311386	BCL2L1	0.82	8.0	0.58	7.65e-13	Subcortical brain region volumes;Putamen volume;
TGCT	cis	rs344364	0.511	rs1742464	chr16:1947335	A/G	cg26617929	chr16:1858877	NA	0.27	4.9	0.4	2.99e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs6840360	0.554	rs6849111	chr4:152708874	T/C	cg22705602	chr4:152727874	NA	-0.33	-5.9	-0.47	3.26e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs4242434	0.672	rs4615566	chr8:22520682	T/C	cg03733263	chr8:22462867	KIAA1967	-1.0	-13.83	-0.78	6.78e-27	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs244731	0.959	rs918459	chr5:176669030	C/T	cg17509989	chr5:176798049	RGS14	-0.62	-7.75	-0.57	2.92e-12	Urate levels in lean individuals;
TGCT	cis	rs611744	0.967	rs650437	chr8:109210927	T/G	cg21045802	chr8:109455806	TTC35	0.52	4.72	0.39	6.21e-6	Dupuytren's disease;
TGCT	cis	rs896854	0.517	rs10112447	chr8:95955701	C/T	cg13393036	chr8:95962371	TP53INP1	-0.49	-5.66	-0.45	9.73e-8	Type 2 diabetes;
TGCT	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg11644478	chr21:40555479	PSMG1	1.01	10.7	0.69	2.56e-19	Cognitive function;
TGCT	cis	rs8016982	0.651	rs1885601	chr14:81641210	C/T	cg01989461	chr14:81687754	GTF2A1	0.81	8.17	0.59	3.09e-13	Schizophrenia;
TGCT	cis	rs7918232	0.556	rs788209	chr10:27434716	G/T	cg14442939	chr10:27389572	ANKRD26	0.78	5.71	0.46	7.72e-8	Breast cancer;
TGCT	cis	rs140365914	1	rs140365914	chr7:155106570	C/T	cg06963709	chr7:155150793	NA	0.35	6.84	0.52	3.2e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.4	-4.76	-0.39	5.24e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4808199	0.739	rs2240117	chr19:19418916	C/T	cg03709012	chr19:19516395	GATAD2A	0.79	5.54	0.45	1.75e-7	Nonalcoholic fatty liver disease;
TGCT	cis	rs897984	0.644	rs73524556	chr16:30823162	G/A	cg02466173	chr16:30829666	NA	-0.31	-5.12	-0.42	1.16e-6	Dementia with Lewy bodies;
TGCT	cis	rs9467773	0.967	rs9295694	chr6:26512994	A/T	cg09904177	chr6:26538194	HMGN4	0.65	6.53	0.51	1.53e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg20891283	chr12:69753455	YEATS4	0.91	10.33	0.68	1.96e-18	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs3540	0.513	rs2601154	chr15:90894284	T/C	cg22089800	chr15:90895588	ZNF774	0.82	9.07	0.63	2.24e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs2797160	1.000	rs6934435	chr6:126017481	T/G	cg05901451	chr6:126070800	HEY2	0.73	6.29	0.49	5.01e-9	Endometrial cancer;
TGCT	cis	rs1538970	0.924	rs4660855	chr1:45899795	A/G	cg05343316	chr1:45956843	TESK2	0.76	6.19	0.49	7.93e-9	Platelet count;
TGCT	cis	rs7940866	0.874	rs10894306	chr11:130873882	A/C	cg05962950	chr11:130786565	SNX19	0.7	6.94	0.53	1.89e-10	Schizophrenia;
TGCT	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg06896619	chr17:61851486	DDX42;CCDC47	-0.48	-4.65	-0.39	8.43e-6	Prudent dietary pattern;
TGCT	cis	rs7552404	0.696	rs1417405	chr1:76457797	T/C	cg10523679	chr1:76189770	ACADM	0.82	6.62	0.51	9.96e-10	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs6089584	0.888	rs6061405	chr20:60617033	A/G	cg16423285	chr20:60520624	NA	-0.61	-6.57	-0.51	1.23e-9	Body mass index;
TGCT	cis	rs7677751	0.708	rs2052699	chr4:55063994	C/T	cg17187183	chr4:55093834	PDGFRA	0.49	6.47	0.5	2.03e-9	Corneal astigmatism;
TGCT	cis	rs8017423	0.967	rs3825662	chr14:90723152	A/G	cg04374321	chr14:90722782	PSMC1	0.76	7.71	0.57	3.59e-12	Mortality in heart failure;
TGCT	cis	rs1971256	0.500	rs9479050	chr6:151806338	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.74	-4.49	-0.37	1.63e-5	Endometriosis;
TGCT	cis	rs1008375	1.000	rs2058337	chr4:17678649	C/T	cg16339924	chr4:17578868	LAP3	0.58	4.94	0.41	2.44e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs11578119	0.933	rs1999523	chr1:170467176	A/C	cg09767346	chr1:170501363	GORAB	0.66	5.29	0.43	5.27e-7	Male-pattern baldness;
TGCT	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs250677	0.524	rs183140	chr5:148438803	G/T	cg18129178	chr5:148520854	ABLIM3	-0.35	-5.07	-0.41	1.4e-6	Breast cancer;
TGCT	cis	rs6933660	0.512	rs13202634	chr6:151800630	C/T	cg03627880	chr6:151815985	C6orf97	-0.71	-6.64	-0.51	8.83e-10	Menarche (age at onset);
TGCT	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.45	-4.55	-0.38	1.27e-5	Mean platelet volume;
TGCT	cis	rs360798	0.532	rs13013218	chr2:63011671	C/T	cg17519650	chr2:63277830	OTX1	-0.6	-5.23	-0.43	7.02e-7	Coronary artery disease;
TGCT	cis	rs13191362	1.000	rs34931503	chr6:163003876	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs16854884	0.673	rs34379944	chr3:143785766	G/A	cg06585982	chr3:143692056	C3orf58	0.63	5.17	0.42	9.3e-7	Economic and political preferences (feminism/equality);
TGCT	cis	rs9534288	0.762	rs1571052	chr13:46554849	A/G	cg15192986	chr13:46630673	CPB2	-0.53	-7.66	-0.57	4.65e-12	Blood protein levels;
TGCT	cis	rs709400	0.930	rs57447494	chr14:104034569	G/A	cg26031613	chr14:104095156	KLC1	1.16	14.92	0.8	1.82e-29	Body mass index;
TGCT	cis	rs6570726	0.905	rs442435	chr6:145815559	C/T	cg23711669	chr6:146136114	FBXO30	0.7	6.6	0.51	1.09e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9818758	0.607	rs56004653	chr3:49072228	T/C	cg00383909	chr3:49044727	WDR6	1.53	5.87	0.47	3.76e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs66573146	1.000	rs67405518	chr4:6965930	C/T	cg00086871	chr4:6988644	TBC1D14	0.98	4.57	0.38	1.16e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs11971779	0.680	rs11980313	chr7:139034643	C/G	cg07862535	chr7:139043722	LUC7L2	0.56	4.46	0.37	1.82e-5	Diisocyanate-induced asthma;
TGCT	cis	rs7819412	0.545	rs11781155	chr8:10917560	C/T	cg21775007	chr8:11205619	TDH	-0.47	-4.66	-0.39	8.07e-6	Triglycerides;
TGCT	cis	rs35146811	0.538	rs3823642	chr7:99796072	T/C	cg00553149	chr7:99775558	STAG3;GPC2	0.31	4.61	0.38	9.75e-6	Coronary artery disease;
TGCT	cis	rs9457247	0.756	rs2345572	chr6:167403441	A/T	cg23791538	chr6:167370224	RNASET2	-0.49	-4.63	-0.38	9.27e-6	Crohn's disease;
TGCT	cis	rs9660992	0.547	rs12143121	chr1:205199142	A/G	cg00857998	chr1:205179979	DSTYK	0.51	4.68	0.39	7.34e-6	Mean corpuscular volume;Mean platelet volume;
TGCT	cis	rs514406	0.505	rs269289	chr1:53167151	A/C	cg01802117	chr1:53393560	SCP2	-0.44	-5.12	-0.42	1.11e-6	Monocyte count;
TGCT	cis	rs7714584	1.000	rs4579248	chr5:150268151	C/T	cg22134413	chr5:150180641	NA	1.14	8.32	0.6	1.32e-13	Crohn's disease;
TGCT	cis	rs1008375	0.932	rs3846356	chr4:17614176	C/T	cg18681998	chr4:17616180	MED28	1.07	11.25	0.71	1.13e-20	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1865760	0.865	rs9467645	chr6:25955176	G/C	cg16482183	chr6:26056742	HIST1H1C	0.52	4.84	0.4	3.78e-6	Height;
TGCT	cis	rs9388451	0.805	rs1028481	chr6:126106573	G/T	cg05901451	chr6:126070800	HEY2	-1.0	-14.45	-0.79	2.37e-28	Brugada syndrome;
TGCT	cis	rs7666738	0.830	rs9998682	chr4:98939009	T/C	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs854765	0.552	rs6502624	chr17:17847936	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	7.76	0.57	2.71e-12	Total body bone mineral density;
TGCT	cis	rs7249142	0.549	rs539	chr19:19287802	A/G	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.56	5.55	0.45	1.67e-7	IgG glycosylation;
TGCT	cis	rs2742417	0.603	rs2742453	chr3:45765858	G/A	cg04837898	chr3:45731254	SACM1L	-0.65	-6.95	-0.53	1.84e-10	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs2797160	1.000	rs984040	chr6:126021277	A/G	cg05901451	chr6:126070800	HEY2	0.75	6.66	0.51	8e-10	Endometrial cancer;
TGCT	cis	rs7727544	0.716	rs6863213	chr5:131575932	C/T	cg22598563	chr5:131563921	P4HA2	-0.29	-4.75	-0.39	5.6e-6	Blood metabolite levels;
TGCT	cis	rs12049351	0.774	rs6704265	chr1:229633056	C/A	cg12130225	chr1:229698885	NA	0.39	4.59	0.38	1.06e-5	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs7552404	0.824	rs1251079	chr1:76189445	C/T	cg10523679	chr1:76189770	ACADM	1.0	14.68	0.8	6.64e-29	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs10883723	0.810	rs1884929	chr10:104275418	C/T	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	trans	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.86	-9.4	-0.65	3.49e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs6582630	0.555	rs10880625	chr12:38526612	A/C	cg26384229	chr12:38710491	ALG10B	0.89	8.13	0.59	3.76e-13	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs137603	0.933	rs137593	chr22:39690021	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	-0.54	-5.07	-0.41	1.42e-6	Primary biliary cholangitis;
TGCT	cis	rs1008375	0.931	rs10019482	chr4:17578079	G/A	cg18681998	chr4:17616180	MED28	0.94	9.56	0.65	1.44e-16	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg21724239	chr8:58056113	NA	0.48	5.12	0.42	1.11e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs28595532	0.841	rs10019311	chr4:119785458	G/A	cg14228332	chr4:119757509	SEC24D	1.19	6.66	0.51	8.07e-10	Cannabis dependence symptom count;
TGCT	cis	rs113084984	0.718	rs4669746	chr2:11682018	G/A	cg25804072	chr2:10829725	NOL10	0.55	4.7	0.39	6.88e-6	Breast cancer;
TGCT	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.2	0.42	8.14e-7	Menopause (age at onset);
TGCT	cis	rs7681440	0.874	rs1372523	chr4:90775923	G/A	cg20003494	chr4:90757398	SNCA	-0.56	-5.35	-0.43	4.11e-7	Dementia with Lewy bodies;
TGCT	cis	rs6840360	0.615	rs1877188	chr4:152607931	T/C	cg22705602	chr4:152727874	NA	-0.32	-5.44	-0.44	2.76e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2806561	0.734	rs2806564	chr1:23506685	T/C	cg12483005	chr1:23474871	LUZP1	0.37	4.76	0.39	5.23e-6	Height;
TGCT	cis	rs899997	0.862	rs8032552	chr15:78971136	T/C	cg04896959	chr15:78267971	NA	-0.3	-4.49	-0.37	1.64e-5	Coronary artery disease or large artery stroke;
TGCT	cis	rs765787	0.530	rs12917187	chr15:45538297	A/G	cg24006582	chr15:45444508	DUOX1	-0.25	-5.54	-0.45	1.76e-7	Uric acid levels;
TGCT	cis	rs2204008	0.557	rs11520191	chr12:38197057	T/A	cg26384229	chr12:38710491	ALG10B	0.87	7.64	0.57	5.22e-12	Bladder cancer;
TGCT	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg05368731	chr17:41323189	NBR1	1.1	12.58	0.75	6.92e-24	Menopause (age at onset);
TGCT	cis	rs7246657	1.000	rs7246657	chr19:37747108	C/T	cg24025825	chr19:37761650	NA	0.25	4.53	0.38	1.34e-5	Coronary artery calcification;
TGCT	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg21724239	chr8:58056113	NA	0.35	4.76	0.39	5.26e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs921968	1.000	rs56191141	chr2:219272145	A/G	cg02176678	chr2:219576539	TTLL4	-0.41	-5.53	-0.45	1.78e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs909002	0.830	rs10914460	chr1:32113216	T/C	cg11573219	chr1:32083031	HCRTR1	-0.41	-5.31	-0.43	4.9e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs4700695	0.841	rs957526	chr5:65345830	A/G	cg21114390	chr5:65439923	SFRS12	0.62	4.69	0.39	7.22e-6	Facial morphology (factor 19);
TGCT	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.14	-0.42	1.03e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs250677	1.000	rs40525	chr5:148432932	G/T	cg18129178	chr5:148520854	ABLIM3	0.44	6.1	0.48	1.22e-8	Breast cancer;
TGCT	cis	rs1044826	0.597	rs1017468	chr3:139145778	A/G	cg00490450	chr3:139108681	COPB2	0.53	4.56	0.38	1.2e-5	Obesity-related traits;
TGCT	cis	rs79349575	0.749	rs519537	chr17:46971140	G/A	cg07967210	chr17:47022446	SNF8	0.44	5.9	0.47	3.17e-8	Type 2 diabetes;
TGCT	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.14	0.42	1.06e-6	Prudent dietary pattern;
TGCT	cis	rs9443645	0.901	rs9352670	chr6:79584433	A/G	cg05283184	chr6:79620031	NA	-0.21	-4.71	-0.39	6.61e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6671200	0.831	rs9659908	chr1:95656127	C/T	cg26537280	chr1:95699037	RWDD3	0.68	5.49	0.44	2.15e-7	Stearic acid (18:0) levels;
TGCT	cis	rs9653442	0.712	rs6749757	chr2:100730111	A/C	cg22139774	chr2:100720529	AFF3	0.4	6.84	0.52	3.26e-10	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs910316	1.000	rs12879542	chr14:75507525	C/T	cg23033748	chr14:75592666	NEK9	0.28	4.68	0.39	7.32e-6	Height;
TGCT	cis	rs9682041	0.736	rs34237232	chr3:170063753	C/T	cg07589077	chr3:170072950	NA	-0.35	-4.99	-0.41	2.01e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs138249	0.699	rs138221	chr22:50555299	G/T	cg24864161	chr22:50528282	MOV10L1	0.48	5.14	0.42	1.03e-6	Gestational age at birth in labor-initiated deliveries (child effect);
TGCT	cis	rs4509693	1.000	rs6584394	chr10:102497258	G/A	cg24127310	chr10:102502104	NA	0.7	5.86	0.47	3.84e-8	Alzheimer's disease;
TGCT	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg12311346	chr5:56204834	C5orf35	-0.67	-6.82	-0.52	3.63e-10	Initial pursuit acceleration;
TGCT	cis	rs62244186	0.748	rs13319803	chr3:44635461	G/A	cg15687855	chr3:44754131	ZNF502	-0.43	-5.09	-0.42	1.29e-6	Depressive symptoms;
TGCT	cis	rs3771570	0.818	rs73008126	chr2:242443157	A/C	cg21155796	chr2:242212141	HDLBP	0.9	6.4	0.5	2.94e-9	Prostate cancer;
TGCT	cis	rs9467773	0.935	rs1056668	chr6:26510605	C/T	cg02458000	chr6:26745757	NA	0.52	5.07	0.41	1.44e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2479724	0.868	rs2249703	chr6:41814760	A/G	cg08135965	chr6:41755394	TOMM6	0.48	4.64	0.38	8.66e-6	Menarche (age at onset);
TGCT	cis	rs9611565	1.000	rs1109151	chr22:41752944	A/G	cg13695892	chr22:41940480	POLR3H	-0.82	-8.22	-0.59	2.36e-13	Vitiligo;
TGCT	cis	rs9393692	0.905	rs7761298	chr6:26278436	C/T	cg05868516	chr6:26286170	HIST1H4H	0.56	5.35	0.43	4.01e-7	Educational attainment;
TGCT	cis	rs35306767	0.953	rs12259338	chr10:969377	C/T	cg20503657	chr10:835505	NA	0.65	9.44	0.65	2.93e-16	Eosinophil percentage of granulocytes;
TGCT	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg13665807	chr20:60559372	TAF4	-0.46	-4.9	-0.4	2.87e-6	Body mass index;
TGCT	cis	rs854765	0.682	rs13306736	chr17:17740281	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.6	-5.62	-0.45	1.19e-7	Total body bone mineral density;
TGCT	cis	rs926938	0.527	rs360580	chr1:115462334	A/G	cg12756093	chr1:115239321	AMPD1	0.34	4.95	0.41	2.35e-6	Autism;
TGCT	cis	rs7635838	0.819	rs7637414	chr3:11522228	C/G	cg00170343	chr3:11313890	ATG7	0.69	6.67	0.51	7.44e-10	HDL cholesterol;
TGCT	cis	rs72634258	0.554	rs4908694	chr1:7850898	C/T	cg26816564	chr1:7831052	VAMP3	0.88	6.36	0.5	3.57e-9	Inflammatory bowel disease;
TGCT	cis	rs2574985	0.548	rs2339505	chr10:52258106	C/T	cg12753529	chr10:51525504	NA	0.22	4.44	0.37	1.95e-5	Subjective well-being;
TGCT	cis	rs11673344	0.598	rs826326	chr19:37494765	T/C	cg08039142	chr19:36980659	ZNF566	0.57	5.44	0.44	2.74e-7	Obesity-related traits;
TGCT	cis	rs79349575	0.756	rs62078385	chr17:47045009	C/T	cg07967210	chr17:47022446	SNF8	0.45	6.27	0.49	5.37e-9	Type 2 diabetes;
TGCT	cis	rs9549367	0.601	rs558869	chr13:113849932	G/T	cg09473364	chr13:112927190	NA	0.29	4.64	0.38	8.73e-6	Platelet distribution width;
TGCT	cis	rs7824557	0.564	rs13274106	chr8:11233958	A/G	cg21775007	chr8:11205619	TDH	-0.67	-6.55	-0.51	1.35e-9	Retinal vascular caliber;
TGCT	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	16.07	0.82	4.21e-32	Prudent dietary pattern;
TGCT	cis	rs7819412	0.875	rs11250121	chr8:11060311	A/C	cg21775007	chr8:11205619	TDH	-0.49	-4.76	-0.39	5.36e-6	Triglycerides;
TGCT	cis	rs796364	0.616	rs7589545	chr2:200676102	T/A	cg17644776	chr2:200775616	C2orf69	0.34	4.84	0.4	3.76e-6	Schizophrenia;
TGCT	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.7	-0.39	6.79e-6	Prudent dietary pattern;
TGCT	cis	rs9952991	0.566	rs482160	chr18:12855646	A/G	cg23544223	chr18:12777786	NA	0.54	4.71	0.39	6.43e-6	Inflammatory skin disease;
TGCT	cis	rs6121246	1.000	rs6121246	chr20:30433352	C/T	cg18721089	chr20:30220636	NA	-0.45	-4.98	-0.41	2.12e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs3806843	0.576	rs246007	chr5:140338748	C/T	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs56235845	0.665	rs4976685	chr5:176766177	C/T	cg06060754	chr5:176797920	RGS14	-0.41	-6.42	-0.5	2.67e-9	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs1215050	0.547	rs6837669	chr4:98630162	T/G	cg05340658	chr4:99064831	C4orf37	-0.41	-4.96	-0.41	2.29e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7666738	0.830	rs11726604	chr4:99000969	T/C	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1008375	1.000	rs28693609	chr4:17645233	C/T	cg18681998	chr4:17616180	MED28	1.0	11.88	0.73	3.32e-22	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg03264133	chr6:25882463	NA	0.74	7.71	0.57	3.43e-12	Blood metabolite levels;
TGCT	cis	rs7666738	0.830	rs7691864	chr4:98971376	G/C	cg17366294	chr4:99064904	C4orf37	0.68	6.94	0.53	1.95e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3540	0.960	rs28539372	chr15:91021412	T/A	cg22089800	chr15:90895588	ZNF774	0.73	6.73	0.52	5.61e-10	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
TGCT	cis	rs2239785	0.959	rs713929	chr22:36657596	A/G	cg15716373	chr22:36655542	APOL1	-0.43	-4.92	-0.4	2.64e-6	Glomerulosclerosis;
TGCT	cis	rs12477438	0.520	rs11890338	chr2:99767868	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.82	0.62	8.67e-15	Chronic sinus infection;
TGCT	trans	rs16892673	0.643	rs7774267	chr6:161901679	T/C	cg14035368	chr9:139258938	CARD9;DNLZ	-0.81	-6.62	-0.51	9.69e-10	Aging;
TGCT	cis	rs1153858	0.887	rs7164139	chr15:45670851	G/A	cg26924012	chr15:45694286	SPATA5L1	1.09	15.08	0.8	7.99e-30	Homoarginine levels;
TGCT	cis	rs7829975	0.623	rs7010753	chr8:8373956	A/G	cg15556689	chr8:8085844	FLJ10661	0.76	7.39	0.55	1.93e-11	Mood instability;
TGCT	cis	rs2115630	0.645	rs4842978	chr15:85197253	T/C	cg11189052	chr15:85197271	WDR73	-0.79	-7.82	-0.57	1.99e-12	P wave terminal force;
TGCT	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs514406	0.584	rs11205997	chr1:53195271	G/C	cg22166914	chr1:53195759	ZYG11B	-0.5	-9.42	-0.65	3.19e-16	Monocyte count;
TGCT	cis	rs9611565	1.000	rs1109151	chr22:41752944	A/G	cg02107564	chr22:41488750	EP300	-0.56	-4.7	-0.39	6.9e-6	Vitiligo;
TGCT	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	8.16	0.59	3.1400000000000003e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs6532194	0.614	rs3775443	chr4:90715674	A/C	cg07409292	chr4:90228685	GPRIN3	0.95	4.61	0.38	1.01e-5	Parkinson's disease;
TGCT	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg18305652	chr10:134549665	INPP5A	0.33	5.2	0.42	8.08e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs4478858	0.684	rs7521463	chr1:31761936	T/A	cg00250761	chr1:31883323	NA	-0.25	-4.52	-0.38	1.45e-5	Alcohol dependence;
TGCT	cis	rs7666738	0.715	rs61114099	chr4:98931270	C/T	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2216164	1.000	rs12313214	chr12:68526290	C/T	cg17065850	chr12:67807625	NA	0.24	4.56	0.38	1.23e-5	Alopecia areata;
TGCT	cis	rs7845219	0.544	rs34208552	chr8:95908067	C/G	cg16049864	chr8:95962084	TP53INP1	-0.5	-5.39	-0.44	3.35e-7	Type 2 diabetes;
TGCT	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg16325326	chr1:53192061	ZYG11B	-0.73	-8.95	-0.63	4.41e-15	Monocyte count;
TGCT	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg05025164	chr4:1340916	KIAA1530	0.78	6.86	0.52	2.86e-10	Longevity;
TGCT	cis	rs9814567	0.964	rs6772406	chr3:134210183	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.95	-9.62	-0.65	1.04e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs7647973	1.000	rs940045	chr3:49449638	G/A	cg07690219	chr3:49449608	TCTA;RHOA	-0.53	-4.45	-0.37	1.87e-5	Menarche (age at onset);
TGCT	cis	rs12188164	0.686	rs72711369	chr5:420517	C/T	cg22025206	chr5:502436	SLC9A3	-0.26	-4.59	-0.38	1.06e-5	Cystic fibrosis severity;
TGCT	cis	rs739496	0.527	rs11066089	chr12:112363267	C/A	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs224278	0.782	rs192007	chr10:64586395	G/A	cg22903908	chr10:64578919	EGR2	0.38	4.76	0.39	5.38e-6	Ewing sarcoma;
TGCT	cis	rs6540559	0.673	rs17015183	chr1:209948711	A/C	cg22029157	chr1:209979665	IRF6	0.76	5.66	0.45	1.01e-7	Cleft lip with or without cleft palate;
TGCT	cis	rs6674176	0.660	rs11210936	chr1:44391438	A/T	cg13606994	chr1:44402422	ARTN	-0.51	-5.48	-0.44	2.29e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs9733	0.565	rs11804276	chr1:150685761	T/A	cg04414720	chr1:150670196	GOLPH3L	0.37	4.91	0.4	2.76e-6	Tonsillectomy;
TGCT	cis	rs13256369	0.802	rs13280101	chr8:8562773	G/A	cg18904891	chr8:8559673	CLDN23	0.58	5.4	0.44	3.23e-7	Obesity-related traits;
TGCT	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg22920501	chr2:26401640	FAM59B	-0.81	-6.42	-0.5	2.63e-9	Gut microbiome composition (summer);
TGCT	cis	rs1878931	0.582	rs9635562	chr16:3416689	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.76	6.35	0.5	3.66e-9	Body mass index (adult);
TGCT	cis	rs9916302	0.561	rs12453198	chr17:37741879	T/C	cg07936489	chr17:37558343	FBXL20	-0.7	-5.49	-0.44	2.21e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs7208859	0.673	rs73265612	chr17:29225983	A/G	cg14008862	chr17:28927542	LRRC37B2	0.72	4.66	0.39	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs868036	0.609	rs13329413	chr15:68097126	C/T	cg27219399	chr15:67835830	MAP2K5	0.34	4.49	0.37	1.6e-5	Restless legs syndrome;
TGCT	cis	rs1801251	0.963	rs13424351	chr2:233573629	A/G	cg08000102	chr2:233561755	GIGYF2	0.63	6.47	0.5	2.07e-9	Coronary artery disease;
TGCT	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg24829409	chr8:58192753	C8orf71	-0.51	-5.05	-0.41	1.55e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs208520	1.000	rs72884017	chr6:66992513	T/G	cg07460842	chr6:66804631	NA	0.78	6.82	0.52	3.61e-10	Exhaled nitric oxide output;
TGCT	cis	rs6684514	0.542	rs11264472	chr1:156292366	A/G	cg16558208	chr1:156270281	VHLL	0.28	5.05	0.41	1.52e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs6977660	0.652	rs58559474	chr7:19751569	C/T	cg05791153	chr7:19748676	TWISTNB	1.21	7.93	0.58	1.07e-12	Thyroid stimulating hormone;
TGCT	cis	rs921968	0.643	rs508157	chr2:219435288	G/A	cg02176678	chr2:219576539	TTLL4	0.38	5.48	0.44	2.31e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs7617773	0.674	rs13069029	chr3:48355024	A/G	cg11946769	chr3:48343235	NME6	0.82	7.09	0.54	9.1e-11	Coronary artery disease;
TGCT	cis	rs4808199	0.948	rs1859287	chr19:19422187	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.69	5.48	0.44	2.24e-7	Nonalcoholic fatty liver disease;
TGCT	cis	rs7172809	0.573	rs60761381	chr15:77533844	G/C	cg22256960	chr15:77711686	NA	-0.49	-4.62	-0.38	9.51e-6	Glucose homeostasis traits;
TGCT	cis	rs904251	0.704	rs2776873	chr6:37483142	A/G	cg25019722	chr6:37503610	NA	-0.47	-5.7	-0.46	8.29e-8	Cognitive performance;
TGCT	cis	rs7681440	0.874	rs10028246	chr4:90766704	G/A	cg14346243	chr4:90757452	SNCA	-0.57	-5.6	-0.45	1.31e-7	Dementia with Lewy bodies;
TGCT	cis	rs11574514	0.744	rs75204333	chr16:67574408	T/C	cg00545966	chr16:67701244	C16orf86;C16orf48	0.72	4.49	0.37	1.63e-5	Crohn's disease;
TGCT	cis	rs889312	0.500	rs865570	chr5:56161975	C/T	cg24531977	chr5:56204891	C5orf35	-0.5	-5.09	-0.42	1.28e-6	Breast cancer;Breast cancer (early onset);
TGCT	cis	rs6903823	0.508	rs1778484	chr6:28240798	A/G	cg18815343	chr6:28367644	ZSCAN12	-0.44	-4.59	-0.38	1.09e-5	Pulmonary function;
TGCT	cis	rs7523875	1.000	rs7523875	chr1:211391316	A/T	cg01421119	chr1:211555733	C1orf97	0.44	4.52	0.38	1.43e-5	Mean corpuscular volume;
TGCT	cis	rs13256369	0.901	rs12681327	chr8:8566414	G/T	cg18904891	chr8:8559673	CLDN23	0.59	5.52	0.44	1.93e-7	Obesity-related traits;
TGCT	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg18110333	chr6:292329	DUSP22	-0.67	-7.41	-0.55	1.7e-11	Menopause (age at onset);
TGCT	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg23982607	chr1:1823379	GNB1	-0.55	-8.57	-0.61	3.52e-14	Body mass index;
TGCT	cis	rs910316	1.000	rs11623413	chr14:75588824	C/T	cg23033748	chr14:75592666	NEK9	-0.27	-4.71	-0.39	6.5e-6	Height;
TGCT	cis	rs523522	0.923	rs1048830	chr12:120882217	G/T	cg27279351	chr12:120934652	DYNLL1	0.74	6.4	0.5	2.95e-9	High light scatter reticulocyte count;
TGCT	cis	rs11585357	0.895	rs2501795	chr1:17633499	A/G	cg08277548	chr1:17600880	PADI3	-0.91	-9.56	-0.65	1.49e-16	Hair shape;
TGCT	cis	rs10791097	0.694	rs11222370	chr11:130744767	T/G	cg05962950	chr11:130786565	SNX19	0.92	11.55	0.72	2.13e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs66573146	0.634	rs55633489	chr4:6988745	C/A	cg00086871	chr4:6988644	TBC1D14	0.94	4.62	0.38	9.61e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs9325144	0.647	rs3759139	chr12:39087609	G/A	cg26384229	chr12:38710491	ALG10B	-0.55	-5.1	-0.42	1.22e-6	Morning vs. evening chronotype;
TGCT	cis	rs2034088	0.833	rs11247554	chr17:407465	C/A	cg06217071	chr17:408420	NA	0.34	5.14	0.42	1.04e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg07061783	chr6:25882402	NA	-0.69	-6.8	-0.52	3.86e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs79349575	0.783	rs61576918	chr17:46985593	A/C	cg07967210	chr17:47022446	SNF8	0.43	6.06	0.48	1.54e-8	Type 2 diabetes;
TGCT	cis	rs797680	0.786	rs7532195	chr1:93617403	T/G	cg17826107	chr1:92977322	EVI5	-0.23	-5.0	-0.41	1.88e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs7607369	0.782	rs514799	chr2:219411203	A/G	cg02176678	chr2:219576539	TTLL4	0.48	6.78	0.52	4.32e-10	Red blood cell count;Amyotrophic lateral sclerosis;
TGCT	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg00684032	chr4:1343700	KIAA1530	0.21	4.53	0.38	1.39e-5	Obesity-related traits;
TGCT	cis	rs7659604	0.502	rs13108419	chr4:122687238	A/G	cg06713675	chr4:122721982	EXOSC9	0.37	4.64	0.38	8.68e-6	Type 2 diabetes;
TGCT	cis	rs2880765	0.835	rs4360874	chr15:86040820	A/T	cg13263323	chr15:86062960	AKAP13	-0.22	-4.77	-0.39	5e-6	Coronary artery disease;
TGCT	cis	rs739496	0.579	rs3782885	chr12:112282583	G/A	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs2836950	0.545	rs2836952	chr21:40616651	G/C	cg17971929	chr21:40555470	PSMG1	-0.54	-4.84	-0.4	3.86e-6	Menarche (age at onset);
TGCT	cis	rs17601876	0.651	rs12050772	chr15:51544871	T/G	cg19946085	chr15:51559439	CYP19A1	-0.34	-4.86	-0.4	3.5e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg11494091	chr17:61959527	GH2	0.6	14.51	0.79	1.71e-28	Prudent dietary pattern;
TGCT	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	8.55	0.61	3.84e-14	Platelet count;
TGCT	cis	rs3806843	1.000	rs4151682	chr5:140201264	C/T	cg19875535	chr5:140030758	IK	0.36	5.84	0.46	4.29e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg18252515	chr7:66147081	NA	-1.31	-8.18	-0.59	2.87e-13	Diabetic kidney disease;
TGCT	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg24060327	chr5:131705240	SLC22A5	0.78	8.46	0.61	6.22e-14	Blood metabolite levels;
TGCT	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	4.71	0.39	6.53e-6	Prudent dietary pattern;
TGCT	cis	rs7727544	0.581	rs10075801	chr5:131677642	A/G	cg14196790	chr5:131705035	SLC22A5	0.34	4.81	0.4	4.37e-6	Blood metabolite levels;
TGCT	cis	rs11997175	0.574	rs4236733	chr8:33655582	G/A	ch.8.33884649F	chr8:33765107	NA	0.28	4.54	0.38	1.33e-5	Body mass index;
TGCT	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg09436375	chr6:42928200	GNMT	-0.42	-5.54	-0.45	1.76e-7	Alzheimer's disease in APOE e4+ carriers;
TGCT	cis	rs12142240	0.698	rs6697123	chr1:46811310	A/C	cg00530320	chr1:46809349	NSUN4	0.29	5.88	0.47	3.63e-8	Menopause (age at onset);
TGCT	cis	rs611744	0.647	rs11774904	chr8:109273435	G/A	cg21045802	chr8:109455806	TTC35	0.7	7.13	0.54	7.42e-11	Dupuytren's disease;
TGCT	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.12	15.17	0.81	4.81e-30	Height;
TGCT	cis	rs6582630	0.519	rs1851121	chr12:38389467	T/C	cg13010199	chr12:38710504	ALG10B	0.58	4.59	0.38	1.05e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs875971	1.000	rs697970	chr7:65560052	G/C	cg18876405	chr7:65276391	NA	-0.35	-5.31	-0.43	4.85e-7	Aortic root size;
TGCT	cis	rs4455778	0.536	rs38773	chr7:48939501	T/C	cg26309511	chr7:48887640	NA	0.48	5.71	0.46	8.04e-8	Lung cancer in never smokers;
TGCT	cis	rs7949030	0.596	rs11231138	chr11:62316195	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.71	8.79	0.62	1.04e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs4713675	0.649	rs568901	chr6:33710038	A/G	cg07979401	chr6:33739406	LEMD2	0.34	4.66	0.39	8e-6	Plateletcrit;
TGCT	cis	rs6840360	0.615	rs6535822	chr4:152679722	A/G	cg22705602	chr4:152727874	NA	-0.35	-5.94	-0.47	2.63e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs3796619	1.000	rs1466215	chr4:1072220	C/T	cg27284194	chr4:1044797	NA	0.46	4.45	0.37	1.85e-5	Recombination rate (males);
TGCT	cis	rs4711350	1.000	rs2395447	chr6:33743174	T/C	cg00334056	chr6:33755658	LEMD2	-0.29	-4.63	-0.38	9.08e-6	Schizophrenia;
TGCT	cis	rs7811142	0.945	rs34989573	chr7:100097895	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.72	5.02	0.41	1.76e-6	Platelet count;
TGCT	cis	rs950169	0.579	rs11633088	chr15:84672181	A/T	cg11189052	chr15:85197271	WDR73	-0.66	-5.14	-0.42	1.04e-6	Schizophrenia;
TGCT	cis	rs4285028	0.948	rs12493952	chr3:121708497	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.77	-6.5	-0.5	1.78e-9	Multiple sclerosis;
TGCT	cis	rs6714710	0.627	rs11680883	chr2:98472610	T/C	cg26665480	chr2:98280029	ACTR1B	0.68	6.37	0.5	3.38e-9	Posterior cortical atrophy and Alzheimer's disease;
TGCT	trans	rs1499614	0.803	rs1796229	chr7:66119661	G/A	cg07424592	chr7:64974309	NA	1.35	8.11	0.59	4.14e-13	Gout;
TGCT	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg07507251	chr3:52567010	NT5DC2	-0.48	-6.9	-0.53	2.39e-10	Bipolar disorder;
TGCT	cis	rs6570726	0.791	rs6912079	chr6:145894949	G/A	cg05347473	chr6:146136440	FBXO30	0.54	5.12	0.42	1.14e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3771570	1.000	rs62193197	chr2:242294301	G/A	cg21155796	chr2:242212141	HDLBP	0.94	6.69	0.51	6.9e-10	Prostate cancer;
TGCT	cis	rs7208859	0.623	rs11650982	chr17:29129955	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs9921338	0.961	rs7195536	chr16:11442028	T/C	cg00044050	chr16:11439710	C16orf75	-0.87	-6.68	-0.51	7.37e-10	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg09060608	chr5:178986726	RUFY1	0.53	6.01	0.48	1.9e-8	Lung cancer;
TGCT	cis	rs75686122	1.000	rs79392847	chr8:104473649	G/C	cg04852977	chr8:104510831	NA	0.6	4.47	0.37	1.74e-5	Cocaine dependence;
TGCT	cis	rs3812831	0.695	rs8000778	chr13:114944310	T/C	cg06611532	chr13:114900021	NA	0.34	6.17	0.48	8.73e-9	Schizophrenia;
TGCT	cis	rs2224391	1.000	rs13191012	chr6:5261292	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.8	-6.02	-0.48	1.87e-8	Height;
TGCT	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	8.39	0.6	9.03e-14	Platelet count;
TGCT	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg11494091	chr17:61959527	GH2	0.61	14.49	0.79	1.92e-28	Prudent dietary pattern;
TGCT	cis	rs9325144	0.957	rs1995419	chr12:38950726	C/G	cg10518543	chr12:38710700	ALG10B	0.53	4.45	0.37	1.91e-5	Morning vs. evening chronotype;
TGCT	cis	rs68170813	0.559	rs12535258	chr7:106971050	T/C	cg02696742	chr7:106810147	HBP1	-0.68	-5.64	-0.45	1.09e-7	Coronary artery disease;
TGCT	cis	rs3845702	0.866	rs818659	chr2:180870893	G/A	cg01881094	chr2:180872142	CWC22	0.68	6.11	0.48	1.16e-8	Schizophrenia;
TGCT	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg11366901	chr6:160182831	ACAT2	0.74	5.55	0.45	1.65e-7	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg24829409	chr8:58192753	C8orf71	-0.57	-4.72	-0.39	6.14e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7267979	1.000	rs2482927	chr20:25327151	T/C	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs727563	0.520	rs132773	chr22:42031768	T/A	cg06634786	chr22:41940651	POLR3H	0.88	8.38	0.6	9.48e-14	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs2019216	0.500	rs2880292	chr17:21869537	A/G	cg22648282	chr17:21454238	C17orf51	-0.57	-5.13	-0.42	1.08e-6	Pelvic organ prolapse;
TGCT	cis	rs11992186	0.597	rs11781841	chr8:8595263	T/A	cg17143192	chr8:8559678	CLDN23	-0.53	-5.12	-0.42	1.13e-6	Neuroticism;
TGCT	cis	rs12142240	0.698	rs17361887	chr1:46834775	A/G	cg14993813	chr1:46806288	NSUN4	-0.58	-4.86	-0.4	3.44e-6	Menopause (age at onset);
TGCT	cis	rs1153858	0.723	rs4580098	chr15:45596909	T/A	cg26924012	chr15:45694286	SPATA5L1	1.01	11.05	0.7	3.45e-20	Homoarginine levels;
TGCT	cis	rs752010	0.645	rs1109254	chr1:42091770	T/C	cg06885757	chr1:42089581	HIVEP3	0.27	4.98	0.41	2.05e-6	Lupus nephritis in systemic lupus erythematosus;
TGCT	cis	rs4319547	0.695	rs10773167	chr12:122934001	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.73	-5.73	-0.46	7.18e-8	Body mass index;
TGCT	cis	rs478304	0.651	rs948494	chr11:65552118	G/A	cg17480646	chr11:65405466	SIPA1	-0.55	-6.45	-0.5	2.25e-9	Acne (severe);
TGCT	cis	rs2075371	0.501	rs1613152	chr7:134019837	A/G	cg11752832	chr7:134001865	SLC35B4	0.58	4.86	0.4	3.43e-6	Mean platelet volume;
TGCT	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg27121462	chr16:89883253	FANCA	-0.71	-7.48	-0.56	1.19e-11	Vitiligo;
TGCT	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg07870213	chr5:140052090	DND1	0.68	8.28	0.6	1.68e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs9399135	0.684	rs1135205	chr6:135281795	C/T	cg24558204	chr6:135376177	HBS1L	0.43	4.46	0.37	1.85e-5	Red blood cell count;
TGCT	cis	rs4862307	0.754	rs6846007	chr4:184991604	A/G	cg06737308	chr4:185021514	ENPP6	-0.4	-5.72	-0.46	7.56e-8	Serum dimethylarginine levels (asymmetric/symetric ratio);
TGCT	cis	rs1577917	1.000	rs12200330	chr6:86656653	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.13	-0.42	1.07e-6	Response to antipsychotic treatment;
TGCT	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg03517284	chr6:25882590	NA	-0.46	-4.62	-0.38	9.46e-6	Height;
TGCT	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg23708337	chr7:1209742	NA	0.54	5.22	0.42	7.2e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs902774	0.515	rs2363635	chr12:53354622	T/C	cg16329197	chr12:53359506	NA	-0.52	-7.44	-0.56	1.48e-11	Prostate cancer;
TGCT	cis	rs739496	0.579	rs11066054	chr12:112306165	G/T	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs422249	0.512	rs174577	chr11:61604814	A/C	cg01500311	chr11:61656094	FADS3	0.32	5.66	0.45	9.89e-8	Trans fatty acid levels;
TGCT	cis	rs12142240	0.698	rs56063031	chr1:46825433	C/T	cg00530320	chr1:46809349	NSUN4	0.28	5.79	0.46	5.42e-8	Menopause (age at onset);
TGCT	cis	rs308971	0.518	rs62242085	chr3:12299345	G/T	cg23769143	chr3:12200667	SYN2;TIMP4	0.5	4.51	0.38	1.46e-5	Fasting blood insulin (BMI interaction);
TGCT	cis	rs739496	0.563	rs6490294	chr12:112190438	A/C	cg10833066	chr12:111807467	FAM109A	-0.32	-4.81	-0.4	4.2e-6	Platelet count;
TGCT	cis	rs6964587	0.839	rs11767135	chr7:91551245	T/G	cg17063962	chr7:91808500	NA	-0.86	-9.28	-0.64	6.82e-16	Breast cancer;
TGCT	cis	rs13191362	0.507	rs2803083	chr6:163111199	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.63	5.67	0.45	9.59e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs6674176	0.628	rs4660759	chr1:44432500	C/G	cg12908607	chr1:44402522	ARTN	-0.72	-8.83	-0.62	8.31e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs117785887	0.536	rs12200649	chr6:146432054	G/C	cg06708562	chr6:146285465	SHPRH	-0.79	-4.59	-0.38	1.09e-5	Interleukin-17 levels;
TGCT	cis	rs4325129	1.000	rs61821537	chr1:159461560	T/C	cg07417683	chr1:159440267	NA	-0.45	-4.63	-0.38	9.16e-6	Obesity-related traits;
TGCT	cis	rs11105298	0.891	rs4842654	chr12:89834428	T/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.67	-4.74	-0.39	5.67e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs7618915	0.773	rs10510760	chr3:52650348	G/A	cg07507251	chr3:52567010	NT5DC2	0.45	6.02	0.48	1.8e-8	Bipolar disorder;
TGCT	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg20203395	chr5:56204925	C5orf35	-0.59	-4.94	-0.41	2.52e-6	Initial pursuit acceleration;
TGCT	cis	rs854765	0.552	rs11078407	chr17:17841083	T/C	cg09796270	chr17:17721594	SREBF1	0.24	4.77	0.39	5.04e-6	Total body bone mineral density;
TGCT	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.85	-9.07	-0.63	2.22e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs3820928	0.874	rs10178731	chr2:227874232	C/T	cg11843606	chr2:227700838	RHBDD1	-0.52	-4.63	-0.38	9.03e-6	Pulmonary function;
TGCT	cis	rs36051895	0.659	rs12343867	chr9:5074189	T/C	cg02405213	chr9:5042618	JAK2	-0.77	-10.15	-0.67	5.61e-18	Pediatric autoimmune diseases;
TGCT	cis	rs9473924	0.505	rs7745565	chr6:50860083	A/G	cg14470998	chr6:50812995	TFAP2B	1.35	8.39	0.6	9.05e-14	Body mass index;
TGCT	cis	rs910316	0.967	rs119076	chr14:75572419	G/T	cg11812906	chr14:75593930	NEK9	-0.72	-6.92	-0.53	2.18e-10	Height;
TGCT	cis	rs208520	0.690	rs4618506	chr6:66756889	A/C	cg07460842	chr6:66804631	NA	-0.93	-9.76	-0.66	4.84e-17	Exhaled nitric oxide output;
TGCT	cis	rs7666738	0.800	rs11941885	chr4:99072921	A/C	cg18180107	chr4:99064573	C4orf37	0.6	5.35	0.43	4e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3020333	0.875	rs2941741	chr6:152008982	G/A	cg22157087	chr6:152012887	ESR1	0.2	4.81	0.4	4.24e-6	Total body bone mineral density;
TGCT	cis	rs3008870	0.755	rs1570838	chr1:67403315	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.78	8.29	0.6	1.59e-13	Lymphocyte percentage of white cells;
TGCT	cis	rs6840360	0.571	rs12647566	chr4:152482525	C/T	cg17479576	chr4:152424074	FAM160A1	-0.73	-7.94	-0.58	1.03e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs13401104	0.587	rs62190973	chr2:237145231	T/A	cg19324714	chr2:237145437	ASB18	0.48	5.03	0.41	1.67e-6	Educational attainment;
TGCT	cis	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg18188782	chr20:61659543	NA	0.44	5.37	0.43	3.73e-7	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7582180	0.629	rs4851297	chr2:100949571	G/A	cg14675211	chr2:100938903	LONRF2	0.5	4.78	0.39	4.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs3858526	0.920	rs10742832	chr11:5926020	C/G	cg13902645	chr11:5959945	NA	-0.43	-4.62	-0.38	9.28e-6	DNA methylation (variation);
TGCT	cis	rs3008870	1.000	rs2815348	chr1:67472165	G/C	cg03991309	chr1:68237761	GNG12	0.27	4.53	0.38	1.36e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs2688608	0.588	rs10128205	chr10:75469648	C/G	cg04320760	chr10:75533139	FUT11	-0.4	-6.16	-0.48	9.39e-9	Inflammatory bowel disease;
TGCT	cis	rs9457247	1.000	rs2149091	chr6:167372786	C/T	cg23791538	chr6:167370224	RNASET2	0.51	5.12	0.42	1.12e-6	Crohn's disease;
TGCT	cis	rs9549260	0.816	rs9532582	chr13:41251207	A/G	cg21288729	chr13:41239152	FOXO1	1.02	10.29	0.68	2.51e-18	Red blood cell count;
TGCT	cis	rs12477438	0.798	rs12477754	chr2:99628073	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-8.52	-0.61	4.5e-14	Chronic sinus infection;
TGCT	cis	rs1878931	0.668	rs2074366	chr16:3439676	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.98	12.16	0.74	6.83e-23	Body mass index (adult);
TGCT	cis	rs3749237	1.000	rs1317140	chr3:49878652	G/A	cg10152585	chr3:50297680	NA	0.53	5.03	0.41	1.69e-6	Resting heart rate;
TGCT	cis	rs950776	0.518	rs55690619	chr15:78833612	A/G	cg06917634	chr15:78832804	PSMA4	-0.95	-9.52	-0.65	1.81e-16	Sudden cardiac arrest;
TGCT	cis	rs17221829	0.600	rs3881248	chr11:89362196	T/C	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.65	-0.39	8.43e-6	Anxiety in major depressive disorder;
TGCT	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg20276088	chr3:133502917	NA	-0.24	-4.82	-0.4	4.13e-6	Iron status biomarkers;
TGCT	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg03264133	chr6:25882463	NA	-0.53	-5.53	-0.44	1.81e-7	Blood metabolite levels;
TGCT	cis	rs2404602	0.716	rs7164813	chr15:76708066	T/C	cg22467129	chr15:76604101	ETFA	-0.59	-7.13	-0.54	7.33e-11	Blood metabolite levels;
TGCT	cis	rs861020	0.771	rs674804	chr1:210014603	C/G	cg05527609	chr1:210001259	C1orf107	1.05	10.03	0.67	1.07e-17	Orofacial clefts;
TGCT	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg11764359	chr7:65958608	NA	0.55	5.08	0.42	1.34e-6	Aortic root size;
TGCT	cis	rs2663905	0.611	rs1509558	chr15:81391244	C/T	cg18837035	chr15:81426597	C15orf26	-0.55	-4.75	-0.39	5.42e-6	QT interval (drug interaction);
TGCT	cis	rs587847	0.737	rs1401900	chr15:37585185	A/G	cg00216138	chr15:37171175	LOC145845	0.31	4.44	0.37	1.98e-5	Intraocular pressure;
TGCT	cis	rs9911578	1.000	rs12938772	chr17:56776320	T/C	cg05425664	chr17:57184151	TRIM37	-0.63	-6.26	-0.49	5.86e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg08439880	chr3:133502540	NA	-0.31	-6.0	-0.47	2.03e-8	Iron status biomarkers;
TGCT	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg03188948	chr7:1209495	NA	0.48	6.91	0.53	2.31e-10	Longevity;Endometriosis;
TGCT	cis	rs62244186	0.545	rs9284880	chr3:44759389	C/T	cg11003573	chr3:44754125	ZNF502	-0.45	-5.08	-0.42	1.32e-6	Depressive symptoms;
TGCT	trans	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg17830980	chr10:43048298	ZNF37B	-0.83	-10.65	-0.69	3.3e-19	Extrinsic epigenetic age acceleration;
TGCT	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg00149659	chr3:10157352	C3orf10	0.93	5.98	0.47	2.25e-8	Alzheimer's disease;
TGCT	cis	rs2245008	0.762	rs168800	chr16:83980391	T/C	cg27171569	chr16:83987465	OSGIN1	0.46	5.28	0.43	5.58e-7	Pursuit maintenance gain;
TGCT	cis	rs7666738	0.830	rs62318906	chr4:99037110	C/T	cg17366294	chr4:99064904	C4orf37	0.73	7.62	0.56	5.65e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9467711	0.606	rs9393712	chr6:26371000	G/C	cg10795676	chr6:26370623	BTN3A2	-0.46	-4.75	-0.39	5.46e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs72781680	0.948	rs113530757	chr2:24142500	G/A	cg08917208	chr2:24149416	ATAD2B	0.73	4.51	0.38	1.48e-5	Lymphocyte counts;
TGCT	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg08280861	chr8:58055591	NA	0.4	4.56	0.38	1.22e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg13342137	chr4:2252803	MXD4	0.17	4.56	0.38	1.23e-5	Obesity-related traits;
TGCT	cis	rs6545883	0.965	rs9989775	chr2:61761774	A/G	cg15711740	chr2:61764176	XPO1	-0.57	-5.23	-0.43	6.89e-7	Tuberculosis;
TGCT	cis	rs933688	1.000	rs332529	chr5:90789470	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.95	7.97	0.58	8.9e-13	Smoking behavior;
TGCT	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg13607699	chr17:42295918	UBTF	0.59	5.31	0.43	4.88e-7	Total body bone mineral density;
TGCT	cis	rs12230513	0.632	rs59213907	chr12:55728911	A/T	cg10672482	chr12:55725839	OR6C3	-0.56	-4.89	-0.4	3.1e-6	Contrast sensitivity;
TGCT	cis	rs6460942	1.000	rs77494477	chr7:12315302	A/T	cg06484146	chr7:12443880	VWDE	-0.55	-4.56	-0.38	1.22e-5	Coronary artery disease;
TGCT	cis	rs2067615	0.560	rs2044304	chr12:107184363	T/G	cg15890332	chr12:107067104	RFX4	0.28	5.61	0.45	1.27e-7	Heart rate;
TGCT	cis	rs17401966	0.522	rs912962	chr1:10348712	G/T	cg19773385	chr1:10388646	KIF1B	0.19	4.52	0.38	1.42e-5	Hepatocellular carcinoma;
TGCT	cis	rs2562456	0.917	rs2562466	chr19:21714204	C/T	cg01304269	chr19:21688519	ZNF429	-0.55	-4.59	-0.38	1.06e-5	Pain;
TGCT	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg12963246	chr6:28129442	ZNF389	0.52	5.01	0.41	1.85e-6	Depression;
TGCT	cis	rs57590327	0.716	rs3772891	chr3:81776760	A/G	cg07356753	chr3:81810745	GBE1	0.76	6.87	0.53	2.71e-10	Extraversion;
TGCT	cis	rs9325144	0.560	rs11183090	chr12:38662293	G/C	cg26384229	chr12:38710491	ALG10B	-0.63	-5.92	-0.47	2.9e-8	Morning vs. evening chronotype;
TGCT	cis	rs7937682	0.924	rs12791699	chr11:111505880	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.1	-11.55	-0.72	2.11e-21	Primary sclerosing cholangitis;
TGCT	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg27454412	chr7:1067447	C7orf50	0.6	4.7	0.39	6.76e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs4325129	0.705	rs4418591	chr1:159491355	C/A	cg07417683	chr1:159440267	NA	0.37	4.64	0.38	8.54e-6	Obesity-related traits;
TGCT	cis	rs854765	0.603	rs854789	chr17:18026566	C/T	cg04398451	chr17:18023971	MYO15A	-0.39	-6.89	-0.53	2.53e-10	Total body bone mineral density;
TGCT	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg11494091	chr17:61959527	GH2	0.42	7.46	0.56	1.29e-11	Height;
TGCT	cis	rs644799	0.623	rs17207890	chr11:95490754	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.75	7.75	0.57	2.9e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs1018836	0.923	rs13255452	chr8:91582988	A/G	cg16814680	chr8:91681699	NA	-0.89	-9.59	-0.65	1.22e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.92	-6.8	-0.52	3.96e-10	Gut microbiome composition (summer);
TGCT	cis	rs7582180	0.607	rs6725052	chr2:100935817	G/A	cg08017756	chr2:100939284	LONRF2	-0.3	-4.78	-0.39	4.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7542091	0.648	rs688464	chr1:209992539	C/T	cg23283495	chr1:209979779	IRF6	-0.55	-5.94	-0.47	2.66e-8	Monobrow;
TGCT	cis	rs7647973	0.593	rs7652179	chr3:49808618	T/A	cg03034192	chr3:50606346	HEMK1;C3orf18	-0.36	-4.64	-0.38	8.68e-6	Menarche (age at onset);
TGCT	cis	rs34014631	1.000	rs74321972	chr10:103643036	T/C	cg22630918	chr10:102748988	C10orf2	0.42	4.94	0.41	2.43e-6	Coronary artery calcification;
TGCT	cis	rs6835098	1.000	rs10027708	chr4:174083116	T/C	cg08422745	chr4:174089978	GALNT7	-0.93	-10.95	-0.7	6.1e-20	Dementia and core Alzheimer's disease neuropathologic changes;
TGCT	cis	rs2354432	0.556	rs59180647	chr1:146772062	C/T	cg25205988	chr1:146714368	CHD1L	-1.34	-6.07	-0.48	1.44e-8	Mitochondrial DNA levels;
TGCT	cis	rs11105298	0.891	rs10858851	chr12:89830870	C/T	cg00757033	chr12:89920650	WDR51B	0.33	5.11	0.42	1.16e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg00024416	chr22:24240387	NA	-0.25	-4.53	-0.38	1.39e-5	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	trans	rs4332037	0.950	rs56403963	chr7:1946130	C/G	cg10840412	chr1:235813424	GNG4	1.04	8.16	0.59	3.22e-13	Bipolar disorder;
TGCT	cis	rs10504229	0.679	rs78941440	chr8:58052095	A/G	cg08280861	chr8:58055591	NA	0.35	5.03	0.41	1.67e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg00149659	chr3:10157352	C3orf10	0.93	5.99	0.47	2.16e-8	Alzheimer's disease;
TGCT	cis	rs6940638	0.688	rs6921388	chr6:27080205	A/G	cg26531700	chr6:26746687	NA	-0.56	-4.88	-0.4	3.25e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs8077577	0.895	rs62072465	chr17:18114494	C/G	cg09161412	chr17:18057145	MYO15A	-0.6	-4.79	-0.4	4.61e-6	Obesity-related traits;
TGCT	cis	rs17767294	0.708	rs72848754	chr6:27878458	T/A	cg08851530	chr6:28072375	NA	1.53	7.17	0.54	6.02e-11	Parkinson's disease;
TGCT	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg08859206	chr1:53392774	SCP2	-0.48	-7.95	-0.58	9.85e-13	Monocyte count;
TGCT	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg09365446	chr1:150670422	GOLPH3L	0.31	4.64	0.38	8.74e-6	Tonsillectomy;
TGCT	cis	rs12681288	0.676	rs2600514	chr8:994175	G/A	cg04851639	chr8:1020857	NA	-0.29	-4.74	-0.39	5.72e-6	Schizophrenia;
TGCT	cis	rs4499344	0.556	rs259230	chr19:33133865	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.82	8.29	0.6	1.58e-13	Mean platelet volume;
TGCT	cis	rs6456156	0.792	rs4710178	chr6:167513532	G/A	cg07741184	chr6:167504864	NA	0.22	4.51	0.38	1.48e-5	Primary biliary cholangitis;
TGCT	cis	rs2050392	0.517	rs160017	chr10:30772894	A/G	cg13289132	chr10:30722225	MAP3K8	-0.38	-4.48	-0.37	1.7e-5	Inflammatory bowel disease;
TGCT	cis	rs9810089	0.708	rs619605	chr3:136087012	G/C	cg12473912	chr3:136751656	NA	0.37	5.2	0.42	7.86e-7	Gestational age at birth (child effect);
TGCT	cis	rs1005224	0.929	rs11625260	chr14:76162293	G/C	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.61	-5.64	-0.45	1.07e-7	Large artery stroke;
TGCT	cis	rs509477	0.962	rs723035	chr18:32562845	T/A	cg23791764	chr18:32556832	MAPRE2	0.55	4.6	0.38	1.04e-5	Cerebrospinal fluid AB1-42 levels;
TGCT	cis	rs6540559	0.611	rs926347	chr1:209965193	T/C	cg23283495	chr1:209979779	IRF6	0.65	5.02	0.41	1.76e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs17376456	0.877	rs7701974	chr5:93311417	C/T	cg25358565	chr5:93447407	FAM172A	0.98	8.39	0.6	9.01e-14	Diabetic retinopathy;
TGCT	cis	rs2290416	0.688	rs34892354	chr8:144690648	G/C	cg17524265	chr8:144659883	NAPRT1	0.71	5.5	0.44	2.05e-7	Attention deficit hyperactivity disorder;
TGCT	cis	rs9916302	0.904	rs2338755	chr17:37419317	C/T	cg15445000	chr17:37608096	MED1	-0.31	-4.59	-0.38	1.06e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs6665290	0.904	rs12409428	chr1:227189969	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.0	-20.53	-0.88	1.06e-41	Myeloid white cell count;
TGCT	cis	rs17270561	0.579	rs10456326	chr6:25919662	G/A	cg16482183	chr6:26056742	HIST1H1C	0.94	7.28	0.55	3.36e-11	Iron status biomarkers;
TGCT	cis	rs807669	0.868	rs762529	chr22:19170205	C/G	cg02655711	chr22:19163373	SLC25A1	0.42	10.01	0.67	1.23e-17	Metabolite levels;
TGCT	cis	rs7666738	0.830	rs11723283	chr4:99001617	C/T	cg18180107	chr4:99064573	C4orf37	0.53	4.85	0.4	3.6e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3764628	1.000	rs72997346	chr19:18762865	G/A	cg20098710	chr19:19640075	YJEFN3	-0.46	-4.78	-0.39	4.8e-6	Orofacial clefts;
TGCT	trans	rs4824093	0.610	rs2208023	chr22:50249983	A/G	cg09872104	chr7:134855509	C7orf49	-0.9	-7.2	-0.54	5.08e-11	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs35934224	0.783	rs45465601	chr22:19868678	T/C	cg11182965	chr22:19864308	TXNRD2	-0.36	-5.11	-0.42	1.16e-6	Glaucoma (primary open-angle);
TGCT	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg12311346	chr5:56204834	C5orf35	-0.57	-6.13	-0.48	1.07e-8	Initial pursuit acceleration;
TGCT	cis	rs12580194	0.630	rs60586348	chr12:55745151	A/T	cg10672482	chr12:55725839	OR6C3	-0.51	-4.43	-0.37	2.01e-5	Cancer;
TGCT	cis	rs1865760	0.865	rs1541987	chr6:25950397	A/G	cg17042849	chr6:26104293	HIST1H4C	0.5	4.63	0.38	9.27e-6	Height;
TGCT	cis	rs10186029	0.676	rs10804213	chr2:213964399	G/A	cg08319019	chr2:214017104	IKZF2	0.63	5.79	0.46	5.4e-8	Systemic sclerosis;
TGCT	cis	rs546131	0.928	rs552627	chr11:34826680	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.54	4.81	0.4	4.36e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs35146811	0.735	rs7811662	chr7:99792608	A/G	cg00553149	chr7:99775558	STAG3;GPC2	0.31	4.61	0.38	9.75e-6	Coronary artery disease;
TGCT	cis	rs4713118	0.615	rs9295747	chr6:27736993	G/T	cg10876282	chr6:28092338	ZSCAN16	-0.48	-4.97	-0.41	2.16e-6	Parkinson's disease;
TGCT	cis	rs933688	1.000	rs985434	chr5:90744509	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.96	8.25	0.6	1.91e-13	Smoking behavior;
TGCT	cis	rs11190604	0.767	rs10883484	chr10:102174803	G/C	cg16342193	chr10:102329863	NA	-0.39	-5.05	-0.41	1.54e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs35306767	0.715	rs11253550	chr10:1028288	C/G	cg26597838	chr10:835615	NA	0.58	6.55	0.51	1.35e-9	Eosinophil percentage of granulocytes;
TGCT	cis	rs2404602	0.583	rs2469542	chr15:76557476	A/G	cg22467129	chr15:76604101	ETFA	0.64	8.34	0.6	1.2e-13	Blood metabolite levels;
TGCT	cis	rs11098499	0.754	rs1814813	chr4:120258207	G/T	cg09307838	chr4:120376055	NA	-0.55	-5.52	-0.44	1.93e-7	Corneal astigmatism;
TGCT	cis	rs478304	0.627	rs1073602	chr11:65455386	G/C	cg27068330	chr11:65405492	SIPA1	-0.99	-11.36	-0.71	6.13e-21	Acne (severe);
TGCT	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg14820908	chr5:178986412	RUFY1	0.45	4.55	0.38	1.24e-5	Lung cancer;
TGCT	cis	rs1372520	0.766	rs2583961	chr4:90779758	A/G	cg14346243	chr4:90757452	SNCA	-0.63	-5.28	-0.43	5.7e-7	Neuroticism;
TGCT	cis	rs231513	1.000	rs231499	chr17:41973507	C/T	cg26893861	chr17:41843967	DUSP3	0.66	4.91	0.4	2.77e-6	Cognitive function;
TGCT	cis	rs7223966	1.000	rs7214312	chr17:61870863	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	4.68	0.39	7.5e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	trans	rs1814175	0.626	rs1722008	chr11:49897676	A/T	cg03929089	chr4:120376271	NA	-0.7	-7.84	-0.58	1.72e-12	Height;
TGCT	cis	rs7267979	0.966	rs6083818	chr20:25346082	G/A	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7659604	0.702	rs6826506	chr4:122710865	T/G	cg20573242	chr4:122745356	CCNA2	0.58	5.1	0.42	1.21e-6	Type 2 diabetes;
TGCT	cis	rs986417	0.748	rs4141684	chr14:61069351	C/T	cg27398547	chr14:60952738	C14orf39	1.34	9.87	0.66	2.58e-17	Gut microbiota (bacterial taxa);
TGCT	cis	rs9303542	0.559	rs8079617	chr17:46610028	T/G	cg25032089	chr17:46643351	HOXB3	0.58	5.47	0.44	2.38e-7	Ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs4886920	0.563	rs12900865	chr15:78075910	G/A	cg25212270	chr15:78015279	NA	-0.23	-4.82	-0.4	4.1e-6	Neuroticism;
TGCT	cis	rs9393692	0.905	rs6908328	chr6:26292855	C/A	cg13736514	chr6:26305472	NA	-0.39	-5.65	-0.45	1.04e-7	Educational attainment;
TGCT	cis	rs72781680	0.800	rs72790306	chr2:24111311	T/G	cg08917208	chr2:24149416	ATAD2B	0.85	5.28	0.43	5.53e-7	Lymphocyte counts;
TGCT	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg22535103	chr8:58192502	C8orf71	-0.42	-4.79	-0.4	4.7e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9640161	0.742	rs11983355	chr7:150016697	A/C	cg10018233	chr7:150070692	REPIN1	0.33	4.5	0.37	1.57e-5	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs7924176	0.580	rs12360119	chr10:76015316	G/C	cg19889307	chr10:75911429	ADK;AP3M1	-0.47	-4.58	-0.38	1.1e-5	Primary tooth development (time to first tooth eruption);Permanent tooth development;Primary tooth development (number of teeth);
TGCT	cis	rs2880765	0.835	rs28874135	chr15:86031503	G/A	cg13263323	chr15:86062960	AKAP13	-0.22	-4.79	-0.4	4.68e-6	Coronary artery disease;
TGCT	cis	rs1670533	1.000	rs10003009	chr4:1050849	G/A	cg20887711	chr4:1340912	KIAA1530	0.7	5.66	0.45	9.77e-8	Recombination rate (females);
TGCT	cis	rs4237845	0.680	rs10877033	chr12:58283731	T/C	cg02175503	chr12:58329896	NA	0.48	4.77	0.39	5.03e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs12477438	0.798	rs6732579	chr2:99560239	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.8	-7.6	-0.56	6.47e-12	Chronic sinus infection;
TGCT	cis	rs6840360	0.533	rs11099829	chr4:152727299	A/G	cg17479576	chr4:152424074	FAM160A1	0.47	4.79	0.4	4.66e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg06636001	chr8:8085503	FLJ10661	0.79	7.59	0.56	6.72e-12	Mood instability;
TGCT	cis	rs55823223	0.646	rs74410877	chr17:73832384	C/T	cg08125733	chr17:73851984	WBP2	0.91	5.79	0.46	5.47e-8	Psoriasis;
TGCT	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.56	-5.21	-0.42	7.76e-7	Prudent dietary pattern;
TGCT	cis	rs7226408	0.857	rs17567920	chr18:34625813	G/A	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs5769765	1.000	rs5769765	chr22:50271176	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	1.11	11.76	0.73	6.5e-22	Schizophrenia;
TGCT	cis	rs10804591	0.832	rs9853950	chr3:129336057	A/T	cg07730360	chr3:128845626	NA	0.26	5.17	0.42	8.92e-7	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Hip circumference adjusted for BMI;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs2486012	1.000	rs1859726	chr1:44396215	C/T	cg12908607	chr1:44402522	ARTN	-0.68	-5.45	-0.44	2.56e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg07507251	chr3:52567010	NT5DC2	0.47	6.75	0.52	5.11e-10	Bipolar disorder;
TGCT	cis	rs4953076	0.573	rs7593987	chr2:44393532	C/T	cg00619915	chr2:44497795	NA	0.23	5.11	0.42	1.17e-6	Height;
TGCT	cis	rs1348850	0.608	rs10176632	chr2:178225934	G/T	cg22681709	chr2:178499509	PDE11A	-0.36	-4.51	-0.38	1.49e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs13256369	0.851	rs13267036	chr8:8566685	G/A	cg06671706	chr8:8559999	CLDN23	0.34	4.61	0.38	9.98e-6	Obesity-related traits;
TGCT	cis	rs981844	0.807	rs56053818	chr4:154638126	T/A	cg14289246	chr4:154710475	SFRP2	1.0	8.17	0.59	2.94e-13	Response to statins (LDL cholesterol change);
TGCT	cis	rs3796352	0.527	rs11715498	chr3:52943551	G/C	cg15956490	chr3:53032818	SFMBT1	0.41	4.59	0.38	1.07e-5	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs6831352	0.744	rs2602847	chr4:100025963	T/C	cg12011299	chr4:100065546	ADH4	0.4	4.82	0.4	4.07e-6	Alcohol dependence;
TGCT	cis	rs13256369	0.951	rs12679360	chr8:8566269	G/T	cg18904891	chr8:8559673	CLDN23	-0.57	-5.55	-0.45	1.64e-7	Obesity-related traits;
TGCT	cis	rs2811893	1.000	rs232872	chr1:59118959	A/G	cg26196860	chr1:59745563	NA	0.24	4.44	0.37	1.96e-5	Diabetic retinopathy;
TGCT	trans	rs114540395	0.687	rs75269434	chr10:103473111	G/C	cg24140841	chr18:77642911	KCNG2	0.75	6.9	0.53	2.36e-10	Schizophrenia;
TGCT	cis	rs9534288	0.912	rs4942468	chr13:46618290	C/A	cg15192986	chr13:46630673	CPB2	-0.49	-6.24	-0.49	6.2e-9	Blood protein levels;
TGCT	cis	rs7584330	0.868	rs2325839	chr2:238386286	T/C	cg08992911	chr2:238395768	MLPH	0.61	4.51	0.38	1.51e-5	Prostate cancer;
TGCT	cis	rs9457247	0.967	rs1211447	chr6:167381979	C/T	cg23791538	chr6:167370224	RNASET2	-0.5	-4.98	-0.41	2.08e-6	Crohn's disease;
TGCT	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg24675658	chr1:53192096	ZYG11B	0.71	8.06	0.59	5.58e-13	Monocyte count;
TGCT	cis	rs7666738	0.791	rs11730069	chr4:98945772	A/G	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10789491	1.000	rs35861275	chr1:47171909	A/C	cg15501359	chr1:47185051	KIAA0494	-0.83	-8.09	-0.59	4.53e-13	Response to hepatitis C treatment;
TGCT	cis	rs4766566	0.609	rs6490042	chr12:111719060	T/A	cg10833066	chr12:111807467	FAM109A	0.36	6.58	0.51	1.18e-9	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
TGCT	cis	rs9486719	1.000	rs11153023	chr6:96968525	C/T	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.21	-0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs2806561	0.734	rs11578046	chr1:23425139	G/A	cg12483005	chr1:23474871	LUZP1	0.38	4.78	0.39	4.81e-6	Height;
TGCT	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg10802521	chr3:52805072	NEK4	-0.71	-8.81	-0.62	9.29e-15	Bipolar disorder;
TGCT	cis	rs12477438	0.520	rs12621007	chr2:99791946	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.9	9.33	0.64	5.15e-16	Chronic sinus infection;
TGCT	cis	rs1008375	0.872	rs2315552	chr4:17627294	A/G	cg10189774	chr4:17578691	LAP3	0.56	5.03	0.41	1.67e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg08280861	chr8:58055591	NA	0.54	6.51	0.5	1.66e-9	Developmental language disorder (linguistic errors);
TGCT	cis	rs151997	0.629	rs152808	chr5:50207382	G/C	cg06027927	chr5:50259733	NA	0.56	5.64	0.45	1.11e-7	Callous-unemotional behaviour;
TGCT	cis	rs9372253	0.645	rs7753212	chr6:110700229	T/C	cg01119278	chr6:110721349	DDO	-0.3	-4.62	-0.38	9.64e-6	Platelet distribution width;
TGCT	cis	rs10927875	0.631	rs945418	chr1:16344730	T/C	cg21385522	chr1:16154831	NA	0.62	6.41	0.5	2.76e-9	Dilated cardiomyopathy;
TGCT	cis	rs1843834	0.505	rs4674911	chr2:225345254	A/G	cg22455342	chr2:225449267	CUL3	1.02	10.7	0.69	2.53e-19	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs4851254	0.618	rs12996621	chr2:100646137	A/G	cg07810366	chr2:100720526	AFF3	-0.47	-4.81	-0.4	4.37e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7089973	0.585	rs7907837	chr10:116610690	G/T	cg03647239	chr10:116582469	FAM160B1	0.61	5.86	0.47	3.87e-8	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs3796352	1.000	rs71617204	chr3:53042951	G/A	cg07884673	chr3:53033167	SFMBT1	0.64	6.39	0.5	3.03e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	trans	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg20587970	chr11:113659929	NA	-0.88	-10.79	-0.7	1.49e-19	Hip circumference adjusted for BMI;
TGCT	cis	rs4886238	0.517	rs9528165	chr13:61176836	G/C	cg23734418	chr13:61221316	NA	-0.29	-5.39	-0.44	3.37e-7	Menopause (age at onset);
TGCT	cis	rs7666738	0.830	rs7662199	chr4:99019766	G/A	cg05340658	chr4:99064831	C4orf37	0.49	5.62	0.45	1.18e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6750047	0.771	rs2855658	chr2:38296890	T/C	cg07380506	chr2:38303506	CYP1B1	0.66	6.01	0.47	1.94e-8	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs910316	0.763	rs2080201	chr14:75629972	C/T	cg08847533	chr14:75593920	NEK9	-0.83	-8.23	-0.59	2.13e-13	Height;
TGCT	cis	rs933688	0.941	rs2887007	chr5:90740531	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.93	8.39	0.6	9.04e-14	Smoking behavior;
TGCT	cis	rs13191362	1.000	rs13190742	chr6:163008758	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.62	0.45	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs6674176	0.597	rs12127737	chr1:44402565	G/A	cg12908607	chr1:44402522	ARTN	-0.75	-9.6	-0.65	1.15e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs1878931	0.580	rs4578649	chr16:3407258	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.91	-10.18	-0.67	4.65e-18	Body mass index (adult);
TGCT	cis	rs17376456	0.569	rs6895356	chr5:93060781	A/G	cg25358565	chr5:93447407	FAM172A	0.66	5.56	0.45	1.57e-7	Diabetic retinopathy;
TGCT	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg05025164	chr4:1340916	KIAA1530	-0.76	-6.84	-0.52	3.13e-10	Longevity;
TGCT	cis	rs3960554	0.808	rs57721466	chr7:75710049	C/T	cg17325771	chr7:75508891	RHBDD2	-0.54	-4.63	-0.38	8.97e-6	Eotaxin levels;
TGCT	cis	rs12908161	1.000	rs11637142	chr15:85295927	A/G	cg17173187	chr15:85201210	NMB	0.57	6.35	0.5	3.65e-9	Schizophrenia;
TGCT	cis	rs7666738	0.546	rs34159897	chr4:98787367	T/C	cg05340658	chr4:99064831	C4orf37	0.51	5.65	0.45	1.03e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1499614	1.000	rs1638731	chr7:66144679	C/T	cg18252515	chr7:66147081	NA	-1.26	-7.95	-0.58	9.71e-13	Gout;
TGCT	cis	rs7474896	0.559	rs10740949	chr10:37978435	A/G	cg13720705	chr10:37990370	NA	0.34	5.0	0.41	1.89e-6	Obesity (extreme);
TGCT	cis	rs7267979	0.934	rs2257464	chr20:25265872	C/T	cg03522245	chr20:25566470	NINL	0.63	6.72	0.52	5.91e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs8073060	0.586	rs225250	chr17:33941963	A/G	cg19694781	chr19:47549865	TMEM160	-0.61	-13.7	-0.78	1.39e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs6484504	0.600	rs366758	chr11:31222499	A/C	cg26647111	chr11:31128758	NA	-0.34	-4.62	-0.38	9.36e-6	Red blood cell count;
TGCT	trans	rs931812	0.825	rs35472498	chr8:101894167	G/A	cg20993868	chr7:22813445	NA	0.42	9.03	0.63	2.75e-15	Attention deficit hyperactivity disorder and conduct disorder;
TGCT	cis	rs6815814	0.898	rs73236616	chr4:38789675	G/A	cg02016764	chr4:38805732	TLR1	-0.34	-5.4	-0.44	3.2e-7	Breast cancer;
TGCT	cis	rs453301	0.686	rs3895823	chr8:8873646	T/C	cg15556689	chr8:8085844	FLJ10661	-0.64	-5.29	-0.43	5.37e-7	Joint mobility (Beighton score);
TGCT	cis	rs12681288	0.676	rs7011999	chr8:1008446	A/G	cg04851639	chr8:1020857	NA	-0.31	-5.17	-0.42	8.94e-7	Schizophrenia;
TGCT	cis	rs35883536	0.647	rs59667512	chr1:101046712	C/T	cg06223162	chr1:101003688	GPR88	-0.41	-7.64	-0.57	5.04e-12	Monocyte count;
TGCT	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg10876282	chr6:28092338	ZSCAN16	0.51	4.69	0.39	6.99e-6	Cardiac Troponin-T levels;
TGCT	cis	rs7312933	0.703	rs7957471	chr12:42545591	G/T	cg19980929	chr12:42632907	YAF2	0.47	6.46	0.5	2.13e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs3008870	0.755	rs2815364	chr1:67498384	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.8	8.48	0.61	5.61e-14	Lymphocyte percentage of white cells;
TGCT	cis	rs7044106	0.762	rs4837790	chr9:123446325	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	6.34	0.49	3.94e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs797680	0.796	rs797661	chr1:93687091	G/T	cg17826107	chr1:92977322	EVI5	0.24	5.29	0.43	5.47e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs36051895	0.589	rs7850294	chr9:5191128	C/T	cg02405213	chr9:5042618	JAK2	0.72	9.26	0.64	7.77e-16	Pediatric autoimmune diseases;
TGCT	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg17971929	chr21:40555470	PSMG1	0.96	8.52	0.61	4.51e-14	Cognitive function;
TGCT	cis	rs9486715	0.867	rs12207471	chr6:96963782	A/G	cg06623918	chr6:96969491	KIAA0776	1.1	15.44	0.81	1.17e-30	Headache;
TGCT	cis	rs10782582	0.609	rs1498311	chr1:76254726	A/C	cg03433033	chr1:76189801	ACADM	0.47	4.75	0.39	5.62e-6	Daytime sleep phenotypes;
TGCT	cis	rs72945132	0.660	rs7121703	chr11:70140296	C/T	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs116103936	chr4:98954531	T/C	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7178572	0.568	rs4886866	chr15:77696166	A/T	cg15453836	chr15:77711506	NA	-0.42	-4.81	-0.4	4.28e-6	Type 2 diabetes;
TGCT	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg22166914	chr1:53195759	ZYG11B	-0.42	-7.46	-0.56	1.33e-11	Monocyte count;
TGCT	cis	rs3862260	0.509	rs10754416	chr1:120163531	A/G	cg11530693	chr1:120165357	ZNF697	0.2	4.54	0.38	1.3e-5	Systemic lupus erythematosus;
TGCT	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.98	-7.22	-0.54	4.68e-11	Gut microbiome composition (summer);
TGCT	cis	rs12478296	1.000	rs4973685	chr2:243019089	A/C	cg06360820	chr2:242988706	NA	-0.83	-5.68	-0.45	9.26e-8	Obesity-related traits;
TGCT	cis	rs9291683	0.507	rs6849273	chr4:10021595	C/T	cg11266682	chr4:10021025	SLC2A9	0.64	8.47	0.61	6.02e-14	Bone mineral density;
TGCT	cis	rs9634489	0.502	rs17189979	chr13:97121087	G/A	cg11411106	chr13:97107445	HS6ST3	0.26	4.51	0.38	1.51e-5	Body mass index;
TGCT	cis	rs9868809	0.505	rs56735597	chr3:48765168	A/G	cg00383909	chr3:49044727	WDR6	1.26	6.32	0.49	4.2e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs4523957	0.583	rs7212589	chr17:2042393	A/G	cg16513277	chr17:2031491	SMG6	-0.2	-4.58	-0.38	1.13e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs17221829	0.720	rs10765237	chr11:89453598	T/G	cg02982614	chr11:89391479	FOLH1B	-0.29	-4.95	-0.41	2.4e-6	Anxiety in major depressive disorder;
TGCT	cis	rs12142240	0.698	rs6703374	chr1:46862332	C/G	cg14993813	chr1:46806288	NSUN4	-0.59	-4.86	-0.4	3.45e-6	Menopause (age at onset);
TGCT	cis	rs7772486	0.840	rs2777478	chr6:146309117	T/C	cg13319975	chr6:146136371	FBXO30	-0.53	-4.68	-0.39	7.44e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7178572	0.568	rs1565757	chr15:77657682	C/T	cg22256960	chr15:77711686	NA	-0.85	-8.73	-0.62	1.4e-14	Type 2 diabetes;
TGCT	cis	rs2795502	1.000	rs2185717	chr10:43343875	G/A	cg20628663	chr10:43360327	NA	0.43	6.22	0.49	7.01e-9	Blood protein levels;
TGCT	cis	rs3008870	1.000	rs2182143	chr1:67378936	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.1	12.08	0.74	1.11e-22	Lymphocyte percentage of white cells;
TGCT	cis	rs2072499	0.966	rs2984615	chr1:156165317	G/C	cg24450063	chr1:156163899	SLC25A44	1.2	18.21	0.85	7.43e-37	Testicular germ cell tumor;
TGCT	cis	rs734999	0.588	rs2985859	chr1:2532416	T/C	cg18854424	chr1:2615690	NA	-0.46	-5.28	-0.43	5.53e-7	Ulcerative colitis;
TGCT	cis	rs6429082	0.715	rs2153204	chr1:235580382	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.57	-5.03	-0.41	1.7e-6	Adiposity;
TGCT	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg06238570	chr21:40685208	BRWD1	0.67	6.12	0.48	1.14e-8	Cognitive function;
TGCT	cis	rs3733585	0.699	rs7677710	chr4:9969517	T/G	cg00071950	chr4:10020882	SLC2A9	-0.57	-6.83	-0.52	3.47e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg00814883	chr7:100076585	TSC22D4	-0.9	-9.56	-0.65	1.5e-16	Platelet count;
TGCT	cis	rs17345786	0.861	rs74768235	chr3:101142821	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.4	-8.39	-0.6	9.01e-14	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4849845	0.612	rs3806491	chr2:121008675	G/A	cg24070213	chr2:121070622	NA	0.35	4.69	0.39	6.98e-6	Mean platelet volume;
TGCT	cis	rs3125734	0.633	rs1873685	chr10:64032126	C/T	cg19640130	chr10:64028056	RTKN2	-0.4	-5.2	-0.42	8.01e-7	Rheumatoid arthritis;
TGCT	cis	rs2354432	0.825	rs10900347	chr1:146800107	G/C	cg25205988	chr1:146714368	CHD1L	1.28	9.92	0.67	1.94e-17	Mitochondrial DNA levels;
TGCT	cis	rs1008375	0.966	rs6449325	chr4:17699509	C/T	cg18681998	chr4:17616180	MED28	-0.72	-6.85	-0.52	3.1e-10	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs700651	0.789	rs6715070	chr2:198898265	A/G	cg00792783	chr2:198669748	PLCL1	-0.59	-5.34	-0.43	4.33e-7	Intracranial aneurysm;
TGCT	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg11845111	chr2:191398756	TMEM194B	0.35	5.44	0.44	2.76e-7	Pulse pressure;
TGCT	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg25767906	chr1:53392781	SCP2	-0.55	-6.64	-0.51	8.87e-10	Monocyte count;
TGCT	cis	rs2153535	0.580	rs7453115	chr6:8447261	A/G	cg07606381	chr6:8435919	SLC35B3	0.53	5.02	0.41	1.79e-6	Motion sickness;
TGCT	cis	rs11577318	0.853	rs4471263	chr1:26622700	C/T	cg04990556	chr1:26633338	UBXN11	-0.61	-5.63	-0.45	1.17e-7	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg19901468	chr14:105411992	AHNAK2	-0.28	-5.93	-0.47	2.77e-8	Rheumatoid arthritis;
TGCT	cis	rs7523273	0.565	rs1998538	chr1:207886487	C/T	cg22525895	chr1:207977042	MIR29B2	-0.36	-5.89	-0.47	3.47e-8	Schizophrenia;
TGCT	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg10047753	chr17:41438598	NA	0.97	9.99	0.67	1.37e-17	Menopause (age at onset);
TGCT	cis	rs35883536	0.846	rs964905	chr1:101087131	T/C	cg06223162	chr1:101003688	GPR88	-0.33	-5.34	-0.43	4.33e-7	Monocyte count;
TGCT	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg08280861	chr8:58055591	NA	0.4	4.73	0.39	5.97e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs734999	0.505	rs4445406	chr1:2539400	T/C	cg18854424	chr1:2615690	NA	0.44	5.1	0.42	1.23e-6	Ulcerative colitis;
TGCT	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg05368731	chr17:41323189	NBR1	1.01	9.09	0.63	1.94e-15	Menopause (age at onset);
TGCT	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg05665937	chr4:1216051	CTBP1	0.27	5.34	0.43	4.28e-7	Obesity-related traits;
TGCT	cis	rs8070128	0.601	rs8080602	chr17:17954728	G/C	cg09796270	chr17:17721594	SREBF1	-0.24	-4.7	-0.39	6.8e-6	Total body bone mineral density;
TGCT	cis	rs2013441	1.000	rs2013441	chr17:20023099	G/A	cg18979559	chr17:20280153	CCDC144C	0.47	4.88	0.4	3.16e-6	Obesity-related traits;
TGCT	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg11764359	chr7:65958608	NA	0.59	5.29	0.43	5.45e-7	Aortic root size;
TGCT	cis	rs4242434	0.854	rs3064	chr8:22451688	C/G	cg03733263	chr8:22462867	KIAA1967	-1.12	-17.66	-0.85	1.22e-35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs317689	0.581	rs315132	chr12:69761996	G/C	cg11871910	chr12:69753446	YEATS4	0.58	5.18	0.42	8.72e-7	Response to diuretic therapy;
TGCT	cis	rs6840360	0.642	rs7680013	chr4:152409477	A/C	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.82e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs3806843	0.576	rs246024	chr5:140333952	C/T	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs12145833	0.596	rs12123491	chr1:243297924	C/G	cg02356786	chr1:243265016	LOC731275	0.52	4.58	0.38	1.12e-5	Obesity (early onset extreme);
TGCT	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg17554472	chr22:41940697	POLR3H	0.49	5.23	0.42	7.08e-7	Vitiligo;
TGCT	cis	rs1348850	0.632	rs12616288	chr2:178503813	G/T	cg22681709	chr2:178499509	PDE11A	-0.53	-6.51	-0.5	1.69e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs10791097	0.694	rs10894275	chr11:130756251	C/T	cg05962950	chr11:130786565	SNX19	0.9	11.06	0.7	3.32e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs7914558	1.000	rs12780843	chr10:104769335	G/C	cg15744005	chr10:104629667	AS3MT	-0.4	-4.88	-0.4	3.25e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg02725872	chr8:58115012	NA	-0.38	-5.05	-0.41	1.55e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4803468	0.967	rs1077856	chr19:41885221	T/C	cg09537434	chr19:41945824	ATP5SL	-0.85	-9.13	-0.63	1.57e-15	Height;
TGCT	cis	rs595982	0.527	rs73061659	chr19:49373556	G/A	cg21252483	chr19:49399788	TULP2	-0.42	-6.36	-0.5	3.58e-9	Red cell distribution width;
TGCT	cis	rs7191439	0.722	rs6500491	chr16:88783521	T/C	cg27087555	chr16:88793112	FAM38A	-0.54	-5.86	-0.47	3.88e-8	Plateletcrit;
TGCT	cis	rs4713118	0.539	rs200951	chr6:27835930	A/G	cg18675097	chr6:28227127	NKAPL	-0.35	-4.54	-0.38	1.34e-5	Parkinson's disease;
TGCT	cis	rs7666738	0.546	rs11727151	chr4:98837353	A/C	cg17366294	chr4:99064904	C4orf37	0.65	6.03	0.48	1.73e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7772486	0.875	rs2748501	chr6:146312258	G/A	cg23711669	chr6:146136114	FBXO30	0.89	9.37	0.64	4.24e-16	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6671200	0.920	rs35403759	chr1:95702890	C/T	cg26537280	chr1:95699037	RWDD3	0.7	5.55	0.45	1.62e-7	Stearic acid (18:0) levels;
TGCT	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg08280861	chr8:58055591	NA	0.52	5.97	0.47	2.35e-8	Developmental language disorder (linguistic errors);
TGCT	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg21724239	chr8:58056113	NA	0.38	5.18	0.42	8.82e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6939532	0.522	rs9358933	chr6:26363688	C/T	cg05738196	chr6:26577821	NA	-0.53	-5.03	-0.41	1.68e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7178615	1	rs7178615	chr15:66869072	A/G	cg08479319	chr15:66648941	TIPIN	-0.5	-4.56	-0.38	1.2e-5	Diastolic blood pressure;
TGCT	cis	rs314370	1.000	rs314370	chr7:100453208	T/C	cg10426581	chr7:100472382	SRRT	0.98	10.52	0.69	7e-19	Resting heart rate;
TGCT	cis	rs3806843	0.576	rs246037	chr5:140331846	C/T	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs1538970	0.748	rs11211137	chr1:46013892	T/A	cg05343316	chr1:45956843	TESK2	0.72	5.48	0.44	2.26e-7	Platelet count;
TGCT	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg21171335	chr12:122356390	WDR66	-0.67	-6.74	-0.52	5.3e-10	Mean corpuscular volume;
TGCT	cis	rs10883723	0.810	rs12265877	chr10:104247247	C/G	cg05855489	chr10:104503620	C10orf26	-0.56	-4.91	-0.4	2.81e-6	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs763121	0.853	rs3788544	chr22:39064966	C/T	cg06022373	chr22:39101656	GTPBP1	0.77	7.57	0.56	7.47e-12	Menopause (age at onset);
TGCT	cis	rs12711979	0.509	rs10181286	chr2:3824567	G/A	cg17052675	chr2:3827356	NA	-0.55	-12.72	-0.75	3.04e-24	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs7635838	0.859	rs6784883	chr3:11444453	G/A	cg00170343	chr3:11313890	ATG7	0.66	6.25	0.49	5.91e-9	HDL cholesterol;
TGCT	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg12963246	chr6:28129442	ZNF389	0.52	5.1	0.42	1.23e-6	Depression;
TGCT	cis	rs72634258	0.554	rs17374292	chr1:7881234	C/T	cg26816564	chr1:7831052	VAMP3	0.87	6.44	0.5	2.34e-9	Inflammatory bowel disease;
TGCT	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg26338869	chr17:61819248	STRADA	-0.55	-5.08	-0.42	1.34e-6	Prudent dietary pattern;
TGCT	cis	rs2964802	0.505	rs7728436	chr5:10814464	T/A	cg14521931	chr5:10832172	NA	-0.28	-4.61	-0.38	9.72e-6	Major depressive disorder;Recurrent major depressive disorder;
TGCT	cis	rs700590	0.723	rs167345	chr5:88118858	A/G	cg22951263	chr5:87985283	NA	0.56	5.4	0.44	3.27e-7	Educational attainment (years of education);
TGCT	cis	rs9993613	0.875	rs13104467	chr4:73455382	C/T	cg15102770	chr4:73434591	ADAMTS3	0.52	4.71	0.39	6.4e-6	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs11711311	1.000	rs9288982	chr3:113470149	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.76	-6.76	-0.52	4.88e-10	IgG glycosylation;
TGCT	cis	rs17433780	0.857	rs12144445	chr1:89465238	C/T	cg09516651	chr1:89888402	LOC400759	0.32	5.89	0.47	3.35e-8	Carotid intima media thickness;
TGCT	cis	rs11096990	0.634	rs2276888	chr4:39279907	C/T	cg20847110	chr4:39482781	LOC401127	-0.17	-4.89	-0.4	3.03e-6	Cognitive function;
TGCT	trans	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.86	9.4	0.65	3.49e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg03352830	chr11:487213	PTDSS2	0.26	4.57	0.38	1.16e-5	Body mass index;
TGCT	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg14893161	chr1:205819251	PM20D1	0.52	7.1	0.54	8.73e-11	Menarche (age at onset);
TGCT	cis	rs6460942	0.818	rs73299043	chr7:12251595	C/G	cg06484146	chr7:12443880	VWDE	-0.58	-4.99	-0.41	2.02e-6	Coronary artery disease;
TGCT	cis	rs6589563	0.609	rs12285095	chr11:116658031	T/G	cg20660624	chr11:117307972	DSCAML1	-0.43	-5.2	-0.42	8.01e-7	Eosinophil counts;
TGCT	cis	rs7647973	1.000	rs9860055	chr3:49506900	C/T	cg05785598	chr3:49045655	WDR6	-0.38	-4.5	-0.37	1.57e-5	Menarche (age at onset);
TGCT	cis	rs6964587	0.773	rs59242586	chr7:91918145	A/G	cg17063962	chr7:91808500	NA	0.85	8.52	0.61	4.45e-14	Breast cancer;
TGCT	cis	rs17221829	0.703	rs11018682	chr11:89364451	A/C	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.65	-0.39	8.43e-6	Anxiety in major depressive disorder;
TGCT	cis	rs1056107	0.572	rs10981383	chr9:115156785	A/G	cg02332936	chr9:115140584	NA	-0.26	-4.6	-0.38	1.02e-5	Colorectal cancer;
TGCT	cis	rs624899	0.655	rs8109248	chr19:11641375	C/T	cg15237152	chr19:11649631	CNN1	0.48	5.22	0.42	7.29e-7	Presence of antiphospholipid antibodies;
TGCT	cis	rs2455799	0.552	rs2470540	chr3:15718652	T/A	cg16303742	chr3:15540471	COLQ	-0.26	-4.93	-0.4	2.58e-6	Mean platelet volume;
TGCT	cis	rs587847	0.708	rs4924149	chr15:37633075	C/T	cg00216138	chr15:37171175	LOC145845	0.32	4.74	0.39	5.71e-6	Intraocular pressure;
TGCT	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg25767906	chr1:53392781	SCP2	-0.55	-6.57	-0.51	1.28e-9	Monocyte count;
TGCT	cis	rs1981331	1.000	rs79694455	chr21:47983979	C/T	cg23283320	chr21:48055893	PRMT2	1.29	5.89	0.47	3.42e-8	Cerebrospinal fluid t-tau:AB1-42 ratio;
TGCT	cis	rs7264396	0.635	rs2064724	chr20:34522520	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.3	-5.31	-0.43	4.87e-7	Total cholesterol levels;
TGCT	cis	rs6700896	0.500	rs57941031	chr1:66087742	G/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.59	4.56	0.38	1.22e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs11190604	1.000	rs11190551	chr10:102204734	A/G	cg16342193	chr10:102329863	NA	-0.4	-5.31	-0.43	4.85e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs1552244	1.000	rs13433680	chr3:10136390	T/A	cg00149659	chr3:10157352	C3orf10	0.93	5.73	0.46	7.25e-8	Alzheimer's disease;
TGCT	trans	rs1814175	0.645	rs10444311	chr11:49986906	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.67	-0.69	2.92e-19	Height;
TGCT	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.46	-4.66	-0.39	7.94e-6	Mean platelet volume;
TGCT	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.45	-5.49	-0.44	2.22e-7	Alzheimer's disease;
TGCT	cis	rs2456568	0.741	rs2102332	chr11:93635281	G/T	cg26875233	chr11:93583750	C11orf90	-0.48	-6.47	-0.5	2.07e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs763121	0.853	rs2284073	chr22:39105948	T/C	cg06022373	chr22:39101656	GTPBP1	0.78	8.1	0.59	4.34e-13	Menopause (age at onset);
TGCT	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg22618164	chr12:122356400	WDR66	0.59	6.03	0.48	1.71e-8	Mean corpuscular volume;
TGCT	cis	rs2224391	0.628	rs2773310	chr6:5250828	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-1.04	-6.69	-0.51	6.87e-10	Height;
TGCT	cis	rs6546537	0.911	rs62133968	chr2:69891910	C/T	cg10773587	chr2:69614142	GFPT1	-0.82	-7.07	-0.54	1.01e-10	Serum thyroid-stimulating hormone levels;
TGCT	cis	rs7923609	0.841	rs7920036	chr10:65293860	T/C	cg08743896	chr10:65200160	JMJD1C	-0.33	-4.48	-0.37	1.69e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9393692	0.875	rs12526215	chr6:26262916	T/C	cg05868516	chr6:26286170	HIST1H4H	0.63	5.91	0.47	3.1e-8	Educational attainment;
TGCT	cis	rs1577917	1.000	rs1577917	chr6:86691940	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-5.06	-0.41	1.46e-6	Response to antipsychotic treatment;
TGCT	cis	rs10782582	0.593	rs77208152	chr1:76124255	T/C	cg22875332	chr1:76189707	ACADM	-0.54	-6.36	-0.5	3.61e-9	Daytime sleep phenotypes;
TGCT	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.7	0.52	6.47e-10	Bipolar disorder;
TGCT	cis	rs8020441	1.000	rs68120925	chr14:51169258	C/A	cg04730355	chr14:51134070	SAV1	0.73	6.02	0.48	1.84e-8	Cognitive performance;
TGCT	cis	rs617219	0.574	rs7732681	chr5:78595246	C/T	cg23514016	chr5:78407564	BHMT	-0.3	-4.51	-0.38	1.49e-5	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs16867321	0.950	rs9677293	chr2:181499459	C/G	cg23363182	chr2:181467187	NA	-0.38	-5.55	-0.45	1.62e-7	Obesity;
TGCT	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg03303774	chr4:1407052	NA	0.35	5.37	0.43	3.78e-7	Obesity-related traits;
TGCT	cis	rs9916302	0.904	rs68178216	chr17:37526241	A/C	cg07936489	chr17:37558343	FBXL20	0.63	4.91	0.4	2.83e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs858239	0.600	rs6956595	chr7:23134256	A/G	cg05602783	chr7:23145260	KLHL7	-0.58	-4.85	-0.4	3.68e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs7698623	0.850	rs6532021	chr4:88769661	C/G	cg02735620	chr4:88950514	PKD2	-0.44	-4.81	-0.4	4.22e-6	Cardiovascular disease risk factors;
TGCT	cis	rs60871478	0.730	rs73042471	chr7:927762	G/A	cg00475322	chr7:917719	C7orf20	0.52	4.99	0.41	2.03e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs9646954	0.542	rs4149512	chr2:101022886	C/T	cg08017756	chr2:100939284	LONRF2	-0.3	-4.73	-0.39	5.95e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6582630	0.519	rs12366667	chr12:38332632	C/T	cg26384229	chr12:38710491	ALG10B	0.79	6.88	0.53	2.65e-10	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs7666738	0.925	rs2865952	chr4:99040305	C/T	cg05340658	chr4:99064831	C4orf37	0.48	4.68	0.39	7.33e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs5760092	0.755	rs11090298	chr22:24262061	G/A	cg02953382	chr22:24373134	LOC391322	0.84	7.25	0.55	4.02e-11	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs10744422	0.686	rs4424710	chr12:123293302	T/G	cg18912006	chr12:123335444	HIP1R	0.56	4.78	0.39	4.84e-6	Schizophrenia;
TGCT	cis	rs79839061	0.656	rs28662837	chr4:879776	G/A	cg15843217	chr4:699224	PCGF3	-0.56	-4.52	-0.38	1.42e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg11644478	chr21:40555479	PSMG1	-0.52	-4.83	-0.4	3.98e-6	Menarche (age at onset);
TGCT	cis	rs7100689	0.646	rs1340376	chr10:82128963	A/G	cg01528321	chr10:82214614	TSPAN14	0.8	7.76	0.57	2.7e-12	Post bronchodilator FEV1;
TGCT	cis	rs8072100	0.967	rs4794001	chr17:45720849	T/C	cg08085267	chr17:45401833	C17orf57	-0.42	-4.6	-0.38	1.04e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs4233949	0.535	rs7605902	chr2:54620459	A/C	cg14634210	chr2:54682758	SPTBN1	0.51	4.62	0.38	9.38e-6	Bone mineral density;
TGCT	cis	rs7551222	0.716	rs10900601	chr1:204572050	A/G	cg09150239	chr1:204347429	NA	0.51	4.73	0.39	6.03e-6	Schizophrenia;
TGCT	cis	rs9467773	0.596	rs2451751	chr6:26646714	T/C	cg02458000	chr6:26745757	NA	0.51	4.59	0.38	1.08e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg08280861	chr8:58055591	NA	0.36	4.89	0.4	3.03e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7918232	0.830	rs9833	chr10:27400861	G/A	cg14442939	chr10:27389572	ANKRD26	0.71	5.33	0.43	4.45e-7	Breast cancer;
TGCT	cis	rs12477438	0.765	rs62154861	chr2:99590235	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-8.79	-0.62	1.04e-14	Chronic sinus infection;
TGCT	cis	rs7666738	0.830	rs7664305	chr4:99037691	G/A	cg18180107	chr4:99064573	C4orf37	0.58	5.39	0.44	3.47e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8067545	0.750	rs11871651	chr17:19997425	T/C	cg13482628	chr17:19912719	NA	0.52	4.48	0.37	1.67e-5	Schizophrenia;
TGCT	cis	rs2050392	1.000	rs2265185	chr10:30691777	A/C	cg18806716	chr10:30721971	MAP3K8	-0.44	-5.18	-0.42	8.82e-7	Inflammatory bowel disease;
TGCT	cis	rs4689388	0.853	rs6817447	chr4:6286847	G/T	cg00701064	chr4:6280414	WFS1	0.46	6.15	0.48	9.62e-9	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg27170947	chr2:26402098	FAM59B	-0.4	-4.63	-0.38	8.93e-6	Gut microbiome composition (summer);
TGCT	cis	rs67478160	0.643	rs6575997	chr14:104228546	C/T	cg26031613	chr14:104095156	KLC1	0.6	6.24	0.49	6.3e-9	Schizophrenia;
TGCT	cis	rs477895	0.838	rs72922039	chr11:64013116	A/C	cg04317338	chr11:64019027	PLCB3	0.81	6.94	0.53	1.98e-10	Mean platelet volume;
TGCT	cis	rs2153535	0.580	rs9406169	chr6:8509470	A/T	cg23788917	chr6:8435910	SLC35B3	0.57	5.3	0.43	5.17e-7	Motion sickness;
TGCT	cis	rs10782582	0.609	rs5745394	chr1:76311731	G/A	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.52	4.53	0.38	1.37e-5	Daytime sleep phenotypes;
TGCT	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.49	-4.61	-0.38	9.67e-6	Prudent dietary pattern;
TGCT	cis	rs1933488	0.898	rs6557261	chr6:153415368	G/A	cg24028809	chr6:153414101	RGS17	0.21	4.67	0.39	7.69e-6	Prostate cancer;
TGCT	cis	rs67311347	0.544	rs6599088	chr3:40329288	T/C	cg13683864	chr3:40499215	RPL14	-0.78	-7.45	-0.56	1.42e-11	Renal cell carcinoma;
TGCT	trans	rs3107575	0.572	rs73169366	chr3:165320307	C/T	cg04770195	chr16:53114571	CHD9	1.14	6.64	0.51	8.63e-10	Morning vs. evening chronotype;
TGCT	cis	rs2880765	0.805	rs34598679	chr15:86042205	G/A	cg13263323	chr15:86062960	AKAP13	-0.23	-4.82	-0.4	4.1e-6	Coronary artery disease;
TGCT	cis	rs4820539	0.902	rs9612237	chr22:23472954	T/C	cg14186256	chr22:23484241	RTDR1	0.98	12.28	0.74	3.5e-23	Bone mineral density;
TGCT	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg23708337	chr7:1209742	NA	0.6	5.57	0.45	1.53e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs12541335	0.615	rs4872464	chr8:22153381	G/A	cg18135555	chr8:22132992	PIWIL2	0.29	5.62	0.45	1.22e-7	Hypertriglyceridemia;
TGCT	cis	rs12693043	0.764	rs13006261	chr2:175404695	G/A	cg11778734	chr2:175439522	WIPF1	-0.36	-4.66	-0.39	8.01e-6	Urate levels (BMI interaction);
TGCT	cis	rs9549367	0.569	rs3024738	chr13:113819921	T/A	cg18105134	chr13:113819100	PROZ	0.47	8.13	0.59	3.68e-13	Platelet distribution width;
TGCT	cis	rs17253792	0.822	rs112238223	chr14:56056144	C/A	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs7078160	0.766	rs61872990	chr10:118649443	T/C	cg10595547	chr10:119310911	NA	-0.57	-4.45	-0.37	1.87e-5	Nonsyndromic cleft lip with or without cleft palate;Orofacial clefts;
TGCT	cis	rs7940866	0.740	rs2162060	chr11:130830763	A/G	cg05962950	chr11:130786565	SNX19	0.66	6.19	0.49	7.96e-9	Schizophrenia;
TGCT	cis	rs9638182	1.000	rs1051921	chr7:73007943	G/A	cg14087351	chr7:73037990	MLXIPL	-0.55	-4.6	-0.38	1.01e-5	Triglycerides;
TGCT	cis	rs754133	0.964	rs894737	chr12:54418143	A/C	cg16264616	chr12:54390824	NA	0.34	5.19	0.42	8.23e-7	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;
TGCT	cis	rs12458462	0.892	rs35928863	chr18:77438956	A/G	cg11879182	chr18:77439856	CTDP1	0.67	7.67	0.57	4.44e-12	Monocyte count;
TGCT	trans	rs2469997	0.925	rs2470018	chr8:120361655	C/T	cg01792902	chr3:178864926	PIK3CA	0.83	6.77	0.52	4.49e-10	Hypertension (SNP x SNP interaction);
TGCT	trans	rs561341	0.769	rs9899093	chr17:30191954	C/G	cg20587970	chr11:113659929	NA	-0.85	-8.52	-0.61	4.49e-14	Hip circumference adjusted for BMI;
TGCT	cis	rs12188164	0.965	rs77101200	chr5:443059	G/T	cg26850624	chr5:429559	AHRR	-0.2	-4.86	-0.4	3.48e-6	Cystic fibrosis severity;
TGCT	cis	rs9868809	0.772	rs9809222	chr3:48714411	C/T	cg00383909	chr3:49044727	WDR6	0.88	5.29	0.43	5.32e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs3733585	0.674	rs7375643	chr4:9955239	A/G	cg00071950	chr4:10020882	SLC2A9	-0.65	-8.23	-0.59	2.24e-13	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs8180040	1.000	rs295461	chr3:47368010	T/C	cg27129171	chr3:47204927	SETD2	0.7	8.88	0.62	6.43e-15	Colorectal cancer;
TGCT	cis	rs892961	0.932	rs7223768	chr17:75410521	G/A	cg05865280	chr17:75406074	SEPT9	0.29	6.99	0.53	1.46e-10	Airflow obstruction;
TGCT	cis	rs3806843	0.576	rs246027	chr5:140333601	A/G	cg01369220	chr5:140248564	PCDHA7;PCDHA6;PCDHA11;PCDHA10;PCDHA4;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA5;PCDHA3	-0.41	-5.24	-0.43	6.79e-7	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7959452	0.901	rs1384	chr12:69747834	C/T	cg14784868	chr12:69753453	YEATS4	0.7	7.22	0.54	4.55e-11	Blood protein levels;
TGCT	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg24829409	chr8:58192753	C8orf71	-0.55	-5.06	-0.41	1.46e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9902453	0.808	rs78154346	chr17:28169493	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	7.17	0.54	5.79e-11	Coffee consumption (cups per day);
TGCT	cis	rs7010267	0.570	rs2326194	chr8:120043960	C/T	cg17171407	chr8:119960777	TNFRSF11B	0.26	4.59	0.38	1.06e-5	Total body bone mineral density (age 45-60);
TGCT	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg12963246	chr6:28129442	ZNF389	0.52	5.01	0.41	1.85e-6	Parkinson's disease;
TGCT	cis	rs9653442	0.527	rs2164712	chr2:100745404	C/G	cg07810366	chr2:100720526	AFF3	-0.38	-5.28	-0.43	5.55e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs655029	0.848	rs10176736	chr2:31465541	G/T	cg14018959	chr2:31480232	EHD3	-0.32	-4.43	-0.37	2.01e-5	Mean platelet volume;Platelet distribution width;Platelet count;Plateletcrit;
TGCT	cis	rs7100689	0.784	rs7082102	chr10:82104890	A/C	cg01528321	chr10:82214614	TSPAN14	0.8	8.0	0.58	7.5e-13	Post bronchodilator FEV1;
TGCT	cis	rs7833790	0.700	rs7834483	chr8:82704828	A/G	cg27398817	chr8:82754497	SNX16	-0.64	-4.98	-0.41	2.05e-6	Diastolic blood pressure;
TGCT	cis	rs2594989	0.779	rs2596815	chr3:11594930	A/G	cg00170343	chr3:11313890	ATG7	-0.69	-5.22	-0.42	7.38e-7	Circulating chemerin levels;
TGCT	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg17971929	chr21:40555470	PSMG1	0.98	9.41	0.65	3.31e-16	Cognitive function;
TGCT	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg26513180	chr16:89883248	FANCA	1.04	14.52	0.79	1.58e-28	Vitiligo;
TGCT	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg13395646	chr4:1353034	KIAA1530	-0.39	-4.97	-0.41	2.2e-6	Obesity-related traits;
TGCT	cis	rs12765878	0.812	rs2984132	chr10:105657892	T/C	cg11005552	chr10:105648138	OBFC1	-0.44	-7.29	-0.55	3.12e-11	Coronary artery disease;
TGCT	cis	rs28595532	0.841	rs115233595	chr4:119744214	T/C	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs6582630	0.638	rs12425379	chr12:38523705	G/A	cg26384229	chr12:38710491	ALG10B	-0.53	-4.78	-0.39	4.9100000000000004e-06	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.34	0.43	4.23e-7	Prudent dietary pattern;
TGCT	cis	rs7917772	0.503	rs7902306	chr10:104290462	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.71	6.65	0.51	8.56e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs6746896	0.959	rs58361269	chr2:97403110	G/A	cg26085987	chr2:97230376	NA	0.19	4.69	0.39	7.03e-6	Bipolar disorder;
TGCT	cis	rs7937682	0.562	rs630002	chr11:111377758	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.68	-6.36	-0.5	3.55e-9	Primary sclerosing cholangitis;
TGCT	trans	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg21659725	chr3:3221576	CRBN	0.76	9.02	0.63	2.92e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs2541522	0.600	rs8057467	chr16:10744950	G/A	cg21839338	chr16:10912331	FAM18A	0.4	4.48	0.37	1.65e-5	Gut microbiome composition (summer);
TGCT	cis	rs7216064	1.000	rs12451721	chr17:65939075	G/A	cg12091567	chr17:66097778	LOC651250	-0.82	-6.11	-0.48	1.17e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs2688608	0.933	rs2688614	chr10:75652876	G/A	cg02947784	chr10:75434997	AGAP5	0.17	4.61	0.38	9.79e-6	Inflammatory bowel disease;
TGCT	cis	rs9611519	0.602	rs8138520	chr22:41412928	A/G	cg03806693	chr22:41940476	POLR3H	-0.64	-6.09	-0.48	1.29e-8	Neuroticism;
TGCT	cis	rs7954584	0.583	rs6486782	chr12:122359172	T/C	cg21171335	chr12:122356390	WDR66	0.59	6.19	0.49	8.15e-9	Mean corpuscular volume;
TGCT	cis	rs7805747	1.000	rs56012466	chr7:151406788	G/A	cg17611936	chr7:151411526	PRKAG2	0.51	6.51	0.5	1.69e-9	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
TGCT	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.58	-5.74	-0.46	6.96e-8	Bipolar disorder;
TGCT	cis	rs6540559	0.673	rs11805830	chr1:209984969	C/T	cg22029157	chr1:209979665	IRF6	0.74	5.53	0.44	1.84e-7	Cleft lip with or without cleft palate;
TGCT	trans	rs1814175	0.817	rs28544182	chr11:50049577	G/T	cg03929089	chr4:120376271	NA	-0.72	-8.55	-0.61	3.8e-14	Height;
TGCT	cis	rs9467773	0.935	rs11752946	chr6:26560364	C/A	cg05738196	chr6:26577821	NA	0.89	12.06	0.73	1.22e-22	Intelligence (multi-trait analysis);
TGCT	cis	rs6860806	0.661	rs6890009	chr5:131580033	G/T	cg24060327	chr5:131705240	SLC22A5	-0.54	-5.36	-0.43	3.97e-7	Breast cancer;
TGCT	cis	rs9868809	0.505	rs9877685	chr3:48748588	C/T	cg00383909	chr3:49044727	WDR6	1.06	6.28	0.49	5.26e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs7119	0.604	rs939488	chr15:77867780	T/C	cg27398640	chr15:77910606	LINGO1	0.27	4.87	0.4	3.31e-6	Type 2 diabetes;
TGCT	cis	rs6570726	0.935	rs384453	chr6:145815145	G/C	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs908922	0.924	rs6669608	chr1:152475233	A/G	cg20991723	chr1:152506922	NA	0.46	5.74	0.46	6.84e-8	Hair morphology;
TGCT	cis	rs7312933	0.703	rs11181380	chr12:42616040	A/T	cg19980929	chr12:42632907	YAF2	0.46	6.1	0.48	1.24e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs2710642	0.861	rs2710644	chr2:63248968	A/C	cg17519650	chr2:63277830	OTX1	0.62	5.42	0.44	3.05e-7	LDL cholesterol levels;LDL cholesterol;
TGCT	cis	rs916888	0.610	rs199536	chr17:44820425	T/C	cg01570182	chr17:44337453	NA	-0.78	-7.51	-0.56	1.01e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7614311	0.594	rs1046025	chr3:63996262	C/T	cg22134162	chr3:63841271	THOC7	-0.34	-4.7	-0.39	6.92e-6	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs6582630	0.531	rs3850000	chr12:38483752	T/C	cg13010199	chr12:38710504	ALG10B	0.58	4.72	0.39	6.16e-6	Drug-induced liver injury (flucloxacillin);
TGCT	trans	rs17685	0.632	rs1859793	chr7:75821283	G/A	cg19862616	chr7:65841803	NCRNA00174	0.51	8.99	0.63	3.42e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg08219700	chr8:58056026	NA	0.4	4.84	0.4	3.81e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1205863	0.541	rs1205845	chr6:11929449	C/A	cg07106625	chr6:11870215	NA	0.46	4.76	0.39	5.38e-6	Disc degeneration (lumbar);
TGCT	cis	rs709400	0.663	rs62007684	chr14:103894223	T/C	cg26031613	chr14:104095156	KLC1	0.88	9.68	0.66	7.7e-17	Body mass index;
TGCT	cis	rs713587	0.967	rs10182181	chr2:25150296	C/T	cg01884057	chr2:25150051	NA	-0.41	-8.56	-0.61	3.57e-14	Body mass index in non-asthmatics;
TGCT	cis	rs6570726	0.791	rs401561	chr6:145835917	G/T	cg05347473	chr6:146136440	FBXO30	0.53	4.95	0.41	2.4e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9325144	0.624	rs10783330	chr12:39114084	A/G	cg13010199	chr12:38710504	ALG10B	-0.52	-4.58	-0.38	1.13e-5	Morning vs. evening chronotype;
TGCT	cis	rs6840360	0.582	rs4473638	chr4:152322146	C/T	cg17479576	chr4:152424074	FAM160A1	-0.63	-6.8	-0.52	3.99e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs9926296	0.682	rs645019	chr16:89716883	C/T	cg26513180	chr16:89883248	FANCA	-0.68	-6.4	-0.5	2.86e-9	Vitiligo;
TGCT	cis	rs739496	0.579	rs6489810	chr12:112277406	T/C	cg10833066	chr12:111807467	FAM109A	0.38	5.61	0.45	1.24e-7	Platelet count;
TGCT	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg21285383	chr16:89894308	SPIRE2	0.44	6.9	0.53	2.42e-10	Vitiligo;
TGCT	cis	rs1580019	0.563	rs34201720	chr7:32568935	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.14	15.01	0.8	1.13e-29	Cognitive ability;
TGCT	cis	rs7677751	0.806	rs4864847	chr4:55071953	G/A	cg17187183	chr4:55093834	PDGFRA	0.47	6.0	0.47	2.01e-8	Corneal astigmatism;
TGCT	cis	rs9814567	0.806	rs1880375	chr3:134322163	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.76	-7.11	-0.54	8.15e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	trans	rs804280	0.509	rs13276433	chr8:11783036	A/G	cg15556689	chr8:8085844	FLJ10661	0.8	7.56	0.56	7.7e-12	Myopia (pathological);
TGCT	cis	rs6840360	0.642	rs2709820	chr4:152384039	A/G	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.34	-0.49	3.98e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs7647973	0.626	rs62262672	chr3:49655927	T/A	cg05785598	chr3:49045655	WDR6	-0.43	-5.13	-0.42	1.07e-6	Menarche (age at onset);
TGCT	cis	rs7398996	1	rs7398996	chr12:53659448	C/T	cg16917193	chr12:54089295	NA	0.68	5.16	0.42	9.53e-7	Total body bone mineral density (age 45-60);
TGCT	cis	rs79349575	0.783	rs12602933	chr17:47029280	G/C	cg07967210	chr17:47022446	SNF8	0.44	6.13	0.48	1.1e-8	Type 2 diabetes;
TGCT	cis	rs16957091	0.647	rs28564939	chr15:43376592	T/C	cg17935677	chr15:44119062	WDR76	0.54	4.83	0.4	3.88e-6	MGMT methylation in smokers;
TGCT	cis	rs7666738	0.830	rs28515641	chr4:98726419	G/A	cg17366294	chr4:99064904	C4orf37	0.65	6.78	0.52	4.31e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3733585	0.673	rs6850143	chr4:9958924	T/C	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.67	-0.51	7.44e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs12510870	0.564	rs12640883	chr4:74408840	A/G	cg05868023	chr4:75230803	EREG	0.54	4.75	0.39	5.46e-6	Iris color (b* coordinate);
TGCT	cis	rs10114408	0.918	rs10992963	chr9:96657624	G/A	cg13679303	chr9:96623674	NA	-0.36	-4.73	-0.39	5.91e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.06	-9.57	-0.65	1.41e-16	Platelet count;
TGCT	cis	rs904251	0.861	rs1757169	chr6:37487076	G/T	cg01843034	chr6:37503916	NA	-0.52	-6.29	-0.49	4.88e-9	Cognitive performance;
TGCT	cis	rs6088590	0.687	rs6088582	chr20:33286798	G/A	cg06115741	chr20:33292138	TP53INP2	0.57	4.86	0.4	3.51e-6	Coronary artery disease;
TGCT	cis	rs1467026	0.523	rs9865548	chr3:12801785	C/T	cg05775895	chr3:12838266	CAND2	0.7	7.16	0.54	6.26e-11	P wave duration;
TGCT	cis	rs11190604	1.000	rs7088827	chr10:102303865	C/G	cg23241863	chr10:102295624	HIF1AN	0.7	5.14	0.42	1.02e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9858542	0.537	rs9874474	chr3:49326178	A/G	cg00383909	chr3:49044727	WDR6	0.69	4.78	0.39	4.84e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs36051895	0.664	rs3780381	chr9:5114523	A/C	cg02405213	chr9:5042618	JAK2	-0.69	-9.14	-0.63	1.54e-15	Pediatric autoimmune diseases;
TGCT	cis	rs11190604	1.000	rs17746014	chr10:102315354	T/C	cg23241863	chr10:102295624	HIF1AN	0.68	5.18	0.42	8.89e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs11585357	0.793	rs11588418	chr1:17616445	A/G	cg08277548	chr1:17600880	PADI3	-0.96	-9.72	-0.66	5.97e-17	Hair shape;
TGCT	cis	rs7772486	0.754	rs4896838	chr6:146015451	T/C	cg05347473	chr6:146136440	FBXO30	-0.51	-4.8	-0.4	4.44e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7809950	0.678	rs62482499	chr7:106975059	C/G	cg23024343	chr7:107201750	COG5	-0.44	-6.03	-0.48	1.75e-8	Coronary artery disease;
TGCT	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg21724239	chr8:58056113	NA	0.49	5.23	0.43	6.92e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2997447	0.802	rs72884792	chr1:26436688	G/C	cg03844060	chr1:26490628	NA	0.28	4.55	0.38	1.27e-5	QRS complex (12-leadsum);
TGCT	cis	rs7192750	0.586	rs4788570	chr16:71920144	G/A	cg06353428	chr16:71660113	MARVELD3	0.82	7.26	0.55	3.82e-11	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs3617	0.573	rs56383738	chr3:52908398	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	0.5	4.9	0.4	2.9e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs13242816	1.000	rs13226307	chr7:116137485	A/T	cg16553024	chr7:116138462	CAV2	0.44	5.31	0.43	4.81e-7	P wave duration;
TGCT	cis	rs17270561	0.666	rs4712976	chr6:25842203	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.58	4.47	0.37	1.78e-5	Iron status biomarkers;
TGCT	cis	rs743757	1.000	rs734767	chr3:50431410	C/G	cg04614380	chr3:50192449	SEMA3F	0.67	4.62	0.38	9.47e-6	Diastolic blood pressure;
TGCT	cis	rs2797160	0.651	rs1268093	chr6:126029235	C/T	cg05901451	chr6:126070800	HEY2	0.76	6.81	0.52	3.83e-10	Endometrial cancer;
TGCT	cis	rs67311347	0.956	rs9822870	chr3:40514890	A/C	cg17264618	chr3:40429014	ENTPD3	-0.33	-4.85	-0.4	3.66e-6	Renal cell carcinoma;
TGCT	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	5.23	0.43	6.92e-7	Menopause (age at onset);
TGCT	cis	rs9913156	0.789	rs56003988	chr17:4600764	G/A	cg19197139	chr17:4613644	ARRB2	0.83	7.74	0.57	3.03e-12	Lymphocyte counts;
TGCT	cis	rs35306767	0.714	rs11250228	chr10:1074887	A/G	cg26597838	chr10:835615	NA	0.51	5.94	0.47	2.71e-8	Eosinophil percentage of granulocytes;
TGCT	cis	rs35306767	0.715	rs1250891	chr10:1040159	G/C	cg18964960	chr10:1102726	WDR37	0.76	5.32	0.43	4.76e-7	Eosinophil percentage of granulocytes;
TGCT	cis	rs4820539	1.000	rs916583	chr22:23469267	C/T	cg14186256	chr22:23484241	RTDR1	0.98	12.28	0.74	3.5e-23	Bone mineral density;
TGCT	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg11890956	chr21:40555474	PSMG1	-0.72	-6.47	-0.5	2.07e-9	Cognitive function;
TGCT	cis	rs62244186	0.659	rs9835270	chr3:44553722	G/A	cg02073558	chr3:44770973	ZNF501	0.61	5.81	0.46	4.92e-8	Depressive symptoms;
TGCT	cis	rs637571	0.584	rs594689	chr11:65635559	G/A	cg26695010	chr11:65641043	EFEMP2	0.58	5.89	0.47	3.4e-8	Eosinophil percentage of white cells;
TGCT	cis	rs6558174	0.965	rs7831119	chr8:22489678	C/T	cg03733263	chr8:22462867	KIAA1967	-0.65	-5.27	-0.43	5.95e-7	Breast cancer;
TGCT	trans	rs1814175	0.817	rs7483795	chr11:49704930	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.38	-7.6	-0.56	6.14e-12	Height;
TGCT	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg14893161	chr1:205819251	PM20D1	-0.53	-7.48	-0.56	1.18e-11	Monocyte percentage of white cells;
TGCT	cis	rs1997103	0.765	rs55686950	chr7:55396552	A/C	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs9291683	0.527	rs3822247	chr4:10094671	G/A	cg11266682	chr4:10021025	SLC2A9	-0.58	-6.64	-0.51	8.94e-10	Bone mineral density;
TGCT	cis	rs9682041	0.696	rs13101192	chr3:170080752	C/G	cg07589077	chr3:170072950	NA	0.28	4.73	0.39	6.1e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs9640161	0.830	rs36069544	chr7:150061538	G/A	cg10018233	chr7:150070692	REPIN1	0.33	4.94	0.41	2.46e-6	Blood protein levels;Circulating chemerin levels;
TGCT	cis	rs13188771	0.651	rs59109546	chr5:100879961	G/A	cg10455971	chr5:101119566	NA	0.44	4.45	0.37	1.87e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs4689388	0.609	rs1046319	chr4:6304286	C/T	cg25554036	chr4:6271136	WFS1	0.55	6.45	0.5	2.31e-9	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs9430161	0.611	rs35033941	chr1:11034382	C/T	cg02454025	chr1:11042201	C1orf127	0.94	11.31	0.71	8.14e-21	Ewing sarcoma;
TGCT	cis	rs6750047	0.747	rs2116229	chr2:38270490	G/T	cg07380506	chr2:38303506	CYP1B1	0.57	5.04	0.41	1.63e-6	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs17681684	0.521	rs12150554	chr17:9753370	T/C	cg15743799	chr17:9805578	RCVRN	-0.26	-5.53	-0.44	1.79e-7	GIP levels in response to oral glucose tolerance test (fasting);
TGCT	cis	rs1371867	0.846	rs1660353	chr8:101250907	C/T	cg06002616	chr8:101225028	SPAG1	0.52	6.2	0.49	7.79e-9	Atrioventricular conduction;
TGCT	cis	rs3096299	0.566	rs4129126	chr16:89561475	A/C	cg06640241	chr16:89574553	SPG7	0.54	4.71	0.39	6.47e-6	Multiple myeloma (IgH translocation);
TGCT	cis	rs11718455	0.585	rs1491708	chr3:43911578	C/T	cg08738300	chr3:44038990	NA	0.66	4.52	0.38	1.44e-5	Coronary artery disease;
TGCT	cis	rs904251	0.737	rs914347	chr6:37484970	A/C	cg25019722	chr6:37503610	NA	-0.48	-6.63	-0.51	9.21e-10	Cognitive performance;
TGCT	cis	rs79057730	0.599	rs4720893	chr7:804434	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.65	5.41	0.44	3.16e-7	Initial pursuit acceleration;
TGCT	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg08280861	chr8:58055591	NA	0.35	4.66	0.39	8.04e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2456568	0.900	rs2511376	chr11:93670388	C/T	cg26875233	chr11:93583750	C11orf90	-0.45	-5.6	-0.45	1.31e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs1059312	0.545	rs7312683	chr12:129280105	T/C	cg09035930	chr12:129282057	SLC15A4	0.51	7.5	0.56	1.09e-11	Systemic lupus erythematosus;
TGCT	cis	rs7226408	0.894	rs72883597	chr18:34393197	T/C	cg06757138	chr18:34340585	FHOD3	0.26	4.79	0.4	4.62e-6	Obesity-related traits;
TGCT	cis	rs76935404	0.811	rs4609955	chr19:41433613	T/C	cg19493303	chr19:41414353	NA	0.41	5.07	0.41	1.4e-6	nicotine metabolite ratio in current smokers;
TGCT	cis	rs10411936	1.000	rs1870071	chr19:16505106	A/G	cg19006008	chr19:16999768	F2RL3	-0.27	-4.97	-0.41	2.21e-6	White blood cell count;Multiple sclerosis;
TGCT	cis	rs904251	0.580	rs62408367	chr6:37444813	G/A	cg25019722	chr6:37503610	NA	-0.47	-6.66	-0.51	7.94e-10	Cognitive performance;
TGCT	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg11062466	chr8:58055876	NA	0.38	4.62	0.38	9.5e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9787249	0.915	rs6664570	chr1:40206298	G/A	cg24920358	chr1:40204285	PPIE	0.57	10.56	0.69	5.57e-19	Blood protein levels;
TGCT	cis	rs7959452	0.640	rs4761233	chr12:69722880	T/C	cg20891283	chr12:69753455	YEATS4	0.67	6.67	0.51	7.56e-10	Blood protein levels;
TGCT	trans	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg17470723	chr8:74884337	TCEB1	0.78	6.87	0.53	2.7e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs10089	0.953	rs72794400	chr5:127516028	C/G	cg19767477	chr5:127420684	SLC12A2	-0.45	-4.65	-0.39	8.47e-6	Ileal carcinoids;
TGCT	cis	rs8017423	1.000	rs2184281	chr14:90685923	A/G	cg04374321	chr14:90722782	PSMC1	-0.76	-7.73	-0.57	3.19e-12	Mortality in heart failure;
TGCT	cis	rs4900538	0.963	rs1190553	chr14:102915331	G/T	cg18135206	chr14:102964638	TECPR2	-0.22	-5.31	-0.43	4.81e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs2832191	0.967	rs2832216	chr21:30521921	C/T	cg08807101	chr21:30365312	RNF160	0.52	4.97	0.41	2.21e-6	Dental caries;
TGCT	cis	rs12777	0.571	rs7720592	chr5:131844744	G/T	cg16609957	chr5:132161867	SHROOM1	-0.34	-4.6	-0.38	1.04e-5	Fibrinogen levels;
TGCT	cis	rs67311347	1.000	rs11707278	chr3:40487075	A/T	cg17264618	chr3:40429014	ENTPD3	0.34	4.94	0.41	2.52e-6	Renal cell carcinoma;
TGCT	cis	rs1008375	1.000	rs28501187	chr4:17643620	G/A	cg10189774	chr4:17578691	LAP3	0.56	5.04	0.41	1.57e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9883204	0.807	rs72964564	chr3:123054770	A/C	cg04890266	chr3:123102914	ADCY5	0.34	4.65	0.39	8.51e-6	Birth weight;
TGCT	cis	rs2070488	0.775	rs762318	chr3:38516369	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.78	7.64	0.57	5.12e-12	Electrocardiographic conduction measures;
TGCT	cis	rs60154123	0.772	rs845452	chr1:210417861	C/T	cg22029157	chr1:209979665	IRF6	0.63	4.52	0.38	1.45e-5	Coronary artery disease;
TGCT	cis	rs3087591	0.683	rs2525567	chr17:29675673	C/A	cg24425628	chr17:29625626	OMG;NF1	0.39	5.52	0.44	1.87e-7	Hip circumference;
TGCT	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9296092	0.538	rs56205713	chr6:33517510	A/G	cg13560919	chr6:33536144	NA	-0.21	-4.74	-0.39	5.72e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
TGCT	cis	rs707040	0.921	rs12617950	chr2:155234278	G/T	cg18104148	chr2:154337490	NA	0.19	4.63	0.38	9.05e-6	Sudden cardiac arrest;
TGCT	cis	rs8013055	0.846	rs7160747	chr14:105983740	A/G	cg19700328	chr14:106028568	NA	-0.48	-5.12	-0.42	1.14e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs3733585	0.699	rs6449157	chr4:9960442	G/A	cg11266682	chr4:10021025	SLC2A9	-0.57	-7.47	-0.56	1.23e-11	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg18876405	chr7:65276391	NA	0.31	4.79	0.4	4.58e-6	Aortic root size;
TGCT	cis	rs58950470	0.887	rs1787034	chr11:65382564	A/G	cg27068330	chr11:65405492	SIPA1	0.54	4.71	0.39	6.47e-6	Schizophrenia;
TGCT	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg06238570	chr21:40685208	BRWD1	-0.59	-6.14	-0.48	1.05e-8	Menarche (age at onset);
TGCT	cis	rs3087591	0.659	rs2525570	chr17:29681245	A/G	cg24425628	chr17:29625626	OMG;NF1	0.39	5.59	0.45	1.36e-7	Hip circumference;
TGCT	cis	rs7100689	0.784	rs7078075	chr10:82162768	A/G	cg01528321	chr10:82214614	TSPAN14	0.87	8.71	0.62	1.62e-14	Post bronchodilator FEV1;
TGCT	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg22535103	chr8:58192502	C8orf71	-0.38	-4.44	-0.37	1.93e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs8020441	0.945	rs4259956	chr14:51170177	T/G	cg04730355	chr14:51134070	SAV1	0.73	5.75	0.46	6.67e-8	Cognitive performance;
TGCT	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.7	0.52	6.47e-10	Bipolar disorder;
TGCT	cis	rs10746514	1.000	rs11122416	chr1:232249928	A/G	cg09506761	chr1:232265262	NA	0.49	4.98	0.41	2.04e-6	Response to statin therapy;
TGCT	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.01	8.32	0.6	1.34e-13	Platelet count;
TGCT	cis	rs4304924	0.500	rs9601109	chr13:79220114	A/G	cg05295671	chr13:79234353	RNF219	0.78	6.17	0.48	8.8e-9	Large artery stroke;
TGCT	cis	rs9291683	0.588	rs34501273	chr4:9996996	C/T	cg11266682	chr4:10021025	SLC2A9	0.7	9.33	0.64	5.22e-16	Bone mineral density;
TGCT	cis	rs763121	0.853	rs138704	chr22:39133410	A/G	cg06022373	chr22:39101656	GTPBP1	0.74	7.15	0.54	6.67e-11	Menopause (age at onset);
TGCT	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg00814883	chr7:100076585	TSC22D4	-0.85	-8.62	-0.61	2.62e-14	Platelet count;
TGCT	cis	rs10782582	0.593	rs11579752	chr1:76178694	C/T	cg10523679	chr1:76189770	ACADM	-0.64	-6.67	-0.51	7.67e-10	Daytime sleep phenotypes;
TGCT	cis	rs12368653	0.582	rs2307095	chr12:58026001	G/A	cg12615879	chr12:58013172	SLC26A10	0.59	7.1	0.54	8.71e-11	Multiple sclerosis;
TGCT	cis	rs524281	0.861	rs10791856	chr11:65964650	T/C	cg00563793	chr11:65837595	PACS1	0.54	4.71	0.39	6.4e-6	Electroencephalogram traits;
TGCT	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg03264133	chr6:25882463	NA	-0.59	-5.37	-0.43	3.68e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs12142240	0.698	rs3991877	chr1:46853749	C/A	cg00530320	chr1:46809349	NSUN4	0.29	5.79	0.46	5.34e-8	Menopause (age at onset);
TGCT	cis	rs11690935	0.632	rs9789538	chr2:172618474	G/C	cg13550731	chr2:172543902	DYNC1I2	0.67	5.87	0.47	3.79e-8	Schizophrenia;
TGCT	cis	rs228437	0.565	rs7765188	chr6:134961316	T/C	cg09872934	chr6:134495829	SGK1	-0.56	-4.76	-0.39	5.38e-6	Melanoma;
TGCT	cis	rs11264213	0.515	rs9660657	chr1:36548941	C/T	cg27506609	chr1:36549197	TEKT2	-0.4	-6.54	-0.51	1.48e-9	Schizophrenia;
TGCT	cis	rs6964587	0.935	rs28412174	chr7:91577245	T/G	cg22709100	chr7:91322751	NA	-0.27	-4.48	-0.37	1.68e-5	Breast cancer;
TGCT	trans	rs324780	0.544	rs3110193	chr12:83906425	G/A	cg27144766	chr5:150604977	CCDC69	0.24	6.63	0.51	9.42e-10	Vertical cup-disc ratio;
TGCT	cis	rs3617	0.573	rs3821873	chr3:52913006	C/T	cg11645453	chr3:52864694	ITIH4	-0.28	-5.32	-0.43	4.65e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs12477438	0.798	rs896886	chr2:99652713	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.83	8.44	0.6	7.12e-14	Chronic sinus infection;
TGCT	cis	rs4924935	0.509	rs8074020	chr17:18801380	T/C	cg26378065	chr17:18585709	ZNF286B	0.51	4.59	0.38	1.09e-5	Pancreatic cancer;
TGCT	cis	rs7209700	0.821	rs4642	chr17:45369777	A/G	cg21624342	chr17:45890973	OSBPL7	0.19	5.09	0.42	1.32e-6	IgG glycosylation;
TGCT	trans	rs208515	0.525	rs12191500	chr6:66668681	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.9	9.56	0.65	1.46e-16	Exhaled nitric oxide levels;
TGCT	cis	rs4378999	0.660	rs9869945	chr3:50849368	A/G	ch.3.1075622R	chr3:50010873	RBM6	-0.37	-4.55	-0.38	1.27e-5	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
TGCT	cis	rs2067615	0.524	rs7959062	chr12:107107334	G/T	cg15890332	chr12:107067104	RFX4	0.29	5.77	0.46	5.9e-8	Heart rate;
TGCT	cis	rs6921919	0.583	rs4357130	chr6:28367683	T/G	cg18815343	chr6:28367644	ZSCAN12	-0.56	-5.27	-0.43	5.78e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2535633	0.631	rs2581819	chr3:53016552	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	-0.49	-4.48	-0.37	1.66e-5	Body mass index;
TGCT	cis	rs9611565	0.802	rs9611577	chr22:41793090	T/G	cg13695892	chr22:41940480	POLR3H	-0.77	-7.47	-0.56	1.24e-11	Vitiligo;
TGCT	cis	rs7582180	0.614	rs10193204	chr2:101004540	A/G	cg14675211	chr2:100938903	LONRF2	-0.5	-4.8	-0.4	4.51e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7523273	0.925	rs4844394	chr1:208000625	C/T	cg22525895	chr1:207977042	MIR29B2	-0.48	-8.57	-0.61	3.42e-14	Schizophrenia;
TGCT	cis	rs1691799	0.867	rs1168348	chr12:66757168	G/A	cg16791601	chr12:66731901	HELB	-0.29	-6.18	-0.49	8.39e-9	White blood cell count (basophil);
TGCT	cis	rs909674	0.515	rs9611170	chr22:39784845	G/C	cg05872129	chr22:39784769	NA	-1.02	-11.79	-0.73	5.43e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs453301	0.624	rs4841083	chr8:8870428	A/G	cg06636001	chr8:8085503	FLJ10661	0.77	6.54	0.51	1.43e-9	Joint mobility (Beighton score);
TGCT	cis	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg25427524	chr10:38739819	LOC399744	-0.4	-8.32	-0.6	1.33e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs5760092	0.842	rs5760103	chr22:24248781	A/G	cg18538332	chr22:24372958	LOC391322	-0.76	-6.14	-0.48	1.05e-8	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs61935443	0.562	rs11107791	chr12:95316374	G/A	cg21533806	chr12:95267307	NA	0.55	4.59	0.38	1.08e-5	Schizophrenia;
TGCT	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg01802117	chr1:53393560	SCP2	-0.44	-5.39	-0.44	3.39e-7	Monocyte count;
TGCT	cis	rs8077889	0.871	rs8065043	chr17:41900984	G/A	cg26893861	chr17:41843967	DUSP3	1.09	13.08	0.76	4.26e-25	Triglycerides;
TGCT	cis	rs922182	0.613	rs894660	chr15:64234334	T/C	cg02919090	chr15:64263738	DAPK2	-0.33	-6.14	-0.48	1.05e-8	Blood protein levels;
TGCT	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg13732083	chr21:47605072	C21orf56	0.37	4.69	0.39	7.07e-6	Testicular germ cell tumor;
TGCT	cis	rs7666738	0.753	rs7698541	chr4:98986351	T/A	cg17366294	chr4:99064904	C4orf37	0.69	7.01	0.53	1.38e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs561341	0.681	rs56064462	chr17:30235116	G/A	cg13647721	chr17:30228624	UTP6	0.62	4.71	0.39	6.43e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs2243480	1.000	rs1404147	chr7:65264524	C/T	cg20637647	chr7:64974828	NA	0.7	4.62	0.38	9.47e-6	Diabetic kidney disease;
TGCT	cis	rs2439831	1.000	rs690316	chr15:43737880	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.81	5.73	0.46	7.15e-8	Lung cancer in ever smokers;
TGCT	cis	rs1018836	0.608	rs10111060	chr8:91491152	T/C	cg16814680	chr8:91681699	NA	-0.68	-6.83	-0.52	3.31e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs3806843	1.000	rs1030165	chr5:140185448	G/A	cg19875535	chr5:140030758	IK	0.35	5.85	0.47	4.01e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs903263	0.965	rs7532712	chr1:84594117	G/C	cg09664975	chr1:84543551	PRKACB	0.5	4.74	0.39	5.69e-6	Breast cancer (male);
TGCT	cis	rs6725041	0.819	rs1996763	chr2:213082269	T/C	cg16329650	chr2:213403929	ERBB4	-0.54	-4.61	-0.38	9.88e-6	QT interval (ambient particulate matter interaction);
TGCT	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg17554472	chr22:41940697	POLR3H	0.42	4.64	0.38	8.64e-6	Vitiligo;
TGCT	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	4.45	0.37	1.91e-5	Height;
TGCT	cis	rs938554	0.558	rs4697701	chr4:9946095	C/T	cg00071950	chr4:10020882	SLC2A9	-0.5	-5.0	-0.41	1.88e-6	Blood metabolite levels;
TGCT	cis	rs908922	0.676	rs4240884	chr1:152529792	C/T	cg20991723	chr1:152506922	NA	-0.46	-6.16	-0.48	9.18e-9	Hair morphology;
TGCT	cis	rs72781680	0.848	rs56371415	chr2:23932603	C/G	cg08917208	chr2:24149416	ATAD2B	0.89	5.41	0.44	3.11e-7	Lymphocyte counts;
TGCT	cis	rs709400	0.633	rs8013101	chr14:103951772	G/C	cg12935359	chr14:103987150	CKB	-0.36	-5.64	-0.45	1.11e-7	Body mass index;
TGCT	cis	rs28595532	0.920	rs17324884	chr4:119771477	C/T	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs6121246	0.697	rs6120970	chr20:30232452	C/T	cg21427119	chr20:30132790	HM13	-0.37	-5.19	-0.42	8.51e-7	Mean corpuscular hemoglobin;
TGCT	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg14893161	chr1:205819251	PM20D1	0.65	10.12	0.67	6.64e-18	Menarche (age at onset);
TGCT	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg00814883	chr7:100076585	TSC22D4	-0.86	-8.48	-0.61	5.77e-14	Platelet count;
TGCT	cis	rs2230307	0.536	rs564938	chr1:100592901	T/C	cg24955406	chr1:100503596	HIAT1	-0.77	-5.23	-0.43	6.91e-7	Carotid intima media thickness;
TGCT	cis	rs3741151	1.000	rs112628073	chr11:73013626	C/T	cg17517138	chr11:73019481	ARHGEF17	1.16	5.54	0.45	1.7e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
TGCT	cis	rs9650657	0.615	rs1549796	chr8:10692359	C/T	cg16664915	chr8:10907788	XKR6	-0.29	-4.58	-0.38	1.1e-5	Neuroticism;
TGCT	cis	rs2159324	1.000	rs10421129	chr19:45695836	G/A	cg24080119	chr19:45644694	NA	0.3	4.81	0.4	4.31e-6	Quantitative traits;
TGCT	cis	rs6674176	0.628	rs12145999	chr1:44428632	C/T	cg12908607	chr1:44402522	ARTN	-0.68	-8.19	-0.59	2.7e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg13012494	chr21:47604986	C21orf56	-0.39	-4.66	-0.39	7.88e-6	Testicular germ cell tumor;
TGCT	trans	rs1814175	0.817	rs7927373	chr11:49957640	A/C	cg15704280	chr7:45808275	SEPT13	-0.73	-8.48	-0.61	5.58e-14	Height;
TGCT	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg21963583	chr11:68658836	MRPL21	-0.34	-5.63	-0.45	1.15e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs6912958	0.967	rs6905947	chr6:88161949	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.39	-5.0	-0.41	1.91e-6	Monocyte percentage of white cells;
TGCT	cis	rs7091068	0.522	rs10748612	chr10:95494458	G/A	cg20715218	chr10:95462985	C10orf4	0.52	5.13	0.42	1.08e-6	Urinary tract infection frequency;
TGCT	cis	rs2072499	0.750	rs55675376	chr1:156165881	C/T	cg25208724	chr1:156163844	SLC25A44	1.02	9.51	0.65	2e-16	Testicular germ cell tumor;
TGCT	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg07167872	chr1:205819463	PM20D1	0.59	7.71	0.57	3.52e-12	Menarche (age at onset);
TGCT	cis	rs11098499	0.863	rs12498539	chr4:120468370	C/T	cg09307838	chr4:120376055	NA	0.72	6.87	0.52	2.81e-10	Corneal astigmatism;
TGCT	cis	rs8017423	0.934	rs2401874	chr14:90682467	C/T	cg04374321	chr14:90722782	PSMC1	0.77	7.94	0.58	1.06e-12	Mortality in heart failure;
TGCT	cis	rs62244186	0.566	rs2135531	chr3:44881158	C/G	cg15687855	chr3:44754131	ZNF502	-0.51	-6.35	-0.5	3.74e-9	Depressive symptoms;
TGCT	cis	rs4642101	0.765	rs1985428	chr3:12829315	A/G	cg05775895	chr3:12838266	CAND2	-0.76	-8.55	-0.61	3.82e-14	QRS complex (12-leadsum);
TGCT	cis	rs12477438	0.520	rs7605843	chr2:99811894	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	17.06	0.84	2.55e-34	Chronic sinus infection;
TGCT	cis	rs17270561	0.943	rs76703022	chr6:25703529	A/C	cg16482183	chr6:26056742	HIST1H1C	0.7	4.62	0.38	9.56e-6	Iron status biomarkers;
TGCT	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg00343986	chr7:65444356	GUSB	0.23	5.16	0.42	9.66e-7	Aortic root size;
TGCT	cis	rs11785400	0.793	rs9774627	chr8:143731267	G/A	cg10596483	chr8:143751796	JRK	0.53	5.21	0.42	7.5e-7	Schizophrenia;
TGCT	cis	rs4253772	0.530	rs9627387	chr22:46684678	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.7	5.27	0.43	5.83e-7	LDL cholesterol;Cholesterol, total;
TGCT	trans	rs10022799	0.725	rs10003880	chr4:168135438	A/C	cg08507725	chr4:8239220	SH3TC1	0.42	7.37	0.55	2.15e-11	Cognitive function;
TGCT	cis	rs8031584	0.697	rs8036176	chr15:31175269	A/G	cg08704250	chr15:31115839	NA	-0.33	-4.98	-0.41	2.05e-6	Huntington's disease progression;
TGCT	cis	rs4253772	0.637	rs11703173	chr22:46660367	G/A	cg24881330	chr22:46731750	TRMU	0.88	4.47	0.37	1.72e-5	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs2970818	0.831	rs7304949	chr12:4609625	A/G	cg09670175	chr12:4923468	KCNA6	0.21	4.67	0.39	7.63e-6	Phosphorus levels;
TGCT	cis	rs425277	0.565	rs2480711	chr1:2111376	A/G	cg03732007	chr1:2071316	PRKCZ	0.28	6.64	0.51	8.63e-10	Height;
TGCT	cis	rs28785552	0.897	rs10424736	chr19:53239176	G/A	cg10871876	chr19:53194124	ZNF83	0.62	8.85	0.62	7.42e-15	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs28595532	1.000	rs55634130	chr4:119655093	C/T	cg11846333	chr4:119757529	SEC24D	0.92	4.59	0.38	1.07e-5	Cannabis dependence symptom count;
TGCT	cis	rs858239	0.636	rs28706766	chr7:23169834	T/A	cg05602783	chr7:23145260	KLHL7	-0.57	-4.78	-0.39	4.87e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs10791323	0.536	rs1944731	chr11:133726067	G/A	cg15485101	chr11:133734466	NA	0.42	5.26	0.43	6.25e-7	Childhood ear infection;
TGCT	cis	rs40363	0.723	rs8060367	chr16:3537919	C/A	cg22508957	chr16:3507546	NAT15	-0.51	-4.69	-0.39	7.08e-6	Tuberculosis;
TGCT	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg10802521	chr3:52805072	NEK4	-0.78	-10.0	-0.67	1.26e-17	Bipolar disorder;
TGCT	cis	rs225245	0.791	rs7216391	chr17:34024706	G/A	cg05299278	chr17:33885742	SLFN14	0.21	4.5	0.37	1.54e-5	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs7666738	0.830	rs13147195	chr4:98893334	G/T	cg18180107	chr4:99064573	C4orf37	0.53	4.84	0.4	3.83e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1691799	0.831	rs6581678	chr12:66776656	A/G	cg16791601	chr12:66731901	HELB	-0.27	-5.5	-0.44	2.08e-7	White blood cell count (basophil);
TGCT	cis	rs1858740	0.509	rs196375	chr3:38422919	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.64	6.02	0.48	1.84e-8	Schizophrenia;
TGCT	cis	rs6831352	0.819	rs2851274	chr4:100025866	G/C	cg12011299	chr4:100065546	ADH4	0.41	5.68	0.45	8.93e-8	Alcohol dependence;
TGCT	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg10560079	chr2:191398806	TMEM194B	-0.36	-5.07	-0.41	1.4e-6	Pulse pressure;
TGCT	cis	rs13217239	0.646	rs7747454	chr6:27034253	T/G	cg26531700	chr6:26746687	NA	-0.68	-6.72	-0.52	5.75e-10	Schizophrenia;
TGCT	cis	rs17331151	0.573	rs79664140	chr3:52866936	A/G	cg11137980	chr3:52469226	SEMA3G	0.29	5.14	0.42	1.04e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	trans	rs1814175	0.619	rs10769623	chr11:49865926	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.45	-11.08	-0.71	2.89e-20	Height;
TGCT	cis	rs9902453	0.933	rs8074028	chr17:28461687	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	5.41	0.44	3.13e-7	Coffee consumption (cups per day);
TGCT	cis	rs2806561	0.765	rs1738469	chr1:23511407	G/C	cg12483005	chr1:23474871	LUZP1	0.39	5.07	0.41	1.44e-6	Height;
TGCT	cis	rs9916302	0.904	rs4794807	chr17:37531718	T/A	cg15445000	chr17:37608096	MED1	-0.33	-4.71	-0.39	6.46e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs9611565	0.921	rs4822021	chr22:41726053	G/A	cg06634786	chr22:41940651	POLR3H	-0.69	-6.38	-0.5	3.26e-9	Vitiligo;
TGCT	cis	rs9796	0.663	rs11853192	chr15:41368515	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.52	-6.88	-0.53	2.64e-10	Menopause (age at onset);
TGCT	cis	rs11030122	0.702	rs10835407	chr11:3993231	C/T	cg18678763	chr11:4115507	RRM1	0.48	5.64	0.45	1.09e-7	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs6582630	0.519	rs11181294	chr12:38312787	C/T	cg13010199	chr12:38710504	ALG10B	0.58	4.54	0.38	1.3e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs981844	0.961	rs56148270	chr4:154660874	C/T	cg14289246	chr4:154710475	SFRP2	1.01	8.46	0.6	6.31e-14	Response to statins (LDL cholesterol change);
TGCT	cis	rs12579753	1.000	rs17692461	chr12:82171755	C/G	cg07988820	chr12:82153109	PPFIA2	-0.65	-6.79	-0.52	4.09e-10	Resting heart rate;
TGCT	cis	rs473651	0.506	rs561264	chr2:239329979	G/T	cg18131467	chr2:239335373	ASB1	0.88	8.17	0.59	3.02e-13	Multiple system atrophy;
TGCT	cis	rs7666738	0.822	rs28367231	chr4:98845726	G/T	cg17366294	chr4:99064904	C4orf37	0.7	7.23	0.54	4.35e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs42648	1.000	rs42649	chr7:89977789	A/T	cg25739043	chr7:89950458	NA	-0.68	-6.7	-0.52	6.58e-10	Homocysteine levels;
TGCT	cis	rs7772486	0.875	rs2328712	chr6:146344563	T/C	cg23711669	chr6:146136114	FBXO30	0.84	9.13	0.63	1.59e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2235642	0.893	rs8051295	chr16:1588087	A/G	cg07341220	chr16:1583899	IFT140;TMEM204	-0.3	-4.65	-0.39	8.35e-6	Coronary artery disease;
TGCT	cis	rs610932	0.517	rs670139	chr11:59971795	G/T	cg18570331	chr11:60101691	MS4A6E	0.51	4.71	0.39	6.55e-6	Alzheimer's disease;
TGCT	cis	rs62244186	0.748	rs2888410	chr3:44655476	A/C	cg11003573	chr3:44754125	ZNF502	-0.41	-4.69	-0.39	6.96e-6	Depressive symptoms;
TGCT	cis	rs936229	0.749	rs8031937	chr15:75181121	A/G	cg10253484	chr15:75165896	SCAMP2	-0.76	-6.29	-0.49	4.87e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
TGCT	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg13695892	chr22:41940480	POLR3H	-0.9	-8.87	-0.62	6.78e-15	Vitiligo;
TGCT	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg15691649	chr6:25882328	NA	0.5	6.02	0.48	1.84e-8	Blood metabolite levels;
TGCT	cis	rs78461346	1.000	rs75241339	chr17:80527441	A/G	cg15014069	chr17:80540666	FOXK2	0.4	5.04	0.41	1.62e-6	3-hydroxypropylmercapturic acid levels in smokers;
TGCT	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg15691649	chr6:25882328	NA	0.44	5.35	0.43	4.12e-7	Blood metabolite levels;
TGCT	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg22105103	chr4:187893119	NA	0.35	4.89	0.4	3.02e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg24675658	chr1:53192096	ZYG11B	-0.7	-8.15	-0.59	3.44e-13	Monocyte count;
TGCT	cis	rs6582630	0.502	rs2204008	chr12:38439203	C/T	cg26384229	chr12:38710491	ALG10B	0.84	7.5	0.56	1.06e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg14773178	chr5:1868261	NA	0.34	5.8	0.46	5.29e-8	Cardiovascular disease risk factors;
TGCT	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.03	0.41	1.68e-6	Prudent dietary pattern;
TGCT	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg20007245	chr22:24372913	LOC391322	-0.72	-7.11	-0.54	8.1e-11	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg05368731	chr17:41323189	NBR1	1.18	13.89	0.78	5e-27	Menopause (age at onset);
TGCT	cis	rs73001065	0.901	rs739846	chr19:19419071	G/A	cg03709012	chr19:19516395	GATAD2A	0.98	4.78	0.39	4.97e-6	LDL cholesterol;
TGCT	cis	rs826838	0.684	rs12367400	chr12:38618673	G/T	cg26384229	chr12:38710491	ALG10B	0.9	8.1	0.59	4.36e-13	Heart rate;
TGCT	cis	rs11209185	0.509	rs12130147	chr1:68446944	G/A	cg22082780	chr1:68452167	NA	0.31	4.84	0.4	3.86e-6	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs9435341	0.965	rs2335077	chr1:107573565	A/G	cg09367891	chr1:107599246	PRMT6	0.65	5.67	0.45	9.45e-8	Facial morphology (factor 21, depth of nasal alae);
TGCT	cis	rs67311347	1.000	rs112619360	chr3:40432645	T/G	cg13683864	chr3:40499215	RPL14	-1.18	-13.2	-0.76	2.14e-25	Renal cell carcinoma;
TGCT	cis	rs514406	0.505	rs431459	chr1:53183230	T/G	cg25767906	chr1:53392781	SCP2	-0.47	-5.41	-0.44	3.17e-7	Monocyte count;
TGCT	cis	rs1887596	0.705	rs1087258	chr13:27200006	T/C	cg01312412	chr13:27282625	NA	0.29	5.13	0.42	1.1e-6	Facial morphology (factor 3, length of philtrum);
TGCT	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg19748678	chr4:122722346	EXOSC9	0.88	8.76	0.62	1.21e-14	Type 2 diabetes;
TGCT	cis	rs67311347	0.911	rs6776044	chr3:40377503	T/G	cg17264618	chr3:40429014	ENTPD3	0.31	4.46	0.37	1.81e-5	Renal cell carcinoma;
TGCT	cis	rs6815814	0.950	rs55830619	chr4:38807364	G/A	cg02016764	chr4:38805732	TLR1	-0.35	-5.65	-0.45	1.04e-7	Breast cancer;
TGCT	cis	rs12681287	0.752	rs4310184	chr8:87245253	T/C	cg27223183	chr8:87520930	FAM82B	-0.83	-5.94	-0.47	2.66e-8	Caudate activity during reward;
TGCT	cis	rs9611565	0.921	rs8137373	chr22:41729216	A/G	cg06634786	chr22:41940651	POLR3H	0.69	6.38	0.5	3.26e-9	Vitiligo;
TGCT	cis	rs9906944	0.641	rs11655587	chr17:47140794	C/T	cg20966754	chr17:47091339	IGF2BP1	-0.41	-4.44	-0.37	1.98e-5	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs3935685	0.874	rs56370262	chr15:77996708	G/C	cg03457338	chr15:78040120	NA	-0.22	-5.67	-0.45	9.51e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs1008375	0.900	rs13101742	chr4:17701297	G/A	cg18681998	chr4:17616180	MED28	-0.8	-7.47	-0.56	1.22e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg24549020	chr5:56110836	MAP3K1	0.7	5.97	0.47	2.34e-8	Initial pursuit acceleration;
TGCT	cis	rs7412746	0.552	rs4970980	chr1:150864992	A/C	cg04414720	chr1:150670196	GOLPH3L	0.37	4.46	0.37	1.81e-5	Melanoma;
TGCT	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg08280861	chr8:58055591	NA	0.54	6.0	0.47	2.05e-8	Developmental language disorder (linguistic errors);
TGCT	cis	rs2019216	0.542	rs7405615	chr17:21935430	C/G	cg22648282	chr17:21454238	C17orf51	-0.59	-5.89	-0.47	3.46e-8	Pelvic organ prolapse;
TGCT	cis	rs3849570	0.925	rs6798680	chr3:81905441	C/A	cg07356753	chr3:81810745	GBE1	-0.74	-6.77	-0.52	4.57e-10	Waist circumference;Body mass index;
TGCT	cis	rs12497850	0.931	rs13316620	chr3:49045355	T/C	cg07636037	chr3:49044803	WDR6	0.97	10.64	0.69	3.45e-19	Parkinson's disease;
TGCT	cis	rs61990749	0.597	rs10136053	chr14:78155205	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	-0.62	-4.59	-0.38	1.09e-5	Fibroblast growth factor basic levels;
TGCT	cis	rs57244997	0.929	rs9346892	chr6:162369314	C/T	cg17173639	chr6:162384350	PARK2	-0.41	-4.53	-0.38	1.38e-5	Mosquito bite size;
TGCT	cis	rs12142240	0.698	rs56049453	chr1:46835468	A/G	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg01802117	chr1:53393560	SCP2	-0.47	-5.62	-0.45	1.17e-7	Monocyte count;
TGCT	cis	rs1401999	1.000	rs939336	chr3:183685534	A/G	cg01324343	chr3:183735012	ABCC5	0.82	10.97	0.7	5.41e-20	Anterior chamber depth;
TGCT	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg00814883	chr7:100076585	TSC22D4	-0.9	-9.56	-0.65	1.5e-16	Platelet count;
TGCT	cis	rs7937682	0.883	rs1612013	chr11:111456293	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.97	-9.75	-0.66	5.24e-17	Primary sclerosing cholangitis;
TGCT	cis	rs9910055	0.529	rs408282	chr17:42182267	A/G	cg19774624	chr17:42201019	HDAC5	0.65	5.98	0.47	2.23e-8	Total body bone mineral density;
TGCT	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg20607798	chr8:58055168	NA	0.45	4.5	0.37	1.52e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs62103177	0.810	rs62103188	chr18:77627661	G/A	cg12964065	chr18:77638022	KCNG2	0.37	4.76	0.39	5.4e-6	Opioid sensitivity;
TGCT	cis	rs9291683	0.609	rs34709913	chr4:10028955	T/C	cg11266682	chr4:10021025	SLC2A9	0.66	9.54	0.65	1.61e-16	Bone mineral density;
TGCT	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg03452623	chr4:187889614	NA	-0.36	-5.31	-0.43	4.97e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg12963246	chr6:28129442	ZNF389	0.52	5.1	0.42	1.23e-6	Depression;
TGCT	cis	rs9611565	0.512	rs2050033	chr22:42159229	G/T	cg03806693	chr22:41940476	POLR3H	1.02	10.49	0.69	7.92e-19	Vitiligo;
TGCT	trans	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg17830980	chr10:43048298	ZNF37B	-0.87	-11.3	-0.71	8.5e-21	Extrinsic epigenetic age acceleration;
TGCT	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg13866156	chr1:1669148	SLC35E2	-0.23	-5.52	-0.44	1.91e-7	Body mass index;
TGCT	cis	rs4689388	0.926	rs6446480	chr4:6295565	C/T	cg00701064	chr4:6280414	WFS1	0.37	4.64	0.38	8.68e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg04352962	chr1:209979756	IRF6	0.65	4.92	0.4	2.65e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs6952808	0.635	rs6952727	chr7:1947958	A/G	cg22963979	chr7:1858916	MAD1L1	-0.37	-5.7	-0.46	8.23e-8	Bipolar disorder and schizophrenia;
TGCT	cis	rs6088580	0.570	rs6058057	chr20:33065283	G/A	cg08999081	chr20:33150536	PIGU	0.29	5.66	0.45	9.97e-8	Glomerular filtration rate (creatinine);
TGCT	cis	rs6964587	1.000	rs12704635	chr7:91737324	T/G	cg22709100	chr7:91322751	NA	0.29	4.79	0.4	4.67e-6	Breast cancer;
TGCT	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg07061783	chr6:25882402	NA	-0.53	-5.07	-0.41	1.41e-6	Intelligence (multi-trait analysis);
TGCT	trans	rs7698623	0.717	rs4693893	chr4:88797765	A/G	cg01186725	chr1:53905612	FLJ40434	-0.48	-6.63	-0.51	9.21e-10	Cardiovascular disease risk factors;
TGCT	cis	rs2439831	0.867	rs76542740	chr15:43891512	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.84	5.49	0.44	2.2e-7	Lung cancer in ever smokers;
TGCT	cis	rs9814567	1.000	rs9854299	chr3:134206728	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.95	-9.62	-0.65	1.04e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs2549003	0.966	rs839	chr5:131819126	C/T	cg21138405	chr5:131827807	IRF1	0.19	4.79	0.4	4.64e-6	Asthma (sex interaction);
TGCT	cis	rs858239	0.601	rs4440529	chr7:23168751	G/C	cg05602783	chr7:23145260	KLHL7	-0.62	-5.18	-0.42	8.52e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs208520	0.690	rs12189780	chr6:66759619	G/A	cg07460842	chr6:66804631	NA	0.96	10.26	0.68	2.92e-18	Exhaled nitric oxide output;
TGCT	cis	rs3829109	0.564	rs13297890	chr9:139274643	C/G	cg13741927	chr9:139327495	INPP5E	-0.23	-4.94	-0.41	2.46e-6	Peak insulin response;Acute insulin response;
TGCT	cis	rs9916302	0.904	rs6503506	chr17:37524653	C/A	cg07936489	chr17:37558343	FBXL20	0.65	5.08	0.41	1.36e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs1008375	0.646	rs13146455	chr4:17565617	T/G	cg18681998	chr4:17616180	MED28	-0.81	-7.32	-0.55	2.73e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10788264	0.513	rs10749455	chr10:124035030	A/G	cg09507567	chr10:124027408	NA	0.37	5.31	0.43	5e-7	Total body bone mineral density;
TGCT	cis	rs9788682	1.000	rs61204066	chr15:78815298	G/A	cg24631222	chr15:78858424	CHRNA5	0.91	7.89	0.58	1.34e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs4383453	0.539	rs931575	chr3:123098842	G/C	cg04890266	chr3:123102914	ADCY5	-0.5	-8.34	-0.6	1.2e-13	Gestational age at birth (maternal effect);
TGCT	cis	rs2370759	1.000	rs2225152	chr10:32574759	T/C	cg01819863	chr10:32635814	EPC1	1.03	10.03	0.67	1.05e-17	Sexual dysfunction (female);
TGCT	cis	rs2153535	0.580	rs1932275	chr6:8442333	T/A	cg23788917	chr6:8435910	SLC35B3	0.63	5.58	0.45	1.42e-7	Motion sickness;
TGCT	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg20007245	chr22:24372913	LOC391322	-0.71	-7.0	-0.53	1.43e-10	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.98	-0.41	2.06e-6	Prudent dietary pattern;
TGCT	cis	rs2836974	0.931	rs2776309	chr21:40715791	A/G	cg11644478	chr21:40555479	PSMG1	0.87	7.77	0.57	2.59e-12	Cognitive function;
TGCT	cis	rs10782582	0.609	rs5745547	chr1:76378275	G/C	cg03433033	chr1:76189801	ACADM	-0.5	-4.88	-0.4	3.15e-6	Daytime sleep phenotypes;
TGCT	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg10802521	chr3:52805072	NEK4	0.76	9.52	0.65	1.86e-16	Electroencephalogram traits;
TGCT	cis	rs2777491	1.000	rs2730057	chr15:41736275	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.74	-10.95	-0.7	6.24e-20	Ulcerative colitis;
TGCT	cis	rs4455778	0.543	rs7808690	chr7:49065751	A/C	cg26309511	chr7:48887640	NA	0.52	6.8	0.52	3.91e-10	Lung cancer in never smokers;
TGCT	cis	rs10507380	0.824	rs9512631	chr13:27918698	T/C	cg25543773	chr13:27185723	WASF3	0.34	4.83	0.4	3.97e-6	Electrocardiographic traits;
TGCT	cis	rs892961	0.932	rs7224116	chr17:75413177	A/G	cg05865280	chr17:75406074	SEPT9	0.28	6.86	0.52	2.9e-10	Airflow obstruction;
TGCT	cis	rs950169	0.580	rs4603535	chr15:85173872	C/T	cg11189052	chr15:85197271	WDR73	0.73	6.01	0.47	1.96e-8	Schizophrenia;
TGCT	cis	rs7824557	0.701	rs2060465	chr8:11162609	T/C	cg21775007	chr8:11205619	TDH	0.58	5.46	0.44	2.46e-7	Retinal vascular caliber;
TGCT	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg11644478	chr21:40555479	PSMG1	1.03	11.02	0.7	4.14e-20	Cognitive function;
TGCT	cis	rs7226408	0.948	rs72883570	chr18:34382041	C/T	cg06757138	chr18:34340585	FHOD3	0.26	4.79	0.4	4.62e-6	Obesity-related traits;
TGCT	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	4.45	0.37	1.87e-5	Height;
TGCT	cis	rs1538970	1.000	rs1417578	chr1:45850590	A/G	cg05343316	chr1:45956843	TESK2	0.66	5.2	0.42	8.13e-7	Platelet count;
TGCT	cis	rs4253772	0.513	rs6008700	chr22:46722560	C/T	cg24881330	chr22:46731750	TRMU	0.94	6.36	0.5	3.54e-9	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs116095464	0.558	rs28558836	chr5:285748	C/G	cg22857025	chr5:266934	NA	-0.34	-6.64	-0.51	8.6e-10	Breast cancer;
TGCT	cis	rs921968	0.643	rs545460	chr2:219392159	A/G	cg02176678	chr2:219576539	TTLL4	0.38	5.48	0.44	2.31e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs7666738	0.830	rs13121558	chr4:99002848	G/A	cg17366294	chr4:99064904	C4orf37	0.66	6.54	0.51	1.42e-9	Colonoscopy-negative controls vs population controls;
TGCT	trans	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg24694675	chr1:76082066	NA	-0.66	-6.82	-0.52	3.58e-10	Bipolar disorder and schizophrenia;
TGCT	cis	rs9790314	0.521	rs1450522	chr3:161077630	A/G	cg03342759	chr3:160939853	NMD3	-0.52	-5.4	-0.44	3.32e-7	Morning vs. evening chronotype;
TGCT	cis	rs877282	0.898	rs71489279	chr10:760510	T/C	cg17470449	chr10:769945	NA	0.36	5.35	0.43	4.04e-7	Uric acid levels;
TGCT	cis	rs6582630	0.538	rs8189550	chr12:38333058	T/G	cg26384229	chr12:38710491	ALG10B	-0.52	-4.46	-0.37	1.84e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg05665937	chr4:1216051	CTBP1	0.25	4.68	0.39	7.33e-6	Obesity-related traits;
TGCT	cis	rs950027	0.549	rs11636114	chr15:45601412	C/G	cg26924012	chr15:45694286	SPATA5L1	0.74	7.57	0.56	7.21e-12	Response to fenofibrate (adiponectin levels);
TGCT	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg05785598	chr3:49045655	WDR6	0.39	5.05	0.41	1.57e-6	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs6840360	0.571	rs4696099	chr4:152501951	C/G	cg17479576	chr4:152424074	FAM160A1	-0.7	-7.33	-0.55	2.65e-11	Intelligence (multi-trait analysis);
TGCT	cis	rs9733	0.519	rs11204717	chr1:150709129	T/A	cg09365446	chr1:150670422	GOLPH3L	0.3	4.53	0.38	1.37e-5	Tonsillectomy;
TGCT	cis	rs17376456	0.825	rs12716454	chr5:93272279	A/C	cg25358565	chr5:93447407	FAM172A	1.03	8.1	0.59	4.5e-13	Diabetic retinopathy;
TGCT	cis	rs2230307	0.536	rs534252	chr1:100472604	A/G	cg24955406	chr1:100503596	HIAT1	0.75	4.88	0.4	3.2e-6	Carotid intima media thickness;
TGCT	cis	rs1797081	1.000	rs812426	chr10:16857133	C/G	cg23933602	chr10:16859644	RSU1	1.08	14.13	0.79	1.3e-27	Platelet distribution width;
TGCT	cis	rs7173743	0.525	rs11856903	chr15:79140017	A/G	cg00540400	chr15:79124168	NA	-0.17	-4.48	-0.37	1.69e-5	Coronary artery disease;
TGCT	cis	rs782590	0.967	rs782592	chr2:55843875	T/A	cg03859395	chr2:55845619	SMEK2	0.75	7.02	0.53	1.26e-10	Metabolic syndrome;
TGCT	cis	rs7818688	0.697	rs11778553	chr8:95978260	C/T	cg16049864	chr8:95962084	TP53INP1	0.54	4.65	0.39	8.51e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs11098499	0.738	rs34566984	chr4:120361270	G/A	cg09307838	chr4:120376055	NA	0.68	6.53	0.51	1.54e-9	Corneal astigmatism;
TGCT	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg18654377	chr3:49208889	KLHDC8B	-0.37	-4.69	-0.39	7.12e-6	Parkinson's disease;
TGCT	cis	rs9811920	0.809	rs902159	chr3:99747445	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.43	-4.75	-0.39	5.49e-6	Axial length;
TGCT	cis	rs751728	1.000	rs9380378	chr6:33765479	T/C	cg13859433	chr6:33739653	LEMD2	-0.38	-6.69	-0.52	6.82e-10	Crohn's disease;
TGCT	cis	rs12049351	0.774	rs12138965	chr1:229655720	T/C	cg12130225	chr1:229698885	NA	0.38	4.63	0.38	8.95e-6	Circulating myeloperoxidase levels (plasma);
TGCT	cis	rs6696846	0.630	rs6692706	chr1:205158561	G/T	cg03948781	chr1:205179583	DSTYK	0.35	4.53	0.38	1.38e-5	Red blood cell count;
TGCT	cis	rs586688	0.625	rs606114	chr1:201664101	C/T	cg07139329	chr1:201708558	NAV1	0.53	5.35	0.43	4.06e-7	Obesity-related traits;
TGCT	cis	rs9372498	0.505	rs62424173	chr6:118780507	C/G	cg07617317	chr6:118971624	C6orf204	0.5	5.39	0.44	3.37e-7	Diastolic blood pressure;
TGCT	cis	rs2836974	0.830	rs2735309	chr21:40715313	C/T	cg11644478	chr21:40555479	PSMG1	0.87	7.77	0.57	2.59e-12	Cognitive function;
TGCT	cis	rs8180040	0.739	rs12488225	chr3:47235107	G/A	cg27129171	chr3:47204927	SETD2	0.76	9.91	0.66	2.12e-17	Colorectal cancer;
TGCT	cis	rs7172809	0.573	rs74027548	chr15:77512516	T/C	cg22256960	chr15:77711686	NA	-0.49	-4.62	-0.38	9.51e-6	Glucose homeostasis traits;
TGCT	cis	rs3771570	0.892	rs59715783	chr2:242366262	C/T	cg21155796	chr2:242212141	HDLBP	0.94	6.69	0.51	6.97e-10	Prostate cancer;
TGCT	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.43	7.54	0.56	8.59e-12	Schizophrenia;
TGCT	cis	rs9527	0.590	rs10786744	chr10:104945028	A/C	cg04362960	chr10:104952993	NT5C2	-0.69	-5.96	-0.47	2.41e-8	Arsenic metabolism;
TGCT	cis	rs10858047	0.883	rs72698003	chr1:115080934	C/G	cg12756093	chr1:115239321	AMPD1	0.45	4.63	0.38	9.24e-6	Autism;
TGCT	cis	rs79349575	0.721	rs3744608	chr17:46993233	C/G	cg26022315	chr17:47021804	SNF8	0.49	4.89	0.4	3.03e-6	Type 2 diabetes;
TGCT	cis	rs13242816	1.000	rs56063232	chr7:116172808	G/T	cg02799643	chr7:116139180	CAV2	-0.43	-5.29	-0.43	5.24e-7	P wave duration;
TGCT	cis	rs9486719	0.947	rs12213375	chr6:96902134	A/G	cg18709589	chr6:96969512	KIAA0776	-0.71	-5.21	-0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	trans	rs8073060	0.586	rs8064895	chr17:34001121	T/C	cg19694781	chr19:47549865	TMEM160	-0.6	-13.37	-0.77	8.63e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs11096990	0.679	rs6531707	chr4:39297684	T/C	cg20847110	chr4:39482781	LOC401127	-0.16	-4.47	-0.37	1.75e-5	Cognitive function;
TGCT	cis	rs981844	0.712	rs6535956	chr4:154746001	G/A	cg14289246	chr4:154710475	SFRP2	-0.99	-9.12	-0.63	1.65e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs8177253	0.665	rs4525863	chr3:133436136	C/A	cg08439880	chr3:133502540	NA	-0.27	-4.78	-0.39	4.8e-6	Iron status biomarkers;
TGCT	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.69	-7.19	-0.54	5.48e-11	Prostate cancer;
TGCT	cis	rs6921919	0.583	rs7773051	chr6:28340316	G/A	cg18815343	chr6:28367644	ZSCAN12	-0.56	-5.37	-0.43	3.8e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1975974	1.000	rs67946006	chr17:21723940	T/C	cg18423549	chr17:21743878	NA	-0.49	-4.76	-0.39	5.3e-6	Psoriasis;
TGCT	cis	rs7095607	0.654	rs12358805	chr10:69960198	T/C	cg18986048	chr10:69913749	MYPN	0.48	4.92	0.4	2.73e-6	Lung function (FVC);
TGCT	cis	rs1564271	0.553	rs2489583	chr10:26987698	A/G	cg24343755	chr10:26987087	PDSS1	-0.58	-4.87	-0.4	3.3e-6	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
TGCT	cis	rs3784262	0.740	rs2044071	chr15:58270804	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.41	-5.94	-0.47	2.71e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs926938	0.618	rs6693491	chr1:115371061	A/G	cg12756093	chr1:115239321	AMPD1	-0.41	-6.02	-0.48	1.79e-8	Autism;
TGCT	cis	rs453301	0.631	rs13250781	chr8:8793343	T/G	cg15556689	chr8:8085844	FLJ10661	-0.63	-5.37	-0.43	3.82e-7	Joint mobility (Beighton score);
TGCT	cis	rs1550973	1.000	rs1550973	chr11:131291728	A/G	cg01699581	chr11:130356112	NA	-0.27	-4.53	-0.38	1.39e-5	Educational attainment (years of education);
TGCT	cis	rs752590	0.806	rs874898	chr2:113974196	C/G	cg27425262	chr2:113953981	PSD4;LOC440839	0.39	4.55	0.38	1.24e-5	Mucinous ovarian carcinoma;
TGCT	cis	rs3820068	0.705	rs4645983	chr1:15850603	G/A	cg05660106	chr1:15850417	CASP9	1.16	14.82	0.8	3.11e-29	Systolic blood pressure;
TGCT	cis	rs72945132	0.769	rs3781645	chr11:70190374	T/C	cg00319359	chr11:70116639	PPFIA1	0.99	7.31	0.55	2.92e-11	Coronary artery disease;
TGCT	cis	rs10419113	0.522	rs13037	chr19:58269173	G/C	cg22020399	chr19:58358583	NA	-0.32	-4.47	-0.37	1.77e-5	Pediatric bone mineral density (spine);
TGCT	cis	rs1008375	0.800	rs35463363	chr4:17613423	G/T	cg16339924	chr4:17578868	LAP3	0.74	5.8	0.46	5.07e-8	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2013441	1.000	rs34644796	chr17:20064128	C/G	cg18979559	chr17:20280153	CCDC144C	0.44	4.61	0.38	9.78e-6	Obesity-related traits;
TGCT	cis	rs7666738	0.830	rs28622458	chr4:98916651	A/G	cg18180107	chr4:99064573	C4orf37	0.53	4.99	0.41	1.98e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7169223	0.653	rs3743057	chr15:79089007	T/C	cg21242079	chr15:79101063	ADAMTS7	0.35	5.66	0.45	9.78e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
TGCT	cis	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg18252515	chr7:66147081	NA	-1.17	-7.17	-0.54	5.94e-11	Diabetic kidney disease;
TGCT	cis	rs114540395	1.000	rs114540395	chr10:103479062	C/T	cg22630918	chr10:102748988	C10orf2	0.41	4.47	0.37	1.72e-5	Schizophrenia;
TGCT	cis	rs6589563	0.737	rs17120029	chr11:116650118	C/T	cg20660624	chr11:117307972	DSCAML1	-0.4	-4.98	-0.41	2.11e-6	Eosinophil counts;
TGCT	cis	rs1062177	0.724	rs2964590	chr5:151118146	C/G	cg12924095	chr5:151150029	G3BP1	-0.34	-4.97	-0.41	2.17e-6	Preschool internalizing problems;
TGCT	cis	rs1218582	0.510	rs2878411	chr1:154823545	C/T	cg16680214	chr1:154839983	KCNN3	-0.26	-4.91	-0.4	2.8e-6	Prostate cancer;
TGCT	cis	rs801193	0.548	rs2659904	chr7:66178602	C/A	cg11764359	chr7:65958608	NA	0.62	5.31	0.43	4.97e-7	Aortic root size;
TGCT	cis	rs11098499	0.954	rs7654587	chr4:120388406	C/T	cg09307838	chr4:120376055	NA	0.68	6.53	0.51	1.54e-9	Corneal astigmatism;
TGCT	cis	rs3093024	1.000	rs3093023	chr6:167534290	A/G	cg07741184	chr6:167504864	NA	-0.23	-4.53	-0.38	1.35e-5	Rheumatoid arthritis;
TGCT	cis	rs887829	0.569	rs4399719	chr2:234666461	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.26	-4.51	-0.38	1.46e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
TGCT	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg17971929	chr21:40555470	PSMG1	0.98	9.13	0.63	1.6e-15	Cognitive function;
TGCT	cis	rs57244997	0.727	rs11965957	chr6:162372993	A/C	cg17173639	chr6:162384350	PARK2	-0.41	-4.44	-0.37	2e-5	Mosquito bite size;
TGCT	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg10047753	chr17:41438598	NA	0.96	9.6	0.65	1.16e-16	Menopause (age at onset);
TGCT	cis	rs1682825	0.858	rs1836292	chr3:10761255	A/T	cg23512531	chr3:10780469	NA	0.64	4.75	0.39	5.42e-6	Economic and political preferences (feminism/equality);
TGCT	cis	rs7267979	0.727	rs4815431	chr20:25532405	T/C	cg14121845	chr20:25566513	NINL	-0.46	-4.76	-0.39	5.36e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1538970	1.000	rs61791368	chr1:45867944	T/C	cg05343316	chr1:45956843	TESK2	0.76	5.86	0.47	3.99e-8	Platelet count;
TGCT	cis	rs908922	0.676	rs11205032	chr1:152527690	A/G	cg20991723	chr1:152506922	NA	0.44	5.96	0.47	2.38e-8	Hair morphology;
TGCT	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg10150615	chr22:24372951	LOC391322	-1.0	-12.91	-0.76	1.1e-24	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs3617	0.591	rs2276823	chr3:52869263	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	-0.48	-4.5	-0.37	1.52e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs73198271	1.000	rs11774744	chr8:8607764	A/G	ch.8.214553F	chr8:8189620	PRAGMIN	-0.27	-4.57	-0.38	1.17e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs7666738	0.830	rs2865980	chr4:99027422	T/G	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.46	8.07e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs78487399	0.908	rs7602701	chr2:43841119	A/G	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.64	4.63	0.38	8.92e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs9814567	0.752	rs13075117	chr3:134329535	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.75	6.83	0.52	3.43e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs11718455	1.000	rs11917515	chr3:44020237	A/G	cg08738300	chr3:44038990	NA	0.88	6.65	0.51	8.52e-10	Coronary artery disease;
TGCT	cis	rs11098499	0.743	rs10003567	chr4:120241674	C/T	cg09307838	chr4:120376055	NA	0.61	5.91	0.47	3.14e-8	Corneal astigmatism;
TGCT	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.62	4.95	0.41	2.34e-6	Lung function (FEV1/FVC);
TGCT	cis	rs13217239	0.646	rs9393789	chr6:27067028	G/T	cg05738196	chr6:26577821	NA	-0.5	-4.77	-0.39	5.05e-6	Schizophrenia;
TGCT	cis	rs595982	0.527	rs12151238	chr19:49368613	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.69	-9.25	-0.64	8.09e-16	Red cell distribution width;
TGCT	cis	rs12497850	0.931	rs6446196	chr3:49004723	A/G	cg07636037	chr3:49044803	WDR6	0.96	10.52	0.69	6.9e-19	Parkinson's disease;
TGCT	cis	rs4900538	0.963	rs1885708	chr14:102960164	A/G	cg18135206	chr14:102964638	TECPR2	0.22	5.19	0.42	8.24e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs13242816	1.000	rs2402078	chr7:116128648	A/C	cg02799643	chr7:116139180	CAV2	-0.46	-5.53	-0.44	1.78e-7	P wave duration;
TGCT	cis	rs7017914	0.934	rs17760050	chr8:71574251	A/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.53	-4.9	-0.4	2.87e-6	Bone mineral density;
TGCT	cis	rs739496	0.947	rs34368158	chr12:111846028	C/T	cg10833066	chr12:111807467	FAM109A	0.37	4.95	0.41	2.41e-6	Platelet count;
TGCT	cis	rs10892173	0.545	rs115865940	chr11:117666711	C/T	cg07621104	chr11:117668040	DSCAML1	0.69	7.61	0.56	5.84e-12	Myopia;
TGCT	cis	rs6582630	0.502	rs11520278	chr12:38359642	T/A	cg26384229	chr12:38710491	ALG10B	0.83	7.25	0.55	4e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs9419702	0.538	rs9419628	chr10:133539299	A/C	cg20568497	chr10:133558893	NA	0.44	4.7	0.39	6.7e-6	Survival in rectal cancer;
TGCT	cis	rs782590	0.748	rs782634	chr2:55897700	T/C	cg18811423	chr2:55921094	PNPT1	0.63	6.3	0.49	4.63e-9	Metabolic syndrome;
TGCT	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs77741769	0.571	rs3897746	chr12:121324727	A/G	cg02419362	chr12:121203948	SPPL3	0.19	4.49	0.37	1.63e-5	Mean corpuscular volume;
TGCT	cis	rs11098499	0.691	rs17009144	chr4:120270795	C/T	cg09307838	chr4:120376055	NA	-0.57	-5.66	-0.45	1.02e-7	Corneal astigmatism;
TGCT	cis	rs56235845	0.665	rs4976685	chr5:176766177	C/T	cg17509989	chr5:176798049	RGS14	-0.57	-7.81	-0.57	2.08e-12	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs57590327	0.555	rs11127740	chr3:81743062	A/C	cg07356753	chr3:81810745	GBE1	-0.78	-7.36	-0.55	2.18e-11	Extraversion;
TGCT	cis	rs7772486	0.719	rs2206141	chr6:146086192	A/G	cg23711669	chr6:146136114	FBXO30	-0.92	-10.41	-0.68	1.3e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1018836	0.892	rs4735224	chr8:91567046	C/A	cg16814680	chr8:91681699	NA	-0.8	-8.57	-0.61	3.46e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7681440	0.804	rs1442140	chr4:90816023	A/G	cg20003494	chr4:90757398	SNCA	-0.58	-5.68	-0.45	8.95e-8	Dementia with Lewy bodies;
TGCT	cis	rs6912958	0.547	rs451089	chr6:88041859	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.48	6.35	0.5	3.65e-9	Monocyte percentage of white cells;
TGCT	cis	rs11190604	0.767	rs10883484	chr10:102174803	G/C	cg23241863	chr10:102295624	HIF1AN	0.6	4.57	0.38	1.17e-5	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs1577917	0.958	rs2324839	chr6:86536942	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-5.53	-0.44	1.82e-7	Response to antipsychotic treatment;
TGCT	cis	rs904251	0.523	rs10807184	chr6:37483713	C/T	cg01843034	chr6:37503916	NA	-0.54	-7.18	-0.54	5.74e-11	Cognitive performance;
TGCT	cis	rs986417	0.818	rs1950315	chr14:61000031	A/C	cg27398547	chr14:60952738	C14orf39	1.49	10.78	0.7	1.64e-19	Gut microbiota (bacterial taxa);
TGCT	cis	rs6598955	0.671	rs10902735	chr1:26617936	C/T	cg04990556	chr1:26633338	UBXN11	0.64	4.91	0.4	2.78e-6	Obesity-related traits;
TGCT	cis	rs1532993	0.518	rs997658	chr4:98552863	T/C	cg05340658	chr4:99064831	C4orf37	-0.42	-5.05	-0.41	1.57e-6	Post bronchodilator FEV1/FVC ratio;
TGCT	cis	rs1215050	0.720	rs7656592	chr4:98624593	G/A	cg05340658	chr4:99064831	C4orf37	-0.41	-4.96	-0.41	2.3e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs12681288	0.550	rs4637864	chr8:959761	C/T	cg04851639	chr8:1020857	NA	-0.27	-4.44	-0.37	1.94e-5	Schizophrenia;
TGCT	trans	rs17834679	1.000	rs17834679	chr19:52270087	C/G	cg13034837	chr18:32924525	ZNF24	0.85	6.86	0.52	2.9e-10	Alopecia areata;
TGCT	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg12756686	chr19:29218302	NA	0.76	6.45	0.5	2.29e-9	Methadone dose in opioid dependence;
TGCT	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg26338869	chr17:61819248	STRADA	-0.54	-5.03	-0.41	1.71e-6	Prudent dietary pattern;
TGCT	cis	rs2299587	0.554	rs13253029	chr8:17749622	C/T	cg04898035	chr8:17640624	MTUS1	-0.2	-4.53	-0.38	1.35e-5	Economic and political preferences;
TGCT	cis	rs595982	0.517	rs10404905	chr19:49406175	A/T	cg11637076	chr19:49575188	KCNA7	0.43	5.26	0.43	6.25e-7	Red cell distribution width;
TGCT	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg02725872	chr8:58115012	NA	-0.36	-4.95	-0.41	2.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10736390	0.538	rs12410550	chr1:55107306	A/G	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.51	-8.92	-0.63	5.16e-15	Survival in pancreatic cancer;
TGCT	cis	rs17376456	0.877	rs12153501	chr5:93360866	T/G	cg21475434	chr5:93447410	FAM172A	0.6	4.73	0.39	6.08e-6	Diabetic retinopathy;
TGCT	cis	rs9522267	0.535	rs11069900	chr13:112233285	G/A	cg10483660	chr13:112241077	NA	-0.26	-4.44	-0.37	1.99e-5	Hepatitis;
TGCT	cis	rs7104764	0.879	rs6598072	chr11:219793	C/T	cg18336825	chr11:236787	PSMD13;SIRT3	1.05	10.74	0.69	2e-19	Menarche (age at onset);
TGCT	cis	rs137603	0.603	rs137581	chr22:39677838	C/T	cg01093212	chr22:39715156	SNORD43;RPL3	-0.5	-4.69	-0.39	7.15e-6	Primary biliary cholangitis;
TGCT	cis	rs7017914	0.967	rs2732090	chr8:71918257	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	0.57	5.31	0.43	4.8e-7	Bone mineral density;
TGCT	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg00814883	chr7:100076585	TSC22D4	-0.9	-9.56	-0.65	1.5e-16	Platelet count;
TGCT	cis	rs3809566	1.000	rs10851721	chr15:63332383	T/C	cg08198488	chr15:63333792	TPM1	-0.35	-5.23	-0.43	7e-7	Platelet count;
TGCT	cis	rs7552404	0.731	rs5745445	chr1:76344332	G/A	cg03433033	chr1:76189801	ACADM	0.78	7.82	0.57	1.94e-12	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs7822232	0.908	rs1127096	chr8:145140472	A/G	cg14631276	chr8:145163102	KIAA1875	-0.56	-5.05	-0.41	1.55e-6	Blood metabolite levels;
TGCT	cis	rs523522	0.962	rs10849754	chr12:120940418	A/C	cg12219531	chr12:120966889	COQ5	0.83	7.27	0.55	3.46e-11	High light scatter reticulocyte count;
TGCT	cis	rs1371867	0.846	rs1788206	chr8:101306966	A/G	cg00191853	chr8:101177733	SPAG1	-0.22	-4.47	-0.37	1.75e-5	Atrioventricular conduction;
TGCT	cis	rs933688	0.536	rs332537	chr5:90794973	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-1.0	-6.39	-0.5	3.08e-9	Smoking behavior;
TGCT	cis	rs13217239	0.646	rs35691005	chr6:26972070	A/G	cg02458000	chr6:26745757	NA	0.5	4.61	0.38	9.84e-6	Schizophrenia;
TGCT	cis	rs62244186	0.593	rs9814298	chr3:44871899	T/A	cg25151919	chr3:44754333	ZNF502	-0.45	-5.24	-0.43	6.63e-7	Depressive symptoms;
TGCT	cis	rs2456568	0.933	rs1518577	chr11:93674907	C/T	cg26875233	chr11:93583750	C11orf90	-0.45	-5.61	-0.45	1.28e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs28595532	1.000	rs114912871	chr4:119697004	G/C	cg14228332	chr4:119757509	SEC24D	1.02	5.06	0.41	1.47e-6	Cannabis dependence symptom count;
TGCT	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg03264133	chr6:25882463	NA	-0.61	-6.51	-0.5	1.69e-9	Blood metabolite levels;
TGCT	cis	rs6921919	0.525	rs6929825	chr6:28378959	A/G	cg18815343	chr6:28367644	ZSCAN12	-0.54	-5.25	-0.43	6.29e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6918586	0.616	rs198836	chr6:26113616	T/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.7	-6.6	-0.51	1.09e-9	Schizophrenia;
TGCT	cis	rs8016982	0.674	rs8004096	chr14:81701082	T/G	cg01989461	chr14:81687754	GTF2A1	0.75	7.01	0.53	1.37e-10	Schizophrenia;
TGCT	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg18876405	chr7:65276391	NA	0.32	4.87	0.4	3.29e-6	Aortic root size;
TGCT	cis	rs3796352	0.527	rs11714793	chr3:52924930	A/G	cg27565382	chr3:53032988	SFMBT1	0.45	5.21	0.42	7.67e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs3008870	0.916	rs2025608	chr1:67422550	C/T	cg03991309	chr1:68237761	GNG12	0.27	4.53	0.38	1.36e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs2204008	0.536	rs12368354	chr12:38042798	G/A	cg26384229	chr12:38710491	ALG10B	0.85	7.63	0.57	5.5e-12	Bladder cancer;
TGCT	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg09359103	chr1:154839909	KCNN3	-0.74	-16.0	-0.82	6.13e-32	Prostate cancer;
TGCT	cis	rs7178572	1.000	rs62007299	chr15:77711719	G/A	cg15453836	chr15:77711506	NA	-0.4	-4.56	-0.38	1.22e-5	Type 2 diabetes;
TGCT	cis	rs7772486	0.743	rs9376955	chr6:145949404	T/A	cg05347473	chr6:146136440	FBXO30	0.51	4.84	0.4	3.82e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7666738	0.830	rs13124127	chr4:98990729	G/A	cg17366294	chr4:99064904	C4orf37	0.68	6.96	0.53	1.75e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs950169	0.580	rs11634322	chr15:85172209	C/T	cg12863693	chr15:85201151	NMB	0.46	5.56	0.45	1.6e-7	Schizophrenia;
TGCT	cis	rs483180	0.511	rs496198	chr1:120207177	A/G	cg19096424	chr1:120255104	PHGDH	-0.56	-5.24	-0.43	6.8e-7	Macular telangiectasia type 2;
TGCT	cis	rs6671200	0.688	rs4950024	chr1:95713499	A/G	cg20701556	chr1:95698924	RWDD3	-0.52	-5.34	-0.43	4.26e-7	Stearic acid (18:0) levels;
TGCT	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg02788857	chr8:22132959	PIWIL2	0.28	5.16	0.42	9.54e-7	Hypertriglyceridemia;
TGCT	cis	rs2204008	0.658	rs12371956	chr12:38298010	A/T	cg13010199	chr12:38710504	ALG10B	0.57	4.45	0.37	1.89e-5	Bladder cancer;
TGCT	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs1499614	0.803	rs1922723	chr7:66175063	C/T	cg18252515	chr7:66147081	NA	-1.26	-7.95	-0.58	9.71e-13	Gout;
TGCT	cis	rs4566357	0.615	rs10174591	chr2:227913140	G/A	cg11843606	chr2:227700838	RHBDD1	-0.55	-5.17	-0.42	8.9e-7	Coronary artery disease;
TGCT	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg22166914	chr1:53195759	ZYG11B	0.37	6.41	0.5	2.77e-9	Monocyte count;
TGCT	cis	rs4372836	0.504	rs7475	chr2:29023749	A/G	cg09522027	chr2:28974177	PPP1CB	-0.56	-5.68	-0.45	9.2e-8	Body mass index;
TGCT	cis	rs904251	0.523	rs9366935	chr6:37480404	C/T	cg01843034	chr6:37503916	NA	-0.55	-7.01	-0.53	1.36e-10	Cognitive performance;
TGCT	cis	rs3796619	0.961	rs62294748	chr4:1082999	G/A	cg27284194	chr4:1044797	NA	0.46	4.45	0.37	1.85e-5	Recombination rate (males);
TGCT	cis	rs447921	0.861	rs56248611	chr17:74448255	G/A	cg09812376	chr17:74270190	QRICH2	-0.45	-4.76	-0.39	5.3e-6	Mitochondrial DNA levels;
TGCT	cis	rs17253792	0.822	rs28392709	chr14:56093685	G/A	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs6460942	0.731	rs75994414	chr7:12307992	C/A	cg06484146	chr7:12443880	VWDE	-0.54	-4.77	-0.39	5.06e-6	Coronary artery disease;
TGCT	cis	rs7760949	0.963	rs1467729	chr6:13911167	C/T	cg27413430	chr6:13925136	RNF182	-0.48	-4.55	-0.38	1.27e-5	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs7044106	0.791	rs735110	chr9:123488940	T/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.49	5.44	0.44	2.74e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg24829409	chr8:58192753	C8orf71	-0.59	-5.18	-0.42	8.54e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg08859206	chr1:53392774	SCP2	0.39	5.78	0.46	5.76e-8	Monocyte count;
TGCT	cis	rs2239547	0.657	rs7620706	chr3:52891756	A/T	cg10802521	chr3:52805072	NEK4	-0.65	-6.12	-0.48	1.16e-8	Schizophrenia;
TGCT	cis	rs7674212	0.541	rs2720464	chr4:104073201	G/A	cg16532752	chr4:104119610	CENPE	-0.57	-5.18	-0.42	8.7e-7	Type 2 diabetes;
TGCT	cis	rs2350702	0.525	rs13030466	chr2:49921390	C/A	cg25565504	chr2:50876837	NRXN1	-0.26	-4.53	-0.38	1.37e-5	Morning vs. evening chronotype;
TGCT	cis	rs4478858	0.684	rs12403136	chr1:31728920	A/G	cg07478791	chr1:31886160	SERINC2	-0.48	-4.63	-0.38	9.12e-6	Alcohol dependence;
TGCT	cis	rs6459788	0.934	rs10251462	chr7:157258183	C/G	cg03453431	chr7:157225567	NA	-0.34	-5.12	-0.42	1.13e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs2228479	0.717	rs2286392	chr16:89809549	A/G	cg26513180	chr16:89883248	FANCA	0.78	4.54	0.38	1.32e-5	Skin colour saturation;
TGCT	cis	rs28595532	0.920	rs115446044	chr4:119754635	T/C	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg08045932	chr20:61659980	NA	0.48	9.28	0.64	7.07e-16	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9814567	0.929	rs1863911	chr3:134205231	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.99	-9.97	-0.67	1.5e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs9611519	1.000	rs9611510	chr22:41569124	T/C	cg13695892	chr22:41940480	POLR3H	-0.5	-4.51	-0.38	1.5e-5	Neuroticism;
TGCT	cis	rs4689592	0.503	rs59640165	chr4:7051661	G/A	cg26116260	chr4:7069785	GRPEL1	-0.91	-6.77	-0.52	4.48e-10	Monocyte percentage of white cells;
TGCT	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg20276088	chr3:133502917	NA	-0.24	-5.06	-0.41	1.5e-6	Iron status biomarkers;
TGCT	cis	rs4285028	0.898	rs73855476	chr3:121633412	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.77	-6.62	-0.51	9.73e-10	Multiple sclerosis;
TGCT	cis	rs17270561	1.000	rs79867288	chr6:25828416	A/G	cg17042849	chr6:26104293	HIST1H4C	-0.91	-6.17	-0.48	9.01e-9	Iron status biomarkers;
TGCT	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg25036284	chr2:26402008	FAM59B	0.65	5.19	0.42	8.36e-7	Gut microbiome composition (summer);
TGCT	cis	rs76878669	0.561	rs4930362	chr11:66154360	T/C	cg18002602	chr11:66138449	SLC29A2	0.53	6.49	0.5	1.87e-9	Educational attainment (years of education);
TGCT	cis	rs9611519	0.929	rs4821991	chr22:41440683	T/C	cg03806693	chr22:41940476	POLR3H	-0.68	-6.1	-0.48	1.25e-8	Neuroticism;
TGCT	cis	rs2180341	0.961	rs7774468	chr6:127592501	G/C	cg27446573	chr6:127587934	RNF146	1.13	10.12	0.67	6.64e-18	Breast cancer;
TGCT	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.55	4.92	0.4	2.74e-6	Prudent dietary pattern;
TGCT	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg00814883	chr7:100076585	TSC22D4	-0.92	-9.76	-0.66	4.73e-17	Platelet count;
TGCT	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg11644478	chr21:40555479	PSMG1	1.0	10.6	0.69	4.32e-19	Cognitive function;
TGCT	cis	rs4566357	0.787	rs12475134	chr2:227880511	C/T	cg11843606	chr2:227700838	RHBDD1	-0.62	-5.32	-0.43	4.59e-7	Coronary artery disease;
TGCT	cis	rs9467711	0.606	rs68112369	chr6:26365759	T/C	cg16898833	chr6:26189333	HIST1H4D	1.09	5.25	0.43	6.41e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4975616	0.869	rs380286	chr5:1320247	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.3	-4.57	-0.38	1.17e-5	Lung cancer;
TGCT	cis	rs13242816	1.000	rs7796429	chr7:116144369	T/C	cg16553024	chr7:116138462	CAV2	-0.44	-5.36	-0.43	3.97e-7	P wave duration;
TGCT	cis	rs9902453	0.933	rs2054846	chr17:28507693	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-6.54	-0.51	1.43e-9	Coffee consumption (cups per day);
TGCT	cis	rs7267979	1.000	rs6083805	chr20:25317356	T/C	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6088580	0.668	rs1205340	chr20:32923871	G/A	cg06115741	chr20:33292138	TP53INP2	-0.53	-4.7	-0.39	6.67e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs9916302	0.610	rs11078902	chr17:37631883	C/G	cg15445000	chr17:37608096	MED1	0.31	4.6	0.38	1.01e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs9677476	0.516	rs59886388	chr2:231995770	G/C	cg27665808	chr2:232055229	NA	0.36	4.52	0.38	1.44e-5	Food antigen IgG levels;
TGCT	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg01416388	chr22:39784598	NA	0.62	6.19	0.49	7.9e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs986417	1.000	rs1254296	chr14:60870389	T/C	cg27398547	chr14:60952738	C14orf39	-1.42	-8.68	-0.61	1.89e-14	Gut microbiota (bacterial taxa);
TGCT	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg17775962	chr7:1200435	ZFAND2A	0.27	4.63	0.38	9.19e-6	Longevity;Endometriosis;
TGCT	cis	rs1153858	1.000	rs1145091	chr15:45649996	A/G	cg26924012	chr15:45694286	SPATA5L1	0.99	12.23	0.74	4.74e-23	Homoarginine levels;
TGCT	cis	rs12220898	0.568	rs4838376	chr10:50482048	T/C	cg06072769	chr10:50146962	WDFY4	0.39	5.1	0.42	1.23e-6	Inflammatory biomarkers;
TGCT	cis	rs7726839	0.561	rs11955068	chr5:582324	C/T	cg09021430	chr5:549028	NA	-0.37	-5.23	-0.42	7.12e-7	Obesity-related traits;
TGCT	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs17221829	0.965	rs7927936	chr11:89460495	C/G	cg02982614	chr11:89391479	FOLH1B	-0.3	-5.15	-0.42	9.89e-7	Anxiety in major depressive disorder;
TGCT	cis	rs7193541	0.684	rs7191665	chr16:74688948	T/G	cg01733217	chr16:74700730	RFWD3	0.99	13.32	0.77	1.14e-25	Multiple myeloma;
TGCT	cis	rs4645881	0.748	rs1010103	chr19:49461211	T/G	cg15040422	chr19:49955266	ALDH16A1;PIH1D1	0.82	4.51	0.38	1.47e-5	Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil counts;
TGCT	cis	rs9926296	0.744	rs164746	chr16:89709019	C/T	cg01097406	chr16:89675127	NA	0.34	6.23	0.49	6.76e-9	Vitiligo;
TGCT	cis	rs67311347	1.000	rs9827461	chr3:40489351	T/A	cg17264618	chr3:40429014	ENTPD3	0.34	4.98	0.41	2.05e-6	Renal cell carcinoma;
TGCT	cis	rs61931739	0.500	rs3934517	chr12:34451396	T/C	cg06521331	chr12:34319734	NA	-0.28	-4.51	-0.38	1.47e-5	Morning vs. evening chronotype;
TGCT	cis	rs17607347	0.542	rs62051130	chr16:72455938	C/T	cg06220725	chr16:72042591	DHODH	-0.72	-4.77	-0.39	5e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6695640	0.756	rs1555661	chr1:17730812	A/G	cg25979543	chr1:17888104	ARHGEF10L	-0.25	-4.57	-0.38	1.14e-5	Mean platelet volume;
TGCT	cis	rs12044355	0.516	rs2356383	chr1:231742973	G/C	cg04892437	chr1:231737901	TSNAX-DISC1	-0.51	-5.04	-0.41	1.58e-6	Alzheimer's disease;
TGCT	cis	rs8179	0.645	rs2282979	chr7:92264993	T/C	cg15732164	chr7:92237376	CDK6	-0.27	-4.66	-0.39	8.16e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
TGCT	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg21226059	chr5:178986404	RUFY1	0.51	5.52	0.44	1.93e-7	Lung cancer;
TGCT	cis	rs2456568	0.803	rs10831140	chr11:93640689	G/A	cg14065697	chr11:93583672	C11orf90	-0.36	-4.46	-0.37	1.83e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs6545883	0.929	rs10193666	chr2:61629408	C/T	cg15711740	chr2:61764176	XPO1	0.53	4.7	0.39	6.67e-6	Tuberculosis;
TGCT	cis	rs12643440	0.538	rs2314601	chr4:17139932	C/T	cg22650099	chr4:17144496	NA	-0.46	-4.66	-0.39	7.88e-6	Metabolite levels (Pyroglutamine);
TGCT	cis	rs4455778	0.659	rs12530914	chr7:49026076	T/C	cg26309511	chr7:48887640	NA	-0.44	-5.22	-0.42	7.26e-7	Lung cancer in never smokers;
TGCT	cis	rs79349575	0.783	rs15563	chr17:47005193	A/G	cg07967210	chr17:47022446	SNF8	0.4	5.5	0.44	2.11e-7	Type 2 diabetes;
TGCT	cis	rs12497850	0.829	rs12636030	chr3:49182237	A/G	cg07636037	chr3:49044803	WDR6	0.94	9.88	0.66	2.51e-17	Parkinson's disease;
TGCT	cis	rs10838634	1.000	rs4128315	chr11:46837201	T/C	cg18332754	chr11:46939436	LRP4	0.89	4.46	0.37	1.82e-5	Schizophrenia;
TGCT	cis	rs2658782	0.950	rs2446061	chr11:93149277	C/T	cg18152523	chr11:93063302	CCDC67	-0.69	-5.41	-0.44	3.11e-7	Pulmonary function decline;
TGCT	cis	rs2839186	0.504	rs4347941	chr21:47938239	T/C	cg12379764	chr21:47803548	PCNT	0.5	5.96	0.47	2.39e-8	Testicular germ cell tumor;
TGCT	cis	rs10435719	0.610	rs80269926	chr8:11790527	T/C	cg02840367	chr8:11660030	FDFT1	-0.54	-4.52	-0.38	1.45e-5	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs7681440	0.904	rs1372521	chr4:90765223	G/A	cg14346243	chr4:90757452	SNCA	-0.57	-5.6	-0.45	1.31e-7	Dementia with Lewy bodies;
TGCT	cis	rs2688608	0.618	rs28553894	chr10:75489843	C/A	cg04320760	chr10:75533139	FUT11	-0.39	-6.01	-0.48	1.89e-8	Inflammatory bowel disease;
TGCT	cis	rs6964587	1.000	rs12333563	chr7:91667326	G/A	cg22709100	chr7:91322751	NA	0.28	4.56	0.38	1.19e-5	Breast cancer;
TGCT	cis	rs9611565	0.921	rs3927	chr22:41722864	A/G	cg03806693	chr22:41940476	POLR3H	-0.98	-10.9	-0.7	8.34e-20	Vitiligo;
TGCT	cis	rs8141529	0.584	rs58004020	chr22:29257050	A/T	cg02153584	chr22:29168773	CCDC117	0.63	5.17	0.42	9.2e-7	Lymphocyte counts;
TGCT	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg00080972	chr5:178986291	RUFY1	0.59	7.77	0.57	2.62e-12	Lung cancer;
TGCT	cis	rs4699052	0.963	rs2085978	chr4:104193614	A/G	cg16532752	chr4:104119610	CENPE	-0.52	-4.76	-0.39	5.34e-6	Testicular germ cell tumor;
TGCT	cis	rs17601876	0.814	rs2899474	chr15:51562076	C/T	cg19946085	chr15:51559439	CYP19A1	-0.33	-5.06	-0.41	1.45e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs9611565	0.921	rs2281332	chr22:41746212	T/C	cg06634786	chr22:41940651	POLR3H	-0.63	-6.01	-0.47	1.93e-8	Vitiligo;
TGCT	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg07061783	chr6:25882402	NA	-0.56	-5.37	-0.43	3.72e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs916888	0.821	rs199504	chr17:44861003	C/T	cg16520312	chr17:43971471	MAPT;LOC100128977	0.55	4.75	0.39	5.52e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs11098499	0.954	rs7436506	chr4:120393769	T/C	cg09307838	chr4:120376055	NA	0.68	6.37	0.5	3.41e-9	Corneal astigmatism;
TGCT	cis	rs57590327	0.516	rs66665538	chr3:81796391	T/A	cg07356753	chr3:81810745	GBE1	-0.79	-6.52	-0.51	1.56e-9	Extraversion;
TGCT	cis	rs7635838	0.718	rs2606736	chr3:11400249	C/T	cg00170343	chr3:11313890	ATG7	0.66	6.47	0.5	2.01e-9	HDL cholesterol;
TGCT	cis	rs4803468	1.000	rs284657	chr19:41929915	G/C	cg09537434	chr19:41945824	ATP5SL	-0.92	-10.72	-0.69	2.27e-19	Height;
TGCT	cis	rs6430585	0.528	rs115469964	chr2:136696608	A/C	cg07169764	chr2:136633963	MCM6	1.26	12.74	0.75	2.79e-24	Corneal structure;
TGCT	cis	rs9914544	1.000	rs1737944	chr17:18840433	G/A	cg26378065	chr17:18585709	ZNF286B	0.53	4.74	0.39	5.79e-6	Educational attainment (years of education);
TGCT	cis	rs9916302	0.752	rs9901219	chr17:37558369	T/G	cg07936489	chr17:37558343	FBXL20	0.91	7.57	0.56	7.21e-12	Glomerular filtration rate (creatinine);
TGCT	cis	rs9522267	0.502	rs9515450	chr13:112234262	T/C	cg10483660	chr13:112241077	NA	-0.27	-4.61	-0.38	9.87e-6	Hepatitis;
TGCT	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg09365446	chr1:150670422	GOLPH3L	0.31	4.64	0.38	8.74e-6	Urate levels;
TGCT	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.63	5.05	0.41	1.57e-6	Lung function (FEV1/FVC);
TGCT	cis	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg07424592	chr7:64974309	NA	1.26	7.79	0.57	2.25e-12	Diabetic kidney disease;
TGCT	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg13206674	chr6:150067644	NUP43	0.52	4.51	0.38	1.5e-5	Lung cancer;
TGCT	cis	rs12497850	1.000	rs10865952	chr3:48744484	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.5	-4.78	-0.39	4.87e-6	Parkinson's disease;
TGCT	cis	rs1075232	0.655	rs80220087	chr15:31555817	G/A	cg01030201	chr15:31746330	NA	-0.87	-4.48	-0.37	1.69e-5	Survival in colorectal cancer (non-distant metastatic);
TGCT	cis	rs854765	0.547	rs9913277	chr17:17919749	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.79	8.41	0.6	8.09e-14	Total body bone mineral density;
TGCT	trans	rs17685	0.753	rs55812043	chr7:75747241	T/C	cg19862616	chr7:65841803	NCRNA00174	0.52	9.01	0.63	3.02e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs910316	1.000	rs7147118	chr14:75610170	G/C	cg08847533	chr14:75593920	NEK9	0.96	10.86	0.7	1.05e-19	Height;
TGCT	cis	rs380904	0.552	rs10099003	chr8:144645460	C/T	cg12686110	chr8:144635478	GSDMD	0.57	4.44	0.37	1.98e-5	Venous thromboembolism (SNP x SNP interaction);
TGCT	cis	rs2455601	0.573	rs2653573	chr11:8989874	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-5.09	-0.42	1.31e-6	Schizophrenia;
TGCT	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg16325326	chr1:53192061	ZYG11B	0.57	6.24	0.49	6.31e-9	Monocyte count;
TGCT	cis	rs3820068	0.603	rs3795763	chr1:15959977	C/T	cg05660106	chr1:15850417	CASP9	0.83	8.19	0.59	2.78e-13	Systolic blood pressure;
TGCT	cis	rs651907	0.557	rs56291106	chr3:101377474	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.91	10.9	0.7	8.24e-20	Colorectal cancer;
TGCT	cis	rs10782582	0.593	rs1412717	chr1:76125471	C/T	cg10523679	chr1:76189770	ACADM	-0.68	-7.05	-0.53	1.11e-10	Daytime sleep phenotypes;
TGCT	cis	rs7296418	0.961	rs1790106	chr12:123591596	G/T	cg00376283	chr12:123451042	ABCB9	0.84	7.68	0.57	4.11e-12	Platelet count;
TGCT	trans	rs1814175	0.754	rs28593359	chr11:50042357	C/T	cg03929089	chr4:120376271	NA	-0.72	-8.55	-0.61	3.8e-14	Height;
TGCT	cis	rs7542091	0.704	rs9429825	chr1:210052133	C/G	cg21951975	chr1:209979733	IRF6	0.59	5.89	0.47	3.41e-8	Monobrow;
TGCT	cis	rs6095298	0.595	rs34326966	chr20:47436646	C/A	cg12307787	chr20:48099359	KCNB1	0.44	4.63	0.38	8.96e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs5769707	0.656	rs135875	chr22:50012419	T/G	cg05373962	chr22:49881684	NA	-0.29	-4.97	-0.41	2.16e-6	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs7666738	0.830	rs11722272	chr4:99000839	C/T	cg05340658	chr4:99064831	C4orf37	0.5	5.44	0.44	2.7e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs56235845	0.694	rs4532376	chr5:176774403	G/A	cg16006841	chr5:176797999	RGS14	0.52	7.69	0.57	3.9e-12	Hemoglobin concentration;Hematocrit;
TGCT	cis	rs1215050	0.791	rs155019	chr4:98759126	G/A	cg17366294	chr4:99064904	C4orf37	0.52	5.61	0.45	1.27e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs1018836	0.812	rs10808619	chr8:91622916	A/T	cg16814680	chr8:91681699	NA	-0.78	-8.2	-0.59	2.54e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2836974	0.799	rs8129303	chr21:40711959	G/A	cg06238570	chr21:40685208	BRWD1	0.65	5.67	0.45	9.37e-8	Cognitive function;
TGCT	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	8.0	0.58	7.67e-13	Platelet count;
TGCT	cis	rs2463822	1.000	rs2513747	chr11:62098735	T/C	cg23876832	chr11:62092739	NA	0.67	4.91	0.4	2.82e-6	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs2046867	0.908	rs9880763	chr3:72789805	G/C	cg25664220	chr3:72788482	NA	-0.54	-6.8	-0.52	3.96e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg08859206	chr1:53392774	SCP2	-0.46	-6.97	-0.53	1.62e-10	Monocyte count;
TGCT	cis	rs11122272	0.701	rs2474628	chr1:231526000	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-6.94	-0.53	1.98e-10	Hemoglobin concentration;
TGCT	cis	rs6570726	0.967	rs418662	chr6:145848832	A/C	cg23711669	chr6:146136114	FBXO30	0.7	6.34	0.49	3.98e-9	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1847505	0.609	rs1514541	chr13:61586096	C/G	cg25164009	chr13:61490935	NA	-0.31	-4.84	-0.4	3.85e-6	Polychlorinated biphenyl levels;
TGCT	cis	rs739496	0.579	rs2158030	chr12:112285591	T/C	cg10833066	chr12:111807467	FAM109A	0.38	5.41	0.44	3.08e-7	Platelet count;
TGCT	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg11965913	chr1:205819406	PM20D1	-0.48	-6.79	-0.52	4.05e-10	Menarche (age at onset);
TGCT	cis	rs7178572	0.568	rs12906708	chr15:77681444	A/G	cg15453836	chr15:77711506	NA	-0.42	-4.78	-0.39	4.92e-6	Type 2 diabetes;
TGCT	cis	rs2658782	0.724	rs2658770	chr11:93261886	A/G	cg15737290	chr11:93063684	CCDC67	0.7	5.2	0.42	8e-7	Pulmonary function decline;
TGCT	cis	rs3812831	0.695	rs422149	chr13:114931086	T/G	cg06611532	chr13:114900021	NA	0.35	6.42	0.5	2.57e-9	Schizophrenia;
TGCT	trans	rs2288327	0.557	rs60488846	chr2:179357842	C/T	cg14011486	chr1:26737247	LIN28	1.03	7.28	0.55	3.41e-11	Atrial fibrillation;
TGCT	cis	rs1801251	0.964	rs6748027	chr2:233629552	T/C	cg25237894	chr2:233734115	C2orf82	0.32	5.88	0.47	3.5e-8	Coronary artery disease;
TGCT	cis	rs6088590	0.648	rs6058105	chr20:33271719	C/T	cg06115741	chr20:33292138	TP53INP2	0.59	5.23	0.43	6.91e-7	Coronary artery disease;
TGCT	cis	rs7570971	1.000	rs7570971	chr2:135837906	C/A	cg07169764	chr2:136633963	MCM6	0.55	4.92	0.4	2.66e-6	Blood metabolite levels;Body mass index;Cholesterol, total;
TGCT	cis	rs62103177	0.714	rs12607447	chr18:77605212	A/G	cg12964065	chr18:77638022	KCNG2	0.33	4.63	0.38	9.06e-6	Opioid sensitivity;
TGCT	cis	rs2172802	1.000	rs2172802	chr4:62453209	C/T	cg04118610	chr4:62707027	LPHN3	0.42	4.88	0.4	3.25e-6	Partial epilepsies;
TGCT	cis	rs7698623	0.717	rs1463094	chr4:88792584	G/A	cg02735620	chr4:88950514	PKD2	-0.44	-4.81	-0.4	4.22e-6	Cardiovascular disease risk factors;
TGCT	cis	rs6912958	0.754	rs10755484	chr6:88244648	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-5.07	-0.41	1.41e-6	Monocyte percentage of white cells;
TGCT	cis	rs7666738	0.712	rs34043080	chr4:99008748	G/C	cg05340658	chr4:99064831	C4orf37	0.49	5.61	0.45	1.28e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7089973	0.604	rs11196939	chr10:116593175	A/G	cg03647239	chr10:116582469	FAM160B1	-0.6	-5.83	-0.46	4.6e-8	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs4886920	0.519	rs4496098	chr15:78117937	C/G	cg25212270	chr15:78015279	NA	0.34	5.02	0.41	1.77e-6	Neuroticism;
TGCT	cis	rs9400467	0.537	rs12212282	chr6:111524838	T/C	cg15721981	chr6:111408429	SLC16A10	0.73	4.79	0.4	4.71e-6	Blood metabolite levels;Amino acid levels;
TGCT	cis	rs7113874	0.569	rs10444316	chr11:8534614	G/A	cg14521421	chr11:8862019	ST5	0.28	4.48	0.37	1.64e-5	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
TGCT	cis	rs7267979	0.966	rs2482918	chr20:25412135	C/T	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs8032315	1.000	rs8032315	chr15:91418297	A/T	cg04510874	chr15:91427884	FES	0.46	5.46	0.44	2.55e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7172809	0.897	rs869302	chr15:77830430	T/C	cg22256960	chr15:77711686	NA	-0.47	-4.76	-0.39	5.23e-6	Glucose homeostasis traits;
TGCT	cis	rs2456568	0.606	rs11020616	chr11:93691594	C/T	cg16099599	chr11:93583650	C11orf90	0.42	4.97	0.41	2.17e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs3008870	1.000	rs11208976	chr1:67434411	A/G	cg03991309	chr1:68237761	GNG12	-0.27	-4.53	-0.38	1.36e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs9899728	1.000	rs7222902	chr17:73019710	T/A	cg00012762	chr17:72744649	SLC9A3R1	-1.0	-4.49	-0.37	1.59e-5	Alzheimer's disease or small vessel stroke;
TGCT	cis	rs9291683	0.588	rs4280729	chr4:10013861	C/T	cg11266682	chr4:10021025	SLC2A9	0.73	10.86	0.7	1.03e-19	Bone mineral density;
TGCT	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.73	-6.5	-0.5	1.8e-9	Tonsillectomy;
TGCT	cis	rs924043	0.636	rs80251809	chr6:170382335	G/A	cg17426568	chr6:170418587	NA	0.44	4.48	0.37	1.69e-5	Type 1 diabetes;
TGCT	cis	rs910316	0.967	rs2010678	chr14:75567178	C/T	cg23033748	chr14:75592666	NEK9	0.27	4.57	0.38	1.16e-5	Height;
TGCT	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg00343986	chr7:65444356	GUSB	-0.23	-5.16	-0.42	9.66e-7	Aortic root size;
TGCT	cis	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg25427524	chr10:38739819	LOC399744	-0.39	-7.9	-0.58	1.31e-12	Extrinsic epigenetic age acceleration;
TGCT	cis	rs317689	0.690	rs7969559	chr12:69655167	A/G	cg14784868	chr12:69753453	YEATS4	0.52	4.5	0.37	1.55e-5	Response to diuretic therapy;
TGCT	cis	rs12479064	0.703	rs28382977	chr2:100018304	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.58	-4.71	-0.39	6.5e-6	Chronic sinus infection;
TGCT	cis	rs2692947	0.537	rs1364394	chr2:96195730	A/G	cg23100626	chr2:96804247	ASTL	-0.44	-5.06	-0.41	1.47e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs7178572	0.568	rs7176302	chr15:77671216	C/G	cg15453836	chr15:77711506	NA	-0.42	-4.78	-0.39	4.92e-6	Type 2 diabetes;
TGCT	cis	rs617219	0.671	rs1316753	chr5:78531337	G/C	cg05890484	chr5:78407552	BHMT	0.34	4.63	0.38	8.97e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs2486288	0.656	rs8039354	chr15:45551756	A/G	cg26924012	chr15:45694286	SPATA5L1	0.72	7.46	0.56	1.34e-11	Glomerular filtration rate;
TGCT	cis	rs910187	0.678	rs6124964	chr20:45812536	T/G	cg27589058	chr20:45804311	EYA2	-0.34	-7.21	-0.54	4.78e-11	Migraine;
TGCT	cis	rs3749237	1.000	rs3749237	chr3:49770032	C/T	cg03060546	chr3:49711283	APEH	0.72	7.38	0.55	2.02e-11	Resting heart rate;
TGCT	trans	rs62103177	0.673	rs62096717	chr18:77616819	C/T	cg05926928	chr17:57297772	GDPD1	1.06	10.79	0.7	1.52e-19	Opioid sensitivity;
TGCT	cis	rs868036	0.718	rs2241420	chr15:68082816	G/A	cg05925327	chr15:68127851	NA	-0.5	-4.86	-0.4	3.4e-6	Restless legs syndrome;
TGCT	cis	rs9911578	1.000	rs3744109	chr17:56594197	C/T	cg05425664	chr17:57184151	TRIM37	0.63	6.26	0.49	5.86e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs3796352	1.000	rs35507120	chr3:53053924	C/T	cg27565382	chr3:53032988	SFMBT1	0.45	4.58	0.38	1.14e-5	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs6582630	0.519	rs7294292	chr12:38349540	C/T	cg13010199	chr12:38710504	ALG10B	0.58	4.52	0.38	1.41e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg06873352	chr17:61820015	STRADA	0.55	5.8	0.46	5.25e-8	Prudent dietary pattern;
TGCT	trans	rs9650657	0.515	rs7820860	chr8:10950396	C/G	cg06636001	chr8:8085503	FLJ10661	-0.76	-6.92	-0.53	2.11e-10	Neuroticism;
TGCT	cis	rs854765	0.506	rs7210400	chr17:17949957	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.8	-8.46	-0.61	6.18e-14	Total body bone mineral density;
TGCT	cis	rs1322512	0.920	rs2695246	chr6:152948466	T/C	cg03415253	chr6:152958462	SYNE1	-0.57	-4.99	-0.41	2e-6	Tonometry;
TGCT	cis	rs228437	0.586	rs9402621	chr6:134937671	A/G	cg09872934	chr6:134495829	SGK1	0.53	4.6	0.38	1.03e-5	Melanoma;
TGCT	cis	rs4455778	0.659	rs4917195	chr7:49021597	T/G	cg26309511	chr7:48887640	NA	-0.43	-5.07	-0.41	1.4e-6	Lung cancer in never smokers;
TGCT	cis	rs4961252	0.505	rs12680168	chr8:142102522	A/T	cg09914555	chr8:142094789	NA	-0.39	-5.74	-0.46	6.97e-8	Isovolumetric relaxation time;Response to interferon beta therapy;
TGCT	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg27436995	chr16:743998	FBXL16	-0.47	-5.17	-0.42	9.29e-7	Height;
TGCT	cis	rs7640424	0.502	rs326359	chr3:107820619	G/A	cg09227934	chr3:107805635	CD47	0.23	4.82	0.4	4.08e-6	Body mass index;
TGCT	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg11890956	chr21:40555474	PSMG1	1.1	12.31	0.74	2.99e-23	Cognitive function;
TGCT	cis	rs7772486	0.790	rs1062067	chr6:146207563	A/G	cg23711669	chr6:146136114	FBXO30	0.89	10.18	0.67	4.61e-18	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7666738	0.830	rs10031751	chr4:98939134	G/A	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs10782582	0.593	rs6673786	chr1:76149637	C/T	cg22875332	chr1:76189707	ACADM	-0.55	-6.28	-0.49	5.25e-9	Daytime sleep phenotypes;
TGCT	trans	rs525455	1.000	rs525455	chr10:13103285	C/T	cg21721093	chr17:8906386	NA	0.66	6.85	0.52	3.03e-10	Platelet aggregation;
TGCT	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg01802117	chr1:53393560	SCP2	-0.46	-5.81	-0.46	4.91e-8	Monocyte count;
TGCT	cis	rs56104184	0.830	rs17272645	chr19:49342366	C/G	cg15549821	chr19:49342101	PLEKHA4	0.91	15.12	0.81	6.49e-30	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.85	7.0	0.53	1.44e-10	Platelet count;
TGCT	cis	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg07424592	chr7:64974309	NA	1.27	7.28	0.55	3.29e-11	Diabetic kidney disease;
TGCT	trans	rs9985766	1.000	rs9968351	chr4:151022261	G/A	cg02993991	chr19:4064177	ZBTB7A	0.57	6.7	0.52	6.59e-10	Coronary artery disease;Myocardial infarction;
TGCT	cis	rs28595532	0.920	rs115738062	chr4:119725490	C/T	cg21605333	chr4:119757512	SEC24D	1.72	8.96	0.63	3.99e-15	Cannabis dependence symptom count;
TGCT	cis	rs1348850	0.914	rs7573763	chr2:178249808	C/T	cg22681709	chr2:178499509	PDE11A	-0.35	-4.57	-0.38	1.15e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs2594989	0.887	rs9850117	chr3:11571991	C/T	cg26283222	chr3:11613257	VGLL4	0.22	4.71	0.39	6.61e-6	Circulating chemerin levels;
TGCT	cis	rs11167764	0.895	rs6882824	chr5:141474300	A/G	cg08523384	chr5:141488047	NDFIP1	-0.24	-4.81	-0.4	4.26e-6	Crohn's disease;
TGCT	cis	rs10876993	0.890	rs2640630	chr12:58067267	T/C	cg15848620	chr12:58087721	OS9	-0.72	-5.91	-0.47	3.12e-8	Celiac disease or Rheumatoid arthritis;
TGCT	cis	rs17122693	1.000	rs35014209	chr14:51054598	A/G	cg04730355	chr14:51134070	SAV1	1.23	8.63	0.61	2.45e-14	Cognitive performance;
TGCT	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg22433210	chr17:43662623	NA	1.05	7.4	0.55	1.83e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs6740322	0.895	rs6738717	chr2:43573670	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.39	-6.58	-0.51	1.17e-9	Coronary artery disease;
TGCT	cis	rs12142240	0.698	rs41294458	chr1:46810304	T/C	cg14993813	chr1:46806288	NSUN4	-0.58	-4.81	-0.4	4.34e-6	Menopause (age at onset);
TGCT	cis	rs2594989	0.943	rs7349536	chr3:11442503	C/T	cg00170343	chr3:11313890	ATG7	-0.67	-5.05	-0.41	1.57e-6	Circulating chemerin levels;
TGCT	cis	rs7666738	0.830	rs62321587	chr4:98997958	T/C	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2235642	0.821	rs2281236	chr16:1603576	G/A	cg11375102	chr16:1583810	IFT140;TMEM204	-0.3	-5.42	-0.44	2.97e-7	Coronary artery disease;
TGCT	cis	rs7666738	0.716	rs6814353	chr4:99074202	A/G	cg18180107	chr4:99064573	C4orf37	0.59	5.27	0.43	5.8e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7824557	0.602	rs11781375	chr8:11204532	A/G	cg21775007	chr8:11205619	TDH	0.72	7.02	0.53	1.27e-10	Retinal vascular caliber;
TGCT	cis	rs7953508	0.506	rs10777530	chr12:93961110	C/T	cg18151635	chr12:93972918	NA	-0.2	-4.66	-0.39	8.15e-6	Pubertal anthropometrics;
TGCT	cis	rs1034435	0.755	rs9615336	chr22:48893090	G/C	cg05992904	chr22:48892994	FAM19A5	-0.34	-4.65	-0.39	8.37e-6	Late-onset Alzheimer's disease;
TGCT	cis	rs12681287	0.547	rs7837569	chr8:87507366	C/T	cg19078186	chr8:87526527	CPNE3	-0.37	-4.57	-0.38	1.15e-5	Caudate activity during reward;
TGCT	cis	rs933688	0.941	rs6452954	chr5:90735692	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.01	9.89	0.66	2.31e-17	Smoking behavior;
TGCT	cis	rs57221529	0.766	rs12522140	chr5:587261	C/A	cg09021430	chr5:549028	NA	-0.37	-4.98	-0.41	2.07e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs1480597	0.518	rs10751358	chr10:45199194	A/G	cg12063947	chr10:45878068	ALOX5	0.26	4.44	0.37	2e-5	Parkinson's disease;
TGCT	cis	rs17374749	0.916	rs9855601	chr3:136768482	T/C	cg12473912	chr3:136751656	NA	-0.48	-7.82	-0.57	1.98e-12	Anxiety in major depressive disorder;
TGCT	cis	rs4919044	0.674	rs115089490	chr10:94793496	G/C	cg05127821	chr10:94822908	CYP26C1	-0.75	-4.75	-0.39	5.59e-6	Coronary artery disease;
TGCT	cis	rs2197308	0.565	rs4123923	chr12:37857684	T/C	cg13010199	chr12:38710504	ALG10B	0.64	5.15	0.42	9.73e-7	Morning vs. evening chronotype;
TGCT	cis	rs1670533	1.000	rs676561	chr4:1083112	C/T	cg20887711	chr4:1340912	KIAA1530	0.68	5.33	0.43	4.53e-7	Recombination rate (females);
TGCT	trans	rs208520	0.802	rs208499	chr6:66932146	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-9.93	-0.67	1.84e-17	Exhaled nitric oxide output;
TGCT	cis	rs1344694	0.566	rs4672790	chr2:216892446	C/T	cg12620499	chr2:216877984	MREG	0.84	9.85	0.66	2.9e-17	Alcohol dependence;
TGCT	cis	rs10751667	1.000	rs6597965	chr11:964476	A/G	cg06064525	chr11:970664	AP2A2	-0.33	-6.53	-0.51	1.54e-9	Alzheimer's disease (late onset);
TGCT	cis	rs4285028	0.747	rs4048703	chr3:121374361	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.92	-7.33	-0.55	2.54e-11	Multiple sclerosis;
TGCT	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg14820908	chr5:178986412	RUFY1	0.54	5.76	0.46	6.13e-8	Lung cancer;
TGCT	cis	rs28595532	0.748	rs113336496	chr4:119336957	C/T	cg21605333	chr4:119757512	SEC24D	0.85	5.43	0.44	2.84e-7	Cannabis dependence symptom count;
TGCT	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.03	0.41	1.68e-6	Prudent dietary pattern;
TGCT	cis	rs7582180	0.613	rs12988464	chr2:100946285	A/G	cg08017756	chr2:100939284	LONRF2	-0.3	-5.0	-0.41	1.93e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2072499	0.966	rs6427307	chr1:156190083	A/G	cg25208724	chr1:156163844	SLC25A44	1.08	15.41	0.81	1.37e-30	Testicular germ cell tumor;
TGCT	cis	rs2115630	0.653	rs61394864	chr15:85170174	T/C	cg11189052	chr15:85197271	WDR73	-0.74	-7.31	-0.55	2.89e-11	P wave terminal force;
TGCT	cis	rs7666738	0.830	rs7680909	chr4:98934604	A/G	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg11941060	chr3:133502564	NA	-0.25	-5.13	-0.42	1.09e-6	Iron status biomarkers;
TGCT	trans	rs9650657	0.530	rs6982381	chr8:10952500	A/T	cg15556689	chr8:8085844	FLJ10661	-0.79	-7.6	-0.56	6.16e-12	Neuroticism;
TGCT	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	5.5	0.44	2.06e-7	Height;
TGCT	cis	rs11249608	0.548	rs7732719	chr5:178463054	A/G	cg01312482	chr5:178451176	ZNF879	-0.49	-4.83	-0.4	3.96e-6	Pubertal anthropometrics;
TGCT	cis	rs4595586	0.545	rs6580894	chr12:39371951	A/G	cg26963002	chr12:38532352	NA	0.54	4.53	0.38	1.36e-5	Morning vs. evening chronotype;
TGCT	cis	rs1218582	0.510	rs2878411	chr1:154823545	C/T	cg09359103	chr1:154839909	KCNN3	-0.52	-8.22	-0.59	2.36e-13	Prostate cancer;
TGCT	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg25767906	chr1:53392781	SCP2	0.52	6.12	0.48	1.14e-8	Monocyte count;
TGCT	cis	rs9467773	0.620	rs2504599	chr6:26641060	C/T	cg05738196	chr6:26577821	NA	0.87	10.75	0.69	1.87e-19	Intelligence (multi-trait analysis);
TGCT	cis	rs10791097	0.582	rs2282578	chr11:130735691	A/T	cg14779329	chr11:130786720	SNX19	0.29	4.91	0.4	2.77e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	trans	rs57221529	0.655	rs72704791	chr5:547896	A/G	cg25482853	chr8:67687455	SGK3	1.19	9.29	0.64	6.72e-16	Lung disease severity in cystic fibrosis;
TGCT	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	4.67	0.39	7.7e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg12419862	chr22:24373484	LOC391322	-0.76	-8.11	-0.59	4.23e-13	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg23719950	chr11:63933701	MACROD1	-0.71	-5.87	-0.47	3.82e-8	Mean platelet volume;
TGCT	cis	rs4663866	0.901	rs71426512	chr2:239187128	C/T	cg17283117	chr2:239148619	HES6	0.99	4.58	0.38	1.12e-5	Irritable bowel syndrome;
TGCT	cis	rs1127311	1.000	rs1127313	chr1:154556425	A/G	cg17218026	chr1:154582156	ADAR	-0.3	-7.51	-0.56	1e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs7582180	0.629	rs11685250	chr2:100955137	C/T	cg14675211	chr2:100938903	LONRF2	0.5	4.78	0.39	4.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7302981	1.000	rs7308356	chr12:50539611	A/G	cg23855989	chr12:50355821	AQP5	-0.3	-4.5	-0.38	1.52e-5	Systolic blood pressure;
TGCT	cis	rs17376456	0.542	rs10070350	chr5:93103753	C/G	cg21475434	chr5:93447410	FAM172A	0.6	4.9	0.4	2.92e-6	Diabetic retinopathy;
TGCT	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg19901468	chr14:105411992	AHNAK2	-0.28	-5.93	-0.47	2.77e-8	Rheumatoid arthritis;
TGCT	cis	rs9926296	0.643	rs2159114	chr16:89831841	A/G	cg04287289	chr16:89883240	FANCA	0.67	6.81	0.52	3.66e-10	Vitiligo;
TGCT	cis	rs4851254	0.618	rs13033732	chr2:100644797	A/G	cg22139774	chr2:100720529	AFF3	-0.45	-4.9	-0.4	2.94e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs68170813	0.559	rs77727587	chr7:106815754	C/G	cg02696742	chr7:106810147	HBP1	-0.72	-6.28	-0.49	5.29e-9	Coronary artery disease;
TGCT	cis	rs9929218	0.551	rs8051095	chr16:68722049	G/A	cg01251360	chr16:68772225	CDH1	-0.25	-4.63	-0.38	9.19e-6	Colorectal cancer;
TGCT	cis	rs9443645	0.901	rs1027813	chr6:79552118	G/T	cg09184832	chr6:79620586	NA	0.47	5.23	0.43	6.98e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2204008	0.837	rs11181857	chr12:38413255	C/G	cg26384229	chr12:38710491	ALG10B	0.82	7.4	0.55	1.81e-11	Bladder cancer;
TGCT	cis	rs6582630	0.519	rs11520262	chr12:38333051	A/G	cg13010199	chr12:38710504	ALG10B	0.59	4.53	0.38	1.37e-5	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs3771570	1.000	rs62193210	chr2:242323616	G/A	cg21155796	chr2:242212141	HDLBP	0.94	6.69	0.51	6.9e-10	Prostate cancer;
TGCT	cis	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg03213289	chr20:61660250	NA	0.68	9.9	0.66	2.25e-17	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2204008	0.720	rs11180923	chr12:38255172	A/T	cg26384229	chr12:38710491	ALG10B	0.86	7.48	0.56	1.19e-11	Bladder cancer;
TGCT	cis	rs4372836	0.504	rs6737027	chr2:29070805	A/G	cg09522027	chr2:28974177	PPP1CB	0.57	5.66	0.45	9.84e-8	Body mass index;
TGCT	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg23131131	chr22:24373011	LOC391322	-0.72	-7.73	-0.57	3.12e-12	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg06238570	chr21:40685208	BRWD1	0.72	6.58	0.51	1.16e-9	Cognitive function;
TGCT	cis	rs7208859	0.623	rs426434	chr17:28925353	C/T	cg13385521	chr17:29058706	SUZ12P	0.81	4.84	0.4	3.78e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs9486719	1.000	rs11153058	chr6:97012746	C/T	cg06623918	chr6:96969491	KIAA0776	-0.99	-8.05	-0.59	5.65e-13	Migraine;Coronary artery disease;
TGCT	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg24675658	chr1:53192096	ZYG11B	0.7	7.98	0.58	8.59e-13	Monocyte count;
TGCT	cis	rs3749237	0.964	rs7431078	chr3:49808190	G/A	cg10152585	chr3:50297680	NA	0.5	4.65	0.39	8.38e-6	Resting heart rate;
TGCT	cis	rs11098499	0.657	rs4463052	chr4:120313258	T/C	cg09307838	chr4:120376055	NA	0.65	6.39	0.5	3.02e-9	Corneal astigmatism;
TGCT	cis	rs35883536	0.631	rs2783704	chr1:101040652	T/A	cg06223162	chr1:101003688	GPR88	0.42	8.0	0.58	7.5e-13	Monocyte count;
TGCT	cis	rs992157	0.835	rs6707559	chr2:219142773	C/T	cg00012203	chr2:219082015	ARPC2	0.8	7.98	0.58	8.26e-13	Colorectal cancer;
TGCT	cis	rs17108533	0.588	rs34799286	chr14:71301968	A/T	cg23900759	chr14:71108106	TTC9	-1.14	-4.61	-0.38	9.92e-6	Response to antipsychotic treatment in schizophrenia (reasoning);
TGCT	cis	rs2982552	0.844	rs3020346	chr6:152056771	C/T	cg22157087	chr6:152012887	ESR1	-0.21	-5.38	-0.43	3.6e-7	Bone properties (heel);
TGCT	cis	rs7904368	0.754	rs12246217	chr10:16853349	G/C	cg14835575	chr10:16859367	RSU1	0.72	7.72	0.57	3.43e-12	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
TGCT	cis	rs9902453	0.817	rs2617880	chr17:28106118	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-7.19	-0.54	5.37e-11	Coffee consumption (cups per day);
TGCT	cis	rs9549367	0.713	rs4907598	chr13:113861385	C/T	cg09473364	chr13:112927190	NA	0.31	4.77	0.39	5e-6	Platelet distribution width;
TGCT	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.5	-5.58	-0.45	1.43e-7	Longevity;Endometriosis;
TGCT	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg22535103	chr8:58192502	C8orf71	-0.41	-5.14	-0.42	1.03e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4455778	0.565	rs7809432	chr7:49014472	C/T	cg26309511	chr7:48887640	NA	-0.42	-5.34	-0.43	4.26e-7	Lung cancer in never smokers;
TGCT	cis	rs9372498	0.536	rs62424195	chr6:118812108	T/A	cg21191810	chr6:118973309	C6orf204	-0.35	-4.72	-0.39	6.2e-6	Diastolic blood pressure;
TGCT	cis	rs7727544	0.507	rs9791170	chr5:131569627	A/G	cg24060327	chr5:131705240	SLC22A5	-0.6	-6.31	-0.49	4.4e-9	Blood metabolite levels;
TGCT	trans	rs1496653	0.602	rs77659073	chr3:23618632	G/A	cg02770683	chr12:57597238	LRP1	0.37	6.68	0.51	7.38e-10	Type 2 diabetes;
TGCT	cis	rs716804	0.654	rs7928170	chr11:10178845	T/C	cg17061862	chr11:9590431	NA	-0.37	-4.87	-0.4	3.37e-6	Neuroticism;
TGCT	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg02725872	chr8:58115012	NA	-0.39	-4.79	-0.4	4.7e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9400467	0.537	rs12213248	chr6:111499394	G/C	cg15721981	chr6:111408429	SLC16A10	0.71	4.6	0.38	1.04e-5	Blood metabolite levels;Amino acid levels;
TGCT	cis	rs9611565	0.559	rs7290991	chr22:41964361	C/G	cg06634786	chr22:41940651	POLR3H	-0.88	-8.25	-0.6	1.98e-13	Vitiligo;
TGCT	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg20607798	chr8:58055168	NA	0.49	4.52	0.38	1.43e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7568458	1.000	rs7568458	chr2:85788175	T/A	cg02493740	chr2:85810744	VAMP5	-0.29	-5.16	-0.42	9.58e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs10089	0.953	rs3805615	chr5:127519049	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.85	8.27	0.6	1.8e-13	Ileal carcinoids;
TGCT	cis	rs9831754	0.906	rs7611939	chr3:78392751	A/C	cg06138941	chr3:78371609	NA	-0.49	-5.4	-0.44	3.25e-7	Calcium levels;
TGCT	cis	rs72781680	0.898	rs72786286	chr2:24074659	T/A	cg08917208	chr2:24149416	ATAD2B	0.77	4.69	0.39	7.06e-6	Lymphocyte counts;
TGCT	cis	rs4372836	0.504	rs12714249	chr2:29055916	G/A	cg09522027	chr2:28974177	PPP1CB	-0.55	-5.51	-0.44	1.97e-7	Body mass index;
TGCT	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg15242686	chr22:24348715	GSTTP1	0.41	5.5	0.44	2.07e-7	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7178572	0.633	rs4886877	chr15:77838535	C/G	cg22256960	chr15:77711686	NA	-0.79	-7.47	-0.56	1.26e-11	Type 2 diabetes;
TGCT	cis	rs13188771	0.690	rs10040426	chr5:100896781	T/C	cg10455971	chr5:101119566	NA	0.44	4.45	0.37	1.87e-5	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg19774624	chr17:42201019	HDAC5	-0.83	-8.49	-0.61	5.19e-14	Total body bone mineral density;
TGCT	cis	rs1046896	0.576	rs8067360	chr17:80694826	T/C	cg00960700	chr17:80709150	TBCD	0.5	4.93	0.4	2.61e-6	Glycated hemoglobin levels;
TGCT	cis	rs4786125	0.588	rs1473516	chr16:6923077	C/T	cg03623568	chr16:6915990	A2BP1	-0.44	-6.44	-0.5	2.39e-9	Heart rate variability traits (SDNN);
TGCT	cis	rs9818758	0.607	rs34343820	chr3:49309534	C/G	cg00383909	chr3:49044727	WDR6	1.28	6.57	0.51	1.23e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs7666738	0.830	rs7697315	chr4:98938764	T/C	cg17366294	chr4:99064904	C4orf37	0.72	7.39	0.55	1.87e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	7.24	0.55	4.17e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs12497850	0.931	rs7431710	chr3:48935583	G/A	cg05785598	chr3:49045655	WDR6	0.35	4.72	0.39	6.35e-6	Parkinson's disease;
TGCT	cis	rs939574	1.000	rs2293078	chr2:220100683	C/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.05	6.38	0.5	3.13e-9	Platelet distribution width;
TGCT	cis	rs500492	0.542	rs416055	chr16:1074931	G/A	cg01366354	chr16:1075121	NA	0.36	5.23	0.43	6.99e-7	Polycystic ovary syndrome;
TGCT	cis	rs1153858	1.000	rs1145085	chr15:45657804	A/G	cg14582100	chr15:45693742	SPATA5L1	0.48	5.69	0.46	8.56e-8	Homoarginine levels;
TGCT	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg17554472	chr22:41940697	POLR3H	0.49	5.16	0.42	9.72e-7	Vitiligo;
TGCT	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg13906792	chr15:75199810	C15orf17	-0.2	-4.46	-0.37	1.85e-5	Breast cancer;
TGCT	cis	rs6586111	1.000	rs7071672	chr10:82375965	C/G	cg03086067	chr10:82368399	SH2D4B	-0.23	-4.54	-0.38	1.33e-5	Capecitabine sensitivity;
TGCT	trans	rs2688608	0.592	rs10762559	chr10:75486453	G/C	cg13918328	chr10:52500089	ASAH2B	0.68	6.7	0.52	6.42e-10	Inflammatory bowel disease;
TGCT	cis	rs36051895	0.623	rs7859361	chr9:5237479	C/T	cg02405213	chr9:5042618	JAK2	-0.68	-8.01	-0.58	7.18e-13	Pediatric autoimmune diseases;
TGCT	cis	rs4654899	0.833	rs10916858	chr1:21086602	C/G	cg01072550	chr1:21505969	NA	-0.49	-7.89	-0.58	1.37e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs10992471	0.603	rs2094281	chr9:95290654	C/G	cg13798575	chr9:95087839	CENPP;NOL8	0.56	5.28	0.43	5.49e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs10984561	0.881	rs73540220	chr9:122249904	C/T	cg14242995	chr9:122249943	NA	0.75	6.12	0.48	1.16e-8	Pulmonary function decline;
TGCT	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg04234412	chr22:24373322	LOC391322	0.93	8.57	0.61	3.38e-14	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs2147959	0.739	rs11587839	chr1:228630979	C/T	cg22700015	chr1:228743131	NA	-0.57	-4.53	-0.38	1.35e-5	Adult asthma;
TGCT	cis	rs9926296	0.562	rs4785725	chr16:89893243	A/G	cg01719998	chr16:89642051	CPNE7	-0.44	-4.46	-0.37	1.81e-5	Vitiligo;
TGCT	cis	rs2239547	0.522	rs6773040	chr3:52935428	C/A	cg11645453	chr3:52864694	ITIH4	-0.37	-6.08	-0.48	1.37e-8	Schizophrenia;
TGCT	cis	rs9902453	0.817	rs2729435	chr17:28121532	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-6.81	-0.52	3.65e-10	Coffee consumption (cups per day);
TGCT	cis	rs11190604	1.000	rs1106565	chr10:102211613	T/C	cg16342193	chr10:102329863	NA	-0.4	-5.31	-0.43	4.85e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs9611565	0.879	rs2235845	chr22:41729294	T/G	cg03806693	chr22:41940476	POLR3H	-0.86	-9.19	-0.64	1.16e-15	Vitiligo;
TGCT	cis	rs36093844	0.898	rs11234462	chr11:85596924	C/T	cg25872744	chr11:85566296	CCDC83	-0.48	-4.71	-0.39	6.45e-6	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
TGCT	cis	rs1901167	0.908	rs1061442	chr5:40982620	G/T	cg02441090	chr5:41871058	OXCT1	-0.29	-4.45	-0.37	1.92e-5	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs9650657	0.537	rs4841457	chr8:10773511	T/G	cg27411982	chr8:10470053	RP1L1	-0.21	-4.44	-0.37	1.94e-5	Neuroticism;
TGCT	cis	rs11623869	0.711	rs2403173	chr14:103909289	T/C	cg26031613	chr14:104095156	KLC1	0.87	9.75	0.66	5.07e-17	Bone mineral density;
TGCT	cis	rs11252926	0.502	rs7072510	chr10:455596	C/T	cg18196295	chr10:418757	DIP2C	0.3	4.85	0.4	3.6e-6	Psychosis in Alzheimer's disease;
TGCT	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg05025164	chr4:1340916	KIAA1530	0.8	6.92	0.53	2.16e-10	Longevity;
TGCT	cis	rs11085466	1.000	rs75079001	chr19:21757375	A/G	cg02997983	chr19:21646781	NA	-0.64	-4.52	-0.38	1.43e-5	Colorectal or endometrial cancer;
TGCT	cis	rs35146811	0.735	rs6948729	chr7:99787372	A/G	cg04778012	chr7:99775508	STAG3;GPC2	0.35	4.93	0.41	2.55e-6	Coronary artery disease;
TGCT	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg24846343	chr22:24311635	DDTL	0.24	6.29	0.49	4.88e-9	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs611744	0.647	rs615126	chr8:109247619	C/T	cg21045802	chr8:109455806	TTC35	0.72	7.28	0.55	3.32e-11	Dupuytren's disease;
TGCT	cis	rs950169	0.580	rs11634320	chr15:85172183	A/C	cg11189052	chr15:85197271	WDR73	-0.73	-6.01	-0.47	1.96e-8	Schizophrenia;
TGCT	cis	rs6969780	0.630	rs3735530	chr7:27189982	C/T	cg17457637	chr7:27170717	HOXA4	-0.44	-4.81	-0.4	4.29e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs1008375	0.932	rs13109475	chr4:17677565	C/G	cg18681998	chr4:17616180	MED28	-0.86	-8.49	-0.61	5.19e-14	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs8072100	0.840	rs2136751	chr17:45456093	A/G	cg08085267	chr17:45401833	C17orf57	-0.46	-5.08	-0.42	1.33e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.6	-5.03	-0.41	1.68e-6	Lung function (FEV1/FVC);
TGCT	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg27454412	chr7:1067447	C7orf50	0.6	4.7	0.39	6.76e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs2115630	0.967	rs11073702	chr15:85310071	G/A	cg12501888	chr15:85177176	SCAND2	-0.48	-4.49	-0.37	1.6e-5	P wave terminal force;
TGCT	cis	rs8031584	0.723	rs11632229	chr15:31179534	A/G	cg08704250	chr15:31115839	NA	0.44	6.28	0.49	5.29e-9	Huntington's disease progression;
TGCT	cis	rs9814567	1.000	rs1917130	chr3:134313773	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.95	9.14	0.63	1.54e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.61	0.38	9.85e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9985766	0.916	rs62339880	chr4:150989230	G/A	cg05926478	chr4:151174724	DCLK2	-0.24	-4.64	-0.38	8.63e-6	Coronary artery disease;Myocardial infarction;
TGCT	cis	rs9486715	1.000	rs11153085	chr6:97066355	A/T	cg18709589	chr6:96969512	KIAA0776	-0.77	-7.12	-0.54	7.74e-11	Headache;
TGCT	cis	rs858239	0.601	rs73272053	chr7:23155525	A/G	cg05602783	chr7:23145260	KLHL7	-0.71	-6.11	-0.48	1.2e-8	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs8013055	0.898	rs8014913	chr14:105977313	T/C	cg23356831	chr14:105996513	TMEM121	0.41	6.33	0.49	4.01e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs7552404	1.000	rs4646961	chr1:76217169	G/A	cg22875332	chr1:76189707	ACADM	0.76	9.2	0.64	1.1e-15	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs10114408	0.921	rs1890374	chr9:96661146	A/G	cg13679303	chr9:96623674	NA	-0.36	-4.63	-0.38	9.04e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs798766	0.779	rs55895920	chr4:1735930	C/T	cg05874882	chr4:1763078	NA	-0.35	-4.45	-0.37	1.86e-5	Bladder cancer;Urinary bladder cancer;
TGCT	cis	rs9611565	0.729	rs202654	chr22:41841034	G/A	cg17554472	chr22:41940697	POLR3H	0.46	5.0	0.41	1.89e-6	Vitiligo;
TGCT	cis	rs7617773	0.780	rs34630841	chr3:48343261	G/A	cg11946769	chr3:48343235	NME6	0.82	7.09	0.54	9.1e-11	Coronary artery disease;
TGCT	cis	rs11642862	1.000	rs111954099	chr16:30789623	A/G	cg02466173	chr16:30829666	NA	-0.36	-4.45	-0.37	1.91e-5	Tonsillectomy;
TGCT	cis	rs7829975	0.533	rs13274028	chr8:8729193	A/C	cg08975724	chr8:8085496	FLJ10661	0.51	4.58	0.38	1.13e-5	Mood instability;
TGCT	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg11764359	chr7:65958608	NA	-0.54	-4.9	-0.4	2.89e-6	Aortic root size;
TGCT	cis	rs10875595	0.836	rs6868387	chr5:140660814	G/A	cg20560182	chr5:140700478	TAF7	-0.66	-5.06	-0.41	1.49e-6	Pulmonary function decline;
TGCT	cis	rs9611565	0.559	rs5758412	chr22:42080803	T/A	cg13695892	chr22:41940480	POLR3H	0.89	8.6	0.61	2.92e-14	Vitiligo;
TGCT	cis	rs12519773	0.597	rs4342312	chr5:92477890	C/A	cg18783429	chr5:92414398	NA	0.31	4.66	0.39	7.94e-6	Migraine;
TGCT	cis	rs4555082	0.834	rs2735825	chr14:105710900	G/A	cg01266790	chr14:105781312	PACS2	0.55	4.49	0.37	1.58e-5	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs9303401	0.659	rs66514313	chr17:56714057	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs4644046	0.545	rs2397048	chr6:51430852	A/G	cg14391730	chr6:52021665	NA	0.31	4.46	0.37	1.8e-5	Coronary artery disease;
TGCT	cis	rs617219	0.698	rs7379187	chr5:78521354	T/C	cg05890484	chr5:78407552	BHMT	0.36	5.01	0.41	1.84e-6	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs6424115	0.830	rs2502994	chr1:24199363	T/C	cg15997130	chr1:24165203	NA	0.86	9.44	0.65	2.86e-16	Immature fraction of reticulocytes;
TGCT	cis	rs2227564	0.620	rs7098573	chr10:75580014	G/A	cg04320760	chr10:75533139	FUT11	-0.32	-4.51	-0.38	1.49e-5	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs12497850	0.931	rs7621015	chr3:49016056	A/G	cg05785598	chr3:49045655	WDR6	0.37	4.83	0.4	3.98e-6	Parkinson's disease;
TGCT	trans	rs797680	0.856	rs10874764	chr1:93661342	C/A	cg27528825	chr2:159282178	CCDC148	-0.35	-6.82	-0.52	3.53e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	trans	rs797680	0.856	rs6685271	chr1:93634590	C/A	cg27528825	chr2:159282178	CCDC148	-0.35	-6.78	-0.52	4.27e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
TGCT	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg20891558	chr2:74357851	NA	0.62	9.13	0.63	1.62e-15	Gestational age at birth (maternal effect);
TGCT	cis	rs7119	0.700	rs4886883	chr15:77888924	C/T	cg27398640	chr15:77910606	LINGO1	-0.31	-6.65	-0.51	8.37e-10	Type 2 diabetes;
TGCT	cis	rs858239	0.632	rs1985769	chr7:23122506	T/G	cg05602783	chr7:23145260	KLHL7	-0.6	-5.02	-0.41	1.76e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs2688608	0.592	rs11000758	chr10:75493610	A/T	cg19442545	chr10:75533431	FUT11	-0.37	-5.77	-0.46	5.89e-8	Inflammatory bowel disease;
TGCT	cis	rs8037137	0.915	rs8026714	chr15:91522253	G/A	cg23684204	chr15:91497937	RCCD1	0.39	4.57	0.38	1.17e-5	Platelet count;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
TGCT	cis	rs1008375	1.000	rs1974624	chr4:17650281	A/G	cg16339924	chr4:17578868	LAP3	0.63	5.26	0.43	6.22e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2549003	1.000	rs9282761	chr5:131822224	T/C	cg02551604	chr5:131831745	NA	-0.9	-12.1	-0.74	9.75e-23	Asthma (sex interaction);
TGCT	cis	rs3617	0.599	rs12487379	chr3:52895785	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.48	-4.73	-0.39	5.88e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs3772130	0.962	rs9812228	chr3:121495682	C/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.72	0.39	6.25e-6	Cognitive performance;
TGCT	cis	rs9381040	0.631	rs13216201	chr6:41162060	G/T	cg03526776	chr6:41159608	TREML2	0.29	5.59	0.45	1.37e-7	Alzheimer's disease (late onset);
TGCT	cis	rs1008375	0.966	rs2191504	chr4:17675592	C/G	cg18681998	chr4:17616180	MED28	0.9	10.33	0.68	1.96e-18	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9357506	0.967	rs6911055	chr6:46307400	G/A	cg21115430	chr6:46460003	NA	-0.26	-5.17	-0.42	9.2e-7	Body mass index;
TGCT	cis	rs587847	0.558	rs643132	chr15:37668511	G/A	cg16890051	chr15:37175029	LOC145845	-0.38	-4.49	-0.37	1.6e-5	Intraocular pressure;
TGCT	cis	rs2857078	0.745	rs4793085	chr17:42320732	A/C	cg19774624	chr17:42201019	HDAC5	0.71	7.27	0.55	3.55e-11	Red cell distribution width;Reticulocyte count;
TGCT	cis	rs6988636	0.536	rs16898043	chr8:124155886	A/G	cg27053337	chr8:124217698	FAM83A	0.74	5.57	0.45	1.51e-7	Urinary uromodulin levels;
TGCT	cis	rs9341808	0.718	rs10943699	chr6:80940541	G/A	cg08355045	chr6:80787529	NA	0.29	5.16	0.42	9.42e-7	Sitting height ratio;
TGCT	cis	rs2404602	0.692	rs1838048	chr15:76931679	A/G	cg22467129	chr15:76604101	ETFA	-0.45	-5.11	-0.42	1.18e-6	Blood metabolite levels;
TGCT	cis	rs4654899	0.965	rs61781115	chr1:21322860	C/T	cg01072550	chr1:21505969	NA	-0.5	-7.94	-0.58	1.04e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs6547741	1.000	rs1972669	chr2:27767107	T/G	cg27432699	chr2:27873401	GPN1	0.18	4.66	0.39	8.09e-6	Oral cavity cancer;
TGCT	cis	rs2204008	0.840	rs7957966	chr12:37953629	A/G	cg26384229	chr12:38710491	ALG10B	-0.7	-6.12	-0.48	1.11e-8	Bladder cancer;
TGCT	trans	rs7819412	0.775	rs4545055	chr8:10935366	T/C	cg06636001	chr8:8085503	FLJ10661	-0.77	-7.07	-0.54	1.01e-10	Triglycerides;
TGCT	cis	rs295140	0.803	rs4516415	chr2:201129608	C/G	cg04283868	chr2:201171347	SPATS2L	0.52	5.2	0.42	8.14e-7	QT interval;
TGCT	cis	rs55883249	1.000	rs62119392	chr2:9714033	G/C	cg23886495	chr2:9695866	ADAM17	0.83	4.99	0.41	2.02e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs13064411	0.696	rs6768979	chr3:113204149	G/A	cg18753928	chr3:113234510	CCDC52	-0.7	-5.75	-0.46	6.6e-8	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg08736216	chr1:53307985	ZYG11A	-0.25	-4.71	-0.39	6.53e-6	Monocyte count;
TGCT	cis	rs933688	1.000	rs1035477	chr5:90743325	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.04	8.8	0.62	9.68e-15	Smoking behavior;
TGCT	cis	rs7552404	0.656	rs11161792	chr1:76336746	C/T	cg10523679	chr1:76189770	ACADM	0.69	6.19	0.49	8e-9	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs2880765	0.835	rs7169632	chr15:86044667	T/G	cg13263323	chr15:86062960	AKAP13	-0.23	-4.82	-0.4	4.1e-6	Coronary artery disease;
TGCT	cis	rs7584330	1.000	rs7584330	chr2:238387228	A/G	cg08992911	chr2:238395768	MLPH	0.67	5.36	0.43	3.89e-7	Prostate cancer;
TGCT	cis	rs62244186	0.627	rs12386385	chr3:44457540	A/G	cg10263370	chr3:44754102	ZNF502	-0.38	-4.47	-0.37	1.75e-5	Depressive symptoms;
TGCT	cis	rs7553864	0.614	rs1886634	chr1:87614821	C/T	cg17420885	chr1:87600446	LOC339524	0.37	4.92	0.4	2.72e-6	Smoking behavior;
TGCT	cis	rs3096299	0.504	rs4785574	chr16:89568875	A/G	cg02187348	chr16:89574699	SPG7	0.55	5.7	0.46	8.45e-8	Multiple myeloma (IgH translocation);
TGCT	cis	rs950169	0.922	rs11638445	chr15:85137694	C/A	cg11189052	chr15:85197271	WDR73	0.76	6.33	0.49	4.13e-9	Schizophrenia;
TGCT	cis	rs3617	0.573	rs4687680	chr3:52907372	G/A	cg11645453	chr3:52864694	ITIH4	0.26	5.05	0.41	1.54e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9549367	0.789	rs9549711	chr13:113900557	C/T	cg00898013	chr13:113819073	PROZ	-0.4	-5.03	-0.41	1.64e-6	Platelet distribution width;
TGCT	cis	rs3771570	1.000	rs60604866	chr2:242352257	A/G	cg21155796	chr2:242212141	HDLBP	0.94	6.69	0.51	6.97e-10	Prostate cancer;
TGCT	cis	rs11650494	0.831	rs73324348	chr17:47455752	G/A	cg08112188	chr17:47440006	ZNF652	0.92	5.04	0.41	1.62e-6	Prostate cancer;
TGCT	cis	rs933688	0.938	rs10063683	chr5:90714595	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.98	8.03	0.58	6.35e-13	Smoking behavior;
TGCT	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg18402987	chr7:1209562	NA	0.78	6.64	0.51	8.96e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg17054783	chr10:134559939	INPP5A	0.23	4.69	0.39	7.06e-6	Migraine;
TGCT	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg26354017	chr1:205819088	PM20D1	0.57	7.08	0.54	9.44e-11	Menarche (age at onset);
TGCT	cis	rs6121246	0.909	rs6060960	chr20:30394517	G/T	cg18721089	chr20:30220636	NA	0.41	4.65	0.39	8.34e-6	Mean corpuscular hemoglobin;
TGCT	trans	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg13615516	chr5:77269221	NA	0.67	8.36	0.6	1.09e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs35934224	0.783	rs7288061	chr22:19864239	C/T	cg11182965	chr22:19864308	TXNRD2	-0.38	-5.2	-0.42	7.82e-7	Glaucoma (primary open-angle);
TGCT	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg26668828	chr6:292823	DUSP22	-0.84	-8.7	-0.62	1.71e-14	Menopause (age at onset);
TGCT	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg10295955	chr4:187884368	NA	-0.93	-12.52	-0.75	9.29e-24	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs514406	0.505	rs269290	chr1:53167027	A/T	cg16325326	chr1:53192061	ZYG11B	0.85	11.53	0.72	2.38e-21	Monocyte count;
TGCT	cis	rs644799	0.763	rs2950521	chr11:95536870	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	10.57	0.69	5.17e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs727563	0.555	rs5751136	chr22:42075581	T/A	cg06481639	chr22:41940642	POLR3H	0.72	6.33	0.49	4e-9	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs9486715	0.838	rs9486275	chr6:96901187	C/T	cg18709589	chr6:96969512	KIAA0776	0.79	7.77	0.57	2.5e-12	Headache;
TGCT	cis	rs2204008	0.837	rs11612125	chr12:38213212	C/T	cg13010199	chr12:38710504	ALG10B	0.62	4.96	0.41	2.32e-6	Bladder cancer;
TGCT	cis	rs55794721	0.509	rs2375313	chr1:25748235	G/A	cg00786635	chr1:25594202	NA	0.6	6.27	0.49	5.44e-9	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.6	-6.01	-0.47	1.96e-8	Bipolar disorder;
TGCT	cis	rs9911578	0.967	rs1267542	chr17:56654690	T/C	cg05425664	chr17:57184151	TRIM37	0.63	6.22	0.49	6.92e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs17767294	0.708	rs72846788	chr6:28130843	A/G	cg08851530	chr6:28072375	NA	1.47	6.82	0.52	3.64e-10	Parkinson's disease;
TGCT	cis	rs2688608	0.933	rs2633307	chr10:75653881	G/A	cg04320760	chr10:75533139	FUT11	-0.29	-4.55	-0.38	1.27e-5	Inflammatory bowel disease;
TGCT	cis	rs17270561	0.887	rs9358870	chr6:25719210	T/C	cg17042849	chr6:26104293	HIST1H4C	-0.69	-4.63	-0.38	8.93e-6	Iron status biomarkers;
TGCT	cis	rs926938	0.584	rs1299780	chr1:115366014	G/A	cg12756093	chr1:115239321	AMPD1	0.42	6.12	0.48	1.12e-8	Autism;
TGCT	cis	rs1801251	0.963	rs35362030	chr2:233612845	A/G	cg25237894	chr2:233734115	C2orf82	0.32	5.68	0.45	8.93e-8	Coronary artery disease;
TGCT	cis	rs2204008	0.837	rs11168504	chr12:37964922	G/T	cg26384229	chr12:38710491	ALG10B	0.86	7.77	0.57	2.55e-12	Bladder cancer;
TGCT	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg22105103	chr4:187893119	NA	-0.33	-4.45	-0.37	1.86e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg24531977	chr5:56204891	C5orf35	-0.71	-5.22	-0.42	7.41e-7	Type 2 diabetes;
TGCT	cis	rs4642101	0.534	rs13316229	chr3:12807371	C/T	cg04715183	chr3:11886989	C3orf31	-0.17	-4.44	-0.37	2e-5	QRS complex (12-leadsum);
TGCT	cis	rs66573146	0.831	rs56320732	chr4:6974319	G/A	cg05069807	chr4:6945702	TBC1D14	0.32	5.01	0.41	1.83e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs7568458	0.636	rs11126995	chr2:85792408	A/T	cg02493740	chr2:85810744	VAMP5	-0.31	-6.04	-0.48	1.69e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs6671200	0.920	rs259350	chr1:95724831	G/C	cg20701556	chr1:95698924	RWDD3	-0.67	-5.63	-0.45	1.13e-7	Stearic acid (18:0) levels;
TGCT	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg22633769	chr20:60982531	CABLES2	-0.55	-4.53	-0.38	1.4e-5	Colorectal cancer;
TGCT	cis	rs611744	0.583	rs1448148	chr8:109333074	T/A	cg18478394	chr8:109455254	TTC35	0.44	4.5	0.37	1.54e-5	Dupuytren's disease;
TGCT	cis	rs7666738	0.822	rs11097599	chr4:98959562	T/A	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs56104184	0.775	rs17272700	chr19:49391770	G/A	cg17863274	chr19:49399704	TULP2	-0.54	-7.43	-0.55	1.58e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs12681287	0.752	rs12679266	chr8:87258833	T/C	cg27223183	chr8:87520930	FAM82B	-0.82	-5.83	-0.46	4.5e-8	Caudate activity during reward;
TGCT	cis	rs7582180	0.764	rs11686293	chr2:100922830	C/T	cg14675211	chr2:100938903	LONRF2	0.49	4.8	0.4	4.49e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9902453	0.619	rs1038088	chr17:28074563	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.8	-7.97	-0.58	8.91e-13	Coffee consumption (cups per day);
TGCT	cis	rs7914558	0.966	rs3902934	chr10:104746649	A/G	cg15744005	chr10:104629667	AS3MT	-0.4	-4.91	-0.4	2.83e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs72627509	0.680	rs3733309	chr4:57857188	A/G	cg26694713	chr4:57773883	REST	0.62	4.66	0.39	8.01e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs13191362	0.507	rs2803083	chr6:163111199	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.58	5.4	0.44	3.23e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs10431058	0.684	rs539814	chr11:107466778	G/T	cg18204760	chr11:107461044	ELMOD1;LOC643923	0.59	5.04	0.41	1.6e-6	Common traits (Other);
TGCT	cis	rs858239	0.601	rs4140959	chr7:23170776	C/T	cg05602783	chr7:23145260	KLHL7	-0.63	-5.28	-0.43	5.64e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs3820068	0.580	rs12760698	chr1:16009814	G/A	cg05660106	chr1:15850417	CASP9	0.65	5.98	0.47	2.2e-8	Systolic blood pressure;
TGCT	cis	rs7833790	0.685	rs13255262	chr8:82728024	T/G	cg17211192	chr8:82754475	SNX16	-0.95	-8.83	-0.62	8.45e-15	Diastolic blood pressure;
TGCT	cis	rs208520	0.690	rs207082	chr6:66773796	G/A	cg07460842	chr6:66804631	NA	-0.95	-10.19	-0.67	4.44e-18	Exhaled nitric oxide output;
TGCT	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg00149659	chr3:10157352	C3orf10	0.93	6.0	0.47	2.05e-8	Alzheimer's disease;
TGCT	cis	rs4746818	1.000	rs6480385	chr10:70904785	A/T	cg04149295	chr10:70884716	VPS26A	0.78	5.37	0.43	3.68e-7	Left atrial antero-posterior diameter;
TGCT	cis	rs1971762	0.545	rs10876466	chr12:53981426	G/C	cg16917193	chr12:54089295	NA	0.89	9.11	0.63	1.74e-15	Height;
TGCT	cis	rs6690583	0.623	rs2083284	chr1:85440023	C/T	cg20280350	chr1:85513789	MCOLN3	-0.67	-4.5	-0.37	1.52e-5	Serum sulfate level;
TGCT	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg17971929	chr21:40555470	PSMG1	0.92	7.81	0.57	2.06e-12	Cognitive function;
TGCT	cis	rs7223966	0.960	rs2319990	chr17:61705397	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	4.93	0.4	2.59e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg18876405	chr7:65276391	NA	-0.35	-5.2	-0.42	7.81e-7	Aortic root size;
TGCT	cis	rs28595532	0.841	rs115851302	chr4:119776504	C/T	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs9399401	0.667	rs6903424	chr6:142699948	A/C	cg03128060	chr6:142623767	GPR126	0.36	4.49	0.37	1.62e-5	Chronic obstructive pulmonary disease;
TGCT	cis	rs727505	0.721	rs56269941	chr7:124768732	T/A	cg23710748	chr7:124431027	NA	-0.25	-4.44	-0.37	1.97e-5	Lewy body disease;
TGCT	cis	rs524023	1.000	rs524023	chr11:64358265	C/T	cg07733098	chr11:64478343	NRXN2	-0.31	-4.64	-0.38	8.56e-6	Urate levels in obese individuals;
TGCT	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg13732083	chr21:47605072	C21orf56	0.35	4.69	0.39	7.17e-6	Testicular germ cell tumor;
TGCT	cis	rs2303759	1.000	rs2303759	chr19:49869051	T/G	cg22307029	chr19:49891270	CCDC155	0.56	5.28	0.43	5.56e-7	Multiple sclerosis;
TGCT	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg11644478	chr21:40555479	PSMG1	0.96	9.96	0.67	1.58e-17	Cognitive function;
TGCT	cis	rs7829975	0.514	rs2945873	chr8:8260445	C/T	cg15556689	chr8:8085844	FLJ10661	0.75	6.77	0.52	4.56e-10	Mood instability;
TGCT	cis	rs13326165	0.663	rs634382	chr3:52482851	A/G	cg27565382	chr3:53032988	SFMBT1	-0.37	-4.87	-0.4	3.29e-6	HDL cholesterol;HDL cholesterol levels;
TGCT	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg06481639	chr22:41940642	POLR3H	-0.76	-6.97	-0.53	1.65e-10	Vitiligo;
TGCT	cis	rs7772486	0.686	rs9399564	chr6:146078907	C/T	cg05347473	chr6:146136440	FBXO30	-0.5	-4.76	-0.39	5.39e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7043114	0.525	rs4744134	chr9:95246833	A/G	cg14631576	chr9:95140430	CENPP	0.29	4.64	0.38	8.83e-6	Height;
TGCT	cis	rs9911578	0.967	rs4132925	chr17:56938016	C/G	cg12560992	chr17:57184187	TRIM37	-0.76	-9.39	-0.64	3.77e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg27170947	chr2:26402098	FAM59B	-0.39	-4.46	-0.37	1.8e-5	Gut microbiome composition (summer);
TGCT	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg02788857	chr8:22132959	PIWIL2	0.28	5.11	0.42	1.2e-6	Hypertriglyceridemia;
TGCT	cis	rs4713118	0.868	rs9468220	chr6:27732976	A/G	cg20933634	chr6:27740509	NA	-0.34	-4.75	-0.39	5.58e-6	Parkinson's disease;
TGCT	cis	rs3806843	0.801	rs801171	chr5:140115303	G/A	cg19875535	chr5:140030758	IK	-0.35	-5.94	-0.47	2.63e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs11935078	chr4:99010476	T/A	cg05340658	chr4:99064831	C4orf37	0.48	5.43	0.44	2.92e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2439831	0.850	rs2957637	chr15:43951118	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.93	6.72	0.52	5.83e-10	Lung cancer in ever smokers;
TGCT	cis	rs4750440	0.637	rs2447010	chr10:14032115	T/C	cg25464840	chr10:14372910	FRMD4A	0.33	4.46	0.37	1.82e-5	Adiponectin levels;
TGCT	cis	rs2153535	0.541	rs9328477	chr6:8519109	T/C	cg07606381	chr6:8435919	SLC35B3	0.54	5.01	0.41	1.86e-6	Motion sickness;
TGCT	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg03388025	chr16:89894329	SPIRE2	0.53	9.45	0.65	2.66e-16	Vitiligo;
TGCT	cis	rs67478160	0.634	rs2295140	chr14:104216293	C/T	cg26031613	chr14:104095156	KLC1	-0.64	-6.49	-0.5	1.89e-9	Schizophrenia;
TGCT	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg04944784	chr2:26401820	FAM59B	-0.78	-6.56	-0.51	1.34e-9	Gut microbiome composition (summer);
TGCT	cis	rs72627509	0.904	rs58408429	chr4:57769824	T/C	cg26694713	chr4:57773883	REST	0.72	6.46	0.5	2.14e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs6964587	0.967	rs10953065	chr7:91808915	A/G	cg22709100	chr7:91322751	NA	-0.28	-4.53	-0.38	1.34e-5	Breast cancer;
TGCT	cis	rs1034435	0.755	rs5768679	chr22:48892847	T/G	cg05992904	chr22:48892994	FAM19A5	-0.34	-4.65	-0.39	8.37e-6	Late-onset Alzheimer's disease;
TGCT	cis	rs17376456	0.569	rs7732578	chr5:93410244	C/T	cg25358565	chr5:93447407	FAM172A	-0.62	-5.98	-0.47	2.22e-8	Diabetic retinopathy;
TGCT	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.51	5.4	0.44	3.28e-7	Lymphocyte counts;
TGCT	cis	rs10883723	0.810	rs7094751	chr10:104274818	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	8.75	0.62	1.33e-14	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs992157	1.000	rs4674280	chr2:219141458	C/G	cg00012203	chr2:219082015	ARPC2	-0.78	-8.14	-0.59	3.57e-13	Colorectal cancer;
TGCT	cis	rs9902453	0.874	rs3936006	chr17:28257660	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.9	8.58	0.61	3.28e-14	Coffee consumption (cups per day);
TGCT	cis	rs6683273	0.779	rs16824089	chr1:3230544	T/C	cg17435683	chr1:3230609	PRDM16	-0.4	-4.53	-0.38	1.35e-5	QRS duration;
TGCT	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg21644426	chr2:191273491	MFSD6	0.62	6.15	0.48	9.57e-9	Pulse pressure;
TGCT	trans	rs1814175	0.817	rs7947286	chr11:49874657	C/T	cg03929089	chr4:120376271	NA	-0.72	-8.26	-0.6	1.84e-13	Height;
TGCT	cis	rs2197308	0.765	rs11182964	chr12:37935052	C/T	cg13010199	chr12:38710504	ALG10B	0.66	5.33	0.43	4.41e-7	Morning vs. evening chronotype;
TGCT	cis	rs9457247	1.000	rs430293	chr6:167404958	A/G	cg23791538	chr6:167370224	RNASET2	-0.49	-4.96	-0.41	2.26e-6	Crohn's disease;
TGCT	cis	rs739496	0.843	rs657197	chr12:111965658	C/A	cg10833066	chr12:111807467	FAM109A	0.37	5.59	0.45	1.4e-7	Platelet count;
TGCT	cis	rs8014204	0.604	rs11625594	chr14:75389833	G/A	cg06637938	chr14:75390232	RPS6KL1	0.94	10.46	0.68	9.58e-19	Caffeine consumption;
TGCT	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7937612	0.965	rs12420378	chr11:120250699	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.28	-4.53	-0.38	1.37e-5	Intraocular pressure;
TGCT	cis	rs250677	0.687	rs40149	chr5:148444275	A/T	cg23229984	chr5:148520753	ABLIM3	0.21	4.99	0.41	1.98e-6	Breast cancer;
TGCT	trans	rs2727020	0.729	rs4315497	chr11:49214499	G/A	cg03929089	chr4:120376271	NA	0.71	7.91	0.58	1.2e-12	Coronary artery disease;
TGCT	cis	rs9467773	1.000	rs4871	chr6:26545632	G/A	cg15659132	chr6:26577336	NA	0.86	11.89	0.73	3.14e-22	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg22535103	chr8:58192502	C8orf71	-0.37	-4.73	-0.39	6.08e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs7726839	0.540	rs7434	chr5:660804	A/G	cg16035780	chr5:759353	NA	-0.43	-4.44	-0.37	1.93e-5	Obesity-related traits;
TGCT	cis	rs3125734	0.633	rs1835862	chr10:64056068	G/A	cg09941381	chr10:64027924	RTKN2	-0.34	-5.04	-0.41	1.62e-6	Rheumatoid arthritis;
TGCT	cis	rs11734570	0.581	rs79354477	chr4:38597448	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.69	5.66	0.45	9.9e-8	Inflammatory bowel disease;Crohn's disease;
TGCT	cis	rs7772486	0.875	rs10457795	chr6:146415665	A/G	cg05347473	chr6:146136440	FBXO30	0.56	5.22	0.42	7.31e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs12135062	0.851	rs2651925	chr1:3101863	C/G	cg21609526	chr1:3105151	PRDM16	0.4	6.59	0.51	1.15e-9	Migraine;
TGCT	cis	rs3096299	0.503	rs4785677	chr16:89555101	A/G	cg02187348	chr16:89574699	SPG7	0.57	5.93	0.47	2.75e-8	Multiple myeloma (IgH translocation);
TGCT	cis	rs28595532	0.920	rs55806110	chr4:119742583	A/G	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	trans	rs17685	0.593	rs56265719	chr7:75796269	C/T	cg19862616	chr7:65841803	NCRNA00174	0.52	9.04	0.63	2.61e-15	Coffee consumption;Coffee consumption (cups per day);
TGCT	cis	rs7223966	1.000	rs7220821	chr17:61704147	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	5.17	0.42	9.12e-7	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs3935685	0.874	rs28406214	chr15:77996537	G/A	cg03457338	chr15:78040120	NA	-0.22	-5.8	-0.46	5.1e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2050392	0.517	rs589980	chr10:30756385	T/A	cg18806716	chr10:30721971	MAP3K8	-0.46	-5.43	-0.44	2.79e-7	Inflammatory bowel disease;
TGCT	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg24503407	chr1:205819492	PM20D1	0.71	11.34	0.71	6.82e-21	Menarche (age at onset);
TGCT	cis	rs75686122	0.892	rs76082564	chr8:104536649	T/C	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs4808199	0.948	rs968525	chr19:19459215	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.67	5.04	0.41	1.58e-6	Nonalcoholic fatty liver disease;
TGCT	cis	rs1949733	0.523	rs16842563	chr4:8545146	C/T	cg13073564	chr4:8508604	NA	0.48	4.99	0.41	2.02e-6	Response to antineoplastic agents;
TGCT	cis	rs3733585	0.762	rs6449217	chr4:10009151	T/A	cg00071950	chr4:10020882	SLC2A9	0.64	7.22	0.54	4.5e-11	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs1577917	1.000	rs1857964	chr6:86635994	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-5.54	-0.45	1.73e-7	Response to antipsychotic treatment;
TGCT	cis	rs2742417	1.000	rs1877932	chr3:45753539	A/G	cg04837898	chr3:45731254	SACM1L	-0.55	-5.72	-0.46	7.45e-8	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs3809566	0.963	rs12148057	chr15:63331509	A/T	cg08198488	chr15:63333792	TPM1	-0.35	-5.23	-0.43	7e-7	Platelet count;
TGCT	cis	rs6684514	1.000	rs59468948	chr1:156288058	A/T	cg20302342	chr1:156215951	PAQR6	0.35	4.74	0.39	5.77e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs992157	0.731	rs1399132	chr2:219159770	G/A	cg00012203	chr2:219082015	ARPC2	0.78	7.72	0.57	3.38e-12	Colorectal cancer;
TGCT	cis	rs12762955	0.528	rs10903358	chr10:1102386	G/A	cg18964960	chr10:1102726	WDR37	0.74	5.36	0.43	3.87e-7	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.18	0.49	8.32e-9	Bipolar disorder;
TGCT	cis	rs8056742	0.642	rs11649265	chr16:85050735	G/T	cg00229868	chr16:85520891	NA	-0.4	-4.88	-0.4	3.18e-6	Amyotrophic lateral sclerosis;
TGCT	cis	rs6684514	1.000	rs10908496	chr1:156264000	G/A	cg20302342	chr1:156215951	PAQR6	0.34	4.6	0.38	1.01e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs6089829	0.888	rs4809268	chr20:61675249	C/G	cg02380750	chr20:61661411	NA	0.35	5.68	0.45	9.19e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2997447	0.655	rs12059101	chr1:26384013	A/G	cg19759804	chr1:25889155	LDLRAP1	0.33	4.55	0.38	1.25e-5	QRS complex (12-leadsum);
TGCT	cis	rs7804356	0.651	rs17372780	chr7:26804018	C/G	cg03456212	chr7:26904342	SKAP2	0.54	4.6	0.38	1.04e-5	Type 1 diabetes;
TGCT	cis	rs9467711	0.606	rs9358938	chr6:26387546	C/T	cg16898833	chr6:26189333	HIST1H4D	1.14	5.41	0.44	3.15e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9527	0.590	rs7910900	chr10:104829898	C/T	cg15744005	chr10:104629667	AS3MT	-0.42	-4.87	-0.4	3.29e-6	Arsenic metabolism;
TGCT	cis	rs8070463	0.520	rs11652969	chr17:45817367	G/A	cg06532163	chr17:45867833	NA	0.26	4.5	0.37	1.52e-5	Multiple sclerosis;Ankylosing spondylitis;
TGCT	cis	rs11644362	0.966	rs35678048	chr16:12989235	A/G	cg06890432	chr16:12997467	SHISA9	-0.62	-6.61	-0.51	1.05e-9	Positive affect;Subjective well-being;
TGCT	cis	rs12887734	0.524	rs12888002	chr14:104238647	T/C	cg26031613	chr14:104095156	KLC1	-0.72	-6.25	-0.49	6.02e-9	Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs595982	0.527	rs73061659	chr19:49373556	G/A	cg17863274	chr19:49399704	TULP2	-0.47	-6.81	-0.52	3.78e-10	Red cell distribution width;
TGCT	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg23172400	chr8:95962367	TP53INP1	-0.4	-6.79	-0.52	4.23e-10	Type 2 diabetes;
TGCT	cis	rs9486719	1.000	rs2472895	chr6:96870387	A/T	cg18709589	chr6:96969512	KIAA0776	0.71	5.21	0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs7829975	0.514	rs2976926	chr8:8261624	T/C	cg08975724	chr8:8085496	FLJ10661	0.58	5.13	0.42	1.09e-6	Mood instability;
TGCT	cis	rs7539409	0.651	rs10747407	chr1:84314754	G/A	cg10977910	chr1:84465055	TTLL7	0.88	5.62	0.45	1.19e-7	Alzheimer's disease;
TGCT	cis	rs6430585	0.583	rs4988145	chr2:136632300	A/C	cg07169764	chr2:136633963	MCM6	1.23	12.35	0.74	2.37e-23	Corneal structure;
TGCT	cis	rs7772486	0.875	rs9403764	chr6:146360582	G/A	cg23711669	chr6:146136114	FBXO30	0.89	10.0	0.67	1.25e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7523273	0.568	rs11118668	chr1:208017915	A/G	cg22525895	chr1:207977042	MIR29B2	0.43	6.03	0.48	1.78e-8	Schizophrenia;
TGCT	cis	rs79349575	0.783	rs12601858	chr17:47017477	T/C	cg07967210	chr17:47022446	SNF8	0.44	6.13	0.48	1.1e-8	Type 2 diabetes;
TGCT	cis	rs9467773	0.595	rs2451736	chr6:26620544	G/A	cg11502198	chr6:26597334	ABT1	0.53	4.9	0.4	2.95e-6	Intelligence (multi-trait analysis);
TGCT	trans	rs2688608	0.618	rs28553894	chr10:75489843	C/A	cg13918328	chr10:52500089	ASAH2B	0.68	6.73	0.52	5.68e-10	Inflammatory bowel disease;
TGCT	cis	rs4788570	0.697	rs4788443	chr16:71805160	G/A	cg06353428	chr16:71660113	MARVELD3	1.55	11.33	0.71	7.48e-21	Intelligence (multi-trait analysis);
TGCT	cis	rs1538970	0.816	rs3790583	chr1:45956828	C/G	cg05343316	chr1:45956843	TESK2	0.81	6.64	0.51	8.93e-10	Platelet count;
TGCT	cis	rs4788815	0.712	rs4788563	chr16:71879868	A/C	cg06353428	chr16:71660113	MARVELD3	0.83	7.37	0.55	2.07e-11	Metabolite levels;
TGCT	cis	rs10838634	1.000	rs7928445	chr11:46784697	A/C	cg18332754	chr11:46939436	LRP4	0.84	4.54	0.38	1.29e-5	Schizophrenia;
TGCT	cis	rs12142240	0.698	rs68083747	chr1:46807416	T/G	cg00530320	chr1:46809349	NSUN4	0.29	5.88	0.47	3.63e-8	Menopause (age at onset);
TGCT	cis	rs72781680	0.898	rs113027486	chr2:24098371	G/A	cg08917208	chr2:24149416	ATAD2B	0.78	4.79	0.4	4.69e-6	Lymphocyte counts;
TGCT	cis	rs7208859	0.623	rs3794796	chr17:29130880	G/C	cg14008862	chr17:28927542	LRRC37B2	0.77	4.61	0.38	9.76e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs12286929	0.699	rs1048932	chr11:115044850	C/A	cg04017736	chr11:115827165	NA	0.2	4.87	0.4	3.29e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs4642101	0.561	rs9812144	chr3:12805910	G/A	cg05775895	chr3:12838266	CAND2	0.53	5.22	0.42	7.19e-7	QRS complex (12-leadsum);
TGCT	cis	rs7208859	0.623	rs75136574	chr17:28934549	C/A	cg14008862	chr17:28927542	LRRC37B2	0.88	5.32	0.43	4.75e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs4319547	0.656	rs10744209	chr12:122931568	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.71	-5.49	-0.44	2.16e-7	Body mass index;
TGCT	cis	rs11785400	0.963	rs9771845	chr8:143726577	C/G	cg24634471	chr8:143751801	JRK	0.55	5.92	0.47	2.93e-8	Schizophrenia;
TGCT	cis	rs868036	0.681	rs28376010	chr15:68063739	G/T	cg05925327	chr15:68127851	NA	-0.51	-4.82	-0.4	4.2e-6	Restless legs syndrome;
TGCT	cis	rs3917265	0.602	rs997049	chr2:102782433	T/A	cg17937070	chr2:102766322	NA	-0.32	-4.48	-0.37	1.66e-5	Atopic dermatitis;
TGCT	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg24549020	chr5:56110836	MAP3K1	0.66	5.79	0.46	5.56e-8	Initial pursuit acceleration;
TGCT	cis	rs427394	0.664	rs274696	chr5:6732213	A/C	cg10857441	chr5:6722123	POLS	-0.29	-7.23	-0.54	4.25e-11	Menopause (age at onset);
TGCT	cis	rs2729354	0.768	rs1001956	chr11:57266949	C/G	cg24343310	chr11:57249947	NA	0.28	4.71	0.39	6.56e-6	Blood protein levels;
TGCT	cis	rs4273100	0.646	rs1472932	chr17:19220666	C/T	cg01534423	chr17:18965556	NA	-0.76	-7.04	-0.53	1.19e-10	Schizophrenia;
TGCT	cis	rs17376456	0.825	rs13361613	chr5:93272176	C/T	cg21475434	chr5:93447410	FAM172A	0.65	4.47	0.37	1.72e-5	Diabetic retinopathy;
TGCT	cis	rs950169	0.840	rs72748702	chr15:84915246	A/G	cg17173187	chr15:85201210	NMB	0.54	5.55	0.45	1.67e-7	Schizophrenia;
TGCT	cis	rs986417	0.892	rs8012339	chr14:60797545	T/G	cg27398547	chr14:60952738	C14orf39	-1.56	-6.75	-0.52	5.13e-10	Gut microbiota (bacterial taxa);
TGCT	cis	rs208520	0.690	rs2208442	chr6:66867004	T/C	cg07460842	chr6:66804631	NA	-0.92	-9.58	-0.65	1.29e-16	Exhaled nitric oxide output;
TGCT	cis	rs6813479	0.562	rs2634900	chr4:137733596	C/A	cg04252851	chr4:137733453	NA	-0.25	-4.48	-0.37	1.69e-5	Longevity;
TGCT	cis	rs2455799	0.613	rs6789076	chr3:15807725	A/T	cg16303742	chr3:15540471	COLQ	0.25	4.85	0.4	3.6e-6	Mean platelet volume;
TGCT	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg19318889	chr4:1322082	MAEA	0.19	4.53	0.38	1.35e-5	Longevity;
TGCT	cis	rs56104184	0.775	rs55737338	chr19:49403141	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.73	-9.15	-0.63	1.47e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs2013441	1.000	rs4924808	chr17:20026548	C/T	cg23224458	chr17:20280056	CCDC144C	-0.37	-4.59	-0.38	1.06e-5	Obesity-related traits;
TGCT	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg25703541	chr22:24373054	LOC391322	-0.81	-8.4	-0.6	8.79e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs986417	0.901	rs6573315	chr14:60996831	A/C	cg27398547	chr14:60952738	C14orf39	1.41	9.14	0.63	1.53e-15	Gut microbiota (bacterial taxa);
TGCT	cis	rs8135665	0.625	rs34385006	chr22:38450291	C/T	cg13116946	chr22:38479732	SLC16A8	0.29	5.67	0.45	9.62e-8	Advanced age-related macular degeneration;Age-related macular degeneration;
TGCT	cis	rs7582180	0.607	rs6725052	chr2:100935817	G/A	cg14675211	chr2:100938903	LONRF2	0.51	4.95	0.41	2.32e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs35000415	0.745	rs117473643	chr7:128698186	G/C	cg06242719	chr7:129414860	MIR183;MIR96	-0.34	-4.67	-0.39	7.58e-6	Systemic lupus erythematosus;
TGCT	cis	rs9341808	0.690	rs2505932	chr6:80839252	G/T	cg08355045	chr6:80787529	NA	0.32	5.38	0.43	3.6e-7	Sitting height ratio;
TGCT	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg27425262	chr2:113953981	PSD4;LOC440839	-0.52	-8.2	-0.59	2.52e-13	Lymphocyte counts;
TGCT	cis	rs2777491	0.957	rs316614	chr15:41746625	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.75	-11.07	-0.71	3.15e-20	Ulcerative colitis;
TGCT	cis	rs35306767	0.714	rs12777800	chr10:1070361	G/A	cg26597838	chr10:835615	NA	0.61	7.08	0.54	9.27e-11	Eosinophil percentage of granulocytes;
TGCT	cis	rs713587	0.719	rs4665736	chr2:25187599	C/T	cg15423357	chr2:25149977	NA	-0.58	-5.9	-0.47	3.22e-8	Body mass index in non-asthmatics;
TGCT	cis	rs877282	0.945	rs11253396	chr10:789754	C/T	cg17470449	chr10:769945	NA	0.3	4.82	0.4	4.14e-6	Uric acid levels;
TGCT	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg00908189	chr16:619842	PIGQ	0.87	10.65	0.69	3.27e-19	Height;
TGCT	cis	rs5769765	0.773	rs4075331	chr22:50302850	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.39	5.61	0.45	1.24e-7	Schizophrenia;
TGCT	cis	rs2334880	0.678	rs12444714	chr16:71452606	C/T	cg06353428	chr16:71660113	MARVELD3	-1.19	-7.9	-0.58	1.3e-12	Malaria;
TGCT	cis	rs259282	0.652	rs2161458	chr19:33129038	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.6	5.82	0.46	4.63e-8	Schizophrenia;
TGCT	cis	rs7772486	0.590	rs1890170	chr6:146071839	G/C	cg23711669	chr6:146136114	FBXO30	-0.74	-6.63	-0.51	9.18e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs67460515	0.892	rs7647374	chr3:160975576	T/A	cg03342759	chr3:160939853	NMD3	-0.49	-5.3	-0.43	5.16e-7	Parkinson's disease;
TGCT	cis	rs1784581	0.928	rs1789995	chr6:162396518	C/T	cg17173639	chr6:162384350	PARK2	-0.51	-9.75	-0.66	5.12e-17	Itch intensity from mosquito bite;
TGCT	cis	rs57994353	0.667	rs34985258	chr9:139327154	C/T	cg13741927	chr9:139327495	INPP5E	-0.27	-6.26	-0.49	5.81e-9	Eosinophil counts;Cutaneous squamous cell carcinoma;
TGCT	cis	rs1451375	1.000	rs10250513	chr7:50621488	T/G	cg18232548	chr7:50535776	DDC	0.43	6.8	0.52	3.98e-10	Malaria;
TGCT	cis	rs3020736	0.500	rs6519306	chr22:42501217	T/C	cg05082376	chr22:42548792	NA	0.23	5.43	0.44	2.83e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs17401966	0.540	rs6682868	chr1:10454773	C/T	cg19773385	chr1:10388646	KIF1B	0.21	5.12	0.42	1.12e-6	Hepatocellular carcinoma;
TGCT	cis	rs739401	0.572	rs739400	chr11:3016520	G/A	cg25174290	chr11:3078921	CARS	0.49	4.59	0.38	1.08e-5	Longevity;
TGCT	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg03452623	chr4:187889614	NA	-0.37	-5.7	-0.46	8.2e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs1334894	1.000	rs755658	chr6:35549670	A/G	cg24281267	chr6:35479648	TULP1	0.43	4.47	0.37	1.78e-5	Coronary artery disease;
TGCT	cis	rs317689	0.658	rs490872	chr12:69645864	A/G	cg14784868	chr12:69753453	YEATS4	0.54	4.5	0.37	1.56e-5	Response to diuretic therapy;
TGCT	cis	rs17376456	0.877	rs10050465	chr5:93349963	C/A	cg21475434	chr5:93447410	FAM172A	0.6	4.74	0.39	5.71e-6	Diabetic retinopathy;
TGCT	cis	rs1555895	0.521	rs1057303	chr10:853155	T/C	cg02193355	chr10:851439	NA	0.24	5.33	0.43	4.45e-7	Survival in rectal cancer;
TGCT	cis	rs1941023	0.503	rs2233238	chr11:60145441	G/C	cg08716584	chr11:60157161	MS4A7	-0.34	-4.84	-0.4	3.81e-6	Congenital heart disease (maternal effect);
TGCT	cis	rs12477438	1.000	rs12466388	chr2:99916538	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.8	-6.4	-0.5	2.91e-9	Chronic sinus infection;
TGCT	cis	rs1008375	1.000	rs114490726	chr4:17680898	T/C	cg16339924	chr4:17578868	LAP3	0.56	4.8	0.4	4.43e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs727505	1.000	rs10265763	chr7:124451514	G/A	cg23710748	chr7:124431027	NA	-0.27	-4.65	-0.39	8.35e-6	Lewy body disease;
TGCT	cis	rs6500602	0.727	rs4786510	chr16:4571247	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.32	5.97	0.47	2.35e-8	Schizophrenia;
TGCT	cis	rs4918072	0.917	rs61861158	chr10:105661686	A/G	cg11005552	chr10:105648138	OBFC1	0.41	5.4	0.44	3.29e-7	Coronary artery disease;
TGCT	cis	rs910316	0.967	rs11159121	chr14:75666029	A/T	cg08847533	chr14:75593920	NEK9	-0.94	-10.27	-0.68	2.77e-18	Height;
TGCT	cis	rs4953076	0.613	rs11124981	chr2:44462133	A/T	cg00619915	chr2:44497795	NA	-0.22	-4.99	-0.41	1.96e-6	Height;
TGCT	cis	rs1150668	0.799	rs853684	chr6:28294550	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.47	-4.65	-0.39	8.37e-6	Pubertal anthropometrics;
TGCT	cis	rs7714584	1.000	rs10061105	chr5:150255185	C/G	cg22134413	chr5:150180641	NA	0.83	6.53	0.51	1.54e-9	Crohn's disease;
TGCT	cis	rs3796352	1.000	rs71617204	chr3:53042951	G/A	cg15956490	chr3:53032818	SFMBT1	0.62	6.82	0.52	3.6e-10	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs11098499	0.863	rs3775844	chr4:120428033	G/A	cg09307838	chr4:120376055	NA	0.68	6.45	0.5	2.28e-9	Corneal astigmatism;
TGCT	cis	rs2885056	0.699	rs34275421	chr19:10644812	T/A	cg04833646	chr19:10679720	CDKN2D	0.83	7.24	0.54	4.24e-11	Red cell distribution width;
TGCT	cis	rs478304	0.654	rs1074155	chr11:65458197	C/T	cg27068330	chr11:65405492	SIPA1	0.96	10.74	0.69	2.05e-19	Acne (severe);
TGCT	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg20203395	chr5:56204925	C5orf35	-0.59	-5.12	-0.42	1.12e-6	Initial pursuit acceleration;
TGCT	cis	rs7707921	0.522	rs9293290	chr5:81474225	A/T	cg15871215	chr5:81402204	ATG10	-0.24	-4.59	-0.38	1.08e-5	Breast cancer;
TGCT	cis	rs7666738	0.618	rs10856932	chr4:98819992	C/T	cg18180107	chr4:99064573	C4orf37	0.55	5.25	0.43	6.31e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1451375	0.657	rs7802148	chr7:50648284	T/C	cg18232548	chr7:50535776	DDC	0.44	6.72	0.52	5.81e-10	Malaria;
TGCT	cis	rs2204008	0.806	rs35534445	chr12:38279093	C/T	cg26384229	chr12:38710491	ALG10B	0.86	7.48	0.56	1.17e-11	Bladder cancer;
TGCT	cis	rs28374715	0.562	rs8036686	chr15:41550333	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.66	-8.71	-0.62	1.61e-14	Ulcerative colitis;
TGCT	cis	rs74233809	1.000	rs1060240	chr10:104883337	A/G	cg05855489	chr10:104503620	C10orf26	0.82	4.44	0.37	1.97e-5	Birth weight;
TGCT	cis	rs17741873	0.836	rs4746155	chr10:75661571	A/G	cg07699608	chr10:75541558	CHCHD1	0.69	4.86	0.4	3.42e-6	Paclitaxel disposition in epithelial ovarian cancer;
TGCT	cis	rs2932538	0.961	rs4838960	chr1:113163632	G/T	cg22162597	chr1:113214053	CAPZA1	-0.26	-5.82	-0.46	4.83e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs6582630	0.555	rs10880607	chr12:38508184	A/G	cg13010199	chr12:38710504	ALG10B	0.64	5.15	0.42	9.97e-7	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs4919694	0.611	rs77328741	chr10:105066314	T/C	cg04362960	chr10:104952993	NT5C2	0.91	6.05	0.48	1.59e-8	Arsenic metabolism;
TGCT	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg01416388	chr22:39784598	NA	-0.7	-6.92	-0.53	2.11e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs10089	1.000	rs4836366	chr5:127482494	A/T	cg19767477	chr5:127420684	SLC12A2	-0.43	-4.55	-0.38	1.27e-5	Ileal carcinoids;
TGCT	cis	rs896854	0.654	rs13248607	chr8:95986637	T/G	cg16049864	chr8:95962084	TP53INP1	-0.72	-10.2	-0.68	4.16e-18	Type 2 diabetes;
TGCT	cis	rs9333029	0.722	rs7540241	chr1:47258219	A/T	cg07352594	chr1:46664316	POMGNT1	-0.71	-4.51	-0.38	1.51e-5	Blood metabolite levels;
TGCT	cis	rs11167764	0.945	rs891991	chr5:141484977	A/T	cg02659431	chr5:141694439	SPRY4	-0.21	-4.54	-0.38	1.33e-5	Crohn's disease;
TGCT	cis	rs12039431	0.748	rs6692773	chr1:38025407	G/A	cg17933807	chr1:38061675	GNL2	-0.8	-7.83	-0.58	1.84e-12	Epithelial ovarian cancer;
TGCT	cis	rs1371867	0.846	rs1660324	chr8:101281271	C/T	cg06636551	chr8:101224915	SPAG1	-0.49	-6.83	-0.52	3.32e-10	Atrioventricular conduction;
TGCT	cis	rs66573146	0.808	rs55942328	chr4:6990960	T/G	cg05069807	chr4:6945702	TBC1D14	0.31	4.85	0.4	3.63e-6	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs2594714	0.538	rs895819	chr19:13947292	A/G	cg18576835	chr19:13944261	NA	-0.5	-7.12	-0.54	7.83e-11	Breast cancer;
TGCT	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg21963583	chr11:68658836	MRPL21	0.39	6.3	0.49	4.78e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7666738	0.830	rs11931166	chr4:99054187	A/T	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs600550	0.963	rs4939329	chr11:60021507	C/A	cg18570331	chr11:60101691	MS4A6E	0.52	4.48	0.37	1.67e-5	Lipoprotein-associated phospholipase A2 activity and mass;
TGCT	trans	rs34421088	0.560	rs2245357	chr8:11399484	A/T	cg15556689	chr8:8085844	FLJ10661	-0.74	-7.03	-0.53	1.23e-10	Neuroticism;
TGCT	cis	rs60843830	0.661	rs55987018	chr2:106655	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.62	5.47	0.44	2.43e-7	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs1371867	0.846	rs1788194	chr8:101277916	T/C	cg00191853	chr8:101177733	SPAG1	-0.22	-4.5	-0.37	1.53e-5	Atrioventricular conduction;
TGCT	cis	rs735396	1.000	rs2464195	chr12:121435475	G/A	cg02403541	chr12:121454288	C12orf43	0.66	6.42	0.5	2.59e-9	N-glycan levels;
TGCT	cis	rs617219	0.726	rs2364596	chr5:78434291	C/T	cg23987322	chr5:78407566	BHMT	0.34	4.48	0.37	1.66e-5	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs6542838	0.641	rs4851176	chr2:99534859	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.56	-5.32	-0.43	4.61e-7	Fear of minor pain;
TGCT	cis	rs4631830	0.900	rs11006274	chr10:51540291	C/T	cg10326726	chr10:51549505	MSMB	0.26	5.28	0.43	5.55e-7	Prostate-specific antigen levels;
TGCT	cis	rs1371867	0.875	rs962452	chr8:101331369	G/A	cg00191853	chr8:101177733	SPAG1	-0.23	-4.76	-0.39	5.2e-6	Atrioventricular conduction;
TGCT	cis	rs4253772	0.591	rs12167567	chr22:46659942	G/C	cg09491104	chr22:46646882	C22orf40	-0.67	-6.65	-0.51	8.56e-10	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs7027203	0.790	rs10123836	chr9:96584109	G/T	cg14396892	chr9:96623032	NA	-0.29	-6.22	-0.49	7.08e-9	DNA methylation (variation);
TGCT	cis	rs8070128	0.534	rs2955350	chr17:17953548	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.79	-8.27	-0.6	1.76e-13	Total body bone mineral density;
TGCT	cis	rs9611519	0.780	rs9611528	chr22:41648502	T/C	cg13695892	chr22:41940480	POLR3H	-0.64	-6.05	-0.48	1.59e-8	Neuroticism;
TGCT	cis	rs67311347	1.000	rs13073003	chr3:40504326	C/T	cg17264618	chr3:40429014	ENTPD3	-0.33	-4.85	-0.4	3.66e-6	Renal cell carcinoma;
TGCT	cis	rs1538970	0.816	rs12029322	chr1:45970446	C/T	cg05343316	chr1:45956843	TESK2	0.81	6.64	0.51	8.93e-10	Platelet count;
TGCT	cis	rs6671200	1.000	rs71654419	chr1:95664497	C/G	cg26537280	chr1:95699037	RWDD3	0.68	5.49	0.44	2.15e-7	Stearic acid (18:0) levels;
TGCT	cis	rs2742417	1.000	rs2742379	chr3:45787835	G/A	cg04837898	chr3:45731254	SACM1L	-0.53	-5.52	-0.44	1.92e-7	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg05368731	chr17:41323189	NBR1	1.09	12.62	0.75	5.36e-24	Menopause (age at onset);
TGCT	cis	rs523522	0.962	rs11065154	chr12:120971417	T/C	cg27279351	chr12:120934652	DYNLL1	0.76	6.59	0.51	1.15e-9	High light scatter reticulocyte count;
TGCT	cis	rs17376456	0.741	rs7718842	chr5:93480568	G/A	cg25358565	chr5:93447407	FAM172A	0.97	8.27	0.6	1.76e-13	Diabetic retinopathy;
TGCT	cis	rs1669338	0.588	rs55959448	chr3:3204000	C/T	cg16797762	chr3:3221439	CRBN	-0.91	-5.73	-0.46	7.34e-8	White matter integrity;
TGCT	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg10253484	chr15:75165896	SCAMP2	-0.6	-5.51	-0.44	2.02e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
TGCT	cis	rs9913156	0.793	rs8074545	chr17:4567337	C/G	cg00122941	chr17:4613640	ARRB2	-0.89	-7.56	-0.56	7.65e-12	Lymphocyte counts;
TGCT	cis	rs4595586	0.545	rs6580896	chr12:39372223	C/T	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs554111	0.656	rs4654900	chr1:21422021	G/C	cg01072550	chr1:21505969	NA	0.36	5.46	0.44	2.51e-7	Facial morphology (factor 17, height of vermillion upper lip);
TGCT	cis	rs7614311	0.636	rs73117066	chr3:63926236	A/G	cg22134162	chr3:63841271	THOC7	-0.49	-6.18	-0.49	8.42e-9	Lung function (FVC);Lung function (FEV1);
TGCT	cis	rs17125944	0.542	rs75723366	chr14:53256882	T/C	cg00686598	chr14:53173677	PSMC6	1.08	6.32	0.49	4.37e-9	Alzheimer's disease (late onset);
TGCT	cis	rs3774830	0.714	rs7688517	chr4:5466392	A/C	cg26943120	chr4:5472116	STK32B	0.23	5.02	0.41	1.78e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9611565	0.592	rs4822046	chr22:41987543	G/A	cg06481639	chr22:41940642	POLR3H	-0.75	-6.47	-0.5	2.1e-9	Vitiligo;
TGCT	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.67	-5.54	-0.45	1.72e-7	Tonsillectomy;
TGCT	cis	rs6831352	0.879	rs1984362	chr4:100070973	G/A	cg12011299	chr4:100065546	ADH4	-0.46	-5.22	-0.42	7.38e-7	Alcohol dependence;
TGCT	cis	rs16866061	1.000	rs10498163	chr2:225434445	A/G	cg12698349	chr2:225449008	CUL3	1.01	9.8	0.66	3.91e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
TGCT	cis	rs2486288	0.656	rs12904150	chr15:45547605	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.72	-7.46	-0.56	1.34e-11	Glomerular filtration rate;
TGCT	cis	rs7568458	0.709	rs56819945	chr2:85755139	C/T	cg02493740	chr2:85810744	VAMP5	-0.28	-5.37	-0.43	3.67e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs2180341	0.960	rs6900074	chr6:127685893	A/G	cg24812749	chr6:127587940	RNF146	0.93	7.28	0.55	3.34e-11	Breast cancer;
TGCT	cis	rs864537	0.676	rs3108155	chr1:167422057	C/G	cg22356347	chr1:167427500	CD247	-0.22	-5.47	-0.44	2.35e-7	Celiac disease or Rheumatoid arthritis;Celiac disease;
TGCT	cis	rs9303401	0.614	rs35245220	chr17:56510305	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.68	6.66	0.51	8.09e-10	Cognitive test performance;
TGCT	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg16423285	chr20:60520624	NA	-0.69	-6.96	-0.53	1.73e-10	Body mass index;
TGCT	cis	rs6809651	0.524	rs7622914	chr3:185790895	T/C	cg00760338	chr3:185826511	ETV5	-0.71	-5.3	-0.43	5.05e-7	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
TGCT	cis	rs17387100	1.000	rs17387100	chr4:15995125	A/G	cg14577840	chr4:16257979	FLJ39653	0.47	4.51	0.38	1.5e-5	Suicide attempts in depression or bipolar disorder;
TGCT	cis	rs7666738	0.724	rs28451676	chr4:98966990	C/T	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.48e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs13256369	0.802	rs11249887	chr8:8562184	T/C	cg18904891	chr8:8559673	CLDN23	0.57	5.29	0.43	5.35e-7	Obesity-related traits;
TGCT	cis	rs2153535	0.623	rs2327055	chr6:8443145	A/G	cg07606381	chr6:8435919	SLC35B3	0.57	5.25	0.43	6.46e-7	Motion sickness;
TGCT	cis	rs4746818	0.688	rs951718	chr10:70928044	A/G	cg11621586	chr10:70884670	VPS26A	1.23	10.93	0.7	6.87e-20	Left atrial antero-posterior diameter;
TGCT	cis	rs76878669	0.538	rs1785633	chr11:66107527	C/A	cg18002602	chr11:66138449	SLC29A2	0.53	6.45	0.5	2.23e-9	Educational attainment (years of education);
TGCT	cis	rs17741873	0.836	rs17631059	chr10:75625558	G/C	cg07699608	chr10:75541558	CHCHD1	0.79	5.64	0.45	1.1e-7	Paclitaxel disposition in epithelial ovarian cancer;
TGCT	cis	rs2832191	0.671	rs2832213	chr21:30512914	A/G	cg24692254	chr21:30365293	RNF160	-0.6	-5.57	-0.45	1.51e-7	Dental caries;
TGCT	cis	rs7582180	0.629	rs4850927	chr2:100969067	A/G	cg08017756	chr2:100939284	LONRF2	-0.29	-4.73	-0.39	5.99e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs262150	0.536	rs73167296	chr7:158783129	C/T	cg01219135	chr7:158766336	NA	-0.44	-4.64	-0.38	8.89e-6	Facial morphology (factor 20);
TGCT	cis	rs4727027	0.834	rs7811446	chr7:148773226	G/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	4.99	0.41	2.02e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
TGCT	cis	rs66561647	0.634	rs7821856	chr8:128939499	A/G	cg11792826	chr8:129160931	MIR1208	0.21	4.8	0.4	4.53e-6	Hemoglobin concentration;
TGCT	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.2	0.42	8.14e-7	Menopause (age at onset);
TGCT	cis	rs7647973	1.000	rs11720542	chr3:49357427	A/G	cg07636037	chr3:49044803	WDR6	0.72	5.84	0.46	4.25e-8	Menarche (age at onset);
TGCT	cis	rs79349575	0.749	rs318093	chr17:46989354	A/G	cg26022315	chr17:47021804	SNF8	0.49	4.87	0.4	3.29e-6	Type 2 diabetes;
TGCT	cis	rs9611565	0.568	rs5751159	chr22:42175365	G/A	cg03806693	chr22:41940476	POLR3H	0.9	8.76	0.62	1.2e-14	Vitiligo;
TGCT	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg26338869	chr17:61819248	STRADA	-0.53	-4.85	-0.4	3.68e-6	Prudent dietary pattern;
TGCT	cis	rs7666738	0.791	rs6532725	chr4:99061479	T/C	cg18180107	chr4:99064573	C4orf37	0.58	5.25	0.43	6.44e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7197653	0.748	rs2279538	chr16:68397106	C/G	cg05110241	chr16:68378359	PRMT7	-0.36	-4.46	-0.37	1.84e-5	Magnesium levels;
TGCT	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg08736216	chr1:53307985	ZYG11A	-0.29	-6.09	-0.48	1.32e-8	Monocyte count;
TGCT	cis	rs302972	0.826	rs303001	chr6:25056769	A/G	cg18428180	chr6:24646492	KIAA0319	-1.03	-4.51	-0.38	1.49e-5	Creatinine levels in ischemic stroke;
TGCT	cis	rs6460942	0.915	rs6460907	chr7:12304449	G/A	cg06484146	chr7:12443880	VWDE	-0.43	-4.61	-0.38	9.7e-6	Coronary artery disease;
TGCT	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg08509172	chr19:19383838	TM6SF2	0.35	4.69	0.39	7.2e-6	Tonsillectomy;
TGCT	cis	rs9952991	0.941	rs1893217	chr18:12809340	A/G	cg24737193	chr18:12778029	NA	-0.51	-5.38	-0.43	3.65e-7	Inflammatory skin disease;
TGCT	cis	rs7666738	0.830	rs11722272	chr4:99000839	C/T	cg17366294	chr4:99064904	C4orf37	0.66	6.36	0.5	3.54e-9	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg22166914	chr1:53195759	ZYG11B	0.36	5.71	0.46	8.05e-8	Monocyte count;
TGCT	cis	rs12142240	0.698	rs72677587	chr1:46813982	G/A	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs8103278	0.507	rs62111759	chr19:46296230	A/T	cg14061069	chr19:46274453	DMPK	0.62	10.75	0.69	1.95e-19	Coronary artery disease;
TGCT	cis	rs789852	0.681	rs789855	chr3:194329272	G/T	cg18000598	chr3:194342907	TMEM44	-0.65	-4.88	-0.4	3.25e-6	QT interval;
TGCT	cis	rs35883536	1.000	rs6681906	chr1:101086414	C/T	cg06223162	chr1:101003688	GPR88	0.31	4.89	0.4	3.07e-6	Monocyte count;
TGCT	cis	rs7772486	0.846	rs1331636	chr6:146338826	T/C	cg13319975	chr6:146136371	FBXO30	-0.51	-4.56	-0.38	1.23e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs727563	0.636	rs2187795	chr22:42092225	C/A	cg17554472	chr22:41940697	POLR3H	0.49	5.22	0.42	7.4e-7	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs514406	0.505	rs146750	chr1:53183447	C/G	cg01802117	chr1:53393560	SCP2	-0.39	-4.61	-0.38	9.88e-6	Monocyte count;
TGCT	cis	rs79349575	0.691	rs28528789	chr17:46986616	C/T	cg07967210	chr17:47022446	SNF8	-0.41	-5.44	-0.44	2.69e-7	Type 2 diabetes;
TGCT	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs853679	0.546	rs55690788	chr6:28436145	T/C	cg10876282	chr6:28092338	ZSCAN16	0.86	4.46	0.37	1.8e-5	Depression;
TGCT	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg06873352	chr17:61820015	STRADA	0.58	6.37	0.5	3.32e-9	Prudent dietary pattern;
TGCT	cis	rs9928842	0.882	rs9319481	chr16:75259478	T/C	cg09066997	chr16:75300724	BCAR1	0.28	5.01	0.41	1.85e-6	Alcoholic chronic pancreatitis;
TGCT	cis	rs2067615	0.579	rs10861665	chr12:107193836	T/C	cg15890332	chr12:107067104	RFX4	0.28	5.61	0.45	1.27e-7	Heart rate;
TGCT	cis	rs12908161	0.959	rs34342559	chr15:85331271	A/G	cg17173187	chr15:85201210	NMB	0.55	6.11	0.48	1.17e-8	Schizophrenia;
TGCT	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg11494091	chr17:61959527	GH2	0.61	14.43	0.79	2.59e-28	Prudent dietary pattern;
TGCT	cis	rs3947	1.000	rs1736085	chr8:11703659	T/C	cg02840367	chr8:11660030	FDFT1	0.9	6.51	0.5	1.64e-9	Blood protein levels;
TGCT	cis	rs2276314	0.857	rs62101393	chr18:33592168	T/C	cg19628046	chr18:33552617	C18orf21	0.51	4.46	0.37	1.79e-5	Endometriosis;Drug-induced torsades de pointes;
TGCT	cis	rs11711311	1.000	rs9828099	chr3:113518402	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.76	-7.16	-0.54	6.29e-11	IgG glycosylation;
TGCT	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg05985448	chr10:134359359	INPP5A	0.24	5.13	0.42	1.1e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs644799	0.710	rs12273579	chr11:95524421	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	8.5	0.61	5.03e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs8177253	0.632	rs6782523	chr3:133438917	C/T	cg11941060	chr3:133502564	NA	-0.26	-5.28	-0.43	5.54e-7	Iron status biomarkers;
TGCT	cis	rs2204008	0.744	rs11514073	chr12:38399553	A/C	cg26384229	chr12:38710491	ALG10B	0.84	7.42	0.55	1.62e-11	Bladder cancer;
TGCT	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg06896619	chr17:61851486	DDX42;CCDC47	-0.51	-4.69	-0.39	7.17e-6	Prudent dietary pattern;
TGCT	cis	rs6840360	0.642	rs11099815	chr4:152343888	G/T	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.41	-0.5	2.8e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	5.03	0.41	1.69e-6	Prudent dietary pattern;
TGCT	cis	rs6840360	0.571	rs4696101	chr4:152528513	A/G	cg17479576	chr4:152424074	FAM160A1	-0.73	-8.0	-0.58	7.69e-13	Intelligence (multi-trait analysis);
TGCT	cis	rs10392	0.571	rs4812350	chr20:37631192	C/T	cg27552599	chr20:37590471	DHX35	0.37	4.59	0.38	1.05e-5	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
TGCT	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg26338869	chr17:61819248	STRADA	-0.55	-5.08	-0.42	1.34e-6	Prudent dietary pattern;
TGCT	cis	rs2115630	0.653	rs61394864	chr15:85170174	T/C	cg17173187	chr15:85201210	NMB	-0.47	-5.91	-0.47	3.05e-8	P wave terminal force;
TGCT	cis	rs1857353	1.000	rs1913118	chr1:75886670	C/A	cg11838876	chr1:75668600	SLC44A5	-0.51	-4.81	-0.4	4.23e-6	Whole-brain volume (Alzheimer's disease interaction);
TGCT	cis	rs2718812	0.792	rs1867504	chr3:133410661	C/T	cg16414030	chr3:133502952	NA	-0.39	-5.14	-0.42	1.06e-6	Iron status biomarkers;
TGCT	cis	rs2439831	0.681	rs511673	chr15:43618863	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	6.63	0.51	9.35e-10	Lung cancer in ever smokers;
TGCT	cis	rs9929218	0.954	rs35794312	chr16:68827785	G/A	cg03880890	chr16:69439245	NA	-0.22	-4.47	-0.37	1.74e-5	Colorectal cancer;
TGCT	cis	rs17270561	0.779	rs12210620	chr6:25884785	T/C	cg17042849	chr6:26104293	HIST1H4C	-0.78	-5.52	-0.44	1.92e-7	Iron status biomarkers;
TGCT	cis	rs6089584	1.000	rs6089587	chr20:60564829	C/T	cg13770153	chr20:60521292	NA	-0.44	-5.69	-0.46	8.52e-8	Body mass index;
TGCT	cis	rs11711311	1.000	rs6792447	chr3:113508335	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.76	-7.16	-0.54	6.29e-11	IgG glycosylation;
TGCT	cis	rs6752107	1.000	rs6708373	chr2:234172846	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.19	4.65	0.39	8.35e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs9303401	0.659	rs34913878	chr17:56897094	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg06112835	chr11:68658793	MRPL21	0.48	8.14	0.59	3.49e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs9467773	1.000	rs9467774	chr6:26505036	C/A	cg09904177	chr6:26538194	HMGN4	0.65	6.53	0.51	1.5e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs11105298	0.891	rs11105316	chr12:89925200	T/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.7	-5.17	-0.42	8.99e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	trans	rs941408	1.000	rs4807332	chr19:2793289	T/C	cg19676328	chr12:49525230	TUBA1B	-0.76	-7.65	-0.57	4.74e-12	Total cholesterol levels;
TGCT	cis	rs4499344	0.730	rs12460663	chr19:33098238	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.85	8.76	0.62	1.23e-14	Mean platelet volume;
TGCT	cis	rs6988636	0.536	rs16898043	chr8:124155886	A/G	cg23067535	chr8:124195133	FAM83A	-0.37	-4.95	-0.41	2.39e-6	Urinary uromodulin levels;
TGCT	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg26338869	chr17:61819248	STRADA	-0.53	-4.87	-0.4	3.29e-6	Prudent dietary pattern;
TGCT	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg15595755	chr5:1867978	NA	0.46	5.29	0.43	5.29e-7	Cardiovascular disease risk factors;
TGCT	cis	rs12780845	0.505	rs7085742	chr10:17248828	G/C	cg01003015	chr10:17271136	VIM	-0.6	-5.53	-0.44	1.83e-7	Homocysteine levels;
TGCT	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.54	-6.95	-0.53	1.86e-10	Longevity;Endometriosis;
TGCT	cis	rs2760061	0.598	rs849904	chr1:228137145	G/C	cg18477163	chr1:228402036	OBSCN	-0.32	-6.34	-0.49	3.86e-9	Diastolic blood pressure;
TGCT	cis	rs9906944	0.713	rs9899580	chr17:47106878	T/G	cg20966754	chr17:47091339	IGF2BP1	-0.45	-5.17	-0.42	9.27e-7	Intelligence (multi-trait analysis);Body fat percentage;
TGCT	cis	rs7647973	1.000	rs13322887	chr3:49555583	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.54	-4.45	-0.37	1.87e-5	Menarche (age at onset);
TGCT	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg12419862	chr22:24373484	LOC391322	-0.84	-9.1	-0.63	1.92e-15	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	trans	rs4819388	0.915	rs7278940	chr21:45648992	C/T	cg17383793	chr5:52405638	MOCS2	-0.67	-6.82	-0.52	3.49e-10	Celiac disease;
TGCT	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg23758822	chr17:41437982	NA	0.69	6.37	0.5	3.34e-9	Menopause (age at onset);
TGCT	cis	rs7246657	0.678	rs2927740	chr19:38140966	A/G	cg03611452	chr19:38183253	ZNF781	-0.57	-4.79	-0.39	4.72e-6	Coronary artery calcification;
TGCT	cis	rs13191362	0.935	rs34934114	chr6:163082480	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.91	6.97	0.53	1.69e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs514406	0.505	rs436363	chr1:53172163	T/C	cg01802117	chr1:53393560	SCP2	-0.41	-4.69	-0.39	7.1e-6	Monocyte count;
TGCT	cis	rs76419734	0.558	rs10019217	chr4:106588509	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.81	5.36	0.43	3.9e-7	Post bronchodilator FEV1;
TGCT	cis	rs4919044	0.808	rs9419765	chr10:94798171	C/T	cg05127821	chr10:94822908	CYP26C1	-0.74	-4.83	-0.4	3.95e-6	Coronary artery disease;
TGCT	cis	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.66	6.54	0.51	1.45e-9	Eosinophil percentage of white cells;
TGCT	cis	rs911263	0.961	rs17105278	chr14:68728479	T/C	cg18825221	chr14:68749962	RAD51L1	-0.27	-5.24	-0.43	6.56e-7	Primary biliary cholangitis;
TGCT	cis	rs9810089	0.814	rs2688600	chr3:136252596	C/A	cg12473912	chr3:136751656	NA	0.35	4.79	0.4	4.67e-6	Gestational age at birth (child effect);
TGCT	cis	rs6570726	0.791	rs6570692	chr6:145904401	T/A	cg05347473	chr6:146136440	FBXO30	0.52	4.95	0.41	2.33e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7949030	0.653	rs17773169	chr11:62318530	G/T	cg22862634	chr11:62369728	EML3;MTA2	0.72	9.17	0.64	1.28e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs68170813	0.559	rs10953530	chr7:106827796	A/C	cg02696742	chr7:106810147	HBP1	-0.72	-6.05	-0.48	1.56e-8	Coronary artery disease;
TGCT	cis	rs10875595	0.691	rs1076361	chr5:140674609	C/T	cg24830062	chr5:140700576	TAF7	-0.73	-6.13	-0.48	1.1e-8	Pulmonary function decline;
TGCT	cis	rs478304	0.934	rs537786	chr11:65494987	C/T	cg17480646	chr11:65405466	SIPA1	0.42	5.02	0.41	1.78e-6	Acne (severe);
TGCT	cis	rs7923452	0.938	rs602473	chr10:30781996	T/C	cg18806716	chr10:30721971	MAP3K8	-0.69	-6.09	-0.48	1.32e-8	Itch intensity from mosquito bite;
TGCT	cis	rs548987	0.529	rs1165165	chr6:25862466	C/T	cg03517284	chr6:25882590	NA	-0.6	-4.92	-0.4	2.7e-6	Homocysteine levels;
TGCT	cis	rs78487399	0.808	rs7581586	chr2:43668176	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.24	-0.43	6.79e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs9858542	0.953	rs9814873	chr3:49454112	A/G	cg03060546	chr3:49711283	APEH	-0.62	-5.41	-0.44	3.09e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs13223928	0.572	rs16870744	chr7:3135781	G/A	cg19214707	chr7:3157722	NA	-0.43	-5.72	-0.46	7.3900000000000007e-08	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
TGCT	cis	rs6690583	0.623	rs12047435	chr1:85452927	T/G	cg20280350	chr1:85513789	MCOLN3	-0.69	-4.67	-0.39	7.58e-6	Serum sulfate level;
TGCT	cis	rs7647973	0.626	rs4855849	chr3:49653378	A/G	cg03034192	chr3:50606346	HEMK1;C3orf18	0.36	4.75	0.39	5.61e-6	Menarche (age at onset);
TGCT	cis	rs3796352	1.000	rs114562844	chr3:52991584	C/T	cg07884673	chr3:53033167	SFMBT1	0.6	5.53	0.44	1.82e-7	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs624899	0.655	rs8109248	chr19:11641375	C/T	cg01045132	chr19:11649571	CNN1	0.63	6.39	0.5	2.98e-9	Presence of antiphospholipid antibodies;
TGCT	cis	rs9653442	0.675	rs2871326	chr2:100662010	T/C	cg22139774	chr2:100720529	AFF3	-0.42	-7.45	-0.56	1.36e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.7	0.52	6.47e-10	Bipolar disorder;
TGCT	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg12310025	chr6:25882481	NA	-0.62	-5.69	-0.45	8.78e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs4987668	0.655	rs4252381	chr7:142629375	G/T	cg21621906	chr7:142494914	NA	-0.9	-4.62	-0.38	9.48e-6	Cancer;
TGCT	cis	rs2708977	0.637	rs687950	chr2:97069612	C/G	cg01950434	chr2:97203154	ARID5A	0.54	4.58	0.38	1.13e-5	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs12530845	0.945	rs73725433	chr7:135313251	C/T	cg23117316	chr7:135346802	PL-5283	-0.51	-4.83	-0.4	3.98e-6	Red blood cell traits;
TGCT	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg11890956	chr21:40555474	PSMG1	1.14	12.22	0.74	4.93e-23	Cognitive function;
TGCT	cis	rs208520	0.661	rs704519	chr6:66801136	T/C	cg07460842	chr6:66804631	NA	-0.94	-9.81	-0.66	3.56e-17	Exhaled nitric oxide output;
TGCT	cis	rs2361718	0.590	rs4527052	chr17:78140910	A/G	cg09238746	chr17:78121135	EIF4A3	-0.77	-7.39	-0.55	1.88e-11	Yeast infection;
TGCT	cis	rs958025	1	rs958025	chr15:78759348	C/T	cg24631222	chr15:78858424	CHRNA5	0.61	4.51	0.38	1.5e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
TGCT	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg21724239	chr8:58056113	NA	0.34	4.54	0.38	1.31e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs711245	0.573	rs11899523	chr2:36800918	T/C	cg10546459	chr2:36825355	FEZ2	0.57	5.18	0.42	8.89e-7	Height;
TGCT	cis	rs17076896	0.786	rs17080523	chr13:19932538	T/C	cg00777926	chr13:20807375	GJB6	-0.37	-4.53	-0.38	1.36e-5	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs11822910	1.000	rs2439448	chr11:57199211	T/C	cg00522883	chr11:57194120	SLC43A3	0.33	4.87	0.4	3.37e-6	Platelet distribution width;
TGCT	cis	rs9303401	0.614	rs62084387	chr17:57148027	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.58	5.83	0.46	4.42e-8	Cognitive test performance;
TGCT	cis	rs7809950	1.000	rs2066735	chr7:107188719	G/T	cg23024343	chr7:107201750	COG5	-0.31	-4.82	-0.4	4.03e-6	Coronary artery disease;
TGCT	cis	rs5769765	1.000	rs2319458	chr22:50236306	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.09	-11.81	-0.73	5.01e-22	Schizophrenia;
TGCT	cis	rs7923609	0.703	rs7100413	chr10:65330208	T/C	cg08743896	chr10:65200160	JMJD1C	0.32	4.46	0.37	1.82e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11098499	0.866	rs12513310	chr4:120288039	T/A	cg09307838	chr4:120376055	NA	0.58	5.76	0.46	6.16e-8	Corneal astigmatism;
TGCT	cis	rs17376456	0.825	rs10061377	chr5:93174513	T/C	cg25358565	chr5:93447407	FAM172A	0.95	7.62	0.56	5.63e-12	Diabetic retinopathy;
TGCT	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg08280861	chr8:58055591	NA	0.4	5.57	0.45	1.49e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs5769765	1.000	rs768619	chr22:50287266	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.4	6.02	0.48	1.81e-8	Schizophrenia;
TGCT	cis	rs7714584	1.000	rs6579804	chr5:150255931	T/C	cg22134413	chr5:150180641	NA	0.83	6.53	0.51	1.54e-9	Crohn's disease;
TGCT	trans	rs4650994	1.000	rs4650995	chr1:178517316	C/T	cg05059571	chr16:84539110	KIAA1609	-0.4	-7.43	-0.56	1.52e-11	HDL cholesterol levels;HDL cholesterol;
TGCT	cis	rs2710642	0.821	rs2710639	chr2:63138963	C/T	cg17519650	chr2:63277830	OTX1	0.58	4.98	0.41	2.11e-6	LDL cholesterol levels;LDL cholesterol;
TGCT	cis	rs12497850	0.897	rs9681717	chr3:48872998	A/G	cg07636037	chr3:49044803	WDR6	0.93	10.13	0.67	6.03e-18	Parkinson's disease;
TGCT	cis	rs7666738	0.830	rs28818180	chr4:98953625	A/G	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6565180	0.962	rs11642676	chr16:30371655	C/G	cg17640201	chr16:30407289	ZNF48	-0.87	-8.21	-0.59	2.4e-13	Tonsillectomy;
TGCT	cis	rs75686122	0.892	rs4734715	chr8:104508013	C/T	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs6540559	0.673	rs7550857	chr1:209956542	C/A	cg23283495	chr1:209979779	IRF6	0.67	5.11	0.42	1.18e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg23708337	chr7:1209742	NA	0.44	4.87	0.4	3.27e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg05457628	chr5:178986728	RUFY1	0.53	5.85	0.47	4.03e-8	Lung cancer;
TGCT	cis	rs694739	0.892	rs647152	chr11:64109118	T/G	cg23796481	chr11:64053134	BAD;GPR137	0.63	6.48	0.5	1.92e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs1865760	0.516	rs9393683	chr6:26066198	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.77	7.45	0.56	1.42e-11	Height;
TGCT	cis	rs28595532	0.800	rs67686161	chr4:119336720	C/T	cg21605333	chr4:119757512	SEC24D	0.85	5.43	0.44	2.84e-7	Cannabis dependence symptom count;
TGCT	cis	rs2070488	1.000	rs1841777	chr3:38484819	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	9.66	0.66	8.59e-17	Electrocardiographic conduction measures;
TGCT	cis	rs6840360	0.642	rs11729923	chr4:152392036	G/T	cg17479576	chr4:152424074	FAM160A1	-0.6	-6.4	-0.5	2.84e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs1348850	0.874	rs13013752	chr2:178456862	A/G	cg22681709	chr2:178499509	PDE11A	-0.4	-4.97	-0.41	2.18e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs9787249	0.957	rs6670841	chr1:40220284	C/G	cg24920358	chr1:40204285	PPIE	0.57	10.63	0.69	3.68e-19	Blood protein levels;
TGCT	cis	rs7726839	0.574	rs12517345	chr5:628294	G/A	cg20362242	chr5:692897	TPPP	0.52	4.65	0.39	8.29e-6	Obesity-related traits;
TGCT	cis	rs9393777	0.513	rs6913660	chr6:27091425	C/A	cg16898833	chr6:26189333	HIST1H4D	0.8	4.85	0.4	3.57e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1903068	0.927	rs12331507	chr4:56011889	A/G	cg09978860	chr4:56023921	NA	-0.51	-5.58	-0.45	1.42e-7	Endometriosis;
TGCT	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.84	0.46	4.39e-8	Height;
TGCT	cis	rs9952991	0.608	rs9960807	chr18:12770851	A/G	cg24737193	chr18:12778029	NA	-0.53	-4.68	-0.39	7.28e-6	Inflammatory skin disease;
TGCT	cis	rs7237497	0.532	rs515151	chr18:12860934	G/C	cg23544223	chr18:12777786	NA	0.55	4.85	0.4	3.57e-6	Inflammatory skin disease;
TGCT	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.27	-0.43	5.94e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7584330	0.826	rs7604315	chr2:238381729	C/G	cg14458575	chr2:238380390	NA	0.54	8.7	0.62	1.69e-14	Prostate cancer;
TGCT	cis	rs1903068	0.719	rs9284955	chr4:56003117	A/G	cg01777861	chr4:56023843	NA	-0.53	-5.73	-0.46	7.13e-8	Endometriosis;
TGCT	cis	rs10435719	0.902	rs7459545	chr8:11804389	G/T	cg02840367	chr8:11660030	FDFT1	-0.52	-4.48	-0.37	1.7e-5	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs9914988	0.943	rs4794839	chr17:27131393	G/A	cg20469991	chr17:27169893	C17orf63	-0.72	-5.09	-0.42	1.29e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs1453308	1.000	rs1377444	chr2:237183481	A/G	cg19324714	chr2:237145437	ASB18	0.58	5.13	0.42	1.11e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs7226408	0.802	rs72887095	chr18:34508949	A/G	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs12477438	0.765	rs13406288	chr2:99589585	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-4.88	-0.4	3.17e-6	Chronic sinus infection;
TGCT	cis	rs9388451	0.626	rs9385383	chr6:126086290	G/T	cg05901451	chr6:126070800	HEY2	-0.96	-12.17	-0.74	6.58e-23	Brugada syndrome;
TGCT	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg27454412	chr7:1067447	C7orf50	0.6	4.72	0.39	6.32e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7829975	0.807	rs519019	chr8:8595104	A/T	cg15556689	chr8:8085844	FLJ10661	-0.65	-5.67	-0.45	9.5e-8	Mood instability;
TGCT	trans	rs1814175	0.817	rs12290508	chr11:49621037	C/T	cg15704280	chr7:45808275	SEPT13	-0.73	-8.64	-0.61	2.35e-14	Height;
TGCT	cis	rs57920188	0.535	rs112660254	chr1:4089921	T/G	cg20703997	chr1:4087676	NA	0.49	6.2	0.49	7.57e-9	Interleukin-17 levels;
TGCT	cis	rs727505	0.865	rs17325193	chr7:124648385	A/G	cg23710748	chr7:124431027	NA	-0.26	-4.55	-0.38	1.27e-5	Lewy body disease;
TGCT	cis	rs6459788	0.585	rs6950818	chr7:157235364	C/G	cg03453431	chr7:157225567	NA	-0.5	-7.79	-0.57	2.3e-12	Epstein-Barr virus copy number in lymphoblastoid cell lines;
TGCT	cis	rs4803468	0.763	rs17318596	chr19:41937095	A/G	cg09537434	chr19:41945824	ATP5SL	-0.9	-9.53	-0.65	1.74e-16	Height;
TGCT	cis	rs79349575	0.721	rs3744608	chr17:46993233	C/G	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.51	-0.38	1.48e-5	Type 2 diabetes;
TGCT	cis	rs4478858	0.660	rs10798844	chr1:31819128	A/G	cg00250761	chr1:31883323	NA	-0.29	-5.12	-0.42	1.13e-6	Alcohol dependence;
TGCT	cis	rs1670533	1.000	rs6599278	chr4:1058798	C/T	cg20887711	chr4:1340912	KIAA1530	0.69	5.69	0.46	8.55e-8	Recombination rate (females);
TGCT	cis	rs1023500	0.956	rs1894713	chr22:42335621	G/A	cg04692870	chr22:42525206	CYP2D6	-0.35	-5.22	-0.42	7.18e-7	Schizophrenia;
TGCT	cis	rs7666738	0.830	rs62321565	chr4:98976571	G/A	cg17366294	chr4:99064904	C4orf37	0.68	6.94	0.53	1.95e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4819052	0.851	rs7279182	chr21:46656112	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	4.76	0.39	5.4e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.38	-5.03	-0.41	1.69e-6	Menarche (age at onset);
TGCT	cis	rs12142240	0.698	rs66483119	chr1:46838389	T/C	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs9733	0.596	rs6681990	chr1:150695929	A/G	cg09365446	chr1:150670422	GOLPH3L	0.3	4.52	0.38	1.4e-5	Tonsillectomy;
TGCT	cis	rs6121246	0.542	rs2376990	chr20:30238744	G/A	cg13852791	chr20:30311386	BCL2L1	0.69	4.45	0.37	1.9e-5	Mean corpuscular hemoglobin;
TGCT	cis	rs7209700	0.644	rs7214468	chr17:45370766	G/A	cg21624342	chr17:45890973	OSBPL7	0.18	5.1	0.42	1.24e-6	IgG glycosylation;
TGCT	cis	rs62064224	0.702	rs2302277	chr17:30791509	C/G	cg09324608	chr17:30823087	MYO1D	0.22	4.45	0.37	1.89e-5	Schizophrenia;
TGCT	cis	rs35306767	0.714	rs66797613	chr10:1090469	C/T	cg20503657	chr10:835505	NA	0.6	6.93	0.53	2e-10	Eosinophil percentage of granulocytes;
TGCT	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.8	6.5	0.5	1.75e-9	Mean platelet volume;
TGCT	cis	rs840163	0.512	rs4759260	chr12:57265375	G/A	cg20779414	chr12:57505882	STAT6	-0.44	-4.87	-0.4	3.31e-6	Alzheimer's disease (survival time);
TGCT	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg27425262	chr2:113953981	PSD4;LOC440839	-0.52	-8.2	-0.59	2.52e-13	Lymphocyte counts;
TGCT	cis	rs2235642	0.717	rs9937922	chr16:1658154	C/G	cg11375102	chr16:1583810	IFT140;TMEM204	-0.27	-4.66	-0.39	7.88e-6	Coronary artery disease;
TGCT	cis	rs860295	0.557	rs12037177	chr1:155877029	C/T	cg13795986	chr1:155880507	RIT1	-0.37	-4.47	-0.37	1.72e-5	Body mass index;
TGCT	cis	rs1520333	0.918	rs11994210	chr8:79344992	A/G	cg16589705	chr8:80226364	NA	-0.3	-4.47	-0.37	1.74e-5	Multiple sclerosis;
TGCT	cis	rs9467603	1.000	rs6940698	chr6:25821580	A/G	cg16898833	chr6:26189333	HIST1H4D	-1.13	-5.87	-0.47	3.65e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs12451471	0.559	rs12452263	chr17:78079310	T/C	cg06718696	chr17:78121285	EIF4A3	0.71	5.89	0.47	3.42e-8	Plateletcrit;Mean corpuscular hemoglobin concentration;
TGCT	cis	rs7267979	0.509	rs6115218	chr20:25566485	A/G	cg15001687	chr20:25566336	NINL	0.45	5.03	0.41	1.7e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	6.07	0.48	1.47e-8	Bipolar disorder;
TGCT	cis	rs2067615	0.579	rs10861655	chr12:107129419	A/G	cg15890332	chr12:107067104	RFX4	-0.28	-5.63	-0.45	1.15e-7	Heart rate;
TGCT	cis	rs453301	0.592	rs4841084	chr8:8883905	C/T	cg15556689	chr8:8085844	FLJ10661	0.82	7.24	0.55	4.15e-11	Joint mobility (Beighton score);
TGCT	cis	rs2663905	0.664	rs2460855	chr15:81361729	G/T	cg27045999	chr15:81426544	C15orf26	-0.53	-5.06	-0.41	1.46e-6	QT interval (drug interaction);
TGCT	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg08736216	chr1:53307985	ZYG11A	-0.25	-4.68	-0.39	7.33e-6	Monocyte count;
TGCT	cis	rs7809950	0.834	rs3801946	chr7:107242995	T/A	cg23024343	chr7:107201750	COG5	0.33	5.29	0.43	5.36e-7	Coronary artery disease;
TGCT	cis	rs13242816	1.000	rs34325296	chr7:116122409	C/T	cg02799643	chr7:116139180	CAV2	-0.49	-5.53	-0.45	1.78e-7	P wave duration;
TGCT	cis	rs4851254	0.660	rs58683655	chr2:100686519	G/C	cg22139774	chr2:100720529	AFF3	-0.45	-4.91	-0.4	2.75e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.54	-0.38	1.33e-5	Bipolar disorder;
TGCT	cis	rs1218582	0.772	rs2061690	chr1:154919080	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.64	-6.55	-0.51	1.35e-9	Prostate cancer;
TGCT	cis	rs3741404	0.609	rs592271	chr11:63872029	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.72	7.39	0.55	1.89e-11	Platelet count;
TGCT	cis	rs7568458	0.684	rs60012532	chr2:85752474	A/C	cg02493740	chr2:85810744	VAMP5	-0.29	-5.68	-0.45	9.08e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs9467773	1.000	rs4713008	chr6:26538268	T/C	cg05738196	chr6:26577821	NA	0.88	12.5	0.75	1.03e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs3764400	0.567	rs12939334	chr17:46302669	A/G	cg02340556	chr17:46797764	NA	0.42	4.51	0.38	1.46e-5	Body mass index;
TGCT	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg03188948	chr7:1209495	NA	0.47	6.15	0.48	9.79e-9	Longevity;Endometriosis;
TGCT	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg14893161	chr1:205819251	PM20D1	0.53	7.0	0.53	1.39e-10	Menarche (age at onset);
TGCT	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg03517284	chr6:25882590	NA	-0.53	-5.43	-0.44	2.88e-7	Blood metabolite levels;
TGCT	cis	rs9653442	0.866	rs11123811	chr2:100760172	T/C	cg07810366	chr2:100720526	AFF3	-0.47	-8.04	-0.59	6.16e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs7914558	1.000	rs10786740	chr10:104935593	G/C	cg15744005	chr10:104629667	AS3MT	-0.39	-4.75	-0.39	5.53e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs6570726	0.791	rs422099	chr6:145806936	C/T	cg05347473	chr6:146136440	FBXO30	0.51	4.72	0.39	6.14e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs453301	0.631	rs17700611	chr8:8793654	A/G	cg06636001	chr8:8085503	FLJ10661	-0.67	-5.73	-0.46	7.16e-8	Joint mobility (Beighton score);
TGCT	cis	rs7617773	1.000	rs6442109	chr3:48192981	G/A	cg11946769	chr3:48343235	NME6	-0.59	-5.33	-0.43	4.54e-7	Coronary artery disease;
TGCT	cis	rs7172809	0.863	rs74026932	chr15:77825729	T/C	cg22256960	chr15:77711686	NA	-0.44	-4.48	-0.37	1.67e-5	Glucose homeostasis traits;
TGCT	cis	rs7264396	0.635	rs6060720	chr20:34548336	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.04	-0.41	1.58e-6	Total cholesterol levels;
TGCT	cis	rs910316	0.904	rs7156089	chr14:75645527	A/G	cg23033748	chr14:75592666	NEK9	-0.29	-4.88	-0.4	3.17e-6	Height;
TGCT	cis	rs28785552	0.931	rs8113078	chr19:53239084	T/G	cg10871876	chr19:53194124	ZNF83	0.6	8.76	0.62	1.2e-14	Response to paliperidone in schizophrenia (PANSS score);
TGCT	cis	rs8077577	0.895	rs16960980	chr17:18100858	C/T	cg09161412	chr17:18057145	MYO15A	-0.6	-4.79	-0.4	4.59e-6	Obesity-related traits;
TGCT	cis	rs7666738	0.830	rs62318470	chr4:98925846	A/C	cg05340658	chr4:99064831	C4orf37	0.52	5.85	0.46	4.16e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2486288	0.656	rs7165039	chr15:45570413	C/G	cg26924012	chr15:45694286	SPATA5L1	-0.78	-7.55	-0.56	8e-12	Glomerular filtration rate;
TGCT	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg14851468	chr5:179071604	C5orf60	0.27	5.56	0.45	1.59e-7	Lung cancer;
TGCT	cis	rs7914558	0.966	rs1971589	chr10:104744406	A/G	cg15744005	chr10:104629667	AS3MT	-0.41	-5.08	-0.42	1.33e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg08045932	chr20:61659980	NA	0.48	9.16	0.64	1.36e-15	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7726839	0.507	rs111707179	chr5:593308	T/A	cg16624210	chr5:671434	TPPP	0.45	4.92	0.4	2.71e-6	Obesity-related traits;
TGCT	trans	rs208520	0.770	rs1342960	chr6:66883514	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.95	-10.37	-0.68	1.58e-18	Exhaled nitric oxide output;
TGCT	cis	rs6964587	0.967	rs12531966	chr7:91765840	A/G	cg17063962	chr7:91808500	NA	0.91	9.72	0.66	5.97e-17	Breast cancer;
TGCT	cis	rs548181	0.609	rs511822	chr11:125534115	C/T	cg03464685	chr11:125439445	EI24	1.38	9.91	0.66	2.14e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg06873352	chr17:61820015	STRADA	0.55	6.1	0.48	1.26e-8	Prudent dietary pattern;
TGCT	cis	rs12477438	0.798	rs10196680	chr2:99628617	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-8.52	-0.61	4.5e-14	Chronic sinus infection;
TGCT	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg26116260	chr4:7069785	GRPEL1	1.1	10.75	0.69	1.89e-19	Monocyte percentage of white cells;
TGCT	cis	rs7666738	0.753	rs6826709	chr4:98714553	C/G	cg17366294	chr4:99064904	C4orf37	0.67	6.91	0.53	2.31e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7631605	0.905	rs72866099	chr3:37259646	C/A	cg17445812	chr3:36986805	TRANK1	0.21	4.59	0.38	1.09e-5	Cerebrospinal P-tau181p levels;
TGCT	cis	rs7613051	0.649	rs6777787	chr3:33057103	A/G	cg19404215	chr3:33155277	CRTAP	0.53	4.53	0.38	1.34e-5	Atopic dermatitis;
TGCT	cis	rs727505	1.000	rs2402751	chr7:124434760	C/T	cg23710748	chr7:124431027	NA	-0.25	-4.49	-0.37	1.6e-5	Lewy body disease;
TGCT	cis	rs7100689	0.697	rs4934084	chr10:82116960	T/C	cg01528321	chr10:82214614	TSPAN14	0.88	8.48	0.61	5.61e-14	Post bronchodilator FEV1;
TGCT	cis	rs2797160	1.000	rs9491471	chr6:125991715	C/T	cg05901451	chr6:126070800	HEY2	-0.74	-6.57	-0.51	1.23e-9	Endometrial cancer;
TGCT	cis	rs8068544	0.818	rs8079958	chr17:40155467	C/T	cg13092355	chr17:39992602	KLHL10;NT5C3L	-0.95	-4.64	-0.38	8.56e-6	Reticulocyte fraction of red cells;Reticulocyte count;
TGCT	cis	rs7959452	0.868	rs12812860	chr12:69746671	T/C	cg20891283	chr12:69753455	YEATS4	0.69	6.81	0.52	3.67e-10	Blood protein levels;
TGCT	cis	rs2862064	0.799	rs4704835	chr5:156443251	G/A	cg12943317	chr5:156479607	HAVCR1	-0.36	-4.79	-0.39	4.73e-6	Platelet count;
TGCT	cis	rs10751647	0.804	rs3809112	chr11:307036	C/T	cg06046490	chr11:320940	IFITM3	0.29	4.95	0.41	2.35e-6	Monocyte count;
TGCT	cis	rs1355023	0.547	rs6568402	chr6:106207093	A/G	cg17356964	chr6:106582638	NA	0.27	4.86	0.4	3.48e-6	Age-related macular degeneration;
TGCT	cis	rs9858542	0.953	rs1801143	chr3:49570200	C/T	cg03060546	chr3:49711283	APEH	-0.61	-5.37	-0.43	3.78e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs7937682	0.575	rs7114617	chr11:111768173	A/T	cg09085632	chr11:111637200	PPP2R1B	0.91	8.56	0.61	3.6e-14	Primary sclerosing cholangitis;
TGCT	cis	rs4253772	0.591	rs6008546	chr22:46686377	T/G	cg24881330	chr22:46731750	TRMU	0.95	5.76	0.46	6.26e-8	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg17554472	chr22:41940697	POLR3H	0.49	5.16	0.42	9.72e-7	Vitiligo;
TGCT	cis	rs3008870	1.000	rs2815371	chr1:67504313	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.07	11.02	0.7	4.12e-20	Lymphocyte percentage of white cells;
TGCT	cis	rs10751667	0.925	rs7115336	chr11:988101	C/G	cg06064525	chr11:970664	AP2A2	-0.31	-6.16	-0.48	9.52e-9	Alzheimer's disease (late onset);
TGCT	cis	rs9653442	0.675	rs961788	chr2:100641459	T/C	cg22139774	chr2:100720529	AFF3	-0.41	-7.31	-0.55	2.85e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg01017244	chr2:74357527	NA	0.5	8.09	0.59	4.65e-13	Gestational age at birth (maternal effect);
TGCT	cis	rs10927875	0.632	rs4661666	chr1:16162471	C/A	cg21385522	chr1:16154831	NA	-1.0	-17.61	-0.85	1.57e-35	Dilated cardiomyopathy;
TGCT	cis	rs9467773	0.526	rs9688946	chr6:26367445	C/A	cg05738196	chr6:26577821	NA	-0.63	-6.61	-0.51	1.01e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs3806843	0.551	rs184996	chr5:140323773	T/A	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	trans	rs9388451	0.626	rs1343115	chr6:126069817	C/G	cg05039488	chr6:79577232	IRAK1BP1	-0.87	-9.71	-0.66	6.39e-17	Brugada syndrome;
TGCT	cis	rs10986311	0.537	rs10818938	chr9:127049237	G/A	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.19	-4.58	-0.38	1.09e-5	Vitiligo;
TGCT	cis	rs7223966	0.729	rs7921	chr17:62006259	G/A	cg18032289	chr17:61959525	GH2	-0.3	-4.46	-0.37	1.81e-5	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs17102423	0.594	rs2781373	chr14:65568215	G/A	cg11161011	chr14:65562177	MAX	-0.47	-6.44	-0.5	2.41e-9	Obesity-related traits;
TGCT	cis	rs7914558	1.000	rs10786733	chr10:104794947	G/A	cg04362960	chr10:104952993	NT5C2	0.62	5.51	0.44	1.97e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs4595586	0.545	rs11615634	chr12:39364704	A/C	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg23719950	chr11:63933701	MACROD1	-0.71	-5.91	-0.47	3.06e-8	Mean platelet volume;
TGCT	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg27286337	chr10:134555280	INPP5A	0.37	4.52	0.38	1.4e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs7131987	0.903	rs1035604	chr12:29393102	G/A	cg09582351	chr12:29534625	ERGIC2	-0.24	-4.55	-0.38	1.26e-5	QT interval;
TGCT	cis	rs3617	0.573	rs56383738	chr3:52908398	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.51	-4.94	-0.41	2.46e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7666738	0.830	rs4619898	chr4:98959646	G/A	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg04414720	chr1:150670196	GOLPH3L	0.39	5.04	0.41	1.58e-6	Tonsillectomy;
TGCT	cis	rs73198271	0.740	rs964771	chr8:8650939	A/G	cg15556689	chr8:8085844	FLJ10661	0.6	4.46	0.37	1.78e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
TGCT	cis	rs12682352	0.602	rs13260419	chr8:8675176	A/G	cg15556689	chr8:8085844	FLJ10661	0.59	5.08	0.41	1.35e-6	Neuroticism;
TGCT	cis	rs9419702	0.538	rs9419625	chr10:133534954	T/G	cg20568497	chr10:133558893	NA	0.43	4.68	0.39	7.31e-6	Survival in rectal cancer;
TGCT	cis	rs73201462	0.901	rs17282209	chr3:127715196	A/G	cg06138505	chr3:127317209	MCM2	0.99	4.77	0.39	5.18e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
TGCT	trans	rs4332037	0.851	rs34040190	chr7:1920356	G/A	cg10840412	chr1:235813424	GNG4	1.06	8.3	0.6	1.53e-13	Bipolar disorder;
TGCT	trans	rs56011263	0.687	rs4690292	chr4:703712	A/G	cg12575136	chr18:32820987	ZNF397	0.79	9.62	0.65	1.06e-16	White blood cell count;
TGCT	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg27436995	chr16:743998	FBXL16	-0.47	-5.12	-0.42	1.13e-6	Height;
TGCT	cis	rs3771570	1.000	rs56156035	chr2:242205955	T/A	cg21155796	chr2:242212141	HDLBP	0.94	6.69	0.51	6.9e-10	Prostate cancer;
TGCT	cis	rs9457247	1.000	rs376551	chr6:167384923	G/A	cg25258033	chr6:167368657	RNASET2	0.18	4.49	0.37	1.63e-5	Crohn's disease;
TGCT	trans	rs783396	0.792	rs783416	chr6:106964765	C/T	cg09013229	chr1:225332226	DNAH14	-0.53	-6.66	-0.51	8.13e-10	Stroke;
TGCT	cis	rs7666738	0.546	rs13148080	chr4:98680947	A/G	cg17366294	chr4:99064904	C4orf37	0.58	5.36	0.43	3.87e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg13902645	chr11:5959945	NA	0.36	4.47	0.37	1.75e-5	DNA methylation (variation);
TGCT	cis	rs11696845	0.626	rs4810439	chr20:43377870	C/G	cg25301532	chr20:43378953	KCNK15	-0.46	-4.85	-0.4	3.58e-6	Obesity-related traits;
TGCT	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg00149659	chr3:10157352	C3orf10	0.78	4.99	0.41	2.04e-6	Alzheimer's disease;
TGCT	cis	rs6987853	0.814	rs2167338	chr8:42455079	A/G	cg20539142	chr8:42623718	CHRNA6	-0.19	-4.63	-0.38	9.1e-6	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs6450176	0.638	rs3822497	chr5:53299693	C/G	ch.5.1024479R	chr5:53302184	ARL15	-0.76	-5.52	-0.44	1.92e-7	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
TGCT	cis	rs28595532	0.920	rs17259173	chr4:119777232	T/C	cg21605333	chr4:119757512	SEC24D	1.53	8.87	0.62	6.71e-15	Cannabis dependence symptom count;
TGCT	cis	rs8033133	0.881	rs3803328	chr15:25330550	T/A	cg14481604	chr15:25334117	SNORD116-22	-0.31	-6.95	-0.53	1.82e-10	Blood osmolality (transformed sodium);
TGCT	cis	rs9926296	0.562	rs4785725	chr16:89893243	A/G	cg26513180	chr16:89883248	FANCA	0.72	7.15	0.54	6.73e-11	Vitiligo;
TGCT	cis	rs8038465	0.638	rs8036954	chr15:73974282	T/C	cg15420318	chr15:73925796	NPTN	0.71	7.83	0.58	1.88e-12	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1008375	1.000	rs6849704	chr4:17652031	G/C	cg16339924	chr4:17578868	LAP3	0.63	5.33	0.43	4.49e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs12048904	0.964	rs3188491	chr1:101338482	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.48	4.62	0.38	9.44e-6	Multiple sclerosis;
TGCT	cis	rs11971779	0.700	rs11763942	chr7:139005795	A/T	cg07862535	chr7:139043722	LUC7L2	0.67	5.38	0.44	3.57e-7	Diisocyanate-induced asthma;
TGCT	cis	rs4455778	0.580	rs4244231	chr7:49103406	G/A	cg26309511	chr7:48887640	NA	0.5	6.49	0.5	1.87e-9	Lung cancer in never smokers;
TGCT	cis	rs12497850	0.866	rs6791234	chr3:48996137	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.42	-5.42	-0.44	2.97e-7	Parkinson's disease;
TGCT	trans	rs941408	1.000	rs941406	chr19:2803623	A/G	cg19676328	chr12:49525230	TUBA1B	-0.88	-8.09	-0.59	4.59e-13	Total cholesterol levels;
TGCT	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg00814883	chr7:100076585	TSC22D4	-0.92	-9.76	-0.66	4.73e-17	Platelet count;
TGCT	cis	rs17030434	0.953	rs74845915	chr4:154696778	G/T	cg14289246	chr4:154710475	SFRP2	-0.95	-7.52	-0.56	9.48e-12	Electrocardiographic conduction measures;
TGCT	cis	rs933688	1.000	rs6452951	chr5:90653868	T/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	9.32	0.64	5.44e-16	Smoking behavior;
TGCT	cis	rs2688608	0.620	rs7080350	chr10:75577843	A/G	cg04320760	chr10:75533139	FUT11	0.36	5.6	0.45	1.33e-7	Inflammatory bowel disease;
TGCT	trans	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg23505145	chr19:12996616	KLF1	0.79	8.3	0.6	1.47e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs7100689	0.622	rs2342816	chr10:82086546	G/A	cg01528321	chr10:82214614	TSPAN14	0.75	7.49	0.56	1.15e-11	Post bronchodilator FEV1;
TGCT	cis	rs9611565	0.504	rs5758452	chr22:42144927	G/A	cg06481639	chr22:41940642	POLR3H	0.53	4.54	0.38	1.29e-5	Vitiligo;
TGCT	trans	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg23505145	chr19:12996616	KLF1	0.79	8.3	0.6	1.47e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg17264618	chr3:40429014	ENTPD3	0.34	4.94	0.41	2.52e-6	Renal cell carcinoma;
TGCT	cis	rs933688	1.000	rs4382199	chr5:90744228	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.94	7.95	0.58	9.95e-13	Smoking behavior;
TGCT	trans	rs1496653	0.602	rs58522464	chr3:23480731	G/A	cg02770683	chr12:57597238	LRP1	0.38	6.89	0.53	2.53e-10	Type 2 diabetes;
TGCT	cis	rs9527	0.590	rs10786744	chr10:104945028	A/C	cg15744005	chr10:104629667	AS3MT	0.42	4.83	0.4	3.9e-6	Arsenic metabolism;
TGCT	cis	rs4304924	0.500	rs7339081	chr13:79235501	A/G	cg05295671	chr13:79234353	RNF219	0.82	6.68	0.51	7.27e-10	Large artery stroke;
TGCT	cis	rs41307935	0.818	rs34339345	chr1:27226089	G/A	cg23921621	chr1:27994728	IFI6	-0.43	-4.61	-0.38	9.95e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs778371	0.723	rs10210953	chr2:233698830	G/A	cg08000102	chr2:233561755	GIGYF2	-0.72	-8.68	-0.61	1.91e-14	Schizophrenia;
TGCT	cis	rs6490294	0.904	rs7295722	chr12:112394260	C/T	cg10833066	chr12:111807467	FAM109A	0.38	5.61	0.45	1.24e-7	Mean platelet volume;
TGCT	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg07507251	chr3:52567010	NT5DC2	0.47	6.64	0.51	8.82e-10	Electroencephalogram traits;
TGCT	cis	rs12220238	0.915	rs10824148	chr10:76078014	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.9	6.28	0.49	5.18e-9	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs13256369	0.802	rs11995449	chr8:8559898	G/A	cg18904891	chr8:8559673	CLDN23	0.56	5.0	0.41	1.94e-6	Obesity-related traits;
TGCT	cis	rs9534288	0.619	rs1326397	chr13:46682122	T/C	cg15192986	chr13:46630673	CPB2	-0.51	-6.11	-0.48	1.17e-8	Blood protein levels;
TGCT	cis	rs861020	0.606	rs627459	chr1:210004682	C/G	cg05527609	chr1:210001259	C1orf107	0.86	7.54	0.56	8.69e-12	Orofacial clefts;
TGCT	cis	rs9486719	1.000	rs2142652	chr6:96868504	A/C	cg18709589	chr6:96969512	KIAA0776	0.71	5.21	0.42	7.61e-7	Migraine;Coronary artery disease;
TGCT	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg13683864	chr3:40499215	RPL14	-1.19	-13.2	-0.76	2.17e-25	Renal cell carcinoma;
TGCT	cis	rs4730250	0.707	rs257382	chr7:106804249	A/G	cg02696742	chr7:106810147	HBP1	-0.7	-5.44	-0.44	2.74e-7	Osteoarthritis;
TGCT	cis	rs1322512	1.000	rs1631457	chr6:152946514	C/T	cg03415253	chr6:152958462	SYNE1	-0.57	-4.99	-0.41	2e-6	Tonometry;
TGCT	cis	rs3008870	1.000	rs2009319	chr1:67481070	G/T	cg03991309	chr1:68237761	GNG12	0.27	4.57	0.38	1.18e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs319204	0.959	rs319237	chr5:146240443	C/T	cg25021259	chr5:146258546	PPP2R2B	0.36	4.53	0.38	1.37e-5	Schizophrenia;
TGCT	cis	rs7582180	0.629	rs11686842	chr2:100956139	C/T	cg14675211	chr2:100938903	LONRF2	0.5	4.78	0.39	4.81e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs2067615	0.507	rs1922432	chr12:107077232	G/A	cg15890332	chr12:107067104	RFX4	0.27	5.21	0.42	7.58e-7	Heart rate;
TGCT	cis	rs11696501	0.793	rs4812909	chr20:44167244	G/A	cg11783356	chr20:44313418	WFDC10B	-0.33	-4.54	-0.38	1.33e-5	Brain structure;
TGCT	cis	rs12579753	1.000	rs12580330	chr12:82241280	T/G	cg07988820	chr12:82153109	PPFIA2	-0.6	-6.48	-0.5	1.91e-9	Resting heart rate;
TGCT	cis	rs6952808	0.931	rs12537479	chr7:1868995	A/G	cg22963979	chr7:1858916	MAD1L1	0.3	4.65	0.39	8.24e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs651907	0.535	rs11717638	chr3:101505468	A/G	cg12386194	chr3:101231763	SENP7	0.48	4.81	0.4	4.36e-6	Colorectal cancer;
TGCT	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg03188948	chr7:1209495	NA	0.71	6.04	0.48	1.68e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9486719	1.000	rs2472880	chr6:96860130	G/A	cg06623918	chr6:96969491	KIAA0776	1.01	8.86	0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs1865760	0.713	rs6928951	chr6:25995554	C/T	cg16482183	chr6:26056742	HIST1H1C	0.54	4.77	0.39	5.15e-6	Height;
TGCT	cis	rs2832191	0.720	rs4643617	chr21:30485278	T/C	cg08807101	chr21:30365312	RNF160	-0.64	-6.01	-0.48	1.9e-8	Dental caries;
TGCT	cis	rs8031584	0.723	rs11632229	chr15:31179534	A/G	cg08109568	chr15:31115862	NA	0.38	4.98	0.41	2.12e-6	Huntington's disease progression;
TGCT	cis	rs7818688	0.697	rs112411609	chr8:95980854	C/A	cg16049864	chr8:95962084	TP53INP1	0.54	4.64	0.38	8.87e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs7259965	0.582	rs3895941	chr19:41531212	T/C	cg27089200	chr19:41531976	NA	0.52	6.7	0.52	6.45e-10	Midgestational circulating levels of PBDEs;Midgestational circulating levels of organochlorine pesticides;
TGCT	cis	rs151997	1.000	rs32483	chr5:50205230	C/T	cg06027927	chr5:50259733	NA	0.47	4.83	0.4	3.9e-6	Callous-unemotional behaviour;
TGCT	cis	rs12142240	0.667	rs55887761	chr1:46826587	C/A	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs208520	0.802	rs4710314	chr6:66883656	G/A	cg07460842	chr6:66804631	NA	-0.9	-9.33	-0.64	5.29e-16	Exhaled nitric oxide output;
TGCT	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg03517284	chr6:25882590	NA	-0.53	-5.43	-0.44	2.88e-7	Blood metabolite levels;
TGCT	cis	rs7267979	0.932	rs6138600	chr20:25521346	A/T	cg03522245	chr20:25566470	NINL	0.6	6.46	0.5	2.14e-9	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg12310025	chr6:25882481	NA	-0.67	-5.99	-0.47	2.11e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs2832077	0.527	rs9981922	chr21:30212718	A/G	cg24692254	chr21:30365293	RNF160	-0.6	-5.24	-0.43	6.82e-7	Cognitive test performance;
TGCT	cis	rs4372836	0.729	rs7567861	chr2:29035849	C/T	cg09522027	chr2:28974177	PPP1CB	-0.7	-7.26	-0.55	3.68e-11	Body mass index;
TGCT	cis	rs6921919	0.583	rs11751693	chr6:28345083	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.56	-5.33	-0.43	4.48e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs11650494	0.908	rs117853079	chr17:47421593	G/C	cg08112188	chr17:47440006	ZNF652	1.04	5.34	0.43	4.3e-7	Prostate cancer;
TGCT	cis	rs651907	0.557	rs3094297	chr3:101399260	A/G	cg12386194	chr3:101231763	SENP7	0.48	4.96	0.41	2.3e-6	Colorectal cancer;
TGCT	cis	rs736801	0.521	rs41525648	chr5:131827775	A/G	cg02551604	chr5:131831745	NA	0.76	8.45	0.6	6.53e-14	Breast cancer;Mosquito bite size;
TGCT	cis	rs12477438	0.765	rs4374423	chr2:99662348	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-7.6	-0.56	6.47e-12	Chronic sinus infection;
TGCT	cis	rs8180040	0.620	rs9875235	chr3:47083621	G/A	cg27129171	chr3:47204927	SETD2	0.71	8.51	0.61	4.8e-14	Colorectal cancer;
TGCT	cis	rs2204008	0.683	rs11519834	chr12:38053575	T/A	cg26384229	chr12:38710491	ALG10B	0.86	7.77	0.57	2.55e-12	Bladder cancer;
TGCT	cis	rs6701037	0.566	rs4344281	chr1:175135376	C/T	cg08873628	chr1:175162347	KIAA0040	0.47	4.57	0.38	1.18e-5	Alcohol dependence;
TGCT	cis	rs3892630	0.588	rs7260037	chr19:33242701	G/A	cg22980127	chr19:33182716	NUDT19	0.74	6.09	0.48	1.3e-8	Red blood cell traits;
TGCT	cis	rs7772486	0.686	rs4896828	chr6:145953339	A/C	cg13319975	chr6:146136371	FBXO30	-0.52	-4.78	-0.39	4.81e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs2075371	0.933	rs1421480	chr7:133958114	A/C	cg11752832	chr7:134001865	SLC35B4	0.68	5.89	0.47	3.32e-8	Mean platelet volume;
TGCT	cis	rs7937682	0.924	rs6589244	chr11:111534333	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.07	-10.2	-0.68	4.05e-18	Primary sclerosing cholangitis;
TGCT	cis	rs9677476	0.516	rs6707708	chr2:232020821	T/C	cg07929768	chr2:232055508	NA	0.33	5.21	0.42	7.7300000000000005e-07	Food antigen IgG levels;
TGCT	trans	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.86	9.38	0.64	3.95e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs9467711	0.606	rs1977	chr6:26377546	A/G	cg10795676	chr6:26370623	BTN3A2	-0.45	-4.91	-0.4	2.76e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs7552404	0.924	rs2153126	chr1:76199345	C/G	cg10523679	chr1:76189770	ACADM	0.89	9.88	0.66	2.42e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	trans	rs459571	0.920	rs455073	chr9:136909141	G/C	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.73	-7.93	-0.58	1.11e-12	Platelet distribution width;
TGCT	cis	rs6460942	0.908	rs112897715	chr7:12241541	T/C	cg06484146	chr7:12443880	VWDE	-0.54	-4.76	-0.39	5.21e-6	Coronary artery disease;
TGCT	cis	rs3101457	0.515	rs4658628	chr1:244516090	T/C	cg09033006	chr1:244517177	C1orf100	-0.41	-4.47	-0.37	1.73e-5	Smoking behavior;
TGCT	cis	rs12580194	1.000	rs7308316	chr12:55709162	T/A	cg20672549	chr12:56432144	IKZF4	0.26	4.71	0.39	6.51e-6	Cancer;
TGCT	cis	rs739496	0.895	rs2073950	chr12:111894072	C/T	cg10833066	chr12:111807467	FAM109A	0.36	5.1	0.42	1.26e-6	Platelet count;
TGCT	cis	rs2243480	1.000	rs383402	chr7:65586653	A/C	cg20637647	chr7:64974828	NA	-0.88	-5.12	-0.42	1.13e-6	Diabetic kidney disease;
TGCT	cis	rs4629710	0.592	rs13195700	chr6:131585299	C/T	cg12606694	chr6:131520996	AKAP7	0.38	4.5	0.37	1.56e-5	Multiple myeloma (IgH translocation);
TGCT	cis	rs7267979	0.966	rs3002698	chr20:25303379	C/G	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3796619	0.503	rs13147452	chr4:1078124	G/A	cg27284194	chr4:1044797	NA	0.71	8.07	0.59	5.03e-13	Recombination rate (males);
TGCT	cis	rs77372450	0.551	rs11739924	chr5:157070236	C/A	cg19063654	chr5:156516798	HAVCR2	-0.37	-4.43	-0.37	2.01e-5	Bipolar disorder (body mass index interaction);
TGCT	cis	rs60154123	0.730	rs12403947	chr1:210456524	A/G	cg22029157	chr1:209979665	IRF6	-0.68	-5.15	-0.42	9.98e-7	Coronary artery disease;
TGCT	cis	rs2013441	0.932	rs2526479	chr17:20130221	T/G	cg18979559	chr17:20280153	CCDC144C	-0.44	-4.61	-0.38	9.78e-6	Obesity-related traits;
TGCT	cis	rs10875746	0.903	rs12315625	chr12:48472453	G/A	cg20731937	chr12:48336164	NA	0.62	4.95	0.41	2.36e-6	Longevity (90 years and older);
TGCT	cis	rs12477438	1.000	rs17760953	chr2:99859863	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.81	-6.36	-0.5	3.59e-9	Chronic sinus infection;
TGCT	cis	rs9814567	1.000	rs7426847	chr3:134267519	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.96	9.11	0.63	1.79e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.06	-9.57	-0.65	1.41e-16	Platelet count;
TGCT	cis	rs9457247	1.000	rs2149090	chr6:167372764	T/C	cg23791538	chr6:167370224	RNASET2	0.51	5.12	0.42	1.12e-6	Crohn's disease;
TGCT	cis	rs6964587	1.000	rs28584017	chr7:91719168	G/A	cg22709100	chr7:91322751	NA	0.29	4.8	0.4	4.45e-6	Breast cancer;
TGCT	cis	rs9916302	0.904	rs679995	chr17:37441679	A/T	cg15445000	chr17:37608096	MED1	-0.33	-4.93	-0.4	2.59e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs3784262	0.565	rs34676542	chr15:58318716	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.39	-5.63	-0.45	1.16e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg07424592	chr7:64974309	NA	1.33	7.68	0.57	4.1e-12	Diabetic kidney disease;
TGCT	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg21724239	chr8:58056113	NA	0.49	5.8	0.46	5.29e-8	Developmental language disorder (linguistic errors);
TGCT	cis	rs12477438	1.000	rs6542873	chr2:99824965	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-6.24	-0.49	6.35e-9	Chronic sinus infection;
TGCT	cis	rs11690935	0.802	rs34636594	chr2:172911094	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.12	-11.05	-0.7	3.57e-20	Schizophrenia;
TGCT	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg12310025	chr6:25882481	NA	-0.63	-5.71	-0.46	7.79e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs11031096	0.678	rs11031219	chr11:4197578	G/A	cg18678763	chr11:4115507	RRM1	-0.46	-6.03	-0.48	1.78e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs7666738	0.819	rs13120307	chr4:99036100	A/C	cg05340658	chr4:99064831	C4orf37	0.51	5.69	0.45	8.74e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs763121	0.853	rs5757211	chr22:39051705	C/T	cg06022373	chr22:39101656	GTPBP1	0.77	7.46	0.56	1.35e-11	Menopause (age at onset);
TGCT	cis	rs6725041	0.547	rs61696052	chr2:213201295	G/C	cg16329650	chr2:213403929	ERBB4	-0.67	-5.86	-0.47	3.89e-8	QT interval (ambient particulate matter interaction);
TGCT	cis	rs7611238	0.560	rs4677838	chr3:195105419	G/A	cg27323046	chr3:195102265	ACAP2	0.39	5.09	0.42	1.29e-6	Body mass index;
TGCT	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg03188948	chr7:1209495	NA	0.45	5.85	0.47	4.04e-8	Longevity;Endometriosis;
TGCT	cis	rs6992820	0.899	rs7013301	chr8:56688226	G/T	cg06880721	chr8:56792545	LYN	-0.53	-4.51	-0.38	1.5e-5	Mean platelet volume;
TGCT	cis	rs4523957	0.614	rs7220685	chr17:2059385	A/G	cg16513277	chr17:2031491	SMG6	-0.2	-4.64	-0.38	8.83e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs9513627	0.573	rs12431100	chr13:100184918	C/G	cg25919922	chr13:100150906	NA	-0.86	-5.48	-0.44	2.32e-7	Obesity-related traits;
TGCT	cis	rs6570726	0.846	rs9376954	chr6:145943737	T/A	cg13319975	chr6:146136371	FBXO30	-0.5	-4.49	-0.37	1.63e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7698623	0.702	rs1599722	chr4:88782786	A/G	cg02735620	chr4:88950514	PKD2	-0.44	-4.81	-0.4	4.22e-6	Cardiovascular disease risk factors;
TGCT	cis	rs13242816	1.000	rs34678019	chr7:116189490	A/G	cg16553024	chr7:116138462	CAV2	-0.44	-5.26	-0.43	6.11e-7	P wave duration;
TGCT	cis	rs739496	1.000	rs7296313	chr12:111878526	T/C	cg10833066	chr12:111807467	FAM109A	0.37	5.63	0.45	1.14e-7	Platelet count;
TGCT	cis	rs13256369	0.802	rs11249884	chr8:8561552	C/T	cg18904891	chr8:8559673	CLDN23	-0.56	-5.23	-0.43	6.88e-7	Obesity-related traits;
TGCT	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg25036284	chr2:26402008	FAM59B	-0.57	-4.97	-0.41	2.15e-6	Gut microbiome composition (summer);
TGCT	cis	rs2239547	0.522	rs9844736	chr3:52931971	T/G	cg10802521	chr3:52805072	NEK4	0.63	5.9	0.47	3.26e-8	Schizophrenia;
TGCT	cis	rs7811142	0.945	rs6978739	chr7:100098680	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.05	-9.12	-0.63	1.65e-15	Platelet count;
TGCT	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg10802521	chr3:52805072	NEK4	0.75	9.1	0.63	1.85e-15	Bipolar disorder;
TGCT	cis	rs2153535	0.563	rs6942177	chr6:8534460	A/G	cg23788917	chr6:8435910	SLC35B3	-0.63	-5.75	-0.46	6.55e-8	Motion sickness;
TGCT	cis	rs1691799	0.799	rs10784525	chr12:66772766	G/A	cg16791601	chr12:66731901	HELB	-0.25	-5.2	-0.42	8.12e-7	White blood cell count (basophil);
TGCT	cis	rs3771570	1.000	rs17386695	chr2:242379751	A/G	cg21155796	chr2:242212141	HDLBP	-0.93	-6.69	-0.51	6.94e-10	Prostate cancer;
TGCT	cis	rs3087591	0.960	rs12943508	chr17:29599954	C/G	cg24425628	chr17:29625626	OMG;NF1	0.48	7.43	0.56	1.52e-11	Hip circumference;
TGCT	cis	rs4786125	0.596	rs12149100	chr16:6922512	T/G	cg03623568	chr16:6915990	A2BP1	-0.45	-6.77	-0.52	4.65e-10	Heart rate variability traits (SDNN);
TGCT	cis	rs12220898	0.749	rs11101075	chr10:50485110	G/T	cg06072769	chr10:50146962	WDFY4	0.38	5.07	0.41	1.38e-6	Inflammatory biomarkers;
TGCT	cis	rs9788721	0.836	rs17484524	chr15:78772676	A/G	cg18825076	chr15:78729989	IREB2	-0.34	-5.11	-0.42	1.18e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
TGCT	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg12419862	chr22:24373484	LOC391322	-0.87	-9.92	-0.67	1.99e-17	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs910316	1.000	rs4903279	chr14:75546583	C/T	cg23033748	chr14:75592666	NEK9	0.28	4.68	0.39	7.29e-6	Height;
TGCT	cis	rs4975709	0.801	rs3797063	chr5:1881549	A/T	cg14773178	chr5:1868261	NA	0.36	4.88	0.4	3.23e-6	Cardiovascular disease risk factors;
TGCT	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg04234412	chr22:24373322	LOC391322	0.93	8.57	0.61	3.38e-14	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg06238570	chr21:40685208	BRWD1	-0.82	-8.76	-0.62	1.22e-14	Cognitive function;
TGCT	cis	rs3026101	0.671	rs1065482	chr17:5284719	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	4.68	0.39	7.51e-6	Body mass index;
TGCT	cis	rs13191362	0.507	rs7772787	chr6:163190981	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.51	4.45	0.37	1.9e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs6141769	0.542	rs2064933	chr20:31314625	A/G	cg13636640	chr20:31349939	DNMT3B	-0.52	-4.54	-0.38	1.34e-5	Subjective well-being;
TGCT	cis	rs8180040	0.966	rs17476234	chr3:47326298	G/A	cg27129171	chr3:47204927	SETD2	-0.7	-8.64	-0.61	2.35e-14	Colorectal cancer;
TGCT	cis	rs3749237	0.595	rs3924462	chr3:49524236	T/G	cg03060546	chr3:49711283	APEH	0.76	8.69	0.62	1.77e-14	Resting heart rate;
TGCT	cis	rs12711979	0.509	rs12711972	chr2:3823786	T/C	cg17052675	chr2:3827356	NA	-0.55	-12.73	-0.75	2.94e-24	Itch intensity from mosquito bite adjusted by bite size;
TGCT	cis	rs7027203	0.595	rs2398876	chr9:96536853	T/C	cg13679303	chr9:96623674	NA	0.52	7.49	0.56	1.12e-11	DNA methylation (variation);
TGCT	cis	rs9486719	1.000	rs4343922	chr6:96876903	C/T	cg06623918	chr6:96969491	KIAA0776	0.97	9.2	0.64	1.06e-15	Migraine;Coronary artery disease;
TGCT	cis	rs6500602	0.702	rs3789038	chr16:4546586	C/G	cg08645402	chr16:4508243	NA	-0.2	-4.89	-0.4	3.12e-6	Schizophrenia;
TGCT	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg06873352	chr17:61820015	STRADA	0.55	6.13	0.48	1.09e-8	Prudent dietary pattern;
TGCT	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.34	0.43	4.23e-7	Prudent dietary pattern;
TGCT	cis	rs7714584	1.000	rs1896709	chr5:150245032	A/G	cg22134413	chr5:150180641	NA	0.83	6.53	0.51	1.54e-9	Crohn's disease;
TGCT	cis	rs2228479	0.867	rs17784386	chr16:89947457	A/G	cg04013166	chr16:89971882	TCF25	0.32	4.46	0.37	1.84e-5	Skin colour saturation;
TGCT	cis	rs7226408	0.948	rs11661681	chr18:34395540	A/G	cg06757138	chr18:34340585	FHOD3	-0.25	-4.55	-0.38	1.25e-5	Obesity-related traits;
TGCT	cis	rs6121246	0.567	rs6060260	chr20:30192907	C/T	cg21427119	chr20:30132790	HM13	-0.42	-6.17	-0.48	8.75e-9	Mean corpuscular hemoglobin;
TGCT	cis	rs3820928	1.000	rs4675116	chr2:227769607	A/C	cg11843606	chr2:227700838	RHBDD1	-0.51	-4.5	-0.37	1.52e-5	Pulmonary function;
TGCT	cis	rs3847687	1.000	rs34853396	chr12:131519265	G/T	cg25772418	chr12:131519998	GPR133	-0.34	-6.26	-0.49	5.81e-9	Longevity;
TGCT	cis	rs68170813	0.559	rs12537733	chr7:106965447	A/T	cg02696742	chr7:106810147	HBP1	-0.7	-5.85	-0.47	4.03e-8	Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs10031751	chr4:98939134	G/A	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7402982	0.934	rs6598539	chr15:99204483	T/C	cg03437748	chr15:99193247	IGF1R	0.55	5.9	0.47	3.21e-8	Birth weight;
TGCT	cis	rs8037137	1.000	rs1105291	chr15:91502383	C/T	cg22570213	chr15:91497863	RCCD1	0.53	4.88	0.4	3.18e-6	Platelet count;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
TGCT	cis	rs137699	0.687	rs4821887	chr22:39756985	C/T	cg05872129	chr22:39784769	NA	-0.71	-6.06	-0.48	1.51e-8	IgG glycosylation;
TGCT	cis	rs2456568	0.835	rs1518578	chr11:93656854	G/T	cg26875233	chr11:93583750	C11orf90	-0.5	-6.3	-0.49	4.79e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs4689388	0.609	rs4234729	chr4:6286087	T/C	cg14416269	chr4:6271139	WFS1	0.47	5.65	0.45	1.07e-7	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs2594989	0.733	rs2447605	chr3:11574296	C/G	cg00170343	chr3:11313890	ATG7	-0.64	-4.85	-0.4	3.63e-6	Circulating chemerin levels;
TGCT	cis	rs9467711	0.606	rs9366655	chr6:26377385	C/G	cg16898833	chr6:26189333	HIST1H4D	1.09	5.27	0.43	5.92e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs6542838	0.698	rs6732017	chr2:99434381	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-4.71	-0.39	6.49e-6	Fear of minor pain;
TGCT	cis	rs8051431	1.000	rs8051431	chr16:72015251	G/C	cg06353428	chr16:71660113	MARVELD3	0.59	5.02	0.41	1.73e-6	LDL cholesterol levels;
TGCT	cis	rs7507204	0.723	rs12610998	chr19:3413653	T/C	cg08380311	chr19:3435252	NFIC	0.98	8.25	0.6	2e-13	Height;
TGCT	cis	rs514406	0.683	rs6588440	chr1:53209587	C/T	cg08859206	chr1:53392774	SCP2	0.36	5.11	0.42	1.2e-6	Monocyte count;
TGCT	cis	rs807669	0.868	rs2800973	chr22:19168616	A/G	cg02655711	chr22:19163373	SLC25A1	0.42	9.86	0.66	2.71e-17	Metabolite levels;
TGCT	cis	rs7647973	1.000	rs56127630	chr3:49438036	C/G	cg06212747	chr3:49208901	KLHDC8B	-0.59	-4.72	-0.39	6.19e-6	Menarche (age at onset);
TGCT	cis	rs2439831	0.850	rs9944216	chr15:44160773	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.74	-4.48	-0.37	1.68e-5	Lung cancer in ever smokers;
TGCT	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg24675658	chr1:53192096	ZYG11B	0.7	7.98	0.58	8.42e-13	Monocyte count;
TGCT	cis	rs7086627	0.515	rs4934189	chr10:82214792	C/T	cg00277334	chr10:82204260	NA	-0.56	-9.04	-0.63	2.62e-15	Post bronchodilator FEV1;
TGCT	cis	rs17270561	0.578	rs76182885	chr6:25904085	G/C	cg17042849	chr6:26104293	HIST1H4C	-0.79	-5.76	-0.46	6.33e-8	Iron status biomarkers;
TGCT	cis	rs514406	0.570	rs1332776	chr1:53189816	C/T	cg16325326	chr1:53192061	ZYG11B	0.8	11.61	0.72	1.54e-21	Monocyte count;
TGCT	cis	rs6988636	1.000	rs28542077	chr8:124190896	T/C	cg22384356	chr8:124195192	FAM83A	-0.42	-5.54	-0.45	1.74e-7	Urinary uromodulin levels;
TGCT	cis	rs6582630	0.555	rs11182148	chr12:38464883	A/C	cg26384229	chr12:38710491	ALG10B	0.82	7.5	0.56	1.07e-11	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs3820068	0.608	rs7552400	chr1:16035892	A/G	cg17385448	chr1:15911702	AGMAT	0.35	4.99	0.41	1.96e-6	Systolic blood pressure;
TGCT	cis	rs2153535	0.580	rs9393016	chr6:8458573	T/A	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs3099143	1.000	rs3102709	chr15:77072260	C/T	cg21673338	chr15:77095150	SCAPER	-0.51	-5.12	-0.42	1.11e-6	Recalcitrant atopic dermatitis;
TGCT	cis	rs7267979	0.966	rs2261790	chr20:25262789	T/C	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs12210905	0.920	rs72839453	chr6:27265761	A/G	cg08851530	chr6:28072375	NA	1.29	5.45	0.44	2.65e-7	Hip circumference adjusted for BMI;
TGCT	cis	rs68092024	0.731	rs793480	chr3:99488364	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.5	5.94	0.47	2.64e-8	Cleft lip with or without cleft palate;
TGCT	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	5.71	0.46	8.05e-8	Alzheimer's disease;
TGCT	cis	rs2806561	0.695	rs66592286	chr1:23333649	G/C	cg12483005	chr1:23474871	LUZP1	0.37	4.72	0.39	6.21e-6	Height;
TGCT	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg12311346	chr5:56204834	C5orf35	-0.67	-6.68	-0.51	7.25e-10	Initial pursuit acceleration;
TGCT	cis	rs950027	0.620	rs1719246	chr15:45625479	T/A	cg26924012	chr15:45694286	SPATA5L1	0.8	8.99	0.63	3.48e-15	Response to fenofibrate (adiponectin levels);
TGCT	trans	rs208520	1.000	rs208521	chr6:66953625	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.88	-8.21	-0.59	2.37e-13	Exhaled nitric oxide output;
TGCT	cis	rs9916302	0.904	rs2338798	chr17:37547269	T/C	cg07936489	chr17:37558343	FBXL20	0.64	4.94	0.41	2.46e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7666738	0.512	rs1648536	chr4:99019881	G/T	cg05340658	chr4:99064831	C4orf37	-0.41	-4.99	-0.41	1.95e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs713587	1.000	rs2384054	chr2:25156773	T/C	cg01884057	chr2:25150051	NA	0.39	8.05	0.59	5.76e-13	Body mass index in non-asthmatics;
TGCT	cis	rs9303401	0.659	rs34170300	chr17:56789905	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.67	6.3	0.49	4.7e-9	Cognitive test performance;
TGCT	cis	rs1568889	1.000	rs66857704	chr11:28212346	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.82	8.31	0.6	1.42e-13	Bipolar disorder;
TGCT	cis	rs55823223	0.564	rs4572466	chr17:73846314	A/C	cg10935138	chr17:73851978	WBP2	0.82	7.57	0.56	7.35e-12	Psoriasis;
TGCT	cis	rs231513	0.954	rs231512	chr17:41965831	G/A	cg26893861	chr17:41843967	DUSP3	-0.75	-5.33	-0.43	4.48e-7	Cognitive function;
TGCT	trans	rs9929218	0.551	rs2281850	chr16:68718750	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.62	-8.17	-0.59	3.03e-13	Colorectal cancer;
TGCT	cis	rs903263	1.000	rs12565896	chr1:84636803	T/G	cg09664975	chr1:84543551	PRKACB	0.47	4.48	0.37	1.65e-5	Breast cancer (male);
TGCT	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg11644478	chr21:40555479	PSMG1	-0.53	-4.55	-0.38	1.28e-5	Cognitive function;
TGCT	cis	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg08045932	chr20:61659980	NA	0.48	9.16	0.64	1.36e-15	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs11190604	0.767	rs10883485	chr10:102174805	G/C	cg16005271	chr10:102321736	NA	0.45	4.57	0.38	1.15e-5	Palmitoleic acid (16:1n-7) levels;
TGCT	trans	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg23505145	chr19:12996616	KLF1	0.79	8.3	0.6	1.47e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9976767	0.608	rs11909987	chr21:43822402	C/A	cg23042151	chr21:43824109	UBASH3A	-0.23	-5.03	-0.41	1.65e-6	Type 1 diabetes;
TGCT	cis	rs881375	0.967	rs7848332	chr9:123669496	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	5.06	0.41	1.49e-6	Rheumatoid arthritis;
TGCT	cis	rs7714584	1.000	rs7709388	chr5:150246539	C/G	cg22134413	chr5:150180641	NA	0.83	6.53	0.51	1.54e-9	Crohn's disease;
TGCT	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.49	0.56	1.15e-11	Prudent dietary pattern;
TGCT	cis	rs9611519	1.000	rs5758264	chr22:41616284	T/G	cg13695892	chr22:41940480	POLR3H	-0.51	-4.71	-0.39	6.49e-6	Neuroticism;
TGCT	cis	rs8054556	0.716	rs11642933	chr16:29946708	G/A	cg26859862	chr16:30389551	SEPT1	-0.53	-4.54	-0.38	1.31e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9368481	0.594	rs2636425	chr6:26799460	A/G	cg18867708	chr6:26865862	GUSBL1	0.4	5.17	0.42	8.99e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2180341	1.000	rs4897207	chr6:127605898	C/T	cg27446573	chr6:127587934	RNF146	1.13	10.12	0.67	6.64e-18	Breast cancer;
TGCT	cis	rs7914558	0.966	rs10883805	chr10:104708251	T/C	cg04362960	chr10:104952993	NT5C2	0.58	5.15	0.42	9.77e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs10782582	0.586	rs112368938	chr1:76336339	C/T	cg03433033	chr1:76189801	ACADM	-0.5	-4.98	-0.41	2.11e-6	Daytime sleep phenotypes;
TGCT	cis	rs7246657	0.943	rs10407084	chr19:37907792	T/C	cg18154014	chr19:37997991	ZNF793	0.95	6.52	0.51	1.58e-9	Coronary artery calcification;
TGCT	cis	rs1153858	0.945	rs1974981	chr15:45729123	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.41	-4.74	-0.39	5.78e-6	Homoarginine levels;
TGCT	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg25036284	chr2:26402008	FAM59B	0.55	4.71	0.39	6.45e-6	Gut microbiome composition (summer);
TGCT	cis	rs2458413	1.000	rs2458414	chr8:105355840	A/G	cg23108931	chr8:105342351	NA	0.36	6.01	0.48	1.91e-8	Paget's disease;
TGCT	cis	rs1865760	1.000	rs9358895	chr6:25924655	C/T	cg16482183	chr6:26056742	HIST1H1C	0.51	4.59	0.38	1.06e-5	Height;
TGCT	cis	rs2688482	0.512	rs1106502	chr3:195517258	G/A	cg13752114	chr3:195489708	MUC4	0.32	4.72	0.39	6.34e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs12220238	0.841	rs11000942	chr10:76025256	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.84	6.02	0.48	1.87e-8	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs9942416	0.660	rs4704234	chr5:75001432	A/G	cg19683494	chr5:74908142	NA	0.62	6.43	0.5	2.51e-9	Age-related disease endophenotypes;
TGCT	trans	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg17830980	chr10:43048298	ZNF37B	-0.83	-10.39	-0.68	1.4e-18	Extrinsic epigenetic age acceleration;
TGCT	cis	rs71636778	0.509	rs56139710	chr1:27269788	C/T	cg23921621	chr1:27994728	IFI6	-0.43	-4.61	-0.38	9.92e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
TGCT	cis	rs62244186	0.632	rs1402751	chr3:44594030	C/A	cg15687855	chr3:44754131	ZNF502	-0.45	-5.35	-0.43	4.04e-7	Depressive symptoms;
TGCT	cis	rs7507204	0.906	rs62125968	chr19:3422261	G/A	cg08380311	chr19:3435252	NFIC	0.94	7.98	0.58	8.23e-13	Height;
TGCT	cis	rs7617773	0.817	rs6806112	chr3:48276077	A/T	cg11946769	chr3:48343235	NME6	0.75	7.14	0.54	7.06e-11	Coronary artery disease;
TGCT	cis	rs950169	0.656	rs748455	chr15:85149575	T/C	cg12863693	chr15:85201151	NMB	0.41	4.88	0.4	3.26e-6	Schizophrenia;
TGCT	cis	rs7647973	0.710	rs2029591	chr3:49646981	C/T	cg05785598	chr3:49045655	WDR6	-0.41	-4.74	-0.39	5.72e-6	Menarche (age at onset);
TGCT	cis	rs3784262	0.565	rs9635350	chr15:58298412	G/A	cg12031962	chr15:58353849	ALDH1A2	0.38	5.53	0.44	1.82e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs6121246	0.909	rs6060633	chr20:30263317	G/T	cg13852791	chr20:30311386	BCL2L1	0.78	5.8	0.46	5.15e-8	Mean corpuscular hemoglobin;
TGCT	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.51	-4.82	-0.4	4.16e-6	Bipolar disorder;
TGCT	cis	rs896854	0.552	rs2515236	chr8:95934907	A/G	cg23172400	chr8:95962367	TP53INP1	0.32	4.81	0.4	4.29e-6	Type 2 diabetes;
TGCT	cis	rs4499344	0.589	rs259233	chr19:33127000	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.83	8.3	0.6	1.52e-13	Mean platelet volume;
TGCT	cis	rs7412746	0.658	rs12405726	chr1:150956128	G/A	cg09365446	chr1:150670422	GOLPH3L	0.36	5.0	0.41	1.9e-6	Melanoma;
TGCT	cis	rs4253772	0.550	rs6008598	chr22:46704243	C/T	cg24881330	chr22:46731750	TRMU	1.05	5.41	0.44	3.15e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg03188948	chr7:1209495	NA	0.5	7.0	0.53	1.44e-10	Longevity;Endometriosis;
TGCT	cis	rs6545883	0.899	rs12473030	chr2:61720497	T/A	cg15711740	chr2:61764176	XPO1	-0.54	-4.95	-0.41	2.39e-6	Tuberculosis;
TGCT	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg24531977	chr5:56204891	C5orf35	0.68	7.22	0.54	4.69e-11	Initial pursuit acceleration;
TGCT	cis	rs1670533	1.000	rs6852155	chr4:1067638	T/G	cg27284194	chr4:1044797	NA	0.68	5.86	0.47	4e-8	Recombination rate (females);
TGCT	cis	rs7666738	0.830	rs113999196	chr4:99041961	C/T	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7819412	0.522	rs13276708	chr8:10989206	T/C	cg21775007	chr8:11205619	TDH	-0.6	-5.27	-0.43	5.9e-7	Triglycerides;
TGCT	cis	rs6866344	0.568	rs10516147	chr5:178094484	A/G	cg10224037	chr5:178157518	ZNF354A	0.59	5.06	0.41	1.46e-6	Neutrophil percentage of white cells;
TGCT	cis	rs7617480	0.648	rs4974088	chr3:48898749	T/C	cg07636037	chr3:49044803	WDR6	0.79	6.43	0.5	2.54e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	5.86	0.47	3.96e-8	Alzheimer's disease;
TGCT	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.7	-0.39	6.79e-6	Prudent dietary pattern;
TGCT	cis	rs6750047	0.585	rs168054	chr2:38260282	C/G	cg07380506	chr2:38303506	CYP1B1	-0.56	-5.21	-0.42	7.68e-7	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs2075371	0.865	rs2544172	chr7:133931338	T/C	cg11752832	chr7:134001865	SLC35B4	0.68	5.89	0.47	3.42e-8	Mean platelet volume;
TGCT	cis	rs2469997	0.800	rs2447177	chr8:120356431	A/G	cg02248809	chr8:120845432	TAF2	0.58	4.47	0.37	1.76e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs4975709	0.544	rs4975748	chr5:1866025	G/A	cg14773178	chr5:1868261	NA	0.35	6.18	0.49	8.45e-9	Cardiovascular disease risk factors;
TGCT	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg08280861	chr8:58055591	NA	0.4	4.56	0.38	1.22e-5	Developmental language disorder (linguistic errors);
TGCT	trans	rs3780486	0.846	rs3780490	chr9:33129839	A/G	cg04842962	chr6:43655489	MRPS18A	1.24	15.83	0.82	1.46e-31	IgG glycosylation;
TGCT	cis	rs6912958	0.559	rs242281	chr6:88048916	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.47	6.29	0.49	5.04e-9	Monocyte percentage of white cells;
TGCT	cis	rs2274273	0.743	rs7161656	chr14:55524530	A/G	cg01923255	chr14:55878535	KIAA0831	0.56	4.76	0.39	5.24e-6	Protein biomarker;
TGCT	cis	rs6088580	0.634	rs6059829	chr20:33017074	G/A	cg08999081	chr20:33150536	PIGU	0.29	5.66	0.45	9.92e-8	Glomerular filtration rate (creatinine);
TGCT	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	15.63	0.81	4.21e-31	Prudent dietary pattern;
TGCT	cis	rs2842992	1.000	rs2758322	chr6:160075188	G/T	cg11366901	chr6:160182831	ACAT2	0.92	6.26	0.49	5.77e-9	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs9430161	0.579	rs11121667	chr1:11038476	C/T	cg27631724	chr1:11040367	C1orf127	0.55	6.55	0.51	1.39e-9	Ewing sarcoma;
TGCT	cis	rs12142240	0.698	rs6683192	chr1:46830257	C/T	cg00530320	chr1:46809349	NSUN4	0.29	6.03	0.48	1.71e-8	Menopause (age at onset);
TGCT	cis	rs2404602	0.647	rs35710279	chr15:77082234	T/A	cg22467129	chr15:76604101	ETFA	0.47	4.62	0.38	9.31e-6	Blood metabolite levels;
TGCT	cis	rs4409675	0.576	rs6691656	chr1:28221130	C/G	cg23691781	chr1:28212827	C1orf38	0.26	5.32	0.43	4.68e-7	Corneal astigmatism;
TGCT	cis	rs3796352	1.000	rs13058817	chr3:53024139	C/T	cg07884673	chr3:53033167	SFMBT1	0.64	6.39	0.5	3.03e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs9818758	0.607	rs9862483	chr3:49195441	G/A	cg07636037	chr3:49044803	WDR6	-1.04	-5.13	-0.42	1.09e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs7301826	0.651	rs7956851	chr12:131319099	C/T	cg15791944	chr12:131647654	NA	0.23	4.64	0.38	8.68e-6	Plasma plasminogen activator levels;
TGCT	cis	rs9325144	0.560	rs10506125	chr12:39120287	C/T	cg13010199	chr12:38710504	ALG10B	0.61	5.7	0.46	8.26e-8	Morning vs. evening chronotype;
TGCT	cis	rs1568889	1.000	rs61889054	chr11:28333000	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	6.72	0.52	5.95e-10	Bipolar disorder;
TGCT	cis	rs11971779	0.938	rs11981688	chr7:139088895	A/G	cg07862535	chr7:139043722	LUC7L2	0.79	5.8	0.46	5.13e-8	Diisocyanate-induced asthma;
TGCT	cis	rs9682041	0.673	rs1511175	chr3:170076006	C/G	cg11886554	chr3:170076028	SKIL	0.84	5.65	0.45	1.05e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
TGCT	cis	rs7226408	0.857	rs72892518	chr18:34665420	G/A	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs514406	0.607	rs6696940	chr1:53203427	C/T	cg08859206	chr1:53392774	SCP2	0.36	5.1	0.42	1.22e-6	Monocyte count;
TGCT	cis	rs8062405	0.573	rs6565300	chr16:28993049	G/T	cg01117621	chr16:28073818	GSG1L	0.36	4.69	0.39	7.21e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
TGCT	cis	rs614226	0.935	rs17431717	chr12:120912210	G/A	cg10072921	chr12:121022843	NA	0.46	4.98	0.41	2.11e-6	Type 1 diabetes nephropathy;
TGCT	cis	rs6663390	0.510	rs73072979	chr1:208072057	G/A	cg03990033	chr1:208084030	CD34	0.73	6.45	0.5	2.32e-9	Facial morphology (factor 18);
TGCT	cis	rs11711311	1.000	rs1073040	chr3:113522123	C/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.69	-6.4	-0.5	2.84e-9	IgG glycosylation;
TGCT	cis	rs12497850	0.931	rs7627404	chr3:48819668	A/C	cg07636037	chr3:49044803	WDR6	0.94	10.39	0.68	1.46e-18	Parkinson's disease;
TGCT	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg25036284	chr2:26402008	FAM59B	-0.57	-4.97	-0.41	2.15e-6	Gut microbiome composition (summer);
TGCT	cis	rs2115630	0.967	rs7171167	chr15:85239123	A/T	cg17173187	chr15:85201210	NMB	-0.4	-4.95	-0.41	2.41e-6	P wave terminal force;
TGCT	cis	rs425277	1.000	rs262676	chr1:2078482	T/A	cg03732007	chr1:2071316	PRKCZ	0.26	5.44	0.44	2.77e-7	Height;
TGCT	cis	rs7611238	0.560	rs62287107	chr3:195052365	T/G	cg27323046	chr3:195102265	ACAP2	0.36	4.9	0.4	2.94e-6	Body mass index;
TGCT	trans	rs9951602	0.512	rs3859325	chr18:76652175	A/G	cg02800362	chr5:177631904	HNRNPAB	1.14	12.9	0.76	1.17e-24	Obesity-related traits;
TGCT	cis	rs1008375	1.000	rs555	chr4:17625658	A/G	cg16339924	chr4:17578868	LAP3	0.64	5.32	0.43	4.72e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7394190	0.748	rs60212594	chr10:75414344	G/C	cg07699608	chr10:75541558	CHCHD1	0.59	4.46	0.37	1.85e-5	Incident atrial fibrillation;
TGCT	cis	rs2456568	0.867	rs7935801	chr11:93658000	G/A	cg26875233	chr11:93583750	C11orf90	-0.47	-5.83	-0.46	4.5e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs2442825	1.000	rs2442825	chr3:9479142	G/A	cg24633833	chr3:10029261	TMEM111	0.54	4.96	0.41	2.28e-6	Cerebrospinal fluid clusterin levels;
TGCT	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg01802117	chr1:53393560	SCP2	-0.44	-5.52	-0.44	1.86e-7	Monocyte count;
TGCT	cis	rs950169	0.922	rs11631096	chr15:85100929	G/C	cg11189052	chr15:85197271	WDR73	0.84	6.67	0.51	7.68e-10	Schizophrenia;
TGCT	cis	rs736408	0.561	rs2276815	chr3:52853747	C/G	cg11645453	chr3:52864694	ITIH4	0.31	5.34	0.43	4.24e-7	Bipolar disorder;
TGCT	cis	rs911555	0.755	rs8014800	chr14:103946302	T/C	cg23461800	chr14:103021989	NA	-0.35	-4.56	-0.38	1.23e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs5417	0.662	rs12601936	chr17:7172609	A/G	cg25256661	chr17:7137939	DVL2	-0.64	-6.54	-0.51	1.45e-9	Diastolic blood pressure;
TGCT	cis	rs6912958	0.712	rs6930600	chr6:88349787	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-4.55	-0.38	1.26e-5	Monocyte percentage of white cells;
TGCT	cis	rs568617	0.953	rs645900	chr11:65648135	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.57	-5.22	-0.42	7.39e-7	Crohn's disease;
TGCT	cis	rs7666738	0.830	rs6848397	chr4:98946738	A/G	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11190604	1.000	rs28522614	chr10:102323141	T/A	cg23241863	chr10:102295624	HIF1AN	0.69	5.12	0.42	1.16e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.18	0.42	8.87e-7	Prudent dietary pattern;
TGCT	cis	rs682748	1.000	rs297181	chr5:17157479	A/T	cg23987134	chr5:17158319	LOC285696	-0.23	-5.43	-0.44	2.9e-7	Hippocampal atrophy;
TGCT	cis	rs710216	0.957	rs2886876	chr1:43432741	A/G	cg03128534	chr1:43423976	SLC2A1	-0.62	-4.78	-0.39	4.92e-6	Red cell distribution width;
TGCT	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg22029157	chr1:209979665	IRF6	0.76	6.32	0.49	4.37e-9	Cleft lip with or without cleft palate;
TGCT	cis	rs12220238	1.000	rs10824078	chr10:75892120	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.89	7.06	0.54	1.05e-10	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs651907	0.513	rs34963630	chr3:101504817	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	4.85	0.4	3.68e-6	Colorectal cancer;
TGCT	cis	rs17152411	1.000	rs7086447	chr10:126593553	C/A	cg07906193	chr10:126599966	NA	0.42	5.28	0.43	5.6e-7	Height;
TGCT	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg06873352	chr17:61820015	STRADA	0.58	6.37	0.5	3.32e-9	Prudent dietary pattern;
TGCT	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg11871910	chr12:69753446	YEATS4	0.87	10.07	0.67	8.72e-18	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg00343986	chr7:65444356	GUSB	-0.23	-5.16	-0.42	9.66e-7	Aortic root size;
TGCT	cis	rs9486715	0.830	rs2255552	chr6:96999643	A/G	cg18709589	chr6:96969512	KIAA0776	-0.79	-7.51	-0.56	9.96e-12	Headache;
TGCT	trans	rs7615952	0.866	rs1976459	chr3:125647486	A/T	cg07211511	chr3:129823064	LOC729375	-0.47	-7.55	-0.56	8.34e-12	Blood pressure (smoking interaction);
TGCT	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg08859206	chr1:53392774	SCP2	0.34	4.9	0.4	2.91e-6	Monocyte count;
TGCT	cis	rs12142240	0.731	rs6658556	chr1:46844180	A/C	cg14993813	chr1:46806288	NSUN4	-0.59	-4.94	-0.41	2.51e-6	Menopause (age at onset);
TGCT	cis	rs10883723	0.962	rs11191294	chr10:104225837	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	7.38	0.55	1.95e-11	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs2025751	0.614	rs9370052	chr6:51638601	T/A	cg20180370	chr6:50691003	TFAP2D	-0.48	-4.51	-0.38	1.51e-5	Intraocular pressure;
TGCT	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg21862992	chr11:68658383	NA	0.46	6.37	0.5	3.37e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.53	-5.1	-0.42	1.23e-6	Bipolar disorder;
TGCT	cis	rs3008870	0.920	rs1925413	chr1:67417101	T/C	cg11518657	chr1:67396239	MIER1	0.54	4.65	0.39	8.44e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg15242686	chr22:24348715	GSTTP1	0.44	5.98	0.47	2.23e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7267979	1.000	rs6050630	chr20:25430745	A/G	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg22968622	chr17:43663579	NA	1.24	11.44	0.72	3.96e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg22963979	chr7:1858916	MAD1L1	-0.36	-5.69	-0.46	8.49e-8	Bipolar disorder and schizophrenia;
TGCT	cis	rs17102884	0.506	rs11845397	chr14:75404587	G/A	cg08847533	chr14:75593920	NEK9	-0.62	-5.5	-0.44	2.09e-7	Neuroticism;
TGCT	cis	rs12477438	0.520	rs13004491	chr2:99738008	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.82	0.62	8.67e-15	Chronic sinus infection;
TGCT	cis	rs1538970	0.961	rs7543428	chr1:45839643	A/G	cg05343316	chr1:45956843	TESK2	0.64	5.06	0.41	1.47e-6	Platelet count;
TGCT	cis	rs6546537	0.955	rs35947226	chr2:69845829	C/G	cg10773587	chr2:69614142	GFPT1	-0.77	-6.45	-0.5	2.28e-9	Serum thyroid-stimulating hormone levels;
TGCT	cis	rs8180040	0.593	rs4018905	chr3:47138170	A/G	cg27129171	chr3:47204927	SETD2	0.7	8.55	0.61	3.75e-14	Colorectal cancer;
TGCT	cis	rs4642101	0.694	rs12631514	chr3:12838293	G/C	cg05775895	chr3:12838266	CAND2	0.91	11.19	0.71	1.61e-20	QRS complex (12-leadsum);
TGCT	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg24675658	chr1:53192096	ZYG11B	-0.71	-8.23	-0.59	2.14e-13	Monocyte count;
TGCT	cis	rs2997447	0.761	rs61776620	chr1:26457980	T/C	cg03844060	chr1:26490628	NA	0.27	4.44	0.37	2e-5	QRS complex (12-leadsum);
TGCT	cis	rs4919694	1.000	rs12257935	chr10:104803062	C/A	cg04362960	chr10:104952993	NT5C2	1.06	7.05	0.53	1.09e-10	Arsenic metabolism;
TGCT	cis	rs2854207	0.505	rs2466957	chr17:61961230	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	5.16	0.42	9.57e-7	Height;
TGCT	cis	rs2468186	0.583	rs2450065	chr8:120096814	T/C	cg02248809	chr8:120845432	TAF2	-0.45	-4.83	-0.4	3.99e-6	Osteoprotegerin levels;
TGCT	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg04267008	chr7:1944627	MAD1L1	-0.38	-4.97	-0.41	2.16e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs28595532	0.920	rs114382134	chr4:119733215	T/C	cg21605333	chr4:119757512	SEC24D	1.66	8.33	0.6	1.28e-13	Cannabis dependence symptom count;
TGCT	cis	rs2299587	0.531	rs28839855	chr8:17855983	T/C	cg01800426	chr8:17659068	MTUS1	-0.55	-4.77	-0.39	5e-6	Economic and political preferences;
TGCT	cis	rs10214930	0.597	rs720437	chr7:27918415	C/T	cg05786569	chr7:27702416	HIBADH	-0.72	-5.01	-0.41	1.82e-6	Hypospadias;
TGCT	cis	rs2067615	0.560	rs4964485	chr12:107121952	A/G	cg15890332	chr12:107067104	RFX4	0.3	5.99	0.47	2.11e-8	Heart rate;
TGCT	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg26338869	chr17:61819248	STRADA	-0.55	-5.08	-0.41	1.37e-6	Prudent dietary pattern;
TGCT	cis	rs2717559	0.522	rs2572924	chr8:143869114	C/T	cg07661805	chr8:143867942	LY6D	0.23	4.46	0.37	1.83e-5	Urinary tract infection frequency;
TGCT	cis	rs12615966	0.789	rs1562882	chr2:105404626	G/A	cg16465502	chr2:105461796	NA	0.8	5.05	0.41	1.51e-6	Pancreatic cancer;
TGCT	trans	rs57221529	0.600	rs11750269	chr5:666270	G/A	cg25482853	chr8:67687455	SGK3	1.21	10.69	0.69	2.58e-19	Lung disease severity in cystic fibrosis;
TGCT	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs12681287	0.547	rs66808088	chr8:87521212	C/T	cg27223183	chr8:87520930	FAM82B	-0.96	-7.03	-0.53	1.21e-10	Caudate activity during reward;
TGCT	cis	rs17253792	0.731	rs28587929	chr14:56097492	C/T	cg01858014	chr14:56050164	KTN1	-0.34	-4.44	-0.37	1.96e-5	Putamen volume;
TGCT	cis	rs11640734	0.609	rs11647746	chr16:89806343	C/A	cg26513180	chr16:89883248	FANCA	0.79	4.57	0.38	1.16e-5	Interleukin-17 levels;
TGCT	cis	rs61774743	0.681	rs10749805	chr1:41850182	C/T	cg01193554	chr1:41846683	NA	-0.44	-5.5	-0.44	2.08e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs9467773	1.000	rs9467774	chr6:26505036	C/A	cg05738196	chr6:26577821	NA	0.88	12.49	0.75	1.09e-23	Intelligence (multi-trait analysis);
TGCT	cis	rs17401966	0.838	rs4623	chr1:10366692	C/G	cg19773385	chr1:10388646	KIF1B	-0.22	-4.8	-0.4	4.52e-6	Hepatocellular carcinoma;
TGCT	cis	rs3858526	0.959	rs4559671	chr11:5923419	C/T	cg13902645	chr11:5959945	NA	-0.44	-4.8	-0.4	4.54e-6	DNA methylation (variation);
TGCT	cis	rs3796352	0.527	rs11716506	chr3:52944328	C/T	cg11137980	chr3:52469226	SEMA3G	0.28	4.61	0.38	9.88e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	trans	rs7824557	0.527	rs2572376	chr8:11237756	C/A	cg15556689	chr8:8085844	FLJ10661	-0.75	-6.65	-0.51	8.2e-10	Retinal vascular caliber;
TGCT	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg23302884	chr18:44338147	ST8SIA5	-0.4	-4.61	-0.38	9.88e-6	Personality dimensions;
TGCT	cis	rs6545883	0.894	rs2694642	chr2:61596180	A/G	cg15711740	chr2:61764176	XPO1	0.54	4.66	0.39	8.14e-6	Tuberculosis;
TGCT	cis	rs2657888	0.965	rs2657902	chr12:56933651	G/A	cg23002907	chr12:56915593	RBMS2	0.44	6.15	0.48	9.65e-9	Adiponectin levels;
TGCT	cis	rs17376456	0.825	rs28610997	chr5:93248374	T/C	cg25358565	chr5:93447407	FAM172A	1.0	7.62	0.56	5.54e-12	Diabetic retinopathy;
TGCT	cis	rs2840044	1.000	rs225259	chr17:33958168	A/G	cg05299278	chr17:33885742	SLFN14	0.22	4.98	0.41	2.07e-6	Response to radiotherapy in cancer (late toxicity);
TGCT	cis	rs9457247	0.967	rs1187532	chr6:167382020	G/A	cg25258033	chr6:167368657	RNASET2	0.18	4.49	0.37	1.63e-5	Crohn's disease;
TGCT	cis	rs9787249	0.957	rs12086750	chr1:40210468	G/C	cg24920358	chr1:40204285	PPIE	0.57	10.56	0.69	5.57e-19	Blood protein levels;
TGCT	trans	rs13064411	0.518	rs2399480	chr3:113228599	T/C	cg00307254	chr3:126706825	PLXNA1	0.34	6.78	0.52	4.36e-10	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs9611519	0.542	rs8139770	chr22:41416181	C/T	cg06634786	chr22:41940651	POLR3H	-0.48	-4.44	-0.37	1.98e-5	Neuroticism;
TGCT	cis	rs3784262	0.967	rs4646612	chr15:58265077	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.5	-7.72	-0.57	3.4e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg07157834	chr1:205819609	PM20D1	-0.41	-6.65	-0.51	8.24e-10	Menarche (age at onset);
TGCT	cis	rs7582180	0.652	rs11123830	chr2:100974747	A/G	cg08017756	chr2:100939284	LONRF2	-0.31	-4.97	-0.41	2.2e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6088580	0.634	rs6088484	chr20:32985961	T/C	cg08999081	chr20:33150536	PIGU	-0.29	-5.65	-0.45	1.02e-7	Glomerular filtration rate (creatinine);
TGCT	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs6752107	0.935	rs1596017	chr2:234147930	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.2	4.91	0.4	2.8e-6	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs57590327	0.508	rs10511101	chr3:81950302	A/C	cg07356753	chr3:81810745	GBE1	-0.74	-6.82	-0.52	3.5e-10	Extraversion;
TGCT	cis	rs35264875	0.898	rs56140802	chr11:68861631	G/A	cg02660097	chr11:68866761	NA	0.32	4.61	0.38	9.94e-6	Blond vs. brown hair color;
TGCT	cis	rs12510870	0.520	rs1528924	chr4:74390976	T/C	cg05868023	chr4:75230803	EREG	0.55	4.7	0.39	6.84e-6	Iris color (b* coordinate);
TGCT	cis	rs916888	0.821	rs199505	chr17:44859410	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.7	-4.82	-0.4	4.1e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs10464366	0.614	rs62442213	chr7:39146933	C/T	cg15212455	chr7:39170539	POU6F2	0.3	6.77	0.52	4.59e-10	IgG glycosylation;
TGCT	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg08219700	chr8:58056026	NA	0.37	4.48	0.37	1.71e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg24060327	chr5:131705240	SLC22A5	-0.66	-6.85	-0.52	3.07e-10	Acylcarnitine levels;
TGCT	cis	rs6969780	0.722	rs3823764	chr7:27187753	C/T	cg04317399	chr7:27170313	HOXA4	-0.44	-5.04	-0.41	1.64e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
TGCT	cis	rs1153858	0.723	rs4580098	chr15:45596909	T/A	cg14582100	chr15:45693742	SPATA5L1	0.47	5.08	0.42	1.34e-6	Homoarginine levels;
TGCT	cis	rs4689592	0.587	rs6825954	chr4:7074226	T/C	cg26116260	chr4:7069785	GRPEL1	1.08	9.87	0.66	2.64e-17	Monocyte percentage of white cells;
TGCT	cis	rs4252435	0.614	rs4252522	chr7:142603944	G/A	cg09833174	chr7:143059591	FAM131B	-0.96	-4.52	-0.38	1.41e-5	Cancer;
TGCT	cis	rs7267979	0.740	rs2259961	chr20:25282626	T/G	cg16686733	chr20:25566563	NINL	0.52	4.93	0.4	2.61e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs1843834	0.505	rs7585047	chr2:225373897	C/T	cg12698349	chr2:225449008	CUL3	0.78	6.41	0.5	2.77e-9	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs2456568	0.741	rs9633811	chr11:93628327	A/G	cg16099599	chr11:93583650	C11orf90	0.41	5.27	0.43	5.95e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7091068	0.522	rs10882323	chr10:95483280	T/C	cg20715218	chr10:95462985	C10orf4	0.5	4.86	0.4	3.49e-6	Urinary tract infection frequency;
TGCT	cis	rs7412746	0.658	rs2864869	chr1:150734655	G/A	cg04414720	chr1:150670196	GOLPH3L	0.37	4.63	0.38	9.12e-6	Melanoma;
TGCT	cis	rs10507380	0.824	rs118067250	chr13:27921825	C/T	cg25543773	chr13:27185723	WASF3	0.33	4.7	0.39	6.81e-6	Electrocardiographic traits;
TGCT	cis	rs4372836	0.677	rs4632298	chr2:29076282	T/C	cg09522027	chr2:28974177	PPP1CB	0.67	6.94	0.53	1.89e-10	Body mass index;
TGCT	cis	rs892961	0.777	rs747483	chr17:75412091	C/T	cg05865280	chr17:75406074	SEPT9	0.28	6.86	0.52	2.9e-10	Airflow obstruction;
TGCT	cis	rs950169	0.724	rs11632668	chr15:84948687	T/C	cg12863693	chr15:85201151	NMB	0.45	4.96	0.41	2.28e-6	Schizophrenia;
TGCT	cis	rs7786808	0.530	rs6459875	chr7:158186141	C/T	cg01191920	chr7:158217561	PTPRN2	0.36	5.06	0.41	1.47e-6	Obesity-related traits;
TGCT	cis	rs9372498	0.505	rs62424204	chr6:118861642	G/A	cg21191810	chr6:118973309	C6orf204	-0.37	-4.79	-0.39	4.73e-6	Diastolic blood pressure;
TGCT	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg06212747	chr3:49208901	KLHDC8B	0.71	6.78	0.52	4.31e-10	Subjective well-being (multi-trait analysis);Menarche (age at onset);
TGCT	cis	rs7824557	0.564	rs2736293	chr8:11234613	T/A	cg21775007	chr8:11205619	TDH	-0.65	-6.4	-0.5	2.97e-9	Retinal vascular caliber;
TGCT	cis	rs7647973	0.626	rs62260720	chr3:49853796	T/A	cg05785598	chr3:49045655	WDR6	-0.43	-5.28	-0.43	5.5e-7	Menarche (age at onset);
TGCT	cis	rs9926296	0.744	rs6860	chr16:89711120	C/T	cg27121462	chr16:89883253	FANCA	-0.53	-4.82	-0.4	4.19e-6	Vitiligo;
TGCT	cis	rs858239	0.539	rs1358442	chr7:23189739	C/T	cg05602783	chr7:23145260	KLHL7	-0.62	-5.03	-0.41	1.67e-6	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs752590	0.774	rs6755077	chr2:113953508	G/A	cg27425262	chr2:113953981	PSD4;LOC440839	0.41	4.7	0.39	6.89e-6	Mucinous ovarian carcinoma;
TGCT	cis	rs2153535	0.601	rs9502719	chr6:8541032	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	5.61	0.45	1.23e-7	Motion sickness;
TGCT	cis	rs10751667	0.643	rs10902244	chr11:949981	A/G	cg06064525	chr11:970664	AP2A2	-0.35	-8.06	-0.59	5.6e-13	Alzheimer's disease (late onset);
TGCT	cis	rs7809950	1.000	rs17154077	chr7:107077941	C/T	cg23024343	chr7:107201750	COG5	0.33	5.32	0.43	4.72e-7	Coronary artery disease;
TGCT	cis	rs514406	0.505	rs440871	chr1:53173052	C/T	cg24675658	chr1:53192096	ZYG11B	-0.78	-9.2	-0.64	1.09e-15	Monocyte count;
TGCT	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg24675658	chr1:53192096	ZYG11B	0.86	11.3	0.71	8.54e-21	Monocyte count;
TGCT	cis	rs3796352	0.667	rs34288509	chr3:52849493	G/C	cg15956490	chr3:53032818	SFMBT1	0.54	4.8	0.4	4.55e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs7829975	0.606	rs11776838	chr8:8794801	C/T	cg06636001	chr8:8085503	FLJ10661	-0.68	-6.03	-0.48	1.71e-8	Mood instability;
TGCT	cis	rs3741404	1.000	rs11603042	chr11:64003843	G/T	cg19570321	chr11:63258214	HRASLS5	0.44	4.98	0.41	2.09e-6	Platelet count;
TGCT	cis	rs968567	1.000	rs968567	chr11:61595564	C/T	cg19610905	chr11:61596333	FADS2	-0.79	-5.45	-0.44	2.66e-7	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
TGCT	cis	rs2486012	1.000	rs2486012	chr1:44373409	A/G	cg12908607	chr1:44402522	ARTN	0.71	5.86	0.47	3.87e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs644799	0.648	rs1255176	chr11:95471465	A/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.51	5.05	0.41	1.55e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9388451	1.000	rs9388451	chr6:126090377	A/G	cg05901451	chr6:126070800	HEY2	-1.03	-14.34	-0.79	4.15e-28	Brugada syndrome;
TGCT	cis	rs8180040	1.000	rs807931	chr3:47389317	C/T	cg27129171	chr3:47204927	SETD2	0.72	8.94	0.63	4.57e-15	Colorectal cancer;
TGCT	cis	rs9303401	0.592	rs66583824	chr17:56639853	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.32	0.49	4.18e-9	Cognitive test performance;
TGCT	cis	rs7904368	0.754	rs66491181	chr10:16849430	T/C	cg14835575	chr10:16859367	RSU1	0.67	7.37	0.55	2.16e-11	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
TGCT	cis	rs514406	0.560	rs1889033	chr1:53211887	A/G	cg25767906	chr1:53392781	SCP2	0.46	5.11	0.42	1.17e-6	Monocyte count;
TGCT	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg23982607	chr1:1823379	GNB1	-0.54	-8.16	-0.59	3.12e-13	Body mass index;
TGCT	cis	rs2072499	0.750	rs10159384	chr1:156160822	C/T	cg25208724	chr1:156163844	SLC25A44	1.01	9.25	0.64	8.38e-16	Testicular germ cell tumor;
TGCT	cis	rs933688	1.000	rs7715402	chr5:90679504	T/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.03	9.55	0.65	1.54e-16	Smoking behavior;
TGCT	cis	rs13242816	0.892	rs34645128	chr7:116078382	T/A	cg16553024	chr7:116138462	CAV2	-0.47	-5.25	-0.43	6.52e-7	P wave duration;
TGCT	cis	rs16958440	0.867	rs75481537	chr18:44719946	C/T	cg17192377	chr18:44677553	HDHD2	0.63	4.7	0.39	6.74e-6	Sitting height ratio;
TGCT	cis	rs79149102	0.579	rs7166105	chr15:75343942	A/G	cg09165964	chr15:75287851	SCAMP5	1.09	6.08	0.48	1.35e-8	Lung cancer;
TGCT	cis	rs10754283	0.934	rs10493829	chr1:90117833	T/C	cg03145924	chr1:90228473	NA	-0.41	-4.68	-0.39	7.24e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs3617	0.573	rs6795646	chr3:52922621	C/T	cg11645453	chr3:52864694	ITIH4	-0.29	-5.52	-0.44	1.85e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs1461503	0.966	rs10790546	chr11:122838426	C/A	cg27398637	chr11:122830231	C11orf63	-0.43	-5.31	-0.43	5e-7	Menarche (age at onset);
TGCT	cis	rs514406	0.505	rs440871	chr1:53173052	C/T	cg25767906	chr1:53392781	SCP2	-0.45	-5.01	-0.41	1.87e-6	Monocyte count;
TGCT	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg23283495	chr1:209979779	IRF6	0.71	8.45	0.6	6.81e-14	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
TGCT	cis	rs9443645	0.901	rs1354831	chr6:79613576	T/C	cg09184832	chr6:79620586	NA	-0.49	-5.29	-0.43	5.29e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	6.75	0.52	5.18e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9467711	0.516	rs1177441	chr6:25859413	A/G	cg03517284	chr6:25882590	NA	-0.73	-4.85	-0.4	3.62e-6	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs67311347	0.635	rs73071706	chr3:40288190	C/A	cg13683864	chr3:40499215	RPL14	-0.84	-7.91	-0.58	1.2e-12	Renal cell carcinoma;
TGCT	cis	rs28595532	0.920	rs114243409	chr4:119756585	C/A	cg14228332	chr4:119757509	SEC24D	1.29	6.0	0.47	1.98e-8	Cannabis dependence symptom count;
TGCT	cis	rs832540	0.801	rs7731700	chr5:56111927	C/T	cg24531977	chr5:56204891	C5orf35	-0.54	-5.34	-0.43	4.33e-7	Coronary artery disease;
TGCT	cis	rs2013441	0.932	rs2526488	chr17:20098617	T/A	cg18979559	chr17:20280153	CCDC144C	-0.43	-4.49	-0.37	1.61e-5	Obesity-related traits;
TGCT	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg25703541	chr22:24373054	LOC391322	-0.81	-8.47	-0.61	6.1e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs1008375	1.000	rs4698634	chr4:17630192	A/C	cg18681998	chr4:17616180	MED28	-1.02	-11.4	-0.72	4.89e-21	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs11190604	0.697	rs4559619	chr10:102199884	C/T	cg23241863	chr10:102295624	HIF1AN	-0.65	-4.9	-0.4	2.9e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs826838	0.935	rs1160162	chr12:38959795	G/A	cg26384229	chr12:38710491	ALG10B	1.03	10.33	0.68	1.97e-18	Heart rate;
TGCT	cis	rs12478296	1.000	rs12474070	chr2:243039738	C/T	cg06360820	chr2:242988706	NA	-0.61	-4.75	-0.39	5.52e-6	Obesity-related traits;
TGCT	cis	rs10411936	1.000	rs16995422	chr19:16519045	A/G	cg19006008	chr19:16999768	F2RL3	-0.27	-4.73	-0.39	5.95e-6	White blood cell count;Multiple sclerosis;
TGCT	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg10295955	chr4:187884368	NA	-0.95	-14.86	-0.8	2.58e-29	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.6	-6.02	-0.48	1.83e-8	Cognitive function;
TGCT	cis	rs12580194	0.593	rs61957936	chr12:55745719	A/G	cg10672482	chr12:55725839	OR6C3	-0.52	-4.66	-0.39	8.13e-6	Cancer;
TGCT	cis	rs6912958	0.712	rs4587138	chr6:88356915	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-4.55	-0.38	1.26e-5	Monocyte percentage of white cells;
TGCT	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.48	-6.74	-0.52	5.26e-10	Alzheimer's disease;
TGCT	trans	rs9388451	0.587	rs1739385	chr6:126099939	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.8	-9.31	-0.64	5.94e-16	Brugada syndrome;
TGCT	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg10802521	chr3:52805072	NEK4	-0.78	-10.01	-0.67	1.23e-17	Electroencephalogram traits;
TGCT	cis	rs2549003	0.966	rs2070730	chr5:131819800	G/A	cg02551604	chr5:131831745	NA	-0.89	-11.95	-0.73	2.33e-22	Asthma (sex interaction);
TGCT	cis	rs2692947	0.770	rs58730124	chr2:96413338	T/C	cg23100626	chr2:96804247	ASTL	0.37	4.49	0.37	1.62e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs7572733	0.534	rs10931794	chr2:198776140	C/T	cg00792783	chr2:198669748	PLCL1	-0.56	-5.11	-0.42	1.21e-6	Dermatomyositis;
TGCT	cis	rs2469997	1.000	rs2447176	chr8:120356892	G/A	cg02248809	chr8:120845432	TAF2	0.58	4.47	0.37	1.76e-5	Hypertension (SNP x SNP interaction);
TGCT	cis	rs4888262	0.545	rs8050624	chr16:74686690	A/G	cg01733217	chr16:74700730	RFWD3	-0.74	-7.35	-0.55	2.3e-11	Testicular germ cell tumor;
TGCT	cis	rs912057	0.797	rs1294430	chr6:6744698	A/G	cg06612196	chr6:6737390	NA	0.37	4.69	0.39	7.03e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
TGCT	cis	rs7267979	0.966	rs2261747	chr20:25261784	G/A	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9916302	0.861	rs8081033	chr17:37506650	A/G	cg15445000	chr17:37608096	MED1	-0.33	-4.71	-0.39	6.46e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs6500602	0.701	rs11643057	chr16:4544505	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.4	7.08	0.54	9.28e-11	Schizophrenia;
TGCT	cis	rs11696501	0.688	rs6073861	chr20:44325708	G/A	cg11783356	chr20:44313418	WFDC10B	-0.33	-4.49	-0.37	1.6e-5	Brain structure;
TGCT	cis	rs7760949	0.889	rs9475807	chr6:13934597	T/C	cg27413430	chr6:13925136	RNF182	0.73	6.79	0.52	4.22e-10	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg04154034	chr17:28927549	LRRC37B2	0.76	4.75	0.39	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs17102423	0.963	rs35002541	chr14:65598704	G/A	cg11161011	chr14:65562177	MAX	-0.52	-6.9	-0.53	2.37e-10	Obesity-related traits;
TGCT	cis	rs8056742	0.730	rs35835594	chr16:85070415	T/C	cg00229868	chr16:85520891	NA	0.42	5.17	0.42	9.14e-7	Amyotrophic lateral sclerosis;
TGCT	cis	rs79349575	0.783	rs4255820	chr17:46996583	T/A	cg26022315	chr17:47021804	SNF8	0.49	4.89	0.4	3.03e-6	Type 2 diabetes;
TGCT	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg24829409	chr8:58192753	C8orf71	-0.59	-4.97	-0.41	2.17e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg22920501	chr2:26401640	FAM59B	-0.71	-6.1	-0.48	1.27e-8	Gut microbiome composition (summer);
TGCT	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg11235426	chr6:292522	DUSP22	-0.68	-6.94	-0.53	1.92e-10	Menopause (age at onset);
TGCT	cis	rs7824557	0.564	rs2736295	chr8:11234780	C/G	cg21775007	chr8:11205619	TDH	0.63	6.24	0.49	6.18e-9	Retinal vascular caliber;
TGCT	cis	rs7267979	0.727	rs2474765	chr20:25245950	G/T	cg16686733	chr20:25566563	NINL	0.51	5.1	0.42	1.22e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg00024416	chr22:24240387	NA	-0.25	-4.76	-0.39	5.27e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs12579753	0.872	rs12319937	chr12:82182545	T/G	cg07988820	chr12:82153109	PPFIA2	-0.59	-6.19	-0.49	7.93e-9	Resting heart rate;
TGCT	cis	rs854765	0.583	rs12452219	chr17:17829423	C/T	cg09796270	chr17:17721594	SREBF1	0.27	5.53	0.44	1.84e-7	Total body bone mineral density;
TGCT	cis	rs67180937	0.583	rs3008614	chr1:222796136	C/T	cg09820183	chr1:222886073	C1orf58;AIDA	0.71	4.58	0.38	1.12e-5	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
TGCT	cis	rs727563	0.552	rs4822045	chr22:41985958	C/A	cg06481639	chr22:41940642	POLR3H	-0.75	-6.47	-0.5	2.1e-9	Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs9914988	0.832	rs9903248	chr17:27127439	G/T	cg20469991	chr17:27169893	C17orf63	-0.72	-5.09	-0.42	1.29e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	trans	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg21659725	chr3:3221576	CRBN	0.76	9.03	0.63	2.74e-15	Intelligence (multi-trait analysis);
TGCT	cis	rs7617773	0.817	rs936427	chr3:48301074	A/G	cg11946769	chr3:48343235	NME6	-0.76	-6.63	-0.51	9.31e-10	Coronary artery disease;
TGCT	cis	rs7666738	0.606	rs13108868	chr4:99083753	C/T	cg05340658	chr4:99064831	C4orf37	0.44	4.8	0.4	4.5e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9921338	0.961	rs7206017	chr16:11440861	C/T	cg00044050	chr16:11439710	C16orf75	-0.87	-6.68	-0.51	7.37e-10	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs6831352	0.918	rs29001194	chr4:100054844	A/G	cg12011299	chr4:100065546	ADH4	-0.4	-4.88	-0.4	3.26e-6	Alcohol dependence;
TGCT	cis	rs3749237	0.964	rs11714957	chr3:49776178	C/T	cg03060546	chr3:49711283	APEH	0.72	7.38	0.55	2.02e-11	Resting heart rate;
TGCT	cis	rs858239	0.632	rs7811903	chr7:23119056	A/G	cg05602783	chr7:23145260	KLHL7	-0.63	-5.31	-0.43	4.93e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs2996428	0.667	rs11578581	chr1:3770642	G/A	cg17848003	chr1:3704513	LRRC47	0.18	5.15	0.42	9.99e-7	Red cell distribution width;
TGCT	cis	rs9948	0.655	rs62152785	chr2:97459403	A/T	cg01990225	chr2:97406019	LMAN2L	-0.88	-4.81	-0.4	4.37e-6	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs600231	0.665	rs1784859	chr11:65220749	A/G	cg21890820	chr11:65308645	LTBP3	-0.39	-4.67	-0.39	7.73e-6	Bone mineral density;
TGCT	cis	rs617219	0.737	rs6453431	chr5:78493873	G/C	cg09550809	chr5:78407562	BHMT	0.39	5.49	0.44	2.19e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg02975922	chr3:195473998	MUC4	-0.24	-5.47	-0.44	2.4e-7	Pancreatic cancer;
TGCT	cis	rs7568458	0.636	rs11126995	chr2:85792408	A/T	cg17127132	chr2:85788382	GGCX	0.55	5.0	0.41	1.88e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
TGCT	cis	rs4663866	0.901	rs3739066	chr2:239184124	G/T	cg17283117	chr2:239148619	HES6	0.99	4.58	0.38	1.12e-5	Irritable bowel syndrome;
TGCT	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg08219700	chr8:58056026	NA	0.3	4.53	0.38	1.35e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg00343986	chr7:65444356	GUSB	-0.24	-5.29	-0.43	5.43e-7	Aortic root size;
TGCT	cis	rs789852	0.717	rs789997	chr3:194328524	A/G	cg18000598	chr3:194342907	TMEM44	-0.9	-5.51	-0.44	2e-7	QT interval;
TGCT	cis	rs3782455	0.590	rs16943539	chr12:114404337	T/G	cg10631684	chr12:113795897	PLBD2	-0.7	-4.61	-0.38	1e-5	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs1215050	0.755	rs1238462	chr4:98850603	A/G	cg17366294	chr4:99064904	C4orf37	-0.57	-6.12	-0.48	1.13e-8	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs6952808	0.931	rs12537430	chr7:1868761	A/G	cg22963979	chr7:1858916	MAD1L1	0.3	4.65	0.39	8.24e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs2229238	0.911	rs60760897	chr1:154504849	C/T	cg13067139	chr1:155221277	FAM189B	0.2	4.51	0.38	1.47e-5	Coronary heart disease;
TGCT	cis	rs10986311	0.722	rs6478660	chr9:127133920	A/T	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.19	4.88	0.4	3.23e-6	Vitiligo;
TGCT	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg23156509	chr2:114033830	PAX8;LOC440839	-0.32	-4.9	-0.4	2.91e-6	Lymphocyte counts;
TGCT	cis	rs79976124	0.879	rs17432710	chr6:66621744	T/C	cg07460842	chr6:66804631	NA	0.58	5.17	0.42	8.91e-7	Type 2 diabetes;
TGCT	cis	rs12497850	0.931	rs9846123	chr3:49088112	C/T	cg18654377	chr3:49208889	KLHDC8B	0.41	5.4	0.44	3.33e-7	Parkinson's disease;
TGCT	cis	rs1113500	0.787	rs473704	chr1:108637310	T/C	cg22161131	chr1:109420278	GPSM2	-0.49	-4.54	-0.38	1.34e-5	Growth-regulated protein alpha levels;
TGCT	cis	rs2762353	0.639	rs566530	chr6:25878361	T/C	cg12310025	chr6:25882481	NA	-0.65	-7.17	-0.54	5.94e-11	Blood metabolite levels;
TGCT	cis	rs11174478	0.966	rs4768204	chr12:40351086	A/T	cg12664938	chr12:40622688	LRRK2	0.23	4.59	0.38	1.05e-5	Insomnia;
TGCT	cis	rs2657888	0.628	rs7314242	chr12:56876372	C/A	cg23002907	chr12:56915593	RBMS2	-0.41	-5.37	-0.43	3.76e-7	Adiponectin levels;
TGCT	cis	rs35306767	0.953	rs11253509	chr10:964306	C/T	cg18964960	chr10:1102726	WDR37	0.57	4.55	0.38	1.27e-5	Eosinophil percentage of granulocytes;
TGCT	cis	rs7666738	0.535	rs6850010	chr4:98971601	A/T	cg18180107	chr4:99064573	C4orf37	0.5	4.46	0.37	1.84e-5	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.0	7.47	0.56	1.24e-11	Platelet count;
TGCT	cis	rs8177253	0.530	rs8177177	chr3:133463195	A/G	cg24879335	chr3:133465180	TF	0.37	4.89	0.4	3.03e-6	Iron status biomarkers;
TGCT	trans	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg25482853	chr8:67687455	SGK3	1.19	10.96	0.7	5.68e-20	Lung disease severity in cystic fibrosis;
TGCT	cis	rs1348850	0.567	rs3770005	chr2:178528874	A/G	cg22681709	chr2:178499509	PDE11A	-0.48	-5.94	-0.47	2.7e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs8072100	0.967	rs2317826	chr17:45730899	C/T	cg08085267	chr17:45401833	C17orf57	-0.47	-5.12	-0.42	1.14e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs4820539	0.902	rs737846	chr22:23460669	A/G	cg21100191	chr22:23484243	RTDR1	0.94	11.48	0.72	3.14e-21	Bone mineral density;
TGCT	cis	rs6977660	0.714	rs17141884	chr7:19790280	A/G	cg07541023	chr7:19748670	TWISTNB	-0.84	-5.05	-0.41	1.55e-6	Thyroid stimulating hormone;
TGCT	cis	rs2692947	0.655	rs2315668	chr2:96429562	T/C	cg23100626	chr2:96804247	ASTL	0.4	4.78	0.39	4.84e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
TGCT	cis	rs473651	0.935	rs472357	chr2:239355454	A/G	cg08773314	chr2:239334832	ASB1	-0.44	-7.21	-0.54	4.93e-11	Multiple system atrophy;
TGCT	cis	rs9393692	0.905	rs6940237	chr6:26282322	T/C	cg13736514	chr6:26305472	NA	-0.41	-5.77	-0.46	6.09e-8	Educational attainment;
TGCT	cis	rs3820068	0.655	rs72645826	chr1:15889741	A/G	cg05660106	chr1:15850417	CASP9	1.17	14.8	0.8	3.47e-29	Systolic blood pressure;
TGCT	cis	rs950776	0.684	rs11637635	chr15:78877150	A/G	cg06917634	chr15:78832804	PSMA4	-0.66	-5.29	-0.43	5.47e-7	Sudden cardiac arrest;
TGCT	cis	rs9807989	0.801	rs10176664	chr2:102976172	G/A	cg09003973	chr2:102972529	NA	0.67	6.03	0.48	1.75e-8	Asthma;
TGCT	cis	rs2239547	0.563	rs4687699	chr3:53101224	C/T	cg11645453	chr3:52864694	ITIH4	0.34	5.59	0.45	1.38e-7	Schizophrenia;
TGCT	cis	rs6840360	0.809	rs6847303	chr4:152730221	G/A	cg22705602	chr4:152727874	NA	0.27	4.82	0.4	4.09e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7563124	1	rs7563124	chr2:113965198	T/A	cg27425262	chr2:113953981	PSD4;LOC440839	0.4	4.67	0.39	7.79e-6	Hematocrit;
TGCT	cis	rs7312933	0.558	rs1796394	chr12:42826359	G/A	cg19980929	chr12:42632907	YAF2	-0.4	-5.7	-0.46	8.24e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs9467773	1.000	rs6910899	chr6:26524339	A/G	cg09904177	chr6:26538194	HMGN4	0.65	6.53	0.51	1.53e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs11190604	0.767	rs10883491	chr10:102196071	G/T	cg23241863	chr10:102295624	HIF1AN	0.64	4.8	0.4	4.42e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs28595532	0.920	rs115334469	chr4:119596194	G/C	cg14228332	chr4:119757509	SEC24D	1.04	5.37	0.43	3.66e-7	Cannabis dependence symptom count;
TGCT	cis	rs5769707	0.681	rs916360	chr22:50041972	T/C	cg05373962	chr22:49881684	NA	-0.34	-5.66	-0.45	1.01e-7	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs1670533	0.872	rs11727135	chr4:1051803	G/C	cg20887711	chr4:1340912	KIAA1530	0.63	5.03	0.41	1.65e-6	Recombination rate (females);
TGCT	cis	rs12681287	0.640	rs6992944	chr8:87419308	G/T	cg27223183	chr8:87520930	FAM82B	0.89	6.36	0.5	3.45e-9	Caudate activity during reward;
TGCT	cis	rs9486719	0.843	rs3860231	chr6:97036563	G/A	cg06623918	chr6:96969491	KIAA0776	-1.04	-10.25	-0.68	3.11e-18	Migraine;Coronary artery disease;
TGCT	cis	rs9534288	0.783	rs7987385	chr13:46634131	A/G	cg15192986	chr13:46630673	CPB2	-0.5	-6.23	-0.49	6.66e-9	Blood protein levels;
TGCT	cis	rs12421382	0.636	rs60266280	chr11:109387766	A/C	cg16359550	chr11:109292809	C11orf87	0.42	4.68	0.39	7.36e-6	Schizophrenia;
TGCT	cis	rs3764400	0.567	rs3897789	chr17:46312777	C/T	cg02340556	chr17:46797764	NA	0.42	4.51	0.38	1.46e-5	Body mass index;
TGCT	cis	rs3849570	1.000	rs3772883	chr3:81802802	C/T	cg07356753	chr3:81810745	GBE1	-0.71	-6.13	-0.48	1.08e-8	Waist circumference;Body mass index;
TGCT	cis	rs2204008	0.774	rs2387811	chr12:38369794	C/A	cg26384229	chr12:38710491	ALG10B	0.84	7.3	0.55	2.97e-11	Bladder cancer;
TGCT	cis	rs9381040	0.655	rs9394756	chr6:41016183	A/G	cg03526776	chr6:41159608	TREML2	0.26	5.06	0.41	1.44e-6	Alzheimer's disease (late onset);
TGCT	cis	rs778371	0.676	rs921055	chr2:233697337	A/C	cg08000102	chr2:233561755	GIGYF2	-0.67	-7.64	-0.57	5.21e-12	Schizophrenia;
TGCT	cis	rs7178572	0.743	rs62009090	chr15:77837055	T/G	cg22256960	chr15:77711686	NA	-0.86	-9.93	-0.67	1.88e-17	Type 2 diabetes;
TGCT	cis	rs155076	0.938	rs261375	chr13:21871882	A/G	cg11317459	chr13:21872234	NA	1.4	11.14	0.71	2.1e-20	White matter hyperintensity burden;
TGCT	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg09365446	chr1:150670422	GOLPH3L	0.31	4.64	0.38	8.7e-6	Tonsillectomy;
TGCT	cis	rs9796	0.689	rs692195	chr15:41444894	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.53	-6.84	-0.52	3.16e-10	Menopause (age at onset);
TGCT	cis	rs453301	0.571	rs2929454	chr8:9083854	A/C	cg06636001	chr8:8085503	FLJ10661	-0.56	-4.97	-0.41	2.14e-6	Joint mobility (Beighton score);
TGCT	cis	rs9614461	0.702	rs3788648	chr22:45727180	G/A	cg01808030	chr22:45809952	RIBC2;SMC1B	0.75	4.45	0.37	1.91e-5	Tonsillectomy;
TGCT	cis	rs9372498	0.536	rs9320656	chr6:118894468	A/G	cg21191810	chr6:118973309	C6orf204	0.39	5.04	0.41	1.59e-6	Diastolic blood pressure;
TGCT	cis	rs1059312	0.932	rs4760592	chr12:129287149	G/C	cg09035930	chr12:129282057	SLC15A4	0.58	11.18	0.71	1.67e-20	Systemic lupus erythematosus;
TGCT	cis	rs3733585	0.699	rs4339211	chr4:9947658	C/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.45	-0.5	2.22e-9	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs6893807	0.667	rs2304607	chr5:87988733	A/G	cg24804195	chr5:87968844	LOC645323	0.66	4.68	0.39	7.26e-6	Body mass index;
TGCT	cis	rs477895	0.838	rs11605738	chr11:64013406	G/A	cg23719950	chr11:63933701	MACROD1	-0.69	-5.74	-0.46	6.94e-8	Mean platelet volume;
TGCT	cis	rs7666738	0.747	rs2865955	chr4:99040518	A/C	cg05340658	chr4:99064831	C4orf37	0.52	5.82	0.46	4.7e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs6582630	0.622	rs11182004	chr12:38441254	G/A	cg26384229	chr12:38710491	ALG10B	-0.54	-4.81	-0.4	4.32e-6	Drug-induced liver injury (flucloxacillin);
TGCT	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg02953382	chr22:24373134	LOC391322	0.81	6.9	0.53	2.34e-10	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs62380364	0.557	rs663046	chr5:88036486	C/T	cg24804195	chr5:87968844	LOC645323	-0.61	-6.27	-0.49	5.52e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs9549367	0.577	rs3024718	chr13:113813853	C/T	cg18105134	chr13:113819100	PROZ	0.45	7.26	0.55	3.75e-11	Platelet distribution width;
TGCT	cis	rs1153858	1.000	rs7494956	chr15:45668565	T/C	cg14582100	chr15:45693742	SPATA5L1	0.49	5.73	0.46	7.14e-8	Homoarginine levels;
TGCT	cis	rs9611565	0.649	rs139540	chr22:42178040	C/T	cg06634786	chr22:41940651	POLR3H	-0.81	-7.44	-0.56	1.45e-11	Vitiligo;
TGCT	cis	rs2074038	1.000	rs2074038	chr11:44087989	G/T	cg00452199	chr11:44088257	ACCS	-0.78	-7.67	-0.57	4.42e-12	IgA nephropathy;
TGCT	cis	rs4285028	0.948	rs10934565	chr3:121664661	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.77	-6.5	-0.5	1.78e-9	Multiple sclerosis;
TGCT	cis	rs11690462	0.963	rs6748996	chr2:26590084	T/G	cg11525280	chr2:26624667	C2orf39	0.37	4.52	0.38	1.4e-5	Coronary artery disease;
TGCT	cis	rs7666738	0.830	rs17027216	chr4:99009152	G/C	cg05340658	chr4:99064831	C4orf37	0.48	5.49	0.44	2.15e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs889312	0.500	rs866223	chr5:56125353	A/G	cg12311346	chr5:56204834	C5orf35	-0.46	-5.01	-0.41	1.85e-6	Breast cancer;Breast cancer (early onset);
TGCT	cis	rs492146	0.819	rs5028437	chr6:52835674	T/C	cg06706454	chr6:52930286	FBXO9	0.5	4.63	0.38	9.12e-6	Epilepsy (remission after treatment);
TGCT	cis	rs6484504	0.600	rs12796587	chr11:31266443	T/C	cg14844989	chr11:31128820	NA	-0.25	-4.84	-0.4	3.76e-6	Red blood cell count;
TGCT	cis	rs9611519	0.929	rs73174660	chr22:41437304	T/C	cg03806693	chr22:41940476	POLR3H	-0.68	-6.1	-0.48	1.25e-8	Neuroticism;
TGCT	cis	rs3091242	0.933	rs11249251	chr1:25770188	C/G	cg09222892	chr1:25734099	RHCE	-0.42	-7.15	-0.54	6.72e-11	Erythrocyte sedimentation rate;
TGCT	cis	rs854765	0.654	rs11078400	chr17:17757728	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.74	-7.65	-0.57	4.87e-12	Total body bone mineral density;
TGCT	cis	rs9322193	0.923	rs9371486	chr6:150153226	T/C	cg13206674	chr6:150067644	NUP43	0.54	4.61	0.38	1e-5	Lung cancer;
TGCT	cis	rs2594989	0.836	rs347607	chr3:11268021	A/C	cg00170343	chr3:11313890	ATG7	-0.77	-4.73	-0.39	6.04e-6	Circulating chemerin levels;
TGCT	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg06618935	chr21:46677482	NA	-0.37	-5.81	-0.46	5.06e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs61990749	0.500	rs8011337	chr14:78272626	T/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.67	4.73	0.39	6.09e-6	Fibroblast growth factor basic levels;
TGCT	cis	rs950169	0.800	rs34302901	chr15:85110943	C/G	cg11189052	chr15:85197271	WDR73	0.77	6.42	0.5	2.68e-9	Schizophrenia;
TGCT	cis	rs8014252	0.803	rs8006487	chr14:71011934	G/A	cg11204974	chr14:71022665	NA	-0.53	-4.46	-0.37	1.79e-5	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
TGCT	cis	rs4268898	0.722	rs6723257	chr2:24391129	A/G	cg05570707	chr2:24270316	C2orf44	0.48	4.59	0.38	1.08e-5	Asthma;
TGCT	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg21644426	chr2:191273491	MFSD6	0.62	6.15	0.48	9.57e-9	Pulse pressure;
TGCT	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg18876405	chr7:65276391	NA	0.31	4.79	0.4	4.58e-6	Aortic root size;
TGCT	cis	rs793571	0.502	rs411007	chr15:59078502	G/C	cg05156742	chr15:59063176	FAM63B	0.57	5.36	0.43	3.92e-7	Schizophrenia;
TGCT	cis	rs6693567	0.565	rs698921	chr1:150379517	G/A	cg09579323	chr1:150459698	TARS2	0.52	4.64	0.38	8.63e-6	Migraine;
TGCT	cis	rs2130392	0.892	rs11728389	chr4:185622046	C/T	cg14471096	chr4:185570637	CCDC111;CASP3	-0.56	-5.06	-0.41	1.49e-6	Kawasaki disease;
TGCT	cis	rs4654899	0.865	rs12131353	chr1:21321163	C/G	cg01072550	chr1:21505969	NA	-0.46	-6.94	-0.53	1.96e-10	Superior frontal gyrus grey matter volume;
TGCT	cis	rs13217239	0.608	rs6930508	chr6:27053142	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.42	-4.61	-0.38	1.01e-5	Schizophrenia;
TGCT	cis	rs9457247	0.967	rs1187532	chr6:167382020	G/A	cg23791538	chr6:167370224	RNASET2	-0.5	-4.98	-0.41	2.08e-6	Crohn's disease;
TGCT	cis	rs6500602	0.702	rs11645519	chr16:4538989	G/A	cg08645402	chr16:4508243	NA	0.18	5.07	0.41	1.39e-6	Schizophrenia;
TGCT	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg11062466	chr8:58055876	NA	0.42	4.49	0.37	1.61e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7824557	0.767	rs11775635	chr8:11164865	G/A	cg21775007	chr8:11205619	TDH	0.58	5.46	0.44	2.46e-7	Retinal vascular caliber;
TGCT	cis	rs7267979	1.000	rs6076339	chr20:25348712	T/C	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs3809566	0.534	rs55962736	chr15:63333892	G/T	cg08198488	chr15:63333792	TPM1	-0.31	-4.62	-0.38	9.38e-6	Platelet count;
TGCT	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg03609598	chr5:56110824	MAP3K1	0.58	4.7	0.39	6.72e-6	Initial pursuit acceleration;
TGCT	cis	rs40363	0.620	rs1137454	chr16:3533577	C/G	cg00484396	chr16:3507460	NAT15	-0.4	-6.06	-0.48	1.5e-8	Tuberculosis;
TGCT	cis	rs2075371	0.897	rs1646702	chr7:134000177	C/G	cg11752832	chr7:134001865	SLC35B4	0.7	6.44	0.5	2.41e-9	Mean platelet volume;
TGCT	cis	rs4253772	0.637	rs6008357	chr22:46652104	T/G	cg09491104	chr22:46646882	C22orf40	-0.62	-6.49	-0.5	1.87e-9	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs909674	0.818	rs8136980	chr22:39844574	G/A	cg24399712	chr22:39784796	NA	-1.05	-11.84	-0.73	4.14e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.16	0.54	6.1e-11	Prudent dietary pattern;
TGCT	cis	rs11718455	0.960	rs13060222	chr3:44005046	A/T	cg08738300	chr3:44038990	NA	0.85	6.34	0.49	3.94e-9	Coronary artery disease;
TGCT	cis	rs2235649	0.592	rs7197113	chr16:1969483	G/A	cg02432467	chr16:1963432	HS3ST6	-0.3	-4.56	-0.38	1.2e-5	Blood metabolite levels;
TGCT	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg00814883	chr7:100076585	TSC22D4	-0.92	-9.76	-0.66	4.73e-17	Platelet count;
TGCT	cis	rs7635838	0.892	rs9836167	chr3:11493392	C/T	cg00170343	chr3:11313890	ATG7	0.66	6.0	0.47	2.03e-8	HDL cholesterol;
TGCT	cis	rs17253792	0.749	rs45458197	chr14:56145018	A/T	cg01858014	chr14:56050164	KTN1	-0.35	-4.62	-0.38	9.37e-6	Putamen volume;
TGCT	cis	rs2688608	0.592	rs11000758	chr10:75493610	A/T	cg23231163	chr10:75533350	FUT11	-0.28	-4.68	-0.39	7.4e-6	Inflammatory bowel disease;
TGCT	cis	rs17001868	0.568	rs2075764	chr22:40758581	C/T	cg07138101	chr22:40742427	ADSL	0.74	5.64	0.45	1.11e-7	Mammographic density (dense area);
TGCT	cis	rs35306767	0.903	rs12762228	chr10:880854	G/A	cg20503657	chr10:835505	NA	0.77	11.34	0.71	6.95e-21	Eosinophil percentage of granulocytes;
TGCT	cis	rs3784262	1.000	rs7165247	chr15:58251786	C/T	cg12031962	chr15:58353849	ALDH1A2	0.5	7.79	0.57	2.33e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs9467773	0.620	rs2494700	chr6:26631306	C/T	cg02458000	chr6:26745757	NA	0.53	5.02	0.41	1.76e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6088590	0.707	rs67159833	chr20:33488079	T/C	cg24642439	chr20:33292090	TP53INP2	0.61	4.85	0.4	3.58e-6	Coronary artery disease;
TGCT	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg04944784	chr2:26401820	FAM59B	-0.67	-6.16	-0.48	9.54e-9	Gut microbiome composition (summer);
TGCT	cis	rs6714710	0.603	rs55776387	chr2:98405034	T/C	cg26665480	chr2:98280029	ACTR1B	0.66	6.27	0.49	5.45e-9	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg01802117	chr1:53393560	SCP2	-0.43	-4.99	-0.41	1.97e-6	Monocyte count;
TGCT	cis	rs12510870	0.599	rs34832471	chr4:74434741	G/A	cg05868023	chr4:75230803	EREG	-0.52	-4.53	-0.38	1.39e-5	Iris color (b* coordinate);
TGCT	cis	rs2404602	0.716	rs17460201	chr15:76673627	C/T	cg26408565	chr15:76604113	ETFA	0.39	4.94	0.41	2.47e-6	Blood metabolite levels;
TGCT	cis	rs6831352	0.918	rs13110176	chr4:100062430	C/T	cg12011299	chr4:100065546	ADH4	0.44	5.28	0.43	5.52e-7	Alcohol dependence;
TGCT	cis	rs2050392	0.624	rs303435	chr10:30731491	T/C	cg13289132	chr10:30722225	MAP3K8	-0.46	-5.83	-0.46	4.59e-8	Inflammatory bowel disease;
TGCT	trans	rs2727020	0.553	rs7479975	chr11:49581964	C/G	cg03929089	chr4:120376271	NA	-0.65	-7.47	-0.56	1.22e-11	Coronary artery disease;
TGCT	cis	rs7731657	0.537	rs4706002	chr5:130373830	C/T	cg08523029	chr5:130500466	HINT1	-0.61	-5.08	-0.42	1.34e-6	Fasting plasma glucose;
TGCT	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg00684032	chr4:1343700	KIAA1530	0.22	4.73	0.39	5.89e-6	Obesity-related traits;
TGCT	cis	rs1153858	1.000	rs4775937	chr15:45678614	C/A	cg14582100	chr15:45693742	SPATA5L1	0.49	5.73	0.46	7.14e-8	Homoarginine levels;
TGCT	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg17179660	chr6:151773299	C6orf211;RMND1	-0.57	-5.41	-0.44	3.08e-7	Menarche (age at onset);
TGCT	cis	rs10465746	0.682	rs882897	chr1:84426049	A/T	cg10977910	chr1:84465055	TTLL7	0.69	7.07	0.54	9.97e-11	Obesity-related traits;
TGCT	cis	rs3749237	0.595	rs4855873	chr3:49459114	A/C	cg02487422	chr3:49467188	NICN1	0.58	5.92	0.47	3e-8	Resting heart rate;
TGCT	cis	rs763014	0.898	rs1045277	chr16:633125	T/C	cg07343612	chr16:622815	PIGQ	-0.41	-7.87	-0.58	1.52e-12	Height;
TGCT	cis	rs5769707	0.874	rs9616714	chr22:50050859	G/A	cg05373962	chr22:49881684	NA	-0.32	-6.56	-0.51	1.34e-9	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs1008375	0.931	rs6831211	chr4:17697009	G/A	cg18681998	chr4:17616180	MED28	0.79	7.42	0.55	1.61e-11	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs739496	0.843	rs848129	chr12:111997502	G/C	cg10833066	chr12:111807467	FAM109A	0.37	5.2	0.42	8.01e-7	Platelet count;
TGCT	cis	rs7829975	0.533	rs7820146	chr8:8699757	T/A	cg08975724	chr8:8085496	FLJ10661	0.55	4.86	0.4	3.5e-6	Mood instability;
TGCT	cis	rs2963155	0.518	rs10515522	chr5:142758394	A/G	cg17617527	chr5:142782415	NR3C1	0.79	4.94	0.41	2.46e-6	Breast cancer;
TGCT	cis	rs7178572	1.000	rs965480	chr15:77781926	A/G	cg22256960	chr15:77711686	NA	-0.95	-10.89	-0.7	8.57e-20	Type 2 diabetes;
TGCT	cis	rs7937682	0.889	rs487985	chr11:111517908	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.1	-11.55	-0.72	2.11e-21	Primary sclerosing cholangitis;
TGCT	cis	rs4925386	0.681	rs2427295	chr20:60927431	G/A	cg06026331	chr20:60912101	LAMA5	0.34	5.46	0.44	2.48e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg27535305	chr1:53392650	SCP2	-0.25	-4.79	-0.4	4.59e-6	Monocyte count;
TGCT	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg24829409	chr8:58192753	C8orf71	-0.56	-5.28	-0.43	5.51e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs899997	1.000	rs9888691	chr15:79010046	T/C	cg00061860	chr15:78953028	NA	-0.25	-4.67	-0.39	7.76e-6	Coronary artery disease or large artery stroke;
TGCT	cis	rs7949030	0.596	rs71490394	chr11:62370155	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.61	8.75	0.62	1.29e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs10193935	1.000	rs13419669	chr2:42387254	T/C	cg27598129	chr2:42591480	NA	-0.39	-5.14	-0.42	1.05e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs13256369	1.000	rs4841016	chr8:8572561	C/T	cg17143192	chr8:8559678	CLDN23	0.62	5.82	0.46	4.82e-8	Obesity-related traits;
TGCT	cis	rs933688	0.532	rs13164949	chr5:90538489	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.54	-4.82	-0.4	4.09e-6	Smoking behavior;
TGCT	cis	rs7208859	0.623	rs9890862	chr17:29125450	C/A	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs11249608	0.548	rs13156530	chr5:178475017	C/T	cg21905437	chr5:178450457	ZNF879	0.43	4.49	0.37	1.59e-5	Pubertal anthropometrics;
TGCT	cis	rs72781680	0.898	rs12619525	chr2:23999565	G/C	cg08917208	chr2:24149416	ATAD2B	0.81	5.01	0.41	1.8e-6	Lymphocyte counts;
TGCT	cis	rs2180341	1.000	rs2038378	chr6:127590400	C/T	cg27446573	chr6:127587934	RNF146	1.11	9.86	0.66	2.76e-17	Breast cancer;
TGCT	cis	rs7937612	1.000	rs10892578	chr11:120308290	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.29	-4.86	-0.4	3.43e-6	Intraocular pressure;
TGCT	trans	rs2688608	0.592	rs12253429	chr10:75496161	C/G	cg13918328	chr10:52500089	ASAH2B	0.68	6.7	0.52	6.48e-10	Inflammatory bowel disease;
TGCT	cis	rs6570726	0.846	rs9399559	chr6:145945778	C/T	cg05347473	chr6:146136440	FBXO30	0.48	4.53	0.38	1.38e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs67311347	1.000	rs9848083	chr3:40466979	A/G	cg17264618	chr3:40429014	ENTPD3	-0.32	-4.76	-0.39	5.36e-6	Renal cell carcinoma;
TGCT	cis	rs7178572	0.568	rs12905951	chr15:77649431	G/A	cg22256960	chr15:77711686	NA	-0.85	-8.73	-0.62	1.4e-14	Type 2 diabetes;
TGCT	cis	rs7017914	0.967	rs13271442	chr8:71585169	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.54	-5.03	-0.41	1.69e-6	Bone mineral density;
TGCT	cis	rs6540559	0.673	rs926346	chr1:209962204	A/T	cg23283495	chr1:209979779	IRF6	0.65	5.02	0.41	1.76e-6	Cleft lip with or without cleft palate;
TGCT	cis	rs644799	0.544	rs1727165	chr11:95521648	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.55	5.67	0.45	9.5e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs9467773	0.620	rs4368798	chr6:26593471	A/G	cg02458000	chr6:26745757	NA	0.51	4.77	0.39	5.08e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6490294	0.529	rs7137386	chr12:112283914	T/G	cg10833066	chr12:111807467	FAM109A	0.32	4.99	0.41	2.02e-6	Mean platelet volume;
TGCT	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg05985448	chr10:134359359	INPP5A	0.22	4.9	0.4	2.97e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs11578119	0.902	rs2183372	chr1:170504019	G/A	cg09767346	chr1:170501363	GORAB	-0.62	-5.11	-0.42	1.18e-6	Male-pattern baldness;
TGCT	cis	rs7547997	0.685	rs12734093	chr1:158358660	G/A	cg03528325	chr1:158223921	CD1A	0.33	4.56	0.38	1.22e-5	QRS duration;
TGCT	cis	rs9388451	0.874	rs13209968	chr6:126089285	G/C	cg05901451	chr6:126070800	HEY2	-1.02	-15.06	-0.8	8.77e-30	Brugada syndrome;
TGCT	cis	rs11098499	0.575	rs907204	chr4:120238654	G/A	cg09307838	chr4:120376055	NA	0.61	5.84	0.46	4.35e-8	Corneal astigmatism;
TGCT	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.15	0.82	2.71e-32	Prudent dietary pattern;
TGCT	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg22105103	chr4:187893119	NA	-0.32	-4.44	-0.37	1.97e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs709400	0.627	rs55859054	chr14:103953666	T/A	cg26031613	chr14:104095156	KLC1	0.83	9.11	0.63	1.75e-15	Body mass index;
TGCT	cis	rs6912958	0.712	rs6908386	chr6:88354746	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-4.55	-0.38	1.26e-5	Monocyte percentage of white cells;
TGCT	cis	rs6087990	0.899	rs4911107	chr20:31374991	G/A	cg13636640	chr20:31349939	DNMT3B	1.1	14.78	0.8	3.97e-29	Ulcerative colitis;
TGCT	cis	rs796364	1.000	rs71424239	chr2:200725473	T/C	cg17644776	chr2:200775616	C2orf69	-0.31	-4.69	-0.39	7.18e-6	Schizophrenia;
TGCT	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg21862992	chr11:68658383	NA	0.46	6.35	0.5	3.74e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs17376456	0.825	rs1470150	chr5:93138654	C/T	cg25358565	chr5:93447407	FAM172A	-0.87	-8.22	-0.59	2.28e-13	Diabetic retinopathy;
TGCT	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg27454412	chr7:1067447	C7orf50	0.56	4.72	0.39	6.28e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg21226059	chr5:178986404	RUFY1	0.51	5.51	0.44	2e-7	Lung cancer;
TGCT	cis	rs2594989	0.943	rs2454492	chr3:11507793	G/A	cg00170343	chr3:11313890	ATG7	0.76	5.57	0.45	1.51e-7	Circulating chemerin levels;
TGCT	cis	rs4891159	0.584	rs689878	chr18:74152017	C/T	cg24786174	chr18:74118243	ZNF516	0.66	11.85	0.73	3.89e-22	Longevity;
TGCT	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg06636001	chr8:8085503	FLJ10661	0.87	8.77	0.62	1.18e-14	Neuroticism;
TGCT	cis	rs10751667	0.666	rs7943140	chr11:973824	T/C	cg06064525	chr11:970664	AP2A2	-0.34	-7.97	-0.58	9.04e-13	Alzheimer's disease (late onset);
TGCT	cis	rs28735056	0.935	rs552957	chr18:77595748	G/A	cg20368463	chr18:77673604	PQLC1	-0.49	-5.93	-0.47	2.81e-8	Schizophrenia;
TGCT	cis	rs6912958	0.781	rs7761814	chr6:88188309	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.54	-5.23	-0.43	7.03e-7	Monocyte percentage of white cells;
TGCT	cis	rs1395	1.000	rs1141313	chr2:27460968	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.51	6.77	0.52	4.66e-10	Blood metabolite levels;
TGCT	cis	rs9303401	0.580	rs12946396	chr17:57164195	T/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.58	5.74	0.46	6.76e-8	Cognitive test performance;
TGCT	cis	rs9929218	0.953	rs2902323	chr16:68736292	C/T	cg01251360	chr16:68772225	CDH1	0.29	4.66	0.39	8.19e-6	Colorectal cancer;
TGCT	cis	rs3741404	0.895	rs2429455	chr11:63995302	C/G	cg03236948	chr11:63997492	DNAJC4	0.37	4.63	0.38	8.93e-6	Platelet count;
TGCT	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg11062466	chr8:58055876	NA	0.46	4.91	0.4	2.8e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs58722170	0.627	rs12039431	chr1:38082122	G/A	cg17933807	chr1:38061675	GNL2	-0.86	-8.69	-0.62	1.83e-14	High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs7552404	0.924	rs1858536	chr1:76161595	G/T	cg22875332	chr1:76189707	ACADM	0.78	9.74	0.66	5.53e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs9467773	0.550	rs9379874	chr6:26440429	A/T	cg15659132	chr6:26577336	NA	-0.43	-4.51	-0.38	1.47e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs1483890	0.723	rs6783070	chr3:69411596	A/C	cg22125112	chr3:69402811	FRMD4B	-0.3	-4.93	-0.4	2.62e-6	Resting heart rate;
TGCT	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg17264618	chr3:40429014	ENTPD3	0.34	4.94	0.41	2.52e-6	Renal cell carcinoma;
TGCT	cis	rs1453308	1.000	rs4663644	chr2:237185511	T/A	cg19324714	chr2:237145437	ASB18	0.59	5.21	0.42	7.8e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
TGCT	cis	rs858239	0.601	rs6461693	chr7:23160133	A/G	cg05602783	chr7:23145260	KLHL7	0.63	5.27	0.43	5.84e-7	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs9325144	0.600	rs12227663	chr12:38734922	C/T	cg26384229	chr12:38710491	ALG10B	-0.61	-5.58	-0.45	1.43e-7	Morning vs. evening chronotype;
TGCT	cis	rs7439150	0.954	rs2227411	chr4:155489085	A/G	cg22130008	chr4:155548532	NA	-0.54	-6.51	-0.5	1.66e-9	Fibrinogen levels;
TGCT	cis	rs11096990	0.576	rs2008679	chr4:39268005	A/C	cg20847110	chr4:39482781	LOC401127	-0.16	-4.53	-0.38	1.36e-5	Cognitive function;
TGCT	cis	rs2688608	0.869	rs2633308	chr10:75653904	A/T	cg04320760	chr10:75533139	FUT11	-0.3	-4.67	-0.39	7.79e-6	Inflammatory bowel disease;
TGCT	cis	rs7226408	0.857	rs3967207	chr18:34474742	T/C	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs2197308	0.692	rs1904964	chr12:37933241	T/A	cg26384229	chr12:38710491	ALG10B	0.87	7.85	0.58	1.7e-12	Morning vs. evening chronotype;
TGCT	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg17178900	chr1:205818956	PM20D1	0.66	9.33	0.64	5.29e-16	Menarche (age at onset);
TGCT	cis	rs12765878	0.603	rs9420904	chr10:105666745	G/A	cg11005552	chr10:105648138	OBFC1	-0.4	-6.2	-0.49	7.61e-9	Coronary artery disease;
TGCT	cis	rs28595532	1.000	rs115915387	chr4:119640854	C/T	cg11846333	chr4:119757529	SEC24D	0.92	4.59	0.38	1.07e-5	Cannabis dependence symptom count;
TGCT	cis	rs6687430	0.526	rs12117392	chr1:10608583	T/C	cg17425144	chr1:10567563	PEX14	0.51	5.81	0.46	4.89e-8	Hand grip strength;
TGCT	cis	rs6141769	0.542	rs6057630	chr20:31318737	A/G	cg13636640	chr20:31349939	DNMT3B	-0.55	-4.62	-0.38	9.33e-6	Subjective well-being;
TGCT	cis	rs9297145	0.565	rs56132062	chr7:98778198	C/T	cg05967295	chr7:98741636	SMURF1	-0.68	-8.35	-0.6	1.12e-13	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg08975724	chr8:8085496	FLJ10661	0.56	4.99	0.41	2.02e-6	Mood instability;
TGCT	cis	rs9583531	0.574	rs61971615	chr13:111353111	C/T	cg24331049	chr13:111365604	ING1	-0.83	-7.99	-0.58	8.11e-13	Coronary artery disease;
TGCT	cis	rs2535633	0.602	rs2581816	chr3:53014657	C/T	cg10802521	chr3:52805072	NEK4	-0.54	-5.75	-0.46	6.64e-8	Body mass index;
TGCT	cis	rs7833790	0.632	rs6415653	chr8:82702536	A/G	cg27398817	chr8:82754497	SNX16	-0.64	-4.91	-0.4	2.85e-6	Diastolic blood pressure;
TGCT	cis	rs60843830	0.964	rs62114538	chr2:256116	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.7	7.1	0.54	8.5e-11	Spherical equivalent (joint analysis main effects and education interaction);
TGCT	cis	rs2228479	0.850	rs11648433	chr16:89965055	G/A	cg06558623	chr16:89946397	TCF25	0.57	6.52	0.51	1.62e-9	Skin colour saturation;
TGCT	cis	rs7572263	0.959	rs6725512	chr2:209050418	A/G	cg23998903	chr2:209048830	C2orf80	-0.32	-4.45	-0.37	1.87e-5	Glioma;Non-glioblastoma glioma;
TGCT	cis	rs4631830	0.832	rs10825652	chr10:51510761	G/A	cg10326726	chr10:51549505	MSMB	0.27	5.2	0.42	7.86e-7	Prostate-specific antigen levels;
TGCT	cis	rs7192750	0.586	rs4788564	chr16:71891862	G/A	cg06353428	chr16:71660113	MARVELD3	0.83	7.37	0.55	2.07e-11	LDL cholesterol levels;Total cholesterol levels;
TGCT	cis	rs7412746	0.658	rs72704682	chr1:150897677	A/T	cg04414720	chr1:150670196	GOLPH3L	0.37	4.46	0.37	1.81e-5	Melanoma;
TGCT	cis	rs854765	0.604	rs12948749	chr17:17949802	G/A	cg09796270	chr17:17721594	SREBF1	-0.28	-5.55	-0.45	1.64e-7	Total body bone mineral density;
TGCT	cis	rs10028773	0.666	rs12498657	chr4:120262866	G/C	cg09307838	chr4:120376055	NA	0.54	5.29	0.43	5.44e-7	Educational attainment;
TGCT	cis	rs12579753	1.000	rs12579753	chr12:82219376	C/T	cg07988820	chr12:82153109	PPFIA2	-0.59	-6.34	-0.49	3.91e-9	Resting heart rate;
TGCT	cis	rs35160687	0.901	rs34069316	chr2:86529792	T/C	cg03171300	chr2:86307199	POLR1A	0.32	5.57	0.45	1.48e-7	Night sleep phenotypes;
TGCT	cis	rs7937682	0.881	rs4936678	chr11:111625085	C/T	cg09085632	chr11:111637200	PPP2R1B	1.1	8.72	0.62	1.48e-14	Primary sclerosing cholangitis;
TGCT	cis	rs4252435	0.520	rs7810229	chr7:142641087	A/G	cg09833174	chr7:143059591	FAM131B	1.02	4.65	0.39	8.26e-6	Cancer;
TGCT	cis	rs28595532	0.920	rs114080496	chr4:119726372	C/T	cg14228332	chr4:119757509	SEC24D	1.38	6.93	0.53	2.07e-10	Cannabis dependence symptom count;
TGCT	cis	rs7666738	0.830	rs13141752	chr4:98893128	G/A	cg17366294	chr4:99064904	C4orf37	0.68	6.87	0.53	2.72e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7666738	0.887	rs34509663	chr4:98982531	C/T	cg05340658	chr4:99064831	C4orf37	0.49	4.88	0.4	3.14e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg11301795	chr4:187892539	NA	-0.3	-4.46	-0.37	1.83e-5	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs11105298	0.891	rs1054807	chr12:89913419	C/T	cg00757033	chr12:89920650	WDR51B	0.34	5.46	0.44	2.52e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs6831352	0.589	rs1133483	chr4:100023923	G/C	cg12011299	chr4:100065546	ADH4	0.39	5.71	0.46	7.97e-8	Alcohol dependence;
TGCT	cis	rs7666738	0.830	rs13125930	chr4:98654695	G/A	cg05340658	chr4:99064831	C4orf37	0.46	5.42	0.44	3.01e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs66573146	0.808	rs56268690	chr4:6923887	C/T	cg01220768	chr4:7056774	TADA2B	0.32	4.56	0.38	1.21e-5	Granulocyte percentage of myeloid white cells;
TGCT	cis	rs2153535	0.580	rs6597335	chr6:8527714	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.75	0.46	6.55e-8	Motion sickness;
TGCT	cis	rs77948430	0.581	rs75036255	chr8:13156597	A/G	cg25598624	chr8:12235727	FAM66A	0.31	4.53	0.38	1.36e-5	Itch intensity from mosquito bite adjusted by bite size;
TGCT	trans	rs6089829	0.851	rs10854168	chr20:61669550	A/G	cg13615516	chr5:77269221	NA	0.73	8.39	0.6	9.12e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs3845702	0.736	rs1904850	chr2:180852767	A/G	cg01881094	chr2:180872142	CWC22	-1.05	-6.79	-0.52	4.16e-10	Schizophrenia;
TGCT	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg04944784	chr2:26401820	FAM59B	-0.65	-5.87	-0.47	3.8e-8	Gut microbiome composition (summer);
TGCT	cis	rs9467711	0.516	rs1165168	chr6:25859508	A/C	cg03264133	chr6:25882463	NA	-0.67	-4.47	-0.37	1.76e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs11098499	0.754	rs34425882	chr4:120253177	G/A	cg09307838	chr4:120376055	NA	0.61	5.91	0.47	3.14e-8	Corneal astigmatism;
TGCT	cis	rs9393777	0.920	rs35768595	chr6:27141904	C/T	cg16898833	chr6:26189333	HIST1H4D	1.29	5.83	0.46	4.6e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs854765	0.964	rs854764	chr17:18011750	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.64	-6.28	-0.49	5.2e-9	Total body bone mineral density;
TGCT	cis	rs4654899	0.931	rs3125161	chr1:21126346	A/G	cg01072550	chr1:21505969	NA	0.48	7.58	0.56	6.95e-12	Superior frontal gyrus grey matter volume;
TGCT	cis	rs826838	1.000	rs7299124	chr12:39002661	T/C	cg13010199	chr12:38710504	ALG10B	0.82	6.88	0.53	2.68e-10	Heart rate;
TGCT	cis	rs7959452	0.590	rs11177628	chr12:69765421	G/A	cg11871910	chr12:69753446	YEATS4	0.82	8.82	0.62	8.61e-15	Blood protein levels;
TGCT	cis	rs17376456	0.825	rs10057130	chr5:93282557	C/T	cg25358565	chr5:93447407	FAM172A	1.02	8.11	0.59	4.23e-13	Diabetic retinopathy;
TGCT	cis	rs7582180	0.663	rs10199518	chr2:100946041	G/A	cg08017756	chr2:100939284	LONRF2	-0.3	-5.0	-0.41	1.93e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs4794106	0.792	rs11365	chr17:48211533	T/G	cg13127421	chr17:48202128	SAMD14	-0.26	-6.5	-0.5	1.74e-9	Temporomandibular joint disorder;
TGCT	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs78487399	0.908	rs72868636	chr2:43838516	T/G	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.62	4.5	0.37	1.56e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs9311474	0.967	rs11717383	chr3:52287468	G/T	cg10802521	chr3:52805072	NEK4	-0.56	-6.25	-0.49	6.16e-9	Electroencephalogram traits;
TGCT	cis	rs1865760	0.532	rs1061482	chr6:26086699	G/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.78	7.51	0.56	9.98e-12	Height;
TGCT	cis	rs6125597	0.967	rs6063380	chr20:47881581	A/C	cg11220565	chr20:47934802	NA	-0.3	-4.61	-0.38	9.8e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9611565	0.546	rs2092274	chr22:42123737	A/G	cg17554472	chr22:41940697	POLR3H	0.48	5.17	0.42	9e-7	Vitiligo;
TGCT	trans	rs11082438	1.000	rs11082438	chr18:42865210	G/T	cg13513804	chr10:50121894	LRRC18;WDFY4	-0.73	-6.64	-0.51	9e-10	Follicular lymphoma;
TGCT	cis	rs2067615	0.579	rs7964605	chr12:107205413	C/T	cg15890332	chr12:107067104	RFX4	-0.28	-5.64	-0.45	1.1e-7	Heart rate;
TGCT	cis	rs6598955	0.724	rs7526545	chr1:26569990	C/A	cg04990556	chr1:26633338	UBXN11	-0.91	-11.99	-0.73	1.8e-22	Obesity-related traits;
TGCT	cis	rs9341808	0.791	rs1324122	chr6:80946061	G/A	cg08355045	chr6:80787529	NA	0.29	5.1	0.42	1.23e-6	Sitting height ratio;
TGCT	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg26516362	chr5:178986906	RUFY1	-0.42	-4.58	-0.38	1.1e-5	Lung cancer;
TGCT	cis	rs2486288	0.656	rs11637364	chr15:45579238	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.81	-8.5	-0.61	5.18e-14	Glomerular filtration rate;
TGCT	cis	rs1008375	1.000	rs2109522	chr4:17658645	T/A	cg18681998	chr4:17616180	MED28	1.01	11.89	0.73	3.17e-22	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2120019	1.000	rs12324912	chr15:75361006	G/A	cg11632617	chr15:75315747	PPCDC	-0.33	-4.63	-0.38	9.1e-6	Blood trace element (Zn levels);
TGCT	cis	rs7211079	0.843	rs73438138	chr17:78122407	T/G	cg09238746	chr17:78121135	EIF4A3	-0.7	-5.82	-0.46	4.79e-8	Myocardial infarction;
TGCT	cis	rs4074961	0.585	rs10752600	chr1:38067552	G/T	cg11397548	chr1:38022522	DNALI1	0.44	5.05	0.41	1.51e-6	Axial length;
TGCT	cis	rs8031584	0.697	rs798080	chr15:31122169	T/C	cg08704250	chr15:31115839	NA	0.44	6.46	0.5	2.18e-9	Huntington's disease progression;
TGCT	cis	rs2948294	0.545	rs11776397	chr8:8115161	C/T	cg15556689	chr8:8085844	FLJ10661	0.78	6.78	0.52	4.31e-10	Red cell distribution width;
TGCT	cis	rs9443645	0.869	rs9343863	chr6:79752792	T/C	cg09184832	chr6:79620586	NA	-0.48	-5.34	-0.43	4.21e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg11644478	chr21:40555479	PSMG1	-0.53	-4.98	-0.41	2.07e-6	Menarche (age at onset);
TGCT	cis	rs9399137	0.507	rs6918512	chr6:135284839	T/G	cg24558204	chr6:135376177	HBS1L	0.47	4.78	0.39	4.95e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
TGCT	cis	rs9674544	0.556	rs1390154	chr17:47071483	A/G	cg07075026	chr17:47091521	IGF2BP1	-0.49	-5.24	-0.43	6.68e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
TGCT	cis	rs9914988	0.943	rs9893782	chr17:27108132	C/T	cg20469991	chr17:27169893	C17orf63	-0.72	-5.04	-0.41	1.58e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
TGCT	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7584330	0.518	rs74478860	chr2:238437364	C/G	cg14458575	chr2:238380390	NA	0.43	4.55	0.38	1.25e-5	Prostate cancer;
TGCT	cis	rs425277	1.000	rs262641	chr1:2104981	C/T	cg24578937	chr1:2090814	PRKCZ	-0.3	-7.61	-0.56	5.87e-12	Height;
TGCT	cis	rs17376456	0.569	rs7702348	chr5:93065683	A/G	cg25358565	chr5:93447407	FAM172A	-0.76	-6.61	-0.51	1.01e-9	Diabetic retinopathy;
TGCT	cis	rs11098499	0.779	rs6815934	chr4:120267310	T/C	cg09307838	chr4:120376055	NA	0.56	5.5	0.44	2.08e-7	Corneal astigmatism;
TGCT	cis	rs6089584	1.000	rs6089583	chr20:60563624	G/A	cg06108461	chr20:60628389	TAF4	-0.57	-8.01	-0.58	7.25e-13	Body mass index;
TGCT	cis	rs8014204	0.762	rs2359237	chr14:75245002	G/A	cg06637938	chr14:75390232	RPS6KL1	0.58	5.13	0.42	1.11e-6	Caffeine consumption;
TGCT	cis	rs3761847	0.622	rs1323471	chr9:123826315	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.43	4.52	0.38	1.42e-5	Rheumatoid arthritis;
TGCT	cis	rs826838	0.967	rs1719854	chr12:39127707	G/A	cg13010199	chr12:38710504	ALG10B	-0.63	-5.06	-0.41	1.46e-6	Heart rate;
TGCT	cis	rs7666738	0.830	rs58367603	chr4:99015350	T/C	cg05340658	chr4:99064831	C4orf37	0.48	5.43	0.44	2.92e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs7208859	0.623	rs3752019	chr17:29151705	C/T	cg14008862	chr17:28927542	LRRC37B2	0.75	5.06	0.41	1.5e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs981844	0.712	rs4525952	chr4:154746606	G/T	cg14289246	chr4:154710475	SFRP2	1.02	8.96	0.63	4.03e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs11148252	0.538	rs2296349	chr13:52710058	T/G	cg00495681	chr13:53174319	NA	0.57	5.86	0.47	3.84e-8	Lewy body disease;
TGCT	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg21433313	chr16:3507492	NAT15	0.36	4.63	0.38	8.91e-6	Tuberculosis;
TGCT	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg18876405	chr7:65276391	NA	-0.35	-5.54	-0.45	1.77e-7	Corneal structure;
TGCT	trans	rs561341	0.883	rs72821942	chr17:30234460	C/T	cg20587970	chr11:113659929	NA	-0.82	-9.83	-0.66	3.19e-17	Hip circumference adjusted for BMI;
TGCT	cis	rs765787	0.530	rs4775836	chr15:45537664	T/C	cg24006582	chr15:45444508	DUOX1	-0.25	-5.54	-0.45	1.76e-7	Uric acid levels;
TGCT	cis	rs9818758	0.607	rs61729488	chr3:49067904	T/C	cg00383909	chr3:49044727	WDR6	1.38	7.1	0.54	8.45e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
TGCT	cis	rs13217239	0.574	rs9366680	chr6:27006123	A/T	cg05738196	chr6:26577821	NA	0.46	4.5	0.37	1.53e-5	Schizophrenia;
TGCT	cis	rs12762955	0.519	rs7094331	chr10:1022816	T/C	cg26597838	chr10:835615	NA	-0.43	-5.8	-0.46	5.31e-8	Response to angiotensin II receptor blocker therapy;
TGCT	cis	rs7542091	0.704	rs7537294	chr1:210043777	A/G	cg23283495	chr1:209979779	IRF6	0.55	5.47	0.44	2.34e-7	Monobrow;
TGCT	cis	rs2742417	0.603	rs2064064	chr3:45759995	C/T	cg04837898	chr3:45731254	SACM1L	-0.66	-7.02	-0.53	1.27e-10	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs7089973	0.604	rs11196932	chr10:116584386	C/T	cg03647239	chr10:116582469	FAM160B1	0.58	5.63	0.45	1.16e-7	Bipolar disorder or attention deficit hyperactivity disorder;
TGCT	cis	rs910316	1.000	rs10142865	chr14:75555624	G/A	cg08847533	chr14:75593920	NEK9	0.96	10.9	0.7	8.37e-20	Height;
TGCT	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg07061783	chr6:25882402	NA	-0.56	-5.52	-0.44	1.86e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs6696846	0.630	rs6692706	chr1:205158561	G/T	cg00857998	chr1:205179979	DSTYK	0.48	4.44	0.37	1.93e-5	Red blood cell count;
TGCT	cis	rs35306767	0.903	rs1341741	chr10:888073	A/G	cg26597838	chr10:835615	NA	0.71	10.12	0.67	6.47e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs10089	1.000	rs17164310	chr5:127493679	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.85	8.15	0.59	3.35e-13	Ileal carcinoids;
TGCT	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg10295955	chr4:187884368	NA	0.82	8.68	0.61	1.85e-14	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg18402987	chr7:1209562	NA	0.39	5.03	0.41	1.64e-6	Longevity;Endometriosis;
TGCT	cis	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg07424592	chr7:64974309	NA	1.34	8.08	0.59	4.95e-13	Diabetic kidney disease;
TGCT	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.48	-0.37	1.66e-5	Bipolar disorder;
TGCT	cis	rs208520	0.633	rs7738469	chr6:66807446	T/C	cg07460842	chr6:66804631	NA	-0.94	-9.83	-0.66	3.3e-17	Exhaled nitric oxide output;
TGCT	cis	rs4252435	0.614	rs11976316	chr7:142600456	T/G	cg09833174	chr7:143059591	FAM131B	-0.96	-4.52	-0.38	1.41e-5	Cancer;
TGCT	cis	rs1205863	1.000	rs1205856	chr6:11942728	C/T	cg07106625	chr6:11870215	NA	0.51	5.05	0.41	1.51e-6	Disc degeneration (lumbar);
TGCT	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg22920501	chr2:26401640	FAM59B	0.81	6.36	0.5	3.52e-9	Gut microbiome composition (summer);
TGCT	cis	rs80282103	0.618	rs1079390	chr10:1161653	C/A	cg18964960	chr10:1102726	WDR37	1.03	4.55	0.38	1.28e-5	Glomerular filtration rate (creatinine);
TGCT	trans	rs28735056	0.818	rs7235615	chr18:77644742	C/T	cg05926928	chr17:57297772	GDPD1	0.65	6.87	0.53	2.7e-10	Schizophrenia;
TGCT	cis	rs9486715	0.867	rs2223238	chr6:96871855	G/A	cg06623918	chr6:96969491	KIAA0776	1.11	16.62	0.83	2.35e-33	Headache;
TGCT	cis	rs8017423	0.630	rs4904678	chr14:90821670	T/C	cg04374321	chr14:90722782	PSMC1	-0.54	-5.41	-0.44	3.13e-7	Mortality in heart failure;
TGCT	cis	rs61990749	0.597	rs176943	chr14:78175797	T/G	cg23188588	chr14:78226832	SNW1;C14orf178	-0.67	-4.73	-0.39	6.09e-6	Fibroblast growth factor basic levels;
TGCT	trans	rs877282	0.898	rs12354872	chr10:763362	G/A	cg22713356	chr15:30763199	NA	1.2	9.16	0.64	1.36e-15	Uric acid levels;
TGCT	trans	rs1814175	0.791	rs10769593	chr11:49616217	T/C	cg03929089	chr4:120376271	NA	-0.74	-8.95	-0.63	4.41e-15	Height;
TGCT	cis	rs6570726	0.935	rs382910	chr6:145865941	G/A	cg23711669	chr6:146136114	FBXO30	0.7	6.78	0.52	4.39e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs12188164	0.840	rs67665078	chr5:428754	G/A	cg26850624	chr5:429559	AHRR	-0.18	-4.47	-0.37	1.74e-5	Cystic fibrosis severity;
TGCT	trans	rs629535	0.814	rs56326813	chr8:70107736	T/A	cg21567404	chr3:27674614	NA	-0.57	-8.89	-0.62	6.09e-15	Dupuytren's disease;
TGCT	cis	rs4664308	0.870	rs1870104	chr2:161032285	A/G	cg03641300	chr2:160917029	PLA2R1	-0.28	-6.9	-0.53	2.38e-10	Idiopathic membranous nephropathy;
TGCT	cis	rs7917772	0.582	rs4919665	chr10:104366042	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-5.36	-0.43	3.84e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs6460942	0.915	rs7802454	chr7:12454508	A/G	cg06484146	chr7:12443880	VWDE	-0.57	-5.52	-0.44	1.92e-7	Coronary artery disease;
TGCT	cis	rs12188164	0.686	rs72711370	chr5:421057	A/C	cg22025206	chr5:502436	SLC9A3	-0.26	-4.57	-0.38	1.18e-5	Cystic fibrosis severity;
TGCT	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg08280861	chr8:58055591	NA	0.4	4.73	0.39	5.97e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2302063	0.627	rs1682802	chr19:3158116	C/G	cg20125501	chr19:3176608	NA	-0.26	-4.75	-0.39	5.42e-6	Glucose homeostasis traits;
TGCT	cis	rs6977660	0.714	rs10251774	chr7:19790489	T/C	cg07541023	chr7:19748670	TWISTNB	0.85	4.84	0.4	3.74e-6	Thyroid stimulating hormone;
TGCT	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg23708337	chr7:1209742	NA	0.64	5.94	0.47	2.63e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs11190604	1.000	rs2495755	chr10:102324649	A/C	cg16342193	chr10:102329863	NA	-0.42	-5.26	-0.43	5.99e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg07092213	chr7:1199455	ZFAND2A	-0.49	-5.58	-0.45	1.45e-7	Longevity;Endometriosis;
TGCT	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg03806693	chr22:41940476	POLR3H	-1.12	-13.03	-0.76	5.66e-25	Vitiligo;
TGCT	cis	rs259282	0.605	rs2302970	chr19:33098632	G/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.61	5.42	0.44	2.93e-7	Schizophrenia;
TGCT	cis	rs11105298	0.891	rs10858903	chr12:89927972	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.7	-5.12	-0.42	1.12e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
TGCT	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg06634786	chr22:41940651	POLR3H	-0.86	-8.32	-0.6	1.34e-13	Vitiligo;
TGCT	cis	rs17221829	0.733	rs72971005	chr11:89358412	G/A	cg02982614	chr11:89391479	FOLH1B	-0.26	-4.65	-0.39	8.43e-6	Anxiety in major depressive disorder;
TGCT	cis	rs9814567	1.000	rs7637227	chr3:134244155	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.92	-8.76	-0.62	1.21e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs8177179	0.967	rs9869311	chr3:133451613	C/T	cg24879335	chr3:133465180	TF	0.37	5.02	0.41	1.72e-6	Iron status biomarkers (transferrin levels);
TGCT	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg02018176	chr4:1364513	KIAA1530	0.26	4.48	0.37	1.68e-5	Longevity;
TGCT	cis	rs9297145	0.509	rs13222381	chr7:98785024	T/G	cg05967295	chr7:98741636	SMURF1	-0.68	-8.29	-0.6	1.54e-13	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
TGCT	cis	rs7726839	0.540	rs4957083	chr5:659343	T/C	cg20362242	chr5:692897	TPPP	0.51	4.49	0.37	1.61e-5	Obesity-related traits;
TGCT	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg22963979	chr7:1858916	MAD1L1	-0.35	-5.43	-0.44	2.85e-7	Bipolar disorder and schizophrenia;
TGCT	cis	rs6433857	0.505	rs12471899	chr2:181369856	C/T	cg23363182	chr2:181467187	NA	-0.3	-4.57	-0.38	1.17e-5	Body mass index;
TGCT	cis	rs2637266	0.745	rs2579733	chr10:78441896	C/T	cg18941641	chr10:78392320	NA	-0.36	-4.64	-0.38	8.6e-6	Pulmonary function;
TGCT	cis	rs9948	0.655	rs17119564	chr2:97384728	G/A	cg01990225	chr2:97406019	LMAN2L	-1.01	-5.14	-0.42	1.02e-6	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs9325144	0.671	rs12818797	chr12:39019409	A/G	cg26384229	chr12:38710491	ALG10B	-0.6	-5.76	-0.46	6.3e-8	Morning vs. evening chronotype;
TGCT	cis	rs6570726	0.935	rs906774	chr6:145813770	T/C	cg23711669	chr6:146136114	FBXO30	0.73	7.04	0.53	1.16e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs10791097	0.608	rs12363140	chr11:130744268	A/C	cg12179176	chr11:130786555	SNX19	0.84	10.17	0.67	4.95e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
TGCT	cis	rs7110818	0.510	rs3862807	chr11:76283081	C/T	cg17647271	chr11:76299819	NA	0.38	4.55	0.38	1.26e-5	Gut microbiota (functional units);
TGCT	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.18	0.49	8.32e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs6882046	0.513	rs42850	chr5:88019474	G/A	cg22951263	chr5:87985283	NA	-0.58	-6.18	-0.49	8.49e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
TGCT	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg21724239	chr8:58056113	NA	0.41	4.97	0.41	2.19e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9926296	0.656	rs2376884	chr16:89826922	C/T	cg27121462	chr16:89883253	FANCA	0.54	4.97	0.41	2.14e-6	Vitiligo;
TGCT	cis	rs7666738	0.830	rs10031190	chr4:98908683	C/A	cg18180107	chr4:99064573	C4orf37	0.55	5.06	0.41	1.44e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg18230493	chr5:56204884	C5orf35	-0.68	-5.85	-0.46	4.13e-8	Initial pursuit acceleration;
TGCT	trans	rs6561151	0.681	rs2121037	chr13:44471317	C/T	cg12856521	chr11:46389249	DGKZ	0.67	6.65	0.51	8.39e-10	Crohn's disease;
TGCT	cis	rs9486719	0.843	rs3860229	chr6:97036559	T/C	cg18709589	chr6:96969512	KIAA0776	-0.78	-6.38	-0.5	3.24e-9	Migraine;Coronary artery disease;
TGCT	cis	rs6088590	1.000	rs910870	chr20:33292893	T/C	cg24642439	chr20:33292090	TP53INP2	0.62	5.75	0.46	6.6e-8	Coronary artery disease;
TGCT	cis	rs986417	0.818	rs10143831	chr14:61081961	G/T	cg27398547	chr14:60952738	C14orf39	1.33	9.79	0.66	4e-17	Gut microbiota (bacterial taxa);
TGCT	cis	rs2361710	0.668	rs2304855	chr17:78118266	T/A	cg09238746	chr17:78121135	EIF4A3	-0.79	-7.49	-0.56	1.13e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
TGCT	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg07217954	chr7:1067459	C7orf50	-0.48	-4.72	-0.39	6.33e-6	Bronchopulmonary dysplasia;
TGCT	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg26338869	chr17:61819248	STRADA	-0.53	-4.85	-0.4	3.68e-6	Prudent dietary pattern;
TGCT	cis	rs7635838	0.859	rs7632040	chr3:11427455	A/G	cg00170343	chr3:11313890	ATG7	0.65	6.23	0.49	6.68e-9	HDL cholesterol;
TGCT	cis	rs9435341	0.965	rs2335104	chr1:107583641	A/T	cg09367891	chr1:107599246	PRMT6	0.66	5.85	0.47	4.04e-8	Facial morphology (factor 21, depth of nasal alae);
TGCT	cis	rs7582180	0.629	rs11686799	chr2:100956055	C/G	cg08017756	chr2:100939284	LONRF2	-0.3	-4.87	-0.4	3.27e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6912958	0.500	rs4707352	chr6:87929705	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.68	-7.03	-0.53	1.2e-10	Monocyte percentage of white cells;
TGCT	cis	rs68170813	0.559	rs76933738	chr7:106814574	T/C	cg02696742	chr7:106810147	HBP1	-0.72	-6.28	-0.49	5.29e-9	Coronary artery disease;
TGCT	cis	rs10927875	0.757	rs4661679	chr1:16321010	C/T	cg22431228	chr1:16359049	CLCNKA	-0.24	-4.64	-0.38	8.71e-6	Dilated cardiomyopathy;
TGCT	cis	rs4074961	0.509	rs4653300	chr1:38024054	A/G	cg17933807	chr1:38061675	GNL2	1.01	16.04	0.82	5.04e-32	Axial length;
TGCT	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg05368731	chr17:41323189	NBR1	1.08	11.0	0.7	4.76e-20	Menopause (age at onset);
TGCT	cis	rs6500602	0.701	rs8129	chr16:4562351	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.26	4.81	0.4	4.3e-6	Schizophrenia;
TGCT	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg00080972	chr5:178986291	RUFY1	0.59	7.77	0.57	2.62e-12	Lung cancer;
TGCT	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg17911788	chr17:44343683	NA	-0.67	-7.15	-0.54	6.59e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs2456568	0.835	rs1518578	chr11:93656854	G/T	cg17595323	chr11:93583763	C11orf90	-0.49	-6.23	-0.49	6.65e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg08219700	chr8:58056026	NA	0.39	4.73	0.39	5.99e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs669446	0.561	rs516921	chr1:44081762	T/G	cg12908607	chr1:44402522	ARTN	-0.6	-5.73	-0.46	7.06e-8	Amyotrophic lateral sclerosis (age of onset);
TGCT	cis	rs35306767	0.903	rs13377166	chr10:886259	G/A	cg26597838	chr10:835615	NA	0.71	10.12	0.67	6.47e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs28595532	0.764	rs115298416	chr4:119565383	C/T	cg14228332	chr4:119757509	SEC24D	1.04	5.37	0.43	3.8e-7	Cannabis dependence symptom count;
TGCT	cis	rs9388451	0.839	rs3757217	chr6:126069636	G/C	cg10911889	chr6:126070802	HEY2	0.57	6.06	0.48	1.51e-8	Brugada syndrome;
TGCT	cis	rs933688	1.000	rs10073935	chr5:90742188	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.0	8.64	0.61	2.4e-14	Smoking behavior;
TGCT	cis	rs12477438	0.520	rs2516827	chr2:99772565	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	17.43	0.84	3.73e-35	Chronic sinus infection;
TGCT	cis	rs4240897	0.935	rs4846082	chr1:12042443	C/T	cg05523254	chr1:12040215	MFN2	0.46	4.48	0.37	1.69e-5	Tuberculosis;
TGCT	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2842992	0.715	rs2277073	chr6:160182749	G/A	cg11366901	chr6:160182831	ACAT2	1.03	6.92	0.53	2.14e-10	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs7296418	0.885	rs1790104	chr12:123709409	C/T	cg00376283	chr12:123451042	ABCB9	0.84	7.67	0.57	4.4e-12	Platelet count;
TGCT	cis	rs56104184	0.578	rs7254608	chr19:49395774	G/T	cg11637076	chr19:49575188	KCNA7	-0.44	-5.23	-0.43	6.99e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg23758822	chr17:41437982	NA	0.69	6.97	0.53	1.66e-10	Menopause (age at onset);
TGCT	cis	rs9303401	0.625	rs66508449	chr17:56691034	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	6.65	0.51	8.41e-10	Cognitive test performance;
TGCT	cis	rs77861329	1.000	rs352147	chr3:52208285	A/G	cg08692210	chr3:52188851	WDR51A	0.94	4.83	0.4	3.91e-6	Macrophage inflammatory protein 1b levels;
TGCT	cis	rs9527	0.615	rs10883811	chr10:104727279	A/G	cg04362960	chr10:104952993	NT5C2	0.66	5.55	0.45	1.66e-7	Arsenic metabolism;
TGCT	cis	rs317689	0.513	rs529268	chr12:69687051	G/A	cg14784868	chr12:69753453	YEATS4	0.66	6.45	0.5	2.31e-9	Response to diuretic therapy;
TGCT	cis	rs763121	0.925	rs5757165	chr22:38994577	C/T	cg06022373	chr22:39101656	GTPBP1	0.79	7.98	0.58	8.44e-13	Menopause (age at onset);
TGCT	cis	rs40363	0.645	rs1690449	chr16:3520893	C/G	cg05754148	chr16:3507555	NAT15	0.4	4.71	0.39	6.65e-6	Tuberculosis;
TGCT	cis	rs11785400	1.000	rs13266249	chr8:143732433	A/C	cg10596483	chr8:143751796	JRK	0.54	5.77	0.46	5.95e-8	Schizophrenia;
TGCT	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg05665937	chr4:1216051	CTBP1	0.26	5.05	0.41	1.54e-6	Obesity-related traits;
TGCT	cis	rs9611565	0.559	rs739136	chr22:42100275	C/T	cg06481639	chr22:41940642	POLR3H	-0.71	-6.43	-0.5	2.56e-9	Vitiligo;
TGCT	cis	rs9362426	1.000	rs9362426	chr6:88089874	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.46	5.23	0.43	6.86e-7	Depressive episodes in bipolar disorder;
TGCT	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg00343986	chr7:65444356	GUSB	0.24	5.26	0.43	6.15e-7	Aortic root size;
TGCT	cis	rs7666738	0.546	rs10025064	chr4:98914060	A/G	cg17366294	chr4:99064904	C4orf37	0.64	5.88	0.47	3.54e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs35306767	0.903	rs7067865	chr10:908387	C/T	cg20503657	chr10:835505	NA	0.75	10.41	0.68	1.3e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs11264213	0.901	rs794222	chr1:36369024	T/C	cg07093915	chr1:36184400	C1orf216	0.66	4.47	0.37	1.73e-5	Schizophrenia;
TGCT	cis	rs1997103	0.911	rs6949931	chr7:55391081	T/C	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs2050392	0.517	rs2480299	chr10:30743197	G/A	cg18806716	chr10:30721971	MAP3K8	-0.46	-5.41	-0.44	3.1e-7	Inflammatory bowel disease;
TGCT	cis	rs7216064	0.953	rs12601759	chr17:65955284	A/G	cg12091567	chr17:66097778	LOC651250	-0.82	-6.2	-0.49	7.54e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
TGCT	cis	rs11239930	0.538	rs56060937	chr1:146555403	G/A	cg00044796	chr1:146552390	NA	-0.34	-4.46	-0.37	1.84e-5	AIDS progression;
TGCT	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg08736216	chr1:53307985	ZYG11A	-0.29	-6.09	-0.48	1.32e-8	Monocyte count;
TGCT	cis	rs114540395	0.858	rs76838593	chr10:103143264	T/G	cg18276125	chr10:102749041	C10orf2	0.38	4.6	0.38	1.05e-5	Schizophrenia;
TGCT	cis	rs3806843	0.520	rs246051	chr5:140326464	G/A	cg07102913	chr5:140593443	PCDHB13	-0.47	-4.7	-0.39	6.77e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs8031584	0.678	rs4779790	chr15:31164595	T/C	cg14829155	chr15:31115871	NA	-0.36	-4.72	-0.39	6.14e-6	Huntington's disease progression;
TGCT	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg03452623	chr4:187889614	NA	-0.36	-5.19	-0.42	8.48e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.48	-0.37	1.66e-5	Bipolar disorder;
TGCT	cis	rs3008870	1.000	rs2815348	chr1:67472165	G/C	cg11518657	chr1:67396239	MIER1	0.54	4.61	0.38	9.72e-6	Lymphocyte percentage of white cells;
TGCT	cis	rs10875746	0.669	rs11168459	chr12:48596241	A/G	cg20731937	chr12:48336164	NA	0.59	4.52	0.38	1.45e-5	Longevity (90 years and older);
TGCT	trans	rs7819412	0.765	rs17783634	chr8:11054097	C/A	cg15556689	chr8:8085844	FLJ10661	-0.74	-6.96	-0.53	1.79e-10	Triglycerides;
TGCT	cis	rs77106637	0.860	rs11603334	chr11:72432985	G/A	cg03713592	chr11:72463424	ARAP1	1.21	9.04	0.63	2.56e-15	Type 2 diabetes;
TGCT	cis	rs910316	1.000	rs175426	chr14:75624134	C/T	cg08847533	chr14:75593920	NEK9	-0.95	-10.32	-0.68	2.09e-18	Height;
TGCT	cis	rs2997447	0.595	rs3008425	chr1:26385660	T/C	cg19633962	chr1:26362018	EXTL1	-0.65	-4.7	-0.39	6.74e-6	QRS complex (12-leadsum);
TGCT	cis	rs4409675	0.576	rs2749119	chr1:28236248	G/A	cg23691781	chr1:28212827	C1orf38	0.26	5.44	0.44	2.76e-7	Corneal astigmatism;
TGCT	cis	rs8067545	0.750	rs888423	chr17:19999409	G/A	cg13482628	chr17:19912719	NA	0.53	4.55	0.38	1.25e-5	Schizophrenia;
TGCT	cis	rs28493229	0.500	rs45545932	chr19:41190875	G/A	cg11601297	chr19:41224147	ITPKC;ADCK4	0.5	5.02	0.41	1.75e-6	Kawasaki disease;
TGCT	cis	rs854765	0.964	rs12950562	chr17:17995166	C/T	cg04398451	chr17:18023971	MYO15A	0.3	4.67	0.39	7.62e-6	Total body bone mineral density;
TGCT	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg06634786	chr22:41940651	POLR3H	0.87	8.25	0.6	1.92e-13	Vitiligo;
TGCT	cis	rs2742234	1.000	rs1864399	chr10:43610455	T/C	cg02780029	chr10:43622663	RET	-0.25	-4.82	-0.4	4.06e-6	Hirschsprung disease;
TGCT	cis	rs116095464	0.558	rs10462755	chr5:246748	T/C	cg22857025	chr5:266934	NA	-0.34	-6.72	-0.52	5.96e-10	Breast cancer;
TGCT	cis	rs12478296	1.000	rs12478296	chr2:243048760	A/G	cg06360820	chr2:242988706	NA	0.58	4.62	0.38	9.38e-6	Obesity-related traits;
TGCT	cis	rs916888	0.647	rs199449	chr17:44808902	G/A	cg17911788	chr17:44343683	NA	-0.5	-5.73	-0.46	7.09e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7100689	0.556	rs3120976	chr10:82025682	C/A	cg01528321	chr10:82214614	TSPAN14	0.7	6.82	0.52	3.53e-10	Post bronchodilator FEV1;
TGCT	cis	rs7772486	0.754	rs9390358	chr6:146145678	C/T	cg23711669	chr6:146136114	FBXO30	0.9	10.04	0.67	1e-17	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs3784262	0.528	rs11071367	chr15:58354152	G/A	cg12031962	chr15:58353849	ALDH1A2	0.38	5.56	0.45	1.55e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
TGCT	cis	rs9325144	0.625	rs11534879	chr12:38968165	A/G	cg26384229	chr12:38710491	ALG10B	-0.59	-5.6	-0.45	1.28e-7	Morning vs. evening chronotype;
TGCT	cis	rs9443645	0.869	rs9443621	chr6:79576499	A/G	cg05283184	chr6:79620031	NA	-0.22	-4.98	-0.41	2.11e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg24675658	chr1:53192096	ZYG11B	0.7	7.98	0.58	8.59e-13	Monocyte count;
TGCT	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg03760483	chr17:6899297	ALOX12	-0.41	-4.89	-0.4	3.07e-6	Tonsillectomy;
TGCT	cis	rs8017423	0.935	rs716122	chr14:90792313	A/C	cg04374321	chr14:90722782	PSMC1	-0.74	-7.09	-0.54	8.75e-11	Mortality in heart failure;
TGCT	cis	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg08045932	chr20:61659980	NA	0.48	9.16	0.64	1.36e-15	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9309473	0.606	rs6759452	chr2:73878352	C/T	cg07208825	chr2:73871855	ALMS1P	0.27	5.09	0.42	1.28e-6	Metabolite levels;
TGCT	cis	rs2404602	0.692	rs12911174	chr15:77149943	G/A	cg22467129	chr15:76604101	ETFA	-0.46	-5.26	-0.43	5.99e-7	Blood metabolite levels;
TGCT	cis	rs9393777	0.513	rs9393739	chr6:26646966	T/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.63	-5.75	-0.46	6.58e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs7937682	0.587	rs611607	chr11:111349765	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.63	-5.91	-0.47	3.12e-8	Primary sclerosing cholangitis;
TGCT	cis	rs612683	0.524	rs479269	chr1:100887616	A/G	cg06223162	chr1:101003688	GPR88	0.28	4.53	0.38	1.38e-5	Breast cancer;
TGCT	cis	rs11122272	0.735	rs2486745	chr1:231505717	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-7.14	-0.54	6.86e-11	Hemoglobin concentration;
TGCT	trans	rs6561151	0.957	rs3764147	chr13:44457925	C/T	cg12856521	chr11:46389249	DGKZ	-0.62	-6.76	-0.52	4.79e-10	Crohn's disease;
TGCT	cis	rs10883723	0.810	rs13287	chr10:104240438	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	8.53	0.61	4.23e-14	Allergic disease (asthma, hay fever or eczema);
TGCT	cis	rs2597513	1.000	rs2597513	chr3:13555836	C/T	cg13071069	chr3:13005914	IQSEC1	-0.4	-4.51	-0.38	1.47e-5	Hip circumference adjusted for BMI;Height;
TGCT	cis	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg25427524	chr10:38739819	LOC399744	-0.39	-8.05	-0.59	5.9e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg18402987	chr7:1209562	NA	0.81	6.94	0.53	1.9e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs7523273	0.606	rs1962149	chr1:207956559	G/A	cg22525895	chr1:207977042	MIR29B2	-0.52	-8.75	-0.62	1.28e-14	Schizophrenia;
TGCT	cis	rs3806843	0.966	rs1030166	chr5:140185473	G/A	cg19875535	chr5:140030758	IK	0.35	5.85	0.47	4.01e-8	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs7312933	0.703	rs10492388	chr12:42608001	T/C	cg19980929	chr12:42632907	YAF2	0.46	6.1	0.48	1.24e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
TGCT	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg16325326	chr1:53192061	ZYG11B	0.63	6.94	0.53	1.92e-10	Monocyte count;
TGCT	cis	rs8084125	0.832	rs62105179	chr18:74950858	A/G	cg07390210	chr18:74961196	GALR1	0.37	4.51	0.38	1.49e-5	Obesity-related traits;
TGCT	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg11366901	chr6:160182831	ACAT2	0.79	5.81	0.46	4.92e-8	Age-related macular degeneration (geographic atrophy);
TGCT	cis	rs7666738	0.761	rs13136913	chr4:98998031	C/T	cg17366294	chr4:99064904	C4orf37	0.69	7.03	0.53	1.21e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2404602	0.647	rs116090606	chr15:77075209	A/G	cg23625390	chr15:77176239	SCAPER	-0.38	-4.81	-0.4	4.29e-6	Blood metabolite levels;
TGCT	cis	rs854765	0.594	rs8066560	chr17:17728043	A/G	cg09796270	chr17:17721594	SREBF1	-0.25	-4.79	-0.4	4.58e-6	Total body bone mineral density;
TGCT	cis	rs854765	0.624	rs4925116	chr17:17731200	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.69	-6.52	-0.5	1.64e-9	Total body bone mineral density;
TGCT	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg26338869	chr17:61819248	STRADA	-0.53	-4.85	-0.4	3.68e-6	Prudent dietary pattern;
TGCT	cis	rs1018836	0.631	rs61276517	chr8:91474406	A/G	cg16814680	chr8:91681699	NA	-0.75	-7.43	-0.56	1.5e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs11711311	0.955	rs12630833	chr3:113390883	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.78	-6.77	-0.52	4.53e-10	IgG glycosylation;
TGCT	cis	rs910316	0.737	rs91144	chr14:75449517	G/A	cg11812906	chr14:75593930	NEK9	-0.58	-5.69	-0.45	8.69e-8	Height;
TGCT	cis	rs7542091	0.669	rs11119357	chr1:210042382	C/T	cg00989853	chr1:209979345	IRF6	0.43	4.57	0.38	1.18e-5	Monobrow;
TGCT	cis	rs6429082	0.846	rs2270538	chr1:235602404	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.59	-4.95	-0.41	2.33e-6	Adiposity;
TGCT	cis	rs9650657	0.515	rs7820860	chr8:10950396	C/G	cg27411982	chr8:10470053	RP1L1	-0.21	-4.55	-0.38	1.29e-5	Neuroticism;
TGCT	cis	rs225245	0.791	rs8067294	chr17:34027964	T/C	cg05299278	chr17:33885742	SLFN14	0.21	4.5	0.37	1.54e-5	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
TGCT	cis	rs1008375	0.686	rs34338142	chr4:17626174	T/A	cg18681998	chr4:17616180	MED28	1.07	11.45	0.72	3.83e-21	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs7267979	0.934	rs2500399	chr20:25354694	T/G	cg14121845	chr20:25566513	NINL	-0.5	-5.44	-0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs11018874	0.597	rs10765243	chr11:89855118	C/G	cg05041596	chr11:89867385	NAALAD2	0.5	4.89	0.4	3.07e-6	White blood cell types;
TGCT	cis	rs1990950	0.692	rs6868660	chr5:156860229	A/G	cg25387487	chr5:157003181	ADAM19	0.29	4.53	0.38	1.37e-5	Lung function (FEV1/FVC);
TGCT	cis	rs6964587	0.967	rs58673519	chr7:91823887	T/G	cg22709100	chr7:91322751	NA	0.28	4.51	0.38	1.49e-5	Breast cancer;
TGCT	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg13683864	chr3:40499215	RPL14	-1.19	-13.2	-0.76	2.17e-25	Renal cell carcinoma;
TGCT	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs7666738	0.753	rs13137152	chr4:98938044	A/T	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg24675658	chr1:53192096	ZYG11B	0.7	7.98	0.58	8.59e-13	Monocyte count;
TGCT	trans	rs4332037	0.615	rs62435127	chr7:1884937	A/G	cg25206134	chr2:45395956	NA	0.93	7.88	0.58	1.43e-12	Bipolar disorder;
TGCT	cis	rs7226408	0.857	rs7228810	chr18:34722050	A/G	cg06757138	chr18:34340585	FHOD3	0.25	4.81	0.4	4.33e-6	Obesity-related traits;
TGCT	cis	rs7914558	0.966	rs10748839	chr10:104953547	A/G	cg04362960	chr10:104952993	NT5C2	0.62	5.53	0.44	1.8e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs7659604	0.628	rs6838153	chr4:122720999	A/G	cg19748678	chr4:122722346	EXOSC9	0.94	9.89	0.66	2.3e-17	Type 2 diabetes;
TGCT	cis	rs28595532	0.841	rs116521340	chr4:119757415	C/A	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg18252515	chr7:66147081	NA	-1.2	-7.16	-0.54	6.16e-11	Diabetic kidney disease;
TGCT	cis	rs57221529	0.709	rs72707024	chr5:667915	G/A	cg20362242	chr5:692897	TPPP	0.52	4.69	0.39	7.16e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs9443645	0.869	rs9448591	chr6:79606490	C/T	cg05283184	chr6:79620031	NA	-0.21	-4.71	-0.39	6.61e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7949030	0.523	rs12223627	chr11:62368557	G/C	cg22862634	chr11:62369728	EML3;MTA2	0.6	6.0	0.47	2.04e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs3796352	0.892	rs9756317	chr3:53088815	T/C	cg07884673	chr3:53033167	SFMBT1	-0.58	-6.25	-0.49	5.99e-9	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs10464366	0.544	rs1525799	chr7:39153131	C/G	cg18850127	chr7:39170497	POU6F2	-0.32	-6.91	-0.53	2.28e-10	IgG glycosylation;
TGCT	cis	rs6121246	0.609	rs6060652	chr20:30266845	A/G	cg13852791	chr20:30311386	BCL2L1	0.84	8.15	0.59	3.38e-13	Mean corpuscular hemoglobin;
TGCT	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg07507251	chr3:52567010	NT5DC2	0.48	6.95	0.53	1.82e-10	Bipolar disorder;
TGCT	cis	rs2013441	0.932	rs3850782	chr17:20181940	A/C	cg18979559	chr17:20280153	CCDC144C	-0.45	-4.67	-0.39	7.61e-6	Obesity-related traits;
TGCT	cis	rs3741404	0.931	rs594942	chr11:64006292	T/C	cg03236948	chr11:63997492	DNAJC4	-0.36	-4.49	-0.37	1.6e-5	Platelet count;
TGCT	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.7	6.24	0.49	6.19e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg03264133	chr6:25882463	NA	0.64	5.89	0.47	3.34e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs1949733	0.816	rs2631746	chr4:8490934	C/T	cg11789530	chr4:8429930	ACOX3	-0.52	-5.43	-0.44	2.87e-7	Response to antineoplastic agents;
TGCT	cis	rs8177179	0.967	rs4443173	chr3:133439378	A/G	cg16262614	chr3:133464971	TF	0.35	4.6	0.38	1.01e-5	Iron status biomarkers (transferrin levels);
TGCT	cis	rs1215050	0.846	rs783923	chr4:98968686	C/T	cg17366294	chr4:99064904	C4orf37	-0.47	-4.67	-0.39	7.61e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg00908189	chr16:619842	PIGQ	0.87	10.78	0.7	1.58e-19	Height;
TGCT	cis	rs2997447	0.748	rs112813126	chr1:26432239	A/T	cg03844060	chr1:26490628	NA	0.28	4.56	0.38	1.19e-5	QRS complex (12-leadsum);
TGCT	cis	rs9311474	1.000	rs1060330	chr3:52288945	T/C	cg07507251	chr3:52567010	NT5DC2	0.43	6.0	0.47	2e-8	Electroencephalogram traits;
TGCT	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg10047753	chr17:41438598	NA	0.97	10.04	0.67	1.04e-17	Menopause (age at onset);
TGCT	cis	rs9388451	0.868	rs10457467	chr6:126045148	T/A	cg05901451	chr6:126070800	HEY2	-1.02	-13.72	-0.78	1.28e-26	Brugada syndrome;
TGCT	cis	rs9443189	0.762	rs2748943	chr6:76435543	C/T	cg01950844	chr6:76311363	SENP6	-0.66	-4.62	-0.38	9.55e-6	Prostate cancer;
TGCT	cis	rs11785400	0.731	rs9720504	chr8:143725502	T/C	cg24634471	chr8:143751801	JRK	0.53	5.33	0.43	4.41e-7	Schizophrenia;
TGCT	cis	rs1552244	1.000	rs7626117	chr3:10140671	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.37	-5.82	-0.46	4.67e-8	Alzheimer's disease;
TGCT	cis	rs2882877	0.560	rs11568351	chr2:190445194	C/G	cg10752008	chr2:190445175	SLC40A1	-0.78	-6.26	-0.49	5.68e-9	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs7647973	0.710	rs9869120	chr3:49624065	T/C	cg03060546	chr3:49711283	APEH	0.63	5.14	0.42	1.03e-6	Menarche (age at onset);
TGCT	cis	rs4294134	0.608	rs35956223	chr7:135245054	C/T	cg08396481	chr7:135194601	CNOT4	-0.62	-4.81	-0.4	4.25e-6	Paget's disease;
TGCT	cis	rs7017914	0.967	rs7819332	chr8:71668265	G/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.53	-4.9	-0.4	2.87e-6	Bone mineral density;
TGCT	cis	rs9583531	0.550	rs7985098	chr13:111386416	G/A	cg24331049	chr13:111365604	ING1	0.74	7.36	0.55	2.18e-11	Coronary artery disease;
TGCT	cis	rs9916302	0.706	rs8067511	chr17:37611352	C/T	cg03321784	chr17:37729644	NA	0.46	4.71	0.39	6.4e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs12142240	0.698	rs17361915	chr1:46847321	C/T	cg14993813	chr1:46806288	NSUN4	-0.59	-4.86	-0.4	3.45e-6	Menopause (age at onset);
TGCT	cis	rs57221529	0.766	rs72703064	chr5:587825	T/C	cg09021430	chr5:549028	NA	-0.37	-4.98	-0.41	2.07e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg24829409	chr8:58192753	C8orf71	-0.56	-5.3	-0.43	5.23e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2235642	0.893	rs2076439	chr16:1587277	C/T	cg07341220	chr16:1583899	IFT140;TMEM204	-0.3	-4.72	-0.39	6.18e-6	Coronary artery disease;
TGCT	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg02725872	chr8:58115012	NA	-0.38	-5.05	-0.41	1.55e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg03188948	chr7:1209495	NA	0.43	5.66	0.45	9.95e-8	Longevity;Endometriosis;
TGCT	cis	rs2549003	0.933	rs3846731	chr5:131814264	T/C	cg02551604	chr5:131831745	NA	-0.89	-11.77	-0.73	6.36e-22	Asthma (sex interaction);
TGCT	cis	rs2046867	0.628	rs7356054	chr3:72912727	A/G	cg25664220	chr3:72788482	NA	-0.41	-5.47	-0.44	2.36e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
TGCT	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg02915803	chr1:1606292	LOC728661;CDK11B	0.22	4.62	0.38	9.5e-6	Body mass index;
TGCT	cis	rs11031096	0.655	rs1372806	chr11:4212308	C/T	cg08557956	chr11:4115526	RRM1	-0.49	-4.56	-0.38	1.2e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs6484504	0.532	rs1929019	chr11:31267030	C/T	cg26647111	chr11:31128758	NA	-0.35	-4.8	-0.4	4.52e-6	Red blood cell count;
TGCT	cis	rs4808199	0.843	rs10402308	chr19:19657500	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.72	5.3	0.43	5.12e-7	Nonalcoholic fatty liver disease;
TGCT	cis	rs12510870	0.634	rs1569204	chr4:74407090	C/T	cg05868023	chr4:75230803	EREG	-0.53	-4.63	-0.38	9.08e-6	Iris color (b* coordinate);
TGCT	cis	rs617219	0.726	rs72764969	chr5:78451409	A/G	cg23514016	chr5:78407564	BHMT	0.36	5.49	0.44	2.17e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg11062466	chr8:58055876	NA	0.35	4.53	0.38	1.35e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs11031096	0.568	rs10767891	chr11:4234524	A/G	cg18678763	chr11:4115507	RRM1	-0.39	-5.14	-0.42	1.03e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
TGCT	cis	rs9513593	1.000	rs1927731	chr13:99925872	G/A	cg21788972	chr13:99853209	UBAC2	0.61	4.86	0.4	3.49e-6	Psoriasis;
TGCT	cis	rs1153858	1.000	rs4625670	chr15:45652926	C/T	cg14582100	chr15:45693742	SPATA5L1	0.49	5.75	0.46	6.62e-8	Homoarginine levels;
TGCT	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.46	-5.47	-0.44	2.36e-7	Longevity;Endometriosis;
TGCT	cis	rs11578119	0.933	rs12142689	chr1:170385558	T/C	cg09767346	chr1:170501363	GORAB	0.71	5.69	0.46	8.67e-8	Male-pattern baldness;
TGCT	cis	rs12188164	0.965	rs11739543	chr5:443676	G/A	cg26850624	chr5:429559	AHRR	-0.2	-4.84	-0.4	3.78e-6	Cystic fibrosis severity;
TGCT	cis	rs17152411	1.000	rs12571196	chr10:126597749	A/C	cg07906193	chr10:126599966	NA	0.4	4.55	0.38	1.24e-5	Height;
TGCT	cis	rs981844	0.683	rs2405423	chr4:154749823	C/A	cg14289246	chr4:154710475	SFRP2	-0.99	-9.12	-0.63	1.65e-15	Response to statins (LDL cholesterol change);
TGCT	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg11764359	chr7:65958608	NA	-0.61	-5.52	-0.44	1.93e-7	Aortic root size;
TGCT	cis	rs9952991	0.622	rs8091566	chr18:12826385	G/A	cg23544223	chr18:12777786	NA	0.53	4.7	0.39	6.94e-6	Inflammatory skin disease;
TGCT	cis	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg20637647	chr7:64974828	NA	-0.95	-5.3	-0.43	5.09e-7	Diabetic kidney disease;
TGCT	cis	rs13064411	0.627	rs9825827	chr3:113182231	T/C	cg18753928	chr3:113234510	CCDC52	-0.67	-5.46	-0.44	2.45e-7	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs7714584	1.000	rs7734928	chr5:150256613	G/A	cg22134413	chr5:150180641	NA	0.83	6.53	0.51	1.54e-9	Crohn's disease;
TGCT	cis	rs1670533	1.000	rs28562028	chr4:1055115	G/A	cg20887711	chr4:1340912	KIAA1530	0.71	5.7	0.46	8.33e-8	Recombination rate (females);
TGCT	cis	rs4478858	0.735	rs6679365	chr1:31787866	A/C	cg00250761	chr1:31883323	NA	0.28	5.01	0.41	1.86e-6	Alcohol dependence;
TGCT	cis	rs7772486	0.597	rs6912351	chr6:146264071	T/C	cg05347473	chr6:146136440	FBXO30	-0.64	-6.06	-0.48	1.48e-8	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4919694	0.711	rs113361908	chr10:104978126	T/C	cg04362960	chr10:104952993	NT5C2	1.09	7.26	0.55	3.68e-11	Arsenic metabolism;
TGCT	cis	rs17767294	0.708	rs74756732	chr6:28152547	T/A	cg08851530	chr6:28072375	NA	1.47	6.82	0.52	3.64e-10	Parkinson's disease;
TGCT	trans	rs79643899	1	rs79643899	chr5:35429449	A/C	cg10378735	chr7:142558305	EPHB6	0.83	6.79	0.52	4.1e-10	Post bronchodilator FEV1 in COPD;
TGCT	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg16680214	chr1:154839983	KCNN3	-0.36	-7.26	-0.55	3.81e-11	Prostate cancer;
TGCT	cis	rs2228479	0.702	rs2074903	chr16:89811663	T/C	cg06558623	chr16:89946397	TCF25	0.45	4.5	0.37	1.55e-5	Skin colour saturation;
TGCT	cis	rs912330	0.825	rs7317938	chr13:99234361	C/T	cg07423050	chr13:99094983	FARP1	-0.23	-4.46	-0.37	1.8e-5	Alzheimer's disease;
TGCT	cis	rs4566357	0.615	rs4675139	chr2:227908527	G/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-5.04	-0.41	1.59e-6	Coronary artery disease;
TGCT	cis	rs7647973	0.626	rs2329021	chr3:49679072	G/A	cg05785598	chr3:49045655	WDR6	0.42	5.24	0.43	6.67e-7	Menarche (age at onset);
TGCT	cis	rs3771570	1.000	rs56363214	chr2:242227157	A/G	cg21155796	chr2:242212141	HDLBP	0.98	6.68	0.51	7.29e-10	Prostate cancer;
TGCT	cis	rs931127	0.512	rs58950470	chr11:65383755	G/T	cg27068330	chr11:65405492	SIPA1	0.59	5.17	0.42	9.24e-7	Systemic lupus erythematosus;
TGCT	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.78	6.27	0.49	5.58e-9	Mean platelet volume;
TGCT	cis	rs6684514	0.922	rs12022657	chr1:156314147	A/G	cg20302342	chr1:156215951	PAQR6	0.34	4.52	0.38	1.45e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg08859206	chr1:53392774	SCP2	-0.41	-6.33	-0.49	4.13e-9	Monocyte count;
TGCT	trans	rs8073060	0.544	rs225249	chr17:33942540	T/C	cg19694781	chr19:47549865	TMEM160	-0.61	-13.7	-0.78	1.39e-26	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
TGCT	cis	rs10501293	0.643	rs10837996	chr11:43028439	A/G	cg03447554	chr11:43094025	NA	0.44	6.28	0.49	5.14e-9	Cognitive performance;
TGCT	cis	rs2073300	1.000	rs12626013	chr20:23442215	G/A	cg09953122	chr20:23471693	CST8	-0.64	-4.56	-0.38	1.19e-5	Peripheral arterial disease (traffic-related air pollution interaction);
TGCT	cis	rs6748734	1.000	rs4344931	chr2:241818527	A/C	cg04034577	chr2:241836375	C2orf54	-0.39	-6.27	-0.49	5.49e-9	Urinary metabolites;
TGCT	cis	rs9914544	0.689	rs11078421	chr17:18804385	A/G	cg26378065	chr17:18585709	ZNF286B	0.51	4.54	0.38	1.33e-5	Educational attainment (years of education);
TGCT	cis	rs6570726	0.846	rs426874	chr6:145880630	A/C	cg23711669	chr6:146136114	FBXO30	0.82	8.6	0.61	2.96e-14	Lobe attachment (rater-scored or self-reported);
TGCT	trans	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg27523141	chr10:43048294	ZNF37B	0.74	8.49	0.61	5.31e-14	Extrinsic epigenetic age acceleration;
TGCT	trans	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.86	9.38	0.64	3.95e-16	Intelligence (multi-trait analysis);
TGCT	cis	rs4242434	0.819	rs2291230	chr8:22463697	C/G	cg03733263	chr8:22462867	KIAA1967	1.08	17.46	0.84	3.22e-35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
TGCT	cis	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg25427524	chr10:38739819	LOC399744	-0.39	-8.03	-0.58	6.56e-13	Extrinsic epigenetic age acceleration;
TGCT	cis	rs1997103	1.000	rs10249105	chr7:55412405	A/G	cg17469321	chr7:55412551	NA	-0.58	-6.22	-0.49	6.9e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs9303542	0.559	rs12603976	chr17:46617163	C/A	cg25032089	chr17:46643351	HOXB3	0.56	5.34	0.43	4.22e-7	Ovarian cancer;Epithelial ovarian cancer;
TGCT	cis	rs6893807	1.000	rs6893807	chr5:87965021	C/T	cg24804195	chr5:87968844	LOC645323	-0.73	-5.57	-0.45	1.52e-7	Body mass index;
TGCT	cis	rs11190604	0.767	rs10748794	chr10:102175918	G/T	cg23241863	chr10:102295624	HIF1AN	-0.64	-4.86	-0.4	3.54e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs8077889	0.871	rs16940243	chr17:41900003	C/G	cg26893861	chr17:41843967	DUSP3	1.09	13.08	0.76	4.26e-25	Triglycerides;
TGCT	cis	rs1008375	0.966	rs3775923	chr4:17585625	T/C	cg10189774	chr4:17578691	LAP3	0.61	5.28	0.43	5.6e-7	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs6840360	0.573	rs4696250	chr4:152266321	T/C	cg17479576	chr4:152424074	FAM160A1	-0.43	-4.48	-0.37	1.68e-5	Intelligence (multi-trait analysis);
TGCT	cis	rs67478160	0.619	rs11160761	chr14:104254856	A/T	cg26031613	chr14:104095156	KLC1	-0.64	-6.58	-0.51	1.2e-9	Schizophrenia;
TGCT	cis	rs7731657	0.537	rs971700	chr5:130361575	T/G	cg08523029	chr5:130500466	HINT1	-0.61	-5.08	-0.42	1.34e-6	Fasting plasma glucose;
TGCT	trans	rs1973993	0.967	rs10489741	chr1:96942406	G/A	cg10631902	chr5:14652156	NA	0.31	7.01	0.53	1.38e-10	Weight;
TGCT	cis	rs16957091	0.647	rs7170376	chr15:43327104	G/C	cg17935677	chr15:44119062	WDR76	0.52	4.71	0.39	6.44e-6	MGMT methylation in smokers;
TGCT	cis	rs11098499	0.863	rs2170276	chr4:120485824	A/C	cg09307838	chr4:120376055	NA	0.72	6.9	0.53	2.41e-10	Corneal astigmatism;
TGCT	cis	rs8014204	0.836	rs12888998	chr14:75292662	G/T	cg06637938	chr14:75390232	RPS6KL1	0.7	6.74	0.52	5.37e-10	Caffeine consumption;
TGCT	cis	rs7209700	0.963	rs1000232	chr17:45356561	T/C	cg21624342	chr17:45890973	OSBPL7	0.17	4.76	0.39	5.39e-6	IgG glycosylation;
TGCT	cis	rs28595532	0.920	rs56364904	chr4:119742504	T/C	cg21605333	chr4:119757512	SEC24D	1.56	8.33	0.6	1.25e-13	Cannabis dependence symptom count;
TGCT	cis	rs6684514	1.000	rs66965793	chr1:156285814	G/A	cg16558208	chr1:156270281	VHLL	0.48	9.6	0.65	1.19e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs394563	0.591	rs237016	chr6:149744859	T/C	cg16235748	chr6:149772707	ZC3H12D	-0.41	-4.62	-0.38	9.34e-6	Dupuytren's disease;
TGCT	cis	rs1018836	0.631	rs9987164	chr8:91470910	T/G	cg16814680	chr8:91681699	NA	-0.77	-7.57	-0.56	7.42e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
TGCT	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg00024416	chr22:24240387	NA	-0.26	-4.93	-0.4	2.61e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs7937612	1.000	rs723937	chr11:120312746	G/A	cg24566217	chr11:120254723	ARHGEF12	-0.31	-5.19	-0.42	8.16e-7	Intraocular pressure;
TGCT	cis	rs9393777	0.513	rs9368448	chr6:26649355	T/C	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.53	-4.88	-0.4	3.19e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg03213289	chr20:61660250	NA	-0.63	-8.45	-0.6	6.67e-14	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9303401	0.659	rs34913878	chr17:56897094	A/G	cg25039879	chr17:56429692	SUPT4H1	0.51	4.5	0.37	1.54e-5	Cognitive test performance;
TGCT	cis	rs7179456	0.547	rs6494035	chr15:59015888	C/G	cg05156742	chr15:59063176	FAM63B	0.53	5.13	0.42	1.09e-6	Asperger disorder;
TGCT	cis	rs950169	0.509	rs71395455	chr15:85153804	A/G	cg17173187	chr15:85201210	NMB	0.53	5.88	0.47	3.53e-8	Schizophrenia;
TGCT	cis	rs12893668	0.667	rs11844466	chr14:104066422	G/A	cg26031613	chr14:104095156	KLC1	-0.55	-4.64	-0.38	8.81e-6	Reticulocyte count;
TGCT	cis	rs7582180	0.629	rs11682557	chr2:100948008	C/A	cg14675211	chr2:100938903	LONRF2	0.51	4.84	0.4	3.83e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs7586879	0.828	rs13012304	chr2:25122246	C/T	cg01884057	chr2:25150051	NA	0.27	4.81	0.4	4.36e-6	Body mass index;
TGCT	trans	rs7698623	0.850	rs4693883	chr4:88770174	A/G	cg01186725	chr1:53905612	FLJ40434	-0.48	-6.63	-0.51	9.21e-10	Cardiovascular disease risk factors;
TGCT	cis	rs832540	0.603	rs6870175	chr5:56093371	A/G	cg24531977	chr5:56204891	C5orf35	-0.54	-5.34	-0.43	4.33e-7	Coronary artery disease;
TGCT	cis	rs12497850	0.931	rs6446205	chr3:49035211	C/T	cg05785598	chr3:49045655	WDR6	0.37	4.89	0.4	3.04e-6	Parkinson's disease;
TGCT	cis	rs1942	1.000	rs1942	chr15:41774423	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.47	-6.67	-0.51	7.59e-10	Eosinophil percentage of granulocytes;
TGCT	cis	rs3806843	0.583	rs408652	chr5:140330013	T/G	cg09824255	chr5:140014002	CD14	0.25	4.62	0.38	9.6e-6	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs1153858	1.000	rs11070456	chr15:45686835	G/A	cg26924012	chr15:45694286	SPATA5L1	1.09	15.16	0.81	5.15e-30	Homoarginine levels;
TGCT	cis	rs7208859	0.524	rs73988172	chr17:29086332	A/C	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg24690094	chr11:67383802	NA	-0.33	-5.07	-0.41	1.44e-6	Mean corpuscular volume;
TGCT	cis	rs6589563	0.609	rs12285095	chr11:116658031	T/G	cg01124546	chr11:117515332	DSCAML1	-0.47	-4.56	-0.38	1.2e-5	Eosinophil counts;
TGCT	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg11494091	chr17:61959527	GH2	0.43	7.47	0.56	1.23e-11	Height;
TGCT	cis	rs13191362	0.810	rs34714603	chr6:163008078	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.57	4.94	0.41	2.45e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
TGCT	cis	rs7698623	0.717	rs1982624	chr4:88790847	A/G	cg27387453	chr4:88533842	DSPP	-0.61	-4.6	-0.38	1.03e-5	Cardiovascular disease risk factors;
TGCT	cis	rs7223966	1.000	rs8076717	chr17:61850301	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.58	-4.62	-0.38	9.63e-6	Hip circumference adjusted for BMI;Body mass index;
TGCT	cis	rs2288884	1.000	rs80278704	chr19:52549183	G/A	cg15405931	chr19:52693188	PPP2R1A	-0.69	-4.5	-0.37	1.56e-5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
TGCT	cis	rs68170813	0.522	rs12531187	chr7:106963650	C/G	cg02696742	chr7:106810147	HBP1	-0.69	-5.61	-0.45	1.27e-7	Coronary artery disease;
TGCT	cis	rs1372520	0.684	rs2737030	chr4:90710099	C/T	cg01966878	chr4:90757139	SNCA	-0.31	-5.01	-0.41	1.83e-6	Neuroticism;
TGCT	cis	rs17125944	0.686	rs7147258	chr14:53337664	G/T	cg00686598	chr14:53173677	PSMC6	-0.86	-4.55	-0.38	1.29e-5	Alzheimer's disease (late onset);
TGCT	cis	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg07424592	chr7:64974309	NA	1.34	8.08	0.59	4.95e-13	Diabetic kidney disease;
TGCT	cis	rs7226408	0.948	rs17567550	chr18:34398678	G/C	cg06757138	chr18:34340585	FHOD3	0.26	4.79	0.4	4.62e-6	Obesity-related traits;
TGCT	cis	rs7246657	0.943	rs13345116	chr19:37847098	A/T	cg03233940	chr19:37894644	NA	-0.34	-4.49	-0.37	1.59e-5	Coronary artery calcification;
TGCT	cis	rs9911578	0.967	rs302843	chr17:56727986	C/T	cg05425664	chr17:57184151	TRIM37	-0.64	-6.48	-0.5	1.99e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs6671200	0.831	rs11582082	chr1:95594697	A/G	cg03123541	chr1:95699097	RWDD3	0.73	4.85	0.4	3.56e-6	Stearic acid (18:0) levels;
TGCT	cis	rs11690935	0.959	rs35391289	chr2:172634983	A/C	cg13550731	chr2:172543902	DYNC1I2	-1.19	-12.78	-0.75	2.24e-24	Schizophrenia;
TGCT	cis	rs6570726	0.935	rs374000	chr6:145855290	C/T	cg23711669	chr6:146136114	FBXO30	0.71	7.03	0.53	1.25e-10	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9372253	0.967	rs1055301	chr6:110713042	A/G	cg13266496	chr6:110720918	DDO	-0.45	-5.5	-0.44	2.11e-7	Platelet distribution width;
TGCT	cis	rs67311347	1.000	rs9842564	chr3:40405810	A/G	cg13683864	chr3:40499215	RPL14	1.07	10.53	0.69	6.45e-19	Renal cell carcinoma;
TGCT	cis	rs319204	0.885	rs577197	chr5:146287207	T/C	cg25021259	chr5:146258546	PPP2R2B	0.35	4.49	0.37	1.64e-5	Schizophrenia;
TGCT	cis	rs739496	0.542	rs7306529	chr12:111780644	A/G	cg10833066	chr12:111807467	FAM109A	0.42	7.72	0.57	3.29e-12	Platelet count;
TGCT	cis	rs732765	0.602	rs2359192	chr14:75410523	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.64	-5.82	-0.46	4.68e-8	Non-small cell lung cancer;
TGCT	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg18402987	chr7:1209562	NA	0.7	5.67	0.45	9.66e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs9611565	0.694	rs5758324	chr22:41787950	G/T	cg17554472	chr22:41940697	POLR3H	-0.45	-4.86	-0.4	3.44e-6	Vitiligo;
TGCT	cis	rs7698623	0.850	rs4693894	chr4:88797798	C/T	cg27387453	chr4:88533842	DSPP	-0.61	-4.6	-0.38	1.03e-5	Cardiovascular disease risk factors;
TGCT	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg11764359	chr7:65958608	NA	-0.55	-4.99	-0.41	1.98e-6	Aortic root size;
TGCT	cis	rs2295359	0.643	rs1569923	chr1:67665210	A/G	cg12940439	chr1:67600707	NA	0.44	4.68	0.39	7.53e-6	Psoriasis;
TGCT	cis	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg18252515	chr7:66147081	NA	-1.1	-6.4	-0.5	2.85e-9	Diabetic kidney disease;
TGCT	cis	rs7552404	1.000	rs7513559	chr1:76173744	A/G	cg03433033	chr1:76189801	ACADM	0.83	9.91	0.66	2.13e-17	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs28374715	0.662	rs111522288	chr15:41480169	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.81	-11.6	-0.72	1.65e-21	Ulcerative colitis;
TGCT	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg22535103	chr8:58192502	C8orf71	-0.35	-4.65	-0.39	8.4e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2115630	1.000	rs56074163	chr15:85351332	C/T	cg11189052	chr15:85197271	WDR73	-0.61	-5.89	-0.47	3.35e-8	P wave terminal force;
TGCT	cis	rs9926296	0.712	rs258332	chr16:89727683	G/A	cg27121462	chr16:89883253	FANCA	-0.54	-4.93	-0.4	2.58e-6	Vitiligo;
TGCT	cis	rs10992471	0.651	rs7043984	chr9:95529408	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.59	-5.59	-0.45	1.39e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
TGCT	cis	rs12134245	0.776	rs12124682	chr1:91995542	A/G	cg02896835	chr1:92012615	NA	-0.27	-4.59	-0.38	1.08e-5	Breast cancer;
TGCT	cis	rs988712	0.622	rs7103411	chr11:27700125	C/T	cg10635145	chr11:27742435	BDNF	0.42	5.96	0.47	2.44e-8	Obesity;
TGCT	cis	rs9916302	0.904	rs8065879	chr17:37515978	G/A	cg15445000	chr17:37608096	MED1	-0.33	-4.74	-0.39	5.87e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg24250549	chr1:154909240	PMVK	0.62	6.16	0.48	9.3e-9	Prostate cancer;
TGCT	cis	rs459571	0.959	rs460888	chr9:136913123	C/G	cg14405625	chr9:136855902	VAV2	-0.32	-4.72	-0.39	6.15e-6	Platelet distribution width;
TGCT	cis	rs2303745	0.589	rs6512182	chr19:17399476	G/T	cg04248312	chr19:17393744	ANKLE1	-0.34	-5.57	-0.45	1.54e-7	Systemic lupus erythematosus;
TGCT	cis	rs4455778	0.659	rs7784468	chr7:49020696	A/C	cg26309511	chr7:48887640	NA	-0.43	-5.07	-0.41	1.4e-6	Lung cancer in never smokers;
TGCT	cis	rs904251	0.523	rs2776870	chr6:37481364	C/A	cg01843034	chr6:37503916	NA	-0.56	-7.56	-0.56	7.84e-12	Cognitive performance;
TGCT	cis	rs10114408	0.959	rs10821248	chr9:96645884	G/A	cg13679303	chr9:96623674	NA	-0.36	-4.68	-0.39	7.28e-6	Colorectal cancer (SNP x SNP interaction);
TGCT	cis	rs12477438	0.765	rs2309454	chr2:99595418	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-7.6	-0.56	6.47e-12	Chronic sinus infection;
TGCT	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg10802521	chr3:52805072	NEK4	-0.74	-9.02	-0.63	2.87e-15	Bipolar disorder;
TGCT	cis	rs7666738	0.791	rs62318641	chr4:98816964	T/C	cg17366294	chr4:99064904	C4orf37	0.7	7.45	0.56	1.42e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs933688	0.941	rs2887007	chr5:90740531	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	9.32	0.64	5.66e-16	Smoking behavior;
TGCT	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg03517284	chr6:25882590	NA	-0.63	-5.65	-0.45	1.04e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7949030	0.626	rs61296092	chr11:62320838	T/C	cg13298116	chr11:62369859	EML3;MTA2	0.65	9.51	0.65	1.98e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7666738	0.962	rs1527515	chr4:99025733	C/A	cg17366294	chr4:99064904	C4orf37	0.76	7.12	0.54	7.6e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9309473	0.687	rs6747145	chr2:73609177	C/T	cg20560298	chr2:73613845	ALMS1	-0.45	-5.01	-0.41	1.82e-6	Metabolite levels;
TGCT	cis	rs172166	0.694	rs203884	chr6:28077374	G/T	cg10876282	chr6:28092338	ZSCAN16	0.49	4.64	0.38	8.6e-6	Cardiac Troponin-T levels;
TGCT	cis	rs12142240	0.698	rs77185326	chr1:46818417	T/C	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	trans	rs9929218	0.507	rs62057805	chr16:68742390	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.62	8.1	0.59	4.5e-13	Colorectal cancer;
TGCT	cis	rs2050392	0.517	rs602966	chr10:30755853	C/T	cg18806716	chr10:30721971	MAP3K8	-0.58	-6.77	-0.52	4.51e-10	Inflammatory bowel disease;
TGCT	cis	rs11809207	0.857	rs11247866	chr1:26517794	A/G	cg03844060	chr1:26490628	NA	0.25	4.62	0.38	9.44e-6	Height;
TGCT	cis	rs7213347	0.555	rs2760751	chr17:2028106	A/G	cg13315690	chr17:1944831	OVCA2;DPH1	-0.39	-4.83	-0.4	3.97e-6	Total body bone mineral density;
TGCT	cis	rs9814567	0.896	rs7653807	chr3:134345724	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-7.38	-0.55	2e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs881375	0.692	rs2072438	chr9:123651301	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.39	4.48	0.37	1.69e-5	Rheumatoid arthritis;
TGCT	cis	rs4911259	0.552	rs11697394	chr20:31460076	G/A	cg13636640	chr20:31349939	DNMT3B	-0.89	-9.82	-0.66	3.4e-17	Inflammatory bowel disease;
TGCT	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg27425262	chr2:113953981	PSD4;LOC440839	-0.52	-7.84	-0.58	1.73e-12	Lymphocyte counts;
TGCT	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	8.39	0.6	9.03e-14	Platelet count;
TGCT	cis	rs9790314	0.812	rs7631479	chr3:161139566	C/T	cg03342759	chr3:160939853	NMD3	-0.45	-4.49	-0.37	1.58e-5	Morning vs. evening chronotype;
TGCT	cis	rs506338	0.517	rs516117	chr11:64433444	T/C	cg19395706	chr11:64412079	NRXN2	0.49	5.96	0.47	2.41e-8	Body mass index;Urate levels;
TGCT	cis	rs1971762	0.527	rs1247956	chr12:53963814	G/T	cg16917193	chr12:54089295	NA	-1.04	-11.02	-0.7	4.2e-20	Height;
TGCT	cis	rs7824557	0.602	rs7839053	chr8:11207431	C/T	cg21775007	chr8:11205619	TDH	0.73	7.03	0.53	1.23e-10	Retinal vascular caliber;
TGCT	cis	rs8017423	0.935	rs7144070	chr14:90753047	T/C	cg04374321	chr14:90722782	PSMC1	0.76	7.46	0.56	1.33e-11	Mortality in heart failure;
TGCT	cis	rs7772486	0.875	rs10457794	chr6:146415608	A/G	cg05347473	chr6:146136440	FBXO30	0.56	5.22	0.42	7.31e-7	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs6088580	0.634	rs6120644	chr20:33023810	G/A	cg06115741	chr20:33292138	TP53INP2	0.55	4.82	0.4	4.15e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs1729951	0.546	rs835634	chr3:136676303	C/T	cg12473912	chr3:136751656	NA	0.39	6.18	0.49	8.36e-9	Neuroticism;
TGCT	cis	rs1997103	0.834	rs10274457	chr7:55390199	G/A	cg17469321	chr7:55412551	NA	0.64	6.55	0.51	1.4e-9	QRS interval (sulfonylurea treatment interaction);
TGCT	cis	rs11711311	1.000	rs10934243	chr3:113430239	T/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.73	-6.83	-0.52	3.45e-10	IgG glycosylation;
TGCT	cis	rs3749237	0.964	rs1799843	chr3:49849723	G/A	cg07636037	chr3:49044803	WDR6	0.61	5.41	0.44	3.08e-7	Resting heart rate;
TGCT	cis	rs2075371	0.835	rs1646724	chr7:134001875	T/G	cg11752832	chr7:134001865	SLC35B4	0.82	7.74	0.57	3.06e-12	Mean platelet volume;
TGCT	cis	rs4499344	0.586	rs2903753	chr19:33053116	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.73	-6.21	-0.49	7.33e-9	Mean platelet volume;
TGCT	cis	rs2760061	0.545	rs1745423	chr1:228224153	G/T	cg02753203	chr1:228287806	NA	-0.36	-7.64	-0.57	5.17e-12	Diastolic blood pressure;
TGCT	cis	rs1541995	0.931	rs6496136	chr15:96319875	A/T	cg00882281	chr15:96346592	NA	0.28	4.56	0.38	1.19e-5	Photic sneeze reflex;
TGCT	cis	rs6964587	0.692	rs2158138	chr7:91700879	A/G	cg17063962	chr7:91808500	NA	0.74	6.96	0.53	1.75e-10	Breast cancer;
TGCT	cis	rs910187	0.678	rs6124965	chr20:45812957	T/G	cg27589058	chr20:45804311	EYA2	-0.35	-7.6	-0.56	6.23e-12	Migraine;
TGCT	cis	rs10186029	0.680	rs10179425	chr2:213978441	T/C	cg08319019	chr2:214017104	IKZF2	0.65	5.95	0.47	2.49e-8	Systemic sclerosis;
TGCT	cis	rs68170813	0.559	rs75203426	chr7:107017589	G/C	cg02696742	chr7:106810147	HBP1	-0.7	-5.7	-0.46	8.16e-8	Coronary artery disease;
TGCT	cis	rs7681440	0.647	rs1442133	chr4:90819195	C/T	cg10208370	chr4:90758469	SNCA	-0.57	-5.4	-0.44	3.19e-7	Dementia with Lewy bodies;
TGCT	cis	rs7267979	1.000	rs2027003	chr20:25350498	A/G	cg16686733	chr20:25566563	NINL	-0.59	-5.99	-0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg24675658	chr1:53192096	ZYG11B	-0.82	-10.02	-0.67	1.1e-17	Monocyte count;
TGCT	cis	rs2832191	0.703	rs2853827	chr21:30443596	T/C	cg24692254	chr21:30365293	RNF160	0.98	11.39	0.72	5.22e-21	Dental caries;
TGCT	cis	rs6840360	1.000	rs6823421	chr4:152604719	T/C	cg17479576	chr4:152424074	FAM160A1	-0.46	-4.8	-0.4	4.53e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs9929218	0.954	rs34530130	chr16:68827620	C/T	cg03880890	chr16:69439245	NA	-0.22	-4.48	-0.37	1.68e-5	Colorectal cancer;
TGCT	cis	rs6785206	0.527	rs4040753	chr3:128656781	C/T	cg25356066	chr3:128598488	ACAD9	-0.71	-4.45	-0.37	1.85e-5	Lymphocyte percentage of white cells;
TGCT	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg24846343	chr22:24311635	DDTL	0.22	5.71	0.46	7.82e-8	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs8056742	0.571	rs9922192	chr16:85003815	A/T	cg00229868	chr16:85520891	NA	0.35	4.51	0.38	1.47e-5	Amyotrophic lateral sclerosis;
TGCT	cis	rs9527	0.590	rs11191547	chr10:104843148	C/T	cg04362960	chr10:104952993	NT5C2	0.69	5.75	0.46	6.42e-8	Arsenic metabolism;
TGCT	cis	rs1865760	0.602	rs2157050	chr6:26020431	C/T	cg16482183	chr6:26056742	HIST1H1C	0.56	4.78	0.39	4.96e-6	Height;
TGCT	cis	rs2013441	1.000	rs2120282	chr17:20209474	C/T	cg18979559	chr17:20280153	CCDC144C	-0.49	-4.99	-0.41	1.97e-6	Obesity-related traits;
TGCT	cis	rs2153535	0.580	rs9405390	chr6:8466209	T/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.09	0.42	1.32e-6	Motion sickness;
TGCT	cis	rs12681287	0.604	rs41469550	chr8:87406544	G/T	cg27223183	chr8:87520930	FAM82B	0.87	6.39	0.5	3e-9	Caudate activity during reward;
TGCT	cis	rs224278	0.782	rs224292	chr10:64588424	G/A	cg22903908	chr10:64578919	EGR2	0.38	4.72	0.39	6.14e-6	Ewing sarcoma;
TGCT	cis	rs9902453	0.817	rs2321333	chr17:28140857	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.83	7.95	0.58	9.99e-13	Coffee consumption (cups per day);
TGCT	cis	rs8038465	1.000	rs8032531	chr15:73977271	A/G	cg15420318	chr15:73925796	NPTN	0.71	6.56	0.51	1.3e-9	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs3845702	0.668	rs3856415	chr2:180807367	G/A	cg01881094	chr2:180872142	CWC22	-1.05	-6.78	-0.52	4.27e-10	Schizophrenia;
TGCT	cis	rs2663905	0.611	rs2663920	chr15:81396404	A/G	cg09888468	chr15:81410853	NA	-0.63	-5.4	-0.44	3.25e-7	QT interval (drug interaction);
TGCT	cis	rs2013441	0.804	rs1811453	chr17:20232193	A/C	cg18979559	chr17:20280153	CCDC144C	-0.45	-4.67	-0.39	7.61e-6	Obesity-related traits;
TGCT	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg26338869	chr17:61819248	STRADA	0.55	5.1	0.42	1.22e-6	Prudent dietary pattern;
TGCT	cis	rs10779751	1.000	rs7549109	chr1:11278813	C/G	cg08854313	chr1:11322531	MTOR	-0.92	-10.06	-0.67	9.08e-18	Body mass index;
TGCT	cis	rs9549260	0.755	rs55920113	chr13:41222112	C/T	cg21288729	chr13:41239152	FOXO1	0.99	10.42	0.68	1.22e-18	Red blood cell count;
TGCT	cis	rs11785400	1.000	rs3735994	chr8:143742683	C/T	cg10596483	chr8:143751796	JRK	0.56	6.05	0.48	1.61e-8	Schizophrenia;
TGCT	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.25	4.48	0.37	1.65e-5	Total body bone mineral density;
TGCT	cis	rs2050392	0.624	rs303436	chr10:30731893	G/T	cg13289132	chr10:30722225	MAP3K8	-0.48	-6.07	-0.48	1.41e-8	Inflammatory bowel disease;
TGCT	cis	rs9653442	0.510	rs13415583	chr2:100764087	T/G	cg07810366	chr2:100720526	AFF3	-0.36	-5.31	-0.43	4.89e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
TGCT	cis	rs3806843	0.520	rs246051	chr5:140326464	G/A	cg09824255	chr5:140014002	CD14	0.25	4.58	0.38	1.14e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs6545883	0.929	rs2592352	chr2:61665336	C/T	cg15711740	chr2:61764176	XPO1	-0.56	-5.07	-0.41	1.42e-6	Tuberculosis;
TGCT	cis	rs79349575	0.783	rs4793996	chr17:47019597	T/C	cg00947319	chr17:47005597	UBE2Z	-0.19	-4.52	-0.38	1.44e-5	Type 2 diabetes;
TGCT	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.36	0.55	2.25e-11	Prudent dietary pattern;
TGCT	cis	rs1030877	1.000	rs2576743	chr2:105901337	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.19	5.69	0.45	8.77e-8	Obesity-related traits;
TGCT	trans	rs1864729	1.000	rs2853318	chr8:98283509	A/T	cg08679828	chr8:102218111	ZNF706	-1.08	-7.52	-0.56	9.47e-12	Estradiol plasma levels (breast cancer);
TGCT	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg22535103	chr8:58192502	C8orf71	-0.41	-5.19	-0.42	8.4e-7	Developmental language disorder (linguistic errors);
TGCT	trans	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg17830980	chr10:43048298	ZNF37B	-0.86	-11.18	-0.71	1.68e-20	Extrinsic epigenetic age acceleration;
TGCT	cis	rs6570726	0.791	rs4896820	chr6:145894957	T/C	cg23711669	chr6:146136114	FBXO30	0.84	8.89	0.62	6.14e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg25036284	chr2:26402008	FAM59B	0.65	5.19	0.42	8.36e-7	Gut microbiome composition (summer);
TGCT	cis	rs9972944	0.729	rs10083872	chr17:63773474	A/G	cg07283582	chr17:63770753	CCDC46	0.26	5.05	0.41	1.53e-6	Total body bone mineral density;
TGCT	cis	rs11673344	0.504	rs8099987	chr19:37623472	T/C	cg08039142	chr19:36980659	ZNF566	0.51	4.68	0.39	7.31e-6	Obesity-related traits;
TGCT	cis	rs36051895	0.664	rs10117459	chr9:5094034	G/A	cg02405213	chr9:5042618	JAK2	-0.7	-9.05	-0.63	2.49e-15	Pediatric autoimmune diseases;
TGCT	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg00343986	chr7:65444356	GUSB	-0.25	-5.81	-0.46	4.89e-8	Aortic root size;
TGCT	cis	rs7811142	1.000	rs6953107	chr7:100095664	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	9.11	0.63	1.81e-15	Platelet count;
TGCT	cis	rs3849570	0.695	rs1851930	chr3:81895318	T/G	cg07356753	chr3:81810745	GBE1	-0.64	-5.59	-0.45	1.35e-7	Waist circumference;Body mass index;
TGCT	cis	rs4783244	0.897	rs4783241	chr16:82650384	G/C	cg09415485	chr16:82663111	CDH13	-0.26	-4.98	-0.41	2.07e-6	Adiponectin levels;
TGCT	cis	rs6001982	0.510	rs55844816	chr22:40803112	C/T	cg07138101	chr22:40742427	ADSL	0.71	4.72	0.39	6.31e-6	Breast cancer;
TGCT	cis	rs1538970	0.962	rs7532762	chr1:45864695	C/A	cg05343316	chr1:45956843	TESK2	0.7	5.35	0.43	4.04e-7	Platelet count;
TGCT	cis	rs1372520	0.935	rs2245801	chr4:90757840	T/C	cg15133208	chr4:90757351	SNCA	-0.53	-5.88	-0.47	3.53e-8	Neuroticism;
TGCT	cis	rs7666738	0.830	rs1426668	chr4:98945585	T/A	cg17366294	chr4:99064904	C4orf37	0.73	7.47	0.56	1.24e-11	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs17197710	0.608	rs4647736	chr11:47253137	C/T	cg13308137	chr11:47528955	CUGBP1	0.4	5.18	0.42	8.8e-7	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs7727544	0.684	rs274567	chr5:131714409	C/T	cg24060327	chr5:131705240	SLC22A5	0.57	6.4	0.5	2.91e-9	Blood metabolite levels;
TGCT	cis	rs748404	0.660	rs509306	chr15:43715171	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	4.75	0.39	5.51e-6	Lung cancer;
TGCT	cis	rs2806561	0.765	rs1738470	chr1:23511911	G/A	cg12483005	chr1:23474871	LUZP1	0.38	4.73	0.39	5.93e-6	Height;
TGCT	cis	rs13188771	0.578	rs17137390	chr5:100918526	C/T	cg10455971	chr5:101119566	NA	0.48	4.77	0.39	5.16e-6	Conduct disorder (maternal expressed emotions interaction);
TGCT	cis	rs7264396	0.635	rs6060675	chr20:34493614	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.29	-5.06	-0.41	1.47e-6	Total cholesterol levels;
TGCT	cis	rs7914558	1.000	rs7077291	chr10:104945751	C/T	cg04362960	chr10:104952993	NT5C2	0.61	5.47	0.44	2.42e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs7523273	0.564	rs1977265	chr1:207880683	G/T	cg22525895	chr1:207977042	MIR29B2	-0.29	-4.51	-0.38	1.48e-5	Schizophrenia;
TGCT	cis	rs73058052	0.935	rs3745474	chr19:50086806	C/T	cg09250473	chr19:50168907	IRF3;BCL2L12	0.85	6.59	0.51	1.12e-9	Fibrinogen levels;
TGCT	cis	rs7267979	0.789	rs4815400	chr20:25292560	T/C	cg03522245	chr20:25566470	NINL	-0.55	-5.55	-0.45	1.68e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6912958	0.559	rs451465	chr6:88043372	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.45	-5.9	-0.47	3.19e-8	Monocyte percentage of white cells;
TGCT	cis	rs79349575	0.783	rs832410	chr17:46972865	C/T	cg26022315	chr17:47021804	SNF8	0.47	4.55	0.38	1.28e-5	Type 2 diabetes;
TGCT	cis	rs1008375	1.000	rs10805358	chr4:17652450	A/C	cg18681998	chr4:17616180	MED28	0.99	11.78	0.73	5.86e-22	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg22535103	chr8:58192502	C8orf71	-0.42	-4.79	-0.4	4.7e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2153535	0.580	rs4960422	chr6:8459309	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	5.72	0.46	7.7e-8	Motion sickness;
TGCT	cis	rs3820928	0.839	rs35068645	chr2:227844265	T/C	cg11843606	chr2:227700838	RHBDD1	-0.52	-4.59	-0.38	1.05e-5	Pulmonary function;
TGCT	cis	rs7666738	0.791	rs4440223	chr4:99044796	G/A	cg17366294	chr4:99064904	C4orf37	0.74	7.57	0.56	7.57e-12	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1467026	0.584	rs9880453	chr3:12804060	C/T	cg05775895	chr3:12838266	CAND2	0.71	7.25	0.55	3.89e-11	P wave duration;
TGCT	cis	rs79387448	0.745	rs79107058	chr2:103164257	C/A	cg09003973	chr2:102972529	NA	0.95	6.15	0.48	9.95e-9	Gut microbiota (bacterial taxa);
TGCT	cis	rs74544699	0.826	rs3756074	chr4:74848065	G/C	cg16072462	chr4:74847758	PF4	1.02	5.45	0.44	2.56e-7	Growth-regulated protein alpha levels;
TGCT	cis	rs763121	0.853	rs3747172	chr22:39067524	A/G	cg06022373	chr22:39101656	GTPBP1	0.77	7.46	0.56	1.35e-11	Menopause (age at onset);
TGCT	cis	rs2562456	0.917	rs2681389	chr19:21692575	G/A	cg01304269	chr19:21688519	ZNF429	-0.55	-4.59	-0.38	1.06e-5	Pain;
TGCT	cis	rs921968	0.643	rs2556386	chr2:219534530	C/T	cg02176678	chr2:219576539	TTLL4	-0.38	-5.47	-0.44	2.34e-7	Mean corpuscular hemoglobin concentration;
TGCT	cis	rs3091242	0.933	rs35403885	chr1:25784551	G/A	cg10117171	chr1:25599238	RHD	0.3	4.92	0.4	2.69e-6	Erythrocyte sedimentation rate;
TGCT	cis	rs67478160	0.643	rs8005225	chr14:104300151	C/T	cg26031613	chr14:104095156	KLC1	0.63	6.53	0.51	1.56e-9	Schizophrenia;
TGCT	cis	rs559928	0.553	rs4930168	chr11:64173058	A/G	cg12453748	chr11:64085041	PRDX5;TRMT112	0.58	5.16	0.42	9.57e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
TGCT	cis	rs11696501	0.688	rs2281211	chr20:44312858	C/T	cg11783356	chr20:44313418	WFDC10B	-0.33	-4.49	-0.37	1.6e-5	Brain structure;
TGCT	cis	rs9549367	0.773	rs9549717	chr13:113908826	A/G	cg18105134	chr13:113819100	PROZ	-0.35	-5.94	-0.47	2.68e-8	Platelet distribution width;
TGCT	cis	rs2997447	0.761	rs112552200	chr1:26456947	G/A	cg03844060	chr1:26490628	NA	0.27	4.44	0.37	2e-5	QRS complex (12-leadsum);
TGCT	cis	rs68170813	0.559	rs10487271	chr7:106898458	T/C	cg02696742	chr7:106810147	HBP1	-0.69	-5.61	-0.45	1.27e-7	Coronary artery disease;
TGCT	cis	rs75686122	0.892	rs769134	chr8:104653444	G/T	cg04852977	chr8:104510831	NA	0.59	4.46	0.37	1.81e-5	Cocaine dependence;
TGCT	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg11644478	chr21:40555479	PSMG1	1.04	10.81	0.7	1.38e-19	Cognitive function;
TGCT	cis	rs7267979	0.816	rs422148	chr20:25512604	G/C	cg14121845	chr20:25566513	NINL	0.46	4.76	0.39	5.36e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4808199	0.689	rs12979148	chr19:19406869	T/C	cg03709012	chr19:19516395	GATAD2A	0.79	5.54	0.45	1.75e-7	Nonalcoholic fatty liver disease;
TGCT	cis	rs11969893	0.649	rs12527901	chr6:101280435	G/A	cg12253828	chr6:101329408	ASCC3	1.22	5.92	0.47	2.93e-8	Economic and political preferences (immigration/crime);
TGCT	cis	rs4499344	0.730	rs259279	chr19:33161274	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.91	-10.19	-0.68	4.27e-18	Mean platelet volume;
TGCT	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg07507251	chr3:52567010	NT5DC2	0.46	6.57	0.51	1.28e-9	Electroencephalogram traits;
TGCT	cis	rs6952809	0.504	rs1978169	chr7:2434522	G/A	cg23289794	chr7:2394357	EIF3B	-0.83	-7.09	-0.54	8.92e-11	Multiple sclerosis;
TGCT	cis	rs13217239	0.646	rs35691005	chr6:26972070	A/G	cg05738196	chr6:26577821	NA	0.49	4.77	0.39	4.98e-6	Schizophrenia;
TGCT	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	6.14	0.48	1.03e-8	Bipolar disorder;
TGCT	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg22920501	chr2:26401640	FAM59B	-0.78	-6.16	-0.48	9.43e-9	Gut microbiome composition (summer);
TGCT	cis	rs903263	0.965	rs11163903	chr1:84592805	G/A	cg09664975	chr1:84543551	PRKACB	0.49	4.59	0.38	1.06e-5	Breast cancer (male);
TGCT	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg05665937	chr4:1216051	CTBP1	0.23	4.59	0.38	1.06e-5	Obesity-related traits;
TGCT	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.01	8.32	0.6	1.34e-13	Platelet count;
TGCT	cis	rs7085104	0.513	rs619824	chr10:104581288	G/T	cg05855489	chr10:104503620	C10orf26	0.58	5.4	0.44	3.31e-7	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs7945705	0.818	rs1988708	chr11:8882893	C/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-5.5	-0.44	2.03e-7	Hemoglobin concentration;
TGCT	cis	rs10931896	0.531	rs295118	chr2:201144004	C/T	cg17644776	chr2:200775616	C2orf69	0.26	4.76	0.39	5.28e-6	Systolic blood pressure;
TGCT	cis	rs60871478	0.636	rs4721834	chr7:896142	C/T	cg00475322	chr7:917719	C7orf20	0.5	4.87	0.4	3.37e-6	Cerebrospinal P-tau181p levels;
TGCT	cis	rs7949030	0.626	rs1061093	chr11:62334908	G/C	cg11742103	chr11:62369870	EML3;MTA2	0.61	8.71	0.62	1.65e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs362272	0.524	rs2857982	chr4:3358665	G/A	cg06533319	chr4:3265114	C4orf44	-0.28	-5.69	-0.46	8.58e-8	Serum sulfate level;
TGCT	cis	rs78487399	0.731	rs13408697	chr2:43706244	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.39	-4.96	-0.41	2.24e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg03352830	chr11:487213	PTDSS2	0.26	4.58	0.38	1.1e-5	Body mass index;
TGCT	cis	rs6912958	0.630	rs4707377	chr6:88280332	C/T	cg06598631	chr6:88300029	RARS2;ORC3L	-0.54	-4.91	-0.4	2.78e-6	Monocyte percentage of white cells;
TGCT	cis	rs2933343	0.649	rs1683786	chr3:128626952	T/C	cg11901034	chr3:128598214	ACAD9	-0.64	-6.12	-0.48	1.16e-8	IgG glycosylation;
TGCT	cis	rs644148	0.836	rs2686776	chr19:45000366	T/C	cg15540054	chr19:45004280	ZNF180	-0.66	-5.36	-0.43	3.83e-7	Personality dimensions;
TGCT	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg20007245	chr22:24372913	LOC391322	-0.78	-8.52	-0.61	4.64e-14	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9357506	1.000	rs9296491	chr6:46315285	C/T	cg21115430	chr6:46460003	NA	-0.26	-5.16	-0.42	9.6e-7	Body mass index;
TGCT	cis	rs9447004	0.584	rs12215671	chr6:74435607	T/C	cg23004174	chr6:74404879	CD109	0.22	4.69	0.39	6.96e-6	Blood protein levels;Calcium levels;
TGCT	cis	rs2239785	0.920	rs78523	chr22:36663248	C/T	cg15716373	chr22:36655542	APOL1	0.45	5.2	0.42	8.01e-7	Glomerulosclerosis;
TGCT	cis	rs6988636	1.000	rs28694222	chr8:124195017	C/T	cg23067535	chr8:124195133	FAM83A	-0.35	-5.22	-0.42	7.34e-7	Urinary uromodulin levels;
TGCT	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg06481639	chr22:41940642	POLR3H	0.6	5.48	0.44	2.23e-7	Vitiligo;
TGCT	cis	rs9443645	0.901	rs9359354	chr6:79590385	A/G	cg09184832	chr6:79620586	NA	-0.49	-5.29	-0.43	5.29e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg02953382	chr22:24373134	LOC391322	-0.76	-7.83	-0.58	1.84e-12	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs735396	1.000	rs1169313	chr12:121442670	C/T	cg02403541	chr12:121454288	C12orf43	-0.65	-6.3	-0.49	4.8e-9	N-glycan levels;
TGCT	cis	rs7432375	1.000	rs940174	chr3:136309710	T/C	cg12473912	chr3:136751656	NA	0.34	4.85	0.4	3.55e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
TGCT	cis	rs4478858	0.775	rs59865338	chr1:31706643	A/G	cg00250761	chr1:31883323	NA	-0.31	-5.6	-0.45	1.34e-7	Alcohol dependence;
TGCT	cis	rs7552404	0.765	rs1251078	chr1:76189488	C/G	cg10523679	chr1:76189770	ACADM	-0.98	-13.66	-0.78	1.69e-26	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs11112613	0.595	rs871219	chr12:105938519	C/A	cg03607813	chr12:105948248	NA	0.46	5.36	0.43	3.88e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
TGCT	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.47	-4.48	-0.37	1.66e-5	Bipolar disorder;
TGCT	cis	rs6586163	0.872	rs7910660	chr10:90743197	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.38	-4.7	-0.39	6.86e-6	Chronic lymphocytic leukemia;
TGCT	cis	rs12643440	0.574	rs12651694	chr4:17139359	G/A	cg22650099	chr4:17144496	NA	-0.46	-4.7	-0.39	6.79e-6	Metabolite levels (Pyroglutamine);
TGCT	cis	rs2013441	1.000	rs2703806	chr17:20108239	A/T	cg18979559	chr17:20280153	CCDC144C	-0.44	-4.61	-0.38	9.78e-6	Obesity-related traits;
TGCT	cis	rs3754214	0.836	rs12023277	chr1:150466737	A/G	cg09579323	chr1:150459698	TARS2	0.52	4.58	0.38	1.12e-5	Cerebrospinal fluid biomarker levels;
TGCT	cis	rs7246657	0.722	rs3829688	chr19:38077100	T/C	cg03611452	chr19:38183253	ZNF781	0.58	4.64	0.38	8.62e-6	Coronary artery calcification;
TGCT	cis	rs36051895	0.664	rs7851455	chr9:5100501	G/C	cg02405213	chr9:5042618	JAK2	-0.77	-10.92	-0.7	7.16e-20	Pediatric autoimmune diseases;
TGCT	cis	rs9837602	0.507	rs6803204	chr3:99680874	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.62	6.98	0.53	1.6e-10	Breast cancer;
TGCT	cis	rs10089	1.000	rs13355233	chr5:127425350	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.84	-8.19	-0.59	2.7e-13	Ileal carcinoids;
TGCT	cis	rs55883249	1.000	rs11692112	chr2:9723732	G/T	cg23886495	chr2:9695866	ADAM17	0.77	4.69	0.39	7.19e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
TGCT	cis	rs9486719	0.857	rs11751075	chr6:97065751	G/A	cg18709589	chr6:96969512	KIAA0776	-0.83	-6.46	-0.5	2.16e-9	Migraine;Coronary artery disease;
TGCT	cis	rs35306767	0.903	rs11815185	chr10:923617	T/A	cg20503657	chr10:835505	NA	0.74	10.3	0.68	2.41e-18	Eosinophil percentage of granulocytes;
TGCT	cis	rs9911578	0.935	rs302873	chr17:56769481	C/G	cg05425664	chr17:57184151	TRIM37	-0.63	-6.26	-0.49	5.86e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs11122272	0.668	rs2749712	chr1:231537751	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-6.24	-0.49	6.42e-9	Hemoglobin concentration;
TGCT	cis	rs10207628	1.000	rs10207628	chr2:127852021	C/G	cg21679674	chr2:128283815	IWS1	-0.67	-4.68	-0.39	7.43e-6	Psychosis and Alzheimer's disease;
TGCT	cis	rs1055129	0.560	rs2608880	chr17:73938957	C/T	cg08125733	chr17:73851984	WBP2	0.57	5.29	0.43	5.29e-7	White matter hyperintensity burden;
TGCT	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg08280861	chr8:58055591	NA	0.4	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs80282103	0.571	rs10047269	chr10:1103058	G/A	cg08668510	chr10:1095578	IDI1	1.01	4.51	0.38	1.48e-5	Glomerular filtration rate (creatinine);
TGCT	cis	rs6430585	0.583	rs12472293	chr2:136648077	T/C	cg07169764	chr2:136633963	MCM6	1.23	11.98	0.73	1.9e-22	Corneal structure;
TGCT	trans	rs4332037	0.851	rs28728306	chr7:1961814	C/A	cg10840412	chr1:235813424	GNG4	1.05	8.44	0.6	7.18e-14	Bipolar disorder;
TGCT	cis	rs6725041	0.819	rs1521645	chr2:213091216	A/G	cg20637307	chr2:213403960	ERBB4	-0.52	-4.6	-0.38	1.02e-5	QT interval (ambient particulate matter interaction);
TGCT	cis	rs7412746	0.611	rs10888391	chr1:150729983	G/A	cg09365446	chr1:150670422	GOLPH3L	0.33	4.78	0.39	4.8e-6	Melanoma;
TGCT	cis	rs950776	0.642	rs61630816	chr15:78965866	T/C	cg21242079	chr15:79101063	ADAMTS7	-0.31	-4.71	-0.39	6.54e-6	Sudden cardiac arrest;
TGCT	cis	rs644799	0.672	rs11021307	chr11:95501407	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.26	0.6	1.89e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs2013441	1.000	rs11871945	chr17:20206883	A/G	cg23224458	chr17:20280056	CCDC144C	-0.41	-4.88	-0.4	3.25e-6	Obesity-related traits;
TGCT	cis	rs2836974	0.563	rs6517522	chr21:40553845	T/C	cg11644478	chr21:40555479	PSMG1	0.77	7.84	0.58	1.78e-12	Cognitive function;
TGCT	trans	rs7726839	0.540	rs3792720	chr5:643028	T/G	cg25482853	chr8:67687455	SGK3	1.19	10.3	0.68	2.4e-18	Obesity-related traits;
TGCT	cis	rs1843834	0.505	rs940317	chr2:225358118	C/T	cg12698349	chr2:225449008	CUL3	0.78	6.41	0.5	2.77e-9	IgE levels in asthmatics (D.p. specific);
TGCT	cis	rs1784581	0.588	rs9346893	chr6:162417511	C/G	cg17173639	chr6:162384350	PARK2	0.4	6.6	0.51	1.07e-9	Itch intensity from mosquito bite;
TGCT	cis	rs8077889	0.956	rs6503476	chr17:41850163	C/T	cg26893861	chr17:41843967	DUSP3	1.1	13.81	0.78	7.45e-27	Triglycerides;
TGCT	cis	rs7226408	0.948	rs11665195	chr18:34389940	T/A	cg06757138	chr18:34340585	FHOD3	0.26	4.79	0.4	4.62e-6	Obesity-related traits;
TGCT	cis	rs2836633	0.859	rs8132069	chr21:40032611	T/C	cg12884169	chr21:40033163	ERG	0.44	4.64	0.38	8.84e-6	Coronary artery disease;
TGCT	cis	rs4076764	0.914	rs6704467	chr1:163364512	A/G	cg24596788	chr1:163392923	NA	-0.17	-4.9	-0.4	2.99e-6	Motion sickness;
TGCT	trans	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg21659725	chr3:3221576	CRBN	-0.99	-15.57	-0.81	5.76e-31	Intelligence (multi-trait analysis);
TGCT	cis	rs7226408	0.802	rs11081969	chr18:34483191	C/T	cg06757138	chr18:34340585	FHOD3	0.27	5.42	0.44	3.04e-7	Obesity-related traits;
TGCT	cis	rs7147624	1.000	rs7153497	chr14:65998415	A/G	cg03016385	chr14:66212404	NA	-0.51	-7.09	-0.54	8.85e-11	Chronic obstructive pulmonary disease-related biomarkers;
TGCT	cis	rs9926296	0.562	rs4785725	chr16:89893243	A/G	cg08627397	chr16:89984028	MC1R	-0.3	-4.78	-0.39	4.93e-6	Vitiligo;
TGCT	cis	rs9644630	0.930	rs6586839	chr8:19365543	A/T	cg01280390	chr8:19363452	CSGALNACT1	-0.27	-4.68	-0.39	7.47e-6	Oropharynx cancer;
TGCT	cis	rs12765878	0.564	rs2073338	chr10:105642803	A/C	cg11005552	chr10:105648138	OBFC1	-0.41	-6.3	-0.49	4.67e-9	Coronary artery disease;
TGCT	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.46	-6.7	-0.52	6.44e-10	Alzheimer's disease;
TGCT	cis	rs8033133	0.602	rs1549477	chr15:25332118	C/T	cg14481604	chr15:25334117	SNORD116-22	-0.25	-5.55	-0.45	1.63e-7	Blood osmolality (transformed sodium);
TGCT	cis	rs6089584	0.566	rs2146852	chr20:60616492	T/G	cg13770153	chr20:60521292	NA	-0.39	-4.77	-0.39	5.17e-6	Body mass index;
TGCT	cis	rs344364	0.511	rs56077812	chr16:1948870	T/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.45	-5.08	-0.42	1.35e-6	Glomerular filtration rate in chronic kidney disease;
TGCT	cis	rs1008375	0.966	rs6813375	chr4:17649499	T/G	cg18681998	chr4:17616180	MED28	1.06	12.43	0.74	1.57e-23	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs35883536	1.000	rs4908087	chr1:101088594	C/T	cg06223162	chr1:101003688	GPR88	0.29	4.56	0.38	1.22e-5	Monocyte count;
TGCT	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg24060327	chr5:131705240	SLC22A5	-0.73	-7.69	-0.57	3.82e-12	Breast cancer;
TGCT	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.34	0.43	4.23e-7	Prudent dietary pattern;
TGCT	cis	rs6669072	0.647	rs698274	chr1:91244177	A/G	cg08895590	chr1:91227319	NA	-0.34	-4.51	-0.38	1.47e-5	Cognitive function;
TGCT	cis	rs11203032	0.831	rs4933494	chr10:90917892	T/A	cg16672925	chr10:90967113	CH25H	0.81	4.94	0.41	2.44e-6	Heart failure;
TGCT	cis	rs7605378	0.528	rs812760	chr2:200724372	C/T	cg17644776	chr2:200775616	C2orf69	0.34	7.44	0.56	1.48e-11	Osteoporosis;
TGCT	cis	rs832540	0.966	rs252923	chr5:56205662	T/G	cg12311346	chr5:56204834	C5orf35	-0.52	-5.67	-0.45	9.59e-8	Coronary artery disease;
TGCT	cis	rs854765	0.663	rs1108648	chr17:17750558	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.73	-7.04	-0.53	1.17e-10	Total body bone mineral density;
TGCT	cis	rs5769707	0.967	rs763126	chr22:49988574	G/T	cg20744362	chr22:50050164	C22orf34	-0.28	-4.6	-0.38	1.04e-5	Monocyte count;Monocyte percentage of white cells;
TGCT	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg21963583	chr11:68658836	MRPL21	0.36	6.17	0.48	9.01e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg04744514	chr10:134541379	INPP5A	0.25	4.49	0.37	1.58e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs9299	0.502	rs4793944	chr17:46667304	C/T	cg25032089	chr17:46643351	HOXB3	-0.39	-4.88	-0.4	3.24e-6	Obesity;
TGCT	cis	rs12497850	0.805	rs6446198	chr3:49007638	T/A	cg05785598	chr3:49045655	WDR6	0.37	4.83	0.4	3.94e-6	Parkinson's disease;
TGCT	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg06896619	chr17:61851486	DDX42;CCDC47	-0.49	-4.67	-0.39	7.73e-6	Prudent dietary pattern;
TGCT	trans	rs10506458	0.915	rs60094497	chr12:63394838	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.47	-7.58	-0.56	6.97e-12	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs17376456	0.825	rs12716453	chr5:93271697	T/C	cg21475434	chr5:93447410	FAM172A	0.65	4.47	0.37	1.72e-5	Diabetic retinopathy;
TGCT	cis	rs2797160	0.547	rs4144549	chr6:125945251	C/G	cg05901451	chr6:126070800	HEY2	0.6	4.99	0.41	2.03e-6	Endometrial cancer;
TGCT	cis	rs3812049	0.784	rs3749748	chr5:127350549	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.59	-5.43	-0.44	2.91e-7	Lymphocyte counts;Red cell distribution width;
TGCT	cis	rs8013055	0.796	rs8005568	chr14:105971794	A/G	cg19700328	chr14:106028568	NA	-0.56	-6.29	-0.49	5.01e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
TGCT	cis	rs4783244	0.897	rs12598679	chr16:82651205	G/A	cg09415485	chr16:82663111	CDH13	-0.25	-4.81	-0.4	4.29e-6	Adiponectin levels;
TGCT	cis	rs250677	0.687	rs2963484	chr5:148451127	A/T	cg23229984	chr5:148520753	ABLIM3	0.21	4.89	0.4	3.11e-6	Breast cancer;
TGCT	cis	rs2404602	0.735	rs1607017	chr15:76726465	G/T	cg22467129	chr15:76604101	ETFA	0.53	5.65	0.45	1.04e-7	Blood metabolite levels;
TGCT	cis	rs11677370	0.574	rs11686118	chr2:3854938	C/T	cg17052675	chr2:3827356	NA	-0.41	-6.46	-0.5	2.19e-9	Type 2 diabetes;
TGCT	cis	rs9534288	0.731	rs4942461	chr13:46551023	C/T	cg15192986	chr13:46630673	CPB2	-0.53	-7.66	-0.57	4.65e-12	Blood protein levels;
TGCT	cis	rs514406	0.698	rs1672913	chr1:53408326	A/T	cg27535305	chr1:53392650	SCP2	-0.28	-5.74	-0.46	6.91e-8	Monocyte count;
TGCT	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg01802117	chr1:53393560	SCP2	0.46	5.51	0.44	1.95e-7	Monocyte count;
TGCT	cis	rs478304	0.934	rs506853	chr11:65521247	C/T	cg27068330	chr11:65405492	SIPA1	0.74	7.41	0.55	1.67e-11	Acne (severe);
TGCT	cis	rs28595532	0.920	rs115506655	chr4:119757667	A/G	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs62185668	0.575	rs1107574	chr20:10931651	A/T	cg17778165	chr20:10414372	MKKS	-0.54	-4.84	-0.4	3.75e-6	Urinary bladder cancer;
TGCT	cis	rs2354432	0.556	rs7516165	chr1:146866418	G/T	cg25205988	chr1:146714368	CHD1L	1.32	5.88	0.47	3.62e-8	Mitochondrial DNA levels;
TGCT	cis	rs7296418	0.699	rs11057254	chr12:123794581	A/C	cg00376283	chr12:123451042	ABCB9	0.62	5.32	0.43	4.7e-7	Platelet count;
TGCT	cis	rs9325144	0.560	rs61929893	chr12:38653366	G/A	cg26384229	chr12:38710491	ALG10B	-0.66	-6.0	-0.47	2.06e-8	Morning vs. evening chronotype;
TGCT	cis	rs10946940	0.896	rs12208078	chr6:27498581	G/A	cg10876282	chr6:28092338	ZSCAN16	-0.46	-4.6	-0.38	1.04e-5	Systemic lupus erythematosus;
TGCT	cis	rs1371867	0.875	rs1788178	chr8:101332518	A/C	cg06002616	chr8:101225028	SPAG1	-0.56	-6.58	-0.51	1.2e-9	Atrioventricular conduction;
TGCT	cis	rs12681287	0.752	rs4282548	chr8:87270792	A/T	cg27223183	chr8:87520930	FAM82B	-0.8	-5.54	-0.45	1.71e-7	Caudate activity during reward;
TGCT	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	6.23	0.49	6.56e-9	Bipolar disorder;
TGCT	cis	rs7523273	0.597	rs11118612	chr1:207979577	T/A	cg22525895	chr1:207977042	MIR29B2	-0.44	-6.49	-0.5	1.88e-9	Schizophrenia;
TGCT	cis	rs611744	0.647	rs2594357	chr8:109255989	A/G	cg21045802	chr8:109455806	TTC35	0.7	6.74	0.52	5.23e-10	Dupuytren's disease;
TGCT	cis	rs6840360	0.593	rs2175409	chr4:152701656	A/G	cg17479576	chr4:152424074	FAM160A1	-0.54	-5.42	-0.44	2.99e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs826838	0.654	rs7977738	chr12:38722460	G/A	cg26384229	chr12:38710491	ALG10B	0.64	6.0	0.47	2.01e-8	Heart rate;
TGCT	cis	rs6815814	0.950	rs5743593	chr4:38802913	A/G	cg02016764	chr4:38805732	TLR1	-0.36	-5.88	-0.47	3.5e-8	Breast cancer;
TGCT	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.04	11.55	0.72	2.13e-21	Height;
TGCT	cis	rs10875746	0.669	rs10875767	chr12:48599257	A/C	cg20731937	chr12:48336164	NA	0.59	4.52	0.38	1.45e-5	Longevity (90 years and older);
TGCT	cis	rs1577917	0.545	rs7755958	chr6:86488511	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.62	5.22	0.42	7.39e-7	Response to antipsychotic treatment;
TGCT	cis	rs55794721	0.509	rs4649085	chr1:25778832	G/A	cg10117171	chr1:25599238	RHD	-0.32	-5.22	-0.42	7.32e-7	Plateletcrit;Mean corpuscular volume;
TGCT	cis	rs1775715	0.737	rs1541260	chr10:32105570	C/T	cg14930904	chr10:32216787	ARHGAP12	0.52	5.07	0.41	1.38e-6	Bipolar disorder with mood-incongruent psychosis;
TGCT	cis	rs2147959	0.700	rs12725863	chr1:228630986	C/T	cg22700015	chr1:228743131	NA	-0.57	-4.53	-0.38	1.35e-5	Adult asthma;
TGCT	cis	rs7830933	0.780	rs11986562	chr8:23609098	T/C	cg04349084	chr8:23602677	NA	0.26	5.22	0.42	7.33e-7	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
TGCT	cis	rs7267979	0.966	rs910996	chr20:25264196	A/G	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	7.06	0.54	1.04e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs11190604	1.000	rs7084810	chr10:102297546	A/G	cg23241863	chr10:102295624	HIF1AN	0.69	5.1	0.42	1.24e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs6938	0.534	rs12913293	chr15:75184458	G/C	cg10253484	chr15:75165896	SCAMP2	-0.55	-5.06	-0.41	1.45e-6	Breast cancer;
TGCT	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg17054783	chr10:134559939	INPP5A	0.24	4.83	0.4	3.92e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
TGCT	cis	rs35306767	0.715	rs12777801	chr10:1036285	T/A	cg20503657	chr10:835505	NA	0.63	6.97	0.53	1.64e-10	Eosinophil percentage of granulocytes;
TGCT	cis	rs9581857	0.579	rs3759434	chr13:27997700	A/C	cg22138327	chr13:27999177	GTF3A	0.87	7.09	0.54	8.89e-11	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
TGCT	cis	rs11785400	0.793	rs11785012	chr8:143748355	G/A	cg24634471	chr8:143751801	JRK	0.55	5.38	0.44	3.52e-7	Schizophrenia;
TGCT	cis	rs7193541	0.510	rs79473128	chr16:74589192	G/A	cg01733217	chr16:74700730	RFWD3	0.63	5.27	0.43	5.76e-7	Multiple myeloma;
TGCT	cis	rs7666738	0.544	rs35160902	chr4:98974690	A/T	cg18180107	chr4:99064573	C4orf37	0.55	5.0	0.41	1.89e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs12497850	0.931	rs6446196	chr3:49004723	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.42	-5.42	-0.44	2.97e-7	Parkinson's disease;
TGCT	cis	rs10984561	0.881	rs917709	chr9:122249535	C/T	cg14242995	chr9:122249943	NA	0.75	6.12	0.48	1.16e-8	Pulmonary function decline;
TGCT	cis	rs6547741	1.000	rs1080060	chr2:27768808	T/A	cg27432699	chr2:27873401	GPN1	0.18	4.66	0.39	8.09e-6	Oral cavity cancer;
TGCT	cis	rs10782582	0.593	rs11164042	chr1:76178440	G/A	cg03433033	chr1:76189801	ACADM	-0.65	-7.42	-0.55	1.59e-11	Daytime sleep phenotypes;
TGCT	cis	rs12220898	0.619	rs10735221	chr10:50483563	G/A	cg09603381	chr10:49954066	WDFY4	0.38	4.45	0.37	1.88e-5	Inflammatory biomarkers;
TGCT	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg03806693	chr22:41940476	POLR3H	1.15	11.99	0.73	1.85e-22	Vitiligo;
TGCT	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg11235426	chr6:292522	DUSP22	-0.65	-6.78	-0.52	4.32e-10	Menopause (age at onset);
TGCT	cis	rs4478858	0.684	rs10798839	chr1:31731758	C/G	cg00250761	chr1:31883323	NA	-0.25	-4.52	-0.38	1.45e-5	Alcohol dependence;
TGCT	cis	rs3829109	0.502	rs4320648	chr9:139294271	G/A	cg13741927	chr9:139327495	INPP5E	-0.24	-5.18	-0.42	8.84e-7	Peak insulin response;Acute insulin response;
TGCT	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg12310025	chr6:25882481	NA	-0.65	-5.82	-0.46	4.61e-8	Intelligence (multi-trait analysis);
TGCT	cis	rs600231	0.708	rs2957269	chr11:65243007	C/G	cg17120908	chr11:65337727	SSSCA1	-0.55	-5.14	-0.42	1.03e-6	Bone mineral density;
TGCT	cis	rs78487399	0.908	rs74501107	chr2:43806012	A/C	cg04879876	chr2:43453558	ZFP36L2;LOC100129726	0.66	4.67	0.39	7.66e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg21963583	chr11:68658836	MRPL21	0.33	5.38	0.43	3.59e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
TGCT	cis	rs78487399	0.808	rs6752448	chr2:43682596	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.24	-0.43	6.79e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
TGCT	cis	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg18188782	chr20:61659543	NA	0.47	5.67	0.45	9.65e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs2832191	0.692	rs2245517	chr21:30357968	C/T	cg08807101	chr21:30365312	RNF160	0.64	5.92	0.47	3e-8	Dental caries;
TGCT	cis	rs12477438	0.798	rs4324365	chr2:99623845	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-5.87	-0.47	3.74e-8	Chronic sinus infection;
TGCT	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg06873352	chr17:61820015	STRADA	-0.48	-5.49	-0.44	2.15e-7	Prudent dietary pattern;
TGCT	cis	rs477895	0.713	rs11600867	chr11:63972052	T/A	cg23719950	chr11:63933701	MACROD1	-0.7	-5.71	-0.46	7.81e-8	Mean platelet volume;
TGCT	cis	rs76935404	0.899	rs73034465	chr19:41419075	A/G	cg19493303	chr19:41414353	NA	0.42	5.11	0.42	1.17e-6	nicotine metabolite ratio in current smokers;
TGCT	cis	rs9948	0.521	rs62156206	chr2:97357108	G/A	cg01990225	chr2:97406019	LMAN2L	-1.01	-5.14	-0.42	1.04e-6	Erectile dysfunction and prostate cancer treatment;
TGCT	cis	rs2070488	0.861	rs2067082	chr3:38438182	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	9.65	0.65	8.88e-17	Electrocardiographic conduction measures;
TGCT	cis	rs7582180	0.764	rs920269	chr2:100918363	G/A	cg08017756	chr2:100939284	LONRF2	-0.32	-5.31	-0.43	4.89e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs7552404	1.000	rs11163924	chr1:76132070	A/C	cg10523679	chr1:76189770	ACADM	-0.92	-10.45	-0.68	1.04e-18	Blood metabolite levels;Acylcarnitine levels;
TGCT	cis	rs6424115	0.862	rs34845821	chr1:24066486	C/T	cg15997130	chr1:24165203	NA	-0.66	-6.1	-0.48	1.24e-8	Immature fraction of reticulocytes;
TGCT	cis	rs9549367	0.713	rs4907599	chr13:113861441	C/T	cg09473364	chr13:112927190	NA	0.29	4.54	0.38	1.31e-5	Platelet distribution width;
TGCT	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg05368731	chr17:41323189	NBR1	1.22	14.73	0.8	5.05e-29	Menopause (age at onset);
TGCT	cis	rs12579753	0.913	rs7965664	chr12:82237340	G/T	cg07988820	chr12:82153109	PPFIA2	-0.58	-6.25	-0.49	6.15e-9	Resting heart rate;
TGCT	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg04287289	chr16:89883240	FANCA	0.92	11.34	0.71	6.88e-21	Vitiligo;
TGCT	cis	rs12367572	0.965	rs10785539	chr12:45233023	G/C	cg04608330	chr12:45269318	NELL2	-0.53	-5.17	-0.42	9.2e-7	Gut microbiome composition (summer);
TGCT	cis	rs73058052	1.000	rs3760707	chr19:50084454	T/C	cg09250473	chr19:50168907	IRF3;BCL2L12	0.84	6.33	0.49	4.16e-9	Fibrinogen levels;
TGCT	cis	rs9926296	0.656	rs11861084	chr16:89875710	G/T	cg03388025	chr16:89894329	SPIRE2	-0.37	-5.43	-0.44	2.79e-7	Vitiligo;
TGCT	cis	rs1062177	1.000	rs12518722	chr5:151231460	A/G	cg12924095	chr5:151150029	G3BP1	0.35	5.05	0.41	1.53e-6	Preschool internalizing problems;
TGCT	cis	rs11190604	0.790	rs11190535	chr10:102197441	A/T	cg16005271	chr10:102321736	NA	0.46	4.68	0.39	7.39e-6	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs4845570	1.000	rs1054479	chr1:151746079	A/T	cg07092448	chr1:151763213	TDRKH	-1.12	-8.18	-0.59	2.84e-13	Coronary artery disease;
TGCT	cis	rs11190604	0.767	rs12360395	chr10:102194074	A/T	cg16342193	chr10:102329863	NA	-0.41	-5.2	-0.42	8.01e-7	Palmitoleic acid (16:1n-7) levels;
TGCT	cis	rs807669	1.000	rs807669	chr22:19154522	T/C	cg02655711	chr22:19163373	SLC25A1	0.39	9.14	0.63	1.53e-15	Metabolite levels;
TGCT	cis	rs28595532	0.920	rs56124677	chr4:119772213	C/T	cg14228332	chr4:119757509	SEC24D	1.23	7.05	0.53	1.13e-10	Cannabis dependence symptom count;
TGCT	cis	rs523522	0.962	rs9040	chr12:120900274	C/T	cg12219531	chr12:120966889	COQ5	0.82	7.34	0.55	2.49e-11	High light scatter reticulocyte count;
TGCT	cis	rs12142240	0.698	rs66575205	chr1:46814092	T/G	cg14993813	chr1:46806288	NSUN4	-0.58	-4.76	-0.39	5.3e-6	Menopause (age at onset);
TGCT	cis	rs6570726	0.764	rs4896821	chr6:145896181	G/A	cg23711669	chr6:146136114	FBXO30	0.84	8.89	0.62	6.14e-15	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg00814883	chr7:100076585	TSC22D4	-0.9	-9.56	-0.65	1.5e-16	Platelet count;
TGCT	cis	rs9911578	0.900	rs717828	chr17:56535932	A/G	cg05425664	chr17:57184151	TRIM37	-0.63	-6.21	-0.49	7.48e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs36051895	0.732	rs7046736	chr9:5015732	C/A	cg02405213	chr9:5042618	JAK2	-0.74	-9.93	-0.67	1.9e-17	Pediatric autoimmune diseases;
TGCT	cis	rs2456568	0.548	rs7113080	chr11:93657520	G/A	cg17595323	chr11:93583763	C11orf90	-0.43	-5.54	-0.45	1.7e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7085104	0.632	rs7096475	chr10:104609676	A/G	cg04362960	chr10:104952993	NT5C2	0.55	4.73	0.39	5.98e-6	Immature fraction of reticulocytes;Schizophrenia;
TGCT	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg00343986	chr7:65444356	GUSB	0.24	5.25	0.43	6.3e-7	Aortic root size;
TGCT	trans	rs17471911	0.708	rs7919499	chr10:100793754	G/A	cg03484267	chr2:207988651	KLF7	-0.52	-6.7	-0.52	6.49e-10	Neuroticism;
TGCT	cis	rs6598955	0.671	rs17163751	chr1:26568698	A/G	cg04990556	chr1:26633338	UBXN11	0.64	5.11	0.42	1.19e-6	Obesity-related traits;
TGCT	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg06481639	chr22:41940642	POLR3H	-0.76	-6.97	-0.53	1.65e-10	Vitiligo;
TGCT	cis	rs9902453	0.833	rs7216631	chr17:28495112	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	6.9	0.53	2.37e-10	Coffee consumption (cups per day);
TGCT	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg11644478	chr21:40555479	PSMG1	1.01	10.47	0.69	8.99e-19	Cognitive function;
TGCT	cis	rs4722404	0.800	rs7809262	chr7:3141137	A/G	cg17467898	chr7:2289054	NUDT1	0.18	4.71	0.39	6.48e-6	Atopic dermatitis;
TGCT	cis	rs2241685	1.000	rs2241685	chr2:1925993	C/T	cg21862353	chr2:1801628	MYT1L	-0.51	-5.15	-0.42	9.86e-7	Attention deficit hyperactivity disorder;
TGCT	cis	rs909674	0.818	rs5750830	chr22:39840828	C/A	cg24399712	chr22:39784796	NA	-1.04	-10.92	-0.7	7.31e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	cis	rs422249	0.512	rs174561	chr11:61582708	T/C	cg19610905	chr11:61596333	FADS2	-1.05	-11.51	-0.72	2.6e-21	Trans fatty acid levels;
TGCT	cis	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg07424592	chr7:64974309	NA	1.33	7.68	0.57	4.1e-12	Diabetic kidney disease;
TGCT	cis	rs763121	0.853	rs11704021	chr22:39074716	G/A	cg06022373	chr22:39101656	GTPBP1	0.76	7.43	0.56	1.52e-11	Menopause (age at onset);
TGCT	cis	rs67311347	1.000	rs6762251	chr3:40531136	A/G	cg13683864	chr3:40499215	RPL14	1.12	11.68	0.72	1.05e-21	Renal cell carcinoma;
TGCT	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg06618935	chr21:46677482	NA	0.33	4.6	0.38	1.04e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
TGCT	cis	rs910316	0.663	rs175034	chr14:75463687	T/G	cg08847533	chr14:75593920	NEK9	-0.84	-8.91	-0.62	5.45e-15	Height;
TGCT	cis	rs854765	0.964	rs854813	chr17:18003845	C/T	cg09796270	chr17:17721594	SREBF1	-0.26	-5.22	-0.42	7.3e-7	Total body bone mineral density;
TGCT	cis	rs9902453	0.791	rs3115100	chr17:28045744	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.84	8.39	0.6	9.14e-14	Coffee consumption (cups per day);
TGCT	cis	rs9399135	0.967	rs6919862	chr6:135352443	C/A	cg24558204	chr6:135376177	HBS1L	0.48	4.77	0.39	5.14e-6	Red blood cell count;
TGCT	cis	rs9549367	0.789	rs2287244	chr13:113887173	C/G	cg18105134	chr13:113819100	PROZ	0.34	5.69	0.45	8.84e-8	Platelet distribution width;
TGCT	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg25703541	chr22:24373054	LOC391322	0.82	6.92	0.53	2.13e-10	Urinary 1,3-butadiene metabolite levels in smokers;
TGCT	cis	rs12681288	0.862	rs11996703	chr8:1009093	T/C	cg04851639	chr8:1020857	NA	-0.36	-6.29	-0.49	4.97e-9	Schizophrenia;
TGCT	cis	rs9457247	0.534	rs7750593	chr6:167387359	C/G	cg23791538	chr6:167370224	RNASET2	0.63	6.24	0.49	6.21e-9	Crohn's disease;
TGCT	cis	rs35264875	0.851	rs7933746	chr11:68867722	A/G	cg02660097	chr11:68866761	NA	0.3	4.71	0.39	6.5e-6	Blond vs. brown hair color;
TGCT	cis	rs492146	0.765	rs423475	chr6:52844583	G/T	cg06706454	chr6:52930286	FBXO9	-0.51	-4.66	-0.39	8.12e-6	Epilepsy (remission after treatment);
TGCT	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg21724239	chr8:58056113	NA	0.39	5.19	0.42	8.42e-7	Developmental language disorder (linguistic errors);
TGCT	cis	rs2439831	0.867	rs486301	chr15:43836949	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.84	5.73	0.46	7.33e-8	Lung cancer in ever smokers;
TGCT	cis	rs12989701	0.877	rs12994718	chr2:127874226	T/A	cg08168897	chr2:127865431	BIN1	0.5	5.34	0.43	4.28e-7	Alzheimer's disease (late onset);
TGCT	cis	rs7267979	1.000	rs7019	chr20:25278278	C/T	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs6866344	0.570	rs11740283	chr5:178136440	T/C	cg03877680	chr5:178157825	ZNF354A	0.76	6.54	0.51	1.47e-9	Neutrophil percentage of white cells;
TGCT	cis	rs2032447	0.641	rs442601	chr6:25934524	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.79	7.56	0.56	7.67e-12	Intelligence (multi-trait analysis);
TGCT	cis	rs4654899	0.865	rs61779075	chr1:21417027	T/C	cg01072550	chr1:21505969	NA	-0.47	-7.1	-0.54	8.54e-11	Superior frontal gyrus grey matter volume;
TGCT	cis	rs12220238	1.000	rs11000941	chr10:76018301	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.9	6.53	0.51	1.51e-9	Soluble interleukin-2 receptor subunit alpha;
TGCT	trans	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg13615516	chr5:77269221	NA	0.67	8.3	0.6	1.47e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs4824093	0.610	rs73443923	chr22:50285348	C/T	cg26441486	chr22:50317300	CRELD2	0.41	4.78	0.39	4.81e-6	Amyotrophic lateral sclerosis (sporadic);
TGCT	cis	rs806215	0.526	rs3757780	chr7:127435520	T/G	cg11539674	chr7:127291444	SND1	-0.36	-4.6	-0.38	1.02e-5	Type 2 diabetes;
TGCT	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg03934478	chr11:495069	RNH1	0.35	5.89	0.47	3.34e-8	Body mass index;
TGCT	cis	rs10875746	0.624	rs10875777	chr12:48622071	T/C	cg20731937	chr12:48336164	NA	0.59	4.52	0.38	1.45e-5	Longevity (90 years and older);
TGCT	cis	rs17376456	0.877	rs28637444	chr5:93495548	C/T	cg25358565	chr5:93447407	FAM172A	0.97	8.32	0.6	1.34e-13	Diabetic retinopathy;
TGCT	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg04267008	chr7:1944627	MAD1L1	0.35	4.79	0.4	4.63e-6	Bipolar disorder and schizophrenia;
TGCT	cis	rs17376456	0.825	rs7715562	chr5:93222034	C/T	cg25358565	chr5:93447407	FAM172A	-0.96	-8.07	-0.59	5.23e-13	Diabetic retinopathy;
TGCT	cis	rs9341808	0.718	rs7740627	chr6:80916347	A/G	cg08355045	chr6:80787529	NA	0.32	5.6	0.45	1.29e-7	Sitting height ratio;
TGCT	cis	rs853679	0.550	rs1225598	chr6:28160799	T/G	cg12963246	chr6:28129442	ZNF389	0.48	4.74	0.39	5.69e-6	Depression;
TGCT	cis	rs478304	0.514	rs75601653	chr11:65483370	C/G	cg27068330	chr11:65405492	SIPA1	-0.98	-9.26	-0.64	7.7e-16	Acne (severe);
TGCT	cis	rs950169	0.580	rs17598114	chr15:85171317	C/T	cg11189052	chr15:85197271	WDR73	0.73	6.1	0.48	1.27e-8	Schizophrenia;
TGCT	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg11890956	chr21:40555474	PSMG1	1.1	12.28	0.74	3.66e-23	Cognitive function;
TGCT	cis	rs1127311	0.905	rs6699729	chr1:154582896	A/T	cg17218026	chr1:154582156	ADAR	0.31	7.7	0.57	3.72e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
TGCT	cis	rs853679	0.546	rs34295134	chr6:27828151	T/A	cg01031101	chr6:28227091	NKAPL	-0.49	-4.66	-0.39	8.09e-6	Depression;
TGCT	trans	rs4332037	0.539	rs3823624	chr7:2110346	T/C	cg25206134	chr2:45395956	NA	0.94	6.93	0.53	2e-10	Bipolar disorder;
TGCT	cis	rs7769051	0.808	rs1467404	chr6:133090141	A/G	cg07930552	chr6:133119739	C6orf192	-0.96	-5.15	-0.42	1.01e-6	Type 2 diabetes nephropathy;
TGCT	cis	rs17076896	0.786	rs117391778	chr13:19931050	C/T	cg00777926	chr13:20807375	GJB6	-0.37	-4.51	-0.38	1.5e-5	Coronary artery aneurysm in Kawasaki disease;
TGCT	cis	rs9517320	0.534	rs61969451	chr13:99167654	A/T	cg07423050	chr13:99094983	FARP1	-0.28	-5.67	-0.45	9.67e-8	Longevity;
TGCT	cis	rs17122693	1.000	rs17122693	chr14:51084235	C/T	cg04730355	chr14:51134070	SAV1	-1.14	-8.9	-0.62	5.62e-15	Cognitive performance;
TGCT	cis	rs9486719	0.894	rs34826652	chr6:96899085	A/G	cg06623918	chr6:96969491	KIAA0776	-1.01	-8.86	-0.62	7.18e-15	Migraine;Coronary artery disease;
TGCT	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg01416388	chr22:39784598	NA	-0.72	-6.98	-0.53	1.61e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs7666738	0.830	rs9998582	chr4:98938949	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg20203395	chr5:56204925	C5orf35	-0.58	-4.87	-0.4	3.34e-6	Initial pursuit acceleration;
TGCT	cis	rs2730260	0.537	rs73169248	chr7:158891742	T/G	cg27122614	chr7:157913741	PTPRN2	0.42	4.47	0.37	1.74e-5	Myopia (pathological);
TGCT	cis	rs546131	0.928	rs483976	chr11:34840167	C/G	cg11058730	chr11:34937778	PDHX;APIP	0.51	4.57	0.38	1.18e-5	Lung disease severity in cystic fibrosis;
TGCT	cis	rs7208859	0.673	rs11658344	chr17:29207745	G/T	cg18442181	chr17:29233375	C17orf42	-0.79	-4.78	-0.39	4.95e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg07167872	chr1:205819463	PM20D1	0.59	7.65	0.57	4.74e-12	Menarche (age at onset);
TGCT	cis	rs57590327	0.555	rs13072957	chr3:81776242	A/G	cg07356753	chr3:81810745	GBE1	0.77	7.2	0.54	5.1e-11	Extraversion;
TGCT	cis	rs7726839	0.540	rs3792720	chr5:643028	T/G	cg20362242	chr5:692897	TPPP	0.5	4.57	0.38	1.17e-5	Obesity-related traits;
TGCT	cis	rs4711350	0.906	rs3957165	chr6:33784864	A/G	cg18005901	chr6:33739558	LEMD2	0.59	6.08	0.48	1.37e-8	Schizophrenia;
TGCT	cis	rs12681287	0.752	rs10435563	chr8:87266060	C/T	cg27223183	chr8:87520930	FAM82B	-0.81	-5.66	-0.45	9.9e-8	Caudate activity during reward;
TGCT	cis	rs10464366	0.746	rs62442210	chr7:39146328	G/T	cg18850127	chr7:39170497	POU6F2	0.3	6.61	0.51	1e-9	IgG glycosylation;
TGCT	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg01416388	chr22:39784598	NA	-0.61	-6.37	-0.5	3.28e-9	Intelligence (multi-trait analysis);
TGCT	cis	rs617219	0.726	rs1275105	chr5:78444148	T/C	cg09550809	chr5:78407562	BHMT	0.39	5.4	0.44	3.29e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs748404	0.604	rs2278857	chr15:43632549	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.46	4.44	0.37	1.98e-5	Lung cancer;
TGCT	cis	rs7267979	0.586	rs6083776	chr20:25186116	G/A	cg16686733	chr20:25566563	NINL	0.53	5.41	0.44	3.06e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs7647973	0.922	rs6809851	chr3:49309787	C/A	cg07636037	chr3:49044803	WDR6	0.68	5.46	0.44	2.45e-7	Menarche (age at onset);
TGCT	cis	rs1990950	0.605	rs7715241	chr5:156880770	G/A	cg25387487	chr5:157003181	ADAM19	0.39	5.97	0.47	2.36e-8	Lung function (FEV1/FVC);
TGCT	cis	rs2153535	0.580	rs2327064	chr6:8454052	C/T	cg23788917	chr6:8435910	SLC35B3	0.6	5.52	0.44	1.88e-7	Motion sickness;
TGCT	cis	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg22857025	chr5:266934	NA	-0.34	-6.7	-0.52	6.65e-10	Breast cancer;
TGCT	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.56	-5.61	-0.45	1.24e-7	Intelligence (multi-trait analysis);
TGCT	cis	rs1403694	0.695	rs1836860	chr3:186436604	C/T	cg12454167	chr3:186435060	KNG1	-0.52	-8.92	-0.63	5.02e-15	Blood protein levels;
TGCT	cis	rs514475	0.526	rs17066649	chr6:137952694	T/C	cg02673417	chr6:137105249	MAP3K5	0.29	4.45	0.37	1.88e-5	Inflammatory skin disease;
TGCT	cis	rs62064224	0.546	rs62065495	chr17:30834617	T/C	cg18200150	chr17:30822561	MYO1D	0.5	6.56	0.51	1.31e-9	Schizophrenia;
TGCT	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg02380750	chr20:61661411	NA	0.33	5.84	0.46	4.23e-8	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs13408808	0.606	rs7589079	chr2:168583144	C/T	cg25427580	chr2:168675357	B3GALT1	0.39	4.71	0.39	6.58e-6	Obesity-related traits;
TGCT	cis	rs3733631	1.000	rs28878597	chr4:104591916	A/G	cg24090629	chr4:104641072	TACR3	-0.73	-5.72	-0.46	7.65e-8	Menarche (age at onset);
TGCT	cis	rs7267979	1.000	rs2258066	chr20:25271326	C/T	cg16686733	chr20:25566563	NINL	0.59	5.99	0.47	2.13e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg06238570	chr21:40685208	BRWD1	0.58	5.11	0.42	1.16e-6	Cognitive function;
TGCT	cis	rs11030122	0.673	rs4910869	chr11:4006438	C/T	cg18678763	chr11:4115507	RRM1	-0.48	-5.88	-0.47	3.54e-8	Mean platelet volume;Platelet distribution width;
TGCT	cis	rs546131	0.963	rs539044	chr11:34841542	G/T	cg06937548	chr11:34938143	PDHX;APIP	0.58	5.24	0.43	6.72e-7	Lung disease severity in cystic fibrosis;
TGCT	cis	rs10507380	0.824	rs75866904	chr13:27921765	C/T	cg25543773	chr13:27185723	WASF3	0.34	4.83	0.4	3.97e-6	Electrocardiographic traits;
TGCT	cis	rs9300255	0.739	rs1980252	chr12:123745178	C/G	cg00376283	chr12:123451042	ABCB9	0.72	5.54	0.45	1.76e-7	Neutrophil percentage of white cells;
TGCT	cis	rs7904368	0.806	rs7087360	chr10:16872337	C/A	cg14835575	chr10:16859367	RSU1	0.66	6.35	0.5	3.62e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
TGCT	cis	rs8032315	0.895	rs4932370	chr15:91404705	A/G	cg06330618	chr15:91428456	FES	-0.18	-4.6	-0.38	1.02e-5	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs2880765	0.835	rs7169429	chr15:86036648	C/T	cg13263323	chr15:86062960	AKAP13	-0.22	-4.73	-0.39	5.93e-6	Coronary artery disease;
TGCT	cis	rs2070488	0.775	rs961179	chr3:38509618	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.78	7.9	0.58	1.26e-12	Electrocardiographic conduction measures;
TGCT	cis	rs3733585	0.673	rs6449156	chr4:9956712	G/C	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.72	-0.52	5.85e-10	Cleft plate (environmental tobacco smoke interaction);
TGCT	cis	rs941873	0.805	rs10824747	chr10:81118464	T/C	cg09469691	chr10:81107165	PPIF	0.5	4.96	0.41	2.27e-6	Height;
TGCT	cis	rs7666738	0.830	rs1869897	chr4:98730997	C/T	cg17366294	chr4:99064904	C4orf37	0.65	6.78	0.52	4.31e-10	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11673344	0.562	rs6510580	chr19:37529354	C/T	cg08039142	chr19:36980659	ZNF566	0.5	4.65	0.39	8.42e-6	Obesity-related traits;
TGCT	cis	rs9467773	1.000	rs9467791	chr6:26562486	A/G	cg05738196	chr6:26577821	NA	-0.89	-12.76	-0.75	2.46e-24	Intelligence (multi-trait analysis);
TGCT	cis	rs61884328	0.733	rs78998999	chr11:47228403	A/T	cg13308137	chr11:47528955	CUGBP1	0.38	4.56	0.38	1.23e-5	Total body bone mineral density (age over 60);
TGCT	cis	rs7819412	0.635	rs4841501	chr8:11000976	T/C	cg03192020	chr8:11204681	TDH	-0.51	-4.45	-0.37	1.88e-5	Triglycerides;
TGCT	cis	rs9300255	0.602	rs1106241	chr12:123627016	T/C	cg00376283	chr12:123451042	ABCB9	0.71	5.54	0.45	1.7e-7	Neutrophil percentage of white cells;
TGCT	cis	rs2486288	0.656	rs11629807	chr15:45547037	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.46	-5.59	-0.45	1.38e-7	Glomerular filtration rate;
TGCT	cis	rs7666738	0.791	rs34152299	chr4:98929862	G/C	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs11676348	0.846	rs7607437	chr2:219008392	A/G	cg00012203	chr2:219082015	ARPC2	-0.51	-4.8	-0.4	4.48e-6	Ulcerative colitis;
TGCT	cis	rs6921919	0.583	rs7764737	chr6:28354615	A/T	cg18815343	chr6:28367644	ZSCAN12	-0.56	-5.32	-0.43	4.76e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs6088580	0.634	rs13041646	chr20:33082881	T/A	cg06115741	chr20:33292138	TP53INP2	0.53	4.63	0.38	8.95e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs6490294	0.904	rs11066111	chr12:112415179	A/T	cg10833066	chr12:111807467	FAM109A	0.35	5.13	0.42	1.09e-6	Mean platelet volume;
TGCT	cis	rs7246657	1.000	rs34544865	chr19:37801242	G/C	cg18154014	chr19:37997991	ZNF793	0.94	6.41	0.5	2.74e-9	Coronary artery calcification;
TGCT	cis	rs2932538	0.922	rs12138335	chr1:113122760	T/C	cg22162597	chr1:113214053	CAPZA1	0.28	5.83	0.46	4.4e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
TGCT	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg13206674	chr6:150067644	NUP43	0.52	4.51	0.38	1.5e-5	Lung cancer;
TGCT	cis	rs1008375	0.932	rs11934968	chr4:17667766	A/G	cg18681998	chr4:17616180	MED28	0.88	8.84	0.62	7.88e-15	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs9858542	0.953	rs7623659	chr3:49414791	C/T	cg03060546	chr3:49711283	APEH	-0.64	-5.61	-0.45	1.27e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
TGCT	cis	rs2012796	0.785	rs61986599	chr14:81860917	G/A	cg02996355	chr14:81879375	NA	0.56	5.52	0.44	1.92e-7	Night sleep phenotypes;
TGCT	cis	rs6840360	0.571	rs718800	chr4:152549307	A/T	cg17479576	chr4:152424074	FAM160A1	0.67	6.71	0.52	6.18e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs3803170	0.513	rs4766574	chr12:111832372	C/T	cg10833066	chr12:111807467	FAM109A	0.35	5.1	0.42	1.23e-6	Mean corpuscular hemoglobin;
TGCT	cis	rs3096299	0.933	rs2965824	chr16:89455306	A/G	cg02187348	chr16:89574699	SPG7	0.49	4.66	0.39	7.93e-6	Multiple myeloma (IgH translocation);
TGCT	cis	rs611744	0.967	rs628340	chr8:109189425	A/G	cg21045802	chr8:109455806	TTC35	0.5	4.55	0.38	1.27e-5	Dupuytren's disease;
TGCT	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.47	-6.63	-0.51	9.04e-10	Alzheimer's disease;
TGCT	cis	rs4689388	0.926	rs11725500	chr4:6293919	C/G	cg00701064	chr4:6280414	WFS1	0.37	4.72	0.39	6.3e-6	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs11122272	0.735	rs2749711	chr1:231537543	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-6.48	-0.5	1.93e-9	Hemoglobin concentration;
TGCT	cis	rs6504663	0.525	rs557	chr17:48563234	C/T	cg03168497	chr17:48586147	MYCBPAP	0.47	4.94	0.41	2.47e-6	Visceral fat;
TGCT	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg23982607	chr1:1823379	GNB1	0.4	5.13	0.42	1.08e-6	Body mass index;
TGCT	trans	rs564343	0.563	rs1642958	chr11:65821973	G/C	cg26701943	chr11:108369231	KDELC2	-0.74	-6.9	-0.53	2.34e-10	Obesity (early onset extreme);
TGCT	cis	rs28595532	0.841	rs115233595	chr4:119744214	T/C	cg14228332	chr4:119757509	SEC24D	1.28	6.68	0.51	7.23e-10	Cannabis dependence symptom count;
TGCT	cis	rs644799	0.710	rs12273579	chr11:95524421	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.79	8.65	0.61	2.18e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs11098499	0.954	rs1022145	chr4:120230979	A/G	cg09307838	chr4:120376055	NA	0.64	5.93	0.47	2.79e-8	Corneal astigmatism;
TGCT	cis	rs28595532	0.920	rs115372254	chr4:119771735	T/C	cg21605333	chr4:119757512	SEC24D	1.51	8.99	0.63	3.38e-15	Cannabis dependence symptom count;
TGCT	cis	rs7191439	0.858	rs2340973	chr16:88773396	G/A	cg27087555	chr16:88793112	FAM38A	-0.64	-7.52	-0.56	9.35e-12	Plateletcrit;
TGCT	cis	rs4886920	0.563	rs4511491	chr15:78079304	A/G	cg03457338	chr15:78040120	NA	0.18	4.51	0.38	1.48e-5	Neuroticism;
TGCT	cis	rs6921919	0.583	rs3800328	chr6:28390843	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.53	-5.16	-0.42	9.45e-7	Autism spectrum disorder or schizophrenia;
TGCT	cis	rs9811920	0.555	rs68092024	chr3:99691522	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.58	6.76	0.52	4.85e-10	Axial length;
TGCT	cis	rs250677	0.687	rs250672	chr5:148446110	A/G	cg18129178	chr5:148520854	ABLIM3	-0.43	-6.29	-0.49	5.05e-9	Breast cancer;
TGCT	cis	rs8017423	0.935	rs3737035	chr14:90745422	T/C	cg04374321	chr14:90722782	PSMC1	-0.74	-7.09	-0.54	9.2e-11	Mortality in heart failure;
TGCT	cis	rs2933343	0.951	rs1055128	chr3:128591048	C/T	cg11901034	chr3:128598214	ACAD9	-0.64	-5.05	-0.41	1.56e-6	IgG glycosylation;
TGCT	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg07507251	chr3:52567010	NT5DC2	0.47	6.63	0.51	9.08e-10	Electroencephalogram traits;
TGCT	cis	rs67478160	0.619	rs1040813	chr14:104306696	T/C	cg26031613	chr14:104095156	KLC1	-0.63	-6.53	-0.51	1.56e-9	Schizophrenia;
TGCT	cis	rs10832963	0.686	rs11024743	chr11:18653712	A/G	cg20219074	chr11:18656078	SPTY2D1	0.98	9.9	0.66	2.19e-17	Breast cancer;
TGCT	cis	rs10838634	1.000	rs61897304	chr11:46809210	A/G	cg18332754	chr11:46939436	LRP4	0.89	4.45	0.37	1.85e-5	Schizophrenia;
TGCT	cis	rs17253792	0.822	rs79807559	chr14:56108117	G/A	cg01858014	chr14:56050164	KTN1	-0.35	-4.5	-0.37	1.53e-5	Putamen volume;
TGCT	cis	rs4886920	0.563	rs55726435	chr15:78071083	C/T	cg25212270	chr15:78015279	NA	-0.23	-4.75	-0.39	5.63e-6	Neuroticism;
TGCT	cis	rs7917772	0.503	rs11191347	chr10:104351617	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.8	8.21	0.59	2.44e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs924607	0.966	rs1709554	chr5:637443	A/G	cg18765565	chr5:669397	TPPP	0.58	6.07	0.48	1.45e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
TGCT	cis	rs3796352	1.000	rs34244302	chr3:53102236	C/G	cg27565382	chr3:53032988	SFMBT1	0.45	4.76	0.39	5.25e-6	Immune reponse to smallpox (secreted IL-2);
TGCT	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg08280861	chr8:58055591	NA	0.36	4.96	0.41	2.23e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs12681288	0.823	rs2701907	chr8:1003292	A/G	cg04851639	chr8:1020857	NA	-0.35	-6.22	-0.49	7.08e-9	Schizophrenia;
TGCT	cis	rs7474896	0.583	rs11011341	chr10:37998500	G/A	cg25427524	chr10:38739819	LOC399744	-0.31	-4.89	-0.4	3.01e-6	Obesity (extreme);
TGCT	cis	rs7246657	0.722	rs35863684	chr19:38109777	C/T	cg18154014	chr19:37997991	ZNF793	0.68	4.6	0.38	1.03e-5	Coronary artery calcification;
TGCT	cis	rs4819852	1.000	rs7285377	chr22:19987202	G/T	cg07821417	chr22:19972146	ARVCF	0.2	5.14	0.42	1.04e-6	Pulse pressure;
TGCT	cis	rs9325144	0.647	rs1386018	chr12:39104360	C/T	cg10518543	chr12:38710700	ALG10B	-0.49	-4.55	-0.38	1.25e-5	Morning vs. evening chronotype;
TGCT	cis	rs9952991	0.566	rs487273	chr18:12853458	T/G	cg23598886	chr18:12777645	NA	0.57	5.05	0.41	1.51e-6	Inflammatory skin disease;
TGCT	cis	rs7267979	1.000	rs6083805	chr20:25317356	T/C	cg03522245	chr20:25566470	NINL	-0.63	-6.8	-0.52	3.92e-10	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs8077889	0.703	rs231534	chr17:41945564	C/T	cg26893861	chr17:41843967	DUSP3	-1.09	-10.35	-0.68	1.81e-18	Triglycerides;
TGCT	cis	rs6750047	0.719	rs336035	chr2:38261467	A/G	cg07380506	chr2:38303506	CYP1B1	-0.55	-4.87	-0.4	3.32e-6	Cutaneous malignant melanoma;Melanoma;
TGCT	cis	rs17767294	0.614	rs78521938	chr6:28279823	G/A	cg08851530	chr6:28072375	NA	1.54	6.89	0.53	2.51e-10	Parkinson's disease;
TGCT	cis	rs28735056	0.875	rs62103176	chr18:77623611	G/C	cg20368463	chr18:77673604	PQLC1	0.39	4.76	0.39	5.21e-6	Schizophrenia;
TGCT	cis	rs1903068	1.000	rs9312658	chr4:56005526	C/A	cg09978860	chr4:56023921	NA	0.59	6.73	0.52	5.59e-10	Endometriosis;
TGCT	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg06636001	chr8:8085503	FLJ10661	0.78	7.25	0.55	3.94e-11	Systolic blood pressure;
TGCT	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg25767906	chr1:53392781	SCP2	0.48	5.55	0.45	1.62e-7	Monocyte count;
TGCT	cis	rs6545883	0.831	rs1186704	chr2:61672991	A/G	cg15711740	chr2:61764176	XPO1	-0.56	-5.06	-0.41	1.5e-6	Tuberculosis;
TGCT	cis	rs7104764	1.000	rs7483951	chr11:231758	G/A	cg18336825	chr11:236787	PSMD13;SIRT3	1.07	11.15	0.71	2.05e-20	Menarche (age at onset);
TGCT	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	5.32	0.43	4.73e-7	Bipolar disorder;
TGCT	cis	rs4595586	0.545	rs7952765	chr12:39375325	C/G	cg10518543	chr12:38710700	ALG10B	0.54	4.44	0.37	1.93e-5	Morning vs. evening chronotype;
TGCT	cis	rs860295	0.557	rs915181	chr1:155914772	C/T	cg13795986	chr1:155880507	RIT1	0.36	4.45	0.37	1.87e-5	Body mass index;
TGCT	cis	rs7727544	0.678	rs7735891	chr5:131597005	C/T	cg21474247	chr5:131268130	NA	0.3	4.44	0.37	1.94e-5	Blood metabolite levels;
TGCT	cis	rs2456568	0.695	rs908748	chr11:93690148	G/A	cg26875233	chr11:93583750	C11orf90	0.39	4.76	0.39	5.28e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs2832191	0.791	rs2832186	chr21:30484151	A/C	cg08807101	chr21:30365312	RNF160	-0.63	-6.01	-0.47	1.96e-8	Dental caries;
TGCT	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg08280861	chr8:58055591	NA	0.39	4.63	0.38	9.06e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs9796	0.576	rs13329511	chr15:41299121	T/C	cg26219294	chr15:41245916	CHAC1	0.38	4.64	0.38	8.63e-6	Menopause (age at onset);
TGCT	cis	rs4862307	0.808	rs6817858	chr4:185000321	G/A	cg06737308	chr4:185021514	ENPP6	-0.37	-5.39	-0.44	3.41e-7	Serum dimethylarginine levels (asymmetric/symetric ratio);
TGCT	cis	rs1580019	0.563	rs4723169	chr7:32567577	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.57	4.9	0.4	2.93e-6	Cognitive ability;
TGCT	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg23708337	chr7:1209742	NA	0.64	5.94	0.47	2.63e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
TGCT	cis	rs10984561	0.881	rs10491525	chr9:122256485	C/G	cg14242995	chr9:122249943	NA	0.74	6.01	0.47	1.96e-8	Pulmonary function decline;
TGCT	cis	rs36051895	0.695	rs10120763	chr9:5002911	C/G	cg02405213	chr9:5042618	JAK2	-0.76	-10.04	-0.67	1e-17	Pediatric autoimmune diseases;
TGCT	cis	rs968567	0.539	rs174560	chr11:61581764	T/C	cg01500311	chr11:61656094	FADS3	-0.29	-4.9	-0.4	2.92e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
TGCT	cis	rs2204008	0.774	rs11495520	chr12:38060605	T/G	cg26384229	chr12:38710491	ALG10B	0.86	7.77	0.57	2.55e-12	Bladder cancer;
TGCT	cis	rs4455778	0.538	rs7779474	chr7:49107537	A/G	cg26309511	chr7:48887640	NA	0.48	5.96	0.47	2.39e-8	Lung cancer in never smokers;
TGCT	cis	rs9486719	0.857	rs4486027	chr6:96911886	T/C	cg06623918	chr6:96969491	KIAA0776	-1.08	-10.73	-0.69	2.15e-19	Migraine;Coronary artery disease;
TGCT	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.53	-6.72	-0.52	6.02e-10	Longevity;Endometriosis;
TGCT	cis	rs34065801	0.632	rs1104539	chr13:36515298	C/T	cg03563146	chr13:37393157	RFXAP	-0.48	-4.47	-0.37	1.75e-5	Breast size;
TGCT	cis	rs2859741	0.967	rs575939	chr1:37513854	T/C	cg09363841	chr1:37513479	NA	-0.2	-4.64	-0.38	8.86e-6	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
TGCT	cis	rs7119038	0.818	rs17122453	chr11:118683564	G/A	cg19308663	chr11:118741387	NA	0.28	5.69	0.45	8.68e-8	Sjögren's syndrome;
TGCT	cis	rs6912958	0.559	rs2985039	chr6:88041757	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.7	7.16	0.54	6.1e-11	Monocyte percentage of white cells;
TGCT	trans	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg11887960	chr12:57824829	NA	1.12	9.19	0.64	1.16e-15	Obesity-related traits;
TGCT	cis	rs3812831	0.599	rs428637	chr13:114927139	T/G	cg06611532	chr13:114900021	NA	0.34	6.19	0.49	8.15e-9	Schizophrenia;
TGCT	trans	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg17470723	chr8:74884337	TCEB1	0.72	6.94	0.53	1.91e-10	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9902453	0.765	rs2169810	chr17:28167941	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.82	7.62	0.56	5.56e-12	Coffee consumption (cups per day);
TGCT	cis	rs617219	0.671	rs2591392	chr5:78546293	G/A	cg09550809	chr5:78407562	BHMT	0.39	5.37	0.43	3.71e-7	Betaine levels in individuals undergoing cardiac evaluation;
TGCT	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg10047753	chr17:41438598	NA	0.92	8.88	0.62	6.26e-15	Menopause (age at onset);
TGCT	cis	rs2197308	0.728	rs7304305	chr12:37932990	T/C	cg26384229	chr12:38710491	ALG10B	-0.7	-6.15	-0.48	9.71e-9	Morning vs. evening chronotype;
TGCT	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg08736216	chr1:53307985	ZYG11A	-0.29	-6.09	-0.48	1.32e-8	Monocyte count;
TGCT	cis	rs7267979	1.000	rs453329	chr20:25440593	G/A	cg14121845	chr20:25566513	NINL	0.5	5.44	0.44	2.79e-7	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9814567	1.000	rs9828815	chr3:134265749	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.95	-9.55	-0.65	1.56e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
TGCT	cis	rs13064411	0.696	rs7610638	chr3:113139656	A/G	cg18753928	chr3:113234510	CCDC52	-0.69	-5.23	-0.43	6.83e-7	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs17253792	0.749	rs79713967	chr14:56124186	T/C	cg01858014	chr14:56050164	KTN1	-0.35	-4.65	-0.39	8.23e-6	Putamen volume;
TGCT	cis	rs7178572	0.568	rs11857294	chr15:77596725	C/T	cg15453836	chr15:77711506	NA	-0.42	-4.79	-0.4	4.68e-6	Type 2 diabetes;
TGCT	cis	rs42648	0.596	rs194520	chr7:89854446	T/G	cg25739043	chr7:89950458	NA	-0.51	-4.85	-0.4	3.65e-6	Homocysteine levels;
TGCT	cis	rs6495122	0.699	rs1378940	chr15:75083494	C/A	cg10253484	chr15:75165896	SCAMP2	-0.68	-5.98	-0.47	2.2e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
TGCT	cis	rs1215050	0.818	rs6532703	chr4:98777486	A/T	cg17366294	chr4:99064904	C4orf37	0.48	4.83	0.4	3.94e-6	Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs9393692	0.905	rs7769028	chr6:26267568	C/T	cg13736514	chr6:26305472	NA	-0.39	-5.6	-0.45	1.31e-7	Educational attainment;
TGCT	cis	rs9487051	0.872	rs1111864	chr6:109611138	A/G	cg01475377	chr6:109611718	NA	-0.29	-4.56	-0.38	1.23e-5	Reticulocyte fraction of red cells;
TGCT	cis	rs752010	0.715	rs4083592	chr1:42099522	A/G	cg06885757	chr1:42089581	HIVEP3	0.28	4.91	0.4	2.79e-6	Lupus nephritis in systemic lupus erythematosus;
TGCT	cis	rs9291683	0.618	rs13137343	chr4:10043028	C/A	cg11266682	chr4:10021025	SLC2A9	0.64	8.75	0.62	1.29e-14	Bone mineral density;
TGCT	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg04546413	chr19:29218101	NA	0.84	6.82	0.52	3.52e-10	Methadone dose in opioid dependence;
TGCT	cis	rs459571	0.804	rs448918	chr9:136885979	G/A	cg14405625	chr9:136855902	VAV2	-0.3	-4.44	-0.37	1.97e-5	Platelet distribution width;
TGCT	cis	rs644799	1.000	rs566204	chr11:95580926	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	8.11	0.59	4.26e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs1008375	0.898	rs4698623	chr4:17594702	T/C	cg16339924	chr4:17578868	LAP3	0.8	6.52	0.51	1.61e-9	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs838147	0.507	rs692854	chr19:49209464	C/A	cg04599840	chr19:48886497	KDELR1	0.21	4.44	0.37	1.97e-5	Dietary macronutrient intake;
TGCT	cis	rs1570884	0.516	rs9316463	chr13:50176844	G/A	cg08779649	chr13:50194554	NA	0.37	5.84	0.46	4.24e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
TGCT	cis	rs12048904	0.964	rs17123467	chr1:101331760	G/A	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.5	4.54	0.38	1.31e-5	Multiple sclerosis;
TGCT	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg07507251	chr3:52567010	NT5DC2	0.47	6.7	0.52	6.47e-10	Bipolar disorder;
TGCT	cis	rs950776	0.616	rs56276142	chr15:78889795	T/C	cg06917634	chr15:78832804	PSMA4	0.65	5.3	0.43	5.01e-7	Sudden cardiac arrest;
TGCT	cis	rs4268898	0.722	rs7563958	chr2:24422381	C/A	cg02683114	chr2:24398427	C2orf84	0.19	4.62	0.38	9.4e-6	Asthma;
TGCT	cis	rs7975161	0.938	rs10400561	chr12:104640920	A/G	cg25273343	chr12:104657179	TXNRD1	-0.33	-5.07	-0.41	1.44e-6	Toenail selenium levels;
TGCT	cis	rs4253772	0.591	rs6008595	chr22:46703860	A/T	cg24881330	chr22:46731750	TRMU	1.04	5.41	0.44	3.12e-7	LDL cholesterol;Cholesterol, total;
TGCT	cis	rs10779751	0.770	rs7553827	chr1:11222393	C/T	cg08854313	chr1:11322531	MTOR	0.82	6.66	0.51	7.99e-10	Body mass index;
TGCT	cis	rs4819852	0.958	rs756653	chr22:19976845	G/A	cg07821417	chr22:19972146	ARVCF	0.19	4.79	0.4	4.7e-6	Pulse pressure;
TGCT	cis	rs10088262	0.629	rs7828192	chr8:124804669	C/T	cg02993010	chr8:124780839	FAM91A1	-0.63	-5.13	-0.42	1.08e-6	Pancreatic cancer;
TGCT	cis	rs12477438	0.684	rs6756880	chr2:99676991	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-4.62	-0.38	9.47e-6	Chronic sinus infection;
TGCT	cis	rs6089829	0.851	rs10854168	chr20:61669550	A/G	cg18188782	chr20:61659543	NA	0.44	4.88	0.4	3.17e-6	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9341808	0.727	rs9352809	chr6:80999316	C/T	cg08355045	chr6:80787529	NA	0.26	4.55	0.38	1.28e-5	Sitting height ratio;
TGCT	cis	rs433598	0.894	rs180149	chr16:20676969	G/A	cg08248577	chr16:19727447	IQCK;C16orf88	-0.22	-5.29	-0.43	5.36e-7	Schizophrenia;
TGCT	trans	rs10506458	1.000	rs17763435	chr12:63416511	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	0.47	7.48	0.56	1.18e-11	Hemostatic factors and hematological phenotypes;
TGCT	cis	rs7666738	0.546	rs9993299	chr4:98815976	G/A	cg05340658	chr4:99064831	C4orf37	0.53	5.82	0.46	4.71e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs2228479	0.717	rs9282682	chr16:89805794	A/G	cg27121462	chr16:89883253	FANCA	0.78	4.65	0.39	8.46e-6	Skin colour saturation;
TGCT	cis	rs1008375	1.000	rs4642241	chr4:17617111	T/C	cg18681998	chr4:17616180	MED28	0.99	11.48	0.72	3.18e-21	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs4499344	0.730	rs405858	chr19:33106621	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.77	-8.08	-0.59	4.96e-13	Mean platelet volume;
TGCT	trans	rs941408	1.000	rs1736177	chr19:2791624	C/T	cg19676328	chr12:49525230	TUBA1B	-0.76	-7.72	-0.57	3.34e-12	Total cholesterol levels;
TGCT	cis	rs6866344	0.570	rs59259518	chr5:178142628	C/T	cg10224037	chr5:178157518	ZNF354A	0.95	8.98	0.63	3.58e-15	Neutrophil percentage of white cells;
TGCT	cis	rs6988636	1.000	rs11992152	chr8:124189455	T/A	cg27053337	chr8:124217698	FAM83A	0.58	4.81	0.4	4.3e-6	Urinary uromodulin levels;
TGCT	cis	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg20637647	chr7:64974828	NA	0.88	5.0	0.41	1.93e-6	Diabetic kidney disease;
TGCT	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg13866156	chr1:1669148	SLC35E2	-0.21	-5.0	-0.41	1.88e-6	Body mass index;
TGCT	cis	rs9549367	0.762	rs9549694	chr13:113870510	G/A	cg00898013	chr13:113819073	PROZ	-0.43	-5.52	-0.44	1.87e-7	Platelet distribution width;
TGCT	cis	rs8072100	0.967	rs11656855	chr17:45714655	C/T	cg08085267	chr17:45401833	C17orf57	0.43	4.63	0.38	9.04e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs644799	0.965	rs3016295	chr11:95554311	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	8.74	0.62	1.39e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
TGCT	cis	rs7666738	0.753	rs11097594	chr4:98944486	A/G	cg18180107	chr4:99064573	C4orf37	0.57	5.16	0.42	9.32e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg00149659	chr3:10157352	C3orf10	-0.73	-4.84	-0.4	3.86e-6	Alzheimer's disease;
TGCT	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg01238044	chr22:24384105	GSTT1	-0.49	-4.61	-0.38	9.74e-6	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs9926296	0.572	rs8047581	chr16:89884502	C/T	cg08627397	chr16:89984028	MC1R	-0.32	-5.25	-0.43	6.31e-7	Vitiligo;
TGCT	cis	rs10193935	0.901	rs10170082	chr2:42623452	T/C	cg27598129	chr2:42591480	NA	-0.37	-5.23	-0.42	7.1e-7	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs9894429	0.966	rs6565605	chr17:79589359	C/T	cg18240062	chr17:79603768	NPLOC4	0.67	6.85	0.52	3.11e-10	Eye color traits;
TGCT	cis	rs752092	1.000	rs752092	chr15:101781934	C/T	cg19997662	chr15:101784653	CHSY1	0.32	5.96	0.47	2.4e-8	Corneal structure;
TGCT	cis	rs7726839	0.540	rs56325086	chr5:640728	G/A	cg16624210	chr5:671434	TPPP	0.4	4.59	0.38	1.07e-5	Obesity-related traits;
TGCT	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg05025164	chr4:1340916	KIAA1530	0.75	6.21	0.49	7.3e-9	Longevity;
TGCT	cis	rs9902453	0.845	rs12601963	chr17:28246358	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.81	7.28	0.55	3.32e-11	Coffee consumption (cups per day);
TGCT	cis	rs67311347	0.955	rs4973999	chr3:40460383	G/A	cg13683864	chr3:40499215	RPL14	-1.04	-10.79	-0.7	1.54e-19	Renal cell carcinoma;
TGCT	cis	rs514406	0.547	rs377808	chr1:53190359	T/G	cg01802117	chr1:53393560	SCP2	-0.4	-4.61	-0.38	9.76e-6	Monocyte count;
TGCT	cis	rs17718580	0.826	rs72679544	chr14:51031469	C/A	cg04730355	chr14:51134070	SAV1	1.0	5.61	0.45	1.24e-7	Cognitive performance;
TGCT	cis	rs6752107	0.500	rs11893210	chr2:234204672	A/G	cg25333460	chr2:234370070	DGKD	0.2	4.44	0.37	2e-5	Crohn's disease;Inflammatory bowel disease;
TGCT	trans	rs1814175	0.935	rs7479914	chr11:49661351	T/C	cg03929089	chr4:120376271	NA	-0.65	-7.42	-0.55	1.59e-11	Height;
TGCT	cis	rs7666738	0.822	rs9992360	chr4:98937123	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.91	0.47	3.12e-8	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs1008375	1.000	rs2872958	chr4:17665032	A/G	cg10189774	chr4:17578691	LAP3	0.54	5.08	0.41	1.38e-6	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs807669	0.548	rs885978	chr22:19198226	A/G	cg02655711	chr22:19163373	SLC25A1	0.3	5.9	0.47	3.22e-8	Metabolite levels;
TGCT	cis	rs6684514	1.000	rs12142808	chr1:156230546	G/A	cg16558208	chr1:156270281	VHLL	0.46	8.56	0.61	3.68e-14	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
TGCT	cis	rs1577917	0.958	rs2875456	chr6:86602284	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.19	-0.42	8.51e-7	Response to antipsychotic treatment;
TGCT	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg04234412	chr22:24373322	LOC391322	-0.94	-11.78	-0.73	5.91e-22	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs79349575	0.715	rs62075844	chr17:47002389	G/A	cg07967210	chr17:47022446	SNF8	0.44	6.12	0.48	1.13e-8	Type 2 diabetes;
TGCT	cis	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg18252515	chr7:66147081	NA	1.25	7.75	0.57	2.92e-12	Diabetic kidney disease;
TGCT	cis	rs1865760	0.516	rs9379818	chr6:26023206	G/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.78	7.56	0.56	7.89e-12	Height;
TGCT	cis	rs981844	0.796	rs11099904	chr4:154681861	A/G	cg14289246	chr4:154710475	SFRP2	0.87	7.49	0.56	1.1e-11	Response to statins (LDL cholesterol change);
TGCT	cis	rs2456568	0.802	rs8181578	chr11:93637442	G/A	cg26875233	chr11:93583750	C11orf90	-0.48	-6.47	-0.5	2.09e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
TGCT	cis	rs7572733	0.576	rs1865586	chr2:198758868	C/T	cg00792783	chr2:198669748	PLCL1	-0.54	-4.93	-0.4	2.57e-6	Dermatomyositis;
TGCT	cis	rs919433	0.679	rs13000656	chr2:198522126	T/C	cg00792783	chr2:198669748	PLCL1	-0.54	-4.78	-0.39	4.82e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
TGCT	cis	rs2549003	1.000	rs17848418	chr5:131821188	C/T	cg00255919	chr5:131827918	IRF1	0.2	4.7	0.39	6.92e-6	Asthma (sex interaction);
TGCT	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg11890956	chr21:40555474	PSMG1	1.14	12.22	0.74	4.93e-23	Cognitive function;
TGCT	cis	rs9326248	0.954	rs10790177	chr11:117048417	A/G	cg16524733	chr11:117070046	TAGLN	0.31	4.49	0.37	1.62e-5	Blood protein levels;
TGCT	cis	rs12216125	0.537	rs12207059	chr6:25922385	C/T	cg17691542	chr6:26056736	HIST1H1C	0.89	6.28	0.49	5.3e-9	Iron status biomarkers;
TGCT	cis	rs7666738	0.830	rs17558151	chr4:99048699	T/C	cg18180107	chr4:99064573	C4orf37	0.56	5.08	0.41	1.37e-6	Colonoscopy-negative controls vs population controls;
TGCT	cis	rs909674	0.514	rs7423	chr22:39781429	C/T	cg05872129	chr22:39784769	NA	-0.96	-11.04	-0.7	3.71e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
TGCT	trans	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg23505145	chr19:12996616	KLF1	0.78	8.12	0.59	4.03e-13	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs3749237	0.595	rs11130192	chr3:49467206	C/G	cg07636037	chr3:49044803	WDR6	0.63	6.07	0.48	1.47e-8	Resting heart rate;
TGCT	cis	rs7267979	0.816	rs8115257	chr20:25207931	A/G	cg14121845	chr20:25566513	NINL	0.46	4.67	0.39	7.74e-6	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs9868809	0.505	rs13434258	chr3:48738491	T/C	cg00383909	chr3:49044727	WDR6	1.06	6.28	0.49	5.26e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
TGCT	cis	rs4689388	0.890	rs4501291	chr4:6298582	C/T	cg25554036	chr4:6271136	WFS1	0.56	7.87	0.58	1.48e-12	Type 2 diabetes and other traits;Type 2 diabetes;
TGCT	cis	rs9399135	0.933	rs9389262	chr6:135376409	G/T	cg24558204	chr6:135376177	HBS1L	0.48	4.76	0.39	5.21e-6	Red blood cell count;
TGCT	cis	rs6977660	0.714	rs17141882	chr7:19790217	C/T	cg05791153	chr7:19748676	TWISTNB	0.88	5.05	0.41	1.52e-6	Thyroid stimulating hormone;
TGCT	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg05721485	chr17:44071124	MAPT	0.24	4.46	0.37	1.84e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
TGCT	cis	rs7208859	0.623	rs55938328	chr17:29117010	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	4.85	0.4	3.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
TGCT	cis	rs77741769	0.534	rs58918988	chr12:121332953	G/A	cg02419362	chr12:121203948	SPPL3	0.19	4.5	0.37	1.56e-5	Mean corpuscular volume;
TGCT	cis	rs7104764	0.917	rs3825075	chr11:217140	C/T	cg18336825	chr11:236787	PSMD13;SIRT3	-0.73	-7.03	-0.53	1.2e-10	Menarche (age at onset);
TGCT	cis	rs8017423	0.967	rs7158180	chr14:90729117	C/T	cg04374321	chr14:90722782	PSMC1	0.78	7.86	0.58	1.59e-12	Mortality in heart failure;
TGCT	cis	rs6570726	0.791	rs370112	chr6:145859853	T/G	cg05347473	chr6:146136440	FBXO30	0.54	5.15	0.42	1.01e-6	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs9916302	0.851	rs11870631	chr17:37645129	C/T	cg07936489	chr17:37558343	FBXL20	-0.62	-4.91	-0.4	2.85e-6	Glomerular filtration rate (creatinine);
TGCT	cis	rs7829975	0.582	rs6983150	chr8:8792426	A/G	cg00184457	chr8:8946301	NA	-0.23	-4.44	-0.37	2e-5	Mood instability;
TGCT	cis	rs903263	0.965	rs6699600	chr1:84592169	C/G	cg09664975	chr1:84543551	PRKACB	0.49	4.55	0.38	1.26e-5	Breast cancer (male);
TGCT	cis	rs2797160	1.000	rs1418951	chr6:125996185	A/G	cg05901451	chr6:126070800	HEY2	-0.74	-6.49	-0.5	1.84e-9	Endometrial cancer;
TGCT	cis	rs7584330	0.666	rs72620818	chr2:238354652	G/A	cg14458575	chr2:238380390	NA	0.56	8.26	0.6	1.84e-13	Prostate cancer;
TGCT	cis	rs910316	0.967	rs4384542	chr14:75658013	A/C	cg11812906	chr14:75593930	NEK9	-0.72	-6.87	-0.53	2.72e-10	Height;
TGCT	cis	rs2760061	0.819	rs708112	chr1:228192452	G/A	cg18477163	chr1:228402036	OBSCN	0.34	7.16	0.54	6.26e-11	Diastolic blood pressure;
TGCT	cis	rs9611565	0.918	rs6002351	chr22:41757223	C/T	cg06481639	chr22:41940642	POLR3H	-0.58	-5.01	-0.41	1.81e-6	Vitiligo;
TGCT	cis	rs79349575	0.783	rs56046215	chr17:47008757	A/T	cg07967210	chr17:47022446	SNF8	0.44	6.13	0.48	1.1e-8	Type 2 diabetes;
TGCT	cis	rs9902453	0.780	rs62068621	chr17:28170382	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	7.17	0.54	5.79e-11	Coffee consumption (cups per day);
TGCT	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.86	-9.43	-0.65	3.05e-16	Menarche (age at onset);
TGCT	cis	rs4713118	0.615	rs57252182	chr6:27720249	C/A	cg10876282	chr6:28092338	ZSCAN16	0.5	5.09	0.42	1.29e-6	Parkinson's disease;
TGCT	cis	rs950169	0.544	rs62021193	chr15:85170583	C/G	cg17173187	chr15:85201210	NMB	0.6	6.81	0.52	3.78e-10	Schizophrenia;
TGCT	cis	rs12220238	1.000	rs4320897	chr10:76017732	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.93	7.36	0.55	2.26e-11	Soluble interleukin-2 receptor subunit alpha;
TGCT	cis	rs72843506	0.586	rs73980762	chr17:19869426	T/C	cg18979559	chr17:20280153	CCDC144C	-0.59	-4.5	-0.37	1.53e-5	Schizophrenia;
TGCT	cis	rs12464483	0.524	rs2593470	chr2:30887402	G/T	cg12454169	chr2:30669597	LCLAT1	0.45	4.91	0.4	2.75e-6	Pre-treatment pain in head and neck squamous cell carcinoma;
TGCT	cis	rs13064411	0.542	rs1463643	chr3:113215447	A/G	cg18753928	chr3:113234510	CCDC52	-0.54	-4.58	-0.38	1.12e-5	Response to simvastatin treatment (PCSK9 protein level change);
TGCT	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg08736216	chr1:53307985	ZYG11A	-0.28	-5.73	-0.46	7.33e-8	Monocyte count;
TGCT	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg13752114	chr3:195489708	MUC4	0.35	4.98	0.41	2.05e-6	Lung disease severity in cystic fibrosis;
TGCT	cis	rs11677370	0.533	rs12711971	chr2:3820821	G/C	cg17052675	chr2:3827356	NA	-0.45	-7.95	-0.58	9.92e-13	Type 2 diabetes;
TGCT	cis	rs826838	0.872	rs826878	chr12:39088837	A/T	cg26384229	chr12:38710491	ALG10B	-0.82	-7.79	-0.57	2.28e-12	Heart rate;
TGCT	cis	rs12188164	1.000	rs56104584	chr5:437542	T/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.4	-4.76	-0.39	5.33e-6	Cystic fibrosis severity;
TGCT	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg10295955	chr4:187884368	NA	-0.98	-15.43	-0.81	1.25e-30	Lobe attachment (rater-scored or self-reported);
TGCT	cis	rs7017914	0.905	rs12542300	chr8:71951395	C/G	cg23757474	chr8:71581111	LACTB2;XKR9	0.54	4.99	0.41	2e-6	Bone mineral density;
TGCT	cis	rs11997175	0.574	rs10954931	chr8:33631066	A/T	ch.8.33884649F	chr8:33765107	NA	0.28	4.45	0.37	1.87e-5	Body mass index;
TGCT	cis	rs2742417	1.000	rs2742386	chr3:45756310	A/C	cg04837898	chr3:45731254	SACM1L	-0.52	-5.28	-0.43	5.58e-7	Response to anti-depressant treatment in major depressive disorder;
TGCT	cis	rs9348729	1	rs9348729	chr6:26664268	T/C	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.5	-4.72	-0.39	6.15e-6	Intelligence (multi-trait analysis);
TGCT	cis	rs1348850	0.632	rs1405718	chr2:178499809	C/T	cg22681709	chr2:178499509	PDE11A	-0.52	-6.73	-0.52	5.53e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
TGCT	cis	rs68170813	0.559	rs76307631	chr7:107058018	A/G	cg02696742	chr7:106810147	HBP1	-0.68	-5.44	-0.44	2.69e-7	Coronary artery disease;
TGCT	cis	rs28595532	0.920	rs114410095	chr4:119731110	G/A	cg21605333	chr4:119757512	SEC24D	1.66	8.33	0.6	1.28e-13	Cannabis dependence symptom count;
TGCT	cis	rs28735056	0.584	rs35614280	chr18:77636679	C/G	cg20368463	chr18:77673604	PQLC1	0.46	5.36	0.43	3.88e-7	Schizophrenia;
TGCT	cis	rs1801251	0.963	rs13011298	chr2:233612996	A/G	cg08000102	chr2:233561755	GIGYF2	0.64	6.52	0.51	1.58e-9	Coronary artery disease;
TGCT	cis	rs6714710	0.603	rs17489984	chr2:98421364	A/G	cg26665480	chr2:98280029	ACTR1B	0.66	6.27	0.49	5.45e-9	Posterior cortical atrophy and Alzheimer's disease;
TGCT	cis	rs2933343	0.700	rs1680779	chr3:128614770	G/A	cg11901034	chr3:128598214	ACAD9	-0.63	-5.72	-0.46	7.48e-8	IgG glycosylation;
TGCT	cis	rs6429082	0.633	rs1416473	chr1:235563259	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.51	-4.44	-0.37	1.93e-5	Adiposity;
TGCT	cis	rs6831352	0.879	rs36034266	chr4:100061388	T/C	cg12011299	chr4:100065546	ADH4	-0.41	-4.97	-0.41	2.21e-6	Alcohol dependence;
TGCT	cis	rs7714584	1.000	rs7714584	chr5:150270420	A/G	cg22134413	chr5:150180641	NA	0.78	6.12	0.48	1.16e-8	Crohn's disease;
TGCT	cis	rs1865760	0.963	rs1540273	chr6:25924158	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.65	6.21	0.49	7.42e-9	Height;
TGCT	cis	rs1062177	0.756	rs2964588	chr5:151118386	C/T	cg12924095	chr5:151150029	G3BP1	-0.34	-4.97	-0.41	2.17e-6	Preschool internalizing problems;
TGCT	cis	rs8031584	0.706	rs798084	chr15:31126935	C/T	cg08109568	chr15:31115862	NA	-0.4	-5.35	-0.43	4.1e-7	Huntington's disease progression;
TGCT	cis	rs7829975	0.511	rs2976902	chr8:8341105	T/G	cg15556689	chr8:8085844	FLJ10661	0.63	6.09	0.48	1.3e-8	Mood instability;
TGCT	cis	rs2439831	1.000	rs2467740	chr15:43746792	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.8	5.7	0.46	8.33e-8	Lung cancer in ever smokers;
TGCT	cis	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg03213289	chr20:61660250	NA	0.7	10.11	0.67	6.94e-18	Prostate cancer (SNP x SNP interaction);
TGCT	cis	rs9650657	0.524	rs10088408	chr8:10817197	C/T	cg21775007	chr8:11205619	TDH	-0.53	-4.96	-0.41	2.25e-6	Neuroticism;
TGCT	cis	rs74054849	0.850	rs78132144	chr1:15939883	A/T	cg05660106	chr1:15850417	CASP9	0.86	4.47	0.37	1.71e-5	Alcoholic chronic pancreatitis;
TGCT	cis	rs3087591	0.639	rs7223589	chr17:29728284	T/C	cg24425628	chr17:29625626	OMG;NF1	0.36	5.06	0.41	1.49e-6	Hip circumference;
TGCT	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg13395646	chr4:1353034	KIAA1530	0.39	4.78	0.39	4.96e-6	Obesity-related traits;
TGCT	cis	rs694739	0.595	rs11606015	chr11:64136877	C/G	cg02228329	chr11:64053129	BAD;GPR137	0.69	6.78	0.52	4.25e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
TGCT	cis	rs9486719	0.857	rs4839833	chr6:96882069	T/C	cg06623918	chr6:96969491	KIAA0776	1.03	10.94	0.7	6.47e-20	Migraine;Coronary artery disease;
TGCT	cis	rs637571	0.522	rs528736	chr11:65705108	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.46	4.65	0.39	8.2e-6	Eosinophil percentage of white cells;
TGCT	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg12419862	chr22:24373484	LOC391322	0.85	10.0	0.67	1.26e-17	Liver enzyme levels (gamma-glutamyl transferase);
TGCT	cis	rs12210905	0.688	rs12199806	chr6:27435943	A/C	cg08851530	chr6:28072375	NA	1.34	6.29	0.49	5.02e-9	Hip circumference adjusted for BMI;
TGCT	cis	rs4733781	0.965	rs1469288	chr8:131226652	G/A	cg16277922	chr8:131349729	ASAP1	0.45	5.54	0.45	1.7e-7	Tuberculosis;
TGCT	cis	rs2718812	0.792	rs3772680	chr3:133371807	A/G	cg16414030	chr3:133502952	NA	-0.4	-5.19	-0.42	8.27e-7	Iron status biomarkers;
TGCT	cis	rs2243480	1.000	rs6964530	chr7:65718851	G/C	cg07424592	chr7:64974309	NA	-1.3	-7.55	-0.56	8.08e-12	Diabetic kidney disease;
TGCT	cis	rs4664308	1.000	rs2175416	chr2:160904021	G/A	cg03641300	chr2:160917029	PLA2R1	-0.26	-6.53	-0.51	1.49e-9	Idiopathic membranous nephropathy;
TGCT	cis	rs4766566	0.609	rs933305	chr12:111738287	G/A	cg10833066	chr12:111807467	FAM109A	0.4	6.35	0.5	3.68e-9	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
TGCT	cis	rs7843479	0.601	rs12056476	chr8:21854188	T/A	cg17168535	chr8:21777572	XPO7	0.8	8.02	0.58	6.73e-13	Mean corpuscular volume;
TGCT	cis	rs4975709	0.544	rs4975748	chr5:1866025	G/A	cg12288994	chr5:1860383	NA	0.26	5.1	0.42	1.22e-6	Cardiovascular disease risk factors;
TGCT	cis	rs7714584	1.000	rs1820682	chr5:150262142	T/C	cg22134413	chr5:150180641	NA	0.78	6.12	0.48	1.16e-8	Crohn's disease;
TGCT	cis	rs4742903	0.935	rs10820602	chr9:106861282	C/T	cg21169611	chr9:106856078	SMC2	0.49	4.6	0.38	1.03e-5	High-grade serous ovarian cancer;Breast cancer;
TGCT	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.69	-7.06	-0.54	1.07e-10	Prostate cancer;
TGCT	cis	rs9291683	0.588	rs3756238	chr4:10013202	C/T	cg00071950	chr4:10020882	SLC2A9	0.76	10.38	0.68	1.55e-18	Bone mineral density;
TGCT	cis	rs5744897	0.655	rs35131280	chr12:133275974	A/G	cg17341477	chr12:133246679	POLE	0.43	5.45	0.44	2.65e-7	Urate levels in overweight individuals;
TGCT	cis	rs2404602	0.608	rs12439484	chr15:76602937	A/C	cg26408565	chr15:76604113	ETFA	-0.47	-6.63	-0.51	9.38e-10	Blood metabolite levels;
TGCT	cis	rs8072100	1.000	rs4794016	chr17:45725931	T/A	cg08085267	chr17:45401833	C17orf57	0.47	5.12	0.42	1.14e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
TGCT	cis	rs782590	0.556	rs782579	chr2:55917604	A/G	cg03859395	chr2:55845619	SMEK2	0.66	6.77	0.52	4.51e-10	Metabolic syndrome;
TGCT	cis	rs17376456	0.569	rs11135394	chr5:93187135	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.56	-4.76	-0.39	5.3e-6	Diabetic retinopathy;
TGCT	cis	rs910316	0.789	rs175457	chr14:75584507	C/T	cg11812906	chr14:75593930	NEK9	-0.64	-5.86	-0.47	3.9e-8	Height;
TGCT	cis	rs9921338	0.923	rs4563054	chr16:11447546	T/G	cg00044050	chr16:11439710	C16orf75	-0.79	-6.09	-0.48	1.28e-8	Vein graft stenosis in coronary artery bypass grafting;
TGCT	cis	rs1372520	0.684	rs2619341	chr4:90741773	A/G	cg20003494	chr4:90757398	SNCA	-0.63	-5.06	-0.41	1.48e-6	Neuroticism;
TGCT	cis	rs2235642	0.653	rs7197288	chr16:1654753	C/A	cg10465839	chr16:1584050	IFT140;TMEM204	-0.28	-4.52	-0.38	1.44e-5	Coronary artery disease;
TGCT	cis	rs1034435	0.755	rs713923	chr22:48891519	C/T	cg05992904	chr22:48892994	FAM19A5	0.37	5.23	0.43	6.89e-7	Late-onset Alzheimer's disease;
TGCT	cis	rs1008375	0.872	rs6831115	chr4:17640463	A/G	cg18681998	chr4:17616180	MED28	1.0	11.93	0.73	2.54e-22	Parasitemia in Tripanosoma cruzi seropositivity;
TGCT	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg11494091	chr17:61959527	GH2	0.42	7.28	0.55	3.36e-11	Height;
TGCT	cis	rs56104184	0.830	rs17206679	chr19:49342237	C/G	cg21252483	chr19:49399788	TULP2	-0.42	-5.58	-0.45	1.46e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
TGCT	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg13395646	chr4:1353034	KIAA1530	-0.47	-5.77	-0.46	5.99e-8	Obesity-related traits;
TGCT	cis	rs868036	0.609	rs2045960	chr15:68092079	G/A	cg27219399	chr15:67835830	MAP2K5	0.34	4.49	0.37	1.59e-5	Restless legs syndrome;
TGCT	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg20607798	chr8:58055168	NA	0.44	4.58	0.38	1.12e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs651907	0.557	rs34947019	chr3:101532235	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.31	-6.5	-0.5	1.8e-9	Colorectal cancer;
TGCT	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg24549020	chr5:56110836	MAP3K1	0.69	5.91	0.47	3.09e-8	Initial pursuit acceleration;
TGCT	cis	rs10779751	0.727	rs4845852	chr1:11233559	C/T	cg08854313	chr1:11322531	MTOR	0.84	8.09	0.59	4.52e-13	Body mass index;
TGCT	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg08219700	chr8:58056026	NA	0.3	4.59	0.38	1.08e-5	Developmental language disorder (linguistic errors);
TGCT	cis	rs7267979	0.816	rs409853	chr20:25506067	T/C	cg03522245	chr20:25566470	NINL	0.56	5.79	0.46	5.51e-8	Liver enzyme levels (alkaline phosphatase);
TGCT	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg09517075	chr8:22133004	PIWIL2	0.25	4.99	0.41	1.95e-6	Hypertriglyceridemia;
TGCT	cis	rs3806843	0.576	rs155359	chr5:140315425	G/T	cg09824255	chr5:140014002	CD14	0.25	4.49	0.37	1.63e-5	Depressive symptoms (multi-trait analysis);
TGCT	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg24675658	chr1:53192096	ZYG11B	0.76	8.75	0.62	1.3e-14	Monocyte count;
TGCT	cis	rs7044106	0.791	rs10760116	chr9:123494681	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.2	4.77	0.39	5.05e-6	Hip circumference adjusted for BMI;
TGCT	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg10047753	chr17:41438598	NA	0.95	9.5	0.65	2.09e-16	Menopause (age at onset);
TGCT	cis	rs7819412	0.594	rs60921132	chr8:10964969	T/A	cg03192020	chr8:11204681	TDH	-0.57	-5.43	-0.44	2.81e-7	Triglycerides;
TGCT	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg21724239	chr8:58056113	NA	0.38	4.72	0.39	6.3e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs2708977	0.965	rs2314109	chr2:97243532	A/G	cg01950434	chr2:97203154	ARID5A	-0.64	-5.85	-0.47	4.09e-8	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
TGCT	cis	rs72634258	0.553	rs112697022	chr1:7949253	G/A	cg26816564	chr1:7831052	VAMP3	0.61	4.61	0.38	9.72e-6	Inflammatory bowel disease;
TGCT	cis	rs9359856	0.564	rs17506403	chr6:90499059	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.47	-4.58	-0.38	1.13e-5	Bipolar disorder;
TGCT	cis	rs62209	0.800	rs11256938	chr10:11009060	A/G	cg26901096	chr10:10994189	LOC254312	0.43	6.99	0.53	1.46e-10	Alzheimer's disease (late onset);
TGCT	cis	rs3785574	0.650	rs7406102	chr17:62004749	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-1.0	-11.19	-0.71	1.62e-20	Height;
TGCT	cis	rs7914558	1.000	rs11191539	chr10:104819770	A/G	cg05855489	chr10:104503620	C10orf26	0.51	4.48	0.37	1.67e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
TGCT	cis	rs4563143	0.514	rs73029079	chr19:29294903	A/G	cg14983838	chr19:29218262	NA	0.71	5.19	0.42	8.21e-7	Methadone dose in opioid dependence;
TGCT	cis	rs1894292	0.527	rs4267705	chr4:74376081	T/C	cg05868023	chr4:75230803	EREG	-0.56	-5.05	-0.41	1.56e-6	Prostate cancer;
TGCT	cis	rs7917772	0.582	rs4285804	chr10:104386309	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.54	-5.58	-0.45	1.45e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
TGCT	cis	rs68170813	0.559	rs7793594	chr7:106891829	C/T	cg02696742	chr7:106810147	HBP1	-0.69	-5.61	-0.45	1.27e-7	Coronary artery disease;
TGCT	cis	rs11785400	1.000	rs4484678	chr8:143730796	A/G	cg24634471	chr8:143751801	JRK	0.54	5.85	0.46	4.19e-8	Schizophrenia;
TGCT	cis	rs11098499	0.789	rs9991166	chr4:120237851	G/A	cg09307838	chr4:120376055	NA	0.61	5.91	0.47	3.14e-8	Corneal astigmatism;
TGCT	cis	rs9372498	0.536	rs62422227	chr6:118957200	C/G	cg07617317	chr6:118971624	C6orf204	0.48	5.08	0.42	1.32e-6	Diastolic blood pressure;
TGCT	cis	rs2658782	1.000	rs2658779	chr11:93163137	G/T	cg18152523	chr11:93063302	CCDC67	0.67	5.46	0.44	2.47e-7	Pulmonary function decline;
TGCT	trans	rs28595532	0.545	rs17516582	chr4:119296763	C/G	cg26518628	chr1:97050305	NA	-0.61	-7.34	-0.55	2.45e-11	Cannabis dependence symptom count;
TGCT	cis	rs2562456	0.917	rs2650805	chr19:21687939	T/G	cg25650185	chr19:21324782	ZNF431	0.61	5.38	0.43	3.6e-7	Pain;
TGCT	cis	rs2440129	0.591	rs312466	chr17:6899221	G/A	cg19536664	chr17:6899085	ALOX12	-0.37	-6.1	-0.48	1.26e-8	Tonsillectomy;
TGCT	cis	rs7100689	0.646	rs1815650	chr10:82157464	C/T	cg01528321	chr10:82214614	TSPAN14	0.73	7.73	0.57	3.25e-12	Post bronchodilator FEV1;
TGCT	cis	rs13082711	0.558	rs1844983	chr3:27370203	C/T	cg02860705	chr3:27208620	NA	-0.29	-4.57	-0.38	1.15e-5	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
TGCT	cis	rs7043114	0.507	rs6479420	chr9:95116406	T/C	cg14631576	chr9:95140430	CENPP	-0.27	-4.45	-0.37	1.87e-5	Height;
TGCT	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg27535305	chr1:53392650	SCP2	-0.28	-5.89	-0.47	3.35e-8	Monocyte count;
TGCT	cis	rs1451375	1.000	rs1451375	chr7:50622712	A/C	cg18232548	chr7:50535776	DDC	-0.41	-6.53	-0.51	1.5e-9	Malaria;
TGCT	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg08219700	chr8:58056026	NA	0.38	4.64	0.38	8.83e-6	Developmental language disorder (linguistic errors);
TGCT	cis	rs1372520	0.684	rs2583978	chr4:90750326	A/C	cg15133208	chr4:90757351	SNCA	-0.5	-5.86	-0.47	4e-8	Neuroticism;
TGCT	cis	rs9911578	0.967	rs6416932	chr17:57148991	G/A	cg05425664	chr17:57184151	TRIM37	-0.68	-6.9	-0.53	2.4e-10	Intelligence (multi-trait analysis);
TGCT	cis	rs2299587	0.573	rs6986123	chr8:17888073	G/A	cg04898035	chr8:17640624	MTUS1	-0.22	-4.75	-0.39	5.54e-6	Economic and political preferences;
TGCT	cis	rs75229567	0.618	rs77168443	chr12:70208563	G/A	cg10114359	chr12:70132523	RAB3IP	1.35	6.68	0.51	7.19e-10	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
TGCT	cis	rs7940866	0.740	rs7131121	chr11:130806424	A/G	cg05962950	chr11:130786565	SNX19	0.67	6.75	0.52	5.05e-10	Schizophrenia;
TGCT	cis	rs4820539	1.000	rs3827316	chr22:23468538	T/C	cg21100191	chr22:23484243	RTDR1	0.88	10.0	0.67	1.28e-17	Bone mineral density;